diff --git "a/dev.tsv" "b/dev.tsv"
new file mode 100644--- /dev/null
+++ "b/dev.tsv"
@@ -0,0 +1,679897 @@
+RNA	O
+transcripts	O
+were	O
+packaged	O
+into	O
+both	O
+BCV	B-SPEC
+and	O
+MHV	B-SPEC
+virions	B-COMP
+when	O
+the	O
+cloned	O
+region	O
+was	O
+appended	O
+to	O
+a	O
+noncoronavirus	O
+RNA	O
+.	O
+
+This	O
+is	O
+the	O
+first	O
+identification	O
+of	O
+a	O
+BCV	B-SPEC
+packaging	O
+signal	O
+.	O
+
+Serum	B-PRGE
+TNF	I-PRGE
+-	I-PRGE
+alpha	I-PRGE
+levels	O
+were	O
+significantly	O
+higher	O
+in	O
+ARDS	O
+patients	O
+(	O
+67	O
+(	O
+57	O
+)	O
+pg	O
+/	O
+ml	O
+)	O
+than	O
+in	O
+patients	O
+with	O
+severe	O
+pneumonia	B-DISO
+(	O
+35	O
+(	O
+20	O
+)	O
+pg	O
+/	O
+ml	O
+;	O
+p	O
+=	O
+0	O
+.	O
+031	O
+)	O
+or	O
+controls	O
+(	O
+17	O
+(	O
+8	O
+)	O
+pg	O
+/	O
+ml	O
+;	O
+p	O
+=	O
+0	O
+.	O
+007	O
+).	O
+
+TNF	B-PRGE
+-	I-PRGE
+alpha	I-PRGE
+(	O
+standardised	O
+coefficient	O
+beta	O
+=	O
+0	O
+.	O
+410	O
+,	O
+p	O
+<	O
+0	O
+.	O
+001	O
+)	O
+and	O
+IL	B-PRGE
+-	I-PRGE
+1beta	I-PRGE
+(	O
+standardised	O
+coefficient	O
+beta	O
+=	O
+0	O
+.	O
+311	O
+,	O
+p	O
+=	O
+0	O
+.	O
+006	O
+)	O
+were	O
+most	O
+strongly	O
+associated	O
+with	O
+the	O
+degree	O
+of	O
+lung	B-ANAT
+injury	O
+,	O
+even	O
+when	O
+the	O
+diagnostic	O
+group	O
+was	O
+included	O
+in	O
+the	O
+statistical	O
+model	O
+.	O
+
+TNF	B-PRGE
+-	I-PRGE
+alpha	I-PRGE
+(	O
+standardised	O
+coefficient	O
+beta	O
+=	O
+0	O
+.	O
+410	O
+,	O
+p	O
+<	O
+0	O
+.	O
+001	O
+)	O
+and	O
+IL	B-PRGE
+-	I-PRGE
+1beta	I-PRGE
+(	O
+standardised	O
+coefficient	O
+beta	O
+=	O
+0	O
+.	O
+311	O
+,	O
+p	O
+=	O
+0	O
+.	O
+006	O
+)	O
+were	O
+most	O
+strongly	O
+associated	O
+with	O
+the	O
+degree	O
+of	O
+lung	B-ANAT
+injury	O
+,	O
+even	O
+when	O
+the	O
+diagnostic	O
+group	O
+was	O
+included	O
+in	O
+the	O
+statistical	O
+model	O
+.	O
+
+The	O
+saline	O
+lavage	O
+procedure	O
+caused	O
+progressive	O
+development	B-PROC
+of	O
+shunt	O
+flow	O
+(	O
+approximately	O
+22	O
+%)	O
+and	O
+perfusion	O
+of	O
+low	O
+V	O
+A	O
+/	O
+Q	O
+areas	O
+(	O
+approximately	O
+7	O
+%),	O
+associated	O
+with	O
+severe	O
+V	O
+A	O
+/	O
+Q	O
+mismatch	O
+.	O
+
+Rescue	O
+""""	O
+tracheal	O
+instillation	O
+of	O
+80	O
+mg	O
+/	O
+kg	O
+bw	O
+surfactant	B-CHED
+in	O
+lavaged	O
+lungs	B-ANAT
+reduced	O
+the	O
+shunt	O
+-	O
+flow	O
+to	O
+approximately	O
+4	O
+%,	O
+but	O
+increased	O
+the	O
+perfusion	O
+of	O
+low	O
+V	O
+A	O
+/	O
+Q	O
+areas	O
+to	O
+10	O
+to	O
+14	O
+%;	O
+V	O
+A	O
+/	O
+Q	O
+mismatch	O
+in	O
+the	O
+midrange	O
+V	O
+A	O
+/	O
+Q	O
+regions	O
+was	O
+not	O
+improved	O
+.	O
+
+Growth	B-PROC
+in	O
+horse	B-SPEC
+serum	B-COMP
+,	O
+which	O
+contains	O
+no	O
+free	O
+queuine	B-CHED
+,	O
+eliminates	O
+Q	O
+from	O
+the	O
+cellular	B-COMP
+tRNA	B-FUNC
+population	O
+upon	O
+repeated	O
+passage	O
+.	O
+
+Supplementation	O
+of	O
+the	O
+growth	B-PROC
+medium	O
+of	O
+cells	B-COMP
+grown	O
+either	O
+on	O
+horse	B-SPEC
+serum	B-COMP
+or	O
+calf	B-ANAT
+serum	B-COMP
+with	O
+free	O
+queuine	B-CHED
+had	O
+no	O
+effect	O
+on	O
+frameshifting	O
+either	O
+.	O
+
+TITLE	O
+:	O
+Retargeting	O
+of	O
+coronavirus	B-SPEC
+by	O
+substitution	O
+of	O
+the	O
+spike	O
+glycoprotein	B-CHED
+ectodomain	O
+:	O
+crossing	O
+the	O
+host	O
+cell	O
+species	B-SPEC
+barrier	O
+.	O
+
+In	O
+addition	O
+,	O
+fMHV	O
+is	O
+potentially	O
+the	O
+ideal	O
+recipient	O
+virus	B-SPEC
+for	O
+carrying	O
+out	O
+reverse	O
+genetics	O
+of	O
+MHV	B-SPEC
+by	O
+targeted	B-PROC
+RNA	O
+recombination	B-PROC
+,	O
+since	O
+it	O
+presents	O
+the	O
+possibility	O
+of	O
+selecting	O
+recombinants	O
+,	O
+no	O
+matter	O
+how	O
+defective	O
+,	O
+that	O
+have	O
+regained	O
+the	O
+ability	O
+to	O
+replicate	O
+in	O
+murine	B-SPEC
+cells	B-COMP
+.	O
+
+Two	O
+chimeric	O
+MHV	B-SPEC
+-	O
+FIPV	O
+S	O
+proteins	B-CHED
+were	O
+constructed	O
+,	O
+consisting	O
+of	O
+the	O
+ectodomain	O
+of	O
+the	O
+one	O
+virus	B-SPEC
+and	O
+the	O
+transmembrane	B-COMP
+and	O
+endodomain	O
+of	O
+the	O
+other	O
+.	O
+
+Animal	B-SPEC
+study	O
+at	O
+the	O
+Asan	O
+Institute	O
+for	O
+Life	O
+Sciences	O
+,	O
+Seoul	O
+,	O
+Korea	O
+.	O
+
+Respiratory	B-PROC
+mechanics	I-PROC
+during	O
+PLV	O
+for	O
+dependent	O
+lung	B-ANAT
+-	O
+dominant	O
+lung	B-ANAT
+injury	O
+were	O
+optimal	O
+at	O
+a	O
+PFC	O
+dose	O
+less	O
+than	O
+the	O
+FRC	B-PROC
+.	O
+
+We	O
+conducted	O
+(	O
+and	O
+reported	O
+elsewhere	O
+)	O
+a	O
+randomized	O
+,	O
+double	O
+-	O
+masked	O
+,	O
+placebo	O
+-	O
+controlled	O
+trial	O
+calcium	B-CHED
+supplementation	O
+of	O
+4589	O
+healthy	O
+nulliparas	B-PROC
+assigned	O
+at	O
+13	O
+-	O
+21	O
+weeks	O
+'	O
+gestation	B-PROC
+.	O
+
+Significantly	O
+increased	O
+maternal	O
+morbidities	O
+included	O
+increased	O
+cesarean	O
+deliveries	O
+,	O
+abruptio	B-DISO
+placentae	I-DISO
+,	O
+and	O
+acute	O
+renal	B-ANAT
+dysfunction	O
+;	O
+and	O
+significantly	O
+increased	O
+perinatal	O
+morbidities	O
+included	O
+respiratory	B-DISO
+distress	I-DISO
+syndrome	I-DISO
+,	O
+ventilatory	O
+support	O
+,	O
+and	O
+fetal	B-DISO
+growth	B-PROC
+restriction	I-DISO
+.	O
+
+Air	B-CHED
+leaks	O
+developed	O
+in	O
+22	O
+of	O
+80	O
+patients	O
+or	O
+in	O
+27	O
+.	O
+5	O
+%.	O
+
+Multiple	O
+logistic	O
+regression	O
+analysis	O
+showed	O
+that	O
+only	O
+V	O
+(	O
+T	O
+)	O
+was	O
+independently	O
+associated	O
+with	O
+the	O
+development	B-PROC
+of	O
+AL	O
+in	O
+children	O
+with	O
+primary	O
+severe	O
+respiratory	B-DISO
+disease	I-DISO
+(	O
+r	O
+(	O
+2	O
+)	O
+=	O
+-	O
+0	O
+.	O
+38	O
+,	O
+P	O
+=	O
+0	O
+.	O
+01	O
+).	O
+
+In	O
+conclusion	O
+,	O
+MV	O
+will	O
+produce	O
+AL	O
+,	O
+particularly	O
+when	O
+high	O
+peak	O
+airway	B-ANAT
+pressures	O
+(	O
+barotrauma	O
+)	O
+or	O
+large	O
+tidal	O
+volumes	O
+(	O
+volotrauma	O
+)	O
+are	O
+delivered	O
+by	O
+the	O
+ventilator	O
+.	O
+
+Sepsis	B-DISO
+,	O
+MOSF	O
+,	O
+and	O
+lung	B-ANAT
+superinfection	B-DISO
+with	O
+Pseudomonas	B-SPEC
+or	O
+Candida	B-SPEC
+species	B-SPEC
+may	O
+be	O
+also	O
+important	O
+factors	O
+in	O
+the	O
+development	B-PROC
+of	O
+AL	O
+in	O
+critically	B-DISO
+ill	I-DISO
+children	O
+.	O
+
+The	O
+smallest	O
+N	B-PRGE
+protein	I-PRGE
+fragment	O
+which	O
+retained	O
+RNA	O
+-	O
+binding	B-PROC
+activity	I-PROC
+was	O
+a	O
+55	O
+aa	O
+segment	O
+containing	O
+residues	O
+177	O
+-	O
+231	O
+which	O
+bound	O
+viral	O
+RNA	O
+with	O
+a	O
+K	O
+(	O
+d	O
+)	O
+of	O
+32	O
+nM	O
+.	O
+A	O
+consensus	O
+viral	O
+sequence	O
+recognized	O
+by	O
+the	O
+N	B-PRGE
+protein	I-PRGE
+was	O
+inferred	O
+from	O
+these	O
+studies	O
+;	O
+AAUCYAAAC	O
+was	O
+identified	O
+to	O
+be	O
+the	O
+potential	O
+minimum	O
+ligand	B-PROC
+for	O
+the	O
+N	B-PRGE
+protein	I-PRGE
+.	O
+
+The	O
+study	O
+was	O
+carried	O
+out	O
+on	O
+71	O
+faecal	B-ANAT
+samples	O
+of	O
+pups	O
+with	O
+enteritis	B-DISO
+.	O
+
+An	O
+alternative	O
+function	O
+of	O
+the	O
+sialic	B-FUNC
+acid	I-FUNC
+binding	B-PROC
+activity	I-PROC
+-	O
+accessory	O
+binding	B-FUNC
+to	O
+intestinal	B-ANAT
+tissues	B-ANAT
+-	O
+is	O
+also	O
+discussed	O
+.	O
+
+TITLE	O
+:	O
+Acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+in	O
+children	O
+with	O
+acute	O
+iron	O
+poisoning	O
+:	O
+the	O
+role	O
+of	O
+intravenous	O
+desferrioxamine	O
+.	O
+
+TITLE	O
+:	O
+Characterization	O
+of	O
+the	O
+coronavirus	B-SPEC
+mouse	B-DISO
+hepatitis	I-DISO
+virus	B-SPEC
+strain	O
+A59	O
+small	O
+membrane	B-COMP
+protein	B-CHED
+E	O
+.	O
+ABSTRACT	O
+:	O
+The	O
+small	O
+envelope	O
+(	O
+E	O
+)	O
+protein	B-CHED
+has	O
+recently	O
+been	O
+shown	O
+to	O
+play	O
+an	O
+essential	O
+role	O
+in	O
+the	O
+assembly	O
+of	O
+coronaviruses	O
+.	O
+
+Since	O
+little	O
+is	O
+known	O
+about	O
+this	O
+generally	O
+low	O
+-	O
+abundance	O
+virion	B-COMP
+component	O
+,	O
+we	O
+have	O
+characterized	O
+the	O
+E	O
+protein	B-CHED
+of	O
+mouse	B-DISO
+hepatitis	I-DISO
+virus	B-SPEC
+strain	O
+A59	O
+(	O
+MHV	B-SPEC
+-	O
+A59	O
+),	O
+an	O
+83	O
+-	O
+residue	O
+polypeptide	B-CHED
+.	O
+
+The	O
+protein	B-CHED
+appeared	O
+to	O
+be	O
+quite	O
+stable	O
+both	O
+during	O
+infection	B-DISO
+and	O
+when	O
+expressed	B-PROC
+individually	O
+using	O
+a	O
+vaccinia	B-SPEC
+virus	I-SPEC
+expression	B-PROC
+system	O
+.	O
+
+The	O
+absence	O
+of	O
+both	O
+Fas	B-DISO
+-	O
+and	O
+perforin	B-PRGE
+-	O
+mediated	O
+cytolysis	B-PROC
+resulted	O
+in	O
+an	O
+uncontrolled	O
+infection	B-DISO
+,	O
+suggesting	O
+a	O
+redundancy	O
+of	O
+cytolytic	O
+pathways	B-PROC
+to	O
+control	O
+virus	B-PROC
+replication	I-PROC
+.	O
+
+ABSTRACT	O
+:	O
+First	O
+,	O
+to	O
+determine	O
+whether	O
+the	O
+severity	O
+of	O
+shock	O
+,	O
+as	O
+measured	O
+by	O
+systemic	O
+hypotension	O
+and	O
+metabolic	O
+acidosis	O
+,	O
+is	O
+significantly	O
+associated	O
+with	O
+a	O
+higher	O
+risk	O
+of	O
+acute	O
+lung	B-ANAT
+injury	O
+in	O
+patients	O
+with	O
+severe	O
+trauma	O
+.	O
+
+Plasma	B-ANAT
+and	O
+bronchoalveolar	B-ANAT
+lavage	I-ANAT
+fluid	I-ANAT
+was	O
+collected	O
+regularly	O
+during	O
+the	O
+first	O
+10	O
+days	O
+after	O
+trauma	O
+or	O
+onset	O
+of	O
+sepsis	B-DISO
+.	O
+
+Our	O
+results	O
+show	O
+that	O
+the	O
+prone	O
+position	O
+may	O
+be	O
+a	O
+useful	O
+maneuver	O
+in	O
+treating	O
+patients	O
+with	O
+severe	O
+hypoxemia	O
+due	O
+to	O
+pulmonary	B-DISO
+edema	I-DISO
+.	O
+
+In	O
+contrast	O
+,	O
+the	O
+presence	O
+of	O
+fibrosis	B-DISO
+,	O
+as	O
+in	O
+late	O
+ARDS	B-DISO
+and	O
+pulmonary	B-DISO
+fibrosis	I-DISO
+,	O
+predisposes	O
+to	O
+nonresponsiveness	O
+to	O
+prone	O
+positioning	O
+.	O
+
+TITLE	O
+:	O
+Alveolar	B-ANAT
+fibrin	O
+formation	B-PROC
+caused	O
+by	O
+enhanced	O
+procoagulant	O
+and	O
+depressed	O
+fibrinolytic	O
+capacities	O
+in	O
+severe	O
+pneumonia	O
+.	O
+
+Acute	O
+inflammatory	O
+lung	B-ANAT
+injury	O
+,	O
+whether	O
+triggered	O
+by	O
+nonpulmonary	O
+systemic	O
+events	O
+or	O
+primary	O
+lung	B-DISO
+infection	I-DISO
+,	O
+is	O
+thus	O
+consistently	O
+characterized	O
+by	O
+both	O
+enhanced	O
+procoagulant	O
+and	O
+depressed	O
+fibrinolytic	O
+activities	O
+in	O
+the	O
+alveolar	B-ANAT
+lining	O
+layer	B-ANAT
+,	O
+with	O
+the	O
+appearance	O
+of	O
+fibrin	O
+formation	B-PROC
+in	O
+this	O
+compartment	B-ANAT
+.	O
+
+Profile	O
+and	O
+extent	O
+of	O
+changes	O
+in	O
+severe	O
+pneumonia	B-DISO
+demanding	O
+respirator	O
+therapy	O
+are	O
+virtually	O
+identical	O
+to	O
+those	O
+in	O
+ARDS	B-DISO
+,	O
+whereas	O
+somewhat	O
+less	O
+prominent	O
+alterations	O
+of	O
+the	O
+alveolar	B-ANAT
+hemostatic	B-PROC
+balance	B-PROC
+are	O
+noted	O
+in	O
+spontaneously	O
+breathing	B-PROC
+patients	O
+with	O
+pneumonia	B-DISO
+.	O
+
+Sequence	O
+analysis	O
+of	O
+the	O
+genomic	O
+RNA	O
+from	O
+the	O
+four	O
+heterologous	O
+IBV	B-SPEC
+strains	O
+(	O
+M41	O
+,	O
+H120	O
+,	O
+HV10	O
+and	O
+D207	O
+)	O
+identified	O
+nucleotide	B-CHED
+differences	O
+of	O
+up	O
+to	O
+17	O
+%	O
+within	O
+the	O
+leader	O
+sequence	O
+and	O
+up	O
+to	O
+4	O
+.	O
+3	O
+%	O
+within	O
+the	O
+whole	O
+of	O
+the	O
+adjacent	O
+5	O
+'	O
+untranslated	O
+region	O
+(	O
+UTR	O
+).	O
+
+For	O
+the	O
+group	O
+of	O
+patients	O
+with	O
+ARDS	B-DISO
+as	O
+a	O
+complication	B-DISO
+of	O
+pneumonia	B-DISO
+mortality	O
+was	O
+only	O
+40	O
+%.	O
+
+ABSTRACT	O
+:	O
+Prone	O
+ventilation	O
+improves	O
+oxygenation	B-PROC
+in	O
+selected	O
+patients	O
+with	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+(	O
+ARDS	B-DISO
+).	O
+
+TITLE	O
+:	O
+Cocaine	B-CHED
+causes	O
+increased	O
+type	B-PROC
+I	I-PROC
+interferon	I-PROC
+secretion	I-PROC
+by	O
+both	O
+L929	O
+cells	B-COMP
+and	O
+murine	B-SPEC
+macrophages	B-ANAT
+.	O
+
+Examine	O
+live	O
+animals	O
+,	O
+i	O
+.	O
+e	O
+.,	O
+obtain	O
+serum	B-COMP
+samples	O
+from	O
+a	O
+random	O
+population	O
+,	O
+take	O
+rectal	O
+temperatures	O
+of	O
+affected	O
+neonates	O
+,	O
+and	O
+evaluate	O
+fecal	B-ANAT
+pH	O
+.	O
+5	O
+.	O
+
+The	O
+causes	O
+of	O
+ARDS	B-DISO
+were	O
+pneumonia	B-DISO
+(	O
+n	O
+=	O
+14	O
+),	O
+extra	O
+-	O
+lung	B-DISO
+infection	I-DISO
+(	O
+n	O
+=	O
+5	O
+),	O
+and	O
+noninfectious	O
+systemic	B-DISO
+inflammatory	I-DISO
+response	I-DISO
+syndrome	I-DISO
+(	O
+n	O
+=	O
+8	O
+).	O
+
+ABSTRACT	O
+:	O
+Acute	O
+severe	O
+pancreatitis	B-DISO
+is	O
+often	O
+associated	O
+with	O
+acute	O
+lung	B-ANAT
+injury	O
+,	O
+including	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+.	O
+
+The	O
+animals	B-SPEC
+were	O
+mechanically	O
+ventilated	O
+with	O
+a	O
+tidal	O
+volume	O
+of	O
+10	O
+mL	O
+/	O
+kg	O
+and	O
+an	O
+Fio2	O
+of	O
+0	O
+.	O
+4	O
+,	O
+and	O
+thereafter	O
+,	O
+they	O
+were	O
+randomly	O
+assigned	O
+to	O
+three	O
+groups	O
+.	O
+
+Light	O
+microscopic	O
+findings	O
+(	O
+lung	B-ANAT
+injury	O
+score	O
+and	O
+number	O
+of	O
+neutrophils	B-ANAT
+)	O
+were	O
+compared	O
+between	O
+the	O
+three	O
+groups	O
+.	O
+
+TITLE	O
+:	O
+Four	O
+proteins	B-CHED
+processed	O
+from	O
+the	O
+replicase	B-PRGE
+gene	I-PRGE
+polyprotein	O
+of	O
+mouse	B-DISO
+hepatitis	I-DISO
+virus	B-SPEC
+colocalize	O
+in	O
+the	O
+cell	O
+periphery	O
+and	O
+adjacent	O
+to	O
+sites	O
+of	O
+virion	B-PROC
+assembly	I-PROC
+.	O
+
+However	O
+,	O
+in	O
+perinuclear	O
+regions	O
+the	O
+gene	O
+1	O
+proteins	B-CHED
+and	O
+nucleocapsid	B-COMP
+were	O
+intercalated	O
+with	O
+sites	O
+of	O
+M	B-PRGE
+protein	I-PRGE
+localization	O
+.	O
+
+Blood	B-ANAT
+samples	I-ANAT
+were	O
+taken	O
+on	O
+Days	O
+0	O
+,	O
+1	O
+,	O
+3	O
+,	O
+7	O
+,	O
+and	O
+10	O
+for	O
+red	B-ANAT
+blood	I-ANAT
+cell	I-ANAT
+(	O
+RBC	B-ANAT
+),	O
+white	B-ANAT
+blood	I-ANAT
+cell	I-ANAT
+(	O
+WBC	B-ANAT
+),	O
+and	O
+platelet	B-ANAT
+counts	O
+,	O
+pH	O
+,	O
+PO	O
+(	O
+2	O
+),	O
+PCO	B-DISO
+(	O
+2	O
+),	O
+carbon	B-CHED
+dioxide	I-CHED
+content	O
+(	O
+HCO	O
+(	O
+3	O
+)(-))	O
+measurements	O
+,	O
+and	O
+renal	B-ANAT
+and	O
+liver	O
+tests	O
+.	O
+
+Treatment	O
+with	O
+the	O
+anti	B-PRGE
+-	I-PRGE
+CD18	I-PRGE
+monoclonal	I-PRGE
+antibody	I-PRGE
+reduced	O
+mortality	O
+by	O
+approximately	O
+40	O
+%	O
+(	O
+p	O
+<	O
+0	O
+.	O
+05	O
+).	O
+
+PO	O
+(	O
+2	O
+)	O
+was	O
+higher	O
+in	O
+these	O
+treated	O
+animals	B-SPEC
+than	O
+in	O
+the	O
+control	O
+animals	B-SPEC
+throughout	O
+the	O
+study	O
+(	O
+p	O
+<	O
+0	O
+.	O
+05	O
+on	O
+Day	O
+1	O
+,	O
+3	O
+,	O
+and	O
+10	O
+).	O
+
+PMN	B-PROC
+infiltration	B-DISO
+correlated	O
+with	O
+the	O
+levels	O
+of	O
+PO	O
+(	O
+2	O
+)	O
+(	O
+p	O
+<	O
+0	O
+.	O
+001	O
+).	O
+
+Nocturnal	O
+sleep	B-PROC
+efficiency	O
+was	O
+severely	O
+reduced	O
+(	O
+38	O
++/-	O
+
+Inoculation	O
+of	O
+DNA	O
+plasmid	O
+expressing	O
+the	O
+carboxyl	O
+terminus	O
+of	O
+Gray	O
+strain	O
+N	O
+resulted	O
+in	O
+induction	O
+of	O
+CTL	B-ANAT
+that	O
+cross	O
+-	O
+react	O
+with	O
+two	O
+distinct	O
+IBV	B-SPEC
+strains	O
+.	O
+
+The	O
+ability	O
+of	O
+the	O
+infected	O
+birds	B-SPEC
+to	O
+mount	O
+an	O
+optimum	O
+humoral	B-PROC
+immune	I-PROC
+response	I-PROC
+as	O
+well	O
+as	O
+normal	O
+macrophage	B-ANAT
+functions	O
+such	O
+as	O
+phagocytosis	B-PROC
+may	O
+be	O
+impaired	B-DISO
+.	O
+
+ABSTRACT	O
+:	O
+All	O
+stages	O
+of	O
+degeneration	B-DISO
+and	O
+regeneration	B-PROC
+in	O
+chicken	B-SPEC
+tracheal	B-ANAT
+epithelium	I-ANAT
+were	O
+studied	O
+morphologically	O
+following	O
+an	O
+intratracheal	O
+inoculation	O
+of	O
+infectious	B-DISO
+bronchitis	B-DISO
+virus	B-SPEC
+(	O
+IBV	B-SPEC
+).	O
+
+At	O
+this	O
+time	O
+,	O
+labelling	O
+index	O
+of	O
+bromodeoxyuridine	B-CHED
+(	O
+BrdU	B-CHED
+)	O
+in	O
+the	O
+basal	B-ANAT
+cells	I-ANAT
+showed	O
+significantly	O
+high	O
+value	O
+compared	O
+with	O
+control	O
+.	O
+
+At	O
+6	O
+to	O
+11	O
+d	O
+.	O
+p	O
+.	O
+i	O
+.,	O
+the	O
+ciliated	B-ANAT
+columnar	I-ANAT
+epithelia	O
+increased	O
+rapidly	O
+in	O
+number	O
+,	O
+and	O
+returned	O
+to	O
+the	O
+normal	O
+appearance	O
+except	O
+for	O
+non	O
+-	O
+ciliated	O
+patch	O
+by	O
+13	O
+d	O
+.	O
+p	O
+.	O
+i	O
+.	O
+
+We	O
+analyzed	O
+the	O
+nucleotide	B-CHED
+sequence	O
+of	O
+a	O
+highly	O
+virulent	O
+strain	O
+MHV	B-SPEC
+-	O
+2	O
+M	O
+-	O
+coding	O
+region	O
+and	O
+demonstrated	O
+that	O
+MHV	B-SPEC
+-	O
+2	O
+had	O
+a	O
+unique	O
+amino	B-CHED
+acid	I-CHED
+,	O
+Asn	B-CHED
+,	O
+at	O
+position	O
+2	O
+at	O
+the	O
+conserved	O
+O	O
+-	O
+glycosylation	B-PROC
+site	O
+.	O
+
+The	O
+antibody	B-PROC
+responses	I-PROC
+to	O
+BCV	B-SPEC
+were	O
+followed	O
+in	O
+milk	O
+and	O
+serum	B-COMP
+from	O
+six	O
+dairy	O
+cows	B-SPEC
+and	O
+in	O
+serum	B-COMP
+from	O
+four	O
+calves	O
+for	O
+a	O
+period	O
+of	O
+1	O
+year	O
+after	O
+an	O
+outbreak	O
+of	O
+winter	B-DISO
+dysentery	I-DISO
+(	O
+WD	O
+).	O
+
+A	O
+reproducible	O
+significant	O
+delay	O
+in	O
+mortality	O
+observed	O
+in	O
+mice	B-SPEC
+to	O
+which	O
+plasma	B-ANAT
+was	O
+passively	O
+transferred	O
+,	O
+together	O
+with	O
+the	O
+presence	O
+of	O
+specific	O
+in	O
+vitro	O
+neutralizing	O
+antiviral	B-CHED
+Ab3	O
+identified	O
+the	O
+humoral	B-PROC
+immune	I-PROC
+response	I-PROC
+as	O
+the	O
+major	O
+element	O
+responsible	O
+for	O
+protection	O
+.	O
+
+The	O
+results	O
+also	O
+indicate	O
+that	O
+within	O
+a	O
+1	O
+-	O
+yr	O
+period	O
+Ark	O
+-	O
+type	O
+IBV	B-SPEC
+in	O
+Mississippi	O
+was	O
+spread	O
+with	O
+little	O
+or	O
+no	O
+change	O
+in	O
+its	O
+genetic	O
+sequence	O
+.	O
+
+ABSTRACT	O
+:	O
+To	O
+evaluate	O
+if	O
+the	O
+preexistant	O
+filling	O
+state	O
+,	O
+assessed	O
+by	O
+right	O
+atrial	O
+pressure	O
+(	O
+RAP	O
+),	O
+pulmonary	B-ANAT
+artery	I-ANAT
+occlusion	O
+pressure	O
+(	O
+PAOP	O
+),	O
+and	O
+right	O
+ventricular	B-PROC
+end	I-PROC
+-	I-PROC
+diastolic	I-PROC
+volume	I-PROC
+index	O
+(	O
+EDVI	O
+),	O
+would	O
+define	O
+the	O
+subsequent	O
+hemodynamic	B-PROC
+effects	O
+of	O
+increases	O
+in	O
+airway	B-ANAT
+pressure	O
+(	O
+Paw	B-ANAT
+).	O
+
+Apneic	B-DISO
+positive	O
+Paw	B-ANAT
+decreased	O
+cardiac	B-ANAT
+output	O
+mainly	O
+by	O
+reducing	O
+venous	B-ANAT
+return	O
+.	O
+
+TITLE	O
+:	O
+Contributions	O
+of	O
+CD8	B-PRGE
++	I-PRGE
+T	I-PRGE
+cells	O
+and	O
+viral	O
+spread	O
+to	O
+demyelinating	B-DISO
+disease	I-DISO
+.	O
+
+ABSTRACT	O
+:	O
+The	O
+transmissible	O
+gastroenteritis	B-DISO
+coronavirus	B-SPEC
+(	O
+TGEV	B-SPEC
+),	O
+like	O
+many	O
+other	O
+viruses	B-SPEC
+,	O
+exerts	B-PROC
+much	O
+of	O
+its	O
+cytopathic	B-DISO
+effect	I-DISO
+through	O
+the	O
+induction	B-PROC
+of	I-PROC
+apoptosis	I-PROC
+of	O
+its	O
+host	B-COMP
+cell	I-COMP
+.	O
+
+Apoptosis	B-PATH
+is	O
+coordinated	O
+by	O
+a	O
+family	B-SPEC
+of	O
+cysteine	B-PRGE
+proteases	I-PRGE
+,	O
+called	O
+caspases	O
+,	O
+that	O
+are	O
+activated	O
+during	O
+apoptosis	B-PATH
+and	O
+participate	O
+in	O
+dismantling	O
+the	O
+cell	B-COMP
+by	O
+cleaving	O
+key	O
+structural	O
+and	O
+regulatory	O
+proteins	B-CHED
+.	O
+
+TITLE	O
+:	O
+Subgenomic	O
+negative	O
+-	O
+strand	O
+RNA	O
+function	O
+during	O
+mouse	B-DISO
+hepatitis	I-DISO
+virus	B-DISO
+infection	I-DISO
+.	O
+
+We	O
+are	O
+interested	O
+in	O
+the	O
+role	O
+of	O
+E	O
+in	O
+the	O
+intracellular	B-COMP
+targeting	B-PROC
+of	O
+infectious	B-DISO
+bronchitis	B-DISO
+virus	B-SPEC
+(	O
+IBV	B-SPEC
+)	O
+membrane	B-COMP
+proteins	B-CHED
+.	O
+
+Thus	O
+,	O
+even	O
+though	O
+IBV	B-SPEC
+E	O
+is	O
+present	O
+at	O
+low	O
+levels	O
+in	O
+virions	B-COMP
+,	O
+it	O
+is	O
+apparently	O
+expressed	B-PROC
+at	O
+high	O
+levels	O
+in	O
+infected	O
+cells	B-COMP
+near	O
+the	O
+site	O
+of	O
+virus	B-PROC
+assembly	I-PROC
+.	O
+
+To	O
+determine	O
+the	O
+stimulus	O
+for	O
+systemic	O
+inflammation	B-DISO
+,	O
+rats	B-SPEC
+treated	O
+with	O
+cryoablation	O
+had	O
+either	O
+immediate	O
+resection	O
+of	O
+the	O
+ablated	O
+segment	O
+or	O
+delayed	O
+resection	O
+after	O
+a	O
+15	O
+-	O
+minute	O
+thawing	O
+interval	O
+.	O
+
+Lung	B-DISO
+inflammation	I-DISO
+is	O
+associated	O
+with	O
+the	O
+thawing	O
+phase	O
+of	O
+cryoablation	O
+and	O
+may	O
+be	O
+related	O
+to	O
+soluble	O
+mediator	O
+(	O
+s	O
+)	O
+released	O
+from	O
+the	O
+cryoablated	O
+tissue	B-ANAT
+.	O
+
+These	O
+findings	O
+correlate	O
+the	O
+clinical	O
+observation	O
+of	O
+an	O
+increased	O
+incidence	O
+of	O
+multisystem	O
+injury	O
+,	O
+including	O
+adult	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+(	O
+ARDS	B-DISO
+),	O
+after	O
+cryoablation	O
+but	O
+not	O
+RFA	O
+.	O
+
+Immediate	O
+resection	O
+of	O
+the	O
+cryoablated	O
+liver	B-ANAT
+tissue	I-ANAT
+prevented	O
+NF	B-PROC
+-	I-PROC
+kappaB	I-PROC
+activation	I-PROC
+and	O
+lung	B-ANAT
+injury	O
+;	O
+however	O
+,	O
+pulmonary	B-ANAT
+inflammatory	O
+changes	O
+were	O
+present	O
+when	O
+as	O
+little	O
+as	O
+a	O
+15	O
+-	O
+minute	O
+thaw	O
+interval	O
+preceded	O
+hepatic	B-ANAT
+resection	O
+.	O
+
+In	O
+visceral	O
+organs	B-ANAT
+,	O
+necrotic	B-PROC
+cells	B-COMP
+were	O
+observed	O
+in	O
+the	O
+hematopoietic	B-ANAT
+tissue	I-ANAT
+,	O
+the	O
+spleen	B-ANAT
+and	O
+the	O
+intestinal	B-ANAT
+tissues	B-ANAT
+as	O
+well	O
+as	O
+in	O
+cardiac	B-ANAT
+muscle	I-ANAT
+fibers	O
+which	O
+showed	O
+no	O
+signs	O
+of	O
+bacterial	O
+invasion	B-DISO
+.	O
+
+Carp	B-DISO
+experimentally	O
+inoculated	O
+with	O
+the	O
+cultured	O
+virus	B-SPEC
+showed	O
+virus	B-SPEC
+transmission	O
+,	O
+and	O
+the	O
+same	O
+pathological	O
+signs	O
+of	O
+the	O
+disease	O
+and	O
+mortalities	O
+as	O
+in	O
+natural	O
+infections	B-DISO
+.	O
+
+The	O
+depth	O
+of	O
+disorders	O
+in	O
+the	O
+gas	B-ENZY
+exchange	O
+function	O
+of	O
+the	O
+lungs	B-ANAT
+clearly	O
+correlates	O
+with	O
+the	O
+severity	O
+of	O
+burn	O
+injury	O
+and	O
+the	O
+terms	O
+of	O
+the	O
+beginning	O
+of	O
+respiratory	O
+support	O
+.	O
+
+ABSTRACT	O
+:	O
+Several	O
+diagnostic	O
+methods	O
+including	O
+immunofluorescence	O
+,	O
+enzyme	O
+-	O
+linked	O
+immunosorbent	O
+assay	O
+,	O
+polymerase	O
+chain	O
+reaction	O
+and	O
+immunohistochemistry	O
+have	O
+been	O
+developed	O
+for	O
+the	O
+detection	O
+of	O
+porcine	B-SPEC
+epidemic	I-SPEC
+diarrhea	I-SPEC
+virus	I-SPEC
+(	O
+PEDV	B-SPEC
+).	O
+
+In	O
+both	O
+the	O
+immunohistochemical	O
+methods	O
+,	O
+PEDV	B-SPEC
+antigens	B-CHED
+were	O
+detected	O
+in	O
+the	O
+cytoplasm	B-COMP
+of	O
+villous	O
+enterocytes	B-ANAT
+and	O
+in	O
+the	O
+macrophages	B-ANAT
+infiltrated	B-DISO
+in	O
+the	O
+lamina	B-ANAT
+propria	I-ANAT
+at	O
+18	O
+to	O
+110	O
+hr	O
+post	O
+inoculation	O
+.	O
+
+ABSTRACT	O
+:	O
+Previous	O
+studies	O
+indicated	O
+that	O
+the	O
+nucleocapsid	O
+(	O
+N	O
+)	O
+protein	B-CHED
+of	O
+infectious	B-DISO
+bronchitis	B-DISO
+virus	B-SPEC
+(	O
+IBV	B-SPEC
+)	O
+interacted	O
+with	O
+specific	O
+sequences	O
+in	O
+the	O
+3	O
+'	O
+non	O
+-	O
+coding	O
+region	O
+of	O
+IBV	B-SPEC
+RNA	O
+.	O
+
+TITLE	O
+:	O
+Liver	B-ANAT
+-	O
+specific	O
+alpha	B-PRGE
+2	I-PRGE
+interferon	I-PRGE
+gene	I-PRGE
+expression	O
+results	O
+in	O
+protection	O
+from	O
+induced	O
+hepatitis	B-DISO
+.	O
+
+In	O
+single	O
+SIV	B-DISO
+infections	B-DISO
+,	O
+typical	O
+signs	O
+of	O
+swine	B-SPEC
+""""	O
+flu	B-DISO
+""""	O
+were	O
+tightly	O
+correlated	O
+with	O
+an	O
+excessive	O
+and	O
+coordinate	O
+production	O
+of	O
+the	O
+3	O
+cytokines	O
+examined	O
+.	O
+
+To	O
+explore	O
+the	O
+mechanism	B-PROC
+of	I-PROC
+action	I-PROC
+of	O
+these	O
+inhibitors	B-CHED
+,	O
+various	O
+novel	O
+styrylquinoline	B-CHED
+derivatives	O
+were	O
+synthesized	O
+and	O
+tested	O
+against	O
+HIV	B-SPEC
+-	I-SPEC
+1	I-SPEC
+IN	O
+and	O
+in	O
+cell	B-COMP
+-	O
+based	O
+assays	O
+.	O
+
+The	O
+aim	O
+of	O
+this	O
+study	O
+was	O
+to	O
+search	O
+for	O
+an	O
+interrelationship	O
+between	O
+the	O
+volume	O
+of	O
+the	O
+bronchial	B-ANAT
+secretion	I-ANAT
+and	O
+the	O
+improvement	O
+of	O
+the	O
+PaO2	O
+/	O
+FIO2	O
+ratio	O
+during	O
+prone	O
+positioning	O
+,	O
+with	O
+NO	O
+inhalation	B-PROC
+or	O
+not	O
+.	O
+
+CONCLUSIONS	O
+:	O
+In	O
+patients	O
+with	O
+little	O
+or	O
+moderate	O
+secretions	B-ANAT
+,	O
+the	O
+improvement	O
+observed	O
+in	O
+oxygenation	B-PROC
+,	O
+with	O
+or	O
+without	O
+NO	O
+,	O
+does	O
+not	O
+depend	O
+on	O
+their	O
+volume	O
+.	O
+
+Seven	O
+patients	O
+were	O
+admitted	O
+to	O
+the	O
+ICU	O
+,	O
+of	O
+whom	O
+three	O
+died	B-PROC
+(	O
+4	O
+%	O
+in	O
+hospital	O
+case	O
+-	O
+fatality	O
+rate	O
+).	O
+
+CONCLUSIONS	O
+:	O
+As	O
+P	B-SPEC
+.	I-SPEC
+falciparum	I-SPEC
+is	O
+a	O
+potentially	O
+life	O
+-	O
+threatening	O
+disease	O
+,	O
+reliable	O
+criteria	O
+for	O
+ICU	O
+admission	O
+should	O
+be	O
+defined	O
+and	O
+risk	O
+factors	O
+identified	O
+.	O
+
+CNI	O
+-	O
+1493	O
+,	O
+which	O
+attenuates	O
+mediator	O
+production	O
+through	O
+p38	B-PRGE
+MAP	B-ENZY
+kinase	I-ENZY
+inhibition	B-PROC
+,	O
+was	O
+administered	O
+intraperitoneally	O
+to	O
+mice	B-SPEC
+while	O
+control	O
+animals	B-SPEC
+received	O
+saline	O
+.	O
+
+Elastase	B-PRGE
+-	O
+treated	O
+animals	B-SPEC
+with	O
+mediator	O
+production	O
+inhibited	O
+(	O
+CNI	O
+-	O
+1493	O
+)	O
+had	O
+attenuated	O
+hepatic	B-ANAT
+enzymes	O
+,	O
+MPO	B-FUNC
+activity	O
+,	O
+TNF	B-PRGE
+protein	I-PRGE
+,	O
+and	O
+TNF	B-PRGE
+mRNA	I-PRGE
+.	O
+
+Activation	O
+of	O
+nuclear	B-PRGE
+factor	I-PRGE
+kappa	I-PRGE
+B	I-PRGE
+occurred	O
+30	O
+min	O
+after	O
+elastase	O
+administration	O
+.	O
+
+Activation	O
+of	O
+nuclear	B-PRGE
+factor	I-PRGE
+kappa	I-PRGE
+B	I-PRGE
+occurred	O
+30	O
+min	O
+after	O
+elastase	O
+administration	O
+.	O
+
+Randomized	O
+controlled	O
+trials	O
+comparing	O
+HFOV	O
+and	O
+CV	O
+in	O
+preterm	O
+or	O
+low	O
+birth	B-PROC
+weight	O
+infants	O
+with	O
+pulmonary	B-ANAT
+dysfunction	O
+,	O
+mainly	O
+due	O
+to	O
+RDS	O
+,	O
+who	O
+are	O
+to	O
+be	O
+given	O
+IPPV	O
+.	O
+
+All	O
+randomized	O
+controlled	O
+trials	O
+of	O
+elective	O
+high	O
+frequency	O
+jet	O
+ventilation	O
+versus	O
+conventional	O
+ventilation	O
+in	O
+preterm	O
+infants	O
+born	O
+at	O
+less	O
+than	O
+35	O
+weeks	O
+GA	O
+or	O
+with	O
+a	O
+birth	O
+weight	O
+less	O
+than	O
+2000	O
+gms	O
+with	O
+respiratory	B-DISO
+distress	I-DISO
+were	O
+included	O
+in	O
+the	O
+systematic	O
+review	O
+.	O
+
+Overall	O
+analysis	O
+of	O
+the	O
+three	O
+trials	O
+showed	O
+that	O
+HFJV	O
+is	O
+associated	O
+with	O
+a	O
+reduction	O
+in	O
+CLD	B-DISO
+at	O
+36	O
+weeks	O
+postmenstrual	O
+age	O
+in	O
+survivors	O
+[	O
+RR	O
+0	O
+.	O
+58	O
+(	O
+0	O
+.	O
+34	O
+,	O
+0	O
+.	O
+98	O
+),	O
+RD	O
+-	O
+0	O
+.	O
+138	O
+(-	O
+0	O
+.	O
+268	O
+,	O
+-	O
+0	O
+.	O
+007	O
+),	O
+NNT	O
+7	O
+(	O
+4	O
+,	O
+90	O
+)].	O
+
+The	O
+overall	O
+analysis	O
+shows	O
+a	O
+benefit	O
+in	O
+pulmonary	B-ANAT
+outcomes	O
+in	O
+the	O
+group	O
+electively	O
+ventilated	O
+with	O
+HFJV	O
+.	O
+
+Data	O
+regarding	O
+clinical	O
+outcomes	O
+including	O
+the	O
+incidence	O
+of	O
+pneumothorax	B-DISO
+,	O
+patent	B-DISO
+ductus	I-DISO
+arteriosus	I-DISO
+,	O
+pulmonary	B-DISO
+interstitial	B-ANAT
+emphysema	I-DISO
+,	O
+pulmonary	B-DISO
+hemorrhage	I-DISO
+,	O
+necrotizing	B-DISO
+enterocolitis	I-DISO
+,	O
+retinopathy	B-DISO
+of	I-DISO
+prematurity	I-DISO
+,	O
+intraventricular	B-DISO
+hemorrhage	I-DISO
+(	O
+any	O
+and	O
+severe	O
+IVH	O
+),	O
+bronchopulmonary	B-DISO
+dysplasia	I-DISO
+,	O
+chronic	B-DISO
+lung	I-DISO
+disease	I-DISO
+,	O
+neonatal	O
+mortality	O
+,	O
+mortality	O
+prior	O
+to	O
+hospital	O
+discharge	B-ANAT
+,	O
+bronchopulmonary	B-DISO
+dysplasia	I-DISO
+or	O
+death	B-PROC
+,	O
+and	O
+chronic	B-DISO
+lung	I-DISO
+disease	I-DISO
+or	O
+death	B-PROC
+were	O
+excerpted	O
+from	O
+the	O
+reports	O
+of	O
+the	O
+clinical	O
+trials	O
+by	O
+the	O
+reviewers	O
+.	O
+
+Four	O
+randomized	O
+controlled	O
+trials	O
+met	B-CHED
+selection	O
+criteria	O
+.	O
+
+ABSTRACT	O
+:	O
+This	O
+report	O
+describes	O
+the	O
+clinical	O
+and	O
+epidemiological	O
+findings	O
+of	O
+an	O
+outbreak	O
+of	O
+histoplasmosis	O
+in	O
+Brazil	O
+involving	O
+four	O
+persons	O
+of	O
+the	O
+same	O
+family	B-SPEC
+,	O
+one	O
+adult	O
+and	O
+three	O
+children	O
+.	O
+
+ABSTRACT	O
+:	O
+RNA	O
+viruses	B-SPEC
+have	O
+5	O
+'	O
+and	O
+3	O
+'	O
+untranslated	O
+regions	O
+(	O
+UTRs	O
+)	O
+that	O
+contain	O
+specific	O
+signals	O
+for	O
+RNA	B-PROC
+synthesis	I-PROC
+.	O
+
+The	O
+virus	B-SPEC
+infected	O
+a	O
+very	O
+limited	O
+part	O
+of	O
+the	O
+brain	B-ANAT
+,	O
+especially	O
+Purkinje	B-ANAT
+cells	I-ANAT
+in	O
+the	O
+cerebellum	B-ANAT
+and	O
+many	O
+neurons	B-ANAT
+in	O
+the	O
+pons	B-ANAT
+,	O
+without	O
+inducing	O
+an	O
+overt	O
+immunologic	B-PROC
+reaction	I-PROC
+from	O
+the	O
+host	B-COMP
+.	O
+
+The	O
+groups	O
+immunized	O
+with	O
+the	O
+CL	B-PRGE
+antigen	I-PRGE
+having	O
+an	O
+HA	O
+titer	O
+of	O
+4000	O
+or	O
+16	O
+000	O
+produced	O
+hemagglutination	B-PROC
+inhibition	B-PROC
+(	O
+HI	O
+)	O
+antibody	B-COMP
+titers	O
+of	O
+>	O
+320	O
+and	O
+serum	O
+neutralizing	O
+(	O
+SN	O
+)	O
+antibody	B-COMP
+titers	O
+of	O
+>	O
+1280	O
+.	O
+
+These	O
+groups	O
+of	O
+animals	B-SPEC
+showed	O
+no	O
+clinical	O
+abnormalities	O
+after	O
+challenge	O
+.	O
+
+In	O
+the	O
+groups	O
+immunized	O
+with	O
+CL	B-PRGE
+antigen	I-PRGE
+at	O
+an	O
+HA	O
+titer	O
+of	O
+1000	O
+or	O
+250	O
+,	O
+HI	O
+antibody	B-COMP
+titers	O
+were	O
+40	O
+to	O
+160	O
+and	O
+SN	O
+titers	O
+were	O
+80	O
+to	O
+640	O
+.	O
+
+The	O
+cattle	B-SPEC
+with	O
+HI	O
+antibody	B-COMP
+titers	O
+of	O
+>	O
+or	O
+=	O
+160	O
+and	O
+the	O
+SN	O
+titers	O
+of	O
+>	O
+or	O
+=	O
+640	O
+showed	O
+no	O
+clinical	O
+signs	O
+,	O
+but	O
+the	O
+cattle	B-SPEC
+with	O
+the	O
+HI	O
+antibody	B-COMP
+titer	O
+<	O
+80	O
+and	O
+the	O
+SN	O
+antibody	B-COMP
+titer	O
+<	O
+160	O
+developed	O
+watery	B-DISO
+diarrhea	I-DISO
+and	O
+fever	B-PROC
+after	O
+challenge	O
+.	O
+
+A	O
+32	O
+-	O
+yr	O
+-	O
+old	O
+woman	O
+with	O
+severe	O
+ARDS	B-DISO
+secondary	O
+to	O
+streptococcal	B-DISO
+sepsis	I-DISO
+.	O
+
+The	O
+patient	O
+had	O
+severe	O
+gas	B-ENZY
+exchange	O
+abnormalities	O
+because	O
+of	O
+acute	O
+lung	B-ANAT
+injury	O
+and	O
+marked	O
+lung	B-DISO
+collapse	I-DISO
+.	O
+
+The	O
+recruitment	B-DISO
+was	O
+maintained	O
+with	O
+25	O
+cm	O
+H2O	B-CHED
+of	O
+PEEP	O
+,	O
+which	O
+was	O
+much	O
+higher	O
+than	O
+the	O
+PEEP	B-CHED
+predicted	O
+by	O
+the	O
+lower	O
+inflection	O
+point	O
+(	O
+P	O
+(	O
+Flex	O
+))	O
+of	O
+the	O
+PV	O
+curve	O
+.	O
+
+A	O
+PV	O
+curve	O
+was	O
+measured	O
+that	O
+demonstrated	O
+a	O
+P	O
+(	O
+Flex	O
+)	O
+of	O
+16	O
+-	O
+18	O
+cm	O
+H2O	B-CHED
+.	O
+
+At	O
+the	O
+time	O
+of	O
+death	B-PROC
+,	O
+79	O
+%	O
+had	O
+a	O
+DNR	O
+order	B-SPEC
+and	O
+31	O
+%	O
+had	O
+an	O
+order	B-SPEC
+to	O
+withhold	O
+ventilator	O
+support	O
+.	O
+
+Surrogates	O
+indicated	O
+that	O
+one	O
+out	O
+of	O
+four	O
+patients	O
+died	B-PROC
+with	O
+severe	B-DISO
+pain	I-DISO
+and	O
+one	O
+out	O
+of	O
+three	O
+with	O
+severe	O
+confusion	B-DISO
+.	O
+
+Family	B-SPEC
+impact	O
+and	O
+physical	O
+and	O
+emotional	O
+suffering	B-DISO
+were	O
+substantial	O
+.	O
+
+ABSTRACT	O
+:	O
+A	O
+closed	O
+household	O
+of	O
+26	O
+cats	B-SPEC
+in	O
+which	O
+feline	B-SPEC
+coronavirus	B-SPEC
+(	O
+FCoV	O
+),	O
+feline	B-SPEC
+leukaemia	B-DISO
+virus	B-SPEC
+(	O
+FeLV	O
+)	O
+and	O
+feline	B-SPEC
+immunodeficiency	I-SPEC
+virus	I-SPEC
+(	O
+FIV	B-SPEC
+)	O
+were	O
+endemic	O
+was	O
+observed	O
+for	O
+10	O
+years	O
+.	O
+
+TITLE	O
+:	O
+Gill	B-ANAT
+-	I-SPEC
+associated	I-SPEC
+virus	I-SPEC
+of	O
+Penaeus	B-SPEC
+monodon	I-SPEC
+prawns	O
+:	O
+an	O
+invertebrate	O
+virus	B-SPEC
+with	O
+ORF1a	O
+and	O
+ORF1b	O
+genes	O
+related	O
+to	O
+arteri	O
+-	O
+and	O
+coronaviruses	O
+.	O
+
+Clones	O
+were	O
+generated	O
+from	O
+a	O
+approximately	O
+22	O
+kb	O
+dsRNA	B-CHED
+purified	O
+from	O
+lymphoid	B-ANAT
+organ	I-ANAT
+total	O
+RNA	O
+of	O
+GAV	O
+-	O
+infected	O
+prawns	O
+.	O
+
+Several	O
+tightly	O
+binding	B-FUNC
+phage	O
+were	O
+amplified	O
+and	O
+used	O
+directly	O
+as	O
+immunogens	O
+in	O
+BALB	O
+/	O
+c	O
+and	O
+C57BL	O
+/	O
+6	O
+mice	B-SPEC
+.	O
+
+Protection	O
+correlated	O
+with	O
+the	O
+presence	O
+of	O
+sufficient	O
+levels	O
+of	O
+specific	O
+antiviral	B-CHED
+antibodies	B-COMP
+recognizing	O
+the	O
+same	O
+immunodominant	O
+domain	O
+and	O
+13	O
+-	O
+mer	O
+peptide	B-CHED
+,	O
+located	O
+within	O
+the	O
+C	O
+-	O
+terminal	O
+S2	O
+subunit	O
+,	O
+as	O
+the	O
+selecting	O
+mAb	O
+.	O
+
+TITLE	O
+:	O
+Pulmonary	B-ANAT
+artery	I-ANAT
+catheterization	O
+and	O
+clinical	O
+outcomes	O
+:	O
+National	O
+Heart	B-ANAT
+,	O
+Lung	B-ANAT
+,	O
+and	O
+Blood	B-ANAT
+Institute	O
+and	O
+Food	O
+and	O
+Drug	O
+Administration	O
+Workshop	O
+Report	O
+.	O
+
+Approximately	O
+85	O
+participants	O
+were	O
+selected	O
+for	O
+their	O
+collective	O
+expertise	O
+in	O
+critical	O
+care	O
+,	O
+pulmonary	B-ANAT
+medicine	B-CHED
+,	O
+cardiovascular	B-ANAT
+medicine	B-CHED
+and	O
+surgery	O
+,	O
+pediatrics	O
+,	O
+nursing	B-PROC
+,	O
+biostatistics	O
+,	O
+and	O
+medical	O
+economics	O
+.	O
+
+TITLE	O
+:	O
+Mucosal	B-ANAT
+and	O
+systemic	O
+immune	B-PROC
+responses	I-PROC
+to	O
+chimeric	O
+fimbriae	B-COMP
+expressed	B-PROC
+by	O
+Salmonella	B-SPEC
+enterica	I-SPEC
+serovar	O
+typhimurium	O
+vaccine	O
+strains	O
+.	O
+
+For	O
+this	O
+,	O
+the	O
+vaccine	O
+strain	O
+was	O
+genetically	O
+engineered	O
+to	O
+express	O
+chimeric	O
+fimbriae	B-COMP
+carrying	O
+the	O
+transmissible	O
+gastroenteritis	B-DISO
+virus	B-SPEC
+(	O
+TGEV	B-SPEC
+)	O
+C	O
+(	O
+379	O
+-	O
+388	O
+)	O
+and	O
+A	O
+(	O
+521	O
+-	O
+531	O
+)	O
+epitopes	O
+of	O
+the	O
+spike	O
+protein	B-CHED
+inserted	O
+into	O
+the	O
+987P	O
+major	O
+fimbrial	O
+subunit	O
+FasA	O
+.	O
+BALB	O
+/	O
+c	O
+mice	B-SPEC
+administered	O
+orally	B-ANAT
+serovar	O
+Typhimurium	O
+chi4550	O
+expressing	O
+the	O
+chimeric	O
+fimbriae	B-COMP
+from	O
+the	O
+tet	B-PRGE
+promoter	I-PRGE
+in	O
+pCS154	O
+(	O
+fas	B-DISO
+(+)	O
+asd	B-DISO
+(+))	O
+produced	O
+systemic	O
+antibodies	B-COMP
+against	O
+both	O
+fimbria	B-COMP
+and	O
+the	O
+TGEV	B-SPEC
+C	O
+epitope	B-CHED
+but	O
+not	O
+against	O
+the	O
+TGEV	B-SPEC
+A	O
+epitope	B-CHED
+.	O
+
+Moreover	O
+,	O
+mucosal	B-ANAT
+IgA	B-PRGE
+against	O
+the	O
+TGEV	B-SPEC
+C	O
+epitope	B-CHED
+was	O
+only	O
+detected	O
+with	O
+serovar	O
+Typhimurium	O
+chi4550	O
+/	O
+pCS155	O
+.	O
+
+The	O
+induced	O
+antibodies	B-COMP
+also	O
+recognized	O
+the	O
+epitopes	O
+in	O
+the	O
+context	O
+of	O
+the	O
+full	O
+-	O
+length	O
+TGEV	B-SPEC
+spike	O
+protein	B-CHED
+.	O
+
+Hence	O
+,	O
+immune	B-PROC
+responses	I-PROC
+to	O
+heterologous	O
+chimeric	O
+fimbriae	B-COMP
+on	O
+Salmonella	B-DISO
+vaccine	O
+vectors	O
+can	O
+be	O
+optimized	O
+by	O
+using	O
+promoters	O
+known	O
+to	O
+be	O
+activated	O
+in	O
+vivo	O
+.	O
+
+TITLE	O
+:	O
+Use	O
+of	O
+extracorporeal	O
+membrane	B-COMP
+oxygenation	B-PROC
+to	O
+rescue	O
+a	O
+child	O
+with	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+.	O
+
+This	O
+case	O
+suggests	O
+that	O
+venovenous	O
+ECMO	O
+can	O
+be	O
+a	O
+rescue	O
+method	O
+for	O
+patients	O
+with	O
+ARDS	B-DISO
+that	O
+is	O
+refractory	O
+to	O
+conventional	O
+treatments	O
+.	O
+
+TITLE	O
+:	O
+Kinetics	O
+of	O
+lymphocytic	O
+subsets	O
+in	O
+chicken	B-SPEC
+tracheal	O
+lesions	O
+infected	O
+with	O
+infectious	B-DISO
+bronchitis	B-DISO
+virus	B-SPEC
+.	O
+
+After	O
+14	O
+days	O
+p	O
+.	O
+i	O
+.,	O
+small	O
+number	O
+of	O
+IgG	O
++	O
+and	O
+IgM	B-PRGE
++	I-PRGE
+cells	B-COMP
+were	O
+detected	O
+in	O
+the	O
+germinal	B-ANAT
+center	I-ANAT
+of	O
+lymph	B-ANAT
+follicles	B-ANAT
+in	O
+the	O
+lamina	B-ANAT
+propria	I-ANAT
+.	O
+
+CD4	B-PRGE
++	I-PRGE
+cells	B-COMP
+were	O
+dramatically	O
+decreased	O
+from	O
+7	O
+days	O
+p	O
+.	O
+i	O
+.,	O
+and	O
+CD3	B-PRGE
++	I-PRGE
+and	O
+CD8	B-PRGE
++	I-PRGE
+cells	B-COMP
+were	O
+decreased	O
+from	O
+14	O
+days	O
+p	O
+.	O
+i	O
+.	O
+
+However	O
+,	O
+both	O
+immunofluorescence	O
+and	O
+electron	O
+microscopic	O
+studies	O
+have	O
+also	O
+detected	O
+gene	B-PRGE
+1	I-PRGE
+proteins	I-PRGE
+at	O
+sites	O
+distinct	O
+from	O
+the	O
+putative	O
+sites	O
+of	O
+viral	O
+RNA	B-PROC
+synthesis	I-PROC
+or	O
+virus	B-PROC
+assembly	I-PROC
+.	O
+
+High	O
+frequency	O
+oscillatory	O
+ventilation	O
+has	O
+also	O
+been	O
+described	O
+as	O
+a	O
+lung	B-ANAT
+protective	O
+strategy	O
+.	O
+
+To	O
+evaluate	O
+the	O
+effect	O
+of	O
+time	O
+to	O
+intervention	O
+with	O
+high	O
+-	O
+frequency	O
+oscillatory	O
+ventilation	O
+(	O
+HFOV	O
+)	O
+on	O
+the	O
+survival	O
+of	O
+children	O
+with	O
+severe	O
+acute	O
+hypoxemic	O
+respiratory	O
+failure	O
+who	O
+were	O
+managed	O
+with	O
+lung	B-ANAT
+protective	O
+strategies	O
+on	O
+conventional	O
+mechanical	O
+ventilation	O
+(	O
+CMV	B-SPEC
+).	O
+
+An	O
+""""	O
+Optimal	O
+Volume	O
+Strategy	O
+""""	O
+with	O
+HFOV	O
+was	O
+utilized	O
+to	O
+recruit	O
+alveoli	B-ANAT
+and	O
+optimize	O
+lung	B-PROC
+volume	I-PROC
+.	O
+
+Early	O
+use	O
+of	O
+HFOV	O
+within	O
+the	O
+first	O
+24	O
+hours	O
+of	O
+acute	O
+hypoxic	B-DISO
+respiratory	B-DISO
+failure	I-DISO
+in	O
+pediatric	O
+patients	O
+is	O
+associated	O
+with	O
+better	O
+survival	O
+.	O
+
+Nasal	B-ANAT
+swab	O
+specimens	O
+were	O
+submitted	O
+for	O
+virus	B-SPEC
+isolation	O
+and	O
+bacterial	O
+culture	O
+;	O
+blood	B-ANAT
+samples	I-ANAT
+were	O
+submitted	O
+for	O
+measurement	O
+of	O
+respiratory	O
+bovine	B-SPEC
+coronavirus	B-SPEC
+(	O
+RBCV	O
+)	O
+hemagglutinin	O
+inhibition	B-PROC
+titers	O
+.	O
+
+TITLE	O
+:	O
+Sleep	B-PROC
+laboratory	O
+studies	O
+in	O
+restless	B-DISO
+legs	I-DISO
+syndrome	I-DISO
+patients	O
+as	O
+compared	O
+with	O
+normals	O
+and	O
+acute	O
+effects	O
+of	O
+ropinirole	O
+.	O
+
+ABSTRACT	O
+:	O
+The	O
+restless	B-DISO
+legs	I-DISO
+syndrome	I-DISO
+(	O
+RLS	B-DISO
+)	O
+is	O
+a	O
+common	O
+sensorimotor	B-DISO
+disorder	I-DISO
+which	O
+leads	O
+to	O
+severe	O
+sleep	B-DISO
+disturbances	I-DISO
+and	O
+showed	O
+a	O
+prevalence	O
+of	O
+7	O
+.	O
+9	O
+%	O
+in	O
+our	O
+sleep	B-PROC
+laboratory	O
+.	O
+
+Further	O
+,	O
+we	O
+found	O
+an	O
+increased	O
+number	O
+of	O
+PLM	O
+(	O
+368	O
+),	O
+PLM	O
+/	O
+h	O
+of	O
+time	O
+in	O
+bed	B-DISO
+(	O
+49	O
+/	O
+h	O
+),	O
+PLM	O
+/	O
+h	O
+of	O
+REM	B-PROC
+sleep	B-PROC
+(	O
+11	O
+),	O
+PLM	O
+/	O
+h	O
+of	O
+non	O
+-	O
+REM	B-PROC
+sleep	B-PROC
+(	O
+46	O
+)	O
+and	O
+PLM	O
+/	O
+h	O
+awake	O
+(	O
+61	O
+).	O
+
+The	O
+arousal	O
+index	O
+was	O
+also	O
+increased	O
+(	O
+32	O
+/	O
+h	O
+;	O
+normal	O
+0	O
+-	O
+25	O
+/	O
+h	O
+),	O
+as	O
+were	O
+arousals	O
+due	O
+to	O
+PLM	B-PRGE
+.	O
+
+TITLE	O
+:	O
+[	O
+Systemic	O
+hemodynamics	B-PROC
+,	O
+oxygenating	O
+lung	B-PROC
+function	I-PROC
+and	O
+oxygen	B-PROC
+transport	B-PROC
+in	O
+patients	O
+with	O
+acute	B-DISO
+intestinal	I-DISO
+obstruction	I-DISO
+and	O
+an	O
+endotoxicosis	B-DISO
+syndrome	B-DISO
+].	O
+
+Many	O
+recall	O
+the	O
+famous	O
+experiments	O
+from	O
+Clark	O
+et	O
+al	O
+.	O
+in	O
+1966	O
+when	O
+he	O
+demonstrated	O
+""""	O
+liquidventilation	O
+with	O
+perfluorocarbons	O
+""""	O
+in	O
+the	O
+mammal	B-SPEC
+species	B-SPEC
+for	O
+the	O
+first	O
+time	O
+.	O
+
+Furthermore	O
+,	O
+the	O
+high	O
+density	O
+of	O
+the	O
+PFC	O
+lead	O
+to	O
+radio	O
+-	O
+opacity	B-DISO
+and	O
+their	O
+distribution	O
+to	O
+dependent	O
+lung	B-ANAT
+areas	O
+.	O
+
+Currently	O
+,	O
+several	O
+mechanisms	O
+of	O
+action	O
+of	O
+perfluorocarbon	O
+fluids	B-ANAT
+in	O
+acute	O
+lung	B-ANAT
+injury	O
+are	O
+discussed	O
+:	O
+recruitment	B-DISO
+of	O
+atelectatic	O
+alveoli	B-ANAT
+,	O
+prevention	O
+of	O
+endexpiratory	O
+collapse	B-DISO
+of	O
+alveoli	B-ANAT
+"("""	O
+liquid	O
+PEEP	B-CHED
+"""),"	O
+redistribution	O
+of	O
+perfusion	O
+,	O
+oxygen	B-PROC
+transport	B-PROC
+,	O
+surfactant	B-CHED
+like	O
+effects	O
+and	O
+decrease	O
+of	O
+inflammation	B-DISO
+.	O
+
+Furthermore	O
+,	O
+the	O
+instillation	O
+of	O
+relatively	O
+large	O
+amounts	O
+of	O
+liquid	O
+into	O
+the	O
+lungs	B-ANAT
+poses	O
+several	O
+technical	O
+challenges	O
+and	O
+may	O
+be	O
+associated	O
+with	O
+complications	O
+such	O
+as	O
+liquithoraces	O
+,	O
+pneumothoraces	O
+and	O
+hypoxia	B-DISO
+.	O
+
+Vaporisation	O
+of	O
+perfluorohexane	B-CHED
+in	O
+a	O
+concentration	O
+of	O
+18	O
+Vol	O
+.%	O
+of	O
+inspired	B-PROC
+gas	B-ENZY
+improved	O
+significantly	O
+oxygenation	B-PROC
+and	O
+lung	B-PROC
+compliance	I-PROC
+.	O
+
+ABSTRACT	O
+:	O
+Disinfectants	B-CHED
+for	O
+medical	O
+devices	O
+are	O
+uncommonly	O
+a	O
+cause	O
+of	O
+iatrogenic	O
+adverse	B-DISO
+effects	I-DISO
+.	O
+
+The	O
+diagnosis	O
+considered	O
+was	O
+a	O
+hyaline	B-DISO
+membrane	B-COMP
+disease	I-DISO
+.	O
+
+ABSTRACT	O
+:	O
+The	O
+acute	O
+chest	O
+syndrome	O
+is	O
+the	O
+leading	O
+cause	O
+of	O
+death	B-PROC
+among	O
+patients	O
+with	O
+sickle	B-DISO
+cell	I-DISO
+disease	I-DISO
+.	O
+
+In	O
+a	O
+30	O
+-	O
+center	O
+study	O
+,	O
+we	O
+analyzed	O
+671	O
+episodes	O
+of	O
+the	O
+acute	B-DISO
+chest	I-DISO
+syndrome	I-DISO
+in	O
+538	O
+patients	O
+with	O
+sickle	B-DISO
+cell	I-DISO
+disease	I-DISO
+to	O
+determine	O
+the	O
+cause	O
+,	O
+outcome	O
+,	O
+and	O
+response	O
+to	O
+therapy	O
+.	O
+
+When	O
+the	O
+acute	B-DISO
+chest	I-DISO
+syndrome	I-DISO
+was	O
+diagnosed	O
+,	O
+patients	O
+had	O
+hypoxia	B-DISO
+,	O
+decreasing	O
+hemoglobin	B-PRGE
+values	O
+,	O
+and	O
+progressive	O
+multilobar	B-DISO
+pneumonia	I-DISO
+.	O
+
+Eighteen	O
+patients	O
+died	B-PROC
+,	O
+and	O
+the	O
+most	O
+common	O
+causes	O
+of	O
+death	B-PROC
+were	O
+pulmonary	B-ANAT
+emboli	O
+and	O
+infectious	B-DISO
+bronchopneumonia	B-DISO
+.	O
+
+Among	O
+patients	O
+with	O
+sickle	B-DISO
+cell	I-DISO
+disease	I-DISO
+,	O
+the	O
+acute	B-DISO
+chest	I-DISO
+syndrome	I-DISO
+is	O
+commonly	O
+precipitated	O
+by	O
+fat	B-DISO
+embolism	I-DISO
+and	O
+infection	B-DISO
+,	O
+especially	O
+community	O
+-	O
+acquired	O
+pneumonia	B-DISO
+.	O
+
+Infection	B-DISO
+was	O
+a	O
+contributing	O
+factor	O
+in	O
+56	O
+percent	O
+of	O
+the	O
+deaths	B-PROC
+.	O
+
+Our	O
+results	O
+show	O
+linear	O
+immunodominant	O
+epitopes	O
+,	O
+which	O
+were	O
+found	O
+in	O
+three	O
+fragments	O
+covering	O
+amino	B-CHED
+acid	I-CHED
+residues	O
+175	O
+-	O
+241	O
+,	O
+310	O
+-	O
+370	O
+and	O
+360	O
+-	O
+409	O
+.	O
+
+PEEP	B-CHED
+was	O
+increased	O
+by	O
+5	O
+cmH2O	O
+from	O
+a	O
+clinically	O
+selected	O
+PEEP	B-CHED
+level	O
+(	O
+8	O
+/	O
+6	O
+-	O
+11	O
+cmH2O	O
+)	O
+up	O
+to	O
+(	O
+13	O
+/	O
+10	O
+-	O
+14	O
+cmH2O	O
+)	O
+followed	O
+by	O
+a	O
+return	O
+to	O
+baseline	O
+.	O
+
+CONCLUSIONS	O
+:	O
+PEEP	B-CHED
+by	O
+itself	O
+does	O
+not	O
+have	O
+a	O
+consistent	O
+effect	O
+on	O
+splanchnic	O
+blood	B-PROC
+flow	I-PROC
+and	O
+metabolism	B-PROC
+when	O
+cardiac	B-ANAT
+index	O
+is	O
+stable	O
+and	O
+patients	O
+are	O
+ventilated	O
+within	O
+the	O
+linear	O
+part	O
+of	O
+the	O
+pv	O
+curve	O
+.	O
+
+The	O
+PCR	O
+products	O
+of	O
+PEDV	B-SPEC
+and	O
+TGEV	B-SPEC
+had	O
+molecular	O
+sizes	O
+of	O
+412	O
+and	O
+612	O
+base	B-FUNC
+pairs	I-FUNC
+,	O
+respectively	O
+.	O
+
+The	O
+results	O
+of	O
+the	O
+assay	O
+correlated	O
+well	O
+with	O
+the	O
+results	O
+of	O
+virus	B-SPEC
+isolation	O
+.	O
+
+ABSTRACT	O
+:	O
+Abdominal	B-ANAT
+compartment	I-ANAT
+syndrome	I-DISO
+(	O
+ACS	B-FUNC
+)	O
+is	O
+defined	O
+as	O
+cardiopulmonary	B-ANAT
+or	O
+renal	B-ANAT
+dysfunction	O
+caused	O
+by	O
+an	O
+acute	O
+increase	O
+in	O
+intraabdominal	B-ANAT
+pressure	O
+.	O
+
+ACS	B-FUNC
+is	O
+a	O
+potentially	O
+lethal	O
+complication	B-DISO
+of	O
+severe	O
+trauma	O
+and	O
+shock	O
+in	O
+children	O
+.	O
+
+It	O
+is	O
+released	O
+from	O
+the	O
+1a	O
+and	O
+1a	O
+/	O
+1b	O
+polyproteins	O
+by	O
+autoprocessing	O
+at	O
+two	O
+Q	O
+-	O
+S	O
+dipeptide	B-CHED
+bonds	O
+(	O
+Q	O
+(	O
+2779	O
+)-	O
+S	O
+(	O
+2780	O
+)	O
+and	O
+Q	O
+(	O
+3086	O
+)-	O
+S	O
+(	O
+3087	O
+)).	O
+
+Analysis	O
+of	O
+the	O
+autoprocessing	O
+kinetics	O
+in	O
+vitro	O
+reveals	O
+that	O
+proteolysis	B-PROC
+at	O
+the	O
+Q	O
+(	O
+2779	O
+)-	O
+S	O
+(	O
+2780	O
+)	O
+site	O
+is	O
+the	O
+first	O
+cleavage	B-PROC
+event	O
+mediated	O
+by	O
+this	O
+proteinase	B-PROC
+.	O
+
+Immunofluorescence	O
+microscopy	O
+and	O
+subcellular	O
+fractionation	O
+studies	O
+further	O
+show	O
+differential	O
+subcellular	O
+localization	B-PROC
+of	O
+the	O
+proteinase	B-PROC
+in	O
+IBV	B-SPEC
+-	O
+infected	O
+cells	B-COMP
+and	O
+in	O
+cells	B-COMP
+expressing	O
+the	O
+3C	B-PRGE
+-	I-PRGE
+like	I-PRGE
+proteinase	I-PRGE
+alone	O
+,	O
+indicating	O
+that	O
+additional	O
+roles	O
+in	O
+viral	B-PROC
+replication	I-PROC
+might	O
+be	O
+played	O
+by	O
+this	O
+protein	B-CHED
+.	O
+
+TITLE	O
+:	O
+Two	O
+cases	O
+of	O
+fulminant	O
+Mycoplasma	B-DISO
+pneumoniae	I-DISO
+pneumonia	I-DISO
+within	O
+4	O
+months	O
+.	O
+
+In	O
+both	O
+of	O
+them	O
+severe	O
+complications	O
+occurred	O
+which	O
+coincided	O
+with	O
+the	O
+acute	O
+MP	O
+respiratory	B-DISO
+infection	I-DISO
+.	O
+
+On	O
+the	O
+basis	O
+of	O
+these	O
+observations	O
+,	O
+we	O
+hypothesized	O
+that	O
+the	O
+thymus	B-SPEC
+harbors	O
+an	O
+agent	O
+(	O
+s	O
+)	O
+involved	O
+in	O
+PEMS	O
+.	O
+
+In	O
+these	O
+studies	O
+,	O
+naïve	O
+turkey	B-SPEC
+poults	O
+were	O
+orally	B-ANAT
+inoculated	O
+with	O
+a	O
+bacteria	B-SPEC
+-	O
+free	O
+filtrate	O
+composed	O
+of	O
+either	O
+the	O
+intestines	O
+and	O
+feces	B-ANAT
+or	O
+the	O
+thymus	B-SPEC
+from	O
+PEMS	O
+-	O
+infected	O
+birds	B-SPEC
+and	O
+were	O
+monitored	O
+for	O
+clinical	O
+signs	O
+of	O
+PEMS	O
+.	O
+
+The	O
+SRV	O
+incubation	O
+with	O
+normal	O
+thymocytes	B-ANAT
+and	O
+splenocytes	O
+in	O
+vitro	O
+resulted	O
+in	O
+significantly	O
+reduced	O
+lymphoproliferative	O
+response	O
+against	O
+Con	B-PRGE
+A	I-PRGE
+(	O
+41	O
+.	O
+2	O
+%	O
+and	O
+10	O
+.	O
+49	O
+%	O
+reductions	O
+at	O
+1	O
+:	O
+50	O
+SRV	O
+dilution	O
+vs	O
+.	O
+controls	O
+in	O
+thymocytes	B-ANAT
+and	O
+splenocytes	O
+,	O
+respectively	O
+).	O
+
+Evidence	O
+suggests	O
+the	O
+occurrence	O
+of	O
+rupture	O
+of	O
+the	O
+basement	B-COMP
+membranes	I-COMP
+and	O
+interstitial	B-COMP
+matrix	I-COMP
+remodeling	O
+during	O
+acute	O
+lung	B-ANAT
+injury	O
+.	O
+
+TITLE	O
+:	O
+A	O
+potential	O
+role	O
+for	O
+tumour	B-PRGE
+necrosis	I-PRGE
+factor	I-PRGE
+-	I-PRGE
+alpha	I-PRGE
+in	O
+synergy	O
+between	O
+porcine	B-SPEC
+respiratory	O
+coronavirus	B-SPEC
+and	O
+bacterial	O
+lipopolysaccharide	B-CHED
+in	O
+the	O
+induction	O
+of	O
+respiratory	B-DISO
+disease	I-DISO
+in	O
+pigs	B-SPEC
+.	O
+
+ABSTRACT	O
+:	O
+This	O
+study	O
+examined	O
+whether	O
+exposure	O
+of	O
+pigs	B-SPEC
+to	O
+both	O
+porcine	B-SPEC
+respiratory	O
+coronavirus	B-SPEC
+(	O
+PRCV	O
+)	O
+and	O
+bacterial	O
+lipopolysaccharide	B-CHED
+(	O
+LPS	B-DISO
+)	O
+can	O
+potentiate	O
+respiratory	B-DISO
+disease	I-DISO
+and	O
+lung	B-ANAT
+secretion	B-PROC
+of	O
+tumour	B-DISO
+necrosis	I-DISO
+factor	O
+-	O
+a	O
+(	O
+TNF	B-PRGE
+-	I-PRGE
+alpha	I-PRGE
+)	O
+and	O
+interleukin	B-PRGE
+-	I-PRGE
+1	I-PRGE
+(	O
+IL	B-FUNC
+-	I-FUNC
+1	I-FUNC
+).	O
+
+In	O
+a	O
+second	O
+study	O
+,	O
+pigs	B-SPEC
+were	O
+inoculated	O
+with	O
+PRCV	O
+and	O
+subsequently	O
+with	O
+LPS	B-DISO
+at	O
+various	O
+time	O
+intervals	O
+ranging	O
+from	O
+0	O
+to	O
+24	O
+h	O
+,	O
+and	O
+killed	O
+5	O
+h	O
+after	O
+inoculation	O
+with	O
+LPS	B-DISO
+.	O
+
+This	O
+is	O
+the	O
+first	O
+in	O
+-	O
+vivo	O
+demonstration	O
+of	O
+synergy	O
+between	O
+respiratory	O
+viruses	B-SPEC
+and	O
+LPS	B-DISO
+.	O
+
+As	O
+with	O
+mouse	B-DISO
+hepatitis	I-DISO
+coronaviruses	O
+(	O
+MHVs	O
+),	O
+the	O
+SDAV	O
+genome	O
+was	O
+able	O
+to	O
+code	O
+for	O
+a	O
+spike	O
+protein	B-CHED
+,	O
+a	O
+small	O
+membrane	B-COMP
+protein	B-CHED
+,	O
+a	O
+membrane	B-COMP
+-	O
+associated	O
+protein	B-CHED
+,	O
+and	O
+a	O
+nucleocapsid	B-COMP
+protein	B-CHED
+.	O
+
+Immediately	O
+upstream	O
+of	O
+the	O
+HE	B-PRGE
+gene	I-PRGE
+and	O
+downstream	O
+of	O
+the	O
+polymerase	B-PRGE
+1b	I-PRGE
+gene	I-PRGE
+,	O
+the	O
+NS2	B-PRGE
+nonstructural	I-PRGE
+-	I-PRGE
+protein	B-CHED
+gene	I-PRGE
+was	O
+identified	O
+with	O
+a	O
+coding	O
+capacity	O
+of	O
+274	O
+aa	O
+.	O
+
+This	O
+is	O
+the	O
+first	O
+report	O
+on	O
+the	O
+comprehensive	O
+genetic	O
+information	O
+of	O
+any	O
+rat	B-SPEC
+coronavirus	B-SPEC
+.	O
+
+One	O
+additional	O
+patient	O
+developed	O
+a	O
+similar	O
+disorder	O
+in	O
+the	O
+setting	O
+of	O
+long	O
+-	O
+standing	B-PROC
+chronic	O
+active	O
+EBV	B-DISO
+infection	I-DISO
+.	O
+
+Detailed	O
+immunophenotyping	O
+,	O
+in	O
+situ	O
+hybridization	B-PROC
+for	O
+EBV	B-PRGE
+early	I-PRGE
+RNA	O
+-	O
+1	O
+(	O
+EBER1	O
+)	O
+and	O
+polymerase	O
+chain	O
+reaction	O
+(	O
+PCR	O
+)	O
+analyses	O
+for	O
+immunoglobulin	B-PROC
+(	O
+Ig	O
+)	O
+heavy	O
+chain	O
+and	O
+T	B-PRGE
+-	I-PRGE
+cell	I-PRGE
+receptor	I-PRGE
+(	O
+TCR	B-COMP
+)-	O
+gamma	O
+gene	B-PROC
+rearrangements	I-PROC
+were	O
+performed	O
+on	O
+paraffin	O
+-	O
+embedded	O
+tissue	B-ANAT
+from	O
+all	O
+patients	O
+.	O
+
+On	O
+histologic	O
+examination	O
+,	O
+the	O
+liver	B-ANAT
+and	I-ANAT
+spleen	I-ANAT
+showed	O
+prominent	O
+sinusoidal	O
+and	O
+portal	B-ANAT
+lymphoid	O
+infiltrates	B-DISO
+of	O
+CD3	B-PRGE
+(+),	I-PRGE
+beta	I-PRGE
+F1	I-PRGE
+(+),	O
+EBER1	O
+(+)	O
+T	B-ANAT
+cells	I-ANAT
+lacking	O
+significant	O
+cytologic	B-DISO
+atypia	I-DISO
+.	O
+
+All	O
+were	O
+TIA	B-PRGE
+-	I-PRGE
+1	I-PRGE
+(+),	I-PRGE
+CD56	B-PRGE
+(-).	O
+
+ABSTRACT	O
+:	O
+We	O
+have	O
+previously	O
+identified	O
+a	O
+functionally	O
+essential	O
+bulged	O
+stem	B-ANAT
+-	O
+loop	O
+in	O
+the	O
+3	O
+'	O
+untranslated	O
+region	O
+of	O
+the	O
+positive	O
+-	O
+stranded	O
+RNA	O
+genome	O
+of	O
+mouse	B-DISO
+hepatitis	I-DISO
+virus	B-SPEC
+.	O
+
+The	O
+functional	O
+importance	O
+of	O
+individual	O
+stem	B-ANAT
+segments	O
+of	O
+this	O
+stem	B-ANAT
+-	O
+loop	O
+was	O
+characterized	O
+by	O
+genetic	O
+analysis	O
+using	O
+targeted	B-PROC
+RNA	O
+recombination	B-PROC
+.	O
+
+These	O
+studies	O
+were	O
+complemented	O
+by	O
+enzymatic	O
+and	O
+chemical	O
+probing	O
+of	O
+the	O
+stem	B-ANAT
+-	O
+loop	O
+.	O
+
+Three	O
+of	O
+the	O
+stem	O
+segments	O
+were	O
+found	O
+to	O
+be	O
+essential	O
+for	O
+viral	B-PROC
+replication	I-PROC
+.	O
+
+All	O
+patients	O
+had	O
+recently	O
+visited	O
+classical	O
+malaria	B-PATH
+regions	O
+some	O
+days	O
+before	O
+admission	O
+:	O
+five	O
+patients	O
+the	O
+sub	O
+-	O
+Saharan	O
+Africa	O
+and	O
+one	O
+patient	O
+Thailand	O
+and	O
+Vietnam	O
+.	O
+
+Only	O
+two	O
+of	O
+six	O
+patients	O
+had	O
+taken	O
+prophylactic	O
+medication	O
+:	O
+one	O
+patient	O
+chloroquine	B-CHED
+and	O
+proguanil	B-CHED
+and	O
+the	O
+other	O
+mefloquine	B-CHED
+(	O
+she	O
+suffered	B-DISO
+from	O
+a	O
+severe	O
+gastroenteritis	B-DISO
+during	O
+the	O
+journey	O
+).	O
+
+Virus	B-PRGE
+-	I-PRGE
+receptor	B-FUNC
+binding	I-FUNC
+tests	O
+failed	O
+to	O
+demonstrate	O
+a	O
+difference	O
+between	O
+the	O
+abilities	O
+of	O
+wt	O
+and	O
+srr18	O
+to	O
+bind	B-FUNC
+MHVR2	O
+.	O
+
+This	O
+suggests	O
+that	O
+the	O
+most	O
+likely	O
+reason	O
+for	O
+inefficient	O
+infection	B-DISO
+by	O
+mutants	O
+in	O
+BHK	O
+-	O
+R2	O
+is	O
+impaired	B-DISO
+virus	B-SPEC
+entry	O
+into	O
+cells	B-COMP
+.	O
+
+We	O
+describe	O
+a	O
+patient	O
+who	O
+had	O
+acute	O
+and	O
+severe	O
+lung	B-ANAT
+injury	O
+from	O
+malaria	B-PATH
+.	O
+
+Physicians	O
+caring	O
+for	O
+patients	O
+who	O
+have	O
+recently	O
+traveled	O
+to	O
+malaria	B-PATH
+-	O
+endemic	O
+areas	O
+need	O
+to	O
+anticipate	O
+the	O
+possible	O
+development	B-PROC
+of	O
+malaria	B-PATH
+with	O
+all	O
+of	O
+its	O
+complications	O
+,	O
+including	O
+acute	O
+lung	B-ANAT
+injury	O
+.	O
+
+ABSTRACT	O
+:	O
+Demyelination	O
+induced	O
+by	O
+mouse	B-DISO
+hepatitis	I-DISO
+virus	B-SPEC
+(	O
+MHV	B-SPEC
+),	O
+strain	O
+JHM	O
+,	O
+is	O
+in	O
+large	O
+part	O
+immune	O
+mediated	O
+,	O
+but	O
+little	O
+is	O
+known	O
+about	O
+the	O
+mechanisms	O
+involved	O
+in	O
+this	O
+process	O
+.	O
+
+Furthermore	O
+,	O
+using	O
+an	O
+established	O
+adoptive	O
+transfer	O
+model	O
+and	O
+pharmacological	O
+inhibitors	B-CHED
+of	O
+NOS2	B-PRGE
+function	O
+,	O
+we	O
+could	O
+demonstrate	O
+no	O
+effect	O
+on	O
+MHV	B-SPEC
+-	O
+induced	O
+demyelination	B-DISO
+.	O
+
+Porcine	B-SPEC
+respiratory	O
+coronavirus	B-SPEC
+(	O
+PRCV	O
+),	O
+a	O
+spike	O
+(	O
+S	O
+)	O
+gene	O
+natural	O
+deletion	O
+mutant	B-DISO
+of	O
+TGEV	B-SPEC
+,	O
+has	O
+a	O
+respiratory	O
+tissue	B-PROC
+tropism	B-PROC
+and	O
+causes	O
+mild	O
+or	O
+subclinical	O
+respiratory	B-DISO
+infections	I-DISO
+.	O
+
+Conventional	O
+antigen	B-CHED
+-	O
+based	O
+diagnostic	O
+tests	O
+fail	O
+to	O
+differentiate	O
+TGEV	B-SPEC
+and	O
+PRCV	O
+,	O
+and	O
+a	O
+blocking	B-DISO
+ELISA	O
+test	O
+to	O
+serologically	O
+differentiate	O
+TGEV	B-SPEC
+/	O
+PRCV	O
+-	O
+infected	O
+pigs	B-SPEC
+is	O
+conducted	O
+on	O
+convalescent	O
+serum	B-COMP
+retrospectively	O
+after	O
+disease	O
+outbreaks	O
+.	O
+
+ABSTRACT	O
+:	O
+Septic	O
+shock	O
+is	O
+characterized	O
+by	O
+a	O
+decrease	O
+in	O
+systemic	B-PROC
+vascular	I-PROC
+resistance	I-PROC
+.	O
+
+In	O
+this	O
+report	O
+,	O
+we	O
+present	O
+evidence	O
+that	O
+terbutaline	B-CHED
+,	O
+a	O
+beta2	B-PRGE
+-	O
+agonist	B-CHED
+,	O
+inhibits	O
+TNFalpha	B-PRGE
+production	O
+and	O
+enhances	O
+interleukin	B-PRGE
+-	I-PRGE
+10	I-PRGE
+(	O
+IL	B-FUNC
+-	I-FUNC
+10	I-FUNC
+)	O
+release	B-PATH
+in	O
+the	O
+anesthetized	O
+rat	B-SPEC
+treated	O
+with	O
+LPS	B-DISO
+.	O
+
+Overall	O
+,	O
+pretreatment	O
+of	O
+rats	B-SPEC
+with	O
+terbutaline	B-CHED
+attenuates	O
+the	O
+delayed	O
+hypotension	O
+and	O
+prevents	O
+vascular	B-ANAT
+hyporeactivity	O
+to	O
+norepinephrine	B-CHED
+.	O
+
+A	O
+total	O
+of	O
+61	O
+infections	B-DISO
+with	O
+rhinoviruses	B-SPEC
+and	O
+coronaviruses	O
+were	O
+identified	O
+from	O
+1198	O
+respiratory	O
+illnesses	O
+(	O
+5	O
+.	O
+1	O
+%);	O
+in	O
+addition	O
+,	O
+9	O
+additional	O
+infections	B-DISO
+associated	O
+with	O
+>/=	O
+1	O
+other	O
+respiratory	O
+viruses	B-SPEC
+were	O
+identified	O
+.	O
+
+TITLE	O
+:	O
+Guillain	O
+-	O
+Barré	O
+syndrome	B-DISO
+:	O
+perspectives	O
+with	O
+infants	O
+and	O
+children	O
+.	O
+
+ABSTRACT	O
+:	O
+An	O
+acute	O
+flaccid	B-DISO
+paraparesis	I-DISO
+or	O
+ascending	O
+quadriparesis	B-DISO
+in	O
+an	O
+infant	O
+or	O
+child	O
+constitutes	O
+a	O
+very	O
+important	O
+pediatric	O
+neurology	O
+emergency	B-DISO
+.	O
+
+The	O
+Guillain	O
+-	O
+Barré	O
+syndrome	B-DISO
+(	O
+GBS	B-DISO
+)	O
+is	O
+the	O
+most	O
+frequent	O
+cause	O
+.	O
+
+Another	O
+clinical	O
+variant	O
+is	O
+the	O
+Miller	B-DISO
+-	I-DISO
+Fisher	I-DISO
+syndrome	I-DISO
+characterized	O
+by	O
+ataxia	B-DISO
+,	O
+ophthalmoparesis	O
+,	O
+and	O
+areflexia	O
+.	O
+
+This	O
+is	O
+associated	O
+with	O
+a	O
+high	O
+frequency	O
+of	O
+the	O
+anti	O
+-	O
+GQ	O
+-	O
+1	O
+-	O
+b	O
+antibodies	B-COMP
+.	O
+
+The	O
+purified	O
+recombinant	O
+protein	B-CHED
+had	O
+in	O
+vitro	O
+ATPase	B-FUNC
+activity	I-FUNC
+that	O
+was	O
+strongly	O
+stimulated	O
+by	O
+poly	O
+(	O
+U	O
+),	O
+poly	O
+(	O
+dT	O
+),	O
+poly	O
+(	O
+C	O
+),	O
+and	O
+poly	O
+(	O
+dA	O
+),	O
+but	O
+not	O
+by	O
+poly	O
+(	O
+G	O
+).	O
+
+ABSTRACT	O
+:	O
+Select	O
+pancreatic	B-ANAT
+enzymes	O
+,	O
+primarily	O
+elastase	B-PRGE
+,	O
+precipitate	O
+pulmonary	B-ANAT
+injury	O
+similar	O
+to	O
+pancreatitis	B-DISO
+-	O
+associated	O
+adult	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+and	O
+stimulate	O
+leukocyte	B-ANAT
+cytokine	B-PROC
+production	I-PROC
+in	O
+vitro	O
+via	O
+nuclear	B-PRGE
+factor	I-PRGE
+kappa	I-PRGE
+B	I-PRGE
+(	O
+NF	B-PRGE
+-	I-PRGE
+kappaB	I-PRGE
+)	O
+activation	O
+.	O
+
+Pancreatic	B-PRGE
+elastase	I-PRGE
+induced	O
+pulmonary	B-ANAT
+IkappaBalpha	B-PRGE
+/	O
+IkappaBbeta	B-PRGE
+degradation	O
+(	O
+30	O
+minutes	O
+),	O
+NF	B-PROC
+-	I-PROC
+kappaB	I-PROC
+activation	I-PROC
+(	O
+60	O
+minutes	O
+),	O
+and	O
+TNF	B-PRGE
+gene	I-PRGE
+expression	O
+(	O
+60	O
+minutes	O
+)	O
+with	O
+subsequent	O
+neutrophilic	B-PROC
+inflammation	B-DISO
+(	O
+4	O
+hours	O
+)	O
+and	O
+microvascular	O
+leakage	B-DISO
+(	O
+24	O
+hours	O
+),	O
+whereas	O
+amylase	B-PRGE
+,	O
+lipase	B-PRGE
+,	O
+and	O
+trypsin	B-PRGE
+did	O
+not	O
+.	O
+
+RESULTS	O
+:	O
+Pancreatic	B-PRGE
+elastase	I-PRGE
+induced	O
+pulmonary	B-ANAT
+IkappaBalpha	B-PRGE
+/	O
+IkappaBbeta	B-PRGE
+degradation	O
+(	O
+30	O
+minutes	O
+),	O
+NF	B-PROC
+-	I-PROC
+kappaB	I-PROC
+activation	I-PROC
+(	O
+60	O
+minutes	O
+),	O
+and	O
+TNF	B-PRGE
+gene	I-PRGE
+expression	O
+(	O
+60	O
+minutes	O
+)	O
+with	O
+subsequent	O
+neutrophilic	B-PROC
+inflammation	B-DISO
+(	O
+4	O
+hours	O
+)	O
+and	O
+microvascular	O
+leakage	B-DISO
+(	O
+24	O
+hours	O
+),	O
+whereas	O
+amylase	B-PRGE
+,	O
+lipase	B-PRGE
+,	O
+and	O
+trypsin	B-PRGE
+did	O
+not	O
+.	O
+
+Demyelination	B-DISO
+is	O
+largely	O
+immune	O
+mediated	O
+.	O
+
+In	O
+this	O
+study	O
+,	O
+the	O
+individual	O
+roles	O
+of	O
+CD4	B-PRGE
+and	O
+CD8	B-PRGE
+T	I-PRGE
+cells	O
+in	O
+MHV	B-SPEC
+-	O
+induced	O
+demyelination	B-DISO
+were	O
+investigated	O
+using	O
+recombination	B-PROC
+-	O
+activating	O
+gene	O
+1	O
+-/-	O
+(	O
+RAG1	B-PRGE
+-/-)	O
+mice	B-SPEC
+infected	O
+with	O
+an	O
+attenuated	O
+strain	O
+of	O
+MHV	B-SPEC
+-	O
+JHM	O
+.	O
+
+In	O
+contrast	O
+,	O
+CD8	B-PRGE
+T	I-PRGE
+cell	O
+-	O
+enriched	O
+recipients	O
+developed	O
+delayed	O
+disease	O
+with	O
+extensive	O
+demyelination	B-DISO
+of	O
+the	O
+spinal	B-ANAT
+cord	I-ANAT
+.	O
+
+If	O
+the	O
+effusion	B-DISO
+is	O
+transudative	O
+,	O
+therapy	O
+should	O
+be	O
+directed	O
+toward	O
+the	O
+underlying	O
+congestive	B-DISO
+heart	I-DISO
+failure	I-DISO
+,	O
+cirrhosis	B-DISO
+,	O
+or	O
+nephrosis	B-DISO
+.	O
+
+Consideration	O
+should	O
+be	O
+given	O
+to	O
+pleurodesis	O
+with	O
+a	O
+sclerosant	O
+if	O
+patients	O
+with	O
+recurrent	O
+transudative	O
+effusion	B-DISO
+have	O
+severe	O
+dyspnea	B-DISO
+due	O
+to	O
+their	O
+effusion	B-DISO
+.	O
+
+During	O
+each	O
+infusion	O
+of	O
+AmBd	O
+over	O
+the	O
+next	O
+3	O
+d	O
+,	O
+the	O
+patient	O
+developed	O
+rigor	B-DISO
+,	O
+chill	B-DISO
+and	O
+elevated	B-PROC
+temperature	I-PROC
+which	O
+was	O
+managed	O
+with	O
+meperidine	O
+.	O
+
+Thus	O
+,	O
+the	O
+decrease	O
+in	O
+pulmonary	B-ANAT
+-	O
+vascular	B-PROC
+resistance	I-PROC
+is	O
+paralleled	O
+by	O
+both	O
+optimized	O
+ventilation	O
+-	O
+perfusion	O
+matching	O
+and	O
+subsequently	O
+improved	O
+gas	B-ENZY
+exchange	O
+.	O
+
+At	O
+present	O
+,	O
+the	O
+use	O
+of	O
+the	O
+long	O
+-	O
+acting	O
+prostacyclin	B-CHED
+analogue	O
+ilomedin	O
+for	O
+ambulant	O
+treatment	O
+of	O
+patients	O
+with	O
+chronic	O
+pulmonary	B-DISO
+hypertension	I-DISO
+is	O
+under	O
+investigation	O
+.	O
+
+By	O
+9	O
+weeks	O
+p	O
+.	O
+i	O
+.,	O
+T	B-ANAT
+cells	I-ANAT
+had	O
+largely	O
+disappeared	O
+from	O
+brains	B-ANAT
+of	O
+both	O
+infected	O
+groups	O
+,	O
+consistent	O
+with	O
+the	O
+decline	O
+of	O
+viral	O
+RNA	O
+.	O
+
+The	O
+replicase	B-PRGE
+is	O
+encoded	O
+in	O
+the	O
+5	O
+'-	O
+most	O
+22	O
+kb	O
+of	O
+the	O
+genomic	O
+RNA	O
+,	O
+which	O
+is	O
+translated	O
+to	O
+produce	O
+a	O
+polyprotein	O
+of	O
+>	O
+800	O
+kDa	O
+.	O
+
+This	O
+study	O
+is	O
+the	O
+first	O
+to	O
+report	O
+enzymatic	B-PROC
+activity	I-PROC
+of	O
+the	O
+PLP2	B-PRGE
+domain	I-PRGE
+and	O
+to	O
+demonstrate	O
+that	O
+three	O
+distinct	O
+viral	B-PRGE
+proteinase	I-PRGE
+activities	O
+process	O
+the	O
+MHV	B-PRGE
+replicase	I-PRGE
+polyprotein	I-PRGE
+.	O
+
+ABSTRACT	O
+:	O
+Coronavirus	O
+contains	O
+three	O
+envelope	B-COMP
+proteins	B-CHED
+,	O
+M	O
+,	O
+E	O
+and	O
+S	O
+,	O
+and	O
+a	O
+nucleocapsid	B-COMP
+,	O
+which	O
+consists	O
+of	O
+genomic	O
+RNA	O
+and	O
+N	B-PRGE
+protein	I-PRGE
+,	O
+within	O
+the	O
+viral	B-COMP
+envelope	I-COMP
+.	O
+
+We	O
+studied	O
+the	O
+macromolecular	O
+interactions	O
+involved	O
+in	O
+coronavirus	B-SPEC
+assembly	O
+in	O
+cells	B-COMP
+infected	O
+with	O
+a	O
+murine	B-SPEC
+coronavirus	I-SPEC
+,	O
+mouse	B-DISO
+hepatitis	I-DISO
+virus	B-SPEC
+(	O
+MHV	B-SPEC
+).	O
+
+Intracellular	B-COMP
+M	O
+protein	B-CHED
+-	O
+N	O
+protein	B-PROC
+interaction	I-PROC
+was	O
+maintained	O
+after	O
+removal	O
+of	O
+viral	O
+RNAs	O
+by	O
+RNase	B-PRGE
+treatment	O
+.	O
+
+These	O
+data	O
+indicated	O
+that	O
+while	O
+the	O
+M	O
+protein	B-CHED
+-	O
+N	O
+protein	B-PROC
+interaction	I-PROC
+,	O
+which	O
+is	O
+independent	O
+of	O
+viral	O
+RNA	O
+,	O
+occurred	O
+in	O
+the	O
+M	B-PRGE
+protein	I-PRGE
+-	I-PRGE
+nucleocapsid	B-COMP
+complex	I-PRGE
+,	O
+some	O
+MHV	B-SPEC
+function	O
+(	O
+s	O
+)	O
+was	O
+necessary	O
+for	O
+the	O
+initiation	O
+of	O
+M	O
+protein	B-CHED
+-	O
+nucleocapsid	B-COMP
+interaction	O
+.	O
+
+Other	O
+species	B-SPEC
+are	O
+not	O
+considered	O
+as	O
+reservoirs	O
+of	O
+IBV	B-SPEC
+.	O
+
+Crimean	B-DISO
+-	I-DISO
+Congo	I-DISO
+haemorrhagic	I-DISO
+fever	I-DISO
+is	O
+transmitted	B-DISO
+to	O
+domestic	O
+animals	B-SPEC
+including	O
+ostriches	B-SPEC
+,	O
+principally	O
+by	O
+ticks	B-SPEC
+of	O
+the	O
+genus	B-SPEC
+Hyalomma	B-SPEC
+.	O
+
+Salmonella	B-DISO
+Gallinarum	O
+and	O
+S	O
+.	O
+Pullorum	O
+are	O
+unknown	O
+in	O
+ostriches	B-SPEC
+.	O
+
+The	O
+viraemic	O
+period	O
+in	O
+vaccinated	O
+slaughter	O
+ostriches	B-SPEC
+is	O
+between	O
+nine	O
+and	O
+eleven	O
+days	O
+and	O
+there	O
+are	O
+no	O
+indications	O
+of	O
+a	O
+carrier	O
+state	O
+or	O
+presence	O
+of	O
+the	O
+virus	B-SPEC
+in	O
+the	O
+meat	O
+or	O
+any	O
+other	O
+tissues	B-ANAT
+after	O
+this	O
+period	O
+,	O
+with	O
+peak	O
+immunoglobulin	B-PRGE
+G	I-PRGE
+response	O
+reached	O
+on	O
+day	O
+fourteen	O
+post	O
+infection	B-DISO
+.	O
+
+Cloacal	B-ANAT
+and	O
+choanal	O
+swabs	O
+used	O
+for	O
+direct	O
+virological	O
+screening	O
+in	O
+clinically	O
+affected	O
+cases	O
+(	O
+field	O
+and	O
+experimental	O
+)	O
+could	O
+not	O
+detect	O
+NDV	B-SPEC
+.	O
+
+Wesselsbron	O
+disease	O
+,	O
+infectious	B-DISO
+bursal	I-DISO
+disease	I-DISO
+(	O
+type	O
+2	O
+),	O
+adenovirus	B-DISO
+and	O
+coronavirus	B-DISO
+infections	I-DISO
+have	O
+been	O
+reported	O
+from	O
+ostriches	B-SPEC
+but	O
+the	O
+significance	O
+of	O
+these	O
+diseases	O
+is	O
+unclear	O
+.	O
+
+The	O
+persistent	O
+presence	O
+of	O
+viruses	B-SPEC
+in	O
+the	O
+upper	B-ANAT
+respiratory	I-ANAT
+tract	I-ANAT
+of	O
+asthmatic	B-DISO
+children	O
+shows	O
+a	O
+possible	O
+connection	O
+between	O
+viral	B-DISO
+infections	I-DISO
+and	O
+asthma	B-PATH
+.	O
+
+Vesicular	B-DISO
+breath	I-DISO
+sounds	I-DISO
+were	O
+reduced	O
+over	O
+the	O
+entire	B-ANAT
+thorax	I-ANAT
+and	O
+there	O
+was	O
+a	O
+systolic	O
+murmur	O
+over	O
+Erb	O
+'	O
+s	O
+point	O
+(	O
+above	O
+the	O
+right	B-ANAT
+clavicle	I-ANAT
+).	O
+
+ARDs	B-DISO
+are	O
+similar	O
+for	O
+most	O
+categories	O
+of	O
+cytotoxic	O
+agents	O
+,	O
+with	O
+chronic	O
+pneumonitis	B-DISO
+and	O
+fibrosis	B-DISO
+being	O
+the	O
+most	O
+common	O
+.	O
+
+ABSTRACT	O
+:	O
+We	O
+report	O
+a	O
+case	O
+of	O
+leptospiral	O
+infection	B-DISO
+in	O
+a	O
+63	O
+-	O
+year	O
+-	O
+old	O
+man	B-CHED
+who	O
+acquired	O
+the	O
+infection	B-DISO
+while	O
+swimming	B-PROC
+in	O
+canals	B-ANAT
+and	O
+streams	O
+in	O
+Hawaii	O
+.	O
+
+Most	O
+patients	O
+experience	O
+self	O
+-	O
+limited	O
+illness	O
+,	O
+with	O
+fever	O
+,	O
+myalgias	B-DISO
+,	O
+and	O
+malaise	B-DISO
+followed	O
+by	O
+an	O
+immune	O
+-	O
+mediated	O
+aseptic	B-DISO
+meningitis	I-DISO
+.	O
+
+A	O
+small	O
+proportion	O
+develop	O
+shock	O
+and	O
+multiple	O
+organ	B-ANAT
+dysfunction	O
+.	O
+
+Whereas	O
+myalgias	B-DISO
+are	O
+ubiquitous	O
+in	O
+leptospiral	B-SPEC
+infection	B-DISO
+,	O
+and	O
+most	O
+patients	O
+show	O
+mildly	O
+elevated	O
+muscle	B-ANAT
+enzymes	O
+,	O
+life	O
+-	O
+threatening	O
+rhabdomyolysis	B-DISO
+is	O
+rare	O
+.	O
+
+ABSTRACT	O
+:	O
+The	O
+contribution	O
+of	O
+the	O
+T	O
+cell	O
+chemoattractant	O
+chemokine	O
+IFN	B-PRGE
+-	O
+inducible	O
+protein	B-CHED
+10	O
+(	O
+IP	O
+-	O
+10	O
+)	O
+in	O
+host	B-PROC
+defense	I-PROC
+following	O
+viral	B-DISO
+infection	I-DISO
+of	O
+the	O
+CNS	B-CHED
+was	O
+examined	O
+.	O
+
+TITLE	O
+:	O
+Molecular	O
+characterization	O
+and	O
+pathogenesis	B-DISO
+of	O
+transmissible	O
+gastroenteritis	B-DISO
+coronavirus	B-SPEC
+(	O
+TGEV	B-SPEC
+)	O
+and	O
+porcine	B-SPEC
+respiratory	O
+coronavirus	B-SPEC
+(	O
+PRCV	O
+)	O
+field	O
+isolates	O
+co	O
+-	O
+circulating	O
+in	O
+a	O
+swine	B-SPEC
+herd	O
+.	O
+
+Sequence	O
+analysis	O
+of	O
+the	O
+TGEV	B-SPEC
+isolate	O
+in	O
+the	O
+partial	O
+S	B-PRGE
+gene	I-PRGE
+and	O
+ORF3	B-PRGE
+/	O
+3a	O
+and	O
+ORF3	B-PRGE
+-	I-PRGE
+1	I-PRGE
+/	I-PRGE
+3b	I-PRGE
+revealed	O
+high	O
+homology	O
+with	O
+enteropathogenic	O
+TGEV	B-SPEC
+strains	O
+.	O
+
+Therefore	O
+,	O
+the	O
+reduced	O
+severity	O
+of	O
+TGE	B-DISO
+observed	O
+in	O
+this	O
+herd	O
+may	O
+be	O
+due	O
+to	O
+the	O
+ongoing	O
+PRCV	O
+infections	B-DISO
+,	O
+which	O
+induce	O
+antibodies	B-COMP
+cross	B-PROC
+-	I-PROC
+reactive	I-PROC
+with	O
+TGEV	B-SPEC
+and	O
+result	O
+in	O
+decreased	O
+disease	O
+severity	O
+.	O
+
+119	O
+ferrets	B-SPEC
+with	O
+epizootic	O
+diarrhea	B-DISO
+of	O
+presumed	O
+viral	O
+cause	O
+and	O
+5	O
+control	O
+ferrets	B-SPEC
+.	O
+
+Characteristic	O
+microscopic	O
+lesions	O
+consistent	O
+with	O
+intestinal	B-ANAT
+coronavirus	B-DISO
+infection	I-DISO
+(	O
+vacuolar	B-COMP
+degeneration	B-DISO
+and	O
+necrosis	B-PROC
+of	O
+villus	B-ANAT
+enterocytes	B-ANAT
+;	O
+villus	B-ANAT
+atrophy	B-DISO
+,	O
+fusion	O
+,	O
+and	O
+blunting	O
+;	O
+and	O
+lymphocytic	O
+enteritis	O
+)	O
+were	O
+consistently	O
+detected	O
+in	O
+affected	O
+ferrets	B-SPEC
+.	O
+
+Immunohistochemical	O
+staining	O
+of	O
+jejunal	B-ANAT
+sections	O
+revealed	O
+coronavirus	B-SPEC
+antigens	B-CHED
+.	O
+
+TITLE	O
+:	O
+Seroprevalence	O
+of	O
+porcine	B-SPEC
+respiratory	O
+coronavirus	B-SPEC
+in	O
+selected	O
+Korean	O
+pigs	B-SPEC
+.	O
+
+Ingestion	O
+is	O
+rare	O
+because	O
+of	O
+alarming	O
+odour	O
+and	O
+irritant	O
+effect	O
+but	O
+documented	O
+in	O
+accidental	O
+,	O
+homicidal	B-DISO
+or	O
+suicidal	O
+attempts	O
+.	O
+
+TITLE	O
+:	O
+Pumpless	O
+extracorporeal	O
+lung	B-ANAT
+assist	O
+and	O
+adult	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+.	O
+
+ABSTRACT	O
+:	O
+We	O
+report	O
+use	O
+of	O
+a	O
+pumpless	O
+extracorporeal	O
+lung	O
+assist	O
+-	O
+a	O
+safe	O
+and	O
+effective	O
+method	O
+in	O
+the	O
+management	O
+of	O
+severe	O
+acute	B-DISO
+respiratory	I-DISO
+failure	I-DISO
+that	O
+allows	O
+an	O
+extracorporal	O
+gas	B-ENZY
+-	O
+exchange	O
+without	O
+the	O
+use	O
+of	O
+a	O
+pump	O
+.	O
+
+The	O
+case	O
+of	O
+a	O
+55	O
+-	O
+year	O
+old	O
+male	O
+patient	O
+admitted	O
+to	O
+the	O
+hospital	O
+because	O
+of	O
+a	O
+bleeding	B-DISO
+diathesis	I-DISO
+is	O
+reported	O
+.	O
+
+Pulmonary	B-DISO
+insufficiency	I-DISO
+was	O
+treated	O
+non	O
+-	O
+invasively	O
+with	O
+CPAP	O
+and	O
+the	O
+patient	O
+recovered	O
+from	O
+pulmonary	B-ANAT
+distress	O
+one	O
+week	O
+later	O
+.	O
+
+We	O
+describe	O
+the	O
+case	O
+of	O
+a	O
+34	O
+-	O
+year	O
+-	O
+old	O
+woman	O
+with	O
+hemorrhage	B-DISO
+into	O
+a	O
+previously	O
+undiscovered	O
+pheochromocytoma	B-DISO
+following	O
+a	O
+fall	O
+on	O
+a	O
+patch	O
+of	O
+ice	O
+.	O
+
+This	O
+is	O
+the	O
+first	O
+reported	O
+case	O
+of	O
+hemorrhagic	O
+pheochromocytoma	B-DISO
+associated	O
+with	O
+traumatic	O
+injury	O
+.	O
+
+In	O
+the	O
+present	O
+study	O
+,	O
+we	O
+demonstrate	O
+that	O
+hnRNP	B-PRGE
+A1	I-PRGE
+also	O
+participates	O
+in	O
+the	O
+transcription	B-PROC
+and	O
+replication	O
+of	O
+a	O
+cytoplasmic	B-COMP
+RNA	O
+virus	B-SPEC
+,	O
+mouse	B-DISO
+hepatitis	I-DISO
+virus	B-SPEC
+(	O
+MHV	B-SPEC
+).	O
+
+Patient	O
+-	O
+related	O
+risk	O
+factors	O
+for	O
+chronic	O
+hypophosphataemia	B-DISO
+were	O
+malnutrition	B-DISO
+,	O
+chronic	B-DISO
+alcoholism	I-DISO
+,	O
+and	O
+diabetes	B-DISO
+mellitus	I-DISO
+.	O
+
+Titers	O
+were	O
+detected	O
+for	O
+antibodies	B-COMP
+against	O
+canine	B-SPEC
+distemper	I-SPEC
+virus	I-SPEC
+,	O
+canine	B-SPEC
+herpesvirus	I-SPEC
+-	O
+1	O
+,	O
+and	O
+canine	O
+parvovirus	B-DISO
+-	O
+2	O
+but	O
+not	O
+for	O
+antibodies	B-COMP
+against	O
+canine	B-SPEC
+adenovirus	I-SPEC
+-	O
+1	O
+,	O
+canine	O
+coronavirus	B-SPEC
+,	O
+canine	B-SPEC
+parainfluenza	I-SPEC
+virus	I-SPEC
+,	O
+rabies	B-SPEC
+virus	I-SPEC
+,	O
+feline	B-SPEC
+herpesvirus	I-SPEC
+-	I-SPEC
+1	I-SPEC
+,	O
+feline	B-SPEC
+calicivirus	I-SPEC
+,	O
+or	O
+feline	B-SPEC
+coronavirus	B-SPEC
+.	O
+
+No	O
+interferon	B-PRGE
+was	O
+detected	O
+in	O
+the	O
+inoculum	O
+used	O
+for	O
+MHV	O
+infection	B-DISO
+.	O
+
+In	O
+situ	O
+hybridization	B-PROC
+confirmed	O
+the	O
+presence	O
+of	O
+viral	O
+RNA	O
+in	O
+brain	B-ANAT
+parenchyma	B-ANAT
+,	O
+outside	O
+blood	B-ANAT
+vessels	I-ANAT
+.	O
+
+As	O
+a	O
+result	O
+,	O
+EDI	O
+RNA	O
+contains	O
+a	O
+truncated	O
+replicase	O
+open	O
+reading	O
+frame	O
+(	O
+EDI	O
+-	O
+ORF	O
+)	O
+and	O
+encodes	O
+a	O
+truncated	O
+replicase	B-PRGE
+polyprotein	O
+.	O
+
+TITLE	O
+:	O
+Demyelination	B-DISO
+determinants	O
+map	O
+to	O
+the	O
+spike	O
+glycoprotein	B-CHED
+gene	O
+of	O
+coronavirus	B-SPEC
+mouse	B-DISO
+hepatitis	I-DISO
+virus	O
+.	O
+
+Recombinant	O
+viruses	B-SPEC
+containing	O
+an	O
+S	O
+gene	O
+derived	O
+from	O
+MHV	B-SPEC
+-	O
+2	O
+in	O
+an	O
+MHV	B-SPEC
+-	O
+A59	O
+background	O
+(	O
+Penn98	O
+-	O
+1	O
+and	O
+Penn98	O
+-	O
+2	O
+)	O
+exhibited	O
+a	O
+persistence	O
+-	O
+positive	O
+,	O
+demyelination	B-DISO
+-	O
+negative	O
+phenotype	O
+.	O
+
+TITLE	O
+:	O
+Human	B-SPEC
+coronavirus	I-SPEC
+229E	I-SPEC
+infects	O
+polarized	O
+airway	B-ANAT
+epithelia	O
+from	O
+the	O
+apical	O
+surface	O
+.	O
+
+As	O
+described	O
+for	O
+MHV	B-SPEC
+,	O
+we	O
+established	O
+that	O
+the	O
+EAV	B-PRGE
+N	I-PRGE
+protein	B-CHED
+colocalizes	O
+with	O
+the	O
+viral	B-COMP
+replication	I-COMP
+complex	I-COMP
+,	O
+suggesting	O
+a	O
+role	O
+in	O
+RNA	B-PROC
+synthesis	I-PROC
+.	O
+
+RESULTS	O
+:	O
+After	O
+the	O
+generalisation	O
+of	O
+the	O
+protease	B-PROC
+inhibitors	I-PROC
+the	O
+visits	O
+rate	O
+decreased	O
+,	O
+the	O
+motives	O
+for	O
+consulting	O
+with	O
+the	O
+physician	O
+and	O
+complementary	O
+examinations	O
+changed	O
+,	O
+invasive	O
+therapeutic	O
+procedures	O
+,	O
+admissions	O
+from	O
+urgencies	O
+and	O
+death	B-PROC
+rates	O
+decreased	O
+.	O
+
+TITLE	O
+:	O
+Comparison	O
+of	O
+serologic	O
+testing	O
+and	O
+slaughter	O
+evaluation	O
+for	O
+assessing	O
+the	O
+effects	O
+of	O
+subclinical	B-DISO
+infection	I-DISO
+on	O
+growth	B-PROC
+in	O
+pigs	B-SPEC
+.	O
+
+Genome	O
+-	O
+length	O
+negative	O
+-	O
+strand	O
+RNA	O
+and	O
+subgenomic	O
+-	O
+length	O
+negative	O
+-	O
+strand	O
+RNAs	O
+,	O
+each	O
+of	O
+which	O
+corresponds	O
+to	O
+each	O
+of	O
+the	O
+subgenomic	O
+mRNAs	O
+,	O
+also	O
+accumulate	O
+in	O
+infected	O
+cells	B-COMP
+.	O
+
+A	O
+recombinant	O
+form	O
+of	O
+nsp10	O
+,	O
+MBP	B-PRGE
+-	I-PRGE
+nsp10	I-PRGE
+,	O
+was	O
+produced	O
+in	O
+Escherichia	B-SPEC
+coli	I-SPEC
+as	O
+a	O
+fusion	O
+protein	B-CHED
+with	O
+the	O
+maltose	B-PRGE
+-	I-PRGE
+binding	B-FUNC
+protein	B-CHED
+.	O
+
+Thus	O
+,	O
+the	O
+combined	O
+data	O
+strongly	O
+support	O
+the	O
+idea	B-SPEC
+that	O
+nidovirus	B-SPEC
+helicases	O
+may	O
+represent	O
+a	O
+separate	O
+group	O
+of	O
+RNA	O
+virus	B-SPEC
+-	O
+encoded	O
+helicases	O
+with	O
+distinct	O
+properties	O
+.	O
+
+There	O
+was	O
+a	O
+severe	O
+evolution	B-PROC
+as	O
+5	O
+children	O
+died	B-PROC
+and	O
+4	O
+survived	O
+with	O
+severe	O
+damage	O
+.	O
+
+Only	O
+one	O
+patient	O
+had	O
+multiple	O
+deletions	O
+in	O
+the	O
+mtDNA	B-COMP
+.	O
+
+ABSTRACT	O
+:	O
+An	O
+antibody	B-COMP
+-	O
+capture	O
+enzyme	O
+-	O
+linked	O
+immunosorbent	O
+assay	O
+(	O
+ELISA	O
+)	O
+for	O
+detection	O
+of	O
+antibody	B-COMP
+to	O
+turkey	B-SPEC
+coronavirus	B-SPEC
+(	O
+TCV	B-SPEC
+)	O
+utilizing	O
+infectious	B-DISO
+bronchitis	B-DISO
+virus	B-SPEC
+(	O
+IBV	B-SPEC
+)	O
+antigen	B-CHED
+was	O
+developed	O
+.	O
+
+Of	O
+the	O
+325	O
+sera	B-COMP
+from	O
+the	O
+field	O
+,	O
+175	O
+were	O
+positive	O
+for	O
+TCV	B-SPEC
+by	O
+immunofluorescent	O
+antibody	B-COMP
+(	O
+IFA	O
+)	O
+assay	O
+.	O
+
+TITLE	O
+:	O
+Morphologic	O
+observations	O
+on	O
+respiratory	B-ANAT
+tracts	I-ANAT
+of	O
+chickens	B-SPEC
+after	O
+hatchery	O
+infectious	B-DISO
+bronchitis	B-DISO
+vaccination	O
+and	O
+formaldehyde	B-CHED
+fumigation	O
+.	O
+
+After	O
+necropsy	O
+on	O
+the	O
+first	O
+,	O
+eighth	O
+,	O
+and	O
+twenty	O
+-	O
+sixth	O
+days	O
+after	O
+birth	B-PROC
+,	O
+samples	O
+from	O
+tracheal	O
+upper	O
+portion	O
+and	O
+lungs	B-ANAT
+were	O
+conventionally	O
+processed	O
+for	O
+light	O
+,	O
+scanning	O
+,	O
+and	O
+transmission	O
+electron	O
+microscopy	O
+.	O
+
+The	O
+nonfumigated	O
+and	O
+vaccinated	O
+birds	B-SPEC
+(	O
+NFV	O
+)	O
+revealed	O
+less	O
+injury	O
+on	O
+the	O
+epithelial	O
+surface	O
+and	O
+a	O
+more	O
+rapid	O
+response	O
+to	O
+epithelial	O
+regeneration	B-PROC
+than	O
+the	O
+in	O
+only	O
+fumigated	O
+animals	B-SPEC
+(	O
+FNV	O
+).	O
+
+In	O
+both	O
+experiments	O
+and	O
+within	O
+IBV	B-SPEC
+challenge	O
+serotype	O
+,	O
+broilers	O
+given	O
+MD	O
+vaccines	O
+(	O
+in	O
+ovo	B-SPEC
+or	O
+at	O
+hatch	B-PROC
+)	O
+and	O
+IB	O
+vaccines	O
+at	O
+hatch	B-PROC
+had	O
+protection	O
+rates	O
+to	O
+IBV	B-SPEC
+challenges	O
+that	O
+were	O
+not	O
+significantly	O
+less	O
+(	O
+P	O
+<	O
+or	O
+=	O
+0	O
+.	O
+05	O
+)	O
+than	O
+IB	O
+protection	O
+rates	O
+of	O
+groups	O
+that	O
+received	O
+only	O
+IB	O
+vaccines	O
+at	O
+hatch	B-PROC
+.	O
+
+These	O
+isolates	O
+were	O
+recovered	O
+from	O
+broiler	O
+flocks	O
+with	O
+respiratory	B-DISO
+disease	I-DISO
+raised	O
+on	O
+the	O
+Delmarva	O
+peninsula	O
+in	O
+spite	O
+of	O
+Ark	B-PRGE
+vaccination	O
+in	O
+the	O
+region	O
+.	O
+
+On	O
+the	O
+basis	O
+of	O
+the	O
+VN	O
+and	O
+sequencing	O
+findings	O
+,	O
+isolates	O
+Ark	B-PRGE
+/	I-PRGE
+213	I-PRGE
+/	I-PRGE
+96	I-PRGE
+,	O
+Ark	B-PRGE
+/	O
+15C	O
+/	O
+96	O
+,	O
+Ark	B-PRGE
+/	O
+1529	O
+/	O
+95	O
+,	O
+and	O
+Ark	B-PRGE
+/	O
+1534	O
+/	O
+95	O
+were	O
+considered	O
+to	O
+be	O
+a	O
+single	O
+subtype	O
+of	O
+the	O
+Ark	B-PRGE
+serotype	I-PRGE
+.	O
+
+TITLE	O
+:	O
+Comparison	O
+of	O
+virus	B-SPEC
+isolation	O
+,	O
+immunohistochemistry	O
+,	O
+and	O
+reverse	B-PRGE
+transcriptase	I-PRGE
+-	O
+polymerase	O
+chain	O
+reaction	O
+procedures	O
+for	O
+detection	O
+of	O
+turkey	O
+coronavirus	B-SPEC
+.	O
+
+TCV	B-SPEC
+was	O
+detected	O
+in	O
+experimentally	O
+infected	O
+turkeys	B-SPEC
+as	O
+early	O
+as	O
+day	O
+1	O
+postexposure	O
+(	O
+PE	O
+)	O
+by	O
+each	O
+of	O
+the	O
+four	O
+detection	O
+procedures	O
+.	O
+
+We	O
+hypothesized	O
+that	O
+low	O
+serum	B-COMP
+total	O
+protein	B-CHED
+levels	O
+might	O
+correlate	O
+with	O
+the	O
+likelihood	O
+of	O
+ARDS	B-DISO
+in	O
+at	O
+-	O
+risk	O
+patients	O
+because	O
+serum	B-COMP
+total	O
+protein	B-CHED
+is	O
+the	O
+chief	O
+determinant	O
+of	O
+oncotic	O
+pressure	O
+in	O
+humans	B-SPEC
+.	O
+
+The	O
+pancytopenia	B-DISO
+was	O
+severe	O
+(	O
+white	B-ANAT
+blood	I-ANAT
+cell	I-ANAT
+count	O
+,	O
+0	O
+.	O
+9	O
+x	O
+10	O
+(	O
+9	O
+)/	O
+L	O
+;	O
+hemoglobin	B-PRGE
+,	O
+59	O
+g	O
+/	O
+L	O
+;	O
+platelets	B-ANAT
+,	O
+36	O
+x	O
+10	O
+(	O
+9	O
+)/	O
+L	O
+),	O
+required	O
+many	O
+transfusions	O
+,	O
+and	O
+resolved	O
+2	O
+months	O
+later	O
+.	O
+
+RHS	B-DISO
+duration	O
+was	O
+20	O
+days	O
+;	O
+the	O
+patient	O
+recovered	O
+completely	O
+.	O
+
+Lymphoplasmacytoid	O
+cells	B-ANAT
+,	I-ANAT
+plasma	I-ANAT
+cells	B-COMP
+,	O
+and	O
+small	O
+lymphocytes	B-ANAT
+were	O
+seen	O
+in	O
+the	O
+bone	B-ANAT
+marrow	I-ANAT
+and	O
+lymphoplasmacytoid	O
+cells	B-COMP
+were	O
+also	O
+seen	O
+in	O
+the	O
+smear	O
+of	O
+the	O
+patient	O
+'	O
+s	O
+peripheral	B-ANAT
+blood	I-ANAT
+.	O
+
+ABSTRACT	O
+:	O
+Acute	O
+lung	O
+injury	O
+(	O
+ALI	O
+)	O
+is	O
+a	O
+syndrome	B-DISO
+of	O
+severe	O
+acute	B-DISO
+respiratory	I-DISO
+failure	I-DISO
+defined	O
+by	O
+a	O
+constellation	O
+of	O
+clinical	O
+criteria	O
+.	O
+
+Role	O
+in	O
+lung	B-ANAT
+fluid	B-PROC
+balance	I-PROC
+in	O
+clinical	O
+lung	B-ANAT
+injury	O
+.	O
+
+This	O
+process	O
+can	O
+be	O
+upregulated	O
+by	O
+several	O
+catecholamine	B-CHED
+-	O
+dependent	O
+and	O
+independent	O
+mechanisms	O
+.	O
+
+In	O
+this	O
+situation	O
+,	O
+the	O
+abnormal	O
+ventilation	B-PROC
+-	I-PROC
+perfusion	I-PROC
+ratio	I-PROC
+is	O
+improved	O
+by	O
+inhaled	B-PROC
+NO	O
+,	O
+limiting	O
+arterial	B-ANAT
+hypoxia	B-DISO
+.	O
+
+In	O
+normal	O
+and	O
+lesioned	O
+white	B-ANAT
+matter	I-ANAT
+,	O
+oligodendrocyte	B-ANAT
+lineage	O
+cells	B-COMP
+,	O
+including	O
+progenitors	O
+and	O
+mature	O
+cells	B-COMP
+,	O
+were	O
+found	O
+to	O
+express	O
+multiple	O
+FGFR	B-FUNC
+types	O
+(	O
+FGFR1	B-PRGE
+,	O
+FGFR2	B-PRGE
+,	O
+and	O
+/	O
+or	O
+FGFR3	B-PRGE
+).	O
+
+Bronchoalveolar	O
+lavage	O
+disclosed	O
+neutrophilic	B-PROC
+alveolitis	B-DISO
+.	O
+
+ABSTRACT	O
+:	O
+Strains	O
+OC43	O
+and	O
+229E	O
+of	O
+human	B-SPEC
+coronaviruses	O
+(	O
+HCoV	O
+)	O
+cause	O
+one	O
+-	O
+third	O
+of	O
+common	B-DISO
+colds	I-DISO
+and	O
+hospital	O
+-	O
+acquired	O
+upper	B-ANAT
+respiratory	I-ANAT
+tract	I-ANAT
+HCoV	O
+infections	B-DISO
+have	O
+been	O
+reported	O
+in	O
+premature	O
+newborns	O
+.	O
+
+Of	O
+the	O
+various	O
+chemical	O
+disinfectants	B-CHED
+tested	O
+,	O
+Proviodine	O
+reduced	O
+the	O
+virus	B-SPEC
+infectious	B-DISO
+titre	O
+by	O
+at	O
+least	O
+50	O
+%.	O
+
+CRRTs	O
+have	O
+certainly	O
+made	O
+the	O
+management	O
+of	O
+critically	B-DISO
+ill	I-DISO
+patients	O
+with	O
+acute	B-DISO
+renal	I-DISO
+failure	I-DISO
+(	O
+ARF	B-DISO
+)	O
+combined	O
+with	O
+cardiovascular	B-ANAT
+instability	O
+,	O
+severe	O
+fluid	B-DISO
+overload	I-DISO
+,	O
+hypercatabolism	B-DISO
+,	O
+cerebral	B-DISO
+edema	I-DISO
+,	O
+adult	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+,	O
+lactic	B-DISO
+acidosis	I-DISO
+,	O
+sepsis	B-DISO
+or	O
+other	O
+inflammatory	O
+syndromes	B-DISO
+,	I-DISO
+crush	I-DISO
+syndrome	B-DISO
+,	O
+congestive	B-DISO
+heart	I-DISO
+failure	I-DISO
+,	O
+and	O
+cardiopulmonary	B-ANAT
+bypass	O
+easier	O
+.	O
+
+This	O
+case	O
+report	O
+indicates	O
+that	O
+nonindustrial	O
+exposures	O
+due	O
+to	O
+household	O
+product	O
+misuse	O
+,	O
+especially	O
+to	O
+mixing	O
+cleaning	O
+agents	O
+,	O
+may	O
+cause	O
+adult	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+and	O
+not	O
+only	O
+irritant	O
+-	O
+induced	O
+asthma	B-PATH
+.	O
+
+Plasma	B-ANAT
+leptin	B-PRGE
+,	O
+adjusted	O
+for	O
+fat	O
+mass	O
+expressed	B-PROC
+as	O
+percentage	O
+of	O
+body	B-ANAT
+weight	O
+(%	O
+FM	O
+),	O
+was	O
+elevated	O
+on	O
+Day	O
+1	O
+compared	O
+with	O
+healthy	O
+subjects	O
+(	O
+1	O
+.	O
+82	O
+[	O
+3	O
+.	O
+85	O
+]	O
+versus	O
+0	O
+.	O
+32	O
+[	O
+0	O
+.	O
+72	O
+]	O
+ng	O
+%/	O
+ml	O
+,	O
+p	O
+=	O
+0	O
+.	O
+008	O
+),	O
+but	O
+decreased	O
+significantly	O
+until	O
+Day	O
+7	O
+(	O
+1	O
+.	O
+46	O
+[	O
+3	O
+.	O
+77	O
+]	O
+ng	O
+%/	O
+ml	O
+,	O
+p	O
+=	O
+0	O
+.	O
+
+ABSTRACT	O
+:	O
+(	O
+a	O
+)	O
+To	O
+assess	O
+whether	O
+differences	O
+in	O
+lung	B-ANAT
+morphology	O
+observed	O
+in	O
+patients	O
+with	O
+adult	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+(	O
+ARDS	B-DISO
+)	O
+are	O
+associated	O
+with	O
+differences	O
+in	O
+cardiorespiratory	O
+parameters	O
+,	O
+lung	B-ANAT
+mechanics	O
+,	O
+and	O
+outcome	O
+.	O
+
+The	O
+only	O
+definitive	O
+antemortem	O
+diagnostic	O
+test	O
+for	O
+FIP	B-DISO
+is	O
+histopathologic	O
+examination	O
+of	O
+tissue	B-ANAT
+.	O
+
+Treatment	O
+of	O
+ocular	B-PROC
+FIP	B-DISO
+is	O
+symptomatic	O
+,	O
+and	O
+the	O
+mainstay	O
+of	O
+palliative	O
+therapy	O
+is	O
+topical	O
+or	O
+systemic	O
+corticosteroids	B-CHED
+or	O
+both	O
+.	O
+
+TITLE	O
+:	O
+In	O
+vitro	O
+efficacy	O
+of	O
+nikkomycin	B-CHED
+Z	I-CHED
+against	O
+the	O
+human	B-SPEC
+isolate	O
+of	O
+the	O
+microsporidian	O
+species	B-SPEC
+Encephalitozoon	B-SPEC
+hellem	I-SPEC
+.	O
+
+When	O
+controlled	O
+for	O
+age	O
+,	O
+RDI	O
+,	O
+and	O
+LSAT	O
+,	O
+the	O
+white	O
+men	O
+were	O
+substantially	O
+more	O
+obese	B-DISO
+(	O
+mean	O
+BMI	O
+,	O
+29	O
+.	O
+7	O
++/-	O
+
+Although	O
+the	O
+posterior	O
+airway	B-ANAT
+space	O
+and	O
+the	O
+distance	O
+from	O
+the	O
+mandibular	B-ANAT
+plane	O
+to	O
+hyoid	B-ANAT
+bone	I-ANAT
+were	O
+less	O
+abnormal	O
+in	O
+the	O
+Far	O
+-	O
+East	O
+Asian	O
+men	O
+,	O
+the	O
+cranial	B-ANAT
+base	I-ANAT
+dimensions	O
+were	O
+significantly	O
+decreased	O
+.	O
+
+Bovine	B-SPEC
+coronavirus	B-SPEC
+was	O
+detected	O
+by	O
+use	O
+of	O
+an	O
+ELISA	O
+and	O
+immune	O
+electron	O
+microscopy	O
+in	O
+fecal	B-ANAT
+and	O
+nasal	B-ANAT
+swab	O
+samples	O
+and	O
+by	O
+immunohistochemical	O
+analysis	O
+of	O
+intestinal	B-ANAT
+sections	O
+collected	O
+from	O
+calves	O
+during	O
+necropsy	O
+.	O
+
+Previous	O
+studies	O
+have	O
+shown	O
+that	O
+the	O
+leader	O
+RNA	O
+in	O
+the	O
+DI	O
+genome	O
+significantly	O
+enhances	O
+the	O
+efficiency	O
+of	O
+DI	O
+subgenomic	O
+mRNA	B-PROC
+transcription	B-PROC
+,	O
+indicating	O
+that	O
+the	O
+leader	O
+RNA	O
+is	O
+a	O
+cis	B-DISO
+-	O
+acting	O
+sequence	O
+for	O
+mRNA	B-PROC
+transcription	B-PROC
+.	O
+
+Analyses	O
+of	O
+the	O
+secondary	O
+structure	O
+indicate	O
+that	O
+this	O
+35	O
+-	O
+nt	O
+sequence	O
+forms	O
+two	O
+stem	B-ANAT
+-	O
+loops	O
+conserved	O
+among	O
+MHVs	O
+.	O
+
+TITLE	O
+:	O
+Strategy	O
+for	O
+systematic	O
+assembly	O
+of	O
+large	O
+RNA	O
+and	O
+DNA	O
+genomes	O
+:	O
+transmissible	O
+gastroenteritis	B-DISO
+virus	O
+model	O
+.	O
+
+We	O
+have	O
+assembled	O
+a	O
+full	O
+-	O
+length	O
+infectious	B-DISO
+construct	O
+of	O
+transmissible	O
+gastroenteritis	B-DISO
+virus	B-SPEC
+(	O
+TGEV	B-SPEC
+),	O
+an	O
+important	O
+pathogen	O
+in	O
+swine	B-SPEC
+.	O
+
+Viral	O
+antigen	B-CHED
+production	O
+and	O
+subgenomic	O
+mRNA	B-PROC
+synthesis	I-PROC
+were	O
+evident	O
+during	O
+infection	B-DISO
+and	O
+throughout	O
+passage	O
+.	O
+
+Plaque	B-DISO
+-	O
+purified	O
+virus	B-SPEC
+derived	O
+from	O
+the	O
+infectious	B-DISO
+construct	O
+replicated	O
+efficiently	O
+and	O
+displayed	O
+similar	O
+plaque	B-DISO
+morphology	O
+in	O
+permissive	O
+host	B-COMP
+cells	B-COMP
+.	O
+
+Host	B-COMP
+range	O
+phenotypes	O
+of	O
+the	O
+molecularly	O
+cloned	O
+and	O
+wild	O
+-	O
+type	O
+viruses	B-SPEC
+were	O
+similar	O
+in	O
+cells	B-COMP
+of	O
+swine	B-SPEC
+and	O
+feline	B-SPEC
+origin	O
+.	O
+
+TITLE	O
+:	O
+Extracorporeal	O
+membrane	B-COMP
+oxygenation	B-PROC
+:	O
+a	O
+ten	O
+-	O
+year	O
+experience	O
+.	O
+
+We	O
+present	O
+outcome	O
+,	O
+clinical	O
+parameters	O
+,	O
+and	O
+complications	O
+in	O
+a	O
+cohort	O
+of	O
+245	O
+ARDS	B-DISO
+patients	O
+of	O
+whom	O
+62	O
+were	O
+treated	O
+with	O
+ECMO	O
+.	O
+
+ECMO	O
+is	O
+a	O
+therapeutic	O
+option	O
+for	O
+patients	O
+with	O
+severe	O
+ARDS	B-DISO
+,	O
+likely	O
+to	O
+increase	O
+survival	O
+.	O
+
+In	O
+the	O
+steroid	B-CHED
+group	O
+,	O
+each	O
+patient	O
+was	O
+given	O
+250	O
+mg	O
+of	O
+methylprednisolone	B-CHED
+intravenously	O
+before	O
+operation	O
+followed	O
+by	O
+125	O
+mg	O
+on	O
+postoperative	O
+days	O
+1	O
+and	O
+2	O
+.	O
+
+TITLE	O
+:	O
+Vitamin	B-CHED
+A	I-CHED
+supplements	O
+and	O
+diarrheal	O
+and	O
+respiratory	B-DISO
+tract	I-DISO
+infections	I-DISO
+among	O
+children	O
+in	O
+Dar	B-DISO
+es	O
+Salaam	O
+,	O
+Tanzania	O
+.	O
+
+In	O
+late	O
+1999	O
+and	O
+early	O
+2000	O
+,	O
+an	O
+outbreak	O
+of	O
+acute	O
+illness	O
+compatible	O
+with	O
+HPS	B-DISO
+was	O
+reported	O
+in	O
+Los	O
+Santos	O
+,	O
+Panama	B-SPEC
+,	O
+with	O
+the	O
+death	B-PROC
+of	O
+3	O
+of	O
+the	O
+12	O
+(	O
+25	O
+%)	O
+suspected	O
+cases	O
+.	O
+
+ABSTRACT	O
+:	O
+Previous	O
+definition	O
+of	O
+classic	O
+dengue	B-DISO
+,	O
+with	O
+or	O
+without	O
+bleeding	B-DISO
+,	O
+and	O
+of	O
+dengue	B-DISO
+hemorrhagic	I-DISO
+fever	I-DISO
+(	O
+DHF	O
+)	O
+that	O
+may	O
+evolve	O
+without	O
+bleeding	B-DISO
+and	O
+with	O
+or	O
+without	O
+dengue	B-DISO
+shock	I-DISO
+syndrome	I-DISO
+(	O
+DSS	B-DISO
+)	O
+are	O
+reviewed	O
+here	O
+.	O
+
+The	O
+classical	O
+approach	O
+to	O
+the	O
+diagnosis	O
+and	O
+treatment	O
+of	O
+dengue	B-DISO
+,	O
+although	O
+useful	O
+in	O
+the	O
+past	O
+,	O
+nowadays	O
+breeds	B-PROC
+confusion	B-DISO
+and	O
+adds	O
+a	O
+burden	O
+to	O
+the	O
+physician	O
+'	O
+s	O
+task	O
+of	O
+decision	O
+-	O
+making	O
+regarding	O
+the	O
+treatment	O
+of	O
+patients	O
+with	O
+severe	O
+forms	O
+of	O
+the	O
+disease	O
+.	O
+
+It	O
+also	O
+approximates	O
+the	O
+dengue	B-DISO
+syndrome	B-DISO
+to	O
+other	O
+protocols	O
+and	O
+medical	O
+procedures	O
+routinely	O
+used	O
+in	O
+intensive	O
+care	O
+units	O
+,	O
+making	O
+it	O
+easier	O
+to	O
+be	O
+followed	O
+by	O
+the	O
+health	O
+personnel	O
+working	O
+in	O
+areas	O
+subject	O
+to	O
+epidemic	O
+bursts	O
+.	O
+
+In	O
+an	O
+effort	B-PROC
+to	O
+optimize	O
+the	O
+expression	B-PROC
+,	O
+we	O
+have	O
+constructed	O
+several	O
+BAV	B-DISO
+-	O
+3	O
+recombinants	O
+carrying	O
+the	O
+hemagglutinin	B-PRGE
+esterase	I-PRGE
+(	O
+HE	O
+)	O
+gene	O
+of	O
+bovine	B-SPEC
+coronavirus	B-SPEC
+(	O
+BCV	B-SPEC
+)	O
+in	O
+the	O
+E3	O
+region	O
+with	O
+or	O
+without	O
+exogenous	O
+transcription	B-PROC
+control	O
+elements	O
+.	O
+
+The	O
+expression	B-PROC
+studies	O
+suggest	O
+that	O
+the	O
+introduction	O
+of	O
+a	O
+137	O
+bp	O
+chimeric	O
+intron	O
+upstream	O
+of	O
+the	O
+HE	B-PRGE
+cDNA	I-PRGE
+is	O
+able	O
+to	O
+increase	O
+the	O
+level	O
+of	O
+HE	B-PRGE
+gene	I-PRGE
+expression	O
+.	O
+
+However	O
+,	O
+the	O
+recombinant	B-PRGE
+BAV	I-PRGE
+-	I-PRGE
+3	I-PRGE
+containing	I-PRGE
+HE	I-PRGE
+under	O
+the	O
+HCMV	O
+IE	O
+promoter	O
+replicated	O
+less	O
+efficiently	O
+than	O
+the	O
+wild	O
+-	O
+type	O
+BAV	B-DISO
+-	O
+3	O
+.	O
+
+TITLE	O
+:	O
+Glucose	B-CHED
+and	O
+galactose	B-CHED
+absorption	O
+after	O
+ingestion	O
+of	O
+milk	O
+containing	O
+hydrolysed	O
+lactose	B-CHED
+in	O
+calves	O
+with	O
+diarrhoea	O
+.	O
+
+Peak	O
+plasma	B-ANAT
+glucose	B-CHED
+and	O
+blood	B-ANAT
+galactose	B-CHED
+concentration	O
+tended	O
+to	O
+be	O
+delayed	O
+after	O
+the	O
+intake	O
+of	O
+lactose	B-CHED
+-	O
+hydrolysed	O
+milk	O
+,	O
+which	O
+implies	O
+that	O
+gastric	B-PROC
+emptying	I-PROC
+was	O
+probably	O
+delayed	O
+.	O
+
+Filter	O
+binding	B-FUNC
+was	O
+used	O
+to	O
+map	O
+N	O
+-	O
+binding	B-FUNC
+sites	O
+within	O
+Drep	O
+,	O
+a	O
+BCV	B-SPEC
+-	O
+defective	O
+genome	O
+that	O
+is	O
+replicated	O
+and	O
+packaged	O
+in	O
+the	O
+presence	O
+of	O
+helper	O
+virus	O
+.	O
+
+The	O
+data	O
+clearly	O
+demonstrate	O
+that	O
+N	O
+binds	B-FUNC
+coronavirus	B-SPEC
+RNAs	O
+more	O
+efficiently	O
+than	O
+nonviral	O
+RNAs	O
+.	O
+
+About	O
+one	O
+third	O
+of	O
+reported	O
+reactions	O
+to	O
+melon	O
+are	O
+confirmed	O
+by	O
+means	O
+of	O
+DBPCFC	O
+,	O
+which	O
+has	O
+been	O
+proven	O
+to	O
+be	O
+the	O
+most	O
+reliable	O
+procedure	O
+in	O
+the	O
+diagnosis	O
+of	O
+clinical	O
+fruit	B-DISO
+allergy	I-DISO
+.	O
+
+The	O
+3	O
+'-	O
+UTR	O
+of	O
+the	O
+D	O
+-	O
+RNAs	O
+was	O
+flanked	O
+by	O
+a	O
+hepatitis	B-PRGE
+delta	I-PRGE
+antigenomic	I-PRGE
+ribozyme	I-PRGE
+and	O
+T7	O
+terminator	O
+sequence	O
+to	O
+generate	O
+suitable	O
+3	O
+'	O
+ends	O
+for	O
+rescue	O
+by	O
+helper	O
+IBV	B-SPEC
+.	O
+
+All	O
+of	O
+these	O
+wt	O
+and	O
+mutated	O
+S	O
+proteins	B-CHED
+were	O
+similarly	O
+transported	O
+onto	O
+the	O
+cell	O
+membrane	O
+independent	O
+of	O
+their	O
+fusogenicity	O
+capability	O
+.	O
+
+Phylogenetic	O
+trees	O
+of	O
+different	O
+topology	O
+indicated	O
+that	O
+the	O
+consensus	O
+IG	O
+sequences	O
+and	O
+the	O
+highly	O
+conserved	O
+sequence	O
+around	O
+this	O
+regions	O
+may	O
+serve	O
+as	O
+recombination	B-PROC
+'	B-DISO
+hot	I-DISO
+spots	I-DISO
+'.	O
+
+Phylogenetic	O
+analysis	O
+of	O
+selected	O
+regions	O
+of	O
+the	O
+genome	O
+of	O
+the	O
+DE072	O
+serotype	O
+field	O
+isolates	O
+further	O
+support	O
+those	O
+results	O
+and	O
+indicate	O
+that	O
+isolates	O
+within	O
+the	O
+same	O
+serotype	O
+may	O
+have	O
+different	O
+amounts	O
+of	O
+nucleotide	O
+sequence	O
+similarity	O
+with	O
+each	O
+other	O
+in	O
+individual	O
+genes	O
+other	O
+than	O
+the	O
+S	B-PRGE
+gene	I-PRGE
+.	O
+
+In	O
+vitro	O
+antigen	B-CHED
+quantification	O
+assays	O
+would	O
+be	O
+attractive	O
+alternatives	O
+for	O
+the	O
+current	O
+potency	O
+assays	O
+because	O
+the	O
+time	O
+and	O
+costs	O
+involved	O
+could	O
+be	O
+greatly	O
+reduced	O
+and	O
+animal	B-SPEC
+use	O
+could	O
+be	O
+avoided	O
+.	O
+
+ECMO	O
+technique	O
+was	O
+an	O
+adaptation	B-PROC
+of	O
+conventional	O
+cardiopulmonary	B-ANAT
+bypass	O
+techniques	O
+and	O
+introduced	O
+into	O
+treatment	O
+of	O
+severe	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+(	O
+ARDS	B-DISO
+)	O
+in	O
+the	O
+1970s	O
+.	O
+
+In	O
+conventional	O
+treatment	O
+lung	B-ANAT
+-	O
+protective	O
+ventilation	O
+strategies	O
+were	O
+introduced	O
+and	O
+ECMO	O
+was	O
+made	O
+safer	O
+by	O
+applying	O
+heparin	B-CHED
+-	O
+coated	O
+equipment	O
+,	O
+membranes	B-ANAT
+and	O
+tubings	O
+.	O
+
+TITLE	O
+:	O
+Guillain	O
+-	O
+Barré	O
+Syndrome	B-DISO
+.	O
+
+Randomized	O
+controlled	O
+trials	O
+show	O
+that	O
+intravenous	O
+immune	O
+globulin	O
+(	O
+IVIg	O
+)	O
+and	O
+plasma	B-ANAT
+exchange	O
+(	O
+PE	O
+)	O
+are	O
+equally	O
+effective	O
+in	O
+reducing	O
+the	O
+time	O
+to	O
+functional	B-DISO
+recovery	I-DISO
+.	O
+
+We	O
+emphasize	O
+the	O
+importance	O
+of	O
+imaging	O
+the	O
+cerebral	B-ANAT
+arteries	I-ANAT
+in	O
+traumatic	O
+patients	O
+,	O
+even	O
+in	O
+the	O
+absence	O
+of	O
+initial	O
+neurological	B-DISO
+symptom	I-DISO
+.	O
+
+CONCLUSIONS	O
+:	O
+This	O
+case	O
+illustrates	O
+the	O
+potential	O
+risk	O
+of	O
+a	O
+traumatic	B-DISO
+aneurysm	I-DISO
+as	O
+a	O
+potential	O
+source	O
+of	O
+ischemic	O
+brain	B-DISO
+infarctions	I-DISO
+.	O
+
+Lactic	O
+acidosis	O
+with	O
+hemolytic	B-DISO
+-	I-DISO
+uremic	I-DISO
+syndrome	I-DISO
+appeared	O
+,	O
+and	O
+he	O
+died	B-PROC
+as	O
+the	O
+result	O
+of	O
+a	O
+multivisceral	O
+(	O
+respiratory	O
+,	O
+renal	B-ANAT
+,	O
+hepatic	B-ANAT
+)	O
+deficiency	O
+.	O
+
+The	O
+RT	O
+-	O
+PCR	O
+product	O
+was	O
+cloned	O
+into	O
+pUC19	O
+and	O
+sequenced	O
+;	O
+the	O
+complete	O
+N	B-PRGE
+protein	I-PRGE
+of	O
+NC99	O
+(	O
+446	O
+amino	B-CHED
+acids	I-CHED
+)	O
+was	O
+then	O
+compared	O
+with	O
+published	O
+N	B-PRGE
+protein	I-PRGE
+sequences	O
+of	O
+other	O
+avian	B-SPEC
+and	O
+mammalian	B-SPEC
+coronaviruses	O
+.	O
+
+Protocol	O
+compliance	O
+was	O
+poor	O
+,	O
+with	O
+only	O
+31	O
+%	O
+of	O
+protocol	O
+A	O
+patients	O
+receiving	O
+prehospital	O
+fluids	B-ANAT
+and	O
+only	O
+80	O
+%	O
+of	O
+protocol	O
+B	O
+patients	O
+not	O
+given	O
+fluids	B-ANAT
+.	O
+
+TITLE	O
+:	O
+[	O
+Meningitis	B-DISO
+with	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+in	O
+adults	O
+and	O
+jaundice	B-DISO
+--	O
+case	O
+report	O
+].	O
+
+The	O
+CPE	O
+was	O
+induced	O
+most	O
+rapidly	O
+in	O
+IC	O
+-	O
+21	O
+cells	B-COMP
+and	O
+was	O
+visible	O
+microscopically	O
+in	O
+all	O
+cell	B-ANAT
+lines	I-ANAT
+tested	O
+.	O
+
+To	O
+determine	O
+the	O
+sensitivity	O
+of	O
+the	O
+cell	B-ANAT
+lines	I-ANAT
+to	O
+murine	B-SPEC
+coronaviruses	O
+,	O
+the	O
+50	O
+%	O
+tissue	B-ANAT
+culture	O
+infectious	B-DISO
+dose	O
+of	O
+the	O
+coronaviruses	O
+was	O
+determined	O
+with	O
+B16	O
+,	O
+DBT	B-CHED
+,	O
+IC	O
+-	O
+21	O
+and	O
+J774A	O
+.	O
+1	O
+cells	B-COMP
+,	O
+and	O
+compared	O
+to	O
+that	O
+with	O
+DBT	B-CHED
+cells	B-COMP
+.	O
+
+Phylogenetic	O
+analysis	O
+of	O
+19	O
+strains	O
+of	O
+IBV	B-SPEC
+and	O
+3	O
+strains	O
+of	O
+turkey	B-SPEC
+coronavirus	B-SPEC
+predicted	O
+a	O
+conserved	O
+stem	B-ANAT
+-	O
+loop	O
+structure	O
+at	O
+the	O
+5	O
+'	O
+end	O
+of	O
+region	O
+II	O
+of	O
+the	O
+3	O
+'	O
+UTR	O
+.	O
+
+ABSTRACT	O
+:	O
+The	O
+coronavirus	O
+nucleoprotein	O
+(	O
+N	O
+)	O
+has	O
+been	O
+reported	O
+to	O
+be	O
+involved	O
+in	O
+various	O
+aspects	O
+of	O
+virus	B-PROC
+replication	I-PROC
+.	O
+
+NF	B-PROC
+-	I-PROC
+kappaB	I-PROC
+activation	I-PROC
+(	O
+by	O
+electrophoretic	O
+mobility	O
+shift	O
+assay	O
+)	O
+is	O
+strikingly	O
+increased	O
+in	O
+the	O
+noncryo	O
+liver	B-ANAT
+(	O
+but	O
+not	O
+in	O
+the	O
+lung	B-ANAT
+)	O
+at	O
+30	O
+min	O
+and	O
+in	O
+both	O
+the	O
+liver	B-ANAT
+and	O
+lung	B-ANAT
+tissue	I-ANAT
+1	O
+h	O
+after	O
+cryo	O
+,	O
+returning	O
+to	O
+the	O
+baseline	O
+by	O
+2	O
+h	O
+and	O
+beyond	O
+.	O
+
+Marginating	O
+PMNs	O
+and	O
+foamy	O
+macrophages	B-ANAT
+were	O
+more	O
+common	O
+after	O
+cryo	O
+at	O
+all	O
+time	O
+points	O
+(	O
+P	O
+<	O
+0	O
+.	O
+05	O
+,	O
+cryo	O
+vs	O
+resection	O
+).	O
+
+This	O
+report	O
+of	O
+a	O
+patient	O
+with	O
+the	O
+Lemierre	B-DISO
+syndrome	I-DISO
+is	O
+complemented	O
+by	O
+a	O
+review	O
+of	O
+the	O
+literature	O
+on	O
+the	O
+subject	O
+.	O
+
+Three	O
+recombinant	O
+viruses	B-SPEC
+were	O
+tested	O
+by	O
+oral	B-ANAT
+immunization	O
+of	O
+pigs	B-SPEC
+and	O
+both	O
+antibody	O
+response	O
+and	O
+virus	B-DISO
+shedding	I-DISO
+were	O
+monitored	O
+.	O
+
+ABSTRACT	O
+:	O
+Numerous	O
+respiratory	O
+bovine	B-SPEC
+coronaviruses	O
+(	O
+RBCV	O
+)	O
+were	O
+isolated	O
+recently	O
+from	O
+nasal	B-ANAT
+swab	O
+samples	O
+and	O
+lung	B-ANAT
+tissues	I-ANAT
+of	O
+feedlot	O
+cattle	B-SPEC
+with	O
+acute	O
+respiratory	B-DISO
+tract	I-DISO
+disease	I-DISO
+.	O
+
+These	O
+results	O
+are	O
+consistent	O
+with	O
+the	O
+hypothesis	O
+that	O
+RBCV	O
+strains	O
+have	O
+evolved	O
+to	O
+selectivelyreplicate	O
+in	O
+respiratory	O
+tissues	B-ANAT
+and	O
+that	O
+HE	O
+may	O
+play	O
+a	O
+role	O
+in	O
+this	O
+tissue	B-PROC
+tropism	B-PROC
+.	O
+
+However	O
+,	O
+when	O
+neuraminidase	B-PRGE
+-	O
+treated	O
+virions	B-COMP
+or	O
+mutants	O
+with	O
+a	O
+defective	O
+sialic	B-FUNC
+acid	I-FUNC
+binding	B-PROC
+activity	I-PROC
+were	O
+analyzed	O
+,	O
+the	O
+S	B-PRGE
+protein	I-PRGE
+remained	O
+in	O
+the	O
+supernatant	O
+rather	O
+than	O
+in	O
+the	O
+pellet	O
+fraction	O
+.	O
+
+These	O
+results	O
+indicate	O
+that	O
+the	O
+interaction	O
+of	O
+the	O
+surface	O
+protein	B-CHED
+S	O
+with	O
+sialoglycoconjugates	O
+is	O
+maintained	O
+after	O
+solubilization	O
+of	O
+this	O
+viral	B-COMP
+glycoprotein	I-COMP
+by	O
+detergent	B-CHED
+treatment	O
+.	O
+
+In	O
+the	O
+case	O
+of	O
+systemic	O
+immunodeficiencies	B-DISO
+such	O
+as	O
+the	O
+antibody	B-DISO
+deficiency	I-DISO
+syndrome	I-DISO
+,	O
+HIV	B-PATH
+infection	I-PATH
+or	O
+immunosuppressive	O
+therapy	O
+,	O
+the	O
+indication	O
+for	O
+antibiotic	B-CHED
+treatment	O
+is	O
+more	O
+liberally	O
+established	O
+.	O
+
+In	O
+combination	O
+with	O
+respiratory	B-DISO
+tract	I-DISO
+infections	I-DISO
+,	O
+serious	O
+underlying	O
+disease	O
+such	O
+as	O
+left	B-ANAT
+heart	I-ANAT
+insufficiency	O
+or	O
+diseases	O
+of	O
+the	O
+lungs	B-ANAT
+,	O
+may	O
+become	O
+life	O
+-	O
+threatening	O
+.	O
+
+The	O
+cGMP	B-CHED
+concentrations	O
+remained	O
+unaltered	O
+during	O
+the	O
+VAI	O
+.	O
+
+These	O
+findings	O
+suggest	O
+that	O
+a	O
+lack	O
+of	O
+increase	O
+in	O
+the	O
+production	O
+of	O
+the	O
+cGMP	B-CHED
+may	O
+account	O
+for	O
+the	O
+pulmonary	B-DISO
+hypertension	I-DISO
+seen	O
+in	O
+air	B-CHED
+embolism	B-DISO
+-	O
+induced	O
+ALI	O
+.	O
+
+In	O
+contrast	O
+,	O
+cGMP	B-CHED
+levels	O
+increased	O
+26	O
+%	O
+(	O
+P	O
+<.	O
+05	O
+)	O
+by	O
+15	O
+minutes	O
+after	O
+the	O
+MAE	O
+and	O
+returned	O
+to	O
+basal	O
+levels	O
+thereafter	O
+.	O
+
+ABSTRACT	O
+:	O
+Viral	O
+induced	O
+demyelination	B-DISO
+,	O
+in	O
+both	O
+humans	B-SPEC
+and	O
+rodent	B-SPEC
+models	O
+,	O
+has	O
+provided	O
+unique	O
+insights	O
+into	O
+the	O
+cell	B-COMP
+biology	O
+of	O
+oligodendroglia	B-ANAT
+,	O
+their	O
+complex	O
+cell	B-COMP
+-	O
+cell	B-PROC
+interactions	I-PROC
+and	O
+mechanisms	O
+of	O
+myelin	B-COMP
+destruction	O
+.	O
+
+Demyelination	B-DISO
+in	O
+both	O
+humans	B-SPEC
+and	O
+rodents	B-SPEC
+can	O
+be	O
+initiated	O
+by	O
+infection	B-DISO
+with	O
+a	O
+diverse	O
+group	O
+of	O
+enveloped	O
+and	O
+non	O
+-	O
+enveloped	O
+RNA	O
+and	O
+DNA	O
+viruses	B-SPEC
+(	O
+Table	O
+1	O
+).	O
+
+Virus	B-SPEC
+-	O
+induced	O
+inflammation	B-DISO
+may	O
+be	O
+associated	O
+with	O
+the	O
+processing	O
+of	O
+myelin	B-COMP
+or	O
+oligodendroglial	O
+components	O
+and	O
+their	O
+presentation	O
+to	O
+the	O
+host	B-COMP
+'	O
+s	O
+own	O
+T	O
+cell	B-ANAT
+compartment	I-ANAT
+.	O
+
+Although	O
+it	O
+is	O
+not	O
+clear	O
+that	O
+each	O
+of	O
+these	O
+potential	O
+mechanisms	O
+participates	O
+in	O
+the	O
+pathogenesis	B-DISO
+of	O
+human	B-SPEC
+demyelinating	B-DISO
+disease	I-DISO
+,	O
+analysis	O
+of	O
+the	O
+diverse	O
+demyelinating	O
+viral	B-DISO
+infections	I-DISO
+of	O
+both	O
+humans	B-SPEC
+and	O
+rodents	B-SPEC
+provides	O
+examples	O
+of	O
+many	O
+of	O
+these	O
+potential	O
+mechanisms	O
+.	O
+
+ABSTRACT	O
+:	O
+The	O
+effects	O
+of	O
+kinetic	O
+therapy	O
+on	O
+the	O
+oxygenation	O
+in	O
+the	O
+injured	O
+lung	B-ANAT
+of	O
+111	O
+polytrauma	O
+patients	O
+were	O
+analysed	O
+in	O
+an	O
+open	O
+prospective	O
+study	O
+.	O
+
+Positioning	O
+therapy	O
+was	O
+administered	O
+in	O
+group	O
+3	O
+in	O
+order	B-SPEC
+to	O
+prevent	O
+atelectases	B-DISO
+,	O
+and	O
+respirator	O
+-	O
+induced	O
+lung	B-ANAT
+injuries	O
+during	O
+a	O
+foreseeable	O
+,	O
+relatively	O
+long	O
+period	O
+in	O
+the	O
+intensive	O
+care	O
+unit	O
+in	O
+view	O
+of	O
+the	O
+severity	O
+of	O
+the	O
+trauma	O
+.	O
+
+TITLE	O
+:	O
+von	B-PRGE
+Willebrand	I-PRGE
+factor	I-PRGE
+antigen	I-PRGE
+as	O
+a	O
+prognostic	O
+marker	O
+in	O
+posttraumatic	O
+acute	O
+lung	B-ANAT
+injury	O
+.	O
+
+ABSTRACT	O
+:	O
+The	O
+specific	O
+endothelial	O
+cell	O
+product	O
+von	B-PRGE
+Willebrand	I-PRGE
+factor	I-PRGE
+antigen	I-PRGE
+(	O
+vWf	B-PRGE
+:	O
+Ag	O
+)	O
+was	O
+measured	O
+in	O
+plasma	B-ANAT
+and	O
+lung	B-PROC
+function	I-PROC
+tests	O
+were	O
+carried	O
+out	O
+and	O
+the	O
+following	O
+lung	B-ANAT
+injury	O
+parameters	O
+measured	O
+:	O
+P	O
+(	O
+a	O
+)	O
+O2	O
+/	O
+F	O
+(	O
+i	O
+)	O
+O2	O
+ratio	O
+,	O
+static	O
+respiratory	O
+compliance	O
+and	O
+Murray	O
+'	O
+s	O
+lung	B-ANAT
+injury	O
+score	O
+(	O
+LIS	B-FUNC
+)	O
+in	O
+a	O
+follow	O
+-	O
+up	O
+study	O
+of	O
+36	O
+severely	O
+traumatized	O
+patients	O
+.	O
+
+Injury	O
+severity	O
+score	O
+(	O
+ISS	B-DISO
+)	O
+and	O
+APACHE	O
+II	O
+scores	O
+were	O
+calculated	O
+.	O
+
+We	O
+examined	O
+retrospectively	O
+the	O
+records	O
+of	O
+54	O
+infants	O
+admitted	O
+during	O
+a	O
+15	O
+month	O
+period	O
+who	O
+were	O
+35	O
+or	O
+more	O
+weeks	O
+of	O
+gestation	B-PROC
+,	O
+and	O
+who	O
+demonstrated	O
+all	O
+the	O
+diagnostic	O
+features	O
+of	O
+RDS	O
+.	O
+
+There	O
+was	O
+no	O
+relationship	O
+between	O
+age	O
+at	O
+treatment	O
+(	O
+6	O
+-	O
+89	O
+hr	O
+)	O
+and	O
+response	O
+to	O
+treatment	O
+as	O
+measured	O
+by	O
+changes	O
+in	O
+AaDO2	O
+,	O
+FiO2	O
+,	O
+or	O
+oxygenation	B-PROC
+index	O
+(	O
+OI	O
+).	O
+
+Such	O
+treatment	O
+resulted	O
+in	O
+a	O
+marked	O
+increase	O
+in	O
+mortality	O
+that	O
+correlated	O
+with	O
+a	O
+>	O
+3	O
+log	O
+increase	O
+in	O
+viral	O
+burden	O
+within	O
+the	O
+brains	B-ANAT
+as	O
+compared	O
+with	O
+control	O
+mice	B-SPEC
+treated	O
+with	O
+normal	O
+rabbit	O
+serum	B-COMP
+.	O
+
+ABSTRACT	O
+:	O
+Recombinant	O
+mouse	B-DISO
+hepatitis	I-DISO
+viruses	B-SPEC
+(	O
+MHV	B-SPEC
+)	O
+differing	O
+only	O
+in	O
+the	O
+spike	O
+gene	O
+,	O
+containing	O
+A59	O
+,	O
+MHV	B-SPEC
+-	O
+4	O
+,	O
+and	O
+MHV	B-SPEC
+-	O
+2	O
+spike	O
+genes	O
+in	O
+the	O
+background	O
+of	O
+the	O
+A59	O
+genome	O
+,	O
+were	O
+compared	O
+for	O
+their	O
+ability	O
+to	O
+replicate	O
+in	O
+the	O
+liver	B-ANAT
+and	O
+induce	O
+hepatitis	B-DISO
+in	O
+weanling	O
+C57BL	O
+/	O
+6	O
+mice	B-SPEC
+infected	O
+with	O
+500	O
+PFU	B-CHED
+of	O
+each	O
+virus	B-SPEC
+by	O
+intrahepatic	O
+injection	O
+.	O
+
+S4R21	O
+,	O
+expressing	O
+the	O
+MHV	B-PRGE
+-	I-PRGE
+4	I-PRGE
+spike	I-PRGE
+gene	I-PRGE
+,	O
+replicated	O
+to	O
+a	O
+minimal	O
+extent	O
+and	O
+induced	O
+few	O
+if	O
+any	O
+pathological	O
+changes	O
+,	O
+similar	O
+to	O
+MHV	B-SPEC
+-	O
+4	O
+.	O
+
+TITLE	O
+:	O
+The	O
+RNA	O
+structures	O
+engaged	O
+in	O
+replication	O
+and	O
+transcription	B-PROC
+of	O
+the	O
+A59	O
+strain	O
+of	O
+mouse	B-SPEC
+hepatitis	I-DISO
+virus	O
+.	O
+
+Viral	O
+RI	B-PRGE
+/	I-PRGE
+TIs	I-PRGE
+and	O
+native	O
+RF	O
+/	O
+TFs	O
+bound	O
+to	O
+magnetic	O
+beads	O
+containing	O
+oligo	O
+(	O
+dT	O
+)(	O
+25	O
+),	O
+suggesting	O
+that	O
+the	O
+poly	O
+(	O
+A	O
+)	O
+sequence	O
+on	O
+the	O
+3	O
+'	O
+end	O
+of	O
+the	O
+positive	O
+strands	O
+was	O
+longer	O
+than	O
+any	O
+poly	O
+(	O
+U	O
+)	O
+on	O
+the	O
+negative	O
+strands	O
+.	O
+
+Eighteen	O
+patients	O
+with	O
+pneumonia	B-DISO
+and	O
+hypotension	O
+,	O
+or	O
+in	O
+the	O
+absence	O
+of	O
+shock	O
+,	O
+two	O
+or	O
+more	O
+end	O
+-	O
+organ	B-ANAT
+dysfunctions	O
+,	O
+were	O
+enrolled	O
+and	O
+treated	O
+.	O
+
+21	O
+mL	O
+/	O
+m2	O
+(	O
+p	O
+<	O
+.	O
+05	O
+);	O
+almitrine	B-CHED
+decreased	O
+right	B-PROC
+ventricular	I-PROC
+ejection	I-PROC
+fraction	O
+from	O
+36	O
+%	O
++/-	O
+
+The	O
+almitrine	B-CHED
+-	O
+induced	O
+changes	O
+in	O
+right	B-PROC
+ventricular	I-PROC
+ejection	I-PROC
+fraction	O
+were	O
+closely	O
+correlated	O
+with	O
+the	O
+baseline	O
+MPAP	O
+(	O
+r2	O
+=	O
+.	O
+71	O
+,	O
+p	O
+<	O
+.	O
+01	O
+).	O
+
+The	O
+decrease	O
+in	O
+right	B-PROC
+ventricular	I-PROC
+ejection	I-PROC
+fraction	O
+induced	O
+by	O
+almitrine	B-CHED
+was	O
+correlated	O
+with	O
+the	O
+baseline	O
+MPAP	O
+.	O
+
+TITLE	O
+:	O
+Nebulized	O
+prostacyclin	B-CHED
+(	O
+PGI2	B-CHED
+)	O
+in	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+:	O
+impact	O
+of	O
+primary	O
+(	O
+pulmonary	B-ANAT
+injury	O
+)	O
+and	O
+secondary	O
+(	O
+extrapulmonary	O
+injury	O
+)	O
+disease	O
+on	O
+gas	B-ENZY
+exchange	O
+response	O
+.	O
+
+16	O
+dyne	O
+x	O
+sec	B-CHED
+/	O
+cm5	B-ANAT
+;	O
+oxygenation	B-PROC
+did	O
+not	O
+change	O
+significantly	O
+.	O
+
+torr	O
+with	O
+a	O
+decrease	O
+in	O
+mean	O
+pulmonary	B-ANAT
+artery	I-ANAT
+pressure	O
+.	O
+
+Nucleic	B-CHED
+acid	I-CHED
+hybridization	B-PROC
+and	O
+polymerase	O
+chain	O
+reactionbased	O
+techniques	O
+have	O
+also	O
+been	O
+used	O
+.	O
+
+Enteric	O
+coronaviruses	O
+have	O
+most	O
+frequently	O
+been	O
+associated	O
+with	O
+gastrointestinal	B-DISO
+disease	I-DISO
+in	O
+neonates	O
+and	O
+children	O
+younger	O
+than	O
+12	O
+years	O
+old	O
+.	O
+
+Our	O
+final	O
+diagnosis	O
+was	O
+ARDS	B-DISO
+induced	O
+by	O
+fulminant	O
+influenza	B-DISO
+(	O
+A	O
+/	O
+Hong	O
+Kong	O
+/	O
+68	O
+(	O
+H3	O
+N2	O
+))	O
+virus	B-SPEC
+pneumonia	B-DISO
+,	O
+because	O
+the	O
+antibody	B-COMP
+titers	O
+of	O
+H3	O
+N2	O
+influenza	B-DISO
+of	O
+paired	O
+sera	B-COMP
+showed	O
+a	O
+128	O
+-	O
+fold	O
+increase	O
+.	O
+
+The	O
+Murray	O
+score	O
+of	O
+pulmonary	B-ANAT
+injury	O
+averaged	O
+3	O
+.	O
+5	O
+(	O
+3	O
+.	O
+0	O
+-	O
+4	O
+.	O
+0	O
+)	O
+and	O
+the	O
+mean	O
+PaO2	O
+/	O
+FIO2	O
+ratio	O
+was	O
+46	O
+(	O
+31	O
+-	O
+65	O
+).	O
+
+Crystol	O
+52	O
+was	O
+composed	O
+of	O
+relatively	O
+few	O
+short	O
+-	O
+chain	O
+hydrocarbons	B-CHED
+(	O
+i	O
+.	O
+e	O
+.,	O
+<	O
+n	O
+-	O
+C16H34	B-CHED
+)	O
+and	O
+long	O
+-	O
+chain	O
+hydrocarbons	B-CHED
+(	O
+i	O
+.	O
+e	O
+.,	O
+>	O
+n	O
+-	O
+C20H42	B-CHED
+).	O
+
+The	O
+vaccine	O
+with	O
+liquid	O
+paraffin	O
+mainly	O
+composed	O
+of	O
+n	O
+-	O
+C16H34	O
+-	O
+n	O
+-	O
+C20H42	B-CHED
+was	O
+suggested	O
+to	O
+induce	O
+fewer	O
+adverse	O
+reactions	O
+.	O
+
+ABSTRACT	O
+:	O
+The	O
+relevance	O
+of	O
+an	O
+elevated	O
+base	O
+deficit	B-DISO
+(	O
+BD	O
+)	O
+during	O
+the	O
+fluid	O
+resuscitation	O
+of	O
+a	O
+thermally	O
+injured	O
+patient	O
+is	O
+not	O
+completely	O
+understood	O
+.	O
+
+Patients	O
+with	O
+a	O
+mean	O
+BD	O
+of	O
+less	O
+than	O
+-	O
+6	O
+mmol	O
+/	O
+L	O
+during	O
+the	O
+first	O
+24	O
+hours	O
+were	O
+compared	O
+with	O
+patients	O
+with	O
+a	O
+mean	O
+BD	O
+of	O
+more	O
+than	O
+-	O
+6	O
+mmol	O
+/	O
+L	O
+.	O
+Despite	O
+adequate	O
+resuscitation	O
+with	O
+good	O
+maintenance	O
+of	O
+urinary	O
+output	O
+,	O
+the	O
+patients	O
+in	O
+the	O
+group	O
+with	O
+a	O
+mean	O
+BD	O
+of	O
+less	O
+than	O
+-	O
+6	O
+mmol	O
+/	O
+L	O
+had	O
+more	O
+florid	O
+systemic	O
+inflammatory	O
+response	O
+syndrome	O
+(	O
+P	O
+=	O
+.	O
+004	O
+),	O
+had	O
+more	O
+prevalent	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+(	O
+P	O
+=	O
+.	O
+012	O
+),	O
+and	O
+experienced	O
+more	O
+severe	O
+multiple	O
+organ	B-ANAT
+dysfunction	O
+(	O
+P	O
+<	O
+.	O
+001	O
+)	O
+compared	O
+with	O
+patients	O
+in	O
+the	O
+group	O
+with	O
+a	O
+mean	O
+BD	O
+of	O
+more	O
+than	O
+-	O
+6	O
+mmol	O
+/	O
+L	O
+.	O
+The	O
+results	O
+suggest	O
+that	O
+abnormal	O
+elevation	O
+of	O
+the	O
+BD	O
+after	O
+burn	O
+injuries	O
+represents	O
+a	O
+malperfusion	O
+state	O
+,	O
+which	O
+may	O
+not	O
+be	O
+recognized	O
+if	O
+only	O
+""""	O
+traditional	O
+""""	O
+parameters	O
+,	O
+such	O
+as	O
+UO	O
+,	O
+are	O
+followed	O
+.	O
+
+TITLE	O
+:	O
+The	O
+use	O
+of	O
+inhaled	B-PROC
+nitric	B-CHED
+oxide	I-CHED
+as	O
+adjuvant	B-CHED
+therapy	O
+in	O
+patients	O
+with	O
+burn	O
+injuries	O
+and	O
+respiratory	B-DISO
+failure	I-DISO
+.	O
+
+Sixteen	O
+patients	O
+had	O
+minor	O
+(	O
+n	O
+=	O
+15	O
+)	O
+or	O
+moderate	O
+(	O
+n	O
+=	O
+1	O
+)	O
+changes	O
+on	O
+a	O
+chest	B-ANAT
+X	O
+-	O
+ray	B-SPEC
+.	O
+
+One	O
+patient	O
+had	O
+a	O
+possible	O
+delay	O
+in	O
+psychomotor	B-PROC
+development	I-PROC
+.	O
+
+The	O
+nucleotide	B-CHED
+sequence	O
+of	O
+S1	B-PRGE
+polypeptide	I-PRGE
+coding	O
+region	O
+of	O
+CT	O
+/	O
+7852	O
+/	O
+97	O
+was	O
+determined	O
+and	O
+compared	O
+with	O
+the	O
+published	O
+sequences	O
+of	O
+12	O
+IBV	B-SPEC
+strains	O
+from	O
+North	O
+America	O
+.	O
+
+TITLE	O
+:	O
+Characterization	O
+of	O
+Mexican	O
+strains	O
+of	O
+avian	B-DISO
+infectious	I-DISO
+bronchitis	I-DISO
+isolated	O
+during	O
+1997	O
+.	O
+
+Viral	B-DISO
+shedding	I-DISO
+may	O
+be	O
+intermittent	O
+.	O
+
+Cattle	B-SPEC
+remaining	O
+negative	O
+in	O
+RBCV	O
+isolation	O
+tests	O
+entered	O
+this	O
+epizootic	O
+with	O
+antibodies	B-COMP
+against	O
+HE	O
+and	O
+S	O
+.	O
+Protection	O
+against	O
+respiratory	B-DISO
+tract	I-DISO
+disease	I-DISO
+was	O
+apparently	O
+associated	O
+with	O
+high	O
+level	O
+of	O
+opsonic	O
+and	O
+virus	B-SPEC
+-	O
+neutralizing	O
+IgG2	B-COMP
+.	O
+
+ABSTRACT	O
+:	O
+Structure	O
+activity	O
+relationships	O
+(	O
+SARs	B-DISO
+)	O
+of	O
+product	O
+-	O
+based	O
+inhibitors	B-CHED
+of	O
+hepatitis	B-PRGE
+C	I-PRGE
+virus	I-PRGE
+NS3	B-DISO
+protease	I-PRGE
+were	O
+evaluated	O
+using	O
+an	O
+in	O
+vitro	O
+assay	O
+system	O
+comprising	O
+the	O
+native	O
+bifunctional	O
+full	O
+-	O
+length	O
+NS3	B-DISO
+(	O
+protease	O
+-	O
+helicase	O
+/	O
+NTPase	B-PRGE
+).	O
+
+Taken	O
+together	O
+,	O
+the	O
+results	O
+suggest	O
+that	O
+the	O
+impact	O
+of	O
+the	O
+helicase	B-PRGE
+domain	I-PRGE
+upon	O
+protease	B-CHED
+inhibitor	I-CHED
+binding	B-FUNC
+is	O
+substantial	O
+.	O
+
+ABSTRACT	O
+:	O
+Implementation	O
+of	O
+lung	B-ANAT
+protective	O
+strategy	O
+in	O
+the	O
+treatment	O
+of	O
+severe	O
+Acute	B-DISO
+Respiratory	I-DISO
+Distress	I-DISO
+Syndrome	I-DISO
+(	O
+ARDS	B-DISO
+)	O
+has	O
+been	O
+reported	O
+to	O
+be	O
+associated	O
+with	O
+improved	O
+outcome	O
+.	O
+
+To	O
+fulfil	O
+this	O
+approach	O
+,	O
+sedation	B-DISO
+,	O
+neuromuscular	O
+blocking	B-DISO
+agents	O
+and	O
+full	O
+mechanical	O
+ventilatory	O
+support	O
+are	O
+often	O
+used	O
+in	O
+critical	O
+failure	O
+of	O
+gas	B-ENZY
+exchange	O
+.	O
+
+ABSTRACT	O
+:	O
+Impairment	B-DISO
+of	O
+alveolar	B-ANAT
+surfactant	B-CHED
+function	O
+has	O
+been	O
+documented	O
+in	O
+the	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+(	O
+ARDS	B-DISO
+)	O
+and	O
+in	O
+severe	O
+pneumonia	B-DISO
+(	O
+PNEU	O
+);	O
+however	O
+,	O
+the	O
+underlying	O
+mechanisms	O
+are	O
+not	O
+completely	O
+understood	O
+.	O
+
+As	O
+compared	O
+with	O
+control	O
+subjects	O
+a	O
+highly	O
+significant	O
+increase	O
+of	O
+gamma	O
+min	O
+from	O
+near	O
+zero	O
+to	O
+approximately	O
+16	O
+mN	O
+/	O
+m	O
+was	O
+observed	O
+in	O
+all	O
+patients	O
+and	O
+was	O
+found	O
+to	O
+be	O
+inversely	O
+correlated	O
+to	O
+the	O
+percentage	O
+of	O
+palmitic	B-CHED
+acid	I-CHED
+in	O
+PC	O
+of	O
+LSA	B-DISO
+or	O
+BALF	O
+.	O
+
+Rabbits	B-SPEC
+were	O
+infected	O
+by	O
+intraperitoneal	O
+inoculation	O
+of	O
+fibrin	O
+clots	B-DISO
+containing	O
+Escherichia	B-SPEC
+coli	I-SPEC
+at	O
+10	O
+(	O
+8	O
+),	O
+10	O
+(	O
+9	O
+),	O
+or	O
+10	O
+(	O
+10	O
+)	O
+cfu	O
+/	O
+clot	B-DISO
+.	O
+
+The	O
+nucleotide	B-CHED
+and	O
+amino	B-CHED
+acid	I-CHED
+sequence	O
+was	O
+most	O
+similar	O
+to	O
+the	O
+D1466	O
+strain	O
+and	O
+was	O
+84	O
+.	O
+8	O
+%	O
+and	O
+89	O
+.	O
+9	O
+%	O
+identity	O
+,	O
+respectively	O
+.	O
+
+Infection	B-DISO
+was	O
+confirmed	O
+with	O
+a	O
+reverse	B-PRGE
+transcriptase	I-PRGE
+-	O
+polymerase	O
+chain	O
+reaction	O
+test	O
+and	O
+by	O
+immunohistochemical	O
+demonstration	O
+of	O
+coronavirus	B-SPEC
+antigen	B-CHED
+in	O
+the	O
+affected	O
+tissues	B-ANAT
+,	O
+including	O
+the	O
+left	B-ANAT
+testicle	I-ANAT
+.	O
+
+The	O
+results	O
+of	O
+this	O
+case	O
+study	O
+indicate	O
+that	O
+orchitis	B-DISO
+,	O
+although	O
+rare	O
+,	O
+should	O
+be	O
+on	O
+the	O
+list	O
+of	O
+lesions	O
+of	O
+FIP	O
+.	O
+
+ABSTRACT	O
+:	O
+The	O
+prototype	O
+JHM	O
+strain	O
+of	O
+murine	B-DISO
+hepatitis	I-DISO
+virus	B-SPEC
+(	O
+MHV	B-SPEC
+)	O
+is	O
+an	O
+enveloped	O
+,	O
+RNA	O
+-	O
+containing	O
+coronavirus	B-SPEC
+that	O
+has	O
+been	O
+selected	O
+in	O
+vivo	O
+for	O
+extreme	O
+neurovirulence	O
+.	O
+
+ABSTRACT	O
+:	O
+Neutralizing	O
+antibodies	B-COMP
+represent	O
+a	O
+major	O
+host	B-PROC
+defense	I-PROC
+mechanism	I-PROC
+against	O
+viral	B-DISO
+infections	I-DISO
+.	O
+
+Milk	O
+from	O
+these	O
+transgenic	B-SPEC
+mice	I-SPEC
+contained	O
+up	O
+to	O
+0	O
+.	O
+7	O
+mg	O
+of	O
+recombinant	O
+antibody	B-COMP
+/	O
+ml	O
+.	O
+
+The	O
+following	O
+laboratory	O
+parameters	O
+were	O
+abnormal	O
+:	O
+sedimentation	O
+rate	O
+64	O
+/	O
+70	O
+mmHg	O
+,	O
+CD4	B-PRGE
++	I-PRGE
+cells	B-COMP
+462	O
+/	O
+ml	O
+,	O
+CD4	B-PRGE
+/	O
+CD8	B-PRGE
+ratio	O
+0	O
+.	O
+3	O
+,	O
+serum	B-COMP
+CRP	B-PRGE
+16	I-PRGE
+mg	I-PRGE
+/	I-PRGE
+l	I-PRGE
+,	O
+antistreptolysin	O
+titre	O
+542	O
+kU	O
+/	O
+l	O
+,	O
+complement	B-PRGE
+C3	I-PRGE
+<	O
+0	O
+.	O
+1	O
+g	O
+/	O
+l	O
+,	O
+GPT	B-FUNC
+37	O
+U	O
+/	O
+l	O
+,	O
+albumin	B-PRGE
+49	I-PRGE
+.	I-PRGE
+5	I-PRGE
+%	I-PRGE
+and	I-PRGE
+gamma	I-PRGE
+-	I-PRGE
+globulin	I-PRGE
+28	O
+.	O
+5	O
+%,	O
+in	O
+urine	B-ANAT
+,	O
+leukocytes	B-ANAT
+25	O
+/	O
+microliter	O
+and	O
+protein	B-CHED
+0	O
+.	O
+25	O
+g	O
+/	O
+l	O
+.	O
+
+However	O
+despite	O
+successful	O
+treatment	O
+of	O
+these	O
+infections	B-DISO
+severe	O
+relapses	O
+of	O
+both	O
+the	O
+skin	B-ANAT
+lesions	O
+and	O
+the	O
+systemic	O
+manifestations	O
+occurred	O
+.	O
+
+For	O
+the	O
+prototype	O
+coronavirus	B-SPEC
+mouse	B-DISO
+hepatitis	I-DISO
+virus	B-SPEC
+(	O
+MHV	B-SPEC
+),	O
+heterogeneous	B-PRGE
+nuclear	I-PRGE
+ribonucleoprotein	I-PRGE
+(	O
+hnRNP	B-ANAT
+)	O
+A1	O
+has	O
+been	O
+shown	O
+to	O
+be	O
+able	O
+to	O
+bind	B-FUNC
+in	O
+vitro	O
+to	O
+the	O
+negative	O
+strand	O
+of	O
+the	O
+intergenic	O
+sequence	O
+,	O
+a	O
+cis	B-DISO
+-	O
+acting	O
+element	O
+found	O
+in	O
+the	O
+leader	O
+RNA	O
+and	O
+preceding	O
+each	O
+downstream	O
+ORF	O
+in	O
+the	O
+genome	O
+.	O
+
+This	O
+replacement	O
+resulted	O
+in	O
+the	O
+loss	O
+of	O
+the	O
+CTAAACTT	O
+leader	O
+RNA	O
+-	O
+binding	O
+site	O
+and	O
+ATG	O
+start	O
+codon	O
+for	O
+the	O
+ORF	B-PRGE
+-	I-PRGE
+3A	I-PRGE
+gene	I-PRGE
+but	O
+it	O
+did	O
+not	O
+affect	O
+the	O
+ORF	B-PRGE
+-	I-PRGE
+3B	I-PRGE
+gene	I-PRGE
+.	O
+
+The	O
+sensitivity	O
+of	O
+the	O
+assay	O
+is	O
+extremely	O
+high	O
+,	O
+detecting	O
+as	O
+little	O
+as	O
+25	O
+50	O
+%	O
+tissue	B-ANAT
+culture	O
+infective	O
+doses	O
+per	O
+g	O
+of	O
+unprocessed	O
+feces	B-ANAT
+.	O
+
+A	O
+clinical	O
+trial	O
+using	O
+dogs	B-SPEC
+challenged	O
+orally	B-ANAT
+with	O
+CCV	B-DISO
+SA4	O
+and	O
+CCV	B-DISO
+NVSL	O
+was	O
+used	O
+to	O
+compare	O
+viral	O
+isolation	O
+and	O
+the	O
+nPCR	O
+assay	O
+as	O
+detection	O
+techniques	O
+over	O
+a	O
+2	O
+-	O
+week	O
+period	O
+of	O
+infection	B-DISO
+.	O
+
+Cloning	O
+and	O
+sequencing	O
+of	O
+the	O
+nPCR	O
+assay	O
+product	O
+enabled	O
+investigation	O
+of	O
+the	O
+evolutionary	O
+relationships	O
+between	O
+strains	O
+within	O
+the	O
+S	B-PRGE
+gene	I-PRGE
+.	O
+
+The	O
+simple	O
+and	O
+rapid	O
+procedure	O
+described	O
+here	O
+makes	O
+this	O
+assay	O
+an	O
+ideal	O
+alternative	O
+technique	O
+to	O
+electron	O
+microscopy	O
+and	O
+viral	O
+isolation	O
+in	O
+cell	O
+culture	O
+for	O
+detection	O
+of	O
+CCV	B-DISO
+shedding	O
+in	O
+feces	B-ANAT
+.	O
+
+TITLE	O
+:	O
+A	O
+single	O
+amino	B-CHED
+acid	I-CHED
+change	O
+within	O
+antigenic	O
+domain	O
+II	O
+of	O
+the	O
+spike	O
+protein	B-CHED
+of	O
+bovine	B-SPEC
+coronavirus	B-SPEC
+confers	O
+resistance	B-PROC
+to	O
+virus	B-PROC
+neutralization	I-PROC
+.	O
+
+Conformational	O
+neutralizing	O
+epitopes	O
+of	O
+group	O
+A	O
+and	O
+group	B-DISO
+B	I-DISO
+monoclonal	O
+antibodies	B-COMP
+(	O
+MAbs	O
+)	O
+have	O
+previously	O
+been	O
+mapped	O
+to	O
+two	O
+domains	O
+at	O
+amino	B-CHED
+acids	I-CHED
+351	O
+to	O
+403	O
+(	O
+domain	O
+I	O
+)	O
+and	O
+amino	B-CHED
+acids	I-CHED
+517	O
+to	O
+621	O
+(	O
+domain	O
+II	O
+).	O
+
+A	O
+substantial	O
+rise	O
+in	O
+the	O
+serum	B-COMP
+HAI	B-PRGE
+antibody	I-PRGE
+was	O
+observed	O
+during	O
+the	O
+initial	O
+phase	O
+among	O
+the	O
+sick	O
+but	O
+not	O
+the	O
+clinically	O
+normal	O
+cattle	O
+which	O
+were	O
+infected	O
+with	O
+RBCV	O
+.	O
+
+Specific	O
+RNA	O
+affinity	O
+chromatography	O
+also	O
+has	O
+revealed	O
+the	O
+presence	O
+of	O
+a	O
+90	O
+-	O
+kDa	O
+protein	O
+associated	O
+with	O
+RNA	O
+containing	O
+the	O
+cis	B-DISO
+-	O
+acting	O
+element	O
+bound	O
+to	O
+magnetic	O
+beads	O
+.	O
+
+The	O
+90	O
+-	O
+kDa	O
+protein	B-CHED
+has	O
+been	O
+purified	O
+from	O
+uninfected	O
+mouse	B-ANAT
+fibroblast	I-ANAT
+crude	O
+lysates	O
+.	O
+
+These	O
+results	O
+are	O
+particularly	O
+interesting	O
+in	O
+terms	O
+of	O
+identification	O
+of	O
+an	O
+RNA	O
+target	O
+for	O
+mitochondrial	B-COMP
+aconitase	B-ENZY
+,	O
+which	O
+has	O
+a	O
+cytoplasmic	B-PRGE
+homolog	I-PRGE
+,	I-PRGE
+cytoplasmic	B-COMP
+aconitase	B-ENZY
+,	O
+also	O
+known	O
+as	O
+iron	B-PRGE
+regulatory	I-PRGE
+protein	I-PRGE
+1	I-PRGE
+,	O
+a	O
+well	O
+-	O
+recognized	O
+RNA	O
+-	O
+binding	B-FUNC
+protein	B-CHED
+.	O
+
+Mice	B-SPEC
+undergoing	O
+sham	O
+H	O
+/	O
+R	O
+(	O
+cannulation	O
+but	O
+no	O
+hemorrhage	B-DISO
+),	O
+followed	O
+5	O
+days	O
+later	O
+by	O
+EL	O
+,	O
+were	O
+labeled	O
+as	O
+the	O
+EL	O
+group	O
+;	O
+and	O
+mice	B-SPEC
+undergoing	O
+H	O
+/	O
+R	O
+,	O
+followed	O
+5	O
+days	O
+later	O
+by	O
+an	O
+EL	O
+,	O
+were	O
+labeled	O
+as	O
+the	O
+H	O
+/	O
+R	O
++	O
+EL	O
+,	O
+or	O
+two	O
+-	O
+hit	O
+,	O
+group	O
+.	O
+
+Serum	B-COMP
+interleukin	B-PRGE
+-	I-PRGE
+6	I-PRGE
+(	O
+IL	B-FUNC
+-	I-FUNC
+6	I-FUNC
+)	O
+and	O
+tumor	O
+necrosis	O
+factor	O
+-	O
+alpha	O
+(	O
+TNF	B-PRGE
+-	I-PRGE
+alpha	I-PRGE
+)	O
+were	O
+assayed	O
+at	O
+1	O
+and	O
+4	O
+hours	O
+after	O
+the	O
+injury	O
+stimuli	O
+.	O
+
+Histologic	O
+evaluation	O
+lungs	B-ANAT
+demonstrated	O
+that	O
+the	O
+most	O
+severe	O
+lung	B-ANAT
+injury	O
+was	O
+seen	O
+in	O
+the	O
+EL	O
+mice	B-SPEC
+.	O
+
+RESULTS	O
+:	O
+Evaluation	O
+of	O
+the	O
+change	O
+in	O
+pulmonary	B-PROC
+function	I-PROC
+after	O
+24	O
+hours	O
+demonstrated	O
+that	O
+EL	O
+alone	O
+induces	O
+a	O
+significant	O
+decrease	O
+in	O
+pulmonary	B-PROC
+function	I-PROC
+,	O
+whereas	O
+two	O
+-	O
+hit	O
+mice	B-SPEC
+did	O
+not	O
+exhibit	O
+a	O
+potentiated	O
+response	O
+.	O
+
+Histologic	O
+evaluation	O
+lungs	B-ANAT
+demonstrated	O
+that	O
+the	O
+most	O
+severe	O
+lung	B-ANAT
+injury	O
+was	O
+seen	O
+in	O
+the	O
+EL	O
+mice	B-SPEC
+.	O
+
+IPC	B-CHED
+were	O
+almost	O
+exclusively	O
+detected	O
+in	O
+intestinal	B-ANAT
+tissues	B-ANAT
+and	O
+mesenteric	B-ANAT
+lymph	I-ANAT
+nodes	I-ANAT
+(	O
+MLN	O
+),	O
+as	O
+early	O
+as	O
+6	O
+h	O
+post	O
+inoculation	O
+(	O
+p	O
+.	O
+i	O
+.),	O
+with	O
+a	O
+peak	O
+at	O
+12	O
+-	O
+18	O
+h	O
+.	O
+They	O
+disappeared	O
+by	O
+24	O
+h	O
+.	O
+IPC	B-CHED
+were	O
+localized	O
+between	O
+enterocytes	B-ANAT
+in	O
+the	O
+small	B-ANAT
+intestine	I-ANAT
+epithelial	O
+layer	B-ANAT
+,	O
+in	O
+the	O
+lamina	B-ANAT
+propria	I-ANAT
+,	O
+around	O
+the	O
+Peyer	B-ANAT
+'	I-ANAT
+s	I-ANAT
+patches	I-ANAT
+and	O
+,	O
+at	O
+highest	O
+frequency	O
+,	O
+in	O
+MLN	O
+.	O
+
+TITLE	O
+:	O
+Albumin	B-PRGE
+and	O
+artificial	O
+colloids	O
+in	O
+fluid	O
+management	O
+:	O
+where	O
+does	O
+the	O
+clinical	O
+evidence	O
+of	O
+their	O
+utility	O
+stand	O
+?	O
+
+The	O
+cost	O
+of	O
+albumin	B-PRGE
+,	O
+nevertheless	O
+,	O
+limits	O
+its	O
+usage	O
+.	O
+
+Colloids	O
+may	O
+be	O
+combined	O
+with	O
+crystalloids	O
+to	O
+obviate	O
+administration	O
+of	O
+large	O
+crystalloid	B-COMP
+volumes	O
+.	O
+
+A	O
+serological	O
+survey	O
+of	O
+antibodies	B-COMP
+to	O
+CCV	B-DISO
+among	O
+different	O
+dog	B-SPEC
+populations	O
+.	O
+
+About	O
+23	O
+%	O
+of	O
+128	O
+dogs	B-SPEC
+positive	O
+for	O
+IgG	B-PRGE
+antibodies	I-PRGE
+to	O
+CCV	B-DISO
+were	O
+also	O
+positive	O
+for	O
+IgM	B-PRGE
+antibodies	B-COMP
+to	O
+CCV	B-DISO
+,	O
+indicating	O
+recent	O
+CCV	B-DISO
+infection	B-DISO
+.	O
+
+Antigens	B-CHED
+expressed	B-PROC
+in	O
+corn	B-DISO
+are	O
+particularly	O
+advantageous	O
+since	O
+the	O
+seed	O
+can	O
+be	O
+produced	O
+in	O
+vast	O
+quantities	O
+and	O
+shipped	O
+over	O
+long	O
+distances	O
+at	O
+ambient	O
+temperature	O
+,	O
+potentially	O
+allowing	O
+global	O
+vaccination	O
+.	O
+
+ABSTRACT	O
+:	O
+Development	B-PROC
+of	O
+complications	O
+is	O
+very	O
+common	O
+among	O
+the	O
+patients	O
+suffering	O
+from	O
+Plasmodium	B-DISO
+falciparum	I-DISO
+infection	I-DISO
+.	O
+
+A	O
+total	O
+of	O
+64	O
+patients	O
+of	O
+Plasmodium	B-SPEC
+falciprum	O
+infections	B-DISO
+were	O
+admitted	O
+to	O
+the	O
+District	O
+Hospital	O
+,	O
+Ukhrul	O
+,	O
+during	O
+the	O
+period	O
+of	O
+1st	O
+May	O
+1996	O
+to	O
+15th	O
+June	O
+1999	O
+;	O
+9	O
+.	O
+37	O
+%	O
+patients	O
+do	O
+not	O
+develop	O
+complication	B-DISO
+while	O
+the	O
+rest	B-FUNC
+90	O
+.	O
+63	O
+%	O
+developed	O
+one	O
+or	O
+more	O
+complications	O
+.	O
+
+ABSTRACT	O
+:	O
+Mice	B-SPEC
+infected	O
+with	O
+neurotropic	O
+strains	O
+of	O
+mouse	O
+hepatitis	O
+virus	B-SPEC
+(	O
+MHV	B-SPEC
+)	O
+clear	O
+infectious	B-DISO
+virus	B-SPEC
+;	O
+nevertheless	O
+,	O
+viral	O
+persistence	O
+in	O
+the	O
+central	B-ANAT
+nervous	I-ANAT
+system	I-ANAT
+(	O
+CNS	B-CHED
+)	O
+is	O
+associated	O
+with	O
+ongoing	O
+primary	B-DISO
+demyelination	I-DISO
+.	O
+
+Acute	B-DISO
+infection	I-DISO
+induces	O
+a	O
+potent	O
+regional	O
+CD8	O
++	O
+T	B-ANAT
+-	I-ANAT
+cell	I-ANAT
+response	O
+.	O
+
+The	O
+high	O
+prevalence	O
+of	O
+virus	B-SPEC
+specific	O
+T	B-ANAT
+cells	I-ANAT
+correlates	O
+with	O
+ex	O
+vivo	O
+cytolytic	O
+activity	O
+,	O
+interferon	B-FUNC
+-	I-FUNC
+gamma	I-FUNC
+(	O
+IFN	B-PRGE
+-	I-PRGE
+gamma	I-PRGE
+)	O
+secretion	B-PROC
+and	O
+efficient	O
+reduction	O
+in	O
+virus	B-SPEC
+.	O
+
+However	O
+,	O
+IFN	B-PRGE
+-	I-PRGE
+gamma	I-PRGE
+is	O
+essential	O
+for	O
+controlling	O
+virus	B-PROC
+replication	I-PROC
+in	O
+oligodendrocytes	B-ANAT
+.	O
+
+Furthermore	O
+,	O
+CD4	B-PRGE
++	I-PRGE
+T	B-ANAT
+cells	I-ANAT
+enhance	O
+CD8	B-PRGE
++	I-PRGE
+T	B-ANAT
+-	I-ANAT
+cell	I-ANAT
+survival	O
+and	O
+effectiveness	O
+.	O
+
+Clearance	O
+of	O
+infectious	B-DISO
+virus	B-SPEC
+is	O
+associated	O
+with	O
+a	O
+gradual	O
+decline	O
+of	O
+CNS	B-CHED
+T	B-ANAT
+cells	I-ANAT
+;	O
+nevertheless	O
+,	O
+activated	O
+T	B-ANAT
+cells	I-ANAT
+are	O
+retained	O
+within	O
+the	O
+CNS	B-CHED
+.	O
+
+The	O
+loss	O
+of	O
+cytolytic	O
+activity	O
+,	O
+but	O
+retention	B-PROC
+of	O
+IFN	B-PROC
+-	I-PROC
+gamma	I-PROC
+secretion	B-ANAT
+during	O
+viral	O
+clearance	O
+suggests	O
+stringent	O
+regulation	O
+of	O
+CD8	B-PRGE
++	I-PRGE
+T	B-ANAT
+-	I-ANAT
+cell	I-ANAT
+effector	B-CHED
+function	O
+,	O
+possibly	O
+as	O
+a	O
+means	O
+to	O
+minimize	O
+CNS	B-CHED
+damage	O
+.	O
+
+TITLE	O
+:	O
+Membrane	B-ANAT
+topology	O
+of	O
+coronavirus	B-SPEC
+E	O
+protein	B-CHED
+.	O
+
+TITLE	O
+:	O
+The	O
+use	O
+of	O
+L	B-CHED
+-	I-CHED
+arginine	I-CHED
+[	O
+correction	O
+of	O
+F	O
+-	O
+arginine	B-CHED
+]	O
+and	O
+phosphodiesterase	B-PROC
+inhibitor	I-PROC
+(	O
+dipyridamole	B-CHED
+)	O
+to	O
+wean	B-PROC
+from	O
+inhaled	B-PROC
+nitric	B-CHED
+oxide	I-CHED
+.	O
+
+Clinical	O
+and	O
+pathological	O
+investigations	O
+resulted	O
+in	O
+a	O
+broad	O
+range	O
+of	O
+diagnoses	O
+such	O
+as	O
+mastitis	B-DISO
+,	O
+abomasal	O
+displacement	O
+,	O
+and	O
+claw	B-ANAT
+disorders	O
+.	O
+
+The	O
+results	O
+indicate	O
+that	O
+wasting	O
+disease	O
+is	O
+not	O
+a	O
+distinct	O
+entity	O
+but	O
+is	O
+characterized	O
+by	O
+a	O
+broad	O
+range	O
+of	O
+diseases	O
+in	O
+which	O
+acute	O
+laminitis	B-DISO
+may	O
+be	O
+the	O
+original	O
+problem	O
+.	O
+
+Nine	O
+patients	O
+recovered	O
+successfully	O
+;	O
+one	O
+died	B-PROC
+from	O
+adult	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+(	O
+ARDS	B-DISO
+)	O
+soon	O
+after	O
+the	O
+operation	O
+.	O
+
+The	O
+technique	O
+can	O
+be	O
+used	O
+to	O
+determine	O
+the	O
+pathologic	O
+extent	O
+of	O
+the	O
+disease	O
+,	O
+to	O
+irrigate	O
+and	O
+drain	O
+the	O
+abdominal	B-ANAT
+cavity	I-ANAT
+,	O
+and	O
+to	O
+decompress	O
+the	O
+pancreas	B-ANAT
+.	O
+
+Almost	O
+every	O
+surgical	O
+procedure	O
+for	O
+acute	B-DISO
+pancreatitis	I-DISO
+can	O
+be	O
+performed	O
+laparoscopically	O
+.	O
+
+Eye	B-PRGE
+injury	O
+is	O
+moderate	O
+at	O
+2	O
+%	O
+and	O
+severe	O
+at	O
+>	O
+or	O
+=	O
+5	O
+%.	O
+
+There	O
+is	O
+no	O
+evidence	O
+for	O
+systemic	O
+target	O
+organ	B-ANAT
+or	O
+tissue	B-ANAT
+toxicity	O
+by	O
+subchronic	O
+repeated	O
+exposure	O
+by	O
+any	O
+route	O
+.	O
+
+Protection	O
+of	O
+individuals	O
+from	O
+the	O
+potential	O
+adverse	B-DISO
+effects	I-DISO
+of	O
+GA	O
+exposure	O
+requires	O
+that	O
+there	O
+be	O
+adequate	O
+protection	O
+of	O
+the	O
+skin	B-ANAT
+,	O
+eyes	B-ANAT
+and	O
+respiratory	B-ANAT
+tract	I-ANAT
+.	O
+
+Those	O
+who	O
+work	O
+with	O
+GA	O
+should	O
+,	O
+through	O
+a	O
+training	O
+program	O
+,	O
+be	O
+aware	O
+of	O
+the	O
+properties	O
+of	O
+GA	O
+,	O
+its	O
+potential	O
+adverse	B-DISO
+effects	I-DISO
+,	O
+how	O
+to	O
+handle	O
+the	O
+material	O
+safely	O
+and	O
+how	O
+to	O
+deal	O
+with	O
+accidental	O
+situations	O
+involving	O
+GA	O
+.	O
+
+She	O
+represents	O
+the	O
+first	O
+patient	O
+with	O
+overlap	B-DISO
+syndrome	I-DISO
+who	O
+developed	O
+an	O
+acute	O
+airway	B-DISO
+obstruction	I-DISO
+due	O
+to	O
+cricoarytenoid	O
+arthritis	B-DISO
+.	O
+
+Those	O
+who	O
+had	O
+been	O
+to	O
+the	O
+Gulf	O
+were	O
+found	O
+disproportionately	O
+(	O
+23	O
+.	O
+8	O
+%)	O
+in	O
+three	O
+clusters	B-CHED
+with	O
+high	O
+mean	O
+severity	O
+scores	O
+;	O
+only	O
+9	O
+.	O
+8	O
+%	O
+of	O
+non	O
+-	O
+Gulf	O
+respondents	O
+were	O
+in	O
+these	O
+clusters	B-CHED
+.	O
+
+Both	O
+groups	O
+of	O
+patients	O
+had	O
+similar	O
+age	O
+,	O
+Acute	O
+Physiology	O
+and	O
+Chronic	O
+Health	O
+Evaluation	O
+(	O
+APACHE	O
+)	O
+II	O
+score	O
+,	O
+and	O
+severity	O
+in	O
+respiratory	B-DISO
+failure	I-DISO
+.	O
+
+Patients	O
+with	O
+bacterial	B-DISO
+pneumonia	I-DISO
+are	O
+less	O
+frequently	O
+admitted	O
+to	O
+the	O
+intensive	O
+care	O
+unit	O
+after	O
+the	O
+introduction	O
+of	O
+highly	O
+active	O
+antiretroviral	O
+therapy	O
+with	O
+protease	B-PROC
+inhibitors	I-PROC
+in	O
+1996	O
+.	O
+
+Escherichia	B-SPEC
+coli	I-SPEC
+isolates	O
+were	O
+tested	O
+further	O
+for	O
+the	O
+enterotoxin	O
+genes	O
+est	B-PRGE
+-	O
+Ia	O
+and	O
+elt	O
+-	O
+I	O
+by	O
+colony	O
+blot	O
+hybridization	B-PROC
+.	O
+
+Isospora	B-SPEC
+suis	I-SPEC
+was	O
+diagnosed	O
+in	O
+26	O
+.	O
+9	O
+%	O
+and	O
+Cryptosporidium	B-SPEC
+parvum	I-SPEC
+in	O
+1	O
+.	O
+4	O
+%	O
+of	O
+the	O
+piglets	O
+investigated	O
+.	O
+
+Coronavirus	B-SPEC
+was	O
+diagnosed	O
+in	O
+66	O
+.	O
+7	O
+%,	O
+I	B-SPEC
+.	I-SPEC
+suis	I-SPEC
+in	O
+62	O
+.	O
+5	O
+%,	O
+rotavirus	B-SPEC
+in	O
+20	O
+.	O
+8	O
+%	O
+and	O
+C	B-SPEC
+.	I-SPEC
+parvum	I-SPEC
+in	O
+8	O
+.	O
+3	O
+%	O
+of	O
+the	O
+farms	O
+.	O
+
+Cats	B-SPEC
+with	O
+FIP	B-DISO
+were	O
+significantly	O
+more	O
+likely	O
+to	O
+be	O
+young	O
+,	O
+purebred	O
+,	O
+and	O
+sexually	O
+intact	O
+males	O
+and	O
+significantly	O
+less	O
+likely	O
+to	O
+be	O
+spayed	O
+females	O
+and	O
+discharged	O
+alive	O
+than	O
+were	O
+control	O
+cats	B-SPEC
+.	O
+
+The	O
+proportion	O
+of	O
+new	O
+accessions	O
+for	O
+which	O
+a	O
+diagnosis	O
+of	O
+FIP	B-DISO
+was	O
+recorded	O
+did	O
+not	O
+vary	O
+significantly	O
+among	O
+years	O
+,	O
+months	O
+,	O
+or	O
+regions	O
+of	O
+the	O
+country	O
+.	O
+
+In	O
+the	O
+present	O
+study	O
+,	O
+to	O
+determine	O
+the	O
+interrelation	O
+between	O
+a	O
+corona	B-CHED
+-	O
+like	O
+virus	B-SPEC
+and	O
+A	B-SPEC
+.	I-SPEC
+hydrophila	I-SPEC
+,	O
+we	O
+conducted	O
+transmission	O
+trials	O
+by	O
+cohabiting	O
+naturally	O
+diseased	O
+carp	B-DISO
+with	O
+healthy	O
+carp	B-DISO
+with	O
+skin	B-ANAT
+that	O
+had	O
+been	O
+slightly	O
+damaged	O
+artificially	O
+.	O
+
+Hemosiderin	B-DISO
+deposition	I-DISO
+occurred	O
+within	O
+macrophages	B-ANAT
+in	O
+the	O
+spleen	B-ANAT
+and	O
+hematopoietic	B-ANAT
+tissue	I-ANAT
+,	O
+and	O
+within	O
+hepatocytes	B-ANAT
+.	O
+
+Baculovirus	B-SPEC
+-	O
+expressed	B-PROC
+N	O
+proteins	B-CHED
+were	O
+used	O
+as	O
+antigen	B-CHED
+in	O
+an	O
+indirect	O
+enzyme	O
+-	O
+linked	O
+immunosorbent	O
+assay	O
+(	O
+ELISA	O
+)	O
+for	O
+detection	O
+of	O
+TCV	B-SPEC
+-	O
+specific	O
+antibodies	B-COMP
+.	O
+
+ABSTRACT	O
+:	O
+The	O
+DB2	O
+calf	B-ANAT
+strain	O
+of	O
+bovine	O
+coronavirus	B-SPEC
+(	O
+BCV	B-SPEC
+)	O
+was	O
+used	O
+to	O
+inoculate	O
+1	O
+-	O
+day	O
+-	O
+old	O
+specific	O
+-	O
+pathogen	O
+-	O
+free	O
+(	O
+SPF	O
+)	O
+turkey	B-SPEC
+poults	O
+in	O
+three	O
+trials	O
+.	O
+
+Birds	B-SPEC
+euthanatized	O
+at	O
+3	O
+,	O
+5	O
+,	O
+and	O
+7	O
+days	O
+postinoculation	O
+(	O
+DPI	O
+)	O
+had	O
+flaccid	O
+,	O
+pale	B-DISO
+intestines	B-ANAT
+with	O
+watery	O
+contents	O
+,	O
+and	O
+the	O
+ceca	O
+were	O
+markedly	O
+enlarged	O
+with	O
+frothy	O
+contents	O
+.	O
+
+Hemagglutinating	O
+antibodies	B-COMP
+were	O
+detected	O
+in	O
+sera	B-COMP
+of	O
+convalescent	O
+birds	B-SPEC
+at	O
+12	O
+DPI	O
+.	O
+
+We	O
+developed	O
+a	O
+restriction	O
+fragment	O
+length	O
+polymorphism	B-PROC
+analysis	O
+that	O
+can	O
+differentiate	O
+this	O
+new	O
+serotype	O
+from	O
+all	O
+other	O
+serotypes	O
+of	O
+IBV	B-SPEC
+.	O
+
+Our	O
+results	O
+also	O
+showed	O
+that	O
+in	O
+vivo	O
+recombination	B-PROC
+of	O
+IBV	B-SPEC
+may	O
+have	O
+occurred	O
+at	O
+a	O
+rather	O
+high	O
+frequency	O
+,	O
+contributing	O
+to	O
+the	O
+diversity	O
+of	O
+these	O
+IBV	B-SPEC
+isolates	O
+.	O
+
+Macrophages	B-ANAT
+from	O
+the	O
+peripheral	B-ANAT
+blood	I-ANAT
+and	O
+the	O
+respiratory	B-ANAT
+tracts	I-ANAT
+of	O
+chickens	B-SPEC
+infected	O
+with	O
+IBV	B-SPEC
+or	O
+IBDV	B-SPEC
+plus	O
+IBV	B-SPEC
+efficiently	O
+performed	O
+in	O
+vitro	O
+phagocytosis	B-PROC
+of	O
+E	B-SPEC
+.	I-SPEC
+coli	I-SPEC
+in	O
+the	O
+presence	O
+of	O
+positive	O
+-	O
+control	O
+serum	B-COMP
+(	O
+i	O
+.	O
+e	O
+.,	O
+E	B-SPEC
+.	I-SPEC
+coli	I-SPEC
+antiserum	O
+produced	O
+in	O
+normal	O
+chickens	B-SPEC
+).	O
+
+These	O
+results	O
+indicate	O
+that	O
+although	O
+IBDV	B-SPEC
+alone	O
+has	O
+the	O
+potential	O
+to	O
+markedly	O
+reduce	O
+opsonizing	O
+ability	O
+of	O
+antibody	B-COMP
+,	O
+this	O
+effect	O
+is	O
+significantly	O
+(	O
+P	O
+<	O
+0	O
+.	O
+05	O
+)	O
+exacerbated	O
+by	O
+IBV	B-SPEC
+infection	B-DISO
+.	O
+
+By	O
+immunoprecipitation	O
+of	O
+UV	O
+-	O
+cross	O
+-	O
+linked	O
+cellular	B-COMP
+proteins	B-CHED
+and	O
+in	O
+vitro	O
+binding	B-FUNC
+of	O
+the	O
+recombinant	O
+protein	B-CHED
+,	O
+we	O
+have	O
+identified	O
+the	O
+major	O
+RNA	O
+-	O
+binding	B-FUNC
+protein	B-CHED
+species	B-SPEC
+as	O
+heterogeneous	B-ANAT
+nuclear	I-ANAT
+ribonucleoprotein	I-ANAT
+A1	O
+(	O
+hnRNP	B-ANAT
+A1	O
+).	O
+
+Furthermore	O
+,	O
+hnRNP	B-ANAT
+A1	O
+and	O
+PTB	B-PRGE
+,	O
+both	O
+of	O
+which	O
+also	O
+bind	B-FUNC
+to	O
+the	O
+complementary	O
+strands	O
+at	O
+the	O
+5	O
+'	O
+end	O
+of	O
+MHV	B-SPEC
+RNA	O
+,	O
+together	O
+mediate	O
+the	O
+formation	B-PROC
+of	O
+an	O
+RNP	B-COMP
+complex	O
+involving	O
+the	O
+5	O
+'-	O
+and	O
+3	O
+'-	O
+end	O
+fragments	O
+of	O
+MHV	B-SPEC
+RNA	O
+in	O
+vitro	O
+.	O
+
+ABSTRACT	O
+:	O
+Sialodacryoadenitis	O
+(	O
+SDA	O
+)	O
+is	O
+a	O
+highly	O
+contagious	O
+common	O
+viral	B-DISO
+infection	I-DISO
+in	O
+rats	B-SPEC
+,	O
+akin	O
+to	O
+mumps	B-DISO
+in	O
+humans	B-SPEC
+.	O
+
+We	O
+thus	O
+studied	O
+seven	O
+male	O
+rats	B-SPEC
+.	O
+
+To	O
+determine	O
+the	O
+involvement	O
+of	O
+individual	O
+MMPs	O
+in	O
+the	O
+development	B-PROC
+of	O
+lung	B-ANAT
+injury	O
+,	O
+mice	B-SPEC
+genetically	O
+deficient	O
+in	O
+gelatinase	B-PRGE
+B	I-PRGE
+(	O
+MMP	B-PRGE
+-	I-PRGE
+9	I-PRGE
+)	O
+and	O
+stromelysin	B-PRGE
+1	I-PRGE
+(	O
+MMP	B-PRGE
+-	I-PRGE
+3	I-PRGE
+)	O
+were	O
+acutely	O
+injured	O
+with	O
+immunoglobulin	B-PRGE
+G	I-PRGE
+immune	O
+complexes	O
+and	O
+the	O
+intensity	O
+of	O
+the	O
+lung	B-ANAT
+injury	O
+was	O
+compared	O
+with	O
+genetically	O
+identical	O
+wild	O
+-	O
+type	O
+(	O
+WT	O
+)	O
+mice	B-SPEC
+with	O
+normal	O
+MMP	B-CHED
+activities	O
+.	O
+
+In	O
+the	O
+WT	O
+mice	B-SPEC
+there	O
+was	O
+upregulation	B-PROC
+of	O
+gelatinase	B-PRGE
+B	I-PRGE
+and	O
+stromelysin	B-PRGE
+1	I-PRGE
+in	O
+the	O
+injured	O
+lungs	B-ANAT
+which	O
+,	O
+as	O
+expected	O
+,	O
+was	O
+absent	O
+in	O
+the	O
+genetically	O
+deficient	O
+gelatinase	B-ENZY
+B	I-ENZY
+-	O
+and	O
+stromelysin	B-ENZY
+1	I-ENZY
+-	O
+deficient	O
+mice	B-SPEC
+,	O
+respectively	O
+.	O
+
+Ten	O
+patients	O
+with	O
+severe	O
+ARDS	B-DISO
+were	O
+studied	O
+in	O
+a	O
+crossover	O
+study	O
+design	O
+,	O
+within	O
+72	O
+hours	O
+after	O
+starting	O
+mechanical	O
+ventilation	O
+.	O
+
+We	O
+studied	O
+the	O
+effects	O
+of	O
+ANP	B-PRGE
+infusion	O
+(	O
+10	O
+ng	O
+/	O
+kg	O
+/	O
+min	O
+for	O
+1	O
+hour	O
+)	O
+and	O
+of	O
+inhalation	B-PROC
+of	O
+NO	O
+(	O
+20	O
+ppm	O
+for	O
+1	O
+hour	O
+)	O
+on	O
+hemodynamic	B-PROC
+and	O
+respiratory	O
+patient	O
+parameters	O
+,	O
+as	O
+well	O
+as	O
+the	O
+effects	O
+on	O
+plasma	B-ANAT
+levels	O
+of	O
+ANP	B-PRGE
+,	O
+guanosine	B-CHED
+3	I-CHED
+',	I-CHED
+5	I-CHED
+'-	I-CHED
+cyclic	I-CHED
+monophosphate	I-CHED
+,	O
+nitrate	B-CHED
+and	O
+endothelin	B-PRGE
+-	I-PRGE
+1	I-PRGE
+.	O
+
+A	O
+previously	O
+normal	O
+child	O
+of	O
+7	O
+months	O
+of	O
+age	O
+presented	O
+an	O
+acute	O
+picture	O
+of	O
+status	B-DISO
+epilepticus	I-DISO
+with	O
+respiratory	B-DISO
+problems	I-DISO
+and	O
+periods	B-PROC
+of	O
+apnea	B-DISO
+.	O
+
+The	O
+follow	O
+-	O
+up	O
+with	O
+MR	O
+studies	O
+revealed	O
+voluminous	O
+subdural	B-ANAT
+bilateral	O
+hygroma	B-DISO
+that	O
+increased	O
+the	O
+size	O
+along	O
+the	O
+following	O
+six	O
+months	O
+,	O
+despite	O
+treatment	O
+with	O
+bilateral	O
+subdural	B-ANAT
+-	O
+peritoneal	B-ANAT
+shunt	O
+,	O
+and	O
+the	O
+patient	O
+showed	O
+infantile	B-DISO
+spasms	I-DISO
+.	O
+
+Four	O
+factors	O
+independently	O
+predicted	O
+mortality	O
+:	O
+a	O
+time	O
+from	O
+symptom	B-DISO
+onset	O
+to	O
+treatment	O
+of	O
+more	O
+than	O
+1	O
+month	O
+(	O
+OR	O
+,	O
+3	O
+.	O
+49	O
+;	O
+CI	O
+,	O
+1	O
+.	O
+20	O
+-	O
+10	O
+.	O
+20	O
+),	O
+the	O
+number	O
+of	O
+organ	B-ANAT
+failures	O
+(	O
+OR	O
+,	O
+3	O
+.	O
+15	O
+;	O
+CI	O
+,	O
+1	O
+.	O
+76	O
+-	O
+5	O
+.	O
+76	O
+),	O
+a	O
+serum	B-COMP
+albumin	B-PRGE
+level	O
+above	O
+20	O
+g	O
+/	O
+l	O
+(	O
+OR	O
+,	O
+3	O
+.	O
+96	O
+;	O
+CI	O
+,	O
+1	O
+.	O
+04	O
+-	O
+15	O
+.	O
+10	O
+),	O
+and	O
+a	O
+larger	O
+number	O
+of	O
+lobes	B-ANAT
+involved	O
+on	O
+chest	B-ANAT
+radiograph	O
+(	O
+OR	O
+,	O
+1	O
+.	O
+83	O
+;	O
+CI	O
+,	O
+1	O
+.	O
+12	O
+-	O
+2	O
+.	O
+98	O
+).	O
+
+TITLE	O
+:	O
+Maternal	O
+antibody	B-COMP
+to	O
+infectious	B-DISO
+bronchitis	B-DISO
+virus	B-SPEC
+:	O
+its	O
+role	O
+in	O
+protection	O
+against	O
+infection	B-DISO
+and	O
+development	O
+of	O
+active	B-PROC
+immunity	I-PROC
+to	O
+vaccine	O
+.	O
+
+Subjects	O
+underwent	O
+repetitive	O
+saline	O
+lavage	O
+to	O
+achieve	O
+a	O
+uniform	O
+degree	O
+of	O
+lung	B-ANAT
+injury	O
+and	O
+then	O
+were	O
+randomized	O
+to	O
+either	O
+CMV	B-SPEC
+or	O
+were	O
+converted	O
+to	O
+HFOV	O
+.	O
+
+Oxygenation	B-PROC
+improvements	O
+were	O
+compared	O
+between	O
+groups	O
+.	O
+
+TITLE	O
+:	O
+Pathophysiology	O
+of	O
+prone	O
+positioning	O
+in	O
+the	O
+healthy	O
+lung	B-ANAT
+and	O
+in	O
+ALI	O
+/	O
+ARDS	B-DISO
+.	O
+
+In	O
+ALI	O
+/	O
+ARDS	B-DISO
+patients	O
+,	O
+prone	O
+position	O
+lead	O
+to	O
+a	O
+reverse	O
+of	O
+the	O
+alveolar	B-ANAT
+inflation	O
+and	O
+ventilation	O
+distribution	O
+,	O
+due	O
+to	O
+the	O
+reverse	O
+of	O
+hydrostatic	O
+pressure	O
+overlying	O
+lung	B-ANAT
+parenchyma	I-ANAT
+,	O
+the	O
+reverse	O
+of	O
+heart	B-ANAT
+weight	O
+,	O
+and	O
+the	O
+changes	O
+in	O
+chest	B-ANAT
+wall	I-ANAT
+shape	O
+and	O
+mechanical	O
+properties	O
+.	O
+
+From	O
+a	O
+clinical	O
+point	O
+of	O
+view	O
+,	O
+prone	O
+position	O
+seems	O
+to	O
+be	O
+a	O
+very	O
+promising	O
+treatment	O
+for	O
+ALI	O
+/	O
+ARDS	B-DISO
+,	O
+even	O
+if	O
+its	O
+use	O
+is	O
+not	O
+yet	O
+a	O
+standard	O
+clinical	O
+practice	O
+.	O
+
+Sequencing	O
+analysis	O
+of	O
+the	O
+S	O
+(	O
+S1	O
+portion	O
+),	O
+HE	O
+,	O
+ORF4	O
+and	O
+ORF5	O
+genes	O
+of	O
+BCoV	O
+isolates	O
+associated	O
+with	O
+different	O
+clinical	O
+syndromes	O
+indicated	O
+that	O
+neither	O
+insertions	O
+or	O
+deletions	O
+could	O
+explain	O
+their	O
+distinct	O
+tropism	B-PROC
+.	O
+
+The	O
+ORF5	O
+,	O
+which	O
+encodes	O
+a	O
+12	O
+.	O
+7	O
+ns	O
+protein	B-CHED
+and	O
+the	O
+9	B-PRGE
+.	I-PRGE
+5	I-PRGE
+kDa	I-PRGE
+E	I-PRGE
+protein	I-PRGE
+,	O
+was	O
+highly	O
+conserved	O
+amongst	O
+the	O
+BCoV	O
+field	O
+isolates	O
+.	O
+
+TITLE	O
+:	O
+Experimental	O
+reproduction	B-PROC
+of	O
+winter	B-DISO
+dysentery	I-DISO
+in	O
+lactating	O
+cows	B-SPEC
+using	O
+BCV	B-SPEC
+--	O
+comparison	O
+with	O
+BCV	O
+infection	B-DISO
+in	O
+milk	O
+-	O
+fed	O
+calves	O
+.	O
+
+Prolonged	O
+IgM	B-COMP
+antibody	B-PROC
+responses	O
+were	O
+detected	O
+in	O
+serum	B-COMP
+and	O
+milk	O
+,	O
+while	O
+those	O
+in	O
+nasal	B-ANAT
+secretions	B-ANAT
+were	O
+much	O
+shorter	O
+.	O
+
+The	O
+cows	B-SPEC
+showed	O
+a	O
+more	O
+severe	O
+general	O
+diseases	O
+than	O
+seronegative	O
+calves	O
+infected	O
+concurrently	O
+.	O
+
+ABSTRACT	O
+:	O
+Based	O
+on	O
+general	O
+SARs	B-DISO
+previously	O
+described	O
+for	O
+anti	O
+-	O
+HIV	B-SPEC
+-	I-SPEC
+1	I-SPEC
+diarylsulfone	O
+derivatives	O
+,	O
+a	O
+series	O
+of	O
+2	O
+-	O
+amino	O
+-	O
+and	O
+2	O
+-	O
+carboxamido	O
+-	O
+3	O
+-	O
+arylsulfonylthiophenes	O
+has	O
+been	O
+prepared	O
+and	O
+evaluated	O
+as	O
+potential	O
+antiviral	B-CHED
+and	O
+antitumor	O
+agents	O
+.	O
+
+Such	O
+treatment	O
+regimens	O
+designed	O
+to	O
+protect	O
+the	O
+heart	B-ANAT
+can	O
+,	O
+however	O
+,	O
+often	O
+lead	O
+to	O
+lung	B-ANAT
+injury	O
+and	O
+,	O
+in	O
+fact	O
+,	O
+several	O
+compounds	O
+with	O
+known	O
+iron	B-PROC
+chelating	I-PROC
+properties	O
+can	O
+induce	O
+severe	O
+lung	B-ANAT
+dysfunction	O
+and	O
+injury	O
+.	O
+
+With	O
+diazepam	B-CHED
+anesthesia	B-DISO
+,	O
+Rint	O
+,	O
+L	O
+decreased	O
+linearly	O
+,	O
+with	O
+increasing	O
+PaCO2	O
+,	O
+from	O
+2	O
+.	O
+3	O
+to	O
+1	O
+.	O
+4	O
+cm	O
+H2O	B-CHED
+.	O
+s	O
+.	O
+l	O
+(-	O
+1	O
+),	O
+whereas	O
+deltaR	O
+,	O
+L	O
+decreased	O
+from	O
+2	O
+to	O
+1	O
+.	O
+7	O
+cm	O
+H2O	B-CHED
+.	O
+s	O
+.	O
+l	O
+(-	O
+1	O
+),	O
+though	O
+not	O
+significantly	O
+.	O
+
+0	O
+.	O
+5	O
+cm	O
+H2O	B-CHED
+.	O
+s	O
+.	O
+l	O
+(-	O
+1	O
+))	O
+was	O
+not	O
+significant	O
+,	O
+and	O
+deltaRL	O
+remained	O
+unchanged	O
+.	O
+
+A	O
+common	O
+trait	O
+of	O
+these	O
+positive	O
+-	O
+stranded	O
+RNA	O
+viruses	B-SPEC
+is	O
+the	O
+3	O
+'-	O
+coterminal	O
+nested	O
+set	O
+of	O
+six	O
+to	O
+eight	O
+leader	O
+-	O
+containing	O
+subgenomic	O
+mRNAs	O
+which	O
+are	O
+generated	O
+by	O
+a	O
+discontinuous	O
+transcription	B-PROC
+mechanism	O
+and	O
+from	O
+which	O
+the	O
+viral	O
+open	O
+reading	O
+frames	O
+downstream	O
+of	O
+the	O
+polymerase	B-PRGE
+gene	I-PRGE
+are	O
+expressed	B-PROC
+.	O
+
+TITLE	O
+:	O
+When	O
+to	O
+suspect	O
+and	O
+how	O
+to	O
+monitor	O
+babesiosis	B-DISO
+.	O
+
+ABSTRACT	O
+:	O
+In	O
+the	O
+past	O
+decade	O
+,	O
+cases	O
+of	O
+babesiosis	B-DISO
+in	O
+humans	B-SPEC
+have	O
+been	O
+reported	O
+with	O
+increasing	O
+frequency	O
+,	O
+especially	O
+in	O
+the	O
+northeastern	O
+United	O
+States	O
+.	O
+
+Factors	O
+associated	O
+with	O
+more	O
+severe	O
+disease	O
+include	O
+advanced	O
+age	O
+,	O
+previous	O
+splenectomy	O
+and	O
+immunodeficient	B-DISO
+states	O
+.	O
+
+It	O
+begins	O
+as	O
+noncardiogenic	O
+pulmonary	B-DISO
+edema	I-DISO
+and	O
+develops	O
+into	O
+a	O
+neutrophilic	B-PROC
+alveolitis	B-DISO
+,	O
+and	O
+,	O
+later	O
+,	O
+pulmonary	B-DISO
+fibrosis	I-DISO
+.	O
+
+Interventions	O
+that	O
+reduce	O
+alveolar	B-ANAT
+inflammation	B-DISO
+,	O
+enhance	O
+alveolar	B-ANAT
+fluid	O
+removal	O
+,	O
+and	O
+reduce	O
+pulmonary	B-DISO
+fibrosis	I-DISO
+will	O
+further	O
+improve	O
+survival	O
+and	O
+recovery	O
+from	O
+ARDS	B-DISO
+in	O
+the	O
+future	O
+.	O
+
+Feline	B-SPEC
+coronavirus	B-SPEC
+(	O
+FCoV	O
+)	O
+genomic	O
+RNA	O
+was	O
+detected	O
+consistently	O
+in	O
+this	O
+study	O
+in	O
+biologic	O
+samples	O
+from	O
+adult	O
+cats	B-SPEC
+,	O
+kittens	O
+suffering	B-DISO
+from	O
+FIP	B-DISO
+,	O
+and	O
+their	O
+siblings	O
+.	O
+
+The	O
+sire	O
+was	O
+determined	O
+to	O
+be	O
+infected	O
+with	O
+both	O
+variants	O
+,	O
+and	O
+was	O
+persistently	O
+virus	B-SPEC
+-	O
+infected	O
+.	O
+
+TITLE	O
+:	O
+Axonal	O
+damage	O
+is	O
+T	B-ANAT
+cell	I-ANAT
+mediated	O
+and	O
+occurs	O
+concomitantly	O
+with	O
+demyelination	B-DISO
+in	O
+mice	B-SPEC
+infected	O
+with	O
+a	O
+neurotropic	O
+coronavirus	O
+.	O
+
+Herein	O
+we	O
+show	O
+that	O
+axonal	O
+damage	O
+occurred	O
+in	O
+areas	O
+of	O
+demyelination	B-DISO
+and	O
+also	O
+in	O
+adjacent	O
+areas	O
+devoid	O
+of	O
+myelin	B-COMP
+damage	O
+.	O
+
+Immunodeficient	B-DISO
+MHV	B-SPEC
+-	O
+infected	O
+RAG1	B-PRGE
+-/-	O
+mice	B-SPEC
+(	O
+mice	B-SPEC
+defective	O
+in	O
+recombinase	B-PRGE
+activating	O
+gene	B-PRGE
+1	I-PRGE
+expression	B-PROC
+)	O
+do	O
+not	O
+develop	O
+demyelination	B-DISO
+unless	O
+they	O
+receive	O
+splenocytes	O
+from	O
+a	O
+mouse	B-SPEC
+previously	O
+immunized	O
+against	O
+MHV	B-SPEC
+(	O
+G	O
+.	O
+F	O
+.	O
+Wu	O
+,	O
+A	O
+.	O
+Dandekar	O
+,	O
+L	O
+.	O
+Pewe	O
+,	O
+and	O
+S	O
+.	O
+Perlman	O
+,	O
+J	O
+.	O
+Immunol	O
+.	O
+
+In	O
+12	O
+consecutive	O
+patients	O
+with	O
+severe	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+and	O
+/	O
+or	O
+circulatory	B-DISO
+failure	I-DISO
+of	O
+different	O
+etiology	O
+who	O
+met	B-CHED
+the	O
+indication	O
+criteria	O
+the	O
+method	O
+of	O
+venoarterial	O
+EMCO	O
+was	O
+used	O
+.	O
+
+In	O
+patients	O
+who	O
+died	B-PROC
+necropsy	O
+confirmed	O
+irreversible	O
+multiorgan	B-DISO
+failure	I-DISO
+.	O
+
+It	O
+was	O
+also	O
+observed	O
+that	O
+the	O
+N	B-PRGE
+gene	I-PRGE
+of	O
+eight	O
+TCV	B-SPEC
+isolates	O
+originating	O
+from	O
+various	O
+regions	O
+of	O
+the	O
+USA	O
+could	O
+not	O
+be	O
+amplified	O
+by	O
+the	O
+primers	O
+designed	O
+from	O
+the	O
+N	B-PRGE
+gene	I-PRGE
+of	O
+bovine	B-SPEC
+coronavirus	B-SPEC
+(	O
+BCV	B-SPEC
+).	O
+
+TITLE	O
+:	O
+Effect	O
+of	O
+an	O
+acute	O
+increase	O
+in	O
+PCO2	O
+on	O
+splanchnic	O
+perfusion	O
+and	O
+metabolism	B-PROC
+.	O
+
+PCO2	O
+was	O
+increased	O
+by	O
+an	O
+added	O
+dead	B-PROC
+space	O
+;	O
+after	O
+60	O
+min	O
+all	O
+measurements	O
+were	O
+repeated	O
+;	O
+after	O
+return	O
+to	O
+baseline	O
+a	O
+third	O
+measurement	O
+followed	O
+.	O
+
+TITLE	O
+:	O
+Use	O
+of	O
+a	O
+reverse	O
+-	O
+transcriptase	B-PROC
+polymerase	O
+chain	O
+reaction	O
+for	O
+monitoring	O
+the	O
+shedding	O
+of	O
+feline	B-SPEC
+coronavirus	B-SPEC
+by	O
+healthy	O
+cats	B-SPEC
+.	O
+
+ABSTRACT	O
+:	O
+The	O
+pattern	O
+of	O
+shedding	O
+of	O
+feline	B-SPEC
+coronavirus	B-SPEC
+(	O
+FCoV	O
+)	O
+was	O
+established	O
+in	O
+155	O
+naturally	O
+infected	O
+pet	O
+cats	B-SPEC
+from	O
+29	O
+households	O
+over	O
+periods	B-PROC
+of	O
+up	O
+to	O
+five	O
+years	O
+.	O
+
+TITLE	O
+:	O
+Feline	B-SPEC
+and	O
+canine	O
+coronaviruses	O
+are	O
+released	O
+from	O
+the	O
+basolateral	O
+side	O
+of	O
+polarized	O
+epithelial	O
+LLC	O
+-	O
+PK1	O
+cells	B-COMP
+expressing	O
+the	O
+recombinant	B-PRGE
+feline	I-PRGE
+aminopeptidase	I-PRGE
+-	I-PRGE
+N	I-PRGE
+cDNA	I-PRGE
+.	O
+
+However	O
+,	O
+whereas	O
+TGEV	B-SPEC
+is	O
+released	O
+apically	O
+,	O
+feline	B-SPEC
+and	O
+canine	O
+coronaviruses	O
+were	O
+found	O
+to	O
+be	O
+released	O
+from	O
+the	O
+basolateral	O
+side	O
+of	O
+the	O
+epithelial	B-ANAT
+cells	I-ANAT
+.	O
+
+Probable	O
+role	O
+of	O
+gemcitabine	B-CHED
+].	O
+
+The	O
+development	B-PROC
+of	O
+brief	O
+mild	O
+episodes	O
+of	O
+dyspnea	B-DISO
+is	O
+considered	O
+to	O
+be	O
+common	O
+after	O
+delivery	O
+of	O
+gemcitabin	O
+.	O
+
+TITLE	O
+:	O
+Recent	O
+epidemiological	O
+status	O
+of	O
+canine	O
+viral	O
+enteric	O
+infections	B-DISO
+and	O
+Giardia	B-DISO
+infection	I-DISO
+in	O
+Japan	O
+.	O
+
+Although	O
+canine	O
+rotavirus	B-SPEC
+,	O
+canine	B-SPEC
+adenovirus	I-SPEC
+,	O
+and	O
+canine	B-SPEC
+distemper	I-SPEC
+virus	I-SPEC
+were	O
+also	O
+detected	O
+in	O
+a	O
+small	O
+number	O
+of	O
+diarrheal	O
+cases	O
+,	O
+no	O
+evidence	O
+for	O
+calicivirus	B-DISO
+infection	I-DISO
+was	O
+obtained	O
+.	O
+
+Addition	O
+of	O
+the	O
+general	O
+caspase	B-PRGE
+inhibitor	B-CHED
+z	B-PRGE
+-	I-PRGE
+VAD	I-PRGE
+-	I-PRGE
+FMK	I-PRGE
+to	O
+the	O
+culture	O
+media	B-ANAT
+showed	O
+inhibition	B-PROC
+of	O
+the	O
+hallmarks	O
+of	O
+apoptosis	B-PROC
+and	O
+increase	O
+of	O
+the	O
+release	B-PATH
+of	O
+virus	B-SPEC
+to	O
+the	O
+culture	O
+media	B-ANAT
+at	O
+16	O
+h	O
+postinfection	O
+.	O
+
+These	O
+putative	O
+replication	O
+complexes	O
+are	O
+composed	O
+of	O
+intimately	O
+associated	O
+but	O
+biochemically	O
+distinct	O
+membrane	B-COMP
+populations	O
+,	O
+each	O
+of	O
+which	O
+contains	O
+proteins	B-CHED
+processed	O
+from	O
+the	O
+replicase	B-PRGE
+(	O
+gene	B-PRGE
+1	I-PRGE
+)	O
+polyprotein	O
+.	O
+
+The	O
+N	B-PRGE
+protein	I-PRGE
+was	O
+expressed	B-PROC
+under	O
+control	O
+of	O
+the	O
+vaccinia	B-PRGE
+virus	I-PRGE
+promoter	I-PRGE
+P7	I-PRGE
+.	I-PRGE
+5	I-PRGE
+in	I-PRGE
+chicken	B-SPEC
+embryo	B-ANAT
+fibroblast	B-ANAT
+cell	I-ANAT
+cultures	O
+as	O
+seen	O
+in	O
+immunofluorescence	O
+assay	O
+and	O
+in	O
+rFPV	O
+-	O
+inoculated	O
+specific	O
+-	O
+pathogen	O
+-	O
+free	O
+(	O
+SPF	O
+)	O
+chickens	B-SPEC
+by	O
+detecting	O
+antibodies	B-COMP
+with	O
+enzyme	O
+-	O
+linked	O
+immunosorbent	O
+assay	O
+(	O
+ELISA	O
+).	O
+
+When	O
+the	O
+chickens	B-SPEC
+were	O
+challenged	O
+with	O
+IBV	B-SPEC
+Ch3	B-CHED
+or	O
+Ch5	O
+,	O
+the	O
+control	O
+birds	O
+had	O
+respiratory	O
+signs	O
+of	O
+infections	B-DISO
+bronchitis	B-DISO
+,	O
+whereas	O
+all	O
+the	O
+vaccinated	O
+birds	B-SPEC
+were	O
+clinically	O
+normal	O
+although	O
+low	O
+levels	O
+of	O
+the	O
+IBV	B-SPEC
+infection	B-DISO
+were	O
+detected	O
+by	O
+a	O
+differential	O
+ELISA	O
+.	O
+
+Our	O
+results	O
+suggest	O
+that	O
+the	O
+C	O
+-	O
+terminal	O
+119	O
+amino	B-CHED
+acid	I-CHED
+of	O
+the	O
+nucleocapsid	B-COMP
+expressed	B-PROC
+by	O
+FPV	B-SPEC
+is	O
+a	O
+host	B-COMP
+-	O
+protective	O
+antigen	B-CHED
+and	O
+may	O
+induce	O
+cross	O
+-	O
+protective	O
+immunity	B-PROC
+against	O
+illness	O
+among	O
+some	O
+IBV	B-SPEC
+strains	O
+.	O
+
+In	O
+this	O
+study	O
+,	O
+we	O
+compared	O
+the	O
+cleavage	B-PROC
+recognition	O
+site	O
+of	O
+55	O
+IBV	B-SPEC
+isolates	O
+to	O
+determine	O
+if	O
+the	O
+cleavage	B-PROC
+recognition	O
+site	O
+sequence	O
+,	O
+which	O
+consists	O
+of	O
+five	O
+basic	O
+amino	B-CHED
+acid	I-CHED
+residues	O
+,	O
+correlates	O
+with	O
+host	B-COMP
+cell	I-COMP
+range	O
+,	O
+serotype	O
+,	O
+geographic	O
+origin	O
+,	O
+and	O
+pathogenicity	O
+as	O
+it	O
+does	O
+in	O
+orthomyxoviruses	B-SPEC
+and	O
+paramyxoviruses	O
+.	O
+
+We	O
+also	O
+determined	O
+that	O
+cleavage	B-PROC
+recognition	O
+site	O
+sequence	O
+does	O
+not	O
+correlate	O
+with	O
+pathogenicity	O
+because	O
+attenuated	O
+and	O
+pathogenic	O
+isolates	O
+(	O
+different	O
+passages	O
+of	O
+the	O
+same	O
+virus	O
+)	O
+contain	O
+identical	O
+cleavage	B-PROC
+recognition	O
+site	O
+sequences	O
+.	O
+
+We	O
+retrospectively	O
+studied	O
+28	O
+patients	O
+,	O
+17	O
+admitted	O
+in	O
+our	O
+Intensive	O
+Care	O
+Unit	O
+(	O
+ICU	O
+-	O
+patients	O
+)	O
+and	O
+treated	O
+by	O
+continuous	O
+renal	B-ANAT
+replacement	O
+therapy	O
+(	O
+particularly	O
+by	O
+continuous	O
+venovenous	O
+hemofiltration	O
+,	O
+continuous	O
+venovenous	O
+hemodialysis	O
+and	O
+continuous	O
+venovenous	O
+hemodiafiltration	O
+)	O
+and	O
+11	O
+admitted	O
+in	O
+our	O
+Nephrology	O
+Department	O
+(	O
+NICU	O
+-	O
+patients	O
+)	O
+and	O
+treated	O
+by	O
+high	O
+-	O
+efficiency	O
+daily	O
+hemodialysis	O
+.	O
+
+Before	O
+starting	O
+the	O
+dialytic	O
+treatment	O
+,	O
+in	O
+ICU	O
+-	O
+patients	O
+CPK	O
+plasma	B-ANAT
+level	O
+was	O
+2615	O
++/-	O
+
+ICU	O
+-	O
+patients	O
+mortality	O
+rate	O
+was	O
+50	O
+%	O
+(	O
+8	O
+/	O
+16	O
+patients	O
+)	O
+in	O
+spite	O
+of	O
+the	O
+good	O
+recovery	O
+of	O
+renal	B-PROC
+function	I-PROC
+and	O
+the	O
+biochemical	O
+RML	O
+indexes	O
+improvement	O
+.	O
+
+In	O
+NICU	O
+-	O
+patients	O
+,	O
+instead	O
+,	O
+only	O
+one	O
+patient	O
+died	B-PROC
+for	O
+septic	O
+complications	O
+(	O
+he	O
+was	O
+a	O
+heroin	B-CHED
+-	O
+addict	O
+and	O
+suffered	B-DISO
+from	O
+overdose	O
+syndrome	B-DISO
+).	O
+
+ABSTRACT	O
+:	O
+We	O
+reviewed	O
+the	O
+frequency	O
+and	O
+mortality	O
+of	O
+acute	O
+lung	B-ANAT
+injury	O
+(	O
+ALI	O
+)	O
+and	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+(	O
+ARDS	B-DISO
+)	O
+in	O
+our	O
+population	O
+of	O
+patients	O
+submitted	O
+to	O
+pulmonary	B-ANAT
+resection	O
+for	O
+primary	O
+bronchogenic	B-DISO
+carcinoma	I-DISO
+.	O
+
+Associated	O
+cardiac	B-ANAT
+risk	O
+factors	O
+were	O
+present	O
+in	O
+eight	O
+patients	O
+.	O
+
+ALI	O
+was	O
+diagnosed	O
+in	O
+10	O
+patients	O
+and	O
+ARDS	B-DISO
+in	O
+17	O
+patients	O
+.	O
+
+(	O
+4	O
+)	O
+ALI	O
+/	O
+ARDS	B-DISO
+may	O
+also	O
+occur	O
+after	O
+sublobar	O
+resections	O
+with	O
+an	O
+associated	O
+high	O
+mortality	O
+rate	O
+.	O
+
+TITLE	O
+:	O
+[	O
+Neonatal	O
+arteriovenous	O
+thrombosis	B-DISO
+:	O
+report	O
+of	O
+a	O
+case	O
+].	O
+
+ABSTRACT	O
+:	O
+Limb	B-ANAT
+vascular	B-ANAT
+thrombosis	B-DISO
+is	O
+a	O
+severe	O
+,	O
+rare	O
+entity	O
+,	O
+often	O
+needing	O
+invasive	O
+surgery	O
+and	O
+sometimes	O
+leading	O
+to	O
+loss	O
+of	O
+function	O
+.	O
+
+The	O
+baby	O
+,	O
+a	O
+female	O
+infant	O
+,	O
+was	O
+born	O
+at	O
+34	O
+weeks	O
+from	O
+a	O
+mother	O
+affected	O
+by	O
+gestational	B-DISO
+diabetes	I-DISO
+.	O
+
+Electron	O
+microscopy	O
+of	O
+the	O
+feces	B-ANAT
+demonstrated	O
+corona	B-CHED
+-	O
+like	O
+virus	B-COMP
+particles	I-COMP
+.	O
+
+There	O
+were	O
+no	O
+hemodynamic	B-PROC
+effects	O
+.	O
+
+Despite	O
+initial	O
+improvement	O
+in	O
+arterial	B-ANAT
+oxygenation	B-PROC
+with	O
+NIPSV	O
+in	O
+patients	O
+with	O
+ARF	B-DISO
+due	O
+to	O
+severe	O
+CAP	B-DISO
+,	O
+the	O
+intubation	O
+rate	O
+is	O
+high	O
+.	O
+
+The	O
+PL1pro	O
+-	O
+mediated	O
+cleavage	B-PROC
+was	O
+slow	O
+and	O
+significantly	O
+suppressed	O
+by	O
+a	O
+non	O
+-	O
+proteolytic	B-PROC
+activity	O
+of	O
+PL2pro	O
+.	O
+
+A	O
+large	O
+subset	O
+of	O
+coronaviruses	O
+may	O
+employ	O
+two	O
+proteases	O
+to	O
+cleave	O
+the	O
+same	O
+site	O
+(	O
+s	O
+)	O
+and	O
+thus	O
+regulate	O
+the	O
+expression	B-PROC
+of	O
+the	O
+viral	B-COMP
+genome	I-COMP
+in	O
+a	O
+unique	O
+way	O
+.	O
+
+TITLE	O
+:	O
+Surfactant	B-CHED
+and	O
+inhaled	B-PROC
+nitric	B-CHED
+oxide	I-CHED
+in	O
+rats	B-SPEC
+alleviate	O
+acute	O
+lung	B-ANAT
+injury	O
+induced	O
+by	O
+intestinal	B-ANAT
+ischemia	I-DISO
+and	O
+reperfusion	O
+.	O
+
+The	O
+authors	O
+hypothesize	O
+that	O
+a	O
+combined	O
+surfactant	B-CHED
+and	O
+inhaled	B-PROC
+nitric	B-CHED
+oxide	I-CHED
+(	O
+iNO	O
+)	O
+may	O
+alleviate	O
+I	O
+/	O
+R	O
+-	O
+induced	O
+ALI	O
+.	O
+
+The	O
+Surf	O
+,	O
+NO	O
+,	O
+and	O
+SNO	B-FUNC
+groups	O
+had	O
+higher	O
+V	O
+(	O
+V	O
+)	O
+and	O
+lower	O
+CV	O
+(	O
+V	O
+(	O
+V	O
+))	O
+values	O
+than	O
+the	O
+P	O
+-	O
+Control	O
+,	O
+but	O
+modest	O
+decrease	O
+of	O
+W	O
+/	O
+D	O
+values	O
+.	O
+
+),	O
+intranasal	O
+(	O
+i	O
+.	O
+n	O
+.),	O
+intraperitoneal	O
+(	O
+i	O
+.	O
+p	O
+.),	O
+subcutaneous	O
+(	O
+s	O
+.	O
+c	O
+.),	O
+intravenous	O
+(	O
+i	O
+.	O
+v	O
+.)	O
+and	O
+oral	B-ANAT
+routes	O
+with	O
+graded	O
+doses	O
+.	O
+
+The	O
+virus	O
+was	O
+first	O
+detected	O
+in	O
+the	O
+brain	B-ANAT
+on	O
+day	O
+1	O
+and	O
+in	O
+the	O
+spinal	B-ANAT
+cord	I-ANAT
+on	O
+day	O
+2	O
+.	O
+
+TITLE	O
+:	O
+Enteric	O
+infections	B-DISO
+with	O
+coronaviruses	O
+and	O
+toroviruses	B-SPEC
+.	O
+
+To	O
+infect	O
+enterocytes	B-ANAT
+,	O
+both	O
+S	O
+glycoproteins	B-CHED
+and	O
+the	O
+viral	B-COMP
+envelope	I-COMP
+must	O
+resist	O
+degradation	O
+by	O
+proteases	O
+,	O
+low	O
+and	O
+high	O
+pH	O
+,	O
+and	O
+bile	B-CHED
+salts	I-CHED
+.	O
+
+19	O
+.	O
+6	O
+)	O
+who	O
+met	B-CHED
+one	O
+of	O
+the	O
+following	O
+criteria	O
+:	O
+Pao2	O
+<	O
+or	O
+=	O
+65	O
+mm	O
+Hg	O
+with	O
+Fio2	O
+>	O
+or	O
+=	O
+0	O
+.	O
+6	O
+,	O
+or	O
+plateau	O
+pressure	O
+>	O
+or	O
+=	O
+35	O
+cm	O
+H2O	B-CHED
+.	O
+
+To	O
+test	O
+this	O
+hypothesis	O
+,	O
+12	O
+plastic	O
+shipping	O
+boxes	O
+with	O
+filters	O
+and	O
+tight	O
+-	O
+fitting	B-DISO
+lids	O
+and	O
+six	O
+cardboard	O
+shipping	O
+boxes	O
+without	O
+filters	O
+(	O
+controls	O
+)	O
+were	O
+each	O
+stocked	O
+with	O
+adult	O
+,	O
+adventitious	O
+disease	O
+-	O
+free	O
+mice	B-SPEC
+.	O
+
+This	O
+study	O
+demonstrates	O
+that	O
+at	O
+least	O
+one	O
+type	O
+of	O
+filtered	O
+shipping	O
+container	O
+protects	O
+mice	B-SPEC
+from	O
+a	O
+field	O
+challenge	O
+of	O
+MHV	B-SPEC
+.	O
+
+Nine	O
+deaths	B-PROC
+occurred	O
+during	O
+the	O
+first	O
+30	O
+days	O
+after	O
+transplantation	O
+among	O
+117	O
+patients	O
+undergoing	O
+123	O
+isolated	O
+lung	B-ANAT
+transplantation	O
+operations	O
+.	O
+
+The	O
+infrequently	O
+used	O
+canonical	O
+sequence	O
+,	O
+by	O
+computer	O
+prediction	O
+,	O
+is	O
+buried	O
+within	O
+the	O
+stem	B-ANAT
+of	O
+a	O
+stable	O
+hairpin	O
+(-	O
+17	O
+.	O
+2	O
+kcal	O
+/	O
+mol	O
+).	O
+
+We	O
+learned	B-PROC
+that	O
+(	O
+i	O
+)	O
+mutations	O
+that	O
+were	O
+predicted	O
+to	O
+unfold	O
+the	O
+stem	B-ANAT
+-	O
+loop	O
+in	O
+various	O
+ways	O
+did	O
+not	O
+switch	O
+RdRp	B-FUNC
+crossover	O
+to	O
+the	O
+upstream	O
+canonical	O
+site	O
+,	O
+(	O
+ii	O
+)	O
+a	O
+totally	O
+nonconforming	O
+downstream	O
+motif	O
+resulted	O
+in	O
+no	O
+measurable	O
+transcription	B-PROC
+from	O
+either	O
+site	O
+,	O
+(	O
+iii	O
+)	O
+the	O
+canonical	O
+upstream	O
+site	O
+does	O
+not	O
+function	O
+ectopically	O
+to	O
+lend	O
+competence	O
+to	O
+the	O
+downstream	O
+noncanonical	O
+site	O
+,	O
+and	O
+(	O
+iv	O
+)	O
+altering	O
+flanking	O
+sequences	O
+downstream	O
+of	O
+the	O
+downstream	O
+noncanonical	O
+motif	O
+in	O
+ways	O
+that	O
+diminish	O
+sequence	O
+similarity	O
+with	O
+the	O
+virus	B-SPEC
+genome	O
+5	O
+'	O
+end	O
+caused	O
+a	O
+dramatic	O
+switch	O
+to	O
+the	O
+upstream	O
+canonical	O
+site	O
+.	O
+
+Thus	O
+,	O
+in	O
+addition	O
+to	O
+the	O
+lack	O
+of	O
+Ab	O
+,	O
+limited	O
+CD8	B-PRGE
+(+)	I-PRGE
+and	O
+CD4	B-PRGE
+(+)	O
+T	B-ANAT
+cell	I-ANAT
+responses	O
+in	O
+muMT	O
+mice	B-SPEC
+contribute	O
+to	O
+the	O
+ultimate	O
+loss	O
+of	O
+control	O
+of	O
+CNS	B-DISO
+infection	I-DISO
+.	O
+
+FeLV	O
+infection	B-DISO
+was	O
+detected	O
+by	O
+immunohistology	O
+for	O
+gp70	B-PRGE
+,	O
+p27	B-PRGE
+,	O
+and	O
+p15E	O
+.	O
+
+L	B-PRGE
+-	I-PRGE
+Selectin	I-PRGE
+levels	O
+did	O
+not	O
+differ	O
+between	O
+survivors	O
+and	O
+nonsurvivors	O
+.	O
+
+Five	O
+patients	O
+progressed	O
+to	O
+acute	O
+lung	B-ANAT
+injury	O
+,	O
+whereas	O
+11	O
+patients	O
+developed	O
+hospital	O
+-	O
+acquired	O
+pneumonia	B-DISO
+.	O
+
+RESULTS	O
+:	O
+Seventy	O
+patients	O
+with	O
+a	O
+mean	O
+age	O
+of	O
+35	O
+.	O
+51	O
+years	O
+(	O
+range	O
+,	O
+10	O
+-	O
+87	O
+years	O
+)	O
+and	O
+a	O
+mean	O
+ISS	B-DISO
+score	O
+of	O
+36	O
+.	O
+61	O
+(	O
+95	O
+%	O
+CI	O
+,	O
+31	O
+.	O
+08	O
+-	O
+42	O
+.	O
+14	O
+)	O
+entered	O
+the	O
+study	O
+.	O
+
+in	O
+this	O
+indication	O
+,	O
+liver	B-ANAT
+transplantation	O
+if	O
+often	O
+associated	O
+with	O
+a	O
+low	O
+risk	O
+of	O
+acute	O
+rejection	O
+and	O
+a	O
+high	O
+rate	O
+cancer	B-DISO
+of	O
+the	O
+upper	O
+respiratory	O
+and	O
+digestive	B-ANAT
+tracts	I-ANAT
+.	O
+
+Acute	B-DISO
+alcoholic	I-DISO
+hepatitis	I-DISO
+is	O
+a	O
+severe	O
+disease	O
+,	O
+fatal	O
+in	O
+50	O
+%	O
+of	O
+the	O
+cases	O
+,	O
+and	O
+resistant	O
+tot	O
+corticosteroid	B-CHED
+therapy	O
+.	O
+
+TITLE	O
+:	O
+[	O
+Acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+after	O
+prolonged	O
+hyperbaric	O
+oxygen	B-CHED
+therapy	O
+:	O
+a	O
+case	O
+of	O
+pulmonary	B-ANAT
+oxygen	B-CHED
+toxicity	O
+?].	O
+
+ABSTRACT	O
+:	O
+Management	O
+of	O
+respiratory	B-DISO
+failure	I-DISO
+in	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+(	O
+ARDS	B-DISO
+)	O
+typically	O
+requires	O
+ventilatory	O
+assistance	O
+.	O
+
+Furthermore	O
+,	O
+these	O
+monoclonal	O
+antibodies	B-COMP
+were	O
+useful	O
+for	O
+boosting	O
+the	O
+efficacy	O
+of	O
+TGEV	B-SPEC
+-	O
+neutralizing	O
+colostrum	B-ANAT
+,	O
+which	O
+by	O
+itself	O
+was	O
+ineffective	O
+.	O
+
+Upon	O
+resolution	O
+of	O
+the	O
+underlying	O
+pathology	O
+mechanical	O
+ventilation	O
+may	O
+be	O
+withdrawn	B-DISO
+.	O
+
+ABSTRACT	O
+:	O
+Angioedema	B-DISO
+without	O
+urticaria	B-DISO
+is	O
+a	O
+clinical	O
+syndrome	O
+characterised	O
+by	O
+self	O
+-	O
+limiting	O
+local	O
+swellings	B-DISO
+involving	O
+the	O
+deeper	O
+cutaneous	O
+and	O
+mucosa	B-ANAT
+tissue	B-ANAT
+layers	B-ANAT
+.	O
+
+A	O
+small	O
+number	O
+of	O
+cases	O
+do	O
+not	O
+respond	O
+to	O
+antihistamine	B-CHED
+treatment	O
+.	O
+
+Such	O
+cases	O
+tend	O
+to	O
+occur	O
+in	O
+patients	O
+with	O
+deficiency	O
+or	O
+dysfunction	O
+of	O
+the	O
+inhibitor	B-CHED
+of	O
+the	O
+first	O
+component	O
+of	O
+the	O
+complement	O
+(	O
+C1	O
+-	O
+INH	O
+),	O
+but	O
+more	O
+rarely	O
+can	O
+occur	O
+in	O
+patients	O
+with	O
+other	O
+conditions	O
+and	O
+as	O
+an	O
+adverse	O
+drug	O
+reaction	O
+.	O
+
+Scattered	O
+reports	O
+suggest	O
+the	O
+possibility	O
+of	O
+angioedema	B-DISO
+associated	O
+with	O
+the	O
+use	O
+of	O
+estrogens	B-CHED
+,	O
+antihypertensive	B-CHED
+drugs	I-CHED
+other	O
+than	O
+ACE	B-PRGE
+inhibitors	B-CHED
+,	O
+and	O
+psychotropic	B-CHED
+drugs	I-CHED
+.	O
+
+Calves	O
+at	O
+2	O
+of	O
+the	O
+3	O
+feedlots	O
+(	O
+n	O
+=	O
+753	O
+)	O
+received	O
+a	O
+modified	O
+live	O
+4	O
+-	O
+way	O
+viral	O
+vaccine	O
+containing	O
+BVDV	B-SPEC
+.	O
+
+Based	O
+on	O
+our	O
+findings	O
+we	O
+infer	O
+that	O
+BCV	B-SPEC
+was	O
+not	O
+causally	O
+related	O
+to	O
+UBRD	O
+occurrence	O
+,	O
+however	O
+consistent	O
+with	O
+other	O
+literature	O
+,	O
+BVDV	B-SPEC
+may	O
+be	O
+causally	O
+related	O
+to	O
+UBRD	O
+occurrence	O
+.	O
+
+The	O
+vaccine	O
+field	O
+trial	O
+involved	O
+systematic	O
+allocation	O
+of	O
+animals	B-SPEC
+into	O
+groups	O
+that	O
+received	O
+either	O
+a	O
+M	B-SPEC
+.	I-SPEC
+haemolytica	I-SPEC
+vaccine	O
+,	O
+an	O
+H	B-SPEC
+.	I-SPEC
+somnus	I-SPEC
+vaccine	O
+,	O
+a	O
+combined	O
+M	B-SPEC
+.	I-SPEC
+haemolytica	I-SPEC
+and	O
+H	B-SPEC
+.	I-SPEC
+somnus	I-SPEC
+vaccine	O
+,	O
+and	O
+an	O
+unvaccinated	O
+control	O
+group	O
+.	O
+
+The	O
+results	O
+show	O
+that	O
+0	O
+.	O
+05	O
+TCID50	O
+of	O
+HCoV	B-SPEC
+-	I-SPEC
+229E	I-SPEC
+and	O
+0	O
+.	O
+01	O
+TCID50	O
+of	O
+HCoV	B-SPEC
+-	I-SPEC
+OC43	I-SPEC
+can	O
+be	O
+detected	O
+by	O
+this	O
+molecular	O
+method	O
+using	O
+the	O
+original	O
+method	O
+.	O
+
+Detection	O
+of	O
+HCoV	B-SPEC
+-	I-SPEC
+229E	I-SPEC
+and	O
+HCoV	B-SPEC
+-	I-SPEC
+OC43	I-SPEC
+in	O
+clinical	O
+specimens	O
+is	O
+possible	O
+using	O
+this	O
+method	O
+:	O
+348	O
+respiratory	O
+specimens	O
+(	O
+202	O
+sputum	B-ANAT
+and	O
+146	O
+nasal	B-ANAT
+aspirates	B-ANAT
+)	O
+were	O
+tested	O
+with	O
+this	O
+RT	O
+-	O
+PCR	O
+-	O
+hybridization	B-PROC
+and	O
+12	O
+human	B-SPEC
+coronavirus	I-SPEC
+are	O
+detected	O
+(	O
+3	O
+%).	O
+
+We	O
+obtained	O
+one	O
+line	O
+of	O
+mice	B-SPEC
+in	O
+which	O
+the	O
+insert	O
+in	O
+the	O
+Ceacam1a	B-PRGE
+gene	I-PRGE
+had	O
+sustained	O
+a	O
+recombination	B-PROC
+event	O
+.	O
+
++/	O
+p	O
+mice	B-SPEC
+were	O
+intermediate	O
+between	O
++/+	O
+and	O
+p	O
+/	O
+p	O
+mice	B-SPEC
+in	O
+susceptibility	O
+to	O
+liver	B-DISO
+damage	I-DISO
+,	O
+virus	B-SPEC
+growth	B-PROC
+in	O
+liver	B-ANAT
+,	O
+and	O
+susceptibility	O
+to	O
+killing	O
+by	O
+MHV	B-SPEC
+.	O
+
+Outcomes	O
+included	O
+maximum	O
+positive	O
+end	B-PROC
+-	I-PROC
+expiratory	I-PROC
+pressure	O
+,	O
+ventilator	O
+days	O
+,	O
+pneumonia	B-DISO
+,	O
+and	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+(	O
+ARDS	B-DISO
+).	O
+
+Survivors	O
+of	O
+PEMS	O
+were	O
+obtained	O
+from	O
+a	O
+research	O
+flock	O
+that	O
+had	O
+been	O
+purposefully	O
+infected	O
+at	O
+5	O
+d	O
+of	O
+age	O
+with	O
+PEMS	O
+inoculum	O
+that	O
+included	O
+turkey	B-SPEC
+corona	B-CHED
+virus	B-SPEC
+.	O
+
+The	O
+digestive	B-PROC
+capabilities	O
+of	O
+PEMS	O
+survivors	O
+were	O
+depressed	O
+proportionally	O
+to	O
+the	O
+degree	O
+of	O
+stunting	O
+.	O
+
+At	O
+all	O
+times	O
+after	O
+bacterial	O
+challenges	O
+,	O
+the	O
+lungs	B-ANAT
+of	O
+the	O
+lpr	O
+mice	B-SPEC
+contained	O
+similar	O
+or	O
+lower	O
+numbers	O
+of	O
+bacteria	B-SPEC
+than	O
+those	O
+of	O
+the	O
+C57BL	O
+/	O
+6	O
+mice	B-SPEC
+.	O
+
+In	O
+response	O
+to	O
+E	B-SPEC
+.	I-SPEC
+coli	I-SPEC
+,	O
+the	O
+lpr	O
+mice	B-SPEC
+had	O
+significantly	O
+more	O
+polymorphonuclear	B-ANAT
+leukocytes	I-ANAT
+(	O
+PMN	B-PROC
+)	O
+and	O
+macrophage	B-PRGE
+inflammatory	I-PRGE
+protein	B-CHED
+2	I-PRGE
+in	O
+the	O
+lungs	B-ANAT
+,	O
+whereas	O
+histopathologic	O
+changes	O
+were	O
+less	O
+severe	O
+.	O
+
+To	O
+better	O
+understand	O
+the	O
+molecular	O
+basis	O
+of	O
+neurotropism	B-DISO
+of	O
+MHVs	O
+,	O
+we	O
+compared	O
+the	O
+pathogenesis	B-DISO
+and	O
+genomic	O
+sequence	O
+of	O
+MHV	B-SPEC
+-	O
+2	O
+with	O
+that	O
+of	O
+MHV	B-SPEC
+-	O
+A59	O
+.	O
+
+ABSTRACT	O
+:	O
+Twenty	O
+-	O
+five	O
+Ayrshire	O
+/	O
+Friesian	O
+cows	B-SPEC
+were	O
+vaccinated	O
+once	O
+with	O
+a	O
+new	O
+combined	O
+vaccine	O
+against	O
+rotavirus	B-SPEC
+,	O
+coronavirus	B-SPEC
+and	O
+Escherichia	B-SPEC
+coli	I-SPEC
+F5	O
+(	O
+K99	O
+)	O
+or	O
+given	O
+a	O
+saline	O
+placebo	O
+31	O
+days	O
+before	O
+the	O
+first	O
+expected	O
+calving	O
+date	O
+.	O
+
+ACP	B-DISO
+was	O
+defined	O
+as	O
+a	O
+ratio	O
+of	O
+right	O
+ventricular	B-ANAT
+end	O
+-	O
+diastolic	O
+area	O
+to	O
+left	O
+ventricular	B-ANAT
+end	O
+-	O
+diastolic	O
+area	O
+in	O
+the	O
+long	O
+axis	B-SPEC
+>	O
+0	O
+.	O
+6	O
+associated	O
+with	O
+septal	O
+dyskinesia	O
+in	O
+the	O
+short	O
+axis	B-SPEC
+during	O
+TEE	O
+examination	O
+.	O
+
+All	O
+echo	B-SPEC
+-	O
+Doppler	O
+abnormalities	O
+were	O
+reversible	O
+in	O
+patients	O
+who	O
+recovered	O
+,	O
+and	O
+the	O
+mortality	O
+rate	O
+was	O
+the	O
+same	O
+in	O
+both	O
+groups	O
+(	O
+32	O
+%).	O
+
+Eighteen	O
+critically	B-DISO
+ill	I-DISO
+patients	O
+.	O
+
+Data	O
+were	O
+collected	O
+immediately	O
+before	O
+and	O
+6	O
+,	O
+12	O
+,	O
+18	O
+,	O
+and	O
+24	O
+hrs	B-DISO
+after	O
+onset	O
+of	O
+fat	O
+infusion	O
+.	O
+
+In	O
+the	O
+sepsis	B-DISO
+group	O
+,	O
+the	O
+P	O
+/	O
+T	O
+ratio	O
+remained	O
+unchanged	O
+at	O
+either	O
+infusion	O
+rate	O
+,	O
+but	O
+pulmonary	B-ANAT
+shunt	O
+fraction	O
+and	O
+P	O
+(	O
+a	O
+-	O
+a	O
+)	O
+o2	O
+/	O
+Pao2	O
+decreased	O
+after	O
+rapid	O
+fat	O
+infusion	O
+,	O
+whereas	O
+Pao2	B-PRGE
+/	O
+Fio2	O
+increased	O
+.	O
+
+In	O
+involves	O
+earlier	O
+(	O
+the	O
+first	O
+days	O
+following	O
+the	O
+onset	O
+of	O
+respiratory	B-DISO
+failure	I-DISO
+)	O
+use	O
+of	O
+surfactant	B-CHED
+,	O
+its	O
+combined	O
+bolus	O
+intratracheal	O
+or	O
+intrabronchial	O
+administration	O
+in	O
+doses	O
+of	O
+200	O
+-	O
+400	O
+mg	O
+/	O
+m2	O
+,	O
+followed	O
+by	O
+continuous	O
+(	O
+5	O
+-	O
+day	O
+)	O
+aerosol	O
+inhalation	B-PROC
+in	O
+doses	O
+of	O
+20	O
+-	O
+30	O
+mg	O
+/	O
+h	O
+for	O
+children	O
+and	O
+30	O
+-	O
+75	O
+mg	O
+/	O
+h	O
+for	O
+adults	O
+until	O
+pronounced	O
+clinical	O
+and	O
+X	O
+-	O
+ray	B-SPEC
+effects	O
+are	O
+shown	O
+.	O
+
+Earlier	O
+use	O
+of	O
+the	O
+drugs	O
+made	O
+it	O
+possible	O
+to	O
+transfer	O
+patients	O
+to	O
+safe	O
+AV	O
+regimens	O
+and	O
+to	O
+eliminate	O
+ALL	O
+and	O
+ARDS	B-DISO
+rapidly	O
+and	O
+to	O
+significantly	O
+reduce	O
+mortality	O
+due	O
+to	O
+critical	O
+states	O
+.	O
+
+ABSTRACT	O
+:	O
+Episodic	O
+wheezing	O
+associated	O
+with	O
+viral	B-DISO
+infections	I-DISO
+of	O
+the	O
+upper	B-ANAT
+respiratory	I-ANAT
+tract	I-ANAT
+(	O
+URT	O
+)	O
+is	O
+a	O
+common	O
+problem	O
+in	O
+young	O
+children	O
+but	O
+also	O
+occurs	O
+in	O
+adults	O
+.	O
+
+Pralidoxime	B-CHED
+could	O
+not	O
+be	O
+given	O
+to	O
+16	O
+patients	O
+:	O
+2	O
+patients	O
+did	O
+not	O
+receive	O
+pralidoxime	B-CHED
+because	O
+they	O
+were	O
+late	O
+admissions	O
+and	O
+14	O
+did	O
+not	O
+receive	O
+pralidoxime	B-CHED
+because	O
+the	O
+Ministry	O
+of	O
+Health	O
+office	O
+was	O
+out	O
+of	O
+stock	O
+.	O
+
+Respiratory	B-DISO
+failure	I-DISO
+is	O
+the	O
+most	O
+troublesome	O
+complication	B-DISO
+,	O
+which	O
+was	O
+observed	O
+in	O
+35	O
+(	O
+74	O
+.	O
+4	O
+%)	O
+patients	O
+.	O
+
+OP	O
+insecticide	B-CHED
+poisoning	O
+is	O
+a	O
+serious	O
+condition	B-DISO
+that	O
+needs	O
+rapid	O
+diagnosis	O
+and	O
+treatment	O
+.	O
+
+Paralytic	O
+use	O
+and	O
+sedative	B-CHED
+use	O
+were	O
+significantly	O
+lower	O
+with	O
+APRV	O
+than	O
+with	O
+PCV	B-CHED
+.	O
+
+Urine	B-ANAT
+output	O
+increased	O
+from	O
+0	O
+.	O
+83	O
++/-	O
+
+ABSTRACT	O
+:	O
+A	O
+nucleotide	B-CHED
+variability	O
+in	O
+the	O
+sequence	O
+of	O
+the	O
+gene	O
+encoding	O
+for	O
+the	O
+transmembrane	B-COMP
+protein	B-CHED
+M	O
+of	O
+canine	O
+coronavirus	B-SPEC
+(	O
+CCV	B-DISO
+)	O
+is	O
+described	O
+.	O
+
+Four	O
+PCR	O
+assays	O
+with	O
+primers	O
+specific	O
+for	O
+N	B-PRGE
+-	I-PRGE
+protein	I-PRGE
+of	O
+human	B-SPEC
+coronavirus	I-SPEC
+strain	I-SPEC
+229E	I-SPEC
+and	O
+three	O
+PCR	O
+assays	O
+with	O
+primers	O
+specific	O
+for	O
+the	O
+nucleocapsid	B-COMP
+protein	B-CHED
+of	O
+human	B-SPEC
+coronavirus	I-SPEC
+strain	O
+OC43	O
+were	O
+performed	O
+.	O
+
+The	O
+model	O
+is	O
+relevant	O
+for	O
+many	O
+classes	O
+of	O
+infectious	B-DISO
+diseases	I-DISO
+where	O
+sporadic	O
+epidemics	O
+occur	O
+,	O
+and	O
+it	O
+is	O
+a	O
+powerful	O
+tool	O
+for	O
+investigating	O
+the	O
+costs	O
+,	O
+benefits	O
+,	O
+and	O
+risks	O
+associated	O
+with	O
+breeding	B-PROC
+for	O
+resistance	B-PROC
+to	O
+specific	O
+diseases	O
+.	O
+
+TITLE	O
+:	O
+Significance	O
+of	O
+the	O
+changes	O
+in	O
+the	O
+respiratory	B-ANAT
+system	I-ANAT
+pressure	O
+-	O
+volume	O
+curve	O
+during	O
+acute	O
+lung	B-ANAT
+injury	O
+in	O
+rats	B-SPEC
+.	O
+
+ventilator	O
+-	O
+induced	O
+lung	B-ANAT
+injury	O
+;	O
+respiratory	B-PROC
+mechanics	I-PROC
+;	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+
+ABSTRACT	O
+:	O
+Murine	O
+coronavirus	O
+mouse	B-DISO
+hepatitis	I-DISO
+virus	B-SPEC
+(	O
+MHV	B-SPEC
+)	O
+produces	O
+a	O
+genome	O
+-	O
+length	O
+mRNA	B-CHED
+,	O
+mRNA	B-CHED
+1	O
+,	O
+and	O
+six	O
+or	O
+seven	O
+species	B-SPEC
+of	O
+subgenomic	O
+mRNAs	O
+in	O
+infected	O
+cells	B-COMP
+.	O
+
+This	O
+M	O
+protein	B-CHED
+-	O
+mRNA	B-CHED
+1	O
+interaction	O
+most	O
+probably	O
+determines	O
+the	O
+selective	O
+packaging	O
+of	O
+mRNA	B-CHED
+1	O
+into	O
+MHV	B-SPEC
+particles	O
+.	O
+
+The	O
+present	O
+study	O
+tested	O
+the	O
+possibility	O
+that	O
+the	O
+selective	O
+M	O
+protein	B-CHED
+-	O
+mRNA	B-CHED
+1	O
+interaction	O
+is	O
+due	O
+to	O
+the	O
+packaging	O
+signal	O
+in	O
+mRNA	B-CHED
+1	O
+.	O
+
+Moreover	O
+,	O
+only	O
+the	O
+RNA	O
+that	O
+interacted	O
+selectively	O
+with	O
+M	B-PRGE
+protein	I-PRGE
+was	O
+efficiently	O
+packaged	O
+into	O
+MHV	B-SPEC
+particles	O
+.	O
+
+TITLE	O
+:	O
+Localization	B-PROC
+to	O
+the	O
+nucleolus	B-COMP
+is	O
+a	O
+common	O
+feature	O
+of	O
+coronavirus	B-SPEC
+nucleoproteins	O
+,	O
+and	O
+the	O
+protein	B-CHED
+may	O
+disrupt	O
+host	B-COMP
+cell	I-COMP
+division	O
+.	O
+
+Thus	O
+,	O
+we	O
+observed	O
+that	O
+approximately	O
+30	O
+%	O
+of	O
+cells	B-COMP
+transfected	O
+with	O
+the	O
+N	B-PRGE
+protein	I-PRGE
+appeared	O
+to	O
+be	O
+undergoing	O
+cell	B-PROC
+division	I-PROC
+.	O
+
+In	O
+a	O
+fraction	O
+of	O
+transfected	O
+cells	B-COMP
+expressing	O
+coronavirus	B-SPEC
+N	O
+proteins	B-CHED
+,	O
+we	O
+observed	O
+multinucleate	O
+cells	B-COMP
+and	O
+dividing	O
+cells	B-COMP
+with	O
+nucleoli	O
+(	O
+which	O
+are	O
+only	O
+present	O
+during	O
+interphase	B-PROC
+).	O
+
+There	O
+were	O
+no	O
+differences	O
+in	O
+the	O
+frequency	O
+of	O
+hospitalization	O
+,	O
+pulmonary	B-ANAT
+illness	O
+,	O
+asthma	B-PATH
+,	O
+or	O
+disabilities	O
+.	O
+
+To	O
+explore	O
+the	O
+events	O
+which	O
+couple	O
+acute	B-DISO
+pancreatitis	I-DISO
+to	O
+lung	B-ANAT
+injury	O
+,	O
+a	O
+number	O
+of	O
+recent	O
+studies	O
+have	O
+been	O
+performed	O
+in	O
+the	O
+author	O
+'	O
+s	O
+laboratory	O
+using	O
+a	O
+variety	O
+of	O
+experimental	O
+models	O
+and	O
+interventions	O
+including	O
+gene	O
+-	O
+targeted	B-PROC
+deletion	O
+of	O
+chemokines	O
+,	O
+cytokines	O
+,	O
+specific	O
+receptors	O
+,	O
+and	O
+adhesion	B-DISO
+molecules	O
+.	O
+
+In	O
+addition	O
+,	O
+infected	O
+CCR5	O
+(-/-)	O
+mice	B-SPEC
+exhibited	O
+reduced	O
+(	O
+P	O
+<	O
+or	O
+=	O
+0	O
+.	O
+02	O
+)	O
+macrophage	B-ANAT
+(	O
+CD45	B-PRGE
+(	O
+high	O
+)	O
+F4	O
+/	O
+80	O
+(+))	O
+infiltration	B-DISO
+,	O
+which	O
+correlated	O
+with	O
+a	O
+significant	O
+reduction	O
+(	O
+P	O
+<	O
+or	O
+=	O
+0	O
+.	O
+001	O
+)	O
+in	O
+the	O
+severity	O
+of	O
+demyelination	B-DISO
+compared	O
+to	O
+CCR5	B-PRGE
+(+/+)	I-PRGE
+mice	B-SPEC
+.	O
+
+Twelve	O
+-	O
+bed	B-DISO
+intensive	O
+care	O
+unit	O
+in	O
+a	O
+1	O
+,	O
+100	O
+-	O
+bed	B-DISO
+primary	O
+care	O
+university	O
+hospital	O
+.	O
+
+A	O
+significant	O
+correlation	O
+for	O
+PCT	B-DISO
+serum	B-COMP
+and	O
+BAL	B-ENZY
+levels	O
+was	O
+found	O
+on	O
+day	O
+2	O
+(	O
+p	O
+=.	O
+0063	O
+).	O
+
+From	O
+1988	O
+to	O
+1999	O
+,	O
+104	O
+fillet	O
+flap	B-ANAT
+procedures	O
+were	O
+performed	O
+on	O
+94	O
+patients	O
+(	O
+50	O
+pedicled	O
+finger	B-ANAT
+and	O
+toe	B-ANAT
+fillets	O
+,	O
+36	O
+pedicled	O
+limb	B-ANAT
+fillets	O
+,	O
+and	O
+18	O
+free	O
+microsurgical	O
+fillet	O
+flaps	B-ANAT
+).	O
+
+In	O
+five	O
+cases	O
+,	O
+defects	O
+of	O
+shoulder	B-ANAT
+,	O
+head	B-ANAT
+,	O
+neck	B-ANAT
+,	O
+and	O
+thoracic	B-ANAT
+wall	I-ANAT
+were	O
+covered	O
+with	O
+upper	O
+-	O
+arm	B-ANAT
+fillet	O
+flaps	B-ANAT
+.	O
+
+One	O
+partial	O
+flap	B-ANAT
+necrosis	B-PROC
+occurred	O
+in	O
+a	O
+patient	O
+with	O
+a	O
+fillet	O
+-	O
+of	O
+-	O
+sole	B-ANAT
+flap	B-ANAT
+.	O
+
+The	O
+majority	O
+of	O
+our	O
+cases	O
+resulted	O
+from	O
+severe	O
+trauma	O
+with	O
+infected	O
+and	O
+necrotic	B-PROC
+soft	B-ANAT
+tissues	I-ANAT
+,	O
+disseminated	O
+tumor	B-DISO
+disease	O
+,	O
+or	O
+ulcers	B-DISO
+in	O
+elderly	O
+,	O
+multimorbid	O
+patients	O
+.	O
+
+TITLE	O
+:	O
+Toxic	B-DISO
+epidermal	I-DISO
+necrolysis	I-DISO
+treated	O
+with	O
+intravenous	O
+high	O
+-	O
+dose	O
+immunoglobulins	O
+:	O
+our	O
+experience	O
+.	O
+
+Three	O
+new	O
+potential	O
+sequence	O
+motifs	O
+with	O
+homology	O
+to	O
+the	O
+alpha	O
+-	O
+subunit	O
+of	O
+the	O
+polymerase	B-PRGE
+-	I-PRGE
+associated	I-PRGE
+nucleocapsid	I-PRGE
+phosphoprotein	I-PRGE
+of	O
+rinderpest	B-SPEC
+virus	I-SPEC
+,	O
+the	O
+Bowman	B-PRGE
+-	I-PRGE
+Birk	I-PRGE
+type	I-PRGE
+of	I-PRGE
+proteinase	I-PRGE
+inhibitors	B-CHED
+,	O
+and	O
+the	O
+metallothionein	B-PRGE
+superfamily	I-PRGE
+of	I-PRGE
+cysteine	B-CHED
+rich	I-PRGE
+chelating	B-PROC
+proteins	B-CHED
+have	O
+been	O
+identified	O
+.	O
+
+ABSTRACT	O
+:	O
+Aminopeptidase	B-PRGE
+N	I-PRGE
+(	O
+APN	B-PRGE
+),	O
+a	O
+150	O
+-	O
+kDa	O
+metalloprotease	B-PRGE
+also	O
+called	O
+CD13	B-PRGE
+,	O
+serves	O
+as	O
+a	O
+receptor	O
+for	O
+serologically	O
+related	O
+coronaviruses	O
+of	O
+humans	B-SPEC
+(	O
+human	B-SPEC
+coronavirus	I-SPEC
+229E	I-SPEC
+[	O
+HCoV	B-SPEC
+-	I-SPEC
+229E	I-SPEC
+]),	O
+pigs	B-SPEC
+,	O
+and	O
+cats	B-SPEC
+.	O
+
+Mutant	B-DISO
+hAPN	O
+lacking	O
+the	O
+sequon	O
+at	O
+amino	B-CHED
+acids	I-CHED
+818	O
+to	O
+820	O
+maintained	O
+HCoV	B-SPEC
+-	I-SPEC
+229E	I-SPEC
+receptor	B-FUNC
+activity	I-FUNC
+but	O
+did	O
+not	O
+gain	O
+receptor	B-FUNC
+activity	I-FUNC
+for	O
+porcine	B-SPEC
+or	O
+feline	B-SPEC
+coronaviruses	O
+.	O
+
+TITLE	O
+:	O
+Evaluation	O
+of	O
+concurrent	O
+shedding	O
+of	O
+bovine	B-SPEC
+coronavirus	B-SPEC
+via	O
+the	O
+respiratory	B-ANAT
+tract	I-ANAT
+and	O
+enteric	O
+route	O
+in	O
+feedlot	O
+cattle	O
+.	O
+
+Paired	O
+fecal	B-ANAT
+samples	O
+and	O
+nasal	B-ANAT
+swab	O
+specimens	O
+were	O
+obtained	O
+and	O
+were	O
+tested	O
+for	O
+BCV	B-SPEC
+,	O
+using	O
+antigen	B-CHED
+-	O
+capture	O
+ELISA	O
+.	O
+
+Number	O
+of	O
+samples	O
+positive	O
+for	O
+bovine	B-SPEC
+respiratory	O
+coronavirus	B-SPEC
+(	O
+BRCV	O
+)	O
+or	O
+bovine	B-SPEC
+enteric	O
+coro	O
+navirus	O
+(	O
+BECV	B-SPEC
+)	O
+was	O
+37	O
+/	O
+224	O
+(	O
+17	O
+%)	O
+and	O
+48	O
+/	O
+223	O
+(	O
+22	O
+%),	O
+respectively	O
+.	O
+
+Treatment	O
+with	O
+anti	O
+-	O
+CXCL10	O
+reduced	O
+CD4	B-ANAT
++	I-ANAT
+T	I-ANAT
+lymphocyte	I-ANAT
+and	O
+macrophage	B-ANAT
+invasion	B-DISO
+,	O
+diminished	O
+expression	B-PROC
+of	O
+IFN	B-PRGE
+-	I-PRGE
+gamma	I-PRGE
+and	O
+CC	O
+chemokine	O
+ligand	B-PROC
+5	O
+,	O
+inhibited	O
+progression	O
+of	O
+demyelination	B-DISO
+,	O
+and	O
+increased	O
+remyelination	B-PROC
+.	O
+
+Anti	B-PRGE
+-	I-PRGE
+CXCL10	I-PRGE
+treatment	O
+also	O
+resulted	O
+in	O
+an	O
+impediment	O
+of	O
+clinical	O
+disease	B-DISO
+progression	I-DISO
+that	O
+was	O
+characterized	O
+by	O
+a	O
+dramatic	O
+improvement	O
+in	O
+neurological	B-PROC
+function	I-PROC
+.	O
+
+Patients	O
+with	O
+SIRS	B-DISO
+and	O
+sepsis	B-DISO
+are	O
+exposed	O
+to	O
+severe	O
+oxidative	B-DISO
+stress	I-DISO
+.	O
+
+Two	O
+other	O
+studies	O
+,	O
+where	O
+selenium	B-CHED
+together	O
+with	O
+other	O
+trace	O
+elements	O
+or	O
+a	O
+mixture	B-CHED
+of	O
+antioxidants	B-CHED
+were	O
+used	O
+in	O
+the	O
+treatment	O
+of	O
+patients	O
+with	O
+severe	O
+burn	O
+injuries	O
+or	O
+trauma	O
+showed	O
+a	O
+significant	O
+reduction	O
+in	O
+the	O
+secondary	B-DISO
+infection	I-DISO
+rate	O
+,	O
+including	O
+sepsis	B-DISO
+.	O
+
+All	O
+six	O
+patients	O
+showed	O
+a	O
+rapid	O
+and	O
+substantial	O
+improvement	O
+in	O
+oxygenation	B-PROC
+after	O
+initiation	O
+of	O
+HFOV	O
+,	O
+with	O
+significant	O
+improvements	O
+in	O
+the	O
+PaO2	O
+/	O
+FIO2	O
+and	O
+OI	O
+by	O
+12	O
+hours	O
+(	O
+P	O
+=	O
+0	O
+.	O
+02	O
+).	O
+
+When	O
+unavoidable	O
+,	O
+hypercapnia	B-DISO
+should	O
+be	O
+induced	O
+slowly	O
+.	O
+
+The	O
+data	O
+from	O
+this	O
+study	O
+do	O
+not	O
+fully	O
+support	O
+the	O
+hypothesis	O
+that	O
+the	O
+emergence	O
+of	O
+acute	O
+PRRS	B-DISO
+is	O
+due	O
+to	O
+reversion	O
+of	O
+MLVs	O
+to	O
+a	O
+pathogenic	O
+phenotype	O
+,	O
+as	O
+only	O
+one	O
+of	O
+the	O
+eight	O
+acute	O
+isolates	O
+was	O
+shown	O
+to	O
+be	O
+very	O
+closely	O
+related	O
+to	O
+the	O
+RespPRRS	O
+MLV	O
+.	O
+
+TITLE	O
+:	O
+Prolonged	O
+nasal	B-ANAT
+eosinophilia	B-DISO
+in	O
+allergic	O
+patients	O
+after	O
+common	B-DISO
+cold	I-DISO
+.	O
+
+ABSTRACT	O
+:	O
+Lymphatic	B-ANAT
+tissues	I-ANAT
+(	O
+spleen	B-ANAT
+,	O
+mesenteric	B-ANAT
+lymph	I-ANAT
+nodes	I-ANAT
+,	O
+thymus	B-SPEC
+)	O
+from	O
+24	O
+cats	B-SPEC
+with	O
+spontaneous	O
+feline	B-DISO
+infectious	I-DISO
+peritonitis	I-DISO
+(	O
+FIP	B-DISO
+)	O
+were	O
+examined	O
+by	O
+light	O
+microscopy	O
+and	O
+immunohistochemistry	O
+for	O
+cellularity	O
+,	O
+cellular	B-COMP
+composition	O
+,	O
+and	O
+degree	O
+of	O
+cellular	B-COMP
+turnover	O
+.	O
+
+Additionally	O
+,	O
+the	O
+formation	B-PROC
+of	O
+granulomatous	B-DISO
+lesions	I-DISO
+in	O
+lymphatic	B-ANAT
+tissues	I-ANAT
+in	O
+cats	B-SPEC
+with	O
+FIP	B-DISO
+was	O
+examined	O
+.	O
+
+For	O
+comparison	O
+,	O
+tissues	B-ANAT
+from	O
+14	O
+specific	O
+pathogen	O
+-	O
+free	O
+(	O
+SPF	O
+)	O
+cats	B-SPEC
+and	O
+seven	O
+cats	B-SPEC
+infected	O
+with	O
+FIP	B-DISO
+virus	B-SPEC
+(	O
+FIPV	O
+;	O
+as	O
+the	O
+result	O
+of	O
+long	O
+-	O
+term	O
+exposure	O
+)	O
+but	O
+free	O
+from	O
+FIP	B-DISO
+were	O
+examined	O
+.	O
+
+In	O
+some	O
+cases	O
+,	O
+the	O
+number	O
+of	O
+apoptotic	O
+lymphocytes	B-ANAT
+was	O
+increased	O
+in	O
+lymphoid	O
+follicles	B-ANAT
+as	O
+well	O
+as	O
+in	O
+T	B-ANAT
+-	I-ANAT
+cell	I-ANAT
+zones	O
+.	O
+
+PCP	B-DISO
+was	O
+diagnosed	O
+by	O
+examination	O
+of	O
+the	O
+bronchoalveolar	B-ANAT
+lavage	I-ANAT
+fluid	I-ANAT
+(	O
+BALF	O
+),	O
+and	O
+the	O
+patient	O
+was	O
+treated	O
+with	O
+intravenously	O
+administered	O
+trimethoprim	B-CHED
+-	O
+sulphamethoxazole	O
+(	O
+TMP	B-CHED
+-	O
+SMX	B-CHED
+)	O
+and	O
+methylprednisolone	B-CHED
+.	O
+
+ABSTRACT	O
+:	O
+The	O
+spike	O
+(	O
+S	O
+)	O
+glycoprotein	O
+of	O
+mouse	B-DISO
+hepatitis	I-DISO
+virus	B-SPEC
+(	O
+MHV	B-SPEC
+)	O
+is	O
+a	O
+major	O
+determinant	O
+of	O
+neurovirulence	O
+.	O
+
+To	O
+identify	O
+the	O
+genetic	O
+determinants	O
+of	O
+neurovirulence	O
+within	O
+the	O
+MHV	B-SPEC
+-	O
+4	O
+spike	O
+,	O
+we	O
+generated	O
+isogenic	O
+recombinant	O
+viruses	B-SPEC
+containing	O
+various	O
+MHV	B-SPEC
+-	O
+4	O
+/	O
+MHV	B-SPEC
+-	O
+A59	O
+chimeric	O
+spike	O
+genes	O
+,	O
+and	O
+studied	O
+their	O
+phenotypes	O
+in	O
+vivo	O
+.	O
+
+The	O
+MHV	B-SPEC
+-	O
+4	O
+/	O
+MHV	B-SPEC
+-	O
+A59	O
+chimeric	O
+spike	O
+genes	O
+consisted	O
+of	O
+either	O
+reciprocal	O
+exchanges	O
+between	O
+the	O
+S1	O
+and	O
+S2	O
+spike	O
+subunits	O
+,	O
+or	O
+smaller	O
+exchanges	O
+specifically	O
+in	O
+the	O
+hypervariable	O
+region	O
+(	O
+HVR	O
+)	O
+of	O
+S1	O
+.	O
+
+The	O
+mucus	B-ANAT
+membranes	B-ANAT
+are	O
+not	O
+involved	O
+.	O
+
+Severe	O
+extensive	O
+forms	O
+have	O
+been	O
+observed	O
+particularly	O
+in	O
+neonates	O
+(	O
+Ritter	B-DISO
+'	I-DISO
+s	I-DISO
+disease	I-DISO
+).	O
+
+Bacteremia	B-DISO
+is	O
+usual	O
+.	O
+
+Staphylococcal	O
+scarlet	B-DISO
+fever	I-DISO
+is	O
+not	O
+related	O
+to	O
+exfoliatin	O
+as	O
+previously	O
+believed	O
+,	O
+but	O
+to	O
+enterotoxins	O
+or	O
+TSST	B-CHED
+-	O
+1	O
+,	O
+so	O
+it	O
+seems	O
+to	O
+be	O
+an	O
+abortive	O
+form	O
+of	O
+toxic	B-DISO
+shock	I-DISO
+syndrome	I-DISO
+.	O
+
+The	O
+disease	O
+is	O
+related	O
+to	O
+an	O
+infection	B-DISO
+or	O
+colonisation	O
+with	O
+a	O
+toxin	O
+(	O
+TSST	B-CHED
+-	O
+1	O
+)	O
+producing	O
+strain	O
+of	O
+Staphylococcus	B-SPEC
+aureus	I-SPEC
+.	O
+
+The	O
+mortality	O
+is	O
+low	O
+(	O
+5	O
+%)	O
+and	O
+mainly	O
+due	O
+to	O
+ARDS	B-DISO
+or	O
+cardiac	B-ANAT
+problems	O
+.	O
+
+Staphylococcus	B-SPEC
+strains	O
+producing	O
+the	O
+Panton	O
+and	O
+Valentine	O
+leucocidin	O
+are	O
+responsible	O
+for	O
+chronic	O
+or	O
+relapsing	O
+furonculosis	O
+and	O
+above	O
+all	O
+for	O
+a	O
+very	O
+severe	O
+necrotizing	B-DISO
+pneumonia	I-DISO
+observed	O
+in	O
+children	O
+and	O
+young	O
+adults	O
+presenting	O
+as	O
+an	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+with	O
+leucopenia	B-DISO
+,	O
+hemoptysis	B-DISO
+and	O
+shock	O
+carrying	O
+a	O
+heavy	O
+mortality	O
+rate	O
+.	O
+
+These	O
+data	O
+indicate	O
+that	O
+oligodendrocytes	B-ANAT
+and	O
+neurons	B-ANAT
+have	O
+the	O
+potential	O
+to	O
+present	O
+antigen	B-CHED
+to	O
+T	B-ANAT
+cells	I-ANAT
+and	O
+thus	O
+be	O
+damaged	O
+by	O
+direct	O
+antigen	B-CHED
+-	O
+specific	O
+interactions	O
+with	O
+CD8	B-PRGE
++	I-PRGE
+T	B-ANAT
+lymphocytes	I-ANAT
+.	O
+
+ABSTRACT	O
+:	O
+Intraocular	B-ANAT
+coronavirus	B-SPEC
+inoculation	O
+results	O
+in	O
+a	O
+biphasic	O
+retinal	B-DISO
+disease	I-DISO
+in	O
+susceptible	O
+mice	B-SPEC
+(	O
+BALB	O
+/	O
+c	O
+)	O
+characterized	O
+by	O
+an	O
+acute	B-DISO
+inflammatory	I-DISO
+response	I-DISO
+,	O
+followed	O
+by	O
+retinal	B-DISO
+degeneration	I-DISO
+associated	O
+with	O
+autoimmune	B-DISO
+reactivity	O
+.	O
+
+A	O
+female	O
+patient	O
+that	O
+since	O
+9	O
+months	O
+age	O
+presented	O
+digestive	B-PROC
+symptoms	O
+:	O
+diarrhea	B-DISO
+,	O
+nauseous	B-DISO
+,	O
+vomits	B-DISO
+,	O
+slow	O
+digestions	B-PROC
+and	O
+abdominal	B-DISO
+pain	I-DISO
+.	O
+
+She	O
+had	O
+myopia	B-DISO
+.	O
+
+In	O
+patients	O
+with	O
+intestinal	B-ANAT
+dysmotility	B-DISO
+manifestations	O
+and	O
+jejunal	B-ANAT
+and	O
+ileal	B-ANAT
+diverticula	B-DISO
+neuropathies	B-DISO
+and	O
+myopathies	B-DISO
+with	O
+visceral	O
+affection	O
+must	O
+be	O
+suspected	O
+,	O
+among	O
+them	O
+MNGIE	B-DISO
+syndrome	B-DISO
+.	O
+
+TITLE	O
+:	O
+Severe	O
+acute	B-DISO
+renal	I-DISO
+failure	I-DISO
+in	O
+malaria	B-PATH
+.	O
+
+ABSTRACT	O
+:	O
+We	O
+have	O
+noticed	O
+a	O
+recent	O
+rise	O
+in	O
+the	O
+incidence	O
+and	O
+severity	O
+of	O
+acute	O
+renal	O
+failure	O
+(	O
+ARF	B-DISO
+)	O
+in	O
+malaria	B-PATH
+.	O
+
+No	O
+response	O
+was	O
+seen	O
+to	O
+chloroquine	B-CHED
+and	O
+artesunate	B-CHED
+given	O
+alone	O
+and	O
+twenty	O
+patients	O
+required	O
+quinine	B-CHED
+.	O
+
+CONCLUSIONS	O
+:	O
+ARF	B-DISO
+necessitating	O
+dialysis	B-SPEC
+was	O
+seen	O
+in	O
+92	O
+%	O
+of	O
+patients	O
+with	O
+ARF	B-DISO
+in	O
+malaria	B-PATH
+.	O
+
+TITLE	O
+:	O
+Lack	O
+of	O
+CCR2	B-PRGE
+results	O
+in	O
+increased	O
+mortality	O
+and	O
+impaired	B-DISO
+leukocyte	B-PROC
+activation	I-PROC
+and	O
+trafficking	B-PROC
+following	O
+infection	B-DISO
+of	O
+the	O
+central	B-ANAT
+nervous	I-ANAT
+system	I-ANAT
+with	O
+a	O
+neurotropic	O
+coronavirus	B-SPEC
+.	O
+
+ABSTRACT	O
+:	O
+Drug	B-DISO
+abuse	I-DISO
+is	O
+a	O
+growing	O
+problem	O
+in	O
+industrialized	O
+countries	O
+,	O
+opening	O
+the	O
+way	O
+to	O
+new	O
+diseases	O
+of	O
+the	O
+respiratory	O
+tract	O
+.	O
+
+Cocaine	B-CHED
+,	O
+amphetamines	B-CHED
+or	O
+crack	O
+expose	O
+the	O
+patient	O
+to	O
+particular	O
+toxic	O
+effects	O
+:	O
+in	O
+addition	O
+to	O
+barotrauma	O
+related	O
+to	O
+the	O
+administration	O
+route	O
+,	O
+syndromes	B-DISO
+of	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+have	O
+been	O
+described	O
+.	O
+
+These	O
+result	O
+either	O
+from	O
+bronchial	B-ANAT
+reactions	O
+,	O
+asthma	B-PATH
+exacerbation	O
+or	O
+eosinophil	B-ANAT
+bronchopneumonia	B-DISO
+,	O
+or	O
+alveolar	B-ANAT
+involvement	O
+:	O
+intra	O
+-	O
+alveolar	B-ANAT
+bleeding	B-DISO
+,	O
+pulmonary	B-DISO
+edema	I-DISO
+or	O
+organized	B-DISO
+pneumonia	I-DISO
+.	O
+
+Respiratory	B-DISO
+complications	I-DISO
+induced	O
+by	O
+opiates	B-DISO
+,	O
+often	O
+used	O
+in	O
+injections	O
+,	O
+are	O
+related	O
+to	O
+central	B-DISO
+alveolar	I-DISO
+hypoventilation	I-DISO
+and	O
+/	O
+or	O
+the	O
+development	B-PROC
+of	O
+injury	O
+from	O
+pulmonary	B-DISO
+edema	I-DISO
+or	O
+pneumonia	B-DISO
+.	O
+
+In	O
+2000	O
+,	O
+an	O
+outbreak	O
+of	O
+HFMD	O
+resulted	O
+in	O
+the	O
+deaths	B-PROC
+of	O
+three	O
+children	O
+who	O
+had	O
+rapid	O
+cardio	O
+-	O
+respiratory	O
+decompensation	O
+and	O
+one	O
+child	O
+who	O
+survived	O
+a	O
+central	B-DISO
+nervous	I-DISO
+system	I-DISO
+infection	I-DISO
+.	O
+
+RESULTS	O
+:	O
+Echovirus	B-SPEC
+7	O
+was	O
+the	O
+sole	B-ANAT
+pathogen	O
+isolated	O
+from	O
+three	O
+cases	O
+of	O
+acute	O
+encephalomyelitis	B-DISO
+,	O
+two	O
+of	O
+which	O
+were	O
+fatal	O
+due	O
+to	O
+severe	O
+left	B-DISO
+ventricular	I-DISO
+dysfunction	I-DISO
+resistant	O
+to	O
+inotropic	O
+support	O
+.	O
+
+Moreover	O
+,	O
+surviving	O
+mitral	O
+cells	B-COMP
+apparently	O
+remain	O
+disconnected	O
+from	O
+the	O
+sensory	B-ANAT
+neuron	I-ANAT
+input	O
+to	O
+the	O
+glomerular	B-ANAT
+layer	B-ANAT
+,	O
+judging	O
+from	O
+retrograde	O
+labeling	O
+studies	O
+using	O
+Dil	O
+.	O
+
+ABSTRACT	O
+:	O
+The	O
+present	O
+study	O
+assessed	O
+the	O
+functional	O
+consequences	O
+of	O
+viral	B-DISO
+infection	I-DISO
+with	O
+a	O
+neurotropic	O
+coronavirus	B-SPEC
+,	O
+designated	O
+MHV	B-SPEC
+OBLV	O
+,	O
+that	O
+specifically	O
+targets	O
+central	O
+olfactory	B-PROC
+structures	O
+.	O
+
+Two	O
+additional	O
+BALB	O
+/	O
+c	O
+mice	B-SPEC
+were	O
+trained	O
+to	O
+discriminate	O
+between	O
+the	O
+presentation	O
+of	O
+air	B-CHED
+and	O
+the	O
+presentation	O
+of	O
+either	O
+vanillin	B-CHED
+or	O
+propionic	B-CHED
+acid	I-CHED
+.	O
+
+Five	O
+of	O
+the	O
+six	O
+inoculated	O
+mice	B-SPEC
+showed	O
+massive	O
+disruption	O
+of	O
+the	O
+olfactory	B-ANAT
+bulb	I-ANAT
+,	O
+including	O
+death	B-PROC
+of	O
+mitral	O
+cells	B-COMP
+;	O
+the	O
+other	O
+was	O
+more	O
+modestly	O
+affected	O
+.	O
+
+In	O
+addition	O
+,	O
+the	O
+density	O
+of	O
+innervation	B-PROC
+of	O
+the	O
+olfactory	B-ANAT
+mucosa	I-ANAT
+by	O
+substance	O
+P	O
+-	O
+containing	O
+trigeminal	O
+fibers	O
+is	O
+also	O
+affected	O
+by	O
+inoculation	O
+.	O
+
+TITLE	O
+:	O
+Acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+due	O
+to	O
+cyanotic	O
+spell	O
+in	O
+an	O
+infant	O
+with	O
+tetralogy	B-DISO
+of	I-DISO
+Fallot	I-DISO
+.	O
+
+We	O
+report	O
+an	O
+unusual	O
+case	O
+of	O
+an	O
+infant	O
+who	O
+developed	O
+severe	O
+ARDS	B-DISO
+in	O
+association	O
+with	O
+a	O
+severe	O
+cyanotic	B-DISO
+attack	I-DISO
+due	O
+to	O
+tetralogy	B-DISO
+of	I-DISO
+Fallot	I-DISO
+.	O
+
+TITLE	O
+:	O
+Origin	O
+and	O
+evolution	B-PROC
+of	O
+Georgia	O
+98	O
+(	O
+GA98	O
+),	O
+a	O
+new	O
+serotype	O
+of	O
+avian	B-DISO
+infectious	I-DISO
+bronchitis	I-DISO
+virus	B-SPEC
+.	O
+
+Together	O
+with	O
+virus	B-PROC
+neutralization	I-PROC
+data	O
+,	O
+it	O
+appears	O
+that	O
+GA98	O
+arose	O
+from	O
+immune	O
+selection	O
+caused	O
+by	O
+DE072	O
+vaccine	O
+use	O
+.	O
+
+The	O
+objective	O
+of	O
+the	O
+present	O
+study	O
+was	O
+to	O
+elucidate	O
+the	O
+kinetics	O
+of	O
+humoral	O
+and	O
+cellular	O
+immune	O
+responses	O
+of	O
+turkey	B-SPEC
+poults	O
+infected	O
+with	O
+turkey	B-SPEC
+coronavirus	B-SPEC
+(	O
+TCV	B-SPEC
+).	O
+
+Total	O
+Ig	O
+to	O
+TCV	B-SPEC
+was	O
+initially	O
+detected	O
+at	O
+7	O
+and	O
+14	O
+d	O
+PI	O
+in	O
+Experiments	O
+1	O
+and	O
+3	O
+.	O
+
+ABSTRACT	O
+:	O
+We	O
+have	O
+previously	O
+reported	O
+the	O
+cloning	O
+and	O
+characterisation	O
+of	O
+the	O
+heavy	O
+and	O
+light	O
+chain	O
+variable	O
+domain	O
+genes	O
+encoding	O
+three	O
+monoclonal	O
+antibodies	B-COMP
+(	O
+Mabs	O
+)	O
+that	O
+bind	B-FUNC
+viral	B-SPEC
+haemorrhagic	I-SPEC
+septicaemia	I-SPEC
+virus	I-SPEC
+(	O
+VHSV	B-SPEC
+).	O
+
+The	O
+variable	O
+domains	O
+of	O
+these	O
+two	O
+antibodies	B-COMP
+differ	O
+by	O
+only	O
+four	O
+residues	O
+(	O
+Lorenzen	O
+et	O
+al	O
+.,	O
+2000a	O
+.	O
+
+To	O
+further	O
+study	O
+the	O
+mechanism	O
+of	O
+neutralisation	O
+,	O
+Fab	B-PRGE
+fragments	I-PRGE
+as	O
+well	O
+as	O
+a	O
+series	O
+of	O
+recombinant	O
+bacterial	O
+single	O
+chain	O
+antibody	B-COMP
+(	O
+scAb	B-DISO
+)	O
+fragments	O
+were	O
+generated	O
+from	O
+the	O
+three	O
+anti	O
+-	O
+VHSV	B-SPEC
+Mabs	O
+and	O
+their	O
+variable	O
+domain	O
+genes	O
+,	O
+respectively	O
+.	O
+
+The	O
+dissociation	O
+constants	O
+of	O
+Mabs	O
+3F1H10	O
+and	O
+3F1A2	O
+and	O
+their	O
+respective	O
+Fab	O
+and	O
+scAb	B-DISO
+fragments	O
+were	O
+measured	O
+by	O
+BIAcore	O
+analysis	O
+and	O
+found	O
+to	O
+correlate	O
+with	O
+the	O
+capacity	O
+of	O
+each	O
+molecule	O
+to	O
+neutralise	O
+DK	O
+-	O
+F1	O
+.	O
+
+TITLE	O
+:	O
+Pulmonary	B-ANAT
+oxygen	B-CHED
+consumption	O
+:	O
+a	O
+hypothesis	O
+to	O
+explain	O
+the	O
+increase	O
+in	O
+oxygen	B-CHED
+consumption	O
+of	O
+low	O
+birth	O
+weight	O
+infants	O
+with	O
+lung	B-DISO
+disease	I-DISO
+.	O
+
+VO2lung	O
+can	O
+account	O
+for	O
+the	O
+elevated	O
+metabolic	B-PROC
+rate	I-PROC
+in	O
+low	O
+-	O
+birthweight	O
+infants	O
+with	O
+lung	B-ANAT
+injury	O
+.	O
+
+However	O
+,	O
+infants	O
+with	O
+the	O
+most	O
+severe	O
+changes	O
+on	O
+follow	O
+-	O
+up	O
+radiography	O
+(	O
+Edwards	O
+score	O
+5	O
+as	O
+assessed	O
+by	O
+radiologist	O
+blinded	O
+for	O
+VO2	B-CHED
+data	O
+)	O
+all	O
+had	O
+a	O
+VO2lung	O
+level	O
+greater	O
+than	O
+2	O
+.	O
+0	O
+ml	O
+x	O
+kg	O
+(-	O
+1	O
+)	O
+x	O
+min	O
+(-	O
+1	O
+).	O
+
+In	O
+this	O
+lavage	O
+-	O
+induced	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+model	O
+the	O
+administration	O
+of	O
+C1	O
+-	O
+INH	O
+might	O
+be	O
+followed	O
+by	O
+a	O
+higher	O
+clinical	O
+efficacy	O
+of	O
+exogenously	O
+supplied	O
+recombinant	O
+SP	O
+-	O
+C	O
+surfactant	B-CHED
+.	O
+
+The	O
+objective	O
+of	O
+this	O
+review	O
+is	O
+to	O
+determine	O
+whether	O
+the	O
+elective	O
+use	O
+of	O
+high	O
+frequency	O
+oscillatory	O
+ventilation	O
+(	O
+HFOV	O
+)	O
+as	O
+compared	O
+to	O
+conventional	O
+ventilation	O
+(	O
+CV	O
+)	O
+in	O
+preterm	O
+infants	O
+who	O
+are	O
+mechanically	O
+ventilated	O
+for	O
+the	O
+respiratory	B-DISO
+distress	I-DISO
+syndrome	I-DISO
+decreases	O
+the	O
+incidence	O
+of	O
+chronic	B-DISO
+lung	I-DISO
+disease	I-DISO
+(	O
+CLD	B-DISO
+)	O
+without	O
+adverse	B-DISO
+effects	I-DISO
+.	O
+
+There	O
+are	O
+trends	O
+toward	O
+decreases	O
+in	O
+CLD	B-DISO
+in	O
+survivors	O
+at	O
+28	O
+-	O
+30	O
+days	O
+,	O
+'	B-PROC
+death	I-PROC
+or	O
+CLD	B-DISO
+at	O
+28	O
+-	O
+30	O
+days	O
+'	O
+and	O
+a	O
+significant	O
+reduction	O
+in	O
+CLD	B-DISO
+in	O
+survivors	O
+at	O
+36	O
+-	O
+37	O
+weeks	O
+postmenstrual	O
+age	O
+or	O
+discharge	B-ANAT
+in	O
+the	O
+HFOV	O
+group	O
+(	O
+six	O
+trials	O
+,	O
+summary	O
+RR	O
+0	O
+.	O
+73	O
+(	O
+0	O
+.	O
+57	O
+,	O
+0	O
+.	O
+93	O
+).	O
+
+In	O
+the	O
+subgroup	O
+of	O
+six	O
+trials	O
+where	O
+a	O
+high	O
+volume	O
+strategy	O
+(	O
+HVS	B-FUNC
+)	O
+was	O
+used	O
+for	O
+HFOV	O
+,	O
+this	O
+is	O
+associated	O
+with	O
+significantly	O
+lower	O
+rates	O
+of	O
+CLD	B-DISO
+in	O
+survivors	O
+at	O
+28	O
+-	O
+30	O
+days	O
+[	O
+three	O
+trials	O
+,	O
+summary	O
+RR	O
+0	O
+.	O
+53	O
+(	O
+0	O
+.	O
+36	O
+,	O
+0	O
+.	O
+76	O
+)],	O
+of	O
+'	B-PROC
+death	I-PROC
+or	O
+CLD	B-DISO
+at	O
+28	O
+-	O
+30	O
+days	O
+'	O
+[	O
+three	O
+trials	O
+,	O
+summary	O
+RR	O
+0	O
+.	O
+56	O
+(	O
+0	O
+.	O
+40	O
+,	O
+0	O
+.	O
+77	O
+)	O
+and	O
+oxygen	B-CHED
+use	O
+at	O
+36	O
+-	O
+37	O
+weeks	O
+postmenstrual	O
+age	O
+or	O
+discharge	B-ANAT
+[	O
+five	O
+trials	O
+,	O
+summary	O
+RR	O
+0	O
+.	O
+72	O
+(	O
+0	O
+.	O
+56	O
+,	O
+0	O
+.	O
+93	O
+)].	O
+
+Future	O
+trials	O
+should	O
+target	O
+very	O
+preterm	O
+infants	O
+who	O
+are	O
+at	O
+most	O
+risk	O
+of	O
+CLD	B-DISO
+and	O
+infants	O
+should	O
+be	O
+randomized	O
+in	O
+gestational	O
+age	O
+strata	O
+.	O
+
+background	O
+supportive	O
+therapy	O
+of	O
+ARDS	B-DISO
+;	O
+3	O
+.	O
+
+MHV	B-SPEC
+strain	O
+JHM	O
+causes	O
+acute	O
+and	O
+chronic	O
+neurological	O
+diseases	O
+in	O
+susceptible	O
+strains	O
+of	O
+rodents	B-SPEC
+.	O
+
+The	O
+decrease	O
+of	O
+tidal	O
+volume	O
+(	O
+by	O
+60	O
+and	O
+25	O
+%	O
+respectively	O
+)	O
+in	O
+association	O
+with	O
+tracheal	O
+gas	B-ENZY
+insufflation	O
+allowed	O
+to	O
+reduce	O
+plateau	O
+airway	B-ANAT
+pressure	O
+(<	O
+35	O
+cm	O
+d	O
+'	O
+H	O
+(	O
+2	O
+)	O
+O	O
+)	O
+and	O
+PaCO	O
+(	O
+2	O
+)	O
+(	O
+in	O
+the	O
+first	O
+case	O
+by	O
+23	O
+%	O
+and	O
+in	O
+the	O
+second	O
+case	O
+,	O
+by	O
+11	O
+%	O
+for	O
+the	O
+second	O
+hour	O
+then	O
+by	O
+24	O
+%),	O
+while	O
+intracranial	B-PROC
+pressure	I-PROC
+remained	O
+constant	O
+or	O
+was	O
+lowered	O
+(	O
+in	O
+the	O
+second	O
+case	O
+by	O
+39	O
+%	O
+for	O
+the	O
+second	O
+hour	O
+).	O
+
+TGI	O
+appears	O
+to	O
+be	O
+an	O
+important	O
+component	O
+of	O
+ventilatory	O
+management	O
+when	O
+ARDS	B-DISO
+is	O
+associated	O
+with	O
+severe	O
+head	B-ANAT
+trauma	O
+.	O
+
+We	O
+examined	O
+using	O
+ICR	O
+mice	B-SPEC
+whether	O
+the	O
+amino	B-CHED
+acids	I-CHED
+mutated	O
+in	O
+the	O
+mutants	O
+were	O
+involved	O
+in	O
+the	O
+neurovirulence	O
+.	O
+
+TITLE	O
+:	O
+FiO2	O
+and	O
+positive	O
+end	B-PROC
+-	I-PROC
+expiratory	I-PROC
+pressure	O
+as	O
+compensation	B-PROC
+for	O
+altitude	O
+-	O
+induced	O
+hypoxemia	O
+in	O
+an	O
+acute	O
+respiratory	O
+distress	O
+syndrome	O
+model	O
+:	O
+implications	O
+for	O
+air	B-CHED
+transportation	O
+of	O
+critically	B-DISO
+ill	I-DISO
+patients	O
+.	O
+
+The	O
+animals	B-SPEC
+were	O
+taken	O
+to	O
+8000	O
+feet	B-ANAT
+(	O
+2440	O
+m	O
+)	O
+in	O
+an	O
+altitude	O
+chamber	B-ANAT
+,	O
+and	O
+then	O
+stepwise	O
+increases	O
+of	O
+either	O
+5	O
+%	O
+FiO2	O
+(	O
+six	O
+animals	O
+)	O
+or	O
+2	O
+.	O
+5	O
+cm	O
+H2O	B-CHED
+positive	O
+end	B-PROC
+-	I-PROC
+expiratory	I-PROC
+pressure	O
+(	O
+six	O
+animals	B-SPEC
+)	O
+were	O
+made	O
+until	O
+PaO2	O
+values	O
+exceeded	O
+75	O
+torr	O
+(	O
+10	O
+.	O
+0	O
+kPa	O
+).	O
+
+Fifty	O
+percent	O
+of	O
+the	O
+animals	B-SPEC
+with	O
+lung	B-ANAT
+injury	O
+had	O
+altitude	O
+-	O
+induced	O
+hypoxia	B-DISO
+that	O
+was	O
+resistant	O
+to	O
+increases	O
+in	O
+FiO2	O
+.	O
+
+Our	O
+data	O
+indicate	O
+that	O
+multiple	O
+stem	B-ANAT
+-	O
+loop	O
+and	O
+hairpin	O
+-	O
+loop	O
+structures	O
+exist	O
+within	O
+this	O
+region	O
+.	O
+
+Three	O
+stem	B-ANAT
+structures	O
+were	O
+chosen	O
+as	O
+targets	O
+for	O
+the	O
+introduction	O
+of	O
+transversion	B-DISO
+mutations	I-DISO
+designed	O
+to	O
+destroy	O
+base	B-FUNC
+pairing	I-FUNC
+structures	O
+.	O
+
+Destruction	O
+of	O
+base	B-FUNC
+pairing	I-FUNC
+between	O
+positions	O
+96	O
+to	O
+99	O
+and	O
+116	O
+to	O
+113	O
+also	O
+decreased	O
+DI	O
+RNA	B-PROC
+replication	I-PROC
+.	O
+
+All	O
+of	O
+the	O
+M	B-PRGE
+protein	I-PRGE
+was	O
+susceptible	O
+to	O
+N	O
+-	O
+glycosidase	O
+F	O
+treatment	O
+of	O
+the	O
+native	O
+virions	B-COMP
+,	O
+which	O
+indicates	O
+that	O
+all	O
+the	O
+M	B-PRGE
+protein	I-PRGE
+molecules	O
+are	O
+exposed	O
+to	O
+the	O
+virus	B-SPEC
+surface	O
+.	O
+
+Coronaviruses	O
+have	O
+the	O
+largest	O
+RNA	O
+virus	B-SPEC
+genomes	O
+and	O
+,	O
+together	O
+with	O
+genetic	O
+instability	O
+of	O
+some	O
+cDNA	O
+sequences	O
+in	O
+Escherichia	B-SPEC
+coli	I-SPEC
+,	O
+this	O
+has	O
+hampered	O
+the	O
+generation	O
+of	O
+a	O
+reverse	O
+-	O
+genetics	O
+system	O
+for	O
+this	O
+group	O
+of	O
+viruses	B-SPEC
+.	O
+
+In	O
+this	O
+report	O
+,	O
+we	O
+describe	O
+the	O
+assembly	O
+of	O
+a	O
+full	O
+-	O
+length	O
+cDNA	O
+from	O
+the	O
+positive	O
+-	O
+sense	B-PROC
+genomic	O
+RNA	O
+of	O
+the	O
+avian	B-SPEC
+coronavirus	I-SPEC
+,	O
+infectious	B-DISO
+bronchitis	B-DISO
+virus	B-SPEC
+(	O
+IBV	B-SPEC
+),	O
+an	O
+important	O
+poultry	O
+pathogen	O
+.	O
+
+The	O
+IBV	B-SPEC
+genomic	O
+cDNA	O
+was	O
+assembled	O
+immediately	O
+downstream	O
+of	O
+a	O
+T7	B-PRGE
+RNA	I-PRGE
+polymerase	I-PRGE
+promoter	I-PRGE
+by	O
+in	O
+vitro	O
+ligation	O
+and	O
+cloned	O
+directly	O
+into	O
+the	O
+vaccinia	B-SPEC
+virus	I-SPEC
+genome	O
+.	O
+
+We	O
+wished	O
+to	O
+extend	O
+this	O
+study	O
+in	O
+a	O
+well	O
+-	O
+defined	O
+group	O
+of	O
+patients	O
+with	O
+major	O
+trauma	O
+,	O
+and	O
+to	O
+investigate	O
+potential	O
+mechanisms	O
+for	O
+rapid	O
+intrapulmonary	O
+IL	B-FUNC
+-	I-FUNC
+8	I-FUNC
+generation	O
+.	O
+
+Acute	O
+hypoxia	B-DISO
+also	O
+increased	O
+rabbit	B-PRGE
+alveolar	B-ANAT
+macrophage	I-ANAT
+IL	B-FUNC
+-	I-FUNC
+8	I-FUNC
+expression	B-PROC
+.	O
+
+Acute	O
+hypoxia	B-DISO
+,	O
+a	O
+clinically	O
+relevant	O
+stimulus	O
+,	O
+rapidly	O
+and	O
+selectively	O
+upregulates	O
+IL	B-FUNC
+-	I-FUNC
+8	I-FUNC
+in	O
+macrophages	B-ANAT
+associated	O
+with	O
+a	O
+novel	O
+pattern	O
+of	O
+transcription	B-PROC
+factor	O
+activation	O
+.	O
+
+Both	O
+the	O
+pattern	O
+of	O
+cytokine	O
+expression	B-PROC
+and	O
+transcription	B-PROC
+factor	O
+activation	O
+by	O
+hypoxia	B-DISO
+was	O
+different	O
+to	O
+that	O
+seen	O
+with	O
+endotoxin	O
+.	O
+
+Cell	B-COMP
+-	O
+free	O
+virions	B-COMP
+consist	O
+of	O
+a	O
+rod	B-ANAT
+-	O
+shaped	O
+nucleocapsid	B-COMP
+(	O
+120	O
+-	O
+150x19	O
+-	O
+22	O
+nm	O
+)	O
+similar	O
+to	O
+that	O
+seen	O
+in	O
+baculoviruses	O
+.	O
+
+Morphologically	O
+similar	O
+viruses	B-SPEC
+had	O
+previously	O
+been	O
+isolated	O
+from	O
+grass	B-SPEC
+carp	I-SPEC
+(	O
+Ctenopharyngodon	B-SPEC
+idella	I-SPEC
+),	O
+blue	B-SPEC
+crab	I-SPEC
+(	O
+Callinectis	O
+sapidus	O
+),	O
+European	O
+shore	O
+crab	B-SPEC
+(	O
+Carcinus	B-SPEC
+maenas	I-SPEC
+)	O
+and	O
+shrimp	O
+(	O
+Penaeus	B-SPEC
+monodon	I-SPEC
+).	O
+
+ORF1a	O
+and	O
+ORF1b	O
+encode	O
+replicative	O
+polyproteins	O
+pp1a	B-PRGE
+and	O
+pp1ab	O
+,	O
+respectively	O
+,	O
+that	O
+contain	O
+all	O
+of	O
+the	O
+putative	O
+functional	O
+domains	O
+documented	O
+previously	O
+for	O
+the	O
+closest	O
+relative	O
+,	O
+mouse	B-DISO
+hepatitis	I-DISO
+virus	B-SPEC
+.	O
+
+ABSTRACT	O
+:	O
+To	O
+find	O
+out	O
+if	O
+pretreatment	O
+with	O
+taurine	O
+would	O
+reduce	O
+the	O
+severity	O
+of	O
+endotoxin	O
+-	O
+induced	O
+acute	O
+lung	B-ANAT
+injury	O
+in	O
+a	O
+large	O
+animal	B-SPEC
+model	O
+.	O
+
+We	O
+performed	O
+a	O
+chart	O
+review	O
+of	O
+consecutive	O
+admissions	O
+for	O
+GBL	O
+withdrawal	B-DISO
+in	O
+a	O
+regional	O
+toxicology	O
+treatment	O
+center	O
+.	O
+
+During	O
+a	O
+6	O
+-	O
+month	O
+period	O
+,	O
+5	O
+patients	O
+presented	O
+with	O
+severe	O
+withdrawal	B-DISO
+attributed	O
+to	O
+abrupt	O
+GBL	B-PRGE
+discontinuation	O
+.	O
+
+Initial	O
+treatment	O
+with	O
+high	O
+doses	O
+of	O
+lorazepam	B-CHED
+proved	O
+ineffective	O
+.	O
+
+No	O
+patient	O
+had	O
+respiratory	B-DISO
+depression	I-DISO
+or	O
+required	O
+mechanical	O
+ventilation	O
+.	O
+
+Patients	O
+were	O
+discharged	O
+on	O
+tapering	O
+doses	O
+of	O
+benzodiazepines	B-CHED
+or	O
+pentobarbital	B-CHED
+and	O
+were	O
+free	O
+of	O
+psychotic	B-DISO
+symptoms	I-DISO
+at	O
+follow	O
+-	O
+up	O
+.	O
+
+In	O
+animals	B-SPEC
+,	O
+urea	B-CHED
+treatment	O
+has	O
+been	O
+clearly	O
+shown	O
+to	O
+protect	O
+again	O
+ODS	O
+,	O
+this	O
+protective	O
+effect	O
+could	O
+be	O
+due	O
+to	O
+its	O
+ability	O
+to	O
+induce	O
+quickly	O
+brain	B-ANAT
+""""	O
+organic	O
+osmolytes	B-CHED
+""""	O
+reaccumulation	O
+.	O
+
+TITLE	O
+:	O
+Differential	O
+detection	O
+of	O
+transmissible	O
+gastroenteritis	B-DISO
+virus	B-SPEC
+and	O
+porcine	B-SPEC
+epidemic	B-DISO
+diarrhea	I-DISO
+virus	I-SPEC
+by	O
+duplex	O
+RT	O
+-	O
+PCR	O
+.	O
+
+Among	O
+90	O
+clinical	O
+samples	O
+,	O
+7	O
+TGE	B-DISO
+viruses	B-SPEC
+and	O
+2	O
+PED	O
+viruses	B-SPEC
+were	O
+detected	O
+by	O
+the	O
+duplex	O
+RT	O
+-	O
+PCR	O
+.	O
+
+ABSTRACT	O
+:	O
+The	O
+sequence	O
+of	O
+the	O
+replicase	O
+gene	O
+of	O
+porcine	B-SPEC
+epidemic	I-SPEC
+diarrhoea	I-SPEC
+virus	I-SPEC
+(	O
+PEDV	B-SPEC
+)	O
+has	O
+been	O
+determined	O
+.	O
+
+The	O
+ORF1a	B-PRGE
+and	I-PRGE
+ORF1b	I-PRGE
+sequences	I-PRGE
+overlapped	O
+at	O
+a	O
+potential	O
+ribosomal	O
+frame	O
+shift	O
+site	O
+.	O
+
+Comparative	O
+amino	B-CHED
+acid	I-CHED
+sequence	O
+alignments	O
+revealed	O
+that	O
+PEDV	B-SPEC
+is	O
+most	O
+closely	O
+related	O
+to	O
+human	B-SPEC
+coronavirus	I-SPEC
+(	O
+HCoV	O
+)-	O
+229E	O
+and	O
+transmissible	O
+gastroenteritis	B-DISO
+virus	B-SPEC
+(	O
+TGEV	B-SPEC
+)	O
+and	O
+less	O
+related	O
+to	O
+murine	B-DISO
+hepatitis	I-DISO
+virus	B-SPEC
+(	O
+MHV	B-SPEC
+)	O
+and	O
+infectious	B-DISO
+bronchitis	B-DISO
+virus	B-SPEC
+(	O
+IBV	B-SPEC
+).	O
+
+In	O
+this	O
+paper	O
+,	O
+we	O
+document	O
+intrahepatic	O
+and	O
+splenic	B-ANAT
+T	B-ANAT
+cell	I-ANAT
+subpopulations	O
+involved	O
+in	O
+the	O
+hepatitis	B-DISO
+process	O
+and	O
+viral	O
+elimination	B-PROC
+identified	O
+in	O
+attenuated	O
+or	O
+pathogenic	O
+MHV3	O
+-	O
+infected	O
+C57BL	O
+/	O
+6	O
+mice	B-SPEC
+.	O
+
+Coronaviral	O
+particles	O
+from	O
+intestinal	B-ANAT
+contents	I-ANAT
+or	O
+the	O
+sucrose	B-CHED
+density	O
+gradient	O
+preparation	O
+were	O
+mainly	O
+spherical	O
+in	O
+shape	O
+and	O
+had	O
+envelope	B-COMP
+and	O
+central	O
+depression	B-DISO
+.	O
+
+Sequence	O
+analysis	O
+of	O
+the	O
+568	O
+bp	O
+PCR	O
+product	O
+revealed	O
+high	O
+degree	O
+of	O
+identity	O
+with	O
+the	O
+corresponding	O
+spike	O
+protein	B-CHED
+gene	O
+sequence	O
+of	O
+human	B-SPEC
+and	O
+bovine	B-SPEC
+coronaviruses	O
+.	O
+
+Among	O
+the	O
+different	O
+processes	O
+contributing	O
+to	O
+the	O
+continuous	O
+generation	O
+of	O
+new	O
+viral	O
+variants	O
+RNA	O
+recombination	B-PROC
+is	O
+of	O
+special	O
+importance	O
+.	O
+
+This	O
+process	O
+has	O
+been	O
+observed	O
+for	O
+human	B-SPEC
+,	O
+animal	B-SPEC
+,	O
+plant	B-SPEC
+and	O
+bacterial	O
+viruses	B-SPEC
+.	O
+
+Unvaccinated	O
+birds	B-SPEC
+in	O
+Experiment	O
+3	O
+fed	O
+an	O
+Arg	B-CHED
+-	O
+deficient	O
+diet	O
+had	O
+lower	O
+(	O
+P	O
+<	O
+or	O
+=	O
+0	O
+.	O
+05	O
+)	O
+feed	O
+conversion	O
+in	O
+comparison	O
+with	O
+vaccinated	O
+birds	B-SPEC
+fed	O
+an	O
+Arg	B-CHED
+-	O
+deficient	O
+diet	O
+.	O
+
+TITLE	O
+:	O
+Relationship	O
+between	O
+the	O
+level	O
+of	O
+dietary	O
+vitamin	B-CHED
+E	I-CHED
+and	O
+the	O
+immune	B-PROC
+response	I-PROC
+of	O
+broiler	O
+chickens	B-SPEC
+.	O
+
+A	O
+range	O
+of	O
+VE	O
+(	O
+0	O
+,	O
+10	O
+,	O
+17	O
+.	O
+5	O
+,	O
+25	O
+,	O
+37	O
+.	O
+5	O
+,	O
+50	O
+,	O
+100	O
+,	O
+and	O
+200	O
+IU	O
+/	O
+kg	O
+)	O
+levels	O
+were	O
+supplemented	O
+to	O
+a	O
+basal	O
+diet	O
+(	O
+corn	B-DISO
+-	O
+soy	O
+)	O
+containing	O
+10	O
+.	O
+2	O
+IU	O
+of	O
+VE	O
+/	O
+kg	O
+.	O
+
+Immunohistochemistry	O
+for	O
+VEGFA	O
+(	O
+165	O
+),	O
+an	O
+endothelial	B-ANAT
+cell	I-ANAT
+mitogen	B-CHED
+,	O
+and	O
+its	O
+receptor	O
+Flt	B-PRGE
+-	I-PRGE
+1	I-PRGE
+,	O
+was	O
+performed	O
+on	O
+lung	B-ANAT
+tissues	I-ANAT
+from	O
+autopsies	O
+from	O
+four	O
+fetuses	B-ANAT
+,	O
+three	O
+preterm	O
+infants	O
+,	O
+four	O
+term	O
+infants	O
+without	O
+primary	O
+lung	B-DISO
+disease	I-DISO
+,	O
+four	O
+infants	O
+with	O
+BPD	B-DISO
+,	O
+and	O
+four	O
+infants	O
+with	O
+PPHN	O
+.	O
+
+We	O
+sought	O
+to	O
+determine	O
+the	O
+immediate	O
+effects	O
+of	O
+specific	O
+tidal	O
+volume	O
+-	O
+PEEP	B-CHED
+combinations	O
+upon	O
+oxygenation	B-PROC
+and	O
+static	O
+compliance	O
+in	O
+patients	O
+with	O
+moderate	O
+to	O
+severe	O
+acute	O
+lung	B-ANAT
+injury	O
+.	O
+
+Similarly	O
+,	O
+PEEP	B-CHED
+set	O
+at	O
+25	O
+cmH2O	O
+did	O
+not	O
+improve	O
+oxygenation	B-PROC
+or	O
+compliance	O
+.	O
+
+Early	O
+screening	O
+of	O
+parasitemia	B-DISO
+using	O
+highly	O
+sensitive	O
+polymerase	O
+chain	O
+reaction	O
+methods	O
+in	O
+seropositive	O
+patients	O
+with	O
+unexplained	O
+fever	B-PROC
+may	O
+be	O
+needed	O
+.	O
+
+Recently	O
+,	O
+cDNA	O
+microarray	O
+analyses	O
+were	O
+performed	O
+that	O
+indicated	O
+several	O
+pathogenic	O
+responses	O
+during	O
+nickel	B-CHED
+-	O
+induced	O
+ALI	O
+,	O
+including	O
+marked	O
+macrophage	B-PROC
+activation	I-PROC
+.	O
+
+Increases	O
+in	O
+cytokine	O
+expression	B-PROC
+and	O
+cellular	B-ANAT
+nitration	O
+can	O
+lead	O
+to	O
+tissue	B-ANAT
+damage	O
+and	O
+are	O
+consistent	O
+with	O
+the	O
+differences	O
+between	O
+genotypes	O
+in	O
+the	O
+early	O
+onset	O
+of	O
+pathology	B-DISO
+and	O
+mortality	O
+in	O
+Ron	O
+tk	O
+-/-	O
+mice	B-SPEC
+.	O
+
+As	O
+of	O
+July	O
+2001	O
+,	O
+the	O
+VirOligo	O
+database	O
+contains	O
+a	O
+complete	O
+listing	O
+of	O
+oligonucleotides	B-CHED
+specific	O
+to	O
+viral	O
+agents	O
+associated	O
+with	O
+bovine	B-SPEC
+respiratory	B-DISO
+disease	I-DISO
+that	O
+were	O
+published	O
+in	O
+English	O
+in	O
+peer	O
+-	O
+reviewed	O
+journals	O
+.	O
+
+However	O
+,	O
+vaccination	O
+by	O
+repeated	O
+injections	O
+of	O
+plasmids	O
+encoding	O
+these	O
+proteins	B-CHED
+did	O
+not	O
+protect	O
+kittens	O
+against	O
+challenge	O
+infection	B-DISO
+with	O
+FIPV	O
+.	O
+
+Also	O
+,	O
+a	O
+prime	O
+-	O
+boost	O
+protocol	O
+failed	O
+to	O
+afford	O
+protection	O
+,	O
+with	O
+priming	O
+using	O
+plasmid	O
+DNA	O
+and	O
+boosting	O
+using	O
+recombinant	O
+vaccinia	B-DISO
+viruses	B-SPEC
+expressing	O
+the	O
+same	O
+coronavirus	B-SPEC
+proteins	B-CHED
+.	O
+
+TITLE	O
+:	O
+Effect	O
+of	O
+methylprednisolone	B-CHED
+on	O
+phospholipase	B-PROC
+A	I-PROC
+(	O
+2	O
+)	O
+activity	O
+and	O
+lung	B-ANAT
+surfactant	B-CHED
+degradation	O
+in	O
+acute	O
+lung	O
+injury	O
+in	O
+rabbits	B-SPEC
+.	O
+
+for	O
+2	O
+h	O
+)	O
+provoked	O
+pulmonary	B-DISO
+hemorrhage	I-DISO
+and	O
+edema	B-DISO
+,	O
+protein	B-CHED
+leakage	B-DISO
+and	O
+massive	O
+neutrophil	B-ANAT
+infiltration	B-DISO
+,	O
+resulted	O
+in	O
+severe	O
+hypoxemia	O
+and	O
+impaired	B-DISO
+lung	B-PROC
+compliance	I-PROC
+,	O
+accompanying	O
+the	O
+increase	O
+of	O
+phospholipase	B-PRGE
+A	I-PRGE
+(	I-PRGE
+2	I-PRGE
+)	I-PRGE
+activity	O
+and	O
+interleukin	B-PRGE
+-	I-PRGE
+8	I-PRGE
+,	O
+and	O
+degradation	O
+of	O
+surfactant	B-CHED
+in	O
+the	O
+bronchoalveolar	B-ANAT
+lavage	I-ANAT
+fluid	I-ANAT
+.	O
+
+for	O
+6	O
+h	O
+)	O
+did	O
+not	O
+improve	O
+the	O
+above	O
+described	O
+lung	O
+injury	O
+induced	O
+by	O
+oleic	B-CHED
+acid	I-CHED
+,	O
+nor	O
+did	O
+it	O
+suppress	O
+phospholipase	B-PROC
+A	I-PROC
+(	O
+2	O
+)	O
+activity	O
+and	O
+degradation	O
+of	O
+surfactant	B-CHED
+in	O
+bronchoalveolar	B-ANAT
+lavage	I-ANAT
+fluid	I-ANAT
+,	O
+while	O
+it	O
+strongly	O
+reduced	O
+interleukin	B-PRGE
+-	I-PRGE
+8	I-PRGE
+levels	O
+in	O
+both	O
+plasma	B-ANAT
+and	O
+bronchoalveolar	B-ANAT
+lavage	I-ANAT
+fluid	I-ANAT
+.	O
+
+TITLE	O
+:	O
+An	O
+autopsy	O
+case	O
+of	O
+primary	B-DISO
+biliary	I-DISO
+cirrhosis	I-DISO
+with	O
+severe	O
+interstitial	B-DISO
+pneumonia	I-DISO
+.	O
+
+Though	O
+the	O
+symptoms	O
+of	O
+these	O
+complications	O
+improved	O
+,	O
+the	O
+interstitial	B-DISO
+pneumonia	I-DISO
+deteriorated	O
+very	O
+quickly	O
+and	O
+the	O
+patient	O
+died	B-PROC
+of	O
+respiratory	B-DISO
+failure	I-DISO
+due	O
+to	O
+acute	O
+exacerbation	O
+of	O
+interstitial	B-DISO
+pneumonia	I-DISO
+when	O
+the	O
+activity	O
+of	O
+PBC	B-DISO
+decreased	O
+.	O
+
+TITLE	O
+:	O
+[	O
+Postoperative	B-DISO
+pain	I-DISO
+as	O
+the	O
+fifth	O
+vital	O
+parameter	O
+].	O
+
+ABSTRACT	O
+:	O
+Acute	O
+postoperative	B-DISO
+pain	I-DISO
+and	O
+its	O
+therapy	O
+is	O
+a	O
+great	O
+challenge	O
+for	O
+all	O
+health	O
+-	O
+care	O
+providers	O
+in	O
+operative	O
+medicine	O
+today	O
+.	O
+
+Introduction	O
+of	O
+the	O
+""""	O
+fifth	O
+vital	O
+parameter	O
+""""	O
+would	O
+solve	O
+many	O
+problems	O
+in	O
+postoperative	B-DISO
+pain	I-DISO
+therapy	O
+,	O
+because	O
+healthcare	O
+workers	O
+take	O
+vital	O
+signs	O
+very	O
+seriously	O
+both	O
+for	O
+monitoring	O
+and	O
+treatment	O
+.	O
+
+These	O
+effects	O
+are	O
+very	O
+harmful	O
+,	O
+changing	O
+quality	O
+of	O
+life	O
+of	O
+the	O
+whole	O
+family	B-SPEC
+because	O
+the	O
+treatment	O
+of	O
+chronic	B-DISO
+pain	I-DISO
+syndrome	I-DISO
+is	O
+very	O
+difficult	O
+and	O
+expensive	O
+.	O
+
+The	O
+purpose	O
+of	O
+this	O
+study	O
+was	O
+to	O
+compare	O
+low	O
+-	O
+dose	O
+(	O
+LD	O
+)	O
+and	O
+high	O
+-	O
+dose	O
+(	O
+HD	O
+)	O
+systemic	O
+heparinization	O
+in	O
+a	O
+prospective	O
+randomized	O
+study	O
+of	O
+arteriovenous	O
+carbon	O
+dioxide	O
+removal	O
+(	O
+AVCO2R	O
+)	O
+during	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+,	O
+using	O
+a	O
+commercially	O
+available	O
+heparin	B-CHED
+-	O
+coated	O
+oxygenator	O
+.	O
+
+At	O
+40	O
+-	O
+48	O
+h	O
+post	O
+-	O
+injury	O
+,	O
+animals	B-SPEC
+underwent	O
+cannulation	O
+of	O
+the	O
+carotid	B-ANAT
+artery	I-ANAT
+and	O
+jugular	B-ANAT
+vein	I-ANAT
+and	O
+were	O
+then	O
+randomized	O
+to	O
+HD	O
+heparin	B-CHED
+(	O
+activated	O
+clotting	B-PROC
+time	O
+,	O
+ACT	O
+>	O
+300s	O
+,	O
+n	O
+=	O
+6	O
+)	O
+and	O
+LD	O
+heparin	B-CHED
+(	O
+ACT	O
+<	O
+200s	O
+,	O
+n	O
+=	O
+7	O
+)	O
+and	O
+placed	O
+on	O
+AVCO2R	O
+for	O
+approximately	O
+72	O
+h	O
+using	O
+an	O
+oxygenator	O
+with	O
+the	O
+Trillium	B-SPEC
+Bio	O
+-	O
+Passive	O
+Surface	O
+.	O
+
+ABSTRACT	O
+:	O
+We	O
+present	O
+a	O
+1	O
+7	O
+-	O
+year	O
+-	O
+old	O
+female	O
+with	O
+acute	O
+extra	O
+-	O
+pyramidal	O
+parkinsonism	O
+complicating	O
+a	O
+suicidal	O
+attempt	O
+with	O
+the	O
+organophosphate	B-CHED
+insecticide	I-CHED
+chlorpyrifos	B-CHED
+,	O
+who	O
+was	O
+initially	O
+suspected	O
+to	O
+have	O
+developed	O
+severe	B-DISO
+depression	I-DISO
+or	O
+psychosis	B-DISO
+.	O
+
+Clustering	O
+of	O
+co	O
+-	O
+regulated	O
+genes	O
+(	O
+displaying	O
+similar	O
+temporal	O
+expression	B-PROC
+patterns	O
+)	O
+revealed	O
+the	O
+altered	O
+expression	B-PROC
+of	O
+relatively	O
+few	O
+genes	O
+.	O
+
+In	O
+addition	O
+,	O
+95	O
+%	O
+(	O
+38	O
+of	O
+40	O
+)	O
+of	O
+the	O
+sampled	O
+animals	B-SPEC
+were	O
+positive	O
+for	O
+RV	O
+antibodies	B-COMP
+,	O
+suggesting	O
+a	O
+high	O
+prevalence	O
+of	O
+RV	O
+infection	B-DISO
+in	O
+the	O
+populations	O
+tested	O
+.	O
+
+ABSTRACT	O
+:	O
+A	O
+serodiagnostic	O
+ELISA	O
+utilizing	O
+the	O
+recombinant	O
+nucleoprotein	O
+(	O
+rN	O
+protein	B-CHED
+)	O
+of	O
+transmissible	O
+gastroenteritis	B-DISO
+virus	B-SPEC
+(	O
+TGEV	B-SPEC
+)	O
+was	O
+developed	O
+,	O
+and	O
+evaluated	O
+by	O
+examining	O
+a	O
+panel	O
+of	O
+141	O
+virus	B-PROC
+neutralization	I-PROC
+(	O
+VN	O
+)	O
+positive	O
+and	O
+101	O
+negative	O
+sera	B-COMP
+.	O
+
+ABSTRACT	O
+:	O
+The	O
+pulmonary	O
+endothelium	B-ANAT
+synthesizes	O
+many	O
+bioactive	O
+compounds	O
+and	O
+their	O
+activation	O
+or	O
+injury	O
+may	O
+cause	O
+release	B-PATH
+these	O
+substances	O
+into	O
+the	O
+blood	B-ANAT
+.	O
+
+Group	O
+I	O
+--	O
+patients	O
+with	O
+ISS	B-DISO
+>	O
+or	O
+=	O
+35	O
+,	O
+Group	O
+II	O
+--	O
+patients	O
+with	O
+ISS	B-DISO
+<	O
+35	O
+.	O
+
+At	O
+the	O
+admission	O
+,	O
+significant	O
+correlation	O
+between	O
+plasma	B-ANAT
+vWF	B-PRGE
+:	O
+Ag	O
+and	O
+ISS	B-DISO
+was	O
+found	O
+(	O
+Rs	O
+=	O
+0	O
+.	O
+568	O
+,	O
+p	O
+<	O
+0	O
+.	O
+001	O
+).	O
+
+ABSTRACT	O
+:	O
+Acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+(	O
+ARDS	B-DISO
+),	O
+is	O
+characterised	O
+by	O
+capillary	B-PROC
+permeability	I-PROC
+and	O
+pulmonary	B-DISO
+oedema	I-DISO
+formation	B-PROC
+and	O
+may	O
+complicate	O
+a	O
+variety	O
+of	O
+medical	O
+and	O
+surgical	O
+illnesses	O
+.	O
+
+ABSTRACT	O
+:	O
+Mouse	O
+hepatitis	O
+virus	B-SPEC
+(	O
+MHV	B-SPEC
+)	O
+infection	B-DISO
+spreads	O
+from	O
+MHV	B-SPEC
+-	O
+infected	O
+DBT	B-CHED
+cells	B-COMP
+,	O
+which	O
+express	O
+the	O
+MHV	B-PRGE
+receptor	I-PRGE
+CEACAM1	I-PRGE
+(	O
+MHVR	B-PRGE
+),	O
+to	O
+BHK	O
+cells	B-COMP
+,	O
+which	O
+are	O
+devoid	O
+of	O
+the	O
+receptor	O
+,	O
+by	O
+intercellular	O
+membrane	B-PROC
+fusion	I-PROC
+(	O
+MHVR	O
+-	O
+independent	O
+fusion	O
+).	O
+
+Thus	O
+,	O
+in	O
+the	O
+presence	O
+of	O
+soMHVR	O
+,	O
+JHMV	O
+srr7	O
+-	O
+infected	O
+DBT	B-CHED
+cells	B-COMP
+overlaid	O
+onto	O
+BHK	O
+cells	B-COMP
+induce	O
+BHK	O
+cell	B-COMP
+syncytia	B-ANAT
+and	O
+the	O
+spread	O
+of	O
+JHMV	O
+srr7	O
+infection	B-DISO
+.	O
+
+Together	O
+with	O
+these	O
+observations	O
+,	O
+direct	O
+binding	O
+of	O
+soMHVR	O
+to	O
+the	O
+virus	B-SPEC
+spike	O
+(	O
+S	O
+)	O
+glycoprotein	B-CHED
+as	O
+revealed	O
+by	O
+coimmunoprecipitation	O
+demonstrated	O
+that	O
+the	O
+effect	O
+is	O
+mediated	O
+by	O
+the	O
+binding	B-FUNC
+of	O
+soMHVR	O
+to	O
+the	O
+S	B-PRGE
+protein	I-PRGE
+.	O
+
+Here	O
+,	O
+we	O
+report	O
+that	O
+neither	O
+the	O
+transmembrane	B-COMP
+domain	O
+nor	O
+the	O
+short	O
+lumenal	O
+domain	O
+of	O
+IBV	B-SPEC
+E	O
+is	O
+required	O
+for	O
+Golgi	B-PROC
+targeting	I-PROC
+.	O
+
+However	O
+,	O
+an	O
+N	O
+-	O
+terminal	O
+truncation	B-DISO
+containing	O
+only	O
+the	O
+cytoplasmic	B-ANAT
+domain	I-ANAT
+(	O
+CTE	B-DISO
+)	O
+was	O
+efficiently	O
+localized	O
+to	O
+the	O
+Golgi	B-COMP
+complex	I-COMP
+,	O
+and	O
+this	O
+domain	O
+could	O
+retain	O
+a	O
+reporter	O
+protein	B-CHED
+in	O
+the	O
+Golgi	B-COMP
+.	O
+
+The	O
+IBV	B-PRGE
+E	I-PRGE
+protein	B-CHED
+is	O
+palmitoylated	O
+on	O
+one	O
+or	O
+two	O
+cysteine	B-CHED
+residues	O
+adjacent	O
+to	O
+its	O
+transmembrane	B-COMP
+domain	O
+,	O
+but	O
+palmitoylation	B-PROC
+was	O
+not	O
+required	O
+for	O
+proper	O
+Golgi	B-PROC
+targeting	I-PROC
+.	O
+
+An	O
+optimized	O
+TRS	B-DISO
+has	O
+been	O
+designed	O
+comprising	O
+88	O
+nt	O
+from	O
+the	O
+N	B-PRGE
+gene	I-PRGE
+TRS	B-DISO
+,	O
+the	O
+CS	O
+,	O
+and	O
+3	O
+nt	O
+3	O
+'	O
+to	O
+the	O
+M	B-PRGE
+gene	I-PRGE
+CS	I-PRGE
+.	O
+
+TITLE	O
+:	O
+Heterologous	O
+gene	B-PROC
+expression	I-PROC
+from	O
+transmissible	O
+gastroenteritis	B-DISO
+virus	B-SPEC
+replicon	O
+particles	O
+.	O
+
+Following	O
+transfection	B-PROC
+of	O
+baby	O
+hamster	B-SPEC
+kidney	B-ANAT
+(	O
+BHK	O
+)	O
+cells	B-COMP
+,	O
+a	O
+recombinant	O
+TGEV	B-SPEC
+(	O
+TGEV	B-SPEC
+-	O
+GFP2	O
+)	O
+was	O
+isolated	O
+that	O
+replicated	O
+efficiently	O
+and	O
+expressed	B-PROC
+GFP	O
+.	O
+
+Following	O
+cotransfection	O
+of	O
+BHK	O
+cells	B-COMP
+with	O
+the	O
+replicon	O
+RNAs	O
+carrying	O
+gfp	O
+,	O
+GFP	O
+expression	O
+was	O
+evident	O
+by	O
+fluorescent	O
+microscopy	O
+and	O
+leader	O
+-	O
+containing	O
+transcripts	O
+carrying	O
+gfp	O
+were	O
+detected	O
+by	O
+reverse	B-PROC
+transcription	I-PROC
+-	O
+PCR	O
+(	O
+RT	O
+-	O
+PCR	O
+).	O
+
+Under	O
+identical	O
+conditions	O
+,	O
+TGEV	B-SPEC
+-	O
+GFP2	O
+spread	O
+throughout	O
+ST	O
+cell	B-COMP
+cultures	O
+,	O
+expressed	B-PROC
+GFP	O
+,	O
+and	O
+formed	O
+viral	O
+plaques	B-DISO
+.	O
+
+The	O
+number	O
+of	O
+documented	O
+cases	O
+of	O
+acute	B-DISO
+renal	I-DISO
+failure	I-DISO
+(	O
+ARF	B-DISO
+)	O
+following	O
+this	O
+event	O
+exceeded	O
+all	O
+similar	O
+cases	O
+previously	O
+reported	O
+for	O
+any	O
+single	O
+earthquake	O
+.	O
+
+RESULTS	O
+:	O
+A	O
+total	O
+of	O
+639	O
+patients	O
+(	O
+291	O
+female	O
+and	O
+348	O
+male	O
+)	O
+with	O
+ARF	B-DISO
+due	O
+to	O
+crush	O
+injury	O
+were	O
+hospitalized	O
+in	O
+35	O
+hospitals	O
+.	O
+
+These	O
+results	O
+suggest	O
+that	O
+the	O
+R120	O
+/	O
+R121	O
+recombinants	O
+most	O
+likely	O
+use	O
+the	O
+endosomal	O
+pathway	B-PROC
+to	O
+enter	O
+cells	B-COMP
+.	O
+
+TITLE	O
+:	O
+Recovery	O
+rate	O
+and	O
+prognosis	O
+in	O
+older	O
+persons	O
+who	O
+develop	O
+acute	O
+lung	B-ANAT
+injury	O
+and	O
+the	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+.	O
+
+The	O
+proportion	O
+of	O
+survivors	O
+achieving	O
+physiologic	O
+recovery	O
+landmarks	O
+did	O
+not	O
+differ	O
+between	O
+the	O
+older	O
+and	O
+younger	O
+age	O
+groups	O
+,	O
+and	O
+the	O
+median	O
+time	O
+to	O
+pass	O
+a	O
+2	O
+-	O
+hour	O
+spontaneous	O
+breathing	B-PROC
+trial	O
+was	O
+similar	O
+between	O
+both	O
+the	O
+older	O
+and	O
+younger	O
+patients	O
+(	O
+4	O
+days	O
+vs	O
+.	O
+5	O
+days	O
+;	O
+P	O
+>	O
+0	O
+.	O
+2	O
+).	O
+
+ABSTRACT	O
+:	O
+Seventeen	O
+infectious	B-DISO
+bronchitis	B-DISO
+virus	B-SPEC
+(	O
+IBV	B-SPEC
+)	O
+field	O
+isolates	O
+recovered	O
+from	O
+commercial	O
+broiler	O
+flocks	O
+in	O
+Mexico	O
+were	O
+identified	O
+by	O
+reverse	B-PROC
+transcription	I-PROC
+-	O
+polymerase	O
+chain	O
+reaction	O
+cycle	O
+sequencing	O
+of	O
+the	O
+S1	B-PRGE
+gene	I-PRGE
+.	O
+
+Previous	O
+studies	O
+have	O
+shown	O
+that	O
+CD8	B-PRGE
+(+)	O
+cytotoxic	B-ANAT
+T	I-ANAT
+lymphocytes	I-ANAT
+(	O
+CTL	B-ANAT
+)	O
+are	O
+critical	O
+in	O
+controlling	O
+acute	O
+IBV	B-SPEC
+infection	B-DISO
+,	O
+but	O
+the	O
+role	O
+of	O
+innate	B-PROC
+immunity	I-PROC
+is	O
+unknown	O
+.	O
+
+Both	O
+natural	O
+and	O
+rChIFN	B-PRGE
+-	I-PRGE
+alpha	I-PRGE
+inhibited	O
+replication	O
+of	O
+the	O
+Beaudette	O
+strain	O
+of	O
+IBV	B-SPEC
+in	O
+chicken	B-PRGE
+kidney	B-ANAT
+cells	B-COMP
+(	O
+CKC	B-PRGE
+)	O
+in	O
+a	O
+dose	O
+-	O
+dependent	O
+manner	O
+,	O
+with	O
+the	O
+antiviral	B-CHED
+activity	O
+of	O
+the	O
+former	O
+accounted	O
+for	O
+entirely	O
+by	O
+its	O
+content	O
+of	O
+type	B-PRGE
+I	I-PRGE
+IFN	I-PRGE
+.	O
+
+Optimal	O
+protection	O
+against	O
+IBV	B-SPEC
+-	O
+induced	O
+respiratory	B-DISO
+disease	I-DISO
+was	O
+obtained	O
+after	O
+intravenous	O
+or	O
+oral	B-ANAT
+administration	O
+of	O
+ChIFN	O
+given	O
+1	O
+day	O
+before	O
+virus	B-SPEC
+challenge	O
+and	O
+each	O
+of	O
+5	O
+days	O
+thereafter	O
+.	O
+
+Monastral	O
+blue	O
+(	O
+MB	O
+)-	O
+labelled	O
+blood	B-ANAT
+vessels	I-ANAT
+and	O
+pathological	O
+changes	O
+in	O
+lungs	B-ANAT
+were	O
+examined	O
+under	O
+a	O
+light	O
+microscope	O
+.	O
+
+Administration	O
+of	O
+exogenous	O
+ONOO	O
+(-)	O
+caused	O
+dose	O
+-	O
+dependent	O
+increase	O
+in	O
+LC	O
+,	O
+W	O
+/	O
+D	O
+,	O
+ater	O
+and	O
+EB	O
+contents	O
+and	O
+in	O
+the	O
+number	O
+of	O
+MB	O
+-	O
+labelled	O
+blood	O
+vessels	O
+in	O
+rat	B-SPEC
+lungs	B-ANAT
+,	O
+together	O
+with	O
+significant	O
+pathological	O
+alterations	O
+such	O
+as	O
+diffuse	O
+alveolar	B-ANAT
+collapse	B-DISO
+,	O
+capillary	B-ANAT
+congestion	B-DISO
+in	O
+the	O
+septa	O
+and	O
+focal	O
+hemorrhage	B-DISO
+.	O
+
+There	O
+is	O
+no	O
+consensus	O
+that	O
+mild	O
+-	O
+to	O
+-	O
+moderate	O
+hypertension	B-DISO
+in	I-DISO
+pregnancy	I-DISO
+should	O
+be	O
+treated	O
+.	O
+
+Nevertheless	O
+,	O
+virus	B-SPEC
+reemerged	O
+within	O
+the	O
+CNS	B-CHED
+of	O
+all	O
+Ab	O
+-	O
+deficient	O
+mice	B-SPEC
+.	O
+
+The	O
+lack	O
+of	O
+B	B-ANAT
+cells	I-ANAT
+and	O
+lymphoid	O
+architecture	O
+thus	O
+appears	O
+to	O
+manifest	O
+itself	O
+on	O
+T	B-ANAT
+cell	I-ANAT
+responses	O
+in	O
+a	O
+genetically	O
+biased	O
+manner	O
+.	O
+
+On	O
+admission	O
+,	O
+signs	O
+of	O
+a	O
+cholinergic	O
+syndrome	B-DISO
+were	O
+observed	O
+:	O
+miosis	B-PROC
+,	O
+rhinorrhoea	B-DISO
+,	O
+and	O
+fasciculations	B-DISO
+.	O
+
+Although	O
+the	O
+serum	B-COMP
+concentrations	O
+of	O
+both	O
+organophosphate	O
+compounds	O
+rapidly	O
+decreased	O
+,	O
+the	O
+activity	O
+of	O
+cholinesterase	B-PRGE
+showed	O
+a	O
+prolonged	O
+inhibition	B-PROC
+.	O
+
+The	O
+clinical	O
+course	O
+was	O
+complicated	O
+by	O
+hypotension	O
+,	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+,	O
+nosocomial	B-DISO
+pneumonia	I-DISO
+,	O
+and	O
+an	O
+epileptic	B-DISO
+seizure	I-DISO
+.	O
+
+ABSTRACT	O
+:	O
+A	O
+ten	O
+-	O
+case	O
+report	O
+of	O
+Streptococcus	B-SPEC
+suis	I-SPEC
+infection	I-DISO
+was	O
+reported	O
+in	O
+Lamphun	O
+,	O
+northern	O
+Thailand	O
+from	O
+1999	O
+to	O
+2000	O
+.	O
+
+The	O
+disease	O
+progressed	O
+rapidly	O
+and	O
+all	O
+patients	O
+died	B-PROC
+within	O
+24	O
+-	O
+48	O
+hours	O
+after	O
+admission	O
+from	O
+complications	O
+such	O
+as	O
+disseminated	B-DISO
+intravascular	I-DISO
+coagulation	I-DISO
+(	O
+DIC	B-DISO
+),	O
+acute	B-DISO
+renal	I-DISO
+failure	I-DISO
+(	O
+ARF	B-DISO
+)	O
+or	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+(	O
+ARDS	B-DISO
+).	O
+
+In	O
+late	O
+convalescence	O
+one	O
+could	O
+observe	O
+affections	O
+of	O
+the	O
+heart	B-ANAT
+,	O
+liver	B-ANAT
+,	O
+kidneys	B-ANAT
+,	O
+bones	B-ANAT
+,	O
+nervous	B-ANAT
+system	I-ANAT
+,	O
+eyes	B-ANAT
+.	O
+
+In	O
+addition	O
+,	O
+low	O
+amounts	O
+of	O
+BCV	B-SPEC
+were	O
+also	O
+detected	O
+only	O
+by	O
+nested	O
+PCR	O
+in	O
+the	O
+fecal	B-ANAT
+and	O
+nasal	B-ANAT
+swab	O
+samples	O
+before	O
+and	O
+after	O
+diarrhea	B-DISO
+.	O
+
+In	O
+-	O
+situ	O
+hybridization	B-PROC
+showed	O
+significant	O
+differences	O
+between	O
+the	O
+Korean	O
+and	O
+American	O
+strains	O
+in	O
+terms	O
+of	O
+the	O
+amount	O
+of	O
+TGEV	B-SPEC
+nucleic	B-CHED
+acid	I-CHED
+at	O
+6	O
+,	O
+12	O
+and	O
+60	O
+hpi	B-DISO
+.	O
+
+TITLE	O
+:	O
+[	O
+Interstitial	B-ANAT
+lung	B-ANAT
+diseases	I-DISO
+in	O
+polymyositis	B-DISO
+and	O
+dermatomyositis	B-DISO
+].	O
+
+Specific	O
+therapy	O
+of	O
+interstitial	B-DISO
+lung	B-ANAT
+disease	I-DISO
+has	O
+not	O
+yet	O
+been	O
+clearly	O
+established	O
+in	O
+polymyositis	B-DISO
+/	O
+dermatomyositis	B-DISO
+patients	O
+.	O
+
+The	O
+most	O
+promising	O
+regulation	B-PROC
+system	O
+is	O
+the	O
+tet	O
+-	O
+on	O
+system	O
+,	O
+which	O
+has	O
+low	O
+basal	O
+transcriptional	B-PROC
+activity	O
+and	O
+high	O
+inducibility	O
+.	O
+
+ABSTRACT	O
+:	O
+Mice	B-SPEC
+infected	O
+with	O
+the	O
+murine	B-SPEC
+coronavirus	I-SPEC
+,	O
+mouse	B-DISO
+hepatitis	I-DISO
+virus	B-SPEC
+,	O
+strain	O
+JHM	O
+(	O
+MHV	B-SPEC
+)	O
+develop	O
+an	O
+immune	O
+-	O
+mediated	O
+demyelinating	O
+encephalomyelitis	B-DISO
+.	O
+
+ABSTRACT	O
+:	O
+An	O
+enzyme	O
+-	O
+linked	O
+immunospot	O
+(	O
+ELISPOT	O
+)	O
+has	O
+been	O
+developed	O
+to	O
+detect	O
+porcine	B-SPEC
+epidemic	I-SPEC
+diarrhea	I-SPEC
+virus	I-SPEC
+(	O
+PEDV	B-SPEC
+)-	O
+specific	O
+antibody	B-ANAT
+secreting	B-PROC
+cells	B-COMP
+(	O
+ASC	O
+)	O
+in	O
+gut	B-ANAT
+associated	O
+lymphoid	B-ANAT
+tissues	I-ANAT
+(	O
+duodenum	B-ANAT
+and	O
+ileum	B-ANAT
+lamina	B-ANAT
+propria	I-ANAT
+and	O
+mesenteric	B-ANAT
+lymph	I-ANAT
+nodes	I-ANAT
+)	O
+and	O
+systemic	O
+locations	O
+(	O
+spleen	B-ANAT
+and	O
+blood	B-ANAT
+)	O
+of	O
+conventional	O
+pigs	B-SPEC
+so	O
+as	O
+to	O
+characterise	O
+the	O
+mucosal	B-ANAT
+and	O
+systemic	O
+antibody	B-PROC
+response	I-PROC
+generated	O
+by	O
+the	O
+infection	B-DISO
+with	O
+PEDV	B-SPEC
+.	O
+
+Immediately	O
+before	O
+inoculation	O
+(	O
+day	O
+0	O
+)	O
+and	O
+3	O
+days	O
+later	O
+(	O
+day	O
+3	O
+),	O
+ciliated	B-ANAT
+epithelium	I-ANAT
+was	O
+obtained	O
+by	O
+brushing	O
+the	O
+inferior	B-ANAT
+nasal	I-ANAT
+turbinate	I-ANAT
+.	O
+
+Around	O
+a	O
+quarter	O
+of	O
+lung	B-ANAT
+cells	B-COMP
+showing	O
+replication	O
+of	O
+the	O
+helper	O
+virus	B-SPEC
+were	O
+also	O
+positive	O
+for	O
+the	O
+reporter	O
+gene	O
+.	O
+
+The	O
+large	O
+cloning	O
+capacity	O
+and	O
+the	O
+tissue	B-PROC
+specificity	I-PROC
+of	O
+the	O
+TGEV	B-SPEC
+-	O
+derived	O
+minigenomes	O
+suggest	O
+that	O
+these	O
+virus	B-SPEC
+vectors	O
+are	O
+very	O
+promising	O
+for	O
+vaccine	O
+development	B-PROC
+.	O
+
+TITLE	O
+:	O
+Conservation	O
+of	O
+substrate	O
+specificities	O
+among	O
+coronavirus	B-SPEC
+main	O
+proteases	O
+.	O
+
+Recombinant	O
+main	O
+proteases	O
+of	O
+human	B-PRGE
+coronavirus	I-PRGE
+(	O
+HCoV	O
+),	O
+transmissible	O
+gastroenteritis	B-DISO
+virus	B-SPEC
+(	O
+TGEV	B-SPEC
+),	O
+feline	B-DISO
+infectious	I-DISO
+peritonitis	I-DISO
+virus	B-SPEC
+,	O
+avian	B-DISO
+infectious	I-DISO
+bronchitis	I-DISO
+virus	B-SPEC
+and	O
+mouse	B-DISO
+hepatitis	I-DISO
+virus	B-SPEC
+(	O
+MHV	B-SPEC
+)	O
+were	O
+tested	O
+in	O
+peptide	B-CHED
+-	O
+based	O
+trans	O
+-	O
+cleavage	B-PROC
+assays	O
+.	O
+
+Two	O
+trials	O
+were	O
+conducted	O
+with	O
+two	O
+separate	O
+hatches	O
+of	O
+turkey	B-SPEC
+poults	O
+.	O
+
+Body	B-ANAT
+weight	O
+gain	O
+of	O
+turkeys	B-SPEC
+treated	O
+with	O
+CY	O
+was	O
+significantly	O
+lower	O
+(	O
+p	O
+<	O
+0	O
+.	O
+05	O
+)	O
+than	O
+that	O
+of	O
+untreated	O
+turkeys	B-SPEC
+at	O
+9	O
+days	O
+post	O
+-	O
+infection	B-DISO
+(	O
+PI	O
+).	O
+
+Turkeys	B-SPEC
+treated	O
+with	O
+CY	O
+had	O
+1	O
+-	O
+2	O
+fold	O
+higher	O
+immunofluorescent	O
+antibody	B-COMP
+assay	O
+(	O
+IFA	O
+)	O
+scores	O
+for	O
+TCV	B-SPEC
+antigens	B-CHED
+(	O
+p	O
+<	O
+0	O
+.	O
+05	O
+)	O
+in	O
+the	O
+intestine	B-ANAT
+than	O
+untreated	O
+turkeys	B-SPEC
+at	O
+9	O
+or	O
+14	O
+days	O
+PI	O
+.	O
+
+The	O
+pathobiology	O
+of	O
+acute	O
+lung	B-ANAT
+injury	O
+(	O
+ALI	O
+)	O
+includes	O
+formidable	O
+hurdles	O
+to	O
+gene	O
+transfer	O
+,	O
+including	O
+alveoli	B-ANAT
+filled	O
+with	O
+fluid	O
+,	O
+inflammatory	B-ANAT
+cells	I-ANAT
+,	O
+and	O
+cytokines	O
+,	O
+all	O
+of	O
+which	O
+may	O
+impair	O
+gene	O
+transfer	O
+after	O
+the	O
+onset	O
+of	O
+injury	O
+.	O
+
+We	O
+tested	O
+the	O
+hypothesis	O
+that	O
+adenovectors	O
+could	O
+efficiently	O
+transduce	O
+injured	O
+alveoli	B-ANAT
+by	O
+exposing	O
+adult	O
+,	O
+male	O
+Sprague	B-SPEC
+-	I-SPEC
+Dawley	I-SPEC
+rats	I-SPEC
+to	O
+100	O
+%	O
+oxygen	B-CHED
+for	O
+48	O
+or	O
+60	O
+h	O
+before	O
+endotracheal	O
+instillation	O
+of	O
+either	O
+1	O
+x	O
+10	O
+(	O
+9	O
+)	O
+or	O
+4	O
+x	O
+10	O
+(	O
+9	O
+)	O
+plaque	B-DISO
+-	O
+forming	O
+units	O
+of	O
+an	O
+adenovirus	B-DISO
+that	O
+expresses	O
+an	O
+Escherichia	B-SPEC
+coli	I-SPEC
+lac	B-CHED
+Z	B-PRGE
+gene	I-PRGE
+(	O
+adbeta	B-PRGE
+-	I-PRGE
+gal	I-PRGE
+)	O
+in	O
+a	O
+surfactant	B-CHED
+-	O
+based	O
+vehicle	O
+(	O
+Survanta	O
+).	O
+
+Net	O
+transgene	O
+expression	B-PROC
+in	O
+hyperoxic	O
+lungs	B-ANAT
+was	O
+not	O
+different	O
+from	O
+room	O
+air	B-CHED
+controls	O
+despite	O
+the	O
+presence	O
+of	O
+pulmonary	B-DISO
+edema	I-DISO
+and	O
+severe	O
+histologic	O
+injury	O
+.	O
+
+These	O
+findings	O
+show	O
+that	O
+adenovectors	O
+can	O
+efficiently	O
+transduce	O
+the	O
+alveoli	B-ANAT
+of	O
+acutely	O
+injured	O
+,	O
+edematous	B-DISO
+lungs	B-ANAT
+.	O
+
+TITLE	O
+:	O
+Virus	B-SPEC
+-	O
+induced	O
+asthma	B-DISO
+attacks	I-DISO
+.	O
+
+Changes	O
+in	O
+the	O
+neural	B-PROC
+control	I-PROC
+of	O
+the	O
+airways	O
+contribute	O
+to	O
+bronchoconstriction	B-PROC
+,	O
+which	O
+is	O
+reflected	O
+in	O
+an	O
+increased	O
+efficacy	O
+of	O
+anticholinergic	O
+medications	O
+during	O
+acute	O
+asthma	B-DISO
+attacks	I-DISO
+.	O
+
+The	O
+AHR	O
+(-/-)	O
+mice	B-SPEC
+were	O
+refractory	O
+to	O
+CYP1A1	B-PRGE
+induction	O
+by	O
+hyperoxia	B-DISO
+and	O
+were	O
+more	O
+sensitive	O
+to	O
+lung	B-ANAT
+injury	O
+than	O
+wild	O
+-	O
+type	O
+mice	B-SPEC
+.	O
+
+ABSTRACT	O
+:	O
+We	O
+previously	O
+showed	O
+that	O
+an	O
+intraperitoneal	O
+infection	O
+with	O
+mouse	B-DISO
+hepatitis	I-DISO
+virus	B-SPEC
+(	O
+MHV	B-SPEC
+)	O
+persists	O
+in	O
+interferon	B-FUNC
+-	I-FUNC
+gamma	I-FUNC
+(	O
+IFN	B-PRGE
+-	I-PRGE
+gamma	I-PRGE
+)-	O
+deficient	O
+C57BL	O
+/	O
+6	O
+(	O
+B6	O
+-	O
+GKO	O
+)	O
+mice	B-SPEC
+and	O
+results	O
+in	O
+subacute	O
+fatal	O
+peritonitis	B-DISO
+,	O
+which	O
+bears	B-SPEC
+a	O
+resemblance	O
+to	O
+feline	B-DISO
+infectious	I-DISO
+peritonitis	I-DISO
+.	O
+
+ABSTRACT	O
+:	O
+Human	B-SPEC
+coronaviruses	O
+,	O
+with	O
+two	O
+known	O
+serogroups	O
+named	O
+229	O
+-	O
+E	O
+and	O
+OC	O
+-	O
+43	O
+,	O
+are	O
+enveloped	O
+positive	O
+-	O
+stranded	O
+RNA	O
+viruses	O
+.	O
+
+The	O
+envelop	O
+contains	O
+2	O
+or	O
+3	O
+glycoproteins	B-CHED
+:	O
+spike	O
+protein	B-CHED
+(	O
+or	O
+protein	B-PRGE
+S	I-PRGE
+),	I-PRGE
+matrix	I-PRGE
+protein	B-CHED
+(	I-PRGE
+or	I-PRGE
+protein	B-CHED
+M	I-PRGE
+)	O
+and	O
+a	O
+hemagglutinin	O
+(	O
+or	O
+protein	B-CHED
+HE	O
+).	O
+
+Human	B-SPEC
+coronaviruses	O
+can	O
+survive	O
+for	O
+as	O
+long	O
+as	O
+6	O
+days	O
+in	O
+suspension	O
+and	O
+3	O
+hours	O
+after	O
+drying	O
+on	O
+surfaces	O
+,	O
+suggesting	O
+that	O
+they	O
+could	O
+be	O
+a	O
+source	O
+of	O
+hospital	O
+-	O
+acquired	O
+infections	B-DISO
+.	O
+
+A	O
+strong	O
+positive	O
+correlation	O
+was	O
+established	O
+between	O
+protection	O
+and	O
+the	O
+ASC	O
+responses	O
+detected	O
+in	O
+gut	B-ANAT
+associated	O
+lymphoid	B-ANAT
+tissues	I-ANAT
+and	O
+blood	B-ANAT
+at	O
+the	O
+challenge	O
+day	O
+and	O
+also	O
+between	O
+protection	O
+and	O
+serum	B-PRGE
+isotype	I-PRGE
+-	I-PRGE
+specific	I-PRGE
+antibody	B-COMP
+titers	O
+on	O
+that	O
+day	O
+.	O
+
+No	O
+increase	O
+was	O
+seen	O
+in	O
+any	O
+of	O
+the	O
+parameters	O
+studied	O
+in	O
+the	O
+pigs	B-SPEC
+inoculated	O
+with	O
+virulent	O
+PEDV	B-SPEC
+.	O
+
+TITLE	O
+:	O
+Antibody	B-FUNC
+responses	I-PROC
+and	O
+morbidity	O
+following	O
+infection	B-DISO
+with	O
+infectious	B-DISO
+bronchitis	B-DISO
+virus	B-SPEC
+and	O
+challenge	O
+with	O
+Escherichia	O
+coli	O
+,	O
+in	O
+lines	O
+divergently	O
+selected	O
+on	O
+antibody	B-PROC
+response	I-PROC
+.	O
+
+This	O
+review	O
+updates	O
+the	O
+indications	O
+for	O
+IPPV	O
+in	O
+adult	O
+patients	O
+with	O
+acute	B-DISO
+respiratory	I-DISO
+failure	I-DISO
+by	O
+examining	O
+available	O
+evidence	O
+from	O
+clinical	O
+trials	O
+and	O
+by	O
+considering	O
+new	O
+management	O
+alternatives	O
+that	O
+have	O
+become	O
+available	O
+in	O
+the	O
+last	O
+20	O
+years	O
+.	O
+
+Compelling	O
+face	B-DISO
+validity	O
+justifies	O
+the	O
+use	O
+of	O
+IPPV	O
+in	O
+cases	O
+of	O
+apnea	B-DISO
+or	O
+when	O
+it	O
+appears	O
+certain	O
+that	O
+respiratory	B-DISO
+arrest	I-DISO
+is	O
+about	O
+to	O
+occur	O
+.	O
+
+However	O
+,	O
+dyspnea	B-DISO
+,	O
+tachypnea	B-DISO
+,	O
+or	O
+the	O
+subjective	O
+impression	O
+of	O
+respiratory	B-DISO
+distress	I-DISO
+are	O
+probably	O
+not	O
+in	O
+themselves	O
+justification	O
+for	O
+emergency	B-DISO
+intubation	O
+.	O
+
+In	O
+acute	O
+exacerbations	O
+of	O
+chronic	B-DISO
+obstructive	I-DISO
+pulmonary	I-DISO
+disease	I-DISO
+,	O
+noninvasive	O
+positive	O
+-	O
+pressure	O
+ventilation	O
+(	O
+NPPV	O
+)	O
+should	O
+be	O
+the	O
+initial	O
+ventilation	O
+approach	O
+unless	O
+the	O
+patient	O
+has	O
+one	O
+of	O
+several	O
+specific	O
+exclusion	O
+criteria	O
+such	O
+as	O
+cardiovascular	B-ANAT
+instability	O
+or	O
+severely	O
+impaired	B-DISO
+mental	O
+status	O
+.	O
+
+Antibody	B-COMP
+titer	O
+to	O
+IBV	B-SPEC
+,	O
+delayed	B-DISO
+-	I-DISO
+type	I-DISO
+hypersensitivity	I-DISO
+(	O
+DTH	B-DISO
+)	O
+response	O
+against	O
+bovine	B-PRGE
+serum	B-COMP
+albumin	I-PRGE
+(	O
+BSA	O
+),	O
+the	O
+absolute	O
+number	O
+and	O
+percentage	O
+of	O
+leukocyte	B-ANAT
+subpopulations	O
+,	O
+and	O
+interferon	B-FUNC
+-	I-FUNC
+gamma	I-FUNC
+(	O
+IFN	B-PRGE
+-	I-PRGE
+gamma	I-PRGE
+)-	O
+like	O
+cytokine	B-PROC
+production	I-PROC
+by	O
+splenocytes	O
+were	O
+evaluated	O
+at	O
+5	O
+-	O
+6	O
+weeks	O
+of	O
+age	O
+.	O
+
+These	O
+changes	O
+were	O
+similar	O
+to	O
+those	O
+previously	O
+reported	O
+in	O
+chickens	B-SPEC
+not	O
+exposed	O
+to	O
+IBV	B-SPEC
+.	O
+
+These	O
+results	O
+suggest	O
+that	O
+low	O
+-	O
+level	O
+exposure	O
+to	O
+lead	O
+has	O
+a	O
+direct	O
+effect	O
+on	O
+the	O
+developing	O
+chicken	B-SPEC
+immune	B-ANAT
+system	I-ANAT
+,	O
+which	O
+is	O
+evident	O
+even	O
+during	O
+a	O
+postnatal	B-DISO
+infection	I-DISO
+.	O
+
+Cats	B-SPEC
+with	O
+positive	O
+lymph	B-ANAT
+nodes	I-ANAT
+had	O
+the	O
+most	O
+evident	O
+changes	O
+in	O
+the	O
+protein	B-CHED
+estimations	O
+.	O
+
+However	O
+,	O
+the	O
+precise	O
+and	O
+relative	O
+roles	O
+of	O
+the	O
+two	O
+proteins	B-CHED
+in	O
+BCV	B-SPEC
+infectivity	O
+remain	O
+elusive	O
+.	O
+
+After	O
+instillation	O
+,	O
+rats	B-SPEC
+were	O
+exposed	O
+to	O
+oxygen	B-CHED
+alone	O
+(	O
+FIO	O
+(	O
+2	O
+)	O
+100	O
+%)	O
+or	O
+to	O
+oxygen	B-CHED
+(	O
+FIO	O
+(	O
+2	O
+)	O
+approximately	O
+100	O
+%)	O
+plus	O
+nitric	B-CHED
+oxide	I-CHED
+(	O
+10	O
+ppm	O
+)	O
+during	O
+24	O
+hrs	B-DISO
+.	O
+
+It	O
+is	O
+manifested	O
+most	O
+frequently	O
+within	O
+first	O
+four	O
+hours	O
+after	O
+transfusion	O
+of	O
+allogenous	O
+haemoproduct	O
+containing	O
+anti	O
+leukocyte	B-ANAT
+antibodies	B-COMP
+.	O
+
+This	O
+rare	O
+,	O
+but	O
+severe	O
+transfusion	B-DISO
+reaction	I-DISO
+with	O
+mortality	O
+rate	O
+of	O
+around	O
+10	O
+%	O
+is	O
+often	O
+misdiagnosed	O
+,	O
+since	O
+TRALI	B-DISO
+signs	O
+are	O
+assigned	O
+to	O
+other	O
+clinical	O
+conditions	O
+.	O
+
+TITLE	O
+:	O
+Vascular	B-ANAT
+immunotargeting	O
+of	O
+glucose	B-ENZY
+oxidase	B-PRGE
+to	O
+the	O
+endothelial	B-ANAT
+antigens	B-CHED
+induces	O
+distinct	O
+forms	O
+of	O
+oxidant	O
+acute	O
+lung	B-ANAT
+injury	O
+:	O
+targeting	B-PROC
+to	O
+thrombomodulin	B-PRGE
+,	O
+but	O
+not	O
+to	O
+PECAM	B-PRGE
+-	I-PRGE
+1	I-PRGE
+,	O
+causes	O
+pulmonary	B-DISO
+thrombosis	I-DISO
+and	O
+neutrophil	B-ANAT
+transmigration	O
+.	O
+
+Moreover	O
+,	O
+anti	O
+-	O
+TM	O
+/	O
+GOX	B-PRGE
+-	O
+induced	O
+injury	O
+was	O
+accompanied	O
+by	O
+PMN	B-PROC
+transmigration	O
+in	O
+the	O
+alveolar	B-ANAT
+space	O
+,	O
+whereas	O
+anti	B-PRGE
+-	I-PRGE
+PECAM	I-PRGE
+/	O
+GOX	B-PRGE
+-	O
+induced	O
+injury	O
+was	O
+accompanied	O
+by	O
+PMN	B-PROC
+degranulation	O
+within	O
+vascular	B-ANAT
+lumen	B-ANAT
+without	O
+PMN	B-PROC
+transmigration	O
+,	O
+likely	O
+because	O
+of	O
+PECAM	O
+blockage	O
+.	O
+
+Anti	B-PRGE
+-	I-PRGE
+TM	I-PRGE
+/	I-PRGE
+GOX	I-PRGE
+caused	O
+markedly	O
+more	O
+severe	O
+pulmonary	B-DISO
+thrombosis	I-DISO
+than	O
+anti	B-PRGE
+-	I-PRGE
+PECAM	I-PRGE
+/	I-PRGE
+GOX	I-PRGE
+,	O
+likely	O
+because	O
+of	O
+TM	O
+inhibition	B-PROC
+.	O
+
+In	O
+the	O
+present	O
+study	O
+,	O
+we	O
+analyzed	O
+the	O
+nucleotide	B-CHED
+and	O
+amino	B-CHED
+acid	I-CHED
+sequence	O
+of	O
+the	O
+S1	O
+subunit	O
+of	O
+the	O
+S	B-PRGE
+glycoprotein	I-PRGE
+,	O
+including	O
+the	O
+cleavage	B-PROC
+site	O
+,	O
+of	O
+both	O
+respiratory	O
+(	O
+n	O
+=	O
+5	O
+)	O
+and	O
+enteric	O
+(	O
+n	O
+=	O
+3	O
+)	O
+BoCV	O
+isolates	O
+including	O
+two	O
+paired	O
+isolates	O
+from	O
+the	O
+same	O
+feedlot	O
+animals	B-SPEC
+and	O
+compared	O
+them	O
+with	O
+the	O
+prototype	O
+Mebus	O
+and	O
+two	O
+enteric	O
+and	O
+one	O
+respiratory	O
+BoCV	O
+strains	O
+from	O
+Quebec	O
+.	O
+
+Seven	O
+hundred	O
+and	O
+twenty	O
+patients	O
+were	O
+selected	O
+on	O
+the	O
+basis	O
+of	O
+seasonal	O
+or	O
+perennial	B-DISO
+rhinitis	I-DISO
+,	O
+or	O
+asthma	B-PATH
+,	O
+or	O
+both	O
+.	O
+
+TITLE	O
+:	O
+IFN	B-PRGE
+-	I-PRGE
+gamma	I-PRGE
+-	I-PRGE
+inducible	I-PRGE
+protein	I-PRGE
+10	I-PRGE
+(	O
+IP	B-PRGE
+-	I-PRGE
+10	I-PRGE
+;	O
+CXCL10	B-PRGE
+)-	O
+deficient	O
+mice	B-SPEC
+reveal	O
+a	O
+role	O
+for	O
+IP	O
+-	O
+10	O
+in	O
+effector	B-CHED
+T	B-ANAT
+cell	I-ANAT
+generation	O
+and	O
+trafficking	B-PROC
+.	O
+
+ABSTRACT	O
+:	O
+IFN	B-PRGE
+-	I-PRGE
+gamma	I-PRGE
+-	I-PRGE
+inducible	I-PRGE
+protein	I-PRGE
+10	I-PRGE
+(	O
+IP	B-PRGE
+-	I-PRGE
+10	I-PRGE
+,	O
+CXCL10	B-PRGE
+),	O
+a	O
+chemokine	O
+secreted	B-PROC
+from	O
+cells	B-COMP
+stimulated	O
+with	O
+type	O
+I	O
+and	O
+II	O
+IFNs	O
+and	O
+LPS	B-DISO
+,	O
+is	O
+a	O
+chemoattractant	O
+for	O
+activated	O
+T	B-ANAT
+cells	I-ANAT
+.	O
+
+To	O
+determine	O
+the	O
+in	O
+vivo	O
+function	O
+of	O
+IP	O
+-	O
+10	O
+,	O
+we	O
+constructed	O
+an	O
+IP	O
+-	O
+10	O
+-	O
+deficient	O
+mouse	B-SPEC
+(	O
+IP	O
+-	O
+10	O
+(-/-))	O
+by	O
+targeted	B-PROC
+gene	O
+disruption	O
+.	O
+
+T	B-PROC
+cell	I-PROC
+proliferation	B-DISO
+to	O
+allogeneic	O
+and	O
+antigenic	O
+stimulation	O
+and	O
+IFN	B-PROC
+-	I-PROC
+gamma	I-PROC
+secretion	B-ANAT
+in	O
+response	O
+to	O
+antigenic	O
+challenge	O
+were	O
+impaired	B-DISO
+in	O
+IP	O
+-	O
+10	O
+(-/-)	O
+mice	B-SPEC
+.	O
+
+Causative	O
+conditions	O
+of	O
+HTG	O
+-	O
+induced	O
+AP	O
+were	O
+familial	O
+HTG	O
+in	O
+eight	O
+patients	O
+,	O
+HTG	O
+caused	O
+by	O
+uncontrolled	O
+diabetes	B-DISO
+mellitus	I-DISO
+in	O
+five	O
+,	O
+HTG	O
+aggravated	O
+by	O
+drugs	O
+in	O
+two	O
+(	O
+one	O
+by	O
+tamoxifen	B-CHED
+and	O
+one	O
+by	O
+fluvastatin	B-CHED
+),	O
+familial	B-DISO
+hyperchylomicronemia	I-DISO
+(	O
+HCM	O
+)	O
+in	O
+one	O
+,	O
+and	O
+lipemia	O
+of	O
+pregnancy	O
+in	O
+one	O
+.	O
+
+ABSTRACT	O
+:	O
+Oligomeric	O
+spike	O
+(	O
+S	O
+)	O
+glycoproteins	B-CHED
+extend	O
+from	O
+coronavirus	B-SPEC
+membranes	B-ANAT
+.	O
+
+Once	O
+on	O
+the	O
+surface	O
+of	O
+infected	O
+cells	B-COMP
+and	O
+virions	B-COMP
+,	O
+peripheral	O
+S1	O
+fragments	O
+bind	B-FUNC
+carcinoembryonic	O
+antigen	B-CHED
+-	O
+related	O
+cell	B-PROC
+adhesion	B-DISO
+molecule	O
+(	O
+CEACAM	O
+)	O
+receptors	O
+,	O
+and	O
+this	O
+triggers	O
+membrane	B-PROC
+fusion	I-PROC
+reactions	O
+mediated	O
+by	O
+integral	O
+membrane	B-COMP
+S2	O
+fragments	O
+.	O
+
+TITLE	O
+:	O
+Pharmacodynamics	O
+and	O
+pharmacokinetics	B-PROC
+of	O
+inhaled	B-PROC
+nitric	B-CHED
+oxide	I-CHED
+in	O
+dogs	B-SPEC
+with	O
+septic	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+.	O
+
+7	O
+%,	O
+and	O
+pulmonary	B-PROC
+vascular	B-ANAT
+resistance	I-PROC
+index	O
+(	O
+PVRI	O
+)	O
+from	O
+(	O
+16	O
++/-	O
+
+m	O
+-	O
+2	O
+(	O
+all	O
+P	O
+<	O
+0	O
+.	O
+05	O
+),	O
+along	O
+with	O
+severe	O
+intrapulmonary	O
+neutrophil	B-PROC
+recruitment	B-DISO
+and	O
+peripheral	O
+neutropenia	O
+.	O
+
+The	O
+animals	B-SPEC
+were	O
+then	O
+treated	O
+as	O
+either	O
+a	O
+control	O
+or	O
+an	O
+NO	O
+group	O
+(	O
+n	O
+=	O
+6	O
+each	O
+,	O
+iNO	B-PRGE
+0	I-PRGE
+.	I-PRGE
+4	I-PRGE
+-	I-PRGE
+3	I-PRGE
+.	I-PRGE
+2	I-PRGE
+micromol	I-PRGE
+/	I-PRGE
+L	I-PRGE
+)	O
+for	O
+another	O
+10	O
+h	O
+.	O
+More	O
+survival	O
+was	O
+found	O
+in	O
+NO	O
+group	O
+(	O
+4	O
+/	O
+6	O
+vs	O
+0	O
+/	O
+6	O
+,	O
+P	O
+<	O
+0	O
+.	O
+05	O
+).	O
+
+CONCLUSIONS	O
+:	O
+Pharmacodynamics	O
+of	O
+iNO	O
+in	O
+this	O
+model	O
+was	O
+related	O
+to	O
+improvement	O
+in	O
+gas	B-ENZY
+exchange	O
+,	O
+Cdyn	O
+,	O
+PVRI	O
+,	O
+and	O
+suppression	B-DISO
+of	O
+proinflammatory	O
+cytokine	O
+expression	B-PROC
+in	O
+the	O
+lungs	B-ANAT
+,	O
+and	O
+its	O
+adverse	B-DISO
+effect	I-DISO
+was	O
+mainly	O
+confined	O
+to	O
+MetHb	O
+at	O
+higher	O
+NO	O
+dose	O
+.	O
+
+ABSTRACT	O
+:	O
+Pressure	O
+-	O
+controlled	O
+inverse	O
+ratio	O
+ventilation	O
+(	O
+PC	O
+-	O
+IRV	B-PROC
+)	O
+was	O
+used	O
+in	O
+patients	O
+with	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+(	O
+ARDS	B-DISO
+)	O
+after	O
+failed	O
+volume	O
+-	O
+cycled	O
+conventional	O
+ratio	O
+ventilation	O
+(	O
+VC	O
+-	O
+CRV	B-DISO
+).	O
+
+RESULTS	O
+:	O
+The	O
+values	O
+of	O
+PIP	B-CHED
+,	O
+mean	O
+airway	B-ANAT
+pressure	O
+,	O
+minute	O
+volumes	O
+,	O
+and	O
+lung	B-ANAT
+injury	O
+score	O
+in	O
+VC	O
+-	O
+CRV	B-DISO
+were	O
+43	O
+.	O
+9	O
++/-	O
+
+Confusion	B-DISO
+as	O
+to	O
+when	O
+and	O
+how	O
+to	O
+use	O
+molecular	O
+methods	O
+abounds	O
+.	O
+
+Specific	O
+combinations	O
+of	O
+viral	O
+strains	O
+and	O
+murine	B-SPEC
+hosts	B-COMP
+may	O
+favor	O
+viral	B-DISO
+infection	I-DISO
+and	O
+disease	O
+,	O
+and	O
+could	O
+potentially	O
+allow	O
+the	O
+unexpected	O
+development	B-PROC
+of	O
+chronic	O
+,	O
+persistent	O
+,	O
+or	O
+latent	O
+infections	B-DISO
+.	O
+
+Transmission	O
+occurred	O
+via	O
+direct	O
+contact	O
+with	O
+seropositive	O
+mice	B-SPEC
+and	O
+exposure	O
+to	O
+contaminated	O
+bedding	O
+.	O
+
+Our	O
+observation	O
+,	O
+together	O
+with	O
+the	O
+constantly	O
+expanding	O
+varieties	O
+of	O
+immune	O
+-	O
+impaired	O
+or	O
+poorly	O
+characterized	O
+murine	B-SPEC
+hosts	B-COMP
+and	O
+the	O
+burgeoning	O
+dissemination	O
+of	O
+these	O
+animals	B-SPEC
+throughout	O
+the	O
+biomedical	O
+research	O
+community	O
+,	O
+indicate	O
+that	O
+unexpected	O
+pathophysiologic	O
+presentations	O
+of	O
+common	O
+murine	B-SPEC
+viral	B-DISO
+diseases	I-DISO
+may	O
+present	O
+new	O
+challenges	O
+to	O
+the	O
+biomedical	O
+research	O
+community	O
+in	O
+the	O
+future	O
+.	O
+
+Liver	B-ANAT
+Dialysis	B-SPEC
+is	O
+used	O
+in	O
+treatment	O
+of	O
+acute	O
+hepatic	B-DISO
+encephalopathy	I-DISO
+(	O
+AHE	B-CHED
+)	O
+because	O
+of	O
+decompensation	O
+of	O
+chronic	B-DISO
+liver	I-DISO
+disease	I-DISO
+(	O
+A	O
+-	O
+on	O
+-	O
+C	O
+)	O
+or	O
+fulminant	B-DISO
+hepatic	I-DISO
+failure	I-DISO
+(	O
+FHF	B-DISO
+).	O
+
+Controlled	O
+,	O
+prospective	O
+and	O
+randomized	O
+studies	O
+of	O
+daily	O
+6	O
+-	O
+hour	O
+Liver	B-ANAT
+Dialysis	B-SPEC
+have	O
+shown	O
+physiologic	O
+and	O
+neurologic	O
+improvement	O
+of	O
+patients	O
+with	O
+AHE	B-CHED
+,	O
+regardless	O
+of	O
+etiology	O
+.	O
+
+In	O
+particular	O
+,	O
+we	O
+investigated	O
+the	O
+effects	O
+of	O
+sPLA	B-PRGE
+(	I-PRGE
+2	I-PRGE
+)	I-PRGE
+inhibitors	B-CHED
+,	O
+specifically	O
+,	O
+the	O
+extracellular	B-COMP
+PLA	B-CHED
+(	O
+2	O
+)	O
+inhibitors	B-CHED
+(	O
+ExPLIs	O
+),	O
+composed	O
+of	O
+N	O
+-	O
+derivatized	O
+phosphatidyl	B-CHED
+-	O
+ethanolamine	B-CHED
+linked	O
+to	O
+polymeric	O
+carriers	O
+,	O
+and	O
+LY311727	O
+,	O
+a	O
+specific	O
+inhibitor	B-CHED
+of	O
+non	O
+-	O
+pancreatic	B-ANAT
+sPLA	O
+(	O
+2	O
+).	O
+
+TITLE	O
+:	O
+Murine	B-SPEC
+hepatitis	I-DISO
+virus	B-SPEC
+--	O
+a	O
+model	O
+for	O
+virus	B-SPEC
+-	O
+induced	O
+CNS	B-CHED
+demyelination	B-DISO
+.	O
+
+The	O
+CNS	B-CHED
+demyelination	B-DISO
+shares	O
+pathological	O
+similarities	O
+with	O
+human	B-SPEC
+CNS	B-CHED
+demyelinating	B-DISO
+diseases	I-DISO
+such	O
+as	O
+multiple	B-DISO
+sclerosis	I-DISO
+(	O
+MS	O
+).	O
+
+No	O
+cleavage	B-PROC
+could	O
+be	O
+detected	O
+using	O
+substrate	O
+that	O
+carried	O
+both	O
+the	O
+p65	B-PRGE
+site	I-PRGE
+and	O
+the	O
+predicted	O
+p72	B-PRGE
+cleavage	B-PROC
+sequence	O
+.	O
+
+ABSTRACT	O
+:	O
+Central	O
+hypoventilation	O
+syndrome	O
+is	O
+defined	O
+as	O
+the	O
+failure	O
+of	O
+automatic	O
+control	O
+of	O
+breathing	B-PROC
+.	O
+
+Ischemia	B-DISO
+of	O
+central	O
+chemoreceptors	B-ANAT
+or	O
+integration	B-PROC
+of	O
+their	O
+informations	O
+could	O
+be	O
+one	O
+of	O
+mechanism	O
+.	O
+
+The	O
+blocking	B-DISO
+ELISA	O
+was	O
+determined	O
+to	O
+be	O
+useful	O
+for	O
+herd	O
+monitoring	O
+programs	O
+and	O
+could	O
+be	O
+used	O
+alone	O
+without	O
+parallel	O
+use	O
+of	O
+the	O
+VN	O
+assay	O
+for	O
+the	O
+assessment	O
+of	O
+large	O
+swine	B-SPEC
+populations	O
+for	O
+the	O
+detection	O
+of	O
+TGEV	B-SPEC
+-	O
+infected	O
+herds	O
+.	O
+
+Histologically	O
+,	O
+Smith	O
+lung	B-ANAT
+injury	O
+score	O
+was	O
+4	O
+.	O
+40	O
++/-	O
+
+SI	O
+with	O
+5P	O
+(	O
+m	O
+)	O
+resulted	O
+in	O
+immediate	O
+significant	O
+increase	O
+in	O
+lung	B-PROC
+volume	I-PROC
+[(	O
+44	O
+.	O
+0	O
++/-	O
+
+With	O
+the	O
+increasing	O
+of	O
+SI	O
+pressure	O
+,	O
+mean	O
+arterial	B-PROC
+pressure	I-PROC
+decreased	O
+markedly	O
+.	O
+
+TITLE	O
+:	O
+Allogeneic	O
+bone	B-ANAT
+marrow	I-ANAT
+transplantation	O
+for	O
+active	O
+Epstein	B-SPEC
+-	I-SPEC
+Barr	I-SPEC
+virus	I-SPEC
+-	O
+related	O
+lymphoproliferative	B-DISO
+disease	I-DISO
+and	O
+hemophagocytic	B-DISO
+lymphohistiocytosis	I-DISO
+in	O
+an	O
+infant	O
+with	O
+severe	B-DISO
+combined	I-DISO
+immunodeficiency	I-DISO
+syndrome	I-DISO
+.	O
+
+Engraftment	B-PROC
+occurred	O
+on	O
+day	O
+6	O
+with	O
+explosive	B-CHED
+proliferation	B-DISO
+of	O
+donor	B-CHED
+CD8	O
+(+)	O
+T	B-ANAT
+cells	I-ANAT
+.	O
+
+Of	O
+5	O
+patients	O
+who	O
+received	O
+multiple	O
+transfusions	O
+from	O
+the	O
+same	O
+donor	B-CHED
+,	O
+2	O
+experienced	O
+2	O
+reactions	O
+:	O
+one	O
+had	O
+2	O
+mild	O
+/	O
+moderate	O
+reactions	O
+and	O
+the	O
+other	O
+had	O
+both	O
+a	O
+mild	O
+/	O
+moderate	O
+and	O
+a	O
+severe	O
+reaction	O
+.	O
+
+TRALI	B-DISO
+was	O
+frequently	O
+underdiagnosed	O
+and	O
+underreported	O
+in	O
+recipients	O
+of	O
+blood	B-ANAT
+products	O
+from	O
+a	O
+donor	B-CHED
+whose	O
+blood	B-ANAT
+products	O
+may	O
+have	O
+caused	O
+TRALI	B-DISO
+in	O
+several	O
+transfusion	O
+recipients	O
+.	O
+
+RESULTS	O
+:	O
+Superimposed	O
+illness	O
+prevented	O
+assessment	O
+of	O
+TRALI	B-DISO
+in	O
+14	O
+patients	O
+.	O
+
+Only	O
+2	O
+reactions	O
+(	O
+1	O
+mild	O
+/	O
+moderate	O
+and	O
+1	O
+severe	O
+)	O
+were	O
+reported	O
+to	O
+the	O
+regional	O
+blood	B-ANAT
+collection	O
+facility	O
+.	O
+
+The	O
+carboxy	B-CHED
+terminus	O
+of	O
+MHV	B-SPEC
+M	O
+has	O
+previously	O
+been	O
+shown	O
+to	O
+be	O
+extremely	O
+sensitive	O
+to	O
+mutation	O
+,	O
+both	O
+in	O
+a	O
+virus	B-COMP
+-	I-COMP
+like	I-COMP
+particle	I-COMP
+expression	B-PROC
+system	O
+and	O
+in	O
+the	O
+intact	O
+virion	B-COMP
+.	O
+
+TITLE	O
+:	O
+Interaction	O
+of	O
+the	O
+coronavirus	B-SPEC
+nucleoprotein	O
+with	O
+nucleolar	B-ANAT
+antigens	B-CHED
+and	O
+the	O
+host	B-COMP
+cell	I-COMP
+.	O
+
+This	O
+result	O
+could	O
+not	O
+to	O
+be	O
+attributed	O
+to	O
+apoptosis	B-PATH
+.	O
+
+Morphological	O
+analysis	O
+of	O
+these	O
+cells	B-COMP
+indicated	O
+that	O
+cytokinesis	B-PROC
+was	O
+disrupted	O
+,	O
+an	O
+observation	O
+subsequently	O
+found	O
+in	O
+primary	O
+cells	B-COMP
+infected	O
+with	O
+IBV	B-SPEC
+.	O
+
+Over	O
+the	O
+18	O
+h	O
+period	O
+studied	O
+there	O
+was	O
+progressive	O
+improvement	O
+in	O
+gas	O
+exchange	O
+,	O
+pulmonary	B-ANAT
+shunt	O
+and	O
+EVLW	O
+.	O
+
+Ectoparasites	O
+of	O
+importance	O
+in	O
+this	O
+group	O
+in	O
+various	O
+parts	O
+of	O
+the	O
+world	O
+include	O
+a	O
+variety	O
+of	O
+ticks	B-SPEC
+,	O
+as	O
+well	O
+as	O
+lice	B-DISO
+,	O
+keds	O
+,	O
+Oestridae	B-SPEC
+,	O
+mange	B-DISO
+mites	O
+and	O
+fire	O
+ants	B-SPEC
+.	O
+
+We	O
+report	O
+a	O
+case	O
+of	O
+cystic	B-DISO
+fibrosis	I-DISO
+with	O
+hemolytic	B-DISO
+uremic	I-DISO
+syndrome	I-DISO
+.	O
+
+Critical	B-DISO
+illness	I-DISO
+polyneuropathy	I-DISO
+occurs	O
+usually	O
+after	O
+long	O
+stays	O
+(	O
+weeks	O
+)	O
+in	O
+intensive	O
+care	O
+units	O
+.	O
+
+TITLE	O
+:	O
+[	O
+Therapeutic	O
+impact	O
+of	O
+streptococcal	O
+and	O
+enterococcal	B-DISO
+bacteremia	I-DISO
+in	O
+hematology	O
+patients	O
+].	O
+
+During	O
+16	O
+episodes	O
+(	O
+64	O
+%),	O
+the	O
+bacteremia	B-DISO
+occurred	O
+within	O
+15	O
+days	O
+after	O
+the	O
+onset	O
+of	O
+neutropenia	O
+consecutive	O
+to	O
+antimitotic	B-CHED
+chemotherapy	O
+,	O
+and	O
+in	O
+nine	O
+episodes	O
+(	O
+36	O
+%)	O
+it	O
+has	O
+occurred	O
+after	O
+a	O
+period	O
+exceeding	O
+15	O
+days	O
+.	O
+
+Most	O
+streptococci	O
+(	O
+20	O
+/	O
+21	O
+)	O
+were	O
+oral	B-ANAT
+streptococci	O
+(	O
+ten	O
+Streptococcus	B-SPEC
+mitis	I-SPEC
+,	O
+five	O
+S	B-SPEC
+.	I-SPEC
+oralis	I-SPEC
+,	O
+two	O
+S	B-SPEC
+.	I-SPEC
+sanguis	I-SPEC
+,	O
+three	O
+S	B-SPEC
+.	I-SPEC
+pneumoniae	I-SPEC
+).	O
+
+For	O
+three	O
+strains	O
+,	O
+the	O
+MICs	O
+of	O
+amoxicillin	B-CHED
+and	O
+cefotaxime	B-CHED
+(	O
+8	O
+-	O
+16	O
+mg	O
+/	O
+L	O
+and	O
+8	O
+-	O
+32	O
+mg	O
+/	O
+L	O
+,	O
+respectively	O
+)	O
+were	O
+higher	O
+.	O
+
+Isoforms	O
+of	O
+murine	B-PRGE
+CEACAM1	I-PRGE
+serve	I-PRGE
+as	O
+receptors	O
+for	O
+mouse	B-DISO
+hepatitis	I-DISO
+virus	B-SPEC
+(	O
+MHV	B-SPEC
+),	O
+a	O
+murine	B-SPEC
+coronavirus	I-SPEC
+.	O
+
+Tympanometry	O
+was	O
+designated	O
+as	O
+abnormal	O
+with	O
+peak	O
+pressure	O
+of	O
+<	O
+or	O
+=-	O
+100	O
+daPa	B-CHED
+or	O
+>	O
+or	O
+=	O
+50	O
+daPa	B-CHED
+and	O
+/	O
+or	O
+a	O
+compliance	O
+peak	O
+of	O
+<	O
+0	O
+.	O
+2	O
+cm	O
+(	O
+3	O
+).	O
+
+Reverse	B-PRGE
+transcriptase	I-PRGE
+polymerase	O
+chain	O
+reaction	O
+was	O
+positive	O
+for	O
+a	O
+respiratory	O
+virus	B-SPEC
+in	O
+56	O
+(	O
+65	O
+%)	O
+of	O
+the	O
+86	O
+illnesses	O
+.	O
+
+Transient	O
+negative	O
+middle	B-ANAT
+ear	I-ANAT
+pressure	O
+occurred	O
+in	O
+two	O
+thirds	O
+of	O
+uncomplicated	O
+colds	B-DISO
+in	O
+healthy	O
+children	O
+.	O
+
+ABSTRACT	O
+:	O
+Reverse	B-PROC
+transcription	I-PROC
+polymerase	O
+chain	O
+reaction	O
+(	O
+RT	O
+-	O
+PCR	O
+),	O
+immunohistochemistry	O
+,	O
+and	O
+in	O
+situ	O
+hybridization	B-PROC
+were	O
+compared	O
+for	O
+the	O
+detection	O
+of	O
+porcine	B-SPEC
+epidemic	I-SPEC
+diarrhea	I-SPEC
+virus	I-SPEC
+(	O
+PEDV	B-SPEC
+).	O
+
+Antigen	B-CHED
+and	O
+nucleic	B-CHED
+acid	I-CHED
+of	O
+PEDV	B-SPEC
+were	O
+detected	O
+in	O
+15	O
+/	O
+15	O
+,	O
+13	O
+/	O
+15	O
+,	O
+and	O
+14	O
+/	O
+15	O
+of	O
+the	O
+intestinal	B-ANAT
+and	O
+fecal	B-ANAT
+samples	O
+from	O
+the	O
+PEDV	B-SPEC
+-	O
+inoculated	O
+pigs	B-SPEC
+by	O
+RT	O
+-	O
+PCR	O
+,	O
+immunohistochemistry	O
+,	O
+and	O
+in	O
+situ	O
+hybridization	B-PROC
+,	O
+respectively	O
+.	O
+
+Neither	O
+PEDV	B-PRGE
+antigen	B-CHED
+nor	O
+PEDV	B-SPEC
+nucleic	B-CHED
+acid	I-CHED
+was	O
+detected	O
+in	O
+the	O
+intestinal	B-ANAT
+and	O
+fecal	B-ANAT
+samples	O
+from	O
+mock	O
+-	O
+infected	O
+control	O
+pigs	B-SPEC
+.	O
+
+Although	O
+RT	O
+-	O
+PCR	O
+identified	O
+the	O
+presence	O
+of	O
+PEDV	B-SPEC
+more	O
+frequently	O
+than	O
+the	O
+other	O
+methods	O
+,	O
+when	O
+only	O
+formalin	B-CHED
+-	O
+fixed	B-ANAT
+tissues	B-ANAT
+are	O
+submitted	O
+,	O
+immunohistochemistry	O
+and	O
+in	O
+situ	O
+hybridization	B-PROC
+would	O
+be	O
+useful	O
+methods	O
+for	O
+the	O
+detection	O
+of	O
+PEDV	B-PRGE
+antigen	B-CHED
+and	O
+nucleic	B-CHED
+acid	I-CHED
+.	O
+
+Purified	O
+fgl2	B-PRGE
+protein	I-PRGE
+generated	O
+in	O
+a	O
+baculovirus	B-SPEC
+expression	B-PROC
+system	O
+had	O
+no	O
+measurable	O
+prothrombinase	B-PRGE
+activity	O
+,	O
+whereas	O
+the	O
+activity	O
+was	O
+restored	O
+when	O
+the	O
+purified	O
+protein	B-CHED
+was	O
+reconstituted	O
+into	O
+phosphatidyl	B-CHED
+-	I-CHED
+L	I-CHED
+-	I-CHED
+serine	I-CHED
+-	O
+containing	O
+vesicles	B-COMP
+.	O
+
+Furthermore	O
+,	O
+fgl2	B-PRGE
+prothrombinase	I-PRGE
+activity	O
+was	O
+not	O
+inhibited	O
+by	O
+antithrombin	B-PRGE
+III	I-PRGE
+,	O
+soybean	B-PRGE
+trypsin	B-ENZY
+inhibitor	B-CHED
+,	O
+4	O
+-	O
+aminobenzamidine	O
+,	O
+aprotinin	B-PRGE
+,	O
+or	O
+phenylmethylsulfonyl	B-CHED
+fluoride	I-CHED
+,	O
+whereas	O
+diisopropylfluorophosphate	B-CHED
+completely	O
+abrogated	O
+the	O
+activity	O
+.	O
+
+Electromyography	O
+revealed	O
+pronounced	O
+denervation	O
+activity	O
+and	O
+markedly	O
+slow	O
+nerve	B-ANAT
+conduction	B-PROC
+velocity	I-PROC
+(	O
+3	O
+m	O
+/	O
+s	O
+)	O
+with	O
+evidence	O
+of	O
+conduction	B-PROC
+block	O
+.	O
+
+In	O
+spite	O
+of	O
+a	O
+high	O
+rate	O
+of	O
+community	B-DISO
+-	I-DISO
+acquired	I-DISO
+infection	I-DISO
+in	O
+hospitalized	O
+children	O
+,	O
+the	O
+incidence	O
+of	O
+NVRI	O
+with	O
+common	O
+respiratory	O
+viruses	B-SPEC
+appears	O
+low	O
+in	O
+neonates	O
+,	O
+HCoV	O
+being	O
+the	O
+most	O
+important	O
+pathogen	O
+of	O
+NRVI	O
+in	O
+neonates	O
+during	O
+this	O
+study	O
+period	O
+.	O
+
+ABSTRACT	O
+:	O
+The	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+in	O
+childhood	O
+is	O
+a	O
+rare	B-DISO
+disease	I-DISO
+,	O
+but	O
+as	O
+in	O
+the	O
+past	O
+still	O
+plagued	O
+with	O
+a	O
+high	O
+mortality	O
+rate	O
+.	O
+
+We	O
+present	O
+the	O
+case	O
+of	O
+a	O
+4	O
+(	O
+3	O
+)/	O
+12	O
+year	O
+old	O
+boy	O
+,	O
+who	O
+suffered	B-DISO
+from	O
+an	O
+acute	B-DISO
+lymphatic	I-DISO
+leukaemia	I-DISO
+.	O
+
+ABSTRACT	O
+:	O
+The	O
+frequency	O
+of	O
+isolation	O
+of	O
+viridans	O
+streptococci	O
+from	O
+the	O
+blood	O
+of	O
+neutropenic	O
+patients	O
+with	O
+cancer	B-DISO
+has	O
+significantly	O
+increased	O
+over	O
+the	O
+course	O
+of	O
+the	O
+last	O
+10	O
+-	O
+15	O
+years	O
+.	O
+
+Acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+occurs	O
+most	O
+frequently	O
+in	O
+the	O
+setting	O
+of	O
+sepsis	B-DISO
+,	O
+aspiration	B-DISO
+of	O
+gastric	B-ANAT
+contents	I-ANAT
+,	O
+trauma	O
+,	O
+or	O
+multiple	O
+transfusions	O
+.	O
+
+Our	O
+data	O
+suggested	O
+that	O
+host	B-COMP
+cells	B-COMP
+,	O
+in	O
+response	O
+to	O
+MHV	B-SPEC
+replication	O
+,	O
+activated	O
+p38	B-FUNC
+MAPK	B-FUNC
+,	O
+which	O
+subsequently	O
+phosphorylated	O
+eIF4E	B-PRGE
+to	O
+efficiently	O
+translate	O
+certain	O
+host	B-COMP
+proteins	B-CHED
+,	O
+including	O
+IL	B-FUNC
+-	I-FUNC
+6	I-FUNC
+,	O
+during	O
+virus	B-SPEC
+-	O
+induced	O
+severe	O
+host	B-COMP
+protein	B-PROC
+synthesis	I-PROC
+inhibition	I-PROC
+.	O
+
+MHV	B-SPEC
+utilized	O
+this	O
+p38	B-FUNC
+MAPK	B-FUNC
+-	O
+dependent	O
+increase	O
+in	O
+eIF4E	B-PRGE
+phosphorylation	B-PROC
+to	O
+promote	O
+virus	B-SPEC
+-	O
+specific	O
+protein	B-PROC
+synthesis	I-PROC
+and	O
+subsequent	O
+progeny	O
+virus	B-SPEC
+production	O
+.	O
+
+Positive	O
+staining	O
+observed	O
+on	O
+nonpermeabilized	O
+cells	B-COMP
+indicates	O
+that	O
+the	O
+protein	B-CHED
+may	O
+get	O
+transported	O
+to	O
+the	O
+cell	B-COMP
+surface	I-COMP
+,	O
+but	O
+no	O
+secretion	B-PROC
+of	O
+the	O
+protein	B-CHED
+out	O
+of	O
+the	O
+cells	B-COMP
+was	O
+observed	O
+.	O
+
+Sequence	O
+comparison	O
+of	O
+the	O
+16	O
+-	O
+kDa	O
+protein	B-CHED
+with	O
+the	O
+equivalent	O
+products	O
+of	O
+other	O
+coronaviruses	O
+showed	O
+multiple	O
+conserved	O
+cysteine	B-CHED
+residues	O
+,	O
+and	O
+site	B-PROC
+-	I-PROC
+directed	I-PROC
+mutagenesis	I-PROC
+studies	O
+revealed	O
+that	O
+these	O
+conserved	O
+residues	O
+may	O
+contribute	O
+to	O
+dimerization	O
+of	O
+the	O
+16	O
+-	O
+kDa	O
+protein	B-CHED
+.	O
+
+ABSTRACT	O
+:	O
+Reverse	O
+transcriptase	O
+-	O
+polymerase	O
+chain	O
+reaction	O
+(	O
+RT	O
+-	O
+PCR	O
+)	O
+assays	O
+have	O
+proved	O
+useful	O
+for	O
+the	O
+detection	O
+of	O
+mouse	B-DISO
+hepatitis	I-DISO
+virus	B-SPEC
+(	O
+MHV	B-SPEC
+)	O
+and	O
+rat	B-SPEC
+coronavirus	B-SPEC
+(	O
+RCV	O
+)	O
+in	O
+acutely	O
+infected	O
+animals	B-SPEC
+and	O
+contaminated	O
+biomaterials	O
+.	O
+
+Fluorogenic	O
+nuclease	O
+RT	O
+-	O
+PCR	O
+assays	O
+combine	O
+RT	O
+-	O
+PCR	O
+with	O
+an	O
+internal	O
+fluorogenic	O
+hybridization	B-PROC
+probe	O
+,	O
+thereby	O
+eliminating	O
+post	O
+-	O
+PCR	O
+processing	O
+and	O
+potentially	O
+enhancing	O
+specificity	O
+.	O
+
+Primer	O
+and	O
+probe	O
+sequences	O
+were	O
+selected	O
+from	O
+the	O
+viral	B-COMP
+genome	I-COMP
+segment	O
+that	O
+encodes	O
+the	O
+membrane	B-COMP
+(	O
+M	O
+)	O
+protein	B-CHED
+that	O
+is	O
+highly	O
+conserved	O
+among	O
+rodent	B-SPEC
+coronaviruses	O
+.	O
+
+Use	O
+of	O
+the	O
+fluorogenic	O
+nuclease	O
+RT	O
+-	O
+PCR	O
+detected	O
+all	O
+strains	O
+of	O
+MHV	B-SPEC
+and	O
+RCV	O
+that	O
+were	O
+evaluated	O
+,	O
+but	O
+did	O
+not	O
+detect	O
+other	O
+RNA	O
+viruses	B-SPEC
+that	O
+naturally	O
+infect	O
+rodents	B-SPEC
+.	O
+
+Use	O
+of	O
+the	O
+assay	O
+detected	O
+as	O
+little	O
+as	O
+two	O
+femtograms	O
+of	O
+in	O
+vitro	O
+transcribed	O
+RNA	O
+generated	O
+from	O
+cloned	O
+amplicon	O
+,	O
+and	O
+when	O
+compared	O
+directly	O
+with	O
+mouse	O
+antibody	B-PROC
+production	I-PROC
+tests	O
+,	O
+had	O
+similar	O
+sensitivity	O
+at	O
+detecting	O
+MHV	B-SPEC
+-	O
+A59	O
+in	O
+infected	O
+cell	B-COMP
+culture	O
+lysates	O
+.	O
+
+Surgical	O
+complications	O
+are	O
+amenable	O
+to	O
+surgical	O
+treatment	O
+during	O
+ECLS	O
+and	O
+bleeding	B-DISO
+problems	I-DISO
+can	O
+be	O
+controlled	O
+.	O
+
+Because	O
+R	O
+(	O
+rs	O
+)	O
+is	O
+substantially	O
+increased	O
+,	O
+long	O
+expiratory	B-PROC
+times	O
+are	O
+required	O
+to	O
+yield	O
+complete	O
+exhalation	B-PROC
+.	O
+
+Far	O
+-	O
+reaching	B-PROC
+or	O
+even	O
+complete	O
+normalization	O
+of	O
+the	O
+PL	O
+profile	O
+,	O
+the	O
+LA	O
+fraction	O
+and	O
+its	O
+SP	B-PRGE
+-	I-PRGE
+B	I-PRGE
+and	O
+SP	B-PRGE
+-	I-PRGE
+C	I-PRGE
+(	O
+but	O
+not	O
+SP	B-PRGE
+-	I-PRGE
+A	I-PRGE
+)	O
+content	O
+as	O
+well	O
+as	O
+the	O
+fatty	B-CHED
+acid	I-CHED
+composition	O
+of	O
+the	O
+phosphatidylcholine	B-CHED
+class	B-SPEC
+was	O
+noted	O
+.	O
+
+Surface	O
+tension	B-DISO
+lowering	O
+properties	O
+(	O
+gammamin	O
+and	O
+gammaads	O
+)	O
+significantly	O
+improved	O
+,	O
+but	O
+were	O
+still	O
+not	O
+fully	O
+normalized	O
+.	O
+
+Direct	O
+laryngoscopic	O
+findings	O
+included	O
+arytenoid	B-ANAT
+edema	B-DISO
+,	O
+postcricoid	B-ANAT
+ulceration	B-DISO
+and	O
+bilateral	O
+vocal	B-DISO
+cord	I-DISO
+paralysis	I-DISO
+in	O
+adduction	O
+.	O
+
+Srr7A	O
+and	O
+srr7B	O
+S	O
+proteins	B-CHED
+showed	O
+high	O
+fusogenicity	O
+in	O
+both	O
+BHK	O
+-	O
+R1	O
+and	O
+BHK	O
+-	O
+R2	O
+cells	B-COMP
+,	O
+like	O
+the	O
+wt	O
+virus	B-SPEC
+,	O
+while	O
+srr7Aa	O
+and	O
+srr7Ba	O
+S	O
+proteins	B-CHED
+,	O
+which	O
+had	O
+mutations	O
+in	O
+S1N330	B-PRGE
+-	I-PRGE
+III	I-PRGE
+but	O
+not	O
+at	O
+amino	B-CHED
+acid	I-CHED
+1114	O
+,	O
+exhibited	O
+profoundly	O
+reduced	O
+fusion	O
+activity	O
+in	O
+these	O
+cell	B-ANAT
+lines	I-ANAT
+.	O
+
+The	O
+physiopathology	O
+of	O
+each	O
+case	O
+,	O
+the	O
+therapeutic	O
+approach	O
+and	O
+the	O
+use	O
+of	O
+leukopheresis	O
+as	O
+a	O
+therapeutic	O
+alternative	O
+in	O
+patients	O
+with	O
+hyperleukocytosis	O
+and	O
+leukostasis	B-DISO
+are	O
+discussed	O
+.	O
+
+We	O
+effectively	O
+and	O
+safely	O
+used	O
+IPP	O
+in	O
+our	O
+patients	O
+with	O
+ARDS	B-DISO
+,	O
+including	O
+many	O
+with	O
+issues	O
+generally	O
+considered	O
+to	O
+be	O
+contraindications	O
+.	O
+
+The	O
+prevalence	O
+of	O
+FeLV	O
+was	O
+3	O
+.	O
+5	O
+per	O
+cent	O
+in	O
+all	O
+the	O
+cats	B-SPEC
+,	O
+1	O
+.	O
+4	O
+per	O
+cent	O
+in	O
+healthy	O
+cats	B-SPEC
+and	O
+6	O
+.	O
+9	O
+per	O
+cent	O
+in	O
+sick	O
+cats	B-SPEC
+.	O
+
+The	O
+prevalence	O
+of	O
+antibodies	B-COMP
+to	O
+FIV	B-SPEC
+was	O
+10	O
+.	O
+4	O
+per	O
+cent	O
+in	O
+all	O
+the	O
+cats	B-SPEC
+,	O
+4	O
+.	O
+9	O
+per	O
+cent	O
+in	O
+healthy	O
+cats	B-SPEC
+and	O
+16	O
+.	O
+7	O
+per	O
+cent	O
+in	O
+sick	O
+cats	B-SPEC
+.	O
+
+This	O
+study	O
+assessed	O
+hormonal	O
+responses	O
+to	O
+ergotamine	B-CHED
+in	O
+heat	O
+-	O
+sensitive	O
+and	O
+heat	O
+-	O
+tolerant	O
+cattle	B-SPEC
+.	O
+
+Ergotamine	B-CHED
+reduced	O
+(	O
+p	O
+<	O
+0	O
+.	O
+01	O
+)	O
+plasma	B-ANAT
+LH	O
+and	O
+increased	O
+(	O
+p	O
+<	O
+0	O
+.	O
+01	O
+)	O
+growth	B-FUNC
+hormone	I-FUNC
+concentrations	O
+in	O
+Brahman	O
+.	O
+
+The	O
+magnitude	O
+of	O
+response	O
+for	O
+cortisol	B-CHED
+,	O
+insulin	B-PRGE
+,	O
+and	O
+glucose	B-CHED
+were	O
+greater	O
+for	O
+the	O
+Brahman	O
+.	O
+
+Acute	O
+ergotamine	B-CHED
+exposure	O
+generally	O
+resulted	O
+in	O
+similar	O
+effects	O
+on	O
+Brahman	O
+and	O
+Hereford	O
+steers	O
+.	O
+
+TITLE	O
+:	O
+Site	O
+-	O
+specific	O
+recombination	B-PROC
+in	O
+eukaryotic	B-ANAT
+cells	I-ANAT
+mediated	O
+by	O
+mutant	B-DISO
+lambda	O
+integrases	O
+:	O
+implications	O
+for	O
+synaptic	O
+complex	O
+formation	O
+and	O
+the	O
+reactivity	O
+of	O
+episomal	O
+DNA	O
+segments	O
+.	O
+
+Therefore	O
+,	O
+one	O
+recombination	B-PROC
+pathway	B-PROC
+in	O
+human	B-SPEC
+cells	B-COMP
+involves	O
+mutant	B-DISO
+integrases	O
+bound	O
+solely	O
+at	O
+core	O
+sites	O
+,	O
+which	O
+is	O
+reminiscent	O
+of	O
+the	O
+Flp	B-PRGE
+/	O
+FRT	B-PRGE
+and	O
+Cre	O
+/	O
+loxP	O
+pathways	B-PROC
+.	O
+
+TITLE	O
+:	O
+Neither	O
+B	B-ANAT
+cells	I-ANAT
+nor	O
+T	B-ANAT
+cells	I-ANAT
+are	O
+required	O
+for	O
+CNS	B-CHED
+demyelination	B-DISO
+in	O
+mice	B-SPEC
+persistently	O
+infected	O
+with	O
+MHV	O
+-	O
+A59	O
+.	O
+
+ABSTRACT	O
+:	O
+Murine	B-DISO
+hepatitis	I-DISO
+virus	B-SPEC
+A59	O
+infection	B-DISO
+of	O
+the	O
+central	B-ANAT
+nervous	I-ANAT
+system	I-ANAT
+(	O
+CNS	B-CHED
+)	O
+results	O
+in	O
+CNS	B-CHED
+demyelination	B-DISO
+in	O
+susceptible	O
+strains	O
+of	O
+mice	B-SPEC
+.	O
+
+In	O
+mice	B-SPEC
+lacking	O
+antibody	B-COMP
+receptors	O
+or	O
+complement	B-PROC
+pathway	I-PROC
+activity	O
+,	O
+virus	B-SPEC
+did	O
+not	O
+persist	O
+yet	O
+demyelination	B-DISO
+was	O
+similar	O
+to	O
+parental	O
+mice	B-SPEC
+.	O
+
+TITLE	O
+:	O
+Infectious	B-DISO
+agents	O
+associated	O
+with	O
+respiratory	B-DISO
+disease	I-DISO
+in	O
+pheasants	O
+.	O
+
+Sinusitis	B-DISO
+was	O
+also	O
+associated	O
+with	O
+pasteurella	B-SPEC
+cultured	O
+from	O
+the	O
+sinus	B-DISO
+(	O
+P	O
+<	O
+0	O
+.	O
+05	O
+),	O
+antibody	B-COMP
+to	O
+avian	B-SPEC
+pneumovirus	I-SPEC
+(	O
+APV	B-SPEC
+)	O
+(	O
+P	O
+<	O
+0	O
+.	O
+01	O
+)	O
+and	O
+avian	B-SPEC
+coronaviruses	O
+as	O
+detected	O
+by	O
+reverse	O
+-	O
+transcriptase	B-PROC
+PCR	O
+(	O
+P	O
+<	O
+0	O
+.	O
+05	O
+);	O
+there	O
+was	O
+no	O
+association	O
+between	O
+disease	O
+and	O
+APV	B-SPEC
+as	O
+detected	O
+by	O
+PCR	O
+.	O
+
+Avian	B-SPEC
+coronaviruses	O
+were	O
+the	O
+most	O
+common	O
+infectious	B-DISO
+agents	O
+detected	O
+.	O
+
+TITLE	O
+:	O
+[	O
+A	O
+case	O
+of	O
+multiple	O
+organ	B-ANAT
+dysfunction	O
+following	O
+postoperative	O
+epididymitis	B-DISO
+].	O
+
+The	O
+patient	O
+'	O
+s	O
+condition	B-DISO
+continued	O
+to	O
+deteriorate	O
+and	O
+we	O
+suspected	O
+septic	B-DISO
+shock	I-DISO
+due	O
+to	O
+left	O
+epididymitis	B-DISO
+.	O
+
+In	O
+conclusion	O
+,	O
+it	O
+is	O
+important	O
+to	O
+note	O
+that	O
+patients	O
+with	O
+SIRS	B-DISO
+should	O
+undergo	O
+further	O
+examinations	O
+of	O
+septic	B-DISO
+shock	I-DISO
+immediately	O
+and	O
+resection	O
+of	O
+the	O
+causative	O
+tissue	B-ANAT
+should	O
+be	O
+performed	O
+as	O
+soon	O
+as	O
+possible	O
+.	O
+
+TITLE	O
+:	O
+Antigenic	O
+relationship	O
+of	O
+turkey	B-SPEC
+coronavirus	B-SPEC
+isolates	O
+from	O
+different	O
+geographic	O
+locations	O
+in	O
+the	O
+United	O
+States	O
+.	O
+
+Reactivity	O
+of	O
+antibodies	B-COMP
+to	O
+unrelated	O
+virus	B-SPEC
+,	O
+rotavirus	B-SPEC
+,	O
+reovirus	B-SPEC
+,	O
+adenovirus	B-DISO
+,	O
+or	O
+enterovirus	B-SPEC
+with	O
+different	O
+TCV	B-SPEC
+isolates	O
+was	O
+all	O
+negative	O
+,	O
+except	O
+positive	O
+response	O
+was	O
+seen	O
+between	O
+enterovirus	B-SPEC
+antibody	B-COMP
+and	O
+a	O
+TCV	B-SPEC
+western	O
+North	O
+Carolina	O
+isolate	O
+,	O
+suggesting	O
+coinfection	B-DISO
+of	O
+turkeys	B-SPEC
+with	O
+TCV	B-SPEC
+and	O
+enterovirus	B-SPEC
+in	O
+that	O
+particular	O
+case	O
+.	O
+
+ABSTRACT	O
+:	O
+Reports	O
+about	O
+anaphylactic	O
+and	O
+anaphylactoid	B-DISO
+reactions	I-DISO
+to	O
+rocuronium	O
+have	O
+increased	O
+recently	O
+.	O
+
+ABSTRACT	O
+:	O
+High	O
+-	O
+frequency	O
+oscillation	O
+(	O
+HFO	O
+)	O
+is	O
+a	O
+widely	O
+used	O
+lung	B-ANAT
+-	O
+protective	O
+ventilatory	O
+strategy	O
+in	O
+paediatric	O
+and	O
+neonatal	O
+acute	O
+lung	B-ANAT
+injury	O
+.	O
+
+Botulinum	O
+toxin	O
+produces	O
+a	O
+descending	O
+flaccid	B-DISO
+paralysis	I-DISO
+.	O
+
+Ammonia	B-CHED
+,	O
+chlorine	B-CHED
+,	O
+vinyl	B-CHED
+chloride	I-CHED
+,	O
+phosgene	B-CHED
+,	O
+sulfur	B-CHED
+dioxide	I-CHED
+,	O
+and	O
+nitrogen	B-CHED
+dioxide	I-CHED
+,	O
+tear	B-ANAT
+gas	B-ENZY
+,	O
+and	O
+zinc	B-CHED
+chloride	I-CHED
+primarily	O
+injure	O
+the	O
+upper	O
+respiratory	O
+tract	O
+and	O
+the	O
+lungs	B-ANAT
+.	O
+
+In	O
+this	O
+study	O
+,	O
+the	O
+effects	O
+of	O
+dietary	O
+arginine	B-CHED
+on	O
+leukocyte	B-ANAT
+population	O
+changes	O
+were	O
+examined	O
+in	O
+the	O
+peripheral	B-ANAT
+blood	I-ANAT
+and	O
+the	O
+respiratory	B-ANAT
+tract	I-ANAT
+of	O
+chickens	B-SPEC
+inoculated	O
+with	O
+infectious	B-DISO
+bronchitis	B-DISO
+virus	B-SPEC
+(	O
+IBV	B-SPEC
+)	O
+strain	O
+M41	O
+.	O
+
+MHV	B-SPEC
+infection	B-DISO
+triggers	O
+a	O
+robust	O
+cell	B-COMP
+-	O
+mediated	O
+response	O
+in	O
+which	O
+both	O
+CD4	B-PRGE
++	I-PRGE
+and	O
+CD8	B-PRGE
++	I-PRGE
+T	B-ANAT
+cells	I-ANAT
+are	O
+essential	O
+in	O
+controlling	O
+viral	B-PROC
+replication	I-PROC
+and	O
+spread	O
+.	O
+
+ABSTRACT	O
+:	O
+The	O
+obesity	O
+-	O
+hypoventilation	O
+syndrome	O
+(	O
+or	O
+alveolar	B-DISO
+hypoventilation	I-DISO
+in	O
+the	O
+obese	B-DISO
+)	O
+is	O
+a	O
+new	O
+name	B-SPEC
+for	O
+an	O
+old	O
+syndrome	B-DISO
+,	I-DISO
+Pickwickian	I-DISO
+syndrome	B-DISO
+.	O
+
+Pulmonary	B-DISO
+hypertension	I-DISO
+is	O
+frequent	O
+but	O
+not	O
+constant	O
+.	O
+
+TITLE	O
+:	O
+The	O
+use	O
+of	O
+bovine	B-PRGE
+serum	B-COMP
+protein	B-CHED
+as	O
+an	O
+oral	B-ANAT
+support	O
+therapy	O
+following	O
+coronavirus	B-SPEC
+challenge	O
+in	O
+calves	O
+.	O
+
+These	O
+data	O
+suggest	O
+that	O
+bovine	B-SPEC
+-	O
+serum	B-COMP
+supplemented	O
+milk	O
+replacer	O
+may	O
+decrease	O
+the	O
+severity	O
+of	O
+disease	O
+in	O
+young	O
+calves	O
+exposed	O
+to	O
+coronavirus	B-SPEC
+.	O
+
+TITLE	O
+:	O
+Purification	O
+of	O
+turkey	B-SPEC
+coronavirus	B-SPEC
+by	O
+Sephacryl	O
+size	O
+-	O
+exclusion	O
+chromatography	O
+.	O
+
+The	O
+purification	O
+methods	O
+included	O
+sucrose	B-CHED
+gradient	O
+and	O
+Sephacryl	O
+S	O
+-	O
+1000	O
+size	O
+-	O
+exclusion	O
+chromatography	O
+.	O
+
+Ultracentrifugation	O
+through	O
+a	O
+cushion	O
+of	O
+60	O
+%	O
+sucrose	B-CHED
+solution	O
+was	O
+better	O
+than	O
+the	O
+other	O
+two	O
+methods	O
+for	O
+concentration	O
+of	O
+TCoV	O
+from	O
+intestinal	B-ANAT
+homogenate	O
+.	O
+
+The	O
+most	O
+effective	O
+method	O
+for	O
+purifying	O
+TCoV	O
+and	O
+removing	O
+extraneous	O
+materials	O
+was	O
+size	O
+-	O
+exclusion	O
+chromatography	O
+as	O
+analyzed	O
+by	O
+sodium	B-CHED
+dodecyl	I-CHED
+sulfate	I-CHED
+-	O
+polyacrylamide	B-CHED
+gel	O
+electrophoresis	O
+.	O
+
+Virulent	O
+BCV	B-SPEC
+was	O
+actively	O
+introduced	O
+in	O
+one	O
+of	O
+the	O
+groups	O
+by	O
+means	O
+of	O
+a	O
+transmitter	O
+calf	B-ANAT
+.	O
+
+In	O
+particular	O
+,	O
+malaria	B-PATH
+and	O
+TB	O
+are	O
+important	O
+infections	B-DISO
+that	O
+predispose	O
+patients	O
+to	O
+ARDS	B-DISO
+in	O
+the	O
+tropics	O
+.	O
+
+Interactions	O
+involving	O
+the	O
+N	O
+-	O
+terminus	O
+and	O
+the	O
+alpha	O
+-	O
+helical	O
+domain	O
+stabilize	O
+the	O
+loop	O
+in	O
+the	O
+orientation	O
+required	O
+for	O
+trans	O
+-	O
+cleavage	B-PROC
+activity	O
+.	O
+
+The	O
+chest	B-ANAT
+radiograph	O
+showed	O
+bilateral	O
+miliary	O
+shadows	O
+.	O
+
+ABSTRACT	O
+:	O
+Granulocyte	B-PRGE
+-	I-PRGE
+macrophage	B-ANAT
+colony	I-PRGE
+-	I-PRGE
+stimulating	I-PRGE
+factor	I-PRGE
+(	O
+GM	B-PRGE
+-	I-PRGE
+CSF	I-PRGE
+)	O
+stimulates	O
+hemopoiesis	B-PROC
+and	O
+effector	B-CHED
+functions	O
+of	O
+granulocytes	B-ANAT
+and	O
+macrophages	B-ANAT
+and	O
+is	O
+involved	O
+in	O
+pulmonary	B-ANAT
+surfactant	B-PROC
+homeostasis	I-PROC
+.	O
+
+Mechanical	O
+ventilation	O
+and	O
+PEEP	B-CHED
+are	O
+still	O
+important	O
+components	O
+of	O
+supportive	O
+therapy	O
+.	O
+
+Two	O
+weeks	O
+later	O
+,	O
+she	O
+developed	O
+progressive	O
+flaccid	B-DISO
+quadriplegia	I-DISO
+and	O
+facial	B-DISO
+weakness	I-DISO
+.	O
+
+ABSTRACT	O
+:	O
+OBJECTIVE	O
+To	O
+investigate	O
+the	O
+expression	B-PROC
+and	O
+pathogenic	O
+role	O
+of	O
+macrophage	B-PRGE
+migration	B-PROC
+inhibitory	I-PRGE
+factor	I-PRGE
+(	O
+MIF	B-PRGE
+)	O
+in	O
+human	B-SPEC
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+(	O
+ARDS	B-DISO
+)	O
+METHODS	O
+The	O
+serum	B-COMP
+level	O
+of	O
+MIF	O
+in	O
+ARDS	B-DISO
+patients	O
+and	O
+normal	O
+persons	O
+were	O
+measured	O
+by	O
+ELISA	O
+method	O
+.	O
+
+RESULTS	O
+The	O
+serum	B-COMP
+level	O
+of	O
+MIF	O
+increased	O
+significantly	O
+in	O
+ARDS	B-DISO
+patients	O
+as	O
+compared	O
+with	O
+normal	O
+persons	O
+(	O
+P	O
+<	O
+0	O
+.	O
+01	O
+).	O
+
+In	O
+contrast	O
+,	O
+there	O
+was	O
+marked	O
+upregulation	B-PROC
+of	O
+MIF	B-PRGE
+mRNA	I-PRGE
+and	O
+protein	B-PROC
+expression	B-PROC
+in	O
+the	O
+ARDS	B-DISO
+lungs	B-ANAT
+.	O
+
+In	O
+ARDS	B-DISO
+macro	O
+phages	O
+infiltrated	B-DISO
+the	O
+alveolar	B-ANAT
+space	O
+and	O
+interstitium	B-ANAT
+,	O
+most	O
+of	O
+which	O
+also	O
+expressed	B-PROC
+MIF	B-PRGE
+.	O
+
+CONCLUSIONS	O
+The	O
+serum	B-COMP
+level	O
+of	O
+MIF	B-PRGE
+and	O
+PBMC	B-PRGE
+MIF	I-PRGE
+expression	B-PROC
+increased	O
+in	O
+ARDS	B-DISO
+patients	O
+with	O
+enhanced	O
+pulmonary	B-ANAT
+MIF	O
+expression	B-PROC
+and	O
+macrophage	B-ANAT
+infiltration	B-DISO
+,	O
+which	O
+suggests	O
+that	O
+MIF	O
+plays	O
+a	O
+pivotal	O
+role	O
+in	O
+the	O
+pathogenesis	B-DISO
+of	O
+ARDS	B-DISO
+.	O
+
+TITLE	O
+:	O
+Severe	O
+reperfusion	O
+lung	B-ANAT
+injury	O
+after	O
+double	O
+lung	B-ANAT
+transplantation	O
+.	O
+
+Notwithstanding	O
+the	O
+patient	O
+received	O
+support	O
+from	O
+cardiovascular	B-CHED
+drugs	I-CHED
+and	O
+pulmonary	B-ANAT
+vasodilators	O
+cardiopulmonary	B-ANAT
+by	O
+-	O
+pass	O
+was	O
+necessary	O
+.	O
+
+One	O
+possibility	O
+is	O
+that	O
+T	B-ANAT
+cells	I-ANAT
+specific	O
+for	O
+the	O
+inciting	O
+microbial	O
+pathogen	O
+are	O
+able	O
+to	O
+effect	O
+demyelination	B-DISO
+at	O
+a	O
+site	O
+of	O
+ongoing	O
+inflammation	B-DISO
+within	O
+the	O
+CNS	B-CHED
+.	O
+
+Using	O
+transgenic	O
+TCR	B-COMP
+/	O
+recombination	B-PROC
+activation	O
+gene	O
+2	O
+(-/-)	O
+mice	B-SPEC
+with	O
+only	O
+non	O
+-	O
+mouse	B-DISO
+hepatitis	I-DISO
+virus	B-SPEC
+-	O
+specific	O
+T	B-ANAT
+cells	I-ANAT
+,	O
+we	O
+show	O
+that	O
+CD8	B-PRGE
+T	I-PRGE
+cells	O
+are	O
+able	O
+to	O
+cause	O
+demyelination	B-DISO
+in	O
+the	O
+absence	O
+of	O
+cognate	O
+Ag	O
+in	O
+the	O
+CNS	B-CHED
+,	O
+but	O
+only	O
+if	O
+specifically	O
+activated	O
+.	O
+
+TITLE	O
+:	O
+Coagulation	B-PROC
+and	O
+inflammation	B-DISO
+in	O
+acute	O
+lung	B-ANAT
+injury	O
+.	O
+
+ABSTRACT	O
+:	O
+The	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+(	O
+ARDS	B-DISO
+)	O
+is	O
+a	O
+severe	O
+lung	B-ANAT
+injury	O
+in	O
+patients	O
+with	O
+sepsis	B-DISO
+and	O
+other	O
+acute	O
+inflammatory	O
+insults	O
+,	O
+which	O
+is	O
+characterized	O
+by	O
+fibrin	B-DISO
+deposition	I-DISO
+in	O
+the	O
+pulmonary	B-ANAT
+parenchyma	B-ANAT
+,	O
+vasculature	B-ANAT
+,	O
+and	O
+airspaces	O
+.	O
+
+Coagulation	B-PROC
+becomes	O
+activated	O
+by	O
+circulating	O
+endotoxin	O
+or	O
+bacteria	B-SPEC
+,	O
+and	O
+a	O
+procoagulant	O
+state	O
+develops	O
+in	O
+the	O
+vascular	B-ANAT
+and	O
+the	O
+alveolar	B-ANAT
+compartments	B-ANAT
+of	O
+the	O
+lung	B-ANAT
+.	O
+
+Fecal	B-ANAT
+and	O
+nasal	B-ANAT
+swab	O
+samples	O
+from	O
+85	O
+Ohio	O
+Agricultural	O
+Research	O
+and	O
+Development	B-PROC
+Center	O
+(	O
+OARDC	O
+)	O
+feedlot	O
+cattle	B-SPEC
+averaging	O
+7	O
+months	O
+of	O
+age	O
+were	O
+collected	O
+at	O
+arrival	O
+(	O
+0	O
+)	O
+and	O
+at	O
+4	O
+,	O
+7	O
+,	O
+14	O
+,	O
+and	O
+21	O
+days	O
+postarrival	O
+(	O
+DPA	B-CHED
+).	O
+
+Thirty	O
+-	O
+two	O
+cattle	B-SPEC
+(	O
+38	O
+%)	O
+showed	O
+concurrent	O
+enteric	O
+and	O
+nasal	B-ANAT
+shedding	O
+detected	O
+by	O
+both	O
+tests	O
+.	O
+
+The	O
+BCV	B-SPEC
+fecal	B-ANAT
+and	O
+nasal	B-ANAT
+shedding	O
+detected	O
+by	O
+ELISA	O
+and	O
+RT	O
+-	O
+PCR	O
+were	O
+statistically	O
+correlated	O
+with	O
+ELISA	O
+antibody	B-COMP
+seroconversion	O
+(	O
+P	O
+<	O
+0	O
+.	O
+0001	O
+);	O
+however	O
+,	O
+BCV	B-SPEC
+fecal	B-ANAT
+and	O
+nasal	B-ANAT
+shedding	O
+were	O
+not	O
+significantly	O
+related	O
+to	O
+clinical	O
+signs	O
+.	O
+
+Seroconversion	O
+to	O
+BCV	B-SPEC
+was	O
+inversely	O
+related	O
+to	O
+average	O
+daily	O
+weight	O
+gains	O
+(	O
+P	O
+<	O
+0	O
+.	O
+06	O
+).	O
+
+These	O
+findings	O
+confirm	O
+the	O
+presence	O
+of	O
+enteric	O
+and	O
+respiratory	O
+BCV	B-SPEC
+infections	B-DISO
+in	O
+feedlot	O
+calves	O
+.	O
+
+Lung	B-ANAT
+fields	O
+were	O
+anatomically	O
+divided	O
+according	O
+to	O
+functional	O
+bronchial	B-ANAT
+divisions	O
+in	O
+ten	O
+segments	O
+on	O
+each	O
+side	O
+.	O
+
+ABSTRACT	O
+:	O
+Severe	O
+pancreatitis	O
+is	O
+frequently	O
+associated	O
+with	O
+acute	O
+lung	B-ANAT
+injury	O
+(	O
+ALI	O
+)	O
+and	O
+the	O
+respiratory	B-DISO
+distress	I-DISO
+syndrome	I-DISO
+.	O
+
+A	O
+lymphoproliferative	O
+assay	O
+was	O
+developed	O
+in	O
+which	O
+mononuclear	B-ANAT
+cells	I-ANAT
+isolated	O
+from	O
+lymphoid	B-ANAT
+tissues	I-ANAT
+at	O
+different	O
+postinoculation	O
+and	O
+postchallenge	O
+days	O
+underwent	O
+a	O
+secondary	O
+in	O
+vitro	O
+stimulation	O
+with	O
+semipurified	O
+antigen	B-CHED
+obtained	O
+from	O
+PEDV	B-SPEC
+-	O
+infected	O
+cell	B-COMP
+cultures	O
+.	O
+
+ABSTRACT	O
+:	O
+Aerosolized	O
+NONOates	O
+have	O
+been	O
+investigated	O
+in	O
+animal	B-SPEC
+models	O
+in	O
+acute	O
+pulmonary	B-DISO
+hypertension	I-DISO
+,	O
+but	O
+none	O
+have	O
+been	O
+used	O
+in	O
+humans	B-SPEC
+.	O
+
+Ten	O
+consecutive	O
+patients	O
+fulfilling	O
+criteria	O
+for	O
+severe	O
+ALI	O
+were	O
+ventilated	O
+with	O
+a	O
+6	O
+ml	O
+/	O
+kg	O
+Vt	O
+,	O
+a	O
+total	O
+PEEP	B-CHED
+level	O
+at	O
+13	O
++/-	O
+3	O
+cmH	B-DISO
+(	O
+2	O
+)	O
+O	O
+and	O
+a	O
+plateau	O
+pressure	O
+kept	O
+at	O
+23	O
++/-	O
+4	O
+cmH	B-DISO
+(	O
+2	O
+)	O
+O	O
+.	O
+The	O
+respiratory	O
+rate	O
+was	O
+randomly	O
+set	O
+below	O
+20	O
+breaths	O
+/	O
+min	O
+(	O
+17	O
++/-	O
+3	O
+breaths	O
+/	O
+min	O
+)	O
+and	O
+increased	O
+to	O
+30	O
+breaths	O
+/	O
+min	O
+(	O
+30	O
++/-	O
+3	O
+breaths	O
+/	O
+min	O
+)	O
+to	O
+compensate	O
+for	O
+hypercapnia	B-DISO
+.	O
+
+PEEPi	O
+was	O
+computed	O
+as	O
+the	O
+difference	O
+between	O
+total	O
+PEEP	B-CHED
+and	O
+external	O
+PEEP	B-CHED
+.	O
+
+The	O
+lung	B-PROC
+volume	I-PROC
+retained	O
+by	O
+PEEPi	O
+was	O
+then	O
+measured	O
+.	O
+
+Drugs	O
+for	O
+cardiovascular	B-ANAT
+support	O
+were	O
+infused	O
+in	O
+59	O
+patients	O
+(	O
+89	O
+%)	O
+during	O
+transfer	O
+.	O
+
+The	O
+use	O
+of	O
+VA	O
+ECMO	O
+in	O
+cardiac	B-ANAT
+patients	O
+has	O
+expanded	O
+from	O
+an	O
+extension	O
+of	O
+intraoperative	O
+cardiopulmonary	B-ANAT
+bypass	O
+and	O
+now	O
+includes	O
+rescue	O
+therapy	O
+during	O
+cardiopulmonary	B-ANAT
+resuscitation	O
+,	O
+temporary	O
+circulatory	B-PROC
+support	O
+for	O
+reversible	O
+heart	B-DISO
+failure	I-DISO
+,	O
+and	O
+bridge	O
+support	O
+preceding	O
+heart	B-ANAT
+or	O
+heart	B-ANAT
+/	O
+lung	B-ANAT
+transplantation	O
+.	O
+
+She	O
+underwent	O
+successful	O
+electrophysiologic	O
+mapping	O
+and	O
+transcatheter	O
+radiofrequency	O
+ablation	O
+of	O
+an	O
+accessory	O
+conduction	B-PROC
+pathway	B-PROC
+,	O
+resulting	O
+in	O
+termination	O
+of	O
+the	O
+tachycardia	O
+.	O
+
+The	O
+case	O
+illustrates	O
+the	O
+proactive	O
+use	O
+of	O
+ECMO	O
+during	O
+a	O
+procedure	O
+in	O
+which	O
+severe	O
+hemodynamic	B-DISO
+instability	I-DISO
+could	O
+be	O
+predicted	O
+.	O
+
+A	O
+19	O
+-	O
+yr	O
+-	O
+old	O
+male	O
+with	O
+smoke	O
+inhalation	B-PROC
+and	O
+flame	O
+burns	O
+to	O
+50	O
+%	O
+total	B-ANAT
+body	I-ANAT
+surface	I-ANAT
+area	O
+was	O
+admitted	O
+to	O
+the	O
+Ross	O
+Tilley	O
+Burn	O
+Centre	O
+.	O
+
+On	O
+day	O
+nine	O
+,	O
+alveolar	B-ANAT
+ventilation	O
+was	O
+severely	O
+compromised	O
+and	O
+was	O
+characterized	O
+by	O
+hypercapnea	O
+(	O
+PaCO	O
+(	O
+2	O
+)	O
+136	O
+mmHg	O
+)	O
+and	O
+acidosis	B-DISO
+(	O
+pH	O
+7	O
+.	O
+10	O
+).	O
+
+ABSTRACT	O
+:	O
+Three	O
+unrecognized	O
+field	O
+isolates	O
+of	O
+Infectious	O
+Bronchitis	B-DISO
+Virus	B-SPEC
+(	O
+IBV	B-SPEC
+)	O
+were	O
+recovered	O
+from	O
+commercial	O
+broiler	O
+chickens	B-SPEC
+vaccinated	O
+with	O
+live	O
+Mass	O
+viral	O
+strain	O
+(	O
+H120	O
+).	O
+
+These	O
+isolates	O
+were	O
+identified	O
+by	O
+immunofluorescence	O
+using	O
+monoclonal	O
+antibodies	B-COMP
+produced	O
+against	O
+reference	O
+serotypes	O
+:	O
+Mass	O
+,	O
+Conn	O
+,	O
+and	O
+Ark	B-PRGE
+.	O
+RT	O
+-	O
+PCRs	O
+were	O
+performed	O
+on	O
+viral	O
+RNAs	O
+to	O
+amplify	O
+S1	B-PRGE
+gene	I-PRGE
+using	O
+a	O
+specific	O
+set	O
+of	O
+primers	O
+S1OLIGO3	O
+'	O
+and	O
+S1OLIGO5	O
+'.	O
+
+It	O
+is	O
+speculated	O
+that	O
+cysteine	B-CHED
+residue	I-CHED
+located	O
+upstream	O
+and	O
+downstream	O
+of	O
+Cys	B-PRGE
+-	I-PRGE
+Ser	B-COMP
+-	I-PRGE
+Asn	B-CHED
+-	I-PRGE
+Ala	B-CHED
+-	I-PRGE
+Ser	B-COMP
+-	I-PRGE
+Cys	B-CHED
+segment	I-PRGE
+might	O
+be	O
+involved	O
+in	O
+the	O
+formation	B-PROC
+of	O
+loop	O
+structure	O
+and	O
+disulfide	B-CHED
+bond	O
+that	O
+could	O
+trigger	O
+important	O
+epitope	B-CHED
+changes	O
+.	O
+
+More	O
+TRALI	B-DISO
+cases	O
+are	O
+unrecognized	O
+and	O
+misdiagnosed	O
+due	O
+to	O
+lack	O
+of	O
+suspicion	O
+and	O
+absence	O
+of	O
+appropriate	O
+investigation	O
+.	O
+
+Of	O
+the	O
+10	O
+U	O
+of	O
+plasma	O
+used	O
+,	O
+one	O
+was	O
+from	O
+a	O
+multiparous	O
+female	O
+donor	B-CHED
+with	O
+HLA	B-PRGE
+antibodies	B-COMP
+reactive	O
+with	O
+patient	O
+'	O
+s	O
+granulocytes	B-ANAT
+in	O
+immunofluorescence	O
+and	O
+agglutination	B-PROC
+assays	O
+.	O
+
+This	O
+case	O
+emphasizes	O
+the	O
+fact	O
+that	O
+the	O
+physicians	O
+and	O
+apheresis	O
+staff	O
+should	O
+consider	O
+TRALI	B-DISO
+in	O
+the	O
+differential	O
+diagnosis	O
+for	O
+patients	O
+developing	O
+respiratory	B-DISO
+distress	I-DISO
+during	O
+or	O
+soon	O
+after	O
+the	O
+procedure	O
+.	O
+
+The	O
+relative	O
+abundance	O
+of	O
+mtDNA	B-COMP
+was	O
+determined	O
+by	O
+co	O
+-	O
+amplifying	O
+mitochondrial	B-COMP
+D	O
+-	O
+loop	O
+versus	O
+the	O
+rat	B-PRGE
+beta	I-PRGE
+-	I-PRGE
+actin	I-PRGE
+gene	I-PRGE
+.	O
+
+The	O
+major	O
+complications	O
+were	O
+severe	O
+infection	B-DISO
+,	O
+hypotension	O
+,	O
+acute	B-DISO
+renal	I-DISO
+failure	I-DISO
+,	O
+adult	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+(	O
+ARDS	B-DISO
+),	O
+and	O
+multiple	O
+organ	B-ANAT
+disfunction	O
+syndrome	B-DISO
+(	O
+MODS	B-DISO
+).	O
+
+Gerhardt	O
+'	O
+s	O
+syndrome	B-DISO
+frequently	O
+induces	O
+severe	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+requiring	O
+ventilatory	O
+support	O
+,	O
+and	O
+this	O
+condition	B-DISO
+might	O
+be	O
+mistaken	O
+for	O
+a	O
+severe	B-DISO
+acute	I-DISO
+asthma	I-DISO
+attack	O
+.	O
+
+TITLE	O
+:	O
+Severe	O
+immune	B-DISO
+dysfunction	I-DISO
+after	O
+lethal	O
+neutron	B-CHED
+irradiation	O
+in	O
+a	O
+JCO	O
+nuclear	O
+facility	O
+accident	O
+victim	O
+.	O
+
+Brain	B-ANAT
+imaging	O
+revealed	O
+ischemic	O
+lesions	O
+in	O
+the	O
+region	O
+of	O
+the	O
+basal	B-ANAT
+ganglia	I-ANAT
+.	O
+
+ABSTRACT	O
+:	O
+The	O
+ability	O
+of	O
+the	O
+isolated	O
+lung	B-ANAT
+tissue	I-ANAT
+to	O
+take	O
+up	O
+glucose	B-CHED
+and	O
+to	O
+release	B-PATH
+lactate	B-CHED
+is	O
+potentially	O
+similar	O
+to	O
+that	O
+of	O
+other	O
+body	B-ANAT
+tissues	I-ANAT
+.	O
+
+Nonetheless	O
+,	O
+when	O
+lung	B-ANAT
+lactate	B-CHED
+exchange	O
+was	O
+assess	O
+in	O
+vivo	O
+in	O
+normal	O
+humans	B-SPEC
+,	O
+no	O
+measurable	O
+lactate	B-CHED
+production	O
+could	O
+be	O
+detected	O
+.	O
+
+ABSTRACT	O
+:	O
+Only	O
+few	O
+data	O
+concerning	O
+weaning	B-PROC
+by	O
+nasal	B-ANAT
+positive	O
+pressure	O
+ventilation	O
+(	O
+NPPV	O
+)	O
+are	O
+available	O
+,	O
+and	O
+successful	O
+weaning	B-PROC
+by	O
+using	O
+NPPV	O
+in	O
+patients	O
+with	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+(	O
+ARDS	B-DISO
+)	O
+and	O
+severe	O
+complications	O
+has	O
+not	O
+yet	O
+been	O
+described	O
+.	O
+
+The	O
+3	O
+'-	O
+terminal	O
+end	O
+of	O
+the	O
+genome	O
+of	O
+the	O
+prototype	O
+HEV	B-SPEC
+-	O
+67N	O
+strain	O
+and	O
+that	O
+of	O
+the	O
+recent	O
+Québec	O
+IAF	O
+-	O
+404	O
+field	O
+isolate	O
+,	O
+both	O
+propagated	O
+in	O
+HRT	O
+-	O
+18	O
+cells	B-COMP
+,	O
+were	O
+sequenced	O
+.	O
+
+Here	O
+,	O
+we	O
+localized	O
+a	O
+conserved	O
+B	B-ANAT
+-	I-ANAT
+cell	I-ANAT
+immunodominant	O
+epitope	B-CHED
+(	O
+IDE	B-CHED
+)	O
+spanning	O
+residues	O
+447	O
+to	O
+455	O
+and	O
+successfully	O
+generated	O
+a	O
+recombinant	O
+NDV	B-SPEC
+lacking	O
+the	O
+IDE	B-CHED
+by	O
+reverse	O
+genetics	O
+.	O
+
+After	O
+withdrawing	O
+the	O
+analgo	O
+-	O
+sedation	B-DISO
+the	O
+patient	O
+'	O
+s	O
+vigilance	O
+rose	B-SPEC
+continuously	O
+.	O
+
+Chicken	B-SPEC
+embryos	B-ANAT
+were	O
+inoculated	O
+in	O
+ovo	B-SPEC
+(	O
+chorioallantoic	O
+sac	B-COMP
+)	O
+with	O
+the	O
+Arkansas	O
+(	O
+Ark	O
+)	O
+serotype	O
+of	O
+IBV	B-SPEC
+at	O
+18	O
+days	O
+of	O
+age	O
+.	O
+
+ABSTRACT	O
+:	O
+Chicken	B-SPEC
+embryos	B-ANAT
+were	O
+inoculated	O
+with	O
+8	O
+different	O
+strains	O
+of	O
+infectious	B-DISO
+bronchitis	B-DISO
+virus	B-SPEC
+(	O
+IBV	B-SPEC
+)	O
+representing	O
+7	O
+different	O
+serotypes	O
+at	O
+17	O
+days	O
+of	O
+embryonation	O
+.	O
+
+TITLE	O
+:	O
+Enteric	B-SPEC
+coronavirus	I-SPEC
+infection	O
+in	O
+a	O
+juvenile	O
+dromedary	B-SPEC
+(	O
+Camelus	B-SPEC
+dromedarius	I-SPEC
+).	O
+
+The	O
+death	B-PROC
+of	O
+the	O
+animal	B-SPEC
+was	O
+attributed	O
+to	O
+a	O
+neutrophilic	B-PROC
+and	O
+emphysematous	O
+colitis	B-DISO
+that	O
+likely	O
+was	O
+caused	O
+by	O
+an	O
+infection	B-DISO
+with	O
+a	O
+Clostridium	B-SPEC
+sp	O
+.	O
+
+The	O
+murine	B-DISO
+hepatitis	I-DISO
+virus	B-SPEC
+strain	O
+A59	O
+(	O
+MHV	B-SPEC
+-	O
+A59	O
+)	O
+model	O
+produces	O
+focal	O
+areas	O
+of	O
+spinal	B-ANAT
+cord	I-ANAT
+demyelination	B-DISO
+with	O
+inflammation	B-DISO
+.	O
+
+In	O
+both	O
+models	O
+,	O
+FGF2	B-PRGE
+expression	B-PROC
+is	O
+upregulated	O
+in	O
+areas	O
+of	O
+demyelination	B-DISO
+in	O
+wild	O
+-	O
+type	O
+mice	B-SPEC
+.	O
+
+Surprisingly	O
+,	O
+in	O
+both	O
+models	O
+,	O
+oligodendrocyte	B-ANAT
+repopulation	O
+of	O
+demyelinated	O
+white	B-ANAT
+matter	I-ANAT
+was	O
+significantly	O
+increased	O
+in	O
+FGF2	B-PRGE
+-/-	O
+mice	B-SPEC
+compared	O
+with	O
+wild	O
+-	O
+type	O
+mice	B-SPEC
+and	O
+even	O
+surpassed	O
+the	O
+oligodendrocyte	B-ANAT
+density	O
+of	O
+nonlesioned	O
+mice	B-SPEC
+.	O
+
+Standard	O
+counting	O
+methods	O
+do	O
+not	O
+distinguish	O
+between	O
+leukocytosis	B-DISO
+,	O
+neutrophil	B-ANAT
+sequestration	O
+,	O
+and	O
+activation	O
+.	O
+
+However	O
+,	O
+18FDG	O
+uptake	O
+uniquely	O
+showed	O
+that	O
+interstitial	B-ANAT
+and	O
+intra	O
+-	O
+alveolar	B-ANAT
+neutrophil	B-DISO
+migration	I-DISO
+and	O
+activation	O
+occurred	O
+in	O
+severe	O
+but	O
+not	O
+in	O
+mild	O
+pancreatitis	B-DISO
+,	O
+consistent	O
+with	O
+clinical	O
+correlations	O
+between	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+and	O
+severity	O
+of	O
+underlying	O
+systemic	B-DISO
+disease	I-DISO
+.	O
+
+This	O
+often	O
+is	O
+a	O
+fatal	O
+complication	B-DISO
+.	O
+
+After	O
+injury	O
+and	O
+the	O
+bacterial	O
+challenge	O
+,	O
+the	O
+animals	B-SPEC
+were	O
+ventilated	O
+mechanically	O
+with	O
+100	O
+%	O
+oxygen	B-CHED
+.	O
+
+On	O
+admission	O
+,	O
+hypertension	B-DISO
+,	O
+nephrotic	B-DISO
+syndrome	I-DISO
+and	O
+hypocomplementemia	B-DISO
+were	O
+evident	O
+together	O
+with	O
+a	O
+high	O
+titer	O
+of	O
+anti	O
+-	O
+streptokinase	O
+(	O
+ASK	B-PRGE
+).	O
+
+Many	O
+interstitial	B-ANAT
+infiltrating	B-DISO
+cells	B-COMP
+were	O
+positive	O
+for	O
+interferon	B-FUNC
+-	I-FUNC
+gamma	I-FUNC
+,	O
+but	O
+their	O
+number	O
+diminished	O
+after	O
+treatment	O
+.	O
+
+TITLE	O
+:	O
+Murine	B-SPEC
+coronavirus	I-SPEC
+spike	I-PRGE
+glycoprotein	B-CHED
+mediates	O
+degree	O
+of	O
+viral	O
+spread	O
+,	O
+inflammation	B-DISO
+,	O
+and	O
+virus	B-SPEC
+-	O
+induced	O
+immunopathology	B-DISO
+in	O
+the	O
+central	B-ANAT
+nervous	I-ANAT
+system	I-ANAT
+.	O
+
+We	O
+investigated	O
+how	O
+alterations	O
+in	O
+spike	O
+affect	O
+neurovirulence	O
+using	O
+two	O
+isogenic	O
+recombinant	O
+viruses	B-SPEC
+differing	O
+exclusively	O
+in	O
+spike	O
+.	O
+
+Main	O
+causes	O
+of	O
+ARDS	B-DISO
+were	O
+pneumonia	B-DISO
+(	O
+9	O
+/	O
+16	O
+)	O
+and	O
+burn	O
+injuries	O
+(	O
+4	O
+/	O
+16	O
+).	O
+
+Within	O
+4	O
+h	O
+of	O
+HFOV	O
+,	O
+Pao2	B-PRGE
+/	O
+FIo2	O
+increased	O
+to	O
+17	O
+.	O
+3	O
+(	O
+SD	O
+5	O
+.	O
+9	O
+)	O
+kPa	O
+(	O
+P	O
+=	O
+0	O
+.	O
+016	O
+).	O
+
+Seven	O
+contiguous	O
+cDNA	O
+clones	O
+that	O
+spanned	O
+the	O
+31	O
+.	O
+5	O
+-	O
+kb	O
+MHV	B-SPEC
+genome	O
+were	O
+isolated	O
+.	O
+
+Importantly	O
+,	O
+the	O
+molecularly	O
+cloned	O
+viruses	B-SPEC
+contained	O
+three	O
+marker	O
+mutations	O
+that	O
+had	O
+been	O
+derived	O
+from	O
+the	O
+engineered	O
+component	O
+clones	O
+.	O
+
+Postmortem	O
+tissues	B-ANAT
+were	O
+stained	O
+using	O
+the	O
+Verhoeff	O
+-	O
+Van	O
+Gieson	O
+procedure	O
+for	O
+elastic	B-COMP
+fibers	I-COMP
+,	O
+and	O
+with	O
+Congo	B-CHED
+red	I-CHED
+for	O
+examination	O
+under	O
+a	O
+polarizing	O
+microscope	O
+.	O
+
+These	O
+enlarged	O
+viruses	B-SPEC
+should	O
+be	O
+easier	O
+to	O
+remove	O
+by	O
+nanofiltration	O
+than	O
+naked	O
+viruses	B-SPEC
+.	O
+
+One	B-PRGE
+-	I-PRGE
+percent	I-PRGE
+IgG	I-PRGE
+or	O
+1	B-PRGE
+-	I-PRGE
+percent	I-PRGE
+albumin	I-PRGE
+solutions	O
+were	O
+spiked	O
+with	O
+bovine	O
+enterovirus	O
+(	O
+BEV	B-SPEC
+)	O
+and	O
+filtered	O
+through	O
+50	O
+-	O
+nm	O
+filters	O
+.	O
+
+This	O
+virus	B-SPEC
+cross	O
+-	O
+reacts	O
+with	O
+antibodies	B-COMP
+in	O
+pooled	O
+human	B-SPEC
+IgG	B-PRGE
+solutions	O
+but	O
+persists	O
+as	O
+free	O
+virions	B-COMP
+in	O
+albumin	B-PRGE
+solutions	O
+.	O
+
+ABSTRACT	O
+:	O
+Critical	B-DISO
+illness	I-DISO
+is	O
+a	O
+severe	O
+and	O
+generalized	O
+monophasic	O
+event	O
+,	O
+and	O
+it	O
+is	O
+likely	O
+that	O
+there	O
+will	O
+be	O
+evidence	O
+of	O
+compromised	O
+reserve	O
+in	O
+all	O
+end	O
+organs	O
+if	O
+one	O
+looks	O
+hard	O
+enough	O
+for	O
+it	O
+.	O
+
+In	O
+addition	O
+,	O
+cell	B-ANAT
+lines	I-ANAT
+stably	O
+expressing	O
+the	O
+E	B-PRGE
+gene	I-PRGE
+under	O
+the	O
+CMV	B-SPEC
+promoter	O
+have	O
+been	O
+developed	O
+.	O
+
+Furthermore	O
+,	O
+since	O
+sera	B-COMP
+from	O
+mice	B-SPEC
+immunized	O
+with	O
+a	O
+purified	O
+fraction	O
+of	O
+the	O
+rat	B-PRGE
+liver	I-PRGE
+enzyme	I-PRGE
+do	O
+react	O
+with	O
+its	O
+homologous	O
+protein	B-CHED
+,	O
+this	O
+antiserum	O
+can	O
+be	O
+used	O
+as	O
+a	O
+positive	O
+control	O
+avoiding	O
+the	O
+manipulation	O
+of	O
+samples	O
+from	O
+MHV	B-SPEC
+-	O
+infected	O
+animals	B-SPEC
+.	O
+
+The	O
+studies	O
+of	O
+molecular	O
+epizootiology	O
+reveal	O
+a	O
+strong	O
+probability	O
+that	O
+the	O
+vaccination	O
+had	O
+lead	O
+to	O
+the	O
+spread	O
+of	O
+the	O
+vaccine	O
+virus	B-SPEC
+,	O
+causing	O
+various	O
+disease	O
+manifestations	O
+and	O
+a	O
+confusing	O
+epizootiological	O
+situation	O
+in	O
+the	O
+poultry	O
+population	O
+.	O
+
+TITLE	O
+:	O
+Systemic	O
+inflammatory	B-DISO
+response	I-DISO
+induced	O
+by	O
+particulate	O
+matter	O
+air	B-CHED
+pollution	O
+:	O
+the	O
+importance	O
+of	O
+bone	O
+-	O
+marrow	O
+stimulation	O
+.	O
+
+The	O
+kinetics	O
+and	O
+distribution	O
+of	O
+TUNEL	O
+staining	O
+correlated	O
+with	O
+the	O
+pathologic	O
+damage	O
+and	O
+colocalized	O
+with	O
+viral	O
+antigen	O
+in	O
+some	O
+cells	B-COMP
+.	O
+
+TITLE	O
+:	O
+The	O
+virulence	B-PROC
+of	O
+mouse	B-DISO
+hepatitis	I-DISO
+virus	B-SPEC
+strain	O
+A59	O
+is	O
+not	O
+dependent	O
+on	O
+efficient	O
+spike	O
+protein	B-CHED
+cleavage	I-PROC
+and	O
+cell	B-COMP
+-	O
+to	O
+-	O
+cell	B-PROC
+fusion	I-PROC
+.	O
+
+Our	O
+data	O
+indicate	O
+that	O
+cleavage	B-PROC
+of	O
+spike	O
+is	O
+not	O
+solely	O
+determined	O
+by	O
+the	O
+amino	B-CHED
+acid	I-CHED
+sequence	O
+at	O
+the	O
+cleavage	B-PROC
+site	O
+,	O
+but	O
+may	O
+also	O
+depend	O
+on	O
+sequences	O
+removed	O
+from	O
+the	O
+cleavage	B-PROC
+site	O
+.	O
+
+Inhaled	B-PROC
+NO	O
+was	O
+started	O
+at	O
+20	O
+ppm	O
+and	O
+weaned	B-PROC
+to	O
+5	O
+ppm	O
+over	O
+24	O
+-	O
+48	O
+hours	O
+.	O
+
+15	O
+.	O
+8	O
+years	O
+)	O
+presented	O
+with	O
+severe	O
+hypoxemia	O
+(	O
+Pa	O
+(	O
+O2	O
+)/	O
+fraction	O
+of	O
+inspired	B-PROC
+oxygen	B-CHED
+ratio	O
+=	O
+156	O
++/-	O
+
+We	O
+conclude	O
+that	O
+:	O
+(	O
+1	O
+)	O
+diagnostic	O
+criteria	O
+of	O
+IAEP	O
+are	O
+compatible	O
+with	O
+a	O
+duration	O
+of	O
+symptoms	O
+for	O
+up	O
+to	O
+1	O
+month	O
+,	O
+but	O
+the	O
+response	O
+to	O
+corticosteroid	B-CHED
+treatment	O
+is	O
+not	O
+diagnostic	O
+because	O
+of	O
+possible	O
+spontaneous	B-PROC
+recovery	I-PROC
+;	O
+(	O
+2	O
+)	O
+IAEP	O
+should	O
+be	O
+considered	O
+as	O
+differential	O
+diagnosis	O
+of	O
+acute	O
+lung	B-ANAT
+injury	O
+or	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+;	O
+(	O
+3	O
+)	O
+bronchoalveolar	O
+lavage	O
+eosinophilia	B-DISO
+obviates	O
+the	O
+need	O
+for	O
+lung	B-ANAT
+biopsy	O
+in	O
+IAEP	O
+.	O
+
+ABSTRACT	O
+:	O
+The	O
+most	O
+frequent	O
+manifestations	O
+of	O
+heteroplasmic	O
+mitochondrial	O
+DNA	O
+(	O
+mtDNA	B-COMP
+)	O
+mutation	O
+8993	O
+T	O
+>	O
+G	O
+are	O
+Leigh	B-DISO
+syndrome	I-DISO
+or	O
+NARP	B-DISO
+syndrome	I-DISO
+(	O
+Neurogenic	O
+Muscle	B-DISO
+Weakness	I-DISO
+,	O
+Ataxia	B-DISO
+,	O
+and	O
+Retinitis	B-DISO
+Pigmentosa	I-DISO
+).	O
+
+TITLE	O
+:	O
+Effect	O
+of	O
+surfactant	B-CHED
+on	O
+ventilation	O
+-	O
+induced	O
+mediator	O
+release	B-PATH
+in	O
+isolated	O
+perfused	O
+mouse	B-SPEC
+lungs	B-ANAT
+.	O
+
+ABSTRACT	O
+:	O
+The	O
+human	B-SPEC
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+(	O
+ARDS	B-DISO
+)	O
+is	O
+a	O
+severe	O
+pulmonary	B-DISO
+complication	I-DISO
+with	O
+high	O
+mortality	O
+rates	O
+.	O
+
+Recently	O
+it	O
+was	O
+shown	O
+that	O
+low	O
+tidal	O
+volume	O
+ventilation	O
+reduces	O
+mortality	O
+and	O
+pro	B-CHED
+-	O
+inflammatory	O
+mediator	O
+release	B-PATH
+in	O
+these	O
+patients	O
+,	O
+suggesting	O
+biotrauma	O
+as	O
+a	O
+side	B-DISO
+effect	I-DISO
+of	O
+mechanical	O
+ventilation	O
+.	O
+
+Patients	O
+with	O
+ARDS	B-DISO
+were	O
+identified	O
+from	O
+the	O
+registry	O
+of	O
+a	O
+Level	O
+I	O
+trauma	O
+center	O
+over	O
+a	O
+4	O
+.	O
+5	O
+-	O
+year	O
+period	O
+.	O
+
+We	O
+reported	O
+that	O
+the	O
+soluble	B-PRGE
+form	I-PRGE
+of	I-PRGE
+MHV	I-PRGE
+receptor	I-PRGE
+(	O
+soMHVR	O
+)	O
+transformed	O
+a	O
+nonfusogenic	O
+S	O
+protein	B-CHED
+into	O
+a	O
+fusogenic	O
+one	O
+(	O
+F	O
+.	O
+Taguchi	O
+and	O
+S	O
+.	O
+Matsuyama	O
+,	O
+J	O
+.	O
+Virol	O
+.	O
+
+soMHVR	O
+induced	O
+conformational	O
+changes	O
+of	O
+the	O
+S	O
+proteins	B-CHED
+of	O
+wild	O
+-	O
+type	O
+(	O
+wt	O
+)	O
+JHMV	O
+cl	O
+-	O
+2	O
+,	O
+as	O
+well	O
+as	O
+revertants	O
+from	O
+srr7	O
+,	O
+srr7A	O
+and	O
+srr7B	O
+;	O
+however	O
+,	O
+a	O
+major	O
+proportion	O
+of	O
+these	O
+S	O
+proteins	B-CHED
+were	O
+resistant	O
+to	O
+proteinase	B-ENZY
+K	I-ENZY
+even	O
+without	O
+soMHVR	O
+treatment	O
+.	O
+
+This	O
+is	O
+the	O
+first	O
+report	O
+on	O
+receptor	O
+-	O
+induced	O
+conformational	O
+changes	O
+of	O
+the	O
+membrane	B-COMP
+-	O
+anchored	O
+fragment	O
+of	O
+the	O
+coronavirus	B-PRGE
+S	I-PRGE
+protein	B-CHED
+.	O
+
+He	O
+concluded	O
+that	O
+these	O
+changes	O
+were	O
+caused	O
+by	O
+hypoxia	B-DISO
+and	O
+were	O
+not	O
+the	O
+cause	O
+of	O
+SIDS	B-DISO
+.	O
+
+He	O
+noted	O
+an	O
+absence	O
+of	O
+astrogliosis	B-DISO
+in	O
+some	O
+older	O
+SIDS	B-DISO
+victims	O
+,	O
+compatible	O
+with	O
+a	O
+single	O
+,	O
+terminal	O
+episode	O
+of	O
+hypoxia	B-DISO
+without	O
+previous	O
+hypoxic	B-DISO
+episodes	O
+,	O
+prenatal	O
+or	O
+postnatal	O
+.	O
+
+The	O
+major	O
+issue	O
+is	O
+when	O
+did	O
+the	O
+brainstem	B-ANAT
+abnormalities	O
+,	O
+astrogliosis	B-DISO
+,	O
+or	O
+neurotransmitter	B-CHED
+changes	O
+occur	O
+and	O
+whether	O
+either	O
+is	O
+specific	O
+to	O
+SIDS	B-DISO
+.	O
+
+This	O
+is	O
+in	O
+contrast	O
+to	O
+the	O
+delay	O
+until	O
+the	O
+postneonatal	O
+period	O
+of	O
+most	O
+SIDS	B-DISO
+deaths	B-PROC
+.	O
+
+TITLE	O
+:	O
+The	O
+role	O
+of	O
+feline	B-PRGE
+aminopeptidase	B-ENZY
+N	I-ENZY
+as	O
+a	O
+receptor	O
+for	O
+infectious	B-DISO
+bronchitis	B-DISO
+virus	B-SPEC
+.	O
+
+The	O
+hamster	B-SPEC
+cells	B-COMP
+became	O
+permissive	O
+to	O
+IBV	B-SPEC
+after	O
+transfection	B-PROC
+with	O
+a	O
+fAPN	B-PRGE
+cDNA	I-PRGE
+suggesting	O
+that	O
+the	O
+feline	B-PRGE
+APN	I-PRGE
+molecule	I-PRGE
+plays	O
+a	O
+role	O
+in	O
+IBV	B-SPEC
+entry	O
+.	O
+
+The	O
+cows	B-SPEC
+received	O
+2	O
+intramuscular	O
+injections	O
+of	O
+vaccine	O
+(	O
+2	O
+mL	O
+)	O
+at	O
+3	O
+-	O
+week	O
+intervals	O
+.	O
+
+Therefore	O
+,	O
+this	O
+vaccine	O
+may	O
+be	O
+useful	O
+for	O
+the	O
+prevention	O
+of	O
+winter	B-DISO
+dysentery	I-DISO
+caused	O
+by	O
+bovine	B-SPEC
+coronavirus	B-DISO
+infection	I-DISO
+.	O
+
+The	O
+usefulness	O
+of	O
+genetic	O
+detection	O
+of	O
+FCoV	O
+using	O
+reverse	B-PROC
+transcription	I-PROC
+and	O
+nested	O
+polymerase	O
+chain	O
+reaction	O
+(	O
+RT	O
+/	O
+nPCR	B-PRGE
+)	O
+for	O
+viral	O
+screening	O
+was	O
+investigated	O
+.	O
+
+Twenty	O
+-	O
+four	O
+animals	B-SPEC
+were	O
+positive	O
+using	O
+RT	B-PRGE
+/	I-PRGE
+nPCR	I-PRGE
+for	O
+virus	B-SPEC
+.	O
+
+Serology	O
+did	O
+not	O
+correlate	O
+with	O
+virus	B-DISO
+shedding	I-DISO
+because	O
+13	O
+animals	B-SPEC
+were	O
+seronegative	O
+to	O
+FCoV	B-PRGE
+type	I-PRGE
+I	I-PRGE
+and	I-PRGE
+II	I-PRGE
+but	O
+positive	O
+using	O
+RT	O
+/	O
+nPCR	O
+for	O
+virus	B-SPEC
+.	O
+
+A	O
+RT	O
+-	O
+PCR	O
+for	O
+the	O
+highly	O
+conserved	O
+region	O
+II	O
+of	O
+the	O
+3	O
+'	O
+untranslated	O
+region	O
+of	O
+the	O
+IBV	B-SPEC
+genome	O
+detected	O
+a	O
+coronavirus	B-SPEC
+in	O
+swabs	O
+from	O
+18	O
+/	O
+21	O
+estates	O
+.	O
+
+A	O
+RT	O
+-	O
+PCR	O
+for	O
+part	O
+of	O
+the	O
+S1	O
+region	O
+of	O
+the	O
+spike	O
+protein	B-CHED
+gene	O
+was	O
+positive	O
+with	O
+13	O
+/	O
+21	O
+of	O
+the	O
+samples	O
+.	O
+
+Further	O
+analysis	O
+of	O
+the	O
+genome	O
+of	O
+one	O
+of	O
+the	O
+viruses	B-SPEC
+revealed	O
+that	O
+it	O
+contained	O
+genes	O
+3	O
+and	O
+5	O
+that	O
+are	O
+typical	O
+of	O
+IBV	B-SPEC
+but	O
+absent	O
+in	O
+both	O
+the	O
+transmissible	O
+gastroenteritis	B-DISO
+virus	B-SPEC
+and	O
+murine	B-DISO
+hepatitis	I-DISO
+virus	B-SPEC
+groups	O
+of	O
+mammalian	B-SPEC
+coronaviruses	O
+.	O
+
+Persistent	O
+adenoviral	B-DISO
+infections	I-DISO
+need	O
+not	O
+be	O
+accompanied	O
+by	O
+any	O
+special	O
+clinical	O
+symptomatology	O
+.	O
+
+Variety	O
+of	O
+antiviral	B-CHED
+drugs	I-CHED
+with	O
+controversial	O
+effects	O
+have	O
+been	O
+reported	O
+in	O
+management	O
+of	O
+adenoviral	B-DISO
+infections	I-DISO
+in	O
+immunocompromised	O
+persons	O
+.	O
+
+Urinary	O
+samples	O
+were	O
+taken	O
+on	O
+admission	O
+and	O
+at	O
+6	O
+-	O
+hour	O
+intervals	O
+for	O
+48	O
+h	O
+,	O
+then	O
+every	O
+12	O
+h	O
+up	O
+to	O
+72	O
+h	O
+,	O
+and	O
+finally	O
+daily	O
+for	O
+at	O
+least	O
+5	O
+days	O
+for	O
+measurement	O
+of	O
+the	O
+activation	O
+peptide	B-CHED
+of	O
+sPLA	O
+(	O
+2	O
+)-	O
+I	O
+(	O
+pro	O
+-	O
+phosphatase	B-FUNC
+A	O
+(	O
+2	O
+);	O
+PROP	O
+)	O
+and	O
+trypsinogen	B-PRGE
+activation	I-PRGE
+peptide	B-CHED
+.	O
+
+RESULTS	O
+:	O
+There	O
+were	O
+18	O
+,	O
+133	O
+patients	O
+identified	O
+,	O
+and	O
+544	O
+were	O
+excluded	O
+because	O
+of	O
+early	O
+death	B-PROC
+.	O
+
+We	O
+have	O
+investigated	O
+the	O
+significance	O
+of	O
+this	O
+remarkable	O
+conservation	O
+by	O
+rearrangement	B-PROC
+of	O
+the	O
+murine	B-SPEC
+coronavirus	I-SPEC
+genome	O
+through	O
+targeted	B-PROC
+recombination	B-PROC
+.	O
+
+Thus	O
+,	O
+viruses	B-SPEC
+were	O
+prepared	O
+with	O
+the	O
+following	O
+gene	O
+order	B-SPEC
+:	O
+5	O
+'-	O
+pol	O
+-	O
+S	O
+-	O
+M	O
+-	O
+E	O
+-	O
+N	O
+-	O
+3	O
+',	O
+5	O
+'-	O
+pol	O
+-	O
+S	O
+-	O
+N	O
+-	O
+E	O
+-	O
+M	O
+-	O
+3	O
+',	O
+5	O
+'-	O
+pol	O
+-	O
+M	O
+-	O
+S	O
+-	O
+E	O
+-	O
+N	O
+-	O
+3	O
+',	O
+and	O
+5	O
+'-	O
+pol	O
+-	O
+E	O
+-	O
+M	O
+-	O
+S	O
+-	O
+N	O
+-	O
+3	O
+'.	O
+
+ABSTRACT	O
+:	O
+The	O
+targeted	B-PROC
+RNA	O
+recombination	B-PROC
+was	O
+attempted	O
+to	O
+substitute	O
+the	O
+membrane	B-COMP
+(	O
+M	O
+)	O
+protein	B-CHED
+gene	O
+and	O
+part	O
+of	O
+the	O
+nucleocapsid	B-COMP
+(	O
+N	O
+)	O
+protein	B-CHED
+gene	O
+of	O
+mouse	B-DISO
+hepatitis	I-DISO
+virus	B-SPEC
+with	O
+the	O
+corresponding	O
+sequences	O
+from	O
+bovine	B-SPEC
+coronavirus	B-SPEC
+.	O
+
+This	O
+study	O
+redirects	O
+our	O
+current	O
+approach	O
+of	O
+utilizing	O
+the	O
+MHV	B-SPEC
+targeted	B-PROC
+RNA	O
+recombination	B-PROC
+as	O
+a	O
+means	O
+to	O
+study	O
+bovine	B-SPEC
+coronavirus	B-SPEC
+genetics	O
+towards	O
+the	O
+construction	O
+of	O
+an	O
+infectious	B-DISO
+cDNA	O
+clone	O
+.	O
+
+ABSTRACT	O
+:	O
+High	O
+-	O
+frequency	O
+oscillatory	O
+ventilation	O
+(	O
+HFOV	O
+)	O
+and	O
+inhaled	B-PROC
+nitric	B-CHED
+oxide	I-CHED
+(	O
+iNO	O
+)	O
+have	O
+been	O
+reported	O
+to	O
+improve	O
+oxygenation	B-PROC
+in	O
+children	O
+with	O
+acute	O
+hypoxemic	O
+respiratory	B-DISO
+failure	I-DISO
+(	O
+AHRF	B-DISO
+),	O
+but	O
+their	O
+roles	O
+in	O
+the	O
+treatment	O
+of	O
+AHRF	B-DISO
+remains	O
+unknown	O
+.	O
+
+The	O
+patient	O
+was	O
+then	O
+randomized	O
+to	O
+treatment	O
+with	O
+or	O
+without	O
+iNO	B-PRGE
+.	O
+
+We	O
+found	O
+that	O
+the	O
+change	O
+in	O
+Pao	B-PROC
+/	O
+Fio	O
+ratio	O
+was	O
+greatest	O
+in	O
+the	O
+HFOV	O
+plus	O
+iNO	O
+group	O
+compared	O
+with	O
+the	O
+other	O
+treatment	O
+groups	O
+at	O
+4	O
+hrs	B-DISO
+(	O
+p	O
+=.	O
+02	O
+)	O
+and	O
+12	O
+hrs	B-DISO
+(	O
+p	O
+=.	O
+01	O
+).	O
+
+We	O
+conclude	O
+that	O
+the	O
+combination	O
+of	O
+HFOV	O
+with	O
+iNO	B-PRGE
+causes	O
+a	O
+greater	O
+improvement	O
+in	O
+oxygenation	B-PROC
+than	O
+either	O
+treatment	O
+strategy	O
+alone	O
+in	O
+children	O
+with	O
+severe	O
+AHRF	O
+.	O
+
+Main	O
+causes	O
+of	O
+death	B-PROC
+were	O
+multiple	B-DISO
+organ	I-DISO
+dysfunction	I-DISO
+syndrome	I-DISO
+,	O
+sepsis	B-DISO
+,	O
+and	O
+septic	B-DISO
+shock	I-DISO
+;	O
+refractory	O
+hypoxemia	O
+was	O
+uncommon	O
+.	O
+
+Independent	O
+predictors	O
+of	O
+death	B-PROC
+72	O
+hrs	B-DISO
+after	O
+admission	O
+emphasize	O
+the	O
+importance	O
+of	O
+both	O
+extrapulmonary	O
+and	O
+pulmonary	B-ANAT
+factors	O
+together	O
+with	O
+preexisting	O
+severe	O
+illnesses	O
+.	O
+
+TITLE	O
+:	O
+Identification	O
+of	O
+the	O
+epitope	B-CHED
+region	O
+capable	O
+of	O
+inducing	O
+neutralizing	O
+antibodies	B-COMP
+against	O
+the	O
+porcine	O
+epidemic	O
+diarrhea	O
+virus	O
+.	O
+
+This	O
+was	O
+based	O
+on	O
+the	O
+sequence	O
+information	O
+for	O
+the	O
+neutralizing	O
+epitope	B-CHED
+of	O
+the	O
+transmissible	O
+gastroenteritis	B-DISO
+virus	B-SPEC
+(	O
+TGEV	B-SPEC
+).	O
+
+The	O
+prone	O
+position	O
+improves	O
+oxygenation	B-PROC
+in	O
+a	O
+significant	O
+proportion	O
+of	O
+children	O
+with	O
+ARDS	B-DISO
+.	O
+
+Proventriculus	B-ANAT
+and	O
+gizzard	B-ANAT
+samples	O
+were	O
+obtained	O
+from	O
+all	O
+embryos	B-ANAT
+and	O
+routinely	O
+processed	O
+for	O
+microscopic	O
+and	O
+ultrastructural	O
+examinations	O
+.	O
+
+During	O
+infection	B-DISO
+,	O
+multiple	O
+subgenomic	O
+(	O
+sg	O
+)	O
+mRNAs	O
+are	O
+transcribed	O
+from	O
+a	O
+mirror	O
+set	O
+of	O
+sg	O
+negative	O
+-	O
+strand	O
+RNA	O
+templates	O
+.	O
+
+The	O
+sg	O
+mRNAs	O
+all	O
+possess	B-DISO
+a	O
+short	O
+5	O
+'	O
+common	O
+leader	O
+sequence	O
+,	O
+derived	O
+from	O
+the	O
+5	O
+'	O
+end	O
+of	O
+the	O
+genomic	O
+RNA	O
+.	O
+
+TITLE	O
+:	O
+Surfactant	B-CHED
+improves	O
+oxygenation	B-PROC
+in	O
+infants	O
+and	O
+children	O
+with	O
+pneumonia	B-DISO
+and	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+.	O
+
+Larger	O
+randomized	O
+controlled	O
+studies	O
+are	O
+necessary	O
+to	O
+evaluate	O
+the	O
+effects	O
+of	O
+surfactant	B-CHED
+treatment	O
+on	O
+morbidity	O
+and	O
+mortality	O
+.	O
+
+CONCLUSIONS	O
+:	O
+Surfactant	B-CHED
+dysfunction	O
+probably	O
+plays	O
+a	O
+role	O
+in	O
+the	O
+pathophysiology	O
+of	O
+severe	O
+paediatric	O
+ARDS	B-DISO
+triggered	O
+by	O
+pneumonia	B-DISO
+,	O
+as	O
+it	O
+was	O
+found	O
+that	O
+surfactant	B-CHED
+instillation	O
+rapidly	O
+improved	O
+gas	B-ENZY
+exchange	O
+in	O
+the	O
+majority	O
+of	O
+the	O
+affected	O
+infants	O
+in	O
+our	O
+study	O
+.	O
+
+TITLE	O
+:	O
+Alternative	O
+strategies	O
+for	O
+the	O
+management	O
+of	O
+respiratory	B-DISO
+failure	I-DISO
+in	O
+the	O
+newborn	O
+--	O
+clinical	O
+realities	O
+.	O
+
+CD4	B-PRGE
+(+)	O
+T	B-ANAT
+cells	I-ANAT
+are	O
+important	O
+in	O
+amplifying	O
+demyelination	B-DISO
+by	O
+attracting	O
+macrophages	B-ANAT
+into	O
+the	O
+central	B-ANAT
+nervous	I-ANAT
+system	I-ANAT
+(	O
+CNS	B-CHED
+)	O
+following	O
+viral	B-DISO
+infection	I-DISO
+;	O
+however	O
+,	O
+the	O
+mechanisms	O
+governing	O
+the	O
+entry	O
+of	O
+these	O
+cells	B-COMP
+into	O
+the	O
+CNS	B-CHED
+are	O
+poorly	O
+understood	O
+.	O
+
+Collectively	O
+these	O
+results	O
+demonstrate	O
+that	O
+CCR5	B-PRGE
+signaling	B-PROC
+is	O
+important	O
+to	O
+migration	B-PROC
+of	O
+CD4	B-PRGE
+(+)	O
+T	B-ANAT
+cells	I-ANAT
+to	O
+the	O
+CNS	B-CHED
+following	O
+MHV	B-SPEC
+infection	B-DISO
+.	O
+
+ABSTRACT	O
+:	O
+The	O
+use	O
+of	O
+recombinant	O
+gene	O
+technologies	O
+by	O
+the	O
+vaccine	O
+industry	O
+has	O
+revolutionized	O
+the	O
+way	O
+antigens	O
+are	O
+generated	O
+,	O
+and	O
+has	O
+provided	O
+safer	O
+,	O
+more	O
+effective	O
+means	O
+of	O
+protecting	O
+animals	B-SPEC
+and	O
+humans	B-SPEC
+against	O
+bacterial	O
+and	O
+viral	O
+pathogens	O
+.	O
+
+TITLE	O
+:	O
+Polypyrimidine	B-PRGE
+-	I-PRGE
+tract	I-PRGE
+-	I-PRGE
+binding	I-PRGE
+protein	B-CHED
+affects	O
+transcription	B-PROC
+but	O
+not	O
+translation	B-PROC
+of	O
+mouse	B-SPEC
+hepatitis	I-DISO
+virus	O
+RNA	O
+.	O
+
+To	O
+further	O
+characterize	O
+the	O
+function	O
+of	O
+PTB	B-PRGE
+in	O
+MHV	B-SPEC
+replication	O
+,	O
+we	O
+generated	O
+dominant	B-DISO
+-	I-DISO
+negative	I-DISO
+mutant	I-DISO
+cell	B-ANAT
+lines	I-ANAT
+that	O
+express	O
+a	O
+full	O
+-	O
+length	O
+PTB	O
+or	O
+a	O
+truncated	O
+form	O
+of	O
+PTB	B-PRGE
+,	O
+which	O
+includes	O
+only	O
+the	O
+N	O
+-	O
+terminal	O
+half	O
+of	O
+the	O
+protein	B-CHED
+,	O
+retaining	O
+its	O
+protein	B-CHED
+-	O
+dimerization	O
+domain	O
+.	O
+
+Given	O
+that	O
+PTB	B-PRGE
+interacts	O
+with	O
+the	O
+viral	B-PRGE
+N	I-PRGE
+protein	I-PRGE
+,	O
+which	O
+is	O
+one	O
+of	O
+the	O
+components	O
+of	O
+the	O
+MHV	B-PRGE
+replication	I-PRGE
+complex	I-PRGE
+,	O
+PTB	B-PRGE
+may	O
+exert	B-PROC
+its	O
+function	O
+on	O
+viral	B-PROC
+replication	I-PROC
+/	O
+transcription	B-PROC
+by	O
+association	O
+with	O
+viral	O
+RNA	O
+as	O
+well	O
+as	O
+other	O
+viral	O
+and	O
+cellular	B-COMP
+factors	O
+in	O
+the	O
+replication	O
+complex	O
+.	O
+
+ABSTRACT	O
+:	O
+A	O
+7	O
+-	O
+year	O
+-	O
+old	O
+boy	O
+with	O
+Down	O
+syndrome	O
+developed	O
+severe	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+after	O
+a	O
+respiratory	B-DISO
+infection	I-DISO
+with	O
+Mycoplasma	B-SPEC
+pneumoniae	I-SPEC
+with	O
+an	O
+unusually	O
+high	O
+agglutination	B-PROC
+titre	O
+(	O
+1	O
+:	O
+10240	O
+).	O
+
+Perforin	B-PRGE
+-	O
+mediated	O
+cytolysis	B-PROC
+controls	O
+virus	B-SPEC
+in	O
+microglia	B-ANAT
+/	O
+macrophages	B-ANAT
+and	O
+astrocytes	B-ANAT
+,	O
+whereas	O
+interferon	B-PRGE
+(	O
+IFN	O
+)-	O
+gamma	O
+regulates	O
+viral	B-PROC
+replication	I-PROC
+in	O
+oligodendroglia	B-ANAT
+.	O
+
+However	O
+,	O
+infectious	B-DISO
+virus	B-SPEC
+reactivates	O
+in	O
+antibody	B-COMP
+-	O
+deficient	O
+mice	B-SPEC
+following	O
+viral	O
+clearance	O
+.	O
+
+ABSTRACT	O
+:	O
+The	O
+spike	O
+1	O
+(	O
+S1	O
+)	O
+surface	O
+glycoprotein	B-CHED
+of	O
+infectious	B-DISO
+bronchitis	B-DISO
+virus	B-SPEC
+(	O
+IBV	B-SPEC
+)	O
+is	O
+the	O
+major	O
+inducer	O
+of	O
+the	O
+generation	O
+of	O
+virus	B-SPEC
+neutralizing	O
+antibodies	B-COMP
+,	O
+and	O
+the	O
+administration	O
+of	O
+purified	O
+S1	O
+has	O
+been	O
+shown	O
+to	O
+elicit	O
+a	O
+protective	O
+immune	B-PROC
+response	I-PROC
+against	O
+virulent	O
+virus	B-SPEC
+challenge	O
+.	O
+
+On	O
+the	O
+basis	O
+of	O
+these	O
+observations	O
+,	O
+recombinant	O
+fowl	O
+poxvirus	B-SPEC
+(	O
+rFPV	O
+)	O
+containing	O
+a	O
+cDNA	O
+copy	O
+of	O
+the	O
+S1	B-PRGE
+gene	I-PRGE
+of	O
+IBV	B-SPEC
+Mass	O
+41	O
+(	O
+rFPV	O
+-	O
+S1	O
+)	O
+was	O
+constructed	O
+and	O
+its	O
+immunogenicity	O
+and	O
+vaccine	O
+potential	O
+were	O
+evaluated	O
+.	O
+
+Thus	O
+,	O
+rFPV	O
+-	O
+S1	O
+has	O
+potential	O
+as	O
+a	O
+poultry	O
+vaccine	O
+against	O
+both	O
+fowl	B-DISO
+pox	I-DISO
+and	O
+infectious	B-DISO
+bronchitis	B-DISO
+.	O
+
+ABSTRACT	O
+:	O
+Nephropathogenic	O
+infectious	O
+bronchitis	B-DISO
+(	O
+NIB	O
+)	O
+was	O
+diagnosed	O
+in	O
+28	O
+infectious	B-DISO
+bronchitis	B-DISO
+virus	B-SPEC
+(	O
+IBV	B-SPEC
+)-	O
+vaccinated	O
+commercial	O
+chicken	B-SPEC
+flocks	O
+in	O
+Pennsylvania	O
+from	O
+December	O
+1997	O
+to	O
+July	O
+2000	O
+.	O
+
+Confirmatory	O
+diagnosis	O
+of	O
+NIB	O
+was	O
+made	O
+by	O
+IBV	B-SPEC
+antigen	B-CHED
+-	O
+specific	O
+immunohistochemical	O
+staining	O
+of	O
+the	O
+renal	O
+tubular	O
+epithelium	B-ANAT
+and	O
+virus	B-SPEC
+isolation	O
+.	O
+
+After	O
+immunization	O
+,	O
+the	O
+specific	O
+antibodies	B-COMP
+(	O
+called	O
+IgY	O
+)	O
+are	O
+transported	O
+to	O
+the	O
+egg	B-ANAT
+yolk	B-COMP
+,	O
+from	O
+which	O
+the	O
+IgY	O
+then	O
+can	O
+be	O
+separated	O
+without	O
+sacrificing	O
+chickens	B-SPEC
+.	O
+
+IgY	O
+is	O
+also	O
+an	O
+alternative	O
+to	O
+antibiotics	B-CHED
+for	O
+treatment	O
+of	O
+enteric	O
+antibiotic	B-CHED
+-	O
+resistant	O
+pathogens	O
+.	O
+
+ABSTRACT	O
+:	O
+IL	B-FUNC
+-	I-FUNC
+2	I-FUNC
+and	O
+IL	B-FUNC
+-	I-FUNC
+15	I-FUNC
+are	O
+thought	O
+to	O
+be	O
+important	O
+cytokines	O
+for	O
+T	B-ANAT
+cell	I-ANAT
+-	O
+dependent	O
+immune	B-PROC
+responses	I-PROC
+.	O
+
+Patients	O
+who	O
+are	O
+unable	O
+to	O
+protect	O
+the	O
+upper	O
+airway	B-ANAT
+,	O
+those	O
+with	O
+severe	O
+life	O
+-	O
+threatening	O
+hypoxaemia	O
+,	O
+or	O
+major	O
+associated	O
+organ	B-ANAT
+dysfunction	O
+are	O
+unlikely	O
+to	O
+benefit	O
+from	O
+this	O
+technique	O
+.	O
+
+Comparative	O
+sequence	O
+analysis	O
+indicated	O
+that	O
+,	O
+like	O
+its	O
+coronavirus	B-SPEC
+homologs	O
+,	O
+3CL	O
+(	O
+pro	B-CHED
+)	O
+has	O
+a	O
+three	O
+-	O
+domain	O
+organization	O
+and	O
+is	O
+flanked	O
+by	O
+hydrophobic	O
+domains	O
+.	O
+
+In	O
+this	O
+instance	O
+,	O
+lesions	O
+develop	O
+from	O
+the	O
+axon	B-COMP
+(	O
+inside	O
+)	O
+to	O
+the	O
+myelin	B-COMP
+(	O
+outside	O
+)	O
+(	O
+Inside	O
+-	O
+Out	O
+model	O
+).	O
+
+Sequence	O
+data	O
+were	O
+obtained	O
+from	O
+the	O
+M	B-PRGE
+gene	I-PRGE
+and	O
+pol1a	O
+and	O
+pol1b	O
+regions	O
+.	O
+
+The	O
+reliability	O
+of	O
+the	O
+classification	O
+results	O
+was	O
+confirmed	O
+by	O
+repeating	O
+the	O
+phylogenetic	O
+analysis	O
+with	O
+nucleotide	B-CHED
+and	O
+amino	B-CHED
+acid	I-CHED
+sequences	O
+from	O
+multiple	O
+genomic	O
+regions	O
+.	O
+
+The	O
+protocol	O
+incorporates	O
+four	O
+graded	O
+sliding	O
+scales	B-ANAT
+.	O
+
+TITLE	O
+:	O
+M	B-PRGE
+gene	I-PRGE
+evolution	B-PROC
+of	O
+canine	O
+coronavirus	B-SPEC
+in	O
+naturally	O
+infected	O
+dogs	B-SPEC
+.	O
+
+Treatment	O
+of	O
+sensitive	O
+Balb	O
+/	O
+cJ	O
+mice	B-SPEC
+with	O
+neutralizing	O
+anti	B-PRGE
+-	I-PRGE
+TGF	I-PRGE
+-	I-PRGE
+beta	I-PRGE
+antibody	I-PRGE
+could	O
+increase	O
+the	O
+STAT1	B-PRGE
+alpha	I-PRGE
+/	O
+beta	O
+ratio	O
+to	O
+<	O
+1	O
+.	O
+0	O
+in	O
+spleens	B-ANAT
+,	O
+predicting	O
+enhanced	O
+rates	O
+of	O
+survival	O
+.	O
+
+ABSTRACT	O
+:	O
+We	O
+studied	O
+the	O
+role	O
+of	O
+viruses	B-SPEC
+and	O
+atypical	O
+bacteria	B-SPEC
+in	O
+children	O
+hospitalized	O
+with	O
+exacerbated	O
+asthma	B-PATH
+by	O
+a	O
+prospective	O
+study	O
+of	O
+children	O
+with	O
+acute	B-DISO
+asthma	I-DISO
+admitted	O
+to	O
+the	O
+Department	O
+of	O
+Pediatrics	O
+in	O
+Lille	O
+,	O
+and	O
+to	O
+15	O
+hospitals	O
+in	O
+the	O
+Nord	O
+-	O
+Pas	B-COMP
+de	O
+Calais	O
+region	O
+,	O
+from	O
+October	O
+1	O
+,	O
+1998	O
+-	O
+June	O
+30	O
+,	O
+1999	O
+.	O
+
+Serological	O
+tests	O
+for	O
+atypical	O
+bacteria	B-SPEC
+were	O
+positive	O
+in	O
+10	O
+%	O
+of	O
+patients	O
+(	O
+C	B-SPEC
+.	I-SPEC
+pneumoniae	I-SPEC
+,	O
+5	O
+%;	O
+M	B-SPEC
+.	I-SPEC
+pneumoniae	I-SPEC
+,	O
+5	O
+%).	O
+
+Because	O
+of	O
+threats	O
+to	O
+the	O
+domestic	O
+poultry	O
+industry	O
+and	O
+wild	O
+birds	B-SPEC
+,	O
+screening	O
+for	O
+selected	O
+infectious	B-DISO
+agents	O
+has	O
+become	O
+routine	O
+since	O
+the	O
+early	O
+1980s	O
+.	O
+
+Samples	O
+from	O
+215	O
+lynx	B-SPEC
+from	O
+six	O
+study	O
+areas	O
+were	O
+tested	O
+for	O
+antibodies	B-COMP
+to	O
+feline	B-SPEC
+parvovirus	I-SPEC
+(	O
+FPV	B-SPEC
+),	O
+feline	B-SPEC
+coronavirus	B-SPEC
+,	O
+canine	B-SPEC
+distemper	I-SPEC
+virus	I-SPEC
+,	O
+feline	B-SPEC
+calicivirus	I-SPEC
+,	O
+feline	B-SPEC
+herpesvirus	I-SPEC
+,	O
+Yersinia	B-SPEC
+pestis	I-SPEC
+,	O
+and	O
+Francisella	B-SPEC
+tularensis	I-SPEC
+.	O
+
+Also	O
+,	O
+more	O
+males	O
+than	O
+females	O
+showed	O
+evidence	O
+of	O
+exposure	O
+to	O
+FPV	B-SPEC
+.	O
+
+Fifty	O
+-	O
+eight	O
+severe	O
+trauma	O
+patients	O
+,	O
+29	O
+with	O
+DIC	B-DISO
+and	O
+29	O
+without	O
+DIC	B-DISO
+were	O
+studied	O
+.	O
+
+Serial	O
+levels	O
+of	O
+soluble	O
+L	O
+-,	O
+P	O
+-,	O
+and	O
+E	O
+-	O
+selectins	O
+,	O
+ICAM	B-PRGE
+-	I-PRGE
+1	I-PRGE
+,	O
+VCAM	B-PRGE
+-	I-PRGE
+1	I-PRGE
+,	O
+thrombomodulin	B-PRGE
+,	O
+and	O
+neutrophil	B-PRGE
+elastase	I-PRGE
+were	O
+measured	O
+on	O
+days	O
+0	O
+-	O
+4	O
+after	O
+trauma	O
+.	O
+
+The	O
+incidence	O
+of	O
+ARDS	B-DISO
+and	O
+MODS	B-DISO
+were	O
+higher	O
+in	O
+patients	O
+with	O
+DIC	B-DISO
+than	O
+in	O
+those	O
+patients	O
+without	O
+DIC	B-DISO
+,	O
+and	O
+the	O
+DIC	B-DISO
+patients	O
+had	O
+poor	O
+outcome	O
+.	O
+
+The	O
+purposes	O
+of	O
+this	O
+study	O
+were	O
+to	O
+assess	O
+the	O
+occurrence	O
+of	O
+RV	O
+,	O
+enterovirus	B-SPEC
+,	O
+and	O
+coronavirus	B-DISO
+infections	I-DISO
+in	O
+wheezing	B-DISO
+infants	O
+and	O
+to	O
+evaluate	O
+the	O
+association	O
+of	O
+these	O
+viral	O
+findings	O
+with	O
+early	O
+school	O
+-	O
+age	O
+asthma	B-PATH
+.	O
+
+In	O
+1999	O
+,	O
+outcome	O
+in	O
+relation	O
+to	O
+asthma	B-PATH
+was	O
+studied	O
+in	O
+82	O
+of	O
+100	O
+initially	O
+recruited	O
+children	O
+who	O
+had	O
+been	O
+hospitalized	O
+for	O
+wheezing	B-DISO
+in	O
+infancy	O
+during	O
+the	O
+period	O
+1992	O
+-	O
+1993	O
+.	O
+
+As	O
+single	O
+viral	O
+findings	O
+,	O
+rhinoviruses	B-SPEC
+were	O
+associated	O
+with	O
+the	O
+development	B-PROC
+of	O
+asthma	B-PATH
+(	O
+P	O
+=.	O
+047	O
+;	O
+odds	O
+ratio	O
+,	O
+4	O
+.	O
+14	O
+;	O
+95	O
+%	O
+CI	O
+,	O
+1	O
+.	O
+02	O
+-	O
+16	O
+.	O
+77	O
+versus	O
+rhinovirus	B-SPEC
+-	O
+negative	O
+cases	O
+[	O
+by	O
+logistic	O
+regression	O
+adjusted	O
+for	O
+age	O
+,	O
+sex	O
+,	O
+and	O
+atopic	B-DISO
+dermatitis	I-DISO
+on	O
+entry	O
+)].	O
+
+CONCLUSIONS	O
+:	O
+Our	O
+results	O
+present	O
+rhinoviruses	B-SPEC
+as	O
+important	O
+inducers	O
+of	O
+wheezing	B-DISO
+even	O
+in	O
+infancy	O
+.	O
+
+A	O
+universal	O
+feature	O
+of	O
+this	O
+repair	B-PROC
+process	O
+is	O
+extensive	O
+proliferation	B-DISO
+of	O
+oligodendrocyte	B-ANAT
+progenitor	B-ANAT
+cells	I-ANAT
+(	O
+OPs	B-DISO
+)	O
+in	O
+response	O
+to	O
+demyelination	B-DISO
+.	O
+
+To	O
+investigate	O
+signals	O
+that	O
+regulate	O
+OP	O
+proliferation	B-DISO
+in	O
+response	O
+to	O
+demyelination	B-DISO
+we	O
+used	O
+murine	B-DISO
+hepatitis	I-DISO
+virus	B-SPEC
+-	O
+A59	O
+(	O
+MHV	B-SPEC
+-	O
+A59	O
+)	O
+infection	B-DISO
+of	O
+adult	O
+mice	B-SPEC
+to	O
+induce	O
+focal	O
+demyelination	B-DISO
+throughout	O
+the	O
+spinal	B-ANAT
+cord	I-ANAT
+followed	O
+by	O
+spontaneous	O
+remyelination	B-PROC
+.	O
+
+This	O
+was	O
+associated	O
+with	O
+an	O
+increase	O
+in	O
+PaO	B-PROC
+(	O
+2	O
+)	O
+and	O
+a	O
+decrease	O
+in	O
+total	O
+static	O
+compliance	O
+.	O
+
+Hyperinflated	O
+tissue	B-ANAT
+increased	O
+up	O
+to	O
+2	O
+.	O
+9	O
++/-	O
+4	O
+.	O
+0	O
+%	O
+with	O
+PEEP	B-CHED
+30	O
+cm	O
+H	O
+(	O
+2	O
+)	O
+O	O
+,	O
+and	O
+to	O
+a	O
+lesser	O
+degree	O
+with	O
+inspiration	B-PROC
+.	O
+
+TITLE	O
+:	O
+Genetic	O
+diversity	O
+of	O
+avian	B-DISO
+infectious	I-DISO
+bronchitis	I-DISO
+virus	B-SPEC
+California	B-SPEC
+variants	O
+isolated	O
+between	O
+1988	O
+and	O
+2001	O
+based	O
+on	O
+the	O
+S1	O
+subunit	O
+of	O
+the	O
+spike	O
+glycoprotein	O
+.	O
+
+ABSTRACT	O
+:	O
+Twenty	O
+-	O
+nine	O
+isolates	O
+of	O
+avian	B-DISO
+infectious	I-DISO
+bronchitis	I-DISO
+virus	B-SPEC
+(	O
+IBV	B-SPEC
+)	O
+recovered	O
+from	O
+commercial	O
+chicken	B-SPEC
+flocks	O
+in	O
+California	B-SPEC
+between	O
+1988	O
+and	O
+2001	O
+and	O
+identified	O
+as	O
+California	B-SPEC
+variants	O
+by	O
+serotype	O
+and	O
+direct	O
+automated	O
+cycle	O
+sequencing	O
+of	O
+the	O
+IBV	B-PRGE
+spike	I-PRGE
+glycoprotein	B-CHED
+S1	I-PRGE
+subunit	I-PRGE
+,	O
+were	O
+further	O
+characterized	O
+phylogenetically	O
+and	O
+by	O
+nucleotide	B-CHED
+sequence	O
+comparison	O
+.	O
+
+A	O
+high	O
+number	O
+of	O
+mutations	O
+at	O
+the	O
+nucleotide	B-CHED
+level	O
+(	O
+p	O
+=	O
+0	O
+.	O
+013	O
+)	O
+and	O
+a	O
+>	O
+or	O
+=	O
+6	O
+bp	O
+deletion	O
+in	O
+the	O
+nucleotide	B-CHED
+sequence	O
+(	O
+p	O
+=	O
+0	O
+.	O
+006	O
+)	O
+was	O
+significantly	O
+associated	O
+with	O
+broiler	O
+-	O
+type	O
+chickens	B-SPEC
+.	O
+
+ABSTRACT	O
+:	O
+Previous	O
+work	O
+has	O
+shown	O
+that	O
+in	O
+vitro	O
+thymulin	O
+treatments	O
+have	O
+the	O
+ability	O
+to	O
+enhance	O
+natural	O
+killer	O
+(	O
+NK	O
+)	O
+cell	B-COMP
+cytotoxicity	B-DISO
+.	O
+
+ARDS	B-DISO
+is	O
+a	O
+biphasic	B-DISO
+disease	I-DISO
+that	O
+includes	O
+an	O
+acute	O
+phase	O
+,	O
+consisting	O
+of	O
+severe	O
+leukocyte	B-ANAT
+infiltration	B-DISO
+,	O
+edema	B-DISO
+,	O
+hemorrhage	B-DISO
+,	O
+and	O
+the	O
+formation	B-PROC
+of	O
+hyaline	B-DISO
+membranes	B-ANAT
+,	O
+and	O
+a	O
+chronic	O
+phase	O
+,	O
+which	O
+is	O
+characterized	O
+by	O
+persistent	O
+intra	O
+-	O
+alveolar	B-ANAT
+and	O
+interstitial	B-DISO
+fibrosis	I-DISO
+.	O
+
+Therefore	O
+,	O
+while	O
+T	B-ANAT
+cells	I-ANAT
+are	O
+necessary	O
+for	O
+the	O
+development	B-PROC
+of	O
+intraluminal	O
+fibrosis	B-DISO
+associated	O
+with	O
+BOOP	B-DISO
+,	O
+they	O
+are	O
+not	O
+necessary	O
+for	O
+the	O
+development	B-PROC
+of	O
+intraluminal	O
+fibrosis	B-DISO
+associated	O
+with	O
+ARDS	B-DISO
+.	O
+
+The	O
+primary	O
+objective	O
+of	O
+this	O
+study	O
+was	O
+to	O
+test	O
+the	O
+hypothesis	O
+that	O
+in	O
+patients	O
+intubated	O
+for	O
+acute	O
+lung	O
+injury	O
+,	O
+lower	O
+concentrations	O
+of	O
+surfactant	B-CHED
+proteins	B-CHED
+A	O
+and	O
+D	O
+in	O
+the	O
+pulmonary	B-DISO
+edema	I-DISO
+fluid	O
+and	O
+higher	O
+concentrations	O
+in	O
+the	O
+plasma	B-ANAT
+are	O
+associated	O
+with	O
+more	O
+severe	O
+lung	B-ANAT
+injury	O
+and	O
+worse	O
+clinical	O
+outcomes	O
+.	O
+
+These	O
+results	O
+demonstrate	O
+that	O
+reduced	O
+pulmonary	B-DISO
+edema	I-DISO
+fluid	O
+surfactant	B-CHED
+protein	B-CHED
+D	O
+and	O
+elevated	O
+plasma	B-PRGE
+surfactant	B-CHED
+protein	B-CHED
+A	I-PRGE
+concentrations	O
+at	O
+the	O
+onset	O
+of	O
+acute	O
+lung	B-ANAT
+injury	O
+may	O
+be	O
+associated	O
+with	O
+more	O
+severe	O
+disease	O
+and	O
+worse	O
+clinical	O
+outcome	O
+and	O
+may	O
+serve	O
+as	O
+valuable	O
+biochemical	O
+markers	O
+of	O
+prognosis	O
+.	O
+
+ABSTRACT	O
+:	O
+High	O
+-	O
+frequency	O
+oscillation	O
+has	O
+been	O
+proposed	O
+for	O
+use	O
+in	O
+adult	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+.	O
+
+Large	O
+-	O
+animal	B-SPEC
+laboratory	O
+of	O
+a	O
+university	O
+-	O
+affiliated	O
+medical	O
+center	O
+.	O
+
+The	O
+use	O
+of	O
+a	O
+low	O
+tidal	O
+volume	O
+with	O
+moderate	O
+to	O
+high	O
+positive	O
+end	B-PROC
+-	I-PROC
+expiratory	I-PROC
+pressure	O
+improves	O
+the	O
+survival	O
+of	O
+patients	O
+with	O
+acute	O
+lung	B-ANAT
+injury	O
+and	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+.	O
+
+TITLE	O
+:	O
+Prevalence	O
+of	O
+enteric	O
+pathogens	O
+in	O
+dogs	B-SPEC
+of	O
+north	O
+-	O
+central	O
+Colorado	O
+.	O
+
+In	O
+fact	O
+,	O
+many	O
+cats	B-SPEC
+from	O
+the	O
+colonies	O
+with	O
+open	O
+management	O
+and	O
+frequent	O
+outbreaks	O
+of	O
+infectious	B-DISO
+diseases	I-DISO
+other	O
+than	O
+FIP	B-DISO
+had	O
+one	O
+or	O
+more	O
+haematological	O
+and	O
+/	O
+or	O
+electrophoretical	O
+changes	O
+consistent	O
+with	O
+FIP	B-DISO
+,	O
+compared	O
+with	O
+the	O
+reference	O
+ranges	O
+.	O
+
+The	O
+use	O
+of	O
+internal	O
+ranges	O
+designed	O
+on	O
+the	O
+basis	O
+of	O
+repeated	O
+samplings	O
+from	O
+non	O
+-	O
+symptomatic	O
+cats	B-SPEC
+allows	O
+avoiding	O
+these	O
+misinterpretations	O
+.	O
+
+TITLE	O
+:	O
+Identification	O
+of	O
+a	O
+receptor	O
+-	O
+binding	B-FUNC
+domain	O
+of	O
+the	O
+spike	O
+glycoprotein	B-CHED
+of	O
+human	B-SPEC
+coronavirus	I-SPEC
+HCoV	B-SPEC
+-	I-SPEC
+229E	I-SPEC
+.	O
+
+ABSTRACT	O
+:	O
+Human	B-PRGE
+coronavirus	I-PRGE
+HCoV	B-SPEC
+-	I-SPEC
+229E	I-SPEC
+uses	O
+human	B-PRGE
+aminopeptidase	B-ENZY
+N	I-ENZY
+(	O
+hAPN	O
+)	O
+as	O
+its	O
+receptor	O
+(	O
+C	O
+.	O
+L	O
+.	O
+Yeager	O
+et	O
+al	O
+.,	O
+Nature	O
+357	O
+:	O
+420	O
+-	O
+422	O
+,	O
+1992	O
+).	O
+
+We	O
+report	O
+here	O
+that	O
+,	O
+unexpectedly	O
+,	O
+some	O
+chimeric	O
+mRNAs	O
+expressing	O
+the	O
+2a	B-PRGE
+polymerase	I-PRGE
+open	I-PRGE
+reading	I-PRGE
+frame	I-PRGE
+from	O
+RNA2	B-PRGE
+were	O
+recruited	O
+by	O
+1a	O
+to	O
+the	O
+replication	O
+complex	O
+and	O
+served	O
+as	O
+templates	O
+for	O
+negative	O
+-	O
+strand	O
+RNA	B-PROC
+synthesis	I-PROC
+,	O
+despite	O
+lacking	O
+the	O
+normally	O
+essential	O
+,	O
+box	O
+B	O
+-	O
+containing	O
+5	O
+'	O
+signal	O
+.	O
+
+TITLE	O
+:	O
+Kinetics	O
+of	O
+virus	B-SPEC
+-	O
+specific	O
+CD8	B-PRGE
++	I-PRGE
+-	O
+T	B-ANAT
+-	I-ANAT
+cell	I-ANAT
+expansion	O
+and	O
+trafficking	B-PROC
+following	O
+central	B-ANAT
+nervous	I-ANAT
+system	I-ANAT
+infection	I-DISO
+.	O
+
+Both	O
+experimental	O
+models	O
+and	O
+studies	O
+in	O
+humans	B-SPEC
+suggest	O
+that	O
+inadequate	O
+hypothalamic	B-ANAT
+pituitary	I-ANAT
+adrenal	I-ANAT
+axis	I-ANAT
+response	B-PROC
+to	I-PROC
+stress	I-PROC
+accounts	O
+,	O
+at	O
+least	O
+partly	O
+,	O
+for	O
+the	O
+genesis	O
+of	O
+shock	O
+and	O
+organ	B-ANAT
+dysfunction	O
+in	O
+sepsis	B-DISO
+and	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+.	O
+
+Relative	O
+adrenal	B-DISO
+insufficiency	I-DISO
+and	O
+peripheral	O
+glucocorticoid	B-DISO
+resistance	B-PROC
+syndrome	B-DISO
+are	O
+the	O
+two	O
+main	O
+features	O
+of	O
+the	O
+inappropriate	O
+hormonal	O
+response	O
+and	O
+provide	O
+the	O
+grounds	O
+for	O
+cortisol	B-CHED
+replacement	O
+in	O
+these	O
+diseases	O
+.	O
+
+However	O
+,	O
+use	O
+of	O
+this	O
+technique	O
+has	O
+adverse	B-DISO
+effects	I-DISO
+,	O
+including	O
+increased	O
+risk	O
+of	O
+pneumonia	B-DISO
+,	O
+impaired	B-DISO
+cardiac	B-ANAT
+performance	O
+,	O
+and	O
+difficulties	O
+associated	O
+with	O
+sedation	B-DISO
+and	O
+paralysis	O
+.	O
+
+Moreover	O
+,	O
+application	O
+of	O
+pressure	O
+to	O
+the	O
+lung	B-ANAT
+,	O
+whether	O
+positive	O
+or	O
+negative	O
+,	O
+can	O
+cause	O
+damage	O
+known	O
+as	O
+ventilator	O
+-	O
+associated	O
+lung	B-ANAT
+injury	O
+(	O
+VALI	O
+).	O
+
+Despite	O
+difficulties	O
+in	O
+distinguishing	O
+the	O
+effects	O
+of	O
+mechanical	O
+ventilation	O
+from	O
+those	O
+of	O
+the	O
+underlying	O
+disorder	O
+,	O
+VALI	O
+greatly	O
+assists	O
+patients	O
+with	O
+the	O
+most	O
+severe	O
+form	O
+of	O
+lung	B-ANAT
+injury	O
+,	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+(	O
+ARDS	B-DISO
+).	O
+
+ABSTRACT	O
+:	O
+Renal	B-ANAT
+involvement	O
+is	O
+common	O
+in	O
+leptospirosis	B-DISO
+.	O
+
+Hemodynamic	B-PROC
+alterations	O
+,	O
+immune	B-PROC
+response	I-PROC
+,	O
+and	O
+direct	O
+nephrotoxicity	O
+are	O
+responsible	O
+for	O
+the	O
+development	B-PROC
+of	O
+renal	B-ANAT
+lesions	O
+.	O
+
+INO	O
+was	O
+initiated	O
+at	O
+a	O
+dose	O
+of	O
+5	O
+ppm	O
+,	O
+and	O
+subsequently	O
+titrated	O
+according	O
+to	O
+a	O
+protocol	O
+,	O
+to	O
+determine	O
+the	O
+dose	O
+(	O
+5	O
+,	O
+10	O
+,	O
+or	O
+20	O
+ppm	O
+)	O
+resulting	O
+in	O
+the	O
+greatest	O
+increase	O
+in	O
+Pao2	B-PRGE
+/	O
+Fio2	O
+.	O
+
+In	O
+these	O
+19	O
+patients	O
+,	O
+Pao2	B-PRGE
+/	O
+Fio2	O
+was	O
+highest	O
+at	O
+20	O
+ppm	O
+in	O
+four	O
+patients	O
+,	O
+at	O
+10	O
+ppm	O
+in	O
+eight	O
+patients	O
+,	O
+and	O
+at	O
+5	O
+ppm	O
+in	O
+seven	O
+patients	O
+.	O
+
+Surfactant	B-CHED
+apoproteins	B-CHED
+may	O
+be	O
+important	O
+markers	O
+of	O
+injury	O
+or	O
+for	O
+prognosis	O
+.	O
+
+Levels	O
+of	O
+surfactant	B-CHED
+apoprotein	B-PRGE
+A	I-PRGE
+(	O
+SP	B-PRGE
+-	I-PRGE
+A	I-PRGE
+)	O
+fall	O
+50	O
+-	O
+75	O
+%	O
+in	O
+patients	O
+with	O
+severe	O
+lung	B-ANAT
+injury	O
+compared	O
+to	O
+normal	O
+patients	O
+.	O
+
+ABSTRACT	O
+:	O
+To	O
+determine	O
+whether	O
+bovine	O
+surfactant	B-CHED
+given	O
+in	O
+cases	O
+of	O
+severe	O
+pediatric	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+(	O
+ARDS	B-DISO
+)	O
+improves	O
+oxygenation	B-PROC
+.	O
+
+Children	O
+after	O
+the	O
+44th	O
+postconceptional	O
+week	O
+and	O
+under	O
+14	O
+years	O
+old	O
+,	O
+admitted	O
+for	O
+at	O
+least	O
+4	O
+h	O
+,	O
+ventilated	O
+for	O
+12	O
+-	O
+120	O
+h	O
+,	O
+and	O
+without	O
+heart	B-DISO
+failure	I-DISO
+or	O
+chronic	B-DISO
+lung	I-DISO
+disease	I-DISO
+.	O
+
+The	O
+rate	O
+of	O
+rescue	O
+therapy	O
+was	O
+significantly	O
+lower	O
+in	O
+the	O
+surfactant	B-CHED
+group	O
+.	O
+
+A	O
+significant	O
+difference	O
+in	O
+PaO	B-PROC
+(	O
+2	O
+)/	O
+FIO	O
+(	O
+2	O
+)	O
+in	O
+favor	O
+of	O
+surfactant	B-CHED
+at	O
+48	O
+h	O
+was	O
+found	O
+in	O
+the	O
+subgroup	O
+with	O
+an	O
+initial	O
+PaO	B-PROC
+(	O
+2	O
+)/	O
+FIO	O
+(	O
+2	O
+)	O
+ratio	O
+higher	O
+than	O
+65	O
+and	O
+in	O
+patients	O
+without	O
+pneumonia	B-DISO
+.	O
+
+This	O
+improvement	O
+is	O
+sustained	O
+only	O
+in	O
+the	O
+subgroup	O
+of	O
+patients	O
+without	O
+pneumonia	B-DISO
+and	O
+that	O
+with	O
+an	O
+initial	O
+PaO	B-PROC
+(	O
+2	O
+)/	O
+FIO	O
+(	O
+2	O
+)	O
+ratio	O
+higher	O
+than	O
+65	O
+
+Anaesthesiological	O
+ICU	O
+,	O
+referral	O
+centre	O
+for	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+(	O
+ARDS	B-DISO
+)	O
+therapy	O
+,	O
+university	O
+hospital	O
+.	O
+
+Two	O
+hundred	O
+three	O
+consecutive	O
+PDTs	O
+were	O
+performed	O
+in	O
+198	O
+patients	O
+on	O
+either	O
+high	O
+(>	O
+10	O
+mbar	O
+,	O
+n	O
+=	O
+88	O
+)	O
+or	O
+low	O
+(</=	O
+10	O
+mbar	O
+,	O
+n	O
+=	O
+115	O
+)	O
+PEEP	B-CHED
+under	O
+bronchoscopic	O
+guidance	O
+.	O
+
+Arterial	B-ANAT
+blood	I-ANAT
+gas	O
+tensions	B-DISO
+were	O
+measured	O
+immediately	O
+before	O
+and	O
+1	O
+and	O
+24	O
+h	O
+after	O
+PDT	B-CHED
+.	O
+
+This	O
+area	O
+of	O
+central	O
+Italy	O
+was	O
+formerly	O
+endemic	O
+for	O
+malaria	B-PATH
+and	O
+it	O
+is	O
+now	O
+covered	O
+by	O
+a	O
+population	O
+-	O
+based	O
+cancer	B-DISO
+registry	O
+.	O
+
+CONCLUSIONS	O
+:	O
+These	O
+results	O
+were	O
+comparable	O
+to	O
+those	O
+derived	O
+from	O
+geographic	O
+areas	O
+at	O
+low	O
+risk	O
+for	O
+KS	O
+where	O
+malaria	B-PATH
+was	O
+not	O
+endemic	O
+(	O
+e	O
+.	O
+g	O
+.	O
+Malta	O
+).	O
+
+In	O
+cell	B-COMP
+-	O
+based	O
+assays	O
+,	O
+the	O
+lead	O
+compound	O
+(	O
+17c	O
+)	O
+prevented	O
+the	O
+HIV	B-SPEC
+-	I-SPEC
+1	I-SPEC
+multiplication	O
+with	O
+an	O
+EC	O
+(	O
+50	O
+)	O
+of	O
+8	O
+microM	O
+.	O
+The	O
+lead	O
+optimization	O
+strategy	O
+was	O
+developed	O
+by	O
+single	O
+or	O
+multiple	O
+modifications	O
+of	O
+the	O
+three	O
+molecular	O
+portions	O
+,	O
+in	O
+which	O
+17c	O
+was	O
+notionally	O
+divided	O
+.	O
+
+TITLE	O
+:	O
+Ventilation	O
+by	O
+the	O
+Open	O
+Lung	B-ANAT
+Concept	O
+in	O
+spite	O
+of	O
+traumatic	B-DISO
+lung	I-DISO
+herniation	B-DISO
+.	O
+
+ABSTRACT	O
+:	O
+Traumatic	O
+herniation	O
+of	O
+the	O
+lung	B-ANAT
+is	O
+uncommon	O
+.	O
+
+TITLE	O
+:	O
+Induction	O
+of	O
+prothrombinase	B-PRGE
+fgl2	I-PRGE
+by	O
+the	O
+nucleocapsid	B-COMP
+protein	B-CHED
+of	O
+virulent	O
+mouse	B-DISO
+hepatitis	I-DISO
+virus	B-SPEC
+is	O
+dependent	O
+on	O
+host	B-PRGE
+hepatic	B-ANAT
+nuclear	I-PRGE
+factor	I-PRGE
+-	I-PRGE
+4	I-PRGE
+alpha	I-PRGE
+.	O
+
+We	O
+demonstrated	O
+that	O
+the	O
+-	O
+331	O
+/-	O
+325	O
+HNF4	B-PRGE
+cis	I-PRGE
+-	I-PRGE
+element	I-PRGE
+and	O
+its	O
+cognate	O
+transcription	B-PROC
+factor	O
+,	O
+HNF4alpha	B-PRGE
+,	O
+are	O
+necessary	O
+for	O
+virus	B-SPEC
+-	O
+induced	O
+fgl2	B-PRGE
+gene	I-PRGE
+transcription	O
+.	O
+
+In	O
+uninfected	O
+macrophages	B-ANAT
+and	O
+macrophages	B-ANAT
+infected	O
+with	O
+MHV	B-SPEC
+-	O
+2	O
+,	O
+an	O
+unidentified	O
+protein	B-CHED
+occupies	O
+the	O
+HNF4	B-PRGE
+cis	I-PRGE
+-	I-PRGE
+element	I-PRGE
+.	O
+
+Collectively	O
+,	O
+the	O
+results	O
+of	O
+this	O
+study	O
+define	O
+both	O
+viral	O
+and	O
+host	B-COMP
+factors	O
+necessary	O
+for	O
+induction	O
+of	O
+fgl2	B-PRGE
+prothrombinase	I-PRGE
+gene	B-PROC
+transcription	I-PROC
+in	O
+MHV	B-SPEC
+infection	B-DISO
+and	O
+may	O
+provide	O
+an	O
+explanation	O
+for	O
+the	O
+hepatotrophic	O
+nature	O
+of	O
+MHV	B-SPEC
+-	O
+induced	O
+fulminant	B-DISO
+hepatic	I-DISO
+failure	I-DISO
+.	O
+
+Their	O
+role	O
+in	O
+precipitating	O
+episodes	O
+of	O
+severe	B-DISO
+anemia	I-DISO
+among	O
+the	O
+patients	O
+studied	O
+could	O
+not	O
+be	O
+fully	O
+evaluated	O
+.	O
+
+Although	O
+it	O
+was	O
+necessary	O
+for	O
+her	O
+to	O
+be	O
+in	O
+the	O
+intensive	O
+care	O
+unit	O
+for	O
+8	O
+days	O
+,	O
+her	O
+condition	B-DISO
+gradually	O
+improved	O
+and	O
+was	O
+discharged	O
+on	O
+the	O
+30th	O
+of	O
+September	O
+.	O
+
+She	O
+was	O
+treated	O
+by	O
+sparfloxacin	B-CHED
+because	O
+the	O
+intrafamilial	O
+infection	B-DISO
+of	O
+M	B-SPEC
+.	I-SPEC
+pneumoniae	I-SPEC
+was	O
+most	O
+likely	O
+.	O
+
+The	O
+diagnosis	O
+was	O
+confirmed	O
+by	O
+the	O
+increased	O
+antibody	B-COMP
+-	O
+titer	O
+to	O
+M	B-SPEC
+.	I-SPEC
+pneumoniae	I-SPEC
+later	O
+.	O
+
+Endothelial	B-ANAT
+cells	I-ANAT
+form	O
+a	O
+major	O
+capillary	B-ANAT
+barrier	O
+,	O
+and	O
+disruption	O
+of	O
+the	O
+barrier	O
+appears	O
+to	O
+involve	O
+a	O
+decreased	O
+level	O
+of	O
+ATP	B-CHED
+in	O
+the	O
+cells	B-COMP
+.	O
+
+We	O
+examined	O
+the	O
+effect	O
+of	O
+PEP	B-CHED
+on	O
+oleic	B-CHED
+acid	I-CHED
+-	O
+induced	O
+lung	B-ANAT
+injury	O
+in	O
+guinea	B-SPEC
+pigs	I-SPEC
+.	O
+
+Furthermore	O
+,	O
+PEP	B-CHED
+attenuated	O
+the	O
+oleic	B-CHED
+acid	I-CHED
+-	O
+induced	O
+increase	O
+in	O
+vascular	B-PROC
+permeability	I-PROC
+in	O
+the	O
+proximal	O
+and	O
+distal	O
+bronchi	O
+,	O
+as	O
+indicated	O
+by	O
+the	O
+extravascular	O
+leakage	B-DISO
+of	O
+Evans	O
+Blue	O
+dye	B-CHED
+.	O
+
+The	O
+combination	O
+of	O
+PEP	B-CHED
+with	O
+ATP	B-CHED
+(	O
+4	O
+micromol	O
+/	O
+kg	O
+)	O
+showed	O
+no	O
+additional	O
+inhibitory	O
+effect	O
+on	O
+oleic	B-CHED
+acid	I-CHED
+-	O
+induced	O
+lung	B-ANAT
+injury	O
+,	O
+compared	O
+with	O
+PEP	B-CHED
+alone	O
+.	O
+
+Blood	B-ANAT
+was	O
+obtained	O
+before	O
+the	O
+induction	O
+of	O
+anesthesia	B-DISO
+,	O
+when	O
+82	O
+%	O
+of	O
+the	O
+patients	O
+met	B-CHED
+the	O
+criteria	O
+for	O
+SIRS	B-DISO
+.	O
+
+We	O
+investigated	O
+the	O
+MBL	O
+concentrations	O
+in	O
+serum	B-COMP
+during	O
+experimental	O
+infectious	B-DISO
+bronchitis	B-DISO
+virus	B-SPEC
+(	O
+IBV	B-SPEC
+)	O
+infections	B-DISO
+in	O
+chickens	B-SPEC
+.	O
+
+The	O
+acute	B-DISO
+phase	I-DISO
+response	I-DISO
+in	O
+chickens	B-SPEC
+challenged	O
+after	O
+12	O
+h	O
+of	O
+activity	O
+peaked	O
+after	O
+4	O
+.	O
+6	O
+d	O
+with	O
+an	O
+increase	O
+of	O
+24	O
+%,	O
+whereas	O
+the	O
+acute	O
+phase	O
+response	O
+in	O
+chickens	B-SPEC
+challenged	O
+after	O
+12	O
+h	O
+of	O
+rest	B-FUNC
+peaked	O
+after	O
+3	O
+.	O
+1	O
+d	O
+with	O
+an	O
+increase	O
+of	O
+51	O
+%.	O
+
+The	O
+transcriptional	B-PROC
+regulatory	O
+factor	B-PRGE
+nuclear	I-PRGE
+factor	I-PRGE
+-	I-PRGE
+kappaB	I-PRGE
+(	O
+NF	B-PRGE
+-	I-PRGE
+kappaB	I-PRGE
+)	O
+is	O
+involved	O
+in	O
+modulating	O
+the	O
+expression	B-PROC
+of	O
+many	O
+cytokines	O
+and	O
+other	O
+proinflammatory	O
+mediators	O
+implicated	O
+in	O
+the	O
+development	B-PROC
+and	O
+progression	O
+of	O
+ALI	O
+.	O
+
+Differential	O
+susceptibility	O
+of	O
+infected	O
+cell	B-COMP
+types	O
+to	O
+clearance	O
+by	O
+perforin	B-PRGE
+or	O
+IFN	B-PRGE
+-	I-PRGE
+gamma	I-PRGE
+uncovered	O
+distinct	O
+,	O
+nonredundant	O
+roles	O
+for	O
+these	O
+antiviral	B-CHED
+mechanisms	O
+.	O
+
+To	O
+separately	O
+evaluate	O
+each	O
+effector	B-CHED
+function	O
+specifically	O
+in	O
+the	O
+context	O
+of	O
+CD8	B-PRGE
+(+)	O
+T	B-ANAT
+cells	I-ANAT
+,	O
+pathogenesis	B-DISO
+was	O
+analyzed	O
+in	O
+mice	B-SPEC
+deficient	O
+in	O
+both	O
+perforin	B-PRGE
+and	O
+IFN	B-PRGE
+-	I-PRGE
+gamma	I-PRGE
+(	O
+PKO	O
+/	O
+GKO	O
+)	O
+or	O
+selectively	O
+reconstituted	O
+for	O
+each	O
+function	O
+by	O
+transfer	O
+of	O
+CD8	B-PRGE
+(+)	O
+T	B-ANAT
+cells	I-ANAT
+.	O
+
+Uncontrolled	O
+infection	B-DISO
+was	O
+associated	O
+with	O
+limited	O
+MHC	B-PROC
+class	B-SPEC
+I	O
+up	B-PROC
+-	I-PROC
+regulation	I-PROC
+and	O
+an	O
+absence	O
+of	O
+class	B-SPEC
+II	O
+expression	B-PROC
+on	O
+microglia	B-ANAT
+,	O
+coinciding	O
+with	O
+decreased	O
+CD4	O
+(+)	O
+T	B-ANAT
+cells	I-ANAT
+in	O
+CNS	B-CHED
+infiltrates	B-DISO
+.	O
+
+TITLE	O
+:	O
+Chronic	B-DISO
+alcohol	I-DISO
+abuse	I-DISO
+is	O
+associated	O
+with	O
+an	O
+increased	O
+incidence	O
+of	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+and	O
+severity	O
+of	O
+multiple	O
+organ	B-ANAT
+dysfunction	O
+in	O
+patients	O
+with	O
+septic	B-DISO
+shock	I-DISO
+.	O
+
+PATIENTS	O
+A	O
+total	O
+of	O
+220	O
+critically	B-DISO
+ill	I-DISO
+patients	O
+with	O
+septic	B-DISO
+shock	I-DISO
+.	O
+
+Based	O
+on	O
+the	O
+highest	O
+daily	O
+Sequential	O
+Organ	B-DISO
+Failure	I-DISO
+Assessment	O
+score	O
+,	O
+patients	O
+with	O
+a	O
+history	O
+of	O
+chronic	B-DISO
+alcohol	I-DISO
+abuse	I-DISO
+had	O
+more	O
+severe	O
+nonpulmonary	O
+organ	B-ANAT
+dysfunction	O
+when	O
+compared	O
+with	O
+nonalcoholics	O
+(	O
+9	O
+.	O
+42	O
++/-	O
+
+We	O
+conclude	O
+that	O
+chronic	B-DISO
+alcohol	I-DISO
+abuse	I-DISO
+is	O
+an	O
+independent	O
+risk	O
+factor	O
+for	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+and	O
+increases	O
+the	O
+severity	O
+of	O
+nonpulmonary	O
+organ	B-ANAT
+dysfunction	O
+in	O
+patients	O
+with	O
+septic	B-DISO
+shock	I-DISO
+.	O
+
+Group	O
+I	O
+received	O
+high	O
+(	O
+recruitive	O
+)	O
+positive	O
+end	B-PROC
+-	I-PROC
+expiratory	I-PROC
+pressure	O
+(	O
+9	O
+-	O
+20	O
+cm	O
+H2O	B-CHED
+),	O
+adjusted	O
+as	O
+needed	O
+;	O
+group	O
+II	O
+received	O
+low	O
+(	O
+supportive	O
+)	O
+positive	O
+end	B-PROC
+-	I-PROC
+expiratory	I-PROC
+pressure	O
+(	O
+2	O
+-	O
+6	O
+cm	O
+H2O	B-CHED
+).	O
+
+This	O
+happened	O
+at	O
+a	O
+younger	O
+age	O
+among	O
+the	O
+more	O
+heavily	O
+infected	O
+sculpins	O
+at	O
+Torbjørnskjaer	O
+than	O
+at	O
+Vega	O
+,	O
+and	O
+we	O
+interpret	O
+this	O
+as	O
+density	O
+dependence	B-DISO
+in	O
+the	O
+fish	B-SPEC
+host	B-COMP
+.	O
+
+In	O
+this	O
+case	O
+,	O
+recruitment	B-DISO
+maneuver	O
+and	O
+high	O
+PEEP	B-CHED
+relieved	O
+postoperative	O
+respiratory	B-DISO
+failure	I-DISO
+.	O
+
+In	O
+ICU	O
+we	O
+repeated	O
+recruitment	B-DISO
+maneuver	O
+(	O
+PEEP	B-CHED
+:	O
+30	O
+cmH2O	O
+,	O
+peak	O
+inspiratory	B-PROC
+pressure	O
+:	O
+42	O
+cmH2O	O
+,	O
+respiratory	O
+rate	O
+;	O
+15	O
+breaths	O
+.	O
+min	O
+-	O
+1	O
+,	O
+for	O
+1	O
+min	O
+)	O
+and	O
+kept	O
+high	O
+PEEP	B-CHED
+(	O
+15	O
+cmH2O	O
+).	O
+
+TITLE	O
+:	O
+Susceptibility	O
+of	O
+three	O
+genetic	O
+lines	O
+of	O
+chicks	O
+to	O
+infection	B-DISO
+with	O
+a	O
+nephropathogenic	O
+T	O
+strain	O
+of	O
+avian	O
+infectious	O
+bronchitis	O
+virus	B-SPEC
+.	O
+
+Histopathological	O
+assessment	O
+indicated	O
+an	O
+earlier	O
+onset	O
+of	O
+a	O
+regenerative	O
+phase	O
+in	O
+the	O
+trachea	B-DISO
+of	O
+W	O
+chicks	O
+than	O
+in	O
+S	O
+chicks	O
+.	O
+
+S	O
+chicks	O
+,	O
+in	O
+contrast	O
+to	O
+W	O
+chicks	O
+,	O
+showed	O
+no	O
+signs	O
+of	O
+renal	B-ANAT
+regeneration	B-PROC
+.	O
+
+Additionally	O
+,	O
+the	O
+kidneys	B-ANAT
+of	O
+S	O
+chicks	O
+differed	O
+from	O
+those	O
+of	O
+W	O
+chicks	O
+in	O
+showing	O
+more	O
+severe	O
+nephritis	B-DISO
+,	O
+more	O
+tubular	B-DISO
+necrosis	I-DISO
+and	O
+less	O
+heterophil	B-ANAT
+infiltration	B-DISO
+and	O
+lymphocytic	O
+response	O
+throughout	O
+the	O
+acute	O
+phase	O
+of	O
+infection	B-DISO
+.	O
+
+were	O
+transferred	O
+to	O
+six	O
+-	O
+day	O
+-	O
+old	O
+syngeneic	O
+chicks	O
+one	O
+day	O
+prior	O
+to	O
+challenging	O
+with	O
+10	O
+(	O
+6	O
+)	O
+EID	O
+(	O
+50	O
+)	O
+of	O
+the	O
+IBV	B-SPEC
+Gray	O
+strain	O
+.	O
+
+We	O
+evaluated	O
+pulmonary	B-ANAT
+VEGF	B-PRGE
+expression	B-PROC
+in	O
+lung	B-ANAT
+autopsy	O
+material	O
+from	O
+septic	O
+patients	O
+who	O
+had	O
+been	O
+cared	O
+for	O
+by	O
+intensive	O
+care	O
+medicine	B-CHED
+using	O
+enzyme	O
+-	O
+linked	O
+immunosorbent	O
+assay	O
+(	O
+ELISA	O
+),	O
+reverse	B-PRGE
+transcriptase	I-PRGE
+-	O
+polymerase	O
+chain	O
+reaction	O
+(	O
+RT	O
+-	O
+PCR	O
+),	O
+and	O
+immunohistochemical	O
+methods	O
+.	O
+
+Within	O
+4	O
+h	O
+after	O
+seawater	O
+perfusion	O
+,	O
+no	O
+pathological	O
+changes	O
+were	O
+seen	O
+in	O
+the	O
+lung	B-ANAT
+tissues	I-ANAT
+without	O
+direct	O
+contact	O
+with	O
+seawater	O
+.	O
+
+TITLE	O
+:	O
+Dose	O
+-	O
+response	O
+characteristics	O
+during	O
+long	O
+-	O
+term	O
+inhalation	B-PROC
+of	O
+nitric	B-CHED
+oxide	I-CHED
+in	O
+patients	O
+with	O
+severe	O
+acute	O
+respiratory	O
+distress	O
+syndrome	O
+:	O
+a	O
+prospective	O
+,	O
+randomized	O
+,	O
+controlled	O
+study	O
+.	O
+
+ABSTRACT	O
+:	O
+Inhaled	B-PROC
+nitric	B-CHED
+oxide	I-CHED
+(	O
+NO	O
+)	O
+improves	O
+systemic	O
+oxygenation	B-PROC
+(	O
+PaO2	O
+/	O
+FIO2	O
+)	O
+in	O
+adult	O
+patients	O
+with	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+(	O
+ARDS	B-DISO
+).	O
+
+Patients	O
+were	O
+randomized	O
+for	O
+conventional	O
+therapy	O
+(	O
+control	O
+)	O
+or	O
+continuous	O
+treatment	O
+with	O
+10	O
+parts	O
+per	O
+million	O
+(	O
+ppm	O
+)	O
+inhaled	B-PROC
+NO	O
+until	O
+weaning	B-PROC
+was	O
+initiated	O
+.	O
+
+BBS	B-PRGE
+-	I-PRGE
+2	I-PRGE
+,	O
+a	O
+potent	O
+and	O
+highly	O
+selective	O
+iNOS	B-PRGE
+dimerization	I-PRGE
+inhibitor	I-PRGE
+,	O
+was	O
+used	O
+to	O
+exclude	O
+effects	O
+on	O
+the	O
+endothelial	B-ANAT
+and	O
+neuronal	O
+NOS	O
+isoforms	O
+.	O
+
+TITLE	O
+:	O
+Future	O
+research	O
+directions	O
+in	O
+acute	O
+lung	B-ANAT
+injury	O
+:	O
+summary	O
+of	O
+a	O
+National	O
+Heart	B-ANAT
+,	O
+Lung	B-ANAT
+,	O
+and	O
+Blood	B-ANAT
+Institute	O
+working	O
+group	O
+.	O
+
+ABSTRACT	O
+:	O
+Feline	O
+infectious	O
+peritonitis	O
+virus	B-SPEC
+(	O
+FIPV	O
+),	O
+a	O
+coronavirus	B-SPEC
+,	O
+is	O
+the	O
+causative	O
+agent	O
+of	O
+an	O
+invariably	O
+lethal	O
+infection	B-DISO
+in	O
+cats	B-SPEC
+.	O
+
+The	O
+r	O
+-	O
+wtFIPV	O
+was	O
+indistinguishable	O
+from	O
+its	O
+parental	O
+virus	B-SPEC
+FIPV	O
+79	O
+-	O
+1146	O
+not	O
+only	O
+for	O
+its	O
+growth	B-PROC
+characteristics	O
+in	O
+tissue	B-ANAT
+culture	O
+but	O
+also	O
+in	O
+cats	B-SPEC
+,	O
+exhibiting	O
+a	O
+highly	O
+lethal	O
+phenotype	O
+.	O
+
+We	O
+establish	O
+the	O
+second	O
+targeted	B-PROC
+RNA	O
+recombination	B-PROC
+system	O
+for	O
+coronaviruses	O
+and	O
+provide	O
+a	O
+powerful	O
+tool	O
+for	O
+the	O
+genetic	O
+engineering	O
+of	O
+the	O
+FIPV	O
+genome	O
+.	O
+
+Expression	B-PROC
+of	O
+the	O
+E	B-PRGE
+protein	I-PRGE
+alone	O
+results	O
+in	O
+its	O
+incorporation	O
+into	O
+vesicles	B-COMP
+that	O
+are	O
+released	O
+from	O
+cells	B-COMP
+,	O
+and	O
+the	O
+coexpression	O
+of	O
+the	O
+E	B-PRGE
+protein	I-PRGE
+with	O
+the	O
+membrane	B-COMP
+protein	B-CHED
+M	O
+leads	O
+to	O
+the	O
+assembly	O
+of	O
+coronavirus	B-SPEC
+-	O
+like	O
+particles	O
+.	O
+
+ABSTRACT	O
+:	O
+Replication	O
+of	O
+the	O
+neurotropic	O
+JHM	O
+strain	O
+of	O
+mouse	O
+hepatitis	O
+virus	B-SPEC
+within	O
+the	O
+central	B-ANAT
+nervous	I-ANAT
+system	I-ANAT
+is	O
+controlled	O
+by	O
+cellular	B-PROC
+immunity	I-PROC
+.	O
+
+TITLE	O
+:	O
+Murine	B-SPEC
+coronavirus	I-SPEC
+-	O
+induced	O
+hepatitis	B-DISO
+:	O
+JHM	O
+genetic	O
+background	O
+eliminates	O
+A59	O
+spike	O
+-	O
+determined	O
+hepatotropism	O
+.	O
+
+The	O
+illness	O
+is	O
+being	O
+referred	O
+to	O
+as	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+(	O
+SARS	B-DISO
+).	O
+
+ABSTRACT	O
+:	O
+Different	O
+therapeutic	O
+approaches	O
+have	O
+recently	O
+been	O
+developed	O
+for	O
+treatment	O
+of	O
+acute	O
+respiratory	O
+distress	O
+syndrome	O
+(	O
+ARDS	B-DISO
+)	O
+with	O
+the	O
+aim	O
+of	O
+improving	O
+the	O
+outcome	O
+.	O
+
+TITLE	O
+:	O
+Viruses	B-SPEC
+causing	O
+gastroenteritis	B-DISO
+.	O
+
+Since	O
+the	O
+Norwalk	B-SPEC
+virus	I-SPEC
+was	O
+identified	O
+as	O
+a	O
+cause	O
+of	O
+gastroenteritis	B-DISO
+,	O
+the	O
+number	O
+of	O
+viral	O
+agents	O
+associated	O
+with	O
+diarrheal	B-DISO
+disease	I-DISO
+in	O
+humans	B-SPEC
+has	O
+steadily	O
+increased	O
+.	O
+
+Rotavirus	B-SPEC
+is	O
+the	O
+most	O
+common	O
+cause	O
+of	O
+severe	B-DISO
+diarrhea	I-DISO
+in	O
+children	O
+under	O
+5	O
+years	O
+of	O
+age	O
+.	O
+
+It	O
+has	O
+been	O
+demonstrated	O
+that	O
+MHV	B-SPEC
+-	O
+specific	O
+CD4	B-PRGE
+and	O
+CD8	B-PRGE
+T	I-PRGE
+cells	O
+are	O
+capable	O
+of	O
+causing	O
+demyelination	B-DISO
+independent	O
+of	O
+the	O
+other	O
+T	B-ANAT
+cell	I-ANAT
+subset	I-ANAT
+.	O
+
+TITLE	O
+:	O
+Detection	O
+of	O
+infectious	B-DISO
+bronchitis	B-DISO
+virus	B-SPEC
+by	O
+multiplex	O
+polymerase	O
+chain	O
+reaction	O
+and	O
+sequence	O
+analysis	O
+.	O
+
+Sequence	O
+analysis	O
+of	O
+the	O
+hypervariable	O
+region	O
+(	O
+HVR	O
+)	O
+of	O
+S1	B-PRGE
+gene	I-PRGE
+exhibited	O
+high	O
+variations	O
+among	O
+Taiwanese	O
+IBV	B-SPEC
+isolates	O
+.	O
+
+This	O
+report	O
+summarizes	O
+the	O
+initial	O
+epidemiologic	O
+findings	O
+,	O
+clinical	O
+description	O
+,	O
+and	O
+diagnostic	B-DISO
+findings	I-DISO
+that	O
+followed	O
+the	O
+identification	O
+of	O
+SARS	B-DISO
+in	O
+Canada	O
+.	O
+
+SARS	B-DISO
+was	O
+first	O
+identified	O
+in	O
+Canada	O
+in	O
+early	O
+March	O
+2003	O
+.	O
+
+There	O
+was	O
+no	O
+evidence	O
+of	O
+infection	B-DISO
+by	O
+Mycoplasma	B-SPEC
+pneumoniae	I-SPEC
+,	O
+Chlamydia	B-SPEC
+pneumoniae	I-SPEC
+,	O
+or	O
+Legionella	B-SPEC
+pneumophila	I-SPEC
+.	O
+
+All	O
+patients	O
+received	O
+corticosteroid	B-CHED
+and	O
+ribavirin	B-CHED
+therapy	O
+a	O
+mean	O
+(+/-	O
+SD	O
+)	O
+of	O
+9	O
+.	O
+6	O
++/-	O
+5	O
+.	O
+42	O
+days	O
+after	O
+the	O
+onset	O
+of	O
+symptoms	O
+,	O
+and	O
+eight	O
+were	O
+treated	O
+earlier	O
+with	O
+a	O
+combination	O
+of	O
+beta	B-CHED
+-	I-CHED
+lactams	I-CHED
+and	O
+macrolide	B-CHED
+for	O
+4	O
++/-	O
+1	O
+.	O
+9	O
+days	O
+,	O
+with	O
+no	O
+clinical	O
+or	O
+radiologic	O
+efficacy	O
+.	O
+
+ABSTRACT	O
+:	O
+We	O
+present	O
+a	O
+rare	O
+entity	O
+of	O
+colonic	O
+pseudo	O
+-	O
+obstruction	O
+,	O
+characterised	O
+by	O
+severe	O
+colonic	B-ANAT
+dilatation	B-DISO
+in	O
+absence	O
+of	O
+any	O
+organic	O
+obstacle	O
+.	O
+
+The	O
+acute	O
+colonic	B-DISO
+pseudo	I-DISO
+-	I-DISO
+obstruction	I-DISO
+,	O
+Ogilvie	B-DISO
+'	I-DISO
+s	I-DISO
+Syndrome	I-DISO
+,	O
+most	O
+often	O
+appears	O
+as	O
+a	O
+complication	B-DISO
+of	O
+other	O
+clinical	O
+conditions	O
+.	O
+
+Fever	B-PROC
+and	O
+exanthema	B-DISO
+were	O
+observed	O
+in	O
+all	O
+patients	O
+,	O
+and	O
+an	O
+eschar	B-DISO
+was	O
+pointed	O
+out	O
+in	O
+20	O
+(	O
+71	O
+%)	O
+patients	O
+.	O
+
+In	O
+the	O
+2	O
+patients	O
+complicated	O
+by	O
+multiorgan	B-DISO
+failure	I-DISO
+,	O
+the	O
+sIL2	B-PRGE
+-	I-PRGE
+R	I-PRGE
+level	O
+,	O
+produced	O
+by	O
+activated	O
+lymphocytes	B-ANAT
+,	O
+was	O
+10	O
+,	O
+000	O
+U	O
+/	O
+ml	O
+or	O
+higher	O
+,	O
+suggesting	O
+that	O
+an	O
+sIL2	B-PRGE
+-	I-PRGE
+R	I-PRGE
+level	O
+of	O
+more	O
+than	O
+10	O
+,	O
+000	O
+U	O
+/	O
+ml	O
+can	O
+be	O
+used	O
+as	O
+a	O
+marker	O
+of	O
+poor	O
+prognosis	O
+.	O
+
+ABSTRACT	O
+:	O
+A	O
+neonate	O
+receiving	O
+hyperalimentation	O
+through	O
+a	O
+peripherally	O
+inserted	O
+central	O
+catheter	O
+(	O
+PICC	O
+)	O
+had	O
+acute	O
+abdominal	B-ANAT
+distension	B-DISO
+and	O
+respiratory	B-DISO
+distress	I-DISO
+.	O
+
+The	O
+lesions	O
+were	O
+characterised	O
+by	O
+necrotising	B-DISO
+bronchiolitis	I-DISO
+,	O
+septal	O
+infiltration	B-DISO
+with	O
+mononuclear	B-ANAT
+cells	I-ANAT
+,	O
+and	O
+a	O
+mixed	O
+alveolar	B-ANAT
+exudate	B-ANAT
+.	O
+
+Other	O
+common	O
+findings	O
+were	O
+lymphopenia	B-DISO
+(	O
+in	O
+69	O
+.	O
+6	O
+percent	O
+),	O
+thrombocytopenia	O
+(	O
+44	O
+.	O
+8	O
+percent	O
+),	O
+and	O
+elevated	O
+lactate	B-PRGE
+dehydrogenase	I-PRGE
+and	O
+creatine	B-PRGE
+kinase	I-PRGE
+levels	O
+(	O
+71	O
+.	O
+0	O
+percent	O
+and	O
+32	O
+.	O
+1	O
+percent	O
+,	O
+respectively	O
+).	O
+
+CONCLUSIONS	O
+:	O
+Although	O
+the	O
+data	O
+support	O
+a	O
+key	O
+role	O
+for	O
+neutrophil	O
+elastase	O
+in	O
+the	O
+pathogenesis	B-DISO
+of	O
+ARDS	B-DISO
+,	O
+further	O
+study	O
+is	O
+needed	O
+to	O
+fully	O
+define	O
+the	O
+actions	O
+of	O
+neutrophil	B-PRGE
+elastase	I-PRGE
+,	O
+and	O
+how	O
+these	O
+actions	O
+affect	O
+host	B-COMP
+functions	O
+,	O
+before	O
+we	O
+can	O
+exploit	O
+this	O
+knowledge	O
+for	O
+therapeutic	O
+benefit	O
+.	O
+
+The	O
+total	O
+protein	B-CHED
+concentration	O
+in	O
+the	O
+epithelial	O
+lining	O
+fluid	O
+also	O
+is	O
+increased	O
+in	O
+these	O
+individuals	O
+with	O
+a	O
+history	O
+of	O
+chronic	B-DISO
+alcohol	I-DISO
+abuse	I-DISO
+compared	O
+with	O
+healthy	O
+controls	O
+,	O
+suggesting	O
+alterations	O
+in	O
+alveolar	B-ANAT
+-	O
+capillary	B-ANAT
+barrier	O
+function	O
+.	O
+
+This	O
+research	O
+has	O
+implications	O
+in	O
+understanding	O
+the	O
+diagnosis	O
+of	O
+,	O
+and	O
+prognosis	O
+for	O
+,	O
+critically	B-DISO
+ill	I-DISO
+patients	O
+who	O
+are	O
+at	O
+risk	O
+of	O
+developing	O
+ARDS	B-DISO
+.	O
+
+It	O
+also	O
+may	O
+lead	O
+to	O
+the	O
+development	B-PROC
+of	O
+novel	O
+therapies	O
+for	O
+those	O
+patients	O
+at	O
+greatest	O
+risk	O
+of	O
+acute	O
+lung	B-ANAT
+injury	O
+as	O
+a	O
+consequence	O
+of	O
+chronic	B-DISO
+alcohol	I-DISO
+abuse	I-DISO
+.	O
+
+Published	O
+articles	O
+on	O
+experimental	O
+and	O
+clinical	O
+studies	O
+of	O
+coagulation	B-PROC
+and	O
+fibrinolysis	B-PROC
+during	O
+infection	B-DISO
+,	O
+inflammation	B-DISO
+,	O
+acute	O
+lung	B-ANAT
+injury	O
+,	O
+and	O
+evolving	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+.	O
+
+TITLE	O
+:	O
+Glucocorticoids	B-CHED
+and	O
+acute	O
+lung	B-ANAT
+injury	O
+.	O
+
+HPA	B-CHED
+axis	B-SPEC
+activation	O
+is	O
+an	O
+important	O
+component	O
+of	O
+the	O
+compensatory	O
+anti	B-PROC
+-	I-PROC
+inflammatory	I-PROC
+response	I-PROC
+to	O
+critical	B-DISO
+illness	I-DISO
+.	O
+
+Replacement	O
+glucocorticoid	B-CHED
+/	O
+mineralocorticoid	B-CHED
+therapy	O
+over	O
+7	O
+days	O
+appears	O
+to	O
+be	O
+beneficial	O
+in	O
+such	O
+individuals	O
+.	O
+
+During	O
+the	O
+last	O
+decade	O
+,	O
+case	O
+reports	O
+and	O
+observational	O
+studies	O
+of	O
+HFOV	O
+in	O
+patients	O
+failing	O
+conventional	O
+ventilation	O
+strategies	O
+have	O
+suggested	O
+improved	O
+oxygenation	B-PROC
+in	O
+adult	O
+patients	O
+with	O
+severe	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+.	O
+
+ABSTRACT	O
+:	O
+To	O
+review	O
+the	O
+rationale	O
+for	O
+evaluating	O
+anticoagulant	O
+therapies	O
+in	O
+acute	O
+lung	B-ANAT
+injury	O
+(	O
+ALI	O
+)	O
+and	O
+to	O
+review	O
+selected	O
+data	O
+regarding	O
+the	O
+effectiveness	O
+of	O
+anticoagulants	B-CHED
+in	O
+animals	B-SPEC
+and	O
+human	B-SPEC
+patients	O
+with	O
+ALI	O
+and	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+.	O
+
+Local	O
+procoagulant	O
+activity	O
+and	O
+reduced	O
+fibrinolysis	B-PROC
+constitute	O
+the	O
+rationale	O
+for	O
+anticoagulant	B-CHED
+use	O
+in	O
+the	O
+treatment	O
+of	O
+ALI	O
+.	O
+
+TITLE	O
+:	O
+Effects	O
+of	O
+exogenous	O
+surfactant	B-CHED
+supplementation	O
+and	O
+partial	O
+liquid	O
+ventilation	O
+on	O
+acute	O
+lung	B-ANAT
+injury	O
+induced	O
+by	O
+wood	O
+smoke	O
+inhalation	O
+in	O
+newborn	O
+piglets	O
+.	O
+
+These	O
+findings	O
+indicate	O
+that	O
+a	O
+combination	O
+of	O
+IFN	B-PRGE
+-	I-PRGE
+alpha	I-PRGE
+and	O
+IFN	B-PRGE
+-	I-PRGE
+gamma	I-PRGE
+exhibits	O
+a	O
+synergistic	O
+antiviral	B-CHED
+effect	O
+on	O
+MHV	B-SPEC
+-	O
+2	O
+infection	B-DISO
+.	O
+
+The	O
+biology	O
+of	O
+MHV	B-SPEC
+-	O
+2	O
+is	O
+quite	O
+different	O
+from	O
+that	O
+of	O
+human	B-SPEC
+hepatitis	B-DISO
+viruses	B-SPEC
+;	O
+however	O
+,	O
+these	O
+results	O
+suggest	O
+the	O
+beneficial	O
+combined	O
+therapy	O
+of	O
+IFN	B-PRGE
+-	I-PRGE
+alpha	I-PRGE
+and	O
+IFN	B-PRGE
+-	I-PRGE
+gamma	I-PRGE
+for	O
+the	O
+treatment	O
+of	O
+human	B-SPEC
+viral	B-DISO
+hepatitis	I-DISO
+.	O
+
+This	O
+virus	B-SPEC
+may	O
+never	O
+before	O
+have	O
+circulated	O
+in	O
+the	O
+U	O
+.	O
+S	O
+.	O
+population	O
+.	O
+
+Calves	O
+that	O
+were	O
+seronegative	O
+or	O
+had	O
+low	O
+antibody	B-COMP
+titers	O
+against	O
+BoTV	O
+(<	O
+or	O
+=	O
+1	O
+:	O
+10	O
+hemagglutination	B-PROC
+inhibition	B-PROC
+units	O
+)	O
+at	O
+arrival	O
+seroconverted	O
+to	O
+BoTV	O
+(>	O
+4	O
+-	O
+fold	O
+increase	O
+in	O
+titer	O
+);	O
+these	O
+calves	O
+were	O
+more	O
+likely	O
+to	O
+shed	O
+virus	B-SPEC
+than	O
+calves	O
+that	O
+were	O
+seropositive	O
+against	O
+BoTV	O
+at	O
+arrival	O
+.	O
+
+RESULTS	O
+:	O
+Fecal	B-ANAT
+shedding	O
+of	O
+BoTV	B-PRGE
+was	O
+detected	O
+in	O
+15	O
+of	O
+62	O
+(	O
+24	O
+%)	O
+calves	O
+by	O
+use	O
+of	O
+ELISA	O
+and	O
+RT	O
+-	O
+PCR	O
+assay	O
+,	O
+with	O
+peak	O
+shedding	O
+on	O
+day	O
+4	O
+.	O
+
+TITLE	O
+:	O
+Outbreak	O
+of	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+in	O
+Hong	O
+Kong	O
+Special	O
+Administrative	O
+Region	O
+:	O
+case	O
+report	O
+.	O
+
+There	O
+is	O
+strong	O
+evidence	O
+that	O
+a	O
+novel	B-SPEC
+coronavirus	I-SPEC
+is	O
+the	O
+pathogen	O
+.	O
+
+Patients	O
+were	O
+then	O
+stratified	O
+according	O
+to	O
+the	O
+severity	O
+of	O
+head	B-ANAT
+injury	O
+on	O
+the	O
+basis	O
+of	O
+admission	O
+Glasgow	O
+Coma	B-DISO
+Scale	O
+(	O
+GCS	O
+)	O
+score	O
+into	O
+three	O
+groups	O
+:	O
+group	O
+1	O
+,	O
+GCS	O
+score	O
+of	O
+13	O
+to	O
+15	O
+(	O
+788	O
+female	O
+patients	O
+,	O
+769	O
+male	O
+patients	O
+);	O
+group	O
+2	O
+,	O
+GCS	O
+score	O
+of	O
+9	O
+to	O
+12	O
+(	O
+40	O
+female	O
+patients	O
+,	O
+42	O
+male	O
+patients	O
+);	O
+and	O
+group	O
+3	O
+,	O
+GCS	O
+score	O
+<	O
+9	O
+(	O
+63	O
+female	O
+patients	O
+,	O
+87	O
+male	O
+patients	O
+).	O
+
+TITLE	O
+:	O
+Unrelated	O
+donor	B-CHED
+bone	B-ANAT
+marrow	I-ANAT
+transplantation	O
+for	O
+acute	O
+mixed	O
+lineage	O
+(	O
+myeloid	O
+and	O
+B	O
+-	O
+lymphoid	O
+lineage	O
+)	O
+leukemia	O
+in	O
+an	O
+adult	O
+with	O
+Down	B-DISO
+syndrome	I-DISO
+.	O
+
+He	O
+achieved	O
+complete	O
+remission	B-DISO
+(	O
+CR	O
+)	O
+by	O
+lymphoid	O
+-	O
+oriented	O
+chemotherapy	O
+performed	O
+after	O
+ineffective	O
+myeloid	O
+-	O
+oriented	O
+therapy	O
+.	O
+
+Thereafter	O
+,	O
+a	O
+second	O
+CR	O
+was	O
+obtained	O
+by	O
+low	O
+dose	O
+cytosine	B-CHED
+arabinoside	I-CHED
+(	O
+AraC	O
+)	O
+therapy	O
+.	O
+
+On	O
+day	O
+205	O
+post	O
+-	O
+BMT	B-ENZY
+,	O
+however	O
+,	O
+bronchiolitis	B-DISO
+obliterans	I-DISO
+(	O
+BO	O
+)	O
+occurred	O
+as	O
+a	O
+chronic	B-DISO
+GVHD	I-DISO
+disorder	O
+.	O
+
+Three	O
+patients	O
+had	O
+travelled	O
+to	O
+China	O
+,	O
+including	O
+Hong	O
+Kong	O
+SAR	B-CHED
+.	O
+
+The	O
+fatality	O
+rate	O
+in	O
+HRV	O
+-	O
+infected	O
+patients	O
+was	O
+high	O
+(	O
+83	O
+%),	O
+but	O
+all	O
+patients	O
+had	O
+significant	O
+coinfections	B-DISO
+,	O
+and	O
+the	O
+overall	O
+mortality	O
+rate	O
+was	O
+not	O
+different	O
+from	O
+that	O
+of	O
+patients	O
+who	O
+were	O
+negative	O
+for	O
+HRV	O
+in	O
+BAL	B-ENZY
+samples	O
+.	O
+
+Microscopic	O
+examination	O
+of	O
+the	O
+left	O
+anterior	B-ANAT
+descending	I-ANAT
+coronary	I-ANAT
+artery	I-ANAT
+showed	O
+an	O
+eccentric	O
+fibroatheromatic	O
+plaque	B-DISO
+complicated	O
+by	O
+thrombosis	B-DISO
+,	O
+endothelial	B-ANAT
+erosion	B-DISO
+and	O
+extensive	O
+T	B-ANAT
+-	I-ANAT
+cell	I-ANAT
+and	O
+macrophage	B-ANAT
+infiltration	B-DISO
+.	O
+
+D	O
+-	O
+RNAs	O
+expressing	O
+chIFN	B-PRGE
+-	I-PRGE
+gamma	I-PRGE
+were	O
+shown	O
+to	O
+be	O
+capable	O
+of	O
+rescue	O
+,	O
+replication	O
+,	O
+and	O
+packaging	O
+into	O
+virions	B-COMP
+in	O
+a	O
+helper	O
+virus	B-SPEC
+-	O
+dependent	O
+system	O
+following	O
+electroporation	O
+of	O
+in	O
+vitro	O
+-	O
+derived	O
+T7	O
+RNA	O
+transcripts	O
+into	O
+IBV	B-SPEC
+-	O
+infected	O
+cells	B-COMP
+.	O
+
+In	O
+addition	O
+,	O
+following	O
+infection	B-DISO
+of	O
+10	O
+-	O
+day	O
+-	O
+old	O
+chicken	B-SPEC
+embryos	B-ANAT
+with	O
+IBV	B-SPEC
+containing	O
+D	O
+-	O
+RNAs	O
+expressing	O
+chIFN	O
+-	O
+gamma	O
+,	O
+the	O
+allantoic	B-ANAT
+fluid	I-ANAT
+was	O
+shown	O
+to	O
+contain	O
+biologically	O
+active	O
+chIFN	B-PRGE
+-	I-PRGE
+gamma	I-PRGE
+,	O
+demonstrating	O
+that	O
+IBV	B-SPEC
+D	O
+-	O
+RNAs	O
+can	O
+express	O
+heterologous	O
+genes	O
+in	O
+vivo	O
+.	O
+
+TITLE	O
+:	O
+Update	O
+:	O
+outbreak	O
+of	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+--	O
+worldwide	O
+,	O
+2003	O
+.	O
+
+The	O
+genome	O
+sequence	O
+reveals	O
+that	O
+this	O
+coronavirus	B-SPEC
+is	O
+only	O
+moderately	O
+related	O
+to	O
+other	O
+known	O
+coronaviruses	O
+,	O
+including	O
+two	O
+human	B-SPEC
+coronaviruses	O
+,	O
+HCoV	B-SPEC
+-	I-SPEC
+OC43	I-SPEC
+and	O
+HCoV	B-SPEC
+-	I-SPEC
+229E	I-SPEC
+.	O
+
+TITLE	O
+:	O
+Severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+(	O
+SARS	B-DISO
+)	O
+and	O
+coronavirus	B-SPEC
+testing	O
+--	O
+United	O
+States	O
+,	O
+2003	O
+.	O
+
+Patients	O
+were	O
+included	O
+if	O
+they	O
+had	O
+fever	B-PROC
+,	O
+a	O
+known	O
+exposure	O
+to	O
+SARS	B-DISO
+,	O
+and	O
+respiratory	B-DISO
+symptoms	I-DISO
+or	O
+infiltrates	B-DISO
+observed	O
+on	O
+chest	B-ANAT
+radiograph	O
+.	O
+
+TITLE	O
+:	O
+Detection	O
+of	O
+bovine	B-SPEC
+torovirus	I-SPEC
+and	O
+other	O
+enteric	O
+pathogens	O
+in	O
+feces	B-ANAT
+from	O
+diarrhea	B-DISO
+cases	O
+in	O
+cattle	B-SPEC
+.	O
+
+The	O
+vaccinated	O
+pups	O
+did	O
+not	O
+display	O
+clinical	O
+signs	O
+and	O
+shed	O
+the	O
+challenge	O
+-	O
+virus	B-SPEC
+for	O
+11	O
+.	O
+25	O
+days	O
+,	O
+evaluated	O
+by	O
+virus	B-SPEC
+isolation	O
+,	O
+and	O
+13	O
+.	O
+5	O
+days	O
+,	O
+evaluated	O
+by	O
+PCR	O
+assay	O
+.	O
+
+The	O
+two	O
+non	O
+vaccinated	O
+pups	O
+displayed	O
+mild	O
+diarrhoea	B-DISO
+at	O
+day	O
+post	O
+-	O
+challenge	O
+4	O
+and	O
+shed	O
+the	O
+challenge	O
+-	O
+virus	B-SPEC
+for	O
+14	O
+and	O
+15	O
+days	O
+respectively	O
+,	O
+by	O
+virus	B-SPEC
+isolation	O
+,	O
+and	O
+for	O
+22	O
+and	O
+24	O
+days	O
+respectively	O
+,	O
+by	O
+PCR	O
+assay	O
+.	O
+
+Practice	O
+of	O
+droplets	O
+precaution	O
+and	O
+contact	O
+precaution	O
+is	O
+adequate	O
+in	O
+significantly	O
+reducing	O
+the	O
+risk	O
+of	O
+infection	O
+after	O
+exposures	O
+to	O
+patients	O
+with	O
+SARS	B-DISO
+.	O
+
+The	O
+protective	O
+role	O
+of	O
+the	O
+mask	O
+suggests	O
+that	O
+in	O
+hospitals	O
+,	O
+infection	B-DISO
+is	O
+transmitted	B-DISO
+by	O
+droplets	O
+.	O
+
+TITLE	O
+:	O
+[	O
+Intensive	O
+care	O
+management	O
+of	O
+28	O
+patients	O
+with	O
+severe	O
+eclampsia	B-DISO
+in	O
+a	O
+tropical	O
+African	O
+setting	O
+].	O
+
+The	O
+following	O
+complications	O
+were	O
+found	O
+:	O
+acute	B-DISO
+oliguric	I-DISO
+renal	I-DISO
+failure	I-DISO
+(	O
+9	O
+),	O
+HELLP	O
+-	O
+syndrome	B-DISO
+(	O
+4	O
+),	O
+cerebral	B-DISO
+haemorrhage	I-DISO
+(	O
+4	O
+),	O
+acute	O
+lung	B-DISO
+oedema	I-DISO
+(	O
+3	O
+)	O
+and	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+(	O
+1	O
+).	O
+
+Common	O
+findings	O
+included	O
+ground	O
+-	O
+glass	O
+opacification	O
+,	O
+sometimes	O
+with	O
+consolidation	O
+,	O
+and	O
+interlobular	O
+septal	O
+and	O
+intralobular	O
+interstitial	B-ANAT
+thickening	O
+.	O
+
+Affected	O
+segments	O
+were	O
+predominantly	O
+in	O
+the	O
+lower	O
+lobes	B-ANAT
+(	O
+91	O
+of	O
+149	O
+affected	O
+segments	O
+).	O
+
+However	O
+,	O
+the	O
+trachea	B-DISO
+was	O
+too	O
+stenotic	O
+to	O
+place	O
+the	O
+tube	O
+in	O
+the	O
+proper	O
+position	O
+.	O
+
+ABSTRACT	O
+:	O
+The	O
+outbreak	O
+of	O
+severe	O
+acute	O
+respiratory	O
+syndrome	O
+(	O
+SARS	B-DISO
+)	O
+in	O
+Toronto	O
+,	O
+which	O
+began	O
+on	O
+Mar	B-DISO
+.	O
+7	O
+,	O
+2003	O
+,	O
+resulted	O
+in	O
+extraordinary	O
+public	O
+health	O
+and	O
+infection	B-DISO
+control	O
+measures	O
+.	O
+
+All	O
+authors	O
+reviewed	O
+and	O
+analyzed	O
+the	O
+descriptions	O
+in	O
+an	O
+iterative	O
+process	O
+between	O
+Apr	B-CHED
+.	O
+3	O
+and	O
+Apr	B-CHED
+.	O
+13	O
+,	O
+2003	O
+.	O
+
+TITLE	O
+:	O
+Coronavirus	B-SPEC
+main	O
+proteinase	B-PROC
+(	O
+3CLpro	O
+)	O
+structure	O
+:	O
+basis	O
+for	O
+design	O
+of	O
+anti	O
+-	O
+SARS	B-DISO
+drugs	O
+.	O
+
+The	O
+structures	O
+reveal	O
+a	O
+remarkable	O
+degree	O
+of	O
+conservation	O
+of	O
+the	O
+substrate	O
+-	O
+binding	B-FUNC
+sites	O
+,	O
+which	O
+is	O
+further	O
+supported	O
+by	O
+recombinant	O
+SARS	B-DISO
+-	O
+CoV	O
+Mpro	O
+-	O
+mediated	O
+cleavage	B-PROC
+of	O
+a	O
+TGEV	B-SPEC
+Mpro	O
+substrate	O
+.	O
+
+Recently	O
+,	O
+biologically	O
+active	O
+lipids	B-CHED
+have	O
+been	O
+also	O
+suggested	O
+to	O
+cause	O
+the	O
+disorder	O
+.	O
+
+TITLE	O
+:	O
+Development	B-PROC
+of	O
+a	O
+standard	O
+treatment	O
+protocol	O
+for	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+.	O
+
+This	O
+is	O
+characterised	O
+by	O
+fever	B-PROC
+of	O
+sudden	O
+onset	O
+lasting	O
+for	O
+more	O
+than	O
+5	O
+days	O
+,	O
+rapidly	O
+changing	O
+consolidations	O
+in	O
+chest	B-ANAT
+x	O
+-	O
+ray	B-SPEC
+not	O
+affected	O
+by	O
+antimicrobial	B-CHED
+therapy	O
+,	O
+leuko	O
+-,	O
+lympho	O
+-	O
+as	O
+well	O
+as	O
+thrombopenia	O
+with	O
+a	O
+compromised	O
+pulmonary	B-PROC
+function	I-PROC
+later	O
+in	O
+the	O
+course	O
+.	O
+
+Close	O
+contacts	O
+with	O
+SARS	B-DISO
+patients	O
+does	O
+not	O
+regularly	O
+result	O
+in	O
+full	O
+development	B-PROC
+of	O
+the	O
+disease	O
+.	O
+
+ABSTRACT	O
+:	O
+CDC	O
+continues	O
+to	O
+work	O
+with	O
+the	O
+World	O
+Health	O
+Organization	O
+(	O
+WHO	O
+)	O
+and	O
+other	O
+partners	O
+to	O
+investigate	O
+cases	O
+of	O
+severe	O
+acute	O
+respiratory	O
+syndrome	O
+(	O
+SARS	B-DISO
+).	O
+
+The	O
+RCV	O
+particles	O
+were	O
+spherical	O
+in	O
+shape	O
+with	O
+a	O
+diameter	O
+of	O
+100	O
+-	O
+130	O
+nm	O
+and	O
+two	O
+distinct	O
+membranes	B-ANAT
+,	O
+the	O
+outer	O
+one	O
+being	O
+the	O
+envelope	B-COMP
+and	O
+the	O
+inner	O
+one	O
+the	O
+nuclear	O
+capsid	B-ANAT
+to	O
+enclose	O
+the	O
+viroplasm	O
+.	O
+
+Between	O
+the	O
+envelop	O
+and	O
+nuclear	O
+capsid	B-ANAT
+was	O
+a	O
+electron	O
+-	O
+lucent	O
+middle	O
+layer	B-ANAT
+comprising	O
+one	O
+to	O
+two	O
+thin	O
+membranous	B-ANAT
+structures	O
+.	O
+
+Specific	O
+fragments	O
+were	O
+amplified	O
+from	O
+the	O
+sputum	B-ANAT
+samples	O
+of	O
+SARS	B-DISO
+patients	O
+,	O
+which	O
+were	O
+confirmed	O
+by	O
+DNA	O
+cloning	O
+and	O
+sequencing	O
+to	O
+belong	O
+to	O
+SARS	B-DISO
+-	I-DISO
+associated	I-DISO
+coronavirus	I-DISO
+.	O
+
+Sequence	O
+analysis	O
+has	O
+confirmed	O
+the	O
+existence	O
+of	O
+SARS	B-DISO
+-	I-DISO
+associated	I-DISO
+coronavirus	I-DISO
+in	O
+the	O
+sputum	B-ANAT
+samples	O
+of	O
+SARS	B-DISO
+patients	O
+,	O
+and	O
+nested	O
+RT	O
+-	O
+PCR	O
+is	O
+a	O
+quick	O
+,	O
+easy	O
+,	O
+and	O
+convenient	O
+way	O
+for	O
+the	O
+detection	O
+of	O
+the	O
+virus	B-SPEC
+.	O
+
+In	O
+30	O
+patients	O
+with	O
+aortic	B-DISO
+arch	I-DISO
+aneurysm	I-DISO
+,	O
+including	O
+22	O
+with	O
+a	O
+non	O
+-	O
+ruptured	O
+and	O
+8	O
+with	O
+a	O
+ruptured	B-DISO
+aneurysm	I-DISO
+,	O
+the	O
+catheter	O
+was	O
+antegradely	O
+inserted	O
+into	O
+the	O
+descending	B-ANAT
+thoracic	I-ANAT
+aorta	I-ANAT
+through	O
+the	O
+aortic	B-ANAT
+arch	I-ANAT
+or	O
+the	O
+aneurysm	B-DISO
+without	O
+opening	O
+the	O
+pleural	B-ANAT
+space	I-ANAT
+after	O
+establishing	O
+antegrade	O
+selective	O
+cerebral	B-ANAT
+perfusion	O
+and	O
+obtaining	O
+cardiac	B-DISO
+arrest	I-DISO
+.	O
+
+The	O
+highest	O
+correlation	O
+(	O
+77	O
+%	O
+nt	O
+and	O
+81	O
+.	O
+7	O
+%	O
+aa	O
+)	O
+was	O
+found	O
+with	O
+feline	B-SPEC
+coronavirus	B-SPEC
+type	O
+I	O
+.	O
+A	O
+PCR	O
+assay	O
+for	O
+the	O
+S	B-PRGE
+gene	I-PRGE
+of	O
+strain	O
+Elmo	O
+/	O
+02	O
+detected	O
+analogous	O
+CCoVs	O
+of	O
+different	O
+geographic	O
+origin	O
+,	O
+all	O
+which	O
+exhibited	O
+at	O
+least	O
+92	O
+-	O
+96	O
+%	O
+nucleotide	B-CHED
+identity	O
+to	O
+each	O
+other	O
+and	O
+to	O
+strain	O
+Elmo	O
+/	O
+02	O
+.	O
+
+Recognizable	O
+patterns	O
+of	O
+radiographic	O
+progression	O
+were	O
+determined	O
+by	O
+comparing	O
+the	O
+overall	O
+mean	O
+percentage	O
+of	O
+lung	B-ANAT
+involvement	O
+for	O
+each	O
+patient	O
+on	O
+serial	O
+radiographs	O
+.	O
+
+Initial	O
+chest	B-ANAT
+radiographs	O
+were	O
+abnormal	O
+in	O
+108	O
+of	O
+138	O
+(	O
+78	O
+.	O
+3	O
+%)	O
+patients	O
+and	O
+showed	O
+air	B-CHED
+-	O
+space	O
+opacity	B-DISO
+.	O
+
+No	O
+cavitation	B-DISO
+,	O
+lymphadenopathy	O
+,	O
+or	O
+pleural	B-DISO
+effusion	I-DISO
+was	O
+demonstrated	O
+.	O
+
+TITLE	O
+:	O
+Will	O
+your	O
+ED	O
+have	O
+staff	O
+quarantined	O
+for	O
+SARS	B-DISO
+?	O
+
+From	O
+1993	O
+to	O
+1997	O
+,	O
+236	O
+(	O
+12	O
+%)	O
+of	O
+the	O
+1915	O
+confirmed	O
+cases	O
+of	O
+work	O
+-	O
+related	O
+asthma	B-PATH
+identified	O
+by	O
+the	O
+four	O
+states	O
+were	O
+associated	O
+with	O
+exposure	O
+to	O
+cleaning	O
+products	O
+.	O
+
+Among	O
+the	O
+new	O
+-	O
+onset	O
+cases	O
+,	O
+22	O
+%	O
+were	O
+consistent	O
+with	O
+reactive	B-DISO
+airways	I-DISO
+dysfunction	I-DISO
+syndrome	I-DISO
+.	O
+
+This	O
+article	O
+describes	O
+current	O
+knowledge	O
+of	O
+the	O
+infection	B-DISO
+and	O
+outlines	O
+the	O
+management	O
+of	O
+SARS	B-DISO
+in	O
+the	O
+UK	O
+.	O
+
+TITLE	O
+:	O
+Transmission	O
+dynamics	O
+of	O
+the	O
+etiological	O
+agent	O
+of	O
+SARS	B-DISO
+in	O
+Hong	O
+Kong	O
+:	O
+impact	O
+of	O
+public	O
+health	O
+interventions	O
+.	O
+
+TITLE	O
+:	O
+Clinical	O
+presentations	O
+and	O
+outcome	O
+of	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+in	O
+children	O
+.	O
+
+TITLE	O
+:	O
+Stem	B-ANAT
+-	O
+loop	O
+III	O
+in	O
+the	O
+5	O
+'	O
+untranslated	O
+region	O
+is	O
+a	O
+cis	B-DISO
+-	O
+acting	O
+element	O
+in	O
+bovine	B-SPEC
+coronavirus	B-SPEC
+defective	O
+interfering	O
+RNA	O
+replication	O
+.	O
+
+ABSTRACT	O
+:	O
+Higher	O
+-	O
+order	B-SPEC
+structures	O
+in	O
+the	O
+5	O
+'	O
+untranslated	O
+region	O
+(	O
+UTR	O
+)	O
+of	O
+plus	O
+-	O
+strand	O
+RNA	O
+viruses	B-SPEC
+are	O
+known	O
+in	O
+many	O
+cases	O
+to	O
+function	O
+as	O
+cis	B-DISO
+-	O
+acting	O
+elements	O
+in	O
+RNA	O
+translation	B-PROC
+,	O
+replication	O
+,	O
+or	O
+transcription	B-PROC
+.	O
+
+Stem	O
+-	O
+loop	O
+III	O
+(	O
+i	O
+)	O
+shows	O
+phylogenetic	O
+conservation	O
+among	O
+group	O
+2	O
+coronaviruses	O
+and	O
+appears	O
+to	O
+have	O
+a	O
+homolog	O
+in	O
+coronavirus	B-SPEC
+groups	O
+1	O
+and	O
+3	O
+,	O
+(	O
+ii	O
+)	O
+has	O
+in	O
+all	O
+coronaviruses	O
+for	O
+which	O
+sequence	O
+is	O
+known	O
+a	O
+closely	O
+associated	O
+short	O
+,	O
+AUG	B-PRGE
+-	I-PRGE
+initiated	I-PRGE
+intra	I-PRGE
+-	I-PRGE
+5	I-PRGE
+'	I-PRGE
+UTR	I-PRGE
+ORF	I-PRGE
+,	O
+(	O
+iii	O
+)	O
+is	O
+supported	O
+by	O
+enzyme	O
+structure	O
+-	O
+probing	O
+evidence	O
+in	O
+BCoV	O
+RNA	O
+,	O
+(	O
+iv	O
+)	O
+must	O
+maintain	O
+stem	B-ANAT
+integrity	O
+for	O
+DI	B-PRGE
+RNA	I-PRGE
+replication	O
+in	O
+BCoV	O
+DI	O
+RNA	O
+,	O
+and	O
+(	O
+v	O
+)	O
+shows	O
+a	O
+positive	O
+correlation	O
+between	O
+maintenance	O
+of	O
+the	O
+short	O
+ORF	O
+and	O
+maximal	O
+DI	O
+RNA	O
+accumulation	O
+in	O
+BCoV	O
+DI	O
+RNA	O
+.	O
+
+It	O
+is	O
+postulated	O
+that	O
+these	O
+two	O
+elements	O
+function	O
+similarly	O
+in	O
+the	O
+virus	B-SPEC
+genome	O
+.	O
+
+We	O
+collected	O
+clinical	O
+and	O
+epidemiological	O
+data	O
+about	O
+patients	O
+and	O
+health	O
+care	O
+workers	O
+at	O
+our	O
+institution	O
+who	O
+during	O
+a	O
+13	O
+-	O
+day	O
+period	O
+had	O
+a	O
+potential	O
+unprotected	O
+exposure	O
+to	O
+2	O
+patients	O
+whose	O
+signs	B-DISO
+and	I-DISO
+symptoms	I-DISO
+were	O
+subsequently	O
+identified	O
+as	O
+meeting	O
+the	O
+case	O
+definition	O
+for	O
+probable	O
+SARS	B-DISO
+.	O
+
+No	O
+additional	O
+cases	O
+were	O
+identified	O
+after	O
+infection	B-DISO
+control	O
+precautions	O
+had	O
+been	O
+implemented	O
+for	O
+8	O
+days	O
+.	O
+
+No	O
+cases	O
+of	O
+secondary	B-DISO
+transmission	I-DISO
+were	O
+identified	O
+in	O
+the	O
+21	O
+days	O
+following	O
+the	O
+implementation	O
+of	O
+these	O
+precautions	O
+at	O
+our	O
+institution	O
+.	O
+
+SARS	B-DISO
+can	O
+easily	O
+be	O
+spread	O
+by	O
+direct	O
+personal	O
+contact	O
+in	O
+the	O
+hospital	O
+setting	O
+.	O
+
+We	O
+investigated	O
+whether	O
+granulocyte	B-FUNC
+colony	I-FUNC
+-	I-FUNC
+stimulating	I-FUNC
+factor	I-FUNC
+(	O
+25	O
+microg	O
+x	O
+kg	O
+(-	O
+1	O
+)	O
+x	O
+day	O
+(-	O
+1	O
+),	O
+4	O
+days	O
+)	O
+enhanced	O
+endotracheal	O
+bleomycin	B-CHED
+-	O
+induced	O
+(	O
+5	O
+mg	O
+/	O
+kg	O
+)	O
+acute	O
+lung	B-ANAT
+injury	O
+and	O
+fibrosis	B-DISO
+in	O
+rats	B-SPEC
+.	O
+
+Granulocyte	B-FUNC
+colony	I-FUNC
+-	I-FUNC
+stimulating	I-FUNC
+factor	I-FUNC
+increased	O
+alveolar	B-ANAT
+neutrophil	B-PROC
+recruitment	B-DISO
+,	O
+pulmonary	B-DISO
+edema	I-DISO
+,	O
+and	O
+lung	B-PRGE
+myeloperoxidase	B-FUNC
+activity	I-FUNC
+on	O
+day	O
+4	O
+.	O
+
+Rats	B-SPEC
+were	O
+subjected	O
+to	O
+either	O
+hemorrhage	B-DISO
+or	O
+endotoxemia	O
+for	O
+1	O
+hr	O
+,	O
+followed	O
+by	O
+resuscitation	O
+to	O
+a	O
+controlled	O
+mean	O
+blood	B-PROC
+pressure	I-PROC
+with	O
+Ringer	O
+'	O
+s	O
+lactate	B-CHED
+,	O
+5	B-PRGE
+%	I-PRGE
+albumin	I-PRGE
+,	O
+or	O
+25	O
+%	O
+albumin	B-PRGE
+for	O
+1	O
+hr	O
+.	O
+
+TITLE	O
+:	O
+Mass	O
+spectrometric	O
+characterization	O
+of	O
+proteins	B-CHED
+from	O
+the	O
+SARS	B-DISO
+virus	B-SPEC
+:	O
+a	O
+preliminary	O
+report	O
+.	O
+
+The	O
+clinical	O
+course	O
+and	O
+successful	O
+treatment	O
+with	O
+convalescent	O
+plasma	B-ANAT
+,	O
+ribavirin	B-CHED
+,	O
+and	O
+corticosteroids	B-CHED
+are	O
+discussed	O
+.	O
+
+TITLE	O
+:	O
+Severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+in	O
+a	O
+doctor	O
+working	O
+at	O
+the	O
+Prince	O
+of	O
+Wales	O
+Hospital	O
+.	O
+
+He	O
+presented	O
+with	O
+sudden	O
+onset	O
+of	O
+fever	B-PROC
+,	O
+chills	B-DISO
+,	O
+myalgia	B-DISO
+,	O
+headache	B-DISO
+,	O
+and	O
+dizziness	B-DISO
+in	O
+early	O
+March	O
+2003	O
+.	O
+
+TITLE	O
+:	O
+Hiding	O
+in	O
+the	O
+bunker	O
+:	O
+Challenges	O
+for	O
+a	O
+radiation	O
+oncology	O
+department	O
+operating	O
+in	O
+the	O
+Severe	B-DISO
+Acute	I-DISO
+Respiratory	I-DISO
+Syndrome	I-DISO
+outbreak	O
+.	O
+
+In	O
+this	O
+article	O
+,	O
+we	O
+outline	O
+the	O
+measures	O
+taken	O
+to	O
+curb	B-DISO
+SARS	B-DISO
+in	O
+Singapore	O
+and	O
+discuss	O
+the	O
+implications	O
+for	O
+Australasian	O
+radiation	O
+oncology	O
+departments	O
+.	O
+
+With	O
+a	O
+mean	O
+activated	O
+clotting	B-PROC
+time	O
+of	O
+121	O
++/-	O
+
+In	O
+controls	O
+,	O
+hemodynamics	B-PROC
+and	O
+gas	B-ENZY
+exchange	O
+remained	O
+unchanged	O
+.	O
+
+For	O
+the	O
+first	O
+6	O
+weeks	O
+of	O
+the	O
+SARS	B-DISO
+outbreak	O
+,	O
+recognized	O
+spread	O
+was	O
+limited	O
+to	O
+one	O
+healthcare	O
+worker	O
+and	O
+three	O
+household	O
+contacts	O
+.	O
+
+We	O
+assessed	O
+the	O
+epidemiology	O
+of	O
+SARS	B-DISO
+in	O
+Hong	O
+Kong	O
+.	O
+
+Fever	B-PROC
+and	O
+pneumonia	B-DISO
+initially	O
+improved	O
+but	O
+64	O
+(	O
+85	O
+%)	O
+patients	O
+developed	O
+recurrent	B-DISO
+fever	I-DISO
+after	O
+a	O
+mean	O
+of	O
+8	O
+.	O
+9	O
+(	O
+SD	O
+3	O
+.	O
+1	O
+)	O
+days	O
+,	O
+55	O
+(	O
+73	O
+%)	O
+had	O
+watery	B-DISO
+diarrhoea	I-DISO
+after	O
+7	O
+.	O
+5	O
+(	O
+2	O
+.	O
+3	O
+)	O
+days	O
+,	O
+60	O
+(	O
+80	O
+%)	O
+had	O
+radiological	O
+worsening	O
+after	O
+7	O
+.	O
+4	O
+(	O
+2	O
+.	O
+2	O
+)	O
+days	O
+,	O
+and	O
+respiratory	B-DISO
+symptoms	I-DISO
+worsened	O
+in	O
+34	O
+(	O
+45	O
+%)	O
+after	O
+8	O
+.	O
+6	O
+(	O
+3	O
+.	O
+0	O
+)	O
+days	O
+.	O
+
+The	O
+consistent	O
+clinical	O
+progression	O
+,	O
+shifting	O
+radiological	O
+infiltrates	B-DISO
+,	O
+and	O
+an	O
+inverted	O
+V	O
+viral	O
+-	O
+load	O
+profile	O
+suggest	O
+that	O
+worsening	O
+in	O
+week	O
+2	O
+is	O
+unrelated	O
+to	O
+uncontrolled	O
+viral	B-PROC
+replication	I-PROC
+but	O
+may	O
+be	O
+related	O
+to	O
+immunopathological	O
+damage	O
+.	O
+
+ABSTRACT	O
+:	O
+Severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+(	O
+SARS	B-DISO
+)	O
+is	O
+a	O
+novel	O
+infectious	B-DISO
+disease	I-DISO
+with	O
+global	O
+impact	O
+.	O
+
+Whole	O
+genome	O
+sequence	O
+analysis	O
+of	O
+various	O
+isolates	O
+might	O
+provide	O
+an	O
+indication	O
+of	O
+potential	O
+strain	O
+differences	O
+of	O
+this	O
+new	O
+virus	B-SPEC
+.	O
+
+Shortly	O
+after	O
+presentation	O
+,	O
+the	O
+patient	O
+developed	O
+therapy	O
+-	O
+refractory	O
+respiratory	B-DISO
+failure	I-DISO
+,	O
+cardiac	B-DISO
+arrest	I-DISO
+,	O
+and	O
+subsequently	O
+suffered	B-DISO
+five	O
+-	O
+organ	B-ANAT
+system	I-ANAT
+failure	O
+(	O
+lung	B-ANAT
+,	O
+heart	B-ANAT
+,	O
+gastrointestinal	O
+,	O
+liver	B-ANAT
+,	O
+kidney	B-ANAT
+),	O
+in	O
+addition	O
+to	O
+burn	O
+injury	O
+,	O
+and	O
+ischemia	O
+related	O
+cerebral	B-DISO
+lesions	I-DISO
+.	O
+
+In	O
+a	O
+patient	O
+with	O
+severe	O
+ARDS	B-DISO
+,	O
+oxygenation	B-PROC
+failure	O
+under	O
+maximized	O
+ventilatory	O
+settings	O
+,	O
+and	O
+subsequent	O
+five	O
+-	O
+organ	B-ANAT
+system	I-ANAT
+failure	O
+,	O
+an	O
+integrated	O
+therapeutical	O
+approach	O
+comprising	O
+ECMO	O
+,	O
+NO	O
+,	O
+kinetic	O
+therapy	O
+,	O
+surfactant	B-CHED
+,	O
+and	O
+urodilatin	O
+did	O
+cross	O
+-	O
+bridge	O
+respiratory	O
+and	O
+vital	O
+functions	O
+,	O
+enabling	O
+overall	O
+survival	O
+.	O
+
+TITLE	O
+:	O
+Detection	O
+of	O
+a	O
+group	O
+2	O
+coronavirus	B-SPEC
+in	O
+dogs	B-SPEC
+with	O
+canine	O
+infectious	B-DISO
+respiratory	B-DISO
+disease	I-DISO
+.	O
+
+Refractory	O
+hypoxemia	O
+and	O
+ventilator	B-DISO
+-	I-DISO
+associated	I-DISO
+pneumonia	I-DISO
+were	O
+the	O
+leading	O
+causes	O
+of	O
+death	B-PROC
+.	O
+
+Pneumonia	B-SPEC
+virus	I-SPEC
+of	I-SPEC
+mice	I-SPEC
+(	O
+PVM	B-SPEC
+)	O
+also	O
+infects	O
+the	O
+respiratory	B-ANAT
+tract	I-ANAT
+and	O
+,	O
+like	O
+Sendai	B-SPEC
+virus	I-SPEC
+,	O
+may	O
+induce	O
+a	O
+persistent	O
+wasting	B-DISO
+disease	I-DISO
+syndrome	B-DISO
+in	O
+immunodeficient	B-DISO
+mice	B-SPEC
+.	O
+
+To	O
+understand	O
+the	O
+role	O
+of	O
+both	O
+agents	O
+in	O
+the	O
+development	B-PROC
+of	O
+peritonitis	B-DISO
+and	O
+pleuritis	B-DISO
+,	O
+IFN	B-PRGE
+-	I-PRGE
+gamma	I-PRGE
+KO	O
+mice	B-SPEC
+were	O
+infected	O
+with	O
+either	O
+agent	O
+or	O
+were	O
+co	O
+-	O
+infected	O
+with	O
+H	B-SPEC
+.	I-SPEC
+hepaticus	I-SPEC
+and	O
+MHV	B-SPEC
+-	O
+G	O
+.	O
+Infection	B-DISO
+with	O
+MHV	B-SPEC
+-	O
+G	O
+induced	O
+a	O
+multisystemic	O
+infection	B-DISO
+similar	O
+to	O
+that	O
+described	O
+in	O
+the	O
+original	O
+cases	O
+,	O
+with	O
+multifocal	O
+hepatic	B-DISO
+necrosis	B-PROC
+,	O
+acute	O
+necrotizing	O
+and	O
+inflammatory	O
+lesions	O
+of	O
+the	O
+gastrointestinal	B-ANAT
+tract	I-ANAT
+,	O
+and	O
+acute	B-DISO
+peritonitis	I-DISO
+and	O
+pleuritis	B-DISO
+with	O
+adhesions	B-DISO
+on	O
+the	O
+serosal	B-ANAT
+surfaces	O
+of	O
+the	O
+viscera	B-ANAT
+.	O
+
+TITLE	O
+:	O
+Detection	O
+of	O
+feline	B-SPEC
+coronavirus	B-DISO
+infection	I-DISO
+in	O
+captive	O
+cheetahs	B-SPEC
+(	O
+Acinonyx	B-SPEC
+jubatus	I-SPEC
+)	O
+by	O
+polymerase	O
+chain	O
+reaction	O
+.	O
+
+Testing	O
+of	O
+samples	O
+from	O
+one	O
+population	O
+over	O
+a	O
+1	O
+-	O
+yr	O
+period	O
+indicated	O
+chronic	B-DISO
+infection	I-DISO
+in	O
+some	O
+animals	B-SPEC
+.	O
+
+Moreover	O
+,	O
+MHC	B-PRGE
+class	B-SPEC
+II	I-PRGE
+DR	I-PRGE
+-	I-PRGE
+expressing	I-PRGE
+PMNs	I-PRGE
+were	O
+also	O
+proved	O
+to	O
+express	O
+a	O
+high	O
+-	O
+affinity	O
+receptor	O
+for	O
+immunoglobulin	B-PRGE
+E	I-PRGE
+(	O
+IgE	B-DISO
+)	O
+(	O
+FcepsilonRI	O
+)	O
+and	O
+to	O
+produce	O
+tumour	B-PRGE
+necrosis	I-PRGE
+factor	I-PRGE
+-	I-PRGE
+alpha	I-PRGE
+,	O
+interferon	B-FUNC
+-	I-FUNC
+gamma	I-FUNC
+and	O
+interleukin	B-PRGE
+-	I-PRGE
+18	I-PRGE
+following	O
+a	O
+challenge	O
+with	O
+an	O
+anti	B-PRGE
+-	I-PRGE
+MHC	I-PRGE
+class	B-SPEC
+II	I-PRGE
+DR	I-PRGE
+monoclonal	B-PRGE
+Ab	I-PRGE
+(	O
+MoAb	O
+)	O
+or	O
+anti	O
+-	O
+DR	O
+antiserum	O
+.	O
+
+Possible	O
+binding	B-FUNC
+sites	O
+in	O
+the	O
+SARS	B-PRGE
+-	I-PRGE
+CoV	I-PRGE
+S	I-PRGE
+protein	B-CHED
+to	O
+CD13	B-PRGE
+have	O
+been	O
+mapped	O
+out	O
+by	O
+using	O
+bioinformatics	O
+analysis	O
+tools	O
+.	O
+
+This	O
+study	O
+also	O
+provides	O
+a	O
+possible	O
+strategy	O
+for	O
+mapping	O
+the	O
+possible	O
+binding	B-FUNC
+receptors	O
+of	O
+the	O
+proteins	B-CHED
+in	O
+a	O
+genome	O
+.	O
+
+TITLE	O
+:	O
+Identification	O
+of	O
+probable	O
+genomic	O
+packaging	O
+signal	O
+sequence	O
+from	O
+SARS	B-DISO
+-	O
+CoV	O
+genome	O
+by	O
+bioinformatics	O
+analysis	O
+.	O
+
+Multi	O
+-	O
+alignment	O
+for	O
+the	O
+genomic	O
+sequences	O
+was	O
+performed	O
+among	O
+SARS	B-PRGE
+-	I-PRGE
+CoV	I-PRGE
+,	O
+MHV	B-SPEC
+,	O
+BCoV	O
+,	O
+PEDV	B-SPEC
+and	O
+HCoV	O
+229E	O
+.	O
+
+Further	O
+more	O
+,	O
+the	O
+genomic	O
+sequence	O
+multi	O
+-	O
+alignment	O
+indicated	O
+that	O
+the	O
+locations	O
+of	O
+packaging	O
+signals	O
+of	O
+SARS	B-PRGE
+-	I-PRGE
+CoV	I-PRGE
+,	O
+PEDV	B-SPEC
+,	O
+and	O
+HCoV	O
+overlaped	O
+each	O
+other	O
+.	O
+
+Either	O
+the	O
+3D	O
+model	O
+of	O
+the	O
+SARS	B-PRGE
+-	I-PRGE
+CoV	I-PRGE
+3CL	I-PRGE
+proteinase	B-PROC
+or	O
+the	O
+X	O
+-	O
+ray	B-SPEC
+crystal	B-ANAT
+structure	O
+of	O
+the	O
+TGEV	B-SPEC
+Mpro	O
+may	O
+be	O
+used	O
+as	O
+a	O
+starting	O
+point	O
+for	O
+design	O
+anti	O
+-	O
+SARS	B-DISO
+drugs	O
+.	O
+
+The	O
+possible	O
+functions	O
+of	O
+this	O
+protein	B-CHED
+were	O
+annotated	O
+by	O
+bioinformatics	O
+methods	O
+,	O
+and	O
+its	O
+possible	O
+three	O
+-	O
+dimensional	O
+model	O
+was	O
+constructed	O
+by	O
+molecular	O
+modeling	O
+.	O
+
+The	O
+pure	B-FUNC
+sample	O
+of	O
+SARS	B-DISO
+E	O
+protein	B-CHED
+was	O
+obtained	O
+.	O
+
+She	O
+presented	O
+in	O
+acute	B-DISO
+respiratory	I-DISO
+failure	I-DISO
+with	O
+hemoptysis	B-DISO
+and	O
+acute	B-DISO
+renal	I-DISO
+failure	I-DISO
+;	O
+interestingly	O
+,	O
+however	O
+,	O
+the	O
+renal	B-ANAT
+biopsy	O
+was	O
+normal	O
+.	O
+
+TITLE	O
+:	O
+Effects	O
+of	O
+gravity	O
+on	O
+lung	B-ANAT
+diffusing	O
+capacity	O
+and	O
+cardiac	B-ANAT
+output	O
+in	O
+prone	O
+and	O
+supine	O
+humans	B-SPEC
+.	O
+
+Also	O
+,	O
+both	O
+conditions	O
+show	O
+an	O
+impaired	B-DISO
+arterial	B-ANAT
+oxygenation	B-PROC
+,	O
+which	O
+is	O
+less	O
+severe	O
+in	O
+the	O
+prone	O
+than	O
+in	O
+the	O
+supine	O
+posture	O
+.	O
+
+TITLE	O
+:	O
+Recombinant	B-PRGE
+platelet	I-PRGE
+-	I-PRGE
+activating	I-PRGE
+factor	I-PRGE
+acetylhydrolase	I-PRGE
+to	O
+prevent	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+and	O
+mortality	O
+in	O
+severe	B-DISO
+sepsis	I-DISO
+:	O
+Phase	O
+IIb	O
+,	O
+multicenter	O
+,	O
+randomized	O
+,	O
+placebo	O
+-	O
+controlled	O
+,	O
+clinical	O
+trial	O
+.	O
+
+A	O
+prospective	O
+,	O
+randomized	O
+,	O
+double	O
+-	O
+blind	B-DISO
+,	O
+placebo	O
+-	O
+controlled	O
+,	O
+multicenter	O
+trial	O
+.	O
+
+Randomization	O
+occurred	O
+within	O
+12	O
+hrs	B-DISO
+of	O
+the	O
+onset	O
+of	O
+severe	B-DISO
+sepsis	I-DISO
+.	O
+
+Demographic	O
+and	O
+baseline	O
+clinical	O
+characteristics	O
+of	O
+the	O
+three	O
+treatment	O
+groups	O
+were	O
+similar	O
+,	O
+except	O
+for	O
+a	O
+significantly	O
+higher	O
+prevalence	O
+of	O
+respiratory	B-DISO
+tract	I-DISO
+infections	I-DISO
+as	O
+the	O
+cause	O
+of	O
+severe	B-DISO
+sepsis	I-DISO
+in	O
+patients	O
+treated	O
+with	O
+1	O
+.	O
+0	O
+mg	O
+/	O
+kg	O
+rPAF	O
+-	O
+AH	O
+.	O
+
+There	O
+were	O
+no	O
+significant	O
+differences	O
+in	O
+the	O
+prevalence	O
+of	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+among	O
+the	O
+three	O
+treatment	O
+groups	O
+.	O
+
+TITLE	O
+:	O
+[	O
+SARS	B-DISO
+.	O
+
+Suddenly	O
+,	O
+she	O
+had	O
+a	O
+terrible	O
+epigastralgia	B-DISO
+and	O
+back	B-DISO
+pain	I-DISO
+.	O
+
+Case	O
+3	O
+(	O
+son	B-PRGE
+case	I-PRGE
+):	O
+48	O
+-	O
+year	O
+-	O
+old	O
+male	O
+was	O
+transferred	O
+to	O
+our	O
+hospital	O
+diagnosed	O
+with	O
+acute	B-DISO
+aortic	I-DISO
+dissection	I-DISO
+(	O
+Stanford	O
+type	O
+A	O
+).	O
+
+TITLE	O
+:	O
+[	O
+The	O
+biological	O
+characteristics	O
+of	O
+SARS	B-DISO
+virus	B-SPEC
+and	O
+its	O
+related	O
+coronaviruses	O
+].	O
+
+Expression	B-PROC
+of	O
+the	O
+S1	B-PRGE
+gene	I-PRGE
+in	O
+the	O
+recombinants	O
+was	O
+confirmed	O
+by	O
+reverse	B-PROC
+transcription	I-PROC
+-	O
+polymerase	O
+chain	O
+reaction	O
+(	O
+RT	O
+-	O
+PCR	O
+)	O
+by	O
+20h	O
+post	O
+-	O
+infection	B-DISO
+.	O
+
+TITLE	O
+:	O
+Advances	O
+in	O
+clinical	O
+diagnosis	O
+and	O
+treatment	O
+of	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+.	O
+
+SARS	B-DISO
+originated	O
+in	O
+Guangdong	O
+Province	O
+,	O
+the	O
+People	O
+'	O
+s	O
+Republic	O
+of	O
+China	O
+at	O
+the	O
+end	O
+of	O
+2002	O
+.	O
+
+NMS	B-DISO
+is	O
+characterized	O
+by	O
+predominant	O
+involvement	O
+of	O
+lower	B-ANAT
+limb	I-ANAT
+muscles	B-ANAT
+in	O
+pathologic	B-DISO
+process	I-DISO
+and	O
+by	O
+rarely	O
+developing	O
+generalized	O
+form	O
+.	O
+
+TITLE	O
+:	O
+Severe	O
+community	O
+-	O
+acquired	O
+pneumonia	B-DISO
+with	O
+acute	O
+hypoxemic	O
+respiratory	B-DISO
+failure	I-DISO
+due	O
+to	O
+primary	B-DISO
+infection	I-DISO
+with	O
+Chlamydia	B-SPEC
+pneumoniae	I-SPEC
+in	O
+a	O
+previously	O
+healthy	O
+adult	O
+.	O
+
+We	O
+report	O
+a	O
+case	O
+of	O
+severe	O
+pneumonia	B-DISO
+complicated	O
+by	O
+acute	O
+hypoxemic	O
+respiratory	B-DISO
+failure	I-DISO
+due	O
+to	O
+primary	B-DISO
+infection	I-DISO
+with	O
+C	B-SPEC
+.	I-SPEC
+pneumoniae	I-SPEC
+in	O
+a	O
+previously	O
+healthy	O
+46	O
+-	O
+year	O
+-	O
+old	O
+woman	O
+.	O
+
+Treatment	O
+consists	O
+of	O
+support	O
+care	O
+and	O
+artificial	O
+respiration	B-PROC
+when	O
+required	O
+.	O
+
+Is	O
+it	O
+a	O
+mistake	O
+or	O
+a	O
+terror	O
+acts	O
+of	O
+leakage	B-DISO
+of	O
+viral	O
+mutant	B-DISO
+from	O
+research	O
+or	O
+other	O
+laboratories	O
+?	O
+
+TITLE	O
+:	O
+Update	O
+:	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+--	O
+United	O
+States	O
+,	O
+June	O
+11	O
+,	O
+2003	O
+.	O
+
+The	O
+nucleotide	B-CHED
+sequence	O
+encoding	O
+the	O
+entire	O
+N	B-PRGE
+gene	I-PRGE
+open	O
+reading	O
+frame	O
+(	O
+ORF	O
+)	O
+of	O
+Chinju99	O
+was	O
+1326	O
+bases	B-CHED
+long	O
+and	O
+encoded	O
+a	O
+protein	B-CHED
+of	O
+441	O
+amino	B-CHED
+acids	I-CHED
+with	O
+predicted	O
+M	O
+(	O
+r	O
+)	O
+of	O
+49	O
+kDa	O
+.	O
+
+The	O
+amino	O
+acid	O
+sequence	O
+contained	O
+seven	O
+potential	O
+sites	O
+for	O
+threonine	B-CHED
+(	O
+T	O
+)-	O
+or	O
+serine	B-CHED
+(	O
+S	O
+)-	O
+linked	O
+phosphorylation	B-PROC
+by	O
+each	O
+protein	B-PRGE
+kinase	I-PRGE
+C	I-PRGE
+and	O
+casein	B-PRGE
+kinase	I-PRGE
+II	I-PRGE
+.	O
+
+ABSTRACT	O
+:	O
+The	O
+replicase	B-PRGE
+polyprotein	O
+of	O
+murine	B-SPEC
+coronavirus	I-SPEC
+is	O
+extensively	O
+processed	O
+by	O
+three	O
+proteinases	O
+,	O
+two	O
+papain	B-PRGE
+-	I-PRGE
+like	I-PRGE
+proteinases	I-PRGE
+(	O
+PLPs	O
+),	O
+termed	O
+PLP1	B-PRGE
+and	O
+PLP2	B-PRGE
+,	O
+and	O
+a	O
+picornavirus	B-PRGE
+3C	I-PRGE
+-	I-PRGE
+like	I-PRGE
+proteinase	B-PROC
+(	O
+3CLpro	O
+).	O
+
+Previously	O
+,	O
+we	O
+established	O
+a	O
+trans	O
+-	O
+cleavage	B-PROC
+assay	O
+and	O
+showed	O
+that	O
+PLP2	B-PRGE
+cleaves	O
+the	O
+replicase	B-PRGE
+polyprotein	I-PRGE
+between	O
+p210	B-PRGE
+and	O
+membrane	B-PRGE
+protein	B-CHED
+1	I-PRGE
+(	O
+MP1	B-PRGE
+)	O
+(	O
+A	O
+.	O
+Kanjanahaluethai	O
+and	O
+S	O
+.	O
+C	O
+.	O
+Baker	O
+,	O
+J	O
+.	O
+Virol	O
+.	O
+
+Therefore	O
+,	O
+murine	B-PRGE
+coronavirus	I-PRGE
+PLP2	I-PRGE
+cleaves	O
+the	O
+replicase	B-PRGE
+polyprotein	O
+between	O
+glycine	B-CHED
+2840	O
+and	O
+alanine	B-CHED
+2841	O
+,	O
+and	O
+the	O
+critical	O
+determinants	O
+for	O
+PLP2	B-PRGE
+recognition	O
+and	O
+processing	O
+occupy	O
+the	O
+P6	O
+,	O
+P2	O
+,	O
+and	O
+P1	O
+positions	O
+of	O
+the	O
+cleavage	B-PROC
+site	O
+.	O
+
+Patients	O
+in	O
+group	O
+1	O
+were	O
+older	O
+(	O
+mean	O
+age	O
+,	O
+45	O
+vs	O
+30	O
+.	O
+3	O
+years	O
+),	O
+had	O
+a	O
+higher	O
+rate	O
+of	O
+intensive	O
+care	O
+unit	O
+admission	O
+(	O
+27	O
+%	O
+[	O
+four	O
+of	O
+15	O
+]	O
+vs	O
+11	O
+%	O
+[	O
+one	O
+of	O
+nine	O
+]),	O
+more	O
+requirement	O
+for	O
+pulsed	O
+intravenous	O
+methylprednisolone	B-CHED
+(	O
+87	O
+%,	O
+[	O
+13	O
+of	O
+15	O
+]	O
+vs	O
+67	O
+%	O
+[	O
+six	O
+of	O
+nine	O
+]),	O
+higher	O
+peak	O
+lactate	B-PRGE
+dehydrogenase	I-PRGE
+level	O
+(	O
+438	O
+.	O
+9	O
+vs	O
+355	O
+.	O
+6	O
+U	O
+/	O
+L	O
+),	O
+and	O
+higher	O
+peak	O
+opacification	O
+on	O
+chest	B-ANAT
+radiographs	O
+(	O
+estimated	O
+area	O
+,	O
+14	O
+%	O
+vs	O
+11	O
+%)	O
+than	O
+patients	O
+in	O
+group	O
+2	O
+.	O
+
+This	O
+is	O
+a	O
+novel	O
+condition	B-DISO
+caused	O
+by	O
+the	O
+SARS	B-DISO
+-	I-DISO
+associated	I-DISO
+coronavirus	I-DISO
+(	O
+SARS	B-DISO
+-	O
+CoV	O
+)	O
+and	O
+is	O
+characterized	O
+by	O
+both	O
+an	O
+atypical	B-DISO
+pneumonia	I-DISO
+and	O
+efficient	O
+nosocomial	O
+transmission	O
+.	O
+
+TITLE	O
+:	O
+Update	O
+:	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+--	O
+United	O
+States	O
+,	O
+2003	O
+.	O
+
+ABSTRACT	O
+:	O
+CDC	O
+,	O
+in	O
+collaboration	O
+with	O
+state	O
+and	O
+local	O
+health	O
+departments	O
+,	O
+the	O
+World	O
+Health	O
+Organization	O
+(	O
+WHO	O
+),	O
+and	O
+other	O
+partners	O
+,	O
+continues	O
+to	O
+investigate	O
+cases	O
+of	O
+severe	O
+acute	O
+respiratory	O
+syndrome	O
+(	O
+SARS	B-DISO
+).	O
+
+Based	O
+on	O
+the	O
+conservation	O
+of	O
+a	O
+characteristic	O
+tetrad	O
+of	O
+residues	O
+,	O
+the	O
+mRNA	B-PRGE
+cap	B-DISO
+-	I-PRGE
+1	I-PRGE
+methyltransferase	I-PRGE
+function	O
+has	O
+been	O
+assigned	O
+to	O
+this	O
+protein	B-CHED
+,	O
+which	O
+has	O
+potential	O
+implications	O
+for	O
+antiviral	B-CHED
+therapy	O
+.	O
+
+Consultation	O
+of	O
+particular	O
+cases	O
+involving	O
+experts	O
+from	O
+multiple	O
+medical	O
+science	O
+fields	O
+should	O
+be	O
+encouraged	O
+,	O
+which	O
+is	O
+also	O
+an	O
+effective	O
+measure	O
+against	O
+newly	O
+emerged	O
+infectious	B-DISO
+diseases	I-DISO
+.	O
+
+Each	O
+infant	O
+had	O
+severe	O
+acute	B-DISO
+respiratory	I-DISO
+failure	I-DISO
+(	O
+as	O
+a	O
+result	O
+of	O
+severe	O
+aspiration	B-DISO
+syndromes	B-DISO
+)	O
+and	O
+a	O
+clinical	O
+diagnosis	O
+of	O
+pulmonary	B-DISO
+hypertension	I-DISO
+and	O
+parenchymal	O
+lung	B-DISO
+disease	I-DISO
+in	O
+the	O
+absence	O
+of	O
+congenital	B-DISO
+malformations	I-DISO
+.	O
+
+TITLE	O
+:	O
+Hemophagocytic	O
+lymphohistiocytic	O
+syndrome	B-DISO
+:	O
+Unrecognized	O
+cause	O
+of	O
+multiple	B-DISO
+organ	I-DISO
+failure	I-DISO
+.	O
+
+Liver	B-DISO
+failure	I-DISO
+occurred	O
+in	O
+three	O
+and	O
+central	B-ANAT
+nervous	I-ANAT
+system	I-ANAT
+involvement	O
+and	O
+coma	B-DISO
+in	O
+three	O
+.	O
+
+CONCLUSIONS	O
+:	O
+Hemophagocytic	O
+lymphohistiocytic	O
+syndrome	B-DISO
+in	O
+the	O
+pediatric	O
+population	O
+may	O
+have	O
+a	O
+dramatic	O
+clinical	O
+picture	O
+,	O
+with	O
+multiple	B-DISO
+organ	I-DISO
+failure	I-DISO
+as	O
+a	O
+presenting	O
+symptom	B-DISO
+or	O
+early	O
+in	O
+the	O
+disease	O
+course	O
+,	O
+mandating	O
+intensive	O
+support	O
+in	O
+the	O
+PICU	B-SPEC
+.	O
+
+Fever	B-PROC
+,	O
+cough	B-DISO
+,	O
+in	O
+most	O
+cases	O
+non	O
+-	O
+productive	O
+,	O
+myalgia	B-DISO
+,	O
+chills	B-DISO
+,	O
+and	O
+rigor	B-DISO
+are	O
+the	O
+leading	O
+symptoms	O
+.	O
+
+Empirical	O
+therapy	O
+with	O
+ribavirin	B-CHED
+in	O
+combination	O
+with	O
+high	O
+dose	O
+corticosteroids	B-CHED
+have	O
+proved	O
+successful	O
+.	O
+
+ABSTRACT	O
+:	O
+Severe	B-DISO
+Acute	I-DISO
+Respiratory	I-DISO
+Syndrome	I-DISO
+(	O
+SARS	B-DISO
+)	O
+is	O
+a	O
+new	O
+infectious	B-DISO
+disease	I-DISO
+that	O
+,	O
+in	O
+the	O
+short	O
+period	O
+between	O
+1	O
+February	O
+and	O
+24	O
+April	O
+2003	O
+,	O
+has	O
+been	O
+diagnosed	O
+in	O
+more	O
+than	O
+4000	O
+patients	O
+.	O
+
+Essential	O
+steps	O
+to	O
+prevent	O
+further	O
+dissemination	O
+of	O
+the	O
+virus	B-SPEC
+are	O
+rapid	O
+identification	O
+,	O
+and	O
+treatment	O
+in	O
+an	O
+isolation	O
+unit	O
+.	O
+
+ABSTRACT	O
+:	O
+The	O
+outbreak	O
+of	O
+SARS	B-DISO
+warrants	O
+the	O
+search	O
+for	O
+antiviral	B-CHED
+compounds	O
+to	O
+treat	O
+the	O
+disease	O
+.	O
+
+Of	O
+all	O
+the	O
+compounds	O
+,	O
+glycyrrhizin	B-CHED
+was	O
+the	O
+most	O
+active	O
+in	O
+inhibiting	O
+replication	O
+of	O
+the	O
+SARS	B-DISO
+-	O
+associated	O
+virus	B-SPEC
+.	O
+
+By	O
+phylogenetic	O
+tree	O
+analysis	O
+,	O
+Korean	O
+field	O
+TGEV	B-SPEC
+strains	O
+were	O
+branched	B-ANAT
+into	O
+different	O
+groups	O
+from	O
+non	O
+-	O
+Korean	O
+TGEV	B-SPEC
+or	O
+PRCV	O
+strains	O
+.	O
+
+Feeding	O
+of	O
+single	O
+dose	O
+of	O
+NAC	B-COMP
+(	O
+0	O
+.	O
+5	O
+g	O
+)	O
+by	O
+gavage	O
+just	O
+before	O
+the	O
+CEES	O
+infusion	O
+was	O
+ineffective	O
+to	O
+counteract	O
+these	O
+effects	O
+.	O
+
+Therefore	O
+,	O
+NAC	B-COMP
+may	O
+be	O
+an	O
+antidote	B-CHED
+for	O
+CEES	O
+-	O
+induced	O
+lung	B-ANAT
+injury	O
+.	O
+
+TITLE	O
+:	O
+Update	O
+:	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+--	O
+United	O
+States	O
+,	O
+June	O
+18	O
+,	O
+2003	O
+.	O
+
+RESULTS	O
+:	O
+Of	O
+the	O
+556	O
+people	O
+,	O
+141	O
+were	O
+admitted	O
+to	O
+hospital	O
+,	O
+and	O
+97	O
+had	O
+confirmed	O
+SARS	B-DISO
+.	O
+
+Lymphopenia	B-DISO
+was	O
+shown	O
+in	O
+haemato	O
+-	O
+lymphoid	B-ANAT
+organs	I-ANAT
+at	O
+postmortem	O
+examination	O
+.	O
+
+Abnormal	O
+haematological	O
+variables	O
+were	O
+common	O
+among	O
+patients	O
+with	O
+SARS	B-DISO
+.	O
+
+The	O
+most	O
+common	O
+radiographic	O
+findings	O
+of	O
+SARS	B-DISO
+patients	O
+at	O
+presentation	O
+are	O
+unilateral	O
+or	O
+bilateral	O
+ground	O
+-	O
+glass	O
+opacities	B-DISO
+or	O
+focal	O
+unilateral	O
+or	O
+bilateral	O
+areas	O
+of	O
+consolidation	O
+.	O
+
+Between	O
+November	O
+2002	O
+and	O
+January	O
+2003	O
+,	O
+there	O
+had	O
+been	O
+7	O
+cities	O
+reported	O
+to	O
+have	O
+identified	O
+index	O
+cases	O
+of	O
+SARS	B-DISO
+with	O
+6	O
+of	O
+them	O
+being	O
+infected	O
+in	O
+their	O
+own	O
+cities	O
+and	O
+1	O
+imported	O
+from	O
+Guangzhou	O
+city	O
+.	O
+
+ABSTRACT	O
+:	O
+To	O
+understand	O
+the	O
+epidemiological	O
+characteristics	O
+of	O
+severe	O
+acute	O
+respiratory	O
+syndrome	O
+(	O
+SARS	B-DISO
+)	O
+outbreaks	O
+in	O
+some	O
+areas	O
+of	O
+Guangdong	O
+province	O
+and	O
+to	O
+provide	O
+scientific	O
+basis	O
+for	O
+prevention	O
+and	O
+control	O
+measures	O
+against	O
+it	O
+.	O
+
+It	O
+is	O
+of	O
+great	O
+importance	O
+to	O
+prevent	O
+clustered	O
+SARS	B-DISO
+cases	O
+and	O
+the	O
+prevention	O
+of	O
+iatrogenic	B-DISO
+infection	I-DISO
+is	O
+essential	O
+.	O
+
+CONCLUSIONS	O
+:	O
+SARS	B-DISO
+is	O
+a	O
+preventable	O
+disease	O
+and	O
+can	O
+be	O
+under	O
+control	O
+.	O
+
+All	O
+patients	O
+experienced	O
+a	O
+drop	O
+in	O
+hemoglobin	B-PRGE
+.	O
+
+Nine	O
+patients	O
+had	O
+hemolytic	B-DISO
+anemia	I-DISO
+.	O
+
+RESULTS	O
+:	O
+The	O
+11	O
+women	O
+and	O
+3	O
+men	O
+described	O
+here	O
+(	O
+mean	O
+age	O
+42	O
+[	O
+standard	O
+deviation	O
+[	O
+SD	O
+]	O
+9	O
+]	O
+years	O
+)	O
+were	O
+all	O
+involved	O
+in	O
+providing	O
+medical	O
+or	O
+ancillary	O
+hospital	O
+services	O
+to	O
+patients	O
+who	O
+were	O
+later	O
+found	O
+to	O
+have	O
+SARS	B-DISO
+.	O
+
+For	O
+5	O
+patients	O
+,	O
+chest	B-ANAT
+radiographs	O
+still	O
+showed	O
+residual	B-DISO
+disease	I-DISO
+.	O
+
+ABSTRACT	O
+:	O
+The	O
+mysterious	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+(	O
+SARS	B-DISO
+)	O
+that	O
+has	O
+originated	O
+from	O
+the	O
+southern	O
+Chinese	O
+province	O
+of	O
+Guangdong	O
+appears	O
+to	O
+be	O
+a	O
+major	O
+public	O
+health	O
+threat	O
+and	O
+medical	O
+challenge	O
+.	O
+
+These	O
+viruses	B-SPEC
+have	O
+been	O
+associated	O
+with	O
+upper	B-DISO
+respiratory	I-DISO
+infections	I-DISO
+and	O
+sometimes	O
+pneumonia	B-DISO
+in	O
+humans	B-SPEC
+.	O
+
+ABSTRACT	O
+:	O
+The	O
+recent	O
+outbreak	O
+of	O
+Severe	O
+Acute	O
+Respiratory	O
+Syndrome	O
+(	O
+SARS	B-DISO
+)	O
+as	O
+a	O
+new	O
+viral	B-DISO
+disease	I-DISO
+is	O
+causing	O
+a	O
+great	O
+concern	O
+for	O
+health	O
+authorities	O
+and	O
+general	O
+population	O
+.	O
+
+Current	O
+treatment	O
+of	O
+SARS	B-DISO
+with	O
+antiviral	B-CHED
+agents	I-CHED
+such	O
+as	O
+ribavirin	B-CHED
+and	O
+corticosteroids	B-CHED
+have	O
+not	O
+achieved	O
+very	O
+satisfactory	O
+results	O
+.	O
+
+ABSTRACT	O
+:	O
+The	O
+Authors	O
+report	O
+a	O
+case	O
+of	O
+acute	O
+White	O
+-	O
+Spirit	O
+poisoning	O
+with	O
+pulmonary	O
+hypertension	O
+associated	O
+to	O
+respiratory	B-DISO
+distress	I-DISO
+syndrome	I-DISO
+.	O
+
+Cardiac	B-ANAT
+ultrasounds	O
+showed	O
+pulmonary	B-DISO
+hypertension	I-DISO
+,	O
+which	O
+rapidly	O
+resolved	O
+with	O
+inhaled	B-PROC
+nitric	B-CHED
+oxide	I-CHED
+.	O
+
+CONCLUSIONS	O
+:	O
+Pulmonary	B-DISO
+hypertension	I-DISO
+should	O
+be	O
+checked	O
+for	O
+in	O
+case	O
+of	O
+White	O
+-	O
+Spirit	O
+ingestion	O
+complicated	O
+with	O
+severe	O
+acute	O
+lung	B-ANAT
+injury	O
+.	O
+
+ABSTRACT	O
+:	O
+To	O
+locate	O
+the	O
+transmissible	O
+gastroenteritis	B-DISO
+coronavirus	B-SPEC
+(	O
+TGEV	B-SPEC
+)	O
+packaging	O
+signal	O
+,	O
+the	O
+incorporation	O
+of	O
+TGEV	B-SPEC
+subgenomic	O
+mRNAs	O
+(	O
+sgmRNAs	O
+)	O
+into	O
+virions	B-COMP
+was	O
+first	O
+addressed	O
+.	O
+
+Detection	O
+of	O
+sgmRNAs	O
+in	O
+virions	B-COMP
+by	O
+specific	O
+reverse	B-PROC
+transcription	I-PROC
+-	O
+PCRs	O
+(	O
+RT	O
+-	O
+PCRs	O
+)	O
+was	O
+related	O
+to	O
+the	O
+purity	O
+of	O
+virus	B-SPEC
+preparations	O
+.	O
+
+Examination	O
+of	O
+the	O
+chest	B-ANAT
+showed	O
+minimal	O
+auscultatory	O
+findings	O
+.	O
+
+Children	O
+younger	O
+than	O
+12	O
+yrs	O
+seemed	O
+less	O
+ill	B-DISO
+but	O
+had	O
+more	O
+coughing	B-DISO
+.	O
+
+To	O
+explore	O
+if	O
+the	O
+least	O
+expressed	B-PROC
+ORF	B-PRGE
+,	O
+ORF	B-PRGE
+3b	I-PRGE
+,	O
+which	O
+encodes	O
+a	O
+nonstructural	O
+protein	B-CHED
+,	O
+is	O
+evolutionarily	O
+conserved	O
+and	O
+functionally	O
+indispensable	O
+for	O
+viral	O
+propagation	O
+in	O
+cultured	B-ANAT
+cells	I-ANAT
+,	O
+the	O
+Beaudette	O
+strain	O
+of	O
+IBV	B-SPEC
+was	O
+propagated	O
+in	O
+chicken	B-SPEC
+embryonated	O
+eggs	O
+for	O
+three	O
+passages	O
+and	O
+then	O
+adapted	O
+to	O
+a	O
+monkey	B-SPEC
+kidney	B-ANAT
+cell	I-ANAT
+line	O
+,	O
+Vero	O
+.	O
+
+The	O
+3b	O
+gene	O
+of	O
+passage	O
+3	O
+in	O
+embryonated	O
+eggs	O
+and	O
+passages	O
+7	O
+,	O
+15	O
+,	O
+20	O
+,	O
+25	O
+,	O
+30	O
+,	O
+35	O
+50	O
+,	O
+and	O
+65	O
+in	O
+Vero	B-ANAT
+cells	I-ANAT
+were	O
+amplified	O
+by	O
+reverse	B-PROC
+transcription	I-PROC
+-	O
+polymerase	O
+chain	O
+reaction	O
+and	O
+sequenced	O
+.	O
+
+The	O
+results	O
+showed	O
+that	O
+viral	O
+RNA	O
+extracted	O
+from	O
+passages	O
+35	O
+,	O
+50	O
+,	O
+and	O
+65	O
+contained	O
+a	O
+single	O
+A	O
+insertion	O
+in	O
+a	O
+6A	O
+stretch	O
+of	O
+the	O
+3b	O
+gene	O
+between	O
+nucleotides	B-CHED
+24075	O
+and	O
+24080	O
+,	O
+whereas	O
+the	O
+early	O
+passages	O
+carried	O
+the	O
+normal	O
+3b	O
+gene	O
+.	O
+
+We	O
+showed	O
+that	O
+the	O
+frameshifting	O
+product	O
+,	O
+cloned	O
+in	O
+a	O
+plasmid	O
+,	O
+was	O
+expressed	B-PROC
+in	O
+vitro	O
+and	O
+in	O
+cells	B-COMP
+transfected	O
+with	O
+the	O
+mutant	B-DISO
+construct	O
+.	O
+
+Of	O
+the	O
+three	O
+enveloped	O
+viruses	B-SPEC
+tested	O
+,	O
+human	B-SPEC
+herpes	B-SPEC
+simplex	I-SPEC
+virus	I-SPEC
+type	I-SPEC
+1	I-SPEC
+(	O
+HSV	B-SPEC
+-	I-SPEC
+1	I-SPEC
+),	O
+bovine	B-SPEC
+parainfluenza	I-SPEC
+virus	I-SPEC
+type	I-SPEC
+3	I-SPEC
+and	O
+porcine	B-SPEC
+respiratory	O
+corona	B-CHED
+virus	B-SPEC
+,	O
+only	O
+HSV	B-SPEC
+-	I-SPEC
+1	I-SPEC
+proved	O
+sensitive	O
+to	O
+the	O
+3	O
+-	O
+HP	O
+-	O
+proteins	B-CHED
+.	O
+
+The	O
+red	O
+fowl	O
+mite	O
+(	O
+Dermanyssus	B-SPEC
+gallinae	I-SPEC
+)	O
+was	O
+isolated	O
+from	O
+some	O
+of	O
+the	O
+birds	B-SPEC
+and	O
+their	O
+nests	O
+.	O
+
+Only	O
+10	O
+.	O
+5	O
+%	O
+of	O
+the	O
+owners	O
+interviewed	O
+had	O
+scientific	O
+knowledge	O
+on	O
+poultry	B-DISO
+diseases	I-DISO
+.	O
+
+Twenty	O
+-	O
+five	O
+patients	O
+suffered	B-DISO
+from	O
+SARS	B-DISO
+with	O
+ARDS	B-DISO
+in	O
+the	O
+intensive	O
+care	O
+unit	O
+were	O
+retrospectively	O
+analyzed	O
+from	O
+December	O
+2002	O
+to	O
+April	O
+2003	O
+.	O
+
+Statistical	O
+analysis	O
+was	O
+made	O
+using	O
+SPSS	O
+10	O
+.	O
+0	O
+and	O
+forward	O
+stepwise	O
+(	O
+wald	O
+)	O
+logistic	O
+regression	O
+analysis	O
+were	O
+used	O
+to	O
+determine	O
+the	O
+interrelationships	O
+between	O
+multiple	O
+variables	O
+and	O
+death	B-PROC
+.	O
+
+In	O
+seven	O
+non	O
+-	O
+survivors	O
+,	O
+the	O
+lesions	O
+were	O
+included	O
+multi	O
+-	O
+lung	B-ANAT
+lobes	B-ANAT
+,	O
+revealing	O
+earlier	O
+appearance	O
+and	O
+faster	O
+progression	O
+compared	O
+with	O
+the	O
+others	O
+.	O
+
+CONCLUSIONS	O
+:	O
+Severe	O
+SARS	B-DISO
+might	O
+develop	O
+rapidly	O
+.	O
+
+The	O
+mortality	O
+of	O
+patients	O
+who	O
+were	O
+given	O
+GC	O
+before	O
+or	O
+during	O
+24	O
+hours	O
+of	O
+the	O
+establishment	O
+of	O
+the	O
+diagnosis	O
+of	O
+ARDS	B-DISO
+(	O
+66	O
+.	O
+7	O
+%	O
+and	O
+68	O
+.	O
+2	O
+%)	O
+was	O
+lower	O
+than	O
+those	O
+who	O
+were	O
+given	O
+GC	O
+24	O
+hours	O
+after	O
+the	O
+diagnosis	O
+of	O
+ARDS	B-DISO
+(	O
+90	O
+.	O
+0	O
+%).	O
+
+Tissue	B-ANAT
+elastance	O
+and	O
+resistance	B-PROC
+augmented	O
+from	O
+control	O
+to	O
+P10	O
+(	O
+1	O
+and	O
+30	O
+days	O
+)	O
+and	O
+P25	O
+.	O
+
+Methylprednisolone	B-CHED
+at	O
+1	O
+or	O
+6	O
+hours	O
+attenuated	O
+in	O
+vivo	O
+and	O
+in	O
+vitro	O
+mechanical	O
+changes	O
+in	O
+P25	O
+,	O
+whereas	O
+P10	O
+parameters	O
+were	O
+similar	O
+to	O
+the	O
+control	O
+.	O
+
+ABSTRACT	O
+:	O
+The	O
+army	O
+of	O
+the	O
+men	O
+of	O
+death	B-PROC
+,	O
+in	O
+John	O
+Bunyan	O
+'	O
+s	O
+memorable	O
+phrase	O
+,	O
+has	O
+a	O
+new	O
+recruit	O
+,	O
+and	O
+fear	O
+has	O
+a	O
+new	O
+face	O
+:	O
+a	O
+face	B-DISO
+wearing	O
+a	O
+surgical	O
+mask	O
+.	O
+
+The	O
+lung	B-ANAT
+tissue	I-ANAT
+specimens	O
+were	O
+studied	O
+further	O
+with	O
+Macchiavello	O
+staining	O
+,	O
+viral	B-ANAT
+inclusion	I-ANAT
+body	I-ANAT
+staining	O
+,	O
+reticulin	B-CHED
+staining	O
+,	O
+PAS	B-COMP
+staining	O
+,	O
+immunohistochemistry	O
+,	O
+ultrathin	O
+sectioning	O
+and	O
+staining	O
+,	O
+light	O
+microscopy	O
+,	O
+and	O
+transmission	O
+electron	O
+microscopy	O
+.	O
+
+There	O
+was	O
+also	O
+massive	B-DISO
+necrosis	I-DISO
+of	O
+splenic	B-ANAT
+lymphoid	B-ANAT
+tissue	I-ANAT
+and	O
+localized	O
+necrosis	B-PROC
+in	O
+lymph	B-ANAT
+nodes	I-ANAT
+.	O
+
+Thrombosis	B-DISO
+was	O
+present	O
+in	O
+small	O
+veins	B-ANAT
+.	O
+
+Electron	O
+microscopy	O
+demonstrated	O
+clusters	B-CHED
+of	O
+viral	B-COMP
+particles	I-COMP
+,	O
+consistent	O
+with	O
+coronavirus	B-SPEC
+,	O
+in	O
+lung	B-ANAT
+tissue	I-ANAT
+.	O
+
+The	O
+lungs	B-ANAT
+,	O
+immune	O
+organs	B-ANAT
+,	O
+and	O
+systemic	O
+small	B-ANAT
+vessels	I-ANAT
+are	O
+the	O
+main	O
+targets	O
+of	O
+virus	B-SPEC
+attack	O
+,	O
+so	O
+that	O
+extensive	O
+consolidation	O
+of	O
+the	O
+lung	B-ANAT
+,	O
+diffuse	B-DISO
+alveolar	I-DISO
+damage	I-DISO
+with	O
+hyaline	B-DISO
+membrane	B-COMP
+formation	B-PROC
+,	O
+respiratory	B-DISO
+distress	I-DISO
+,	O
+and	O
+decreased	O
+immune	B-PROC
+function	I-PROC
+are	O
+the	O
+main	O
+causes	O
+of	O
+death	B-PROC
+.	O
+
+TITLE	O
+:	O
+[	O
+Analyses	O
+on	O
+one	O
+case	O
+of	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+'	O
+super	O
+transmitter	O
+'	O
+and	O
+chain	O
+of	O
+transmission	O
+].	O
+
+Standardized	O
+questionnaire	O
+was	O
+used	O
+to	O
+conduct	B-PROC
+case	O
+investigation	O
+and	O
+contact	O
+tracing	O
+by	O
+combining	O
+the	O
+field	O
+investigation	O
+and	O
+telephone	O
+interview	O
+.	O
+
+There	O
+was	O
+no	O
+evidence	O
+indicating	O
+that	O
+SARS	B-DISO
+cases	O
+were	O
+infectious	B-DISO
+during	O
+their	O
+incubation	O
+period	O
+.	O
+
+20	O
+deaths	B-PROC
+occurred	O
+in	O
+that	O
+period	O
+with	O
+the	O
+mortality	O
+rate	O
+4	O
+.	O
+49	O
+%.	O
+
+Another	O
+131	O
+cases	O
+were	O
+excluded	O
+the	O
+original	O
+diagnoses	O
+of	O
+SARS	B-DISO
+including	O
+10	O
+confirmed	O
+cases	O
+and	O
+121	O
+suspected	O
+cases	O
+.	O
+
+RESULTS	O
+:	O
+The	O
+first	O
+SARS	B-DISO
+case	O
+was	O
+reported	O
+in	O
+Inner	O
+Mongolian	O
+Autonomous	O
+Region	O
+on	O
+March	O
+27	O
+,	O
+2003	O
+.	O
+
+Fluctuation	B-DISO
+of	O
+the	O
+epidemics	O
+was	O
+mainly	O
+affected	O
+by	O
+the	O
+mobility	O
+of	O
+working	O
+population	O
+who	O
+recently	O
+returned	O
+to	O
+their	O
+hometowns	O
+.	O
+
+Sensitivity	O
+,	O
+specificity	O
+and	O
+agreement	O
+value	O
+of	O
+IFA	O
+regarding	O
+the	O
+diagnosis	O
+of	O
+SARS	B-DISO
+were	O
+all	O
+higher	O
+than	O
+90	O
+%.	O
+
+ABSTRACT	O
+:	O
+To	O
+review	O
+radiographic	O
+findings	O
+of	O
+patients	O
+with	O
+probable	O
+severe	O
+acute	O
+respiratory	O
+syndrome	O
+(	O
+SARS	B-DISO
+)	O
+who	O
+were	O
+seen	O
+at	O
+a	O
+University	O
+of	O
+Toronto	O
+(	O
+Ontario	O
+,	O
+Canada	O
+)	O
+teaching	O
+hospital	O
+.	O
+
+Subsegmental	O
+atelectasis	B-DISO
+and	O
+pleural	O
+complications	O
+were	O
+rarely	O
+observed	O
+.	O
+
+TITLE	O
+:	O
+Severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+:	O
+management	O
+and	O
+reconfiguration	O
+of	O
+a	O
+radiology	O
+department	O
+in	O
+an	O
+infectious	O
+disease	O
+situation	O
+.	O
+
+ABSTRACT	O
+:	O
+Severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+,	O
+or	O
+SARS	B-DISO
+,	O
+is	O
+a	O
+new	O
+infectious	B-DISO
+disease	I-DISO
+pandemic	O
+with	O
+important	O
+public	O
+health	O
+concerns	O
+.	O
+
+Barrier	O
+precautions	O
+,	O
+reconfiguration	O
+of	O
+the	O
+department	O
+,	O
+separation	B-DISO
+of	O
+imaging	O
+equipment	O
+,	O
+cleaning	O
+procedures	O
+,	O
+personal	O
+protective	O
+equipment	O
+,	O
+and	O
+staff	O
+safety	O
+are	O
+discussed	O
+.	O
+
+Patients	O
+included	O
+in	O
+the	O
+study	O
+met	B-CHED
+the	O
+following	O
+criteria	O
+:	O
+mechanical	O
+ventilation	O
+>	O
+24	O
+hours	O
+,	O
+head	B-ANAT
+Abbreviated	O
+Injury	O
+Scale	O
+score	O
+>	O
+or	O
+=	O
+3	O
+,	O
+no	O
+other	O
+body	B-ANAT
+region	I-ANAT
+Abbreviated	O
+Injury	O
+Scale	O
+score	O
+>	O
+or	O
+=	O
+3	O
+,	O
+and	O
+age	O
+between	O
+18	O
+and	O
+54	O
+years	O
+.	O
+
+Glasgow	O
+Coma	B-DISO
+Scale	O
+(	O
+GCS	O
+)	O
+score	O
+,	O
+Marshall	O
+CT	O
+scan	O
+score	O
+,	O
+and	O
+intracranial	B-ANAT
+abnormality	O
+were	O
+correlated	O
+with	O
+the	O
+development	B-PROC
+of	O
+ALI	O
+.	O
+
+Only	O
+3	O
+of	O
+16	O
+(	O
+19	O
+%)	O
+of	O
+the	O
+deaths	B-PROC
+within	O
+the	O
+ALI	O
+group	O
+were	O
+directly	O
+related	O
+to	O
+ALI	O
+.	O
+
+RESULTS	O
+:	O
+One	O
+hundred	O
+thirty	O
+-	O
+seven	O
+patients	O
+with	O
+isolated	O
+head	B-ANAT
+trauma	O
+were	O
+enrolled	O
+in	O
+the	O
+study	O
+over	O
+a	O
+4	O
+-	O
+year	O
+period	O
+.	O
+
+TITLE	O
+:	O
+[	O
+Clinical	O
+features	O
+of	O
+77	O
+patients	O
+with	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+].	O
+
+ABSTRACT	O
+:	O
+We	O
+have	O
+previously	O
+reported	O
+an	O
+experimental	O
+infection	B-DISO
+of	O
+young	O
+adults	O
+with	O
+a	O
+history	O
+of	O
+episodic	O
+and	O
+exclusive	O
+viral	O
+wheeze	B-DISO
+(	O
+EVW	B-DISO
+)	O
+using	O
+human	B-SPEC
+coronavirus	I-SPEC
+,	O
+in	O
+which	O
+16	O
+of	O
+24	O
+with	O
+EVW	B-DISO
+(	O
+15	O
+atopic	B-DISO
+)	O
+and	O
+11	O
+of	O
+19	O
+healthy	O
+controls	O
+(	O
+seven	O
+atopic	B-DISO
+)	O
+developed	O
+a	O
+symptomatic	O
+cold	B-DISO
+with	O
+evidence	O
+of	O
+infection	B-DISO
+,	O
+but	O
+only	O
+those	O
+with	O
+EVW	B-DISO
+developed	O
+lower	B-ANAT
+respiratory	I-ANAT
+tract	I-ANAT
+symptoms	O
+and	O
+increased	O
+airway	B-ANAT
+responsiveness	O
+.	O
+
+IL	B-FUNC
+-	I-FUNC
+8	I-FUNC
+increased	O
+in	O
+both	O
+the	O
+upper	O
+and	O
+lower	O
+respiratory	B-ANAT
+tracts	I-ANAT
+in	O
+both	O
+EVW	O
+and	O
+control	O
+subjects	O
+with	O
+colds	B-DISO
+,	O
+the	O
+largest	O
+change	O
+being	O
+seen	O
+on	O
+day	O
+4	O
+in	O
+the	O
+sputum	B-ANAT
+of	O
+those	O
+with	O
+EVW	O
+(	O
+mean	O
+difference	O
+from	O
+baseline	O
+(	O
+95	O
+%	O
+confidence	O
+interval	O
+)	O
+2	O
+.	O
+5	O
+(	O
+0	O
+.	O
+55	O
+-	O
+4	O
+.	O
+46	O
+)	O
+ng	O
+/	O
+mL	O
+).	O
+
+Only	O
+modest	O
+changes	O
+were	O
+seen	O
+in	O
+IFN	B-PRGE
+-	I-PRGE
+gamma	I-PRGE
+and	O
+no	O
+changes	O
+were	O
+seen	O
+in	O
+IL	B-FUNC
+-	I-FUNC
+5	I-FUNC
+or	O
+ECP	B-PRGE
+.	O
+
+EVW	O
+wheeze	B-DISO
+is	O
+characterized	O
+by	O
+neutrophilic	B-PROC
+inflammation	B-DISO
+in	O
+both	O
+the	O
+upper	O
+and	O
+lower	O
+respiratory	B-ANAT
+tracts	I-ANAT
+without	O
+eosinophilia	B-DISO
+(	O
+even	O
+in	O
+atopic	B-DISO
+subjects	O
+).	O
+
+The	O
+etiology	O
+of	O
+SARS	B-DISO
+is	O
+likely	O
+a	O
+novel	B-SPEC
+coronavirus	I-SPEC
+.	O
+
+We	O
+describe	O
+a	O
+patient	O
+post	O
+liver	B-ANAT
+transplant	B-ANAT
+who	O
+contracted	O
+SARS	B-DISO
+and	O
+died	B-PROC
+during	O
+the	O
+outbreak	O
+,	O
+with	O
+subsequent	O
+infection	B-DISO
+of	O
+family	B-SPEC
+and	O
+several	O
+health	O
+-	O
+care	O
+workers	O
+.	O
+
+TITLE	O
+:	O
+Experimental	O
+infection	B-DISO
+of	O
+piglets	O
+with	O
+a	O
+korean	O
+strain	O
+of	O
+porcine	B-SPEC
+epidemic	I-SPEC
+diarrhoea	I-SPEC
+virus	I-SPEC
+.	O
+
+A	O
+web	B-DISO
+service	O
+is	O
+provided	O
+,	O
+by	O
+which	O
+a	O
+user	O
+can	O
+obtain	O
+the	O
+annotated	O
+result	O
+immediately	O
+by	O
+pasting	O
+the	O
+SARS	B-DISO
+-	O
+CoV	O
+genome	O
+sequences	O
+into	O
+the	O
+input	O
+window	O
+on	O
+the	O
+web	B-DISO
+site	O
+(	O
+http	O
+://	O
+tubic	O
+.	O
+tju	O
+.	O
+edu	O
+.	O
+cn	O
+/	O
+sars	B-DISO
+/).	O
+
+In	O
+acute	O
+(<	O
+48	O
+hours	O
+)	O
+hyponatremia	O
+,	O
+usually	O
+observed	O
+in	O
+the	O
+postoperative	O
+period	O
+,	O
+prompt	O
+treatment	O
+with	O
+hypertonic	O
+saline	O
+(	O
+3	O
+%)	O
+can	O
+prevent	O
+seizures	B-DISO
+and	O
+respiratory	B-DISO
+arrest	I-DISO
+.	O
+
+The	O
+use	O
+of	O
+urea	B-CHED
+to	O
+treat	O
+hyponatremia	O
+represents	O
+an	O
+advantageous	O
+alternative	O
+to	O
+hypertonic	O
+saline	O
+.	O
+
+The	O
+further	O
+experiments	O
+demonstrated	O
+that	O
+N1	O
+peptide	B-CHED
+-	O
+induced	O
+polyclonal	O
+antibodies	B-COMP
+had	O
+a	O
+high	O
+affinity	O
+to	O
+bind	B-FUNC
+to	O
+E	B-SPEC
+.	I-SPEC
+coli	I-SPEC
+expressed	B-PROC
+N	B-PRGE
+protein	I-PRGE
+of	O
+SARS	B-PRGE
+-	I-PRGE
+CoV	I-PRGE
+.	O
+Furthermore	O
+,	O
+it	O
+was	O
+confirmed	O
+that	O
+N1	B-PRGE
+peptide	I-PRGE
+-	I-PRGE
+specific	I-PRGE
+IgG	I-PRGE
+antibodies	B-COMP
+were	O
+detectable	O
+in	O
+the	O
+sera	B-COMP
+of	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+(	O
+SARS	B-DISO
+)	O
+patients	O
+.	O
+
+ABSTRACT	O
+:	O
+To	O
+assess	O
+serum	B-COMP
+antibody	B-PROC
+responses	I-PROC
+of	O
+patients	O
+with	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+(	O
+SARS	B-DISO
+)	O
+to	O
+nucleocapsid	B-PRGE
+(	I-PRGE
+N	I-PRGE
+)	I-PRGE
+antigen	B-CHED
+of	O
+SARS	B-DISO
+-	I-DISO
+associated	I-DISO
+coronavirus	B-SPEC
+.	O
+
+In	O
+13	O
+patients	O
+with	O
+SARS	B-DISO
+,	O
+the	O
+antibody	B-PROC
+responses	I-PROC
+to	O
+N	B-PRGE
+antigen	I-PRGE
+were	O
+not	O
+detectable	O
+in	O
+the	O
+first	O
+week	O
+after	O
+the	O
+onset	O
+of	O
+symptoms	O
+.	O
+
+The	O
+IgM	B-PRGE
+and	O
+IgG	B-PRGE
+seroprotection	O
+rates	O
+were	O
+83	O
+.	O
+3	O
+%	O
+and	O
+66	O
+.	O
+7	O
+%	O
+respectively	O
+in	O
+the	O
+second	O
+week	O
+,	O
+both	O
+reaching	B-PROC
+100	O
+%	O
+at	O
+the	O
+third	O
+week	O
+.	O
+
+This	O
+ELISA	O
+-	O
+based	O
+test	O
+for	O
+detecting	O
+anti	B-PRGE
+-	I-PRGE
+N	I-PRGE
+antigen	I-PRGE
+may	O
+be	O
+of	O
+significant	O
+value	O
+for	O
+SARS	B-DISO
+diagnosis	O
+.	O
+
+CONCLUSIONS	O
+:	O
+The	O
+antibody	B-PROC
+responses	I-PROC
+suggest	O
+that	O
+N	B-PRGE
+protein	I-PRGE
+of	O
+SARS	B-DISO
+is	O
+immunodominant	O
+and	O
+plays	O
+an	O
+important	O
+role	O
+in	O
+viral	B-DISO
+pathogenesis	I-DISO
+.	O
+
+ABSTRACT	O
+:	O
+Severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+(	O
+SARS	B-DISO
+)	O
+is	O
+a	O
+newly	O
+recognized	O
+infectious	B-DISO
+disease	I-DISO
+capable	O
+of	O
+causing	O
+severe	O
+respiratory	B-DISO
+failure	I-DISO
+.	O
+
+Secondary	O
+outcomes	O
+included	O
+rate	O
+of	O
+SARS	B-DISO
+-	O
+related	O
+critical	B-DISO
+illness	I-DISO
+,	O
+number	O
+of	O
+tertiary	O
+care	O
+ICUs	O
+and	O
+staff	O
+placed	O
+under	O
+quarantine	O
+,	O
+and	O
+number	O
+of	O
+health	O
+care	O
+workers	O
+(	O
+HCWs	O
+)	O
+contracting	O
+SARS	B-DISO
+secondary	O
+to	O
+ICU	O
+-	O
+acquired	O
+transmission	O
+.	O
+
+Patients	O
+who	O
+died	B-PROC
+were	O
+more	O
+often	O
+older	O
+,	O
+had	O
+preexisting	O
+diabetes	B-DISO
+mellitus	I-DISO
+,	O
+and	O
+on	O
+admission	O
+to	O
+hospital	O
+were	O
+more	O
+likely	O
+to	O
+have	O
+bilateral	O
+radiographic	O
+infiltrates	B-DISO
+.	O
+
+The	O
+SARS	B-DISO
+outbreak	O
+greatly	O
+strained	O
+regional	O
+critical	O
+care	O
+resources	O
+.	O
+
+To	O
+describe	O
+the	O
+clinical	O
+spectrum	O
+and	O
+outcomes	O
+of	O
+ALI	O
+/	O
+ARDS	B-DISO
+in	O
+patients	O
+with	O
+SARS	B-DISO
+-	O
+related	O
+critical	B-DISO
+illness	I-DISO
+.	O
+
+There	O
+was	O
+no	O
+response	O
+to	O
+antibiotics	B-CHED
+.	O
+
+Until	O
+the	O
+validation	O
+of	O
+diagnostic	O
+kits	O
+is	O
+completed	O
+,	O
+clinical	B-DISO
+findings	I-DISO
+,	O
+contact	O
+history	O
+,	O
+and	O
+radiologic	O
+findings	O
+are	O
+the	O
+key	O
+to	O
+diagnosis	O
+of	O
+this	O
+disease	O
+.	O
+
+Since	O
+then	O
+,	O
+probable	O
+cases	O
+of	O
+SARS	B-DISO
+have	O
+been	O
+reported	O
+in	O
+30	O
+countries	O
+and	O
+the	O
+current	O
+cumulative	O
+number	O
+of	O
+cases	O
+is	O
+8	O
+,	O
+240	O
+with	O
+745	O
+deaths	B-PROC
+and	O
+a	O
+global	O
+fatality	O
+rate	O
+of	O
+9	O
+%.	O
+
+Most	O
+cases	O
+of	O
+SARS	B-DISO
+to	O
+date	O
+have	O
+occurred	O
+in	O
+young	O
+adults	O
+and	O
+this	O
+disease	O
+appears	O
+to	O
+spread	O
+most	O
+commonly	O
+by	O
+close	O
+person	O
+-	O
+to	O
+-	O
+person	O
+contact	O
+,	O
+involving	O
+exposure	O
+to	O
+infectious	B-DISO
+droplets	O
+and	O
+body	B-ANAT
+fluids	I-ANAT
+.	O
+
+The	O
+spread	O
+of	O
+SARS	B-DISO
+,	O
+to	O
+less	O
+developed	O
+country	O
+with	O
+limited	O
+resource	O
+for	O
+public	O
+health	O
+programs	O
+,	O
+represent	O
+the	O
+emerging	O
+alarming	O
+threat	O
+in	O
+the	O
+new	O
+global	O
+scenario	O
+.	O
+
+The	O
+nucleotide	O
+and	O
+deduced	O
+amino	B-CHED
+acid	I-CHED
+alignment	O
+between	O
+this	O
+coronavirus	B-SPEC
+and	O
+others	O
+was	O
+not	O
+more	O
+than	O
+40	O
+%	O
+and	O
+70	O
+%	O
+to	O
+82	O
+%,	O
+respectively	O
+,	O
+while	O
+the	O
+nucleotide	B-CHED
+sequence	O
+cloned	O
+from	O
+the	O
+6	O
+patients	O
+were	O
+identical	O
+.	O
+
+The	O
+SARS	B-DISO
+patients	O
+in	O
+Shenzhen	O
+were	O
+infected	O
+with	O
+coronavirus	B-SPEC
+and	O
+this	O
+novel	B-SPEC
+coronavirus	I-SPEC
+is	O
+associated	O
+with	O
+SARS	B-DISO
+.	O
+
+During	O
+the	O
+respiratory	O
+phase	O
+that	O
+begins	O
+around	O
+day	O
+3	O
+,	O
+patients	O
+start	O
+developing	O
+a	O
+dry	B-DISO
+cough	I-DISO
+,	O
+shortness	B-DISO
+of	I-DISO
+breath	I-DISO
+and	O
+hypoxemia	O
+.	O
+
+Treatment	O
+of	O
+SARS	B-DISO
+includes	O
+supportive	O
+measures	O
+and	O
+the	O
+empiric	O
+use	O
+of	O
+ribavirin	B-CHED
+.	O
+
+ABSTRACT	O
+:	O
+To	O
+observe	O
+the	O
+effect	O
+of	O
+103	O
+patients	O
+of	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+(	O
+SARS	B-DISO
+)	O
+treated	O
+by	O
+integrative	O
+traditional	O
+Chinese	O
+and	O
+western	O
+medicine	B-CHED
+.	O
+
+For	O
+the	O
+protection	O
+of	O
+neonatal	O
+and	O
+older	O
+animals	B-SPEC
+,	O
+oral	B-ANAT
+live	O
+vaccines	O
+present	O
+the	O
+attractive	O
+property	O
+of	O
+inducing	O
+desired	O
+mucosal	B-PROC
+immune	I-PROC
+responses	I-PROC
+,	O
+including	O
+colostral	O
+antibodies	B-COMP
+in	O
+sows	O
+--	O
+an	O
+effective	O
+means	O
+to	O
+passively	O
+protect	O
+suckling	O
+piglets	O
+.	O
+
+The	O
+nucleotide	B-CHED
+sequence	O
+encoding	O
+the	O
+entire	O
+S	B-PRGE
+gene	I-PRGE
+open	O
+reading	O
+frame	O
+(	O
+ORF	O
+)	O
+of	O
+Chinju99	O
+was	O
+4	O
+,	O
+152	O
+bases	B-CHED
+long	O
+encoding	O
+1	O
+,	O
+383	O
+amino	B-CHED
+acids	I-CHED
+.	O
+
+TITLE	O
+:	O
+A	O
+retrospective	O
+study	O
+of	O
+78	O
+patients	O
+with	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+.	O
+
+A	O
+retrospective	O
+study	O
+was	O
+conducted	O
+on	O
+78	O
+cases	O
+of	O
+SARS	B-DISO
+referred	O
+to	O
+the	O
+Guangzhou	O
+Institute	O
+of	O
+Respiratory	B-DISO
+Diseases	I-DISO
+(	O
+GIRD	O
+)	O
+between	O
+December	O
+22	O
+,	O
+2002	O
+and	O
+near	O
+the	O
+end	O
+of	O
+March	O
+2003	O
+.	O
+
+3	O
+.	O
+1	O
+)%	O
+with	O
+supplementary	O
+oxygen	B-CHED
+.	O
+
+SARS	B-DISO
+is	O
+a	O
+disease	O
+with	O
+high	O
+infectivity	O
+and	O
+has	O
+its	O
+own	O
+clinical	O
+and	O
+radiological	O
+features	O
+.	O
+
+TITLE	O
+:	O
+Early	O
+X	O
+-	O
+ray	B-SPEC
+and	O
+CT	O
+appearances	O
+of	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+:	O
+an	O
+analysis	O
+of	O
+28	O
+cases	O
+.	O
+
+Chest	B-ANAT
+radiography	O
+and	O
+CT	O
+were	O
+performed	O
+in	O
+28	O
+patients	O
+with	O
+SARS	B-DISO
+within	O
+one	O
+to	O
+three	O
+days	O
+after	O
+onset	O
+of	O
+the	O
+disease	O
+.	O
+
+Abnormal	O
+CT	O
+findings	O
+were	O
+noted	O
+in	O
+all	O
+the	O
+patients	O
+,	O
+but	O
+abnormal	O
+chest	B-ANAT
+radiographic	O
+findings	O
+in	O
+17	O
+cases	O
+(	O
+60	O
+.	O
+7	O
+%,	O
+17	O
+/	O
+28	O
+).	O
+
+The	O
+numbers	O
+of	O
+CD	O
+(	O
+3	O
+)(+),	O
+CD	O
+(	O
+4	O
+)(+),	O
+and	O
+CD	O
+(	O
+8	O
+)(+)	O
+lymphocytes	B-ANAT
+all	O
+significantly	O
+decreased	O
+in	O
+acute	O
+phase	O
+of	O
+patients	O
+with	O
+SARS	B-DISO
+[(	O
+722	O
++/-	O
+533	O
+)/	O
+microliter	O
+,	O
+(	O
+438	O
++/-	O
+353	O
+)/	O
+microliter	O
+,	O
+(	O
+307	O
++/-	O
+
+The	O
+aim	O
+of	O
+our	O
+study	O
+was	O
+to	O
+evaluate	O
+the	O
+therapeutic	O
+efficacy	O
+of	O
+red	B-ANAT
+cell	I-ANAT
+-	O
+exchange	O
+during	O
+ACS	B-FUNC
+.	O
+
+During	O
+follow	O
+up	O
+(	O
+14	O
+-	O
+32	O
+months	O
+),	O
+none	O
+of	O
+the	O
+6	O
+patients	O
+developed	O
+viral	O
+complications	O
+related	O
+to	O
+transfusion	O
+therapy	O
+,	O
+alloimmunization	O
+or	O
+recurrence	B-DISO
+of	O
+ACS	B-FUNC
+.	O
+
+Occupational	O
+health	O
+nurses	O
+must	O
+educate	O
+themselves	O
+and	O
+their	O
+employees	O
+about	O
+SARS	B-DISO
+to	O
+allow	O
+for	O
+accurate	O
+and	O
+timely	O
+sharing	O
+of	O
+information	O
+.	O
+
+SARS	B-DISO
+is	O
+a	O
+recently	O
+recognized	O
+infectious	B-DISO
+disease	I-DISO
+that	O
+may	O
+lead	O
+to	O
+death	B-PROC
+and	O
+severe	O
+pulmonary	B-ANAT
+sequelae	O
+.	O
+
+TITLE	O
+:	O
+Use	O
+of	O
+quarantine	O
+to	O
+prevent	O
+transmission	O
+of	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+--	O
+Taiwan	O
+,	O
+2003	O
+.	O
+
+ABSTRACT	O
+:	O
+On	O
+July	O
+5	O
+,	O
+2003	O
+,	O
+Taiwan	O
+was	O
+removed	O
+from	O
+the	O
+World	O
+Health	O
+Organization	O
+(	O
+WHO	O
+)	O
+list	O
+of	O
+severe	O
+acute	O
+respiratory	O
+syndrome	O
+(	O
+SARS	B-DISO
+)-	O
+affected	O
+countries	O
+.	O
+
+Initial	O
+efforts	O
+to	O
+control	O
+SARS	B-DISO
+appeared	O
+to	O
+be	O
+effective	O
+;	O
+these	O
+efforts	O
+included	O
+isolation	O
+of	O
+suspect	O
+and	O
+probable	O
+SARS	B-DISO
+patients	O
+,	O
+use	O
+of	O
+personal	O
+protective	O
+equipment	O
+(	O
+PPE	B-CHED
+)	O
+for	O
+health	O
+-	O
+care	O
+workers	O
+(	O
+HCWs	O
+)	O
+and	O
+visitors	O
+,	O
+and	O
+quarantine	O
+of	O
+contacts	O
+of	O
+known	O
+SARS	B-DISO
+patients	O
+.	O
+
+Chinese	O
+term	O
+of	O
+SARS	B-DISO
+has	O
+been	O
+recommended	O
+in	O
+the	O
+paper	O
+.	O
+
+All	O
+patients	O
+were	O
+operated	O
+on	O
+under	O
+cardiopulmonary	B-ANAT
+bypass	O
+with	O
+implantation	B-PROC
+of	O
+25	O
+-	O
+29	O
+mm	O
+size	O
+home	O
+-	O
+made	O
+tilting	O
+disc	B-COMP
+valve	B-ANAT
+prosthesis	O
+.	O
+
+There	O
+were	O
+16	O
+late	O
+deaths	B-PROC
+due	O
+to	O
+heart	B-DISO
+failure	I-DISO
+,	O
+anticoagulation	B-PROC
+related	O
+bleeding	B-DISO
+,	O
+thromboembolism	B-DISO
+and	O
+recurrence	B-DISO
+of	O
+rheumatic	B-DISO
+fever	I-DISO
+.	O
+
+Among	O
+the	O
+patients	O
+who	O
+survived	O
+over	O
+20	O
+years	O
+,	O
+37	O
+patients	O
+had	O
+the	O
+cardiac	B-ANAT
+functional	O
+status	O
+returned	O
+to	O
+Class	B-SPEC
+II	O
+,	O
+13	O
+Class	B-SPEC
+III	O
+,	O
+and	O
+Class	B-SPEC
+IV	O
+.	O
+
+TITLE	O
+:	O
+[	O
+Study	O
+on	O
+etiology	O
+and	O
+pathology	B-DISO
+of	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+].	O
+
+Thrombosis	B-DISO
+was	O
+seen	O
+in	O
+part	O
+of	O
+the	O
+small	O
+veins	B-ANAT
+.	O
+
+Extensive	O
+consolidation	O
+of	O
+lungs	B-ANAT
+,	O
+formation	B-PROC
+of	O
+hyaline	B-DISO
+membrane	B-COMP
+to	O
+a	O
+large	O
+extent	O
+,	O
+respiratory	B-DISO
+distress	I-DISO
+and	O
+decrease	O
+of	O
+immune	B-PROC
+function	I-PROC
+are	O
+the	O
+main	O
+causes	O
+of	O
+death	B-PROC
+.	O
+
+ABSTRACT	O
+:	O
+To	O
+study	O
+the	O
+pathological	O
+characteristics	O
+of	O
+severe	O
+acute	O
+respiratory	O
+syndrome	O
+(	O
+SARS	B-DISO
+)	O
+and	O
+its	O
+relationship	O
+to	O
+clinical	O
+manifestation	O
+.	O
+
+A	O
+mixture	B-CHED
+features	O
+of	O
+serous	O
+,	O
+fibrinous	O
+and	O
+hemorrhagic	B-DISO
+inflammation	I-DISO
+were	O
+seen	O
+in	O
+most	O
+pulmonary	B-ANAT
+alveoli	I-ANAT
+with	O
+engorgement	B-DISO
+of	O
+capillary	B-ANAT
+and	O
+there	O
+were	O
+microthrombosis	O
+in	O
+some	O
+capillary	B-ANAT
+.	O
+
+Fibrinoid	O
+materials	O
+and	O
+erythrocytes	B-ANAT
+could	O
+be	O
+found	O
+in	O
+alveolar	B-ANAT
+spaces	O
+.	O
+
+There	O
+were	O
+thrombo	O
+-	O
+embolisms	B-DISO
+in	O
+some	O
+bronchial	B-ANAT
+artery	I-ANAT
+.	O
+
+CONCLUSIONS	O
+:	O
+Severe	O
+damages	O
+of	O
+pulmonary	B-ANAT
+and	O
+immunological	O
+system	O
+damage	O
+are	O
+responsible	O
+for	O
+clinical	O
+features	O
+of	O
+SARS	B-DISO
+and	O
+may	O
+lead	O
+to	O
+death	B-PROC
+of	O
+patients	O
+.	O
+
+Meanwhile	O
+,	O
+in	O
+the	O
+immunohistochemical	O
+study	O
+,	O
+CD	O
+(	O
+20	O
+)(+)	O
+B	B-ANAT
+cells	I-ANAT
+were	O
+fully	O
+expressed	B-PROC
+in	O
+lymph	B-ANAT
+nodes	I-ANAT
+and	O
+spleen	B-ANAT
+,	O
+and	O
+the	O
+CD45RO	O
+(	O
+UCHL	B-PRGE
+-	I-PRGE
+1	I-PRGE
+)(+)	O
+T	B-ANAT
+cells	I-ANAT
+were	O
+scatteredly	O
+expressed	B-PROC
+.	O
+
+RESULTS	O
+:	O
+The	O
+principal	O
+lesions	O
+of	O
+the	O
+SARS	B-DISO
+case	O
+consisted	O
+of	O
+acute	O
+lobular	O
+intrastitial	O
+pneumonia	B-DISO
+,	O
+hyaloid	O
+membranes	B-ANAT
+of	O
+pulmonic	O
+alveoli	B-ANAT
+and	O
+hyperplasia	B-DISO
+and	O
+shedding	O
+of	O
+alveolar	B-ANAT
+epithelium	I-ANAT
+of	O
+.	O
+
+Infectious	B-DISO
+virons	O
+entered	O
+cells	B-COMP
+by	O
+endocytosis	B-PATH
+or	O
+membrane	B-PROC
+fusion	I-PROC
+and	O
+released	O
+through	O
+a	O
+budding	B-PATH
+process	O
+.	O
+
+RESULTS	O
+:	O
+Virus	B-DISO
+infection	I-DISO
+in	O
+BALB	O
+/	O
+c	O
+mice	B-SPEC
+was	O
+associated	O
+with	O
+an	O
+increase	O
+in	O
+the	O
+incidence	O
+and	O
+levels	O
+of	O
+systemic	B-PRGE
+IFN	I-PRGE
+-	I-PRGE
+gamma	I-PRGE
+.	O
+
+TITLE	O
+:	O
+The	O
+coronavirus	B-SPEC
+spike	O
+protein	B-CHED
+is	O
+a	O
+class	B-PRGE
+I	I-PRGE
+virus	B-SPEC
+fusion	I-PRGE
+protein	B-CHED
+:	O
+structural	O
+and	O
+functional	O
+characterization	O
+of	O
+the	O
+fusion	O
+core	O
+complex	O
+.	O
+
+The	O
+180	B-PRGE
+-	I-PRGE
+kDa	I-PRGE
+oligomeric	I-PRGE
+S	I-PRGE
+protein	I-PRGE
+of	O
+the	O
+murine	B-SPEC
+coronavirus	I-SPEC
+mouse	B-DISO
+hepatitis	I-DISO
+virus	B-SPEC
+strain	O
+A59	O
+is	O
+posttranslationally	O
+cleaved	B-ANAT
+into	O
+an	O
+S1	B-PRGE
+receptor	I-PRGE
+binding	O
+unit	O
+and	O
+an	O
+S2	O
+membrane	B-PROC
+fusion	I-PROC
+unit	O
+.	O
+
+ABSTRACT	O
+:	O
+Severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+(	O
+SARS	B-DISO
+)	O
+was	O
+diagnosed	O
+in	O
+Hong	O
+Kong	O
+in	O
+over	O
+1700	O
+patients	O
+between	O
+March	O
+and	O
+early	O
+June	O
+2003	O
+.	O
+
+Transcription	B-PROC
+of	O
+the	O
+S1	B-PRGE
+gene	I-PRGE
+was	O
+confirmed	O
+in	O
+lung	B-ANAT
+tissue	I-ANAT
+after	O
+in	O
+ovo	B-SPEC
+vaccination	O
+by	O
+an	O
+antisense	O
+riboprobe	O
+,	O
+and	O
+the	O
+S1	B-PRGE
+protein	I-PRGE
+was	O
+detected	O
+by	O
+immunohistology	O
+in	O
+the	O
+heart	B-ANAT
+and	O
+bursa	B-SPEC
+.	O
+
+Experiments	O
+were	O
+conducted	O
+to	O
+determine	O
+1	O
+)	O
+effect	O
+of	O
+EPEC	O
+dose	O
+,	O
+with	O
+and	O
+without	O
+concurrent	O
+TCV	B-SPEC
+infection	B-DISO
+,	O
+and	O
+2	O
+)	O
+effect	O
+of	O
+TCV	B-SPEC
+exposure	O
+,	O
+before	O
+and	O
+after	O
+EPEC	O
+exposure	O
+,	O
+on	O
+development	B-PROC
+of	O
+clinical	O
+disease	O
+.	O
+
+Organ	B-ANAT
+samples	O
+of	O
+7	O
+dead	B-PROC
+cases	O
+of	O
+SARS	B-DISO
+were	O
+collected	O
+from	O
+Guangdong	O
+,	O
+Shanxi	O
+,	O
+Sichuan	O
+Provinces	O
+and	O
+Beijing	O
+for	O
+electron	O
+microscopic	O
+examination	O
+.	O
+
+Since	O
+the	O
+novel	O
+Chlamydia	B-SPEC
+-	O
+like	O
+agent	O
+was	O
+found	O
+co	O
+-	O
+existing	O
+with	O
+a	O
+coronavirus	B-SPEC
+-	O
+like	O
+agent	O
+in	O
+the	O
+dead	B-PROC
+cases	O
+of	O
+SARS	B-DISO
+,	O
+it	O
+looks	O
+most	O
+likely	O
+that	O
+both	O
+the	O
+agents	O
+play	O
+some	O
+roles	O
+in	O
+the	O
+disease	O
+.	O
+
+TITLE	O
+:	O
+[	O
+The	O
+study	O
+of	O
+cis	B-DISO
+-	O
+element	O
+HNF4	B-PRGE
+in	O
+the	O
+regulation	B-PROC
+of	O
+mfg12	O
+prothrombinase	B-PRGE
+/	O
+fibroleukin	B-PRGE
+gene	B-PROC
+expression	I-PROC
+in	O
+response	O
+to	O
+nucleocapsid	B-COMP
+protein	B-CHED
+of	O
+MHV	B-SPEC
+-	O
+3	O
+].	O
+
+Confocus	O
+microscope	O
+immunofluorescence	O
+was	O
+performed	O
+to	O
+show	O
+whether	O
+N	B-PRGE
+protein	I-PRGE
+of	O
+MHV	B-SPEC
+enters	O
+into	O
+the	O
+nucleus	B-COMP
+of	O
+infected	O
+cells	B-COMP
+,	O
+which	O
+is	O
+a	O
+critical	O
+step	O
+for	O
+the	O
+N	B-PRGE
+protein	I-PRGE
+to	O
+facilitate	O
+its	O
+transactivation	B-PROC
+property	O
+.	O
+
+Western	O
+blotting	O
+displayed	O
+that	O
+HNF4	B-PRGE
+was	O
+constitutively	O
+expressed	B-PROC
+in	O
+macrophages	B-ANAT
+and	O
+did	O
+not	O
+show	O
+significant	O
+change	O
+under	O
+the	O
+stimulation	O
+of	O
+different	O
+MHV	B-SPEC
+.	O
+
+Safety	O
+issues	O
+involving	O
+breathing	B-PROC
+-	O
+circuit	O
+filters	O
+.	O
+
+ECRI	O
+recommends	O
+that	O
+breathing	B-PROC
+-	O
+circuit	O
+filters	O
+be	O
+incorporated	O
+in	O
+the	O
+exhalation	B-PROC
+limb	B-ANAT
+of	O
+any	O
+ventilator	O
+used	O
+on	O
+a	O
+patient	O
+with	O
+SARS	B-DISO
+.	O
+
+In	O
+this	O
+article	O
+,	O
+we	O
+review	O
+the	O
+issues	O
+behind	O
+our	O
+recommendations	O
+and	O
+describe	O
+steps	O
+hospitals	O
+can	O
+take	O
+to	O
+prevent	O
+any	O
+adverse	B-DISO
+effects	I-DISO
+on	O
+ventilation	O
+.	O
+
+ABSTRACT	O
+:	O
+The	O
+CDC	O
+and	O
+the	O
+World	O
+Health	O
+Organization	O
+have	O
+characterized	O
+a	O
+highly	O
+contagious	O
+syndrome	O
+that	O
+has	O
+resulted	O
+in	O
+numerous	O
+deaths	B-PROC
+worldwide	O
+.	O
+
+METHODS	O
+:	O
+Patients	O
+with	O
+the	O
+diagnosis	O
+of	O
+probable	O
+or	O
+suspected	O
+SARS	B-DISO
+admitted	O
+to	O
+the	O
+Taipei	O
+Veterans	O
+General	O
+Hospital	O
+during	O
+the	O
+period	O
+from	O
+March	O
+26	O
+,	O
+2003	O
+to	O
+May	O
+25	O
+,	O
+2003	O
+were	O
+included	O
+.	O
+
+ABSTRACT	O
+:	O
+Outbreak	O
+of	O
+severe	O
+acute	O
+respiratory	O
+syndrome	O
+(	O
+SARS	B-DISO
+)	O
+in	O
+Taipei	O
+has	O
+been	O
+associated	O
+with	O
+Taiwanese	O
+back	B-ANAT
+from	O
+Guangdong	O
+,	O
+China	O
+.	O
+
+All	O
+patients	O
+received	O
+standard	O
+treatment	O
+:	O
+ribavirin	B-CHED
+1000	O
+mg	O
+orally	B-ANAT
+daily	O
+for	O
+10	O
+days	O
+,	O
+Levofloxacin	B-CHED
+500	O
+mg	O
+orally	B-ANAT
+daily	O
+for	O
+7	O
+days	O
+,	O
+and	O
+intravenous	B-PRGE
+immunoglobulin	I-PRGE
+(	O
+IVIG	O
+)	O
+1	O
+g	O
+/	O
+kg	O
+/	O
+day	O
+for	O
+2	O
+day	O
+after	O
+the	O
+onset	O
+of	O
+symptoms	O
+.	O
+
+Initial	O
+presentation	O
+of	O
+radiographic	O
+patterns	O
+includes	O
+normal	O
+,	O
+interstitial	B-ANAT
+or	O
+airspace	O
+shadowing	O
+.	O
+
+Fever	B-PROC
+and	O
+lymphopenia	B-DISO
+are	O
+occasionally	O
+followed	O
+by	O
+rapidly	O
+progressive	O
+respiratory	O
+compromise	O
+.	O
+
+Patient	O
+3	O
+was	O
+a	O
+19	O
+-	O
+yr	O
+-	O
+old	O
+male	O
+with	O
+pretransplant	O
+Hct	O
+of	O
+43	O
+%	O
+who	O
+received	O
+a	O
+cadaveric	O
+renal	O
+transplant	B-ANAT
+after	O
+23	O
+.	O
+5	O
+-	O
+h	O
+cold	B-DISO
+-	O
+ischemia	B-DISO
+;	O
+3	O
+.	O
+5	O
+L	O
+normal	O
+saline	O
+was	O
+given	O
+during	O
+surgery	O
+.	O
+
+The	O
+patient	O
+died	B-PROC
+following	O
+a	O
+sudden	O
+cardiopulmonary	B-DISO
+arrest	I-DISO
+on	O
+POD	O
+no	O
+.	O
+3	O
+.	O
+
+Potential	O
+mechanisms	O
+for	O
+the	O
+development	B-PROC
+of	O
+PE	O
+include	O
+cytokine	O
+release	B-PATH
+from	O
+basiliximab	O
+with	O
+increased	B-PROC
+capillary	I-PROC
+permeability	I-PROC
+,	O
+volume	B-DISO
+overload	I-DISO
+and	O
+ischemic	O
+-	O
+reperfusion	O
+injury	O
+.	O
+
+Improved	O
+awareness	O
+of	O
+this	O
+potential	O
+complication	B-DISO
+,	O
+prudent	O
+fluid	O
+management	O
+,	O
+and	O
+efforts	O
+to	O
+minimize	O
+graft	B-ANAT
+-	O
+ischemia	B-DISO
+are	O
+recommended	O
+to	O
+prevent	O
+further	O
+cases	O
+.	O
+
+TITLE	O
+:	O
+Description	O
+and	O
+evaluation	O
+of	O
+a	O
+delivery	O
+system	O
+for	O
+aerosolized	O
+prostacyclin	B-CHED
+.	O
+
+The	O
+effectiveness	O
+of	O
+the	O
+delivery	O
+system	O
+was	O
+retrospectively	O
+evaluated	O
+by	O
+way	O
+of	O
+the	O
+responses	O
+of	O
+11	O
+severely	O
+hypoxemic	O
+acute	O
+respiratory	O
+distress	O
+syndrome	O
+patients	O
+who	O
+received	O
+PGI	B-CHED
+(	O
+2	O
+)	O
+via	O
+the	O
+system	O
+we	O
+describe	O
+.	O
+
+Aerosolized	O
+PGI	B-CHED
+(	O
+2	O
+)	O
+therapy	O
+(	O
+mean	O
+dose	O
+28	O
++/-	O
+
+17	O
+mm	O
+Hg	O
+,	O
+p	O
+=	O
+0	O
+.	O
+003	O
+)	O
+and	O
+arterial	B-PROC
+oxygen	B-CHED
+saturation	I-PROC
+measured	O
+via	O
+pulse	B-PROC
+oximetry	O
+(	O
+86	O
++/-	O
+
+There	O
+were	O
+91	O
+patients	O
+with	O
+common	O
+SARS	B-DISO
+,	O
+and	O
+23	O
+patients	O
+with	O
+severe	O
+SARS	B-DISO
+,	O
+and	O
+61	O
+common	O
+pneumonia	B-DISO
+patients	O
+served	O
+as	O
+the	O
+controls	O
+.	O
+
+The	O
+damage	O
+possibility	O
+of	O
+liver	B-PROC
+function	I-PROC
+in	O
+SARS	B-DISO
+patients	O
+is	O
+higher	O
+than	O
+that	O
+in	O
+common	O
+pneumonia	B-DISO
+patients	O
+.	O
+
+Large	O
+patch	O
+of	O
+infiltration	B-DISO
+,	O
+large	O
+area	O
+of	O
+consolidation	O
+,	O
+ground	O
+-	O
+glass	O
+shadow	O
+,	O
+diffuse	O
+lung	B-ANAT
+lesion	O
+and	O
+involvement	O
+of	O
+both	O
+lungs	B-ANAT
+were	O
+the	O
+main	O
+X	O
+-	O
+ray	B-SPEC
+image	O
+characteristics	O
+of	O
+patients	O
+with	O
+severe	O
+SARS	B-DISO
+.	O
+
+The	O
+typical	O
+pathological	O
+changes	O
+of	O
+lungs	B-ANAT
+were	O
+diffuse	O
+hemorrhaging	O
+on	O
+the	O
+surface	O
+.	O
+
+RESULTS	O
+:	O
+The	O
+typical	O
+pathological	O
+changes	O
+of	O
+lungs	B-ANAT
+were	O
+diffuse	O
+hemorrhaging	O
+on	O
+the	O
+surface	O
+.	O
+
+The	O
+level	O
+of	O
+serum	B-PRGE
+IL	I-PRGE
+was	O
+increased	O
+to	O
+a	O
+great	O
+extent	O
+in	O
+the	O
+35	O
+SARS	B-DISO
+patients	O
+,	O
+and	O
+the	O
+levels	O
+of	O
+serum	B-PRGE
+IL	B-FUNC
+-	I-FUNC
+2	I-FUNC
+,	O
+IL	B-FUNC
+-	I-FUNC
+10	I-FUNC
+and	O
+IL	B-FUNC
+-	I-FUNC
+12	I-FUNC
+were	O
+242	O
+.	O
+53	O
+(	O
+92	O
+.	O
+69	O
+)	O
+pg	O
+/	O
+ml	O
+,	O
+77	O
+.	O
+43	O
+(	O
+63	O
+.	O
+37	O
+)	O
+pg	O
+/	O
+ml	O
+and	O
+65	O
+.	O
+94	O
+(	O
+43	O
+.	O
+21	O
+)	O
+pg	O
+/	O
+ml	O
+,	O
+respectively	O
+.	O
+
+The	O
+peripheral	B-ANAT
+blood	I-ANAT
+CD	O
+(	O
+3	O
+)(+),	O
+CD	O
+(	O
+4	O
+)(+)	O
+and	O
+CD	O
+(	O
+8	O
+)(+)	O
+counts	O
+were	O
+lower	O
+than	O
+normal	O
+in	O
+23	O
+patients	O
+(	O
+67	O
+.	O
+7	O
+%),	O
+26	O
+patients	O
+(	O
+74	O
+.	O
+3	O
+%)	O
+and	O
+15	O
+patients	O
+(	O
+42	O
+.	O
+9	O
+%),	O
+respectively	O
+.	O
+
+The	O
+peripheral	B-ANAT
+blood	I-ANAT
+WBC	B-ANAT
+counts	O
+were	O
+(	O
+4	O
+.	O
+0	O
+-	O
+10	O
+.	O
+0	O
+)	O
+x	O
+10	O
+(	O
+9	O
+)/	O
+L	O
+in	O
+20	O
+patients	O
+,	O
+and	O
+their	O
+CD	O
+(	O
+3	O
+)(+),	O
+CD	O
+(	O
+4	O
+)(+)	O
+and	O
+CD	O
+(	O
+8	O
+)(+)	O
+counts	O
+were	O
+700	O
+.	O
+00	O
+(	O
+502	O
+.	O
+96	O
+)	O
+x	O
+10	O
+(	O
+6	O
+)/	O
+L	O
+,	O
+347	O
+.	O
+00	O
+(	O
+247	O
+.	O
+58	O
+)	O
+x	O
+10	O
+(	O
+6	O
+)/	O
+L	O
+and	O
+322	O
+.	O
+05	O
+(	O
+228	O
+.	O
+47	O
+)	O
+x	O
+10	O
+(	O
+6	O
+)/	O
+L	O
+,	O
+respectively	O
+.	O
+
+The	O
+level	O
+of	O
+serum	B-PRGE
+IL	I-PRGE
+is	O
+closely	O
+related	O
+to	O
+cell	B-COMP
+immunity	B-PROC
+in	O
+SARS	B-DISO
+patients	O
+.	O
+
+RESULTS	O
+:	O
+The	O
+level	O
+of	O
+serum	B-PRGE
+IL	I-PRGE
+was	O
+increased	O
+to	O
+a	O
+great	O
+extent	O
+in	O
+the	O
+35	O
+SARS	B-DISO
+patients	O
+,	O
+and	O
+the	O
+levels	O
+of	O
+serum	B-PRGE
+IL	B-FUNC
+-	I-FUNC
+2	I-FUNC
+,	O
+IL	B-FUNC
+-	I-FUNC
+10	I-FUNC
+and	O
+IL	B-FUNC
+-	I-FUNC
+12	I-FUNC
+were	O
+242	O
+.	O
+53	O
+(	O
+92	O
+.	O
+69	O
+)	O
+pg	O
+/	O
+ml	O
+,	O
+77	O
+.	O
+43	O
+(	O
+63	O
+.	O
+37	O
+)	O
+pg	O
+/	O
+ml	O
+and	O
+65	O
+.	O
+94	O
+(	O
+43	O
+.	O
+21	O
+)	O
+pg	O
+/	O
+ml	O
+,	O
+respectively	O
+.	O
+
+ABSTRACT	O
+:	O
+To	O
+establish	O
+a	O
+fluorescent	O
+polymerase	O
+chain	O
+reaction	O
+(	O
+F	O
+-	O
+PCR	O
+)	O
+method	O
+for	O
+detecting	O
+the	O
+coronavirus	B-SPEC
+related	O
+to	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+(	O
+SARS	B-DISO
+)	O
+and	O
+to	O
+evaluate	O
+its	O
+value	O
+for	O
+clinical	O
+application	O
+.	O
+
+The	O
+primers	O
+and	O
+the	O
+fluorescence	O
+-	O
+labeled	O
+probe	O
+were	O
+designed	O
+and	O
+synthesized	O
+according	O
+to	O
+the	O
+published	O
+sequence	O
+of	O
+the	O
+SARS	B-DISO
+-	I-DISO
+associated	I-DISO
+coronavirus	I-DISO
+genes	O
+.	O
+
+Forty	O
+-	O
+nine	O
+out	O
+of	O
+67	O
+samples	O
+from	O
+identified	O
+SARS	B-DISO
+patients	O
+and	O
+8	O
+of	O
+18	O
+samples	O
+from	O
+persons	O
+having	O
+close	O
+contact	O
+with	O
+SARS	B-DISO
+patients	O
+showed	O
+positive	O
+results	O
+.	O
+
+Also	O
+,	O
+a	O
+clear	O
+definition	O
+of	O
+the	O
+binding	B-FUNC
+pocket	O
+for	O
+KZ7088	O
+has	O
+been	O
+presented	O
+.	O
+
+Published	O
+experience	O
+in	O
+adults	O
+suggests	O
+that	O
+extracorporeal	O
+membrane	B-COMP
+oxygenation	B-PROC
+(	O
+ECMO	O
+)	O
+can	O
+successfully	O
+support	O
+trauma	O
+victims	O
+with	O
+pulmonary	B-DISO
+failure	I-DISO
+.	O
+
+Hemorrhage	B-DISO
+occurs	O
+frequently	O
+but	O
+is	O
+manageable	O
+.	O
+
+SARS	B-DISO
+-	I-DISO
+CoV	I-DISO
+infection	I-DISO
+was	O
+diagnosed	O
+in	O
+329	O
+(	O
+75	O
+%)	O
+of	O
+436	O
+patients	O
+fitting	B-DISO
+the	O
+case	O
+definition	O
+of	O
+SARS	B-DISO
+;	O
+human	B-SPEC
+metapneumovirus	I-SPEC
+was	O
+diagnosed	O
+in	O
+41	O
+(	O
+12	O
+%)	O
+of	O
+335	O
+,	O
+and	O
+other	O
+respiratory	O
+pathogens	O
+were	O
+diagnosed	O
+only	O
+sporadically	O
+.	O
+
+SARS	B-DISO
+-	O
+CoV	O
+was	O
+detected	O
+in	O
+pneumonic	O
+areas	O
+by	O
+virus	B-SPEC
+isolation	O
+and	O
+RT	O
+-	O
+PCR	O
+,	O
+and	O
+was	O
+localised	O
+to	O
+alveolar	B-ANAT
+epithelial	B-ANAT
+cells	I-ANAT
+and	O
+syncytia	B-ANAT
+by	O
+immunohistochemistry	O
+and	O
+transmission	O
+electron	O
+microscopy	O
+.	O
+
+The	O
+patient	O
+undergone	O
+to	O
+lumbar	B-ANAT
+puncture	O
+,	O
+spinal	O
+MRI	O
+and	O
+SEPs	O
+which	O
+were	O
+all	O
+normal	O
+.	O
+
+Therefore	O
+,	O
+it	O
+is	O
+most	O
+likely	O
+that	O
+SARS	B-DISO
+virus	B-SPEC
+is	O
+a	O
+zoonotic	O
+agent	O
+.	O
+
+TITLE	O
+:	O
+[	O
+Analysis	O
+of	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+in	O
+Beijing	O
+].	O
+
+Other	O
+common	O
+findings	O
+included	O
+elevated	O
+levels	O
+of	O
+serum	B-PRGE
+alanine	B-ENZY
+aminotransferase	I-ENZY
+,	O
+lactate	B-PRGE
+dehydrogenase	I-PRGE
+and	O
+erythrocyte	B-ANAT
+sedimentation	O
+(	O
+76	O
+.	O
+2	O
+%,	O
+28	O
+.	O
+6	O
+%	O
+and	O
+47	O
+.	O
+8	O
+%,	O
+respectively	O
+),	O
+and	O
+decreased	O
+levels	O
+of	O
+serum	B-COMP
+iron	O
+and	O
+albumin	B-PRGE
+(	O
+63	O
+.	O
+2	O
+%	O
+and	O
+47	O
+.	O
+8	O
+%,	O
+respectively	O
+).	O
+
+In	O
+a	O
+multivariate	O
+analysis	O
+(	O
+Stata	B-PRGE
+7	I-PRGE
+.	I-PRGE
+0	I-PRGE
+),	O
+the	O
+independent	O
+predictor	O
+of	O
+an	O
+adverse	O
+outcome	O
+was	O
+advanced	O
+age	O
+(	O
+odds	O
+ratio	O
+per	O
+decade	O
+of	O
+life	O
+,	O
+1	O
+.	O
+6	O
+;	O
+95	O
+%	O
+CI	O
+,	O
+1	O
+.	O
+08	O
+to	O
+2	O
+.	O
+63	O
+;	O
+P	O
+=	O
+0	O
+.	O
+007	O
+).	O
+
+Fever	B-PROC
+,	O
+lymphopenia	B-DISO
+,	O
+low	O
+serum	B-COMP
+iron	O
+and	O
+chest	B-ANAT
+radiograph	O
+are	O
+helpful	O
+to	O
+diagnose	O
+SARS	B-DISO
+early	O
+;	O
+age	O
+is	O
+the	O
+independent	O
+predictor	O
+of	O
+an	O
+outcome	O
+.	O
+
+TITLE	O
+:	O
+[	O
+Glucocorticoid	B-CHED
+in	O
+the	O
+treatment	O
+of	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+patients	O
+:	O
+a	O
+preliminary	O
+report	O
+].	O
+
+383	O
+)	O
+cells	B-COMP
+/	O
+microl	O
+.	O
+
+Thus	O
+the	O
+disease	O
+is	O
+aggravated	O
+and	O
+patients	O
+are	O
+likely	O
+to	O
+suffer	B-DISO
+from	O
+severe	O
+secondary	B-DISO
+infection	I-DISO
+.	O
+
+The	O
+spike	O
+protein	B-CHED
+is	O
+the	O
+main	O
+surface	O
+antigen	B-CHED
+of	O
+the	O
+coronavirus	B-SPEC
+and	O
+there	O
+should	O
+be	O
+antibodies	B-COMP
+against	O
+spike	O
+protein	B-CHED
+in	O
+patients	O
+serum	B-COMP
+.	O
+
+Other	O
+46	O
+cases	O
+were	O
+accompanied	O
+by	O
+diarrhea	B-DISO
+.	O
+
+Continual	O
+positive	O
+airway	B-ANAT
+pressure	O
+(	O
+CPAP	O
+)	O
+and	O
+glucocorticoid	O
+was	O
+required	O
+that	O
+can	O
+control	O
+deprivation	O
+of	O
+the	O
+disease	O
+when	O
+toxicosis	B-DISO
+symptom	B-DISO
+of	O
+patients	O
+was	O
+severity	O
+and	O
+shadow	O
+of	O
+lungs	B-ANAT
+diffuse	O
+more	O
+and	O
+more	O
+.	O
+
+Management	O
+with	O
+corticosteroids	B-CHED
+effectively	O
+ameliorated	O
+and	O
+suppressed	O
+the	O
+development	B-PROC
+of	O
+pulmonary	B-DISO
+fibrosis	I-DISO
+.	O
+
+Specific	O
+antibodies	B-COMP
+of	O
+IgM	B-PRGE
+and	O
+IgG	B-PRGE
+against	O
+SARS	B-DISO
+virus	B-SPEC
+in	O
+267	O
+serum	B-COMP
+specimens	O
+from	O
+patients	O
+with	O
+SARS	B-DISO
+and	O
+132	O
+from	O
+non	O
+-	O
+SARS	B-DISO
+patients	O
+or	O
+healthy	O
+persons	O
+were	O
+assayed	O
+with	O
+IFA	O
+or	O
+ELISA	O
+.	O
+
+CONCLUSIONS	O
+:	O
+The	O
+patients	O
+with	O
+SARS	B-DISO
+were	O
+found	O
+having	O
+damage	O
+of	O
+cellular	B-PROC
+immunity	I-PROC
+markedly	O
+.	O
+
+The	O
+opacity	B-DISO
+disappeared	O
+gradually	O
+in	O
+5	O
+weeks	O
+in	O
+84	O
+%	O
+of	O
+the	O
+patients	O
+.	O
+
+Lungs	B-ANAT
+complicated	B-DISO
+infection	I-DISO
+were	O
+found	O
+in	O
+6	O
+patients	O
+with	O
+a	O
+prolonged	O
+duration	O
+of	O
+the	O
+illness	O
+.	O
+
+The	O
+levels	O
+of	O
+CD3	B-PRGE
+(+),	I-PRGE
+CD4	B-PRGE
+(+)	O
+and	O
+CD8	B-PRGE
+(+)	O
+T	B-ANAT
+-	I-ANAT
+lymphocyte	I-ANAT
+subsets	I-ANAT
+in	O
+peripheral	B-ANAT
+blood	I-ANAT
+of	O
+SARS	B-DISO
+patients	O
+decrease	O
+significantly	O
+and	O
+go	O
+down	O
+to	O
+the	O
+lowest	O
+point	O
+at	O
+days	O
+10	O
+approximately	O
+12	O
+after	O
+onset	O
+of	O
+the	O
+disease	O
+.	O
+
+RESULTS	O
+:	O
+The	O
+levels	O
+of	O
+CD3	B-PRGE
+(+),	I-PRGE
+CD4	B-PRGE
+(+)	O
+and	O
+CD8	B-PRGE
+(+)	O
+T	B-ANAT
+-	I-ANAT
+lymphocytes	I-ANAT
+in	O
+SARS	B-DISO
+group	O
+[(	O
+589	O
++/-	O
+435	O
+)	O
+x	O
+10	O
+(	O
+6	O
+)/	O
+L	O
+,	O
+(	O
+316	O
++/-	O
+267	O
+)	O
+x	O
+10	O
+(	O
+6	O
+)/	O
+L	O
+and	O
+(	O
+215	O
++/-	O
+165	O
+)	O
+x	O
+10	O
+(	O
+6	O
+)/	O
+L	O
+,	O
+respectively	O
+]	O
+were	O
+significantly	O
+lower	O
+than	O
+those	O
+of	O
+the	O
+normal	O
+group	O
+(	O
+P	O
+<	O
+0	O
+.	O
+01	O
+).	O
+
+Both	O
+serum	B-COMP
+IgG	B-PRGE
+and	O
+IgE	B-DISO
+in	O
+SARS	B-DISO
+group	O
+[(	O
+15	O
+.	O
+1	O
++/-	O
+8	O
+.	O
+5	O
+)	O
+g	O
+/	O
+L	O
+and	O
+(	O
+0	O
+.	O
+6	O
++/-	O
+0	O
+.	O
+9	O
+)	O
+g	O
+/	O
+L	O
+,	O
+respectively	O
+]	O
+were	O
+higher	O
+than	O
+those	O
+of	O
+the	O
+normal	O
+group	O
+.	O
+
+Twenty	O
+-	O
+nine	O
+patients	O
+(	O
+11	O
+men	O
+and	O
+18	O
+women	O
+,	O
+20	O
+-	O
+74	O
+years	O
+old	O
+age	O
+range	O
+)	O
+were	O
+diagnosed	O
+with	O
+infectious	B-DISO
+SARS	B-DISO
+and	O
+admitted	O
+in	O
+our	O
+hospital	O
+from	O
+the	O
+March	O
+5th	O
+to	O
+April	O
+14th	O
+,	O
+2003	O
+in	O
+this	O
+study	O
+.	O
+
+Early	O
+diagnosis	O
+,	O
+early	O
+isolation	O
+,	O
+early	O
+antiviral	B-CHED
+therapy	O
+for	O
+patients	O
+and	O
+efficient	O
+prevention	O
+for	O
+health	O
+care	O
+providers	O
+are	O
+urgently	O
+recommended	O
+.	O
+
+High	O
+solution	O
+CT	O
+showed	O
+solitary	O
+or	O
+multiple	O
+cotton	B-SPEC
+wadding	O
+like	O
+images	O
+and	O
+ground	O
+glass	O
+-	O
+like	O
+or	O
+consolidation	O
+images	O
+.	O
+
+CONCLUSIONS	O
+:	O
+SARS	B-DISO
+mainly	O
+affects	O
+youth	O
+and	O
+people	O
+in	O
+their	O
+prime	O
+of	O
+life	O
+.	O
+
+Based	O
+on	O
+the	O
+results	O
+of	O
+epidemiological	O
+investigation	O
+,	O
+the	O
+incubation	O
+period	O
+of	O
+SARS	B-DISO
+typically	O
+ranges	O
+from	O
+2	O
+-	O
+7	O
+days	O
+,	O
+but	O
+can	O
+be	O
+over	O
+10	O
+day	O
+.	O
+
+Outbreak	O
+control	O
+measures	O
+include	O
+:	O
+firstly	O
+,	O
+controlling	O
+the	O
+source	O
+of	O
+infection	B-DISO
+through	O
+early	O
+detection	O
+,	O
+early	O
+diagnosis	O
+,	O
+early	O
+reporting	O
+,	O
+early	O
+isolation	O
+and	O
+early	O
+treatment	O
+:	O
+secondly	O
+,	O
+break	O
+the	O
+chain	O
+of	O
+transmission	O
+:	O
+thirdly	O
+,	O
+protecting	O
+the	O
+vulnerable	O
+;	O
+and	O
+fourthly	O
+,	O
+dissemination	O
+of	O
+information	O
+.	O
+
+Among	O
+the	O
+275	O
+contacts	O
+of	O
+the	O
+index	O
+case	O
+,	O
+41	O
+fell	O
+ill	B-DISO
+of	O
+SARS	B-DISO
+with	O
+an	O
+attack	O
+rate	O
+of	O
+14	O
+.	O
+9	O
+%	O
+and	O
+5	O
+deaths	B-PROC
+with	O
+a	O
+fatality	O
+rate	O
+of	O
+12	O
+.	O
+2	O
+%.	O
+
+The	O
+transmission	O
+chain	O
+of	O
+this	O
+outbreak	O
+could	O
+be	O
+clearly	O
+delineated	O
+,	O
+and	O
+all	O
+the	O
+41	O
+cases	O
+had	O
+close	O
+contacts	O
+with	O
+their	O
+infectors	O
+,	O
+SARS	B-DISO
+cases	O
+of	O
+the	O
+previous	O
+generation	O
+within	O
+the	O
+symptomatic	O
+period	O
+thereof	O
+.	O
+
+Seven	O
+cases	O
+are	O
+treated	O
+by	O
+steroid	B-CHED
+in	O
+the	O
+first	O
+3	O
+days	O
+when	O
+the	O
+chest	B-ANAT
+X	O
+-	O
+ray	B-SPEC
+is	O
+normal	O
+,	O
+but	O
+they	O
+become	O
+positive	O
+during	O
+6	O
+-	O
+8	O
+days	O
+of	O
+the	O
+course	O
+.	O
+
+During	O
+the	O
+fastigium	B-ANAT
+,	O
+the	O
+disease	O
+transform	O
+very	O
+quickly	O
+,	O
+we	O
+need	O
+pay	O
+more	O
+attention	O
+to	O
+the	O
+patient	O
+.	O
+
+The	O
+model	O
+is	O
+fitted	B-DISO
+to	O
+data	O
+from	O
+the	O
+Ontario	O
+(	O
+Toronto	O
+)	O
+in	O
+Canada	O
+,	O
+Hong	O
+Kong	O
+in	O
+China	O
+and	O
+Singapore	O
+outbreaks	O
+and	O
+predictions	O
+are	O
+made	O
+based	O
+on	O
+various	O
+assumptions	O
+and	O
+observations	O
+,	O
+including	O
+the	O
+current	O
+effect	O
+of	O
+isolating	O
+individuals	O
+diagnosed	O
+with	O
+SARS	B-DISO
+.	O
+
+Although	O
+it	O
+would	O
+not	O
+be	O
+surprising	O
+to	O
+see	O
+levels	O
+of	O
+SARS	B-DISO
+infection	B-DISO
+higher	O
+than	O
+10	O
+%	O
+in	O
+some	O
+regions	O
+of	O
+the	O
+world	O
+(	O
+if	O
+unchecked	O
+),	O
+lack	O
+of	O
+data	O
+and	O
+the	O
+observed	O
+heterogeneity	O
+and	O
+sensitivity	O
+of	O
+parameters	O
+prevent	O
+us	O
+from	O
+predicting	O
+the	O
+long	O
+-	O
+term	O
+impact	O
+of	O
+SARS	B-DISO
+.	O
+
+ABSTRACT	O
+:	O
+Recently	O
+,	O
+more	O
+SARS	B-DISO
+-	O
+CoV	O
+virus	B-SPEC
+genome	O
+sequences	O
+are	O
+released	O
+to	O
+the	O
+GenBank	O
+database	O
+.	O
+
+CONCLUSIONS	O
+:	O
+SARS	B-PRGE
+-	I-PRGE
+CoV	I-PRGE
+virus	B-SPEC
+replicase	I-PRGE
+polyprotein	I-PRGE
+ORF1b	I-PRGE
+is	O
+undergoing	O
+negative	O
+selection	O
+;	O
+negative	O
+selection	O
+force	O
+is	O
+also	O
+probably	O
+operating	O
+on	O
+spike	B-PRGE
+protein	I-PRGE
+gene	I-PRGE
+.	O
+
+These	O
+three	O
+stages	O
+depict	O
+the	O
+effectiveness	O
+of	O
+interventive	O
+measures	O
+against	O
+SARS	B-DISO
+in	O
+Beijing	O
+since	O
+late	O
+April	O
+.	O
+
+All	O
+lungs	B-ANAT
+from	O
+these	O
+cases	O
+were	O
+extremely	O
+expanded	O
+and	O
+became	O
+solid	O
+.	O
+
+Foci	O
+of	O
+haemorrhage	B-DISO
+and	O
+lobular	B-DISO
+pneumonia	I-DISO
+,	O
+even	O
+diffuse	O
+fungal	B-DISO
+infection	I-DISO
+were	O
+frequently	O
+seen	O
+in	O
+these	O
+specimens	O
+.	O
+
+Twenty	O
+-	O
+one	O
+SARS	B-DISO
+patients	O
+who	O
+reached	O
+the	O
+standard	O
+of	O
+Ministry	O
+of	O
+Health	O
+'	O
+s	O
+""""	O
+critical	O
+level	O
+""""	O
+were	O
+transferred	O
+into	O
+our	O
+ICU	O
+in	O
+an	O
+average	O
+of	O
+11	O
+days	O
+after	O
+onset	O
+and	O
+enrolled	O
+in	O
+this	O
+clinical	O
+trial	O
+.	O
+
+All	O
+patients	O
+underwent	O
+respiratory	O
+support	O
+and	O
+clinical	O
+nutrition	B-PROC
+support	O
+as	O
+scheduled	O
+.	O
+
+The	O
+longest	O
+stool	B-ANAT
+shedding	O
+case	O
+in	O
+this	O
+study	O
+lasted	O
+64	O
+days	O
+.	O
+
+Our	O
+study	O
+observed	O
+longest	O
+stool	B-ANAT
+shedding	O
+of	O
+SARS	B-DISO
+patients	O
+to	O
+be	O
+64	O
+days	O
+after	O
+initial	O
+onset	O
+of	O
+SARS	B-DISO
+.	O
+
+TITLE	O
+:	O
+['	O
+Severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+'	O
+(	O
+SARS	B-DISO
+):	O
+epidemiology	O
+,	O
+clinical	O
+signs	O
+,	O
+diagnosis	O
+and	O
+prevention	O
+].	O
+
+ABSTRACT	O
+:	O
+Severe	O
+acute	O
+respiratory	O
+syndrome	O
+(	O
+SARS	B-DISO
+)	O
+is	O
+caused	O
+by	O
+a	O
+recently	O
+identified	O
+Coronavirus	B-SPEC
+(	O
+SARS	B-DISO
+-	O
+CoV	O
+).	O
+
+Since	O
+November	O
+2002	O
+the	O
+virus	B-SPEC
+has	O
+spread	O
+from	O
+South	O
+China	O
+to	O
+almost	O
+30	O
+other	O
+countries	O
+,	O
+where	O
+about	O
+8500	O
+infected	O
+individuals	O
+have	O
+been	O
+registered	O
+;	O
+about	O
+800	O
+people	O
+have	O
+already	O
+died	B-PROC
+from	O
+the	O
+disease	O
+(	O
+9	O
+.	O
+5	O
+%).	O
+
+TITLE	O
+:	O
+Novel	O
+synthesis	B-PROC
+of	O
+polymorphous	O
+nanocrystalline	O
+KNbO3	O
+by	O
+a	O
+low	O
+temperature	O
+solution	O
+method	O
+.	O
+
+ABSTRACT	O
+:	O
+Orthorhombic	O
+and	O
+rhombohedral	O
+single	O
+nanocrystalline	O
+KNbO3	O
+with	O
+different	O
+morphologies	O
+was	O
+synthesized	O
+respectively	O
+at	O
+a	O
+relatively	O
+low	O
+temperature	O
+by	O
+simply	O
+changing	O
+the	O
+reaction	O
+solvent	B-CHED
+;	O
+a	O
+conceivable	O
+reaction	O
+process	O
+was	O
+illustrated	O
+based	O
+on	O
+the	O
+finding	O
+of	O
+a	O
+hexahedral	O
+intermediate	O
+product	O
+during	O
+the	O
+formation	B-PROC
+of	O
+KNbO3	O
+.	O
+
+TITLE	O
+:	O
+[	O
+Viral	O
+nosocomial	B-DISO
+infections	I-DISO
+:	O
+the	O
+problem	O
+of	O
+contemporary	O
+hospital	O
+management	O
+].	O
+
+So	O
+called	O
+enteric	O
+viruses	B-SPEC
+which	O
+are	O
+rotaviruses	B-SPEC
+,	O
+adenoviruses	B-SPEC
+,	O
+small	O
+round	O
+viruses	B-SPEC
+,	O
+astroviruses	O
+,	O
+caliciviruses	O
+,	O
+corona	B-CHED
+viruses	B-SPEC
+,	O
+Coxackie	O
+,	O
+ECHO	B-SPEC
+may	O
+be	O
+the	O
+agents	O
+of	O
+disorders	O
+in	O
+digestive	B-ANAT
+tract	I-ANAT
+in	O
+the	O
+form	O
+of	O
+intoxications	O
+.	O
+
+26	O
+mmHg	O
+,	O
+and	O
+that	O
+of	O
+diastolic	O
+blood	B-PROC
+pressure	I-PROC
+was	O
+98	O
+.	O
+5	O
++/-	O
+
+TITLE	O
+:	O
+[	O
+The	O
+epidemiologic	O
+characteristics	O
+of	O
+patients	O
+with	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+(	O
+SARS	B-DISO
+)].	O
+
+The	O
+result	O
+showed	O
+that	O
+72	O
+/	O
+80	O
+patients	O
+had	O
+exposed	O
+to	O
+SARS	B-DISO
+patient	O
+,	O
+and	O
+the	O
+least	O
+contact	O
+time	O
+was	O
+only	O
+20	O
+minutes	O
+,	O
+the	O
+average	O
+incubation	O
+period	O
+was	O
+(	O
+7	O
+.	O
+6	O
++/-	O
+
+The	O
+lack	O
+of	O
+isolation	O
+and	O
+self	O
+-	O
+protection	O
+was	O
+the	O
+most	O
+important	O
+factor	O
+for	O
+the	O
+hospital	B-DISO
+infection	I-DISO
+,	O
+and	O
+early	O
+isolation	O
+could	O
+efficiently	O
+prevent	O
+the	O
+spread	O
+of	O
+the	O
+disease	O
+.	O
+
+RESULTS	O
+:	O
+The	O
+result	O
+showed	O
+that	O
+72	O
+/	O
+80	O
+patients	O
+had	O
+exposed	O
+to	O
+SARS	B-DISO
+patient	O
+,	O
+and	O
+the	O
+least	O
+contact	O
+time	O
+was	O
+only	O
+20	O
+minutes	O
+,	O
+the	O
+average	O
+incubation	O
+period	O
+was	O
+(	O
+7	O
+.	O
+6	O
++/-	O
+
+TITLE	O
+:	O
+[	O
+Retrospective	O
+analysis	O
+for	O
+first	O
+-	O
+visiting	O
+case	O
+data	O
+of	O
+272	O
+SARS	B-DISO
+inpatients	O
+in	O
+Peking	O
+University	O
+Third	O
+Hospital	O
+].	O
+
+ABSTRACT	O
+:	O
+The	O
+first	O
+-	O
+visiting	O
+cases	O
+of	O
+total	O
+272	O
+SARS	O
+inpatients	O
+admitted	O
+in	O
+SARS	B-DISO
+wards	O
+in	O
+Third	O
+Hospital	O
+from	O
+April	O
+10	O
+,	O
+2003	O
+to	O
+May	O
+12	O
+were	O
+analyzed	O
+retrospectively	O
+.	O
+
+RESULTS	O
+:	O
+The	O
+characteristics	O
+of	O
+gender	O
+,	O
+age	O
+,	O
+occupation	O
+,	O
+contagious	O
+history	O
+and	O
+previous	O
+therapy	O
+were	O
+described	O
+in	O
+SARS	B-DISO
+inpatients	O
+when	O
+they	O
+visited	O
+the	O
+outpatient	O
+department	O
+for	O
+SARS	B-DISO
+in	O
+the	O
+first	O
+time	O
+;	O
+the	O
+clinical	O
+symptoms	O
+,	O
+physical	O
+signs	O
+,	O
+blood	B-ANAT
+WBC	B-ANAT
+counts	O
+and	O
+X	O
+-	O
+ray	B-SPEC
+in	O
+lungs	B-ANAT
+were	O
+also	O
+analyzed	O
+.	O
+
+TITLE	O
+:	O
+[	O
+Retrospective	O
+analysis	O
+of	O
+the	O
+corticosteroids	B-CHED
+treatment	O
+on	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+(	O
+SARS	B-DISO
+)].	O
+
+The	O
+initial	O
+dosage	O
+and	O
+the	O
+highest	O
+dosage	O
+of	O
+prednisolone	B-CHED
+were	O
+investigated	O
+.	O
+
+TITLE	O
+:	O
+[	O
+Primary	O
+investigation	O
+on	O
+the	O
+changing	O
+mode	O
+of	O
+plasma	B-ANAT
+specific	O
+IgG	B-COMP
+antibody	I-COMP
+in	O
+SARS	B-DISO
+patients	O
+and	O
+their	O
+physicians	O
+and	O
+nurses	O
+].	O
+
+Plasma	B-PRGE
+anti	I-PRGE
+-	I-PRGE
+SARS	B-DISO
+coronavirus	B-SPEC
+IgG	B-COMP
+antibody	I-COMP
+was	O
+not	O
+detected	O
+in	O
+normal	O
+subjects	O
+and	O
+the	O
+clinical	O
+personnel	O
+.	O
+
+The	O
+specificity	O
+and	O
+sensitivity	O
+of	O
+ELISA	O
+to	O
+detect	O
+plasma	B-PRGE
+anti	I-PRGE
+-	I-PRGE
+SARS	B-DISO
+IgG	B-COMP
+antibody	I-COMP
+were	O
+satisfactory	O
+.	O
+
+we	O
+can	O
+closely	O
+observe	O
+the	O
+condition	B-DISO
+of	O
+the	O
+disease	O
+and	O
+no	O
+more	O
+glucocortisteroids	O
+needed	O
+to	O
+be	O
+given	O
+to	O
+the	O
+patients	O
+.	O
+
+In	O
+the	O
+early	O
+stage	O
+,	O
+the	O
+most	O
+common	O
+findings	O
+were	O
+patchy	O
+ground	O
+-	O
+glass	O
+opacification	O
+(	O
+GGO	O
+)	O
+(	O
+79	O
+.	O
+5	O
+%	O
+on	O
+X	O
+-	O
+ray	B-SPEC
+and	O
+81	O
+.	O
+
+RESULTS	O
+:	O
+In	O
+the	O
+early	O
+stage	O
+,	O
+the	O
+most	O
+common	O
+findings	O
+were	O
+patchy	O
+ground	O
+-	O
+glass	O
+opacification	O
+(	O
+GGO	O
+)	O
+(	O
+79	O
+.	O
+5	O
+%	O
+on	O
+X	O
+-	O
+ray	B-SPEC
+and	O
+81	O
+.	O
+
+TITLE	O
+:	O
+[	O
+The	O
+investigation	O
+of	O
+clinical	O
+images	O
+of	O
+88	O
+hospital	O
+staff	O
+with	O
+SARS	B-DISO
+].	O
+
+ABSTRACT	O
+:	O
+To	O
+observe	O
+the	O
+radiological	O
+features	O
+of	O
+chest	O
+X	O
+ray	B-SPEC
+in	O
+SARS	B-DISO
+patients	O
+.	O
+
+The	O
+sequential	O
+chest	B-ANAT
+film	O
+were	O
+evaluated	O
+hemiquantitatively	O
+.	O
+
+The	O
+ill	B-DISO
+-	O
+defined	O
+and	O
+variable	O
+opacities	B-DISO
+showed	O
+to	O
+be	O
+dominant	O
+.	O
+
+To	O
+analyze	O
+retrospectively	O
+the	O
+data	O
+of	O
+NIPPV	O
+in	O
+105	O
+SARS	B-DISO
+cases	O
+hospitalized	O
+from	O
+8	O
+Apr	B-CHED
+to	O
+14	O
+May	O
+,	O
+2003	O
+.	O
+
+The	O
+most	O
+common	O
+side	B-DISO
+effect	I-DISO
+was	O
+subcutaneous	B-DISO
+emphysema	I-DISO
+,	O
+of	O
+which	O
+the	O
+incidence	O
+rate	O
+was	O
+16	O
+.	O
+7	O
+%.	O
+
+There	O
+was	O
+no	O
+SARS	B-DISO
+affected	O
+among	O
+the	O
+medical	O
+faculty	O
+during	O
+the	O
+course	O
+of	O
+NIPPV	O
+.	O
+
+Early	O
+recognition	O
+,	O
+prompt	O
+isolation	O
+,	O
+and	O
+appropriate	O
+therapy	O
+are	O
+the	O
+key	O
+in	O
+combating	O
+this	O
+infection	B-DISO
+.	O
+
+ABSTRACT	O
+:	O
+It	O
+is	O
+described	O
+the	O
+mental	O
+stress	O
+reaction	O
+in	O
+the	O
+diagnosed	O
+or	O
+suspicious	O
+patients	O
+with	O
+the	O
+SARS	B-DISO
+,	O
+the	O
+doctors	O
+and	O
+nurses	O
+treating	O
+the	O
+SARS	B-DISO
+,	O
+other	O
+related	O
+people	O
+and	O
+the	O
+masses	O
+;	O
+and	O
+put	O
+out	O
+the	O
+gist	B-DISO
+and	O
+principles	O
+of	O
+mental	O
+crisis	O
+intervention	O
+respectively	O
+.	O
+
+TITLE	O
+:	O
+[	O
+Analysis	O
+of	O
+medical	O
+workers	O
+suffered	B-DISO
+from	O
+SARS	B-DISO
+].	O
+
+ABSTRACT	O
+:	O
+To	O
+analyse	O
+the	O
+reason	O
+and	O
+countermeasure	O
+for	O
+the	O
+infection	B-DISO
+of	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+(	O
+SARS	B-DISO
+)	O
+in	O
+health	O
+care	O
+workers	O
+,	O
+to	O
+provide	O
+reference	O
+for	O
+the	O
+health	O
+care	O
+workers	O
+to	O
+control	O
+infection	B-DISO
+of	O
+SARS	B-DISO
+.	O
+
+It	O
+was	O
+concluded	O
+that	O
+reasonable	O
+and	O
+strict	O
+infection	B-DISO
+control	O
+precaution	O
+help	O
+to	O
+reduce	O
+infection	B-DISO
+rate	O
+among	O
+health	O
+care	O
+workers	O
+,	O
+and	O
+careful	O
+supervision	O
+helped	O
+to	O
+achieve	O
+the	O
+reduction	O
+.	O
+
+ABSTRACT	O
+:	O
+SARS	O
+coronavirus	B-SPEC
+3CL	O
+proteinase	B-PROC
+is	O
+the	O
+key	O
+enzyme	O
+for	O
+virus	B-PROC
+replication	I-PROC
+which	O
+may	O
+serve	O
+as	O
+the	O
+target	O
+for	O
+drug	O
+discovery	O
+against	O
+SARS	B-DISO
+.	O
+
+The	O
+main	O
+results	O
+of	O
+our	O
+simulation	O
+are	O
+that	O
+the	O
+feedback	O
+mechanism	O
+can	O
+effectively	O
+slow	O
+down	O
+the	O
+SARS	B-DISO
+infecting	O
+rate	O
+,	O
+but	O
+it	O
+may	O
+cause	O
+sustained	O
+oscillations	O
+in	O
+number	O
+of	O
+infection	B-DISO
+cases	O
+.	O
+
+EIRIS	O
+was	O
+an	O
+effective	O
+method	O
+to	O
+break	O
+the	O
+transmission	O
+route	O
+of	O
+SARS	B-DISO
+within	O
+the	O
+hospital	O
+.	O
+
+ABSTRACT	O
+:	O
+To	O
+analyze	O
+the	O
+relationship	O
+between	O
+the	O
+rate	O
+of	O
+the	O
+in	O
+-	O
+hospital	O
+medical	O
+staff	O
+SARS	B-DISO
+infection	B-DISO
+and	O
+the	O
+measure	O
+of	O
+isolation	O
+which	O
+including	O
+the	O
+application	O
+of	O
+the	O
+emergency	B-DISO
+-	O
+isolation	O
+radiology	O
+information	O
+system	O
+(	O
+EIRIS	O
+)	O
+in	O
+polyclinic	O
+.	O
+
+The	O
+rate	O
+showed	O
+a	O
+little	O
+descending	O
+trend	O
+in	O
+Group	B-DISO
+B	I-DISO
+compared	O
+with	O
+that	O
+in	O
+Group	O
+A	O
+with	O
+the	O
+regression	O
+coefficient	O
+of	O
+0	O
+.	O
+000164	O
+,	O
+P	O
+=	O
+0	O
+.	O
+140	O
+.	O
+
+CONCLUSIONS	O
+:	O
+The	O
+trend	O
+of	O
+the	O
+in	O
+-	O
+hospital	O
+medical	O
+staffs	O
+infection	B-DISO
+rate	O
+changed	O
+with	O
+different	O
+style	O
+of	O
+prevention	O
+and	O
+protection	O
+measures	O
+.	O
+
+ABSTRACT	O
+:	O
+To	O
+avoid	O
+the	O
+staff	O
+'	O
+s	O
+infection	O
+and	O
+environmental	O
+contamination	O
+,	O
+we	O
+establish	O
+the	O
+rules	O
+suited	O
+for	O
+severe	O
+infectious	B-DISO
+disease	I-DISO
+in	O
+our	O
+laboratory	O
+.	O
+
+The	O
+sources	O
+of	O
+stress	O
+included	O
+fatal	B-DISO
+outcomes	I-DISO
+,	O
+lack	O
+of	O
+efficient	O
+treatment	O
+,	O
+rapid	O
+spreading	O
+and	O
+high	O
+risk	O
+of	O
+medical	O
+workers	O
+.	O
+
+86	O
+.	O
+8	O
+%	O
+felt	O
+the	O
+media	B-ANAT
+often	O
+over	O
+-	O
+reported	O
+.	O
+
+ABSTRACT	O
+:	O
+To	O
+study	O
+the	O
+difference	O
+among	O
+the	O
+ratios	O
+of	O
+SARS	O
+suspect	O
+cases	O
+to	O
+the	O
+confirmed	O
+ones	O
+in	O
+a	O
+district	O
+of	O
+Beijing	O
+,	O
+the	O
+whole	O
+China	O
+and	O
+in	O
+Beijing	O
+,	O
+and	O
+to	O
+provide	O
+the	O
+suggestions	O
+for	O
+clinical	O
+diagnoses	O
+in	O
+SARS	B-DISO
+epidemic	O
+areas	O
+.	O
+
+CONCLUSIONS	O
+:	O
+There	O
+was	O
+the	O
+condition	B-DISO
+to	O
+avoid	O
+the	O
+SARS	B-DISO
+to	O
+diffuse	O
+and	O
+extend	O
+in	O
+the	O
+rural	O
+area	O
+as	O
+Pinggu	O
+.	O
+
+SARS	B-DISO
+smashes	O
+the	O
+people	O
+'	O
+s	O
+tranquil	O
+life	O
+and	O
+many	O
+people	O
+live	O
+in	O
+horror	O
+,	O
+worry	O
+and	O
+anxiety	O
+.	O
+
+In	O
+this	O
+study	O
+,	O
+we	O
+show	O
+that	O
+limitin	B-PRGE
+has	O
+antiviral	B-CHED
+activity	O
+in	O
+vitro	O
+as	O
+well	O
+as	O
+in	O
+vivo	O
+.	O
+
+We	O
+have	O
+cloned	O
+,	O
+expressed	B-PROC
+,	O
+and	O
+purified	O
+this	O
+protein	B-CHED
+as	O
+an	O
+N	O
+-	O
+terminal	O
+hexahistidine	O
+fusion	O
+in	O
+Escherichia	B-SPEC
+coli	I-SPEC
+and	O
+have	O
+characterized	O
+its	O
+helicase	B-PRGE
+and	O
+NTPase	B-PRGE
+activities	O
+.	O
+
+We	O
+provide	O
+the	O
+first	O
+quantitative	O
+analysis	O
+of	O
+the	O
+polynucleic	O
+acid	O
+binding	B-FUNC
+and	O
+NTPase	B-PRGE
+activities	O
+of	O
+a	O
+Nidovirus	B-SPEC
+helicase	B-PRGE
+,	O
+using	O
+a	O
+high	O
+throughput	O
+phosphate	B-CHED
+release	B-PATH
+assay	O
+that	O
+will	O
+be	O
+readily	O
+adaptable	O
+to	O
+the	O
+future	O
+testing	O
+of	O
+helicase	B-PRGE
+inhibitors	B-CHED
+.	O
+
+The	O
+enzyme	O
+exhibited	O
+a	O
+preference	O
+for	O
+ATP	B-CHED
+,	O
+dATP	B-CHED
+,	O
+and	O
+dCTP	B-CHED
+over	O
+the	O
+other	O
+NTP	B-PRGE
+/	I-PRGE
+dNTP	B-CHED
+substrates	O
+.	O
+
+Here	O
+,	O
+we	O
+determined	O
+the	O
+sequence	O
+of	O
+SARS	B-DISO
+coronavirus	B-SPEC
+(	O
+SARS	B-DISO
+-	O
+CoV	O
+),	O
+isolate	O
+Frankfurt	O
+1	O
+,	O
+and	O
+characterized	O
+key	O
+RNA	O
+elements	O
+and	O
+protein	B-CHED
+functions	O
+involved	O
+in	O
+viral	B-PROC
+genome	I-PROC
+expression	I-PROC
+.	O
+
+The	O
+main	O
+treatments	O
+include	O
+corticosteroid	B-CHED
+therapy	O
+,	O
+anti	B-CHED
+-	I-CHED
+viral	I-CHED
+agents	I-CHED
+,	O
+anti	O
+-	O
+infection	B-DISO
+,	O
+mechanical	O
+ventilation	O
+and	O
+isolation	O
+.	O
+
+Among	O
+32	O
+patients	O
+,	O
+24	O
+were	O
+cured	O
+,	O
+2	O
+died	B-PROC
+of	O
+respiratory	B-DISO
+failure	I-DISO
+,	O
+6	O
+died	B-PROC
+of	O
+their	O
+primary	O
+diseases	O
+,	O
+and	O
+the	O
+overall	O
+mortality	O
+was	O
+25	O
+.	O
+00	O
+percent	O
+.	O
+
+In	O
+addition	O
+,	O
+hyperglycemia	B-DISO
+was	O
+found	O
+in	O
+4	O
+patients	O
+,	O
+upper	O
+intestinal	B-DISO
+hemorrhage	I-DISO
+occurred	O
+in	O
+another	O
+4	O
+patients	O
+and	O
+cardiac	B-DISO
+failure	I-DISO
+occurred	O
+in	O
+6	O
+patients	O
+.	O
+
+TITLE	O
+:	O
+[	O
+Comparison	O
+of	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+with	O
+community	O
+-	O
+acquired	O
+pneumonia	B-DISO
+].	O
+
+(	O
+5	O
+)	O
+The	O
+ratio	O
+of	O
+severe	O
+pneumonia	B-DISO
+and	O
+mortality	O
+in	O
+SARS	B-DISO
+was	O
+much	O
+higher	O
+than	O
+in	O
+CAP	B-DISO
+(	O
+both	O
+P	O
+<	O
+0	O
+.	O
+01	O
+).	O
+
+ABSTRACT	O
+:	O
+Targeted	B-PROC
+recombination	B-PROC
+was	O
+carried	O
+out	O
+to	O
+select	O
+mouse	B-DISO
+hepatitis	I-DISO
+viruses	B-SPEC
+(	O
+MHVs	O
+)	O
+in	O
+a	O
+defined	O
+genetic	O
+background	O
+,	O
+containing	O
+an	O
+MHV	B-SPEC
+-	O
+JHM	O
+spike	O
+gene	O
+encoding	O
+either	O
+three	O
+heptad	O
+repeat	O
+1	O
+(	O
+HR1	O
+)	O
+substitutions	O
+(	O
+Q1067H	O
+,	O
+Q1094H	O
+,	O
+and	O
+L1114R	O
+)	O
+or	O
+L1114R	O
+alone	O
+.	O
+
+The	O
+recombinant	O
+virus	B-SPEC
+,	O
+which	O
+expresses	O
+spike	O
+with	O
+the	O
+three	O
+substitutions	O
+,	O
+was	O
+nonfusogenic	O
+at	O
+neutral	O
+pH	O
+.	O
+Its	O
+replication	O
+was	O
+significantly	O
+inhibited	O
+by	O
+lysosomotropic	O
+agents	O
+,	O
+and	O
+it	O
+was	O
+highly	O
+neuroattenuated	O
+in	O
+vivo	O
+.	O
+
+Klenow	O
+-	O
+FragELTM	O
+DNA	B-PROC
+Fragmentation	I-PROC
+Detection	O
+Kit	B-FUNC
+and	O
+immunohistochemical	O
+alkaline	B-PRGE
+phosphatase	I-PRGE
+detection	O
+reagent	B-CHED
+kit	B-FUNC
+were	O
+used	O
+to	O
+detect	O
+cell	B-COMP
+apoptosis	B-PATH
+and	O
+expressions	O
+of	O
+CD68	B-PRGE
+,	O
+CD20	B-PRGE
+,	O
+CD4	B-PRGE
+,	O
+CD8	B-PRGE
+and	O
+CD45RA	O
+in	O
+the	O
+pathological	O
+tissues	B-ANAT
+of	O
+SARS	B-DISO
+patients	O
+.	O
+
+RESULTS	O
+:	O
+Apoptotic	O
+cells	B-COMP
+increased	O
+significantly	O
+in	O
+the	O
+spleen	B-ANAT
+,	O
+lung	B-ANAT
+and	O
+lymph	B-ANAT
+nodes	I-ANAT
+of	O
+SARS	B-DISO
+patients	O
+as	O
+compared	O
+with	O
+normal	O
+tissues	B-ANAT
+.	O
+
+TITLE	O
+:	O
+[	O
+Expression	B-PROC
+of	O
+immune	O
+cells	B-COMP
+and	O
+their	O
+roles	O
+in	O
+the	O
+involved	O
+tissues	B-ANAT
+of	O
+SARS	B-DISO
+patients	O
+].	O
+
+Decreased	O
+left	O
+ventricular	B-ANAT
+stroke	B-DISO
+work	O
+index	O
+and	O
+stroke	B-DISO
+volume	O
+index	O
+with	O
+elevated	O
+left	O
+atrial	B-ANAT
+pressure	O
+indicated	O
+myocardial	B-DISO
+depression	I-DISO
+.	O
+
+The	O
+initial	O
+temperature	O
+was	O
+(	O
+38	O
+.	O
+3	O
++/-	O
+0	O
+.	O
+6	O
+)	O
+degrees	O
+C	O
+,	O
+while	O
+the	O
+highest	O
+was	O
+(	O
+39	O
+.	O
+2	O
++/-	O
+0	O
+.	O
+6	O
+)	O
+degrees	O
+C	O
+(	O
+P	O
+<	O
+0	O
+.	O
+001	O
+),	O
+with	O
+a	O
+mean	O
+fever	B-PROC
+duration	O
+of	O
+(	O
+9	O
+.	O
+0	O
++/-	O
+4	O
+.	O
+2	O
+)	O
+days	O
+.	O
+
+The	O
+positive	O
+rates	O
+of	O
+TnI	B-PRGE
+,	O
+CK	B-FUNC
+-	I-FUNC
+MB	I-FUNC
+and	O
+MYO	O
+in	O
+patients	O
+were	O
+higher	O
+than	O
+those	O
+in	O
+controls	O
+(	O
+P	O
+<	O
+0	O
+.	O
+05	O
+).	O
+
+Fifteen	O
+patients	O
+died	B-PROC
+,	O
+the	O
+mortality	O
+rate	O
+was	O
+28	O
+.	O
+3	O
+%.	O
+
+Fifteen	O
+patients	O
+died	B-PROC
+,	O
+the	O
+mortality	O
+rate	O
+was	O
+28	O
+.	O
+3	O
+%.	O
+
+TITLE	O
+:	O
+Investigation	O
+of	O
+a	O
+nosocomial	O
+outbreak	O
+of	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+(	O
+SARS	B-DISO
+)	O
+in	O
+Toronto	O
+,	O
+Canada	O
+.	O
+
+ABSTRACT	O
+:	O
+Severe	O
+acute	O
+respiratory	O
+syndrome	O
+(	O
+SARS	B-DISO
+)	O
+was	O
+introduced	O
+into	O
+Canada	O
+by	O
+a	O
+visitor	O
+to	O
+Hong	O
+Kong	O
+who	O
+returned	O
+to	O
+Toronto	O
+on	O
+Feb	O
+.	O
+23	O
+,	O
+2003	O
+.	O
+
+Transmission	O
+to	O
+a	O
+family	B-SPEC
+member	O
+who	O
+was	O
+later	O
+admitted	O
+to	O
+a	O
+community	O
+hospital	O
+in	O
+Toronto	O
+led	O
+to	O
+a	O
+large	O
+nosocomial	O
+outbreak	O
+.	O
+
+Seventeen	O
+deaths	B-PROC
+were	O
+reported	O
+(	O
+case	O
+-	O
+fatality	O
+rate	O
+13	O
+.	O
+3	O
+%).	O
+
+TITLE	O
+:	O
+Structural	O
+genomics	O
+of	O
+the	O
+SARS	B-DISO
+coronavirus	B-SPEC
+:	O
+cloning	O
+,	O
+expression	B-PROC
+,	O
+crystallization	O
+and	O
+preliminary	O
+crystallographic	O
+study	O
+of	O
+the	O
+Nsp9	O
+protein	O
+.	O
+
+TITLE	O
+:	O
+Severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+(	O
+SARS	B-DISO
+)	O
+in	O
+a	O
+paediatric	O
+cluster	O
+in	O
+Singapore	O
+.	O
+
+The	O
+chest	B-ANAT
+radiographs	O
+of	O
+four	O
+related	O
+children	O
+ranging	O
+in	O
+age	O
+from	O
+18	O
+months	O
+to	O
+9	O
+years	O
+diagnosed	O
+as	O
+having	O
+SARS	B-DISO
+were	O
+reviewed	O
+for	O
+the	O
+presence	O
+of	O
+air	B-CHED
+-	O
+space	O
+shadowing	O
+,	O
+air	B-CHED
+bronchograms	O
+,	O
+peribronchial	O
+thickening	O
+,	O
+interstitial	B-DISO
+disease	I-DISO
+,	O
+pleural	B-DISO
+effusion	I-DISO
+,	O
+pneumothorax	B-DISO
+,	O
+hilar	B-DISO
+lymphadenopathy	I-DISO
+and	O
+mediastinal	B-ANAT
+widening	O
+.	O
+
+Intravenous	O
+quinine	B-CHED
+and	O
+quinidine	B-CHED
+are	O
+the	O
+most	O
+widely	O
+used	O
+drugs	O
+in	O
+the	O
+initial	O
+treatment	O
+of	O
+severe	O
+falciparum	B-DISO
+malaria	I-DISO
+,	O
+whereas	O
+artemisinin	B-CHED
+derivatives	I-CHED
+are	O
+currently	O
+recommended	O
+for	O
+quinine	B-CHED
+-	O
+resistant	O
+cases	O
+.	O
+
+Exchange	O
+blood	B-ANAT
+transfusion	O
+has	O
+been	O
+suggested	O
+for	O
+the	O
+treatment	O
+of	O
+patients	O
+with	O
+severe	O
+malaria	B-PATH
+and	O
+high	O
+parasitemia	B-DISO
+.	O
+
+Several	O
+observations	O
+support	O
+the	O
+hypothesis	O
+of	O
+an	O
+animal	B-SPEC
+origin	O
+for	O
+the	O
+disease	O
+.	O
+
+(	O
+1	O
+)	O
+Sixty	O
+-	O
+three	O
+of	O
+70	O
+cases	O
+of	O
+SARS	B-DISO
+recovered	O
+and	O
+seven	O
+cases	O
+died	B-PROC
+,	O
+with	O
+a	O
+case	O
+-	O
+fatality	O
+ratio	O
+of	O
+10	O
+%.	O
+
+One	O
+patient	O
+showed	O
+no	O
+clinical	O
+symptoms	O
+,	O
+and	O
+bilateral	O
+infiltrates	B-DISO
+was	O
+found	O
+in	O
+his	O
+chest	B-ANAT
+X	O
+-	O
+ray	B-SPEC
+.	O
+
+At	O
+the	O
+first	O
+week	O
+,	O
+the	O
+counts	O
+of	O
+white	B-ANAT
+blood	I-ANAT
+cells	I-ANAT
+(	O
+WBCs	O
+),	O
+lymphocyte	B-ANAT
+and	O
+platelets	B-ANAT
+were	O
+(	O
+4	O
+.	O
+4	O
++/-	O
+1	O
+.	O
+5	O
+)	O
+x	O
+10	O
+(	O
+9	O
+)/	O
+L	O
+,	O
+0	O
+.	O
+22	O
++/-	O
+0	O
+.	O
+12	O
+and	O
+(	O
+143	O
++/-	O
+37	O
+)	O
+x	O
+10	O
+(	O
+9	O
+)/	O
+L	O
+,	O
+which	O
+were	O
+significantly	O
+lower	O
+when	O
+compared	O
+with	O
+those	O
+at	O
+the	O
+2nd	O
+to	O
+4th	O
+week	O
+.	O
+
+One	O
+such	O
+mechanism	O
+could	O
+be	O
+an	O
+animal	B-SPEC
+vector	O
+,	O
+most	O
+probably	O
+roof	B-SPEC
+rats	I-SPEC
+,	O
+that	O
+was	O
+infected	O
+by	O
+the	O
+index	O
+patient	O
+and	O
+subsequently	O
+spread	O
+the	O
+disease	O
+to	O
+more	O
+than	O
+150	O
+households	O
+.	O
+
+Maintaining	O
+a	O
+healthy	O
+and	O
+hygienic	O
+environment	O
+can	O
+be	O
+one	O
+of	O
+the	O
+effective	O
+public	O
+health	O
+measures	O
+to	O
+combat	B-CHED
+infectious	B-DISO
+disease	I-DISO
+.	O
+
+The	O
+microbial	O
+findings	O
+has	O
+been	O
+:	O
+pathogenics	O
+bacteria	B-SPEC
+(	O
+31	O
+.	O
+7	O
+%),	O
+fungus	B-SPEC
+(	O
+17	O
+%),	O
+parasites	O
+(	O
+1	O
+.	O
+2	O
+%),	O
+rotavirus	B-SPEC
+(	O
+16	O
+.	O
+4	O
+%),	O
+calicivirus	O
+(	O
+1	O
+.	O
+6	O
+%),	O
+adenovirus	B-DISO
+and	O
+coronavirus	B-SPEC
+(	O
+1	O
+.	O
+6	O
+%).	O
+
+it	O
+'	O
+s	O
+possible	O
+in	O
+Río	O
+Cuarto	O
+to	O
+made	O
+a	O
+fast	B-FUNC
+and	O
+direct	O
+virology	O
+diagnostic	O
+using	O
+an	O
+electron	O
+microscopy	O
+.	O
+
+Limited	O
+information	O
+is	O
+available	O
+on	O
+the	O
+public	O
+health	O
+risk	O
+of	O
+many	O
+exogenous	O
+swine	B-SPEC
+viruses	B-SPEC
+,	O
+and	O
+reliable	O
+and	O
+rapid	O
+diagnostic	O
+tests	O
+are	O
+available	O
+for	O
+only	O
+a	O
+few	O
+of	O
+these	O
+.	O
+
+TITLE	O
+:	O
+The	O
+expression	B-PROC
+of	O
+a	O
+novel	O
+stress	O
+protein	B-CHED
+'	O
+150	O
+-	O
+kDa	O
+oxygen	B-CHED
+regulated	O
+protein	B-CHED
+'	O
+in	O
+sudden	B-DISO
+infant	I-DISO
+death	I-DISO
+.	O
+
+Moreover	O
+,	O
+both	O
+groups	O
+of	O
+litters	O
+from	O
+primed	O
+gilts	O
+suffered	B-DISO
+less	O
+clinical	O
+illness	O
+(	O
+as	O
+measured	O
+by	O
+the	O
+extent	O
+of	O
+weight	O
+loss	O
+post	O
+-	O
+challenge	O
+)	O
+than	O
+control	O
+litters	O
+.	O
+
+ABSTRACT	O
+:	O
+The	O
+Severe	B-DISO
+Acute	I-DISO
+Respiratory	I-DISO
+Syndrome	I-DISO
+(	O
+SARS	B-DISO
+)	O
+is	O
+a	O
+newly	O
+discovered	O
+infectious	B-DISO
+disease	I-DISO
+caused	O
+by	O
+a	O
+novel	B-SPEC
+coronavirus	I-SPEC
+,	O
+which	O
+can	O
+readily	O
+spread	O
+in	O
+the	O
+healthcare	O
+setting	O
+.	O
+
+TITLE	O
+:	O
+[	O
+The	O
+treatment	O
+of	O
+molecular	O
+adsorbents	O
+recirculating	O
+system	O
+artificial	O
+liver	B-ANAT
+in	O
+severe	O
+liver	B-ANAT
+failure	I-DISO
+patients	O
+with	O
+multiple	O
+organ	O
+dysfunction	O
+syndrome	O
+].	O
+
+TITLE	O
+:	O
+[	O
+Clinical	O
+characteristics	O
+and	O
+mechanism	O
+of	O
+liver	B-ANAT
+injury	O
+in	O
+patients	O
+with	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+].	O
+
+Other	O
+two	O
+groups	O
+including	O
+15	O
+healthy	O
+care	O
+workers	O
+and	O
+22	O
+patients	O
+with	O
+chronic	B-DISO
+hepatitis	I-DISO
+in	O
+the	O
+same	O
+period	O
+were	O
+selected	O
+and	O
+analyzed	O
+as	O
+controls	O
+.	O
+
+Serum	B-COMP
+total	O
+bilirubin	B-CHED
+values	O
+elevated	O
+in	O
+8	O
+.	O
+4	O
+%	O
+patients	O
+.	O
+
+The	O
+six	O
+kinds	O
+of	O
+interleukins	O
+and	O
+TNF	B-PRGE
+-	I-PRGE
+alpha	I-PRGE
+levels	O
+during	O
+the	O
+first	O
+week	O
+of	O
+hospitalization	O
+were	O
+higher	O
+than	O
+those	O
+in	O
+the	O
+fourth	O
+week	O
+and	O
+in	O
+control	O
+groups	O
+(	O
+t	O
+>	O
+or	O
+=	O
+1	O
+.	O
+67	O
+,	O
+P	O
+<	O
+0	O
+.	O
+05	O
+).	O
+
+The	O
+levels	O
+of	O
+some	O
+factors	O
+,	O
+such	O
+as	O
+IL	B-PRGE
+-	I-PRGE
+1beta	I-PRGE
+,	O
+IL	B-FUNC
+-	I-FUNC
+6	I-FUNC
+and	O
+IL	B-FUNC
+-	I-FUNC
+10	I-FUNC
+in	O
+patients	O
+with	O
+elevated	O
+ALT	B-FUNC
+,	O
+were	O
+higher	O
+than	O
+those	O
+in	O
+ALT	B-FUNC
+normal	O
+patients	O
+(	O
+t	O
+>	O
+or	O
+=	O
+2	O
+.	O
+36	O
+,	O
+P	O
+<	O
+0	O
+.	O
+05	O
+).	O
+
+RESULTS	O
+:	O
+When	O
+being	O
+admitted	O
+to	O
+hospital	O
+,	O
+serum	B-COMP
+ALT	B-FUNC
+and	O
+(	O
+or	O
+)	O
+AST	B-ENZY
+levels	O
+were	O
+elevated	O
+in	O
+37	O
+.	O
+7	O
+%	O
+SARS	B-DISO
+patients	O
+.	O
+
+Forty	O
+two	O
+nucleotide	B-CHED
+mismatches	O
+were	O
+found	O
+in	O
+addition	O
+to	O
+the	O
+five	O
+and	O
+six	O
+gaps	O
+in	O
+two	O
+genomes	O
+.	O
+
+ABSTRACT	O
+:	O
+In	O
+March	O
+2003	O
+,	O
+SARS	O
+-	O
+CoV	O
+,	O
+a	O
+novel	B-SPEC
+coronavirus	I-SPEC
+which	O
+has	O
+been	O
+proved	O
+to	O
+be	O
+a	O
+pathogen	O
+causing	O
+Severe	B-DISO
+Acute	I-DISO
+Respiratory	I-DISO
+Syndrome	I-DISO
+(	O
+SARS	B-DISO
+).	O
+
+The	O
+patient	O
+was	O
+placed	O
+on	O
+assisted	O
+respiration	B-PROC
+support	O
+in	O
+addition	O
+to	O
+anti	O
+-	O
+viral	O
+medication	O
+.	O
+
+The	O
+further	O
+improvement	O
+of	O
+organ	B-ANAT
+functions	O
+allowed	O
+withdrawing	O
+the	O
+patient	O
+from	O
+ventilatory	O
+support	O
+13	O
+days	O
+after	O
+start	O
+of	O
+MARS	O
+,	O
+and	O
+44	O
+days	O
+after	O
+admission	O
+he	O
+was	O
+discharged	O
+home	O
+with	O
+completely	O
+resolved	O
+organ	B-ANAT
+functions	O
+and	O
+laboratory	O
+abnormalities	O
+.	O
+
+To	O
+take	O
+advantage	O
+of	O
+these	O
+features	O
+,	O
+we	O
+have	O
+developed	O
+a	O
+multigene	O
+expression	B-PROC
+vector	O
+based	O
+on	O
+human	B-SPEC
+coronavirus	I-SPEC
+229E	I-SPEC
+.	O
+
+TITLE	O
+:	O
+Evidence	O
+of	O
+biological	O
+efficacy	O
+for	O
+prolonged	O
+glucocorticoid	B-CHED
+treatment	O
+in	O
+patients	O
+with	O
+unresolving	O
+ARDS	O
+.	O
+
+Initial	O
+use	O
+of	O
+pulse	B-PROC
+methylprednisolone	B-CHED
+therapy	O
+appears	O
+to	O
+be	O
+a	O
+more	O
+efficacious	O
+and	O
+an	O
+equally	O
+safe	O
+steroid	B-CHED
+regimen	O
+when	O
+compared	O
+with	O
+regimens	O
+with	O
+lower	O
+dosage	O
+and	O
+should	O
+be	O
+considered	O
+as	O
+the	O
+preferred	O
+steroid	B-CHED
+regimen	O
+in	O
+the	O
+treatment	O
+of	O
+SARS	B-DISO
+,	O
+pending	O
+data	O
+from	O
+future	O
+randomized	O
+controlled	O
+trials	O
+.	O
+
+Many	O
+adult	O
+patients	O
+will	O
+develop	O
+progressive	O
+hypoxia	B-DISO
+,	O
+and	O
+a	O
+large	O
+proportion	O
+will	O
+develop	O
+respiratory	B-DISO
+distress	I-DISO
+syndrome	I-DISO
+(	O
+RDS	O
+),	O
+possibly	O
+related	O
+to	O
+massive	O
+and	O
+uncontrolled	O
+activation	O
+of	O
+the	O
+immune	B-ANAT
+system	I-ANAT
+.	O
+
+TITLE	O
+:	O
+Rapidly	O
+progressing	O
+case	O
+of	O
+Mounier	B-DISO
+-	I-DISO
+Kuhn	I-DISO
+Syndrome	I-DISO
+in	O
+early	O
+childhood	O
+.	O
+
+Incidence	O
+may	O
+be	O
+higher	O
+than	O
+previously	O
+estimated	O
+,	O
+and	O
+tracheobronchomegaly	B-DISO
+(	O
+TBM	O
+)	O
+should	O
+be	O
+considered	O
+as	O
+a	O
+cause	O
+of	O
+respiratory	B-DISO
+failure	I-DISO
+and	O
+recurrent	B-DISO
+pneumonia	I-DISO
+in	O
+children	O
+where	O
+other	O
+investigations	O
+,	O
+including	O
+chest	B-ANAT
+X	O
+-	O
+ray	B-SPEC
+(	O
+CXR	O
+),	O
+are	O
+normal	O
+.	O
+
+The	O
+concerted	O
+efforts	O
+of	O
+a	O
+globally	O
+united	O
+scientific	O
+community	O
+have	O
+led	O
+to	O
+the	O
+independent	O
+isolation	O
+and	O
+identification	O
+of	O
+a	O
+novel	B-SPEC
+coronavirus	I-SPEC
+from	O
+SARS	B-DISO
+patients	O
+by	O
+several	O
+groups	O
+.	O
+
+Sixty	O
+single	O
+MARS	O
+treatments	O
+were	O
+performed	O
+with	O
+length	O
+of	O
+6	O
+-	O
+24	O
+h	O
+on	O
+24	O
+severe	O
+liver	B-DISO
+failure	I-DISO
+patients	O
+(	O
+18	O
+males	O
+/	O
+6	O
+females	O
+)	O
+with	O
+MODS	B-DISO
+.	O
+
+RESULTS	O
+:	O
+The	O
+MARS	O
+therapy	O
+was	O
+associated	O
+with	O
+a	O
+significant	O
+removal	O
+of	O
+NO	O
+and	O
+certain	O
+cytokines	O
+such	O
+as	O
+TNF	B-PRGE
+-	I-PRGE
+alpha	I-PRGE
+,	O
+IL	B-FUNC
+-	I-FUNC
+6	I-FUNC
+,	O
+IL	B-FUNC
+-	I-FUNC
+8	I-FUNC
+,	O
+and	O
+INF	B-PRGE
+-	I-PRGE
+gamma	I-PRGE
+,	O
+together	O
+with	O
+marked	O
+reduction	O
+of	O
+other	O
+non	O
+-	O
+water	B-CHED
+-	O
+soluble	O
+albumin	B-PRGE
+bound	O
+toxins	B-CHED
+and	O
+water	B-CHED
+-	O
+soluble	O
+toxins	B-CHED
+,	O
+these	O
+were	O
+associated	O
+with	O
+a	O
+improvement	O
+of	O
+the	O
+patients	O
+'	O
+clinical	O
+conditions	O
+including	O
+hepatic	B-DISO
+encephalopathy	I-DISO
+,	O
+deranged	O
+hemodynamic	B-PROC
+situation	O
+and	O
+as	O
+well	O
+as	O
+renal	B-ANAT
+and	O
+respiratory	B-PROC
+function	I-PROC
+,	O
+thus	O
+resulted	O
+into	O
+marked	O
+decrease	O
+of	O
+Sequential	O
+Organ	B-DISO
+Failure	I-DISO
+Assessment	O
+(	O
+SOFA	O
+)	O
+score	O
+and	O
+improved	O
+outcome	O
+:	O
+nine	O
+patients	O
+were	O
+able	O
+to	O
+be	O
+discharged	O
+from	O
+the	O
+hospital	O
+or	O
+bridged	O
+to	O
+successful	O
+liver	B-ANAT
+transplantation	O
+,	O
+the	O
+overall	O
+survival	O
+of	O
+24	O
+patients	O
+was	O
+37	O
+.	O
+5	O
+%.	O
+
+TITLE	O
+:	O
+Chest	B-ANAT
+radiographic	O
+findings	O
+of	O
+a	O
+case	O
+of	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+(	O
+SARS	B-DISO
+)	O
+in	O
+Singapore	O
+.	O
+
+As	O
+SARS	B-DISO
+is	O
+a	O
+contagious	O
+,	O
+rapidly	O
+progressive	O
+and	O
+potentially	O
+fatal	O
+condition	B-DISO
+,	O
+early	O
+diagnosis	O
+is	O
+crucial	O
+for	O
+prompt	O
+management	O
+and	O
+isolation	O
+of	O
+patients	O
+.	O
+
+Recognition	O
+of	O
+chest	B-ANAT
+radiographic	O
+findings	O
+aids	O
+in	O
+the	O
+early	O
+diagnosis	O
+and	O
+containment	O
+of	O
+SARS	B-DISO
+.	O
+
+TITLE	O
+:	O
+Zardaverine	B-CHED
+and	O
+aerosolised	O
+iloprost	B-CHED
+in	O
+a	O
+model	O
+of	O
+acute	B-DISO
+respiratory	I-DISO
+failure	I-DISO
+.	O
+
+To	O
+guarantee	O
+the	O
+availability	O
+of	O
+the	O
+equipment	O
+in	O
+the	O
+needed	O
+quantities	O
+,	O
+infection	B-DISO
+control	O
+authorities	O
+should	O
+take	O
+into	O
+account	O
+the	O
+number	O
+of	O
+isolation	O
+units	O
+needed	O
+and	O
+the	O
+length	O
+of	O
+time	O
+that	O
+containment	O
+measures	O
+will	O
+need	O
+to	O
+be	O
+in	O
+place	O
+.	O
+
+Our	O
+data	O
+suggested	O
+that	O
+these	O
+patients	O
+'	O
+immune	B-ANAT
+systems	I-ANAT
+were	O
+impaired	B-DISO
+during	O
+the	O
+course	O
+of	O
+SARS	B-DISO
+.	O
+
+All	O
+the	O
+animal	B-SPEC
+isolates	O
+retain	O
+a	O
+29	O
+-	O
+nucleotide	B-CHED
+sequence	O
+that	O
+is	O
+not	O
+found	O
+in	O
+most	O
+human	B-SPEC
+isolates	O
+.	O
+
+The	O
+detection	O
+of	O
+SCoV	O
+-	O
+like	O
+viruses	B-SPEC
+in	O
+small	O
+,	O
+live	O
+wild	O
+mammals	B-SPEC
+in	O
+a	O
+retail	O
+market	O
+indicates	O
+a	O
+route	O
+of	O
+interspecies	O
+transmission	O
+,	O
+although	O
+the	O
+natural	O
+reservoir	O
+is	O
+not	O
+known	O
+.	O
+
+CCl	B-DISO
+(	O
+4	O
+)	O
+treatment	O
+(	O
+1	O
+mL	O
+/	O
+kg	O
+,	O
+intraperitoneally	O
+)	O
+produced	O
+severe	O
+hepatic	B-ANAT
+injury	O
+in	O
+rats	B-SPEC
+as	O
+revealed	O
+by	O
+significant	O
+increases	O
+in	O
+serum	B-COMP
+alanine	B-PRGE
+transaminase	I-PRGE
+(	O
+ALT	B-FUNC
+)	O
+(	O
+EC	O
+2	O
+.	O
+6	O
+.	O
+1	O
+.	O
+2	O
+)	O
+activity	O
+and	O
+hepatic	B-ANAT
+malondialdehyde	B-CHED
+(	O
+MDA	B-CHED
+)	O
+content	O
+,	O
+severe	O
+liver	B-ANAT
+cell	I-ANAT
+injury	O
+,	O
+and	O
+increases	O
+in	O
+hepatic	B-ANAT
+tumor	B-PRGE
+necrosis	I-PRGE
+factor	I-PRGE
+-	I-PRGE
+alpha	I-PRGE
+(	O
+TNF	O
+-	O
+alpha	O
+)	O
+mRNA	B-PROC
+expression	B-PROC
+and	O
+DNA	B-FUNC
+binding	I-FUNC
+activity	O
+of	O
+nuclear	B-PRGE
+factor	I-PRGE
+-	I-PRGE
+kappa	I-PRGE
+B	I-PRGE
+(	O
+NF	B-PRGE
+-	I-PRGE
+kappa	I-PRGE
+B	I-PRGE
+).	O
+
+Following	O
+CCl	B-DISO
+(	O
+4	O
+)	O
+treatment	O
+,	O
+hepatic	B-ANAT
+HO	B-PRGE
+-	I-PRGE
+1	I-PRGE
+expression	B-PROC
+was	O
+markedly	O
+increased	O
+both	O
+at	O
+transcriptional	O
+and	O
+protein	B-CHED
+levels	O
+in	O
+hepatocytes	B-ANAT
+,	O
+especially	O
+around	O
+the	O
+central	B-ANAT
+vein	I-ANAT
+.	O
+
+These	O
+findings	O
+indicate	O
+that	O
+induction	O
+of	O
+HO	B-PRGE
+-	I-PRGE
+1	I-PRGE
+is	O
+an	O
+adaptive	O
+response	O
+to	O
+CCl	B-DISO
+(	O
+4	O
+)	O
+treatment	O
+,	O
+and	O
+it	O
+may	O
+be	O
+critical	O
+in	O
+the	O
+recovery	O
+of	O
+hepatocytes	B-ANAT
+from	O
+injury	O
+.	O
+
+Finally	O
+,	O
+we	O
+could	O
+,	O
+within	O
+the	O
+framework	O
+of	O
+the	O
+model	O
+,	O
+fix	O
+limits	O
+to	O
+the	O
+future	O
+development	B-PROC
+of	O
+the	O
+epidemic	O
+,	O
+allowing	O
+us	O
+to	O
+identify	O
+landmarks	O
+that	O
+may	O
+be	O
+useful	O
+to	O
+set	O
+up	O
+a	O
+monitoring	O
+system	O
+to	O
+follow	O
+the	O
+evolution	B-PROC
+of	O
+the	O
+epidemic	O
+.	O
+
+The	O
+model	O
+also	O
+suggests	O
+that	O
+there	O
+might	O
+exist	O
+a	O
+SARS	B-DISO
+precursor	O
+in	O
+a	O
+large	O
+reservoir	O
+,	O
+prompting	O
+for	O
+implementation	O
+of	O
+precautionary	O
+measures	O
+when	O
+the	O
+weather	O
+cools	O
+down	O
+.	O
+
+The	O
+induction	O
+of	O
+myelin	B-COMP
+-	O
+like	O
+membrane	B-COMP
+whorls	O
+was	O
+obvious	O
+within	O
+the	O
+same	O
+vacuoles	B-COMP
+as	O
+the	O
+core	O
+particles	O
+.	O
+
+The	O
+significance	O
+of	O
+this	O
+virus	B-SPEC
+-	O
+induced	O
+change	O
+is	O
+unknown	O
+at	O
+this	O
+stage	O
+.	O
+
+They	O
+were	O
+no	O
+longer	O
+in	O
+large	O
+vacuoles	B-COMP
+but	O
+packaged	O
+into	O
+smaller	O
+vacuoles	B-COMP
+in	O
+the	O
+cytoplasm	B-COMP
+,	O
+and	O
+occasionally	O
+in	O
+small	O
+groups	O
+.	O
+
+During	O
+the	O
+Taiwan	O
+epidemic	O
+of	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+(	O
+SARS	B-DISO
+),	O
+many	O
+health	O
+care	O
+workers	O
+were	O
+infected	O
+.	O
+
+These	O
+results	O
+appeared	O
+to	O
+indicate	O
+association	O
+of	O
+HLA	B-PRGE
+-	I-PRGE
+B	I-PRGE
+*	I-PRGE
+4601	O
+with	O
+the	O
+severity	O
+of	O
+SARS	B-DISO
+infection	B-DISO
+in	O
+Asian	O
+populations	O
+.	O
+
+EBC	O
+was	O
+collected	O
+and	O
+analyzed	O
+for	O
+NO	O
+(	O
+2	O
+)(-),	O
+interleukin	B-PRGE
+(	O
+IL	O
+)-	O
+6	O
+,	O
+and	O
+IL	B-FUNC
+-	I-FUNC
+8	I-FUNC
+.	O
+
+The	O
+ratio	O
+of	O
+EBC	O
+NO	O
+(	O
+2	O
+)(-)	O
+to	O
+VT	O
+is	O
+assumed	O
+to	O
+reflect	O
+NO	O
+(	O
+2	O
+)(-)	O
+release	B-PATH
+at	O
+a	O
+given	O
+VT	O
+.	O
+
+The	O
+ratio	O
+of	O
+EBC	O
+NO	O
+(	O
+2	O
+)(-)	O
+and	O
+the	O
+size	O
+of	O
+the	O
+VT	O
+correlated	O
+directly	O
+with	O
+lung	B-ANAT
+injury	O
+(	O
+AECC	O
+,	O
+r	O
+=	O
+0	O
+.	O
+66	O
+,	O
+p	O
+<	O
+0	O
+.	O
+0001	O
+;	O
+LISS	O
+,	O
+r	O
+=	O
+0	O
+.	O
+84	O
+,	O
+p	O
+<	O
+0	O
+.	O
+0001	O
+).	O
+
+Using	O
+recombinant	O
+virus	B-SPEC
+technology	O
+,	O
+we	O
+found	O
+that	O
+the	O
+differences	O
+between	O
+the	O
+two	O
+viruses	B-SPEC
+mapped	O
+to	O
+the	O
+spike	B-PRGE
+(	I-PRGE
+S	I-PRGE
+)	I-PRGE
+glycoprotein	I-PRGE
+and	O
+that	O
+the	O
+two	O
+S	O
+proteins	B-CHED
+differed	O
+at	O
+four	O
+amino	B-CHED
+acids	I-CHED
+.	O
+
+The	O
+increased	O
+neurovirulence	O
+mediated	O
+by	O
+the	O
+virus	O
+encoding	O
+glycine	B-CHED
+at	O
+position	O
+S310	O
+was	O
+not	O
+associated	O
+with	O
+a	O
+different	O
+tropism	B-PROC
+within	O
+the	O
+central	B-ANAT
+nervous	I-ANAT
+system	I-ANAT
+(	O
+CNS	B-CHED
+)	O
+but	O
+was	O
+associated	O
+with	O
+increased	O
+lateral	O
+spread	O
+in	O
+the	O
+CNS	B-CHED
+,	O
+leading	O
+to	O
+significantly	O
+higher	O
+brain	B-ANAT
+viral	O
+titers	O
+.	O
+
+Expression	B-PROC
+of	O
+Gpol	O
+deletion	O
+mutants	O
+established	O
+that	O
+the	O
+conserved	O
+enzymatic	O
+domains	O
+of	O
+Pol	B-PRGE
+were	O
+dispensable	O
+for	O
+replication	O
+complex	O
+association	O
+,	O
+but	O
+a	O
+38	O
+-	O
+amino	O
+-	O
+acid	O
+domain	O
+in	O
+the	O
+RdRp	B-FUNC
+unique	O
+region	O
+of	O
+Pol	B-PRGE
+was	O
+required	O
+.	O
+
+Some	O
+of	O
+these	O
+hnRNPs	O
+have	O
+previously	O
+been	O
+shown	O
+to	O
+replace	O
+hnRNP	B-PRGE
+A1	I-PRGE
+in	O
+regulating	O
+RNA	B-PROC
+splicing	I-PROC
+.	O
+
+hnRNP	B-ANAT
+A2	O
+/	O
+B1	O
+,	O
+which	O
+is	O
+predominantly	O
+localized	O
+to	O
+the	O
+nucleus	B-COMP
+and	O
+shuttles	O
+between	O
+the	O
+nucleus	B-COMP
+and	O
+the	O
+cytoplasm	B-COMP
+,	O
+was	O
+shown	O
+to	O
+relocalize	O
+to	O
+the	O
+cytoplasm	B-COMP
+in	O
+MHV	B-SPEC
+-	O
+infected	O
+CB3	O
+cells	B-COMP
+.	O
+
+TITLE	O
+:	O
+Canadian	O
+clinical	O
+practice	O
+guidelines	O
+for	O
+nutrition	B-PROC
+support	O
+in	O
+mechanically	O
+ventilated	O
+,	O
+critically	B-DISO
+ill	I-DISO
+adult	O
+patients	O
+.	O
+
+We	O
+recommend	O
+the	O
+use	O
+of	O
+a	O
+standard	O
+,	O
+polymeric	O
+enteral	O
+formula	O
+that	O
+is	O
+initiated	O
+within	O
+24	O
+to	O
+48	O
+hours	O
+after	O
+admission	O
+to	O
+ICU	O
+,	O
+that	O
+patients	O
+be	O
+cared	O
+for	O
+in	O
+the	O
+semirecumbent	O
+position	O
+,	O
+and	O
+that	O
+arginine	B-CHED
+-	O
+containing	O
+enteral	O
+products	O
+not	O
+be	O
+used	O
+.	O
+
+A	O
+glutamine	B-CHED
+-	O
+enriched	O
+formula	O
+should	O
+be	O
+considered	O
+for	O
+patients	O
+with	O
+severe	O
+burns	O
+and	O
+trauma	O
+.	O
+
+When	O
+PN	O
+is	O
+used	O
+,	O
+we	O
+recommend	O
+that	O
+it	O
+be	O
+supplemented	O
+with	O
+glutamine	B-CHED
+,	O
+where	O
+available	O
+.	O
+
+The	O
+artery	B-ANAT
+blood	B-PROC
+gas	B-ENZY
+analysis	O
+is	O
+useful	O
+for	O
+judging	O
+the	O
+conditions	O
+and	O
+prognosis	O
+of	O
+patients	O
+with	O
+SARS	B-DISO
+,	O
+and	O
+is	O
+beneficial	O
+for	O
+clinical	O
+treatment	O
+.	O
+
+RESULTS	O
+:	O
+Seven	O
+cases	O
+of	O
+SARS	B-DISO
+death	B-PROC
+patients	O
+were	O
+all	O
+infected	O
+secondly	O
+and	O
+5	O
+cases	O
+were	O
+polyinfection	B-DISO
+.	O
+
+The	O
+retrospective	O
+analyses	O
+were	O
+made	O
+on	O
+12	O
+dead	B-PROC
+cases	O
+and	O
+32	O
+recovered	O
+cases	O
+with	O
+SARS	B-DISO
+.	O
+
+The	O
+mean	O
+age	O
+was	O
+67	O
+years	O
+old	O
+in	O
+12	O
+dead	B-PROC
+cases	O
+with	O
+SARS	B-DISO
+and	O
+was	O
+42	O
+in	O
+recovered	O
+control	O
+group	O
+.	O
+
+In	O
+dead	B-PROC
+group	O
+,	O
+the	O
+occurrence	O
+rates	O
+of	O
+electrolyte	O
+maladjustment	B-DISO
+and	O
+kidney	B-ANAT
+injury	O
+were	O
+41	O
+.	O
+67	O
+percent	O
+.	O
+
+RESULTS	O
+:	O
+The	O
+mean	O
+age	O
+was	O
+67	O
+years	O
+old	O
+in	O
+12	O
+dead	B-PROC
+cases	O
+with	O
+SARS	B-DISO
+and	O
+was	O
+42	O
+in	O
+recovered	O
+control	O
+group	O
+.	O
+
+The	O
+prognosis	O
+of	O
+critical	O
+patients	O
+with	O
+the	O
+acute	O
+renal	B-ANAT
+dysfunction	O
+correlate	O
+with	O
+degree	O
+of	O
+basic	O
+diseases	O
+.	O
+
+Around	O
+5	O
+,	O
+000	O
+delegates	O
+from	O
+more	O
+than	O
+80	O
+countries	O
+attended	O
+the	O
+congress	O
+,	O
+which	O
+saw	O
+the	O
+presentation	O
+of	O
+more	O
+than	O
+400	O
+oral	B-ANAT
+communications	O
+and	O
+1	O
+,	O
+700	O
+posters	O
+.	O
+
+TITLE	O
+:	O
+The	O
+threat	O
+of	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+(	O
+SARS	B-DISO
+).	O
+
+It	O
+presents	O
+with	O
+non	O
+-	O
+specific	O
+signs	B-DISO
+and	I-DISO
+symptoms	I-DISO
+and	O
+because	O
+no	O
+definitive	O
+laboratory	O
+test	O
+is	O
+readily	O
+available	O
+,	O
+it	O
+poses	O
+a	O
+great	O
+risk	O
+to	O
+healthcare	O
+workers	O
+as	O
+well	O
+as	O
+difficulty	O
+in	O
+quarantine	O
+.	O
+
+Contents	O
+of	O
+the	O
+questionnaire	O
+would	O
+include	O
+:	O
+history	O
+of	O
+contact	O
+with	O
+SARS	B-DISO
+patient	O
+,	O
+route	O
+of	O
+infection	B-DISO
+,	O
+methods	O
+used	O
+for	O
+protection	O
+and	O
+so	O
+on	O
+.	O
+
+People	O
+with	O
+latent	B-DISO
+infection	I-DISO
+who	O
+had	O
+close	O
+contact	O
+with	O
+SARS	B-DISO
+patients	O
+might	O
+also	O
+serve	O
+as	O
+the	O
+possible	O
+source	O
+of	O
+transmission	O
+.	O
+
+Nosocomial	B-DISO
+infection	I-DISO
+appeared	O
+to	O
+be	O
+the	O
+main	O
+characteristic	O
+of	O
+the	O
+SARS	B-DISO
+epidemic	O
+in	O
+the	O
+early	O
+stage	O
+of	O
+this	O
+hospital	O
+.	O
+
+Other	O
+than	O
+close	O
+contact	O
+and	O
+near	O
+space	O
+airborne	O
+transmission	O
+of	O
+SARS	B-DISO
+virus	B-SPEC
+,	O
+the	O
+possibility	O
+of	O
+long	O
+-	O
+distance	O
+aerosol	O
+transmission	O
+called	O
+for	O
+further	O
+epidemiological	O
+and	O
+experimental	O
+studies	O
+in	O
+the	O
+future	O
+.	O
+
+TITLE	O
+:	O
+[	O
+Analysis	O
+on	O
+the	O
+epidemiological	O
+features	O
+and	O
+the	O
+transmission	O
+of	O
+an	O
+imported	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+case	O
+in	O
+Beijing	O
+].	O
+
+ABSTRACT	O
+:	O
+To	O
+explore	O
+the	O
+characteristics	O
+of	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+(	O
+SARS	B-DISO
+)	O
+transmission	O
+in	O
+the	O
+population	O
+base	O
+on	O
+analyzing	O
+the	O
+first	O
+imported	O
+case	O
+and	O
+the	O
+chains	O
+of	O
+transmission	O
+.	O
+
+CONCLUSIONS	O
+:	O
+One	O
+of	O
+the	O
+epidemiological	O
+characteristics	O
+of	O
+SARS	B-DISO
+in	O
+Beijing	O
+was	O
+noticed	O
+that	O
+the	O
+disease	O
+clustered	O
+in	O
+families	O
+and	O
+hospitals	O
+.	O
+
+Four	O
+hundred	O
+and	O
+three	O
+SARS	B-DISO
+cases	O
+were	O
+identified	O
+and	O
+27	O
+of	O
+them	O
+died	B-PROC
+from	O
+March	O
+18	O
+and	O
+May	O
+31	O
+,	O
+2003	O
+.	O
+
+The	O
+intensity	O
+of	O
+SARS	B-DISO
+epidemic	O
+among	O
+the	O
+residents	O
+of	O
+Haidian	O
+district	O
+was	O
+recognized	O
+as	O
+similar	O
+to	O
+the	O
+other	O
+parts	O
+of	O
+Beijing	O
+.	O
+
+CONCLUSIONS	O
+:	O
+The	O
+intensity	O
+of	O
+SARS	B-DISO
+epidemic	O
+among	O
+the	O
+residents	O
+of	O
+Haidian	O
+district	O
+was	O
+recognized	O
+as	O
+similar	O
+to	O
+the	O
+other	O
+parts	O
+of	O
+Beijing	O
+.	O
+
+ABSTRACT	O
+:	O
+To	O
+analyze	O
+the	O
+epidemiologic	O
+characteristics	O
+of	O
+severe	O
+acute	O
+respiratory	O
+syndrome	O
+(	O
+SARS	B-DISO
+)	O
+and	O
+to	O
+evaluate	O
+the	O
+effectiveness	O
+on	O
+its	O
+major	O
+control	O
+measures	O
+in	O
+Tianjn	O
+.	O
+
+Among	O
+the	O
+10	O
+index	O
+cases	O
+,	O
+only	O
+the	O
+super	O
+spreader	O
+and	O
+another	O
+one	O
+index	O
+case	O
+transmitted	B-DISO
+the	O
+virus	B-SPEC
+to	O
+their	O
+contacts	O
+but	O
+the	O
+rest	B-FUNC
+of	O
+index	O
+cases	O
+did	O
+not	O
+cause	O
+any	O
+secondary	B-DISO
+infection	I-DISO
+.	O
+
+Antibiotherapy	O
+was	O
+not	O
+conform	O
+to	O
+current	O
+guidelines	O
+in	O
+20	O
+%	O
+of	O
+cases	O
+and	O
+hence	O
+led	O
+to	O
+90	O
+%	O
+death	B-PROC
+.	O
+
+ABSTRACT	O
+:	O
+Twenty	O
+eight	O
+pyrrolo	O
+[	O
+1	O
+,	O
+2	O
+-	O
+a	O
+]	O
+quinoxalines	B-CHED
+bearing	O
+at	O
+position	O
+4	O
+various	O
+substituents	O
+related	O
+to	O
+the	O
+moieties	O
+present	O
+in	O
+classical	O
+and	O
+non	O
+classical	O
+antifolic	O
+agents	O
+were	O
+prepared	O
+and	O
+evaluated	O
+in	O
+vitro	O
+for	O
+antiproliferative	O
+activity	O
+.	O
+
+More	O
+recently	O
+,	O
+a	O
+compound	O
+of	O
+classical	O
+antifolate	O
+type	O
+has	O
+been	O
+reported	O
+to	O
+be	O
+a	O
+potent	O
+inhibitor	B-CHED
+of	O
+hDHFR	O
+in	O
+vitro	O
+(	O
+Farmaco	B-CHED
+58	O
+(	O
+2003	O
+)	O
+51	O
+).	O
+
+Factors	O
+that	O
+influence	O
+whether	O
+FCoV	O
+establishes	O
+lifelong	O
+infection	B-DISO
+in	O
+some	O
+cats	B-SPEC
+and	O
+not	O
+others	O
+are	O
+determined	O
+mainly	O
+by	O
+the	O
+host	B-PROC
+response	I-PROC
+to	O
+infection	B-DISO
+.	O
+
+The	O
+disease	O
+has	O
+been	O
+etiologically	O
+linked	O
+to	O
+a	O
+novel	B-SPEC
+coronavirus	I-SPEC
+that	O
+has	O
+been	O
+named	O
+the	O
+SARS	B-DISO
+-	I-DISO
+associated	I-DISO
+coronavirus	I-DISO
+(	O
+SARS	B-DISO
+-	O
+CoV	O
+),	O
+whose	O
+genome	O
+was	O
+recently	O
+sequenced	O
+.	O
+
+The	O
+protein	B-CHED
+responsible	O
+for	O
+viral	B-PROC
+-	I-PROC
+induced	I-PROC
+membrane	I-PROC
+fusion	I-PROC
+of	O
+HIV	B-SPEC
+-	I-SPEC
+1	I-SPEC
+(	O
+gp41	O
+)	O
+differs	O
+in	O
+length	O
+,	O
+and	O
+has	O
+no	O
+sequence	O
+homology	O
+with	O
+S2	O
+.	O
+
+These	O
+include	O
+(	O
+1	O
+)	O
+an	O
+N	O
+-	O
+terminal	O
+leucine	B-CHED
+/	O
+isoleucine	B-CHED
+zipper	O
+-	O
+like	O
+sequence	O
+,	O
+and	O
+(	O
+2	O
+)	O
+a	O
+C	O
+-	O
+terminal	O
+heptad	O
+repeat	O
+located	O
+upstream	O
+of	O
+(	O
+3	O
+)	O
+an	O
+aromatic	O
+residue	O
+-	O
+rich	O
+region	O
+juxtaposed	O
+to	O
+the	O
+(	O
+4	O
+)	O
+transmembrane	B-COMP
+segment	O
+.	O
+
+These	O
+patterns	O
+were	O
+subsequently	O
+used	O
+to	O
+classify	O
+the	O
+selected	O
+viruses	B-SPEC
+.	O
+
+RESULTS	O
+:	O
+Both	O
+approaches	O
+yielded	O
+relationship	O
+outcomes	O
+that	O
+are	O
+consistent	O
+with	O
+the	O
+known	O
+virus	B-SPEC
+classification	O
+.	O
+
+TITLE	O
+:	O
+[	O
+Dynamic	O
+analysis	O
+of	O
+TCM	O
+syndrome	B-DISO
+in	O
+63	O
+patients	O
+of	O
+SARS	B-DISO
+].	O
+
+In	O
+the	O
+early	O
+stage	O
+,	O
+patients	O
+'	O
+tongue	B-ANAT
+was	O
+pink	O
+or	O
+red	O
+in	O
+tongue	B-ANAT
+tip	I-ANAT
+,	O
+with	O
+thin	O
+-	O
+white	O
+,	O
+white	O
+-	O
+greasy	O
+or	O
+yellow	O
+-	O
+greasy	O
+coating	O
+;	O
+in	O
+middle	O
+stage	O
+,	O
+tongue	B-ANAT
+in	O
+most	O
+patients	O
+were	O
+red	O
+,	O
+with	O
+white	O
+-	O
+greasy	O
+or	O
+yellow	O
+-	O
+thick	O
+-	O
+greasy	O
+coating	O
+;	O
+in	O
+recovery	O
+stage	O
+,	O
+tongues	B-ANAT
+of	O
+patients	O
+were	O
+mostly	O
+pink	O
+or	O
+red	O
+in	O
+tongue	B-ANAT
+tip	I-ANAT
+,	O
+few	O
+were	O
+dark	O
+purple	O
+,	O
+with	O
+thin	O
+-	O
+white	O
+or	O
+white	O
+-	O
+greasy	O
+,	O
+occasionally	O
+yellow	O
+-	O
+greasy	O
+coating	O
+.	O
+
+CD3	B-PRGE
+,	O
+CD4	B-PRGE
+and	O
+CD8	B-PRGE
+in	O
+20	O
+patients	O
+,	O
+which	O
+were	O
+lower	O
+than	O
+the	O
+normal	O
+range	O
+when	O
+hospitalization	O
+,	O
+began	O
+to	O
+increase	O
+3	O
+days	O
+later	O
+and	O
+gradually	O
+recovered	O
+to	O
+the	O
+normal	O
+in	O
+6	O
+-	O
+10	O
+days	O
+.	O
+
+CONCLUSIONS	O
+:	O
+ICWM	O
+can	O
+improve	O
+the	O
+symptoms	O
+and	O
+regulate	O
+the	O
+immune	B-PROC
+function	I-PROC
+in	O
+uncertain	O
+SARS	B-DISO
+patients	O
+.	O
+
+Histological	O
+examination	O
+of	O
+the	O
+heart	B-ANAT
+in	O
+the	O
+patient	O
+with	O
+the	O
+lowest	O
+EF	O
+(	O
+30	O
+.	O
+2	O
+%)	O
+revealed	O
+no	O
+interstitial	B-ANAT
+lymphocytic	B-DISO
+infiltrate	I-DISO
+or	O
+myocyte	B-ANAT
+necrosis	B-PROC
+.	O
+
+This	O
+impairment	B-DISO
+may	O
+be	O
+reversible	O
+on	O
+clinical	O
+recovery	O
+.	O
+
+The	O
+development	B-PROC
+of	O
+a	O
+vaccine	O
+to	O
+prevent	O
+SARS	B-DISO
+should	O
+be	O
+pursued	O
+with	O
+the	O
+same	O
+urgency	O
+and	O
+cooperative	O
+spirit	O
+,	O
+as	O
+SARS	B-DISO
+is	O
+highly	O
+lethal	O
+and	O
+,	O
+if	O
+not	O
+controlled	O
+during	O
+the	O
+first	O
+few	O
+generations	O
+of	O
+transmission	O
+,	O
+is	O
+likely	O
+to	O
+become	O
+endemic	O
+in	O
+regions	O
+of	O
+the	O
+world	O
+where	O
+health	O
+-	O
+care	O
+infrastructure	O
+is	O
+underdeveloped	O
+and	O
+epidemiological	O
+control	O
+measures	O
+are	O
+weak	O
+.	O
+
+Cases	O
+of	O
+more	O
+than	O
+10	O
+days	O
+'	O
+duration	O
+exhibited	O
+organizing	O
+-	O
+phase	O
+DAD	O
+,	O
+type	B-ANAT
+II	I-ANAT
+pneumocyte	I-ANAT
+hyperplasia	B-DISO
+,	O
+squamous	B-DISO
+metaplasia	I-DISO
+,	O
+multinucleated	B-ANAT
+giant	I-ANAT
+cells	B-COMP
+,	O
+and	O
+acute	B-DISO
+bronchopneumonia	I-DISO
+.	O
+
+From	O
+personalized	O
+medicine	B-CHED
+to	O
+extraterrestrial	O
+life	O
+.	O
+
+TITLE	O
+:	O
+Fas	B-PRGE
+ligand	B-PROC
+-	O
+induced	O
+murine	B-SPEC
+pulmonary	B-DISO
+inflammation	I-DISO
+is	O
+reduced	O
+by	O
+a	O
+stable	O
+decoy	O
+receptor	O
+3	O
+analogue	O
+.	O
+
+ABSTRACT	O
+:	O
+Severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+(	O
+SARS	O
+)	O
+is	O
+a	O
+severe	O
+pulmonary	B-DISO
+infection	I-DISO
+that	O
+has	O
+been	O
+identified	O
+in	O
+multiple	O
+outbreaks	O
+around	O
+the	O
+world	O
+after	O
+emerging	O
+from	O
+mainland	O
+China	O
+in	O
+early	O
+2003	O
+.	O
+
+The	O
+syndrome	B-DISO
+is	O
+caused	O
+by	O
+SARS	B-DISO
+-	I-DISO
+associated	I-DISO
+coronavirus	I-DISO
+,	O
+a	O
+novel	O
+human	B-SPEC
+infection	B-DISO
+.	O
+
+IL	B-FUNC
+-	I-FUNC
+8	I-FUNC
+came	O
+back	B-ANAT
+to	O
+normal	O
+control	O
+levels	O
+one	O
+month	O
+after	O
+discharged	O
+from	O
+hospital	O
+.	O
+
+Meanwhile	O
+,	O
+SARS	B-DISO
+patients	O
+also	O
+showed	O
+high	O
+a	O
+TNF	B-PRGE
+alpha	I-PRGE
+level	O
+(	O
+median	O
+23	O
+.	O
+12	O
+ng	O
+/	O
+L	O
+)	O
+(	O
+P	O
+<	O
+0	O
+.	O
+01	O
+)	O
+at	O
+the	O
+second	O
+week	O
+and	O
+reached	O
+a	O
+peak	O
+median	O
+of	O
+136	O
+.	O
+35	O
+ng	O
+/	O
+L	O
+(	O
+P	O
+<	O
+0	O
+.	O
+05	O
+)	O
+at	O
+the	O
+third	O
+an	O
+fourth	O
+weeks	O
+.	O
+
+One	O
+month	O
+after	O
+discharged	O
+from	O
+hospital	O
+the	O
+plasma	B-ANAT
+TNF	B-PRGE
+alpha	I-PRGE
+concentration	O
+fell	O
+down	O
+to	O
+a	O
+median	O
+of	O
+94	O
+.	O
+88	O
+ng	O
+/	O
+L	O
+,	O
+but	O
+it	O
+was	O
+still	O
+much	O
+higher	O
+than	O
+normal	O
+controls	O
+(	O
+3	O
+.	O
+77	O
+ng	O
+/	O
+L	O
+,	O
+P	O
+<	O
+0	O
+.	O
+01	O
+).	O
+
+Intestinal	B-ANAT
+biopsy	O
+specimens	O
+obtained	O
+by	O
+colonoscopy	O
+or	O
+autopsy	O
+showed	O
+minimal	O
+architectural	O
+disruption	O
+but	O
+the	O
+presence	O
+of	O
+active	O
+viral	B-PROC
+replication	I-PROC
+within	O
+both	O
+the	O
+small	O
+and	O
+large	B-ANAT
+intestine	I-ANAT
+.	O
+
+China	O
+will	O
+also	O
+be	O
+able	O
+to	O
+contribute	O
+key	O
+data	O
+about	O
+how	O
+the	O
+causative	O
+agent	O
+is	O
+transmitted	B-DISO
+and	O
+how	O
+it	O
+is	O
+evolving	O
+,	O
+as	O
+well	O
+as	O
+identifying	O
+pivotal	O
+factors	O
+influencing	O
+disease	O
+outcome	O
+.	O
+
+ABSTRACT	O
+:	O
+Severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+(	O
+SARS	B-DISO
+)	O
+is	O
+now	O
+a	O
+global	O
+public	O
+health	O
+threat	O
+with	O
+many	O
+medical	O
+,	O
+ethical	O
+,	O
+social	O
+,	O
+economic	O
+,	O
+political	O
+,	O
+and	O
+legal	O
+implications	O
+.	O
+
+TITLE	O
+:	O
+Microbiologic	O
+characteristics	O
+,	O
+serologic	O
+responses	O
+,	O
+and	O
+clinical	O
+manifestations	O
+in	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+,	O
+Taiwan	O
+.	O
+
+ABSTRACT	O
+:	O
+The	O
+genome	O
+of	O
+one	O
+Taiwanese	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+-	O
+associated	O
+coronavirus	B-SPEC
+(	O
+SARS	B-DISO
+-	O
+CoV	O
+)	O
+strain	O
+(	O
+TW1	O
+)	O
+was	O
+29	O
+,	O
+729	O
+nt	O
+in	O
+length	O
+.	O
+
+TITLE	O
+:	O
+Safe	O
+tracheostomy	O
+for	O
+patients	O
+with	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+.	O
+
+ABSTRACT	O
+:	O
+The	O
+sudden	O
+appearance	O
+and	O
+potential	O
+lethality	O
+of	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+associated	O
+coronavirus	B-SPEC
+(	O
+SARS	B-DISO
+-	O
+CoV	O
+)	O
+in	O
+humans	B-SPEC
+has	O
+focused	O
+attention	O
+on	O
+understanding	O
+its	O
+origins	O
+.	O
+
+Conservation	O
+of	O
+RDRP	B-FUNC
+allowed	O
+us	O
+to	O
+use	O
+a	O
+set	O
+of	O
+Arteriviridae	B-SPEC
+taxa	O
+to	O
+root	B-ANAT
+the	O
+Coronaviridae	B-SPEC
+phylogeny	O
+.	O
+
+In	O
+four	O
+experiments	O
+,	O
+29	O
+-	O
+day	O
+-	O
+old	O
+female	O
+commercial	O
+broilers	O
+housed	O
+in	O
+isolators	O
+,	O
+were	O
+infected	O
+intratracheally	O
+and	O
+oculonasally	O
+with	O
+IB	O
+vaccine	O
+strains	O
+(	O
+H120	O
+and	O
+H52	O
+)	O
+or	O
+virulent	O
+IB	O
+field	O
+strains	O
+(	O
+D387	O
+and	O
+M41	O
+)	O
+(	O
+4	O
+.	O
+8	O
+or	O
+6	O
+.	O
+8	O
+log	O
+(	O
+10	O
+)	O
+median	O
+embryo	B-ANAT
+infective	O
+dose	O
+,	O
+per	O
+broiler	O
+).	O
+
+Apart	O
+from	O
+H52	O
+and	O
+D387	O
+,	O
+differences	O
+between	O
+IBV	B-SPEC
+strains	O
+were	O
+significant	O
+.	O
+
+ABSTRACT	O
+:	O
+As	O
+an	O
+immunogen	B-CHED
+of	O
+the	O
+coronavirus	B-SPEC
+,	O
+the	O
+nucleoprotein	O
+(	O
+N	O
+)	O
+is	O
+a	O
+potential	O
+antigen	B-CHED
+for	O
+the	O
+serological	O
+monitoring	O
+of	O
+infectious	B-DISO
+bronchitis	B-DISO
+virus	B-SPEC
+(	O
+IBV	B-SPEC
+).	O
+
+Our	O
+data	O
+indicated	O
+that	O
+N	B-PRGE
+protein	I-PRGE
+purified	O
+from	O
+E	B-SPEC
+.	I-SPEC
+coli	I-SPEC
+was	O
+more	O
+sensitive	O
+to	O
+anti	O
+-	O
+IBV	B-SPEC
+serum	B-COMP
+than	O
+the	O
+protein	B-CHED
+from	O
+Sf9	O
+cells	B-COMP
+.	O
+
+During	O
+the	O
+community	O
+outbreak	O
+in	O
+Hong	O
+Kong	O
+,	O
+5	O
+liveborn	O
+infants	O
+were	O
+born	O
+to	O
+pregnant	O
+women	O
+with	O
+SARS	B-DISO
+.	O
+
+ABSTRACT	O
+:	O
+An	O
+outbreak	O
+of	O
+severe	O
+acute	O
+respiratory	O
+syndrome	O
+(	O
+SARS	B-DISO
+)	O
+occurred	O
+in	O
+the	O
+greater	O
+Toronto	O
+area	O
+between	O
+February	O
+and	O
+June	O
+2003	O
+.	O
+
+A	O
+prospective	O
+investigational	O
+study	O
+protocol	O
+was	O
+established	O
+for	O
+the	O
+management	O
+of	O
+children	O
+with	O
+a	O
+presumptive	O
+diagnosis	O
+of	O
+suspect	O
+or	O
+probable	O
+SARS	B-DISO
+.	O
+
+Twenty	O
+-	O
+five	O
+children	O
+were	O
+included	O
+;	O
+10	O
+were	O
+classified	O
+as	O
+probable	O
+SARS	B-DISO
+and	O
+5	O
+were	O
+classified	O
+as	O
+suspect	O
+SARS	B-DISO
+,	O
+and	O
+in	O
+10	O
+another	O
+cause	O
+was	O
+identified	O
+.	O
+
+The	O
+predominant	O
+clinical	O
+manifestations	O
+of	O
+probable	O
+cases	O
+were	O
+fever	B-PROC
+,	O
+cough	B-DISO
+,	O
+and	O
+rhinorrhea	B-DISO
+.	O
+
+ABSTRACT	O
+:	O
+Although	O
+information	O
+on	O
+efficacy	O
+and	O
+adverse	O
+drug	O
+reactions	O
+is	O
+lacking	O
+,	O
+ribavirin	B-CHED
+has	O
+been	O
+used	O
+empirically	O
+for	O
+the	O
+treatment	O
+of	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+(	O
+SARS	B-DISO
+).	O
+
+We	O
+report	O
+confirmed	O
+persistent	O
+transmission	O
+of	O
+MHV	B-SPEC
+from	O
+tumor	B-FUNC
+necrosis	I-FUNC
+factor	I-FUNC
+(	O
+TNF	B-FUNC
+)	O
+knockout	O
+mice	B-SPEC
+,	O
+B6	O
+.	O
+129S1	O
+-	O
+Tnftm1Lj	O
+(	O
+TNF	B-FUNC
+-/-),	O
+to	O
+nude	O
+and	O
+immunocompetent	O
+sentinel	O
+mice	B-SPEC
+over	O
+a	O
+period	O
+of	O
+five	O
+months	O
+.	O
+
+In	O
+addition	O
+,	O
+immunocompetent	O
+mice	O
+had	O
+evidence	O
+of	O
+seroconversion	O
+to	O
+MHV	B-SPEC
+infection	B-DISO
+and	O
+RT	O
+-	O
+PCR	O
+-	O
+positive	O
+fecal	B-ANAT
+and	O
+ascending	B-ANAT
+colon	I-ANAT
+specimens	O
+after	O
+only	O
+24	O
+h	O
+of	O
+direct	O
+contact	O
+with	O
+the	O
+TNF	B-PRGE
+-/-	O
+mice	B-SPEC
+.	O
+
+To	O
+restrain	O
+further	O
+outbreak	O
+of	O
+SARS	B-DISO
+,	O
+the	O
+World	O
+Health	O
+Organization	O
+has	O
+posted	O
+several	O
+pairs	O
+of	O
+polymerase	O
+chain	O
+reaction	O
+(	O
+PCR	O
+)	O
+primers	O
+for	O
+early	O
+diagnosis	O
+and	O
+urged	O
+more	O
+research	O
+to	O
+be	O
+done	O
+on	O
+PCR	O
+protocols	O
+.	O
+
+TITLE	O
+:	O
+Dynamic	O
+changes	O
+in	O
+blood	B-ANAT
+cytokine	O
+levels	O
+as	O
+clinical	O
+indicators	O
+in	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+.	O
+
+The	O
+mean	O
+concentration	O
+of	O
+serum	B-PRGE
+IL	B-FUNC
+-	I-FUNC
+18	I-FUNC
+in	O
+SARS	B-DISO
+patients	O
+was	O
+significantly	O
+lower	O
+than	O
+that	O
+of	O
+the	O
+control	O
+group	O
+during	O
+all	O
+clinical	O
+courses	O
+(	O
+P	O
+<	O
+0	O
+.	O
+05	O
+).	O
+
+The	O
+mean	O
+concentration	O
+of	O
+serum	B-COMP
+TGF	B-PRGE
+-	I-PRGE
+beta1	I-PRGE
+in	O
+SARS	B-DISO
+patients	O
+was	O
+higher	O
+than	O
+that	O
+of	O
+the	O
+control	O
+group	O
+during	O
+all	O
+clinical	O
+courses	O
+.	O
+
+RESULTS	O
+:	O
+By	O
+bioinformatics	O
+processing	O
+and	O
+analysis	O
+,	O
+the	O
+5	O
+loci	O
+nucleotides	B-CHED
+at	O
+ZJ01	O
+genome	O
+were	O
+found	O
+being	O
+T	O
+,	O
+T	O
+,	O
+G	O
+,	O
+T	O
+and	O
+T	O
+,	O
+respectively	O
+.	O
+
+Numbers	O
+of	O
+SARS	B-DISO
+cases	O
+in	O
+the	O
+wards	O
+mentioned	O
+above	O
+were	O
+1	O
+,	O
+1	O
+,	O
+1	O
+and	O
+96	O
+,	O
+respectively	O
+.	O
+
+TITLE	O
+:	O
+A	O
+system	O
+of	O
+protein	B-PROC
+target	I-PROC
+sequences	O
+for	O
+anti	O
+-	O
+RNA	O
+-	O
+viral	O
+chemotherapy	O
+by	O
+a	O
+vitamin	B-CHED
+B6	I-CHED
+-	O
+derived	O
+zinc	O
+-	O
+chelating	B-PROC
+trioxa	O
+-	O
+adamantane	B-CHED
+-	O
+triol	B-CHED
+.	O
+
+Brown	O
+BN	O
+is	O
+finally	O
+achieved	O
+by	O
+base	O
+-	O
+catalyzed	O
+elimination	O
+of	O
+hydrogen	B-CHED
+chloride	I-CHED
+from	O
+(	O
+4	O
+'	O
+RS	O
+)-	O
+4	O
+'-	O
+chloro	B-CHED
+-	O
+1	O
+',	O
+4	O
+'-	O
+dihydrobananin	O
+.	O
+
+40	O
+hospital	O
+workers	O
+infected	O
+with	O
+SARS	B-DISO
+-	I-DISO
+associated	I-DISO
+coronavirus	I-DISO
+over	O
+a	O
+6	O
+-	O
+week	O
+period	O
+(	O
+25	O
+March	O
+through	O
+5	O
+May	O
+2003	O
+).	O
+
+CONCLUSIONS	O
+:	O
+Before	O
+isolation	O
+of	O
+all	O
+patients	O
+with	O
+clinically	O
+confirmed	O
+or	O
+suspected	O
+SARS	B-DISO
+,	O
+routine	O
+use	O
+of	O
+several	O
+protective	O
+devices	O
+,	O
+and	O
+training	O
+of	O
+staff	O
+in	O
+infection	B-DISO
+control	O
+,	O
+many	O
+health	O
+care	O
+workers	O
+were	O
+infected	O
+with	O
+SARS	B-DISO
+from	O
+patients	O
+with	O
+unsuspected	O
+cases	O
+.	O
+
+Finally	O
+,	O
+SARS	B-DISO
+also	O
+emphasized	O
+the	O
+importance	O
+of	O
+the	O
+duty	O
+of	O
+health	O
+care	O
+administrators	O
+and	O
+senior	O
+physicians	O
+to	O
+rapidly	O
+institute	O
+procedures	O
+to	O
+maximize	O
+the	O
+safety	O
+of	O
+frontline	O
+physicians	O
+and	O
+nurses	O
+.	O
+
+We	O
+cloned	O
+some	O
+expressed	B-PROC
+sequence	O
+tags	O
+and	O
+identified	O
+one	O
+complementary	O
+DNA	O
+fragment	O
+.	O
+
+The	O
+expression	B-PROC
+of	O
+rat	B-PRGE
+NIP3L	I-PRGE
+identified	O
+in	O
+this	O
+study	O
+increased	O
+slightly	O
+in	O
+the	O
+pancreas	B-ANAT
+after	O
+induction	O
+of	O
+acute	B-DISO
+pancreatitis	I-DISO
+but	O
+showed	O
+a	O
+marked	O
+increase	O
+in	O
+the	O
+lung	B-ANAT
+by	O
+both	O
+Northern	O
+and	O
+Western	O
+blot	O
+analysis	O
+.	O
+
+TITLE	O
+:	O
+[	O
+Severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+--	O
+SARS	B-DISO
+].	O
+
+This	O
+virus	B-SPEC
+was	O
+possibly	O
+transmitted	B-DISO
+from	O
+an	O
+animal	B-SPEC
+reservoir	O
+to	O
+humans	B-SPEC
+,	O
+and	O
+from	O
+February	O
+2003	O
+,	O
+the	O
+epidemic	O
+was	O
+spread	O
+internationally	O
+by	O
+further	O
+person	O
+-	O
+to	O
+-	O
+person	O
+transmission	O
+.	O
+
+Thirty	O
+six	O
+caveolin	B-PRGE
+-	I-PRGE
+binding	I-PRGE
+motifs	I-PRGE
+in	O
+the	O
+SARS	B-PRGE
+-	I-PRGE
+CoV	I-PRGE
+proteins	B-CHED
+have	O
+been	O
+mapped	O
+out	O
+using	O
+bioinformatics	O
+analysis	O
+tools	O
+.	O
+
+Of	O
+442973	O
+air	B-CHED
+passengers	O
+screened	O
+after	O
+measures	O
+were	O
+implemented	O
+,	O
+136	O
+were	O
+sent	O
+to	O
+a	O
+designated	O
+hospital	O
+for	O
+further	O
+SARS	B-DISO
+screening	O
+;	O
+none	O
+was	O
+diagnosed	O
+as	O
+having	O
+SARS	B-DISO
+.	O
+
+The	O
+SARS	B-DISO
+outbreak	O
+in	O
+Singapore	O
+can	O
+be	O
+traced	O
+to	O
+the	O
+first	O
+imported	O
+case	O
+.	O
+
+A	O
+total	O
+of	O
+303	O
+clinical	O
+specimens	O
+were	O
+collected	O
+from	O
+163	O
+patients	O
+suspected	O
+to	O
+have	O
+SARS	B-DISO
+.	O
+
+For	O
+patients	O
+confirmed	O
+to	O
+have	O
+SARS	B-DISO
+CoV	O
+and	O
+from	O
+whom	O
+two	O
+or	O
+more	O
+respiratory	O
+specimens	O
+were	O
+collected	O
+,	O
+testing	O
+the	O
+second	O
+specimen	O
+increased	O
+the	O
+sensitivity	O
+from	O
+64	O
+and	O
+71	O
+%	O
+to	O
+75	O
+and	O
+79	O
+%	O
+for	O
+the	O
+WHO	O
+-	O
+HKU	O
+and	O
+WHO	O
+-	O
+Hamburg	O
+RT	O
+-	O
+PCR	O
+assays	O
+,	O
+respectively	O
+.	O
+
+TITLE	O
+:	O
+Churg	B-DISO
+-	I-DISO
+Strauss	I-DISO
+syndrome	I-DISO
+with	O
+myocarditis	B-DISO
+manifesting	O
+as	O
+acute	B-DISO
+myocardial	I-DISO
+infarction	I-DISO
+with	O
+cardiogenic	B-DISO
+shock	I-DISO
+:	O
+case	O
+report	O
+and	O
+review	O
+of	O
+the	O
+literature	O
+.	O
+
+Treatment	O
+with	O
+a	O
+high	O
+dose	O
+of	O
+corticosteroids	B-CHED
+was	O
+initiated	O
+.	O
+
+However	O
+,	O
+clinical	O
+improvement	O
+has	O
+been	O
+demonstrated	O
+in	O
+conditions	O
+such	O
+as	O
+haemophilia	B-DISO
+[	O
+82	O
+],	O
+cardiovascular	B-DISO
+disease	I-DISO
+[	O
+83	O
+],	O
+head	B-DISO
+and	I-DISO
+neck	I-DISO
+cancer	B-SPEC
+[	O
+84	O
+]	O
+and	O
+X	B-DISO
+-	I-DISO
+linked	I-DISO
+severe	I-DISO
+combined	I-DISO
+immunodeficiency	I-DISO
+disease	O
+[	O
+85	O
+].	O
+
+The	O
+lack	O
+of	O
+success	O
+of	O
+pulmonary	B-ANAT
+gene	O
+therapy	O
+is	O
+due	O
+,	O
+in	O
+part	O
+on	O
+the	O
+physical	O
+barriers	O
+to	O
+transfection	B-PROC
+perfected	O
+by	O
+the	O
+lung	B-ANAT
+to	O
+prevent	O
+toxicity	O
+from	O
+inhaled	B-PROC
+particles	O
+,	O
+and	O
+partly	O
+due	O
+to	O
+the	O
+poor	O
+transfection	B-PROC
+efficiency	O
+of	O
+non	O
+-	O
+viral	O
+systems	O
+,	O
+and	O
+the	O
+immunogenicity	O
+of	O
+viral	O
+systems	O
+,	O
+of	O
+gene	O
+transfer	O
+.	O
+
+With	O
+continued	O
+improvements	O
+in	O
+the	O
+properties	O
+of	O
+both	O
+viral	O
+and	O
+non	O
+-	O
+viral	O
+gene	B-PROC
+delivery	I-PROC
+systems	O
+leading	O
+to	O
+improved	O
+transfection	B-PROC
+efficiency	O
+with	O
+reduced	O
+toxicity	O
+,	O
+as	O
+well	O
+as	O
+the	O
+development	B-PROC
+of	O
+strategies	O
+aimed	O
+at	O
+reducing	O
+the	O
+physical	O
+barriers	O
+to	O
+pulmonary	B-ANAT
+transfection	B-PROC
+,	O
+and	O
+targeting	B-PROC
+gene	B-PROC
+delivery	I-PROC
+systems	O
+to	O
+the	O
+site	O
+of	O
+injury	O
+,	O
+it	O
+is	O
+likely	O
+that	O
+pulmonary	B-ANAT
+gene	O
+therapy	O
+will	O
+be	O
+used	O
+successfully	O
+to	O
+ameliorate	O
+a	O
+number	O
+of	O
+devastating	O
+pulmonary	B-ANAT
+conditions	O
+.	O
+
+In	O
+France	O
+,	O
+5	O
+probable	O
+cases	O
+of	O
+SARS	B-DISO
+were	O
+diagnosed	O
+until	O
+May	O
+2003	O
+.	O
+
+This	O
+54	O
+year	O
+-	O
+old	O
+man	B-CHED
+was	O
+infected	O
+during	O
+the	O
+Air	B-CHED
+France	O
+flight	B-PROC
+from	O
+Hanoi	O
+to	O
+Paris	B-SPEC
+via	O
+Bangkok	O
+by	O
+the	O
+index	O
+case	O
+,	O
+who	O
+himself	O
+had	O
+been	O
+contaminated	O
+at	O
+the	O
+French	O
+hospital	O
+in	O
+Hanoi	O
+and	O
+who	O
+was	O
+hospitalized	O
+in	O
+a	O
+critical	O
+state	O
+in	O
+the	O
+Tourcoing	O
+hospital	O
+shortly	O
+after	O
+his	O
+arrival	O
+in	O
+France	O
+.	O
+
+The	O
+first	O
+clinical	O
+signs	O
+(	O
+fever	B-PROC
+and	O
+dry	B-DISO
+cough	I-DISO
+)	O
+appeared	O
+4	O
+days	O
+after	O
+contact	O
+with	O
+the	O
+index	O
+case	O
+.	O
+
+The	O
+chest	B-ANAT
+X	O
+-	O
+ray	B-SPEC
+showed	O
+a	O
+pulmonary	B-DISO
+consolidation	I-DISO
+6	O
+days	O
+after	O
+the	O
+first	O
+clinical	O
+symptoms	O
+.	O
+
+CONCLUSIONS	O
+:	O
+The	O
+clinical	O
+symptoms	O
+of	O
+SARS	B-DISO
+are	O
+unspecific	O
+and	O
+its	O
+evolution	B-PROC
+may	O
+be	O
+misleading	O
+.	O
+
+Some	O
+patients	O
+still	O
+had	O
+psychological	B-DISO
+problems	O
+.	O
+
+TITLE	O
+:	O
+[	O
+Severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+:	O
+update	O
+].	O
+
+TITLE	O
+:	O
+[	O
+Dynamic	O
+observation	O
+IgG	O
+and	O
+IgM	O
+antibodies	B-COMP
+in	O
+patients	O
+with	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+].	O
+
+ABSTRACT	O
+:	O
+To	O
+observe	O
+IgG	B-PRGE
+and	O
+IgM	B-PRGE
+antibodies	B-COMP
+in	O
+patients	O
+with	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+(	O
+SARS	B-DISO
+)	O
+and	O
+to	O
+explore	O
+their	O
+significance	O
+.	O
+
+ABSTRACT	O
+:	O
+To	O
+proceed	O
+the	O
+retrospective	O
+analysis	O
+of	O
+the	O
+dead	O
+reasons	O
+of	O
+patients	O
+with	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+(	O
+SARS	B-DISO
+),	O
+in	O
+order	B-SPEC
+to	O
+provide	O
+experience	O
+for	O
+decreasing	O
+mortality	O
+of	O
+SARS	B-DISO
+patients	O
+in	O
+clinic	O
+.	O
+
+CONCLUSIONS	O
+:	O
+Age	O
+and	O
+basic	O
+diseases	O
+are	O
+sensitive	O
+indexes	O
+for	O
+predicting	O
+dead	B-PROC
+tendency	O
+of	O
+SARS	B-DISO
+.	O
+
+Twenty	O
+-	O
+five	O
+SARS	B-DISO
+patients	O
+with	O
+respiratory	B-DISO
+dysfunction	I-DISO
+treated	O
+with	O
+NIPPV	O
+were	O
+studied	O
+retrospectively	O
+in	O
+order	B-SPEC
+to	O
+evaluate	O
+the	O
+influences	O
+within	O
+24	O
+hours	O
+after	O
+initiation	O
+of	O
+ventilatory	O
+support	O
+on	O
+their	O
+physiological	O
+indices	O
+and	O
+oxygenation	B-PROC
+.	O
+
+TITLE	O
+:	O
+Coronaviruses	O
+as	O
+vectors	O
+:	O
+position	O
+dependence	B-DISO
+of	O
+foreign	O
+gene	B-PROC
+expression	I-PROC
+.	O
+
+Recombinant	O
+viruses	B-SPEC
+were	O
+generated	O
+by	O
+using	O
+a	O
+convenient	O
+method	O
+based	O
+on	O
+targeted	O
+recombination	B-PROC
+and	O
+host	B-COMP
+cell	I-COMP
+switching	O
+.	O
+
+The	O
+foreign	O
+gene	B-DISO
+insertions	I-DISO
+generally	O
+reduced	O
+the	O
+expression	B-PROC
+of	O
+upstream	O
+viral	O
+genes	O
+.	O
+
+Altogether	O
+,	O
+our	O
+observations	O
+clearly	O
+demonstrate	O
+the	O
+potential	O
+of	O
+coronaviruses	O
+as	O
+(	O
+multivalent	O
+)	O
+expression	B-PROC
+vectors	O
+.	O
+
+The	O
+enterotropism	O
+of	O
+TGEV	B-SPEC
+is	O
+connected	O
+with	O
+the	O
+sialic	B-FUNC
+acid	I-FUNC
+binding	B-PROC
+activity	I-PROC
+of	O
+the	O
+viral	O
+surface	O
+protein	B-CHED
+S	O
+.	O
+Here	O
+we	O
+show	O
+that	O
+,	O
+among	O
+porcine	B-SPEC
+intestinal	B-ANAT
+brush	B-COMP
+border	I-COMP
+membrane	I-COMP
+proteins	B-CHED
+,	O
+TGEV	B-SPEC
+recognizes	O
+a	O
+mucin	B-PRGE
+-	I-PRGE
+type	I-PRGE
+glycoprotein	I-PRGE
+designated	O
+MGP	B-PRGE
+in	O
+a	O
+sialic	B-CHED
+acid	I-CHED
+-	O
+dependent	O
+fashion	O
+.	O
+
+ABSTRACT	O
+:	O
+Severe	O
+acute	O
+respiratory	O
+syndrome	O
+(	O
+SARS	B-DISO
+)	O
+has	O
+been	O
+transmitted	B-DISO
+extensively	O
+within	O
+hospitals	O
+,	O
+and	O
+healthcare	O
+workers	O
+(	O
+HCWs	O
+)	O
+have	O
+comprised	O
+a	O
+large	O
+proportion	O
+of	O
+SARS	B-DISO
+cases	O
+worldwide	O
+.	O
+
+For	O
+R	O
+(	O
+0	O
+)	O
+=	O
+3	O
+,	O
+case	O
+isolation	O
+alone	O
+can	O
+control	O
+a	O
+SARS	B-DISO
+outbreak	O
+only	O
+if	O
+isolation	O
+reduces	O
+transmission	O
+by	O
+at	O
+least	O
+a	O
+factor	O
+of	O
+four	O
+and	O
+the	O
+mean	O
+symptom	B-DISO
+-	O
+onset	O
+-	O
+to	O
+-	O
+isolation	O
+time	O
+is	O
+less	O
+than	O
+3	O
+days	O
+.	O
+
+This	O
+study	O
+provides	O
+a	O
+basic	O
+understanding	O
+of	O
+the	O
+enzyme	O
+catalysis	O
+and	O
+a	O
+full	O
+substrate	O
+specificity	O
+spectrum	O
+for	O
+SARS	B-PRGE
+3C	I-PRGE
+-	I-PRGE
+like	I-PRGE
+proteinase	B-PROC
+,	O
+which	O
+are	O
+helpful	O
+for	O
+structural	O
+-	O
+based	O
+inhibitor	B-CHED
+design	O
+against	O
+SARS	B-DISO
+and	O
+other	O
+coronavirus	B-SPEC
+.	O
+
+Detection	O
+of	O
+SARS	B-DISO
+-	O
+like	O
+coronavirus	B-SPEC
+has	O
+been	O
+reported	O
+previously	O
+in	O
+masked	B-SPEC
+palm	I-SPEC
+civets	I-SPEC
+(	O
+sometimes	O
+called	O
+civet	B-SPEC
+cats	I-SPEC
+)	O
+and	O
+a	O
+raccoon	B-SPEC
+dog	I-SPEC
+for	O
+sale	O
+in	O
+a	O
+live	O
+animal	B-SPEC
+market	O
+in	O
+Shenzhen	O
+municipality	O
+.	O
+
+Content	O
+analysis	O
+of	O
+local	O
+and	O
+national	O
+news	O
+media	B-ANAT
+documents	O
+in	O
+Canada	O
+.	O
+
+The	O
+4	O
+-	O
+wk	O
+-	O
+old	O
+turkeys	B-SPEC
+had	O
+no	O
+clinical	O
+signs	O
+or	O
+gross	O
+lesions	O
+.	O
+
+In	O
+another	O
+experiment	O
+,	O
+mean	O
+plasma	O
+D	B-CHED
+-	I-CHED
+xylose	I-CHED
+concentrations	O
+in	O
+3	O
+-	O
+day	O
+-	O
+old	O
+turkey	B-SPEC
+poults	O
+inoculated	O
+with	O
+TCV	B-SPEC
+,	O
+turkey	B-SPEC
+astrovirus	I-SPEC
+,	O
+or	O
+a	O
+combination	O
+of	O
+both	O
+viruses	B-SPEC
+were	O
+significantly	O
+lower	O
+than	O
+in	O
+the	O
+uninoculated	O
+controls	O
+.	O
+
+Establishment	O
+of	O
+a	O
+carrier	O
+state	O
+in	O
+IBV	B-SPEC
+infection	B-DISO
+and	O
+the	O
+potential	O
+for	O
+the	O
+persistent	O
+virus	B-SPEC
+to	O
+undergo	O
+mutations	O
+and	O
+recombination	B-PROC
+in	O
+chicken	B-SPEC
+tissues	B-ANAT
+have	O
+important	O
+consequences	O
+for	O
+disease	O
+management	O
+.	O
+
+In	O
+the	O
+present	O
+study	O
+,	O
+IBV	B-SPEC
+shedding	O
+and	O
+tissue	B-ANAT
+persistence	O
+were	O
+monitored	O
+in	O
+individual	O
+chickens	B-SPEC
+maintained	O
+under	O
+strict	O
+isolation	O
+that	O
+precluded	O
+reinfection	O
+from	O
+exogenous	O
+sources	O
+.	O
+
+TITLE	O
+:	O
+Detection	O
+of	O
+infectious	B-DISO
+bronchitis	B-DISO
+virus	B-SPEC
+by	O
+real	O
+-	O
+time	O
+reverse	B-PRGE
+transcriptase	I-PRGE
+-	O
+polymerase	O
+chain	O
+reaction	O
+and	O
+identification	O
+of	O
+a	O
+quasispecies	O
+in	O
+the	O
+Beaudette	O
+strain	O
+.	O
+
+ABSTRACT	O
+:	O
+In	O
+this	O
+report	O
+,	O
+we	O
+describe	O
+a	O
+real	O
+-	O
+time	O
+reverse	O
+transcriptase	O
+-	O
+polymerase	O
+chain	O
+reaction	O
+(	O
+RRT	O
+-	O
+PCR	O
+)	O
+diagnostic	O
+test	O
+for	O
+infectious	B-DISO
+bronchitis	B-DISO
+virus	B-SPEC
+(	O
+IBV	B-SPEC
+)	O
+with	O
+the	O
+use	O
+of	O
+fluorescence	O
+resonance	O
+energy	B-PROC
+transfer	I-PROC
+(	O
+FRET	O
+)	O
+technology	O
+.	O
+
+Two	O
+primers	O
+that	O
+amplify	O
+a	O
+383	O
+-	O
+base	B-FUNC
+pair	I-FUNC
+product	O
+between	O
+nucleotide	B-CHED
+positions	O
+703	O
+and	O
+1086	O
+relative	O
+to	O
+the	O
+start	O
+codon	O
+for	O
+the	O
+S1	B-PRGE
+gene	I-PRGE
+of	O
+the	O
+Massachusetts	O
+41	O
+virus	B-SPEC
+were	O
+designed	O
+and	O
+used	O
+to	O
+amplify	O
+the	O
+Beaudette	O
+,	O
+Massachusetts	O
+41	O
+,	O
+Florida	O
+18288	O
+,	O
+Connecticut	O
+,	O
+Iowa	O
+97	O
+,	O
+Arkansas	O
+DPI	O
+,	O
+CA	O
+/	O
+NE95	O
+/	O
+99	O
+,	O
+DE	O
+/	O
+072	O
+/	O
+92	O
+,	O
+and	O
+GA	O
+/	O
+0470	O
+/	O
+98	O
+strains	O
+of	O
+IBV	B-SPEC
+.	O
+
+TITLE	O
+:	O
+Characterization	O
+of	O
+infectious	B-DISO
+bronchitis	B-DISO
+virus	B-SPEC
+isolates	O
+by	O
+slot	O
+blot	O
+hybridization	B-PROC
+.	O
+
+We	O
+synthesized	O
+digoxigenin	B-CHED
+-	O
+labeled	O
+probes	O
+from	O
+reference	O
+and	O
+unknown	O
+field	O
+viruses	B-SPEC
+and	O
+hybridized	O
+them	O
+to	O
+template	O
+DNA	O
+.	O
+
+ABSTRACT	O
+:	O
+While	O
+the	O
+risks	O
+of	O
+transfusion	O
+-	O
+transmitted	O
+human	B-DISO
+immunodeficiency	I-DISO
+virus	I-DISO
+,	O
+hepatitis	B-SPEC
+C	I-SPEC
+virus	I-SPEC
+,	O
+and	O
+human	B-SPEC
+T	B-DISO
+-	I-DISO
+cell	I-DISO
+leukemia	I-DISO
+virus	B-SPEC
+I	O
+/	O
+II	O
+continue	O
+to	O
+decrease	O
+,	O
+additional	O
+threats	O
+to	O
+transfusion	O
+safety	O
+are	O
+posed	O
+by	O
+emerging	O
+""""	O
+new	O
+""""	O
+infectious	B-DISO
+diseases	I-DISO
+.	O
+
+Nucleic	B-CHED
+acid	I-CHED
+testing	O
+for	O
+West	B-DISO
+Nile	I-DISO
+virus	I-DISO
+began	O
+in	O
+the	O
+United	O
+States	O
+in	O
+2003	O
+under	O
+an	O
+investigational	O
+new	O
+drug	O
+program	O
+.	O
+
+ABSTRACT	O
+:	O
+We	O
+present	O
+a	O
+retrospective	O
+analysis	O
+of	O
+the	O
+available	O
+articles	O
+on	O
+severe	O
+acute	O
+respiratory	O
+syndrome	O
+(	O
+SARS	B-DISO
+)	O
+published	O
+since	O
+the	O
+outbreak	O
+of	O
+the	O
+disease	O
+.	O
+
+Even	O
+in	O
+a	O
+situation	O
+of	O
+no	O
+new	O
+cases	O
+of	O
+infection	O
+,	O
+SARS	B-DISO
+remains	O
+a	O
+major	O
+respiratory	O
+health	O
+hazard	O
+.	O
+
+Positive	O
+results	O
+to	O
+FIV	B-SPEC
+/	O
+PLV	O
+in	O
+wildcats	O
+and	O
+feral	O
+cats	B-SPEC
+confirmed	O
+the	O
+occurrence	O
+of	O
+a	O
+feline	B-SPEC
+lentivirus	B-SPEC
+in	O
+the	O
+sampled	O
+population	O
+.	O
+
+Eighty	O
+-	O
+nine	O
+(	O
+82	O
+.	O
+4	O
+%)	O
+and	O
+12	O
+(	O
+11	O
+.	O
+1	O
+%)	O
+patients	O
+were	O
+categorized	O
+as	O
+probable	O
+cases	O
+and	O
+suspected	O
+cases	O
+respectively	O
+at	O
+their	O
+first	O
+visit	O
+and	O
+a	O
+clinical	O
+diagnosis	O
+of	O
+SARS	B-DISO
+was	O
+made	O
+subsequently	O
+.	O
+
+The	O
+chest	B-ANAT
+radiograph	O
+was	O
+interpreted	O
+as	O
+unremarkable	O
+in	O
+26	O
+(	O
+24	O
+.	O
+1	O
+%)	O
+cases	O
+at	O
+their	O
+first	O
+visit	O
+,	O
+and	O
+the	O
+diagnosis	O
+was	O
+made	O
+in	O
+4	O
+days	O
+(	O
+range	O
+2	O
+-	O
+8	O
+days	O
+),	O
+which	O
+was	O
+significantly	O
+longer	O
+compared	O
+with	O
+other	O
+cases	O
+(	O
+P	O
+<	O
+0	O
+.	O
+001	O
+).	O
+
+ABSTRACT	O
+:	O
+To	O
+investigate	O
+the	O
+possibility	O
+of	O
+early	O
+prevention	O
+and	O
+treatment	O
+of	O
+acute	O
+lung	B-ANAT
+injury	O
+by	O
+using	O
+composite	O
+Rhodiolae	O
+(	O
+CR	O
+)	O
+in	O
+patients	O
+with	O
+severe	O
+pulmonary	B-DISO
+hypertension	I-DISO
+during	O
+extracorporeal	O
+circulation	B-PROC
+.	O
+
+Seventy	O
+-	O
+six	O
+patients	O
+with	O
+severe	O
+pulmonary	B-DISO
+hypertension	I-DISO
+screened	O
+out	O
+by	O
+color	O
+2D	O
+-	O
+Doppler	O
+ultrasonography	O
+were	O
+randomly	O
+divided	O
+into	O
+the	O
+treated	O
+group	O
+(	O
+n	O
+=	O
+40	O
+)	O
+and	O
+the	O
+control	O
+group	O
+(	O
+n	O
+=	O
+36	O
+).	O
+
+By	O
+controlled	O
+paralled	O
+design	O
+,	O
+49	O
+patients	O
+of	O
+SARS	B-DISO
+were	O
+studied	O
+,	O
+they	O
+were	O
+divided	O
+into	O
+the	O
+control	O
+group	O
+(	O
+n	O
+=	O
+29	O
+)	O
+and	O
+the	O
+ICWM	O
+group	O
+(	O
+n	O
+=	O
+20	O
+).	O
+
+The	O
+infections	B-DISO
+among	O
+the	O
+medical	O
+and	O
+health	O
+workers	O
+are	O
+high	O
+.	O
+
+On	O
+6	O
+April	O
+(	O
+day	O
+40	O
+)	O
+there	O
+were	O
+74	O
+cases	O
+and	O
+7	O
+deaths	B-PROC
+.	O
+
+If	O
+this	O
+trend	O
+continues	O
+,	O
+SARS	B-DISO
+numbers	O
+in	O
+Canada	O
+are	O
+predicted	O
+to	O
+be	O
+as	O
+follows	O
+:	O
+387	O
+cases	O
+and	O
+34	O
+deaths	B-PROC
+by	O
+26	O
+April	O
+(	O
+day	O
+60	O
+),	O
+4432	O
+cases	O
+and	O
+394	O
+deaths	B-PROC
+by	O
+26	O
+May	O
+(	O
+day	O
+90	O
+),	O
+and	O
+50	O
+500	O
+cases	O
+and	O
+4489	O
+deaths	B-PROC
+by	O
+25	O
+June	O
+(	O
+day	O
+120	O
+).	O
+
+By	O
+comparison	O
+,	O
+the	O
+best	O
+parameters	O
+to	O
+fit	B-DISO
+Hong	O
+Kong	O
+data	O
+as	O
+of	O
+10	O
+April	O
+2003	O
+are	O
+R	O
+(	O
+o	O
+)	O
+=	O
+2	O
+.	O
+0	O
+,	O
+F	O
+=	O
+20	O
+%,	O
+i	O
+=	O
+5	O
+days	O
+,	O
+d	O
+=	O
+14	O
+days	O
+.	O
+
+A	O
+possible	O
+cause	O
+of	O
+false	O
+-	O
+positive	O
+of	O
+SARS	B-PRGE
+-	I-PRGE
+CoV	I-PRGE
+-	I-PRGE
+IgG	I-PRGE
+and	O
+IgM	B-COMP
+antibody	B-PROC
+in	O
+SLE	B-DISO
+patients	O
+is	O
+coated	O
+antigens	B-CHED
+with	O
+SARS	B-DISO
+-	O
+CoV	O
+and	O
+Vero	O
+-	O
+E6	O
+cells	B-COMP
+in	O
+ELISA	O
+methods	O
+.	O
+
+It	O
+was	O
+concluded	O
+that	O
+not	O
+all	O
+SARS	B-DISO
+patients	O
+could	O
+produce	O
+the	O
+anti	B-PRGE
+-	I-PRGE
+SARS	B-DISO
+-	I-PRGE
+coronavirus	B-SPEC
+specific	I-PRGE
+antibody	B-COMP
+.	O
+
+Although	O
+NO	O
+is	O
+important	O
+in	O
+maintaining	O
+vasodilator	B-CHED
+tone	O
+,	O
+hypoxia	B-DISO
+-	O
+induced	O
+pulmonary	B-ANAT
+vasoconstriction	B-DISO
+is	O
+accompanied	O
+by	O
+an	O
+increase	O
+instead	O
+of	O
+a	O
+decrease	O
+in	O
+NO	O
+release	B-PATH
+.	O
+
+TITLE	O
+:	O
+A	O
+comparative	O
+sequence	O
+analysis	O
+to	O
+revise	O
+the	O
+current	O
+taxonomy	O
+of	O
+the	O
+family	B-SPEC
+Coronaviridae	I-SPEC
+.	O
+
+ABSTRACT	O
+:	O
+The	O
+Coronaviridae	O
+family	B-SPEC
+,	O
+comprising	O
+the	O
+Coronavirus	B-SPEC
+and	O
+Torovirus	B-SPEC
+genera	O
+,	O
+is	O
+part	O
+of	O
+the	O
+Nidovirales	B-SPEC
+order	B-SPEC
+that	O
+also	O
+includes	O
+two	O
+other	O
+families	O
+,	O
+Arteriviridae	B-SPEC
+and	O
+Roniviridae	B-SPEC
+.	O
+
+Comparative	O
+sequence	O
+analysis	O
+of	O
+RdRp	B-FUNC
+and	O
+HEL	O
+domains	O
+were	O
+extended	O
+to	O
+include	O
+arterivirus	B-SPEC
+and	O
+ronivirus	O
+homologs	O
+.	O
+
+The	O
+pairwise	O
+scores	O
+between	O
+sequences	O
+of	O
+the	O
+genera	O
+Coronavirus	B-SPEC
+and	O
+Torovirus	B-SPEC
+(	O
+22	O
+-	O
+25	O
+%	O
+and	O
+21	O
+-	O
+25	O
+%)	O
+were	O
+found	O
+to	O
+be	O
+very	O
+close	O
+to	O
+or	O
+overlapped	O
+with	O
+the	O
+value	O
+ranges	O
+(	O
+12	O
+to	O
+22	O
+%	O
+and	O
+17	O
+to	O
+25	O
+%)	O
+obtained	O
+for	O
+interfamily	O
+pairwise	O
+comparisons	O
+,	O
+but	O
+were	O
+much	O
+smaller	O
+than	O
+values	O
+derived	O
+from	O
+pairwise	O
+comparisons	O
+within	O
+the	O
+Coronavirus	B-SPEC
+genus	B-SPEC
+(	O
+63	O
+-	O
+71	O
+%	O
+and	O
+59	O
+-	O
+67	O
+%).	O
+
+In	O
+humans	B-SPEC
+it	O
+is	O
+readily	O
+absorbed	O
+by	O
+ingestion	O
+and	O
+inhalation	B-PROC
+but	O
+is	O
+less	O
+well	O
+absorbed	O
+dermally	O
+.	O
+
+Pulmonary	B-DISO
+oedema	I-DISO
+,	O
+intravascular	B-DISO
+haemolysis	I-DISO
+,	O
+pancreatitis	B-DISO
+,	O
+jaundice	B-DISO
+and	O
+acute	B-DISO
+renal	I-DISO
+failure	I-DISO
+have	O
+been	O
+reported	O
+.	O
+
+Supportive	O
+care	O
+and	O
+vigorous	O
+management	O
+of	O
+hyperthermia	B-PROC
+should	O
+produce	O
+a	O
+satisfactory	O
+outcome	O
+.	O
+
+TITLE	O
+:	O
+Induction	O
+of	O
+caspase	B-PROC
+-	I-PROC
+dependent	I-PROC
+apoptosis	B-PATH
+in	O
+cultured	O
+rat	B-SPEC
+oligodendrocytes	B-ANAT
+by	O
+murine	B-SPEC
+coronavirus	I-SPEC
+is	O
+mediated	O
+during	O
+cell	B-COMP
+entry	O
+and	O
+does	O
+not	O
+require	O
+virus	B-PROC
+replication	I-PROC
+.	O
+
+We	O
+described	O
+the	O
+clinical	O
+course	O
+of	O
+the	O
+first	O
+long	O
+-	O
+term	O
+hemodialysis	O
+patient	O
+who	O
+developed	O
+SARS	B-DISO
+in	O
+the	O
+literature	O
+,	O
+and	O
+our	O
+experience	O
+in	O
+performing	O
+hemodialysis	O
+for	O
+this	O
+patient	O
+.	O
+
+Other	O
+common	O
+findings	O
+were	O
+lymphopenia	B-DISO
+(	O
+57	O
+%,	O
+26	O
+/	O
+46	O
+),	O
+thrombocytopenia	O
+(	O
+39	O
+%,	O
+18	O
+/	O
+46	O
+),	O
+elevated	O
+lactate	B-PRGE
+dehydrogenase	I-PRGE
+(	O
+63	O
+%,	O
+29	O
+/	O
+46	O
+),	O
+and	O
+elevated	O
+creatine	B-PRGE
+kinase	I-PRGE
+(	O
+24	O
+%,	O
+11	O
+/	O
+46	O
+).	O
+
+Thereafter	O
+,	O
+severe	O
+vitamin	B-DISO
+B1	I-DISO
+deficiency	I-DISO
+in	O
+infants	O
+was	O
+diagnosed	O
+and	O
+treated	O
+promptly	O
+.	O
+
+Before	O
+its	O
+recognition	O
+approximately	O
+7	O
+%	O
+of	O
+all	O
+infants	O
+in	O
+this	O
+population	O
+died	B-PROC
+from	O
+infantile	O
+beri	B-DISO
+-	I-DISO
+beri	B-SPEC
+.	O
+
+A	O
+novel	B-SPEC
+coronavirus	I-SPEC
+,	O
+SARS	B-DISO
+coronavirus	B-SPEC
+(	O
+CoV	O
+),	O
+was	O
+isolated	O
+from	O
+specimens	O
+from	O
+three	O
+patients	O
+with	O
+SARS	B-DISO
+.	O
+
+48	O
+of	O
+55	O
+(	O
+87	O
+%)	O
+patients	O
+had	O
+antibodies	B-COMP
+to	O
+SARS	B-DISO
+CoV	O
+in	O
+their	O
+convalescent	O
+sera	B-COMP
+.	O
+
+SARS	B-DISO
+CoV	O
+is	O
+the	O
+infectious	B-DISO
+agent	O
+responsible	O
+for	O
+the	O
+epidemic	O
+outbreak	O
+of	O
+SARS	B-DISO
+in	O
+Guangdong	O
+.	O
+
+The	O
+virus	B-SPEC
+isolated	O
+from	O
+patients	O
+in	O
+Guangdong	O
+is	O
+the	O
+prototype	O
+of	O
+the	O
+SARS	B-PRGE
+CoV	I-PRGE
+in	O
+other	O
+regions	O
+and	O
+countries	O
+.	O
+
+TITLE	O
+:	O
+The	O
+crystal	B-ANAT
+structures	O
+of	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+virus	B-SPEC
+main	O
+protease	O
+and	O
+its	O
+complex	O
+with	O
+an	O
+inhibitor	O
+.	O
+
+BAL	B-ENZY
+fluid	O
+obtained	O
+from	O
+RDS	O
+but	O
+not	O
+CLD	B-DISO
+patients	O
+was	O
+proapoptotic	O
+to	O
+neutrophils	B-ANAT
+(	O
+apoptosis	B-PATH
+ratio	O
+BAL	B-ENZY
+fluid	O
+/	O
+saline	O
+control	O
+:	O
+day	O
+1	O
+,	O
+RDS	O
+9	O
+.	O
+8	O
+(	O
+5	O
+.	O
+5	O
+)	O
+v	O
+CLD	B-DISO
+1	O
+.	O
+2	O
+(	O
+0	O
+.	O
+1	O
+)	O
+(	O
+p	O
+<	O
+0	O
+.	O
+05	O
+);	O
+day	O
+2	O
+,	O
+RDS	O
+4	O
+.	O
+32	O
+(	O
+2	O
+.	O
+8	O
+)	O
+v	O
+CLD	B-DISO
+0	O
+.	O
+5	O
+(	O
+0	O
+.	O
+4	O
+)	O
+(	O
+p	O
+<	O
+0	O
+.	O
+05	O
+)).	O
+
+Moreover	O
+,	O
+during	O
+FIP	B-DISO
+many	O
+lymphocytes	B-ANAT
+do	O
+not	O
+express	O
+any	O
+membrane	B-COMP
+antigen	B-CHED
+,	O
+most	O
+likely	O
+due	O
+to	O
+early	O
+apoptosis	B-PATH
+.	O
+
+TITLE	O
+:	O
+Vacuolating	O
+encephalitis	B-DISO
+in	O
+mice	B-SPEC
+infected	O
+by	O
+human	B-SPEC
+coronavirus	I-SPEC
+OC43	O
+.	O
+
+ABSTRACT	O
+:	O
+To	O
+evaluate	O
+the	O
+relationship	O
+among	O
+chest	O
+radiographs	O
+,	O
+oxygen	B-CHED
+supplementation	O
+requirement	O
+,	O
+and	O
+treatment	O
+response	O
+in	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+(	O
+SARS	B-DISO
+).	O
+
+Parameters	O
+that	O
+influenced	O
+treatment	O
+response	O
+were	O
+time	O
+from	O
+symptom	B-DISO
+onset	O
+to	O
+treatment	O
+day	O
+(	O
+P	O
+=.	O
+003	O
+),	O
+time	O
+from	O
+admission	O
+to	O
+treatment	O
+day	O
+(	O
+P	O
+<.	O
+001	O
+),	O
+time	O
+to	O
+maximal	O
+radiographic	O
+score	O
+from	O
+treatment	O
+day	O
+(	O
+P	O
+=.	O
+001	O
+),	O
+maximal	O
+radiographic	O
+score	O
+(	O
+P	O
+=.	O
+009	O
+),	O
+Sao2	B-PROC
+at	O
+maximal	O
+radiographic	O
+score	O
+(	O
+P	O
+=.	O
+13	O
+),	O
+and	O
+treatment	O
+radiographic	O
+score	O
+(	O
+P	O
+=.	O
+03	O
+).	O
+
+Quarantine	O
+hospital	O
+for	O
+patients	O
+with	O
+SARS	B-DISO
+in	O
+Hong	O
+Kong	O
+.	O
+
+During	O
+hospitalization	O
+,	O
+incidence	O
+of	O
+diarrhea	B-DISO
+(	O
+53	O
+%),	O
+anemia	B-DISO
+(	O
+53	O
+%),	O
+and	O
+acute	B-DISO
+renal	I-DISO
+failure	I-DISO
+(	O
+6	O
+%)	O
+increased	O
+.	O
+
+It	O
+is	O
+known	O
+to	O
+be	O
+valuable	O
+to	O
+keep	O
+spontaneous	O
+breathing	B-PROC
+in	I-PROC
+these	O
+cases	O
+.	O
+
+Suddenly	O
+it	O
+became	O
+difficult	O
+to	O
+ventilate	O
+her	O
+and	O
+her	O
+oxygenation	B-PROC
+saturation	O
+declined	O
+with	O
+bradycardia	B-DISO
+.	O
+
+This	O
+report	O
+describes	O
+observations	O
+made	O
+by	O
+two	O
+authors	O
+on	O
+a	O
+journey	O
+from	O
+Manchester	O
+in	O
+the	O
+United	O
+Kingdom	B-SPEC
+to	O
+Chiang	O
+Mai	B-SPEC
+in	O
+Thailand	O
+during	O
+the	O
+peak	O
+of	O
+global	O
+transmission	O
+.	O
+
+Ten	O
+similar	O
+and	O
+sequential	O
+telephone	O
+surveys	O
+were	O
+conducted	O
+during	O
+outbreak	O
+of	O
+SARS	B-DISO
+,	O
+which	O
+are	O
+classified	O
+as	O
+belonging	O
+to	O
+the	O
+first	O
+and	O
+second	O
+phases	O
+of	O
+the	O
+epidemic	O
+.	O
+
+ABSTRACT	O
+:	O
+To	O
+investigate	O
+the	O
+impact	O
+of	O
+SARS	B-DISO
+on	O
+heart	O
+initially	O
+.	O
+
+The	O
+clinical	O
+and	O
+laboratory	O
+data	O
+of	O
+86	O
+patients	O
+with	O
+SARS	B-DISO
+were	O
+collected	O
+and	O
+analyzed	O
+statistically	O
+.	O
+
+CONCLUSIONS	O
+:	O
+SARS	B-DISO
+,	O
+which	O
+mainly	O
+resulted	O
+in	O
+pulmonary	B-ANAT
+damage	O
+,	O
+may	O
+involve	O
+heart	B-ANAT
+.	O
+
+ARDS	B-DISO
+patients	O
+in	O
+general	O
+ICU	O
+were	O
+enrolled	O
+for	O
+the	O
+study	O
+.	O
+
+Ninety	O
+-	O
+three	O
+cases	O
+were	O
+non	O
+-	O
+SARS	B-DISO
+-	O
+pneumonia	B-DISO
+,	O
+2	O
+were	O
+epidemic	B-DISO
+encephalitis	I-DISO
+,	O
+8	O
+were	O
+epidemic	O
+cerebrospinal	B-DISO
+meningitis	I-DISO
+,	O
+and	O
+3	O
+cases	O
+were	O
+epidemic	B-DISO
+hemorrhagic	I-DISO
+fever	I-DISO
+.	O
+
+Fully	O
+mature	O
+protein	B-CHED
+and	O
+the	O
+N	O
+-	O
+terminal	O
+416	O
+amino	B-CHED
+acids	I-CHED
+(	O
+SpaA416	O
+)	O
+showed	O
+sufficient	O
+antigenicities	O
+,	O
+and	O
+further	O
+examination	O
+was	O
+done	O
+with	O
+SpaA416	O
+because	O
+of	O
+its	O
+higher	O
+yield	O
+.	O
+
+The	O
+antibody	B-COMP
+titers	O
+of	O
+pigs	B-SPEC
+experimentally	O
+immunized	O
+with	O
+commercial	O
+live	O
+vaccine	O
+and	O
+two	O
+types	O
+of	O
+inactivated	O
+vaccines	O
+clearly	O
+increased	O
+after	O
+immunization	O
+,	O
+and	O
+all	O
+pigs	B-SPEC
+were	O
+completely	O
+protected	O
+against	O
+challenge	O
+with	O
+virulent	O
+strains	O
+.	O
+
+These	O
+results	O
+indicate	O
+that	O
+the	O
+SpaA416	O
+ELISA	O
+is	O
+an	O
+effective	O
+method	O
+not	O
+only	O
+for	O
+evaluating	O
+pigs	B-SPEC
+for	O
+the	O
+presence	O
+of	O
+protective	O
+antibody	B-COMP
+levels	O
+resulting	O
+from	O
+vaccination	O
+or	O
+maternal	O
+antibody	B-COMP
+but	O
+also	O
+for	O
+detecting	O
+antibody	B-COMP
+produced	O
+by	O
+natural	O
+infection	B-DISO
+.	O
+
+This	O
+enzyme	O
+catalyses	O
+three	O
+steps	O
+in	O
+the	O
+beta	B-PATH
+-	I-PATH
+oxidation	I-PATH
+of	O
+long	B-CHED
+-	I-CHED
+chain	I-CHED
+fatty	I-CHED
+acids	I-CHED
+.	O
+
+Additional	O
+information	O
+and	O
+references	O
+were	O
+obtained	O
+from	O
+the	O
+Web	B-DISO
+sites	O
+for	O
+the	O
+Centers	O
+for	O
+Disease	O
+Control	O
+and	O
+Prevention	O
+,	O
+World	O
+Health	O
+Organization	O
+,	O
+and	O
+Health	O
+Canada	O
+.	O
+
+The	O
+most	O
+common	O
+clinical	O
+symptoms	B-DISO
+and	I-DISO
+signs	I-DISO
+are	O
+fever	B-PROC
+,	O
+cough	B-DISO
+,	O
+dyspnea	B-DISO
+,	O
+myalgias	B-DISO
+,	O
+malaise	B-DISO
+,	O
+and	O
+inspiratory	B-PROC
+crackles	B-DISO
+.	O
+
+Predictors	O
+of	O
+mortality	O
+included	O
+advanced	O
+age	O
+,	O
+the	O
+presence	O
+of	O
+comorbidities	O
+,	O
+and	O
+a	O
+high	B-PRGE
+lactic	I-PRGE
+dehydrogenase	I-PRGE
+or	O
+high	O
+neutrophil	B-ANAT
+count	O
+at	O
+admission	O
+.	O
+
+CONCLUSIONS	O
+:	O
+According	O
+to	O
+the	O
+time	O
+of	O
+the	O
+occurrence	O
+of	O
+complications	O
+,	O
+we	O
+divide	O
+the	O
+courses	O
+of	O
+the	O
+disease	O
+into	O
+three	O
+stages	O
+:	O
+early	O
+phase	O
+(	O
+first	O
+4	O
+days	O
+)	O
+with	O
+ARDS	B-DISO
+,	O
+kidney	B-DISO
+failure	I-DISO
+,	O
+shock	O
+,	O
+encephalopathy	B-DISO
+and	O
+hemorrhage	B-DISO
+of	O
+the	O
+digestive	B-ANAT
+tract	I-ANAT
+;	O
+middle	O
+phase	O
+(	O
+5	O
+-	O
+15	O
+days	O
+)	O
+with	O
+bacterial	B-DISO
+infection	I-DISO
+and	O
+fungous	O
+infection	B-DISO
+;	O
+late	O
+phase	O
+(	O
+15	O
+days	O
+after	O
+the	O
+onset	O
+)	O
+with	O
+abscess	B-DISO
+.	O
+
+TITLE	O
+:	O
+Characterizing	O
+degradation	O
+products	O
+of	O
+peptides	B-CHED
+containing	O
+N	O
+-	O
+terminal	O
+Cys	B-CHED
+residues	O
+by	O
+(	O
+off	O
+-	O
+line	O
+high	O
+-	O
+performance	O
+liquid	O
+chromatography	O
+)/	O
+matrix	O
+-	O
+assisted	O
+laser	O
+desorption	O
+/	O
+ionization	O
+quadrupole	O
+time	O
+-	O
+of	O
+-	O
+flight	B-PROC
+measurements	O
+.	O
+
+The	O
+average	O
+degree	O
+of	O
+degradation	O
+during	O
+overnight	O
+digestion	B-PROC
+was	O
+found	O
+to	O
+be	O
+approximately	O
+51	O
+and	O
+approximately	O
+34	O
+%	O
+for	O
+Cys	B-CHED
+and	O
+Gln	B-CHED
+,	O
+respectively	O
+;	O
+more	O
+detailed	O
+information	O
+on	O
+the	O
+time	O
+course	O
+of	O
+the	O
+reactions	O
+was	O
+obtained	O
+for	O
+the	O
+peptides	O
+CCTESLVNR	O
+and	O
+QYYTVFDR	O
+.	O
+
+TITLE	O
+:	O
+[	O
+Respiratory	B-ANAT
+tract	I-ANAT
+viruses	B-SPEC
+].	O
+
+In	O
+addition	O
+new	O
+viral	O
+pathogens	O
+were	O
+discovered	O
+and	O
+found	O
+to	O
+cause	O
+respiratory	B-DISO
+infections	I-DISO
+,	O
+metapneumovirus	B-SPEC
+and	O
+SARS	B-DISO
+-	I-DISO
+associated	I-DISO
+coronavirus	I-DISO
+being	O
+the	O
+most	O
+important	O
+ones	O
+.	O
+
+Where	O
+single	O
+agent	O
+therapy	O
+fails	O
+,	O
+combination	O
+antiviral	B-CHED
+and	O
+anti	B-PRGE
+-	I-PRGE
+CCL3	I-PRGE
+treatment	O
+is	O
+synergistic	O
+and	O
+able	O
+to	O
+prevent	O
+mortality	O
+in	O
+mice	B-SPEC
+infected	O
+with	O
+the	O
+highly	O
+lethal	O
+pneumonia	B-SPEC
+virus	I-SPEC
+of	I-SPEC
+mice	I-SPEC
+.	O
+
+With	O
+regard	O
+to	O
+blockade	O
+,	O
+combination	O
+antiviral	B-CHED
+/	O
+antichemokine	O
+therapy	O
+is	O
+a	O
+new	O
+strategy	O
+worth	O
+considering	O
+as	O
+a	O
+general	O
+therapeutic	O
+approach	O
+to	O
+viral	B-DISO
+infections	I-DISO
+,	O
+including	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+(	O
+SARS	B-DISO
+).	O
+
+The	O
+presence	O
+of	O
+HSV	B-SPEC
+in	O
+the	O
+throat	B-ANAT
+was	O
+a	O
+risk	O
+factor	O
+for	O
+development	B-PROC
+of	O
+HSV	B-SPEC
+infections	B-DISO
+in	O
+the	O
+lower	B-ANAT
+respiratory	I-ANAT
+tract	I-ANAT
+(	O
+p	O
+<	O
+0	O
+.	O
+001	O
+).	O
+
+Four	O
+hours	O
+later	O
+she	O
+developed	O
+progressive	O
+respiratory	B-DISO
+distress	I-DISO
+,	O
+diffuse	O
+geographical	O
+airspace	O
+disease	O
+and	O
+bilateral	O
+pulmonary	B-DISO
+edema	I-DISO
+.	O
+
+Granulocyte	B-PRGE
+or	O
+human	B-PRGE
+leukocyte	B-ANAT
+antigen	B-CHED
+antibodies	B-COMP
+in	O
+donor	B-CHED
+plasma	B-ANAT
+may	O
+confirm	O
+a	O
+diagnosis	O
+of	O
+transfusion	O
+injury	O
+.	O
+
+By	O
+mid	O
+-	O
+July	O
+,	O
+five	O
+international	O
+airports	O
+in	O
+Southeast	O
+Asia	O
+had	O
+been	O
+inspected	O
+and	O
+found	O
+to	O
+be	O
+in	O
+full	O
+compliance	O
+with	O
+the	O
+ICAO	B-PRGE
+anti	I-PRGE
+-	I-PRGE
+SARS	I-PRGE
+protective	O
+measures	O
+.	O
+
+It	O
+is	O
+aimed	O
+at	O
+preventing	O
+a	O
+resurgence	O
+of	O
+SARS	B-DISO
+,	O
+but	O
+it	O
+also	O
+contains	O
+elements	O
+to	O
+make	O
+the	O
+methodology	O
+developed	O
+applicable	O
+to	O
+future	O
+outbreaks	O
+of	O
+any	O
+other	O
+communicable	B-DISO
+disease	I-DISO
+in	O
+which	O
+the	O
+mode	O
+of	O
+transmission	O
+could	O
+involve	O
+aviation	O
+and	O
+/	O
+or	O
+the	O
+need	O
+to	O
+prevent	O
+the	O
+spread	O
+of	O
+the	O
+disease	O
+by	O
+air	B-CHED
+travel	O
+.	O
+
+Such	O
+an	O
+analysis	O
+,	O
+embodied	O
+within	O
+the	O
+DS	O
+GeneAtlas	O
+pipeline	O
+,	O
+has	O
+been	O
+used	O
+to	O
+critically	O
+evaluate	O
+the	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+(	O
+SARS	B-DISO
+)	O
+genome	O
+with	O
+the	O
+goal	O
+of	O
+identifying	O
+new	O
+potential	O
+targets	O
+for	O
+viral	O
+therapeutic	O
+intervention	O
+.	O
+
+This	O
+increase	O
+persisted	O
+only	O
+in	O
+cats	B-SPEC
+that	O
+developed	O
+FIP	B-DISO
+(	O
+in	O
+spite	O
+of	O
+a	O
+decrease	O
+in	O
+alpha	B-PRGE
+(	I-PRGE
+2	I-PRGE
+)-	I-PRGE
+globulins	I-PRGE
+)	O
+but	O
+it	O
+was	O
+only	O
+transient	O
+in	O
+FCoV	O
+-	O
+exposed	O
+cats	O
+,	O
+in	O
+which	O
+a	O
+long	O
+lasting	O
+increase	O
+in	O
+alpha	B-PRGE
+(	I-PRGE
+2	I-PRGE
+)-	I-PRGE
+globulins	I-PRGE
+was	O
+observed	O
+.	O
+
+A	O
+large	O
+component	O
+of	O
+the	O
+variance	O
+(	O
+91	O
+.	O
+7	O
+%)	O
+was	O
+accounted	O
+for	O
+by	O
+levels	O
+of	O
+IL	B-FUNC
+-	I-FUNC
+6	I-FUNC
+,	O
+MIP	B-PRGE
+-	I-PRGE
+1	I-PRGE
+alpha	I-PRGE
+,	O
+and	O
+RANTES	B-PRGE
+.	O
+
+In	O
+contrast	O
+,	O
+evidence	O
+of	O
+inflammatory	O
+signs	O
+in	O
+the	O
+otolaryngological	O
+field	O
+may	O
+explain	O
+the	O
+flulike	O
+symptoms	O
+,	O
+and	O
+serve	O
+as	O
+a	O
+differential	O
+diagnostic	O
+tool	O
+between	O
+influenza	B-DISO
+and	O
+SARS	B-DISO
+.	O
+
+RESULTS	O
+:	O
+Clinical	O
+manifestations	O
+included	O
+fever	B-PROC
+in	O
+31	O
+patients	O
+(	O
+97	O
+%),	O
+followed	O
+by	O
+cough	B-DISO
+,	O
+dyspnea	B-DISO
+,	O
+chill	B-DISO
+,	O
+headache	B-DISO
+,	O
+sore	B-DISO
+throat	I-DISO
+,	O
+diarrhea	B-DISO
+,	O
+rhinorrhea	B-DISO
+,	O
+and	O
+otalgia	B-DISO
+.	O
+
+In	O
+this	O
+review	O
+,	O
+the	O
+authors	O
+shall	O
+focus	O
+on	O
+the	O
+molecular	O
+biology	O
+of	O
+the	O
+coronavirus	B-SPEC
+and	O
+suggest	O
+how	O
+this	O
+information	O
+can	O
+be	O
+used	O
+to	O
+identify	O
+possible	O
+targets	O
+for	O
+antiviral	B-CHED
+drugs	I-CHED
+.	O
+
+Within	O
+a	O
+remarkably	O
+short	O
+period	O
+of	O
+time	O
+,	O
+the	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+coronavirus	B-SPEC
+has	O
+been	O
+isolated	O
+,	O
+its	O
+genome	O
+has	O
+been	O
+sequenced	O
+and	O
+the	O
+structure	O
+of	O
+at	O
+least	O
+one	O
+key	O
+viral	O
+enzyme	O
+has	O
+been	O
+deduced	O
+.	O
+
+This	O
+combination	O
+of	O
+array	O
+hybridization	B-PROC
+followed	O
+by	O
+direct	O
+viral	O
+sequence	O
+recovery	O
+should	O
+prove	O
+to	O
+be	O
+a	O
+general	O
+strategy	O
+for	O
+the	O
+rapid	O
+identification	O
+and	O
+characterization	O
+of	O
+novel	O
+viruses	B-SPEC
+and	O
+emerging	B-DISO
+infectious	I-DISO
+disease	I-DISO
+.	O
+
+The	O
+radiographic	O
+presentations	O
+,	O
+as	O
+expected	O
+,	O
+were	O
+relatively	O
+more	O
+pronounced	O
+in	O
+the	O
+SARS	B-DISO
+probable	O
+cases	O
+.	O
+
+The	O
+genomic	O
+complexity	O
+of	O
+FCoVs	O
+was	O
+investigated	O
+using	O
+single	O
+-	O
+strand	O
+conformational	O
+polymorphism	B-PROC
+(	O
+SSCP	O
+)	O
+analysis	O
+of	O
+N	O
+and	O
+ORF7b	O
+amplicons	O
+,	O
+and	O
+the	O
+evolutionary	O
+process	O
+was	O
+investigated	O
+by	O
+sequence	O
+-	O
+based	O
+phylogenetic	O
+analysis	O
+.	O
+
+Phylogenetic	O
+analysis	O
+of	O
+the	O
+nucleotide	B-CHED
+sequences	O
+showed	O
+the	O
+clear	O
+separation	B-DISO
+of	O
+sequences	O
+analysed	O
+on	O
+the	O
+basis	O
+of	O
+virulence	B-PROC
+and	O
+geographical	O
+origin	O
+.	O
+
+ABSTRACT	O
+:	O
+Talking	B-PROC
+about	O
+stress	O
+implies	O
+that	O
+we	O
+are	O
+talking	O
+about	O
+two	O
+things	O
+:	O
+an	O
+event	O
+and	O
+a	O
+response	O
+to	O
+that	O
+event	O
+.	O
+
+ABSTRACT	O
+:	O
+SARS	B-DISO
+posed	O
+a	O
+serious	O
+challenge	O
+for	O
+the	O
+healthcare	O
+field	O
+,	O
+not	O
+just	O
+from	O
+the	O
+point	O
+of	O
+view	O
+of	O
+how	O
+we	O
+provide	O
+care	O
+but	O
+also	O
+how	O
+we	O
+communicate	O
+with	O
+hospital	O
+staff	O
+and	O
+the	O
+public	O
+.	O
+
+TITLE	O
+:	O
+Low	O
+risk	O
+of	O
+transmission	O
+of	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+on	O
+airplanes	O
+:	O
+the	O
+Singapore	O
+experience	O
+.	O
+
+TITLE	O
+:	O
+Air	B-CHED
+pollution	O
+and	O
+case	O
+fatality	O
+of	O
+SARS	B-DISO
+in	O
+the	O
+People	O
+'	O
+s	O
+Republic	O
+of	O
+China	O
+:	O
+an	O
+ecologic	O
+study	O
+.	O
+
+ABSTRACT	O
+:	O
+Severe	O
+acute	O
+respiratory	O
+syndrome	O
+(	O
+SARS	B-DISO
+)	O
+has	O
+claimed	O
+349	O
+lives	O
+with	O
+5	O
+,	O
+327	O
+probable	O
+cases	O
+reported	O
+in	O
+mainland	O
+China	O
+since	O
+November	O
+2002	O
+.	O
+
+SARS	B-DISO
+case	O
+fatality	O
+has	O
+varied	O
+across	O
+geographical	O
+areas	O
+,	O
+which	O
+might	O
+be	O
+partially	O
+explained	O
+by	O
+air	B-CHED
+pollution	O
+level	O
+.	O
+
+Air	B-CHED
+pollution	O
+was	O
+evaluated	O
+by	O
+air	B-CHED
+pollution	O
+index	O
+(	O
+API	B-SPEC
+)	O
+derived	O
+from	O
+the	O
+concentrations	O
+of	O
+particulate	O
+matter	O
+,	O
+sulfur	B-CHED
+dioxide	I-CHED
+,	O
+nitrogen	B-CHED
+dioxide	I-CHED
+,	O
+carbon	B-CHED
+monoxide	I-CHED
+and	O
+ground	O
+-	O
+level	O
+ozone	B-CHED
+.	O
+
+Partially	O
+ecologic	O
+analysis	O
+based	O
+on	O
+long	O
+-	O
+term	O
+exposure	O
+to	O
+ambient	O
+air	B-CHED
+pollution	O
+showed	O
+the	O
+similar	O
+association	O
+.	O
+
+Although	O
+ecologic	O
+fallacy	O
+and	O
+uncontrolled	O
+confounding	O
+effect	O
+might	O
+have	O
+biased	O
+the	O
+results	O
+,	O
+the	O
+possibility	O
+of	O
+a	O
+detrimental	O
+effect	O
+of	O
+air	B-CHED
+pollution	O
+on	O
+the	O
+prognosis	O
+of	O
+SARS	B-DISO
+patients	O
+deserves	O
+further	O
+investigation	O
+.	O
+
+ABSTRACT	O
+:	O
+Severe	O
+acute	O
+respiratory	O
+syndrome	O
+(	O
+SARS	B-DISO
+)	O
+is	O
+a	O
+newly	O
+recognised	O
+and	O
+highly	O
+contagious	O
+respiratory	B-DISO
+infection	I-DISO
+caused	O
+by	O
+a	O
+new	O
+strain	O
+of	O
+coronavirus	B-SPEC
+.	O
+
+Viruses	B-SPEC
+stayed	O
+stable	O
+at	O
+4	O
+degrees	O
+C	O
+,	O
+at	O
+room	O
+temperature	O
+(	O
+20	O
+degrees	O
+C	O
+)	O
+and	O
+at	O
+37	O
+degrees	O
+C	O
+for	O
+at	O
+least	O
+2	O
+h	O
+without	O
+remarkable	O
+change	O
+in	O
+the	O
+infectious	B-DISO
+ability	O
+in	O
+cells	B-COMP
+,	O
+but	O
+were	O
+converted	O
+to	O
+be	O
+non	O
+-	O
+infectious	B-DISO
+after	O
+90	O
+-,	O
+60	O
+-	O
+and	O
+30	O
+-	O
+min	O
+exposure	O
+at	O
+56	O
+degrees	O
+C	O
+,	O
+at	O
+67	O
+degrees	O
+C	O
+and	O
+at	O
+75	O
+degrees	O
+C	O
+,	O
+respectively	O
+.	O
+
+Severe	O
+acute	O
+respiratory	O
+syndrome	O
+(	O
+SARS	B-DISO
+)	O
+is	O
+used	O
+as	O
+a	O
+case	O
+example	O
+because	O
+it	O
+is	O
+an	O
+emerging	O
+infection	B-DISO
+and	O
+a	O
+prime	O
+example	O
+of	O
+the	O
+type	O
+of	O
+disease	O
+that	O
+pharmacists	O
+may	O
+encounter	O
+in	O
+daily	O
+practice	O
+(	O
+e	O
+.	O
+g	O
+.,	O
+easily	O
+transmitted	B-DISO
+,	O
+resembles	O
+the	O
+common	B-DISO
+cold	I-DISO
+).	O
+
+Data	O
+on	O
+current	O
+SARS	B-DISO
+cases	O
+in	O
+Hong	O
+Kong	O
+were	O
+obtained	O
+from	O
+the	O
+Hong	O
+Kong	O
+Department	O
+of	O
+Health	O
+Web	B-DISO
+site	O
+.	O
+
+Descriptive	O
+statistics	O
+were	O
+calculated	O
+for	O
+incidence	O
+,	O
+prevalence	O
+,	O
+and	O
+the	O
+number	O
+of	O
+deaths	B-PROC
+due	O
+to	O
+SARS	B-DISO
+in	O
+Hong	O
+Kong	O
+from	O
+March	O
+14	O
+to	O
+May	O
+31	O
+,	O
+2003	O
+.	O
+
+In	O
+this	O
+review	O
+,	O
+the	O
+potential	O
+of	O
+the	O
+zoonotic	O
+transmission	O
+of	O
+bovine	B-SPEC
+,	O
+feline	B-SPEC
+and	O
+equine	B-SPEC
+foamy	O
+retroviruses	B-SPEC
+will	O
+be	O
+discussed	O
+in	O
+the	O
+light	O
+of	O
+well	O
+-	O
+documented	O
+cases	O
+of	O
+zoonotic	O
+transmissions	O
+of	O
+different	O
+simian	O
+foamy	O
+viruses	O
+to	O
+humans	B-SPEC
+.	O
+
+The	O
+serum	B-PRGE
+anti	I-PRGE
+-	I-PRGE
+coronavirus	B-SPEC
+IgG	B-COMP
+antibody	I-COMP
+titer	O
+in	O
+patients	O
+recovered	O
+from	O
+SARS	B-DISO
+was	O
+0	O
+.	O
+07	O
++/-	O
+
+0	O
+.	O
+20	O
+,	O
+which	O
+was	O
+also	O
+significantly	O
+higher	O
+as	O
+compared	O
+with	O
+those	O
+in	O
+community	B-DISO
+acquired	I-DISO
+pneumonia	I-DISO
+patients	O
+and	O
+healthy	O
+persons	O
+.	O
+
+0	O
+.	O
+25	O
+and	O
+that	O
+of	O
+samples	O
+from	O
+Shandong	O
+province	O
+where	O
+SARS	B-DISO
+was	O
+not	O
+found	O
+in	O
+May	O
+,	O
+2003	O
+-	O
+1	O
+.	O
+95	O
++/-	O
+0	O
+.	O
+44	O
+.	O
+
+CONCLUSIONS	O
+:	O
+Close	O
+contact	O
+with	O
+SARS	B-DISO
+patients	O
+can	O
+cause	O
+the	O
+serum	B-PRGE
+anti	I-PRGE
+-	I-PRGE
+coronavirus	B-SPEC
+antibody	B-COMP
+titer	O
+to	O
+increase	O
+significantly	O
+in	O
+medical	O
+personnel	O
+,	O
+a	O
+phenomenon	O
+deserves	O
+further	O
+study	O
+.	O
+
+ABSTRACT	O
+:	O
+To	O
+investigate	O
+the	O
+dynamic	O
+changes	O
+observed	O
+in	O
+serum	O
+levels	O
+of	O
+interleukins	O
+(	O
+ILs	B-DISO
+),	O
+tumor	B-PRGE
+necrosis	I-PRGE
+factor	I-PRGE
+-	I-PRGE
+alpha	I-PRGE
+(	O
+TNF	B-PRGE
+-	I-PRGE
+alpha	I-PRGE
+)	O
+and	O
+transforming	B-PRGE
+growth	I-PRGE
+factor	I-PRGE
+-	I-PRGE
+beta1	I-PRGE
+(	O
+TGF	B-PRGE
+-	I-PRGE
+beta1	I-PRGE
+)	O
+in	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+(	O
+SARS	B-DISO
+).	O
+
+Serum	B-COMP
+antibodies	B-COMP
+to	O
+SARS	B-DISO
+-	O
+coronavirus	B-SPEC
+(	O
+SARS	B-DISO
+-	O
+CoV	O
+)	O
+were	O
+measured	O
+only	O
+in	O
+SARS	B-DISO
+cases	O
+.	O
+
+RESULTS	O
+:	O
+The	O
+mean	O
+concentration	O
+of	O
+serum	B-COMP
+IL	B-FUNC
+-	I-FUNC
+6	I-FUNC
+in	O
+SARS	B-DISO
+patients	O
+did	O
+not	O
+differ	O
+from	O
+the	O
+control	O
+group	O
+in	O
+3	O
+-	O
+7	O
+day	O
+group	O
+and	O
+8	O
+-	O
+14	O
+day	O
+group	O
+,	O
+but	O
+became	O
+significantly	O
+higher	O
+in	O
+over	O
+14	O
+day	O
+group	O
+as	O
+compared	O
+to	O
+the	O
+control	O
+group	O
+,	O
+3	O
+-	O
+7	O
+day	O
+group	O
+and	O
+8	O
+-	O
+14	O
+day	O
+group	O
+(	O
+P	O
+<	O
+0	O
+.	O
+01	O
+).	O
+
+Peripheral	B-ANAT
+blood	I-ANAT
+from	O
+162	O
+cases	O
+of	O
+SARS	B-DISO
+,	O
+30	O
+cases	O
+of	O
+mycoplasma	B-DISO
+pneumonia	I-DISO
+and	O
+30	O
+healthy	O
+adult	O
+volunteers	O
+were	O
+measured	O
+for	O
+the	O
+number	O
+of	O
+total	O
+B	B-ANAT
+cells	I-ANAT
+(	O
+CD19	B-PRGE
++	I-PRGE
+B	I-PRGE
+cell	O
+),	O
+CD5	B-PRGE
+positive	O
+B	B-ANAT
+cells	I-ANAT
+(	O
+B1	O
+cell	B-COMP
+)	O
+and	O
+mean	O
+fluorescent	O
+intensity	O
+of	O
+CD40	B-PRGE
+on	O
+B	B-PRGE
+cell	I-PRGE
+(	O
+CD40MF	O
+)	O
+using	O
+tri	O
+-	O
+color	O
+flow	O
+cytometry	O
+to	O
+analyze	O
+the	O
+distribution	O
+of	O
+the	O
+above	O
+parameters	O
+in	O
+SARS	B-DISO
+,	O
+mycoplasma	B-DISO
+pneumonia	I-DISO
+and	O
+healthy	O
+adult	O
+volunteers	O
+and	O
+their	O
+relation	O
+to	O
+the	O
+severity	O
+of	O
+SARS	B-DISO
+.	O
+
+The	O
+B	B-ANAT
+cell	I-ANAT
+count	O
+correlated	O
+with	O
+the	O
+severity	O
+of	O
+SARS	B-DISO
+.	O
+
+ABSTRACT	O
+:	O
+To	O
+evaluate	O
+the	O
+epidemiologic	O
+feature	O
+,	O
+diagnosis	O
+and	O
+treatment	O
+of	O
+severe	O
+acute	O
+respiratory	O
+syndrome	O
+(	O
+SARS	B-DISO
+).	O
+
+It	O
+was	O
+suggested	O
+that	O
+the	O
+causes	O
+for	O
+cardiac	B-DISO
+arrest	I-DISO
+in	O
+SARS	B-DISO
+patients	O
+may	O
+include	O
+:	O
+(	O
+1	O
+)	O
+the	O
+lung	B-ANAT
+injury	O
+caused	O
+by	O
+the	O
+SARS	O
+virus	B-SPEC
+leads	O
+to	O
+hypoxemia	O
+and	O
+thus	O
+an	O
+unsteady	O
+state	O
+of	O
+the	O
+myocardial	O
+electricity	O
+;	O
+(	O
+2	O
+)	O
+SARS	B-DISO
+virus	B-SPEC
+directly	O
+causes	O
+injury	O
+to	O
+the	O
+myocardial	O
+cells	B-COMP
+and	O
+/	O
+or	O
+the	O
+conduct	B-PROC
+system	O
+;	O
+(	O
+3	O
+)	O
+SARS	B-DISO
+infection	B-DISO
+aggravates	O
+the	O
+original	O
+myocardial	O
+pathological	O
+change	O
+,	O
+worsening	O
+the	O
+conduct	B-PROC
+block	O
+;	O
+(	O
+4	O
+)	O
+extreme	O
+anxiety	O
+leads	O
+to	O
+extra	O
+secretion	B-PROC
+of	O
+catecholamine	B-CHED
+,	O
+which	O
+causes	O
+instability	O
+of	O
+myocardial	O
+electricity	O
+;	O
+(	O
+5	O
+)	O
+defecation	B-PROC
+worsens	O
+hypoxemia	O
+,	O
+which	O
+induces	O
+arrhythmia	B-DISO
+(	O
+ventricular	B-DISO
+fibrillation	I-DISO
+)	O
+and	O
+causes	O
+cardiac	B-DISO
+arrest	I-DISO
+.	O
+
+RESULTS	O
+:	O
+The	O
+RT	O
+-	O
+PCR	O
+system	O
+for	O
+the	O
+polymerase	O
+region	O
+detected	O
+SARS	B-DISO
+-	O
+CoV	O
+RNA	O
+in	O
+50	O
+%	O
+of	O
+plasma	B-ANAT
+and	O
+78	O
+%	O
+of	O
+serum	B-COMP
+samples	O
+from	O
+SARS	B-DISO
+patients	O
+during	O
+the	O
+first	O
+week	O
+of	O
+illness	O
+.	O
+
+N385	O
+had	O
+the	O
+highest	O
+affinity	O
+for	O
+forming	O
+peptide	B-CHED
+-	O
+antibody	B-COMP
+complexes	O
+with	O
+SARS	B-DISO
+serum	B-COMP
+.	O
+
+N385	O
+had	O
+the	O
+highest	O
+affinity	O
+for	O
+forming	O
+peptide	B-CHED
+-	O
+antibody	B-COMP
+complexes	O
+with	O
+SARS	B-DISO
+serum	B-COMP
+.	O
+
+Generally	O
+,	O
+affected	O
+tissues	B-ANAT
+had	O
+lower	O
+levels	O
+of	O
+IL	B-FUNC
+-	I-FUNC
+4	I-FUNC
+and	O
+IL	B-PRGE
+-	I-PRGE
+12	I-PRGE
+-	I-PRGE
+p40	B-COMP
+mRNA	B-CHED
+and	O
+higher	O
+levels	O
+of	O
+IL	B-PRGE
+-	I-PRGE
+10	I-PRGE
+mRNA	B-CHED
+.	O
+
+Although	O
+no	O
+differences	O
+in	O
+IFN	B-PRGE
+-	I-PRGE
+gamma	I-PRGE
+or	O
+TNF	B-PRGE
+-	I-PRGE
+alpha	I-PRGE
+mRNA	I-PRGE
+were	O
+measured	O
+,	O
+TNF	B-PRGE
+-	I-PRGE
+alpha	I-PRGE
+protein	I-PRGE
+expression	B-PROC
+was	O
+greater	O
+in	O
+affected	O
+tissues	B-ANAT
+and	O
+demonstrated	O
+a	O
+shift	O
+in	O
+the	O
+source	O
+of	O
+TNF	B-PRGE
+-	I-PRGE
+alpha	I-PRGE
+from	O
+macrophages	B-ANAT
+to	O
+lymphocytes	B-ANAT
+.	O
+
+Together	O
+,	O
+these	O
+results	O
+colocalize	O
+FIPV	O
+replication	O
+,	O
+lymphocyte	B-ANAT
+depletion	O
+in	O
+tissues	B-ANAT
+,	O
+and	O
+alterations	O
+in	O
+cytokine	O
+transcription	B-PROC
+and	O
+translation	B-PROC
+.	O
+
+This	O
+antibody	B-COMP
+-	O
+dependent	O
+enhancement	O
+(	O
+ADE	B-CHED
+)	O
+activity	O
+increased	O
+with	O
+the	O
+MAb	O
+that	O
+showed	O
+a	O
+neutralizing	O
+activity	O
+with	O
+feline	B-SPEC
+kidney	B-ANAT
+cells	B-COMP
+,	O
+suggesting	O
+that	O
+there	O
+was	O
+a	O
+distinct	O
+correlation	O
+between	O
+ADE	B-CHED
+activity	O
+and	O
+the	O
+neutralizing	O
+activity	O
+.	O
+
+When	O
+these	O
+vaccinated	O
+cats	B-SPEC
+were	O
+challenged	O
+with	O
+a	O
+high	O
+dose	O
+of	O
+heterologous	O
+FIPV	O
+,	O
+the	O
+survival	O
+rate	O
+was	O
+75	O
+%	O
+(	O
+6	O
+/	O
+8	O
+),	O
+while	O
+the	O
+survival	O
+rate	O
+in	O
+the	O
+control	O
+group	O
+immunized	O
+with	O
+SF	O
+-	O
+9	O
+cell	B-COMP
+-	O
+derived	O
+antigen	B-CHED
+was	O
+12	O
+.	O
+5	O
+%	O
+(	O
+1	O
+/	O
+8	O
+).	O
+
+TITLE	O
+:	O
+Predominance	O
+of	O
+rhinovirus	B-SPEC
+in	O
+the	O
+nose	B-ANAT
+of	O
+symptomatic	O
+and	O
+asymptomatic	O
+infants	O
+.	O
+
+Rhinovirus	B-SPEC
+was	O
+the	O
+most	O
+prevalent	O
+pathogen	O
+during	O
+URTI	B-DISO
+and	O
+rhinitis	B-DISO
+in	O
+0	O
+-	O
+to	O
+2	O
+-	O
+year	O
+-	O
+old	O
+infants	O
+(	O
+approximately	O
+40	O
+%).	O
+
+In	O
+conclusion	O
+,	O
+rhinovirus	B-DISO
+infection	I-DISO
+is	O
+the	O
+most	O
+prevalent	O
+respiratory	B-DISO
+viral	I-DISO
+infection	I-DISO
+in	O
+infants	O
+.	O
+
+ABSTRACT	O
+:	O
+Although	O
+most	O
+influenza	B-DISO
+infections	B-DISO
+are	O
+self	O
+-	O
+limited	O
+,	O
+few	O
+other	O
+diseases	O
+exert	O
+such	O
+a	O
+huge	O
+toll	O
+of	O
+suffering	B-DISO
+and	O
+economic	O
+loss	O
+.	O
+
+During	O
+the	O
+past	O
+decade	O
+,	O
+evidence	O
+has	O
+accrued	O
+on	O
+the	O
+protection	O
+afforded	O
+by	O
+inactivated	O
+vaccines	O
+and	O
+the	O
+safety	O
+and	O
+efficacy	O
+in	O
+children	O
+of	O
+live	O
+influenza	B-DISO
+-	O
+virus	B-SPEC
+vaccines	O
+.	O
+
+The	O
+contrast	O
+between	O
+recent	O
+cases	O
+of	O
+H5N1	B-DISO
+infection	B-DISO
+,	O
+associated	O
+with	O
+high	O
+mortality	O
+,	O
+and	O
+the	O
+typically	O
+mild	O
+,	O
+self	O
+-	O
+limiting	O
+nature	O
+of	O
+human	B-SPEC
+infections	B-DISO
+with	O
+avian	B-SPEC
+H7N7	O
+and	O
+H9N2	O
+influenza	B-DISO
+shows	O
+the	O
+gaps	O
+in	O
+our	O
+understanding	O
+of	O
+molecular	O
+correlates	O
+of	O
+pathogenicity	O
+and	O
+underlines	O
+the	O
+need	O
+for	O
+continuing	O
+international	O
+research	O
+into	O
+pandemic	O
+influenza	B-DISO
+.	O
+
+Here	O
+we	O
+consider	O
+progress	O
+to	O
+date	O
+in	O
+preparedness	O
+for	O
+an	O
+influenza	B-DISO
+pandemic	O
+and	O
+review	O
+what	O
+remains	O
+to	O
+be	O
+done	O
+.	O
+
+The	O
+replication	O
+cycle	O
+of	O
+the	O
+virus	B-SPEC
+was	O
+followed	O
+from	O
+1	O
+to	O
+30	O
+h	O
+post	O
+-	O
+infection	B-DISO
+(	O
+p	O
+.	O
+i	O
+.).	O
+
+in	O
+about	O
+5	O
+%	O
+of	O
+the	O
+cells	B-COMP
+and	O
+this	O
+increased	O
+dramatically	O
+to	O
+about	O
+30	O
+%	O
+of	O
+the	O
+cell	B-COMP
+population	O
+within	O
+an	O
+hour	O
+(	O
+6	O
+h	O
+p	O
+.	O
+i	O
+.).	O
+
+Swollen	O
+Golgi	B-COMP
+sacs	B-DISO
+contained	O
+virus	B-SPEC
+nucleocapsids	O
+at	O
+different	O
+stages	O
+of	O
+maturation	B-PROC
+.	O
+
+These	O
+virus	B-SPEC
+precursors	O
+were	O
+also	O
+in	O
+large	O
+vacuoles	B-COMP
+and	O
+in	O
+close	O
+association	O
+with	O
+membrane	B-COMP
+whorls	O
+.	O
+
+By	O
+24	O
+to	O
+30	O
+h	O
+p	O
+.	O
+i	O
+.,	O
+crystalline	O
+arrays	O
+of	O
+the	O
+extracellular	B-COMP
+virus	B-COMP
+particles	I-COMP
+were	O
+seen	O
+commonly	O
+at	O
+the	O
+cell	B-COMP
+surface	I-COMP
+.	O
+
+293T	O
+cells	B-COMP
+transfected	O
+with	O
+ACE2	B-PRGE
+,	O
+but	O
+not	O
+those	O
+transfected	O
+with	O
+human	B-PRGE
+immunodeficiency	I-PRGE
+virus	I-PRGE
+-	I-PRGE
+1	I-PRGE
+receptors	I-PRGE
+,	O
+formed	O
+multinucleated	O
+syncytia	B-ANAT
+with	O
+cells	B-COMP
+expressing	O
+S	B-PRGE
+protein	I-PRGE
+.	O
+
+New	O
+surfactants	O
+with	O
+the	O
+addition	O
+of	O
+substances	O
+to	O
+control	O
+inhibition	B-PROC
+,	O
+such	O
+as	O
+polyethyleneglycol	O
+,	O
+are	O
+being	O
+tested	O
+for	O
+diseases	O
+in	O
+which	O
+inactivation	B-DISO
+seems	O
+to	O
+be	O
+a	O
+significant	O
+factor	O
+.	O
+
+Therapy	O
+with	O
+exogenous	O
+surfactants	B-CHED
+,	O
+even	O
+as	O
+a	O
+treatment	O
+for	O
+RDS	O
+,	O
+has	O
+not	O
+been	O
+thoroughly	O
+investigated	O
+.	O
+
+CONCLUSION	O
+:	O
+Prone	O
+positioning	O
+during	O
+mechanical	O
+ventilation	O
+of	O
+children	O
+with	O
+severe	O
+hypoxemia	O
+may	O
+improve	O
+the	O
+PaO	B-PROC
+(	O
+2	O
+)/	O
+FiO	O
+(	O
+2	O
+)	O
+ratio	O
+in	O
+the	O
+first	O
+hour	O
+.	O
+
+The	O
+cDNA	O
+library	O
+of	O
+SARS	B-DISO
+-	O
+CoV	O
+(	O
+PUMC01	O
+isolate	O
+)	O
+was	O
+constructed	O
+by	O
+means	O
+of	O
+random	O
+-	O
+priming	O
+strategy	O
+.	O
+
+Using	O
+the	O
+SARS	B-PRGE
+-	I-PRGE
+CoV	I-PRGE
+PUMC2	I-PRGE
+strain	O
+genomic	O
+RNA	O
+as	O
+the	O
+template	O
+,	O
+the	O
+cDNA	O
+fragments	O
+were	O
+amplified	O
+by	O
+RT	O
+-	O
+PCR	O
+,	O
+the	O
+PCR	O
+products	O
+were	O
+further	O
+purified	O
+and	O
+ligated	O
+into	O
+the	O
+pGEM	B-CHED
+-	O
+T	O
+vector	O
+,	O
+and	O
+all	O
+the	O
+clones	O
+obtained	O
+were	O
+sequenced	O
+.	O
+
+The	O
+SARS	B-DISO
+coronavirus	B-SPEC
+recombinant	O
+N	O
+protein	B-CHED
+obtained	O
+by	O
+genetic	O
+engineering	O
+methods	O
+can	O
+be	O
+used	O
+for	O
+further	O
+functional	O
+study	O
+of	O
+SARS	B-DISO
+coronavirus	B-SPEC
+N	O
+protein	B-CHED
+.	O
+
+The	O
+number	O
+of	O
+capillaries	B-ANAT
+increased	O
+and	O
+the	O
+capillaries	B-ANAT
+clearly	O
+outlined	O
+the	O
+contour	O
+of	O
+alveolar	B-ANAT
+wall	I-ANAT
+from	O
+beginning	O
+to	O
+early	O
+stage	O
+of	O
+organization	O
+,	O
+the	O
+number	O
+of	O
+lymphocytes	B-ANAT
+decreased	O
+sharply	O
+while	O
+the	O
+number	O
+of	O
+macrophage	B-ANAT
+remarkably	O
+increased	O
+,	O
+together	O
+with	O
+proliferation	B-DISO
+of	O
+type	B-ANAT
+II	I-ANAT
+pneumocytes	I-ANAT
+.	O
+
+The	O
+numbers	O
+of	O
+blood	B-ANAT
+vessels	I-ANAT
+decreased	O
+in	O
+the	O
+fibrotic	O
+and	O
+consolidated	O
+lung	B-ANAT
+tissue	I-ANAT
+,	O
+and	O
+the	O
+vessel	B-ANAT
+cavities	B-DISO
+enlarged	O
+,	O
+losing	O
+the	O
+normal	O
+contour	O
+of	O
+alveolar	O
+septa	O
+.	O
+
+The	O
+lesions	O
+in	O
+the	O
+lung	B-ANAT
+from	O
+SARS	B-DISO
+patients	O
+are	O
+consisted	O
+of	O
+the	O
+tissue	B-ANAT
+reaction	O
+to	O
+the	O
+inflammatory	O
+injury	O
+,	O
+including	O
+extensive	O
+exudation	B-PROC
+,	O
+capillary	B-ANAT
+proliferation	B-DISO
+,	O
+fibrosis	B-DISO
+,	O
+and	O
+obvious	O
+infiltration	B-DISO
+of	O
+macrophages	B-ANAT
+which	O
+may	O
+play	O
+a	O
+key	O
+role	O
+in	O
+the	O
+pathogenesis	B-DISO
+of	O
+pulmonary	B-ANAT
+lesions	O
+of	O
+SARS	B-DISO
+.	O
+
+The	O
+patients	O
+had	O
+a	O
+moderately	O
+degree	O
+physiological	O
+impairment	B-DISO
+and	O
+increased	O
+SGRQ	O
+score	O
+.	O
+
+Scores	O
+of	O
+all	O
+four	O
+part	O
+of	O
+SGRQ	O
+correlated	O
+significantly	O
+with	O
+diffuse	O
+capacity	O
+of	O
+the	O
+lung	B-ANAT
+for	O
+carbon	B-CHED
+monoxide	I-CHED
+/	O
+pre	O
+(	O
+DLco	O
+%).	O
+
+The	O
+cured	O
+SARS	B-DISO
+patients	O
+'	O
+quality	O
+of	O
+life	O
+decrease	O
+moderately	O
+.	O
+
+ABSTRACT	O
+:	O
+To	O
+study	O
+dynamics	O
+of	O
+T	B-ANAT
+lymphocyte	I-ANAT
+subsets	I-ANAT
+in	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+(	O
+SARS	B-DISO
+).	O
+
+Fifty	O
+-	O
+six	O
+normal	O
+healthy	O
+blood	B-ANAT
+donors	O
+were	O
+also	O
+detected	O
+as	O
+normal	O
+controls	O
+.	O
+
+Compared	O
+with	O
+the	O
+results	O
+of	O
+normal	O
+controls	O
+,	O
+both	O
+of	O
+the	O
+percentages	O
+of	O
+CD4	B-PRGE
++	I-PRGE
+cells	B-COMP
+and	O
+CD8	B-PRGE
++	I-PRGE
+cells	B-COMP
+of	O
+SARS	B-DISO
+patients	O
+were	O
+in	O
+normal	O
+levels	O
+during	O
+the	O
+1st	O
+week	O
+,	O
+but	O
+the	O
+cell	B-COMP
+counts	O
+decreased	O
+significantly	O
+to	O
+(	O
+306	O
++/-	O
+
+ABSTRACT	O
+:	O
+To	O
+investigate	O
+the	O
+pulmonary	O
+function	O
+in	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+(	O
+SARS	B-DISO
+)	O
+patients	O
+during	O
+the	O
+convalescent	O
+period	O
+.	O
+
+Followup	O
+89	O
+outpatients	O
+of	O
+SARS	B-DISO
+.	O
+
+The	O
+follow	O
+-	O
+up	O
+study	O
+included	O
+interview	O
+,	O
+physical	O
+examination	O
+,	O
+and	O
+pulmonary	B-PROC
+function	I-PROC
+test	O
+.	O
+
+Dyspnea	B-DISO
+during	O
+acute	O
+phase	O
+and	O
+CT	O
+during	O
+the	O
+convalescent	O
+period	O
+were	O
+found	O
+to	O
+have	O
+significant	O
+influences	O
+on	O
+DLco	O
+and	O
+total	O
+lung	B-PROC
+capacity	I-PROC
+(	O
+TLC	O
+).	O
+
+RESULTS	O
+:	O
+The	O
+interval	O
+between	O
+hospital	O
+discharge	B-ANAT
+and	O
+functional	O
+assessment	O
+was	O
+1	O
+.	O
+75	O
++/-	O
+
+Forty	O
+-	O
+one	O
+of	O
+them	O
+died	B-PROC
+,	O
+with	O
+a	O
+case	O
+-	O
+fatality	O
+ratio	O
+of	O
+8	O
+.	O
+7	O
+%.	O
+
+There	O
+were	O
+34	O
+.	O
+7	O
+%	O
+of	O
+SARS	B-DISO
+cases	O
+without	O
+any	O
+contact	O
+histories	O
+before	O
+their	O
+onset	O
+.	O
+
+Current	O
+available	O
+measures	O
+to	O
+prevent	O
+and	O
+control	O
+SARS	B-DISO
+proved	O
+effective	O
+.	O
+
+And	O
+,	O
+7	O
+.	O
+4	O
+%	O
+(	O
+attack	O
+rate	O
+)	O
+in	O
+those	O
+exposed	O
+to	O
+SARS	B-DISO
+cases	O
+suffered	B-DISO
+the	O
+illness	O
+during	O
+the	O
+periods	B-PROC
+of	O
+quarantine	O
+.	O
+
+RESULTS	O
+:	O
+Statistical	O
+analysis	O
+by	O
+means	O
+of	O
+SAS	O
+software	O
+showed	O
+that	O
+there	O
+was	O
+significant	O
+decrease	O
+in	O
+absolute	O
+counts	O
+(	O
+AC	O
+)	O
+of	O
+T	B-ANAT
+lymphocyte	I-ANAT
+and	O
+its	O
+subsets	O
+in	O
+SARS	B-DISO
+patients	O
+when	O
+compared	O
+with	O
+normal	O
+people	O
+,	O
+while	O
+percentages	O
+(	O
+PC	O
+)	O
+of	O
+CD3	B-PRGE
++	I-PRGE
+CD25	I-PRGE
++	I-PRGE
+and	O
+CD3	B-PRGE
++	I-PRGE
+HLA	I-PRGE
+-	I-PRGE
+DR	I-PRGE
++	I-PRGE
+subsets	I-PRGE
+were	O
+increased	O
+markedly	O
+.	O
+
+TITLE	O
+:	O
+[	O
+Clinical	O
+diagnosis	O
+,	O
+treatment	O
+and	O
+prognosis	O
+of	O
+elderly	O
+SARS	B-DISO
+patients	O
+].	O
+
+Elderly	O
+patients	O
+had	O
+more	O
+respiratory	B-DISO
+symptoms	I-DISO
+,	O
+such	O
+as	O
+cough	B-DISO
+,	O
+sputum	B-ANAT
+,	O
+and	O
+shortness	B-DISO
+of	I-DISO
+breath	I-DISO
+(	O
+P	O
+<	O
+0	O
+.	O
+05	O
+).	O
+
+RESULTS	O
+:	O
+Three	O
+of	O
+thirteen	O
+patients	O
+had	O
+been	O
+intubated	O
+or	O
+received	O
+tracheotomy	O
+before	O
+they	O
+entered	O
+into	O
+ICU	O
+,	O
+the	O
+other	O
+patients	O
+received	O
+treatment	O
+of	O
+nasal	O
+cannula	B-SPEC
+or	O
+oxygen	B-CHED
+mask	O
+.	O
+
+ABSTRACT	O
+:	O
+We	O
+have	O
+cloned	O
+,	O
+expressed	O
+,	O
+and	O
+characterized	O
+the	O
+full	O
+-	O
+length	O
+and	O
+various	O
+soluble	O
+fragments	O
+of	O
+the	O
+SARS	B-PRGE
+-	I-PRGE
+CoV	I-PRGE
+(	O
+Tor2	O
+isolate	O
+)	O
+S	O
+glycoprotein	B-CHED
+.	O
+
+S	O
+and	O
+its	O
+soluble	O
+ectodomain	O
+,	O
+S	O
+(	O
+e	O
+),	O
+were	O
+not	O
+cleaved	B-ANAT
+to	O
+any	O
+significant	O
+degree	O
+.	O
+
+Together	O
+with	O
+data	O
+for	O
+inhibition	O
+of	O
+binding	O
+by	O
+antibodies	B-COMP
+developed	O
+against	O
+peptides	B-CHED
+from	O
+S	O
+,	O
+these	O
+findings	O
+suggest	O
+that	O
+the	O
+receptor	O
+-	O
+binding	B-FUNC
+domain	O
+is	O
+located	O
+between	O
+amino	B-CHED
+acid	I-CHED
+residues	O
+303	O
+and	O
+537	O
+.	O
+
+ABSTRACT	O
+:	O
+An	O
+enhanced	O
+polymerase	O
+chain	O
+reaction	O
+(	O
+PCR	O
+)	O
+assay	O
+to	O
+detect	O
+the	O
+coronavirus	O
+associated	O
+with	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+(	O
+SARS	B-DISO
+-	O
+CoV	O
+)	O
+was	O
+developed	O
+in	O
+which	O
+a	O
+target	O
+gene	O
+pre	O
+-	O
+amplification	B-DISO
+step	O
+preceded	O
+TaqMan	O
+real	O
+-	O
+time	O
+fluorescent	O
+PCR	O
+.	O
+
+TITLE	O
+:	O
+How	O
+would	O
+schools	O
+step	O
+up	O
+public	O
+health	O
+measures	O
+to	O
+control	O
+spread	O
+of	O
+SARS	B-DISO
+?	O
+
+Its	O
+emergence	O
+should	O
+be	O
+perceived	O
+as	O
+a	O
+disturbing	O
+alarm	O
+that	O
+underscores	O
+the	O
+need	O
+to	O
+strengthen	O
+public	O
+health	O
+and	O
+facilitate	O
+construction	O
+of	O
+a	O
+human	B-SPEC
+security	O
+""""	O
+umbrella	O
+""""	O
+in	O
+the	O
+event	O
+of	O
+future	O
+disasters	O
+.	O
+
+We	O
+predict	O
+important	O
+structural	O
+attributes	O
+of	O
+potential	O
+anti	B-PRGE
+-	I-PRGE
+SARS	I-PRGE
+-	I-PRGE
+CoV	I-PRGE
+RdRp	B-FUNC
+nucleotide	B-CHED
+analog	O
+inhibitors	B-CHED
+:	O
+hydrogen	B-CHED
+-	O
+bonding	O
+capability	O
+for	O
+the	O
+2	O
+'	O
+and	O
+3	O
+'	O
+groups	O
+of	O
+the	O
+sugar	O
+ring	O
+and	O
+C3	O
+'	O
+endo	O
+sugar	O
+puckering	O
+,	O
+and	O
+the	O
+absence	O
+of	O
+a	O
+hydrophobic	O
+binding	B-FUNC
+pocket	O
+for	O
+non	O
+-	O
+nucleoside	B-CHED
+analog	O
+inhibitors	B-CHED
+similar	O
+to	O
+those	O
+observed	O
+in	O
+hepatitis	B-PRGE
+C	I-PRGE
+virus	I-PRGE
+RdRp	B-FUNC
+and	I-PRGE
+human	B-SPEC
+immunodeficiency	I-SPEC
+virus	I-SPEC
+type	I-SPEC
+1	I-SPEC
+reverse	B-ENZY
+transcriptase	I-ENZY
+.	O
+
+We	O
+propose	O
+that	O
+the	O
+clinically	O
+observed	O
+resistance	B-PROC
+of	O
+SARS	B-DISO
+to	O
+ribavirin	B-CHED
+is	O
+probably	O
+due	O
+to	O
+perturbation	O
+of	O
+the	O
+conserved	O
+motif	O
+A	O
+that	O
+controls	O
+rNTP	O
+binding	B-FUNC
+and	O
+fidelity	O
+of	O
+polymerization	O
+.	O
+
+ABSTRACT	O
+:	O
+The	O
+SARS	O
+virus	B-SPEC
+origin	O
+which	O
+obviously	O
+differs	O
+from	O
+the	O
+theory	O
+of	O
+out	O
+-	O
+space	O
+origin	O
+and	O
+the	O
+theory	O
+of	O
+wildlife	O
+origin	O
+was	O
+theoretically	O
+discussed	O
+based	O
+on	O
+principles	O
+of	O
+pollution	O
+-	O
+evolution	B-PROC
+ecology	O
+,	O
+pathogenesis	B-DISO
+and	O
+infectant	O
+characteristics	O
+of	O
+SARS	B-DISO
+,	O
+and	O
+some	O
+relevant	O
+experimental	O
+evidence	O
+.	O
+
+The	O
+SARS	B-DISO
+outbreak	O
+in	O
+Toronto	O
+was	O
+the	O
+result	O
+of	O
+a	O
+single	O
+index	O
+patient	O
+.	O
+
+CONCLUSIONS	O
+:	O
+In	O
+containing	O
+the	O
+spread	O
+of	O
+SARS	B-DISO
+,	O
+vigilance	O
+and	O
+strict	O
+infection	B-DISO
+control	O
+are	O
+important	O
+.	O
+
+Diagnostic	O
+assays	O
+on	O
+the	O
+fluid	O
+in	O
+cats	B-SPEC
+with	O
+body	B-ANAT
+effusion	B-DISO
+had	O
+good	O
+predictive	O
+values	O
+.	O
+
+Definitive	O
+diagnosis	O
+of	O
+FIP	B-DISO
+on	O
+the	O
+basis	O
+of	O
+measurement	O
+of	O
+various	O
+variables	O
+in	O
+serum	B-COMP
+was	O
+not	O
+possible	O
+.	O
+
+Serum	B-COMP
+tests	O
+can	O
+only	O
+be	O
+used	O
+to	O
+facilitate	O
+the	O
+decision	O
+for	O
+more	O
+invasive	O
+diagnostic	O
+methods	O
+.	O
+
+Among	O
+the	O
+intracellular	B-COMP
+viral	O
+RNP	B-COMP
+complexes	O
+,	O
+only	O
+the	O
+genomic	O
+RNP	B-COMP
+complex	O
+is	O
+packaged	O
+into	O
+virus	B-COMP
+particles	I-COMP
+.	O
+
+Tissue	B-ANAT
+sections	O
+were	O
+stained	O
+with	O
+haematoxylin	B-CHED
+and	O
+eosin	O
+(	O
+H	O
+&	O
+E	O
+),	O
+and	O
+in	O
+situ	O
+reverse	B-ENZY
+transcriptase	I-ENZY
+polymerase	O
+chain	O
+reaction	O
+(	O
+RT	O
+-	O
+PCR	O
+)	O
+on	O
+lung	B-ANAT
+sections	O
+was	O
+performed	O
+using	O
+SARS	B-DISO
+coronavirus	B-SPEC
+-	O
+specific	O
+primers	O
+.	O
+
+There	O
+were	O
+thromboemboli	O
+in	O
+some	O
+bronchial	B-ANAT
+arterioles	B-ANAT
+.	O
+
+Matching	O
+was	O
+done	O
+with	O
+respect	O
+to	O
+age	O
+,	O
+sex	O
+,	O
+the	O
+presence	O
+of	O
+co	O
+-	O
+morbidities	O
+,	O
+lactate	B-PRGE
+dehydrogenase	I-PRGE
+level	O
+and	O
+the	O
+use	O
+of	O
+pulse	B-PROC
+steroid	B-CHED
+therapy	O
+.	O
+
+The	O
+75	O
+patients	O
+treated	O
+with	O
+lopinavir	O
+/	O
+ritonavir	B-CHED
+were	O
+divided	O
+into	O
+two	O
+subgroups	O
+for	O
+analysis	O
+:	O
+lopinavir	O
+/	O
+ritonavir	B-CHED
+as	O
+initial	O
+treatment	O
+,	O
+and	O
+lopinavir	O
+/	O
+ritonavir	B-CHED
+as	O
+rescue	O
+therapy	O
+.	O
+
+The	O
+addition	O
+of	O
+lopinavir	O
+/	O
+ritonavir	B-CHED
+as	O
+initial	O
+treatment	O
+was	O
+associated	O
+with	O
+a	O
+reduction	O
+in	O
+the	O
+overall	O
+death	B-PROC
+rate	O
+(	O
+2	O
+.	O
+3	O
+%)	O
+and	O
+intubation	O
+rate	O
+(	O
+0	O
+%),	O
+when	O
+compared	O
+with	O
+a	O
+matched	O
+cohort	O
+who	O
+received	O
+standard	O
+treatment	O
+(	O
+15	O
+.	O
+6	O
+%	O
+and	O
+11	O
+.	O
+0	O
+%	O
+respectively	O
+,	O
+P	O
+<	O
+0	O
+.	O
+05	O
+)	O
+and	O
+a	O
+lower	O
+rate	O
+of	O
+use	O
+of	O
+methylprednisolone	B-CHED
+at	O
+a	O
+lower	O
+mean	O
+dose	O
+.	O
+
+The	O
+subgroup	O
+who	O
+had	O
+received	O
+lopinavir	O
+/	O
+ritonavir	B-CHED
+as	O
+rescue	O
+therapy	O
+,	O
+showed	O
+no	O
+difference	O
+in	O
+overall	O
+death	B-PROC
+rate	O
+and	O
+rates	O
+of	O
+oxygen	B-CHED
+desaturation	O
+and	O
+intubation	O
+compared	O
+with	O
+the	O
+matched	O
+cohort	O
+,	O
+and	O
+received	O
+a	O
+higher	O
+mean	O
+dose	O
+of	O
+methylprednisolone	B-CHED
+.	O
+
+ABSTRACT	O
+:	O
+Emerging	O
+viral	B-DISO
+infections	I-DISO
+in	O
+both	O
+humans	O
+and	O
+animals	B-SPEC
+have	O
+been	O
+reported	O
+with	O
+increased	O
+frequency	O
+in	O
+recent	O
+years	O
+.	O
+
+TITLE	O
+:	O
+Diagnosis	O
+of	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+(	O
+SARS	B-DISO
+)	O
+by	O
+detection	O
+of	O
+SARS	B-DISO
+coronavirus	B-SPEC
+nucleocapsid	B-ANAT
+antibodies	B-COMP
+in	O
+an	O
+antigen	B-CHED
+-	O
+capturing	O
+enzyme	O
+-	O
+linked	O
+immunosorbent	O
+assay	O
+.	O
+
+Antinucleocapsid	B-PRGE
+protein	I-PRGE
+antibodies	B-COMP
+could	O
+be	O
+detected	O
+in	O
+68	O
+.	O
+4	O
+%	O
+of	O
+probable	O
+SARS	B-DISO
+patients	O
+6	O
+to	O
+10	O
+days	O
+after	O
+illness	O
+and	O
+in	O
+89	O
+.	O
+6	O
+%	O
+of	O
+the	O
+patients	O
+11	O
+to	O
+61	O
+days	O
+after	O
+illness	O
+.	O
+
+Among	O
+940	O
+other	O
+non	O
+-	O
+SARS	B-DISO
+clinical	O
+serum	B-COMP
+samples	O
+,	O
+only	O
+1	O
+was	O
+found	O
+to	O
+be	O
+weakly	O
+positive	O
+.	O
+
+TITLE	O
+:	O
+Severe	O
+community	O
+-	O
+acquired	O
+pneumococcal	B-DISO
+pneumonia	I-DISO
+(	O
+CAP	B-DISO
+)	O
+-	O
+a	O
+potentially	O
+fatal	O
+illness	O
+.	O
+
+These	O
+two	O
+cases	O
+illustrate	O
+the	O
+usefulness	O
+of	O
+the	O
+British	O
+Thoracic	B-DISO
+Society	O
+severity	O
+criteria	O
+and	O
+serve	O
+to	O
+emphasize	O
+the	O
+importance	O
+of	O
+early	O
+recognition	O
+of	O
+adverse	O
+physiology	O
+in	O
+critically	B-DISO
+ill	I-DISO
+patients	O
+.	O
+
+The	O
+nucleotide	B-CHED
+sequence	O
+and	O
+projected	O
+amino	B-CHED
+acid	I-CHED
+sequence	O
+comparison	O
+of	O
+the	O
+P	B-PRGE
+gene	I-PRGE
+of	O
+different	O
+isolates	O
+of	O
+TCoV	O
+from	O
+5	O
+different	O
+states	O
+in	O
+the	O
+United	O
+States	O
+revealed	O
+a	O
+close	O
+association	O
+among	O
+the	O
+different	O
+isolates	O
+of	O
+TCoV	O
+.	O
+
+ABSTRACT	O
+:	O
+The	O
+causative	O
+agent	O
+of	O
+severe	O
+acute	O
+respiratory	O
+syndrome	O
+(	O
+SARS	B-DISO
+)	O
+has	O
+been	O
+identified	O
+as	O
+a	O
+new	O
+type	O
+of	O
+coronavirus	B-SPEC
+.	O
+
+Presenting	O
+symptoms	O
+included	O
+fever	B-PROC
+(	O
+100	O
+%),	O
+cough	B-DISO
+(	O
+69	O
+.	O
+0	O
+%),	O
+chills	B-DISO
+or	O
+rigor	B-DISO
+(	O
+62	O
+.	O
+1	O
+%),	O
+and	O
+shortness	B-DISO
+of	I-DISO
+breath	I-DISO
+(	O
+41	O
+.	O
+4	O
+%).	O
+
+The	O
+193	O
+-	O
+residue	O
+fragment	O
+blocked	O
+S	O
+protein	B-CHED
+-	O
+mediated	O
+infection	B-DISO
+with	O
+an	O
+IC	O
+(	O
+50	O
+)	O
+of	O
+less	O
+than	O
+10	O
+nm	O
+,	O
+whereas	O
+the	O
+IC	O
+(	O
+50	O
+)	O
+of	O
+the	O
+S1	B-PRGE
+domain	I-PRGE
+was	O
+approximately	O
+50	O
+nm	O
+.	O
+
+These	O
+data	O
+identify	O
+an	O
+independently	O
+folded	O
+receptor	O
+-	O
+binding	O
+domain	O
+of	O
+the	O
+SARS	B-PRGE
+-	I-PRGE
+CoV	I-PRGE
+S	I-PRGE
+protein	B-CHED
+.	O
+
+TITLE	O
+:	O
+Mosaic	O
+evolution	B-PROC
+of	O
+the	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+coronavirus	B-SPEC
+.	O
+
+These	O
+data	O
+support	O
+the	O
+phylogenetic	O
+analyses	O
+and	O
+suggest	O
+a	O
+possible	O
+past	O
+recombination	B-PROC
+event	O
+between	O
+mammalian	B-SPEC
+-	O
+like	O
+and	O
+avian	B-SPEC
+-	O
+like	O
+parent	O
+viruses	B-SPEC
+.	O
+
+These	O
+results	O
+collectively	O
+indicated	O
+that	O
+the	O
+N	B-PRGE
+domain	I-PRGE
+retains	O
+all	O
+biological	O
+activities	O
+necessary	O
+for	O
+receptor	B-PROC
+function	I-PROC
+.	O
+
+Each	O
+deletion	O
+strain	O
+was	O
+transformed	O
+to	O
+express	O
+BMV	O
+replicase	O
+proteins	B-CHED
+and	O
+a	O
+BMV	B-SPEC
+RNA	B-PROC
+replication	I-PROC
+template	O
+with	O
+the	O
+capsid	B-PRGE
+gene	I-PRGE
+replaced	O
+by	O
+a	O
+luciferase	B-ENZY
+reporter	O
+.	O
+
+Newly	O
+identified	O
+genes	O
+include	O
+some	O
+in	O
+RNA	O
+,	O
+protein	B-CHED
+,	O
+or	O
+membrane	B-COMP
+modification	O
+pathways	B-PROC
+and	O
+genes	O
+of	O
+unknown	O
+function	O
+.	O
+
+A	O
+group	O
+at	O
+the	O
+Joint	B-ANAT
+Centre	O
+for	O
+Bioethics	O
+(	O
+JCB	O
+)	O
+at	O
+the	O
+University	O
+of	O
+Toronto	O
+formally	O
+explored	O
+the	O
+ethical	O
+dimensions	O
+of	O
+this	O
+outbreak	O
+.	O
+
+TITLE	O
+:	O
+The	O
+secret	O
+life	O
+of	O
+ACE2	O
+as	O
+a	O
+receptor	O
+for	O
+the	O
+SARS	B-DISO
+virus	B-SPEC
+.	O
+
+All	O
+patients	O
+demonstrated	O
+C	O
+-	O
+peptide	B-CHED
+and	O
+insulin	B-PRGE
+production	O
+indicating	O
+graft	B-ANAT
+function	O
+.	O
+
+When	O
+the	O
+outbreak	O
+of	O
+this	O
+apparently	O
+novel	O
+infectious	B-DISO
+disease	I-DISO
+termed	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+(	O
+SARS	B-DISO
+)	O
+came	O
+to	O
+an	O
+end	O
+in	O
+July	O
+2003	O
+,	O
+it	O
+had	O
+caused	O
+over	O
+8000	O
+probable	O
+cases	O
+worldwide	O
+and	O
+more	O
+than	O
+700	O
+deaths	B-PROC
+.	O
+
+ABSTRACT	O
+:	O
+Vaccines	O
+against	O
+infectious	B-DISO
+bronchitis	B-DISO
+of	O
+chickens	B-SPEC
+(	O
+Gallus	B-SPEC
+gallus	I-SPEC
+domesticus	I-SPEC
+)	O
+have	O
+arguably	O
+been	O
+the	O
+most	O
+successful	O
+,	O
+and	O
+certainly	O
+the	O
+most	O
+widely	O
+used	O
+,	O
+of	O
+vaccines	O
+for	O
+diseases	O
+caused	O
+by	O
+coronaviruses	O
+,	O
+the	O
+others	O
+being	O
+against	O
+bovine	B-SPEC
+,	O
+canine	O
+,	O
+feline	B-SPEC
+and	O
+porcine	B-SPEC
+coronaviruses	O
+.	O
+
+The	O
+virus	B-SPEC
+can	O
+persist	O
+,	O
+being	O
+re	O
+-	O
+excreted	O
+at	O
+the	O
+onset	O
+of	O
+egg	B-PROC
+laying	I-PROC
+(	O
+4	O
+to	O
+5	O
+months	O
+of	O
+age	O
+),	O
+believed	O
+to	O
+be	O
+a	O
+consequence	O
+of	O
+the	O
+stress	O
+of	O
+coming	O
+into	O
+lay	O
+.	O
+
+Although	O
+100	O
+%	O
+of	O
+chickens	B-SPEC
+may	O
+be	O
+protected	O
+(	O
+against	O
+clinical	O
+signs	O
+and	O
+loss	O
+of	O
+ciliary	O
+activity	O
+in	O
+trachea	B-DISO
+),	O
+sometimes	O
+10	O
+%	O
+of	O
+vaccinated	O
+chicks	O
+do	O
+not	O
+respond	O
+with	O
+a	O
+protective	O
+immune	B-PROC
+response	I-PROC
+.	O
+
+IBV	B-SPEC
+exists	O
+as	O
+scores	O
+of	O
+serotypes	O
+(	O
+defined	O
+by	O
+the	O
+neutralization	O
+test	O
+),	O
+cross	O
+-	O
+protection	O
+often	O
+being	O
+poor	O
+.	O
+
+In	O
+practice	O
+in	O
+the	O
+field	O
+,	O
+inactivated	O
+vaccines	O
+are	O
+used	O
+in	O
+laying	O
+birds	B-SPEC
+that	O
+have	O
+previously	O
+been	O
+primed	O
+with	O
+two	O
+or	O
+three	O
+live	O
+attenuated	O
+virus	B-SPEC
+vaccinations	O
+.	O
+
+In	O
+conclusion	O
+,	O
+live	O
+attenuated	O
+IBV	B-SPEC
+vaccines	O
+induce	O
+good	O
+,	O
+although	O
+short	O
+-	O
+lived	O
+,	O
+protection	O
+against	O
+homologous	O
+challenge	O
+,	O
+although	O
+a	O
+minority	O
+of	O
+individuals	O
+may	O
+respond	O
+poorly	O
+.	O
+
+ABSTRACT	O
+:	O
+The	O
+emergence	O
+rate	O
+of	O
+novel	O
+viruses	B-SPEC
+,	O
+such	O
+as	O
+the	O
+coronavirus	B-SPEC
+that	O
+sparked	O
+SARS	B-DISO
+,	O
+could	O
+well	O
+be	O
+on	O
+the	O
+rise	O
+.	O
+
+Data	O
+of	O
+the	O
+index	O
+SARS	B-DISO
+cases	O
+and	O
+the	O
+subsequent	O
+case	O
+clusters	B-CHED
+were	O
+collected	O
+by	O
+means	O
+of	O
+face	B-DISO
+-	O
+to	O
+-	O
+face	B-DISO
+interview	O
+in	O
+combination	O
+with	O
+field	O
+investigation	O
+and	O
+case	O
+history	O
+consultations	O
+.	O
+
+RESULTS	O
+:	O
+In	O
+all	O
+three	O
+SARS	B-DISO
+clusters	B-CHED
+,	O
+the	O
+index	O
+cases	O
+all	O
+had	O
+chronic	B-DISO
+disease	I-DISO
+and	O
+played	O
+the	O
+role	O
+of	O
+infection	B-DISO
+source	O
+that	O
+transmitted	B-DISO
+the	O
+virus	B-SPEC
+to	O
+the	O
+patients	O
+'	O
+family	B-SPEC
+members	O
+,	O
+attending	O
+medical	O
+staff	O
+as	O
+well	O
+as	O
+other	O
+non	O
+-	O
+SARS	B-DISO
+patients	O
+sharing	O
+the	O
+same	O
+ward	O
+with	O
+them	O
+.	O
+
+In	O
+a	O
+1	O
+-	O
+year	O
+community	O
+-	O
+based	O
+study	O
+,	O
+we	O
+prospectively	O
+investigated	O
+the	O
+possible	O
+virologic	O
+cause	O
+of	O
+acute	B-DISO
+respiratory	I-DISO
+infections	I-DISO
+in	O
+107	O
+symptomatic	O
+case	O
+episodes	O
+and	O
+91	O
+symptom	B-DISO
+-	O
+free	O
+control	O
+periods	B-PROC
+.	O
+
+RESULTS	O
+:	O
+In	O
+58	O
+%	O
+of	O
+the	O
+case	O
+episodes	O
+a	O
+pathogen	O
+was	O
+demonstrated	O
+,	O
+the	O
+most	O
+common	O
+being	O
+rhinoviruses	B-SPEC
+(	O
+32	O
+%),	O
+coronaviruses	O
+(	O
+17	O
+%),	O
+and	O
+influenzaviruses	O
+(	O
+7	O
+%).	O
+
+We	O
+attempted	O
+to	O
+interview	O
+passengers	O
+and	O
+crew	O
+members	O
+at	O
+least	O
+10	O
+days	O
+after	O
+they	O
+had	O
+taken	O
+one	O
+of	O
+three	O
+flights	O
+that	O
+transported	O
+a	O
+patient	O
+or	O
+patients	O
+with	O
+SARS	B-DISO
+.	O
+
+After	O
+one	O
+flight	B-PROC
+carrying	O
+a	O
+symptomatic	O
+person	O
+and	O
+119	O
+other	O
+persons	O
+,	O
+laboratory	O
+-	O
+confirmed	O
+SARS	B-DISO
+developed	O
+in	O
+16	O
+persons	O
+,	O
+2	O
+others	O
+were	O
+given	O
+diagnoses	O
+of	O
+probable	O
+SARS	B-DISO
+,	O
+and	O
+4	O
+were	O
+reported	O
+to	O
+have	O
+SARS	O
+but	O
+could	O
+not	O
+be	O
+interviewed	O
+.	O
+
+Among	O
+the	O
+22	O
+persons	O
+with	O
+illness	O
+,	O
+the	O
+mean	O
+time	O
+from	O
+the	O
+flight	B-PROC
+to	O
+the	O
+onset	O
+of	O
+symptoms	O
+was	O
+four	O
+days	O
+(	O
+range	O
+,	O
+two	O
+to	O
+eight	O
+),	O
+and	O
+there	O
+were	O
+no	O
+recognized	O
+exposures	O
+to	O
+patients	O
+with	O
+SARS	B-DISO
+before	O
+or	O
+after	O
+the	O
+flight	B-PROC
+.	O
+
+Transmission	O
+of	O
+SARS	B-DISO
+may	O
+occur	O
+on	O
+an	O
+aircraft	O
+when	O
+infected	O
+persons	O
+fly	B-SPEC
+during	O
+the	O
+symptomatic	O
+phase	O
+of	O
+illness	O
+.	O
+
+Reticulation	O
+with	O
+associated	O
+architectural	O
+distortion	B-DISO
+and	O
+mild	O
+traction	B-DISO
+bronchiectasis	I-DISO
+was	O
+present	O
+in	O
+eight	O
+patients	O
+.	O
+
+There	O
+was	O
+no	O
+evidence	O
+of	O
+pleural	O
+reaction	O
+,	O
+lymphadenopathy	O
+,	O
+or	O
+interstitial	B-ANAT
+changes	O
+.	O
+
+ABSTRACT	O
+:	O
+Severe	O
+acute	O
+respiratory	O
+syndrome	O
+(	O
+SARS	B-DISO
+)	O
+is	O
+a	O
+serious	O
+atypical	B-DISO
+pneumonia	I-DISO
+caused	O
+by	O
+a	O
+novel	O
+pathogen	O
+.	O
+
+This	O
+scanner	O
+was	O
+used	O
+exclusively	O
+for	O
+patients	O
+with	O
+SARS	B-DISO
+and	O
+patients	O
+with	O
+other	O
+illnesses	O
+who	O
+were	O
+also	O
+thought	O
+to	O
+have	O
+SARS	B-DISO
+.	O
+
+CONCLUSIONS	O
+:	O
+Mobile	O
+CT	O
+may	O
+be	O
+used	O
+to	O
+provide	O
+dedicated	O
+radiology	O
+services	O
+to	O
+seriously	O
+ill	B-DISO
+patients	O
+requiring	O
+strict	O
+isolation	O
+during	O
+an	O
+infectious	O
+disease	O
+outbreak	O
+.	O
+
+TITLE	O
+:	O
+Identification	O
+of	O
+a	O
+putative	O
+cellular	B-COMP
+receptor	O
+150	O
+kDa	O
+polypeptide	B-CHED
+for	O
+porcine	B-SPEC
+epidemic	B-DISO
+diarrhea	I-DISO
+virus	I-SPEC
+in	O
+porcine	B-SPEC
+enterocytes	B-ANAT
+.	O
+
+The	O
+virus	B-SPEC
+is	O
+notoriously	O
+fickle	O
+and	O
+may	O
+attack	O
+citizens	O
+in	O
+say	O
+two	O
+adjacent	O
+countries	O
+but	O
+not	O
+the	O
+third	O
+.	O
+
+Both	O
+drugs	O
+can	O
+be	O
+used	O
+prophylactically	O
+to	O
+prevent	O
+spread	O
+of	O
+infection	B-DISO
+in	O
+families	O
+and	O
+communities	O
+where	O
+80	O
+-	O
+90	O
+%	O
+protection	O
+has	O
+been	O
+documented	O
+.	O
+
+ABSTRACT	O
+:	O
+We	O
+have	O
+previously	O
+shown	O
+that	O
+mitochondrial	B-PRGE
+-	I-PRGE
+aconitase	B-ENZY
+binds	B-FUNC
+specifically	O
+to	O
+the	O
+3	O
+'	O
+terminal	O
+42	O
+nucleotides	B-CHED
+of	O
+the	O
+Murine	B-DISO
+hepatitis	I-DISO
+virus	B-SPEC
+(	O
+MHV	B-SPEC
+)	O
+RNA	O
+along	O
+with	O
+three	O
+additional	O
+proteins	B-CHED
+of	O
+70	O
+,	O
+58	O
+and	O
+40	O
+kDa	O
+to	O
+form	O
+a	O
+stable	O
+RNA	B-COMP
+-	I-COMP
+protein	I-COMP
+complex	I-COMP
+.	O
+
+ABSTRACT	O
+:	O
+Paroxetine	O
+,	O
+a	O
+selective	O
+serotonin	B-CHED
+reuptake	I-CHED
+inhibitor	I-CHED
+(	O
+SSRI	B-CHED
+)	O
+may	O
+be	O
+given	O
+in	O
+severe	O
+cases	O
+of	O
+maternal	O
+depression	B-DISO
+and	O
+panic	B-DISO
+disorders	I-DISO
+during	O
+pregnancy	O
+.	O
+
+Later	O
+we	O
+learned	B-PROC
+that	O
+the	O
+patient	O
+'	O
+s	O
+mother	O
+had	O
+been	O
+treated	O
+with	O
+Paroxetine	B-CHED
+during	O
+pregnancy	O
+.	O
+
+At	O
+day	O
+10	O
+she	O
+was	O
+discharged	O
+in	O
+good	O
+condition	B-DISO
+.	O
+
+Paroxetine	B-CHED
+withdrawal	B-DISO
+syndrome	I-DISO
+should	O
+be	O
+considered	O
+as	O
+one	O
+of	O
+the	O
+differential	O
+diagnosis	O
+of	O
+neonatal	B-DISO
+encephalopathy	I-DISO
+.	O
+
+Near	O
+-	O
+drowning	O
+in	O
+the	O
+Dead	B-PROC
+Sea	O
+is	O
+expected	O
+to	O
+result	O
+in	O
+severe	O
+electrolyte	O
+abnormalities	O
+and	O
+respiratory	B-DISO
+failure	I-DISO
+.	O
+
+To	O
+evaluate	O
+the	O
+clinical	O
+and	O
+biochemical	O
+manifestations	O
+and	O
+disease	O
+outcome	O
+of	O
+near	O
+-	O
+drowning	O
+in	O
+the	O
+Dead	B-PROC
+Sea	O
+.	O
+
+The	O
+cohort	O
+comprised	O
+69	O
+patients	O
+who	O
+nearly	O
+drowned	O
+in	O
+the	O
+Dead	B-PROC
+Sea	O
+.	O
+
+Median	O
+serum	B-COMP
+electrolyte	O
+levels	O
+(	O
+and	O
+range	O
+)	O
+on	O
+admission	O
+were	O
+10	O
+.	O
+9	O
+mg	O
+/	O
+dl	O
+(	O
+9	O
+-	O
+24	O
+)	O
+for	O
+calcium	B-CHED
+,	O
+4	O
+.	O
+3	O
+mg	O
+/	O
+dl	O
+(	O
+1	O
+-	O
+30	O
+)	O
+for	O
+magnesium	B-CHED
+,	O
+and	O
+4	O
+.	O
+1	O
+mg	O
+/	O
+dl	O
+(	O
+2	O
+-	O
+9	O
+)	O
+for	O
+phosphorus	B-CHED
+.	O
+
+These	O
+levels	O
+quickly	O
+normalized	O
+with	O
+forced	O
+diuresis	B-PROC
+within	O
+24	O
+hours	O
+.	O
+
+ABSTRACT	O
+:	O
+To	O
+identify	O
+potential	O
+pathogens	O
+in	O
+feces	O
+from	O
+llama	B-SPEC
+and	O
+alpaca	B-SPEC
+crias	O
+with	O
+diarrhea	B-DISO
+.	O
+
+Results	O
+suggest	O
+that	O
+a	O
+variety	O
+of	O
+potential	O
+pathogens	O
+may	O
+be	O
+isolated	O
+from	O
+young	O
+crias	O
+with	O
+diarrhea	B-DISO
+.	O
+
+Many	O
+crias	O
+shed	O
+coronavirus	B-SPEC
+,	O
+which	O
+may	O
+also	O
+have	O
+been	O
+affecting	O
+older	O
+camelids	O
+.	O
+
+Coronavirus	B-SPEC
+was	O
+detected	O
+throughout	O
+the	O
+year	O
+,	O
+whereas	O
+protozoa	O
+were	O
+most	O
+commonly	O
+isolated	O
+during	O
+the	O
+fall	O
+and	O
+winter	O
+.	O
+
+Health	O
+care	O
+worker	O
+training	O
+in	O
+use	O
+of	O
+personal	O
+protective	O
+equipment	O
+and	O
+management	O
+of	O
+patients	O
+with	O
+SARS	O
+and	O
+establishing	O
+fever	B-PROC
+clinics	O
+and	O
+designated	O
+SARS	B-DISO
+wards	O
+in	O
+hospitals	O
+predated	O
+the	O
+steepest	O
+decline	O
+in	O
+cases	O
+.	O
+
+RESULTS	O
+:	O
+Health	O
+care	O
+worker	O
+training	O
+in	O
+use	O
+of	O
+personal	O
+protective	O
+equipment	O
+and	O
+management	O
+of	O
+patients	O
+with	O
+SARS	B-DISO
+and	O
+establishing	O
+fever	B-PROC
+clinics	O
+and	O
+designated	O
+SARS	B-DISO
+wards	O
+in	O
+hospitals	O
+predated	O
+the	O
+steepest	O
+decline	O
+in	O
+cases	O
+.	O
+
+Clinical	O
+parameters	O
+,	O
+including	O
+oxygen	B-CHED
+saturation	O
+and	O
+requirement	O
+,	O
+laboratory	O
+measures	O
+,	O
+and	O
+serial	O
+chest	B-ANAT
+radiography	O
+results	O
+.	O
+
+The	O
+interferon	B-PRGE
+alfacon	I-PRGE
+-	I-PRGE
+1	I-PRGE
+treatment	O
+group	O
+had	O
+a	O
+shorter	O
+time	O
+to	O
+50	O
+%	O
+resolution	O
+of	O
+lung	B-ANAT
+radiographic	O
+abnormalities	O
+(	O
+median	O
+time	O
+,	O
+4	O
+days	O
+vs	O
+9	O
+days	O
+;	O
+P	O
+=.	O
+001	O
+),	O
+had	O
+better	O
+oxygen	B-CHED
+saturation	O
+(	O
+P	O
+=.	O
+02	O
+),	O
+resolved	O
+their	O
+need	O
+for	O
+supplemental	O
+oxygen	B-CHED
+more	O
+rapidly	O
+(	O
+median	O
+,	O
+10	O
+days	O
+vs	O
+16	O
+days	O
+;	O
+P	O
+=.	O
+02	O
+),	O
+had	O
+less	O
+of	O
+an	O
+increase	O
+in	O
+creatine	B-PRGE
+kinase	I-PRGE
+levels	O
+(	O
+P	O
+=.	O
+03	O
+),	O
+and	O
+showed	O
+a	O
+trend	O
+toward	O
+more	O
+rapid	O
+resolution	O
+of	O
+lactate	B-PRGE
+dehydrogenase	I-PRGE
+levels	O
+compared	O
+with	O
+the	O
+group	O
+receiving	O
+corticosteroids	B-CHED
+alone	O
+.	O
+
+In	O
+this	O
+preliminary	O
+,	O
+uncontrolled	O
+study	O
+of	O
+patients	O
+with	O
+SARS	B-DISO
+,	O
+use	O
+of	O
+interferon	B-PRGE
+alfacon	I-PRGE
+-	I-PRGE
+1	I-PRGE
+plus	O
+corticosteroids	B-CHED
+was	O
+associated	O
+with	O
+reduced	O
+disease	O
+-	O
+associated	O
+impaired	B-DISO
+oxygen	B-CHED
+saturation	O
+,	O
+more	O
+rapid	O
+resolution	O
+of	O
+radiographic	O
+lung	B-ANAT
+abnormalities	O
+,	O
+and	O
+lower	O
+levels	O
+of	O
+creatine	B-PRGE
+kinase	I-PRGE
+.	O
+
+Herein	O
+,	O
+we	O
+evaluated	O
+the	O
+contributions	O
+of	O
+CXC	B-PRGE
+chemokine	I-PRGE
+ligand	I-PRGE
+10	I-PRGE
+(	O
+CXCL10	B-PRGE
+)	O
+in	O
+promoting	O
+innate	O
+defense	O
+mechanisms	O
+following	O
+coronavirus	B-DISO
+infection	I-DISO
+of	O
+the	O
+CNS	B-CHED
+.	O
+
+This	O
+led	O
+us	O
+to	O
+hypothesize	O
+that	O
+they	O
+form	O
+a	O
+molecular	O
+switch	O
+,	O
+possibly	O
+regulating	O
+a	O
+transition	B-DISO
+occurring	O
+during	O
+viral	O
+RNA	B-PROC
+synthesis	I-PROC
+.	O
+
+This	O
+template	O
+switch	O
+takes	O
+place	O
+after	O
+copying	O
+the	O
+CS	O
+sequence	O
+and	O
+was	O
+predicted	O
+in	O
+silico	O
+based	O
+on	O
+high	O
+base	O
+-	O
+pairing	O
+score	O
+between	O
+the	O
+nascent	O
+negative	O
+RNA	O
+strand	O
+and	O
+the	O
+TRS	B-DISO
+-	O
+L	O
+and	O
+minimum	O
+DeltaG	O
+.	O
+
+MHV	B-SPEC
+infection	B-DISO
+induces	O
+autophagy	B-PROC
+by	O
+a	O
+mechanism	O
+that	O
+is	O
+resistant	O
+to	O
+3	B-CHED
+-	I-CHED
+methyladenine	I-CHED
+inhibition	B-PROC
+.	O
+
+MHV	B-SPEC
+replication	O
+is	O
+impaired	B-DISO
+in	O
+autophagy	B-PROC
+knockout	O
+,	O
+APG5	B-PRGE
+-/-,	O
+embryonic	B-ANAT
+stem	I-ANAT
+cell	I-ANAT
+lines	O
+,	O
+but	O
+wild	O
+-	O
+type	O
+levels	O
+of	O
+MHV	B-SPEC
+replication	O
+are	O
+restored	O
+by	O
+expression	B-PROC
+of	O
+Apg5	B-PRGE
+in	O
+the	O
+APG5	B-PRGE
+-/-	O
+cells	B-COMP
+.	O
+
+ABSTRACT	O
+:	O
+A	O
+quantitative	O
+,	O
+real	O
+-	O
+time	O
+,	O
+nested	O
+polymerase	O
+chain	O
+reaction	O
+(	O
+PCR	O
+)	O
+method	O
+,	O
+combining	O
+the	O
+high	O
+sensitivity	O
+of	O
+nested	O
+PCR	O
+with	O
+time	O
+-	O
+saving	O
+real	O
+-	O
+time	O
+instrumentation	O
+,	O
+was	O
+developed	O
+for	O
+large	O
+-	O
+scale	O
+screening	O
+for	O
+severe	O
+acute	O
+coronavirus	O
+(	O
+SARS	B-DISO
+)	O
+coronavirus	B-SPEC
+.	O
+
+Plasma	B-ANAT
+inflammatory	O
+cytokine	O
+concentrations	O
+(	O
+interleukin	B-PRGE
+[	I-PRGE
+IL	I-PRGE
+]-	I-PRGE
+1beta	I-PRGE
+,	O
+IL	B-FUNC
+-	I-FUNC
+6	I-FUNC
+,	O
+IL	B-FUNC
+-	I-FUNC
+8	I-FUNC
+,	O
+IL	B-FUNC
+-	I-FUNC
+10	I-FUNC
+,	O
+IL	O
+-	O
+12p70	O
+,	O
+and	O
+TNF	B-PRGE
+-	I-PRGE
+alpha	I-PRGE
+)	O
+were	O
+monitored	O
+longitudinally	O
+on	O
+admission	O
+,	O
+immediately	O
+before	O
+corticosteroids	B-CHED
+,	O
+and	O
+1	O
+to	O
+2	O
+days	O
+and	O
+7	O
+to	O
+10	O
+days	O
+after	O
+the	O
+drug	O
+treatment	O
+in	O
+a	O
+cohort	O
+of	O
+pediatric	O
+patients	O
+(	O
+n	O
+=	O
+8	O
+)	O
+with	O
+virologic	O
+confirmed	O
+SARS	B-DISO
+-	I-DISO
+associated	I-DISO
+coronavirus	I-DISO
+infection	B-DISO
+.	O
+
+In	O
+addition	O
+,	O
+plasma	B-PRGE
+IL	B-FUNC
+-	I-FUNC
+10	I-FUNC
+concentration	O
+was	O
+significantly	O
+lower	O
+1	O
+to	O
+2	O
+days	O
+and	O
+7	O
+to	O
+10	O
+days	O
+after	O
+corticosteroid	B-CHED
+treatment	O
+,	O
+compared	O
+with	O
+the	O
+immediate	O
+pretreatment	O
+level	O
+.	O
+
+Other	O
+key	O
+proinflammatory	O
+cytokines	O
+,	O
+IL	B-FUNC
+-	I-FUNC
+6	I-FUNC
+and	O
+TNF	B-PRGE
+-	I-PRGE
+alpha	I-PRGE
+,	O
+showed	O
+only	O
+mildly	O
+elevated	O
+levels	O
+at	O
+the	O
+initial	O
+phase	O
+of	O
+the	O
+illness	O
+.	O
+
+91	O
+.	O
+4	O
+%	O
+and	O
+80	O
+.	O
+6	O
+%	O
+of	O
+the	O
+patients	O
+had	O
+decreased	O
+CD	O
+(	O
+4	O
+)(+)	O
+and	O
+CD	O
+(	O
+8	O
+)(+)	O
+cell	B-COMP
+counts	O
+,	O
+respectively	O
+.	O
+
+General	O
+combination	O
+therapy	O
+including	O
+antibiotics	B-CHED
+,	O
+anti	B-CHED
+-	I-CHED
+viral	I-CHED
+agents	I-CHED
+,	O
+glucocorticoids	B-CHED
+and	O
+immunity	B-PROC
+-	O
+enhancing	O
+agents	O
+,	O
+was	O
+used	O
+.	O
+
+Artificial	O
+ventilation	O
+was	O
+used	O
+in	O
+196	O
+patients	O
+including	O
+8	O
+for	O
+whom	O
+invasive	O
+mechanical	O
+ventilation	O
+was	O
+used	O
+Eighty	O
+-	O
+one	O
+(	O
+32	O
+.	O
+4	O
+%)	O
+were	O
+diagnosed	O
+as	O
+having	O
+severe	O
+type	O
+of	O
+SARS	B-DISO
+.	O
+
+25	O
+patients	O
+died	B-PROC
+of	O
+SARS	B-DISO
+.	O
+
+ABSTRACT	O
+:	O
+Severe	O
+acute	O
+respiratory	O
+syndrome	O
+(	O
+SARS	B-DISO
+)	O
+is	O
+an	O
+emerging	B-DISO
+infectious	I-DISO
+disease	I-DISO
+associated	O
+with	O
+a	O
+novel	B-SPEC
+coronavirus	I-SPEC
+and	O
+causing	O
+worldwide	O
+outbreaks	O
+.	O
+
+After	O
+the	O
+isopropyl	B-CHED
+-	I-CHED
+beta	I-CHED
+-	I-CHED
+D	I-CHED
+-	I-CHED
+thiogalactoside	I-CHED
+induction	O
+,	O
+S	B-PRGE
+protein	I-PRGE
+was	O
+expressed	B-PROC
+in	O
+the	O
+soluble	O
+form	O
+and	O
+purified	O
+by	O
+nickel	B-CHED
+-	O
+affinity	O
+chromatography	O
+to	O
+homogeneity	O
+.	O
+
+TITLE	O
+:	O
+Interpretation	O
+of	O
+diagnostic	O
+laboratory	O
+tests	O
+for	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+:	O
+the	O
+Toronto	O
+experience	O
+.	O
+
+The	O
+initial	O
+diagnosis	O
+of	O
+SARS	B-DISO
+was	O
+based	O
+on	O
+clinical	O
+and	O
+epidemiological	O
+criteria	O
+.	O
+
+Focusing	O
+on	O
+tests	O
+for	O
+SARS	B-DISO
+-	O
+CoV	O
+,	O
+we	O
+attempted	O
+to	O
+determine	O
+the	O
+optimal	O
+specimen	O
+types	O
+and	O
+timing	O
+of	O
+specimen	O
+collection	O
+.	O
+
+SARS	B-DISO
+-	O
+CoV	O
+was	O
+detected	O
+by	O
+means	O
+of	O
+reverse	O
+-	O
+transcriptase	B-PROC
+polymerase	O
+chain	O
+reaction	O
+(	O
+RT	O
+-	O
+PCR	O
+)	O
+in	O
+at	O
+least	O
+one	O
+specimen	O
+in	O
+59	O
+(	O
+54	O
+.	O
+1	O
+%)	O
+of	O
+109	O
+patients	O
+.	O
+
+Serologic	O
+test	O
+results	O
+of	O
+convalescent	O
+samples	O
+were	O
+positive	O
+in	O
+50	O
+(	O
+96	O
+.	O
+2	O
+%)	O
+of	O
+52	O
+patients	O
+for	O
+whom	O
+paired	O
+serum	B-COMP
+samples	O
+were	O
+collected	O
+during	O
+the	O
+acute	O
+and	O
+convalescent	O
+phases	O
+of	O
+the	O
+illness	O
+.	O
+
+As	O
+tests	O
+for	O
+SARS	B-DISO
+-	O
+CoV	O
+continue	O
+to	O
+be	O
+optimized	O
+,	O
+evaluation	O
+of	O
+the	O
+clinical	O
+presentation	O
+and	O
+elucidation	O
+of	O
+a	O
+contact	O
+history	O
+must	O
+remain	O
+the	O
+cornerstone	O
+of	O
+SARS	B-DISO
+diagnosis	O
+.	O
+
+TITLE	O
+:	O
+Infliximab	O
+:	O
+a	O
+new	O
+therapeutic	O
+agent	O
+in	O
+acute	B-DISO
+pancreatitis	I-DISO
+?	O
+
+ABSTRACT	O
+:	O
+Tumor	B-FUNC
+necrosis	I-FUNC
+factor	I-FUNC
+alpha	I-PRGE
+(	O
+TNF	O
+-	O
+alpha	O
+)	O
+has	O
+a	O
+central	O
+role	O
+in	O
+the	O
+pathogenesis	B-DISO
+of	O
+acute	B-DISO
+pancreatitis	I-DISO
+and	O
+related	O
+systemic	O
+complications	O
+.	O
+
+One	O
+hundred	O
+rats	B-SPEC
+were	O
+randomly	O
+divided	O
+into	O
+10	O
+groups	O
+.	O
+
+TITLE	O
+:	O
+Predictive	O
+model	O
+of	O
+diagnosing	O
+probable	O
+cases	O
+of	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+in	O
+febrile	B-PROC
+patients	O
+with	O
+exposure	O
+risk	O
+.	O
+
+ABSTRACT	O
+:	O
+Since	O
+the	O
+World	O
+Health	O
+Organization	O
+issued	O
+a	O
+global	O
+alert	O
+about	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+(	O
+SARS	B-DISO
+)	O
+on	O
+March	O
+12	O
+,	O
+2003	O
+,	O
+the	O
+illness	O
+has	O
+become	O
+a	O
+major	O
+public	O
+health	O
+challenge	O
+worldwide	O
+.	O
+
+A	O
+screening	O
+questionnaire	O
+and	O
+a	O
+set	O
+of	O
+admission	O
+criteria	O
+were	O
+applied	O
+after	O
+assessment	O
+of	O
+clinical	O
+features	O
+and	O
+chest	B-ANAT
+radiograph	O
+findings	O
+.	O
+
+However	O
+,	O
+the	O
+time	O
+sequence	O
+of	O
+symptom	B-DISO
+development	B-PROC
+was	O
+rarely	O
+discussed	O
+.	O
+
+TITLE	O
+:	O
+Validation	O
+of	O
+a	O
+novel	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+scoring	O
+system	O
+.	O
+
+All	O
+adult	O
+patients	O
+with	O
+documented	O
+fever	B-PROC
+,	O
+measured	O
+at	O
+home	O
+or	O
+at	O
+the	O
+hospital	O
+,	O
+and	O
+presenting	O
+to	O
+the	O
+ED	O
+of	O
+National	O
+Taiwan	O
+University	O
+Hospital	O
+,	O
+a	O
+2	O
+,	O
+400	O
+-	O
+bed	B-DISO
+tertiary	O
+care	O
+teaching	O
+hospital	O
+in	O
+northern	O
+Taiwan	O
+,	O
+were	O
+prospectively	O
+enrolled	O
+.	O
+
+The	O
+final	O
+diagnosis	O
+of	O
+SARS	B-DISO
+was	O
+made	O
+by	O
+the	O
+Expert	O
+Committee	O
+of	O
+the	O
+Center	O
+for	O
+Disease	O
+Control	O
+Taiwan	O
+,	O
+Republic	O
+of	O
+China	O
+,	O
+according	O
+to	O
+the	O
+criteria	O
+of	O
+Centers	O
+for	O
+Disease	O
+Control	O
+and	O
+Prevention	O
+,	O
+Atlanta	B-SPEC
+,	O
+GA	O
+.	O
+
+Eighty	O
+-	O
+two	O
+patients	O
+were	O
+finally	O
+diagnosed	O
+with	O
+SARS	B-DISO
+.	O
+
+The	O
+overall	O
+impact	O
+of	O
+these	O
+measures	O
+in	O
+preventing	O
+international	O
+spread	O
+of	O
+SARS	B-DISO
+is	O
+unknown	O
+,	O
+but	O
+the	O
+experience	O
+could	O
+contribute	O
+to	O
+the	O
+control	O
+of	O
+future	O
+epidemics	O
+.	O
+
+The	O
+use	O
+of	O
+these	O
+primers	O
+allowed	O
+the	O
+detection	O
+of	O
+viruses	B-SPEC
+that	O
+have	O
+undergone	O
+recombination	B-PROC
+around	O
+this	O
+hot	O
+spot	O
+.	O
+
+Commercial	O
+Mass	O
+-	O
+Conn	O
+and	O
+Mass	O
+-	O
+Ark	O
+vaccines	O
+were	O
+used	O
+to	O
+vaccinate	O
+commercial	O
+broiler	O
+chickens	B-SPEC
+via	O
+eye	B-ANAT
+drop	O
+once	O
+at	O
+1	O
+or	O
+10	O
+days	O
+of	O
+age	O
+or	O
+twice	O
+at	O
+1	O
+and	O
+10	O
+days	O
+of	O
+age	O
+.	O
+
+Protection	O
+was	O
+measured	O
+by	O
+failure	O
+to	O
+reisolate	O
+the	O
+challenge	O
+virus	B-SPEC
+from	O
+tracheas	B-ANAT
+5	O
+days	O
+postchallenge	O
+and	O
+complemented	O
+withthe	O
+tracheal	O
+and	O
+epithelium	B-ANAT
+thickness	O
+scores	O
+.	O
+
+The	O
+real	O
+-	O
+time	O
+quantitative	O
+RT	O
+-	O
+PCR	O
+assay	O
+for	O
+SARS	B-DISO
+CoV	O
+is	O
+potentially	O
+useful	O
+for	O
+early	O
+detection	O
+of	O
+SARS	B-DISO
+CoV	O
+.	O
+Our	O
+results	O
+suggest	O
+that	O
+genomic	O
+RNA	O
+is	O
+the	O
+predominant	O
+viral	O
+RNA	O
+species	B-SPEC
+in	O
+clinical	O
+samples	O
+.	O
+
+The	O
+study	O
+was	O
+carried	O
+out	O
+to	O
+identify	O
+the	O
+clinical	O
+pattern	O
+of	O
+Indian	O
+patients	O
+who	O
+died	B-PROC
+of	O
+ARDS	B-DISO
+.	O
+
+Thirty	O
+patients	O
+had	O
+primary	O
+pulmonary	B-DISO
+infection	I-DISO
+,	O
+18	O
+had	O
+severe	B-DISO
+sepsis	I-DISO
+with	O
+multiorgan	B-DISO
+failure	I-DISO
+,	O
+12	O
+patients	O
+had	O
+polytrauma	O
+and	O
+10	O
+each	O
+had	O
+recent	O
+abdominal	B-ANAT
+surgery	O
+and	O
+pancreatitis	B-DISO
+.	O
+
+Primary	O
+pulmonary	B-DISO
+infection	I-DISO
+was	O
+associated	O
+with	O
+ARDS	B-DISO
+is	O
+one	O
+-	O
+third	O
+of	O
+patients	O
+.	O
+
+ABSTRACT	O
+:	O
+Pulmonary	O
+involvement	O
+in	O
+cryoglobulinemia	B-DISO
+usually	O
+is	O
+mild	O
+.	O
+
+He	O
+recovered	O
+with	O
+successful	O
+steroid	B-CHED
+pulse	B-PROC
+therapy	O
+under	O
+mechanical	O
+ventilation	O
+.	O
+
+Concentrations	O
+of	O
+surfactant	B-CHED
+protein	B-CHED
+(	O
+SP	B-CHED
+)-	O
+A	O
+and	O
+SP	B-CHED
+-	O
+D	O
+in	O
+sera	B-COMP
+reflected	O
+the	O
+clinical	O
+features	O
+.	O
+
+It	O
+is	O
+recommended	O
+that	O
+these	O
+or	O
+similar	O
+protocols	O
+be	O
+used	O
+when	O
+an	O
+obstetrical	O
+unit	O
+is	O
+confronted	O
+with	O
+a	O
+large	O
+-	O
+scale	O
+nosocomial	O
+infectious	O
+outbreak	O
+that	O
+has	O
+a	O
+mechanism	O
+of	O
+transmission	O
+similar	O
+to	O
+that	O
+of	O
+SARS	B-DISO
+.	O
+
+These	O
+results	O
+suggest	O
+a	O
+possible	O
+binding	B-FUNC
+region	O
+for	O
+the	O
+SARS	B-PRGE
+-	I-PRGE
+CoV	I-PRGE
+S	I-PRGE
+-	I-PRGE
+glycoprotein	B-CHED
+on	O
+ACE2	B-PRGE
+and	O
+could	O
+help	O
+in	O
+the	O
+design	O
+of	O
+experiments	O
+to	O
+further	O
+elucidate	O
+the	O
+structure	O
+and	O
+function	O
+of	O
+ACE2	B-PRGE
+.	O
+
+ABSTRACT	O
+:	O
+Profiles	O
+of	O
+antibodies	B-COMP
+to	O
+the	O
+nucleocapsid	B-COMP
+protein	B-CHED
+of	O
+the	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+(	O
+SARS	B-DISO
+)-	O
+associated	O
+coronavirus	B-SPEC
+in	O
+445	O
+probable	O
+SARS	B-DISO
+patients	O
+and	O
+3	O
+,	O
+749	O
+healthy	O
+people	O
+or	O
+non	O
+-	O
+SARS	B-DISO
+patients	O
+were	O
+analyzed	O
+by	O
+antigen	B-CHED
+-	O
+capturing	O
+enzyme	O
+-	O
+linked	O
+immunosorbent	O
+assay	O
+.	O
+
+RESULTS	O
+:	O
+Among	O
+47	O
+suspected	O
+SARS	B-DISO
+patients	O
+with	O
+normal	O
+chest	B-ANAT
+radiographs	O
+,	O
+27	O
+had	O
+SARS	B-DISO
+-	I-DISO
+associated	I-DISO
+coronavirus	I-DISO
+infection	B-DISO
+confirmed	O
+by	O
+RT	O
+-	O
+PCR	O
+and	O
+/	O
+or	O
+positive	O
+serological	O
+testing	O
+.	O
+
+TITLE	O
+:	O
+[	O
+Infectious	B-DISO
+diseases	I-DISO
+-	O
+part	O
+I	O
+:	O
+epidemiology	O
+].	O
+
+ABSTRACT	O
+:	O
+The	O
+outstanding	O
+issue	O
+regarding	O
+recent	O
+trends	O
+in	O
+the	O
+epidemiology	O
+of	O
+infectious	O
+diseases	O
+is	O
+the	O
+epidemic	O
+occurrence	O
+of	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+(	O
+SARS	B-DISO
+)	O
+in	O
+2003	O
+.	O
+
+This	O
+new	O
+agent	O
+was	O
+rapidly	O
+identified	O
+and	O
+characterized	O
+,	O
+the	O
+outbreak	O
+was	O
+terminated	O
+in	O
+early	O
+summer	O
+2003	O
+after	O
+implementation	O
+of	O
+strict	O
+infectious	B-DISO
+control	O
+measures	O
+.	O
+
+Both	O
+false	O
+positive	O
+and	O
+false	O
+negative	O
+cases	O
+are	O
+commonly	O
+encountered	O
+and	O
+this	O
+could	O
+have	O
+far	O
+-	O
+reaching	B-PROC
+detrimental	O
+effects	O
+on	O
+the	O
+patients	O
+,	O
+their	O
+family	B-SPEC
+and	O
+the	O
+clinicians	O
+alike	O
+.	O
+
+Co	B-DISO
+-	I-DISO
+infection	I-DISO
+and	O
+other	O
+treatable	O
+conditions	O
+should	O
+not	O
+be	O
+missed	O
+and	O
+conventional	O
+antibiotics	B-CHED
+should	O
+remain	O
+as	O
+part	O
+of	O
+the	O
+first	O
+-	O
+line	O
+treatment	O
+regimen	O
+.	O
+
+ABSTRACT	O
+:	O
+Septic	B-DISO
+abortion	I-DISO
+is	O
+an	O
+infection	B-DISO
+of	O
+the	O
+uterus	B-ANAT
+and	O
+its	O
+appendages	B-ANAT
+following	O
+any	O
+abortion	O
+especially	O
+,	O
+illegally	O
+performed	O
+induced	O
+abortions	O
+.	O
+
+We	O
+compared	O
+symptoms	O
+of	O
+156	O
+SARS	B-DISO
+-	O
+positive	O
+and	O
+62	O
+SARS	B-DISO
+-	O
+negative	O
+patients	O
+in	O
+Hong	O
+Kong	O
+;	O
+SARS	B-DISO
+was	O
+confirmed	O
+by	O
+RT	O
+-	O
+PCR	O
+.	O
+
+We	O
+examined	O
+the	O
+seroprevalence	O
+of	O
+SARS	B-DISO
+-	O
+CoV	O
+among	O
+674	O
+healthcare	O
+workers	O
+from	O
+a	O
+hospital	O
+in	O
+which	O
+a	O
+SARS	B-DISO
+outbreak	O
+had	O
+occurred	O
+.	O
+
+Activation	B-PROC
+of	I-PROC
+NF	I-PROC
+-	I-PROC
+kappaB	I-PROC
+has	O
+been	O
+demonstrated	O
+in	O
+mineral	B-CHED
+dust	B-DISO
+diseases	I-DISO
+and	O
+probably	O
+plays	O
+a	O
+role	O
+in	O
+the	O
+pathogenesis	B-DISO
+of	O
+these	O
+chronic	B-DISO
+illnesses	I-DISO
+.	O
+
+The	O
+complex	O
+NF	B-PRGE
+-	I-PRGE
+kappaB	I-PRGE
+pathway	B-PROC
+offers	O
+a	O
+variety	O
+of	O
+potential	O
+molecular	O
+targets	O
+for	O
+chemotherapeutic	O
+intervention	O
+.	O
+
+A	O
+variety	O
+of	O
+agents	O
+aimed	O
+at	O
+modulating	O
+NF	B-PRGE
+-	I-PRGE
+kappaB	I-PRGE
+activity	O
+are	O
+in	O
+various	O
+stages	O
+of	O
+investigation	O
+.	O
+
+Blood	B-ANAT
+samples	I-ANAT
+of	O
+22	O
+SARS	B-DISO
+patients	O
+were	O
+studied	O
+,	O
+and	O
+4	O
+healthy	O
+blood	B-ANAT
+samples	I-ANAT
+were	O
+observed	O
+as	O
+negative	O
+controls	O
+.	O
+
+CD45RO	O
+antibody	B-COMP
+was	O
+used	O
+for	O
+pre	O
+-	O
+embedding	O
+immunoelectron	O
+microscopy	O
+.	O
+
+The	O
+SARS	B-DISO
+viral	O
+sequence	O
+was	O
+detected	O
+with	O
+real	O
+-	O
+time	O
+polymerase	O
+chain	O
+reaction	O
+(	O
+RT	O
+-	O
+PCR	O
+).	O
+
+Our	O
+data	O
+suggested	O
+that	O
+lymphocytes	B-ANAT
+,	O
+particularly	O
+T	B-ANAT
+cells	I-ANAT
+,	O
+were	O
+probably	O
+the	O
+target	B-ANAT
+cells	I-ANAT
+of	O
+SARS	B-DISO
+CoV	O
+.	O
+The	O
+viruses	B-SPEC
+may	O
+actively	O
+infected	O
+the	O
+immune	O
+cells	B-COMP
+during	O
+SARS	B-DISO
+CoV	O
+acute	B-DISO
+infection	I-DISO
+phase	O
+and	O
+the	O
+destruction	O
+of	O
+target	B-ANAT
+cells	I-ANAT
+may	O
+be	O
+one	O
+of	O
+the	O
+important	O
+reasons	O
+for	O
+the	O
+death	B-PROC
+of	O
+the	O
+circulating	O
+leukocytes	B-ANAT
+in	O
+SARS	B-DISO
+.	O
+
+Virus	B-SPEC
+entered	O
+cells	B-COMP
+by	O
+endocytosis	B-PATH
+or	O
+membrane	B-PROC
+fusion	I-PROC
+and	O
+was	O
+released	O
+through	O
+a	O
+budding	B-PATH
+process	O
+.	O
+
+Mice	B-SPEC
+with	O
+CD8	B-PRGE
+(+)	O
+T	B-ANAT
+cells	I-ANAT
+specific	O
+for	O
+gp33	O
+-	O
+41	O
+(	O
+an	O
+H	O
+-	O
+2D	O
+(	O
+b	O
+)-	O
+restricted	O
+CD8	B-PRGE
+(+)	O
+T	B-ANAT
+-	I-ANAT
+cell	I-ANAT
+epitope	B-CHED
+derived	O
+from	O
+lymphocytic	B-DISO
+choriomeningitis	I-DISO
+glycoprotein	B-CHED
+)	O
+were	O
+infected	O
+with	O
+a	O
+recombinant	O
+MHV	B-SPEC
+-	O
+A59	O
+,	O
+also	O
+expressing	O
+gp33	B-PRGE
+-	I-PRGE
+41	I-PRGE
+,	O
+as	O
+a	O
+fusion	O
+protein	B-CHED
+with	O
+enhanced	B-PRGE
+green	I-PRGE
+fluorescent	I-PRGE
+protein	I-PRGE
+(	O
+EGFP	O
+).	O
+
+They	O
+will	O
+need	O
+to	O
+implement	O
+and	O
+ensure	O
+strict	O
+adherence	O
+to	O
+infection	B-DISO
+control	O
+measures	O
+and	O
+,	O
+in	O
+some	O
+circumstances	O
+,	O
+isolation	O
+and	O
+quarantine	O
+may	O
+be	O
+warranted	O
+.	O
+
+Three	O
+hybridomas	B-ANAT
+producing	O
+mAbs	O
+specific	O
+to	O
+the	O
+S1	B-PRGE
+domain	I-PRGE
+was	O
+obtained	O
+,	O
+with	O
+a	O
+relative	O
+molecular	O
+mass	O
+of	O
+48	O
+,	O
+500	O
+.	O
+
+None	O
+of	O
+the	O
+3	O
+mAbs	O
+were	O
+reactive	O
+with	O
+human	B-SPEC
+coronaviruses	O
+229E	O
+and	O
+OC43	O
+.	O
+
+This	O
+is	O
+the	O
+first	O
+report	O
+of	O
+mAbs	O
+produced	O
+against	O
+S	B-PRGE
+-	I-PRGE
+protein	I-PRGE
+receptor	I-PRGE
+-	I-PRGE
+binding	B-FUNC
+domain	I-PRGE
+of	O
+SARS	B-PRGE
+-	I-PRGE
+CoV	I-PRGE
+.	O
+The	O
+3	O
+S1	O
+-	O
+specific	O
+mAbs	O
+may	O
+be	O
+useful	O
+for	O
+further	O
+study	O
+of	O
+the	O
+function	O
+of	O
+the	O
+S	B-PRGE
+protein	I-PRGE
+and	O
+for	O
+diagnosis	O
+of	O
+SARS	B-DISO
+-	I-DISO
+CoV	I-DISO
+infection	I-DISO
+.	O
+
+METHODS	O
+:	O
+Using	O
+primer	O
+Premier	O
+5	O
+.	O
+0	O
+software	O
+,	O
+two	O
+pairs	O
+of	O
+nested	O
+PCR	O
+primers	O
+were	O
+designed	O
+to	O
+amplify	O
+the	O
+N	B-PRGE
+gene	I-PRGE
+.	O
+
+In	O
+the	O
+twenty	O
+-	O
+one	O
+German	O
+guests	O
+traced	O
+as	O
+having	O
+stayed	O
+at	O
+Hotel	O
+""""	O
+M	O
+""""	O
+during	O
+this	O
+period	O
+,	O
+one	O
+case	O
+of	O
+laboratory	O
+confirmed	O
+SARS	B-DISO
+was	O
+found	O
+.	O
+
+ABSTRACT	O
+:	O
+Severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+(	O
+SARS	B-DISO
+)	O
+is	O
+a	O
+newly	O
+emerged	O
+disease	O
+caused	O
+by	O
+a	O
+novel	B-SPEC
+coronavirus	I-SPEC
+(	O
+SARS	B-DISO
+-	O
+CoV	O
+),	O
+which	O
+spread	O
+globally	O
+in	O
+early	O
+2003	O
+,	O
+affecting	O
+over	O
+30	O
+countries	O
+.	O
+
+The	O
+case	O
+definition	O
+of	O
+SARS	B-DISO
+was	O
+based	O
+on	O
+that	O
+recommended	O
+by	O
+WHO	O
+.	O
+
+RESULTS	O
+:	O
+The	O
+index	O
+patient	O
+presented	O
+with	O
+gastrointestinal	B-DISO
+bleeding	I-DISO
+,	O
+initially	O
+without	O
+changes	O
+to	O
+his	O
+chest	B-ANAT
+radiograph	O
+.	O
+
+Prednisone	B-CHED
+was	O
+used	O
+at	O
+a	O
+dose	O
+of	O
+1	O
+mg	O
+/(	O
+kg	O
+.	O
+d	O
+)	O
+in	O
+3	O
+cases	O
+.	O
+
+METHODS	O
+:	O
+Clinical	O
+manifestation	O
+,	O
+chest	B-ANAT
+X	O
+-	O
+ray	B-SPEC
+,	O
+computed	O
+tomography	O
+(	O
+CT	O
+)	O
+and	O
+pulmonary	B-PROC
+function	I-PROC
+of	O
+4	O
+cases	O
+with	O
+bronchiolitis	B-DISO
+obliterans	I-DISO
+were	O
+retrospectively	O
+analyzed	O
+.	O
+
+The	O
+major	O
+clinical	O
+features	O
+included	O
+diffuse	O
+amyotrophy	B-DISO
+,	O
+bilateral	O
+facial	B-DISO
+paresis	I-DISO
+,	O
+and	O
+fasciculations	B-DISO
+,	O
+suggesting	O
+motor	B-DISO
+neuropathy	I-DISO
+.	O
+
+ABSTRACT	O
+:	O
+Stepping	B-DISO
+acquired	B-DISO
+immunodeficiency	I-DISO
+syndrome	I-DISO
+(	O
+AIDS	O
+),	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+(	O
+SARS	B-DISO
+)	O
+as	O
+another	O
+type	O
+of	O
+disease	O
+has	O
+been	O
+threatening	O
+mankind	O
+since	O
+late	O
+last	O
+year	O
+.	O
+
+In	O
+this	O
+work	O
+,	O
+we	O
+used	O
+Wolfram	B-CHED
+approach	O
+to	O
+study	O
+the	O
+relationship	O
+among	O
+SARS	B-DISO
+viruses	B-SPEC
+and	O
+between	O
+SARS	B-DISO
+viruses	B-SPEC
+and	O
+other	O
+types	O
+of	O
+viruses	B-SPEC
+,	O
+the	O
+effect	O
+of	O
+variations	O
+on	O
+the	O
+whole	O
+genome	O
+and	O
+the	O
+advantages	O
+in	O
+the	O
+analysis	O
+of	O
+SARS	B-DISO
+based	O
+on	O
+this	O
+novel	O
+approach	O
+.	O
+
+TITLE	O
+:	O
+DNA	O
+vaccine	O
+of	O
+SARS	B-DISO
+-	O
+Cov	O
+S	B-PRGE
+gene	I-PRGE
+induces	O
+antibody	B-PROC
+response	I-PROC
+in	O
+mice	B-SPEC
+.	O
+
+The	O
+mouse	B-PRGE
+serum	B-COMP
+IgG	B-COMP
+antibody	I-COMP
+against	O
+SARS	B-PRGE
+-	I-PRGE
+CoV	I-PRGE
+was	O
+measured	O
+by	O
+ELISA	O
+with	O
+E	B-SPEC
+.	I-SPEC
+coli	I-SPEC
+expressed	B-PROC
+truncated	B-PRGE
+S	I-PRGE
+protein	I-PRGE
+or	O
+SARS	B-PRGE
+-	I-PRGE
+CoV	I-PRGE
+lysate	O
+as	O
+diagnostic	O
+antigen	B-CHED
+.	O
+
+The	O
+results	O
+showed	O
+that	O
+all	O
+the	O
+three	O
+fragments	O
+of	O
+S	B-PRGE
+protein	I-PRGE
+expressed	B-PROC
+by	O
+E	B-SPEC
+.	I-SPEC
+coli	I-SPEC
+was	O
+able	O
+to	O
+react	O
+with	O
+sera	B-COMP
+of	O
+SARS	B-DISO
+patients	O
+and	O
+the	O
+S	O
+gene	O
+DNA	O
+candidate	O
+vaccine	O
+could	O
+induce	O
+the	O
+production	O
+of	O
+specific	O
+IgG	B-COMP
+antibody	I-COMP
+against	O
+SARS	B-PRGE
+-	I-PRGE
+CoV	I-PRGE
+efficiently	O
+in	O
+mice	B-SPEC
+with	O
+seroconversion	O
+ratio	O
+of	O
+75	O
+%	O
+after	O
+3	O
+times	O
+of	O
+immunization	O
+.	O
+
+TITLE	O
+:	O
+Comparison	O
+of	O
+clinical	O
+course	O
+of	O
+patients	O
+with	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+among	O
+the	O
+multiple	O
+generations	O
+of	O
+nosocomial	O
+transmission	O
+.	O
+
+The	O
+clinical	O
+data	O
+of	O
+84	O
+epidemiologically	O
+-	O
+linked	O
+SARS	B-DISO
+patients	O
+from	O
+a	O
+hospital	O
+outbreak	O
+were	O
+retrospectively	O
+studied	O
+.	O
+
+The	O
+genotyping	O
+and	O
+phylogeny	O
+of	O
+SARS	B-PRGE
+-	I-PRGE
+CoV	I-PRGE
+were	O
+analyzed	O
+and	O
+reported	O
+in	O
+this	O
+paper	O
+.	O
+
+Therefore	O
+a	O
+novel	O
+definition	O
+is	O
+put	O
+forward	O
+that	O
+according	O
+to	O
+these	O
+7	O
+loci	O
+of	O
+mutation	O
+,	O
+40	O
+strains	O
+of	O
+SARS	B-DISO
+-	O
+CoV	O
+in	O
+GenBank	O
+can	O
+be	O
+grouped	O
+into	O
+two	O
+genotypes	O
+,	O
+T	O
+:	O
+T	O
+:	O
+A	O
+:	O
+G	O
+:	O
+T	O
+:	O
+C	O
+:	O
+T	O
+and	O
+C	O
+:	O
+G	O
+:	O
+G	O
+:	O
+A	O
+:	O
+C	O
+:	O
+T	O
+:	O
+C	O
+,	O
+and	O
+named	O
+as	O
+SARS	B-PRGE
+-	I-PRGE
+CoV	I-PRGE
+Yexin	I-PRGE
+genotype	O
+and	O
+Xiaohong	O
+genotype	O
+.	O
+
+These	O
+genotypes	O
+can	O
+also	O
+be	O
+approved	O
+by	O
+phylogenetic	O
+tree	O
+of	O
+three	O
+levels	O
+of	O
+44	O
+loci	O
+of	O
+mutation	O
+,	O
+spike	O
+glycoprotein	B-CHED
+gene	O
+and	O
+complete	O
+genome	O
+sequence	O
+.	O
+
+Compared	O
+to	O
+various	O
+strains	O
+among	O
+SARS	B-DISO
+-	O
+CoV	O
+Yexin	O
+genotype	O
+and	O
+Xiaohong	O
+genotype	O
+,	O
+GD01	O
+strain	O
+of	O
+Yexin	O
+genotype	O
+is	O
+more	O
+closely	O
+related	O
+to	O
+SARS	B-DISO
+-	O
+CoV	O
+like	O
+-	O
+virus	B-SPEC
+from	O
+animals	B-SPEC
+.	O
+
+TITLE	O
+:	O
+[	O
+SARS	B-DISO
+-	I-DISO
+associated	I-DISO
+coronavirus	I-DISO
+gene	O
+fragments	O
+were	O
+detected	O
+from	O
+a	O
+suspected	O
+pediatric	O
+SARS	B-DISO
+patient	O
+].	O
+
+All	O
+the	O
+primers	O
+derived	O
+from	O
+the	O
+sequence	O
+at	O
+the	O
+1b	B-PRGE
+frame	I-PRGE
+of	I-PRGE
+coronavirus	I-PRGE
+replicase	I-PRGE
+gene	I-PRGE
+and	O
+products	O
+with	O
+a	O
+size	O
+of	O
+368	O
+or	O
+348	O
+bp	O
+were	O
+expected	O
+with	O
+2	O
+different	O
+primer	O
+pairs	O
+.	O
+
+It	O
+is	O
+of	O
+great	O
+importance	O
+to	O
+differentiate	O
+SARS	B-DISO
+patients	O
+from	O
+those	O
+infected	O
+with	O
+common	O
+respiratory	O
+viruses	B-SPEC
+during	O
+SARS	B-DISO
+epidemic	O
+,	O
+especially	O
+for	O
+pediatric	O
+patients	O
+,	O
+because	O
+most	O
+of	O
+the	O
+patients	O
+visiting	O
+the	O
+outpatient	O
+department	O
+present	O
+with	O
+the	O
+symptoms	O
+of	O
+fever	B-PROC
+,	O
+cough	B-DISO
+and	O
+normal	O
+WBC	B-ANAT
+count	O
+.	O
+
+The	O
+data	O
+mentioned	O
+above	O
+indicate	O
+that	O
+antigen	B-CHED
+and	O
+gene	O
+detections	O
+for	O
+those	O
+common	O
+respiratory	O
+viruses	B-SPEC
+are	O
+useful	O
+methods	O
+for	O
+the	O
+differentiation	B-PROC
+to	O
+avoid	O
+the	O
+spread	O
+of	O
+SARS	B-DISO
+.	O
+
+IgG	B-PRGE
+and	O
+IgM	B-PRGE
+antibodies	B-COMP
+to	O
+Mycoplasma	B-SPEC
+pneumoniae	I-SPEC
+and	O
+Chlamydia	B-SPEC
+pneumoniae	I-SPEC
+as	O
+well	O
+as	O
+blood	B-ANAT
+culture	O
+for	O
+bacteria	B-SPEC
+were	O
+all	O
+negative	O
+.	O
+
+TITLE	O
+:	O
+Analysis	O
+of	O
+deaths	B-PROC
+during	O
+the	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+(	O
+SARS	B-DISO
+)	O
+epidemic	O
+in	O
+Singapore	O
+:	O
+challenges	O
+in	O
+determining	O
+a	O
+SARS	O
+diagnosis	O
+.	O
+
+Although	O
+nonspecific	O
+by	O
+itself	O
+,	O
+the	O
+term	O
+does	O
+not	O
+accurately	O
+reflect	O
+the	O
+underlying	O
+dangers	O
+of	O
+viral	B-DISO
+pneumonia	I-DISO
+,	O
+which	O
+may	O
+progress	O
+rapidly	O
+to	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+.	O
+
+RESULTS	O
+:	O
+Abnormal	O
+findings	O
+on	O
+a	O
+chest	B-ANAT
+radiograph	O
+were	O
+noted	O
+at	O
+presentation	O
+in	O
+80	O
+.	O
+4	O
+%	O
+(	O
+41	O
+/	O
+51	O
+)	O
+of	O
+patients	O
+.	O
+
+In	O
+group	O
+3	O
+,	O
+one	O
+(	O
+7	O
+.	O
+7	O
+%)	O
+of	O
+the	O
+13	O
+patients	O
+died	B-PROC
+.	O
+
+Despite	O
+the	O
+widespread	O
+availability	O
+of	O
+affordable	O
+refrigeration	O
+,	O
+many	O
+Asian	O
+people	O
+prefer	O
+live	O
+animals	B-SPEC
+for	O
+fresh	B-ANAT
+produce	O
+.	O
+
+These	O
+researchers	O
+also	O
+found	O
+serological	O
+evidence	O
+of	O
+infection	B-DISO
+in	O
+raccoon	B-SPEC
+dogs	I-SPEC
+(	O
+Nyctereutes	B-SPEC
+procuyoinboides	O
+).	O
+
+Serological	O
+evidence	O
+for	O
+SARS	B-PRGE
+CoV	I-PRGE
+in	O
+human	B-SPEC
+beings	O
+working	O
+in	O
+these	O
+markets	O
+,	O
+taken	O
+together	O
+with	O
+the	O
+earliest	O
+cases	O
+of	O
+SARS	B-DISO
+in	O
+restaurant	O
+workers	O
+,	O
+supports	O
+the	O
+contention	O
+of	O
+a	O
+potential	O
+zoonotic	O
+origin	O
+for	O
+SARS	B-DISO
+.	O
+
+Will	O
+the	O
+virus	B-SPEC
+re	O
+-	O
+emerge	O
+from	O
+wet	O
+markets	O
+or	O
+from	O
+laboratories	O
+working	O
+with	O
+SARS	B-PRGE
+CoV	I-PRGE
+,	O
+or	O
+are	O
+asymptomatic	B-DISO
+infections	I-DISO
+ongoing	O
+in	O
+human	B-SPEC
+beings	O
+?	O
+
+The	O
+N	O
+protein	B-CHED
+gene	O
+was	O
+amplified	O
+from	O
+the	O
+extracted	O
+RNA	O
+by	O
+reverse	B-PROC
+transcription	I-PROC
+-	O
+polymerase	O
+chain	O
+reaction	O
+and	O
+cloned	O
+.	O
+
+The	O
+recombinant	O
+expression	B-PROC
+construct	O
+(	O
+pTri	O
+-	O
+N	O
+)	O
+was	O
+identified	O
+by	O
+polymerase	O
+chain	O
+reaction	O
+and	O
+sequencing	O
+analysis	O
+.	O
+
+Adult	O
+intensive	O
+care	O
+unit	O
+in	O
+a	O
+tertiary	O
+referral	O
+university	O
+hospital	O
+involved	O
+in	O
+a	O
+major	O
+outbreak	O
+of	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+(	O
+SARS	B-DISO
+).	O
+
+Mortality	O
+amongst	O
+critically	B-DISO
+ill	I-DISO
+patients	O
+with	O
+SARS	B-DISO
+is	O
+high	O
+.	O
+
+ABSTRACT	O
+:	O
+To	O
+investigate	O
+the	O
+effects	O
+of	O
+treatment	O
+with	O
+propofol	B-CHED
+administration	O
+at	O
+different	O
+time	O
+point	O
+in	O
+acute	O
+lung	B-ANAT
+injury	O
+of	O
+endotoxin	O
+-	O
+induced	O
+shock	O
+rats	B-SPEC
+.	O
+
+PaO2	O
+,	O
+pH	O
+,	O
+MAP	O
+and	O
+survival	O
+rate	O
+were	O
+recorded	O
+and	O
+plasma	B-ANAT
+NO	I-PRGE
+,	O
+TNF	B-PRGE
+-	I-PRGE
+alpha	I-PRGE
+were	O
+measured	O
+during	O
+5	O
+-	O
+hr	O
+after	O
+the	O
+injection	O
+of	O
+LPS	B-DISO
+.	O
+
+Compared	O
+with	O
+the	O
+endotoxemic	O
+group	O
+,	O
+both	O
+the	O
+pretreatment	O
+and	O
+simultaneously	O
+treatment	O
+groups	O
+,	O
+significantly	O
+improved	O
+PaO2	O
+,	O
+pH	O
+,	O
+MAP	O
+and	O
+5th	O
+hour	O
+survival	O
+rate	O
+of	O
+rats	B-SPEC
+,	O
+and	O
+attenuated	O
+endotoxin	O
+-	O
+induced	O
+increased	O
+iNOSmRNA	O
+,	O
+NT	O
+expression	B-PROC
+,	O
+MPO	B-FUNC
+activity	O
+and	O
+MDA	B-CHED
+level	O
+in	O
+lung	B-ANAT
+tissue	I-ANAT
+,	O
+and	O
+decreased	O
+pulmonary	B-ANAT
+microvascular	B-PROC
+permeability	I-PROC
+,	O
+TNF	B-PRGE
+-	I-PRGE
+alpha	I-PRGE
+,	O
+NO	O
+in	O
+plasma	B-ANAT
+.	O
+
+The	O
+pathogenesis	B-DISO
+of	O
+this	O
+'	O
+malignant	O
+'	O
+clinical	O
+form	O
+has	O
+not	O
+been	O
+fully	O
+elucidated	O
+.	O
+
+Systemic	O
+leukocyte	B-PROC
+activation	I-PROC
+,	O
+however	O
+,	O
+is	O
+a	O
+direct	O
+consequence	O
+of	O
+a	O
+SIRS	B-DISO
+and	O
+if	O
+excessive	O
+,	O
+can	O
+lead	O
+to	O
+distant	O
+organ	B-ANAT
+damage	O
+and	O
+multiple	B-DISO
+organ	I-DISO
+dysfunction	I-DISO
+syndrome	I-DISO
+(	O
+MODS	B-DISO
+).	O
+
+Inflammatory	O
+mediators	O
+play	O
+a	O
+key	O
+role	O
+in	O
+the	O
+pathogenesis	B-DISO
+of	O
+ARDS	B-DISO
+,	O
+which	O
+is	O
+the	O
+primary	O
+cause	O
+of	O
+death	B-PROC
+in	O
+these	O
+conditions	O
+.	O
+
+It	O
+is	O
+reasonable	O
+to	O
+speculate	O
+that	O
+elucidation	O
+of	O
+the	O
+key	O
+mediators	O
+in	O
+ARDS	B-DISO
+coupled	O
+with	O
+the	O
+discovery	O
+of	O
+specific	O
+inhibitors	B-CHED
+would	O
+make	O
+it	O
+possible	O
+to	O
+develop	O
+clinically	O
+effective	O
+anti	O
+-	O
+inflammatory	O
+therapy	O
+.	O
+
+All	O
+the	O
+18	O
+patients	O
+but	O
+one	O
+presented	O
+with	O
+fever	B-PROC
+and	O
+cough	B-DISO
+.	O
+
+Thirteen	O
+children	O
+had	O
+chest	B-ANAT
+radiographic	O
+consolidation	O
+.	O
+
+A	O
+highly	O
+pathogenic	O
+avian	B-DISO
+influenza	B-SPEC
+A	I-SPEC
+virus	I-SPEC
+of	O
+subtype	O
+H7N7	O
+,	O
+closely	O
+related	O
+to	O
+low	O
+pathogenic	O
+virus	B-SPEC
+isolates	O
+obtained	O
+from	O
+wild	O
+ducks	B-SPEC
+,	O
+was	O
+isolated	O
+from	O
+chickens	B-SPEC
+.	O
+
+Of	O
+these	O
+89	O
+patients	O
+,	O
+78	O
+presented	O
+with	O
+conjunctivitis	B-DISO
+,	O
+5	O
+presented	O
+with	O
+conjunctivitis	B-DISO
+and	O
+influenza	B-DISO
+-	I-DISO
+like	I-DISO
+illness	I-DISO
+,	O
+2	O
+presented	O
+with	O
+influenza	B-DISO
+-	I-DISO
+like	I-DISO
+illness	I-DISO
+,	O
+and	O
+4	O
+did	O
+not	O
+fit	B-DISO
+the	O
+case	O
+definitions	O
+.	O
+
+However	O
+,	O
+the	O
+virus	B-SPEC
+isolated	O
+from	O
+the	O
+fatal	O
+case	O
+displayed	O
+14	O
+amino	B-PROC
+acid	I-PROC
+substitutions	I-PROC
+,	O
+some	O
+of	O
+which	O
+may	O
+be	O
+associated	O
+with	O
+enhanced	O
+disease	O
+in	O
+this	O
+case	O
+.	O
+
+TITLE	O
+:	O
+Case	O
+report	O
+:	O
+requirement	O
+of	O
+supplemental	O
+morphine	B-CHED
+during	O
+sedation	B-DISO
+with	O
+propofol	B-CHED
+in	O
+a	O
+critically	B-DISO
+ill	I-DISO
+patient	O
+undergoing	O
+hemodiafiltration	O
+.	O
+
+On	O
+the	O
+10th	O
+postoperative	O
+day	O
+,	O
+the	O
+patient	O
+was	O
+admitted	O
+into	O
+our	O
+intensive	O
+care	O
+unit	O
+(	O
+ICU	O
+)	O
+for	O
+acute	O
+respiratory	O
+and	O
+renal	B-DISO
+failure	I-DISO
+due	O
+to	O
+ARDS	B-DISO
+and	O
+left	O
+renal	B-DISO
+infarction	I-DISO
+.	O
+
+ARDS	B-DISO
+resolved	O
+and	O
+,	O
+10	O
+days	O
+later	O
+,	O
+the	O
+patient	O
+was	O
+transferred	O
+to	O
+the	O
+surgical	O
+unit	O
+,	O
+then	O
+discharged	O
+home	O
+after	O
+14	O
+days	O
+.	O
+
+ARDS	B-DISO
+resolved	O
+and	O
+,	O
+10	O
+days	O
+later	O
+,	O
+the	O
+patient	O
+was	O
+transferred	O
+to	O
+the	O
+surgical	O
+unit	O
+,	O
+then	O
+discharged	O
+home	O
+after	O
+14	O
+days	O
+.	O
+
+At	O
+the	O
+same	O
+time	O
+,	O
+teachers	O
+need	O
+to	O
+develop	O
+a	O
+current	O
+listing	O
+of	O
+seminal	O
+papers	O
+for	O
+trainees	O
+and	O
+practitioners	O
+of	O
+this	O
+newest	O
+cross	O
+-	O
+over	O
+subspecialty	O
+of	O
+psychiatry	O
+-	O
+now	O
+called	O
+Psychosomatic	O
+Medicine	B-CHED
+.	O
+
+This	O
+paper	O
+reviews	O
+several	O
+geographic	O
+mapping	O
+efforts	O
+of	O
+SARS	B-DISO
+on	O
+the	O
+Internet	O
+that	O
+employ	O
+a	O
+variety	O
+of	O
+techniques	O
+like	O
+choropleth	O
+rendering	O
+,	O
+graduated	O
+circles	O
+,	O
+graduated	O
+pie	O
+charts	O
+,	O
+buffering	O
+,	O
+overlay	O
+analysis	O
+and	O
+animation	O
+.	O
+
+The	O
+aim	O
+of	O
+these	O
+mapping	O
+services	O
+is	O
+to	O
+educate	O
+the	O
+public	O
+(	O
+especially	O
+travellers	O
+to	O
+potentially	O
+at	O
+-	O
+risk	O
+areas	O
+)	O
+and	O
+assist	O
+public	O
+health	O
+authorities	O
+in	O
+analysing	O
+the	O
+spatial	O
+and	O
+temporal	O
+trends	O
+and	O
+patterns	O
+of	O
+SARS	B-DISO
+and	O
+in	O
+assessing	O
+/	O
+revising	O
+current	O
+control	O
+measures	O
+.	O
+
+The	O
+present	O
+study	O
+aimed	O
+to	O
+understand	O
+clinical	O
+characteristics	O
+and	O
+prognosis	O
+of	O
+pediatric	O
+SARS	B-DISO
+patients	O
+in	O
+Guangzhou	O
+area	O
+.	O
+
+Though	O
+there	O
+were	O
+severe	O
+changes	O
+in	O
+the	O
+lung	B-ANAT
+,	O
+the	O
+patients	O
+might	O
+not	O
+have	O
+corresponding	O
+symptoms	O
+or	O
+signs	O
+.	O
+
+ABSTRACT	O
+:	O
+Sixty	O
+-	O
+one	O
+SARS	O
+coronavirus	B-SPEC
+genomic	O
+sequences	O
+derived	O
+from	O
+the	O
+early	O
+,	O
+middle	O
+,	O
+and	O
+late	O
+phases	O
+of	O
+the	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+(	O
+SARS	B-DISO
+)	O
+epidemic	O
+were	O
+analyzed	O
+together	O
+with	O
+two	O
+viral	O
+sequences	O
+from	O
+palm	B-ANAT
+civets	B-SPEC
+.	O
+
+Images	O
+were	O
+evaluated	O
+for	O
+ground	O
+-	O
+glass	O
+opacification	O
+,	O
+consolidation	O
+,	O
+interstitial	B-ANAT
+thickening	O
+,	O
+evidence	O
+of	O
+fibrosis	B-DISO
+,	O
+and	O
+any	O
+other	O
+abnormalities	O
+.	O
+
+All	O
+patients	O
+received	O
+high	O
+-	O
+dose	O
+pulse	B-PROC
+methylprednisolone	B-CHED
+(	O
+minimum	O
+,	O
+2	O
+.	O
+5	O
+g	O
+total	O
+),	O
+and	O
+all	O
+patients	O
+who	O
+received	O
+ventilation	O
+received	O
+low	O
+-	O
+pressure	O
+,	O
+low	O
+-	O
+volume	O
+ventilation	O
+.	O
+
+The	O
+CT	O
+features	O
+of	O
+late	O
+-	O
+stage	O
+ARDS	B-DISO
+caused	O
+by	O
+SARS	B-DISO
+are	O
+similar	O
+to	O
+those	O
+seen	O
+in	O
+late	O
+-	O
+stage	O
+ARDS	B-DISO
+of	O
+other	O
+causes	O
+,	O
+with	O
+no	O
+apparent	O
+differences	O
+between	O
+patients	O
+who	O
+do	O
+and	O
+patients	O
+who	O
+do	O
+not	O
+receive	O
+prolonged	O
+mechanical	O
+ventilation	O
+.	O
+
+Comparison	O
+of	O
+these	O
+structures	O
+revealed	O
+a	O
+large	O
+inhibitor	B-CHED
+-	O
+dependent	O
+hinge	O
+-	O
+bending	B-DISO
+movement	B-PROC
+of	O
+one	O
+catalytic	O
+subdomain	O
+relative	O
+to	O
+the	O
+other	O
+(	O
+approximately	O
+16	O
+degrees	O
+)	O
+that	O
+brings	O
+important	O
+residues	O
+into	O
+position	O
+for	O
+catalysis	O
+.	O
+
+The	O
+clinical	O
+course	O
+,	O
+intensive	O
+care	O
+,	O
+and	O
+outcome	O
+of	O
+adolescent	O
+twin	O
+sisters	O
+with	O
+SARS	B-DISO
+are	O
+described	O
+.	O
+
+The	O
+life	O
+of	O
+contemporary	O
+man	B-CHED
+is	O
+characterized	O
+,	O
+among	O
+others	O
+,	O
+by	O
+a	O
+huge	O
+thirst	B-PROC
+for	O
+traveling	O
+,	O
+for	O
+varied	O
+reasons	O
+,	O
+consequence	O
+of	O
+the	O
+globalization	O
+process	O
+.	O
+
+TITLE	O
+:	O
+Current	O
+challenges	O
+in	O
+lower	O
+respiratory	B-DISO
+infections	I-DISO
+in	O
+children	O
+.	O
+
+Its	O
+R	O
+value	O
+(	O
+the	O
+average	O
+number	O
+of	O
+secondary	O
+cases	O
+infected	O
+by	O
+a	O
+primary	O
+case	O
+)	O
+is	O
+lower	O
+than	O
+that	O
+for	O
+measles	B-PATH
+,	O
+human	B-DISO
+parvovirus	B-SPEC
+,	O
+chickenpox	B-DISO
+,	O
+mumps	B-DISO
+,	O
+rubella	B-DISO
+,	O
+and	O
+poliomyelitis	B-DISO
+;	O
+only	O
+the	O
+value	O
+for	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+(	O
+SARS	B-DISO
+)	O
+is	O
+lower	O
+.	O
+
+ABSTRACT	O
+:	O
+To	O
+describe	O
+the	O
+screening	O
+tool	O
+that	O
+was	O
+used	O
+to	O
+screen	O
+for	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+(	O
+SARS	B-DISO
+),	O
+the	O
+three	O
+revisions	O
+that	O
+were	O
+made	O
+,	O
+and	O
+the	O
+factors	O
+that	O
+led	O
+to	O
+these	O
+revisions	O
+.	O
+
+On	O
+March	O
+13	O
+,	O
+2003	O
+,	O
+on	O
+receiving	O
+notification	O
+of	O
+an	O
+outbreak	O
+of	O
+atypical	B-DISO
+pneumonia	I-DISO
+,	O
+nurses	O
+from	O
+the	O
+study	O
+emergency	B-DISO
+department	O
+(	O
+ED	O
+)	O
+started	O
+screening	O
+patients	O
+for	O
+the	O
+disease	O
+that	O
+became	O
+known	O
+as	O
+SARS	B-DISO
+.	O
+
+Then	O
+,	O
+sodium	B-CHED
+dodecyl	I-CHED
+sulfate	I-CHED
+-	O
+polyacrylamide	B-CHED
+gel	O
+electrophoresis	O
+(	O
+SDS	B-DISO
+-	O
+PAGE	O
+)	O
+was	O
+used	O
+to	O
+separate	O
+the	O
+complex	B-CHED
+protein	I-CHED
+constituents	O
+,	O
+and	O
+the	O
+strategy	O
+of	O
+continuous	O
+slicing	O
+from	O
+loading	O
+well	O
+to	O
+the	O
+bottom	O
+of	O
+the	O
+gels	O
+was	O
+utilized	O
+to	O
+search	O
+thoroughly	O
+the	O
+structural	O
+proteins	B-CHED
+of	O
+the	O
+virus	B-SPEC
+.	O
+
+The	O
+results	O
+demonstrated	O
+that	O
+these	O
+shorter	O
+isoforms	O
+could	O
+be	O
+the	O
+products	O
+from	O
+cleavage	B-PROC
+of	O
+caspase	B-PRGE
+-	I-PRGE
+3	I-PRGE
+rather	O
+than	O
+that	O
+of	O
+caspase	B-PRGE
+-	I-PRGE
+6	I-PRGE
+.	O
+
+However	O
+,	O
+administration	O
+of	O
+anti	O
+-	O
+IP	O
+-	O
+10	O
+serum	B-COMP
+caused	O
+no	O
+difference	O
+in	O
+clinical	O
+signs	O
+,	O
+inflammation	B-DISO
+,	O
+demyelination	B-DISO
+,	O
+virus	B-SPEC
+persistence	O
+or	O
+anti	O
+-	O
+virus	B-SPEC
+antibody	B-PROC
+response	I-PROC
+in	O
+TMEV	O
+infection	B-DISO
+,	O
+while	O
+levels	O
+of	O
+virus	B-SPEC
+specific	O
+and	O
+autoreactive	O
+lymphoproliferation	O
+increased	O
+.	O
+
+The	O
+alveolar	B-ANAT
+spaces	O
+are	O
+filled	O
+with	O
+fibrinous	O
+exudates	B-ANAT
+and	O
+lined	O
+with	O
+hyaline	B-DISO
+membrane	B-COMP
+.	O
+
+All	O
+of	O
+the	O
+lungs	B-ANAT
+show	O
+bronchopneumonia	B-DISO
+,	O
+scattered	O
+hemorrhage	B-DISO
+,	O
+and	O
+proliferation	B-DISO
+of	O
+alveolar	B-ANAT
+epithelial	B-ANAT
+cells	I-ANAT
+with	O
+desquamation	O
+.	O
+
+The	O
+SARS	O
+patients	O
+were	O
+diagnosed	O
+and	O
+verified	O
+according	O
+to	O
+the	O
+diagnosis	O
+criteria	O
+released	O
+by	O
+Chinese	O
+Ministry	O
+of	O
+Health	O
+which	O
+was	O
+equivalent	O
+to	O
+the	O
+SARS	B-DISO
+'	O
+probable	O
+case	O
+'	O
+definition	O
+of	O
+WHO	O
+.	O
+
+61	O
+%	O
+of	O
+the	O
+quarantinees	O
+had	O
+a	O
+direct	O
+contact	O
+history	O
+with	O
+SARS	B-DISO
+patients	O
+,	O
+and	O
+all	O
+secondary	O
+SARS	B-DISO
+patients	O
+developed	O
+through	O
+contact	O
+to	O
+these	O
+quarantinees	O
+.	O
+
+ABSTRACT	O
+:	O
+To	O
+describe	O
+the	O
+epidemiologic	O
+features	O
+of	O
+severe	O
+acute	O
+respiratory	O
+syndrome	O
+(	O
+SARS	B-DISO
+)	O
+in	O
+Beijing	O
+.	O
+
+Beijing	O
+was	O
+the	O
+most	O
+severe	O
+epidemic	O
+region	O
+of	O
+SARS	B-DISO
+in	O
+the	O
+world	O
+,	O
+but	O
+the	O
+fatality	O
+was	O
+the	O
+lowest	O
+.	O
+
+The	O
+availability	O
+of	O
+complete	O
+genome	O
+sequence	O
+of	O
+several	O
+strains	O
+of	O
+SARS	B-DISO
+virus	B-SPEC
+provides	O
+the	O
+possibility	O
+of	O
+identification	O
+of	O
+protein	B-CHED
+-	O
+coding	O
+genes	O
+and	O
+defining	O
+their	O
+functions	O
+.	O
+
+Putative	O
+functions	O
+of	O
+all	O
+predicted	O
+protein	B-CHED
+-	O
+coding	O
+genes	O
+have	O
+been	O
+suggested	O
+using	O
+conserved	O
+peptides	B-CHED
+present	O
+in	O
+their	O
+open	O
+reading	O
+frames	O
+.	O
+
+Detailed	O
+results	O
+of	O
+GeneDecipher	O
+analysis	O
+of	O
+all	O
+the	O
+18	O
+strains	O
+of	O
+SARS	B-DISO
+-	O
+CoV	O
+genomes	O
+are	O
+available	O
+at	O
+http	O
+://	O
+www	O
+.	O
+igib	O
+.	O
+res	O
+.	O
+in	O
+/	O
+sarsanalysis	O
+.	O
+html	O
+RESULTS	O
+:	O
+In	O
+this	O
+paper	O
+,	O
+a	O
+novel	O
+analysis	O
+of	O
+SARS	B-DISO
+genome	O
+using	O
+gene	O
+prediction	O
+method	O
+GeneDecipher	O
+developed	O
+in	O
+our	O
+laboratory	O
+has	O
+been	O
+presented	O
+.	O
+
+However	O
+,	O
+diarrhea	B-DISO
+was	O
+not	O
+associated	O
+with	O
+mortality	O
+.	O
+
+The	O
+lung	B-ANAT
+and	O
+the	O
+gastrointestinal	B-ANAT
+tract	I-ANAT
+may	O
+react	O
+differently	O
+to	O
+SARS	B-DISO
+coronavirus	B-DISO
+infection	I-DISO
+.	O
+
+ABSTRACT	O
+:	O
+This	O
+study	O
+analyzes	O
+single	O
+factors	O
+that	O
+affect	O
+the	O
+prognosis	O
+of	O
+severe	O
+acute	O
+respiratory	O
+syndrome	O
+(	O
+SARS	B-DISO
+)	O
+and	O
+establishes	O
+a	O
+prognosis	O
+model	O
+by	O
+multivariate	O
+analysis	O
+.	O
+
+We	O
+retrospectively	O
+analyzed	O
+the	O
+clinical	O
+features	O
+of	O
+SARS	B-DISO
+in	O
+165	O
+clinically	O
+confirmed	O
+severe	O
+cases	O
+.	O
+
+During	O
+the	O
+acute	O
+phase	O
+of	O
+SARS	B-DISO
+,	O
+lactate	B-PRGE
+dehydrogenase	I-PRGE
+level	O
+,	O
+degree	O
+of	O
+hypoxemia	O
+,	O
+respiratory	O
+rate	O
+,	O
+alpha	B-PRGE
+-	I-PRGE
+hydroxybutyric	I-PRGE
+dehydrogenase	I-PRGE
+level	O
+,	O
+creatine	B-PRGE
+kinase	I-PRGE
+isoenzyme	I-PRGE
+-	I-PRGE
+MB	I-PRGE
+,	O
+platelet	B-ANAT
+count	O
+,	O
+and	O
+number	O
+of	O
+involved	O
+lobes	B-ANAT
+noted	O
+on	O
+chest	B-ANAT
+radiographs	O
+,	O
+and	O
+so	O
+on	O
+,	O
+correlated	O
+markedly	O
+with	O
+the	O
+prognosis	O
+(	O
+r	O
+=	O
+0	O
+.	O
+257	O
+-	O
+0	O
+.	O
+788	O
+;	O
+P	O
+<.	O
+05	O
+).	O
+
+Further	O
+studies	O
+showed	O
+the	O
+susceptibility	O
+of	O
+this	O
+cell	B-COMP
+was	O
+due	O
+to	O
+the	O
+expression	B-PROC
+of	O
+endogenous	O
+angiotensin	B-PRGE
+-	I-PRGE
+converting	I-PRGE
+enzyme	I-PRGE
+2	I-PRGE
+(	O
+ACE2	B-PRGE
+)	O
+which	O
+was	O
+activated	O
+by	O
+inserted	O
+LTR	O
+from	O
+retroviral	B-SPEC
+vector	O
+used	O
+for	O
+expression	B-PROC
+cloning	O
+.	O
+
+These	O
+data	O
+clearly	O
+demonstrated	O
+that	O
+ACE2	B-PRGE
+was	O
+the	O
+functional	O
+receptor	O
+for	O
+SARS	B-PRGE
+-	I-PRGE
+CoV	I-PRGE
+.	O
+
+Intensive	O
+care	O
+unit	O
+(	O
+ICU	O
+)	O
+nurses	O
+and	O
+other	O
+healthcare	O
+workers	O
+who	O
+care	O
+for	O
+SARS	B-DISO
+patients	O
+are	O
+at	O
+risk	O
+of	O
+contracting	O
+the	O
+disease	O
+.	O
+
+This	O
+article	O
+provides	O
+critical	O
+care	O
+nurses	O
+with	O
+an	O
+update	O
+on	O
+the	O
+first	O
+SARS	B-DISO
+outbreak	O
+,	O
+its	O
+origin	O
+,	O
+case	O
+definition	O
+,	O
+clinical	O
+manifestations	O
+,	O
+diagnosis	O
+,	O
+relevant	O
+infection	B-DISO
+control	O
+practices	O
+,	O
+management	O
+,	O
+and	O
+recommendations	O
+for	O
+the	O
+role	O
+of	O
+ICU	O
+nurses	O
+in	O
+dealing	O
+with	O
+future	O
+outbreaks	O
+.	O
+
+This	O
+has	O
+implications	O
+for	O
+surveillance	O
+and	O
+infection	B-DISO
+control	O
+planning	O
+,	O
+in	O
+the	O
+event	O
+that	O
+SARS	B-DISO
+returns	O
+next	O
+winter	O
+.	O
+
+TITLE	O
+:	O
+Significant	O
+changes	O
+of	O
+peripheral	O
+T	B-ANAT
+lymphocyte	I-ANAT
+subsets	I-ANAT
+in	O
+patients	O
+with	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+.	O
+
+In	O
+recovering	O
+patients	O
+,	O
+a	O
+rapid	O
+and	O
+dramatic	O
+restoration	O
+of	O
+peripheral	O
+T	B-ANAT
+cell	I-ANAT
+subsets	I-ANAT
+was	O
+seen	O
+in	O
+the	O
+periphery	O
+.	O
+
+BAL	B-ENZY
+was	O
+performed	O
+within	O
+12	O
+h	O
+and	O
+24	O
+h	O
+after	O
+onset	O
+of	O
+lung	B-ANAT
+injury	O
+.	O
+
+A	O
+straightforward	O
+protocol	O
+,	O
+in	O
+which	O
+splenocyte	B-ANAT
+preparations	O
+served	O
+both	O
+as	O
+APCs	B-DISO
+and	O
+effector	B-CHED
+cells	B-COMP
+,	O
+consistently	O
+yielded	O
+best	O
+results	O
+.	O
+
+This	O
+protein	B-CHED
+,	O
+encoded	O
+by	O
+ORF1a	O
+,	O
+has	O
+no	O
+designated	O
+function	O
+but	O
+is	O
+most	O
+likely	O
+involved	O
+with	O
+viral	O
+RNA	B-PROC
+synthesis	I-PROC
+.	O
+
+ABSTRACT	O
+:	O
+Severe	O
+acute	O
+respiratory	O
+syndrome	O
+(	O
+SARS	B-DISO
+)	O
+is	O
+a	O
+newly	O
+emerging	B-DISO
+infectious	I-DISO
+disease	I-DISO
+and	O
+how	O
+the	O
+frontline	O
+community	O
+doctors	O
+respond	O
+to	O
+it	O
+is	O
+not	O
+known	O
+.	O
+
+To	O
+explore	O
+the	O
+impact	O
+of	O
+SARS	B-DISO
+on	O
+general	O
+practitioners	O
+(	O
+GPs	B-DISO
+)	O
+in	O
+Hong	O
+Kong	O
+.	O
+
+The	O
+clinical	O
+practice	O
+of	O
+GPs	B-DISO
+changed	O
+significantly	O
+as	O
+a	O
+result	O
+of	O
+SARS	B-DISO
+.	O
+
+Exposure	O
+to	O
+SARS	B-DISO
+,	O
+the	O
+infection	B-DISO
+rates	O
+in	O
+their	O
+working	O
+district	O
+,	O
+and	O
+anxiety	O
+levels	O
+had	O
+significant	O
+impact	O
+on	O
+the	O
+level	O
+of	O
+protection	O
+or	O
+prescribing	O
+behaviour	B-PROC
+.	O
+
+The	O
+outbreak	O
+in	O
+Hong	O
+Kong	O
+has	O
+been	O
+dramatic	O
+due	O
+to	O
+its	O
+geographical	O
+proximity	O
+with	O
+Guangdong	O
+province	O
+,	O
+China	O
+where	O
+the	O
+first	O
+case	O
+of	O
+SARS	B-DISO
+was	O
+reported	O
+.	O
+
+SARS	B-DISO
+has	O
+been	O
+described	O
+as	O
+a	O
+rapidly	O
+progressive	O
+,	O
+sometimes	O
+fatal	O
+pneumonia	B-DISO
+with	O
+a	O
+case	O
+fatality	O
+rate	O
+of	O
+7	O
+.	O
+6	O
+%	O
+requiring	O
+intensive	O
+care	O
+.	O
+
+TITLE	O
+:	O
+Secondary	O
+structure	O
+and	O
+function	O
+of	O
+the	O
+5	O
+'-	O
+proximal	O
+region	O
+of	O
+the	O
+equine	B-SPEC
+arteritis	I-SPEC
+virus	I-SPEC
+RNA	O
+genome	O
+.	O
+
+In	O
+addition	O
+,	O
+arterivirus	B-SPEC
+and	O
+coronavirus	B-SPEC
+mRNAs	O
+contain	O
+a	O
+common	O
+5	O
+'	O
+leader	O
+sequence	O
+,	O
+derived	O
+from	O
+the	O
+genomic	O
+5	O
+'	O
+end	O
+.	O
+
+To	O
+identify	O
+RNA	O
+structures	O
+in	O
+the	O
+5	O
+'-	O
+proximal	O
+region	O
+of	O
+the	O
+equine	B-SPEC
+arteritis	I-SPEC
+virus	I-SPEC
+genome	O
+that	O
+may	O
+be	O
+involved	O
+in	O
+subgenomic	O
+mRNA	B-PROC
+synthesis	I-PROC
+,	O
+a	O
+detailed	O
+secondary	O
+RNA	O
+structure	O
+model	O
+was	O
+established	O
+using	O
+bioinformatics	O
+,	O
+phylogenetic	O
+analysis	O
+,	O
+and	O
+RNA	O
+structure	O
+probing	O
+.	O
+
+The	O
+importance	O
+of	O
+the	O
+LTH	O
+was	O
+supported	O
+by	O
+the	O
+results	O
+of	O
+a	O
+mutagenesis	B-PROC
+study	O
+using	O
+an	O
+EAV	B-SPEC
+molecular	O
+clone	O
+.	O
+
+Sequencing	O
+analysis	O
+confirmed	O
+that	O
+the	O
+desired	O
+DNA	O
+sequence	O
+in	O
+recombinant	O
+plasmid	O
+was	O
+correct	O
+and	O
+had	O
+the	O
+same	O
+sequence	O
+of	O
+natural	O
+N	O
+-	O
+terminal	O
+of	O
+SARS	B-PRGE
+virus	B-SPEC
+S1	I-PRGE
+subunit	I-PRGE
+.	O
+
+The	O
+recombinant	O
+N	O
+-	O
+terminal	O
+protein	O
+of	O
+SARS	B-DISO
+virus	B-SPEC
+S1	O
+subunit	O
+displays	O
+specific	O
+reaction	O
+with	O
+SARS	B-PRGE
+antibody	B-COMP
+and	O
+may	O
+provide	O
+a	O
+good	O
+tool	O
+for	O
+further	O
+research	O
+of	O
+immune	B-PROC
+response	I-PROC
+to	O
+SARS	B-DISO
+virus	B-SPEC
+.	O
+
+CONCLUSIONS	O
+:	O
+The	O
+recombinant	B-PRGE
+N	I-PRGE
+-	I-PRGE
+terminal	I-PRGE
+protein	I-PRGE
+of	O
+SARS	B-DISO
+virus	B-SPEC
+S1	O
+subunit	O
+displays	O
+specific	O
+reaction	O
+with	O
+SARS	B-PRGE
+antibody	B-COMP
+and	O
+may	O
+provide	O
+a	O
+good	O
+tool	O
+for	O
+further	O
+research	O
+of	O
+immune	B-PROC
+response	I-PROC
+to	O
+SARS	B-DISO
+virus	B-SPEC
+.	O
+
+We	O
+have	O
+employed	O
+molecular	O
+docking	B-PROC
+of	O
+a	O
+chemical	O
+database	O
+into	O
+the	O
+active	O
+site	O
+of	O
+3CLpro	O
+to	O
+search	O
+for	O
+non	O
+-	O
+peptidyl	O
+inhibitors	B-CHED
+.	O
+
+Unexpectedly	O
+,	O
+genes	O
+other	O
+than	O
+S	O
+appeared	O
+to	O
+modulate	O
+events	O
+critical	O
+to	O
+viral	B-PROC
+replication	I-PROC
+and	O
+survival	O
+.	O
+
+The	O
+current	O
+SARS	B-DISO
+outbreak	O
+,	O
+especially	O
+in	O
+North	O
+American	O
+health	O
+care	O
+centers	O
+,	O
+has	O
+motivated	O
+a	O
+re	O
+-	O
+evaluation	O
+of	O
+infection	B-DISO
+control	O
+practices	O
+in	O
+the	O
+hospital	O
+and	O
+clinic	O
+environment	O
+.	O
+
+Here	O
+it	O
+is	O
+hypothesized	O
+that	O
+concurrent	O
+with	O
+emergence	O
+of	O
+chloroquine	B-CHED
+-	O
+resistant	O
+malaria	B-PATH
+(	O
+presumably	O
+with	O
+enhanced	O
+anti	O
+-	O
+apoptotic	O
+capabilities	O
+),	O
+other	O
+intracellular	O
+parasites	O
+have	O
+evolved	O
+to	O
+enhance	O
+their	O
+ability	O
+to	O
+prevent	O
+apoptosis	B-PATH
+in	O
+host	B-COMP
+cells	B-COMP
+.	O
+
+Two	O
+examples	O
+of	O
+viral	B-DISO
+diseases	I-DISO
+that	O
+have	O
+emerged	O
+from	O
+areas	O
+of	O
+high	O
+incidence	O
+of	O
+chloroquine	B-CHED
+-	O
+resistant	O
+malaria	B-PATH
+are	O
+AIDS	O
+from	O
+HIV	B-DISO
+and	O
+SARS	B-DISO
+from	O
+coronavirus	B-SPEC
+.	O
+
+Currently	O
+,	O
+an	O
+antisense	O
+drug	O
+targeting	B-PROC
+Bcl	B-PRGE
+-	I-PRGE
+2	I-PRGE
+(	O
+G3139	O
+/	O
+Genasense	O
+(	O
+TM	O
+),	O
+Genta	O
+,	O
+Inc	O
+.)	O
+is	O
+in	O
+late	O
+-	O
+stage	O
+cancer	B-DISO
+trials	O
+and	O
+may	O
+be	O
+on	O
+the	O
+market	O
+for	O
+those	O
+indications	O
+in	O
+months	O
+.	O
+
+This	O
+approach	O
+to	O
+prevent	O
+or	O
+eliminate	O
+active	O
+infections	B-DISO
+might	O
+be	O
+particularly	O
+attractive	O
+against	O
+a	O
+range	O
+of	O
+parasites	O
+(	O
+virus	B-SPEC
+,	O
+bacteria	B-SPEC
+,	O
+protozoa	O
+,	O
+fungus	B-SPEC
+)	O
+when	O
+safe	O
+and	O
+effective	O
+vaccines	O
+are	O
+not	O
+available	O
+.	O
+
+The	O
+mortality	O
+of	O
+SARS	B-DISO
+is	O
+in	O
+the	O
+region	O
+of	O
+10	O
+to	O
+15	O
+%;	O
+the	O
+presence	O
+of	O
+underlying	O
+disease	O
+,	O
+high	O
+initial	O
+C	B-PRGE
+-	I-PRGE
+reactive	I-PRGE
+protein	B-CHED
+levels	O
+,	O
+and	O
+positive	O
+SARS	B-DISO
+-	O
+CoV	O
+in	O
+nasopharyngeal	B-ANAT
+aspirate	I-ANAT
+samples	O
+are	O
+associated	O
+with	O
+a	O
+higher	O
+risk	O
+of	O
+respiratory	B-DISO
+failure	I-DISO
+and	O
+mortality	O
+.	O
+
+Despite	O
+the	O
+disappearance	O
+of	O
+SARS	B-DISO
+cases	O
+worldwide	O
+,	O
+the	O
+potential	O
+evolution	B-PROC
+of	O
+SARS	B-DISO
+-	O
+CoV	O
+in	O
+animals	B-SPEC
+suggests	O
+the	O
+disease	O
+may	O
+re	O
+-	O
+emerge	O
+in	O
+the	O
+future	O
+.	O
+
+Further	O
+ongoing	O
+requirements	O
+for	O
+successful	O
+management	O
+include	O
+research	O
+on	O
+the	O
+immunopathogenesis	O
+of	O
+SARS	B-DISO
+and	O
+the	O
+development	B-PROC
+of	O
+timely	O
+and	O
+reliable	O
+diagnostic	O
+tests	O
+,	O
+effective	O
+antiviral	B-CHED
+and	O
+immunomodulatory	O
+agents	O
+,	O
+and	O
+vaccines	O
+for	O
+the	O
+disease	O
+.	O
+
+Twenty	O
+-	O
+eight	O
+cases	O
+were	O
+P	B-SPEC
+.	I-SPEC
+falciparum	I-SPEC
+infections	B-DISO
+;	O
+two	O
+were	O
+P	B-SPEC
+.	I-SPEC
+vivax	I-SPEC
+and	O
+one	O
+was	O
+a	O
+mixed	B-DISO
+infection	I-DISO
+of	O
+P	B-SPEC
+.	I-SPEC
+falciparum	I-SPEC
+and	O
+P	B-SPEC
+.	I-SPEC
+vivax	I-SPEC
+.	O
+
+Patients	O
+with	O
+both	O
+abdominal	B-DISO
+pain	I-DISO
+and	O
+hepatomegaly	B-DISO
+have	O
+significantly	O
+higher	O
+mortality	O
+.	O
+
+The	O
+major	O
+complications	O
+include	O
+acute	O
+renal	B-ANAT
+failure	O
+,	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+,	O
+cerebral	B-DISO
+malaria	B-PATH
+and	O
+disseminated	O
+intravascular	O
+coagulopathy	B-DISO
+,	O
+haemolytic	B-DISO
+anaemia	I-DISO
+and	O
+liver	B-DISO
+dysfunction	I-DISO
+.	O
+
+Higher	O
+mortality	O
+rate	O
+was	O
+documented	O
+if	O
+the	O
+antimalarial	B-CHED
+medication	O
+was	O
+not	O
+commenced	O
+on	O
+the	O
+day	O
+of	O
+admission	O
+into	O
+hospital	O
+.	O
+
+The	O
+differences	O
+between	O
+the	O
+two	O
+groups	O
+were	O
+compared	O
+in	O
+terms	O
+of	O
+development	B-PROC
+of	O
+illness	O
+,	O
+time	O
+of	O
+using	O
+corticosteroid	B-CHED
+and	O
+absorption	O
+time	O
+of	O
+pulmonary	B-ANAT
+inflammatory	O
+lesion	O
+,	O
+etc	O
+.	O
+
+As	O
+compared	O
+with	O
+the	O
+western	O
+treatment	O
+,	O
+ICWM	O
+treatment	O
+could	O
+evidently	O
+shorten	O
+the	O
+course	B-DISO
+of	I-DISO
+illness	I-DISO
+,	O
+prevent	O
+the	O
+rebounding	O
+of	O
+fever	B-PROC
+and	O
+reduce	O
+the	O
+time	O
+of	O
+using	O
+corticosteroid	B-CHED
+.	O
+
+CONCLUSIONS	O
+:	O
+Patients	O
+of	O
+SARS	B-DISO
+are	O
+mainly	O
+youth	O
+and	O
+adults	O
+in	O
+the	O
+prime	O
+of	O
+life	O
+,	O
+fever	B-PROC
+always	O
+appears	O
+as	O
+the	O
+initiation	O
+of	O
+illness	O
+and	O
+some	O
+accompanying	O
+symptoms	O
+would	O
+appear	O
+.	O
+
+In	O
+agreement	O
+with	O
+our	O
+previous	O
+results	O
+,	O
+the	O
+number	O
+of	O
+different	O
+clonotypes	O
+responding	O
+to	O
+all	O
+three	O
+epitopes	O
+fit	B-DISO
+a	O
+log	O
+-	O
+series	O
+distribution	O
+.	O
+
+HPS	B-DISO
+is	O
+a	O
+zoonotic	O
+disease	O
+caused	O
+by	O
+transmission	O
+of	O
+Sin	B-PRGE
+Nombre	I-PRGE
+virus	I-PRGE
+(	O
+SNV	O
+)	O
+from	O
+chronically	O
+infected	O
+deer	B-SPEC
+mice	B-SPEC
+.	O
+
+In	O
+humans	B-SPEC
+,	O
+this	O
+fulminant	O
+infection	B-DISO
+is	O
+characterized	O
+by	O
+lung	B-ANAT
+capillary	B-ANAT
+leakage	B-DISO
+,	O
+respiratory	B-DISO
+failure	I-DISO
+,	O
+and	O
+cardiogenic	B-DISO
+shock	I-DISO
+.	O
+
+This	O
+may	O
+also	O
+be	O
+the	O
+immunopathologic	O
+basis	O
+of	O
+other	O
+life	O
+-	O
+threatening	O
+human	B-SPEC
+virus	B-SPEC
+infections	B-DISO
+.	O
+
+The	O
+impact	O
+of	O
+the	O
+ventilator	O
+should	O
+be	O
+limited	O
+with	O
+regard	O
+to	O
+aspiratory	O
+pressure	O
+,	O
+tidal	O
+volume	O
+,	O
+inspired	B-PROC
+oxygen	B-CHED
+,	O
+and	O
+levels	O
+of	O
+expiratory	B-PROC
+end	O
+expiratory	B-PROC
+pressure	O
+.	O
+
+ABSTRACT	O
+:	O
+The	O
+primary	O
+cause	O
+of	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+(	O
+SARS	B-DISO
+)	O
+is	O
+a	O
+newly	O
+discovered	O
+coronavirus	B-SPEC
+.	O
+
+Replication	O
+of	O
+this	O
+SARS	B-DISO
+coronavirus	B-SPEC
+(	O
+SCV	B-SPEC
+)	O
+occurs	O
+mainly	O
+in	O
+the	O
+lower	B-ANAT
+respiratory	I-ANAT
+tract	I-ANAT
+,	O
+and	O
+causes	O
+diffuse	B-DISO
+alveolar	I-DISO
+damage	I-DISO
+.	O
+
+Lack	O
+of	O
+understanding	O
+of	O
+the	O
+pathogenesis	B-DISO
+of	O
+SARS	B-DISO
+has	O
+prevented	O
+the	O
+rational	O
+development	B-PROC
+of	O
+a	O
+therapy	O
+against	O
+this	O
+disease	O
+.	O
+
+Recruitment	B-DISO
+maneuver	O
+was	O
+safe	O
+and	O
+useful	O
+to	O
+improve	O
+oxygenation	B-PROC
+and	O
+Cs	O
+in	O
+patients	O
+with	O
+severe	O
+ARDS	B-DISO
+ventilated	O
+with	O
+lung	B-ANAT
+-	O
+protective	O
+strategy	O
+.	O
+
+Obstructive	O
+mucus	B-DISO
+plugging	I-DISO
+and	O
+the	O
+development	B-PROC
+of	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+may	O
+underlie	O
+the	O
+pathophysiology	O
+of	O
+refractory	O
+hypoxemia	O
+in	O
+acute	B-DISO
+chest	I-DISO
+syndrome	I-DISO
+.	O
+
+Individual	O
+mutation	O
+and	O
+other	O
+combinations	O
+of	O
+mutations	O
+in	O
+the	O
+S	B-PRGE
+gene	I-PRGE
+only	O
+interfere	O
+with	O
+virulence	B-PROC
+and	O
+hepatitis	B-DISO
+and	O
+only	O
+reduce	O
+demyelination	O
+(	O
+I375M	O
+),	O
+but	O
+do	O
+not	O
+abolish	O
+demyelination	B-DISO
+completely	O
+.	O
+
+The	O
+antiviral	B-CHED
+mechanism	O
+of	O
+GA	O
+appears	O
+to	O
+be	O
+associated	O
+with	O
+Hsp90	B-PRGE
+inactivation	B-DISO
+and	O
+cell	B-PATH
+cycle	I-PATH
+restoration	O
+,	O
+which	O
+indicates	O
+that	O
+GA	O
+exhibits	O
+broad	O
+-	O
+spectrum	O
+antiviral	B-CHED
+activity	O
+.	O
+
+Since	O
+GA	O
+inhibits	O
+HSV	B-SPEC
+-	I-SPEC
+1	I-SPEC
+through	O
+a	O
+cellular	B-COMP
+mechanism	O
+unique	O
+among	O
+HSV	B-SPEC
+-	I-SPEC
+1	I-SPEC
+agents	O
+,	O
+we	O
+consider	O
+it	O
+a	O
+new	O
+candidate	O
+agent	O
+for	O
+HSV	B-SPEC
+-	I-SPEC
+1	I-SPEC
+.	O
+
+Mapping	O
+of	O
+the	O
+80R	O
+epitope	B-CHED
+showed	O
+it	O
+is	O
+located	O
+within	O
+the	O
+N	O
+-	O
+terminal	O
+261	O
+-	O
+672	O
+amino	B-CHED
+acids	I-CHED
+of	O
+S	B-PRGE
+protein	I-PRGE
+and	O
+is	O
+not	O
+glycosylation	B-PROC
+-	O
+dependent	O
+.	O
+
+80R	O
+scFv	O
+competed	O
+with	O
+soluble	O
+ACE2	B-PRGE
+for	O
+association	O
+with	O
+the	O
+S1	B-PRGE
+domain	I-PRGE
+and	O
+bound	O
+S1	O
+with	O
+high	O
+affinity	O
+(	O
+equilibrium	O
+dissociation	B-DISO
+constant	O
+,	O
+Kd	O
+=	O
+32	O
+.	O
+3	O
+nM	O
+).	O
+
+RESULTS	O
+:	O
+In	O
+vitro	O
+antiviral	B-CHED
+activity	O
+against	O
+SARS	B-DISO
+associated	O
+coronavirus	B-SPEC
+was	O
+demonstrated	O
+for	O
+lopinavir	O
+and	O
+ribavirin	B-CHED
+at	O
+concentrations	O
+of	O
+4	O
+micro	O
+g	O
+/	O
+ml	O
+and	O
+50	O
+micro	O
+g	O
+/	O
+ml	O
+,	O
+respectively	O
+,	O
+only	O
+at	O
+48	O
+hours	O
+.	O
+
+TITLE	O
+:	O
+[	O
+Characterization	O
+of	O
+peripheral	O
+dendritic	B-ANAT
+cell	B-COMP
+subsets	O
+and	O
+its	O
+implication	O
+in	O
+patients	O
+infected	O
+with	O
+severe	O
+acute	O
+respiratory	O
+syndrome	O
+].	O
+
+CONCLUSIONS	O
+:	O
+Our	O
+results	O
+showed	O
+SARS	B-DISO
+patients	O
+had	O
+a	O
+significant	O
+decrease	O
+of	O
+circulating	O
+DC	O
+cell	B-COMP
+subset	O
+frequency	O
+,	O
+which	O
+maybe	O
+lead	O
+to	O
+the	O
+host	B-COMP
+immunodeficiency	B-DISO
+response	O
+to	O
+SARS	B-DISO
+-	I-DISO
+associated	I-DISO
+coronavirus	I-DISO
+(	O
+SARS	B-DISO
+-	O
+CoV	O
+).	O
+
+TITLE	O
+:	O
+Transmission	O
+of	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+during	O
+intubation	O
+and	O
+mechanical	O
+ventilation	O
+.	O
+
+This	O
+new	O
+human	B-SPEC
+emergent	O
+infectious	B-DISO
+disease	I-DISO
+is	O
+dominated	O
+by	O
+severe	O
+lower	O
+respiratory	O
+illness	O
+and	O
+is	O
+aetiologically	O
+linked	O
+to	O
+a	O
+new	O
+coronavirus	B-SPEC
+(	O
+SARS	B-DISO
+-	O
+CoV	O
+).	O
+
+The	O
+pathological	O
+features	O
+were	O
+dominated	O
+by	O
+diffuse	B-DISO
+alveolar	I-DISO
+damage	I-DISO
+,	O
+with	O
+the	O
+presence	O
+of	O
+multinucleated	O
+pneumocytes	B-ANAT
+.	O
+
+RESULTS	O
+:	O
+Positive	O
+viral	O
+culture	O
+for	O
+coronavirus	B-SPEC
+was	O
+detected	O
+in	O
+most	O
+premortem	O
+nasopharyngeal	B-ANAT
+aspirate	I-ANAT
+specimens	O
+(	O
+five	O
+of	O
+six	O
+)	O
+and	O
+postmortem	O
+lung	B-ANAT
+tissues	I-ANAT
+(	O
+two	O
+of	O
+seven	O
+).	O
+
+TITLE	O
+:	O
+Requirements	O
+for	O
+CEACAMs	O
+and	O
+cholesterol	B-CHED
+during	O
+murine	B-SPEC
+coronavirus	I-SPEC
+cell	B-COMP
+entry	O
+.	O
+
+ABSTRACT	O
+:	O
+Previous	O
+reports	O
+have	O
+documented	O
+that	O
+cholesterol	O
+supplementations	O
+increase	O
+cytopathic	B-DISO
+effects	I-DISO
+in	O
+tissue	B-ANAT
+culture	O
+and	O
+also	O
+intensify	O
+in	O
+vivo	O
+pathogenicities	O
+during	O
+infection	B-DISO
+by	O
+the	O
+enveloped	O
+coronavirus	B-SPEC
+murine	B-DISO
+hepatitis	I-DISO
+virus	B-SPEC
+(	O
+MHV	B-SPEC
+).	O
+
+These	O
+various	O
+cholesterol	B-CHED
+levels	O
+had	O
+no	O
+effect	O
+on	O
+the	O
+binding	B-FUNC
+of	O
+viral	O
+spike	O
+(	O
+S	O
+)	O
+proteins	B-CHED
+to	O
+cellular	B-COMP
+carcinoembryonic	O
+antigen	B-PRGE
+-	I-PRGE
+related	I-PRGE
+cell	B-PROC
+adhesion	B-DISO
+molecule	I-PRGE
+(	I-PRGE
+CEACAM	I-PRGE
+)	I-PRGE
+receptors	I-PRGE
+,	O
+rather	O
+they	O
+correlated	O
+directly	O
+with	O
+S	O
+-	O
+protein	B-CHED
+-	O
+mediated	O
+membrane	B-PROC
+fusion	I-PROC
+activities	O
+.	O
+
+However	O
+,	O
+the	O
+vast	O
+majority	O
+of	O
+CEACAMs	O
+were	O
+solubilized	O
+by	O
+cold	B-DISO
+Triton	B-CHED
+X	I-CHED
+-	I-CHED
+100	I-CHED
+(	O
+TX	O
+-	O
+100	O
+),	O
+indicating	O
+their	O
+absence	O
+from	O
+lipid	B-COMP
+rafts	I-COMP
+.	O
+
+These	O
+findings	O
+argued	O
+against	O
+the	O
+importance	O
+of	O
+cholesterol	B-CHED
+-	O
+dependent	O
+CEACAM	O
+localizations	O
+into	O
+membrane	B-COMP
+microdomains	O
+for	O
+MHV	B-SPEC
+entry	O
+,	O
+instead	O
+suggesting	O
+that	O
+cholesterol	B-CHED
+had	O
+a	O
+more	O
+direct	O
+role	O
+.	O
+
+We	O
+conclude	O
+that	O
+cholesterol	B-CHED
+is	O
+an	O
+essential	O
+membrane	B-PROC
+fusion	I-PROC
+cofactor	B-CHED
+that	O
+can	O
+act	O
+with	O
+or	O
+without	O
+CEACAMs	O
+to	O
+promote	O
+MHV	B-SPEC
+entry	O
+.	O
+
+ABSTRACT	O
+:	O
+Infectious	B-SPEC
+salmon	I-SPEC
+anemia	B-DISO
+virus	I-SPEC
+(	O
+ISAV	B-SPEC
+)	O
+is	O
+the	O
+causative	O
+agent	O
+of	O
+infections	B-DISO
+in	O
+farmed	O
+Atlantic	B-SPEC
+salmon	I-SPEC
+.	O
+
+After	O
+the	O
+4th	O
+week	O
+,	O
+12	O
+(	O
+55	O
+%)	O
+of	O
+22	O
+patients	O
+had	O
+irregular	O
+linear	O
+opacities	B-DISO
+with	O
+or	O
+without	O
+associated	O
+ground	O
+-	O
+glass	O
+opacities	B-DISO
+and	O
+CT	O
+scores	O
+greater	O
+than	O
+5	O
+;	O
+five	O
+of	O
+these	O
+patients	O
+had	O
+bronchial	B-ANAT
+dilatation	B-DISO
+.	O
+
+There	O
+is	O
+a	O
+temporal	O
+pattern	O
+of	O
+lung	B-ANAT
+abnormalities	O
+at	O
+thin	O
+-	O
+section	O
+CT	O
+in	O
+SARS	B-DISO
+.	O
+
+Severe	O
+complications	O
+occurred	O
+in	O
+17	O
+patients	O
+in	O
+the	O
+standard	O
+treatment	O
+group	O
+,	O
+vs	O
+4	O
+patients	O
+in	O
+the	O
+noninvasive	O
+continuous	O
+positive	O
+airway	B-ANAT
+pressure	O
+group	O
+(	O
+p	O
+=	O
+0	O
+.	O
+002	O
+).	O
+
+Early	O
+48	O
+-	O
+h	O
+mortality	O
+was	O
+7	O
+%	O
+in	O
+the	O
+noninvasive	O
+continuous	O
+positive	O
+airway	B-ANAT
+pressure	O
+group	O
+,	O
+compared	O
+with	O
+24	O
+%	O
+in	O
+the	O
+standard	O
+treatment	O
+group	O
+(	O
+p	O
+=	O
+0	O
+.	O
+017	O
+);	O
+however	O
+,	O
+no	O
+sustained	O
+benefits	O
+were	O
+observed	O
+during	O
+the	O
+overall	O
+hospital	O
+stay	O
+.	O
+
+CONCLUSIONS	O
+:	O
+Noninvasive	O
+continuous	O
+positive	O
+airway	B-ANAT
+pressure	O
+promotes	O
+early	O
+clinical	O
+improvement	O
+in	O
+elderly	O
+patients	O
+attending	O
+emergency	B-DISO
+departments	O
+for	O
+a	O
+severe	O
+pulmonary	B-DISO
+edema	I-DISO
+,	O
+but	O
+only	O
+reduces	O
+early	O
+48	O
+-	O
+h	O
+mortality	O
+.	O
+
+In	O
+specialized	O
+centers	O
+patients	O
+with	O
+severe	O
+ARDS	B-DISO
+and	O
+imminent	O
+hypoxia	B-DISO
+despite	O
+intensive	O
+conventional	O
+therapy	O
+,	O
+are	O
+treated	O
+with	O
+ECMO	O
+using	O
+blood	B-ANAT
+pumps	O
+and	O
+artificial	O
+membrane	B-COMP
+lungs	B-ANAT
+(	O
+oxygenators	O
+)	O
+for	O
+extracorporeal	O
+lung	B-ANAT
+assist	O
+.	O
+
+ABSTRACT	O
+:	O
+Fifteen	O
+isolates	O
+of	O
+Infectious	O
+bronchitis	B-DISO
+virus	B-SPEC
+(	O
+IBV	B-SPEC
+)	O
+were	O
+obtained	O
+from	O
+the	O
+kidney	B-ANAT
+,	O
+trachea	B-DISO
+,	O
+and	O
+cecal	B-ANAT
+tonsil	I-ANAT
+of	O
+IB	O
+suspected	O
+chickens	B-SPEC
+between	O
+2001	O
+and	O
+2002	O
+years	O
+in	O
+Korea	O
+.	O
+
+The	O
+S1	B-PRGE
+glycoprotein	I-PRGE
+gene	O
+of	O
+IBV	B-SPEC
+isolates	O
+were	O
+amplified	O
+by	O
+reverse	B-PRGE
+transcriptase	I-PRGE
+-	O
+polymerase	O
+chain	O
+reaction	O
+(	O
+RT	O
+-	O
+PCR	O
+)	O
+and	O
+analyzed	O
+by	O
+restriction	O
+fragment	O
+length	O
+polymorphism	B-PROC
+(	O
+RFLP	O
+)	O
+analysis	O
+.	O
+
+Ten	O
+of	O
+15	O
+isolates	O
+generated	O
+unique	O
+KM91	O
+RFLP	O
+pattern	O
+that	O
+was	O
+observed	O
+in	O
+the	O
+IBV	B-SPEC
+KM	O
+91	O
+strain	O
+previously	O
+isolated	O
+in	O
+Korea	O
+.	O
+
+To	O
+confirm	O
+genetic	O
+diversity	O
+in	O
+the	O
+S1	O
+genes	O
+of	O
+IBV	B-SPEC
+isolates	O
+,	O
+viral	O
+RNAs	O
+of	O
+representative	O
+9	O
+of	O
+15	O
+IBV	B-SPEC
+isolates	O
+were	O
+amplified	O
+,	O
+cloned	O
+,	O
+sequenced	O
+and	O
+compared	O
+with	O
+published	O
+sequences	O
+for	O
+non	O
+-	O
+Korean	O
+IBV	O
+strains	O
+.	O
+
+A	O
+combination	O
+treatment	O
+of	O
+steroids	B-CHED
+and	O
+ribavirin	B-CHED
+was	O
+widely	O
+used	O
+empirically	O
+from	O
+the	O
+outset	O
+of	O
+the	O
+epidemic	O
+.	O
+
+In	O
+general	O
+,	O
+the	O
+use	O
+of	O
+steroids	B-CHED
+for	O
+SARS	B-DISO
+seemed	O
+beneficial	O
+,	O
+but	O
+the	O
+optimal	O
+timing	O
+,	O
+dosage	O
+,	O
+and	O
+duration	O
+of	O
+treatment	O
+have	O
+not	O
+yet	O
+been	O
+determined	O
+.	O
+
+The	O
+purpose	O
+of	O
+the	O
+present	O
+study	O
+was	O
+to	O
+investigate	O
+the	O
+prognostic	O
+role	O
+of	O
+severe	O
+hypoxemia	O
+on	O
+admission	O
+as	O
+an	O
+independent	O
+risk	O
+factor	O
+of	O
+pulmonary	B-DISO
+complications	I-DISO
+and	O
+mortality	O
+in	O
+patients	O
+with	O
+acute	B-DISO
+pancreatitis	I-DISO
+.	O
+
+Pulmonary	B-DISO
+complications	I-DISO
+were	O
+studied	O
+in	O
+166	O
+previously	O
+healthy	O
+patients	O
+with	O
+acute	B-DISO
+pancreatitis	I-DISO
+.	O
+
+TITLE	O
+:	O
+A	O
+retrospective	O
+study	O
+on	O
+clinical	O
+features	O
+of	O
+and	O
+treatment	O
+methods	O
+for	O
+77	O
+severe	O
+cases	O
+of	O
+SARS	B-DISO
+.	O
+
+Twenty	O
+-	O
+nine	O
+(	O
+37	O
+.	O
+6	O
+%)	O
+of	O
+the	O
+77	O
+severe	O
+cases	O
+of	O
+SARS	B-DISO
+patients	O
+demonstrated	O
+an	O
+extensive	O
+lung	B-ANAT
+involvement	O
+.	O
+
+The	O
+role	O
+Chinese	O
+medicine	B-CHED
+played	O
+in	O
+the	O
+treatment	O
+of	O
+SARS	B-DISO
+was	O
+discussed	O
+.	O
+
+Logistic	O
+regression	O
+analysis	O
+identified	O
+4	O
+factors	O
+as	O
+being	O
+significantly	O
+associated	O
+with	O
+increased	O
+levels	O
+of	O
+concern	O
+for	O
+personal	O
+or	O
+family	B-SPEC
+health	O
+:	O
+perception	O
+of	O
+a	O
+greater	O
+risk	O
+of	O
+death	B-PROC
+from	O
+SARS	B-DISO
+(	O
+adjusted	O
+odds	O
+ratio	O
+[	O
+OR	O
+]	O
+5	O
+.	O
+0	O
+,	O
+95	O
+%	O
+confidence	O
+interval	O
+[	O
+CI	O
+]	O
+2	O
+.	O
+6	O
+-	O
+9	O
+.	O
+6	O
+),	O
+living	O
+with	O
+children	O
+(	O
+adjusted	O
+OR	O
+1	O
+.	O
+8	O
+,	O
+95	O
+%	O
+CI	O
+1	O
+.	O
+5	O
+-	O
+2	O
+.	O
+3	O
+),	O
+personal	O
+or	O
+family	B-SPEC
+lifestyle	O
+affected	O
+by	O
+SARS	B-DISO
+outbreak	O
+(	O
+adjusted	O
+OR	O
+3	O
+.	O
+3	O
+,	O
+95	O
+%	O
+CI	O
+2	O
+.	O
+5	O
+-	O
+4	O
+.	O
+3	O
+)	O
+and	O
+being	O
+treated	O
+differently	O
+by	O
+people	O
+because	O
+of	O
+working	O
+in	O
+a	O
+hospital	O
+(	O
+adjusted	O
+OR	O
+1	O
+.	O
+6	O
+,	O
+95	O
+%	O
+CI	O
+1	O
+.	O
+2	O
+-	O
+2	O
+.	O
+1	O
+).	O
+
+Four	O
+factors	O
+were	O
+identified	O
+as	O
+being	O
+significantly	O
+associated	O
+with	O
+the	O
+presence	O
+of	O
+emotional	B-DISO
+distress	I-DISO
+:	O
+being	O
+a	O
+nurse	O
+(	O
+adjusted	O
+OR	O
+2	O
+.	O
+8	O
+,	O
+95	O
+%	O
+CI	O
+1	O
+.	O
+5	O
+-	O
+5	O
+.	O
+5	O
+),	O
+part	O
+-	O
+time	O
+employment	O
+status	O
+(	O
+adjusted	O
+OR	O
+2	O
+.	O
+6	O
+,	O
+95	O
+%	O
+CI	O
+1	O
+.	O
+2	O
+-	O
+5	O
+.	O
+4	O
+),	O
+lifestyle	O
+affected	O
+by	O
+SARS	B-DISO
+outbreak	O
+(	O
+adjusted	O
+OR	O
+2	O
+.	O
+2	O
+,	O
+95	O
+%	O
+CI	O
+1	O
+.	O
+4	O
+-	O
+3	O
+.	O
+5	O
+)	O
+and	O
+ability	O
+to	O
+do	O
+one	O
+'	O
+s	O
+job	O
+affected	O
+by	O
+the	O
+precautionary	O
+measures	O
+(	O
+adjusted	O
+OR	O
+2	O
+.	O
+9	O
+,	O
+95	O
+%	O
+CI	O
+1	O
+.	O
+9	O
+-	O
+4	O
+.	O
+6	O
+).	O
+
+Repeated	O
+bacteriological	O
+testing	O
+in	O
+lungs	B-ANAT
+and	O
+blood	B-ANAT
+remained	O
+negative	O
+.	O
+
+Its	O
+pathogenesis	B-DISO
+is	O
+unknown	O
+.	O
+
+The	O
+Agency	O
+for	O
+Cooperation	O
+in	O
+International	O
+Health	O
+,	O
+a	O
+Japanese	O
+non	O
+-	O
+governmental	O
+organisation	B-PROC
+,	O
+has	O
+developed	O
+on	O
+a	O
+voluntary	O
+basis	O
+a	O
+sentinel	O
+surveillance	O
+system	O
+for	O
+selected	O
+target	O
+infectious	B-DISO
+diseases	I-DISO
+,	O
+covering	O
+South	O
+America	O
+,	O
+Africa	O
+,	O
+and	O
+Asia	O
+.	O
+
+After	O
+the	O
+appearance	O
+of	O
+an	O
+index	O
+patient	O
+in	O
+Hong	O
+Kong	O
+in	O
+February	O
+2003	O
+,	O
+SARS	B-DISO
+outbreaks	O
+occurred	O
+rapidly	O
+in	O
+hospitals	O
+and	O
+spread	O
+to	O
+the	O
+community	O
+.	O
+
+Between	O
+13	O
+March	O
+and	O
+23	O
+June	O
+,	O
+38	O
+patients	O
+with	O
+probable	O
+and	O
+suspected	O
+SARS	O
+,	O
+90	O
+patients	O
+with	O
+non	O
+-	O
+SARS	B-DISO
+pneumonia	B-DISO
+,	O
+and	O
+510	O
+patients	O
+without	O
+pneumonia	B-DISO
+were	O
+admitted	O
+into	O
+our	O
+unit	O
+.	O
+
+In	O
+addition	O
+,	O
+there	O
+was	O
+no	O
+nosocomial	O
+spread	O
+of	O
+SARS	B-DISO
+-	I-DISO
+associated	I-DISO
+coronavirus	I-DISO
+to	O
+other	O
+patients	O
+or	O
+visitors	O
+during	O
+this	O
+period	O
+.	O
+
+The	O
+improved	O
+oxygenation	B-PROC
+in	O
+this	O
+patient	O
+should	O
+encourage	O
+the	O
+use	O
+of	O
+prone	O
+ventilation	O
+in	O
+other	O
+patients	O
+with	O
+pulmonary	B-ANAT
+haemorrhage	I-DISO
+and	O
+severe	O
+hypoxia	B-DISO
+.	O
+
+TITLE	O
+:	O
+Dispersal	O
+of	O
+respiratory	O
+droplets	O
+with	O
+open	O
+vs	O
+closed	O
+oxygen	B-CHED
+delivery	O
+masks	O
+:	O
+implications	O
+for	O
+the	O
+transmission	O
+of	O
+severe	O
+acute	O
+respiratory	O
+syndrome	O
+.	O
+
+We	O
+show	O
+that	O
+SARS	B-PRGE
+-	I-PRGE
+CoV	I-PRGE
+nsp9	I-PRGE
+is	O
+a	O
+single	O
+-	O
+stranded	O
+RNA	O
+-	O
+binding	B-FUNC
+protein	B-CHED
+displaying	O
+a	O
+previously	O
+unreported	O
+,	O
+oligosaccharide	B-CHED
+/	O
+oligonucleotide	B-CHED
+fold	O
+-	O
+like	O
+fold	O
+.	O
+
+ABSTRACT	O
+:	O
+Risk	O
+factors	O
+for	O
+acute	O
+wheezing	B-DISO
+among	O
+children	O
+in	O
+subtropical	O
+areas	O
+are	O
+largely	O
+unknown	O
+.	O
+
+In	O
+children	O
+under	O
+2	O
+years	O
+of	O
+age	O
+,	O
+infection	O
+with	O
+respiratory	O
+viruses	B-SPEC
+and	O
+family	B-SPEC
+history	O
+of	O
+allergy	B-DISO
+were	O
+independently	O
+associated	O
+with	O
+wheezing	B-DISO
+(	O
+odds	O
+ratio	O
+,	O
+15	O
+.	O
+5	O
+and	O
+4	O
+.	O
+2	O
+;	O
+P	O
+=	O
+.	O
+0001	O
+and	O
+P	O
+=	O
+.	O
+008	O
+,	O
+respectively	O
+).	O
+
+RESULTS	O
+:	O
+In	O
+children	O
+under	O
+2	O
+years	O
+of	O
+age	O
+,	O
+infection	B-DISO
+with	O
+respiratory	O
+viruses	B-SPEC
+and	O
+family	B-SPEC
+history	O
+of	O
+allergy	B-DISO
+were	O
+independently	O
+associated	O
+with	O
+wheezing	B-DISO
+(	O
+odds	O
+ratio	O
+,	O
+15	O
+.	O
+5	O
+and	O
+4	O
+.	O
+2	O
+;	O
+P	O
+=	O
+.	O
+0001	O
+and	O
+P	O
+=	O
+.	O
+008	O
+,	O
+respectively	O
+).	O
+
+We	O
+report	O
+a	O
+patient	O
+who	O
+complained	O
+of	O
+recurrent	O
+unexplained	O
+""""	O
+fevers	O
+""""	O
+during	O
+the	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+(	O
+SARS	B-DISO
+)	O
+outbreak	O
+in	O
+Singapore	O
+.	O
+
+ABSTRACT	O
+:	O
+Chickenpox	B-DISO
+(	O
+varicella	B-DISO
+)	O
+in	O
+adults	O
+can	O
+be	O
+severe	O
+with	O
+increased	O
+mortality	O
+.	O
+
+ABSTRACT	O
+:	O
+The	O
+recent	O
+worldwide	O
+epidemic	O
+of	O
+Severe	O
+Acute	O
+Respiratory	O
+Disease	O
+(	O
+SARS	B-DISO
+)	O
+caused	O
+over	O
+800	O
+deaths	B-PROC
+and	O
+had	O
+a	O
+major	O
+impact	O
+on	O
+the	O
+health	O
+services	O
+in	O
+affected	O
+communities	O
+.	O
+
+The	O
+SARS	B-DISO
+epidemic	O
+resulted	O
+in	O
+reductions	O
+of	O
+52	O
+%	O
+for	O
+new	O
+outpatient	O
+attendances	O
+,	O
+59	O
+%	O
+for	O
+review	O
+attendances	O
+,	O
+51	O
+%	O
+for	O
+admissions	O
+,	O
+32	O
+%	O
+for	O
+surgical	O
+procedures	O
+and	O
+48	O
+%	O
+for	O
+colonoscopies	O
+.	O
+
+Numbers	O
+of	O
+interferon	B-FUNC
+-	I-FUNC
+gamma	I-FUNC
+,	O
+interleukin	B-PRGE
+(	O
+IL	O
+)-	O
+2	O
+,	O
+IL	B-FUNC
+-	I-FUNC
+4	I-FUNC
+,	O
+IL	B-FUNC
+-	I-FUNC
+10	I-FUNC
+and	O
+IL	B-FUNC
+-	I-FUNC
+12	I-FUNC
+secreting	B-PROC
+cells	B-COMP
+induced	O
+by	O
+T	B-ANAT
+cell	I-ANAT
+activators	O
+were	O
+below	O
+normal	O
+in	O
+many	O
+or	O
+most	O
+patients	O
+before	O
+and	O
+during	O
+treatment	O
+with	O
+corticosteroids	B-CHED
+and	O
+ribavirin	B-CHED
+but	O
+returned	O
+essentially	O
+to	O
+normal	O
+after	O
+completion	O
+of	O
+treatment	O
+.	O
+
+Here	O
+we	O
+describe	O
+conditions	O
+that	O
+result	O
+not	O
+only	O
+in	O
+the	O
+efficient	O
+expression	B-PROC
+of	O
+the	O
+SARS	B-DISO
+-	O
+CoV	O
+spike	O
+(	O
+S	O
+)	O
+protein	B-CHED
+on	O
+the	O
+surface	O
+of	O
+cells	B-COMP
+,	O
+but	O
+in	O
+its	O
+incorporation	O
+into	O
+lentiviral	O
+particles	O
+that	O
+can	O
+be	O
+used	O
+to	O
+transduce	O
+cells	B-COMP
+in	O
+an	O
+S	B-PRGE
+glycoprotein	I-PRGE
+-	O
+dependent	O
+manner	O
+.	O
+
+ABSTRACT	O
+:	O
+Acute	O
+respiratory	O
+distress	O
+syndrome	O
+(	O
+ARDS	B-DISO
+)	O
+is	O
+the	O
+most	O
+severe	O
+lung	B-ANAT
+injury	O
+caused	O
+by	O
+many	O
+pathologic	O
+states	O
+.	O
+
+We	O
+treated	O
+a	O
+patient	O
+who	O
+suffered	B-DISO
+from	O
+ARDS	B-DISO
+caused	O
+by	O
+splenic	B-DISO
+infarction	I-DISO
+.	O
+
+We	O
+diagnosed	O
+her	O
+ARDS	B-DISO
+.	O
+
+The	O
+administration	O
+of	O
+methylprednisolone	B-CHED
+was	O
+started	O
+according	O
+to	O
+Meduri	O
+'	O
+s	O
+report	O
+.	O
+
+Hypoxia	B-DISO
+was	O
+improved	O
+gradually	O
+and	O
+on	O
+ICU	O
+day	O
+7	O
+,	O
+she	O
+was	O
+weaned	B-PROC
+from	O
+mechanical	O
+ventilation	O
+,	O
+and	O
+extubated	O
+.	O
+
+SARS	B-DISO
+outbreak	O
+opened	O
+doors	O
+for	O
+HIV	B-DISO
+prevention	O
+.	O
+
+Outbreak	O
+of	O
+SARS	B-DISO
+in	O
+Dongcheng	O
+District	O
+started	O
+on	O
+March	O
+14	O
+,	O
+2003	O
+with	O
+a	O
+peak	O
+in	O
+mid	O
+-	O
+and	O
+late	O
+April	O
+,	O
+and	O
+dropped	O
+in	O
+early	O
+May	O
+.	O
+A	O
+total	O
+of	O
+572	O
+reported	O
+cases	O
+were	O
+collected	O
+during	O
+this	O
+period	O
+in	O
+Dongcheng	O
+District	O
+,	O
+Beijing	O
+,	O
+and	O
+99	O
+of	O
+them	O
+were	O
+excluded	O
+from	O
+SARS	O
+,	O
+because	O
+of	O
+diagnosis	O
+of	O
+common	B-DISO
+cold	I-DISO
+,	O
+regular	O
+pneumonia	B-DISO
+,	O
+measles	B-PATH
+and	O
+rubella	B-DISO
+,	O
+etc	O
+.	O
+
+Eighteen	O
+of	O
+85	O
+cases	O
+of	O
+SARS	B-DISO
+occurred	O
+in	O
+HCWs	O
+of	O
+local	O
+hospitals	O
+,	O
+accounting	O
+for	O
+4	O
+.	O
+5	O
+%	O
+of	O
+the	O
+total	O
+number	O
+of	O
+HCWs	O
+working	O
+at	O
+wards	O
+caring	O
+for	O
+SARS	B-DISO
+patients	O
+or	O
+fever	B-PROC
+clinics	O
+.	O
+
+And	O
+7	O
+.	O
+4	O
+%	O
+(	O
+attack	O
+rate	O
+)	O
+of	O
+those	O
+exposed	O
+to	O
+SARS	B-DISO
+cases	O
+suffered	B-DISO
+from	O
+the	O
+illness	O
+during	O
+the	O
+periods	B-PROC
+of	O
+quarantine	O
+.	O
+
+The	O
+crosscutting	O
+concepts	O
+of	O
+'	O
+clinical	O
+uncertainty	O
+'	O
+and	O
+'	O
+flow	O
+of	O
+human	B-SPEC
+contacts	O
+'	O
+are	O
+used	O
+to	O
+explain	O
+disease	O
+transmission	O
+characteristics	O
+and	O
+urban	O
+spatial	O
+diffusion	O
+and	O
+to	O
+guide	O
+the	O
+particular	O
+strategies	O
+developed	O
+.	O
+
+The	O
+same	O
+recombinant	O
+proteins	B-CHED
+were	O
+also	O
+applied	O
+to	O
+a	O
+newly	O
+developed	O
+platform	O
+for	O
+the	O
+development	B-PROC
+of	O
+a	O
+15	O
+-	O
+min	O
+rapid	O
+test	O
+.	O
+
+ABSTRACT	O
+:	O
+A	O
+new	O
+coronavirus	B-SPEC
+(	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+coronavirus	B-SPEC
+[	O
+SARS	B-DISO
+-	O
+CoV	O
+])	O
+has	O
+been	O
+identified	O
+to	O
+be	O
+the	O
+etiological	O
+agent	O
+of	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+.	O
+
+A	O
+truncated	O
+195	O
+-	O
+amino	O
+-	O
+acid	O
+fragment	O
+from	O
+the	O
+C	O
+terminus	O
+of	O
+the	O
+nucleocapsid	B-COMP
+protein	B-CHED
+(	O
+N195	O
+)	O
+was	O
+identified	O
+that	O
+had	O
+a	O
+strong	O
+ability	O
+to	O
+detect	O
+antibodies	B-COMP
+against	O
+SARS	B-DISO
+coronavirus	B-SPEC
+.	O
+
+According	O
+to	O
+the	O
+experience	O
+and	O
+information	O
+,	O
+to	O
+select	O
+several	O
+perspective	O
+candidates	O
+from	O
+anti	O
+-	O
+SARS	B-DISO
+effective	O
+TCM	O
+prescriptions	O
+and	O
+drugs	O
+.	O
+
+TITLE	O
+:	O
+Screening	O
+of	O
+traditional	O
+Chinese	O
+remedies	O
+for	O
+SARS	B-DISO
+treatment	O
+.	O
+
+RESULTS	O
+:	O
+ICWM	O
+showed	O
+better	O
+effect	O
+than	O
+that	O
+of	O
+western	O
+medicine	B-CHED
+alone	O
+in	O
+improving	O
+clinical	O
+symptoms	O
+,	O
+promoting	O
+the	O
+absorption	O
+of	O
+inflammation	B-DISO
+in	O
+lung	B-ANAT
+,	O
+increased	O
+oxygen	B-CHED
+saturation	O
+(	O
+P	O
+<	O
+0	O
+.	O
+01	O
+)	O
+and	O
+decreased	O
+the	O
+dosage	O
+of	O
+corticoid	O
+used	O
+(	O
+P	O
+<	O
+0	O
+.	O
+05	O
+).	O
+
+ABSTRACT	O
+:	O
+A	O
+novel	B-SPEC
+coronavirus	I-SPEC
+,	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+(	O
+SARS	B-DISO
+)-	O
+associated	O
+coronavirus	B-SPEC
+(	O
+SARS	B-DISO
+-	O
+CoV	O
+),	O
+has	O
+been	O
+identified	O
+as	O
+the	O
+causal	O
+agent	O
+of	O
+SARS	B-DISO
+.	O
+
+A	O
+panel	O
+of	O
+S	O
+protein	B-CHED
+-	O
+derived	O
+peptides	B-CHED
+was	O
+tested	O
+for	O
+their	O
+binding	B-FUNC
+affinity	O
+to	O
+HLA	B-PRGE
+-	I-PRGE
+A	I-PRGE
+*	I-PRGE
+0201	I-PRGE
+molecules	O
+.	O
+
+SARS	B-PRGE
+-	I-PRGE
+CoV	I-PRGE
+protein	B-CHED
+-	I-PRGE
+derived	I-PRGE
+peptide	B-CHED
+-	I-PRGE
+1	I-PRGE
+(	O
+SSp	B-PRGE
+-	I-PRGE
+1	I-PRGE
+RLNEVAKNL	I-PRGE
+),	O
+induced	O
+peptide	B-CHED
+-	O
+specific	O
+CTLs	O
+both	O
+in	O
+vivo	O
+(	O
+transgenic	B-SPEC
+mice	I-SPEC
+)	O
+and	O
+in	O
+vitro	O
+(	O
+human	B-SPEC
+PBLs	O
+),	O
+which	O
+specifically	O
+released	O
+interferon	B-FUNC
+-	I-FUNC
+gamma	I-FUNC
+(	O
+IFN	B-PRGE
+-	I-PRGE
+gamma	I-PRGE
+)	O
+upon	O
+stimulation	O
+with	O
+SSp	B-PRGE
+-	I-PRGE
+1	I-PRGE
+-	O
+pulsed	O
+autologous	O
+dendritic	B-ANAT
+cells	B-COMP
+(	O
+DCs	B-DISO
+)	O
+or	O
+T2	O
+cells	B-COMP
+.	O
+
+Viral	O
+antigen	B-CHED
+and	O
+nucleic	B-CHED
+acid	I-CHED
+were	O
+detected	O
+in	O
+bronchiolar	B-ANAT
+epithelial	B-ANAT
+cells	I-ANAT
+during	O
+peak	O
+viral	B-PROC
+replication	I-PROC
+.	O
+
+Mice	B-SPEC
+developed	O
+a	O
+neutralizing	O
+antibody	B-PROC
+response	I-PROC
+and	O
+were	O
+protected	O
+from	O
+reinfection	O
+28	O
+days	O
+following	O
+primary	B-DISO
+infection	I-DISO
+.	O
+
+CDC	O
+recommends	O
+that	O
+pediatric	O
+intensive	O
+care	O
+units	O
+(	O
+PICUs	B-SPEC
+)	O
+report	O
+cases	O
+that	O
+meet	O
+the	O
+CDC	O
+case	O
+definition	O
+to	O
+state	O
+health	O
+departments	O
+.	O
+
+If	O
+these	O
+reviews	O
+establish	O
+that	O
+AIPH	O
+among	O
+infants	O
+is	O
+a	O
+public	O
+health	O
+problem	O
+,	O
+on	O
+the	O
+basis	O
+of	O
+its	O
+magnitude	O
+or	O
+geographic	O
+or	O
+temporal	O
+distribution	O
+,	O
+targeted	B-PROC
+case	O
+surveillance	O
+will	O
+be	O
+initiated	O
+based	O
+on	O
+the	O
+distribution	O
+of	O
+cases	O
+.	O
+
+TITLE	O
+:	O
+Overview	O
+on	O
+SARS	B-DISO
+in	O
+Asia	O
+and	O
+the	O
+world	O
+.	O
+
+The	O
+SARS	B-PRGE
+-	I-PRGE
+CoV	I-PRGE
+has	O
+probably	O
+jumped	O
+from	O
+an	O
+animal	B-SPEC
+host	B-COMP
+to	O
+humans	B-SPEC
+.	O
+
+Within	O
+the	O
+first	O
+10	O
+days	O
+the	O
+histological	O
+picture	O
+is	O
+that	O
+of	O
+acute	O
+phase	O
+diffuse	O
+alveolar	O
+damage	O
+(	O
+DAD	O
+)	O
+with	O
+a	O
+mixture	B-CHED
+of	O
+inflammatory	O
+infiltrate	B-DISO
+,	O
+oedema	B-DISO
+and	O
+hyaline	B-DISO
+membrane	B-COMP
+formation	B-PROC
+.	O
+
+In	O
+the	O
+majority	O
+of	O
+patients	O
+,	O
+ground	O
+glass	O
+opacities	B-DISO
+on	O
+chest	B-ANAT
+radiographs	O
+progress	O
+rapidly	O
+to	O
+focal	O
+,	O
+multifocal	O
+or	O
+diffuse	O
+consolidation	O
+.	O
+
+Unilateral	O
+involvement	O
+is	O
+common	O
+in	O
+the	O
+early	O
+acute	O
+phase	O
+,	O
+becoming	O
+bilateral	O
+at	O
+maximal	O
+lung	B-ANAT
+involvement	O
+.	O
+
+Less	O
+common	O
+symptoms	O
+include	O
+sputum	B-PROC
+production	I-PROC
+,	O
+sore	B-DISO
+throat	I-DISO
+,	O
+coryza	B-DISO
+,	O
+dizziness	B-DISO
+,	O
+nausea	B-DISO
+,	I-DISO
+vomiting	I-DISO
+and	I-DISO
+diarrhoea	I-DISO
+.	O
+
+ABSTRACT	O
+:	O
+The	O
+pharmacotherapy	O
+for	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+(	O
+SARS	O
+)	O
+is	O
+controversial	O
+and	O
+largely	O
+anecdotal	O
+.	O
+
+There	O
+is	O
+a	O
+spectrum	O
+of	O
+severity	O
+and	O
+rate	O
+of	O
+progression	O
+in	O
+SARS	B-DISO
+,	O
+and	O
+the	O
+stages	O
+of	O
+viral	B-PROC
+replication	I-PROC
+,	O
+inflammatory	O
+pneumonitis	B-DISO
+and	O
+residual	O
+pulmonary	B-DISO
+fibrosis	I-DISO
+are	O
+clinically	O
+non	O
+-	O
+distinct	O
+.	O
+
+Patients	O
+who	O
+fail	O
+to	O
+tolerate	O
+NIV	O
+or	O
+fail	O
+NIV	O
+with	O
+progressive	O
+dyspnoea	B-DISO
+,	O
+tachypnoea	B-DISO
+and	O
+hypoxaemia	O
+should	O
+be	O
+intubated	O
+and	O
+mechanically	O
+ventilated	O
+.	O
+
+In	O
+a	O
+small	O
+series	O
+of	O
+subjects	O
+who	O
+underwent	O
+CT	O
+scan	O
+of	O
+the	O
+chest	B-ANAT
+,	O
+over	O
+half	O
+showed	O
+some	O
+patchy	O
+changes	O
+consistent	O
+with	O
+pulmonary	B-DISO
+fibrosis	I-DISO
+.	O
+
+Psychobehavioural	O
+problems	O
+of	O
+anxiety	O
+and	O
+/	O
+or	O
+depression	B-DISO
+were	O
+not	O
+uncommon	O
+in	O
+the	O
+early	O
+recovery	O
+phase	O
+,	O
+and	O
+improved	O
+over	O
+time	O
+in	O
+the	O
+majority	O
+of	O
+patients	O
+.	O
+
+Independent	O
+of	O
+virulence	B-PROC
+variations	O
+they	O
+are	O
+separated	O
+into	O
+two	O
+different	O
+types	O
+,	O
+type	O
+I	O
+,	O
+the	O
+original	O
+FCoV	O
+,	O
+and	O
+type	O
+II	O
+,	O
+which	O
+is	O
+closely	O
+related	O
+to	O
+canine	O
+coronavirus	B-SPEC
+(	O
+CCV	B-DISO
+).	O
+
+ABSTRACT	O
+:	O
+A	O
+1	O
+.	O
+78	O
+kb	O
+sequence	O
+,	O
+including	O
+the	O
+E	O
+,	O
+M	O
+,	O
+5a	O
+and	O
+5b	O
+genes	O
+,	O
+and	O
+the	O
+intergenic	O
+region	O
+between	O
+the	O
+M	O
+and	O
+5a	O
+genes	O
+,	O
+of	O
+six	O
+US	O
+strains	O
+of	O
+infectious	B-DISO
+bronchitis	B-DISO
+(	O
+corona	B-CHED
+)	O
+virus	B-SPEC
+(	O
+IBV	B-SPEC
+)	O
+were	O
+sequenced	O
+and	O
+compared	O
+to	O
+the	O
+published	O
+sequences	O
+for	O
+two	O
+additional	O
+strains	O
+.	O
+
+Nucleotide	B-CHED
+sequencing	O
+of	O
+recent	O
+field	O
+isolates	O
+from	O
+Alabama	B-SPEC
+(	O
+Ala1	O
+)	O
+and	O
+California	B-SPEC
+(	O
+Cal3	O
+)	O
+revealed	O
+distinct	O
+shifts	O
+in	O
+homology	O
+in	O
+the	O
+M	B-PRGE
+gene	I-PRGE
+,	O
+indicating	O
+two	O
+apparent	O
+recombination	B-PROC
+events	O
+between	O
+the	O
+Holland	O
+52	O
+/	O
+Mass41	O
+-	O
+like	O
+strain	O
+and	O
+an	O
+Ark	B-PRGE
+-	O
+like	O
+strain	O
+,	O
+both	O
+origins	O
+of	O
+commonly	O
+used	O
+vaccine	O
+strains	O
+.	O
+
+Four	O
+canine	O
+sera	B-COMP
+-	O
+positive	O
+for	O
+CCoV	B-PRGE
+type	I-PRGE
+II	I-PRGE
+,	O
+four	O
+sera	B-COMP
+-	O
+positive	O
+for	O
+CCoV	B-PRGE
+type	I-PRGE
+I	I-PRGE
+and	O
+10	O
+negative	O
+control	O
+sera	B-COMP
+were	O
+examined	O
+.	O
+
+By	O
+using	O
+mammalian	B-SPEC
+two	O
+-	O
+hybrid	O
+system	O
+and	O
+sucrose	B-CHED
+gradient	O
+fractionations	O
+,	O
+a	O
+homotypic	O
+interaction	O
+of	O
+N	O
+,	O
+but	O
+not	O
+M	O
+,	O
+was	O
+detected	O
+by	O
+the	O
+two	O
+-	O
+hybrid	O
+analysis	O
+.	O
+
+There	O
+are	O
+many	O
+challenges	O
+in	O
+preventing	O
+and	O
+managing	O
+community	O
+-	O
+acquired	O
+pneumonia	B-DISO
+in	O
+the	O
+elderly	O
+.	O
+
+Using	O
+barrier	O
+precautions	O
+,	O
+the	O
+transmission	O
+of	O
+SARS	B-DISO
+-	O
+CoV	O
+can	O
+be	O
+prevented	O
+.	O
+
+However	O
+,	O
+neuraminidase	B-PROC
+inhibitors	I-PROC
+can	O
+only	O
+be	O
+applied	O
+in	O
+specific	O
+infections	B-DISO
+and	O
+the	O
+spectrum	O
+of	O
+agents	O
+with	O
+antiviral	B-CHED
+activity	O
+is	O
+broad	O
+.	O
+
+ABSTRACT	O
+:	O
+Neutrophil	B-ANAT
+-	O
+mediated	O
+lung	O
+injury	O
+is	O
+a	O
+cause	O
+of	O
+significant	O
+morbidity	O
+and	O
+mortality	O
+in	O
+patients	O
+with	O
+multiple	O
+injuries	O
+.	O
+
+We	O
+have	O
+shown	O
+previously	O
+that	O
+fracture	O
+hematoma	B-DISO
+can	O
+activate	O
+neutrophils	B-ANAT
+and	O
+is	O
+thus	O
+a	O
+putative	O
+mediator	O
+of	O
+the	O
+systemic	B-DISO
+inflammatory	I-DISO
+response	I-DISO
+syndrome	I-DISO
+(	O
+SIRS	B-DISO
+),	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+(	O
+ARDS	B-DISO
+)	O
+and	O
+multiple	B-DISO
+organ	I-DISO
+failure	I-DISO
+(	O
+MOF	B-DISO
+)	O
+in	O
+those	O
+patients	O
+with	O
+severe	O
+skeletal	B-ANAT
+trauma	O
+.	O
+
+The	O
+rats	B-SPEC
+were	O
+killed	O
+24	O
+hours	O
+after	O
+injury	O
+and	O
+some	O
+parameters	O
+of	O
+lung	B-ANAT
+injury	O
+were	O
+evaluated	O
+--	O
+i	O
+.	O
+e	O
+.,	O
+bronchoalveolar	O
+lavage	O
+(	O
+BAL	B-ENZY
+),	O
+lung	B-PRGE
+tissue	I-PRGE
+myeloperoxidase	B-ENZY
+levels	O
+(	O
+MPO	B-FUNC
+)	O
+and	O
+wet	O
+/	O
+dry	O
+ratios	O
+of	O
+lung	B-ANAT
+tissue	I-ANAT
+.	O
+
+This	O
+effect	O
+was	O
+attenuated	O
+by	O
+treatment	O
+with	O
+N	B-CHED
+-	I-CHED
+acetylcysteine	I-CHED
+(	O
+MPO	B-FUNC
+43	O
+-	O
+9	O
+microg	O
+/	O
+mL	O
+,	O
+BAL	B-ENZY
+protein	B-CHED
+605	O
+-	O
+198	O
+microg	O
+/	O
+mL	O
+).	O
+
+TITLE	O
+:	O
+A	O
+DNA	O
+vaccine	O
+induces	O
+SARS	B-DISO
+coronavirus	B-SPEC
+neutralization	O
+and	O
+protective	O
+immunity	B-PROC
+in	O
+mice	B-SPEC
+.	O
+
+Here	O
+,	O
+we	O
+show	O
+that	O
+a	O
+DNA	O
+vaccine	O
+encoding	O
+the	O
+spike	O
+(	O
+S	O
+)	O
+glycoprotein	B-CHED
+of	O
+the	O
+SARS	B-PRGE
+-	I-PRGE
+CoV	I-PRGE
+induces	O
+T	B-ANAT
+cell	I-ANAT
+and	O
+neutralizing	O
+antibody	B-PROC
+responses	I-PROC
+,	O
+as	O
+well	O
+as	O
+protective	O
+immunity	B-PROC
+,	O
+in	O
+a	O
+mouse	B-SPEC
+model	O
+.	O
+
+Yes	O
+,	O
+steroids	B-CHED
+are	O
+a	O
+key	O
+component	O
+of	O
+the	O
+treatment	O
+regimen	O
+for	O
+SARS	B-DISO
+.	O
+
+The	O
+C57BL	O
+/	O
+6	O
+mice	B-SPEC
+also	O
+developed	O
+subclinical	O
+intestinal	B-DISO
+infection	I-DISO
+,	O
+but	O
+only	O
+transmitted	B-DISO
+virus	B-SPEC
+for	O
+two	O
+weeks	O
+.	O
+
+Viral	O
+RNA	O
+detected	O
+in	O
+the	O
+feces	B-ANAT
+of	O
+infected	O
+mice	B-SPEC
+was	O
+almost	O
+always	O
+infectious	B-DISO
+.	O
+
+We	O
+propose	O
+a	O
+mathematical	O
+model	O
+to	O
+estimate	O
+the	O
+evolution	B-PROC
+rate	O
+of	O
+the	O
+SARS	B-DISO
+coronavirus	B-SPEC
+genome	O
+and	O
+the	O
+time	O
+of	O
+the	O
+last	O
+common	O
+ancestor	O
+of	O
+the	O
+sequenced	O
+SARS	B-DISO
+strains	O
+.	O
+
+We	O
+investigated	O
+changes	O
+in	O
+plasma	B-ANAT
+T	O
+helper	O
+(	O
+Th	O
+)	O
+cell	B-COMP
+cytokines	O
+,	O
+inflammatory	O
+cytokines	O
+and	O
+chemokines	O
+in	O
+20	O
+patients	O
+diagnosed	O
+with	O
+SARS	B-DISO
+.	O
+
+The	O
+chemokine	O
+profile	O
+demonstrated	O
+significant	O
+elevation	O
+of	O
+neutrophil	B-PRGE
+chemokine	I-PRGE
+IL	B-FUNC
+-	I-FUNC
+8	I-FUNC
+,	I-PRGE
+monocyte	B-ANAT
+chemoattractant	I-PRGE
+protein	B-CHED
+-	I-PRGE
+1	I-PRGE
+(	O
+MCP	B-PRGE
+-	I-PRGE
+1	I-PRGE
+),	O
+and	O
+Th1	B-PRGE
+chemokine	I-PRGE
+IFN	I-PRGE
+-	I-PRGE
+gamma	I-PRGE
+-	O
+inducible	O
+protein	B-CHED
+-	O
+10	O
+(	O
+IP	O
+-	O
+10	O
+).	O
+
+Attempts	O
+at	O
+virus	B-SPEC
+isolation	O
+were	O
+unsuccessful	O
+;	O
+however	O
+,	O
+viral	O
+RNA	O
+was	O
+detected	O
+by	O
+reverse	B-PRGE
+transcriptase	I-PRGE
+-	O
+polymerase	O
+chain	O
+reaction	O
+in	O
+blood	B-ANAT
+of	O
+both	O
+species	B-SPEC
+during	O
+the	O
+first	O
+week	O
+after	O
+inoculation	O
+,	O
+and	O
+in	O
+chicken	B-SPEC
+organs	B-ANAT
+at	O
+2	O
+weeks	O
+after	O
+inoculation	O
+.	O
+
+Of	O
+1	O
+,	O
+460	O
+unexplained	O
+respiratory	O
+illnesses	O
+reported	O
+by	O
+state	O
+and	O
+local	O
+health	O
+departments	O
+to	O
+the	O
+Centers	O
+for	O
+Disease	O
+Control	O
+and	O
+Prevention	O
+from	O
+March	O
+17	O
+to	O
+July	O
+30	O
+,	O
+2003	O
+,	O
+a	O
+total	O
+of	O
+398	O
+(	O
+27	O
+%)	O
+met	B-CHED
+clinical	O
+and	O
+epidemiologic	O
+SARS	B-DISO
+case	O
+criteria	O
+.	O
+
+Successes	O
+and	O
+limitations	O
+of	O
+this	O
+emergency	B-DISO
+surveillance	O
+can	O
+guide	O
+preparations	O
+for	O
+future	O
+outbreaks	O
+of	O
+SARS	B-DISO
+or	O
+respiratory	B-DISO
+diseases	I-DISO
+of	O
+unknown	O
+etiology	O
+.	O
+
+TITLE	O
+:	O
+SARS	B-DISO
+outbreak	O
+,	O
+Taiwan	O
+,	O
+2003	O
+.	O
+
+This	O
+investigation	O
+documents	O
+that	O
+,	O
+under	O
+certain	O
+circumstances	O
+,	O
+SARS	B-DISO
+-	O
+CoV	O
+is	O
+not	O
+readily	O
+transmitted	B-DISO
+to	O
+close	O
+contacts	O
+,	O
+despite	O
+ample	O
+unprotected	O
+exposures	O
+.	O
+
+Possible	O
+transmission	O
+of	O
+SARS	B-DISO
+-	O
+CoV	O
+occurred	O
+in	O
+one	O
+household	O
+contact	O
+,	O
+but	O
+this	O
+person	O
+had	O
+also	O
+traveled	O
+to	O
+a	O
+SARS	B-DISO
+-	O
+affected	O
+area	O
+.	O
+
+TITLE	O
+:	O
+Lack	O
+of	O
+SARS	B-DISO
+transmission	O
+among	O
+healthcare	O
+workers	O
+,	O
+United	O
+States	O
+.	O
+
+We	O
+conducted	O
+an	O
+investigation	O
+of	O
+healthcare	O
+workers	O
+exposed	O
+to	O
+laboratory	O
+-	O
+confirmed	O
+SARS	B-DISO
+patients	O
+in	O
+the	O
+United	O
+States	O
+to	O
+evaluate	O
+infection	B-DISO
+-	O
+control	O
+practices	O
+and	O
+possible	O
+SARS	B-DISO
+-	I-DISO
+associated	I-DISO
+coronavirus	I-DISO
+(	O
+SARS	B-DISO
+-	O
+CoV	O
+)	O
+transmission	O
+.	O
+
+A	O
+sensitive	O
+dot	O
+blot	O
+enzyme	O
+-	O
+linked	O
+immunosorbent	O
+assay	O
+,	O
+complemented	O
+by	O
+a	O
+specific	O
+neutralization	O
+test	O
+,	O
+shows	O
+that	O
+only	O
+persons	O
+in	O
+whom	O
+probable	O
+SARS	B-DISO
+was	O
+diagnosed	O
+had	O
+specific	O
+antibodies	B-COMP
+and	O
+suggests	O
+that	O
+subclinical	O
+SARS	B-DISO
+is	O
+not	O
+an	O
+important	O
+feature	O
+of	O
+the	O
+disease	O
+.	O
+
+ABSTRACT	O
+:	O
+Superspreading	O
+events	O
+were	O
+pivotal	O
+in	O
+the	O
+global	O
+spread	O
+of	O
+severe	O
+acute	O
+respiratory	O
+syndrome	O
+(	O
+SARS	B-DISO
+).	O
+
+Superspreading	O
+appeared	O
+to	O
+be	O
+associated	O
+with	O
+older	O
+age	O
+(	O
+mean	O
+56	O
+vs	O
+.	O
+44	O
+years	O
+),	O
+case	O
+fatality	O
+(	O
+75	O
+%	O
+vs	O
+.	O
+16	O
+%,	O
+p	O
+=	O
+0	O
+.	O
+02	O
+,	O
+Fisher	B-SPEC
+exact	O
+test	O
+),	O
+number	O
+of	O
+close	O
+contacts	O
+(	O
+36	O
+vs	O
+.	O
+0	O
+.	O
+37	O
+)	O
+and	O
+attack	O
+rate	O
+among	O
+close	O
+contacts	O
+(	O
+43	O
+%	O
+vs	O
+.	O
+18	O
+.	O
+5	O
+%,	O
+p	O
+<	O
+0	O
+.	O
+025	O
+).	O
+
+SARS	B-DISO
+should	O
+be	O
+considered	O
+even	O
+if	O
+a	O
+contact	O
+history	O
+is	O
+unavailable	O
+,	O
+during	O
+an	O
+ongoing	O
+outbreak	O
+.	O
+
+ABSTRACT	O
+:	O
+The	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+(	O
+SARS	B-DISO
+)	O
+outbreak	O
+in	O
+Vietnam	O
+was	O
+amplified	O
+by	O
+nosocomial	O
+spread	O
+within	O
+hospital	O
+A	O
+,	O
+but	O
+no	O
+transmission	O
+was	O
+reported	O
+in	O
+hospital	O
+B	O
+,	O
+the	O
+second	O
+of	O
+two	O
+designated	O
+SARS	B-DISO
+hospitals	O
+.	O
+
+We	O
+conducted	O
+a	O
+case	O
+-	O
+control	O
+study	O
+of	O
+72	O
+hospital	O
+workers	O
+with	O
+SARS	B-DISO
+and	O
+144	O
+matched	O
+controls	O
+.	O
+
+The	O
+likelihood	O
+of	O
+SARS	B-DISO
+infection	B-DISO
+was	O
+strongly	O
+associated	O
+with	O
+the	O
+amount	O
+of	O
+personal	O
+protection	O
+equipment	O
+perceived	O
+to	O
+be	O
+inadequate	O
+,	O
+having	O
+<	O
+2	O
+hours	O
+of	O
+infection	B-DISO
+control	O
+training	O
+,	O
+and	O
+not	O
+understanding	O
+infection	B-DISO
+control	O
+procedures	O
+.	O
+
+TITLE	O
+:	O
+Possible	O
+SARS	B-DISO
+coronavirus	B-SPEC
+transmission	O
+during	O
+cardiopulmonary	B-ANAT
+resuscitation	O
+.	O
+
+We	O
+investigated	O
+a	O
+possible	O
+cluster	O
+of	O
+SARS	B-DISO
+-	O
+CoV	O
+infections	B-DISO
+in	O
+healthcare	O
+workers	O
+who	O
+used	O
+contact	O
+and	O
+droplet	O
+precautions	O
+during	O
+attempted	O
+cardiopulmonary	B-ANAT
+resuscitation	O
+of	O
+a	O
+SARS	B-DISO
+patient	O
+.	O
+
+However	O
+,	O
+before	O
+intubation	O
+,	O
+the	O
+patient	O
+was	O
+ventilated	O
+with	O
+a	O
+bag	O
+-	O
+valve	B-ANAT
+-	O
+mask	O
+that	O
+may	O
+have	O
+contributed	O
+to	O
+aerosolization	O
+of	O
+SARS	B-PRGE
+-	I-PRGE
+CoV	I-PRGE
+.	O
+On	O
+the	O
+basis	O
+of	O
+the	O
+results	O
+of	O
+this	O
+investigation	O
+and	O
+previous	O
+reports	O
+of	O
+SARS	O
+transmission	O
+during	O
+aerosol	O
+-	O
+generating	O
+procedures	O
+,	O
+a	O
+systematic	O
+approach	O
+to	O
+the	O
+problem	O
+is	O
+outlined	O
+,	O
+including	O
+the	O
+use	O
+of	O
+the	O
+following	O
+:	O
+1	O
+)	O
+administrative	O
+controls	O
+,	O
+2	O
+)	O
+environmental	O
+engineering	O
+controls	O
+,	O
+3	O
+)	O
+personal	O
+protective	O
+equipment	O
+,	O
+and	O
+4	O
+)	O
+quality	O
+control	O
+.	O
+
+TITLE	O
+:	O
+Real	O
+-	O
+time	O
+polymerase	O
+chain	O
+reaction	O
+for	O
+detecting	O
+SARS	B-DISO
+coronavirus	B-SPEC
+,	O
+Beijing	O
+,	O
+2003	O
+.	O
+
+With	O
+the	O
+neutralization	O
+test	O
+as	O
+a	O
+reference	O
+method	O
+,	O
+the	O
+sensitivity	O
+,	O
+specificity	O
+,	O
+positive	O
+predictive	O
+value	O
+,	O
+and	O
+negative	O
+predictive	O
+value	O
+were	O
+98	O
+.	O
+2	O
+%,	O
+98	O
+.	O
+7	O
+%,	O
+98	O
+.	O
+7	O
+%,	O
+and	O
+98	O
+.	O
+4	O
+%	O
+for	O
+ELISA	O
+;	O
+99	O
+.	O
+1	O
+%,	O
+87	O
+.	O
+8	O
+%,	O
+88	O
+.	O
+1	O
+%	O
+and	O
+99	O
+.	O
+1	O
+%	O
+for	O
+IFA	O
+;	O
+33	O
+.	O
+6	O
+%,	O
+98	O
+.	O
+2	O
+%,	O
+95	O
+.	O
+7	O
+%,	O
+and	O
+56	O
+.	O
+1	O
+%	O
+for	O
+ICT	B-DISO
+,	O
+respectively	O
+.	O
+
+TITLE	O
+:	O
+Interferon	B-PRGE
+-	I-PRGE
+beta	I-PRGE
+1a	I-PRGE
+and	O
+SARS	B-DISO
+coronavirus	B-SPEC
+replication	O
+.	O
+
+We	O
+show	O
+that	O
+infection	B-DISO
+with	O
+the	O
+SARS	B-DISO
+-	I-DISO
+associated	I-DISO
+coronavirus	I-DISO
+resulted	O
+in	O
+distinct	O
+ultrastructural	O
+features	O
+:	O
+double	O
+-	O
+membrane	B-COMP
+vesicles	B-COMP
+,	O
+nucleocapsid	B-COMP
+inclusions	O
+,	O
+and	O
+large	O
+granular	B-ANAT
+areas	O
+of	O
+cytoplasm	B-COMP
+.	O
+
+These	O
+three	O
+structures	O
+and	O
+the	O
+coronavirus	B-SPEC
+particles	O
+were	O
+shown	O
+to	O
+be	O
+positive	O
+for	O
+viral	O
+proteins	B-CHED
+and	O
+RNA	O
+by	O
+using	O
+ultrastructural	O
+immunogold	O
+and	O
+in	O
+situ	O
+hybridization	B-PROC
+assays	O
+.	O
+
+Clinical	O
+features	O
+alone	O
+cannot	O
+with	O
+certainty	O
+distinguish	O
+SARS	B-DISO
+from	O
+other	O
+respiratory	O
+illnesses	O
+rapidly	O
+enough	O
+to	O
+inform	O
+early	O
+management	O
+decisions	O
+.	O
+
+TITLE	O
+:	O
+Clinical	O
+description	O
+of	O
+a	O
+completed	O
+outbreak	O
+of	O
+SARS	B-DISO
+in	O
+Vietnam	O
+,	O
+February	O
+-	O
+May	O
+2003	O
+.	O
+
+TITLE	O
+:	O
+Index	O
+patient	O
+and	O
+SARS	B-DISO
+outbreak	O
+in	O
+Hong	O
+Kong	O
+.	O
+
+We	O
+report	O
+the	O
+case	O
+history	O
+of	O
+the	O
+index	O
+patient	O
+in	O
+a	O
+hospital	O
+outbreak	O
+of	O
+SARS	B-DISO
+in	O
+Hong	O
+Kong	O
+.	O
+
+Cerebrospinal	B-ANAT
+fluid	I-ANAT
+tested	O
+positive	O
+for	O
+SARS	B-DISO
+coronavirus	B-SPEC
+(	O
+SARS	B-DISO
+-	O
+CoV	O
+)	O
+by	O
+reverse	B-PRGE
+transcriptase	I-PRGE
+-	O
+polymerase	O
+chain	O
+reaction	O
+.	O
+
+SARS	B-DISO
+developed	O
+in	O
+a	O
+cluster	O
+of	O
+healthcare	O
+workers	O
+who	O
+had	O
+contact	O
+with	O
+this	O
+patient	O
+.	O
+
+All	O
+positive	O
+samples	O
+were	O
+confirmed	O
+by	O
+two	O
+separate	O
+western	O
+-	O
+blot	O
+assays	O
+(	O
+with	O
+recombinant	B-PRGE
+nucleocapsid	I-PRGE
+protein	B-CHED
+and	O
+recombinant	B-PRGE
+spike	I-PRGE
+polypeptide	I-PRGE
+).	O
+
+ELISA	O
+was	O
+used	O
+to	O
+detect	O
+antibody	B-COMP
+to	O
+SARS	B-PRGE
+CoV	I-PRGE
+.	O
+Reverse	O
+-	O
+transcriptase	B-PROC
+polymerase	O
+chain	O
+reaction	O
+was	O
+used	O
+to	O
+detect	O
+SARS	B-PRGE
+CoV	I-PRGE
+RNA	I-PRGE
+.	O
+
+T	B-ANAT
+cells	I-ANAT
+in	O
+peripheral	B-ANAT
+blood	I-ANAT
+of	O
+patients	O
+were	O
+quantified	O
+by	O
+flow	O
+cytometry	O
+.	O
+
+Of	O
+36	O
+patients	O
+with	O
+probable	O
+SARS	B-DISO
+CoV	O
+infection	B-DISO
+,	O
+30	O
+(	O
+83	O
+.	O
+3	O
+%)	O
+were	O
+positive	O
+for	O
+IgG	B-COMP
+antibody	I-COMP
+to	O
+SARS	B-PRGE
+CoV	I-PRGE
+;	O
+in	O
+contrast	O
+,	O
+only	O
+3	O
+of	O
+48	O
+patients	O
+with	O
+suspected	O
+SARS	B-DISO
+CoV	O
+infection	B-DISO
+,	O
+0	O
+of	O
+112	O
+patients	O
+with	O
+fever	B-PROC
+but	O
+without	O
+SARS	B-DISO
+,	O
+and	O
+0	O
+of	O
+96	O
+healthy	O
+control	O
+individuals	O
+were	O
+positive	O
+for	O
+it	O
+.	O
+
+RESULTS	O
+:	O
+Of	O
+36	O
+patients	O
+with	O
+probable	O
+SARS	B-DISO
+CoV	O
+infection	B-DISO
+,	O
+30	O
+(	O
+83	O
+.	O
+3	O
+%)	O
+were	O
+positive	O
+for	O
+IgG	B-COMP
+antibody	I-COMP
+to	O
+SARS	B-PRGE
+CoV	I-PRGE
+;	O
+in	O
+contrast	O
+,	O
+only	O
+3	O
+of	O
+48	O
+patients	O
+with	O
+suspected	O
+SARS	B-DISO
+CoV	O
+infection	B-DISO
+,	O
+0	O
+of	O
+112	O
+patients	O
+with	O
+fever	B-PROC
+but	O
+without	O
+SARS	B-DISO
+,	O
+and	O
+0	O
+of	O
+96	O
+healthy	O
+control	O
+individuals	O
+were	O
+positive	O
+for	O
+it	O
+.	O
+
+In	O
+contrast	O
+,	O
+IFN	B-PRGE
+-	I-PRGE
+alpha	I-PRGE
+showed	O
+an	O
+in	O
+vitro	O
+inhibitory	O
+effect	O
+starting	O
+at	O
+concentrations	O
+of	O
+1000	O
+IU	O
+/	O
+mL	O
+.	O
+In	O
+conclusion	O
+,	O
+ribavirin	B-CHED
+alone	O
+is	O
+unlikely	O
+to	O
+be	O
+beneficial	O
+in	O
+the	O
+prophylaxis	O
+or	O
+treatment	O
+of	O
+SARS	B-DISO
+CoV	O
+infections	B-DISO
+.	O
+
+ABSTRACT	O
+:	O
+The	O
+human	B-SPEC
+genome	O
+and	O
+other	O
+genome	O
+sequencing	O
+projects	O
+have	O
+generated	O
+huge	O
+amounts	O
+of	O
+protein	O
+sequence	O
+information	O
+.	O
+
+Recently	O
+,	O
+a	O
+structural	O
+genomics	O
+project	O
+that	O
+aims	O
+to	O
+determine	O
+at	O
+least	O
+one	O
+representative	O
+three	O
+-	O
+dimensional	O
+structure	O
+from	O
+every	O
+protein	B-CHED
+family	B-SPEC
+experimentally	O
+has	O
+been	O
+started	O
+.	O
+
+TITLE	O
+:	O
+Antibody	B-FUNC
+targeting	B-PROC
+of	O
+the	O
+CC	O
+chemokine	O
+ligand	B-PROC
+5	O
+results	O
+in	O
+diminished	O
+leukocyte	B-ANAT
+infiltration	B-DISO
+into	O
+the	O
+central	O
+nervous	O
+system	O
+and	O
+reduced	O
+neurologic	O
+disease	O
+in	O
+a	O
+viral	O
+model	O
+of	O
+multiple	B-DISO
+sclerosis	I-DISO
+.	O
+
+ABSTRACT	O
+:	O
+Three	O
+human	B-SPEC
+coronaviruses	O
+are	O
+known	O
+to	O
+exist	O
+:	O
+human	O
+coronavirus	O
+229E	O
+(	O
+HCoV	B-SPEC
+-	I-SPEC
+229E	I-SPEC
+),	O
+HCoV	B-SPEC
+-	I-SPEC
+OC43	I-SPEC
+and	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+(	O
+SARS	B-DISO
+)-	O
+associated	O
+coronavirus	B-SPEC
+(	O
+SARS	B-DISO
+-	O
+CoV	O
+).	O
+
+Here	O
+we	O
+report	O
+the	O
+identification	O
+of	O
+a	O
+fourth	O
+human	B-SPEC
+coronavirus	I-SPEC
+,	O
+HCoV	B-SPEC
+-	I-SPEC
+NL63	I-SPEC
+,	O
+using	O
+a	O
+new	O
+method	O
+of	O
+virus	B-SPEC
+discovery	O
+.	O
+
+The	O
+viral	B-COMP
+genome	I-COMP
+contains	O
+distinctive	O
+features	O
+,	O
+including	O
+a	O
+unique	O
+N	O
+-	O
+terminal	O
+fragment	O
+within	O
+the	O
+spike	O
+protein	B-CHED
+.	O
+
+Findings	O
+suggest	O
+that	O
+,	O
+even	O
+at	O
+a	O
+relatively	O
+low	O
+level	O
+of	O
+spread	O
+among	O
+the	O
+population	O
+,	O
+the	O
+SARS	B-DISO
+outbreak	O
+had	O
+a	O
+significant	O
+psychological	B-DISO
+and	O
+economic	O
+impact	O
+.	O
+
+ABSTRACT	O
+:	O
+We	O
+observed	O
+that	O
+0	O
+of	O
+19	O
+patients	O
+with	O
+human	B-SPEC
+immunodeficiency	I-SPEC
+virus	I-SPEC
+type	I-SPEC
+1	I-SPEC
+(	O
+HIV	B-SPEC
+-	I-SPEC
+1	I-SPEC
+)	O
+infection	B-DISO
+,	O
+including	O
+those	O
+with	O
+acquired	B-DISO
+immunodeficiency	I-DISO
+syndrome	I-DISO
+(	O
+AIDS	O
+),	O
+who	O
+were	O
+hospitalized	O
+together	O
+and	O
+who	O
+had	O
+close	O
+contact	O
+with	O
+95	O
+patients	O
+with	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+(	O
+SARS	B-DISO
+)	O
+on	O
+the	O
+same	O
+hospital	O
+floor	O
+contracted	O
+SARS	B-DISO
+,	O
+whereas	O
+6	O
+of	O
+28	O
+medical	O
+workers	O
+who	O
+served	O
+on	O
+this	O
+floor	O
+contracted	O
+SARS	B-DISO
+while	O
+caring	O
+for	O
+these	O
+patients	O
+.	O
+
+TITLE	O
+:	O
+SARS	B-DISO
+--	O
+beginning	O
+to	O
+understand	O
+a	O
+new	O
+virus	B-SPEC
+.	O
+
+TITLE	O
+:	O
+Studying	O
+the	O
+global	O
+distribution	O
+of	O
+infectious	B-DISO
+diseases	I-DISO
+using	O
+GIS	O
+and	O
+RS	O
+.	O
+
+The	O
+left	B-ANAT
+lungs	I-ANAT
+of	O
+male	O
+Wistar	B-SPEC
+rats	I-SPEC
+were	O
+rendered	O
+ischemic	O
+for	O
+90	O
+min	O
+and	O
+then	O
+reperfused	O
+for	O
+2	O
+h	O
+.	O
+Treated	O
+animals	O
+received	O
+pioglitazone	B-CHED
+(	O
+10	O
+mg	O
+/	O
+kg	O
+)	O
+2	O
+h	O
+before	O
+induction	O
+of	O
+ischemia	B-DISO
+.	O
+
+The	O
+results	O
+lead	O
+to	O
+several	O
+findings	O
+;	O
+1	O
+)	O
+although	O
+two	O
+dissected	O
+parts	O
+folded	O
+into	O
+the	O
+native	O
+-	O
+like	O
+structures	O
+,	O
+the	O
+chymotrypsin	B-PRGE
+fold	O
+only	O
+had	O
+weak	O
+activity	O
+as	O
+compared	O
+with	O
+the	O
+entire	O
+enzyme	O
+,	O
+and	O
+2	O
+)	O
+although	O
+the	O
+chymotrypsin	B-PRGE
+fold	O
+remained	O
+a	O
+monomer	O
+within	O
+a	O
+wide	O
+range	O
+of	O
+protein	B-CHED
+concentrations	O
+,	O
+the	O
+extra	O
+domain	O
+existed	O
+as	O
+a	O
+stable	O
+dimer	O
+even	O
+at	O
+a	O
+very	O
+low	O
+concentration	O
+.	O
+
+This	O
+observation	O
+strongly	O
+indicates	O
+that	O
+the	O
+extra	O
+domain	O
+contributes	O
+to	O
+the	O
+dimerization	O
+of	O
+the	O
+SARS	B-PRGE
+3CL	I-PRGE
+protease	I-PRGE
+,	O
+thus	O
+,	O
+switching	O
+the	O
+enzyme	O
+from	O
+the	O
+inactive	O
+form	O
+(	O
+monomer	O
+)	O
+to	O
+the	O
+active	O
+form	O
+(	O
+dimer	O
+).	O
+
+The	O
+frequency	O
+of	O
+pulmonary	B-DISO
+edema	I-DISO
+,	O
+placental	B-DISO
+abruption	I-DISO
+,	O
+postpartum	B-DISO
+hemorrhage	I-DISO
+,	O
+and	O
+aspiration	B-DISO
+pneumonia	I-DISO
+was	O
+not	O
+significantly	O
+different	O
+between	O
+the	O
+two	O
+groups	O
+.	O
+
+All	O
+six	O
+maternal	B-PROC
+deaths	I-PROC
+during	O
+the	O
+period	O
+of	O
+the	O
+study	O
+occurred	O
+in	O
+eclamptic	O
+cases	O
+(	O
+mortality	O
+rate	O
+18	O
+%),	O
+four	O
+relating	O
+to	O
+patients	O
+who	O
+had	O
+not	O
+received	O
+prenatal	O
+care	O
+.	O
+
+TITLE	O
+:	O
+The	O
+role	O
+of	O
+secretory	B-PROC
+phospholipase	B-PRGE
+A2	I-PRGE
+in	O
+acute	B-DISO
+chest	I-DISO
+syndrome	I-DISO
+.	O
+
+TITLE	O
+:	O
+Analysis	O
+of	O
+synonymous	O
+codon	O
+usage	O
+in	O
+SARS	B-DISO
+Coronavirus	B-SPEC
+and	O
+other	O
+viruses	B-SPEC
+in	O
+the	O
+Nidovirales	B-SPEC
+.	O
+
+The	O
+source	O
+of	O
+SARS	B-DISO
+infection	B-DISO
+was	O
+identified	O
+as	O
+the	O
+husband	O
+of	O
+a	O
+tumor	B-DISO
+patient	O
+who	O
+received	O
+chemotherapy	O
+in	O
+the	O
+Department	O
+of	O
+Oncology	O
+,	O
+during	O
+which	O
+they	O
+maintained	O
+intimate	O
+contact	O
+for	O
+at	O
+least	O
+two	O
+weeks	O
+when	O
+the	O
+husband	O
+had	O
+typical	O
+symptoms	O
+of	O
+SARS	B-DISO
+.	O
+
+CONCLUSIONS	O
+:	O
+SARS	B-DISO
+patients	O
+may	O
+have	O
+no	O
+or	O
+very	O
+limited	O
+infectivity	O
+during	O
+the	O
+latent	O
+period	O
+.	O
+
+All	O
+11	O
+patients	O
+met	B-CHED
+the	O
+WHO	O
+diagnostic	O
+criteria	O
+for	O
+probable	O
+SARS	B-DISO
+.	O
+
+Special	O
+attention	O
+must	O
+be	O
+paid	O
+to	O
+patients	O
+with	O
+cancer	O
+who	O
+have	O
+symptoms	O
+similar	O
+to	O
+those	O
+seen	O
+in	O
+SARS	B-DISO
+.	O
+
+Increase	O
+personnel	O
+in	O
+the	O
+respiratory	B-DISO
+diseases	I-DISO
+department	O
+at	O
+the	O
+N	O
+'	O
+Djaména	O
+General	O
+Hospital	O
+.	O
+
+TITLE	O
+:	O
+Severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+:	O
+scientific	O
+and	O
+anecdotal	O
+evidence	O
+for	O
+drug	O
+treatment	O
+.	O
+
+A	O
+SARS	B-DISO
+coronavirus	B-SPEC
+(	O
+SARS	B-DISO
+-	O
+CoV	O
+)	O
+detection	O
+kit	B-FUNC
+developed	O
+by	O
+C	O
+.	O
+Drosten	O
+(	O
+Bernhard	O
+Nocht	O
+Institute	O
+,	O
+BNI	O
+)	O
+was	O
+used	O
+to	O
+amplify	O
+SARS	B-DISO
+-	O
+CoV	O
+sequences	O
+from	O
+blood	B-ANAT
+donor	B-CHED
+samples	O
+.	O
+
+We	O
+tested	O
+the	O
+inhibitory	O
+activity	O
+against	O
+infection	B-DISO
+of	O
+two	O
+sets	O
+of	O
+peptides	B-CHED
+corresponding	O
+to	O
+sequences	O
+of	O
+SARS	B-DISO
+-	O
+CoV	O
+spike	O
+protein	B-CHED
+HR1	O
+and	O
+HR2	O
+regions	O
+and	O
+investigated	O
+the	O
+interactions	O
+between	O
+the	O
+HR1	O
+and	O
+HR2	O
+peptides	B-CHED
+by	O
+surface	O
+plasmon	O
+resonance	O
+,	O
+sedimentation	O
+equilibration	O
+analysis	O
+,	O
+circular	O
+dichroism	O
+,	O
+native	O
+polyacrylamide	B-CHED
+-	O
+gel	O
+electrophoresis	O
+,	O
+size	O
+exclusion	O
+high	O
+-	O
+performance	O
+liquid	O
+chromatography	O
+,	O
+and	O
+computer	O
+-	O
+aided	O
+homology	O
+modelling	O
+and	O
+molecule	O
+docking	B-PROC
+analysis	O
+.	O
+
+77	O
+:	O
+4528	O
+-	O
+4538	O
+,	O
+2003	O
+)	O
+for	O
+the	O
+development	B-PROC
+of	O
+a	O
+modified	O
+live	O
+FIP	B-DISO
+vaccine	O
+.	O
+
+The	O
+passive	O
+transfer	O
+of	O
+anti	B-PRGE
+-	I-PRGE
+human	I-PRGE
+leukocyte	B-ANAT
+antigen	B-CHED
+(	O
+HLA	B-PRGE
+)	O
+or	O
+antineutrophil	O
+antibodies	B-COMP
+in	O
+the	O
+donated	O
+blood	B-ANAT
+products	O
+are	O
+responsible	O
+for	O
+the	O
+pathophysiological	O
+process	O
+in	O
+TRALI	B-DISO
+.	O
+
+The	O
+case	O
+of	O
+70	O
+-	O
+year	O
+-	O
+old	O
+woman	O
+with	O
+the	O
+fracture	O
+of	O
+the	O
+right	O
+femoral	O
+bone	B-ANAT
+,	O
+who	O
+developed	O
+TRALI	B-DISO
+after	O
+transfusion	O
+of	O
+packed	O
+red	O
+cells	B-COMP
+is	O
+presented	O
+in	O
+the	O
+paper	O
+.	O
+
+TITLE	O
+:	O
+Serum	B-ANAT
+LD1	I-PRGE
+isoenzyme	I-PRGE
+and	O
+blood	B-ANAT
+lymphocyte	B-ANAT
+subsets	O
+as	O
+prognostic	O
+indicators	O
+for	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+.	O
+
+Blood	B-ANAT
+CD3	B-PRGE
++,	I-PRGE
+CD4	B-PRGE
++,	I-PRGE
+CD8	B-PRGE
++	I-PRGE
+and	O
+natural	B-ANAT
+killer	I-ANAT
+cell	I-ANAT
+counts	O
+were	O
+found	O
+to	O
+be	O
+good	O
+prognostic	O
+indicators	O
+for	O
+predicting	O
+admission	O
+to	O
+ICU	O
+in	O
+patients	O
+with	O
+SARS	B-DISO
+compared	O
+with	O
+age	O
+,	O
+leucocyte	B-ANAT
+count	O
+and	O
+LD	O
+isoenzymes	O
+.	O
+
+Patients	O
+with	O
+increased	O
+serum	B-PRGE
+LD1	I-PRGE
+should	O
+be	O
+closely	O
+monitored	O
+to	O
+ensure	O
+prompt	O
+management	O
+,	O
+and	O
+preparation	O
+for	O
+admission	O
+to	O
+ICU	O
+could	O
+be	O
+planned	O
+ahead	O
+for	O
+patients	O
+with	O
+suppressed	O
+lymphocyte	B-ANAT
+subsets	O
+.	O
+
+Two	O
+other	O
+HCoV	O
+(	O
+HCoV	B-SPEC
+-	I-SPEC
+229E	I-SPEC
+and	O
+HCoV	B-SPEC
+-	I-SPEC
+OC43	I-SPEC
+)	O
+have	O
+been	O
+known	O
+for	O
+30	O
+years	O
+.	O
+
+In	O
+hospitalized	O
+children	O
+(	O
+children	O
+and	O
+newborns	O
+)	O
+and	O
+staff	O
+members	O
+we	O
+found	O
+a	O
+high	O
+incidence	O
+of	O
+HcoV	B-SPEC
+-	I-SPEC
+229E	I-SPEC
+infection	B-DISO
+.	O
+
+This	O
+reverse	B-PROC
+transcription	I-PROC
+-	O
+PCR	O
+-	O
+hybridization	O
+assay	O
+gave	O
+a	O
+high	O
+specificity	O
+and	O
+a	O
+sensitivity	O
+of	O
+0	O
+.	O
+5	O
+50	O
+%	O
+Tissue	B-ANAT
+Culture	O
+Infective	O
+Dose	O
+per	O
+ml	O
+.	O
+
+ABSTRACT	O
+:	O
+Using	O
+interrupted	O
+time	O
+-	O
+series	O
+analysis	O
+and	O
+National	O
+Health	O
+Insurance	O
+data	O
+between	O
+January	O
+2000	O
+and	O
+August	O
+2003	O
+,	O
+this	O
+study	O
+assessed	O
+the	O
+impacts	O
+of	O
+the	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+(	O
+SARS	B-DISO
+)	O
+epidemic	O
+on	O
+medical	O
+service	O
+utilization	O
+in	O
+Taiwan	O
+.	O
+
+At	O
+the	O
+peak	O
+of	O
+the	O
+SARS	B-DISO
+epidemic	O
+,	O
+significant	O
+reductions	O
+in	O
+ambulatory	O
+care	O
+(	O
+23	O
+.	O
+9	O
+%),	O
+inpatient	O
+care	O
+(	O
+35	O
+.	O
+2	O
+%),	O
+and	O
+dental	O
+care	O
+(	O
+16	O
+.	O
+7	O
+%)	O
+were	O
+observed	O
+.	O
+
+After	O
+purification	O
+,	O
+all	O
+of	O
+the	O
+protein	B-CHED
+fragments	O
+were	O
+printed	O
+on	O
+glass	O
+slides	O
+to	O
+fabricate	O
+a	O
+protein	B-CHED
+microarray	O
+and	O
+then	O
+probed	O
+with	O
+the	O
+sera	B-COMP
+from	O
+SARS	B-DISO
+patients	O
+to	O
+determine	O
+the	O
+reactivity	O
+of	O
+these	O
+protein	B-CHED
+fragments	O
+.	O
+
+EP3	B-PRGE
+and	O
+EP4	B-PRGE
+also	O
+formed	O
+conformational	O
+epitopes	O
+,	O
+and	O
+antibodies	B-COMP
+against	O
+these	O
+epitopes	O
+existed	O
+in	O
+all	O
+52	O
+of	O
+the	O
+sera	B-COMP
+tested	O
+.	O
+
+The	O
+N	B-PRGE
+protein	I-PRGE
+is	O
+a	O
+potential	O
+diagnostic	O
+antigen	B-CHED
+and	O
+vaccine	O
+candidate	O
+for	O
+SARS	B-PRGE
+-	I-PRGE
+CoV	I-PRGE
+.	O
+
+TITLE	O
+:	O
+SARS	B-DISO
+preparedness	O
+.	O
+
+TITLE	O
+:	O
+Psychiatric	O
+complications	O
+in	O
+patients	O
+with	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+(	O
+SARS	B-DISO
+)	O
+during	O
+the	O
+acute	O
+treatment	O
+phase	O
+:	O
+a	O
+series	O
+of	O
+10	O
+cases	O
+.	O
+
+We	O
+found	O
+that	O
+both	O
+the	O
+direct	O
+and	O
+indirect	O
+effects	O
+of	O
+SARS	B-DISO
+such	O
+as	O
+symptom	B-DISO
+severity	O
+,	O
+total	O
+isolation	O
+during	O
+treatment	O
+and	O
+administration	O
+of	O
+steroid	B-CHED
+were	O
+probable	O
+causes	O
+of	O
+psychiatric	O
+complications	O
+.	O
+
+ABSTRACT	O
+:	O
+Optimal	O
+usability	O
+is	O
+crucial	O
+in	O
+providing	O
+protection	O
+for	O
+health	O
+care	O
+workers	O
+who	O
+are	O
+exposed	O
+to	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+day	O
+and	O
+night	O
+while	O
+taking	O
+care	O
+of	O
+patients	O
+with	O
+the	O
+virus	B-SPEC
+.	O
+
+PPC	O
+available	O
+in	O
+Hong	O
+Kong	O
+were	O
+sorted	B-PROC
+by	O
+their	O
+physical	O
+properties	O
+in	O
+the	O
+first	O
+stage	O
+.	O
+
+TITLE	O
+:	O
+Bioterrorism	O
+and	O
+emerging	B-DISO
+infectious	I-DISO
+disease	I-DISO
+-	O
+antimicrobials	B-CHED
+,	O
+therapeutics	O
+and	O
+immune	O
+-	O
+modulators	O
+.	O
+
+SARS	O
+coronavirus	B-SPEC
+.	O
+
+Severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+(	O
+SARS	B-DISO
+)	O
+and	O
+progress	O
+toward	O
+understanding	O
+the	O
+epidemic	O
+was	O
+addressed	O
+,	O
+and	O
+other	O
+sessions	O
+were	O
+presented	O
+concerning	O
+immune	O
+therapy	O
+and	O
+immunopotentiation	B-PROC
+of	O
+disease	O
+,	O
+siRNA	O
+and	O
+gene	B-PROC
+silencing	I-PROC
+,	O
+host	B-COMP
+responses	O
+to	O
+pathogen	O
+infections	B-DISO
+,	O
+as	O
+well	O
+as	O
+the	O
+use	O
+of	O
+genetic	O
+engineering	O
+to	O
+circumvent	O
+and	O
+direct	O
+the	O
+immune	B-PROC
+response	I-PROC
+.	O
+
+Acute	O
+lung	B-ANAT
+injury	O
+was	O
+associated	O
+with	O
+higher	O
+PRL	B-PRGE
+serum	B-COMP
+level	O
+and	O
+was	O
+independent	O
+from	O
+the	O
+LH	O
+and	O
+T	O
+serum	B-COMP
+level	O
+.	O
+
+They	O
+may	O
+originate	O
+from	O
+the	O
+endogenous	O
+flora	O
+of	O
+the	O
+patient	O
+as	O
+a	O
+result	O
+of	O
+translocation	B-DISO
+of	O
+microorganisms	O
+from	O
+a	O
+physiologically	O
+colonized	O
+area	O
+to	O
+an	O
+area	O
+,	O
+where	O
+they	O
+act	O
+as	O
+pathogens	O
+.	O
+
+ABSTRACT	O
+:	O
+Over	O
+-	O
+dose	O
+glucocorticoid	B-CHED
+was	O
+frequently	O
+used	O
+in	O
+patients	O
+with	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+(	O
+SARS	B-DISO
+),	O
+the	O
+aim	O
+of	O
+the	O
+present	O
+study	O
+is	O
+to	O
+investigate	O
+the	O
+frequency	O
+and	O
+risk	O
+factors	O
+of	O
+corticosteroid	B-CHED
+-	O
+induced	O
+diabetes	B-DISO
+in	O
+this	O
+situation	O
+.	O
+
+RESULTS	O
+:	O
+Ninety	O
+five	O
+patients	O
+(	O
+71	O
+.	O
+9	O
+%)	O
+were	O
+prescribed	O
+with	O
+glucocorticoid	B-CHED
+among	O
+the	O
+132	O
+patients	O
+.	O
+
+Fundus	B-ANAT
+examinations	O
+were	O
+unremarkable	O
+in	O
+all	O
+patients	O
+.	O
+
+Development	B-PROC
+and	O
+implementation	O
+took	O
+place	O
+in	O
+three	O
+distinct	O
+but	O
+overlapping	O
+phases	O
+:	O
+needs	O
+assessment	O
+,	O
+design	O
+and	O
+implementation	O
+,	O
+and	O
+expansion	O
+and	O
+ongoing	O
+operations	O
+.	O
+
+Overall	O
+rate	O
+of	O
+infection	B-DISO
+with	O
+SARS	B-DISO
+-	O
+CoV	O
+in	O
+635	O
+traders	O
+was	O
+16	O
+.	O
+69	O
+%,	O
+varying	O
+in	O
+three	O
+different	O
+markets	O
+.	O
+
+Infection	B-DISO
+with	O
+SARS	B-DISO
+-	O
+CoV	O
+in	O
+traders	O
+of	O
+animal	B-SPEC
+markets	O
+possibly	O
+related	O
+to	O
+their	O
+direct	O
+exposure	O
+to	O
+wild	O
+animals	B-SPEC
+,	O
+particularly	O
+to	O
+civet	B-SPEC
+cats	I-SPEC
+.	O
+
+TITLE	O
+:	O
+[	O
+Re	O
+-	O
+survey	O
+on	O
+epidemiological	O
+history	O
+of	O
+1	O
+091	O
+probable	O
+cases	O
+with	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+in	O
+Beijing	O
+].	O
+
+Comprehensive	O
+judgement	O
+based	O
+on	O
+epidemiological	O
+history	O
+showed	O
+that	O
+probale	O
+history	O
+of	O
+contact	O
+with	O
+SARS	B-DISO
+patients	O
+could	O
+be	O
+found	O
+in	O
+72	O
+.	O
+9	O
+%	O
+of	O
+1	O
+,	O
+091	O
+probale	O
+cases	O
+of	O
+SARS	B-DISO
+in	O
+the	O
+second	O
+survey	O
+.	O
+
+TITLE	O
+:	O
+[	O
+An	O
+investigation	O
+on	O
+nosocomial	B-DISO
+infection	I-DISO
+with	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+in	O
+health	O
+-	O
+care	O
+workers	O
+at	O
+13	O
+key	O
+hospitals	O
+in	O
+Guangdong	O
+Province	O
+].	O
+
+Nosocomial	B-DISO
+infection	I-DISO
+of	O
+SARS	B-DISO
+in	O
+health	O
+-	O
+care	O
+workers	O
+was	O
+affected	O
+by	O
+clinical	O
+condition	B-DISO
+of	O
+SARS	B-DISO
+patients	O
+,	O
+characteristics	O
+and	O
+environment	O
+of	O
+hospitals	O
+and	O
+their	O
+personal	O
+protective	O
+measures	O
+adopted	O
+.	O
+
+CONCLUSIONS	O
+:	O
+Nosocomial	B-DISO
+infection	I-DISO
+of	O
+SARS	B-DISO
+in	O
+health	O
+-	O
+care	O
+workers	O
+was	O
+affected	O
+by	O
+clinical	O
+condition	B-DISO
+of	O
+SARS	B-DISO
+patients	O
+,	O
+characteristics	O
+and	O
+environment	O
+of	O
+hospitals	O
+and	O
+their	O
+personal	O
+protective	O
+measures	O
+adopted	O
+.	O
+
+CONCLUSIONS	O
+:	O
+Positive	O
+rate	O
+and	O
+load	O
+of	O
+SARS	B-PRGE
+-	I-PRGE
+CoV	I-PRGE
+RNA	I-PRGE
+in	O
+stool	B-ANAT
+of	O
+SARS	B-DISO
+patients	O
+was	O
+the	O
+highest	O
+at	O
+their	O
+acute	O
+phase	O
+,	O
+and	O
+decreased	O
+with	O
+the	O
+extension	O
+of	O
+its	O
+course	O
+.	O
+
+Serum	B-COMP
+level	O
+of	O
+PA	O
+was	O
+significantly	O
+lower	O
+and	O
+levels	O
+of	O
+C4	O
+and	O
+CRP	B-PRGE
+significantly	O
+in	O
+patients	O
+with	O
+SARS	B-DISO
+higher	O
+than	O
+those	O
+in	O
+patients	O
+with	O
+other	O
+pneumonia	B-DISO
+and	O
+normal	O
+persons	O
+(	O
+P	O
+<	O
+0	O
+.	O
+01	O
+).	O
+
+Determination	O
+of	O
+serum	B-COMP
+level	O
+of	O
+C4	O
+,	O
+CRP	B-PRGE
+and	O
+PA	O
+in	O
+suspected	O
+patients	O
+is	O
+beneficial	O
+to	O
+early	O
+differential	O
+diagnosis	O
+for	O
+SARS	B-DISO
+.	O
+
+RESULTS	O
+:	O
+Serum	B-COMP
+concentrations	O
+of	O
+C3	O
+,	O
+C4	O
+,	O
+CRP	B-PRGE
+and	O
+PA	O
+were	O
+(	O
+1	O
+.	O
+18	O
++/-	O
+
+A	O
+case	O
+-	O
+control	O
+study	O
+from	O
+ten	O
+hospitals	O
+in	O
+Guangdong	O
+,	O
+with	O
+180	O
+non	O
+-	O
+infected	O
+and	O
+77	O
+infected	O
+staff	O
+members	O
+that	O
+accessed	O
+the	O
+isolation	O
+unit	O
+every	O
+day	O
+,	O
+and	O
+participated	O
+in	O
+direct	O
+first	O
+aid	O
+for	O
+severe	O
+SARS	B-DISO
+patients	O
+.	O
+
+Statistical	O
+analysis	O
+was	O
+done	O
+with	O
+either	O
+chi	B-CHED
+(	O
+2	O
+)	O
+or	O
+Fisher	B-SPEC
+'	O
+s	O
+exact	O
+test	O
+for	O
+univariate	O
+analysis	O
+,	O
+whereas	O
+we	O
+used	O
+forward	O
+stepwise	O
+selection	O
+(	O
+Waldesian	O
+)	O
+for	O
+logistic	O
+regression	O
+.	O
+
+It	O
+seemed	O
+that	O
+the	O
+more	O
+the	O
+protective	O
+measures	O
+were	O
+used	O
+,	O
+the	O
+higher	O
+the	O
+protective	O
+effect	O
+was	O
+(	O
+P	O
+<	O
+0	O
+.	O
+001	O
+),	O
+and	O
+could	O
+reach	B-PROC
+100	O
+%	O
+if	O
+mask	O
+,	O
+gown	O
+,	O
+gloves	O
+,	O
+goggles	O
+,	O
+footwear	O
+,	O
+""""	O
+hand	O
+-	O
+washing	O
+and	O
+disinfecting	O
+""""	O
+were	O
+all	O
+used	O
+at	O
+the	O
+same	O
+time	O
+.	O
+
+Nosocomial	B-DISO
+infection	I-DISO
+of	O
+SARS	B-DISO
+can	O
+be	O
+prevented	O
+effectively	O
+by	O
+precautions	O
+against	O
+droplets	O
+and	O
+personal	O
+contact	O
+.	O
+
+ABSTRACT	O
+:	O
+To	O
+study	O
+the	O
+emotional	O
+and	O
+depressive	O
+differences	O
+between	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+(	O
+SARS	B-DISO
+)	O
+patients	O
+whose	O
+occupations	O
+were	O
+doctor	O
+/	O
+nurse	O
+and	O
+others	O
+.	O
+
+TITLE	O
+:	O
+Preoperative	O
+preparation	O
+of	O
+patients	O
+with	O
+advanced	O
+liver	B-DISO
+disease	I-DISO
+.	O
+
+The	O
+most	O
+common	O
+complications	O
+are	O
+secondary	O
+to	O
+acute	B-DISO
+liver	I-DISO
+failure	I-DISO
+and	O
+include	O
+severe	O
+coagulopathy	B-DISO
+,	O
+encephalopathy	B-DISO
+,	O
+adult	O
+respiratory	B-DISO
+distress	I-DISO
+syndrome	I-DISO
+,	I-DISO
+acute	I-DISO
+renal	B-DISO
+failure	I-DISO
+,	O
+and	O
+sepsis	B-DISO
+.	O
+
+Portal	B-DISO
+hypertension	I-DISO
+is	O
+a	O
+prominent	O
+feature	O
+of	O
+advanced	O
+liver	B-DISO
+disease	I-DISO
+,	O
+and	O
+it	O
+predisposes	O
+the	O
+patient	O
+to	O
+variceal	B-DISO
+hemorrhage	I-DISO
+,	O
+hepatorenal	O
+syndrome	B-DISO
+,	I-DISO
+hepatopulmonary	I-DISO
+syndrome	B-DISO
+,	O
+and	O
+uncontrolled	O
+ascites	O
+.	O
+
+If	O
+well	O
+-	O
+defined	O
+contraindications	O
+are	O
+not	O
+present	O
+,	O
+patients	O
+with	O
+advanced	O
+liver	B-DISO
+disease	I-DISO
+should	O
+be	O
+evaluated	O
+for	O
+orthotopic	O
+liver	B-ANAT
+transplantation	O
+from	O
+a	O
+cadaver	B-ANAT
+donor	B-CHED
+or	O
+possible	O
+living	O
+-	O
+related	O
+liver	B-ANAT
+transplantation	O
+.	O
+
+In	O
+the	O
+setting	O
+of	O
+pneumonia	B-DISO
+with	O
+a	O
+finding	O
+of	O
+low	O
+PCT	B-DISO
+,	O
+testing	O
+for	O
+SARS	B-DISO
+should	O
+be	O
+considered	O
+,	O
+especially	O
+if	O
+there	O
+is	O
+a	O
+positive	O
+travel	O
+or	O
+contact	O
+history	O
+.	O
+
+TITLE	O
+:	O
+Tissue	B-ANAT
+distribution	O
+and	O
+duration	O
+of	O
+mouse	B-DISO
+hepatitis	I-DISO
+virus	B-SPEC
+in	O
+naturally	O
+infected	O
+immunocompetent	O
+ICR	O
+(	O
+CD	O
+-	O
+1	O
+)	O
+and	O
+immunodeficient	O
+athymic	O
+nude	O
+-	O
+nu	O
+mouse	B-SPEC
+strains	O
+used	O
+for	O
+ovarian	B-ANAT
+transplantation	O
+and	O
+in	O
+vitro	O
+fertilization	B-PROC
+.	O
+
+The	O
+commercial	O
+assay	O
+was	O
+the	O
+RealArt	B-PRGE
+HPA	I-PRGE
+CoV	I-PRGE
+RT	I-PRGE
+-	O
+PCR	O
+assay	O
+(	O
+Artus	O
+),	O
+which	O
+was	O
+run	O
+in	O
+the	O
+LC	O
+.	O
+
+Testing	O
+68	O
+clinical	O
+specimens	O
+(	O
+including	O
+17	O
+respiratory	O
+tract	O
+specimens	O
+,	O
+29	O
+urine	B-ANAT
+samples	O
+,	O
+and	O
+22	O
+stools	B-ANAT
+or	O
+rectal	O
+swabs	O
+)	O
+demonstrated	O
+that	O
+six	O
+of	O
+the	O
+seven	O
+assays	O
+detected	O
+at	O
+least	O
+17	O
+of	O
+18	O
+positives	O
+(	O
+defined	O
+as	O
+positive	O
+in	O
+at	O
+least	O
+two	O
+assays	O
+),	O
+and	O
+two	O
+of	O
+the	O
+assays	O
+had	O
+a	O
+sensitivity	O
+of	O
+100	O
+%.	O
+
+TITLE	O
+:	O
+Two	O
+genotypes	O
+of	O
+canine	O
+coronavirus	B-SPEC
+simultaneously	O
+detected	O
+in	O
+the	O
+fecal	B-ANAT
+samples	O
+of	O
+dogs	B-SPEC
+with	O
+diarrhea	O
+.	O
+
+We	O
+conclude	O
+that	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+and	O
+smallpox	B-DISO
+are	O
+easier	O
+to	O
+control	O
+using	O
+these	O
+simple	O
+public	O
+health	O
+measures	O
+.	O
+
+ABSTRACT	O
+:	O
+In	O
+November	O
+2003	O
+,	O
+a	O
+new	O
+,	O
+life	O
+-	O
+threatening	O
+,	O
+respiratory	O
+illness	O
+named	O
+severe	O
+acute	O
+respiratory	O
+syndrome	O
+(	O
+SARS	B-DISO
+)	O
+arose	O
+from	O
+Guangdong	O
+Province	O
+in	O
+China	O
+.	O
+
+SARS	B-DISO
+is	O
+caused	O
+by	O
+a	O
+novel	B-SPEC
+coronavirus	I-SPEC
+that	O
+primarily	O
+affects	O
+the	O
+lower	B-ANAT
+respiratory	I-ANAT
+tract	I-ANAT
+.	O
+
+There	O
+are	O
+several	O
+other	O
+neuraminidase	B-PROC
+inhibitors	I-PROC
+in	O
+development	B-PROC
+.	O
+
+External	O
+PEEP	B-CHED
+and	O
+intrinsic	B-DISO
+PEEP	I-DISO
+were	O
+combined	O
+to	O
+keep	O
+recruited	O
+lung	B-ANAT
+units	O
+open	O
+.	O
+
+We	O
+generated	O
+intrinsic	B-DISO
+PEEP	I-DISO
+by	O
+pressure	O
+-	O
+cycled	O
+high	O
+-	O
+frequency	O
+inverse	O
+ratio	O
+ventilation	O
+(	O
+80	O
+min	O
+,	O
+inspiratory	O
+/	O
+expiratory	B-PROC
+ratio	O
+2	O
+:	O
+1	O
+)	O
+and	O
+maintained	O
+our	O
+ventilatory	O
+strategy	O
+for	O
+24	O
+hrs	B-DISO
+.	O
+
+Data	O
+from	O
+computed	O
+tomography	O
+before	O
+and	O
+after	O
+the	O
+open	O
+lung	B-ANAT
+concept	O
+were	O
+analyzed	O
+for	O
+volumetric	O
+quantification	O
+of	O
+lung	B-ANAT
+aeration	O
+and	O
+collapse	B-DISO
+.	O
+
+Lung	B-ANAT
+recruitment	B-DISO
+increased	O
+arterial	B-ANAT
+oxygenation	B-PROC
+,	O
+normally	O
+aerated	O
+lung	B-PROC
+volume	I-PROC
+,	O
+and	O
+total	O
+lung	B-PROC
+volume	I-PROC
+while	O
+decreasing	O
+the	O
+amount	O
+of	O
+collapsed	O
+tissue	B-ANAT
+.	O
+
+An	O
+18	O
+-	O
+bed	B-DISO
+adult	O
+medical	O
+-	O
+surgical	O
+intensive	O
+care	O
+unit	O
+in	O
+a	O
+1	O
+,	O
+100	O
+-	O
+bed	B-DISO
+regional	O
+and	O
+teaching	O
+hospital	O
+in	O
+France	O
+.	O
+
+The	O
+separation	B-DISO
+and	O
+purification	O
+of	O
+glycyrrhizin	B-CHED
+from	O
+a	O
+methanol	B-CHED
+-	O
+water	B-CHED
+(	O
+70	O
+:	O
+30	O
+(	O
+v	O
+/	O
+v	O
+))	O
+extract	O
+of	O
+liquorice	O
+roots	O
+was	O
+achieved	O
+using	O
+high	O
+-	O
+speed	O
+counter	B-CHED
+-	O
+current	O
+chromatography	O
+.	O
+
+The	O
+separation	B-DISO
+was	O
+performed	O
+at	O
+a	O
+preparative	O
+scale	O
+in	O
+a	O
+one	O
+-	O
+step	O
+separation	B-DISO
+with	O
+a	O
+two	O
+-	O
+phase	O
+solvent	B-CHED
+system	O
+composed	O
+of	O
+ethyl	B-CHED
+acetate	I-CHED
+-	O
+methanol	B-CHED
+-	O
+water	B-CHED
+(	O
+5	O
+:	O
+2	O
+:	O
+5	O
+(	O
+v	O
+/	O
+v	O
+)).	O
+
+The	O
+lower	O
+phase	O
+was	O
+used	O
+as	O
+the	O
+mobile	O
+phase	O
+in	O
+the	O
+head	B-ANAT
+-	O
+to	O
+-	O
+tail	O
+elution	O
+mode	O
+.	O
+
+Here	O
+we	O
+describe	O
+the	O
+identification	O
+and	O
+characterization	O
+of	O
+a	O
+not	O
+previously	O
+recognized	O
+coronavirus	B-SPEC
+obtained	O
+from	O
+an	O
+8	O
+-	O
+mo	O
+-	O
+old	O
+boy	O
+suffering	B-DISO
+from	O
+pneumonia	B-DISO
+.	O
+
+Using	O
+these	O
+tests	O
+,	O
+the	O
+virus	B-SPEC
+was	O
+detected	O
+in	O
+four	O
+of	O
+139	O
+individuals	O
+(	O
+3	O
+%)	O
+who	O
+were	O
+suffering	B-DISO
+from	O
+respiratory	O
+illness	O
+with	O
+unknown	O
+etiology	O
+.	O
+
+G	B-SPEC
+.	I-SPEC
+intestinalis	I-SPEC
+was	O
+the	O
+most	O
+common	O
+agent	O
+found	O
+but	O
+the	O
+importance	O
+of	O
+this	O
+parasite	O
+remains	O
+unclear	O
+.	O
+
+Cytopathic	B-DISO
+effect	I-DISO
+reduction	O
+assays	O
+visually	O
+determined	O
+with	O
+spectrophotometric	O
+verification	O
+by	O
+neutral	B-PRGE
+red	I-PRGE
+(	O
+NR	O
+)	O
+uptake	O
+assay	O
+were	O
+used	O
+to	O
+evaluate	O
+cytotoxicity	B-DISO
+and	O
+antiviral	B-CHED
+potency	O
+of	O
+the	O
+compounds	O
+.	O
+
+Significantly	O
+inhibitory	O
+compounds	O
+were	O
+then	O
+evaluated	O
+in	O
+virus	B-SPEC
+yield	O
+reduction	O
+assays	O
+.	O
+
+TITLE	O
+:	O
+Negative	O
+-	O
+pressure	O
+pulmonary	B-DISO
+edema	I-DISO
+complicated	O
+by	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+in	O
+an	O
+orangutan	B-SPEC
+(	O
+Pongo	B-SPEC
+pygmaeus	I-SPEC
+abelii	I-SPEC
+).	O
+
+A	O
+large	O
+volume	O
+of	O
+pink	O
+-	O
+tinged	O
+frothy	O
+fluid	O
+flowed	O
+from	O
+the	O
+trachea	B-DISO
+when	O
+the	O
+laryngoscope	O
+was	O
+inserted	O
+into	O
+the	O
+oropharynx	B-ANAT
+.	O
+
+From	O
+the	O
+pH	O
+dependency	O
+of	O
+catalytic	O
+activity	O
+,	O
+the	O
+pK	O
+(	O
+a	O
+)'	O
+s	O
+for	O
+His41	O
+and	O
+Cys145	O
+in	O
+the	O
+wild	O
+-	O
+type	O
+enzyme	O
+were	O
+estimated	O
+to	O
+be	O
+6	O
+.	O
+38	O
+and	O
+8	O
+.	O
+34	O
+,	O
+while	O
+the	O
+pK	O
+(	O
+a	O
+)'	O
+s	O
+for	O
+His41	O
+and	O
+Ser145	O
+in	O
+the	O
+C145S	O
+mutant	B-DISO
+were	O
+estimated	O
+to	O
+be	O
+6	O
+.	O
+15	O
+and	O
+9	O
+.	O
+09	O
+,	O
+respectively	O
+.	O
+
+ABSTRACT	O
+:	O
+Efforts	O
+to	O
+contain	O
+severe	O
+acute	O
+respiratory	O
+syndrome	O
+(	O
+SARS	B-DISO
+)	O
+have	O
+been	O
+limited	O
+by	O
+the	O
+lack	O
+of	O
+a	O
+standardized	O
+,	O
+sensitive	O
+,	O
+and	O
+specific	O
+test	O
+for	O
+SARS	B-DISO
+-	I-DISO
+associated	I-DISO
+coronavirus	I-DISO
+(	O
+CoV	O
+).	O
+
+SARS	B-DISO
+-	O
+CoV	O
+appears	O
+similar	O
+to	O
+other	O
+coronaviruses	O
+in	O
+both	O
+virion	B-COMP
+structure	O
+and	O
+genome	O
+organization	O
+.	O
+
+In	O
+an	O
+effort	B-PROC
+to	O
+map	O
+the	O
+ligand	B-PROC
+-	O
+binding	B-FUNC
+domain	O
+of	O
+the	O
+SARS	B-PRGE
+-	I-PRGE
+CoV	I-PRGE
+S	I-PRGE
+glycoprotein	B-CHED
+,	O
+carboxy	B-CHED
+-	O
+and	O
+amino	O
+-	O
+terminal	O
+truncations	O
+of	O
+the	O
+S	B-PRGE
+(	I-PRGE
+1190	I-PRGE
+)	I-PRGE
+glycoprotein	I-PRGE
+were	O
+constructed	O
+.	O
+
+We	O
+speculate	O
+that	O
+amino	B-CHED
+acids	I-CHED
+1	O
+to	O
+510	O
+of	O
+the	O
+SARS	B-PRGE
+-	I-PRGE
+CoV	I-PRGE
+S	I-PRGE
+glycoprotein	B-CHED
+represent	O
+a	O
+unique	O
+domain	O
+containing	O
+the	O
+receptor	O
+-	O
+binding	B-FUNC
+site	O
+(	O
+amino	B-CHED
+acids	I-CHED
+270	O
+to	O
+510	O
+),	O
+analogous	O
+to	O
+the	O
+S1	O
+subunit	O
+of	O
+other	O
+coronavirus	B-SPEC
+S	O
+glycoproteins	B-CHED
+.	O
+
+Thus	O
+,	O
+vaccination	O
+against	O
+SARS	B-DISO
+-	O
+CoV	O
+may	O
+represent	O
+an	O
+effective	O
+approach	O
+to	O
+controlling	O
+SARS	B-DISO
+.	O
+
+DNA	O
+vaccines	O
+are	O
+an	O
+attractive	O
+approach	O
+for	O
+SARS	B-DISO
+vaccine	O
+development	B-PROC
+,	O
+as	O
+they	O
+offer	O
+many	O
+advantages	O
+over	O
+conventional	O
+vaccines	O
+,	O
+including	O
+stability	O
+,	O
+simplicity	O
+,	O
+and	O
+safety	O
+.	O
+
+In	O
+this	O
+study	O
+,	O
+we	O
+have	O
+employed	O
+this	O
+CRT	B-CHED
+-	O
+based	O
+enhancement	O
+strategy	O
+to	O
+create	O
+effective	O
+DNA	O
+vaccines	O
+using	O
+SARS	B-PRGE
+-	I-PRGE
+CoV	I-PRGE
+nucleocapsid	B-COMP
+(	I-PRGE
+N	I-PRGE
+)	I-PRGE
+protein	B-CHED
+as	O
+a	O
+target	O
+antigen	B-CHED
+.	O
+
+These	O
+results	O
+show	O
+that	O
+a	O
+DNA	O
+vaccine	O
+encoding	O
+CRT	B-CHED
+linked	O
+to	O
+a	O
+SARS	B-PRGE
+-	I-PRGE
+CoV	I-PRGE
+antigen	B-CHED
+is	O
+capable	O
+of	O
+generating	O
+strong	O
+N	O
+-	O
+specific	O
+humoral	O
+and	O
+cellular	B-PROC
+immunity	I-PROC
+and	O
+may	O
+potentially	O
+be	O
+useful	O
+for	O
+control	O
+of	O
+infection	B-DISO
+with	O
+SARS	B-DISO
+-	O
+CoV	O
+.	O
+
+Monitoring	O
+the	O
+total	O
+number	O
+of	O
+NK	O
+and	O
+CD158b	O
++	O
+NK	B-ANAT
+cells	I-ANAT
+and	O
+the	O
+percentage	O
+of	O
+CDD158b	O
++	O
+NK	B-ANAT
+cells	I-ANAT
+might	O
+aid	O
+in	O
+differentiating	O
+SARS	B-DISO
+from	O
+M	B-SPEC
+.	I-SPEC
+pneumoniae	I-SPEC
+infection	B-DISO
+.	O
+
+TITLE	O
+:	O
+Detection	O
+of	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+-	O
+associated	O
+coronavirus	B-SPEC
+in	O
+pneumocytes	B-ANAT
+of	O
+the	O
+lung	B-ANAT
+.	O
+
+The	O
+important	O
+thing	O
+is	O
+to	O
+understand	O
+its	O
+binding	B-FUNC
+mechanism	O
+with	O
+possible	O
+ligands	O
+.	O
+
+We	O
+also	O
+expressed	B-PROC
+recombinant	O
+N	O
+proteins	B-CHED
+in	O
+Escherichia	B-SPEC
+coli	I-SPEC
+and	O
+prepared	O
+N	O
+protein	B-CHED
+-	O
+specific	O
+polyclonal	O
+antibodies	B-COMP
+.	O
+
+When	O
+C3H	O
+/	O
+He	O
+mice	O
+were	O
+immunized	O
+by	O
+three	O
+separate	O
+injections	O
+,	O
+high	O
+antibody	B-COMP
+titre	O
+(	O
+1	O
+:	O
+3200	O
+-	O
+1	O
+:	O
+6400	O
+,	O
+average	O
+titre	O
+is	O
+1	O
+:	O
+4580	O
+)	O
+and	O
+high	O
+CTL	B-ANAT
+activity	O
+(	O
+67	O
+.	O
+4	O
++/-	O
+8	O
+.	O
+4	O
+%	O
+(	O
+E	O
+:	O
+T	O
+=	O
+25	O
+:	O
+1	O
+),	O
+69	O
+.	O
+6	O
++/-	O
+6	O
+.	O
+7	O
+%	O
+(	O
+E	O
+:	O
+T	O
+=	O
+50	O
+:	O
+1	O
+)	O
+and	O
+71	O
+.	O
+8	O
++/-	O
+6	O
+.	O
+2	O
+%	O
+(	O
+E	O
+:	O
+T	O
+=	O
+100	O
+:	O
+1	O
+))	O
+were	O
+observed	O
+.	O
+
+Many	O
+of	O
+the	O
+ethical	O
+issues	O
+raised	O
+by	O
+infectious	B-DISO
+diseases	I-DISO
+are	O
+related	O
+to	O
+these	O
+diseases	O
+'	O
+powerful	O
+ability	O
+to	O
+engender	O
+fear	O
+in	O
+individuals	O
+and	O
+panic	O
+in	O
+populations	O
+.	O
+
+Spinal	B-ANAT
+fluid	I-ANAT
+protein	B-CHED
+in	O
+them	O
+is	O
+often	O
+elevated	O
+,	O
+higher	O
+values	O
+seeming	O
+to	O
+auger	O
+a	O
+better	O
+intravenous	O
+immunoglobulin	O
+-	O
+G	O
+response	O
+.	O
+
+RESULTS	O
+:	O
+Key	O
+recommendations	O
+,	O
+listed	O
+by	O
+category	O
+and	O
+not	O
+by	O
+hierarchy	O
+,	O
+include	O
+early	O
+goal	O
+-	O
+directed	O
+resuscitation	O
+of	O
+the	O
+septic	O
+patient	O
+during	O
+the	O
+first	O
+6	O
+hrs	B-DISO
+after	O
+recognition	O
+;	O
+appropriate	O
+diagnostic	O
+studies	O
+to	O
+ascertain	O
+causative	O
+organisms	O
+before	O
+starting	O
+antibiotics	B-CHED
+;	O
+early	O
+administration	O
+of	O
+broad	O
+-	O
+spectrum	O
+antibiotic	B-CHED
+therapy	O
+;	O
+reassessment	O
+of	O
+antibiotic	B-CHED
+therapy	O
+with	O
+microbiology	O
+and	O
+clinical	O
+data	O
+to	O
+narrow	O
+coverage	O
+,	O
+when	O
+appropriate	O
+;	O
+a	O
+usual	O
+7	O
+-	O
+10	O
+days	O
+of	O
+antibiotic	B-CHED
+therapy	O
+guided	O
+by	O
+clinical	O
+response	O
+;	O
+source	O
+control	O
+with	O
+attention	O
+to	O
+the	O
+method	O
+that	O
+balances	O
+risks	O
+and	O
+benefits	O
+;	O
+equivalence	O
+of	O
+crystalloid	B-COMP
+and	O
+colloid	B-ANAT
+resuscitation	O
+;	O
+aggressive	B-DISO
+fluid	O
+challenge	O
+to	O
+restore	O
+mean	O
+circulating	O
+filling	O
+pressure	O
+;	O
+vasopressor	O
+preference	O
+for	O
+norepinephrine	B-CHED
+and	O
+dopamine	B-CHED
+;	O
+cautious	O
+use	O
+of	O
+vasopressin	B-CHED
+pending	O
+further	O
+studies	O
+;	O
+avoiding	O
+low	O
+-	O
+dose	O
+dopamine	B-CHED
+administration	O
+for	O
+renal	B-ANAT
+protection	O
+;	O
+consideration	O
+of	O
+dobutamine	B-CHED
+inotropic	O
+therapy	O
+in	O
+some	O
+clinical	O
+situations	O
+;	O
+avoidance	O
+of	O
+supranormal	O
+oxygen	B-CHED
+delivery	O
+as	O
+a	O
+goal	O
+of	O
+therapy	O
+;	O
+stress	O
+-	O
+dose	O
+steroid	B-CHED
+therapy	O
+for	O
+septic	B-DISO
+shock	I-DISO
+;	O
+use	O
+of	O
+recombinant	B-PRGE
+activated	I-PRGE
+protein	I-PRGE
+C	I-PRGE
+in	O
+patients	O
+with	O
+severe	B-DISO
+sepsis	I-DISO
+and	O
+high	O
+risk	O
+for	O
+death	B-PROC
+;	O
+with	O
+resolution	O
+of	O
+tissue	B-ANAT
+hypoperfusion	O
+and	O
+in	O
+the	O
+absence	O
+of	O
+coronary	B-DISO
+artery	I-DISO
+disease	I-DISO
+or	O
+acute	B-DISO
+hemorrhage	I-DISO
+,	O
+targeting	B-PROC
+a	O
+hemoglobin	B-PRGE
+of	O
+7	O
+-	O
+9	O
+g	O
+/	O
+dL	O
+;	O
+appropriate	O
+use	O
+of	O
+fresh	B-ANAT
+frozen	I-ANAT
+plasma	I-ANAT
+and	O
+platelets	B-ANAT
+;	O
+a	O
+low	O
+tidal	O
+volume	O
+and	O
+limitation	O
+of	O
+inspiratory	B-PROC
+plateau	O
+pressure	O
+strategy	O
+for	O
+acute	O
+lung	B-ANAT
+injury	O
+and	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+;	O
+application	O
+of	O
+a	O
+minimal	O
+amount	O
+of	O
+positive	O
+end	B-PROC
+-	I-PROC
+expiratory	I-PROC
+pressure	O
+in	O
+acute	O
+lung	B-ANAT
+injury	O
+/	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+;	O
+a	O
+semirecumbent	O
+bed	B-DISO
+position	O
+unless	O
+contraindicated	O
+;	O
+protocols	O
+for	O
+weaning	B-PROC
+and	O
+sedation	B-DISO
+/	O
+analgesia	B-DISO
+,	O
+using	O
+either	O
+intermittent	O
+bolus	O
+sedation	B-DISO
+or	O
+continuous	O
+infusion	O
+sedation	B-DISO
+with	O
+daily	O
+interruptions	O
+/	O
+lightening	O
+;	O
+avoidance	O
+of	O
+neuromuscular	O
+blockers	O
+,	O
+if	O
+at	O
+all	O
+possible	O
+;	O
+maintenance	O
+of	O
+blood	B-ANAT
+glucose	B-CHED
+<	O
+150	O
+mg	O
+/	O
+dL	O
+after	O
+initial	O
+stabilization	O
+;	O
+equivalence	O
+of	O
+continuous	O
+veno	O
+-	O
+veno	O
+hemofiltration	O
+and	O
+intermittent	O
+hemodialysis	O
+;	O
+lack	O
+of	O
+utility	O
+of	O
+bicarbonate	B-CHED
+use	O
+for	O
+pH	O
+>	O
+or	O
+=	O
+7	O
+.	O
+15	O
+;	O
+use	O
+of	O
+deep	B-DISO
+vein	I-DISO
+thrombosis	I-DISO
+/	O
+stress	B-DISO
+ulcer	I-DISO
+prophylaxis	O
+;	O
+and	O
+consideration	O
+of	O
+limitation	O
+of	O
+support	O
+where	O
+appropriate	O
+.	O
+
+This	O
+respiratory	O
+syndrome	B-DISO
+,	O
+caused	O
+by	O
+a	O
+coronavirus	B-SPEC
+,	O
+spread	O
+rapidly	O
+across	O
+30	O
+nations	O
+since	O
+its	O
+first	O
+recognition	O
+in	O
+late	O
+2002	O
+.	O
+
+The	O
+SARS	B-PRGE
+-	I-PRGE
+CoV	I-PRGE
+nucleocapsid	B-COMP
+(	I-PRGE
+N	I-PRGE
+)	I-PRGE
+protein	B-CHED
+is	O
+a	O
+423	O
+amino	O
+-	O
+acid	O
+,	O
+predicted	O
+phospho	O
+-	O
+protein	B-CHED
+of	O
+46	O
+kDa	O
+that	O
+shares	O
+little	O
+homology	O
+with	O
+other	O
+members	O
+of	O
+the	O
+coronavirus	O
+family	B-SPEC
+.	O
+
+ABSTRACT	O
+:	O
+Severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+(	O
+SARS	B-DISO
+)	O
+is	O
+a	O
+new	O
+respiratory	O
+illness	O
+due	O
+to	O
+a	O
+novel	O
+coronavirus	O
+called	O
+SARS	B-DISO
+-	O
+CoV	O
+.	O
+Cases	O
+of	O
+SARS	B-DISO
+were	O
+first	O
+identified	O
+from	O
+Guangdong	O
+Province	O
+in	O
+southern	O
+China	O
+in	O
+November	O
+2002	O
+.	O
+
+The	O
+economic	O
+and	O
+psychological	B-DISO
+impact	O
+of	O
+this	O
+mysterious	O
+illness	O
+was	O
+profound	O
+.	O
+
+With	O
+the	O
+SARS	B-DISO
+coronavirus	B-SPEC
+serologic	O
+test	O
+as	O
+the	O
+gold	B-CHED
+standard	O
+,	O
+the	O
+clinical	O
+diagnosis	O
+of	O
+probable	O
+SARS	B-DISO
+at	O
+hospitalization	O
+had	O
+a	O
+sensitivity	O
+of	O
+0	O
+.	O
+96	O
+(	O
+95	O
+%	O
+CI	O
+,	O
+0	O
+.	O
+91	O
+to	O
+0	O
+.	O
+98	O
+)	O
+and	O
+a	O
+specificity	O
+of	O
+0	O
+.	O
+96	O
+(	O
+CI	O
+,	O
+0	O
+.	O
+92	O
+to	O
+0	O
+.	O
+97	O
+).	O
+
+TITLE	O
+:	O
+Antibody	B-FUNC
+response	I-PROC
+and	O
+viraemia	B-DISO
+during	O
+the	O
+course	O
+of	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+(	O
+SARS	B-DISO
+)-	O
+associated	O
+coronavirus	O
+infection	O
+.	O
+
+TITLE	O
+:	O
+Respiratory	O
+and	O
+fecal	B-ANAT
+shedding	O
+of	O
+porcine	B-SPEC
+respiratory	O
+coronavirus	B-SPEC
+(	O
+PRCV	B-SPEC
+)	O
+in	O
+sentinel	O
+weaned	B-PROC
+pigs	B-SPEC
+and	O
+sequence	O
+of	O
+the	O
+partial	B-PRGE
+S	I-PRGE
+-	I-PRGE
+gene	I-PRGE
+of	O
+the	O
+PRCV	B-SPEC
+isolates	O
+.	O
+
+Nasal	B-ANAT
+shedding	O
+of	O
+PRCV	O
+was	O
+detected	O
+in	O
+57	O
+%	O
+and	O
+63	O
+%	O
+of	O
+samples	O
+by	O
+nested	O
+-	O
+RT	O
+-	O
+PCR	O
+and	O
+cell	B-COMP
+culture	O
+immunofluorescence	O
+(	O
+CCIF	O
+),	O
+respectively	O
+.	O
+
+Risk	O
+assessment	O
+remains	O
+a	O
+balance	B-PROC
+between	O
+cost	O
+and	O
+benefit	O
+.	O
+
+It	O
+is	O
+used	O
+in	O
+the	O
+treatment	O
+of	O
+patients	O
+with	O
+extremely	O
+severe	O
+,	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+in	O
+order	B-SPEC
+to	O
+provide	O
+gas	B-ENZY
+exchange	O
+through	O
+an	O
+extracorporeal	O
+artificial	O
+oxygenator	O
+.	O
+
+ECMO	O
+has	O
+been	O
+concluded	O
+to	O
+be	O
+life	O
+saving	O
+in	O
+selected	O
+cases	O
+of	O
+extremely	O
+severe	O
+acute	B-DISO
+respiratory	I-DISO
+failure	I-DISO
+.	O
+
+TITLE	O
+:	O
+Evidence	O
+of	O
+airborne	O
+transmission	O
+of	O
+the	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+virus	B-SPEC
+.	O
+
+We	O
+analyzed	O
+the	O
+temporal	O
+and	O
+spatial	O
+distributions	O
+of	O
+cases	O
+in	O
+a	O
+large	O
+community	O
+outbreak	O
+of	O
+SARS	B-DISO
+in	O
+Hong	O
+Kong	O
+and	O
+examined	O
+the	O
+correlation	O
+of	O
+these	O
+data	O
+with	O
+the	O
+three	O
+-	O
+dimensional	O
+spread	O
+of	O
+a	O
+virus	B-SPEC
+-	O
+laden	O
+aerosol	O
+plume	O
+that	O
+was	O
+modeled	O
+using	O
+studies	O
+of	O
+airflow	B-PROC
+dynamics	O
+.	O
+
+The	O
+distribution	O
+of	O
+risk	O
+in	O
+buildings	O
+B	O
+,	O
+C	O
+,	O
+and	O
+D	O
+corresponded	O
+well	O
+with	O
+the	O
+three	O
+-	O
+dimensional	O
+spread	O
+of	O
+virus	B-SPEC
+-	O
+laden	O
+aerosols	O
+predicted	O
+with	O
+the	O
+use	O
+of	O
+computational	O
+fluid	O
+-	O
+dynamics	O
+modeling	O
+.	O
+
+ABSTRACT	O
+:	O
+The	O
+emergence	O
+of	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+(	O
+SARS	B-DISO
+)	O
+has	O
+highlighted	O
+the	O
+importance	O
+of	O
+hospital	B-DISO
+infection	I-DISO
+-	O
+control	O
+programs	O
+.	O
+
+In	O
+April	O
+2003	O
+,	O
+SARS	B-DISO
+-	O
+related	O
+screening	O
+in	O
+a	O
+hospital	O
+in	O
+Taipei	O
+resulted	O
+in	O
+the	O
+detection	O
+of	O
+suspected	O
+TB	O
+among	O
+HCWs	O
+.	O
+
+Human	B-SPEC
+PMs	B-DISO
+were	O
+collected	O
+during	O
+elective	O
+laparoscopic	O
+procedures	O
+,	O
+cultured	O
+,	O
+and	O
+stimulated	O
+with	O
+IL	B-PRGE
+-	I-PRGE
+1beta	I-PRGE
+.	O
+
+There	O
+was	O
+no	O
+difference	O
+in	O
+IL	B-PRGE
+-	I-PRGE
+1beta	I-PRGE
+-	O
+induced	O
+IL	B-PROC
+-	I-PROC
+8	I-PROC
+production	I-PROC
+in	O
+children	O
+compared	O
+with	O
+adults	O
+.	O
+
+Exact	O
+knowledge	O
+of	O
+how	O
+the	O
+immune	B-ANAT
+system	I-ANAT
+handles	O
+protein	B-CHED
+antigens	B-CHED
+would	O
+allow	O
+for	O
+the	O
+identification	O
+of	O
+such	O
+linear	O
+sequences	O
+directly	O
+from	O
+genomic	O
+/	O
+proteomic	O
+sequence	O
+information	O
+(	O
+Lauemoller	O
+et	O
+al	O
+.,	O
+Rev	B-PRGE
+Immunogenet	I-PRGE
+2001	O
+:	O
+2	O
+:	O
+477	O
+-	O
+91	O
+).	O
+
+Here	O
+,	O
+we	O
+have	O
+combined	O
+advanced	O
+bioinformatics	O
+and	O
+high	O
+-	O
+throughput	O
+immunology	O
+to	O
+perform	O
+an	O
+HLA	B-PRGE
+supertype	O
+-,	O
+genome	O
+-	O
+wide	O
+scan	O
+for	O
+SARS	B-DISO
+-	O
+specific	O
+CTL	B-ANAT
+epitopes	O
+.	O
+
+We	O
+suggest	O
+that	O
+immunobioinformatics	O
+may	O
+become	O
+a	O
+fast	B-FUNC
+and	O
+valuable	O
+tool	O
+in	O
+rational	O
+vaccine	O
+design	O
+.	O
+
+TITLE	O
+:	O
+A	O
+cluster	O
+of	O
+patients	O
+with	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+in	O
+a	O
+chest	B-ANAT
+ward	O
+in	O
+southern	O
+Taiwan	O
+.	O
+
+This	O
+retrospective	O
+case	O
+series	O
+was	O
+collected	O
+during	O
+the	O
+SARS	B-DISO
+outbreak	O
+.	O
+
+Gas	B-PRGE
+exchange	O
+deteriorated	O
+and	O
+the	O
+patient	O
+was	O
+transferred	O
+to	O
+our	O
+intensive	O
+care	O
+unit	O
+(	O
+ICU	O
+).	O
+
+Clinically	O
+relevant	O
+outcome	O
+measures	O
+should	O
+be	O
+assessed	O
+(	O
+mortality	O
+at	O
+discharge	B-ANAT
+and	O
+later	O
+,	O
+duration	O
+of	O
+respiratory	O
+support	O
+and	O
+hospital	O
+stay	O
+,	O
+and	O
+long	O
+-	O
+term	O
+neurodevelopmental	O
+outcomes	O
+)	O
+and	O
+the	O
+studies	O
+should	O
+be	O
+published	O
+in	O
+full	O
+.	O
+
+The	O
+study	O
+estimated	O
+the	O
+utilisation	O
+of	O
+resources	O
+related	O
+to	O
+infection	B-DISO
+control	O
+,	O
+SARS	B-DISO
+related	O
+medical	O
+services	O
+,	O
+and	O
+routine	O
+medical	O
+services	O
+,	O
+and	O
+SARS	B-DISO
+related	O
+medical	O
+outcomes	O
+at	O
+National	O
+Cheng	O
+Kung	O
+University	O
+Hospital	O
+(	O
+NCKUH	O
+)	O
+from	O
+25	O
+March	O
+to	O
+16	O
+June	O
+2003	O
+through	O
+a	O
+cross	O
+sectional	O
+survey	O
+of	O
+hospital	O
+records	O
+.	O
+
+SARS	B-DISO
+and	O
+avian	B-DISO
+influenza	I-DISO
+are	O
+zoonoses	B-DISO
+with	O
+the	O
+potential	O
+to	O
+spread	O
+from	O
+person	O
+to	O
+person	O
+.	O
+
+A	O
+key	O
+enzyme	O
+for	O
+the	O
+maturation	B-PROC
+of	O
+this	O
+virus	B-SPEC
+and	O
+,	O
+therefore	O
+,	O
+a	O
+target	O
+for	O
+drug	O
+development	B-PROC
+is	O
+the	O
+main	B-PRGE
+protease	I-PRGE
+3CL	I-PRGE
+(	O
+pro	B-PRGE
+)	O
+(	O
+also	O
+termed	O
+SARS	B-PRGE
+-	I-PRGE
+CoV	I-PRGE
+3CL	I-PRGE
+(	O
+pro	B-CHED
+)).	O
+
+ABSTRACT	O
+:	O
+Acute	B-DISO
+pneumonia	I-DISO
+developed	O
+in	O
+a	O
+previously	O
+healthy	O
+man	O
+during	O
+the	O
+outbreak	O
+of	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+(	O
+SARS	B-DISO
+)	O
+in	O
+southern	O
+China	O
+in	O
+March	O
+2003	O
+.	O
+
+Apart	O
+from	O
+frequently	O
+causing	O
+infections	B-DISO
+in	O
+the	O
+general	O
+community	O
+,	O
+many	O
+types	O
+of	O
+viruses	B-SPEC
+are	O
+also	O
+significant	O
+nosocomial	O
+pathogens	O
+.	O
+
+While	O
+it	O
+is	O
+generally	O
+agreed	O
+that	O
+we	O
+underestimate	O
+the	O
+proportion	O
+of	O
+nosocomial	B-DISO
+infections	I-DISO
+that	O
+are	O
+viral	O
+,	O
+due	O
+to	O
+a	O
+lack	O
+of	O
+routine	O
+monitoring	O
+,	O
+viruses	B-SPEC
+easily	O
+account	O
+for	O
+more	O
+than	O
+30	O
+%	O
+of	O
+the	O
+cases	O
+of	O
+hospital	O
+-	O
+acquired	O
+infections	B-DISO
+in	O
+many	O
+paediatric	O
+settings	O
+.	O
+
+This	O
+,	O
+in	O
+turn	O
+,	O
+has	O
+stimulated	O
+considerable	O
+interest	O
+in	O
+the	O
+development	B-PROC
+of	O
+formulations	O
+that	O
+are	O
+not	O
+only	O
+safer	O
+but	O
+which	O
+also	O
+have	O
+demonstrated	O
+activity	O
+against	O
+major	O
+types	O
+of	O
+nosocomial	O
+viral	O
+pathogens	O
+.	O
+
+Further	O
+,	O
+much	O
+work	O
+is	O
+now	O
+underway	O
+to	O
+design	O
+better	O
+methods	O
+to	O
+assess	O
+the	O
+virucidal	O
+activity	O
+of	O
+microbicides	B-CHED
+used	O
+to	O
+decontaminate	O
+hands	B-ANAT
+,	O
+reusable	O
+medical	O
+devices	O
+and	O
+environmental	O
+surfaces	O
+in	O
+critical	O
+areas	O
+of	O
+healthcare	O
+settings	O
+.	O
+
+To	O
+evaluate	O
+use	O
+of	O
+the	O
+Internet	O
+in	O
+accessing	O
+information	O
+related	O
+to	O
+the	O
+anthrax	B-DISO
+scare	O
+in	O
+the	O
+United	O
+States	O
+in	O
+late	O
+2001	O
+,	O
+and	O
+to	O
+strategize	O
+about	O
+the	O
+most	O
+effective	O
+use	O
+of	O
+this	O
+technology	O
+as	O
+a	O
+communication	O
+vehicle	O
+during	O
+times	O
+of	O
+public	O
+health	O
+crises	O
+.	O
+
+One	O
+hundred	O
+and	O
+thirty	O
+eight	O
+patients	O
+were	O
+treated	O
+with	O
+broad	O
+spectrum	O
+antibiotics	B-CHED
+,	O
+a	O
+combination	O
+of	O
+ribavirin	B-CHED
+and	O
+low	O
+dose	O
+corticosteroid	B-CHED
+,	O
+and	O
+then	O
+intravenous	O
+high	O
+dose	O
+methylprednisolone	B-CHED
+according	O
+to	O
+responses	O
+.	O
+
+A	O
+high	O
+level	O
+of	O
+C	B-PRGE
+-	I-PRGE
+reactive	I-PRGE
+protein	I-PRGE
+at	O
+presentation	O
+was	O
+the	O
+only	O
+independent	O
+predictor	O
+for	O
+use	O
+of	O
+methylprednisolone	B-CHED
+(	O
+odds	O
+ratio	O
+2	O
+.	O
+18	O
+per	O
+10	O
+mg	O
+/	O
+dl	O
+increase	O
+,	O
+95	O
+%	O
+confidence	O
+interval	O
+1	O
+.	O
+12	O
+to	O
+4	O
+.	O
+25	O
+,	O
+p	O
+=	O
+0	O
+.	O
+02	O
+).	O
+
+Aerosolization	O
+means	O
+the	O
+formation	B-PROC
+of	O
+aerosols	O
+and	O
+droplets	O
+when	O
+blood	B-ANAT
+or	O
+other	O
+body	B-ANAT
+fluids	I-ANAT
+are	O
+mechanically	O
+disturbed	O
+.	O
+
+ABSTRACT	O
+:	O
+The	O
+SARS	B-DISO
+-	O
+coronavirus	B-SPEC
+(	O
+SARS	B-DISO
+-	O
+CoV	O
+)	O
+is	O
+a	O
+newly	O
+emerged	O
+,	O
+highly	O
+pathogenic	O
+agent	O
+that	O
+caused	O
+over	O
+8	O
+,	O
+000	O
+human	O
+infections	B-DISO
+with	O
+nearly	O
+800	O
+deaths	B-PROC
+between	O
+November	O
+2002	O
+and	O
+September	O
+2003	O
+.	O
+
+ABSTRACT	O
+:	O
+Three	O
+newly	O
+recognized	O
+encephalitogenic	O
+zoonotic	O
+viruses	B-SPEC
+spread	O
+from	O
+fruit	O
+bats	B-SPEC
+of	O
+the	O
+genus	B-SPEC
+Pteropus	I-SPEC
+(	O
+order	B-SPEC
+Chiroptera	I-SPEC
+,	O
+suborder	B-SPEC
+Megachiroptera	B-SPEC
+)	O
+have	O
+been	O
+recognised	O
+over	O
+the	O
+past	O
+decade	O
+.	O
+
+Direct	O
+contact	O
+with	O
+the	O
+infected	O
+animals	B-SPEC
+was	O
+the	O
+method	O
+of	O
+infection	B-DISO
+,	O
+and	O
+although	O
+human	B-SPEC
+to	O
+human	B-SPEC
+transmission	O
+was	O
+thought	O
+to	O
+have	O
+occurred	O
+,	O
+this	O
+was	O
+not	O
+confirmed	O
+by	O
+follow	O
+up	O
+testing	O
+.	O
+
+Quarantine	O
+of	O
+the	O
+potentially	O
+infected	O
+employee	O
+and	O
+her	O
+boyfriend	O
+uncovered	O
+issues	O
+that	O
+must	O
+be	O
+addressed	O
+if	O
+other	B-DISO
+infectious	I-DISO
+diseases	I-DISO
+requiring	O
+quarantine	O
+or	O
+isolation	O
+of	O
+individuals	O
+emerge	O
+or	O
+re	O
+-	O
+emerge	O
+.	O
+
+We	O
+describe	O
+the	O
+aetiology	O
+of	O
+viral	B-DISO
+diarrhoea	I-DISO
+and	O
+the	O
+characteristics	O
+of	O
+rotavirus	B-DISO
+infection	I-DISO
+in	O
+Shahrekord	O
+,	O
+Iran	O
+.	O
+
+Stool	B-ANAT
+samples	O
+were	O
+screened	O
+for	O
+enteric	O
+viruses	B-SPEC
+using	O
+EM	O
+.	O
+
+One	O
+hundred	O
+and	O
+eighty	O
+six	O
+viruses	B-SPEC
+were	O
+identified	O
+,	O
+of	O
+which	O
+146	O
+(	O
+78	O
+%)	O
+were	O
+rotavirus	B-SPEC
+.	O
+
+The	O
+RT	O
+-	O
+PCR	O
+successfully	O
+typed	O
+139	O
+of	O
+the	O
+146	O
+(	O
+95	O
+%)	O
+rotavirus	B-SPEC
+G	I-SPEC
+types	O
+and	O
+124	O
+(	O
+85	O
+%)	O
+P	O
+types	O
+.	O
+
+ABSTRACT	O
+:	O
+Two	O
+thousand	O
+,	O
+two	O
+hundred	O
+and	O
+seven	O
+cats	O
+from	O
+14	O
+shelters	O
+of	O
+a	O
+major	O
+UK	O
+cat	B-SPEC
+charity	O
+were	O
+blood	B-ANAT
+tested	O
+for	O
+feline	B-SPEC
+coronavirus	B-SPEC
+(	O
+FCoV	O
+)	O
+antibodies	B-COMP
+.	O
+
+Data	O
+was	O
+collated	O
+on	O
+breed	B-PROC
+,	O
+sex	O
+,	O
+age	O
+,	O
+number	O
+of	O
+cats	B-SPEC
+at	O
+original	O
+location	O
+,	O
+outdoor	O
+access	O
+,	O
+health	O
+status	O
+,	O
+and	O
+time	O
+spent	O
+in	O
+the	O
+shelter	O
+prior	O
+to	O
+sampling	O
+(	O
+range	O
+0	O
+to	O
+4	O
+years	O
+).	O
+
+Whether	O
+pet	B-PRGE
+,	O
+stray	O
+or	O
+feral	O
+,	O
+health	O
+status	O
+,	O
+indoor	O
+/	O
+outdoor	O
+access	O
+,	O
+and	O
+sex	O
+had	O
+no	O
+significant	O
+effect	O
+.	O
+
+Significant	O
+variation	O
+existed	O
+in	O
+seropositivity	O
+between	O
+individual	O
+shelters	O
+overall	O
+and	O
+in	O
+cats	B-SPEC
+rescued	O
+for	O
+less	O
+than	O
+5	O
+days	O
+.	O
+
+Examination	O
+of	O
+the	O
+FCoV	O
+genome	O
+has	O
+shown	O
+that	O
+the	O
+same	O
+strain	O
+of	O
+virus	B-SPEC
+can	O
+produce	O
+different	O
+clinical	O
+manifestations	O
+,	O
+suggesting	O
+that	O
+host	B-COMP
+genetic	O
+factors	O
+may	O
+also	O
+play	O
+a	O
+role	O
+in	O
+the	O
+outcome	O
+of	O
+infection	B-DISO
+.	O
+
+FIP	B-DISO
+is	O
+most	O
+prevalent	O
+amongst	O
+pedigree	O
+cats	B-SPEC
+,	O
+although	O
+how	O
+much	O
+of	O
+this	O
+is	O
+due	O
+to	O
+them	O
+living	O
+in	O
+large	O
+groups	O
+(	O
+leading	O
+to	O
+higher	O
+virus	B-SPEC
+challenge	O
+and	O
+stress	O
+which	O
+predisposes	O
+to	O
+FIP	B-DISO
+)	O
+and	O
+how	O
+much	O
+is	O
+due	O
+to	O
+genetic	O
+susceptibility	O
+is	O
+not	O
+known	O
+.	O
+
+Individual	O
+cats	B-SPEC
+were	O
+shown	O
+to	O
+have	O
+between	O
+two	O
+and	O
+six	O
+FLA	B-PRGE
+-	I-PRGE
+DRB	I-PRGE
+alleles	I-PRGE
+.	O
+
+There	O
+was	O
+no	O
+statistically	O
+significant	O
+association	O
+between	O
+the	O
+number	O
+of	O
+alleles	O
+and	O
+the	O
+outcome	O
+of	O
+FCoV	O
+infection	B-DISO
+.	O
+
+Pathological	O
+findings	O
+were	O
+restricted	O
+to	O
+generalized	O
+lymphatic	B-ANAT
+hyperplasia	B-DISO
+.	O
+
+These	O
+findings	O
+demonstrate	O
+the	O
+presence	O
+of	O
+systemic	O
+FCoV	O
+infection	B-DISO
+with	O
+high	O
+viral	O
+loads	O
+in	O
+the	O
+absence	O
+of	O
+clinical	O
+and	O
+pathological	O
+signs	O
+.	O
+
+Fifteen	O
+percent	O
+of	O
+cats	B-SPEC
+were	O
+shedding	O
+FCV	B-CHED
+,	O
+52	O
+%	O
+FHV	O
+,	O
+and	O
+60	O
+%	O
+FECV	B-SPEC
+after	O
+1	O
+week	O
+.	O
+
+The	O
+mean	O
+levels	O
+of	O
+FECV	B-SPEC
+shedding	O
+among	O
+adults	O
+were	O
+the	O
+same	O
+for	O
+primary	O
+and	O
+chronic	B-DISO
+infections	I-DISO
+.	O
+
+FECV	B-SPEC
+shedding	O
+increased	O
+10	O
+to	O
+1	O
+,	O
+000	O
+,	O
+000	O
+fold	O
+in	O
+1	O
+week	O
+among	O
+cats	B-SPEC
+that	O
+were	O
+already	O
+infected	O
+at	O
+entry	O
+,	O
+and	O
+more	O
+than	O
+one	O
+-	O
+half	O
+of	O
+initially	O
+negative	O
+cats	B-SPEC
+were	O
+shedding	O
+FECV	B-SPEC
+a	O
+week	O
+later	O
+.	O
+
+ABSTRACT	O
+:	O
+Feline	B-SPEC
+alpha	O
+(	O
+1	O
+)-	O
+acid	O
+glycoprotein	B-CHED
+(	O
+fAGP	O
+)	O
+increases	O
+during	O
+feline	B-DISO
+infectious	I-DISO
+peritonitis	I-DISO
+(	O
+FIP	B-DISO
+).	O
+
+Compared	O
+to	O
+controls	O
+,	O
+fAGPrP	O
+-	O
+expressing	O
+cells	B-COMP
+often	O
+increased	O
+in	O
+number	O
+and	O
+were	O
+diffusely	O
+distributed	O
+in	O
+lymph	B-ANAT
+nodes	I-ANAT
+,	O
+as	O
+usually	O
+occurs	O
+for	O
+IgM	B-PRGE
+-	O
+producing	O
+plasma	B-ANAT
+cells	I-ANAT
+during	O
+early	O
+immune	B-PROC
+responses	I-PROC
+.	O
+
+In	O
+our	O
+study	O
+,	O
+we	O
+report	O
+the	O
+construction	O
+of	O
+another	O
+poxvirus	B-SPEC
+,	O
+the	O
+modified	O
+vaccinia	B-SPEC
+virus	I-SPEC
+Ankara	O
+(	O
+MVA	B-CHED
+),	O
+as	O
+an	O
+expression	B-PROC
+vector	O
+for	O
+the	O
+FIPV	O
+M	O
+protein	B-CHED
+.	O
+
+The	O
+vaccine	O
+was	O
+then	O
+tested	O
+in	O
+cats	B-SPEC
+to	O
+evaluate	O
+its	O
+efficacy	O
+in	O
+an	O
+FIPV	O
+79	O
+-	O
+1146	O
+challenge	O
+.	O
+
+Vaccinated	O
+kittens	O
+developed	O
+FIPV	O
+-	O
+specific	O
+antibodies	B-COMP
+after	O
+immunization	O
+,	O
+however	O
+,	O
+none	O
+of	O
+them	O
+was	O
+protected	O
+against	O
+FIPV	O
+.	O
+
+Replication	O
+-	O
+incompetent	O
+feline	B-SPEC
+foamy	I-SPEC
+virus	I-SPEC
+(	O
+FFV	O
+)	O
+transducing	O
+vectors	O
+are	O
+being	O
+developed	O
+as	O
+potential	O
+vaccine	O
+agents	O
+,	O
+into	O
+which	O
+immunogenic	O
+fragments	O
+of	O
+feline	B-SPEC
+coronavirus	B-SPEC
+(	O
+FCoV	O
+)	O
+proteins	B-CHED
+will	O
+be	O
+inserted	O
+.	O
+
+Highly	O
+conserved	O
+heptad	O
+repeat	O
+1	O
+(	O
+HR1	O
+)	O
+and	O
+HR2	O
+regions	O
+in	O
+coronavirus	B-SPEC
+spike	O
+proteins	B-CHED
+indicate	O
+a	O
+similar	O
+three	O
+-	O
+dimensional	O
+structure	O
+among	O
+these	O
+fusion	O
+cores	O
+and	O
+common	O
+mechanisms	O
+for	O
+the	O
+viral	O
+fusion	O
+.	O
+
+ABSTRACT	O
+:	O
+Postinfectious	O
+proliferative	O
+glomerulonephritis	O
+may	O
+occur	O
+in	O
+HIV	B-DISO
+-	O
+infected	O
+patients	O
+,	O
+although	O
+it	O
+is	O
+not	O
+a	O
+common	O
+cause	O
+of	O
+severe	O
+acute	B-DISO
+renal	I-DISO
+failure	I-DISO
+in	O
+them	O
+.	O
+
+No	O
+opportunistic	B-DISO
+infections	I-DISO
+have	O
+occurred	O
+during	O
+1	O
+-	O
+year	O
+follow	O
+-	O
+up	O
+.	O
+
+The	O
+development	B-PROC
+of	O
+venous	B-DISO
+thrombosis	I-DISO
+was	O
+likely	O
+to	O
+have	O
+been	O
+multifactorial	O
+.	O
+
+It	O
+is	O
+recognized	O
+that	O
+there	O
+is	O
+an	O
+increased	O
+incidence	O
+of	O
+congenital	O
+lymphatic	B-ANAT
+anomalies	O
+in	O
+Down	B-DISO
+syndrome	I-DISO
+,	O
+which	O
+may	O
+have	O
+been	O
+a	O
+contributing	O
+factor	O
+in	O
+the	O
+development	B-PROC
+of	O
+chylothorax	B-DISO
+in	O
+this	O
+patient	O
+.	O
+
+TITLE	O
+:	O
+Aerosols	O
+and	O
+splatter	O
+in	O
+dentistry	O
+:	O
+a	O
+brief	O
+review	O
+of	O
+the	O
+literature	O
+and	O
+infection	B-DISO
+control	O
+implications	O
+.	O
+
+The	O
+literature	O
+also	O
+documents	O
+that	O
+airborne	O
+contamination	O
+can	O
+be	O
+minimized	O
+easily	O
+and	O
+inexpensively	O
+by	O
+layering	O
+several	O
+infection	B-DISO
+control	O
+steps	O
+into	O
+the	O
+routine	O
+precautions	O
+used	O
+during	O
+all	O
+dental	O
+procedures	O
+.	O
+
+The	O
+aetiological	O
+diagnosis	O
+by	O
+infective	O
+agent	O
+is	O
+as	O
+follows	O
+:	O
+150	O
+patients	O
+(	O
+25	O
+.	O
+2	O
+%)	O
+had	O
+virus	O
+infections	B-DISO
+,	O
+of	O
+which	O
+90	O
+.	O
+7	O
+%	O
+(	O
+136	O
+/	O
+150	O
+)	O
+were	O
+by	O
+rhinovirus	B-SPEC
+.	O
+
+The	O
+occurrence	O
+of	O
+dyspnea	B-DISO
+,	O
+malaise	B-DISO
+and	O
+gastrointestinal	B-DISO
+symptom	I-DISO
+were	O
+more	O
+often	O
+in	O
+SARS	B-DISO
+patient	O
+than	O
+in	O
+non	O
+-	O
+SARS	B-DISO
+patients	O
+.	O
+
+40	O
+of	O
+51	O
+patients	O
+with	O
+lung	B-ANAT
+diffusion	O
+abnormity	O
+showed	O
+lung	B-DISO
+fibrosis	I-DISO
+,	O
+and	O
+the	O
+fibrosis	B-DISO
+decreased	O
+in	O
+55	O
+%	O
+patients	O
+(	O
+22	O
+of	O
+40	O
+patients	O
+)	O
+after	O
+one	O
+month	O
+.	O
+
+40	O
+of	O
+51	O
+patients	O
+with	O
+lung	B-ANAT
+diffusion	O
+abnormity	O
+showed	O
+lung	B-DISO
+fibrosis	I-DISO
+,	O
+and	O
+the	O
+fibrosis	B-DISO
+decreased	O
+in	O
+55	O
+%	O
+patients	O
+(	O
+22	O
+of	O
+40	O
+patients	O
+)	O
+after	O
+one	O
+month	O
+.	O
+
+ABSTRACT	O
+:	O
+To	O
+study	O
+severe	O
+acute	O
+respiratory	O
+syndrome	O
+(	O
+SARS	B-DISO
+)	O
+covert	O
+infection	B-DISO
+in	O
+health	O
+-	O
+care	O
+professionals	O
+and	O
+its	O
+relation	O
+to	O
+work	O
+intensity	O
+and	O
+type	O
+of	O
+work	O
+.	O
+
+Medical	O
+examination	O
+was	O
+also	O
+carried	O
+out	O
+for	O
+313	O
+people	O
+who	O
+had	O
+close	O
+contact	O
+with	O
+the	O
+29	O
+antibody	B-FUNC
+positive	O
+health	O
+care	O
+professionals	O
+,	O
+but	O
+no	O
+clinical	O
+SARS	B-DISO
+was	O
+found	O
+.	O
+
+TITLE	O
+:	O
+Development	B-PROC
+and	O
+evaluation	O
+of	O
+a	O
+novel	O
+loop	O
+-	O
+mediated	O
+isothermal	O
+amplification	B-DISO
+method	O
+for	O
+rapid	O
+detection	O
+of	O
+severe	O
+acute	O
+respiratory	O
+syndrome	O
+coronavirus	B-SPEC
+.	O
+
+The	O
+concentration	O
+of	O
+virus	B-SPEC
+in	O
+most	O
+of	O
+the	O
+clinical	O
+samples	O
+was	O
+0	O
+.	O
+1	O
+PFU	B-CHED
+(	O
+0	O
+.	O
+1	O
+to	O
+10	O
+(	O
+2	O
+)	O
+PFU	B-CHED
+),	O
+as	O
+determined	O
+from	O
+the	O
+standard	O
+curve	O
+of	O
+SARS	B-DISO
+RT	O
+-	O
+LAMP	O
+and	O
+based	O
+on	O
+the	O
+time	O
+of	O
+positivity	O
+.	O
+
+ABSTRACT	O
+:	O
+Recent	O
+outbreaks	O
+of	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+(	O
+SARS	B-DISO
+)	O
+have	O
+spurred	O
+intense	O
+research	O
+efforts	O
+around	O
+the	O
+world	O
+to	O
+deal	O
+with	O
+the	O
+serious	O
+threat	O
+to	O
+health	O
+posed	O
+by	O
+this	O
+novel	B-SPEC
+coronavirus	I-SPEC
+.	O
+
+Samples	O
+were	O
+analyzed	O
+by	O
+a	O
+reverse	B-PRGE
+transcriptase	I-PRGE
+PCR	O
+assay	O
+.	O
+
+Northern	O
+blot	O
+analysis	O
+was	O
+performed	O
+to	O
+demonstrate	O
+differences	O
+in	O
+subgenomic	O
+transcripts	O
+of	O
+the	O
+virus	B-SPEC
+,	O
+and	O
+a	O
+real	O
+-	O
+time	O
+quantitative	O
+PCR	O
+was	O
+employed	O
+to	O
+compare	O
+the	O
+sensitivities	O
+of	O
+two	O
+loci	O
+(	O
+1b	O
+and	O
+N	O
+).	O
+
+In	O
+conclusion	O
+,	O
+the	O
+nucleocapsid	B-COMP
+gene	O
+represents	O
+an	O
+additional	O
+sensitive	O
+molecular	O
+marker	O
+for	O
+the	O
+diagnosis	O
+of	O
+the	O
+SARS	B-DISO
+coronavirus	B-SPEC
+and	O
+can	O
+be	O
+further	O
+adapted	O
+for	O
+use	O
+in	O
+a	O
+high	O
+-	O
+throughput	O
+platform	O
+assay	O
+.	O
+
+The	O
+kits	O
+achieved	O
+sensitivities	O
+of	O
+70	O
+.	O
+8	O
+%	O
+(	O
+Artus	O
+)	O
+and	O
+67	O
+.	O
+1	O
+%	O
+(	O
+Roche	O
+)	O
+in	O
+66	O
+specimens	O
+from	O
+patients	O
+with	O
+confirmed	O
+SARS	B-DISO
+(	O
+samples	O
+primarily	O
+from	O
+the	O
+upper	O
+and	O
+lower	B-ANAT
+respiratory	I-ANAT
+tract	I-ANAT
+and	O
+stool	B-ANAT
+).	O
+
+Culture	O
+cells	O
+initially	O
+contained	O
+five	O
+times	O
+more	O
+N	O
+-	O
+than	O
+R	O
+-	O
+gene	O
+RNA	O
+,	O
+but	O
+the	O
+respective	O
+levels	O
+converged	O
+during	O
+4	O
+days	O
+of	O
+virus	B-PROC
+replication	I-PROC
+.	O
+
+ABSTRACT	O
+:	O
+To	O
+study	O
+the	O
+changes	O
+in	O
+liver	B-ANAT
+function	I-PROC
+and	O
+histopathology	O
+,	O
+and	O
+investigate	O
+the	O
+underlying	O
+mechanism	O
+and	O
+clinical	O
+significance	O
+of	O
+damage	O
+of	O
+liver	B-ANAT
+in	O
+patients	O
+with	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+(	O
+SARS	B-DISO
+).	O
+
+According	O
+the	O
+clinical	O
+diagnostic	O
+standard	O
+of	O
+atypical	B-DISO
+pneumonia	I-DISO
+of	O
+Ministry	O
+of	O
+Health	O
+P	O
+.	O
+R	O
+.	O
+China	O
+,	O
+liver	B-PROC
+function	I-PROC
+was	O
+assessed	O
+in	O
+110	O
+SARS	B-DISO
+patients	O
+admitted	O
+from	O
+February	O
+2003	O
+to	O
+June	O
+2003	O
+.	O
+
+Direct	O
+reaction	O
+bilirubin	B-CHED
+(	O
+DBil	O
+),	O
+total	O
+bile	B-CHED
+acid	I-CHED
+(	O
+TBA	O
+),	O
+gamma	B-PRGE
+-	I-PRGE
+glutamyltransferase	I-PRGE
+(	O
+GGT	B-PRGE
+)	O
+and	O
+alkaline	B-PRGE
+phosphatase	I-PRGE
+(	O
+ALP	B-PRGE
+)	O
+showed	O
+no	O
+marked	O
+difference	O
+between	O
+SARS	B-DISO
+patients	O
+and	O
+controls	O
+,	O
+all	O
+P	O
+>	O
+0	O
+.	O
+05	O
+.	O
+
+CONCLUSIONS	O
+:	O
+The	O
+patients	O
+with	O
+SARS	B-DISO
+are	O
+prone	O
+to	O
+have	O
+mild	O
+non	O
+-	O
+specific	O
+hepatitis	B-DISO
+.	O
+
+ABSTRACT	O
+:	O
+To	O
+analyze	O
+relation	O
+between	O
+the	O
+use	O
+of	O
+corticosteroids	B-CHED
+in	O
+the	O
+treatment	O
+for	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+(	O
+SARS	B-DISO
+)	O
+patients	O
+and	O
+arthralgia	B-DISO
+as	O
+a	O
+sequela	O
+.	O
+
+The	O
+degree	O
+of	O
+arthralgia	B-DISO
+was	O
+only	O
+correlated	O
+with	O
+the	O
+total	O
+dosage	O
+,	O
+and	O
+the	O
+duration	O
+of	O
+arthralgia	B-DISO
+was	O
+correlated	O
+with	O
+administration	O
+time	O
+of	O
+glucocorticosteroids	O
+by	O
+multifactor	O
+analysis	O
+.	O
+
+CONCLUSIONS	O
+:	O
+There	O
+is	O
+a	O
+dosage	O
+-	O
+effect	O
+relation	O
+between	O
+the	O
+degree	O
+of	O
+arthralgia	B-DISO
+and	O
+the	O
+total	O
+dosage	O
+of	O
+corticosteroid	B-CHED
+,	O
+and	O
+a	O
+time	O
+-	O
+effect	O
+relation	O
+between	O
+the	O
+duration	O
+of	O
+arthralgia	B-DISO
+and	O
+length	O
+of	O
+the	O
+use	O
+of	O
+corticosteroids	B-CHED
+.	O
+
+ABSTRACT	O
+:	O
+To	O
+analyze	O
+the	O
+clinical	O
+data	O
+of	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+(	O
+SARS	B-DISO
+)	O
+patients	O
+with	O
+pneumothorax	B-DISO
+and	O
+mediastinal	B-DISO
+emphysema	I-DISO
+occurring	O
+after	O
+the	O
+non	O
+-	O
+invasive	O
+positive	O
+pressure	O
+ventilation	O
+(	O
+NIPPV	O
+),	O
+and	O
+to	O
+inquire	O
+into	O
+relevant	O
+strategy	O
+in	O
+respiratory	O
+treatment	O
+in	O
+the	O
+SARS	B-DISO
+patients	O
+.	O
+
+The	O
+pneumothorax	B-DISO
+and	O
+mediastinal	B-DISO
+emphysema	I-DISO
+improve	O
+gradually	O
+in	O
+all	O
+cases	O
+after	O
+reasonable	O
+adjustment	O
+of	O
+mechanical	O
+ventilative	O
+pressure	O
+.	O
+
+Seven	O
+cases	O
+of	O
+pneumothorax	B-DISO
+and	O
+mediastinal	B-DISO
+emphysema	I-DISO
+improved	O
+gradually	O
+.	O
+
+TITLE	O
+:	O
+[	O
+Study	O
+on	O
+the	O
+correlation	O
+between	O
+positive	O
+rates	O
+of	O
+SARS	B-DISO
+RNA	O
+in	O
+clinical	O
+confirmed	O
+SARS	B-DISO
+patients	O
+and	O
+the	O
+appearance	O
+of	O
+RNA	O
+in	O
+relation	O
+to	O
+the	O
+development	O
+of	O
+the	O
+disease	O
+].	O
+
+The	O
+fragments	O
+amplified	O
+from	O
+the	O
+sputum	B-ANAT
+specimens	O
+of	O
+SARS	B-DISO
+patients	O
+were	O
+shown	O
+to	O
+share	O
+100	O
+%	O
+homology	O
+with	O
+the	O
+published	O
+SARS	B-DISO
+-	I-DISO
+associated	I-DISO
+coronavirus	B-SPEC
+.	O
+
+CONCLUSIONS	O
+:	O
+One	O
+-	O
+step	O
+RT	O
+-	O
+PCR	O
+proved	O
+to	O
+be	O
+an	O
+effective	O
+method	O
+for	O
+the	O
+detection	O
+of	O
+SARS	B-DISO
+-	I-DISO
+associated	I-DISO
+coronavirus	I-DISO
+from	O
+clinical	O
+specimens	O
+.	O
+
+Using	O
+flow	O
+cytometry	O
+,	O
+the	O
+absolute	O
+numbers	O
+of	O
+peripheral	B-ANAT
+blood	I-ANAT
+lymphocytes	B-ANAT
+and	O
+their	O
+subpopulations	O
+in	O
+240	O
+SARS	B-DISO
+patients	O
+(	O
+696	O
+specimens	O
+)	O
+and	O
+51	O
+individuals	O
+as	O
+controls	O
+,	O
+were	O
+counted	O
+and	O
+compared	O
+.	O
+
+RESULTS	O
+:	O
+The	O
+absolute	O
+numbers	O
+of	O
+peripheral	B-ANAT
+blood	I-ANAT
+lymphocytes	B-ANAT
+and	O
+their	O
+subpopulations	O
+(	O
+CD45	B-PRGE
+,	O
+CD3	B-PRGE
+,	O
+CD4	B-PRGE
+,	O
+CD8	B-PRGE
+)	O
+were	O
+1298	O
++/-	O
+
+ABSTRACT	O
+:	O
+A	O
+novel	O
+coronavirus	O
+,	O
+SARS	B-DISO
+-	O
+CoV	O
+,	O
+has	O
+been	O
+confirmed	O
+to	O
+be	O
+the	O
+aetiological	O
+agent	O
+of	O
+SARS	B-DISO
+.	O
+
+Expression	B-PROC
+of	O
+SARS	B-PRGE
+protein	B-CHED
+3a	I-PRGE
+was	O
+detected	O
+at	O
+8	O
+-	O
+12	O
+h	O
+after	O
+infection	B-DISO
+and	O
+reached	O
+a	O
+higher	O
+level	O
+after	O
+approximately	O
+24	O
+h	O
+in	O
+SARS	B-DISO
+-	O
+CoV	O
+-	O
+infected	O
+Vero	O
+E6	O
+cells	B-COMP
+.	O
+
+Interferons	O
+are	O
+cytokines	O
+which	O
+induce	O
+the	O
+synthesis	B-PROC
+of	O
+several	O
+antivirally	O
+active	O
+proteins	B-CHED
+in	O
+the	O
+cell	B-COMP
+.	O
+
+TITLE	O
+:	O
+A	O
+one	O
+step	O
+quantitative	O
+RT	O
+-	O
+PCR	O
+for	O
+detection	O
+of	O
+SARS	B-DISO
+coronavirus	B-SPEC
+with	O
+an	O
+internal	O
+control	O
+for	O
+PCR	O
+inhibitors	O
+.	O
+
+This	O
+study	O
+presents	O
+a	O
+purification	O
+method	O
+for	O
+feline	B-SPEC
+AGP	O
+(	O
+fAGP	O
+)	O
+from	O
+serum	B-COMP
+,	O
+using	O
+an	O
+ion	B-PROC
+exchange	I-PROC
+chromatography	O
+strategy	O
+.	O
+
+In	O
+contrast	O
+,	O
+during	O
+FIP	B-DISO
+disease	O
+,	O
+fAGP	O
+underwent	O
+several	O
+modifications	O
+in	O
+the	O
+sialic	B-CHED
+acid	I-CHED
+content	O
+,	O
+including	O
+decreased	O
+expression	B-PROC
+of	O
+both	O
+alpha	O
+(	O
+2	O
+-	O
+6	O
+)-	O
+linked	O
+and	O
+alpha	O
+(	O
+2	O
+-	O
+3	O
+)-	O
+linked	O
+sialic	B-CHED
+acid	I-CHED
+(	O
+76	O
+and	O
+44	O
+%,	O
+respectively	O
+when	O
+compared	O
+to	O
+non	O
+-	O
+pathological	O
+feline	B-SPEC
+AGP	O
+).	O
+
+A	O
+47	O
+year	O
+old	O
+patient	O
+with	O
+progression	O
+of	O
+multiple	B-DISO
+myeloma	I-DISO
+after	O
+standard	O
+therapy	O
+received	O
+an	O
+allogeneic	O
+marrow	O
+graft	B-ANAT
+from	O
+a	O
+matched	O
+unrelated	O
+donor	B-CHED
+.	O
+
+The	O
+emphasis	O
+in	O
+traditional	O
+Chinese	O
+medicine	B-CHED
+is	O
+on	O
+primary	O
+and	O
+tertiary	O
+prevention	O
+.	O
+
+The	O
+effect	O
+of	O
+these	O
+viruses	B-SPEC
+on	O
+hyena	B-SPEC
+health	O
+should	O
+be	O
+further	O
+investigated	O
+.	O
+
+TITLE	O
+:	O
+Exposure	O
+to	O
+feline	B-SPEC
+and	O
+canine	O
+pathogens	O
+in	O
+bobcats	B-SPEC
+and	O
+gray	O
+foxes	O
+in	O
+urban	O
+and	O
+rural	O
+zones	O
+of	O
+a	O
+national	O
+park	O
+in	O
+California	B-SPEC
+.	O
+
+Antibodies	B-COMP
+against	O
+CDV	B-CHED
+were	O
+detected	O
+in	O
+cheetahs	B-SPEC
+of	O
+all	O
+ages	O
+sampled	O
+between	O
+1995	O
+and	O
+1998	O
+,	O
+suggesting	O
+the	O
+occurrence	O
+of	O
+an	O
+epidemic	O
+in	O
+Namibia	B-SPEC
+during	O
+the	O
+time	O
+when	O
+CDV	B-CHED
+swept	O
+through	O
+other	O
+parts	O
+of	O
+sub	O
+-	O
+Saharan	O
+Africa	O
+.	O
+
+The	O
+management	O
+principles	O
+are	O
+broadly	O
+similar	O
+to	O
+treating	O
+any	O
+community	B-DISO
+acquired	I-DISO
+pneumonia	I-DISO
+but	O
+the	O
+infection	B-DISO
+control	O
+measures	O
+take	O
+a	O
+pivotal	O
+role	O
+.	O
+
+The	O
+immunogenicity	O
+of	O
+all	O
+these	O
+peptides	B-CHED
+was	O
+assessed	O
+by	O
+using	O
+T	B-ANAT
+cells	I-ANAT
+obtained	O
+from	O
+donors	O
+who	O
+had	O
+fully	O
+recovered	O
+from	O
+SARS	B-DISO
+-	I-DISO
+CoV	I-DISO
+infection	I-DISO
+and	O
+from	O
+healthy	O
+donors	O
+with	O
+no	O
+history	O
+of	O
+SARS	B-DISO
+-	I-DISO
+CoV	I-DISO
+infection	I-DISO
+.	O
+
+Coronavirus	B-SPEC
+replication	O
+and	O
+transcription	B-PROC
+are	O
+highly	O
+specialized	O
+processes	O
+of	O
+cytoplasmic	B-COMP
+RNA	B-PROC
+synthesis	I-PROC
+that	O
+localize	O
+to	O
+virus	B-SPEC
+-	O
+induced	O
+membrane	B-COMP
+structures	O
+and	O
+were	O
+recently	O
+proposed	O
+to	O
+involve	O
+a	O
+complex	O
+enzymatic	O
+machinery	O
+that	O
+,	O
+besides	O
+RNA	B-PRGE
+-	I-PRGE
+dependent	I-PRGE
+RNA	I-PRGE
+polymerase	I-PRGE
+,	O
+helicase	B-PRGE
+,	O
+and	O
+protease	O
+activities	O
+,	O
+also	O
+involves	O
+a	O
+series	O
+of	O
+RNA	O
+-	O
+processing	O
+enzymes	O
+that	O
+are	O
+not	O
+found	O
+in	O
+most	O
+other	O
+RNA	O
+virus	B-SPEC
+families	O
+.	O
+
+The	O
+data	O
+suggest	O
+that	O
+the	O
+(	O
+d	O
+)	O
+NTPase	B-PRGE
+and	O
+RNA	B-PRGE
+5	I-PRGE
+'-	I-PRGE
+triphosphatase	I-PRGE
+activities	O
+of	O
+nsp13	O
+have	O
+a	O
+common	O
+active	O
+site	O
+.	O
+
+ABSTRACT	O
+:	O
+The	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+coronavirus	B-SPEC
+(	O
+SARS	B-DISO
+-	O
+CoV	O
+)	O
+synthesizes	O
+several	O
+putative	O
+viral	B-PRGE
+envelope	I-PRGE
+proteins	B-CHED
+,	O
+including	O
+the	O
+spike	O
+(	O
+S	O
+),	O
+membrane	B-COMP
+(	O
+M	O
+),	O
+and	O
+small	B-PRGE
+envelope	I-PRGE
+(	I-PRGE
+E	I-PRGE
+)	I-PRGE
+glycoproteins	B-CHED
+.	O
+
+Although	O
+these	O
+proteins	B-CHED
+likely	O
+are	O
+essential	O
+for	O
+viral	B-PROC
+replication	I-PROC
+,	O
+their	O
+specific	O
+roles	O
+in	O
+SARS	B-DISO
+-	O
+CoV	O
+entry	O
+have	O
+not	O
+been	O
+defined	O
+.	O
+
+MHV	B-SPEC
+infection	B-DISO
+in	O
+quiescent	O
+17Cl	B-CHED
+-	O
+1	O
+cells	B-COMP
+prevented	O
+normal	O
+increases	O
+in	O
+Cdk4	B-PRGE
+,	O
+Cdk6	B-PRGE
+,	O
+cyclin	B-PRGE
+D1	I-PRGE
+,	O
+and	O
+cyclin	B-PRGE
+D3	I-PRGE
+levels	O
+after	O
+serum	B-COMP
+stimulation	O
+.	O
+
+Inhibition	B-PROC
+of	O
+virus	B-SPEC
+infectivity	O
+by	O
+peptide	B-CHED
+-	O
+conjugated	O
+morpholino	O
+was	O
+comparable	O
+to	O
+the	O
+antiviral	B-CHED
+activity	O
+of	O
+the	O
+aminoglycoside	B-CHED
+hygromycin	B-CHED
+B	I-CHED
+used	O
+at	O
+a	O
+concentration	O
+fivefold	O
+higher	O
+than	O
+the	O
+oligomer	O
+.	O
+
+Here	O
+we	O
+demonstrate	O
+that	O
+the	O
+spike	O
+(	O
+S	O
+)	O
+protein	B-CHED
+from	O
+the	O
+group	O
+3	O
+coronavirus	B-SPEC
+infectious	B-DISO
+bronchitis	B-DISO
+virus	B-SPEC
+(	O
+IBV	B-SPEC
+)	O
+contains	O
+a	O
+canonical	O
+dilysine	O
+endoplasmic	B-COMP
+reticulum	I-COMP
+retrieval	O
+signal	O
+(-	O
+KKXX	O
+-	O
+COOH	O
+)	O
+in	O
+its	O
+cytoplasmic	B-ANAT
+tail	I-ANAT
+.	O
+
+This	O
+signal	O
+can	O
+retain	O
+a	O
+chimeric	O
+reporter	O
+protein	B-CHED
+in	O
+the	O
+ERGIC	B-COMP
+and	O
+when	O
+mutated	O
+allows	O
+transport	B-PROC
+of	O
+the	O
+full	O
+-	O
+length	O
+S	B-PRGE
+protein	I-PRGE
+as	O
+well	O
+as	O
+the	O
+chimera	B-DISO
+to	O
+the	O
+plasma	B-COMP
+membrane	I-COMP
+.	O
+
+TITLE	O
+:	O
+Cleavage	B-PROC
+between	O
+replicase	B-PRGE
+proteins	B-CHED
+p28	B-COMP
+and	O
+p65	B-PRGE
+of	O
+mouse	B-DISO
+hepatitis	I-DISO
+virus	B-SPEC
+is	O
+not	O
+required	O
+for	O
+virus	O
+replication	O
+.	O
+
+Cleavage	B-PROC
+between	O
+p28	B-COMP
+and	O
+p65	B-PRGE
+has	O
+been	O
+shown	O
+to	O
+occur	O
+in	O
+vitro	O
+at	O
+cleavage	B-PROC
+site	O
+1	O
+(	O
+CS1	O
+),	O
+(	O
+247	O
+)	O
+Gly	B-CHED
+downward	O
+arrow	O
+Val	B-CHED
+(	O
+248	O
+),	O
+in	O
+the	O
+polyprotein	O
+.	O
+
+TITLE	O
+:	O
+Cleavage	B-PROC
+inhibition	B-PROC
+of	O
+the	O
+murine	B-PRGE
+coronavirus	I-PRGE
+spike	I-PRGE
+protein	B-CHED
+by	O
+a	O
+furin	B-PRGE
+-	I-PRGE
+like	I-PRGE
+enzyme	I-PRGE
+affects	O
+cell	B-ANAT
+-	O
+cell	B-COMP
+but	O
+not	O
+virus	B-SPEC
+-	O
+cell	B-PROC
+fusion	I-PROC
+.	O
+
+ABSTRACT	O
+:	O
+We	O
+previously	O
+identified	O
+the	O
+major	O
+pathological	O
+changes	O
+in	O
+the	O
+respiratory	O
+and	O
+immune	B-ANAT
+systems	I-ANAT
+of	O
+patients	O
+who	O
+died	B-PROC
+of	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+(	O
+SARS	B-DISO
+)	O
+but	O
+gained	O
+little	O
+information	O
+on	O
+the	O
+organ	B-ANAT
+distribution	O
+of	O
+SARS	B-DISO
+-	I-DISO
+associated	I-DISO
+coronavirus	I-DISO
+(	O
+SARS	B-DISO
+-	O
+CoV	O
+).	O
+
+TITLE	O
+:	O
+Tissue	B-ANAT
+distribution	O
+of	O
+ACE2	B-PRGE
+protein	I-PRGE
+,	O
+the	O
+functional	O
+receptor	O
+for	O
+SARS	B-DISO
+coronavirus	B-SPEC
+.	O
+
+A	O
+distinct	O
+coronavirus	B-SPEC
+(	O
+SARS	B-DISO
+-	O
+CoV	O
+)	O
+has	O
+been	O
+identified	O
+as	O
+the	O
+aetiological	O
+agent	O
+of	O
+SARS	B-DISO
+.	O
+
+Recently	O
+,	O
+a	O
+metallopeptidase	B-PRGE
+named	O
+angiotensin	B-PRGE
+-	I-PRGE
+converting	I-PRGE
+enzyme	I-PRGE
+2	I-PRGE
+(	O
+ACE2	B-PRGE
+)	O
+has	O
+been	O
+identified	O
+as	O
+the	O
+functional	O
+receptor	O
+for	O
+SARS	B-PRGE
+-	I-PRGE
+CoV	I-PRGE
+.	O
+Although	O
+ACE2	B-PRGE
+mRNA	I-PRGE
+is	O
+known	O
+to	O
+be	O
+present	O
+in	O
+virtually	O
+all	O
+organs	B-ANAT
+,	O
+its	O
+protein	B-PROC
+expression	B-PROC
+is	O
+largely	O
+unknown	O
+.	O
+
+Since	O
+identifying	O
+the	O
+possible	O
+route	O
+of	O
+infection	B-DISO
+has	O
+major	O
+implications	O
+for	O
+understanding	O
+the	O
+pathogenesis	B-DISO
+and	O
+future	O
+treatment	O
+strategies	O
+for	O
+SARS	B-DISO
+,	O
+the	O
+present	O
+study	O
+investigated	O
+the	O
+localization	B-PROC
+of	O
+ACE2	B-PRGE
+protein	I-PRGE
+in	O
+various	O
+human	B-SPEC
+organs	B-ANAT
+(	O
+oral	B-ANAT
+and	O
+nasal	B-ANAT
+mucosa	I-ANAT
+,	O
+nasopharynx	B-ANAT
+,	O
+lung	B-ANAT
+,	O
+stomach	B-ANAT
+,	O
+small	B-ANAT
+intestine	I-ANAT
+,	O
+colon	B-ANAT
+,	O
+skin	B-ANAT
+,	O
+lymph	B-ANAT
+nodes	I-ANAT
+,	O
+thymus	B-SPEC
+,	O
+bone	B-ANAT
+marrow	I-ANAT
+,	O
+spleen	B-ANAT
+,	O
+liver	B-ANAT
+,	O
+kidney	B-ANAT
+,	O
+and	O
+brain	B-ANAT
+).	O
+
+In	O
+conclusion	O
+,	O
+ACE2	B-PRGE
+is	O
+abundantly	O
+present	O
+in	O
+humans	B-SPEC
+in	O
+the	O
+epithelia	O
+of	O
+the	O
+lung	B-ANAT
+and	O
+small	B-ANAT
+intestine	I-ANAT
+,	O
+which	O
+might	O
+provide	O
+possible	O
+routes	O
+of	O
+entry	O
+for	O
+the	O
+SARS	B-DISO
+-	O
+CoV	O
+.	O
+This	O
+epithelial	O
+expression	B-PROC
+,	O
+together	O
+with	O
+the	O
+presence	O
+of	O
+ACE2	B-PRGE
+in	O
+vascular	B-ANAT
+endothelium	I-ANAT
+,	O
+also	O
+provides	O
+a	O
+first	O
+step	O
+in	O
+understanding	O
+the	O
+pathogenesis	B-DISO
+of	O
+the	O
+main	O
+SARS	B-DISO
+disease	O
+manifestations	O
+.	O
+
+Whether	O
+outbreaks	O
+of	O
+SARS	B-DISO
+will	O
+return	O
+is	O
+debatable	O
+,	O
+but	O
+no	O
+one	O
+disagrees	O
+that	O
+it	O
+is	O
+important	O
+to	O
+be	O
+prepared	O
+for	O
+this	O
+possibility	O
+.	O
+
+ABSTRACT	O
+:	O
+Approximately	O
+20	O
+%	O
+of	O
+patients	O
+with	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+(	O
+SARS	B-DISO
+)	O
+develop	O
+respiratory	B-DISO
+failure	I-DISO
+that	O
+requires	O
+admission	O
+to	O
+an	O
+intensive	O
+care	O
+unit	O
+(	O
+ICU	O
+).	O
+
+Many	O
+procedures	O
+in	O
+ICUs	O
+pose	O
+a	O
+high	O
+risk	O
+for	O
+transmission	O
+of	O
+SARS	B-DISO
+coronavirus	B-SPEC
+to	O
+health	O
+care	O
+workers	O
+.	O
+
+TITLE	O
+:	O
+Remyelination	B-PROC
+,	O
+axonal	O
+sparing	O
+,	O
+and	O
+locomotor	O
+recovery	O
+following	O
+transplantation	O
+of	O
+glial	B-ANAT
+-	O
+committed	O
+progenitor	O
+cells	O
+into	O
+the	O
+MHV	B-SPEC
+model	O
+of	O
+multiple	B-DISO
+sclerosis	I-DISO
+.	O
+
+Transplantation	O
+of	O
+glial	B-ANAT
+-	O
+committed	O
+progenitor	B-ANAT
+cells	I-ANAT
+into	O
+the	O
+T8	O
+spinal	B-ANAT
+cord	I-ANAT
+of	O
+MHV	B-SPEC
+-	O
+infected	O
+mice	B-SPEC
+demonstrating	O
+complete	O
+hindlimb	B-ANAT
+paralysis	O
+resulted	O
+in	O
+migration	B-PROC
+of	O
+cells	B-COMP
+up	O
+to	O
+12	O
+mm	O
+from	O
+the	O
+implantation	B-PROC
+site	O
+and	O
+remyelination	B-PROC
+of	O
+up	O
+to	O
+67	O
+%	O
+of	O
+axons	B-COMP
+.	O
+
+TITLE	O
+:	O
+HIV	B-SPEC
+protease	I-CHED
+inhibitor	I-CHED
+nelfinavir	O
+inhibits	O
+replication	O
+of	O
+SARS	B-DISO
+-	I-DISO
+associated	I-DISO
+coronavirus	I-DISO
+.	O
+
+The	O
+protein	B-CHED
+consists	O
+of	O
+a	O
+five	O
+-	O
+stranded	O
+beta	B-ANAT
+sheet	I-ANAT
+with	O
+a	O
+folding	O
+topology	O
+distinct	O
+from	O
+other	O
+RNA	B-PRGE
+-	I-PRGE
+binding	I-PRGE
+proteins	B-CHED
+.	O
+
+This	O
+makes	O
+finding	O
+the	O
+tight	O
+inhibitor	B-CHED
+(	O
+nanomolar	O
+range	O
+IC50	O
+)	O
+impossible	O
+.	O
+
+The	O
+purpose	O
+of	O
+this	O
+study	O
+was	O
+to	O
+describe	O
+the	O
+radiographic	O
+findings	O
+and	O
+evolution	O
+of	O
+round	O
+pneumonia	B-DISO
+found	O
+in	O
+eight	O
+patients	O
+with	O
+confirmed	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+(	O
+SARS	B-DISO
+).	O
+
+Although	O
+most	O
+respondents	O
+knew	O
+of	O
+SARS	B-DISO
+,	O
+there	O
+was	O
+still	O
+8	O
+.	O
+4	O
+%	O
+who	O
+did	O
+not	O
+know	O
+about	O
+it	O
+.	O
+
+Their	O
+efficacy	O
+was	O
+,	O
+however	O
+,	O
+significantly	O
+lower	O
+than	O
+that	O
+of	O
+corresponding	O
+HR2	O
+peptides	B-CHED
+of	O
+the	O
+murine	B-SPEC
+coronavirus	I-SPEC
+mouse	B-DISO
+hepatitis	I-DISO
+virus	B-SPEC
+(	O
+MHV	B-SPEC
+)	O
+in	O
+inhibiting	O
+MHV	B-SPEC
+infection	B-DISO
+.	O
+
+ABSTRACT	O
+:	O
+The	O
+effect	O
+of	O
+storage	B-PROC
+temperature	O
+was	O
+determined	O
+for	O
+the	O
+detection	O
+of	O
+porcine	B-SPEC
+epidemic	I-SPEC
+diarrhea	I-SPEC
+virus	I-SPEC
+(	O
+PEDV	B-SPEC
+)	O
+and	O
+transmissible	O
+gastroenteritis	B-DISO
+virus	B-SPEC
+(	O
+TGEV	B-SPEC
+)	O
+in	O
+fecal	B-ANAT
+samples	O
+from	O
+experimentally	O
+and	O
+naturally	O
+infected	O
+pigs	B-SPEC
+by	O
+multiplex	O
+reverse	B-PROC
+transcription	I-PROC
+-	O
+polymerase	O
+chain	O
+reaction	O
+(	O
+RT	O
+-	O
+PCR	O
+).	O
+
+ABSTRACT	O
+:	O
+Pharmacophore	O
+modeling	O
+can	O
+provide	O
+valuable	O
+insight	O
+into	O
+ligand	O
+-	O
+receptor	B-PROC
+interactions	I-PROC
+.	O
+
+TITLE	O
+:	O
+Severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+in	O
+Singapore	O
+.	O
+
+There	O
+are	O
+no	O
+distinguishing	O
+clinical	O
+features	O
+of	O
+paediatric	O
+SARS	B-DISO
+.	O
+
+All	O
+had	O
+abnormal	O
+chest	B-ANAT
+radiographs	O
+versus	O
+39	O
+%	O
+of	O
+S	O
+cases	O
+,	O
+and	O
+27	O
+%	O
+of	O
+O	O
+cases	O
+.	O
+
+TITLE	O
+:	O
+Induction	O
+of	O
+enhanced	O
+green	B-PRGE
+fluorescent	I-PRGE
+protein	I-PRGE
+expression	B-PROC
+in	O
+response	O
+to	O
+lesions	O
+in	O
+the	O
+nervous	B-DISO
+system	I-ANAT
+.	O
+
+ABSTRACT	O
+:	O
+We	O
+have	O
+generated	O
+a	O
+mouse	B-SPEC
+strain	O
+carrying	O
+a	O
+transgene	O
+driven	O
+by	O
+a	O
+strong	O
+and	O
+ubiquitous	O
+promoter	O
+(	O
+human	B-PRGE
+cytomegalovirus	I-PRGE
+hCMV	I-PRGE
+/	I-PRGE
+beta	I-PRGE
+-	I-PRGE
+actin	I-PRGE
+)	O
+and	O
+containing	O
+an	O
+enhanced	B-PRGE
+green	I-PRGE
+fluorescent	I-PRGE
+protein	I-PRGE
+(	O
+eGFP	O
+)	O
+coding	O
+sequence	O
+upstream	O
+of	O
+the	O
+3	O
+'	O
+untranslated	O
+region	O
+(	O
+3	O
+'	O
+UTR	O
+)	O
+of	O
+tissue	B-PRGE
+-	I-PRGE
+type	I-PRGE
+plasminogen	I-PRGE
+activator	I-PRGE
+(	O
+t	B-PRGE
+-	I-PRGE
+PA	I-PRGE
+)	O
+mRNA	B-CHED
+.	O
+
+This	O
+increased	O
+fluorescence	O
+is	O
+correlated	O
+with	O
+an	O
+increased	O
+transcription	B-PROC
+of	O
+eGFP	O
+in	O
+lesioned	O
+cells	B-COMP
+,	O
+presumably	O
+enhanced	O
+by	O
+a	O
+release	B-PATH
+of	O
+the	O
+translational	B-PROC
+silencing	O
+mediated	O
+by	O
+the	O
+3	O
+'	O
+UTR	O
+region	O
+of	O
+the	O
+t	B-PRGE
+-	I-PRGE
+PA	I-PRGE
+mRNA	I-PRGE
+.	O
+
+Prions	O
+responsible	O
+for	O
+inducing	O
+a	O
+zoonotic	O
+variant	O
+of	O
+Creutzfeldt	B-DISO
+-	I-DISO
+Jakob	I-DISO
+disease	I-DISO
+(	O
+vCJD	B-DISO
+)	O
+are	O
+considered	O
+to	O
+be	O
+a	O
+potential	O
+cause	O
+of	O
+work	O
+-	O
+related	O
+infections	B-DISO
+in	O
+agricultural	O
+and	O
+health	O
+care	O
+workers	O
+,	O
+however	O
+,	O
+this	O
+assumption	O
+has	O
+not	O
+as	O
+yet	O
+been	O
+supported	O
+by	O
+any	O
+conclusive	O
+evidence	O
+.	O
+
+Vaccinations	O
+effectively	O
+restricted	O
+the	O
+number	O
+of	O
+occupational	O
+infections	B-DISO
+with	O
+hepatitis	B-SPEC
+B	I-SPEC
+virus	I-SPEC
+(	O
+HBV	B-DISO
+),	O
+and	O
+work	O
+-	O
+related	O
+infections	B-DISO
+with	O
+human	B-DISO
+immunodeficiency	I-DISO
+virus	I-DISO
+(	O
+HIV	B-DISO
+)	O
+causing	O
+acquired	B-DISO
+immunodeficiency	I-DISO
+syndrome	I-DISO
+(	O
+AIDS	O
+)	O
+are	O
+very	O
+rare	O
+.	O
+
+ABSTRACT	O
+:	O
+To	O
+investigate	O
+the	O
+positive	O
+rate	O
+of	O
+anti	O
+-	O
+SARS	O
+antibody	B-COMP
+in	O
+children	O
+and	O
+adults	O
+without	O
+SARS	B-DISO
+,	O
+197	O
+paediatric	O
+patients	O
+under	O
+14	O
+years	O
+old	O
+from	O
+inpatient	O
+and	O
+outpatient	O
+department	O
+of	O
+our	O
+hospital	O
+,	O
+156	O
+healthy	O
+children	O
+pupils	B-ANAT
+from	O
+primary	O
+school	O
+,	O
+453	O
+adult	O
+patients	O
+over	O
+18	O
+years	O
+old	O
+from	O
+inpatient	O
+and	O
+outpatient	O
+department	O
+of	O
+our	O
+hospital	O
+and	O
+other	O
+502	O
+healthy	O
+adult	O
+blood	B-ANAT
+donors	O
+were	O
+selected	O
+.	O
+
+Anti	B-PRGE
+-	I-PRGE
+SARS	I-PRGE
+antibodies	B-COMP
+were	O
+determined	O
+by	O
+anti	B-PRGE
+-	I-PRGE
+SARS	I-PRGE
+specific	I-PRGE
+antibody	B-COMP
+detection	O
+kit	B-FUNC
+and	O
+ELISA	O
+method	O
+.	O
+
+The	O
+difference	O
+between	O
+the	O
+positive	O
+rates	O
+of	O
+children	O
+and	O
+adults	O
+was	O
+significant	O
+(	O
+chi	B-CHED
+(	O
+2	O
+)	O
+=	O
+11	O
+.	O
+61	O
+,	O
+P	O
+<	O
+0	O
+.	O
+001	O
+).	O
+
+It	O
+is	O
+concluded	O
+that	O
+the	O
+anti	O
+-	O
+SARS	O
+IgG	B-COMP
+antibody	I-COMP
+positive	O
+rate	O
+in	O
+children	O
+was	O
+obvious	O
+higher	O
+than	O
+that	O
+in	O
+adults	O
+.	O
+
+This	O
+may	O
+be	O
+the	O
+cause	O
+why	O
+the	O
+cases	O
+with	O
+SARS	B-DISO
+in	O
+children	O
+is	O
+much	O
+less	O
+than	O
+in	O
+adults	O
+.	O
+
+ABSTRACT	O
+:	O
+A	O
+TaqMan	O
+fluorogenic	O
+reverse	O
+transcriptase	O
+-	O
+polymerase	O
+chain	O
+reaction	O
+(	O
+RT	O
+-	O
+PCR	O
+)	O
+assay	O
+was	O
+developed	O
+for	O
+the	O
+detection	O
+and	O
+quantitation	O
+of	O
+canine	O
+coronavirus	B-SPEC
+(	O
+CCoV	O
+)	O
+RNA	O
+in	O
+the	O
+faeces	B-ANAT
+of	O
+naturally	O
+or	O
+experimentally	O
+infected	O
+dogs	B-SPEC
+.	O
+
+Positive	O
+rates	O
+peaked	O
+at	O
+6	O
+-	O
+11	O
+days	O
+after	O
+onset	O
+of	O
+illness	O
+for	O
+nasopharyngeal	B-ANAT
+aspirates	B-ANAT
+(	O
+87	O
+of	O
+149	O
+[	O
+58	O
+%],	O
+to	O
+37	O
+of	O
+62	O
+[	O
+60	O
+%]),	O
+and	O
+9	O
+-	O
+14	O
+days	O
+for	O
+faeces	B-ANAT
+(	O
+15	O
+of	O
+22	O
+[	O
+68	O
+%],	O
+to	O
+26	O
+of	O
+37	O
+[	O
+70	O
+%]).	O
+
+Low	O
+rate	O
+of	O
+viral	B-DISO
+shedding	I-DISO
+in	O
+the	O
+first	O
+few	O
+days	O
+of	O
+illness	O
+meant	O
+that	O
+early	O
+isolation	O
+measures	O
+would	O
+probably	O
+be	O
+effective	O
+.	O
+
+It	O
+may	O
+help	O
+with	O
+the	O
+development	B-PROC
+of	O
+effective	O
+treatment	O
+.	O
+
+TITLE	O
+:	O
+Experimental	O
+human	B-SPEC
+metapneumovirus	I-SPEC
+infection	O
+of	O
+cynomolgus	O
+macaques	B-SPEC
+(	O
+Macaca	B-SPEC
+fascicularis	I-SPEC
+)	O
+results	O
+in	O
+virus	O
+replication	O
+in	O
+ciliated	O
+epithelial	B-ANAT
+cells	I-ANAT
+and	O
+pneumocytes	B-ANAT
+with	O
+associated	O
+lesions	O
+throughout	O
+the	O
+respiratory	B-ANAT
+tract	I-ANAT
+.	O
+
+They	O
+were	O
+euthanized	O
+at	O
+5	O
+(	O
+n	O
+=	O
+2	O
+)	O
+or	O
+9	O
+(	O
+n	O
+=	O
+2	O
+)	O
+days	O
+post	O
+-	O
+infection	B-DISO
+(	O
+dpi	O
+),	O
+or	O
+monitored	O
+until	O
+14	O
+dpi	O
+(	O
+n	O
+=	O
+2	O
+).	O
+
+HR1	O
+and	O
+HR2	O
+of	O
+SARS	B-DISO
+-	O
+CoV	O
+associate	O
+into	O
+an	O
+antiparallel	O
+six	O
+-	O
+helix	O
+bundle	O
+,	O
+with	O
+structural	O
+features	O
+typical	O
+of	O
+the	O
+other	O
+known	O
+class	O
+I	O
+fusion	O
+proteins	B-CHED
+.	O
+
+Inhibitors	B-CHED
+binding	B-FUNC
+to	O
+HR	O
+regions	O
+of	O
+fusion	O
+proteins	B-CHED
+have	O
+been	O
+shown	O
+to	O
+be	O
+efficacious	O
+against	O
+many	O
+viruses	B-SPEC
+,	O
+notably	O
+HIV	B-DISO
+.	O
+
+ABSTRACT	O
+:	O
+To	O
+evaluate	O
+the	O
+hepatic	O
+function	O
+in	O
+patients	O
+with	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+(	O
+SARS	B-DISO
+)	O
+and	O
+possible	O
+causes	O
+of	O
+hepatic	B-DISO
+disorder	I-DISO
+in	O
+these	O
+patients	O
+.	O
+
+Specific	O
+antibody	B-PROC
+responses	I-PROC
+to	O
+the	O
+purified	O
+recombinant	O
+N	O
+protein	B-CHED
+after	O
+10	O
+,	O
+20	O
+,	O
+and	O
+30	O
+days	O
+of	O
+disease	O
+onset	O
+were	O
+observed	O
+in	O
+13	O
+of	O
+16	O
+(	O
+81	O
+.	O
+3	O
+%),	O
+16	O
+of	O
+16	O
+(	O
+100	O
+%)	O
+and	O
+16	O
+of	O
+16	O
+(	O
+100	O
+%)	O
+SARS	B-DISO
+patients	O
+sera	B-COMP
+,	O
+respectively	O
+.	O
+
+However	O
+,	O
+there	O
+is	O
+no	O
+current	O
+bronchoscopic	O
+classification	O
+of	O
+inhalation	B-PROC
+injury	O
+for	O
+the	O
+prediction	O
+of	O
+acute	O
+lung	B-ANAT
+injury	O
+(	O
+ALI	O
+).	O
+
+The	O
+diagnosis	O
+of	O
+DIC	B-DISO
+was	O
+made	O
+based	O
+on	O
+a	O
+modified	O
+version	O
+of	O
+the	O
+criteria	O
+established	O
+by	O
+the	O
+Ministry	O
+of	O
+Health	O
+,	O
+Labor	B-PROC
+and	O
+Welfare	O
+of	O
+Japan	O
+.	O
+
+As	O
+the	O
+level	O
+of	O
+SF	O
+reflects	O
+the	O
+thrombin	B-PRGE
+generation	O
+activity	O
+in	O
+plasma	B-ANAT
+,	O
+it	O
+would	O
+serve	O
+as	O
+a	O
+strong	O
+tool	O
+to	O
+selectively	O
+kick	O
+up	O
+the	O
+state	O
+of	O
+thrombin	B-PRGE
+generation	O
+.	O
+
+The	O
+excessive	O
+life	O
+response	O
+to	O
+serious	O
+clinical	O
+insults	O
+,	O
+such	O
+as	O
+sepsis	B-DISO
+,	I-DISO
+severe	I-DISO
+pancreatitis	B-DISO
+,	O
+trauma	O
+and	O
+shock	O
+,	O
+is	O
+called	O
+systemic	B-DISO
+inflammatory	I-DISO
+response	I-DISO
+syndrome	I-DISO
+(	O
+SIRS	B-DISO
+).	O
+
+The	O
+diagnosis	O
+of	O
+SIRS	B-DISO
+was	O
+based	O
+on	O
+the	O
+criteria	O
+established	O
+by	O
+American	O
+College	O
+of	O
+Chest	B-ANAT
+Physicians	O
+(	O
+ACCP	O
+)/	O
+Society	O
+of	O
+Critical	O
+Care	O
+Medicine	B-CHED
+(	O
+SCCM	O
+)	O
+Consensus	O
+Conference	O
+held	O
+in	O
+August	O
+of	O
+1991	O
+in	O
+Northbrook	O
+,	O
+IL	O
+(	O
+USA	O
+).	O
+
+Post	O
+-	O
+mortem	O
+examination	O
+,	O
+carried	O
+out	O
+on	O
+two	O
+pups	O
+which	O
+died	B-PROC
+without	O
+neurological	O
+signs	O
+,	O
+showed	O
+pneumonia	B-DISO
+and	O
+enteritis	B-DISO
+,	O
+more	O
+severe	O
+in	O
+one	O
+of	O
+the	O
+two	O
+examined	O
+pups	O
+.	O
+
+ABSTRACT	O
+:	O
+The	O
+zinc	B-CHED
+metallopeptidase	I-PRGE
+angiotensin	B-CHED
+-	I-PRGE
+converting	I-PRGE
+enzyme	I-PRGE
+2	I-PRGE
+(	O
+ACE2	B-PRGE
+)	O
+is	O
+the	O
+only	O
+known	O
+human	B-SPEC
+homologue	O
+of	O
+the	O
+key	O
+regulator	O
+of	O
+blood	B-PROC
+pressure	I-PROC
+angiotensin	B-PRGE
+-	I-PRGE
+converting	I-PRGE
+enzyme	I-PRGE
+(	O
+ACE	B-PRGE
+).	O
+
+Amongst	O
+those	O
+,	O
+interferon	B-PRGE
+-	I-PRGE
+alpha	I-PRGE
+displayed	O
+the	O
+strongest	O
+inhibitory	O
+activity	O
+.	O
+
+TITLE	O
+:	O
+Infection	B-DISO
+control	O
+measures	O
+for	O
+operative	O
+procedures	O
+in	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+-	O
+related	O
+patients	O
+.	O
+
+ABSTRACT	O
+:	O
+Acute	O
+lung	B-ANAT
+injury	O
+(	O
+ALI	O
+)	O
+and	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+(	O
+ARDS	B-DISO
+)	O
+are	O
+diseases	O
+with	O
+a	O
+significant	O
+influence	O
+in	O
+the	O
+public	O
+health	O
+.	O
+
+Future	O
+research	O
+must	O
+to	O
+include	O
+study	O
+of	O
+genetic	B-PROC
+polymorphisms	I-PROC
+of	O
+the	O
+mediators	O
+involve	O
+in	O
+the	O
+development	B-PROC
+of	O
+ALI	O
+/	O
+ARDS	B-DISO
+.	O
+
+ABSTRACT	O
+:	O
+Severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+(	O
+SARS	B-DISO
+)	O
+is	O
+a	O
+new	O
+disease	O
+that	O
+caused	O
+large	O
+outbreaks	O
+in	O
+several	O
+countries	O
+in	O
+the	O
+first	O
+half	O
+of	O
+2003	O
+,	O
+resulting	O
+in	O
+infection	B-DISO
+in	O
+more	O
+than	O
+8000	O
+people	O
+and	O
+more	O
+than	O
+900	O
+deaths	B-PROC
+.	O
+
+During	O
+that	O
+time	O
+,	O
+a	O
+large	O
+body	B-ANAT
+of	O
+literature	O
+rapidly	O
+emerged	O
+describing	O
+the	O
+clinical	O
+disease	O
+,	O
+the	O
+etiologic	O
+viral	O
+agent	O
+,	O
+and	O
+management	O
+options	O
+.	O
+
+Approximately	O
+20	O
+%	O
+of	O
+patients	O
+develop	O
+progressive	O
+pulmonary	B-DISO
+infiltrates	I-DISO
+and	O
+respiratory	B-DISO
+failure	I-DISO
+,	O
+and	O
+the	O
+mortality	O
+rate	O
+is	O
+as	O
+high	O
+as	O
+10	O
+%.	O
+
+The	O
+purpose	O
+of	O
+this	O
+paper	O
+is	O
+to	O
+review	O
+new	O
+bioterrorist	O
+and	O
+emerging	O
+infectious	O
+threats	O
+to	O
+public	O
+health	O
+in	O
+Ontario	O
+,	O
+Canada	O
+,	O
+and	O
+to	O
+propose	O
+a	O
+means	O
+of	O
+integrating	O
+a	O
+telephone	O
+-	O
+based	O
+health	O
+information	O
+service	O
+and	O
+emergency	B-DISO
+department	O
+triage	O
+with	O
+a	O
+first	O
+-	O
+line	O
+real	O
+-	O
+time	O
+,	O
+24	O
+-	O
+h	O
+a	O
+day	O
+syndrome	B-DISO
+surveillance	O
+system	O
+.	O
+
+This	O
+automated	O
+system	O
+could	O
+be	O
+beneficial	O
+in	O
+detecting	O
+a	O
+bioterrorist	O
+threat	O
+as	O
+well	O
+as	O
+in	O
+detecting	O
+and	O
+monitoring	O
+disease	O
+outbreaks	O
+such	O
+as	O
+influenza	B-DISO
+,	O
+Norwalk	O
+,	O
+West	B-DISO
+Nile	I-DISO
+virus	I-DISO
+,	O
+Escherichia	B-SPEC
+coli	I-SPEC
+0157	O
+or	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+.	O
+
+The	O
+websites	O
+of	O
+the	O
+Ontario	O
+Ministry	O
+of	O
+Health	O
+and	O
+Long	O
+-	O
+Term	O
+Care	O
+,	O
+Ontario	O
+Ministry	O
+of	O
+Public	O
+Safety	O
+and	O
+Security	O
+,	O
+Centers	O
+for	O
+Disease	O
+Control	O
+and	O
+Canadian	O
+Population	O
+and	O
+Public	O
+Health	O
+Branch	B-ANAT
+of	I-ANAT
+Health	O
+Canada	O
+were	O
+searched	O
+for	O
+articles	O
+relating	O
+to	O
+bioterrorism	O
+and	O
+syndromic	O
+surveillance	O
+.	O
+
+RESULTS	O
+:	O
+Real	O
+-	O
+time	O
+syndrome	B-DISO
+surveillance	O
+is	O
+a	O
+new	O
+means	O
+of	O
+detecting	O
+disease	O
+outbreaks	O
+or	O
+possibly	O
+acts	O
+of	O
+bioterrorism	O
+at	O
+the	O
+first	O
+contact	O
+with	O
+the	O
+healthcare	O
+system	O
+.	O
+
+ABSTRACT	O
+:	O
+Organophosphates	O
+may	O
+cause	O
+serious	O
+life	O
+-	O
+threatening	O
+conditions	O
+,	O
+such	O
+as	O
+an	O
+initial	O
+acute	O
+cholinergic	B-DISO
+crisis	I-DISO
+and	O
+intermediate	B-DISO
+syndrome	I-DISO
+.	O
+
+This	O
+observation	O
+has	O
+some	O
+implications	O
+for	O
+the	O
+SARS	B-DISO
+-	O
+CoV	O
+pathogenicity	O
+:	O
+SARS	B-DISO
+-	O
+CoV	O
+does	O
+induce	O
+apoptosis	B-PATH
+in	O
+cell	B-COMP
+cultures	O
+and	O
+might	O
+have	O
+the	O
+same	O
+effect	O
+in	O
+vivo	O
+,	O
+responsible	O
+for	O
+the	O
+severe	O
+damage	O
+of	O
+the	O
+respiratory	B-ANAT
+system	I-ANAT
+.	O
+
+ABSTRACT	O
+:	O
+Severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+(	O
+SARS	B-DISO
+)-	O
+CoV	O
+is	O
+a	O
+newly	O
+emerging	O
+virus	B-SPEC
+that	O
+causes	O
+SARS	B-DISO
+with	O
+high	O
+mortality	O
+rate	O
+in	O
+infected	O
+people	O
+.	O
+
+By	O
+Western	O
+blotting	O
+,	O
+97	O
+.	O
+5	O
+%	O
+of	O
+the	O
+SARS	B-DISO
+patients	O
+were	O
+positive	O
+for	O
+N	B-PRGE
+protein	I-PRGE
+-	I-PRGE
+specific	I-PRGE
+antibodies	B-COMP
+whereas	O
+only	O
+47	O
+.	O
+5	O
+%	O
+of	O
+the	O
+samples	O
+were	O
+positive	O
+for	O
+S	B-PRGE
+protein	B-CHED
+-	I-PRGE
+specific	I-PRGE
+antibodies	B-COMP
+.	O
+
+Immunoblotting	O
+was	O
+useful	O
+for	O
+detecting	O
+the	O
+humoral	B-PROC
+immune	I-PROC
+response	I-PROC
+after	O
+SARS	B-DISO
+-	I-DISO
+CoV	I-DISO
+infection	I-DISO
+.	O
+
+Children	O
+<	O
+18	O
+years	O
+of	O
+age	O
+,	O
+from	O
+a	O
+single	O
+-	O
+site	O
+outbreak	O
+,	O
+who	O
+satisfied	O
+a	O
+clinical	O
+case	O
+definition	O
+for	O
+SARS	B-DISO
+,	O
+with	O
+subsequent	O
+serologic	O
+confirmation	O
+,	O
+were	O
+treated	O
+according	O
+to	O
+a	O
+standard	O
+protocol	O
+and	O
+prospectively	O
+monitored	O
+.	O
+
+Radiographic	O
+findings	O
+were	O
+nonspecific	O
+,	O
+but	O
+high	O
+-	O
+resolution	O
+computed	O
+tomography	O
+of	O
+the	O
+thorax	B-ANAT
+was	O
+an	O
+early	O
+diagnostic	B-CHED
+aid	I-CHED
+.	O
+
+Thus	O
+,	O
+besides	O
+basic	O
+treatment	O
+of	O
+the	O
+underlying	O
+disease	O
+the	O
+use	O
+of	O
+vasodilators	O
+is	O
+a	O
+valuable	O
+therapeutic	O
+option	O
+to	O
+decrease	O
+right	O
+ventricular	B-ANAT
+afterload	O
+,	O
+but	O
+intravenous	O
+vasodilators	O
+may	O
+provoke	O
+systemic	O
+arterial	B-ANAT
+hypotension	O
+and	O
+impair	O
+gas	B-ENZY
+exchange	O
+due	O
+to	O
+vasodilation	B-DISO
+of	O
+pulmonary	B-ANAT
+shunt	O
+areas	O
+.	O
+
+Although	O
+effective	O
+in	O
+experimental	O
+studies	O
+no	O
+clear	O
+recommendation	O
+can	O
+be	O
+made	O
+in	O
+view	O
+to	O
+the	O
+use	O
+of	O
+other	O
+vasodilators	O
+such	O
+as	O
+phosphodiesterase	B-PROC
+inhibitors	I-PROC
+or	O
+endothelin	O
+antagonists	B-CHED
+.	O
+
+ABSTRACT	O
+:	O
+To	O
+develop	O
+a	O
+diagnostic	O
+kit	O
+for	O
+detection	O
+of	O
+SARS	B-DISO
+(	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+)-	O
+related	O
+coronavirus	B-SPEC
+RNA	O
+based	O
+on	O
+reverse	B-PROC
+transcription	I-PROC
+and	O
+polymerase	O
+chain	O
+reaction	O
+and	O
+to	O
+estimate	O
+its	O
+specificity	O
+and	O
+sensitivity	O
+.	O
+
+The	O
+sensitivity	O
+of	O
+the	O
+kit	B-FUNC
+in	O
+different	O
+clinical	O
+samples	O
+was	O
+2	O
+.	O
+2	O
+x	O
+10	O
+(	O
+3	O
+)	O
+genome	O
+equivalents	O
+of	O
+recombinant	O
+SARS	B-DISO
+RNA	O
+in	O
+1	O
+ml	O
+of	O
+the	O
+specimen	O
+.	O
+
+The	O
+kit	B-FUNC
+contains	O
+reagents	B-CHED
+for	O
+RNA	O
+isolation	O
+and	O
+purification	O
+,	O
+cDNA	O
+synthesis	B-PROC
+by	O
+reverse	B-PROC
+transcription	I-PROC
+of	O
+RNA	O
+,	O
+for	O
+PCR	O
+and	O
+for	O
+electrophoretic	O
+analysis	O
+of	O
+amplified	O
+products	O
+.	O
+
+RESULTS	O
+:	O
+The	O
+specificity	O
+of	O
+the	O
+kit	B-FUNC
+was	O
+determined	O
+using	O
+animal	B-SPEC
+coronaviruses	O
+and	O
+other	O
+bacterial	O
+and	O
+viral	O
+strains	O
+,	O
+causing	O
+acute	O
+respiratory	O
+and	O
+intestinal	B-DISO
+infections	I-DISO
+,	O
+and	O
+was	O
+shown	O
+to	O
+be	O
+100	O
+%.	O
+
+TITLE	O
+:	O
+Vaccines	O
+for	O
+the	O
+prevention	O
+of	O
+respiratory	O
+viral	B-DISO
+infections	I-DISO
+:	O
+problems	O
+and	O
+current	O
+status	O
+.	O
+
+University	O
+hospitals	O
+in	O
+Toronto	O
+,	O
+Canada	O
+,	O
+during	O
+the	O
+SARS	B-DISO
+outbreak	O
+in	O
+2003	O
+.	O
+
+However	O
+,	O
+there	O
+were	O
+several	O
+examples	O
+of	O
+strained	O
+professional	O
+behaviour	B-PROC
+witnessed	O
+by	O
+the	O
+participants	O
+and	O
+these	O
+examples	O
+highlight	O
+aspects	O
+of	O
+medical	O
+professionalism	O
+that	O
+medical	O
+educators	O
+and	O
+professional	O
+organisations	O
+should	O
+address	O
+in	O
+the	O
+future	O
+,	O
+including	O
+the	O
+balance	B-PROC
+between	O
+personal	O
+safety	O
+and	O
+duty	O
+of	O
+care	O
+.	O
+
+RESULTS	O
+:	O
+Of	O
+14	O
+attending	O
+physicians	O
+,	O
+four	O
+became	O
+ill	B-DISO
+during	O
+the	O
+outbreak	O
+.	O
+
+The	O
+most	O
+frequent	O
+neurological	B-DISO
+complication	I-DISO
+of	O
+inorganic	O
+arsenic	B-CHED
+intoxication	O
+is	O
+a	O
+distal	O
+symmetrical	O
+polyneuropathy	B-DISO
+.	O
+
+We	O
+report	O
+here	O
+a	O
+patient	O
+who	O
+developed	O
+a	O
+systemic	B-DISO
+illness	I-DISO
+followed	O
+with	O
+severe	O
+acute	B-DISO
+polyneuropathy	I-DISO
+.	O
+
+A	O
+diagnosis	O
+of	O
+arsenic	B-CHED
+toxicity	O
+was	O
+made	O
+.	O
+
+First	O
+high	O
+fever	B-PROC
+,	O
+parainfluenza	B-DISO
+syndrome	B-DISO
+followed	O
+by	O
+increasing	O
+respiratory	B-DISO
+distress	I-DISO
+.	O
+
+This	O
+article	O
+provides	O
+a	O
+summary	O
+of	O
+our	O
+work	O
+with	O
+such	O
+cytokines	O
+,	O
+which	O
+includes	O
+attempts	O
+to	O
+define	O
+optimum	O
+dosing	O
+schedules	O
+that	O
+lead	O
+to	O
+optimal	O
+primary	O
+and	O
+lasting	O
+memory	B-PROC
+antigen	B-CHED
+-	O
+specific	O
+immune	B-PROC
+responses	I-PROC
+.	O
+
+TITLE	O
+:	O
+Outcome	O
+of	O
+coronavirus	B-SPEC
+-	O
+associated	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+using	O
+a	O
+standard	O
+treatment	O
+protocol	O
+.	O
+
+TITLE	O
+:	O
+Occult	O
+pneumomediastinum	B-DISO
+in	O
+a	O
+SARS	B-DISO
+patient	O
+presenting	O
+as	O
+recurrent	O
+chest	B-DISO
+pain	I-DISO
+and	O
+acute	O
+ECG	O
+changes	O
+mimicking	O
+acute	O
+coronary	O
+syndrome	O
+.	O
+
+She	O
+developed	O
+progressive	O
+subcutaneous	B-DISO
+emphysema	I-DISO
+a	O
+few	O
+days	O
+later	O
+.	O
+
+ABSTRACT	O
+:	O
+To	O
+establish	O
+a	O
+clinical	O
+staging	O
+system	O
+for	O
+patients	O
+with	O
+severe	O
+acute	O
+respiratory	O
+syndrome	O
+(	O
+SARS	B-DISO
+)	O
+based	O
+on	O
+clinical	O
+feature	O
+,	O
+laboratory	O
+tests	O
+as	O
+well	O
+as	O
+dynamic	O
+changes	O
+of	O
+chest	B-ANAT
+X	O
+-	O
+ray	B-SPEC
+images	O
+.	O
+
+The	O
+data	O
+may	O
+suggest	O
+a	O
+new	O
+approach	O
+for	O
+treatment	O
+of	O
+SARS	B-DISO
+patients	O
+.	O
+
+All	O
+the	O
+coronavirus	B-SPEC
+5	O
+'-	O
+termini	O
+and	O
+PL	O
+(	O
+pro	B-CHED
+)	O
+domains	O
+were	O
+divergent	O
+,	O
+unlike	O
+the	O
+M	O
+(	O
+pro	B-CHED
+)	O
+and	O
+the	O
+RdRp	B-FUNC
+domains	O
+that	O
+were	O
+highly	O
+conserved	O
+with	O
+28	O
+%	O
+and	O
+48	O
+%	O
+conserved	O
+residues	O
+,	O
+respectively	O
+.	O
+
+The	O
+BJ	O
+strain	O
+was	O
+the	O
+most	O
+different	O
+from	O
+other	O
+IBVs	O
+in	O
+all	O
+four	O
+regions	O
+of	O
+the	O
+replicase	B-PRGE
+.	O
+
+However	O
+,	O
+the	O
+IBV	B-SPEC
+strain	O
+classification	O
+based	O
+on	O
+replicase	B-PRGE
+gene	O
+domains	O
+did	O
+not	O
+correlate	O
+with	O
+that	O
+of	O
+the	O
+type	O
+-	O
+specific	O
+antigenic	O
+groups	O
+.	O
+
+There	O
+was	O
+no	O
+correlation	O
+between	O
+the	O
+genotype	O
+of	O
+any	O
+region	O
+of	O
+the	O
+replicase	B-PRGE
+gene	I-PRGE
+and	O
+pathotype	O
+,	O
+suggesting	O
+that	O
+the	O
+replicase	B-PRGE
+is	O
+not	O
+the	O
+sole	B-ANAT
+determinant	O
+of	O
+IBV	B-SPEC
+pathogenicity	O
+.	O
+
+Peptides	B-CHED
+derived	O
+from	O
+the	O
+HR	O
+regions	O
+of	O
+some	O
+viruses	B-SPEC
+have	O
+been	O
+shown	O
+to	O
+inhibit	O
+the	O
+entry	O
+of	O
+these	O
+viruses	B-SPEC
+.	O
+
+It	O
+plays	O
+an	O
+important	O
+role	O
+in	O
+interaction	O
+with	O
+receptor	O
+and	O
+inducing	O
+neutralizing	O
+antibodies	B-COMP
+.	O
+
+The	O
+nucleocapsid	B-COMP
+(	O
+N	O
+)	O
+protein	B-CHED
+of	O
+SARS	B-DISO
+-	I-DISO
+associated	I-DISO
+coronavirus	I-DISO
+(	O
+SARS	B-DISO
+-	O
+CoV	O
+)	O
+is	O
+abundantly	O
+expressed	B-PROC
+in	O
+infected	O
+-	O
+cell	B-COMP
+culture	O
+filtrate	O
+as	O
+demonstrable	O
+by	O
+Western	O
+blotting	O
+using	O
+convalescent	O
+-	O
+phase	O
+sera	B-COMP
+from	O
+patients	O
+with	O
+SARS	B-DISO
+.	O
+
+In	O
+conclusion	O
+,	O
+a	O
+sensitive	O
+and	O
+quantitative	O
+antigen	B-CHED
+capture	O
+ELISA	O
+was	O
+established	O
+for	O
+the	O
+early	O
+diagnosis	O
+and	O
+disease	O
+monitoring	O
+of	O
+SARS	B-DISO
+-	I-DISO
+CoV	I-DISO
+infection	I-DISO
+.	O
+
+The	O
+transmission	O
+route	O
+of	O
+SARS	B-DISO
+has	O
+been	O
+clarified	O
+,	O
+but	O
+the	O
+immunopathogenesis	O
+of	O
+SARS	B-DISO
+is	O
+unclear	O
+.	O
+
+TITLE	O
+:	O
+Complete	O
+nucleotide	B-CHED
+sequences	O
+of	O
+S1	O
+and	O
+N	O
+genes	O
+of	O
+infectious	B-DISO
+bronchitis	B-DISO
+virus	B-SPEC
+isolated	O
+in	O
+Japan	O
+and	O
+Taiwan	O
+.	O
+
+None	O
+of	O
+the	O
+six	O
+patients	O
+had	O
+a	O
+history	O
+of	O
+smoking	O
+or	O
+pulmonary	B-DISO
+disease	I-DISO
+.	O
+
+As	O
+long	O
+as	O
+no	O
+cases	O
+of	O
+person	O
+-	O
+to	O
+-	O
+person	O
+disease	B-DISO
+transmission	I-DISO
+are	O
+reported	O
+anywhere	O
+in	O
+the	O
+world	O
+,	O
+efforts	O
+should	O
+be	O
+aimed	O
+at	O
+early	O
+detection	O
+and	O
+notification	O
+of	O
+cases	O
+and	O
+of	O
+groups	O
+of	O
+people	O
+who	O
+are	O
+in	O
+contact	O
+with	O
+one	O
+another	O
+and	O
+who	O
+have	O
+severe	O
+respiratory	B-DISO
+infections	I-DISO
+of	O
+undetermined	O
+cause	O
+,	O
+such	O
+as	O
+pneumonia	B-DISO
+,	O
+which	O
+could	O
+signal	O
+the	O
+reemergence	O
+of	O
+SARS	B-DISO
+.	O
+
+If	O
+cases	O
+of	O
+transmission	O
+of	O
+SARS	B-PRGE
+-	I-PRGE
+CoV	I-PRGE
+have	O
+been	O
+reported	O
+,	O
+the	O
+aim	O
+should	O
+be	O
+to	O
+immediately	O
+identify	O
+and	O
+notify	O
+any	O
+cases	O
+detected	O
+in	O
+order	B-SPEC
+to	O
+take	O
+appropriate	O
+diagnostic	O
+and	O
+therapeutic	O
+measures	O
+and	O
+to	O
+facilitate	O
+outbreak	O
+control	O
+.	O
+
+Physicians	O
+and	O
+public	O
+health	O
+workers	O
+should	O
+be	O
+familiar	O
+with	O
+ways	O
+to	O
+detect	O
+SARS	B-DISO
+cases	O
+early	O
+,	O
+as	O
+well	O
+as	O
+with	O
+existing	O
+norms	O
+for	O
+reporting	O
+any	O
+cases	O
+detected	O
+.	O
+
+ABSTRACT	O
+:	O
+To	O
+express	O
+S2	O
+protein	O
+of	O
+SARS	B-DISO
+virus	B-SPEC
+fused	O
+with	O
+Trx	O
+and	O
+then	O
+detect	O
+its	O
+reactivity	O
+to	O
+the	O
+sera	B-COMP
+from	O
+convalescent	O
+SARS	B-DISO
+patients	O
+.	O
+
+The	O
+Trx	B-PRGE
+-	O
+S2	O
+fusion	O
+protein	B-CHED
+provides	O
+a	O
+basis	O
+for	O
+the	O
+research	O
+on	O
+its	O
+role	O
+in	O
+the	O
+course	O
+of	O
+SARS	B-DISO
+virus	B-DISO
+infection	I-DISO
+of	O
+host	B-COMP
+cells	B-COMP
+and	O
+preparation	O
+of	O
+recombinant	O
+vaccine	O
+against	O
+SARS	B-DISO
+virus	B-SPEC
+.	O
+
+In	O
+two	O
+follow	O
+-	O
+up	O
+surveys	O
+of	O
+the	O
+SARS	B-DISO
+patients	O
+discharged	O
+from	O
+our	O
+hospital	O
+,	O
+the	O
+changes	O
+of	O
+CD3	B-PRGE
+(+),	I-PRGE
+CD4	B-PRGE
+(+),	O
+CD8	B-PRGE
+(+),	O
+CD8	B-PRGE
+(+)	I-PRGE
+CD28	I-PRGE
+(+),	I-PRGE
+CD8	B-PRGE
+(+)	I-PRGE
+CD28	I-PRGE
+(-),	I-PRGE
+CD3	B-PRGE
+(+)	I-PRGE
+CD25	I-PRGE
+(+),	I-PRGE
+CD3	B-PRGE
+(+)	I-PRGE
+CD69	I-PRGE
+(+),	I-PRGE
+CD3	B-PRGE
+(+)	I-PRGE
+HLA	I-PRGE
+-	I-PRGE
+DR	I-PRGE
+(+)	O
+T	B-ANAT
+cells	I-ANAT
+and	O
+the	O
+ratio	O
+of	O
+CD4	B-PRGE
+(+)/	O
+CD8	B-PRGE
+(+)	O
+T	B-ANAT
+cells	I-ANAT
+in	O
+peripheral	B-ANAT
+blood	I-ANAT
+of	O
+SARS	B-DISO
+patients	O
+treated	O
+unitedly	O
+with	O
+Chinese	O
+and	O
+Western	O
+medicines	O
+were	O
+detected	O
+by	O
+flow	O
+cytometry	O
+.	O
+
+RESULTS	O
+:	O
+In	O
+two	O
+follow	O
+-	O
+up	O
+surveys	O
+,	O
+the	O
+percentages	O
+of	O
+CD3	B-PRGE
+(+),	I-PRGE
+CD4	B-PRGE
+(+),	O
+CD8	B-PRGE
+(+)	O
+CD28	O
+(+)	O
+T	B-ANAT
+cells	I-ANAT
+and	O
+the	O
+ratio	O
+of	O
+CD4	B-PRGE
+(+)/	O
+CD8	B-PRGE
+(+)	O
+T	B-ANAT
+cells	I-ANAT
+were	O
+remarkably	O
+lower	O
+than	O
+those	O
+of	O
+normal	O
+values	O
+(	O
+P	O
+<	O
+0	O
+.	O
+05	O
+),	O
+while	O
+the	O
+percentage	O
+of	O
+CD8	B-PRGE
+(+)	O
+CD28	O
+(-)	O
+T	B-ANAT
+cells	I-ANAT
+was	O
+higher	O
+(	O
+P	O
+<	O
+0	O
+.	O
+01	O
+).	O
+
+CONCLUSIONS	O
+:	O
+The	O
+convalescent	O
+SARS	B-DISO
+patients	O
+'	O
+immune	B-PROC
+function	I-PROC
+gradually	O
+recovers	O
+,	O
+and	O
+the	O
+effect	O
+of	O
+SARS	B-DISO
+virus	B-SPEC
+on	O
+activation	O
+of	O
+T	B-ANAT
+cells	I-ANAT
+gradually	O
+disappears	O
+.	O
+
+Thus	O
+,	O
+this	O
+vaccine	O
+candidate	O
+is	O
+effective	O
+at	O
+boosting	O
+lactogenic	O
+immunity	B-PROC
+and	O
+is	O
+appropriate	O
+to	O
+pursue	O
+through	O
+large	O
+-	O
+scale	O
+field	O
+trials	O
+preceding	O
+commercialization	O
+.	O
+
+Deletion	O
+of	O
+a	O
+major	O
+portion	O
+of	O
+the	O
+cytoplasmic	B-ANAT
+domain	I-ANAT
+of	O
+ACE2	B-PRGE
+had	O
+no	O
+effect	O
+on	O
+S	O
+-	O
+driven	O
+infection	B-DISO
+,	O
+indicating	O
+that	O
+this	O
+domain	O
+is	O
+not	O
+important	O
+for	O
+receptor	B-PROC
+function	I-PROC
+.	O
+
+Understanding	O
+the	O
+molecular	O
+mechanisms	O
+of	O
+SARS	B-DISO
+-	O
+induced	O
+cytopathic	B-DISO
+effects	I-DISO
+(	O
+CPEs	B-DISO
+)	O
+is	O
+a	O
+rational	O
+approach	O
+for	O
+the	O
+prevention	O
+of	O
+SARS	B-DISO
+,	O
+and	O
+an	O
+understanding	O
+of	O
+the	O
+cellular	B-DISO
+stress	I-DISO
+responses	O
+induced	O
+by	O
+viral	B-DISO
+infection	I-DISO
+is	O
+important	O
+for	O
+understanding	O
+the	O
+CPEs	B-DISO
+.	O
+
+The	O
+downstream	O
+targets	O
+of	O
+p38	B-PRGE
+MAPK	B-FUNC
+,	O
+MAPKAPK	B-PRGE
+-	I-PRGE
+2	I-PRGE
+,	O
+HSP	B-PRGE
+-	I-PRGE
+27	I-PRGE
+,	O
+CREB	B-PRGE
+,	O
+and	O
+eIF4E	B-PRGE
+were	O
+phosphorylated	O
+in	O
+virus	O
+-	O
+infected	O
+cells	B-COMP
+.	O
+
+Identification	O
+of	O
+a	O
+conserved	O
+antigenic	B-CHED
+determinant	I-CHED
+on	O
+the	O
+S2	O
+domain	O
+of	O
+the	O
+SARS	B-PRGE
+-	I-PRGE
+CoV	I-PRGE
+S	I-PRGE
+protein	B-CHED
+,	O
+which	O
+has	O
+the	O
+potential	O
+for	O
+inducing	O
+neutralizing	O
+antibodies	B-COMP
+,	O
+has	O
+implications	O
+in	O
+the	O
+development	B-PROC
+of	O
+effective	O
+vaccines	O
+against	O
+SARS	B-DISO
+-	O
+CoV	O
+.	O
+
+Concurrently	O
+,	O
+splenic	B-ANAT
+and	O
+myeloid	O
+NK1	O
+.	O
+1	O
++	O
+cells	B-COMP
+decreased	O
+in	O
+L2	O
+-	O
+MHV3	O
+-	O
+infected	O
+mice	B-SPEC
+.	O
+
+In	O
+vitro	O
+viral	B-DISO
+infections	I-DISO
+of	O
+interleukin	B-PRGE
+(	O
+IL	O
+)-	O
+15	O
+-	O
+stimulated	O
+lymphoid	B-ANAT
+cells	I-ANAT
+from	O
+liver	B-ANAT
+and	O
+bone	B-ANAT
+marrow	I-ANAT
+revealed	O
+that	O
+L2	O
+-	O
+MHV3	O
+induced	O
+higher	O
+decreases	O
+in	O
+cell	B-PROC
+viability	I-PROC
+of	O
+NK1	B-PRGE
+.	O
+1	O
++	O
+cells	B-COMP
+than	O
+the	O
+YAC	O
+-	O
+MHV3	O
+variant	O
+.	O
+
+These	O
+results	O
+suggest	O
+that	O
+NK	B-ANAT
+cell	I-ANAT
+production	O
+is	O
+impaired	B-DISO
+by	O
+viral	B-DISO
+infection	I-DISO
+favouring	O
+fulminant	B-DISO
+hepatitis	I-DISO
+.	O
+
+Whether	O
+or	O
+not	O
+our	O
+patients	O
+had	O
+been	O
+suspected	O
+of	O
+or	O
+treated	O
+as	O
+having	O
+SARS	B-DISO
+,	O
+was	O
+recorded	O
+.	O
+
+Three	O
+patients	O
+refused	O
+further	O
+chemotherapy	O
+because	O
+of	O
+a	O
+fear	O
+of	O
+getting	O
+SARS	B-DISO
+if	O
+they	O
+visited	O
+the	O
+hospital	O
+.	O
+
+In	O
+conclusion	O
+,	O
+SARS	B-DISO
+is	O
+a	O
+new	O
+disease	O
+entity	O
+that	O
+is	O
+highly	O
+contagious	O
+.	O
+
+TITLE	O
+:	O
+[	O
+Ventilatory	O
+management	O
+of	O
+the	O
+severely	O
+brain	B-ANAT
+-	O
+injured	O
+patient	O
+].	O
+
+One	O
+example	O
+,	O
+the	O
+PiCCO	O
+monitor	O
+,	O
+combines	O
+arterial	B-ANAT
+thermodilution	O
+with	O
+analysis	O
+of	O
+the	O
+pulse	B-PROC
+waveform	O
+,	O
+providing	O
+a	O
+series	O
+of	O
+hemodynamic	B-PROC
+parameters	O
+useful	O
+for	O
+managing	O
+the	O
+critically	B-DISO
+ill	I-DISO
+patient	O
+.	O
+
+ABSTRACT	O
+:	O
+The	O
+healthcare	O
+setting	O
+was	O
+important	O
+in	O
+the	O
+early	O
+spread	O
+of	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+(	O
+SARS	B-DISO
+)	O
+in	O
+both	O
+Toronto	O
+and	O
+Taiwan	O
+.	O
+
+Healthcare	O
+workers	O
+,	O
+patients	O
+,	O
+and	O
+visitors	O
+were	O
+at	O
+increased	O
+risk	O
+for	O
+infection	B-DISO
+.	O
+
+ABSTRACT	O
+:	O
+Thirty	O
+-	O
+one	O
+cases	O
+of	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+(	O
+SARS	B-DISO
+)	O
+occurred	O
+after	O
+exposure	O
+in	O
+the	O
+emergency	B-DISO
+room	O
+at	O
+the	O
+National	O
+Taiwan	O
+University	O
+Hospital	O
+.	O
+
+ABSTRACT	O
+:	O
+To	O
+characterize	O
+genetic	O
+variation	O
+of	O
+severe	O
+acute	O
+respiratory	O
+syndrome	O
+-	O
+associated	O
+coronavirus	B-SPEC
+(	O
+SARS	B-DISO
+-	O
+CoV	O
+)	O
+transmitted	B-DISO
+in	O
+the	O
+Beijing	O
+area	O
+during	O
+the	O
+epidemic	O
+outbreak	O
+of	O
+2003	O
+,	O
+we	O
+sequenced	O
+29	O
+full	O
+-	O
+length	O
+S	O
+genes	O
+of	O
+SARS	B-PRGE
+-	I-PRGE
+CoV	I-PRGE
+from	O
+20	O
+hospitalized	O
+SARS	B-DISO
+patients	O
+on	O
+our	O
+unit	O
+,	O
+the	O
+Beijing	O
+302	O
+Hospital	O
+.	O
+
+We	O
+conducted	O
+a	O
+prospective	O
+study	O
+on	O
+the	O
+clinical	O
+,	O
+radiologic	O
+,	O
+and	O
+hematologic	O
+findings	O
+of	O
+SARS	B-DISO
+patients	O
+with	O
+pneumonia	B-DISO
+,	O
+who	O
+were	O
+admitted	O
+to	O
+National	O
+Taiwan	O
+University	O
+Hospital	O
+from	O
+March	O
+8	O
+to	O
+June	O
+15	O
+,	O
+2003	O
+.	O
+
+TITLE	O
+:	O
+Laboratory	O
+diagnosis	O
+of	O
+SARS	B-DISO
+.	O
+
+Nonetheless	O
+,	O
+given	O
+that	O
+SARS	B-DISO
+has	O
+been	O
+highly	O
+transmissible	O
+on	O
+some	O
+occasions	O
+,	O
+we	O
+still	O
+recommend	O
+strict	O
+precautions	O
+.	O
+
+This	O
+finding	O
+suggests	O
+that	O
+domestic	O
+poultry	O
+were	O
+unlikely	O
+to	O
+have	O
+been	O
+the	O
+reservoir	O
+,	O
+or	O
+associated	O
+with	O
+dissemination	O
+,	O
+of	O
+SARS	B-DISO
+coronavirus	B-SPEC
+in	O
+the	O
+animal	B-SPEC
+markets	O
+of	O
+southern	O
+China	O
+.	O
+
+ABSTRACT	O
+:	O
+Severe	O
+acute	O
+respiratory	O
+syndrome	O
+(	O
+SARS	B-DISO
+)	O
+is	O
+an	O
+infectious	B-DISO
+disease	I-DISO
+caused	O
+by	O
+a	O
+newly	O
+identified	O
+human	B-SPEC
+coronavirus	I-SPEC
+(	O
+SARS	B-DISO
+-	O
+CoV	O
+).	O
+
+Currently	O
+,	O
+no	O
+effective	O
+drug	O
+exists	O
+to	O
+treat	O
+SARS	B-DISO
+-	I-DISO
+CoV	I-DISO
+infection	I-DISO
+.	O
+
+The	O
+remaining	O
+347	O
+case	O
+-	O
+patients	O
+(	O
+29	O
+.	O
+1	O
+%)	O
+had	O
+undefined	O
+sources	O
+of	O
+infection	B-DISO
+.	O
+
+From	O
+a	O
+probabilistic	O
+viewpoint	O
+,	O
+we	O
+can	O
+theoretically	O
+select	O
+the	O
+amino	B-CHED
+acid	I-CHED
+pairs	O
+as	O
+potential	O
+candidates	O
+for	O
+anti	O
+-	O
+SARS	B-DISO
+drugs	O
+.	O
+
+Tear	B-ANAT
+samples	O
+were	O
+collected	O
+from	O
+36	O
+consecutive	O
+patients	O
+who	O
+were	O
+suspected	O
+of	O
+having	O
+SARS	B-DISO
+in	O
+Singapore	O
+over	O
+a	O
+period	O
+of	O
+12	O
+days	O
+(	O
+7	O
+-	O
+18	O
+April	O
+2003	O
+),	O
+and	O
+analysed	O
+by	O
+PCR	O
+using	O
+protocols	O
+developed	O
+by	O
+the	O
+WHO	O
+network	O
+of	O
+laboratories	O
+.	O
+
+Three	O
+patients	O
+with	O
+probable	O
+SARS	B-DISO
+(	O
+one	O
+female	O
+and	O
+two	O
+male	O
+patients	O
+)	O
+had	O
+positive	O
+results	O
+from	O
+their	O
+tear	B-ANAT
+samples	O
+.	O
+
+The	O
+positive	O
+specimens	O
+were	O
+found	O
+in	O
+cases	O
+sampled	O
+early	O
+in	O
+their	O
+course	O
+of	O
+infection	B-DISO
+.	O
+
+TITLE	O
+:	O
+SARS	B-DISO
+and	O
+common	O
+viral	B-DISO
+infections	I-DISO
+.	O
+
+TITLE	O
+:	O
+[	O
+The	O
+expression	B-PROC
+and	O
+activity	O
+detection	O
+of	O
+a	O
+variant	O
+N	O
+protein	B-CHED
+of	O
+SARS	B-DISO
+-	O
+CoV	O
+].	O
+
+We	O
+probed	O
+these	O
+membranes	B-ANAT
+with	O
+four	O
+pairs	O
+of	O
+acute	O
+and	O
+convalescent	O
+sera	B-COMP
+from	O
+recovered	O
+SARS	B-DISO
+cases	O
+.	O
+
+This	O
+suggests	O
+that	O
+antibodies	B-COMP
+against	O
+the	O
+epitopes	O
+represented	O
+by	O
+these	O
+peptides	B-CHED
+could	O
+be	O
+responsible	O
+for	O
+much	O
+of	O
+the	O
+SARS	B-PRGE
+-	I-PRGE
+CoV	I-PRGE
+neutralizing	O
+activity	O
+.	O
+
+All	O
+patients	O
+received	O
+steroids	B-CHED
+and	O
+ribavirin	B-CHED
+treatment	O
+.	O
+
+Three	O
+patients	O
+had	O
+early	O
+bilateral	O
+AVN	O
+of	O
+the	O
+femoral	B-ANAT
+head	I-ANAT
+,	O
+four	O
+patients	O
+of	O
+one	O
+femoral	B-ANAT
+head	I-ANAT
+,	O
+five	O
+patients	O
+of	O
+the	O
+bilateral	O
+hips	B-ANAT
+and	O
+knees	B-ANAT
+,	O
+four	O
+patients	O
+of	O
+the	O
+ipsilateral	O
+hip	B-ANAT
+and	O
+knees	B-ANAT
+,	O
+10	O
+patients	O
+of	O
+the	O
+knee	B-ANAT
+(	O
+s	O
+),	O
+one	O
+patient	O
+of	O
+the	O
+right	O
+proximal	B-ANAT
+fibula	I-ANAT
+,	O
+and	O
+one	O
+patient	O
+of	O
+the	O
+knees	B-ANAT
+and	O
+talus	B-ANAT
+.	O
+
+Results	O
+of	O
+hip	B-ANAT
+,	O
+knee	B-ANAT
+and	O
+ankle	B-ANAT
+plain	O
+radiographs	O
+were	O
+negative	O
+.	O
+
+RESULTS	O
+:	O
+Twenty	O
+-	O
+eight	O
+patients	O
+were	O
+identified	O
+with	O
+AVN	O
+,	O
+The	O
+mean	O
+time	O
+to	O
+diagnosis	O
+of	O
+AVN	O
+was	O
+119	O
+days	O
+after	O
+the	O
+onset	O
+of	O
+SARS	B-DISO
+,	O
+or	O
+116	O
+days	O
+after	O
+steroid	B-CHED
+use	O
+.	O
+
+NOS2	O
+-/-	O
+animals	B-SPEC
+exhibited	O
+significantly	O
+less	O
+physiologic	O
+lung	B-ANAT
+dysfunction	O
+and	O
+loss	O
+of	O
+SP	B-PRGE
+-	I-PRGE
+B	I-PRGE
+expression	B-PROC
+than	O
+did	O
+WT	O
+animals	B-SPEC
+.	O
+
+Furthermore	O
+,	O
+administration	O
+of	O
+NO	O
+donors	O
+,	O
+independent	O
+of	O
+cytokine	O
+stimulation	O
+,	O
+decreased	O
+SP	B-PRGE
+-	I-PRGE
+B	I-PRGE
+promoter	I-PRGE
+activity	O
+and	O
+mRNA	B-PROC
+expression	B-PROC
+in	O
+mouse	B-ANAT
+lung	I-ANAT
+epithelial	B-ANAT
+cells	I-ANAT
+.	O
+
+These	O
+results	O
+identify	O
+S	O
+among	O
+the	O
+structural	O
+proteins	B-CHED
+as	O
+the	O
+only	O
+significant	O
+SARS	B-PRGE
+-	I-PRGE
+CoV	I-PRGE
+neutralization	I-PRGE
+antigen	B-CHED
+and	O
+protective	O
+antigen	B-CHED
+and	O
+show	O
+that	O
+a	O
+single	O
+mucosal	B-ANAT
+immunization	O
+is	O
+highly	O
+protective	O
+in	O
+an	O
+experimental	O
+animal	B-SPEC
+that	O
+supports	O
+efficient	O
+replication	O
+of	O
+SARS	B-DISO
+-	O
+CoV	O
+.	O
+
+The	O
+occurence	O
+of	O
+hypencapnia	O
+or	O
+CO	O
+(	O
+2	O
+)	O
+retention	B-PROC
+and	O
+was	O
+accompanied	O
+by	O
+myalgias	B-DISO
+.	O
+
+We	O
+conclude	O
+that	O
+NPPV	O
+is	O
+a	O
+feasible	O
+and	O
+appropriate	O
+treatment	O
+for	O
+ARF	B-DISO
+occurring	O
+as	O
+a	O
+result	O
+of	O
+a	O
+SARS	B-DISO
+infection	B-DISO
+.	O
+
+The	O
+recognition	O
+of	O
+the	O
+association	O
+between	O
+the	O
+provision	O
+of	O
+food	O
+in	O
+these	O
+circumstances	O
+and	O
+the	O
+serious	O
+clinical	O
+consequences	O
+,	O
+generally	O
+heartbeat	B-PROC
+disorders	O
+,	O
+has	O
+led	O
+this	O
+condition	B-DISO
+to	O
+be	O
+described	O
+as	O
+""""	O
+re	O
+-	O
+feeding	O
+syndrome	B-DISO
+"""."	O
+
+With	O
+appropriate	O
+protection	O
+measures	O
+,	O
+hemodialysis	O
+was	O
+performed	O
+in	O
+a	O
+dedicated	O
+area	O
+of	O
+the	O
+SARS	B-DISO
+isolation	O
+ward	O
+,	O
+while	O
+PD	O
+was	O
+continued	O
+as	O
+intermittent	O
+PD	O
+.	O
+
+With	O
+appropriate	O
+protective	O
+measures	O
+,	O
+dialysis	B-SPEC
+could	O
+be	O
+safely	O
+performed	O
+.	O
+
+ABSTRACT	O
+:	O
+In	O
+this	O
+study	O
+,	O
+two	O
+homology	O
+models	O
+(	O
+denoted	O
+as	O
+MproST	O
+and	O
+MproSH	O
+)	O
+of	O
+main	O
+proteinase	O
+(	O
+Mpro	B-PROC
+)	O
+from	O
+the	O
+novel	B-SPEC
+coronavirus	I-SPEC
+associated	O
+with	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+(	O
+SARS	B-DISO
+-	O
+CoV	O
+)	O
+were	O
+constructed	O
+based	O
+on	O
+the	O
+crystal	B-ANAT
+structures	O
+of	O
+Mpro	B-PROC
+from	O
+transmissible	O
+gastroenteritis	B-DISO
+coronavirus	B-SPEC
+(	O
+TGEV	B-SPEC
+)	O
+(	O
+MproT	O
+)	O
+and	O
+human	B-PRGE
+coronavirus	I-PRGE
+HcoV	B-SPEC
+-	I-SPEC
+229E	I-SPEC
+(	O
+MproH	O
+),	O
+respectively	O
+.	O
+
+Patients	O
+in	O
+the	O
+plasma	B-ANAT
+group	O
+had	O
+a	O
+shorter	O
+hospital	O
+stay	O
+(	O
+p	O
+0	O
+.	O
+001	O
+)	O
+and	O
+lower	O
+mortality	O
+(	O
+p	O
+0	O
+.	O
+049	O
+)	O
+than	O
+the	O
+comparator	O
+group	O
+.	O
+
+We	O
+showed	O
+that	O
+niclosamide	O
+,	O
+an	O
+existing	O
+antihelminthic	O
+drug	O
+,	O
+was	O
+able	O
+to	O
+inhibit	O
+replication	O
+of	O
+a	O
+newly	O
+discovered	O
+coronavirus	B-SPEC
+,	O
+SARS	B-PRGE
+-	I-PRGE
+CoV	I-PRGE
+;	O
+viral	B-PRGE
+antigen	I-PRGE
+synthesis	B-PROC
+was	O
+totally	O
+abolished	O
+at	O
+a	O
+niclosamide	O
+concentration	O
+of	O
+1	O
+.	O
+56	O
+microM	O
+,	O
+as	O
+revealed	O
+by	O
+immunoblot	O
+analysis	O
+.	O
+
+We	O
+examined	O
+serum	B-COMP
+samples	O
+obtained	O
+from	O
+46	O
+patients	O
+with	O
+SARS	B-DISO
+,	O
+40	O
+patients	O
+with	O
+non	O
+-	O
+SARS	B-DISO
+pneumonia	B-DISO
+,	O
+and	O
+38	O
+healthy	O
+individuals	O
+,	O
+by	O
+use	O
+of	O
+Western	O
+blotting	O
+(	O
+WB	O
+),	O
+enzyme	O
+-	O
+linked	O
+immunoassay	O
+(	O
+ELISA	O
+),	O
+and	O
+immunofluorescence	O
+assay	O
+,	O
+using	O
+both	O
+native	O
+and	O
+bacterially	O
+produced	O
+antigens	B-CHED
+of	O
+the	O
+virus	B-SPEC
+.	O
+
+Almost	O
+all	O
+of	O
+the	O
+subjects	O
+without	O
+SARS	B-DISO
+had	O
+no	O
+antinucleocapsid	O
+antibodies	B-COMP
+.	O
+
+Some	O
+newborn	O
+infants	O
+,	O
+however	O
+,	O
+developed	O
+severe	O
+intrauterine	B-DISO
+growth	B-PROC
+retardation	I-DISO
+and	O
+life	O
+-	O
+threatening	O
+gastrointestinal	B-DISO
+complications	I-DISO
+.	O
+
+Young	O
+children	O
+(<	O
+12	O
+years	O
+),	O
+in	O
+general	O
+,	O
+run	O
+a	O
+less	O
+aggressive	B-DISO
+clinical	O
+course	O
+than	O
+do	O
+teenage	O
+and	O
+adult	O
+patients	O
+.	O
+
+Transcription	B-PROC
+and	O
+translation	B-PROC
+of	O
+S	B-PRGE
+gene	I-PRGE
+for	O
+IBV	B-SPEC
+were	O
+confirmed	O
+by	O
+Northern	O
+blot	O
+and	O
+Western	O
+blot	O
+analyses	O
+in	O
+transgenic	O
+plantlets	O
+.	O
+
+The	O
+data	O
+generated	O
+in	O
+this	O
+animal	B-SPEC
+model	O
+show	O
+that	O
+administration	O
+of	O
+a	O
+human	B-SPEC
+monoclonal	O
+antibody	B-COMP
+might	O
+offer	O
+a	O
+feasible	O
+and	O
+effective	O
+prophylaxis	O
+for	O
+the	O
+control	O
+of	O
+human	B-SPEC
+SARS	B-DISO
+coronavirus	B-SPEC
+infection	I-DISO
+.	O
+
+U122	O
+is	O
+localized	O
+to	O
+the	O
+perinuclear	O
+region	O
+of	O
+both	O
+SARS	O
+-	O
+CoV	O
+-	O
+infected	O
+and	O
+transfected	O
+cells	B-COMP
+and	O
+colocalized	O
+with	O
+ER	O
+and	O
+intermediate	O
+compartment	B-ANAT
+markers	O
+.	O
+
+The	O
+efficiency	O
+of	O
+incorporation	O
+of	O
+the	O
+chimeric	O
+protein	B-CHED
+into	O
+particles	O
+was	O
+,	O
+however	O
+,	O
+reduced	O
+relative	O
+to	O
+that	O
+in	O
+wild	O
+-	O
+type	O
+particles	O
+which	O
+may	O
+explain	O
+,	O
+at	O
+least	O
+in	O
+part	O
+,	O
+the	O
+reduced	O
+infectivity	O
+produced	O
+by	O
+MHV	B-SPEC
+-	O
+SGFP	O
+infection	B-DISO
+.	O
+
+We	O
+conclude	O
+that	O
+the	O
+incorporation	O
+of	O
+spikes	O
+carrying	O
+the	O
+large	O
+GFP	O
+moiety	O
+is	O
+apparently	O
+impaired	B-DISO
+by	O
+geometrical	O
+constraints	O
+and	O
+selected	O
+against	O
+during	O
+the	O
+assembly	O
+of	O
+virions	B-COMP
+.	O
+
+The	O
+cause	O
+was	O
+determined	O
+as	O
+a	O
+novel	B-SPEC
+coronavirus	I-SPEC
+(	O
+CoV	B-SPEC
+),	O
+SARS	B-PRGE
+-	I-PRGE
+associated	I-PRGE
+CoV	B-SPEC
+(	O
+SARS	B-PRGE
+-	I-PRGE
+CoV	B-SPEC
+),	O
+with	O
+a	O
+single	O
+-	O
+stranded	O
+,	O
+plus	O
+-	O
+sense	B-PROC
+RNA	O
+.	O
+
+TITLE	O
+:	O
+Expression	B-PROC
+of	O
+the	O
+mouse	B-DISO
+hepatitis	I-DISO
+virus	B-SPEC
+receptor	O
+by	O
+central	B-ANAT
+nervous	I-ANAT
+system	I-ANAT
+microglia	B-ANAT
+.	O
+
+ABSTRACT	O
+:	O
+Detection	O
+of	O
+the	O
+mouse	O
+hepatitis	O
+virus	B-SPEC
+receptor	O
+within	O
+the	O
+central	B-ANAT
+nervous	I-ANAT
+system	I-ANAT
+(	O
+CNS	B-CHED
+)	O
+has	O
+been	O
+elusive	O
+.	O
+
+Receptor	B-PROC
+expression	I-PROC
+on	O
+microglia	B-ANAT
+was	O
+reduced	O
+during	O
+acute	B-DISO
+infection	I-DISO
+and	O
+restored	O
+following	O
+immune	O
+-	O
+mediated	O
+virus	B-SPEC
+control	O
+.	O
+
+ABSTRACT	O
+:	O
+The	O
+human	B-PRGE
+coronavirus	I-PRGE
+229E	I-PRGE
+(	O
+HCoV	B-SPEC
+-	I-SPEC
+229E	I-SPEC
+)	O
+replicase	O
+gene	O
+-	O
+encoded	O
+nonstructural	B-PRGE
+protein	I-PRGE
+13	I-PRGE
+(	O
+nsp13	O
+)	O
+contains	O
+an	O
+N	O
+-	O
+terminal	O
+zinc	B-CHED
+-	O
+binding	B-FUNC
+domain	O
+and	O
+a	O
+C	B-PRGE
+-	I-PRGE
+terminal	I-PRGE
+superfamily	I-PRGE
+1	I-PRGE
+helicase	I-PRGE
+domain	I-PRGE
+.	O
+
+However	O
+,	O
+mortality	O
+remains	O
+high	O
+in	O
+patients	O
+suffering	B-DISO
+from	O
+severe	O
+ARDS	B-DISO
+despite	O
+newer	O
+treatment	O
+modalities	O
+.	O
+
+Despite	O
+the	O
+fact	O
+that	O
+SARS	B-DISO
+-	O
+CoV	O
+can	O
+infect	O
+the	O
+lung	B-ANAT
+and	O
+intestine	B-ANAT
+,	O
+the	O
+tissue	B-ANAT
+responses	O
+in	O
+these	O
+two	O
+organs	B-ANAT
+are	O
+different	O
+.	O
+
+Remarkably	O
+,	O
+endothelial	B-ANAT
+cells	I-ANAT
+,	O
+which	O
+express	O
+ACE2	B-PRGE
+to	O
+a	O
+high	O
+level	O
+,	O
+have	O
+not	O
+been	O
+shown	O
+to	O
+be	O
+infected	O
+by	O
+SARS	B-DISO
+-	O
+CoV	O
+.	O
+There	O
+is	O
+also	O
+evidence	O
+that	O
+cell	B-COMP
+types	O
+without	O
+detectable	O
+ACE2	B-PRGE
+expression	B-PROC
+may	O
+also	O
+be	O
+infected	O
+by	O
+the	O
+virus	B-SPEC
+.	O
+
+ABSTRACT	O
+:	O
+Pneumonia	B-DISO
+and	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+are	O
+life	O
+-	O
+threatening	O
+complications	O
+after	O
+pneumonectomy	O
+carrying	O
+high	O
+mortality	O
+.	O
+
+Titre	O
+increases	O
+were	O
+seen	O
+for	O
+IBV	B-SPEC
+D274	O
+(	O
+one	O
+control	O
+flock	O
+)	O
+and	O
+O	B-SPEC
+.	I-SPEC
+rhinotracheale	I-SPEC
+(	O
+one	O
+control	O
+and	O
+one	O
+colibacillosis	B-DISO
+flock	O
+).	O
+
+ABSTRACT	O
+:	O
+A	O
+method	O
+is	O
+described	O
+for	O
+enabling	O
+safe	O
+transit	O
+of	O
+denatured	O
+virus	B-SPEC
+samples	O
+for	O
+polymerase	O
+chain	O
+reaction	O
+(	O
+PCR	O
+)	O
+identification	O
+without	O
+the	O
+risk	O
+of	O
+unwanted	O
+viable	O
+viruses	B-SPEC
+.	O
+
+TITLE	O
+:	O
+Egg	B-ANAT
+:	O
+embryo	B-ANAT
+weight	O
+ratio	O
+as	O
+an	O
+indicator	B-CHED
+of	O
+dwarfism	B-DISO
+induced	O
+by	O
+infectious	B-DISO
+bronchitis	B-DISO
+virus	B-SPEC
+.	O
+
+The	O
+eggs	O
+and	O
+the	O
+respective	O
+embryos	B-ANAT
+were	O
+weighed	O
+and	O
+embryo	B-ANAT
+:	O
+egg	B-ANAT
+weight	O
+(	O
+EE	O
+)	O
+ratios	O
+were	O
+calculated	O
+.	O
+
+These	O
+results	O
+demonstrated	O
+,	O
+for	O
+the	O
+first	O
+time	O
+,	O
+that	O
+there	O
+is	O
+a	O
+new	O
+genotype	O
+of	O
+nephropathogenic	O
+IBV	B-SPEC
+circulating	O
+in	O
+vaccinated	O
+and	O
+non	O
+-	O
+vaccinated	O
+flocks	O
+in	O
+China	O
+.	O
+
+ABSTRACT	O
+:	O
+High	O
+frequency	O
+oscillatory	O
+ventilation	O
+(	O
+HFOV	O
+)	O
+improves	O
+gas	B-ENZY
+exchange	O
+while	O
+providing	O
+lung	B-ANAT
+protective	O
+effects	O
+during	O
+the	O
+ventilation	O
+of	O
+patients	O
+with	O
+the	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+(	O
+ARDS	B-DISO
+).	O
+
+Of	O
+>	O
+10	O
+,	O
+000	O
+agents	O
+tested	O
+,	O
+approximately	O
+50	O
+compounds	O
+were	O
+found	O
+active	O
+at	O
+10	O
+microM	O
+;	O
+among	O
+these	O
+compounds	O
+,	O
+two	O
+are	O
+existing	O
+drugs	O
+(	O
+Reserpine	B-CHED
+13	O
+and	O
+Aescin	O
+5	O
+)	O
+and	O
+several	O
+are	O
+in	O
+clinical	O
+development	B-PROC
+.	O
+
+These	O
+50	O
+active	O
+compounds	O
+were	O
+tested	O
+again	O
+,	O
+and	O
+compounds	O
+2	O
+-	O
+6	O
+,	O
+10	O
+,	O
+and	O
+13	O
+showed	O
+active	O
+at	O
+3	O
+microM	O
+.	O
+The	O
+50	O
+%	O
+inhibitory	O
+concentrations	O
+for	O
+the	O
+inhibition	B-PROC
+of	O
+viral	B-PROC
+replication	I-PROC
+(	O
+EC	O
+(	O
+50	O
+))	O
+and	O
+host	B-COMP
+growth	B-PROC
+(	O
+CC	O
+(	O
+50	O
+))	O
+were	O
+then	O
+measured	O
+and	O
+the	O
+selectivity	O
+index	O
+(	O
+SI	O
+=	O
+CC	O
+(	O
+50	O
+)/	O
+EC	O
+(	O
+50	O
+))	O
+was	O
+determined	O
+.	O
+
+Additional	O
+studies	O
+were	O
+carried	O
+out	O
+to	O
+further	O
+understand	O
+the	O
+mode	O
+of	O
+action	O
+of	O
+some	O
+active	O
+compounds	O
+,	O
+including	O
+ELISA	O
+,	O
+Western	O
+blot	O
+analysis	O
+,	O
+immunofluorescence	O
+and	O
+flow	O
+cytometry	O
+assays	O
+,	O
+and	O
+inhibition	B-PROC
+against	O
+the	O
+3CL	B-PRGE
+protease	I-PRGE
+and	O
+viral	O
+entry	O
+.	O
+
+ABSTRACT	O
+:	O
+The	O
+seroprevalence	O
+of	O
+antibody	B-COMP
+to	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+(	O
+SARS	B-DISO
+)-	O
+associated	O
+coronavirus	B-SPEC
+(	O
+SARS	B-DISO
+-	O
+CoV	O
+)	O
+in	O
+cohorts	O
+of	O
+health	O
+care	O
+workers	O
+(	O
+HCWs	O
+)	O
+with	O
+subclinical	B-DISO
+infection	I-DISO
+in	O
+SARS	B-DISO
+and	O
+non	O
+-	O
+SARS	B-DISO
+medical	O
+wards	O
+was	O
+2	O
+.	O
+3	O
+%	O
+(	O
+3	O
+of	O
+131	O
+HCWs	O
+)	O
+and	O
+0	O
+%	O
+(	O
+0	O
+of	O
+192	O
+HCWs	O
+),	O
+respectively	O
+.	O
+
+Rates	O
+for	O
+clinical	O
+SARS	B-DISO
+-	I-DISO
+CoV	I-DISO
+infection	I-DISO
+among	O
+742	O
+HCWs	O
+on	O
+these	O
+wards	O
+were	O
+highest	O
+among	O
+nurses	O
+(	O
+11	O
+.	O
+6	O
+%)	O
+and	O
+health	O
+care	O
+assistants	O
+(	O
+11	O
+.	O
+8	O
+%),	O
+indicating	O
+that	O
+these	O
+occupations	O
+are	O
+associated	O
+with	O
+the	O
+highest	O
+risks	O
+for	O
+exposure	O
+.	O
+
+This	O
+article	O
+provides	O
+a	O
+brief	O
+review	O
+of	O
+the	O
+surveillance	O
+,	O
+viral	O
+causes	O
+and	O
+current	O
+diagnostic	O
+methods	O
+used	O
+to	O
+identify	O
+viruses	B-SPEC
+causing	O
+ILI	O
+.	O
+
+Nucleotide	B-CHED
+acid	O
+sequence	O
+of	O
+S1	B-PRGE
+gene	I-PRGE
+of	O
+the	O
+isolate	O
+SC021202	O
+was	O
+further	O
+sequenced	O
+and	O
+analysed	O
+.	O
+
+In	O
+a	O
+pathogenicity	O
+experiment	O
+,	O
+the	O
+clinical	O
+signs	O
+and	O
+related	O
+gross	O
+lesions	O
+resembling	O
+those	O
+of	O
+field	O
+outbreak	O
+were	O
+reproduced	O
+and	O
+the	O
+virus	B-SPEC
+isolate	O
+SC021202	O
+was	O
+re	O
+-	O
+isolated	O
+from	O
+the	O
+kidneys	B-ANAT
+of	O
+the	O
+infected	O
+chicken	B-SPEC
+.	O
+
+TITLE	O
+:	O
+Inactivated	O
+SARS	B-DISO
+-	O
+CoV	O
+vaccine	O
+prepared	O
+from	O
+whole	O
+virus	B-SPEC
+induces	O
+a	O
+high	O
+level	O
+of	O
+neutralizing	O
+antibodies	B-COMP
+in	O
+BALB	O
+/	O
+c	O
+mice	B-SPEC
+.	O
+
+RESULTS	O
+:	O
+Results	O
+from	O
+simple	O
+factor	O
+logistic	O
+regression	O
+analysis	O
+showed	O
+that	O
+jobs	O
+which	O
+dealing	O
+with	O
+domestic	O
+livestock	O
+,	O
+wild	O
+livestock	O
+,	O
+wild	O
+animals	O
+,	O
+aquatics	O
+were	O
+related	O
+to	O
+risk	O
+factors	O
+of	O
+SARS	B-DISO
+-	I-DISO
+CoV	I-DISO
+infection	I-DISO
+.	O
+
+CONCLUSIONS	O
+:	O
+Job	O
+that	O
+dealing	O
+with	O
+palm	B-ANAT
+civets	B-SPEC
+was	O
+the	O
+main	O
+risk	O
+factor	O
+of	O
+SARS	B-DISO
+-	I-DISO
+CoV	I-DISO
+infection	I-DISO
+in	O
+animal	B-SPEC
+market	O
+workers	O
+.	O
+
+Methods	O
+as	O
+television	O
+,	O
+radio	B-CHED
+,	O
+newspapers	O
+,	O
+magazines	O
+,	O
+printing	O
+and	O
+distribution	O
+of	O
+specific	O
+materials	O
+on	O
+SARS	B-DISO
+were	O
+included	O
+,	O
+and	O
+hotlines	O
+of	O
+telephone	O
+and	O
+mobile	O
+phone	O
+,	O
+web	B-DISO
+-	O
+based	O
+sites	O
+,	O
+electronic	O
+screening	O
+advertisements	O
+,	O
+and	O
+consultation	O
+or	O
+forum	O
+for	O
+the	O
+public	O
+etc	O
+.	O
+were	O
+used	O
+.	O
+
+TITLE	O
+:	O
+[	O
+The	O
+'	O
+Beijing	O
+clinical	O
+database	O
+'	O
+on	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+patients	O
+:	O
+its	O
+design	O
+,	O
+process	O
+,	O
+quality	O
+control	O
+and	O
+evaluation	O
+].	O
+
+The	O
+database	O
+was	O
+designed	O
+by	O
+specialists	O
+,	O
+under	O
+the	O
+organization	O
+of	O
+the	O
+Beijing	O
+Commanding	O
+Center	O
+for	O
+SARS	B-DISO
+Treatment	O
+and	O
+Cure	O
+,	O
+including	O
+686	O
+data	O
+items	O
+in	O
+six	O
+sub	O
+-	O
+databases	O
+:	O
+primary	O
+medical	O
+-	O
+care	O
+seeking	O
+,	O
+vital	O
+signs	O
+,	O
+common	O
+symptoms	B-DISO
+and	I-DISO
+signs	I-DISO
+,	O
+treatment	O
+,	O
+laboratory	O
+and	O
+auxiliary	O
+test	O
+,	O
+and	O
+cost	O
+.	O
+
+A	O
+series	O
+of	O
+procedures	O
+had	O
+been	O
+taken	O
+before	O
+the	O
+database	O
+was	O
+finally	O
+established	O
+which	O
+included	O
+programmed	O
+logic	O
+checking	O
+,	O
+digit	O
+-	O
+by	O
+-	O
+digit	B-ANAT
+check	O
+on	O
+5	O
+%	O
+random	O
+sample	O
+,	O
+data	O
+linkage	B-PROC
+for	O
+transferred	O
+cases	O
+,	O
+coding	O
+of	O
+characterized	O
+information	O
+,	O
+database	O
+structure	O
+standardization	O
+,	O
+case	O
+reviewe	O
+by	O
+computer	O
+program	O
+according	O
+to	O
+SARS	B-DISO
+Clinical	O
+Diagnosis	O
+Criteria	O
+issued	O
+by	O
+the	O
+Ministry	O
+of	O
+Health	O
+,	O
+and	O
+exclusion	O
+of	O
+unqualified	O
+patients	O
+.	O
+
+Specifically	O
+,	O
+the	O
+data	O
+completion	O
+rate	O
+was	O
+73	O
+%	O
+-	O
+100	O
+%	O
+in	O
+primary	O
+medical	O
+-	O
+care	O
+seeking	O
+,	O
+90	O
+%	O
+in	O
+common	O
+symptoms	B-DISO
+and	I-DISO
+signs	I-DISO
+,	O
+100	O
+%	O
+for	O
+treatment	O
+,	O
+98	O
+%	O
+for	O
+temperature	O
+,	O
+90	O
+%	O
+for	O
+pulse	B-PROC
+,	O
+100	O
+%	O
+for	O
+outcomes	O
+and	O
+98	O
+%	O
+for	O
+costs	O
+in	O
+hospital	O
+.	O
+
+TITLE	O
+:	O
+[	O
+Relationship	O
+between	O
+the	O
+severity	O
+,	O
+course	O
+,	O
+fatality	O
+of	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+patients	O
+and	O
+the	O
+timing	O
+of	O
+hospitalization	O
+].	O
+
+The	O
+average	O
+numbers	O
+of	O
+abnormal	O
+lung	B-ANAT
+field	I-ANAT
+(	O
+the	O
+lung	B-ANAT
+were	O
+divided	O
+into	O
+6	O
+fields	O
+)	O
+were	O
+1	O
+.	O
+7	O
+,	O
+1	O
+.	O
+9	O
+,	O
+2	O
+.	O
+5	O
+and	O
+2	O
+.	O
+6	O
+(	O
+P	O
+<	O
+0	O
+.	O
+001	O
+);	O
+The	O
+numbers	O
+of	O
+cases	O
+receiving	O
+continuous	O
+oxygen	B-CHED
+supply	O
+treatment	O
+were	O
+33	O
+.	O
+6	O
+%,	O
+50	O
+.	O
+0	O
+%,	O
+53	O
+.	O
+7	O
+%	O
+and	O
+74	O
+.	O
+0	O
+%	O
+(	O
+P	O
+<	O
+0	O
+.	O
+001	O
+),	O
+and	O
+the	O
+numbers	O
+of	O
+cases	O
+receiving	O
+glucocorticosteroids	O
+treatment	O
+were	O
+28	O
+.	O
+2	O
+%,	O
+35	O
+.	O
+9	O
+%,	O
+53	O
+.	O
+7	O
+%	O
+and	O
+62	O
+.	O
+0	O
+%	O
+(	O
+P	O
+<	O
+0	O
+.	O
+001	O
+),	O
+respectively	O
+.	O
+
+ABSTRACT	O
+:	O
+Human	B-PRGE
+aminopeptidase	B-ENZY
+N	I-ENZY
+(	O
+APN	B-PRGE
+/	O
+CD13	B-PRGE
+/	O
+ANPEP	B-PRGE
+)	O
+has	O
+been	O
+identified	O
+as	O
+the	O
+receptor	O
+for	O
+human	B-SPEC
+coronavirus	I-SPEC
+(	O
+HCoV	O
+)	O
+229E	O
+.	O
+
+ABSTRACT	O
+:	O
+The	O
+recent	O
+outbreak	O
+of	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+(	O
+SARS	B-DISO
+)	O
+warrants	O
+the	O
+search	O
+for	O
+effective	O
+antiviral	B-CHED
+agents	I-CHED
+to	O
+treat	O
+the	O
+disease	O
+.	O
+
+Two	O
+organic	O
+NO	O
+donor	B-CHED
+compounds	O
+,	O
+S	O
+-	O
+nitroso	B-CHED
+-	O
+N	B-CHED
+-	I-CHED
+acetylpenicillamine	I-CHED
+(	O
+SNAP	B-FUNC
+)	O
+and	O
+sodium	B-CHED
+nitroprusside	I-CHED
+(	O
+SNP	O
+),	O
+were	O
+tested	O
+in	O
+a	O
+broad	O
+range	O
+of	O
+concentrations	O
+.	O
+
+No	O
+anti	B-PRGE
+-	I-PRGE
+SARS	I-PRGE
+-	I-PRGE
+CoV	I-PRGE
+effect	O
+could	O
+be	O
+detected	O
+for	O
+SNP	O
+and	O
+NAP	B-PROC
+.	O
+
+CONCLUSIONS	O
+:	O
+The	O
+survival	O
+rate	O
+of	O
+SARS	B-DISO
+-	O
+CoV	O
+infected	O
+cells	B-COMP
+was	O
+greatly	O
+increased	O
+by	O
+the	O
+treatment	O
+with	O
+SNAP	B-FUNC
+,	O
+and	O
+the	O
+concentration	O
+of	O
+this	O
+compound	O
+needed	O
+to	O
+inhibit	O
+the	O
+viral	B-DISO
+cytopathic	I-DISO
+effect	I-DISO
+to	O
+50	O
+%	O
+was	O
+222	O
+microM	O
+,	O
+with	O
+a	O
+selectivity	O
+index	O
+of	O
+3	O
+.	O
+
+It	O
+was	O
+preliminarily	O
+demonstrated	O
+that	O
+the	O
+assay	O
+could	O
+efficiently	O
+detect	O
+SARS	B-PRGE
+-	I-PRGE
+CoV	I-PRGE
+from	O
+clinical	O
+specimens	O
+of	O
+SARS	B-DISO
+probable	O
+and	O
+suspected	O
+patients	O
+identified	O
+in	O
+Taiwan	O
+.	O
+
+Antibody	B-COMP
+from	O
+convalescent	O
+SARS	B-DISO
+patients	O
+,	O
+but	O
+not	O
+normal	O
+human	B-SPEC
+serum	B-COMP
+,	O
+is	O
+also	O
+shown	O
+to	O
+specifically	O
+compete	O
+off	O
+binding	B-FUNC
+of	O
+mAbs	O
+to	O
+whole	O
+SARS	B-DISO
+-	O
+CoV	O
+.	O
+These	O
+studies	O
+highlight	O
+the	O
+importance	O
+of	O
+using	O
+standardised	O
+assays	O
+and	O
+reagents	B-CHED
+.	O
+
+SARS	B-DISO
+-	O
+CoV	O
+immunoglobulin	B-PRGE
+G	I-PRGE
+(	O
+IgG	B-PRGE
+)	O
+antibody	B-COMP
+was	O
+determined	O
+by	O
+enzyme	O
+linked	O
+immunoadsorbent	O
+assay	O
+(	O
+ELISA	O
+).	O
+
+The	O
+absorbance	O
+(	O
+A	O
+)	O
+value	O
+of	O
+SARS	B-PRGE
+-	I-PRGE
+CoV	I-PRGE
+IgG	B-COMP
+antibody	I-COMP
+ranged	O
+from	O
+0	O
+.	O
+81	O
+to	O
+2	O
+.	O
+06	O
+in	O
+patients	O
+after	O
+half	O
+an	O
+year	O
+of	O
+SARS	B-DISO
+onset	O
+,	O
+and	O
+form	O
+0	O
+.	O
+79	O
+to	O
+2	O
+.	O
+01	O
+in	O
+patients	O
+before	O
+half	O
+an	O
+year	O
+of	O
+SARS	B-DISO
+onset	O
+.	O
+
+CONCLUSIONS	O
+:	O
+The	O
+A	O
+value	O
+of	O
+SARS	B-PRGE
+-	I-PRGE
+CoV	I-PRGE
+IgG	B-COMP
+antibody	I-COMP
+in	O
+serum	B-COMP
+of	O
+convalescent	O
+patients	O
+tended	O
+to	O
+elevate	O
+in	O
+half	O
+an	O
+year	O
+after	O
+SARS	B-DISO
+onset	O
+.	O
+
+Since	O
+then	O
+,	O
+a	O
+large	O
+body	B-ANAT
+of	O
+research	O
+on	O
+the	O
+syndrome	B-DISO
+has	O
+been	O
+published	O
+;	O
+the	O
+most	O
+updated	O
+developments	O
+are	O
+summarized	O
+here	O
+.	O
+
+For	O
+IgA	B-PRGE
+,	O
+the	O
+median	O
+OD450	O
+turned	O
+positive	O
+at	O
+day	O
+17	O
+,	O
+peaked	O
+at	O
+about	O
+day	O
+50	O
+,	O
+and	O
+fell	O
+to	O
+below	O
+the	O
+baseline	O
+level	O
+at	O
+about	O
+day	O
+180	O
+.	O
+
+One	O
+,	O
+four	O
+,	O
+and	O
+one	O
+of	O
+the	O
+six	O
+patients	O
+who	O
+died	B-PROC
+did	O
+not	O
+produce	O
+any	O
+IgG	B-PRGE
+,	O
+IgM	B-PRGE
+,	O
+and	O
+IgA	B-PRGE
+antibodies	I-PRGE
+against	O
+the	O
+nucleocapsid	B-COMP
+protein	B-CHED
+of	O
+SARS	B-PRGE
+-	I-PRGE
+CoV	I-PRGE
+,	O
+respectively	O
+,	O
+although	O
+these	O
+antibodies	B-COMP
+were	O
+detected	O
+in	O
+all	O
+six	O
+patients	O
+by	O
+the	O
+indirect	O
+immunofluorescence	O
+assay	O
+.	O
+
+The	O
+assay	O
+was	O
+carried	O
+out	O
+with	O
+hyperimmune	O
+polyclonal	O
+nucleocapsid	B-COMP
+-	O
+specific	O
+antibodies	B-COMP
+from	O
+guinea	B-SPEC
+pigs	I-SPEC
+and	O
+rabbits	B-SPEC
+immunized	O
+with	O
+recombinant	O
+His	O
+(	O
+6	O
+)-	O
+tagged	O
+SARS	B-PRGE
+CoV	I-PRGE
+nucleocapsid	B-COMP
+protein	B-CHED
+.	O
+
+ABSTRACT	O
+:	O
+The	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+coronavirus	B-SPEC
+(	O
+SARS	B-DISO
+-	O
+CoV	O
+)	O
+is	O
+the	O
+causative	O
+agent	O
+of	O
+the	O
+recent	O
+outbreak	O
+of	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+.	O
+
+Cells	B-COMP
+derived	O
+from	O
+three	O
+species	B-SPEC
+of	O
+monkey	B-SPEC
+were	O
+susceptible	O
+to	O
+SARS	B-DISO
+-	O
+CoV	O
+.	O
+However	O
+,	O
+the	O
+levels	O
+of	O
+SARS	B-PRGE
+-	I-PRGE
+CoV	I-PRGE
+produced	O
+differed	O
+by	O
+4	O
+log	O
+(	O
+10	O
+).	O
+
+TITLE	O
+:	O
+Identification	O
+of	O
+the	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+coronavirus	B-SPEC
+by	O
+simultaneous	O
+multigene	O
+DNA	O
+sequencing	O
+.	O
+
+Although	O
+the	O
+identity	O
+of	O
+the	O
+SARS	B-DISO
+coronavirus	B-SPEC
+(	O
+SARS	B-DISO
+-	O
+CoV	O
+)	O
+genome	O
+was	O
+confirmed	O
+by	O
+DNA	O
+sequencing	O
+,	O
+it	O
+is	O
+impractical	O
+to	O
+sequence	O
+the	O
+entire	O
+29	O
+-	O
+kb	O
+SARS	B-DISO
+-	O
+CoV	O
+genome	O
+on	O
+a	O
+routine	O
+basis	O
+.	O
+
+ABSTRACT	O
+:	O
+Health	O
+care	O
+facilities	O
+need	O
+to	O
+review	O
+their	O
+infection	B-DISO
+control	O
+plans	O
+to	O
+prepare	O
+for	O
+the	O
+possible	O
+resurgence	O
+of	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+,	O
+other	O
+emerging	O
+pathogens	O
+,	O
+familiar	O
+infectious	B-DISO
+agents	O
+such	O
+as	O
+tuberculosis	B-PATH
+and	O
+influenza	B-DISO
+,	O
+and	O
+bioterrorist	O
+threats	O
+.	O
+
+ABSTRACT	O
+:	O
+Passive	O
+serotherapy	O
+can	O
+confer	O
+immediate	O
+protection	O
+against	O
+microbial	O
+infection	B-DISO
+,	O
+but	O
+methods	O
+to	O
+rapidly	O
+generate	O
+human	B-PRGE
+neutralizing	I-PRGE
+monoclonal	I-PRGE
+antibodies	B-COMP
+are	O
+not	O
+yet	O
+available	O
+.	O
+
+TITLE	O
+:	O
+Potent	O
+and	O
+selective	O
+inhibition	B-PROC
+of	O
+SARS	B-DISO
+coronavirus	B-SPEC
+replication	O
+by	O
+aurintricarboxylic	O
+acid	O
+.	O
+
+ABSTRACT	O
+:	O
+The	O
+severe	O
+acute	O
+respiratory	O
+syndrome	O
+virus	B-SPEC
+(	O
+SARS	B-DISO
+)	O
+is	O
+a	O
+coronavirus	B-SPEC
+that	O
+instigated	O
+regional	O
+epidemics	O
+in	O
+Canada	O
+and	O
+several	O
+Asian	O
+countries	O
+in	O
+2003	O
+.	O
+
+The	O
+newly	O
+identified	O
+SARS	B-DISO
+coronavirus	B-SPEC
+(	O
+SARS	B-DISO
+-	O
+CoV	O
+)	O
+can	O
+be	O
+transmitted	B-DISO
+among	O
+humans	B-SPEC
+and	O
+cause	O
+severe	O
+or	O
+even	O
+fatal	O
+illnesses	O
+.	O
+
+As	O
+preventive	O
+vaccine	O
+development	B-PROC
+takes	O
+years	O
+to	O
+complete	O
+and	O
+adverse	O
+reactions	O
+have	O
+been	O
+reported	O
+to	O
+some	O
+veterinary	O
+coronaviral	O
+vaccines	O
+,	O
+anti	O
+-	O
+viral	O
+compounds	O
+must	O
+be	O
+relentlessly	O
+pursued	O
+.	O
+
+When	O
+a	O
+protocol	O
+is	O
+placed	O
+in	O
+a	O
+government	O
+forum	O
+for	O
+analysis	O
+,	O
+the	O
+public	O
+has	O
+a	O
+unique	O
+opportunity	O
+to	O
+debate	O
+the	O
+balancing	B-PROC
+of	O
+research	O
+risks	O
+and	O
+benefits	O
+on	O
+behalf	O
+of	O
+children	O
+who	O
+are	O
+unable	O
+to	O
+assent	O
+to	O
+research	O
+themselves	O
+,	O
+as	O
+well	O
+as	O
+to	O
+express	O
+views	O
+about	O
+vaccination	O
+policy	O
+broadly	O
+.	O
+
+Nineteen	O
+patients	O
+who	O
+recovered	O
+from	O
+SARS	B-DISO
+-	O
+related	O
+hospitalization	O
+.	O
+
+Glycocorticosteroid	O
+and	O
+Chinese	O
+herbal	O
+medicine	B-CHED
+treatments	O
+could	O
+promote	O
+the	O
+recovery	O
+of	O
+T	B-ANAT
+-	I-ANAT
+lymphocyte	I-ANAT
+profile	O
+,	O
+rationally	O
+use	O
+of	O
+them	O
+is	O
+the	O
+effective	O
+therapeutic	O
+method	O
+.	O
+
+These	O
+issues	O
+need	O
+to	O
+be	O
+addressed	O
+in	O
+case	O
+the	O
+virus	B-SPEC
+becomes	O
+more	O
+widespread	O
+in	O
+the	O
+near	O
+future	O
+.	O
+
+The	O
+combination	O
+of	O
+these	O
+gel	O
+-	O
+base	O
+and	O
+non	O
+-	O
+gel	O
+methods	O
+provides	O
+fast	B-FUNC
+and	O
+complimentary	O
+approaches	O
+to	O
+SARS	O
+-	O
+CoV	O
+proteome	O
+and	O
+can	O
+be	O
+widely	O
+used	O
+in	O
+the	O
+analysis	O
+of	O
+other	O
+viruses	B-SPEC
+.	O
+
+Common	O
+laboratory	O
+features	O
+include	O
+lymphopenia	B-DISO
+,	O
+thrombocytopenia	O
+,	O
+raised	O
+alanine	B-CHED
+transaminases	O
+,	O
+lactate	B-PRGE
+dehydrogenase	I-PRGE
+,	O
+and	O
+creatine	B-PRGE
+kinase	I-PRGE
+.	O
+
+In	O
+addition	O
+,	O
+glucocorticoids	B-CHED
+could	O
+induce	O
+lymphopenia	B-DISO
+and	O
+the	O
+use	O
+of	O
+steroids	B-CHED
+may	O
+account	O
+for	O
+the	O
+decrease	O
+of	O
+lymphocytes	B-ANAT
+in	O
+some	O
+SARS	B-DISO
+patients	O
+.	O
+
+Clinical	O
+studies	O
+in	O
+ARDS	B-DISO
+demonstrated	O
+that	O
+the	O
+combination	O
+of	O
+iNO	O
+with	O
+other	O
+interventions	O
+,	O
+such	O
+as	O
+positive	O
+end	B-PROC
+-	I-PROC
+expiratory	I-PROC
+pressure	O
+(	O
+PEEP	B-CHED
+)	O
+and	O
+prone	O
+positioning	O
+,	O
+yielded	O
+beneficial	O
+and	O
+additive	O
+effects	O
+on	O
+arterial	B-ANAT
+oxygenation	B-PROC
+.	O
+
+The	O
+peptides	B-CHED
+from	O
+S1	O
+domain	O
+of	O
+SARS	B-PRGE
+-	I-PRGE
+Cov	I-PRGE
+S	I-PRGE
+-	I-PRGE
+protein	B-CHED
+were	O
+synthesized	O
+by	O
+peptide	B-CHED
+synthesizer	O
+,	O
+and	O
+the	O
+immunological	O
+reaction	O
+of	O
+the	O
+peptides	B-CHED
+with	O
+the	O
+serum	B-COMP
+of	O
+SARS	B-DISO
+patients	O
+were	O
+examined	O
+by	O
+means	O
+of	O
+ELISA	O
+.	O
+
+In	O
+contrast	O
+to	O
+Vero	B-ANAT
+cells	I-ANAT
+,	O
+SARS	B-PRGE
+-	I-PRGE
+CoV	I-PRGE
+did	O
+not	O
+produce	O
+cytopathic	B-DISO
+effects	I-DISO
+on	O
+LoVo	O
+cells	B-COMP
+.	O
+
+A	O
+new	O
+,	O
+modified	O
+point	O
+of	O
+care	O
+(	O
+POC	O
+)	O
+diagnostic	O
+test	O
+(	O
+ZstatFlu	O
+)	O
+was	O
+assessed	O
+on	O
+469	O
+nasopharyngeal	B-ANAT
+aspirates	B-ANAT
+(	O
+NPAs	O
+)	O
+and	O
+260	O
+nose	B-ANAT
+/	O
+throat	B-ANAT
+swabs	O
+(	O
+TS	O
+)	O
+taken	O
+from	O
+children	O
+and	O
+adults	O
+.	O
+
+48	O
+siRNA	O
+sequences	O
+were	O
+designed	O
+for	O
+targeting	B-PROC
+regions	O
+throughout	O
+entire	O
+SARS	B-DISO
+-	O
+CoV	O
+genome	O
+RNA	O
+including	O
+open	O
+-	O
+reading	O
+frames	O
+for	O
+several	O
+key	O
+proteins	B-CHED
+.	O
+
+The	O
+diagnosis	O
+of	O
+RSV	B-DISO
+infection	I-DISO
+was	O
+sought	O
+by	O
+PCR	O
+in	O
+all	O
+cases	O
+,	O
+and	O
+compared	O
+to	O
+antigen	B-CHED
+detection	O
+and	O
+culture	O
+in	O
+two	O
+studies	O
+.	O
+
+In	O
+the	O
+21	O
+acute	B-DISO
+pneumonia	I-DISO
+'	O
+s	O
+,	O
+1	O
+RSV	B-SPEC
+,	O
+1	O
+influenza	B-SPEC
+virus	I-SPEC
+A	O
+and	O
+2	O
+rhinovirus	B-SPEC
+cases	O
+were	O
+detected	O
+as	O
+well	O
+as	O
+1	O
+RSV	B-SPEC
+,	O
+1	O
+parainfluenza	B-DISO
+3	O
+viruses	B-SPEC
+and	O
+4	O
+rhinovirus	B-SPEC
+cases	O
+in	O
+the	O
+11	O
+lower	B-ANAT
+respiratory	I-ANAT
+tract	I-ANAT
+illnesses	O
+in	O
+patients	O
+with	O
+pre	O
+-	O
+existing	O
+lung	B-DISO
+disease	I-DISO
+.	O
+
+There	O
+were	O
+6	O
+bacterial	O
+-	O
+associated	O
+infections	B-DISO
+,	O
+and	O
+4	O
+were	O
+hospital	O
+-	O
+acquired	O
+.	O
+
+We	O
+were	O
+able	O
+to	O
+pseudotype	O
+murine	B-SPEC
+leukemia	I-SPEC
+virus	B-COMP
+particles	I-COMP
+with	O
+S	B-PRGE
+-	I-PRGE
+protein	I-PRGE
+and	O
+produce	O
+SARS	B-DISO
+pseudoviruses	O
+.	O
+
+Our	O
+predictions	O
+against	O
+experimental	O
+data	O
+from	O
+four	O
+melanoma	B-PATH
+-	O
+related	O
+proteins	B-CHED
+showed	O
+that	O
+MULTIPRED	O
+ANN	O
+and	O
+HMM	B-CHED
+models	O
+could	O
+predict	O
+T	B-PRGE
+-	I-PRGE
+cell	I-PRGE
+epitopes	I-PRGE
+with	O
+high	O
+accuracy	O
+.	O
+
+TITLE	O
+:	O
+Advancements	O
+in	O
+the	O
+battle	O
+against	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+.	O
+
+TITLE	O
+:	O
+[	O
+Quantitative	O
+detection	O
+of	O
+SARS	B-PRGE
+-	I-PRGE
+CoV	I-PRGE
+RNA	I-PRGE
+in	O
+excreta	O
+and	O
+oropharyngeal	B-ANAT
+washing	O
+fluid	O
+from	O
+convalescence	O
+patients	O
+with	O
+severe	O
+acute	O
+respiratory	O
+syndrome	O
+].	O
+
+No	O
+significant	O
+difference	O
+was	O
+found	O
+among	O
+urine	B-ANAT
+,	O
+stool	B-ANAT
+,	O
+and	O
+OWF	O
+on	O
+the	O
+difference	O
+grade	O
+quantity	O
+of	O
+SARS	B-DISO
+-	O
+CoV	O
+RNA	O
+quantity	O
+.	O
+
+ABSTRACT	O
+:	O
+In	O
+Europe	O
+,	O
+hantavirus	O
+infections	O
+usually	O
+present	O
+as	O
+hemorrhagic	B-DISO
+fever	I-DISO
+with	I-DISO
+renal	B-ANAT
+syndrome	I-DISO
+and	O
+its	O
+mild	O
+form	O
+nephropathia	B-DISO
+epidemica	I-DISO
+,	O
+while	O
+clinical	O
+cases	O
+with	O
+severe	O
+pulmonary	B-ANAT
+affections	O
+are	O
+extremely	O
+rare	O
+and	O
+appear	O
+to	O
+be	O
+confined	O
+to	O
+infections	B-DISO
+by	O
+New	O
+World	O
+hanta	O
+viruses	B-SPEC
+in	O
+the	O
+Americas	O
+.	O
+
+TITLE	O
+:	O
+Mandatory	O
+temperature	O
+monitoring	O
+in	O
+schools	O
+during	O
+SARS	B-DISO
+.	O
+
+ABSTRACT	O
+:	O
+During	O
+the	O
+SARS	B-DISO
+outbreak	O
+,	O
+temperature	O
+monitoring	O
+was	O
+mandatory	O
+for	O
+all	O
+Singapore	O
+schoolchildren	O
+.	O
+
+Cases	O
+and	O
+controls	O
+were	O
+matched	O
+with	O
+respect	O
+to	O
+sex	O
+,	O
+age	O
+,	O
+timing	O
+of	O
+contracting	O
+SARS	B-DISO
+,	O
+health	O
+care	O
+workers	O
+status	O
+and	O
+underlying	O
+illness	O
+.	O
+
+There	O
+were	O
+three	O
+deaths	B-PROC
+in	O
+the	O
+pregnant	O
+group	O
+,	O
+whereas	O
+there	O
+was	O
+no	O
+death	B-PROC
+in	O
+the	O
+non	O
+-	O
+pregnant	O
+control	O
+group	O
+(	O
+P	O
+=	O
+0	O
+.	O
+006	O
+).	O
+
+The	O
+cumulative	O
+30	O
+-	O
+and	O
+150	O
+-	O
+day	O
+mortality	O
+rates	O
+were	O
+3	O
+.	O
+8	O
+%	O
+and	O
+7	O
+.	O
+6	O
+%,	O
+respectively	O
+,	O
+in	O
+young	O
+patients	O
+with	O
+SARS	B-DISO
+and	O
+56	O
+%	O
+and	O
+60	O
+%,	O
+respectively	O
+,	O
+in	O
+older	O
+patients	O
+(	O
+P	O
+<.	O
+001	O
+).	O
+
+ABSTRACT	O
+:	O
+Severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+(	O
+SARS	B-DISO
+)	O
+is	O
+an	O
+acute	B-DISO
+infectious	I-DISO
+disease	I-DISO
+of	O
+the	O
+respiratory	B-ANAT
+system	I-ANAT
+.	O
+
+In	O
+this	O
+study	O
+,	O
+sera	B-COMP
+were	O
+collected	O
+from	O
+healthy	O
+donors	O
+,	O
+patients	O
+with	O
+SARS	B-DISO
+,	O
+patients	O
+with	O
+severe	O
+SARS	B-DISO
+,	O
+and	O
+patients	O
+with	O
+SARS	B-DISO
+in	O
+convalescence	O
+.	O
+
+The	O
+IL	B-FUNC
+-	I-FUNC
+6	I-FUNC
+concentration	O
+was	O
+increased	O
+in	O
+SARS	B-DISO
+patients	O
+and	O
+was	O
+significantly	O
+elevated	O
+in	O
+severe	O
+SARS	B-DISO
+patients	O
+,	O
+but	O
+the	O
+IL	B-FUNC
+-	I-FUNC
+6	I-FUNC
+concentrations	O
+were	O
+similar	O
+in	O
+convalescent	O
+patients	O
+and	O
+control	O
+subjects	O
+,	O
+suggesting	O
+that	O
+there	O
+was	O
+a	O
+positive	O
+relationship	O
+between	O
+the	O
+serum	O
+IL	B-FUNC
+-	I-FUNC
+6	I-FUNC
+concentration	O
+and	O
+SARS	B-DISO
+severity	O
+.	O
+
+The	O
+concentrations	O
+of	O
+IL	B-FUNC
+-	I-FUNC
+8	I-FUNC
+and	O
+TGF	B-PRGE
+-	I-PRGE
+beta	I-PRGE
+were	O
+decreased	O
+in	O
+SARS	B-DISO
+patients	O
+and	O
+significantly	O
+reduced	O
+in	O
+severe	O
+SARS	B-DISO
+patients	O
+,	O
+but	O
+they	O
+were	O
+comparable	O
+in	O
+convalescent	O
+SARS	B-DISO
+patients	O
+and	O
+control	O
+subjects	O
+,	O
+suggesting	O
+that	O
+there	O
+was	O
+a	O
+negative	O
+relationship	O
+between	O
+the	O
+IL	B-FUNC
+-	I-FUNC
+8	I-FUNC
+and	O
+TGF	B-PRGE
+-	I-PRGE
+beta	I-PRGE
+concentrations	O
+and	O
+SARS	B-DISO
+severity	O
+.	O
+
+Post	O
+-	O
+mortem	O
+lung	B-ANAT
+tissues	I-ANAT
+from	O
+19	O
+of	O
+20	O
+patients	O
+with	O
+probable	O
+SARS	B-DISO
+were	O
+positive	O
+for	O
+SARS	B-DISO
+-	I-DISO
+associated	I-DISO
+coronavirus	I-DISO
+by	O
+RT	O
+-	O
+PCR	O
+.	O
+
+TITLE	O
+:	O
+Severe	B-DISO
+Acute	I-DISO
+Respiratory	I-DISO
+Syndrome	I-DISO
+(	O
+SARS	B-DISO
+)	O
+and	O
+the	O
+GDP	B-CHED
+.	O
+
+These	O
+phageborne	O
+peptides	B-CHED
+had	O
+4	O
+consensus	O
+motifs	O
+,	O
+of	O
+which	O
+2	O
+corresponded	O
+to	O
+amino	B-CHED
+acid	I-CHED
+sequences	O
+reported	O
+for	O
+SARS	B-DISO
+-	I-DISO
+associated	I-DISO
+coronavirus	I-DISO
+(	O
+SARS	B-DISO
+-	O
+CoV	O
+).	O
+
+On	O
+each	O
+radiograph	O
+,	O
+each	O
+lung	B-ANAT
+was	O
+separated	O
+into	O
+upper	O
+,	O
+middle	O
+,	O
+and	O
+lower	O
+zones	O
+.	O
+
+Survival	O
+and	O
+mortality	O
+groups	O
+showed	O
+no	O
+significant	O
+differences	O
+with	O
+respect	O
+to	O
+patient	O
+sex	O
+,	O
+duration	O
+of	O
+SARS	O
+-	O
+related	O
+lesions	O
+,	O
+development	B-PROC
+of	O
+lesion	O
+shifting	O
+,	O
+and	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+.	O
+
+We	O
+estimated	O
+that	O
+admission	O
+of	O
+a	O
+SARS	B-DISO
+patient	O
+to	O
+the	O
+unit	O
+would	O
+result	O
+in	O
+a	O
+20	O
+%	O
+decrease	O
+in	O
+the	O
+cumulative	O
+total	O
+number	O
+of	O
+outpatients	O
+in	O
+the	O
+hospital	O
+during	O
+a	O
+180	O
+-	O
+day	O
+interval	O
+after	O
+admission	O
+of	O
+a	O
+SARS	B-DISO
+patient	O
+to	O
+the	O
+unit	O
+,	O
+and	O
+the	O
+cumulative	O
+total	O
+number	O
+of	O
+outpatients	O
+increased	O
+by	O
+7	O
+%	O
+after	O
+they	O
+read	O
+the	O
+information	O
+.	O
+
+Cg	B-PRGE
+-	I-PRGE
+Foxn1	I-PRGE
+(	O
+nu	O
+)/	O
+Foxn1	B-PRGE
+(	O
+nu	O
+)	O
+mice	B-SPEC
+and	O
+M	B-SPEC
+.	I-SPEC
+pulmonis	I-SPEC
+antigen	B-CHED
+in	O
+Wistar	B-SPEC
+rats	I-SPEC
+were	O
+immunolabelled	O
+in	O
+tissue	B-ANAT
+sections	O
+.	O
+
+ABSTRACT	O
+:	O
+Severe	B-DISO
+Acute	I-DISO
+Respiratory	I-DISO
+Syndrome	I-DISO
+(	O
+SARS	B-DISO
+)	O
+is	O
+caused	O
+by	O
+a	O
+newly	O
+identified	O
+coronavirus	B-SPEC
+,	O
+called	O
+SARS	B-DISO
+-	I-DISO
+associated	I-DISO
+coronavirus	I-DISO
+(	O
+SARS	B-DISO
+-	O
+CoV	O
+)	O
+that	O
+appears	O
+to	O
+be	O
+transmitted	B-DISO
+primarily	O
+through	O
+droplets	O
+of	O
+saliva	B-ANAT
+.	O
+
+This	O
+is	O
+possible	O
+only	O
+if	O
+a	O
+suspected	O
+case	O
+of	O
+SARS	B-DISO
+is	O
+correctly	O
+and	O
+promptly	O
+identified	O
+.	O
+
+In	O
+conclusion	O
+a	O
+fully	O
+effective	O
+control	O
+of	O
+the	O
+cross	O
+-	O
+infection	B-DISO
+risk	O
+will	O
+be	O
+obtained	O
+only	O
+by	O
+adopting	O
+a	O
+correct	O
+,	O
+integrated	O
+use	O
+of	O
+different	O
+infection	B-DISO
+control	O
+procedures	O
+.	O
+
+TITLE	O
+:	O
+The	O
+spectrum	O
+of	O
+pathological	O
+changes	O
+in	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+(	O
+SARS	B-DISO
+).	O
+
+One	O
+case	O
+showed	O
+superimposed	O
+bronchopneumonia	B-DISO
+.	O
+
+The	O
+predominant	O
+pathological	B-DISO
+process	I-DISO
+of	O
+SARS	B-DISO
+is	O
+diffuse	B-DISO
+alveolar	I-DISO
+damage	I-DISO
+and	O
+,	O
+in	O
+patients	O
+who	O
+die	O
+from	O
+the	O
+disease	O
+,	O
+there	O
+is	O
+evidence	O
+of	O
+organization	O
+and	O
+fibrosis	B-DISO
+.	O
+
+The	O
+aggregated	O
+labeling	O
+of	O
+CD13	B-PRGE
+colocalized	O
+with	O
+caveolin	B-PRGE
+-	I-PRGE
+1	I-PRGE
+in	O
+most	O
+cells	B-COMP
+.	O
+
+These	O
+six	O
+mutations	O
+are	O
+scattered	O
+throughout	O
+the	O
+genome	O
+and	O
+give	O
+rise	O
+to	O
+only	O
+two	O
+amino	B-PROC
+acid	I-PROC
+substitutions	I-PROC
+:	O
+one	O
+in	O
+the	O
+spike	O
+protein	B-CHED
+gene	O
+(	O
+I958F	O
+)	O
+and	O
+the	O
+other	O
+in	O
+the	O
+nucleocapsid	B-PRGE
+protein	B-CHED
+gene	I-PRGE
+(	O
+V81A	O
+).	O
+
+These	O
+results	O
+suggest	O
+that	O
+HCoV	B-SPEC
+-	I-SPEC
+OC43	I-SPEC
+and	O
+SARS	B-DISO
+-	O
+HCoV	O
+may	O
+share	O
+several	O
+important	O
+functional	O
+properties	O
+and	O
+that	O
+HCoV	B-SPEC
+-	I-SPEC
+OC43	I-SPEC
+may	O
+be	O
+used	O
+as	O
+a	O
+model	O
+to	O
+study	O
+the	O
+biology	O
+of	O
+SARS	B-DISO
+-	O
+HCoV	O
+without	O
+the	O
+need	O
+for	O
+level	O
+three	O
+biological	O
+facilities	O
+.	O
+
+TITLE	O
+:	O
+Stress	O
+and	O
+psychological	B-DISO
+impact	O
+on	O
+SARS	B-DISO
+patients	O
+during	O
+the	O
+outbreak	O
+.	O
+
+Of	O
+SARS	B-DISO
+patients	O
+,	O
+39	O
+%	O
+(	O
+n	O
+=	O
+30	O
+)	O
+were	O
+infected	O
+health	O
+care	O
+workers	O
+;	O
+these	O
+individuals	O
+reported	O
+significantly	O
+more	O
+fatigue	B-DISO
+and	O
+worries	O
+about	O
+health	O
+than	O
+did	O
+other	O
+patients	O
+.	O
+
+RESULTS	O
+:	O
+Stress	O
+was	O
+significantly	O
+higher	O
+in	O
+SARS	B-DISO
+patients	O
+than	O
+in	O
+healthy	O
+control	O
+subjects	O
+.	O
+
+ABSTRACT	O
+:	O
+To	O
+quantify	O
+stress	O
+and	O
+the	O
+psychological	O
+impact	O
+of	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+(	O
+SARS	B-DISO
+)	O
+on	O
+high	O
+-	O
+risk	O
+health	O
+care	O
+workers	O
+(	O
+HCWs	O
+).	O
+
+Stress	O
+levels	O
+were	O
+raised	O
+in	O
+both	O
+groups	O
+(	O
+PSS	B-DISO
+=	O
+18	O
+)	O
+but	O
+were	O
+not	O
+relatively	O
+increased	O
+in	O
+the	O
+HCWs	O
+.	O
+
+In	O
+HCWs	O
+,	O
+adaptive	O
+responses	O
+to	O
+stress	O
+and	O
+the	O
+positive	O
+effects	O
+of	O
+infection	B-DISO
+control	O
+training	O
+may	O
+be	O
+protective	O
+in	O
+future	O
+outbreaks	O
+.	O
+
+METHODS	O
+:	O
+We	O
+evaluated	O
+271	O
+HCWs	O
+from	O
+SARS	B-DISO
+units	O
+and	O
+342	O
+healthy	O
+control	O
+subjects	O
+,	O
+using	O
+the	O
+Perceived	O
+Stress	O
+Scale	O
+(	O
+PSS	B-DISO
+)	O
+to	O
+assess	O
+stress	O
+levels	O
+and	O
+a	O
+structured	O
+list	O
+of	O
+putative	O
+psychological	B-DISO
+effects	O
+of	O
+SARS	B-DISO
+to	O
+assess	O
+its	O
+psychological	B-DISO
+effects	O
+.	O
+
+HCWs	O
+declared	O
+confidence	O
+in	O
+infection	B-DISO
+-	O
+control	O
+measures	O
+.	O
+
+To	O
+assess	O
+SARS	B-DISO
+-	O
+related	O
+stress	O
+and	O
+its	O
+immediate	O
+psychological	B-DISO
+impact	O
+and	O
+responses	O
+among	O
+health	O
+workers	O
+.	O
+
+Health	O
+workers	O
+in	O
+a	O
+tertiary	O
+hospital	O
+affected	O
+by	O
+SARS	B-DISO
+were	O
+invited	O
+to	O
+complete	O
+a	O
+questionnaire	O
+designed	O
+to	O
+evaluate	O
+exposure	O
+experience	O
+,	O
+psychological	B-DISO
+impact	O
+and	O
+psychiatric	O
+morbidity	O
+.	O
+
+Neutralizing	O
+viral	O
+antibodies	O
+were	O
+demonstrated	O
+in	O
+the	O
+sera	B-COMP
+from	O
+all	O
+of	O
+the	O
+patients	O
+with	O
+SARS	B-DISO
+symptoms	O
+.	O
+
+RESULTS	O
+:	O
+Anti	O
+-	O
+viral	O
+(	O
+IgG	B-PRGE
+)	O
+and	O
+anti	O
+-	O
+nucleocaspid	O
+antibodies	B-COMP
+were	O
+observed	O
+in	O
+13	O
+of	O
+14	O
+patients	O
+at	O
+14	O
+days	O
+after	O
+the	O
+onset	O
+of	O
+symptoms	O
+,	O
+and	O
+in	O
+all	O
+14	O
+patients	O
+at	O
+30	O
+-	O
+210	O
+days	O
+thereafter	O
+.	O
+
+Here	O
+we	O
+describe	O
+the	O
+molecular	O
+characterization	O
+of	O
+SCoV	B-PRGE
+E	I-PRGE
+protein	I-PRGE
+,	O
+a	O
+critical	O
+component	O
+of	O
+the	O
+virus	B-SPEC
+responsible	O
+for	O
+virion	B-COMP
+envelope	B-COMP
+morphogenesis	B-PROC
+.	O
+
+We	O
+conclusively	O
+show	O
+that	O
+SCoV	B-PRGE
+E	I-PRGE
+protein	I-PRGE
+contains	O
+an	O
+unusually	O
+short	O
+,	O
+palindromic	O
+transmembrane	B-COMP
+helical	O
+hairpin	O
+around	O
+a	O
+previously	O
+unidentified	O
+pseudo	O
+-	O
+center	O
+of	O
+symmetry	O
+,	O
+a	O
+structural	O
+feature	O
+which	O
+seems	O
+to	O
+be	O
+unique	O
+to	O
+SCoV	O
+.	O
+The	O
+hairpin	O
+deforms	O
+lipid	B-ANAT
+bilayers	I-ANAT
+by	O
+way	O
+of	O
+increasing	O
+their	O
+curvature	O
+,	O
+providing	O
+for	O
+the	O
+first	O
+time	O
+a	O
+molecular	O
+explanation	O
+of	O
+E	O
+protein	B-CHED
+'	O
+s	O
+pivotal	O
+role	O
+in	O
+viral	O
+budding	B-PATH
+.	O
+
+An	O
+immunofluorescence	O
+assay	O
+indicated	O
+high	O
+levels	O
+of	O
+exposure	O
+to	O
+coronavirus	B-SPEC
+among	O
+Serengeti	O
+hyenas	B-SPEC
+:	O
+95	O
+%	O
+when	O
+considering	O
+sera	B-COMP
+with	O
+titer	O
+levels	O
+of	O
+>	O
+or	O
+=	O
+1	O
+:	O
+10	O
+and	O
+74	O
+%	O
+when	O
+considering	O
+sera	B-COMP
+with	O
+titer	O
+levels	O
+of	O
+>	O
+or	O
+=	O
+1	O
+:	O
+40	O
+.	O
+
+All	O
+three	O
+positive	O
+fecal	B-ANAT
+samples	O
+were	O
+from	O
+the	O
+15	O
+juvenile	O
+animals	B-SPEC
+(<	O
+24	O
+months	O
+of	O
+age	O
+)	O
+sampled	O
+,	O
+and	O
+none	O
+from	O
+the	O
+12	O
+adults	O
+sampled	O
+.	O
+
+For	O
+detection	O
+of	O
+MMVp	O
+,	O
+the	O
+PCR	O
+(	O
+10	O
+(-	O
+10	O
+)	O
+dilution	O
+)	O
+proved	O
+to	O
+be	O
+10	O
+(	O
+6	O
+)	O
+times	O
+more	O
+sensitive	O
+than	O
+the	O
+viral	O
+plaque	O
+assay	O
+(	O
+10	O
+(-	O
+4	O
+)	O
+dilution	O
+)	O
+and	O
+the	O
+mouse	B-SPEC
+antibody	B-PROC
+production	I-PROC
+test	O
+on	O
+day	O
+28	O
+(	O
+10	O
+(-	O
+4	O
+)	O
+dilution	O
+)	O
+which	O
+were	O
+equally	O
+sensitive	O
+.	O
+
+Until	O
+recently	O
+,	O
+in	O
+spite	O
+of	O
+major	O
+progresses	O
+in	O
+our	O
+understanding	O
+of	O
+the	O
+pathogenic	O
+mechanisms	O
+of	O
+this	O
+syndrome	B-DISO
+,	O
+clinicians	O
+had	O
+only	O
+a	O
+limited	O
+therapeutic	O
+arsenal	O
+.	O
+
+Considerable	O
+efforts	O
+have	O
+been	O
+made	O
+in	O
+the	O
+past	O
+few	O
+years	O
+to	O
+develop	O
+novel	O
+therapeutic	O
+interventions	O
+to	O
+reduce	O
+mortality	O
+in	O
+sepsis	B-DISO
+.	O
+
+Addition	O
+of	O
+either	O
+2x10	O
+(-	O
+3	O
+)	O
+M	O
+amiloride	B-CHED
+or	O
+5x10	O
+(-	O
+4	O
+)	O
+M	O
+ouabain	B-CHED
+to	O
+the	O
+instillation	O
+further	O
+reduced	O
+ALC	O
+and	O
+increased	O
+EVLW	O
+.	O
+
+CONCLUSIONS	O
+:	O
+SARS	B-DISO
+during	O
+pregnancy	O
+is	O
+associated	O
+with	O
+high	O
+incidences	O
+of	O
+spontaneous	O
+miscarriage	B-DISO
+,	O
+preterm	B-DISO
+delivery	I-DISO
+,	O
+and	O
+intrauterine	B-DISO
+growth	B-PROC
+restriction	I-DISO
+.	O
+
+Immunocompromised	O
+patients	O
+who	O
+may	O
+silently	O
+carry	O
+SARS	B-DISO
+are	O
+common	O
+in	O
+rehabilitation	O
+and	O
+include	O
+those	O
+with	O
+renal	B-DISO
+failure	I-DISO
+,	O
+diabetes	B-DISO
+,	O
+and	O
+cancer	B-DISO
+.	O
+
+Our	O
+experiences	O
+strongly	O
+suggest	O
+that	O
+rehabilitation	O
+institutions	O
+should	O
+have	O
+emergency	B-DISO
+preparedness	O
+plans	O
+because	O
+such	O
+epidemics	O
+may	O
+recur	O
+,	O
+whether	O
+as	O
+a	O
+result	O
+of	O
+nature	O
+or	O
+of	O
+bioterrorism	O
+.	O
+
+ABSTRACT	O
+:	O
+We	O
+sought	O
+to	O
+investigate	O
+the	O
+anti	O
+-	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+(	O
+SARS	B-DISO
+)-	O
+associated	O
+coronavirus	B-SPEC
+(	O
+SCoV	O
+)	O
+activities	O
+of	O
+type	O
+I	O
+(	O
+alpha	O
+and	O
+beta	O
+)	O
+and	O
+type	O
+II	O
+(	O
+gamma	O
+)	O
+interferons	O
+(	O
+IFN	B-PRGE
+)	O
+in	O
+vitro	O
+.	O
+
+Type	B-PRGE
+I	I-PRGE
+IFNs	I-PRGE
+could	O
+be	O
+used	O
+as	O
+potential	O
+agents	O
+for	O
+anti	B-PRGE
+-	I-PRGE
+SARS	I-PRGE
+treatment	O
+.	O
+
+Virus	B-SPEC
+was	O
+isolated	O
+from	O
+the	O
+kidneys	B-ANAT
+of	O
+chickens	B-SPEC
+infected	O
+with	O
+the	O
+Gray	O
+-,	O
+CV56b	O
+-,	O
+and	O
+Wolgemuth	O
+-	O
+strains	O
+of	O
+IBV	B-SPEC
+.	O
+
+These	O
+results	O
+indicate	O
+that	O
+the	O
+pathological	O
+changes	O
+in	O
+kidneys	O
+from	O
+chickens	B-SPEC
+infected	O
+with	O
+Gray	O
+and	O
+CV56b	O
+may	O
+not	O
+have	O
+resulted	O
+from	O
+the	O
+cytolytic	O
+action	O
+of	O
+the	O
+virus	B-SPEC
+.	O
+
+The	O
+objective	O
+of	O
+the	O
+study	O
+was	O
+to	O
+explore	O
+the	O
+knowledge	O
+,	O
+attitude	O
+and	O
+practice	O
+of	O
+the	O
+population	O
+of	O
+Qatar	O
+towards	O
+severe	O
+acute	O
+respiratory	O
+syndrome	O
+(	O
+SARS	B-DISO
+).	O
+
+The	O
+study	O
+showed	O
+that	O
+although	O
+79	O
+.	O
+4	O
+%	O
+of	O
+the	O
+total	O
+subjects	O
+claimed	O
+to	O
+know	O
+about	O
+SARS	B-DISO
+,	O
+only	O
+8	O
+.	O
+0	O
+%	O
+had	O
+accurate	O
+knowledge	O
+about	O
+all	O
+of	O
+the	O
+symptoms	O
+of	O
+SARS	B-DISO
+.	O
+
+Half	O
+of	O
+the	O
+subjects	O
+said	O
+they	O
+had	O
+gained	O
+most	O
+of	O
+their	O
+knowledge	O
+on	O
+SARS	B-DISO
+through	O
+television	O
+and	O
+radio	B-CHED
+programmes	O
+(	O
+52	O
+.	O
+2	O
+%).	O
+
+The	O
+level	O
+of	O
+knowledge	O
+about	O
+SARS	B-DISO
+was	O
+better	O
+among	O
+educated	O
+subjects	O
+.	O
+
+TITLE	O
+:	O
+A	O
+single	O
+amino	B-CHED
+acid	I-CHED
+mutation	O
+in	O
+the	O
+spike	O
+protein	B-CHED
+of	O
+coronavirus	B-SPEC
+infectious	B-DISO
+bronchitis	B-DISO
+virus	B-SPEC
+hampers	O
+its	O
+maturation	O
+and	O
+incorporation	O
+into	O
+virions	B-COMP
+at	O
+the	O
+nonpermissive	O
+temperature	O
+.	O
+
+The	O
+complete	O
+sequences	O
+of	O
+wild	O
+type	O
+(	O
+wt	O
+)	O
+virus	B-SPEC
+,	O
+two	O
+ts	O
+mutants	O
+,	O
+and	O
+the	O
+revertant	O
+were	O
+compared	O
+and	O
+variations	O
+linked	O
+to	O
+phenotypes	O
+were	O
+mapped	O
+.	O
+
+Only	O
+two	O
+patients	O
+with	O
+preexisting	O
+illnesses	O
+had	O
+cough	B-DISO
+on	O
+the	O
+same	O
+day	O
+the	O
+fever	B-PROC
+began	O
+.	O
+
+The	O
+majority	O
+of	O
+patients	O
+(	O
+63	O
+%)	O
+first	O
+developed	O
+unifocal	O
+infiltrates	B-DISO
+at	O
+a	O
+mean	O
+time	O
+of	O
+4	O
+.	O
+5	O
++/-	O
+
+HFOV	O
+was	O
+discontinued	O
+within	O
+4	O
+h	O
+in	O
+19	O
+patients	O
+(	O
+12	O
+%)	O
+because	O
+of	O
+difficulties	O
+with	O
+oxygenation	B-PROC
+,	O
+ventilation	O
+,	O
+or	O
+hemodynamics	B-PROC
+.	O
+
+Pao	B-PROC
+(	O
+2	O
+)/	O
+Fio	O
+(	O
+2	O
+)	O
+ratios	O
+and	O
+OI	O
+([	O
+Fio	O
+(	O
+2	O
+)	O
+x	O
+mean	O
+airway	B-ANAT
+pressure	O
+x	O
+100	O
+]/	O
+Pao	B-PROC
+(	O
+2	O
+))	O
+improved	O
+significantly	O
+with	O
+the	O
+application	O
+of	O
+HFOV	O
+,	O
+and	O
+this	O
+benefit	O
+persisted	O
+for	O
+the	O
+72	O
+-	O
+h	O
+study	O
+duration	O
+.	O
+
+Multivariate	O
+analysis	O
+was	O
+performed	O
+using	O
+Cox	O
+regression	O
+model	O
+with	O
+death	B-PROC
+as	O
+the	O
+outcome	O
+of	O
+interest	O
+.	O
+
+TITLE	O
+:	O
+Major	O
+genetic	B-PROC
+marker	I-PROC
+of	O
+nidoviruses	B-SPEC
+encodes	O
+a	O
+replicative	O
+endoribonuclease	O
+.	O
+
+It	O
+is	O
+considered	O
+a	O
+major	O
+genetic	B-PROC
+marker	I-PROC
+that	O
+discriminates	O
+nidoviruses	B-SPEC
+(	O
+Coronaviridae	B-SPEC
+,	O
+Arteriviridae	B-SPEC
+,	O
+and	O
+Roniviridae	B-SPEC
+)	O
+from	O
+all	O
+other	O
+RNA	O
+virus	B-SPEC
+families	O
+.	O
+
+ABSTRACT	O
+:	O
+This	O
+study	O
+estimated	O
+case	O
+fatality	O
+rates	O
+in	O
+Hong	O
+Kong	O
+,	O
+Singapore	O
+and	O
+Beijing	O
+using	O
+the	O
+number	O
+of	O
+new	O
+admissions	O
+,	O
+deaths	O
+and	O
+discharges	B-ANAT
+by	O
+cure	O
+.	O
+
+TITLE	O
+:	O
+Viral	O
+evolution	B-PROC
+and	O
+the	O
+emergence	O
+of	O
+SARS	B-DISO
+coronavirus	B-SPEC
+.	O
+
+We	O
+know	O
+little	O
+about	O
+the	O
+processes	O
+that	O
+allowed	O
+the	O
+cross	O
+-	O
+species	B-SPEC
+transfer	O
+of	O
+this	O
+previously	O
+unknown	O
+virus	B-SPEC
+.	O
+
+I	O
+discuss	O
+what	O
+we	O
+have	O
+learned	B-PROC
+about	O
+the	O
+movement	B-PROC
+of	O
+viruses	B-SPEC
+into	O
+humans	B-SPEC
+from	O
+studies	O
+of	O
+influenza	B-PATH
+A	I-PATH
+,	O
+both	O
+how	O
+it	O
+crossed	O
+from	O
+birds	B-SPEC
+to	O
+humans	B-SPEC
+and	O
+how	O
+it	O
+subsequently	O
+evolved	O
+within	O
+the	O
+human	B-SPEC
+population	O
+.	O
+
+First	O
+,	O
+I	O
+present	O
+a	O
+reanalysis	O
+of	O
+data	O
+used	O
+to	O
+test	O
+the	O
+hypothesis	O
+that	O
+swine	B-SPEC
+served	O
+as	O
+a	O
+""""	O
+mixing	O
+vessel	B-ANAT
+""""	O
+or	O
+intermediate	O
+host	B-COMP
+in	O
+the	O
+transmission	O
+of	O
+avian	B-DISO
+influenza	I-DISO
+to	O
+humans	B-SPEC
+during	O
+the	O
+1918	O
+""""	O
+Spanish	O
+flu	B-DISO
+""""	O
+pandemic	O
+.	O
+
+TITLE	O
+:	O
+Confronting	O
+SARS	B-DISO
+:	O
+a	O
+view	O
+from	O
+Hong	O
+Kong	O
+.	O
+
+ABSTRACT	O
+:	O
+The	O
+emergence	O
+of	O
+new	O
+viral	B-DISO
+infections	I-DISO
+of	O
+man	B-CHED
+requires	O
+the	O
+development	O
+of	O
+robust	O
+diagnostic	O
+tests	O
+that	O
+can	O
+be	O
+applied	O
+in	O
+the	O
+differential	O
+diagnosis	O
+of	O
+acute	O
+illness	O
+,	O
+or	O
+to	O
+determine	O
+past	O
+exposure	O
+,	O
+so	O
+as	O
+to	O
+establish	O
+the	O
+true	O
+burden	O
+of	O
+disease	O
+.	O
+
+Developments	O
+in	O
+the	O
+dissection	O
+of	O
+the	O
+human	B-SPEC
+immune	B-PROC
+response	I-PROC
+to	O
+SARS	B-DISO
+indicate	O
+that	O
+serological	O
+tests	O
+on	O
+convalescent	O
+sera	B-COMP
+are	O
+essential	O
+to	O
+confirm	O
+SARS	B-DISO
+infection	B-DISO
+,	O
+given	O
+the	O
+sub	O
+-	O
+optimal	O
+predictive	O
+value	O
+of	O
+molecular	O
+detection	O
+tests	O
+performed	O
+during	O
+acute	O
+SARS	B-DISO
+illness	O
+.	O
+
+ABSTRACT	O
+:	O
+This	O
+paper	O
+reviews	O
+current	O
+understanding	O
+of	O
+the	O
+epidemiology	O
+,	O
+transmission	O
+dynamics	O
+and	O
+control	O
+of	O
+the	O
+aetiological	O
+agent	O
+of	O
+severe	O
+acute	O
+respiratory	O
+syndrome	O
+(	O
+SARS	B-DISO
+).	O
+
+TITLE	O
+:	O
+The	O
+experience	O
+of	O
+the	O
+2003	O
+SARS	B-DISO
+outbreak	O
+as	O
+a	O
+traumatic	O
+stress	O
+among	O
+frontline	O
+healthcare	O
+workers	O
+in	O
+Toronto	O
+:	O
+lessons	O
+learned	O
+.	O
+
+TITLE	O
+:	O
+Preparedness	O
+for	O
+SARS	B-DISO
+in	O
+the	O
+UK	O
+in	O
+2003	O
+.	O
+
+Recent	O
+cases	O
+confirm	O
+that	O
+SARS	B-DISO
+has	O
+not	O
+""""	O
+gone	O
+away	O
+"""."	O
+
+The	O
+human	B-SPEC
+population	O
+was	O
+lucky	O
+that	O
+only	O
+a	O
+small	O
+proportion	O
+of	O
+infected	O
+persons	O
+proved	O
+to	O
+be	O
+highly	O
+infectious	B-DISO
+to	O
+others	O
+,	O
+and	O
+that	O
+they	O
+did	O
+not	O
+become	O
+so	O
+before	O
+they	O
+felt	O
+ill	B-DISO
+.	O
+
+Neither	O
+transaminase	O
+elevation	O
+nor	O
+HBsAg	O
+was	O
+related	O
+to	O
+the	O
+prognosis	O
+of	O
+SARS	B-DISO
+,	O
+and	O
+only	O
+advanced	O
+age	O
+was	O
+an	O
+independent	O
+predictor	O
+of	O
+poor	O
+outcome	O
+.	O
+
+TITLE	O
+:	O
+Hospital	O
+preparedness	O
+for	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+in	O
+the	O
+United	O
+States	O
+:	O
+views	O
+from	O
+a	O
+national	O
+survey	O
+of	O
+infectious	O
+diseases	O
+consultants	O
+.	O
+
+ABSTRACT	O
+:	O
+In	O
+this	O
+survey	O
+of	O
+infectious	B-DISO
+diseases	I-DISO
+consultants	O
+,	O
+90	O
+%	O
+reported	O
+that	O
+their	O
+health	O
+care	O
+facilities	O
+have	O
+plans	O
+in	O
+place	O
+to	O
+address	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+(	O
+SARS	B-DISO
+).	O
+
+Sixty	O
+-	O
+one	O
+percent	O
+of	O
+the	O
+respondents	O
+expressed	B-PROC
+some	O
+concern	O
+about	O
+their	O
+facility	O
+'	O
+s	O
+preparation	O
+and	O
+capacity	O
+for	O
+managing	O
+patients	O
+with	O
+SARS	B-DISO
+.	O
+
+The	O
+initial	O
+frontal	O
+chest	B-ANAT
+radiographs	O
+of	O
+these	O
+201	O
+patients	O
+were	O
+assessed	O
+in	O
+a	O
+blinded	O
+fashion	O
+by	O
+3	O
+radiologists	O
+;	O
+individual	O
+findings	O
+were	O
+accepted	O
+if	O
+at	O
+least	O
+2	O
+of	O
+the	O
+radiologists	O
+concurred	O
+.	O
+
+Independent	O
+predictors	O
+of	O
+an	O
+adverse	O
+outcome	O
+,	O
+defined	O
+as	O
+the	O
+need	O
+for	O
+assisted	O
+ventilation	O
+,	O
+death	B-PROC
+,	O
+or	O
+both	O
+,	O
+were	O
+identified	O
+by	O
+multivariate	O
+analysis	O
+.	O
+
+Taken	O
+together	O
+,	O
+these	O
+results	O
+indicate	O
+that	O
+MLV	O
+(	O
+SARS	B-DISO
+)	O
+pseudotypes	O
+are	O
+highly	O
+valuable	O
+for	O
+functional	O
+studies	O
+of	O
+viral	O
+tropism	B-PROC
+and	O
+entry	O
+and	O
+,	O
+in	O
+addition	O
+,	O
+can	O
+be	O
+a	O
+powerful	O
+tool	O
+for	O
+the	O
+development	B-PROC
+of	O
+therapeutic	O
+entry	O
+inhibitors	B-CHED
+without	O
+posing	O
+a	O
+biohazard	O
+to	O
+human	B-SPEC
+beings	O
+.	O
+
+The	O
+spike	O
+(	O
+S	O
+)	O
+gene	O
+of	O
+MHV	B-SPEC
+/	O
+BHK	O
+had	O
+63	O
+point	B-PROC
+mutations	I-PROC
+and	O
+a	O
+21	O
+-	O
+bp	O
+insert	O
+that	O
+encoded	O
+56	O
+amino	B-PROC
+acid	I-PROC
+substitutions	I-PROC
+and	O
+a	O
+7	O
+-	O
+amino	O
+-	O
+acid	O
+insert	O
+compared	O
+to	O
+the	O
+parental	O
+MHV	B-SPEC
+strain	O
+A59	O
+.	O
+
+Flow	O
+cytometry	O
+showed	O
+that	O
+MHV	B-SPEC
+-	O
+A59	O
+bound	O
+only	O
+to	O
+cells	B-COMP
+that	O
+expressed	B-PROC
+the	O
+murine	B-PRGE
+glycoprotein	B-CHED
+receptor	I-PRGE
+CEACAM1a	I-PRGE
+.	O
+
+Education	O
+programmes	O
+,	O
+special	O
+services	O
+and	O
+effective	O
+thermal	O
+screening	O
+are	O
+required	O
+to	O
+minimize	O
+the	O
+chance	O
+of	O
+the	O
+spread	O
+of	O
+SARS	O
+by	O
+air	B-CHED
+travellers	O
+.	O
+
+Special	O
+management	O
+protocols	O
+and	O
+modified	O
+measures	O
+that	O
+regulate	O
+droplet	O
+and	O
+aerosol	O
+contamination	O
+in	O
+a	O
+dental	O
+setting	O
+have	O
+to	O
+be	O
+introduced	O
+and	O
+may	O
+include	O
+the	O
+reduction	O
+or	O
+avoidance	O
+of	O
+droplet	O
+/	O
+aerosol	O
+generation	O
+,	O
+the	O
+disinfection	O
+of	O
+the	O
+treatment	O
+field	O
+,	O
+application	O
+of	O
+rubber	B-CHED
+dam	O
+,	O
+pre	O
+-	O
+procedural	O
+antiseptic	O
+mouthrinse	O
+and	O
+the	O
+dilution	O
+and	O
+efficient	O
+removal	O
+of	O
+contaminated	O
+ambient	O
+air	B-CHED
+.	O
+
+Disease	O
+can	O
+be	O
+transmitted	B-DISO
+around	O
+the	O
+world	O
+in	O
+a	O
+day	O
+,	O
+but	O
+the	O
+development	B-PROC
+of	O
+medications	O
+does	O
+not	O
+occur	O
+at	O
+this	O
+rate	O
+.	O
+
+SARS	B-DISO
+affected	O
+people	O
+on	O
+three	O
+continents	O
+in	O
+a	O
+matter	O
+of	O
+days	O
+.	O
+
+RESULTS	O
+:	O
+The	O
+results	O
+of	O
+oxygenation	B-PROC
+index	O
+were	O
+significantly	O
+getting	O
+worsen	O
+after	O
+lung	B-ANAT
+injury	O
+,	O
+and	O
+after	O
+receiving	O
+lung	B-ANAT
+protective	O
+ventilation	O
+(	O
+including	O
+low	O
+tidal	O
+volume	O
++	O
+PEEP	B-CHED
+,	O
+prone	O
+position	O
++	O
+low	O
+tidal	O
+volume	O
++	O
+PEEP	B-CHED
+),	O
+the	O
+indexes	O
+were	O
+taking	O
+a	O
+turn	O
+to	O
+the	O
+better	O
+.	O
+
+CONCLUSIONS	O
+:	O
+We	O
+indicated	O
+that	O
+the	O
+one	O
+of	O
+the	O
+main	O
+mechanisms	O
+of	O
+severe	O
+hypoxemia	O
+in	O
+ARDS	B-DISO
+might	O
+be	O
+caught	O
+by	O
+the	O
+shunt	O
+between	O
+pulmonary	B-ANAT
+artery	I-ANAT
+and	O
+pulmonary	B-ANAT
+vein	I-ANAT
+just	O
+like	O
+physiological	O
+right	O
+to	O
+left	O
+shunt	O
+,	O
+which	O
+caused	O
+severe	O
+ventilation	O
+/	O
+perfusion	O
+disturbance	O
+.	O
+
+TITLE	O
+:	O
+[	O
+Immunological	O
+characteristics	O
+of	O
+1291	O
+cases	O
+of	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+in	O
+Beijing	O
+].	O
+
+The	O
+initial	O
+symptom	B-DISO
+of	O
+SARS	B-DISO
+was	O
+pyrexia	B-PROC
+and	O
+the	O
+temperature	O
+was	O
+>	O
+38	O
+degrees	O
+C	O
+.	O
+The	O
+natural	O
+course	O
+of	O
+fever	B-PROC
+was	O
+about	O
+14	O
+days	O
+.	O
+
+Among	O
+the	O
+7	O
+SARS	B-DISO
+patients	O
+,	O
+3	O
+recovered	O
+from	O
+SARS	B-DISO
+and	O
+4	O
+died	B-PROC
+.	O
+
+Intensified	O
+disinfection	O
+of	O
+surroundings	O
+,	O
+self	O
+-	O
+protection	O
+for	O
+health	O
+care	O
+workers	O
+and	O
+education	O
+for	O
+patients	O
+in	O
+personal	O
+hygiene	O
+habit	O
+may	O
+be	O
+helpful	O
+to	O
+prevention	O
+of	O
+SARS	B-DISO
+in	O
+hemodialysis	O
+units	O
+.	O
+
+ABSTRACT	O
+:	O
+To	O
+explore	O
+the	O
+effectiveness	O
+of	O
+corticosteroids	O
+(	O
+GCS	O
+)	O
+and	O
+to	O
+determine	O
+how	O
+to	O
+use	O
+it	O
+in	O
+the	O
+treatment	O
+of	O
+SARS	B-DISO
+.	O
+
+The	O
+dose	O
+of	O
+GCS	O
+was	O
+all	O
+expressed	B-PROC
+in	O
+that	O
+of	O
+methylprednisolone	B-CHED
+.	O
+
+In	O
+the	O
+treatment	O
+of	O
+SARS	B-DISO
+,	O
+GCS	O
+seems	O
+to	O
+be	O
+effective	O
+.	O
+
+ABSTRACT	O
+:	O
+In	O
+order	B-SPEC
+to	O
+explore	O
+the	O
+existence	O
+of	O
+SARS	O
+coronavirus	B-SPEC
+(	O
+Co	O
+-	O
+V	O
+)	O
+and	O
+/	O
+or	O
+its	O
+RNA	O
+in	O
+sewage	O
+of	O
+hospitals	O
+administered	O
+SARS	B-DISO
+patients	O
+.	O
+
+It	O
+provides	O
+evidence	O
+that	O
+there	O
+is	O
+no	O
+live	O
+SARS	B-DISO
+-	O
+Cov	O
+in	O
+the	O
+sewage	O
+from	O
+hospitals	O
+with	O
+SARS	B-DISO
+patients	O
+though	O
+SARS	O
+-	O
+CoV	O
+RNA	O
+can	O
+be	O
+detected	O
+.	O
+
+ABSTRACT	O
+:	O
+Extracorporeal	O
+membrane	B-COMP
+oxygenation	B-PROC
+(	O
+ECMO	O
+)	O
+has	O
+been	O
+used	O
+successfully	O
+for	O
+early	O
+,	O
+severe	O
+reperfusion	O
+injury	O
+after	O
+lung	B-ANAT
+transplantation	O
+.	O
+
+We	O
+retrospectively	O
+reviewed	O
+charts	O
+of	O
+172	O
+patients	O
+having	O
+lung	B-ANAT
+transplants	B-ANAT
+at	O
+our	O
+institution	O
+from	O
+1997	O
+through	O
+2002	O
+.	O
+
+TITLE	O
+:	O
+Analysis	O
+of	O
+IR	O
+thermal	O
+imager	O
+for	O
+mass	O
+blind	B-DISO
+fever	B-PROC
+screening	O
+.	O
+
+ABSTRACT	O
+:	O
+Obtaining	O
+meaningful	O
+temperature	O
+for	O
+the	O
+human	O
+body	O
+requires	O
+identifying	O
+a	O
+body	B-ANAT
+site	I-ANAT
+that	O
+will	O
+provide	O
+reliable	O
+data	O
+across	O
+a	O
+large	O
+population	O
+.	O
+
+The	O
+results	O
+are	O
+vital	O
+in	O
+determining	O
+two	O
+very	O
+important	O
+pieces	O
+of	O
+information	O
+:	O
+the	O
+best	O
+and	O
+yet	O
+practical	O
+region	O
+on	O
+the	O
+face	B-DISO
+to	O
+take	O
+readings	O
+and	O
+optimal	O
+pre	O
+-	O
+set	O
+threshold	O
+temperature	O
+for	O
+the	O
+thermal	O
+imager	O
+.	O
+
+We	O
+chose	O
+aluminum	B-CHED
+hydroxide	I-CHED
+gel	O
+(	O
+alum	O
+)	O
+as	O
+an	O
+adjuvant	B-CHED
+,	O
+because	O
+of	O
+its	O
+long	O
+safety	O
+history	O
+for	O
+human	B-SPEC
+use	O
+.	O
+
+Several	O
+pulmonary	B-DISO
+diseases	I-DISO
+have	O
+distinguishing	O
+features	O
+,	O
+which	O
+are	O
+better	O
+delineated	O
+on	O
+high	O
+resolution	O
+CT	O
+scans	O
+than	O
+plain	O
+chest	B-ANAT
+radiographs	O
+.	O
+
+Reversed	O
+halo	B-DISO
+sign	I-DISO
+has	O
+a	O
+high	O
+specificity	O
+for	O
+cryptogenic	B-DISO
+organizing	I-DISO
+pneumonia	I-DISO
+.	O
+
+In	O
+permissive	O
+cell	B-ANAT
+lines	I-ANAT
+,	O
+effects	O
+of	O
+SARS	B-DISO
+-	O
+CoV	O
+on	O
+cellular	B-COMP
+gene	B-PROC
+expression	I-PROC
+were	O
+analysed	O
+using	O
+high	O
+-	O
+density	O
+oligonucleotide	B-CHED
+arrays	O
+.	O
+
+This	O
+study	O
+describes	O
+the	O
+results	O
+of	O
+a	O
+rapid	O
+assessment	O
+of	O
+the	O
+effectiveness	O
+of	O
+a	O
+helpdesk	O
+service	O
+designed	O
+to	O
+meet	O
+the	O
+immediate	O
+needs	O
+of	O
+relatives	O
+of	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+patients	O
+in	O
+Hong	O
+Kong	O
+.	O
+
+ABSTRACT	O
+:	O
+In	O
+patients	O
+with	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+(	O
+ARDS	B-DISO
+),	O
+recruitment	B-DISO
+maneuvers	O
+have	O
+been	O
+proposed	O
+as	O
+an	O
+adjunct	O
+to	O
+mechanical	O
+ventilation	O
+to	O
+open	O
+up	O
+atelectasis	B-DISO
+and	O
+to	O
+keep	O
+these	O
+alveoli	B-ANAT
+open	O
+by	O
+the	O
+application	O
+of	O
+adequate	O
+high	O
+levels	O
+of	O
+positive	O
+end	B-PROC
+-	I-PROC
+expiratory	I-PROC
+pressure	O
+(	O
+PEEP	B-CHED
+).	O
+
+Though	O
+several	O
+studies	O
+reported	O
+that	O
+the	O
+responsiveness	O
+to	O
+recruitment	B-DISO
+maneuvers	O
+resulted	O
+in	O
+a	O
+marked	O
+improvement	O
+of	O
+oxygenation	B-PROC
+with	O
+a	O
+concomitant	O
+decrease	O
+in	O
+airway	B-ANAT
+pressure	O
+and	O
+/	O
+or	O
+inspiratory	B-PROC
+fraction	O
+of	O
+oxygen	B-CHED
+,	O
+the	O
+performance	O
+of	O
+recruitment	B-DISO
+maneuvers	O
+still	O
+remains	O
+a	O
+matter	O
+of	O
+dispute	O
+,	O
+especially	O
+in	O
+patients	O
+ventilated	O
+with	O
+a	O
+lung	B-ANAT
+protective	O
+ventilation	O
+strategy	O
+.	O
+
+In	O
+this	O
+review	O
+we	O
+discuss	O
+the	O
+pathophysiological	O
+background	O
+,	O
+factors	O
+affecting	O
+the	O
+responsiveness	O
+to	O
+recruitment	B-DISO
+maneuvers	O
+and	O
+their	O
+clinical	O
+impact	O
+in	O
+the	O
+light	O
+of	O
+recently	O
+published	O
+studies	O
+.	O
+
+TITLE	O
+:	O
+Neutralizing	O
+antibodies	B-COMP
+in	O
+patients	O
+with	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+-	O
+associated	O
+coronavirus	B-SPEC
+infection	I-DISO
+.	O
+
+APC	B-COMP
+regulates	O
+the	O
+coagulation	B-PROC
+system	O
+by	O
+inactivating	O
+the	O
+activated	O
+form	O
+of	O
+factors	O
+V	O
+and	O
+VIII	O
+in	O
+the	O
+presence	O
+of	O
+protein	B-CHED
+S	O
+.	O
+Tumor	B-PRGE
+necrosis	I-PRGE
+factor	I-PRGE
+-	I-PRGE
+alpha	I-PRGE
+(	O
+TNF	B-PRGE
+-	I-PRGE
+alpha	I-PRGE
+)	O
+plays	O
+critical	O
+roles	O
+in	O
+the	O
+development	B-PROC
+of	O
+disseminated	B-DISO
+intravascular	I-DISO
+coagulation	I-DISO
+,	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+and	O
+shock	O
+in	O
+sepsis	B-DISO
+by	O
+inducing	O
+endothelial	B-ANAT
+cell	I-ANAT
+damage	O
+through	O
+activation	O
+of	O
+neutrophils	B-ANAT
+.	O
+
+The	O
+major	O
+function	O
+of	O
+N	B-PRGE
+protein	I-PRGE
+is	O
+to	O
+assemble	O
+the	O
+RNA	O
+of	O
+coronavirus	B-SPEC
+.	O
+
+In	O
+the	O
+present	O
+study	O
+,	O
+the	O
+gene	O
+encoding	O
+the	O
+N	B-PRGE
+protein	I-PRGE
+was	O
+cloned	O
+and	O
+the	O
+protein	B-CHED
+was	O
+expressed	B-PROC
+,	O
+purified	O
+,	O
+and	O
+refolded	O
+as	O
+shown	O
+by	O
+(	O
+1	O
+)	O
+H	O
+NMR	O
+measurement	O
+.	O
+
+N	B-PRGE
+protein	I-PRGE
+is	O
+denatured	O
+reversibly	O
+at	O
+pH	O
+7	O
+.	O
+4	O
+either	O
+by	O
+urea	B-CHED
+(	O
+with	O
+C	O
+(	O
+m	O
+)	O
+of	O
+2	O
+.	O
+77	O
+M	O
+and	O
+m	O
+value	O
+of	O
+2	O
+.	O
+74	O
+kcal	O
+mol	O
+(-	O
+1	O
+)	O
+M	O
+(-	O
+1	O
+))	O
+or	O
+GdmCl	O
+(	O
+with	O
+C	O
+(	O
+m	O
+)	O
+of	O
+1	O
+.	O
+46	O
+M	O
+and	O
+m	O
+value	O
+of	O
+4	O
+.	O
+50	O
+kcal	O
+mol	O
+(-	O
+1	O
+)	O
+M	O
+(-	O
+1	O
+)).	O
+
+ABSTRACT	O
+:	O
+Severe	O
+acute	O
+respiratory	O
+syndrome	O
+(	O
+SARS	B-DISO
+)	O
+is	O
+a	O
+major	O
+new	O
+infectious	B-DISO
+disease	I-DISO
+of	O
+this	O
+century	O
+that	O
+is	O
+unique	O
+in	O
+its	O
+high	O
+morbidity	O
+and	O
+concentration	O
+in	O
+health	O
+care	O
+settings	O
+.	O
+
+SARS	B-DISO
+-	O
+related	O
+psychiatric	O
+and	O
+posttraumatic	O
+morbidities	O
+were	O
+present	O
+in	O
+the	O
+medical	O
+staff	O
+within	O
+a	O
+primary	O
+health	O
+care	O
+setting	O
+.	O
+
+They	O
+assisted	O
+with	O
+designing	O
+and	O
+evaluating	O
+ventilation	O
+modifications	O
+for	O
+infection	O
+control	O
+,	O
+developed	O
+guidelines	O
+for	O
+converting	O
+hospital	O
+rooms	O
+into	O
+SARS	B-DISO
+patient	O
+isolation	O
+rooms	O
+,	O
+prepared	O
+designs	O
+for	O
+the	O
+rapid	O
+conversion	O
+of	O
+a	O
+vacated	O
+military	O
+facility	O
+into	O
+a	O
+SARS	B-DISO
+screening	O
+and	O
+observation	O
+facility	O
+,	O
+assessed	O
+environmental	O
+aspects	O
+of	O
+dedicated	O
+SARS	B-DISO
+hospitals	O
+,	O
+and	O
+worked	O
+in	O
+concert	O
+with	O
+the	O
+Taiwanese	O
+to	O
+develop	O
+hospital	O
+ventilation	O
+guidelines	O
+.	O
+
+ABSTRACT	O
+:	O
+As	O
+a	O
+transmissible	O
+infectious	O
+disease	O
+,	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+(	O
+SARS	B-DISO
+)	O
+was	O
+successfully	O
+contained	O
+globally	O
+by	O
+instituting	O
+widespread	O
+quarantine	O
+measures	O
+.	O
+
+The	O
+129	O
+quarantined	O
+persons	O
+who	O
+responded	O
+to	O
+a	O
+Web	B-DISO
+-	O
+based	O
+survey	O
+exhibited	O
+a	O
+high	O
+prevalence	O
+of	O
+psychological	B-DISO
+distress	I-DISO
+.	O
+
+Acquaintance	O
+with	O
+or	O
+direct	O
+exposure	O
+to	O
+someone	O
+with	O
+a	O
+diagnosis	O
+of	O
+SARS	O
+was	O
+also	O
+associated	O
+with	O
+PTSD	B-DISO
+and	O
+depressive	B-DISO
+symptoms	I-DISO
+.	O
+
+TITLE	O
+:	O
+Model	O
+parameters	O
+and	O
+outbreak	O
+control	O
+for	O
+SARS	B-DISO
+.	O
+
+We	O
+used	O
+uncertainty	O
+and	O
+sensitivity	O
+analysis	O
+of	O
+the	O
+basic	O
+reproductive	B-PROC
+number	O
+R0	O
+to	O
+assess	O
+the	O
+role	O
+that	O
+model	O
+parameters	O
+play	O
+in	O
+outbreak	O
+control	O
+.	O
+
+TITLE	O
+:	O
+SARS	B-DISO
+coronavirus	B-SPEC
+detection	O
+.	O
+
+TITLE	O
+:	O
+Sequence	O
+similarity	O
+and	O
+structural	O
+homologies	O
+are	O
+involved	O
+in	O
+the	O
+autoimmune	B-DISO
+response	I-DISO
+elicited	O
+by	O
+mouse	O
+hepatitis	O
+virus	B-SPEC
+A59	O
+.	O
+
+Results	O
+indicated	O
+that	O
+two	O
+homologous	O
+peptides	B-CHED
+were	O
+recognized	O
+by	O
+most	O
+Ab	O
+:	O
+the	O
+N	O
+-	O
+terminal	O
+sequences	O
+(	O
+1	O
+-	O
+10	O
+)	O
+from	O
+FAH	B-PRGE
+and	O
+the	O
+nucleocapside	O
+,	O
+both	O
+sharing	O
+50	O
+%	O
+of	O
+identity	O
+,	O
+and	O
+sequence	O
+2317	O
+-	O
+2326	O
+of	O
+the	O
+RNA	B-PATH
+polymerase	I-PATH
+,	O
+a	O
+peptide	B-CHED
+showing	O
+30	O
+%	O
+of	O
+identity	O
+with	O
+FAH	B-PRGE
+11	I-PRGE
+-	I-PRGE
+20	I-PRGE
+.	O
+
+TITLE	O
+:	O
+Pathogenic	O
+role	O
+of	O
+HMGB1	B-PRGE
+in	O
+SARS	B-DISO
+?	O
+
+These	O
+viruses	B-SPEC
+illustrate	O
+how	O
+such	O
+agents	O
+emerge	O
+:	O
+by	O
+encroaching	O
+on	O
+previously	O
+unvisited	O
+habitats	O
+(	O
+eg	O
+,	O
+hantaviruses	B-SPEC
+),	O
+by	O
+air	B-CHED
+travel	O
+(	O
+eg	O
+,	O
+SARS	B-DISO
+),	O
+and	O
+by	O
+accidental	O
+importation	O
+(	O
+eg	O
+,	O
+monkeypox	B-DISO
+).	O
+
+ABSTRACT	O
+:	O
+Respiratory	O
+infectious	B-DISO
+diseases	I-DISO
+such	O
+as	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+and	O
+tuberculosis	B-PATH
+create	O
+unique	O
+risks	O
+for	O
+anyone	O
+who	O
+may	O
+be	O
+exposed	O
+.	O
+
+Age	O
+65	O
+years	O
+and	O
+older	O
+and	O
+younger	O
+than	O
+18	O
+years	O
+and	O
+the	O
+presence	O
+of	O
+sputum	B-ANAT
+,	O
+abdominal	B-DISO
+pain	I-DISO
+,	O
+sore	B-DISO
+throat	I-DISO
+,	O
+and	O
+rhinorrhea	B-DISO
+were	O
+inversely	O
+related	O
+to	O
+having	O
+SARS	B-DISO
+.	O
+
+Diminished	O
+CD8alpha	O
+-	O
+DC	O
+activation	O
+correlated	O
+with	O
+reduced	O
+IFN	B-PRGE
+-	I-PRGE
+gamma	I-PRGE
+expression	B-PROC
+by	O
+virus	B-SPEC
+-	O
+specific	O
+T	B-ANAT
+cells	I-ANAT
+accompanied	O
+by	O
+increased	O
+IL	B-PROC
+-	I-PROC
+10	I-PROC
+production	I-PROC
+suggesting	O
+that	O
+CCL3	B-PRGE
+contributes	O
+to	O
+an	O
+effective	O
+host	B-PROC
+response	I-PROC
+to	O
+viral	B-DISO
+infection	I-DISO
+by	O
+enhancing	O
+the	O
+T	B-PRGE
+cell	I-PRGE
+activation	I-PRGE
+potential	I-PRGE
+of	I-PRGE
+DC	I-PRGE
+.	O
+
+TITLE	O
+:	O
+Celecoxib	B-CHED
+-	O
+induced	O
+methemoglobinemia	B-DISO
+.	O
+
+The	O
+meeting	O
+included	O
+the	O
+symposium	O
+'	O
+Clinical	O
+Update	O
+on	O
+Antiviral	B-CHED
+Drugs	I-CHED
+',	O
+plenary	O
+sessions	O
+dedicated	O
+to	O
+each	O
+of	O
+the	O
+individual	O
+classes	O
+of	O
+infectious	B-DISO
+agents	O
+,	O
+a	O
+symposium	O
+on	O
+new	O
+developments	O
+surrounding	O
+emerging	O
+pathogens	O
+,	O
+and	O
+three	O
+special	O
+award	O
+lectures	O
+,	O
+which	O
+discussed	O
+the	O
+history	O
+of	O
+nucleotide	B-CHED
+antiviral	B-CHED
+agents	I-CHED
+,	O
+mechanisms	O
+of	O
+viral	O
+persistence	O
+and	O
+drug	B-PROC
+resistance	I-PROC
+,	O
+and	O
+the	O
+therapy	O
+of	O
+herpes	B-SPEC
+virus	I-SPEC
+infections	B-DISO
+.	O
+
+Our	O
+results	O
+establish	O
+that	O
+assembly	O
+competence	O
+maps	O
+to	O
+the	O
+endodomain	O
+of	O
+S	O
+,	O
+which	O
+was	O
+shown	O
+to	O
+be	O
+sufficient	O
+to	O
+target	O
+a	O
+heterologous	O
+integral	O
+membrane	B-COMP
+protein	B-CHED
+for	O
+incorporation	O
+into	O
+MHV	B-SPEC
+virions	B-COMP
+.	O
+
+TITLE	O
+:	O
+Identification	O
+and	O
+characterization	O
+of	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+coronavirus	B-SPEC
+replicase	B-PRGE
+proteins	B-CHED
+.	O
+
+Dual	O
+-	O
+labeling	O
+studies	O
+demonstrated	O
+colocalization	O
+of	O
+replicase	O
+protein	O
+nsp8	O
+with	O
+nsp2	B-PRGE
+and	O
+nsp3	B-PRGE
+in	O
+cytoplasmic	B-COMP
+complexes	O
+and	O
+also	O
+with	O
+LC3	B-PRGE
+,	O
+a	O
+protein	B-CHED
+marker	O
+for	O
+autophagic	B-COMP
+vacuoles	I-COMP
+.	O
+
+CEACAM1a	O
+functions	O
+as	O
+an	O
+intercellular	O
+adhesion	B-DISO
+molecule	O
+,	O
+an	O
+angiogenic	B-PROC
+factor	O
+,	O
+and	O
+a	O
+tumor	B-ANAT
+cell	B-COMP
+growth	O
+inhibitor	B-CHED
+.	O
+
+Whereas	O
+virus	B-SPEC
+-	O
+inoculated	O
+wild	O
+-	O
+type	O
++/+	O
+C57BL	O
+/	O
+6	O
+mice	B-SPEC
+showed	O
+profound	O
+liver	B-DISO
+damage	I-DISO
+and	O
+spinal	B-ANAT
+cord	I-ANAT
+demyelination	B-DISO
+under	O
+these	O
+conditions	O
+,	O
+Ceacam1a	O
+-/-	O
+mice	B-SPEC
+displayed	O
+normal	O
+livers	B-ANAT
+and	O
+spinal	B-ANAT
+cords	I-ANAT
+.	O
+
+Virus	B-SPEC
+was	O
+recovered	O
+from	O
+liver	B-ANAT
+and	O
+spinal	B-ANAT
+cord	I-ANAT
+tissues	B-ANAT
+of	O
++/+	O
+mice	B-SPEC
+but	O
+not	O
+of	O
+-/-	O
+mice	B-SPEC
+.	O
+
+These	O
+results	O
+indicate	O
+that	O
+CEACAM1a	O
+is	O
+the	O
+sole	B-ANAT
+receptor	O
+for	O
+MHV	B-SPEC
+-	O
+A59	O
+in	O
+both	O
+liver	B-ANAT
+and	O
+brain	B-ANAT
+and	O
+that	O
+its	O
+deletion	O
+from	O
+the	O
+mouse	B-SPEC
+renders	O
+the	O
+mouse	B-SPEC
+completely	O
+resistant	O
+to	O
+infection	B-DISO
+by	O
+this	O
+virus	B-SPEC
+.	O
+
+TITLE	O
+:	O
+Syndromic	O
+surveillance	O
+using	O
+regional	O
+emergency	B-DISO
+medicine	B-CHED
+internet	O
+.	O
+
+ABSTRACT	O
+:	O
+We	O
+demonstrate	O
+the	O
+feasibility	O
+and	O
+utility	O
+of	O
+emergency	O
+department	O
+(	O
+ED	O
+)	O
+syndromic	O
+surveillance	O
+using	O
+a	O
+regional	O
+emergency	B-DISO
+medicine	B-CHED
+Internet	O
+application	O
+to	O
+minimize	O
+impact	O
+on	O
+ED	O
+and	O
+public	O
+health	O
+staffing	O
+.	O
+
+Regional	O
+(	O
+multi	O
+-	O
+ED	O
+)	O
+surveillance	O
+was	O
+established	O
+for	O
+2	O
+periods	B-PROC
+,	O
+one	O
+characterized	O
+by	O
+a	O
+high	O
+-	O
+profile	O
+national	O
+sports	O
+event	O
+and	O
+the	O
+other	O
+during	O
+an	O
+international	O
+disease	O
+outbreak	O
+.	O
+
+Counts	O
+of	O
+patient	O
+visits	O
+meeting	O
+syndrome	B-DISO
+criteria	O
+and	O
+total	O
+patient	O
+visits	O
+were	O
+reported	O
+daily	O
+on	O
+the	O
+secure	O
+regional	O
+emergency	B-DISO
+medicine	B-CHED
+Internet	O
+site	O
+and	O
+downloaded	O
+by	O
+public	O
+health	O
+staff	O
+.	O
+
+This	O
+latter	O
+finding	O
+markedly	O
+changes	O
+our	O
+concept	O
+of	O
+host	B-COMP
+-	O
+pathogen	O
+interactions	O
+and	O
+creates	O
+a	O
+new	O
+paradigm	O
+for	O
+the	O
+study	O
+of	O
+such	O
+phenomena	O
+.	O
+
+The	O
+label	B-CHED
+was	O
+also	O
+politically	O
+convenient	O
+.	O
+
+TITLE	O
+:	O
+Antibodies	B-COMP
+to	O
+selected	O
+pathogens	O
+in	O
+free	O
+-	O
+ranging	O
+terrestrial	O
+carnivores	B-SPEC
+and	O
+marine	O
+mammals	B-SPEC
+in	O
+Canada	O
+.	O
+
+The	O
+only	O
+one	O
+patient	O
+who	O
+didn	O
+'	O
+t	O
+take	O
+glucocorticoid	B-CHED
+therapy	O
+was	O
+complementarily	O
+treated	O
+with	O
+traditional	O
+Chinese	O
+herbs	O
+through	O
+the	O
+whole	O
+treating	O
+procedure	O
+.	O
+
+There	O
+are	O
+obvious	O
+advantages	O
+of	O
+the	O
+integrated	O
+traditional	O
+Chinese	O
+and	O
+western	O
+medicine	B-CHED
+on	O
+the	O
+treatment	O
+of	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+(	O
+SARS	B-DISO
+).	O
+
+Combining	O
+the	O
+ancient	O
+and	O
+present	O
+literature	O
+with	O
+the	O
+special	O
+epidemic	O
+patterns	O
+,	O
+pathological	O
+changes	O
+and	O
+clinical	O
+symptoms	O
+of	O
+SARS	B-DISO
+,	O
+the	O
+paper	O
+discussed	O
+the	O
+methods	O
+of	O
+application	O
+of	O
+the	O
+integrated	O
+traditional	O
+Chinese	O
+and	O
+western	O
+medicine	B-CHED
+on	O
+the	O
+treatment	O
+of	O
+SARS	B-DISO
+,	O
+and	O
+some	O
+matters	O
+needing	O
+attention	O
+in	O
+clinic	O
+.	O
+
+This	O
+is	O
+the	O
+first	O
+report	O
+to	O
+prove	O
+that	O
+tranilast	O
+prevents	O
+pulmonary	B-ANAT
+and	O
+airway	B-ANAT
+vascular	B-PROC
+permeability	I-PROC
+and	O
+hypoxemia	O
+induced	O
+by	O
+OA	O
+.	O
+
+ABSTRACT	O
+:	O
+To	O
+find	O
+out	O
+the	O
+timing	O
+of	O
+serologic	O
+responses	O
+after	O
+illness	O
+onset	O
+and	O
+distribution	O
+of	O
+IgG	O
+antibody	O
+to	O
+SARS	B-DISO
+-	O
+CoV	O
+in	O
+SARS	B-DISO
+cases	O
+of	O
+transmission	O
+chain	O
+or	O
+non	O
+-	O
+transmission	O
+chain	O
+.	O
+
+The	O
+chain	O
+of	O
+transmission	O
+could	O
+spread	O
+to	O
+four	O
+generations	O
+,	O
+but	O
+the	O
+SARS	B-DISO
+cases	O
+were	O
+reduced	O
+with	O
+increase	O
+of	O
+generations	O
+.	O
+
+The	O
+cumulated	O
+positive	O
+rate	O
+of	O
+SARS	B-PRGE
+-	I-PRGE
+CoV	I-PRGE
+IgM	I-PRGE
+during	O
+days	O
+0	O
+-	O
+7	O
+after	O
+onset	O
+was	O
+the	O
+same	O
+to	O
+that	O
+of	O
+IgG	B-PRGE
+.	O
+During	O
+days	O
+8	O
+-	O
+14	O
+,	O
+55	O
+.	O
+17	O
+%	O
+of	O
+cases	O
+had	O
+seroconversion	O
+for	O
+IgM	B-PRGE
+which	O
+reached	O
+a	O
+peak	O
+(	O
+86	O
+.	O
+96	O
+%)	O
+during	O
+days	O
+21	O
+-	O
+30	O
+.	O
+
+Then	O
+the	O
+high	O
+rate	O
+of	O
+antibody	B-COMP
+was	O
+maintained	O
+for	O
+more	O
+than	O
+6	O
+months	O
+.	O
+
+CONCLUSIONS	O
+:	O
+More	O
+than	O
+94	O
+%	O
+of	O
+cases	O
+with	O
+SARS	B-DISO
+could	O
+produce	O
+IgG	B-COMP
+antibody	I-COMP
+when	O
+they	O
+were	O
+infected	O
+by	O
+SARS	B-DISO
+-	O
+CoV	O
+.	O
+Detecting	O
+SARS	B-PRGE
+-	I-PRGE
+CoV	I-PRGE
+IgG	I-PRGE
+could	O
+provide	O
+a	O
+diagnostic	O
+evidence	O
+for	O
+case	O
+confirmation	O
+.	O
+
+TITLE	O
+:	O
+[	O
+Difference	O
+and	O
+significance	O
+of	O
+T	B-ANAT
+-	I-ANAT
+lymphocyte	I-ANAT
+subsets	I-ANAT
+in	O
+differential	O
+diagnosis	O
+between	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+and	O
+common	O
+atypical	B-DISO
+pneumonia	I-DISO
+].	O
+
+RESULTS	O
+:	O
+Sixty	O
+-	O
+five	O
+of	O
+the	O
+patients	O
+were	O
+confirmed	O
+to	O
+have	O
+common	O
+type	O
+of	O
+SARS	B-DISO
+,	O
+including	O
+26	O
+males	O
+and	O
+39	O
+females	O
+,	O
+50	O
+cases	O
+received	O
+methylprednisolone	B-CHED
+treatment	O
+.	O
+
+CONCLUSIONS	O
+:	O
+With	O
+or	O
+without	O
+treatment	O
+with	O
+glucocorticoids	B-CHED
+,	O
+the	O
+lowered	O
+CD3	B-PRGE
++,	I-PRGE
+CD4	B-PRGE
++,	I-PRGE
+CD8	B-ANAT
++	I-ANAT
+T	I-ANAT
+-	I-ANAT
+lymphocyte	I-ANAT
+counts	O
+in	O
+the	O
+early	O
+stage	O
+are	O
+of	O
+very	O
+important	O
+significance	O
+in	O
+differential	O
+diagnosis	O
+between	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+and	O
+common	O
+atypical	B-DISO
+pneumonia	I-DISO
+.	O
+
+TITLE	O
+:	O
+[	O
+Studies	O
+on	O
+IgG	B-PRGE
+antibodies	I-PRGE
+of	O
+SARS	B-DISO
+patients	O
+].	O
+
+The	O
+decrease	O
+of	O
+arterial	B-ANAT
+partial	B-PROC
+pressure	I-PROC
+of	I-PROC
+oxygen	I-PROC
+occurred	O
+in	O
+26	O
+patients	O
+(	O
+49	O
+.	O
+1	O
+%).	O
+
+ABSTRACT	O
+:	O
+To	O
+investigate	O
+the	O
+changes	O
+of	O
+blood	O
+corpuscles	O
+of	O
+patients	O
+with	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+(	O
+SARS	B-DISO
+)	O
+in	O
+Beijing	O
+.	O
+
+Totally	O
+43	O
+patients	O
+(	O
+21	O
+male	O
+and	O
+22	O
+female	O
+,	O
+19	O
+-	O
+74	O
+years	O
+old	O
+age	O
+range	O
+)	O
+diagnosed	O
+as	O
+of	O
+probable	O
+SARS	B-DISO
+were	O
+included	O
+in	O
+this	O
+study	O
+.	O
+
+Patients	O
+with	O
+SARS	B-DISO
+were	O
+more	O
+likely	O
+to	O
+develop	O
+leukocytopenia	B-DISO
+,	O
+lymphopenia	B-DISO
+and	O
+thrombocytopenia	O
+in	O
+the	O
+early	O
+period	O
+of	O
+disease	O
+than	O
+those	O
+in	O
+control	O
+group	O
+.	O
+
+TITLE	O
+:	O
+[	O
+Anti	B-PRGE
+-	I-PRGE
+SARS	I-PRGE
+virus	B-SPEC
+activities	O
+of	O
+different	O
+recombinant	O
+human	B-SPEC
+interferons	O
+in	O
+cell	B-COMP
+culture	O
+system	O
+].	O
+
+CONCLUSIONS	O
+:	O
+A	O
+SARS	B-DISO
+virus	B-SPEC
+whole	O
+genome	O
+cDNA	O
+chip	O
+was	O
+established	O
+.	O
+
+TITLE	O
+:	O
+[	O
+Clinical	O
+pathology	B-DISO
+and	O
+pathogenesis	B-DISO
+of	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+].	O
+
+The	O
+location	O
+and	O
+semi	O
+-	O
+quantitative	O
+analysis	O
+of	O
+SARS	B-DISO
+coronavirus	B-SPEC
+in	O
+the	O
+tissue	B-ANAT
+specimens	O
+were	O
+studied	O
+by	O
+electron	O
+microscopy	O
+,	O
+in	O
+situ	O
+hybridization	B-PROC
+and	O
+immunohistochemistry	O
+.	O
+
+Meanwhile	O
+,	O
+the	O
+immune	O
+organs	B-ANAT
+,	O
+including	O
+lymph	B-ANAT
+nodes	I-ANAT
+and	O
+spleens	B-ANAT
+from	O
+2	O
+autopsy	O
+cases	O
+of	O
+SARS	B-DISO
+whose	O
+disease	O
+courses	O
+were	O
+less	O
+than	O
+12	O
+days	O
+showed	O
+extensive	O
+hemorrhagic	B-DISO
+necrosis	I-DISO
+,	O
+reactive	O
+macrophage	B-ANAT
+/	O
+histocyte	B-ANAT
+proliferation	B-DISO
+,	O
+with	O
+relative	O
+depression	B-DISO
+of	O
+mononuclear	O
+and	O
+granulocytic	B-ANAT
+clones	O
+in	O
+the	O
+bone	B-ANAT
+marrows	B-SPEC
+.	O
+
+However	O
+,	O
+spleen	B-ANAT
+and	O
+bone	B-ANAT
+marrow	I-ANAT
+biopsy	O
+tissue	B-ANAT
+samples	O
+from	O
+4	O
+dead	B-PROC
+SARS	B-DISO
+cases	O
+whose	O
+clinical	O
+course	O
+lasted	O
+from	O
+21	O
+to	O
+40	O
+days	O
+presented	O
+repairing	B-PROC
+changes	O
+.	O
+
+RESULTS	O
+:	O
+In	O
+total	O
+of	O
+6	O
+cases	O
+,	O
+diffuse	B-DISO
+alveolar	I-DISO
+damage	I-DISO
+and	O
+alveolar	B-ANAT
+cell	I-ANAT
+proliferation	O
+were	O
+common	O
+.	O
+
+The	O
+clinical	O
+data	O
+of	O
+60	O
+SARS	B-DISO
+patients	O
+were	O
+analyzed	O
+by	O
+logistic	O
+regression	O
+and	O
+Cox	O
+'	O
+s	O
+proportional	O
+hazards	O
+analysis	O
+.	O
+
+ABSTRACT	O
+:	O
+To	O
+describe	O
+the	O
+impact	O
+on	O
+delegates	O
+of	O
+attending	O
+the	O
+Canadian	O
+Pain	O
+Society	O
+'	O
+s	O
+annual	O
+meeting	O
+in	O
+Toronto	O
+during	O
+the	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+(	O
+SARS	B-DISO
+)	O
+crisis	O
+in	O
+May	O
+2003	O
+.	O
+
+Data	O
+on	O
+the	O
+physiological	B-DISO
+stress	I-DISO
+imposed	O
+by	O
+the	O
+wearing	O
+of	O
+N95	O
+masks	O
+remains	O
+limited	O
+.	O
+
+ESRD	B-DISO
+patients	O
+who	O
+received	O
+regular	O
+HD	O
+at	O
+National	O
+Taiwan	O
+University	O
+Hospital	O
+between	O
+April	O
+to	O
+June	O
+2003	O
+were	O
+enrolled	O
+.	O
+
+The	O
+fusion	O
+core	O
+protein	B-CHED
+of	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+coronavirus	B-SPEC
+spike	O
+protein	B-CHED
+was	O
+crystallized	O
+,	O
+and	O
+the	O
+structure	O
+was	O
+determined	O
+at	O
+2	O
+.	O
+8	O
+A	O
+of	O
+resolution	O
+.	O
+
+Drug	O
+discovery	O
+strategies	O
+aimed	O
+at	O
+inhibiting	O
+viral	O
+entry	O
+by	O
+blocking	B-DISO
+hairpin	O
+formation	B-PROC
+,	O
+which	O
+have	O
+been	O
+successfully	O
+used	O
+in	O
+human	B-SPEC
+immunodeficiency	I-SPEC
+virus	I-SPEC
+1	I-SPEC
+inhibitor	B-CHED
+development	B-PROC
+,	O
+may	O
+be	O
+applicable	O
+to	O
+the	O
+inhibition	B-PROC
+of	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+coronavirus	B-SPEC
+on	O
+the	O
+basis	O
+of	O
+structural	O
+information	O
+provided	O
+here	O
+.	O
+
+TITLE	O
+:	O
+[	O
+On	O
+the	O
+epidemiological	O
+situation	O
+in	O
+quarantine	O
+,	O
+natural	O
+focal	O
+and	O
+other	O
+infections	B-DISO
+on	O
+the	O
+territory	O
+of	O
+the	O
+Southern	O
+Federal	O
+District	O
+].	O
+
+Special	O
+attention	O
+has	O
+been	O
+given	O
+to	O
+""""	O
+new	O
+and	O
+newly	O
+returning	O
+infections	B-DISO
+""","	O
+and	O
+among	O
+them	O
+to	O
+the	O
+spread	O
+of	O
+SARS	B-DISO
+"("""	O
+atypical	B-DISO
+pneumonia	I-DISO
+""")."	O
+
+TITLE	O
+:	O
+Mutational	O
+dynamics	O
+of	O
+the	O
+SARS	B-DISO
+coronavirus	B-SPEC
+in	O
+cell	B-COMP
+culture	O
+and	O
+human	B-SPEC
+populations	O
+isolated	O
+in	O
+2003	O
+.	O
+
+ABSTRACT	O
+:	O
+The	O
+SARS	O
+coronavirus	B-SPEC
+is	O
+the	O
+etiologic	O
+agent	O
+for	O
+the	O
+epidemic	O
+of	O
+the	O
+Severe	B-DISO
+Acute	I-DISO
+Respiratory	I-DISO
+Syndrome	I-DISO
+.	O
+
+We	O
+sequenced	O
+complete	O
+SARS	B-DISO
+-	O
+CoV	O
+genomes	O
+taken	O
+from	O
+primary	O
+human	B-ANAT
+tissues	I-ANAT
+(	O
+SIN3408	O
+,	O
+SIN3725V	O
+,	O
+SIN3765V	O
+),	O
+cultured	O
+isolates	O
+(	O
+SIN848	O
+,	O
+SIN846	O
+,	O
+SIN842	O
+,	O
+SIN845	O
+,	O
+SIN847	O
+,	O
+SIN849	O
+,	O
+SIN850	O
+,	O
+SIN852	O
+,	O
+SIN3408L	O
+),	O
+and	O
+five	O
+consecutive	O
+Vero	B-ANAT
+cell	I-ANAT
+passages	O
+(	O
+SIN2774_P1	O
+,	O
+SIN2774_P2	O
+,	O
+SIN2774_P3	O
+,	O
+SIN2774_P4	O
+,	O
+SIN2774_P5	O
+)	O
+arising	O
+from	O
+SIN2774	O
+isolate	O
+.	O
+
+Probable	O
+/	O
+suspect	O
+cases	O
+of	O
+SARS	B-DISO
+were	O
+defined	O
+by	O
+World	O
+Health	O
+Organization	O
+criteria	O
+.	O
+
+One	O
+of	O
+them	O
+died	B-PROC
+soon	O
+thereafter	O
+.	O
+
+The	O
+incidence	O
+of	O
+P	O
+-	O
+SARS	B-DISO
+was	O
+0	O
+.	O
+6	O
+%	O
+(	O
+95	O
+%	O
+CI	O
+=	O
+0	O
+.	O
+2	O
+%	O
+to	O
+2	O
+.	O
+2	O
+%),	O
+or	O
+0	O
+.	O
+1	O
+%	O
+(	O
+95	O
+%	O
+CI	O
+=	O
+0	O
+.	O
+03	O
+%	O
+to	O
+0	O
+.	O
+4	O
+%)	O
+per	O
+transport	B-PROC
+.	O
+
+Compared	O
+with	O
+the	O
+general	O
+population	O
+,	O
+EMS	O
+providers	O
+are	O
+at	O
+higher	O
+risk	O
+of	O
+contracting	O
+the	O
+SARS	B-DISO
+virus	B-SPEC
+regardless	O
+of	O
+different	O
+perceived	O
+levels	O
+of	O
+risk	O
+.	O
+
+Many	O
+paramedics	O
+developed	O
+SARS	B-DISO
+-	O
+like	O
+symptoms	O
+without	O
+being	O
+diagnosed	O
+as	O
+having	O
+SARS	B-DISO
+.	O
+
+A	O
+dedicated	O
+paramedic	O
+surveillance	O
+and	O
+quarantine	O
+program	O
+provided	O
+a	O
+useful	O
+means	O
+to	O
+manage	O
+the	O
+paramedic	O
+resource	O
+during	O
+the	O
+SARS	B-DISO
+outbreak	O
+.	O
+
+ABSTRACT	O
+:	O
+We	O
+have	O
+developed	O
+a	O
+new	O
+experimental	O
+system	O
+based	O
+on	O
+a	O
+microfluidic	O
+chip	O
+to	O
+determine	O
+severe	O
+acute	O
+respiratory	O
+syndrome	O
+coronavirus	B-SPEC
+(	O
+SARS	B-DISO
+-	O
+CoV	O
+).	O
+
+A	O
+similar	O
+trend	O
+was	O
+noted	O
+for	O
+neutralising	O
+antibodies	B-COMP
+.	O
+
+Our	O
+recent	O
+study	O
+indicated	O
+that	O
+SARS	B-DISO
+-	I-DISO
+CoV	I-DISO
+infection	I-DISO
+induces	O
+activation	O
+of	O
+the	O
+p38	B-FUNC
+mitogen	B-PRGE
+-	I-PRGE
+activated	I-PRGE
+protein	B-CHED
+kinase	I-PRGE
+(	O
+MAPK	B-FUNC
+)	O
+signaling	B-PROC
+pathway	I-PROC
+and	O
+the	O
+p38	B-PRGE
+MAPK	B-FUNC
+inhibitor	B-CHED
+partially	O
+inhibited	O
+its	O
+cytopathic	B-DISO
+effect	I-DISO
+in	O
+Vero	O
+E6	O
+cells	B-COMP
+.	O
+
+The	O
+results	O
+of	O
+the	O
+present	O
+study	O
+indicated	O
+that	O
+before	O
+cell	B-PROC
+death	I-PROC
+,	O
+Akt	B-PRGE
+,	O
+which	O
+is	O
+an	O
+inhibitor	B-CHED
+of	O
+apoptosis	B-PATH
+,	O
+was	O
+also	O
+activated	O
+in	O
+response	O
+to	O
+viral	B-PROC
+replication	I-PROC
+.	O
+
+Phosphorylation	B-PROC
+of	O
+a	O
+serine	B-CHED
+residue	I-CHED
+on	O
+Akt	B-PRGE
+was	O
+detected	O
+at	O
+least	O
+8	O
+h	O
+postinfection	O
+(	O
+hpi	B-DISO
+),	O
+which	O
+declined	O
+after	O
+18	O
+hpi	B-DISO
+.	O
+
+However	O
+,	O
+a	O
+threonine	B-CHED
+residue	I-CHED
+was	O
+not	O
+phosphorylated	O
+.	O
+
+A	O
+downstream	O
+target	O
+of	O
+Akt	B-PRGE
+,	O
+glycogen	B-PRGE
+synthase	I-PRGE
+kinase	I-PRGE
+3beta	I-PRGE
+(	O
+GSK	B-PRGE
+-	I-PRGE
+3beta	I-PRGE
+),	O
+was	O
+slightly	O
+phosphorylated	O
+,	O
+indicating	O
+that	O
+the	O
+level	O
+of	O
+activation	O
+of	O
+Akt	O
+was	O
+very	O
+low	O
+.	O
+
+ABSTRACT	O
+:	O
+A	O
+murine	B-SPEC
+model	O
+of	O
+lipopolysaccharide	B-CHED
+(	O
+LPS	B-DISO
+)-	O
+induced	O
+acute	O
+lung	B-ANAT
+injury	O
+(	O
+ALI	O
+)	O
+was	O
+used	O
+to	O
+evaluate	O
+whether	O
+aquaporin	B-PRGE
+-	I-PRGE
+1	I-PRGE
+(	O
+AQP1	B-PRGE
+)	O
+is	O
+involved	O
+in	O
+lung	B-DISO
+inflammation	I-DISO
+and	O
+lung	B-DISO
+edema	I-DISO
+formation	B-PROC
+.	O
+
+Swiss	O
+strain	O
+mice	B-SPEC
+(	O
+n	O
+=	O
+122	O
+)	O
+had	O
+LPS	B-DISO
+(	O
+5	O
+mg	O
+/	O
+kg	O
+)	O
+instilled	O
+intratracheally	O
+(	O
+IT	O
+),	O
+and	O
+were	O
+then	O
+treated	O
+with	O
+either	O
+0	O
+.	O
+9	O
+%	O
+saline	O
+or	O
+dexamethasone	B-CHED
+(	O
+5	O
+mg	O
+/	O
+kg	O
+/	O
+day	O
+).	O
+
+Mice	B-SPEC
+were	O
+euthanized	O
+at	O
+2	O
+days	O
+and	O
+7	O
+days	O
+after	O
+treatment	O
+.	O
+
+Lung	B-ANAT
+wet	O
+-	O
+to	O
+-	O
+dry	O
+weight	O
+ratio	O
+and	O
+lung	B-ANAT
+vascular	B-PROC
+permeability	I-PROC
+were	O
+also	O
+measured	O
+in	O
+the	O
+AQP1	B-PRGE
+knockout	O
+mice	B-SPEC
+(	O
+n	O
+=	O
+9	O
+)	O
+that	O
+received	O
+IT	O
+LPS	B-DISO
+(	O
+5	O
+mg	O
+/	O
+kg	O
+)	O
+at	O
+2	O
+days	O
+.	O
+
+The	O
+results	O
+suggest	O
+that	O
+although	O
+AQP1	B-PRGE
+expression	B-PROC
+is	O
+decreased	O
+after	O
+lung	B-ANAT
+injury	O
+,	O
+depletion	O
+of	O
+AQP1	B-PRGE
+does	O
+not	O
+alter	O
+lung	B-DISO
+inflammation	I-DISO
+and	O
+lung	B-DISO
+edema	I-DISO
+induced	O
+by	O
+LPS	B-DISO
+.	O
+
+Sequence	O
+analysis	O
+of	O
+the	O
+virus	B-SPEC
+indicates	O
+that	O
+there	O
+is	O
+only	O
+20	O
+%	O
+amino	B-CHED
+acid	I-CHED
+(	O
+aa	O
+)	O
+identity	O
+with	O
+known	O
+coronaviruses	O
+.	O
+
+Yet	O
+,	O
+little	O
+sequence	O
+homology	O
+between	O
+the	O
+newly	O
+identified	O
+SARS	B-PRGE
+-	I-PRGE
+CoV	I-PRGE
+and	O
+those	O
+previously	O
+studied	O
+coronaviruses	O
+suggests	O
+that	O
+determination	O
+of	O
+protein	B-PROC
+-	I-PROC
+protein	B-CHED
+interaction	I-PROC
+and	O
+identification	O
+of	O
+amino	B-CHED
+acid	I-CHED
+sequences	O
+,	O
+responsible	O
+for	O
+such	O
+interaction	O
+in	O
+SARS	B-PRGE
+-	I-PRGE
+CoV	I-PRGE
+,	O
+are	O
+necessary	O
+for	O
+the	O
+elucidation	O
+of	O
+the	O
+molecular	O
+mechanism	O
+of	O
+SARS	B-DISO
+-	O
+CoV	O
+replication	O
+and	O
+rationalization	O
+of	O
+anti	B-PRGE
+-	I-PRGE
+SARS	I-PRGE
+therapeutic	O
+intervention	O
+.	O
+
+We	O
+found	O
+that	O
+interaction	O
+of	O
+the	O
+N	O
+and	O
+M	O
+proteins	B-CHED
+takes	O
+place	O
+in	O
+vivo	O
+and	O
+identified	O
+that	O
+a	O
+stretch	O
+of	O
+amino	B-CHED
+acids	I-CHED
+(	O
+168	O
+-	O
+208	O
+)	O
+in	O
+the	O
+N	B-PRGE
+protein	I-PRGE
+may	O
+be	O
+critical	O
+for	O
+such	O
+protein	B-CHED
+-	O
+protein	B-CHED
+interactions	O
+.	O
+
+We	O
+tested	O
+chloroquine	B-CHED
+phosphate	B-CHED
+for	O
+its	O
+antiviral	B-CHED
+potential	O
+against	O
+SARS	B-DISO
+-	O
+CoV	O
+-	O
+induced	O
+cytopathicity	O
+in	O
+Vero	O
+E6	O
+cell	B-COMP
+culture	O
+.	O
+
+TITLE	O
+:	O
+Different	O
+epidemic	O
+curves	O
+for	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+reveal	O
+similar	O
+impacts	O
+of	O
+control	O
+measures	O
+.	O
+
+ABSTRACT	O
+:	O
+New	O
+emerging	O
+infections	B-DISO
+over	O
+the	O
+last	O
+few	O
+years	O
+demonstrate	O
+the	O
+potential	O
+for	O
+the	O
+introduction	O
+of	O
+epidemic	O
+illness	O
+through	O
+global	O
+migration	B-PROC
+.	O
+
+For	O
+avian	B-DISO
+influenza	I-DISO
+aspects	O
+of	O
+the	O
+agrarian	O
+economy	O
+in	O
+southeast	O
+Asia	O
+enabled	O
+the	O
+virus	B-SPEC
+to	O
+reach	B-PROC
+the	O
+human	B-SPEC
+population	O
+.	O
+
+SARS	B-DISO
+evolved	O
+in	O
+rural	O
+China	O
+and	O
+spread	O
+worldwide	O
+in	O
+one	O
+season	O
+with	O
+an	O
+approximate	O
+10	O
+%	O
+mortality	O
+.	O
+
+Warning	O
+of	O
+atmospheric	O
+conditions	O
+favorable	O
+to	O
+SARS	B-DISO
+,	O
+and	O
+improvement	O
+in	O
+occupational	O
+hygiene	O
+management	O
+is	O
+the	O
+key	O
+to	O
+prevention	O
+from	O
+SARS	B-DISO
+outbreak	O
+.	O
+
+A	O
+clinical	O
+isolate	O
+of	O
+the	O
+virus	B-SPEC
+introduced	O
+intranasally	O
+replicated	O
+transiently	O
+to	O
+high	O
+levels	O
+in	O
+the	O
+lungs	B-ANAT
+of	O
+these	O
+mice	B-SPEC
+,	O
+with	O
+a	O
+peak	O
+on	O
+day	O
+3	O
+and	O
+clearance	O
+by	O
+day	O
+9	O
+postinfection	O
+.	O
+
+ABSTRACT	O
+:	O
+The	O
+spike	O
+(	O
+S	O
+)	O
+protein	B-CHED
+of	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+(	O
+SARS	B-DISO
+)	O
+coronavirus	B-SPEC
+(	O
+SARS	B-DISO
+-	O
+CoV	O
+)	O
+is	O
+not	O
+only	O
+responsible	O
+for	O
+receptor	B-FUNC
+binding	I-FUNC
+and	O
+virus	B-SPEC
+fusion	O
+,	O
+but	O
+also	O
+a	O
+major	O
+Ag	O
+among	O
+the	O
+SARS	B-PRGE
+-	I-PRGE
+CoV	I-PRGE
+proteins	B-CHED
+that	O
+induces	O
+protective	O
+Ab	O
+responses	O
+.	O
+
+In	O
+this	O
+study	O
+,	O
+we	O
+showed	O
+that	O
+the	O
+S	B-PRGE
+protein	I-PRGE
+of	O
+SARS	B-PRGE
+-	I-PRGE
+CoV	I-PRGE
+is	O
+highly	O
+immunogenic	O
+during	O
+infection	B-DISO
+and	O
+immunizations	O
+,	O
+and	O
+contains	O
+five	O
+linear	O
+immunodominant	O
+sites	O
+(	O
+sites	O
+I	O
+to	O
+V	O
+)	O
+as	O
+determined	O
+by	O
+Pepscan	O
+analysis	O
+with	O
+a	O
+set	O
+of	O
+synthetic	O
+peptides	B-CHED
+overlapping	O
+the	O
+entire	B-PRGE
+S	I-PRGE
+protein	I-PRGE
+sequence	I-PRGE
+against	O
+the	O
+convalescent	O
+sera	B-COMP
+from	O
+SARS	B-DISO
+patients	O
+and	O
+antisera	O
+from	O
+small	O
+animals	B-SPEC
+immunized	O
+with	O
+inactivated	O
+SARS	B-PRGE
+-	I-PRGE
+CoV	I-PRGE
+.	O
+Site	O
+IV	O
+located	O
+in	O
+the	O
+middle	O
+region	O
+of	O
+the	O
+S	B-PRGE
+protein	I-PRGE
+(	O
+residues	O
+528	O
+-	O
+635	O
+)	O
+is	O
+a	O
+major	O
+immunodominant	O
+epitope	B-CHED
+.	O
+
+The	O
+data	O
+suggest	O
+that	O
+MRSA	B-DISO
+cross	O
+-	O
+transmission	O
+may	O
+be	O
+increased	O
+if	O
+gloves	O
+and	O
+gowns	O
+are	O
+worn	O
+all	O
+the	O
+time	O
+.	O
+
+In	O
+March	O
+2002	O
+,	O
+Esteve	O
+and	O
+Hemispherx	O
+Biopharma	O
+entered	O
+into	O
+a	O
+collaborative	O
+agreement	O
+under	O
+which	O
+Esteve	O
+will	O
+be	O
+the	O
+sole	B-ANAT
+distributor	O
+of	O
+Ampligen	O
+in	O
+Spain	O
+,	O
+Portugal	O
+and	O
+Andorra	O
+for	O
+the	O
+treatment	O
+of	O
+chronic	B-DISO
+fatigue	I-DISO
+syndrome	I-DISO
+.	O
+
+Empire	O
+Health	O
+Resources	O
+,	O
+a	O
+healthcare	O
+management	O
+firm	O
+,	O
+will	O
+be	O
+responsible	O
+for	O
+accrual	O
+and	O
+retention	B-PROC
+of	O
+patients	O
+for	O
+HIV	B-DISO
+trials	O
+,	O
+and	O
+protocols	O
+for	O
+trials	O
+in	O
+patients	O
+with	O
+hepatitis	B-PATH
+C	I-PATH
+or	O
+both	O
+HIV	B-DISO
+and	O
+hepatitis	B-PATH
+C	I-PATH
+infections	B-DISO
+.	O
+
+The	O
+active	O
+substance	O
+for	O
+Ampligen	O
+is	O
+manufactured	O
+by	O
+F	O
+.	O
+H	O
+.	O
+Faulding	O
+Ltd	O
+.	O
+Clinical	O
+treatment	O
+programmes	O
+for	O
+chronic	B-DISO
+fatigue	I-DISO
+syndrome	I-DISO
+in	O
+other	O
+Pacific	O
+Rim	O
+countries	O
+are	O
+planned	O
+.	O
+
+Ampligen	O
+is	O
+available	O
+for	O
+severe	O
+chronic	B-DISO
+fatigue	I-DISO
+syndrome	I-DISO
+on	O
+a	O
+named	O
+patient	O
+,	O
+cost	O
+-	O
+recovery	O
+basis	O
+in	O
+South	O
+Africa	O
+.	O
+
+Hemispherx	O
+has	O
+also	O
+developed	O
+an	O
+oral	B-ANAT
+version	O
+of	O
+the	O
+drug	O
+(	O
+Oragen	O
+),	O
+which	O
+is	O
+undergoing	O
+preclinical	O
+evaluation	O
+.	O
+
+In	O
+February	O
+2001	O
+,	O
+Hemispherx	O
+Biopharma	O
+announced	O
+that	O
+it	O
+was	O
+initiating	O
+phase	O
+II	O
+/	O
+III	O
+trials	O
+of	O
+Ampligen	O
+in	O
+the	O
+treatment	O
+of	O
+late	O
+-	O
+stage	O
+,	O
+multidrug	O
+-	O
+resistant	O
+strains	O
+of	O
+HIV	B-DISO
+in	O
+the	O
+European	O
+Union	O
+.	O
+
+TITLE	O
+:	O
+A	O
+human	B-SPEC
+in	O
+vitro	O
+model	O
+system	O
+for	O
+investigating	O
+genome	O
+-	O
+wide	O
+host	B-COMP
+responses	O
+to	O
+SARS	B-DISO
+coronavirus	B-SPEC
+infection	I-DISO
+.	O
+
+The	O
+identification	O
+of	O
+human	B-SPEC
+blood	B-ANAT
+mononuclear	B-ANAT
+cells	I-ANAT
+as	O
+a	O
+direct	O
+target	O
+of	O
+SARS	B-DISO
+-	O
+CoV	O
+in	O
+the	O
+model	O
+system	O
+described	O
+here	O
+provides	O
+a	O
+new	O
+insight	O
+into	O
+disease	O
+pathology	B-DISO
+and	O
+a	O
+tool	O
+for	O
+investigating	O
+the	O
+host	B-PROC
+response	I-PROC
+and	O
+mechanisms	O
+of	O
+pathogenesis	B-DISO
+.	O
+
+The	O
+reliability	O
+of	O
+the	O
+binding	B-FUNC
+sites	O
+derived	O
+by	O
+the	O
+molecular	O
+modeling	O
+was	O
+confirmed	O
+by	O
+the	O
+fact	O
+that	O
+the	O
+computationally	O
+predicted	O
+values	O
+of	O
+the	O
+relative	O
+free	O
+energies	O
+of	O
+the	O
+binding	B-FUNC
+for	O
+SARS_NP	O
+(	O
+or	O
+hCypA	O
+)	O
+mutants	O
+to	O
+the	O
+wild	O
+-	O
+type	O
+hCypA	O
+(	O
+or	O
+SARS_NP	O
+)	O
+are	O
+in	O
+good	O
+agreement	O
+with	O
+the	O
+data	O
+determined	O
+by	O
+SPR	O
+.	O
+
+As	O
+well	O
+,	O
+1	O
+-	O
+10	O
+microM	O
+of	O
+each	O
+compound	O
+inhibited	O
+viral	B-PROC
+replication	I-PROC
+in	O
+Vero	O
+E6	O
+cell	B-COMP
+culture	O
+.	O
+
+TITLE	O
+:	O
+Characterization	O
+of	O
+trans	O
+-	O
+and	O
+cis	B-DISO
+-	O
+cleavage	B-PROC
+activity	O
+of	O
+the	O
+SARS	B-PRGE
+coronavirus	B-SPEC
+3CLpro	I-PRGE
+protease	I-PRGE
+:	O
+basis	O
+for	O
+the	O
+in	O
+vitro	O
+screening	O
+of	O
+anti	O
+-	O
+SARS	O
+drugs	O
+.	O
+
+Therefore	O
+,	O
+this	O
+study	O
+not	O
+only	O
+established	O
+the	O
+quantifiable	O
+and	O
+reliable	O
+assay	O
+for	O
+the	O
+in	O
+vitro	O
+and	O
+cell	B-COMP
+-	O
+based	O
+measurement	O
+of	O
+the	O
+3CLpro	O
+activity	O
+,	O
+but	O
+also	O
+characterized	O
+the	O
+molecular	B-FUNC
+interaction	I-FUNC
+of	O
+the	O
+SARS	B-PRGE
+-	I-PRGE
+CoV	I-PRGE
+3CLpro	I-PRGE
+with	O
+the	O
+substrates	O
+.	O
+
+In	O
+total	O
+,	O
+44	O
+of	O
+these	O
+patients	O
+underwent	O
+cardiopulmonary	B-ANAT
+exercise	O
+testing	O
+.	O
+
+No	O
+abnormalities	O
+were	O
+detected	O
+in	O
+the	O
+pulmonary	B-PROC
+function	I-PROC
+tests	O
+in	O
+23	O
+(	O
+50	O
+%)	O
+of	O
+the	O
+patients	O
+.	O
+
+We	O
+questioned	O
+whether	O
+CKLF1	B-PRGE
+could	O
+be	O
+involved	O
+in	O
+the	O
+pathogenesis	B-DISO
+of	O
+inflammation	B-DISO
+and	O
+proliferation	B-DISO
+in	O
+the	O
+lung	B-ANAT
+.	O
+
+We	O
+report	O
+5	O
+children	O
+with	O
+magnetic	O
+resonance	O
+imaging	O
+evidence	O
+of	O
+osteonecrosis	B-DISO
+.	O
+
+In	O
+view	O
+of	O
+the	O
+high	O
+prevalence	O
+and	O
+asymptomatic	O
+presentation	O
+of	O
+osteonecrosis	B-DISO
+,	O
+we	O
+suggest	O
+magnetic	O
+resonance	O
+imaging	O
+screening	O
+for	O
+osteonecrosis	B-DISO
+in	O
+children	O
+with	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+.	O
+
+According	O
+to	O
+the	O
+morphologic	O
+changes	O
+,	O
+lung	B-ANAT
+lesions	O
+in	O
+SARS	B-DISO
+were	O
+subcategorized	O
+into	O
+3	O
+phases	O
+:	O
+acute	B-DISO
+exudative	I-DISO
+inflammation	I-DISO
+,	O
+fibrous	O
+proliferation	B-DISO
+and	O
+the	O
+final	O
+fibrotic	O
+stage	O
+.	O
+
+The	O
+acute	O
+exudative	O
+protein	B-CHED
+was	O
+PAS	B-COMP
+-	O
+positive	O
+.	O
+
+The	O
+mesenchymal	O
+cells	B-COMP
+showed	O
+either	O
+myofibroblastic	O
+(	O
+which	O
+expressed	B-PROC
+desmin	B-COMP
+,	O
+HHF	O
+-	O
+35	O
+,	O
+smooth	B-PRGE
+muscle	I-PRGE
+actin	I-PRGE
+and	O
+vimentin	B-COMP
+)	O
+or	O
+fibroblastic	O
+(	O
+which	O
+expressed	B-PROC
+vimentin	B-COMP
+only	O
+)	O
+differentiation	B-PROC
+.	O
+
+NIPPV	O
+was	O
+applied	O
+to	O
+20	O
+patients	O
+(	O
+11	O
+male	O
+patients	O
+)	O
+with	O
+ARF	B-DISO
+secondary	O
+to	O
+SARS	B-DISO
+.	O
+
+SAA	O
+was	O
+not	O
+markedly	O
+increased	O
+in	O
+the	O
+fourth	O
+patient	O
+,	O
+who	O
+had	O
+low	O
+x	O
+-	O
+ray	B-SPEC
+scores	O
+and	O
+whose	O
+clinical	O
+course	O
+was	O
+relatively	O
+mild	O
+.	O
+
+CONCLUSIONS	O
+:	O
+Phage	O
+antibody	B-COMP
+library	O
+for	O
+human	B-SPEC
+Fab	B-PRGE
+fragment	I-PRGE
+has	O
+been	O
+constructed	O
+successfully	O
+,	O
+which	O
+lays	O
+the	O
+foundation	O
+for	O
+further	O
+study	O
+.	O
+
+Chemical	O
+cross	O
+-	O
+linking	O
+,	O
+thermal	O
+denaturation	B-PROC
+,	O
+and	O
+size	O
+fractionation	O
+analyses	O
+suggested	O
+that	O
+the	O
+full	B-PRGE
+-	I-PRGE
+length	I-PRGE
+S	I-PRGE
+glycoprotein	I-PRGE
+of	O
+SARS	B-PRGE
+-	I-PRGE
+CoV	I-PRGE
+forms	O
+a	O
+higher	B-ANAT
+order	I-ANAT
+structure	I-ANAT
+of	O
+approximately	O
+500	O
+kDa	O
+,	O
+which	O
+is	O
+consistent	O
+with	O
+it	O
+being	O
+an	O
+S	O
+homotrimer	O
+.	O
+
+The	O
+latter	O
+was	O
+also	O
+observed	O
+in	O
+purified	O
+virions	B-COMP
+.	O
+
+TITLE	O
+:	O
+Murine	B-SPEC
+coronavirus	I-SPEC
+nonstructural	O
+protein	B-CHED
+p28	B-COMP
+arrests	O
+cell	B-PATH
+cycle	I-PATH
+in	O
+G0	O
+/	O
+G1	B-PROC
+phase	I-PROC
+.	O
+
+Transient	O
+expression	B-PROC
+of	O
+cloned	O
+p28	B-COMP
+in	O
+several	O
+different	O
+cultured	B-ANAT
+cells	I-ANAT
+inhibited	O
+cell	B-PROC
+growth	B-PROC
+,	O
+indicating	O
+that	O
+p28	B-COMP
+expression	B-PROC
+suppressed	O
+cell	B-PROC
+proliferation	B-DISO
+.	O
+
+Our	O
+present	O
+data	O
+suggest	O
+the	O
+following	O
+model	O
+of	O
+p28	B-COMP
+-	O
+induced	O
+G	O
+(	O
+0	O
+)/	O
+G	O
+(	O
+1	O
+)	O
+cell	B-PROC
+cycle	I-PROC
+arrest	I-PROC
+.	O
+
+We	O
+also	O
+found	O
+that	O
+two	O
+retroviruses	B-SPEC
+,	O
+simian	B-SPEC
+immunodeficiency	I-SPEC
+virus	I-SPEC
+(	O
+SIV	B-DISO
+)	O
+and	O
+murine	B-SPEC
+leukemia	I-SPEC
+virus	I-SPEC
+,	O
+both	O
+expressing	O
+green	B-PRGE
+fluorescent	I-PRGE
+protein	I-PRGE
+and	O
+pseudotyped	O
+with	O
+SARS	B-PRGE
+-	I-PRGE
+CoV	I-PRGE
+S	I-PRGE
+protein	B-CHED
+or	O
+S	B-PRGE
+-	I-PRGE
+protein	I-PRGE
+variants	I-PRGE
+,	O
+efficiently	O
+infected	O
+HEK293T	O
+cells	B-COMP
+stably	O
+expressing	O
+ACE2	B-PRGE
+.	O
+
+ABSTRACT	O
+:	O
+SARS	B-DISO
+is	O
+the	O
+first	O
+major	O
+new	O
+infectious	B-DISO
+disease	I-DISO
+in	O
+the	O
+21st	O
+century	O
+(	O
+Rodier	O
+,	O
+2003	O
+)	O
+and	O
+is	O
+described	O
+as	O
+a	O
+""""	O
+serious	O
+disaster	O
+""""	O
+in	O
+mainland	O
+China	O
+where	O
+it	O
+caused	O
+unprecedented	O
+panic	O
+and	O
+social	O
+and	O
+economic	O
+consequences	O
+.	O
+
+Patients	O
+were	O
+ventilated	O
+in	O
+assist	O
+/	O
+control	O
+mode	O
+with	O
+a	O
+ventilatory	O
+strategy	O
+providing	O
+adequate	O
+oxygenation	B-PROC
+(	O
+PaO	B-PROC
+(	O
+2	O
+)	O
+>	O
+70	O
+mmHg	O
+)	O
+and	O
+normocapnia	O
+(	O
+PaCO	O
+(	O
+2	O
+)	O
+between	O
+35	O
+-	O
+40	O
+mmHg	O
+).	O
+
+No	O
+changes	O
+in	O
+hemodynamic	B-PROC
+or	O
+cerebral	B-ANAT
+parameters	O
+were	O
+observed	O
+during	O
+the	O
+study	O
+.	O
+
+RESULTS	O
+:	O
+SPAAN	O
+had	O
+optimal	O
+sensitivity	O
+of	O
+89	O
+%	O
+and	O
+specificity	O
+of	O
+100	O
+%	O
+on	O
+a	O
+defined	O
+test	O
+set	O
+and	O
+could	O
+identify	O
+97	O
+.	O
+4	O
+%	O
+of	O
+known	O
+adhesins	O
+at	O
+high	O
+Pad	B-DISO
+value	O
+from	O
+a	O
+wide	O
+range	O
+of	O
+bacteria	B-SPEC
+.	O
+
+Plateau	O
+pressures	O
+well	O
+below	O
+the	O
+""""	O
+upper	O
+corner	O
+point	O
+""""	O
+(	O
+airway	B-ANAT
+pressure	O
+where	O
+compliance	O
+decreases	O
+)	O
+resulted	O
+in	O
+significant	O
+alveolar	B-ANAT
+overstretching	O
+.	O
+
+These	O
+findings	O
+indicate	O
+that	O
+increased	O
+TF	B-PRGE
+-	I-PRGE
+alpha	I-PRGE
+(	I-PRGE
+1	I-PRGE
+)-	I-PRGE
+AT	I-PRGE
+may	O
+be	O
+therapeutically	O
+relevant	O
+,	O
+and	O
+may	O
+also	O
+be	O
+a	O
+useful	O
+biological	B-CHED
+marker	I-CHED
+for	O
+the	O
+diagnosis	O
+of	O
+SARS	B-DISO
+.	O
+
+In	O
+a	O
+preliminary	O
+study	O
+,	O
+angiotensin	B-PRGE
+II	I-PRGE
+blockade	O
+appeared	O
+to	O
+hasten	O
+recovery	O
+from	O
+West	B-DISO
+Nile	I-DISO
+virus	I-DISO
+encephalitis	B-DISO
+;	O
+it	O
+may	O
+be	O
+equally	O
+useful	O
+in	O
+SARS	B-DISO
+.	O
+
+The	O
+ACE	B-PRGE
+gene	I-PRGE
+underwent	O
+duplication	B-DISO
+at	O
+the	O
+origin	O
+of	O
+Chordata	O
+,	O
+just	O
+before	O
+the	O
+""""	O
+Cambrian	O
+Explosion	O
+""""	O
+in	O
+the	O
+number	O
+of	O
+species	B-SPEC
+.	O
+
+The	O
+crystal	B-ANAT
+structure	O
+of	O
+testicular	B-PRGE
+ACE	I-PRGE
+(	O
+tACE	B-PRGE
+)	O
+was	O
+recently	O
+published	O
+.	O
+
+TITLE	O
+:	O
+Identification	O
+of	O
+novel	O
+small	O
+-	O
+molecule	O
+inhibitors	B-CHED
+of	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+-	O
+associated	O
+coronavirus	O
+by	O
+chemical	O
+genetics	O
+.	O
+
+ABSTRACT	O
+:	O
+The	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+-	O
+associated	O
+coronavirus	B-SPEC
+(	O
+SARS	B-DISO
+-	O
+CoV	O
+)	O
+infected	O
+more	O
+than	O
+8	O
+,	O
+000	O
+people	O
+across	O
+29	O
+countries	O
+and	O
+caused	O
+more	O
+than	O
+900	O
+fatalities	O
+.	O
+
+In	O
+a	O
+series	O
+of	O
+autopsy	O
+patients	O
+,	O
+the	O
+accuracy	O
+of	O
+the	O
+American	O
+-	O
+European	O
+Consensus	O
+Conference	O
+definition	O
+of	O
+ARDS	B-DISO
+was	O
+only	O
+moderate	O
+.	O
+
+RESULTS	O
+:	O
+127	O
+patients	O
+(	O
+33	O
+%)	O
+met	B-CHED
+the	O
+clinical	O
+criteria	O
+,	O
+and	O
+112	O
+(	O
+29	O
+%)	O
+had	O
+diffuse	B-DISO
+alveolar	I-DISO
+damage	I-DISO
+.	O
+
+Compared	O
+with	O
+patients	O
+with	O
+pulmonary	B-ANAT
+risk	O
+factors	O
+,	O
+patients	O
+with	O
+extrapulmonary	O
+risk	O
+factors	O
+had	O
+significantly	O
+higher	O
+sensitivity	O
+(	O
+61	O
+%	O
+vs	O
+.	O
+85	O
+%;	O
+P	O
+=	O
+0	O
+.	O
+009	O
+)	O
+and	O
+the	O
+specificity	O
+did	O
+not	O
+statistically	O
+significantly	O
+differ	O
+(	O
+69	O
+%	O
+vs	O
+.	O
+78	O
+%;	O
+P	O
+>	O
+0	O
+.	O
+2	O
+).	O
+
+A	O
+crossover	O
+design	O
+was	O
+used	O
+,	O
+and	O
+all	O
+patients	O
+received	O
+both	O
+anesthetic	O
+methods	O
+sequentially	O
+in	O
+randomized	O
+order	B-SPEC
+.	O
+
+ABSTRACT	O
+:	O
+Occupational	B-DISO
+asthma	I-DISO
+(	O
+OA	O
+)	O
+is	O
+a	O
+frequent	O
+work	O
+-	O
+related	O
+disease	O
+in	O
+industrialised	O
+countries	O
+.	O
+
+A	O
+distinction	O
+must	O
+be	O
+made	O
+between	O
+OA	O
+with	O
+a	O
+latency	O
+period	O
+,	O
+the	O
+origin	O
+of	O
+which	O
+is	O
+essentially	O
+allergic	O
+,	O
+and	O
+OA	O
+without	O
+a	O
+latency	O
+period	O
+or	O
+Reactive	O
+airways	O
+dysfunction	O
+syndrome	O
+(	O
+RADS	O
+),	O
+induced	O
+by	O
+acute	O
+inhalation	B-PROC
+of	O
+irritant	O
+substances	O
+.	O
+
+Bronchial	B-ANAT
+challenge	O
+tests	O
+specifically	O
+identify	O
+the	O
+causal	O
+agent	O
+,	O
+but	O
+such	O
+examinations	O
+are	O
+long	O
+,	O
+expensive	O
+,	O
+potentially	O
+dangerous	O
+and	O
+therefore	O
+cannot	O
+be	O
+used	O
+in	O
+routine	O
+.	O
+
+Twenty	O
+-	O
+three	O
+patients	O
+underwent	O
+ictus	O
+therapy	O
+of	O
+corticosteroids	B-CHED
+for	O
+(	O
+8	O
++/-	O
+
+0	O
+.	O
+24	O
+)	O
+and	O
+4	O
+patients	O
+were	O
+IgG	B-PRGE
+negative	O
+.	O
+
+The	O
+influencing	O
+factors	O
+of	O
+femoral	B-ANAT
+necrosis	B-PROC
+included	O
+the	O
+degree	O
+of	O
+healing	B-PROC
+activity	O
+,	O
+the	O
+dosage	O
+summation	B-PROC
+of	O
+corticosteroids	B-CHED
+,	O
+and	O
+length	O
+of	O
+ictus	O
+therapy	O
+.	O
+
+The	O
+influencing	O
+factors	O
+of	O
+bone	B-ANAT
+density	O
+included	O
+age	O
+,	O
+dosage	O
+summation	B-PROC
+,	O
+and	O
+length	O
+of	O
+ictus	O
+therapy	O
+.	O
+
+Statistics	O
+showed	O
+that	O
+serum	B-COMP
+IgG	B-PRGE
+was	O
+not	O
+related	O
+with	O
+avascular	B-DISO
+necrosis	I-DISO
+of	I-DISO
+femoral	B-ANAT
+head	I-ANAT
+and	O
+osteoporosis	B-DISO
+.	O
+
+TITLE	O
+:	O
+[	O
+Effects	O
+of	O
+underlying	O
+cerebrocardiovascular	O
+diseases	O
+on	O
+the	O
+incidence	O
+of	O
+critical	O
+conditions	O
+and	O
+multiple	O
+organs	B-ANAT
+dysfunction	O
+syndrome	B-DISO
+in	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+cases	O
+].	O
+
+We	O
+found	O
+that	O
+the	O
+mice	B-SPEC
+exhibited	O
+specific	O
+IgM	B-PRGE
+on	O
+day	O
+4	O
+and	O
+IgG	B-PRGE
+on	O
+day	O
+8	O
+.	O
+
+Neutralization	O
+assay	O
+demonstrated	O
+that	O
+the	O
+antisera	O
+could	O
+protect	O
+Vero	O
+-	O
+E6	O
+cells	B-COMP
+from	O
+SARS	B-DISO
+-	O
+CoV	O
+'	O
+s	O
+infection	B-DISO
+.	O
+
+She	O
+gave	O
+a	O
+10	O
+-	O
+day	O
+history	O
+of	O
+severe	O
+diarrhea	B-DISO
+and	I-DISO
+vomiting	I-DISO
+.	O
+
+TITLE	O
+:	O
+[	O
+Current	O
+topics	O
+on	O
+SARS	B-DISO
+coronavirus	B-SPEC
+].	O
+
+Topics	O
+of	O
+the	O
+research	O
+on	O
+the	O
+present	O
+SARS	B-DISO
+-	O
+research	O
+field	O
+are	O
+development	B-PROC
+of	O
+vaccine	O
+,	O
+inspecting	O
+of	O
+medicine	B-CHED
+and	O
+establishment	O
+of	O
+diagnostic	O
+method	O
+.	O
+
+When	O
+S2	O
+Ab	O
+was	O
+used	O
+to	O
+perform	O
+immune	O
+precipitation	B-PROC
+with	O
+lysate	O
+of	O
+SARS	B-DISO
+-	O
+CoV	O
+infected	O
+cells	B-COMP
+,	O
+a	O
+cleaved	B-ANAT
+S2	O
+fragment	O
+was	O
+detected	O
+with	O
+S2	O
+-	O
+specific	O
+mAb	O
+by	O
+Western	O
+blot	O
+analysis	O
+.	O
+
+IBV	B-SPEC
+,	O
+causing	O
+a	O
+highly	O
+contagious	O
+respiratory	B-DISO
+disease	I-DISO
+in	O
+chickens	B-SPEC
+,	O
+resembles	O
+the	O
+recently	O
+described	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+virus	B-SPEC
+in	O
+pathogenesis	B-DISO
+and	O
+genome	O
+organization	O
+.	O
+
+TITLE	O
+:	O
+Detection	O
+of	O
+antibodies	B-COMP
+against	O
+SARS	B-DISO
+-	O
+CoV	O
+in	O
+serum	B-COMP
+from	O
+SARS	B-DISO
+-	O
+infected	O
+donors	O
+with	O
+ELISA	O
+and	O
+Western	O
+blot	O
+.	O
+
+CD8	B-PRGE
++	I-PRGE
+DimerX	I-PRGE
+-	I-PRGE
+S1203	I-PRGE
++	I-PRGE
+CTLs	I-PRGE
+were	O
+detected	O
+in	O
+the	O
+PBMC	O
+from	O
+these	O
+donors	O
+up	O
+to	O
+3	O
+months	O
+after	O
+recovery	O
+.	O
+
+Here	O
+we	O
+compare	O
+human	B-SPEC
+,	O
+mouse	B-SPEC
+,	O
+and	O
+rat	B-PRGE
+ACE2	I-PRGE
+molecules	I-PRGE
+for	O
+their	O
+ability	O
+to	O
+serve	O
+as	O
+receptors	O
+for	O
+SARS	B-PRGE
+-	I-PRGE
+CoV	I-PRGE
+.	O
+We	O
+found	O
+that	O
+,	O
+compared	O
+to	O
+human	B-PRGE
+ACE2	I-PRGE
+,	O
+murine	B-PRGE
+ACE2	I-PRGE
+less	O
+efficiently	O
+bound	O
+the	O
+S1	B-PRGE
+domain	I-PRGE
+of	O
+SARS	B-DISO
+-	O
+CoV	O
+and	O
+supported	O
+less	O
+-	O
+efficient	O
+S	O
+protein	B-CHED
+-	O
+mediated	O
+infection	B-DISO
+.	O
+
+ABSTRACT	O
+:	O
+Effective	O
+surveillance	O
+is	O
+necessary	O
+for	O
+the	O
+successful	O
+management	O
+of	O
+emerging	O
+infection	B-DISO
+.	O
+
+The	O
+results	O
+show	O
+that	O
+TB	O
+surveillance	O
+is	O
+more	O
+appropriate	O
+than	O
+influenza	B-DISO
+surveillance	O
+as	O
+a	O
+model	O
+because	O
+it	O
+is	O
+more	O
+complete	O
+in	O
+its	O
+reporting	O
+.	O
+
+TITLE	O
+:	O
+Six	O
+month	O
+radiological	O
+and	O
+physiological	O
+outcomes	O
+in	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+(	O
+SARS	B-DISO
+)	O
+survivors	O
+.	O
+
+TITLE	O
+:	O
+Recombinant	O
+viral	O
+sialate	B-CHED
+-	O
+O	O
+-	O
+acetylesterases	O
+.	O
+
+The	O
+recombinant	O
+esterases	B-FUNC
+were	O
+shown	O
+to	O
+specifically	O
+de	O
+-	O
+O	O
+-	O
+acetylate	O
+sialic	B-CHED
+acids	I-CHED
+on	O
+glycoconjugates	O
+.	O
+
+This	O
+study	O
+tests	O
+the	O
+hypothesis	O
+that	O
+standard	O
+ARDS	B-DISO
+criteria	O
+applied	O
+to	O
+the	O
+trauma	O
+population	O
+will	O
+capture	O
+widely	O
+disparate	O
+forms	O
+of	O
+acute	O
+lung	B-ANAT
+injury	O
+and	O
+are	O
+too	O
+nonspecific	O
+to	O
+identify	O
+a	O
+population	O
+at	O
+risk	O
+for	O
+prolonged	O
+respiratory	B-DISO
+failure	I-DISO
+and	O
+associated	O
+complications	O
+.	O
+
+TITLE	O
+:	O
+Effect	O
+of	O
+intranasal	O
+vaccination	O
+against	O
+bovine	B-SPEC
+enteric	B-SPEC
+coronavirus	I-SPEC
+on	O
+the	O
+occurrence	O
+of	O
+respiratory	B-ANAT
+tract	I-ANAT
+disease	I-DISO
+in	O
+a	O
+commercial	O
+backgrounding	O
+feedlot	O
+.	O
+
+Calves	O
+were	O
+randomly	O
+assigned	O
+to	O
+receive	O
+3	O
+.	O
+0	O
+mL	O
+of	O
+a	O
+modified	O
+-	O
+live	O
+virus	B-SPEC
+vaccine	O
+against	O
+bovine	B-SPEC
+enteric	B-SPEC
+coronavirus	I-SPEC
+and	O
+rotavirus	B-SPEC
+or	O
+3	O
+.	O
+0	O
+mL	O
+of	O
+saline	O
+(	O
+0	O
+.	O
+9	O
+%	O
+NaCl	B-CHED
+)	O
+solution	O
+.	O
+
+Intranasal	O
+BCV	O
+(	O
+125	O
+/	O
+407	O
+[	O
+31	O
+%])	O
+and	O
+serum	B-PRGE
+antibody	B-COMP
+titers	O
+>	O
+or	O
+=	O
+20	O
+against	O
+BCV	B-SPEC
+(	O
+246	O
+/	O
+396	O
+[	O
+62	O
+%])	O
+were	O
+identified	O
+in	O
+calves	O
+entering	O
+the	O
+feedlot	O
+.	O
+
+Vaccination	O
+was	O
+associated	O
+with	O
+significant	O
+decrease	O
+in	O
+risk	O
+of	O
+treatment	O
+for	O
+BRD	O
+;	O
+intranasal	O
+BCV	B-SPEC
+on	O
+entry	O
+to	O
+the	O
+feedlot	O
+was	O
+associated	O
+with	O
+increased	O
+risk	O
+of	O
+treatment	O
+.	O
+
+Univariate	O
+analysis	O
+revealed	O
+that	O
+control	O
+calves	O
+with	O
+intranasal	O
+BRD	O
+on	O
+entry	O
+to	O
+the	O
+feedlot	O
+and	O
+those	O
+with	O
+antibody	B-COMP
+titer	O
+<	O
+20	O
+were	O
+significantly	O
+more	O
+likely	O
+to	O
+be	O
+treated	O
+for	O
+BRD	O
+.	O
+
+These	O
+data	O
+provide	O
+further	O
+evidence	O
+of	O
+an	O
+association	O
+between	O
+BCV	B-SPEC
+and	O
+respiratory	B-DISO
+tract	I-DISO
+disease	I-DISO
+in	O
+feedlot	O
+calves	O
+.	O
+
+This	O
+paper	O
+describes	O
+the	O
+epidemiological	O
+features	O
+of	O
+cases	O
+reported	O
+by	O
+Australian	O
+states	O
+and	O
+territories	O
+to	O
+the	O
+Australian	O
+Government	O
+Department	O
+of	O
+Health	O
+and	O
+Ageing	B-PROC
+between	O
+17	O
+March	O
+and	O
+31	O
+July	O
+2003	O
+.	O
+
+ABSTRACT	O
+:	O
+Two	O
+replicate	O
+lines	O
+of	O
+mice	O
+,	O
+selected	O
+for	O
+hyperactivity	O
+and	O
+hypoactivity	B-DISO
+after	O
+ethanol	B-CHED
+administration	O
+,	O
+had	O
+been	O
+enzootically	O
+infected	O
+with	O
+mouse	B-DISO
+hepatitis	I-DISO
+virus	B-SPEC
+(	O
+MHV	B-SPEC
+)	O
+for	O
+over	O
+a	O
+decade	O
+.	O
+
+Subsequent	O
+investigation	O
+demonstrated	O
+persistent	O
+shedding	O
+of	O
+MHV	B-SPEC
+in	O
+two	O
+lines	O
+of	O
+mice	B-SPEC
+for	O
+at	O
+least	O
+7	O
+weeks	O
+.	O
+
+To	O
+the	O
+author	O
+'	O
+s	O
+knowledge	O
+,	O
+this	O
+is	O
+the	O
+first	O
+documented	O
+case	O
+of	O
+clinically	O
+inapparent	O
+persistent	O
+shedding	O
+of	O
+MHV	B-SPEC
+in	O
+mice	B-SPEC
+that	O
+are	O
+not	O
+genetically	O
+engineered	O
+.	O
+
+TITLE	O
+:	O
+[	O
+Bacterial	O
+and	O
+viral	O
+epidemics	O
+of	O
+zoonotic	O
+origin	O
+;	O
+the	O
+role	O
+of	O
+hunting	O
+and	O
+cutting	O
+up	O
+wild	O
+animals	B-SPEC
+].	O
+
+Although	O
+a	O
+multiplex	O
+RT	O
+-	O
+PCR	O
+could	O
+detect	O
+and	O
+differentiate	O
+NDV	B-SPEC
+and	O
+IBV	B-SPEC
+genomes	O
+present	O
+in	O
+the	O
+same	O
+sample	O
+,	O
+there	O
+was	O
+a	O
+slight	O
+inhibition	B-PROC
+of	O
+the	O
+IBV	B-SPEC
+PCR	O
+if	O
+a	O
+high	O
+amount	O
+of	O
+NDV	B-SPEC
+genome	O
+was	O
+present	O
+in	O
+the	O
+sample	O
+.	O
+
+The	O
+results	O
+strongly	O
+suggested	O
+that	O
+the	O
+infection	B-DISO
+did	O
+not	O
+depend	O
+on	O
+the	O
+total	O
+number	O
+of	O
+symptomatic	O
+cases	O
+,	O
+with	O
+only	O
+a	O
+very	O
+small	O
+proportion	O
+of	O
+symptomatic	O
+individuals	O
+being	O
+shown	O
+to	O
+be	O
+infectious	O
+(	O
+i	O
+.	O
+e	O
+.,	O
+able	O
+to	O
+infect	O
+other	O
+individuals	O
+).	O
+
+It	O
+is	O
+used	O
+to	O
+treat	O
+influenza	B-DISO
+,	O
+epidemic	O
+cerebrospinal	B-DISO
+meningitis	I-DISO
+,	O
+encephalitis	B-DISO
+B	O
+,	O
+viral	B-DISO
+pneumonia	I-DISO
+,	O
+mumps	B-DISO
+,	O
+and	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+(	O
+SARS	B-DISO
+).	O
+
+The	O
+algorithm	O
+was	O
+tested	O
+on	O
+42	O
+patients	O
+with	O
+affections	O
+of	O
+the	O
+central	B-ANAT
+nervous	I-ANAT
+system	I-ANAT
+(	O
+CNS	B-CHED
+)	O
+due	O
+to	O
+severe	O
+craniocerebral	O
+trauma	O
+,	O
+spinal	O
+trauma	O
+,	O
+cerebral	B-DISO
+stroke	I-DISO
+and	O
+multitrauma	O
+.	O
+
+The	O
+three	O
+most	O
+important	O
+viral	O
+agents	O
+are	O
+noroviruses	B-SPEC
+(	O
+NV	O
+)	O
+(	O
+formerly	O
+known	O
+as	O
+Norwalk	B-SPEC
+-	I-SPEC
+like	I-SPEC
+viruses	I-SPEC
+),	O
+Rotavirus	B-SPEC
+(	O
+RV	O
+)	O
+and	O
+Hepatitis	B-DISO
+A	I-DISO
+-	O
+Virus	B-SPEC
+(	O
+HAV	B-DISO
+).	O
+
+The	O
+sudden	O
+outbreak	O
+of	O
+severe	O
+acute	O
+respiratory	O
+syndrome	O
+(	O
+SARS	B-DISO
+),	O
+or	O
+a	O
+similar	O
+contagious	O
+pathogen	O
+,	O
+will	O
+restrict	O
+the	O
+number	O
+of	O
+people	O
+entering	O
+the	O
+hospital	O
+.	O
+
+Business	O
+representatives	O
+from	O
+various	O
+therapeutic	O
+antibody	B-COMP
+companies	O
+discussed	O
+in	O
+detail	O
+various	O
+aspects	O
+and	O
+challenges	O
+of	O
+building	O
+a	O
+viable	O
+therapeutic	O
+antibody	B-COMP
+company	O
+.	O
+
+The	O
+development	B-PROC
+of	O
+PCR	O
+assays	O
+for	O
+the	O
+detection	O
+of	O
+CPIV	O
+,	O
+canine	B-SPEC
+adenovirus	I-SPEC
+types	O
+1	O
+and	O
+2	O
+,	O
+and	O
+canine	B-SPEC
+herpesvirus	I-SPEC
+(	O
+CHV	O
+)	O
+is	O
+described	O
+.	O
+
+TITLE	O
+:	O
+Temporal	O
+relationship	O
+of	O
+viral	O
+load	O
+,	O
+ribavirin	B-CHED
+,	O
+interleukin	B-PRGE
+(	O
+IL	O
+)-	O
+6	O
+,	O
+IL	B-FUNC
+-	I-FUNC
+8	I-FUNC
+,	O
+and	O
+clinical	O
+progression	O
+in	O
+patients	O
+with	O
+severe	O
+acute	O
+respiratory	O
+syndrome	O
+.	O
+
+We	O
+report	O
+that	O
+ribavirin	B-CHED
+was	O
+not	O
+effective	O
+in	O
+reducing	O
+the	O
+SARS	B-DISO
+coronavirus	B-SPEC
+load	O
+in	O
+3	O
+of	O
+8	O
+probable	O
+cases	O
+studied	O
+and	O
+that	O
+elevated	O
+levels	O
+of	O
+interleukin	B-PRGE
+(	O
+IL	O
+)-	O
+6	O
+and	O
+IL	B-FUNC
+-	I-FUNC
+8	I-FUNC
+subsequent	O
+to	O
+the	O
+peak	O
+viral	O
+load	O
+were	O
+found	O
+in	O
+8	O
+and	O
+6	O
+cases	O
+,	O
+respectively	O
+.	O
+
+The	O
+nadir	O
+lymphocyte	B-ANAT
+count	O
+during	O
+lymphopenia	B-DISO
+,	O
+the	O
+peak	O
+level	O
+of	O
+lactate	B-PRGE
+dehydrogenase	I-PRGE
+,	O
+and	O
+the	O
+peak	O
+density	O
+of	O
+pulmonary	B-DISO
+infiltrates	I-DISO
+lag	O
+further	O
+behind	O
+the	O
+peak	O
+viral	O
+load	O
+by	O
+a	O
+median	O
+of	O
+4	O
+,	O
+5	O
+,	O
+and	O
+3	O
+.	O
+5	O
+days	O
+,	O
+respectively	O
+.	O
+
+In	O
+univariate	O
+analysis	O
+,	O
+contact	O
+with	O
+respiratory	O
+secretions	B-ANAT
+elevated	O
+the	O
+odds	O
+ratio	O
+to	O
+6	O
+.	O
+9	O
+(	O
+95	O
+%	O
+CI	O
+1	O
+.	O
+4	O
+-	O
+34	O
+.	O
+6	O
+,	O
+P	O
+=	O
+0	O
+.	O
+02	O
+).	O
+
+TITLE	O
+:	O
+Applying	O
+theory	O
+of	O
+planned	O
+behavior	O
+to	O
+predict	O
+nurses	O
+'	O
+intention	O
+and	O
+volunteering	O
+to	O
+care	O
+for	O
+SARS	B-DISO
+patients	O
+in	O
+southern	O
+Taiwan	O
+.	O
+
+ABSTRACT	O
+:	O
+Severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+(	O
+SARS	B-DISO
+)	O
+spread	O
+worldwide	O
+after	O
+an	O
+outbreak	O
+in	O
+Guangdong	O
+Province	O
+,	O
+China	O
+,	O
+in	O
+mid	O
+-	O
+November	O
+2002	O
+.	O
+
+TITLE	O
+:	O
+Efficient	O
+assembly	O
+and	O
+release	B-PATH
+of	O
+SARS	B-DISO
+coronavirus	B-SPEC
+-	O
+like	O
+particles	O
+by	O
+a	O
+heterologous	O
+expression	B-PROC
+system	O
+.	O
+
+ABSTRACT	O
+:	O
+In	O
+the	O
+Spring	O
+of	O
+2003	O
+,	O
+there	O
+was	O
+a	O
+huge	O
+interest	O
+in	O
+the	O
+global	O
+news	O
+media	O
+following	O
+the	O
+emergence	O
+of	O
+a	O
+new	O
+infectious	B-DISO
+disease	I-DISO
+:	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+(	O
+SARS	B-DISO
+).	O
+
+All	O
+mutants	O
+showed	O
+undetectable	O
+activity	O
+in	O
+trans	O
+-	O
+cleavage	B-PROC
+assay	O
+.	O
+
+In	O
+addition	O
+,	O
+we	O
+introduced	O
+a	O
+31	O
+-	O
+mer	O
+peptide	B-CHED
+containing	O
+an	O
+auto	O
+-	O
+cleavage	B-PROC
+site	O
+to	O
+the	O
+N	O
+-	O
+terminal	O
+of	O
+the	O
+proteases	O
+and	O
+found	O
+the	O
+peptide	B-CHED
+could	O
+be	O
+cleaved	B-ANAT
+efficiently	O
+by	O
+3CLsc	O
+itself	O
+,	O
+but	O
+,	O
+among	O
+the	O
+four	O
+mutants	O
+,	O
+only	O
+the	O
+mutant	B-DISO
+Cys145	O
+-->	O
+Ser	B-COMP
+showed	O
+residual	O
+activity	O
+as	O
+detected	O
+by	O
+the	O
+auto	O
+-	O
+cleavage	B-PROC
+assay	O
+.	O
+
+Two	O
+peptides	B-CHED
+denoted	O
+HR	O
+-	O
+N	O
+(	O
+SN50	O
+)	O
+and	O
+HR	O
+-	O
+C	O
+(	O
+SC40	O
+),	O
+corresponding	O
+to	O
+the	O
+Leu	B-CHED
+/	O
+Ile	B-CHED
+/	O
+Val	B-CHED
+-	O
+rich	O
+heptad	O
+-	O
+repeat	O
+regions	O
+from	O
+the	O
+N	O
+-	O
+terminal	O
+and	O
+C	O
+-	O
+terminal	O
+segments	O
+of	O
+the	O
+SARS	B-PRGE
+-	I-PRGE
+CoV	I-PRGE
+spike	I-PRGE
+S2	I-PRGE
+sequence	I-PRGE
+,	O
+respectively	O
+,	O
+were	O
+synthesized	O
+and	O
+predicted	O
+to	O
+form	O
+trimeric	O
+assembly	O
+of	O
+hairpin	O
+-	O
+like	O
+structures	O
+.	O
+
+We	O
+report	O
+here	O
+the	O
+first	O
+crystallographic	O
+study	O
+of	O
+the	O
+SARS	B-DISO
+spike	O
+HR	O
+-	O
+N	O
+/	O
+HR	O
+-	O
+C	O
+complex	O
+.	O
+
+Rabbit	B-SPEC
+antisera	O
+effectively	O
+blocked	O
+binding	B-FUNC
+of	O
+S1	O
+,	O
+which	O
+contains	O
+RBD	O
+,	O
+to	O
+ACE2	B-PRGE
+.	O
+
+It	O
+appears	O
+that	O
+the	O
+combination	O
+of	O
+an	O
+effective	O
+antiviral	B-CHED
+and	O
+steroid	B-CHED
+was	O
+associated	O
+with	O
+a	O
+better	O
+outcome	O
+.	O
+
+ABSTRACT	O
+:	O
+Upper	B-DISO
+respiratory	I-DISO
+tract	I-DISO
+infections	I-DISO
+(	O
+ie	O
+,	O
+""""	O
+the	O
+common	B-DISO
+cold	I-DISO
+""")"	O
+have	O
+several	O
+hundred	O
+causes	O
+,	O
+the	O
+most	O
+common	O
+of	O
+which	O
+include	O
+rhino	O
+-	O
+virus	B-SPEC
+,	O
+coronavirus	B-SPEC
+,	O
+and	O
+respiratory	B-SPEC
+syncytial	I-SPEC
+virus	I-SPEC
+.	O
+
+Here	O
+we	O
+introduce	O
+a	O
+probabilistic	O
+model	O
+that	O
+describes	O
+the	O
+worldwide	O
+spread	O
+of	O
+infectious	B-DISO
+diseases	I-DISO
+and	O
+demonstrate	O
+that	O
+a	O
+forecast	O
+of	O
+the	O
+geographical	O
+spread	O
+of	O
+epidemics	O
+is	O
+indeed	O
+possible	O
+.	O
+
+Replicase	B-PRGE
+protein	I-PRGE
+precursors	I-PRGE
+and	O
+mature	O
+products	O
+are	O
+thought	O
+to	O
+mediate	O
+the	O
+formation	B-PROC
+and	O
+function	O
+of	O
+viral	B-PROC
+replication	I-PROC
+complexes	O
+on	O
+the	O
+surfaces	O
+of	O
+intracellular	B-COMP
+double	O
+-	O
+membrane	B-COMP
+vesicles	B-COMP
+.	O
+
+Severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+has	O
+likely	O
+stressed	O
+the	O
+public	O
+health	O
+care	O
+system	O
+.	O
+
+Second	O
+,	O
+we	O
+employed	O
+7	O
+recombination	B-PROC
+detection	O
+techniques	O
+well	O
+documented	O
+in	O
+successfully	O
+detecting	O
+recombination	B-PROC
+events	O
+to	O
+explore	O
+the	O
+presence	O
+of	O
+recombination	B-PROC
+in	O
+SARS	B-DISO
+-	O
+CoV	O
+genome	O
+.	O
+
+ABSTRACT	O
+:	O
+As	O
+the	O
+result	O
+of	O
+prolonged	O
+(	O
+17	O
+years	O
+)	O
+observations	O
+of	O
+patients	O
+with	O
+acute	O
+respiratory	O
+infections	O
+hospitalized	O
+in	O
+basic	O
+departments	O
+of	O
+clinics	O
+of	O
+the	O
+Research	O
+Institute	O
+of	O
+Influenza	B-DISO
+,	O
+coronavirus	B-DISO
+infection	I-DISO
+was	O
+found	O
+to	O
+be	O
+the	O
+cause	O
+of	O
+respiratory	B-DISO
+diseases	I-DISO
+,	O
+on	O
+the	O
+average	O
+,	O
+in	O
+12	O
+%	O
+of	O
+cases	O
+(	O
+in	O
+some	O
+years	O
+in	O
+6	O
+.	O
+8	O
+%	O
+to	O
+28	O
+.	O
+6	O
+%	O
+of	O
+cases	O
+).	O
+
+Three	O
+year	O
+cycles	O
+of	O
+this	O
+infection	B-DISO
+were	O
+established	O
+.	O
+
+Information	O
+from	O
+the	O
+human	B-SPEC
+genome	O
+project	O
+applied	O
+to	O
+microbial	O
+organisms	O
+and	O
+their	O
+hosts	B-COMP
+will	O
+provide	O
+new	O
+opportunities	O
+for	O
+detection	O
+,	O
+diagnosis	O
+,	O
+treatment	O
+,	O
+prevention	O
+,	O
+control	O
+and	O
+prognosis	O
+.	O
+
+Three	O
+venous	B-ANAT
+thromboembolic	O
+complications	O
+occurred	O
+in	O
+the	O
+ICU	O
+(	O
+1	O
+.	O
+7	O
+%)	O
+and	O
+one	O
+during	O
+follow	O
+-	O
+up	O
+.	O
+
+Pathogens	O
+for	O
+which	O
+there	O
+is	O
+more	O
+-	O
+compelling	O
+evidence	O
+of	O
+survival	O
+in	O
+environmental	O
+reservoirs	O
+include	O
+Clostridium	B-SPEC
+difficile	I-SPEC
+,	O
+vancomycin	B-CHED
+-	O
+resistant	O
+enterococci	O
+,	O
+and	O
+methicillin	B-DISO
+-	I-DISO
+resistant	I-DISO
+Staphylococcus	B-SPEC
+aureus	I-SPEC
+,	O
+and	O
+pathogens	O
+for	O
+which	O
+there	O
+is	O
+evidence	O
+of	O
+probable	O
+survival	O
+in	O
+environmental	O
+reservoirs	O
+include	O
+norovirus	B-SPEC
+,	O
+influenza	B-SPEC
+virus	I-SPEC
+,	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+-	O
+associated	O
+coronavirus	B-SPEC
+,	O
+and	O
+Candida	B-SPEC
+species	B-SPEC
+.	O
+
+ABSTRACT	O
+:	O
+Real	O
+-	O
+time	O
+RT	O
+-	O
+PCR	O
+assay	O
+,	O
+based	O
+on	O
+light	O
+upon	O
+extension	O
+(	O
+LUX	O
+)	O
+fluorogenic	O
+primer	O
+and	O
+LightCycle	O
+technology	O
+,	O
+was	O
+developed	O
+for	O
+rapid	O
+detection	O
+of	O
+transmissible	O
+gastroenteritis	B-DISO
+virus	B-SPEC
+(	O
+TGEV	B-SPEC
+).	O
+
+When	O
+the	O
+host	B-COMP
+produces	O
+antibodies	B-COMP
+against	O
+these	O
+viral	O
+antigens	B-CHED
+,	O
+the	O
+antibodies	B-COMP
+also	O
+bind	B-FUNC
+to	O
+the	O
+host	B-COMP
+'	O
+s	O
+own	O
+ACTH	B-PRGE
+,	O
+which	O
+limits	O
+the	O
+host	B-COMP
+'	O
+s	O
+stress	B-PATH
+response	I-PATH
+by	O
+interfering	O
+with	O
+ACTH	B-PRGE
+'	O
+s	O
+ability	O
+to	O
+stimulate	O
+the	O
+secretion	B-PROC
+of	O
+corticosteroids	B-CHED
+.	O
+
+For	O
+instance	O
+,	O
+one	O
+evident	O
+trend	O
+is	O
+high	O
+sequence	O
+conservation	O
+in	O
+the	O
+V	O
+(	O
+H	O
+)	O
+chains	O
+of	O
+the	O
+neutralizing	O
+mAbs	O
+,	O
+particularly	O
+in	O
+CDR	B-PRGE
+-	I-PRGE
+1	I-PRGE
+and	O
+CDR	B-PRGE
+-	I-PRGE
+2	I-PRGE
+.	O
+
+We	O
+sought	O
+to	O
+identify	O
+novel	O
+inhibitors	B-CHED
+of	O
+3CLpro	O
+to	O
+advance	O
+the	O
+development	B-PROC
+of	O
+appropriate	O
+therapies	O
+in	O
+the	O
+treatment	O
+of	O
+SARS	B-DISO
+.	O
+
+A	O
+quenched	O
+fluorescence	O
+resonance	O
+energy	B-PROC
+transfer	I-PROC
+assay	O
+was	O
+developed	O
+for	O
+3CLpro	O
+to	O
+screen	O
+the	O
+proteinase	B-PROC
+against	O
+50	O
+,	O
+000	O
+drug	O
+-	O
+like	O
+small	O
+molecules	O
+on	O
+a	O
+fully	O
+automated	O
+system	O
+.	O
+
+ABSTRACT	O
+:	O
+To	O
+analysis	O
+the	O
+relationship	O
+between	O
+glucocorticosteroids	O
+(	O
+GCS	O
+)	O
+usage	O
+and	O
+side	O
+effects	O
+in	O
+the	O
+treatment	O
+of	O
+severe	O
+acute	O
+respiratory	O
+syndrome	O
+(	O
+SARS	B-DISO
+).	O
+
+Hyperglycemia	B-DISO
+and	O
+hypokalemia	O
+are	O
+correlated	O
+with	O
+GCS	O
+dosage	O
+and	O
+duration	O
+.	O
+
+Autopsy	O
+was	O
+performed	O
+in	O
+9	O
+of	O
+the	O
+suspected	O
+SARS	B-DISO
+patients	O
+who	O
+died	B-PROC
+during	O
+the	O
+outbreak	O
+,	O
+but	O
+SARS	B-DISO
+was	O
+the	O
+cause	O
+of	O
+death	B-PROC
+in	O
+only	O
+1	O
+of	O
+these	O
+patients	O
+.	O
+
+Shunt	O
+should	O
+more	O
+often	O
+be	O
+measured	O
+directly	O
+or	O
+be	O
+estimated	O
+assuming	O
+a	O
+constant	O
+arteriovenous	O
+oxygen	B-PROC
+content	I-PROC
+difference	O
+.	O
+
+Thus	O
+,	O
+the	O
+molecular	O
+docking	B-PROC
+approach	O
+resulting	O
+in	O
+the	O
+inhibitory	O
+capacity	O
+of	O
+N	O
+-(	O
+2	B-CHED
+-	I-CHED
+aminoethyl	I-CHED
+)-	O
+1	O
+aziridine	B-CHED
+-	O
+ethanamine	B-CHED
+provides	O
+an	O
+attractive	O
+small	O
+molecule	O
+lead	O
+compound	O
+on	O
+which	O
+the	O
+development	B-PROC
+of	O
+more	O
+effective	O
+therapeutic	O
+agents	O
+could	O
+be	O
+developed	O
+to	O
+modulate	O
+hypertension	B-DISO
+and	O
+for	O
+controlling	O
+SARS	B-DISO
+infections	B-DISO
+.	O
+
+The	O
+RT	O
+-	O
+PCR	O
+of	O
+coronavirus	B-SPEC
+was	O
+positive	O
+in	O
+three	O
+(	O
+18	O
+.	O
+8	O
+%)	O
+of	O
+16	O
+throat	B-ANAT
+swabs	O
+and	O
+in	O
+none	O
+(	O
+0	O
+%)	O
+of	O
+seven	O
+rectal	O
+swabs	O
+.	O
+
+Serum	B-PRGE
+anti	I-PRGE
+-	I-PRGE
+coronavirus	B-SPEC
+IgG	I-PRGE
+was	O
+positive	O
+in	O
+13	O
+of	O
+the	O
+15	O
+patients	O
+(	O
+86	O
+.	O
+7	O
+%).	O
+
+In	O
+contrast	O
+to	O
+the	O
+high	O
+positive	O
+rate	O
+of	O
+feces	B-ANAT
+RT	O
+-	O
+PCR	O
+(	O
+97	O
+%)	O
+in	O
+Amoy	O
+Gardens	O
+,	O
+our	O
+positive	O
+rate	O
+in	O
+rectal	B-ANAT
+swab	I-ANAT
+RT	O
+-	O
+PCT	B-DISO
+(	O
+0	O
+%)	O
+was	O
+significantly	O
+lower	O
+(	O
+P	O
+=	O
+0	O
+.	O
+00000002	O
+).	O
+
+The	O
+dental	O
+community	O
+should	O
+reflect	O
+on	O
+this	O
+outbreak	O
+to	O
+reinforce	O
+the	O
+currently	O
+applied	O
+infection	B-DISO
+control	O
+measures	O
+.	O
+
+The	O
+median	O
+time	O
+for	O
+SARS	B-DISO
+-	O
+CoV	O
+to	O
+become	O
+undetectable	O
+in	O
+plasma	B-ANAT
+was	O
+12	O
+days	O
+(	O
+11	O
+-	O
+20	O
+days	O
+)	O
+versus	O
+8	O
+days	O
+(	O
+8	O
+-	O
+15	O
+days	O
+),	O
+respectively	O
+.	O
+
+CONCLUSIONS	O
+:	O
+Our	O
+findings	O
+suggested	O
+""""	O
+early	O
+""""	O
+corticosteroid	B-CHED
+treatment	O
+was	O
+associated	O
+with	O
+a	O
+higher	O
+subsequent	O
+plasma	B-ANAT
+viral	O
+load	O
+.	O
+
+There	O
+is	O
+no	O
+evidence	O
+from	O
+randomized	O
+controlled	O
+trials	O
+to	O
+support	O
+or	O
+refute	O
+the	O
+use	O
+of	O
+partial	O
+liquid	O
+ventilation	O
+in	O
+adults	O
+with	O
+ALI	O
+or	O
+ARDS	B-DISO
+;	O
+adequately	O
+powered	O
+,	O
+high	O
+quality	O
+randomized	O
+controlled	O
+trials	O
+are	O
+still	O
+needed	O
+to	O
+assess	O
+its	O
+efficacy	O
+.	O
+
+Consequently	O
+,	O
+we	O
+tested	O
+for	O
+the	O
+reactivity	O
+of	O
+these	O
+42	O
+peptides	B-CHED
+to	O
+patients	O
+'	O
+sera	B-COMP
+(	O
+n	O
+=	O
+45	O
+)	O
+at	O
+6	O
+-	O
+month	O
+post	O
+-	O
+infection	B-DISO
+.	O
+
+These	O
+three	O
+peptides	B-CHED
+,	O
+recognized	O
+by	O
+their	O
+long	O
+-	O
+lasting	O
+immunity	B-PROC
+,	O
+may	O
+provide	O
+a	O
+better	O
+understanding	O
+of	O
+the	O
+immunogenicity	O
+of	O
+SARS	B-DISO
+-	I-PRGE
+CoV	I-PRGE
+.	O
+
+One	O
+mechanism	O
+involves	O
+the	O
+presence	O
+of	O
+antibodies	B-COMP
+to	O
+white	B-ANAT
+blood	I-ANAT
+cells	I-ANAT
+,	O
+usually	O
+in	O
+a	O
+transfused	O
+blood	B-ANAT
+component	I-ANAT
+.	O
+
+ABSTRACT	O
+:	O
+Angiotensin	B-CHED
+-	I-PRGE
+converting	I-PRGE
+enzyme	I-PRGE
+2	I-PRGE
+(	O
+ACE2	B-PRGE
+)	O
+is	O
+a	O
+receptor	O
+for	O
+SARS	B-PRGE
+-	I-PRGE
+CoV	I-PRGE
+,	O
+the	O
+novel	B-SPEC
+coronavirus	I-SPEC
+that	O
+causes	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+[	O
+Li	B-SPEC
+,	O
+W	O
+.	O
+Moore	O
+,	O
+M	O
+.	O
+J	O
+.,	O
+Vasilieva	O
+,	O
+N	O
+.,	O
+Sui	O
+,	O
+J	O
+.,	O
+Wong	O
+,	O
+S	O
+.	O
+K	O
+.,	O
+Berne	O
+,	O
+M	O
+.	O
+A	O
+.,	O
+Somasundaran	O
+,	O
+M	O
+.,	O
+Sullivan	O
+,	O
+J	O
+.	O
+L	O
+.,	O
+Luzuriaga	B-SPEC
+,	O
+K	O
+.,	O
+Greenough	O
+,	O
+T	O
+.	O
+C	O
+.,	O
+et	O
+al	O
+.	O
+(	O
+2003	O
+)	O
+Nature	O
+426	O
+,	O
+450	O
+-	O
+454	O
+].	O
+
+The	O
+impact	O
+of	O
+SARS	B-DISO
+on	O
+quality	O
+of	O
+medical	O
+care	O
+can	O
+be	O
+minimised	O
+when	O
+adequate	O
+infection	B-DISO
+control	O
+measures	O
+are	O
+applied	O
+.	O
+
+Though	O
+the	O
+DHSS	O
+hopes	O
+that	O
+these	O
+surveillance	O
+efforts	O
+will	O
+contribute	O
+to	O
+the	O
+early	O
+detection	O
+of	O
+sentinel	O
+events	O
+that	O
+might	O
+represent	O
+possible	O
+bioterrorist	O
+or	O
+emerging	B-DISO
+infectious	I-DISO
+disease	I-DISO
+threats	O
+,	O
+the	O
+DHSS	O
+will	O
+also	O
+need	O
+to	O
+engage	O
+the	O
+medical	O
+community	O
+more	O
+fully	O
+in	O
+surveillance	O
+activities	O
+.	O
+
+Therefore	O
+,	O
+to	O
+further	O
+ensure	O
+the	O
+success	O
+of	O
+its	O
+surveillance	O
+efforts	O
+,	O
+the	O
+DHSS	O
+will	O
+also	O
+need	O
+to	O
+continue	O
+educating	O
+clinicians	O
+about	O
+its	O
+surveillance	O
+activities	O
+and	O
+the	O
+importance	O
+of	O
+timely	O
+reporting	O
+of	O
+patients	O
+with	O
+illness	O
+patterns	O
+that	O
+might	O
+suggest	O
+an	O
+unusual	O
+infectious	B-DISO
+disease	I-DISO
+outbreak	O
+associated	O
+with	O
+bioterrorism	O
+or	O
+emerging	B-DISO
+infectious	I-DISO
+diseases	I-DISO
+.	O
+
+ABSTRACT	O
+:	O
+A	O
+retrospective	O
+viral	O
+load	O
+study	O
+was	O
+performed	O
+on	O
+clinical	O
+specimens	O
+from	O
+154	O
+patients	O
+with	O
+laboratory	O
+-	O
+confirmed	O
+severe	O
+acute	O
+respiratory	O
+syndrome	O
+(	O
+SARS	B-DISO
+);	O
+the	O
+specimens	O
+were	O
+prospectively	O
+collected	O
+during	O
+patients	O
+'	O
+illness	O
+.	O
+
+Serum	B-COMP
+viral	O
+load	O
+(	O
+n	O
+=	O
+53	O
+)	O
+was	O
+associated	O
+with	O
+oxygen	B-CHED
+desaturation	O
+,	O
+mechanical	O
+ventilation	O
+,	O
+and	O
+death	B-PROC
+.	O
+
+Stool	B-ANAT
+viral	O
+load	O
+(	O
+n	O
+=	O
+94	O
+)	O
+was	O
+associated	O
+with	O
+diarrhea	B-DISO
+,	O
+and	O
+urine	B-ANAT
+viral	O
+load	O
+(	O
+n	O
+=	O
+111	O
+)	O
+was	O
+associated	O
+with	O
+abnormal	O
+urinalysis	O
+results	O
+.	O
+
+SARS	B-DISO
+rarely	O
+manifests	O
+as	O
+a	O
+subclinical	B-DISO
+infection	I-DISO
+,	O
+and	O
+at	O
+present	O
+,	O
+wild	O
+animal	B-SPEC
+species	B-SPEC
+are	O
+the	O
+only	O
+important	O
+natural	O
+reservoirs	O
+of	O
+the	O
+virus	B-SPEC
+.	O
+
+At	O
+6	O
+weeks	O
+of	O
+SARS	B-DISO
+onset	O
+,	O
+25	O
+%	O
+(	O
+30	O
+/	O
+120	O
+)	O
+patients	O
+had	O
+respiratory	B-DISO
+failure	I-DISO
+with	O
+ALI	O
+/	O
+ARDS	B-DISO
+.	O
+
+No	O
+SARS	B-DISO
+occurred	O
+in	O
+medical	O
+staff	O
+taking	O
+care	O
+of	O
+NPPV	O
+patients	O
+.	O
+
+We	O
+have	O
+cloned	O
+and	O
+overexpressed	O
+the	O
+SARS	B-PRGE
+-	I-PRGE
+CoV	I-PRGE
+Mpro	I-PRGE
+in	I-PRGE
+Escherichia	B-SPEC
+coli	I-SPEC
+,	O
+and	O
+purified	O
+the	O
+recombinant	O
+Mpro	O
+to	O
+homogeneity	O
+.	O
+
+A	O
+decentralized	O
+and	O
+fragmented	O
+health	O
+system	O
+,	O
+such	O
+as	O
+the	O
+one	O
+found	O
+in	O
+China	O
+,	O
+is	O
+not	O
+well	O
+-	O
+suited	O
+to	O
+making	O
+a	O
+rapid	O
+and	O
+coordinated	O
+response	O
+to	O
+public	O
+health	O
+emergencies	B-DISO
+.	O
+
+For	O
+the	O
+past	O
+25	O
+years	O
+,	O
+the	O
+Chinese	O
+Government	O
+has	O
+kept	O
+economic	O
+development	B-PROC
+at	O
+the	O
+top	O
+of	O
+the	O
+policy	O
+agenda	O
+at	O
+the	O
+expense	O
+of	O
+public	O
+health	O
+,	O
+especially	O
+in	O
+terms	O
+of	O
+access	O
+to	O
+health	O
+care	O
+for	O
+the	O
+800	O
+million	O
+people	O
+living	O
+in	O
+rural	O
+areas	O
+.	O
+
+ABSTRACT	O
+:	O
+The	O
+cleavage	O
+mechanism	O
+of	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+(	O
+SARS	B-DISO
+)	O
+coronavirus	B-SPEC
+main	O
+proteinase	B-PROC
+(	O
+M	B-PRGE
+(	I-PRGE
+pro	I-PRGE
+)	I-PRGE
+or	I-PRGE
+3CL	I-PRGE
+(	O
+pro	B-PRGE
+))	O
+for	O
+the	O
+octapeptide	O
+AVLQSGFR	O
+is	O
+studied	O
+using	O
+molecular	O
+mechanics	O
+(	O
+MM	O
+)	O
+and	O
+quantum	O
+mechanics	O
+(	O
+QM	O
+).	O
+
+The	O
+scissile	O
+peptide	B-CHED
+bond	O
+between	O
+Gln	B-CHED
+and	O
+Ser	B-COMP
+is	O
+found	O
+to	O
+be	O
+solidified	O
+through	O
+""""	O
+hybrid	O
+peptide	B-CHED
+bond	O
+""""	O
+by	O
+changing	O
+the	O
+carbonyl	B-CHED
+group	I-CHED
+CO	O
+of	O
+Gln	B-CHED
+to	O
+CH	O
+(	O
+2	O
+)	O
+or	O
+CF	O
+(	O
+2	O
+).	O
+
+The	O
+derivative	O
+crystals	B-ANAT
+were	O
+obtained	O
+under	O
+similar	O
+conditions	O
+and	O
+three	O
+different	O
+wavelength	O
+data	O
+sets	O
+were	O
+collected	O
+to	O
+2	O
+.	O
+4	O
+A	O
+resolution	O
+from	O
+a	O
+single	O
+derivative	O
+crystal	B-ANAT
+at	O
+BSRF	O
+(	O
+Beijing	O
+Synchrotron	O
+Radiation	O
+Facility	O
+).	O
+
+TITLE	O
+:	O
+Large	B-ANAT
+artery	I-ANAT
+ischaemic	B-DISO
+stroke	I-DISO
+in	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+(	O
+SARS	B-DISO
+).	O
+
+Conjunctival	O
+,	O
+throat	B-ANAT
+,	O
+stool	B-ANAT
+,	O
+and	O
+urine	B-ANAT
+specimens	O
+were	O
+collected	O
+weekly	O
+from	O
+64	O
+patients	O
+and	O
+tested	O
+for	O
+SARS	B-PRGE
+-	I-PRGE
+CoV	I-PRGE
+RNA	I-PRGE
+by	O
+real	O
+-	O
+time	O
+polymerase	O
+chain	O
+reaction	O
+;	O
+serum	B-COMP
+samples	O
+were	O
+collected	O
+weekly	O
+and	O
+tested	O
+for	O
+SARS	B-PRGE
+-	I-PRGE
+CoV	I-PRGE
+antibody	B-COMP
+with	O
+indirect	O
+enzyme	O
+immunoassay	O
+and	O
+immunofluorescence	O
+assay	O
+.	O
+
+In	O
+this	O
+study	O
+,	O
+5	O
+(	O
+7	O
+.	O
+8	O
+%)	O
+of	O
+64	O
+patients	O
+continued	O
+to	O
+shed	O
+viral	O
+RNA	O
+in	O
+stool	B-ANAT
+samples	O
+only	O
+,	O
+for	O
+up	O
+to	O
+week	O
+8	O
+of	O
+illness	O
+.	O
+
+Although	O
+SARS	B-PRGE
+-	I-PRGE
+CoV	I-PRGE
+was	O
+not	O
+isolated	O
+from	O
+any	O
+patient	O
+,	O
+specimens	O
+from	O
+three	O
+patients	O
+were	O
+positive	O
+for	O
+viral	O
+RNA	O
+by	O
+reverse	B-PROC
+transcription	I-PROC
+-	O
+polymerase	O
+chain	O
+reaction	O
+assay	O
+,	O
+and	O
+all	O
+patients	O
+had	O
+detectable	O
+rises	O
+in	O
+SARS	B-PRGE
+-	I-PRGE
+CoV	I-PRGE
+-	I-PRGE
+specific	I-PRGE
+antibodies	B-COMP
+.	O
+
+This	O
+study	O
+shows	O
+the	O
+effectiveness	O
+of	O
+a	O
+collaborative	O
+,	O
+multilaboratory	O
+response	O
+to	O
+diagnose	O
+SARS	B-DISO
+.	O
+
+ABSTRACT	O
+:	O
+This	O
+study	O
+investigated	O
+the	O
+long	O
+-	O
+term	O
+excretion	O
+of	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+-	O
+associated	O
+coronavirus	B-SPEC
+in	O
+sputum	B-ANAT
+and	O
+stool	B-ANAT
+specimens	O
+from	O
+56	O
+infected	O
+patients	O
+.	O
+
+TITLE	O
+:	O
+Silencing	O
+of	O
+SARS	B-PRGE
+-	I-PRGE
+CoV	I-PRGE
+spike	I-PRGE
+gene	I-PRGE
+by	O
+small	O
+interfering	O
+RNA	O
+in	O
+HEK	O
+293T	O
+cells	B-COMP
+.	O
+
+ABSTRACT	O
+:	O
+Two	O
+candidate	O
+small	O
+interfering	O
+RNAs	O
+(	O
+siRNAs	O
+)	O
+corresponding	O
+to	O
+severe	O
+acute	O
+respiratory	O
+syndrome	O
+-	O
+associated	O
+coronavirus	B-SPEC
+(	O
+SARS	B-DISO
+-	O
+CoV	O
+)	O
+spike	O
+gene	O
+were	O
+designed	O
+and	O
+in	O
+vitro	O
+transcribed	O
+to	O
+explore	O
+the	O
+possibility	O
+of	O
+silencing	O
+SARS	B-PRGE
+-	I-PRGE
+CoV	I-PRGE
+S	I-PRGE
+gene	I-PRGE
+.	O
+
+The	O
+plasmid	O
+pEGFP	O
+-	O
+optS	O
+,	O
+which	O
+contains	O
+the	O
+codon	O
+-	O
+optimized	O
+SARS	B-PRGE
+-	I-PRGE
+CoV	I-PRGE
+S	I-PRGE
+gene	I-PRGE
+and	O
+expresses	O
+spike	O
+-	O
+EGFP	O
+fusion	O
+protein	B-CHED
+(	O
+S	O
+-	O
+EGFP	O
+)	O
+as	O
+silencing	O
+target	O
+and	O
+expressing	O
+reporter	O
+,	O
+was	O
+transfected	O
+with	O
+siRNAs	O
+into	O
+HEK	O
+293T	O
+cells	B-COMP
+.	O
+
+TITLE	O
+:	O
+Programmed	O
+-	O
+1	O
+ribosomal	B-PROC
+frameshifting	I-PROC
+in	O
+the	O
+SARS	B-DISO
+coronavirus	B-SPEC
+.	O
+
+ABSTRACT	O
+:	O
+Many	O
+viruses	O
+achieve	O
+reversible	O
+attachment	O
+to	O
+sialic	B-CHED
+acid	I-CHED
+(	O
+Sia	B-SPEC
+)	O
+by	O
+encoding	O
+envelope	B-COMP
+glycoproteins	B-CHED
+with	O
+receptor	O
+-	O
+binding	B-FUNC
+and	O
+receptor	O
+-	O
+destroying	O
+activities	O
+.	O
+
+Under	O
+the	O
+premise	O
+that	O
+HE	O
+specificity	O
+reflects	O
+receptor	O
+usage	O
+,	O
+we	O
+propose	O
+that	O
+two	O
+types	O
+of	O
+Sias	O
+serve	O
+as	O
+initial	O
+attachment	O
+factors	O
+for	O
+coronaviruses	O
+in	O
+mice	B-SPEC
+.	O
+
+Reminiscent	O
+of	O
+antigenic	O
+shifts	O
+in	O
+orthomyxoviruses	B-SPEC
+,	O
+rodent	B-SPEC
+coronaviruses	O
+exchanged	O
+S	O
+and	O
+HE	O
+sequences	O
+through	O
+recombination	B-PROC
+to	O
+extents	O
+not	O
+appreciated	O
+before	O
+.	O
+
+Glutaraldehyde	B-CHED
+cross	O
+-	O
+linking	O
+SDS	B-DISO
+-	O
+PAGE	O
+and	O
+size	O
+-	O
+exclusion	O
+chromatography	O
+results	O
+show	O
+that	O
+,	O
+similar	O
+to	O
+the	O
+full	B-PRGE
+-	I-PRGE
+length	I-PRGE
+SARS	I-PRGE
+3CL	I-PRGE
+(	O
+pro	B-PRGE
+),	O
+the	O
+N	O
+-	O
+terminal	O
+deleted	O
+SARS	B-PRGE
+3CL	I-PRGE
+(	O
+pro	B-CHED
+)	O
+still	O
+remains	O
+a	O
+dimer	O
+/	O
+monomer	O
+mixture	O
+within	O
+a	O
+wide	O
+range	O
+of	O
+protein	B-CHED
+concentrations	O
+.	O
+
+Mn	O
+(	O
+2	O
++)	O
+at	O
+2	O
+to	O
+10	O
+mM	O
+was	O
+needed	O
+for	O
+optimal	O
+endoribonuclease	B-FUNC
+activity	I-FUNC
+,	O
+but	O
+Mg	O
+(	O
+2	O
++)	O
+and	O
+several	O
+other	O
+divalent	O
+metals	B-CHED
+were	O
+capable	O
+of	O
+supporting	O
+only	O
+a	O
+low	O
+level	O
+of	O
+activity	O
+.	O
+
+This	O
+work	O
+presents	O
+an	O
+initial	O
+biochemical	O
+characterization	O
+of	O
+a	O
+novel	B-SPEC
+coronavirus	I-SPEC
+endoribonuclease	O
+.	O
+
+Immunized	O
+ferrets	B-SPEC
+developed	O
+a	O
+more	O
+rapid	O
+and	O
+vigorous	O
+neutralizing	O
+antibody	B-PROC
+response	I-PROC
+than	O
+control	O
+animals	B-SPEC
+after	O
+challenge	O
+with	O
+SARS	B-DISO
+-	O
+CoV	O
+;	O
+however	O
+,	O
+they	O
+also	O
+exhibited	O
+strong	O
+inflammatory	B-DISO
+responses	I-DISO
+in	O
+liver	B-ANAT
+tissue	I-ANAT
+.	O
+
+Efficient	O
+activity	O
+of	O
+TGEV	B-SPEC
+replicons	O
+was	O
+associated	O
+with	O
+the	O
+presence	O
+of	O
+the	O
+nucleoprotein	O
+provided	O
+either	O
+in	O
+cis	B-DISO
+or	O
+in	O
+trans	O
+.	O
+
+ABSTRACT	O
+:	O
+The	O
+causative	O
+agent	O
+of	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+(	O
+SARS	B-DISO
+)	O
+is	O
+a	O
+previously	O
+unidentified	O
+coronavirus	B-SPEC
+,	O
+SARS	B-DISO
+-	O
+CoV	O
+.	O
+The	O
+nucleocapsid	B-COMP
+(	O
+N	O
+)	O
+protein	B-CHED
+of	O
+SARS	B-PRGE
+-	I-PRGE
+CoV	I-PRGE
+is	O
+a	O
+major	O
+viral	O
+protein	B-CHED
+recognized	O
+by	O
+acute	O
+and	O
+early	O
+convalescent	O
+sera	B-COMP
+from	O
+SARS	B-DISO
+patients	O
+.	O
+
+TITLE	O
+:	O
+Radiological	O
+and	O
+pulmonary	B-PROC
+function	I-PROC
+outcomes	O
+of	O
+children	O
+with	O
+SARS	B-DISO
+.	O
+
+In	O
+each	O
+subject	O
+,	O
+high	O
+-	O
+resolution	O
+computed	O
+tomography	O
+(	O
+HRCT	O
+)	O
+of	O
+the	O
+thorax	B-ANAT
+and	O
+pulmonary	B-PROC
+function	I-PROC
+were	O
+assessed	O
+.	O
+
+Mild	O
+pulmonary	B-ANAT
+abnormalities	O
+were	O
+detected	O
+on	O
+HRCT	O
+in	O
+16	O
+(	O
+34	O
+.	O
+0	O
+%)	O
+subjects	O
+,	O
+including	O
+residual	O
+ground	O
+-	O
+glass	O
+opacification	O
+(	O
+n	O
+=	O
+5	O
+),	O
+air	B-DISO
+trapping	I-DISO
+(	O
+n	O
+=	O
+8	O
+),	O
+and	O
+a	O
+combination	O
+of	O
+ground	O
+-	O
+glass	O
+changes	O
+and	O
+air	B-DISO
+trapping	I-DISO
+(	O
+n	O
+=	O
+3	O
+).	O
+
+TITLE	O
+:	O
+Characterization	O
+of	O
+the	O
+heptad	O
+repeat	O
+regions	O
+,	O
+HR1	O
+and	O
+HR2	O
+,	O
+and	O
+design	O
+of	O
+a	O
+fusion	O
+core	O
+structure	O
+model	O
+of	O
+the	O
+spike	O
+protein	B-CHED
+from	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+(	O
+SARS	B-DISO
+)	O
+coronavirus	B-SPEC
+.	O
+
+Intracerebral	O
+infection	B-DISO
+of	O
+CCL2	B-CHED
+(-/-)	O
+mice	B-SPEC
+with	O
+MHV	B-SPEC
+did	O
+not	O
+result	O
+in	O
+increased	O
+morbidity	O
+or	O
+mortality	O
+as	O
+compared	O
+to	O
+either	O
+wild	O
+type	O
+or	O
+CCR2	O
+(-/-)	O
+mice	B-SPEC
+and	O
+CCL2	B-CHED
+(-/-)	O
+mice	B-SPEC
+cleared	O
+replicating	O
+virus	B-SPEC
+from	O
+the	O
+brain	B-ANAT
+.	O
+
+TITLE	O
+:	O
+Childhood	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+in	O
+Taiwan	O
+and	O
+how	O
+to	O
+differentiate	O
+it	O
+from	O
+childhood	O
+influenza	O
+infection	B-DISO
+.	O
+
+This	O
+analysis	O
+of	O
+the	O
+complete	O
+data	O
+on	O
+the	O
+2003	O
+SARS	B-DISO
+epidemic	O
+in	O
+Hong	O
+Kong	O
+has	O
+revealed	O
+key	O
+epidemiologic	O
+features	O
+of	O
+the	O
+epidemic	O
+as	O
+it	O
+evolved	O
+.	O
+
+TITLE	O
+:	O
+SARS	B-DISO
+changes	O
+the	O
+ED	O
+paradigm	O
+.	O
+
+The	O
+SARS	B-DISO
+outbreak	O
+in	O
+Singapore	O
+started	O
+in	O
+mid	O
+-	O
+March	O
+2003	O
+.	O
+
+In	O
+this	O
+study	O
+,	O
+we	O
+show	O
+that	O
+the	O
+envelope	B-PRGE
+(	I-PRGE
+E	I-PRGE
+)	I-PRGE
+protein	B-CHED
+of	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+-	O
+associated	O
+coronavirus	B-SPEC
+can	O
+induce	O
+membrane	B-PROC
+permeability	I-PROC
+changes	O
+when	O
+expressed	B-PROC
+in	O
+Escherichia	B-SPEC
+coli	I-SPEC
+.	O
+
+Site	B-PROC
+-	I-PROC
+directed	I-PROC
+mutagenesis	I-PROC
+studies	O
+revealed	O
+that	O
+two	O
+cysteine	B-CHED
+residues	O
+of	O
+the	O
+E	B-PRGE
+protein	I-PRGE
+were	O
+essential	O
+for	O
+oligomerization	O
+,	O
+leading	O
+to	O
+induction	O
+of	O
+membrane	B-PROC
+permeability	I-PROC
+.	O
+
+A	O
+novel	B-SPEC
+coronavirus	I-SPEC
+was	O
+later	O
+identified	O
+in	O
+patients	O
+with	O
+SARS	B-DISO
+.	O
+
+The	O
+rapid	O
+progress	O
+in	O
+the	O
+aetiology	O
+,	O
+the	O
+development	B-PROC
+of	O
+laboratory	O
+diagnostic	O
+tests	O
+,	O
+and	O
+the	O
+defining	O
+of	O
+routes	O
+of	O
+viral	B-PROC
+transmission	I-PROC
+were	O
+facilitated	O
+through	O
+a	O
+unique	O
+WHO	O
+-	O
+coordinated	O
+virtual	O
+network	O
+of	O
+laboratories	O
+,	O
+which	O
+shared	O
+information	O
+on	O
+a	O
+real	O
+-	O
+time	O
+basis	O
+through	O
+daily	O
+teleconferences	O
+.	O
+
+A	O
+critical	O
+review	O
+of	O
+problems	O
+and	O
+solutions	O
+encountered	O
+during	O
+the	O
+2003	O
+-	O
+2004	O
+SARS	B-DISO
+epidemics	O
+will	O
+serve	O
+as	O
+the	O
+basis	O
+for	O
+considering	O
+national	O
+preparedness	O
+steps	O
+that	O
+can	O
+be	O
+taken	O
+to	O
+facilitate	O
+the	O
+early	O
+detection	O
+of	O
+avian	B-DISO
+influenza	I-DISO
+,	O
+and	O
+a	O
+rapid	O
+response	O
+to	O
+an	O
+influenza	B-DISO
+pandemic	O
+should	O
+it	O
+occur	O
+.	O
+
+TITLE	O
+:	O
+Collateral	B-ANAT
+damage	O
+:	O
+the	O
+unforeseen	O
+effects	O
+of	O
+emergency	B-DISO
+outbreak	O
+policies	O
+.	O
+
+Most	O
+established	O
+coronaviruses	O
+exhibit	O
+winter	O
+seasonality	O
+,	O
+with	O
+a	O
+unique	O
+ability	O
+to	O
+establish	O
+persistent	O
+infections	O
+in	O
+a	O
+minority	O
+of	O
+infected	O
+animals	B-SPEC
+.	O
+
+ABSTRACT	O
+:	O
+Human	B-SPEC
+metapneumovirus	I-SPEC
+(	O
+hMPV	B-SPEC
+)	O
+is	O
+a	O
+newly	O
+identified	O
+virus	B-SPEC
+responsible	O
+for	O
+occasionally	O
+severe	O
+respiratory	B-DISO
+infections	I-DISO
+,	O
+mainly	O
+observed	O
+in	O
+children	O
+.	O
+
+hMPV	B-SPEC
+testing	O
+has	O
+clinical	O
+utility	O
+in	O
+adult	O
+patients	O
+with	O
+acute	O
+respiratory	O
+tract	O
+infection	O
+.	O
+
+In	O
+this	O
+study	O
+virological	O
+and	O
+serological	O
+investigations	O
+were	O
+performed	O
+to	O
+demonstrate	O
+the	O
+existence	O
+and	O
+prevalence	O
+of	O
+CCoV	O
+infection	B-DISO
+in	O
+a	O
+Turkish	O
+dog	B-SPEC
+population	O
+.	O
+
+A	O
+total	O
+of	O
+269	O
+animals	B-SPEC
+were	O
+subjected	O
+to	O
+the	O
+study	O
+.	O
+
+Early	O
+in	O
+the	O
+SARS	B-DISO
+epidemic	O
+,	O
+mobile	O
+teams	O
+found	O
+wide	O
+variations	O
+in	O
+infection	B-DISO
+control	O
+practices	O
+and	O
+resources	O
+among	O
+Asian	O
+hospitals	O
+evaluating	O
+patients	O
+for	O
+SARS	B-DISO
+,	O
+indicating	O
+the	O
+importance	O
+of	O
+ongoing	O
+assessment	O
+during	O
+SARS	B-DISO
+preparedness	O
+.	O
+
+At	O
+the	O
+time	O
+of	O
+mobile	O
+team	O
+visits	O
+,	O
+5	O
+(	O
+25	O
+%)	O
+hospitals	O
+implemented	O
+infection	B-DISO
+control	O
+practices	O
+consistent	O
+with	O
+World	O
+Health	O
+Organization	O
+recommendations	O
+on	O
+visitor	O
+policies	O
+,	O
+private	O
+negative	O
+-	O
+pressure	O
+rooms	O
+,	O
+and	O
+personal	O
+protective	O
+equipment	O
+.	O
+
+The	O
+importance	O
+of	O
+individualized	O
+design	O
+and	O
+implementation	O
+of	O
+infection	B-DISO
+control	O
+measures	O
+is	O
+highlighted	O
+and	O
+discussed	O
+.	O
+
+The	O
+current	O
+available	O
+randomized	O
+controlled	O
+trials	O
+of	O
+integrated	O
+traditional	O
+Chinese	O
+and	O
+Western	O
+medicine	B-CHED
+on	O
+SARS	B-DISO
+were	O
+identified	O
+through	O
+systematically	O
+searching	O
+literature	O
+in	O
+any	O
+languages	O
+or	O
+any	O
+types	O
+of	O
+publications	O
+.	O
+
+Some	O
+patients	O
+deteriorate	O
+relentlessly	O
+despite	O
+treatment	O
+with	O
+antibiotic	B-CHED
+,	O
+corticosteroid	B-CHED
+and	O
+mechanical	O
+ventilation	O
+.	O
+
+TITLE	O
+:	O
+Evolutional	O
+insights	O
+on	O
+uncharacterized	O
+SARS	B-PRGE
+coronavirus	B-SPEC
+genes	I-PRGE
+.	O
+
+In	O
+the	O
+present	O
+study	O
+,	O
+we	O
+demonstrated	O
+that	O
+signal	B-PRGE
+transducer	I-PRGE
+and	I-PRGE
+activator	I-PRGE
+of	I-PRGE
+transcription	I-PRGE
+(	O
+STAT	O
+)	O
+3	O
+,	O
+which	O
+is	O
+constitutively	O
+phosphorylated	O
+at	O
+tyrosine	B-CHED
+(	O
+Tyr	B-CHED
+)-	O
+705	O
+and	O
+slightly	O
+phosphorylated	O
+at	O
+serine	B-CHED
+(	O
+Ser	B-COMP
+)-	O
+727	O
+in	O
+Vero	O
+E6	O
+cells	B-COMP
+,	O
+was	O
+dephosphorylated	O
+at	O
+Tyr	B-CHED
+-	O
+705	O
+on	O
+SARS	B-DISO
+-	I-DISO
+CoV	I-DISO
+infection	I-DISO
+.	O
+
+Although	O
+inhibitors	B-CHED
+of	O
+ERK1	B-PRGE
+/	I-PRGE
+2	I-PRGE
+and	O
+JNK	B-FUNC
+(	O
+PD98059	O
+and	O
+SP600125	O
+)	O
+had	O
+no	O
+effect	O
+on	O
+phosphorylation	B-PROC
+status	O
+of	O
+STAT3	B-PRGE
+,	O
+inhibitors	B-CHED
+of	O
+p38	B-FUNC
+MAPK	B-FUNC
+(	O
+SB203580	O
+and	O
+SB202190	O
+)	O
+partially	O
+inhibited	O
+dephosphorylation	B-PROC
+of	O
+STAT3	B-PRGE
+at	O
+Tyr	B-CHED
+-	O
+705	O
+.	O
+
+Affinity	O
+-	O
+purified	O
+polyclonal	O
+antibodies	B-COMP
+recognizing	O
+the	O
+N	O
+-	O
+terminal	O
+19	O
+residues	O
+of	O
+SARS	B-PRGE
+-	I-PRGE
+CoV	I-PRGE
+E	I-PRGE
+protein	B-CHED
+were	O
+used	O
+to	O
+establish	O
+the	O
+specificity	O
+of	O
+channel	O
+formation	B-PROC
+by	O
+inhibiting	O
+the	O
+ion	O
+currents	O
+generated	O
+in	O
+the	O
+presence	O
+of	O
+the	O
+E	O
+protein	B-CHED
+peptides	B-CHED
+.	O
+
+These	O
+data	O
+suggest	O
+that	O
+an	O
+instructional	O
+program	O
+intrinsic	O
+to	O
+T	B-PROC
+cell	I-PROC
+differentiation	I-PROC
+,	O
+rather	O
+than	O
+Ag	O
+load	O
+or	O
+factors	O
+in	O
+the	O
+inflamed	O
+CNS	B-CHED
+,	O
+prominently	O
+regulate	O
+CD8	B-PRGE
++	I-PRGE
+T	B-ANAT
+cell	I-ANAT
+function	O
+.	O
+
+Two	O
+major	O
+immunodominant	O
+epitopes	O
+located	O
+in	O
+the	O
+C	O
+-	O
+terminal	O
+region	O
+(	O
+amino	B-CHED
+acids	I-CHED
+[	O
+aa	O
+]	O
+362	O
+to	O
+412	O
+)	O
+and	O
+middle	O
+region	O
+(	O
+aa	O
+153	O
+to	O
+178	O
+)	O
+reacted	O
+with	O
+more	O
+than	O
+75	O
+%	O
+of	O
+sera	B-COMP
+from	O
+SARS	B-DISO
+patients	O
+.	O
+
+Antisera	O
+from	O
+mice	B-SPEC
+immunized	O
+with	O
+inactivated	O
+SARS	B-PRGE
+-	I-PRGE
+CoV	I-PRGE
+recognized	O
+the	O
+two	O
+major	O
+immunodominant	O
+epitopes	O
+and	O
+one	O
+antigenic	O
+site	O
+located	O
+adjacent	O
+to	O
+the	O
+N	O
+-	O
+terminal	O
+region	O
+(	O
+aa	O
+76	O
+to	O
+101	O
+),	O
+which	O
+did	O
+not	O
+react	O
+with	O
+the	O
+sera	B-COMP
+from	O
+SARS	B-DISO
+patients	O
+.	O
+
+These	O
+results	O
+suggest	O
+that	O
+the	O
+above	O
+antigenic	O
+sites	O
+on	O
+the	O
+N	B-PRGE
+protein	I-PRGE
+are	O
+important	O
+in	O
+eliciting	O
+humoral	B-PROC
+immune	I-PROC
+response	I-PROC
+against	O
+SARS	B-PRGE
+-	I-PRGE
+CoV	I-PRGE
+in	O
+humans	B-SPEC
+and	O
+animals	B-SPEC
+and	O
+can	O
+be	O
+used	O
+as	O
+antigens	B-CHED
+for	O
+developing	O
+diagnostic	O
+tests	O
+.	O
+
+ABSTRACT	O
+:	O
+The	O
+disease	O
+caused	O
+by	O
+infectious	O
+bronchitis	B-DISO
+virus	B-SPEC
+(	O
+IBV	B-SPEC
+)	O
+produces	O
+great	O
+economic	O
+for	O
+the	O
+poultry	O
+industry	O
+.	O
+
+However	O
+,	O
+the	O
+S1	B-PRGE
+gene	I-PRGE
+showed	O
+a	O
+noticeably	O
+higher	O
+divergence	O
+than	O
+the	O
+N	B-PRGE
+gene	I-PRGE
+.	O
+
+TITLE	O
+:	O
+Identification	O
+of	O
+a	O
+novel	O
+nephropathogenic	O
+infectious	B-DISO
+bronchitis	B-DISO
+virus	B-SPEC
+in	O
+Israel	O
+.	O
+
+ABSTRACT	O
+:	O
+Severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+(	O
+SARS	B-DISO
+)	O
+is	O
+a	O
+newly	O
+described	O
+respiratory	B-DISO
+infection	I-DISO
+with	O
+pandemic	O
+potential	O
+.	O
+
+ABSTRACT	O
+:	O
+The	O
+recent	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+(	O
+SARS	B-DISO
+)	O
+outbreak	O
+has	O
+almost	O
+mandated	O
+a	O
+re	O
+-	O
+evaluation	O
+of	O
+infection	B-DISO
+control	O
+practices	O
+in	O
+hospitals	O
+,	O
+clinics	O
+,	O
+schools	O
+and	O
+domestic	O
+environments	O
+,	O
+especially	O
+for	O
+patients	O
+with	O
+respiratory	B-ANAT
+tract	I-ANAT
+symptoms	O
+.	O
+
+Published	O
+data	O
+on	O
+long	O
+-	O
+term	O
+sequelae	O
+of	O
+SARS	B-DISO
+are	O
+very	O
+limited	O
+.	O
+
+TITLE	O
+:	O
+Understanding	O
+the	O
+spatial	O
+clustering	O
+of	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+(	O
+SARS	B-DISO
+)	O
+in	O
+Hong	O
+Kong	O
+.	O
+
+ABSTRACT	O
+:	O
+We	O
+applied	O
+cartographic	O
+and	O
+geostatistical	O
+methods	O
+in	O
+analyzing	O
+the	O
+patterns	O
+of	O
+disease	O
+spread	O
+during	O
+the	O
+2003	O
+severe	O
+acute	O
+respiratory	O
+syndrome	O
+(	O
+SARS	B-DISO
+)	O
+outbreak	O
+in	O
+Hong	O
+Kong	O
+using	O
+geographic	O
+information	O
+system	O
+(	O
+GIS	O
+)	O
+technology	O
+.	O
+
+Origin	O
+-	O
+and	O
+-	O
+destination	O
+plots	O
+showed	O
+the	O
+directional	O
+bias	O
+and	O
+radius	B-ANAT
+of	O
+spread	O
+of	O
+superspreading	O
+events	O
+.	O
+
+TITLE	O
+:	O
+A	O
+study	O
+on	O
+SARS	B-DISO
+awareness	O
+and	O
+health	O
+-	O
+seeking	O
+behaviour	B-PROC
+-	O
+findings	O
+from	O
+a	O
+sampled	O
+population	O
+attending	O
+National	O
+Healthcare	O
+Group	O
+Polyclinics	O
+.	O
+
+The	O
+majority	O
+(	O
+92	O
+.	O
+7	O
+%)	O
+of	O
+the	O
+respondents	O
+were	O
+aware	O
+of	O
+SARS	B-DISO
+symptoms	O
+.	O
+
+In	O
+particular	O
+,	O
+the	O
+retired	O
+with	O
+lower	O
+educational	O
+levels	O
+were	O
+likely	O
+to	O
+be	O
+oblivious	O
+both	O
+to	O
+the	O
+symptoms	O
+of	O
+SARS	B-DISO
+and	O
+the	O
+possible	O
+consequences	O
+of	O
+travelling	O
+by	O
+inappropriate	O
+transport	B-PROC
+.	O
+
+A	O
+man	B-CHED
+developed	O
+myopathy	B-DISO
+and	O
+a	O
+third	O
+woman	O
+experienced	O
+neuropathy	B-DISO
+and	O
+myopathy	B-DISO
+.	O
+
+Full	O
+length	O
+cDNA	O
+of	O
+SCoV	O
+nucleocapsid	B-COMP
+(	O
+SCoVN	O
+)	O
+protein	B-CHED
+was	O
+amplified	O
+through	O
+polymerase	O
+chain	O
+reaction	O
+(	O
+PCR	O
+)	O
+and	O
+cloned	O
+into	O
+yeast	B-SPEC
+expression	B-PROC
+vector	O
+pPIC3	O
+.	O
+5K	O
+to	O
+construct	O
+plasmid	O
+of	O
+pPIC3	O
+.	O
+5K	O
+-	O
+SCoVN	O
+.	O
+
+The	O
+plasmid	O
+was	O
+linearized	O
+and	O
+then	O
+transformed	O
+into	O
+Pichia	B-SPEC
+pastoris	I-SPEC
+(	O
+P	B-SPEC
+.	I-SPEC
+pastoris	I-SPEC
+)	O
+GS115	O
+(	O
+His	O
+-	O
+Mut	O
++)	O
+by	O
+electroporation	O
+.	O
+
+The	O
+influence	O
+of	O
+different	O
+factors	O
+on	O
+biomass	O
+and	O
+rSCoVN	O
+protein	B-CHED
+production	O
+during	O
+induction	O
+phase	O
+,	O
+such	O
+as	O
+various	O
+induction	O
+media	B-ANAT
+,	O
+dissolved	O
+oxygen	B-CHED
+(	O
+DO	O
+)	O
+and	O
+different	O
+final	O
+concentrations	O
+of	O
+methanol	B-CHED
+,	O
+was	O
+subsequently	O
+studied	O
+.	O
+
+The	O
+rSCoVN	B-PRGE
+protein	I-PRGE
+expressed	B-PROC
+in	O
+recombinant	O
+strains	O
+was	O
+about	O
+8	O
+%	O
+of	O
+the	O
+total	O
+cell	B-COMP
+protein	B-CHED
+,	O
+520	O
+mg	O
+/	O
+L	O
+of	O
+rSCoVN	O
+protein	B-CHED
+was	O
+achieved	O
+,	O
+and	O
+a	O
+maximum	O
+cell	B-COMP
+A	O
+at	O
+600	O
+nm	O
+of	O
+62	O
+was	O
+achieved	O
+in	O
+shake	B-DISO
+flask	O
+culture	O
+.	O
+
+This	O
+provides	O
+a	O
+basis	O
+for	O
+further	O
+researches	O
+on	O
+the	O
+early	O
+diagnosis	O
+of	O
+SARS	B-DISO
+and	O
+the	O
+mechanism	O
+of	O
+SCoV	O
+.	O
+RESULTS	O
+:	O
+All	O
+of	O
+the	O
+recombinants	O
+were	O
+His	O
+(+)	O
+Mut	O
+(+)	O
+after	O
+transformation	B-DISO
+of	O
+P	B-SPEC
+.	I-SPEC
+pastoris	I-SPEC
+with	O
+linearized	O
+plasmids	O
+.	O
+
+This	O
+provides	O
+a	O
+basis	O
+for	O
+further	O
+researches	O
+on	O
+the	O
+early	O
+diagnosis	O
+of	O
+SARS	B-DISO
+and	O
+the	O
+mechanism	O
+of	O
+SCoV	O
+.	O
+
+A	B-SPEC
+.	I-SPEC
+diaperinus	I-SPEC
+were	O
+capable	O
+of	O
+mechanical	O
+transmission	O
+of	O
+TCV	B-SPEC
+.	O
+
+Laboratory	O
+studies	O
+demonstrating	O
+PEMS	O
+transmission	O
+by	O
+A	B-SPEC
+.	I-SPEC
+diaperinus	I-SPEC
+are	O
+continuing	O
+.	O
+
+Its	O
+incidence	O
+rate	O
+was	O
+high	O
+,	O
+the	O
+patients	O
+'	O
+condition	B-DISO
+was	O
+severe	O
+,	O
+and	O
+the	O
+mortality	O
+was	O
+higher	O
+.	O
+
+SARS	B-DISO
+could	O
+end	O
+in	O
+MODS	B-DISO
+and	O
+the	O
+mortality	O
+was	O
+92	O
+.	O
+3x	O
+.	O
+
+CONCLUSIONS	O
+:	O
+Dysfunction	O
+of	O
+organs	B-ANAT
+are	O
+closely	O
+correlated	O
+with	O
+prognosis	O
+of	O
+SARS	B-DISO
+.	O
+
+But	O
+serum	B-COMP
+total	O
+protein	B-CHED
+remained	O
+normal	O
+during	O
+the	O
+whole	O
+clinical	O
+course	O
+.	O
+
+But	O
+serum	B-COMP
+total	O
+protein	B-CHED
+remained	O
+normal	O
+during	O
+the	O
+whole	O
+clinical	O
+course	O
+.	O
+
+Serum	B-COMP
+total	O
+protein	B-CHED
+(	O
+TP	O
+),	O
+albumin	B-PRGE
+(	O
+Alb	B-PRGE
+),	O
+total	O
+cholesterol	B-CHED
+(	O
+TC	O
+),	O
+triglyceride	B-CHED
+(	O
+TG	O
+),	O
+calcium	B-CHED
+(	O
+Ca	O
+),	O
+ferrum	B-CHED
+(	O
+Fe	O
+),	O
+lactate	B-PRGE
+dehydrogenase	I-PRGE
+(	O
+LDH	B-PRGE
+),	O
+creatine	B-PRGE
+kinase	I-PRGE
+(	O
+CK	O
+),	O
+alanine	B-PRGE
+aminotransferase	I-PRGE
+(	O
+ALT	B-FUNC
+)	O
+and	O
+aspartate	B-PRGE
+aminotransferase	I-PRGE
+(	O
+AST	B-PRGE
+)	O
+between	O
+SARS	B-DISO
+and	O
+other	O
+viral	B-DISO
+pneumonias	I-DISO
+were	O
+examined	O
+by	O
+Roche	O
+Diagnostics	O
+assay	O
+,	O
+HITACHI7600	O
+automatic	O
+analyzer	O
+.	O
+
+ABSTRACT	O
+:	O
+To	O
+observe	O
+the	O
+method	O
+of	O
+fluorescent	O
+-	O
+polymerase	O
+chain	O
+reaction	O
+(	O
+F	O
+-	O
+PCR	O
+)	O
+and	O
+gene	O
+-	O
+hip	O
+technique	O
+in	O
+detecting	O
+coronavirus	B-SPEC
+in	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+(	O
+SARS	B-DISO
+)	O
+and	O
+its	O
+value	O
+for	O
+clinical	O
+application	O
+.	O
+
+Serum	B-COMP
+of	O
+60	O
+SARS	B-DISO
+patients	O
+,	O
+20	O
+samples	O
+of	O
+serum	B-COMP
+and	O
+20	O
+samples	O
+of	O
+gargling	B-PROC
+fluid	O
+of	O
+medical	O
+staff	O
+of	O
+the	O
+""""	O
+Fever	B-PROC
+Clinic	O
+""","	O
+and	O
+one	O
+cDNA	O
+specimen	O
+obtained	O
+from	O
+one	O
+SARS	B-DISO
+suspect	O
+patient	O
+were	O
+examined	O
+with	O
+F	O
+-	O
+PCR	O
+diagnosis	O
+kit	B-FUNC
+and	O
+gene	O
+-	O
+chip	O
+technique	O
+for	O
+SARS	B-DISO
+coronavirus	B-SPEC
+.	O
+
+We	O
+assessed	O
+thyroid	B-PROC
+function	I-PROC
+in	O
+patients	O
+with	O
+severe	O
+respiratory	B-DISO
+failure	I-DISO
+from	O
+pulmonary	B-DISO
+disorders	I-DISO
+,	O
+and	O
+needing	O
+invasive	O
+or	O
+noninvasive	O
+mechanical	O
+ventilation	O
+,	O
+in	O
+order	B-SPEC
+to	O
+evaluate	O
+the	O
+prognostic	O
+value	O
+of	O
+nonthyroidal	O
+illness	O
+syndrome	B-DISO
+.	O
+
+Measured	O
+variables	O
+upon	O
+admission	O
+included	O
+APACHE	O
+II	O
+score	O
+,	O
+the	O
+ratio	O
+of	O
+the	O
+partial	B-PROC
+pressure	I-PROC
+of	I-PROC
+oxygen	I-PROC
+in	O
+arterial	B-ANAT
+blood	I-ANAT
+to	O
+the	O
+fraction	O
+of	O
+oxygen	B-CHED
+in	O
+inspired	B-PROC
+gas	B-ENZY
+(	O
+PaO	B-PROC
+(	O
+2	O
+)/	O
+FiO	O
+(	O
+2	O
+)),	O
+and	O
+plasma	B-ANAT
+levels	O
+of	O
+free	O
+T3	O
+(	O
+fT3	O
+)	O
+and	O
+free	O
+thyroxine	B-CHED
+(	O
+fT4	O
+),	O
+and	O
+TSH	B-PRGE
+levels	O
+.	O
+
+Quick	O
+diagnostic	O
+tests	O
+and	O
+specific	O
+treatments	O
+for	O
+SARS	B-DISO
+are	O
+not	O
+yet	O
+available	O
+;	O
+thus	O
+,	O
+prevention	O
+is	O
+of	O
+paramount	O
+importance	O
+to	O
+contain	O
+its	O
+global	O
+spread	O
+.	O
+
+Potential	O
+protection	O
+of	O
+fetus	B-ANAT
+from	O
+infection	B-DISO
+was	O
+suggested	O
+.	O
+
+Here	O
+,	O
+we	O
+identified	O
+another	O
+cellular	B-COMP
+protein	B-CHED
+,	O
+p70	B-PRGE
+,	O
+which	O
+has	O
+been	O
+shown	O
+by	O
+UV	O
+cross	O
+-	O
+linking	O
+to	O
+bind	B-FUNC
+both	O
+the	O
+positive	O
+-	O
+and	O
+negative	O
+-	O
+strand	O
+UTRs	O
+of	O
+MHV	B-SPEC
+RNA	O
+specifically	O
+.	O
+
+Furthermore	O
+,	O
+downregulation	B-PROC
+of	O
+the	O
+endogenous	O
+SYNCRIP	O
+with	O
+a	O
+specific	O
+short	O
+interfering	O
+RNA	O
+delayed	O
+MHV	B-PRGE
+RNA	B-PROC
+synthesis	I-PROC
+;	O
+in	O
+contrast	O
+,	O
+overexpression	B-PROC
+or	O
+downregulation	B-PROC
+of	O
+SYNCRIP	O
+did	O
+not	O
+affect	O
+MHV	B-SPEC
+translation	B-PROC
+.	O
+
+This	O
+study	O
+identified	O
+an	O
+additional	O
+cellular	B-COMP
+hnRNP	B-ANAT
+as	O
+an	O
+MHV	B-SPEC
+RNA	O
+-	O
+binding	B-FUNC
+protein	B-CHED
+potentially	O
+involved	O
+in	O
+viral	O
+RNA	B-PROC
+synthesis	I-PROC
+.	O
+
+ARDS	B-DISO
+survivors	O
+report	O
+moderate	O
+to	O
+severe	B-DISO
+depression	I-DISO
+(	O
+16	O
+%	O
+and	O
+23	O
+%)	O
+and	O
+anxiety	O
+(	O
+24	O
+%	O
+and	O
+23	O
+%)	O
+at	O
+1	O
+and	O
+2	O
+years	O
+,	O
+respectively	O
+.	O
+
+TITLE	O
+:	O
+Recombinant	B-PRGE
+human	I-PRGE
+activated	I-PRGE
+protein	B-CHED
+C	I-PRGE
+in	O
+the	O
+treatment	O
+of	O
+severe	B-DISO
+sepsis	I-DISO
+:	O
+an	O
+evidence	O
+-	O
+based	O
+review	O
+.	O
+
+The	O
+modified	O
+Delphi	O
+methodology	O
+used	O
+for	O
+grading	O
+recommendations	O
+built	O
+on	O
+a	O
+2001	O
+publication	O
+sponsored	O
+by	O
+the	O
+International	O
+Sepsis	B-DISO
+Forum	O
+.	O
+
+A	O
+minimum	O
+amount	O
+of	O
+positive	O
+end	O
+-	O
+expiratory	O
+pressure	O
+should	O
+be	O
+set	O
+to	O
+prevent	O
+lung	B-DISO
+collapse	I-DISO
+at	O
+end	O
+expiration	B-PROC
+in	O
+ARDS	B-DISO
+.	O
+
+Small	O
+tidal	O
+volume	O
+ventilation	O
+and	O
+limitation	O
+of	O
+end	O
+-	O
+inspiratory	B-PROC
+plateau	O
+pressure	O
+is	O
+important	O
+in	O
+the	O
+management	O
+of	O
+ARDS	B-DISO
+and	O
+may	O
+be	O
+facilitated	O
+by	O
+permissive	O
+hypercapnia	B-DISO
+.	O
+
+Weaning	B-PROC
+protocols	O
+should	O
+be	O
+in	O
+place	O
+that	O
+include	O
+spontaneous	O
+breathing	B-PROC
+trials	O
+and	O
+criteria	O
+for	O
+initiating	O
+such	O
+trials	O
+.	O
+
+The	O
+antisense	O
+effect	O
+was	O
+further	O
+proved	O
+by	O
+down	O
+-	O
+regulating	O
+the	O
+expression	B-PROC
+of	O
+the	O
+fusion	O
+proteins	B-CHED
+containing	O
+the	O
+structural	O
+proteins	B-CHED
+E	O
+,	O
+M	O
+or	O
+N	O
+in	O
+frame	O
+with	O
+the	O
+reporter	O
+protein	B-CHED
+EGFP	O
+.	O
+
+In	O
+Vero	O
+E6	O
+cells	B-COMP
+,	O
+the	O
+antisense	O
+effect	O
+was	O
+dependent	O
+on	O
+the	O
+concentrations	O
+of	O
+the	O
+antisense	O
+PS	O
+-	O
+ODNs	O
+in	O
+a	O
+range	O
+of	O
+0	O
+-	O
+10	O
+microM	O
+or	O
+0	O
+-	O
+30	O
+microM	O
+.	O
+The	O
+antisense	O
+PS	O
+-	O
+ODNs	O
+are	O
+effective	O
+in	O
+downregulation	B-PROC
+of	O
+SARS	B-DISO
+.	O
+
+CONCLUSIONS	O
+:	O
+The	O
+clinical	O
+picture	O
+of	O
+our	O
+patients	O
+presenting	O
+with	O
+hospital	O
+-	O
+acquired	O
+SARS	B-DISO
+revealed	O
+atypical	B-DISO
+pneumonia	I-DISO
+associated	O
+with	O
+lymphopenia	B-DISO
+,	O
+elevated	O
+serum	B-COMP
+levels	O
+of	O
+LDH	B-PRGE
+,	O
+rapid	O
+clinical	O
+deterioration	O
+,	O
+and	O
+lack	O
+of	O
+response	O
+to	O
+empirical	O
+antibiotic	B-CHED
+therapy	O
+.	O
+
+Remotely	O
+sensed	O
+IRT	O
+readings	O
+were	O
+obtained	O
+from	O
+various	O
+parts	O
+of	O
+the	O
+front	O
+and	O
+side	O
+of	O
+the	O
+face	B-DISO
+(	O
+at	O
+distances	O
+of	O
+1	O
+.	O
+5	O
+and	O
+0	O
+.	O
+5	O
+m	O
+),	O
+and	O
+compared	O
+to	O
+concurrently	O
+determined	O
+body	B-ANAT
+temperature	O
+measurements	O
+using	O
+conventional	O
+means	O
+(	O
+aural	O
+tympanic	O
+IRT	O
+and	O
+oral	B-ANAT
+mercury	B-CHED
+thermometry	O
+).	O
+
+Optimal	O
+correlations	O
+were	O
+found	O
+between	O
+conventionally	O
+measured	O
+body	O
+temperatures	O
+and	O
+IRT	O
+readings	O
+from	O
+(	O
+1	O
+)	O
+the	O
+front	O
+of	O
+the	O
+face	B-DISO
+at	O
+1	O
+.	O
+5m	O
+with	O
+the	O
+mouth	B-ANAT
+open	O
+(	O
+r	O
+=	O
+0	O
+.	O
+80	O
+),	O
+(	O
+2	O
+)	O
+the	O
+ear	B-ANAT
+at	O
+0	O
+.	O
+5	O
+m	O
+(	O
+r	O
+=	O
+0	O
+.	O
+79	O
+),	O
+and	O
+(	O
+3	O
+)	O
+the	O
+side	O
+of	O
+the	O
+face	B-DISO
+at	O
+1	O
+.	O
+5m	O
+(	O
+r	O
+=	O
+0	O
+.	O
+76	O
+).	O
+
+Ear	B-ANAT
+IRT	O
+readings	O
+at	O
+0	O
+.	O
+5	O
+m	O
+yielded	O
+the	O
+narrowest	O
+confidence	O
+intervals	O
+and	O
+could	O
+be	O
+used	O
+to	O
+predict	O
+conventional	O
+body	B-ANAT
+temperature	O
+readings	O
+of	O
+<	O
+or	O
+=	O
+38	O
+degrees	O
+C	O
+with	O
+a	O
+sensitivity	O
+and	O
+specificity	O
+of	O
+83	O
+%	O
+and	O
+88	O
+%	O
+respectively	O
+.	O
+
+One	O
+or	O
+more	O
+viral	O
+pathogens	O
+were	O
+detected	O
+in	O
+65	O
+(	O
+87	O
+%)	O
+children	O
+,	O
+with	O
+respiratory	B-SPEC
+syncytial	I-SPEC
+virus	I-SPEC
+being	O
+the	O
+most	O
+commonly	O
+identified	O
+virus	B-SPEC
+(	O
+36	O
+children	O
+).	O
+
+Multiple	O
+infections	B-DISO
+were	O
+identified	O
+in	O
+20	O
+(	O
+27	O
+%)	O
+children	O
+.	O
+
+TITLE	O
+:	O
+SARS	B-DISO
+related	O
+preventive	O
+and	O
+risk	O
+behaviours	O
+practised	O
+by	O
+Hong	O
+Kong	O
+-	O
+mainland	O
+China	O
+cross	O
+border	B-ANAT
+travellers	O
+during	O
+the	O
+outbreak	O
+of	O
+the	O
+SARS	B-DISO
+epidemic	O
+in	O
+Hong	O
+Kong	O
+.	O
+
+ABSTRACT	O
+:	O
+To	O
+investigate	O
+patterns	O
+of	O
+behaviours	O
+and	O
+attitudes	O
+related	O
+to	O
+SARS	B-DISO
+prevention	O
+in	O
+the	O
+Hong	O
+Kong	O
+cross	O
+border	B-ANAT
+traveller	O
+population	O
+.	O
+
+Around	O
+40	O
+%	O
+of	O
+the	O
+respondents	O
+were	O
+using	O
+masks	O
+all	O
+or	O
+most	O
+of	O
+the	O
+time	O
+in	O
+public	O
+places	O
+or	O
+washing	O
+their	O
+hands	B-ANAT
+frequently	O
+(>	O
+10	O
+times	O
+per	O
+day	O
+)	O
+and	O
+about	O
+one	O
+third	O
+avoided	O
+visiting	O
+crowded	O
+places	O
+in	O
+mainland	O
+China	O
+.	O
+
+It	O
+seems	O
+that	O
+those	O
+travelling	O
+during	O
+the	O
+SARS	B-DISO
+epidemic	O
+were	O
+a	O
+""""	O
+self	O
+selected	O
+""""	O
+group	O
+,	O
+and	O
+they	O
+were	O
+using	O
+less	O
+preventive	O
+measures	O
+.	O
+
+The	O
+genome	O
+of	O
+HCoV	B-SPEC
+-	I-SPEC
+NL63	I-SPEC
+has	O
+the	O
+following	O
+gene	O
+order	B-SPEC
+:	O
+1a	O
+-	O
+1b	O
+-	O
+S	O
+-	O
+ORF3	O
+-	O
+E	O
+-	O
+M	O
+-	O
+N	O
+.	O
+The	O
+GC	O
+content	O
+of	O
+the	O
+HCoV	B-SPEC
+-	I-SPEC
+NL63	I-SPEC
+genome	O
+is	O
+extremely	O
+low	O
+(	O
+34	O
+%)	O
+compared	O
+to	O
+other	O
+coronaviruses	O
+,	O
+and	O
+we	O
+therefore	O
+performed	O
+additional	O
+analysis	O
+of	O
+the	O
+nucleotide	B-CHED
+composition	O
+.	O
+
+TITLE	O
+:	O
+Angiotensin	B-CHED
+-	I-PRGE
+converting	I-PRGE
+enzyme	I-PRGE
+-	I-PRGE
+2	I-PRGE
+:	O
+a	O
+molecular	O
+and	O
+cellular	B-COMP
+perspective	O
+.	O
+
+ABSTRACT	O
+:	O
+Angiotensin	B-CHED
+-	I-PRGE
+converting	I-PRGE
+enzyme	I-PRGE
+-	I-PRGE
+2	I-PRGE
+(	O
+ACE2	B-PRGE
+)	O
+is	O
+the	O
+first	O
+human	B-SPEC
+homologue	O
+of	O
+ACE	B-PRGE
+to	O
+be	O
+described	O
+.	O
+
+However	O
+,	O
+ACE2	B-PRGE
+also	O
+hydrolyses	O
+dynorphin	O
+A	O
+(	O
+1	O
+-	O
+13	O
+),	O
+apelin	O
+-	O
+13	O
+and	O
+des	B-DISO
+-	O
+Arg	B-CHED
+(	O
+9	O
+)	O
+bradykinin	B-CHED
+.	O
+
+It	O
+may	O
+also	O
+contribute	O
+to	O
+the	O
+development	B-PROC
+of	O
+additional	O
+animal	B-SPEC
+models	O
+for	O
+studying	O
+SARS	B-DISO
+pathogenesis	B-PROC
+,	O
+and	O
+could	O
+help	O
+identify	O
+the	O
+animal	B-SPEC
+reservoir	O
+of	O
+SARS	B-DISO
+-	O
+CoV	O
+.	O
+
+We	O
+examined	O
+multiple	O
+studies	O
+in	O
+an	O
+attempt	O
+to	O
+determine	O
+whether	O
+early	B-PRGE
+sCD62L	I-PRGE
+concentrations	O
+are	O
+predictive	O
+of	O
+major	O
+complications	O
+after	O
+severe	O
+trauma	O
+.	O
+
+We	O
+performed	O
+a	O
+systematic	O
+review	O
+of	O
+six	O
+electronic	O
+databases	O
+and	O
+a	O
+manual	O
+search	O
+for	O
+clinical	O
+studies	O
+comparing	O
+outcomes	O
+of	O
+multiply	O
+injured	O
+patients	O
+(	O
+Injury	O
+Severity	O
+Score	O
+>	O
+or	O
+=	O
+16	O
+)	O
+depending	O
+on	O
+their	O
+early	O
+sCD62L	O
+blood	B-ANAT
+concentrations	O
+.	O
+
+Pathologic	O
+changes	O
+in	O
+response	O
+to	O
+viral	B-DISO
+infection	I-DISO
+might	O
+be	O
+reflected	O
+in	O
+proteomic	O
+patterns	O
+in	O
+sera	B-COMP
+of	O
+SARS	B-DISO
+patients	O
+.	O
+
+Diluted	O
+samples	O
+were	O
+applied	O
+to	O
+WCX	O
+-	O
+2	O
+ProteinChip	O
+arrays	O
+(	O
+Ciphergen	O
+),	O
+and	O
+the	O
+bound	O
+proteins	B-CHED
+were	O
+assessed	O
+on	O
+a	O
+ProteinChip	O
+Reader	O
+(	O
+Model	O
+PBS	B-DISO
+II	O
+).	O
+
+More	O
+importantly	O
+,	O
+this	O
+classifier	O
+accurately	O
+distinguished	O
+acute	O
+SARS	B-DISO
+from	O
+fever	B-PROC
+and	O
+influenza	B-DISO
+with	O
+100	O
+%	O
+specificity	O
+(	O
+187	O
+of	O
+187	O
+).	O
+
+Their	O
+blood	B-ANAT
+sera	B-COMP
+and	O
+secretions	B-ANAT
+of	O
+the	O
+nasal	B-ANAT
+cavity	I-ANAT
+were	O
+examined	O
+in	O
+the	O
+indirect	O
+hemagglutination	B-PROC
+(	O
+IHA	O
+)	O
+test	O
+with	O
+dried	B-ANAT
+standard	O
+erythrocyte	B-ANAT
+diagnostic	O
+preparations	O
+.	O
+
+The	O
+frequent	O
+substitution	O
+of	O
+the	O
+external	O
+masks	O
+with	O
+a	O
+new	O
+one	O
+will	O
+improve	O
+the	O
+filtering	O
+activity	O
+against	O
+droplets	O
+produced	O
+by	O
+cough	B-DISO
+or	O
+sneezes	O
+of	O
+the	O
+patient	O
+.	O
+
+When	O
+corrosion	O
+,	O
+bleaching	O
+or	O
+gas	B-ENZY
+production	O
+have	O
+to	O
+be	O
+avoided	O
+,	O
+chlorine	B-CHED
+compounds	O
+may	O
+be	O
+substituted	O
+by	O
+phenolic	O
+detergent	B-CHED
+disinfectants	B-CHED
+.	O
+
+TITLE	O
+:	O
+Quaternary	O
+structure	O
+of	O
+the	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+(	O
+SARS	B-DISO
+)	O
+coronavirus	B-SPEC
+main	O
+protease	O
+.	O
+
+Twenty	O
+-	O
+seven	O
+of	O
+the	O
+49	O
+factors	O
+under	O
+study	O
+were	O
+significantly	O
+associated	O
+with	O
+SARS	B-DISO
+infection	B-DISO
+,	O
+in	O
+which	O
+22	O
+factors	O
+were	O
+protective	O
+,	O
+and	O
+the	O
+other	O
+5	O
+were	O
+risk	O
+factors	O
+.	O
+
+ABSTRACT	O
+:	O
+To	O
+evaluate	O
+the	O
+acute	O
+physiology	O
+and	O
+chronic	O
+health	O
+evaluation	O
+III	O
+(	O
+APACHE	O
+III	O
+)	O
+and	O
+acute	O
+lung	B-ANAT
+injury	O
+(	O
+ALI	O
+)	O
+scale	O
+in	O
+the	O
+severity	O
+and	O
+prognosis	O
+of	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+(	O
+SARS	B-DISO
+).	O
+
+The	O
+score	O
+of	O
+APACHE	O
+III	O
+in	O
+the	O
+SARS	B-DISO
+are	O
+correlated	O
+with	O
+the	O
+patient	O
+'	O
+s	O
+condition	B-DISO
+and	O
+prognosis	O
+.	O
+
+ABSTRACT	O
+:	O
+To	O
+understand	O
+the	O
+risk	O
+factors	O
+on	O
+severe	O
+acute	O
+respiratory	O
+syndrome	O
+(	O
+SARS	B-DISO
+)	O
+among	O
+their	O
+contacts	O
+and	O
+to	O
+develop	O
+effective	O
+strategy	O
+for	O
+its	O
+control	O
+.	O
+
+Among	O
+colleagues	O
+and	O
+classmates	O
+of	O
+SARS	B-DISO
+patients	O
+,	O
+the	O
+infection	B-DISO
+rate	O
+was	O
+0	O
+.	O
+36	O
+%	O
+versus	O
+31	O
+.	O
+71	O
+%	O
+in	O
+contacts	O
+among	O
+families	O
+and	O
+hospitals	O
+,	O
+0	O
+.	O
+77	O
+%	O
+in	O
+schools	O
+.	O
+
+No	O
+one	O
+was	O
+infected	O
+among	O
+459	O
+close	O
+contacts	O
+to	O
+SARS	B-DISO
+in	O
+the	O
+working	O
+unit	O
+.	O
+
+TITLE	O
+:	O
+[	O
+Dynamics	O
+of	O
+peripheral	B-ANAT
+blood	I-ANAT
+B	B-ANAT
+lymphocytes	I-ANAT
+and	O
+natural	B-ANAT
+killer	I-ANAT
+cells	I-ANAT
+in	O
+patients	O
+with	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+].	O
+
+The	O
+absolute	O
+numbers	O
+of	O
+peripheral	B-ANAT
+blood	I-ANAT
+B	B-ANAT
+lymphocytes	I-ANAT
+and	O
+NK	B-ANAT
+cells	I-ANAT
+in	O
+602	O
+serial	O
+samples	O
+from	O
+240	O
+patients	O
+with	O
+SARS	B-DISO
+were	O
+counted	O
+,	O
+using	O
+flow	O
+cytometry	O
+,	O
+and	O
+compared	O
+with	O
+that	O
+of	O
+normal	O
+population	O
+.	O
+
+The	O
+absolute	O
+numbers	O
+of	O
+peripheral	B-ANAT
+blood	I-ANAT
+B	B-ANAT
+lymphocytes	I-ANAT
+and	O
+NK	B-ANAT
+cells	I-ANAT
+were	O
+associated	O
+with	O
+the	O
+severity	O
+of	O
+the	O
+disease	O
+,	O
+and	O
+detection	O
+of	O
+these	O
+two	O
+kinds	O
+of	O
+cells	B-COMP
+was	O
+useful	O
+for	O
+predicting	O
+the	O
+prognosis	O
+of	O
+SARS	B-DISO
+.	O
+
+CAP	B-DISO
+results	O
+in	O
+more	O
+than	O
+10	O
+million	O
+visits	O
+to	O
+physicians	O
+,	O
+64	O
+million	O
+days	O
+of	O
+restricted	O
+activity	O
+,	O
+and	O
+600	O
+,	O
+000	O
+hospitalizations	O
+.	O
+
+This	O
+article	O
+discusses	O
+the	O
+epidemiology	O
+and	O
+bacterial	O
+causes	O
+of	O
+CAP	B-DISO
+in	O
+immunocompetent	O
+adults	O
+and	O
+the	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+coronavirus	B-SPEC
+.	O
+
+TITLE	O
+:	O
+Initial	O
+viral	O
+load	O
+and	O
+the	O
+outcomes	O
+of	O
+SARS	B-DISO
+.	O
+
+ABSTRACT	O
+:	O
+Severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+(	O
+SARS	B-DISO
+)	O
+is	O
+caused	O
+by	O
+a	O
+novel	B-SPEC
+coronavirus	I-SPEC
+.	O
+
+Thirty	O
+-	O
+two	O
+patients	O
+(	O
+24	O
+.	O
+1	O
+%)	O
+met	B-CHED
+the	O
+criteria	O
+for	O
+acute	O
+respiratory	O
+distress	O
+syndrome	O
+,	O
+and	O
+24	O
+patients	O
+(	O
+18	O
+.	O
+0	O
+%)	O
+died	B-PROC
+.	O
+
+ABSTRACT	O
+:	O
+The	O
+Greater	O
+Toronto	O
+Area	O
+(	O
+GTA	O
+)	O
+was	O
+considered	O
+a	O
+""""	O
+hot	O
+zone	O
+""""	O
+for	O
+severe	O
+acute	O
+respiratory	O
+syndrome	O
+(	O
+SARS	B-DISO
+)	O
+in	O
+2003	O
+.	O
+
+We	O
+compared	O
+HSC	B-COMP
+emergency	B-DISO
+department	O
+patient	O
+volumes	O
+,	O
+admission	O
+rates	O
+and	O
+length	O
+of	O
+stay	O
+in	O
+the	O
+emergency	B-DISO
+department	O
+in	O
+the	O
+baseline	O
+years	O
+of	O
+2000	O
+-	O
+2002	O
+(	O
+non	O
+-	O
+SARS	B-DISO
+years	O
+)	O
+with	O
+those	O
+in	O
+2003	O
+(	O
+SARS	B-DISO
+year	O
+).	O
+
+Real	O
+-	O
+time	O
+reverse	B-PROC
+transcription	I-PROC
+-	O
+PCR	O
+confirmed	O
+the	O
+LPS	B-DISO
+-	O
+induced	O
+up	O
+-	O
+regulation	O
+of	O
+selected	O
+genes	O
+identified	O
+by	O
+microarray	O
+analysis	O
+,	O
+including	O
+LIX	B-PRGE
+.	O
+
+The	O
+up	B-PROC
+-	I-PROC
+regulation	I-PROC
+of	O
+LIX	B-PRGE
+,	O
+tumor	B-PRGE
+necrosis	I-PRGE
+factor	I-PRGE
+alpha	I-PRGE
+,	O
+and	O
+macrophage	B-PRGE
+inflammatory	I-PRGE
+protein	B-CHED
+2	I-PRGE
+was	O
+confirmed	O
+at	O
+the	O
+protein	B-CHED
+level	O
+by	O
+enzyme	O
+-	O
+linked	O
+immunosorbent	O
+assays	O
+.	O
+
+ABSTRACT	O
+:	O
+Macrophages	B-ANAT
+are	O
+critical	O
+for	O
+natural	O
+immunity	O
+and	O
+play	O
+a	O
+central	O
+role	O
+in	O
+specific	O
+acquired	B-PROC
+immunity	I-PROC
+.	O
+
+TITLE	O
+:	O
+[	O
+Legionella	B-SPEC
+pneumonia	I-DISO
+which	O
+occurred	O
+in	O
+a	O
+private	O
+whirlpool	O
+bath	O
+user	O
+].	O
+
+Her	O
+respiratory	B-DISO
+failure	I-DISO
+was	O
+gradually	O
+improved	O
+and	O
+she	O
+was	O
+discharged	O
+on	O
+the	O
+44	O
+the	O
+hospital	O
+day	O
+.	O
+
+This	O
+is	O
+the	O
+first	O
+adult	O
+case	O
+of	O
+Legionella	B-DISO
+pneumophila	I-DISO
+pneumonia	I-DISO
+infected	O
+from	O
+a	O
+private	O
+whirlpool	O
+bath	O
+confirmed	O
+by	O
+genetic	O
+analysis	O
+.	O
+
+ABSTRACT	O
+:	O
+Severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+(	O
+SARS	B-DISO
+)	O
+struck	B-DISO
+1755	O
+patients	O
+in	O
+Hong	O
+Kong	O
+and	O
+developed	O
+into	O
+a	O
+global	O
+health	O
+crisis	O
+.	O
+
+A	O
+new	O
+strain	O
+of	O
+coronavirus	B-SPEC
+was	O
+identified	O
+as	O
+the	O
+causative	O
+agent	O
+.	O
+
+Furthermore	O
+,	O
+these	O
+statistical	O
+methods	O
+were	O
+applied	O
+to	O
+prove	O
+that	O
+the	O
+effects	O
+of	O
+anisomycin	B-CHED
+on	O
+programmed	O
+-	O
+1	O
+frameshifting	O
+are	O
+statistically	O
+significant	O
+.	O
+
+The	O
+current	O
+outbreak	O
+of	O
+avian	B-DISO
+influenza	I-DISO
+in	O
+South	O
+East	O
+Asia	O
+has	O
+resulted	O
+in	O
+a	O
+small	O
+number	O
+of	O
+human	B-SPEC
+deaths	B-PROC
+.	O
+
+ABSTRACT	O
+:	O
+SARS	B-DISO
+is	O
+a	O
+respiratory	B-DISO
+infection	I-DISO
+caused	O
+by	O
+Coronavirus	B-SPEC
+(	O
+Nidoviruses	B-SPEC
+,	O
+RNA	O
+)	O
+from	O
+which	O
+3	O
+groups	O
+are	O
+known	O
+.	O
+
+And	O
+group	O
+3	O
+corresponds	O
+to	O
+the	O
+avian	B-SPEC
+pathology	B-DISO
+....	O
+
+There	O
+is	O
+no	O
+evidence	O
+on	O
+interperson	O
+contagion	O
+from	O
+chicken	B-SPEC
+contagion	O
+,	O
+nor	O
+on	O
+food	O
+-	O
+borne	O
+contagion	O
+to	O
+humans	B-SPEC
+.	O
+
+The	O
+association	O
+of	O
+Impact	O
+of	O
+Event	O
+Scale	O
+scores	O
+to	O
+job	O
+role	O
+and	O
+contact	O
+with	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+patients	O
+was	O
+tested	O
+by	O
+analysis	O
+of	O
+variance	O
+.	O
+
+RESULTS	O
+:	O
+Higher	O
+Impact	O
+of	O
+Event	O
+Scale	O
+scores	O
+are	O
+found	O
+in	O
+nurses	O
+and	O
+healthcare	O
+workers	O
+having	O
+contact	O
+with	O
+patients	O
+with	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+.	O
+
+These	O
+studies	O
+revealed	O
+that	O
+PLpro	O
+can	O
+cleave	O
+in	O
+trans	O
+at	O
+the	O
+three	O
+predicted	O
+cleavage	B-PROC
+sites	O
+and	O
+that	O
+it	O
+requires	O
+membrane	B-COMP
+association	O
+to	O
+process	O
+the	O
+nsp3	B-PRGE
+/	I-PRGE
+4	I-PRGE
+cleavage	B-PROC
+site	O
+.	O
+
+The	O
+results	O
+are	O
+promising	O
+for	O
+the	O
+prospects	O
+of	O
+S	O
+-	O
+gene	O
+exchange	O
+for	O
+IBV	B-SPEC
+vaccine	O
+development	B-PROC
+.	O
+
+TITLE	O
+:	O
+Overexpression	B-PROC
+of	O
+7a	O
+,	O
+a	O
+protein	B-CHED
+specifically	O
+encoded	O
+by	O
+the	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+coronavirus	B-SPEC
+,	O
+induces	O
+apoptosis	B-PATH
+via	O
+a	O
+caspase	B-PRGE
+-	O
+dependent	O
+pathway	B-PROC
+.	O
+
+ABSTRACT	O
+:	O
+A	O
+novel	O
+coronavirus	O
+(	O
+SCoV	O
+)	O
+is	O
+the	O
+etiological	O
+agent	O
+of	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+.	O
+
+This	O
+simple	O
+and	O
+highly	O
+specific	O
+assay	O
+can	O
+be	O
+used	O
+to	O
+monitor	O
+the	O
+activity	O
+of	O
+the	O
+SCoV	B-PRGE
+3C	I-PRGE
+-	I-PRGE
+like	I-PRGE
+protease	I-PRGE
+,	O
+and	O
+it	O
+has	O
+the	O
+potential	O
+to	O
+be	O
+used	O
+for	O
+screening	O
+specific	O
+inhibitors	B-CHED
+.	O
+
+We	O
+sought	O
+to	O
+determine	O
+whether	O
+bronchoalveolar	B-ANAT
+lavage	I-ANAT
+fluid	I-ANAT
+(	O
+BALF	O
+)	O
+from	O
+patients	O
+with	O
+lung	B-ANAT
+injury	O
+contained	O
+mediators	O
+that	O
+would	O
+activate	O
+procollagen	B-PRGE
+I	I-PRGE
+promoter	I-PRGE
+and	O
+if	O
+this	O
+activation	O
+predicted	O
+important	O
+clinical	O
+outcomes	O
+.	O
+
+Bronchoalveolar	B-ANAT
+lavage	I-ANAT
+fluid	I-ANAT
+was	O
+collected	O
+within	O
+48	O
+h	O
+of	O
+intubation	O
+from	O
+ALI	O
+/	O
+ARDS	B-DISO
+patients	O
+.	O
+
+Twenty	O
+-	O
+nine	O
+ARDS	B-DISO
+patients	O
+,	O
+nine	O
+negative	O
+and	O
+six	O
+positive	O
+controls	O
+were	O
+enrolled	O
+.	O
+
+BALF	O
+from	O
+ARDS	B-DISO
+patients	O
+induced	O
+41	O
+%	O
+greater	O
+procollagen	B-PRGE
+I	I-PRGE
+promoter	I-PRGE
+activation	O
+than	O
+that	O
+from	O
+negative	O
+controls	O
+(	O
+p	O
+<	O
+0	O
+.	O
+05	O
+)	O
+and	O
+a	O
+TGF	B-PRGE
+-	I-PRGE
+beta1	I-PRGE
+blocking	B-DISO
+antibody	B-COMP
+significantly	O
+reduced	O
+this	O
+activation	O
+in	O
+ARDS	B-DISO
+patients	O
+.	O
+
+Procollagen	B-PRGE
+I	I-PRGE
+promoter	I-PRGE
+activation	O
+was	O
+not	O
+associated	O
+with	O
+mortality	O
+;	O
+however	O
+,	O
+lower	O
+TGF	B-PRGE
+-	I-PRGE
+beta1	I-PRGE
+levels	O
+were	O
+associated	O
+with	O
+more	O
+ventilator	O
+-	O
+free	O
+and	O
+ICU	O
+-	O
+free	O
+days	O
+.	O
+
+TITLE	O
+:	O
+A	O
+branching	O
+model	O
+for	O
+the	O
+spread	O
+of	O
+infectious	B-DISO
+animal	B-DISO
+diseases	I-DISO
+in	O
+varying	O
+environments	O
+.	O
+
+Femoral	B-ANAT
+and	O
+jugular	B-ANAT
+veins	I-ANAT
+,	O
+and	O
+femoral	B-ANAT
+and	O
+carotid	B-ANAT
+arteries	I-ANAT
+were	O
+instrumented	O
+for	O
+the	O
+AV	O
+-	O
+ECMO	O
+circuit	O
+,	O
+systemic	O
+and	O
+pulmonary	B-ANAT
+artery	I-ANAT
+blood	I-ANAT
+pressure	O
+monitoring	O
+,	O
+gas	B-ENZY
+exchange	O
+,	O
+and	O
+cardiac	B-ANAT
+output	O
+determination	O
+(	O
+thermodilution	O
+technique	O
+).	O
+
+The	O
+outcome	O
+measures	O
+were	O
+the	O
+degree	O
+of	O
+inotropic	O
+and	O
+ventilator	O
+support	O
+needed	O
+to	O
+maintain	O
+hemodynamic	B-PROC
+stability	O
+and	O
+normocapnia	O
+,	O
+respectively	O
+.	O
+
+Traditional	O
+approaches	O
+to	O
+mechanical	O
+ventilatory	O
+support	O
+of	O
+patients	O
+with	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+require	O
+adaptation	B-PROC
+of	O
+the	O
+patient	O
+to	O
+the	O
+mechanical	O
+ventilator	O
+using	O
+heavy	O
+sedation	B-DISO
+and	O
+even	O
+muscle	B-DISO
+relaxation	I-DISO
+.	O
+
+The	O
+virus	B-SPEC
+,	O
+SARS	B-DISO
+-	O
+CoV	O
+,	O
+differs	O
+from	O
+the	O
+previously	O
+described	O
+human	B-SPEC
+coronaviruses	O
+,	O
+229E	O
+and	O
+OC43	O
+.	O
+
+Various	O
+experiments	O
+were	O
+carried	O
+out	O
+,	O
+such	O
+as	O
+the	O
+immobilization	O
+efficiency	O
+and	O
+hybridization	B-PROC
+assays	O
+to	O
+test	O
+the	O
+modified	O
+slides	O
+,	O
+which	O
+were	O
+then	O
+used	O
+tentatively	O
+in	O
+the	O
+preparation	O
+of	O
+microarrays	O
+for	O
+SARS	B-DISO
+coronavirus	B-SPEC
+detection	O
+.	O
+
+CONCLUSIONS	O
+:	O
+The	O
+modified	O
+slide	O
+surface	O
+is	O
+satisfactory	O
+to	O
+immobilize	O
+unmodified	O
+oligonucleotide	B-CHED
+by	O
+covalent	B-PROC
+binding	B-FUNC
+,	O
+which	O
+enhances	O
+not	O
+only	O
+the	O
+sensitivity	O
+of	O
+the	O
+prepared	O
+oligonucleotide	B-CHED
+microarray	O
+but	O
+also	O
+the	O
+binding	B-FUNC
+of	O
+the	O
+oligonucleotide	B-CHED
+to	O
+the	O
+slide	O
+surface	O
+.	O
+
+ABSTRACT	O
+:	O
+To	O
+investigate	O
+the	O
+dynamic	O
+changes	O
+of	O
+the	O
+antibody	B-COMP
+specific	O
+to	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+(	O
+SARS	B-DISO
+)	O
+coronavirus	B-SPEC
+in	O
+convalescents	O
+who	O
+have	O
+suffered	B-DISO
+from	O
+SARS	B-DISO
+.	O
+
+A	O
+curve	O
+of	O
+level	O
+of	O
+IgG	B-PRGE
+was	O
+drawn	O
+to	O
+describe	O
+the	O
+change	O
+by	O
+the	O
+specific	O
+month	O
+in	O
+the	O
+year	O
+.	O
+
+The	O
+mean	O
+IgG	O
+level	O
+peaked	O
+in	O
+July	O
+(	O
+1	O
+.	O
+203	O
+),	O
+about	O
+35	O
+days	O
+after	O
+discharge	B-ANAT
+,	O
+and	O
+then	O
+gradually	O
+declined	O
+to	O
+0	O
+.	O
+857	O
+in	O
+December	O
+,	O
+a	O
+decline	O
+by	O
+27	O
+.	O
+3	O
+%.	O
+
+ABSTRACT	O
+:	O
+The	O
+etiologic	O
+agent	O
+of	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+(	O
+SARS	B-DISO
+)	O
+has	O
+been	O
+confirmed	O
+to	O
+be	O
+a	O
+novel	B-SPEC
+coronavirus	I-SPEC
+(	O
+CoV	B-SPEC
+),	O
+namely	O
+SARS	B-DISO
+-	O
+CoV	B-SPEC
+.	O
+Developing	O
+safe	O
+and	O
+effective	O
+SARS	B-DISO
+-	O
+CoV	O
+vaccines	O
+is	O
+essential	O
+for	O
+us	O
+to	O
+prevent	O
+the	O
+possible	O
+reemergence	O
+of	O
+its	O
+epidemic	O
+.	O
+
+RESULTS	O
+:	O
+Rapid	O
+and	O
+potent	O
+humoral	B-PROC
+immune	I-PROC
+responses	I-PROC
+were	O
+induced	O
+by	O
+the	O
+inactivated	O
+SARS	B-DISO
+-	O
+CoV	O
+vaccine	O
+in	O
+all	O
+the	O
+eight	O
+test	O
+rabbits	B-SPEC
+.	O
+
+Cross	O
+neutralization	O
+response	O
+existed	O
+between	O
+SARS	B-PRGE
+-	I-PRGE
+CoV	I-PRGE
+F69	I-PRGE
+strain	O
+and	O
+Z2	O
+-	O
+Y3	O
+strain	O
+.	O
+
+TITLE	O
+:	O
+Diagnosis	O
+and	O
+pharmacotherapy	O
+of	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+:	O
+what	O
+have	O
+we	O
+learnt	O
+?	O
+
+ABSTRACT	O
+:	O
+In	O
+2003	O
+,	O
+the	O
+onset	O
+of	O
+severe	O
+acute	O
+respiratory	O
+syndrome	O
+(	O
+SARS	B-DISO
+)	O
+caused	O
+worldwide	O
+chaos	B-SPEC
+.	O
+
+Medline	O
+reviews	O
+and	O
+reviews	O
+of	O
+infection	B-DISO
+control	O
+and	O
+infectious	B-DISO
+diseases	I-DISO
+journals	O
+were	O
+used	O
+for	O
+this	O
+period	O
+.	O
+
+The	O
+latest	O
+guidelines	O
+and	O
+publications	O
+on	O
+antimicrobial	B-CHED
+resistance	B-PROC
+,	O
+nursing	B-PROC
+or	O
+infection	B-DISO
+control	O
+professional	O
+staffing	O
+,	O
+West	B-DISO
+Nile	I-DISO
+virus	I-DISO
+,	O
+and	O
+Severe	B-DISO
+Acute	I-DISO
+Respiratory	I-DISO
+Syndrome	I-DISO
+(	O
+SARS	B-DISO
+)	O
+are	O
+included	O
+.	O
+
+TITLE	O
+:	O
+Sepsis	B-SPEC
+strategies	O
+:	O
+an	O
+ICU	O
+package	O
+?	O
+
+Although	O
+a	O
+specific	O
+antiviral	B-CHED
+agent	I-CHED
+and	O
+vaccines	O
+for	O
+SARS	B-DISO
+are	O
+not	O
+available	O
+at	O
+the	O
+time	O
+of	O
+writing	O
+,	O
+a	O
+standard	O
+treatment	O
+protocol	O
+for	O
+SARS	B-DISO
+has	O
+been	O
+developed	O
+.	O
+
+Maintaining	O
+personal	O
+hygiene	O
+and	O
+frequent	O
+hand	O
+washing	O
+can	O
+also	O
+reduce	O
+the	O
+risk	O
+of	O
+infection	B-DISO
+.	O
+
+Increasingly	O
+we	O
+have	O
+found	O
+that	O
+proteomic	O
+approaches	O
+allow	O
+the	O
+rapid	O
+analysis	O
+of	O
+a	O
+whole	O
+plethora	O
+of	O
+cell	B-PATH
+cycle	I-PATH
+proteins	B-CHED
+that	O
+may	O
+be	O
+affected	O
+by	O
+virus	B-DISO
+infection	I-DISO
+.	O
+
+Rapid	O
+progress	O
+has	O
+been	O
+made	O
+in	O
+understanding	O
+the	O
+clinical	O
+disease	O
+of	O
+SARS	B-DISO
+in	O
+adults	O
+and	O
+children	O
+.	O
+
+Such	O
+variants	O
+will	O
+be	O
+platforms	O
+for	O
+the	O
+safe	O
+growth	B-PROC
+of	O
+SARS	B-DISO
+-	O
+CoV	O
+and	O
+candidates	O
+for	O
+live	O
+attenuated	O
+vaccines	O
+.	O
+
+Numerous	O
+approaches	O
+to	O
+the	O
+development	B-PROC
+of	O
+SARS	B-DISO
+-	O
+CoV	O
+vaccines	O
+have	O
+been	O
+undertaken	O
+,	O
+and	O
+there	O
+is	O
+evidence	O
+that	O
+antibodies	B-COMP
+to	O
+the	O
+spike	O
+protein	B-CHED
+may	O
+be	O
+protective	O
+from	O
+replication	O
+and	O
+pathology	B-DISO
+in	O
+animal	B-SPEC
+models	O
+.	O
+
+ABSTRACT	O
+:	O
+This	O
+special	O
+supplement	O
+of	O
+Nature	O
+Medicine	O
+,	O
+directed	O
+at	O
+the	O
+topic	O
+of	O
+emerging	B-DISO
+infectious	I-DISO
+diseases	I-DISO
+,	O
+is	O
+very	O
+timely	O
+.	O
+
+Recent	O
+high	O
+-	O
+profile	O
+outbreaks	O
+have	O
+highlighted	O
+the	O
+global	O
+risk	O
+that	O
+infectious	B-DISO
+agents	O
+,	O
+both	O
+new	O
+and	O
+old	O
+,	O
+represent	O
+for	O
+society	O
+.	O
+
+Diseases	O
+such	O
+as	O
+drug	O
+-	O
+resistant	O
+malaria	B-PATH
+continue	O
+to	O
+be	O
+threats	O
+.	O
+
+There	O
+is	O
+a	O
+need	O
+to	O
+enhance	O
+global	O
+resources	O
+to	O
+investigate	O
+,	O
+detect	O
+and	O
+respond	O
+to	O
+emerging	O
+infections	B-DISO
+,	O
+and	O
+to	O
+appropriately	O
+coordinate	O
+and	O
+direct	O
+research	O
+efforts	O
+to	O
+meet	O
+the	O
+challenges	O
+presented	O
+by	O
+these	O
+diseases	O
+.	O
+
+ABSTRACT	O
+:	O
+Severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+(	O
+SARS	B-DISO
+)	O
+was	O
+caused	O
+by	O
+a	O
+previously	O
+unrecognized	O
+animal	O
+coronavirus	B-SPEC
+that	O
+exploited	O
+opportunities	O
+provided	O
+by	O
+'	O
+wet	O
+markets	O
+'	O
+in	O
+southern	O
+China	O
+to	O
+adapt	O
+to	O
+become	O
+a	O
+virus	B-SPEC
+readily	O
+transmissible	O
+between	O
+humans	B-SPEC
+.	O
+
+Features	O
+independently	O
+predictive	O
+of	O
+dengue	B-DISO
+were	O
+modeled	O
+by	O
+multivariate	O
+logistic	O
+regression	O
+to	O
+create	O
+a	O
+diagnostic	O
+tool	O
+with	O
+100	O
+%	O
+specificity	O
+for	O
+dengue	B-DISO
+.	O
+
+The	O
+combination	O
+of	O
+interferon	B-PRGE
+plus	O
+corticosteroids	B-CHED
+appears	O
+to	O
+be	O
+better	O
+than	O
+corticosteroids	B-CHED
+alone	O
+.	O
+
+For	O
+this	O
+study	O
+,	O
+72	O
+Sprague	B-SPEC
+-	I-SPEC
+Dawley	I-SPEC
+rats	I-SPEC
+weighing	O
+250	O
+to	O
+300	O
+g	O
+were	O
+subjected	O
+to	O
+a	O
+model	O
+of	O
+uncontrolled	O
+hemorrhagic	B-DISO
+shock	I-DISO
+for	O
+150	O
+minutes	O
+.	O
+
+These	O
+data	O
+suggest	O
+that	O
+limiting	O
+inducible	O
+NO	B-PRGE
+synthase	I-PRGE
+-	O
+generated	O
+NO	O
+availability	O
+with	O
+the	O
+exogenous	O
+NO	O
+donor	B-CHED
+,	O
+sodium	B-CHED
+nitroprusside	I-CHED
+,	O
+may	O
+reduce	O
+lung	B-ANAT
+injury	O
+after	O
+severe	O
+hemorrhage	B-DISO
+,	O
+possibly	O
+,	O
+among	O
+other	O
+effects	O
+,	O
+by	O
+downregulating	O
+the	O
+expression	B-PROC
+of	O
+inflammatory	O
+cytokines	O
+.	O
+
+ABSTRACT	O
+:	O
+Under	O
+a	O
+new	O
+accreditation	O
+standard	O
+,	O
+EDs	O
+and	O
+all	O
+departments	O
+must	O
+be	O
+prepared	O
+to	O
+handle	O
+an	O
+influx	O
+,	O
+or	O
+the	O
+risk	O
+of	O
+an	O
+influx	O
+,	O
+of	O
+infectious	B-DISO
+patients	O
+.	O
+
+The	O
+study	O
+shows	O
+that	O
+N	B-PRGE
+protein	I-PRGE
+of	O
+SARS	B-PRGE
+-	I-PRGE
+CoV	I-PRGE
+not	O
+only	O
+is	O
+an	O
+important	O
+B	B-ANAT
+cell	I-ANAT
+immunogen	B-CHED
+,	O
+but	O
+also	O
+can	O
+elicit	O
+broad	O
+-	O
+based	O
+cellular	B-PROC
+immune	I-PROC
+responses	I-PROC
+.	O
+
+The	O
+ectodomain	O
+of	O
+the	O
+S	B-PRGE
+glycoprotein	I-PRGE
+is	O
+localized	O
+on	O
+the	O
+surface	O
+of	O
+CHO	B-FUNC
+-	O
+SG	O
+cells	B-COMP
+with	O
+N	O
+-	O
+acetyl	B-CHED
+-	O
+glucosamine	B-CHED
+-	O
+terminated	O
+carbohydrate	B-CHED
+structure	O
+.	O
+
+CHO	B-FUNC
+-	O
+SG	O
+cells	B-COMP
+associated	O
+tightly	O
+with	O
+Vero	O
+E6	O
+cells	B-COMP
+,	O
+a	O
+SARS	B-PRGE
+-	I-PRGE
+CoV	I-PRGE
+receptor	I-PRGE
+(	O
+ACE2	B-PRGE
+)	O
+expressing	O
+cell	B-COMP
+-	O
+line	O
+,	O
+and	O
+the	O
+interaction	O
+remained	O
+stable	O
+under	O
+highly	O
+stringent	O
+condition	B-DISO
+(	O
+1M	O
+NaCl	B-CHED
+).	O
+
+We	O
+find	O
+that	O
+some	O
+normal	O
+human	B-SPEC
+subjects	O
+expire	O
+many	O
+more	O
+bioaerosol	O
+particles	O
+than	O
+other	O
+individuals	O
+during	O
+quiet	O
+breathing	B-PROC
+and	O
+therefore	O
+bear	B-SPEC
+the	O
+burden	O
+of	O
+production	O
+of	O
+exhaled	B-PROC
+bioaerosols	O
+.	O
+
+ABSTRACT	O
+:	O
+Using	O
+paired	O
+serum	B-COMP
+samples	O
+obtained	O
+from	O
+patients	O
+with	O
+illness	O
+associated	O
+with	O
+increases	O
+in	O
+anti	B-PRGE
+-	I-PRGE
+human	I-PRGE
+coronavirus	I-PRGE
+OC43	I-PRGE
+(	O
+HCoV	B-SPEC
+-	I-SPEC
+OC43	I-SPEC
+)	O
+or	O
+anti	O
+-	O
+HCoV	B-SPEC
+-	I-SPEC
+229E	I-SPEC
+antibodies	B-COMP
+,	O
+we	O
+examined	O
+the	O
+possibility	O
+of	O
+false	O
+-	O
+positive	O
+results	O
+detected	O
+in	O
+a	O
+recombinant	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+(	O
+SARS	B-DISO
+)-	O
+associated	O
+coronavirus	B-SPEC
+(	O
+SARS	B-DISO
+-	O
+CoV	O
+)	O
+nucleocapsid	B-COMP
+protein	B-CHED
+immunoglobulin	B-PROC
+G	B-PROC
+enzyme	I-PROC
+-	O
+linked	O
+immunosorbent	O
+assay	O
+(	O
+ELISA	O
+).	O
+
+Being	O
+a	O
+healthcare	O
+worker	O
+,	O
+severity	O
+of	O
+SARS	B-DISO
+symptoms	O
+,	O
+steroid	B-CHED
+dosage	O
+,	O
+and	O
+social	O
+support	O
+accounted	O
+for	O
+a	O
+portion	O
+of	O
+variances	O
+of	O
+different	O
+measures	O
+.	O
+
+It	O
+is	O
+characterized	O
+by	O
+the	O
+acute	O
+onset	O
+of	O
+hypoxemia	O
+with	O
+radiographic	O
+infiltrates	B-DISO
+consistent	O
+with	O
+pulmonary	B-DISO
+edema	I-DISO
+,	O
+without	O
+elevations	O
+in	O
+the	O
+pulmonary	B-ANAT
+capillary	I-ANAT
+wedge	O
+pressure	O
+.	O
+
+Interest	O
+in	O
+this	O
+syndrome	B-DISO
+has	O
+recently	O
+been	O
+renewed	O
+as	O
+the	O
+rate	O
+of	O
+other	O
+perioperative	O
+complications	O
+has	O
+declined	O
+.	O
+
+TITLE	O
+:	O
+[	O
+Pre	O
+-	O
+hospital	O
+systematic	O
+treatment	O
+for	O
+patients	O
+with	O
+severe	O
+acute	O
+organophosphorus	B-CHED
+pesticide	I-CHED
+poisoning	O
+].	O
+
+Antidotes	B-CHED
+including	O
+pralidoxime	B-CHED
+chloride	I-CHED
+and	O
+atropine	B-CHED
+were	O
+used	O
+simultaneously	O
+based	O
+on	O
+the	O
+patients	O
+'	O
+conditions	O
+.	O
+
+TITLE	O
+:	O
+Induction	O
+of	O
+IL	B-FUNC
+-	I-FUNC
+8	I-FUNC
+release	B-PATH
+in	O
+lung	B-ANAT
+cells	B-COMP
+via	O
+activator	B-PRGE
+protein	I-PRGE
+-	I-PRGE
+1	I-PRGE
+by	O
+recombinant	O
+baculovirus	B-SPEC
+displaying	O
+severe	O
+acute	O
+respiratory	O
+syndrome	O
+-	O
+coronavirus	B-SPEC
+spike	O
+proteins	B-CHED
+:	O
+identification	O
+of	O
+two	O
+functional	O
+regions	O
+.	O
+
+TITLE	O
+:	O
+Chemokines	O
+in	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+.	O
+
+Chemokines	O
+and	O
+their	O
+receptors	O
+are	O
+involved	O
+in	O
+the	O
+pathogenesis	B-DISO
+of	O
+several	O
+diseases	O
+.	O
+
+Acute	O
+lung	B-ANAT
+injury	O
+that	O
+clinically	O
+manifests	O
+as	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+(	O
+ARDS	B-DISO
+)	O
+is	O
+caused	O
+by	O
+an	O
+uncontrolled	O
+systemic	O
+inflammatory	B-DISO
+response	I-DISO
+resulting	O
+from	O
+clinical	O
+events	O
+including	O
+major	O
+surgery	O
+,	O
+trauma	O
+,	O
+multiple	O
+transfusions	O
+,	O
+severe	O
+burns	O
+,	O
+pancreatitis	B-DISO
+,	O
+and	O
+sepsis	B-DISO
+.	O
+
+Systemic	B-DISO
+inflammatory	I-DISO
+response	I-DISO
+syndrome	I-DISO
+involves	O
+activation	O
+of	O
+alveolar	B-ANAT
+macrophages	I-ANAT
+and	O
+sequestered	O
+neutrophils	B-ANAT
+in	O
+the	O
+lung	B-ANAT
+.	O
+
+TITLE	O
+:	O
+Clinical	O
+issues	O
+and	O
+research	O
+in	O
+respiratory	B-DISO
+failure	I-DISO
+from	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+.	O
+
+TITLE	O
+:	O
+[	O
+Severe	O
+imported	O
+malaria	B-PATH
+in	O
+adults	O
+:	O
+a	O
+retrospective	O
+study	O
+of	O
+32	O
+cases	O
+admitted	O
+to	O
+intensive	O
+care	O
+units	O
+].	O
+
+All	O
+patients	O
+acquired	O
+falciparum	B-DISO
+malaria	I-DISO
+in	O
+sub	O
+-	O
+Sahara	O
+Africa	O
+and	O
+25	O
+patients	O
+were	O
+nonimmune	O
+.	O
+
+The	O
+mean	O
+time	O
+from	O
+symptom	B-DISO
+onset	O
+and	O
+treatment	O
+initiation	O
+was	O
+6	O
+days	O
+.	O
+
+Mean	O
+parasitemia	B-DISO
+on	O
+admission	O
+was	O
+15	O
+%.	O
+
+Severe	O
+imported	O
+malaria	B-PATH
+remains	O
+associated	O
+with	O
+a	O
+bad	O
+outcome	O
+.	O
+
+However	O
+,	O
+the	O
+precise	O
+mechanism	O
+of	O
+MHV	B-SPEC
+persistence	O
+in	O
+the	O
+CNS	B-CHED
+remains	O
+elusive	O
+.	O
+
+Significantly	O
+,	O
+overexpression	B-PROC
+of	O
+Bcl	B-PRGE
+-	I-PRGE
+xL	I-PRGE
+alone	O
+was	O
+sufficient	O
+to	O
+convert	O
+acute	O
+to	O
+persistent	O
+,	O
+nonproductive	O
+infection	B-DISO
+in	O
+CG	O
+-	O
+4	O
+cells	B-COMP
+.	O
+
+The	O
+data	O
+also	O
+suggest	O
+that	O
+direct	O
+virus	B-SPEC
+-	O
+host	B-COMP
+cell	I-COMP
+interaction	O
+is	O
+one	O
+of	O
+the	O
+underlying	O
+mechanisms	O
+that	O
+regulate	O
+viral	O
+persistence	O
+in	O
+CNS	B-CHED
+cells	B-COMP
+.	O
+
+TITLE	O
+:	O
+Severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+coronavirus	B-DISO
+infection	I-DISO
+of	O
+golden	O
+Syrian	B-SPEC
+hamsters	I-SPEC
+.	O
+
+Hamsters	B-SPEC
+challenged	O
+with	O
+SARS	B-DISO
+CoV	O
+at	O
+day	O
+28	O
+p	O
+.	O
+i	O
+.	O
+
+were	O
+completely	O
+protected	O
+from	O
+virus	B-PROC
+replication	I-PROC
+and	O
+accompanying	O
+pathology	B-DISO
+in	O
+the	O
+respiratory	B-ANAT
+tract	I-ANAT
+.	O
+
+Potential	O
+pathophysiologic	O
+mechanisms	O
+linking	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+,	O
+inhaled	B-PROC
+nitric	B-CHED
+oxide	I-CHED
+,	O
+methemoglobin	B-PRGE
+,	O
+and	O
+carboxyhemoglobin	O
+are	O
+discussed	O
+.	O
+
+In	O
+addition	O
+,	O
+human	B-SPEC
+coronavirus	I-SPEC
+(	O
+hCoV	O
+)	O
+groups	O
+I	O
+(	O
+229E	O
+-	O
+like	O
+)	O
+and	O
+II	O
+(	O
+OC43	O
+-	O
+like	O
+),	O
+as	O
+well	O
+as	O
+the	O
+new	O
+human	B-SPEC
+metapneumovirus	I-SPEC
+(	O
+hMPV	B-SPEC
+),	O
+types	O
+A	O
+and	O
+B	O
+,	O
+were	O
+searched	O
+for	O
+by	O
+RT	O
+-	O
+PCR	O
+alone	O
+.	O
+
+When	O
+results	O
+obtained	O
+by	O
+both	O
+methods	O
+were	O
+added	O
+,	O
+the	O
+overall	O
+percentage	O
+of	O
+patients	O
+positive	O
+for	O
+at	O
+least	O
+one	O
+respiratory	O
+virus	O
+peaked	O
+at	O
+44	O
+.	O
+2	O
+%,	O
+involving	O
+92	O
+/	O
+208	O
+patients	O
+(	O
+81	O
+pediatric	O
+,	O
+and	O
+11	O
+adults	O
+),	O
+while	O
+116	O
+patients	O
+(	O
+55	O
+.	O
+8	O
+%)	O
+were	O
+negative	O
+for	O
+any	O
+respiratory	O
+virus	B-SPEC
+tested	O
+.	O
+
+In	O
+lung	B-ANAT
+transplant	B-ANAT
+recipients	O
+,	O
+viruses	B-SPEC
+present	O
+in	O
+bronchoalveolar	O
+lavage	O
+appeared	O
+to	O
+be	O
+associated	O
+frequently	O
+with	O
+lower	B-DISO
+respiratory	I-DISO
+tract	I-DISO
+infections	I-DISO
+.	O
+
+the	O
+combination	O
+of	O
+immunological	O
+and	O
+molecular	O
+assays	O
+is	O
+the	O
+most	O
+sensitive	O
+approach	O
+to	O
+the	O
+diagnosis	O
+of	O
+respiratory	O
+viral	B-DISO
+infections	I-DISO
+;	O
+and	O
+infections	B-DISO
+caused	O
+by	O
+the	O
+less	O
+investigated	O
+hCoVs	O
+and	O
+hMPVs	O
+represent	O
+a	O
+fair	O
+proportion	O
+of	O
+respiratory	B-DISO
+infections	I-DISO
+.	O
+
+TITLE	O
+:	O
+An	O
+interferon	B-PRGE
+-	I-PRGE
+gamma	I-PRGE
+-	I-PRGE
+related	I-PRGE
+cytokine	B-DISO
+storm	I-DISO
+in	O
+SARS	B-DISO
+patients	O
+.	O
+
+The	O
+evaluation	O
+of	O
+a	O
+commercial	O
+recombinant	O
+nucleocapsid	B-COMP
+protein	B-CHED
+-	O
+based	O
+microtitre	O
+plate	O
+enzyme	O
+immunoassay	O
+,	O
+ELISARS	O
+is	O
+described	O
+.	O
+
+The	O
+implication	O
+of	O
+differences	O
+in	O
+antibody	B-PROC
+response	I-PROC
+to	O
+the	O
+nucleocapsid	O
+protein	B-CHED
+deserves	O
+further	O
+investigation	O
+.	O
+
+The	O
+model	O
+'	O
+s	O
+use	O
+in	O
+the	O
+design	O
+of	O
+strategies	O
+to	O
+minimize	O
+the	O
+risk	O
+of	O
+SARS	B-DISO
+in	O
+a	O
+previously	O
+unexposed	O
+community	O
+is	O
+demonstrated	O
+.	O
+
+The	O
+titer	O
+of	O
+serum	B-COMP
+neutralizing	O
+antibodies	B-COMP
+was	O
+up	O
+to	O
+1	O
+:	O
+640	O
+.	O
+
+In	O
+mice	B-SPEC
+immunized	O
+with	O
+adjuvants	B-CHED
+or	O
+PEG	B-CHED
+precipitated	O
+GZ50	O
+,	O
+specific	O
+IgA	B-PRGE
+was	O
+detected	O
+in	O
+tracheal	O
+-	O
+lung	B-ANAT
+wash	O
+fluid	O
+by	O
+immunofluorescence	O
+.	O
+
+ABSTRACT	O
+:	O
+A	O
+coronavirus	B-SPEC
+(	O
+CoV	O
+)	O
+has	O
+recently	O
+been	O
+identified	O
+as	O
+the	O
+causative	O
+agent	O
+of	O
+the	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+(	O
+SARS	B-DISO
+)	O
+in	O
+humans	B-SPEC
+.	O
+
+Seroconversion	O
+for	O
+IgG	B-PRGE
+(	O
+mean	O
+10	O
+days	O
+)	O
+occurred	O
+simultaneously	O
+,	O
+or	O
+1	O
+day	O
+earlier	O
+,	O
+than	O
+that	O
+for	O
+IgM	B-PRGE
+and	O
+IgA	B-PRGE
+(	O
+mean	O
+11	O
+days	O
+for	O
+both	O
+).	O
+
+Its	O
+specificity	O
+was	O
+verified	O
+by	O
+inclusion	O
+of	O
+control	O
+samples	O
+containing	O
+transmissible	O
+gastroenteritis	B-DISO
+virus	B-SPEC
+(	O
+TGEV	B-SPEC
+)	O
+and	O
+rotavirus	B-SPEC
+A	I-SPEC
+in	O
+each	O
+analysis	O
+.	O
+
+Determination	O
+of	O
+the	O
+virus	B-SPEC
+yield	O
+indicated	O
+highly	O
+synergistic	O
+anti	B-PRGE
+-	I-PRGE
+SARS	I-PRGE
+-	I-PRGE
+CoV	I-PRGE
+action	O
+of	O
+the	O
+combination	O
+suggesting	O
+the	O
+consideration	O
+of	O
+ribavirin	B-CHED
+plus	O
+IFN	B-PRGE
+-	I-PRGE
+beta	I-PRGE
+for	O
+the	O
+treatment	O
+of	O
+SARS	B-DISO
+.	O
+
+We	O
+report	O
+on	O
+the	O
+distribution	O
+and	O
+viral	O
+load	O
+of	O
+SARS	B-DISO
+-	O
+CoV	O
+in	O
+multiple	O
+organ	B-ANAT
+samples	O
+from	O
+patients	O
+who	O
+died	B-PROC
+of	O
+SARS	B-DISO
+during	O
+the	O
+Toronto	O
+outbreak	O
+.	O
+
+TITLE	O
+:	O
+Coronavirus	B-SPEC
+genome	O
+structure	O
+and	O
+replication	O
+.	O
+
+We	O
+review	O
+the	O
+experimental	O
+evidence	O
+that	O
+led	O
+us	O
+to	O
+formulate	O
+a	O
+third	O
+model	O
+proposing	O
+that	O
+the	O
+discontinuous	O
+event	O
+in	O
+coronavirus	O
+RNA	B-PROC
+synthesis	I-PROC
+occurs	O
+during	O
+minus	O
+strand	O
+synthesis	B-PROC
+.	O
+
+Besides	O
+RNA	B-PRGE
+-	I-PRGE
+dependent	I-PRGE
+RNA	I-PRGE
+polymerase	I-PRGE
+,	O
+RNA	B-PRGE
+helicase	I-PRGE
+,	O
+and	O
+protease	O
+activities	O
+,	O
+which	O
+are	O
+common	O
+to	O
+RNA	O
+viruses	B-SPEC
+,	O
+the	O
+coronavirus	B-SPEC
+replicase	B-PRGE
+was	O
+recently	O
+predicted	O
+to	O
+employ	O
+a	O
+variety	O
+of	O
+RNA	B-PROC
+processing	I-PROC
+enzymes	O
+that	O
+are	O
+not	O
+(	O
+or	O
+extremely	O
+rarely	O
+)	O
+found	O
+in	O
+other	O
+RNA	O
+viruses	B-SPEC
+and	O
+include	O
+putative	O
+sequence	O
+-	O
+specific	O
+endoribonuclease	O
+,	O
+3	O
+'-	O
+to	O
+-	O
+5	O
+'	O
+exoribonuclease	O
+,	O
+2	B-PRGE
+'-	I-PRGE
+O	I-PRGE
+-	I-PRGE
+ribose	I-PRGE
+methyltransferase	I-PRGE
+,	O
+ADP	B-PRGE
+ribose	I-PRGE
+1	I-PRGE
+"""-"	I-PRGE
+phosphatase	B-FUNC
+and	O
+,	O
+in	O
+a	O
+subset	O
+of	O
+group	O
+2	O
+coronaviruses	O
+,	O
+cyclic	O
+phosphodiesterase	B-PROC
+activities	O
+.	O
+
+ABSTRACT	O
+:	O
+As	O
+the	O
+largest	O
+RNA	O
+virus	O
+,	O
+coronavirus	B-SPEC
+replication	O
+employs	O
+complex	O
+mechanisms	O
+and	O
+involves	O
+various	O
+viral	O
+and	O
+cellular	B-COMP
+proteins	B-CHED
+.	O
+
+Genetic	O
+studies	O
+suggest	O
+that	O
+most	O
+of	O
+these	O
+proteins	B-CHED
+are	O
+involved	O
+in	O
+viral	O
+RNA	B-PROC
+replication	I-PROC
+.	O
+
+A	O
+new	O
+family	B-SPEC
+of	O
+vectors	O
+based	O
+on	O
+single	O
+coronavirus	B-SPEC
+genomes	O
+,	O
+in	O
+which	O
+essential	O
+genes	O
+have	O
+been	O
+deleted	O
+,	O
+has	O
+emerged	O
+including	O
+replication	O
+-	O
+competent	O
+,	O
+propagation	O
+-	O
+deficient	O
+vectors	O
+.	O
+
+This	O
+system	O
+represents	O
+a	O
+generic	O
+approach	O
+to	O
+coronavirus	B-SPEC
+reverse	O
+genetics	O
+and	O
+was	O
+first	O
+described	O
+for	O
+the	O
+generation	O
+of	O
+recombinant	O
+human	B-SPEC
+coronavirus	I-SPEC
+229E	I-SPEC
+representing	O
+a	O
+group	O
+I	O
+coronavirus	B-SPEC
+.	O
+
+These	O
+include	O
+the	O
+production	O
+of	O
+proteins	B-CHED
+derived	O
+from	O
+recombinant	O
+DNA	O
+yeast	B-SPEC
+technology	O
+(	O
+aerobically	O
+grown	O
+Saccharomyces	B-SPEC
+cerevisiae	I-SPEC
+).	O
+
+Previously	O
+,	O
+mutations	O
+in	O
+the	O
+equine	B-SPEC
+arteritis	I-SPEC
+virus	I-SPEC
+(	O
+EAV	B-SPEC
+)	O
+nsp10	O
+ZBD	O
+were	O
+shown	O
+to	O
+block	O
+arterivirus	B-SPEC
+reproduction	B-PROC
+by	O
+disrupting	O
+RNA	B-PROC
+synthesis	I-PROC
+and	O
+possibly	O
+virion	B-COMP
+biogenesis	B-PROC
+.	O
+
+Here	O
+,	O
+we	O
+characterized	O
+the	O
+ATPase	B-PRGE
+and	O
+helicase	B-PRGE
+activities	O
+of	O
+bacterially	O
+expressed	B-PROC
+mutant	B-DISO
+forms	O
+of	O
+nsp10	O
+and	O
+its	O
+human	B-SPEC
+coronavirus	I-SPEC
+229E	I-SPEC
+ortholog	O
+,	O
+nsp13	O
+,	O
+and	O
+correlated	O
+these	O
+in	O
+vitro	O
+activities	O
+with	O
+specific	O
+virus	B-SPEC
+phenotypes	O
+.	O
+
+Replacement	O
+of	O
+conserved	O
+Cys	B-CHED
+or	O
+His	O
+residues	O
+with	O
+Ala	B-CHED
+proved	O
+to	O
+be	O
+more	O
+deleterious	O
+than	O
+Cys	B-CHED
+-	O
+for	O
+-	O
+His	O
+or	O
+His	O
+-	O
+for	O
+-	O
+Cys	B-CHED
+replacements	O
+.	O
+
+Consistently	O
+,	O
+no	O
+viral	O
+RNA	B-PROC
+synthesis	I-PROC
+was	O
+detected	O
+after	O
+transfection	B-PROC
+of	O
+EAV	B-PRGE
+full	I-PRGE
+-	I-PRGE
+length	I-PRGE
+RNAs	I-PRGE
+encoding	I-PRGE
+ATPase	B-ENZY
+/	O
+helicase	B-PRGE
+-	O
+deficient	O
+nsp10	O
+into	O
+susceptible	O
+cells	B-COMP
+.	O
+
+In	O
+the	O
+past	O
+3	O
+years	O
+,	O
+several	O
+novel	O
+respiratory	O
+viruses	B-SPEC
+,	O
+including	O
+human	B-SPEC
+metapneumovirus	I-SPEC
+,	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+(	O
+SARS	B-DISO
+)	O
+coronavirus	B-SPEC
+(	O
+SARS	B-DISO
+-	O
+CoV	O
+),	O
+and	O
+human	B-SPEC
+coronavirus	I-SPEC
+NL63	I-SPEC
+,	O
+were	O
+discovered	O
+.	O
+
+ABSTRACT	O
+:	O
+We	O
+describe	O
+the	O
+natural	O
+history	O
+,	O
+viral	O
+dynamics	O
+,	O
+and	O
+immunobiology	O
+of	O
+feline	O
+infectious	O
+peritonitis	O
+(	O
+FIP	B-DISO
+),	O
+a	O
+highly	O
+lethal	O
+coronavirus	B-DISO
+infection	I-DISO
+.	O
+
+The	O
+pathogenic	O
+phenomena	O
+described	O
+here	O
+likely	O
+bear	O
+relevance	O
+to	O
+other	O
+severe	O
+coronavirus	B-DISO
+infections	I-DISO
+,	O
+in	O
+particular	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+,	O
+for	O
+which	O
+multiphasic	O
+disease	B-DISO
+progression	I-DISO
+and	O
+acute	O
+T	B-ANAT
+-	I-ANAT
+cell	I-ANAT
+lymphopenia	B-DISO
+have	O
+also	O
+been	O
+reported	O
+.	O
+
+Group	O
+D	O
+served	O
+as	O
+a	O
+control	O
+of	O
+pAPN	O
+treatment	O
+or	O
+PEDV	O
+infection	B-DISO
+.	O
+
+Continuously	O
+high	O
+SOFA	O
+score	O
+(	O
+p	O
+<	O
+0	O
+.	O
+05	O
+),	O
+more	O
+significant	O
+circulatory	B-PROC
+instability	O
+during	O
+the	O
+first	O
+days	O
+of	O
+the	O
+treatment	O
+,	O
+expressed	B-PROC
+by	O
+a	O
+higher	O
+need	O
+for	O
+the	O
+adrenaline	B-CHED
+use	O
+,	O
+and	O
+continuously	O
+increased	O
+CRP	B-PRGE
+values	O
+during	O
+the	O
+follow	O
+-	O
+up	O
+treatment	O
+(	O
+day	O
+7	O
+-	O
+14	O
+,	O
+p	O
+<	O
+0	O
+.	O
+05	O
+),	O
+all	O
+of	O
+it	O
+signalized	O
+unfavourable	O
+results	O
+.	O
+
+A	O
+favourable	O
+turn	O
+in	O
+the	O
+course	O
+of	O
+the	O
+disease	O
+was	O
+signalized	O
+by	O
+a	O
+drop	O
+in	O
+the	O
+serum	B-PRGE
+CRP	I-PRGE
+and	O
+by	O
+a	O
+decreasing	O
+need	O
+for	O
+vasopressors	O
+medication	O
+.	O
+
+In	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+,	O
+the	O
+debate	O
+concerning	O
+the	O
+use	O
+of	O
+long	B-CHED
+-	I-CHED
+chain	I-CHED
+fatty	I-CHED
+acids	I-CHED
+as	O
+opposed	O
+to	O
+physical	O
+mixtures	O
+of	O
+medium	O
+-	O
+and	O
+long	B-CHED
+-	I-CHED
+chain	I-CHED
+fatty	I-CHED
+acids	I-CHED
+,	O
+specifically	O
+regarding	O
+their	O
+effects	O
+on	O
+gas	B-ENZY
+exchange	O
+and	O
+pulmonary	B-ANAT
+hemodynamics	B-PROC
+,	O
+still	O
+remains	O
+unresolved	O
+.	O
+
+Overall	O
+,	O
+lipids	B-CHED
+,	O
+in	O
+particular	O
+n	O
+-	O
+3	O
+fatty	B-CHED
+acids	I-CHED
+,	O
+emerge	O
+as	O
+powerful	O
+nutrients	B-CHED
+with	O
+pharmacologic	O
+properties	O
+potentially	O
+improving	O
+prognosis	O
+in	O
+critically	B-DISO
+ill	I-DISO
+patients	O
+.	O
+
+Consequently	O
+,	O
+larger	O
+prospective	O
+,	O
+randomized	O
+,	O
+double	O
+-	O
+blind	B-DISO
+trials	O
+with	O
+comparable	O
+methodologies	O
+are	O
+necessary	O
+for	O
+detailed	O
+evaluation	O
+of	O
+the	O
+pharmacologic	O
+impact	O
+of	O
+lipids	B-CHED
+.	O
+
+In	O
+addition	O
+,	O
+a	O
+better	O
+knowledge	O
+of	O
+the	O
+influence	O
+of	O
+genotypic	O
+variation	O
+and	O
+postinjury	O
+inflammatory	O
+/	O
+immune	O
+temporal	O
+patterns	O
+may	O
+improve	O
+our	O
+current	O
+therapeutic	O
+use	O
+of	O
+various	O
+fatty	B-CHED
+acids	I-CHED
+.	O
+
+ABSTRACT	O
+:	O
+Patients	O
+who	O
+experience	O
+severe	O
+trauma	O
+are	O
+at	O
+increased	O
+risk	O
+for	O
+the	O
+development	B-PROC
+of	O
+acute	O
+lung	B-ANAT
+injury	O
+and	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+.	O
+
+Current	O
+trends	O
+in	O
+the	O
+management	O
+of	O
+acute	O
+lung	B-ANAT
+injury	O
+and	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+consist	O
+of	O
+maintaining	O
+acceptable	O
+gas	B-ENZY
+exchange	O
+while	O
+limiting	O
+ventilator	O
+-	O
+associated	O
+lung	B-ANAT
+injury	O
+.	O
+
+Airway	B-ANAT
+pressure	O
+release	B-PATH
+ventilation	O
+is	O
+a	O
+mode	O
+of	O
+mechanical	O
+ventilation	O
+that	O
+maintains	O
+lung	B-PROC
+volume	I-PROC
+to	O
+limit	O
+intra	O
+tidal	O
+recruitment	B-DISO
+/	O
+derecruitment	O
+and	O
+improves	O
+gas	B-ENZY
+exchange	O
+while	O
+limiting	O
+over	O
+distension	B-DISO
+.	O
+
+Mechanical	O
+ventilation	O
+with	O
+airway	B-ANAT
+pressure	O
+release	B-PATH
+ventilation	O
+permits	B-SPEC
+spontaneous	O
+breathing	B-PROC
+throughout	O
+the	O
+entire	O
+respiratory	O
+cycle	O
+,	O
+improves	O
+patient	O
+comfort	O
+,	O
+reduces	O
+the	O
+use	O
+of	O
+sedation	B-DISO
+,	O
+and	O
+may	O
+reduce	O
+ventilator	O
+days	O
+.	O
+
+Their	O
+treatment	O
+modalities	O
+included	O
+empirical	O
+antibiotics	B-CHED
+,	O
+steroids	B-CHED
+,	O
+and	O
+anti	B-CHED
+-	I-CHED
+viral	I-CHED
+agents	I-CHED
+.	O
+
+The	O
+histological	O
+findings	O
+of	O
+the	O
+first	O
+renal	B-ANAT
+biopsy	O
+,	O
+done	O
+at	O
+21	O
+years	O
+of	O
+age	O
+,	O
+revealed	O
+mild	O
+mesangial	B-DISO
+proliferative	I-DISO
+glomerulonephritis	I-DISO
+with	O
+mesangial	O
+IgA	B-PRGE
+deposition	O
+.	O
+
+This	O
+inter	O
+-	O
+species	B-SPEC
+crossing	O
+is	O
+promoted	O
+by	O
+various	O
+circumstances	O
+:	O
+environmental	O
+and	O
+climatic	O
+variations	O
+,	O
+bioterrorism	O
+,	O
+evolutive	O
+potential	O
+of	O
+the	O
+virus	B-SPEC
+,	O
+etc	O
+.	O
+
+But	O
+group	O
+2	O
+AB	O
+were	O
+under	O
+-	O
+prescribed	O
+in	O
+25	O
+%	O
+of	O
+patients	O
+suffering	B-DISO
+from	O
+severe	O
+obstructive	O
+CB	O
+.	O
+
+This	O
+RT	O
+-	O
+PCR	O
+-	O
+based	O
+dot	O
+blot	O
+hybridization	B-PROC
+increased	O
+1000	O
+-	O
+fold	O
+in	O
+sensitivity	O
+for	O
+PEDV	B-SPEC
+and	O
+100	O
+-	O
+fold	O
+for	O
+TGEV	B-SPEC
+;	O
+weakly	O
+positive	O
+bands	O
+in	O
+the	O
+agarose	B-CHED
+gel	O
+electrophoresis	O
+gave	O
+a	O
+clear	O
+positive	O
+result	O
+with	O
+dot	O
+blot	O
+hybridization	O
+.	O
+
+TITLE	O
+:	O
+Generation	O
+of	O
+a	O
+recombinant	O
+avian	B-SPEC
+coronavirus	I-SPEC
+infectious	B-DISO
+bronchitis	B-DISO
+virus	B-SPEC
+using	O
+transient	O
+dominant	O
+selection	O
+.	O
+
+Recombinant	O
+avian	B-DISO
+infectious	I-DISO
+bronchitis	I-DISO
+virus	B-SPEC
+expressing	O
+a	O
+heterologous	O
+spike	O
+gene	O
+demonstrates	O
+that	O
+the	O
+spike	O
+protein	B-CHED
+is	O
+a	O
+determinant	O
+of	O
+cell	B-COMP
+tropism	B-PROC
+.	O
+
+These	O
+data	O
+indicate	O
+that	O
+the	O
+user	O
+seal	B-SPEC
+check	O
+should	O
+not	O
+be	O
+used	O
+as	O
+a	O
+surrogate	O
+fit	B-DISO
+test	O
+.	O
+
+Control	O
+measures	O
+for	O
+MRSA	B-DISO
+include	O
+the	O
+screening	O
+of	O
+patient	O
+lesions	O
+,	O
+isolating	O
+or	O
+cohorting	O
+patients	O
+who	O
+are	O
+already	O
+infected	O
+,	O
+covering	O
+wounds	O
+with	O
+impermeable	O
+dressings	O
+,	O
+treating	O
+staff	O
+and	O
+patient	O
+carriers	O
+with	O
+antibiotics	B-CHED
+,	O
+and	O
+improved	O
+hygiene	O
+.	O
+
+Control	O
+measures	O
+for	O
+C	B-SPEC
+.	I-SPEC
+difficile	I-SPEC
+Control	O
+measures	O
+include	O
+paying	O
+close	O
+attention	O
+to	O
+the	O
+hygiene	O
+of	O
+the	O
+clinical	O
+setting	O
+,	O
+disinfecting	O
+using	O
+bleach	O
+and	O
+the	O
+isolation	O
+of	O
+infected	O
+patients	O
+.	O
+
+However	O
+,	O
+SARS	B-DISO
+patients	O
+had	O
+more	O
+severe	O
+lymphopenia	B-DISO
+(	O
+p	O
+=	O
+0	O
+.	O
+013	O
+)	O
+and	O
+anemia	B-DISO
+(	O
+p	O
+=	O
+0	O
+.	O
+007	O
+),	O
+and	O
+more	O
+persistent	O
+pulmonary	B-DISO
+infiltrates	I-DISO
+(	O
+p	O
+=	O
+0	O
+.	O
+023	O
+).	O
+
+Respiratory	B-DISO
+failure	I-DISO
+developed	O
+in	O
+15	O
+.	O
+4	O
+%	O
+of	O
+the	O
+SARS	B-DISO
+patients	O
+and	O
+in	O
+none	O
+of	O
+the	O
+M	B-SPEC
+.	I-SPEC
+pneumoniae	I-SPEC
+patients	O
+.	O
+
+In	O
+this	O
+series	O
+,	O
+lymphopenia	B-DISO
+and	O
+anemia	B-DISO
+were	O
+more	O
+severe	O
+in	O
+SARS	B-DISO
+than	O
+in	O
+M	B-SPEC
+.	I-SPEC
+pneumoniae	I-SPEC
+infection	B-DISO
+,	O
+and	O
+SARS	B-DISO
+patients	O
+had	O
+more	O
+persistent	O
+and	O
+more	O
+new	O
+pulmonary	B-DISO
+infiltrates	I-DISO
+after	O
+hospitalization	O
+.	O
+
+TITLE	O
+:	O
+Surgical	O
+treatment	O
+of	O
+tracheoesophageal	B-DISO
+fistula	I-DISO
+in	O
+a	O
+patient	O
+with	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+complicated	O
+with	O
+extensive	O
+pulmonary	B-DISO
+fibrosis	I-DISO
+.	O
+
+Thirty	O
+three	O
+days	O
+after	O
+admission	O
+,	O
+she	O
+underwent	O
+tracheostomy	O
+because	O
+of	O
+difficulty	O
+in	O
+weaning	B-PROC
+from	O
+the	O
+ventilator	O
+.	O
+
+However	O
+,	O
+since	O
+sequencing	O
+methods	O
+can	O
+read	O
+fragments	O
+of	O
+up	O
+to	O
+1000	O
+bp	O
+only	O
+,	O
+methods	O
+for	O
+sequence	O
+assembling	O
+are	O
+required	O
+in	O
+order	B-SPEC
+to	O
+read	O
+whole	O
+genomes	O
+.	O
+
+ABSTRACT	O
+:	O
+We	O
+report	O
+a	O
+complete	O
+genomic	O
+sequence	O
+of	O
+rare	O
+isolates	O
+(	O
+minor	O
+genotype	O
+)	O
+of	O
+the	O
+SARS	B-DISO
+-	O
+CoV	O
+from	O
+SARS	B-DISO
+patients	O
+in	O
+Guangdong	O
+,	O
+China	O
+,	O
+where	O
+the	O
+first	O
+few	O
+cases	O
+emerged	O
+.	O
+
+The	O
+discovery	O
+of	O
+this	O
+minor	O
+genotype	O
+,	O
+GD	O
+-	O
+Ins29	O
+,	O
+suggests	O
+a	O
+significant	O
+genetic	O
+event	O
+and	O
+differentiates	O
+it	O
+from	O
+the	O
+previously	O
+reported	O
+genotype	O
+,	O
+the	O
+dominant	O
+form	O
+among	O
+all	O
+sequenced	O
+SARS	B-DISO
+-	O
+CoV	O
+isolates	O
+.	O
+
+It	O
+provides	O
+a	O
+new	O
+avenue	O
+for	O
+the	O
+exploration	O
+of	O
+the	O
+virus	B-PROC
+-	I-PROC
+host	B-COMP
+interaction	I-PROC
+in	O
+viral	O
+evolution	B-PROC
+,	O
+host	B-COMP
+pathogenesis	B-DISO
+,	O
+and	O
+vaccine	O
+development	B-PROC
+.	O
+
+TITLE	O
+:	O
+The	O
+M	B-PRGE
+protein	I-PRGE
+of	O
+SARS	B-PRGE
+-	I-PRGE
+CoV	I-PRGE
+:	O
+basic	O
+structural	O
+and	O
+immunological	O
+properties	O
+.	O
+
+The	O
+functional	O
+domains	O
+in	O
+all	O
+NSPs	O
+of	O
+the	O
+R	B-PRGE
+protein	I-PRGE
+give	O
+different	O
+phylogenetic	O
+results	O
+that	O
+suggest	O
+their	O
+different	O
+mutation	O
+rate	O
+under	O
+selective	O
+pressure	O
+.	O
+
+We	O
+report	O
+the	O
+epidemiologic	O
+linkage	B-PROC
+of	O
+SARS	B-DISO
+within	O
+an	O
+extended	O
+family	B-SPEC
+.	O
+
+TITLE	O
+:	O
+Acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+in	O
+Pena	B-DISO
+-	I-DISO
+Shokeir	I-DISO
+syndrome	I-DISO
+.	O
+
+To	O
+the	O
+best	O
+of	O
+our	O
+knowledge	O
+,	O
+she	O
+is	O
+the	O
+oldest	O
+living	O
+individual	O
+with	O
+Pena	B-DISO
+-	I-DISO
+Shokeir	I-DISO
+syndrome	I-DISO
+,	O
+and	O
+the	O
+only	O
+such	O
+patient	O
+whose	O
+intelligence	O
+was	O
+not	O
+impaired	B-DISO
+.	O
+
+Rooted	O
+phylogenetic	O
+trees	O
+,	O
+proposed	O
+on	O
+the	O
+basis	O
+of	O
+haplotypes	O
+and	O
+other	O
+sequence	O
+variations	O
+of	O
+SARS	B-DISO
+-	O
+CoV	O
+isolates	O
+from	O
+Canada	O
+,	O
+USA	O
+,	O
+Singapore	O
+,	O
+and	O
+China	O
+,	O
+gave	O
+rise	O
+to	O
+different	O
+paradigms	O
+but	O
+positioned	O
+the	O
+BJ	O
+Group	O
+,	O
+together	O
+with	O
+the	O
+newly	O
+discovered	O
+GD01	O
+(	O
+GD	O
+-	O
+Ins29	O
+)	O
+in	O
+the	O
+same	O
+clade	O
+,	O
+followed	O
+by	O
+the	O
+H	O
+-	O
+U	O
+Group	O
+(	O
+from	O
+Hong	O
+Kong	O
+to	O
+USA	O
+)	O
+and	O
+the	O
+H	O
+-	O
+T	O
+Group	O
+(	O
+from	O
+Hong	O
+Kong	O
+to	O
+Toronto	O
+),	O
+leaving	O
+the	O
+SP	O
+Group	O
+(	O
+Singapore	O
+)	O
+more	O
+distant	O
+.	O
+
+To	O
+determine	O
+its	O
+antigenicity	O
+,	O
+the	O
+fusion	O
+protein	B-CHED
+was	O
+challenged	O
+with	O
+serum	B-COMP
+samples	O
+from	O
+SARS	B-DISO
+patients	O
+and	O
+normal	O
+controls	O
+.	O
+
+ABSTRACT	O
+:	O
+The	O
+nucleocapsid	B-PRGE
+protein	B-CHED
+(	O
+N	O
+protein	O
+)	O
+has	O
+been	O
+found	O
+to	O
+be	O
+an	O
+antigenic	O
+protein	B-CHED
+in	O
+a	O
+number	O
+of	O
+coronaviruses	O
+.	O
+
+All	O
+patient	O
+sera	B-COMP
+in	O
+this	O
+study	O
+displayed	O
+strong	O
+positive	O
+immunoreactivities	O
+against	O
+the	O
+recombinant	O
+N	O
+proteins	B-CHED
+,	O
+whereas	O
+normal	O
+sera	B-COMP
+gave	O
+negative	O
+immunoresponses	O
+to	O
+these	O
+proteins	B-CHED
+,	O
+indicating	O
+that	O
+the	O
+N	B-PRGE
+protein	I-PRGE
+of	O
+SARS	B-PRGE
+-	I-PRGE
+CoV	I-PRGE
+is	O
+an	O
+antigenic	O
+protein	B-CHED
+.	O
+
+One	O
+epitope	B-CHED
+site	O
+located	O
+at	O
+the	O
+C	O
+-	O
+terminus	O
+was	O
+confirmed	O
+as	O
+the	O
+most	O
+antigenic	O
+region	O
+in	O
+this	O
+protein	B-CHED
+.	O
+
+TITLE	O
+:	O
+Evolution	B-PROC
+and	O
+variation	O
+of	O
+the	O
+SARS	B-DISO
+-	O
+CoV	O
+genome	O
+.	O
+
+ABSTRACT	O
+:	O
+Knowledge	O
+of	O
+the	O
+evolution	B-PROC
+of	O
+pathogens	O
+is	O
+of	O
+great	O
+medical	O
+and	O
+biological	O
+significance	O
+to	O
+the	O
+prevention	O
+,	O
+diagnosis	O
+,	O
+and	O
+therapy	O
+of	O
+infectious	O
+diseases	O
+.	O
+
+TITLE	O
+:	O
+Genome	O
+organization	O
+of	O
+the	O
+SARS	B-DISO
+-	O
+CoV	O
+.	O
+ABSTRACT	O
+:	O
+Annotation	O
+of	O
+the	O
+genome	O
+sequence	O
+of	O
+the	O
+SARS	B-DISO
+-	O
+CoV	O
+(	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+-	O
+associated	O
+coronavirus	B-SPEC
+)	O
+is	O
+indispensable	O
+to	O
+understand	O
+its	O
+evolution	B-PROC
+and	O
+pathogenesis	B-DISO
+.	O
+
+Totally	O
+,	O
+21	O
+open	O
+reading	O
+frames	O
+(	O
+ORFs	O
+)	O
+of	O
+genes	O
+or	O
+putative	O
+uncharacterized	O
+proteins	B-CHED
+(	O
+PUPs	O
+)	O
+were	O
+predicted	O
+.	O
+
+After	O
+three	O
+rounds	O
+of	O
+panning	O
+with	O
+SARS	B-DISO
+virus	B-SPEC
+antigen	B-CHED
+,	O
+phage	O
+antibodies	B-COMP
+against	O
+SARS	B-DISO
+virus	B-SPEC
+were	O
+specifically	O
+enriched	O
+.	O
+
+CONCLUSIONS	O
+:	O
+The	O
+prepared	O
+recombinant	O
+N	O
+protein	B-CHED
+and	O
+mAbs	O
+against	O
+N	O
+protein	B-CHED
+lay	O
+the	O
+foundation	O
+for	O
+further	O
+development	B-PROC
+of	O
+early	O
+diagnosis	O
+assays	O
+for	O
+SARS	B-DISO
+coronavirus	B-DISO
+infection	I-DISO
+.	O
+
+Besides	O
+,	O
+the	O
+expressions	O
+of	O
+TCR	B-PRGE
+Vbeta1	I-PRGE
+,	O
+Vbeta5	O
+.	O
+2	O
+,	O
+Vbeta5	O
+.	O
+3	O
+,	O
+Vbeta7	O
+.	O
+2	O
+,	O
+Vbeta9	O
+,	O
+Vbeta11	O
+,	O
+Vbeta13	O
+.	O
+1	O
+,	O
+Vbeta13	O
+.	O
+2	O
+,	O
+Vbeta17	O
+,	O
+Vbeta18	O
+,	O
+Vbeta22	O
+and	O
+Vbeta23	O
+in	O
+SARS	B-DISO
+group	O
+were	O
+all	O
+significantly	O
+higher	O
+than	O
+those	O
+in	O
+normal	O
+group	O
+.	O
+
+TITLE	O
+:	O
+Immune	B-PROC
+responses	I-PROC
+with	O
+DNA	O
+vaccines	O
+encoded	O
+different	O
+gene	O
+fragments	O
+of	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+coronavirus	B-SPEC
+in	O
+BALB	O
+/	O
+c	O
+mice	B-SPEC
+.	O
+
+After	O
+mice	B-SPEC
+were	O
+immunized	O
+intramuscularly	O
+with	O
+pcDNAM	O
+,	O
+pcDNAN	O
+or	O
+pcDNASa	O
+-	O
+pcDNASb	O
+plasmid	O
+,	O
+blood	B-ANAT
+was	O
+collected	O
+and	O
+serum	B-COMP
+was	O
+separated	O
+.	O
+
+The	O
+present	O
+results	O
+not	O
+only	O
+suggest	O
+that	O
+DNA	O
+immunization	O
+with	O
+pcDNAM	O
+,	O
+pcDNAN	O
+or	O
+pcDNASa	O
+-	O
+pcDNASb	O
+could	O
+be	O
+used	O
+as	O
+potential	O
+DNA	O
+vaccination	O
+approaches	O
+to	O
+induce	O
+antibody	B-COMP
+in	O
+BALB	O
+/	O
+c	O
+mice	B-SPEC
+,	O
+but	O
+also	O
+to	O
+illustrate	O
+that	O
+gene	O
+immunization	O
+with	O
+these	O
+SARS	B-DISO
+DNA	O
+vaccines	O
+different	O
+immune	B-PROC
+response	I-PROC
+characters	O
+.	O
+
+Based	O
+on	O
+tertiary	O
+structural	O
+comparisons	O
+,	O
+we	O
+propose	O
+the	O
+s2m	O
+RNA	O
+binds	B-FUNC
+one	O
+or	O
+more	O
+proteins	B-CHED
+possessing	O
+an	O
+oligomer	O
+-	O
+binding	B-FUNC
+-	O
+like	O
+fold	O
+,	O
+and	O
+we	O
+suggest	O
+a	O
+possible	O
+mechanism	O
+for	O
+SARS	B-DISO
+viral	O
+RNA	O
+hijacking	O
+of	O
+host	B-COMP
+protein	B-PROC
+synthesis	I-PROC
+,	O
+both	O
+based	O
+upon	O
+observed	O
+s2m	O
+RNA	O
+macromolecular	O
+mimicry	B-DISO
+of	O
+a	O
+relevant	O
+ribosomal	B-COMP
+RNA	I-COMP
+fold	O
+.	O
+
+TITLE	O
+:	O
+[	O
+A	O
+preliminary	O
+investigation	O
+on	O
+the	O
+serological	O
+and	O
+epidemiological	O
+characteristics	O
+of	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+in	O
+children	O
+].	O
+
+(	O
+2	O
+)	O
+Specific	O
+antibodies	B-COMP
+against	O
+SARS	B-DISO
+-	O
+CoV	O
+were	O
+assayed	O
+with	O
+two	O
+methods	O
+,	O
+indirect	O
+immunofluorescence	O
+assay	O
+(	O
+IFA	O
+)	O
+for	O
+detecting	O
+IgG	B-PRGE
+antibodies	I-PRGE
+and	O
+enzyme	O
+linked	O
+immunosorbent	O
+assay	O
+(	O
+ELISA	O
+)	O
+for	O
+mixed	O
+antibodies	B-COMP
+.	O
+
+ABSTRACT	O
+:	O
+To	O
+study	O
+the	O
+response	O
+of	O
+specific	O
+antibodies	B-COMP
+against	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+(	O
+SARS	B-DISO
+)-	O
+CoV	O
+in	O
+patients	O
+infected	O
+with	O
+SARS	B-DISO
+.	O
+
+Specific	O
+IgG	B-COMP
+antibody	I-COMP
+against	O
+SARS	B-DISO
+-	O
+CoV	O
+in	O
+serum	B-COMP
+samples	O
+from	O
+contacts	O
+to	O
+patients	O
+,	O
+five	O
+months	O
+before	O
+an	O
+SARS	B-DISO
+outbreak	O
+in	O
+Beijing	O
+.	O
+
+All	O
+SARS	B-DISO
+cases	O
+were	O
+positive	O
+except	O
+one	O
+by	O
+immunity	B-PROC
+adherence	O
+test	O
+.	O
+
+Autopsy	O
+lung	B-ANAT
+tissue	I-ANAT
+sections	O
+from	O
+SARS	B-DISO
+patients	O
+were	O
+stained	O
+with	O
+ascites	O
+of	O
+monoclonal	O
+antibody	B-COMP
+(	O
+M2	O
+strain	O
+)	O
+by	O
+immunohistochemical	O
+technique	O
+.	O
+
+Brown	O
+particles	O
+were	O
+seen	O
+in	O
+macrophages	B-ANAT
+and	O
+pneumocytes	B-ANAT
+in	O
+autopsy	O
+lung	B-ANAT
+tissues	I-ANAT
+from	O
+SARS	B-DISO
+patients	O
+.	O
+
+Brown	O
+particles	O
+were	O
+seen	O
+in	O
+macrophages	B-ANAT
+and	O
+pneumocytes	B-ANAT
+in	O
+autopsy	O
+lung	B-ANAT
+tissues	I-ANAT
+from	O
+SARS	B-DISO
+patients	O
+.	O
+
+Bilateral	O
+femoral	B-ANAT
+and	O
+tibial	B-ANAT
+marrow	O
+edema	B-DISO
+were	O
+found	O
+in	O
+one	O
+case	O
+.	O
+
+TITLE	O
+:	O
+Foundations	O
+of	O
+the	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+preparedness	O
+and	O
+response	O
+plan	B-DISO
+for	O
+healthcare	O
+facilities	O
+.	O
+
+The	O
+recommendations	O
+in	O
+the	O
+CDC	O
+document	O
+were	O
+based	O
+on	O
+some	O
+of	O
+the	O
+important	O
+lessons	O
+learned	B-PROC
+in	O
+healthcare	O
+settings	O
+around	O
+the	O
+world	O
+during	O
+the	O
+SARS	B-DISO
+outbreak	O
+of	O
+2003	O
+,	O
+including	O
+that	O
+(	O
+1	O
+)	O
+a	O
+SARS	B-DISO
+outbreak	O
+requires	O
+a	O
+coordinated	O
+and	O
+dynamic	O
+response	O
+by	O
+multiple	O
+groups	O
+;	O
+(	O
+2	O
+)	O
+unrecognized	O
+cases	O
+of	O
+SARS	B-DISO
+-	I-DISO
+associated	I-DISO
+coronavirus	I-DISO
+are	O
+a	O
+significant	O
+source	O
+of	O
+transmission	O
+;	O
+(	O
+3	O
+)	O
+restricting	O
+access	O
+to	O
+the	O
+healthcare	O
+facility	O
+can	O
+minimize	O
+transmission	O
+;	O
+(	O
+4	O
+)	O
+airborne	O
+infection	B-DISO
+isolation	O
+is	O
+recommended	O
+,	O
+but	O
+facilities	O
+and	O
+equipment	O
+may	O
+not	O
+be	O
+available	O
+;	O
+and	O
+(	O
+5	O
+)	O
+staffing	O
+needs	O
+and	O
+support	O
+will	O
+pose	O
+a	O
+significant	O
+challenge	O
+.	O
+
+Better	O
+training	O
+and	O
+improvements	O
+in	O
+infection	B-DISO
+control	O
+infrastructure	O
+may	O
+limit	O
+the	O
+impact	O
+of	O
+SARS	B-DISO
+.	O
+
+Our	O
+results	O
+indicate	O
+that	O
+the	O
+auditory	O
+meatus	O
+temperature	O
+is	O
+a	O
+superior	O
+alternative	O
+compared	O
+with	O
+the	O
+forehead	B-ANAT
+body	B-ANAT
+surface	O
+temperature	O
+due	O
+to	O
+its	O
+close	O
+approximation	O
+to	O
+the	O
+tympanic	O
+temperature	O
+.	O
+
+TITLE	O
+:	O
+A	O
+large	O
+-	O
+volume	O
+nebulizer	O
+would	O
+not	O
+be	O
+an	O
+infectious	B-DISO
+source	O
+for	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+.	O
+
+Dynamic	O
+hyperinflation	B-DISO
+affects	O
+tidal	O
+ventilation	O
+,	O
+increases	O
+airways	O
+resistance	B-PROC
+,	O
+and	O
+causes	O
+intrinsic	O
+positive	O
+end	B-PROC
+-	I-PROC
+expiratory	I-PROC
+pressure	O
+(	O
+auto	B-DISO
+-	I-DISO
+PEEP	I-DISO
+).	O
+
+ABSTRACT	O
+:	O
+This	O
+study	O
+explored	O
+whether	O
+nurses	O
+who	O
+were	O
+working	O
+during	O
+the	O
+severe	O
+acute	O
+respiratory	O
+syndrome	O
+(	O
+SARS	B-DISO
+)	O
+crisis	O
+showed	O
+symptoms	O
+of	O
+distress	O
+.	O
+
+Synergistic	O
+activation	O
+by	O
+IL	B-FUNC
+-	I-FUNC
+12	I-FUNC
+/	O
+IL	B-FUNC
+-	I-FUNC
+18	I-FUNC
+induced	O
+the	O
+expression	B-PROC
+of	O
+the	O
+IFNgamma	B-PRGE
+gene	I-PRGE
+in	O
+Mphi	O
+from	O
+both	O
+mouse	B-SPEC
+strains	O
+.	O
+
+For	O
+pneumococcal	B-DISO
+pneumonia	I-DISO
+in	O
+adults	O
+,	O
+PCR	O
+adds	O
+little	O
+to	O
+existing	O
+diagnostic	O
+tests	O
+,	O
+and	O
+is	O
+unable	O
+to	O
+distinguish	O
+pneumococcal	O
+colonization	O
+from	O
+infection	B-DISO
+when	O
+testing	O
+respiratory	B-ANAT
+samples	I-ANAT
+.	O
+
+The	O
+intent	O
+of	O
+this	O
+study	O
+was	O
+to	O
+examine	O
+the	O
+recovery	O
+of	O
+individuals	O
+who	O
+had	O
+been	O
+hospitalized	O
+for	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+(	O
+SARS	B-DISO
+)	O
+in	O
+the	O
+year	O
+following	O
+their	O
+discharge	B-ANAT
+from	O
+the	O
+hospital	O
+.	O
+
+TITLE	O
+:	O
+HMGB1	B-PRGE
+contributes	O
+to	O
+the	O
+development	B-PROC
+of	O
+acute	O
+lung	B-ANAT
+injury	O
+after	O
+hemorrhage	B-DISO
+.	O
+
+ABSTRACT	O
+:	O
+High	B-PRGE
+mobility	I-PRGE
+group	I-PRGE
+box	I-PRGE
+1	I-PRGE
+(	O
+HMGB1	B-PRGE
+)	O
+is	O
+a	O
+novel	O
+late	O
+mediator	O
+of	O
+inflammatory	B-DISO
+responses	I-DISO
+that	O
+contributes	O
+to	O
+endotoxin	O
+-	O
+induced	O
+acute	O
+lung	B-ANAT
+injury	O
+and	O
+sepsis	B-DISO
+-	O
+associated	O
+lethality	O
+.	O
+
+These	O
+results	O
+demonstrate	O
+that	O
+hemorrhage	B-DISO
+results	O
+in	O
+increased	O
+HMGB1	B-PRGE
+expression	B-PROC
+in	O
+the	O
+lungs	B-ANAT
+,	O
+primarily	O
+through	O
+neutrophil	B-ANAT
+sources	O
+,	O
+and	O
+that	O
+HMGB1	B-PRGE
+participates	O
+in	O
+hemorrhage	B-DISO
+-	O
+induced	O
+acute	O
+lung	B-ANAT
+injury	O
+.	O
+
+ABSTRACT	O
+:	O
+Severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+(	O
+SARS	B-DISO
+)	O
+is	O
+a	O
+highly	O
+infectious	B-DISO
+respiratory	B-DISO
+infection	I-DISO
+with	O
+a	O
+high	O
+mortality	O
+.	O
+
+On	O
+discharge	B-ANAT
+from	O
+the	O
+hospital	O
+,	O
+18	O
+(	O
+40	O
+%)	O
+remained	O
+RT	O
+-	O
+PCR	O
+positive	O
+in	O
+at	O
+least	O
+one	O
+site	O
+.	O
+
+A	O
+significant	O
+proportion	O
+of	O
+severe	O
+acute	O
+respiratory	O
+syndrome	O
+patients	O
+remained	O
+RT	O
+-	O
+PCR	O
+positive	O
+for	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+-	O
+associated	O
+coronavirus	B-SPEC
+for	O
+a	O
+substantial	O
+duration	O
+after	O
+discharge	B-ANAT
+.	O
+
+The	O
+Toronto	O
+critical	O
+care	O
+community	O
+has	O
+learned	B-PROC
+important	O
+lessons	O
+from	O
+SARS	B-DISO
+,	O
+which	O
+will	O
+help	O
+in	O
+preparation	O
+for	O
+future	O
+disease	O
+outbreaks	O
+.	O
+
+ARDS	B-DISO
+develops	O
+in	O
+the	O
+majority	O
+of	O
+these	O
+patients	O
+.	O
+
+The	O
+ELISA	O
+for	O
+detection	O
+of	O
+SARS	B-PRGE
+virus	B-SPEC
+antigen	B-CHED
+was	O
+developed	O
+by	O
+using	O
+antibody	B-COMP
+with	O
+the	O
+highest	O
+affinity	O
+.	O
+
+The	O
+monoclonal	O
+antibody	B-COMP
+has	O
+good	O
+specificity	O
+and	O
+may	O
+be	O
+used	O
+to	O
+detect	O
+SARS	B-PRGE
+virus	B-SPEC
+antigen	B-CHED
+.	O
+
+TITLE	O
+:	O
+[	O
+Potent	O
+neutralization	O
+antibody	B-COMP
+elicited	O
+in	O
+mice	B-SPEC
+by	O
+SARS	B-DISO
+-	I-DISO
+associated	I-DISO
+coronavirus	I-DISO
+spike	O
+protein	B-CHED
+S1	O
+domain	O
+].	O
+
+ABSTRACT	O
+:	O
+To	O
+study	O
+the	O
+antigenicity	O
+of	O
+SARS	B-DISO
+associated	O
+coronavirus	B-SPEC
+(	O
+CoV	O
+)	O
+spike	O
+S1	O
+(	O
+12	O
+-	O
+672Aa	O
+)	O
+domain	O
+.	O
+
+A	O
+total	O
+of	O
+207	O
+oral	B-ANAT
+swab	I-ANAT
+samples	O
+were	O
+obtained	O
+in	O
+16	O
+collections	O
+from	O
+SARS	B-DISO
+patients	O
+and	O
+suspected	O
+influenza	B-DISO
+outbreak	O
+cases	O
+.	O
+
+ABSTRACT	O
+:	O
+To	O
+construct	O
+a	O
+recombinant	O
+plasmid	O
+Pet23a	O
+-	O
+M	O
+,	O
+the	O
+gene	O
+encoding	O
+severe	O
+acute	O
+respiratory	O
+syndrome	O
+(	O
+SARS	B-DISO
+)	O
+coronavirus	B-SPEC
+membrane	B-COMP
+protein	B-CHED
+was	O
+amplified	O
+by	O
+RT	O
+-	O
+PCR	O
+and	O
+cloned	O
+into	O
+the	O
+expression	B-PROC
+plasmid	O
+Pet23a	O
+.	O
+
+ABSTRACT	O
+:	O
+The	O
+open	O
+reading	O
+frame	O
+(	O
+ORF	O
+)	O
+7a	O
+of	O
+the	O
+SARS	O
+-	O
+associated	O
+coronavirus	O
+(	O
+SARS	B-DISO
+-	O
+CoV	O
+)	O
+encodes	O
+a	O
+unique	O
+type	O
+I	O
+transmembrane	B-COMP
+protein	B-CHED
+of	O
+unknown	O
+function	O
+.	O
+
+We	O
+also	O
+demonstrate	O
+that	O
+,	O
+in	O
+SARS	B-DISO
+-	O
+CoV	O
+-	O
+infected	O
+cells	B-COMP
+,	O
+the	O
+orf7a	B-PRGE
+protein	I-PRGE
+is	O
+expressed	B-PROC
+and	O
+retained	O
+intracellularly	O
+.	O
+
+Unexpectedly	O
+,	O
+Abs	O
+that	O
+neutralized	O
+most	O
+human	B-PRGE
+S	I-PRGE
+glycoproteins	B-CHED
+enhanced	O
+entry	O
+mediated	O
+by	O
+the	O
+civet	B-SPEC
+virus	B-SPEC
+S	O
+glycoproteins	B-CHED
+.	O
+
+The	O
+N	B-PRGE
+protein	I-PRGE
+was	O
+not	O
+detected	O
+in	O
+66	O
+patients	O
+with	O
+cases	O
+of	O
+what	O
+was	O
+initially	O
+suspected	O
+to	O
+be	O
+SARS	B-DISO
+but	O
+serologically	O
+proven	O
+to	O
+be	O
+negative	O
+for	O
+SARS	B-DISO
+and	O
+in	O
+197	O
+serum	B-COMP
+samples	O
+from	O
+healthy	O
+donors	O
+and	O
+non	O
+-	O
+SARS	B-DISO
+febrile	B-PROC
+patients	O
+.	O
+
+N	O
+protein	B-CHED
+detection	O
+exhibited	O
+a	O
+high	O
+positive	O
+rate	O
+,	O
+96	O
+to	O
+100	O
+%,	O
+between	O
+day	O
+3	O
+and	O
+day	O
+5	O
+after	O
+the	O
+onset	O
+of	O
+symptoms	O
+for	O
+27	O
+neutralization	O
+test	O
+-	O
+positive	O
+SARS	B-DISO
+patients	O
+and	O
+298	O
+serologically	O
+confirmed	O
+patients	O
+.	O
+
+TITLE	O
+:	O
+Research	O
+gaps	O
+in	O
+protecting	O
+healthcare	O
+workers	O
+from	O
+SARS	B-DISO
+and	O
+other	O
+respiratory	O
+pathogens	O
+:	O
+an	O
+interdisciplinary	O
+,	O
+multi	O
+-	O
+stakeholder	O
+,	O
+evidence	O
+-	O
+based	O
+approach	O
+.	O
+
+Proper	O
+disposal	O
+of	O
+patient	O
+excreta	O
+is	O
+important	O
+to	O
+prevent	O
+the	O
+spread	O
+of	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+.	O
+
+TITLE	O
+:	O
+Fulminant	O
+varicella	B-DISO
+infection	I-DISO
+complicated	O
+with	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+,	O
+and	O
+disseminated	B-DISO
+intravascular	I-DISO
+coagulation	I-DISO
+in	O
+an	O
+immunocompetent	O
+young	O
+adult	O
+.	O
+
+Our	O
+results	O
+show	O
+that	O
+corticosteroids	B-CHED
+may	O
+be	O
+of	O
+limited	O
+benefit	O
+in	O
+the	O
+suppression	B-DISO
+of	O
+chemokine	B-PROC
+production	I-PROC
+by	O
+SARS	B-DISO
+-	O
+CoV	O
+-	O
+infected	O
+cells	B-COMP
+.	O
+
+A	O
+total	O
+of	O
+118	O
+nasopharyngeal	B-ANAT
+swab	I-ANAT
+samples	O
+from	O
+118	O
+hospitalized	O
+young	O
+children	O
+aged	O
+less	O
+than	O
+2	O
+years	O
+with	O
+bronchiolitis	B-DISO
+who	O
+were	O
+not	O
+infected	O
+with	O
+human	B-SPEC
+respiratory	I-SPEC
+syncytial	I-SPEC
+virus	I-SPEC
+,	O
+influenza	B-PATH
+A	I-PATH
+or	O
+B	O
+,	O
+or	O
+human	B-SPEC
+metaneumovirus	O
+were	O
+selected	O
+.	O
+
+The	O
+current	O
+study	O
+aimed	O
+to	O
+examine	O
+retrospectively	O
+stored	O
+specimens	O
+for	O
+the	O
+presence	O
+of	O
+HCoV	B-SPEC
+-	I-SPEC
+NL63	I-SPEC
+using	O
+nested	O
+RT	O
+-	O
+PCR	O
+assays	O
+targeting	B-PROC
+the	O
+1a	B-PRGE
+and	I-PRGE
+1b	I-PRGE
+genes	I-PRGE
+.	O
+
+HCoV	B-SPEC
+-	I-SPEC
+NL63	I-SPEC
+positive	O
+individuals	O
+were	O
+diagnosed	O
+most	O
+commonly	O
+with	O
+lower	B-ANAT
+respiratory	I-ANAT
+tract	I-ANAT
+(	O
+LRT	B-ANAT
+)	O
+disease	O
+(	O
+81	O
+%).	O
+
+It	O
+was	O
+shown	O
+that	O
+HCoV	B-SPEC
+-	I-SPEC
+NL63	I-SPEC
+is	O
+associated	O
+with	O
+severe	O
+LRT	B-ANAT
+disease	O
+in	O
+an	O
+Australian	O
+hospital	O
+setting	O
+during	O
+the	O
+cooler	O
+months	O
+of	O
+the	O
+year	O
+.	O
+
+We	O
+propose	O
+that	O
+HCoV	B-SPEC
+-	I-SPEC
+NL63	I-SPEC
+is	O
+a	O
+global	O
+and	O
+seasonal	O
+pathogen	O
+of	O
+both	O
+children	O
+and	O
+adults	O
+associated	O
+with	O
+severe	O
+LRT	B-ANAT
+illness	O
+.	O
+
+We	O
+identified	O
+eight	O
+human	B-SPEC
+MAbs	O
+binding	B-FUNC
+to	O
+virus	B-SPEC
+and	O
+infected	O
+cells	B-COMP
+,	O
+six	O
+of	O
+which	O
+could	O
+be	O
+mapped	O
+to	O
+two	O
+SARS	B-PRGE
+-	I-PRGE
+CoV	I-PRGE
+structural	I-PRGE
+proteins	B-CHED
+:	O
+the	O
+nucleocapsid	B-COMP
+(	O
+N	O
+)	O
+and	O
+spike	O
+(	O
+S	O
+)	O
+proteins	B-CHED
+.	O
+
+The	O
+complete	O
+set	O
+of	O
+SARS	B-PRGE
+-	I-PRGE
+CoV	I-PRGE
+MAbs	I-PRGE
+described	O
+here	O
+may	O
+be	O
+useful	O
+for	O
+diagnosis	O
+,	O
+chemoprophylaxis	O
+,	O
+and	O
+therapy	O
+of	O
+SARS	B-DISO
+-	I-DISO
+CoV	I-DISO
+infection	I-DISO
+and	O
+disease	O
+.	O
+
+ABSTRACT	O
+:	O
+We	O
+have	O
+identified	O
+the	O
+membrane	B-COMP
+-	O
+active	O
+regions	O
+of	O
+the	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+coronavirus	B-SPEC
+(	O
+SARS	B-DISO
+CoV	O
+)	O
+spike	O
+glycoprotein	B-CHED
+by	O
+determining	O
+the	O
+effect	O
+on	O
+model	O
+membrane	B-COMP
+integrity	O
+of	O
+a	O
+16	O
+/	O
+18	O
+-	O
+mer	O
+SARS	B-PRGE
+CoV	I-PRGE
+spike	I-PRGE
+glycoprotein	B-CHED
+peptide	B-CHED
+library	O
+.	O
+
+TITLE	O
+:	O
+Identification	O
+of	O
+two	O
+neutralizing	O
+regions	O
+on	O
+the	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+coronavirus	B-SPEC
+spike	O
+glycoprotein	B-CHED
+produced	O
+from	O
+the	O
+mammalian	B-SPEC
+expression	B-PROC
+system	O
+.	O
+
+ABSTRACT	O
+:	O
+The	O
+Spike	B-PRGE
+(	I-PRGE
+S	I-PRGE
+)	I-PRGE
+protein	I-PRGE
+of	O
+the	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+-	O
+associated	O
+coronavirus	B-SPEC
+(	O
+SARS	B-DISO
+-	O
+CoV	O
+)	O
+plays	O
+important	O
+roles	O
+in	O
+viral	B-DISO
+pathogenesis	I-DISO
+and	O
+potentially	O
+in	O
+the	O
+development	B-PROC
+of	O
+an	O
+effective	O
+vaccine	O
+against	O
+this	O
+virulent	O
+infectious	B-DISO
+disease	I-DISO
+.	O
+
+High	O
+titer	B-PRGE
+S	I-PRGE
+-	I-PRGE
+specific	I-PRGE
+immunoglobulin	I-PRGE
+G	I-PRGE
+antibody	B-PROC
+responses	I-PROC
+were	O
+elicited	O
+in	O
+rabbits	B-SPEC
+immunized	O
+with	O
+DNA	O
+against	O
+various	O
+segments	O
+of	O
+the	O
+S	B-PRGE
+protein	I-PRGE
+.	O
+
+TITLE	O
+:	O
+[	O
+Sero	O
+-	O
+epidemiological	O
+characteristics	O
+of	O
+antibody	B-COMP
+to	O
+SARS	B-DISO
+-	I-DISO
+associated	I-DISO
+coronavirus	I-DISO
+in	O
+Gansu	O
+Province	O
+].	O
+
+TITLE	O
+:	O
+Increased	O
+sensitivity	O
+of	O
+SARS	B-DISO
+-	O
+coronavirus	B-SPEC
+to	O
+a	O
+combination	O
+of	O
+human	B-SPEC
+type	O
+I	O
+and	O
+type	O
+II	O
+interferons	O
+.	O
+
+Recently	O
+,	O
+siRNA	O
+-	O
+induced	O
+RNA	B-PROC
+interference	I-PROC
+(	O
+RNAi	B-PROC
+)	O
+may	O
+provide	O
+a	O
+new	O
+approach	O
+to	O
+therapy	O
+for	O
+pathogenic	O
+viruses	B-SPEC
+,	O
+e	O
+.	O
+g	O
+.	O
+HIV	B-DISO
+and	O
+HCV	B-SPEC
+.	O
+
+ABSTRACT	O
+:	O
+Primary	B-DISO
+graft	I-DISO
+failure	I-DISO
+(	O
+PGF	B-CHED
+)	O
+is	O
+a	O
+severe	O
+acute	O
+lung	B-ANAT
+injury	O
+syndrome	B-DISO
+that	O
+occurs	O
+following	O
+lung	B-ANAT
+transplantation	O
+.	O
+
+Survivors	O
+of	O
+PGF	B-CHED
+have	O
+a	O
+protracted	O
+recovery	O
+with	O
+impaired	B-DISO
+physical	O
+function	O
+up	O
+to	O
+1	O
+year	O
+following	O
+transplantation	O
+.	O
+
+ABSTRACT	O
+:	O
+To	O
+assess	O
+the	O
+burden	O
+of	O
+respiratory	O
+syncytial	O
+virus	O
+(	O
+RSV	B-SPEC
+)-	O
+associated	O
+lower	O
+respiratory	B-DISO
+infections	I-DISO
+(	O
+LRI	O
+)	O
+in	O
+children	O
+in	O
+four	O
+developing	O
+countries	O
+.	O
+
+Among	O
+children	O
+aged	O
+<	O
+5	O
+years	O
+,	O
+the	O
+incidence	O
+of	O
+RSV	B-SPEC
+-	O
+associated	O
+LRI	O
+per	O
+1000	O
+child	O
+-	O
+years	O
+was	O
+34	O
+in	O
+Indonesia	O
+and	O
+94	O
+in	O
+Nigeria	O
+.	O
+
+These	O
+studies	O
+demonstrate	O
+that	O
+RSV	B-PRGE
+contributes	O
+to	O
+a	O
+substantial	O
+but	O
+quite	O
+variable	O
+burden	O
+of	O
+LRI	O
+in	O
+children	O
+aged	O
+<	O
+5	O
+years	O
+in	O
+four	O
+developing	O
+countries	O
+.	O
+
+The	O
+possible	O
+explanations	O
+for	O
+this	O
+variation	O
+include	O
+social	O
+factors	O
+,	O
+such	O
+as	O
+family	B-SPEC
+size	O
+and	O
+patterns	O
+of	O
+seeking	O
+health	O
+care	O
+;	O
+the	O
+proportion	O
+of	O
+children	O
+infected	O
+by	O
+human	B-SPEC
+immunodeficiency	B-DISO
+syndrome	I-DISO
+(	O
+HIV	B-DISO
+);	O
+and	O
+differences	O
+in	O
+clinical	O
+definitions	O
+used	O
+for	O
+obtaining	O
+samples	O
+.	O
+
+These	O
+peptides	B-CHED
+strongly	O
+partitioned	O
+into	O
+lipid	B-CHED
+membranes	B-ANAT
+and	O
+induced	O
+lipid	B-CHED
+vesicle	B-COMP
+permeabilization	O
+at	O
+peptide	B-CHED
+/	O
+lipid	B-CHED
+ratios	O
+of	O
+1	O
+:	O
+100	O
+in	O
+two	O
+independent	O
+leakage	B-DISO
+assays	O
+.	O
+
+Thus	O
+,	O
+partitioning	O
+of	O
+the	O
+peptides	B-CHED
+into	O
+the	O
+lipid	B-CHED
+interface	O
+is	O
+sufficient	O
+to	O
+disorganize	O
+membrane	B-COMP
+integrity	O
+.	O
+
+No	O
+evidence	O
+of	O
+direct	O
+viral	B-DISO
+infection	I-DISO
+was	O
+found	O
+in	O
+the	O
+esophagus	B-ANAT
+,	O
+the	O
+stomach	B-ANAT
+,	O
+the	O
+salivary	B-ANAT
+gland	I-ANAT
+,	O
+the	O
+liver	B-ANAT
+,	O
+or	O
+the	O
+pancreas	B-ANAT
+.	O
+
+In	O
+addition	O
+to	O
+the	O
+lungs	B-ANAT
+,	O
+the	O
+gastrointestinal	B-ANAT
+tract	I-ANAT
+is	O
+another	O
+target	O
+of	O
+SARS	B-DISO
+-	I-DISO
+CoV	I-DISO
+infection	I-DISO
+,	O
+as	O
+the	O
+intestinal	B-ANAT
+epithelial	B-ANAT
+cells	I-ANAT
+and	O
+mucosal	B-ANAT
+lymphoid	B-ANAT
+tissue	I-ANAT
+are	O
+infected	O
+.	O
+
+No	O
+evidence	O
+of	O
+direct	O
+viral	B-DISO
+infection	I-DISO
+was	O
+found	O
+in	O
+the	O
+esophagus	B-ANAT
+,	O
+the	O
+stomach	B-ANAT
+,	O
+the	O
+salivary	B-ANAT
+gland	I-ANAT
+,	O
+the	O
+liver	B-ANAT
+,	O
+or	O
+the	O
+pancreas	B-ANAT
+.	O
+
+This	O
+differential	O
+gene	O
+expression	O
+profiling	O
+of	O
+PBMCs	O
+from	O
+patients	O
+with	O
+SARS	B-DISO
+strongly	O
+suggests	O
+that	O
+the	O
+response	O
+of	O
+SARS	B-DISO
+affected	O
+patients	O
+seems	O
+to	O
+be	O
+mainly	O
+an	O
+innate	O
+inflammatory	B-DISO
+response	I-DISO
+,	O
+rather	O
+than	O
+a	O
+specific	B-PROC
+immune	I-PROC
+response	I-PROC
+against	O
+a	O
+viral	B-DISO
+infection	I-DISO
+,	O
+as	O
+we	O
+observed	O
+a	O
+complete	O
+lack	O
+of	O
+cytokine	O
+genes	O
+usually	O
+triggered	O
+during	O
+a	O
+viral	B-DISO
+infection	I-DISO
+.	O
+
+Problem	O
+severity	O
+in	O
+the	O
+ED	O
+and	O
+stress	O
+levels	O
+of	O
+ED	O
+staff	O
+during	O
+the	O
+SARS	B-DISO
+catastrophe	O
+were	O
+rated	O
+from	O
+mild	O
+(	O
+1	O
+point	O
+)	O
+to	O
+severe	O
+(	O
+5	O
+points	O
+).	O
+
+There	O
+was	O
+a	O
+2	O
+.	O
+1	O
+%	O
+(	O
+95	O
+%	O
+CI	O
+,	O
+0	O
+.	O
+4	O
+-	O
+3	O
+.	O
+8	O
+)	O
+increase	O
+in	O
+the	O
+percentage	O
+of	O
+male	O
+patients	O
+,	O
+a	O
+2	O
+.	O
+5	O
+%	O
+(	O
+95	O
+%	O
+CI	O
+,	O
+1	O
+.	O
+5	O
+-	O
+3	O
+.	O
+7	O
+)	O
+increase	O
+in	O
+percentage	O
+of	O
+fever	B-PROC
+(>	O
+38	O
+degrees	O
+C	O
+),	O
+and	O
+a	O
+4	O
+.	O
+0	O
+%	O
+(	O
+95	O
+%	O
+CI	O
+,	O
+2	O
+.	O
+6	O
+-	O
+5	O
+.	O
+4	O
+%)	O
+increase	O
+in	O
+chief	O
+complaint	O
+of	O
+fever	B-PROC
+in	O
+period	O
+2	O
+.	O
+
+During	O
+the	O
+SARS	B-DISO
+outbreak	O
+,	O
+the	O
+most	O
+severe	O
+stress	O
+experienced	O
+by	O
+either	O
+physicians	O
+or	O
+nurses	O
+occurred	O
+during	O
+emergency	B-DISO
+resuscitation	O
+(	O
+median	O
+stress	O
+rating	O
+point	O
+,	O
+4	O
+;	O
+interquartile	O
+range	O
+,	O
+1	O
+).	O
+
+CONCLUSIONS	O
+:	O
+The	O
+SARS	B-DISO
+catastrophe	O
+affected	O
+the	O
+ED	O
+visit	O
+volume	O
+,	O
+finances	O
+,	O
+various	O
+patient	O
+characteristics	O
+,	O
+and	O
+stress	O
+levels	O
+in	O
+the	O
+ED	O
+physicians	O
+and	O
+nurses	O
+.	O
+
+This	O
+newly	O
+discovered	O
+virus	B-SPEC
+may	O
+have	O
+worldwide	O
+distribution	O
+and	O
+may	O
+account	O
+for	O
+a	O
+significant	O
+proportion	O
+of	O
+respiratory	B-DISO
+tract	I-DISO
+disease	I-DISO
+in	O
+infants	O
+and	O
+young	O
+children	O
+.	O
+
+Human	B-SPEC
+monoclonal	O
+antibodies	B-COMP
+(	O
+MAbs	O
+)	O
+that	O
+neutralize	O
+SARS	B-DISO
+-	I-DISO
+associated	I-DISO
+coronavirus	B-SPEC
+(	O
+SARS	B-DISO
+-	O
+CoV	O
+)	O
+could	O
+provide	O
+protection	O
+for	O
+exposed	O
+individuals	O
+.	O
+
+Two	O
+neutralizing	O
+epitopes	O
+were	O
+defined	O
+for	O
+MAbs	O
+to	O
+SARS	B-PRGE
+-	I-PRGE
+CoV	I-PRGE
+S	I-PRGE
+glycoprotein	B-CHED
+.	O
+
+The	O
+authors	O
+recommend	O
+health	O
+surveillance	O
+not	O
+only	O
+in	O
+humans	B-SPEC
+but	O
+also	O
+in	O
+animals	B-SPEC
+;	O
+the	O
+teaching	O
+of	O
+zoonoses	B-DISO
+,	O
+and	O
+research	O
+on	O
+animal	B-DISO
+diseases	I-DISO
+transmissible	O
+to	O
+humans	B-SPEC
+.	O
+
+TITLE	O
+:	O
+SARS	B-DISO
+(	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+):	O
+reflective	O
+practice	O
+of	O
+a	O
+nurse	O
+manager	O
+.	O
+
+SARS	B-DISO
+infection	B-DISO
+was	O
+a	O
+crisis	O
+for	O
+everyone	O
+in	O
+endemic	O
+areas	O
+because	O
+of	O
+its	O
+threat	O
+to	O
+physical	O
+and	O
+emotional	O
+health	O
+.	O
+
+TITLE	O
+:	O
+Characterization	O
+of	O
+cytokine	O
+/	O
+chemokine	O
+profiles	O
+of	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+.	O
+
+Reverse	B-PROC
+transcription	I-PROC
+-	O
+polymerase	O
+chain	O
+reaction	O
+was	O
+performed	O
+to	O
+amplify	O
+mRNA	B-CHED
+.	O
+
+The	O
+levels	O
+of	O
+interleukin	B-PRGE
+-	I-PRGE
+6	I-PRGE
+,	O
+interleukin	B-PRGE
+-	I-PRGE
+8	I-PRGE
+,	I-PRGE
+and	I-PRGE
+monocyte	I-PRGE
+chemoattractant	I-PRGE
+protein	B-CHED
+-	I-PRGE
+1	I-PRGE
+were	O
+concomitantly	O
+increased	O
+in	O
+the	O
+blood	B-ANAT
+of	O
+the	O
+patients	O
+with	O
+superinfection	B-DISO
+,	O
+and	O
+the	O
+mRNAs	O
+for	O
+these	O
+cytokines	O
+were	O
+also	O
+increased	O
+in	O
+lung	B-ANAT
+tissues	I-ANAT
+.	O
+
+Based	O
+on	O
+the	O
+fluorescence	O
+resonance	O
+energy	B-PROC
+transfer	I-PROC
+(	O
+FRET	O
+)	O
+principle	O
+using	O
+5	O
+-[(	O
+2	O
+'-	O
+aminoethyl	O
+)-	O
+amino	O
+]	O
+naphthelenesulfonic	O
+acid	O
+(	O
+EDANS	O
+)	O
+and	O
+4	O
+-[[	O
+4	O
+-(	O
+dimethylamino	O
+)	O
+phenyl	B-CHED
+]	O
+azo	B-CHED
+]	O
+benzoic	B-CHED
+acid	I-CHED
+(	O
+Dabcyl	O
+)	O
+as	O
+the	O
+energy	B-PROC
+transfer	I-PROC
+pair	O
+,	O
+one	O
+fluorogenic	O
+substrate	O
+was	O
+designed	O
+for	O
+the	O
+evaluation	O
+of	O
+SARS	B-PRGE
+-	I-PRGE
+CoV	I-PRGE
+3CL	I-PRGE
+(	O
+pro	B-PRGE
+)	O
+proteolytic	B-PROC
+activity	O
+.	O
+
+By	O
+allowing	O
+patients	O
+with	O
+acute	O
+lung	B-ANAT
+injury	O
+to	O
+breathe	O
+spontaneously	O
+,	O
+one	O
+can	O
+expect	O
+improvement	O
+in	O
+gas	B-ENZY
+exchange	O
+and	O
+in	O
+systemic	O
+blood	B-PROC
+flow	I-PROC
+,	O
+on	O
+the	O
+basis	O
+of	O
+both	O
+experimental	O
+and	O
+clinical	O
+trials	O
+.	O
+
+Until	O
+recently	O
+,	O
+traditional	O
+approaches	O
+to	O
+mechanical	O
+ventilatory	O
+support	O
+of	O
+patients	O
+with	O
+acute	O
+lung	B-ANAT
+injury	O
+have	O
+called	O
+for	O
+adaptation	B-PROC
+of	O
+the	O
+patient	O
+to	O
+the	O
+mechanical	O
+ventilator	O
+using	O
+heavy	O
+sedation	B-DISO
+and	O
+administration	O
+of	O
+neuromuscular	O
+blocking	B-DISO
+agents	O
+.	O
+
+Further	O
+,	O
+evidence	O
+exists	O
+that	O
+lowering	O
+sedation	B-DISO
+levels	O
+will	O
+decrease	O
+the	O
+duration	O
+of	O
+mechanical	O
+ventilatory	O
+support	O
+,	O
+the	O
+length	O
+of	O
+stay	O
+in	O
+the	O
+intensive	O
+care	O
+unit	O
+,	O
+and	O
+the	O
+overall	O
+costs	O
+of	O
+hospitalization	O
+.	O
+
+Noninvasive	O
+ventilation	O
+also	O
+does	O
+not	O
+seem	O
+to	O
+increase	O
+the	O
+risk	O
+of	O
+dissemination	O
+of	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+to	O
+health	O
+care	O
+workers	O
+as	O
+long	O
+as	O
+strict	O
+isolation	O
+procedures	O
+are	O
+used	O
+.	O
+
+Human	B-SPEC
+metapneumovirus	I-SPEC
+(	O
+HMPV	B-SPEC
+)	O
+is	O
+now	O
+recognized	O
+to	O
+cause	O
+LRI	O
+illness	O
+similar	O
+to	O
+respiratory	B-SPEC
+syncytial	I-SPEC
+virus	I-SPEC
+(	O
+RSV	B-SPEC
+)	O
+in	O
+infants	O
+and	O
+children	O
+.	O
+
+Results	O
+indicated	O
+that	O
+orally	B-ANAT
+delivered	O
+MG1363	O
+/	O
+pSECN	O
+induced	O
+significant	O
+N	O
+-	O
+specific	O
+IgG	B-PRGE
+in	O
+the	O
+sera	B-COMP
+.	O
+
+A	O
+novel	B-SPEC
+coronavirus	I-SPEC
+was	O
+implicated	O
+and	O
+its	O
+entire	O
+genome	O
+was	O
+sequenced	O
+by	O
+mid	O
+-	O
+April	O
+2003	O
+.	O
+
+ABSTRACT	O
+:	O
+Molecular	O
+clones	O
+of	O
+infectious	O
+bronchitis	B-DISO
+virus	B-SPEC
+(	O
+IBV	B-SPEC
+),	O
+derived	O
+from	O
+the	O
+Vero	B-ANAT
+cell	I-ANAT
+adapted	O
+Beaudette	O
+strain	O
+,	O
+were	O
+constructed	O
+,	O
+using	O
+an	O
+in	O
+vitro	O
+assembly	O
+method	O
+.	O
+
+The	O
+recombinant	O
+virus	B-SPEC
+was	O
+further	O
+manipulated	O
+to	O
+express	O
+enhanced	B-PRGE
+green	I-PRGE
+fluorescent	I-PRGE
+protein	I-PRGE
+(	O
+EGFP	B-CHED
+)	O
+by	O
+replacing	O
+an	O
+open	O
+reading	O
+frame	O
+(	O
+ORF	O
+)	O
+of	O
+the	O
+group	O
+-	O
+specific	O
+gene	O
+,	O
+ORF	B-PRGE
+5a	I-PRGE
+,	O
+with	O
+the	O
+EGFP	B-PRGE
+ORF	I-PRGE
+.	O
+
+A	O
+75	O
+kDa	O
+fragment	O
+of	O
+transmissible	O
+gastroenteritis	B-DISO
+coronavirus	B-SPEC
+(	O
+TGEV	B-SPEC
+)	O
+spike	O
+glycoprotein	B-CHED
+S	O
+was	O
+used	O
+as	O
+the	O
+model	O
+coronavirus	B-SPEC
+antigen	B-CHED
+.	O
+
+TITLE	O
+:	O
+Viral	O
+and	O
+bacterial	O
+pathogens	O
+in	O
+bovine	B-SPEC
+respiratory	B-DISO
+disease	I-DISO
+in	O
+Finland	O
+.	O
+
+Pasteurella	B-SPEC
+sp	O
+.	O
+strains	O
+showed	O
+no	O
+resistance	B-PROC
+to	O
+tested	O
+antimicrobials	B-CHED
+.	O
+
+ABSTRACT	O
+:	O
+A	O
+reverse	B-ENZY
+transcriptase	B-FUNC
+polymerase	O
+chain	O
+reaction	O
+(	O
+RT	O
+-	O
+PCR	O
+)	O
+for	O
+the	O
+detection	O
+of	O
+feline	B-SPEC
+coronavirus	B-SPEC
+(	O
+FCoV	O
+)	O
+messenger	B-CHED
+RNA	I-CHED
+in	O
+peripheral	B-ANAT
+blood	I-ANAT
+mononuclear	I-ANAT
+cells	I-ANAT
+(	O
+PBMCs	O
+)	O
+is	O
+described	O
+.	O
+
+It	O
+is	O
+based	O
+on	O
+a	O
+well	O
+-	O
+documented	O
+key	O
+event	O
+in	O
+the	O
+development	B-PROC
+of	O
+FIP	B-DISO
+:	O
+the	O
+replication	O
+of	O
+virulent	O
+FCoV	O
+mutants	O
+in	O
+monocytes	B-ANAT
+/	O
+macrophages	B-ANAT
+.	O
+
+Eight	O
+different	O
+IBV	B-SPEC
+strains	O
+representing	O
+seven	O
+serotypes	O
+were	O
+tested	O
+and	O
+each	O
+chimeric	O
+oligonucleotide	O
+mediated	O
+cleavage	B-PROC
+of	O
+target	O
+RNA	O
+only	O
+from	O
+strains	O
+within	O
+the	O
+serotype	O
+that	O
+the	O
+chimeric	O
+was	O
+designed	O
+against	O
+.	O
+
+This	O
+underscores	O
+the	O
+necessity	O
+of	O
+developing	O
+a	O
+clinically	O
+relevant	O
+model	O
+of	O
+ARDS	B-DISO
+.	O
+
+Pigs	O
+were	O
+treated	O
+with	O
+antibiotics	B-CHED
+and	O
+fluids	B-ANAT
+,	O
+placed	O
+on	O
+a	O
+ventilator	O
+before	O
+sacrifice	O
+to	O
+obtain	O
+hemodynamic	B-PROC
+and	O
+pulmonary	B-ANAT
+parameters	O
+,	O
+and	O
+underwent	O
+histologic	O
+lung	B-ANAT
+assessment	O
+.	O
+
+By	O
+closely	O
+paralleling	O
+the	O
+clinical	O
+development	B-PROC
+of	O
+pulmonary	B-ANAT
+injury	O
+,	O
+this	O
+model	O
+should	O
+prove	O
+invaluable	O
+in	O
+the	O
+study	O
+of	O
+human	B-DISO
+ARDS	I-DISO
+.	O
+
+Blood	B-ANAT
+was	O
+drawn	O
+weekly	O
+to	O
+monitor	O
+antibodies	B-COMP
+to	O
+AIBV	O
+.	O
+
+Comparing	O
+daily	O
+sperm	B-ANAT
+production	O
+on	O
+a	O
+per	O
+gram	O
+basis	O
+,	O
+vaccinated	O
+roosters	O
+with	O
+epididymal	B-ANAT
+stones	O
+had	O
+4	O
+.	O
+38	O
++/-	O
+
+Forty	O
+compounds	O
+were	O
+purchased	O
+and	O
+tested	O
+by	O
+HPLC	O
+and	O
+colorimetric	O
+assay	O
+against	O
+SARS	B-PRGE
+3C	I-PRGE
+-	I-PRGE
+like	I-PRGE
+proteinase	B-PROC
+.	O
+
+Anecdotally	O
+,	O
+many	O
+people	O
+complain	O
+of	O
+respiratory	B-DISO
+symptoms	I-DISO
+following	O
+air	B-CHED
+travel	O
+.	O
+
+However	O
+,	O
+studies	O
+of	O
+ventilation	O
+systems	O
+and	O
+patient	O
+outcomes	O
+indicate	O
+the	O
+spread	O
+of	O
+pathogens	O
+during	O
+flight	B-PROC
+occurs	O
+rarely	O
+.	O
+
+Twelve	O
+severely	O
+brain	B-ANAT
+-	O
+injured	O
+patients	O
+with	O
+acute	O
+lung	B-ANAT
+injury	O
+and	O
+intracranial	B-PROC
+pressure	I-PROC
+higher	O
+than	O
+applied	O
+PEEP	B-CHED
+.	O
+
+In	O
+all	O
+patients	O
+intracranial	B-PROC
+pressure	I-PROC
+,	O
+flow	O
+velocity	O
+by	O
+transcranial	O
+Doppler	O
+of	O
+middle	B-ANAT
+cerebral	I-ANAT
+artery	I-ANAT
+,	O
+and	O
+jugular	O
+oxygen	B-CHED
+saturation	O
+were	O
+recorded	O
+.	O
+
+Intracranial	B-PROC
+pressure	I-PROC
+,	O
+Doppler	O
+flow	O
+velocity	O
+,	O
+and	O
+jugular	O
+saturation	O
+remained	O
+constant	O
+in	O
+recruiters	O
+but	O
+significantly	O
+increased	O
+(	O
+P	O
+<	O
+0	O
+.	O
+0001	O
+)	O
+in	O
+non	O
+-	O
+recruiters	O
+.	O
+
+Seven	O
+patients	O
+with	O
+histories	O
+of	O
+only	O
+urban	O
+exposure	O
+to	O
+leptospires	O
+had	O
+severe	O
+pulmonary	B-ANAT
+manifestations	O
+;	O
+of	O
+these	O
+,	O
+5	O
+patients	O
+died	B-PROC
+;	O
+4	O
+of	O
+the	O
+deaths	B-PROC
+were	O
+caused	O
+by	O
+pulmonary	B-DISO
+hemorrhage	I-DISO
+,	O
+and	O
+1	O
+was	O
+caused	O
+by	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+and	O
+multiorgan	B-DISO
+failure	I-DISO
+.	O
+
+Presumptive	O
+treatment	O
+for	O
+leptospirosis	B-DISO
+should	O
+be	O
+initiated	O
+immediately	O
+in	O
+the	O
+appropriate	O
+epidemiological	O
+and	O
+clinical	O
+context	O
+.	O
+
+To	O
+explore	O
+the	O
+possible	O
+molecular	O
+mechanisms	O
+of	O
+the	O
+invasion	B-DISO
+and	O
+virulence	B-PROC
+of	O
+SARS	B-PRGE
+-	I-PRGE
+CoV	I-PRGE
+,	O
+we	O
+investigated	O
+the	O
+structural	O
+basis	O
+of	O
+the	O
+viral	O
+proteins	B-CHED
+using	O
+computational	O
+biology	O
+.	O
+
+Comparison	O
+of	O
+SARS	B-DISO
+-	O
+CoV	O
+with	O
+other	O
+viruses	B-SPEC
+(	O
+OC43	O
+,	O
+PEDV	B-SPEC
+,	O
+HRSV	B-SPEC
+,	O
+HHerpV	O
+and	O
+HAdenoV	O
+)	O
+showed	O
+that	O
+each	O
+group	O
+of	O
+motifs	O
+was	O
+different	O
+for	O
+each	O
+type	O
+of	O
+virus	B-SPEC
+.	O
+
+(	O
+2	O
+)	O
+The	O
+evidence	O
+for	O
+immune	O
+implication	O
+in	O
+distress	O
+strongly	O
+supports	O
+immunomodulators	O
+for	O
+therapy	O
+:	O
+phosphodiesterase	B-PROC
+inhibitors	I-PROC
+(	O
+due	O
+to	O
+their	O
+down	O
+-	O
+modulating	O
+activity	O
+on	O
+proinflammatory	O
+cytokines	O
+);	O
+inhaled	O
+corticoids	O
+(	O
+aimed	O
+at	O
+producing	O
+a	O
+local	O
+immunomodulation	B-PROC
+);	O
+teophylline	O
+or	O
+nedocromil	B-CHED
+sodium	I-CHED
+(	O
+which	O
+prevents	O
+inflammatory	B-ANAT
+cell	I-ANAT
+recruitment	B-DISO
+into	O
+the	O
+airway	B-ANAT
+wall	O
+).	O
+
+Apart	O
+from	O
+fever	B-PROC
+and	O
+respiratory	B-DISO
+complications	I-DISO
+,	O
+acute	B-DISO
+renal	I-DISO
+impairment	I-DISO
+has	O
+been	O
+observed	O
+in	O
+some	O
+patients	O
+with	O
+SARS	B-DISO
+.	O
+
+Electronic	O
+and	O
+manual	O
+searches	O
+identified	O
+RCTs	O
+comparing	O
+Chinese	O
+medicine	B-CHED
+integrated	O
+to	O
+conventional	O
+medicine	B-CHED
+versus	O
+conventional	O
+medicine	B-CHED
+alone	O
+.	O
+
+There	O
+were	O
+no	O
+significant	O
+effects	O
+on	O
+quality	O
+of	O
+life	O
+or	O
+glucocorticoid	B-CHED
+dosage	O
+.	O
+
+CONCLUSIONS	O
+:	O
+Chinese	O
+herbal	O
+medicine	B-CHED
+combined	O
+with	O
+conventional	O
+medicine	B-CHED
+may	O
+have	O
+beneficial	O
+effects	O
+in	O
+patients	O
+with	O
+SARS	B-DISO
+.	O
+
+The	O
+initial	O
+laboratory	O
+tests	O
+and	O
+immunological	O
+evaluation	O
+confirmed	O
+active	O
+systemic	B-PATH
+lupus	I-PATH
+erythematosus	I-PATH
+complicated	O
+by	O
+severe	B-DISO
+pre	I-DISO
+-	I-DISO
+eclampsia	I-DISO
+.	O
+
+One	O
+week	O
+after	O
+admission	O
+,	O
+she	O
+became	O
+suddenly	O
+confused	B-DISO
+and	O
+had	O
+a	O
+convulsion	B-DISO
+with	O
+Glascow	O
+Coma	B-DISO
+Score	O
+10	O
+(	O
+3	O
++	O
+3	O
++	O
+4	O
+).	O
+
+In	O
+situ	O
+hybridization	B-PROC
+was	O
+used	O
+to	O
+identify	O
+sites	O
+of	O
+virus	B-PROC
+replication	I-PROC
+,	O
+and	O
+reverse	B-PRGE
+transcriptase	I-PRGE
+-	O
+polymerase	O
+chain	O
+reaction	O
+analysis	O
+was	O
+used	O
+to	O
+detect	O
+viral	O
+RNA	O
+in	O
+feces	B-ANAT
+and	O
+blood	B-ANAT
+.	O
+
+TITLE	O
+:	O
+Evaluation	O
+of	O
+a	O
+safe	O
+and	O
+sensitive	O
+Spike	O
+protein	B-CHED
+-	O
+based	O
+immunofluorescence	O
+assay	O
+for	O
+the	O
+detection	O
+of	O
+antibody	O
+responses	O
+to	O
+SARS	B-PRGE
+-	I-PRGE
+CoV	I-PRGE
+.	O
+ABSTRACT	O
+:	O
+Previously	O
+,	O
+we	O
+have	O
+identified	O
+a	O
+truncated	O
+antigenic	O
+fragment	O
+named	O
+protein	B-CHED
+C	O
+[	O
+441	O
+to	O
+700	O
+amino	B-CHED
+acids	I-CHED
+(	O
+a	O
+.	O
+a	O
+.)]	O
+as	O
+the	O
+immunodominant	O
+fragment	O
+of	O
+Spike	O
+(	O
+S	O
+)	O
+protein	B-CHED
+of	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+(	O
+SARS	B-DISO
+)	O
+coronavirus	B-SPEC
+(	O
+SARS	B-DISO
+-	O
+CoV	O
+).	O
+
+It	O
+is	O
+also	O
+more	O
+user	O
+-	O
+friendly	O
+and	O
+cost	O
+-	O
+effective	O
+than	O
+the	O
+whole	O
+virus	B-SPEC
+-	O
+based	O
+IFA	O
+.	O
+
+TITLE	O
+:	O
+Programmed	O
+ribosomal	B-PROC
+frameshifting	I-PROC
+in	O
+decoding	O
+the	O
+SARS	B-DISO
+-	O
+CoV	O
+genome	O
+.	O
+
+ABSTRACT	O
+:	O
+Programmed	O
+ribosomal	B-ANAT
+frameshifting	I-PROC
+is	O
+an	O
+essential	O
+mechanism	O
+used	O
+for	O
+the	O
+expression	B-PROC
+of	O
+orf1b	O
+in	O
+coronaviruses	O
+.	O
+
+TITLE	O
+:	O
+Surviving	O
+severe	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+:	O
+utility	O
+of	O
+open	O
+-	O
+lung	B-ANAT
+biopsy	O
+and	O
+large	O
+doses	O
+of	O
+dexamethasone	O
+.	O
+
+ABSTRACT	O
+:	O
+The	O
+etiology	O
+of	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+is	O
+wide	O
+and	O
+mortality	O
+is	O
+extremely	O
+high	O
+.	O
+
+Thirty	O
+-	O
+six	O
+hours	O
+after	O
+the	O
+large	O
+dose	O
+of	O
+corticosteroids	B-CHED
+,	O
+the	O
+respiratory	B-PROC
+mechanics	I-PROC
+and	O
+oxygenation	B-PROC
+were	O
+acceptable	O
+for	O
+extubation	O
+.	O
+
+TITLE	O
+:	O
+Identification	O
+of	O
+a	O
+novel	B-SPEC
+coronavirus	I-SPEC
+in	O
+bats	B-SPEC
+.	O
+
+Other	O
+signs	O
+of	O
+IRF	B-PRGE
+-	I-PRGE
+3	I-PRGE
+activation	O
+such	O
+as	O
+hyperphosphorylation	O
+,	O
+homodimer	O
+formation	B-PROC
+,	O
+and	O
+recruitment	B-DISO
+of	O
+the	O
+coactivator	O
+CREB	B-PRGE
+-	I-PRGE
+binding	I-PRGE
+protein	B-CHED
+(	O
+CBP	B-PRGE
+)	O
+were	O
+found	O
+late	O
+after	O
+infection	B-DISO
+with	O
+the	O
+control	O
+virus	B-SPEC
+but	O
+not	O
+with	O
+SARS	B-DISO
+-	O
+CoV	O
+.	O
+Our	O
+data	O
+suggest	O
+that	O
+nuclear	B-PROC
+transport	I-PROC
+of	O
+IRF	B-PRGE
+-	I-PRGE
+3	I-PRGE
+is	O
+an	O
+immediate	O
+-	O
+early	O
+reaction	O
+to	O
+virus	B-DISO
+infection	I-DISO
+and	O
+may	O
+precede	O
+its	O
+hyperphosphorylation	O
+,	O
+homodimer	O
+formation	B-PROC
+,	O
+and	O
+binding	B-FUNC
+to	O
+CBP	B-PRGE
+.	O
+
+ABSTRACT	O
+:	O
+Outbreaks	O
+of	O
+Severe	B-DISO
+Acute	I-DISO
+Respiratory	I-DISO
+Syndrome	I-DISO
+(	O
+SARS	B-DISO
+)	O
+in	O
+2003	O
+and	O
+renewed	O
+concerns	O
+regarding	O
+pandemic	O
+influenza	B-DISO
+have	O
+resulted	O
+in	O
+widespread	O
+planning	O
+for	O
+future	O
+respiratory	B-DISO
+disease	I-DISO
+outbreaks	O
+.	O
+
+The	O
+immunological	O
+fragment	O
+of	O
+the	O
+S	B-PRGE
+protein	I-PRGE
+(	O
+Ala251	O
+-	O
+His641	O
+,	O
+SARS_S1b	O
+)	O
+is	O
+believed	O
+to	O
+be	O
+essential	O
+for	O
+SARS_CoV	O
+entering	O
+the	O
+host	B-COMP
+cell	I-COMP
+through	O
+S	B-PRGE
+protein	I-PRGE
+-	O
+ACE	B-PRGE
+-	O
+2	O
+interaction	O
+.	O
+
+We	O
+have	O
+quantitatively	O
+characterized	O
+the	O
+thermally	O
+induced	O
+and	O
+GuHCl	O
+-	O
+induced	O
+unfolding	O
+features	O
+of	O
+SARS_S1b	O
+using	O
+circular	O
+dichroism	O
+(	O
+CD	O
+),	O
+tryptophan	B-CHED
+fluorescence	O
+,	O
+and	O
+stopped	O
+-	O
+flow	O
+spectral	O
+techniques	O
+.	O
+
+GL	O
+itself	O
+,	O
+at	O
+400	O
+mg	O
+/	O
+kg	O
+,	O
+produced	O
+no	O
+detectable	O
+abnormalities	O
+in	O
+the	O
+appearance	O
+or	O
+activity	O
+of	O
+mice	B-SPEC
+.	O
+
+Intraperitoneal	O
+injection	O
+of	O
+aspirin	B-CHED
+or	O
+dexamethasone	B-CHED
+had	O
+only	O
+marginal	O
+effects	O
+on	O
+LPS	B-DISO
+-	O
+induced	O
+platelet	B-ANAT
+responses	O
+and	O
+lethality	O
+.	O
+
+The	O
+immunological	O
+effect	O
+of	O
+anti	B-PRGE
+-	I-PRGE
+SARS	I-PRGE
+-	I-PRGE
+CoV	I-PRGE
+antibody	B-COMP
+was	O
+tested	O
+with	O
+purified	O
+rS	O
+(	O
+a	O
+)	O
+and	O
+rS	O
+(	O
+b	O
+)	O
+proteins	B-CHED
+by	O
+enzyme	O
+-	O
+linked	O
+immunosorbent	O
+assay	O
+(	O
+ELISA	O
+).	O
+
+The	O
+prokaryotically	O
+expressed	B-PROC
+recombinant	B-PRGE
+truncated	I-PRGE
+S	I-PRGE
+protein	I-PRGE
+had	O
+similar	O
+antigenicity	O
+with	O
+SARS	B-PRGE
+-	I-PRGE
+CoV	I-PRGE
+S	I-PRGE
+protein	B-CHED
+.	O
+
+ABSTRACT	O
+:	O
+Phytochemical	O
+investigation	O
+of	O
+the	O
+roots	O
+of	O
+Calophyllum	O
+blancoi	O
+growing	O
+in	O
+Taiwan	O
+resulted	O
+in	O
+the	O
+isolation	O
+of	O
+three	O
+new	O
+pyranoxanthones	B-CHED
+,	O
+blancoxanthone	B-CHED
+(	O
+1	O
+),	O
+acetyl	B-CHED
+blancoxanthone	B-CHED
+(	O
+2	O
+)	O
+and	O
+3	O
+-	O
+hydroxyblancoxanthone	O
+(	O
+3	O
+),	O
+in	O
+addition	O
+to	O
+two	O
+known	O
+pyranoxanthones	B-CHED
+,	O
+pyranojacaeubin	O
+(	O
+4	O
+)	O
+and	O
+caloxanthone	O
+(	O
+5	O
+).	O
+
+TITLE	O
+:	O
+TCM	O
+treatment	O
+of	O
+infectious	B-DISO
+atypical	B-DISO
+pneumonia	I-DISO
+--	O
+a	O
+report	O
+of	O
+16	O
+cases	O
+.	O
+
+1	O
+.	O
+46	O
+days	O
+and	O
+the	O
+mean	O
+absorption	O
+time	O
+of	O
+gross	O
+pulmonary	B-DISO
+infiltration	I-DISO
+was	O
+10	O
+.	O
+87	O
++/-	O
+
+METHODS	O
+:	O
+Twelve	O
+TCM	O
+prescriptions	O
+of	O
+herbal	O
+drugs	O
+(	O
+orally	B-ANAT
+or	O
+i	O
+.	O
+v	O
+.)	O
+were	O
+used	O
+to	O
+treat	O
+16	O
+cases	O
+of	O
+SARS	O
+without	O
+using	O
+glucocorticoids	B-CHED
+,	O
+anti	B-CHED
+-	I-CHED
+viral	I-CHED
+agents	I-CHED
+,	O
+immune	O
+-	O
+regulators	O
+or	O
+antibiotics	B-CHED
+(	O
+in	O
+case	O
+there	O
+was	O
+no	O
+definite	O
+bacterial	B-DISO
+infections	I-DISO
+).	O
+
+Acute	O
+transient	O
+lameness	B-DISO
+on	O
+the	O
+ranch	O
+was	O
+attributed	O
+to	O
+use	O
+of	O
+2	O
+irritating	O
+biological	O
+vaccines	O
+in	O
+the	O
+hip	B-ANAT
+muscles	I-ANAT
+of	O
+cows	B-SPEC
+that	O
+were	O
+close	O
+to	O
+parturition	B-PROC
+.	O
+
+ABSTRACT	O
+:	O
+Chronic	B-DISO
+obstructive	I-DISO
+pulmonary	I-DISO
+disease	I-DISO
+(	O
+COPD	B-DISO
+)	O
+is	O
+a	O
+major	O
+public	O
+health	O
+problem	O
+and	O
+its	O
+prevalence	O
+and	O
+mortality	O
+are	O
+increasing	O
+throughout	O
+the	O
+world	O
+,	O
+including	O
+the	O
+Asia	O
+-	O
+Pacific	O
+region	O
+.	O
+
+Perceptions	O
+of	O
+comfort	O
+,	O
+ease	O
+of	O
+use	O
+,	O
+visual	O
+,	O
+hearing	B-PROC
+,	O
+breathing	B-PROC
+and	O
+speech	B-DISO
+impairment	I-DISO
+,	O
+perceived	O
+protection	O
+against	O
+SARS	B-DISO
+and	O
+usage	O
+preferences	O
+were	O
+recorded	O
+.	O
+
+However	O
+,	O
+opinions	O
+were	O
+equally	O
+divided	O
+regarding	O
+its	O
+use	O
+when	O
+treating	O
+patients	O
+with	O
+pulmonary	B-DISO
+tuberculosis	B-PATH
+;	O
+with	O
+51	O
+%	O
+being	O
+in	O
+favour	O
+.	O
+
+In	O
+this	O
+study	O
+,	O
+the	O
+cleavage	B-PROC
+mechanism	O
+of	O
+the	O
+SARS	B-DISO
+coronavirus	B-SPEC
+main	O
+proteinase	B-PROC
+(	O
+Mpro	O
+or	O
+3CLpro	O
+)	O
+on	O
+the	O
+octapeptide	O
+NH2	O
+-	O
+AVLQ	O
+downward	O
+arrowSGFR	O
+-	O
+COOH	O
+was	O
+investigated	O
+using	O
+molecular	O
+mechanics	O
+and	O
+quantum	O
+mechanics	O
+simulations	O
+based	O
+on	O
+the	O
+experimental	O
+structure	O
+of	O
+the	O
+proteinase	B-PROC
+.	O
+
+Ndelta1	O
+on	O
+the	O
+imidazole	B-CHED
+ring	O
+plays	O
+the	O
+acid	O
+-	O
+base	O
+catalytic	O
+role	O
+.	O
+
+In	O
+the	O
+killed	O
+-	O
+virus	B-SPEC
+and	O
+high	O
+-	O
+dose	O
+live	O
+-	O
+virus	B-SPEC
+test	O
+groups	O
+,	O
+IBV	B-SPEC
+vaccination	O
+protected	O
+against	O
+challenge	O
+by	O
+homologous	O
+but	O
+not	O
+heterologous	O
+IBV	O
+strains	O
+.	O
+
+The	O
+results	O
+were	O
+analyzed	O
+by	O
+statistic	O
+methods	O
+to	O
+eliminate	O
+the	O
+bias	B-SPEC
+in	O
+target	O
+-	O
+based	O
+database	O
+screening	O
+toward	O
+higher	O
+molecular	O
+weight	O
+compounds	O
+for	O
+enhancing	O
+the	O
+hit	O
+rate	O
+.	O
+
+TITLE	O
+:	O
+When	O
+animal	B-SPEC
+viruses	B-SPEC
+attack	O
+:	O
+SARS	B-DISO
+and	O
+avian	B-DISO
+influenza	I-DISO
+.	O
+
+A	O
+1999	O
+Centers	O
+for	O
+Disease	O
+Control	O
+and	O
+Prevention	O
+projection	O
+of	O
+an	O
+influenza	B-DISO
+pandemic	O
+in	O
+the	O
+US	O
+paints	O
+a	O
+grim	O
+picture	O
+:	O
+89	O
+,	O
+000	O
+to	O
+207	O
+,	O
+000	O
+deaths	B-PROC
+,	O
+314	O
+,	O
+000	O
+to	O
+734	O
+,	O
+000	O
+hospitalizations	O
+,	O
+18	O
+million	O
+to	O
+42	O
+million	O
+outpatient	O
+visits	O
+,	O
+and	O
+20	O
+million	O
+to	O
+47	O
+million	O
+additional	O
+illnesses	O
+,	O
+at	O
+a	O
+cost	O
+to	O
+society	O
+of	O
+at	O
+least	O
+dollars	O
+71	O
+.	O
+3	O
+billion	O
+to	O
+dollars	O
+166	O
+.	O
+5	O
+billion	O
+.	O
+
+Clinical	O
+characteristics	O
+and	O
+chronic	O
+oxygen	B-CHED
+requirement	O
+pattern	O
+of	O
+CLD	B-DISO
+without	O
+RDS	O
+seems	O
+to	O
+be	O
+less	O
+severe	O
+than	O
+those	O
+of	O
+CLD	B-DISO
+with	O
+RDS	O
+.	O
+
+Among	O
+them	O
+,	O
+17	O
+are	O
+polymorphic	O
+in	O
+palm	B-ANAT
+civets	B-SPEC
+only	O
+.	O
+
+The	O
+ratio	O
+of	O
+nonsynonymous	O
+/	O
+synonymous	O
+nucleotide	B-CHED
+substitution	O
+in	O
+palm	B-ANAT
+civets	B-SPEC
+collected	O
+1	O
+yr	O
+apart	O
+from	O
+different	O
+geographic	O
+locations	O
+is	O
+very	O
+high	O
+,	O
+suggesting	O
+a	O
+rapid	O
+evolving	O
+process	O
+of	O
+viral	O
+proteins	B-CHED
+in	O
+civet	B-SPEC
+as	O
+well	O
+,	O
+much	O
+like	O
+their	O
+adaptation	B-PROC
+in	O
+the	O
+human	B-SPEC
+host	B-COMP
+in	O
+the	O
+early	O
+2002	O
+-	O
+2003	O
+epidemic	O
+.	O
+
+ABSTRACT	O
+:	O
+We	O
+describe	O
+the	O
+emergence	O
+of	O
+a	O
+nephropathogenic	O
+avian	O
+infectious	O
+bronchitis	O
+virus	B-SPEC
+(	O
+IBV	B-SPEC
+)	O
+with	O
+a	O
+novel	O
+genotype	O
+in	O
+India	O
+.	O
+
+ABSTRACT	O
+:	O
+We	O
+examined	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+-	O
+associated	O
+coronavirus	B-SPEC
+(	O
+SARS	B-DISO
+-	O
+CoV	O
+)	O
+RNA	O
+in	O
+plasma	B-ANAT
+of	O
+32	O
+patients	O
+(	O
+probable	O
+SARS	B-DISO
+cases	O
+)	O
+by	O
+a	O
+quantitative	O
+real	O
+-	O
+time	O
+reverse	B-PROC
+transcription	I-PROC
+-	O
+PCR	O
+assay	O
+and	O
+reported	O
+that	O
+the	O
+highest	O
+detection	O
+rate	O
+,	O
+75	O
+%,	O
+was	O
+found	O
+between	O
+day	O
+5	O
+and	O
+day	O
+7	O
+of	O
+illness	O
+,	O
+followed	O
+by	O
+rates	O
+of	O
+64	O
+,	O
+50	O
+,	O
+and	O
+38	O
+%	O
+found	O
+between	O
+day	O
+8	O
+and	O
+day	O
+11	O
+,	O
+day	O
+2	O
+and	O
+day	O
+4	O
+,	O
+and	O
+day	O
+12	O
+and	O
+day	O
+16	O
+,	O
+respectively	O
+.	O
+
+After	O
+adjustments	O
+for	O
+age	O
+and	O
+sex	O
+,	O
+high	O
+FE	O
+UA	O
+was	O
+significantly	O
+associated	O
+with	O
+the	O
+lowest	O
+blood	B-ANAT
+oxygenation	B-PROC
+(	O
+P	O
+=	O
+0	O
+.	O
+001	O
+;	O
+r	O
+=	O
+-	O
+0	O
+.	O
+624	O
+).	O
+
+The	O
+number	O
+of	O
+catastrophic	O
+outcomes	O
+(	O
+endotracheal	O
+intubation	O
+and	O
+/	O
+or	O
+death	B-PROC
+)	O
+adjusted	O
+for	O
+older	O
+age	O
+and	O
+sex	O
+showed	O
+that	O
+hypouremic	O
+patients	O
+had	O
+an	O
+odds	O
+ratio	O
+of	O
+10	O
+.	O
+57	O
+(	O
+confidence	O
+interval	O
+,	O
+2	O
+.	O
+33	O
+to	O
+47	O
+.	O
+98	O
+;	O
+P	O
+=	O
+0	O
+.	O
+002	O
+).	O
+
+Serum	B-PRGE
+IL	B-FUNC
+-	I-FUNC
+8	I-FUNC
+levels	O
+correlated	O
+significantly	O
+with	O
+FE	O
+UA	O
+(	O
+P	O
+<	O
+0	O
+.	O
+001	O
+;	O
+r	O
+=	O
+0	O
+.	O
+785	O
+)	O
+and	O
+inversely	O
+with	O
+serum	B-COMP
+UA	O
+level	O
+(	O
+P	O
+=	O
+0	O
+.	O
+044	O
+;	O
+r	O
+=	O
+-	O
+0	O
+.	O
+509	O
+);	O
+neither	O
+IL	B-FUNC
+-	I-FUNC
+6	I-FUNC
+nor	O
+TNF	B-PRGE
+-	I-PRGE
+alpha	I-PRGE
+level	O
+showed	O
+such	O
+correlations	O
+.	O
+
+The	O
+Beck	O
+Anxiety	O
+Inventory	O
+,	O
+the	O
+Beck	O
+Depression	B-DISO
+Inventory	O
+,	O
+and	O
+a	O
+newly	O
+developed	O
+measure	O
+,	O
+the	O
+SARS	B-DISO
+Impact	O
+Scale	O
+(	O
+SIS	O
+),	O
+were	O
+mailed	O
+to	O
+453	O
+Hong	O
+Kong	O
+Chinese	O
+SARS	B-DISO
+survivors	O
+discharged	O
+from	O
+hospital	O
+for	O
+4	O
+weeks	O
+or	O
+more	O
+.	O
+
+The	O
+General	O
+Health	O
+Questionnaire	O
+was	O
+used	O
+to	O
+identify	O
+psychological	B-DISO
+distress	I-DISO
+.	O
+
+Socio	O
+-	O
+demographic	O
+and	O
+stress	O
+variables	O
+were	O
+entered	O
+into	O
+a	O
+logistic	O
+regression	O
+analysis	O
+to	O
+find	O
+out	O
+the	O
+variables	O
+associated	O
+with	O
+psychological	B-DISO
+morbidity	O
+.	O
+
+CONCLUSIONS	O
+:	O
+These	O
+findings	O
+shed	O
+light	O
+on	O
+the	O
+need	O
+for	O
+hospital	O
+administrators	O
+to	O
+be	O
+aware	O
+of	O
+the	O
+extent	O
+and	O
+sources	O
+of	O
+stress	O
+and	O
+psychological	B-DISO
+distress	I-DISO
+among	O
+frontline	O
+healthcare	O
+workers	O
+during	O
+disease	O
+outbreak	O
+.	O
+
+TITLE	O
+:	O
+Hugs	O
+and	O
+kisses	O
+:	O
+HIV	B-DISO
+-	O
+infected	O
+parents	O
+'	O
+fears	O
+about	O
+contagion	O
+and	O
+the	O
+effects	O
+on	O
+parent	O
+-	O
+child	O
+interaction	O
+in	O
+a	O
+nationally	O
+representative	O
+sample	O
+.	O
+
+In	O
+-	O
+person	O
+interviews	O
+with	O
+344	O
+parents	O
+from	O
+a	O
+nationally	O
+representative	O
+probability	O
+sample	O
+of	O
+adults	O
+receiving	O
+health	O
+care	O
+for	O
+HIV	B-DISO
+in	O
+the	O
+contiguous	O
+United	O
+States	O
+.	O
+
+ABSTRACT	O
+:	O
+Severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+(	O
+SARS	B-DISO
+)	O
+is	O
+caused	O
+by	O
+a	O
+novel	O
+and	O
+highly	O
+infectious	B-DISO
+virus	B-SPEC
+named	O
+SARS	B-DISO
+coronavirus	B-SPEC
+(	O
+SARS	B-DISO
+-	O
+CoV	O
+).	O
+
+This	O
+study	O
+showed	O
+that	O
+the	O
+SARS	B-DISO
+crisis	O
+enhanced	O
+a	O
+reconstruction	O
+of	O
+worldview	O
+and	O
+affirmed	O
+the	O
+professional	O
+identity	O
+of	O
+nursing	B-PROC
+students	O
+.	O
+
+This	O
+study	O
+provided	O
+insights	O
+to	O
+nursing	B-PROC
+education	O
+that	O
+acquisition	O
+of	O
+professional	O
+identity	O
+could	O
+be	O
+enhanced	O
+through	O
+reflective	O
+appreciation	O
+of	O
+critical	O
+events	O
+such	O
+as	O
+SARS	O
+.	O
+
+TITLE	O
+:	O
+A	O
+child	O
+with	O
+avian	B-DISO
+influenza	B-PATH
+A	I-PATH
+(	O
+H5N1	B-DISO
+)	O
+infection	B-DISO
+.	O
+
+These	O
+factors	O
+are	O
+becoming	O
+increasingly	O
+prevalent	O
+,	O
+suggesting	O
+that	O
+infections	B-DISO
+will	O
+continue	O
+to	O
+emerge	O
+and	O
+probably	O
+increase	O
+.	O
+
+Although	O
+the	O
+emergence	O
+of	O
+SARS	B-DISO
+surprised	O
+the	O
+medical	O
+community	O
+,	O
+veterinary	O
+coronavirologists	O
+had	O
+previously	O
+isolated	O
+CoVs	O
+from	O
+wildlife	O
+and	O
+documented	O
+their	O
+interspecies	O
+transmission	O
+to	O
+livestock	O
+.	O
+
+The	O
+goal	O
+is	O
+to	O
+provide	O
+insights	O
+into	O
+CoV	O
+transmission	O
+and	O
+disease	O
+mechanisms	O
+that	O
+could	O
+potentially	O
+be	O
+applicable	O
+to	O
+SARS	B-DISO
+,	O
+highlighting	O
+the	O
+contributions	O
+of	O
+veterinary	O
+scientists	O
+to	O
+this	O
+area	O
+of	O
+study	O
+.	O
+
+RESULTS	O
+:	O
+One	O
+hundred	O
+thirty	O
+-	O
+four	O
+(	O
+53	O
+%)	O
+of	O
+254	O
+patients	O
+had	O
+recent	O
+onset	O
+of	O
+large	O
+joint	B-DISO
+pain	I-DISO
+,	O
+but	O
+211	O
+(	O
+80	O
+%)	O
+of	O
+264	O
+painful	B-DISO
+joints	I-DISO
+were	O
+not	O
+associated	O
+with	O
+abnormality	O
+on	O
+MR	O
+images	O
+.	O
+
+The	O
+expression	B-PROC
+levels	O
+of	O
+these	O
+genes	O
+and	O
+the	O
+viral	B-PROC
+replication	I-PROC
+were	O
+determined	O
+by	O
+real	O
+-	O
+time	O
+PCR	O
+.	O
+
+However	O
+,	O
+over	O
+all	O
+,	O
+beta	B-PRGE
+-	I-PRGE
+actin	I-PRGE
+is	O
+an	O
+unsuitable	O
+as	O
+reference	O
+gene	O
+,	O
+whereas	O
+TATA	B-PRGE
+-	I-PRGE
+Box	I-PRGE
+binding	I-PRGE
+protein	B-CHED
+and	O
+peptidyl	O
+-	O
+prolyl	B-CHED
+-	O
+isomerase	O
+A	O
+are	O
+stable	O
+reference	O
+genes	O
+for	O
+expression	B-PROC
+studies	O
+in	O
+virus	B-SPEC
+infected	O
+cells	B-COMP
+.	O
+
+Low	O
+level	O
+of	O
+immunity	B-PROC
+among	O
+unaffected	O
+healthcare	O
+workers	O
+reinforces	O
+the	O
+need	O
+for	O
+adequate	O
+personal	O
+protection	O
+and	O
+other	O
+infection	B-DISO
+control	O
+measures	O
+in	O
+hospitals	O
+to	O
+prevent	O
+future	O
+epidemics	O
+.	O
+
+ABSTRACT	O
+:	O
+We	O
+sought	O
+to	O
+describe	O
+the	O
+implementation	O
+of	O
+the	O
+Hospital	O
+Emergency	B-DISO
+Incident	O
+Command	O
+System	O
+(	O
+HEICS	O
+)	O
+at	O
+National	O
+Cheng	O
+Kung	O
+University	O
+Hospital	O
+(	O
+NCKUH	O
+)	O
+in	O
+Taiwan	O
+,	O
+ROC	O
+during	O
+the	O
+outbreak	O
+of	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+(	O
+SARS	B-DISO
+)	O
+in	O
+early	O
+2003	O
+.	O
+
+In	O
+this	O
+outbreak	O
+,	O
+an	O
+emergency	B-DISO
+plan	B-DISO
+consisted	O
+of	O
+patient	O
+isolation	O
+and	O
+strict	O
+hospital	B-DISO
+infection	I-DISO
+control	O
+.	O
+
+RESULTS	O
+:	O
+Between	O
+14	O
+March	O
+and	O
+30	O
+July	O
+2003	O
+a	O
+total	O
+of	O
+668	O
+probable	O
+cases	O
+of	O
+SARS	B-DISO
+were	O
+reported	O
+.	O
+
+Among	O
+them	O
+,	O
+46	O
+(	O
+3	O
+.	O
+0	O
+/	O
+10	O
+,	O
+000	O
+)	O
+were	O
+subsequently	O
+classified	O
+as	O
+being	O
+probable	O
+SARS	B-DISO
+cases	O
+.	O
+
+ABSTRACT	O
+:	O
+Transfusion	B-DISO
+related	I-DISO
+acute	I-DISO
+lung	I-DISO
+injury	I-DISO
+(	O
+TRALI	B-DISO
+)	O
+is	O
+a	O
+rare	O
+but	O
+potentially	O
+severe	O
+complication	B-DISO
+of	I-DISO
+blood	I-DISO
+transfusion	I-DISO
+,	O
+manifested	O
+by	O
+pulmonary	B-DISO
+oedema	I-DISO
+,	O
+fever	B-PROC
+and	O
+hypotension	O
+.	O
+
+Diagnosis	O
+is	O
+based	O
+on	O
+antibody	B-COMP
+screening	O
+in	O
+blood	B-ANAT
+components	I-ANAT
+and	O
+on	O
+specific	O
+-	O
+antigen	B-CHED
+detection	O
+in	O
+the	O
+recipient	O
+.	O
+
+In	O
+this	O
+article	O
+,	O
+we	O
+summarise	O
+what	O
+is	O
+known	O
+about	O
+TRALI	B-DISO
+,	O
+and	O
+we	O
+focus	O
+attention	O
+on	O
+unanswered	O
+questions	O
+and	O
+controversial	O
+issues	O
+related	O
+to	O
+TRALI	B-DISO
+.	O
+
+TITLE	O
+:	O
+Severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+coronavirus	B-SPEC
+3a	O
+protein	B-CHED
+is	O
+a	O
+viral	O
+structural	O
+protein	B-CHED
+.	O
+
+We	O
+correlated	O
+the	O
+MR	O
+imaging	O
+findings	O
+with	O
+the	O
+clinical	O
+presentations	O
+and	O
+outcomes	O
+of	O
+WNV	B-DISO
+infection	B-DISO
+.	O
+
+Methylprednisolone	B-CHED
+was	O
+more	O
+effective	O
+than	O
+lidocaine	B-CHED
+at	O
+reducing	O
+lung	O
+damage	O
+.	O
+
+RESULTS	O
+:	O
+Neutrophils	B-ANAT
+increased	O
+with	O
+time	O
+.	O
+
+TITLE	O
+:	O
+Daily	O
+Emergency	B-DISO
+Department	O
+Surveillance	O
+System	O
+---	O
+Bergen	O
+County	O
+,	O
+New	O
+Jersey	O
+.	O
+
+A	O
+method	O
+for	O
+determining	O
+the	O
+difference	O
+between	O
+random	O
+and	O
+systemic	O
+variation	O
+was	O
+used	O
+to	O
+identify	O
+differences	O
+of	O
+>/=	O
+3	O
+standard	O
+deviations	O
+for	O
+each	O
+syndrome	O
+from	O
+a	O
+6	O
+-	O
+month	O
+moving	B-PROC
+average	O
+.	O
+
+Chest	B-ANAT
+radiographs	O
+on	O
+admission	O
+are	O
+often	O
+non	O
+-	O
+specific	O
+(	O
+5	O
+,	O
+6	O
+),	O
+but	O
+indicators	O
+include	O
+indoor	O
+fires	O
+,	O
+facial	B-ANAT
+burns	O
+,	O
+bronchoscopic	O
+findings	O
+of	O
+soot	O
+in	O
+the	O
+airways	O
+,	O
+and	O
+detection	O
+of	O
+carbon	B-CHED
+monoxide	I-CHED
+or	O
+cyanide	B-CHED
+in	O
+the	O
+blood	B-ANAT
+(	O
+7	O
+).	O
+
+The	O
+diagnosis	O
+of	O
+avian	B-DISO
+influenza	B-PATH
+A	I-PATH
+(	O
+H5N1	B-DISO
+)	O
+was	O
+established	O
+by	O
+isolation	O
+of	O
+the	O
+virus	B-SPEC
+from	O
+cerebrospinal	B-ANAT
+fluid	I-ANAT
+,	O
+fecal	B-ANAT
+,	O
+throat	B-ANAT
+,	O
+and	O
+serum	B-COMP
+specimens	O
+.	O
+
+In	O
+both	O
+siblings	O
+,	O
+the	O
+clinical	O
+diagnosis	O
+was	O
+acute	O
+encephalitis	B-DISO
+.	O
+
+RESULTS	O
+:	O
+In	O
+November	O
+2002	O
+,	O
+a	O
+series	O
+of	O
+citywide	O
+signals	O
+for	O
+diarrhea	B-DISO
+and	I-DISO
+vomiting	I-DISO
+syndromes	B-DISO
+,	O
+which	O
+coincided	O
+with	O
+institutional	O
+outbreaks	O
+consistent	O
+with	O
+viral	B-DISO
+gastroenteritis	I-DISO
+,	O
+prompted	O
+DOHMH	O
+to	O
+send	O
+mass	O
+e	O
+-	O
+mail	O
+notification	O
+to	O
+NYC	O
+ED	O
+directors	O
+and	O
+institute	O
+collection	O
+of	O
+stool	B-ANAT
+specimens	O
+.	O
+
+EDs	B-DISO
+then	O
+were	O
+invited	O
+to	O
+report	O
+visit	O
+frequencies	O
+with	O
+various	O
+SARS	O
+syndrome	B-DISO
+elements	O
+to	O
+local	O
+public	O
+health	O
+authorities	O
+by	O
+using	O
+the	O
+REMI	O
+Internet	O
+application	O
+(	O
+first	O
+in	O
+one	O
+metropolitan	O
+area	O
+,	O
+and	O
+later	O
+in	O
+four	O
+).	O
+
+TITLE	O
+:	O
+From	O
+SARS	B-DISO
+to	O
+systems	O
+:	O
+developing	O
+advanced	O
+knowledge	O
+management	O
+for	O
+public	O
+health	O
+.	O
+
+Ready	O
+to	O
+use	O
+technologies	O
+are	O
+lacking	O
+not	O
+only	O
+for	O
+the	O
+management	O
+of	O
+emerging	O
+infections	B-DISO
+or	O
+bio	O
+-	O
+terrorism	O
+but	O
+also	O
+for	O
+the	O
+coordination	B-PROC
+of	O
+prevention	O
+and	O
+chronic	O
+care	O
+initiatives	O
+.	O
+
+We	O
+need	O
+to	O
+find	O
+ways	O
+to	O
+integrate	O
+new	O
+scientific	O
+knowledge	O
+into	O
+our	O
+environment	O
+in	O
+order	B-SPEC
+to	O
+expedite	O
+the	O
+translation	B-PROC
+of	O
+research	O
+to	O
+practice	O
+.	O
+
+Screening	O
+to	O
+detect	O
+a	O
+potential	O
+SARS	B-DISO
+infected	O
+person	O
+plays	O
+an	O
+important	O
+role	O
+in	O
+preventing	O
+the	O
+spread	O
+of	O
+SARS	B-DISO
+.	O
+
+Infrared	O
+thermography	O
+provides	O
+a	O
+digital	B-ANAT
+image	O
+showing	O
+temperature	O
+patterns	O
+.	O
+
+The	O
+time	O
+course	O
+of	O
+a	O
+typical	O
+fever	B-PROC
+can	O
+be	O
+divided	O
+into	O
+three	O
+stages	O
+.	O
+
+Two	O
+important	O
+conclusions	O
+were	O
+drawn	O
+from	O
+the	O
+analysis	O
+:	O
+the	O
+best	O
+region	O
+on	O
+the	O
+face	B-DISO
+to	O
+obtain	O
+temperature	O
+readings	O
+and	O
+the	O
+optimal	O
+preset	O
+threshold	O
+temperature	O
+for	O
+the	O
+thermal	O
+imager	O
+.	O
+
+As	O
+elevation	O
+of	O
+body	B-ANAT
+temperature	O
+is	O
+a	O
+common	O
+presenting	O
+symptom	B-DISO
+for	O
+many	O
+illnesses	O
+including	O
+infectious	B-DISO
+diseases	I-DISO
+,	O
+thermal	O
+imagers	O
+are	O
+useful	O
+tools	O
+for	O
+mass	O
+screening	O
+of	O
+body	B-ANAT
+temperature	O
+not	O
+only	O
+for	O
+SARS	B-DISO
+but	O
+also	O
+during	O
+other	O
+public	O
+health	O
+crisis	O
+where	O
+widespread	O
+transmission	O
+of	O
+infection	B-DISO
+is	O
+a	O
+concern	O
+.	O
+
+ABSTRACT	O
+:	O
+Preoccupied	O
+with	O
+the	O
+diagnosis	O
+of	O
+SARS	B-DISO
+(	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+)	O
+in	O
+a	O
+SARS	B-DISO
+outbreak	O
+,	O
+doctors	O
+tend	O
+to	O
+overlook	O
+other	O
+endemic	B-DISO
+diseases	I-DISO
+,	O
+such	O
+as	O
+tuberculosis	B-PATH
+.	O
+
+Incorrectly	O
+labeling	O
+a	O
+patient	O
+as	O
+SARS	B-DISO
+may	O
+result	O
+in	O
+serious	O
+consequences	O
+.	O
+
+Single	O
+isolation	O
+being	O
+not	O
+always	O
+possible	O
+,	O
+the	O
+patient	O
+may	O
+have	O
+to	O
+be	O
+isolated	O
+with	O
+a	O
+group	O
+of	O
+SARS	B-DISO
+patients	O
+.	O
+
+The	O
+spike	O
+,	O
+membrane	B-COMP
+and	O
+nucleocapsid	B-COMP
+protein	B-CHED
+genes	O
+of	O
+pf	O
+/	O
+CH	O
+/	O
+LKQ3	O
+/	O
+03	O
+had	O
+>	O
+99	O
+%	O
+identity	O
+to	O
+those	O
+of	O
+the	O
+avian	B-DISO
+infectious	I-DISO
+bronchitis	I-DISO
+coronavirus	B-SPEC
+H120	O
+vaccine	O
+strain	O
+(	O
+Massachusetts	O
+serotype	O
+)	O
+and	O
+other	O
+Massachusetts	O
+serotype	O
+isolates	O
+.	O
+
+Furthermore	O
+,	O
+when	O
+pf	O
+/	O
+CH	O
+/	O
+LKQ3	O
+/	O
+03	O
+was	O
+inoculated	O
+experimentally	O
+into	O
+chickens	B-SPEC
+(	O
+specific	O
+-	O
+pathogen	O
+-	O
+free	O
+),	O
+no	O
+disease	O
+signs	O
+were	O
+apparent	O
+.	O
+
+Helicobacter	B-SPEC
+spp	B-ENZY
+.	O
+
+This	O
+paper	O
+describes	O
+bacteriological	O
+,	O
+parasitological	O
+,	O
+and	O
+virological	O
+examinations	O
+of	O
+the	O
+animals	B-SPEC
+.	O
+
+The	O
+recent	O
+hospital	O
+-	O
+based	O
+outbreak	O
+of	O
+Severe	B-DISO
+Acute	I-DISO
+Respiratory	I-DISO
+Syndrome	I-DISO
+(	O
+SARS	B-DISO
+)	O
+has	O
+once	O
+again	O
+highlighted	O
+the	O
+vulnerability	O
+of	O
+HCWs	O
+.	O
+
+The	O
+new	O
+epidemic	O
+of	O
+the	O
+21st	O
+century	O
+resulted	O
+in	O
+tremendous	O
+economic	O
+and	O
+psychological	B-DISO
+impact	O
+with	O
+its	O
+high	O
+rates	O
+of	O
+mortality	O
+and	O
+nosocomial	O
+transmission	O
+.	O
+
+By	O
+day	O
+7	O
+,	O
+crude	O
+odds	O
+ratio	O
+of	O
+death	B-PROC
+was	O
+1	O
+.	O
+73	O
+per	O
+5	O
+%	O
+of	O
+AO	O
+%	O
+(	O
+p	O
+<	O
+0	O
+.	O
+0001	O
+)	O
+or	O
+2	O
+.	O
+93	O
+per	O
+lung	B-ANAT
+zone	O
+opacified	O
+(	O
+p	O
+<	O
+0	O
+.	O
+0001	O
+).	O
+
+The	O
+PaCO	O
+(	O
+2	O
+)	O
+and	O
+the	O
+static	O
+respiratory	B-ANAT
+system	I-ANAT
+compliance	O
+(	O
+Cstrs	O
+)	O
+did	O
+not	O
+differ	O
+significantly	O
+between	O
+the	O
+prone	O
+position	O
+and	O
+the	O
+supine	O
+position	O
+in	O
+the	O
+two	O
+groups	O
+.	O
+
+1	O
+.	O
+8	O
+)	O
+cm	O
+H2O	B-CHED
+.	O
+s	O
+(-	O
+1	O
+).	O
+L	O
+(-	O
+1	O
+)	O
+(	O
+P	O
+<	O
+0	O
+.	O
+05	O
+).	O
+
+RESULTS	O
+:	O
+(	O
+1	O
+)	O
+The	O
+delay	O
+in	O
+diagnosis	O
+of	O
+this	O
+SARS	O
+case	O
+was	O
+largely	O
+associated	O
+with	O
+unclear	O
+epidemiologic	O
+history	O
+;	O
+(	O
+2	O
+)	O
+The	O
+SARS	B-DISO
+patient	O
+showed	O
+characteristics	O
+of	O
+typical	O
+pneumonia	B-DISO
+in	O
+the	O
+early	O
+stage	O
+.	O
+
+TITLE	O
+:	O
+Distinct	O
+roles	O
+of	O
+pattern	O
+recognition	O
+receptors	O
+CD14	B-PRGE
+and	O
+Toll	B-PRGE
+-	I-PRGE
+like	I-PRGE
+receptor	I-PRGE
+4	I-PRGE
+in	O
+acute	O
+lung	B-ANAT
+injury	O
+.	O
+
+On	O
+the	O
+other	O
+hand	O
+,	O
+when	O
+a	O
+10	O
+-	O
+fold	O
+-	O
+higher	O
+dose	O
+of	O
+LPS	B-DISO
+(	O
+3	O
+mg	O
+/	O
+ml	O
+)	O
+was	O
+used	O
+,	O
+these	O
+responses	O
+were	O
+only	O
+partially	O
+dependent	O
+on	O
+CD14	B-PRGE
+and	O
+they	O
+were	O
+totally	O
+dependent	O
+on	O
+TLR4	B-PRGE
+.	O
+
+A	O
+TLR4	B-PRGE
+blocking	B-DISO
+antibody	B-COMP
+abolished	O
+microvascular	O
+leakage	B-DISO
+,	O
+neutrophil	B-ANAT
+accumulation	O
+,	O
+cytokine	O
+responses	O
+,	O
+and	O
+lung	B-ANAT
+pathology	B-DISO
+with	O
+a	O
+low	O
+dose	O
+of	O
+LPS	B-DISO
+but	O
+only	O
+attenuated	O
+the	O
+responses	O
+with	O
+a	O
+high	O
+dose	O
+of	O
+LPS	B-DISO
+.	O
+
+These	O
+data	O
+are	O
+the	O
+first	O
+to	O
+demonstrate	O
+that	O
+LPS	B-DISO
+-	O
+induced	O
+CD14	B-PRGE
+-	O
+dependent	O
+and	O
+-	O
+independent	O
+(	O
+CD11b	B-PRGE
+-	O
+dependent	O
+)	O
+signaling	B-PROC
+pathways	B-PROC
+in	O
+the	O
+lung	B-ANAT
+are	O
+entirely	O
+dependent	O
+on	O
+TLR4	B-PRGE
+and	O
+that	O
+blocking	B-DISO
+TLR4	B-PRGE
+might	O
+be	O
+beneficial	O
+in	O
+lung	B-DISO
+diseases	I-DISO
+caused	O
+by	O
+LPS	B-DISO
+from	O
+gram	O
+-	O
+negative	O
+pathogens	O
+.	O
+
+By	O
+applying	O
+an	O
+adapted	O
+,	O
+sequential	O
+software	O
+engineering	O
+process	O
+,	O
+a	O
+complex	O
+biological	O
+system	O
+(	O
+severe	O
+acquired	O
+respiratory	O
+syndrome	O
+-	O
+coronavirus	B-SPEC
+viral	B-DISO
+infection	I-DISO
+)	O
+has	O
+been	O
+reverse	O
+-	O
+engineered	O
+and	O
+represented	O
+as	O
+an	O
+object	O
+-	O
+oriented	O
+software	O
+system	O
+.	O
+
+Recently	O
+,	O
+we	O
+showed	O
+how	O
+to	O
+do	O
+this	O
+for	O
+the	O
+point	O
+substitution	O
+component	O
+of	O
+the	O
+evolutionary	O
+process	O
+;	O
+here	O
+,	O
+we	O
+extend	O
+these	O
+results	O
+to	O
+the	O
+indel	B-PROC
+process	O
+.	O
+
+The	O
+algorithm	O
+converges	O
+extremely	O
+rapidly	O
+,	O
+gives	O
+accurate	O
+results	O
+on	O
+simulated	O
+data	O
+that	O
+are	O
+an	O
+improvement	O
+over	O
+parsimonious	O
+estimates	O
+(	O
+which	O
+are	O
+shown	O
+to	O
+underestimate	O
+the	O
+true	O
+indel	B-PROC
+rate	O
+),	O
+and	O
+gives	O
+plausible	O
+results	O
+on	O
+experimental	O
+data	O
+(	O
+coronavirus	B-SPEC
+envelope	B-COMP
+domains	O
+).	O
+
+TITLE	O
+:	O
+Amino	B-CHED
+acids	I-CHED
+1055	O
+to	O
+1192	O
+in	O
+the	O
+S2	O
+region	O
+of	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+coronavirus	B-SPEC
+S	O
+protein	O
+induce	O
+neutralizing	O
+antibodies	B-COMP
+:	O
+implications	O
+for	O
+the	O
+development	B-PROC
+of	O
+vaccines	O
+and	O
+antiviral	B-CHED
+agents	I-CHED
+.	O
+
+ABSTRACT	O
+:	O
+CD8	B-PRGE
++	I-PRGE
+T	B-ANAT
+cells	I-ANAT
+are	O
+important	O
+for	O
+clearance	O
+of	O
+neurotropic	O
+mouse	B-DISO
+hepatitis	I-DISO
+virus	B-SPEC
+(	O
+MHV	B-SPEC
+)	O
+strain	O
+A59	O
+,	O
+although	O
+their	O
+possible	O
+role	O
+in	O
+A59	O
+-	O
+induced	O
+demyelination	B-DISO
+is	O
+not	O
+well	O
+understood	O
+.	O
+
+Protection	O
+in	O
+mice	B-SPEC
+receiving	O
+P14	O
+splenocytes	O
+prior	O
+to	O
+infection	B-DISO
+correlated	O
+with	O
+a	O
+robust	O
+gp33	B-PRGE
+-	O
+specific	B-PROC
+immune	I-PROC
+response	I-PROC
+that	O
+was	O
+not	O
+observed	O
+in	O
+mice	B-SPEC
+receiving	O
+the	O
+later	O
+transfers	O
+.	O
+
+Thus	O
+,	O
+an	O
+early	O
+robust	O
+CD8	B-PRGE
++	I-PRGE
+T	B-ANAT
+-	I-ANAT
+cell	I-ANAT
+response	O
+was	O
+necessary	O
+to	O
+reduce	O
+virus	B-PROC
+replication	I-PROC
+and	O
+spread	O
+,	O
+specifically	O
+to	O
+the	O
+spinal	B-ANAT
+cord	I-ANAT
+,	O
+which	O
+protected	O
+against	O
+demyelination	B-DISO
+in	O
+the	O
+chronic	O
+phase	O
+of	O
+the	O
+disease	O
+.	O
+
+Sequencing	O
+of	O
+the	O
+cloned	O
+genome	O
+cDNA	O
+fragments	O
+identified	O
+two	O
+single	O
+-	O
+nucleotide	B-CHED
+mutations	O
+in	O
+cloned	O
+genome	O
+fragment	O
+F	O
+,	O
+encoding	O
+a	O
+Tyr6398His	O
+substitution	O
+in	O
+open	O
+reading	O
+frame	O
+(	O
+ORF	O
+)	O
+1b	O
+p59	B-PRGE
+-	O
+nsp14	O
+and	O
+a	O
+Leu94Pro	O
+substitution	O
+in	O
+the	O
+ORF	O
+2a	O
+30	O
+-	O
+kDa	O
+protein	B-CHED
+.	O
+
+The	O
+study	O
+also	O
+demonstrates	O
+the	O
+usefulness	O
+of	O
+the	O
+reverse	O
+genetic	O
+system	O
+to	O
+confirm	O
+the	O
+role	O
+of	O
+residues	O
+or	O
+proteins	B-CHED
+in	O
+coronavirus	B-SPEC
+replication	O
+and	O
+pathogenesis	B-DISO
+.	O
+
+We	O
+determined	O
+the	O
+continuous	O
+viral	O
+epitopes	O
+targeted	B-PROC
+by	O
+antibodies	B-COMP
+in	O
+plasma	B-ANAT
+samples	O
+from	O
+convalescent	O
+SARS	B-DISO
+patients	O
+through	O
+biopanning	O
+with	O
+a	O
+vast	O
+M13	O
+phage	O
+display	O
+dodecapeptide	O
+library	O
+.	O
+
+Multistep	O
+growth	B-PROC
+kinetics	O
+were	O
+identical	O
+in	O
+Vero	O
+E6	O
+and	O
+MA104	O
+cells	B-COMP
+,	O
+with	O
+maximum	O
+titer	O
+reached	O
+24	O
+h	O
+postinoculation	O
+(	O
+hpi	B-DISO
+).	O
+
+CaCo	O
+-	O
+2	O
+was	O
+the	O
+only	O
+human	B-SPEC
+cell	B-COMP
+type	I-COMP
+of	O
+13	O
+tested	O
+that	O
+supported	O
+efficient	O
+SARS	B-DISO
+-	O
+CoV	O
+replication	O
+.	O
+
+Autologous	O
+stem	B-ANAT
+cell	I-ANAT
+transplantation	O
+might	O
+be	O
+effective	O
+in	O
+the	O
+treatment	O
+advanced	O
+solid	B-DISO
+tumors	I-DISO
+in	O
+children	O
+.	O
+
+SARS	B-PRGE
+-	I-PRGE
+CoV	I-PRGE
+and	O
+GAPDH	B-PRGE
+mRNA	B-CHED
+were	O
+both	O
+measured	O
+in	O
+26	O
+specimens	O
+from	O
+16	O
+patients	O
+with	O
+SARS	B-DISO
+,	O
+40	O
+follow	O
+up	O
+specimens	O
+from	O
+the	O
+same	O
+batch	O
+of	O
+patients	O
+,	O
+and	O
+appropriate	O
+control	O
+subjects	O
+.	O
+
+Moreover	O
+,	O
+GAPDH	B-PRGE
+mRNA	B-CHED
+concentrations	O
+were	O
+highly	O
+correlated	O
+with	O
+SARS	B-DISO
+-	O
+CoV	O
+positivity	O
+(	O
+chi2	O
+=	O
+5	O
+.	O
+43	O
+;	O
+p	O
+<	O
+0	O
+.	O
+05	O
+).	O
+
+Finally	O
+,	O
+SARS	B-PRGE
+-	I-PRGE
+CoV	I-PRGE
+and	O
+GAPDH	B-PRGE
+mRNA	B-CHED
+were	O
+both	O
+detected	O
+in	O
+three	O
+follow	O
+up	O
+urine	B-ANAT
+specimens	O
+that	O
+were	O
+initially	O
+negative	O
+when	O
+the	O
+amount	O
+of	O
+cDNA	O
+used	O
+was	O
+increased	O
+from	O
+5	O
+microl	O
+to	O
+10	O
+and	O
+15	O
+microl	O
+.	O
+
+Several	O
+influenza	O
+A	O
+virus	O
+subtypes	O
+were	O
+transmitted	B-DISO
+from	O
+birds	B-SPEC
+to	O
+humans	B-SPEC
+,	O
+and	O
+these	O
+viruses	B-SPEC
+continue	O
+to	O
+constitute	O
+a	O
+pandemic	O
+threat	O
+.	O
+
+The	O
+clinical	O
+symptoms	O
+associated	O
+with	O
+these	O
+zoonotic	O
+transmissions	O
+range	O
+from	O
+mild	O
+respiratory	O
+illnesses	O
+and	O
+conjunctivitis	B-DISO
+to	O
+pneumonia	B-DISO
+and	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+,	O
+sometimes	O
+resulting	O
+in	O
+death	B-PROC
+.	O
+
+The	O
+success	O
+rate	O
+of	O
+the	O
+MS	O
+-	O
+based	O
+analysis	O
+for	O
+detecting	O
+SARS	B-DISO
+coronavirus	B-SPEC
+(	O
+SARS	B-DISO
+-	O
+CoV	O
+)	O
+sequence	O
+variations	O
+was	O
+determined	O
+to	O
+be	O
+95	O
+%	O
+with	O
+75	O
+copies	O
+of	O
+viral	O
+RNA	O
+per	O
+reaction	O
+,	O
+which	O
+is	O
+sufficient	O
+to	O
+directly	O
+analyze	O
+both	O
+clinical	O
+and	O
+cultured	O
+samples	O
+.	O
+
+Analysis	O
+of	O
+13	O
+SARS	B-DISO
+-	O
+CoV	O
+isolates	O
+from	O
+the	O
+different	O
+stages	O
+of	O
+the	O
+Singapore	O
+outbreak	O
+identified	O
+nine	O
+sequence	O
+variations	O
+that	O
+could	O
+define	O
+the	O
+molecular	O
+relationship	O
+between	O
+them	O
+and	O
+pointed	O
+to	O
+a	O
+new	O
+,	O
+previously	O
+unidentified	O
+,	O
+primary	O
+route	O
+of	O
+introduction	O
+of	O
+SARS	B-DISO
+-	O
+CoV	O
+into	O
+the	O
+Singapore	O
+population	O
+.	O
+
+Our	O
+direct	O
+determination	O
+of	O
+viral	O
+sequence	O
+variation	O
+from	O
+a	O
+clinical	O
+sample	O
+also	O
+clarified	O
+an	O
+unresolved	O
+epidemiological	O
+link	O
+regarding	O
+the	O
+acquisition	O
+of	O
+SARS	B-DISO
+in	O
+a	O
+German	O
+patient	O
+.	O
+
+The	O
+predicted	O
+bio	O
+-	O
+aerosol	O
+concentration	O
+distribution	O
+in	O
+the	O
+ward	O
+seemed	O
+to	O
+agree	O
+fairly	O
+well	O
+with	O
+the	O
+spatial	O
+infection	O
+pattern	O
+of	O
+SARS	B-DISO
+cases	O
+.	O
+
+The	O
+well	O
+-	O
+established	O
+multi	O
+-	O
+zone	O
+airflow	B-PROC
+modeling	O
+method	O
+was	O
+used	O
+to	O
+analyze	O
+the	O
+virus	B-SPEC
+-	O
+laden	O
+bio	O
+-	O
+aerosol	O
+dispersion	O
+between	O
+flats	O
+through	O
+door	O
+and	O
+window	O
+leakage	B-DISO
+areas	O
+in	O
+Block	O
+E	O
+under	O
+six	O
+different	O
+scenarios	O
+.	O
+
+These	O
+factors	O
+included	O
+perceived	O
+threat	O
+of	O
+SARS	B-DISO
+,	O
+perceived	O
+benefits	O
+and	O
+barriers	O
+in	O
+practicing	O
+SARS	B-DISO
+preventive	O
+health	O
+behaviors	B-PROC
+,	O
+cues	O
+to	O
+action	O
+,	O
+knowledge	O
+of	O
+SARS	B-DISO
+,	O
+and	O
+self	O
+-	O
+efficacy	O
+.	O
+
+Results	O
+of	O
+hierarchical	O
+regression	O
+analyses	O
+showed	O
+that	O
+habitual	O
+health	O
+behaviors	B-PROC
+against	O
+SARS	B-DISO
+were	O
+related	O
+to	O
+perceived	O
+health	O
+threat	O
+and	O
+environmental	O
+cues	O
+.	O
+
+Of	O
+the	O
+45	O
+human	O
+SCoVs	O
+,	O
+one	O
+isolate	O
+from	O
+Guangdong	O
+province	O
+,	O
+China	O
+,	O
+exhibited	O
+an	O
+extra	O
+29	O
+-	O
+nucleotide	B-CHED
+fragment	O
+between	O
+Orf	B-PRGE
+10	I-PRGE
+and	O
+Orf	B-PRGE
+11	I-PRGE
+--	I-PRGE
+similar	I-PRGE
+to	O
+the	O
+civet	B-SPEC
+SCoV	O
+genome	O
+.	O
+
+ABSTRACT	O
+:	O
+The	O
+province	O
+of	O
+British	O
+Columbia	O
+,	O
+Canada	O
+,	O
+experienced	O
+2	O
+major	O
+health	O
+emergency	O
+situations	O
+during	O
+2003	O
+:	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+(	O
+SARS	B-DISO
+)	O
+in	O
+early	O
+2003	O
+and	O
+wildland	O
+-	O
+urban	O
+interface	O
+fires	O
+during	O
+the	O
+summer	O
+of	O
+2003	O
+.	O
+
+Both	O
+organizations	O
+subsequently	O
+conducted	O
+quality	O
+management	O
+reviews	O
+of	O
+their	O
+handling	O
+of	O
+these	O
+emergency	B-DISO
+situations	O
+.	O
+
+In	O
+retrospect	O
+,	O
+many	O
+patients	O
+survived	O
+due	O
+to	O
+careful	O
+nursing	B-PROC
+.	O
+
+Coronavirus	B-SPEC
+replicon	O
+systems	O
+should	O
+facilitate	O
+rapid	O
+screening	O
+of	O
+new	O
+inhibitors	B-CHED
+and	O
+the	O
+complex	O
+mechanism	O
+of	O
+viral	B-PROC
+replication	I-PROC
+will	O
+ensure	O
+that	O
+drugs	O
+are	O
+developed	O
+against	O
+at	O
+least	O
+five	O
+molecular	O
+targets	O
+,	O
+in	O
+particular	O
+the	O
+viral	B-PRGE
+protease	I-PRGE
+.	O
+
+The	O
+possible	O
+clinical	O
+use	O
+of	O
+several	O
+synthetic	O
+peptides	B-CHED
+,	O
+including	O
+those	O
+that	O
+mimic	O
+the	O
+S	O
+-	O
+binding	B-FUNC
+domain	O
+,	O
+the	O
+HR2	B-PRGE
+fusion	I-PRGE
+protein	I-PRGE
+and	O
+SARS	B-PRGE
+proteinase	B-PROC
+substrates	O
+,	O
+will	O
+be	O
+discussed	O
+.	O
+
+The	O
+diagnosis	O
+of	O
+SARS	B-DISO
+in	O
+surgical	O
+patients	O
+differs	O
+from	O
+that	O
+previously	O
+described	O
+in	O
+normal	O
+patients	O
+.	O
+
+METHODS	O
+:	O
+We	O
+report	O
+a	O
+retrospective	O
+case	O
+series	O
+of	O
+10	O
+surgical	O
+inpatients	O
+diagnosed	O
+with	O
+SARS	B-DISO
+following	O
+an	O
+outbreak	O
+in	O
+the	O
+surgical	O
+wards	O
+.	O
+
+CONCLUSIONS	O
+:	O
+The	O
+diagnosis	O
+of	O
+SARS	B-DISO
+in	O
+surgical	O
+patients	O
+differs	O
+from	O
+that	O
+previously	O
+described	O
+in	O
+normal	O
+patients	O
+.	O
+
+The	O
+preliminary	O
+function	O
+of	O
+protein	B-CHED
+X4	O
+was	O
+evaluated	O
+by	O
+treatment	O
+with	O
+and	O
+over	O
+-	O
+expression	B-PROC
+of	O
+protein	B-CHED
+X4	O
+in	O
+cell	B-ANAT
+lines	I-ANAT
+.	O
+
+ABSTRACT	O
+:	O
+Severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+(	O
+SARS	O
+)	O
+emerged	O
+in	O
+China	O
+and	O
+spread	O
+globally	O
+as	O
+a	O
+human	B-SPEC
+pandemic	O
+.	O
+
+In	O
+addition	O
+avian	B-DISO
+infectious	I-DISO
+bronchitis	I-DISO
+CoV	O
+(	O
+IBV	B-SPEC
+)	O
+vaccines	O
+targeted	B-PROC
+for	O
+protection	O
+of	O
+the	O
+upper	B-ANAT
+respiratory	I-ANAT
+tract	I-ANAT
+of	O
+chickens	B-SPEC
+are	O
+discussed	O
+.	O
+
+TITLE	O
+:	O
+Clinical	O
+features	O
+and	O
+outcomes	O
+of	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+and	O
+predictive	O
+factors	O
+for	O
+acute	O
+respiratory	O
+distress	O
+syndrome	O
+.	O
+
+ABSTRACT	O
+:	O
+Severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+(	O
+SARS	B-DISO
+)	O
+is	O
+an	O
+emerging	B-DISO
+infectious	I-DISO
+disease	I-DISO
+,	O
+and	O
+indeed	O
+,	O
+the	O
+SARS	B-DISO
+epidemic	O
+in	O
+Taiwan	O
+from	O
+March	O
+to	O
+July	O
+2003	O
+had	O
+a	O
+great	O
+impact	O
+.	O
+
+Multivariate	O
+analyses	O
+showed	O
+that	O
+age	O
+greater	O
+than	O
+65	O
+years	O
+(	O
+odds	O
+ratio	O
+,	O
+OR	O
+,	O
+10	O
+.	O
+6	O
+;	O
+95	O
+%	O
+confidence	O
+interval	O
+,	O
+CI	O
+,	O
+2	O
+.	O
+1	O
+-	O
+54	O
+.	O
+1	O
+),	O
+pre	O
+-	O
+existing	O
+diabetes	B-DISO
+mellitus	I-DISO
+(	O
+OR	O
+,	O
+13	O
+.	O
+7	O
+;	O
+95	O
+%	O
+CI	O
+,	O
+1	O
+.	O
+3	O
+-	O
+146	O
+.	O
+9	O
+),	O
+and	O
+elevated	O
+levels	O
+of	O
+LDH	B-PRGE
+(	O
+OR	O
+,	O
+8	O
+.	O
+4	O
+;	O
+95	O
+%	O
+CI	O
+,	O
+1	O
+.	O
+9	O
+-	O
+36	O
+.	O
+9	O
+)	O
+at	O
+admission	O
+,	O
+were	O
+independent	O
+predictors	O
+of	O
+ARDS	B-DISO
+.	O
+
+Virus	B-SPEC
+was	O
+isolated	O
+followed	O
+by	O
+the	O
+determination	O
+of	O
+its	O
+genome	O
+sequences	O
+,	O
+which	O
+were	O
+then	O
+analyzed	O
+by	O
+comparing	O
+with	O
+other	O
+46	O
+SARS	B-DISO
+-	O
+CoV	O
+genomes	O
+.	O
+
+TITLE	O
+:	O
+Public	O
+hospital	O
+preparations	O
+for	O
+SARS	B-DISO
+outbreak	O
+:	O
+experience	O
+of	O
+Alexandra	B-SPEC
+Hospital	O
+.	O
+
+Being	O
+the	O
+only	O
+public	O
+hospital	O
+that	O
+remained	O
+""""	O
+SARS	B-DISO
+-	O
+free	O
+""","	O
+i	O
+.	O
+e	O
+.,	O
+with	O
+no	O
+documented	O
+intra	O
+-	O
+institutional	O
+spread	O
+of	O
+disease	O
+,	O
+AH	O
+had	O
+to	O
+tackle	O
+a	O
+sudden	O
+,	O
+two	O
+-	O
+fold	O
+surge	O
+in	O
+hospital	O
+attendances	O
+and	O
+patient	O
+volume	O
+.	O
+
+Viruses	B-SPEC
+with	O
+Y162H	O
+or	O
+Y162Q	O
+substitutions	O
+were	O
+never	O
+recovered	O
+,	O
+while	O
+Y162A	O
+viruses	B-SPEC
+formed	O
+minute	O
+plaques	B-DISO
+.	O
+
+However	O
+,	O
+viruses	O
+with	O
+Y162F	O
+substitutions	O
+had	O
+wild	O
+type	O
+growth	B-PROC
+,	O
+suggesting	O
+that	O
+Y162	O
+may	O
+comprise	O
+part	O
+of	O
+a	O
+hydrophobic	O
+domain	O
+that	O
+contacts	O
+the	O
+MHV	B-PRGE
+-	I-PRGE
+binding	B-FUNC
+site	I-PRGE
+of	O
+mCEACAM1a	O
+.	O
+
+TITLE	O
+:	O
+Epitope	B-CHED
+mapping	O
+and	O
+biological	B-PROC
+function	I-PROC
+analysis	O
+of	O
+antibodies	B-COMP
+produced	O
+by	O
+immunization	O
+of	O
+mice	B-SPEC
+with	O
+an	O
+inactivated	O
+Chinese	O
+isolate	O
+of	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+-	O
+associated	O
+coronavirus	B-SPEC
+(	O
+SARS	B-DISO
+-	O
+CoV	O
+).	O
+
+Some	O
+of	O
+these	O
+S	O
+-	O
+specific	O
+mAbs	O
+were	O
+able	O
+to	O
+recognize	O
+cleaved	B-ANAT
+products	O
+of	O
+S	B-PRGE
+protein	I-PRGE
+in	O
+SARS	B-DISO
+-	O
+CoV	O
+-	O
+infected	O
+Vero	O
+E6	O
+cells	B-COMP
+.	O
+
+In	O
+particular	O
+,	O
+inhibitors	B-CHED
+of	O
+viral	O
+entry	O
+,	O
+comprising	O
+therapeutic	O
+peptides	B-CHED
+,	O
+were	O
+based	O
+on	O
+the	O
+recently	O
+launched	O
+anti	O
+-	O
+HIV	B-DISO
+drug	O
+enfuvirtide	B-CHED
+.	O
+
+The	O
+best	O
+combination	O
+of	O
+five	O
+surgical	O
+masks	O
+scored	O
+a	O
+fit	O
+factor	O
+of	O
+13	O
+.	O
+7	O
+,	O
+which	O
+is	O
+well	O
+below	O
+the	O
+minimum	O
+level	O
+of	O
+100	O
+required	O
+for	O
+a	O
+half	O
+face	B-DISO
+respirator	O
+.	O
+
+Therefore	O
+,	O
+we	O
+investigated	O
+the	O
+causative	O
+agents	O
+of	O
+WD	O
+by	O
+using	O
+electron	O
+microscopy	O
+,	O
+ELISA	O
+,	O
+RT	O
+-	O
+PCR	O
+,	O
+and	O
+nested	O
+PCR	O
+from	O
+97	O
+fecal	B-ANAT
+samples	O
+of	O
+32	O
+WD	O
+-	O
+affected	O
+herds	O
+collected	O
+from	O
+8	O
+provinces	O
+during	O
+2002	O
+-	O
+2004	O
+.	O
+
+None	O
+of	O
+the	O
+health	O
+care	O
+workers	O
+who	O
+used	O
+the	O
+supplement	O
+subsequently	O
+contracted	O
+SARS	B-DISO
+compared	O
+to	O
+0	O
+.	O
+4	O
+%	O
+of	O
+the	O
+health	O
+care	O
+workers	O
+who	O
+did	O
+not	O
+use	O
+the	O
+supplement	O
+(	O
+p	O
+=	O
+0	O
+.	O
+014	O
+).	O
+
+The	O
+anesthetic	O
+technique	O
+is	O
+critical	O
+for	O
+these	O
+patients	O
+with	O
+a	O
+high	O
+risk	O
+of	O
+uncontrollable	O
+hypertension	O
+,	O
+bleeding	B-DISO
+and	O
+multiple	B-DISO
+organ	I-DISO
+failure	I-DISO
+.	O
+
+We	O
+report	O
+the	O
+management	O
+of	O
+a	O
+patient	O
+presenting	O
+in	O
+labor	B-PROC
+with	O
+HELLP	B-DISO
+syndrome	I-DISO
+,	O
+and	O
+describe	O
+the	O
+successful	O
+use	O
+of	O
+remifentanil	B-CHED
+as	O
+part	O
+of	O
+the	O
+anesthetic	O
+technique	O
+for	O
+her	O
+subsequent	O
+Cesarean	O
+section	O
+.	O
+
+TITLE	O
+:	O
+Late	O
+recognition	O
+of	O
+SARS	B-DISO
+in	O
+nosocomial	O
+outbreak	O
+,	O
+Toronto	O
+.	O
+
+One	O
+hour	O
+later	O
+(	O
+at	O
+7h	O
+post	O
+-	O
+infection	B-DISO
+),	O
+the	O
+levels	O
+of	O
+extracellular	B-COMP
+SARS	B-DISO
+-	O
+CoV	O
+RNA	O
+also	O
+began	O
+to	O
+rise	O
+.	O
+
+Adverse	B-DISO
+effects	I-DISO
+occur	O
+with	O
+G	B-PRGE
+-	I-PRGE
+CSF	I-PRGE
+use	O
+in	O
+approximately	O
+30	O
+%	O
+of	O
+cases	O
+,	O
+comprised	O
+predominantly	O
+of	O
+bone	B-DISO
+pain	I-DISO
+,	O
+headache	B-DISO
+,	O
+and	O
+general	O
+fatigue	B-DISO
+.	O
+
+As	O
+a	O
+high	O
+level	O
+of	O
+IL	B-PRGE
+-	I-PRGE
+1beta	I-PRGE
+was	O
+detected	O
+at	O
+the	O
+onset	O
+of	O
+ALI	O
+,	O
+on	O
+day	O
+4	O
+after	O
+G	O
+-	O
+CSF	B-ANAT
+administration	O
+,	O
+and	O
+decreased	O
+to	O
+below	O
+the	O
+level	O
+of	O
+detection	O
+on	O
+day	O
+11	O
+,	O
+it	O
+is	O
+possible	O
+in	O
+a	O
+certain	O
+part	O
+that	O
+IL	O
+-	O
+1beta	O
+was	O
+involved	O
+in	O
+the	O
+onset	O
+of	O
+G	B-PRGE
+-	I-PRGE
+CSF	I-PRGE
+-	I-PRGE
+related	I-PRGE
+ALI	I-PRGE
+in	O
+the	O
+present	O
+case	O
+.	O
+
+Granulocyte	B-PRGE
+-	I-PRGE
+colony	I-PRGE
+stimulating	I-PRGE
+factor	I-PRGE
+(	O
+G	B-PRGE
+-	I-PRGE
+CSF	I-PRGE
+)	O
+is	O
+commonly	O
+administered	O
+to	O
+healthy	O
+donors	O
+to	O
+mobilize	O
+peripheral	B-ANAT
+blood	I-ANAT
+stem	I-ANAT
+cells	I-ANAT
+(	O
+PBSC	O
+)	O
+for	O
+allogeneic	O
+hematopoietic	B-ANAT
+stem	I-ANAT
+cell	I-ANAT
+transplantation	O
+(	O
+allo	O
+-	O
+HSCT	O
+).	O
+
+Adverse	O
+events	O
+from	O
+G	B-PRGE
+-	I-PRGE
+CSF	I-PRGE
+use	O
+in	O
+healthy	O
+donors	O
+have	O
+been	O
+described	O
+in	O
+approximately	O
+30	O
+%	O
+of	O
+cases	O
+,	O
+and	O
+are	O
+comprised	O
+predominantly	O
+of	O
+bone	B-DISO
+pain	I-DISO
+,	O
+headache	B-DISO
+,	O
+and	O
+general	O
+fatigue	B-DISO
+.	O
+
+This	O
+article	O
+aims	O
+to	O
+review	O
+the	O
+published	O
+studies	O
+of	O
+HFOV	O
+in	O
+adults	O
+with	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+with	O
+regard	O
+to	O
+its	O
+safety	O
+and	O
+efficacy	O
+.	O
+
+High	O
+-	O
+frequency	O
+oscillatory	O
+ventilation	O
+(	O
+HFOV	O
+)	O
+has	O
+been	O
+used	O
+successfully	O
+in	O
+our	O
+regional	O
+burn	O
+center	O
+since	O
+1999	O
+for	O
+the	O
+management	O
+of	O
+oxygenation	B-PROC
+failure	O
+secondary	O
+to	O
+ARDS	B-DISO
+and	O
+as	O
+a	O
+method	O
+of	O
+intraoperative	O
+ventilation	O
+to	O
+allow	O
+surgical	O
+burn	O
+wound	O
+excision	O
+to	O
+proceed	O
+,	O
+despite	O
+the	O
+presence	O
+of	O
+severe	O
+ARDS	B-DISO
+.	O
+
+HFOV	O
+produced	O
+a	O
+slower	O
+and	O
+less	O
+robust	O
+reversal	O
+of	O
+oxygenation	B-PROC
+failure	O
+in	O
+those	O
+with	O
+smoke	O
+inhalation	B-PROC
+compared	O
+with	O
+patients	O
+with	O
+burns	O
+alone	O
+.	O
+
+TITLE	O
+:	O
+Sedation	B-DISO
+,	O
+analgesia	B-DISO
+,	O
+and	O
+neuromuscular	B-DISO
+blockade	I-DISO
+for	O
+high	O
+-	O
+frequency	O
+oscillatory	O
+ventilation	O
+.	O
+
+In	O
+particular	O
+,	O
+the	O
+use	O
+of	O
+NMBA	O
+has	O
+been	O
+higher	O
+than	O
+for	O
+other	O
+ARDS	B-DISO
+populations	O
+.	O
+
+High	O
+-	O
+frequency	O
+percussive	O
+ventilation	O
+has	O
+been	O
+shown	O
+to	O
+provide	O
+favorable	O
+gas	B-ENZY
+exchange	O
+in	O
+several	O
+well	O
+-	O
+defined	O
+patient	O
+populations	O
+.	O
+
+It	O
+reliably	O
+improves	O
+oxygenation	B-PROC
+and	O
+provides	O
+adequate	O
+ventilation	O
+at	O
+lower	O
+peak	O
+pressures	O
+than	O
+conventional	O
+ventilation	O
+.	O
+
+Recruitment	B-DISO
+maneuvers	O
+were	O
+repeated	O
+for	O
+hypoxemia	O
+and	O
+routinely	O
+at	O
+least	O
+twice	O
+daily	O
+if	O
+the	O
+Fio2	O
+was	O
+>	O
+0	O
+.	O
+4	O
+.	O
+
+TITLE	O
+:	O
+Secondary	O
+effects	O
+of	O
+femoral	B-ANAT
+instrumentation	O
+on	O
+pulmonary	B-ANAT
+physiology	O
+in	O
+a	O
+standardised	O
+sheep	B-SPEC
+model	O
+:	O
+what	O
+is	O
+the	O
+effect	O
+of	O
+lung	O
+contusion	O
+and	O
+reaming	O
+?	O
+
+In	O
+a	O
+standardised	O
+sheep	B-SPEC
+model	O
+,	O
+this	O
+study	O
+aimed	O
+to	O
+quantify	O
+the	O
+development	B-PROC
+of	O
+acute	O
+pulmonary	B-ANAT
+endothelial	B-ANAT
+changes	O
+,	O
+to	O
+assess	O
+the	O
+activation	O
+of	O
+polymorphonuclear	O
+leucocytes	B-ANAT
+(	O
+PMNL	O
+)	O
+and	O
+to	O
+observe	O
+the	O
+effects	O
+on	O
+the	O
+coagulation	B-PROC
+system	O
+associated	O
+with	O
+the	O
+reamed	O
+nailing	O
+procedure	O
+.	O
+
+This	O
+was	O
+exacerbated	O
+in	O
+the	O
+presence	O
+of	O
+lung	B-ANAT
+contusion	O
+along	O
+with	O
+increased	O
+PMNL	O
+activation	O
+.	O
+
+TITLE	O
+:	O
+Web	B-DISO
+-	O
+based	O
+electronic	O
+patient	O
+records	O
+for	O
+collaborative	O
+medical	O
+applications	O
+.	O
+
+In	O
+the	O
+absence	O
+of	O
+effective	O
+vaccines	O
+,	O
+nucleic	B-CHED
+acid	I-CHED
+-	O
+based	O
+immunomodulators	O
+have	O
+the	O
+potential	O
+to	O
+offer	O
+effective	O
+,	O
+broad	O
+-	O
+spectrum	O
+protection	O
+against	O
+these	O
+deadly	O
+pathogens	O
+.	O
+
+CpG	O
+oligos	O
+in	O
+liposomes	O
+also	O
+provided	O
+high	O
+level	O
+of	O
+protection	O
+against	O
+the	O
+lethal	O
+influenza	B-DISO
+challenge	O
+.	O
+
+TITLE	O
+:	O
+The	O
+development	B-PROC
+of	O
+vaccines	O
+against	O
+SARS	B-DISO
+corona	B-CHED
+virus	B-SPEC
+in	O
+mice	B-SPEC
+and	O
+SCID	B-DISO
+-	O
+PBL	O
+/	O
+hu	O
+mice	B-SPEC
+.	O
+
+CTL	B-ANAT
+responses	O
+were	O
+also	O
+detected	O
+to	O
+SARS	B-DISO
+DNA	O
+-	O
+transfected	O
+type	O
+II	O
+alveolar	B-ANAT
+epithelial	B-ANAT
+cells	I-ANAT
+(	O
+T7	O
+cell	B-ANAT
+clone	I-ANAT
+),	O
+which	O
+are	O
+thought	O
+to	O
+be	O
+initial	O
+target	B-ANAT
+cells	I-ANAT
+for	O
+SARS	B-DISO
+virus	B-DISO
+infection	I-DISO
+in	O
+human	B-SPEC
+.	O
+
+This	O
+is	O
+amazing	O
+since	O
+the	O
+number	O
+of	O
+human	B-DISO
+rabies	I-DISO
+deaths	B-PROC
+worldwide	O
+is	O
+greater	O
+than	O
+that	O
+from	O
+polio	B-DISO
+,	O
+meningococcal	B-DISO
+meningitis	I-DISO
+,	O
+Japanese	B-DISO
+encephalitis	I-DISO
+,	O
+yellow	B-DISO
+fever	I-DISO
+,	O
+SARS	B-DISO
+,	O
+bird	B-SPEC
+flue	O
+and	O
+other	O
+scourges	O
+that	O
+attract	O
+more	O
+attention	O
+.	O
+
+Reduced	O
+dose	O
+effective	O
+and	O
+less	O
+expensive	O
+post	O
+-	O
+exposure	O
+vaccination	O
+regimens	O
+have	O
+helped	O
+eliminate	O
+nerve	B-ANAT
+tissue	I-ANAT
+vaccines	O
+in	O
+Thailand	O
+,	O
+Philippines	O
+and	O
+Sri	O
+Lanka	B-SPEC
+.	O
+
+The	O
+process	O
+uses	O
+broad	O
+-	O
+range	O
+polymerase	O
+chain	O
+reaction	O
+(	O
+PCR	O
+)	O
+to	O
+amplify	O
+nucleic	B-CHED
+acid	I-CHED
+targets	O
+from	O
+large	O
+groupings	O
+of	O
+organisms	O
+,	O
+electrospray	O
+ionization	O
+mass	O
+spectrometry	O
+for	O
+accurate	O
+mass	O
+measurements	O
+of	O
+PCR	O
+products	O
+,	O
+and	O
+base	O
+composition	O
+signature	O
+analysis	O
+to	O
+identify	O
+organisms	O
+in	O
+a	O
+sample	O
+.	O
+
+We	O
+conducted	O
+a	O
+survey	O
+concerning	O
+perception	O
+of	O
+risk	O
+and	O
+countermeasures	O
+for	O
+SARS	B-DISO
+in	O
+7	O
+tertiary	O
+hospitals	O
+in	O
+Japan	O
+from	O
+July	O
+through	O
+September	O
+2003	O
+,	O
+immediately	O
+after	O
+the	O
+SARS	B-DISO
+epidemic	O
+in	O
+neighboring	O
+countries	O
+.	O
+
+Neutralization	O
+titers	O
+measured	O
+by	O
+this	O
+assay	O
+are	O
+highly	O
+correlated	O
+to	O
+those	O
+measured	O
+by	O
+an	O
+assay	O
+using	O
+replication	O
+-	O
+competent	O
+SARS	B-DISO
+-	O
+CoV	O
+.	O
+No	O
+cross	O
+-	O
+neutralization	O
+occurred	O
+with	O
+human	B-SPEC
+sera	B-COMP
+known	O
+to	O
+contain	O
+antibodies	B-COMP
+to	O
+coronavirus	B-SPEC
+strains	O
+OC43	O
+and	O
+229E	O
+.	O
+
+High	O
+percentages	O
+of	O
+respondents	O
+felt	O
+helpless	O
+,	O
+horrified	O
+,	O
+and	O
+apprehensive	O
+because	O
+of	O
+SARS	B-DISO
+.	O
+
+Approximately	O
+16	O
+%	O
+showed	O
+signs	O
+of	O
+posttraumatic	O
+symptoms	O
+,	O
+and	O
+approximately	O
+equals	O
+40	O
+%	O
+perceived	O
+increased	O
+stress	O
+in	O
+family	B-SPEC
+or	O
+work	O
+settings	O
+.	O
+
+ABSTRACT	O
+:	O
+Severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+(	O
+SARS	B-DISO
+)	O
+is	O
+a	O
+serious	O
+health	O
+threat	O
+and	O
+its	O
+early	O
+diagnosis	O
+is	O
+important	O
+for	O
+infection	B-DISO
+control	O
+and	O
+potential	O
+treatment	O
+of	O
+the	O
+disease	O
+.	O
+
+Polyclonal	O
+antibodies	B-COMP
+against	O
+the	O
+SARS	B-DISO
+N	I-PRGE
+protein	B-CHED
+have	O
+been	O
+produced	O
+and	O
+the	O
+strong	O
+binding	B-FUNC
+sites	O
+of	O
+the	O
+anti	B-PRGE
+-	I-PRGE
+nucleocapsid	I-PRGE
+protein	B-CHED
+(	I-PRGE
+NP	I-PRGE
+)	I-PRGE
+antibodies	B-COMP
+produced	O
+were	O
+mapped	O
+to	O
+aa	O
+1	O
+-	O
+20	O
+,	O
+aa	O
+150	O
+-	O
+170	O
+and	O
+aa	O
+390	O
+-	O
+410	O
+.	O
+
+These	O
+sites	O
+are	O
+generally	O
+consistent	O
+with	O
+those	O
+mapped	O
+by	O
+sera	B-COMP
+obtained	O
+from	O
+SARS	B-DISO
+patients	O
+.	O
+
+Further	O
+refinement	O
+of	O
+these	O
+antibodies	B-COMP
+,	O
+particularly	O
+large	O
+-	O
+scale	O
+production	O
+of	O
+monoclonal	O
+antibodies	B-COMP
+,	O
+could	O
+lead	O
+to	O
+the	O
+development	B-PROC
+of	O
+useful	O
+diagnostic	O
+kits	O
+for	O
+diseases	O
+associated	O
+with	O
+SARS	B-DISO
+and	O
+other	O
+human	B-SPEC
+coronaviruses	O
+.	O
+
+ABSTRACT	O
+:	O
+Traditional	O
+infection	B-DISO
+control	O
+policies	O
+have	O
+focused	O
+on	O
+engineering	O
+controls	O
+,	O
+specific	O
+protocols	O
+,	O
+and	O
+personal	O
+protective	O
+equipment	O
+(	O
+PPE	B-CHED
+).	O
+
+TITLE	O
+:	O
+Protecting	O
+health	O
+care	O
+workers	O
+from	O
+SARS	B-DISO
+and	O
+other	O
+respiratory	O
+pathogens	O
+:	O
+a	O
+review	O
+of	O
+the	O
+infection	B-DISO
+control	O
+literature	O
+.	O
+
+The	O
+effectiveness	O
+of	O
+infection	B-DISO
+control	O
+policies	O
+and	O
+procedures	O
+used	O
+in	O
+clinical	O
+practice	O
+is	O
+examined	O
+.	O
+
+However	O
+,	O
+the	O
+possibility	O
+of	O
+a	O
+gradation	O
+of	O
+infectious	B-DISO
+particles	O
+generated	O
+by	O
+aerosolizing	O
+procedures	O
+suggests	O
+that	O
+traditional	O
+droplet	O
+transmission	O
+prevention	O
+measures	O
+may	O
+be	O
+inadequate	O
+in	O
+some	O
+settings	O
+.	O
+
+TITLE	O
+:	O
+Subcellular	O
+localization	B-PROC
+and	O
+membrane	B-COMP
+association	O
+of	O
+SARS	B-PRGE
+-	I-PRGE
+CoV	I-PRGE
+3a	I-PRGE
+protein	B-CHED
+.	O
+
+ABSTRACT	O
+:	O
+SARS	B-DISO
+-	I-PRGE
+CoV	I-PRGE
+3a	I-PRGE
+protein	I-PRGE
+was	O
+a	O
+unique	O
+protein	B-CHED
+of	O
+SARS	B-DISO
+coronavirus	B-SPEC
+(	O
+SARS	B-DISO
+-	O
+CoV	O
+),	O
+which	O
+was	O
+identified	O
+in	O
+SARS	B-DISO
+-	O
+CoV	O
+infected	O
+cells	B-COMP
+and	O
+SARS	B-DISO
+patients	O
+'	O
+specimen	O
+.	O
+
+The	O
+localization	B-PROC
+pattern	O
+was	O
+similar	O
+in	O
+different	O
+transfected	O
+cells	B-COMP
+.	O
+
+Morphological	O
+findings	O
+showed	O
+that	O
+the	O
+oleic	B-CHED
+acid	I-CHED
+group	O
+demonstrated	O
+a	O
+marked	O
+lung	B-ANAT
+injury	O
+represented	O
+by	O
+prominent	O
+atelectasis	B-DISO
+,	O
+intraalveolar	O
+and	O
+interstitial	B-ANAT
+patchy	O
+hemorrhage	B-DISO
+,	O
+edema	B-DISO
+,	O
+thickened	O
+alveolar	B-ANAT
+septum	I-ANAT
+,	O
+formation	B-PROC
+of	O
+hyaline	B-DISO
+membranes	B-ANAT
+and	O
+the	O
+existence	O
+of	O
+inflammatory	B-ANAT
+cells	I-ANAT
+in	O
+alveolar	B-ANAT
+spaces	O
+.	O
+
+Furthermore	O
+,	O
+pretreatment	O
+with	O
+oxymatrine	O
+significantly	O
+alleviated	O
+oleic	O
+acid	O
+-	O
+induced	O
+lung	B-ANAT
+injury	O
+accompanied	O
+by	O
+reduction	O
+of	O
+lung	B-ANAT
+index	O
+and	O
+wet	O
+-	O
+to	O
+-	O
+dry	O
+weight	O
+ratio	O
+,	O
+decreases	O
+in	O
+serum	B-PRGE
+TNF	I-PRGE
+-	I-PRGE
+alpha	I-PRGE
+level	O
+and	O
+inhibition	B-PROC
+of	O
+phosphorylated	O
+p38	B-FUNC
+MAPK	B-FUNC
+.	O
+
+TITLE	O
+:	O
+Aerosol	O
+-	O
+induced	O
+Mycoplasma	B-SPEC
+synoviae	I-SPEC
+arthritis	B-DISO
+:	O
+the	O
+synergistic	O
+effect	O
+of	O
+infectious	B-DISO
+bronchitis	B-DISO
+virus	B-DISO
+infection	I-DISO
+.	O
+
+Mycoplasma	B-DISO
+-	O
+free	O
+brown	O
+layer	B-ANAT
+pullets	O
+,	O
+approximately	O
+5	O
+weeks	O
+old	O
+,	O
+were	O
+exposed	O
+to	O
+an	O
+aerosol	O
+dose	O
+of	O
+>	O
+or	O
+=	O
+10	O
+(	O
+2	O
+-	O
+3	O
+)	O
+colony	O
+-	O
+forming	O
+units	O
+(	O
+CFU	O
+)	O
+of	O
+M	B-SPEC
+.	I-SPEC
+synoviae	I-SPEC
+alone	O
+or	O
+3	O
+days	O
+after	O
+inoculation	O
+of	O
+a	O
+field	O
+strain	O
+of	O
+IBV	B-SPEC
+(	O
+D1466	O
+)	O
+by	O
+the	O
+ocular	B-PROC
+-	O
+nasal	B-ANAT
+route	O
+.	O
+
+In	O
+a	O
+repeat	O
+experiment	O
+an	O
+additional	O
+group	O
+was	O
+exposed	O
+to	O
+M	B-SPEC
+.	I-SPEC
+synoviae	I-SPEC
+aerosol	O
+3	O
+days	O
+after	O
+infection	B-DISO
+with	O
+IBV	B-SPEC
+M41	O
+strain	O
+.	O
+
+The	O
+mortality	O
+that	O
+occurred	O
+using	O
+this	O
+less	O
+-	O
+attenuated	O
+vaccine	O
+was	O
+significantly	O
+influenced	O
+by	O
+the	O
+genetic	O
+line	O
+,	O
+and	O
+the	O
+MHC	B-PRGE
+(	I-PRGE
+B	I-PRGE
+)	I-PRGE
+haplotype	I-PRGE
+in	I-PRGE
+chickens	B-SPEC
+of	O
+three	O
+B	O
+congenic	O
+lines	O
+.	O
+
+These	O
+retrospective	O
+data	O
+from	O
+two	O
+repeated	O
+hatches	O
+confirm	O
+earlier	O
+data	O
+indicating	O
+chicken	B-SPEC
+genes	O
+influence	O
+resistance	B-PROC
+to	O
+IBV	B-SPEC
+,	O
+and	O
+indicate	O
+for	O
+the	O
+first	O
+time	O
+that	O
+genes	O
+tightly	O
+linked	O
+to	O
+the	O
+B	O
+haplotype	O
+are	O
+relevant	O
+in	O
+resistance	B-PROC
+to	O
+IBV	B-SPEC
+.	O
+
+ABSTRACT	O
+:	O
+To	O
+study	O
+the	O
+incidence	O
+and	O
+severity	O
+of	O
+organ	O
+dysfunction	O
+associated	O
+with	O
+sepsis	B-DISO
+.	O
+
+Thirty	O
+-	O
+five	O
+ICUs	O
+in	O
+nonuniversity	O
+and	O
+university	O
+hospitals	O
+located	O
+in	O
+the	O
+Paris	B-SPEC
+area	O
+.	O
+
+The	O
+autopsy	O
+lung	B-ANAT
+tissue	I-ANAT
+from	O
+patient	O
+1	O
+,	O
+who	O
+died	B-PROC
+7	O
+days	O
+after	O
+symptoms	O
+onset	O
+due	O
+to	O
+the	O
+complication	B-DISO
+of	O
+acute	B-DISO
+myocardial	I-DISO
+infarction	I-DISO
+,	O
+revealed	O
+mild	O
+histologic	O
+change	O
+in	O
+the	O
+lung	B-ANAT
+.	O
+
+The	O
+lung	B-ANAT
+biopsy	O
+specimen	B-ANAT
+from	I-ANAT
+patient	I-ANAT
+4	O
+taken	O
+21	O
+days	O
+after	O
+symptom	B-DISO
+onset	O
+showed	O
+characteristics	O
+of	O
+the	O
+fibrotic	O
+stage	O
+,	O
+with	O
+significant	O
+myofibroblastic	O
+proliferation	B-DISO
+in	O
+the	O
+alveolar	B-ANAT
+space	O
+and	O
+interstitium	B-ANAT
+resulting	O
+in	O
+loss	O
+of	O
+pulmonary	B-ANAT
+architecture	O
+.	O
+
+The	O
+histologic	O
+evolution	B-PROC
+of	O
+SARS	B-DISO
+coincided	O
+with	O
+the	O
+different	O
+stages	O
+of	O
+DAD	O
+:	O
+acute	O
+,	O
+proliferative	B-DISO
+organizing	O
+,	O
+and	O
+fibrotic	O
+stages	O
+.	O
+
+The	O
+absence	O
+of	O
+DAD	O
+does	O
+not	O
+rule	O
+out	O
+the	O
+possibility	O
+of	O
+SARS	B-DISO
+-	I-DISO
+CoV	I-DISO
+infection	I-DISO
+,	O
+particularly	O
+in	O
+the	O
+early	O
+stage	O
+of	O
+the	O
+disease	O
+.	O
+
+Thus	O
+,	O
+the	O
+optimal	O
+treatment	O
+for	O
+SARS	B-DISO
+is	O
+unknown	O
+.	O
+
+TITLE	O
+:	O
+Viral	O
+induction	O
+of	O
+central	B-ANAT
+nervous	I-ANAT
+system	I-ANAT
+innate	B-DISO
+immune	I-DISO
+responses	I-DISO
+.	O
+
+Cultures	O
+containing	O
+CNS	B-CHED
+cells	B-COMP
+were	O
+infected	O
+with	O
+mouse	B-DISO
+hepatitis	I-DISO
+virus	B-SPEC
+-	O
+JHM	O
+,	O
+which	O
+causes	O
+fatal	O
+encephalitis	B-DISO
+in	O
+mice	B-SPEC
+.	O
+
+And	O
+the	O
+antibody	B-COMP
+detective	O
+rate	O
+was	O
+decreased	O
+by	O
+the	O
+month	O
+.	O
+
+As	O
+a	O
+whole	O
+SARS	B-DISO
+-	O
+CoV	O
+Ab	O
+-	O
+IgG	B-PRGE
+detective	O
+rate	O
+for	O
+the	O
+clinic	O
+diagnosed	O
+SARS	B-DISO
+patients	O
+was	O
+53	O
+.	O
+7	O
+%	O
+only	O
+.	O
+
+Patients	O
+with	O
+SARS	B-DISO
+showing	O
+severe	O
+psychological	B-DISO
+symptoms	I-DISO
+constituted	O
+about	O
+41	O
+%	O
+(	O
+group	O
+I	O
+)	O
+and	O
+patients	O
+with	O
+SARS	B-DISO
+showing	O
+mild	O
+psychological	B-DISO
+symptoms	I-DISO
+(	O
+group	O
+II	O
+)	O
+constituted	O
+about	O
+59	O
+%.	O
+
+RESULTS	O
+:	O
+Patients	O
+with	O
+SARS	B-DISO
+showing	O
+severe	O
+psychological	B-DISO
+symptoms	I-DISO
+constituted	O
+about	O
+41	O
+%	O
+(	O
+group	O
+I	O
+)	O
+and	O
+patients	O
+with	O
+SARS	B-DISO
+showing	O
+mild	O
+psychological	B-DISO
+symptoms	I-DISO
+(	O
+group	O
+II	O
+)	O
+constituted	O
+about	O
+59	O
+%.	O
+
+TITLE	O
+:	O
+Multimodal	O
+percutaneous	O
+intervention	O
+for	O
+critical	O
+venous	B-ANAT
+occlusive	O
+disease	O
+.	O
+
+The	O
+relief	O
+of	O
+pain	O
+and	O
+resolution	O
+of	O
+acutely	O
+life	O
+and	O
+limb	B-ANAT
+-	O
+threatening	O
+conditions	O
+in	O
+this	O
+most	O
+severely	O
+symptomatic	O
+subset	O
+of	O
+patients	O
+represents	O
+the	O
+immediate	O
+goal	O
+of	O
+treatment	O
+.	O
+
+TITLE	O
+:	O
+SARS	B-DISO
+and	O
+the	O
+Academic	O
+Health	O
+Sector	O
+.	O
+
+ABSTRACT	O
+:	O
+SARS	B-DISO
+illustrated	O
+the	O
+vulnerability	O
+of	O
+the	O
+entire	O
+country	O
+to	O
+the	O
+importation	O
+of	O
+new	O
+organisms	O
+and	O
+other	O
+unexpected	O
+health	O
+crises	O
+.	O
+
+*	O
+Coordinated	O
+processes	O
+to	O
+move	B-PROC
+appropriate	O
+people	O
+and	O
+resources	O
+into	O
+place	O
+when	O
+a	O
+health	O
+crisis	O
+requires	O
+such	O
+action	O
+.	O
+
+In	O
+a	O
+case	O
+-	O
+control	O
+evaluation	O
+of	O
+573	O
+cats	B-SPEC
+in	O
+eight	O
+shelters	O
+in	O
+California	B-SPEC
+in	O
+2001	O
+and	O
+2002	O
+,	O
+the	O
+prevalence	O
+of	O
+feline	B-SPEC
+calicivirus	I-SPEC
+(	O
+FCV	B-CHED
+)	O
+was	O
+from	O
+13	O
+to	O
+36	O
+%,	O
+feline	B-SPEC
+herpesvirus	I-SPEC
+(	O
+FHV	O
+)	O
+was	O
+from	O
+3	O
+to	O
+38	O
+%,	O
+and	O
+prevalence	O
+of	O
+Bordetella	B-SPEC
+bronchiseptica	I-SPEC
+,	O
+Chlamydophila	B-SPEC
+felis	I-SPEC
+,	O
+and	O
+Mycoplasma	B-DISO
+species	B-SPEC
+was	O
+from	O
+2	O
+to	O
+14	O
+%.	O
+
+ABSTRACT	O
+:	O
+SARS	B-DISO
+-	O
+CoV	O
+(	O
+the	O
+SARS	O
+-	O
+Associated	O
+Coronavirus	O
+)	O
+was	O
+reported	O
+as	O
+a	O
+novel	O
+virus	B-SPEC
+member	O
+in	O
+the	O
+coronavirus	B-SPEC
+family	B-SPEC
+,	O
+which	O
+was	O
+the	O
+cause	O
+of	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+.	O
+
+Coronavirus	B-SPEC
+replication	O
+occurs	O
+through	O
+a	O
+unique	O
+mechanism	O
+employing	O
+Leader	O
+sequence	O
+in	O
+the	O
+transcripts	O
+when	O
+initiating	O
+transcription	B-PROC
+from	O
+the	O
+genome	O
+.	O
+
+In	O
+each	O
+patient	O
+,	O
+transpulmonary	O
+thermodilution	O
+was	O
+used	O
+to	O
+measure	O
+cardiovascular	B-ANAT
+hemodynamics	B-PROC
+and	O
+EVLW	O
+for	O
+7	O
+days	O
+via	O
+an	O
+arterial	B-ANAT
+catheter	O
+placed	O
+within	O
+72	O
+hours	O
+of	O
+meeting	O
+criteria	O
+for	O
+severe	B-DISO
+sepsis	I-DISO
+.	O
+
+More	O
+than	O
+half	O
+of	O
+the	O
+patients	O
+with	O
+severe	B-DISO
+sepsis	I-DISO
+but	O
+without	O
+ARDS	B-DISO
+had	O
+increased	O
+EVLW	O
+,	O
+possibly	O
+representing	O
+subclinical	O
+lung	B-ANAT
+injury	O
+.	O
+
+Antigenic	O
+screening	O
+indicated	O
+that	O
+recombinant	O
+GST	B-PRGE
+-	O
+N2	O
+fusion	O
+protein	B-CHED
+,	O
+the	O
+carboxy	B-CHED
+-	O
+terminus	O
+213aa	O
+-	O
+423aa	O
+of	O
+N	B-PRGE
+protein	I-PRGE
+,	O
+was	O
+strongest	O
+positive	O
+and	O
+weakest	O
+non	O
+-	O
+specific	O
+compared	O
+with	O
+others	O
+.	O
+
+Reported	O
+data	O
+showed	O
+that	O
+this	O
+was	O
+a	O
+relatively	O
+high	O
+degree	O
+of	O
+sensitivity	O
+and	O
+specificity	O
+for	O
+SARS	O
+-	O
+CoV	O
+antibody	B-COMP
+testing	O
+.	O
+
+Modified	O
+levels	O
+of	O
+several	O
+transcripts	O
+involved	O
+in	O
+pro	B-CHED
+-	O
+inflammatory	O
+and	O
+anti	O
+-	O
+inflammatory	O
+processes	O
+exemplified	O
+the	O
+balance	B-PROC
+between	O
+opposing	O
+forces	O
+during	O
+SARS	B-DISO
+pathogenesis	B-DISO
+.	O
+
+Alterations	O
+in	O
+the	O
+levels	O
+of	O
+several	O
+novel	O
+transcripts	O
+encoding	O
+hypothetical	O
+proteins	B-CHED
+and	O
+expressed	B-PROC
+sequence	O
+tags	O
+were	O
+also	O
+identified	O
+.	O
+
+Microarray	O
+analysis	O
+identifies	O
+the	O
+critical	O
+host	B-COMP
+-	O
+pathogen	O
+interactions	O
+during	O
+SARS	B-DISO
+-	I-DISO
+CoV	I-DISO
+infection	I-DISO
+and	O
+provides	O
+new	O
+insights	O
+into	O
+the	O
+pathophysiology	O
+of	O
+SARS	B-DISO
+.	O
+
+Some	O
+syncytial	O
+cells	B-COMP
+contained	O
+enlarged	O
+C	B-SPEC
+.	I-SPEC
+abortus	I-SPEC
+or	O
+C	B-SPEC
+.	I-SPEC
+pecorum	I-SPEC
+inclusions	O
+with	O
+abnormally	O
+large	O
+developmental	O
+forms	O
+.	O
+
+TITLE	O
+:	O
+Inhibition	B-PROC
+of	O
+genes	O
+expression	B-PROC
+of	O
+SARS	B-DISO
+coronavirus	B-SPEC
+by	O
+synthetic	O
+small	O
+interfering	O
+RNAs	O
+.	O
+
+Mice	B-SPEC
+received	O
+the	O
+affinity	O
+-	O
+purified	O
+protein	B-CHED
+with	O
+either	O
+a	O
+saponin	B-CHED
+(	O
+QS21	O
+)	O
+or	O
+a	O
+Ribi	O
+(	O
+MPL	O
++	O
+TDM	O
+)	O
+adjuvant	B-CHED
+subcutaneously	O
+and	O
+were	O
+challenged	O
+intranasally	O
+with	O
+SARS	B-DISO
+-	O
+CoV	O
+.	O
+Both	O
+regimens	O
+induced	O
+binding	B-FUNC
+and	O
+neutralizing	O
+antibodies	B-COMP
+and	O
+protection	O
+against	O
+SARS	B-DISO
+-	O
+CoV	O
+intranasal	O
+infection	B-DISO
+.	O
+
+TITLE	O
+:	O
+Spike	B-PRGE
+protein	I-PRGE
+assembly	O
+into	O
+the	O
+coronavirion	O
+:	O
+exploring	O
+the	O
+limits	O
+of	O
+its	O
+sequence	O
+requirements	O
+.	O
+
+Consistently	O
+,	O
+only	O
+short	O
+C	O
+-	O
+terminal	O
+truncations	O
+of	O
+the	O
+S	B-PRGE
+protein	I-PRGE
+were	O
+tolerated	O
+when	O
+introduced	O
+into	O
+the	O
+virus	B-SPEC
+by	O
+targeted	B-PROC
+recombination	B-PROC
+.	O
+
+The	O
+important	O
+role	O
+of	O
+the	O
+about	O
+38	O
+-	O
+residues	O
+cytoplasmic	B-ANAT
+domain	I-ANAT
+in	O
+the	O
+assembly	O
+of	O
+and	O
+membrane	B-PROC
+fusion	I-PROC
+by	O
+this	O
+approximately	O
+1300	O
+amino	B-CHED
+acids	I-CHED
+long	O
+protein	B-CHED
+is	O
+discussed	O
+.	O
+
+Several	O
+scenarios	O
+can	O
+be	O
+proposed	O
+:	O
+1	O
+)	O
+the	O
+appearance	O
+of	O
+a	O
+new	O
+infection	B-DISO
+(	O
+AIDS	O
+or	O
+SARS	B-DISO
+);	O
+2	O
+)	O
+the	O
+appearance	O
+of	O
+a	O
+known	O
+infection	B-DISO
+where	O
+it	O
+did	O
+not	O
+exist	O
+previously	O
+(	O
+West	B-DISO
+Nile	I-DISO
+virus	I-DISO
+infection	I-DISO
+in	O
+the	O
+USA	O
+);	O
+3	O
+)	O
+an	O
+infection	B-DISO
+that	O
+existed	O
+but	O
+that	O
+was	O
+not	O
+diagnosed	O
+or	O
+could	O
+not	O
+be	O
+linked	O
+precisely	O
+to	O
+a	O
+particular	O
+infectious	B-DISO
+agent	O
+(	O
+hepatitis	B-PATH
+C	I-PATH
+before	O
+the	O
+discovery	O
+of	O
+the	O
+hepatitis	B-SPEC
+C	I-SPEC
+virus	I-SPEC
+;	O
+4	O
+)	O
+a	O
+known	O
+infection	B-DISO
+that	O
+increases	O
+its	O
+usual	O
+incidence	O
+(	O
+outbreaks	O
+...);	O
+5	O
+)	O
+infectious	B-DISO
+diseases	I-DISO
+for	O
+which	O
+current	O
+conditions	O
+may	O
+facilitate	O
+transmission	O
+(	O
+decrease	O
+of	O
+immunization	O
+coverage	O
+...).	O
+
+However	O
+,	O
+synthesis	B-PROC
+of	O
+these	O
+peptides	B-CHED
+is	O
+at	O
+high	O
+cost	O
+.	O
+
+Compared	O
+to	O
+other	O
+diagnostic	O
+techniques	O
+,	O
+however	O
+,	O
+EM	O
+excells	O
+by	O
+speed	O
+and	O
+""""	O
+open	O
+view	O
+""","	O
+i	O
+.	O
+e	O
+.	O
+by	O
+the	O
+ability	O
+to	O
+detect	O
+also	O
+the	O
+""""	O
+un	O
+-	O
+expected	O
+""""	O
+without	O
+the	O
+need	O
+for	O
+specific	O
+reagents	B-CHED
+.	O
+
+TITLE	O
+:	O
+Detection	O
+of	O
+respiratory	O
+and	O
+enteric	O
+shedding	O
+of	O
+bovine	B-SPEC
+coronaviruses	O
+in	O
+cattle	B-SPEC
+in	O
+Northwestern	O
+Turkey	O
+.	O
+
+The	O
+analysis	O
+showed	O
+that	O
+there	O
+was	O
+a	O
+significant	O
+difference	O
+(	O
+P	O
+<	O
+0	O
+.	O
+0001	O
+)	O
+with	O
+respect	O
+to	O
+faecal	B-ANAT
+shedding	O
+between	O
+the	O
+clinical	O
+signs	O
+and	O
+the	O
+age	O
+groups	O
+.	O
+
+The	O
+seroconversion	O
+rate	O
+was	O
+7	O
+.	O
+3	O
+%	O
+(	O
+7	O
+/	O
+96	O
+)	O
+in	O
+animals	B-SPEC
+shedding	O
+BoCV	O
+in	O
+the	O
+faeces	B-ANAT
+and	O
+42	O
+.	O
+7	O
+%	O
+(	O
+41	O
+/	O
+96	O
+)	O
+in	O
+cattle	B-SPEC
+negative	O
+for	O
+faecal	B-ANAT
+shedding	O
+as	O
+detected	O
+by	O
+ELISA	O
+,	O
+and	O
+20	O
+.	O
+8	O
+%	O
+of	O
+cattle	B-SPEC
+with	O
+no	O
+seroconversion	O
+shed	O
+BCoV	O
+in	O
+the	O
+faeces	B-ANAT
+.	O
+
+These	O
+findings	O
+confirm	O
+the	O
+presence	O
+of	O
+BCoV	O
+infections	B-DISO
+in	O
+Turkey	B-SPEC
+.	O
+
+CONCLUSIONS	O
+:	O
+SARS	B-DISO
+-	O
+CoV	O
+seemed	O
+to	O
+elicit	O
+effective	O
+humoral	B-PROC
+immunity	I-PROC
+but	O
+inhibited	O
+cellular	B-PROC
+immunity	I-PROC
+,	O
+especially	O
+CD8	B-PRGE
++	I-PRGE
+memory	B-PROC
+T	B-ANAT
+lymphocytes	I-ANAT
+over	O
+time	O
+.	O
+
+ABSTRACT	O
+:	O
+We	O
+present	O
+the	O
+first	O
+proteomic	O
+analysis	O
+on	O
+the	O
+cellular	B-COMP
+response	O
+to	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+-	O
+associated	O
+coronavirus	B-SPEC
+(	O
+SARS	B-DISO
+-	O
+CoV	O
+)	O
+infection	B-DISO
+.	O
+
+The	O
+clear	O
+differences	O
+between	O
+groups	O
+defined	O
+by	O
+demographics	O
+,	O
+professions	O
+and	O
+clinical	O
+roles	O
+suggest	O
+a	O
+subtle	O
+and	O
+pervasive	O
+secondary	O
+impact	O
+of	O
+the	O
+SARS	B-DISO
+outbreak	O
+,	O
+with	O
+repercussions	O
+health	O
+care	O
+facilities	O
+must	O
+contend	O
+with	O
+while	O
+maintaining	O
+increased	O
+levels	O
+of	O
+vigilance	O
+in	O
+the	O
+wake	B-PROC
+of	O
+SARS	B-DISO
+.	O
+
+Nurses	O
+relied	O
+more	O
+on	O
+peer	O
+support	O
+than	O
+doctors	O
+,	O
+felt	O
+less	O
+informed	O
+and	O
+less	O
+involved	O
+in	O
+decision	O
+-	O
+making	O
+than	O
+doctors	O
+felt	O
+,	O
+and	O
+were	O
+more	O
+likely	O
+to	O
+report	O
+that	O
+infection	B-DISO
+control	O
+procedures	O
+were	O
+not	O
+strict	O
+enough	O
+.	O
+
+TITLE	O
+:	O
+Evaluation	O
+by	O
+indirect	O
+immunofluorescent	O
+assay	O
+and	O
+enzyme	O
+linked	O
+immunosorbent	O
+assay	O
+of	O
+the	O
+dynamic	O
+changes	O
+of	O
+serum	B-COMP
+antibody	B-PROC
+responses	I-PROC
+against	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+coronavirus	B-SPEC
+.	O
+
+The	O
+serum	B-COMP
+antibody	B-COMP
+profiles	O
+were	O
+investigated	O
+at	O
+different	O
+times	O
+over	O
+one	O
+and	O
+a	O
+half	O
+years	O
+in	O
+18	O
+of	O
+the	O
+SARS	B-DISO
+patients	O
+.	O
+
+The	O
+detection	O
+of	O
+antibodies	B-COMP
+against	O
+SARS	B-DISO
+virus	B-SPEC
+is	O
+helpful	O
+in	O
+the	O
+clinical	O
+diagnosis	O
+of	O
+SARS	B-DISO
+.	O
+
+The	O
+presence	O
+of	O
+viral	B-COMP
+particles	I-COMP
+in	O
+passage	O
+11	O
+cells	B-COMP
+was	O
+assessed	O
+by	O
+electron	O
+microscopy	O
+.	O
+
+Electron	O
+microscopy	O
+confirmed	O
+the	O
+presence	O
+of	O
+viral	B-COMP
+particles	I-COMP
+in	O
+passage	O
+11	O
+cells	B-COMP
+.	O
+
+This	O
+model	O
+may	O
+provide	O
+insight	O
+into	O
+SARS	B-DISO
+-	O
+related	O
+lung	B-ANAT
+pathology	B-DISO
+and	O
+mechanisms	O
+by	O
+which	O
+humans	B-SPEC
+and	O
+animals	B-SPEC
+can	O
+serve	O
+as	O
+reservoirs	O
+for	O
+infection	B-DISO
+.	O
+
+TITLE	O
+:	O
+Mechanism	O
+of	O
+the	O
+maturation	B-PROC
+process	O
+of	O
+SARS	B-PRGE
+-	I-PRGE
+CoV	I-PRGE
+3CL	I-PRGE
+protease	I-PRGE
+.	O
+
+Cumulative	O
+data	O
+showed	O
+that	O
+67	O
+of	O
+the	O
+73	O
+SARS	B-DISO
+patients	O
+demonstrated	O
+seroconversion	O
+by	O
+week	O
+5	O
+of	O
+illness	O
+.	O
+
+These	O
+findings	O
+suggest	O
+that	O
+SARS	B-DISO
+-	O
+CoV	O
+may	O
+remain	O
+viable	O
+in	O
+the	O
+excretions	B-PROC
+of	O
+convalescent	O
+patients	O
+.	O
+
+The	O
+SARS	B-DISO
+database	O
+contained	O
+data	O
+for	O
+144	O
+patients	O
+with	O
+SARS	B-DISO
+from	O
+the	O
+2003	O
+Toronto	O
+SARS	B-DISO
+outbreak	O
+.	O
+
+By	O
+contrast	O
+,	O
+in	O
+the	O
+immunosuppressed	O
+host	B-PRGE
+TIMP	I-PRGE
+-	I-PRGE
+1	I-PRGE
+mRNA	B-CHED
+was	O
+expressed	B-PROC
+by	O
+CNS	B-CHED
+resident	O
+cells	B-COMP
+.	O
+
+These	O
+data	O
+suggest	O
+that	O
+in	O
+contrast	O
+to	O
+the	O
+results	O
+seen	O
+with	O
+MMPs	O
+,	O
+inhibition	B-PROC
+of	O
+protease	B-PROC
+activity	I-PROC
+via	O
+TIMP	B-PRGE
+-	I-PRGE
+1	I-PRGE
+expression	B-PROC
+correlates	O
+with	O
+the	O
+differential	O
+tissue	B-ANAT
+distribution	O
+of	O
+T	B-ANAT
+-	I-ANAT
+cell	I-ANAT
+subsets	I-ANAT
+during	O
+acute	O
+coronavirus	B-SPEC
+-	O
+induced	O
+encephalitis	B-DISO
+.	O
+
+Sample	O
+1	O
+participants	O
+had	O
+stronger	O
+fear	O
+related	O
+to	O
+infection	B-DISO
+than	O
+Sample	O
+2	O
+participants	O
+,	O
+who	O
+seemed	O
+to	O
+be	O
+concerned	O
+more	O
+about	O
+other	O
+health	O
+problems	O
+and	O
+discrimination	O
+.	O
+
+In	O
+a	O
+cell	B-COMP
+culture	O
+system	O
+of	O
+SCV	B-SPEC
+,	O
+bananin	O
+exhibited	O
+an	O
+EC50	O
+of	O
+less	O
+than	O
+10	O
+microM	O
+and	O
+a	O
+CC50	O
+of	O
+over	O
+300	O
+microM	O
+.	O
+Kinetics	O
+of	O
+inhibition	B-PROC
+are	O
+consistent	O
+with	O
+bananin	O
+inhibiting	O
+an	O
+intracellular	O
+process	O
+or	O
+processes	O
+involved	O
+in	O
+SCV	B-SPEC
+replication	O
+.	O
+
+Amino	B-CHED
+acid	I-CHED
+residues	O
+450	O
+-	O
+650	O
+of	O
+the	O
+spike	O
+(	O
+S	O
+)	O
+glycoprotein	B-CHED
+of	O
+SARS	B-PRGE
+-	I-PRGE
+CoV	I-PRGE
+(	O
+S450	O
+-	O
+650	O
+)	O
+contains	O
+dominant	O
+epitopes	O
+for	O
+anti	O
+-	O
+viral	O
+antibodies	B-COMP
+(	O
+Abs	O
+)	O
+in	O
+patient	O
+sera	B-COMP
+.	O
+
+To	O
+develop	O
+and	O
+evaluate	O
+an	O
+ELISA	O
+system	O
+for	O
+detection	O
+of	O
+anti	B-PRGE
+-	I-PRGE
+S	I-PRGE
+Abs	I-PRGE
+in	O
+patient	O
+sera	B-COMP
+.	O
+
+None	O
+of	O
+the	O
+serum	B-COMP
+samples	O
+from	O
+100	O
+healthy	O
+blood	B-ANAT
+donors	O
+was	O
+positive	O
+in	O
+the	O
+S450	O
+-	O
+650	O
+-	O
+based	O
+assay	O
+.	O
+
+ABSTRACT	O
+:	O
+The	O
+protocols	O
+of	O
+WHO	O
+network	O
+laboratories	O
+facilitated	O
+development	B-PROC
+of	O
+rapid	O
+diagnosis	O
+for	O
+SARS	B-DISO
+coronavirus	B-SPEC
+(	O
+CoV	O
+)	O
+using	O
+reverse	B-PROC
+transcription	I-PROC
+(	O
+RT	O
+)-	O
+PCR	O
+assays	O
+.	O
+
+A	O
+specificity	O
+of	O
+100	O
+%	O
+was	O
+exhibited	O
+by	O
+both	O
+PCR	O
+assays	O
+except	O
+Artus	O
+attained	O
+only	O
+a	O
+92	O
+%	O
+specificity	O
+for	O
+stool	B-ANAT
+.	O
+
+As	O
+no	O
+SARS	B-PRGE
+CoV	I-PRGE
+was	O
+detected	O
+among	O
+specimens	O
+collected	O
+during	O
+post	O
+-	O
+epidemic	O
+period	O
+,	O
+the	O
+positive	O
+predictive	O
+value	O
+of	O
+real	O
+-	O
+time	O
+PCR	O
+assays	O
+for	O
+detection	O
+of	O
+SARS	B-PRGE
+CoV	I-PRGE
+during	O
+low	O
+epidemic	O
+requires	O
+further	O
+evaluation	O
+.	O
+
+RESULTS	O
+:	O
+In	O
+the	O
+SARS	B-DISO
+epidemic	O
+,	O
+Artus	O
+and	O
+Roche	O
+PCR	O
+assays	O
+exhibited	O
+sensitivities	O
+of	O
+87	O
+%	O
+and	O
+85	O
+%	O
+for	O
+respiratory	O
+specimens	O
+(	O
+n	O
+=	O
+64	O
+),	O
+91	O
+%	O
+and	O
+88	O
+%	O
+for	O
+stool	B-ANAT
+(	O
+n	O
+=	O
+44	O
+),	O
+and	O
+82	O
+%	O
+for	O
+urine	B-ANAT
+(	O
+n	O
+=	O
+29	O
+).	O
+
+Eighteen	O
+sequences	O
+of	O
+coronavirus	O
+polyprotein	O
+were	O
+downloaded	O
+from	O
+NCBI	O
+(	O
+http	O
+://	O
+www	O
+.	O
+ncbi	O
+.	O
+nlm	O
+.	O
+nih	B-PRGE
+.	I-PRGE
+gov	I-PRGE
+).	O
+
+ABSTRACT	O
+:	O
+On	O
+22	O
+March	O
+2003	O
+,	O
+the	O
+Ministry	O
+of	O
+Health	O
+,	O
+Singapore	O
+,	O
+designated	O
+Tan	O
+Tock	O
+Seng	O
+Hospital	O
+as	O
+the	O
+nationwide	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+(	O
+SARS	B-DISO
+)	O
+hospital	O
+and	O
+its	O
+Emergency	B-DISO
+Department	O
+(	O
+ED	O
+)	O
+took	O
+over	O
+the	O
+role	O
+as	O
+the	O
+screening	O
+center	O
+for	O
+SARS	B-DISO
+on	O
+26	O
+March	O
+2003	O
+.	O
+
+Of	O
+these	O
+,	O
+117	O
+patients	O
+were	O
+diagnosed	O
+to	O
+have	O
+probable	O
+SARS	B-DISO
+and	O
+146	O
+suspect	O
+SARS	B-DISO
+.	O
+
+Travel	O
+history	O
+was	O
+less	O
+common	O
+in	O
+probable	O
+SARS	B-DISO
+cases	O
+than	O
+in	O
+suspect	O
+SARS	B-DISO
+cases	O
+as	O
+the	O
+epidemic	O
+was	O
+due	O
+mainly	O
+to	O
+local	O
+transmission	O
+.	O
+
+In	O
+the	O
+ED	O
+,	O
+249	O
+(	O
+94	O
+.	O
+7	O
+percent	O
+)	O
+patients	O
+had	O
+chest	B-ANAT
+radiographs	O
+and	O
+86	O
+(	O
+32	O
+.	O
+7	O
+percent	O
+)	O
+had	O
+full	O
+blood	B-ANAT
+count	O
+done	O
+.	O
+
+22	O
+.	O
+2	O
+percent	O
+of	O
+probable	O
+SARS	B-DISO
+patients	O
+had	O
+normal	O
+chest	B-ANAT
+radiographs	O
+when	O
+they	O
+first	O
+presented	O
+to	O
+the	O
+ED	O
+.	O
+
+CONCLUSIONS	O
+:	O
+The	O
+World	O
+Health	O
+Organisation	B-PROC
+criteria	O
+were	O
+important	O
+screening	O
+tools	O
+and	O
+admission	O
+guides	O
+,	O
+but	O
+should	O
+not	O
+be	O
+strictly	O
+followed	O
+.	O
+
+Of	O
+27	O
+cases	O
+with	O
+fever	B-PROC
+,	O
+pneumonia	B-DISO
+and	O
+a	O
+total	O
+white	O
+count	O
+of	O
+less	O
+than	O
+10	O
+,	O
+000	O
+cells	B-COMP
+per	O
+cubic	O
+mm	O
+as	O
+per	O
+Ministry	O
+of	O
+Health	O
+,	O
+Singapore	O
+criteria	O
+for	O
+the	O
+diagnosis	O
+of	O
+atypical	B-DISO
+pneumonia	I-DISO
+,	O
+only	O
+five	O
+were	O
+identified	O
+by	O
+clinicians	O
+.	O
+
+TITLE	O
+:	O
+Maintenance	O
+of	O
+CD8	B-PRGE
++	I-PRGE
+T	B-ANAT
+cells	I-ANAT
+during	O
+acute	O
+viral	B-DISO
+infection	I-DISO
+of	O
+the	O
+central	B-ANAT
+nervous	I-ANAT
+system	I-ANAT
+requires	O
+CD4	O
++	O
+T	B-ANAT
+cells	I-ANAT
+but	O
+not	O
+interleukin	B-PRGE
+-	I-PRGE
+2	I-PRGE
+.	O
+
+ABSTRACT	O
+:	O
+The	O
+JHM	O
+strain	O
+of	O
+mouse	B-DISO
+hepatitis	I-DISO
+virus	B-SPEC
+(	O
+JHMV	O
+)	O
+is	O
+rapidly	O
+cleared	O
+from	O
+the	O
+central	B-ANAT
+nervous	I-ANAT
+system	I-ANAT
+(	O
+CNS	B-CHED
+)	O
+by	O
+CD8	B-PRGE
+(+)	O
+T	B-ANAT
+cells	I-ANAT
+.	O
+
+CONCLUSIONS	O
+:	O
+The	O
+large	O
+amount	O
+of	O
+patients	O
+shifting	O
+from	O
+the	O
+maternity	O
+wards	O
+of	O
+more	O
+advanced	O
+hospitals	O
+to	O
+those	O
+of	O
+less	O
+advanced	O
+hospitals	O
+,	O
+coupled	O
+with	O
+the	O
+substantial	O
+reduction	O
+in	O
+their	O
+length	O
+of	O
+maternity	O
+stay	O
+due	O
+to	O
+their	O
+fears	O
+of	O
+SARS	B-DISO
+could	O
+also	O
+lead	O
+to	O
+serious	O
+concerns	O
+for	O
+quality	O
+of	O
+care	O
+,	O
+especially	O
+regarding	O
+a	O
+patient	O
+'	O
+s	O
+accessibility	O
+to	O
+quality	O
+providers	O
+and	O
+continuity	O
+of	O
+care	O
+.	O
+
+TITLE	O
+:	O
+[	O
+Global	O
+strategies	O
+in	O
+prevention	O
+of	O
+infectious	B-DISO
+diseases	I-DISO
+on	O
+the	O
+turn	O
+of	O
+the	O
+second	O
+and	O
+third	O
+millennium	O
+:	O
+expectation	O
+versus	O
+reality	O
+].	O
+
+Although	O
+great	O
+advances	O
+have	O
+been	O
+made	O
+,	O
+a	O
+considerable	O
+burden	O
+of	O
+morbidity	O
+and	O
+mortality	O
+from	O
+infectious	B-DISO
+diseases	I-DISO
+remains	O
+globally	O
+.	O
+
+TITLE	O
+:	O
+Detection	O
+of	O
+airborne	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+(	O
+SARS	B-DISO
+)	O
+coronavirus	B-SPEC
+and	O
+environmental	O
+contamination	O
+in	O
+SARS	O
+outbreak	O
+units	O
+.	O
+
+TITLE	O
+:	O
+Molecular	O
+epidemiology	O
+of	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+-	O
+associated	O
+coronavirus	B-SPEC
+infections	I-DISO
+in	O
+Taiwan	O
+.	O
+
+ABSTRACT	O
+:	O
+Elevation	O
+of	O
+alanine	O
+aminotransferase	O
+(	O
+ALT	B-FUNC
+)	O
+level	O
+is	O
+commonly	O
+seen	O
+among	O
+patients	O
+suffering	B-DISO
+from	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+(	O
+SARS	B-DISO
+).	O
+
+Ninety	O
+-	O
+three	O
+percent	O
+of	O
+the	O
+survived	O
+patients	O
+had	O
+ALT	B-FUNC
+levels	O
+normalized	O
+or	O
+were	O
+on	O
+the	O
+improving	O
+trend	O
+during	O
+follow	O
+-	O
+up	O
+.	O
+
+Reactive	O
+hepatitis	B-DISO
+is	O
+a	O
+common	O
+complication	B-DISO
+of	O
+SARS	B-DISO
+-	O
+coronavirus	B-DISO
+infection	I-DISO
+.	O
+
+We	O
+developed	O
+a	O
+very	O
+economical	O
+and	O
+rapid	O
+method	O
+to	O
+sequence	O
+the	O
+whole	O
+genome	O
+of	O
+SARS	B-DISO
+-	O
+CoV	O
+,	O
+which	O
+can	O
+avoid	O
+cultural	O
+influence	O
+.	O
+
+RESULTS	O
+:	O
+We	O
+sequenced	O
+the	O
+genomes	O
+of	O
+SARS	B-DISO
+-	O
+CoV	O
+from	O
+3	O
+clinical	O
+specimens	O
+obtained	O
+in	O
+Taiwan	O
+.	O
+
+A	O
+total	O
+of	O
+20	O
+patients	O
+(	O
+55	O
+.	O
+6	O
+%)	O
+required	O
+supplemental	O
+oxygen	B-CHED
+,	O
+and	O
+8	O
+(	O
+22	O
+.	O
+2	O
+%)	O
+were	O
+intubated	O
+with	O
+mechanical	O
+ventilatory	O
+support	O
+.	O
+
+While	O
+the	O
+efficacy	O
+of	O
+different	O
+treatments	O
+could	O
+not	O
+be	O
+evaluated	O
+from	O
+this	O
+retrospective	O
+study	O
+,	O
+a	O
+higher	O
+value	O
+of	O
+C	B-PRGE
+-	I-PRGE
+reactive	I-PRGE
+protein	I-PRGE
+was	O
+associated	O
+with	O
+the	O
+development	B-PROC
+of	O
+respiratory	B-DISO
+failure	I-DISO
+and	O
+subsequent	O
+intubation	O
+.	O
+
+In	O
+22	O
+/	O
+32	O
+spasm	B-DISO
+control	O
+was	O
+achieved	O
+within	O
+15	O
+days	O
+.	O
+
+The	O
+mean	O
+follow	O
+-	O
+up	O
+in	O
+27	O
+children	O
+was	O
+4	O
+.	O
+6	O
+(	O
+0	O
+.	O
+5	O
+to	O
+9	O
+.	O
+9	O
+years	O
+)	O
+whereas	O
+5	O
+were	O
+lost	B-CHED
+from	O
+follow	O
+-	O
+up	O
+.	O
+
+TITLE	O
+:	O
+Severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+:	O
+pertinent	O
+clinical	O
+characteristics	O
+and	O
+therapy	O
+.	O
+
+SARS	B-DISO
+has	O
+been	O
+defined	O
+using	O
+clinical	O
+and	O
+epidemiological	O
+criteria	O
+and	O
+cases	O
+are	O
+considered	O
+laboratory	O
+-	O
+confirmed	O
+if	O
+SARS	B-DISO
+coronavirus	B-SPEC
+is	O
+isolated	O
+,	O
+if	O
+antibody	B-COMP
+to	O
+SARS	B-DISO
+coronavirus	B-SPEC
+is	O
+detected	O
+,	O
+or	O
+a	O
+polymerase	O
+chain	O
+reaction	O
+test	O
+by	O
+appropriate	O
+criteria	O
+is	O
+positive	O
+.	O
+
+In	O
+light	O
+of	O
+reports	O
+of	O
+new	O
+cases	O
+identified	O
+during	O
+the	O
+winter	O
+of	O
+2003	O
+-	O
+4	O
+in	O
+China	O
+,	O
+it	O
+seems	O
+possible	O
+that	O
+SARS	B-DISO
+will	O
+be	O
+an	O
+important	O
+cause	O
+of	O
+pneumonia	B-DISO
+in	O
+the	O
+future	O
+,	O
+and	O
+the	O
+screening	O
+of	O
+outpatients	O
+at	O
+risk	O
+for	O
+SARS	B-DISO
+may	O
+become	O
+part	O
+of	O
+the	O
+pneumonia	B-DISO
+evaluation	O
+.	O
+
+ABSTRACT	O
+:	O
+Since	O
+the	O
+emergence	O
+of	O
+HIV	O
+/	O
+AIDS	O
+in	O
+the	O
+1980s	O
+,	O
+social	O
+scientists	O
+and	O
+sociologists	O
+of	O
+health	O
+and	O
+illness	O
+have	O
+been	O
+exploring	O
+the	O
+metaphorical	O
+framing	O
+of	O
+this	O
+infectious	B-DISO
+disease	I-DISO
+in	O
+its	O
+social	O
+context	O
+.	O
+
+SARS	B-DISO
+as	O
+a	O
+killer	O
+was	O
+a	O
+single	O
+unified	O
+entity	O
+,	O
+not	O
+an	O
+army	O
+or	O
+force	O
+.	O
+
+TITLE	O
+:	O
+Receptor	O
+-	O
+binding	B-FUNC
+domain	O
+of	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+coronavirus	B-SPEC
+spike	O
+protein	B-CHED
+contains	O
+multiple	O
+conformation	O
+-	O
+dependent	O
+epitopes	O
+that	O
+induce	O
+highly	O
+potent	O
+neutralizing	O
+antibodies	O
+.	O
+
+In	O
+this	O
+study	O
+,	O
+we	O
+demonstrated	O
+that	O
+a	O
+fusion	O
+protein	B-CHED
+containing	O
+RBD	O
+linked	O
+to	O
+human	B-PRGE
+IgG1	B-COMP
+Fc	I-PRGE
+fragment	I-PRGE
+(	O
+designated	O
+RBD	O
+-	O
+Fc	O
+)	O
+induced	O
+high	O
+titer	O
+of	O
+RBD	O
+-	O
+specific	O
+Abs	O
+in	O
+the	O
+immunized	O
+mice	B-SPEC
+.	O
+
+The	O
+Conf	B-PRGE
+IV	I-PRGE
+and	O
+Conf	B-PRGE
+V	I-PRGE
+mAbs	I-PRGE
+significantly	O
+blocked	O
+RBD	O
+-	O
+Fc	O
+binding	B-FUNC
+to	O
+angiotensin	B-PRGE
+-	I-PRGE
+converting	I-PRGE
+enzyme	I-PRGE
+2	I-PRGE
+,	O
+suggesting	O
+that	O
+their	O
+epitopes	O
+overlap	O
+with	O
+the	O
+receptor	O
+-	O
+binding	B-FUNC
+sites	O
+in	O
+the	O
+S	B-PRGE
+protein	I-PRGE
+.	O
+
+ABSTRACT	O
+:	O
+A	O
+Saccharomyces	B-SPEC
+cerevisiae	I-SPEC
+-	O
+expressed	B-PROC
+nucleocapsid	B-COMP
+(	O
+N	O
+)	O
+polypeptide	B-CHED
+of	O
+the	O
+M41	O
+strain	O
+of	O
+infectious	B-DISO
+bronchitis	B-DISO
+virus	B-SPEC
+(	O
+IBV	B-SPEC
+)	O
+was	O
+used	O
+as	O
+antigen	B-CHED
+in	O
+a	O
+recombinant	O
+yeast	B-SPEC
+-	O
+expressed	B-PROC
+N	O
+protein	B-CHED
+-	O
+based	O
+enzyme	O
+-	O
+linked	O
+immunosorbent	O
+assay	O
+(	O
+Y	O
+-	O
+N	O
+-	O
+ELISA	O
+).	O
+
+A	O
+case	O
+of	O
+a	O
+25	O
+-	O
+year	O
+-	O
+old	O
+male	O
+with	O
+a	O
+severe	O
+chest	O
+pain	O
+associated	O
+with	O
+ST	O
+segment	O
+changes	O
+,	O
+elevated	O
+serum	B-PRGE
+C	I-PRGE
+-	I-PRGE
+reactive	I-PRGE
+protein	B-CHED
+,	O
+myocardial	B-DISO
+necrosis	I-DISO
+markers	O
+and	O
+normal	O
+epicardial	O
+coronary	B-ANAT
+arteries	I-ANAT
+is	O
+presented	O
+.	O
+
+HCoV	B-SPEC
+-	I-SPEC
+OC43	I-SPEC
+was	O
+also	O
+detected	O
+in	O
+surveillance	O
+and	O
+diagnostic	O
+respiratory	B-ANAT
+samples	I-ANAT
+in	O
+the	O
+same	O
+months	O
+.	O
+
+The	O
+intent	O
+of	O
+this	O
+paper	O
+was	O
+to	O
+reflect	O
+on	O
+the	O
+SARS	B-DISO
+precautionary	O
+measures	O
+that	O
+had	O
+been	O
+taken	O
+in	O
+a	O
+severe	B-DISO
+intellectual	I-DISO
+disabilities	I-DISO
+hospital	O
+in	O
+Hong	O
+Kong	O
+.	O
+
+A	O
+review	O
+on	O
+six	O
+SARS	B-DISO
+precautionary	O
+measures	O
+were	O
+conducted	O
+.	O
+
+A	O
+SARS	B-DISO
+Quarantine	O
+Unit	O
+,	O
+isolation	O
+ward	O
+,	O
+was	O
+opened	O
+to	O
+isolate	O
+patients	O
+who	O
+might	O
+have	O
+had	O
+close	O
+contact	O
+with	O
+SARS	B-DISO
+patients	O
+during	O
+a	O
+stay	O
+in	O
+a	O
+general	O
+hospital	O
+or	O
+when	O
+they	O
+returned	O
+from	O
+home	O
+leave	O
+.	O
+
+TITLE	O
+:	O
+Species	B-SPEC
+-	O
+independent	O
+detection	O
+of	O
+RNA	O
+virus	B-SPEC
+by	O
+representational	O
+difference	O
+analysis	O
+using	O
+non	O
+-	O
+ribosomal	O
+hexanucleotides	O
+for	O
+reverse	B-PROC
+transcription	I-PROC
+.	O
+
+The	O
+results	O
+demonstrated	O
+that	O
+the	O
+subjects	O
+either	O
+had	O
+rarely	O
+been	O
+exposed	O
+to	O
+the	O
+virus	B-SPEC
+before	O
+the	O
+2003	O
+SARS	B-DISO
+outbreak	O
+or	O
+had	O
+not	O
+been	O
+exposed	O
+but	O
+the	O
+nucleocapsid	B-COMP
+protein	B-CHED
+cross	O
+-	O
+reacted	O
+with	O
+other	O
+antibodies	B-COMP
+in	O
+humans	B-SPEC
+.	O
+
+An	O
+association	O
+between	O
+hyperglycemia	B-DISO
+and	O
+CIP	B-PRGE
+/	O
+CIM	B-PRGE
+has	O
+been	O
+found	O
+.	O
+
+TITLE	O
+:	O
+Hepatobiliary	B-ANAT
+pathology	B-DISO
+.	O
+
+The	O
+role	O
+of	O
+portal	B-ANAT
+myofibroblasts	B-ANAT
+in	O
+cirrhosis	B-DISO
+was	O
+examined	O
+in	O
+several	O
+studies	O
+.	O
+
+Streptococcus	B-SPEC
+pneumoniae	I-SPEC
+is	O
+the	O
+most	O
+prevalent	O
+bacterial	O
+pathogen	O
+in	O
+all	O
+ages	O
+.	O
+
+During	O
+the	O
+period	O
+covered	O
+by	O
+this	O
+review	O
+,	O
+two	O
+new	O
+agents	O
+causing	O
+pneumonia	B-DISO
+were	O
+extensively	O
+studied	O
+.	O
+
+The	O
+continued	O
+evolution	B-PROC
+of	O
+bacterial	B-DISO
+resistance	I-DISO
+highlights	O
+the	O
+need	O
+for	O
+appropriate	O
+use	O
+of	O
+antibacterials	B-CHED
+.	O
+
+TITLE	O
+:	O
+Progressive	O
+and	O
+nonresolving	O
+pneumonia	B-DISO
+.	O
+
+It	O
+is	O
+critical	O
+to	O
+be	O
+able	O
+to	O
+identify	O
+patients	O
+with	O
+nonresponding	O
+pneumonia	B-DISO
+and	O
+to	O
+identify	O
+patients	O
+at	O
+risk	O
+for	O
+progressive	O
+pneumonia	B-DISO
+to	O
+institute	O
+appropriate	O
+therapy	O
+.	O
+
+The	O
+SARS	B-DISO
+-	O
+CoV	O
+-	O
+infected	O
+cells	B-COMP
+had	O
+a	O
+patchy	O
+distribution	O
+and	O
+tended	O
+to	O
+be	O
+present	O
+in	O
+the	O
+periphery	O
+of	O
+the	O
+lung	B-ANAT
+.	O
+
+One	O
+hundred	O
+and	O
+forty	O
+genetically	O
+unrelated	O
+Chinese	O
+SARS	B-DISO
+patients	O
+and	O
+326	O
+healthy	O
+volunteers	O
+were	O
+recruited	O
+.	O
+
+Moreover	O
+,	O
+there	O
+is	O
+also	O
+no	O
+evidence	O
+that	O
+ACE	B-PRGE
+I	I-PRGE
+/	I-PRGE
+D	I-PRGE
+polymorphism	B-PROC
+is	O
+associated	O
+with	O
+the	O
+progression	O
+to	O
+ARDS	B-DISO
+or	O
+the	O
+requirement	O
+of	O
+intensive	O
+care	O
+in	O
+the	O
+SARS	B-DISO
+patients	O
+.	O
+
+CONCLUSIONS	O
+:	O
+The	O
+ACE	B-PRGE
+I	I-PRGE
+/	I-PRGE
+D	I-PRGE
+polymorphism	B-PROC
+is	O
+not	O
+directly	O
+related	O
+to	O
+increased	O
+susceptibility	O
+to	O
+SARS	B-DISO
+-	O
+coronavirus	B-DISO
+infection	I-DISO
+and	O
+is	O
+not	O
+associated	O
+with	O
+poor	O
+outcomes	O
+after	O
+SARS	B-DISO
+-	O
+coronavirus	B-DISO
+infection	I-DISO
+.	O
+
+Patients	O
+recovering	O
+from	O
+SARS	B-DISO
+had	O
+palpitation	O
+in	O
+the	O
+form	O
+of	O
+sinus	B-DISO
+tachycardia	I-DISO
+.	O
+
+Physical	O
+and	O
+psychological	B-DISO
+fitness	O
+should	O
+be	O
+restored	O
+with	O
+rehabilitation	O
+.	O
+
+CD8	B-PRGE
+T	B-ANAT
+-	I-ANAT
+cell	I-ANAT
+responses	O
+were	O
+mapped	O
+to	O
+two	O
+H	O
+-	O
+2	O
+(	O
+b	O
+)-	O
+restricted	O
+epitopes	O
+(	O
+S436	O
+-	O
+443	O
+and	O
+S525	O
+-	O
+532	O
+)	O
+and	O
+one	O
+H	O
+-	O
+2	O
+(	O
+d	O
+)-	O
+restricted	O
+epitope	B-CHED
+(	O
+S366	O
+-	O
+374	O
+).	O
+
+The	O
+optimized	O
+recombinant	O
+adenoviral	B-SPEC
+vaccine	O
+vectors	O
+encoding	O
+spike	O
+can	O
+generate	O
+robust	O
+antigen	B-CHED
+-	O
+specific	O
+cellular	B-PROC
+immunity	I-PROC
+in	O
+mice	B-SPEC
+and	O
+may	O
+potentially	O
+be	O
+useful	O
+for	O
+control	O
+of	O
+SARS	B-DISO
+-	I-DISO
+CoV	I-DISO
+infection	I-DISO
+.	O
+
+They	O
+are	O
+more	O
+likely	O
+to	O
+have	O
+inadequate	O
+immunity	B-PROC
+to	O
+vaccine	O
+-	O
+preventable	O
+illnesses	O
+.	O
+
+Finally	O
+,	O
+many	O
+will	O
+have	O
+suffered	B-DISO
+psychological	B-DISO
+trauma	I-DISO
+in	O
+either	O
+institutions	O
+or	O
+refugee	O
+camps	O
+.	O
+
+Candida	B-SPEC
+albicans	I-SPEC
+is	O
+the	O
+most	O
+frequent	O
+pathogen	O
+in	O
+microbiological	O
+findings	O
+.	O
+
+Subsequently	O
+detection	O
+of	O
+Rhizopus	B-PRGE
+spp	B-ENZY
+.	O
+
+It	O
+is	O
+strongly	O
+recommended	O
+to	O
+settle	B-DISO
+germfree	O
+urine	B-ANAT
+in	O
+the	O
+preoperative	O
+period	O
+.	O
+
+The	O
+thromboembolic	O
+risk	O
+of	O
+radical	B-CHED
+retropubic	O
+prostatectomy	O
+for	O
+cancer	B-DISO
+parallels	O
+lower	B-ANAT
+abdomen	I-ANAT
+oncologic	O
+surgery	O
+and	O
+is	O
+prolonged	O
+.	O
+
+Preoperative	O
+evaluation	O
+of	O
+cardiovascular	B-ANAT
+,	O
+respiratory	O
+,	O
+neurological	O
+and	O
+metabolic	B-PROC
+comorbidity	O
+is	O
+a	O
+source	O
+of	O
+prognostic	O
+information	O
+and	O
+an	O
+essential	O
+tool	O
+in	O
+the	O
+management	O
+of	O
+elderly	O
+patients	O
+with	O
+prostate	B-DISO
+disease	I-DISO
+.	O
+
+Except	O
+for	O
+FPV	B-SPEC
+antibodies	B-COMP
+in	O
+one	O
+lynx	B-SPEC
+and	O
+A	B-SPEC
+.	I-SPEC
+phagocytophila	I-SPEC
+in	O
+four	O
+lynx	B-SPEC
+,	O
+all	O
+serology	O
+was	O
+negative	O
+.	O
+
+TITLE	O
+:	O
+Suspected	O
+SARS	B-DISO
+patients	O
+hospitalised	O
+in	O
+French	O
+isolation	O
+units	O
+during	O
+the	O
+early	O
+SARS	B-DISO
+epidemic	O
+:	O
+the	O
+French	O
+experience	O
+.	O
+
+49	O
+.	O
+6	O
+%	O
+had	O
+fever	B-PROC
+and	O
+non	O
+specific	O
+symptoms	O
+.	O
+
+The	O
+SARS	B-DISO
+experience	O
+provided	O
+us	O
+a	O
+lesson	O
+on	O
+the	O
+importance	O
+of	O
+promoting	O
+hygienic	O
+practices	O
+among	O
+individuals	O
+and	O
+different	O
+working	O
+sectors	O
+.	O
+
+ABSTRACT	O
+:	O
+Although	O
+optimists	O
+once	O
+imagined	O
+that	O
+serious	O
+infectious	B-DISO
+disease	I-DISO
+threats	O
+would	O
+by	O
+now	O
+be	O
+conquered	O
+,	O
+newly	O
+emerging	O
+(	O
+e	O
+.	O
+g	O
+.,	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+[	O
+SARS	B-DISO
+]),	O
+reemerging	O
+(	O
+e	O
+.	O
+g	O
+.,	O
+West	B-DISO
+Nile	I-DISO
+virus	I-DISO
+),	O
+and	O
+even	O
+deliberately	O
+disseminated	O
+infectious	B-DISO
+diseases	I-DISO
+(	O
+e	O
+.	O
+g	O
+.,	O
+anthrax	B-DISO
+bioterrorism	O
+)	O
+continue	O
+to	O
+appear	O
+throughout	O
+the	O
+world	O
+.	O
+
+Intramural	O
+and	O
+extramural	O
+investigators	O
+supported	O
+by	O
+the	O
+National	O
+Institute	O
+of	O
+Allergy	B-DISO
+and	O
+Infectious	B-DISO
+Diseases	I-DISO
+(	O
+NIAID	O
+)	O
+have	O
+contributed	O
+substantially	O
+to	O
+this	O
+effort	B-PROC
+.	O
+
+Many	O
+basic	O
+research	O
+discoveries	O
+have	O
+been	O
+translated	O
+into	O
+novel	O
+diagnostics	O
+,	O
+antiviral	B-CHED
+and	O
+antimicrobial	B-CHED
+compounds	O
+,	O
+and	O
+vaccines	O
+,	O
+often	O
+with	O
+extraordinary	O
+speed	O
+.	O
+
+They	O
+provided	O
+technical	O
+assistance	O
+to	O
+countries	O
+reporting	O
+large	O
+numbers	O
+of	O
+cases	O
+and	O
+requesting	O
+assistance	O
+,	O
+met	B-CHED
+passengers	O
+and	O
+crew	O
+from	O
+these	O
+locations	O
+upon	O
+arrival	O
+in	O
+the	O
+United	O
+States	O
+,	O
+and	O
+assured	O
+that	O
+the	O
+syndrome	B-DISO
+was	O
+reported	O
+and	O
+thoroughly	O
+investigated	O
+within	O
+the	O
+United	O
+States	O
+.	O
+
+Both	O
+groups	O
+received	O
+2	O
+ml	O
+kg	O
+(-	O
+1	O
+)	O
+HCl	B-CHED
+(	O
+hydrochloric	B-CHED
+acid	I-CHED
+)	O
+i	O
+.	O
+t	O
+..	O
+
+Histopathological	O
+changes	O
+were	O
+less	O
+severe	O
+in	O
+the	O
+dexamethasone	B-CHED
+group	O
+.	O
+
+Histopathological	O
+changes	O
+were	O
+less	O
+severe	O
+in	O
+the	O
+dexamethasone	B-CHED
+group	O
+.	O
+
+The	O
+public	O
+health	O
+laboratory	O
+in	O
+a	O
+global	O
+emergency	B-DISO
+].	O
+
+This	O
+new	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+(	O
+SARS	B-DISO
+)	O
+was	O
+produced	O
+by	O
+a	O
+novel	B-SPEC
+coronavirus	I-SPEC
+.	O
+
+TITLE	O
+:	O
+Differential	O
+maturation	B-PROC
+and	O
+subcellular	O
+localization	B-PROC
+of	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+coronavirus	B-SPEC
+surface	O
+proteins	B-CHED
+S	O
+,	O
+M	O
+and	O
+E	O
+.	O
+ABSTRACT	O
+:	O
+Post	B-PROC
+-	I-PROC
+translational	I-PROC
+modifications	I-PROC
+and	O
+correct	O
+subcellular	O
+localization	B-PROC
+of	O
+viral	O
+structural	O
+proteins	B-CHED
+are	O
+prerequisites	O
+for	O
+assembly	O
+and	O
+budding	B-PATH
+of	O
+enveloped	O
+viruses	B-SPEC
+.	O
+
+In	O
+conclusion	O
+,	O
+SARS	B-PRGE
+-	I-PRGE
+CoV	I-PRGE
+surface	I-PRGE
+proteins	B-CHED
+S	I-PRGE
+,	I-PRGE
+M	I-PRGE
+and	I-PRGE
+E	I-PRGE
+show	O
+differential	O
+subcellular	O
+localizations	O
+when	O
+expressed	B-PROC
+alone	O
+suggesting	O
+that	O
+additional	O
+cellular	B-COMP
+or	O
+viral	O
+factors	O
+might	O
+be	O
+required	O
+for	O
+coordinated	O
+trafficking	B-PROC
+to	O
+the	O
+virus	B-PROC
+assembly	I-PROC
+site	O
+in	O
+the	O
+endoplasmic	B-COMP
+reticulum	I-COMP
+-	I-COMP
+Golgi	I-COMP
+intermediate	I-COMP
+compartment	I-COMP
+.	O
+
+TITLE	O
+:	O
+Molecular	O
+advances	O
+in	O
+the	O
+cell	B-COMP
+biology	O
+of	O
+SARS	B-DISO
+-	O
+CoV	O
+and	O
+current	O
+disease	O
+prevention	O
+strategies	O
+.	O
+
+However	O
+,	O
+there	O
+is	O
+still	O
+a	O
+large	O
+gap	O
+in	O
+our	O
+understanding	O
+of	O
+how	O
+SARS	B-PRGE
+-	I-PRGE
+CoV	I-PRGE
+interacts	O
+with	O
+the	O
+host	B-COMP
+cell	I-COMP
+and	O
+the	O
+rapidly	O
+changing	O
+viral	B-COMP
+genome	I-COMP
+adds	O
+another	O
+variable	O
+to	O
+this	O
+equation	O
+.	O
+
+TITLE	O
+:	O
+Transcriptome	O
+profile	O
+within	O
+the	O
+mouse	B-ANAT
+central	I-ANAT
+nervous	B-DISO
+system	I-ANAT
+and	O
+activation	O
+of	O
+myelin	B-COMP
+-	O
+reactive	O
+T	O
+cells	O
+following	O
+murine	B-SPEC
+coronavirus	I-SPEC
+infection	O
+.	O
+
+Thus	O
+,	O
+virus	B-SPEC
+is	O
+released	O
+into	O
+the	O
+basement	B-COMP
+membrane	I-COMP
+where	O
+it	O
+can	O
+easily	O
+gain	O
+access	O
+to	O
+the	O
+bloodstream	B-PROC
+for	O
+dissemination	O
+.	O
+
+To	O
+clarify	O
+which	O
+mutation	O
+(	O
+s	O
+)	O
+are	O
+necessary	O
+for	O
+plaque	B-DISO
+formation	B-PROC
+,	O
+plaque	B-DISO
+assays	O
+were	O
+done	O
+using	O
+other	O
+recombinant	O
+viruses	B-SPEC
+.	O
+
+Another	O
+virus	B-SPEC
+with	O
+the	O
+F115	O
+and	O
+both	O
+M	O
+changes	O
+gave	O
+the	O
+same	O
+result	O
+.	O
+
+Therefore	O
+,	O
+more	O
+than	O
+one	O
+mutation	O
+in	O
+the	O
+F	B-PRGE
+gene	I-PRGE
+contributes	O
+to	O
+the	O
+ability	O
+of	O
+F1	O
+-	O
+R	O
+to	O
+form	O
+plaques	B-DISO
+without	O
+trypsin	B-PRGE
+addition	O
+.	O
+
+TITLE	O
+:	O
+Recombinant	O
+protein	B-CHED
+-	O
+based	O
+ELISA	O
+and	O
+immuno	O
+-	O
+cytochemical	O
+assay	O
+for	O
+the	O
+diagnosis	O
+of	O
+SARS	B-DISO
+.	O
+
+High	O
+-	O
+titre	O
+positive	O
+reactions	O
+were	O
+detected	O
+in	O
+all	O
+SARS	B-DISO
+positive	O
+sera	B-COMP
+.	O
+
+Specific	O
+hyper	O
+-	O
+immune	O
+sera	B-COMP
+to	O
+SARS	B-DISO
+-	I-PRGE
+CoV	I-PRGE
+and	O
+the	O
+recombinant	O
+proteins	O
+,	O
+N	O
+,	O
+N1	O
+,	O
+N2	O
+,	O
+N3	O
+,	O
+and	O
+M2	O
+were	O
+also	O
+generated	O
+in	O
+mice	B-SPEC
+and	O
+rabbits	B-SPEC
+.	O
+
+The	O
+specificity	O
+of	O
+these	O
+sera	B-COMP
+was	O
+confirmed	O
+by	O
+an	O
+immunocytochemical	O
+assay	O
+on	O
+biochips	O
+of	O
+SARS	B-DISO
+-	O
+CoV	O
+infected	O
+and	O
+uninfected	O
+cells	B-COMP
+.	O
+
+ABSTRACT	O
+:	O
+Although	O
+acute	B-DISO
+inflammatory	I-DISO
+polyneuropathy	I-DISO
+(	O
+AIP	B-DISO
+)	O
+and	O
+immune	B-DISO
+thrombocytopenic	I-DISO
+purpura	I-DISO
+(	O
+ITP	B-DISO
+)	O
+are	O
+both	O
+believed	O
+to	O
+be	O
+immune	O
+-	O
+mediated	O
+disorders	O
+,	O
+only	O
+a	O
+few	O
+cases	O
+have	O
+been	O
+reported	O
+in	O
+which	O
+these	O
+two	O
+diseases	O
+co	O
+-	O
+existed	O
+.	O
+
+By	O
+reviewing	O
+past	O
+similar	O
+reports	O
+,	O
+we	O
+noticed	O
+that	O
+AIP	B-DISO
+associated	O
+with	O
+ITP	B-DISO
+tends	O
+to	O
+manifest	O
+severe	O
+sensory	O
+impairment	B-DISO
+and	O
+is	O
+often	O
+preceded	O
+by	O
+upper	B-DISO
+respiratory	I-DISO
+tract	I-DISO
+infection	I-DISO
+,	O
+but	O
+not	O
+by	O
+gastrointestinal	B-DISO
+infection	I-DISO
+.	O
+
+The	O
+purpose	O
+of	O
+the	O
+present	O
+paper	O
+was	O
+to	O
+carry	O
+out	O
+a	O
+retrospective	O
+study	O
+of	O
+the	O
+clinical	O
+and	O
+demographic	O
+data	O
+of	O
+SARS	B-DISO
+patients	O
+with	O
+diarrhea	B-DISO
+in	O
+Princess	O
+Margaret	O
+Hospital	O
+.	O
+
+Diarrhea	B-DISO
+occurred	O
+in	O
+20	O
+.	O
+4	O
+%	O
+of	O
+patients	O
+after	O
+admission	O
+.	O
+
+The	O
+proportions	O
+of	O
+patients	O
+requiring	O
+ventilatory	O
+care	O
+and	O
+mortality	O
+in	O
+the	O
+diarrhea	B-DISO
+group	O
+were	O
+8	O
+.	O
+2	O
+%	O
+and	O
+2	O
+%,	O
+respectively	O
+,	O
+which	O
+were	O
+significantly	O
+lower	O
+than	O
+those	O
+in	O
+the	O
+non	O
+-	O
+diarrhea	B-DISO
+group	O
+(	O
+27	O
+.	O
+6	O
+%	O
+and	O
+16	O
+.	O
+2	O
+%,	O
+P	O
+<	O
+0	O
+.	O
+005	O
+).	O
+
+The	O
+diarrhea	B-DISO
+group	O
+had	O
+a	O
+better	O
+prognosis	O
+.	O
+
+Titers	O
+of	O
+specific	O
+IgG	B-PRGE
+antibodies	I-PRGE
+in	O
+three	O
+test	O
+groups	O
+all	O
+peaked	O
+in	O
+the	O
+sixth	O
+week	O
+after	O
+first	O
+vaccination	O
+,	O
+but	O
+significant	O
+differences	O
+existed	O
+in	O
+the	O
+kinetics	O
+of	O
+specific	O
+IgG	B-COMP
+antibody	I-COMP
+levels	O
+.	O
+
+No	O
+systematic	O
+side	O
+effects	O
+were	O
+observed	O
+in	O
+vaccinated	O
+animals	B-SPEC
+post	O
+-	O
+immunization	O
+,	O
+even	O
+in	O
+at	O
+the	O
+high	O
+dose	O
+of	O
+5000	O
+microg	O
+.	O
+
+Using	O
+the	O
+helminth	O
+-	O
+derived	O
+adjuvant	B-CHED
+,	O
+IgG	B-PRGE
+isotype	I-PRGE
+responses	O
+to	O
+OVA	B-ANAT
+were	O
+of	O
+a	O
+mixed	O
+Th1	O
+/	O
+Th2	O
+profile	O
+and	O
+spleen	B-ANAT
+cell	B-COMP
+cytokines	O
+exclusively	O
+Th1	O
+-	O
+type	O
+.	O
+
+TRFIA	O
+is	O
+a	O
+new	O
+,	O
+sensitive	O
+and	O
+specific	O
+immunoassay	O
+for	O
+detecting	O
+SARS	B-PRGE
+N	I-PRGE
+protein	B-CHED
+with	O
+potential	O
+value	O
+in	O
+clinical	O
+applications	O
+.	O
+
+Here	O
+,	O
+we	O
+describe	O
+a	O
+case	O
+-	O
+control	O
+study	O
+that	O
+included	O
+569	O
+patients	O
+with	O
+SARS	B-DISO
+and	O
+1188	O
+control	O
+subjects	O
+and	O
+used	O
+in	O
+vitro	O
+assays	O
+to	O
+investigate	O
+the	O
+role	O
+that	O
+MBL	B-PRGE
+plays	O
+in	O
+SARS	B-DISO
+-	I-DISO
+CoV	I-DISO
+infection	I-DISO
+.	O
+
+The	O
+use	O
+of	O
+FTA	O
+cards	O
+for	O
+the	O
+collection	O
+,	O
+transport	B-PROC
+,	O
+and	O
+storage	B-PROC
+of	O
+IBV	B-SPEC
+-	O
+containing	O
+samples	O
+is	O
+safe	O
+,	O
+inexpensive	O
+,	O
+and	O
+adequate	O
+for	O
+molecular	O
+diagnosis	O
+.	O
+
+ABSTRACT	O
+:	O
+Poult	O
+enteritis	B-DISO
+complex	O
+(	O
+PEC	O
+)	O
+is	O
+an	O
+economically	O
+important	O
+disease	O
+of	O
+young	O
+turkeys	B-SPEC
+characterized	O
+by	O
+diarrhea	B-DISO
+,	O
+poor	B-DISO
+weight	I-DISO
+gain	I-DISO
+,	O
+and	O
+,	O
+in	O
+some	O
+cases	O
+,	O
+high	O
+mortality	O
+.	O
+
+Virus	B-SPEC
+detection	O
+was	O
+evaluated	O
+with	O
+samples	O
+collected	O
+from	O
+poults	O
+inoculated	O
+at	O
+1	O
+day	O
+of	O
+age	O
+with	O
+each	O
+of	O
+the	O
+viruses	B-SPEC
+.	O
+
+During	O
+purification	O
+,	O
+the	O
+full	O
+-	O
+length	O
+GST	B-PRGE
+-	O
+RdRp	B-FUNC
+was	O
+found	O
+to	O
+cleave	O
+into	O
+three	O
+main	O
+fragments	O
+:	O
+an	O
+N	O
+-	O
+terminal	O
+p12	B-PRGE
+fragment	O
+,	O
+a	O
+middle	O
+p30	B-PRGE
+fragment	I-PRGE
+,	O
+and	O
+a	O
+C	O
+-	O
+terminal	O
+p64	B-PRGE
+fragment	O
+comprising	O
+the	O
+catalytic	O
+domain	O
+,	O
+presumably	O
+due	O
+to	O
+bacterial	O
+proteases	O
+.	O
+
+A	O
+mouse	B-SPEC
+line	O
+transgenic	O
+for	O
+the	O
+receptor	O
+of	O
+human	B-SPEC
+coronavirus	I-SPEC
+-	O
+229E	O
+(	O
+HCoV	B-SPEC
+-	I-SPEC
+229E	I-SPEC
+)	O
+was	O
+created	O
+using	O
+human	B-PRGE
+APN	I-PRGE
+(	O
+hAPN	O
+)	O
+cDNA	O
+driven	O
+by	O
+a	O
+hAPN	O
+promoter	O
+.	O
+
+hAPN	B-PRGE
+protein	I-PRGE
+was	O
+specifically	O
+expressed	B-PROC
+on	O
+epithelial	B-ANAT
+cells	I-ANAT
+of	O
+the	O
+proximal	O
+convoluted	O
+renal	B-ANAT
+tubules	I-ANAT
+,	O
+bronchi	B-ANAT
+,	O
+alveolar	B-ANAT
+sacs	B-DISO
+,	O
+and	O
+intestinal	B-ANAT
+villi	I-ANAT
+.	O
+
+Although	O
+hAPN	O
+-	O
+transgenic	B-SPEC
+mice	I-SPEC
+were	O
+resistant	O
+to	O
+HCoV	B-SPEC
+-	I-SPEC
+229E	I-SPEC
+in	O
+vivo	O
+,	O
+primary	O
+embryonic	B-ANAT
+cells	B-COMP
+and	O
+bone	O
+marrow	O
+dendritic	B-ANAT
+cells	B-COMP
+were	O
+infected	O
+in	O
+vitro	O
+.	O
+
+hAPN	O
+-	O
+transgenic	B-SPEC
+mice	I-SPEC
+are	O
+valuable	O
+as	O
+a	O
+source	O
+of	O
+primary	O
+mouse	B-SPEC
+cells	B-COMP
+expressing	O
+hAPN	O
+.	O
+
+In	O
+that	O
+kennel	O
+antibody	B-PROC
+responses	I-PROC
+to	O
+CRCoV	O
+indicated	O
+a	O
+seasonal	O
+occurrence	O
+of	O
+the	O
+virus	B-SPEC
+,	O
+which	O
+coincided	O
+with	O
+two	O
+outbreaks	O
+of	O
+respiratory	O
+disease	O
+.	O
+
+In	O
+the	O
+other	O
+kennel	O
+,	O
+which	O
+reported	O
+few	O
+cases	O
+of	O
+CIRD	O
+a	O
+high	O
+prevalence	O
+of	O
+antibodies	B-COMP
+to	O
+CRCoV	O
+was	O
+detected	O
+on	O
+entry	O
+but	O
+only	O
+sporadic	O
+seroconversions	O
+to	O
+CRCoV	O
+or	O
+CHV	O
+.	O
+
+Virus	B-SPEC
+culture	O
+failed	O
+to	O
+detect	O
+any	O
+viruses	B-SPEC
+in	O
+either	O
+kennel	O
+.	O
+
+A	O
+nested	O
+RT	O
+-	O
+PCR	O
+was	O
+used	O
+for	O
+detecting	O
+one	O
+fragment	O
+of	O
+SARS	B-DISO
+-	O
+CoV	O
+RNA	O
+in	O
+oropharyngeal	B-ANAT
+swabs	O
+from	O
+3	O
+SARS	B-DISO
+probable	O
+patients	O
+,	O
+4	O
+SARS	B-DISO
+suspect	O
+patients	O
+and	O
+other	O
+27	O
+patients	O
+with	O
+fever	B-PROC
+in	O
+Hangzhou	O
+,	O
+and	O
+the	O
+nested	O
+RT	O
+-	O
+PCR	O
+product	O
+from	O
+one	O
+SARS	B-DISO
+probable	O
+patient	O
+was	O
+sequenced	O
+.	O
+
+In	O
+22	O
+patients	O
+with	O
+intraperitoneal	O
+colorectal	O
+injury	O
+,	O
+19	O
+were	O
+managed	O
+with	O
+primary	O
+repair	B-PROC
+or	O
+anastomosis	B-DISO
+while	O
+3	O
+received	O
+a	O
+colostomy	O
+.	O
+
+In	O
+stage	O
+I	O
+(	O
+late	O
+-	O
+February	O
+to	O
+mid	O
+-	O
+April	O
+)	O
+patients	O
+had	O
+traceable	O
+contact	O
+with	O
+infected	O
+patients	O
+or	O
+travel	O
+histories	O
+to	O
+known	O
+affected	O
+areas	O
+of	O
+SARS	B-DISO
+.	O
+
+Real	O
+-	O
+time	O
+qRT	O
+-	O
+PCR	O
+was	O
+used	O
+to	O
+confirm	O
+the	O
+regulated	O
+expression	B-PROC
+of	O
+genes	O
+related	O
+to	O
+several	O
+functional	O
+classes	O
+including	O
+kinases	O
+,	O
+interferon	B-PRGE
+induced	O
+genes	O
+,	O
+chemokines	O
+and	O
+adhesion	B-DISO
+molecules	O
+,	O
+vesicular	O
+trafficking	B-PROC
+and	O
+fusion	O
+protein	B-CHED
+genes	O
+,	O
+extracellular	B-PRGE
+matrix	I-PRGE
+protein	B-CHED
+genes	I-PRGE
+,	O
+cell	B-PATH
+cycle	I-PATH
+,	O
+metabolism	B-PROC
+,	O
+cell	B-COMP
+physiology	I-COMP
+and	O
+development	B-PROC
+,	O
+translation	B-PROC
+,	O
+RNA	B-FUNC
+binding	I-FUNC
+,	O
+lysosomal	B-ANAT
+,	O
+protein	B-PROC
+degradation	I-PROC
+and	O
+ubiquitination	B-PROC
+related	O
+genes	O
+.	O
+
+Microarray	O
+analysis	O
+served	O
+as	O
+an	O
+efficient	O
+tool	O
+in	O
+facilitating	O
+a	O
+comparative	O
+analysis	O
+of	O
+avian	B-SPEC
+respiratory	O
+viral	B-DISO
+infections	I-DISO
+and	O
+provided	O
+insight	O
+into	O
+host	B-COMP
+transcriptional	B-PROC
+changes	O
+that	O
+were	O
+conserved	O
+as	O
+well	O
+as	O
+those	O
+which	O
+were	O
+unique	O
+to	O
+individual	O
+pathogens	O
+.	O
+
+TITLE	O
+:	O
+Epidemic	O
+of	O
+leptospirosis	B-DISO
+:	O
+an	O
+ICU	O
+experience	O
+.	O
+
+The	O
+poor	O
+prognostic	O
+factors	O
+are	O
+preponderance	O
+of	O
+male	O
+sex	O
+,	O
+alcohol	B-DISO
+dependence	I-DISO
+,	O
+age	O
+group	O
+>	O
+50	O
+years	O
+,	O
+MODS	B-DISO
+,	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+(	O
+ARDS	B-DISO
+),	O
+presence	O
+of	O
+acidosis	B-DISO
+and	O
+need	O
+for	O
+mechanical	O
+ventilation	O
+.	O
+
+Driven	O
+by	O
+economic	O
+liberalization	O
+and	O
+changing	O
+technologies	O
+,	O
+the	O
+phenomenon	O
+of	O
+'	O
+access	O
+'	O
+is	O
+likely	O
+to	O
+dominate	O
+to	O
+an	O
+increasing	O
+extent	O
+the	O
+unfolding	O
+experience	O
+of	O
+human	B-SPEC
+disease	O
+and	O
+wellbeing	O
+.	O
+
+ABSTRACT	O
+:	O
+Three	O
+multiplex	O
+hemi	O
+-	O
+nested	O
+RT	O
+-	O
+PCR	O
+assays	O
+were	O
+developed	O
+to	O
+detect	O
+simultaneously	O
+12	O
+RNA	O
+respiratory	O
+viruses	O
+:	O
+influenza	B-SPEC
+viruses	I-SPEC
+A	O
+,	O
+B	O
+and	O
+C	O
+,	O
+human	B-SPEC
+respiratory	I-SPEC
+syncytial	I-SPEC
+virus	I-SPEC
+(	O
+hRSV	B-SPEC
+),	O
+human	B-SPEC
+metapneumovirus	I-SPEC
+(	O
+hMPV	B-SPEC
+),	O
+parainfluenza	B-DISO
+virus	B-SPEC
+types	O
+1	O
+-	O
+4	O
+(	O
+PIV	O
+-	O
+1	O
+,	O
+-	O
+2	O
+,	O
+-	O
+3	O
+and	O
+-	O
+4	O
+),	O
+human	B-SPEC
+coronavirus	I-SPEC
+OC43	O
+and	O
+229E	O
+(	O
+HCoV	O
+)	O
+and	O
+rhinovirus	B-SPEC
+(	O
+hRV	O
+).	O
+
+The	O
+overall	O
+sensitivity	O
+(	O
+98	O
+%),	O
+rapidity	O
+and	O
+enhanced	O
+efficiency	O
+of	O
+these	O
+multiplex	O
+hemi	O
+-	O
+nested	O
+RT	O
+-	O
+PCR	O
+assays	O
+suggest	O
+that	O
+they	O
+would	O
+be	O
+a	O
+significant	O
+improvement	O
+over	O
+conventional	O
+methods	O
+for	O
+the	O
+detection	O
+of	O
+a	O
+broad	O
+spectrum	O
+of	O
+respiratory	O
+viruses	B-SPEC
+.	O
+
+TITLE	O
+:	O
+Effects	O
+of	O
+cold	B-DISO
+storage	B-PROC
+on	O
+detection	O
+of	O
+avian	B-DISO
+infectious	I-DISO
+bronchitis	I-DISO
+virus	B-SPEC
+in	O
+chicken	B-SPEC
+carcasses	O
+and	O
+local	O
+antibodies	O
+in	O
+tracheal	O
+washes	O
+.	O
+
+ABSTRACT	O
+:	O
+In	O
+order	B-SPEC
+to	O
+test	O
+the	O
+survivability	O
+of	O
+infectious	B-DISO
+bronchitis	B-DISO
+virus	B-SPEC
+(	O
+IBV	B-SPEC
+)	O
+in	O
+dead	B-PROC
+chicken	B-SPEC
+carcasses	O
+during	O
+24	O
+h	O
+of	O
+cold	B-DISO
+storage	B-PROC
+,	O
+7	O
+week	O
+-	O
+old	O
+specific	O
+-	O
+pathogen	O
+-	O
+free	O
+chickens	B-SPEC
+were	O
+infected	O
+with	O
+virulent	O
+IBV	B-SPEC
+Massachusetts	O
+strain	O
+M41	O
+,	O
+and	O
+were	O
+killed	O
+humanely	O
+10	O
+days	O
+later	O
+.	O
+
+ABSTRACT	O
+:	O
+In	O
+this	O
+study	O
+,	O
+the	O
+persistence	O
+of	O
+severe	O
+acute	O
+respiratory	O
+syndrome	O
+-	O
+associated	O
+coronavirus	B-SPEC
+(	O
+SARS	B-DISO
+-	O
+CoV	O
+)	O
+was	O
+observed	O
+in	O
+feces	B-ANAT
+,	O
+urine	B-ANAT
+and	O
+water	B-CHED
+.	O
+
+In	O
+vitro	O
+experiments	O
+demonstrated	O
+that	O
+the	O
+virus	B-SPEC
+could	O
+only	O
+persist	O
+for	O
+2	O
+days	O
+in	O
+hospital	O
+wastewater	O
+,	O
+domestic	O
+sewage	O
+and	O
+dechlorinated	O
+tap	O
+water	B-CHED
+,	O
+while	O
+3	O
+days	O
+in	O
+feces	B-ANAT
+,	O
+14	O
+days	O
+in	O
+PBS	B-DISO
+and	O
+17	O
+days	O
+in	O
+urine	B-ANAT
+at	O
+20	O
+degrees	O
+C	O
+.	O
+However	O
+,	O
+at	O
+4	O
+degrees	O
+C	O
+,	O
+the	O
+SARS	B-PRGE
+-	I-PRGE
+CoV	I-PRGE
+could	O
+persist	O
+for	O
+14	O
+days	O
+in	O
+wastewater	O
+and	O
+at	O
+least	O
+17	O
+days	O
+in	O
+feces	B-ANAT
+or	O
+urine	B-ANAT
+.	O
+
+APHS	O
+did	O
+not	O
+affect	O
+the	O
+replication	O
+of	O
+feline	B-SPEC
+immunodeficiency	I-SPEC
+virus	I-SPEC
+,	O
+HIV	B-SPEC
+-	I-SPEC
+2	I-SPEC
+and	O
+a	O
+HIV	B-SPEC
+-	I-SPEC
+1	I-SPEC
+strain	O
+resistant	O
+to	O
+non	B-PROC
+-	I-PROC
+nucleoside	I-PROC
+reverse	B-CHED
+transcriptase	I-CHED
+inhibitors	I-CHED
+(	O
+NNRTI	O
+).	O
+
+The	O
+method	O
+employed	O
+was	O
+to	O
+have	O
+subjects	O
+wear	O
+a	O
+small	O
+photometer	O
+that	O
+recorded	O
+total	O
+ultraviolet	O
+dose	O
+over	O
+the	O
+period	O
+of	O
+exposure	O
+while	O
+subjects	O
+went	O
+about	O
+their	O
+normal	O
+routine	O
+,	O
+and	O
+comparing	O
+this	O
+value	O
+with	O
+a	O
+hypothetical	O
+dose	O
+calculated	O
+from	O
+the	O
+highest	O
+measured	O
+eye	B-ANAT
+-	O
+level	O
+irradiance	O
+.	O
+
+TITLE	O
+:	O
+Recombinant	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+(	O
+SARS	B-DISO
+)	O
+coronavirus	B-SPEC
+nucleocapsid	B-COMP
+protein	B-CHED
+forms	O
+a	O
+dimer	O
+through	O
+its	O
+C	O
+-	O
+terminal	O
+domain	O
+.	O
+
+Real	O
+-	O
+time	O
+PCR	O
+was	O
+used	O
+to	O
+investigate	O
+the	O
+effort	B-PROC
+of	O
+RANTES	O
+on	O
+the	O
+replication	O
+of	O
+SARS	B-DISO
+-	O
+CoV	O
+in	O
+vitro	O
+.	O
+
+TITLE	O
+:	O
+Prediction	O
+of	O
+smallpox	B-DISO
+outbreak	O
+and	O
+evaluation	O
+of	O
+control	O
+-	O
+measure	O
+policy	O
+in	O
+Japan	O
+,	O
+using	O
+a	O
+mathematical	O
+model	O
+.	O
+
+Ten	O
+episodes	O
+of	O
+multiorgan	B-DISO
+failure	I-DISO
+were	O
+identified	O
+with	O
+sickle	B-DISO
+cell	I-DISO
+disease	I-DISO
+and	O
+defining	O
+criteria	O
+of	O
+organ	B-DISO
+failure	I-DISO
+of	O
+two	O
+or	O
+more	O
+organs	B-ANAT
+that	O
+is	O
+lung	B-ANAT
+,	O
+liver	B-ANAT
+,	O
+or	O
+renal	B-ANAT
+were	O
+established	O
+according	O
+to	O
+Acute	O
+Physiological	O
+and	O
+Chronic	O
+Health	O
+Evaluation	O
+-	O
+II	O
+(	O
+APACHE	O
+-	O
+II	O
+)	O
+criteria	O
+.	O
+
+CONCLUSIONS	O
+:	O
+Acute	O
+multiorgan	B-DISO
+failure	I-DISO
+is	O
+a	O
+life	O
+threatening	O
+complication	B-DISO
+of	O
+SCD	B-DISO
+,	O
+which	O
+can	O
+exhibit	O
+without	O
+any	O
+evidence	O
+of	O
+chronic	O
+organ	B-ANAT
+damage	O
+and	O
+is	O
+easily	O
+reversed	O
+by	O
+prompt	O
+and	O
+aggressive	B-DISO
+transfusion	O
+therapy	O
+.	O
+
+The	O
+essential	O
+core	O
+region	O
+of	O
+S	B-PRGE
+protein	I-PRGE
+required	O
+for	O
+80R	O
+binding	B-FUNC
+was	O
+identified	O
+as	O
+a	O
+conformationally	O
+sensitive	O
+fragment	O
+(	O
+residues	O
+324	O
+to	O
+503	O
+)	O
+that	O
+overlaps	O
+the	O
+receptor	B-PRGE
+ACE2	I-PRGE
+-	I-PRGE
+binding	I-PRGE
+domain	I-PRGE
+.	O
+
+Thus	O
+,	O
+the	O
+present	O
+study	O
+indicates	O
+that	O
+microglial	B-ANAT
+cells	B-COMP
+are	O
+the	O
+major	O
+population	O
+of	O
+the	O
+initial	O
+target	O
+for	O
+MHV	B-SPEC
+infection	B-DISO
+and	O
+that	O
+the	O
+wt	O
+spreads	O
+from	O
+initially	O
+infected	O
+microglia	B-ANAT
+to	O
+a	O
+variety	O
+of	O
+cells	B-COMP
+in	O
+an	O
+MHVR	O
+-	O
+independent	O
+fashion	O
+.	O
+
+Our	O
+results	O
+suggest	O
+that	O
+IBV	B-SPEC
+3a	O
+is	O
+partially	O
+targeted	B-PROC
+to	O
+a	O
+novel	O
+domain	O
+of	O
+the	O
+smooth	B-COMP
+ER	I-COMP
+.	O
+
+The	O
+early	O
+transcriptional	B-PROC
+profiles	O
+of	O
+host	B-COMP
+cell	I-COMP
+response	O
+to	O
+both	O
+types	O
+of	O
+infection	B-DISO
+at	O
+2	O
+and	O
+4	O
+h	O
+postinoculation	O
+were	O
+determined	O
+by	O
+using	O
+the	O
+Affymetrix	O
+HG	O
+-	O
+U133A	O
+microarray	O
+(	O
+about	O
+22	O
+,	O
+000	O
+genes	O
+).	O
+
+By	O
+screening	O
+2	O
+,	O
+880	O
+generated	O
+hybridomas	B-ANAT
+,	O
+we	O
+established	O
+three	O
+hybridoma	B-ANAT
+clones	O
+that	O
+secreted	B-PROC
+antibodies	B-COMP
+specific	O
+for	O
+nucleocapsid	B-COMP
+protein	B-CHED
+(	O
+N	O
+)	O
+and	O
+27	O
+clones	O
+that	O
+secreted	B-PROC
+antibodies	B-COMP
+specific	O
+for	O
+spike	O
+protein	B-CHED
+(	O
+S	O
+).	O
+
+ABSTRACT	O
+:	O
+Hydrogen	B-CHED
+cyanamide	B-CHED
+is	O
+used	O
+in	O
+agriculture	O
+as	O
+a	O
+plant	B-CHED
+growth	B-PROC
+regulator	I-PROC
+and	O
+is	O
+applied	O
+to	O
+many	O
+deciduous	O
+plants	B-SPEC
+to	O
+stimulate	O
+uniform	O
+budbreak	O
+after	O
+dormancy	B-PROC
+,	O
+resulting	O
+in	O
+uniform	O
+flowering	B-PROC
+and	O
+maturity	O
+.	O
+
+Hydrogen	B-CHED
+cyanamide	B-CHED
+is	O
+highly	O
+toxic	O
+,	O
+and	O
+adverse	O
+health	O
+effects	O
+from	O
+contact	O
+include	O
+severe	O
+irritation	O
+and	O
+ulceration	B-DISO
+of	O
+the	O
+eyes	B-ANAT
+,	O
+skin	B-ANAT
+,	O
+and	O
+respiratory	B-ANAT
+tract	I-ANAT
+.	O
+
+This	O
+report	O
+describes	O
+28	O
+additional	O
+cases	O
+of	O
+hydrogen	B-CHED
+cyanamide	B-CHED
+-	O
+related	O
+illness	O
+that	O
+occurred	O
+during	O
+2002	O
+-	O
+2004	O
+,	O
+14	O
+of	O
+which	O
+occurred	O
+after	O
+sales	B-CHED
+resumed	O
+.	O
+
+ABSTRACT	O
+:	O
+Lymphopenia	O
+and	O
+increasing	O
+viral	O
+load	O
+in	O
+the	O
+first	O
+10	O
+days	O
+of	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+(	O
+SARS	B-DISO
+)	O
+suggested	O
+immune	B-PROC
+evasion	I-PROC
+by	O
+SARS	B-DISO
+-	O
+coronavirus	B-SPEC
+(	O
+CoV	O
+).	O
+
+In	O
+this	O
+study	O
+,	O
+we	O
+focused	O
+on	O
+dendritic	B-ANAT
+cells	B-COMP
+(	O
+DCs	B-DISO
+)	O
+which	O
+play	O
+important	O
+roles	O
+in	O
+linking	O
+the	O
+innate	O
+and	O
+adaptive	O
+immunity	B-PROC
+.	O
+
+No	O
+induction	B-PROC
+of	I-PROC
+apoptosis	I-PROC
+or	O
+maturation	B-PROC
+was	O
+detected	O
+in	O
+SARS	B-DISO
+-	O
+CoV	O
+-	O
+infected	O
+DCs	B-DISO
+.	O
+
+There	O
+were	O
+44	O
+men	O
+and	O
+66	O
+women	O
+with	O
+a	O
+mean	O
+(	O
+SD	O
+)	O
+age	O
+of	O
+35	O
+.	O
+6	O
+(	O
+9	O
+.	O
+8	O
+)	O
+years	O
+and	O
+body	B-ANAT
+mass	O
+index	O
+of	O
+23	O
+.	O
+1	O
+(	O
+4	O
+.	O
+8	O
+)	O
+kg	O
+/	O
+m2	O
+.	O
+
+The	O
+functional	O
+disability	O
+appears	O
+out	O
+of	O
+proportion	O
+to	O
+the	O
+degree	O
+of	O
+lung	B-PROC
+function	I-PROC
+impairment	B-DISO
+and	O
+may	O
+be	O
+related	O
+to	O
+additional	O
+factors	O
+such	O
+as	O
+muscle	B-ANAT
+deconditioning	O
+and	O
+steroid	B-DISO
+myopathy	I-DISO
+.	O
+
+The	O
+relative	O
+risks	O
+(	O
+RRs	B-DISO
+)	O
+values	O
+depended	O
+largely	O
+on	O
+the	O
+selection	O
+of	O
+lag	O
+days	O
+.	O
+
+ABSTRACT	O
+:	O
+Public	O
+health	O
+measures	O
+employed	O
+to	O
+fight	O
+against	O
+the	O
+spread	O
+of	O
+SARS	B-DISO
+need	O
+to	O
+be	O
+guided	O
+by	O
+biomedical	O
+knowledge	O
+as	O
+well	O
+as	O
+an	O
+understanding	O
+of	O
+the	O
+social	O
+science	O
+aspects	O
+of	O
+the	O
+disease	O
+.	O
+
+ABSTRACT	O
+:	O
+Severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+(	O
+SARS	B-DISO
+)	O
+is	O
+an	O
+emerging	B-DISO
+infectious	I-DISO
+disease	I-DISO
+caused	O
+by	O
+a	O
+novel	O
+SARS	B-DISO
+-	I-DISO
+associated	I-DISO
+coronavirus	I-DISO
+(	O
+SARS	B-DISO
+-	O
+CoV	O
+).	O
+
+The	O
+cut	O
+-	O
+off	O
+O	O
+.	O
+D	O
+.	O
+value	O
+was	O
+defined	O
+as	O
+0	O
+.	O
+175	O
+by	O
+calculating	O
+the	O
+mean	O
+O	O
+.	O
+D	O
+.	O
+value	O
+of	O
+the	O
+86	O
+sera	B-COMP
+plus	O
+3	O
+standard	O
+deviations	O
+.	O
+
+We	O
+report	O
+on	O
+serum	B-COMP
+cytokine	O
+levels	O
+,	O
+viral	O
+load	O
+and	O
+clinical	O
+parameters	O
+over	O
+the	O
+course	O
+of	O
+the	O
+disease	O
+in	O
+a	O
+cohort	O
+of	O
+nine	O
+adult	O
+SARS	B-DISO
+patients	O
+treated	O
+with	O
+steroids	B-CHED
+and	O
+interferon	B-PRGE
+alfacon	I-PRGE
+-	I-PRGE
+1	I-PRGE
+at	O
+North	O
+York	O
+General	O
+Hospital	O
+in	O
+Toronto	O
+,	O
+Ontario	O
+.	O
+
+The	O
+protein	B-CHED
+was	O
+validated	O
+by	O
+western	O
+blot	O
+and	O
+MS	O
+analysis	O
+.	O
+
+The	O
+recombinant	O
+K	O
+-	O
+COE	O
+constituted	O
+up	O
+to	O
+0	O
+.	O
+1	O
+%	O
+of	O
+the	O
+total	O
+soluble	O
+protein	B-CHED
+in	O
+the	O
+leaves	O
+of	O
+transgenic	O
+tobacco	B-SPEC
+plants	B-SPEC
+.	O
+
+The	O
+report	O
+highlights	O
+the	O
+importance	O
+of	O
+collaboration	O
+of	O
+CCL	B-DISO
+personnel	O
+with	O
+relevant	O
+hospital	O
+engineering	O
+and	O
+management	O
+teams	O
+to	O
+develop	O
+a	O
+contingency	O
+infection	B-DISO
+control	O
+plan	B-DISO
+to	O
+prepare	O
+for	O
+future	O
+outbreaks	O
+of	O
+SARS	B-DISO
+or	O
+other	O
+epidemics	O
+.	O
+
+ABSTRACT	O
+:	O
+This	O
+paper	O
+describes	O
+mapping	O
+of	O
+antigenic	O
+and	O
+host	B-COMP
+-	O
+protective	O
+epitopes	O
+of	O
+infectious	B-DISO
+bronchitis	B-DISO
+virus	B-SPEC
+proteins	B-CHED
+by	O
+assessing	O
+the	O
+ability	O
+of	O
+defined	O
+peptide	B-CHED
+regions	O
+within	O
+the	O
+S1	O
+,	O
+S2	O
+and	O
+N	O
+proteins	B-CHED
+to	O
+elicit	O
+humoral	O
+,	O
+cell	B-COMP
+-	O
+mediated	O
+and	O
+protective	O
+immune	B-PROC
+responses	I-PROC
+.	O
+
+All	O
+S1	B-PRGE
+and	I-PRGE
+S2	I-PRGE
+peptides	I-PRGE
+were	O
+antigenic	O
+,	O
+being	O
+recognised	O
+by	O
+IBV	B-SPEC
+immune	O
+sera	B-COMP
+and	O
+also	O
+induced	O
+an	O
+antibody	B-PROC
+response	I-PROC
+following	O
+inoculation	O
+into	O
+chicks	O
+.	O
+
+In	O
+this	O
+study	O
+,	O
+a	O
+dynamic	O
+model	O
+has	O
+been	O
+built	O
+to	O
+quantitatively	O
+investigate	O
+the	O
+effect	O
+of	O
+the	O
+relative	O
+humidity	O
+on	O
+the	O
+transport	B-PROC
+of	O
+liquid	O
+-	O
+droplets	O
+in	O
+air	B-CHED
+using	O
+coupled	O
+mass	O
+transfer	O
+and	O
+momentum	O
+equations	O
+.	O
+
+The	O
+quantification	O
+results	O
+for	O
+SARS	B-DISO
+-	O
+CoV	O
+from	O
+cell	B-COMP
+culture	O
+correlated	O
+well	O
+with	O
+those	O
+of	O
+the	O
+RT	O
+-	O
+PCR	O
+by	O
+using	O
+any	O
+two	O
+of	O
+the	O
+three	O
+sets	O
+of	O
+primer	O
+and	O
+probe	O
+used	O
+in	O
+this	O
+assay	O
+.	O
+
+ABSTRACT	O
+:	O
+The	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+(	O
+SARS	B-DISO
+)	O
+epidemic	O
+of	O
+2003	O
+was	O
+responsible	O
+for	O
+774	O
+deaths	B-PROC
+and	O
+caused	O
+significant	O
+economic	O
+damage	O
+worldwide	O
+.	O
+
+The	O
+main	O
+advantage	O
+of	O
+RCA	O
+is	O
+that	O
+it	O
+can	O
+be	O
+performed	O
+under	O
+isothermal	O
+conditions	O
+with	O
+minimal	O
+reagents	B-CHED
+and	O
+avoids	O
+the	O
+generation	O
+of	O
+false	O
+-	O
+positive	O
+results	O
+,	O
+a	O
+problem	O
+that	O
+is	O
+frequently	O
+encountered	O
+in	O
+PCR	O
+-	O
+based	O
+assays	O
+.	O
+
+ABSTRACT	O
+:	O
+An	O
+antigen	B-CHED
+detection	O
+assay	O
+for	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+(	O
+SARS	B-DISO
+)	O
+coronavirus	B-SPEC
+was	O
+established	O
+in	O
+this	O
+study	O
+by	O
+an	O
+indirect	O
+immunofluorescence	O
+test	O
+,	O
+which	O
+utilized	O
+cells	B-COMP
+derived	O
+from	O
+throat	B-ANAT
+wash	O
+samples	O
+of	O
+patients	O
+with	O
+SARS	B-DISO
+and	O
+a	O
+rabbit	B-SPEC
+serum	B-COMP
+that	O
+recognized	O
+the	O
+nucleocapsid	B-COMP
+protein	B-CHED
+of	O
+SARS	B-DISO
+-	I-DISO
+associated	I-DISO
+coronavirus	I-DISO
+(	O
+SARS	B-DISO
+-	O
+CoV	O
+)	O
+but	O
+not	O
+that	O
+of	O
+other	O
+human	B-SPEC
+coronavirus	I-SPEC
+tested	O
+.	O
+
+Compared	O
+with	O
+other	O
+diagnostic	O
+modalities	O
+for	O
+detecting	O
+SARS	B-PRGE
+-	I-PRGE
+CoV	I-PRGE
+,	O
+this	O
+assay	O
+is	O
+simpler	O
+,	O
+more	O
+convenient	O
+,	O
+and	O
+economical	O
+.	O
+
+Ninety	O
+-	O
+nine	O
+porcine	B-SPEC
+field	O
+faecal	B-ANAT
+samples	O
+obtained	O
+from	O
+37	O
+herds	O
+affected	O
+with	O
+diarrhoea	B-DISO
+were	O
+examined	O
+,	O
+and	O
+various	O
+TGEV	B-SPEC
+levels	O
+were	O
+found	O
+in	O
+nine	O
+samples	O
+from	O
+six	O
+herds	O
+.	O
+
+ABSTRACT	O
+:	O
+Many	O
+new	O
+infectious	O
+diseases	O
+in	O
+humans	B-SPEC
+have	O
+been	O
+derived	O
+from	O
+animal	B-SPEC
+sources	O
+in	O
+the	O
+past	O
+20	O
+years	O
+.	O
+
+Ophthalmologists	O
+may	O
+be	O
+particularly	O
+susceptible	O
+to	O
+the	O
+infection	B-DISO
+as	O
+routine	O
+ophthalmic	B-CHED
+examinations	O
+like	O
+direct	O
+ophthalmoscopy	O
+and	O
+slit	O
+-	O
+lamp	O
+examination	O
+are	O
+usually	O
+performed	O
+in	O
+a	O
+setting	O
+that	O
+has	O
+close	O
+doctor	O
+-	O
+patient	O
+contact	O
+.	O
+
+SARS	B-DISO
+is	O
+one	O
+of	O
+the	O
+many	O
+viruses	B-SPEC
+against	O
+which	O
+personnel	O
+will	O
+need	O
+protecting	O
+in	O
+an	O
+ophthalmic	B-CHED
+setting	O
+.	O
+
+TITLE	O
+:	O
+Antibody	B-FUNC
+responses	I-PROC
+to	O
+individual	O
+proteins	B-CHED
+of	O
+SARS	B-DISO
+coronavirus	B-SPEC
+and	O
+their	O
+neutralization	O
+activities	O
+.	O
+
+ABSTRACT	O
+:	O
+A	O
+novel	O
+coronavirus	O
+,	O
+the	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+(	O
+SARS	B-DISO
+)	O
+coronavirus	B-SPEC
+(	O
+SARS	B-DISO
+-	O
+CoV	O
+),	O
+was	O
+identified	O
+as	O
+the	O
+causative	O
+agent	O
+of	O
+SARS	B-DISO
+.	O
+
+The	O
+development	B-PROC
+of	O
+vaccines	O
+against	O
+SARS	B-DISO
+-	O
+CoV	O
+may	O
+take	O
+years	O
+.	O
+
+The	O
+patient	O
+underwent	O
+emergency	B-DISO
+coronary	B-ANAT
+angiography	O
+,	O
+which	O
+showed	O
+no	O
+severe	O
+coronary	B-ANAT
+obstruction	B-DISO
+,	O
+although	O
+his	O
+left	B-ANAT
+ventricle	I-ANAT
+had	O
+significant	O
+systolic	B-DISO
+dysfunction	I-DISO
+with	O
+characteristic	O
+alterations	O
+,	O
+on	O
+ventriculography	O
+,	O
+of	O
+the	O
+syndrome	B-DISO
+described	O
+as	O
+transient	O
+ventricular	B-DISO
+dysfunction	I-DISO
+or	O
+Takotsubo	B-DISO
+syndrome	I-DISO
+.	O
+
+Of	O
+10	O
+patients	O
+tested	O
+,	O
+2	O
+had	O
+severe	O
+GERD	B-DISO
+(	O
+Ft	O
+>	O
+20	O
+%),	O
+5	O
+had	O
+moderate	O
+GERD	B-DISO
+(	O
+Ft	O
+10	O
+-	O
+20	O
+%),	O
+2	O
+had	O
+mild	O
+GERD	B-DISO
+(	O
+Ft	O
+5	O
+-	O
+10	O
+%),	O
+and	O
+1	O
+had	O
+no	O
+GERD	B-DISO
+.	O
+
+This	O
+susceptibility	O
+is	O
+particularly	O
+evident	O
+for	O
+novel	O
+infectious	B-DISO
+agents	O
+such	O
+as	O
+in	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+but	O
+is	O
+also	O
+all	O
+too	O
+apparent	O
+for	O
+common	O
+pathogens	O
+such	O
+as	O
+influenza	B-DISO
+.	O
+
+Many	O
+years	O
+ago	O
+,	O
+it	O
+was	O
+noted	O
+that	O
+the	O
+elderly	O
+possessed	B-DISO
+oligoclonal	O
+expansions	O
+of	O
+T	B-ANAT
+cells	I-ANAT
+,	O
+especially	O
+of	O
+CD8	B-PRGE
+(+)	O
+cells	B-COMP
+.	O
+
+At	O
+the	O
+same	O
+time	O
+,	O
+it	O
+was	O
+established	O
+that	O
+cytomegalovirus	B-SPEC
+(	O
+CMV	B-SPEC
+)	O
+seropositivity	O
+was	O
+associated	O
+with	O
+many	O
+of	O
+the	O
+same	O
+phenotypic	O
+and	O
+functional	O
+alterations	O
+to	O
+T	B-ANAT
+-	I-ANAT
+cell	I-ANAT
+immunity	B-PROC
+that	O
+were	O
+being	O
+reported	O
+as	O
+biomarkers	O
+associated	O
+with	O
+aging	B-PROC
+.	O
+
+We	O
+have	O
+identified	O
+a	O
+new	O
+RNA	O
+structural	O
+motif	O
+that	O
+is	O
+capable	O
+of	O
+promoting	O
+efficient	O
+programmed	O
+ribosomal	B-PROC
+frameshifting	I-PROC
+.	O
+
+Twenty	O
+-	O
+six	O
+mAbs	O
+were	O
+reactive	O
+to	O
+SARS	B-PRGE
+-	I-PRGE
+CoV	I-PRGE
+by	O
+ELISA	O
+,	O
+and	O
+nine	O
+were	O
+chosen	O
+for	O
+detailed	O
+characterization	O
+.	O
+
+Two	O
+of	O
+five	O
+S	O
+protein	B-CHED
+mAbs	O
+neutralized	O
+SARS	B-DISO
+-	I-DISO
+CoV	I-DISO
+infection	I-DISO
+of	O
+Vero	O
+E6	O
+cells	B-COMP
+and	O
+reacted	O
+to	O
+an	O
+epitope	B-CHED
+within	O
+amino	B-CHED
+acids	I-CHED
+490	O
+-	O
+510	O
+in	O
+the	O
+S	B-PRGE
+protein	I-PRGE
+.	O
+
+Using	O
+a	O
+0	O
+.	O
+01	O
+%	O
+dilution	O
+of	O
+SARS	B-DISO
+-	O
+CoV	O
+,	O
+all	O
+44	O
+clinical	O
+samples	O
+tested	O
+positive	O
+in	O
+our	O
+assay	O
+.	O
+
+In	O
+comparison	O
+,	O
+using	O
+a	O
+0	O
+.	O
+1	O
+%	O
+dilution	O
+of	O
+SARS	B-PRGE
+-	I-PRGE
+CoV	I-PRGE
+,	O
+26	O
+of	O
+the	O
+44	O
+samples	O
+tested	O
+positive	O
+using	O
+the	O
+WHO	O
+primers	O
+.	O
+
+At	O
+60	O
+days	O
+,	O
+compared	O
+to	O
+normal	O
+controls	O
+,	O
+SARS	B-DISO
+patients	O
+had	O
+increased	O
+cellularity	O
+of	O
+BALF	O
+with	O
+increased	O
+alveolar	B-ANAT
+macrophages	I-ANAT
+(	O
+AM	O
+)	O
+and	O
+CD8	B-ANAT
+cells	B-COMP
+.	O
+
+Electron	O
+microscopy	O
+of	O
+purified	O
+influenza	B-SPEC
+A	I-SPEC
+virus	I-SPEC
+showed	O
+extensive	O
+clumping	O
+and	O
+morphological	O
+changes	O
+in	O
+spike	O
+configuration	O
+after	O
+contact	O
+with	O
+the	O
+virucidal	O
+mixture	B-CHED
+,	O
+but	O
+no	O
+overt	O
+destruction	O
+of	O
+the	O
+viral	B-COMP
+membrane	I-COMP
+.	O
+
+Regarding	O
+infection	B-DISO
+isolation	O
+ward	O
+,	O
+Infectious	B-DISO
+Control	O
+Nurse	O
+and	O
+Infection	B-DISO
+Control	O
+Committee	O
+Chairman	O
+in	O
+the	O
+hospital	O
+,	O
+the	O
+proportions	O
+of	O
+staff	O
+that	O
+could	O
+correctly	O
+name	B-SPEC
+them	O
+were	O
+39	O
+.	O
+7	O
+%,	O
+38	O
+.	O
+3	O
+%	O
+and	O
+15	O
+.	O
+7	O
+%	O
+respectively	O
+.	O
+
+TITLE	O
+:	O
+Media	B-ANAT
+effects	O
+on	O
+students	O
+during	O
+SARS	B-DISO
+outbreak	O
+.	O
+
+TITLE	O
+:	O
+Coronavirus	B-SPEC
+phylogeny	O
+based	O
+on	O
+a	O
+geometric	O
+approach	O
+.	O
+
+Here	O
+,	O
+we	O
+report	O
+a	O
+reverse	O
+genetic	O
+approach	O
+to	O
+elucidate	O
+the	O
+role	O
+of	O
+N	O
+in	O
+coronavirus	B-SPEC
+replication	O
+and	O
+transcription	B-PROC
+.	O
+
+ABSTRACT	O
+:	O
+The	O
+3C	B-PRGE
+-	I-PRGE
+like	I-PRGE
+proteinase	I-PRGE
+(	O
+3CLpro	O
+)	O
+of	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+-	O
+associated	O
+coronavirus	B-SPEC
+(	O
+SARS	B-DISO
+-	O
+CoV	O
+)	O
+is	O
+one	O
+of	O
+the	O
+most	O
+promising	O
+targets	O
+for	O
+anti	O
+-	O
+SARS	B-DISO
+-	O
+CoV	O
+drugs	O
+due	O
+to	O
+its	O
+crucial	O
+role	O
+in	O
+the	O
+viral	B-PROC
+life	I-PROC
+cycle	I-PROC
+.	O
+
+Only	O
+the	O
+SARS	B-DISO
+(	O
+WW	O
+-	O
+I	O
+)	O
+peptide	B-CHED
+strongly	O
+partitioned	O
+into	O
+the	O
+membranes	B-ANAT
+of	O
+large	O
+unilamellar	O
+vesicles	B-COMP
+(	O
+LUV	O
+),	O
+adopting	O
+a	O
+beta	O
+-	O
+sheet	O
+structure	O
+.	O
+
+Based	O
+on	O
+the	O
+activity	O
+of	O
+SARS	B-DISO
+(	O
+WW	O
+-	O
+I	O
+),	O
+we	O
+propose	O
+that	O
+the	O
+hydrophobic	O
+stretch	O
+of	O
+19	O
+aa	O
+corresponding	O
+to	O
+residues	O
+770	O
+to	O
+788	O
+is	O
+a	O
+fusion	O
+peptide	B-CHED
+of	O
+the	O
+SARS	B-PRGE
+-	I-PRGE
+CoV	I-PRGE
+S2	I-PRGE
+subunit	I-PRGE
+.	O
+
+TITLE	O
+:	O
+An	O
+animal	B-SPEC
+model	O
+of	O
+SARS	B-DISO
+produced	O
+by	O
+infection	B-DISO
+of	O
+Macaca	B-SPEC
+mulatta	I-SPEC
+with	O
+SARS	B-DISO
+coronavirus	B-SPEC
+.	O
+
+ABSTRACT	O
+:	O
+A	O
+new	O
+SARS	O
+animal	B-SPEC
+model	O
+was	O
+established	O
+by	O
+inoculating	O
+SARS	B-DISO
+coronavirus	B-SPEC
+(	O
+SARS	B-DISO
+-	O
+CoV	O
+)	O
+into	O
+rhesus	B-SPEC
+macaques	I-SPEC
+(	O
+Macaca	B-SPEC
+mulatta	I-SPEC
+)	O
+through	O
+the	O
+nasal	B-ANAT
+cavity	I-ANAT
+.	O
+
+HIV	B-SPEC
+-	I-SPEC
+1	I-SPEC
+(	O
+human	B-SPEC
+immunodeficiency	I-SPEC
+virus	I-SPEC
+type	I-SPEC
+1	I-SPEC
+)	O
+lipopeptide	B-CHED
+vaccine	O
+candidate	O
+elicits	O
+immune	B-PROC
+responses	I-PROC
+,	O
+and	O
+sustains	O
+HIV	B-DISO
+control	O
+after	O
+highly	O
+active	O
+antiretroviral	O
+therapy	O
+(	O
+HAART	O
+).	O
+
+Compared	O
+to	O
+CDV	B-CHED
+(	O
+cidofovir	B-CHED
+),	O
+CDV	B-CHED
+ether	B-CHED
+lipid	I-CHED
+esters	B-CHED
+have	O
+enhanced	O
+activity	O
+against	O
+vaccinia	B-DISO
+(	O
+VV	O
+)	O
+and	O
+cowpox	B-DISO
+(	O
+CV	O
+)	O
+viruses	B-SPEC
+in	O
+vitro	O
+.	O
+
+TITLE	O
+:	O
+Forecasting	O
+versus	O
+projection	O
+models	O
+in	O
+epidemiology	O
+:	O
+the	O
+case	O
+of	O
+the	O
+SARS	B-DISO
+epidemics	O
+.	O
+
+Development	B-PROC
+of	O
+a	O
+Western	O
+blot	O
+assay	O
+for	O
+detection	O
+of	O
+antibodies	B-COMP
+against	O
+coronavirus	B-SPEC
+causing	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+.	O
+
+N	B-PRGE
+protein	I-PRGE
+was	O
+detected	O
+in	O
+18	B-PRGE
+IFA	I-PRGE
+IgM	I-PRGE
+-	O
+positive	O
+serum	B-COMP
+samples	O
+collected	O
+from	O
+SARS	B-DISO
+confirmed	O
+patients	O
+,	O
+but	O
+not	O
+in	O
+nine	O
+samples	O
+collected	O
+from	O
+SARS	B-DISO
+recovery	O
+patient	O
+.	O
+
+ABSTRACT	O
+:	O
+When	O
+unexpected	O
+diseases	O
+such	O
+as	O
+the	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+(	O
+SARS	B-DISO
+)	O
+and	O
+avian	B-DISO
+influenza	I-DISO
+become	O
+a	O
+serious	O
+threat	O
+to	O
+public	O
+health	O
+,	O
+an	O
+immediate	O
+response	O
+is	O
+imperative	O
+.	O
+
+This	O
+should	O
+take	O
+into	O
+consideration	O
+existing	O
+licensed	O
+antiviral	B-CHED
+drugs	I-CHED
+against	O
+other	O
+viral	B-DISO
+diseases	I-DISO
+already	O
+known	O
+to	O
+be	O
+safe	O
+for	O
+use	O
+in	O
+humans	B-SPEC
+.	O
+
+In	O
+this	O
+report	O
+,	O
+evidence	O
+is	O
+presented	O
+that	O
+HIV	B-PRGE
+-	I-PRGE
+1	I-PRGE
+protease	B-PROC
+inhibitors	I-PROC
+(	O
+PIs	B-CHED
+)	O
+currently	O
+used	O
+in	O
+anti	O
+-	O
+HIV	B-SPEC
+-	I-SPEC
+1	I-SPEC
+therapies	O
+might	O
+exert	B-PROC
+some	O
+effects	O
+on	O
+SARS	B-DISO
+and	O
+perhaps	O
+,	O
+on	O
+avian	B-DISO
+influenza	I-DISO
+.	O
+
+In	O
+the	O
+current	O
+study	O
+,	O
+we	O
+established	O
+the	O
+utility	O
+of	O
+two	O
+additional	O
+assays	O
+to	O
+measure	O
+the	O
+neutralizing	O
+activities	O
+against	O
+SCV	B-SPEC
+:	O
+the	O
+plaque	B-DISO
+reduction	O
+(	O
+PR	O
+)	O
+and	O
+the	O
+neutral	O
+red	O
+staining	O
+(	O
+NRS	O
+)	O
+assays	O
+.	O
+
+The	O
+NRS	O
+neutralization	O
+assay	O
+was	O
+adopted	O
+from	O
+a	O
+similar	O
+system	O
+used	O
+for	O
+detecting	O
+neutralizing	O
+antibody	B-PROC
+responses	I-PROC
+against	O
+human	B-SPEC
+immunodeficiency	I-SPEC
+virus	I-SPEC
+type	I-SPEC
+1	I-SPEC
+(	O
+HIV	B-SPEC
+-	I-SPEC
+1	I-SPEC
+).	O
+
+TITLE	O
+:	O
+Physiologic	O
+,	O
+biochemical	O
+,	O
+and	O
+imaging	O
+characterization	O
+of	O
+acute	O
+lung	B-ANAT
+injury	O
+in	O
+mice	B-SPEC
+.	O
+
+As	O
+SARS	B-DISO
+emerged	O
+as	O
+a	O
+global	O
+disease	O
+,	O
+better	O
+understanding	O
+of	O
+practice	O
+differences	O
+among	O
+physicians	O
+from	O
+different	O
+countries	O
+would	O
+facilitate	O
+globalization	O
+of	O
+public	O
+health	O
+.	O
+
+Potent	O
+neutralizing	O
+activity	O
+directed	O
+against	O
+NL63	O
+-	O
+but	O
+not	O
+229E	O
+-	O
+S	O
+protein	O
+was	O
+detected	O
+in	O
+virtually	O
+all	O
+sera	B-COMP
+from	O
+patients	O
+8	O
+years	O
+of	O
+age	O
+or	O
+older	O
+,	O
+suggesting	O
+that	O
+HCoV	B-SPEC
+-	I-SPEC
+NL63	I-SPEC
+infection	B-DISO
+of	O
+humans	B-SPEC
+is	O
+common	O
+and	O
+usually	O
+acquired	O
+during	O
+childhood	O
+.	O
+
+Because	O
+the	O
+two	O
+viruses	B-SPEC
+differ	O
+dramatically	O
+in	O
+their	O
+ability	O
+to	O
+induce	O
+disease	O
+,	O
+analysis	O
+of	O
+HCoV	B-SPEC
+-	I-SPEC
+NL63	I-SPEC
+might	O
+unravel	O
+pathogenicity	O
+factors	O
+in	O
+SARS	B-DISO
+-	O
+CoV	O
+.	O
+The	O
+frequent	O
+HCoV	B-SPEC
+-	I-SPEC
+NL63	I-SPEC
+infection	B-DISO
+of	O
+humans	B-SPEC
+suggests	O
+that	O
+highly	O
+pathogenic	O
+variants	O
+have	O
+ample	O
+opportunity	O
+to	O
+evolve	O
+,	O
+underlining	O
+the	O
+need	O
+for	O
+vaccines	O
+against	O
+HCoVs	O
+.	O
+
+TITLE	O
+:	O
+Virus	B-SPEC
+-	O
+associated	O
+hemophagocytic	B-DISO
+syndrome	I-DISO
+in	O
+an	O
+international	O
+traveler	O
+as	O
+a	O
+differential	O
+diagnosis	O
+of	O
+SARS	O
+.	O
+
+Virus	B-SPEC
+-	O
+associated	O
+hemophagocytic	B-DISO
+syndrome	I-DISO
+in	O
+an	O
+international	O
+traveler	O
+should	O
+be	O
+included	O
+in	O
+the	O
+differential	O
+diagnosis	O
+of	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+.	O
+
+One	O
+hundred	O
+twenty	O
+-	O
+four	O
+patients	O
+with	O
+severe	B-DISO
+sepsis	I-DISO
+with	O
+or	O
+without	O
+septic	B-DISO
+shock	I-DISO
+were	O
+included	O
+in	O
+this	O
+analysis	O
+.	O
+
+Blood	B-ANAT
+samples	I-ANAT
+were	O
+obtained	O
+at	O
+baseline	O
+and	O
+on	O
+days	O
+1	O
+through	O
+4	O
+,	O
+and	O
+were	O
+evaluated	O
+for	O
+proinflammatory	O
+and	O
+anti	O
+-	O
+inflammatory	O
+cytokine	O
+concentrations	O
+,	O
+as	O
+well	O
+as	O
+for	O
+procalcitonin	O
+and	O
+total	O
+protein	O
+C	O
+levels	O
+.	O
+
+The	O
+nucleotide	B-CHED
+sequence	O
+and	O
+protein	B-CHED
+sequence	O
+of	O
+GD	B-PRGE
+nsp2	I-PRGE
+were	O
+compared	O
+with	O
+that	O
+of	O
+other	O
+SARS	B-PRGE
+-	I-PRGE
+CoV	I-PRGE
+strains	O
+by	O
+nucleotide	B-CHED
+-	O
+nucleotide	B-CHED
+basic	O
+local	O
+alignment	O
+search	O
+tool	O
+(	O
+BLASTN	O
+)	O
+and	O
+protein	B-CHED
+-	O
+protein	B-CHED
+basic	O
+local	O
+alignment	O
+search	O
+tool	O
+(	O
+BLASTP	O
+)	O
+to	O
+investigate	O
+its	O
+variance	O
+trend	O
+during	O
+the	O
+transmission	O
+.	O
+
+The	O
+results	O
+suggest	O
+that	O
+polymerase	O
+nsp2	B-PRGE
+is	O
+relatively	O
+stable	O
+during	O
+the	O
+phase	O
+of	O
+epidemic	O
+.	O
+
+The	O
+amino	B-CHED
+acid	I-CHED
+and	O
+secondary	O
+structure	O
+change	O
+may	O
+be	O
+important	O
+for	O
+viral	B-DISO
+infection	I-DISO
+.	O
+
+ABSTRACT	O
+:	O
+Severe	O
+acute	O
+respiratory	O
+syndrome	O
+(	O
+SARS	B-DISO
+)	O
+is	O
+an	O
+infectious	B-DISO
+disease	I-DISO
+caused	O
+by	O
+SARS	B-DISO
+-	O
+CoV	O
+.	O
+There	O
+are	O
+no	O
+effective	O
+antiviral	B-CHED
+drugs	I-CHED
+for	O
+SARS	B-DISO
+although	O
+the	O
+epidemic	O
+of	O
+SARS	B-DISO
+was	O
+controlled	O
+.	O
+
+The	O
+introduction	O
+of	O
+RNAi	B-PROC
+plasmid	O
+efficiently	O
+and	O
+specifically	O
+inhibited	O
+the	O
+synthesis	B-PROC
+of	O
+protein	B-CHED
+N	O
+.	O
+RT	O
+-	O
+PCR	O
+showed	O
+that	O
+RNAs	O
+of	O
+N	B-PRGE
+gene	I-PRGE
+were	O
+clearly	O
+reduced	O
+when	O
+the	O
+pEGFP	O
+-	O
+C1	O
+-	O
+N	O
+was	O
+cotransfected	O
+with	O
+pshRNA	O
+-	O
+N	O
+,	O
+whereas	O
+the	O
+control	O
+vector	O
+did	O
+not	O
+exhibit	O
+inhibitory	O
+effect	O
+on	O
+N	B-PRGE
+gene	I-PRGE
+transcription	O
+.	O
+
+We	O
+retrospectively	O
+analyzed	O
+data	O
+from	O
+n	O
+=	O
+25	O
+ARDS	B-DISO
+patients	O
+who	O
+received	O
+iNO	O
+,	O
+and	O
+underwent	O
+chest	B-ANAT
+CT	O
+within	O
+72	O
+h	O
+prior	O
+to	O
+inhaled	B-PROC
+treatment	O
+.	O
+
+CONCLUSIONS	O
+:	O
+Our	O
+data	O
+demonstrate	O
+that	O
+the	O
+gross	O
+morphological	O
+distribution	O
+of	O
+pathological	O
+lung	B-ANAT
+tissue	I-ANAT
+influences	O
+iNO	O
+response	O
+in	O
+ARDS	B-DISO
+.	O
+
+TITLE	O
+:	O
+Clinical	O
+features	O
+of	O
+probable	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+in	O
+Beijing	O
+.	O
+
+The	O
+software	O
+and	O
+source	O
+code	O
+for	O
+SPR	B-PRGE
+Opt	I-PRGE
+is	O
+publicly	O
+available	O
+and	O
+free	O
+for	O
+non	O
+-	O
+profit	O
+use	O
+at	O
+http	O
+://	O
+www	O
+.	O
+llnl	O
+.	O
+gov	O
+/	O
+IPandC	O
+/	O
+technology	O
+/	O
+software	O
+/	O
+softwaretitles	O
+/	O
+spropt	O
+.	O
+php	O
+.	O
+
+Phylogenetic	O
+trees	O
+created	O
+based	O
+on	O
+SNPs	O
+,	O
+PCR	B-PRGE
+-	I-PRGE
+RFLPs	I-PRGE
+,	O
+and	O
+full	O
+genomes	O
+are	O
+compared	O
+for	O
+SARS	B-DISO
+virus	B-SPEC
+,	O
+illustrating	O
+that	O
+purported	O
+phylogenies	O
+based	O
+only	O
+on	O
+SNP	O
+or	O
+PCR	O
+-	O
+RFLP	O
+variations	O
+do	O
+not	O
+match	O
+those	O
+based	O
+on	O
+multiple	O
+sequence	O
+alignment	O
+of	O
+the	O
+full	O
+genomes	O
+.	O
+
+On	O
+the	O
+34th	O
+day	O
+after	O
+birth	B-PROC
+,	O
+urine	B-ANAT
+volume	O
+suddenly	O
+decreased	O
+and	O
+hypotension	O
+,	O
+oliguria	B-DISO
+,	O
+and	O
+generalized	B-DISO
+edema	I-DISO
+developed	O
+.	O
+
+Two	O
+weeks	O
+later	O
+,	O
+cranial	B-ANAT
+ultrasonography	O
+revealed	O
+multiple	O
+,	O
+right	O
+-	O
+sided	O
+,	O
+cystic	O
+lesions	O
+that	O
+were	O
+subsequently	O
+diagnosed	O
+as	O
+cerebral	B-DISO
+infarction	I-DISO
+by	O
+magnetic	O
+resonance	O
+imaging	O
+.	O
+
+SARS	B-DISO
+,	O
+as	O
+an	O
+emergency	B-DISO
+of	O
+Public	O
+Health	O
+System	O
+(	O
+PHS	B-DISO
+),	O
+alarmed	O
+health	O
+workers	O
+throughout	O
+the	O
+world	O
+proving	O
+there	O
+is	O
+still	O
+the	O
+potential	O
+for	O
+an	O
+epidemic	O
+of	O
+an	O
+emerging	O
+infection	B-DISO
+both	O
+in	O
+developed	O
+and	O
+developing	O
+areas	O
+.	O
+
+In	O
+this	O
+study	O
+,	O
+we	O
+attempt	O
+to	O
+demonstrate	O
+some	O
+of	O
+the	O
+categories	O
+of	O
+PHS	B-DISO
+that	O
+contributed	O
+to	O
+the	O
+SARS	B-DISO
+epidemic	O
+.	O
+
+In	O
+their	O
+article	O
+""""	O
+Meeting	O
+the	O
+challenge	O
+of	O
+epidemic	O
+infectious	B-DISO
+diseases	I-DISO
+outbreaks	O
+:	O
+an	O
+agenda	O
+for	O
+research	O
+""","	O
+Kai	B-PRGE
+-	I-PRGE
+Lit	I-PRGE
+Phua	I-PRGE
+and	O
+Lai	O
+Kah	O
+Lee	O
+clearly	O
+demonstrate	O
+how	O
+social	O
+,	O
+behavioural	O
+and	O
+environmental	O
+factors	O
+,	O
+linked	O
+to	O
+a	O
+host	B-COMP
+of	O
+human	B-SPEC
+activities	O
+,	O
+have	O
+accelerated	O
+and	O
+amplified	O
+these	O
+natural	O
+phenomena	O
+.	O
+
+Using	O
+random	O
+-	O
+digit	B-ANAT
+dialing	O
+,	O
+we	O
+sampled	O
+4481	O
+Hong	O
+Kong	O
+residents	O
+in	O
+6	O
+population	O
+-	O
+based	O
+surveys	O
+that	O
+were	O
+conducted	O
+at	O
+different	O
+times	O
+during	O
+and	O
+after	O
+the	O
+2003	O
+outbreak	O
+of	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+(	O
+SARS	B-DISO
+).	O
+
+Coronavirus	B-DISO
+infections	I-DISO
+were	O
+detected	O
+in	O
+26	O
+(	O
+4	O
+.	O
+4	O
+%)	O
+of	O
+587	O
+children	O
+studied	O
+;	O
+15	O
+(	O
+2	O
+.	O
+6	O
+%)	O
+were	O
+positive	O
+for	O
+HCoV	B-SPEC
+-	I-SPEC
+NL63	I-SPEC
+,	O
+9	O
+(	O
+1	O
+.	O
+5	O
+%)	O
+were	O
+positive	O
+for	O
+HCoV	B-SPEC
+-	I-SPEC
+OC43	I-SPEC
+,	O
+and	O
+2	O
+(	O
+0	O
+.	O
+3	O
+%)	O
+were	O
+positive	O
+for	O
+HCoV	B-SPEC
+-	I-SPEC
+229E	I-SPEC
+.	O
+
+HCoV	B-SPEC
+-	I-SPEC
+NL63	I-SPEC
+infections	B-DISO
+were	O
+noted	O
+in	O
+the	O
+spring	O
+and	O
+summer	O
+months	O
+of	O
+2002	O
+,	O
+whereas	O
+HCoV	B-SPEC
+-	I-SPEC
+OC43	I-SPEC
+infection	B-DISO
+mainly	O
+occurred	O
+in	O
+the	O
+fall	O
+and	O
+winter	O
+months	O
+of	O
+2001	O
+.	O
+
+ABSTRACT	O
+:	O
+A	O
+water	O
+-	O
+soluble	O
+extract	O
+of	O
+fermented	O
+Polygonum	B-SPEC
+tinctorium	I-SPEC
+Aiton	I-SPEC
+(	O
+Polygonaceae	B-SPEC
+)	O
+called	O
+Sukumo	O
+,	O
+exhibited	O
+a	O
+potent	O
+inhibitory	O
+activity	O
+against	O
+HIV	B-DISO
+type	O
+1	O
+in	O
+vitro	O
+.	O
+
+It	O
+also	O
+suppressed	O
+replication	O
+of	O
+herpes	B-SPEC
+simplex	I-SPEC
+virus	I-SPEC
+type	I-SPEC
+1	I-SPEC
+in	O
+Vero	B-ANAT
+cells	I-ANAT
+with	O
+an	O
+EC	O
+50	O
+of	O
+11	O
+.	O
+56	O
+microg	O
+/	O
+ml	O
+.	O
+
+Mizoribine	O
+inhibited	O
+replication	O
+of	O
+SARS	B-DISO
+-	O
+CoV	O
+more	O
+strongly	O
+than	O
+ribavirin	B-CHED
+.	O
+
+Few	O
+tests	O
+allow	O
+confirmation	O
+or	O
+exclusion	O
+of	O
+SARS	B-DISO
+within	O
+the	O
+first	O
+few	O
+days	O
+of	O
+infection	B-DISO
+.	O
+
+Superimposed	O
+bacterial	O
+and	O
+other	O
+opportunistic	B-DISO
+infections	I-DISO
+are	O
+common	O
+,	O
+especially	O
+in	O
+those	O
+treated	O
+with	O
+mechanical	O
+ventilation	O
+.	O
+
+Subcutaneous	B-DISO
+emphysema	I-DISO
+,	O
+pneumothoraces	O
+and	O
+pneumomediastinum	O
+may	O
+arise	O
+spontaneously	O
+or	O
+as	O
+a	O
+result	O
+of	O
+positive	O
+ventilatory	O
+assistance	O
+.	O
+
+Aspiration	O
+of	O
+microbe	O
+-	O
+laden	O
+oropharyngeal	B-ANAT
+,	O
+gastric	B-ANAT
+,	O
+or	O
+tracheal	O
+secretions	B-ANAT
+around	O
+the	O
+cuffed	O
+endotracheal	O
+tube	O
+into	O
+the	O
+normally	O
+sterile	B-DISO
+lower	B-ANAT
+respiratory	I-ANAT
+tract	I-ANAT
+results	O
+in	O
+most	O
+cases	O
+of	O
+endemic	O
+VAP	O
+.	O
+
+We	O
+here	O
+describe	O
+specific	O
+characteristics	O
+associated	O
+with	O
+circulating	O
+HCoV	B-SPEC
+-	I-SPEC
+OC43	I-SPEC
+strains	O
+,	O
+and	O
+we	O
+provide	O
+substantial	O
+evidence	O
+for	O
+the	O
+genetic	O
+variability	O
+of	O
+HCoV	B-SPEC
+-	I-SPEC
+OC43	I-SPEC
+.	O
+
+TITLE	O
+:	O
+JNK	B-ENZY
+and	O
+PI3k	B-FUNC
+/	O
+Akt	B-PRGE
+signaling	B-PROC
+pathways	B-PROC
+are	O
+required	O
+for	O
+establishing	O
+persistent	O
+SARS	B-DISO
+-	I-DISO
+CoV	I-DISO
+infection	I-DISO
+in	O
+Vero	O
+E6	O
+cells	B-COMP
+.	O
+
+Serum	B-COMP
+levels	O
+of	O
+Hsp60	B-PRGE
+detected	O
+within	O
+30	O
+min	O
+after	O
+trauma	O
+correlate	O
+with	O
+the	O
+development	B-PROC
+of	O
+ALI	O
+.	O
+
+Those	O
+who	O
+worried	O
+about	O
+contracting	O
+SARS	B-DISO
+were	O
+more	O
+likely	O
+to	O
+have	O
+improved	O
+health	O
+-	O
+seeking	O
+behaviors	B-PROC
+.	O
+
+ABSTRACT	O
+:	O
+A	O
+novel	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+(	O
+SARS	B-DISO
+)-	O
+associated	O
+coronavirus	B-SPEC
+(	O
+SARS	B-DISO
+-	O
+CoV	O
+)	O
+has	O
+been	O
+identified	O
+as	O
+the	O
+aetiological	O
+agent	O
+of	O
+SARS	B-DISO
+.	O
+
+SARS	B-DISO
+-	O
+CoV	O
+infectivity	O
+was	O
+reduced	O
+over	O
+10	O
+000	O
+-	O
+fold	O
+through	O
+pre	O
+-	O
+incubation	O
+with	O
+two	O
+of	O
+these	O
+peptides	O
+,	O
+while	O
+it	O
+was	O
+completely	O
+inhibited	O
+in	O
+the	O
+presence	O
+of	O
+three	O
+peptides	B-CHED
+.	O
+
+The	O
+peptides	B-CHED
+identified	O
+in	O
+this	O
+study	O
+could	O
+be	O
+further	O
+developed	O
+into	O
+antiviral	B-CHED
+drugs	I-CHED
+.	O
+
+TITLE	O
+:	O
+Overview	O
+of	O
+antiviral	B-CHED
+and	O
+anti	O
+-	O
+inflammatory	O
+treatment	O
+for	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+.	O
+
+The	O
+ensuing	O
+challenges	O
+to	O
+hospital	O
+and	O
+public	O
+health	O
+workers	O
+rose	B-SPEC
+to	O
+a	O
+level	O
+never	O
+before	O
+seen	O
+in	O
+healthcare	O
+,	O
+in	O
+part	O
+due	O
+to	O
+the	O
+unknown	O
+nature	O
+of	O
+the	O
+disease	O
+,	O
+the	O
+fear	O
+of	O
+the	O
+human	B-SPEC
+-	O
+to	O
+-	O
+human	B-SPEC
+transmission	O
+and	O
+the	O
+significant	O
+media	B-ANAT
+involvement	O
+.	O
+
+A	O
+number	O
+of	O
+antiviral	B-CHED
+and	O
+anti	O
+-	O
+inflammatory	O
+treatment	O
+strategies	O
+were	O
+explored	O
+during	O
+the	O
+epidemic	O
+,	O
+with	O
+varying	O
+success	O
+.	O
+
+In	O
+patients	O
+who	O
+died	B-PROC
+at	O
+a	O
+Swedish	O
+University	O
+Hospital	O
+,	O
+we	O
+did	O
+not	O
+find	O
+a	O
+single	O
+case	O
+in	O
+which	O
+it	O
+was	O
+regarded	O
+as	O
+unethical	O
+not	O
+to	O
+start	O
+CPR	B-ENZY
+.	O
+
+The	O
+patient	O
+group	O
+studied	O
+here	O
+had	O
+a	O
+poor	O
+prognosis	O
+due	O
+to	O
+a	O
+severe	O
+deterioration	O
+in	O
+their	O
+condition	B-DISO
+.	O
+
+RESULTS	O
+:	O
+Among	O
+674	O
+patients	O
+,	O
+71	O
+%	O
+suffered	B-DISO
+respiratory	B-DISO
+insufficiency	I-DISO
+,	O
+43	O
+%	O
+were	O
+unconscious	O
+and	O
+32	O
+%	O
+had	O
+congestive	B-DISO
+heart	I-DISO
+failure	I-DISO
+during	O
+the	O
+24h	O
+before	O
+death	B-PROC
+.	O
+
+Pathological	O
+studies	O
+were	O
+undertaken	O
+in	O
+10	O
+patients	O
+and	O
+thrombotic	B-DISO
+microangiopathy	I-DISO
+was	O
+present	O
+in	O
+seven	O
+.	O
+
+RESULTS	O
+:	O
+Pulmonary	B-DISO
+involvement	I-DISO
+was	O
+reported	O
+in	O
+150	O
+of	O
+220	O
+patients	O
+with	O
+catastrophic	O
+APS	B-DISO
+(	O
+68	O
+%)	O
+and	O
+47	O
+patients	O
+(	O
+21	O
+%)	O
+were	O
+diagnosed	O
+as	O
+having	O
+ARDS	B-DISO
+.	O
+
+ABSTRACT	O
+:	O
+Human	B-SPEC
+coronavirus	I-SPEC
+(	O
+HCoV	O
+)	O
+229E	O
+is	O
+a	O
+group	O
+1	O
+coronavirus	B-SPEC
+and	O
+is	O
+specific	O
+to	O
+humans	B-SPEC
+.	O
+
+We	O
+have	O
+previously	O
+shown	O
+that	O
+mutants	O
+of	O
+A59	O
+,	O
+unable	O
+to	O
+induce	O
+hepatitis	B-DISO
+,	O
+may	O
+be	O
+selected	O
+by	O
+persistent	B-DISO
+infection	I-DISO
+of	O
+primary	O
+glial	B-ANAT
+cells	I-ANAT
+in	O
+vitro	O
+.	O
+
+Our	O
+results	O
+provide	O
+compelling	O
+evidence	O
+of	O
+the	O
+ability	O
+of	O
+coronaviruses	O
+to	O
+rapidly	O
+evolve	O
+in	O
+vivo	O
+to	O
+highly	O
+virulent	O
+phenotypes	O
+by	O
+functional	O
+compensation	B-PROC
+of	O
+a	O
+detrimental	O
+amino	B-CHED
+acid	I-CHED
+substitution	O
+in	O
+the	O
+receptor	B-FUNC
+binding	I-FUNC
+domain	O
+of	O
+the	O
+spike	O
+glycoprotein	B-CHED
+.	O
+
+The	O
+gene	B-PROC
+expression	I-PROC
+profiles	O
+of	O
+macrophages	B-ANAT
+infected	O
+with	O
+SARS	B-DISO
+-	O
+CoV	O
+,	O
+human	B-SPEC
+coronavirus	I-SPEC
+229E	I-SPEC
+,	O
+and	O
+influenza	B-PATH
+A	I-PATH
+(	O
+H1N1	O
+)	O
+virus	B-SPEC
+were	O
+compared	O
+by	O
+using	O
+microarrays	O
+and	O
+real	O
+-	O
+time	O
+quantitative	O
+reverse	B-PRGE
+transcriptase	I-PRGE
+PCR	O
+.	O
+
+These	O
+antipeptide	O
+antibodies	B-COMP
+can	O
+be	O
+useful	O
+for	O
+the	O
+diagnosis	O
+of	O
+SARS	B-DISO
+at	O
+the	O
+tissue	B-ANAT
+level	O
+.	O
+
+TITLE	O
+:	O
+[	O
+The	O
+effects	O
+of	O
+4	O
+laboratory	O
+test	O
+kits	O
+in	O
+early	O
+detecting	O
+of	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+coronavirus	B-SPEC
+].	O
+
+Other	O
+than	O
+F	O
+-	O
+PCR	O
+,	O
+N	O
+protein	B-CHED
+had	O
+good	O
+effect	O
+in	O
+the	O
+early	O
+detection	O
+on	O
+dubious	O
+patients	O
+which	O
+could	O
+lead	O
+to	O
+effective	O
+prevention	O
+and	O
+control	O
+of	O
+the	O
+epidemic	O
+.	O
+
+Six	O
+different	O
+experimental	O
+situations	O
+were	O
+designed	O
+to	O
+control	O
+the	O
+status	O
+of	O
+exhaust	O
+fan	O
+in	O
+bathrooms	O
+,	O
+exhaust	O
+fan	O
+in	O
+the	O
+top	O
+of	O
+building	O
+and	O
+fresh	B-ANAT
+air	B-CHED
+exchange	O
+system	O
+.	O
+
+TITLE	O
+:	O
+[	O
+Surveillance	O
+on	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+associated	O
+coronavirus	B-SPEC
+in	O
+animals	B-SPEC
+at	O
+a	O
+live	O
+animal	O
+market	O
+of	O
+Guangzhou	O
+in	O
+2004	O
+].	O
+
+ABSTRACT	O
+:	O
+To	O
+study	O
+the	O
+prevalence	O
+of	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+coronavirus	B-SPEC
+(	O
+SARS	B-DISO
+-	O
+CoV	O
+)	O
+like	O
+virus	B-SPEC
+in	O
+animals	B-SPEC
+at	O
+a	O
+live	O
+animal	B-SPEC
+market	O
+of	O
+Guanzhou	O
+in	O
+2004	O
+before	O
+and	O
+after	O
+culling	O
+of	O
+wild	O
+animal	B-SPEC
+action	O
+taken	O
+by	O
+the	O
+local	O
+authority	O
+,	O
+in	O
+order	B-SPEC
+to	O
+predict	O
+the	O
+re	O
+-	O
+emerging	O
+of	O
+SARS	B-DISO
+from	O
+animal	B-SPEC
+originals	O
+in	O
+this	O
+region	O
+.	O
+
+Animals	B-SPEC
+at	O
+live	O
+animal	B-SPEC
+market	O
+were	O
+sampled	O
+for	O
+rectal	O
+and	O
+throat	B-ANAT
+swabs	O
+in	O
+triplicate	O
+.	O
+
+A	O
+single	O
+step	O
+realtime	O
+reverse	B-PROC
+transcription	I-PROC
+-	O
+polymerase	O
+chain	O
+reaction	O
+(	O
+RT	O
+-	O
+PCR	O
+)	O
+diagnostic	O
+kit	B-FUNC
+was	O
+performed	O
+for	O
+screening	O
+SARS	B-DISO
+-	O
+CoV	O
+like	O
+virus	B-SPEC
+,	O
+the	O
+manual	O
+nested	O
+RT	O
+-	O
+PCR	O
+and	O
+DNA	O
+sequencing	O
+were	O
+performed	O
+for	O
+confirmation	O
+.	O
+
+In	O
+31	O
+animals	B-SPEC
+sampled	O
+in	O
+January	O
+5	O
+2004	O
+before	O
+culling	O
+of	O
+wild	O
+animals	B-SPEC
+at	O
+Guangdong	O
+Province	O
+,	O
+including	O
+20	O
+cats	B-SPEC
+(	O
+Felis	B-SPEC
+catus	I-SPEC
+),	O
+5	O
+red	B-SPEC
+fox	I-SPEC
+(	O
+Vulpes	B-SPEC
+vulpes	I-SPEC
+)	O
+and	O
+6	O
+Lesser	O
+rice	B-SPEC
+field	O
+rats	B-SPEC
+(	O
+Rattus	B-SPEC
+losea	I-SPEC
+),	O
+8	O
+(	O
+25	O
+.	O
+8	O
+%)	O
+animals	B-SPEC
+were	O
+tested	O
+positive	O
+for	O
+SARS	B-PRGE
+-	I-PRGE
+CoV	I-PRGE
+like	I-PRGE
+virus	B-SPEC
+by	O
+RT	O
+-	O
+PCR	O
+methods	O
+,	O
+of	O
+which	O
+4	O
+cats	B-SPEC
+,	O
+3	O
+red	B-SPEC
+fox	I-SPEC
+and	O
+one	O
+Lesser	O
+rice	B-SPEC
+field	O
+rats	B-SPEC
+were	O
+included	O
+.	O
+
+CONCLUSIONS	O
+:	O
+This	O
+findings	O
+revealed	O
+that	O
+animals	B-SPEC
+being	O
+sampled	O
+in	O
+April	O
+,	O
+May	O
+,	O
+June	O
+,	O
+July	O
+,	O
+August	O
+and	O
+November	O
+of	O
+2004	O
+,	O
+only	O
+one	O
+rectal	B-ANAT
+swab	I-ANAT
+from	O
+a	O
+pig	B-SPEC
+was	O
+tested	O
+positive	O
+as	O
+SARS	B-PRGE
+-	I-PRGE
+CoV	I-PRGE
+like	I-PRGE
+virus	B-SPEC
+,	O
+much	O
+lower	O
+than	O
+the	O
+results	O
+from	O
+the	O
+previous	O
+year	O
+,	O
+suggesting	O
+that	O
+the	O
+possibility	O
+of	O
+re	O
+-	O
+emerging	O
+of	O
+human	B-SPEC
+infection	B-DISO
+from	O
+animal	B-SPEC
+origins	O
+is	O
+low	O
+for	O
+the	O
+winter	O
+of	O
+2004	O
+-	O
+2005	O
+.	O
+
+However	O
+,	O
+only	O
+limited	O
+data	O
+were	O
+available	O
+to	O
+demonstrate	O
+their	O
+efficacy	O
+against	O
+SARS	B-DISO
+coronavirus	B-SPEC
+(	O
+SARS	B-DISO
+-	O
+CoV	O
+).	O
+
+In	O
+summary	O
+,	O
+SARS	B-DISO
+-	O
+CoV	O
+can	O
+be	O
+inactivated	O
+quite	O
+easily	O
+with	O
+many	O
+commonly	O
+used	O
+disinfectants	B-CHED
+.	O
+
+Withdrawal	B-DISO
+of	O
+FP	O
+in	O
+COPD	B-DISO
+patients	O
+using	O
+SFC	O
+resulted	O
+in	O
+acute	O
+and	O
+persistent	O
+deterioration	O
+in	O
+lung	B-PROC
+function	I-PROC
+and	O
+dyspnoea	B-DISO
+and	O
+in	O
+an	O
+increase	O
+in	O
+mild	O
+exacerbations	O
+and	O
+percentage	O
+of	O
+disturbed	O
+nights	O
+.	O
+
+TITLE	O
+:	O
+The	O
+SARS	B-DISO
+epidemic	O
+in	O
+Hong	O
+Kong	O
+--	O
+a	O
+human	B-SPEC
+calamity	O
+in	O
+the	O
+21st	O
+century	O
+.	O
+
+The	O
+second	O
+phase	O
+in	O
+April	O
+was	O
+the	O
+spread	O
+of	O
+the	O
+infection	B-DISO
+from	O
+the	O
+hospital	O
+to	O
+the	O
+community	O
+.	O
+
+TITLE	O
+:	O
+Reducing	O
+the	O
+impact	O
+of	O
+viral	O
+respiratory	B-DISO
+infections	I-DISO
+in	O
+children	O
+.	O
+
+Serum	B-COMP
+neopterin	B-CHED
+may	O
+allow	O
+early	O
+assessment	O
+of	O
+the	O
+severity	O
+of	O
+SARS	B-DISO
+.	O
+
+From	O
+this	O
+research	O
+,	O
+we	O
+determined	O
+that	O
+nursing	B-PROC
+staff	O
+members	O
+were	O
+anxious	O
+,	O
+depressed	O
+,	O
+and	O
+they	O
+could	O
+not	O
+sleep	B-PROC
+well	O
+at	O
+the	O
+SARS	B-DISO
+outbreak	O
+.	O
+
+However	O
+,	O
+the	O
+systematic	O
+SARS	B-DISO
+prevention	O
+program	O
+improved	O
+these	O
+factors	O
+.	O
+
+TITLE	O
+:	O
+Monitoring	O
+of	O
+right	O
+-	O
+sided	O
+heart	B-PROC
+function	I-PROC
+.	O
+
+TITLE	O
+:	O
+New	O
+and	O
+emerging	B-DISO
+infectious	I-DISO
+diseases	I-DISO
+.	O
+
+The	O
+normal	O
+follicular	B-ANAT
+epithelial	B-ANAT
+cells	I-ANAT
+were	O
+strongly	O
+TG	O
+positive	O
+,	O
+however	O
+,	O
+the	O
+number	O
+and	O
+intensity	O
+of	O
+TG	O
+positive	O
+follicular	B-ANAT
+epithelial	B-ANAT
+cells	I-ANAT
+were	O
+significantly	O
+lower	O
+in	O
+the	O
+SARS	B-DISO
+patients	O
+.	O
+
+TITLE	O
+:	O
+Clinical	O
+,	O
+virologic	O
+and	O
+immunologic	O
+profiles	O
+of	O
+a	O
+young	O
+infant	O
+with	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+.	O
+
+Ribavirin	B-CHED
+failed	O
+to	O
+inhibit	O
+SARS	B-DISO
+coronavirus	B-SPEC
+(	O
+SARS	B-DISO
+-	O
+CoV	O
+)	O
+replication	O
+.	O
+
+ABSTRACT	O
+:	O
+3C	B-PRGE
+-	I-PRGE
+like	I-PRGE
+proteinase	I-PRGE
+of	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+(	O
+SARS	B-DISO
+)	O
+coronavirus	B-SPEC
+has	O
+been	O
+demonstrated	O
+to	O
+be	O
+a	O
+key	O
+target	O
+for	O
+drug	O
+design	O
+against	O
+SARS	B-DISO
+.	O
+
+TITLE	O
+:	O
+The	O
+effects	O
+of	O
+disease	O
+severity	O
+,	O
+use	O
+of	O
+corticosteroids	B-CHED
+and	O
+social	O
+factors	O
+on	O
+neuropsychiatric	O
+complaints	O
+in	O
+severe	O
+acute	O
+respiratory	O
+syndrome	O
+(	O
+SARS	B-DISO
+)	O
+patients	O
+at	O
+acute	O
+and	O
+convalescent	O
+phases	O
+.	O
+
+Severe	O
+disease	O
+,	O
+high	O
+dose	O
+corticosteroids	B-CHED
+and	O
+being	O
+health	O
+care	O
+workers	O
+were	O
+independent	O
+predictors	O
+of	O
+neuropsychiatric	O
+complaints	O
+in	O
+both	O
+acute	O
+and	O
+convalescent	O
+phases	O
+.	O
+
+Severity	O
+of	O
+symptoms	O
+,	O
+corticosteroids	B-CHED
+and	O
+social	O
+factors	O
+explained	O
+about	O
+half	O
+of	O
+the	O
+variances	O
+(	O
+R	O
+(	O
+2	O
+)	O
+=	O
+52	O
+)	O
+in	O
+anxiety	O
+-	O
+depression	B-DISO
+at	O
+acute	O
+phase	O
+and	O
+33	O
+%	O
+at	O
+convalescent	O
+phase	O
+.	O
+
+Although	O
+coagulation	B-PROC
+abnormalities	O
+are	O
+common	O
+in	O
+these	O
+patients	O
+,	O
+clinically	O
+overt	O
+thromboembolic	B-DISO
+events	I-DISO
+are	O
+rarely	O
+reported	O
+.	O
+
+The	O
+virally	O
+encoded	O
+3C	B-PRGE
+-	I-PRGE
+like	I-PRGE
+protease	I-PRGE
+(	O
+3CL	O
+(	O
+Pro	B-PRGE
+))	O
+has	O
+been	O
+presumed	O
+critical	O
+for	O
+the	O
+viral	B-PROC
+replication	I-PROC
+of	O
+SARS	B-DISO
+-	O
+CoV	O
+in	O
+infected	O
+host	B-COMP
+cells	B-COMP
+.	O
+
+This	O
+study	O
+has	O
+resulted	O
+in	O
+the	O
+identification	O
+of	O
+new	O
+compounds	O
+that	O
+are	O
+effective	O
+3CL	O
+(	O
+Pro	B-CHED
+)	O
+inhibitors	B-CHED
+.	O
+
+Nevertheless	O
+,	O
+identification	O
+of	O
+new	O
+5	O
+'-	O
+untranslated	O
+exon	O
+and	O
+new	O
+SNPs	O
+is	O
+considered	O
+helpful	O
+in	O
+investigating	O
+regulation	B-PROC
+of	O
+ACE2	B-PRGE
+gene	I-PRGE
+expression	O
+in	O
+the	O
+future	O
+.	O
+
+ABSTRACT	O
+:	O
+The	O
+study	O
+was	O
+undertaken	O
+to	O
+study	O
+the	O
+frequency	O
+,	O
+causes	O
+,	O
+and	O
+efficiency	O
+of	O
+treatment	O
+for	O
+acute	O
+renal	O
+failure	O
+(	O
+ARF	B-DISO
+)	O
+at	O
+the	O
+intensive	O
+nephrological	O
+care	O
+unit	O
+.	O
+
+TITLE	O
+:	O
+[	O
+The	O
+assessment	O
+of	O
+severity	O
+of	O
+lung	B-ANAT
+injury	O
+in	O
+sepsis	B-DISO
+].	O
+
+The	O
+study	O
+was	O
+aimed	O
+at	O
+the	O
+assessment	O
+of	O
+the	O
+severity	O
+of	O
+the	O
+lung	B-ANAT
+injury	O
+in	O
+patients	O
+who	O
+had	O
+suffered	B-DISO
+from	O
+sepsis	B-DISO
+of	O
+the	O
+gynecological	O
+origin	O
+and	O
+its	O
+influence	O
+on	O
+the	O
+outcome	O
+of	O
+the	O
+disease	O
+.	O
+
+The	O
+obtained	O
+results	O
+indicate	O
+that	O
+high	O
+values	O
+of	O
+the	O
+lung	B-ANAT
+injury	O
+score	O
+are	O
+suggestive	O
+of	O
+the	O
+severe	O
+respiratory	B-DISO
+dysfunction	I-DISO
+as	O
+well	O
+as	O
+that	O
+lethal	O
+outcome	O
+is	O
+dependent	O
+on	O
+LIS	B-FUNC
+value	O
+.	O
+
+TRALI	B-DISO
+is	O
+characterized	O
+by	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+and	O
+non	O
+-	O
+cardiogenic	O
+lung	B-DISO
+oedema	I-DISO
+developing	O
+during	O
+,	O
+or	O
+within	O
+6	O
+h	O
+of	O
+,	O
+transfusion	O
+.	O
+
+TRALI	B-DISO
+must	O
+be	O
+carefully	O
+differentiated	B-PROC
+from	O
+transfusion	O
+-	O
+associated	O
+circulatory	B-PROC
+overload	O
+.	O
+
+TITLE	O
+:	O
+Serum	B-ANAT
+C	O
+-	O
+reactive	O
+protein	B-CHED
+elevation	O
+predicts	O
+poor	O
+clinical	O
+outcome	O
+in	O
+patients	O
+with	O
+distal	O
+type	O
+acute	O
+aortic	O
+dissection	O
+:	O
+association	O
+with	O
+the	O
+occurrence	O
+of	O
+oxygenation	B-PROC
+impairment	B-DISO
+.	O
+
+ABSTRACT	O
+:	O
+Acute	B-DISO
+aortic	I-DISO
+dissection	I-DISO
+(	O
+AAD	B-CHED
+)	O
+is	O
+sometimes	O
+complicated	O
+by	O
+respiratory	B-DISO
+failure	I-DISO
+due	O
+to	O
+severe	O
+lung	B-ANAT
+oxygenation	B-PROC
+impairment	B-DISO
+.	O
+
+The	O
+aim	O
+of	O
+this	O
+study	O
+was	O
+to	O
+determine	O
+the	O
+significance	O
+of	O
+serum	B-PRGE
+C	I-PRGE
+-	I-PRGE
+reactive	I-PRGE
+protein	B-CHED
+(	O
+CRP	B-PRGE
+)	O
+elevation	O
+in	O
+the	O
+development	B-PROC
+of	O
+oxygenation	B-PROC
+impairment	B-DISO
+and	O
+clinical	O
+outcome	O
+with	O
+distal	O
+type	O
+AAD	B-CHED
+.	O
+
+The	O
+greater	O
+serum	B-COMP
+CRP	B-PRGE
+elevation	O
+after	O
+distal	O
+type	O
+AAD	B-CHED
+was	O
+associated	O
+with	O
+a	O
+higher	O
+incidence	O
+of	O
+oxygenation	B-PROC
+impairment	B-DISO
+and	O
+poor	O
+clinical	O
+outcome	O
+.	O
+
+In	O
+this	O
+study	O
+we	O
+evaluated	O
+the	O
+manufacturing	O
+process	O
+of	O
+an	O
+immunoglobulin	B-PROC
+preparation	O
+(	O
+OCTAGAM	O
+,	O
+manufactured	O
+by	O
+Octapharma	O
+Pharmazeutika	O
+Produktionsges	O
+.	O
+m	O
+.	O
+b	O
+.	O
+
+These	O
+purified	O
+proteins	B-CHED
+have	O
+been	O
+used	O
+to	O
+generate	O
+highly	O
+specific	O
+polyclonal	O
+antibodies	B-COMP
+.	O
+
+Our	O
+study	O
+suggests	O
+that	O
+the	O
+SUMO	B-PRGE
+-	I-PRGE
+fusion	I-PRGE
+technology	O
+will	O
+be	O
+useful	O
+for	O
+enhancing	O
+expression	B-PROC
+and	O
+purification	O
+of	O
+the	O
+viral	O
+proteins	B-CHED
+for	O
+structural	O
+and	O
+functional	O
+studies	O
+as	O
+well	O
+as	O
+for	O
+therapeutic	O
+uses	O
+.	O
+
+The	O
+B1	O
+also	O
+has	O
+potent	O
+neutralizing	O
+activities	O
+against	O
+infection	B-DISO
+by	O
+pseudovirus	O
+expressing	O
+SARS	B-PRGE
+-	I-PRGE
+CoV	I-PRGE
+S	I-PRGE
+protein	B-CHED
+in	O
+vitro	O
+.	O
+
+Pilot	O
+study	O
+revealed	O
+that	O
+the	O
+fitness	O
+existed	O
+in	O
+modeling	O
+the	O
+outbreak	O
+of	O
+SARS	O
+in	O
+Beijing	O
+and	O
+the	O
+intervention	O
+measures	O
+implemented	O
+around	O
+April	O
+20	O
+,	O
+2003	O
+,	O
+had	O
+major	O
+contribution	O
+to	O
+the	O
+control	O
+of	O
+SARS	B-DISO
+.	O
+
+The	O
+model	O
+of	O
+SARS	B-DISO
+epidemics	O
+seemed	O
+to	O
+be	O
+stable	O
+and	O
+reliable	O
+to	O
+be	O
+used	O
+to	O
+evaluate	O
+the	O
+effectiveness	O
+of	O
+intervention	O
+measures	O
+implemented	O
+during	O
+the	O
+SARS	B-DISO
+outbreak	O
+in	O
+a	O
+quantitative	O
+way	O
+.	O
+
+CONCLUSIONS	O
+:	O
+The	O
+model	O
+of	O
+SARS	B-DISO
+epidemics	O
+seemed	O
+to	O
+be	O
+stable	O
+and	O
+reliable	O
+to	O
+be	O
+used	O
+to	O
+evaluate	O
+the	O
+effectiveness	O
+of	O
+intervention	O
+measures	O
+implemented	O
+during	O
+the	O
+SARS	B-DISO
+outbreak	O
+in	O
+a	O
+quantitative	O
+way	O
+.	O
+
+RESULTS	O
+:	O
+(	O
+1	O
+)	O
+The	O
+mean	O
+duration	O
+between	O
+disease	O
+onset	O
+and	O
+hospital	O
+admission	O
+,	O
+rate	O
+of	O
+contacts	O
+of	O
+each	O
+infectious	B-DISO
+individual	O
+as	O
+well	O
+as	O
+the	O
+rate	O
+of	O
+contacts	O
+in	O
+hospital	O
+of	O
+each	O
+infectious	B-DISO
+individual	O
+appeared	O
+to	O
+be	O
+the	O
+key	O
+variables	O
+in	O
+the	O
+process	O
+of	O
+SARS	B-DISO
+transmission	O
+.	O
+
+(	O
+3	O
+)	O
+""""	O
+Screening	O
+for	O
+fever	B-PROC
+""""	O
+practice	O
+on	O
+each	O
+patient	O
+at	O
+the	O
+entrance	O
+of	O
+the	O
+hospital	O
+did	O
+not	O
+seem	O
+to	O
+act	O
+as	O
+an	O
+important	O
+factor	O
+to	O
+the	O
+control	O
+of	O
+the	O
+epidemics	O
+.	O
+
+IgG	B-COMP
+antibody	B-PROC
+against	O
+coronavirus	B-SPEC
+was	O
+detected	O
+by	O
+ELISA	O
+in	O
+the	O
+blood	B-ANAT
+of	O
+311	O
+convalescent	O
+SARS	B-DISO
+patients	O
+for	O
+every	O
+2	O
+-	O
+4	O
+weeks	O
+.	O
+
+The	O
+identification	O
+of	O
+antibodies	B-COMP
+was	O
+performed	O
+using	O
+indirect	O
+enzyme	O
+-	O
+linked	O
+immunosorbent	O
+assay	O
+(	O
+ELISA	O
+),	O
+indirect	O
+fluorescent	O
+-	O
+antibody	B-COMP
+assay	O
+(	O
+IFA	O
+),	O
+and	O
+Western	O
+immunoblotting	O
+.	O
+
+CONCLUSIONS	O
+:	O
+Specific	O
+and	O
+high	O
+affinity	O
+mAbs	O
+and	O
+rabbit	B-SPEC
+polyclonal	O
+antibodies	B-COMP
+were	O
+obtained	O
+.	O
+
+TITLE	O
+:	O
+Expression	B-PROC
+of	O
+feline	B-SPEC
+interferon	B-PRGE
+-	I-PRGE
+alpha	I-PRGE
+subtypes	O
+in	O
+Esherichia	O
+coli	O
+,	O
+and	O
+their	O
+antiviral	B-CHED
+activity	O
+and	O
+animal	O
+species	B-SPEC
+specificity	O
+.	O
+
+To	O
+address	O
+the	O
+significance	O
+of	O
+the	O
+immunosuppression	B-PROC
+associated	O
+with	O
+lung	B-ANAT
+contusion	O
+,	O
+we	O
+investigated	O
+how	O
+the	O
+consecutive	O
+addition	O
+of	O
+moderate	O
+or	O
+severe	B-DISO
+sepsis	I-DISO
+affected	O
+survival	O
+after	O
+blunt	O
+chest	B-ANAT
+trauma	O
+.	O
+
+Sepsis	B-DISO
+was	O
+induced	O
+via	O
+cecal	B-ANAT
+ligation	O
+and	O
+puncture	O
+24	O
+hrs	B-DISO
+after	O
+lung	B-ANAT
+contusion	O
+.	O
+
+These	O
+results	O
+indicate	O
+that	O
+pulmonary	B-ANAT
+contusion	O
+causes	O
+severe	O
+immunodysfunction	O
+of	O
+splenocytes	O
+,	O
+macrophages	B-ANAT
+,	O
+and	O
+monocytes	B-ANAT
+in	O
+different	O
+local	O
+compartments	B-ANAT
+and	O
+systemically	O
+.	O
+
+Eight	O
+species	B-SPEC
+of	O
+Bacillus	B-SPEC
+,	O
+including	O
+five	O
+new	O
+species	B-SPEC
+,	O
+and	O
+one	O
+new	O
+species	B-SPEC
+of	O
+Kurthia	B-SPEC
+were	O
+isolated	O
+from	O
+the	O
+cigarettes	O
+.	O
+
+Some	O
+of	O
+these	O
+species	B-SPEC
+have	O
+been	O
+identified	O
+elsewhere	O
+as	O
+causes	O
+of	O
+hypersensitivity	B-DISO
+pneumonitis	I-DISO
+and	O
+other	O
+respiratory	O
+syndromes	B-DISO
+.	O
+
+D	O
+(	O
+LCO	B-CHED
+)	O
+improved	O
+in	O
+80	O
+.	O
+4	O
+%	O
+of	O
+patients	O
+(	O
+41	O
+of	O
+51	O
+patients	O
+).	O
+
+In	O
+mounting	O
+large	O
+-	O
+scale	O
+quarantine	O
+operations	O
+,	O
+a	O
+framework	O
+for	O
+contact	O
+tracing	O
+,	O
+serving	O
+quarantine	O
+orders	O
+,	O
+surveillance	O
+,	O
+enforcement	O
+,	O
+health	O
+education	O
+,	O
+transport	B-PROC
+,	O
+and	O
+financial	O
+support	O
+was	O
+developed	O
+and	O
+urgently	O
+put	O
+in	O
+place	O
+.	O
+
+Three	O
+examples	O
+--	O
+the	O
+Manhattan	O
+Project	O
+,	O
+mapping	O
+the	O
+human	B-SPEC
+genome	O
+,	O
+and	O
+rapidly	O
+understanding	O
+the	O
+nature	O
+of	O
+the	O
+SARS	B-DISO
+virus	B-SPEC
+--	O
+are	O
+analyzed	O
+,	O
+showing	O
+a	O
+trend	O
+away	O
+from	O
+the	O
+individual	O
+scientist	O
+to	O
+a	O
+model	O
+based	O
+on	O
+simultaneous	O
+competition	O
+and	O
+collaboration	O
+.	O
+
+CONCLUSIONS	O
+:	O
+The	O
+N	B-PRGE
+protein	I-PRGE
+and	O
+S1	B-PRGE
+protein	I-PRGE
+may	O
+be	O
+used	O
+as	O
+antigens	B-CHED
+in	O
+the	O
+development	B-PROC
+of	O
+serological	O
+assay	O
+for	O
+detection	O
+of	O
+SARS	B-DISO
+-	I-DISO
+CoV	I-DISO
+infection	I-DISO
+.	O
+
+ABSTRACT	O
+:	O
+To	O
+establish	O
+a	O
+new	O
+technique	O
+for	O
+SARS	B-DISO
+-	O
+CoV	O
+antibody	B-COMP
+test	O
+to	O
+detect	O
+infection	B-DISO
+of	O
+severer	O
+acute	O
+respiratory	O
+syndrome	B-DISO
+(	O
+SARS	B-DISO
+).	O
+
+7	O
+samples	O
+of	O
+sera	B-COMP
+from	O
+4	O
+SARS	B-DISO
+patients	O
+in	O
+acute	O
+progressive	O
+stage	O
+in	O
+Guangdong	O
+province	O
+were	O
+all	O
+IFA	O
+positive	O
+.	O
+
+The	O
+binding	B-FUNC
+mode	O
+was	O
+competitive	O
+,	O
+and	O
+the	O
+inhibitory	O
+effect	O
+was	O
+dependent	O
+on	O
+preincubation	O
+time	O
+.	O
+
+The	O
+tissue	B-PROC
+tropism	B-PROC
+of	O
+SARS	B-PRGE
+-	I-PRGE
+CoV	I-PRGE
+includes	O
+not	O
+only	O
+the	O
+lung	B-ANAT
+,	O
+but	O
+also	O
+the	O
+gastrointestinal	B-ANAT
+tract	I-ANAT
+,	O
+kidney	B-ANAT
+and	O
+liver	B-ANAT
+.	O
+
+ABSTRACT	O
+:	O
+At	O
+the	O
+end	O
+of	O
+2002	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+(	O
+SARS	B-DISO
+)	O
+emerged	O
+and	O
+spread	O
+worldwide	O
+.	O
+
+This	O
+article	O
+examines	O
+the	O
+ethical	O
+aspects	O
+of	O
+the	O
+process	O
+undertaken	O
+to	O
+cope	O
+with	O
+SARS	B-DISO
+in	O
+our	O
+medical	O
+centre	O
+.	O
+
+Recent	O
+studies	O
+indicate	O
+that	O
+SARS	B-DISO
+-	O
+coronavirus	B-SPEC
+(	O
+CoV	O
+)	O
+spike	B-PRGE
+protein	I-PRGE
+(	O
+S	B-PRGE
+protein	I-PRGE
+)	O
+and	O
+its	O
+truncated	O
+fragments	O
+are	O
+considered	O
+the	O
+best	O
+candidates	O
+for	O
+generation	O
+of	O
+the	O
+recombinant	O
+vaccine	O
+.	O
+
+Mice	B-SPEC
+showed	O
+significantly	O
+increased	O
+levels	O
+of	O
+SARS	B-PRGE
+-	I-PRGE
+CoV	I-PRGE
+-	I-PRGE
+specific	I-PRGE
+IgA	I-PRGE
+after	O
+oral	B-ANAT
+ingestion	O
+of	O
+tomato	B-SPEC
+fruits	O
+expressing	O
+S1	B-PRGE
+protein	I-PRGE
+.	O
+
+We	O
+produced	O
+a	O
+series	O
+of	O
+recombinant	O
+viruses	B-SPEC
+,	O
+with	O
+an	O
+isogenic	O
+background	O
+,	O
+in	O
+which	O
+complete	O
+expression	O
+of	O
+gene	O
+5	O
+products	O
+was	O
+prevented	O
+by	O
+the	O
+inactivation	B-DISO
+of	O
+gene	O
+5	O
+following	O
+scrambling	O
+of	O
+the	O
+transcription	B-PROC
+-	O
+associated	O
+sequence	O
+,	O
+thereby	O
+preventing	O
+the	O
+expression	B-PROC
+of	O
+IBV	B-SPEC
+subgenomic	O
+mRNA	B-CHED
+5	O
+,	O
+or	O
+scrambling	O
+either	O
+separately	O
+or	O
+together	O
+of	O
+the	O
+translation	B-PROC
+initiation	I-PROC
+codons	O
+for	O
+the	O
+two	O
+gene	O
+5	O
+products	O
+.	O
+
+This	O
+is	O
+the	O
+first	O
+systematic	O
+study	O
+investigating	O
+hospital	O
+nurses	O
+'	O
+physical	O
+and	O
+psychological	B-DISO
+health	O
+status	O
+and	O
+the	O
+kinds	O
+of	O
+healthcare	O
+used	O
+-	O
+stratified	O
+by	O
+the	O
+level	O
+of	O
+contact	O
+with	O
+SARS	B-DISO
+patients	O
+-	O
+during	O
+the	O
+2003	O
+outbreak	O
+in	O
+Hong	O
+Kong	O
+.	O
+
+Nurses	O
+in	O
+moderate	O
+-	O
+risk	O
+areas	O
+appeared	O
+to	O
+have	O
+more	O
+stress	B-DISO
+symptoms	I-DISO
+than	O
+those	O
+working	O
+in	O
+high	O
+-	O
+risk	O
+areas	O
+.	O
+
+It	O
+is	O
+essential	O
+to	O
+design	O
+hospital	O
+support	O
+systems	O
+and	O
+occupational	O
+health	O
+policy	O
+to	O
+promote	O
+the	O
+psychological	B-DISO
+well	O
+-	O
+being	O
+of	O
+nurses	O
+during	O
+future	O
+outbreaks	O
+of	O
+emerging	O
+infections	B-DISO
+.	O
+
+Initial	O
+clinical	O
+symptoms	O
+were	O
+respiratory	B-DISO
+acidosis	I-DISO
+,	O
+dypnea	O
+,	O
+intense	O
+wheezing	B-DISO
+,	O
+and	O
+deterioration	O
+of	O
+the	O
+level	O
+of	O
+consciousness	O
+,	O
+which	O
+required	O
+orotracheal	O
+intubation	O
+and	O
+mechanical	O
+ventilation	O
+.	O
+
+We	O
+administered	O
+neuromuscular	O
+blocking	B-DISO
+agents	O
+,	O
+corticosteroids	B-CHED
+,	O
+and	O
+antibiotics	B-CHED
+.	O
+
+The	O
+development	B-PROC
+of	O
+rapid	O
+screening	O
+assays	O
+is	O
+essential	O
+for	O
+antiviral	B-CHED
+drug	I-CHED
+discovery	O
+.	O
+
+Cell	B-ANAT
+lines	I-ANAT
+were	O
+engineered	O
+to	O
+constitutively	O
+express	O
+an	O
+enhanced	B-PRGE
+green	I-PRGE
+fluorescent	I-PRGE
+protein	I-PRGE
+(	O
+EGFP	O
+)	O
+and	O
+used	O
+to	O
+detect	O
+(	O
+1	O
+)	O
+antiviral	B-CHED
+potency	O
+in	O
+SARS	B-DISO
+-	I-DISO
+CoV	I-DISO
+infection	I-DISO
+tests	O
+;	O
+(	O
+2	O
+)	O
+antiviral	B-CHED
+specificity	O
+in	O
+tests	O
+using	O
+the	O
+porcine	B-SPEC
+coronavirus	B-SPEC
+transmissible	O
+gastroenteritis	B-DISO
+virus	B-SPEC
+(	O
+TGEV	B-SPEC
+);	O
+and	O
+(	O
+3	O
+)	O
+cytotoxicity	B-DISO
+in	O
+the	O
+same	O
+assays	O
+without	O
+virus	B-SPEC
+challenge	O
+.	O
+
+The	O
+assay	O
+system	O
+involves	O
+minimal	O
+manipulation	O
+after	O
+assay	O
+set	O
+-	O
+up	O
+,	O
+facilitates	O
+automated	O
+read	O
+-	O
+out	O
+and	O
+minimizes	O
+risks	O
+associated	O
+with	O
+hazardous	O
+viruses	B-SPEC
+.	O
+
+The	O
+results	O
+show	O
+that	O
+these	O
+assays	O
+can	O
+be	O
+applied	O
+to	O
+high	O
+-	O
+throughput	O
+screening	O
+for	O
+identification	O
+of	O
+inhibitors	B-CHED
+selectively	O
+active	O
+against	O
+SARS	B-PRGE
+-	I-PRGE
+CoV	I-PRGE
+.	O
+
+To	O
+study	O
+usage	O
+of	O
+personal	O
+protective	O
+equipment	O
+(	O
+PPE	B-CHED
+)	O
+among	O
+three	O
+groups	O
+of	O
+healthcare	O
+workers	O
+(	O
+HCWs	O
+:	O
+doctors	O
+,	O
+nurses	O
+,	O
+and	O
+administrative	O
+staff	O
+),	O
+to	O
+determine	O
+if	O
+the	O
+appropriate	O
+PPE	B-CHED
+were	O
+used	O
+by	O
+the	O
+different	O
+groups	O
+and	O
+to	O
+examine	O
+the	O
+factors	O
+that	O
+may	O
+determine	O
+inappropriate	O
+use	O
+.	O
+
+A	O
+total	O
+of	O
+32	O
+.	O
+5	O
+%	O
+of	O
+doctors	O
+,	O
+48	O
+.	O
+7	O
+%	O
+of	O
+nurses	O
+,	O
+and	O
+77	O
+.	O
+1	O
+%	O
+of	O
+the	O
+administrative	O
+staff	O
+agreed	O
+that	O
+paper	O
+and	O
+/	O
+or	O
+surgical	O
+masks	O
+were	O
+""""	O
+useful	O
+in	O
+protecting	O
+from	O
+contracting	O
+SARS	B-DISO
+"""."	O
+
+TITLE	O
+:	O
+Emergency	B-DISO
+management	O
+and	O
+infection	B-DISO
+control	O
+in	O
+a	O
+radiology	O
+department	O
+during	O
+an	O
+outbreak	O
+of	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+.	O
+
+Radiographers	O
+were	O
+easily	O
+infected	O
+by	O
+SARS	B-DISO
+because	O
+they	O
+had	O
+close	O
+contact	O
+with	O
+suspected	O
+or	O
+probable	O
+cases	O
+while	O
+conducting	B-PROC
+chest	B-ANAT
+X	O
+-	O
+ray	B-SPEC
+examinations	O
+.	O
+
+We	O
+report	O
+here	O
+that	O
+viral	O
+RNA	O
+from	O
+clinical	O
+samples	O
+obtained	O
+from	O
+SARS	B-DISO
+-	O
+CoV	O
+infected	O
+patients	O
+also	O
+contains	O
+a	O
+heterogeneous	O
+population	O
+of	O
+wild	O
+-	O
+type	O
+and	O
+mutant	B-DISO
+3a	O
+transcripts	O
+.	O
+
+Viroporins	O
+are	O
+a	O
+growing	O
+family	B-SPEC
+of	O
+viral	O
+proteins	B-CHED
+able	O
+to	O
+enhance	O
+membrane	B-PROC
+permeability	I-PROC
+,	O
+promoting	O
+virus	B-SPEC
+budding	B-PATH
+.	O
+
+We	O
+also	O
+used	O
+cell	B-COMP
+culture	O
+,	O
+RT	O
+-	O
+PCR	O
+and	O
+gene	O
+sequencing	O
+to	O
+detect	O
+and	O
+identify	O
+the	O
+viruses	B-SPEC
+from	O
+sewage	O
+.	O
+
+These	O
+findings	O
+will	O
+aid	O
+the	O
+framing	O
+of	O
+further	O
+studies	O
+of	O
+the	O
+immunopathogenesis	O
+of	O
+SARS	B-DISO
+.	O
+
+TITLE	O
+:	O
+Dynamics	O
+of	O
+virus	B-SPEC
+infections	B-DISO
+involved	O
+in	O
+the	O
+bovine	B-DISO
+respiratory	I-DISO
+disease	I-DISO
+complex	I-DISO
+in	O
+Swedish	O
+dairy	O
+herds	O
+.	O
+
+TITLE	O
+:	O
+Using	O
+DNA	O
+shuffling	O
+to	O
+create	O
+novel	O
+infectious	B-DISO
+bronchitis	B-DISO
+virus	B-SPEC
+S1	O
+genes	O
+:	O
+implications	O
+for	O
+S1	B-PRGE
+gene	I-PRGE
+recombination	B-PROC
+.	O
+
+Our	O
+data	O
+suggests	O
+that	O
+recombination	B-PROC
+between	O
+distantly	O
+related	O
+IBV	B-SPEC
+strains	O
+within	O
+the	O
+S1	B-PRGE
+gene	I-PRGE
+probably	O
+does	O
+not	O
+readily	O
+occur	O
+.	O
+
+TITLE	O
+:	O
+A	O
+Severe	B-DISO
+Acute	I-DISO
+Respiratory	I-DISO
+Syndrome	I-DISO
+Extranet	O
+:	O
+supporting	O
+local	O
+communication	O
+and	O
+information	O
+dissemination	O
+.	O
+
+No	O
+one	O
+encountered	O
+personal	O
+barriers	O
+in	O
+his	O
+or	O
+her	O
+use	O
+of	O
+the	O
+site	O
+,	O
+but	O
+several	O
+mentioned	O
+that	O
+time	O
+and	O
+duplication	B-DISO
+of	O
+email	O
+information	O
+were	O
+challenges	O
+.	O
+
+No	O
+one	O
+encountered	O
+personal	O
+barriers	O
+in	O
+his	O
+or	O
+her	O
+use	O
+of	O
+the	O
+site	O
+,	O
+but	O
+several	O
+mentioned	O
+that	O
+time	O
+and	O
+duplication	B-DISO
+of	O
+email	O
+information	O
+were	O
+challenges	O
+.	O
+
+Early	O
+(	O
+36	O
+hours	O
+)	O
+PCR	O
+studies	O
+of	O
+nasopharyngeal	B-ANAT
+washings	I-ANAT
+were	O
+negative	O
+for	O
+the	O
+coronavirus	B-SPEC
+associated	O
+with	O
+SARS	B-DISO
+.	O
+
+In	O
+this	O
+context	O
+the	O
+recognition	O
+of	O
+probably	O
+infectious	B-DISO
+asymptomatic	O
+forms	O
+is	O
+essential	O
+.	O
+
+Firefly	B-ENZY
+luciferase	I-ENZY
+expression	B-PROC
+of	O
+pGL	B-PRGE
+-	I-PRGE
+R	I-PRGE
+was	O
+reduced	O
+to	O
+13	O
+%	O
+by	O
+esiRNA	O
+-	O
+R	O
+.	O
+Expression	B-PROC
+of	O
+pGLS	O
+was	O
+reduced	O
+to	O
+11	O
+%	O
+by	O
+esiRNA	O
+-	O
+S	O
+.	O
+Expression	B-PROC
+of	O
+pGL	B-DISO
+-	O
+N	O
+was	O
+reduced	O
+to	O
+40	O
+%	O
+by	O
+esiRNA	O
+-	O
+N	O
+.	O
+Control	O
+esiRNAs	O
+didn	O
+'	O
+t	O
+affect	O
+luciferase	B-ENZY
+expression	B-PROC
+;	O
+Hybrid	O
+mRNAs	O
+'	O
+abundance	O
+was	O
+dramatically	O
+reduced	O
+by	O
+corresponding	O
+esiRNAs	O
+.	O
+
+TITLE	O
+:	O
+[	O
+Over	O
+-	O
+expression	B-PROC
+in	O
+Escherichia	B-SPEC
+coli	I-SPEC
+and	O
+purification	O
+of	O
+nucleocaspid	O
+and	O
+membrane	B-COMP
+protein	B-CHED
+of	O
+SARS	O
+coronavirus	B-SPEC
+].	O
+
+The	O
+significance	O
+of	O
+changes	O
+in	O
+pulmonary	B-PROC
+function	I-PROC
+indexes	O
+was	O
+analyzed	O
+.	O
+
+Leukopenia	B-DISO
+and	O
+lymphocytopenia	B-DISO
+were	O
+seen	O
+in	O
+all	O
+the	O
+patients	O
+.	O
+
+All	O
+the	O
+indexes	O
+examined	O
+recover	B-PROC
+to	O
+normal	O
+levels	O
+half	O
+year	O
+after	O
+discharge	B-ANAT
+.	O
+
+SARS	B-DISO
+coronavirus	B-SPEC
+(	O
+SARS	B-DISO
+-	O
+CoV	O
+)-	O
+specific	O
+CTL	B-ANAT
+responses	O
+,	O
+in	O
+particular	O
+their	O
+magnitude	O
+and	O
+duration	O
+of	O
+postinfection	O
+immunity	B-PROC
+,	O
+have	O
+not	O
+been	O
+extensively	O
+studied	O
+.	O
+
+Intriguingly	O
+,	O
+heat	O
+-	O
+inactivated	O
+SARS	B-DISO
+-	O
+CoV	O
+elicited	O
+recall	O
+-	O
+like	O
+CTL	B-ANAT
+responses	O
+to	O
+SSp	B-PRGE
+-	I-PRGE
+1	I-PRGE
+but	O
+not	O
+to	O
+S978	O
+,	O
+S1202	O
+,	O
+or	O
+dominant	O
+epitopes	O
+from	O
+several	O
+other	O
+human	B-SPEC
+viruses	B-SPEC
+in	O
+5	O
+of	O
+36	O
+(	O
+13	O
+.	O
+8	O
+%)	O
+HLA	B-ANAT
+-	O
+A	O
+*	O
+0201	O
+(+)	O
+healthy	O
+donors	O
+without	O
+any	O
+contact	O
+history	O
+with	O
+SARS	B-DISO
+-	O
+CoV	O
+.	O
+SSp	B-PRGE
+-	I-PRGE
+1	I-PRGE
+-	I-PRGE
+specific	I-PRGE
+CTLs	I-PRGE
+expanded	O
+from	O
+memory	B-PROC
+T	B-ANAT
+cells	I-ANAT
+of	O
+both	O
+recovered	O
+SARS	B-DISO
+patients	O
+,	O
+and	O
+the	O
+five	O
+exceptional	O
+healthy	O
+donors	O
+shared	O
+a	O
+differentiated	B-PROC
+effector	B-CHED
+CTL	B-ANAT
+phenotype	O
+,	O
+CD45RA	B-PRGE
+(+)	I-PRGE
+CCR7	I-PRGE
+(-)	I-PRGE
+CD62L	I-PRGE
+(-),	O
+and	O
+expressed	B-PROC
+CCR5	B-PRGE
+and	O
+CD44	B-PRGE
+.	O
+
+Mutations	O
+in	O
+the	O
+membrane	B-COMP
+protein	B-CHED
+and	O
+a	O
+deletion	O
+in	O
+ORF	B-PRGE
+6	I-PRGE
+--	I-PRGE
+8	I-PRGE
+were	O
+already	O
+observed	O
+in	O
+passage	O
+0	O
+,	O
+suggesting	O
+these	O
+amino	B-PROC
+acid	I-PROC
+substitutions	I-PROC
+are	O
+important	O
+in	O
+the	O
+adaptation	B-PROC
+of	O
+the	O
+virus	B-SPEC
+isolate	O
+in	O
+primate	B-SPEC
+cell	B-COMP
+culture	O
+.	O
+
+TITLE	O
+:	O
+The	O
+probability	O
+of	O
+failing	O
+in	O
+detecting	O
+an	O
+infectious	B-DISO
+disease	I-DISO
+at	O
+entry	O
+points	O
+into	O
+a	O
+country	O
+.	O
+
+In	O
+this	O
+paper	O
+,	O
+a	O
+molecular	O
+docking	B-PROC
+model	O
+of	O
+SARS	B-PRGE
+-	I-PRGE
+CoV	I-PRGE
+S1	I-PRGE
+protein	B-CHED
+in	O
+complex	O
+with	O
+human	B-PRGE
+ACE2	I-PRGE
+was	O
+constructed	O
+.	O
+
+Our	O
+model	O
+,	O
+supported	O
+by	O
+significant	O
+biochemical	O
+evidence	O
+,	O
+suggested	O
+receptor	O
+-	O
+binding	B-FUNC
+residues	O
+were	O
+concentrated	O
+in	O
+two	O
+segments	O
+of	O
+S1	B-PRGE
+protein	I-PRGE
+.	O
+
+In	O
+particular	O
+,	O
+the	O
+S1	O
+residue	O
+ARG453	O
+and	O
+ACE2	O
+residue	O
+LYS341	O
+might	O
+be	O
+the	O
+key	O
+residues	O
+in	O
+the	O
+complex	O
+formation	B-PROC
+.	O
+
+ABSTRACT	O
+:	O
+Because	O
+phosphorylation	B-PROC
+of	O
+the	O
+infectious	B-DISO
+bronchitis	B-DISO
+virus	B-SPEC
+(	O
+IBV	B-SPEC
+)	O
+nucleocapsid	B-COMP
+protein	B-CHED
+(	O
+N	O
+)	O
+may	O
+regulate	O
+its	O
+multiple	O
+roles	O
+in	O
+viral	B-PROC
+replication	I-PROC
+,	O
+the	O
+dynamics	O
+of	O
+N	O
+phosphorylation	B-PROC
+were	O
+examined	O
+.	O
+
+The	O
+EVW	O
+allows	O
+breath	B-ANAT
+-	O
+by	O
+-	O
+breath	B-ANAT
+estimates	O
+of	O
+frequency	O
+dependence	B-DISO
+of	O
+lung	B-ANAT
+and	O
+total	O
+respiratory	O
+resistance	B-PROC
+(	O
+R	O
+)	O
+and	O
+elastance	O
+(	O
+E	O
+)	O
+from	O
+0	O
+.	O
+2	O
+to	O
+8	O
+Hz	O
+.	O
+
+TITLE	O
+:	O
+Aggressive	B-PROC
+management	O
+of	O
+dengue	B-DISO
+shock	I-DISO
+syndrome	I-DISO
+may	O
+decrease	O
+mortality	O
+rate	O
+:	O
+a	O
+suggested	O
+protocol	O
+.	O
+
+The	O
+objective	O
+of	O
+this	O
+study	O
+was	O
+to	O
+compare	O
+outcomes	O
+(	O
+duration	O
+of	O
+ventilation	O
+,	O
+pediatric	O
+intensive	O
+care	O
+unit	O
+stay	O
+,	O
+incidence	O
+of	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+,	O
+and	O
+intensive	O
+care	O
+unit	O
+and	O
+hospital	O
+mortality	O
+)	O
+before	O
+and	O
+after	O
+the	O
+protocol	O
+.	O
+
+ABSTRACT	O
+:	O
+Angiotensin	B-PRGE
+-	I-PRGE
+converting	I-PRGE
+enzyme	I-PRGE
+-	I-PRGE
+2	I-PRGE
+(	O
+ACE2	B-PRGE
+)	O
+is	O
+a	O
+critical	O
+regulator	O
+of	O
+heart	B-PROC
+function	I-PROC
+and	O
+a	O
+cellular	B-COMP
+receptor	O
+for	O
+the	O
+causative	O
+agent	O
+of	O
+severe	O
+-	O
+acute	O
+respiratory	O
+syndrome	B-DISO
+(	O
+SARS	B-DISO
+),	O
+SARS	B-DISO
+-	O
+CoV	O
+(	O
+coronavirus	B-SPEC
+).	O
+
+ACE2	B-PRGE
+is	O
+a	O
+type	B-PRGE
+I	I-PRGE
+transmembrane	I-PRGE
+protein	B-CHED
+,	O
+with	O
+an	O
+extracellular	B-COMP
+N	O
+-	O
+terminal	O
+domain	O
+containing	O
+the	O
+active	O
+site	O
+and	O
+a	O
+short	O
+intracellular	B-COMP
+C	O
+-	O
+terminal	O
+tail	O
+.	O
+
+Furthermore	O
+,	O
+ablation	O
+of	O
+ADAM17	B-PRGE
+expression	B-PROC
+using	O
+specific	O
+small	O
+interfering	O
+RNA	O
+duplexes	O
+reduced	O
+regulated	O
+ACE2	O
+shedding	O
+,	O
+whereas	O
+overexpression	B-PROC
+of	O
+ADAM17	B-PRGE
+significantly	O
+increased	O
+shedding	O
+.	O
+
+The	O
+identification	O
+of	O
+ADAM17	B-PRGE
+as	O
+the	O
+protease	O
+responsible	O
+for	O
+ACE2	O
+shedding	O
+may	O
+provide	O
+new	O
+insight	O
+into	O
+the	O
+physiological	O
+roles	O
+of	O
+ACE2	B-PRGE
+.	O
+
+ABSTRACT	O
+:	O
+Bovine	B-SPEC
+torovirus	I-SPEC
+(	O
+BoTV	O
+)	O
+is	O
+a	O
+pleomorphic	O
+virus	O
+with	O
+a	O
+spike	O
+-	O
+bearing	O
+envelope	B-COMP
+and	O
+a	O
+linear	O
+,	O
+non	O
+-	O
+segmented	O
+,	O
+positive	O
+-	O
+sense	B-PROC
+single	O
+-	O
+stranded	O
+RNA	O
+genome	O
+.	O
+
+The	O
+distribution	O
+,	O
+host	B-COMP
+range	O
+,	O
+pathogenesis	B-DISO
+,	O
+disease	O
+and	O
+clinical	O
+signs	O
+(	O
+under	O
+experimental	O
+and	O
+natural	O
+exposure	O
+),	O
+pathology	B-DISO
+,	O
+diagnosis	O
+,	O
+prevention	O
+,	O
+treatment	O
+and	O
+control	O
+of	O
+BoTV	O
+infections	O
+are	O
+also	O
+described	O
+.	O
+
+Statistically	O
+significant	O
+decreases	O
+(	O
+p	O
+<	O
+0	O
+.	O
+05	O
+)	O
+were	O
+noted	O
+in	O
+mean	O
+attendance	O
+at	O
+peak	O
+-	O
+versus	O
+pre	O
+-	O
+and	O
+early	O
+-	O
+epidemic	O
+stages	O
+for	O
+patients	O
+with	O
+cardiovascular	B-DISO
+disease	I-DISO
+,	O
+inflammatory	O
+or	O
+functional	B-DISO
+bowel	I-DISO
+disease	I-DISO
+,	O
+endocrine	B-DISO
+disease	I-DISO
+,	O
+dizziness	B-DISO
+or	O
+vertigo	B-DISO
+,	O
+or	O
+trauma	O
+.	O
+
+CONCLUSIONS	O
+:	O
+The	O
+SARS	B-DISO
+outbreak	O
+did	O
+not	O
+eliminate	O
+the	O
+need	O
+of	O
+critically	B-DISO
+ill	I-DISO
+patients	O
+for	O
+advanced	O
+medical	O
+support	O
+.	O
+
+Expression	B-PROC
+of	O
+SP	O
+-	O
+B	O
+,	O
+-	O
+C	O
+,	O
+and	O
+ABCA3	B-PRGE
+are	O
+coregulated	O
+during	O
+late	O
+gestation	B-PROC
+by	O
+transcriptional	B-PROC
+programs	O
+influenced	O
+by	O
+thyroid	B-PRGE
+transcription	B-PROC
+factor	I-PRGE
+-	I-PRGE
+1	I-PRGE
+and	O
+forkhead	B-PRGE
+box	I-PRGE
+a2	I-PRGE
+,	O
+transcription	B-PROC
+factors	O
+that	O
+regulate	O
+both	O
+differentiation	B-PROC
+of	O
+the	O
+respiratory	B-ANAT
+epithelium	I-ANAT
+and	O
+transcription	B-PROC
+of	O
+genes	O
+required	O
+for	O
+perinatal	O
+adaptation	B-PROC
+to	O
+air	B-CHED
+breathing	B-PROC
+.	O
+
+These	O
+studies	O
+show	O
+that	O
+multiple	O
+doses	O
+may	O
+be	O
+needed	O
+if	O
+surfactant	B-CHED
+is	O
+used	O
+to	O
+treat	O
+established	O
+RDS	B-PRGE
+but	O
+early	O
+or	O
+prophylactic	O
+treatment	O
+is	O
+superior	O
+for	O
+infants	O
+with	O
+gestational	O
+ages	O
+less	O
+than	O
+30	O
+weeks	O
+.	O
+
+Chronic	O
+lung	O
+disease	O
+remains	O
+a	O
+problem	O
+but	O
+it	O
+is	O
+hoped	O
+that	O
+early	O
+treatment	O
+with	O
+surfactant	B-CHED
+combined	O
+with	O
+extubation	O
+to	O
+continuous	O
+positive	O
+airway	B-ANAT
+pressure	O
+will	O
+reduce	O
+this	O
+complication	B-DISO
+of	I-DISO
+prematurity	I-DISO
+.	O
+
+The	O
+last	O
+25	O
+years	O
+have	O
+seen	O
+a	O
+large	O
+increase	O
+in	O
+basic	O
+science	O
+research	O
+on	O
+surfactants	B-CHED
+with	O
+determination	O
+of	O
+the	O
+structure	O
+and	O
+function	O
+of	O
+the	O
+four	O
+surfactant	B-CHED
+proteins	B-CHED
+probably	O
+being	O
+the	O
+most	O
+important	O
+advances	O
+.	O
+
+Twenty	O
+-	O
+four	O
+rats	B-SPEC
+underwent	O
+one	O
+of	O
+three	O
+'	O
+first	O
+-	O
+hit	O
+'	O
+scenarios	O
+:	O
+(	O
+1	O
+)	O
+severe	O
+AP	O
+induced	O
+by	O
+intraductal	O
+glycodeoxycholic	B-CHED
+acid	I-CHED
+injection	O
+and	O
+intravenous	O
+caerulein	B-CHED
+infusion	O
+,	O
+(	O
+2	O
+)	O
+sham	O
+laparotomy	O
+,	O
+or	O
+(	O
+3	O
+)	O
+no	O
+first	O
+intervention	O
+.	O
+
+Neutrophil	B-PROC
+activation	I-PROC
+by	O
+the	O
+perfusate	O
+was	O
+assayed	O
+using	O
+dihydrorhodamine	O
+-	O
+123	O
+fluorescence	O
+.	O
+
+No	O
+differential	O
+neutrophil	B-PROC
+activation	I-PROC
+by	O
+the	O
+perfusate	O
+was	O
+seen	O
+.	O
+
+RESULTS	O
+:	O
+We	O
+observed	O
+a	O
+six	O
+-	O
+fold	O
+increase	O
+in	O
+IL	B-FUNC
+-	I-FUNC
+6	I-FUNC
+concentration	O
+across	O
+the	O
+liver	B-ANAT
+during	O
+AP	O
+.	O
+
+TITLE	O
+:	O
+Emerging	O
+viral	B-DISO
+infections	I-DISO
+in	O
+transplant	B-ANAT
+recipients	O
+.	O
+
+Veno	O
+-	O
+venous	B-ANAT
+ECMO	O
+therapy	O
+at	O
+present	O
+is	O
+an	O
+important	O
+therapeutic	O
+option	O
+in	O
+severe	O
+ARDS	B-DISO
+with	O
+persisiting	O
+life	O
+threatening	O
+gas	B-ENZY
+exchange	O
+disorder	O
+as	O
+a	O
+rescue	O
+therapy	O
+.	O
+
+For	O
+more	O
+effective	O
+treatment	O
+and	O
+prevention	O
+of	O
+SARS	B-DISO
+,	O
+human	B-PRGE
+SARS	B-DISO
+hyperimmune	I-PRGE
+globulins	I-PRGE
+for	O
+intravenous	O
+(	O
+IV	O
+)	O
+injection	O
+were	O
+purified	O
+in	O
+this	O
+study	O
+.	O
+
+A	O
+combination	O
+of	O
+cold	B-DISO
+ethanol	B-CHED
+precipitation	B-PROC
+and	O
+ion	O
+-	O
+exchange	O
+chromatography	O
+was	O
+used	O
+to	O
+process	O
+pooled	O
+SARS	B-DISO
+convalescent	O
+plasma	B-ANAT
+samples	O
+.	O
+
+CONCLUSIONS	O
+:	O
+IV	O
+-	O
+injectable	O
+,	O
+purified	O
+,	O
+and	O
+concentrated	O
+human	B-PRGE
+SARS	B-DISO
+hyperimmune	I-PRGE
+globulins	I-PRGE
+were	O
+prepared	O
+from	O
+pooled	O
+convalescent	O
+plasma	B-ANAT
+samples	O
+,	O
+which	O
+are	O
+ready	O
+to	O
+be	O
+further	O
+evaluated	O
+.	O
+
+TITLE	O
+:	O
+[	O
+Two	O
+genotypes	O
+of	O
+Canine	O
+coronavirus	B-SPEC
+simultaneously	O
+detected	O
+in	O
+the	O
+fecal	B-ANAT
+samples	O
+of	O
+healthy	O
+foxes	O
+and	O
+raccoon	O
+dogs	O
+].	O
+
+ABSTRACT	O
+:	O
+61	O
+fecal	B-ANAT
+samples	O
+from	O
+healthy	O
+foxes	O
+and	O
+24	O
+from	O
+healthy	O
+raccoon	B-SPEC
+dogs	I-SPEC
+were	O
+examined	O
+by	O
+RT	O
+-	O
+nested	O
+PCR	O
+assays	O
+for	O
+the	O
+presence	O
+and	O
+genotypic	O
+identification	O
+of	O
+Canine	O
+coronaviruses	O
+(	O
+CCVs	O
+).	O
+
+77	O
+.	O
+0	O
+%	O
+fox	O
+samples	O
+were	O
+recognized	O
+as	O
+CCV	B-DISO
+positive	O
+,	O
+43	O
+of	O
+which	O
+belonged	O
+to	O
+type	O
+II	O
+and	O
+29	O
+to	O
+type	O
+I	O
+,	O
+as	O
+well	O
+as	O
+both	O
+genotypes	O
+were	O
+simultaneously	O
+detected	O
+in	O
+25	O
+samples	O
+.	O
+
+Sequence	O
+analysis	O
+showed	O
+that	O
+the	O
+M	B-PRGE
+gene	I-PRGE
+of	O
+CCV	B-DISO
+type	O
+I	O
+had	O
+a	O
+high	O
+similarity	O
+of	O
+96	O
+.	O
+7	O
+%	O
+-	O
+98	O
+.	O
+1	O
+%	O
+between	O
+the	O
+fox	O
+-	O
+and	O
+raccoon	B-SPEC
+dog	I-SPEC
+strains	O
+and	O
+the	O
+reported	O
+Italian	O
+strain	O
+from	O
+diarrhea	B-DISO
+dogs	B-SPEC
+.	O
+
+CONCLUSIONS	O
+:	O
+A	O
+large	O
+human	O
+scFv	O
+library	O
+against	O
+SARS	B-DISO
+virus	B-SPEC
+with	O
+good	O
+diversity	O
+was	O
+constructed	O
+,	O
+which	O
+may	O
+be	O
+used	O
+for	O
+screening	O
+antibodies	B-COMP
+to	O
+SARS	B-DISO
+virus	B-SPEC
+antigens	B-CHED
+.	O
+
+Computed	O
+tomography	O
+scan	O
+confirmed	O
+a	O
+homogeneous	O
+tumor	B-DISO
+that	O
+filled	O
+the	O
+left	B-ANAT
+thorax	I-ANAT
+and	O
+displaced	O
+the	O
+mediastinum	B-ANAT
+to	O
+the	O
+right	O
+without	O
+invasion	B-DISO
+.	O
+
+Surgical	O
+biopsy	O
+informed	O
+of	O
+a	O
+highly	O
+vascularized	O
+mesenchymal	B-DISO
+tumor	I-DISO
+.	O
+
+Here	O
+,	O
+we	O
+examined	O
+the	O
+susceptibility	O
+of	O
+neural	B-ANAT
+cell	I-ANAT
+lines	O
+of	O
+human	B-SPEC
+(	O
+OL	O
+)	O
+and	O
+rat	B-SPEC
+(	O
+C6	O
+)	O
+origins	O
+to	O
+SARS	B-DISO
+-	I-DISO
+associated	I-DISO
+coronavirus	I-DISO
+.	O
+
+TITLE	O
+:	O
+Nuclear	O
+/	O
+nucleolar	B-ANAT
+localization	B-PROC
+properties	O
+of	O
+C	B-PRGE
+-	I-PRGE
+terminal	I-PRGE
+nucleocapsid	I-PRGE
+protein	B-CHED
+of	O
+SARS	B-DISO
+coronavirus	B-SPEC
+.	O
+
+Nucleocapsid	B-COMP
+(	O
+N	O
+)	O
+proteins	B-CHED
+of	O
+the	O
+Coronaviridae	B-SPEC
+family	B-SPEC
+have	O
+no	O
+discernable	O
+homology	O
+,	O
+but	O
+they	O
+share	O
+a	O
+common	O
+nucleolar	B-ANAT
+-	O
+cytoplasmic	B-COMP
+distribution	O
+pattern	O
+.	O
+
+The	O
+C	O
+-	O
+terminus	O
+of	O
+the	O
+N	O
+,	O
+which	O
+contains	O
+both	O
+NLS2	O
+(	O
+aa257	O
+-	O
+265	O
+)	O
+and	O
+NLS3	O
+(	O
+aa369	O
+-	O
+390	O
+)	O
+was	O
+localized	O
+to	O
+the	O
+cytoplasm	B-COMP
+and	O
+the	O
+nucleolus	B-COMP
+.	O
+
+Results	O
+derived	O
+from	O
+analysis	O
+of	O
+various	O
+deletion	O
+mutations	O
+show	O
+that	O
+the	O
+region	O
+containing	O
+amino	B-CHED
+acids	I-CHED
+226	O
+-	O
+289	O
+is	O
+able	O
+to	O
+mediate	O
+nucleolar	B-ANAT
+localization	B-PROC
+.	O
+
+The	O
+bone	B-ANAT
+mineral	B-CHED
+density	O
+of	O
+224	O
+patients	O
+with	O
+SARS	B-DISO
+,	O
+who	O
+were	O
+treated	O
+with	O
+an	O
+average	O
+of	O
+2753	O
+mg	O
+(	O
+SD	O
+=	O
+2152	O
+mg	O
+)	O
+prednisolone	B-CHED
+and	O
+29	O
+,	O
+344	O
+mg	O
+(	O
+SD	O
+=	O
+15	O
+,	O
+849	O
+mg	O
+)	O
+of	O
+ribavirin	B-CHED
+was	O
+compared	O
+to	O
+normal	O
+data	O
+.	O
+
+S	O
+-	O
+peptide	B-CHED
+,	O
+mice	B-SPEC
+primed	O
+with	O
+oral	B-ANAT
+live	O
+-	O
+attenuated	O
+S	O
+.	O
+typhimurium	O
+that	O
+contained	O
+tPA	B-FUNC
+-	O
+optimize800	O
+DNA	O
+vaccine	O
+(	O
+Salmonella	B-DISO
+-	O
+tPA	B-FUNC
+-	O
+S	O
+-	O
+DNA	O
+)	O
+and	O
+boosted	O
+with	O
+i	O
+.	O
+p	O
+.	O
+
+No	O
+statistical	O
+significant	O
+difference	O
+was	O
+observed	O
+among	O
+the	O
+Th1	O
+/	O
+Th2	O
+index	O
+among	O
+these	O
+six	O
+groups	O
+of	O
+mice	B-SPEC
+with	O
+high	O
+IgG	B-PRGE
+levels	O
+.	O
+
+S	O
+-	O
+peptide	B-CHED
+,	O
+i	O
+.	O
+m	O
+.	O
+
+CTLA4	B-PRGE
+-	I-PRGE
+S	I-PRGE
+-	I-PRGE
+DNA	I-PRGE
+,	O
+oral	B-ANAT
+Salmonella	B-DISO
+-	O
+S	O
+-	O
+DNA	O
+-	O
+control	O
+boosted	O
+with	O
+i	O
+.	O
+p	O
+.	O
+
+The	O
+present	O
+observation	O
+may	O
+have	O
+major	O
+practical	O
+value	O
+,	O
+such	O
+as	O
+immunization	O
+of	O
+civet	B-SPEC
+cats	I-SPEC
+,	O
+since	O
+production	O
+of	O
+recombinant	O
+proteins	B-CHED
+from	O
+E	B-SPEC
+.	I-SPEC
+coli	I-SPEC
+is	O
+far	O
+less	O
+expensive	O
+than	O
+production	O
+of	O
+recombinant	O
+proteins	B-CHED
+using	O
+eukaryotic	O
+systems	O
+.	O
+
+The	O
+former	O
+was	O
+less	O
+laborious	O
+with	O
+shorter	O
+time	O
+for	O
+completion	O
+and	O
+can	O
+easily	O
+be	O
+adapted	O
+to	O
+an	O
+automated	O
+system	O
+such	O
+as	O
+the	O
+MagNa	O
+Pure	B-FUNC
+-	O
+LC	O
+,	O
+which	O
+can	O
+extract	O
+nucleic	B-CHED
+acid	I-CHED
+from	O
+clinical	O
+samples	O
+and	O
+load	O
+it	O
+into	O
+the	O
+sample	O
+capillaries	B-ANAT
+of	O
+the	O
+LightCycler	O
+.	O
+
+As	O
+exemplified	O
+by	O
+this	O
+study	O
+,	O
+the	O
+continued	O
+refinement	O
+and	O
+evaluation	O
+of	O
+PCR	O
+procedures	O
+will	O
+greatly	O
+benefit	O
+the	O
+diagnostic	O
+laboratory	O
+during	O
+an	O
+outbreak	O
+of	O
+SARS	B-DISO
+.	O
+
+ABSTRACT	O
+:	O
+The	O
+proteolytic	B-PROC
+processing	I-PROC
+of	O
+polyproteins	O
+by	O
+the	O
+3CL	B-PRGE
+protease	I-PRGE
+of	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+coronavirus	B-SPEC
+is	O
+essential	O
+for	O
+the	O
+viral	O
+propagation	O
+.	O
+
+Though	O
+AG7088	O
+is	O
+inactive	O
+(	O
+IC50	O
+>	O
+100	O
+microM	O
+),	O
+the	O
+ketomethylene	O
+isosteres	O
+and	O
+tripeptide	B-CHED
+alpha	O
+,	O
+beta	O
+-	O
+unsaturated	O
+esters	B-CHED
+containing	O
+both	O
+P1	O
+and	O
+P2	O
+phenylalanine	B-CHED
+residues	O
+show	O
+modest	O
+inhibitory	O
+activity	O
+(	O
+IC50	O
+=	O
+11	O
+-	O
+39	O
+microM	O
+).	O
+
+VEGF	B-PRGE
+levels	O
+are	O
+reported	O
+to	O
+be	O
+lower	O
+in	O
+bronchoalveolar	O
+lavage	O
+from	O
+ALI	O
+patients	O
+compared	O
+with	O
+normals	O
+,	O
+but	O
+these	O
+studies	O
+did	O
+not	O
+include	O
+a	O
+comparably	O
+ill	B-DISO
+control	O
+group	O
+with	O
+noninflammatory	O
+pulmonary	B-DISO
+oedema	I-DISO
+.	O
+
+The	O
+aim	O
+of	O
+the	O
+present	O
+study	O
+was	O
+to	O
+report	O
+clinical	O
+,	O
+radiological	O
+and	O
+bronchoalveolar	O
+lavage	O
+(	O
+BAL	O
+)	O
+findings	O
+in	O
+patients	O
+with	O
+pulmonary	B-ANAT
+manifestations	O
+of	O
+HIV	B-DISO
+-	O
+associated	O
+multicentric	B-DISO
+Castleman	I-DISO
+'	I-DISO
+s	I-DISO
+disease	I-DISO
+(	O
+MCD	B-DISO
+).	O
+
+Two	O
+patients	O
+developed	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+.	O
+
+In	O
+conclusion	O
+,	O
+the	O
+pulmonary	B-ANAT
+manifestation	O
+of	O
+HIV	B-DISO
+-	O
+related	O
+multicentric	B-DISO
+Castleman	I-DISO
+'	I-DISO
+s	I-DISO
+disease	I-DISO
+is	O
+an	O
+acute	O
+reticulo	O
+-	O
+nodular	O
+interstitial	B-DISO
+pneumonitis	I-DISO
+,	O
+associated	O
+with	O
+severe	O
+systemic	O
+symptoms	O
+and	O
+peripheral	B-DISO
+lymphadenopathy	I-DISO
+.	O
+
+The	O
+clinical	O
+course	O
+is	O
+specific	O
+due	O
+to	O
+a	O
+rapid	O
+onset	O
+and	O
+regression	O
+,	O
+frequent	O
+relapses	O
+and	O
+a	O
+high	O
+occurrence	O
+of	O
+non	B-DISO
+-	I-DISO
+Hodgkin	I-DISO
+'	I-DISO
+s	I-DISO
+lymphoma	I-DISO
+.	O
+
+In	O
+contrast	O
+to	O
+observations	O
+in	O
+suckling	O
+mice	B-SPEC
+in	O
+which	O
+viruses	B-SPEC
+encoding	O
+inactivating	O
+mutations	O
+within	O
+the	O
+S510	O
+epitope	B-CHED
+(	O
+epitope	B-CHED
+escape	O
+mutants	O
+)	O
+were	O
+associated	O
+with	O
+persistent	O
+virus	B-SPEC
+and	O
+increased	O
+neurovirulence	O
+(	O
+Pewe	O
+et	O
+al	O
+.,	O
+J	O
+Virol	O
+.	O
+
+Recombinant	O
+viruses	B-SPEC
+expressing	O
+the	O
+JHM	O
+spike	O
+,	O
+wild	O
+type	O
+or	O
+encoding	O
+the	O
+N514S	O
+substitution	O
+,	O
+were	O
+also	O
+selected	O
+in	O
+which	O
+background	O
+genes	O
+were	O
+derived	O
+from	O
+the	O
+neuroattenuated	O
+A59	O
+strain	O
+of	O
+MHV	B-SPEC
+.	O
+
+ABSTRACT	O
+:	O
+A	O
+retrospective	O
+analysis	O
+was	O
+performed	O
+to	O
+estimate	O
+the	O
+practicability	O
+of	O
+a	O
+pumpless	O
+extracorporeal	O
+lung	B-ANAT
+assist	O
+system	O
+(	O
+pECLA	O
+)	O
+in	O
+trauma	O
+patients	O
+suffering	B-DISO
+from	O
+severe	O
+brain	B-ANAT
+injury	O
+and	O
+the	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+(	O
+ARDS	B-DISO
+).	O
+
+With	O
+pECLA	O
+hypercapnia	B-DISO
+was	O
+eliminated	O
+in	O
+all	O
+patients	O
+while	O
+the	O
+minute	O
+volume	O
+of	O
+artificial	O
+ventilation	O
+could	O
+be	O
+reduced	O
+.	O
+
+ABSTRACT	O
+:	O
+Recent	O
+major	O
+disease	O
+outbreaks	O
+,	O
+such	O
+as	O
+severe	O
+acute	O
+respiratory	O
+syndrome	O
+and	O
+foot	B-DISO
+-	I-DISO
+and	I-DISO
+-	I-DISO
+mouth	B-ANAT
+disease	I-DISO
+in	O
+the	O
+UK	O
+,	O
+coupled	O
+with	O
+fears	O
+of	O
+emergence	O
+of	O
+human	B-SPEC
+-	O
+to	O
+-	O
+human	B-SPEC
+transmissible	O
+variants	O
+of	O
+avian	B-DISO
+influenza	I-DISO
+,	O
+have	O
+highlighted	O
+the	O
+importance	O
+of	O
+accurate	O
+quantification	O
+of	O
+disease	O
+threat	O
+when	O
+relatively	O
+few	O
+cases	O
+have	O
+occurred	O
+.	O
+
+A	O
+cohort	O
+of	O
+100	O
+patients	O
+was	O
+enrolled	O
+from	O
+2001	O
+to	O
+2003	O
+in	O
+which	O
+50	O
+patients	O
+had	O
+clinically	O
+diagnosed	O
+viral	O
+RTI	B-DISO
+and	O
+50	O
+were	O
+asymptomatic	O
+.	O
+
+All	O
+patients	O
+had	O
+pulmonary	B-PROC
+function	I-PROC
+tests	O
+at	O
+regular	O
+intervals	O
+for	O
+12	O
+months	O
+.	O
+
+In	O
+six	O
+of	O
+these	O
+nine	O
+patients	O
+,	O
+the	O
+decline	O
+in	O
+FEV	B-SPEC
+-	O
+1	O
+was	O
+sustained	O
+over	O
+a	O
+1	O
+-	O
+year	O
+period	O
+consistent	O
+with	O
+bronchiolitis	B-DISO
+obliterans	I-DISO
+syndrome	B-DISO
+(	O
+BOS	B-DISO
+).	O
+
+Community	O
+-	O
+acquired	O
+respiratory	O
+viruses	B-SPEC
+may	O
+be	O
+associated	O
+with	O
+the	O
+development	B-PROC
+of	O
+acute	O
+rejection	O
+and	O
+BOS	B-DISO
+.	O
+
+ABSTRACT	O
+:	O
+Human	B-PRGE
+coronavirus	I-PRGE
+NL63	I-PRGE
+recently	O
+found	O
+in	O
+The	O
+Netherlands	O
+has	O
+been	O
+detected	O
+in	O
+Japan	O
+with	O
+a	O
+reverse	O
+transcription	O
+-	O
+polymerase	O
+chain	O
+reaction	O
+technique	O
+in	O
+clinical	O
+specimens	O
+from	O
+pediatric	O
+patients	O
+with	O
+respiratory	B-DISO
+symptoms	I-DISO
+.	O
+
+Sequencing	O
+and	O
+sequential	O
+comparison	O
+was	O
+performed	O
+to	O
+analyze	O
+the	O
+mutation	O
+trend	O
+of	O
+the	O
+polymerase	B-PRGE
+nsp5	I-PRGE
+gene	I-PRGE
+during	O
+the	O
+epidemic	O
+process	O
+using	O
+a	O
+nucleotide	B-CHED
+-	O
+nucleotide	B-CHED
+basic	O
+local	O
+alignment	O
+search	O
+tool	O
+(	O
+BLASTN	O
+)	O
+and	O
+a	O
+protein	B-CHED
+-	O
+protein	B-CHED
+basic	O
+local	O
+alignment	O
+search	O
+tool	O
+(	O
+BLASTP	O
+).	O
+
+After	O
+PP1	B-PRGE
+PaO2	O
+/	O
+FIO2	O
+remained	O
+significantly	O
+improved	O
+,	O
+and	O
+the	O
+PaO2	O
+/	O
+FIO2	O
+improvement	O
+from	O
+SP1	B-PRGE
+to	O
+SP2	B-PRGE
+was	O
+linearly	O
+related	O
+to	O
+PaO2	B-PRGE
+/	O
+FIO2	O
+during	O
+PP1	B-PRGE
+(	O
+r	O
+=	O
+0	O
+.	O
+8	O
+).	O
+
+Immuno	O
+-	O
+chromatographic	O
+rapid	O
+tests	O
+(	O
+FASTest	O
+Strips	O
+)	O
+were	O
+applied	O
+in	O
+the	O
+field	O
+and	O
+their	O
+results	O
+were	O
+compared	O
+to	O
+the	O
+ones	O
+obtained	O
+with	O
+standard	O
+methods	O
+(	O
+modified	O
+Ziehl	O
+-	O
+Neelsen	O
+stain	O
+,	O
+antigen	B-CHED
+-	O
+ELISA	O
+and	O
+cultivation	O
+).	O
+
+Compared	O
+to	O
+the	O
+modified	O
+Ziehl	O
+-	O
+Neelsen	O
+stain	O
+or	O
+the	O
+antigen	B-CHED
+-	O
+ELISA	O
+,	O
+the	O
+FASTest	O
+Strips	O
+CRYPTO	B-DISO
+and	O
+ROTA	O
+were	O
+of	O
+very	O
+high	O
+diagnostic	O
+specificity	O
+of	O
+100	O
+%	O
+each	O
+and	O
+their	O
+diagnostic	O
+sensitivity	O
+was	O
+75	O
+%	O
+and	O
+57	O
+%,	O
+respectively	O
+.	O
+
+ABSTRACT	O
+:	O
+The	O
+use	O
+of	O
+recombinant	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+-	O
+coronavirus	B-SPEC
+(	O
+SARS	B-DISO
+-	O
+CoV	O
+)	O
+nucleocapsid	B-COMP
+protein	B-CHED
+(	O
+N	O
+)	O
+enzyme	O
+-	O
+linked	O
+immunosorbent	O
+assay	O
+(	O
+ELISA	O
+)-	O
+based	O
+antibody	B-COMP
+and	O
+antigen	B-CHED
+tests	O
+for	O
+diagnosis	O
+of	O
+SARS	B-DISO
+-	O
+CoV	O
+infections	B-DISO
+have	O
+been	O
+widely	O
+reported	O
+.	O
+
+ABSTRACT	O
+:	O
+We	O
+compared	O
+the	O
+performance	O
+of	O
+a	O
+recently	O
+established	O
+real	O
+-	O
+time	O
+loop	O
+-	O
+mediated	O
+amplification	B-DISO
+(	O
+LAMP	O
+)	O
+assay	O
+with	O
+the	O
+one	O
+from	O
+a	O
+highly	O
+sensitive	O
+quantitative	O
+PCR	O
+assay	O
+.	O
+
+Results	O
+indicate	O
+that	O
+HCWs	O
+were	O
+most	O
+able	O
+to	O
+report	O
+to	O
+work	O
+for	O
+a	O
+mass	O
+casualty	O
+incident	O
+(	O
+MCI	B-DISO
+)	O
+(	O
+83	O
+%),	O
+environmental	O
+disaster	O
+(	O
+81	O
+%),	O
+and	O
+chemical	O
+event	O
+(	O
+71	O
+%)	O
+and	O
+least	O
+able	O
+to	O
+report	O
+during	O
+a	O
+smallpox	B-SPEC
+epidemic	O
+(	O
+69	O
+%),	O
+radiological	O
+event	O
+(	O
+64	O
+%),	O
+sudden	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+(	O
+SARS	B-DISO
+)	O
+outbreak	O
+(	O
+64	O
+%),	O
+or	O
+severe	O
+snow	O
+storm	O
+(	O
+49	O
+%).	O
+
+However	O
+,	O
+other	O
+components	O
+of	O
+the	O
+renin	B-PATH
+-	I-PATH
+angiotensin	B-CHED
+system	I-PATH
+,	O
+including	O
+ACE	B-PRGE
+,	O
+angiotensin	B-PRGE
+II	I-PRGE
+and	O
+the	O
+angiotensin	B-PRGE
+II	I-PRGE
+type	I-PRGE
+1a	I-PRGE
+receptor	I-PRGE
+(	O
+AT1a	B-PRGE
+),	O
+promote	O
+disease	O
+pathogenesis	B-DISO
+,	O
+induce	O
+lung	B-ANAT
+oedemas	B-DISO
+and	O
+impair	O
+lung	B-PROC
+function	I-PROC
+.	O
+
+Data	O
+of	O
+SARS	B-DISO
+cases	O
+notified	O
+from	O
+the	O
+Beijing	O
+Municipal	O
+Center	O
+for	O
+Disease	O
+Control	O
+and	O
+Prevention	O
+(	O
+BCDC	O
+)	O
+and	O
+supplemented	O
+by	O
+other	O
+channels	O
+were	O
+collected	O
+.	O
+
+(	O
+1	O
+)	O
+The	O
+susceptible	O
+persons	O
+with	O
+contact	O
+history	O
+may	O
+not	O
+get	O
+infected	O
+,	O
+and	O
+the	O
+contact	O
+history	O
+is	O
+just	O
+a	O
+sufficient	O
+condition	O
+of	O
+infecting	O
+SARS	B-DISO
+;	O
+(	O
+2	O
+)	O
+There	O
+are	O
+3	O
+conceivable	O
+reasons	O
+for	O
+the	O
+descending	O
+trend	O
+of	O
+the	O
+proportion	O
+in	O
+probable	O
+cases	O
+with	O
+contact	O
+history	O
+;	O
+(	O
+3	O
+)	O
+The	O
+contact	O
+history	O
+is	O
+one	O
+of	O
+the	O
+risk	O
+factors	O
+of	O
+the	O
+death	B-PROC
+of	O
+SARS	B-DISO
+cases	O
+;	O
+(	O
+4	O
+)	O
+The	O
+risk	O
+of	O
+contacting	O
+with	O
+SARS	B-DISO
+among	O
+health	O
+care	O
+workers	O
+is	O
+approximately	O
+5	O
+times	O
+higher	O
+than	O
+that	O
+of	O
+non	O
+-	O
+HCWs	O
+.	O
+
+In	O
+multivariate	O
+analysis	O
+,	O
+independent	O
+prognostic	O
+variables	O
+for	O
+hypocapnica	O
+were	O
+plasmatic	O
+levels	O
+of	O
+protrombin	O
+time	O
+,	O
+albumin	B-PRGE
+and	O
+sodium	O
+.	O
+
+Hypocapnia	B-DISO
+was	O
+significantly	O
+more	O
+evident	O
+in	O
+Child	O
+C	O
+than	O
+in	O
+A	O
+and	O
+B	O
+(	O
+31	O
+.	O
+2	O
++/-	O
+3	O
+.	O
+1	O
+vs	O
+.	O
+38	O
+.	O
+1	O
++/-	O
+
+HPS	B-DISO
+was	O
+confirmed	O
+in	O
+8	O
+patients	O
+(	O
+16	O
+%).	O
+
+TITLE	O
+:	O
+Evaluation	O
+of	O
+inapparent	O
+nosocomial	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+coronavirus	B-DISO
+infection	I-DISO
+in	O
+Vietnam	O
+by	O
+use	O
+of	O
+highly	O
+specific	O
+recombinant	O
+truncated	O
+nucleocapsid	O
+protein	B-CHED
+-	O
+based	O
+enzyme	O
+-	O
+linked	O
+immunosorbent	O
+assay	O
+.	O
+
+Serum	B-COMP
+samples	O
+collected	O
+from	O
+healthy	O
+volunteers	O
+and	O
+SARS	B-DISO
+patients	O
+in	O
+Vietnam	O
+were	O
+used	O
+to	O
+evaluate	O
+the	O
+newly	O
+developed	O
+methods	O
+.	O
+
+protein	B-CHED
+-	O
+based	O
+ELISA	O
+is	O
+not	O
+only	O
+safe	O
+but	O
+also	O
+a	O
+more	O
+specific	O
+and	O
+more	O
+sensitive	O
+method	O
+to	O
+diagnose	O
+SARS	B-DISO
+-	I-DISO
+CoV	I-DISO
+infection	I-DISO
+and	O
+hence	O
+a	O
+useful	O
+tool	O
+for	O
+large	O
+-	O
+scale	O
+epidemiological	O
+studies	O
+.	O
+
+The	O
+DNA	O
+vaccine	O
+contained	O
+a	O
+plasmid	O
+encoding	O
+the	O
+SARS	B-DISO
+coronavirus	B-SPEC
+(	O
+SARS	B-DISO
+-	O
+CoV	O
+)	O
+S	O
+protein	B-CHED
+under	O
+the	O
+control	O
+of	O
+the	O
+human	B-PRGE
+CMV	B-SPEC
+promoter	I-PRGE
+and	O
+intron	O
+A	O
+.	O
+The	O
+whole	O
+killed	O
+virus	B-SPEC
+vaccine	O
+was	O
+comprised	O
+of	O
+SARS	B-PRGE
+-	I-PRGE
+CoV	I-PRGE
+,	O
+propagated	O
+in	O
+Vero	O
+-	O
+E6	O
+cells	B-COMP
+,	O
+with	O
+subsequent	O
+beta	O
+-	O
+propilactone	O
+inactivation	B-DISO
+and	O
+formulated	O
+with	O
+aluminum	B-CHED
+hydroxide	I-CHED
+adjuvant	B-CHED
+.	O
+
+These	O
+results	O
+demonstrate	O
+that	O
+combination	O
+of	O
+the	O
+DNA	O
+vaccine	O
+and	O
+the	O
+whole	O
+killed	O
+virus	B-SPEC
+vaccine	O
+can	O
+be	O
+used	O
+to	O
+enhance	O
+the	O
+magnitude	O
+and	O
+change	O
+the	O
+bias	B-SPEC
+of	O
+the	O
+immune	B-PROC
+responses	I-PROC
+to	O
+SARS	B-PRGE
+-	I-PRGE
+CoV	I-PRGE
+.	O
+
+We	O
+monitored	O
+pulmonary	B-PROC
+vascular	B-ANAT
+resistance	I-PROC
+,	O
+oxygenation	B-PROC
+,	O
+neutrophil	B-ANAT
+count	O
+,	O
+lung	B-DISO
+edema	I-DISO
+as	O
+reflected	O
+by	O
+wet	O
+-	O
+dry	O
+weights	O
+of	O
+lung	B-ANAT
+tissue	I-ANAT
+,	O
+perfusate	O
+concentrations	O
+of	O
+TNF	B-PRGE
+-	I-PRGE
+alpha	I-PRGE
+,	O
+IL	B-FUNC
+-	I-FUNC
+6	I-FUNC
+,	O
+and	O
+8	B-CHED
+-	I-CHED
+isoprostane	I-CHED
+(	O
+a	O
+marker	O
+of	O
+oxidative	B-DISO
+stress	I-DISO
+),	O
+and	O
+activation	O
+of	O
+the	O
+transcription	B-PROC
+factor	O
+(	O
+NF	B-PRGE
+-	I-PRGE
+kappaB	I-PRGE
+)	O
+in	O
+lung	B-ANAT
+tissue	I-ANAT
+before	O
+and	O
+for	O
+2	O
+h	O
+after	O
+endotoxin	O
+.	O
+
+Notably	O
+,	O
+injection	O
+of	O
+SARS	B-DISO
+-	O
+CoV	O
+Spike	O
+into	O
+mice	B-SPEC
+worsens	O
+acute	O
+lung	B-ANAT
+failure	O
+in	O
+vivo	O
+that	O
+can	O
+be	O
+attenuated	O
+by	O
+blocking	B-DISO
+the	O
+renin	B-PRGE
+-	O
+angiotensin	B-CHED
+pathway	B-PROC
+.	O
+
+Tuberculosis	B-PATH
+(	O
+TB	O
+)	O
+commonly	O
+causes	O
+respiratory	B-DISO
+failure	I-DISO
+in	O
+patients	O
+with	O
+extensive	O
+pulmonary	B-ANAT
+parenchymal	O
+involvement	O
+,	O
+but	O
+it	O
+is	O
+a	O
+rare	O
+cause	O
+of	O
+ARDS	B-DISO
+.	O
+
+Nine	O
+(	O
+4	O
+.	O
+9	O
+%)	O
+of	O
+187	O
+patients	O
+had	O
+ARDS	B-DISO
+secondary	O
+to	O
+tuberculosis	B-PATH
+.	O
+
+These	O
+pandemic	O
+viral	B-DISO
+diseases	I-DISO
+originated	O
+in	O
+South	O
+East	O
+Asia	O
+.	O
+
+Bird	B-SPEC
+faeces	B-ANAT
+are	O
+also	O
+key	O
+carriers	O
+of	O
+the	O
+viruses	B-SPEC
+.	O
+
+Other	O
+important	O
+players	O
+are	O
+migrating	O
+birds	B-SPEC
+from	O
+North	O
+Asia	O
+,	O
+which	O
+are	O
+principal	O
+vectors	O
+of	O
+avian	B-DISO
+influenza	B-SPEC
+viruses	I-SPEC
+.	O
+
+Our	O
+modern	O
+water	B-CHED
+technology	O
+can	O
+find	O
+good	O
+solutions	O
+for	O
+the	O
+problem	O
+.	O
+
+The	O
+difference	O
+in	O
+chloride	O
+sensitivity	O
+between	O
+ACE2	B-PRGE
+and	O
+ACE	B-PRGE
+was	O
+investigated	O
+,	O
+and	O
+the	O
+absence	O
+of	O
+a	O
+second	O
+chloride	B-PRGE
+-	I-PRGE
+binding	B-FUNC
+site	I-PRGE
+(	O
+CL2	B-PRGE
+)	O
+in	O
+ACE2	B-PRGE
+confirmed	O
+.	O
+
+METHODS	O
+:	O
+Postmortem	O
+skeletal	B-ANAT
+muscles	I-ANAT
+from	O
+8	O
+consecutive	O
+patients	O
+who	O
+died	B-PROC
+of	O
+SARS	B-DISO
+in	O
+March	O
+2003	O
+were	O
+studied	O
+under	O
+light	O
+and	O
+electron	O
+microscopy	O
+as	O
+well	O
+as	O
+immunohistochemistry	O
+.	O
+
+TITLE	O
+:	O
+Congenital	B-DISO
+neutropenia	I-DISO
+and	O
+primary	B-PATH
+immunodeficiency	I-PATH
+disorders	O
+:	O
+a	O
+survey	O
+of	O
+26	O
+Iranian	O
+patients	O
+.	O
+
+259	O
+.	O
+3	O
+cells	B-COMP
+/	O
+mm	O
+(	O
+range	O
+74	O
+-	O
+1	O
+,	O
+152	O
+/	O
+mm	O
+)	O
+at	O
+the	O
+first	O
+visit	O
+.	O
+
+Stem	O
+cell	B-ANAT
+lines	I-ANAT
+should	O
+be	O
+tested	O
+for	O
+prion	O
+particles	O
+and	O
+a	O
+virus	B-SPEC
+of	O
+animal	B-SPEC
+origin	O
+that	O
+assure	O
+an	O
+acceptable	O
+quality	O
+.	O
+
+ABSTRACT	O
+:	O
+The	O
+incubation	O
+period	O
+of	O
+SARS	O
+is	O
+the	O
+time	O
+between	O
+infection	B-DISO
+of	O
+disease	O
+and	O
+onset	O
+of	O
+symptoms	O
+.	O
+
+The	O
+basic	O
+reproduction	B-PROC
+number	O
+was	O
+estimated	O
+,	O
+and	O
+the	O
+use	O
+of	O
+masks	O
+alone	O
+was	O
+shown	O
+to	O
+be	O
+insufficient	O
+in	O
+containing	O
+an	O
+epidemic	O
+.	O
+
+NKG2D	B-PRGE
+may	O
+serve	O
+as	O
+a	O
+primary	B-PRGE
+recognition	I-PRGE
+receptor	I-PRGE
+or	O
+as	O
+a	O
+costimulatory	O
+molecule	O
+.	O
+
+We	O
+show	O
+that	O
+NKG2D	B-PRGE
+(+)	O
+gammadelta	O
+T	B-ANAT
+cells	I-ANAT
+in	O
+the	O
+JHM	O
+-	O
+infected	O
+central	B-ANAT
+nervous	I-ANAT
+system	I-ANAT
+express	O
+the	O
+adaptor	O
+molecule	O
+DAP12	B-PRGE
+and	O
+an	O
+NKG2D	B-PRGE
+isoform	O
+(	O
+NKG2D	B-PRGE
+short	O
+),	O
+both	O
+required	O
+for	O
+NKG2D	B-PRGE
+to	O
+serve	O
+as	O
+a	O
+primary	O
+receptor	O
+.	O
+
+TITLE	O
+:	O
+Apical	O
+entry	O
+and	O
+release	B-PATH
+of	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+-	O
+associated	O
+coronavirus	B-SPEC
+in	O
+polarized	O
+Calu	O
+-	O
+3	O
+lung	O
+epithelial	B-ANAT
+cells	I-ANAT
+.	O
+
+However	O
+,	O
+an	O
+in	O
+vitro	O
+model	O
+of	O
+SARS	B-DISO
+-	I-DISO
+CoV	I-DISO
+infection	I-DISO
+using	O
+relevant	O
+lung	B-ANAT
+epithelial	B-ANAT
+cells	I-ANAT
+is	O
+not	O
+yet	O
+available	O
+,	O
+making	O
+it	O
+difficult	O
+to	O
+dissect	O
+the	O
+pathogenesis	B-DISO
+of	O
+SARS	B-DISO
+-	O
+CoV	O
+in	O
+the	O
+lungs	B-ANAT
+.	O
+
+Here	O
+,	O
+we	O
+report	O
+that	O
+SARS	B-DISO
+-	O
+CoV	O
+can	O
+productively	O
+infect	O
+human	B-SPEC
+bronchial	B-ANAT
+epithelial	O
+Calu	O
+-	O
+3	O
+cells	B-COMP
+,	O
+causing	O
+cytopathic	B-DISO
+effects	I-DISO
+,	O
+a	O
+process	O
+reflective	O
+of	O
+its	O
+natural	O
+course	O
+of	O
+infection	B-DISO
+in	O
+the	O
+lungs	B-ANAT
+.	O
+
+Taken	O
+together	O
+,	O
+these	O
+results	O
+indicate	O
+that	O
+SARS	B-DISO
+-	O
+CoV	O
+almost	O
+exclusively	O
+entered	O
+and	O
+was	O
+released	O
+from	O
+the	O
+apical	O
+domain	O
+of	O
+polarized	O
+Calu	O
+-	O
+3	O
+cells	B-COMP
+,	O
+which	O
+might	O
+provide	O
+important	O
+insight	O
+into	O
+the	O
+mechanism	O
+of	O
+transmission	O
+and	O
+pathogenesis	B-DISO
+of	O
+SARS	B-DISO
+-	O
+CoV	O
+.	O
+
+The	O
+P	O
+-	O
+PMO	O
+were	O
+tested	O
+for	O
+their	O
+capacity	O
+to	O
+inhibit	O
+production	O
+of	O
+infectious	B-DISO
+virus	B-SPEC
+as	O
+well	O
+as	O
+to	O
+probe	O
+the	O
+function	O
+of	O
+conserved	O
+viral	O
+RNA	O
+motifs	O
+and	O
+secondary	O
+structures	O
+.	O
+
+Two	O
+P	O
+-	O
+PMO	O
+targeting	B-PROC
+the	O
+viral	B-PRGE
+transcription	I-PRGE
+-	I-PRGE
+regulatory	I-PRGE
+sequence	I-PRGE
+(	O
+TRS	B-DISO
+)	O
+region	O
+in	O
+the	O
+5	O
+'	O
+untranslated	O
+region	O
+were	O
+the	O
+most	O
+effective	O
+inhibitors	B-CHED
+tested	O
+.	O
+
+Those	O
+partially	O
+resistant	O
+viruses	B-SPEC
+grew	O
+more	O
+slowly	O
+and	O
+formed	O
+smaller	O
+plaques	B-DISO
+than	O
+wild	O
+-	O
+type	O
+SARS	B-DISO
+-	O
+CoV	O
+.	O
+These	O
+results	O
+suggest	O
+PMO	O
+compounds	O
+have	O
+powerful	O
+therapeutic	O
+and	O
+investigative	O
+potential	O
+toward	O
+coronavirus	B-DISO
+infection	I-DISO
+.	O
+
+TITLE	O
+:	O
+Murine	B-SPEC
+coronavirus	I-SPEC
+requires	O
+lipid	B-COMP
+rafts	I-COMP
+for	O
+virus	B-SPEC
+entry	O
+and	O
+cell	B-PROC
+-	I-PROC
+cell	B-COMP
+fusion	I-PROC
+but	O
+not	O
+for	O
+virus	B-SPEC
+release	B-PATH
+.	O
+
+Correspondingly	O
+,	O
+cell	B-PROC
+-	I-PROC
+cell	B-COMP
+fusion	I-PROC
+induced	O
+by	O
+MHV	B-SPEC
+was	O
+retarded	O
+by	O
+cholesterol	B-DISO
+depletion	I-DISO
+,	O
+consistent	O
+with	O
+the	O
+association	O
+of	O
+the	O
+spike	O
+protein	B-CHED
+with	O
+lipid	B-COMP
+rafts	I-COMP
+in	O
+the	O
+plasma	B-COMP
+membrane	I-COMP
+.	O
+
+TITLE	O
+:	O
+The	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+coronavirus	B-SPEC
+3a	O
+protein	B-CHED
+up	O
+-	O
+regulates	O
+expression	B-PROC
+of	O
+fibrinogen	B-ANAT
+in	O
+lung	B-ANAT
+epithelial	B-ANAT
+cells	I-ANAT
+.	O
+
+While	O
+the	O
+former	O
+is	O
+the	O
+result	O
+of	O
+decreases	O
+in	O
+CD4	B-PRGE
++	I-PRGE
+or	O
+CD8	B-PRGE
++	I-PRGE
+T	B-ANAT
+-	I-ANAT
+lymphocytes	I-ANAT
+related	O
+to	O
+the	O
+onset	O
+of	O
+disease	O
+or	O
+use	O
+of	O
+glucocorticoids	B-CHED
+,	O
+the	O
+latter	O
+may	O
+involve	O
+a	O
+number	O
+of	O
+potential	O
+mechanisms	O
+.	O
+
+Moreover	O
+,	O
+even	O
+craniotomy	O
+may	O
+be	O
+performed	O
+during	O
+ECMO	O
+therapy	O
+without	O
+major	O
+bleeding	B-DISO
+and	O
+adverse	B-DISO
+effects	I-DISO
+on	O
+neurological	B-PROC
+function	I-PROC
+.	O
+
+Acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+(	O
+ARDS	B-DISO
+)	O
+as	O
+a	O
+component	O
+of	O
+MOFS	O
+was	O
+diagnosed	O
+in	O
+39	O
+(	O
+26	O
+.	O
+2	O
+%)	O
+patients	O
+.	O
+
+However	O
+,	O
+despite	O
+acknowledgment	O
+of	O
+risk	O
+,	O
+the	O
+occupational	O
+death	B-PROC
+rate	O
+for	O
+healthcare	O
+workers	O
+is	O
+unknown	O
+.	O
+
+ABSTRACT	O
+:	O
+The	O
+causative	O
+agent	O
+of	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+(	O
+SARS	B-DISO
+)	O
+has	O
+been	O
+identified	O
+as	O
+SARS	B-DISO
+-	I-DISO
+associated	I-DISO
+coronavirus	I-DISO
+(	O
+SARS	B-DISO
+-	O
+CoV	O
+),	O
+but	O
+the	O
+prophylactic	O
+treatment	O
+of	O
+SARS	B-DISO
+-	O
+CoV	O
+is	O
+still	O
+under	O
+investigation	O
+.	O
+
+RT	O
+-	O
+PCR	O
+detected	O
+human	B-SPEC
+metapneumovirus	I-SPEC
+in	O
+40	O
+/	O
+306	O
+(	O
+13	O
+.	O
+1	O
+%)	O
+children	O
+positive	O
+for	O
+respiratory	O
+viruses	B-SPEC
+,	O
+with	O
+an	O
+incidence	O
+intermediate	O
+between	O
+that	O
+of	O
+respiratory	O
+syncytial	O
+virus	O
+(	O
+58	O
+patients	O
+,	O
+18	O
+.	O
+9	O
+%)	O
+and	O
+that	O
+of	O
+influenzavirus	B-SPEC
+infections	B-DISO
+(	O
+29	O
+patients	O
+,	O
+9	O
+.	O
+5	O
+%).	O
+
+However	O
+,	O
+SARS	B-PRGE
+-	I-PRGE
+CoV	I-PRGE
+membrane	B-COMP
+protein	B-CHED
+seems	O
+to	O
+be	O
+more	O
+sensitive	B-DISO
+to	I-DISO
+heat	I-DISO
+treatment	O
+,	O
+since	O
+the	O
+membrane	B-COMP
+protein	B-CHED
+of	O
+MHV	B-SPEC
+-	O
+JHM	O
+,	O
+another	O
+member	O
+of	O
+the	O
+Coronaviridae	B-SPEC
+,	O
+would	O
+not	O
+aggregate	O
+after	O
+the	O
+same	O
+treatment	O
+.	O
+
+ABSTRACT	O
+:	O
+Severe	O
+acute	O
+respiratory	O
+syndrome	O
+(	O
+SARS	B-DISO
+)	O
+is	O
+an	O
+emerging	B-DISO
+infectious	I-DISO
+disease	I-DISO
+that	O
+first	O
+occurred	O
+in	O
+humans	B-SPEC
+in	O
+the	O
+People	O
+'	O
+s	O
+Republic	O
+of	O
+China	O
+in	O
+November	O
+2002	O
+and	O
+has	O
+subsequently	O
+spread	O
+worldwide	O
+.	O
+
+The	O
+severity	O
+of	O
+the	O
+disease	O
+combined	O
+with	O
+its	O
+rapid	O
+spread	O
+requires	O
+the	O
+development	B-PROC
+of	O
+fast	B-FUNC
+and	O
+sensitive	O
+diagnostic	O
+assays	O
+.	O
+
+ABSTRACT	O
+:	O
+Two	O
+genotype	O
+-	O
+specific	O
+fluorogenic	O
+RT	O
+-	O
+PCR	O
+assays	O
+were	O
+developed	O
+for	O
+the	O
+detection	O
+and	O
+quantitation	O
+of	O
+canine	O
+coronavirus	B-SPEC
+(	O
+CCoV	O
+)	O
+type	O
+I	O
+and	O
+type	O
+II	O
+RNA	O
+in	O
+the	O
+faeces	B-ANAT
+of	O
+dogs	B-SPEC
+with	O
+diarrhoea	B-DISO
+.	O
+
+The	O
+genotype	O
+-	O
+specific	O
+fluorogenic	O
+assays	O
+were	O
+then	O
+used	O
+to	O
+detect	O
+and	O
+measure	O
+viral	O
+loads	O
+in	O
+the	O
+faecal	B-ANAT
+samples	O
+collected	O
+from	O
+dogs	B-SPEC
+naturally	O
+or	O
+experimentally	O
+infected	O
+with	O
+type	O
+I	O
+,	O
+type	O
+II	O
+,	O
+or	O
+both	O
+genotypes	O
+.	O
+
+TITLE	O
+:	O
+Variations	O
+in	O
+the	O
+nucleocapsid	B-PRGE
+protein	B-CHED
+gene	I-PRGE
+of	O
+infectious	B-DISO
+bronchitis	B-DISO
+viruses	B-SPEC
+isolated	O
+in	O
+Korea	O
+.	O
+
+The	O
+Korean	O
+IBV	B-SPEC
+isolates	O
+shared	O
+amino	B-CHED
+acid	I-CHED
+sequence	O
+similarity	O
+of	O
+between	O
+89	O
+.	O
+2	O
+%	O
+(	O
+K203	O
+-	O
+02	O
+and	O
+K1255	O
+-	O
+03	O
+)	O
+and	O
+98	O
+.	O
+3	O
+%	O
+(	O
+K434	O
+-	O
+01	O
+and	O
+K281	O
+-	O
+01	O
+)	O
+with	O
+each	O
+other	O
+and	O
+exhibited	O
+amino	B-CHED
+acid	I-CHED
+sequence	O
+similarity	O
+between	O
+57	O
+.	O
+0	O
+%	O
+(	O
+K774	O
+-	O
+01	O
+and	O
+V18	O
+/	O
+91	O
+)	O
+and	O
+96	O
+.	O
+6	O
+%	O
+(	O
+K507	O
+-	O
+01	O
+and	O
+JP8147	O
+)	O
+with	O
+non	O
+-	O
+Korean	O
+IBV	B-SPEC
+strains	O
+.	O
+
+Phylogenetic	O
+analysis	O
+of	O
+the	O
+deduced	O
+N	B-PRGE
+protein	I-PRGE
+amino	B-CHED
+acid	I-CHED
+sequences	O
+resulted	O
+in	O
+the	O
+segregation	O
+of	O
+Korean	O
+IBV	B-SPEC
+isolates	O
+into	O
+three	O
+different	O
+clusters	B-CHED
+,	O
+with	O
+cluster	O
+assignments	O
+differing	O
+for	O
+some	O
+of	O
+the	O
+isolates	O
+from	O
+those	O
+obtained	O
+with	O
+analysis	O
+of	O
+the	O
+S1	O
+glycoprotein	O
+.	O
+
+Another	O
+Korean	O
+IBV	B-SPEC
+isolate	O
+,	O
+K210	O
+-	O
+02	O
+,	O
+belonged	O
+to	O
+a	O
+cluster	O
+that	O
+included	O
+IBV	B-SPEC
+strains	O
+isolated	O
+in	O
+USA	O
+,	O
+the	O
+Netherlands	O
+and	O
+China	O
+.	O
+
+RICT	O
+with	O
+several	O
+pairs	O
+of	O
+MoAbs	O
+showed	O
+a	O
+high	O
+sensitivity	O
+for	O
+the	O
+detection	O
+of	O
+recombinant	O
+N	O
+-	O
+Ag	O
+as	O
+well	O
+as	O
+viral	O
+N	O
+-	O
+Ag	O
+of	O
+SARS	O
+-	O
+CoV	O
+.	O
+rSN122	O
+and	O
+rSN21	O
+-	O
+2	O
+were	O
+the	O
+best	O
+MoAbs	O
+for	O
+immobilized	O
+antibody	B-COMP
+and	O
+enzyme	O
+labeling	O
+,	O
+respectively	O
+.	O
+
+ABSTRACT	O
+:	O
+An	O
+outpatient	O
+radiotherapy	O
+department	O
+assessed	O
+how	O
+precautions	O
+implemented	O
+during	O
+the	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+(	O
+SARS	B-DISO
+)	O
+outbreak	O
+affected	O
+patient	O
+satisfaction	O
+with	O
+doctor	O
+-	O
+patient	O
+interaction	O
+and	O
+explored	O
+variables	O
+potentially	O
+influencing	O
+satisfaction	O
+.	O
+
+An	O
+extensive	O
+diagnostic	O
+work	O
+-	O
+up	O
+revealed	O
+no	O
+evidence	O
+of	O
+infection	B-DISO
+.	O
+
+Twenty	O
+-	O
+six	O
+of	O
+27	O
+SARS	B-DISO
+patients	O
+and	O
+5	O
+of	O
+18	O
+healthy	O
+controls	O
+had	O
+strongly	O
+stained	O
+columnar	O
+epithelia	O
+of	O
+the	O
+bronchiole	B-ANAT
+,	O
+especially	O
+the	O
+lumen	B-ANAT
+border	B-ANAT
+of	O
+the	O
+epithelia	O
+?	O
+the	O
+difference	O
+between	O
+two	O
+groups	O
+was	O
+significant	O
+.	O
+
+TITLE	O
+:	O
+[	O
+Conditions	O
+for	O
+SARS	B-DISO
+-	O
+CoV	O
+cultivation	O
+and	O
+inactivation	B-DISO
+].	O
+
+Vero	O
+and	O
+Vero	O
+-	O
+E6	O
+cell	B-ANAT
+lines	I-ANAT
+were	O
+sensitive	O
+to	O
+SARS	B-PRGE
+-	I-PRGE
+CoV	I-PRGE
+.	O
+The	O
+cytopathic	O
+changes	O
+of	O
+the	O
+cells	B-COMP
+were	O
+75	O
+%	O
+at	O
+37	O
+degrees	O
+C	O
+in	O
+5	O
+percent	O
+CO2	B-CHED
+incubator	O
+after	O
+infection	B-DISO
+.	O
+
+ABSTRACT	O
+:	O
+To	O
+establish	O
+a	O
+simple	O
+rapid	O
+and	O
+sensitive	O
+nested	O
+RT	O
+-	O
+PCR	O
+method	O
+for	O
+detection	O
+of	O
+SARS	O
+coronavirus	B-SPEC
+RNA	O
+by	O
+designing	O
+the	O
+specific	O
+primers	O
+for	O
+SARS	B-DISO
+and	O
+optimizing	O
+the	O
+parameters	O
+for	O
+PCR	O
+.	O
+
+The	O
+positive	O
+rate	O
+of	O
+patient	O
+serum	B-COMP
+and	O
+mouthwash	O
+was	O
+33	O
+.	O
+6	O
+%,	O
+(	O
+12	O
+/	O
+36	O
+)	O
+and	O
+67	O
+.	O
+5	O
+%,	O
+(	O
+27	O
+/	O
+40	O
+),	O
+respectively	O
+,	O
+while	O
+the	O
+positive	O
+rate	O
+of	O
+healthy	O
+people	O
+was	O
+zero	O
+(	O
+0	O
+/	O
+160	O
+).	O
+
+Nose	B-ANAT
+and	O
+throat	B-ANAT
+swabs	O
+of	O
+participants	O
+were	O
+tested	O
+for	O
+a	O
+broad	O
+range	O
+of	O
+pathogens	O
+.	O
+
+Routine	O
+vaccination	O
+against	O
+this	O
+virus	B-SPEC
+is	O
+not	O
+recommended	O
+.	O
+
+Antibodies	B-COMP
+in	O
+sera	B-COMP
+of	O
+patients	O
+and	O
+healthy	O
+controls	O
+against	O
+:	O
+(	O
+1	O
+)	O
+A549	O
+human	B-SPEC
+pulmonary	B-ANAT
+epithelial	B-ANAT
+cell	I-ANAT
+-	O
+line	O
+,	O
+(	O
+2	O
+)	O
+human	B-SPEC
+umbilical	O
+venous	B-ANAT
+endothelial	B-ANAT
+cells	I-ANAT
+(	O
+HUVEC	O
+),	O
+(	O
+3	O
+)	O
+primary	O
+human	B-SPEC
+pulmonary	B-ANAT
+endothelial	B-ANAT
+cells	I-ANAT
+(	O
+HPEC	B-DISO
+)	O
+were	O
+detected	O
+by	O
+cell	B-COMP
+-	O
+based	O
+ELISA	O
+and	O
+indirect	O
+immunofluorescence	O
+staining	O
+.	O
+
+ABSTRACT	O
+:	O
+A	O
+consensus	O
+sequence	O
+of	O
+the	O
+Feline	O
+coronavirus	B-SPEC
+(	O
+FCoV	O
+)	O
+(	O
+strain	O
+FIPV	O
+WSU	O
+-	O
+79	O
+/	O
+1146	O
+)	O
+genome	O
+was	O
+determined	O
+from	O
+overlapping	O
+cDNA	O
+fragments	O
+produced	O
+by	O
+RT	O
+-	O
+PCR	O
+amplification	B-DISO
+of	O
+viral	O
+RNA	O
+.	O
+
+The	O
+genomic	O
+RNA	O
+was	O
+analysed	O
+for	O
+putative	O
+cis	B-DISO
+-	O
+acting	O
+elements	O
+and	O
+the	O
+pattern	O
+of	O
+subgenomic	O
+mRNA	B-PROC
+synthesis	I-PROC
+was	O
+analysed	O
+by	O
+Northern	O
+blotting	O
+.	O
+
+Phylogenetic	O
+analyses	O
+confirmed	O
+that	O
+FIPV	O
+WSU	O
+-	O
+79	O
+/	O
+1146	O
+belongs	O
+to	O
+the	O
+coronavirus	B-SPEC
+subgroup	O
+G1	O
+-	O
+1	O
+.	O
+
+Phosphorylated	O
+N	B-PRGE
+protein	I-PRGE
+was	O
+also	O
+present	O
+in	O
+purified	O
+virions	B-COMP
+,	O
+containing	O
+at	O
+least	O
+phosphoserines	O
+156	O
+and	O
+256	O
+.	O
+
+Whilst	O
+serine	B-CHED
+9	O
+was	O
+present	O
+in	O
+a	O
+non	O
+-	O
+conserved	O
+domain	O
+,	O
+serines	O
+156	O
+,	O
+254	O
+and	O
+256	O
+were	O
+localized	O
+close	O
+to	O
+highly	O
+conserved	O
+secondary	O
+structural	O
+elements	O
+within	O
+the	O
+central	O
+domain	O
+of	O
+coronavirus	B-SPEC
+N	O
+proteins	B-CHED
+.	O
+
+Partial	O
+deletion	O
+of	O
+the	O
+SARS	B-PRGE
+-	I-PRGE
+CoV	I-PRGE
+-	I-PRGE
+S	I-PRGE
+protein	B-CHED
+cytoplasmic	B-ANAT
+domain	I-ANAT
+allowed	O
+efficient	O
+incorporation	O
+into	O
+VSV	O
+particles	O
+and	O
+led	O
+to	O
+the	O
+generation	O
+of	O
+a	O
+pseudotype	O
+(	O
+VSV	O
+-	O
+SARS	B-DISO
+-	O
+St19	B-ANAT
+)	O
+at	O
+high	O
+titre	O
+.	O
+
+The	O
+infected	O
+cat	B-SPEC
+displayed	O
+loss	O
+of	O
+weight	O
+,	O
+respiratory	B-DISO
+distress	I-DISO
+,	O
+ascitis	B-ANAT
+,	O
+anemia	B-DISO
+and	O
+died	B-PROC
+within	O
+15	O
+days	O
+after	O
+the	O
+first	O
+appearance	O
+of	O
+clinical	O
+signs	O
+.	O
+
+Recent	O
+studies	O
+suggest	O
+that	O
+SARS	B-PRGE
+-	I-PRGE
+CoV	I-PRGE
+is	O
+zoonotic	O
+and	O
+may	O
+have	O
+a	O
+broad	O
+host	B-COMP
+range	O
+besides	O
+humans	B-SPEC
+.	O
+
+A	O
+number	O
+of	O
+candidate	O
+vaccines	O
+,	O
+using	O
+a	O
+variety	O
+of	O
+approaches	O
+,	O
+are	O
+under	O
+development	B-PROC
+.	O
+
+Nucleic	B-CHED
+acid	I-CHED
+of	O
+SARS	B-DISO
+-	O
+CoV	O
+can	O
+be	O
+excreted	O
+through	O
+the	O
+stool	B-ANAT
+of	O
+patients	O
+into	O
+sewage	O
+system	O
+,	O
+and	O
+the	O
+possibility	O
+of	O
+SARS	O
+-	O
+CoV	O
+transmitting	O
+through	O
+digestive	B-ANAT
+system	I-ANAT
+cannot	O
+be	O
+excluded	O
+.	O
+
+Initial	O
+chest	B-ANAT
+radiographs	O
+of	O
+79	O
+patients	O
+,	O
+15	O
+to	O
+69	O
+years	O
+old	O
+(	O
+mean	O
+age	O
+34	O
+.	O
+1	O
+years	O
+,	O
+40	O
+men	O
+and	O
+39	O
+women	O
+),	O
+were	O
+retrospectively	O
+reviewed	O
+in	O
+the	O
+study	O
+.	O
+
+No	O
+significant	O
+difference	O
+of	O
+mean	O
+age	O
+and	O
+day	O
+(	O
+form	O
+onset	O
+of	O
+the	O
+fever	B-PROC
+to	O
+the	O
+time	O
+of	O
+initial	O
+radiographs	O
+taken	O
+)	O
+was	O
+found	O
+between	O
+the	O
+patients	O
+with	O
+and	O
+without	O
+abnormal	O
+initial	O
+chest	B-ANAT
+radiographs	O
+(	O
+P	O
+>	O
+0	O
+.	O
+05	O
+).	O
+
+Results	O
+showed	O
+that	O
+the	O
+plasmid	O
+-	O
+derived	O
+siRNAs	O
+targeting	B-PROC
+the	O
+non	B-PRGE
+-	I-PRGE
+structural	I-PRGE
+protein	I-PRGE
+1	I-PRGE
+(	O
+NSP1	B-PRGE
+)	O
+sequence	O
+of	O
+the	O
+SARS	B-DISO
+-	O
+CoV	O
+genome	O
+could	O
+specifically	O
+inhibit	O
+the	O
+expression	B-PROC
+of	O
+the	O
+NSP1	B-PRGE
+sequence	I-PRGE
+and	O
+effectively	O
+suppress	O
+the	O
+replication	O
+and	O
+propagation	O
+of	O
+SARS	B-PRGE
+-	I-PRGE
+CoV	I-PRGE
+in	O
+cultured	O
+Vero	O
+E6	O
+cell	O
+lines	O
+.	O
+
+The	O
+corticosteroid	B-CHED
+group	O
+had	O
+more	O
+adverse	O
+outcomes	O
+(	O
+37	O
+.	O
+9	O
+%	O
+vs	O
+.	O
+16	O
+.	O
+7	O
+%)	O
+despite	O
+younger	O
+age	O
+and	O
+less	O
+comorbidity	O
+.	O
+
+CONCLUSIONS	O
+:	O
+Despite	O
+more	O
+favourable	O
+baseline	O
+characteristics	O
+and	O
+similar	O
+peak	O
+LDH	B-PRGE
+levels	O
+,	O
+SARS	B-DISO
+patients	O
+given	O
+corticosteroid	B-CHED
+had	O
+more	O
+adverse	O
+outcomes	O
+.	O
+
+All	O
+residues	O
+except	O
+Thr2p	O
+and	O
+Lys9p	B-PRGE
+are	O
+accessible	O
+for	O
+T	B-ANAT
+-	I-ANAT
+cell	I-ANAT
+recognition	O
+.	O
+
+TITLE	O
+:	O
+Papain	B-ENZY
+-	I-PRGE
+like	I-PRGE
+protease	I-PRGE
+2	I-PRGE
+(	O
+PLP2	B-PRGE
+)	O
+from	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+coronavirus	B-SPEC
+(	O
+SARS	B-DISO
+-	O
+CoV	O
+):	O
+expression	O
+,	O
+purification	O
+,	O
+characterization	O
+,	O
+and	O
+inhibition	B-PROC
+.	O
+
+ABSTRACT	O
+:	O
+Although	O
+the	O
+recent	O
+SARS	O
+coronavirus	B-SPEC
+(	O
+SARS	B-DISO
+-	O
+CoV	O
+)	O
+that	O
+appeared	O
+in	O
+2002	O
+has	O
+now	O
+been	O
+contained	O
+,	O
+the	O
+possibility	O
+of	O
+re	O
+-	O
+emergence	O
+of	O
+SARS	B-PRGE
+-	I-PRGE
+CoV	I-PRGE
+remains	O
+.	O
+
+Mice	B-SPEC
+vaccinated	O
+with	O
+VSV	O
+-	O
+S	O
+developed	O
+SARS	B-PRGE
+-	I-PRGE
+neutralizing	I-PRGE
+antibody	B-COMP
+and	O
+were	O
+able	O
+to	O
+control	O
+a	O
+challenge	O
+with	O
+SARS	B-DISO
+-	O
+CoV	O
+performed	O
+at	O
+1	O
+month	O
+or	O
+4	O
+months	O
+after	O
+a	O
+single	O
+vaccination	O
+.	O
+
+TITLE	O
+:	O
+Multiple	O
+organ	B-ANAT
+infection	B-DISO
+and	O
+the	O
+pathogenesis	B-DISO
+of	O
+SARS	B-DISO
+.	O
+
+ABSTRACT	O
+:	O
+Both	O
+viral	O
+effect	O
+and	O
+immune	O
+-	O
+mediated	O
+mechanism	O
+are	O
+involved	O
+in	O
+the	O
+pathogenesis	B-DISO
+of	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+-	O
+associated	O
+coronavirus	B-SPEC
+(	O
+SARS	B-DISO
+-	O
+CoV	O
+)	O
+infection	B-DISO
+.	O
+
+Tests	O
+of	O
+non	O
+-	O
+SARS	B-DISO
+-	O
+pneumonia	B-DISO
+patients	O
+did	O
+not	O
+show	O
+the	O
+same	O
+autoAb	O
+production	O
+as	O
+in	O
+SARS	B-DISO
+patients	O
+.	O
+
+TITLE	O
+:	O
+[	O
+Bacterial	B-DISO
+tracheitis	I-DISO
+:	O
+an	O
+infectious	B-DISO
+cause	O
+of	O
+upper	B-DISO
+airway	I-DISO
+obstruction	I-DISO
+to	O
+be	O
+considered	O
+in	O
+children	O
+].	O
+
+Four	O
+children	O
+had	O
+a	O
+history	O
+of	O
+acute	B-DISO
+laryngotracheitis	I-DISO
+,	O
+one	O
+had	O
+Down	B-DISO
+syndrome	I-DISO
+and	O
+another	O
+had	O
+interauricular	B-DISO
+communication	I-DISO
+.	O
+
+Bacterial	O
+pathogens	O
+were	O
+isolated	O
+from	O
+tracheal	O
+secretion	B-PROC
+culture	O
+in	O
+seven	O
+children	O
+(	O
+58	O
+%)	O
+and	O
+the	O
+most	O
+common	O
+was	O
+Staphylococcus	B-SPEC
+aureus	I-SPEC
+(	O
+42	O
+%).	O
+
+Three	O
+children	O
+(	O
+25	O
+%)	O
+developed	O
+lobar	B-DISO
+pneumonia	I-DISO
+and	O
+one	O
+developed	O
+congestive	O
+cardiac	B-DISO
+insufficiency	I-DISO
+as	O
+a	O
+complication	B-DISO
+of	O
+bacterial	B-DISO
+tracheitis	I-DISO
+.	O
+
+Based	O
+on	O
+the	O
+potent	O
+vasoactive	O
+role	O
+of	O
+PGD	B-CHED
+(	O
+2	O
+),	O
+it	O
+appears	O
+that	O
+the	O
+chicken	B-SPEC
+HG	O
+is	O
+a	O
+site	O
+of	O
+active	O
+mucosal	B-PROC
+immunity	I-PROC
+partially	O
+mediated	O
+by	O
+PGD	B-CHED
+(	O
+2	O
+)	O
+synthesized	O
+by	O
+H	O
+-	O
+PGDS	O
+in	O
+the	O
+gland	B-ANAT
+.	O
+
+ABSTRACT	O
+:	O
+The	O
+open	O
+reading	O
+frame	O
+3	O
+(	O
+ORF3	O
+)	O
+of	O
+the	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+coronavirus	B-SPEC
+(	O
+SARS	B-DISO
+-	O
+CoV	O
+)	O
+genome	O
+encodes	O
+a	O
+predicted	O
+154	O
+-	O
+amino	B-CHED
+acid	I-CHED
+protein	B-CHED
+,	O
+which	O
+lacks	O
+similarities	O
+to	O
+any	O
+known	O
+protein	B-CHED
+,	O
+and	O
+is	O
+named	O
+3b	O
+.	O
+
+Immediately	O
+after	O
+the	O
+diagnosis	O
+of	O
+DNM	O
+,	O
+broad	O
+-	O
+spectrum	O
+antibiotics	O
+were	O
+administered	O
+empirically	O
+,	O
+and	O
+surgical	O
+treatments	O
+consisting	O
+of	O
+cervical	B-ANAT
+drainage	B-ANAT
+,	O
+thoracotomy	O
+with	O
+radical	B-CHED
+surgical	O
+debridement	O
+of	O
+the	O
+mediastinum	B-ANAT
+and	O
+excision	O
+of	O
+necrotic	B-PROC
+tissue	B-ANAT
+,	O
+decortication	O
+,	O
+and	O
+irrigation	B-PROC
+were	O
+performed	O
+in	O
+all	O
+cases	O
+.	O
+
+Herbal	O
+preparations	O
+had	O
+been	O
+used	O
+historically	O
+in	O
+China	O
+to	O
+treat	O
+influenza	B-DISO
+-	O
+like	O
+diseases	O
+.	O
+
+We	O
+hypothesized	O
+that	O
+SARS	B-PRGE
+-	I-PRGE
+CoV	I-PRGE
+encodes	O
+a	O
+small	B-PRGE
+envelope	I-PRGE
+E	I-PRGE
+protein	B-CHED
+that	O
+is	O
+homologous	O
+with	O
+MHV	B-PRGE
+E	I-PRGE
+protein	B-CHED
+,	O
+thus	O
+inducing	O
+T	B-PROC
+-	I-PROC
+cell	I-PROC
+apoptosis	B-PATH
+.	O
+
+To	O
+test	O
+this	O
+hypothesis	O
+,	O
+a	O
+cDNA	O
+encoding	O
+SARS	B-PRGE
+-	I-PRGE
+CoV	I-PRGE
+E	I-PRGE
+protein	B-CHED
+was	O
+created	O
+using	O
+whole	O
+gene	O
+synthesis	B-PROC
+.	O
+
+TITLE	O
+:	O
+Fatal	O
+herpes	B-DISO
+simplex	I-DISO
+virus	B-PROC
+infection	I-PROC
+in	O
+Darier	B-DISO
+disease	I-DISO
+under	O
+corticotherapy	O
+.	O
+
+A	O
+skin	B-ANAT
+biopsy	O
+was	O
+performed	O
+and	O
+immunohistochemical	O
+examination	O
+identified	O
+a	O
+type	O
+-	O
+2	O
+HSV	B-DISO
+infection	I-DISO
+.	O
+
+At	O
+autopsy	O
+,	O
+a	O
+severe	O
+interstitial	B-ANAT
+type	O
+-	O
+2	O
+HSV	B-SPEC
+pneumonitis	B-DISO
+with	O
+extensive	O
+necrotic	B-PROC
+areas	O
+was	O
+found	O
+,	O
+in	O
+association	O
+with	O
+gastro	B-ANAT
+-	O
+intestinal	B-ANAT
+involvement	O
+.	O
+
+The	O
+different	O
+risk	O
+factors	O
+for	O
+HSV	B-DISO
+infection	I-DISO
+in	O
+this	O
+patient	O
+are	O
+reviewed	O
+.	O
+
+ABSTRACT	O
+:	O
+Severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+(	O
+SARS	B-DISO
+)	O
+is	O
+a	O
+significant	O
+emerging	B-DISO
+infectious	I-DISO
+disease	I-DISO
+.	O
+
+We	O
+present	O
+two	O
+cases	O
+of	O
+treating	O
+severe	B-DISO
+sepsis	I-DISO
+utilizing	O
+recombinant	B-PRGE
+human	I-PRGE
+activated	I-PRGE
+protein	B-CHED
+C	I-PRGE
+(	O
+rhAPC	O
+)	O
+in	O
+the	O
+course	O
+of	O
+bilateral	B-DISO
+pneumonia	I-DISO
+in	O
+patients	O
+with	O
+hairy	B-DISO
+cell	I-DISO
+leukemia	I-DISO
+(	O
+HCL	B-CHED
+)	O
+and	O
+T	B-DISO
+-	I-DISO
+cell	I-DISO
+acute	I-DISO
+lymphoblastic	B-ANAT
+leukemia	I-DISO
+(	O
+ALL	O
+).	O
+
+Among	O
+10	O
+,	O
+075	O
+(	O
+87	O
+.	O
+9	O
+percent	O
+)	O
+discharged	O
+from	O
+the	O
+ED	O
+,	O
+there	O
+were	O
+28	O
+re	O
+-	O
+attendees	O
+diagnosed	O
+to	O
+have	O
+SARS	B-DISO
+later	O
+,	O
+giving	O
+an	O
+undertriage	O
+rate	O
+of	O
+0	O
+.	O
+3	O
+percent	O
+.	O
+
+TITLE	O
+:	O
+Emerging	O
+infectious	B-DISO
+agents	O
+.	O
+
+The	O
+rest	B-FUNC
+could	O
+be	O
+infected	O
+with	O
+FECV	B-SPEC
+and	O
+FIPV	O
+but	O
+10	O
+/	O
+22	O
+cats	B-SPEC
+had	O
+monocytes	B-ANAT
+that	O
+only	O
+sustained	O
+FIPV	O
+infection	B-DISO
+and	O
+9	O
+/	O
+22	O
+sustained	O
+neither	O
+FIPV	O
+nor	O
+FECV	B-SPEC
+infection	B-DISO
+.	O
+
+TITLE	O
+:	O
+Pulmonary	B-ANAT
+vasodilator	B-CHED
+therapy	O
+in	O
+congenital	B-DISO
+diaphragmatic	I-DISO
+hernia	I-DISO
+:	O
+acute	O
+,	O
+late	O
+,	O
+and	O
+chronic	O
+pulmonary	B-ANAT
+hypertension	I-DISO
+.	O
+
+Previous	O
+studies	O
+on	O
+various	O
+coronaviruses	O
+indicate	O
+that	O
+protein	B-CHED
+-	O
+protein	B-CHED
+interactions	O
+amongst	O
+various	O
+coronavirus	B-SPEC
+proteins	B-CHED
+are	O
+critical	O
+for	O
+viral	B-PROC
+assembly	I-PROC
+and	O
+morphogenesis	B-PROC
+.	O
+
+Our	O
+results	O
+show	O
+that	O
+the	O
+interaction	O
+between	O
+the	O
+M	O
+and	O
+N	O
+proteins	B-CHED
+does	O
+take	O
+place	O
+in	O
+vitro	O
+.	O
+
+TITLE	O
+:	O
+Reversible	O
+myocardial	B-DISO
+dysfunction	I-DISO
+after	O
+cardiopulmonary	B-ANAT
+resuscitation	O
+.	O
+
+The	O
+aim	O
+of	O
+the	O
+present	O
+work	O
+has	O
+been	O
+to	O
+study	O
+and	O
+describe	O
+the	O
+possible	O
+development	B-PROC
+of	O
+myocardial	B-DISO
+dysfunction	I-DISO
+in	O
+patients	O
+resuscitated	O
+after	O
+cardio	B-DISO
+-	I-DISO
+respiratory	I-DISO
+arrest	I-DISO
+,	O
+in	O
+the	O
+absence	O
+of	O
+acute	O
+or	O
+previous	O
+coronary	B-DISO
+artery	I-DISO
+disease	I-DISO
+.	O
+
+Chest	B-ANAT
+radiograph	O
+revealed	O
+diffuse	O
+bilateral	O
+infiltrates	B-DISO
+.	O
+
+After	O
+unsuccessful	O
+fluid	O
+resuscitation	O
+with	O
+crystalloid	B-COMP
+fluid	O
+,	O
+the	O
+patient	O
+'	O
+s	O
+condition	B-DISO
+improved	O
+rapidly	O
+with	O
+human	B-PRGE
+albumin	I-PRGE
+boluses	O
+.	O
+
+Acute	B-DISO
+renal	I-DISO
+failure	I-DISO
+required	O
+dialysis	B-SPEC
+but	O
+with	O
+subsequent	O
+recovery	O
+.	O
+
+Rapid	O
+infusion	O
+of	O
+albumin	B-PRGE
+might	O
+be	O
+a	O
+rescue	O
+option	O
+in	O
+cases	O
+of	O
+severe	O
+TRALI	B-DISO
+with	O
+extensive	O
+pulmonary	B-ANAT
+capillary	I-ANAT
+leak	O
+during	O
+the	O
+acute	O
+phase	O
+.	O
+
+Here	O
+ACE2	O
+is	O
+poised	O
+to	O
+metabolise	O
+circulating	O
+peptides	B-CHED
+which	O
+may	O
+include	O
+angiotensin	B-PRGE
+II	I-PRGE
+,	O
+a	O
+potent	O
+vasoconstrictor	O
+and	O
+the	O
+product	O
+of	O
+angiotensin	B-PRGE
+I	I-PRGE
+cleavage	B-PROC
+by	O
+ACE	B-PRGE
+.	O
+
+The	O
+skin	B-ANAT
+lesions	O
+were	O
+caused	O
+by	O
+a	O
+pyogranulomatous	O
+-	O
+necrotising	O
+dermal	O
+phlebitis	B-DISO
+and	O
+periphlebitis	B-DISO
+.	O
+
+An	O
+atypical	O
+RNA	O
+pseudoknot	O
+with	O
+an	O
+extra	O
+stem	B-ANAT
+formed	O
+by	O
+complementary	O
+sequences	O
+within	O
+loop	O
+2	O
+of	O
+an	O
+H	O
+-	O
+type	O
+pseudoknot	O
+is	O
+characterized	O
+in	O
+the	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+coronavirus	B-SPEC
+(	O
+SARS	B-DISO
+CoV	O
+)	O
+genome	O
+.	O
+
+Four	O
+(	O
+6	O
+.	O
+7	O
+%)	O
+were	O
+biochemically	O
+hypothyroid	B-DISO
+,	O
+being	O
+comprised	O
+of	O
+three	O
+with	O
+central	B-DISO
+hypothyroidism	I-DISO
+and	O
+one	O
+with	O
+primary	B-DISO
+hypothyroidism	I-DISO
+.	O
+
+TITLE	O
+:	O
+[	O
+Choice	O
+of	O
+optimal	O
+respiratory	O
+support	O
+in	O
+acute	O
+parenchymatous	O
+respiratory	B-DISO
+failure	I-DISO
+].	O
+
+In	O
+acute	O
+lung	B-ANAT
+lesion	O
+syndrome	B-DISO
+(	O
+ALLS	O
+)	O
+and	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+(	O
+ARDS	B-DISO
+),	O
+the	O
+oxygenation	B-PROC
+index	O
+(	O
+PaO2	O
+/	O
+FiO2	O
+)	O
+reflects	O
+the	O
+degree	O
+of	O
+alveolar	B-ANAT
+-	O
+capillary	B-ANAT
+membrane	B-COMP
+damage	O
+.	O
+
+It	O
+has	O
+been	O
+established	O
+that	O
+the	O
+function	O
+of	O
+the	O
+alveolar	B-ANAT
+-	O
+capillary	B-ANAT
+membrane	B-COMP
+is	O
+not	O
+impaired	B-DISO
+with	O
+the	O
+PaO2	O
+/	O
+FiO2	O
+ratio	O
+of	O
+more	O
+than	O
+1	O
+.	O
+5	O
+and	O
+the	O
+ratio	O
+of	O
+less	O
+than	O
+1	O
+.	O
+0	O
+is	O
+typical	O
+of	O
+the	O
+severe	O
+course	O
+of	O
+the	O
+severe	O
+course	O
+of	O
+ARDS	O
+and	O
+suggests	O
+both	O
+alveolar	B-ANAT
+-	O
+capillary	B-ANAT
+membrane	B-COMP
+damage	O
+and	O
+energy	O
+deficiency	O
+.	O
+
+TITLE	O
+:	O
+Methods	O
+for	O
+estimating	O
+the	O
+case	O
+fatality	O
+ratio	O
+for	O
+a	O
+novel	O
+,	O
+emerging	B-DISO
+infectious	I-DISO
+disease	I-DISO
+.	O
+
+TITLE	O
+:	O
+Quality	O
+assurance	O
+for	O
+the	O
+diagnostics	O
+of	O
+viral	B-DISO
+diseases	I-DISO
+to	O
+enhance	O
+the	O
+emergency	B-DISO
+preparedness	O
+in	O
+Europe	O
+.	O
+
+ENIVD	O
+fulfils	O
+many	O
+of	O
+the	O
+important	O
+tasks	O
+required	O
+for	O
+the	O
+surveillance	O
+and	O
+control	O
+of	O
+imported	O
+,	O
+rare	O
+and	O
+emerging	O
+viral	B-DISO
+infections	I-DISO
+such	O
+as	O
+the	O
+exchange	O
+of	O
+expertise	O
+and	O
+the	O
+organisation	B-PROC
+of	O
+external	O
+quality	O
+assurance	O
+(	O
+EQA	O
+)	O
+programmes	O
+,	O
+both	O
+of	O
+which	O
+are	O
+needed	O
+to	O
+improve	O
+diagnostics	O
+.	O
+
+The	O
+word	O
+""""	O
+atypical	O
+""""	O
+is	O
+reserved	O
+for	O
+unusual	O
+presentations	O
+of	O
+KD	O
+such	O
+as	O
+those	O
+with	O
+hemophagocytic	B-DISO
+syndrome	I-DISO
+or	O
+nerve	B-DISO
+palsy	I-DISO
+.	O
+
+ABSTRACT	O
+:	O
+A	O
+ProSeal	O
+laryngeal	B-ANAT
+mask	O
+airway	B-ANAT
+was	O
+used	O
+for	O
+anaesthesia	B-DISO
+for	O
+laparoscopic	O
+surgery	O
+in	O
+a	O
+26	O
+y	O
+old	O
+male	O
+patient	O
+with	O
+acute	B-DISO
+appendicitis	I-DISO
+.	O
+
+Long	O
+-	O
+term	O
+corticotherapy	O
+,	O
+chronic	O
+immune	B-DISO
+diseases	I-DISO
+,	O
+fever	B-PROC
+of	O
+38	O
+degrees	O
+C	O
+or	O
+higher	O
+,	O
+white	B-ANAT
+blood	I-ANAT
+cell	I-ANAT
+count	O
+,	O
+pulse	B-PROC
+rate	I-PROC
+,	O
+FIM	B-DISO
+,	O
+SIRS	B-DISO
+,	O
+sepsis	B-DISO
+,	O
+CRP	O
+of	O
+3	O
+mg	O
+/	O
+mL	O
+or	O
+higher	O
+,	O
+and	O
+PCT	B-DISO
+of	O
+0	O
+.	O
+5	O
+ng	O
+/	O
+mL	O
+or	O
+higher	O
+were	O
+associated	O
+with	O
+an	O
+infection	B-DISO
+at	O
+admission	O
+.	O
+
+In	O
+multivariate	O
+analysis	O
+,	O
+only	O
+sepsis	B-DISO
+and	O
+CRP	O
+of	O
+3	O
+mg	O
+/	O
+mL	O
+or	O
+higher	O
+were	O
+still	O
+associated	O
+with	O
+an	O
+infection	B-DISO
+;	O
+PCT	B-DISO
+levels	O
+do	O
+not	O
+show	O
+any	O
+significant	O
+association	O
+in	O
+the	O
+multivariate	O
+analysis	O
+.	O
+
+TITLE	O
+:	O
+Serine	B-CHED
+-	O
+scanning	O
+mutagenesis	B-PROC
+studies	O
+of	O
+the	O
+C	O
+-	O
+terminal	O
+heptad	O
+repeats	O
+in	O
+the	O
+SARS	B-DISO
+coronavirus	B-SPEC
+S	I-PRGE
+glycoprotein	I-PRGE
+highlight	O
+the	O
+important	O
+role	O
+of	O
+the	O
+short	O
+helical	O
+region	O
+.	O
+
+Here	O
+,	O
+we	O
+have	O
+applied	O
+serine	B-CHED
+-	O
+scanning	O
+mutagenesis	B-PROC
+to	O
+the	O
+C	O
+-	O
+terminal	O
+-	O
+most	O
+heptad	O
+-	O
+repeat	O
+region	O
+in	O
+the	O
+SARS	B-PRGE
+-	I-PRGE
+CoV	I-PRGE
+S	I-PRGE
+glycoprotein	B-CHED
+to	O
+investigate	O
+the	O
+functional	O
+role	O
+of	O
+this	O
+region	O
+in	O
+membrane	B-PROC
+fusion	I-PROC
+.	O
+
+ABSTRACT	O
+:	O
+Severe	O
+acute	O
+respiratory	O
+syndrome	O
+(	O
+SARS	B-DISO
+)	O
+is	O
+caused	O
+by	O
+an	O
+emergent	O
+coronavirus	B-SPEC
+(	O
+SARS	B-DISO
+-	O
+CoV	O
+),	O
+for	O
+which	O
+there	O
+is	O
+currently	O
+no	O
+effective	O
+treatment	O
+.	O
+
+Synthetic	O
+peptides	B-CHED
+M1	O
+-	O
+31	O
+derived	O
+from	O
+the	O
+N	O
+-	O
+terminal	O
+epitope	B-CHED
+and	O
+M132	O
+-	O
+161	O
+derived	O
+from	O
+the	O
+C	O
+-	O
+terminal	O
+epitope	B-CHED
+were	O
+highly	O
+reactive	O
+with	O
+all	O
+of	O
+the	O
+convalescent	O
+-	O
+phase	O
+sera	B-COMP
+from	O
+40	O
+SARS	B-DISO
+patients	O
+but	O
+not	O
+with	O
+30	O
+control	O
+serum	B-COMP
+samples	O
+from	O
+healthy	O
+blood	O
+donors	O
+,	O
+suggesting	O
+their	O
+potential	O
+application	O
+for	O
+serologic	O
+diagnosis	O
+of	O
+SARS	B-DISO
+.	O
+
+TITLE	O
+:	O
+Performance	O
+of	O
+single	O
+-	O
+step	O
+gel	O
+-	O
+based	O
+reverse	B-PROC
+transcription	I-PROC
+-	O
+PCR	O
+(	O
+RT	O
+-	O
+PCR	O
+)	O
+assays	O
+equivalent	O
+to	O
+that	O
+of	O
+real	O
+-	O
+time	O
+RT	O
+-	O
+PCR	O
+assays	O
+for	O
+detection	O
+of	O
+the	O
+severe	O
+acute	O
+respiratory	O
+syndrome	O
+-	O
+associated	O
+coronavirus	B-SPEC
+.	O
+
+The	O
+framework	O
+is	O
+an	O
+adaptation	B-PROC
+of	O
+narrative	O
+analysis	O
+,	O
+a	O
+qualitative	O
+method	O
+that	O
+is	O
+used	O
+to	O
+investigate	O
+a	O
+phenomenon	O
+through	O
+interpretation	O
+of	O
+the	O
+stories	O
+people	O
+tell	O
+about	O
+their	O
+experiences	O
+.	O
+
+ABSTRACT	O
+:	O
+To	O
+confirm	O
+an	O
+infection	O
+with	O
+the	O
+new	O
+coronavirus	B-SPEC
+(	O
+SARS	B-DISO
+-	O
+CoV	O
+)	O
+causing	O
+the	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+(	O
+SARS	B-DISO
+)	O
+diagnostic	O
+assays	O
+for	O
+detection	O
+of	O
+SARS	B-PRGE
+-	I-PRGE
+CoV	I-PRGE
+specific	I-PRGE
+antibody	B-COMP
+are	O
+necessary	O
+.	O
+
+Participating	O
+laboratories	O
+(	O
+9	O
+/	O
+20	O
+)	O
+correctly	O
+detected	O
+anti	B-PRGE
+-	I-PRGE
+SARS	I-PRGE
+antibodies	B-COMP
+in	O
+serum	B-COMP
+samples	O
+without	O
+false	O
+positive	O
+results	O
+in	O
+an	O
+immunofluorescence	O
+assay	O
+.	O
+
+The	O
+overall	O
+results	O
+clearly	O
+demonstrate	O
+that	O
+serological	O
+diagnosis	O
+of	O
+SARS	B-PRGE
+-	I-PRGE
+CoV	I-PRGE
+remains	O
+at	O
+an	O
+early	O
+stage	O
+of	O
+development	B-PROC
+,	O
+with	O
+further	O
+technical	O
+improvements	O
+required	O
+,	O
+particularly	O
+with	O
+respect	O
+to	O
+the	O
+use	O
+of	O
+SARS	B-DISO
+specific	O
+EIAs	O
+.	O
+
+(	O
+2	O
+)	O
+Respiratory	B-DISO
+symptoms	I-DISO
+after	O
+ARDS	B-DISO
+are	O
+more	O
+prevalent	O
+than	O
+previously	O
+indicated	O
+,	O
+but	O
+improve	O
+over	O
+the	O
+first	O
+12	O
+months	O
+of	O
+recovery	O
+.	O
+
+TITLE	O
+:	O
+Expression	B-PROC
+and	O
+purification	O
+of	O
+N	O
+and	O
+E	O
+proteins	B-CHED
+from	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+(	O
+SARS	B-DISO
+)-	O
+associated	O
+coronavirus	O
+:	O
+a	O
+comparative	O
+study	O
+.	O
+
+ABSTRACT	O
+:	O
+Histidine	B-CHED
+-	O
+tagged	O
+N	B-PRGE
+(	I-PRGE
+rNH	I-PRGE
+)	I-PRGE
+and	I-PRGE
+E	I-PRGE
+(	O
+rEH	B-PRGE
+)	O
+proteins	B-CHED
+of	O
+Severe	B-DISO
+Acute	I-DISO
+Respiratory	I-DISO
+Syndrome	I-DISO
+(	O
+SARS	B-DISO
+)-	O
+coronovirus	O
+were	O
+expressed	B-PROC
+in	O
+the	O
+baculovirus	B-SPEC
+/	O
+insect	B-SPEC
+cell	B-COMP
+system	O
+and	O
+purified	O
+by	O
+immobilized	O
+metal	B-CHED
+affinity	O
+chromatography	O
+.	O
+
+Virus	B-PROC
+replication	I-PROC
+is	O
+not	O
+necessary	O
+for	O
+IFN	B-PRGE
+induction	O
+since	O
+efficient	O
+IFN	B-PRGE
+expression	B-PROC
+could	O
+be	O
+obtained	O
+also	O
+by	O
+the	O
+cocultivation	O
+of	O
+normal	O
+PBMC	O
+with	O
+fixed	B-ANAT
+SARS	B-DISO
+-	O
+CoV	O
+-	O
+infected	O
+cells	B-COMP
+.	O
+
+A	O
+combination	O
+of	O
+IFN	B-PRGE
+-	I-PRGE
+alpha	I-PRGE
+and	I-PRGE
+-	I-PRGE
+gamma	I-PRGE
+strongly	O
+inhibited	O
+SARS	B-DISO
+-	O
+CoV	O
+replication	O
+in	O
+Vero	B-ANAT
+cells	I-ANAT
+,	O
+while	O
+the	O
+single	O
+cytokines	O
+were	O
+much	O
+less	O
+effective	O
+.	O
+
+Neutrophil	B-PRGE
+elastase	I-PRGE
+activities	O
+in	O
+the	O
+bronchoalveolar	B-ANAT
+lavage	I-ANAT
+fluid	I-ANAT
+,	O
+serum	B-COMP
+,	O
+and	O
+lung	B-ANAT
+tissue	I-ANAT
+were	O
+all	O
+significantly	O
+lower	O
+in	O
+the	O
+sivelestat	O
+group	O
+than	O
+in	O
+the	O
+lipopolysaccharide	B-CHED
+group	O
+(	O
+p	O
+<	O
+.	O
+05	O
+).	O
+
+Lipopolysaccharide	B-CHED
+induces	O
+leukocyte	B-PROC
+adhesion	B-DISO
+in	O
+the	O
+pulmonary	B-ANAT
+microcirculation	B-PROC
+,	O
+resulting	O
+in	O
+decreased	O
+tissue	B-PRGE
+hemoglobin	B-CHED
+oxygen	B-CHED
+and	O
+alveolar	B-ANAT
+and	O
+interstitial	B-DISO
+edema	I-DISO
+.	O
+
+The	O
+selective	O
+neutrophil	B-CHED
+elastase	I-CHED
+inhibitor	I-CHED
+sivelestat	O
+reduces	O
+neutrophil	B-PRGE
+elastase	I-PRGE
+activity	O
+and	O
+attenuates	O
+acute	O
+changes	O
+in	O
+the	O
+pulmonary	B-ANAT
+microcirculation	B-PROC
+.	O
+
+Nine	O
+thousand	O
+one	O
+hundred	O
+twenty	O
+-	O
+six	O
+with	O
+blunt	O
+injury	O
+were	O
+ICU	O
+admissions	O
+,	O
+and	O
+5	O
+,	O
+260	O
+(	O
+58	O
+%)	O
+met	B-CHED
+study	O
+criteria	O
+(	O
+72	O
+%	O
+male	O
+).	O
+
+Incidences	O
+of	O
+VAP	O
+,	O
+ARDS	B-DISO
+,	O
+and	O
+death	B-PROC
+were	O
+5	O
+%,	O
+1	O
+%,	O
+and	O
+1	O
+%,	O
+respectively	O
+.	O
+
+ABSTRACT	O
+:	O
+Severe	O
+acute	O
+respiratory	O
+syndrome	O
+(	O
+SARS	B-DISO
+)	O
+is	O
+a	O
+recently	O
+emerged	O
+infectious	B-DISO
+disease	I-DISO
+caused	O
+by	O
+a	O
+novel	B-SPEC
+coronavirus	I-SPEC
+,	O
+which	O
+has	O
+been	O
+designated	O
+the	O
+SARS	B-DISO
+coronavirus	B-SPEC
+(	O
+SARS	B-DISO
+-	O
+CoV	O
+).	O
+
+To	O
+date	O
+,	O
+molecular	O
+assays	O
+for	O
+the	O
+detection	O
+of	O
+SARS	B-PRGE
+-	I-PRGE
+CoV	I-PRGE
+has	O
+focused	O
+mainly	O
+on	O
+reverse	B-PRGE
+transcriptase	I-PRGE
+-	O
+PCR	B-PRGE
+(	O
+RT	O
+-	O
+PCR	O
+)	O
+analysis	O
+of	O
+specimens	O
+.	O
+
+This	O
+nucleic	B-CHED
+acid	I-CHED
+capture	O
+system	O
+was	O
+effective	O
+in	O
+improving	O
+the	O
+sensitivity	O
+of	O
+the	O
+RT	O
+-	O
+PCR	O
+,	O
+due	O
+to	O
+enriching	O
+and	O
+purifying	O
+SARS	B-PRGE
+-	I-PRGE
+CoV	I-PRGE
+RNA	I-PRGE
+.	O
+
+It	O
+is	O
+believed	O
+that	O
+the	O
+modulation	O
+of	O
+apoptosis	B-PATH
+is	O
+relevant	O
+to	O
+diseases	O
+that	O
+are	O
+caused	O
+by	O
+various	O
+viruses	B-SPEC
+.	O
+
+These	O
+preliminary	O
+data	O
+provide	O
+important	O
+information	O
+on	O
+both	O
+the	O
+pathogenesis	B-DISO
+and	O
+potential	O
+antiviral	B-CHED
+targets	O
+of	O
+SARS	B-PRGE
+-	I-PRGE
+CoV	I-PRGE
+.	O
+
+TITLE	O
+:	O
+Elicitation	O
+of	O
+immunity	B-PROC
+in	O
+mice	B-SPEC
+after	O
+immunization	O
+with	O
+the	O
+S2	O
+subunit	O
+of	O
+the	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+coronavirus	B-SPEC
+.	O
+
+ABSTRACT	O
+:	O
+The	O
+S2	O
+domain	O
+of	O
+the	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+coronavirus	B-SPEC
+(	O
+SARS	B-DISO
+-	O
+CoV	O
+)	O
+spike	O
+(	O
+S	O
+)	O
+protein	B-CHED
+is	O
+responsible	O
+for	O
+fusion	O
+between	O
+virus	B-SPEC
+and	O
+target	O
+cell	B-COMP
+membranes	I-COMP
+,	O
+and	O
+is	O
+expected	O
+to	O
+be	O
+immungenic	O
+.	O
+
+These	O
+results	O
+suggest	O
+that	O
+the	O
+recombinant	O
+proteins	B-CHED
+N	O
+and	O
+S3	O
+are	O
+potentially	O
+useful	O
+antigens	B-CHED
+for	O
+a	O
+serological	O
+diagnosis	O
+of	O
+SARS	B-DISO
+.	O
+
+In	O
+consideration	O
+of	O
+possible	O
+cross	O
+-	O
+reactivity	O
+among	O
+N	O
+proteins	B-CHED
+of	O
+SARS	B-PRGE
+-	I-PRGE
+CoV	I-PRGE
+and	O
+other	O
+coronaviruses	O
+,	O
+immunoassays	O
+using	O
+recombinant	O
+N	B-PRGE
+protein	I-PRGE
+in	O
+combination	O
+with	O
+S3	O
+as	O
+antigens	B-CHED
+might	O
+improve	O
+the	O
+specificity	O
+of	O
+SARS	B-DISO
+diagnoses	O
+.	O
+
+TITLE	O
+:	O
+Amotosalen	O
+photochemical	O
+inactivation	B-DISO
+of	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+coronavirus	B-SPEC
+in	O
+human	B-SPEC
+platelet	B-ANAT
+concentrates	O
+.	O
+
+Potent	O
+inactivation	B-DISO
+of	O
+SARS	B-PRGE
+-	I-PRGE
+CoV	I-PRGE
+therefore	O
+extends	O
+the	O
+capability	O
+of	O
+the	O
+INTERCEPT	O
+Blood	B-ANAT
+System	O
+in	O
+inactivating	O
+a	O
+broad	O
+spectrum	O
+of	O
+human	B-SPEC
+pathogens	O
+including	O
+recently	O
+emerging	O
+respiratory	O
+viruses	B-SPEC
+.	O
+
+Phylogenetic	O
+analysis	O
+indicated	O
+that	O
+strains	O
+with	O
+different	O
+genetic	B-PROC
+markers	I-PROC
+cocirculate	O
+in	O
+France	O
+.	O
+
+Risk	O
+factors	O
+associated	O
+with	O
+psychological	B-DISO
+distress	I-DISO
+were	O
+identified	O
+.	O
+
+ABSTRACT	O
+:	O
+The	O
+chemokines	O
+keratinocyte	O
+-	O
+Derived	O
+Cytokine	O
+(	O
+KC	O
+)	O
+and	O
+macrophage	B-ANAT
+inflammatory	O
+protein	B-CHED
+(	O
+MIP	B-DISO
+)-	O
+2	O
+,	O
+murine	B-SPEC
+equivalents	O
+of	O
+human	B-SPEC
+interleukin	B-PRGE
+8	I-PRGE
+,	O
+have	O
+been	O
+implicated	O
+in	O
+remote	O
+injury	O
+after	O
+acute	O
+hind	B-ANAT
+limb	I-ANAT
+ischemia	B-DISO
+/	O
+reperfusion	O
+(	O
+I	O
+/	O
+R	O
+).	O
+
+B6	O
+,	O
+129SF2	O
+/	O
+J	O
+mice	B-SPEC
+were	O
+subjected	O
+to	O
+either	O
+3	O
+hours	O
+of	O
+unilateral	O
+hind	B-ANAT
+limb	I-ANAT
+ischemia	B-DISO
+alone	O
+(	O
+IA	O
+)	O
+or	O
+3	O
+hours	O
+of	O
+ischemia	B-DISO
+followed	O
+by	O
+4	O
+or	O
+24	O
+hours	O
+of	O
+reperfusion	O
+(	O
+I	O
+/	O
+R	O
+).	O
+
+After	O
+IA	O
+or	O
+I	O
+/	O
+R	O
+,	O
+experimental	O
+and	O
+control	O
+(	O
+nonischemic	O
+)	O
+contralateral	O
+hind	O
+limbs	B-ANAT
+were	O
+harvested	O
+for	O
+analysis	O
+of	O
+protein	B-CHED
+content	O
+,	O
+messenger	B-CHED
+RNA	I-CHED
+(	O
+mRNA	B-CHED
+),	O
+tissue	B-ANAT
+edema	B-DISO
+,	O
+and	O
+viability	O
+.	O
+
+In	O
+this	O
+article	O
+,	O
+the	O
+data	O
+presented	O
+indicate	O
+that	O
+murine	B-SPEC
+skeletal	B-ANAT
+muscle	I-ANAT
+produces	O
+potent	O
+proinflammatory	O
+neutrophil	B-ANAT
+and	O
+macrophage	B-ANAT
+chemokines	O
+during	O
+reperfusion	O
+,	O
+but	O
+not	O
+during	O
+ischemia	B-DISO
+.	O
+
+These	O
+findings	O
+suggest	O
+that	O
+measurement	O
+of	O
+tissue	B-ANAT
+and	O
+/	O
+or	O
+serum	B-COMP
+levels	O
+of	O
+chemokines	O
+during	O
+reperfusion	O
+may	O
+be	O
+an	O
+important	O
+adjunct	O
+to	O
+predicting	O
+tissue	B-ANAT
+injury	O
+along	O
+with	O
+ongoing	O
+inflammation	B-DISO
+during	O
+the	O
+clinical	O
+course	O
+of	O
+reperfusion	O
+injury	O
+.	O
+
+New	O
+techniques	O
+to	O
+noninvasively	O
+image	O
+thrombin	B-PRGE
+activation	O
+(	O
+by	O
+using	O
+magnetic	O
+resonance	O
+imaging	O
+)	O
+in	O
+reperfused	O
+limbs	B-ANAT
+may	O
+coincide	O
+with	O
+the	O
+pattern	O
+of	O
+murine	B-SPEC
+skeletal	B-ANAT
+muscle	I-ANAT
+chemokine	O
+expression	B-PROC
+in	O
+humans	B-SPEC
+.	O
+
+RESULTS	O
+:	O
+IA	O
+did	O
+not	O
+increase	O
+KC	O
+or	O
+MIP	B-PRGE
+-	I-PRGE
+2	I-PRGE
+mRNA	B-CHED
+or	O
+protein	B-CHED
+levels	O
+.	O
+
+KC	B-PRGE
+protein	I-PRGE
+levels	O
+were	O
+increased	O
+10	O
+-	O
+fold	O
+after	O
+4	O
+hours	O
+of	O
+reperfusion	O
+and	O
+30	O
+-	O
+fold	O
+after	O
+24	O
+hours	O
+(	O
+vs	O
+IA	O
+or	O
+sham	O
+;	O
+P	O
+<	O
+.	O
+001	O
+).	O
+
+TITLE	O
+:	O
+A	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+-	O
+associated	O
+coronavirus	B-SPEC
+-	O
+specific	O
+protein	B-CHED
+enhances	O
+virulence	B-PROC
+of	O
+an	O
+attenuated	O
+murine	B-SPEC
+coronavirus	I-SPEC
+.	O
+
+ABSTRACT	O
+:	O
+The	O
+nucleocapsid	B-COMP
+(	O
+N	O
+)	O
+protein	B-CHED
+of	O
+several	O
+members	O
+within	O
+the	O
+order	B-SPEC
+Nidovirales	I-SPEC
+localizes	O
+to	O
+the	O
+nucleolus	B-COMP
+during	O
+infection	B-DISO
+and	O
+after	O
+transfection	B-PROC
+of	O
+cells	B-COMP
+with	O
+N	O
+genes	O
+.	O
+
+Amino	B-CHED
+acids	I-CHED
+369	O
+to	O
+389	O
+,	O
+which	O
+contain	O
+putative	O
+nuclear	O
+localization	B-PROC
+signal	O
+(	O
+NLS	B-DISO
+)	O
+and	O
+nucleolar	B-ANAT
+localization	B-PROC
+signal	O
+motifs	O
+,	O
+failed	O
+to	O
+restore	O
+nuclear	O
+localization	B-PROC
+to	O
+an	O
+NLS	B-PRGE
+-	I-PRGE
+minus	I-PRGE
+mutant	B-DISO
+Rev	I-PRGE
+protein	B-CHED
+.	O
+
+According	O
+to	O
+the	O
+official	O
+files	O
+of	O
+reported	O
+cases	O
+of	O
+SARS	B-DISO
+from	O
+February	O
+21	O
+to	O
+June	O
+19	O
+,	O
+2003	O
+,	O
+there	O
+were	O
+586	O
+cases	O
+in	O
+southern	O
+Taiwan	O
+.	O
+
+TITLE	O
+:	O
+Croup	B-DISO
+is	O
+associated	O
+with	O
+the	O
+novel	B-SPEC
+coronavirus	I-SPEC
+NL63	O
+.	O
+
+HCoV	B-SPEC
+-	I-SPEC
+NL63	I-SPEC
+infections	B-DISO
+occur	O
+frequently	O
+in	O
+young	O
+children	O
+with	O
+LRTI	B-DISO
+and	O
+show	O
+a	O
+strong	O
+association	O
+with	O
+croup	B-DISO
+,	O
+suggesting	O
+a	O
+causal	O
+relationship	O
+.	O
+
+Among	O
+the	O
+potential	O
+SARS	B-PRGE
+-	I-PRGE
+CoV	I-PRGE
+non	I-PRGE
+-	I-PRGE
+structural	I-PRGE
+proteins	B-CHED
+,	O
+3b	O
+protein	B-CHED
+(	O
+ORF4	O
+)	O
+is	O
+predicted	O
+encoding	O
+154	O
+amino	B-CHED
+acids	I-CHED
+,	O
+lacking	O
+significant	O
+similarities	O
+to	O
+any	O
+known	O
+proteins	B-CHED
+.	O
+
+In	O
+this	O
+study	O
+,	O
+3b	O
+gene	O
+was	O
+linked	O
+with	O
+the	O
+EGFP	O
+tag	B-DISO
+at	O
+the	O
+C	O
+-	O
+terminus	O
+.	O
+
+A	O
+specially	O
+designed	O
+biosafety	O
+level	O
+3	O
+(	O
+BSL	O
+-	O
+3	O
+)	O
+autopsy	O
+laboratory	O
+was	O
+constructed	O
+and	O
+divided	O
+into	O
+a	O
+clean	O
+area	O
+,	O
+a	O
+semicontaminated	O
+area	O
+,	O
+a	O
+contaminated	O
+area	O
+,	O
+and	O
+2	O
+buffer	B-CHED
+zones	O
+.	O
+
+RESULTS	O
+:	O
+When	O
+a	O
+given	O
+concentration	O
+of	O
+particulate	O
+sarin	O
+simulant	O
+was	O
+introduced	O
+into	O
+the	O
+contaminated	O
+area	O
+,	O
+it	O
+could	O
+not	O
+be	O
+detected	O
+in	O
+either	O
+the	O
+semicontaminated	O
+area	O
+or	O
+clean	O
+area	O
+,	O
+and	O
+particles	O
+>	O
+0	O
+.	O
+3	O
+microm	O
+in	O
+size	O
+were	O
+not	O
+detected	O
+in	O
+the	O
+exhaust	O
+air	B-CHED
+.	O
+
+TITLE	O
+:	O
+Characterization	O
+of	O
+viral	O
+agents	O
+causing	O
+acute	B-DISO
+respiratory	I-DISO
+infection	I-DISO
+in	O
+a	O
+San	O
+Francisco	O
+University	O
+Medical	O
+Center	O
+Clinic	O
+during	O
+the	O
+influenza	O
+season	O
+.	O
+
+TITLE	O
+:	O
+[	O
+Study	O
+on	O
+the	O
+animal	B-SPEC
+model	O
+for	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+].	O
+
+This	O
+suggested	O
+cynomolgus	O
+and	O
+rhesus	B-SPEC
+macaques	I-SPEC
+were	O
+not	O
+the	O
+ideal	O
+animal	B-SPEC
+model	O
+for	O
+SARS	B-DISO
+in	O
+fact	O
+,	O
+but	O
+they	O
+could	O
+serve	O
+as	O
+animal	B-SPEC
+model	O
+for	O
+SARS	B-DISO
+when	O
+a	O
+more	O
+ideal	O
+animal	B-SPEC
+model	O
+is	O
+absent	O
+.	O
+
+Acinar	B-ANAT
+cell	I-ANAT
+injury	O
+early	O
+in	O
+acute	B-DISO
+pancreatitis	I-DISO
+leads	O
+to	O
+a	O
+local	O
+inflammatory	B-DISO
+reaction	I-DISO
+;	O
+if	O
+marked	O
+this	O
+leads	O
+to	O
+a	O
+systemic	B-DISO
+inflammatory	I-DISO
+response	I-DISO
+syndrome	I-DISO
+(	O
+SIRS	B-DISO
+).	O
+
+MODS	B-DISO
+associated	O
+with	O
+acute	B-DISO
+pancreatitis	I-DISO
+is	O
+the	O
+primary	O
+cause	O
+of	O
+morbidity	O
+and	O
+mortality	O
+in	O
+this	O
+condition	B-DISO
+.	O
+
+Recent	O
+studies	O
+by	O
+us	O
+and	O
+other	O
+investigators	O
+have	O
+established	O
+the	O
+critical	O
+role	O
+played	O
+by	O
+inflammatory	O
+mediators	O
+such	O
+as	O
+TNF	B-PRGE
+-	I-PRGE
+alpha	I-PRGE
+,	O
+IL	B-PRGE
+-	I-PRGE
+1beta	I-PRGE
+,	O
+IL	B-FUNC
+-	I-FUNC
+6	I-FUNC
+,	O
+IL	B-FUNC
+-	I-FUNC
+8	I-FUNC
+,	O
+CINC	B-PRGE
+/	O
+GRO	B-PRGE
+-	I-PRGE
+alpha	I-PRGE
+,	O
+MCP	B-PRGE
+-	I-PRGE
+1	I-PRGE
+,	O
+PAF	B-DISO
+,	O
+IL	B-FUNC
+-	I-FUNC
+10	I-FUNC
+,	O
+CD40L	B-PRGE
+,	O
+C5a	B-PRGE
+,	O
+ICAM	B-PRGE
+-	I-PRGE
+1	I-PRGE
+,	O
+MIP1	B-PRGE
+-	I-PRGE
+alpha	I-PRGE
+,	O
+RANTES	B-PRGE
+,	O
+substance	O
+P	O
+,	O
+and	O
+hydrogen	B-CHED
+sulfide	I-CHED
+in	O
+acute	B-DISO
+pancreatitis	I-DISO
+and	O
+the	O
+resultant	O
+MODS	B-DISO
+.	O
+
+Higher	O
+IgG	B-PRGE
+levels	O
+were	O
+detected	O
+in	O
+patients	O
+who	O
+required	O
+supplemental	O
+oxygen	B-CHED
+(	O
+Mann	O
+-	O
+Whitney	O
+;	O
+p	O
+=	O
+0	O
+.	O
+002	O
+),	O
+ICU	O
+-	O
+admission	O
+(	O
+p	O
+=	O
+0	O
+.	O
+001	O
+),	O
+had	O
+negative	O
+pre	O
+-	O
+discharge	B-ANAT
+fecal	B-ANAT
+RT	O
+-	O
+PCR	O
+results	O
+(	O
+p	O
+=	O
+0	O
+.	O
+004	O
+),	O
+and	O
+lymphopenia	B-DISO
+at	O
+presentation	O
+(	O
+p	O
+=	O
+0	O
+.	O
+028	O
+).	O
+
+Peak	O
+IgG	B-PRGE
+titres	O
+also	O
+correlated	O
+positively	O
+with	O
+peak	O
+LDH	B-PRGE
+levels	O
+(	O
+Spearman	O
+'	O
+s	O
+r	O
+=+	O
+0	O
+.	O
+360	O
+;	O
+p	O
+<	O
+0	O
+.	O
+001	O
+)	O
+among	O
+survivors	O
+.	O
+
+Majority	O
+of	O
+them	O
+have	O
+good	O
+attitude	O
+towards	O
+SARS	B-DISO
+based	O
+on	O
+the	O
+formulated	O
+scoring	O
+system	O
+.	O
+
+These	O
+inhibitory	O
+effects	O
+are	O
+observed	O
+when	O
+the	O
+cells	B-COMP
+are	O
+treated	O
+with	O
+the	O
+drug	O
+either	O
+before	O
+or	O
+after	O
+exposure	O
+to	O
+the	O
+virus	B-SPEC
+,	O
+suggesting	O
+both	O
+prophylactic	O
+and	O
+therapeutic	O
+advantage	O
+.	O
+
+Chloroquine	O
+is	O
+effective	O
+in	O
+preventing	O
+the	O
+spread	O
+of	O
+SARS	B-DISO
+CoV	O
+in	O
+cell	B-COMP
+culture	O
+.	O
+
+Although	O
+this	O
+virus	B-SPEC
+grows	O
+in	O
+a	O
+variety	O
+of	O
+tissues	B-ANAT
+that	O
+express	O
+its	O
+receptor	O
+,	O
+the	O
+mechanism	O
+of	O
+the	O
+severe	O
+respiratory	O
+illness	O
+caused	O
+by	O
+this	O
+virus	B-SPEC
+is	O
+not	O
+well	O
+understood	O
+.	O
+
+These	O
+results	O
+suggest	O
+that	O
+the	O
+proteases	O
+produced	O
+in	O
+the	O
+lungs	B-ANAT
+by	O
+inflammatory	B-ANAT
+cells	I-ANAT
+are	O
+responsible	O
+for	O
+high	O
+multiplication	O
+of	O
+SARS	B-DISO
+-	O
+CoV	O
+,	O
+which	O
+results	O
+in	O
+severe	O
+lung	B-ANAT
+tissue	I-ANAT
+damage	O
+.	O
+
+The	O
+present	O
+surveillance	O
+system	O
+will	O
+be	O
+of	O
+use	O
+in	O
+the	O
+early	O
+detection	O
+of	O
+a	O
+SARS	B-DISO
+epidemic	O
+in	O
+a	O
+hospital	O
+as	O
+well	O
+as	O
+in	O
+early	O
+detection	O
+of	O
+similar	O
+illnesses	O
+accompanied	O
+by	O
+acute	O
+respiratory	O
+symptoms	O
+,	O
+such	O
+as	O
+influenza	B-DISO
+.	O
+
+TITLE	O
+:	O
+Using	O
+siRNA	O
+in	O
+prophylactic	O
+and	O
+therapeutic	O
+regimens	O
+against	O
+SARS	B-DISO
+coronavirus	B-SPEC
+in	O
+Rhesus	B-SPEC
+macaque	I-SPEC
+.	O
+
+Potent	O
+siRNA	O
+inhibitors	B-CHED
+of	O
+SARS	B-DISO
+coronavirus	B-SPEC
+(	O
+SCV	B-SPEC
+)	O
+in	O
+vitro	O
+were	O
+further	O
+evaluated	O
+for	O
+efficacy	O
+and	O
+safety	O
+in	O
+a	O
+rhesus	B-SPEC
+macaque	I-SPEC
+(	O
+Macaca	B-SPEC
+mulatta	I-SPEC
+)	O
+SARS	B-DISO
+model	O
+using	O
+clinically	O
+viable	O
+delivery	O
+while	O
+comparing	O
+three	O
+dosing	O
+regimens	O
+.	O
+
+Observations	O
+of	O
+SARS	B-DISO
+-	O
+like	O
+symptoms	O
+,	O
+measurements	O
+of	O
+SCV	B-SPEC
+RNA	O
+presence	O
+and	O
+lung	B-ANAT
+histopathology	O
+and	O
+immunohistochemistry	O
+consistently	O
+showed	O
+siRNA	O
+-	O
+mediated	O
+anti	O
+-	O
+SARS	B-DISO
+efficacy	O
+by	O
+either	O
+prophylactic	O
+or	O
+therapeutic	O
+regimens	O
+.	O
+
+The	O
+first	O
+experiments	O
+detected	O
+seven	O
+human	B-SPEC
+virus	B-SPEC
+species	B-SPEC
+without	O
+the	O
+use	O
+of	O
+any	O
+specific	O
+reagent	B-CHED
+.	O
+
+To	O
+detect	O
+early	O
+SARS	B-DISO
+-	I-DISO
+CoV	I-DISO
+infection	I-DISO
+,	O
+a	O
+one	O
+-	O
+step	O
+,	O
+real	O
+-	O
+time	O
+quantitative	O
+reverse	B-PROC
+transcription	I-PROC
+-	O
+polymerase	O
+chain	O
+reaction	O
+(	O
+RT	O
+-	O
+PCR	O
+)	O
+assay	O
+was	O
+developed	O
+that	O
+could	O
+simultaneously	O
+detect	O
+nucleocapsid	B-COMP
+(	O
+N	O
+),	O
+membrane	B-COMP
+(	O
+M	O
+),	O
+and	O
+spike	O
+(	O
+S	O
+)	O
+genes	O
+of	O
+SARS	B-PRGE
+-	I-PRGE
+CoV	I-PRGE
+with	O
+the	O
+same	O
+PCR	O
+condition	B-DISO
+using	O
+either	O
+Applied	O
+Biosystems	O
+(	O
+ABI	O
+)	O
+Prism	O
+7700	O
+Sequence	O
+Detection	O
+System	O
+or	O
+Roche	O
+LightCycler	O
+.	O
+
+It	O
+showed	O
+that	O
+SARS	B-DISO
+-	O
+N	O
+has	O
+comparable	O
+detection	O
+efficiencies	O
+to	O
+SARS2	B-PRGE
+and	O
+SARS3	O
+which	O
+are	O
+primers	O
+sets	O
+designed	O
+by	O
+Centers	O
+for	O
+Disease	O
+Control	O
+and	O
+Prevention	O
+.	O
+
+They	O
+were	O
+admitted	O
+to	O
+a	O
+high	O
+security	O
+infectious	B-DISO
+disease	I-DISO
+unit	O
+as	O
+epidemiological	O
+data	O
+pointed	O
+to	O
+an	O
+outbreak	O
+of	O
+unknown	O
+etiology	O
+.	O
+
+ABSTRACT	O
+:	O
+Detection	O
+of	O
+viral	O
+antigens	B-CHED
+and	O
+isolation	O
+methods	O
+has	O
+long	O
+been	O
+used	O
+for	O
+the	O
+diagnosis	O
+of	O
+respiratory	O
+virus	B-SPEC
+infections	B-DISO
+.	O
+
+The	O
+objective	O
+was	O
+to	O
+determine	O
+the	O
+ability	O
+of	O
+HuH7	O
+cells	B-COMP
+to	O
+support	O
+the	O
+replication	O
+of	O
+prototype	O
+and	O
+wild	O
+strains	O
+of	O
+respiratory	O
+viruses	B-SPEC
+.	O
+
+During	O
+the	O
+three	O
+winters	O
+of	O
+1999	O
+-	O
+2000	O
+,	O
+2000	O
+-	O
+2001	O
+,	O
+and	O
+2001	O
+-	O
+2002	O
+,	O
+of	O
+the	O
+1	O
+,	O
+226	O
+(	O
+23	O
+.	O
+3	O
+%)	O
+direct	O
+fluorescent	O
+assay	O
+-	O
+positive	O
+nasal	B-ANAT
+aspirates	B-ANAT
+from	O
+children	O
+admitted	O
+to	O
+hospital	O
+,	O
+788	O
+were	O
+positive	O
+for	O
+respiratory	B-SPEC
+syncytial	I-SPEC
+virus	I-SPEC
+,	O
+228	O
+for	O
+influenza	B-SPEC
+virus	I-SPEC
+,	O
+133	O
+for	O
+parainfluenza	B-DISO
+virus	B-SPEC
+,	O
+and	O
+77	O
+for	O
+adenovirus	B-DISO
+.	O
+
+The	O
+shortest	O
+of	O
+these	O
+fragments	O
+still	O
+able	O
+to	O
+bind	B-FUNC
+the	O
+receptor	O
+ACE2	O
+did	O
+not	O
+include	O
+residue	O
+318	O
+(	O
+which	O
+is	O
+a	O
+potential	O
+glycosylation	B-PROC
+site	O
+),	O
+but	O
+started	O
+at	O
+residue	O
+319	O
+,	O
+and	O
+has	O
+only	O
+two	O
+potential	O
+glycosylation	B-PROC
+sites	O
+(	O
+residues	O
+330	O
+and	O
+357	O
+).	O
+
+The	O
+finding	O
+that	O
+most	O
+of	O
+the	O
+mutations	O
+(	O
+23	O
+out	O
+of	O
+34	O
+including	O
+glycosylation	B-PROC
+sites	O
+)	O
+do	O
+not	O
+affect	O
+the	O
+RBD	O
+binding	B-FUNC
+function	O
+indicates	O
+possible	O
+mechanisms	O
+for	O
+evasion	O
+of	O
+immune	B-PROC
+responses	I-PROC
+.	O
+
+Chronic	O
+aspiration	B-DISO
+and	O
+gastro	B-DISO
+-	I-DISO
+esophageal	I-DISO
+reflux	I-DISO
+were	O
+recognized	O
+in	O
+12	O
+patients	O
+.	O
+
+Patients	O
+had	O
+the	O
+rapid	O
+onset	O
+of	O
+dyspnea	B-DISO
+refractory	O
+to	O
+oxygen	B-CHED
+therapy	O
+.	O
+
+She	O
+delivered	O
+at	O
+40	O
+weeks	O
+of	O
+gestation	B-PROC
+a	O
+healthy	O
+baby	O
+girl	O
+.	O
+
+cDNA	O
+microarrays	O
+were	O
+used	O
+to	O
+screen	O
+the	O
+gene	B-PROC
+expression	I-PROC
+profiles	O
+of	O
+peripheral	B-ANAT
+blood	I-ANAT
+mononuclear	I-ANAT
+cells	I-ANAT
+(	O
+PBMCs	O
+)	O
+in	O
+two	O
+SARS	B-DISO
+patients	O
+(	O
+one	O
+in	O
+the	O
+acute	O
+severe	O
+phase	O
+and	O
+the	O
+other	O
+in	O
+the	O
+convalescent	O
+phase	O
+)	O
+and	O
+a	O
+healthy	O
+donor	B-CHED
+.	O
+
+However	O
+,	O
+anti	B-CHED
+-	I-CHED
+inflammatory	I-CHED
+agents	I-CHED
+such	O
+as	O
+IL	B-PRGE
+-	I-PRGE
+4	I-PRGE
+receptor	I-PRGE
+,	O
+IL	B-PRGE
+-	I-PRGE
+13	I-PRGE
+receptor	I-PRGE
+,	O
+IL	B-FUNC
+-	I-FUNC
+1Ra	I-FUNC
+,	O
+and	O
+TNF	B-PRGE
+-	I-PRGE
+alpha	I-PRGE
+-	O
+induced	O
+proteins	B-CHED
+3	O
+and	O
+6	O
+also	O
+increased	O
+dramatically	O
+in	O
+the	O
+acute	O
+severe	O
+case	O
+.	O
+
+The	O
+others	O
+are	O
+used	O
+in	O
+the	O
+treatment	O
+of	O
+herpesvirus	B-SPEC
+(	O
+e	O
+.	O
+g	O
+.	O
+herpes	B-SPEC
+simplex	I-SPEC
+virus	I-SPEC
+,	O
+varicella	B-SPEC
+zoster	I-SPEC
+virus	I-SPEC
+and	O
+cytomegalo	O
+virus	B-SPEC
+),	O
+hepatitis	B-SPEC
+B	I-SPEC
+virus	I-SPEC
+,	O
+hepatitis	B-SPEC
+C	I-SPEC
+virus	I-SPEC
+or	O
+influenza	B-SPEC
+virus	I-SPEC
+infections	B-DISO
+.	O
+
+TITLE	O
+:	O
+Design	O
+of	O
+wide	O
+-	O
+spectrum	O
+inhibitors	B-CHED
+targeting	B-PROC
+coronavirus	B-SPEC
+main	O
+proteases	O
+.	O
+
+While	O
+companies	O
+are	O
+adopting	O
+advanced	O
+high	O
+-	O
+throughput	O
+methods	O
+,	O
+the	O
+major	O
+technologies	O
+used	O
+by	O
+veterinary	O
+and	O
+medical	O
+research	O
+laboratories	O
+are	O
+classical	O
+hybridoma	B-ANAT
+fusion	O
+and	O
+recombinant	O
+library	O
+selection	O
+techniques	O
+.	O
+
+In	O
+addition	O
+,	O
+both	O
+epithelial	O
+and	O
+fibroblastic	O
+cell	B-ANAT
+lines	I-ANAT
+were	O
+able	O
+to	O
+secrete	B-PROC
+large	O
+quantities	O
+of	O
+T	B-ANAT
+cell	I-ANAT
+-	O
+targeting	B-PROC
+chemokines	O
+,	O
+similar	O
+to	O
+the	O
+ones	O
+detected	O
+in	O
+SARS	B-DISO
+patients	O
+.	O
+
+TITLE	O
+:	O
+Efficient	O
+and	O
+quick	O
+inactivation	B-DISO
+of	O
+SARS	B-DISO
+coronavirus	B-SPEC
+and	O
+other	O
+microbes	O
+exposed	O
+to	O
+the	O
+surfaces	O
+of	O
+some	O
+metal	O
+catalysts	O
+.	O
+
+Two	O
+metal	B-CHED
+catalysts	O
+Ag	O
+/	O
+Al2O3	B-CHED
+and	O
+Cu	O
+/	O
+Al2O3	B-CHED
+were	O
+pressed	O
+into	O
+wafers	O
+.	O
+
+One	O
+hundred	O
+microL	O
+10	O
+(	O
+6	O
+)	O
+TCID50	O
+/	O
+mL	O
+SARS	B-DISO
+-	O
+CoV	O
+,	O
+100	O
+microL	O
+10	O
+(	O
+6	O
+)	O
+PFU	B-CHED
+/	O
+mL	O
+recombinant	O
+baculovirus	B-SPEC
+expressing	O
+hamster	B-SPEC
+'	O
+s	O
+prion	O
+protein	B-CHED
+(	O
+haPrP	O
+)	O
+protein	B-CHED
+and	O
+roughly	O
+10	O
+(	O
+6	O
+)	O
+E	B-SPEC
+.	I-SPEC
+coli	I-SPEC
+were	O
+slowly	O
+dropped	O
+onto	O
+the	O
+surfaces	O
+of	O
+the	O
+catalyst	B-CHED
+wafers	O
+and	O
+exposed	O
+for	O
+5	O
+and	O
+20	O
+min	O
+,	O
+respectively	O
+.	O
+
+The	O
+expression	B-PROC
+of	O
+PrP	B-PRGE
+protein	B-CHED
+was	O
+determined	O
+by	O
+Western	O
+blot	O
+.	O
+
+Several	O
+BALB	O
+/	O
+c	O
+mAbs	O
+were	O
+found	O
+to	O
+be	O
+effectively	O
+to	O
+neutralize	O
+the	O
+infection	B-DISO
+of	O
+Vero	O
+E6	O
+cells	B-COMP
+by	O
+SARS	B-PRGE
+-	I-PRGE
+CoV	I-PRGE
+in	O
+a	O
+dose	O
+-	O
+dependent	O
+manner	O
+.	O
+
+Systematic	O
+epitope	B-CHED
+mapping	O
+showed	O
+that	O
+all	O
+these	O
+neutralizing	O
+mAbs	O
+recognized	O
+a	O
+15	O
+-	O
+residues	O
+peptide	B-CHED
+(	O
+CB	O
+-	O
+119	O
+)	O
+corresponding	O
+to	O
+residues	O
+1143	O
+-	O
+1157	O
+(	O
+SPDVDLGDISGINAS	O
+)	O
+that	O
+was	O
+located	O
+to	O
+the	O
+second	O
+heptad	O
+repeat	O
+(	O
+HR2	O
+)	O
+region	O
+of	O
+the	O
+SARS	O
+-	O
+CoV	O
+spike	O
+protein	B-CHED
+.	O
+
+ABSTRACT	O
+:	O
+The	O
+study	O
+presented	O
+here	O
+was	O
+conducted	O
+to	O
+evaluate	O
+the	O
+performance	O
+of	O
+a	O
+double	B-PRGE
+-	I-PRGE
+antigen	I-PRGE
+sandwich	O
+ELISA	O
+to	O
+detect	O
+antibodies	B-COMP
+in	O
+human	B-SPEC
+serum	B-COMP
+against	O
+the	O
+coronavirus	B-SPEC
+associated	O
+with	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+(	O
+SARS	B-DISO
+).	O
+
+These	O
+results	O
+indicate	O
+that	O
+the	O
+double	B-PRGE
+-	I-PRGE
+antigen	I-PRGE
+sandwich	O
+ELISA	O
+is	O
+an	O
+effective	O
+screening	O
+method	O
+for	O
+the	O
+serodiagnosis	O
+of	O
+SARS	O
+-	O
+associated	O
+coronavirus	O
+.	O
+
+The	O
+scoring	O
+system	O
+of	O
+attributing	O
+11	O
+,	O
+10	O
+,	O
+3	O
+,	O
+3	O
+and	O
+3	O
+points	O
+to	O
+the	O
+presence	O
+of	O
+independent	O
+risk	O
+factors	O
+,	O
+namely	O
+:	O
+epidemiological	O
+link	O
+,	O
+radiographical	O
+deterioration	O
+,	O
+myalgia	B-DISO
+,	O
+lymphopenia	B-DISO
+and	O
+elevated	O
+ALT	B-FUNC
+respectively	O
+,	O
+generated	O
+high	O
+and	O
+low	O
+-	O
+risk	O
+(	O
+total	O
+score	O
+11	O
+-	O
+30	O
+and	O
+0	O
+-	O
+10	O
+,	O
+respectively	O
+)	O
+groups	O
+for	O
+SARS	O
+.	O
+
+The	O
+sensitivity	O
+and	O
+specificity	O
+of	O
+this	O
+prediction	O
+rule	O
+in	O
+positively	O
+identifying	O
+a	O
+SARS	B-DISO
+patient	O
+were	O
+97	O
+.	O
+7	O
+and	O
+81	O
+.	O
+3	O
+%,	O
+respectively	O
+.	O
+
+IAH	B-FUNC
+is	O
+a	O
+frequent	O
+finding	O
+in	O
+patients	O
+admitted	O
+to	O
+the	O
+ICU	O
+because	O
+of	O
+SAP	B-PRGE
+,	O
+and	O
+is	O
+associated	O
+with	O
+a	O
+high	O
+occurrence	O
+rate	O
+of	O
+organ	B-ANAT
+dysfunction	O
+.	O
+
+Mortality	O
+is	O
+high	O
+in	O
+patients	O
+with	O
+IAH	B-FUNC
+,	O
+and	O
+because	O
+the	O
+direct	O
+causal	O
+relationship	O
+between	O
+IAH	B-FUNC
+and	O
+organ	B-ANAT
+dysfunction	O
+is	O
+not	O
+proven	O
+in	O
+patients	O
+with	O
+SAP	O
+,	O
+surgical	O
+decompression	O
+should	O
+not	O
+routinely	O
+be	O
+performed	O
+.	O
+
+Four	O
+patients	O
+underwent	O
+abdominal	B-ANAT
+decompression	O
+because	O
+of	O
+abdominal	B-DISO
+compartment	I-DISO
+syndrome	I-DISO
+,	O
+three	O
+of	O
+whom	O
+died	B-PROC
+in	O
+the	O
+early	O
+postoperative	O
+course	O
+.	O
+
+TITLE	O
+:	O
+Bench	O
+-	O
+to	O
+-	O
+bedside	O
+review	O
+:	O
+outcome	O
+predictions	O
+for	O
+critically	B-DISO
+ill	I-DISO
+patients	O
+in	O
+the	O
+emergency	B-DISO
+department	O
+.	O
+
+However	O
+,	O
+there	O
+is	O
+limited	O
+experience	O
+with	O
+scoring	O
+systems	O
+in	O
+the	O
+ED	O
+,	O
+while	O
+early	O
+and	O
+aggressive	B-DISO
+intervention	O
+in	O
+critically	B-DISO
+ill	I-DISO
+patients	O
+in	O
+the	O
+ED	O
+is	O
+becoming	O
+increasingly	O
+important	O
+.	O
+
+Other	O
+ED	O
+specific	O
+scoring	O
+systems	O
+have	O
+been	O
+developed	O
+for	O
+various	O
+applications	O
+:	O
+recognition	O
+of	O
+patients	O
+at	O
+risk	O
+for	O
+infection	O
+;	O
+prediction	O
+of	O
+mortality	O
+after	O
+critical	O
+care	O
+transport	B-PROC
+;	O
+prediction	O
+of	O
+in	O
+-	O
+hospital	O
+mortality	O
+after	O
+admission	O
+;	O
+assessment	O
+of	O
+prehospital	O
+therapeutic	O
+efficacy	O
+;	O
+screening	O
+for	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+;	O
+and	O
+prediction	O
+of	O
+pediatric	O
+hospital	O
+admission	O
+.	O
+
+This	O
+review	O
+explores	O
+the	O
+Toronto	O
+critical	O
+care	O
+experience	O
+of	O
+coping	O
+in	O
+the	O
+SARS	B-DISO
+outbreak	O
+disaster	O
+.	O
+
+The	O
+PCR	O
+products	O
+were	O
+detected	O
+on	O
+agarose	B-CHED
+gel	O
+stained	O
+with	O
+ethidium	B-CHED
+bromide	I-CHED
+.	O
+
+The	O
+genus	B-SPEC
+Torovirus	I-SPEC
+,	O
+within	O
+the	O
+family	B-SPEC
+Coronaviridae	I-SPEC
+,	O
+is	O
+less	O
+well	O
+characterized	O
+,	O
+in	O
+part	O
+because	O
+toroviruses	B-SPEC
+cannot	O
+yet	O
+be	O
+grown	O
+in	O
+cell	B-COMP
+culture	O
+(	O
+except	O
+for	O
+the	O
+Berne	O
+virus	B-SPEC
+).	O
+
+In	O
+this	O
+study	O
+,	O
+we	O
+determined	O
+the	O
+sequence	O
+of	O
+the	O
+complete	O
+genome	O
+of	O
+Breda	B-SPEC
+-	O
+1	O
+(	O
+BoTV	B-PRGE
+-	I-PRGE
+1	I-PRGE
+),	O
+a	O
+bovine	B-SPEC
+torovirus	I-SPEC
+.	O
+
+Often	O
+one	O
+new	O
+infection	B-DISO
+meant	O
+tracing	O
+of	O
+several	O
+people	O
+to	O
+monitor	O
+their	O
+health	O
+conditions	O
+as	O
+well	O
+.	O
+
+The	O
+current	O
+breed	B-PROC
+of	O
+health	O
+-	O
+care	O
+information	O
+systems	O
+(	O
+HCIS	O
+)	O
+was	O
+not	O
+sufficient	O
+to	O
+handle	O
+new	O
+information	O
+-	O
+sharing	O
+needs	O
+during	O
+the	O
+crisis	O
+.	O
+
+ABSTRACT	O
+:	O
+Neutralizing	O
+antibodies	B-COMP
+(	O
+NAbs	O
+)	O
+against	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+(	O
+SARS	B-DISO
+)	O
+coronavirus	B-SPEC
+(	O
+SARS	B-PRGE
+-	I-PRGE
+CoV	I-PRGE
+)	O
+spike	B-PRGE
+(	I-PRGE
+S	I-PRGE
+)	I-PRGE
+glycoprotein	I-PRGE
+confer	O
+protection	O
+to	O
+animals	B-SPEC
+experimentally	O
+infected	O
+with	O
+the	O
+pathogenic	O
+virus	B-SPEC
+.	O
+
+We	O
+and	O
+others	O
+previously	O
+demonstrated	O
+that	O
+a	O
+major	O
+mechanism	O
+for	O
+neutralizing	O
+SARS	B-DISO
+-	O
+CoV	O
+was	O
+through	O
+blocking	B-DISO
+the	O
+interaction	O
+between	O
+the	O
+S	B-PRGE
+glycoprotein	I-PRGE
+and	O
+the	O
+cellular	B-COMP
+receptor	O
+angiotensin	B-PRGE
+-	I-PRGE
+converting	I-PRGE
+enzyme	I-PRGE
+2	I-PRGE
+(	O
+ACE2	B-PRGE
+).	O
+
+ABSTRACT	O
+:	O
+Massive	O
+numbers	O
+of	O
+palm	B-ANAT
+civets	B-SPEC
+were	O
+culled	O
+to	O
+remove	O
+sources	O
+for	O
+the	O
+reemergence	O
+of	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+(	O
+SARS	B-DISO
+)	O
+in	O
+Guangdong	O
+Province	O
+,	O
+China	O
+,	O
+in	O
+January	O
+2004	O
+,	O
+following	O
+SARS	B-DISO
+coronavirus	B-SPEC
+detection	O
+in	O
+market	O
+animals	B-SPEC
+.	O
+
+The	O
+virus	B-SPEC
+was	O
+identified	O
+in	O
+all	O
+91	O
+palm	B-ANAT
+civets	B-SPEC
+and	O
+15	O
+raccoon	B-SPEC
+dogs	I-SPEC
+of	O
+animal	B-SPEC
+market	O
+origin	O
+sampled	O
+prior	O
+to	O
+culling	O
+,	O
+but	O
+not	O
+in	O
+1	O
+,	O
+107	O
+palm	B-ANAT
+civets	B-SPEC
+later	O
+sampled	O
+at	O
+25	O
+farms	O
+,	O
+spread	O
+over	O
+12	O
+provinces	O
+,	O
+which	O
+were	O
+claimed	O
+to	O
+be	O
+the	O
+source	O
+of	O
+traded	O
+animals	B-SPEC
+.	O
+
+Survival	O
+of	O
+the	O
+virus	B-SPEC
+on	O
+different	O
+environmental	O
+surfaces	O
+,	O
+including	O
+a	O
+laboratory	O
+request	O
+form	O
+,	O
+an	O
+impervious	O
+disposable	O
+gown	O
+,	O
+and	O
+a	O
+cotton	B-SPEC
+nondisposable	O
+gown	O
+,	O
+was	O
+investigated	O
+.	O
+
+All	O
+disinfectants	B-CHED
+tested	O
+were	O
+shown	O
+to	O
+be	O
+able	O
+to	O
+reduce	O
+the	O
+virus	B-SPEC
+load	O
+by	O
+>	O
+3	O
+log	O
+within	O
+5	O
+min	O
+.	O
+
+Absorbent	O
+material	O
+,	O
+such	O
+as	O
+cotton	B-SPEC
+,	O
+is	O
+preferred	O
+to	O
+nonabsorptive	O
+material	O
+for	O
+personal	O
+protective	O
+clothing	O
+for	O
+routine	O
+patient	O
+care	O
+where	O
+risk	O
+of	O
+large	O
+spillage	B-DISO
+is	O
+unlikely	O
+.	O
+
+RESULTS	O
+:	O
+SARS	B-DISO
+-	O
+CoV	O
+GVU6109	O
+can	O
+survive	O
+for	O
+4	O
+days	O
+in	O
+diarrheal	O
+stool	B-ANAT
+samples	O
+with	O
+an	O
+alkaline	O
+pH	O
+,	O
+and	O
+it	O
+can	O
+remain	O
+infectious	B-DISO
+in	O
+respiratory	O
+specimens	O
+for	O
+>	O
+7	O
+days	O
+at	O
+room	O
+temperature	O
+.	O
+
+The	O
+mechanism	O
+by	O
+which	O
+SARS	B-PRGE
+-	I-PRGE
+CoV	I-PRGE
+causes	O
+atypical	B-DISO
+pneumonia	I-DISO
+remains	O
+unclear	O
+.	O
+
+Important	O
+questions	O
+pertaining	O
+to	O
+the	O
+contribution	O
+of	O
+HCoV	B-SPEC
+-	I-SPEC
+NL63	I-SPEC
+to	O
+ARI	B-PRGE
+and	O
+its	O
+impact	O
+on	O
+public	O
+health	O
+remain	O
+.	O
+
+Obstructive	O
+apnea	B-DISO
+is	O
+associated	O
+with	O
+myocardial	B-DISO
+ischemia	I-DISO
+(	O
+silent	O
+or	O
+symptomatic	O
+),	O
+acute	O
+coronary	B-ANAT
+events	O
+,	O
+stroke	B-DISO
+and	O
+transient	B-DISO
+ischemic	I-DISO
+attacks	I-DISO
+,	O
+cardiac	B-DISO
+arrhythmia	I-DISO
+,	O
+pulmonary	B-DISO
+hypertension	I-DISO
+and	O
+heart	B-DISO
+failure	I-DISO
+.	O
+
+Most	O
+heart	B-DISO
+failure	I-DISO
+patients	O
+with	O
+pulmonary	B-DISO
+congestion	I-DISO
+chronically	O
+hyperventilate	O
+because	O
+of	O
+stimulation	O
+of	O
+vagal	O
+irritant	O
+receptors	O
+and	O
+central	O
+and	O
+peripheral	O
+chemosensitivity	O
+.	O
+
+The	O
+indications	O
+were	O
+bone	B-DISO
+marrow	I-DISO
+failure	I-DISO
+in	O
+five	O
+cases	O
+,	O
+and	O
+myelodysplastic	B-DISO
+syndrome	I-DISO
+(	O
+MDS	B-DISO
+)	O
+or	O
+leukemia	B-DISO
+in	O
+five	O
+cases	O
+.	O
+
+Engraftment	B-PROC
+was	O
+complete	O
+in	O
+eight	O
+patients	O
+and	O
+unassessable	O
+in	O
+two	O
+patients	O
+.	O
+
+Up	O
+to	O
+now	O
+,	O
+there	O
+have	O
+been	O
+no	O
+specific	O
+drugs	O
+to	O
+protect	O
+against	O
+SARS	B-DISO
+-	I-DISO
+CoV	I-DISO
+infection	I-DISO
+,	O
+thus	O
+developing	O
+effective	O
+strategies	O
+against	O
+this	O
+newly	O
+emerged	O
+viral	B-DISO
+infection	I-DISO
+warrants	O
+urgent	O
+efforts	O
+.	O
+
+To	O
+investigate	O
+whether	O
+a	O
+neutralizing	O
+antibody	B-COMP
+against	O
+SARS	B-DISO
+-	O
+CoV	O
+raised	O
+in	O
+an	O
+artiodactylous	O
+host	B-COMP
+can	O
+have	O
+a	O
+protective	O
+role	O
+on	O
+primate	B-SPEC
+cells	B-COMP
+,	O
+we	O
+prepared	O
+serum	B-PRGE
+IgGs	I-PRGE
+and	O
+their	O
+pepsin	B-PRGE
+-	O
+digested	B-PROC
+F	O
+(	O
+ab	O
+')	O
+2	O
+fragments	O
+from	O
+horses	B-SPEC
+inoculated	O
+with	O
+purified	O
+SARS	B-PRGE
+-	I-PRGE
+CoV	I-PRGE
+(	O
+BJ	O
+-	O
+01	O
+strain	O
+).	O
+
+Additionally	O
+,	O
+we	O
+observed	O
+that	O
+F	O
+(	O
+ab	O
+')	O
+2	O
+,	O
+against	O
+BJ	O
+-	O
+01	O
+strain	O
+could	O
+also	O
+protect	O
+cells	B-COMP
+from	O
+infection	B-DISO
+by	O
+the	O
+variant	O
+GZ	O
+-	O
+01	O
+strain	O
+in	O
+vitro	O
+and	O
+in	O
+vivo	O
+.	O
+
+ABSTRACT	O
+:	O
+Vero	O
+cells	O
+transfected	O
+with	O
+either	O
+neo	O
+-	O
+or	O
+bcl	O
+-	O
+2	O
+-	O
+plasmid	O
+were	O
+infected	O
+with	O
+SARS	B-DISO
+-	O
+CoV	O
+at	O
+a	O
+high	O
+multiplicity	O
+of	O
+infection	B-DISO
+.	O
+
+The	O
+detection	O
+limit	O
+was	O
+10	O
+(	O
+0	O
+)	O
+copies	O
+/	O
+microL	O
+.	O
+The	O
+results	O
+of	O
+the	O
+asymmetric	O
+multiplex	O
+nested	O
+reverse	B-PROC
+transcription	I-PROC
+-	O
+PCR	O
+were	O
+in	O
+agreement	O
+with	O
+the	O
+results	O
+of	O
+the	O
+microarray	O
+hybridization	B-PROC
+;	O
+no	O
+hybridization	B-PROC
+signal	O
+was	O
+lost	B-CHED
+as	O
+happened	O
+with	O
+applicons	O
+from	O
+symmetric	O
+amplifications	O
+.	O
+
+Possible	O
+mechanisms	O
+for	O
+this	O
+cubic	O
+membrane	B-COMP
+change	O
+are	O
+discussed	O
+with	O
+respect	O
+to	O
+viral	O
+severity	O
+,	O
+persistence	O
+and	O
+free	B-CHED
+radical	I-CHED
+production	O
+.	O
+
+Retrospective	O
+analysis	O
+was	O
+conducted	O
+on	O
+all	O
+respiratory	B-DISO
+failure	I-DISO
+patients	O
+identified	O
+from	O
+the	O
+Hong	O
+Kong	O
+Hospital	O
+Authority	O
+Severe	B-DISO
+Acute	I-DISO
+Respiratory	I-DISO
+Syndrome	I-DISO
+Database	O
+.	O
+
+CONCLUSIONS	O
+:	O
+Compared	O
+to	O
+invasive	O
+mechanical	O
+ventilation	O
+,	O
+non	O
+-	O
+invasive	O
+ventilation	O
+as	O
+initial	O
+ventilatory	O
+support	O
+for	O
+acute	B-DISO
+respiratory	I-DISO
+failure	I-DISO
+in	O
+the	O
+presence	O
+of	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+appeared	O
+to	O
+be	O
+associated	O
+with	O
+reduced	O
+intubation	O
+need	O
+and	O
+mortality	O
+.	O
+
+The	O
+gene	O
+for	O
+the	O
+SARS	B-PRGE
+-	I-PRGE
+CoV	I-PRGE
+non	O
+-	O
+structural	O
+protein	B-CHED
+10	O
+,	O
+which	O
+is	O
+located	O
+in	O
+the	O
+open	O
+reading	O
+frame	O
+of	O
+pp1a	B-PRGE
+/	O
+pp1ab	O
+gene	O
+,	O
+was	O
+synthesized	O
+and	O
+used	O
+to	O
+screen	O
+for	O
+the	O
+specific	O
+cellular	B-COMP
+gene	O
+coding	O
+for	O
+the	O
+protein	B-CHED
+interacting	O
+with	O
+this	O
+nsp10	B-PRGE
+protein	I-PRGE
+in	O
+a	O
+human	B-ANAT
+embryo	I-ANAT
+lung	B-ANAT
+cDNA	O
+library	O
+using	O
+a	O
+yeast	B-SPEC
+trap	O
+method	O
+.	O
+
+In	O
+2004	O
+,	O
+a	O
+second	O
+coronavirus	B-SPEC
+was	O
+discovered	O
+(	O
+CoV	O
+-	O
+NL63	O
+)	O
+and	O
+in	O
+2005	O
+a	O
+third	O
+new	O
+coronavirus	B-SPEC
+was	O
+described	O
+(	O
+CoV	B-SPEC
+-	I-SPEC
+HKU1	I-SPEC
+).	O
+
+Respiratory	B-DISO
+infection	I-DISO
+has	O
+been	O
+a	O
+considerable	O
+problem	O
+for	O
+humans	B-SPEC
+for	O
+centuries	O
+.	O
+
+All	O
+babies	O
+who	O
+received	O
+ECMO	O
+within	O
+14	O
+days	O
+of	O
+birth	B-PROC
+.	O
+
+A	O
+total	O
+of	O
+145	O
+neonates	O
+received	O
+ECMO	O
+for	O
+treatment	O
+of	O
+respiratory	B-DISO
+failure	I-DISO
+.	O
+
+TITLE	O
+:	O
+Propylene	B-CHED
+glycol	I-CHED
+-	O
+induced	O
+lactic	B-DISO
+acidosis	I-DISO
+in	O
+a	O
+patient	O
+with	O
+normal	O
+renal	B-PROC
+function	I-PROC
+:	O
+a	O
+proposed	O
+mechanism	O
+and	O
+monitoring	O
+recommendations	O
+.	O
+
+To	O
+maintain	O
+adequate	O
+sedation	B-DISO
+and	O
+ventilation	O
+and	O
+reduce	O
+airway	B-ANAT
+pressure	O
+,	O
+several	O
+relaxation	O
+strategies	O
+were	O
+used	O
+including	O
+high	O
+-	O
+dose	O
+intravenous	O
+lorazepam	B-CHED
+,	O
+fentanyl	B-CHED
+,	O
+and	O
+cisatracurium	O
+.	O
+
+TITLE	O
+:	O
+[	O
+Rhabdomyolysis	B-DISO
+,	O
+disseminated	B-DISO
+intravascular	I-DISO
+coagulation	I-DISO
+and	O
+acute	B-DISO
+renal	I-DISO
+failure	I-DISO
+after	O
+severe	O
+narcotics	O
+intoxication	O
+(	O
+MDMA	B-CHED
+,	O
+THC	B-DISO
+,	O
+amphetamine	B-CHED
+)].	O
+
+No	O
+pulmonary	B-PROC
+function	I-PROC
+abnormalities	O
+were	O
+detected	O
+in	O
+59	O
+patients	O
+(	O
+63	O
+%).	O
+
+The	O
+main	O
+determinants	O
+of	O
+morbidity	O
+in	O
+recovered	O
+SARS	B-DISO
+patients	O
+need	O
+to	O
+be	O
+further	O
+defined	O
+.	O
+
+TITLE	O
+:	O
+Detection	O
+of	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+coronavirus	B-SPEC
+in	O
+the	O
+brain	B-ANAT
+:	O
+potential	O
+role	O
+of	O
+the	O
+chemokine	O
+mig	O
+in	O
+pathogenesis	O
+.	O
+
+In	O
+the	O
+present	O
+study	O
+,	O
+we	O
+isolated	O
+a	O
+SARS	B-DISO
+coronavirus	B-SPEC
+strain	O
+from	O
+a	O
+brain	O
+tissue	B-ANAT
+specimen	I-ANAT
+obtained	O
+from	O
+a	O
+patient	O
+with	O
+SARS	B-DISO
+with	O
+significant	O
+central	O
+nervous	B-DISO
+symptoms	O
+.	O
+
+This	O
+study	O
+provides	O
+direct	O
+evidence	O
+that	O
+SARS	B-DISO
+human	B-SPEC
+coronavirus	I-SPEC
+is	O
+capable	O
+of	O
+infecting	O
+the	O
+central	B-ANAT
+nervous	I-ANAT
+system	I-ANAT
+,	O
+and	O
+that	O
+Mig	B-PRGE
+might	O
+be	O
+involved	O
+in	O
+the	O
+brain	B-ANAT
+immunopathology	B-DISO
+of	O
+SARS	B-DISO
+.	O
+
+TITLE	O
+:	O
+Acute	O
+lung	B-ANAT
+injury	O
+/	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+in	O
+15	O
+foals	O
+.	O
+
+Nine	O
+patients	O
+survived	O
+,	O
+4	O
+died	B-PROC
+due	O
+to	O
+respiratory	B-DISO
+failure	I-DISO
+and	O
+2	O
+were	O
+subjected	O
+to	O
+euthanasia	O
+in	O
+a	O
+moribund	O
+state	O
+.	O
+
+The	O
+T	B-ANAT
+cell	I-ANAT
+array	O
+is	O
+an	O
+early	O
+and	O
+sensitive	O
+multiplex	O
+measure	O
+of	O
+active	O
+infection	B-DISO
+,	O
+exposure	O
+to	O
+a	O
+pathogen	O
+,	O
+or	O
+effective	O
+,	O
+recent	O
+vaccination	O
+.	O
+
+The	O
+crystal	B-ANAT
+structure	O
+at	O
+2	O
+.	O
+9	O
+angstrom	O
+resolution	O
+of	O
+the	O
+RBD	O
+bound	O
+with	O
+the	O
+peptidase	B-PRGE
+domain	I-PRGE
+of	I-PRGE
+human	I-PRGE
+ACE2	I-PRGE
+shows	O
+that	O
+the	O
+RBD	O
+presents	O
+a	O
+gently	O
+concave	O
+surface	O
+,	O
+which	O
+cradles	O
+the	O
+N	O
+-	O
+terminal	O
+lobe	B-ANAT
+of	O
+the	O
+peptidase	O
+.	O
+
+This	O
+descriptive	O
+study	O
+,	O
+which	O
+was	O
+conducted	O
+from	O
+May	O
+to	O
+June	O
+2003	O
+,	O
+intended	O
+to	O
+identify	O
+staff	O
+stress	O
+and	O
+coping	O
+strategies	O
+among	O
+a	O
+SARS	B-DISO
+team	O
+of	O
+nursing	B-PROC
+staff	O
+during	O
+the	O
+outbreak	O
+.	O
+
+Twenty	O
+-	O
+six	O
+female	O
+nurses	O
+of	O
+the	O
+SARS	B-DISO
+team	O
+completed	O
+a	O
+questionnaire	O
+about	O
+their	O
+experiences	O
+serving	O
+in	O
+the	O
+SARS	B-DISO
+team	O
+.	O
+
+SARS	B-DISO
+had	O
+both	O
+positive	O
+and	O
+negative	O
+psychological	B-DISO
+impacts	O
+on	O
+the	O
+nurses	O
+.	O
+
+Additional	O
+findings	O
+include	O
+the	O
+need	O
+for	O
+more	O
+psychiatric	O
+staff	O
+to	O
+provide	O
+flexible	O
+and	O
+continuous	O
+service	O
+,	O
+the	O
+importance	O
+of	O
+meetings	O
+to	O
+improve	O
+teamwork	O
+and	O
+reduce	O
+conflict	O
+between	O
+doctors	O
+and	O
+nurses	O
+and	O
+the	O
+useful	O
+discovery	O
+that	O
+video	O
+cell	B-COMP
+phones	O
+provided	O
+needed	O
+reassurance	O
+from	O
+afar	O
+to	O
+the	O
+worried	O
+families	O
+of	O
+the	O
+nurses	O
+.	O
+
+Sequencing	O
+and	O
+analysis	O
+of	O
+three	O
+bat	B-ENZY
+-	O
+SARS	B-DISO
+-	O
+CoV	O
+genomes	O
+from	O
+samples	O
+collected	O
+at	O
+different	O
+dates	O
+showed	O
+that	O
+bat	B-ENZY
+-	O
+SARS	B-DISO
+-	O
+CoV	O
+is	O
+closely	O
+related	O
+to	O
+SARS	B-PRGE
+-	I-PRGE
+CoV	I-PRGE
+from	O
+humans	B-SPEC
+and	O
+civets	B-SPEC
+.	O
+
+TITLE	O
+:	O
+Association	O
+between	O
+mannose	B-PRGE
+-	I-PRGE
+binding	B-FUNC
+lectin	I-PRGE
+gene	B-PROC
+polymorphisms	I-PROC
+and	O
+susceptibility	O
+to	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+coronavirus	B-DISO
+infection	I-DISO
+.	O
+
+Their	O
+value	O
+for	O
+the	O
+detection	O
+of	O
+disease	O
+-	O
+associated	O
+mRNA	B-CHED
+expressed	B-PROC
+by	O
+circulating	O
+tumour	O
+cells	B-COMP
+in	O
+patients	O
+with	O
+solid	O
+malignancies	B-DISO
+is	O
+far	O
+less	O
+apparent	O
+,	O
+and	O
+the	O
+clinical	O
+significance	O
+of	O
+results	O
+obtained	O
+from	O
+such	O
+tests	O
+remains	O
+unclear	O
+.	O
+
+The	O
+human	B-PRGE
+scFv	I-PRGE
+antibodies	B-COMP
+isolated	O
+and	O
+described	O
+in	O
+this	O
+study	O
+represent	O
+useful	O
+reagents	B-CHED
+for	O
+rapid	O
+detection	O
+of	O
+N	B-PRGE
+SARS	I-PRGE
+-	I-PRGE
+CoV	I-PRGE
+protein	B-CHED
+and	O
+SARS	B-DISO
+virus	B-COMP
+particles	I-COMP
+in	O
+infected	O
+target	B-ANAT
+cells	I-ANAT
+.	O
+
+RESULTS	O
+:	O
+Human	B-PRGE
+scFv	I-PRGE
+antibodies	B-COMP
+to	O
+N	B-PRGE
+protein	I-PRGE
+of	O
+SARS	B-PRGE
+-	I-PRGE
+CoV	I-PRGE
+can	O
+be	O
+easily	O
+isolated	O
+by	O
+selecting	O
+the	O
+ETH	B-CHED
+-	O
+2	O
+phage	O
+library	O
+on	O
+immunotubes	O
+coated	O
+with	O
+antigen	B-CHED
+.	O
+
+Ribavirin	B-CHED
+and	O
+corticosteroids	B-CHED
+were	O
+used	O
+extensively	O
+during	O
+the	O
+SARS	B-DISO
+outbreak	O
+.	O
+
+Therefore	O
+,	O
+antibodies	B-COMP
+against	O
+HTLV	O
+were	O
+examined	O
+in	O
+paired	O
+-	O
+sera	B-COMP
+from	O
+26	O
+SARS	B-DISO
+patients	O
+.	O
+
+The	O
+findings	O
+that	O
+antibody	O
+to	O
+HTLV	O
+can	O
+be	O
+detected	O
+in	O
+blood	B-ANAT
+samples	I-ANAT
+collected	O
+from	O
+SARS	B-DISO
+patients	O
+provide	O
+important	O
+information	O
+for	O
+safe	O
+handling	O
+of	O
+blood	B-ANAT
+products	O
+.	O
+
+Without	O
+such	O
+knowledge	O
+,	O
+blood	B-ANAT
+products	O
+can	O
+be	O
+discarded	O
+mistakenly	O
+even	O
+though	O
+they	O
+contain	O
+anti	B-PRGE
+-	I-PRGE
+SARS	I-PRGE
+-	I-PRGE
+CoV	I-PRGE
+antibodies	B-COMP
+that	O
+may	O
+be	O
+potentially	O
+valuable	O
+for	O
+SARS	B-DISO
+therapy	O
+.	O
+
+The	O
+binding	B-FUNC
+behaviors	B-PROC
+of	O
+modified	O
+oligodeoxynucleotides	O
+to	O
+the	O
+complementary	O
+sequence	O
+were	O
+studied	O
+by	O
+UV	O
+,	O
+CD	O
+,	O
+and	O
+molecular	B-PROC
+dynamics	I-PROC
+simulation	O
+.	O
+
+The	O
+results	O
+showed	O
+that	O
+although	O
+the	O
+incorporated	O
+isonucleotides	O
+at	O
+certain	O
+positions	O
+of	O
+the	O
+sequence	O
+interfere	O
+with	O
+the	O
+binding	B-FUNC
+ability	O
+to	O
+a	O
+different	O
+extent	O
+,	O
+B	O
+-	O
+form	O
+duplexes	O
+were	O
+maintained	O
+and	O
+the	O
+binding	B-FUNC
+abilities	O
+of	O
+the	O
+3	O
+'-	O
+end	O
+-	O
+modified	O
+duplexes	O
+were	O
+better	O
+than	O
+the	O
+corresponding	O
+mismatched	O
+duplexes	O
+.	O
+
+First	O
+reported	O
+in	O
+Asia	O
+,	O
+SARS	B-DISO
+quickly	O
+spread	O
+worldwide	O
+through	O
+international	O
+travelling	O
+.	O
+
+As	O
+of	O
+July	O
+2003	O
+,	O
+the	O
+World	O
+Health	O
+Organization	O
+reported	O
+a	O
+total	O
+of	O
+8	O
+,	O
+437	O
+people	O
+afflicted	O
+with	O
+SARS	B-DISO
+with	O
+a	O
+9	O
+.	O
+6	O
+%	O
+mortality	O
+rate	O
+.	O
+
+Both	O
+components	O
+of	O
+the	O
+fusion	O
+proteins	B-CHED
+were	O
+detected	O
+in	O
+Western	O
+blot	O
+analysis	O
+,	O
+and	O
+binding	B-FUNC
+assay	O
+confirmed	O
+that	O
+plant	B-SPEC
+-	O
+synthesized	O
+pentameric	O
+LTB	B-PRGE
+-	O
+PEDV	B-SPEC
+fusion	O
+bound	O
+to	O
+the	O
+intestinal	B-ANAT
+membrane	B-COMP
+GM1	B-PRGE
+-	I-PRGE
+ganglioside	B-CHED
+receptor	I-PRGE
+.	O
+
+TITLE	O
+:	O
+[	O
+Temperature	O
+changes	O
+of	O
+patients	O
+with	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+:	O
+a	O
+comparative	O
+study	O
+].	O
+
+Hormone	B-CHED
+therapy	O
+did	O
+not	O
+significantly	O
+affect	O
+the	O
+temperature	O
+of	O
+SARS	B-DISO
+patients	O
+(	O
+P	O
+=	O
+0	O
+.	O
+180	O
+),	O
+who	O
+had	O
+longer	O
+duration	O
+of	O
+high	O
+fever	B-PROC
+.	O
+
+CONCLUSIONS	O
+:	O
+SARS	B-DISO
+patients	O
+have	O
+higher	O
+body	B-ANAT
+temperature	O
+and	O
+longer	O
+duration	O
+of	O
+high	O
+fever	B-PROC
+.	O
+
+ABSTRACT	O
+:	O
+The	O
+full	O
+length	O
+cDNA	O
+of	O
+SARS	O
+coronavirus	B-SPEC
+nucleocapsid	B-COMP
+(	O
+N	O
+)	O
+protein	B-CHED
+was	O
+amplified	O
+by	O
+PCR	O
+and	O
+cloned	O
+into	O
+yeast	B-SPEC
+expression	B-PROC
+vector	O
+pPIC3	O
+.	O
+5K	O
+to	O
+generate	O
+expression	B-PROC
+vector	O
+pPIC3	O
+.	O
+5K	O
+-	O
+SCoVN	O
+.	O
+
+According	O
+to	O
+the	O
+analysis	O
+of	O
+the	O
+main	O
+antigen	B-CHED
+of	O
+the	O
+SARS	B-DISO
+spike	O
+protein	B-CHED
+,	O
+5	O
+fragments	O
+of	O
+the	O
+whole	O
+spike	O
+gene	O
+were	O
+cloned	O
+,	O
+and	O
+ligated	O
+to	O
+the	O
+vector	O
+pNMT1	O
+.	O
+
+SDS	B-DISO
+-	O
+PAGE	O
+or	O
+Western	O
+blot	O
+analysis	O
+of	O
+the	O
+induced	O
+expression	B-PROC
+products	O
+demonstrated	O
+that	O
+the	O
+5	O
+recombinant	O
+proteins	B-CHED
+were	O
+expressed	B-PROC
+in	O
+the	O
+fission	B-SPEC
+yeast	I-SPEC
+respectively	O
+.	O
+
+ABSTRACT	O
+:	O
+In	O
+concert	O
+with	O
+increased	O
+concerns	O
+regarding	O
+both	O
+biologic	O
+terrorism	O
+and	O
+new	O
+natural	O
+infectious	B-DISO
+disease	I-DISO
+threats	O
+(	O
+e	O
+.	O
+g	O
+.,	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+[	O
+SARS	B-DISO
+]	O
+and	O
+West	B-DISO
+Nile	I-DISO
+virus	I-DISO
+),	O
+as	O
+a	O
+result	O
+of	O
+advances	O
+in	O
+medical	O
+informatics	O
+,	O
+various	O
+data	O
+sources	O
+are	O
+available	O
+to	O
+epidemiologists	O
+for	O
+routine	O
+,	O
+prospective	O
+monitoring	O
+of	O
+public	O
+health	O
+.	O
+
+ABSTRACT	O
+:	O
+Bovine	O
+coronavirus	B-SPEC
+(	O
+BCoV	O
+),	O
+a	O
+positive	O
+sense	B-PROC
+single	O
+-	O
+stranded	O
+RNA	O
+virus	B-SPEC
+,	O
+is	O
+an	O
+important	O
+causative	O
+agent	O
+of	O
+neonatal	B-DISO
+diarrhoea	I-DISO
+in	O
+calves	O
+from	O
+beef	O
+and	O
+dairy	O
+cattle	B-SPEC
+worldwide	O
+.	O
+
+The	O
+inclusion	O
+of	O
+an	O
+internal	O
+control	O
+provides	O
+a	O
+way	O
+to	O
+detect	O
+assay	O
+inhibition	B-PROC
+in	O
+faecal	B-ANAT
+samples	O
+and	O
+failure	O
+of	O
+nucleic	B-CHED
+acid	I-CHED
+extraction	O
+that	O
+allow	O
+reduction	O
+of	O
+the	O
+number	O
+of	O
+false	O
+-	O
+negative	O
+results	O
+.	O
+
+Inhibition	B-PROC
+of	I-PROC
+cell	I-PROC
+adhesion	B-DISO
+and	O
+caspase	B-PRGE
+-	I-PRGE
+3	I-PRGE
+activation	O
+could	O
+,	O
+therefore	O
+,	O
+have	O
+prevented	O
+SARS	B-DISO
+patients	O
+from	O
+developing	O
+thrombocytopenia	O
+and	O
+lymphopenia	B-DISO
+.	O
+
+TITLE	O
+:	O
+Cellular	B-ANAT
+composition	O
+and	O
+interferon	B-FUNC
+-	I-FUNC
+gamma	I-FUNC
+expression	B-PROC
+of	O
+the	O
+local	O
+inflammatory	B-DISO
+response	I-DISO
+in	O
+feline	B-SPEC
+infectious	I-DISO
+peritonitis	I-DISO
+(	O
+FIP	B-DISO
+).	O
+
+ABSTRACT	O
+:	O
+Feline	B-DISO
+infectious	I-DISO
+peritonitis	I-DISO
+(	O
+FIP	B-DISO
+)	O
+is	O
+one	O
+of	O
+the	O
+most	O
+important	O
+viral	B-DISO
+diseases	I-DISO
+of	O
+cats	B-SPEC
+.	O
+
+International	O
+studies	O
+estimate	O
+that	O
+approximately	O
+80	O
+%	O
+of	O
+all	O
+purebred	O
+cats	B-SPEC
+are	O
+infected	O
+with	O
+the	O
+causative	O
+agent	O
+,	O
+feline	B-SPEC
+coronavirus	B-SPEC
+(	O
+FCoV	O
+).	O
+
+Serial	O
+serum	B-COMP
+samples	O
+obtained	O
+from	O
+the	O
+recipients	O
+of	O
+the	O
+convalescent	O
+plasma	B-ANAT
+were	O
+collected	O
+to	O
+undertake	O
+real	O
+-	O
+time	O
+quantitative	O
+RT	O
+-	O
+PCR	O
+for	O
+SARS	O
+-	O
+CoV	O
+for	O
+direct	O
+measurement	O
+of	O
+viral	O
+concentration	O
+.	O
+
+ABSTRACT	O
+:	O
+Polymorphisms	O
+of	O
+human	B-PRGE
+Fc	I-PRGE
+gamma	I-PRGE
+-	I-PRGE
+receptor	I-PRGE
+IIA	I-PRGE
+(	O
+FcgammaRIIA	O
+)	O
+and	O
+mannose	B-PRGE
+-	I-PRGE
+binding	B-FUNC
+lectin	I-PRGE
+(	O
+MBL	B-PRGE
+)	O
+genes	O
+have	O
+been	O
+associated	O
+with	O
+susceptibility	O
+to	O
+or	O
+severity	O
+of	O
+some	O
+infectious	B-DISO
+diseases	I-DISO
+.	O
+
+ABSTRACT	O
+:	O
+Infectious	B-DISO
+bronchitis	B-DISO
+virus	B-SPEC
+(	O
+IBV	B-SPEC
+)	O
+is	O
+produced	O
+in	O
+vitro	O
+using	O
+specific	O
+pathogen	O
+free	O
+chicken	B-SPEC
+embryos	B-ANAT
+,	O
+primary	O
+chicken	B-SPEC
+kidney	B-ANAT
+cells	B-COMP
+(	O
+CKC	O
+)	O
+and	O
+/	O
+or	O
+tracheal	O
+organ	B-ANAT
+culture	O
+(	O
+TOC	B-DISO
+).	O
+
+CER	B-CHED
+monolayers	O
+adapted	O
+to	O
+SF	O
+or	O
+APF	O
+were	O
+infected	O
+with	O
+IBV	B-SPEC
+(	O
+M41	O
+strain	O
+)	O
+in	O
+agitated	B-DISO
+suspended	O
+culture	O
+and	O
+the	O
+IBV	B-SPEC
+titre	O
+obtained	O
+48	O
+h	O
+post	O
+infection	B-DISO
+was	O
+2	O
+.	O
+8	O
+x	O
+104	O
+PFU	B-CHED
+/	O
+ml	O
+in	O
+both	O
+cases	O
+.	O
+
+The	O
+patients	O
+were	O
+divided	O
+into	O
+four	O
+groups	O
+according	O
+to	O
+the	O
+presence	O
+of	O
+drug	B-DISO
+withdrawal	I-DISO
+as	O
+well	O
+as	O
+seizure	B-DISO
+attack	O
+.	O
+
+In	O
+each	O
+group	O
+,	O
+seizures	B-DISO
+occurring	O
+during	O
+three	O
+different	O
+periods	B-PROC
+were	O
+compared	O
+.	O
+
+The	O
+major	O
+risk	O
+factors	O
+for	O
+withdrawal	B-DISO
+seizures	I-DISO
+were	O
+symptomatic	O
+etiologies	O
+,	O
+polytherapy	O
+and	O
+non	O
+-	O
+seizure	B-DISO
+free	O
+before	O
+AED	B-CHED
+withdrawal	B-DISO
+.	O
+
+The	O
+major	O
+risk	O
+factors	O
+for	O
+withdrawal	B-DISO
+seizures	I-DISO
+were	O
+symptomatic	O
+etiologies	O
+,	O
+polytherapy	O
+and	O
+non	O
+-	O
+seizure	B-DISO
+free	O
+before	O
+AED	B-CHED
+withdrawal	B-DISO
+.	O
+
+The	O
+biological	O
+significance	O
+of	O
+the	O
+novel	O
+enzymatic	B-PROC
+activity	I-PROC
+in	O
+vivo	O
+remains	O
+to	O
+be	O
+investigated	O
+.	O
+
+ABSTRACT	O
+:	O
+Coronaviruses	O
+are	O
+enveloped	O
+,	O
+positive	O
+-	O
+stranded	O
+RNA	O
+viruses	O
+considered	O
+to	O
+be	O
+promising	O
+vectors	O
+for	O
+vaccine	O
+development	B-PROC
+,	O
+as	O
+(	O
+i	O
+)	O
+genes	O
+can	O
+be	O
+deleted	O
+,	O
+resulting	O
+in	O
+attenuated	O
+viruses	B-SPEC
+;	O
+(	O
+ii	O
+)	O
+their	O
+tropism	B-PROC
+can	O
+be	O
+modified	O
+by	O
+manipulation	O
+of	O
+their	O
+spike	O
+protein	B-CHED
+;	O
+and	O
+(	O
+iii	O
+)	O
+heterologous	O
+genes	O
+can	O
+be	O
+expressed	B-PROC
+by	O
+simply	O
+inserting	O
+them	O
+with	O
+appropriate	O
+coronaviral	O
+transcription	B-PROC
+signals	O
+into	O
+the	O
+genome	O
+.	O
+
+In	O
+this	O
+study	O
+,	O
+the	O
+Renilla	B-SPEC
+and	O
+the	O
+firefly	B-ENZY
+luciferase	I-ENZY
+genes	O
+were	O
+systematically	O
+analyzed	O
+for	O
+their	O
+stability	O
+after	O
+insertion	O
+at	O
+various	O
+genomic	O
+positions	O
+in	O
+the	O
+group	O
+1	O
+coronavirus	B-SPEC
+feline	B-DISO
+infectious	I-DISO
+peritonitis	I-DISO
+virus	B-SPEC
+and	O
+in	O
+the	O
+group	O
+2	O
+coronavirus	B-SPEC
+mouse	B-DISO
+hepatitis	I-DISO
+virus	B-SPEC
+.	O
+
+This	O
+difference	O
+was	O
+not	O
+caused	O
+by	O
+genome	O
+size	O
+restrictions	O
+,	O
+by	O
+different	O
+effects	O
+of	O
+the	O
+encoded	O
+proteins	B-CHED
+,	O
+or	O
+by	O
+different	O
+consequences	O
+of	O
+the	O
+synthesis	B-PROC
+of	O
+the	O
+additional	O
+subgenomic	O
+mRNAs	O
+.	O
+
+TITLE	O
+:	O
+Structural	O
+genomics	O
+of	O
+the	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+coronavirus	B-SPEC
+:	O
+nuclear	O
+magnetic	O
+resonance	O
+structure	O
+of	O
+the	O
+protein	O
+nsP7	O
+.	O
+
+ABSTRACT	O
+:	O
+Here	O
+,	O
+we	O
+report	O
+the	O
+three	O
+-	O
+dimensional	O
+structure	O
+of	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+coronavirus	B-SPEC
+(	O
+SARS	B-PRGE
+-	I-PRGE
+CoV	I-PRGE
+)	O
+nsP7	O
+,	O
+a	O
+component	O
+of	O
+the	O
+SARS	B-PRGE
+-	I-PRGE
+CoV	I-PRGE
+replicase	I-PRGE
+polyprotein	I-PRGE
+.	O
+
+ABSTRACT	O
+:	O
+The	O
+emergence	O
+of	O
+the	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+(	O
+SARS	B-DISO
+)	O
+that	O
+resulted	O
+in	O
+a	O
+pandemic	O
+in	O
+2003	O
+spurred	O
+a	O
+flurry	O
+of	O
+interest	O
+in	O
+the	O
+development	B-PROC
+of	O
+vaccines	O
+to	O
+prevent	O
+and	O
+treat	O
+the	O
+potentially	O
+deadly	O
+viral	B-DISO
+infection	I-DISO
+.	O
+
+While	O
+significant	O
+advances	O
+have	O
+been	O
+made	O
+in	O
+the	O
+development	B-PROC
+of	O
+animal	B-SPEC
+models	O
+,	O
+the	O
+practicality	O
+of	O
+their	O
+use	O
+may	O
+be	O
+hampered	O
+by	O
+a	O
+lack	O
+of	O
+pathological	O
+similarity	O
+with	O
+human	B-SPEC
+disease	O
+.	O
+
+Within	O
+4	O
+h	O
+after	O
+injection	O
+her	O
+arterial	B-ANAT
+oxygen	B-PROC
+tension	B-DISO
+was	O
+8	O
+.	O
+1	O
+kPa	O
+(	O
+60	O
+mm	O
+Hg	O
+)	O
+at	O
+an	O
+inspired	B-PROC
+oxygen	B-CHED
+fraction	O
+(	O
+F	O
+(	O
+IO2	B-CHED
+))	O
+of	O
+0	O
+.	O
+7	O
+(	O
+P	O
+/	O
+F	O
+ratio	O
+:	O
+85	O
+)	O
+despite	O
+a	O
+positive	O
+end	O
+expiratory	B-PROC
+pressure	O
+(	O
+PEEP	B-CHED
+)	O
+of	O
+20	O
+mbar	O
+,	O
+therefore	O
+meeting	O
+criteria	O
+for	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+(	O
+ARDS	B-DISO
+).	O
+
+ABSTRACT	O
+:	O
+Ortho	O
+-	O
+phenylphenol	O
+(	O
+OPP	O
+)	O
+and	O
+its	O
+sodium	O
+salt	O
+are	O
+used	O
+as	O
+fungicides	B-CHED
+and	O
+antibacterial	B-CHED
+agents	I-CHED
+,	O
+ingestion	O
+of	O
+which	O
+has	O
+been	O
+found	O
+to	O
+cause	O
+liver	B-ANAT
+toxicity	O
+,	O
+renal	B-DISO
+toxicity	I-DISO
+and	O
+carcinomas	B-DISO
+in	O
+the	O
+urinary	B-ANAT
+tract	I-ANAT
+of	O
+rats	B-SPEC
+.	O
+
+Open	O
+lung	B-ANAT
+biopsy	O
+showed	O
+diffuse	B-DISO
+alveolar	I-DISO
+damage	I-DISO
+.	O
+
+She	O
+was	O
+discharged	O
+after	O
+34	O
+days	O
+of	O
+hospitalization	O
+with	O
+continuing	O
+domiciliary	O
+oxygen	B-CHED
+therapy	O
+.	O
+
+There	O
+were	O
+ON	O
+of	O
+femoral	B-ANAT
+head	I-ANAT
+in	O
+130	O
+cases	O
+(	O
+210	O
+hips	B-ANAT
+),	O
+ON	O
+of	O
+knee	B-ANAT
+in	O
+98	O
+cases	O
+(	O
+130	O
+knees	B-ANAT
+),	O
+ON	O
+of	O
+humeral	B-ANAT
+head	I-ANAT
+in	O
+21	O
+cases	O
+(	O
+36	O
+shoulders	B-ANAT
+),	O
+ON	O
+of	O
+talus	B-ANAT
+and	O
+calcaneus	B-ANAT
+in	O
+16	O
+cases	O
+(	O
+26	O
+ankles	B-ANAT
+),	O
+ON	O
+of	O
+scaphoid	B-ANAT
+and	O
+lunate	B-ANAT
+in	O
+11	O
+cases	O
+(	O
+17	O
+wrists	B-ANAT
+),	O
+ON	O
+of	O
+patella	B-SPEC
+in	O
+3	O
+cases	O
+(	O
+4	O
+patella	B-SPEC
+),	O
+ON	O
+of	O
+ilium	B-ANAT
+in	O
+1	O
+case	O
+and	O
+bone	B-DISO
+infarction	I-DISO
+(	O
+femur	B-ANAT
+,	O
+tibia	B-ANAT
+)	O
+in	O
+18	O
+cases	O
+.	O
+
+All	O
+osteonecrosis	B-DISO
+of	O
+the	O
+knee	B-ANAT
+and	O
+humoral	O
+head	B-ANAT
+was	O
+stage	O
+I	O
+.	O
+Thirty	O
+-	O
+four	O
+patients	O
+with	O
+ON	O
+had	O
+one	O
+joint	B-ANAT
+affected	O
+,	O
+45	O
+patients	O
+had	O
+2	O
+joints	B-ANAT
+,	O
+93	O
+patients	O
+had	O
+more	O
+than	O
+3	O
+joints	B-ANAT
+.	O
+
+About	O
+one	O
+-	O
+third	O
+patients	O
+with	O
+SARS	B-DISO
+who	O
+were	O
+treated	O
+with	O
+a	O
+high	O
+dose	O
+of	O
+corticosteroid	B-CHED
+occurred	O
+osteonecrosis	B-DISO
+.	O
+
+TITLE	O
+:	O
+Influence	O
+of	O
+intron	O
+and	O
+exon	O
+splicing	B-PROC
+enhancers	O
+on	O
+mammalian	B-ANAT
+cell	B-COMP
+expression	B-PROC
+of	O
+a	O
+truncated	O
+spike	O
+protein	O
+of	O
+SARS	B-PRGE
+-	I-PRGE
+CoV	I-PRGE
+and	O
+its	O
+implication	O
+for	O
+subunit	O
+vaccine	O
+development	B-PROC
+.	O
+
+ABSTRACT	O
+:	O
+The	O
+spike	O
+(	O
+S	O
+)	O
+protein	B-CHED
+of	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+coronavirus	B-SPEC
+(	O
+SARS	B-DISO
+-	O
+CoV	O
+)	O
+is	O
+important	O
+for	O
+vaccine	O
+development	B-PROC
+.	O
+
+TITLE	O
+:	O
+Early	O
+enhanced	O
+expression	B-PROC
+of	O
+interferon	B-PRGE
+-	O
+inducible	O
+protein	B-CHED
+-	O
+10	O
+(	O
+CXCL	O
+-	O
+10	O
+)	O
+and	O
+other	O
+chemokines	O
+predicts	O
+adverse	O
+outcome	O
+in	O
+severe	O
+acute	O
+respiratory	O
+syndrome	O
+.	O
+
+After	O
+adjusting	O
+for	O
+other	O
+risk	O
+factors	O
+,	O
+plasma	B-ANAT
+IP	O
+-	O
+10	O
+concentration	O
+at	O
+the	O
+first	O
+week	O
+remained	O
+as	O
+an	O
+independent	O
+prognostic	O
+factor	O
+,	O
+with	O
+an	O
+odds	O
+ratio	O
+for	O
+adverse	O
+outcome	O
+of	O
+1	O
+.	O
+52	O
+(	O
+95	O
+%	O
+confidence	O
+interval	O
+,	O
+1	O
+.	O
+05	O
+-	O
+2	O
+.	O
+55	O
+)	O
+per	O
+fold	O
+increase	O
+in	O
+plasma	B-ANAT
+IP	O
+-	O
+10	O
+concentration	O
+above	O
+the	O
+median	O
+.	O
+
+Increased	O
+plasma	B-ANAT
+IP	O
+-	O
+10	O
+during	O
+the	O
+first	O
+week	O
+of	O
+SARS	B-DISO
+symptoms	O
+is	O
+an	O
+independent	O
+predictor	O
+of	O
+outcome	O
+.	O
+
+IP	O
+-	O
+10	O
+was	O
+increased	O
+in	O
+lung	B-ANAT
+tissue	I-ANAT
+from	O
+patients	O
+who	O
+died	B-PROC
+of	O
+SARS	B-DISO
+.	O
+
+TITLE	O
+:	O
+Bats	B-SPEC
+are	O
+natural	O
+reservoirs	O
+of	O
+SARS	B-DISO
+-	O
+like	O
+coronaviruses	O
+.	O
+
+ABSTRACT	O
+:	O
+Severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+(	O
+SARS	B-DISO
+)	O
+emerged	O
+in	O
+2002	O
+to	O
+2003	O
+in	O
+southern	O
+China	O
+.	O
+
+The	O
+origin	O
+of	O
+its	O
+etiological	O
+agent	O
+,	O
+the	O
+SARS	B-DISO
+coronavirus	B-SPEC
+(	O
+SARS	B-DISO
+-	O
+CoV	O
+),	O
+remains	O
+elusive	O
+.	O
+
+TITLE	O
+:	O
+Alcohol	O
+-	O
+induced	O
+lung	B-ANAT
+damage	O
+and	O
+increased	O
+oxidative	B-DISO
+stress	I-DISO
+.	O
+
+The	O
+ethanol	B-CHED
+group	O
+received	O
+2	O
+g	O
+/	O
+kg	O
+ethanol	B-CHED
+(	O
+total	O
+:	O
+3	O
+ml	O
+)	O
+intraperitoneally	O
+.	O
+
+Oxidative	B-DISO
+stress	I-DISO
+was	O
+assessed	O
+by	O
+measuring	O
+the	O
+levels	O
+of	O
+erythrocyte	B-ANAT
+reduced	B-CHED
+glutathione	I-CHED
+(	O
+GSH	B-DISO
+),	O
+tissue	B-ANAT
+malondialdehyde	B-CHED
+(	O
+MDA	B-CHED
+),	O
+myeloperoxidase	B-PRGE
+(	O
+MPO	B-FUNC
+)	O
+and	O
+Na	B-PRGE
+(+)-	I-PRGE
+K	I-PRGE
+(+)	I-PRGE
+ATPase	I-PRGE
+.	O
+
+Histopathologic	O
+examination	O
+demonstrated	O
+alveolocapillary	O
+thickening	O
+,	O
+alveolar	O
+degeneration	B-DISO
+,	O
+leukocyte	B-ANAT
+infiltration	B-DISO
+and	O
+erythrocyte	B-ANAT
+extravasation	B-DISO
+in	O
+the	O
+lungs	B-ANAT
+of	O
+the	O
+ethanol	B-CHED
+group	O
+(	O
+p	O
+<	O
+0	O
+.	O
+05	O
+).	O
+
+The	O
+description	O
+of	O
+procedures	O
+for	O
+sanitation	O
+of	O
+infected	O
+cell	B-ANAT
+lines	I-ANAT
+or	O
+tumours	B-DISO
+is	O
+sparse	O
+.	O
+
+RESULTS	O
+:	O
+The	O
+recombinant	O
+expression	B-PROC
+vector	O
+produced	O
+high	O
+level	O
+of	O
+the	O
+N	B-PRGE
+fusion	I-PRGE
+protein	I-PRGE
+after	O
+induction	O
+,	O
+and	O
+that	O
+protein	B-CHED
+was	O
+purified	O
+successfully	O
+by	O
+affinity	O
+chromatography	O
+and	O
+displayed	O
+higher	O
+antigenicity	O
+and	O
+specificity	O
+as	O
+compared	O
+with	O
+whole	O
+virus	B-SPEC
+lysates	O
+.	O
+
+The	O
+most	O
+common	O
+cause	O
+of	O
+death	B-PROC
+was	O
+sepsis	B-DISO
+,	O
+caused	O
+by	O
+organ	B-ANAT
+involvement	O
+and	O
+direct	O
+cytotoxicity	B-DISO
+of	O
+Bacillus	B-SPEC
+anthracis	I-SPEC
+,	O
+in	O
+addition	O
+to	O
+its	O
+exotoxin	O
+production	O
+.	O
+
+The	O
+physician	O
+'	O
+s	O
+primary	O
+responsibility	O
+in	O
+such	O
+emergencies	B-DISO
+is	O
+to	O
+the	O
+public	O
+rather	O
+than	O
+to	O
+the	O
+individual	O
+patient	O
+.	O
+
+TITLE	O
+:	O
+Impact	O
+of	O
+the	O
+pulmonary	B-ANAT
+artery	I-ANAT
+catheter	O
+in	O
+critically	B-DISO
+ill	I-DISO
+patients	O
+:	O
+meta	B-SPEC
+-	O
+analysis	O
+of	O
+randomized	O
+clinical	O
+trials	O
+.	O
+
+In	O
+critically	B-DISO
+ill	I-DISO
+patients	O
+,	O
+use	O
+of	O
+the	O
+PAC	B-DISO
+neither	O
+increased	O
+overall	O
+mortality	O
+or	O
+days	O
+in	O
+hospital	O
+nor	O
+conferred	O
+benefit	O
+.	O
+
+TITLE	O
+:	O
+Feline	B-SPEC
+coronavirus	B-SPEC
+serotypes	O
+1	O
+and	O
+2	O
+:	O
+seroprevalence	O
+and	O
+association	O
+with	O
+disease	O
+in	O
+Switzerland	O
+.	O
+
+FCoV	O
+type	O
+1	O
+viruses	B-SPEC
+induced	O
+higher	O
+antibody	B-COMP
+titers	O
+than	O
+FCoV	O
+type	O
+2	O
+,	O
+and	O
+were	O
+more	O
+frequently	O
+associated	O
+with	O
+clinical	O
+signs	O
+and	O
+/	O
+or	O
+feline	B-DISO
+infectious	I-DISO
+peritonitis	I-DISO
+.	O
+
+van	O
+Kaam	O
+'	O
+s	O
+phenomenological	O
+research	O
+method	O
+,	O
+with	O
+the	O
+human	B-SPEC
+becoming	O
+theory	O
+as	O
+the	O
+theoretical	O
+perspective	O
+,	O
+was	O
+used	O
+to	O
+gather	O
+and	O
+analyse	O
+data	O
+from	O
+63	O
+participants	O
+who	O
+agreed	O
+to	O
+describe	O
+a	O
+situation	O
+that	O
+illuminated	O
+their	O
+experience	O
+of	O
+persevering	O
+through	O
+a	O
+difficult	O
+time	O
+(	O
+either	O
+online	O
+or	O
+using	O
+a	O
+voicemail	O
+system	O
+).	O
+
+ABSTRACT	O
+:	O
+Patent	O
+applications	O
+that	O
+incorporate	O
+the	O
+genomic	O
+sequence	O
+of	O
+the	O
+severe	O
+acute	O
+respiratory	O
+syndrome	O
+(	O
+SARS	B-DISO
+)	O
+coronavirus	B-SPEC
+,	O
+have	O
+been	O
+filed	O
+by	O
+a	O
+number	O
+of	O
+organizations	O
+.	O
+
+TITLE	O
+:	O
+Detection	O
+of	O
+infectious	B-DISO
+bronchitis	B-DISO
+virus	B-SPEC
+and	O
+specific	O
+anti	O
+-	O
+viral	O
+antibodies	B-COMP
+using	O
+a	O
+Concanavalin	O
+A	O
+-	O
+Sandwich	O
+-	O
+ELISA	O
+.	O
+
+The	O
+nucleocapsid	B-COMP
+(	O
+N	O
+)	O
+and	O
+spike	O
+(	O
+S	O
+)	O
+proteins	B-CHED
+of	O
+SARS	B-DISO
+-	O
+CoV	O
+appear	O
+to	O
+be	O
+the	O
+dominant	O
+antigens	B-CHED
+recognized	O
+by	O
+serum	B-PRGE
+Abs	I-PRGE
+.	O
+
+novel	O
+protein	B-CHED
+,	O
+and	O
+its	O
+expression	B-PROC
+has	O
+been	O
+confirmed	O
+in	O
+SARS	B-DISO
+patients	O
+.	O
+
+TITLE	O
+:	O
+The	O
+performance	O
+of	O
+RT	O
+-	O
+PCR	O
+compared	O
+with	O
+a	O
+rapid	O
+serological	O
+assay	O
+for	O
+acute	O
+dengue	B-DISO
+fever	I-DISO
+in	O
+a	O
+diagnostic	O
+laboratory	O
+.	O
+
+A	O
+total	O
+of	O
+343	O
+results	O
+for	O
+RT	O
+-	O
+PCR	O
+and	O
+439	O
+results	O
+for	O
+serology	O
+were	O
+analysed	O
+and	O
+compared	O
+with	O
+the	O
+final	O
+discharge	B-ANAT
+diagnosis	O
+.	O
+
+It	O
+was	O
+chosen	O
+as	O
+one	O
+of	O
+eight	O
+types	O
+of	O
+traditional	O
+Chinese	O
+medicine	B-CHED
+that	O
+play	O
+a	O
+unique	O
+role	O
+in	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+(	O
+SARS	B-DISO
+)	O
+owing	O
+to	O
+the	O
+effect	O
+of	O
+curbing	B-DISO
+inflammation	B-DISO
+.	O
+
+We	O
+found	O
+that	O
+the	O
+secondary	O
+structure	O
+of	O
+the	O
+dimerization	O
+domain	O
+consists	O
+of	O
+five	O
+alpha	O
+helices	B-SPEC
+and	O
+a	O
+beta	O
+-	O
+hairpin	O
+.	O
+
+It	O
+is	O
+characterized	O
+pathologically	O
+by	O
+damage	O
+to	O
+pulmonary	B-ANAT
+epithelial	O
+and	O
+endothelial	B-ANAT
+cells	I-ANAT
+,	O
+with	O
+subsequent	O
+alveolar	B-ANAT
+-	O
+capillary	B-ANAT
+leak	O
+and	O
+exudative	O
+pulmonary	B-DISO
+edema	I-DISO
+.	O
+
+Prompt	O
+diagnosis	O
+and	O
+treatment	O
+with	O
+contemporary	O
+antimicrobial	B-CHED
+therapy	O
+and	O
+intensive	O
+care	O
+unit	O
+management	O
+of	O
+respiratory	O
+compromise	O
+has	O
+reduced	O
+the	O
+maternal	O
+morbidity	O
+and	O
+mortality	O
+due	O
+to	O
+pneumonia	B-DISO
+in	O
+pregnancy	O
+.	O
+
+Prevention	O
+with	O
+vaccination	O
+in	O
+at	O
+-	O
+risk	O
+populations	O
+may	O
+reduce	O
+the	O
+prevalence	O
+and	O
+severity	O
+of	O
+pneumonia	B-DISO
+in	O
+pregnant	O
+women	O
+.	O
+
+TITLE	O
+:	O
+Mechanisms	O
+of	O
+decreased	O
+intestinal	B-ANAT
+epithelial	B-DISO
+proliferation	I-DISO
+and	O
+increased	O
+apoptosis	B-PATH
+in	O
+murine	B-SPEC
+acute	O
+lung	B-ANAT
+injury	O
+.	O
+
+This	O
+idea	B-SPEC
+was	O
+supported	O
+by	O
+titration	O
+experiments	O
+showing	O
+that	O
+enzyme	B-FUNC
+activity	I-FUNC
+was	O
+strongly	O
+concentration	O
+-	O
+dependent	O
+,	O
+indicating	O
+that	O
+oligomeric	O
+Nsp15	O
+is	O
+the	O
+active	O
+form	O
+.	O
+
+The	O
+SARS	B-DISO
+coronavirus	B-SPEC
+epidemic	O
+,	O
+which	O
+began	O
+in	O
+the	O
+Fall	O
+of	O
+2002	O
+,	O
+was	O
+related	O
+to	O
+the	O
+exotic	O
+food	O
+industry	O
+in	O
+southern	O
+China	O
+,	O
+initially	O
+involving	O
+disproportionate	O
+numbers	O
+of	O
+animal	B-SPEC
+handlers	O
+,	O
+chefs	O
+,	O
+and	O
+caterers	O
+.	O
+
+The	O
+spike	O
+protein	B-CHED
+and	O
+neucleocapsid	B-PRGE
+protein	I-PRGE
+are	O
+most	O
+abundant	O
+in	O
+SARS	B-PRGE
+-	I-PRGE
+Cov	I-PRGE
+and	O
+contribute	O
+dominantly	O
+to	O
+the	O
+antibody	B-PROC
+production	I-PROC
+during	O
+the	O
+course	O
+of	O
+disease	O
+.	O
+
+ABSTRACT	O
+:	O
+Partial	O
+liquid	O
+ventilation	O
+(	O
+PLV	O
+)	O
+with	O
+perfluorochemical	O
+(	O
+PFC	O
+)	O
+has	O
+been	O
+advocated	O
+as	O
+a	O
+new	O
+therapy	O
+for	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+in	O
+both	O
+clinical	O
+and	O
+animal	B-SPEC
+studies	O
+,	O
+meconium	B-DISO
+aspiration	I-DISO
+syndrome	I-DISO
+,	O
+and	O
+RDS	O
+.	O
+
+Specifically	O
+,	O
+HFO	O
+with	O
+aggressive	B-DISO
+and	O
+adequate	O
+lung	B-PROC
+volume	I-PROC
+recruitment	B-DISO
+has	O
+been	O
+shown	O
+to	O
+reduce	O
+the	O
+incidence	O
+of	O
+chronic	B-DISO
+lung	I-DISO
+disease	I-DISO
+in	O
+very	O
+low	O
+birth	B-PROC
+weight	O
+infants	O
+.	O
+
+We	O
+hypothesized	O
+that	O
+PLV	O
+along	O
+with	O
+HFO	O
+might	O
+be	O
+effective	O
+in	O
+ARDS	B-DISO
+in	O
+an	O
+adult	O
+rabbit	B-SPEC
+model	O
+.	O
+
+After	O
+induction	O
+of	O
+severe	O
+lung	B-ANAT
+injury	O
+by	O
+repeated	O
+saline	O
+lung	B-ANAT
+lavage	O
+,	O
+19	O
+adult	O
+white	O
+Japanese	O
+rabbits	B-SPEC
+were	O
+randomized	O
+into	O
+two	O
+groups	O
+that	O
+received	O
+PLV	O
+with	O
+HFO	O
+(	O
+n	O
+=	O
+9	O
+)	O
+or	O
+HFO	O
+gas	B-ENZY
+ventilation	O
+(	O
+n	O
+=	O
+10	O
+).	O
+
+RESULTS	O
+:	O
+The	O
+HFO	O
+-	O
+PLV	O
+group	O
+showed	O
+improved	O
+total	O
+lung	B-PROC
+compliance	I-PROC
+with	O
+maintenance	O
+of	O
+significantly	O
+lower	O
+mean	O
+airway	B-ANAT
+pressure	O
+as	O
+compared	O
+with	O
+the	O
+HFO	O
+-	O
+GAS	B-PRGE
+group	O
+so	O
+as	O
+to	O
+keep	O
+SpO2	O
+>	O
+90	O
+%.	O
+
+The	O
+second	O
+survey	O
+asked	O
+practice	O
+principals	O
+how	O
+they	O
+organised	O
+their	O
+practice	O
+to	O
+respond	O
+to	O
+the	O
+SARS	B-DISO
+threat	O
+in	O
+2003	O
+,	O
+any	O
+difficulties	O
+they	O
+had	O
+with	O
+implementing	O
+this	O
+response	O
+,	O
+use	O
+of	O
+SARS	B-DISO
+infection	B-DISO
+control	O
+guidelines	O
+and	O
+current	O
+policies	O
+.	O
+
+Suggestions	O
+and	O
+comments	O
+on	O
+how	O
+ACT	B-PRGE
+GPs	I-PRGE
+could	O
+be	O
+better	O
+prepared	O
+to	O
+respond	O
+to	O
+future	O
+outbreaks	O
+included	O
+the	O
+need	O
+for	O
+timeliness	O
+of	O
+information	O
+,	O
+information	O
+delivery	O
+mechanisms	O
+,	O
+communication	O
+issues	O
+,	O
+education	O
+,	O
+the	O
+availability	O
+of	O
+guidelines	O
+and	O
+protocols	O
+,	O
+planning	O
+,	O
+role	O
+delineation	O
+,	O
+the	O
+use	O
+of	O
+response	O
+teams	O
+,	O
+provision	O
+of	O
+equipment	O
+,	O
+and	O
+vaccination	O
+.	O
+
+TITLE	O
+:	O
+Risk	O
+assessment	O
+of	O
+mouse	B-DISO
+hepatitis	I-DISO
+virus	B-DISO
+infection	I-DISO
+via	O
+in	O
+vitro	O
+fertilization	B-PROC
+and	O
+embryo	B-ANAT
+transfer	O
+by	O
+the	O
+use	O
+of	O
+zona	O
+-	O
+intact	O
+and	O
+laser	B-SPEC
+-	O
+microdissected	O
+oocytes	B-ANAT
+.	O
+
+In	O
+addition	O
+,	O
+resistance	B-PROC
+to	O
+infection	B-DISO
+of	O
+zona	B-DISO
+-	O
+intact	O
+and	O
+laser	B-SPEC
+-	O
+microdissected	O
+oocytes	B-ANAT
+was	O
+compared	O
+.	O
+
+For	O
+this	O
+purpose	O
+,	O
+infectious	B-DISO
+mouse	B-DISO
+hepatitis	I-DISO
+virus	B-SPEC
+,	O
+a	O
+common	O
+viral	O
+pathogen	O
+in	O
+mouse	B-SPEC
+facilities	O
+,	O
+was	O
+used	O
+.	O
+
+ABSTRACT	O
+:	O
+The	O
+emergence	O
+and	O
+rapid	O
+global	O
+spread	O
+of	O
+the	O
+severe	O
+acute	O
+respiratory	O
+syndrome	O
+(	O
+SARS	B-DISO
+)	O
+coronavirus	B-SPEC
+in	O
+2002	O
+-	O
+2003	O
+prompted	O
+efforts	O
+by	O
+modelers	O
+to	O
+characterize	O
+SARS	B-DISO
+epidemiology	O
+and	O
+inform	O
+control	O
+policies	O
+.	O
+
+This	O
+represents	O
+an	O
+increase	O
+of	O
+119	O
+new	O
+cases	O
+and	O
+8	O
+new	O
+deaths	B-PROC
+compared	O
+with	O
+9	O
+May	O
+2003	O
+(	O
+China	O
+(	O
+85	O
+),	O
+Taiwan	O
+(	O
+23	O
+),	O
+and	O
+Hong	O
+Kong	O
+(	O
+7	O
+)	O
+represented	O
+the	O
+overwhelming	O
+majority	O
+,	O
+with	O
+one	O
+additional	O
+case	O
+each	O
+reported	O
+from	O
+France	O
+,	O
+Malaysia	O
+,	O
+Singapore	O
+,	O
+and	O
+the	O
+United	O
+States	O
+).	O
+
+The	O
+positive	O
+results	O
+of	O
+in	O
+-	O
+situ	O
+hybridization	B-PROC
+showed	O
+that	O
+the	O
+lung	B-ANAT
+tissues	I-ANAT
+of	O
+all	O
+cases	O
+expressed	B-PROC
+SARS	B-PRGE
+-	I-PRGE
+CoV	I-PRGE
+RNA	I-PRGE
+,	O
+and	O
+positive	O
+signals	O
+displayed	O
+in	O
+cytoplasms	B-COMP
+(	O
+purple	O
+-	O
+blue	O
+,	O
+NBP	O
+-	O
+BCIP	O
+.	O
+
+The	O
+positive	O
+results	O
+of	O
+double	O
+staining	O
+indicated	O
+that	O
+bronchial	B-ANAT
+epithelial	B-ANAT
+cells	I-ANAT
+,	O
+type	B-ANAT
+II	I-ANAT
+pneumocytes	I-ANAT
+,	O
+endothelial	B-ANAT
+cells	I-ANAT
+,	O
+macrophages	B-ANAT
+,	O
+fibroblasts	B-ANAT
+and	O
+T	B-ANAT
+lymphocytes	I-ANAT
+were	O
+diffusely	O
+infected	O
+by	O
+SARS	B-DISO
+-	O
+CoV	O
+.	O
+This	O
+study	O
+of	O
+ISH	B-DISO
+-	O
+IHC	O
+double	O
+staining	O
+in	O
+lung	B-ANAT
+tissues	I-ANAT
+of	O
+SARS	B-DISO
+patients	O
+showed	O
+that	O
+bronchial	B-ANAT
+epithelial	B-ANAT
+cells	I-ANAT
+,	O
+type	B-ANAT
+II	I-ANAT
+pneumocytes	I-ANAT
+,	O
+endothelial	B-ANAT
+cells	I-ANAT
+,	O
+macrophages	B-ANAT
+,	O
+T	B-ANAT
+lymphocytes	I-ANAT
+and	O
+fibroblasts	B-ANAT
+were	O
+attacked	O
+diffusely	O
+in	O
+SARS	B-DISO
+lungs	B-ANAT
+.	O
+
+TITLE	O
+:	O
+[	O
+Preparation	O
+and	O
+identification	O
+of	O
+monoclonal	O
+antibodies	B-COMP
+against	O
+SARS	B-DISO
+-	O
+CoV	O
+putative	O
+protein	B-CHED
+X4	O
+].	O
+
+ABSTRACT	O
+:	O
+To	O
+obtain	O
+monoclonal	O
+antibodies	O
+against	O
+putative	O
+protein	B-CHED
+X4	O
+of	O
+SARS	B-DISO
+-	O
+CoV	O
+for	O
+further	O
+study	O
+of	O
+the	O
+structure	O
+and	O
+function	O
+of	O
+protein	B-CHED
+X4	O
+.	O
+
+Indirect	O
+Immunofluorescence	O
+assay	O
+indicated	O
+that	O
+they	O
+could	O
+specifically	O
+bind	B-FUNC
+to	O
+protein	B-CHED
+X4	O
+expressed	B-PROC
+in	O
+SARS	B-DISO
+-	O
+CoV	O
+infected	O
+Vero	O
+E6	O
+cells	B-COMP
+.	O
+
+In	O
+this	O
+study	O
+,	O
+we	O
+intended	O
+to	O
+identify	O
+potential	O
+3CL	B-PRGE
+(	I-PRGE
+pro	I-PRGE
+)-	I-PRGE
+interacting	I-PRGE
+cellular	B-COMP
+protein	B-CHED
+(	I-PRGE
+s	I-PRGE
+)	I-PRGE
+using	O
+the	O
+phage	O
+-	O
+displayed	O
+human	B-SPEC
+lung	B-ANAT
+cDNA	O
+library	O
+.	O
+
+The	O
+vacuolar	B-COMP
+-	O
+H	O
++	O
+ATPase	B-ENZY
+(	O
+V	O
+-	O
+ATPase	B-ENZY
+)	O
+G1	O
+subunit	O
+that	O
+contained	O
+a	O
+3CL	O
+(	O
+pro	B-CHED
+)	O
+cleavage	B-PROC
+site	O
+-	O
+like	O
+motif	O
+was	O
+identified	O
+as	O
+a	O
+3CL	B-PRGE
+(	I-PRGE
+pro	I-PRGE
+)-	I-PRGE
+interacting	I-PRGE
+protein	B-CHED
+,	O
+as	O
+confirmed	O
+using	O
+the	O
+co	O
+-	O
+immunoprecipitation	O
+assay	O
+and	O
+the	O
+relative	O
+affinity	O
+assay	O
+.	O
+
+Moreover	O
+,	O
+loading	O
+cells	B-COMP
+with	O
+SNARF	O
+-	O
+1	O
+pH	O
+-	O
+sensitive	O
+dye	B-CHED
+showed	O
+that	O
+the	O
+intracellular	B-COMP
+pH	O
+in	O
+3CL	O
+(	O
+pro	B-CHED
+)-	O
+expressing	O
+cells	B-COMP
+was	O
+significantly	O
+lower	O
+as	O
+compared	O
+to	O
+mock	O
+cells	O
+.	O
+
+Further	O
+analysis	O
+confirmed	O
+that	O
+the	O
+mutant	B-PRGE
+S	I-PRGE
+protein	B-CHED
+trafficked	B-PROC
+though	O
+the	O
+secretory	B-PROC
+pathway	I-PROC
+faster	O
+than	O
+wild	O
+-	O
+type	O
+S	O
+protein	B-CHED
+.	O
+
+One	O
+of	O
+these	O
+mutants	O
+,	O
+CCA4	B-DISO
+,	O
+had	O
+a	O
+highly	O
+defective	O
+phenotype	O
+similar	O
+to	O
+that	O
+of	O
+MDelta2	O
+.	O
+
+Murine	B-DISO
+hepatitis	I-DISO
+virus	B-SPEC
+(	O
+MHV	B-SPEC
+)	O
+and	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+coronavirus	B-SPEC
+(	O
+SARS	B-DISO
+-	O
+CoV	O
+)	O
+polyproteins	O
+incorporate	O
+16	O
+protein	B-CHED
+domains	O
+(	O
+nsps	O
+),	O
+with	O
+nsp1	B-PRGE
+and	O
+nsp2	B-PRGE
+being	O
+the	O
+most	O
+variable	O
+among	O
+the	O
+coronaviruses	O
+and	O
+having	O
+no	O
+experimentally	O
+confirmed	O
+or	O
+predicted	O
+functions	O
+in	O
+replication	O
+.	O
+
+It	O
+binds	B-FUNC
+to	O
+the	O
+viral	O
+RNA	O
+genome	O
+and	O
+forms	O
+the	O
+ribonucleoprotein	B-COMP
+core	O
+.	O
+
+350	O
+throat	B-ANAT
+washes	O
+of	O
+confirmed	O
+,	O
+suspected	O
+and	O
+observed	O
+SARS	B-DISO
+cases	O
+were	O
+tested	O
+by	O
+TaqMan	O
+and	O
+molecular	O
+beacon	O
+fluorescence	O
+RT	O
+-	O
+PCR	O
+methods	O
+.	O
+
+The	O
+positive	O
+rate	O
+of	O
+PCR	O
+for	O
+nasal	B-ANAT
+and	O
+fecal	B-ANAT
+swabs	O
+from	O
+109	O
+major	O
+wild	O
+animals	B-SPEC
+is	O
+44	O
+.	O
+04	O
+%,	O
+but	O
+the	O
+positive	O
+rate	O
+of	O
+145	O
+wild	O
+live	O
+-	O
+animals	B-SPEC
+is	O
+0	O
+.	O
+
+We	O
+have	O
+developed	O
+a	O
+simple	O
+and	O
+accurate	O
+method	O
+for	O
+the	O
+characterization	O
+and	O
+screening	O
+of	O
+SARS	B-DISO
+-	O
+coronavirus	B-SPEC
+genotypes	O
+.	O
+
+The	O
+same	O
+series	O
+of	O
+mutations	O
+occurring	O
+in	O
+separate	O
+geographic	O
+locations	O
+and	O
+at	O
+different	O
+times	O
+suggests	O
+a	O
+dominant	O
+process	O
+of	O
+viral	O
+adaptation	O
+to	O
+the	O
+host	B-COMP
+.	O
+
+The	O
+detection	O
+of	O
+viral	O
+pathogens	O
+by	O
+PCR	O
+was	O
+associated	O
+with	O
+the	O
+winter	O
+season	O
+,	O
+less	O
+infiltrates	B-DISO
+on	O
+chest	B-ANAT
+radiographs	O
+,	O
+lower	O
+C	B-PRGE
+-	I-PRGE
+reactive	I-PRGE
+protein	I-PRGE
+levels	O
+,	O
+and	O
+shorter	O
+duration	O
+of	O
+symptoms	O
+.	O
+
+TITLE	O
+:	O
+[	O
+Clinical	O
+observation	O
+and	O
+treatment	O
+of	O
+extensive	O
+severe	O
+burn	O
+accompanied	O
+by	O
+blast	B-ANAT
+injury	O
+of	O
+the	O
+lungs	O
+].	O
+
+The	O
+clinical	O
+data	O
+of	O
+16	O
+patients	O
+with	O
+blast	B-ANAT
+injury	O
+of	O
+the	O
+lungs	B-ANAT
+and	O
+extensive	O
+burns	O
+were	O
+analyzed	O
+.	O
+
+Low	O
+tide	O
+volume	B-PROC
+lung	I-PROC
+-	O
+protective	O
+ventilation	O
+strategy	O
+and	O
+lung	B-ANAT
+recruitment	B-DISO
+measures	O
+may	O
+prove	O
+beneficial	O
+.	O
+
+ABSTRACT	O
+:	O
+Kawasaki	B-DISO
+disease	I-DISO
+(	O
+KD	O
+)	O
+is	O
+a	O
+self	O
+-	O
+limited	O
+,	O
+systemic	O
+vasculitis	B-DISO
+of	O
+children	O
+for	O
+which	O
+an	O
+infectious	B-DISO
+trigger	O
+is	O
+suspected	O
+.	O
+
+She	O
+had	O
+persistent	O
+metabolic	B-DISO
+acidosis	I-DISO
+with	O
+severe	O
+hypokalaemia	O
+and	O
+required	O
+mechanical	O
+ventilation	O
+and	O
+potassium	B-CHED
+replacement	O
+.	O
+
+We	O
+evaluated	O
+survivors	O
+with	O
+confirmed	O
+SARS	B-DISO
+at	O
+the	O
+Prince	O
+of	O
+Wales	O
+Hospital	O
+,	O
+Hong	O
+Kong	O
+,	O
+at	O
+3	O
+,	O
+6	O
+,	O
+and	O
+12	O
+months	O
+after	O
+symptom	B-DISO
+onset	O
+.	O
+
+Four	O
+patients	O
+(	O
+4	O
+.	O
+1	O
+%),	O
+5	O
+patients	O
+(	O
+5	O
+.	O
+2	O
+%),	O
+and	O
+23	O
+patients	O
+(	O
+23	O
+.	O
+7	O
+%)	O
+had	O
+FVC	B-PROC
+,	O
+TLC	O
+,	O
+and	O
+D	O
+(	O
+LCO	B-CHED
+)	O
+values	O
+<	O
+80	O
+%	O
+of	O
+predicted	O
+values	O
+,	O
+respectively	O
+.	O
+
+Patients	O
+who	O
+required	O
+ICU	O
+admission	O
+(	O
+n	O
+=	O
+31	O
+)	O
+showed	O
+higher	O
+CXR	O
+scores	O
+(	O
+1	O
+.	O
+6	O
+[	O
+SD	O
+,	O
+3	O
+.	O
+1	O
+];	O
+vs	O
+0	O
+.	O
+4	O
+[	O
+SD	O
+,	O
+1	O
+.	O
+1	O
+];	O
+p	O
+=	O
+0	O
+.	O
+04	O
+)	O
+and	O
+lower	O
+percentage	O
+of	O
+predicted	O
+FVC	B-PROC
+,	O
+TLC	O
+,	O
+and	O
+Dlco	O
+than	O
+those	O
+who	O
+did	O
+not	O
+,	O
+but	O
+there	O
+were	O
+no	O
+differences	O
+in	O
+6MWD	O
+and	O
+health	O
+status	O
+.	O
+
+Exercise	O
+capacity	O
+and	O
+health	O
+status	O
+of	O
+SARS	B-DISO
+survivors	O
+were	O
+remarkably	O
+lower	O
+than	O
+those	O
+of	O
+a	O
+normal	O
+population	O
+.	O
+
+CONCLUSIONS	O
+:	O
+Significant	O
+impairment	B-DISO
+in	O
+Dlco	O
+was	O
+noted	O
+in	O
+23	O
+.	O
+7	O
+%	O
+of	O
+survivors	O
+1	O
+year	O
+after	O
+illness	O
+onset	O
+.	O
+
+Results	O
+suggested	O
+that	O
+SARS	B-DISO
+caused	O
+orchitis	B-DISO
+.	O
+
+ABSTRACT	O
+:	O
+The	O
+setting	O
+of	O
+a	O
+quarantine	O
+time	O
+for	O
+an	O
+emerging	B-DISO
+infectious	I-DISO
+disease	I-DISO
+will	O
+depend	O
+on	O
+current	O
+knowledge	O
+concerning	O
+incubation	O
+times	O
+.	O
+
+Results	O
+suggest	O
+that	O
+a	O
+wide	O
+class	B-SPEC
+of	O
+models	O
+for	O
+incubation	O
+times	O
+should	O
+be	O
+considered	O
+because	O
+the	O
+apparent	O
+informativeness	O
+of	O
+a	O
+likelihood	O
+depends	O
+on	O
+the	O
+choice	O
+and	O
+generalizability	O
+of	O
+a	O
+model	O
+.	O
+
+TITLE	O
+:	O
+Genomic	O
+classification	O
+using	O
+an	O
+information	O
+-	O
+based	O
+similarity	O
+index	O
+:	O
+application	O
+to	O
+the	O
+SARS	B-DISO
+coronavirus	B-SPEC
+.	O
+
+We	O
+present	O
+a	O
+novel	O
+alignment	O
+-	O
+free	O
+approach	O
+to	O
+measuring	O
+the	O
+similarity	O
+among	O
+genetic	O
+sequences	O
+that	O
+incorporates	O
+elements	O
+from	O
+both	O
+word	O
+rank	O
+order	B-SPEC
+-	O
+frequency	O
+statistics	O
+and	O
+information	O
+theory	O
+.	O
+
+The	O
+low	O
+enzymatic	B-PROC
+activity	I-PROC
+of	O
+the	O
+M	O
+(	O
+pro	B-CHED
+)	O
+monomer	O
+and	O
+the	O
+need	O
+for	O
+dimerization	O
+are	O
+also	O
+discussed	O
+.	O
+
+A	O
+high	O
+proportion	O
+of	O
+trauma	O
+patients	O
+treated	O
+with	O
+ECMO	O
+for	O
+severe	O
+lung	B-ANAT
+injury	O
+survived	O
+.	O
+
+It	O
+is	O
+important	O
+to	O
+assess	O
+these	O
+patients	O
+on	O
+a	O
+regular	O
+basis	O
+to	O
+detect	O
+and	O
+provide	O
+appropriate	O
+management	O
+for	O
+any	O
+persistent	O
+or	O
+emerging	O
+long	O
+term	O
+sequelae	O
+in	O
+the	O
+physical	O
+,	O
+psychological	B-DISO
+,	O
+and	O
+social	O
+domains	O
+.	O
+
+TITLE	O
+:	O
+Alternatives	O
+to	O
+endotracheal	O
+intubation	O
+for	O
+patients	O
+with	O
+neuromuscular	B-DISO
+diseases	I-DISO
+.	O
+
+During	O
+chemotherapy	O
+for	O
+lymphoma	B-DISO
+,	O
+the	O
+white	B-ANAT
+blood	I-ANAT
+cell	I-ANAT
+count	O
+was	O
+significantly	O
+reduced	O
+at	O
+days	O
+1	O
+and	O
+3	O
+,	O
+but	O
+significantly	O
+increased	O
+at	O
+days	O
+7	O
+and	O
+9	O
+.	O
+
+Plasma	B-ANAT
+concentrations	O
+of	O
+granulocyte	B-PRGE
+elastase	I-PRGE
+derived	O
+-	O
+XDP	B-DISO
+(	O
+GEXDP	O
+)	O
+levels	O
+correlated	O
+with	O
+D	O
+-	O
+dimer	O
+levels	O
+,	O
+suggesting	O
+that	O
+almost	O
+all	O
+elevated	O
+D	O
+-	O
+dimer	O
+is	O
+GE	O
+-	O
+XDP	B-DISO
+.	O
+
+To	O
+gain	O
+the	O
+recombinant	O
+Canine	B-SPEC
+adenovirus	I-SPEC
+,	O
+the	O
+recombinant	O
+plasmid	O
+pCAV	O
+-	O
+2	O
+-	O
+CCV	B-DISO
+-	O
+S1	O
+was	O
+linearized	O
+by	O
+Cla	B-PRGE
+I	I-PRGE
+/	I-PRGE
+Asc	I-PRGE
+I	I-PRGE
+to	O
+release	B-PATH
+recombinant	O
+genome	O
+,	O
+and	O
+then	O
+transfected	O
+into	O
+MDCK	B-ANAT
+cell	I-ANAT
+.	O
+
+TITLE	O
+:	O
+Static	O
+pressure	O
+volume	O
+curves	O
+and	O
+body	B-ANAT
+posture	O
+in	O
+acute	B-DISO
+respiratory	I-DISO
+failure	I-DISO
+.	O
+
+An	O
+X	O
+-	O
+ray	B-SPEC
+crystal	B-ANAT
+structure	O
+of	O
+our	O
+lead	O
+inhibitor	B-CHED
+(	O
+4	O
+)	O
+bound	O
+to	O
+SARS	B-PRGE
+-	I-PRGE
+3CLpro	I-PRGE
+provided	O
+important	O
+drug	O
+-	O
+design	O
+templates	O
+for	O
+the	O
+design	O
+of	O
+small	O
+-	O
+molecule	O
+inhibitors	B-CHED
+.	O
+
+To	O
+examine	O
+the	O
+assembly	O
+of	O
+the	O
+viral	O
+genomic	O
+RNA	O
+,	O
+a	O
+plasmid	O
+representing	O
+the	O
+GFP	B-PRGE
+-	I-PRGE
+PS580	I-PRGE
+cDNA	I-PRGE
+fragment	I-PRGE
+encompassing	O
+the	O
+viral	O
+genomic	O
+RNA	O
+from	O
+nucleotides	B-CHED
+19715	O
+to	O
+20294	O
+inserted	O
+into	O
+the	O
+3	O
+'	O
+noncoding	O
+region	O
+of	O
+the	O
+green	B-PRGE
+fluorescent	I-PRGE
+protein	I-PRGE
+(	O
+GFP	O
+)	O
+gene	O
+was	O
+constructed	O
+and	O
+applied	O
+to	O
+the	O
+cotransfection	O
+experiments	O
+with	O
+the	O
+four	O
+structural	O
+proteins	B-CHED
+.	O
+
+These	O
+results	O
+indicate	O
+that	O
+N	B-PRGE
+protein	I-PRGE
+has	O
+an	O
+essential	O
+role	O
+in	O
+the	O
+packaging	O
+of	O
+SARS	B-PRGE
+-	I-PRGE
+CoV	I-PRGE
+RNA	I-PRGE
+.	O
+
+A	O
+filter	O
+binding	B-FUNC
+assay	O
+and	O
+competition	O
+analysis	O
+further	O
+demonstrated	O
+that	O
+the	O
+N	O
+-	O
+terminal	O
+and	O
+C	O
+-	O
+terminal	O
+regions	O
+of	O
+the	O
+SARS	B-PRGE
+-	I-PRGE
+CoV	I-PRGE
+N	I-PRGE
+protein	B-CHED
+each	O
+contain	O
+a	O
+binding	B-PROC
+activity	I-PROC
+specific	O
+to	O
+the	O
+viral	O
+RNA	O
+.	O
+
+Deletions	O
+that	O
+presumably	O
+disrupt	O
+the	O
+structure	O
+of	O
+the	O
+N	O
+-	O
+terminal	O
+domain	O
+diminished	O
+its	O
+RNA	O
+-	O
+binding	B-PROC
+activity	I-PROC
+.	O
+
+The	O
+use	O
+of	O
+inactivated	O
+SARS	B-DISO
+virus	B-SPEC
+with	O
+MF59	O
+enhanced	O
+the	O
+CD4	B-PRGE
+and	O
+antibody	B-PROC
+response	I-PROC
+even	O
+after	O
+gene	O
+-	O
+based	O
+vaccination	O
+.	O
+
+The	O
+DNA	O
+vaccine	O
+pSecN	O
+was	O
+injected	O
+to	O
+immunize	O
+the	O
+BALB	O
+/	O
+c	O
+mice	B-SPEC
+to	O
+produce	O
+the	O
+antiserum	O
+against	O
+N	B-PRGE
+protein	I-PRGE
+of	O
+SARS	B-PRGE
+-	I-PRGE
+CoV	I-PRGE
+.	O
+Subsequently	O
+,	O
+the	O
+reactivity	O
+of	O
+the	O
+antiserum	O
+with	O
+recombinant	B-PRGE
+N	I-PRGE
+protein	I-PRGE
+and	O
+SARS	B-DISO
+-	O
+CoV	O
+particles	O
+was	O
+assayed	O
+by	O
+ELISA	O
+.	O
+
+Recombinant	B-PRGE
+N	I-PRGE
+protein	I-PRGE
+reacted	O
+strongly	O
+and	O
+specifically	O
+with	O
+the	O
+sera	B-COMP
+from	O
+immunized	O
+mice	B-SPEC
+and	O
+SARS	B-DISO
+patients	O
+.	O
+
+The	O
+DNA	O
+vaccine	O
+pSecN	O
+could	O
+also	O
+efficiently	O
+induce	O
+the	O
+production	O
+of	O
+IgG	B-PRGE
+against	O
+N	B-PRGE
+protein	I-PRGE
+of	O
+SARS	B-PRGE
+-	I-PRGE
+CoV	I-PRGE
+,	O
+which	O
+offered	O
+clues	O
+to	O
+the	O
+development	B-PROC
+of	O
+a	O
+potential	O
+DNA	O
+vaccine	O
+.	O
+
+CONCLUSIONS	O
+:	O
+The	O
+recombinant	B-PRGE
+N	I-PRGE
+protein	I-PRGE
+could	O
+be	O
+used	O
+as	O
+a	O
+good	O
+antigen	B-CHED
+to	O
+detect	O
+SARS	B-DISO
+.	O
+
+These	O
+results	O
+suggest	O
+that	O
+HIV	B-DISO
+-	O
+NS	O
+provides	O
+an	O
+efficient	O
+vaccine	O
+delivery	O
+system	O
+for	O
+the	O
+induction	O
+of	O
+a	O
+mucosal	B-PROC
+immune	I-PROC
+response	I-PROC
+and	O
+the	O
+development	B-PROC
+of	O
+a	O
+mucosal	B-ANAT
+vaccine	O
+.	O
+
+Through	O
+pathological	O
+examination	O
+,	O
+the	O
+morphology	O
+of	O
+the	O
+lung	B-ANAT
+tissues	I-ANAT
+of	O
+two	O
+Macaques	B-SPEC
+in	O
+the	O
+treated	O
+group	O
+was	O
+normal	O
+,	O
+while	O
+the	O
+other	O
+three	O
+displayed	O
+the	O
+interstitial	B-DISO
+pneumonia	I-DISO
+with	O
+the	O
+thickened	O
+septum	B-COMP
+and	O
+infiltration	B-DISO
+with	O
+mononuclear	B-ANAT
+cells	I-ANAT
+.	O
+
+No	O
+significant	O
+abnormity	O
+was	O
+detected	O
+in	O
+other	O
+organs	B-ANAT
+.	O
+
+Recombinant	B-PRGE
+IFN	I-PRGE
+-	I-PRGE
+alpha2b	I-PRGE
+could	O
+effectively	O
+interdict	O
+or	O
+weaken	O
+SARS	B-DISO
+-	O
+CoV	O
+injury	O
+in	O
+monkeys	B-SPEC
+.	O
+
+RESULTS	O
+:	O
+After	O
+virus	B-SPEC
+attack	O
+,	O
+the	O
+level	O
+of	O
+SARS	B-PRGE
+-	I-PRGE
+CoV	I-PRGE
+-	I-PRGE
+specific	I-PRGE
+IgG	I-PRGE
+and	I-PRGE
+neutralizing	I-PRGE
+antibody	B-COMP
+were	O
+induced	O
+by	O
+SARS	B-PRGE
+-	I-PRGE
+CoV	I-PRGE
+in	O
+the	O
+interferon	B-PRGE
+group	I-PRGE
+was	O
+weaker	O
+than	O
+in	O
+control	O
+group	O
+.	O
+
+ABSTRACT	O
+:	O
+To	O
+evaluate	O
+the	O
+safety	O
+of	O
+recombinant	O
+human	O
+interferon	O
+alpha	O
+-	O
+2b	O
+for	O
+nasal	B-ANAT
+spray	O
+for	O
+the	O
+prevention	O
+of	O
+SARS	B-DISO
+and	O
+other	O
+upper	O
+respiratory	O
+viral	B-DISO
+infections	I-DISO
+.	O
+
+During	O
+the	O
+period	O
+of	O
+using	O
+interferon	O
+,	O
+body	B-ANAT
+temperature	O
+of	O
+the	O
+experimental	O
+group	O
+was	O
+normal	O
+compared	O
+to	O
+the	O
+control	O
+group	O
+.	O
+
+A	O
+randomized	O
+,	O
+placebo	O
+-	O
+controlled	O
+,	O
+double	O
+-	O
+blind	B-DISO
+field	O
+trial	O
+study	O
+in	O
+populations	O
+with	O
+14	O
+,	O
+391	O
+persons	O
+from	O
+SARS	B-DISO
+prevalent	O
+cities	O
+or	O
+provinces	O
+in	O
+China	O
+during	O
+May	O
+-	O
+Jun	O
+,	O
+2003	O
+and	O
+Dec	B-PRGE
+-	I-PRGE
+Apr	B-CHED
+,	O
+2004	O
+.	O
+
+On	O
+the	O
+other	O
+hand	O
+,	O
+after	O
+using	O
+interferon	O
+,	O
+all	O
+four	O
+respiratory	O
+viruses	B-SPEC
+(	O
+parainfluenza	B-DISO
+virus	B-SPEC
+types	O
+1	O
+-	O
+3	O
+influenza	B-DISO
+B	O
+,	O
+adenovirus	B-DISO
+types	O
+3	O
+,	O
+7	O
+and	O
+respiratory	B-SPEC
+syncytial	I-SPEC
+virus	I-SPEC
+)	O
+in	O
+interferon	B-PRGE
+group	I-PRGE
+had	I-PRGE
+lower	I-PRGE
+IgM	I-PRGE
+antibody	I-PRGE
+positive	O
+rates	O
+than	O
+those	O
+in	O
+control	O
+group	O
+.	O
+
+Among	O
+them	O
+there	O
+were	O
+statistically	O
+significant	O
+differences	O
+between	O
+the	O
+interferon	B-PRGE
+and	O
+control	O
+groups	O
+for	O
+parainfluenza	B-DISO
+virus	B-SPEC
+,	O
+influenza	B-DISO
+B	O
+and	O
+adenovirus	B-DISO
+.	O
+
+Three	O
+recombinant	O
+plasmids	O
+(	O
+pQE	O
+-	O
+30	O
+/	O
+S1a	O
+,	O
+pQE	O
+-	O
+30	O
+/	O
+S1b	B-PRGE
+,	O
+pQE	O
+-	O
+30	O
+/	O
+S1c	O
+)	O
+were	O
+constructed	O
+.	O
+
+There	O
+are	O
+also	O
+many	O
+opportunities	O
+in	O
+academia	O
+,	O
+certainly	O
+in	O
+colleges	O
+of	O
+veterinary	O
+medicine	B-CHED
+but	O
+,	O
+beyond	O
+that	O
+,	O
+also	O
+in	O
+human	B-SPEC
+medicine	B-CHED
+and	O
+in	O
+the	O
+biology	O
+disciplines	O
+.	O
+
+To	O
+profile	O
+the	O
+anti	O
+-	O
+N	O
+antibodies	B-COMP
+,	O
+a	O
+phage	O
+-	O
+displayed	O
+scFv	O
+library	O
+was	O
+prepared	O
+from	O
+mice	B-SPEC
+immunized	O
+with	O
+heat	O
+-	O
+inactivated	O
+SARS	B-DISO
+-	O
+CoV	O
+-	O
+infected	O
+Vero	O
+E6	O
+cell	B-COMP
+lysate	O
+.	O
+
+TITLE	O
+:	O
+Structural	O
+insights	O
+into	O
+SARS	B-DISO
+coronavirus	B-SPEC
+proteins	B-CHED
+.	O
+
+The	O
+time	O
+of	O
+symptoms	O
+disappearance	O
+,	O
+the	O
+recovery	O
+time	O
+of	O
+AChE	B-DISO
+,	O
+atropinization	O
+time	O
+,	O
+atropine	B-CHED
+dosage	O
+,	O
+pralidoxime	B-CHED
+chloride	I-CHED
+dosage	O
+,	O
+naloxone	B-CHED
+dosage	O
+,	O
+hospitalization	O
+days	O
+in	O
+treatment	O
+group	O
+were	O
+significantly	O
+superior	O
+to	O
+those	O
+in	O
+control	O
+group	O
+(	O
+P	O
+<	O
+0	O
+.	O
+05	O
+or	O
+P	O
+<	O
+0	O
+.	O
+01	O
+).	O
+
+ABSTRACT	O
+:	O
+Recently	O
+,	O
+we	O
+described	O
+the	O
+discovery	O
+of	O
+a	O
+novel	O
+group	O
+2	O
+coronavirus	B-SPEC
+,	O
+coronavirus	B-SPEC
+HKU1	O
+(	O
+CoV	B-SPEC
+-	I-SPEC
+HKU1	I-SPEC
+),	O
+from	O
+a	O
+patient	O
+with	O
+pneumonia	B-DISO
+.	O
+
+The	O
+2	O
+patients	O
+who	O
+died	B-PROC
+had	O
+significantly	O
+lower	O
+hemoglobin	B-PRGE
+levels	O
+,	O
+monocyte	B-ANAT
+counts	O
+,	O
+albumin	B-PRGE
+levels	O
+,	O
+and	O
+oxygen	B-CHED
+saturation	O
+levels	O
+on	O
+admission	O
+and	O
+had	O
+more	O
+-	O
+extensive	O
+involvement	O
+visible	O
+on	O
+chest	B-ANAT
+radiographs	O
+.	O
+
+In	O
+patients	O
+with	O
+uncomplicated	O
+malaria	B-PATH
+,	O
+Vc	O
+was	O
+reduced	O
+at	O
+presentation	O
+but	O
+improved	O
+thereafter	O
+.	O
+
+One	O
+patient	O
+had	O
+ARF	B-DISO
+and	O
+adult	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+(	O
+ARDS	B-DISO
+).	O
+
+TITLE	O
+:	O
+The	O
+feasibility	O
+of	O
+nitric	B-CHED
+oxide	I-CHED
+delivery	O
+with	O
+high	O
+frequency	O
+jet	O
+ventilation	O
+.	O
+
+ABSTRACT	O
+:	O
+A	O
+27	O
+-	O
+year	O
+-	O
+old	O
+female	O
+with	O
+acute	O
+monocytic	O
+leukaemia	O
+(	O
+M5	O
+)	O
+developed	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+(	O
+ARDS	B-DISO
+).	O
+
+TITLE	O
+:	O
+Intestinal	B-ANAT
+circulation	B-PROC
+,	O
+oxygenation	B-PROC
+and	O
+metabolism	B-PROC
+is	O
+not	O
+affected	O
+by	O
+oleic	B-CHED
+acid	I-CHED
+lung	B-ANAT
+injury	O
+.	O
+
+Thirteen	O
+juvenile	O
+anaesthetized	O
+pigs	B-SPEC
+were	O
+used	O
+in	O
+the	O
+main	O
+study	O
+,	O
+where	O
+seven	O
+were	O
+given	O
+an	O
+intravenous	O
+infusion	O
+of	O
+0	O
+.	O
+1	O
+ml	O
+kg	O
+(-	O
+1	O
+)	O
+OA	O
+and	O
+six	O
+served	O
+as	O
+control	O
+(	O
+surgery	O
+only	O
+).	O
+
+These	O
+Vero	O
+E6	O
+cells	B-COMP
+persistently	O
+infected	O
+with	O
+SARS	B-DISO
+-	O
+CoV	O
+may	O
+be	O
+useful	O
+for	O
+clarifying	O
+the	O
+mechanism	O
+of	O
+the	O
+persistent	B-DISO
+infection	I-DISO
+and	O
+also	O
+for	O
+elucidating	O
+the	O
+possible	O
+pathophysiologic	O
+significance	O
+of	O
+such	O
+long	O
+-	O
+term	O
+maintenance	O
+of	O
+this	O
+virus	B-SPEC
+.	O
+
+The	O
+purified	O
+AGP	O
+in	O
+a	O
+complete	O
+Freund	O
+'	O
+s	O
+adjuvant	B-CHED
+and	O
+Tween	B-CHED
+20	I-CHED
+mixture	B-CHED
+was	O
+injected	O
+into	O
+a	O
+sheep	B-SPEC
+and	O
+blood	B-ANAT
+was	O
+collected	O
+at	O
+monthly	O
+intervals	O
+.	O
+
+TCB	O
+and	O
+FNAB	O
+specimens	O
+collected	O
+mainly	O
+at	O
+necropsy	O
+from	O
+25	O
+cats	B-SPEC
+with	O
+FIP	B-DISO
+were	O
+analyzed	O
+.	O
+
+Diagnostic	O
+sensitivity	O
+was	O
+higher	O
+for	O
+hepatic	B-ANAT
+TCB	O
+(	O
+64	O
+%)	O
+and	O
+FNAB	O
+(	O
+82	O
+%)	O
+than	O
+for	O
+renal	O
+(	O
+39	O
+%	O
+and	O
+42	O
+%,	O
+respectively	O
+)	O
+procedures	O
+.	O
+
+RESULTS	O
+:	O
+Diagnostic	O
+sensitivity	O
+was	O
+higher	O
+for	O
+hepatic	B-ANAT
+TCB	O
+(	O
+64	O
+%)	O
+and	O
+FNAB	O
+(	O
+82	O
+%)	O
+than	O
+for	O
+renal	B-ANAT
+(	O
+39	O
+%	O
+and	O
+42	O
+%,	O
+respectively	O
+)	O
+procedures	O
+.	O
+
+This	O
+encouraging	O
+outcome	O
+trend	O
+reflects	O
+evolving	O
+advances	O
+such	O
+as	O
+use	O
+of	O
+recombinant	B-PRGE
+hematopoietic	I-PRGE
+growth	I-PRGE
+factors	I-PRGE
+,	O
+use	O
+of	O
+mobilized	O
+blood	B-ANAT
+cells	I-ANAT
+rather	O
+than	O
+marrow	O
+,	O
+protective	O
+strategies	O
+for	O
+acute	O
+lung	B-ANAT
+injury	O
+and	O
+early	O
+goal	O
+-	O
+directed	O
+therapy	O
+for	O
+sepsis	B-DISO
+syndrome	I-DISO
+.	O
+
+The	O
+receptor	B-FUNC
+binding	I-FUNC
+ability	O
+of	O
+the	O
+purified	O
+soluble	O
+RBD	B-PRGE
+protein	I-PRGE
+was	O
+then	O
+detected	O
+by	O
+ELISA	O
+and	O
+flow	O
+cytometry	O
+assay	O
+.	O
+
+And	O
+the	O
+recombinant	O
+RBD	O
+derived	O
+from	O
+E	B-SPEC
+.	I-SPEC
+coli	I-SPEC
+can	O
+be	O
+used	O
+to	O
+developing	O
+subunit	O
+vaccine	O
+to	O
+block	O
+S	B-PRGE
+protein	I-PRGE
+binding	O
+with	O
+receptor	O
+and	O
+to	O
+neutralizing	O
+SARS	B-DISO
+-	I-DISO
+Cov	I-DISO
+infection	I-DISO
+.	O
+
+ABSTRACT	O
+:	O
+To	O
+study	O
+the	O
+effects	O
+of	O
+microcirculation	O
+disturbance	O
+(	O
+MD	O
+)	O
+on	O
+rats	B-SPEC
+with	O
+acute	O
+severe	O
+pancreatitis	B-DISO
+(	O
+ASP	B-CHED
+).	O
+
+We	O
+developed	O
+ASP	B-CHED
+rat	B-SPEC
+models	O
+,	O
+and	O
+anatomized	O
+separately	O
+after	O
+1	O
+,	O
+3	O
+,	O
+5	O
+,	O
+7	O
+,	O
+and	O
+9	O
+h	O
+.	O
+We	O
+took	O
+out	O
+blood	B-ANAT
+and	O
+did	O
+hemorrheologic	O
+examination	O
+and	O
+erythrocyte	B-ANAT
+osmotic	O
+fragility	B-DISO
+test	O
+,	O
+checked	O
+up	O
+the	O
+water	B-CHED
+content	O
+,	O
+capillary	B-PROC
+permeability	I-PROC
+,	O
+and	O
+genetic	O
+expression	B-PROC
+of	O
+intercellular	B-PRGE
+adhesion	I-PRGE
+molecule	I-PRGE
+-	I-PRGE
+1	I-PRGE
+(	O
+ICAM	B-PRGE
+-	I-PRGE
+1	I-PRGE
+)	O
+in	O
+lung	B-ANAT
+tissues	I-ANAT
+,	O
+examined	O
+the	O
+apoptosis	B-PATH
+degree	O
+of	O
+blood	B-ANAT
+vessel	I-ANAT
+endothelium	I-ANAT
+while	O
+we	O
+tested	O
+related	O
+gene	B-PROC
+expression	I-PROC
+of	O
+Bax	B-PRGE
+and	O
+Bcl	B-PRGE
+-	I-PRGE
+2	I-PRGE
+in	O
+lung	B-ANAT
+tissues	I-ANAT
+.	O
+
+RESULTS	O
+:	O
+The	O
+viscosity	O
+of	O
+total	O
+blood	B-ANAT
+and	O
+plasma	B-ANAT
+,	O
+the	O
+hematocrit	O
+,	O
+and	O
+the	O
+erythrocyte	B-ANAT
+osmotic	O
+fragility	B-DISO
+were	O
+all	O
+increased	O
+.	O
+
+Data	O
+of	O
+SARS	B-DISO
+cases	O
+notified	O
+from	O
+Beijing	O
+Center	O
+for	O
+Disease	O
+Control	O
+and	O
+Prevention	O
+(	O
+BCDC	O
+)	O
+and	O
+supplemented	O
+by	O
+other	O
+channels	O
+were	O
+collected	O
+.	O
+
+Beijing	O
+is	O
+successful	O
+in	O
+controlling	O
+and	O
+treating	O
+SARS	B-DISO
+.	O
+
+ABSTRACT	O
+:	O
+To	O
+describe	O
+the	O
+epidemiologic	O
+features	O
+of	O
+an	O
+outbreak	O
+of	O
+severe	O
+acute	O
+respiratory	O
+syndrome	O
+(	O
+SARS	B-DISO
+)	O
+in	O
+urban	O
+and	O
+suburb	O
+areas	O
+in	O
+Beijing	O
+and	O
+to	O
+explore	O
+their	O
+differences	O
+between	O
+these	O
+two	O
+areas	O
+.	O
+
+Beijing	O
+urban	O
+area	O
+suffered	O
+a	O
+more	O
+serious	O
+SARS	B-DISO
+epidemic	O
+than	O
+the	O
+suburb	O
+area	O
+in	O
+2003	O
+.	O
+
+CONCLUSIONS	O
+:	O
+Beijing	O
+urban	O
+area	O
+suffered	B-DISO
+a	O
+more	O
+serious	O
+SARS	B-DISO
+epidemic	O
+than	O
+the	O
+suburb	O
+area	O
+in	O
+2003	O
+.	O
+
+TITLE	O
+:	O
+Elevated	O
+plasma	B-PRGE
+tissue	B-ENZY
+-	I-ENZY
+type	I-ENZY
+plasminogen	I-ENZY
+activator	I-ENZY
+(	O
+t	B-PRGE
+-	I-PRGE
+PA	I-PRGE
+)	O
+and	O
+soluble	O
+thrombomodulin	B-PRGE
+in	O
+patients	O
+suffering	O
+from	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+(	O
+SARS	B-DISO
+)	O
+as	O
+a	O
+possible	O
+index	O
+for	O
+prognosis	O
+and	O
+treatment	O
+strategy	O
+.	O
+
+The	O
+only	O
+patient	O
+who	O
+died	B-PROC
+had	O
+extremely	O
+high	O
+levels	O
+of	O
+these	O
+endothelial	B-ANAT
+injury	O
+markers	O
+(	O
+t	B-PRGE
+-	I-PRGE
+PA	I-PRGE
+:	O
+2	O
+.	O
+77	O
+nmol	O
+/	O
+L	O
+and	O
+sTM	O
+:	O
+1	O
+.	O
+01	O
+nmol	O
+/	O
+L	O
+).	O
+
+The	O
+numerical	O
+coefficient	O
+of	O
+correlation	O
+Pearson	O
+r	O
+between	O
+t	B-PRGE
+-	I-PRGE
+PA	I-PRGE
+and	O
+sTM	B-PRGE
+was	O
+0	O
+.	O
+5867	O
+(	O
+P	O
+<	O
+0	O
+.	O
+05	O
+).	O
+
+Although	O
+SARS	B-PRGE
+CoV	I-PRGE
+IgM	I-PRGE
+was	O
+still	O
+detectable	O
+by	O
+IF	O
+tests	O
+with	O
+8	O
+of	O
+11	O
+patients	O
+at	O
+7	O
+months	O
+postinfection	O
+,	O
+the	O
+geometric	O
+mean	O
+titers	O
+dropped	O
+from	O
+282	O
+at	O
+1	O
+month	O
+postinfection	O
+to	O
+19	O
+at	O
+7	O
+months	O
+(	O
+P	O
+=	O
+0	O
+.	O
+001	O
+).	O
+
+Using	O
+a	O
+novel	O
+data	O
+representation	O
+,	O
+we	O
+developed	O
+a	O
+system	O
+termed	O
+MULTIPRED	O
+that	O
+can	O
+predict	O
+peptide	B-FUNC
+binding	I-FUNC
+to	O
+multiple	O
+related	O
+human	B-PRGE
+leukocyte	B-ANAT
+antigens	B-CHED
+(	O
+HLA	B-PRGE
+).	O
+
+By	O
+implementing	O
+ANN	O
+as	O
+a	O
+classification	O
+engine	O
+,	O
+we	O
+enabled	O
+both	O
+the	O
+prediction	O
+of	O
+peptides	B-CHED
+binding	B-FUNC
+to	O
+multiple	O
+individual	O
+HLA	B-PRGE
+-	I-PRGE
+A2	I-PRGE
+molecules	I-PRGE
+and	O
+the	O
+prediction	O
+of	O
+promiscuous	O
+binders	O
+using	O
+a	O
+single	O
+model	O
+.	O
+
+Design	O
+,	O
+synthesis	O
+,	O
+and	O
+biological	O
+evaluation	O
+of	O
+novel	O
+,	O
+potent	O
+,	O
+and	O
+broad	O
+spectrum	O
+NNRTIs	O
+with	O
+antiviral	B-CHED
+activity	O
+.	O
+
+ABSTRACT	O
+:	O
+Pyrrolobenzoxazepinones	O
+(	O
+PBOs	O
+)	O
+represent	O
+a	O
+new	O
+class	B-SPEC
+of	O
+human	B-SPEC
+immunodeficiency	I-SPEC
+virus	I-SPEC
+type	I-SPEC
+1	I-SPEC
+(	O
+HIV	B-SPEC
+-	I-SPEC
+1	I-SPEC
+)	O
+nonnucleoside	O
+reverse	B-PRGE
+transcriptase	I-PRGE
+(	O
+RT	O
+)	O
+inhibitors	B-CHED
+(	O
+NNRTIs	O
+)	O
+whose	O
+prototype	O
+is	O
+5	O
+.	O
+
+Molecular	O
+modeling	O
+studies	O
+based	O
+on	O
+the	O
+X	O
+-	O
+ray	B-SPEC
+structures	O
+of	O
+HIV	B-SPEC
+-	I-SPEC
+1	I-SPEC
+RT	O
+prompted	O
+the	O
+synthesis	B-PROC
+of	O
+novel	O
+analogues	O
+which	O
+were	O
+tested	O
+as	O
+anti	B-CHED
+-	I-CHED
+HIV	I-CHED
+agents	I-CHED
+.	O
+
+Data	O
+on	O
+annual	O
+patient	O
+-	O
+days	O
+and	O
+annual	O
+consumption	O
+(	O
+defined	O
+daily	O
+dose	O
+(	O
+DDD	B-DISO
+)	O
+per	O
+1000	O
+patient	O
+-	O
+days	O
+)	O
+of	O
+extended	O
+-	O
+spectrum	O
+cephalosporins	B-CHED
+(	O
+cefotaxime	B-CHED
+,	O
+ceftriaxone	B-CHED
+,	O
+ceftazidime	B-CHED
+,	O
+flumoxef	O
+,	O
+cefepime	B-CHED
+and	O
+cefpirome	B-CHED
+),	O
+beta	B-PRGE
+-	I-PRGE
+lactam	I-PRGE
+-	I-PRGE
+beta	B-CHED
+-	I-CHED
+lactamase	I-CHED
+inhibitor	I-CHED
+combinations	O
+(	O
+ticarcillin	B-CHED
+/	O
+clavulanic	B-CHED
+acid	I-CHED
+and	O
+piperacillin	B-CHED
+/	O
+tazobactam	O
+),	O
+carbapenems	B-CHED
+(	O
+imipenem	B-CHED
+and	O
+meropenem	B-CHED
+),	O
+aminoglycosides	B-CHED
+(	O
+amikacin	B-CHED
+,	O
+gentamicin	B-CHED
+and	O
+tobramycin	B-CHED
+),	O
+fluoroquinolones	O
+(	O
+ciprofloxacin	B-CHED
+(	O
+oral	B-ANAT
+and	O
+injectable	O
+)	O
+and	O
+oral	B-ANAT
+levofloxacin	B-CHED
+and	O
+moxifloxacin	B-CHED
+)	O
+from	O
+1991	O
+to	O
+2003	O
+were	O
+analysed	O
+.	O
+
+The	O
+rise	O
+in	O
+cefotaxime	B-CHED
+-	O
+resistant	O
+or	O
+ciprofloxacin	B-CHED
+-	O
+resistant	O
+E	B-SPEC
+.	I-SPEC
+coli	I-SPEC
+and	O
+meropenem	B-CHED
+-	O
+resistant	O
+P	B-SPEC
+.	I-SPEC
+aeruginosa	I-SPEC
+was	O
+significantly	O
+correlated	O
+with	O
+increased	O
+consumption	O
+of	O
+extended	O
+-	O
+spectrum	O
+cephalosporins	B-CHED
+,	O
+beta	B-PRGE
+-	I-PRGE
+lactam	I-PRGE
+-	I-PRGE
+beta	B-CHED
+-	I-CHED
+lactamase	I-CHED
+inhibitor	I-CHED
+combinations	O
+,	O
+carbapenems	B-CHED
+,	O
+fluoroquinolones	O
+and	O
+aminoglycosides	B-CHED
+(	O
+for	O
+ciprofloxacin	B-CHED
+-	O
+resistant	O
+E	B-SPEC
+.	I-SPEC
+coli	I-SPEC
+and	O
+meropenem	B-CHED
+-	O
+resistant	O
+P	B-SPEC
+.	I-SPEC
+aeruginosa	I-SPEC
+only	O
+)	O
+in	O
+the	O
+hospital	O
+(	O
+Pearson	O
+'	O
+s	O
+correlation	O
+coefficient	O
+,	O
+r	O
+>	O
+0	O
+.	O
+72	O
+(	O
+or	O
+<	O
+-	O
+0	O
+.	O
+72	O
+)	O
+and	O
+P	O
+-	O
+value	O
+<	O
+0	O
+.	O
+05	O
+).	O
+
+Additionally	O
+we	O
+have	O
+identified	O
+a	O
+role	O
+for	O
+the	O
+3	O
+'-	O
+terminal	O
+42	O
+-	O
+nucleotide	B-CHED
+host	B-COMP
+protein	B-FUNC
+binding	I-FUNC
+element	O
+in	O
+RNA	B-PROC
+replication	I-PROC
+and	O
+transcription	B-PROC
+using	O
+DI	O
+RNA	B-PROC
+replication	I-PROC
+assays	O
+and	O
+targeted	B-PROC
+recombination	B-PROC
+and	O
+by	O
+directly	O
+constructing	O
+mutants	O
+in	O
+this	O
+protein	B-FUNC
+binding	I-FUNC
+element	O
+using	O
+a	O
+recently	O
+described	O
+MHV	B-SPEC
+reverse	O
+genetic	O
+system	O
+.	O
+
+ABSTRACT	O
+:	O
+SARS	B-DISO
+coronavirus	B-SPEC
+(	O
+SARS	B-DISO
+-	O
+CoV	O
+)	O
+encodes	O
+several	O
+unique	O
+group	O
+-	O
+specific	O
+open	O
+reading	O
+frames	O
+(	O
+ORFs	O
+)	O
+relative	O
+to	O
+other	O
+known	O
+coronaviruses	O
+.	O
+
+Deletion	O
+of	O
+ORF3a	O
+did	O
+not	O
+alter	O
+subcellular	O
+localization	B-PROC
+of	O
+the	O
+S	B-PRGE
+glycoprotein	I-PRGE
+from	O
+distinct	O
+punctuate	O
+localization	B-PROC
+in	O
+the	O
+rER	B-COMP
+/	O
+Golgi	B-COMP
+apparatus	I-COMP
+.	O
+
+ABSTRACT	O
+:	O
+Coronavirus	O
+NL63	O
+has	O
+been	O
+identified	O
+as	O
+a	O
+new	O
+member	O
+of	O
+the	O
+coronavirus	B-SPEC
+genus	B-SPEC
+,	O
+but	O
+its	O
+role	O
+as	O
+a	O
+cause	O
+of	O
+respiratory	B-DISO
+disease	I-DISO
+needs	O
+to	O
+be	O
+established	O
+.	O
+
+The	O
+affinity	O
+of	O
+ScFv	B-PRGE
+H12	I-PRGE
+to	O
+SARS	B-PRGE
+-	I-PRGE
+CoV	I-PRGE
+virion	B-COMP
+was	O
+detected	O
+as	O
+Kd	O
+=	O
+73	O
+.	O
+5	O
+nmol	O
+/	O
+mL	O
+.	O
+
+TITLE	O
+:	O
+SR	O
+-	O
+rich	O
+motif	O
+plays	O
+a	O
+pivotal	O
+role	O
+in	O
+recombinant	B-PRGE
+SARS	I-PRGE
+coronavirus	B-SPEC
+nucleocapsid	B-COMP
+protein	B-CHED
+multimerization	O
+.	O
+
+Characterization	O
+of	O
+SARS	B-PRGE
+-	I-PRGE
+CoV	I-PRGE
+N	I-PRGE
+multimerization	O
+may	O
+thereby	O
+help	O
+us	O
+better	O
+understand	O
+the	O
+coronavirus	B-SPEC
+assembly	O
+.	O
+
+ABSTRACT	O
+:	O
+The	O
+world	O
+was	O
+shocked	B-DISO
+in	O
+early	O
+2003	O
+when	O
+a	O
+pandemic	O
+of	O
+severe	O
+acute	O
+respiratory	O
+syndrome	O
+(	O
+SARS	B-DISO
+)	O
+was	O
+imminent	O
+.	O
+
+METHODS	O
+:	O
+The	O
+psychometric	O
+properties	O
+of	O
+a	O
+SARS	B-DISO
+patient	O
+care	O
+attrition	B-DISO
+prediction	O
+tool	O
+,	O
+based	O
+on	O
+the	O
+Theory	O
+of	O
+Planned	O
+Behavior	O
+,	O
+were	O
+examined	O
+in	O
+this	O
+study	O
+.	O
+
+As	O
+it	O
+happens	O
+with	O
+other	O
+viruses	B-SPEC
+peptidic	O
+fusion	O
+inhibitors	B-CHED
+,	O
+SARS	B-PRGE
+-	I-PRGE
+CoV	I-PRGE
+S	I-PRGE
+protein	B-CHED
+HR2	I-PRGE
+-	I-PRGE
+derived	I-PRGE
+peptides	B-CHED
+are	O
+potential	O
+therapeutic	O
+drugs	O
+against	O
+the	O
+virus	B-SPEC
+.	O
+
+It	O
+is	O
+believed	O
+that	O
+HR2	O
+peptides	B-CHED
+block	O
+the	O
+six	O
+-	O
+helix	O
+bundle	O
+formation	B-PROC
+,	O
+a	O
+key	O
+structure	O
+in	O
+the	O
+viral	O
+fusion	O
+,	O
+by	O
+interacting	O
+with	O
+the	O
+HR1	O
+region	O
+.	O
+
+ABSTRACT	O
+:	O
+Severe	O
+acute	O
+respiratory	O
+syndrome	O
+(	O
+SARS	B-DISO
+)	O
+is	O
+an	O
+emerging	O
+infection	B-DISO
+that	O
+causes	O
+a	O
+potentially	O
+fatal	O
+respiratory	B-DISO
+disease	I-DISO
+.	O
+
+Potential	O
+maternal	O
+outcomes	O
+include	O
+spontaneous	O
+miscarriage	B-DISO
+during	O
+the	O
+first	O
+trimester	O
+,	O
+preterm	B-DISO
+birth	I-DISO
+,	O
+emergency	B-DISO
+cesarean	O
+section	O
+,	O
+renal	B-ANAT
+failure	I-DISO
+,	O
+secondary	O
+bacterial	O
+pneumonia	O
+,	O
+sepsis	B-DISO
+,	O
+adult	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+,	O
+disseminated	B-DISO
+intravascular	I-DISO
+coagulation	I-DISO
+,	O
+surgical	B-DISO
+site	I-DISO
+infection	I-DISO
+,	O
+and	O
+maternal	B-PROC
+death	I-PROC
+.	O
+
+ABSTRACT	O
+:	O
+An	O
+indirect	O
+porcine	B-SPEC
+epidemic	B-DISO
+diarrhea	I-DISO
+(	O
+PED	B-DISO
+)	O
+virus	B-SPEC
+(	O
+PEDV	B-SPEC
+)	O
+enzyme	O
+-	O
+linked	O
+immunosorbent	O
+assay	O
+(	O
+ELISA	O
+)	O
+was	O
+compared	O
+with	O
+the	O
+serum	B-COMP
+neutralization	O
+(	O
+SN	O
+)	O
+test	O
+by	O
+testing	O
+46	O
+samples	O
+from	O
+experimentally	O
+infected	O
+sows	O
+,	O
+73	O
+samples	O
+from	O
+naive	O
+sows	O
+,	O
+and	O
+1	O
+,	O
+024	O
+field	O
+sow	O
+samples	O
+from	O
+48	O
+commercial	O
+swine	B-SPEC
+farms	O
+of	O
+undefined	O
+PED	B-DISO
+status	O
+.	O
+
+He	O
+also	O
+explores	O
+monotherapy	O
+versus	O
+combination	O
+therapy	O
+,	O
+the	O
+efficacy	O
+of	O
+rapid	O
+initiation	O
+of	O
+treatment	O
+,	O
+and	O
+short	O
+-	O
+course	O
+therapy	O
+as	O
+a	O
+hedge	O
+against	O
+antimicrobial	B-CHED
+resistance	B-PROC
+.	O
+
+We	O
+estimate	O
+that	O
+a	O
+single	O
+case	O
+of	O
+SARS	B-DISO
+will	O
+infect	O
+2	O
+.	O
+6	O
+secondary	O
+cases	O
+on	O
+average	O
+in	O
+a	O
+population	O
+from	O
+nosocomial	O
+transmission	O
+,	O
+whereas	O
+less	O
+than	O
+1	O
+secondary	B-DISO
+infection	I-DISO
+was	O
+generated	O
+per	O
+case	O
+among	O
+school	O
+children	O
+.	O
+
+Here	O
+,	O
+we	O
+show	O
+that	O
+virulence	B-PROC
+of	O
+the	O
+organism	O
+factors	O
+,	O
+infectious	B-DISO
+quantum	O
+generation	O
+rates	O
+(	O
+quanta	O
+/	O
+s	O
+by	O
+an	O
+infected	O
+person	O
+),	O
+and	O
+host	B-COMP
+factors	O
+determine	O
+the	O
+risk	O
+for	O
+inhalation	B-PROC
+of	O
+indoor	O
+airborne	O
+infection	B-DISO
+.	O
+
+Developing	O
+high	O
+titers	O
+of	O
+anti	B-PRGE
+-	I-PRGE
+SARS	I-PRGE
+hyperimmune	I-PRGE
+globulin	I-PRGE
+to	O
+provide	O
+an	O
+alternative	O
+pathway	B-PROC
+for	O
+emergent	O
+future	O
+prevention	O
+and	O
+treatment	O
+of	O
+SARS	B-DISO
+.	O
+
+Fragment	O
+of	O
+approximately	O
+15	O
+g	O
+F	O
+(	O
+ab	O
+')	O
+2	O
+was	O
+obtained	O
+from	O
+1litre	O
+antiserum	O
+and	O
+the	O
+purity	O
+was	O
+above	O
+90	O
+%	O
+with	O
+the	O
+titer	O
+of	O
+1	O
+:	O
+5120	O
+,	O
+which	O
+could	O
+neutralize	O
+the	O
+other	O
+strain	O
+(	O
+SARS	B-DISO
+-	O
+CoV	O
+Z2	O
+-	O
+Y3	O
+)	O
+as	O
+well	O
+.	O
+
+The	O
+causative	O
+agent	O
+of	O
+SARS	B-DISO
+was	O
+identified	O
+as	O
+a	O
+novel	B-SPEC
+coronavirus	I-SPEC
+,	O
+the	O
+SARS	B-DISO
+coronavirus	B-SPEC
+.	O
+
+To	O
+prevent	O
+infection	B-DISO
+within	O
+healthcare	O
+facilities	O
+,	O
+cases	O
+were	O
+centralized	O
+in	O
+a	O
+SARS	B-DISO
+-	O
+designated	O
+hospital	O
+,	O
+a	O
+no	O
+-	O
+visitors	O
+rule	O
+was	O
+applied	O
+and	O
+movement	B-PROC
+of	O
+patients	O
+and	O
+healthcare	O
+staff	O
+were	O
+restricted	O
+.	O
+
+Hospitals	O
+were	O
+surveyed	O
+for	O
+fever	B-PROC
+clusters	B-CHED
+.	O
+
+A	O
+large	O
+wholesale	O
+market	O
+closure	O
+resulted	O
+in	O
+massive	O
+quarantine	O
+thereby	O
+limiting	O
+the	O
+spread	O
+of	O
+infection	B-DISO
+.	O
+
+A	O
+mass	O
+education	O
+campaign	O
+was	O
+implemented	O
+in	O
+order	B-SPEC
+to	O
+educate	O
+and	O
+raise	O
+awareness	O
+of	O
+the	O
+public	O
+.	O
+
+Moreover	O
+,	O
+progenitor	B-ANAT
+cell	I-ANAT
+implantation	B-PROC
+did	O
+not	O
+affect	O
+local	O
+cytokine	O
+/	O
+chemokine	O
+gene	B-PROC
+expression	I-PROC
+in	O
+the	O
+CNS	B-CHED
+.	O
+
+Finally	O
+,	O
+remyelination	B-PROC
+associated	O
+with	O
+transplantation	O
+did	O
+not	O
+result	O
+in	O
+an	O
+imbalance	B-DISO
+of	O
+T	O
+(	O
+H	O
+)	O
+1	O
+-	O
+associated	O
+cytokine	B-PROC
+production	I-PROC
+by	O
+virus	B-SPEC
+-	O
+specific	O
+T	B-ANAT
+cells	I-ANAT
+.	O
+
+TITLE	O
+:	O
+Anti	B-PRGE
+-	I-PRGE
+SARS	I-PRGE
+-	I-PRGE
+CoV	I-PRGE
+immunity	B-PROC
+induced	O
+by	O
+a	O
+novel	O
+CpG	O
+oligodeoxynucleotide	O
+.	O
+
+Furthermore	O
+,	O
+we	O
+demonstrated	O
+that	O
+BW001	O
+could	O
+activate	O
+CD19	B-PRGE
++	I-PRGE
+B	I-PRGE
+cells	O
+and	O
+CD56	B-PRGE
++	I-PRGE
+NK	I-PRGE
+cells	O
+in	O
+human	B-SPEC
+PBMCs	O
+.	O
+
+In	O
+addition	O
+,	O
+BW001	O
+could	O
+enhance	O
+NK	O
+cytotoxicity	B-DISO
+and	O
+IFN	B-PROC
+-	I-PROC
+gamma	I-PROC
+secretion	B-ANAT
+in	O
+human	B-SPEC
+PBMCs	O
+.	O
+
+TITLE	O
+:	O
+Severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+(	O
+SARS	B-DISO
+):	O
+knowledge	O
+,	O
+attitudes	O
+,	O
+practices	O
+and	O
+sources	O
+of	O
+information	O
+among	O
+physicians	O
+answering	O
+a	O
+SARS	O
+fever	B-PROC
+hotline	O
+service	O
+.	O
+
+Hospital	O
+guidelines	O
+and	O
+news	O
+media	B-ANAT
+were	O
+the	O
+major	O
+information	O
+sources	O
+.	O
+
+A	O
+previous	O
+report	O
+(	O
+Virology	O
+2003	O
+,	O
+311	O
+:	O
+16	O
+-	O
+27	O
+)	O
+indicated	O
+that	O
+transfected	O
+IBV	B-SPEC
+3b	O
+localized	O
+to	O
+the	O
+nucleus	B-COMP
+in	O
+mammalian	B-SPEC
+cells	B-COMP
+using	O
+a	O
+vaccinia	B-DISO
+-	O
+virus	B-SPEC
+expression	B-PROC
+system	O
+.	O
+
+Progressive	O
+hypoxemia	O
+mandated	O
+endotracheal	O
+intubation	O
+1	O
+week	O
+after	O
+rituximab	O
+administration	O
+and	O
+led	O
+to	O
+death	B-PROC
+4	O
+weeks	O
+after	O
+admission	O
+.	O
+
+N	B-PRGE
+protein	I-PRGE
+is	O
+composed	O
+of	O
+three	O
+distinct	O
+regions	O
+containing	O
+RNA	O
+-	O
+binding	B-FUNC
+motif	O
+(	O
+s	O
+),	O
+and	O
+appropriate	O
+signals	O
+for	O
+modulating	O
+cell	B-COMP
+signalling	B-PROC
+.	O
+
+In	O
+contrast	O
+to	O
+the	O
+avian	B-PRGE
+coronavirus	I-PRGE
+N	I-PRGE
+protein	B-CHED
+,	O
+overexpressed	O
+SARS	B-PRGE
+-	I-PRGE
+CoV	I-PRGE
+N	I-PRGE
+protein	B-CHED
+remained	O
+principally	O
+localized	O
+to	O
+the	O
+cytoplasm	B-COMP
+,	O
+with	O
+very	O
+few	O
+cells	B-COMP
+exhibiting	O
+nucleolar	B-ANAT
+localization	B-PROC
+.	O
+
+Four	O
+patients	O
+died	B-PROC
+during	O
+further	O
+treatment	O
+due	O
+to	O
+multiple	O
+trauma	O
+or	O
+multiple	B-DISO
+organ	I-DISO
+failure	I-DISO
+.	O
+
+TITLE	O
+:	O
+Antibody	B-FUNC
+responses	I-PROC
+against	O
+SARS	B-DISO
+coronavirus	B-SPEC
+are	O
+correlated	O
+with	O
+disease	O
+outcome	O
+of	O
+infected	O
+individuals	O
+.	O
+
+ABSTRACT	O
+:	O
+Epidemiologic	O
+data	O
+suggested	O
+that	O
+there	O
+was	O
+an	O
+obvious	O
+predominance	O
+of	O
+young	O
+adult	O
+patients	O
+with	O
+a	O
+slight	O
+female	O
+proneness	O
+in	O
+severe	O
+acute	O
+respiratory	O
+syndrome	O
+(	O
+SARS	B-DISO
+).	O
+
+However	O
+,	O
+among	O
+patients	O
+who	O
+died	B-PROC
+,	O
+older	O
+patients	O
+had	O
+less	O
+extensive	O
+radiographic	O
+opacification	O
+at	O
+the	O
+worst	O
+stage	O
+of	O
+disease	O
+and	O
+just	O
+before	O
+death	B-PROC
+than	O
+did	O
+younger	O
+patients	O
+.	O
+
+Radiographic	O
+scores	O
+correlated	O
+with	O
+the	O
+ratio	O
+of	O
+PaO2	O
+to	O
+the	O
+fraction	O
+of	O
+inspired	B-PROC
+oxygen	B-CHED
+,	O
+lymphocyte	B-ANAT
+count	O
+,	O
+lactate	B-PRGE
+dehydrogenase	I-PRGE
+level	O
+,	O
+and	O
+neutrophil	B-ANAT
+count	O
+at	O
+each	O
+milestone	O
+and	O
+in	O
+terms	O
+of	O
+changes	O
+between	O
+milestones	O
+(	O
+P	O
+<	O
+.	O
+01	O
+for	O
+all	O
+correlation	O
+coefficients	O
+,	O
+except	O
+for	O
+radiographic	O
+score	O
+and	O
+neutrophil	B-ANAT
+count	O
+between	O
+the	O
+first	O
+two	O
+milestones	O
+).	O
+
+ABSTRACT	O
+:	O
+A	O
+20	O
+-	O
+year	O
+-	O
+old	O
+man	B-CHED
+developed	O
+a	O
+giant	O
+pseudoaneurysm	B-DISO
+of	O
+the	O
+innominate	B-ANAT
+artery	I-ANAT
+5	O
+months	O
+after	O
+blunt	O
+chest	B-ANAT
+trauma	O
+,	O
+causing	O
+severe	O
+respiratory	B-DISO
+distress	I-DISO
+and	O
+superior	B-ANAT
+vena	I-ANAT
+cava	I-ANAT
+compression	O
+symptoms	O
+.	O
+
+HIV	B-DISO
+/	I-DISO
+AIDS	I-DISO
+,	O
+malaria	O
+,	O
+tuberculosis	B-PATH
+,	O
+influenza	B-DISO
+,	O
+SARS	B-DISO
+,	O
+West	B-DISO
+Nile	I-DISO
+virus	I-DISO
+,	O
+Marburg	B-SPEC
+virus	I-SPEC
+,	O
+and	O
+bioterrorism	O
+are	O
+examples	O
+of	O
+some	O
+of	O
+the	O
+emerging	O
+and	O
+reemerging	O
+threats	O
+.	O
+
+In	O
+the	O
+past	O
+,	O
+U	O
+.	O
+S	O
+.	O
+government	O
+-	O
+sponsored	O
+biomedical	O
+researchers	O
+have	O
+focused	O
+on	O
+basic	O
+research	O
+and	O
+concept	O
+development	B-PROC
+,	O
+leaving	O
+product	O
+development	B-PROC
+to	O
+the	O
+pharmaceutical	B-CHED
+industry	O
+.	O
+
+No	O
+relationship	O
+between	O
+these	O
+observations	O
+and	O
+RNA	O
+secondary	O
+-	O
+structure	O
+predictions	O
+was	O
+found	O
+,	O
+indicating	O
+that	O
+mutations	O
+at	O
+nucleotide	O
+637	O
+most	O
+likely	O
+had	O
+an	O
+effect	O
+at	O
+the	O
+protein	B-CHED
+level	O
+.	O
+
+A	O
+correlation	O
+was	O
+found	O
+between	O
+predicted	O
+cleaving	O
+and	O
+noncleaving	O
+mutations	O
+and	O
+efficient	O
+virus	B-SPEC
+rescue	O
+from	O
+cDNA	O
+and	O
+minigenome	O
+amplification	B-DISO
+,	O
+respectively	O
+.	O
+
+During	O
+the	O
+propagation	O
+of	O
+recombinant	O
+MHV	B-SPEC
+-	O
+HE	O
++,	O
+two	O
+types	O
+of	O
+spontaneous	O
+mutants	O
+accumulated	O
+.	O
+
+ABSTRACT	O
+:	O
+Murine	O
+hepatitis	O
+virus	B-SPEC
+(	O
+MHV	B-SPEC
+)	O
+infection	B-DISO
+provides	O
+a	O
+model	O
+system	O
+for	O
+the	O
+study	O
+of	O
+hepatitis	B-DISO
+,	O
+acute	O
+encephalitis	B-DISO
+,	O
+and	O
+chronic	O
+demyelinating	B-DISO
+disease	I-DISO
+.	O
+
+A	O
+second	O
+,	O
+mirror	O
+set	O
+of	O
+recombinant	O
+viruses	O
+was	O
+constructed	O
+in	O
+which	O
+,	O
+in	O
+addition	O
+,	O
+the	O
+MHV	B-PRGE
+-	I-PRGE
+A59	I-PRGE
+S	I-PRGE
+gene	I-PRGE
+had	O
+been	O
+replaced	O
+with	O
+that	O
+from	O
+MHV	B-SPEC
+-	O
+JHM	O
+.	O
+
+However	O
+,	O
+in	O
+combination	O
+with	O
+JHM	O
+S	O
+,	O
+the	O
+expression	B-PROC
+of	O
+HE	O
+,	O
+regardless	O
+of	O
+whether	O
+it	O
+retained	O
+esterase	B-FUNC
+activity	I-FUNC
+or	O
+not	O
+,	O
+resulted	O
+in	O
+increased	O
+viral	O
+spread	O
+within	O
+the	O
+central	B-ANAT
+nervous	I-ANAT
+system	I-ANAT
+and	O
+in	O
+increased	O
+neurovirulence	O
+.	O
+
+Our	O
+findings	O
+suggest	O
+that	O
+the	O
+properties	O
+of	O
+S	B-PRGE
+receptor	I-PRGE
+utilization	O
+and	O
+/	O
+or	O
+fusogenicity	O
+mainly	O
+determine	O
+organ	B-ANAT
+and	O
+host	B-COMP
+cell	I-COMP
+tropism	B-PROC
+but	O
+that	O
+HE	O
+enhances	O
+the	O
+efficiency	O
+of	O
+infection	B-DISO
+and	O
+promotes	O
+viral	O
+dissemination	O
+,	O
+at	O
+least	O
+in	O
+some	O
+tissues	B-ANAT
+,	O
+presumably	O
+by	O
+serving	O
+as	O
+a	O
+second	O
+receptor	O
+-	O
+binding	B-FUNC
+protein	B-CHED
+.	O
+
+We	O
+tested	O
+this	O
+hypothesis	O
+by	O
+measuring	O
+the	O
+deubiquitinating	B-PROC
+activity	O
+of	O
+PLpro	O
+by	O
+two	O
+independent	O
+assays	O
+.	O
+
+SARS	B-DISO
+CoV	O
+-	O
+PLpro	O
+hydrolyzed	O
+both	O
+diubiquitin	B-PRGE
+and	O
+ubiquitin	B-PRGE
+-	I-PRGE
+7	B-CHED
+-	I-CHED
+amino	I-CHED
+-	I-CHED
+4	I-CHED
+-	I-CHED
+methylcoumarin	I-CHED
+(	O
+AMC	B-DISO
+)	O
+substrates	O
+,	O
+and	O
+hydrolysis	O
+of	O
+ubiquitin	B-PROC
+-	O
+AMC	B-DISO
+is	O
+approximately	O
+180	O
+-	O
+fold	O
+more	O
+efficient	O
+than	O
+hydrolysis	O
+of	O
+a	O
+peptide	B-CHED
+substrate	O
+that	O
+mimics	O
+the	O
+PLpro	B-PRGE
+replicase	I-PRGE
+recognition	I-PRGE
+sequence	I-PRGE
+.	O
+
+ABSTRACT	O
+:	O
+The	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+coronavirus	B-SPEC
+papain	B-PRGE
+-	I-PRGE
+like	I-PRGE
+protease	I-PRGE
+(	O
+SARS	B-PRGE
+-	I-PRGE
+CoV	I-PRGE
+PLpro	I-PRGE
+)	O
+is	O
+involved	O
+in	O
+the	O
+processing	O
+of	O
+the	O
+viral	O
+polyprotein	O
+and	O
+,	O
+thereby	O
+,	O
+contributes	O
+to	O
+the	O
+biogenesis	B-PROC
+of	O
+the	O
+virus	B-PROC
+replication	I-PROC
+complex	O
+.	O
+
+In	O
+addition	O
+,	O
+SARS	B-PRGE
+-	I-PRGE
+CoV	I-PRGE
+PLpro	I-PRGE
+was	O
+inhibited	O
+by	O
+the	O
+specific	O
+deubiquitinating	B-PROC
+enzyme	B-CHED
+inhibitor	I-CHED
+ubiquitin	O
+aldehyde	B-CHED
+,	O
+with	O
+an	O
+inhibition	B-PROC
+constant	O
+of	O
+210	O
+nM	O
+.	O
+The	O
+purified	O
+SARS	B-PRGE
+-	I-PRGE
+CoV	I-PRGE
+PLpro	I-PRGE
+disassembles	O
+branched	B-PRGE
+polyubiquitin	B-PROC
+chains	I-PRGE
+with	O
+lengths	O
+of	O
+two	O
+to	O
+seven	O
+(	O
+Ub2	O
+-	O
+7	O
+)	O
+or	O
+four	O
+(	O
+Ub4	O
+)	O
+units	O
+,	O
+which	O
+involves	O
+isopeptide	O
+bond	O
+cleavage	B-PROC
+.	O
+
+The	O
+SARS	B-PRGE
+-	I-PRGE
+CoV	I-PRGE
+receptor	I-PRGE
+,	O
+human	B-PRGE
+angiotensin	B-CHED
+1	O
+-	O
+converting	O
+enzyme	O
+2	O
+(	O
+hACE2	O
+),	O
+was	O
+detected	O
+in	O
+ciliated	O
+airway	B-ANAT
+epithelial	B-ANAT
+cells	I-ANAT
+of	O
+human	B-SPEC
+airway	B-ANAT
+tissues	B-ANAT
+derived	O
+from	O
+nasal	B-ANAT
+or	O
+tracheobronchial	O
+regions	O
+,	O
+suggesting	O
+that	O
+SARS	B-DISO
+-	O
+CoV	O
+may	O
+infect	O
+the	O
+proximal	O
+airways	O
+.	O
+
+SARS	B-DISO
+-	O
+CoV	O
+specifically	O
+infected	O
+HAE	O
+via	O
+the	O
+apical	O
+surface	O
+and	O
+replicated	O
+to	O
+titers	O
+of	O
+10	O
+(	O
+7	O
+)	O
+PFU	B-CHED
+/	O
+ml	O
+by	O
+48	O
+h	O
+postinfection	O
+.	O
+
+Polyclonal	O
+antisera	O
+directed	O
+against	O
+hACE2	O
+blocked	O
+virus	B-DISO
+infection	I-DISO
+and	O
+replication	O
+,	O
+suggesting	O
+that	O
+hACE2	O
+is	O
+the	O
+primary	O
+receptor	O
+for	O
+SARS	B-DISO
+-	I-DISO
+CoV	I-DISO
+infection	I-DISO
+of	O
+HAE	O
+.	O
+
+TITLE	O
+:	O
+Virucidal	O
+activity	O
+of	O
+a	O
+new	O
+hand	O
+disinfectant	B-CHED
+with	O
+reduced	O
+ethanol	B-CHED
+content	O
+:	O
+comparison	O
+with	O
+other	O
+alcohol	O
+-	O
+based	O
+formulations	O
+.	O
+
+In	O
+quantitative	O
+suspension	O
+tests	O
+,	O
+with	O
+and	O
+without	O
+protein	B-CHED
+load	O
+,	O
+this	O
+formulation	O
+reduced	O
+the	O
+infectivity	O
+titre	O
+of	O
+seven	O
+enveloped	O
+(	O
+influenza	B-PATH
+A	I-PATH
+and	O
+B	O
+,	O
+herpes	B-DISO
+simplex	I-DISO
+1	I-DISO
+and	O
+2	O
+,	O
+bovine	B-SPEC
+corona	B-CHED
+,	O
+respiratory	O
+syncytial	O
+,	O
+vaccinia	B-DISO
+,	O
+hepatitis	B-DISO
+B	I-DISO
+,	O
+bovine	B-DISO
+viral	I-DISO
+diarrhoea	I-DISO
+)	O
+and	O
+four	O
+non	O
+-	O
+enveloped	O
+(	O
+hepatitis	B-DISO
+A	I-DISO
+,	O
+polio	B-DISO
+,	O
+rota	O
+,	O
+feline	B-SPEC
+calici	O
+)	O
+viruses	B-SPEC
+>	O
+10	O
+(	O
+3	O
+)-	O
+fold	O
+within	O
+30s	O
+.	O
+
+However	O
+,	O
+a	O
+real	O
+-	O
+time	O
+-	O
+imaging	O
+analysis	O
+of	O
+Simian	O
+virus	O
+40	O
+(	O
+SV40	B-SPEC
+)	O
+'	O
+s	O
+entry	O
+in	O
+cells	B-COMP
+has	O
+indicated	O
+the	O
+existence	O
+of	O
+caveolar	O
+endocytosis	B-PATH
+during	O
+virus	B-SPEC
+entry	O
+.	O
+
+In	O
+addition	O
+,	O
+it	O
+was	O
+demonstrated	O
+that	O
+human	B-SPEC
+coronavirus	I-SPEC
+-	O
+229E	O
+enters	O
+the	O
+cell	B-COMP
+through	O
+caveolae	B-COMP
+.	O
+
+Single	O
+crown	B-COMP
+-	O
+like	O
+virion	B-COMP
+was	O
+directly	O
+visualized	O
+and	O
+quantitative	O
+measurements	O
+of	O
+the	O
+dimensions	O
+for	O
+the	O
+structural	O
+proteins	B-CHED
+were	O
+provided	O
+.	O
+
+A	O
+corona	B-CHED
+of	O
+large	O
+,	O
+distinctive	O
+spikes	O
+in	O
+the	O
+envelope	B-COMP
+was	O
+measured	O
+after	O
+treatment	O
+with	O
+hydroxyoctanoic	O
+acid	O
+.	O
+
+There	O
+are	O
+no	O
+specific	O
+effective	O
+therapies	O
+for	O
+ARDS	B-DISO
+and	O
+novel	O
+therapeutic	O
+approaches	O
+are	O
+desperately	O
+needed	O
+.	O
+
+ABSTRACT	O
+:	O
+The	O
+pro	B-CHED
+-	O
+apoptotic	O
+properties	O
+of	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+coronavirus	B-SPEC
+(	O
+SARS	B-DISO
+-	O
+CoV	O
+)	O
+structural	O
+proteins	B-CHED
+were	O
+studied	O
+in	O
+vitro	O
+.	O
+
+By	O
+monitoring	O
+apoptosis	B-PATH
+indicators	O
+including	O
+chromatin	B-COMP
+condensation	B-DISO
+,	O
+cellular	B-COMP
+DNA	B-PROC
+fragmentation	I-PROC
+and	O
+cell	B-COMP
+membrane	I-COMP
+asymmetry	O
+,	O
+we	O
+demonstrated	O
+that	O
+the	O
+adenovirus	B-DISO
+-	O
+mediated	O
+over	O
+-	O
+expression	B-PROC
+of	O
+SARS	B-DISO
+-	O
+CoV	O
+spike	O
+(	O
+S	O
+)	O
+protein	B-CHED
+and	O
+its	O
+C	O
+-	O
+terminal	O
+domain	O
+(	O
+S2	O
+)	O
+induce	O
+apoptosis	B-PATH
+in	O
+Vero	O
+E6	O
+cells	B-COMP
+in	O
+a	O
+time	O
+-	O
+and	O
+dosage	O
+-	O
+dependent	O
+manner	O
+,	O
+whereas	O
+the	O
+expression	B-PROC
+of	O
+its	O
+N	O
+-	O
+terminal	O
+domain	O
+(	O
+S1	O
+)	O
+and	O
+other	O
+structural	O
+proteins	B-CHED
+,	O
+including	O
+envelope	B-COMP
+(	O
+E	O
+),	O
+membrane	B-COMP
+(	O
+M	O
+)	O
+and	O
+nucleocapsid	B-COMP
+(	O
+N	O
+)	O
+protein	B-CHED
+do	O
+not	O
+.	O
+
+TITLE	O
+:	O
+The	O
+putative	O
+protein	B-CHED
+6	O
+of	O
+the	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+-	O
+associated	O
+coronavirus	B-SPEC
+:	O
+expression	B-PROC
+and	O
+functional	O
+characterization	O
+.	O
+
+In	O
+this	O
+study	O
+,	O
+we	O
+have	O
+confirmed	O
+the	O
+SARS	B-PRGE
+6	I-PRGE
+protein	B-PROC
+expression	B-PROC
+in	O
+lung	B-ANAT
+and	O
+intestine	B-ANAT
+tissues	B-ANAT
+of	O
+the	O
+SARS	B-DISO
+patients	O
+and	O
+in	O
+SARS	B-DISO
+-	O
+CoV	O
+infected	O
+Vero	O
+E6	O
+cells	B-COMP
+by	O
+immunohistochemistry	O
+.	O
+
+The	O
+nature	O
+of	O
+the	O
+frameshift	B-DISO
+signals	O
+of	O
+HIV	B-SPEC
+-	I-SPEC
+1	I-SPEC
+and	O
+the	O
+SARS	B-PRGE
+-	I-PRGE
+CoV	I-PRGE
+will	O
+be	O
+described	O
+and	O
+the	O
+impact	O
+of	O
+this	O
+knowledge	O
+on	O
+models	O
+of	O
+frameshifting	O
+will	O
+be	O
+considered	O
+.	O
+
+Chile	O
+was	O
+able	O
+to	O
+manage	O
+those	O
+emergencies	B-DISO
+using	O
+the	O
+local	O
+health	O
+system	O
+.	O
+
+That	O
+particular	O
+evidence	O
+may	O
+indicate	O
+that	O
+the	O
+virus	B-SPEC
+could	O
+adapt	O
+to	O
+infect	O
+humans	B-SPEC
+,	O
+since	O
+a	O
+similar	O
+situation	O
+was	O
+observed	O
+in	O
+several	O
+of	O
+the	O
+influenza	O
+pandemics	O
+.	O
+
+It	O
+is	O
+possible	O
+that	O
+we	O
+may	O
+have	O
+a	O
+vaccine	O
+before	O
+the	O
+outbreak	O
+;	O
+this	O
+development	B-PROC
+is	O
+even	O
+faster	O
+than	O
+for	O
+SARS	B-DISO
+.	O
+
+The	O
+role	O
+of	O
+interferon	O
+and	O
+systemic	O
+steroid	B-CHED
+in	O
+preventing	O
+immune	O
+-	O
+mediated	O
+lung	B-ANAT
+injury	O
+deserves	O
+further	O
+investigation	O
+.	O
+
+There	O
+was	O
+no	O
+live	O
+SARS	B-DISO
+-	O
+CoV	O
+detected	O
+in	O
+the	O
+sewage	O
+in	O
+these	O
+assays	O
+.	O
+
+We	O
+showed	O
+that	O
+in	O
+vitro	O
+and	O
+in	O
+vivo	O
+infections	B-DISO
+across	O
+the	O
+species	B-SPEC
+barrier	O
+differ	O
+in	O
+their	O
+requirements	O
+.	O
+
+Transgenic	B-SPEC
+mice	I-SPEC
+,	O
+however	O
+,	O
+could	O
+not	O
+be	O
+infected	O
+suggesting	O
+additional	O
+requirements	O
+for	O
+in	O
+vivo	O
+virus	B-SPEC
+susceptibility	O
+.	O
+
+Seven	O
+children	O
+died	B-PROC
+between	O
+11	O
+months	O
+and	O
+14	O
+years	O
+of	O
+age	O
+.	O
+
+These	O
+findings	O
+reveal	O
+the	O
+cogent	O
+effects	O
+of	O
+SARS	B-DISO
+on	O
+family	B-SPEC
+-	O
+centered	O
+care	O
+.	O
+
+ABSTRACT	O
+:	O
+To	O
+develop	O
+a	O
+reverse	O
+transcriptase	O
+-	O
+polymerase	O
+chain	O
+reaction	O
+(	O
+RT	O
+-	O
+PCR	O
+)	O
+assay	O
+to	O
+detect	O
+infectious	B-DISO
+bronchitis	B-DISO
+virus	B-SPEC
+(	O
+IBV	B-SPEC
+)	O
+from	O
+commercially	O
+-	O
+raised	O
+poultry	O
+in	O
+New	O
+Zealand	O
+and	O
+compare	O
+results	O
+with	O
+those	O
+from	O
+virus	B-SPEC
+isolation	O
+.	O
+
+Sequence	O
+analysis	O
+of	O
+a	O
+hypervariable	O
+region	O
+from	O
+the	O
+S1	B-PRGE
+gene	I-PRGE
+was	O
+informative	O
+for	O
+the	O
+differentiation	B-PROC
+of	O
+closely	O
+-	O
+related	O
+strains	O
+.	O
+
+Patients	O
+with	O
+a	O
+longer	O
+illness	O
+showed	O
+a	O
+lower	O
+neutralizing	O
+antibody	B-PROC
+response	I-PROC
+than	O
+patients	O
+with	O
+a	O
+shorter	O
+illness	O
+duration	O
+(	O
+p	O
+=	O
+0	O
+.	O
+008	O
+).	O
+
+TITLE	O
+:	O
+Respiratory	B-DISO
+infections	I-DISO
+during	O
+SARS	B-DISO
+outbreak	O
+,	O
+Hong	O
+Kong	O
+,	O
+2003	O
+.	O
+
+As	O
+discussed	O
+in	O
+this	O
+Review	O
+,	O
+studies	O
+of	O
+animals	B-SPEC
+that	O
+are	O
+infected	O
+with	O
+other	O
+coronaviruses	O
+indicate	O
+that	O
+excessive	O
+and	O
+sometimes	O
+dysregulated	O
+responses	O
+by	O
+macrophages	B-ANAT
+and	O
+other	O
+pro	B-CHED
+-	O
+inflammatory	B-ANAT
+cells	I-ANAT
+might	O
+be	O
+particularly	O
+important	O
+in	O
+the	O
+pathogenesis	B-DISO
+of	O
+disease	O
+that	O
+is	O
+caused	O
+by	O
+infection	B-DISO
+with	O
+these	O
+viruses	B-SPEC
+.	O
+
+TITLE	O
+:	O
+[	O
+Intermittent	O
+asphyxia	B-DISO
+syndrome	B-DISO
+caused	O
+by	O
+a	O
+bronchial	B-ANAT
+cast	B-ANAT
+in	O
+the	O
+subglottic	B-ANAT
+region	O
+].	O
+
+TITLE	O
+:	O
+Godzilla	O
+in	O
+the	O
+corridor	O
+:	O
+The	O
+Ontario	O
+SARS	B-DISO
+crisis	O
+in	O
+historical	O
+perspective	O
+.	O
+
+The	O
+historical	O
+literature	O
+on	O
+nursing	B-PROC
+in	O
+yellow	B-DISO
+fever	I-DISO
+,	O
+cholera	B-DISO
+and	O
+influenza	B-DISO
+epidemics	O
+has	O
+been	O
+employed	O
+to	O
+offer	O
+insight	O
+.	O
+
+Nurses	O
+'	O
+responses	O
+to	O
+SARS	B-DISO
+can	O
+be	O
+usefully	O
+studied	O
+within	O
+a	O
+larger	O
+historical	O
+vision	B-PROC
+of	O
+crisis	O
+nursing	B-PROC
+,	O
+and	O
+information	O
+or	O
+impressions	O
+from	O
+earlier	O
+crises	O
+are	O
+potentially	O
+of	O
+interest	O
+to	O
+the	O
+nursing	B-PROC
+profession	O
+.	O
+
+ABSTRACT	O
+:	O
+Severe	O
+acute	O
+respiratory	O
+syndrome	O
+(	O
+SARS	B-DISO
+)	O
+is	O
+a	O
+recently	O
+discovered	O
+viral	B-DISO
+disease	I-DISO
+,	O
+characterized	O
+by	O
+fever	B-PROC
+,	O
+cough	B-DISO
+,	O
+acute	O
+fibrinous	O
+pneumonia	B-DISO
+and	O
+high	O
+infectivity	O
+.	O
+
+Specific	O
+pathogen	O
+-	O
+free	O
+(	O
+SPF	O
+)	O
+chickens	B-SPEC
+were	O
+immunized	O
+with	O
+inactivated	O
+SARS	B-DISO
+coronavirus	B-SPEC
+and	O
+their	O
+eggs	O
+were	O
+harvested	O
+at	O
+regular	O
+intervals	O
+.	O
+
+SDS	B-DISO
+-	O
+polyacrylamide	B-CHED
+gel	O
+electrophoresis	O
+(	O
+SDS	B-DISO
+-	O
+PAGE	O
+),	O
+Western	O
+blot	O
+and	O
+neutralization	O
+test	O
+results	O
+showed	O
+that	O
+the	O
+IgY	O
+obtained	O
+was	O
+of	O
+a	O
+high	O
+purity	O
+and	O
+had	O
+a	O
+strong	O
+reactive	O
+activity	O
+with	O
+a	O
+neutralization	O
+titer	O
+of	O
+1	O
+:	O
+640	O
+.	O
+
+Rev	O
+.	O
+Drug	O
+Disc	B-COMP
+.	O
+2002	O
+,	O
+1	O
+220	O
+],	O
+is	O
+limited	O
+by	O
+a	O
+known	O
+challenge	O
+in	O
+crystallographically	O
+determining	O
+flexible	O
+regions	O
+of	O
+proteins	B-CHED
+.	O
+
+This	O
+study	O
+suggests	O
+that	O
+terascale	O
+computing	O
+can	O
+complement	O
+crystallography	O
+,	O
+broaden	O
+the	O
+scope	O
+of	O
+virtual	O
+screening	O
+,	O
+and	O
+accelerate	O
+the	O
+development	B-PROC
+of	O
+therapeutics	O
+to	O
+treat	O
+emerging	B-DISO
+infectious	I-DISO
+diseases	I-DISO
+such	O
+as	O
+SARS	B-DISO
+and	O
+Bird	B-DISO
+Flu	I-DISO
+.	O
+
+The	O
+patients	O
+present	O
+mainly	O
+with	O
+multiorgan	B-DISO
+failure	I-DISO
+resulting	O
+from	O
+predominantly	O
+small	B-ANAT
+vessel	I-ANAT
+occlusions	B-DISO
+affecting	O
+mainly	O
+intra	O
+-	O
+abdominal	B-ANAT
+organs	I-ANAT
+such	O
+as	O
+bowel	B-ANAT
+,	O
+liver	B-ANAT
+,	O
+pancreas	B-ANAT
+,	O
+and	O
+adrenals	B-ANAT
+,	O
+although	O
+large	B-ANAT
+vessel	I-ANAT
+occlusions	B-DISO
+do	O
+occur	O
+and	O
+comprise	O
+mainly	O
+deep	B-DISO
+vein	I-DISO
+thromboses	I-DISO
+(	O
+DVT	B-DISO
+)	O
+of	O
+the	O
+veins	B-ANAT
+of	O
+the	O
+lower	B-ANAT
+limbs	I-ANAT
+and	O
+arterial	B-DISO
+occlusions	I-DISO
+causing	O
+strokes	B-DISO
+and	O
+peripheral	B-DISO
+gangrene	I-DISO
+.	O
+
+the	O
+rapid	O
+development	B-PROC
+of	O
+multiorgan	B-DISO
+failure	I-DISO
+following	O
+the	O
+above	O
+-	O
+mentioned	O
+identifiable	O
+precipitating	O
+factors	O
+,	O
+the	O
+involvement	O
+of	O
+unusual	O
+organs	B-ANAT
+such	O
+as	O
+bowel	B-ANAT
+,	O
+reproductive	B-PROC
+organs	B-ANAT
+,	O
+and	O
+bone	B-ANAT
+marrow	I-ANAT
+,	O
+complicating	O
+features	O
+of	O
+disseminated	B-DISO
+intravascular	I-DISO
+coagulation	I-DISO
+in	O
+20	O
+%	O
+of	O
+cases	O
+,	O
+the	O
+acute	O
+(	O
+adult	O
+)	O
+respiratory	B-DISO
+distress	I-DISO
+syndrome	I-DISO
+(	O
+ARDS	B-DISO
+)	O
+in	O
+one	O
+third	O
+of	O
+patients	O
+,	O
+and	O
+severe	O
+thrombocytopenia	O
+;	O
+these	O
+not	O
+being	O
+encountered	O
+in	O
+the	O
+simple	O
+/	O
+classic	O
+APS	B-DISO
+.	O
+
+Parenteral	O
+antibiotics	B-CHED
+may	O
+be	O
+indicated	O
+where	O
+an	O
+underlying	B-DISO
+infection	I-DISO
+is	O
+suspected	O
+.	O
+
+All	O
+patients	O
+admitted	O
+to	O
+the	O
+unit	O
+for	O
+acute	O
+respiratory	O
+or	O
+cardiac	B-DISO
+failure	I-DISO
+were	O
+enrolled	O
+.	O
+
+TITLE	O
+:	O
+Solution	O
+structure	O
+of	O
+the	O
+X4	O
+protein	B-CHED
+coded	O
+by	O
+the	O
+SARS	B-DISO
+related	O
+coronavirus	B-SPEC
+reveals	O
+an	O
+immunoglobulin	B-PRGE
+like	O
+fold	O
+and	O
+suggests	O
+a	O
+binding	B-PROC
+activity	I-PROC
+to	O
+integrin	B-PRGE
+I	I-PRGE
+domains	I-PRGE
+.	O
+
+The	O
+dimer	O
+dissociation	B-DISO
+constant	O
+of	O
+the	O
+wild	O
+-	O
+type	O
+protein	B-CHED
+was	O
+determined	O
+to	O
+be	O
+14	O
+.	O
+0microM	O
+by	O
+analytical	O
+ultracentrifugation	O
+method	O
+.	O
+
+RESULTS	O
+:	O
+Prior	O
+to	O
+the	O
+recognition	O
+of	O
+the	O
+SARS	B-DISO
+outbreak	O
+in	O
+March	O
+2003	O
+,	O
+35	O
+.	O
+2	O
+%	O
+of	O
+the	O
+students	O
+washed	O
+their	O
+hands	B-ANAT
+before	O
+and	O
+72	O
+.	O
+5	O
+%	O
+after	O
+they	O
+physically	O
+examined	O
+patients	O
+in	O
+the	O
+wards	O
+.	O
+
+ABSTRACT	O
+:	O
+Influenza	O
+pneumonia	O
+and	O
+influenza	O
+-	O
+associated	O
+severe	O
+exacerbation	O
+of	O
+pre	O
+-	O
+existing	O
+heart	B-ANAT
+and	I-ANAT
+lung	I-ANAT
+disease	O
+are	O
+responsible	O
+for	O
+major	O
+complications	O
+that	O
+may	O
+require	O
+intensive	O
+care	O
+unit	O
+admission	O
+.	O
+
+This	O
+patient	O
+had	O
+received	O
+a	O
+classical	O
+antibiotic	B-CHED
+treatment	O
+by	O
+amoxycillin	B-CHED
+(	O
+3	O
+g	O
+/	O
+24	O
+hours	O
+per	O
+os	O
+);	O
+48	O
+hours	O
+later	O
+,	O
+he	O
+was	O
+admitted	O
+in	O
+ICU	O
+for	O
+a	O
+respiratory	B-DISO
+failure	I-DISO
+that	O
+evolved	O
+rapidly	O
+towards	O
+an	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+.	O
+
+TITLE	O
+:	O
+Study	O
+on	O
+substrate	O
+specificity	O
+at	O
+subsites	O
+for	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+coronavirus	B-SPEC
+3CL	O
+protease	O
+.	O
+
+In	O
+contrast	O
+to	O
+the	O
+previous	O
+suggestion	O
+that	O
+only	O
+small	O
+residues	O
+in	O
+substrate	O
+could	O
+be	O
+accommodated	O
+to	O
+the	O
+S1	O
+'	O
+subsite	O
+,	O
+we	O
+have	O
+found	O
+that	O
+bulky	O
+residues	O
+such	O
+as	O
+Tyr	B-CHED
+and	O
+Trp	B-ENZY
+were	O
+also	O
+acceptable	O
+.	O
+
+SP	O
+-	O
+4	O
+(	O
+residues	O
+192	O
+-	O
+203	O
+),	O
+SP	O
+-	O
+8	O
+(	O
+residues	O
+483	O
+-	O
+494	O
+),	O
+and	O
+SP	O
+-	O
+10	O
+(	O
+residues	O
+668	O
+-	O
+679	O
+)	O
+significantly	O
+blocked	O
+the	O
+interaction	O
+between	O
+S	B-PRGE
+protein	I-PRGE
+and	O
+ACE2	B-PRGE
+by	O
+biotinylated	O
+enzyme	O
+-	O
+linked	O
+immunosorbent	O
+assay	O
+,	O
+with	O
+IC	O
+(	O
+50	O
+)	O
+values	O
+of	O
+4	O
+.	O
+30	O
++/-	O
+
+Peptide	B-CHED
+scanning	O
+suggested	O
+the	O
+region	O
+spanning	O
+residues	O
+660	O
+-	O
+683	O
+might	O
+act	O
+as	O
+a	O
+receptor	O
+-	O
+binding	B-FUNC
+domain	O
+.	O
+
+In	O
+conclusion	O
+,	O
+this	O
+is	O
+the	O
+first	O
+report	O
+of	O
+small	O
+peptides	B-CHED
+designed	O
+to	O
+disrupt	O
+the	O
+binding	B-FUNC
+of	O
+SARS	B-PRGE
+-	I-PRGE
+CoV	I-PRGE
+S	I-PRGE
+protein	B-CHED
+to	O
+ACE2	B-PRGE
+.	O
+
+TITLE	O
+:	O
+The	O
+nucleocapsid	B-COMP
+protein	B-CHED
+of	O
+coronavirus	B-SPEC
+infectious	B-DISO
+bronchitis	B-DISO
+virus	B-SPEC
+:	O
+crystal	B-ANAT
+structure	O
+of	O
+its	O
+N	O
+-	O
+terminal	O
+domain	O
+and	O
+multimerization	O
+properties	O
+.	O
+
+Furthermore	O
+,	O
+the	O
+authors	O
+also	O
+explored	O
+the	O
+influence	O
+of	O
+various	O
+factors	O
+on	O
+the	O
+SARS	B-DISO
+incubation	O
+period	O
+by	O
+analysis	O
+of	O
+variance	O
+,	O
+linear	O
+regression	O
+analysis	O
+,	O
+and	O
+analysis	O
+of	O
+covariance	O
+.	O
+
+TITLE	O
+:	O
+Longitudinal	O
+analysis	O
+of	O
+Severe	B-DISO
+Acute	I-DISO
+Respiratory	I-DISO
+Syndrome	I-DISO
+(	O
+SARS	B-DISO
+)	O
+coronavirus	B-SPEC
+-	O
+specific	O
+antibody	B-FUNC
+in	O
+SARS	B-DISO
+patients	O
+.	O
+
+ABSTRACT	O
+:	O
+The	O
+serum	B-COMP
+antibodies	B-COMP
+to	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+(	O
+SARS	B-DISO
+)	O
+coronavirus	B-SPEC
+of	O
+18	O
+SARS	B-DISO
+patients	O
+were	O
+checked	O
+at	O
+1	O
+month	O
+and	O
+every	O
+3	O
+months	O
+after	O
+disease	O
+onset	O
+.	O
+
+Fifteen	O
+out	O
+of	O
+17	O
+tested	O
+positive	O
+for	O
+the	O
+IgM	B-COMP
+antibody	I-COMP
+at	O
+1	O
+month	O
+.	O
+
+The	O
+serum	B-PRGE
+IgM	B-COMP
+antibody	I-COMP
+of	O
+most	O
+patients	O
+became	O
+undetectable	O
+within	O
+6	O
+months	O
+after	O
+the	O
+onset	O
+of	O
+SARS	B-DISO
+.	O
+
+ABSTRACT	O
+:	O
+Viruses	B-SPEC
+require	O
+specific	O
+cellular	B-COMP
+receptors	O
+to	O
+infect	O
+their	O
+target	B-ANAT
+cells	I-ANAT
+.	O
+
+Angiotensin	B-PRGE
+-	I-PRGE
+converting	I-PRGE
+enzyme	I-PRGE
+2	I-PRGE
+(	O
+ACE2	B-PRGE
+)	O
+is	O
+a	O
+cellular	B-COMP
+receptor	O
+for	O
+two	O
+divergent	O
+coronaviruses	O
+,	O
+SARS	B-DISO
+coronavirus	B-SPEC
+(	O
+SARS	B-DISO
+-	O
+CoV	O
+)	O
+and	O
+human	B-PRGE
+coronavirus	I-PRGE
+NL63	I-PRGE
+(	O
+HCoV	B-SPEC
+-	I-SPEC
+NL63	I-SPEC
+).	O
+
+Finally	O
+,	O
+an	O
+inhibitor	B-CHED
+of	O
+endosomal	O
+acidification	B-PROC
+had	O
+substantially	O
+less	O
+effect	O
+on	O
+infection	B-DISO
+mediated	O
+by	O
+the	O
+HCoV	B-PRGE
+-	I-PRGE
+NL63	I-PRGE
+S	I-PRGE
+protein	B-CHED
+than	O
+on	O
+that	O
+mediated	O
+by	O
+the	O
+SARS	B-PRGE
+-	I-PRGE
+CoV	I-PRGE
+S	I-PRGE
+protein	B-CHED
+.	O
+
+Porcine	B-SPEC
+pulmonary	B-ANAT
+artery	I-ANAT
+endothelial	B-ANAT
+cells	I-ANAT
+(	O
+PAEC	O
+)	O
+were	O
+treated	O
+with	O
+EtOH	B-CHED
+(	O
+0	O
+.	O
+04	O
+-	O
+0	O
+.	O
+16	O
+%,	O
+w	O
+/	O
+v	O
+)	O
+for	O
+72	O
+hr	O
+in	O
+sealed	O
+chambers	O
+to	O
+prevent	O
+evaporation	O
+.	O
+
+ABSTRACT	O
+:	O
+A	O
+subgroup	O
+of	O
+patients	O
+infected	O
+with	O
+the	O
+Hantavirus	B-SPEC
+develops	O
+a	O
+pulmonary	B-ANAT
+syndrome	B-DISO
+(	O
+HPS	B-DISO
+)	O
+characterized	O
+by	O
+severe	O
+acute	B-DISO
+respiratory	I-DISO
+failure	I-DISO
+and	O
+myocardial	B-DISO
+depression	I-DISO
+,	O
+that	O
+has	O
+a	O
+high	O
+mortality	O
+rate	O
+.	O
+
+About	O
+35	O
+%-	O
+40	O
+%	O
+took	O
+more	O
+time	O
+to	O
+rest	B-FUNC
+,	O
+for	O
+relaxation	O
+or	O
+doing	O
+exercise	O
+.	O
+
+TITLE	O
+:	O
+Severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+coronavirus	B-SPEC
+membrane	B-COMP
+protein	B-CHED
+interacts	O
+with	O
+nucleocapsid	B-COMP
+protein	B-CHED
+mostly	O
+through	O
+their	O
+carboxyl	O
+termini	O
+by	O
+electrostatic	O
+attraction	O
+.	O
+
+Kinetic	O
+assays	O
+indicated	O
+that	O
+the	O
+endodomain	O
+(	O
+aa102	O
+-	O
+221	O
+)	O
+of	O
+the	O
+membrane	O
+protein	B-CHED
+interacts	O
+with	O
+the	O
+nucleocapsid	B-PRGE
+protein	B-CHED
+with	O
+high	O
+affinity	O
+(	O
+K	O
+(	O
+D	O
+)=	O
+0	O
+.	O
+55	O
++/-	O
+0	O
+.	O
+04	O
+microM	O
+),	O
+however	O
+,	O
+this	O
+interaction	O
+could	O
+be	O
+weakened	O
+greatly	O
+by	O
+acidification	B-PROC
+,	O
+higher	O
+salt	B-CHED
+concentration	O
+(	O
+400	O
+mM	O
+NaCl	B-CHED
+)	O
+and	O
+divalent	B-CHED
+cation	I-CHED
+(	O
+50	O
+mM	O
+Ca2	O
++),	O
+which	O
+suggests	O
+that	O
+electrostatic	O
+attraction	O
+might	O
+play	O
+an	O
+important	O
+role	O
+in	O
+this	O
+interaction	O
+.	O
+
+These	O
+results	O
+might	O
+facilitate	O
+therapeutic	O
+strategies	O
+aiming	O
+at	O
+the	O
+disruption	O
+of	O
+the	O
+association	O
+between	O
+SARS	B-PRGE
+-	I-PRGE
+CoV	I-PRGE
+membrane	B-COMP
+and	I-PRGE
+nucleocapsid	B-COMP
+proteins	B-CHED
+.	O
+
+A	O
+novel	O
+theory	O
+known	O
+as	O
+autoantigen	O
+complementarity	O
+suggests	O
+that	O
+an	O
+infectious	B-DISO
+agent	O
+could	O
+trigger	O
+antineutrophil	O
+cytoplasmic	B-COMP
+antibody	B-COMP
+-	O
+associated	O
+vasculitis	B-DISO
+.	O
+
+Glycoform	O
+separation	B-DISO
+of	O
+turkey	B-PRGE
+ovalbumin	I-PRGE
+in	O
+a	O
+lectin	B-PRGE
+monolithic	O
+column	B-ANAT
+and	O
+an	O
+electrophoresis	O
+channel	O
+was	O
+performed	O
+on	O
+an	O
+integrated	O
+microchip	O
+.	O
+
+Using	O
+this	O
+technology	O
+,	O
+carbohydrate	B-CHED
+-	O
+containing	O
+macromolecules	B-CHED
+of	O
+diverse	O
+structures	O
+,	O
+including	O
+polysaccharides	B-CHED
+,	O
+natural	O
+glycoconjugates	O
+,	O
+and	O
+mono	B-DISO
+-	O
+and	O
+oligosaccharides	B-CHED
+coupled	O
+to	O
+carrier	O
+molecules	O
+,	O
+can	O
+be	O
+stably	O
+immobilized	O
+on	O
+a	O
+glass	O
+chip	O
+without	O
+chemical	O
+modification	O
+.	O
+
+TITLE	O
+:	O
+Severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+coronavirus	B-SPEC
+3a	O
+protein	B-CHED
+is	O
+released	O
+in	O
+membranous	B-ANAT
+structures	O
+from	O
+3a	O
+protein	O
+-	O
+expressing	O
+cells	B-COMP
+and	O
+infected	O
+cells	B-COMP
+.	O
+
+TITLE	O
+:	O
+Neither	O
+the	O
+RNA	O
+nor	O
+the	O
+proteins	B-CHED
+of	O
+open	O
+reading	O
+frames	O
+3a	O
+and	O
+3b	O
+of	O
+the	O
+coronavirus	B-SPEC
+infectious	B-DISO
+bronchitis	B-DISO
+virus	B-SPEC
+are	O
+essential	O
+for	O
+replication	O
+.	O
+
+Analyses	O
+of	O
+cytochrome	B-PROC
+c	I-PROC
+release	B-PATH
+further	O
+revealed	O
+an	O
+activation	O
+of	O
+the	O
+mitochondrial	B-COMP
+apoptotic	O
+pathway	B-PROC
+.	O
+
+To	O
+identify	O
+upstream	O
+signals	O
+,	O
+we	O
+determined	O
+caspase	B-PROC
+-	I-PROC
+8	I-PROC
+activity	I-PROC
+,	O
+cleavage	B-PROC
+of	O
+Bid	B-PRGE
+,	O
+and	O
+expression	B-PROC
+of	O
+Bax	B-PRGE
+and	O
+Bad	B-PRGE
+by	O
+Western	O
+blotting	O
+.	O
+
+in	O
+virus	B-SPEC
+-	O
+infected	O
+cells	B-COMP
+,	O
+suggesting	O
+that	O
+Bid	B-PRGE
+may	O
+serve	O
+as	O
+a	O
+messenger	O
+to	O
+relay	O
+the	O
+signals	O
+from	O
+caspase	B-PRGE
+-	I-PRGE
+8	I-PRGE
+to	O
+mitochondria	B-COMP
+.	O
+
+Furthermore	O
+,	O
+we	O
+found	O
+that	O
+Bax	B-PRGE
+but	O
+not	O
+Bad	B-PRGE
+was	O
+significantly	O
+increased	O
+at	O
+12	O
+h	O
+p	O
+.	O
+i	O
+.	O
+
+These	O
+results	O
+thus	O
+establish	O
+the	O
+involvement	O
+of	O
+the	O
+mitochondrial	B-COMP
+pathway	B-PROC
+in	O
+MHV	B-SPEC
+-	O
+induced	O
+oligodendrocyte	B-PROC
+apoptosis	B-PATH
+.	O
+
+However	O
+,	O
+when	O
+multiple	O
+members	O
+of	O
+a	O
+cardiac	B-DISO
+arrest	I-DISO
+team	O
+were	O
+dressing	O
+simultaneously	O
+,	O
+the	O
+time	O
+to	O
+don	O
+the	O
+PPS	B-DISO
+increased	O
+to	O
+between	O
+3	O
+1	O
+/	O
+2	O
+and	O
+5	O
+1	O
+/	O
+2	O
+minutes	O
+.	O
+
+The	O
+insight	O
+gained	O
+from	O
+this	O
+experience	O
+will	O
+be	O
+valuable	O
+for	O
+future	O
+infectious	B-DISO
+disease	I-DISO
+challenges	O
+in	O
+critical	O
+care	O
+.	O
+
+Errors	O
+in	O
+infection	B-DISO
+control	O
+as	O
+well	O
+as	O
+in	O
+medical	O
+management	O
+of	O
+advanced	O
+cardiac	B-ANAT
+life	O
+support	O
+(	O
+ACLS	B-DISO
+)	O
+were	O
+corrected	O
+.	O
+
+The	O
+objective	O
+of	O
+the	O
+experiment	O
+was	O
+to	O
+evaluate	O
+effects	O
+of	O
+increased	O
+milk	O
+replacer	O
+feeding	O
+on	O
+growth	B-PROC
+,	O
+intake	O
+,	O
+feed	O
+efficiency	O
+,	O
+and	O
+health	O
+parameters	O
+in	O
+stressed	O
+calves	O
+.	O
+
+There	O
+was	O
+no	O
+effect	O
+of	O
+milk	O
+replacer	O
+feeding	O
+on	O
+concentrations	O
+of	O
+nonesterified	O
+fatty	B-CHED
+acids	I-CHED
+,	O
+total	O
+protein	B-CHED
+,	O
+or	O
+growth	B-FUNC
+hormone	I-FUNC
+concentrations	O
+.	O
+
+Under	O
+conditions	O
+of	O
+this	O
+study	O
+,	O
+calves	O
+fed	O
+variable	O
+amount	O
+of	O
+milk	O
+replacer	O
+and	O
+exposed	O
+to	O
+immunological	O
+challenge	O
+before	O
+weaning	B-PROC
+had	O
+greater	O
+BW	O
+gain	O
+,	O
+but	O
+also	O
+increased	O
+incidence	O
+of	O
+diarrhea	B-DISO
+that	O
+required	O
+added	O
+veterinary	O
+treatments	O
+.	O
+
+TITLE	O
+:	O
+Binding	B-FUNC
+site	O
+-	O
+based	O
+classification	O
+of	O
+coronaviral	B-PRGE
+papain	I-PRGE
+-	I-PRGE
+like	I-PRGE
+proteases	I-PRGE
+.	O
+
+ABSTRACT	O
+:	O
+The	O
+coronavirus	B-SPEC
+replicase	I-PRGE
+gene	I-PRGE
+encodes	O
+one	O
+or	O
+two	O
+papain	B-PRGE
+-	I-PRGE
+like	I-PRGE
+proteases	I-PRGE
+(	O
+termed	O
+PL1pro	O
+and	O
+PL2pro	O
+)	O
+implicated	O
+in	O
+the	O
+N	O
+-	O
+terminal	O
+processing	O
+of	O
+the	O
+replicase	B-PRGE
+polyprotein	O
+and	O
+thus	O
+contributing	O
+to	O
+the	O
+formation	B-PROC
+of	O
+the	O
+viral	B-PRGE
+replicase	I-PRGE
+complex	I-PRGE
+that	O
+mediates	O
+genome	O
+replication	O
+.	O
+
+We	O
+report	O
+on	O
+an	O
+adolescent	O
+with	O
+an	O
+acute	O
+onset	O
+of	O
+dyspnea	B-DISO
+and	O
+pleuritic	B-DISO
+chest	I-DISO
+pain	I-DISO
+with	O
+severe	O
+restrictive	O
+lung	B-ANAT
+physiology	O
+on	O
+pulmonary	B-PROC
+function	I-PROC
+testing	O
+(	O
+forced	B-PROC
+vital	I-PROC
+capacity	I-PROC
+,	O
+20	O
+%	O
+of	O
+predicted	O
+)	O
+who	O
+had	O
+no	O
+evidence	O
+of	O
+parenchymal	O
+lung	B-ANAT
+or	O
+pleural	B-DISO
+disease	I-DISO
+.	O
+
+He	O
+was	O
+found	O
+to	O
+have	O
+restricted	O
+diaphragmatic	B-PROC
+movement	I-PROC
+as	O
+assessed	O
+by	O
+fluoroscopy	O
+,	O
+without	O
+evidence	O
+of	O
+generalized	O
+respiratory	B-ANAT
+muscle	I-ANAT
+weakness	O
+.	O
+
+His	O
+clinical	O
+presentation	O
+and	O
+results	O
+of	O
+diagnostic	O
+tests	O
+were	O
+typical	O
+for	O
+shrinking	B-DISO
+lung	I-DISO
+syndrome	I-DISO
+.	O
+
+Given	O
+the	O
+rarity	O
+of	O
+shrinking	B-DISO
+lung	I-DISO
+syndrome	I-DISO
+in	O
+the	O
+pediatric	O
+age	O
+range	O
+,	O
+many	O
+clinicians	O
+are	O
+not	O
+aware	O
+of	O
+it	O
+as	O
+a	O
+clinical	O
+entity	O
+.	O
+
+Shrinking	B-DISO
+lung	I-DISO
+syndrome	I-DISO
+should	O
+be	O
+included	O
+in	O
+the	O
+differential	O
+diagnosis	O
+of	O
+dyspnea	B-DISO
+in	O
+both	O
+children	O
+and	O
+adults	O
+with	O
+systemic	B-PATH
+lupus	I-PATH
+erythematosus	I-PATH
+.	O
+
+TITLE	O
+:	O
+Application	O
+of	O
+transmission	O
+electron	O
+microscopy	O
+to	O
+the	O
+clinical	O
+study	O
+of	O
+viral	O
+and	O
+bacterial	B-DISO
+infections	I-DISO
+:	O
+present	O
+and	O
+future	O
+.	O
+
+ABSTRACT	O
+:	O
+Transmission	O
+electron	O
+microscopy	O
+has	O
+had	O
+a	O
+profound	O
+impact	O
+on	O
+our	O
+knowledge	O
+and	O
+understanding	O
+of	O
+viruses	B-SPEC
+and	O
+bacteria	B-SPEC
+.	O
+
+There	O
+is	O
+continuing	O
+use	O
+of	O
+EM	O
+for	O
+the	O
+investigation	O
+of	O
+new	O
+and	O
+emerging	O
+agents	O
+,	O
+such	O
+as	O
+SARS	B-DISO
+and	O
+human	B-DISO
+monkeypox	B-SPEC
+virus	I-SPEC
+.	O
+
+ABSTRACT	O
+:	O
+We	O
+investigated	O
+whether	O
+infection	B-DISO
+with	O
+a	O
+novel	O
+human	B-SPEC
+coronavirus	I-SPEC
+(	O
+HCoV	B-SPEC
+),	O
+called	O
+""""	O
+New	O
+Haven	O
+coronavirus	B-SPEC
+""""	O
+(	O
+HCoV	B-SPEC
+-	O
+NH	O
+)--	O
+which	O
+is	O
+similar	O
+to	O
+and	O
+likely	O
+represents	O
+the	O
+same	O
+species	B-SPEC
+as	O
+another	O
+novel	O
+HCoV	B-SPEC
+,	O
+HCoV	B-SPEC
+-	I-SPEC
+NL63	I-SPEC
+--	O
+is	O
+associated	O
+with	O
+Kawasaki	B-DISO
+disease	I-DISO
+(	O
+KD	O
+)	O
+in	O
+Taiwan	O
+.	O
+
+The	O
+intracellular	B-COMP
+effects	O
+of	O
+bacteria	B-SPEC
+are	O
+addressed	O
+in	O
+a	O
+review	O
+of	O
+Listeria	B-DISO
+infection	I-DISO
+and	O
+a	O
+further	O
+review	O
+outlines	O
+recent	O
+advances	O
+in	O
+our	O
+knowledge	O
+of	O
+syphilis	B-DISO
+.	O
+
+The	O
+outbreaks	O
+of	O
+avian	B-DISO
+influenza	I-DISO
+among	O
+fowls	B-SPEC
+have	O
+been	O
+occurred	O
+since	O
+2004	O
+,	O
+and	O
+some	O
+fatal	O
+human	B-SPEC
+cases	O
+infected	O
+with	O
+avian	B-SPEC
+influenza	I-SPEC
+virus	I-SPEC
+are	O
+detected	O
+in	O
+Viet	O
+Nam	O
+,	O
+Thailand	O
+,	O
+Cambodia	O
+and	O
+Indonesia	O
+.	O
+
+The	O
+control	O
+and	O
+simvastatin	B-CHED
+groups	O
+had	O
+similar	O
+serum	B-COMP
+levels	O
+and	O
+similar	O
+bronchoalveolar	B-ANAT
+lavage	I-ANAT
+fluid	I-ANAT
+levels	O
+of	O
+cytokines	O
+(	O
+interleukin	B-PRGE
+-	I-PRGE
+1	I-PRGE
+,	O
+interleukin	B-PRGE
+-	I-PRGE
+6	I-PRGE
+,	O
+and	O
+tumor	B-PRGE
+necrosis	I-PRGE
+factor	I-PRGE
+-	I-PRGE
+alpha	I-PRGE
+)	O
+and	O
+P	B-PRGE
+-	I-PRGE
+selectin	I-PRGE
+at	O
+all	O
+measurements	O
+,	O
+except	O
+for	O
+a	O
+significantly	O
+higher	O
+level	O
+of	O
+bronchoalveolar	B-ANAT
+lavage	I-ANAT
+fluid	I-ANAT
+P	B-PRGE
+-	I-PRGE
+selectin	I-PRGE
+in	O
+the	O
+control	O
+group	O
+(	O
+P	O
+=	O
+0	O
+.	O
+006	O
+).	O
+
+Pretreatment	O
+with	O
+simvastatin	B-CHED
+reduces	O
+the	O
+severity	O
+of	O
+acute	O
+lung	B-ANAT
+injury	O
+induced	O
+by	O
+intestinal	B-ANAT
+I	O
+/	O
+R	O
+in	O
+rats	B-SPEC
+.	O
+
+L	O
+-	O
+SIGN	O
+,	O
+encoded	O
+by	O
+CLEC4M	O
+(	O
+also	O
+known	O
+as	O
+CD209L	O
+),	O
+is	O
+a	O
+SARS	B-PRGE
+-	I-PRGE
+CoV	I-PRGE
+binding	B-FUNC
+receptor	I-PRGE
+that	O
+has	O
+polymorphism	B-PROC
+in	O
+its	O
+extracellular	B-COMP
+neck	B-ANAT
+region	I-ANAT
+encoded	O
+by	O
+the	O
+tandem	O
+repeat	O
+domain	O
+in	O
+exon	O
+4	O
+.	O
+
+Compared	O
+with	O
+cells	B-COMP
+heterozygous	O
+for	B-PRGE
+L	I-PRGE
+-	I-PRGE
+SIGN	I-PRGE
+,	O
+cells	B-COMP
+homozygous	O
+for	O
+L	O
+-	O
+SIGN	O
+show	O
+higher	O
+binding	B-FUNC
+capacity	O
+for	O
+SARS	B-PRGE
+-	I-PRGE
+CoV	I-PRGE
+,	O
+higher	O
+proteasome	B-PATH
+-	O
+dependent	O
+viral	O
+degradation	O
+and	O
+a	O
+lower	O
+capacity	O
+for	O
+trans	O
+infection	B-DISO
+.	O
+
+In	O
+this	O
+report	O
+we	O
+summarized	O
+the	O
+results	O
+from	O
+an	O
+epidemiological	O
+investigation	O
+of	O
+a	O
+SARS	B-DISO
+outbreak	O
+in	O
+a	O
+hospital	O
+in	O
+Tianjin	O
+,	O
+between	O
+April	O
+and	O
+May	O
+2003	O
+.	O
+
+We	O
+collected	O
+epidemiological	O
+and	O
+clinical	O
+data	O
+on	O
+111	O
+suspect	O
+and	O
+probable	O
+cases	O
+of	O
+SARS	B-DISO
+associated	O
+with	O
+the	O
+outbreak	O
+.	O
+
+The	O
+outbreak	O
+was	O
+single	O
+sourced	O
+and	O
+had	O
+eight	O
+clusters	B-CHED
+.	O
+
+All	O
+SARS	B-DISO
+cases	O
+in	O
+the	O
+hospital	O
+were	O
+traced	O
+to	O
+a	O
+single	O
+patient	O
+who	O
+directly	O
+infected	O
+33	O
+people	O
+.	O
+
+Since	O
+the	O
+driving	O
+force	O
+is	O
+the	O
+patient	O
+'	O
+s	O
+blood	B-PROC
+pressure	I-PROC
+,	O
+a	O
+roller	O
+pump	O
+with	O
+its	O
+negative	O
+side	O
+effects	O
+is	O
+not	O
+needed	O
+.	O
+
+We	O
+performed	O
+a	O
+prospective	O
+study	O
+of	O
+symptomatic	O
+(	O
+case	O
+subjects	O
+with	O
+ARTI	O
+)	O
+and	O
+asymptomatic	O
+(	O
+control	O
+subjects	O
+undergoing	O
+elective	O
+surgery	O
+)	O
+children	O
+,	O
+<	O
+or	O
+=	O
+3	O
+years	O
+of	O
+age	O
+,	O
+hospitalized	O
+in	O
+Canada	O
+during	O
+2	O
+winter	O
+seasons	O
+(	O
+2001	O
+-	O
+2003	O
+),	O
+to	O
+look	O
+at	O
+the	O
+prevalence	O
+of	O
+respiratory	O
+viruses	B-SPEC
+.	O
+
+HCoV	O
+-	O
+NL	O
+was	O
+detected	O
+in	O
+nasopharyngeal	B-ANAT
+aspirates	B-ANAT
+from	O
+3	O
+.	O
+0	O
+%	O
+of	O
+young	O
+children	O
+(	O
+12	O
+of	O
+396	O
+children	O
+)	O
+hospitalized	O
+for	O
+treatment	O
+of	O
+ARTI	O
+(	O
+case	O
+subjects	O
+),	O
+compared	O
+with	O
+1	O
+.	O
+7	O
+%	O
+of	O
+asymptomatic	O
+control	O
+subjects	O
+(	O
+3	O
+of	O
+177	O
+children	O
+)	O
+(	O
+P	O
+=	O
+0	O
+.	O
+6	O
+).	O
+
+Variability	O
+was	O
+more	O
+pronounced	O
+for	O
+the	O
+spike	O
+gene	O
+,	O
+with	O
+2	O
+clusters	B-CHED
+of	O
+strains	O
+.	O
+
+TITLE	O
+:	O
+History	O
+and	O
+recent	O
+advances	O
+in	O
+coronavirus	B-SPEC
+discovery	O
+.	O
+
+NL63	O
+,	O
+representing	O
+a	O
+group	O
+of	O
+newly	O
+identified	O
+group	O
+I	O
+coronaviruses	O
+that	O
+includes	O
+NL	O
+and	O
+the	O
+New	O
+Haven	O
+coronavirus	B-SPEC
+,	O
+has	O
+been	O
+identified	O
+worldwide	O
+.	O
+
+These	O
+viruses	B-SPEC
+are	O
+associated	O
+with	O
+both	O
+upper	O
+and	O
+lower	B-ANAT
+respiratory	I-ANAT
+tract	I-ANAT
+disease	O
+and	O
+are	O
+likely	O
+common	O
+human	B-SPEC
+pathogens	O
+.	O
+
+TITLE	O
+:	O
+7a	O
+protein	B-CHED
+of	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+coronavirus	B-SPEC
+inhibits	O
+cellular	B-COMP
+protein	B-CHED
+synthesis	I-PROC
+and	O
+activates	O
+p38	O
+mitogen	B-ENZY
+-	I-ENZY
+activated	I-ENZY
+protein	B-CHED
+kinase	I-ENZY
+.	O
+
+The	O
+inhibition	B-PROC
+of	O
+translation	B-PROC
+and	O
+other	O
+cellular	B-COMP
+processes	O
+of	O
+gene	B-PROC
+expression	I-PROC
+have	O
+been	O
+associated	O
+with	O
+the	O
+induction	O
+of	O
+a	O
+stress	B-PATH
+response	I-PATH
+in	O
+cells	B-COMP
+.	O
+
+TITLE	O
+:	O
+Monoclonal	O
+antibodies	B-COMP
+targeting	B-PROC
+the	O
+HR2	B-PRGE
+domain	I-PRGE
+and	O
+the	O
+region	O
+immediately	O
+upstream	O
+of	O
+the	O
+HR2	O
+of	O
+the	O
+S	O
+protein	O
+neutralize	O
+in	O
+vitro	O
+infection	B-DISO
+of	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+coronavirus	B-SPEC
+.	O
+
+SARS	B-DISO
+-	O
+CoV	O
+nucleoprotein	O
+and	O
+RNA	O
+were	O
+detected	O
+by	O
+immunohistochemistry	O
+and	O
+ISH	B-DISO
+,	O
+respectively	O
+,	O
+primarily	O
+in	O
+alveolar	B-ANAT
+pneumocytes	B-ANAT
+and	O
+,	O
+less	O
+frequently	O
+,	O
+in	O
+macrophages	B-ANAT
+.	O
+
+The	O
+pulmonary	B-ANAT
+alveolar	I-ANAT
+epithelium	I-ANAT
+is	O
+the	O
+chief	O
+target	O
+of	O
+SARS	B-PRGE
+-	I-PRGE
+CoV	I-PRGE
+,	O
+with	O
+macrophages	B-ANAT
+infected	O
+subsequently	O
+.	O
+
+Many	O
+homologous	O
+proteins	B-CHED
+were	O
+separated	O
+a	O
+very	O
+long	O
+time	O
+ago	O
+in	O
+their	O
+evolutionary	O
+history	O
+and	O
+thus	O
+their	O
+sequences	O
+share	O
+low	O
+sequence	O
+identity	O
+.	O
+
+In	O
+order	B-SPEC
+to	O
+elucidate	O
+the	O
+pathogenic	O
+mechanisms	O
+of	O
+SARS	B-DISO
+,	O
+we	O
+analyzed	O
+clinical	O
+manifestations	O
+and	O
+levels	O
+of	O
+serum	B-COMP
+cytokines	O
+of	O
+SARS	B-DISO
+patients	O
+.	O
+
+Serial	O
+plasma	B-ANAT
+inflammatory	O
+cytokines	O
+,	O
+including	O
+interleukin	O
+(	O
+IL	O
+)-	O
+1beta	O
+(	O
+IL	B-PRGE
+-	I-PRGE
+1beta	I-PRGE
+),	O
+IL	B-FUNC
+-	I-FUNC
+6	I-FUNC
+,	O
+IL	B-FUNC
+-	I-FUNC
+8	I-FUNC
+and	O
+tumor	B-PRGE
+necrosis	I-PRGE
+factor	I-PRGE
+-	I-PRGE
+alpha	I-PRGE
+(	O
+TNF	B-PRGE
+-	I-PRGE
+alpha	I-PRGE
+)	O
+of	O
+preserved	O
+serum	B-COMP
+were	O
+measured	O
+by	O
+enzyme	O
+immunoassay	O
+.	O
+
+The	O
+8	O
+patients	O
+who	O
+died	B-PROC
+tended	O
+to	O
+have	O
+higher	O
+peak	O
+levels	O
+of	O
+serum	B-PRGE
+TNF	I-PRGE
+-	I-PRGE
+alpha	I-PRGE
+compared	O
+to	O
+those	O
+who	O
+survived	O
+(	O
+14	O
+vs	O
+9	O
+.	O
+1	O
+pg	O
+/	O
+mL	O
+;	O
+p	O
+=	O
+0	O
+.	O
+06	O
+).	O
+
+The	O
+timing	O
+of	O
+elevations	O
+in	O
+inflammatory	O
+cytokines	O
+and	O
+CRP	B-PRGE
+is	O
+correlated	O
+with	O
+progression	O
+of	O
+pulmonary	B-DISO
+infiltrates	I-DISO
+of	O
+SARS	B-DISO
+patients	O
+.	O
+
+Atypical	O
+pathogens	O
+accounted	O
+for	O
+40	O
+%	O
+of	O
+CAP	B-DISO
+.	O
+
+This	O
+study	O
+indicates	O
+that	O
+penicillin	B-CHED
+-	O
+resistant	O
+S	B-SPEC
+.	I-SPEC
+pneumoniae	I-SPEC
+play	O
+a	O
+very	O
+limited	O
+role	O
+in	O
+this	O
+condition	B-DISO
+in	O
+adults	O
+.	O
+
+CONCLUSIONS	O
+:	O
+S	B-SPEC
+.	I-SPEC
+pneumoniae	I-SPEC
+,	O
+M	B-SPEC
+.	I-SPEC
+pneumoniae	I-SPEC
+and	O
+C	B-SPEC
+.	I-SPEC
+pneumoniae	I-SPEC
+were	O
+the	O
+3	O
+leading	O
+causes	O
+of	O
+mild	O
+to	O
+moderate	O
+CAP	B-DISO
+in	O
+Taiwan	O
+.	O
+
+In	O
+the	O
+20	O
+SARS	B-DISO
+cases	O
+,	O
+the	O
+level	O
+of	O
+antibodies	B-COMP
+was	O
+found	O
+to	O
+descend	O
+gradually	O
+and	O
+slowly	O
+during	O
+2	O
+years	O
+after	O
+convalescence	O
+.	O
+
+At	O
+the	O
+first	O
+re	O
+-	O
+examination	O
+,	O
+the	O
+rate	O
+of	O
+abnormal	O
+chest	B-ANAT
+CT	O
+was	O
+65	O
+%,	O
+and	O
+the	O
+main	O
+abnormal	O
+images	O
+included	O
+ground	O
+glass	O
+opacities	B-DISO
+,	O
+thickening	O
+of	O
+inter	O
+-	O
+lobular	O
+and	O
+intra	O
+-	O
+lobular	O
+septa	O
+,	O
+distorted	O
+lobular	O
+structure	O
+,	O
+thickened	O
+bronchovascular	O
+bundles	O
+,	O
+thickened	O
+pleura	B-ANAT
+,	O
+arc	B-DISO
+shadow	O
+under	O
+the	O
+pleura	B-ANAT
+,	O
+bronchiolar	B-ANAT
+dilation	B-DISO
+,	O
+and	O
+honey	O
+comb	B-ANAT
+like	O
+shadows	O
+.	O
+
+The	O
+rate	O
+of	O
+abnormal	O
+chest	B-ANAT
+CT	O
+was	O
+30	O
+%	O
+at	O
+the	O
+4	O
+fourth	O
+examination	O
+.	O
+
+At	O
+the	O
+first	O
+re	O
+-	O
+examination	O
+,	O
+the	O
+abnormal	O
+rate	O
+of	O
+KCO	O
+was	O
+highest	O
+,	O
+accompanied	O
+by	O
+abnormalities	O
+of	O
+forced	B-PROC
+expiratory	I-PROC
+volume	I-PROC
+in	O
+1	O
+second	O
+(	O
+FEV1	O
+)	O
+and	O
+the	O
+diffusing	O
+capacity	O
+of	O
+the	O
+lung	B-ANAT
+for	O
+carbon	B-CHED
+monoxide	I-CHED
+(	O
+DLCO	O
+),	O
+and	O
+it	O
+began	O
+to	O
+recover	B-PROC
+since	O
+the	O
+third	O
+examination	O
+.	O
+
+At	O
+the	O
+first	O
+re	O
+-	O
+examination	O
+,	O
+the	O
+abnormal	O
+rate	O
+of	O
+KCO	O
+was	O
+highest	O
+,	O
+accompanied	O
+by	O
+abnormalities	O
+of	O
+forced	B-PROC
+expiratory	I-PROC
+volume	I-PROC
+in	O
+1	O
+second	O
+(	O
+FEV1	O
+)	O
+and	O
+the	O
+diffusing	O
+capacity	O
+of	O
+the	O
+lung	B-ANAT
+for	O
+carbon	B-CHED
+monoxide	I-CHED
+(	O
+DLCO	O
+),	O
+and	O
+it	O
+began	O
+to	O
+recover	B-PROC
+since	O
+the	O
+third	O
+examination	O
+.	O
+
+ABSTRACT	O
+:	O
+Correspondence	O
+between	O
+the	O
+T	O
+-	O
+cell	O
+epitope	B-CHED
+responses	O
+of	O
+vaccine	O
+immunogens	O
+and	O
+those	O
+of	O
+pathogen	O
+antigens	B-CHED
+is	O
+critical	O
+to	O
+vaccine	O
+efficacy	O
+.	O
+
+In	O
+the	O
+present	O
+study	O
+,	O
+we	O
+analyzed	O
+the	O
+spectrum	O
+of	O
+immune	B-PROC
+responses	I-PROC
+of	O
+mice	B-SPEC
+to	O
+three	O
+different	O
+forms	O
+of	O
+the	O
+SARS	B-DISO
+coronavirus	B-SPEC
+nucleocapsid	B-COMP
+(	O
+N	O
+):	O
+(	O
+1	O
+)	O
+exogenous	O
+recombinant	O
+protein	B-CHED
+(	O
+N	B-PRGE
+-	I-PRGE
+GST	I-PRGE
+)	O
+with	O
+Freund	O
+'	O
+s	O
+adjuvant	B-CHED
+;	O
+(	O
+2	O
+)	O
+DNA	O
+encoding	O
+unmodified	O
+N	O
+as	O
+an	O
+endogenous	O
+cytoplasmic	B-COMP
+protein	B-CHED
+(	O
+pN	O
+);	O
+and	O
+(	O
+3	O
+)	O
+DNA	O
+encoding	O
+N	O
+as	O
+a	O
+LAMP	O
+-	O
+1	O
+chimera	B-DISO
+targeted	B-PROC
+to	O
+the	O
+lysosomal	B-PRGE
+MHC	B-PROC
+II	I-PRGE
+compartment	B-ANAT
+(	O
+p	O
+-	O
+LAMP	O
+-	O
+N	O
+).	O
+
+Nevertheless	O
+,	O
+the	O
+profiles	O
+of	O
+T	B-ANAT
+-	I-ANAT
+cell	I-ANAT
+responses	O
+were	O
+distinctly	O
+different	O
+.	O
+
+ABSTRACT	O
+:	O
+Enveloped	O
+animal	B-SPEC
+viruses	B-SPEC
+such	O
+as	O
+human	B-DISO
+immunodeficiency	I-DISO
+virus	I-DISO
+(	O
+HIV	B-DISO
+),	O
+hepatitis	B-SPEC
+B	I-SPEC
+virus	I-SPEC
+,	O
+hepatitis	B-SPEC
+C	I-SPEC
+virus	I-SPEC
+,	O
+human	B-SPEC
+papillomavirus	I-SPEC
+,	O
+Marburg	O
+,	O
+and	O
+influenza	B-DISO
+are	O
+major	O
+public	O
+health	O
+concerns	O
+around	O
+the	O
+world	O
+.	O
+
+Secomet	O
+-	O
+V	O
+,	O
+therefore	O
+,	O
+is	O
+a	O
+broad	O
+-	O
+spectrum	O
+antiviral	B-CHED
+,	O
+which	O
+possibly	O
+works	O
+by	O
+neutralizing	O
+viral	O
+infectivity	O
+,	O
+resulting	O
+in	O
+the	O
+prevention	O
+of	O
+viral	O
+attachment	O
+.	O
+
+The	O
+anti	O
+-	O
+cytopathic	O
+activity	O
+of	O
+the	O
+pyridine	B-CHED
+N	I-CHED
+-	I-CHED
+oxide	I-CHED
+derivatives	O
+was	O
+monitored	O
+by	O
+spectrophotometric	O
+analysis	O
+.	O
+
+Additionally	O
+,	O
+three	O
+groups	O
+of	O
+rhesus	B-SPEC
+monkeys	I-SPEC
+were	O
+immunized	O
+with	O
+different	O
+doses	O
+of	O
+the	O
+purified	O
+inactivated	O
+SARS	B-DISO
+vaccine	O
+(	O
+0	O
+.	O
+5	O
+,	O
+1	O
+and	O
+2mug	O
+/	O
+time	O
+/	O
+monkey	B-SPEC
+)	O
+on	O
+days	O
+0	O
+and	O
+7	O
+,	O
+and	O
+the	O
+monkeys	B-SPEC
+were	O
+challenged	O
+with	O
+SARS	B-DISO
+-	O
+CoV	O
+GZ	O
+-	O
+01	O
+strain	O
+.	O
+
+CONCLUSIONS	O
+:	O
+mxA	B-PRGE
+promoter	I-PRGE
+-	I-PRGE
+88G	I-PRGE
+/	I-PRGE
+T	I-PRGE
+SNP	I-PRGE
+might	O
+be	O
+confered	O
+to	O
+host	B-COMP
+genetic	O
+susceptibility	O
+to	O
+SARS	B-DISO
+in	O
+Chinese	O
+Han	O
+population	O
+.	O
+
+TITLE	O
+:	O
+Safety	O
+of	O
+direct	O
+administration	O
+of	O
+AAV2	B-SPEC
+(	O
+CU	O
+)	O
+hCLN2	O
+,	O
+a	O
+candidate	O
+treatment	O
+for	O
+the	O
+central	B-ANAT
+nervous	B-DISO
+system	I-ANAT
+manifestations	O
+of	O
+late	B-DISO
+infantile	I-DISO
+neuronal	I-DISO
+ceroid	I-DISO
+lipofuscinosis	I-DISO
+,	O
+to	O
+the	O
+brain	B-ANAT
+of	O
+rats	B-SPEC
+and	O
+nonhuman	O
+primates	B-SPEC
+.	O
+
+Fischer	O
+344	O
+rats	B-SPEC
+were	O
+injected	O
+bilaterally	O
+via	O
+the	O
+striatum	B-ANAT
+with	O
+2	O
+x	O
+10	O
+(	O
+10	O
+)	O
+particle	O
+units	O
+(	O
+PU	O
+)	O
+of	O
+AAV2	B-SPEC
+(	O
+CU	O
+)	O
+hCLN2	O
+,	O
+using	O
+saline	O
+as	O
+a	O
+control	O
+.	O
+
+The	O
+present	O
+study	O
+was	O
+carried	O
+out	O
+to	O
+evaluate	O
+the	O
+performance	O
+of	O
+SARS	B-DISO
+resequencing	O
+GeneChips	O
+.	O
+
+The	O
+results	O
+of	O
+this	O
+study	O
+suggest	O
+that	O
+GeneChip	O
+-	O
+based	O
+genome	O
+characterization	O
+is	O
+fast	B-FUNC
+and	O
+reproducible	O
+.	O
+
+ABSTRACT	O
+:	O
+Patients	O
+with	O
+immunodeficiencies	B-DISO
+or	O
+some	O
+types	O
+of	O
+autoimmune	B-DISO
+diseases	I-DISO
+are	O
+dependent	O
+on	O
+safe	O
+therapy	O
+with	O
+intravenous	O
+immunoglobulins	O
+.	O
+
+The	O
+worst	O
+-	O
+case	O
+scenario	O
+would	O
+be	O
+the	O
+emergence	O
+of	O
+a	O
+transmissible	O
+,	O
+small	O
+,	O
+nonenveloped	O
+virus	O
+in	O
+the	O
+blood	B-ANAT
+donor	B-CHED
+population	O
+.	O
+
+Specific	O
+best	O
+-	O
+fit	B-DISO
+mediators	O
+or	O
+mediator	O
+pairs	O
+varied	O
+with	O
+aspirate	B-ANAT
+type	O
+,	O
+animal	B-SPEC
+type	O
+,	O
+and	O
+time	O
+of	O
+injury	O
+.	O
+
+Although	O
+introduced	O
+as	O
+weaning	B-PROC
+techniques	O
+,	O
+partial	O
+ventilator	O
+support	O
+modes	O
+have	O
+become	O
+standard	O
+techniques	O
+for	O
+primary	O
+mechanical	O
+ventilator	O
+support	O
+.	O
+
+Thus	O
+,	O
+spontaneous	O
+breathing	B-PROC
+during	O
+ventilator	O
+support	O
+counters	O
+the	O
+undesirable	O
+cyclic	O
+alveolar	B-ANAT
+collapse	B-DISO
+in	O
+dependent	O
+lung	B-ANAT
+regions	O
+.	O
+
+TITLE	O
+:	O
+Febrile	B-PROC
+respiratory	O
+illness	O
+in	O
+the	O
+intensive	O
+care	O
+unit	O
+setting	O
+:	O
+an	O
+infection	B-DISO
+control	O
+perspective	O
+.	O
+
+The	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+may	O
+be	O
+transmitted	B-DISO
+by	O
+the	O
+droplet	O
+,	O
+contact	O
+and	O
+occasionally	O
+the	O
+airborne	O
+route	O
+.	O
+
+Experimental	O
+studies	O
+have	O
+confirmed	O
+that	O
+distribution	B-PROC
+of	I-PROC
+ventilation	I-PROC
+was	O
+more	O
+homogeneous	O
+in	O
+the	O
+prone	O
+position	O
+but	O
+showed	O
+that	O
+positive	O
+end	B-PROC
+-	I-PROC
+expiratory	I-PROC
+pressure	O
+affected	O
+ventilation	O
+distribution	O
+differently	O
+in	O
+the	O
+prone	O
+and	O
+in	O
+the	O
+supine	O
+position	O
+.	O
+
+Another	O
+eight	O
+IBV	B-SPEC
+isolates	O
+clustered	O
+in	O
+genotype	O
+IV	O
+and	O
+showed	O
+larger	O
+evolutionary	O
+distances	O
+.	O
+
+Four	O
+Chinese	O
+IBV	O
+isolates	O
+formed	O
+another	O
+genotype	O
+and	O
+showed	O
+larger	O
+evolutionary	O
+distances	O
+from	O
+other	O
+Chinese	O
+IBV	B-SPEC
+genotypes	O
+(	O
+genotype	O
+VII	O
+).	O
+
+The	O
+results	O
+showed	O
+that	O
+IBVs	O
+in	O
+China	O
+came	O
+from	O
+genetic	O
+changes	O
+both	O
+in	O
+IBV	B-SPEC
+populations	O
+that	O
+existed	O
+before	O
+the	O
+advent	O
+of	O
+vaccination	O
+and	O
+in	O
+the	O
+viruses	B-SPEC
+that	O
+were	O
+introduced	O
+through	O
+live	O
+vaccines	O
+.	O
+
+TITLE	O
+:	O
+Novel	O
+five	O
+-	O
+membered	O
+iminocyclitol	O
+derivatives	O
+as	O
+selective	O
+and	O
+potent	O
+glycosidase	B-CHED
+inhibitors	I-CHED
+:	O
+new	O
+structures	O
+for	O
+antivirals	O
+and	O
+osteoarthritis	B-DISO
+.	O
+
+TITLE	O
+:	O
+[	O
+Systematic	O
+review	O
+and	O
+meta	B-SPEC
+-	O
+analysis	O
+on	O
+the	O
+integrative	O
+traditional	O
+Chinese	O
+and	O
+Western	O
+medicine	B-CHED
+in	O
+treating	O
+SARS	B-DISO
+].	O
+
+Electronic	O
+and	O
+manual	O
+searches	O
+was	O
+conducted	O
+to	O
+identify	O
+randomised	O
+controlled	O
+trials	O
+(	O
+RCTs	O
+)	O
+for	O
+comparing	O
+the	O
+effects	O
+of	O
+integrative	O
+traditional	O
+Chinese	O
+and	O
+Western	O
+medicine	B-CHED
+versus	O
+the	O
+effects	O
+of	O
+Western	O
+medicine	B-CHED
+alone	O
+in	O
+treating	O
+SARS	B-DISO
+.	O
+
+Results	O
+of	O
+Meta	B-SPEC
+-	O
+analysis	O
+showed	O
+that	O
+the	O
+integrative	O
+therapy	O
+could	O
+significantly	O
+reduce	O
+the	O
+mortality	O
+(	O
+relative	O
+risk	O
+0	O
+.	O
+32	O
+[	O
+95	O
+%	O
+CI	O
+0	O
+.	O
+12	O
+-	O
+0	O
+.	O
+91	O
+])	O
+and	O
+the	O
+occurrence	O
+of	O
+fungal	B-DISO
+infection	I-DISO
+in	O
+patients	O
+who	O
+received	O
+hormone	B-CHED
+(	O
+glucocorticoid	B-CHED
+)	O
+therapy	O
+(	O
+0	O
+.	O
+35	O
+:	O
+0	O
+.	O
+14	O
+-	O
+0	O
+.	O
+90	O
+),	O
+shorten	O
+the	O
+duration	O
+of	O
+fever	B-PROC
+(	O
+weighted	O
+mean	O
+difference	O
+-	O
+0	O
+.	O
+83	O
+day	O
+;	O
+-	O
+1	O
+.	O
+30	O
+-	O
+-	O
+0	O
+.	O
+35	O
+)	O
+and	O
+symptom	B-DISO
+relieving	O
+time	O
+(-	O
+1	O
+.	O
+23	O
+;	O
+-	O
+2	O
+.	O
+09	O
+-	O
+-	O
+0	O
+.	O
+37	O
+),	O
+reduce	O
+the	O
+persistent	O
+time	O
+of	O
+chest	B-ANAT
+radiograph	O
+abnormalities	O
+(-	O
+2	O
+.	O
+61	O
+;	O
+-	O
+3	O
+.	O
+74	O
+-	O
+-	O
+1	O
+.	O
+49	O
+).	O
+
+ZCURVE_V	O
+is	O
+also	O
+used	O
+to	O
+analyze	O
+well	O
+-	O
+studied	O
+genomes	O
+,	O
+such	O
+as	O
+HIV	B-SPEC
+-	I-SPEC
+1	I-SPEC
+,	O
+HBV	B-DISO
+and	O
+SARS	B-DISO
+-	O
+CoV	O
+.	O
+Accordingly	O
+,	O
+the	O
+performance	O
+of	O
+ZCURVE_V	O
+is	O
+generally	O
+better	O
+than	O
+that	O
+of	O
+GeneMark	O
+.	O
+
+ABSTRACT	O
+:	O
+Sixteen	O
+infectious	O
+bronchitis	B-DISO
+virus	B-SPEC
+(	O
+IBV	B-SPEC
+)	O
+isolates	O
+were	O
+recovered	O
+from	O
+broilers	O
+and	O
+layers	B-ANAT
+from	O
+five	O
+geographic	O
+poultry	O
+regions	O
+in	O
+Colombia	O
+.	O
+
+ABSTRACT	O
+:	O
+Vaccination	O
+against	O
+infectious	B-DISO
+bronchitis	B-DISO
+(	O
+IB	B-DISO
+)	O
+is	O
+aimed	O
+to	O
+protect	O
+against	O
+clinical	O
+IB	B-DISO
+.	O
+
+The	O
+question	O
+is	O
+,	O
+however	O
+,	O
+whether	O
+vaccinated	O
+birds	B-SPEC
+are	O
+also	O
+protected	O
+against	O
+predisposure	O
+for	O
+colibacillosis	B-DISO
+after	O
+a	O
+subsequent	O
+IBV	B-SPEC
+infection	B-DISO
+.	O
+
+Using	O
+that	O
+test	O
+at	O
+the	O
+Poultry	O
+Diagnostic	O
+and	O
+Research	O
+Center	O
+(	O
+PDRC	O
+,	O
+University	O
+of	O
+Georgia	O
+,	O
+Athens	O
+,	O
+GA	O
+),	O
+we	O
+have	O
+identified	O
+a	O
+total	O
+of	O
+1523	O
+IBV	B-SPEC
+isolates	O
+in	O
+the	O
+past	O
+11	O
+yr	O
+.	O
+
+By	O
+far	O
+,	O
+the	O
+Ark	B-PRGE
+-	I-PRGE
+DPI	I-PRGE
+strain	O
+was	O
+the	O
+most	O
+frequently	O
+identified	O
+type	O
+of	O
+IBV	B-SPEC
+and	O
+ranged	O
+from	O
+23	O
+%	O
+to	O
+65	O
+%	O
+of	O
+total	O
+isolations	O
+per	O
+year	O
+.	O
+
+The	O
+Florida	O
+,	O
+Gray	O
+,	O
+Holte	O
+,	O
+Iowa	O
+,	O
+and	O
+JMK	O
+types	O
+were	O
+not	O
+detected	O
+during	O
+the	O
+11	O
+-	O
+yr	O
+period	O
+,	O
+and	O
+no	O
+foreign	O
+virus	B-SPEC
+types	O
+were	O
+detected	O
+in	O
+the	O
+United	O
+States	O
+.	O
+
+Thus	O
+,	O
+the	O
+main	O
+problem	O
+in	O
+acute	B-DISO
+pancreatitis	I-DISO
+,	O
+especially	O
+in	O
+the	O
+severe	O
+form	O
+of	O
+the	O
+disease	O
+,	O
+is	O
+the	O
+difficulty	O
+of	O
+planning	O
+clinical	O
+studies	O
+capable	O
+of	O
+giving	O
+hard	O
+statistically	O
+significant	O
+answers	O
+regarding	O
+the	O
+benefits	O
+of	O
+the	O
+various	O
+proposed	O
+therapeutic	O
+agents	O
+previously	O
+tested	O
+in	O
+experimental	O
+settings	O
+.	O
+
+Another	O
+great	O
+problem	O
+is	O
+prevention	O
+of	O
+the	O
+infection	B-DISO
+of	O
+pancreatic	B-DISO
+necrosis	B-PROC
+.	O
+
+A	O
+study	O
+named	O
+PROPATRIA	O
+(	O
+Probiotic	O
+Prophylaxis	O
+in	O
+Patients	O
+with	O
+Predicted	O
+Severe	O
+Acute	B-DISO
+Pancreatitis	I-DISO
+)	O
+has	O
+been	O
+planned	O
+to	O
+give	O
+a	O
+more	O
+robust	O
+confirmation	O
+to	O
+the	O
+previous	O
+study	O
+.	O
+
+TITLE	O
+:	O
+[	O
+Ultrastructural	O
+changes	O
+in	O
+the	O
+cells	B-COMP
+of	O
+human	B-ANAT
+embryo	I-ANAT
+lung	B-ANAT
+fibroblasts	B-ANAT
+in	O
+the	O
+reproduction	B-PROC
+of	O
+the	O
+coronavirus	O
+HCoV	O
+/	O
+SPb	B-COMP
+/	O
+01	O
+/	O
+03	O
+].	O
+
+These	O
+data	O
+suggest	O
+that	O
+some	O
+coronaviruses	O
+,	O
+including	O
+HCoV	B-SPEC
+-	I-SPEC
+OC43	I-SPEC
+and	O
+SARS	B-PRGE
+-	I-PRGE
+CoV	I-PRGE
+,	O
+readily	O
+adapt	O
+to	O
+growth	B-PROC
+in	O
+cells	B-COMP
+from	O
+heterologous	O
+species	B-SPEC
+.	O
+
+Infection	B-DISO
+is	O
+usually	O
+initiated	O
+after	O
+inhalation	B-PROC
+of	O
+rodent	B-SPEC
+excreta	O
+containing	O
+virus	B-COMP
+particles	I-COMP
+,	O
+but	O
+human	B-SPEC
+-	O
+to	O
+-	O
+human	B-SPEC
+transmission	O
+has	O
+been	O
+documented	O
+.	O
+
+Our	O
+data	O
+suggest	O
+that	O
+hantavirus	B-DISO
+infection	I-DISO
+of	O
+the	O
+respiratory	B-ANAT
+epithelium	I-ANAT
+may	O
+play	O
+an	O
+important	O
+role	O
+in	O
+the	O
+early	O
+or	O
+prodrome	B-DISO
+phase	O
+of	O
+disease	O
+as	O
+well	O
+as	O
+serving	O
+as	O
+a	O
+source	O
+of	O
+virus	B-SPEC
+involved	O
+in	O
+transmission	O
+.	O
+
+However	O
+,	O
+the	O
+C1347F	O
+/	O
+C1348S	O
+mutant	B-DISO
+viruses	B-SPEC
+exhibited	O
+relatively	O
+low	O
+specific	O
+infectivities	O
+,	O
+similar	O
+to	O
+virions	B-COMP
+secreted	B-PROC
+from	O
+2	O
+-	O
+BP	O
+-	O
+treated	O
+cultures	O
+.	O
+
+Our	O
+collective	O
+results	O
+indicate	O
+that	O
+the	O
+palmitate	B-CHED
+adducts	O
+on	O
+coronavirus	B-SPEC
+S	O
+proteins	B-CHED
+are	O
+necessary	O
+in	O
+assembly	O
+and	O
+also	O
+in	O
+positioning	O
+the	O
+assembled	B-PRGE
+envelope	I-PRGE
+proteins	B-CHED
+for	O
+maximal	O
+infectivity	O
+.	O
+
+Examination	O
+of	O
+the	O
+oligomeric	O
+state	O
+of	O
+the	O
+chimeric	O
+S	O
+proteins	B-CHED
+in	O
+SARSpp	O
+revealed	O
+that	O
+S	O
+(	O
+VSV	O
+-	O
+TMDCyt	O
+)	O
+trimers	O
+were	O
+less	O
+stable	O
+than	O
+wild	O
+-	O
+type	O
+S	O
+trimers	O
+,	O
+possibly	O
+explaining	O
+the	O
+lowered	O
+fusogenicity	O
+and	O
+infectivity	O
+.	O
+
+Despite	O
+T	B-ANAT
+-	I-ANAT
+cell	I-ANAT
+-	O
+mediated	O
+control	O
+of	O
+acute	O
+virus	B-DISO
+infection	I-DISO
+,	O
+host	B-COMP
+regulatory	O
+mechanisms	O
+,	O
+probably	O
+designed	O
+to	O
+protect	O
+CNS	B-CHED
+integrity	O
+,	O
+contribute	O
+to	O
+the	O
+failure	O
+to	O
+eliminate	O
+virus	B-SPEC
+.	O
+
+The	O
+two	O
+recombinant	O
+proteins	B-CHED
+were	O
+separately	O
+verified	O
+by	O
+Western	O
+blot	O
+,	O
+purified	O
+by	O
+nickel	B-CHED
+-	O
+affinity	O
+chromatography	O
+,	O
+and	O
+incubated	O
+with	O
+Vero	B-ANAT
+cells	I-ANAT
+,	O
+a	O
+susceptible	O
+cell	B-ANAT
+line	I-ANAT
+of	O
+SARS	B-DISO
+-	I-DISO
+CoV	I-DISO
+infection	I-DISO
+,	O
+for	O
+cell	B-COMP
+binding	B-FUNC
+assay	O
+.	O
+
+Thus	O
+,	O
+lithium	B-CHED
+intoxication	O
+is	O
+a	O
+frequent	O
+complication	B-DISO
+of	O
+chronic	O
+lithium	B-CHED
+therapy	O
+.	O
+
+A	O
+diagnosis	O
+of	O
+severe	O
+lithium	B-CHED
+toxicity	O
+was	O
+made	O
+and	O
+the	O
+patient	O
+was	O
+admitted	O
+to	O
+the	O
+telemetry	O
+unit	O
+.	O
+
+One	O
+hundred	O
+ninety	O
+-	O
+seven	O
+children	O
+,	O
+aged	O
+4	O
+to	O
+8	O
+years	O
+,	O
+and	O
+their	O
+parents	O
+were	O
+recruited	O
+from	O
+the	O
+pediatric	O
+emergency	B-DISO
+department	O
+of	O
+a	O
+tertiary	O
+care	O
+center	O
+.	O
+
+Two	O
+sets	O
+of	O
+4	O
+photographs	O
+-	O
+the	O
+same	O
+man	B-CHED
+in	O
+formal	B-CHED
+attire	O
+,	O
+a	O
+white	O
+coat	B-ANAT
+,	O
+greens	O
+,	O
+and	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+(	O
+SARS	B-DISO
+)	O
+standard	O
+precautions	O
+attire	O
+,	O
+and	O
+the	O
+same	O
+woman	O
+in	O
+formal	B-CHED
+attire	O
+,	O
+a	O
+white	O
+coat	B-ANAT
+,	O
+greens	O
+,	O
+and	O
+SARS	B-DISO
+standard	O
+precautions	O
+attire	O
+-	O
+were	O
+shown	O
+to	O
+the	O
+children	O
+and	O
+their	O
+caregiver	O
+.	O
+
+The	O
+children	O
+selected	O
+the	O
+physician	O
+in	O
+SARS	B-DISO
+standard	O
+precautions	O
+attire	O
+as	O
+most	O
+liked	O
+17	O
+.	O
+5	O
+%	O
+of	O
+the	O
+time	O
+and	O
+least	O
+liked	O
+53	O
+.	O
+3	O
+%	O
+of	O
+the	O
+time	O
+.	O
+
+Physicians	O
+wearing	O
+standard	O
+precautions	O
+attire	O
+while	O
+working	O
+in	O
+the	O
+pediatric	O
+emergency	B-DISO
+department	O
+need	O
+to	O
+be	O
+aware	O
+that	O
+this	O
+attire	O
+may	O
+negatively	O
+impact	O
+their	O
+relationship	O
+with	O
+pediatric	O
+patients	O
+4	O
+to	O
+8	O
+years	O
+of	O
+age	O
+.	O
+
+Coinfections	B-DISO
+and	O
+sequential	O
+infections	B-DISO
+by	O
+HCMV	O
+and	O
+respiratory	O
+viruses	B-SPEC
+were	O
+significantly	O
+more	O
+frequent	O
+in	O
+patients	O
+with	O
+acute	O
+rejection	O
+and	O
+steroid	B-CHED
+treatment	O
+.	O
+
+TITLE	O
+:	O
+When	O
+is	O
+quarantine	O
+a	O
+useful	O
+control	O
+strategy	O
+for	O
+emerging	B-DISO
+infectious	I-DISO
+diseases	I-DISO
+?	O
+
+TITLE	O
+:	O
+Viral	B-DISO
+pneumonia	I-DISO
+in	O
+older	O
+adults	O
+.	O
+
+Presently	O
+,	O
+influenza	B-SPEC
+virus	I-SPEC
+A	O
+H3N2	B-CHED
+and	O
+respiratory	B-SPEC
+syncytial	I-SPEC
+virus	I-SPEC
+are	O
+the	O
+most	O
+commonly	O
+identified	O
+viral	O
+pathogens	O
+in	O
+older	O
+adults	O
+with	O
+viral	B-DISO
+pneumonia	I-DISO
+.	O
+
+TITLE	O
+:	O
+The	O
+effect	O
+of	O
+fostering	O
+on	O
+the	O
+genetic	O
+expression	B-PROC
+of	O
+locomotor	O
+sensitivity	O
+to	O
+alcohol	O
+.	O
+
+At	O
+approximately	O
+50	O
+days	O
+of	O
+age	O
+,	O
+the	O
+offspring	O
+were	O
+tested	O
+for	O
+locomotor	O
+behavior	O
+after	O
+intraperitoneal	O
+administration	O
+of	O
+ethanol	B-CHED
+or	O
+normal	O
+saline	O
+.	O
+
+There	O
+were	O
+no	O
+statistically	O
+significant	O
+effects	O
+of	O
+embryo	O
+transfer	O
+on	O
+the	O
+ethanol	B-CHED
+phenotype	O
+(	O
+ethanol	B-CHED
+-	O
+induced	O
+locomotor	O
+depression	B-DISO
+).	O
+
+ABSTRACT	O
+:	O
+Severe	O
+acute	O
+respiratory	O
+syndrome	O
+(	O
+SARS	B-DISO
+)	O
+is	O
+a	O
+newly	O
+discovered	O
+disease	O
+caused	O
+by	O
+a	O
+novel	B-SPEC
+coronavirus	I-SPEC
+.	O
+
+The	O
+present	O
+study	O
+studied	O
+the	O
+longitudinal	O
+profile	O
+of	O
+antibodies	B-COMP
+against	O
+SARS	B-DISO
+-	O
+coronavirus	B-SPEC
+(	O
+SARS	B-DISO
+-	O
+CoV	O
+)	O
+in	O
+SARS	B-DISO
+patients	O
+and	O
+evaluated	O
+the	O
+clinical	O
+significance	O
+of	O
+these	O
+antibodies	B-COMP
+.	O
+
+In	O
+18	O
+patients	O
+,	O
+serum	B-COMP
+antibody	B-COMP
+profiles	O
+were	O
+investigated	O
+and	O
+antibody	B-COMP
+neutralization	O
+tests	O
+were	O
+performed	O
+from	O
+7	O
+to	O
+720	O
+days	O
+after	O
+the	O
+onset	O
+of	O
+symptoms	O
+.	O
+
+Moreover	O
+,	O
+in	O
+order	B-SPEC
+to	O
+get	O
+the	O
+antigen	B-CHED
+for	O
+ELISA	O
+and	O
+in	O
+vitro	O
+stimulation	O
+assay	O
+,	O
+N	B-PRGE
+protein	I-PRGE
+were	O
+expressed	B-PROC
+and	O
+purified	O
+from	O
+E	B-SPEC
+.	I-SPEC
+coli	I-SPEC
+bacteria	B-SPEC
+.	O
+
+Using	O
+surface	O
+-	O
+enhanced	O
+laser	B-SPEC
+desorption	O
+/	O
+ionization	O
+(	O
+SELDI	O
+)	O
+ProteinChip	O
+technology	O
+,	O
+we	O
+profiled	O
+and	O
+compared	O
+serum	B-COMP
+proteins	B-CHED
+of	O
+39	O
+patients	O
+with	O
+early	O
+-	O
+stage	O
+SARS	B-DISO
+infection	B-DISO
+and	O
+39	O
+non	O
+-	O
+SARS	B-DISO
+patients	O
+who	O
+were	O
+suspected	O
+cases	O
+during	O
+the	O
+SARS	B-DISO
+outbreak	O
+period	O
+.	O
+
+Immunoglobulin	B-PRGE
+kappa	I-PRGE
+light	I-PRGE
+chain	I-PRGE
+(	O
+m	O
+/	O
+z	O
+24	O
+505	O
+)	O
+positively	O
+correlated	O
+with	O
+viral	O
+load	O
+.	O
+
+SD	O
+)	O
+of	O
+RNA	O
+per	O
+milliliter	O
+in	O
+the	O
+NPS	B-DISO
+and	O
+had	O
+detectable	O
+anti	B-PRGE
+-	I-PRGE
+SARS	I-PRGE
+antibodies	B-COMP
+.	O
+
+227	O
+copies	O
+of	O
+RNA	O
+per	O
+milliliter	O
+;	O
+antibodies	B-COMP
+developed	O
+in	O
+none	O
+of	O
+these	O
+25	O
+HCWs	O
+.	O
+
+TITLE	O
+:	O
+Underuse	O
+of	O
+lung	B-ANAT
+protective	O
+ventilation	O
+:	O
+analysis	O
+of	O
+potential	O
+factors	O
+to	O
+explain	O
+physician	O
+behavior	O
+.	O
+
+After	O
+the	O
+one	O
+-	O
+day	O
+group	O
+debriefing	O
+,	O
+participants	O
+showed	O
+significant	O
+decrease	O
+in	O
+depression	O
+level	O
+,	O
+as	O
+measured	O
+by	O
+Brief	O
+Symptom	B-DISO
+Inventory	O
+(	O
+Derogatis	O
+&	O
+Melisaratos	O
+,	O
+1983	O
+,	O
+Psychological	B-DISO
+Medicine	B-CHED
+,	O
+13	O
+(	O
+3	O
+),	O
+595	O
+-	O
+605	O
+)	O
+and	O
+changes	O
+in	O
+cognitive	O
+appraisal	O
+towards	O
+SARS	B-DISO
+.	O
+
+Delivery	O
+of	O
+a	O
+vaccine	O
+to	O
+a	O
+mucosal	B-ANAT
+surface	O
+optimizes	O
+the	O
+induction	O
+of	O
+mucosal	B-PROC
+immunity	I-PROC
+.	O
+
+Molecular	O
+approaches	O
+can	O
+serve	O
+to	O
+boost	O
+expression	B-PROC
+levels	O
+and	O
+target	O
+the	O
+expressed	B-PROC
+protein	B-CHED
+for	O
+appropriate	O
+post	B-PROC
+-	I-PROC
+translational	I-PROC
+modification	I-PROC
+.	O
+
+The	O
+ectodomain	O
+-	O
+specific	O
+antibodies	B-COMP
+from	O
+the	O
+convalescent	O
+-	O
+phase	O
+plasma	B-ANAT
+readily	O
+recognized	O
+and	O
+induced	O
+destruction	O
+of	O
+3a	O
+-	O
+expressing	O
+cells	B-COMP
+in	O
+the	O
+presence	O
+of	O
+the	O
+human	B-PRGE
+complement	I-PRGE
+system	I-PRGE
+,	O
+demonstrating	O
+their	O
+potential	O
+ability	O
+to	O
+provide	O
+immune	O
+protection	O
+by	O
+recognizing	O
+and	O
+eliminating	O
+SARS	B-DISO
+coronavirus	B-SPEC
+-	O
+infected	O
+cells	B-COMP
+that	O
+express	O
+the	O
+target	O
+protein	B-CHED
+.	O
+
+These	O
+results	O
+showed	O
+that	O
+the	O
+N	O
+terminus	O
+of	O
+the	O
+3a	O
+protein	B-CHED
+is	O
+highly	O
+immunogenic	O
+and	O
+elicits	O
+potentially	O
+protective	O
+humoral	O
+responses	O
+in	O
+infected	O
+patients	O
+.	O
+
+It	O
+is	O
+now	O
+believed	O
+that	O
+the	O
+availability	O
+of	O
+antiviral	B-CHED
+drugs	I-CHED
+effective	O
+against	O
+SARS	B-PRGE
+-	I-PRGE
+CoV	I-PRGE
+will	O
+be	O
+crucial	O
+for	O
+the	O
+control	O
+of	O
+future	O
+SARS	B-DISO
+outbreaks	O
+.	O
+
+Recently	O
+,	O
+RNA	B-PROC
+interference	I-PROC
+has	O
+been	O
+successfully	O
+used	O
+as	O
+a	O
+more	O
+specific	O
+and	O
+efficient	O
+method	O
+for	O
+gene	B-PROC
+silencing	I-PROC
+.	O
+
+This	O
+review	O
+provides	O
+an	O
+overview	O
+of	O
+current	O
+information	O
+on	O
+coronavirus	B-SPEC
+and	O
+the	O
+application	O
+of	O
+small	O
+interfering	O
+RNA	O
+in	O
+viral	O
+therapeutics	O
+,	O
+with	O
+particular	O
+reference	O
+to	O
+SARS	B-DISO
+-	O
+CoV	O
+.	O
+
+TITLE	O
+:	O
+Intubation	O
+of	O
+SARS	B-DISO
+patients	O
+:	O
+infection	B-DISO
+and	O
+perspectives	O
+of	O
+healthcare	O
+workers	O
+.	O
+
+Nine	O
+percent	O
+of	O
+the	O
+interviewed	O
+HCWs	O
+who	O
+intubated	O
+patients	O
+contracted	O
+SARS	B-DISO
+.	O
+
+However	O
+,	O
+it	O
+should	O
+not	O
+be	O
+forgotten	O
+that	O
+a	O
+radiograph	O
+is	O
+2	O
+-	O
+dimensional	O
+and	O
+a	O
+single	O
+image	O
+of	O
+a	O
+catheter	O
+tip	O
+can	O
+correspond	O
+to	O
+a	O
+variety	O
+of	O
+locations	O
+(	O
+superior	O
+vena	O
+cava	O
+,	O
+vena	B-ANAT
+innominata	O
+,	O
+extravascular	O
+location	O
+,	O
+and	O
+more	O
+).	O
+
+To	O
+evaluate	O
+the	O
+possible	O
+effectiveness	O
+and	O
+safety	O
+of	O
+Chinese	O
+herbs	O
+combined	O
+with	O
+Western	O
+medicines	O
+versus	O
+Western	O
+medicines	O
+alone	O
+for	O
+SARS	B-DISO
+patients	O
+.	O
+
+Four	O
+herbs	O
+may	O
+decrease	O
+the	O
+dosage	O
+of	O
+corticosteroids	B-CHED
+.	O
+
+It	O
+is	O
+possible	O
+that	O
+Chinese	O
+herbs	O
+combined	O
+with	O
+Western	O
+medicines	O
+may	O
+improve	O
+symptoms	O
+,	O
+quality	O
+of	O
+life	O
+,	O
+and	O
+lung	B-ANAT
+infiltrate	B-DISO
+absorption	O
+and	O
+decrease	O
+the	O
+corticosteroid	B-CHED
+dosage	O
+for	O
+SARS	B-DISO
+patients	O
+.	O
+
+Irrespective	O
+of	O
+Ag	O
+deprivation	O
+,	O
+CNS	B-CHED
+retention	B-PROC
+of	O
+ASC	O
+coincided	O
+with	O
+elevated	O
+BAFF	O
+expression	B-PROC
+and	O
+ongoing	O
+differentiation	B-PROC
+of	O
+class	B-SPEC
+II	O
++	O
+to	O
+class	B-PRGE
+II	I-PRGE
+-	I-PRGE
+CD138	I-PRGE
++	I-PRGE
+CD19	I-PRGE
++	I-PRGE
+plasmablasts	I-PRGE
+.	O
+
+TITLE	O
+:	O
+Fibrinogen	B-ANAT
+-	I-PRGE
+like	I-PRGE
+protein	B-CHED
+2	I-PRGE
+fibroleukin	I-PRGE
+expression	B-PROC
+and	O
+its	O
+correlation	O
+with	O
+disease	B-DISO
+progression	I-DISO
+in	O
+murine	B-DISO
+hepatitis	I-DISO
+virus	B-SPEC
+type	O
+3	O
+-	O
+induced	O
+fulminant	B-DISO
+hepatitis	I-DISO
+and	O
+in	O
+patients	O
+with	O
+severe	O
+viral	B-DISO
+hepatitis	I-DISO
+B	I-DISO
+.	O
+ABSTRACT	O
+:	O
+To	O
+evaluate	O
+the	O
+expression	B-PROC
+of	O
+fibrinogen	B-PRGE
+-	I-PRGE
+like	I-PRGE
+protein	B-CHED
+2	I-PRGE
+(	O
+fgl2	B-PRGE
+)	O
+and	O
+its	O
+correlation	O
+with	O
+disease	B-DISO
+progression	I-DISO
+in	O
+both	O
+mice	B-SPEC
+and	O
+patients	O
+with	O
+severe	O
+viral	B-DISO
+hepatitis	I-DISO
+.	O
+
+We	O
+investigated	O
+the	O
+immunomodulating	O
+effects	O
+of	O
+an	O
+innovative	O
+TCM	O
+regimen	O
+derived	O
+from	O
+two	O
+herbal	O
+formulas	O
+(	O
+Sang	O
+Ju	O
+Yin	O
+and	O
+Yu	B-PRGE
+Ping	I-PRGE
+Feng	I-PRGE
+San	I-PRGE
+)	O
+for	O
+treating	O
+febrile	B-PROC
+diseases	O
+.	O
+
+Two	O
+volunteers	O
+withdrew	O
+on	O
+day	O
+2	O
+,	O
+due	O
+to	O
+headache	B-DISO
+and	O
+dizziness	B-DISO
+.	O
+
+Among	O
+five	O
+medicinal	O
+herbs	O
+prescribed	O
+in	O
+that	O
+formula	O
+,	O
+Herba	O
+Patriniae	O
+,	O
+Radix	B-SPEC
+Astragali	O
+and	O
+Radix	B-SPEC
+Glycyrrhizae	O
+played	O
+important	O
+roles	O
+.	O
+
+ABSTRACT	O
+:	O
+The	O
+immediate	O
+and	O
+long	O
+-	O
+term	O
+impact	O
+of	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+(	O
+SARS	B-DISO
+)	O
+outbreak	O
+on	O
+emergency	B-DISO
+department	O
+(	O
+ED	O
+)	O
+visits	O
+and	O
+hospital	O
+expenditures	O
+for	O
+these	O
+visits	O
+has	O
+not	O
+been	O
+thoroughly	O
+investigated	O
+.	O
+
+Common	O
+laboratory	O
+features	O
+included	O
+lymphopenia	B-DISO
+and	O
+elevated	O
+aspartate	B-PRGE
+aminotransferase	I-PRGE
+,	O
+alanine	B-PRGE
+aminotransferase	I-PRGE
+,	O
+lactate	B-PRGE
+dehydrogenase	I-PRGE
+,	O
+C	B-PRGE
+-	I-PRGE
+reactive	I-PRGE
+protein	I-PRGE
+and	O
+creatine	B-PRGE
+kinase	I-PRGE
+values	O
+.	O
+
+A	O
+scoring	O
+system	O
+which	O
+was	O
+developed	O
+to	O
+differentiate	O
+SARS	B-DISO
+patients	O
+from	O
+other	O
+febrile	B-PROC
+patients	O
+in	O
+the	O
+emergency	B-DISO
+room	O
+could	O
+differentiate	O
+probable	O
+cases	O
+from	O
+excluded	O
+cases	O
+with	O
+a	O
+sensitivity	O
+of	O
+36	O
+.	O
+4	O
+%	O
+and	O
+a	O
+specificity	O
+of	O
+70	O
+.	O
+6	O
+%.	O
+
+A	O
+major	O
+problem	O
+in	O
+the	O
+development	B-PROC
+of	O
+effective	O
+therapeutic	O
+agents	O
+against	O
+viruses	B-SPEC
+,	O
+including	O
+therapeutic	O
+antibodies	B-COMP
+,	O
+is	O
+the	O
+viruses	B-SPEC
+'	O
+heterogeneity	O
+and	O
+mutability	O
+.	O
+
+ABSTRACT	O
+:	O
+During	O
+the	O
+2003	O
+severe	O
+acute	O
+respiratory	O
+distress	O
+syndrome	O
+epidemic	O
+,	O
+healthcare	O
+workers	O
+mandatorily	O
+wore	O
+the	O
+protective	O
+N95	O
+face	B-DISO
+-	O
+mask	O
+.	O
+
+ABSTRACT	O
+:	O
+Acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+(	O
+ARDS	B-DISO
+)	O
+caused	O
+by	O
+pneumonia	B-DISO
+after	O
+renal	B-ANAT
+transplantation	O
+was	O
+usually	O
+associated	O
+with	O
+overimmunosuppression	O
+and	O
+high	O
+mortality	O
+rate	O
+.	O
+
+Immunosuppressants	O
+were	O
+adjusted	O
+according	O
+to	O
+the	O
+value	O
+of	O
+CD4	B-PRGE
++,	I-PRGE
+CD8	B-ANAT
++	I-ANAT
+T	I-ANAT
+lymphocytes	I-ANAT
+in	O
+peripheral	B-ANAT
+blood	I-ANAT
+.	O
+
+TITLE	O
+:	O
+Characterization	O
+of	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+coronavirus	B-SPEC
+membrane	B-COMP
+protein	B-CHED
+.	O
+
+Using	O
+a	O
+newly	O
+established	O
+human	B-PRGE
+monoclonal	I-PRGE
+anti	I-PRGE
+-	I-PRGE
+M	I-PRGE
+antibody	B-COMP
+we	O
+detected	O
+glycosylated	O
+and	O
+nonglycosylated	O
+membrane	B-COMP
+-	O
+associated	O
+M	O
+in	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+-	O
+associated	O
+coronavirus	B-SPEC
+(	O
+SARS	B-DISO
+-	O
+CoV	O
+)	O
+infected	O
+cells	B-COMP
+and	O
+in	O
+purified	O
+virions	B-COMP
+.	O
+
+Recombinant	O
+M	O
+was	O
+transported	O
+to	O
+the	O
+plasma	B-COMP
+membrane	I-COMP
+and	O
+gained	O
+complex	O
+-	O
+type	O
+N	O
+-	O
+glycosylation	B-PROC
+.	O
+
+ABSTRACT	O
+:	O
+New	O
+pathogens	O
+and	O
+antimicrobial	B-CHED
+-	O
+resistant	O
+forms	O
+of	O
+older	O
+pathogens	O
+continue	O
+to	O
+emerge	O
+,	O
+some	O
+with	O
+the	O
+potential	O
+for	O
+rapid	O
+,	O
+global	O
+spread	O
+and	O
+high	O
+morbidity	O
+and	O
+mortality	O
+.	O
+
+To	O
+the	O
+best	O
+of	O
+our	O
+knowledge	O
+,	O
+there	O
+is	O
+no	O
+other	O
+report	O
+to	O
+date	O
+about	O
+the	O
+detection	O
+of	O
+this	O
+new	O
+virus	B-SPEC
+.	O
+
+HCoV	O
+-	O
+HKU1	O
+was	O
+detected	O
+in	O
+6	O
+(	O
+4	O
+.	O
+4	O
+%)	O
+of	O
+the	O
+135	O
+nasal	B-ANAT
+specimens	O
+and	O
+in	O
+2	O
+(	O
+33	O
+.	O
+3	O
+%)	O
+of	O
+the	O
+6	O
+stool	B-ANAT
+samples	O
+;	O
+the	O
+positive	O
+samples	O
+were	O
+obtained	O
+from	O
+6	O
+patients	O
+(	O
+5	O
+children	O
+and	O
+1	O
+adult	O
+).	O
+
+HCoV	O
+-	O
+HKU1	O
+can	O
+be	O
+detected	O
+in	O
+respiratory	O
+and	O
+stool	B-ANAT
+samples	O
+from	O
+children	O
+and	O
+adults	O
+in	O
+a	O
+part	O
+of	O
+the	O
+world	O
+other	O
+than	O
+Hong	O
+Kong	O
+.	O
+
+The	O
+clinical	O
+presentation	O
+of	O
+these	O
+6	O
+patients	O
+was	O
+as	O
+follows	O
+:	O
+3	O
+were	O
+admitted	O
+to	O
+the	O
+hospital	O
+for	O
+acute	O
+enteric	O
+disease	O
+resulting	O
+in	O
+severe	B-DISO
+dehydration	I-DISO
+associated	O
+with	O
+upper	O
+respiratory	B-DISO
+symptoms	I-DISO
+;	O
+1	O
+had	O
+fever	B-PROC
+,	O
+otitis	B-DISO
+,	O
+and	O
+febrile	B-DISO
+seizure	I-DISO
+;	O
+1	O
+had	O
+a	O
+sample	O
+obtained	O
+to	O
+investigate	O
+failure	B-DISO
+to	I-DISO
+thrive	I-DISO
+;	O
+and	O
+1	O
+had	O
+a	O
+sample	O
+obtained	O
+for	O
+exploration	O
+of	O
+X	B-DISO
+-	I-DISO
+linked	I-DISO
+agammaglobulinemia	I-DISO
+and	O
+hyperleucocytosis	O
+.	O
+
+The	O
+aim	O
+of	O
+the	O
+work	O
+reported	O
+here	O
+was	O
+to	O
+develop	O
+a	O
+rapid	O
+and	O
+sensitive	O
+method	O
+for	O
+typing	O
+isolates	O
+of	O
+IBV	B-SPEC
+,	O
+if	O
+possible	O
+directly	O
+from	O
+tissues	B-ANAT
+of	O
+infected	O
+birds	B-SPEC
+.	O
+
+Absolute	O
+and	O
+mass	O
+related	O
+peak	O
+V	O
+o	O
+(	O
+2	O
+)	O
+in	O
+the	O
+patient	O
+group	O
+remained	O
+impaired	B-DISO
+at	O
+15	O
+months	O
+despite	O
+normalisation	O
+of	O
+lung	B-PROC
+function	I-PROC
+in	O
+all	O
+patients	O
+.	O
+
+From	O
+a	O
+total	O
+of	O
+61	O
+healthy	O
+fox	O
+feces	B-ANAT
+,	O
+43	O
+were	O
+positive	O
+for	O
+type	O
+II	O
+and	O
+29	O
+for	O
+type	O
+I	O
+CCV	B-DISO
+,	O
+out	O
+of	O
+which	O
+25	O
+were	O
+simultaneously	O
+positive	O
+for	O
+the	O
+two	O
+different	O
+genotypes	O
+.	O
+
+ABSTRACT	O
+:	O
+A	O
+practical	O
+and	O
+convenient	O
+methodology	O
+for	O
+the	O
+synthesis	B-PROC
+of	O
+chiral	O
+cyclopentenol	O
+derivative	O
+(+)-	O
+12a	O
+has	O
+been	O
+developed	O
+as	O
+the	O
+key	O
+intermediate	O
+that	O
+was	O
+utilized	O
+for	O
+the	O
+synthesis	B-PROC
+of	O
+biologically	O
+active	O
+carbocyclic	O
+nucleosides	B-CHED
+.	O
+
+We	O
+assessed	O
+the	O
+changes	O
+in	O
+respiratory	B-PROC
+mechanics	I-PROC
+and	O
+gas	B-ENZY
+exchange	O
+during	O
+ARDS	B-DISO
+.	O
+
+Cardiovascular	B-ANAT
+profiles	O
+remained	O
+stable	O
+in	O
+both	O
+groups	O
+.	O
+
+Recently	O
+,	O
+a	O
+patient	O
+who	O
+inhaled	B-PROC
+CHX	O
+solution	O
+died	B-PROC
+from	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+(	O
+ARDS	B-DISO
+).	O
+
+The	O
+odds	O
+ratio	O
+for	O
+contracting	O
+a	O
+SARS	B-DISO
+-	I-DISO
+CoV	I-DISO
+infection	I-DISO
+among	O
+persons	O
+with	O
+either	O
+a	O
+homozygous	O
+or	O
+a	O
+heterozygous	O
+Cw	O
+*	O
+0801	O
+genotype	O
+was	O
+4	O
+.	O
+4	O
+(	O
+95	O
+%	O
+confidence	O
+interval	O
+,	O
+1	O
+.	O
+5	O
+to	O
+12	O
+.	O
+9	O
+;	O
+P	O
+=	O
+0	O
+.	O
+007	O
+).	O
+
+Only	O
+by	O
+the	O
+combined	O
+efforts	O
+of	O
+the	O
+European	O
+Respiratory	O
+Society	O
+(	O
+ERS	O
+)	O
+and	O
+the	O
+American	O
+Thoracic	B-DISO
+Society	O
+(	O
+ATS	B-DISO
+)	O
+has	O
+has	O
+been	O
+possible	O
+to	O
+standardize	O
+the	O
+formerly	O
+different	O
+European	O
+and	O
+Northern	O
+American	O
+nomenclature	O
+of	O
+interstitial	B-DISO
+lung	B-ANAT
+diseases	I-DISO
+(	O
+alveolitis	B-DISO
+versus	O
+interstitial	B-DISO
+pneumonia	I-DISO
+)	O
+in	O
+adults	O
+and	O
+to	O
+clearly	O
+and	O
+unambiguously	O
+define	O
+the	O
+diagnostic	O
+criteria	O
+.	O
+
+In	O
+the	O
+present	O
+study	O
+,	O
+we	O
+investigated	O
+the	O
+phosphorylation	B-PROC
+status	O
+of	O
+p90RSK	B-PRGE
+,	O
+which	O
+is	O
+a	O
+well	O
+-	O
+known	O
+substrate	O
+of	O
+these	O
+signaling	B-PROC
+pathways	B-PROC
+,	O
+in	O
+SARS	B-DISO
+-	O
+CoV	O
+-	O
+infected	O
+cells	B-COMP
+.	O
+
+Phosphorylation	B-PROC
+of	O
+Thr573	O
+was	O
+not	O
+upregulated	O
+in	O
+SARS	B-DISO
+-	O
+CoV	O
+-	O
+infected	O
+cells	B-COMP
+.	O
+
+Ser220	O
+was	O
+constitutively	O
+phosphorylated	O
+despite	O
+infection	B-DISO
+.	O
+
+In	O
+this	O
+review	O
+we	O
+explore	O
+the	O
+biotrauma	O
+hypothesis	O
+,	O
+the	O
+causal	O
+relationship	O
+between	O
+biophysical	O
+injury	O
+and	O
+organ	O
+failure	O
+,	O
+and	O
+its	O
+implications	O
+for	O
+the	O
+future	O
+therapy	O
+and	O
+management	O
+of	O
+critically	B-DISO
+ill	I-DISO
+patients	O
+.	O
+
+ABSTRACT	O
+:	O
+Serum	B-COMP
+samples	O
+collected	O
+from	O
+178	O
+shot	O
+wild	O
+boars	O
+(	O
+Sus	B-SPEC
+scrofa	I-SPEC
+)	O
+were	O
+tested	O
+for	O
+the	O
+presence	O
+of	O
+antibodies	B-COMP
+against	O
+classical	B-SPEC
+swine	I-SPEC
+fever	I-SPEC
+virus	I-SPEC
+,	O
+Aujeszky	B-SPEC
+'	I-SPEC
+s	I-SPEC
+disease	I-SPEC
+virus	I-SPEC
+(	O
+ADV	O
+),	O
+porcine	B-SPEC
+reproductive	I-SPEC
+and	I-SPEC
+respiratory	I-SPEC
+syndrome	I-SPEC
+virus	I-SPEC
+,	O
+porcine	B-SPEC
+respiratory	O
+coronavirus	B-SPEC
+(	O
+PRCV	O
+),	O
+transmissible	O
+gastroenteritis	B-DISO
+virus	B-SPEC
+,	O
+swine	B-SPEC
+influenza	I-SPEC
+virus	I-SPEC
+,	O
+porcine	B-SPEC
+parvovirus	I-SPEC
+(	O
+PPV	B-CHED
+),	O
+swine	B-DISO
+vesicular	I-DISO
+disease	I-DISO
+virus	B-SPEC
+,	O
+Actinobacillus	B-SPEC
+pleuropneumoniae	I-SPEC
+(	O
+APP	B-CHED
+),	O
+Mycoplasma	B-SPEC
+hyopneumoniae	I-SPEC
+,	O
+Salmonella	B-DISO
+spp	B-ENZY
+.,	O
+Brucella	B-SPEC
+spp	B-ENZY
+.	O
+
+For	O
+the	O
+SARS	B-DISO
+unit	O
+nurses	O
+,	O
+significant	O
+reduction	O
+in	O
+mood	O
+ratings	O
+,	O
+insomnia	B-DISO
+rate	O
+and	O
+perceived	O
+negative	O
+feelings	O
+as	O
+well	O
+as	O
+increasing	O
+knowledge	O
+and	O
+understanding	O
+of	O
+SARS	B-DISO
+at	O
+the	O
+end	O
+of	O
+the	O
+study	O
+(	O
+all	O
+p	O
+<	O
+0	O
+.	O
+001	O
+)	O
+indicated	O
+that	O
+a	O
+gradual	O
+psychological	B-DISO
+adaptation	B-PROC
+had	O
+occurred	O
+.	O
+
+In	O
+conclusion	O
+,	O
+the	O
+psychological	B-DISO
+impact	O
+on	O
+the	O
+caring	O
+staffs	O
+facing	O
+future	O
+bio	O
+-	O
+disaster	O
+will	O
+be	O
+minimized	O
+with	O
+lowered	O
+risk	O
+factors	O
+and	O
+a	O
+safer	O
+and	O
+more	O
+structured	O
+work	O
+environment	O
+.	O
+
+In	O
+patients	O
+with	O
+SARS	B-DISO
+,	O
+cardiovascular	B-ANAT
+complications	O
+including	O
+hypotension	O
+and	O
+tachycardia	O
+were	O
+common	O
+but	O
+usually	O
+self	O
+limiting	O
+.	O
+
+SARS	B-DISO
+has	O
+caused	O
+an	O
+outbreak	O
+in	O
+the	O
+world	O
+during	O
+2003	O
+and	O
+2004	O
+,	O
+with	O
+8098	O
+individuals	O
+being	O
+infected	O
+and	O
+a	O
+death	B-PROC
+toll	O
+of	O
+774	O
+in	O
+28	O
+regions	O
+around	O
+the	O
+world	O
+.	O
+
+To	O
+analyse	O
+the	O
+antigenicity	O
+of	O
+the	O
+SARS	B-DISO
+-	O
+CoV	O
+genome	O
+and	O
+identify	O
+potential	O
+antigenic	O
+epitopes	O
+in	O
+the	O
+structural	O
+proteins	B-CHED
+.	O
+
+Of	O
+the	O
+protease	O
+and	O
+entry	O
+inhibitors	B-CHED
+approved	O
+for	O
+treating	O
+HIV	B-DISO
+-	O
+infected	O
+patients	O
+,	O
+none	O
+was	O
+effective	O
+against	O
+SARS	B-PRGE
+-	I-PRGE
+CoV	I-PRGE
+,	O
+although	O
+in	O
+vitro	O
+activity	O
+against	O
+this	O
+virus	B-SPEC
+was	O
+reported	O
+for	O
+the	O
+protease	B-CHED
+inhibitor	I-CHED
+lopinavir	O
+/	O
+ritonavir	B-CHED
+,	O
+in	O
+results	O
+that	O
+have	O
+not	O
+been	O
+confirmed	O
+in	O
+the	O
+most	O
+recent	O
+studies	O
+.	O
+
+TITLE	O
+:	O
+[	O
+Severe	O
+pneumonia	B-DISO
+from	O
+psittacosis	B-DISO
+in	O
+a	O
+bird	B-SPEC
+-	O
+keeper	O
+].	O
+
+CONCLUSIONS	O
+:	O
+As	O
+the	O
+diagnostic	O
+efficiency	O
+and	O
+prognostic	O
+value	O
+of	O
+the	O
+serum	B-COMP
+SARS	B-DISO
+-	O
+CoV	O
+RNA	O
+RT	O
+-	O
+PCR	O
+test	O
+is	O
+critically	O
+associated	O
+with	O
+the	O
+analytical	O
+sensitivity	O
+and	O
+quantitative	O
+performance	O
+contributed	O
+both	O
+by	O
+the	O
+RNA	O
+extraction	O
+and	O
+RT	O
+-	O
+PCR	O
+components	O
+of	O
+the	O
+test	O
+,	O
+we	O
+recommend	O
+the	O
+use	O
+of	O
+the	O
+column	B-ANAT
+-	O
+based	O
+manual	O
+RNA	O
+extraction	O
+method	O
+.	O
+
+The	O
+origin	O
+of	O
+the	O
+higher	O
+stability	O
+of	O
+LightUp	O
+probe	O
+kits	O
+compared	O
+to	O
+others	O
+,	O
+based	O
+on	O
+alternative	O
+probe	O
+technologies	O
+,	O
+is	O
+partly	O
+the	O
+relatively	O
+good	O
+stability	O
+of	O
+cyanine	B-CHED
+dyes	I-CHED
+but	O
+also	O
+the	O
+resistance	B-PROC
+towards	O
+nucleases	O
+and	O
+proteases	O
+of	O
+the	O
+synthetic	O
+DNA	O
+analogue	O
+peptide	B-CHED
+nucleic	I-CHED
+acid	I-CHED
+that	O
+is	O
+used	O
+as	O
+the	O
+sequence	O
+recognizing	O
+element	O
+in	O
+LightUp	O
+probes	O
+.	O
+
+The	O
+mean	O
+FIC	O
+-	O
+symptom	B-DISO
+and	O
+FIC	O
+-	O
+disability	O
+score	O
+were	O
+24	O
+.	O
+12	O
+(	O
+SD	O
++/-	O
+
+Both	O
+FIC	O
+scales	B-ANAT
+correlated	O
+stronger	O
+with	O
+physical	O
+component	O
+summary	O
+(	O
+PCS	B-DISO
+)	O
+(-	O
+0	O
+.	O
+41	O
+and	O
+-	O
+0	O
+.	O
+55	O
+)	O
+than	O
+with	O
+mental	O
+component	O
+summary	O
+(	O
+MCS	B-COMP
+)	O
+(-	O
+0	O
+.	O
+30	O
+and	O
+-	O
+0	O
+.	O
+23	O
+).	O
+
+The	O
+full	O
+sequence	O
+of	O
+the	O
+SARS	B-PRGE
+-	I-PRGE
+CoV	I-PRGE
+5	I-PRGE
+'	I-PRGE
+UTR	I-PRGE
+is	O
+a	O
+264nt	O
+,	O
+and	O
+18	O
+deletion	O
+mutants	O
+were	O
+found	O
+.	O
+
+Ranked	O
+by	O
+the	O
+luciferase	B-PROC
+activity	I-PROC
+from	O
+the	O
+highest	O
+to	O
+the	O
+lowest	O
+,	O
+the	O
+order	B-SPEC
+is	O
+A549	O
+,	O
+HepG2	O
+,	O
+ECV304	O
+,	O
+HeLa	B-ANAT
+and	O
+Vero	O
+E6	O
+.	O
+
+A	O
+:	O
+The	O
+5	O
+'	O
+UTR	O
+sequences	O
+of	O
+different	O
+SARS	B-DISO
+-	O
+CoV	O
+isolates	O
+are	O
+relatively	O
+conserved	O
+,	O
+and	O
+a	O
+full	O
+sequence	O
+would	O
+form	O
+a	O
+secondary	O
+structure	O
+containing	O
+four	O
+stem	B-ANAT
+-	O
+loop	O
+domains	O
+.	O
+
+D	O
+:	O
+The	O
+56th	O
+nucleotide	B-CHED
+and	O
+its	O
+down	O
+stream	O
+TRS	B-DISO
+of	O
+SARS	B-PRGE
+-	I-PRGE
+CoV	I-PRGE
+5	I-PRGE
+'	I-PRGE
+UTR	I-PRGE
+plays	O
+a	O
+key	O
+role	O
+in	O
+regulating	O
+transcription	B-PROC
+.	O
+
+The	O
+present	O
+study	O
+was	O
+designed	O
+to	O
+evaluate	O
+the	O
+oral	B-ANAT
+immunoadjuvant	B-CHED
+effects	O
+of	O
+the	O
+synbiotic	O
+in	O
+layer	B-ANAT
+chickens	B-SPEC
+.	O
+
+These	O
+patients	O
+were	O
+evaluated	O
+in	O
+a	O
+Toronto	O
+,	O
+Ontario	O
+,	O
+community	O
+hospital	O
+identified	O
+as	O
+the	O
+epicentre	O
+for	O
+the	O
+second	O
+SARS	B-DISO
+outbreak	O
+.	O
+
+ABSTRACT	O
+:	O
+Coronaviruses	O
+are	O
+positive	O
+-	O
+strand	O
+,	O
+RNA	B-PRGE
+-	I-PRGE
+dependent	I-PRGE
+RNA	I-PRGE
+polymerase	I-PRGE
+-	O
+utilizing	O
+viruses	B-SPEC
+that	O
+require	O
+a	O
+polymerase	O
+template	O
+switch	O
+,	O
+characterized	O
+as	O
+discontinuous	O
+transcription	B-PROC
+,	O
+to	O
+place	O
+a	O
+5	O
+'-	O
+terminal	O
+genomic	O
+leader	O
+onto	O
+subgenomic	O
+mRNAs	O
+(	O
+sgmRNAs	O
+).	O
+
+The	O
+conserved	O
+glycosylation	B-PROC
+of	O
+the	O
+coronavirus	B-SPEC
+M	O
+proteins	B-CHED
+and	O
+the	O
+resemblance	O
+of	O
+the	O
+3a	O
+protein	O
+to	O
+them	O
+led	O
+us	O
+to	O
+investigate	O
+the	O
+glycosylation	B-PROC
+of	O
+these	O
+two	O
+SARS	B-PRGE
+-	I-PRGE
+CoV	I-PRGE
+membrane	B-COMP
+proteins	B-CHED
+.	O
+
+While	O
+the	O
+M	O
+protein	B-CHED
+acquired	O
+cotranslationally	O
+oligosaccharides	B-CHED
+that	O
+could	O
+be	O
+removed	O
+by	O
+PNGaseF	O
+,	O
+the	O
+3a	O
+protein	B-CHED
+acquired	O
+its	O
+modifications	O
+posttranslationally	O
+,	O
+and	O
+they	O
+were	O
+not	O
+sensitive	O
+to	O
+the	O
+N	O
+-	O
+glycosidase	O
+enzyme	O
+.	O
+
+Well	O
+-	O
+described	O
+receptor	O
+-	O
+mediated	O
+signaling	B-PROC
+events	O
+result	O
+in	O
+transcriptional	B-PROC
+regulation	I-PROC
+of	O
+IFN	B-PRGE
+sensitive	I-PRGE
+genes	I-PRGE
+,	O
+effectors	O
+of	O
+this	O
+antiviral	B-PROC
+response	I-PROC
+.	O
+
+Additionally	O
+,	O
+we	O
+provide	O
+evidence	O
+for	O
+the	O
+contribution	O
+of	O
+two	O
+kinases	O
+,	O
+the	O
+MAP	B-PRGE
+kinase	I-PRGE
+p38MAPK	B-PRGE
+,	O
+and	O
+protein	B-PRGE
+kinase	I-PRGE
+C	I-PRGE
+(	O
+PKC	B-DISO
+)	O
+delta	O
+to	O
+antiviral	B-CHED
+protection	O
+from	O
+MHV	B-SPEC
+-	O
+1	O
+infection	B-DISO
+.	O
+
+Within	O
+72	O
+hours	O
+,	O
+the	O
+puppy	O
+began	O
+to	O
+vomit	B-DISO
+,	O
+had	O
+diarrhea	B-DISO
+,	O
+and	O
+was	O
+admitted	O
+to	O
+the	O
+veterinary	O
+clinic	O
+,	O
+where	O
+it	O
+was	O
+placed	O
+on	O
+IV	O
+fluids	B-ANAT
+.	O
+
+There	O
+was	O
+moderate	O
+depletion	O
+and	O
+necrosis	B-PROC
+of	O
+lymphoid	O
+follicles	B-ANAT
+.	O
+
+A	O
+high	O
+proportion	O
+of	O
+cats	B-SPEC
+with	O
+antibodies	B-COMP
+against	O
+FCoV	O
+had	O
+relatively	O
+high	O
+antibody	B-COMP
+titres	O
+,	O
+and	O
+was	O
+therefore	O
+likely	O
+to	O
+be	O
+shedding	O
+FCoV	O
+in	O
+faeces	B-ANAT
+.	O
+
+The	O
+whole	O
+killed	O
+virus	B-SPEC
+(	O
+WKV	O
+)	O
+vaccine	O
+given	O
+subcutaneously	O
+to	O
+129S6	O
+/	O
+SvEv	O
+mice	B-SPEC
+was	O
+more	O
+effective	O
+than	O
+the	O
+Ad	O
+S	O
+/	O
+N	O
+vaccine	O
+administered	O
+either	O
+intranasally	O
+or	O
+intramuscularly	O
+in	O
+inhibiting	O
+SARS	B-DISO
+-	O
+CoV	O
+replication	O
+in	O
+the	O
+murine	B-SPEC
+respiratory	B-ANAT
+tract	I-ANAT
+.	O
+
+However	O
+,	O
+Ad	O
+S	O
+/	O
+N	O
+administered	O
+intranasally	O
+,	O
+but	O
+not	O
+intramuscularly	O
+,	O
+significantly	O
+limited	O
+SARS	B-DISO
+-	O
+CoV	O
+replication	O
+in	O
+the	O
+lungs	B-ANAT
+.	O
+
+By	O
+using	O
+an	O
+antiserum	O
+raised	O
+against	O
+the	O
+pp1a	B-PRGE
+/	O
+pp1ab	O
+residues	O
+526	O
+-	O
+713	O
+,	O
+the	O
+upstream	O
+processing	O
+product	O
+,	O
+nsp2	B-PRGE
+,	O
+was	O
+identified	O
+as	O
+an	O
+85	O
+kDa	O
+protein	B-CHED
+in	O
+TGEV	B-SPEC
+-	O
+infected	O
+cells	B-COMP
+.	O
+
+TITLE	O
+:	O
+The	O
+catalysis	O
+of	O
+the	O
+SARS	B-PRGE
+3C	I-PRGE
+-	I-PRGE
+like	I-PRGE
+protease	I-PRGE
+is	O
+under	O
+extensive	O
+regulation	B-PROC
+by	O
+its	O
+extra	O
+domain	O
+.	O
+
+TITLE	O
+:	O
+Differential	O
+roles	O
+for	O
+CXCR3	B-PRGE
+in	O
+CD4	B-PRGE
++	I-PRGE
+and	O
+CD8	B-PRGE
++	I-PRGE
+T	B-ANAT
+cell	I-ANAT
+trafficking	B-PROC
+following	O
+viral	B-DISO
+infection	I-DISO
+of	O
+the	O
+CNS	O
+.	O
+
+The	O
+majority	O
+of	O
+CD4	B-PRGE
++	I-PRGE
+and	O
+CD8	B-PRGE
++	I-PRGE
+T	B-ANAT
+cells	I-ANAT
+infiltrating	B-DISO
+the	O
+CNS	B-CHED
+following	O
+MHV	B-SPEC
+infection	B-DISO
+express	O
+CXCR3	B-PRGE
+.	O
+
+Moreover	O
+,	O
+the	O
+method	O
+provides	O
+a	O
+good	O
+estimate	O
+of	O
+the	O
+initial	O
+reproduction	B-PROC
+number	O
+,	O
+and	O
+the	O
+reproduction	B-PROC
+number	O
+in	O
+the	O
+latter	O
+stages	O
+of	O
+the	O
+outbreak	O
+.	O
+
+TITLE	O
+:	O
+Characteristics	O
+and	O
+outcome	O
+of	O
+patients	O
+with	O
+active	O
+pulmonary	B-DISO
+tuberculosis	B-PATH
+requiring	O
+intensive	O
+care	O
+.	O
+
+The	O
+present	O
+study	O
+aimed	O
+to	O
+describe	O
+this	O
+condition	B-DISO
+and	O
+to	O
+determine	O
+the	O
+mortality	O
+rate	O
+and	O
+risk	O
+factors	O
+associated	O
+with	O
+mortality	O
+.	O
+
+TITLE	O
+:	O
+Cytokine	O
+regulation	B-PROC
+in	O
+SARS	B-DISO
+coronavirus	B-DISO
+infection	I-DISO
+compared	O
+to	O
+other	O
+respiratory	O
+virus	B-SPEC
+infections	B-DISO
+.	O
+
+SARS	B-DISO
+-	O
+CoV	O
+and	O
+RSV	B-SPEC
+induced	O
+high	O
+levels	O
+of	O
+IL	B-FUNC
+-	I-FUNC
+6	I-FUNC
+and	O
+RANTES	O
+compared	O
+with	O
+FluAV	O
+and	O
+hPIV2	O
+.	O
+
+Toll	B-PRGE
+-	I-PRGE
+like	I-PRGE
+receptors	I-PRGE
+4	O
+and	O
+9	O
+,	O
+which	O
+correlate	O
+with	O
+the	O
+induction	O
+of	O
+inflammatory	O
+response	O
+,	O
+were	O
+upregulated	O
+by	O
+SARS	B-DISO
+-	I-DISO
+CoV	I-DISO
+infection	I-DISO
+.	O
+
+TITLE	O
+:	O
+Absence	O
+of	O
+infection	B-DISO
+in	O
+asymptomatic	O
+contacts	O
+of	O
+index	O
+SARS	B-DISO
+case	O
+in	O
+France	O
+.	O
+
+These	O
+findings	O
+support	O
+a	O
+SARS	B-DISO
+case	O
+definition	O
+that	O
+is	O
+essentially	O
+based	O
+on	O
+clinical	O
+and	O
+epidemiological	O
+assessment	O
+,	O
+should	O
+SARS	B-DISO
+re	O
+-	O
+emerge	O
+.	O
+
+TITLE	O
+:	O
+SARS	B-DISO
+-	I-DISO
+CoV	I-DISO
+infection	I-DISO
+in	O
+a	O
+restaurant	O
+from	O
+palm	B-ANAT
+civet	B-SPEC
+.	O
+
+All	O
+6	O
+palm	B-ANAT
+civets	B-SPEC
+at	O
+the	O
+restaurant	O
+were	O
+positive	O
+for	O
+SARS	B-DISO
+-	I-DISO
+associated	I-DISO
+coronavirus	I-DISO
+(	O
+SARS	B-DISO
+-	O
+CoV	O
+).	O
+
+SARS	B-DISO
+cases	O
+at	O
+the	O
+restaurant	O
+were	O
+the	O
+result	O
+of	O
+recent	O
+interspecies	O
+transfer	O
+from	O
+the	O
+putative	O
+palm	B-ANAT
+civet	B-SPEC
+reservoir	O
+,	O
+and	O
+not	O
+the	O
+result	O
+of	O
+continued	O
+circulation	B-PROC
+of	O
+SARS	B-PRGE
+-	I-PRGE
+CoV	I-PRGE
+in	O
+the	O
+human	B-SPEC
+population	O
+.	O
+
+Higher	O
+nasopharyngeal	B-ANAT
+viral	O
+load	O
+was	O
+found	O
+in	O
+patients	O
+living	O
+in	O
+adjacent	O
+units	O
+of	O
+the	O
+same	O
+block	O
+inhabited	O
+by	O
+the	O
+index	O
+patient	O
+,	O
+while	O
+a	O
+lower	O
+but	O
+detectable	O
+nasopharyngeal	B-ANAT
+viral	O
+load	O
+was	O
+found	O
+in	O
+patients	O
+living	O
+further	O
+away	O
+from	O
+the	O
+index	O
+patient	O
+.	O
+
+None	O
+of	O
+the	O
+paediatric	O
+patients	O
+was	O
+eventually	O
+diagnosed	O
+of	O
+SARS	B-DISO
+.	O
+
+A	O
+major	O
+nursing	B-PROC
+care	O
+issue	O
+for	O
+SARS	B-DISO
+paediatric	O
+patients	O
+was	O
+to	O
+achieve	O
+a	O
+careful	O
+balance	B-PROC
+between	O
+attending	O
+to	O
+patients	O
+'	O
+physical	O
+and	O
+psychological	B-DISO
+needs	O
+and	O
+adhering	O
+to	O
+the	O
+infection	B-DISO
+control	O
+guidelines	O
+,	O
+while	O
+at	O
+the	O
+same	O
+time	O
+offering	O
+psychological	B-DISO
+support	O
+to	O
+family	B-SPEC
+members	O
+.	O
+
+In	O
+days	O
+with	O
+a	O
+lower	O
+air	B-CHED
+temperature	O
+during	O
+the	O
+epidemic	O
+,	O
+the	O
+risk	O
+of	O
+increased	O
+daily	O
+incidence	O
+of	O
+SARS	B-DISO
+was	O
+18	O
+.	O
+18	O
+-	O
+fold	O
+(	O
+95	O
+%	O
+confidence	O
+interval	O
+5	O
+.	O
+6	O
+-	O
+58	O
+.	O
+8	O
+)	O
+higher	O
+than	O
+in	O
+days	O
+with	O
+a	O
+higher	O
+temperature	O
+.	O
+
+SARS	B-DISO
+transmission	O
+appeared	O
+to	O
+be	O
+dependent	O
+on	O
+seasonal	O
+temperature	O
+changes	O
+and	O
+the	O
+multiplicative	O
+effect	O
+of	O
+hospital	B-DISO
+infection	I-DISO
+.	O
+
+TITLE	O
+:	O
+Inactivation	B-DISO
+of	O
+SARS	B-DISO
+coronavirus	B-SPEC
+by	O
+means	O
+of	O
+povidone	B-CHED
+-	O
+iodine	B-CHED
+,	O
+physical	O
+conditions	O
+and	O
+chemical	O
+reagents	O
+.	O
+
+ABSTRACT	O
+:	O
+The	O
+efficacy	O
+of	O
+several	O
+povidone	B-CHED
+-	O
+iodine	B-CHED
+(	O
+PVP	B-CHED
+-	O
+I	O
+)	O
+products	O
+,	O
+a	O
+number	O
+of	O
+other	O
+chemical	O
+agents	O
+and	O
+various	O
+physical	O
+conditions	O
+were	O
+evaluated	O
+for	O
+their	O
+ability	O
+to	O
+inactivate	O
+the	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+coronavirus	B-SPEC
+(	O
+SARS	B-DISO
+-	O
+CoV	O
+).	O
+
+Fixation	O
+of	O
+SARS	B-DISO
+-	O
+CoV	O
+-	O
+infected	O
+Vero	O
+E6	O
+cells	B-COMP
+with	O
+a	O
+fixative	B-CHED
+including	O
+formalin	B-CHED
+,	O
+glutaraldehyde	B-CHED
+,	O
+methanol	B-CHED
+and	O
+acetone	B-CHED
+for	O
+5	O
+min	O
+or	O
+longer	O
+eliminated	O
+all	O
+infectivity	O
+.	O
+
+ABSTRACT	O
+:	O
+Noncytopathic	O
+viruses	O
+use	O
+multiple	O
+strategies	O
+to	O
+evade	O
+immune	O
+detection	O
+,	O
+challenging	O
+a	O
+role	O
+for	O
+vaccine	O
+induced	O
+CTL	B-ANAT
+in	O
+preventing	O
+microbial	O
+persistence	O
+.	O
+
+In	O
+contrast	O
+to	O
+primary	O
+effectors	O
+,	O
+reactivated	O
+memory	B-ANAT
+cells	B-COMP
+persisted	O
+in	O
+the	O
+CNS	B-CHED
+at	O
+higher	O
+frequencies	O
+and	O
+retained	O
+ex	O
+vivo	O
+cytolytic	O
+activity	O
+.	O
+
+Nevertheless	O
+,	O
+despite	O
+earlier	O
+and	O
+prolonged	O
+T	B-ANAT
+cell	I-ANAT
+-	O
+mediated	O
+control	O
+in	O
+the	O
+CNS	B-CHED
+of	O
+vaccinated	O
+mice	B-SPEC
+,	O
+virus	B-SPEC
+ultimately	O
+reactivated	O
+.	O
+
+ABSTRACT	O
+:	O
+This	O
+study	O
+examined	O
+whether	O
+social	O
+capital	O
+can	O
+enhance	O
+an	O
+individual	O
+'	O
+s	O
+ability	O
+in	O
+reducing	O
+emotional	O
+exhaustion	O
+and	O
+job	O
+tension	B-DISO
+when	O
+medical	O
+professionals	O
+encounter	O
+a	O
+crisis	O
+such	O
+as	O
+Severe	B-DISO
+Acute	I-DISO
+Respiratory	I-DISO
+Syndrome	I-DISO
+(	O
+SARS	B-DISO
+).	O
+
+TITLE	O
+:	O
+Pandemic	O
+influenza	B-DISO
+threat	O
+and	O
+preparedness	O
+.	O
+
+This	O
+study	O
+shows	O
+that	O
+SARS	B-PRGE
+-	I-PRGE
+CoV	I-PRGE
+can	O
+be	O
+isolated	O
+in	O
+several	O
+cell	B-ANAT
+lines	I-ANAT
+commonly	O
+used	O
+for	O
+diagnostic	O
+or	O
+research	O
+purposes	O
+.	O
+
+TITLE	O
+:	O
+Coordinated	O
+response	O
+to	O
+SARS	B-DISO
+,	O
+Vancouver	O
+,	O
+Canada	O
+.	O
+
+In	O
+animal	B-SPEC
+immunogenicity	O
+studies	O
+,	O
+we	O
+found	O
+that	O
+most	O
+anti	B-PRGE
+-	I-PRGE
+rN	I-PRGE
+protein	I-PRGE
+antibodies	B-COMP
+were	O
+IgG2a	B-COMP
+in	O
+BALB	O
+/	O
+c	O
+mice	B-SPEC
+vaccinated	O
+with	O
+rN	O
+emulsified	O
+in	O
+Montanide	O
+ISA	B-SPEC
+-	O
+51	O
+containing	O
+the	O
+synthetic	O
+oligodeoxynucleotide	O
+,	O
+CpG	O
+.	O
+In	O
+contrast	O
+,	O
+anti	B-PRGE
+-	I-PRGE
+rN	I-PRGE
+protein	I-PRGE
+antibodies	B-COMP
+of	O
+mice	B-SPEC
+immunized	O
+with	O
+rN	O
+protein	B-CHED
+in	O
+PBS	B-DISO
+were	O
+found	O
+to	O
+mainly	O
+be	O
+IgG1	B-COMP
+.	O
+
+Our	O
+current	O
+results	O
+together	O
+with	O
+those	O
+of	O
+others	O
+suggest	O
+that	O
+some	O
+immunodominant	O
+B	B-ANAT
+-	I-ANAT
+cell	I-ANAT
+and	O
+T	B-ANAT
+-	I-ANAT
+cell	I-ANAT
+epitopes	O
+are	O
+conserved	O
+in	O
+the	O
+mouse	B-SPEC
+,	O
+monkey	B-SPEC
+,	O
+and	O
+human	B-SPEC
+.	O
+
+ABSTRACT	O
+:	O
+Side	O
+effects	O
+of	O
+interferon	O
+-	O
+ribavirin	O
+combination	O
+therapy	O
+limit	O
+the	O
+sustained	O
+viral	O
+response	O
+achievable	O
+in	O
+hepatitis	B-SPEC
+C	I-SPEC
+virus	I-SPEC
+(	O
+HCV	B-SPEC
+)	O
+patients	O
+.	O
+
+TITLE	O
+:	O
+[	O
+Exhaled	B-PROC
+nitric	B-CHED
+oxide	I-CHED
+as	O
+a	O
+marker	O
+of	O
+diseases	O
+].	O
+
+Clinical	O
+application	O
+of	O
+exhaled	O
+NO	O
+measurement	O
+include	O
+monitoring	O
+compliance	O
+and	O
+response	O
+to	O
+treatment	O
+,	O
+disease	O
+activity	O
+,	O
+diagnosis	O
+of	O
+asthma	B-PATH
+,	O
+and	O
+the	O
+prediction	O
+of	O
+acute	O
+exacerbations	O
+.	O
+
+Exhaled	B-PROC
+NO	O
+concentration	O
+may	O
+be	O
+increased	O
+also	O
+in	O
+other	O
+diseases	O
+,	O
+as	O
+COPD	B-DISO
+,	O
+bronchiectasis	B-DISO
+and	O
+some	O
+connective	B-DISO
+tissue	I-DISO
+diseases	I-DISO
+(	O
+SLE	B-DISO
+and	O
+systemic	B-DISO
+sclerosis	I-DISO
+).	O
+
+An	O
+increased	O
+NO	O
+production	O
+from	O
+alveolar	B-ANAT
+source	O
+has	O
+been	O
+shown	O
+to	O
+be	O
+involved	O
+in	O
+oxygenation	B-PROC
+impairment	B-DISO
+of	O
+patients	O
+with	O
+liver	B-DISO
+disease	I-DISO
+,	O
+particularly	O
+in	O
+case	O
+of	O
+hepato	B-DISO
+-	I-DISO
+pulmonary	I-DISO
+syndrome	I-DISO
+.	O
+
+TITLE	O
+:	O
+A	O
+recombinant	O
+baculovirus	B-SPEC
+-	O
+expressed	B-PROC
+S	B-PRGE
+glycoprotein	I-PRGE
+vaccine	O
+elicits	O
+high	O
+titers	O
+of	O
+SARS	B-DISO
+-	I-DISO
+associated	I-DISO
+coronavirus	I-DISO
+(	O
+SARS	B-DISO
+-	O
+CoV	O
+)	O
+neutralizing	O
+antibodies	B-COMP
+in	O
+mice	B-SPEC
+.	O
+
+Both	O
+antigens	B-CHED
+in	O
+each	O
+formulation	O
+elicited	O
+a	O
+strong	O
+immune	B-PROC
+response	I-PROC
+after	O
+two	O
+or	O
+three	O
+vaccinations	O
+with	O
+the	O
+antigen	B-CHED
+.	O
+
+The	O
+SARS	B-DISO
+scoring	O
+system	O
+described	O
+is	O
+easily	O
+applicable	O
+and	O
+highly	O
+effective	O
+in	O
+screening	O
+patients	O
+during	O
+outbreaks	O
+.	O
+
+RESULTS	O
+:	O
+Of	O
+737	O
+patients	O
+who	O
+presented	O
+to	O
+our	O
+ED	O
+for	O
+possible	O
+SARS	B-DISO
+from	O
+March	O
+to	O
+June	O
+2003	O
+,	O
+we	O
+enrolled	O
+484	O
+patients	O
+with	O
+a	O
+temperature	O
+>	O
+38	O
+.	O
+0	O
+degrees	O
+C	O
+(>	O
+100	O
+.	O
+3	O
+degrees	O
+F	O
+)	O
+(	O
+age	O
+>	O
+18	O
+years	O
+).	O
+
+Specifically	O
+,	O
+the	O
+median	O
+Coronase	O
+antibody	B-COMP
+titres	O
+of	O
+Siamese	O
+,	O
+Persians	O
+,	O
+Domestic	O
+Shorthairs	O
+and	O
+Bengal	O
+cats	B-SPEC
+(	O
+100	O
+)	O
+were	O
+significantly	O
+lower	O
+than	O
+that	O
+of	O
+British	O
+Shorthairs	O
+,	O
+Cornish	O
+Rex	B-FUNC
+and	O
+Burmese	O
+cats	B-SPEC
+(	O
+400	O
+,	O
+P	O
+<	O
+0	O
+.	O
+0005	O
+).	O
+
+This	O
+study	O
+reinforces	O
+the	O
+complexity	O
+of	O
+interpreting	O
+serological	O
+tests	O
+for	O
+FCoV	O
+in	O
+both	O
+healthy	O
+cats	B-SPEC
+and	O
+patients	O
+with	O
+signs	O
+compatible	O
+with	O
+FIR	B-SPEC
+Unique	O
+to	O
+this	O
+study	O
+is	O
+the	O
+detection	O
+of	O
+a	O
+significant	O
+relationship	O
+between	O
+breed	B-PROC
+and	O
+median	O
+FCoV	O
+antibody	B-COMP
+titre	O
+.	O
+
+CONCLUSIONS	O
+:	O
+This	O
+study	O
+reinforces	O
+the	O
+complexity	O
+of	O
+interpreting	O
+serological	O
+tests	O
+for	O
+FCoV	O
+in	O
+both	O
+healthy	O
+cats	B-SPEC
+and	O
+patients	O
+with	O
+signs	O
+compatible	O
+with	O
+FIR	B-SPEC
+Unique	O
+to	O
+this	O
+study	O
+is	O
+the	O
+detection	O
+of	O
+a	O
+significant	O
+relationship	O
+between	O
+breed	B-PROC
+and	O
+median	O
+FCoV	O
+antibody	B-COMP
+titre	O
+.	O
+
+ABSTRACT	O
+:	O
+To	O
+evaluate	O
+the	O
+effects	O
+of	O
+traditional	O
+Chinese	O
+medicine	B-CHED
+in	O
+461	O
+cases	O
+of	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+(	O
+SARS	B-DISO
+)	O
+on	O
+glucocorticoid	B-CHED
+'	O
+s	O
+dosage	O
+.	O
+
+The	O
+use	O
+of	O
+TCM	O
+in	O
+the	O
+forepart	O
+of	O
+treatment	O
+can	O
+be	O
+capable	O
+of	O
+decreasing	O
+glucocorticoid	B-CHED
+'	O
+s	O
+dosage	O
+.	O
+
+CDV	B-CHED
+1	O
+mg	O
+/	O
+kg	O
+was	O
+given	O
+three	O
+times	O
+per	O
+week	O
+intravenously	O
+with	O
+intravenous	O
+hydration	O
+and	O
+oral	B-ANAT
+probenecid	B-CHED
+.	O
+
+FECV	B-SPEC
+is	O
+more	O
+similar	O
+to	O
+feline	B-SPEC
+coronavirus	B-SPEC
+,	O
+porcine	B-DISO
+transmissible	I-DISO
+gastroenteritis	I-DISO
+virus	B-SPEC
+,	O
+and	O
+canine	O
+coronavirus	B-SPEC
+than	O
+to	O
+porcine	B-SPEC
+epidemic	B-DISO
+diarrhea	I-DISO
+virus	I-SPEC
+and	O
+human	B-SPEC
+coronavirus	I-SPEC
+229E	I-SPEC
+.	O
+
+Over	O
+the	O
+course	O
+of	O
+cloning	O
+and	O
+expression	B-PROC
+of	O
+the	O
+gene	O
+,	O
+a	O
+mixed	O
+population	O
+of	O
+clones	O
+with	O
+six	O
+,	O
+seven	O
+,	O
+eight	O
+and	O
+nine	O
+T	O
+stretches	B-DISO
+located	O
+14	O
+nt	O
+downstream	O
+of	O
+the	O
+initiation	O
+codon	O
+was	O
+found	O
+.	O
+
+TITLE	O
+:	O
+Modeling	O
+the	O
+early	O
+events	O
+of	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+coronavirus	B-DISO
+infection	I-DISO
+in	O
+vitro	O
+.	O
+
+TITLE	O
+:	O
+Isolation	O
+of	O
+a	O
+variant	O
+infectious	B-DISO
+bronchitis	B-DISO
+virus	B-SPEC
+in	O
+Australia	O
+that	O
+further	O
+illustrates	O
+diversity	O
+among	O
+emerging	O
+strains	O
+.	O
+
+The	O
+rats	B-SPEC
+received	O
+a	O
+total	O
+of	O
+60	O
+,	O
+120	O
+,	O
+and	O
+600	O
+microU	O
+/	O
+kg	O
+insulin	B-PRGE
+as	O
+well	O
+as	O
+0	O
+.	O
+12	O
+,	O
+0	O
+.	O
+36	O
+,	O
+and	O
+0	O
+.	O
+96	O
+g	O
+of	O
+glucose	B-CHED
+in	O
+respective	O
+groups	O
+.	O
+
+Thirty	O
+-	O
+five	O
+doctors	O
+and	O
+152	O
+nurses	O
+and	O
+healthcare	O
+assistants	O
+who	O
+worked	O
+in	O
+the	O
+ICU	O
+during	O
+the	O
+SARS	B-DISO
+epidemic	O
+.	O
+
+ABSTRACT	O
+:	O
+A	O
+diverse	O
+group	O
+of	O
+cytolytic	O
+animal	B-SPEC
+viruses	B-SPEC
+encodes	O
+small	O
+,	O
+hydrophobic	O
+proteins	B-CHED
+to	O
+modify	O
+host	B-COMP
+cell	I-COMP
+membrane	I-COMP
+permeability	O
+to	O
+ions	B-CHED
+and	O
+small	O
+molecules	O
+during	O
+their	O
+infection	B-DISO
+cycles	O
+.	O
+
+Immunofluorescent	O
+staining	O
+and	O
+cell	B-COMP
+fractionation	O
+studies	O
+demonstrate	O
+that	O
+this	O
+protein	B-CHED
+is	O
+an	O
+integral	O
+membrane	B-COMP
+protein	B-CHED
+.	O
+
+Similar	O
+to	O
+other	O
+class	B-SPEC
+1	O
+viral	O
+fusion	O
+proteins	B-CHED
+,	O
+the	O
+heptad	O
+repeat	O
+regions	O
+of	O
+SARS	B-DISO
+-	O
+CoV	O
+spike	O
+are	O
+thought	O
+to	O
+undergo	O
+conformational	O
+changes	O
+from	O
+a	O
+prefusion	O
+form	O
+to	O
+a	O
+subsequent	O
+post	O
+-	O
+fusion	O
+form	O
+that	O
+enables	O
+fusion	O
+of	O
+the	O
+viral	O
+and	O
+host	B-COMP
+membranes	B-ANAT
+.	O
+
+Recently	O
+,	O
+the	O
+structure	O
+of	O
+a	O
+post	O
+-	O
+fusion	O
+form	O
+of	O
+SARS	B-DISO
+-	O
+CoV	O
+spike	O
+,	O
+which	O
+consists	O
+of	O
+isolated	O
+domains	O
+of	O
+heptad	O
+repeats	O
+1	O
+and	O
+2	O
+(	O
+HR1	O
+and	O
+HR2	O
+),	O
+has	O
+been	O
+determined	O
+by	O
+x	O
+-	O
+ray	B-SPEC
+crystallography	O
+.	O
+
+In	O
+this	O
+work	O
+we	O
+present	O
+the	O
+NMR	O
+structure	O
+of	O
+the	O
+HR2	O
+domain	O
+(	O
+residues	O
+1141	O
+-	O
+1193	O
+)	O
+from	O
+SARS	B-PRGE
+-	I-PRGE
+CoV	I-PRGE
+(	O
+termed	O
+S2	O
+-	O
+HR2	O
+)	O
+in	O
+the	O
+presence	O
+of	O
+the	O
+co	O
+-	O
+solvent	B-CHED
+trifluoroethanol	B-CHED
+.	O
+
+Surprisingly	O
+,	O
+increased	O
+viral	O
+load	O
+in	O
+oligodendroglia	B-ANAT
+did	O
+not	O
+affect	O
+the	O
+extent	O
+of	O
+myelin	B-ANAT
+loss	O
+,	O
+the	O
+frequency	O
+of	O
+oligodendroglial	O
+apoptosis	B-PATH
+,	O
+or	O
+CNS	B-CHED
+recruitment	B-DISO
+of	O
+macrophages	B-ANAT
+.	O
+
+These	O
+data	O
+demonstrate	O
+that	O
+IFN	B-PRGE
+-	I-PRGE
+gamma	I-PRGE
+receptor	I-PRGE
+signaling	O
+is	O
+critical	O
+for	O
+the	O
+control	O
+of	O
+JHMV	O
+replication	O
+in	O
+oligodendroglia	B-ANAT
+.	O
+
+In	O
+addition	O
+,	O
+the	O
+absence	O
+of	O
+a	O
+correlation	O
+between	O
+increased	O
+oligodendroglial	O
+infection	B-DISO
+and	O
+the	O
+extent	O
+of	O
+demyelination	B-DISO
+suggests	O
+a	O
+complex	O
+pathobiology	O
+of	O
+myelin	B-COMP
+loss	O
+in	O
+which	O
+infection	B-DISO
+of	O
+oligodendroglia	B-ANAT
+is	O
+required	O
+but	O
+not	O
+sufficient	O
+.	O
+
+22	O
+-	O
+44	O
+and	O
+351	O
+-	O
+357	O
+)	O
+artificially	O
+linked	O
+together	O
+by	O
+glycine	B-CHED
+,	O
+exhibited	O
+a	O
+potent	O
+antiviral	B-CHED
+activity	O
+with	O
+IC50	O
+of	O
+about	O
+0	O
+.	O
+1	O
+microM	O
+.	O
+This	O
+novel	O
+peptide	B-CHED
+is	O
+a	O
+promising	O
+candidate	O
+as	O
+a	O
+therapeutic	O
+agent	O
+against	O
+this	O
+deadly	O
+emerging	O
+pathogen	O
+.	O
+
+IL	B-FUNC
+-	I-FUNC
+15	I-FUNC
+and	O
+NK	B-ANAT
+cells	I-ANAT
+thus	O
+appear	O
+dispensable	O
+for	O
+anti	O
+-	O
+viral	O
+immunity	B-PROC
+and	O
+CNS	B-CHED
+pathogenesis	B-DISO
+during	O
+acute	O
+JHMV	O
+infection	B-DISO
+.	O
+
+Aimed	O
+at	O
+generating	O
+analogues	O
+by	O
+metabolic	B-PROC
+engineering	O
+,	O
+the	O
+valinomycin	B-CHED
+biosynthetic	B-PROC
+gene	O
+cluster	O
+has	O
+been	O
+cloned	O
+from	O
+Streptomyces	B-SPEC
+tsusimaensis	I-SPEC
+ATCC	O
+15141	O
+.	O
+
+Studies	O
+of	O
+the	O
+1918	O
+pandemic	O
+virus	B-SPEC
+have	O
+shown	O
+the	O
+potential	O
+for	O
+direct	O
+interspecies	O
+transmission	O
+from	O
+an	O
+avian	B-SPEC
+host	B-COMP
+.	O
+
+ABSTRACT	O
+:	O
+So	O
+far	O
+,	O
+most	O
+monoclonal	O
+antibodies	O
+have	O
+been	O
+developed	O
+for	O
+treating	O
+cancer	B-DISO
+or	O
+immunological	B-DISO
+diseases	I-DISO
+.	O
+
+TITLE	O
+:	O
+Severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+(	O
+SARS	B-DISO
+)	O
+coronavirus	B-SPEC
+:	O
+application	O
+of	O
+monoclonal	O
+antibodies	B-COMP
+and	O
+development	O
+of	O
+an	O
+effective	O
+vaccine	O
+.	O
+
+We	O
+also	O
+focus	O
+on	O
+a	O
+variety	O
+of	O
+vaccines	O
+currently	O
+under	O
+development	B-PROC
+and	O
+discuss	O
+the	O
+immune	B-PROC
+response	I-PROC
+elicited	O
+by	O
+these	O
+vaccines	O
+in	O
+animal	B-SPEC
+models	O
+,	O
+hopefully	O
+to	O
+better	O
+understand	O
+what	O
+we	O
+need	O
+to	O
+do	O
+next	O
+to	O
+fight	O
+against	O
+newly	O
+emerging	O
+pathogens	O
+in	O
+the	O
+future	O
+.	O
+
+TITLE	O
+:	O
+A	O
+human	B-SPEC
+neutralizing	O
+antibody	B-COMP
+against	O
+a	O
+conformational	O
+epitope	B-CHED
+shared	O
+by	O
+oligomeric	O
+SARS	B-DISO
+S1	I-PRGE
+protein	B-CHED
+.	O
+
+The	O
+facts	O
+that	O
+scFv	B-PRGE
+H12	I-PRGE
+bound	O
+to	O
+the	O
+SARS	B-PRGE
+-	I-PRGE
+S1	I-PRGE
+protein	B-CHED
+under	O
+non	O
+-	O
+reducing	O
+conditions	O
+and	O
+that	O
+it	O
+did	O
+not	O
+bind	B-FUNC
+to	O
+monomeric	O
+S1	B-PRGE
+protein	I-PRGE
+under	O
+reducing	O
+conditions	O
+strongly	O
+suggest	O
+that	O
+scFv	B-PRGE
+H12	I-PRGE
+recognizes	O
+a	O
+conformational	O
+epitope	B-CHED
+shared	O
+by	O
+oligomeric	O
+S1	O
+proteins	B-CHED
+.	O
+
+ABSTRACT	O
+:	O
+The	O
+fusogenic	O
+potential	O
+of	O
+Class	B-PRGE
+I	I-PRGE
+viral	B-COMP
+envelope	I-COMP
+glycoproteins	B-CHED
+is	O
+activated	O
+by	O
+proteloytic	O
+cleavage	B-PROC
+of	O
+the	O
+precursor	O
+glycoprotein	B-CHED
+to	O
+generate	O
+the	O
+mature	O
+receptor	O
+-	O
+binding	B-FUNC
+and	O
+transmembrane	B-COMP
+fusion	O
+subunits	O
+.	O
+
+The	O
+spike	O
+(	O
+S	O
+)	O
+protein	B-CHED
+of	O
+this	O
+virus	B-SPEC
+is	O
+a	O
+type	B-PRGE
+I	I-PRGE
+surface	I-PRGE
+glycoprotein	I-PRGE
+that	O
+mediates	O
+binding	B-FUNC
+of	O
+the	O
+virus	B-SPEC
+to	O
+the	O
+host	B-COMP
+receptor	O
+and	O
+the	O
+subsequent	O
+fusion	O
+between	O
+the	O
+viral	O
+and	O
+host	B-COMP
+membranes	B-ANAT
+.	O
+
+Previous	O
+infections	B-DISO
+were	O
+noted	O
+in	O
+6	O
+cases	O
+,	O
+and	O
+5	O
+of	O
+those	O
+respiratory	O
+,	O
+and	O
+one	O
+case	O
+of	O
+gastrointestinal	O
+.	O
+
+TITLE	O
+:	O
+[	O
+Prolonged	O
+infusion	O
+of	O
+hydrocortisone	B-CHED
+in	O
+patients	O
+with	O
+severe	O
+community	B-DISO
+acquired	I-DISO
+pneumonia	I-DISO
+].	O
+
+ABSTRACT	O
+:	O
+Despite	O
+advances	O
+in	O
+antimicrobial	O
+therapy	O
+and	O
+supportive	O
+measures	O
+,	O
+mortality	O
+for	O
+patients	O
+with	O
+severe	O
+community	O
+-	O
+acquired	O
+pneumonia	B-DISO
+admitted	O
+to	O
+the	O
+intensive	O
+care	O
+unit	O
+remains	O
+high	O
+,	O
+especially	O
+in	O
+case	O
+of	O
+development	B-PROC
+of	O
+sepsis	B-DISO
+with	O
+its	O
+complications	O
+.	O
+
+(	O
+2	O
+)	O
+Diffuse	B-DISO
+alveolar	I-DISO
+damage	I-DISO
+was	O
+universal	O
+(	O
+6	O
+/	O
+6	O
+)	O
+with	O
+hyaline	B-DISO
+membrane	B-COMP
+formation	B-PROC
+(	O
+6	O
+/	O
+6	O
+),	O
+intra	O
+-	O
+alveolar	B-DISO
+edema	I-DISO
+/	O
+hemorrhage	B-DISO
+(	O
+6	O
+/	O
+6	O
+),	O
+fibrin	B-DISO
+deposition	I-DISO
+(	O
+6	O
+/	O
+6	O
+),	O
+pneumocyte	B-ANAT
+desquamation	O
+(	O
+6	O
+/	O
+6	O
+).	O
+
+A	O
+marked	O
+disruption	O
+in	O
+the	O
+integrity	O
+of	O
+the	O
+alveolar	B-ANAT
+epithelium	I-ANAT
+was	O
+confirmed	O
+by	O
+immunostaining	O
+for	O
+the	O
+epithelial	O
+marker	O
+AE1	O
+/	O
+AE3	O
+(	O
+6	O
+/	O
+6	O
+).	O
+
+The	O
+correlation	O
+of	O
+preoperative	O
+pulmonary	B-PROC
+function	I-PROC
+of	O
+esophageal	B-DISO
+cancer	I-DISO
+to	O
+postoperative	O
+ARDS	B-DISO
+has	O
+seldom	O
+been	O
+reported	O
+.	O
+
+TITLE	O
+:	O
+Severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+diagnostics	O
+using	O
+a	O
+coronavirus	B-SPEC
+protein	B-CHED
+microarray	O
+.	O
+
+We	O
+further	O
+show	O
+that	O
+IBV	B-SPEC
+was	O
+not	O
+inactivated	O
+,	O
+and	O
+fusion	O
+was	O
+unaffected	O
+,	O
+by	O
+prior	O
+exposure	O
+to	O
+pH	O
+5	O
+.	O
+0	O
+buffer	B-CHED
+.	O
+
+ABSTRACT	O
+:	O
+This	O
+study	O
+describes	O
+the	O
+assembly	O
+of	O
+a	O
+full	O
+-	O
+length	O
+cDNA	O
+clone	O
+of	O
+human	O
+coronavirus	O
+(	O
+HCoV	O
+)-	O
+OC43	O
+in	O
+a	O
+bacterial	O
+artificial	O
+chromosome	B-COMP
+(	O
+BAC	O
+).	O
+
+In	O
+this	O
+study	O
+,	O
+novel	O
+bifunctional	O
+quinolonyl	O
+diketo	O
+acid	O
+derivatives	O
+were	O
+designed	O
+,	O
+synthesized	O
+,	O
+and	O
+tested	O
+for	O
+their	O
+inhibitory	O
+ability	O
+against	O
+HIV	B-PRGE
+-	I-PRGE
+1	I-PRGE
+integrase	I-PRGE
+.	O
+
+Hypercapnia	B-DISO
+was	O
+promptly	O
+and	O
+markedly	O
+reversed	O
+by	O
+iLA	O
+within	O
+2	O
+hrs	B-DISO
+(	O
+Paco2	O
+,	O
+36	O
+mm	O
+Hg	O
+[	O
+30	O
+-	O
+44	O
+])	O
+in	O
+comparison	O
+with	O
+before	O
+(	O
+60	O
+mm	O
+Hg	O
+[	O
+48	O
+-	O
+80	O
+],	O
+p	O
+<	O
+.	O
+05	O
+],	O
+which	O
+allowed	O
+a	O
+less	O
+aggressive	B-DISO
+ventilation	O
+.	O
+
+On	O
+multivariate	O
+analysis	O
+of	O
+the	O
+corticosteroid	B-CHED
+groups	O
+,	O
+independent	O
+factors	O
+related	O
+to	O
+death	B-PROC
+were	O
+:	O
+corticosteroid	B-CHED
+group	O
+,	O
+older	O
+age	O
+,	O
+co	O
+-	O
+morbidity	O
+,	O
+worse	O
+chest	B-ANAT
+X	O
+-	O
+ray	B-SPEC
+score	O
+,	O
+worse	O
+respiratory	O
+status	O
+at	O
+Days	O
+8	O
+-	O
+10	O
+and	O
+higher	O
+admission	O
+white	B-ANAT
+cell	I-ANAT
+count	O
+.	O
+
+Patients	O
+on	O
+hydrocortisone	B-CHED
+(	O
+Group	O
+HC	O
+)	O
+had	O
+the	O
+highest	O
+positive	O
+culture	O
+rates	O
+.	O
+
+CONCLUSIONS	O
+:	O
+ICG	B-COMP
+-	O
+PDR	B-DISO
+does	O
+reflect	O
+ICG	B-COMP
+blood	B-ANAT
+clearance	O
+with	O
+sufficient	O
+accuracy	O
+in	O
+critically	B-DISO
+ill	I-DISO
+patients	O
+and	O
+may	O
+be	O
+used	O
+as	O
+a	O
+surrogate	O
+.	O
+
+To	O
+obtain	O
+the	O
+neutralizing	O
+antibody	B-COMP
+to	O
+SARS	B-DISO
+virus	B-SPEC
+surface	O
+proteins	B-CHED
+,	O
+the	O
+library	O
+panning	O
+procedure	O
+was	O
+performed	O
+on	O
+purified	O
+SARS	B-DISO
+virions	B-COMP
+and	O
+the	O
+specific	O
+Fab	B-PRGE
+antibody	I-PRGE
+clones	O
+were	O
+enriched	O
+by	O
+four	O
+rounds	O
+of	O
+repeated	O
+panning	O
+procedure	O
+and	O
+screened	O
+by	O
+highthroughput	O
+selection	O
+.	O
+
+Most	O
+of	O
+these	O
+were	O
+identified	O
+to	O
+recognize	O
+both	O
+natural	O
+and	O
+recombinant	O
+SARS	B-DISO
+spike	O
+(	O
+S	O
+)	O
+proteins	B-CHED
+,	O
+two	O
+Fab	B-PRGE
+antibodies	I-PRGE
+were	O
+specific	O
+for	O
+the	O
+virus	B-SPEC
+membrane	B-COMP
+(	O
+M	O
+)	O
+protein	B-CHED
+,	O
+only	O
+one	O
+bound	O
+to	O
+SARS	B-PRGE
+-	I-PRGE
+CoV	I-PRGE
+nucleocapsid	B-COMP
+protein	B-CHED
+.	O
+
+The	O
+SARS	B-PRGE
+-	I-PRGE
+CoV	I-PRGE
+spike	I-PRGE
+protein	B-CHED
+and	I-PRGE
+membrane	B-COMP
+proteins	B-CHED
+are	O
+able	O
+to	O
+elicite	O
+efficient	O
+neutralizing	O
+antibodies	B-COMP
+in	O
+SARS	B-DISO
+patients	O
+.	O
+
+COX	B-PRGE
+-	I-PRGE
+2	I-PRGE
+promoter	I-PRGE
+mutations	I-PRGE
+suggested	O
+that	O
+activation	O
+of	O
+COX	B-PRGE
+-	I-PRGE
+2	I-PRGE
+transcription	B-PROC
+depended	O
+on	O
+two	O
+regulatory	O
+elements	O
+,	O
+a	O
+nuclear	B-PRGE
+factor	I-PRGE
+-	I-PRGE
+kappa	I-PRGE
+B	I-PRGE
+(	O
+NF	B-PRGE
+-	I-PRGE
+kappaB	I-PRGE
+)	O
+binding	B-FUNC
+site	O
+,	O
+and	O
+a	O
+CCAAT	B-PRGE
+/	I-PRGE
+enhancer	I-PRGE
+binding	I-PRGE
+protein	B-CHED
+(	O
+C	B-PRGE
+/	I-PRGE
+EBP	I-PRGE
+)	O
+binding	B-FUNC
+site	O
+.	O
+
+Protein	B-CHED
+mutation	O
+analysis	O
+revealed	O
+that	O
+a	O
+Lys	B-CHED
+-	O
+rich	O
+motif	O
+of	O
+N	B-PRGE
+protein	I-PRGE
+acted	O
+as	O
+a	O
+nuclear	O
+localization	B-PROC
+signal	O
+and	O
+was	O
+essential	O
+for	O
+the	O
+activation	O
+of	O
+COX	B-PRGE
+-	I-PRGE
+2	I-PRGE
+.	O
+
+In	O
+addition	O
+,	O
+a	O
+Leu	B-CHED
+-	O
+rich	O
+motif	O
+was	O
+found	O
+to	O
+be	O
+required	O
+for	O
+the	O
+N	B-PRGE
+protein	I-PRGE
+function	O
+.	O
+
+TITLE	O
+:	O
+[	O
+Antigenicity	O
+analysis	O
+of	O
+nucleocapsid	B-COMP
+proteins	B-CHED
+of	O
+3	O
+human	B-SPEC
+coronaviruses	O
+SARS	B-DISO
+-	O
+CoV	O
+,	O
+229E	O
+and	O
+OC43	O
+with	O
+their	O
+monoclonal	O
+antibodies	O
+].	O
+
+CONCLUSIONS	O
+:	O
+The	O
+prepared	O
+mAbs	O
+against	O
+the	O
+recombinant	O
+N	O
+proteins	B-CHED
+may	O
+provide	O
+valuable	O
+assistance	O
+in	O
+studying	O
+antigenic	O
+relationships	O
+of	O
+N	O
+proteins	B-CHED
+between	O
+the	O
+3	O
+human	B-SPEC
+coronaviruses	O
+.	O
+
+Activated	B-PRGE
+partial	I-PRGE
+thromboplastin	I-PRGE
+time	I-PRGE
+(	O
+APTT	O
+),	O
+protein	B-PRGE
+C	I-PRGE
+(	O
+PC	O
+),	O
+antithrombin	B-PRGE
+III	I-PRGE
+(	O
+AT	B-PRGE
+-	I-PRGE
+III	I-PRGE
+),	O
+plasminogen	B-PRGE
+activator	O
+inhibitor	B-CHED
+(	O
+PAI	B-PRGE
+),	O
+activated	B-DISO
+protein	I-DISO
+C	I-DISO
+resistance	B-PROC
+(	O
+APC	B-COMP
+-	O
+R	O
+),	O
+plasminogen	B-PRGE
+(	O
+PLG	B-PRGE
+),	O
+von	O
+Willebrand	O
+'	O
+s	O
+factor	O
+(	O
+vWF	B-PRGE
+),	O
+D	O
+-	O
+dimer	O
+(	O
+D	O
+-	O
+D	O
+),	O
+fibrinogen	B-COMP
+(	O
+Fib	B-PRGE
+),	O
+and	O
+homocysteine	B-CHED
+(	O
+HCY	B-CHED
+)	O
+were	O
+examined	O
+by	O
+enzyme	O
+-	O
+linked	O
+immunosorbent	O
+assay	O
+(	O
+ELISA	O
+).	O
+
+ABSTRACT	O
+:	O
+RNA	O
+viruses	O
+are	O
+notorious	O
+for	O
+their	O
+genetic	O
+plasticity	O
+and	O
+propensity	O
+to	O
+exploit	O
+new	O
+host	B-COMP
+-	O
+range	O
+opportunities	O
+,	O
+which	O
+can	O
+lead	O
+to	O
+the	O
+emergence	O
+of	O
+human	B-SPEC
+disease	O
+epidemics	O
+such	O
+as	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+,	O
+AIDS	O
+,	O
+dengue	B-DISO
+,	O
+and	O
+influenza	B-DISO
+.	O
+
+Therefore	O
+,	O
+ecological	O
+and	O
+epidemiological	O
+factors	O
+probably	O
+constrain	O
+the	O
+frequency	O
+of	O
+VEE	O
+epidemics	O
+more	O
+than	O
+the	O
+generation	O
+,	O
+via	O
+mutation	O
+,	O
+of	O
+amplification	B-DISO
+-	O
+competent	O
+(	O
+high	O
+equine	B-SPEC
+viremia	B-DISO
+)	O
+virus	B-SPEC
+strains	O
+.	O
+
+An	O
+ELISA	O
+,	O
+used	O
+to	O
+test	O
+for	O
+the	O
+presence	O
+of	O
+antibodies	O
+to	O
+CRCoV	O
+in	O
+canine	O
+serum	B-COMP
+samples	O
+,	O
+identified	O
+seropositive	O
+dogs	B-SPEC
+in	O
+UK	O
+,	O
+USA	O
+,	O
+Canada	O
+,	O
+Republic	O
+of	O
+Ireland	O
+and	O
+Greece	O
+.	O
+
+The	O
+cross	O
+-	O
+reactivity	O
+demonstrated	O
+between	O
+CRCoV	O
+antibodies	B-COMP
+from	O
+different	O
+countries	O
+and	O
+a	O
+UK	O
+viral	O
+isolate	O
+suggests	O
+immunological	O
+similarity	O
+.	O
+
+ABSTRACT	O
+:	O
+Severe	O
+sepsis	O
+is	O
+sepsis	B-DISO
+associated	O
+with	O
+acute	O
+organ	B-ANAT
+dysfunction	O
+.	O
+
+Once	O
+the	O
+patient	O
+'	O
+s	O
+cardiorespiratory	O
+status	O
+is	O
+stabilized	O
+,	O
+efforts	O
+must	O
+be	O
+directed	O
+at	O
+uncovering	O
+the	O
+source	O
+and	O
+empirically	O
+yet	O
+accurately	O
+treating	O
+the	O
+infective	O
+underpinnings	O
+of	O
+severe	B-DISO
+sepsis	I-DISO
+.	O
+
+The	O
+recombinant	O
+adenovirus	B-DISO
+bearing	O
+S	B-PRGE
+-	I-PRGE
+protein	I-PRGE
+gene	I-PRGE
+was	O
+generated	O
+by	O
+ligation	O
+method	O
+.	O
+
+The	O
+S	B-PRGE
+-	I-PRGE
+protein	I-PRGE
+was	O
+detected	O
+by	O
+Western	O
+blot	O
+and	O
+its	O
+biologic	O
+activity	O
+was	O
+analyzed	O
+by	O
+binding	B-FUNC
+to	O
+Vero	B-ANAT
+cells	I-ANAT
+.	O
+
+CONCLUSIONS	O
+:	O
+The	O
+high	O
+-	O
+level	O
+expression	B-PROC
+of	O
+S	B-PRGE
+-	I-PRGE
+protein	I-PRGE
+in	O
+HEK293	O
+cells	B-COMP
+mediated	O
+by	O
+adenovirus	B-DISO
+can	O
+be	O
+achieved	O
+under	O
+the	O
+optimized	O
+expression	B-PROC
+conditions	O
+.	O
+
+All	O
+three	O
+components	O
+of	O
+occupational	O
+and	O
+organizational	O
+commitments	O
+were	O
+negatively	O
+associated	O
+with	O
+nurses	O
+'	O
+intentions	O
+to	O
+leave	O
+the	O
+nursing	B-PROC
+profession	O
+and	O
+the	O
+organization	O
+.	O
+
+The	O
+fluorescence	O
+intensity	O
+of	O
+dihydrorhodamine	O
+123	O
+staining	O
+indicated	O
+that	O
+cellular	B-COMP
+reactive	B-CHED
+oxygen	I-CHED
+species	I-CHED
+were	O
+markedly	O
+increased	O
+in	O
+SARS	B-DISO
+-	O
+CoV	O
+3CLpro	O
+-	O
+expressing	O
+cells	B-COMP
+.	O
+
+Moreover	O
+,	O
+in	O
+vivo	O
+signalling	B-PROC
+pathway	I-PROC
+assay	O
+indicated	O
+that	O
+3CLpro	O
+increased	O
+the	O
+activation	O
+of	O
+the	O
+nuclear	B-PRGE
+factor	I-PRGE
+-	I-PRGE
+kappa	I-PRGE
+B	I-PRGE
+-	O
+dependent	O
+reporter	O
+,	O
+but	O
+inhibited	O
+activator	B-PRGE
+protein	I-PRGE
+-	I-PRGE
+1	I-PRGE
+-	O
+dependent	O
+transcription	B-PROC
+.	O
+
+ABSTRACT	O
+:	O
+The	O
+advantages	O
+of	O
+nucleic	B-CHED
+acid	I-CHED
+amplification	B-DISO
+tests	O
+(	O
+NAT	B-ENZY
+)	O
+over	O
+conventional	O
+methods	O
+for	O
+the	O
+detection	O
+of	O
+pathogens	O
+in	O
+lower	B-ANAT
+respiratory	I-ANAT
+tract	I-ANAT
+samples	O
+have	O
+not	O
+been	O
+established	O
+.	O
+
+NAT	B-ENZY
+for	O
+respiratory	O
+pathogens	O
+were	O
+performed	O
+on	O
+439	O
+endotracheal	O
+tube	O
+(	O
+ETT	O
+)	O
+and	O
+bronchoalveolar	O
+lavage	O
+(	O
+BAL	B-ENZY
+)	O
+samples	O
+.	O
+
+An	O
+additional	O
+73	O
+pathogens	O
+were	O
+detected	O
+by	O
+NAT	B-ENZY
+in	O
+65	O
+samples	O
+including	O
+30	O
+pathogens	O
+that	O
+were	O
+missed	O
+by	O
+conventional	O
+methods	O
+(	O
+19	O
+adenovirus	B-DISO
+,	O
+6	O
+respiratory	B-SPEC
+syncytial	I-SPEC
+virus	I-SPEC
+,	O
+3	O
+parainfluenza	B-DISO
+virus	B-SPEC
+1	O
+-	O
+4	O
+,	O
+2	O
+influenza	B-PATH
+A	I-PATH
+),	O
+41	O
+pathogens	O
+not	O
+routinely	O
+identified	O
+by	O
+conventional	O
+methods	O
+in	O
+most	O
+laboratories	O
+(	O
+23	O
+rhinovirus	O
+,	O
+8	B-PRGE
+human	I-PRGE
+coronavirus	I-PRGE
+OC43	I-PRGE
+,	I-PRGE
+5	I-PRGE
+human	B-SPEC
+metapneumovirus	I-SPEC
+(	I-PRGE
+hMPV	B-SPEC
+),	I-PRGE
+2	I-PRGE
+human	B-SPEC
+coronavirus	I-SPEC
+229E	I-SPEC
+,	I-PRGE
+2	I-PRGE
+human	B-SPEC
+coronavirus	I-SPEC
+NL63	I-SPEC
+,	I-PRGE
+1	I-PRGE
+Chlamydophila	B-SPEC
+pneumoniae	I-SPEC
+)	O
+and	O
+2	O
+pathogens	O
+from	O
+samples	O
+where	O
+no	O
+respiratory	O
+virus	B-SPEC
+testing	O
+was	O
+requested	O
+(	O
+1	O
+influenza	B-PATH
+A	I-PATH
+,	O
+1	O
+parainfluenza	B-DISO
+virus	B-SPEC
+).	O
+
+Testing	O
+of	O
+nasopharyngeal	B-ANAT
+aspirates	B-ANAT
+(	O
+NPA	B-CHED
+)	O
+from	O
+children	O
+,	O
+throat	B-ANAT
+swabs	O
+,	O
+and	O
+nasal	B-ANAT
+swabs	O
+from	O
+adults	O
+indicated	O
+ImmunoCard	O
+STAT	B-PRGE
+!	O
+
+Overall	O
+results	O
+were	O
+very	O
+similar	O
+for	O
+both	O
+testing	O
+devices	O
+with	O
+the	O
+advantage	O
+of	O
+ImmunoCard	O
+STAT	B-PRGE
+!	O
+
+TITLE	O
+:	O
+Seroprevalence	O
+study	O
+of	O
+feline	B-SPEC
+coronavirus	B-SPEC
+in	O
+owned	O
+and	O
+feral	O
+cats	B-SPEC
+in	O
+Sydney	O
+,	O
+Australia	O
+.	O
+
+TITLE	O
+:	O
+A	O
+multicenter	O
+trial	O
+of	O
+prolonged	O
+prone	O
+ventilation	O
+in	O
+severe	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+.	O
+
+We	O
+enrolled	O
+136	O
+patients	O
+within	O
+48	O
+h	O
+of	O
+tracheal	O
+intubation	O
+for	O
+severe	O
+ARDS	B-DISO
+,	O
+60	O
+randomized	O
+to	O
+supine	O
+and	O
+76	O
+to	O
+prone	O
+ventilation	O
+.	O
+
+Prone	O
+ventilation	O
+is	O
+feasible	O
+and	O
+safe	O
+,	O
+and	O
+may	O
+reduce	O
+mortality	O
+in	O
+patients	O
+with	O
+severe	O
+ARDS	B-DISO
+when	O
+it	O
+is	O
+initiated	O
+early	O
+and	O
+applied	O
+for	O
+most	O
+of	O
+the	O
+day	O
+.	O
+
+Evidence	O
+for	O
+inflammation	B-DISO
+-	O
+induced	O
+target	O
+tissue	B-ANAT
+resistance	B-PROC
+to	O
+glucocorticoids	B-CHED
+.	O
+
+In	O
+both	O
+groups	O
+,	O
+Fio2	O
+was	O
+set	O
+to	O
+maintain	O
+arterial	B-PROC
+oxygen	B-CHED
+saturation	I-PROC
+>	O
+90	O
+%	O
+and	O
+Pao2	O
+70	O
+-	O
+100	O
+mm	O
+Hg	O
+,	O
+and	O
+respiratory	O
+rate	O
+was	O
+adjusted	O
+to	O
+maintain	O
+Paco2	O
+between	O
+35	O
+and	O
+50	O
+mm	O
+Hg	O
+.	O
+
+In	O
+approximately	O
+45	O
+%	O
+of	O
+cases	O
+the	O
+disorder	O
+is	O
+associated	O
+with	O
+cholelithiasis	B-DISO
+,	O
+with	O
+ethanol	B-DISO
+abuse	I-DISO
+accounting	O
+for	O
+a	O
+further	O
+35	O
+%	O
+of	O
+patients	O
+.	O
+
+For	O
+example	O
+,	O
+ERCP	O
+will	O
+reduce	O
+morbidity	O
+in	O
+patients	O
+with	O
+ampullary	O
+or	O
+common	O
+bile	B-ANAT
+duct	I-ANAT
+stones	I-ANAT
+associated	O
+with	O
+acute	B-DISO
+pancreatitis	I-DISO
+,	O
+if	O
+obstructive	B-DISO
+jaundice	I-DISO
+or	O
+cholangitis	B-DISO
+are	O
+present	O
+.	O
+
+In	O
+the	O
+remaining	O
+10	O
+%-	O
+15	O
+%	O
+of	O
+cases	O
+the	O
+disorder	O
+is	O
+life	O
+threatening	O
+with	O
+management	O
+of	O
+the	O
+disorder	O
+requiring	O
+admission	O
+to	O
+an	O
+intensive	O
+care	O
+unit	O
+with	O
+cardiovascular	B-ANAT
+,	O
+respiratory	O
+,	O
+and	O
+renal	B-ANAT
+monitoring	O
+and	O
+support	O
+.	O
+
+ABSTRACT	O
+:	O
+Lung	B-ANAT
+and	O
+kidney	B-ANAT
+function	I-PROC
+are	O
+intimately	O
+related	O
+in	O
+both	O
+health	O
+and	O
+disease	O
+.	O
+
+Successful	O
+lung	B-ANAT
+-	O
+protective	O
+ventilation	O
+in	O
+patients	O
+with	O
+acute	O
+lung	B-ANAT
+injury	O
+and	O
+renal	B-DISO
+failure	I-DISO
+may	O
+require	O
+modification	O
+of	O
+hemodialysis	O
+in	O
+order	B-SPEC
+to	O
+combat	B-CHED
+severe	O
+acidemia	B-DISO
+.	O
+
+Since	O
+the	O
+Hajj	O
+is	O
+dictated	O
+by	O
+the	O
+lunar	O
+calendar	O
+,	O
+which	O
+is	O
+shorter	O
+than	O
+the	O
+Gregorian	O
+calendar	O
+,	O
+it	O
+presents	O
+public	O
+-	O
+health	O
+policy	O
+planners	O
+with	O
+a	O
+moving	B-PROC
+target	O
+,	O
+demanding	O
+constant	O
+preparedness	O
+.	O
+
+ABSTRACT	O
+:	O
+The	O
+pathology	B-DISO
+of	O
+2	O
+zoonotic	O
+human	B-SPEC
+viral	B-DISO
+infections	I-DISO
+that	O
+recently	O
+emerged	O
+,	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+(	O
+SARS	B-DISO
+)	O
+due	O
+to	O
+coronavirus	B-SPEC
+(	O
+SARS	B-DISO
+-	O
+CoV	O
+)	O
+and	O
+avian	B-DISO
+influenza	B-PATH
+A	I-PATH
+subtype	O
+H5N1	B-DISO
+,	O
+is	O
+reviewed	O
+and	O
+compared	O
+based	O
+on	O
+the	O
+literature	O
+and	O
+the	O
+cases	O
+examined	O
+by	O
+the	O
+authors	O
+.	O
+
+TITLE	O
+:	O
+Only	O
+one	O
+protomer	O
+is	O
+active	O
+in	O
+the	O
+dimer	O
+of	O
+SARS	B-PRGE
+3C	I-PRGE
+-	I-PRGE
+like	I-PRGE
+proteinase	B-PROC
+.	O
+
+In	O
+this	O
+report	O
+,	O
+we	O
+have	O
+investigated	O
+,	O
+using	O
+molecular	B-PROC
+dynamics	I-PROC
+simulation	O
+and	O
+mutational	O
+studies	O
+,	O
+the	O
+problems	O
+as	O
+to	O
+why	O
+only	O
+the	O
+dimer	O
+is	O
+active	O
+and	O
+whether	O
+both	O
+of	O
+the	O
+two	O
+protomers	O
+in	O
+the	O
+dimer	O
+are	O
+active	O
+.	O
+
+The	O
+enzyme	B-FUNC
+activity	I-FUNC
+of	O
+the	O
+hybrid	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+coronavirus	B-SPEC
+3C	O
+-	O
+like	O
+protease	O
+of	O
+the	O
+wild	O
+-	O
+type	O
+protein	B-CHED
+and	O
+the	O
+inactive	O
+mutant	B-DISO
+proves	O
+that	O
+the	O
+dimerization	O
+is	O
+important	O
+for	O
+enzyme	B-FUNC
+activity	I-FUNC
+and	O
+only	O
+one	O
+active	O
+protomer	O
+in	O
+the	O
+dimer	O
+is	O
+enough	O
+for	O
+the	O
+catalysis	O
+.	O
+
+These	O
+results	O
+suggest	O
+that	O
+the	O
+enzyme	O
+may	O
+follow	O
+the	O
+association	O
+,	O
+activation	O
+,	O
+catalysis	O
+,	O
+and	O
+dissociation	B-DISO
+mechanism	O
+for	O
+activity	O
+control	O
+.	O
+
+Expression	B-PROC
+of	O
+recombinant	O
+human	B-SPEC
+ALX	O
+in	O
+A549	O
+airway	B-ANAT
+epithelial	B-ANAT
+cells	I-ANAT
+uncovered	O
+ALX	B-PRGE
+-	O
+dependent	O
+inhibition	B-PROC
+of	O
+cytokine	O
+release	B-PATH
+by	O
+LXA	O
+(	O
+4	O
+).	O
+
+ABSTRACT	O
+:	O
+As	O
+influenza	B-DISO
+A	I-DISO
+/	I-DISO
+H5N1	I-DISO
+spreads	O
+around	O
+the	O
+globe	O
+the	O
+risk	O
+of	O
+an	O
+epidemic	O
+increases	O
+.	O
+
+ABSTRACT	O
+:	O
+Acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+(	O
+ARDS	B-DISO
+)	O
+is	O
+the	O
+first	O
+potentially	O
+lethal	O
+complication	B-DISO
+in	O
+rabies	B-DISO
+virus	I-DISO
+infection	I-DISO
+,	O
+although	O
+its	O
+occurrence	O
+is	O
+rare	O
+.	O
+
+Even	O
+though	O
+approximately	O
+10	O
+(	O
+14	O
+)	O
+molecules	O
+are	O
+inoculated	O
+in	O
+the	O
+studies	O
+in	O
+rabbits	B-SPEC
+,	O
+by	O
+day	O
+8	O
+or	O
+9	O
+(	O
+approximately	O
+1	O
+week	O
+postinoculation	O
+),	O
+already	O
+all	O
+but	O
+on	O
+the	O
+order	B-SPEC
+of	O
+10	O
+(	O
+4	O
+)-	O
+10	O
+(	O
+6	O
+)	O
+molecules	O
+per	O
+microgram	O
+of	O
+DNA	O
+extracted	O
+from	O
+tissue	B-ANAT
+have	O
+been	O
+cleared	O
+at	O
+the	O
+injection	O
+site	O
+.	O
+
+However	O
+,	O
+synthesis	B-PROC
+of	O
+IP	B-PRGE
+-	I-PRGE
+10	I-PRGE
+and	O
+IL	B-FUNC
+-	I-FUNC
+8	I-FUNC
+,	O
+which	O
+are	O
+established	O
+markers	O
+for	O
+acute	O
+-	O
+stage	O
+SARS	B-DISO
+,	O
+escapes	O
+the	O
+virus	B-SPEC
+-	O
+induced	O
+silencing	O
+at	O
+least	O
+in	O
+some	O
+cell	B-COMP
+types	O
+.	O
+
+Therefore	O
+,	O
+the	O
+progressive	O
+infiltration	B-DISO
+of	O
+immune	O
+cells	B-COMP
+into	O
+the	O
+infected	O
+lungs	B-ANAT
+observed	O
+in	O
+SARS	B-DISO
+patients	O
+could	O
+be	O
+due	O
+to	O
+the	O
+production	O
+of	O
+these	O
+chemokines	O
+by	O
+the	O
+infected	O
+tissue	B-ANAT
+cells	B-COMP
+.	O
+
+ABSTRACT	O
+:	O
+Induction	O
+of	O
+mucosal	B-PROC
+immunity	I-PROC
+may	O
+be	O
+important	O
+for	O
+preventing	O
+SARS	B-DISO
+-	O
+CoV	O
+infections	B-DISO
+.	O
+
+Surface	O
+localization	B-PROC
+of	O
+the	O
+fusion	O
+protein	B-CHED
+was	O
+verified	O
+by	O
+cellular	B-COMP
+fractionation	O
+analyses	O
+,	O
+immunofluorescence	O
+microscopy	O
+,	O
+and	O
+flow	O
+cytometry	O
+.	O
+
+EToV	O
+M	O
+(	O
+pro	B-PRGE
+)	O
+combines	O
+several	O
+traits	O
+of	O
+its	O
+closest	O
+relatives	O
+.	O
+
+TITLE	O
+:	O
+Neurologic	O
+complications	O
+of	O
+critical	B-DISO
+illness	I-DISO
+:	O
+part	O
+II	O
+.	O
+
+Treatment	O
+of	O
+critical	B-DISO
+illness	I-DISO
+polyneuropathy	I-DISO
+or	O
+myopathy	B-DISO
+requires	O
+largely	O
+management	O
+of	O
+the	O
+underlying	O
+disorder	O
+.	O
+
+For	O
+bovine	B-SPEC
+coronavirus	B-SPEC
+(	O
+BCoV	O
+)	O
+and	O
+related	O
+viruses	B-SPEC
+,	O
+binding	B-FUNC
+to	O
+cell	B-COMP
+surface	I-COMP
+components	O
+containing	O
+N	O
+-	O
+acetyl	B-CHED
+-	O
+9	O
+-	O
+O	B-CHED
+-	I-CHED
+acetylneuraminic	I-CHED
+acid	I-CHED
+is	O
+essential	O
+for	O
+initiation	O
+of	O
+an	O
+infection	B-DISO
+.	O
+
+Interaction	O
+with	O
+sialoglycoconjugates	O
+may	O
+help	O
+the	O
+virus	B-SPEC
+to	O
+pass	O
+through	O
+the	O
+sialic	B-CHED
+acid	I-CHED
+-	O
+rich	O
+mucus	B-COMP
+layer	I-COMP
+that	O
+covers	O
+the	O
+viral	O
+target	B-ANAT
+cells	I-ANAT
+in	O
+the	O
+epithelium	B-ANAT
+of	O
+the	O
+small	B-ANAT
+intestine	I-ANAT
+.	O
+
+ABSTRACT	O
+:	O
+Virus	B-SPEC
+attachment	O
+to	O
+host	B-COMP
+cells	B-COMP
+is	O
+mediated	O
+by	O
+dedicated	O
+virion	B-COMP
+proteins	B-CHED
+,	O
+which	O
+specifically	O
+recognize	O
+one	O
+or	O
+,	O
+at	O
+most	O
+,	O
+a	O
+limited	O
+number	O
+of	O
+cell	B-COMP
+surface	I-COMP
+molecules	O
+.	O
+
+ABSTRACT	O
+:	O
+Infections	B-DISO
+by	O
+mouse	B-DISO
+hepatitis	I-DISO
+viruses	B-SPEC
+result	O
+in	O
+disease	O
+of	O
+the	O
+liver	B-ANAT
+,	O
+the	O
+gastrointestinal	B-ANAT
+tract	I-ANAT
+,	O
+respiratory	B-ANAT
+tract	I-ANAT
+,	O
+and	O
+the	O
+central	B-ANAT
+nervous	I-ANAT
+system	I-ANAT
+.	O
+
+Coronaviruses	O
+related	O
+to	O
+mouse	B-DISO
+hepatitis	I-DISO
+virus	B-SPEC
+express	O
+a	O
+hemagglutinin	B-PRGE
+-	I-PRGE
+esterase	I-PRGE
+surface	I-PRGE
+glycoprotein	I-PRGE
+,	O
+which	O
+specifically	O
+hydrolyses	O
+either	O
+5	O
+-	O
+N	O
+-	O
+acetyl	B-CHED
+-	O
+4	O
+-	O
+O	O
+-	O
+acetyl	B-CHED
+neuraminic	B-CHED
+acid	I-CHED
+(	O
+Neu4	O
+,	O
+5Ac	O
+(	O
+2	O
+))	O
+or	O
+5	O
+-	O
+N	O
+-	O
+acetyl	B-CHED
+-	O
+9	O
+-	O
+O	O
+-	O
+acetyl	B-CHED
+neuraminic	B-CHED
+acid	I-CHED
+(	O
+Neu5	O
+,	O
+9Ac	O
+(	O
+2	O
+)).	O
+
+Using	O
+a	O
+sensitive	O
+method	O
+of	O
+gas	B-ENZY
+chromatography	O
+coupled	O
+to	O
+mass	O
+spectrometry	O
+in	O
+the	O
+electron	O
+impact	O
+mode	O
+of	O
+ionization	O
+this	O
+manuscript	O
+demonstrates	O
+the	O
+occurrence	O
+of	O
+13	O
+different	O
+sialic	O
+acids	O
+varying	O
+in	O
+their	O
+alkyl	O
+and	O
+acyl	O
+substituents	O
+in	O
+mouse	B-SPEC
+tissues	B-ANAT
+including	O
+5	O
+-	O
+N	O
+-	O
+acetyl	B-CHED
+-	O
+4	O
+-	O
+O	O
+-	O
+acetyl	B-CHED
+-	O
+9	O
+-	O
+O	O
+-	O
+lactyl	O
+-	O
+neuraminic	B-CHED
+acid	I-CHED
+(	O
+Neu4	B-PRGE
+,	O
+5Ac	O
+(	O
+2	O
+)	O
+9Lt	O
+),	O
+5	O
+-	O
+N	O
+-	O
+acetyl	B-CHED
+-	O
+9	O
+-	O
+O	O
+-	O
+lactyl	O
+-	O
+neuraminic	B-CHED
+acid	I-CHED
+(	O
+Neu5Ac9Lt	O
+),	O
+5	O
+-	O
+N	O
+-	O
+acetyl	B-CHED
+-	O
+8	O
+-	O
+O	O
+-	O
+methyl	B-CHED
+-	O
+neuraminic	B-CHED
+acid	I-CHED
+(	O
+Neu5Ac8Me	O
+)	O
+and	O
+the	O
+1	O
+,	O
+7	O
+-	O
+lactone	B-CHED
+(	O
+Neu5Ac1	O
+,	O
+7L	O
+)	O
+of	O
+neuraminic	B-CHED
+acid	I-CHED
+.	O
+
+Neu4	B-PRGE
+,	O
+5Ac	O
+(	O
+2	O
+),	O
+relatively	O
+abundant	O
+in	O
+the	O
+gut	B-ANAT
+,	O
+was	O
+present	O
+as	O
+a	O
+minor	O
+compound	O
+in	O
+all	O
+tissues	B-ANAT
+,	O
+including	O
+liver	B-ANAT
+,	O
+olfactory	B-ANAT
+lobe	I-ANAT
+,	O
+telencephalon	B-ANAT
+,	O
+metencephalon	B-ANAT
+and	O
+hippocampus	B-SPEC
+.	O
+
+It	O
+is	O
+suggested	O
+that	O
+these	O
+sialic	B-CHED
+acids	I-CHED
+represent	O
+the	O
+endogenous	O
+substrate	O
+and	O
+receptor	O
+determinants	O
+for	O
+murine	B-SPEC
+coronaviruses	O
+.	O
+
+ABSTRACT	O
+:	O
+A	O
+mysterious	O
+new	O
+respiratory	O
+illness	O
+known	O
+as	O
+severe	O
+acute	O
+respiratory	O
+syndrome	O
+(	O
+SARS	B-DISO
+)	O
+has	O
+become	O
+the	O
+most	O
+perplexing	O
+infectious	B-DISO
+disease	I-DISO
+to	O
+emerge	O
+in	O
+the	O
+21st	O
+century	O
+.	O
+
+To	O
+remain	O
+mission	O
+ready	O
+,	O
+the	O
+U	O
+.	O
+S	O
+.	O
+Forces	O
+Korea	O
+(	O
+USFK	O
+)	O
+commander	O
+declared	O
+a	O
+""""	O
+War	O
+on	O
+SARS	B-DISO
+""""	O
+and	O
+directed	O
+his	O
+medical	O
+staff	O
+to	O
+develop	O
+a	O
+plan	B-DISO
+to	O
+prevent	O
+a	O
+SARS	B-DISO
+outbreak	O
+among	O
+USFK	O
+personnel	O
+.	O
+
+Coronavirus	B-SPEC
+helicases	O
+are	O
+very	O
+conserved	O
+and	O
+peculiar	O
+proteins	B-CHED
+which	O
+have	O
+been	O
+proposed	O
+as	O
+suitable	O
+targets	O
+for	O
+antiviral	B-CHED
+drugs	I-CHED
+,	O
+such	O
+as	O
+bananins	O
+,	O
+which	O
+have	O
+been	O
+recently	O
+shown	O
+to	O
+inhibit	O
+the	O
+SCV	B-PRGE
+helicase	I-PRGE
+in	O
+vitro	O
+.	O
+
+In	O
+this	O
+study	O
+,	O
+we	O
+report	O
+the	O
+interaction	O
+of	O
+a	O
+SARS	B-PRGE
+-	I-PRGE
+CoV	I-PRGE
+7a	I-PRGE
+and	O
+small	O
+glutamine	B-CHED
+-	O
+rich	O
+tetratricopeptide	O
+repeat	O
+-	O
+containing	O
+protein	B-CHED
+(	O
+SGT	O
+).	O
+
+These	O
+proteases	O
+are	O
+important	O
+targets	O
+for	O
+development	B-PROC
+of	O
+antiviral	B-CHED
+drugs	I-CHED
+that	O
+would	O
+inhibit	O
+viral	B-PROC
+replication	I-PROC
+and	O
+reduce	O
+mortality	O
+associated	O
+with	O
+outbreaks	O
+of	O
+SARS	B-DISO
+-	O
+CoV	O
+.	O
+In	O
+this	O
+work	O
+,	O
+we	O
+describe	O
+the	O
+1	O
+.	O
+85	O
+-	O
+A	O
+crystal	B-ANAT
+structure	O
+of	O
+the	O
+catalytic	O
+core	O
+of	O
+SARS	B-PRGE
+-	I-PRGE
+CoV	I-PRGE
+PLpro	I-PRGE
+and	O
+show	O
+that	O
+the	O
+overall	O
+architecture	O
+adopts	O
+a	O
+fold	O
+closely	O
+resembling	O
+that	O
+of	O
+known	O
+deubiquitinating	B-PROC
+enzymes	O
+.	O
+
+ABSTRACT	O
+:	O
+Bovine	B-SPEC
+coronavirus	B-SPEC
+(	O
+BCoV	O
+)	O
+causes	O
+enteric	O
+and	O
+respiratory	O
+dis	O
+-	O
+orders	O
+in	O
+calves	O
+and	O
+dysentery	B-DISO
+in	O
+cows	B-SPEC
+.	O
+
+Findings	O
+were	O
+compared	O
+between	O
+patients	O
+with	O
+laboratory	O
+-	O
+confirmed	O
+SARS	B-DISO
+and	O
+those	O
+in	O
+whom	O
+SARS	B-DISO
+was	O
+excluded	O
+by	O
+laboratory	O
+or	O
+public	O
+health	O
+investigation	O
+.	O
+
+Fever	B-PROC
+occurred	O
+in	O
+97	O
+%	O
+of	O
+patients	O
+by	O
+the	O
+time	O
+of	O
+admission	O
+.	O
+
+Respiratory	O
+findings	O
+including	O
+cough	B-DISO
+,	O
+dyspnea	B-DISO
+and	O
+pulmonary	B-DISO
+infiltrates	I-DISO
+evolved	O
+later	O
+and	O
+were	O
+present	O
+in	O
+only	O
+59	O
+,	O
+37	O
+and	O
+68	O
+%	O
+of	O
+patients	O
+,	O
+respectively	O
+,	O
+at	O
+admission	O
+.	O
+
+In	O
+the	O
+absence	O
+of	O
+fever	B-PROC
+or	O
+significant	O
+exposure	O
+,	O
+SARS	B-DISO
+is	O
+unlikely	O
+.	O
+
+In	O
+addition	O
+,	O
+in	O
+vitro	O
+experiments	O
+demonstrated	O
+that	O
+stimulated	O
+V	B-PRGE
+gamma	I-PRGE
+9V	I-PRGE
+delta	I-PRGE
+2	I-PRGE
+T	B-ANAT
+cells	I-ANAT
+display	O
+an	O
+interferon	B-PRGE
+-	I-PRGE
+gamma	I-PRGE
+-	I-PRGE
+dependent	I-PRGE
+anti	I-PRGE
+-	I-PRGE
+SARS	I-PRGE
+-	I-PRGE
+CoV	I-PRGE
+activity	O
+and	O
+are	O
+able	O
+to	O
+directly	O
+kill	O
+SARS	B-DISO
+-	O
+CoV	O
+-	O
+infected	O
+target	B-ANAT
+cells	I-ANAT
+.	O
+
+Moreover	O
+,	O
+phylogenetic	O
+analysis	O
+of	O
+the	O
+S1	B-PRGE
+gene	I-PRGE
+suggested	O
+that	O
+the	O
+Italy	O
+02	O
+genotype	O
+has	O
+undergone	O
+a	O
+recombination	B-PROC
+event	O
+.	O
+
+The	O
+deduced	O
+sequence	O
+of	O
+66	O
+amino	B-CHED
+acids	I-CHED
+had	O
+66	O
+to	O
+74	O
+%	O
+amino	B-CHED
+acid	I-CHED
+identity	O
+with	O
+the	O
+corresponding	O
+sequence	O
+of	O
+coronaviruses	O
+in	O
+groups	O
+1	O
+,	O
+2	O
+and	O
+3	O
+.	O
+
+Several	O
+other	O
+oligonucleotide	B-CHED
+primer	O
+pairs	O
+that	O
+give	O
+PCR	O
+products	O
+corresponding	O
+to	O
+genes	O
+3	O
+,	O
+5	O
+,	O
+N	O
+and	O
+the	O
+3	O
+'-	O
+untranslated	O
+region	O
+of	O
+infectious	B-DISO
+bronchitis	B-DISO
+virus	B-SPEC
+,	O
+turkey	B-SPEC
+coronavirus	B-SPEC
+and	O
+pheasant	O
+coronavirus	B-SPEC
+(	O
+all	O
+in	O
+group	O
+3	O
+)	O
+failed	O
+to	O
+do	O
+so	O
+with	O
+RNA	O
+from	O
+the	O
+parrot	O
+coronavirus	B-SPEC
+.	O
+
+Various	O
+other	O
+compounds	O
+,	O
+often	O
+with	O
+an	O
+ill	B-DISO
+-	O
+defined	O
+mode	O
+of	O
+action	O
+but	O
+selectivity	O
+indexes	O
+up	O
+to	O
+100	O
+,	O
+have	O
+been	O
+reported	O
+to	O
+exhibit	O
+in	O
+vitro	O
+activity	O
+against	O
+SARS	B-PRGE
+-	I-PRGE
+CoV	I-PRGE
+:	O
+valinomycin	B-CHED
+,	O
+glycopeptide	B-CHED
+antibiotics	B-CHED
+,	O
+plant	B-SPEC
+lectins	O
+,	O
+hesperetin	B-CHED
+,	O
+glycyrrhizin	B-CHED
+,	O
+aurintricarboxylic	O
+acid	O
+,	O
+chloroquine	B-CHED
+,	O
+niclosamide	O
+,	O
+nelfinavir	O
+and	O
+calpain	O
+inhibitors	B-CHED
+.	O
+
+By	O
+mimicking	O
+immune	B-PROC
+responses	I-PROC
+with	O
+the	O
+use	O
+of	O
+RBD	O
+as	O
+an	O
+antigen	B-CHED
+to	O
+screen	O
+a	O
+large	O
+human	B-SPEC
+antibody	B-COMP
+library	O
+derived	O
+from	O
+healthy	O
+volunteers	O
+,	O
+we	O
+identified	O
+a	O
+novel	O
+potent	O
+cross	B-PROC
+-	I-PROC
+reactive	I-PROC
+SCV	B-PRGE
+-	I-PRGE
+neutralizing	I-PRGE
+monoclonal	I-PRGE
+antibody	B-COMP
+,	O
+m396	O
+,	O
+which	O
+competes	O
+with	O
+ACE2	B-PRGE
+for	O
+binding	B-FUNC
+to	O
+RBD	O
+,	O
+and	O
+determined	O
+the	O
+crystal	O
+structure	O
+of	O
+the	O
+RBD	O
+-	O
+antibody	B-COMP
+complex	O
+at	O
+2	O
+.	O
+3	O
+-	O
+A	O
+resolution	O
+.	O
+
+Each	O
+received	O
+inhaled	O
+NO	O
+(	O
+20	O
+-	O
+25	O
+ppm	O
+)	O
+via	O
+the	O
+inspiratory	B-PROC
+side	O
+of	O
+the	O
+breathing	B-PROC
+circuit	O
+of	O
+the	O
+ventilator	O
+.	O
+
+Inhaled	B-PROC
+NO	O
+may	O
+be	O
+useful	O
+in	O
+treating	O
+acute	B-DISO
+massive	I-DISO
+pulmonary	I-DISO
+embolism	I-DISO
+.	O
+
+Further	O
+decreases	O
+in	O
+prevalence	O
+rates	O
+in	O
+the	O
+last	O
+10	O
+years	O
+were	O
+found	O
+for	O
+infections	B-DISO
+such	O
+as	O
+pneumonia	B-SPEC
+virus	I-SPEC
+of	I-SPEC
+mice	I-SPEC
+,	O
+reovirus	B-SPEC
+type	O
+3	O
+,	O
+Sendai	B-SPEC
+virus	I-SPEC
+,	O
+sialodacryoadenitis	O
+/	O
+rat	B-SPEC
+coronavirus	B-SPEC
+and	O
+Mycoplasma	B-SPEC
+pulmonis	I-SPEC
+.	O
+
+Guinea	B-SPEC
+pig	I-SPEC
+cytomegalovirus	I-SPEC
+and	O
+para	B-DISO
+-	I-DISO
+influenza	B-SPEC
+virus	I-SPEC
+appeared	O
+to	O
+be	O
+the	O
+most	O
+prevalent	O
+agents	O
+among	O
+laboratory	O
+guinea	B-SPEC
+pigs	I-SPEC
+.	O
+
+In	O
+the	O
+clinical	O
+experiments	O
+,	O
+the	O
+doctors	O
+wearing	O
+the	O
+equipment	O
+who	O
+performed	O
+the	O
+tracheotomy	O
+for	O
+a	O
+SARS	B-DISO
+patient	O
+in	O
+a	O
+deep	O
+coma	B-DISO
+were	O
+not	O
+infected	O
+.	O
+
+RESULTS	O
+:	O
+The	O
+HEPA	O
+filter	O
+could	O
+filtrate	O
+99	O
+.	O
+99	O
+%	O
+simulating	O
+viruses	B-SPEC
+in	O
+the	O
+air	B-CHED
+.	O
+
+The	O
+binding	B-FUNC
+interface	O
+of	O
+SARS	B-PRGE
+-	I-PRGE
+CoV	I-PRGE
+3CL	I-PRGE
+(	O
+pro	B-PRGE
+)	O
+that	O
+is	O
+facing	O
+the	O
+P1	O
+'	O
+position	O
+is	O
+suggested	O
+to	O
+be	O
+occupied	O
+by	O
+acidic	O
+amino	B-CHED
+acids	I-CHED
+,	O
+thus	O
+the	O
+P1	O
+'	O
+position	O
+is	O
+intolerant	O
+to	O
+acidic	O
+residue	O
+substitution	O
+,	O
+owing	O
+to	O
+electrostatic	O
+repulsion	O
+.	O
+
+Seldom	O
+,	O
+the	O
+classical	O
+trial	O
+of	O
+muscle	B-DISO
+pain	I-DISO
+,	O
+weakness	B-DISO
+,	O
+and	O
+dark	B-DISO
+urine	I-DISO
+is	O
+observed	O
+.	O
+
+Severe	O
+complications	O
+are	O
+hypovolemia	O
+,	O
+electrolyte	O
+disorders	O
+,	O
+a	O
+compartment	B-DISO
+syndrome	I-DISO
+,	O
+disseminated	B-DISO
+intravascular	I-DISO
+coagulation	I-DISO
+and	O
+acute	B-DISO
+renal	I-DISO
+failure	I-DISO
+,	O
+which	O
+causes	O
+death	B-PROC
+in	O
+20	O
+%	O
+of	O
+the	O
+patients	O
+,	O
+although	O
+non	O
+-	O
+traumatic	O
+causes	O
+seem	O
+to	O
+have	O
+better	O
+outcome	O
+.	O
+
+Previous	O
+studies	O
+of	O
+geographically	O
+and	O
+chronologically	O
+distinct	O
+Human	B-PRGE
+coronavirus	I-PRGE
+229E	I-PRGE
+(	O
+HCoV	B-SPEC
+-	I-SPEC
+229E	I-SPEC
+)	O
+isolates	O
+have	O
+found	O
+only	O
+limited	O
+variation	O
+within	O
+S	B-PRGE
+gene	I-PRGE
+nucleotide	B-CHED
+sequences	O
+.	O
+
+In	O
+previous	O
+studies	O
+,	O
+with	O
+respect	O
+to	O
+the	O
+haemagglutinating	O
+activity	O
+of	O
+IBV	B-SPEC
+,	O
+it	O
+has	O
+been	O
+shown	O
+that	O
+the	O
+virus	B-SPEC
+preferentially	O
+recognizes	O
+alpha2	O
+,	O
+3	O
+-	O
+linked	O
+sialic	B-CHED
+acid	I-CHED
+.	O
+
+In	O
+the	O
+previous	O
+our	O
+study	O
+,	O
+we	O
+demonstrated	O
+that	O
+the	O
+spike	O
+glycoprotein	B-CHED
+gene	O
+of	O
+Korean	O
+winter	B-DISO
+dysentery	I-DISO
+(	O
+WD	O
+)	O
+BCoV	O
+had	O
+a	O
+genetic	O
+property	O
+of	O
+both	O
+enteric	O
+(	O
+EBCV	O
+)	O
+and	O
+respiratory	O
+BCoV	O
+(	O
+RBCV	O
+)	O
+and	O
+were	O
+significantly	O
+distinct	O
+from	O
+the	O
+ancestral	O
+enteric	O
+strains	O
+.	O
+
+The	O
+third	O
+group	O
+possessed	B-DISO
+only	O
+all	O
+Korean	O
+WD	O
+strains	O
+which	O
+were	O
+more	O
+homologous	O
+to	O
+each	O
+other	O
+and	O
+were	O
+sharply	O
+distinct	O
+from	O
+the	O
+other	O
+known	O
+BCoV	O
+,	O
+suggesting	O
+Korean	O
+WD	O
+strains	O
+had	O
+evolutionary	O
+distinct	O
+pathway	B-PROC
+.	O
+
+In	O
+contrast	O
+,	O
+the	O
+relative	O
+conservation	O
+of	O
+the	O
+M	O
+and	O
+E	O
+proteins	B-CHED
+of	O
+BCoV	O
+including	O
+Korean	O
+WD	O
+strains	O
+and	O
+the	O
+other	O
+coronaviruses	O
+suggested	O
+that	O
+structural	O
+constraints	O
+on	O
+these	O
+proteins	B-CHED
+are	O
+rigid	B-DISO
+,	O
+resulting	O
+in	O
+more	O
+limited	O
+evolution	B-PROC
+of	O
+these	O
+proteins	B-CHED
+.	O
+
+All	O
+NHPs	O
+demonstrated	O
+evidence	O
+of	O
+viral	B-PROC
+replication	I-PROC
+and	O
+developed	O
+neutralizing	O
+antibodies	B-COMP
+.	O
+
+Both	O
+femoral	B-ANAT
+arteries	I-ANAT
+and	O
+one	O
+femoral	B-ANAT
+vein	I-ANAT
+were	O
+cannulated	O
+and	O
+connected	O
+with	O
+ILA	O
+.	O
+
+Acute	O
+lung	B-ANAT
+injury	O
+was	O
+induced	O
+by	O
+repeated	O
+bronchoalveolar	O
+lavage	O
+until	O
+the	O
+arterial	B-ANAT
+partial	O
+pressure	O
+of	O
+O2	O
+was	O
+lower	O
+than	O
+100	O
+Torr	O
+for	O
+at	O
+least	O
+30	O
+minutes	O
+during	O
+ventilation	O
+with	O
+100	O
+%	O
+O2	O
+.	O
+
+Oxygenation	B-PROC
+is	O
+increased	O
+by	O
+ILA	B-PRGE
+in	O
+severe	O
+lung	B-ANAT
+injury	O
+.	O
+
+Pulmonary	B-ANAT
+artery	I-ANAT
+pressures	O
+were	O
+significantly	O
+reduced	O
+when	O
+ILA	O
+was	O
+in	O
+operation	O
+.	O
+
+ABSTRACT	O
+:	O
+Volume	O
+replacement	O
+was	O
+studied	O
+prospectively	O
+in	O
+208	O
+infants	O
+with	O
+dengue	O
+hemorrhagic	O
+fever	O
+/	O
+dengue	B-DISO
+shock	I-DISO
+syndrome	I-DISO
+(	O
+DHF	O
+/	O
+DSS	B-DISO
+).	O
+
+The	O
+mean	O
+volumes	O
+of	O
+intravenous	O
+fluid	O
+replacement	O
+in	O
+infants	O
+with	O
+DSS	B-DISO
+was	O
+significantly	O
+higher	O
+than	O
+in	O
+those	O
+with	O
+non	O
+-	O
+shock	O
+DHF	O
+(	O
+129	O
+.	O
+8	O
+mL	O
+/	O
+kg	O
+versus	O
+102	O
+.	O
+1	O
+mL	O
+/	O
+kg	O
+;	O
+P	O
+=	O
+0	O
+.	O
+001	O
+).	O
+
+Recurrent	O
+shock	O
+,	O
+prolonged	O
+shock	O
+,	O
+and	O
+acute	B-DISO
+respiratory	I-DISO
+failure	I-DISO
+were	O
+recorded	O
+in	O
+8	O
+,	O
+6	O
+,	O
+and	O
+13	O
+patients	O
+,	O
+respectively	O
+.	O
+
+Acute	B-DISO
+renal	I-DISO
+failure	I-DISO
+(	O
+ARF	B-DISO
+)	O
+may	O
+also	O
+occur	O
+and	O
+/	O
+or	O
+complicate	O
+the	O
+disease	O
+course	O
+,	O
+however	O
+,	O
+its	O
+incidence	O
+,	O
+causes	O
+and	O
+impact	O
+in	O
+SARS	B-DISO
+patients	O
+are	O
+not	O
+known	O
+.	O
+
+The	O
+clinical	O
+features	O
+of	O
+patients	O
+with	O
+ARF	B-DISO
+were	O
+characterized	O
+,	O
+and	O
+the	O
+etiologies	O
+analyzed	O
+.	O
+
+ARF	B-DISO
+developed	O
+7	O
+.	O
+2	O
++/-	O
+
+Multiple	B-DISO
+organ	I-DISO
+system	I-DISO
+failure	I-DISO
+usually	O
+accompanied	O
+ARF	B-DISO
+.	O
+
+Of	O
+the	O
+16	O
+medical	O
+staff	O
+performing	O
+renal	B-ANAT
+replacement	O
+therapy	O
+,	O
+none	O
+was	O
+subsequently	O
+infected	O
+with	O
+SARS	B-DISO
+coronavirus	B-SPEC
+.	O
+
+Antisense	O
+technologies	O
+,	O
+which	O
+encompass	O
+small	O
+interfering	O
+RNA	O
+,	O
+antisense	O
+oligonucleotides	B-CHED
+,	O
+ribozymes	O
+and	O
+their	O
+chemically	O
+modified	O
+analogs	O
+,	O
+involve	O
+small	O
+sequence	O
+-	O
+specific	O
+nucleic	B-COMP
+-	O
+acid	O
+-	O
+based	O
+molecules	O
+that	O
+inhibit	O
+viral	B-PROC
+replication	I-PROC
+at	O
+the	O
+level	O
+of	O
+translation	B-PROC
+.	O
+
+The	O
+helicase	B-PRGE
+inhibitors	B-CHED
+discussed	O
+here	O
+influence	O
+rates	O
+of	O
+helicase	B-PRGE
+-	O
+catalyzed	O
+DNA	O
+(	O
+or	O
+RNA	O
+)	O
+unwinding	O
+by	O
+preventing	O
+ATP	B-PROC
+hydrolysis	I-PROC
+,	O
+nucleic	B-FUNC
+acid	I-FUNC
+binding	I-FUNC
+,	O
+nucleic	B-CHED
+acid	I-CHED
+release	B-PATH
+,	O
+or	O
+by	O
+disrupting	O
+the	O
+interaction	O
+of	O
+a	O
+helicase	B-PRGE
+with	O
+a	O
+required	O
+cofactor	B-CHED
+.	O
+
+A	O
+chymotrypsin	B-PRGE
+-	I-PRGE
+like	I-PRGE
+cysteine	B-CHED
+protease	I-PRGE
+named	I-PRGE
+3C	I-PRGE
+-	I-PRGE
+like	I-PRGE
+protease	I-PRGE
+(	O
+3CLpro	O
+)	O
+is	O
+essential	O
+for	O
+the	O
+life	O
+cycle	O
+of	O
+the	O
+SARS	B-DISO
+-	O
+CoV	O
+.	O
+This	O
+main	O
+protease	O
+is	O
+responsible	O
+for	O
+maturation	B-PROC
+of	O
+functional	O
+proteins	B-CHED
+and	O
+represents	O
+a	O
+key	O
+anti	O
+-	O
+viral	O
+target	O
+.	O
+
+The	O
+different	O
+classes	O
+of	O
+inhibitors	B-CHED
+reported	O
+in	O
+these	O
+studies	O
+are	O
+summarized	O
+in	O
+this	O
+review	O
+.	O
+
+Some	O
+of	O
+these	O
+inhibitors	B-CHED
+could	O
+be	O
+developed	O
+into	O
+potential	O
+drug	O
+candidates	O
+,	O
+which	O
+may	O
+provide	O
+a	O
+solution	O
+to	O
+combat	B-CHED
+possible	O
+reoccurrence	O
+of	O
+the	O
+SARS	B-DISO
+and	O
+other	O
+life	O
+-	O
+threatening	O
+viruses	B-SPEC
+with	O
+3CL	O
+proteases	O
+.	O
+
+Aspartic	B-CHED
+acid	I-CHED
+residues	O
+440	O
+and	O
+441	O
+were	O
+identified	O
+as	O
+functionally	O
+important	O
+.	O
+
+No	O
+statistically	O
+significant	O
+associations	O
+between	O
+PP	O
+response	O
+and	O
+age	O
+,	O
+gender	O
+,	O
+weight	O
+,	O
+PEEP	B-CHED
+level	O
+,	O
+tidal	O
+volume	O
+,	O
+respiratory	O
+rate	O
+,	O
+PaO2	O
+/	O
+FiO2	O
+or	O
+duration	O
+of	O
+mechanical	O
+ventilation	O
+were	O
+detected	O
+.	O
+
+TITLE	O
+:	O
+SARS	B-DISO
+outbreak	O
+in	O
+Germany	O
+2003	O
+:	O
+workload	O
+of	O
+local	O
+health	O
+departments	O
+and	O
+their	O
+compliance	O
+in	O
+quarantine	O
+measures	O
+--	O
+implications	O
+for	O
+outbreak	O
+modeling	O
+and	O
+surge	O
+capacity	O
+?	O
+
+Of	O
+the	O
+patients	O
+with	O
+moderate	O
+and	O
+severe	O
+pulmonary	B-DISO
+hypertension	I-DISO
+,	O
+43	O
+had	O
+a	O
+pulmonary	B-ANAT
+artery	I-ANAT
+trunk	B-ANAT
+diameter	O
+>	O
+or	O
+=	O
+29	O
+mm	O
+yielding	O
+a	O
+sensitivity	O
+of	O
+0	O
+.	O
+54	O
+and	O
+a	O
+specificity	O
+of	O
+0	O
+.	O
+63	O
+.	O
+
+Pulmonary	B-ANAT
+artery	I-ANAT
+trunk	B-ANAT
+diameter	O
+correlated	O
+significantly	O
+but	O
+weakly	O
+with	O
+mean	O
+pulmonary	B-ANAT
+artery	I-ANAT
+pressure	O
+(	O
+r	O
+=	O
+0	O
+.	O
+34	O
+,	O
+p	O
+=	O
+0	O
+.	O
+0004	O
+).	O
+
+Measurement	O
+of	O
+PAT	B-DISO
+diameter	O
+on	O
+admission	O
+CT	O
+scan	O
+is	O
+an	O
+unreliable	O
+tool	O
+for	O
+identification	O
+of	O
+ARDS	B-DISO
+patients	O
+with	O
+pulmonary	B-DISO
+hypertension	I-DISO
+.	O
+
+TITLE	O
+:	O
+A	O
+single	O
+amino	B-CHED
+acid	I-CHED
+substitution	O
+(	O
+R441A	O
+)	O
+in	O
+the	O
+receptor	O
+-	O
+binding	B-FUNC
+domain	O
+of	O
+SARS	B-DISO
+coronavirus	B-SPEC
+spike	I-PRGE
+protein	I-PRGE
+disrupts	O
+the	O
+antigenic	O
+structure	O
+and	O
+binding	B-PROC
+activity	I-PROC
+.	O
+
+The	O
+Wimley	O
+and	O
+White	O
+interfacial	O
+hydrophobicity	O
+scale	O
+was	O
+used	O
+to	O
+identify	O
+regions	O
+within	O
+the	O
+CoV	B-PRGE
+S2	I-PRGE
+subunit	I-PRGE
+that	O
+may	O
+preferentially	O
+associate	O
+with	O
+lipid	B-CHED
+membranes	B-ANAT
+with	O
+the	O
+premise	O
+that	O
+peptides	B-CHED
+analogous	O
+to	O
+these	O
+regions	O
+may	O
+function	O
+as	O
+inhibitors	B-CHED
+of	O
+viral	O
+infectivity	O
+.	O
+
+It	O
+seems	O
+that	O
+patients	O
+attempt	O
+to	O
+reduce	O
+the	O
+effect	O
+of	O
+external	O
+stressors	O
+by	O
+living	O
+in	O
+an	O
+""""	O
+autistic	B-DISO
+bubble	O
+""""	O
+(	O
+in	O
+which	O
+outside	O
+threats	O
+cannot	O
+enter	O
+)	O
+or	O
+by	O
+denying	O
+the	O
+significance	O
+of	O
+these	O
+stressors	O
+and	O
+over	O
+-	O
+emphasizing	O
+the	O
+power	O
+of	O
+medical	O
+authorities	O
+to	O
+protect	O
+them	O
+.	O
+
+Patients	O
+felt	O
+more	O
+protected	O
+by	O
+the	O
+authorities	O
+and	O
+some	O
+perceived	O
+the	O
+epidemic	O
+in	O
+a	O
+psychotic	B-DISO
+manner	O
+.	O
+
+The	O
+spleen	B-ANAT
+,	O
+mesenteric	B-ANAT
+lymph	I-ANAT
+nodes	I-ANAT
+and	O
+bone	B-ANAT
+marrow	I-ANAT
+from	O
+naturally	O
+FCoV	O
+-	O
+infected	O
+cats	B-SPEC
+with	O
+and	O
+without	O
+FIP	B-DISO
+and	O
+specific	O
+pathogen	O
+-	O
+free	O
+(	O
+SPF	O
+)	O
+control	O
+cats	B-SPEC
+were	O
+examined	O
+for	O
+the	O
+quantity	O
+and	O
+activation	O
+state	O
+of	O
+monocytes	B-ANAT
+/	O
+macrophages	B-ANAT
+both	O
+by	O
+immunohistology	O
+and	O
+by	O
+quantitative	O
+real	O
+time	O
+PCR	O
+for	O
+the	O
+transcription	B-PROC
+of	O
+interleukin	B-PRGE
+(	O
+IL	O
+)-	O
+1beta	O
+,	O
+IL	B-FUNC
+-	I-FUNC
+6	I-FUNC
+,	O
+IL	B-FUNC
+-	I-FUNC
+10	I-FUNC
+,	O
+IL	B-PRGE
+-	I-PRGE
+12	I-PRGE
+p40	B-COMP
+,	O
+tumour	B-DISO
+necrosis	I-DISO
+factor	O
+(	O
+TNF	B-PRGE
+),	O
+granulocyte	B-PRGE
+colony	I-PRGE
+stimulating	I-PRGE
+factor	I-PRGE
+(	O
+G	B-PRGE
+-	I-PRGE
+CSF	I-PRGE
+),	O
+macrophage	B-PRGE
+-	I-PRGE
+CSF	B-ANAT
+(	O
+M	B-PRGE
+-	I-PRGE
+CSF	I-PRGE
+)	O
+and	O
+GM	B-PRGE
+-	I-PRGE
+CSF	I-PRGE
+.	O
+
+In	O
+cats	B-SPEC
+with	O
+FIP	B-DISO
+,	O
+however	O
+,	O
+IL	B-PRGE
+-	I-PRGE
+12	I-PRGE
+p40	B-COMP
+levels	O
+were	O
+significantly	O
+lower	O
+in	O
+lymphatic	B-ANAT
+tissues	I-ANAT
+in	O
+comparison	O
+to	O
+both	O
+SPF	O
+cats	B-SPEC
+and	O
+FCoV	O
+-	O
+infected	O
+cats	B-SPEC
+without	O
+FIP	B-DISO
+.	O
+
+By	O
+not	O
+inhibiting	O
+viral	B-PROC
+replication	I-PROC
+in	O
+the	O
+lungs	B-ANAT
+of	O
+infected	O
+mice	B-SPEC
+,	O
+ribavirin	B-CHED
+treatment	O
+may	O
+have	O
+provided	O
+a	O
+continual	O
+source	O
+of	O
+stimulation	O
+for	O
+the	O
+inflammatory	B-DISO
+response	I-DISO
+thought	O
+to	O
+contribute	O
+to	O
+the	O
+pathogenesis	B-DISO
+of	O
+the	O
+infection	B-DISO
+.	O
+
+Our	O
+data	O
+do	O
+not	O
+support	O
+the	O
+use	O
+of	O
+ribavirin	B-CHED
+or	O
+other	O
+IMP	B-PRGE
+dehydrogenase	I-PRGE
+inhibitors	B-CHED
+for	O
+treating	O
+SARS	B-DISO
+infections	B-DISO
+in	O
+humans	B-SPEC
+.	O
+
+Taken	O
+together	O
+,	O
+these	O
+data	O
+demonstrate	O
+that	O
+immunization	O
+with	O
+SARS	B-DISO
+-	O
+CoV	O
+S	O
+DNA	O
+vaccine	O
+can	O
+generate	O
+antigen	B-CHED
+-	O
+specific	O
+humoral	O
+and	O
+cellular	B-PROC
+immune	I-PROC
+responses	I-PROC
+that	O
+may	O
+contribute	O
+to	O
+long	O
+-	O
+term	O
+protection	O
+.	O
+
+RESULTS	O
+:	O
+Three	O
+(	O
+1	O
+.	O
+2	O
+%)	O
+out	O
+of	O
+the	O
+245	O
+samples	O
+were	O
+positive	O
+for	O
+HCoV	B-SPEC
+-	I-SPEC
+NL63	I-SPEC
+by	O
+nested	O
+-	O
+PCR	O
+using	O
+primers	O
+on	O
+1b	O
+gene	O
+.	O
+
+ABSTRACT	O
+:	O
+To	O
+determine	O
+the	O
+sequence	O
+of	O
+S2	B-PRGE
+gene	I-PRGE
+of	O
+SARS	B-DISO
+-	I-DISO
+associated	I-DISO
+coronavirus	I-DISO
+(	O
+SARS	B-PRGE
+-	I-PRGE
+CoV	I-PRGE
+)	O
+GD322	O
+and	O
+analyze	O
+the	O
+phyletic	O
+evolution	B-PROC
+of	O
+S2	B-PRGE
+gene	I-PRGE
+.	O
+
+S2	O
+gene	O
+fragment	O
+was	O
+amplified	O
+from	O
+SARS	B-DISO
+-	O
+CoV	O
+GD322	O
+genome	O
+with	O
+RT	O
+-	O
+PCR	O
+and	O
+ligated	O
+to	O
+pGEM	B-CHED
+-	O
+T	O
+vector	O
+for	O
+sequence	O
+analysis	O
+after	O
+transformation	B-DISO
+of	O
+the	O
+plasmid	O
+into	O
+E	B-PRGE
+.	I-PRGE
+coli	I-PRGE
+DH5a	I-PRGE
+.	O
+
+CONCLUSIONS	O
+:	O
+S2	O
+gene	O
+of	O
+GD322	B-PRGE
+SARS	I-PRGE
+-	I-PRGE
+CoV	I-PRGE
+is	O
+relatively	O
+stable	O
+during	O
+the	O
+epidemic	O
+spread	O
+of	O
+the	O
+virus	B-SPEC
+,	O
+and	O
+mutation	O
+at	O
+the	O
+57th	O
+amino	B-CHED
+acids	I-CHED
+of	O
+S2	B-PRGE
+protein	I-PRGE
+may	O
+affect	O
+the	O
+T	B-PRGE
+cell	I-PRGE
+antigen	B-CHED
+epitope	B-CHED
+.	O
+
+Prospectively	O
+randomized	O
+crossover	O
+animal	B-SPEC
+study	O
+.	O
+
+The	O
+genome	O
+was	O
+directly	O
+accessed	O
+from	O
+the	O
+stool	B-ANAT
+sample	I-ANAT
+of	O
+a	O
+patient	O
+in	O
+Beijing	O
+.	O
+
+Comparative	O
+genomics	O
+methods	O
+were	O
+used	O
+to	O
+analyze	O
+the	O
+sequence	O
+variations	O
+of	O
+116	O
+SARS	B-DISO
+-	O
+CoV	O
+genomes	O
+(	O
+including	O
+BJ202	O
+)	O
+available	O
+in	O
+the	O
+NCBI	O
+GenBank	O
+.	O
+
+The	O
+nucleotide	B-CHED
+composition	O
+of	O
+this	O
+site	O
+is	O
+A	O
+(	O
+8	O
+)	O
+to	O
+G	O
+(	O
+6	O
+).	O
+
+Health	O
+care	O
+professionals	O
+(	O
+HCPs	O
+)	O
+and	O
+hospital	O
+systems	O
+that	O
+bore	B-CHED
+the	O
+brunt	O
+of	O
+the	O
+SARS	B-DISO
+outbreak	O
+continue	O
+to	O
+struggle	O
+with	O
+the	O
+aftermath	O
+of	O
+the	O
+crisis	O
+.	O
+
+Many	O
+were	O
+exposed	O
+to	O
+serious	O
+risk	O
+of	O
+morbidity	O
+and	O
+mortality	O
+,	O
+as	O
+evidenced	O
+by	O
+the	O
+World	O
+Health	O
+Organization	O
+figures	O
+showing	O
+that	O
+approximately	O
+30	O
+%	O
+of	O
+reported	O
+cases	O
+were	O
+among	O
+HCPs	O
+,	O
+some	O
+of	O
+whom	O
+died	B-PROC
+from	O
+the	O
+infection	B-DISO
+.	O
+
+In	O
+this	O
+paper	O
+,	O
+we	O
+address	O
+the	O
+issue	O
+of	O
+special	O
+obligations	O
+of	O
+HCPs	O
+during	O
+an	O
+infectious	B-DISO
+disease	I-DISO
+outbreak	O
+.	O
+
+Staff	O
+who	O
+considered	O
+combined	O
+infection	B-DISO
+control	O
+measures	O
+effective	O
+in	O
+protecting	O
+patients	O
+and	O
+healthcare	O
+workers	O
+did	O
+not	O
+report	O
+increased	O
+compliance	O
+.	O
+
+Global	O
+interconnectedness	O
+continues	O
+to	O
+increase	O
+with	O
+international	O
+travel	O
+and	O
+trade	O
+;	O
+economic	O
+,	O
+political	O
+,	O
+and	O
+cultural	O
+interactions	O
+;	O
+and	O
+human	B-SPEC
+-	O
+to	O
+-	O
+human	B-SPEC
+and	O
+animal	B-SPEC
+-	O
+to	O
+-	O
+human	B-SPEC
+interactions	O
+.	O
+
+These	O
+conditions	O
+made	O
+designing	O
+appropriate	O
+,	O
+effective	O
+and	O
+standard	O
+infection	B-DISO
+control	O
+responses	O
+difficult	O
+.	O
+
+Interferon	B-PRGE
+-	I-PRGE
+alpha	I-PRGE
+(	O
+IFN	B-PRGE
+-	I-PRGE
+alpha	I-PRGE
+)	O
+alone	O
+was	O
+a	O
+poor	O
+inducer	O
+of	O
+MoDC	O
+maturation	B-PROC
+,	O
+but	O
+in	O
+association	O
+with	O
+tumour	B-PRGE
+necrosis	I-PRGE
+factor	I-PRGE
+-	I-PRGE
+alpha	I-PRGE
+(	O
+TNF	B-PRGE
+-	I-PRGE
+alpha	I-PRGE
+),	O
+or	O
+TLR	O
+ligands	O
+such	O
+as	O
+lipopolysaccharide	B-CHED
+and	O
+polyinosinic	O
+-	O
+polycytidylic	O
+acid	O
+I	O
+:	O
+C	O
+,	O
+an	O
+up	B-PROC
+-	I-PROC
+regulation	I-PROC
+of	O
+major	B-PROC
+histocompatibility	I-PROC
+complex	I-PROC
+II	O
+and	O
+CD80	B-PRGE
+/	I-PRGE
+86	I-PRGE
+expression	B-PROC
+was	O
+noted	O
+,	O
+along	O
+with	O
+reduced	O
+endocytic	O
+activity	O
+.	O
+
+Indeed	O
+,	O
+MoDC	O
+did	O
+not	O
+respond	O
+to	O
+transmissible	O
+gastroenteritis	B-DISO
+virus	B-SPEC
+(	O
+TGEV	B-SPEC
+),	O
+whereas	O
+NIPC	O
+produced	O
+high	O
+levels	O
+of	O
+IFN	B-PRGE
+-	I-PRGE
+alpha	I-PRGE
+and	O
+TNF	B-PRGE
+-	I-PRGE
+alpha	I-PRGE
+after	O
+TGEV	B-SPEC
+stimulation	O
+.	O
+
+In	O
+addition	O
+,	O
+previous	O
+reports	O
+identified	O
+three	O
+HLA	B-PRGE
+-	I-PRGE
+A	I-PRGE
+*	I-PRGE
+0201	I-PRGE
+-	O
+restricted	O
+CTL	B-ANAT
+epitopes	O
+of	O
+S	B-PRGE
+protein	I-PRGE
+(	O
+S978	O
+-	O
+986	O
+,	O
+S1203	O
+-	O
+1211	O
+,	O
+and	O
+S1167	O
+-	O
+1175	O
+),	O
+here	O
+we	O
+found	O
+two	O
+novel	O
+peptides	B-CHED
+S787	O
+-	O
+795	O
+and	O
+S1042	O
+-	O
+1050	O
+as	O
+S	O
+-	O
+specific	O
+CTL	B-ANAT
+epitopes	O
+.	O
+
+These	O
+peptides	B-CHED
+,	O
+which	O
+had	O
+no	O
+apparent	O
+homologous	O
+motif	O
+within	O
+or	O
+between	O
+the	O
+peptide	B-CHED
+pools	O
+and	O
+spike	O
+protein	B-CHED
+,	O
+were	O
+deconvoluted	O
+into	O
+amino	O
+acid	O
+pairs	O
+(	O
+AAPs	O
+)	O
+by	O
+Mapitope	O
+and	O
+the	O
+statistically	O
+significant	O
+pairs	O
+(	O
+SSPs	B-DISO
+)	O
+were	O
+defined	O
+.	O
+
+The	O
+sources	O
+of	O
+data	O
+include	O
+population	O
+figures	O
+on	O
+the	O
+development	B-PROC
+of	O
+these	O
+epidemics	O
+and	O
+findings	O
+from	O
+two	O
+sociological	O
+studies	O
+of	O
+representative	O
+samples	O
+of	O
+Singapore	O
+'	O
+s	O
+multi	O
+-	O
+ethnic	O
+population	O
+.	O
+
+SARS	B-PRGE
+-	I-PRGE
+3CL	I-PRGE
+(	I-PRGE
+pro	B-CHED
+)	I-PRGE
+has	O
+been	O
+shown	O
+to	O
+be	O
+essential	O
+for	O
+replication	O
+and	O
+is	O
+thus	O
+a	O
+target	O
+for	O
+drug	O
+discovery	O
+.	O
+
+ABSTRACT	O
+:	O
+SARS	B-DISO
+-	I-DISO
+associated	I-DISO
+coronavirus	I-DISO
+was	O
+identified	O
+as	O
+the	O
+etiological	O
+agent	O
+of	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+and	O
+a	O
+large	O
+virus	B-SPEC
+pool	O
+was	O
+identified	O
+in	O
+wild	O
+animals	B-SPEC
+.	O
+
+Successful	O
+balloon	O
+valvuloplasty	O
+was	O
+performed	O
+with	O
+ICE	B-PRGE
+proving	O
+highly	O
+valuable	O
+in	O
+guiding	O
+balloon	O
+position	O
+as	O
+well	O
+as	O
+monitoring	O
+the	O
+efficacy	O
+of	O
+the	O
+subsequent	O
+inflations	O
+.	O
+
+As	O
+intravenous	O
+administration	O
+of	O
+nifekalant	O
+terminated	O
+VT	O
+,	O
+we	O
+started	O
+oral	B-ANAT
+administration	O
+of	O
+amiodarone	B-CHED
+(	O
+day	O
+1	O
+).	O
+
+A	O
+total	O
+of	O
+16	O
+patients	O
+with	O
+confirmed	O
+H5N1	B-DISO
+were	O
+identified	O
+for	O
+the	O
+case	O
+-	O
+control	O
+study	O
+.	O
+
+Early	O
+avian	B-DISO
+influenza	I-DISO
+in	O
+children	O
+resembled	O
+the	O
+more	O
+common	O
+dengue	B-DISO
+fever	I-DISO
+,	O
+but	O
+presence	O
+of	O
+cough	B-DISO
+and	O
+absence	O
+of	O
+hemoconcentration	O
+distinguished	O
+avian	B-DISO
+influenza	I-DISO
+,	O
+which	O
+often	O
+progressed	O
+rapidly	O
+to	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+,	O
+requiring	O
+intensive	O
+care	O
+.	O
+
+In	O
+August	O
+of	O
+each	O
+of	O
+the	O
+years	O
+1998	O
+-	O
+2003	O
+,	O
+between	O
+149	O
+and	O
+185	O
+4	O
+-	O
+8	O
+-	O
+month	O
+-	O
+old	O
+calves	O
+arrived	O
+at	O
+the	O
+station	O
+from	O
+99	O
+to	O
+124	O
+different	O
+beef	O
+-	O
+breeding	B-PROC
+herds	O
+,	O
+and	O
+remained	O
+until	O
+March	O
+the	O
+following	O
+year	O
+.	O
+
+Serological	O
+testing	O
+on	O
+samples	O
+obtained	O
+in	O
+August	O
+,	O
+November	O
+and	O
+January	O
+indicated	O
+that	O
+bovine	B-SPEC
+parainfluenza	I-SPEC
+virus	I-SPEC
+3	I-SPEC
+(	O
+PIV	O
+-	O
+3	O
+)	O
+infections	B-DISO
+occurred	O
+each	O
+year	O
+before	O
+November	O
+after	O
+entry	O
+.	O
+
+Bovine	B-SPEC
+respiratory	I-SPEC
+syncytial	I-SPEC
+virus	I-SPEC
+(	O
+BRSV	B-SPEC
+)	O
+infections	B-DISO
+occurred	O
+only	O
+every	O
+second	O
+year	O
+and	O
+were	O
+associated	O
+with	O
+a	O
+treatment	O
+peak	O
+and	O
+one	O
+death	B-PROC
+on	O
+one	O
+occasion	O
+(	O
+December	O
+).	O
+
+Coronavirus	B-SPEC
+assembly	O
+also	O
+takes	O
+place	O
+at	O
+pre	O
+-	O
+Golgi	B-COMP
+membranes	B-ANAT
+.	O
+
+Here	O
+,	O
+we	O
+generated	O
+coronavirus	B-SPEC
+-	O
+like	O
+particles	O
+carrying	O
+in	O
+their	O
+envelope	B-PRGE
+chimeric	I-PRGE
+HCV	B-SPEC
+glycoproteins	B-CHED
+composed	O
+of	O
+the	O
+ectodomains	O
+of	O
+E1	O
+and	O
+E2	O
+,	O
+each	O
+fused	O
+to	O
+the	O
+transmembrane	B-COMP
+plus	O
+endodomain	O
+of	O
+the	O
+mouse	B-DISO
+hepatitis	B-PRGE
+coronavirus	I-PRGE
+spike	I-PRGE
+glycoprotein	B-CHED
+.	O
+
+A	O
+novel	O
+member	O
+of	O
+the	O
+coronavirus	B-SPEC
+,	O
+SARS	B-PRGE
+-	I-PRGE
+CoV	I-PRGE
+,	O
+has	O
+been	O
+identified	O
+as	O
+the	O
+causative	O
+agent	O
+.	O
+
+ABSTRACT	O
+:	O
+Little	O
+is	O
+known	O
+about	O
+the	O
+long	O
+-	O
+term	O
+consequence	O
+of	O
+severe	O
+acute	O
+respiratory	O
+syndrome	O
+(	O
+SARS	B-DISO
+).	O
+
+Postal	O
+survey	O
+comprising	O
+Health	O
+-	O
+Related	O
+Quality	O
+of	O
+Life	O
+(	O
+HRQoL	O
+)	O
+questionnaires	O
+and	O
+anxiety	O
+and	O
+depression	B-DISO
+measures	O
+was	O
+sent	O
+to	O
+them	O
+at	O
+3	O
+months	O
+'	O
+postdischarge	O
+.	O
+
+METHODS	O
+:	O
+Postal	O
+survey	O
+comprising	O
+Health	O
+-	O
+Related	O
+Quality	O
+of	O
+Life	O
+(	O
+HRQoL	O
+)	O
+questionnaires	O
+and	O
+anxiety	O
+and	O
+depression	B-DISO
+measures	O
+was	O
+sent	O
+to	O
+them	O
+at	O
+3	O
+months	O
+'	O
+postdischarge	O
+.	O
+
+CONCLUSIONS	O
+:	O
+SARS	B-DISO
+has	O
+significant	O
+impact	O
+on	O
+HRQoL	O
+and	O
+psychological	B-DISO
+status	O
+at	O
+3	O
+months	O
+.	O
+
+ABSTRACT	O
+:	O
+A	O
+high	O
+initial	O
+or	O
+peak	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+(	O
+SARS	B-DISO
+)-	O
+associated	O
+coronavirus	B-SPEC
+(	O
+SARS	B-DISO
+-	O
+CoV	O
+)	O
+load	O
+in	O
+nasopharyngeal	B-ANAT
+specimens	O
+was	O
+shown	O
+to	O
+be	O
+associated	O
+with	O
+a	O
+high	O
+mortality	O
+rate	O
+.	O
+
+The	O
+nationwide	O
+SARS	B-DISO
+database	O
+in	O
+Taiwan	O
+was	O
+analyzed	O
+,	O
+and	O
+genotyping	O
+of	O
+281	O
+single	O
+-	O
+nucleotide	B-CHED
+polymorphisms	B-PROC
+(	O
+SNPs	B-PROC
+)	O
+of	O
+65	O
+genes	O
+was	O
+performed	O
+for	O
+94	O
+patients	O
+with	O
+SARS	B-DISO
+,	O
+to	O
+identify	O
+SNPs	B-PROC
+for	O
+which	O
+distribution	O
+between	O
+patients	O
+with	O
+or	O
+without	O
+detectable	O
+nasopharyngeal	B-ANAT
+shedding	O
+of	O
+SARS	B-PRGE
+-	I-PRGE
+CoV	I-PRGE
+was	O
+biased	O
+.	O
+
+Titers	O
+of	O
+SARS	B-DISO
+-	O
+CoV	O
+shed	O
+in	O
+nasopharyngeal	B-ANAT
+specimens	O
+varied	O
+widely	O
+,	O
+ranging	O
+from	O
+nondetectable	O
+to	O
+10	O
+(	O
+8	O
+)	O
+SARS	B-DISO
+-	O
+CoV	O
+RNA	O
+copies	O
+/	O
+mL	O
+,	O
+and	O
+they	O
+were	O
+correlated	O
+positively	O
+with	O
+a	O
+high	O
+mortality	O
+rate	O
+(	O
+P	O
+<.	O
+0001	O
+,	O
+by	O
+trend	O
+test	O
+)	O
+and	O
+with	O
+early	O
+death	O
+(	O
+i	O
+.	O
+e	O
+.,	O
+death	B-PROC
+occurring	O
+within	O
+2	O
+weeks	O
+of	O
+the	O
+onset	O
+of	O
+illness	O
+)	O
+(	O
+P	O
+=.	O
+0015	O
+,	O
+by	O
+trend	O
+test	O
+).	O
+
+Detectable	O
+nasopharyngeal	B-ANAT
+shedding	O
+of	O
+SARS	B-PRGE
+-	I-PRGE
+CoV	I-PRGE
+was	O
+associated	O
+with	O
+polymorphic	O
+alleles	O
+of	O
+interleukins	O
+18	O
+(	O
+P	O
+=.	O
+014	O
+)	O
+and	O
+1A	O
+(	O
+P	O
+=.	O
+031	O
+)	O
+and	O
+a	O
+member	O
+of	O
+NF	B-PRGE
+kappa	I-PRGE
+B	I-PRGE
+complex	I-PRGE
+(	O
+reticuloendotheliosis	B-PRGE
+viral	I-PRGE
+oncogene	I-PRGE
+homolog	I-PRGE
+B	I-PRGE
+[	I-PRGE
+RelB	I-PRGE
+])	I-PRGE
+(	O
+P	O
+=.	O
+034	O
+),	O
+all	O
+of	O
+which	O
+are	O
+proinflammatory	O
+in	O
+nature	O
+,	O
+as	O
+well	O
+as	O
+the	O
+procoagulation	B-PRGE
+molecule	I-PRGE
+fibrinogen	I-PRGE
+-	I-PRGE
+like	I-PRGE
+protein	B-CHED
+2	I-PRGE
+(	O
+P	O
+=.	O
+008	O
+).	O
+
+RESULTS	O
+:	O
+Titers	O
+of	O
+SARS	B-DISO
+-	O
+CoV	O
+shed	O
+in	O
+nasopharyngeal	B-ANAT
+specimens	O
+varied	O
+widely	O
+,	O
+ranging	O
+from	O
+nondetectable	O
+to	O
+10	O
+(	O
+8	O
+)	O
+SARS	B-DISO
+-	O
+CoV	O
+RNA	O
+copies	O
+/	O
+mL	O
+,	O
+and	O
+they	O
+were	O
+correlated	O
+positively	O
+with	O
+a	O
+high	O
+mortality	O
+rate	O
+(	O
+P	O
+<.	O
+0001	O
+,	O
+by	O
+trend	O
+test	O
+)	O
+and	O
+with	O
+early	O
+death	B-PROC
+(	O
+i	O
+.	O
+e	O
+.,	O
+death	B-PROC
+occurring	O
+within	O
+2	O
+weeks	O
+of	O
+the	O
+onset	O
+of	O
+illness	O
+)	O
+(	O
+P	O
+=.	O
+0015	O
+,	O
+by	O
+trend	O
+test	O
+).	O
+
+ABSTRACT	O
+:	O
+The	O
+spike	O
+(	O
+S	O
+)	O
+protein	B-CHED
+of	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+coronavirus	B-SPEC
+(	O
+SARS	B-DISO
+-	O
+CoV	O
+)	O
+is	O
+considered	O
+as	O
+a	O
+protective	O
+Ag	O
+for	O
+vaccine	O
+design	O
+.	O
+
+Interestingly	O
+,	O
+the	O
+Conf	O
+V	O
+epitope	B-CHED
+,	O
+which	O
+may	O
+overlap	O
+the	O
+receptor	O
+-	O
+binding	B-FUNC
+motif	O
+and	O
+induce	O
+most	O
+potent	O
+neutralizing	O
+Abs	O
+,	O
+was	O
+conserved	O
+in	O
+these	O
+mutants	O
+.	O
+
+Medical	O
+personnel	O
+were	O
+infected	O
+only	O
+if	O
+they	O
+cared	O
+for	O
+patients	O
+with	O
+unrecognized	O
+SARS	B-DISO
+,	O
+and	O
+caretakers	O
+played	O
+important	O
+roles	O
+in	O
+transmission	O
+of	O
+SARS	B-DISO
+to	O
+family	B-SPEC
+members	O
+.	O
+
+As	O
+the	O
+number	O
+of	O
+cases	O
+of	O
+nosocomial	O
+SARS	B-DISO
+increased	O
+,	O
+the	O
+hospital	O
+closed	O
+the	O
+affected	O
+ward	O
+and	O
+expedited	O
+construction	O
+of	O
+negative	O
+-	O
+pressure	O
+rooms	O
+on	O
+other	O
+vacated	O
+floors	O
+for	O
+patient	O
+cohorting	O
+,	O
+and	O
+the	O
+last	O
+case	O
+in	O
+the	O
+hospital	O
+was	O
+identified	O
+1	O
+week	O
+later	O
+.	O
+
+Seventeen	O
+HCWs	O
+from	O
+6	O
+hospitals	O
+developed	O
+disease	O
+that	O
+met	B-CHED
+the	O
+case	O
+definition	O
+for	O
+SARS	B-DISO
+after	O
+implementation	O
+of	O
+infection	B-DISO
+control	O
+precautions	O
+.	O
+
+RESULTS	O
+:	O
+Seventeen	O
+HCWs	O
+from	O
+6	O
+hospitals	O
+developed	O
+disease	O
+that	O
+met	B-CHED
+the	O
+case	O
+definition	O
+for	O
+SARS	B-DISO
+after	O
+implementation	O
+of	O
+infection	B-DISO
+control	O
+precautions	O
+.	O
+
+We	O
+examined	O
+whether	O
+polymorphisms	B-PROC
+of	O
+IFN	B-PRGE
+-	I-PRGE
+gamma	I-PRGE
+,	O
+TNF	B-PRGE
+-	I-PRGE
+alpha	I-PRGE
+and	O
+IL	B-FUNC
+-	I-FUNC
+10	I-FUNC
+affect	O
+the	O
+susceptibility	O
+to	O
+and	O
+outcome	O
+of	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+(	O
+SARS	B-DISO
+).	O
+
+The	O
+polymorphisms	B-PROC
+of	O
+IL	B-FUNC
+-	I-FUNC
+10	I-FUNC
+and	O
+TNF	B-PRGE
+-	I-PRGE
+alpha	I-PRGE
+were	O
+not	O
+associated	O
+with	O
+SARS	B-PRGE
+susceptibility	I-PRGE
+.	O
+
+The	O
+polymorphisms	B-PROC
+of	O
+IL	B-FUNC
+-	I-FUNC
+10	I-FUNC
+and	O
+TNF	B-PRGE
+-	I-PRGE
+alpha	I-PRGE
+were	O
+not	O
+associated	O
+with	O
+SARS	B-PRGE
+susceptibility	I-PRGE
+.	O
+
+CONCLUSIONS	O
+:	O
+IFN	B-PRGE
+-	I-PRGE
+gamma	I-PRGE
++	I-PRGE
+874A	I-PRGE
+allele	I-PRGE
+was	O
+shown	O
+to	O
+be	O
+a	O
+risk	O
+factor	O
+in	O
+SARS	B-PRGE
+susceptibility	I-PRGE
+.	O
+
+ABSTRACT	O
+:	O
+The	O
+recombinant	O
+antigen	B-CHED
+obtained	O
+by	O
+cloning	O
+and	O
+expressing	O
+two	O
+IBV	B-SPEC
+nucleocapsid	B-COMP
+protein	B-CHED
+fragments	O
+(	O
+143	O
+-	O
+414	O
+aa	O
+,	O
+281	O
+-	O
+414	O
+aa	O
+)	O
+in	O
+Escherichia	B-SPEC
+coli	I-SPEC
+was	O
+used	O
+for	O
+the	O
+detection	O
+of	O
+avian	B-DISO
+infectious	I-DISO
+bronchitis	I-DISO
+virus	B-SPEC
+(	O
+IBV	B-SPEC
+)	O
+specific	O
+antibodies	B-COMP
+in	O
+chicken	B-SPEC
+sera	B-COMP
+by	O
+the	O
+indirect	O
+ELISA	O
+(	O
+rNpIBV	O
+-	O
+ELISA	O
+).	O
+
+The	O
+treatment	O
+of	O
+rhinovirus	B-SPEC
+infections	B-DISO
+:	O
+progress	O
+and	O
+potential	O
+.	O
+
+Association	O
+of	O
+rhinovirus	B-SPEC
+infections	B-DISO
+with	O
+asthma	B-PATH
+.	O
+
+Detection	O
+of	O
+rhinovirus	B-SPEC
+in	O
+sinus	B-DISO
+brushings	O
+of	O
+patients	O
+with	O
+acute	O
+community	O
+-	O
+acquired	O
+sinusitis	B-DISO
+by	O
+reverse	B-PROC
+transcription	I-PROC
+-	O
+PCR	O
+.	O
+
+Although	O
+effective	O
+over	O
+-	O
+the	O
+-	O
+counter	B-CHED
+products	O
+have	O
+been	O
+described	O
+that	O
+alleviate	O
+symptoms	O
+associated	O
+with	O
+the	O
+common	B-DISO
+cold	I-DISO
+[	O
+Anzueto	O
+,	O
+A	O
+.,	O
+Niederman	O
+,	O
+M	O
+.	O
+S	O
+.,	O
+2003	O
+.	O
+
+Chemotherapy	O
+of	O
+rhinovirus	B-SPEC
+colds	B-DISO
+.	O
+
+32	O
+,	O
+409	O
+-	O
+419	O
+],	O
+this	O
+review	O
+will	O
+primarily	O
+focus	O
+on	O
+the	O
+discovery	O
+and	O
+development	B-PROC
+of	O
+those	O
+agents	O
+that	O
+directly	O
+or	O
+indirectly	O
+impact	O
+virus	B-PROC
+replication	I-PROC
+specifically	O
+highlighting	O
+new	O
+advances	O
+and	O
+/	O
+or	O
+specific	O
+challenges	O
+with	O
+their	O
+development	B-PROC
+.	O
+
+Remarkably	O
+,	O
+we	O
+noted	O
+that	O
+W	O
+/	O
+O	O
+-	O
+type	O
+emulsions	O
+induced	O
+the	O
+best	O
+immune	B-PROC
+responses	I-PROC
+,	O
+while	O
+they	O
+released	O
+no	O
+antigen	B-CHED
+during	O
+3	O
+weeks	O
+.	O
+
+The	O
+DNA	O
+sequencing	O
+data	O
+showed	O
+no	O
+homology	O
+between	O
+the	O
+sequences	O
+of	O
+the	O
+deduced	O
+amino	B-CHED
+acid	I-CHED
+of	O
+the	O
+two	O
+mimic	O
+antigen	B-CHED
+peptides	B-CHED
+and	O
+the	O
+sequence	O
+of	O
+SARS	B-DISO
+.	O
+
+This	O
+method	O
+might	O
+provide	O
+a	O
+new	O
+approach	O
+for	O
+SARS	B-DISO
+therapy	O
+and	O
+vaccine	O
+development	B-PROC
+.	O
+
+In	O
+the	O
+differential	O
+diagnosis	O
+of	O
+major	O
+nasal	B-ANAT
+airway	B-DISO
+obstruction	I-DISO
+in	O
+the	O
+newborn	O
+,	O
+choanal	B-DISO
+atresia	I-DISO
+is	O
+by	O
+far	O
+the	O
+most	O
+common	O
+aetiology	O
+.	O
+
+Surgery	O
+was	O
+performed	O
+at	O
+4	O
+months	O
+through	O
+an	O
+unusual	O
+endonasal	B-ANAT
+approach	O
+which	O
+seems	O
+to	O
+be	O
+less	O
+traumatic	O
+than	O
+the	O
+classical	O
+sublabial	O
+approach	O
+.	O
+
+Moist	B-DISO
+rales	I-DISO
+were	O
+heard	O
+in	O
+4	O
+patients	O
+.	O
+
+The	O
+most	O
+common	O
+imaging	O
+abnormalities	O
+were	O
+unilateral	O
+and	O
+(	O
+or	O
+)	O
+bilateral	O
+multi	O
+-	O
+focal	O
+or	O
+solitary	O
+alveolar	B-ANAT
+nodular	O
+opacities	B-DISO
+(	O
+9	O
+patients	O
+).	O
+
+The	O
+colony	O
+occurrences	O
+and	O
+similar	O
+clinical	O
+and	O
+chest	B-ANAT
+imaging	O
+manifestations	O
+are	O
+characteristics	O
+of	O
+an	O
+outbreak	O
+of	O
+respiratory	B-DISO
+infection	I-DISO
+caused	O
+by	O
+CP	O
+in	O
+medical	O
+workers	O
+.	O
+
+An	O
+outbreak	O
+of	O
+respiratory	B-DISO
+infection	I-DISO
+caused	O
+by	O
+CP	O
+should	O
+be	O
+differentiated	B-PROC
+from	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+(	O
+SARS	B-DISO
+).	O
+
+Real	O
+-	O
+time	O
+PCR	O
+was	O
+used	O
+to	O
+detect	O
+the	O
+mutation	O
+of	O
+factor	B-PRGE
+V	I-PRGE
+G1601A	I-PRGE
+(	I-PRGE
+FV	I-PRGE
+Leiden	I-PRGE
+)	I-PRGE
+and	O
+prothrombin	B-PRGE
+G20210A	I-PRGE
+.	O
+
+The	O
+percentage	O
+of	O
+patients	O
+with	O
+3	O
+or	O
+more	O
+abnormal	O
+indicators	O
+was	O
+72	O
+.	O
+1	O
+%	O
+(	O
+44	O
+/	O
+61	O
+)	O
+in	O
+the	O
+osteonecrosis	B-DISO
+group	O
+,	O
+significantly	O
+higher	O
+than	O
+that	O
+of	O
+the	O
+control	O
+group	O
+(	O
+17	O
+.	O
+3	O
+%,	O
+9	O
+/	O
+52	O
+,	O
+P	O
+<	O
+0	O
+.	O
+01	O
+).	O
+
+RESULTS	O
+:	O
+The	O
+levels	O
+of	O
+PC	O
+,	O
+AT	B-PRGE
+-	I-PRGE
+III	I-PRGE
+,	O
+and	O
+PLG	B-CHED
+of	O
+the	O
+osteonecrosis	B-DISO
+group	O
+were	O
+85	O
+%	O
++/-	O
+
+CONCLUSIONS	O
+:	O
+Trends	O
+of	O
+hypercoagulation	O
+and	O
+hypofibrinolysis	O
+exist	O
+in	O
+the	O
+post	O
+-	O
+SARS	B-DISO
+patients	O
+with	O
+osteonecrosis	B-DISO
+.	O
+
+These	O
+rDIs	O
+elicited	O
+SARS	B-DISO
+-	O
+CoV	O
+-	O
+specific	O
+serum	B-COMP
+IgG	B-COMP
+antibody	I-COMP
+and	O
+T	B-ANAT
+-	I-ANAT
+cell	I-ANAT
+responses	O
+in	O
+vaccinated	O
+mice	B-SPEC
+following	O
+intranasal	O
+or	O
+subcutaneous	O
+administration	O
+.	O
+
+ABSTRACT	O
+:	O
+Taiwan	O
+experienced	O
+one	O
+of	O
+the	O
+most	O
+serious	O
+outbreaks	O
+of	O
+severe	O
+acute	O
+respiratory	O
+syndrome	O
+(	O
+SARS	B-DISO
+)	O
+during	O
+the	O
+2003	O
+epidemic	O
+.	O
+
+TITLE	O
+:	O
+A	O
+climatologic	O
+investigation	O
+of	O
+the	O
+SARS	B-DISO
+-	O
+CoV	O
+outbreak	O
+in	O
+Beijing	O
+,	O
+China	O
+.	O
+
+The	O
+dissociation	B-DISO
+constant	O
+of	O
+AS3	B-CHED
+-	O
+3	O
+was	O
+1	O
+.	O
+98	O
+x	O
+10	O
+(-	O
+8	O
+)	O
+M	O
+.	O
+Immunofluorescent	O
+microscopy	O
+revealed	O
+that	O
+it	O
+reacted	O
+with	O
+SARS	B-DISO
+-	O
+CoV	O
+-	O
+infected	O
+cells	B-COMP
+.	O
+
+We	O
+recruited	O
+353	O
+and	O
+361	O
+children	O
+,	O
+respectively	O
+,	O
+from	O
+the	O
+high	O
+-	O
+risk	O
+and	O
+low	O
+-	O
+risk	O
+areas	O
+and	O
+collected	O
+3	O
+to	O
+5	O
+mL	O
+of	O
+blood	O
+for	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+coronavirus	B-SPEC
+IgG	B-COMP
+antibody	I-COMP
+testing	O
+by	O
+immunofluorescence	O
+antibody	B-COMP
+assay	O
+and	O
+confirmation	O
+by	O
+neutralization	O
+test	O
+.	O
+
+The	O
+genome	O
+of	O
+SARS	B-DISO
+-	O
+CoV	O
+contains	O
+four	O
+structural	O
+genes	O
+that	O
+are	O
+homologous	O
+to	O
+genes	O
+found	O
+in	O
+other	O
+coronaviruses	O
+,	O
+as	O
+well	O
+as	O
+six	O
+subgroup	O
+-	O
+specific	O
+open	O
+reading	O
+frames	O
+(	O
+ORFs	O
+).	O
+
+This	O
+increased	O
+susceptibility	O
+to	O
+developing	O
+acute	O
+lung	B-ANAT
+injury	O
+has	O
+been	O
+evaluated	O
+by	O
+many	O
+investigators	O
+,	O
+and	O
+the	O
+common	O
+variable	O
+appears	O
+to	O
+be	O
+oxidative	B-DISO
+stress	I-DISO
+.	O
+
+ABSTRACT	O
+:	O
+For	O
+patients	O
+with	O
+most	O
+severe	O
+acute	O
+respiratory	O
+distress	O
+syndrome	O
+(	O
+ARDS	B-DISO
+)	O
+conservative	O
+treatment	O
+with	O
+lung	B-ANAT
+protective	O
+ventilation	O
+is	O
+often	O
+not	O
+sufficient	O
+to	O
+prevent	O
+life	O
+-	O
+threatening	O
+hypoxemia	O
+and	O
+additional	O
+strategies	O
+are	O
+necessary	O
+.	O
+
+Conventional	O
+practice	O
+from	O
+the	O
+findings	O
+consisted	O
+of	O
+cubicle	O
+and	O
+named	O
+nurse	O
+nursing	B-PROC
+.	O
+
+While	O
+the	O
+former	O
+reflected	O
+modified	O
+team	O
+and	O
+functional	O
+nursing	B-PROC
+,	O
+it	O
+did	O
+not	O
+confine	O
+patient	O
+care	O
+within	O
+a	O
+cubicle	O
+as	O
+suggested	O
+by	O
+its	O
+name	B-SPEC
+.	O
+
+The	O
+latter	O
+depicted	O
+a	O
+modified	O
+primary	O
+nursing	B-PROC
+approach	O
+in	O
+a	O
+team	O
+,	O
+with	O
+delegation	O
+of	O
+care	O
+.	O
+
+Earlier	O
+treatment	O
+with	O
+drotrecogin	O
+alfa	O
+(	O
+activated	O
+)	O
+(	O
+DrotAA	O
+)	O
+may	O
+also	O
+improve	O
+outcomes	O
+in	O
+severe	B-DISO
+sepsis	I-DISO
+.	O
+
+The	O
+presence	O
+of	O
+two	O
+distinct	O
+membrane	B-COMP
+topologies	O
+of	O
+the	O
+SARS	B-PRGE
+-	I-PRGE
+CoV	I-PRGE
+E	I-PRGE
+protein	B-CHED
+may	O
+provide	O
+a	O
+useful	O
+clue	O
+to	O
+the	O
+pathogenesis	B-DISO
+of	O
+SARS	B-DISO
+-	O
+CoV	O
+.	O
+
+The	O
+beneficial	O
+effects	O
+of	O
+CVVH	O
+on	O
+arterial	B-ANAT
+oxygenation	B-PROC
+and	O
+pulmonary	B-PROC
+function	I-PROC
+may	O
+be	O
+connected	O
+with	O
+improvements	O
+in	O
+systemic	O
+hemodynamics	B-PROC
+,	O
+reduction	O
+in	O
+plasma	B-ANAT
+cytokine	O
+concentration	O
+and	O
+decreased	B-DISO
+activity	I-DISO
+of	O
+NF	O
+-	O
+ê	O
+B	O
+in	O
+peripheral	B-ANAT
+blood	I-ANAT
+mononuclear	I-ANAT
+cells	I-ANAT
+.	O
+
+PaO	B-PROC
+(	O
+2	O
+)	O
+was	O
+significantly	O
+higher	O
+in	O
+HV	O
+group	O
+than	O
+in	O
+LV	O
+group	O
+at	O
+6	O
+h	O
+,	O
+12	O
+h	O
+,	O
+24	O
+h	O
+and	O
+48	O
+h	O
+(	O
+p	O
+<	O
+0	O
+.	O
+01	O
+).	O
+
+In	O
+Phase	O
+2	O
+,	O
+MIGET	O
+showed	O
+diversion	O
+of	O
+blood	B-PROC
+flow	I-PROC
+from	O
+normal	O
+to	O
+true	O
+-	O
+shunt	O
+lung	B-ANAT
+compartments	B-ANAT
+and	O
+,	O
+transiently	O
+,	O
+to	O
+poorly	O
+ventilated	O
+compartments	B-ANAT
+.	O
+
+Frameshifting	O
+is	O
+promoted	O
+by	O
+an	O
+mRNA	B-CHED
+signal	O
+composed	O
+of	O
+two	O
+essential	O
+elements	O
+:	O
+a	O
+heptanucleotide	O
+'	O
+slippery	O
+'	O
+sequence	O
+and	O
+an	O
+adjacent	O
+mRNA	B-CHED
+secondary	O
+structure	O
+,	O
+most	O
+often	O
+an	O
+mRNA	B-CHED
+pseudoknot	O
+.	O
+
+ABSTRACT	O
+:	O
+A	O
+method	O
+for	O
+the	O
+parallel	O
+solid	O
+-	O
+phase	O
+synthesis	B-PROC
+of	O
+peptide	B-CHED
+aldehydes	B-CHED
+has	O
+been	O
+developed	O
+.	O
+
+Protected	O
+amino	B-CHED
+acid	I-CHED
+aldehydes	B-CHED
+obtained	O
+by	O
+the	O
+racemization	B-PROC
+-	O
+free	O
+oxidation	B-PROC
+of	O
+amino	B-CHED
+alcohols	I-CHED
+with	O
+Dess	O
+-	O
+Martin	O
+periodinane	O
+were	O
+immobilized	O
+on	O
+threonyl	B-CHED
+resins	O
+as	O
+oxazolidines	B-CHED
+.	O
+
+ABSTRACT	O
+:	O
+To	O
+the	O
+authors	O
+'	O
+knowledge	O
+,	O
+no	O
+satisfactory	O
+therapy	O
+is	O
+available	O
+for	O
+patients	O
+with	O
+refractory	O
+germ	B-DISO
+cell	I-DISO
+neoplasms	I-DISO
+.	O
+
+In	O
+the	O
+current	O
+study	O
+,	O
+arsenic	B-CHED
+trioxide	I-CHED
+in	O
+the	O
+dose	O
+regimen	O
+and	O
+schedule	O
+employed	O
+was	O
+found	O
+to	O
+have	O
+no	O
+activity	O
+in	O
+men	O
+with	O
+refractory	O
+germ	B-ANAT
+cell	I-ANAT
+malignancies	B-DISO
+.	O
+
+In	O
+this	O
+study	O
+,	O
+we	O
+found	O
+that	O
+peripheral	B-ANAT
+blood	I-ANAT
+mononuclear	I-ANAT
+cells	I-ANAT
+(	O
+PBMCs	O
+)	O
+from	O
+fully	O
+recovered	O
+SARS	B-DISO
+individuals	O
+rapidly	O
+produced	O
+IFN	B-PRGE
+-	I-PRGE
+gamma	I-PRGE
+and	O
+IL	B-FUNC
+-	I-FUNC
+2	I-FUNC
+following	O
+stimulation	O
+with	O
+a	O
+pool	O
+of	O
+overlapping	O
+peptides	B-CHED
+that	O
+cover	O
+the	O
+entire	O
+N	O
+protein	B-CHED
+sequence	O
+.	O
+
+Coronavirus	B-SPEC
+and	O
+arterivirus	B-SPEC
+subgenomic	O
+transcripts	O
+are	O
+not	O
+only	O
+3	O
+'	O
+co	O
+-	O
+terminal	O
+but	O
+also	O
+contain	O
+a	O
+common	O
+5	O
+'	O
+leader	O
+sequence	O
+,	O
+which	O
+is	O
+derived	O
+from	O
+the	O
+genomic	O
+5	O
+'	O
+end	O
+.	O
+
+In	O
+view	O
+of	O
+the	O
+presumed	O
+common	O
+ancestry	O
+of	O
+nidoviruses	B-SPEC
+,	O
+the	O
+recent	O
+finding	O
+that	O
+ronivirus	O
+and	O
+torovirus	B-SPEC
+mRNAs	O
+do	O
+not	O
+contain	O
+a	O
+common	O
+5	O
+'	O
+leader	O
+sequence	O
+is	O
+surprising	O
+.	O
+
+These	O
+studies	O
+have	O
+focused	O
+on	O
+a	O
+particular	O
+outbreak	O
+event	O
+,	O
+the	O
+rapid	O
+spread	O
+of	O
+SARS	B-DISO
+throughout	O
+Amoy	O
+Gardens	O
+,	O
+a	O
+large	O
+,	O
+private	O
+apartment	O
+complex	O
+.	O
+
+Two	O
+relevant	O
+protein	B-CHED
+families	O
+,	O
+the	O
+alpha	B-PRGE
+-	I-PRGE
+carbonic	I-PRGE
+anhydrases	I-PRGE
+and	O
+the	O
+protein	B-CHED
+kinases	O
+,	O
+are	O
+used	O
+to	O
+demonstrate	O
+the	O
+scope	O
+of	O
+our	O
+cluster	O
+approach	O
+.	O
+
+ABSTRACT	O
+:	O
+Reproductive	B-PROC
+losses	O
+in	O
+camelids	O
+are	O
+due	O
+to	O
+infertility	O
+,	O
+pregnancy	B-DISO
+loss	I-DISO
+,	O
+udder	B-ANAT
+diseases	O
+and	O
+neonatal	O
+mortality	O
+caused	O
+by	O
+a	O
+variety	O
+of	O
+infectious	B-DISO
+diseases	I-DISO
+.	O
+
+In	O
+camels	B-SPEC
+,	O
+brucellosis	B-DISO
+and	O
+trypanosomiasis	B-DISO
+represent	O
+the	O
+major	O
+causes	O
+of	O
+infectious	B-DISO
+abortion	O
+in	O
+the	O
+Middle	O
+East	O
+and	O
+Africa	O
+.	O
+
+Udder	B-ANAT
+infections	B-DISO
+are	O
+primarily	O
+due	O
+to	O
+Streptococcus	B-SPEC
+agalactiae	I-SPEC
+and	O
+Staphylococcus	B-SPEC
+aureus	I-SPEC
+.	O
+
+These	O
+results	O
+suggest	O
+that	O
+antibodies	B-COMP
+that	O
+are	O
+more	O
+specific	O
+for	O
+the	O
+pre	O
+-	O
+fusogenic	O
+state	O
+of	O
+HRC	B-PRGE
+may	O
+be	O
+better	O
+neutralizing	O
+antibodies	B-COMP
+.	O
+
+Gnotobiotic	O
+pigs	B-SPEC
+were	O
+inoculated	O
+intratracheally	O
+with	O
+PRCV	O
+(	O
+n	O
+=	O
+34	O
+)	O
+or	O
+saline	O
+(	O
+n	O
+=	O
+5	O
+)	O
+and	O
+euthanized	O
+1	O
+-	O
+15days	O
+post	O
+inoculation	O
+(	O
+DPI	O
+).	O
+
+LBP	B-DISO
+and	O
+soluble	O
+CD14	B-PRGE
+levels	O
+in	O
+bronchoalveolar	B-ANAT
+lavage	I-ANAT
+fluids	I-ANAT
+were	O
+elevated	O
+from	O
+1	O
+-	O
+12DPI	O
+,	O
+with	O
+up	O
+to	O
+35	O
+-	O
+and	O
+4	O
+-	O
+fold	O
+increases	O
+,	O
+respectively	O
+.	O
+
+When	O
+considered	O
+together	O
+,	O
+the	O
+structural	O
+and	O
+thermodynamic	O
+features	O
+of	O
+the	O
+four	O
+domains	O
+suggest	O
+a	O
+possible	O
+mechanism	O
+whereby	O
+the	O
+HR	O
+regions	O
+,	O
+initially	O
+sequestered	O
+in	O
+the	O
+native	B-PRGE
+S	I-PRGE
+glycoprotein	I-PRGE
+spike	O
+,	O
+are	O
+released	O
+and	O
+refold	O
+sequentially	O
+to	O
+promote	O
+membrane	B-PROC
+fusion	I-PROC
+.	O
+
+For	O
+the	O
+diagnosis	O
+of	O
+SARS	B-DISO
+virus	B-DISO
+infection	I-DISO
+,	O
+an	O
+epidemiological	O
+investigation	O
+is	O
+necessary	O
+to	O
+know	O
+whether	O
+the	O
+patient	O
+has	O
+been	O
+exposed	O
+to	O
+a	O
+risk	O
+in	O
+a	O
+country	O
+where	O
+the	O
+SARS	B-DISO
+virus	B-SPEC
+is	O
+circulating	O
+or	O
+whether	O
+the	O
+patient	O
+had	O
+worked	O
+in	O
+a	O
+laboratory	O
+handling	O
+SARS	B-DISO
+virus	B-SPEC
+.	O
+
+The	O
+detection	O
+of	O
+SARS	B-DISO
+virus	B-SPEC
+is	O
+possible	O
+in	O
+various	O
+clinical	O
+samples	O
+(	O
+including	O
+urine	B-ANAT
+)	O
+by	O
+viral	O
+culture	O
+or	O
+RT	O
+-	O
+PCR	O
+.	O
+
+The	O
+handling	O
+of	O
+those	O
+samples	O
+and	O
+RNA	O
+extraction	O
+must	O
+be	O
+performed	O
+in	O
+a	O
+BSL3	B-PRGE
+laboratory	O
+.	O
+
+The	O
+SARS	B-DISO
+virus	B-SPEC
+RT	O
+-	O
+PCR	O
+is	O
+poorly	O
+sensitive	O
+,	O
+therefore	O
+the	O
+test	O
+should	O
+be	O
+performed	O
+on	O
+samples	O
+collected	O
+consecutively	O
+for	O
+several	O
+days	O
+.	O
+
+The	O
+presence	O
+of	O
+A	O
+/	O
+H5N1	B-DISO
+virus	B-SPEC
+is	O
+confirmed	O
+by	O
+viral	O
+isolation	O
+or	O
+RNA	O
+detection	O
+by	O
+RT	O
+-	O
+PCR	O
+.	O
+
+We	O
+report	O
+an	O
+outbreak	O
+of	O
+fatal	O
+disease	O
+in	O
+puppies	O
+caused	O
+by	O
+a	O
+pathogenic	O
+variant	O
+of	O
+CCoV	O
+that	O
+was	O
+isolated	O
+from	O
+organs	B-ANAT
+with	O
+severe	O
+lesions	O
+.	O
+
+We	O
+screened	O
+respiratory	O
+specimens	O
+collected	O
+from	O
+December	O
+16	O
+,	O
+2001	O
+,	O
+to	O
+December	O
+15	O
+,	O
+2002	O
+,	O
+from	O
+children	O
+<	O
+5	O
+years	O
+of	O
+age	O
+who	O
+tested	O
+negative	O
+for	O
+respiratory	O
+syncytial	O
+virus	O
+,	O
+parainfluenza	B-DISO
+viruses	B-SPEC
+,	O
+influenza	B-SPEC
+virus	I-SPEC
+,	O
+and	O
+adenovirus	B-DISO
+for	O
+HCoV	O
+-	O
+HKU1	O
+by	O
+reverse	B-PROC
+transcription	I-PROC
+-	O
+polymerase	O
+chain	O
+reaction	O
+.	O
+
+Children	O
+who	O
+had	O
+HCoV	O
+-	O
+HKU1	O
+infection	B-DISO
+had	O
+evidence	O
+of	O
+either	O
+upper	O
+or	O
+lower	B-DISO
+respiratory	I-DISO
+tract	I-DISO
+infection	I-DISO
+or	O
+both	O
+.	O
+
+HCoV	O
+-	O
+HKU1	O
+is	O
+therefore	O
+likely	O
+circulating	O
+in	O
+the	O
+United	O
+States	O
+and	O
+is	O
+associated	O
+with	O
+upper	O
+and	O
+lower	B-ANAT
+respiratory	B-DISO
+tract	I-DISO
+disease	I-DISO
+.	O
+
+TITLE	O
+:	O
+Phase	O
+I	O
+trial	O
+of	O
+the	O
+trifunctional	O
+anti	O
+-	O
+HER2	B-PRGE
+x	O
+anti	B-PRGE
+-	I-PRGE
+CD3	I-PRGE
+antibody	I-PRGE
+ertumaxomab	O
+in	O
+metastatic	B-DISO
+breast	B-ANAT
+cancer	B-SPEC
+.	O
+
+Antitumor	B-PROC
+response	I-PROC
+was	O
+seen	O
+in	O
+5	O
+out	O
+of	O
+15	O
+evaluable	B-DISO
+patients	O
+(	O
+one	O
+with	O
+a	O
+complete	O
+response	O
+,	O
+two	O
+with	O
+partial	O
+responses	O
+,	O
+two	O
+with	O
+stable	O
+disease	O
+)	O
+at	O
+dose	O
+levels	O
+of	O
+>	O
+or	O
+=	O
+100	O
+microg	O
+.	O
+
+Measurements	O
+of	O
+cytokines	O
+(	O
+interleukin	B-PRGE
+-	I-PRGE
+6	I-PRGE
+,	O
+interleukin	B-PRGE
+-	I-PRGE
+2	I-PRGE
+,	O
+tumor	B-PRGE
+necrosis	I-PRGE
+factor	I-PRGE
+-	I-PRGE
+alpha	I-PRGE
+,	O
+and	O
+IFN	B-PRGE
+-	I-PRGE
+gamma	I-PRGE
+)	O
+suggest	O
+a	O
+strong	O
+T	B-ANAT
+helper	I-ANAT
+cell	I-ANAT
+type	O
+1	O
+-	O
+associated	O
+immune	B-PROC
+response	I-PROC
+.	O
+
+Direct	O
+involvement	O
+of	O
+the	O
+KKS	O
+in	O
+the	O
+pathogenesis	B-DISO
+of	O
+experimental	O
+acute	B-DISO
+arthritis	I-DISO
+and	O
+acute	O
+and	O
+chronic	B-DISO
+enterocolitis	I-DISO
+has	O
+been	O
+documented	O
+by	O
+previous	O
+studies	O
+from	O
+our	O
+laboratory	O
+using	O
+experimental	O
+animal	B-SPEC
+models	O
+.	O
+
+We	O
+showed	O
+a	O
+genetic	O
+difference	O
+in	O
+kininogen	O
+structure	O
+between	O
+resistant	O
+Buffalo	O
+and	O
+susceptible	O
+Lewis	O
+rats	B-SPEC
+,	O
+which	O
+results	O
+in	O
+accelerated	O
+cleavage	B-PROC
+of	O
+HK	O
+and	O
+it	O
+is	O
+responsible	O
+for	O
+the	O
+susceptibility	O
+to	O
+the	O
+inflammatory	O
+process	O
+in	O
+the	O
+Lewis	O
+rats	B-SPEC
+.	O
+
+TITLE	O
+:	O
+Modelling	O
+the	O
+utility	O
+of	O
+body	B-ANAT
+temperature	O
+readings	O
+from	O
+primary	O
+care	O
+consults	O
+for	O
+SARS	B-DISO
+surveillance	O
+in	O
+an	O
+army	O
+medical	O
+centre	O
+.	O
+
+We	O
+model	O
+the	O
+detection	O
+limits	O
+of	O
+a	O
+potential	O
+system	O
+based	O
+on	O
+primary	O
+care	O
+consults	O
+for	O
+the	O
+detection	O
+of	O
+an	O
+outbreak	O
+of	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+(	O
+SARS	B-DISO
+).	O
+
+ABSTRACT	O
+:	O
+Infection	B-DISO
+by	O
+different	O
+coronaviruses	O
+(	O
+CoVs	O
+)	O
+causes	O
+alterations	O
+in	O
+the	O
+transcriptional	B-PROC
+and	O
+translational	B-PROC
+patterns	O
+,	O
+cell	B-PATH
+cycle	I-PATH
+,	O
+cytoskeleton	B-COMP
+,	O
+and	O
+apoptosis	B-PATH
+pathways	B-PROC
+of	O
+the	O
+host	B-COMP
+cells	B-COMP
+.	O
+
+In	O
+addition	O
+,	O
+CoV	O
+infection	B-DISO
+may	O
+cause	O
+inflammation	B-DISO
+,	O
+alter	O
+immune	O
+and	O
+stress	O
+responses	O
+,	O
+and	O
+modify	O
+the	O
+coagulation	B-PROC
+pathways	B-PROC
+.	O
+
+The	O
+balance	B-PROC
+between	O
+the	O
+up	O
+-	O
+and	O
+downregulated	O
+genes	O
+could	O
+explain	O
+the	O
+pathogenesis	B-DISO
+caused	O
+by	O
+these	O
+viruses	B-SPEC
+.	O
+
+CoV	O
+transcription	B-PROC
+involves	O
+a	O
+discontinuous	O
+RNA	B-PROC
+synthesis	I-PROC
+(	O
+template	O
+switching	O
+)	O
+during	O
+the	O
+extension	O
+of	O
+a	O
+negative	O
+copy	O
+of	O
+the	O
+subgenomic	O
+mRNAs	O
+.	O
+
+CoV	O
+N	O
+proteins	B-CHED
+have	O
+RNA	O
+chaperone	B-PROC
+activity	I-PROC
+that	O
+may	O
+help	O
+initiate	O
+template	O
+switching	O
+.	O
+
+Multiple	O
+lines	O
+of	O
+experimental	O
+data	O
+including	O
+gel	O
+-	O
+filtration	O
+,	O
+chemical	O
+cross	O
+-	O
+linking	O
+,	O
+and	O
+circular	O
+diagram	O
+(	O
+CD	O
+)	O
+demonstrated	O
+that	O
+the	O
+HCoV	B-SPEC
+-	I-SPEC
+229E	I-SPEC
+fusion	O
+core	O
+possesses	B-DISO
+the	O
+typical	O
+properties	O
+of	O
+the	O
+trimer	O
+of	O
+coiled	O
+-	O
+coil	O
+heterodimer	O
+(	O
+six	O
+alpha	O
+-	O
+helix	O
+bundle	O
+).	O
+
+Collectively	O
+,	O
+HCoV	O
+-	O
+229E	O
+S	O
+protein	B-CHED
+belongs	O
+to	O
+the	O
+type	B-PRGE
+I	I-PRGE
+fusion	I-PRGE
+protein	I-PRGE
+,	O
+which	O
+is	O
+characterized	O
+by	O
+the	O
+existence	O
+of	O
+two	O
+heptad	O
+-	O
+repeat	O
+regions	O
+(	O
+HR1	O
+and	O
+HR2	O
+),	O
+furthermore	O
+,	O
+the	O
+available	O
+knowledge	O
+concerning	O
+HCoV	B-SPEC
+-	I-SPEC
+229E	I-SPEC
+fusion	O
+core	O
+may	O
+make	O
+it	O
+possible	O
+to	O
+design	O
+small	O
+molecule	O
+or	O
+polypeptide	B-CHED
+drugs	O
+targeting	B-PROC
+the	O
+membrane	B-PROC
+fusion	I-PROC
+,	O
+a	O
+crucial	O
+step	O
+of	O
+HCoV	B-SPEC
+-	I-SPEC
+229E	I-SPEC
+infection	B-DISO
+.	O
+
+The	O
+clinical	O
+data	O
+for	O
+these	O
+patients	O
+were	O
+correlated	O
+to	O
+identify	O
+risk	O
+factors	O
+that	O
+might	O
+increase	O
+the	O
+likelihood	O
+of	O
+the	O
+development	B-PROC
+of	O
+CT	O
+abnormalities	O
+.	O
+
+The	O
+AutoDock	O
+3	O
+.	O
+011	O
+was	O
+used	O
+to	O
+carry	O
+out	O
+molecular	O
+docking	B-PROC
+of	O
+50	O
+ligands	O
+to	O
+their	O
+macromolecular	O
+protein	B-CHED
+receptors	O
+.	O
+
+As	O
+PRCoV	O
+shares	O
+some	O
+epitopes	O
+for	O
+neutralizing	O
+antibodies	B-COMP
+with	O
+TGEV	B-SPEC
+,	O
+it	O
+acts	O
+like	O
+a	O
+nature	O
+-	O
+made	O
+vaccine	O
+against	O
+TGEV	B-SPEC
+resulting	O
+in	O
+a	O
+drastic	O
+reduction	O
+of	O
+TGE	B-DISO
+outbreaks	O
+in	O
+Europe	O
+.	O
+
+In	O
+contrast	O
+,	O
+preexisting	O
+anti	B-PRGE
+-	I-PRGE
+AdH5	I-PRGE
+NAbs	I-PRGE
+have	O
+a	O
+minimal	O
+effect	O
+on	O
+the	O
+potency	O
+of	O
+the	O
+AdC7	O
+-	O
+based	O
+genetic	O
+vaccine	O
+.	O
+
+NL63	B-PRGE
+-	I-PRGE
+like	I-PRGE
+strains	O
+were	O
+not	O
+found	O
+to	O
+circulate	O
+in	O
+2003	O
+-	O
+2004	O
+,	O
+and	O
+229E	O
+-	O
+like	O
+strains	O
+did	O
+not	O
+circulate	O
+in	O
+2004	O
+-	O
+2005	O
+,	O
+while	O
+OC43	B-PRGE
+-	I-PRGE
+like	I-PRGE
+strains	O
+were	O
+detected	O
+in	O
+both	O
+seasons	O
+.	O
+
+TITLE	O
+:	O
+Inhibition	B-PROC
+of	O
+human	B-SPEC
+coronavirus	I-SPEC
+NL63	I-SPEC
+infection	B-DISO
+at	O
+early	O
+stages	O
+of	O
+the	O
+replication	O
+cycle	O
+.	O
+
+TITLE	O
+:	O
+Identification	O
+and	O
+characterization	O
+of	O
+novel	O
+neutralizing	O
+epitopes	O
+in	O
+the	O
+receptor	O
+-	O
+binding	B-FUNC
+domain	O
+of	O
+SARS	O
+-	O
+CoV	O
+spike	O
+protein	B-CHED
+:	O
+revealing	O
+the	O
+critical	O
+antigenic	O
+determinants	O
+in	O
+inactivated	O
+SARS	B-DISO
+-	O
+CoV	O
+vaccine	O
+.	O
+
+Mycobacterium	B-SPEC
+bovis	I-SPEC
+DNA	O
+was	O
+identified	O
+by	O
+PCR	O
+in	O
+blood	B-ANAT
+samples	I-ANAT
+and	O
+bronchoaspirate	O
+(	O
+BAS	B-CHED
+).	O
+
+ABSTRACT	O
+:	O
+A	O
+Vero	O
+cell	O
+attenuated	O
+porcine	B-SPEC
+epidemic	I-SPEC
+diarrhea	I-SPEC
+virus	I-SPEC
+(	O
+PEDV	B-SPEC
+)	O
+strain	O
+,	O
+DR13	O
+,	O
+was	O
+distinguished	O
+from	O
+wild	O
+-	O
+type	O
+PEDV	B-SPEC
+using	O
+restriction	O
+enzyme	O
+fragment	O
+length	O
+polymorphism	B-PROC
+(	O
+RFLP	O
+).	O
+
+The	O
+IC	O
+(	O
+50	O
+)	O
+values	O
+for	O
+Radix	B-SPEC
+et	O
+Rhizoma	O
+Rhei	O
+(	O
+the	O
+root	B-ANAT
+tubers	B-SPEC
+of	O
+Rheum	B-SPEC
+officinale	I-SPEC
+Baill	O
+.),	O
+Radix	B-SPEC
+Polygoni	O
+multiflori	O
+(	O
+the	O
+root	B-ANAT
+tubers	B-SPEC
+of	O
+Polygonum	B-SPEC
+multiflorum	I-SPEC
+Thunb	O
+.),	O
+and	O
+Caulis	O
+Polygoni	O
+multiflori	O
+(	O
+the	O
+vines	O
+of	O
+P	B-SPEC
+.	I-SPEC
+multiflorum	I-SPEC
+Thunb	O
+.)	O
+ranged	O
+from	O
+1	O
+to	O
+10	O
+microg	O
+/	O
+ml	O
+.	O
+
+The	O
+3	O
+emerging	B-DISO
+infectious	I-DISO
+diseases	I-DISO
+pose	O
+very	O
+different	O
+threats	O
+:	O
+Severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+is	O
+a	O
+newly	O
+identified	O
+pathogen	O
+that	O
+caused	O
+an	O
+international	O
+pandemic	O
+;	O
+the	O
+West	B-DISO
+Nile	I-DISO
+virus	I-DISO
+investigation	O
+involved	O
+an	O
+old	O
+pathogen	O
+that	O
+was	O
+identified	O
+in	O
+a	O
+new	O
+location	O
+;	O
+and	O
+the	O
+anthrax	B-DISO
+attacks	O
+involved	O
+the	O
+intentional	O
+introduction	O
+of	O
+a	O
+pathogen	O
+.	O
+
+RESULTS	O
+:	O
+The	O
+3	O
+emerging	O
+infectious	O
+diseases	O
+pose	O
+very	O
+different	O
+threats	O
+:	O
+Severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+is	O
+a	O
+newly	O
+identified	O
+pathogen	O
+that	O
+caused	O
+an	O
+international	O
+pandemic	O
+;	O
+the	O
+West	B-DISO
+Nile	I-DISO
+virus	I-DISO
+investigation	O
+involved	O
+an	O
+old	O
+pathogen	O
+that	O
+was	O
+identified	O
+in	O
+a	O
+new	O
+location	O
+;	O
+and	O
+the	O
+anthrax	B-DISO
+attacks	O
+involved	O
+the	O
+intentional	O
+introduction	O
+of	O
+a	O
+pathogen	O
+.	O
+
+Among	O
+the	O
+anti	O
+-	O
+S1	O
+MAbs	O
+,	O
+17	O
+MAbs	O
+targeted	B-PROC
+the	O
+N	O
+-	O
+terminal	O
+region	O
+(	O
+amino	B-CHED
+acids	I-CHED
+[	O
+aa	O
+]	O
+12	O
+to	O
+327	O
+),	O
+9	O
+MAbs	O
+recognized	O
+the	O
+receptor	O
+-	O
+binding	B-FUNC
+domain	O
+(	O
+RBD	O
+;	O
+aa	O
+318	O
+to	O
+510	O
+),	O
+and	O
+6	O
+MAbs	O
+reacted	O
+with	O
+the	O
+C	O
+-	O
+terminal	O
+region	O
+of	O
+S1	O
+domain	O
+that	O
+contains	O
+the	O
+major	O
+immunodominant	O
+site	O
+(	O
+aa	O
+528	O
+to	O
+635	O
+).	O
+
+This	O
+panel	O
+of	O
+anti	O
+-	O
+S	O
+MAbs	O
+can	O
+be	O
+used	O
+as	O
+tools	O
+for	O
+studying	O
+the	O
+structure	O
+and	O
+function	O
+of	O
+the	O
+SARS	B-PRGE
+-	I-PRGE
+CoV	I-PRGE
+S	I-PRGE
+protein	B-CHED
+.	O
+
+TITLE	O
+:	O
+Endosomal	O
+proteolysis	B-PROC
+by	O
+cathepsins	O
+is	O
+necessary	O
+for	O
+murine	B-SPEC
+coronavirus	I-SPEC
+mouse	B-DISO
+hepatitis	I-DISO
+virus	B-SPEC
+type	O
+2	O
+spike	O
+-	O
+mediated	O
+entry	O
+.	O
+
+We	O
+show	O
+here	O
+that	O
+while	O
+infection	B-DISO
+of	O
+the	O
+prototype	O
+MHV	B-SPEC
+-	O
+A59	O
+strain	O
+is	O
+not	O
+sensitive	O
+to	O
+pretreatment	O
+with	O
+lysosomotropic	O
+agents	O
+,	O
+MHV	B-SPEC
+-	O
+2	O
+replication	O
+is	O
+significantly	O
+inhibited	O
+by	O
+these	O
+agents	O
+.	O
+
+However	O
+,	O
+acidification	B-PROC
+is	O
+likely	O
+not	O
+a	O
+direct	O
+trigger	O
+for	O
+MHV	B-SPEC
+-	O
+2	O
+spike	O
+-	O
+mediated	O
+membrane	B-PROC
+fusion	I-PROC
+,	O
+as	O
+low	O
+-	O
+pH	O
+treatment	O
+is	O
+unable	O
+to	O
+overcome	O
+ammonium	O
+chloride	O
+inhibition	B-PROC
+,	O
+and	O
+it	O
+also	O
+cannot	O
+induce	O
+cell	B-PROC
+-	I-PROC
+cell	B-COMP
+fusion	I-PROC
+between	O
+MHV	B-SPEC
+-	O
+2	O
+-	O
+infected	O
+cells	B-COMP
+.	O
+
+In	O
+immunoelectron	O
+microscopy	O
+,	O
+the	O
+virus	B-SPEC
+-	O
+induced	O
+vesicles	B-COMP
+could	O
+be	O
+labeled	O
+with	O
+replicase	B-PRGE
+-	O
+specific	O
+antibodies	B-COMP
+.	O
+
+Opposite	O
+to	O
+what	O
+was	O
+described	O
+for	O
+mouse	B-DISO
+hepatitis	I-DISO
+virus	B-SPEC
+,	O
+we	O
+did	O
+not	O
+observe	O
+the	O
+late	O
+relocalization	O
+of	O
+specific	O
+replicase	B-PRGE
+subunits	O
+to	O
+the	O
+presumed	O
+site	O
+of	O
+virus	B-PROC
+assembly	I-PROC
+,	O
+which	O
+was	O
+labeled	O
+using	O
+an	O
+antiserum	O
+against	O
+the	O
+viral	B-COMP
+membrane	I-COMP
+protein	B-CHED
+.	O
+
+This	O
+conclusion	O
+was	O
+further	O
+supported	O
+using	O
+organelle	B-COMP
+-	O
+specific	O
+marker	O
+proteins	B-CHED
+and	O
+electron	O
+microscopy	O
+.	O
+
+Similar	O
+morphological	O
+studies	O
+and	O
+labeling	O
+experiments	O
+argued	O
+against	O
+the	O
+previously	O
+proposed	O
+involvement	O
+of	O
+the	O
+autophagic	O
+pathway	B-PROC
+as	O
+the	O
+source	O
+for	O
+the	O
+vesicles	B-COMP
+with	O
+which	O
+the	O
+replicase	B-PRGE
+is	O
+associated	O
+and	O
+instead	O
+suggested	O
+the	O
+endoplasmic	B-COMP
+reticulum	I-COMP
+to	O
+be	O
+the	O
+most	O
+likely	O
+donor	B-CHED
+of	O
+the	O
+membranes	B-ANAT
+that	O
+carry	O
+the	O
+SARS	B-PRGE
+-	I-PRGE
+CoV	I-PRGE
+replication	I-PRGE
+complex	I-PRGE
+.	O
+
+ABSTRACT	O
+:	O
+Unlike	O
+nuclear	O
+localization	B-PROC
+signals	O
+,	O
+there	O
+is	O
+no	O
+obvious	O
+consensus	O
+sequence	O
+for	O
+the	O
+targeting	B-PROC
+of	O
+proteins	B-CHED
+to	O
+the	O
+nucleolus	B-COMP
+.	O
+
+Additionally	O
+,	O
+a	O
+classical	O
+nuclear	B-PROC
+export	I-PROC
+signal	O
+(	O
+NES	B-SPEC
+)	O
+functioned	O
+to	O
+direct	O
+N	B-PRGE
+protein	I-PRGE
+to	O
+the	O
+cytoplasm	B-ANAT
+.	O
+
+We	O
+hypothesise	O
+that	O
+the	O
+N	B-PRGE
+-	I-PRGE
+protein	I-PRGE
+uses	O
+these	O
+signals	O
+to	O
+traffic	O
+to	O
+and	O
+from	O
+the	O
+nucleolus	B-COMP
+and	O
+the	O
+cytoplasm	B-COMP
+.	O
+
+ABSTRACT	O
+:	O
+Ulcerative	B-DISO
+colitis	I-DISO
+(	O
+UC	O
+)	O
+can	O
+manifest	O
+with	O
+a	O
+variety	O
+of	O
+extra	O
+-	O
+intestinal	B-DISO
+disorders	I-DISO
+frequently	O
+affecting	O
+the	O
+skin	B-ANAT
+,	O
+joints	B-ANAT
+,	O
+and	O
+liver	B-ANAT
+.	O
+
+Testing	O
+for	O
+alpha1	B-PRGE
+-	I-PRGE
+antitrypsin	I-PRGE
+deficiency	O
+in	O
+UC	O
+patients	O
+may	O
+detect	O
+individuals	O
+at	O
+higher	O
+risk	O
+of	O
+severe	O
+extra	O
+-	O
+intestinal	B-ANAT
+involvement	O
+.	O
+
+ABSTRACT	O
+:	O
+A	O
+22	O
+-	O
+year	O
+-	O
+old	O
+woman	O
+is	O
+presented	O
+with	O
+acute	O
+gastric	O
+dilation	O
+after	O
+an	O
+eating	B-PROC
+binge	B-DISO
+,	O
+who	O
+died	B-PROC
+of	O
+complications	O
+of	O
+acute	O
+reperfusion	O
+syndrome	B-DISO
+.	O
+
+Femoral	B-PROC
+pulses	I-PROC
+were	O
+absent	O
+.	O
+
+Several	O
+cases	O
+documenting	O
+complications	O
+of	O
+gastric	B-DISO
+dilatation	I-DISO
+were	O
+published	O
+;	O
+however	O
+,	O
+such	O
+severe	O
+complications	O
+,	O
+involving	O
+gastric	B-ANAT
+infarction	B-DISO
+and	O
+compression	O
+of	O
+the	O
+aorta	B-ANAT
+with	O
+ischemic	O
+injury	O
+of	O
+the	O
+bowels	B-ANAT
+and	O
+lower	B-ANAT
+extremities	I-ANAT
+,	O
+are	O
+rare	O
+.	O
+
+METHODS	O
+:	O
+A	O
+young	O
+patient	O
+was	O
+admitted	O
+in	O
+our	O
+clinic	O
+with	O
+critical	O
+condition	B-DISO
+without	O
+any	O
+significant	O
+previous	O
+medical	O
+history	O
+.	O
+
+CONCLUSIONS	O
+:	O
+Acute	O
+gastric	B-DISO
+dilatation	I-DISO
+is	O
+very	O
+uncommon	O
+and	O
+is	O
+of	O
+various	O
+etiologies	O
+,	O
+two	O
+of	O
+these	O
+being	O
+anorexia	B-DISO
+nervosa	I-DISO
+and	O
+bulimia	B-DISO
+.	O
+
+Further	O
+studies	O
+are	O
+required	O
+to	O
+delineate	O
+the	O
+relationship	O
+between	O
+severe	O
+maternal	O
+respiratory	B-DISO
+disease	I-DISO
+,	O
+placental	B-ANAT
+pathology	B-DISO
+and	O
+pregnancy	O
+outcome	O
+.	O
+
+The	O
+aetiology	O
+of	O
+the	O
+FTV	O
+might	O
+be	O
+related	O
+to	O
+thrombotic	O
+tendency	O
+due	O
+to	O
+SARS	B-DISO
+or	O
+placental	B-ANAT
+hypoxia	B-DISO
+.	O
+
+There	O
+were	O
+also	O
+significant	O
+positive	O
+correlations	O
+amongst	O
+various	O
+biochemical	O
+bone	B-ANAT
+markers	O
+in	O
+this	O
+patient	O
+cohort	O
+.	O
+
+The	O
+Day	O
+28	O
+-	O
+44	O
+increase	O
+in	O
+the	O
+serum	B-COMP
+CTx	B-DISO
+coincided	O
+with	O
+the	O
+timing	O
+of	O
+corticosteroid	B-CHED
+use	O
+.	O
+
+There	O
+were	O
+also	O
+significant	O
+positive	O
+correlations	O
+amongst	O
+various	O
+biochemical	O
+bone	B-ANAT
+markers	O
+in	O
+this	O
+patient	O
+cohort	O
+.	O
+
+Complement	O
+titres	O
+in	O
+non	O
+-	O
+vaccinated	O
+birds	B-SPEC
+were	O
+significantly	O
+higher	O
+in	O
+WLH	O
+birds	B-SPEC
+compared	O
+to	O
+RIR	O
+birds	B-SPEC
+.	O
+
+The	O
+lentogenic	O
+viral	B-DISO
+infection	I-DISO
+resulted	O
+in	O
+an	O
+immediate	O
+stimulation	O
+of	O
+complement	B-PROC
+activity	I-PROC
+,	O
+followed	O
+by	O
+a	O
+decrease	O
+to	O
+initial	O
+complement	O
+levels	O
+within	O
+2	O
+weeks	O
+post	O
+vaccination	O
+,	O
+when	O
+the	O
+antibody	B-PROC
+response	I-PROC
+took	O
+over	O
+immune	O
+defence	O
+.	O
+
+As	O
+compared	O
+to	O
+WLH	O
+chickens	B-SPEC
+,	O
+RIR	O
+birds	B-SPEC
+mounted	O
+a	O
+faster	O
+and	O
+significantly	O
+higher	O
+antibody	B-PROC
+response	I-PROC
+to	O
+the	O
+vaccine	O
+viruses	B-SPEC
+used	O
+.	O
+
+However	O
+,	O
+the	O
+clinical	O
+spectrum	O
+of	O
+disease	O
+and	O
+the	O
+epidemiology	O
+of	O
+CoV	B-SPEC
+-	I-SPEC
+HKU1	I-SPEC
+infections	B-DISO
+in	O
+relation	O
+to	O
+infections	B-DISO
+with	O
+other	O
+respiratory	O
+viruses	B-SPEC
+are	O
+unknown	O
+.	O
+
+Similar	O
+to	O
+the	O
+case	O
+for	O
+other	O
+coronaviruses	O
+,	O
+upper	B-DISO
+respiratory	I-DISO
+infection	I-DISO
+was	O
+the	O
+most	O
+common	O
+presentation	O
+of	O
+CoV	B-SPEC
+-	I-SPEC
+HKU1	I-SPEC
+infections	B-DISO
+,	O
+although	O
+pneumonia	B-DISO
+,	O
+acute	B-DISO
+bronchiolitis	I-DISO
+,	O
+and	O
+asthmatic	B-DISO
+exacerbation	O
+also	O
+occurred	O
+.	O
+
+CoV	B-SPEC
+-	I-SPEC
+HKU1	I-SPEC
+and	O
+HCoV	B-SPEC
+-	I-SPEC
+OC43	I-SPEC
+infections	B-DISO
+peaked	O
+in	O
+winter	O
+,	O
+although	O
+cases	O
+of	O
+the	O
+former	O
+also	O
+occurred	O
+in	O
+spring	O
+to	O
+early	O
+summer	O
+.	O
+
+Two	O
+of	O
+the	O
+siRNA	O
+expression	O
+cassettes	O
+for	O
+RDRP	B-FUNC
+successfully	O
+inhibited	O
+the	O
+expression	B-PROC
+of	O
+the	O
+gene	O
+,	O
+whereas	O
+both	O
+of	O
+the	O
+siRNA	O
+expression	B-PROC
+cassettes	O
+for	O
+envelope	B-COMP
+E	O
+decreased	O
+approx	O
+90	O
+%	O
+of	O
+the	O
+envelope	B-PRGE
+E	I-PRGE
+gene	B-PROC
+expression	I-PROC
+.	O
+
+ABSTRACT	O
+:	O
+The	O
+role	O
+of	O
+viruses	O
+in	O
+community	O
+-	O
+acquired	O
+pneumonia	B-DISO
+may	O
+have	O
+been	O
+previously	O
+underestimated	O
+.	O
+
+Of	O
+340	O
+patients	O
+diagnosed	O
+with	O
+CAP	B-DISO
+,	O
+198	O
+had	O
+nasopharyngeal	B-ANAT
+swabs	O
+available	O
+and	O
+were	O
+included	O
+in	O
+this	O
+study	O
+.	O
+
+The	O
+most	O
+common	O
+aetiological	O
+agent	O
+was	O
+S	O
+.	O
+neumoniae	O
+(	O
+58	O
+patients	O
+,	O
+29	O
+%),	O
+followed	O
+by	O
+respiratory	O
+viruses	B-SPEC
+(	O
+46	O
+patients	O
+,	O
+23	O
+%).	O
+
+The	O
+only	O
+clinical	O
+characteristic	O
+that	O
+significantly	O
+distinguished	O
+viral	O
+from	O
+bacterial	O
+aetiology	O
+was	O
+a	O
+lower	O
+number	O
+of	O
+leukocytes	B-ANAT
+(	O
+P	O
+=	O
+0	O
+.	O
+004	O
+).	O
+
+There	O
+is	O
+an	O
+urgent	O
+need	O
+to	O
+reconsider	O
+routine	O
+laboratory	O
+tests	O
+for	O
+an	O
+adequate	O
+diagnosis	O
+of	O
+respiratory	O
+viruses	B-SPEC
+,	O
+as	O
+clinical	O
+characteristics	O
+are	O
+unable	O
+to	O
+reliably	O
+distinguish	O
+viral	O
+from	O
+bacterial	O
+aetiology	O
+.	O
+
+The	O
+only	O
+clinical	O
+characteristic	O
+that	O
+significantly	O
+distinguished	O
+viral	O
+from	O
+bacterial	O
+aetiology	O
+was	O
+a	O
+lower	O
+number	O
+of	O
+leukocytes	B-ANAT
+(	O
+P	O
+=	O
+0	O
+.	O
+004	O
+).	O
+
+TITLE	O
+:	O
+Isatin	B-CHED
+compounds	O
+as	O
+noncovalent	O
+SARS	B-PRGE
+coronavirus	B-SPEC
+3C	I-PRGE
+-	I-PRGE
+like	I-PRGE
+protease	B-PROC
+inhibitors	I-PROC
+.	O
+
+ABSTRACT	O
+:	O
+A	O
+series	O
+of	O
+isatin	O
+derivatives	O
+were	O
+synthesized	O
+and	O
+tested	O
+against	O
+SARS	B-PRGE
+CoV	I-PRGE
+3C	I-PRGE
+-	I-PRGE
+like	I-PRGE
+protease	I-PRGE
+.	O
+
+Further	O
+,	O
+they	O
+were	O
+only	O
+10	O
+-	O
+15	O
+-	O
+fold	O
+less	O
+inhibitory	O
+against	O
+human	B-SPEC
+HBV	B-DISO
+in	O
+2	O
+.	O
+2	O
+.	O
+15	O
+cells	B-COMP
+than	O
+the	O
+reference	O
+drug	O
+,	O
+lamivudine	B-CHED
+.	O
+
+ABSTRACT	O
+:	O
+To	O
+investigate	O
+the	O
+relationships	O
+between	O
+a	O
+known	O
+history	O
+of	O
+diabetes	B-DISO
+and	O
+ambient	O
+fasting	O
+plasma	B-ANAT
+glucose	B-CHED
+(	O
+FPG	O
+)	O
+levels	O
+with	O
+death	B-PROC
+and	O
+morbidity	O
+rates	O
+in	O
+patients	O
+with	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+(	O
+SARS	B-DISO
+).	O
+
+In	O
+the	O
+SARS	B-DISO
+group	O
+,	O
+the	O
+percentage	O
+of	O
+patients	O
+with	O
+a	O
+known	O
+history	O
+of	O
+diabetes	B-DISO
+was	O
+significantly	O
+higher	O
+in	O
+the	O
+deceased	B-PROC
+patients	O
+than	O
+in	O
+the	O
+survivors	O
+(	O
+21	O
+.	O
+5	O
+%	O
+vs	O
+.	O
+3	O
+.	O
+9	O
+%,	O
+P	O
+<	O
+0	O
+.	O
+01	O
+).	O
+
+Survival	O
+analysis	O
+showed	O
+that	O
+FPG	B-PRGE
+was	O
+independently	O
+associated	O
+with	O
+an	O
+increased	O
+hazard	O
+ratio	O
+(	O
+HR	O
+)	O
+of	O
+mortality	O
+(	O
+HR	O
+=	O
+1	O
+.	O
+1	O
+,	O
+95	O
+%	O
+CI	O
+1	O
+.	O
+0	O
+,	O
+1	O
+.	O
+1	O
+,	O
+P	O
+=	O
+0	O
+.	O
+001	O
+)	O
+and	O
+hypoxia	B-DISO
+(	O
+HR	O
+=	O
+1	O
+.	O
+1	O
+,	O
+95	O
+%	O
+CI	O
+1	O
+.	O
+0	O
+,	O
+1	O
+.	O
+1	O
+,	O
+P	O
+=	O
+0	O
+.	O
+002	O
+)	O
+after	O
+controlling	O
+for	O
+age	O
+and	O
+gender	O
+.	O
+
+TITLE	O
+:	O
+Management	O
+of	O
+acute	B-DISO
+pancreatitis	I-DISO
+:	O
+current	O
+knowledge	O
+and	O
+future	O
+perspectives	O
+.	O
+
+According	O
+to	O
+the	O
+pathophysiology	O
+of	O
+acute	O
+pancreatitis	O
+,	O
+the	O
+efficacy	O
+of	O
+the	O
+drugs	O
+already	O
+available	O
+,	O
+such	O
+as	O
+gabexate	O
+mesilate	O
+,	O
+lexipafant	O
+and	O
+somatostatin	B-PRGE
+should	O
+be	O
+re	O
+-	O
+evaluated	O
+and	O
+should	O
+be	O
+probably	O
+administered	O
+in	O
+a	O
+different	O
+manner	O
+.	O
+
+SARS	B-DISO
+-	O
+CoV	O
+infected	O
+both	O
+immature	O
+and	O
+mature	O
+DCs	B-DISO
+,	O
+although	O
+replication	O
+efficiency	O
+was	O
+low	O
+.	O
+
+Interferon	O
+responses	O
+are	O
+not	O
+triggered	O
+during	O
+infection	B-DISO
+,	O
+although	O
+the	O
+L	O
+cells	B-COMP
+can	O
+be	O
+readily	O
+stimulated	O
+to	O
+produce	O
+interferon	B-PRGE
+by	O
+dsRNA	B-CHED
+,	O
+a	O
+known	O
+potent	O
+inducer	O
+of	O
+interferon	B-PRGE
+.	O
+
+The	O
+transmission	O
+of	O
+SARS	B-DISO
+was	O
+elucidated	O
+based	O
+on	O
+information	O
+from	O
+standardised	O
+questionnaires	O
+,	O
+and	O
+records	O
+of	O
+investigation	O
+and	O
+surveillance	O
+by	O
+the	O
+Department	O
+of	O
+Health	O
+.	O
+
+Other	O
+pathogens	O
+identified	O
+included	O
+coronavirus	B-SPEC
+OC43	O
+,	O
+respiratory	B-SPEC
+syncytial	I-SPEC
+virus	I-SPEC
+,	O
+and	O
+rhinovirus	B-SPEC
+.	O
+
+With	O
+heightened	O
+concern	O
+over	O
+the	O
+potential	O
+for	O
+another	O
+global	O
+influenza	B-DISO
+pandemic	O
+,	O
+such	O
+surveillance	O
+could	O
+prove	O
+critical	O
+for	O
+the	O
+detection	O
+of	O
+emerging	O
+influenza	B-DISO
+and	O
+respiratory	O
+pathogen	O
+strains	O
+with	O
+potential	O
+for	O
+importation	O
+to	O
+the	O
+United	O
+States	O
+.	O
+
+Data	O
+was	O
+collected	O
+prospectively	O
+through	O
+an	O
+ongoing	O
+emergency	B-DISO
+airway	B-ANAT
+registry	O
+.	O
+
+The	O
+complication	B-DISO
+rates	O
+were	O
+10	O
+.	O
+5	O
+%,	O
+9	O
+.	O
+9	O
+%	O
+and	O
+9	O
+.	O
+4	O
+%	O
+in	O
+periods	B-PROC
+1	O
+-	O
+3	O
+,	O
+respectively	O
+.	O
+
+Restriction	O
+in	O
+the	O
+number	O
+of	O
+healthcare	O
+staff	O
+attending	O
+to	O
+each	O
+patient	O
+may	O
+have	O
+influenced	O
+the	O
+department	O
+'	O
+s	O
+decision	O
+to	O
+allow	O
+only	O
+the	O
+most	O
+confident	O
+or	O
+experienced	O
+personnel	O
+to	O
+manage	O
+the	O
+airway	B-ANAT
+.	O
+
+The	O
+majority	O
+of	O
+EDs	B-DISO
+would	O
+isolate	O
+patients	O
+with	O
+potential	O
+infectious	B-DISO
+diseases	I-DISO
+,	O
+however	O
+,	O
+47	O
+(	O
+23	O
+%)	O
+would	O
+not	O
+isolate	O
+patients	O
+with	O
+suspected	O
+chickenpox	B-DISO
+,	O
+37	O
+(	O
+18	O
+%)	O
+EDS	B-DISO
+would	O
+not	O
+isolate	O
+patients	O
+with	O
+suspected	O
+TB	O
+,	O
+12	O
+(	O
+6	O
+%)	O
+EDS	B-DISO
+would	O
+not	O
+isolate	O
+patients	O
+with	O
+suspected	O
+SARS	B-DISO
+and	O
+55	O
+(	O
+27	O
+%)	O
+EDS	B-DISO
+would	O
+not	O
+isolate	O
+patients	O
+with	O
+other	O
+suspicious	O
+infections	B-DISO
+.	O
+
+TITLE	O
+:	O
+Biophysical	O
+characterization	O
+of	O
+HRC	B-PRGE
+peptide	I-PRGE
+analogs	O
+interaction	O
+with	O
+heptad	O
+repeat	O
+regions	O
+of	O
+the	O
+SARS	O
+-	O
+coronavirus	B-SPEC
+Spike	O
+fusion	O
+protein	B-CHED
+core	O
+.	O
+
+Findings	O
+showed	O
+that	O
+public	O
+stigma	O
+was	O
+the	O
+highest	O
+towards	O
+HIV	B-DISO
+/	I-DISO
+AIDS	I-DISO
+,	O
+followed	O
+by	O
+TB	O
+and	O
+SARS	B-DISO
+.	O
+
+Clinical	O
+diagnosis	O
+comprises	O
+severe	O
+hypoxemia	O
+assessed	O
+by	O
+arterial	B-ANAT
+oxygen	B-PROC
+tension	B-DISO
+/	O
+fraction	O
+of	O
+inspired	B-PROC
+oxygen	B-CHED
+ratio	O
+of	O
+less	O
+than	O
+200	O
+and	O
+bilateral	O
+infiltrate	B-DISO
+on	O
+a	O
+chest	B-ANAT
+radiograph	O
+in	O
+the	O
+absence	O
+of	O
+left	O
+atrial	B-ANAT
+hypertension	B-DISO
+.	O
+
+Bronchoalveolar	B-ANAT
+lavage	I-ANAT
+fluid	I-ANAT
+in	O
+patients	O
+with	O
+ARDS	B-DISO
+shows	O
+neutrophil	B-ANAT
+predominance	O
+with	O
+increased	O
+edema	B-DISO
+fluid	O
+to	O
+serum	B-COMP
+protein	B-CHED
+ratio	O
+.	O
+
+ABSTRACT	O
+:	O
+Describe	O
+initial	O
+development	B-PROC
+and	O
+validation	O
+of	O
+a	O
+test	O
+battery	O
+composed	O
+of	O
+established	O
+instruments	O
+designed	O
+to	O
+detect	O
+,	O
+via	O
+telephone	O
+interview	O
+,	O
+cognitive	O
+abnormalities	O
+in	O
+survivors	O
+of	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+.	O
+
+There	O
+was	O
+convergence	O
+of	O
+cognitive	B-DISO
+impairment	I-DISO
+with	O
+moderate	O
+/	O
+severe	O
+anxiety	O
+(	O
+P	O
+=	O
+.	O
+008	O
+),	O
+the	O
+Sickness	O
+Impact	O
+Profile	O
+Psychosocial	O
+Summary	O
+Score	O
+(	O
+mean	O
+difference	O
+,	O
+15	O
+.	O
+3	O
+;	O
+95	O
+%	O
+CI	O
+,	O
+7	O
+.	O
+74	O
+-	O
+22	O
+.	O
+9	O
+;	O
+P	O
+=	O
+.	O
+0001	O
+),	O
+and	O
+the	O
+mental	O
+health	O
+domains	O
+of	O
+the	O
+Short	O
+Form	O
+36	O
+.	O
+
+ABSTRACT	O
+:	O
+In	O
+this	O
+study	O
+,	O
+we	O
+report	O
+a	O
+serum	B-COMP
+-	O
+free	O
+culture	O
+system	O
+for	O
+primary	O
+neonatal	O
+pulmonary	B-ANAT
+cells	B-COMP
+that	O
+can	O
+support	O
+the	O
+growth	B-PROC
+of	O
+octamer	B-PRGE
+-	I-PRGE
+binding	I-PRGE
+transcription	B-PROC
+factor	I-PRGE
+4	I-PRGE
++	I-PRGE
+(	O
+Oct	B-PRGE
+-	I-PRGE
+4	I-PRGE
++)	I-PRGE
+epithelial	O
+colonies	O
+with	O
+a	O
+surrounding	O
+mesenchymal	O
+stroma	B-ANAT
+.	O
+
+Lastly	O
+,	O
+these	O
+Oct	B-PRGE
+-	I-PRGE
+4	I-PRGE
++	I-PRGE
+epithelial	O
+colony	O
+cells	B-COMP
+,	O
+which	O
+also	O
+express	O
+angiotensin	B-PRGE
+-	I-PRGE
+converting	I-PRGE
+enzyme	I-PRGE
+2	I-PRGE
+,	O
+are	O
+the	O
+target	B-ANAT
+cells	I-ANAT
+for	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+coronavirus	B-DISO
+infection	I-DISO
+in	O
+primary	O
+cultures	O
+and	O
+support	O
+active	O
+virus	B-PROC
+replication	I-PROC
+leading	O
+to	O
+their	O
+own	O
+destruction	O
+.	O
+
+These	O
+observations	O
+imply	O
+the	O
+possible	O
+involvement	O
+of	O
+lung	B-ANAT
+stem	B-ANAT
+/	O
+progenitor	B-ANAT
+cells	I-ANAT
+,	O
+in	O
+addition	O
+to	O
+pneumocytes	B-ANAT
+,	O
+in	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+coronavirus	B-DISO
+infection	I-DISO
+,	O
+accounting	O
+for	O
+the	O
+continued	O
+deterioration	O
+of	O
+lung	B-ANAT
+tissues	I-ANAT
+and	O
+apparent	O
+loss	O
+of	O
+capacity	O
+for	O
+lung	B-ANAT
+repair	B-PROC
+.	O
+
+The	O
+NTD	O
+of	O
+the	O
+IBV	B-SPEC
+Gray	O
+strain	O
+at	O
+1	O
+.	O
+3	O
+-	O
+A	O
+resolution	O
+exhibits	O
+a	O
+U	O
+-	O
+shaped	O
+structure	O
+,	O
+with	O
+two	O
+arms	B-DISO
+rich	O
+in	O
+basic	O
+residues	O
+,	O
+providing	O
+a	O
+module	O
+for	O
+specific	O
+interaction	O
+with	O
+RNA	O
+.	O
+
+The	O
+variety	O
+of	O
+quaternary	O
+arrangements	O
+of	O
+the	O
+NTD	O
+and	O
+CTD	O
+revealed	O
+by	O
+the	O
+analysis	O
+of	O
+the	O
+different	O
+crystal	B-ANAT
+forms	O
+delineates	O
+possible	O
+interfaces	O
+that	O
+could	O
+be	O
+used	O
+for	O
+the	O
+formation	B-PROC
+of	O
+a	O
+flexible	O
+filamentous	O
+ribonucleocapsid	O
+.	O
+
+ABSTRACT	O
+:	O
+Zoonosis	B-DISO
+is	O
+the	O
+cause	O
+of	O
+the	O
+vast	O
+majority	O
+of	O
+emerging	O
+diseases	O
+.	O
+
+ABSTRACT	O
+:	O
+Our	O
+previous	O
+reports	O
+,	O
+both	O
+experimental	O
+and	O
+human	B-SPEC
+studies	O
+,	O
+have	O
+shown	O
+the	O
+importance	O
+of	O
+fibrinogen	B-PRGE
+-	I-PRGE
+like	I-PRGE
+protein	B-CHED
+-	I-PRGE
+2	I-PRGE
+(	O
+fgl2	B-PRGE
+)	O
+prothrombinase	B-PRGE
+in	O
+the	O
+development	B-PROC
+of	O
+fulminant	O
+viral	B-DISO
+hepatitis	I-DISO
+,	O
+a	O
+disease	O
+with	O
+a	O
+mortality	O
+of	O
+more	O
+than	O
+80	O
+%	O
+in	O
+cases	O
+lacking	O
+immediate	O
+organ	B-ANAT
+transplantation	O
+.	O
+
+On	O
+hydrodynamic	O
+delivery	O
+,	O
+mfgl2	O
+antisense	O
+plasmid	O
+significantly	O
+reduced	O
+mfgl2	O
+expression	B-PROC
+in	O
+vivo	O
+;	O
+markedly	O
+ameliorated	O
+inflammatory	B-DISO
+cell	I-DISO
+infiltration	I-DISO
+,	O
+fibrin	B-DISO
+deposition	I-DISO
+,	O
+and	O
+hepatocyte	B-ANAT
+necrosis	B-PROC
+;	O
+prolonged	O
+the	O
+survival	O
+time	O
+period	O
+;	O
+and	O
+elevated	O
+the	O
+survival	O
+rate	O
+among	O
+BALB	O
+/	O
+cJ	O
+mice	B-SPEC
+with	O
+murine	B-DISO
+hepatitis	I-DISO
+virus	B-SPEC
+type	O
+3	O
+-	O
+induced	O
+fulminant	B-DISO
+hepatitis	I-DISO
+.	O
+
+TITLE	O
+:	O
+Whole	B-ANAT
+blood	I-ANAT
+cytokine	O
+profiles	O
+in	O
+cats	B-SPEC
+infected	O
+by	O
+feline	B-SPEC
+coronavirus	B-SPEC
+and	O
+healthy	O
+non	O
+-	O
+FCoV	O
+infected	O
+specific	O
+pathogen	O
+-	O
+free	O
+cats	O
+.	O
+
+ABSTRACT	O
+:	O
+We	O
+studied	O
+the	O
+psychological	B-DISO
+impact	O
+of	O
+the	O
+outbreak	O
+of	O
+Severe	B-DISO
+Acute	I-DISO
+Respiratory	I-DISO
+Syndrome	I-DISO
+(	O
+SARS	B-DISO
+)	O
+to	O
+understand	O
+if	O
+age	O
+and	O
+residential	O
+location	O
+were	O
+risk	O
+factors	O
+associated	O
+with	O
+post	O
+-	O
+traumatic	O
+disturbance	O
+,	O
+namely	O
+intrusion	O
+,	O
+avoidance	O
+,	O
+and	O
+hyperarousal	O
+.	O
+
+Furthermore	O
+,	O
+the	O
+prevalence	O
+of	O
+probable	O
+post	B-DISO
+-	I-DISO
+traumatic	I-DISO
+stress	I-DISO
+disorder	I-DISO
+(	O
+PTSD	B-DISO
+)	O
+cases	O
+was	O
+significantly	O
+higher	O
+in	O
+older	O
+people	O
+and	O
+in	O
+residents	O
+of	O
+SARS	B-DISO
+-	O
+prevalent	O
+regions	O
+.	O
+
+Data	O
+of	O
+these	O
+patients	O
+retrieved	O
+from	O
+a	O
+database	O
+were	O
+retrospectively	O
+analyzed	O
+by	O
+logistic	O
+regression	O
+and	O
+Cox	O
+regression	O
+for	O
+the	O
+effect	O
+of	O
+corticosteroid	B-CHED
+therapy	O
+on	O
+death	B-PROC
+,	O
+hospitalization	O
+days	O
+,	O
+and	O
+complication	B-DISO
+presentation	O
+.	O
+
+102	O
+.	O
+3	O
+mg	O
+,	O
+and	O
+25	O
+died	B-PROC
+.	O
+
+Analysis	O
+of	O
+these	O
+401	O
+confirmed	O
+cases	O
+did	O
+not	O
+show	O
+any	O
+benefits	O
+of	O
+corticosteroid	B-CHED
+on	O
+the	O
+death	B-PROC
+rate	O
+and	O
+hospitalization	O
+days	O
+.	O
+
+ABSTRACT	O
+:	O
+To	O
+investigate	O
+the	O
+protective	O
+factors	O
+and	O
+risk	O
+factors	O
+of	O
+nosocomial	O
+infection	O
+of	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+(	O
+SARS	B-DISO
+)	O
+among	O
+health	O
+care	O
+workers	O
+(	O
+HCWs	O
+),	O
+and	O
+thus	O
+provide	O
+the	O
+scientific	O
+basis	O
+for	O
+prevention	O
+and	O
+control	O
+of	O
+nosocomial	B-DISO
+infection	I-DISO
+.	O
+
+With	O
+the	O
+case	O
+-	O
+control	O
+study	O
+,	O
+a	O
+standardized	O
+questionnaire	O
+was	O
+used	O
+for	O
+data	O
+collection	O
+in	O
+three	O
+general	O
+hospitals	O
+where	O
+nosocomial	B-DISO
+infection	I-DISO
+had	O
+occurred	O
+.	O
+
+All	O
+concerned	O
+factors	O
+about	O
+SARS	B-DISO
+infection	B-DISO
+were	O
+scanned	O
+by	O
+using	O
+Chi	B-CHED
+-	O
+square	O
+test	O
+and	O
+Fisher	B-SPEC
+'	O
+s	O
+exact	O
+test	O
+one	O
+by	O
+one	O
+,	O
+and	O
+determined	O
+as	O
+to	O
+whether	O
+they	O
+were	O
+risk	O
+factors	O
+or	O
+protective	O
+factors	O
+according	O
+to	O
+odd	O
+ratio	O
+(	O
+OR	O
+)	O
+score	O
+.	O
+
+Three	O
+days	O
+later	O
+an	O
+abnormal	O
+chest	B-ANAT
+shadow	O
+was	O
+pointed	O
+out	O
+.	O
+
+Considering	O
+the	O
+clinical	O
+course	O
+and	O
+laboratory	O
+data	O
+,	O
+this	O
+was	O
+probably	O
+drug	O
+-	O
+induced	O
+lung	B-ANAT
+injury	O
+caused	O
+by	O
+oseltamivir	B-CHED
+.	O
+
+Serum	B-COMP
+specimens	O
+were	O
+also	O
+collected	O
+from	O
+49	O
+children	O
+from	O
+Anhui	O
+province	O
+which	O
+was	O
+non	O
+-	O
+epidemic	O
+region	O
+and	O
+93	O
+healthy	O
+kindergarten	O
+children	O
+without	O
+history	O
+of	O
+contacting	O
+with	O
+SARS	B-DISO
+patients	O
+in	O
+Beijing	O
+during	O
+SARS	B-DISO
+epidemic	O
+.	O
+
+In	O
+children	O
+and	O
+adults	O
+who	O
+closely	O
+contacted	O
+with	O
+these	O
+clinically	O
+diagnosed	O
+SARS	B-DISO
+adult	O
+patients	O
+,	O
+the	O
+positive	O
+rates	O
+of	O
+specific	O
+IgG	B-PRGE
+and	O
+whole	O
+antibodies	B-COMP
+against	O
+SARS	B-DISO
+-	O
+CoV	O
+were	O
+0	O
+to	O
+9	O
+.	O
+7	O
+%	O
+and	O
+4	O
+.	O
+4	O
+%	O
+to	O
+7	O
+.	O
+1	O
+%,	O
+respectively	O
+.	O
+
+None	O
+of	O
+the	O
+serum	B-COMP
+specimens	O
+collected	O
+from	O
+healthy	O
+children	O
+before	O
+and	O
+during	O
+epidemic	O
+in	O
+Beijing	O
+and	O
+children	O
+from	O
+non	O
+-	O
+epidemic	O
+region	O
+was	O
+positive	O
+when	O
+IFA	O
+methods	O
+and	O
+ELISA	O
+with	O
+Beier	O
+kits	O
+were	O
+used	O
+for	O
+detection	O
+,	O
+but	O
+some	O
+were	O
+positive	O
+when	O
+ELISA	O
+with	O
+the	O
+diagnostic	O
+kit	B-FUNC
+from	O
+other	O
+source	O
+was	O
+applied	O
+.	O
+
+TITLE	O
+:	O
+Amino	B-CHED
+acids	I-CHED
+15	O
+-	O
+28	O
+in	O
+the	O
+ectodomain	O
+of	O
+SARS	B-PRGE
+coronavirus	B-SPEC
+3a	I-PRGE
+protein	B-CHED
+induces	O
+neutralizing	O
+antibodies	B-COMP
+.	O
+
+The	O
+latter	O
+targeted	B-PROC
+the	O
+C	O
+-	O
+terminal	O
+cytoplasmic	B-ANAT
+domain	I-ANAT
+of	O
+3a	O
+(	O
+aa	O
+134	O
+-	O
+274	O
+).	O
+
+Interestingly	O
+,	O
+most	O
+of	O
+SARS	B-PRGE
+-	I-PRGE
+CoV	I-PRGE
+S	I-PRGE
+-	I-PRGE
+specific	I-PRGE
+memory	B-PROC
+CD4	I-PRGE
+(+)	O
+T	B-ANAT
+cells	I-ANAT
+were	O
+central	O
+memory	B-ANAT
+cells	B-COMP
+expressing	O
+CD45RO	B-PRGE
+(+)	I-PRGE
+CCR7	I-PRGE
+(+)	I-PRGE
+CD62L	I-PRGE
+(-).	O
+
+These	O
+data	O
+may	O
+have	O
+an	O
+important	O
+implication	O
+in	O
+the	O
+possibility	O
+of	O
+designing	O
+effective	O
+vaccine	O
+against	O
+SARS	O
+-	O
+CoV	O
+infection	O
+,	O
+specifically	O
+in	O
+defining	O
+T	B-ANAT
+-	I-ANAT
+cell	I-ANAT
+populations	O
+that	O
+are	O
+implicated	O
+in	O
+protective	O
+immunity	B-PROC
+.	O
+
+Intravenous	O
+infusion	O
+of	O
+cobra	O
+venom	O
+factor	O
+(	O
+CVF	O
+)	O
+has	O
+been	O
+used	O
+as	O
+an	O
+animal	B-SPEC
+model	O
+of	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+(	O
+ARDS	B-DISO
+),	O
+and	O
+reliably	O
+and	O
+selectively	O
+induces	O
+rapid	O
+intravascular	O
+activation	O
+of	O
+the	O
+complement	O
+system	O
+,	O
+leading	O
+to	O
+acute	O
+organ	B-ANAT
+damage	O
+.	O
+
+These	O
+cytokines	O
+,	O
+especially	O
+IL	B-FUNC
+-	I-FUNC
+1	I-FUNC
+,	O
+TNF	B-PRGE
+-	I-PRGE
+alpha	I-PRGE
+and	O
+IL	B-FUNC
+-	I-FUNC
+8	I-FUNC
+,	O
+have	O
+important	O
+roles	O
+in	O
+the	O
+lung	B-ANAT
+dysfunction	O
+.	O
+
+In	O
+view	O
+of	O
+this	O
+,	O
+the	O
+softwares	O
+,	O
+ZCURVE_CoV	O
+1	O
+.	O
+0	O
+and	O
+ZCURVE_CoV	O
+2	O
+.	O
+0	O
+(	O
+http	O
+://	O
+tubic	O
+.	O
+tju	O
+.	O
+edu	O
+.	O
+cn	O
+/	O
+sars	B-DISO
+/),	O
+developed	O
+recently	O
+for	O
+SARS	B-DISO
+-	O
+Coronavirus	B-SPEC
+are	O
+used	O
+to	O
+analyze	O
+the	O
+36	O
+complete	O
+SARS	B-DISO
+-	O
+Coronavirus	B-SPEC
+RNA	O
+sequences	O
+in	O
+the	O
+gene	O
+bank	O
+NCBI	O
+(	O
+http	O
+://	O
+www	O
+.	O
+ncbi	O
+.	O
+nlm	O
+.	O
+nih	O
+.	O
+gov	O
+/)	O
+from	O
+different	O
+sources	O
+for	O
+protein	B-CHED
+coding	O
+genes	O
+,	O
+and	O
+to	O
+search	O
+for	O
+the	O
+cleavage	B-PROC
+sites	O
+of	O
+SARS	B-PRGE
+-	I-PRGE
+CoV	I-PRGE
+M	I-PRGE
+(	I-PRGE
+pro	B-CHED
+)	I-PRGE
+in	O
+polyproteins	O
+pp1a	B-PRGE
+and	O
+pp1ab	O
+.	O
+
+TITLE	O
+:	O
+Molecular	O
+analysis	O
+of	O
+chronic	B-DISO
+eosinophilic	I-DISO
+leukemia	I-DISO
+with	O
+t	O
+(	O
+4	O
+;	O
+10	O
+)	O
+showing	O
+good	O
+response	O
+to	O
+imatinib	B-CHED
+mesylate	I-CHED
+.	O
+
+However	O
+,	O
+karyotypic	O
+examination	O
+of	O
+bone	B-ANAT
+marrow	I-ANAT
+cells	I-ANAT
+revealed	O
+that	O
+chromosomal	B-DISO
+translocation	B-PROC
+with	O
+t	O
+(	O
+4	O
+;	O
+10	O
+)(	O
+q12	O
+;	O
+p11	O
+)	O
+had	O
+occurred	O
+in	O
+2000	O
+,	O
+and	O
+chronic	B-DISO
+eosinophilic	I-DISO
+leukemia	I-DISO
+was	O
+diagnosed	O
+.	O
+
+In	O
+this	O
+case	O
+,	O
+we	O
+performed	O
+molecular	O
+analysis	O
+using	O
+peripheral	B-ANAT
+blood	I-ANAT
+.	O
+
+Saikosaponins	O
+isolated	O
+from	O
+medicinal	O
+plants	B-SPEC
+such	O
+as	O
+Bupleurum	B-PRGE
+spp	B-ENZY
+.,	I-PRGE
+Heteromorpha	B-SPEC
+spp	B-ENZY
+.	O
+
+Using	O
+the	O
+2	O
+,	O
+3	O
+-	O
+bis	B-FUNC
+[	O
+2	O
+-	O
+methoxy	B-CHED
+-	O
+4	O
+-	O
+nitro	B-CHED
+-	O
+5	O
+-	O
+sulfophenyl	O
+]-	O
+5	O
+-[(	O
+phenylamino	B-CHED
+)	O
+carbonyl	B-CHED
+-	O
+2H	O
+-	O
+tetrazolium	O
+hydroxide	B-CHED
+]	O
+(	O
+XTT	O
+)	O
+assay	O
+,	O
+results	O
+showed	O
+that	O
+all	O
+saikosaponins	O
+tested	O
+demonstrated	O
+antiviral	B-CHED
+activity	O
+at	O
+concentrations	O
+of	O
+0	O
+.	O
+25	O
+-	O
+25	O
+micromol	O
+/	O
+L	O
+,	O
+with	O
+the	O
+strongest	O
+activity	O
+being	O
+noted	O
+for	O
+saikosaponin	O
+B2	O
+(	O
+IC50	O
+=	O
+1	O
+.	O
+7	O
++/-	O
+
+In	O
+the	O
+time	O
+-	O
+of	O
+-	O
+addition	O
+studies	O
+,	O
+saikosaponin	O
+B2	O
+,	O
+at	O
+6	O
+micromol	O
+/	O
+L	O
+,	O
+significantly	O
+inhibited	O
+human	B-SPEC
+coronavirus	I-SPEC
+229E	I-SPEC
+infection	B-DISO
+following	O
+its	O
+addition	O
+at	O
+various	O
+time	O
+pre	O
+-	O
+infection	B-DISO
+(-	O
+4	O
+to	O
+-	O
+1	O
+h	O
+),	O
+coinfection	B-DISO
+(	O
+0	O
+h	O
+)	O
+and	O
+post	O
+-	O
+infection	B-DISO
+(	O
+1	O
+-	O
+4	O
+h	O
+).	O
+
+TITLE	O
+:	O
+Perinatal	O
+outcomes	O
+with	O
+laser	B-SPEC
+surgery	O
+for	O
+twin	B-DISO
+-	I-DISO
+twin	I-DISO
+transfusion	I-DISO
+syndrome	I-DISO
+.	O
+
+On	O
+brain	B-ANAT
+imaging	O
+,	O
+ischemic	O
+brain	B-ANAT
+injury	O
+was	O
+seen	O
+in	O
+12	O
+%	O
+of	O
+the	O
+amnioreduction	O
+group	O
+and	O
+none	O
+of	O
+the	O
+laser	B-SPEC
+group	O
+of	O
+infants	O
+(	O
+p	O
+=	O
+.	O
+01	O
+).	O
+
+In	O
+conclusion	O
+,	O
+these	O
+findings	O
+indicate	O
+that	O
+perinatal	O
+outcomes	O
+are	O
+improved	O
+with	O
+less	O
+neonatal	O
+morbidity	O
+for	O
+monochorionic	O
+pregnancies	B-PROC
+with	O
+severe	O
+TTTS	O
+treated	O
+by	O
+laser	B-SPEC
+ablation	O
+of	O
+communicating	O
+placental	B-ANAT
+vessels	B-ANAT
+when	O
+compared	O
+to	O
+treatment	O
+by	O
+amnioreduction	O
+.	O
+
+ABSTRACT	O
+:	O
+To	O
+compare	O
+the	O
+effect	O
+of	O
+a	O
+sustained	O
+inflation	O
+followed	O
+by	O
+an	O
+incremental	O
+mean	O
+airway	B-ANAT
+pressure	O
+trial	O
+during	O
+conventional	O
+and	O
+high	O
+-	O
+frequency	O
+oscillatory	O
+ventilation	O
+on	O
+oxygenation	B-PROC
+and	O
+hemodynamics	B-PROC
+in	O
+a	O
+large	O
+porcine	B-SPEC
+model	O
+of	O
+early	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+.	O
+
+5	O
+vs	O
+.	O
+PCV	B-CHED
+:	O
+62	O
++/-	O
+13	O
+and	O
+T	O
+(	O
+Ali	O
+):	O
+55	O
++/-	O
+
+We	O
+show	O
+that	O
+the	O
+final	O
+size	O
+formula	O
+is	O
+unchanged	O
+if	O
+there	O
+is	O
+a	O
+latent	O
+stage	O
+,	O
+any	O
+number	O
+of	O
+distinct	O
+infectious	B-DISO
+stages	O
+and	O
+/	O
+or	O
+a	O
+stage	O
+during	O
+which	O
+infectives	O
+are	O
+isolated	O
+(	O
+the	O
+durations	O
+of	O
+each	O
+stage	O
+can	O
+be	O
+drawn	O
+from	O
+any	O
+integrable	O
+distribution	O
+).	O
+
+We	O
+therefore	O
+screened	O
+an	O
+antibody	O
+-	O
+phage	O
+library	O
+derived	O
+from	O
+blood	B-ANAT
+of	O
+a	O
+convalescent	O
+SARS	B-DISO
+patient	O
+for	O
+antibodies	B-COMP
+complementary	O
+to	O
+CR3014	O
+.	O
+
+The	O
+mixture	B-CHED
+of	O
+both	O
+mAbs	O
+showed	O
+neutralization	O
+of	O
+SARS	B-PRGE
+-	I-PRGE
+CoV	I-PRGE
+in	O
+a	O
+synergistic	O
+fashion	O
+by	O
+recognizing	O
+different	O
+epitopes	O
+on	O
+the	O
+receptor	O
+-	O
+binding	B-FUNC
+domain	O
+.	O
+
+ABSTRACT	O
+:	O
+Acute	O
+lung	B-ANAT
+injury	O
+(	O
+ALI	O
+)	O
+is	O
+a	O
+clinical	O
+syndrome	O
+in	O
+which	O
+patients	O
+develop	O
+severe	O
+and	O
+progressive	O
+pulmonary	B-PROC
+gas	B-ENZY
+exchange	I-PROC
+defects	O
+and	O
+pulmonary	B-ANAT
+mechanical	O
+dysfunction	O
+.	O
+
+TITLE	O
+:	O
+Accelerated	O
+induction	B-PROC
+of	I-PROC
+apoptosis	I-PROC
+in	O
+insect	B-SPEC
+cells	B-COMP
+by	O
+baculovirus	B-SPEC
+-	O
+expressed	B-PROC
+SARS	B-DISO
+-	I-PRGE
+CoV	I-PRGE
+membrane	B-ANAT
+protein	B-CHED
+.	O
+
+This	O
+is	O
+the	O
+first	O
+report	O
+describing	O
+the	O
+induction	B-PROC
+of	I-PROC
+apoptosis	I-PROC
+by	O
+SARS	B-PRGE
+-	I-PRGE
+CoV	I-PRGE
+M	I-PRGE
+protein	B-CHED
+in	O
+animal	B-SPEC
+cells	B-COMP
+and	O
+possible	O
+implications	O
+are	O
+discussed	O
+.	O
+
+The	O
+high	O
+incidence	O
+and	O
+cluster	O
+occurrence	O
+immediately	O
+after	O
+SARS	B-DISO
+could	O
+be	O
+related	O
+to	O
+changes	O
+in	O
+the	O
+provision	O
+of	O
+nursing	B-PROC
+care	O
+and	O
+the	O
+level	O
+of	O
+parental	O
+supervision	O
+,	O
+in	O
+addition	O
+to	O
+more	O
+difficult	O
+operations	O
+encountered	O
+as	O
+reflected	O
+by	O
+more	O
+extensive	O
+clefts	O
+and	O
+longer	O
+operation	O
+time	O
+.	O
+
+Initial	O
+lymphocyte	B-ANAT
+counts	O
+were	O
+low	O
+in	O
+both	O
+fatalities	O
+(	O
+814	O
++/-	O
+
+After	O
+controlling	O
+for	O
+age	O
+and	O
+sex	O
+,	O
+multiple	O
+logistic	O
+regression	O
+analysis	O
+showed	O
+that	O
+hematological	O
+factors	O
+significantly	O
+associated	O
+with	O
+fatality	O
+included	O
+initial	O
+neutrophil	B-ANAT
+count	O
+>	O
+7000	O
+/	O
+microL	O
+(	O
+odds	O
+ratio	O
+[	O
+OR	O
+]	O
+=	O
+6	O
+.	O
+4	O
+),	O
+initial	O
+CRP	B-PRGE
+concentration	O
+>	O
+47	O
+.	O
+5	O
+mg	O
+/	O
+L	O
+(	O
+OR	O
+=	O
+5	O
+.	O
+8	O
+)	O
+and	O
+lactic	B-PRGE
+acid	I-PRGE
+dehydrogenase	I-PRGE
+(	O
+LDH	B-PRGE
+)	O
+>	O
+593	O
+.	O
+5	O
+IU	O
+/	O
+L	O
+(	O
+OR	O
+=	O
+4	O
+.	O
+2	O
+).	O
+
+Initial	O
+neutrophil	B-ANAT
+count	O
+,	O
+CRP	B-PRGE
+and	O
+LDH	B-PRGE
+levels	O
+are	O
+important	O
+predictors	O
+of	O
+mortality	O
+from	O
+SARS	B-DISO
+.	O
+
+Despite	O
+its	O
+highly	O
+sensitive	O
+and	O
+specific	O
+algorithm	O
+,	O
+it	O
+did	O
+incorrectly	O
+deny	O
+authorization	O
+to	O
+a	O
+very	O
+small	O
+number	O
+of	O
+patients	O
+without	O
+SARS	B-DISO
+.	O
+
+ABSTRACT	O
+:	O
+This	O
+paper	O
+analyses	O
+data	O
+arising	O
+from	O
+a	O
+SARS	O
+epidemic	O
+in	O
+Shanxi	O
+province	O
+of	O
+China	O
+involving	O
+a	O
+total	O
+of	O
+354	O
+people	O
+infected	O
+with	O
+SARS	B-DISO
+-	O
+CoV	O
+between	O
+late	O
+February	O
+and	O
+late	O
+May	O
+2003	O
+.	O
+
+The	O
+estimated	O
+mean	O
+incubation	O
+period	O
+was	O
+5	O
+.	O
+3	O
+days	O
+(	O
+95	O
+%	O
+CI	O
+4	O
+.	O
+2	O
+-	O
+6	O
+.	O
+8	O
+days	O
+),	O
+mean	O
+time	O
+to	O
+hospitalisation	O
+was	O
+3	O
+.	O
+5	O
+days	O
+(	O
+95	O
+%	O
+CI	O
+2	O
+.	O
+8	O
+-	O
+3	O
+.	O
+6	O
+days	O
+),	O
+mean	O
+time	O
+from	O
+symptom	B-DISO
+onset	O
+to	O
+recovery	O
+was	O
+26	O
+days	O
+(	O
+95	O
+%	O
+CI	O
+25	O
+-	O
+27	O
+days	O
+)	O
+and	O
+mean	O
+time	O
+from	O
+symptom	B-DISO
+onset	O
+to	O
+death	B-PROC
+was	O
+21	O
+days	O
+(	O
+95	O
+%	O
+CI	O
+16	O
+-	O
+26	O
+days	O
+).	O
+
+In	O
+this	O
+brief	O
+review	O
+,	O
+we	O
+describe	O
+the	O
+current	O
+understanding	O
+of	O
+how	O
+the	O
+SARS	B-PRGE
+-	I-PRGE
+CoV	I-PRGE
+is	O
+able	O
+to	O
+use	O
+the	O
+cellular	B-COMP
+machinery	O
+for	O
+its	O
+replication	O
+.	O
+
+TITLE	O
+:	O
+Surge	O
+capacity	O
+associated	O
+with	O
+restrictions	O
+on	O
+nonurgent	O
+hospital	O
+utilization	O
+and	O
+expected	O
+admissions	O
+during	O
+an	O
+influenza	B-DISO
+pandemic	O
+:	O
+lessons	O
+from	O
+the	O
+Toronto	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+outbreak	O
+.	O
+
+ABSTRACT	O
+:	O
+Severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+(	O
+SARS	B-DISO
+)	O
+is	O
+a	O
+highly	O
+infectious	B-DISO
+,	O
+rapidly	O
+progressive	O
+,	O
+emerging	O
+disease	O
+.	O
+
+ABSTRACT	O
+:	O
+Various	O
+strains	O
+of	O
+mouse	O
+hepatitis	O
+virus	B-SPEC
+(	O
+MHV	B-SPEC
+)	O
+exhibit	O
+different	O
+pathogenic	O
+phenotypes	O
+.	O
+
+Using	O
+a	O
+relaxed	O
+molecular	O
+clock	O
+approach	O
+,	O
+we	O
+reconstructed	O
+the	O
+evolutionary	O
+relationships	O
+between	O
+PHEV	O
+,	O
+BCoV	O
+,	O
+and	O
+HCoV	B-SPEC
+-	I-SPEC
+OC43	I-SPEC
+in	O
+real	O
+-	O
+time	O
+units	O
+,	O
+which	O
+indicated	O
+relatively	O
+recent	O
+common	O
+ancestors	O
+for	O
+these	O
+species	B-SPEC
+-	O
+specific	O
+coronaviruses	O
+.	O
+
+RESULTS	O
+:	O
+After	O
+detection	O
+,	O
+different	O
+levels	O
+of	O
+anti	O
+-	O
+N	O
+humoral	O
+and	O
+cellular	B-COMP
+responses	O
+are	O
+shown	O
+compared	O
+to	O
+controls	O
+.	O
+
+TITLE	O
+:	O
+Hexamethylene	B-CHED
+amiloride	B-CHED
+blocks	O
+E	O
+protein	B-CHED
+ion	B-FUNC
+channels	I-FUNC
+and	O
+inhibits	O
+coronavirus	B-SPEC
+replication	O
+.	O
+
+These	O
+E	O
+proteins	B-CHED
+were	O
+from	O
+coronaviruses	O
+representative	O
+of	O
+taxonomic	O
+groups	O
+1	O
+-	O
+3	O
+:	O
+human	B-SPEC
+coronavirus	I-SPEC
+229E	I-SPEC
+(	O
+HCoV	B-SPEC
+-	I-SPEC
+229E	I-SPEC
+),	O
+mouse	B-DISO
+hepatitis	I-DISO
+virus	B-SPEC
+(	O
+MHV	B-SPEC
+),	O
+and	O
+infectious	B-DISO
+bronchitis	B-DISO
+virus	B-SPEC
+(	O
+IBV	B-SPEC
+),	O
+respectively	O
+.	O
+
+We	O
+engineered	O
+a	O
+recombinant	O
+JHMV	O
+with	O
+mutations	O
+in	O
+the	O
+immunodominant	B-PRGE
+CD4	I-PRGE
+T	I-PRGE
+-	I-PRGE
+cell	I-PRGE
+epitope	B-CHED
+(	O
+rJ	O
+.	O
+M	O
+(	O
+Y135Q	O
+)).	O
+
+However	O
+,	O
+introduction	O
+of	O
+a	O
+CD4	B-PRGE
+T	B-ANAT
+-	I-ANAT
+cell	I-ANAT
+epitope	B-CHED
+from	O
+Listeria	B-SPEC
+monocytogenes	I-SPEC
+into	O
+rJ	O
+.	O
+M	O
+(	O
+Y135Q	O
+)	O
+generated	O
+a	O
+highly	O
+virulent	O
+virus	B-SPEC
+.	O
+
+The	O
+decrease	O
+in	O
+disease	O
+severity	O
+was	O
+not	O
+due	O
+to	O
+a	O
+switch	O
+from	O
+Th1	O
+to	O
+Th2	O
+predominance	O
+in	O
+rJ	O
+.	O
+M	O
+(	O
+Y135Q	O
+)-	O
+infected	O
+mice	O
+,	O
+an	O
+effect	O
+on	O
+CD8	B-PRGE
+T	B-ANAT
+-	I-ANAT
+cell	I-ANAT
+function	O
+,	O
+or	O
+differential	O
+expression	B-PROC
+of	O
+tumor	B-PRGE
+necrosis	I-PRGE
+factor	I-PRGE
+-	I-PRGE
+alpha	I-PRGE
+by	O
+JHMV	B-PRGE
+-	I-PRGE
+specific	I-PRGE
+CD4	I-PRGE
+T	I-PRGE
+cells	O
+.	O
+
+The	O
+sequences	O
+of	O
+these	O
+poliovirus	B-SPEC
+were	O
+highly	O
+homologous	O
+to	O
+that	O
+of	O
+human	B-PRGE
+poliovirus	B-SPEC
+type	I-PRGE
+1	I-PRGE
+strain	I-PRGE
+sabin	I-PRGE
+1	I-PRGE
+genome	O
+at	O
+nucleotide	B-CHED
+level	O
+,	O
+but	O
+back	B-ANAT
+mutations	O
+have	O
+occurred	O
+in	O
+the	O
+primary	O
+attenuating	O
+mutation	O
+sites	O
+at	O
+nucleotide	B-CHED
+position	O
+480	O
+(	O
+G	O
+-->	O
+A	O
+)	O
+in	O
+the	O
+5	O
+'	O
+UTR	O
+and	O
+the	O
+nucleotide	B-CHED
+position	O
+2795	O
+(	O
+A	O
+-->	O
+G	O
+).	O
+
+No	O
+SARS	B-PRGE
+-	I-PRGE
+CoV	I-PRGE
+,	O
+reovirus	B-SPEC
+,	O
+and	O
+poliovirus	B-SPEC
+were	O
+found	O
+in	O
+the	O
+normal	O
+controls	O
+.	O
+
+ABSTRACT	O
+:	O
+The	O
+nucleolus	B-COMP
+is	O
+a	O
+dynamic	O
+subnuclear	O
+structure	O
+involved	O
+in	O
+ribosome	B-COMP
+subunit	I-COMP
+biogenesis	B-PROC
+,	O
+cell	B-PROC
+cycle	I-PROC
+control	I-PROC
+and	O
+mediating	O
+responses	O
+to	O
+cell	B-COMP
+stress	O
+,	O
+among	O
+other	O
+functions	O
+.	O
+
+We	O
+found	O
+that	O
+the	O
+tumour	B-DISO
+suppressor	O
+protein	B-CHED
+,	O
+p53	B-PRGE
+,	O
+which	O
+localizes	O
+normally	O
+to	O
+the	O
+nucleus	B-COMP
+and	O
+nucleolus	B-COMP
+,	O
+was	O
+redistributed	O
+predominately	O
+to	O
+the	O
+cytoplasm	B-COMP
+.	O
+
+During	O
+the	O
+height	O
+of	O
+the	O
+SARS	B-DISO
+epidemic	O
+in	O
+Asia	O
+,	O
+SARS	B-DISO
+Grid	O
+and	O
+the	O
+SARShope	O
+website	O
+significantly	O
+curved	O
+the	O
+spread	O
+of	O
+SARS	B-DISO
+by	O
+helping	O
+doctors	O
+manage	O
+the	O
+in	O
+-	O
+hospital	O
+and	O
+in	O
+-	O
+home	O
+care	O
+of	O
+quarantined	O
+SARS	B-DISO
+patients	O
+through	O
+medical	O
+data	O
+exchange	O
+and	O
+the	O
+monitoring	O
+of	O
+the	O
+patient	O
+'	O
+s	O
+symptoms	O
+.	O
+
+ABSTRACT	O
+:	O
+Host	B-COMP
+genetic	O
+factors	O
+may	O
+play	O
+a	O
+role	O
+in	O
+susceptibility	O
+and	O
+resistance	B-PROC
+to	O
+SARS	B-DISO
+associated	O
+coronavirus	B-SPEC
+(	O
+SARS	B-DISO
+-	O
+CoV	O
+)	O
+infection	B-DISO
+.	O
+
+Also	O
+,	O
+a	O
+GT	O
+genotype	O
+at	O
+position	O
+88	O
+in	O
+the	O
+MxA	B-PRGE
+gene	I-PRGE
+promoter	I-PRGE
+was	O
+associated	O
+with	O
+increased	O
+susceptibility	O
+to	O
+SARS	B-DISO
+infection	B-DISO
+compared	O
+to	O
+a	O
+GG	O
+genotype	O
+(	O
+OR	O
+=	O
+3	O
+.	O
+06	O
+,	O
+95	O
+%	O
+CI	O
+:	O
+1	O
+.	O
+25	O
+-	O
+7	O
+.	O
+50	O
+).	O
+
+The	O
+expression	B-PROC
+of	O
+pulmonary	B-ANAT
+surfactant	B-CHED
+associated	O
+protein	B-CHED
+A	O
+in	O
+AT	O
+group	O
+was	O
+significantly	O
+higher	O
+in	O
+the	O
+AT	O
+group	O
+(	O
+18	O
+.	O
+97	O
+%	O
++/-	O
+
+RESULTS	O
+:	O
+The	O
+mortality	O
+rate	O
+of	O
+rats	B-SPEC
+in	O
+the	O
+PQ	O
+group	O
+was	O
+50	O
+.	O
+0	O
+%	O
+on	O
+the	O
+seventh	O
+day	O
+while	O
+the	O
+mortality	O
+rate	O
+in	O
+the	O
+AT	O
+group	O
+was	O
+25	O
+.	O
+0	O
+%.	O
+
+CONCLUSIONS	O
+:	O
+Ambroxol	O
+plays	O
+a	O
+role	O
+in	O
+facilitating	O
+synthesis	B-PROC
+and	O
+secretion	B-PROC
+of	O
+pulmonary	B-ANAT
+surfactant	B-CHED
+protein	B-CHED
+A	O
+and	O
+relieves	O
+the	O
+lung	B-ANAT
+tissue	I-ANAT
+injury	O
+induced	O
+by	O
+paraquat	B-CHED
+poisoning	O
+.	O
+
+TITLE	O
+:	O
+Identification	O
+and	O
+structure	O
+-	O
+based	O
+optimization	O
+of	O
+novel	O
+dihydropyrones	O
+as	O
+potent	O
+HCV	B-SPEC
+RNA	B-PATH
+polymerase	I-PATH
+inhibitors	I-CHED
+.	O
+
+ABSTRACT	O
+:	O
+A	O
+novel	O
+class	B-SPEC
+of	O
+non	O
+-	O
+nucleoside	B-PRGE
+HCV	B-SPEC
+NS5B	I-PRGE
+polymerase	I-PRGE
+inhibitors	B-CHED
+has	O
+been	O
+identified	O
+from	O
+screening	O
+.	O
+
+Herein	O
+we	O
+report	O
+the	O
+structure	O
+-	O
+activity	O
+relationships	O
+(	O
+SARs	B-DISO
+)	O
+of	O
+this	O
+novel	O
+class	B-SPEC
+of	O
+dihydropyrone	O
+-	O
+containing	O
+compounds	O
+that	O
+show	O
+potent	O
+inhibitory	O
+activities	O
+against	O
+the	O
+HCV	B-PRGE
+RNA	B-PATH
+polymerase	I-PATH
+in	O
+biochemical	O
+assays	O
+.	O
+
+Among	O
+the	O
+control	O
+beliefs	O
+,	O
+""""	O
+SARS	B-DISO
+-	O
+patient	O
+caring	O
+would	O
+be	O
+a	O
+challenge	O
+""""	O
+""""	O
+SARS	B-DISO
+-	O
+patient	O
+caring	O
+is	O
+a	O
+professional	O
+responsibility	O
+""","	O
+""""	O
+tension	B-DISO
+during	O
+the	O
+care	O
+of	O
+SARS	B-DISO
+patients	O
+""""	O
+and	O
+""""	O
+support	O
+from	O
+team	O
+members	O
+""""	O
+were	O
+the	O
+significant	O
+determinants	O
+of	O
+the	O
+intentions	O
+.	O
+
+Korean	O
+clinical	O
+nurses	O
+in	O
+this	O
+study	O
+were	O
+not	O
+willing	O
+to	O
+care	O
+for	O
+SARS	B-DISO
+patients	O
+and	O
+showed	O
+negative	O
+attitude	O
+toward	O
+the	O
+care	O
+.	O
+
+Among	O
+the	O
+control	O
+beliefs	O
+,	O
+""""	O
+SARS	B-DISO
+-	O
+patient	O
+caring	O
+would	O
+be	O
+a	O
+challenge	O
+""""	O
+""""	O
+SARS	B-DISO
+-	O
+patient	O
+caring	O
+is	O
+a	O
+professional	O
+responsibility	O
+""","	O
+""""	O
+tension	B-DISO
+during	O
+the	O
+care	O
+of	O
+SARS	B-DISO
+patients	O
+""""	O
+and	O
+""""	O
+support	O
+from	O
+team	O
+members	O
+""""	O
+were	O
+the	O
+significant	O
+determinants	O
+of	O
+the	O
+intentions	O
+.	O
+
+TITLE	O
+:	O
+Surge	O
+capacity	O
+and	O
+casualization	O
+:	O
+Human	B-SPEC
+resource	O
+issues	O
+in	O
+the	O
+post	O
+-	O
+SARS	B-DISO
+health	O
+system	O
+.	O
+
+ABSTRACT	O
+:	O
+The	O
+non	O
+-	O
+structural	O
+protein	O
+Nsp10	O
+of	O
+coronaviruses	O
+is	O
+a	O
+small	O
+cleavage	B-PROC
+product	O
+of	O
+the	O
+viral	B-PRGE
+replicase	I-PRGE
+polyprotein	I-PRGE
+that	O
+has	O
+been	O
+implicated	O
+in	O
+RNA	B-PROC
+synthesis	I-PROC
+.	O
+
+Moreover	O
+,	O
+MHV	B-SPEC
+Nsp10	O
+interacts	O
+with	O
+tRNA	B-FUNC
+,	O
+single	O
+-	O
+stranded	O
+RNA	O
+,	O
+double	B-CHED
+-	I-CHED
+stranded	I-CHED
+DNA	I-CHED
+and	O
+,	O
+to	O
+a	O
+lesser	O
+extent	O
+,	O
+single	B-CHED
+-	I-CHED
+stranded	I-CHED
+DNA	I-CHED
+as	O
+shown	O
+by	O
+gel	O
+-	O
+shift	O
+experiments	O
+.	O
+
+Based	O
+on	O
+the	O
+analysis	O
+of	O
+RNA	O
+products	O
+separated	O
+by	O
+denaturing	O
+gel	O
+electrophoresis	O
+,	O
+Nsp15	O
+has	O
+been	O
+reported	O
+to	O
+cleave	O
+both	O
+5	O
+'	O
+and	O
+3	O
+'	O
+of	O
+the	O
+uridine	B-CHED
+.	O
+
+Several	O
+modified	O
+RNAs	O
+that	O
+are	O
+not	O
+cleaved	O
+by	O
+Nsp15	O
+can	O
+bind	B-FUNC
+Nsp15	O
+as	O
+competitive	O
+inhibitors	B-CHED
+.	O
+
+We	O
+describe	O
+the	O
+case	O
+of	O
+a	O
+young	O
+woman	O
+who	O
+experienced	O
+a	O
+profound	O
+reversible	O
+cardiomyopathy	B-DISO
+with	O
+typical	O
+features	O
+of	O
+Tako	O
+-	O
+Tsubo	O
+'	O
+s	O
+syndrome	B-DISO
+during	O
+an	O
+anaphylactic	B-DISO
+reaction	I-DISO
+.	O
+
+Thirty	O
+-	O
+two	O
+patients	O
+were	O
+initially	O
+not	O
+recognised	O
+as	O
+probable	O
+SARS	B-DISO
+and	O
+were	O
+reclassified	O
+when	O
+the	O
+serology	O
+test	O
+results	O
+were	O
+available	O
+.	O
+
+CONCLUSIONS	O
+:	O
+Patients	O
+infected	O
+with	O
+the	O
+SARS	B-DISO
+coronavirus	B-SPEC
+had	O
+a	O
+wide	O
+clinical	O
+presentation	O
+with	O
+non	O
+-	O
+specific	O
+symptoms	O
+.	O
+
+TITLE	O
+:	O
+Radiographic	O
+features	O
+of	O
+SARS	B-DISO
+in	O
+paediatric	O
+patients	O
+:	O
+a	O
+review	O
+of	O
+cases	O
+in	O
+Singapore	O
+.	O
+
+Of	O
+these	O
+,	O
+we	O
+subsequently	O
+selected	O
+those	O
+patients	O
+with	O
+suspected	O
+or	O
+probable	O
+SARS	B-DISO
+for	O
+analysis	O
+.	O
+
+The	O
+radiographic	O
+features	O
+in	O
+children	O
+with	O
+suspected	O
+or	O
+probable	O
+SARS	B-DISO
+in	O
+our	O
+study	O
+were	O
+comparable	O
+to	O
+other	O
+clusters	B-CHED
+of	O
+paediatric	O
+patients	O
+during	O
+initial	O
+presentation	O
+.	O
+
+Strong	O
+political	O
+leadership	O
+and	O
+effective	O
+command	O
+,	O
+control	O
+and	O
+coordination	B-PROC
+of	O
+responses	O
+were	O
+critical	O
+factors	O
+for	O
+the	O
+containment	O
+of	O
+the	O
+outbreak	O
+.	O
+
+Audits	O
+of	O
+these	O
+laboratories	O
+in	O
+2004	O
+showed	O
+that	O
+laboratory	O
+safety	O
+and	O
+containment	O
+requirements	O
+as	O
+recommended	O
+were	O
+generally	O
+met	B-CHED
+.	O
+
+This	O
+paper	O
+highlights	O
+how	O
+we	O
+can	O
+apply	O
+our	O
+knowledge	O
+of	O
+its	O
+epidemiology	O
+,	O
+mode	O
+of	O
+transmission	O
+,	O
+clinical	O
+course	O
+,	O
+ICU	O
+admission	O
+,	O
+complications	O
+,	O
+predictors	O
+of	O
+poor	O
+outcome	O
+,	O
+treatment	O
+and	O
+infection	B-DISO
+control	O
+to	O
+help	O
+us	O
+avert	O
+a	O
+catastrophic	O
+outbreak	O
+,	O
+and	O
+to	O
+manage	O
+our	O
+resources	O
+and	O
+patients	O
+.	O
+
+Even	O
+if	O
+SARS	O
+does	O
+not	O
+reemerge	O
+,	O
+the	O
+experience	O
+gained	O
+from	O
+such	O
+planning	O
+is	O
+valuable	O
+in	O
+preparing	O
+for	O
+threats	O
+of	O
+bioterrorism	O
+or	O
+a	O
+global	O
+avian	B-DISO
+influenza	B-PATH
+A	I-PATH
+(	O
+H5N1	B-DISO
+)	O
+virus	B-SPEC
+pandemic	O
+.	O
+
+Indeed	O
+,	O
+HCWs	O
+had	O
+lost	B-CHED
+their	O
+lives	O
+to	O
+SARS	B-DISO
+.	O
+
+Understandably	O
+,	O
+some	O
+HCWs	O
+refused	O
+to	O
+look	O
+after	O
+SARS	B-DISO
+patients	O
+or	O
+even	O
+resigned	O
+.	O
+
+Plasma	B-ANAT
+function	O
+was	O
+evaluated	O
+through	O
+measurement	O
+of	O
+coagulation	B-PROC
+factors	O
+and	O
+antithrombotic	B-PRGE
+protein	I-PRGE
+activities	O
+.	O
+
+PCT	B-DISO
+has	O
+the	O
+potential	O
+to	O
+reduce	O
+the	O
+risk	O
+of	O
+transfusion	O
+-	O
+transmitted	B-DISO
+diseases	O
+in	O
+patients	O
+requiring	O
+plasma	B-ANAT
+transfusion	O
+support	O
+.	O
+
+However	O
+,	O
+the	O
+emergence	O
+of	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+coronavirus	B-SPEC
+(	O
+SARS	B-DISO
+-	O
+CoV	O
+)	O
+has	O
+prompted	O
+the	O
+discovery	O
+of	O
+such	O
+drugs	O
+.	O
+
+TITLE	O
+:	O
+Severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+coronavirus	B-SPEC
+7a	O
+accessory	O
+protein	B-CHED
+is	O
+a	O
+viral	O
+structural	O
+protein	B-CHED
+.	O
+
+These	O
+data	O
+established	O
+that	O
+,	O
+in	O
+addition	O
+to	O
+3a	O
+protein	B-CHED
+,	O
+7a	O
+protein	B-CHED
+was	O
+a	O
+SCoV	B-PRGE
+accessory	I-PRGE
+protein	I-PRGE
+identified	O
+as	O
+a	O
+SCoV	B-PRGE
+structural	I-PRGE
+protein	I-PRGE
+.	O
+
+Further	O
+genetic	O
+analyses	O
+showed	O
+that	O
+different	O
+species	B-SPEC
+of	O
+bats	B-SPEC
+maintain	O
+coronaviruses	O
+from	O
+different	O
+groups	O
+and	O
+that	O
+a	O
+single	O
+bat	B-ENZY
+species	B-SPEC
+from	O
+different	O
+geographic	O
+locations	O
+supports	O
+similar	O
+coronaviruses	O
+.	O
+
+TITLE	O
+:	O
+Antiviral	B-CHED
+drug	I-CHED
+discovery	O
+against	O
+SARS	B-DISO
+-	O
+CoV	O
+.	O
+ABSTRACT	O
+:	O
+Severe	B-DISO
+Acute	I-DISO
+Respiratory	I-DISO
+Syndrome	I-DISO
+(	O
+SARS	B-DISO
+)	O
+is	O
+a	O
+life	O
+-	O
+threatening	O
+infectious	B-DISO
+disease	I-DISO
+caused	O
+by	O
+SARS	B-DISO
+-	O
+CoV	O
+.	O
+In	O
+the	O
+2003	O
+outbreak	O
+,	O
+it	O
+infected	O
+more	O
+than	O
+8	O
+,	O
+000	O
+people	O
+worldwide	O
+and	O
+claimed	O
+the	O
+lives	O
+of	O
+more	O
+than	O
+900	O
+victims	O
+.	O
+
+Substitution	O
+of	O
+R190	O
+with	O
+W190	O
+enhanced	O
+the	O
+affinity	O
+for	O
+a	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+coronavirus	B-SPEC
+peptide	B-CHED
+6	O
+fold	O
+but	O
+reduced	O
+the	O
+affinity	O
+for	O
+N	O
+-	O
+formyl	B-CHED
+-	O
+Nle	B-CHED
+-	O
+Leu	B-CHED
+-	O
+Phe	B-CHED
+by	O
+2	O
+.	O
+5	O
+fold	O
+.	O
+
+TITLE	O
+:	O
+Microwave	O
+-	O
+assisted	O
+tissue	B-ANAT
+processing	O
+for	O
+same	O
+-	O
+day	O
+EM	O
+-	O
+diagnosis	O
+of	O
+potential	O
+bioterrorism	O
+and	O
+clinical	O
+samples	O
+.	O
+
+Subsequently	O
+,	O
+all	O
+samples	O
+were	O
+divided	O
+to	O
+evaluate	O
+alternative	O
+processing	O
+protocols	O
+:	O
+one	O
+part	O
+of	O
+the	O
+sample	O
+was	O
+OsO4	O
+-	O
+postfixed	O
+,	O
+ethanol	B-CHED
+-	O
+dehydrated	B-DISO
+,	O
+Epon	O
+-	O
+infiltrated	B-DISO
+(	O
+overnight	O
+)	O
+in	O
+an	O
+automated	O
+tissue	B-ANAT
+processor	O
+(	O
+LYNX	B-SPEC
+,	O
+Leica	O
+),	O
+and	O
+polymerized	O
+at	O
+60	O
+degrees	O
+C	O
+for	O
+48	O
+h	O
+;	O
+in	O
+parallel	O
+the	O
+other	O
+part	O
+was	O
+microwave	O
+-	O
+assisted	O
+processed	O
+in	O
+the	O
+bench	O
+microwave	O
+device	O
+(	O
+REM	B-PROC
+,	O
+Milestone	O
+),	O
+including	O
+post	O
+-	O
+osmication	O
+and	O
+the	O
+resin	O
+block	O
+polymerization	O
+.	O
+
+The	O
+structures	O
+of	O
+complexes	O
+of	O
+griffithsin	O
+with	O
+mannose	B-CHED
+and	O
+N	B-CHED
+-	I-CHED
+acetylglucosamine	I-CHED
+defined	O
+the	O
+locations	O
+of	O
+three	O
+almost	O
+identical	O
+carbohydrate	B-FUNC
+binding	I-FUNC
+sites	O
+on	O
+each	O
+monomer	O
+.	O
+
+TITLE	O
+:	O
+The	O
+crystal	B-ANAT
+structure	O
+of	O
+ORF	B-PRGE
+-	I-PRGE
+9b	I-PRGE
+,	O
+a	O
+lipid	B-FUNC
+binding	I-FUNC
+protein	B-CHED
+from	O
+the	O
+SARS	B-DISO
+coronavirus	B-SPEC
+.	O
+
+These	O
+alternative	O
+protein	B-CHED
+products	O
+are	O
+,	O
+as	O
+yet	O
+,	O
+poorly	O
+characterized	O
+structurally	O
+.	O
+
+Analysis	O
+of	O
+ORF	B-PRGE
+-	I-PRGE
+9b	I-PRGE
+and	O
+other	O
+overlapping	O
+genes	O
+suggests	O
+that	O
+they	O
+provide	O
+snapshots	O
+of	O
+the	O
+early	O
+evolution	O
+of	O
+novel	O
+protein	B-CHED
+folds	O
+.	O
+
+TITLE	O
+:	O
+Human	B-SPEC
+memory	B-PROC
+T	B-ANAT
+cell	I-ANAT
+responses	O
+to	O
+SARS	B-PRGE
+-	I-PRGE
+CoV	I-PRGE
+E	I-PRGE
+protein	B-CHED
+.	O
+
+However	O
+,	O
+the	O
+cellular	B-PROC
+immune	I-PROC
+responses	I-PROC
+to	O
+E	B-PRGE
+protein	I-PRGE
+remain	O
+unclear	O
+in	O
+humans	B-SPEC
+.	O
+
+siVirus	O
+searches	O
+for	O
+functional	O
+,	O
+off	O
+-	O
+target	O
+minimized	O
+siRNAs	O
+targeting	B-PROC
+highly	O
+conserved	O
+regions	O
+of	O
+divergent	O
+viral	O
+sequences	O
+.	O
+
+ABSTRACT	O
+:	O
+The	O
+emergence	O
+in	O
+2003	O
+of	O
+a	O
+new	O
+coronavirus	O
+(	O
+CoV	O
+)	O
+responsible	O
+for	O
+the	O
+atypical	B-DISO
+pneumonia	I-DISO
+termed	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+(	O
+SARS	B-DISO
+)	O
+was	O
+a	O
+stark	O
+reminder	O
+that	O
+hitherto	O
+unknown	O
+viruses	B-SPEC
+have	O
+the	O
+potential	O
+to	O
+cross	O
+species	B-SPEC
+barriers	O
+to	O
+become	O
+new	O
+human	B-SPEC
+pathogens	O
+.	O
+
+TITLE	O
+:	O
+Time	O
+course	O
+of	O
+lung	B-ANAT
+injury	O
+in	O
+rat	B-SPEC
+acute	B-DISO
+pancreatitis	I-DISO
+.	O
+
+While	O
+pancreatic	B-ANAT
+injury	O
+persists	O
+over	O
+the	O
+full	O
+experimental	O
+period	O
+,	O
+pulmonary	B-ANAT
+injury	O
+is	O
+transient	O
+in	O
+our	O
+experimental	O
+model	O
+.	O
+
+We	O
+found	O
+that	O
+in	O
+the	O
+absence	O
+of	O
+serum	B-COMP
+about	O
+16	O
+.	O
+34	O
+%	O
+of	O
+cells	B-COMP
+transfected	O
+by	O
+pcDNA3	O
+.	O
+1	O
+-	O
+M	O
+and	O
+21	O
+.	O
+72	O
+%	O
+of	O
+N	O
+-	O
+transfected	O
+cells	B-COMP
+showed	O
+typical	O
+apoptotic	O
+characteristics	O
+,	O
+significantly	O
+different	O
+from	O
+mock	O
+-	O
+transfected	O
+cells	B-COMP
+(	O
+only	O
+6	O
+.	O
+23	O
+%,	O
+p	O
+<	O
+0	O
+.	O
+01	O
+).	O
+
+Furthermore	O
+,	O
+the	O
+cells	B-COMP
+that	O
+were	O
+co	O
+-	O
+transfected	O
+with	O
+M	O
+and	O
+N	O
+proteins	B-CHED
+showed	O
+more	O
+obvious	O
+phenomena	O
+of	O
+cell	B-PROC
+death	I-PROC
+(	O
+about	O
+36	O
+.	O
+03	O
+%).	O
+
+The	O
+results	O
+show	O
+that	O
+M	O
+and	O
+N	O
+proteins	B-CHED
+of	O
+SARS	B-DISO
+-	O
+CoV	O
+can	O
+induce	O
+apoptosis	B-PATH
+of	O
+HPF	O
+cells	B-COMP
+.	O
+
+The	O
+main	O
+clinical	O
+features	O
+upon	O
+admission	O
+were	O
+paresthesia	B-DISO
+(	O
+local	O
+,	O
+n	O
+=	O
+9	O
+;	O
+generalized	O
+,	O
+n	O
+=	O
+2	O
+),	O
+local	O
+pain	O
+(	O
+n	O
+=	O
+8	O
+),	O
+palpebral	B-ANAT
+ptosis	B-DISO
+(	O
+n	O
+=	O
+8	O
+),	O
+weakness	B-DISO
+(	O
+n	O
+=	O
+4	O
+)	O
+and	O
+inability	O
+to	O
+stand	O
+up	O
+(	O
+n	O
+=	O
+3	O
+).	O
+
+ABSTRACT	O
+:	O
+The	O
+basic	O
+reproductive	B-PROC
+ratio	O
+,	O
+R0	O
+,	O
+is	O
+defined	O
+as	O
+the	O
+expected	O
+number	O
+of	O
+secondary	O
+infections	O
+arising	O
+from	O
+a	O
+single	O
+individual	O
+during	O
+his	O
+or	O
+her	O
+entire	O
+infectious	B-DISO
+period	O
+,	O
+in	O
+a	O
+population	O
+of	O
+susceptibles	O
+.	O
+
+SP	B-PRGE
+-	I-PRGE
+B	I-PRGE
+and	O
+SP	B-PRGE
+-	I-PRGE
+C	I-PRGE
+content	O
+in	O
+LA	O
+remained	O
+unchanged	O
+in	O
+PCP	B-DISO
+compared	O
+with	O
+controls	O
+but	O
+decreased	O
+significantly	O
+in	O
+ARDS	B-DISO
+and	O
+PNEU	O
+.	O
+
+Gamma	B-PRGE
+interferon	I-PRGE
+(	O
+IFN	B-PRGE
+-	I-PRGE
+gamma	I-PRGE
+)	O
+is	O
+an	O
+important	O
+cytokine	O
+produced	O
+during	O
+the	O
+early	O
+stages	O
+of	O
+an	O
+infection	B-DISO
+by	O
+macrophages	B-ANAT
+,	O
+natural	O
+killer	O
+(	O
+NK	O
+)	O
+cells	B-COMP
+,	O
+and	O
+other	O
+cell	B-COMP
+types	O
+,	O
+and	O
+it	O
+is	O
+also	O
+a	O
+central	O
+cytokine	O
+mediator	O
+for	O
+the	O
+induction	O
+of	O
+cellular	B-COMP
+or	O
+Th1	O
+immunity	B-PROC
+.	O
+
+Two	O
+other	O
+respiratory	O
+viruses	B-SPEC
+of	O
+pigs	B-SPEC
+,	O
+Porcine	B-SPEC
+respiratory	O
+coronavirus	B-SPEC
+and	O
+Swine	B-SPEC
+influenza	I-SPEC
+virus	I-SPEC
+,	O
+do	O
+not	O
+appear	O
+to	O
+induce	O
+serum	B-PRGE
+IFN	I-PRGE
+-	I-PRGE
+gamma	I-PRGE
+.	O
+
+TITLE	O
+:	O
+Safety	O
+and	O
+efficacy	O
+of	O
+an	O
+infectious	B-DISO
+bronchitis	B-DISO
+virus	B-SPEC
+used	O
+for	O
+chicken	B-SPEC
+embryo	B-ANAT
+vaccination	O
+.	O
+
+ABSTRACT	O
+:	O
+Commercial	O
+vaccines	O
+for	O
+in	O
+ovo	O
+vaccination	O
+have	O
+not	O
+yet	O
+been	O
+developed	O
+for	O
+infectious	B-DISO
+bronchitis	B-DISO
+virus	B-SPEC
+(	O
+IBV	B-SPEC
+),	O
+the	O
+major	O
+coronavirus	B-SPEC
+in	O
+the	O
+poultry	O
+industry	O
+.	O
+
+Assessment	O
+of	O
+the	O
+BeauR	O
+-	O
+M41	O
+(	O
+S	O
+)	O
+strain	O
+for	O
+efficacy	O
+showed	O
+that	O
+it	O
+protected	O
+up	O
+to	O
+90	O
+%	O
+of	O
+chicks	O
+against	O
+challenge	O
+with	O
+virulent	O
+IB	O
+virus	B-SPEC
+(	O
+M41	O
+)	O
+in	O
+a	O
+dose	O
+dependent	O
+manner	O
+.	O
+
+BeauR	B-PRGE
+-	I-PRGE
+M41	I-PRGE
+(	I-PRGE
+S	I-PRGE
+)	I-PRGE
+EP10	I-PRGE
+induced	O
+a	O
+serological	O
+response	O
+similar	O
+to	O
+that	O
+of	O
+a	O
+commercial	O
+vaccine	O
+given	O
+at	O
+day	O
+-	O
+old	O
+though	O
+the	O
+commercial	O
+vaccine	O
+provided	O
+slightly	O
+higher	O
+efficacy	O
+.	O
+
+TITLE	O
+:	O
+High	O
+-	O
+frequency	O
+percussive	O
+ventilation	O
+improves	O
+oxygenation	B-PROC
+in	O
+trauma	O
+patients	O
+with	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+:	O
+a	O
+retrospective	O
+review	O
+.	O
+
+Oxygenation	B-PROC
+parameters	O
+(	O
+oxygenation	B-PROC
+index	O
+,	O
+OI	O
+;	O
+Pao	B-PROC
+(	O
+2	O
+)/	O
+Fio	O
+(	O
+2	O
+)	O
+ratio	O
+,	O
+P	O
+/	O
+F	O
+)	O
+and	O
+mean	O
+airway	B-ANAT
+pressures	O
+(	O
+mPaw	O
+)	O
+were	O
+recorded	O
+at	O
+baseline	O
+and	O
+at	O
+1	O
+to	O
+4	O
+,	O
+8	O
+to	O
+12	O
+,	O
+and	O
+12	O
+to	O
+24	O
+hours	O
+after	O
+initiation	O
+of	O
+HFPV	O
+.	O
+
+This	O
+result	O
+suggests	O
+a	O
+mechanism	O
+of	O
+inactivation	O
+of	O
+3C	O
+peptidases	O
+by	O
+methyl	B-CHED
+ketone	I-CHED
+inhibitors	B-CHED
+that	O
+is	O
+distinct	O
+from	O
+that	O
+occurring	O
+in	O
+the	O
+structurally	O
+related	O
+serine	B-PRGE
+proteinases	I-PRGE
+or	O
+in	O
+the	O
+papain	B-ENZY
+-	O
+like	O
+cysteine	B-PRGE
+peptidases	I-PRGE
+.	O
+
+TITLE	O
+:	O
+Seroprevalence	O
+of	O
+avian	B-SPEC
+influenza	I-SPEC
+virus	I-SPEC
+,	O
+infectious	B-DISO
+bronchitis	B-DISO
+virus	B-SPEC
+,	O
+reovirus	B-SPEC
+,	O
+avian	B-SPEC
+pneumovirus	I-SPEC
+,	O
+infectious	B-SPEC
+laryngotracheitis	B-DISO
+virus	I-SPEC
+,	O
+and	O
+avian	B-SPEC
+leukosis	I-SPEC
+virus	I-SPEC
+in	O
+Nigerian	O
+poultry	O
+.	O
+
+Further	O
+studies	O
+are	O
+necessary	O
+to	O
+assess	O
+economic	O
+losses	O
+due	O
+to	O
+these	O
+avian	B-SPEC
+viruses	B-SPEC
+and	O
+the	O
+costs	O
+and	O
+benefits	O
+of	O
+countermeasures	O
+.	O
+
+In	O
+general	O
+,	O
+the	O
+Mass	O
+strain	O
+was	O
+more	O
+frequently	O
+recovered	O
+from	O
+the	O
+tracheal	O
+and	O
+cecal	B-ANAT
+tonsil	I-ANAT
+tissues	B-ANAT
+at	O
+earlier	O
+stages	O
+of	O
+infection	B-DISO
+and	O
+the	O
+Ark	B-PRGE
+strain	O
+was	O
+recovered	O
+at	O
+later	O
+stages	O
+of	O
+infection	B-DISO
+.	O
+
+No	O
+SARS	B-PRGE
+-	I-PRGE
+CoV	I-PRGE
+and	O
+SARS	B-PRGE
+-	I-PRGE
+like	I-PRGE
+-	I-PRGE
+CoV	I-PRGE
+were	O
+detected	O
+in	O
+the	O
+3043	O
+samples	O
+,	O
+indicating	O
+the	O
+current	O
+absence	O
+of	O
+SARS	O
+-	O
+CoV	O
+and	O
+SARS	B-PRGE
+-	I-PRGE
+like	I-PRGE
+-	I-PRGE
+CoV	I-PRGE
+in	O
+the	O
+bats	B-SPEC
+captured	O
+in	O
+Guangzhou	O
+and	O
+its	O
+vicinity	O
+.	O
+
+ABSTRACT	O
+:	O
+Research	O
+on	O
+risk	O
+factors	O
+for	O
+premenstrual	O
+syndrome	O
+(	O
+PMS	B-DISO
+)	O
+is	O
+lacking	O
+for	O
+the	O
+Gulf	O
+countries	O
+of	O
+the	O
+Middle	O
+East	O
+,	O
+a	O
+region	O
+with	O
+unique	O
+cultural	O
+features	O
+that	O
+might	O
+influence	O
+expectations	O
+and	O
+self	O
+-	O
+perception	O
+of	O
+the	O
+disease	O
+.	O
+
+Nine	O
+persons	O
+with	O
+serological	O
+evidence	O
+of	O
+SARS	B-DISO
+infection	B-DISO
+were	O
+identified	O
+amongst	O
+212	O
+close	O
+contacts	O
+of	O
+45	O
+laboratory	O
+-	O
+confirmed	O
+SARS	B-DISO
+cases	O
+(	O
+secondary	O
+attack	O
+rate	O
+4	O
+.	O
+2	O
+%,	O
+95	O
+%	O
+CI	O
+1	O
+.	O
+5	O
+-	O
+7	O
+).	O
+
+In	O
+this	O
+cohort	O
+,	O
+the	O
+average	O
+number	O
+of	O
+secondary	B-DISO
+infections	I-DISO
+caused	O
+by	O
+a	O
+single	O
+infectious	B-DISO
+case	O
+was	O
+0	O
+.	O
+2	O
+.	O
+
+Furthermore	O
+,	O
+high	O
+-	O
+titered	O
+antibodies	B-COMP
+to	O
+E	B-SPEC
+.	I-SPEC
+canis	I-SPEC
+or	O
+a	O
+closely	O
+related	O
+agent	O
+were	O
+detected	O
+in	O
+a	O
+puma	O
+for	O
+the	O
+first	O
+time	O
+.	O
+
+Themes	O
+and	O
+subthemes	O
+from	O
+the	O
+data	O
+were	O
+organized	O
+into	O
+2	O
+categories	O
+:	O
+The	O
+Experience	O
+(	O
+operational	O
+,	O
+organizational	O
+,	O
+and	O
+personal	O
+narratives	O
+),	O
+and	O
+Learning	B-PROC
+from	O
+the	O
+Experience	O
+(	O
+opportunities	O
+for	O
+personal	O
+learning	B-PROC
+,	O
+professional	O
+and	O
+policy	O
+development	B-PROC
+,	O
+and	O
+insight	O
+into	O
+policy	O
+and	O
+administrative	O
+implications	O
+).	O
+
+The	O
+first	O
+open	O
+reading	O
+frame	O
+encodes	O
+replicase	B-PRGE
+polyproteins	I-PRGE
+1a	O
+and	O
+1ab	O
+,	O
+which	O
+are	O
+cleaved	B-ANAT
+to	O
+generate	O
+16	O
+""""	O
+nonstructural	O
+""""	O
+proteins	B-CHED
+,	O
+nsp1	B-PRGE
+to	O
+nsp16	O
+,	O
+involved	O
+in	O
+viral	B-PROC
+replication	I-PROC
+and	O
+/	O
+or	O
+RNA	B-PROC
+processing	I-PROC
+.	O
+
+The	O
+second	O
+Zn	O
+finger	B-ANAT
+,	O
+with	O
+four	O
+cysteines	O
+,	O
+is	O
+a	O
+distant	O
+member	O
+of	O
+the	O
+""""	O
+gag	B-SPEC
+-	O
+knuckle	B-ANAT
+fold	O
+group	O
+""""	O
+of	O
+Zn2	O
++-	O
+binding	B-FUNC
+domains	O
+and	O
+appears	O
+to	O
+maintain	O
+the	O
+structural	O
+integrity	O
+of	O
+the	O
+C	O
+-	O
+terminal	O
+tail	O
+.	O
+
+However	O
+,	O
+its	O
+exact	O
+role	O
+within	O
+the	O
+replicase	B-PRGE
+complex	I-PRGE
+is	O
+still	O
+not	O
+clear	O
+.	O
+
+Two	O
+-	O
+dimensional	O
+images	O
+of	O
+the	O
+S	O
+,	O
+M	O
+,	O
+and	O
+N	O
+structural	O
+proteins	B-CHED
+of	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+coronavirus	B-SPEC
+and	O
+two	O
+other	O
+coronaviruses	O
+were	O
+refined	O
+to	O
+a	O
+resolution	O
+of	O
+approximately	O
+4	O
+nm	O
+.	O
+
+Proteins	B-CHED
+near	O
+the	O
+viral	B-COMP
+membrane	I-COMP
+were	O
+arranged	O
+in	O
+overlapping	O
+lattices	O
+surrounding	O
+a	O
+disordered	O
+core	O
+.	O
+
+However	O
+,	O
+the	O
+spikes	O
+were	O
+dispensable	O
+for	O
+ribonucleoprotein	B-COMP
+lattice	O
+formation	B-PROC
+.	O
+
+ABSTRACT	O
+:	O
+To	O
+evaluate	O
+the	O
+effect	O
+of	O
+extracorporeal	O
+gas	O
+exchange	O
+(	O
+ECMO	O
+)	O
+on	O
+mortality	O
+of	O
+patients	O
+referred	O
+with	O
+severe	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+(	O
+ARDS	B-DISO
+).	O
+
+Here	O
+,	O
+we	O
+compared	O
+the	O
+cellular	B-COMP
+properties	O
+of	O
+the	O
+8a	O
+,	O
+8b	O
+and	O
+8ab	O
+proteins	B-CHED
+by	O
+examining	O
+their	O
+cellular	B-COMP
+localizations	O
+and	O
+their	O
+abilities	O
+to	O
+interact	O
+with	O
+other	O
+SARS	B-PRGE
+-	I-PRGE
+CoV	I-PRGE
+proteins	B-CHED
+.	O
+
+These	O
+findings	O
+suggest	O
+that	O
+8b	O
+may	O
+modulate	O
+viral	B-PROC
+replication	I-PROC
+and	O
+/	O
+or	O
+pathogenesis	B-DISO
+.	O
+
+At	O
+the	O
+molecular	O
+level	O
+,	O
+coronaviruses	O
+employ	O
+a	O
+variety	O
+of	O
+unusual	O
+strategies	O
+to	O
+accomplish	O
+a	O
+complex	O
+program	O
+of	O
+gene	B-PROC
+expression	I-PROC
+.	O
+
+Increased	O
+plasma	B-ANAT
+levels	O
+of	O
+BNP	B-PRGE
+may	O
+reflect	O
+not	O
+only	O
+the	O
+severity	O
+of	O
+myocardial	B-DISO
+depression	I-DISO
+but	O
+also	O
+the	O
+disease	O
+severity	O
+and	O
+could	O
+be	O
+of	O
+prognostic	O
+value	O
+in	O
+patients	O
+with	O
+septic	B-DISO
+shock	I-DISO
+.	O
+
+General	B-PROC
+anesthesia	I-PROC
+was	O
+used	O
+in	O
+12	O
+and	O
+spinal	O
+anesthesia	B-DISO
+in	O
+25	O
+patients	O
+.	O
+
+All	O
+patients	O
+required	O
+transfusions	O
+using	O
+blood	B-ANAT
+products	O
+.	O
+
+Because	O
+of	O
+high	O
+maternal	O
+mortality	O
+and	O
+morbidity	O
+found	O
+among	O
+patients	O
+with	O
+HELLP	B-DISO
+syndrome	I-DISO
+,	O
+standard	O
+antenatal	O
+follow	O
+-	O
+up	O
+protocols	O
+should	O
+be	O
+applied	O
+,	O
+so	O
+as	O
+to	O
+obtain	O
+early	O
+diagnosis	O
+and	O
+improve	O
+the	O
+speed	O
+of	O
+transfer	O
+to	O
+obstetric	O
+departments	O
+with	O
+expertise	O
+in	O
+this	O
+field	O
+.	O
+
+There	O
+were	O
+11	O
+maternal	B-PROC
+deaths	I-PROC
+(	O
+30	O
+%).	O
+
+The	O
+population	O
+comprised	O
+34	O
+patients	O
+including	O
+17	O
+with	O
+valvular	O
+disease	O
+and	O
+revascularisable	O
+coronary	B-ANAT
+lesions	O
+(	O
+15	O
+symptomatic	O
+severe	O
+aortic	B-ANAT
+stenoses	B-DISO
+and	O
+two	O
+acute	O
+mitral	O
+insufficiencies	O
+)	O
+plus	O
+17	O
+multitrunk	O
+coronary	B-ANAT
+patients	O
+without	O
+valvular	O
+disease	O
+but	O
+with	O
+an	O
+indication	O
+for	O
+revascularisation	O
+.	O
+
+Nasal	B-ANAT
+swab	O
+specimens	O
+,	O
+fecal	B-ANAT
+samples	O
+,	O
+and	O
+serum	B-COMP
+samples	O
+were	O
+obtained	O
+before	O
+shipping	O
+,	O
+at	O
+arrival	O
+,	O
+and	O
+periodically	O
+thereafter	O
+.	O
+
+In	O
+contrast	O
+,	O
+AR	O
+calves	O
+had	O
+low	O
+antibody	B-COMP
+titers	O
+against	O
+BCV	B-SPEC
+at	O
+arrival	O
+(	O
+GMT	B-ENZY
+,	O
+102	O
+)	O
+and	O
+64	O
+%	O
+shed	O
+BCV	B-SPEC
+in	O
+nasal	B-ANAT
+secretions	B-ANAT
+and	O
+65	O
+%	O
+in	O
+feces	B-ANAT
+.	O
+
+Replication	O
+and	O
+shedding	O
+of	O
+BCV	B-SPEC
+may	O
+start	O
+in	O
+the	O
+upper	B-ANAT
+respiratory	I-ANAT
+tract	I-ANAT
+and	O
+spread	O
+to	O
+the	O
+gastrointestinal	B-ANAT
+tract	I-ANAT
+.	O
+
+TITLE	O
+:	O
+Crystal	B-ANAT
+structure	O
+and	O
+mechanistic	O
+determinants	O
+of	O
+SARS	B-PRGE
+coronavirus	B-SPEC
+nonstructural	I-PRGE
+protein	B-CHED
+15	O
+define	O
+an	O
+endoribonuclease	O
+family	O
+.	O
+
+The	O
+structure	O
+and	O
+the	O
+spatial	O
+arrangement	O
+of	O
+the	O
+catalytic	O
+residues	O
+into	O
+an	O
+RNase	O
+A	O
+-	O
+like	O
+active	O
+site	O
+define	O
+a	O
+separate	B-PRGE
+endonuclease	I-PRGE
+family	I-PRGE
+,	O
+endoU	B-PRGE
+,	O
+and	O
+represent	O
+another	O
+spectacular	O
+example	O
+of	O
+convergent	O
+evolution	B-PROC
+toward	O
+an	O
+enzymatic	O
+function	O
+that	O
+is	O
+critically	O
+involved	O
+in	O
+the	O
+coronavirus	B-SPEC
+replication	O
+cycle	O
+.	O
+
+Finally	O
+,	O
+we	O
+show	O
+a	O
+simple	O
+and	O
+cost	O
+-	O
+effective	O
+method	O
+of	O
+using	O
+human	B-SPEC
+nasal	B-ANAT
+cannulas	O
+for	O
+delivering	O
+oxygen	B-CHED
+to	O
+pigtailed	O
+macaques	B-SPEC
+during	O
+bronchoscopic	O
+procedures	O
+,	O
+and	O
+we	O
+believe	O
+that	O
+,	O
+after	O
+further	O
+testing	O
+,	O
+this	O
+method	O
+could	O
+be	O
+used	O
+safely	O
+and	O
+effectively	O
+in	O
+other	O
+nonhuman	O
+primate	B-SPEC
+species	B-SPEC
+.	O
+
+ABSTRACT	O
+:	O
+A	O
+potent	O
+SARS	B-DISO
+coronavirus	B-SPEC
+(	O
+CoV	O
+)	O
+3CL	O
+protease	B-CHED
+inhibitor	I-CHED
+(	O
+TG	O
+-	O
+0205221	O
+,	O
+Ki	O
+=	O
+53	O
+nM	O
+)	O
+has	O
+been	O
+developed	O
+.	O
+
+Structural	O
+comparisons	O
+between	O
+TG	O
+-	O
+0205221	O
+and	O
+a	O
+natural	O
+peptide	B-CHED
+substrate	O
+were	O
+also	O
+discussed	O
+.	O
+
+This	O
+information	O
+may	O
+be	O
+applied	O
+toward	O
+the	O
+design	O
+of	O
+other	O
+3CL	B-PRGE
+protease	I-PRGE
+inhibitors	O
+.	O
+
+Demographic	O
+data	O
+,	O
+SARS	B-DISO
+experience	O
+,	O
+self	O
+-	O
+perceived	O
+health	O
+state	O
+,	O
+neighborhood	O
+relationships	O
+,	O
+and	O
+depression	B-DISO
+were	O
+surveyed	O
+by	O
+telephone	O
+interviewing	O
+.	O
+
+The	O
+neighborhood	O
+relationship	O
+factor	O
+was	O
+negatively	O
+associated	O
+with	O
+depression	B-DISO
+for	O
+the	O
+'	B-DISO
+impacted	I-DISO
+group	O
+',	O
+but	O
+not	O
+for	O
+the	O
+'	O
+non	O
+-	O
+impacted	B-DISO
+group	O
+'.	O
+
+Data	O
+analyzed	O
+were	O
+from	O
+a	O
+clinical	O
+trial	O
+of	O
+zanamivir	B-CHED
+in	O
+children	O
+5	O
+-	O
+12	O
+years	O
+of	O
+age	O
+and	O
+from	O
+a	O
+trial	O
+of	O
+oseltamivir	B-CHED
+in	O
+children	O
+1	O
+-	O
+12	O
+years	O
+of	O
+age	O
+.	O
+
+RESULTS	O
+:	O
+In	O
+the	O
+pediatric	O
+study	O
+of	O
+zanamivir	B-CHED
+,	O
+as	O
+in	O
+the	O
+adult	O
+zanamivir	B-CHED
+study	O
+,	O
+cough	B-DISO
+and	O
+fever	B-PROC
+were	O
+the	O
+best	O
+predictors	O
+of	O
+influenza	B-SPEC
+virus	B-DISO
+infection	I-DISO
+;	O
+a	O
+temperature	O
+>	O
+or	O
+=	O
+38	O
+.	O
+2	O
+degrees	O
+C	O
+plus	O
+cough	B-DISO
+predicted	O
+83	O
+%	O
+(	O
+95	O
+%	O
+CI	O
+,	O
+79	O
+%-	O
+88	O
+%)	O
+of	O
+illnesses	O
+that	O
+were	O
+determined	O
+to	O
+be	O
+influenza	B-SPEC
+virus	I-SPEC
+positive	O
+.	O
+
+The	O
+number	O
+of	O
+hMPV	B-SPEC
+infections	B-DISO
+peaked	O
+between	O
+February	O
+and	O
+April	O
+,	O
+whereas	O
+the	O
+number	O
+of	O
+HCoV	B-SPEC
+-	I-SPEC
+NL63	I-SPEC
+infections	B-DISO
+peaked	O
+between	O
+April	O
+and	O
+May	O
+.	O
+This	O
+study	O
+describes	O
+the	O
+features	O
+of	O
+LRTIs	O
+associated	O
+with	O
+newly	O
+identified	O
+viruses	B-SPEC
+in	O
+children	O
+,	O
+compared	O
+with	O
+those	O
+associated	O
+with	O
+known	O
+viruses	B-SPEC
+.	O
+
+RESULTS	O
+:	O
+Viruses	B-SPEC
+were	O
+identified	O
+in	O
+312	O
+(	O
+60	O
+.	O
+6	O
+%)	O
+of	O
+the	O
+515	O
+patients	O
+.	O
+
+Specifically	O
+,	O
+that	O
+of	O
+travelers	O
+disguising	O
+symptoms	O
+of	O
+respiratory	B-DISO
+tract	I-DISO
+infection	I-DISO
+at	O
+international	O
+airports	O
+,	O
+in	O
+order	B-SPEC
+to	O
+board	O
+aircraft	O
+to	O
+return	O
+to	O
+their	O
+home	O
+countries	O
+-	O
+notwithstanding	O
+the	O
+infection	B-DISO
+risks	O
+this	O
+involves	O
+to	O
+others	O
+.	O
+
+ABSTRACT	O
+:	O
+SARS	B-DISO
+and	O
+travel	O
+are	O
+intricately	O
+interlinked	O
+.	O
+
+The	O
+outbreak	O
+of	O
+SARS	O
+created	O
+international	O
+anxiety	O
+because	O
+of	O
+its	O
+novelty	O
+,	O
+its	O
+ease	O
+of	O
+transmission	O
+in	O
+certain	O
+settings	O
+,	O
+and	O
+the	O
+speed	O
+of	O
+its	O
+spread	O
+through	O
+jet	O
+travel	O
+,	O
+combined	O
+with	O
+extensive	O
+media	B-ANAT
+coverage	O
+.	O
+
+Bayesian	O
+estimation	O
+of	O
+the	O
+reproduction	B-PROC
+number	O
+R	O
+(	O
+mean	O
+number	O
+of	O
+cases	O
+generated	O
+by	O
+a	O
+single	O
+infectious	B-DISO
+person	O
+)	O
+during	O
+an	O
+outbreak	O
+allows	O
+them	O
+to	O
+judge	O
+rapidly	O
+whether	O
+the	O
+epidemic	O
+is	O
+under	O
+control	O
+(	O
+R	O
+<	O
+1	O
+).	O
+
+In	O
+this	O
+study	O
+,	O
+potential	O
+HLA	B-PRGE
+-	I-PRGE
+A	I-PRGE
+*	I-PRGE
+0201	I-PRGE
+-	O
+restricted	O
+spike	O
+(	O
+S	O
+)	O
+and	O
+nucleocapsid	B-PRGE
+protein	B-CHED
+-	I-PRGE
+derived	I-PRGE
+peptides	B-CHED
+were	O
+selected	O
+from	O
+an	O
+online	O
+database	O
+and	O
+screened	O
+for	O
+potential	O
+CTL	B-ANAT
+epitopes	O
+by	O
+in	O
+vitro	O
+refolding	O
+and	O
+T2	O
+cell	B-COMP
+-	O
+stabilization	O
+assays	O
+.	O
+
+Furthermore	O
+,	O
+significant	O
+P15	O
+-	O
+specific	O
+CTLs	O
+were	O
+induced	O
+from	O
+HLA	B-PRGE
+-	O
+A2	O
+.	O
+1	O
+-	O
+transgenic	B-SPEC
+mice	I-SPEC
+immunized	O
+by	O
+a	O
+DNA	O
+vaccine	O
+encoding	O
+the	O
+S	B-PRGE
+protein	I-PRGE
+;	O
+suggesting	O
+that	O
+P15	B-PRGE
+was	O
+a	O
+naturally	O
+processed	O
+epitope	B-CHED
+.	O
+
+The	O
+mortality	O
+in	O
+patients	O
+with	O
+ARDS	B-DISO
+is	O
+more	O
+commonly	O
+associated	O
+with	O
+the	O
+sequels	O
+of	O
+sepsis	B-DISO
+and	O
+multiple	O
+organ	B-ANAT
+dysfunction	O
+than	O
+with	O
+respiratory	B-DISO
+failure	I-DISO
+although	O
+the	O
+latest	O
+papers	O
+on	O
+protective	O
+ventilation	O
+suggest	O
+that	O
+death	B-PROC
+in	O
+these	O
+patients	O
+directly	O
+results	O
+from	O
+lung	B-ANAT
+lesion	O
+in	O
+a	O
+number	O
+of	O
+cases	O
+.	O
+
+Actuarial	O
+1	O
+-	O
+year	O
+patient	O
+and	O
+graft	B-PROC
+survival	I-PROC
+were	O
+98	O
+.	O
+6	O
+%	O
+and	O
+98	O
+.	O
+1	O
+%	O
+in	O
+the	O
+alemtuzumab	O
+group	O
+,	O
+compared	O
+to	O
+93	O
+.	O
+6	O
+%	O
+and	O
+91	O
+.	O
+5	O
+%	O
+in	O
+the	O
+control	O
+group	O
+,	O
+respectively	O
+.	O
+
+Engineering	O
+regulatory	O
+transcription	B-PROC
+circuits	O
+of	O
+intercommunicating	O
+alleles	O
+successfully	O
+introduces	O
+genetic	O
+traps	B-DISO
+into	O
+a	O
+viral	B-COMP
+genome	I-COMP
+that	O
+are	O
+lethal	O
+in	O
+RNA	O
+recombinant	O
+progeny	O
+viruses	B-SPEC
+.	O
+
+Stool	B-ANAT
+samples	O
+have	O
+been	O
+shown	O
+to	O
+be	O
+appropriate	O
+for	O
+diagnostic	O
+testing	O
+for	O
+SARS	B-DISO
+CoV	O
+,	O
+although	O
+it	O
+has	O
+been	O
+recognized	O
+to	O
+be	O
+a	O
+heterogeneous	O
+and	O
+difficult	O
+sample	O
+that	O
+contains	O
+amplification	B-DISO
+inhibitors	B-CHED
+.	O
+
+The	O
+sensitivities	O
+of	O
+the	O
+manual	O
+methods	O
+ranged	O
+from	O
+50	O
+%	O
+to	O
+100	O
+%,	O
+with	O
+the	O
+Cortex	B-ANAT
+Biochem	O
+Magazorb	O
+method	O
+,	O
+a	O
+magnetic	O
+bead	O
+isolation	O
+method	O
+,	O
+allowing	O
+detection	O
+of	O
+all	O
+12	O
+positive	O
+samples	O
+.	O
+
+A	O
+total	O
+of	O
+51	O
+%	O
+of	O
+the	O
+participants	O
+correctly	O
+identified	O
+the	O
+incubation	O
+period	O
+of	O
+SARS	B-DISO
+;	O
+48	O
+%	O
+correctly	O
+identified	O
+the	O
+symptoms	O
+of	O
+SARS	B-DISO
+;	O
+and	O
+60	O
+%	O
+knew	O
+the	O
+recommended	O
+infection	B-DISO
+control	O
+precautions	O
+to	O
+take	O
+for	O
+families	O
+.	O
+
+Over	O
+thousands	O
+of	O
+years	O
+the	O
+virus	B-SPEC
+has	O
+crossed	O
+species	B-SPEC
+lines	O
+many	O
+times	O
+(	O
+with	O
+little	O
+effect	O
+)	O
+and	O
+typically	O
+adapts	O
+to	O
+the	O
+host	B-COMP
+quickly	O
+.	O
+
+A	O
+neutralizing	O
+test	O
+on	O
+purified	O
+M1A	B-CHED
+demonstrated	O
+that	O
+0	O
+.	O
+5	O
+mg	O
+/	O
+ml	O
+of	O
+M1A	B-CHED
+completely	O
+inhibited	O
+SARS	B-DISO
+-	O
+CoV	O
+activity	O
+,	O
+with	O
+an	O
+absence	O
+of	O
+cytopathic	B-DISO
+effect	I-DISO
+for	O
+7	O
+days	O
+.	O
+
+ORF	O
+3a	O
+of	O
+SARS	B-DISO
+-	O
+CoV	O
+codes	O
+for	O
+a	O
+recently	O
+identified	O
+transmembrane	B-COMP
+protein	B-CHED
+,	O
+but	O
+its	O
+function	O
+remains	O
+unknown	O
+.	O
+
+We	O
+have	O
+determined	O
+by	O
+crystallography	O
+the	O
+structure	O
+of	O
+XendoU	B-PRGE
+that	O
+,	O
+by	O
+refined	O
+search	O
+methodologies	O
+,	O
+appears	O
+to	O
+display	O
+a	O
+unique	O
+fold	O
+.	O
+
+Based	O
+on	O
+sequence	O
+conservation	O
+,	O
+mutagenesis	B-PROC
+,	O
+and	O
+docking	O
+simulations	O
+,	O
+we	O
+have	O
+identified	O
+the	O
+active	O
+site	O
+.	O
+
+CONCLUSIONS	O
+:	O
+The	O
+occurrence	O
+of	O
+clusters	B-CHED
+of	O
+two	O
+or	O
+more	O
+cases	O
+of	O
+pneumonia	B-DISO
+in	O
+HCW	O
+in	O
+the	O
+same	O
+hospital	O
+unit	O
+appears	O
+to	O
+be	O
+an	O
+uncommon	O
+event	O
+,	O
+and	O
+thus	O
+the	O
+alert	O
+system	O
+proposed	O
+is	O
+not	O
+likely	O
+to	O
+result	O
+in	O
+large	O
+numbers	O
+of	O
+false	O
+positive	O
+alerts	O
+.	O
+
+Only	O
+4	O
+.	O
+9	O
+%	O
+of	O
+individuals	O
+displayed	O
+aggressive	B-DISO
+behaviour	I-DISO
+leading	O
+to	O
+injury	O
+of	O
+the	O
+victim	O
+.	O
+
+Independent	O
+of	O
+line	O
+of	O
+chicken	B-SPEC
+,	O
+the	O
+percentage	O
+dam	O
+-	O
+to	O
+-	O
+chick	O
+(	O
+3	O
+d	O
+)	O
+plasma	B-ANAT
+transfer	O
+of	O
+IgY	O
+was	O
+estimated	O
+to	O
+be	O
+approximately	O
+30	O
+%,	O
+with	O
+that	O
+for	O
+IgM	B-PRGE
+and	O
+IgA	B-PRGE
+less	O
+than	O
+1	O
+%.	O
+
+Chicks	O
+synthesized	O
+IgM	B-PRGE
+first	O
+,	O
+followed	O
+by	O
+IgA	B-PRGE
+and	O
+IgY	O
+.	O
+Anti	O
+-	O
+NDV	B-SPEC
+and	O
+anti	O
+-	O
+IBV	B-SPEC
+antibodies	B-COMP
+were	O
+detected	O
+in	O
+the	O
+dams	O
+'	O
+plasma	B-ANAT
+,	O
+egg	B-ANAT
+yolks	O
+,	O
+and	O
+in	O
+the	O
+chicks	O
+'	O
+plasma	B-ANAT
+on	O
+d	O
+3	O
+and	O
+7	O
+,	O
+with	O
+line	O
+2	O
+having	O
+higher	O
+anti	O
+-	O
+IBV	B-SPEC
+and	O
+lower	O
+anti	O
+-	O
+NDV	B-SPEC
+levels	O
+than	O
+line	O
+1	O
+in	O
+all	O
+samples	O
+(	O
+P	O
+<	O
+0	O
+.	O
+0001	O
+).	O
+
+The	O
+inclusion	B-COMP
+bodies	I-COMP
+were	O
+successfully	O
+solubilized	O
+,	O
+purified	O
+under	O
+denaturing	O
+conditions	O
+employing	O
+IMAC	O
+column	B-ANAT
+and	O
+refolded	O
+.	O
+
+The	O
+NP	B-PRGE
+antigen	I-PRGE
+or	O
+a	O
+subfragment	O
+could	O
+be	O
+useful	O
+for	O
+developing	O
+a	O
+sensitive	O
+serum	B-COMP
+diagnostic	O
+assay	O
+to	O
+monitor	O
+SARS	B-DISO
+-	O
+CoV	O
+outbreaks	O
+by	O
+detecting	O
+the	O
+early	B-PRGE
+human	I-PRGE
+anti	I-PRGE
+-	I-PRGE
+SARS	B-DISO
+antibodies	B-COMP
+.	O
+
+Serologic	O
+evidence	O
+of	O
+SARS	B-DISO
+-	I-DISO
+CoV	I-DISO
+infection	I-DISO
+was	O
+detected	O
+in	O
+4	O
+individuals	O
+,	O
+including	O
+2	O
+non	O
+-	O
+clinical	O
+workers	O
+,	O
+who	O
+had	O
+not	O
+previously	O
+been	O
+identified	O
+as	O
+SARS	B-DISO
+cases	O
+;	O
+none	O
+reported	O
+having	O
+had	O
+fever	B-PROC
+or	O
+cough	B-DISO
+.	O
+
+Entering	O
+the	O
+index	O
+patient	O
+'	O
+s	O
+room	O
+and	O
+having	O
+seen	O
+(	O
+viewed	O
+)	O
+the	O
+patient	O
+were	O
+the	O
+behaviors	B-PROC
+associated	O
+with	O
+highest	O
+risk	O
+for	O
+infection	B-DISO
+by	O
+univariate	O
+analysis	O
+(	O
+odds	O
+ratios	O
+20	O
+.	O
+0	O
+,	O
+14	O
+.	O
+0	O
+;	O
+95	O
+%	O
+confidence	O
+intervals	O
+4	O
+.	O
+1	O
+-	O
+97	O
+.	O
+1	O
+,	O
+3	O
+.	O
+6	O
+-	O
+55	O
+.	O
+3	O
+,	O
+respectively	O
+).	O
+
+Astrocytes	B-ANAT
+are	O
+one	O
+of	O
+the	O
+major	O
+targets	O
+for	O
+MHV	B-SPEC
+infection	B-DISO
+in	O
+the	O
+CNS	B-CHED
+,	O
+and	O
+respond	O
+to	O
+MHV	B-SPEC
+infection	B-DISO
+by	O
+expressing	O
+diverse	O
+molecules	O
+that	O
+may	O
+contribute	O
+to	O
+CNS	B-CHED
+pathogenesis	B-DISO
+.	O
+
+Experiments	O
+with	O
+ultraviolet	O
+light	O
+-	O
+inactivated	O
+virus	B-SPEC
+revealed	O
+that	O
+the	O
+induction	O
+of	O
+Egr	B-PRGE
+-	I-PRGE
+1	I-PRGE
+did	O
+not	O
+require	O
+virus	B-PROC
+replication	I-PROC
+and	O
+was	O
+likely	O
+mediated	O
+during	O
+cell	O
+entry	O
+.	O
+
+This	O
+finding	O
+may	O
+provide	O
+an	O
+explanation	O
+for	O
+our	O
+previously	O
+observed	O
+down	B-PROC
+-	I-PROC
+regulation	I-PROC
+of	O
+BNip3	B-PRGE
+by	O
+MHV	B-SPEC
+infection	B-DISO
+in	O
+astrocytoma	B-DISO
+cells	B-COMP
+(	O
+Cai	O
+,	O
+Liu	O
+,	O
+Yu	B-SPEC
+,	O
+and	O
+Zhang	O
+,	O
+Virology	O
+316	O
+:	O
+104	O
+-	O
+115	O
+,	O
+2003	O
+).	O
+
+Despite	O
+evidence	O
+of	O
+the	O
+multiple	O
+cytokine	O
+-	O
+release	B-PATH
+syndrome	B-DISO
+,	O
+all	O
+six	O
+patients	O
+survived	O
+.	O
+
+TRALI	B-DISO
+remains	O
+a	O
+clinical	O
+diagnosis	O
+supported	O
+by	O
+serologic	O
+studies	O
+if	O
+these	O
+are	O
+available	O
+.	O
+
+ABSTRACT	O
+:	O
+Acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+(	O
+ARDS	B-DISO
+)	O
+is	O
+a	O
+heterogeneous	O
+disorder	O
+that	O
+may	O
+be	O
+triggered	O
+by	O
+myriad	O
+etiologies	O
+(	O
+both	O
+pulmonary	B-ANAT
+and	O
+extrapulmonary	O
+).	O
+
+Mortality	O
+rates	O
+for	O
+ARDS	B-DISO
+range	O
+from	O
+30	O
+to	O
+75	O
+%,	O
+and	O
+most	O
+deaths	B-PROC
+are	O
+a	O
+consequence	O
+of	O
+multiorgan	B-DISO
+failure	I-DISO
+(	O
+MOF	B-DISO
+).	O
+
+This	O
+review	O
+discusses	O
+limitations	O
+of	O
+various	O
+criteria	O
+utilized	O
+to	O
+diagnosis	O
+ARDS	B-DISO
+and	O
+ALI	O
+,	O
+and	O
+why	O
+some	O
+criteria	O
+may	O
+be	O
+problematic	O
+when	O
+designing	O
+clinical	O
+trials	O
+.	O
+
+Also	O
+discussed	O
+are	O
+the	O
+myriad	O
+causes	O
+of	O
+ARDS	B-DISO
+,	O
+incidence	O
+,	O
+epidemiology	O
+,	O
+mortality	O
+,	O
+and	O
+factors	O
+that	O
+influence	O
+outcome	O
+.	O
+
+ABSTRACT	O
+:	O
+Sepsis	B-DISO
+is	O
+a	O
+common	O
+and	O
+life	O
+-	O
+threatening	O
+condition	B-DISO
+with	O
+a	O
+high	O
+mortality	O
+rate	O
+.	O
+
+Severe	B-DISO
+sepsis	I-DISO
+includes	O
+multiorgan	O
+dysfunction	O
+syndrome	B-DISO
+.	O
+
+Our	O
+understanding	O
+of	O
+inflammation	B-DISO
+in	O
+the	O
+pathogenesis	B-DISO
+of	O
+sepsis	B-DISO
+and	O
+ALI	O
+is	O
+continually	O
+growing	O
+.	O
+
+However	O
+,	O
+therapies	O
+aimed	O
+at	O
+the	O
+inflammatory	O
+cascade	O
+in	O
+sepsis	B-DISO
+have	O
+been	O
+unsuccessful	O
+.	O
+
+With	O
+this	O
+clinical	O
+success	O
+,	O
+administration	O
+of	O
+drotecogin	O
+alfa	O
+(	O
+recombinant	O
+activated	O
+protein	B-CHED
+C	O
+),	O
+the	O
+importance	O
+of	O
+coagulation	B-PROC
+in	O
+the	O
+pathogenesis	B-DISO
+of	O
+human	B-SPEC
+sepsis	B-DISO
+is	O
+becoming	O
+clearer	O
+.	O
+
+TITLE	O
+:	O
+Severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+coronavirus	B-SPEC
+nsp1	B-PRGE
+protein	I-PRGE
+suppresses	O
+host	B-COMP
+gene	B-PROC
+expression	I-PROC
+by	O
+promoting	O
+host	O
+mRNA	B-PROC
+degradation	I-PROC
+.	O
+
+SCoV	O
+replication	O
+also	O
+promoted	O
+degradation	O
+of	O
+expressed	B-PROC
+RNA	O
+transcripts	O
+and	O
+host	B-COMP
+mRNAs	O
+,	O
+suggesting	O
+that	O
+nsp1	B-PRGE
+exerted	B-PROC
+its	O
+mRNA	B-PROC
+destabilization	I-PROC
+function	O
+in	O
+infected	O
+cells	B-COMP
+.	O
+
+Information	O
+derived	O
+from	O
+structural	O
+,	O
+mutational	O
+,	O
+and	O
+sequence	O
+analyses	O
+suggests	O
+a	O
+close	O
+phylogenetic	O
+and	O
+,	O
+most	O
+probably	O
+,	O
+functional	O
+relationship	O
+between	O
+viral	O
+and	O
+cellular	B-COMP
+macro	O
+domain	O
+homologs	O
+.	O
+
+The	O
+data	O
+revealed	O
+that	O
+viral	O
+macro	O
+domains	O
+have	O
+relatively	O
+poor	O
+ADP	O
+-	O
+ribose	B-CHED
+1	O
+"""-"	O
+phosphohydrolase	O
+activities	O
+(	O
+which	O
+were	O
+previously	O
+proposed	O
+to	O
+be	O
+their	O
+biologically	O
+relevant	O
+function	O
+)	O
+but	O
+bind	B-FUNC
+efficiently	O
+free	O
+and	O
+poly	O
+(	O
+ADP	B-CHED
+-	O
+ribose	B-CHED
+)	O
+polymerase	O
+1	O
+-	O
+bound	O
+poly	O
+(	O
+ADP	B-CHED
+-	O
+ribose	B-CHED
+)	O
+in	O
+vitro	O
+.	O
+
+ABSTRACT	O
+:	O
+We	O
+have	O
+recently	O
+demonstrated	O
+that	O
+the	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+coronavirus	B-SPEC
+(	O
+SARS	B-DISO
+-	O
+CoV	O
+)	O
+receptor	O
+angiotensin	B-PRGE
+converting	I-PRGE
+enzyme	I-PRGE
+2	I-PRGE
+(	O
+ACE2	B-PRGE
+)	O
+also	O
+mediates	O
+cellular	B-COMP
+entry	O
+of	O
+the	O
+newly	O
+discovered	O
+human	B-SPEC
+coronavirus	I-SPEC
+(	O
+hCoV	O
+)	O
+NL63	O
+.	O
+
+NL63	O
+-	O
+S	O
+does	O
+not	O
+exhibit	O
+significant	O
+homology	O
+to	O
+SARS	B-PRGE
+-	I-PRGE
+S	I-PRGE
+but	O
+is	O
+highly	O
+related	O
+to	O
+the	O
+S	O
+-	O
+protein	B-CHED
+of	O
+hCoV	B-SPEC
+-	I-SPEC
+229E	I-SPEC
+,	O
+which	O
+enters	O
+target	B-ANAT
+cells	I-ANAT
+by	O
+engaging	O
+CD13	B-PRGE
+.	O
+
+Recent	O
+research	O
+suggests	O
+that	O
+host	B-COMP
+factors	O
+have	O
+a	O
+major	O
+bearing	O
+on	O
+the	O
+development	B-PROC
+of	O
+ARDS	B-DISO
+.	O
+
+TITLE	O
+:	O
+Structure	O
+-	O
+based	O
+drug	O
+design	O
+and	O
+structural	O
+biology	O
+study	O
+of	O
+novel	O
+nonpeptide	O
+inhibitors	B-CHED
+of	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+coronavirus	B-SPEC
+main	O
+protease	O
+.	O
+
+ABSTRACT	O
+:	O
+Severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+coronavirus	B-SPEC
+(	O
+SARS	B-DISO
+-	O
+CoV	O
+)	O
+main	O
+protease	O
+(	O
+M	O
+(	O
+pro	B-CHED
+)),	O
+a	O
+protein	B-CHED
+required	O
+for	O
+the	O
+maturation	B-PROC
+of	O
+SARS	B-PRGE
+-	I-PRGE
+CoV	I-PRGE
+,	O
+is	O
+vital	O
+for	O
+its	O
+life	O
+cycle	O
+,	O
+making	O
+it	O
+an	O
+attractive	O
+target	O
+for	O
+structure	O
+-	O
+based	O
+drug	O
+design	O
+of	O
+anti	O
+-	O
+SARS	B-DISO
+drugs	O
+.	O
+
+These	O
+quantitative	O
+systems	O
+are	O
+potentially	O
+useful	O
+for	O
+the	O
+early	O
+diagnosis	O
+of	O
+SARS	B-DISO
+and	O
+can	O
+also	O
+provide	O
+viral	O
+load	O
+information	O
+that	O
+might	O
+assist	O
+clinicians	O
+in	O
+making	O
+a	O
+prognostic	O
+evaluation	O
+of	O
+an	O
+infected	O
+individual	O
+.	O
+
+ABSTRACT	O
+:	O
+The	O
+epidemics	O
+of	O
+severe	O
+acute	O
+respiratory	O
+syndrome	O
+(	O
+SARS	B-DISO
+)	O
+in	O
+2003	O
+highlighted	O
+both	O
+short	O
+-	O
+and	O
+long	O
+-	O
+range	O
+transmission	O
+routes	O
+,	O
+i	O
+.	O
+e	O
+.	O
+between	O
+infected	O
+patients	O
+and	O
+healthcare	O
+workers	O
+,	O
+and	O
+between	O
+distant	O
+locations	O
+.	O
+
+On	O
+this	O
+basis	O
+,	O
+recommendations	O
+are	O
+made	O
+to	O
+improve	O
+the	O
+control	O
+of	O
+aerosol	O
+-	O
+transmitted	O
+infections	B-DISO
+in	O
+hospitals	O
+as	O
+well	O
+as	O
+in	O
+the	O
+design	O
+and	O
+construction	O
+of	O
+future	O
+isolation	O
+facilities	O
+.	O
+
+When	O
+SR	O
+-	O
+COS7	O
+cells	B-COMP
+or	O
+R	O
+-	O
+COS7	O
+cells	B-COMP
+were	O
+cocultured	O
+with	O
+AG	O
+-	O
+COS7	O
+cells	B-COMP
+,	O
+syncytia	B-ANAT
+with	O
+yellow	O
+fluorescence	O
+were	O
+conveniently	O
+observed	O
+after	O
+12	O
+h	O
+in	O
+SR	O
+-	O
+COS7	O
+cells	B-COMP
+plus	O
+AG	O
+-	O
+COS7	O
+cells	B-COMP
+,	O
+but	O
+not	O
+in	O
+R	O
+-	O
+COS7	O
+cells	B-COMP
+plus	O
+AG	O
+-	O
+COS7	O
+cells	B-COMP
+.	O
+
+TITLE	O
+:	O
+Acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+induced	O
+by	O
+avian	B-DISO
+influenza	B-PATH
+A	I-PATH
+(	O
+H5N1	B-DISO
+)	O
+virus	B-SPEC
+in	O
+mice	B-SPEC
+.	O
+
+Here	O
+we	O
+present	O
+a	O
+mouse	B-SPEC
+model	O
+of	O
+ARDS	B-DISO
+induced	O
+by	O
+H5N1	B-DISO
+virus	B-SPEC
+.	O
+
+Lung	B-ANAT
+injury	O
+was	O
+assessed	O
+by	O
+observation	O
+of	O
+lung	B-ANAT
+water	B-CHED
+content	O
+and	O
+histopathology	O
+.	O
+
+Arterial	B-ANAT
+blood	I-ANAT
+gas	O
+,	O
+white	B-ANAT
+blood	I-ANAT
+cell	I-ANAT
+count	O
+in	O
+bronchial	B-ANAT
+alveolar	I-ANAT
+lavage	I-ANAT
+fluid	I-ANAT
+,	O
+and	O
+tumor	B-PRGE
+necrosis	I-PRGE
+factor	I-PRGE
+-	I-PRGE
+alpha	I-PRGE
+and	O
+interleukin	B-PRGE
+-	I-PRGE
+6	I-PRGE
+in	O
+bronchoalveolar	B-ANAT
+lavage	I-ANAT
+fluid	I-ANAT
+and	O
+serum	B-COMP
+were	O
+measured	O
+at	O
+the	O
+indicated	O
+time	O
+points	O
+.	O
+
+These	O
+results	O
+suggested	O
+that	O
+we	O
+successfully	O
+established	O
+a	O
+mouse	B-SPEC
+model	O
+of	O
+ARDS	B-DISO
+with	O
+H5N1	B-DISO
+viral	B-DISO
+infection	I-DISO
+,	O
+which	O
+may	O
+benefit	O
+further	O
+investigation	O
+into	O
+the	O
+pathogenesis	B-DISO
+of	O
+human	B-DISO
+ARDS	I-DISO
+induced	O
+by	O
+H5N1	B-DISO
+virus	B-SPEC
+.	O
+
+The	O
+pharmacologic	O
+strategies	O
+(	O
+including	O
+corticosteroids	O
+,	O
+surfactant	B-CHED
+,	O
+and	O
+nitric	B-CHED
+oxide	I-CHED
+)	O
+investigated	O
+for	O
+the	O
+treatment	O
+of	O
+severe	O
+respiratory	B-DISO
+failure	I-DISO
+are	O
+also	O
+reviewed	O
+.	O
+
+The	O
+S	O
+protein	B-CHED
+fragment	O
+was	O
+purified	O
+from	O
+the	O
+culture	O
+supernatant	O
+of	O
+stably	O
+transformed	O
+HEK293T	O
+cells	B-COMP
+secreting	B-PROC
+a	O
+tagged	O
+version	O
+of	O
+the	O
+protein	B-CHED
+.	O
+
+ABSTRACT	O
+:	O
+A	O
+member	O
+of	O
+the	O
+family	B-SPEC
+of	O
+coronaviruses	O
+has	O
+previously	O
+been	O
+identified	O
+as	O
+the	O
+cause	O
+of	O
+the	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+(	O
+SARS	B-DISO
+).	O
+
+Confocal	O
+microscopic	O
+analysis	O
+identified	O
+nucleocapsids	O
+packaged	O
+in	O
+vesicles	B-COMP
+in	O
+the	O
+perinuclear	O
+area	O
+indicating	O
+viral	O
+synthesis	B-PROC
+at	O
+the	O
+endoplasmic	B-COMP
+reticulum	I-COMP
+and	O
+Golgi	B-COMP
+apparatus	I-COMP
+.	O
+
+Leukocytosis	B-DISO
+and	O
+slight	O
+hypoxemia	O
+were	O
+observed	O
+.	O
+
+TITLE	O
+:	O
+Genotypic	O
+and	O
+phenotypic	O
+characterization	O
+of	O
+the	O
+California	B-SPEC
+99	O
+(	O
+Cal99	O
+)	O
+variant	O
+of	O
+infectious	B-DISO
+bronchitis	O
+virus	B-SPEC
+.	O
+
+ABSTRACT	O
+:	O
+The	O
+California	B-SPEC
+99	O
+(	O
+Cal99	O
+)	O
+variant	O
+of	O
+infectious	B-DISO
+bronchitis	B-DISO
+virus	B-SPEC
+(	O
+IBV	B-SPEC
+)	O
+was	O
+first	O
+recovered	O
+in	O
+1999	O
+from	O
+vaccinated	O
+broiler	O
+chicken	B-SPEC
+flocks	O
+in	O
+Central	O
+California	B-SPEC
+.	O
+
+In	O
+this	O
+study	O
+,	O
+the	O
+complete	O
+genome	O
+of	O
+Cal99	O
+was	O
+sequenced	O
+,	O
+and	O
+the	O
+structural	O
+protein	B-CHED
+genes	O
+were	O
+compared	O
+with	O
+those	O
+of	O
+commonly	O
+used	O
+IBV	B-SPEC
+vaccines	O
+as	O
+well	O
+as	O
+those	O
+of	O
+isolates	O
+from	O
+naturally	O
+occurring	O
+outbreaks	O
+in	O
+different	O
+parts	O
+of	O
+the	O
+world	O
+,	O
+to	O
+elucidate	O
+potential	O
+sources	O
+of	O
+genetic	O
+material	O
+.	O
+
+ABSTRACT	O
+:	O
+The	O
+engineering	O
+of	O
+a	O
+full	O
+-	O
+length	O
+infectious	B-DISO
+cDNA	O
+clone	O
+and	O
+a	O
+functional	O
+replicon	O
+of	O
+the	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+coronavirus	B-SPEC
+(	O
+SARS	B-DISO
+-	O
+CoV	O
+)	O
+Urbani	O
+strain	O
+as	O
+bacterial	O
+artificial	O
+chromosomes	B-COMP
+(	O
+BACs	O
+)	O
+is	O
+described	O
+in	O
+this	O
+study	O
+.	O
+
+In	O
+this	O
+system	O
+,	O
+the	O
+viral	O
+RNA	O
+was	O
+expressed	B-PROC
+in	O
+the	O
+cell	B-COMP
+nucleus	I-COMP
+under	O
+the	O
+control	O
+of	O
+the	O
+cytomegalovirus	B-SPEC
+promoter	O
+and	O
+further	O
+amplified	O
+in	O
+the	O
+cytoplasm	B-COMP
+by	O
+the	O
+viral	B-PRGE
+replicase	I-PRGE
+.	O
+
+Both	O
+the	O
+infectious	B-DISO
+clone	O
+and	O
+the	O
+replicon	O
+were	O
+fully	O
+stable	O
+in	O
+Escherichia	B-SPEC
+coli	I-SPEC
+.	O
+
+The	O
+SARS	B-DISO
+reverse	O
+genetic	O
+system	O
+developed	O
+as	O
+a	O
+BAC	O
+constitutes	O
+a	O
+useful	O
+tool	O
+for	O
+the	O
+study	O
+of	O
+fundamental	O
+viral	O
+processes	O
+and	O
+also	O
+for	O
+developing	O
+genetically	O
+defined	O
+vaccines	O
+.	O
+
+Therefore	O
+,	O
+PEEP	B-CHED
+had	O
+to	O
+be	O
+tapered	O
+to	O
+6	O
+cmH	B-DISO
+(	O
+2	O
+)	O
+O	O
+,	O
+and	O
+ventilation	O
+carried	O
+out	O
+at	O
+FIO	O
+(	O
+2	O
+)	O
+of	O
+1	O
+until	O
+the	O
+lung	B-ANAT
+condition	B-DISO
+improved	O
+.	O
+
+The	O
+disease	O
+was	O
+caused	O
+by	O
+a	O
+previously	O
+unrecognized	O
+coronavirus	B-SPEC
+,	O
+SARS	B-DISO
+-	O
+CoV	O
+.	O
+Drawing	O
+on	O
+experience	O
+with	O
+animal	B-SPEC
+coronavirus	B-SPEC
+vaccines	O
+,	O
+several	O
+vaccine	O
+candidates	O
+have	O
+been	O
+developed	O
+and	O
+evaluated	O
+in	O
+pre	O
+-	O
+clinical	O
+trials	O
+.	O
+
+In	O
+the	O
+absence	O
+of	O
+clinical	O
+cases	O
+of	O
+SARS	B-DISO
+,	O
+candidate	O
+vaccines	O
+should	O
+be	O
+evaluated	O
+for	O
+efficacy	O
+in	O
+animal	B-SPEC
+models	O
+,	O
+and	O
+although	O
+it	O
+is	O
+uncertain	O
+whether	O
+the	O
+United	O
+States	O
+Food	O
+and	O
+Drug	O
+Administration	O
+'	O
+s	O
+""""	O
+animal	O
+rule	O
+""""	O
+would	O
+apply	O
+to	O
+licensure	O
+of	O
+a	O
+SARS	B-DISO
+vaccine	O
+,	O
+it	O
+is	O
+important	O
+to	O
+develop	O
+standardized	O
+animal	B-SPEC
+models	O
+and	O
+immunological	O
+assays	O
+in	O
+preparation	O
+for	O
+this	O
+eventuality	O
+.	O
+
+Hepatitis	B-SPEC
+C	I-SPEC
+virus	I-SPEC
+causes	O
+various	O
+forms	O
+of	O
+glomerulonephritis	B-DISO
+,	O
+including	O
+cryoglobulinemia	B-DISO
+-	O
+mediated	O
+glomerulonephritis	B-DISO
+.	O
+
+TITLE	O
+:	O
+Development	B-PROC
+and	O
+evaluation	O
+of	O
+a	O
+real	O
+-	O
+time	O
+Taqman	O
+RT	O
+-	O
+PCR	O
+assay	O
+for	O
+the	O
+detection	O
+of	O
+infectious	B-DISO
+bronchitis	B-DISO
+virus	B-SPEC
+from	O
+infected	O
+chickens	B-SPEC
+.	O
+
+We	O
+tested	O
+229	O
+tracheal	O
+swabs	O
+submitted	O
+to	O
+two	O
+different	O
+diagnostic	O
+laboratories	O
+and	O
+found	O
+79	O
+.	O
+04	O
+%	O
+of	O
+the	O
+tracheal	O
+swabs	O
+positive	O
+for	O
+IBV	B-SPEC
+by	O
+real	O
+-	O
+time	O
+RT	O
+-	O
+PCR	O
+,	O
+whereas	O
+only	O
+27	O
+.	O
+51	O
+%	O
+of	O
+the	O
+samples	O
+were	O
+positive	O
+by	O
+virus	B-SPEC
+isolation	O
+,	O
+which	O
+is	O
+the	O
+reference	O
+standard	O
+test	O
+.	O
+
+Finally	O
+,	O
+we	O
+tested	O
+300	O
+total	O
+tracheal	O
+swab	O
+samples	O
+,	O
+from	O
+a	O
+flock	O
+of	O
+commercial	O
+broilers	O
+spray	O
+vaccinated	O
+for	O
+IBV	B-SPEC
+in	O
+the	O
+field	O
+.	O
+
+Herein	O
+,	O
+we	O
+screened	O
+12	O
+,	O
+000	O
+people	O
+in	O
+a	O
+community	O
+stricken	O
+by	O
+SARS	B-DISO
+10	O
+months	O
+previously	O
+and	O
+found	O
+53	O
+individuals	O
+(	O
+0	O
+.	O
+44	O
+%)	O
+who	O
+had	O
+immunoglobulin	B-PRGE
+G	I-PRGE
+antibodies	B-COMP
+to	O
+the	O
+SARS	B-DISO
+coronavirus	B-SPEC
+(	O
+SARS	B-DISO
+-	O
+CoV	O
+)	O
+nucleocapsid	B-COMP
+(	O
+N	O
+)	O
+produced	O
+in	O
+bacteria	B-SPEC
+.	O
+
+The	O
+remaining	O
+person	O
+,	O
+as	O
+well	O
+as	O
+the	O
+46	O
+other	O
+individuals	O
+(	O
+group	O
+2	O
+),	O
+were	O
+healthy	O
+and	O
+had	O
+no	O
+history	O
+of	O
+SARS	B-DISO
+.	O
+
+The	O
+N	B-PRGE
+antigen	I-PRGE
+is	O
+thus	O
+highly	O
+unique	O
+.	O
+
+Taken	O
+together	O
+,	O
+our	O
+findings	O
+suggest	O
+that	O
+SARS	B-PRGE
+-	I-PRGE
+CoV	I-PRGE
+S	I-PRGE
+protein	B-CHED
+specifically	O
+modulates	O
+the	O
+UPR	O
+to	O
+facilitate	O
+viral	B-PROC
+replication	I-PROC
+.	O
+
+The	O
+etiology	O
+of	O
+leptospirosis	B-DISO
+-	O
+induced	O
+pulmonary	B-DISO
+edema	I-DISO
+is	O
+unclear	O
+.	O
+
+Immunoblotting	O
+was	O
+used	O
+to	O
+determine	O
+expression	B-PROC
+and	O
+abundance	O
+of	O
+water	B-CHED
+and	O
+sodium	O
+transporters	O
+.	O
+
+In	O
+the	O
+lungs	B-ANAT
+,	O
+expression	B-PROC
+of	O
+the	O
+epithelial	B-FUNC
+sodium	I-FUNC
+channel	I-FUNC
+was	O
+lower	O
+,	O
+and	O
+NKCC1	B-PRGE
+expression	B-PROC
+was	O
+upregulated	O
+.	O
+
+Two	O
+research	O
+groups	O
+independently	O
+discovered	O
+the	O
+presence	O
+of	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+coronavirus	B-SPEC
+-	O
+like	O
+viruses	B-SPEC
+in	O
+horseshoe	B-SPEC
+bats	I-SPEC
+.	O
+
+For	O
+the	O
+recent	O
+and	O
+still	O
+ongoing	O
+avian	B-DISO
+influenza	I-DISO
+H5N1	B-DISO
+outbreak	O
+that	O
+originated	O
+in	O
+Southeast	O
+Asia	O
+,	O
+from	O
+2003	O
+to	O
+21	O
+April	O
+2006	O
+,	O
+204	O
+humans	B-SPEC
+have	O
+been	O
+infected	O
+,	O
+with	O
+113	O
+deaths	O
+.	O
+
+In	O
+Chinese	O
+wet	O
+-	O
+markets	O
+,	O
+unique	O
+epicenters	O
+for	O
+transmission	O
+of	O
+potential	O
+viral	O
+pathogens	O
+,	O
+new	O
+genes	O
+may	O
+be	O
+acquired	O
+or	O
+existing	O
+genes	O
+modified	O
+through	O
+various	O
+mechanisms	O
+such	O
+as	O
+genetic	O
+reassortment	O
+,	O
+recombination	B-PROC
+and	O
+mutation	O
+.	O
+
+TITLE	O
+:	O
+Extrarenal	O
+manifestations	O
+of	O
+severe	O
+acute	B-DISO
+pyelonephritis	I-DISO
+:	O
+CT	O
+findings	O
+in	O
+21	O
+cases	O
+.	O
+
+Twenty	O
+-	O
+one	O
+CT	O
+examinations	O
+of	O
+20	O
+patients	O
+[	O
+19	O
+women	O
+and	O
+one	O
+man	B-CHED
+,	O
+with	O
+ages	O
+ranging	O
+from	O
+18	O
+to	O
+57	O
+years	O
+(	O
+mean	O
+-	O
+35	O
+.	O
+2	O
+years	O
+)],	O
+presenting	O
+either	O
+with	O
+a	O
+clinical	O
+diagnosis	O
+of	O
+APN	O
+(	O
+n	O
+=	O
+17	O
+)	O
+or	O
+with	O
+a	O
+suspected	O
+acute	B-DISO
+appendicitis	I-DISO
+,	O
+fever	B-DISO
+of	I-DISO
+unknown	I-DISO
+origin	I-DISO
+,	O
+and	O
+adult	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+,	O
+one	O
+in	O
+each	O
+,	O
+were	O
+retrospectively	O
+reviewed	O
+.	O
+
+In	O
+the	O
+future	O
+,	O
+various	O
+biomarkers	O
+may	O
+be	O
+available	O
+to	O
+non	O
+-	O
+invasively	O
+classify	O
+ARDS	B-DISO
+patients	O
+from	O
+the	O
+standpoint	O
+of	O
+responsiveness	O
+to	O
+various	O
+therapies	O
+,	O
+such	O
+as	O
+glucocorticoids	B-CHED
+.	O
+
+Three	O
+IgG	B-PRGE
+(	I-PRGE
+2b	I-PRGE
+)	I-PRGE
+mAbs	I-PRGE
+were	O
+recognized	O
+within	O
+the	O
+N	O
+-	O
+terminus	O
+of	O
+N	B-PRGE
+protein	I-PRGE
+,	O
+whereas	O
+the	O
+epitope	B-CHED
+of	O
+two	O
+IgG	B-PRGE
+(	I-PRGE
+1	I-PRGE
+)	I-PRGE
+mAbs	I-PRGE
+localized	O
+within	O
+the	O
+C	O
+-	O
+terminus	O
+.	O
+
+In	O
+contrast	O
+,	O
+emergence	O
+or	O
+re	O
+-	O
+emergence	O
+of	O
+severe	O
+viral	B-DISO
+infections	I-DISO
+,	O
+including	O
+tick	B-DISO
+borne	I-DISO
+encephalitis	I-DISO
+virus	B-SPEC
+,	O
+and	O
+viral	B-DISO
+haemorrhagic	I-DISO
+fever	I-DISO
+caused	O
+by	O
+Hantavirus	B-SPEC
+and	O
+dengue	B-SPEC
+virus	I-SPEC
+have	O
+been	O
+frequently	O
+reported	O
+in	O
+several	O
+European	O
+countries	O
+.	O
+
+CONCLUSIONS	O
+:	O
+Chlorine	B-CHED
+disinfection	O
+seems	O
+to	O
+be	O
+the	O
+best	O
+available	O
+technology	O
+for	O
+coliform	O
+and	O
+bacteria	B-SPEC
+inactivation	B-DISO
+.	O
+
+The	O
+transmission	O
+of	O
+tuberculosis	B-PATH
+,	O
+hepatitis	B-DISO
+B	I-DISO
+,	O
+and	O
+measles	B-PATH
+from	O
+adopted	O
+children	O
+to	O
+family	B-SPEC
+members	O
+has	O
+been	O
+documented	O
+.	O
+
+Diseases	O
+such	O
+as	O
+severe	O
+acute	O
+respiratory	O
+syndrome	O
+or	O
+avian	B-DISO
+influenza	I-DISO
+have	O
+not	O
+been	O
+reported	O
+among	O
+international	O
+adoptees	O
+,	O
+but	O
+transmission	O
+is	O
+possible	O
+if	O
+infection	B-DISO
+is	O
+present	O
+.	O
+
+To	O
+investigate	O
+the	O
+subcellular	O
+localization	B-PROC
+of	O
+S1	O
+during	O
+transient	O
+expression	B-PROC
+in	O
+tobacco	B-SPEC
+leaves	O
+,	O
+a	O
+translational	B-PROC
+fusion	O
+consisting	O
+of	O
+S1	O
+and	O
+the	O
+green	O
+fluorescent	O
+protein	O
+(	O
+GFP	O
+)	O
+was	O
+generated	O
+.	O
+
+When	O
+the	O
+S1	O
+was	O
+expressed	B-PROC
+in	O
+transplastomic	O
+tobacco	B-SPEC
+,	O
+S1	B-PRGE
+messenger	I-PRGE
+RNA	I-PRGE
+and	O
+its	O
+corresponding	O
+protein	B-CHED
+were	O
+detected	O
+on	O
+Northern	O
+and	O
+Western	O
+blot	O
+analyses	O
+,	O
+respectively	O
+.	O
+
+TITLE	O
+:	O
+Molecular	O
+modeling	O
+studies	O
+of	O
+peptide	B-CHED
+drug	O
+candidates	O
+against	O
+SARS	B-DISO
+.	O
+
+ABSTRACT	O
+:	O
+Flexible	O
+alignment	O
+and	O
+docking	O
+studies	O
+were	O
+conducted	O
+for	O
+the	O
+three	O
+octapeptides	O
+,	O
+ATLQANEV	O
+,	O
+AVLQSGFR	O
+,	O
+and	O
+ATLQAIAS	O
+,	O
+that	O
+were	O
+cleavable	O
+by	O
+SARS	B-PRGE
+-	I-PRGE
+CoV	I-PRGE
+Mpro	I-PRGE
+.	O
+
+The	O
+present	O
+studies	O
+suggest	O
+that	O
+the	O
+octapeptides	O
+ATLQANEV	O
+and	O
+ATLQAIAS	O
+,	O
+like	O
+AVLQSGFR	O
+,	O
+might	O
+also	O
+be	O
+the	O
+good	O
+starting	O
+points	O
+for	O
+designing	O
+potential	O
+drugs	O
+against	O
+SARS	B-DISO
+.	O
+
+PSH050513	O
+has	O
+been	O
+tentatively	O
+identified	O
+as	O
+a	O
+novel	O
+member	O
+of	O
+group	O
+3	O
+coronaviruses	O
+that	O
+have	O
+close	O
+genetic	O
+relationships	O
+with	O
+IBV	B-SPEC
+strains	O
+.	O
+
+RESULTS	O
+:	O
+PSH050513	O
+was	O
+isolated	O
+and	O
+identified	O
+from	O
+the	O
+experimentally	O
+infected	O
+pigeons	B-SPEC
+by	O
+a	O
+routine	O
+method	O
+,	O
+which	O
+was	O
+in	O
+accordance	O
+with	O
+Koch	O
+'	O
+s	O
+postulates	O
+.	O
+
+ABSTRACT	O
+:	O
+When	O
+considering	O
+how	O
+people	O
+are	O
+infected	O
+and	O
+what	O
+can	O
+be	O
+done	O
+to	O
+prevent	O
+the	O
+infections	O
+,	O
+answers	O
+from	O
+many	O
+disciplines	O
+are	O
+sought	O
+:	O
+microbiology	O
+,	O
+epidemiology	O
+,	O
+medicine	B-CHED
+,	O
+engineering	O
+,	O
+and	O
+physics	O
+.	O
+
+Every	O
+day	O
+tens	O
+of	O
+millions	O
+of	O
+people	O
+worldwide	O
+suffer	B-DISO
+from	O
+viral	B-DISO
+infections	I-DISO
+of	O
+different	O
+severity	O
+at	O
+immense	O
+economic	O
+cost	O
+.	O
+
+TITLE	O
+:	O
+Structural	O
+basis	O
+of	O
+neutralization	O
+by	O
+a	O
+human	B-SPEC
+anti	O
+-	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+spike	O
+protein	B-CHED
+antibody	B-COMP
+,	O
+80R	O
+.	O
+
+The	O
+coronaviral	O
+surface	O
+spike	O
+protein	B-CHED
+S	O
+is	O
+a	O
+type	B-PRGE
+I	I-PRGE
+transmembrane	I-PRGE
+glycoprotein	B-CHED
+that	O
+mediates	O
+initial	O
+host	B-COMP
+binding	B-FUNC
+via	O
+the	O
+cell	B-COMP
+surface	I-COMP
+receptor	O
+angiotensin	B-PRGE
+-	I-PRGE
+converting	I-PRGE
+enzyme	I-PRGE
+2	I-PRGE
+(	O
+ACE2	B-PRGE
+),	O
+as	O
+well	O
+as	O
+the	O
+subsequent	O
+membrane	B-PROC
+fusion	I-PROC
+events	O
+required	O
+for	O
+cell	B-COMP
+entry	O
+.	O
+
+We	O
+further	O
+show	O
+that	O
+the	O
+RBD	O
+of	O
+S1	O
+forms	O
+dimers	O
+via	O
+an	O
+extensive	O
+interface	O
+that	O
+is	O
+disrupted	O
+in	O
+receptor	O
+-	O
+and	O
+antibody	B-COMP
+-	O
+bound	O
+crystal	B-ANAT
+structures	O
+,	O
+and	O
+we	O
+propose	O
+a	O
+role	O
+for	O
+the	O
+dimer	O
+in	O
+virus	B-SPEC
+stability	O
+and	O
+infectivity	O
+.	O
+
+Of	O
+these	O
+107	O
+positive	O
+samples	O
+,	O
+90	O
+fecal	B-ANAT
+samples	O
+from	O
+33	O
+herds	O
+tested	O
+positive	O
+for	O
+BCoV	O
+alone	O
+and	O
+17	O
+fecal	B-ANAT
+samples	O
+from	O
+14	O
+herds	O
+also	O
+tested	O
+positive	O
+for	O
+other	O
+pathogens	O
+.	O
+
+The	O
+main	O
+reasons	O
+for	O
+admission	O
+to	O
+the	O
+ICU	O
+were	O
+:	O
+infection	B-DISO
+/	O
+septic	B-DISO
+syndrome	I-DISO
+(	O
+n	O
+=	O
+4	O
+),	O
+scleroderma	B-DISO
+renal	B-ANAT
+crisis	I-DISO
+(	O
+SRC	B-PRGE
+)	O
+with	O
+pulmonary	B-DISO
+congestion	I-DISO
+(	O
+n	O
+=	O
+2	O
+),	O
+acute	B-DISO
+renal	I-DISO
+failure	I-DISO
+associated	O
+with	O
+diffuse	O
+alveolar	B-ANAT
+hemorrhage	B-DISO
+namely	O
+scleroderma	B-DISO
+-	O
+pulmonary	B-ANAT
+-	O
+renal	B-ANAT
+syndrome	B-DISO
+(	O
+SPRS	O
+)	O
+(	O
+n	O
+=	O
+1	O
+),	O
+iatrogenic	O
+pericardial	B-DISO
+tamponade	I-DISO
+(	O
+n	O
+=	O
+1	O
+),	O
+mesenteric	B-DISO
+ischemia	I-DISO
+(	O
+n	O
+=	O
+1	O
+).	O
+
+Eight	O
+out	O
+of	O
+nine	O
+patients	O
+(	O
+89	O
+%)	O
+that	O
+were	O
+admitted	O
+to	O
+the	O
+ICU	O
+died	B-PROC
+during	O
+the	O
+hospitalization	O
+,	O
+six	O
+(	O
+66	O
+.	O
+6	O
+%)	O
+of	O
+them	O
+died	B-PROC
+in	O
+the	O
+ICU	O
+.	O
+
+The	O
+outcome	O
+of	O
+scleroderma	B-DISO
+patients	O
+admitted	O
+to	O
+the	O
+ICU	O
+was	O
+extremely	O
+poor	O
+.	O
+
+Six	O
+patients	O
+had	O
+diffuse	O
+SSc	O
+,	O
+two	O
+patients	O
+had	O
+limited	O
+SSc	O
+and	O
+one	O
+patient	O
+had	O
+juvenile	O
+diffuse	O
+morphea	B-DISO
+.	O
+
+Substitutions	O
+in	O
+a	O
+restricted	O
+,	O
+downstream	O
+part	O
+of	O
+the	O
+S	B-PRGE
+protein	I-PRGE
+encompassing	O
+heptad	O
+repeat	O
+region	O
+1	O
+(	O
+HR1	O
+)	O
+and	O
+putative	O
+fusion	O
+peptide	B-CHED
+(	O
+FP	O
+)	O
+did	O
+not	O
+alter	O
+the	O
+CEACAM1a	O
+dependence	B-DISO
+.	O
+
+We	O
+conducted	O
+a	O
+systematic	O
+search	O
+of	O
+the	O
+English	O
+-	O
+language	O
+literature	O
+for	O
+original	O
+CEAs	B-FUNC
+of	O
+critical	O
+care	O
+interventions	O
+published	O
+from	O
+1993	O
+through	O
+2003	O
+.	O
+
+Specific	O
+interventions	O
+such	O
+as	O
+activated	O
+protein	B-CHED
+C	O
+for	O
+patients	O
+with	O
+severe	B-DISO
+sepsis	I-DISO
+have	O
+been	O
+shown	O
+to	O
+provide	O
+good	O
+value	O
+for	O
+money	O
+.	O
+
+RESULTS	O
+:	O
+We	O
+identified	O
+19	O
+CEAs	B-FUNC
+published	O
+through	O
+2003	O
+with	O
+48	O
+cost	O
+-	O
+effectiveness	O
+ratios	O
+pertaining	O
+to	O
+treatment	O
+of	O
+severe	B-DISO
+sepsis	I-DISO
+,	O
+acute	B-DISO
+respiratory	I-DISO
+failure	I-DISO
+,	O
+and	O
+general	O
+critical	O
+care	O
+interventions	O
+.	O
+
+TITLE	O
+:	O
+A	O
+brief	O
+overview	O
+of	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+.	O
+
+ABSTRACT	O
+:	O
+Persistent	O
+impaired	B-DISO
+pulmonary	B-PROC
+function	I-PROC
+and	O
+functional	O
+capacity	O
+are	O
+common	O
+among	O
+survivors	O
+of	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+(	O
+SARS	B-DISO
+).	O
+
+Nurses	O
+'	O
+fear	O
+about	O
+an	O
+unknown	O
+infectious	B-DISO
+disease	I-DISO
+,	O
+such	O
+as	O
+the	O
+H5N1	B-DISO
+influenza	I-DISO
+virus	O
+,	O
+could	O
+easily	O
+be	O
+heightened	O
+to	O
+levels	O
+above	O
+those	O
+occurring	O
+during	O
+the	O
+2003	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+outbreak	O
+in	O
+Taiwan	O
+.	O
+
+TITLE	O
+:	O
+Identification	O
+of	O
+cell	B-ANAT
+lines	I-ANAT
+permissive	O
+for	O
+human	B-SPEC
+coronavirus	I-SPEC
+NL63	I-SPEC
+.	O
+
+TITLE	O
+:	O
+Airflows	O
+around	O
+oxygen	B-CHED
+masks	O
+:	O
+A	O
+potential	O
+source	O
+of	O
+infection	B-DISO
+?	O
+
+Most	O
+research	O
+ferrets	B-SPEC
+are	O
+males	O
+,	O
+due	O
+to	O
+estrus	B-PROC
+-	O
+related	O
+health	O
+problems	O
+in	O
+females	O
+.	O
+
+ABSTRACT	O
+:	O
+The	O
+genome	O
+of	O
+the	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+coronavirus	B-SPEC
+encodes	O
+for	O
+eight	O
+accessory	O
+viral	O
+proteins	B-CHED
+with	O
+no	O
+known	O
+homologues	O
+in	O
+other	O
+coronaviruses	O
+.	O
+
+One	O
+of	O
+these	O
+is	O
+the	O
+3b	O
+protein	B-CHED
+,	O
+which	O
+is	O
+encoded	O
+by	O
+the	O
+second	O
+open	O
+reading	O
+frame	O
+in	O
+subgenomic	O
+RNA	O
+3	O
+and	O
+contains	O
+154	O
+amino	B-CHED
+acids	I-CHED
+.	O
+
+At	O
+all	O
+the	O
+time	O
+-	O
+points	O
+analysed	O
+,	O
+the	O
+apoptosis	B-PATH
+induced	O
+by	O
+the	O
+expression	B-PROC
+of	O
+3b	O
+was	O
+less	O
+than	O
+the	O
+level	O
+induced	O
+by	O
+Bax	O
+but	O
+the	O
+level	O
+of	O
+necrosis	B-PROC
+was	O
+comparable	O
+.	O
+
+The	O
+study	O
+group	O
+consisted	O
+of	O
+120	O
+children	O
+aged	O
+6	O
+to	O
+144	O
+months	O
+with	O
+AOM	B-DISO
+.	O
+
+Clinical	O
+trials	O
+should	O
+be	O
+designed	O
+to	O
+validate	O
+a	O
+standard	O
+protocol	O
+for	O
+dosage	O
+and	O
+timing	O
+,	O
+and	O
+to	O
+accrue	O
+data	O
+in	O
+real	O
+time	O
+during	O
+future	O
+outbreaks	O
+to	O
+monitor	O
+specific	O
+adverse	B-DISO
+effects	I-DISO
+and	O
+help	O
+inform	O
+treatment	O
+.	O
+
+TITLE	O
+:	O
+Replication	O
+of	O
+murine	B-DISO
+hepatitis	I-DISO
+virus	B-SPEC
+is	O
+regulated	O
+by	O
+papain	B-PRGE
+-	I-PRGE
+like	I-PRGE
+proteinase	B-PROC
+1	I-PRGE
+processing	O
+of	O
+nonstructural	O
+proteins	O
+1	O
+,	O
+2	O
+,	O
+and	O
+3	O
+.	O
+
+TITLE	O
+:	O
+Cross	O
+-	O
+protection	O
+against	O
+a	O
+human	B-SPEC
+enteric	B-SPEC
+coronavirus	I-SPEC
+and	O
+a	O
+virulent	O
+bovine	B-SPEC
+enteric	B-SPEC
+coronavirus	I-SPEC
+in	O
+gnotobiotic	O
+calves	O
+.	O
+
+They	O
+confirm	O
+its	O
+infectivity	O
+for	O
+calves	O
+and	O
+complete	O
+cross	O
+-	O
+protection	O
+against	O
+a	O
+bovine	B-SPEC
+coronavirus	B-SPEC
+(	O
+DB2	O
+strain	O
+)	O
+showing	O
+98	O
+.	O
+2	O
+%	O
+amino	B-CHED
+acid	I-CHED
+identity	O
+to	O
+HECV	O
+-	O
+4408	O
+in	O
+the	O
+S	B-PRGE
+protein	I-PRGE
+.	O
+
+Hemodynamics	B-PROC
+were	O
+analyzed	O
+after	O
+insertion	O
+of	O
+biventricular	O
+conductance	O
+catheters	O
+and	O
+a	O
+pulmonary	B-ANAT
+artery	I-ANAT
+catheter	O
+.	O
+
+The	O
+protective	O
+strategies	O
+led	O
+to	O
+higher	O
+mean	O
+airway	B-ANAT
+pressures	O
+and	O
+severe	O
+hypercapnia	O
+with	O
+acidosis	B-DISO
+,	O
+which	O
+was	O
+only	O
+significant	O
+with	O
+CLPV	O
+.	O
+
+The	O
+nucleotide	B-CHED
+sequence	O
+encoding	O
+the	O
+entire	O
+N	B-PRGE
+gene	I-PRGE
+open	O
+reading	O
+frame	O
+(	O
+ORF	O
+)	O
+of	O
+LJB	O
+/	O
+03	O
+was	O
+1326	O
+bases	B-CHED
+long	O
+and	O
+encoded	O
+a	O
+protein	B-CHED
+of	O
+441	O
+amino	B-CHED
+acids	I-CHED
+with	O
+predicted	O
+Mr	O
+of	O
+49	O
+kDa	O
+.	O
+
+The	O
+encoded	O
+protein	B-CHED
+shared	O
+96	O
+.	O
+4	O
+%	O
+amino	B-CHED
+acid	I-CHED
+identities	O
+compared	O
+with	O
+CV777	O
+,	O
+96	O
+.	O
+1	O
+%	O
+with	O
+Brl	O
+/	O
+87	O
+,	O
+98	O
+%	O
+with	O
+JS2004	O
+,	O
+96	O
+.	O
+90	O
+%	O
+with	O
+chinju99	O
+,	O
+respectively	O
+.	O
+
+This	O
+model	O
+was	O
+further	O
+utilized	O
+to	O
+design	O
+small	O
+molecules	O
+that	O
+are	O
+expected	O
+to	O
+block	O
+an	O
+ATPase	B-PRGE
+catalytic	O
+pocket	O
+thus	O
+inhibit	O
+the	O
+enzymatic	B-PROC
+activity	I-PROC
+.	O
+
+Therefore	O
+,	O
+we	O
+investigated	O
+whether	O
+transmissible	O
+gastroenteritis	B-DISO
+coronavirus	B-SPEC
+(	O
+TGEV	B-SPEC
+)	O
+N	O
+protein	B-CHED
+was	O
+an	O
+RNA	B-PROC
+chaperone	I-PROC
+.	O
+
+When	O
+the	O
+in	O
+vitro	O
+-	O
+synthesized	O
+full	O
+-	O
+length	O
+transcripts	O
+containing	O
+this	O
+mutation	O
+were	O
+introduced	O
+into	O
+Vero	B-ANAT
+cells	I-ANAT
+,	O
+no	O
+infectious	B-DISO
+virus	B-SPEC
+was	O
+rescued	O
+.	O
+
+On	O
+the	O
+contrary	O
+,	O
+a	O
+G	O
+-	O
+C	O
+and	O
+a	O
+G	O
+-	O
+A	O
+point	B-PROC
+mutations	I-PROC
+at	O
+nucleotide	B-CHED
+positions	O
+4330	O
+and	O
+9230	O
+,	O
+respectively	O
+,	O
+causing	O
+Glu	B-CHED
+-	O
+Gln	B-CHED
+and	O
+Gly	B-CHED
+-	O
+Glu	B-CHED
+mutations	O
+in	O
+or	O
+near	O
+the	O
+catalytic	O
+centers	O
+of	O
+the	O
+papain	B-PRGE
+-	I-PRGE
+like	I-PRGE
+(	O
+Nsp3	B-PRGE
+)	O
+and	O
+3C	B-PRGE
+-	I-PRGE
+like	I-PRGE
+(	O
+Nsp5	B-PRGE
+)	O
+proteinases	O
+,	O
+did	O
+not	O
+show	O
+detectable	O
+detrimental	O
+effect	O
+on	O
+the	O
+rescue	O
+of	O
+infectious	B-DISO
+viruses	B-SPEC
+and	O
+the	O
+infectivity	O
+of	O
+the	O
+rescued	O
+viruses	B-SPEC
+.	O
+
+Screening	O
+to	O
+detect	O
+potential	O
+SARS	B-DISO
+-	O
+infected	O
+subjects	O
+with	O
+elevated	O
+body	B-ANAT
+temperature	O
+plays	O
+an	O
+important	O
+role	O
+in	O
+preventing	O
+the	O
+spread	O
+of	O
+SARS	B-DISO
+.	O
+
+Thermography	O
+is	O
+being	O
+used	O
+with	O
+ANN	O
+/	O
+AI	O
+to	O
+analyse	O
+the	O
+data	O
+collected	O
+from	O
+the	O
+designated	O
+SARS	B-DISO
+hospital	O
+in	O
+Singapore	O
+,	O
+and	O
+conclusive	O
+results	O
+are	O
+drawn	O
+.	O
+
+We	O
+also	O
+found	O
+that	O
+the	O
+GxxxG	O
+motif	O
+contributes	O
+toward	O
+the	O
+trimerization	O
+of	O
+the	O
+entire	O
+spike	O
+protein	B-CHED
+;	O
+in	O
+that	O
+,	O
+mutations	O
+in	O
+the	O
+GxxxG	O
+motif	O
+decrease	O
+trimerization	O
+of	O
+the	O
+full	O
+-	O
+length	O
+protein	O
+expressed	B-PROC
+in	O
+mammalian	B-SPEC
+cells	B-COMP
+.	O
+
+TITLE	O
+:	O
+Does	O
+marriage	O
+between	O
+first	O
+cousins	O
+have	O
+any	O
+predictive	O
+value	O
+for	O
+maternal	O
+and	O
+perinatal	O
+outcomes	O
+in	O
+pre	B-DISO
+-	I-DISO
+eclampsia	I-DISO
+?	O
+
+Univariate	O
+analysis	O
+yielded	O
+significant	O
+differences	O
+in	O
+parity	O
+(	O
+P	O
+=	O
+0	O
+.	O
+034	O
+),	O
+maternal	O
+platelet	B-ANAT
+counts	O
+(	O
+P	O
+=	O
+0	O
+.	O
+02	O
+),	O
+and	O
+maternal	O
+serum	B-COMP
+potassium	B-CHED
+levels	O
+(	O
+P	O
+=	O
+0	O
+.	O
+016	O
+)	O
+among	O
+the	O
+groups	O
+.	O
+
+Third	O
+-	O
+degree	O
+consanguinity	O
+in	O
+terms	O
+of	O
+a	O
+union	O
+between	O
+first	O
+cousins	O
+seems	O
+to	O
+have	O
+no	O
+effect	O
+on	O
+the	O
+development	B-PROC
+of	O
+maternal	O
+and	O
+perinatal	O
+complications	O
+in	O
+established	O
+pre	B-DISO
+-	I-DISO
+eclampsia	I-DISO
+.	O
+
+TITLE	O
+:	O
+Control	O
+of	O
+coronavirus	B-DISO
+infection	I-DISO
+through	O
+plasmacytoid	O
+dendritic	B-COMP
+-	O
+cell	B-COMP
+-	O
+derived	O
+type	B-PRGE
+I	I-PRGE
+interferon	I-PRGE
+.	O
+
+ABSTRACT	O
+:	O
+This	O
+study	O
+demonstrates	O
+a	O
+unique	O
+and	O
+crucial	O
+role	O
+of	O
+plasmacytoid	B-ANAT
+dendritic	I-ANAT
+cells	B-COMP
+(	O
+pDCs	O
+)	O
+and	O
+pDC	B-DISO
+-	O
+derived	O
+type	O
+I	O
+interferons	O
+(	O
+IFNs	O
+)	O
+in	O
+the	O
+pathogenesis	B-DISO
+of	O
+mouse	B-SPEC
+coronavirus	B-DISO
+infection	I-DISO
+.	O
+
+Furthermore	O
+,	O
+the	O
+particular	O
+type	O
+I	O
+IFN	B-PRGE
+response	O
+pattern	O
+was	O
+not	O
+restricted	O
+to	O
+the	O
+murine	B-SPEC
+coronavirus	I-SPEC
+,	O
+but	O
+was	O
+also	O
+found	O
+in	O
+infection	B-DISO
+with	O
+the	O
+highly	O
+cytopathic	O
+human	B-SPEC
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+(	O
+SARS	B-DISO
+)	O
+coronavirus	B-SPEC
+.	O
+
+ABSTRACT	O
+:	O
+Severe	O
+acute	O
+respiratory	O
+syndrome	O
+-	O
+associated	O
+coronavirus	B-SPEC
+(	O
+SARS	B-DISO
+-	O
+CoV	O
+)	O
+was	O
+introduced	O
+to	O
+the	O
+United	O
+States	O
+through	O
+air	B-CHED
+travel	O
+.	O
+
+Although	O
+the	O
+risk	O
+of	O
+SARS	B-DISO
+-	O
+CoV	O
+transmission	O
+within	O
+aircraft	O
+cabins	O
+has	O
+been	O
+addressed	O
+by	O
+several	O
+studies	O
+,	O
+the	O
+magnitude	O
+of	O
+the	O
+risk	O
+remains	O
+unclear	O
+.	O
+
+Consenting	O
+participants	O
+responded	O
+to	O
+a	O
+questionnaire	O
+,	O
+and	O
+a	O
+serum	B-ANAT
+sample	I-ANAT
+was	O
+collected	O
+at	O
+least	O
+38	O
+days	O
+after	O
+the	O
+flight	B-PROC
+and	O
+tested	O
+for	O
+SARS	B-PRGE
+-	I-PRGE
+CoV	I-PRGE
+-	I-PRGE
+associated	I-PRGE
+antibodies	B-COMP
+.	O
+
+Serology	O
+was	O
+negative	O
+for	O
+all	O
+127	O
+participants	O
+,	O
+including	O
+three	O
+of	O
+four	O
+who	O
+met	B-CHED
+the	O
+clinical	O
+case	O
+criteria	O
+for	O
+SARS	B-DISO
+,	O
+and	O
+the	O
+fourth	O
+had	O
+a	O
+mild	O
+illness	O
+that	O
+lasted	O
+only	O
+5	O
+days	O
+.	O
+
+Enhanced	O
+IRF	B-PRGE
+-	I-PRGE
+1	I-PRGE
+/	O
+DNA	O
+complex	O
+formation	B-PROC
+was	O
+observed	O
+in	O
+interferon	B-PRGE
+co	O
+-	O
+treatment	O
+group	O
+by	O
+gel	O
+shift	O
+analysis	O
+.	O
+
+In	O
+conclusion	O
+,	O
+hyper	O
+-	O
+activation	O
+of	O
+IRF	B-PRGE
+-	I-PRGE
+1	I-PRGE
+and	O
+elevated	O
+STAT1	B-PRGE
+dimer	O
+formation	B-PROC
+may	O
+be	O
+two	O
+general	O
+switches	O
+which	O
+contribute	O
+to	O
+a	O
+much	O
+more	O
+robust	O
+antiviral	B-CHED
+symphony	O
+against	O
+virus	B-PROC
+replication	I-PROC
+when	O
+type	O
+I	O
+and	O
+type	O
+II	O
+IFNs	O
+are	O
+co	O
+-	O
+administered	O
+.	O
+
+In	O
+WBV	O
+-	O
+infected	O
+cells	B-COMP
+,	O
+three	O
+subgenomic	O
+RNAs	O
+expressing	O
+the	O
+structural	O
+proteins	B-CHED
+S	O
+,	O
+M	O
+,	O
+and	O
+N	O
+were	O
+identified	O
+.	O
+
+Here	O
+we	O
+review	O
+the	O
+role	O
+of	O
+ACE2	B-PRGE
+in	O
+disease	O
+pathogenesis	B-DISO
+,	O
+including	O
+lung	B-DISO
+diseases	I-DISO
+and	O
+cardiovascular	B-DISO
+diseases	I-DISO
+.	O
+
+Future	O
+licensure	O
+of	O
+these	O
+and	O
+other	O
+candidate	O
+vaccines	O
+will	O
+depend	O
+on	O
+their	O
+safety	O
+and	O
+immunogenicity	O
+profiles	O
+in	O
+humans	B-SPEC
+,	O
+and	O
+their	O
+ability	O
+to	O
+confer	O
+protection	O
+in	O
+animal	O
+models	O
+of	O
+inhalational	B-DISO
+anthrax	I-DISO
+.	O
+
+Moreover	O
+,	O
+both	O
+anti	O
+-	O
+S1	O
+and	O
+anti	O
+-	O
+S2	O
+IgGs	O
+were	O
+able	O
+to	O
+abolish	O
+the	O
+binding	B-FUNC
+between	O
+S	B-PRGE
+protein	I-PRGE
+and	O
+its	O
+cellular	B-COMP
+receptor	O
+(	O
+s	O
+),	O
+although	O
+anti	B-PRGE
+-	I-PRGE
+S1	I-PRGE
+IgG	I-PRGE
+showed	O
+a	O
+significantly	O
+higher	O
+blocking	B-DISO
+efficiency	O
+.	O
+
+On	O
+the	O
+other	O
+hand	O
+,	O
+the	O
+functional	O
+roles	O
+of	O
+the	O
+previously	O
+reported	O
+neutralizing	O
+epitopes	O
+within	O
+S2	O
+subunit	O
+were	O
+investigated	O
+using	O
+an	O
+antigen	B-CHED
+specific	O
+antibody	B-COMP
+depletion	O
+assay	O
+.	O
+
+Depletion	O
+of	O
+antibodies	B-COMP
+against	O
+these	O
+regions	O
+significantly	O
+diminished	O
+,	O
+though	O
+not	O
+completely	O
+abolished	O
+,	O
+the	O
+neutralizing	O
+effects	O
+of	O
+anti	B-PRGE
+-	I-PRGE
+S2	I-PRGE
+IgG	I-PRGE
+.	O
+It	O
+suggests	O
+the	O
+absence	O
+of	O
+a	O
+major	O
+neutralizing	O
+domain	O
+on	O
+S2	B-PRGE
+protein	I-PRGE
+.	O
+
+The	O
+aim	O
+of	O
+the	O
+study	O
+was	O
+to	O
+identify	O
+early	O
+risk	O
+factors	O
+for	O
+development	O
+of	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+(	O
+ARDS	B-DISO
+)	O
+in	O
+severe	O
+trauma	O
+patients	O
+.	O
+
+RESULTS	O
+:	O
+Acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+developed	O
+in	O
+6	O
+.	O
+9	O
+%	O
+of	O
+patients	O
+who	O
+were	O
+more	O
+severely	O
+ill	B-DISO
+with	O
+higher	O
+APACHE	O
+II	O
+(	O
+P	O
+<	O
+.	O
+001	O
+)	O
+and	O
+Injury	O
+Severity	O
+Score	O
+(	O
+P	O
+=	O
+.	O
+002	O
+)	O
+scores	O
+vs	O
+patients	O
+not	O
+developing	O
+ARDS	B-DISO
+.	O
+
+To	O
+explore	O
+the	O
+relationship	O
+between	O
+S	O
+and	O
+COX	B-PRGE
+-	I-PRGE
+2	I-PRGE
+,	O
+we	O
+constructed	O
+a	O
+series	O
+of	O
+plasmids	O
+containing	O
+truncated	O
+N	O
+-	O
+terminal	O
+fragments	O
+of	O
+the	O
+SARS	B-PRGE
+-	I-PRGE
+CoV	I-PRGE
+S	I-PRGE
+gene	I-PRGE
+(	O
+designated	O
+from	O
+Sa	O
+to	O
+Si	O
+),	O
+which	O
+encoded	O
+truncated	B-PRGE
+S	I-PRGE
+proteins	I-PRGE
+,	O
+and	O
+investigated	O
+whether	O
+these	O
+truncated	O
+proteins	B-CHED
+could	O
+induce	O
+effective	O
+expression	B-PROC
+of	O
+COX	B-PRGE
+-	I-PRGE
+2	I-PRGE
+in	O
+293T	O
+cells	B-COMP
+.	O
+
+Our	O
+results	O
+showed	O
+that	O
+S	O
+(	O
+d	O
+)	O
+that	O
+encoded	O
+a	O
+truncated	B-PRGE
+S	I-PRGE
+protein	I-PRGE
+with	O
+422	O
+amino	B-CHED
+acid	I-CHED
+residues	O
+(	O
+from	O
+1	O
+to	O
+422	O
+aa	O
+),	O
+a	O
+part	O
+of	O
+672	O
+amino	O
+-	O
+acid	O
+S1	O
+subunit	O
+is	O
+crucial	O
+for	O
+the	O
+induction	O
+of	O
+COX	O
+-	O
+2	O
+expression	B-PROC
+.	O
+
+We	O
+also	O
+compared	O
+S	O
+protein	B-CHED
+sequences	O
+of	O
+SARS	B-PRGE
+-	I-PRGE
+CoV	I-PRGE
+isolated	O
+during	O
+the	O
+SARS	B-DISO
+break	O
+with	O
+that	O
+from	O
+palm	B-ANAT
+civets	B-SPEC
+,	O
+a	O
+possible	O
+source	O
+of	O
+SARS	B-DISO
+-	O
+CoV	O
+found	O
+in	O
+humans	B-SPEC
+.	O
+
+S	O
+protein	B-CHED
+residues	O
+(	O
+344	O
+,	O
+360	O
+),	O
+which	O
+mutated	O
+in	O
+the	O
+epitome	O
+from	O
+palm	B-ANAT
+civet	B-SPEC
+to	O
+human	B-SPEC
+being	O
+were	O
+characterized	O
+in	O
+3D	O
+modeling	O
+of	O
+252	O
+-	O
+375	O
+amino	B-CHED
+acid	I-CHED
+fragment	O
+.	O
+
+Collectively	O
+,	O
+these	O
+results	O
+indicate	O
+that	O
+S	B-PRGE
+protein	I-PRGE
+of	O
+SARS	B-PRGE
+-	I-PRGE
+CoV	I-PRGE
+induces	O
+the	O
+expression	B-PROC
+of	O
+COX	B-PRGE
+-	I-PRGE
+2	I-PRGE
+and	O
+an	O
+N	O
+-	O
+terminal	O
+fragment	O
+of	O
+the	O
+Spike	B-PRGE
+protein	I-PRGE
+is	O
+crucial	O
+for	O
+the	O
+induction	O
+.	O
+
+Our	O
+finding	O
+may	O
+provide	O
+clue	O
+for	O
+the	O
+induction	O
+of	O
+inflammation	B-DISO
+by	O
+SARS	B-DISO
+-	O
+CoV	O
+and	O
+cast	B-ANAT
+insight	O
+into	O
+the	O
+severity	O
+of	O
+the	O
+SARS	B-DISO
+epidemic	O
+.	O
+
+TITLE	O
+:	O
+Modification	O
+of	O
+SARS	B-PRGE
+-	I-PRGE
+CoV	I-PRGE
+S1	I-PRGE
+gene	I-PRGE
+render	O
+expression	B-PROC
+in	O
+Pichia	B-SPEC
+pastoris	I-SPEC
+.	O
+
+However	O
+,	O
+to	O
+date	O
+,	O
+little	O
+has	O
+been	O
+reported	O
+about	O
+the	O
+effects	O
+of	O
+this	O
+infection	B-DISO
+on	O
+the	O
+thyroid	B-ANAT
+gland	I-ANAT
+.	O
+
+This	O
+may	O
+provide	O
+an	O
+explanation	O
+both	O
+for	O
+low	O
+serum	B-COMP
+triiodothyronine	B-CHED
+and	O
+thyroxine	B-CHED
+levels	O
+and	O
+the	O
+osteonecrosis	B-DISO
+of	O
+the	O
+femoral	B-ANAT
+head	I-ANAT
+associated	O
+with	O
+patients	O
+with	O
+SARS	B-DISO
+.	O
+
+The	O
+SARS	B-PRGE
+-	I-PRGE
+CoV	I-PRGE
+nucleocapsid	B-COMP
+(	I-PRGE
+N	I-PRGE
+)	I-PRGE
+protein	B-CHED
+is	O
+an	O
+important	O
+structural	O
+and	O
+functional	O
+protein	B-CHED
+.	O
+
+To	O
+identify	O
+cellular	B-COMP
+proteins	B-CHED
+that	O
+interact	O
+with	O
+the	O
+SARS	B-PRGE
+-	I-PRGE
+CoV	I-PRGE
+N	I-PRGE
+protein	B-CHED
+and	O
+to	O
+elucidate	O
+the	O
+possible	O
+involvement	O
+of	O
+N	B-PRGE
+protein	I-PRGE
+in	O
+SARS	B-DISO
+-	O
+CoV	O
+pathogenesis	B-DISO
+,	O
+a	O
+human	B-SPEC
+lymphocyte	B-ANAT
+cDNA	O
+library	O
+was	O
+screened	O
+using	O
+a	O
+yeast	B-SPEC
+two	O
+-	O
+hybrid	O
+system	O
+assay	O
+.	O
+
+Mapping	O
+studies	O
+localized	O
+the	O
+critical	O
+N	O
+sequences	O
+for	O
+this	O
+interaction	O
+to	O
+amino	B-CHED
+acids	I-CHED
+170	O
+-	O
+210	O
+,	O
+which	O
+includes	O
+the	O
+SR	O
+-	O
+rich	O
+motif	O
+.	O
+
+TITLE	O
+:	O
+Comparison	O
+of	O
+multiplex	O
+PCR	O
+assays	O
+and	O
+conventional	O
+techniques	O
+for	O
+the	O
+diagnostic	O
+of	O
+respiratory	O
+virus	B-SPEC
+infections	B-DISO
+in	O
+children	O
+admitted	O
+to	O
+hospital	O
+with	O
+an	O
+acute	O
+respiratory	O
+illness	O
+.	O
+
+Our	O
+calculations	O
+demonstrated	O
+that	O
+the	O
+airflow	B-PROC
+contained	O
+the	O
+dispersion	O
+of	O
+infectious	B-DISO
+particles	O
+released	O
+from	O
+the	O
+patient	O
+sufficiently	O
+to	O
+protect	O
+the	O
+surgical	O
+team	O
+,	O
+and	O
+vice	O
+versa	O
+.	O
+
+TITLE	O
+:	O
+[	O
+Combating	O
+infectious	B-DISO
+disease	I-DISO
+using	O
+mathematical	O
+modelling	O
+].	O
+
+The	O
+integration	B-PROC
+of	O
+knowledge	O
+from	O
+various	O
+disciplines	O
+can	O
+be	O
+supported	O
+by	O
+more	O
+research	O
+into	O
+the	O
+theoretical	O
+epidemiology	O
+of	O
+infectious	B-DISO
+disease	I-DISO
+and	O
+by	O
+better	O
+integration	O
+of	O
+mathematical	O
+models	O
+into	O
+policy	O
+development	B-PROC
+.	O
+
+TITLE	O
+:	O
+Carboxyl	O
+terminus	O
+of	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+coronavirus	B-SPEC
+nucleocapsid	B-COMP
+protein	B-CHED
+:	O
+self	O
+-	O
+association	O
+analysis	O
+and	O
+nucleic	O
+acid	O
+binding	O
+characterization	O
+.	O
+
+The	O
+fact	O
+that	O
+nucleic	B-FUNC
+acid	I-FUNC
+binding	I-FUNC
+could	O
+promote	O
+the	O
+SARS	B-PRGE
+-	I-PRGE
+CoV	I-PRGE
+N	I-PRGE
+protein	B-CHED
+C	I-PRGE
+-	I-PRGE
+terminus	I-PRGE
+to	O
+form	O
+high	O
+-	O
+order	B-SPEC
+oligomers	O
+implies	O
+that	O
+the	O
+oligomeric	O
+SARS	B-DISO
+-	O
+CoV	O
+N	O
+protein	B-CHED
+probably	O
+combines	O
+with	O
+the	O
+viral	O
+genomic	O
+RNA	O
+in	O
+triggering	O
+long	O
+nucleocapsid	B-COMP
+formation	B-PROC
+.	O
+
+ABSTRACT	O
+:	O
+Severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+coronavirus	B-SPEC
+(	O
+SARS	B-DISO
+-	O
+CoV	O
+)	O
+has	O
+been	O
+detected	O
+in	O
+the	O
+blood	B-ANAT
+of	O
+infected	O
+individuals	O
+,	O
+which	O
+may	O
+have	O
+the	O
+potential	O
+to	O
+contaminate	O
+donated	O
+blood	B-ANAT
+and	O
+plasma	B-ANAT
+-	O
+derived	O
+products	O
+in	O
+the	O
+event	O
+of	O
+a	O
+future	O
+outbreak	O
+.	O
+
+S	O
+/	O
+D	O
+treatment	O
+required	O
+2	O
+,	O
+4	O
+,	O
+and	O
+up	O
+to	O
+24	O
+hours	O
+for	O
+Triton	B-CHED
+X	I-CHED
+-	I-CHED
+100	I-CHED
+,	O
+Tween	B-CHED
+80	I-CHED
+,	O
+and	O
+sodium	B-CHED
+cholate	I-CHED
+inactivation	B-DISO
+,	O
+respectively	O
+.	O
+
+Eight	O
+small	O
+group	O
+interviews	O
+were	O
+conducted	O
+with	O
+a	O
+total	O
+of	O
+twenty	O
+-	O
+one	O
+nurses	O
+with	O
+experience	O
+caring	O
+for	O
+SARS	B-DISO
+patients	O
+.	O
+
+In	O
+this	O
+study	O
+,	O
+the	O
+authors	O
+further	O
+addressed	O
+relationships	O
+between	O
+suffering	B-DISO
+and	O
+ethical	O
+practice	O
+,	O
+the	O
+calling	O
+and	O
+a	O
+nurse	O
+'	O
+s	O
+professional	O
+responsibilities	O
+,	O
+and	O
+transcendence	O
+in	O
+intersubjectivity	O
+.	O
+
+The	O
+alphaSIP	O
+molecule	O
+consisted	O
+of	O
+a	O
+single	O
+chain	O
+antibody	B-COMP
+(	O
+scFv	O
+)	O
+specific	O
+for	O
+the	O
+porcine	B-SPEC
+coronavirus	B-SPEC
+,	O
+transmissible	O
+gastroenteritis	B-DISO
+virus	B-SPEC
+(	O
+TGEV	B-SPEC
+)	O
+linked	O
+to	O
+the	O
+alpha	B-PRGE
+-	I-PRGE
+CH3	I-PRGE
+domain	I-PRGE
+from	O
+human	B-PRGE
+IgA	I-PRGE
+.	O
+To	O
+express	O
+the	O
+full	O
+-	O
+length	O
+IgA	B-PRGE
+,	O
+the	O
+individual	O
+light	O
+and	O
+heavy	O
+chains	O
+from	O
+the	O
+TGEV	B-SPEC
+-	O
+specific	O
+mAb	O
+6A	O
+.	O
+C3	O
+were	O
+inserted	O
+into	O
+separate	O
+PVX	B-SPEC
+constructs	O
+and	O
+plants	B-SPEC
+were	O
+co	O
+-	O
+infected	O
+with	O
+both	O
+constructs	O
+.	O
+
+ABSTRACT	O
+:	O
+The	O
+incidence	O
+of	O
+methicillin	B-DISO
+-	I-DISO
+resistant	I-DISO
+Staphylococcus	B-SPEC
+aureus	I-SPEC
+(	O
+MRSA	B-DISO
+)	O
+and	O
+vancomycin	B-CHED
+-	O
+resistant	O
+Enterococcus	B-SPEC
+(	O
+VRE	O
+)	O
+infections	B-DISO
+continues	O
+to	O
+rise	O
+in	O
+National	O
+Nosocomial	B-DISO
+Infections	I-DISO
+Surveillance	O
+system	O
+hospitals	O
+,	O
+and	O
+these	O
+pathogens	O
+are	O
+reportedly	O
+causing	O
+more	O
+than	O
+100	O
+,	O
+000	O
+infections	B-DISO
+and	O
+many	O
+deaths	B-PROC
+each	O
+year	O
+in	O
+US	O
+healthcare	O
+facilities	O
+.	O
+
+Studies	O
+suggesting	O
+problems	O
+with	O
+using	O
+such	O
+data	O
+to	O
+control	O
+MRSA	B-DISO
+colonization	O
+and	O
+infection	B-DISO
+have	O
+their	O
+own	O
+problems	O
+,	O
+which	O
+are	O
+discussed	O
+.	O
+
+In	O
+the	O
+event	O
+of	O
+an	O
+outbreak	O
+alert	O
+,	O
+the	O
+authorities	O
+must	O
+be	O
+able	O
+to	O
+quickly	O
+investigate	O
+cases	O
+/	O
+deaths	B-PROC
+and	O
+institute	O
+comprehensive	O
+control	O
+measures	O
+to	O
+break	O
+the	O
+chain	O
+of	O
+transmission	O
+.	O
+
+TITLE	O
+:	O
+Prognosis	O
+and	O
+risk	O
+factors	O
+of	O
+early	O
+onset	O
+pneumonia	B-DISO
+in	O
+ventilated	O
+patients	O
+with	O
+Guillain	O
+-	O
+Barré	O
+syndrome	O
+.	O
+
+Our	O
+objective	O
+was	O
+to	O
+determine	O
+the	O
+incidence	O
+,	O
+characteristics	O
+,	O
+outcomes	O
+,	O
+and	O
+risk	O
+factors	O
+of	O
+pneumonia	B-DISO
+in	O
+GBS	B-DISO
+patients	O
+receiving	O
+mechanical	O
+ventilation	O
+.	O
+
+Pneumonia	O
+developed	O
+in	O
+63	O
+patients	O
+(	O
+78	O
+%),	O
+including	O
+48	O
+with	O
+early	O
+-	O
+onset	O
+pneumonia	B-DISO
+.	O
+
+In	O
+the	O
+univariate	O
+analysis	O
+milder	O
+weakness	B-DISO
+,	O
+a	O
+lower	O
+risk	O
+of	O
+intubation	O
+(	O
+score	O
+<	O
+2	O
+),	O
+and	O
+time	O
+from	O
+admission	O
+to	O
+intubation	O
+longer	O
+than	O
+2	O
+days	O
+were	O
+associated	O
+with	O
+early	O
+-	O
+onset	O
+pneumonia	B-DISO
+.	O
+
+The	O
+spike	O
+(	O
+S	O
+)	O
+protein	B-CHED
+is	O
+one	O
+of	O
+the	O
+best	O
+characterized	O
+proteins	B-CHED
+of	O
+SARS	B-PRGE
+-	I-PRGE
+CoV	I-PRGE
+,	O
+which	O
+plays	O
+a	O
+key	O
+role	O
+in	O
+SARS	B-DISO
+-	O
+CoV	O
+overcoming	O
+species	B-SPEC
+barrier	O
+and	O
+accomplishing	O
+interspecies	O
+transmission	O
+from	O
+animals	B-SPEC
+to	O
+humans	B-SPEC
+,	O
+suggesting	O
+that	O
+it	O
+may	O
+be	O
+the	O
+major	O
+target	O
+of	O
+selective	O
+pressure	O
+.	O
+
+Moreover	O
+,	O
+it	O
+was	O
+showed	O
+that	O
+a	O
+larger	O
+proportion	O
+(	O
+24	O
+%)	O
+of	O
+positively	O
+selected	O
+sites	O
+was	O
+located	O
+in	O
+receptor	O
+-	O
+binding	B-FUNC
+domain	O
+(	O
+RBD	O
+)	O
+than	O
+in	O
+heptad	O
+repeat	O
+(	O
+HR	O
+)	O
+1	O
+-	O
+HR2	O
+region	O
+in	O
+02	O
+-	O
+04	O
+interspecies	O
+epidemic	O
+group	O
+(	O
+p	O
+=	O
+0	O
+.	O
+0208	O
+),	O
+and	O
+a	O
+greater	O
+percentage	O
+(	O
+25	O
+%)	O
+of	O
+these	O
+sites	O
+occurred	O
+in	O
+HR1	O
+-	O
+HR2	O
+region	O
+than	O
+in	O
+RBD	O
+in	O
+03	O
+-	O
+early	O
+-	O
+mid	O
+epidemic	O
+group	O
+(	O
+p	O
+=	O
+0	O
+.	O
+0721	O
+).	O
+
+The	O
+variation	O
+of	O
+positive	O
+selective	O
+pressures	O
+and	O
+positively	O
+selected	O
+sites	O
+are	O
+likely	O
+to	O
+contribute	O
+to	O
+the	O
+adaptive	O
+evolution	B-PROC
+of	O
+S	B-PRGE
+protein	I-PRGE
+from	O
+animals	B-SPEC
+to	O
+humans	B-SPEC
+.	O
+
+The	O
+results	O
+indicate	O
+that	O
+MMV	B-SPEC
+but	O
+not	O
+MHV	B-SPEC
+can	O
+be	O
+transmitted	B-DISO
+to	O
+recipients	O
+even	O
+after	O
+washing	O
+embryos	B-ANAT
+10	O
+times	O
+before	O
+embryo	B-ANAT
+transfer	O
+.	O
+
+A	O
+parallel	O
+between	O
+the	O
+nsp8	O
+RdRp	O
+and	O
+cellular	B-COMP
+DNA	O
+-	O
+dependent	O
+RNA	O
+primases	O
+is	O
+drawn	O
+to	O
+propose	O
+that	O
+the	O
+nsp8	O
+RdRp	B-FUNC
+produces	O
+primers	O
+utilized	O
+by	O
+the	O
+primer	O
+-	O
+dependent	O
+nsp12	O
+RdRp	B-FUNC
+.	O
+
+Our	O
+clinical	O
+evidence	O
+obtained	O
+with	O
+the	O
+aid	O
+of	O
+polymerase	O
+chain	O
+reaction	O
+featured	O
+genomes	O
+of	O
+adenoviruses	B-SPEC
+,	O
+influenza	B-PATH
+A	I-PATH
+and	O
+B	O
+viruses	B-SPEC
+,	O
+respiratory	O
+-	O
+scintillating	O
+virus	B-SPEC
+and	O
+coronaviruses	O
+.	O
+
+Similarly	O
+,	O
+the	O
+important	O
+cause	O
+of	O
+mortality	O
+in	O
+2001	O
+was	O
+multiple	B-DISO
+organ	I-DISO
+dysfunction	I-DISO
+syndrome	I-DISO
+(	O
+71	O
+.	O
+10	O
+%)	O
+with	O
+predominant	O
+presentation	O
+of	O
+jaundice	B-DISO
+and	O
+renal	B-DISO
+failure	I-DISO
+,	O
+whereas	O
+in	O
+1994	O
+,	O
+it	O
+was	O
+cerebral	B-DISO
+malaria	B-PATH
+(	O
+77	O
+.	O
+96	O
+%).	O
+
+TITLE	O
+:	O
+Adverse	O
+skin	B-ANAT
+reactions	O
+to	O
+personal	O
+protective	O
+equipment	O
+against	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+--	O
+a	O
+descriptive	O
+study	O
+in	O
+Singapore	O
+.	O
+
+64	O
+(	O
+21	O
+.	O
+4	O
+%)	O
+of	O
+the	O
+299	O
+who	O
+used	O
+gloves	O
+regularly	O
+reported	O
+dry	B-DISO
+skin	I-DISO
+(	O
+73	O
+.	O
+4	O
+%),	O
+itch	B-DISO
+(	O
+56	O
+.	O
+3	O
+%),	O
+and	O
+rash	B-DISO
+(	O
+37	O
+.	O
+5	O
+%).	O
+
+TITLE	O
+:	O
+Real	O
+-	O
+time	O
+RT	O
+-	O
+PCR	O
+detection	O
+of	O
+Bovine	B-DISO
+Viral	I-DISO
+Diarrhoea	I-DISO
+virus	B-SPEC
+in	O
+whole	B-ANAT
+blood	I-ANAT
+using	O
+an	O
+external	O
+RNA	O
+reference	O
+.	O
+
+During	O
+infection	B-DISO
+animals	B-SPEC
+experience	O
+a	O
+characteristic	O
+transient	O
+leucopenia	B-DISO
+and	O
+the	O
+number	O
+of	O
+cells	B-COMP
+per	O
+volume	O
+of	O
+blood	B-ANAT
+changes	O
+over	O
+time	O
+;	O
+so	O
+quantitation	O
+of	O
+viral	O
+load	O
+by	O
+reference	O
+to	O
+a	O
+cellular	B-COMP
+housekeeping	O
+gene	O
+is	O
+not	O
+ideal	O
+as	O
+this	O
+may	O
+hide	B-ANAT
+significant	O
+animal	B-SPEC
+to	O
+animal	B-SPEC
+variation	O
+.	O
+
+This	O
+study	O
+demonstrates	O
+encouraging	O
+results	O
+for	O
+rapid	O
+,	O
+sensitive	O
+and	O
+reliable	O
+detection	O
+of	O
+acute	O
+BVDV	B-SPEC
+infection	B-DISO
+and	O
+provides	O
+an	O
+alternative	O
+real	O
+-	O
+time	O
+RT	O
+-	O
+PCR	O
+method	O
+for	O
+use	O
+on	O
+whole	O
+blood	B-ANAT
+samples	I-ANAT
+or	O
+samples	O
+where	O
+suitable	O
+housekeeping	O
+genes	O
+are	O
+not	O
+available	O
+.	O
+
+In	O
+this	O
+study	O
+,	O
+complete	O
+genome	O
+sequences	O
+of	O
+two	O
+additional	O
+group	O
+2b	O
+coronaviruses	O
+(	O
+G2b	O
+-	O
+CoVs	O
+)	O
+were	O
+determined	O
+from	O
+horseshoe	B-PRGE
+bat	I-PRGE
+Rhinolophus	B-SPEC
+ferrumequinum	I-SPEC
+(	O
+G2b	B-PRGE
+-	I-PRGE
+CoV	I-PRGE
+Rf1	I-PRGE
+)	O
+and	O
+Rhinolophus	B-SPEC
+macrotis	I-SPEC
+(	O
+G2b	B-PRGE
+-	I-PRGE
+CoV	I-PRGE
+Rm1	I-PRGE
+).	O
+
+Genetic	O
+analysis	O
+demonstrated	O
+that	O
+a	O
+diverse	O
+G2b	O
+-	O
+CoV	O
+population	O
+exists	O
+in	O
+the	O
+bat	O
+habitat	O
+and	O
+has	O
+evolved	O
+from	O
+a	O
+common	O
+ancestor	O
+of	O
+SARS	B-PRGE
+-	I-PRGE
+CoV	I-PRGE
+.	O
+
+TITLE	O
+:	O
+Genotypes	O
+and	O
+subtypes	O
+of	O
+Cryptosporidium	B-SPEC
+spp	B-ENZY
+.	O
+
+Sequence	O
+analysis	O
+of	O
+the	O
+60	B-PRGE
+-	I-PRGE
+kDa	I-PRGE
+glycoprotein	I-PRGE
+gene	I-PRGE
+identified	O
+16	O
+IIa	O
+subtypes	O
+and	O
+a	O
+new	O
+subtype	O
+family	B-SPEC
+,	O
+with	O
+120	O
+of	O
+the	O
+216	O
+(	O
+55	O
+.	O
+6	O
+%)	O
+positive	O
+specimens	O
+having	O
+the	O
+subtype	O
+IIaA18G3R1	O
+.	O
+
+TITLE	O
+:	O
+Expression	B-PROC
+of	O
+elevated	O
+levels	O
+of	O
+pro	B-CHED
+-	O
+inflammatory	O
+cytokines	O
+in	O
+SARS	B-DISO
+-	O
+CoV	O
+-	O
+infected	O
+ACE2	O
++	O
+cells	B-COMP
+in	O
+SARS	O
+patients	O
+:	O
+relation	O
+to	O
+the	O
+acute	O
+lung	B-ANAT
+injury	O
+and	O
+pathogenesis	B-DISO
+of	O
+SARS	B-DISO
+.	O
+
+SARS	B-PRGE
+-	I-PRGE
+CoV	I-PRGE
+S	I-PRGE
+protein	B-CHED
+and	O
+its	O
+RNA	O
+were	O
+only	O
+detected	O
+in	O
+ACE2	O
++	O
+cells	B-COMP
+in	O
+the	O
+lungs	B-ANAT
+and	O
+other	O
+organs	B-ANAT
+,	O
+indicating	O
+that	O
+ACE2	B-PRGE
+-	O
+expressing	O
+cells	B-COMP
+are	O
+the	O
+primary	O
+targets	O
+for	O
+SARS	O
+-	O
+CoV	O
+infection	O
+in	O
+vivo	O
+in	O
+humans	B-SPEC
+.	O
+
+Oxygenation	B-PROC
+,	O
+ventilation	O
+,	O
+and	O
+hemodynamic	B-PROC
+parameters	O
+were	O
+measured	O
+during	O
+conventional	O
+ventilation	O
+before	O
+initiating	O
+HFOV	O
+and	O
+during	O
+HFOV	O
+support	O
+for	O
+a	O
+total	O
+of	O
+40	O
+hours	O
+.	O
+
+The	O
+successful	O
+weaning	B-PROC
+rate	O
+from	O
+HFOV	O
+to	O
+conventional	O
+ventilation	O
+was	O
+75	O
+%.	O
+
+Uremic	O
+mice	B-SPEC
+,	O
+by	O
+contrast	O
+,	O
+showed	O
+a	O
+significant	O
+protection	O
+from	O
+ALI	O
+(	O
+decrease	O
+in	O
+arterial	O
+partial	O
+pressure	O
+of	O
+O	O
+(	O
+2	O
+)	O
+<	O
+40	O
+%);	O
+this	O
+was	O
+independent	O
+of	O
+the	O
+type	O
+of	O
+AU	O
+.	O
+
+TITLE	O
+:	O
+[	O
+Identification	O
+of	O
+mimotope	B-CHED
+peptides	B-CHED
+which	O
+bind	B-FUNC
+to	O
+the	O
+SARS	B-DISO
+-	I-PRGE
+CoV	I-PRGE
+spike	I-PRGE
+protein	B-CHED
+specific	I-PRGE
+monoclonal	I-PRGE
+antibody	I-PRGE
+2C5	I-PRGE
+with	O
+phage	O
+-	O
+displayed	O
+peptides	B-CHED
+library	O
+].	O
+
+ABSTRACT	O
+:	O
+The	O
+results	O
+presented	O
+here	O
+demonstrate	O
+that	O
+the	O
+MHV	B-SPEC
+and	O
+SARS	B-PRGE
+-	I-PRGE
+CoV	I-PRGE
+nsp2	I-PRGE
+proteins	B-CHED
+are	O
+not	O
+required	O
+for	O
+the	O
+production	O
+of	O
+infectious	B-DISO
+virus	B-SPEC
+,	O
+for	O
+polyprotein	O
+expression	B-PROC
+or	O
+processing	O
+,	O
+or	O
+for	O
+viral	B-COMP
+replication	I-COMP
+complex	I-COMP
+formation	B-PROC
+in	O
+cell	B-COMP
+culture	O
+.	O
+
+Such	O
+may	O
+prove	O
+to	O
+be	O
+the	O
+case	O
+for	O
+nsp2	B-PRGE
+,	O
+as	O
+well	O
+.	O
+
+Mice	B-SPEC
+vaccinated	O
+with	O
+SARS	B-DISO
+CoV	O
+(	O
+N	O
+)	O
+DNA	O
+or	O
+(	O
+M	O
+)	O
+DNA	O
+using	O
+pcDNA	O
+3	O
+.	O
+1	O
+(+)	O
+plasmid	O
+vector	O
+showed	O
+T	B-ANAT
+-	I-ANAT
+cell	I-ANAT
+immune	B-PROC
+responses	I-PROC
+(	O
+CTL	B-ANAT
+induction	O
+and	O
+proliferation	B-DISO
+)	O
+against	O
+type	O
+II	O
+alveolar	B-ANAT
+epithelial	B-ANAT
+cells	I-ANAT
+(	O
+T7	O
+)	O
+transfected	O
+with	O
+SARS	B-DISO
+(	O
+N	O
+)	O
+or	O
+(	O
+M	O
+)	O
+DNA	O
+,	O
+respectively	O
+.	O
+
+into	O
+IL	B-PRGE
+-	I-PRGE
+2	I-PRGE
+receptor	I-PRGE
+gamma	I-PRGE
+-	I-PRGE
+chain	I-PRGE
+-	O
+disrupted	O
+NOD	B-DISO
+-	O
+SCID	B-DISO
+mice	B-SPEC
+[	O
+IL	B-FUNC
+-	I-FUNC
+2R	I-FUNC
+(-/-)	O
+NOD	B-DISO
+-	O
+SCID	B-DISO
+].	O
+
+SCID	B-DISO
+-	O
+PBL	B-PRGE
+/	O
+hu	O
+mice	B-SPEC
+thus	O
+constructed	O
+can	O
+be	O
+used	O
+to	O
+analyze	O
+the	O
+human	B-SPEC
+immune	B-PROC
+response	I-PROC
+in	O
+vivo	O
+.	O
+
+These	O
+vaccines	O
+are	O
+expected	O
+to	O
+induce	O
+immune	B-PROC
+responses	I-PROC
+specific	O
+for	O
+SARS	B-PRGE
+CoV	I-PRGE
+in	O
+human	B-SPEC
+and	O
+should	O
+provide	O
+useful	O
+tool	O
+for	O
+development	B-PROC
+of	O
+protective	O
+vaccines	O
+.	O
+
+ABSTRACT	O
+:	O
+An	O
+efficient	O
+strategy	O
+for	O
+immobilizing	O
+proteins	O
+on	O
+a	O
+gold	B-CHED
+surface	O
+was	O
+developed	O
+by	O
+employing	O
+the	O
+gold	B-CHED
+binding	B-FUNC
+polypeptide	B-CHED
+(	O
+GBP	O
+)	O
+as	O
+a	O
+fusion	O
+partner	O
+.	O
+
+They	O
+can	O
+cause	O
+respiratory	O
+,	O
+enteric	O
+,	O
+and	O
+in	O
+some	O
+cases	O
+hepatic	B-ANAT
+and	O
+neurological	O
+diseases	O
+in	O
+a	O
+wide	O
+variety	O
+of	O
+animals	B-SPEC
+and	O
+humans	B-SPEC
+.	O
+
+Although	O
+a	O
+SARS	B-DISO
+-	O
+like	O
+coronavirus	B-SPEC
+isolated	O
+from	O
+a	O
+bat	B-ENZY
+is	O
+thought	O
+to	O
+be	O
+the	O
+progenitor	O
+of	O
+SARS	B-PRGE
+-	I-PRGE
+CoV	I-PRGE
+,	O
+a	O
+lack	O
+of	O
+genomic	O
+sequences	O
+for	O
+the	O
+animal	B-SPEC
+coronaviruses	O
+has	O
+prevented	O
+elucidation	O
+of	O
+the	O
+true	O
+origin	O
+of	O
+SARS	B-DISO
+-	O
+CoV	O
+.	O
+Sequence	O
+analysis	O
+of	O
+SARS	B-PRGE
+-	I-PRGE
+CoV	I-PRGE
+shows	O
+that	O
+the	O
+5	B-PRGE
+'	I-PRGE
+polymerase	I-PRGE
+gene	I-PRGE
+has	O
+a	O
+mammalian	B-SPEC
+ancestry	O
+;	O
+whereas	O
+the	O
+3	O
+'	O
+end	O
+structural	O
+genes	O
+(	O
+excluding	O
+the	O
+spike	O
+glycoprotein	B-CHED
+)	O
+have	O
+an	O
+avian	B-SPEC
+origin	O
+.	O
+
+An	O
+enhancement	O
+assay	O
+using	O
+the	O
+HKU39849	B-PRGE
+SARS	I-PRGE
+-	I-PRGE
+CoV	I-PRGE
+strain	O
+and	O
+human	B-SPEC
+immature	O
+dendritic	B-COMP
+cells	B-COMP
+confirmed	O
+our	O
+observation	O
+.	O
+
+Results	O
+from	O
+a	O
+capture	O
+assay	O
+testing	O
+three	O
+pseudotyped	O
+viruses	B-SPEC
+with	O
+mutated	O
+N	O
+-	O
+linked	O
+glycosylation	B-PROC
+sites	O
+of	O
+the	O
+S	B-PRGE
+protein	I-PRGE
+indicate	O
+that	O
+only	O
+two	O
+pseudotyped	O
+viruses	B-SPEC
+(	O
+N330Q	O
+and	O
+N357Q	O
+,	O
+both	O
+of	O
+which	O
+lost	B-CHED
+glycosylation	B-PROC
+sites	O
+near	O
+the	O
+SIa5	O
+epitope	B-CHED
+)	O
+had	O
+diminished	O
+DC	O
+-	O
+SIGN	O
+-	O
+binding	B-FUNC
+capacity	O
+.	O
+
+Infected	O
+A	O
+/	O
+J	O
+mice	B-SPEC
+had	O
+significantly	O
+higher	O
+cytokine	O
+levels	O
+,	O
+particularly	O
+macrophage	B-PRGE
+chemoattractant	I-PRGE
+protein	B-CHED
+1	I-PRGE
+(	O
+MCP	B-PRGE
+-	I-PRGE
+1	I-PRGE
+/	O
+CCL	B-PRGE
+-	I-PRGE
+2	I-PRGE
+),	O
+gamma	B-PRGE
+interferon	I-PRGE
+,	O
+and	O
+tumor	B-PRGE
+necrosis	I-PRGE
+factor	I-PRGE
+alpha	I-PRGE
+.	O
+
+ABSTRACT	O
+:	O
+Amongst	O
+the	O
+60	O
+viral	O
+species	O
+reported	O
+to	O
+be	O
+associated	O
+with	O
+bats	B-SPEC
+,	O
+59	O
+are	O
+RNA	O
+viruses	B-SPEC
+,	O
+which	O
+are	O
+potentially	O
+important	O
+in	O
+the	O
+generation	O
+of	O
+emerging	O
+and	O
+re	O
+-	O
+emerging	O
+infections	B-DISO
+in	O
+humans	B-SPEC
+.	O
+
+The	O
+prime	O
+examples	O
+of	O
+these	O
+are	O
+the	O
+lyssaviruses	B-SPEC
+and	O
+Henipavirus	B-SPEC
+.	O
+
+A	O
+systematic	O
+survey	O
+of	O
+bats	B-SPEC
+is	O
+warranted	O
+to	O
+better	O
+understand	O
+the	O
+ecology	O
+of	O
+these	O
+viruses	B-SPEC
+.	O
+
+RESULTS	O
+:	O
+Oxygenation	B-PROC
+and	O
+lung	B-PROC
+compliance	I-PROC
+improved	O
+rapidly	O
+and	O
+aeration	O
+of	O
+the	O
+entire	B-ANAT
+lung	I-ANAT
+was	O
+confirmed	O
+by	O
+computed	O
+tomography	O
+27	O
+h	O
+after	O
+the	O
+recruitment	B-DISO
+manoeuvre	O
+.	O
+
+ABSTRACT	O
+:	O
+We	O
+investigated	O
+health	O
+-	O
+related	O
+quality	O
+of	O
+life	O
+(	O
+HRQoL	O
+)	O
+and	O
+persistent	O
+symptoms	O
+of	O
+post	B-DISO
+-	I-DISO
+traumatic	I-DISO
+stress	I-DISO
+disorder	I-DISO
+(	O
+PTSD	B-DISO
+)	O
+in	O
+long	O
+-	O
+term	O
+survivors	O
+of	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+(	O
+ARDS	B-DISO
+).	O
+
+This	O
+was	O
+independent	O
+of	O
+physical	O
+condition	B-DISO
+and	O
+was	O
+associated	O
+with	O
+traumatic	O
+memories	O
+of	O
+anxiety	O
+during	O
+their	O
+ICU	O
+stay	O
+.	O
+
+Thus	O
+,	O
+three	O
+variant	O
+IBVs	O
+of	O
+novel	O
+Italy	O
+-	O
+02	O
+genotype	O
+,	O
+which	O
+had	O
+96	O
+.	O
+7	O
+-	O
+99	O
+.	O
+2	O
+%	O
+S1	O
+gene	O
+nucleotide	B-CHED
+identity	O
+with	O
+each	O
+other	O
+,	O
+belonged	O
+to	O
+three	O
+separate	O
+subgroups	O
+based	O
+on	O
+N	O
+gene	O
+sequences	O
+.	O
+
+624	O
+/	O
+I	O
+-	O
+type	O
+isolate	O
+Italy	O
+-	O
+06	O
+together	O
+with	O
+Italy	O
+-	O
+03	O
+,	O
+which	O
+was	O
+undetectable	O
+using	O
+S1	B-PRGE
+gene	I-PRGE
+primers	O
+,	O
+shared	O
+97	O
+.	O
+7	O
+%	O
+and	O
+99	O
+.	O
+3	O
+%	O
+identity	O
+,	O
+respectively	O
+,	O
+in	O
+N	B-PRGE
+gene	I-PRGE
+region	O
+with	O
+vaccine	O
+strain	O
+H120	O
+.	O
+
+In	O
+this	O
+study	O
+,	O
+we	O
+showed	O
+that	O
+lymphopenia	B-DISO
+observed	O
+in	O
+FIP	B-DISO
+cats	B-SPEC
+was	O
+due	O
+to	O
+apoptosis	B-PATH
+,	O
+and	O
+that	O
+the	O
+ascitic	B-ANAT
+fluid	I-ANAT
+,	O
+plasma	B-ANAT
+,	O
+and	O
+culture	O
+supernatant	O
+of	O
+peritoneal	B-ANAT
+exudate	B-ANAT
+cells	B-COMP
+(	O
+adherent	O
+cells	B-COMP
+with	O
+macrophage	B-ANAT
+morphology	O
+,	O
+or	O
+PEC	O
+)	O
+from	O
+FIP	B-DISO
+cats	B-SPEC
+readily	O
+induced	O
+apoptosis	B-PATH
+in	O
+specific	O
+pathogen	O
+-	O
+free	O
+cat	B-SPEC
+peripheral	B-ANAT
+blood	I-ANAT
+mononuclear	I-ANAT
+cells	I-ANAT
+,	O
+particularly	O
+CD8	B-PRGE
++	I-PRGE
+cells	B-COMP
+.	O
+
+In	O
+particular	O
+,	O
+in	O
+CD8	B-PRGE
++	I-PRGE
+cells	B-ANAT
+cultured	I-ANAT
+in	O
+the	O
+presence	O
+of	O
+the	O
+PEC	O
+culture	O
+supernatant	O
+,	O
+the	O
+expression	B-PROC
+levels	O
+of	O
+TNFR1	B-PRGE
+and	O
+TNFR2	B-PRGE
+mRNA	I-PRGE
+were	O
+increased	O
+,	O
+indicating	O
+that	O
+CD8	O
++	O
+cells	B-COMP
+are	O
+more	O
+susceptible	O
+to	O
+apoptosis	B-PROC
+induction	I-PROC
+by	O
+TNF	B-PRGE
+-	I-PRGE
+alpha	I-PRGE
+than	O
+other	O
+lymphocyte	B-ANAT
+subsets	O
+,	O
+particularly	O
+B	B-ANAT
+cells	I-ANAT
+(	O
+CD21	O
++	O
+cells	B-COMP
+).	O
+
+ABSTRACT	O
+:	O
+The	O
+3C	B-PRGE
+-	I-PRGE
+like	I-PRGE
+protease	I-PRGE
+(	O
+3CL	O
+(	O
+pro	B-CHED
+))	O
+of	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+-	O
+associated	O
+coronavirus	B-SPEC
+(	O
+SARS	B-DISO
+-	O
+CoV	O
+)	O
+is	O
+one	O
+of	O
+the	O
+most	O
+promising	O
+targets	O
+for	O
+discovery	O
+of	O
+drugs	O
+against	O
+SARS	B-DISO
+,	O
+because	O
+of	O
+its	O
+critical	O
+role	O
+in	O
+the	O
+viral	B-PROC
+life	I-PROC
+cycle	I-PROC
+.	O
+
+With	O
+the	O
+help	O
+of	O
+molecular	O
+modeling	O
+,	O
+eight	O
+new	O
+derivatives	O
+of	O
+the	O
+natural	B-CHED
+product	I-CHED
+were	O
+designed	O
+and	O
+synthesized	O
+.	O
+
+We	O
+assess	O
+if	O
+any	O
+epidemiological	O
+or	O
+clinical	O
+factors	O
+in	O
+SARS	B-DISO
+index	O
+patients	O
+were	O
+associated	O
+with	O
+increased	O
+probability	O
+of	O
+transmission	O
+.	O
+
+Serum	B-COMP
+IgG	B-PRGE
+blocked	O
+binding	B-FUNC
+of	O
+the	O
+S	B-PRGE
+-	I-PRGE
+protein	I-PRGE
+to	O
+the	O
+ACE2	B-PRGE
+receptor	I-PRGE
+and	O
+neutralized	O
+SARS	B-DISO
+-	I-DISO
+CoV	I-DISO
+infection	I-DISO
+in	O
+vitro	O
+.	O
+
+TITLE	O
+:	O
+Temporal	O
+changes	O
+in	O
+cytokine	O
+/	O
+chemokine	O
+profiles	O
+and	O
+pulmonary	B-DISO
+involvement	I-DISO
+in	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+.	O
+
+The	O
+serum	B-COMP
+levels	O
+of	O
+interferon	B-FUNC
+-	I-FUNC
+gamma	I-FUNC
+-	O
+inducible	O
+protein	B-CHED
+-	O
+10	O
+(	O
+IP	O
+-	O
+10	O
+),	O
+IL	B-FUNC
+-	I-FUNC
+2	I-FUNC
+and	O
+IL	B-FUNC
+-	I-FUNC
+6	I-FUNC
+were	O
+significantly	O
+elevated	O
+during	O
+SARS	B-DISO
+infection	B-DISO
+.	O
+
+Among	O
+the	O
+chemokines	O
+/	O
+cytokines	O
+,	O
+IL	B-FUNC
+-	I-FUNC
+6	I-FUNC
+levels	O
+correlated	O
+most	O
+strongly	O
+with	O
+radiographic	O
+scores	O
+(	O
+r	O
+=	O
+0	O
+.	O
+62	O
+).	O
+
+RESULTS	O
+:	O
+The	O
+serum	B-COMP
+levels	O
+of	O
+interferon	B-FUNC
+-	I-FUNC
+gamma	I-FUNC
+-	O
+inducible	O
+protein	B-CHED
+-	O
+10	O
+(	O
+IP	O
+-	O
+10	O
+),	O
+IL	B-FUNC
+-	I-FUNC
+2	I-FUNC
+and	O
+IL	B-FUNC
+-	I-FUNC
+6	I-FUNC
+were	O
+significantly	O
+elevated	O
+during	O
+SARS	B-DISO
+infection	B-DISO
+.	O
+
+ABSTRACT	O
+:	O
+The	O
+emergency	B-DISO
+department	O
+(	O
+ED	O
+)	O
+is	O
+an	O
+essential	O
+component	O
+of	O
+the	O
+public	O
+health	O
+response	O
+plan	O
+for	O
+control	O
+of	O
+acute	O
+respiratory	O
+infectious	B-DISO
+threats	O
+.	O
+
+N	B-PRGE
+protein	I-PRGE
+underwent	O
+a	O
+conformational	B-PROC
+change	I-PROC
+upon	O
+binding	B-FUNC
+viral	O
+RNA	O
+and	O
+the	O
+data	O
+indicated	O
+electrostatic	O
+interactions	O
+were	O
+involved	O
+in	O
+the	O
+binding	B-FUNC
+of	O
+the	O
+protein	B-CHED
+to	O
+RNA	O
+.	O
+
+The	O
+aim	O
+of	O
+this	O
+study	O
+was	O
+to	O
+explore	O
+the	O
+impact	O
+of	O
+the	O
+severe	O
+acute	O
+respiratory	O
+syndrome	O
+(	O
+SARS	B-DISO
+)	O
+on	O
+health	O
+care	O
+workers	O
+in	O
+Taiwan	O
+.	O
+
+All	O
+participants	O
+completed	O
+questionnaires	O
+,	O
+including	O
+the	O
+Chinese	O
+Health	O
+Questionnaire	O
+,	O
+Eysenck	O
+Personality	B-DISO
+Questionnaire	O
+and	O
+Parental	O
+Bonding	O
+Instrument	O
+.	O
+
+The	O
+structural	O
+equation	O
+model	O
+showed	O
+that	O
+maternal	O
+care	O
+(	O
+beta	O
+=	O
+-	O
+0	O
+.	O
+18	O
+,	O
+p	O
+=	O
+0	O
+.	O
+011	O
+)	O
+and	O
+neuroticism	B-DISO
+(	O
+beta	O
+=	O
+0	O
+.	O
+54	O
+,	O
+p	O
+<	O
+10	O
+(-	O
+6	O
+))	O
+directly	O
+influenced	O
+the	O
+ability	O
+of	O
+health	O
+care	O
+workers	O
+to	O
+deal	O
+with	O
+the	O
+impact	O
+of	O
+SARS	B-DISO
+.	O
+
+TITLE	O
+:	O
+Societal	O
+responses	O
+to	O
+familiar	O
+versus	O
+unfamiliar	O
+risk	O
+:	O
+comparisons	O
+of	O
+influenza	B-DISO
+and	O
+SARS	B-DISO
+in	O
+Korea	O
+.	O
+
+This	O
+belief	O
+undoubtedly	O
+was	O
+influenced	O
+by	O
+a	O
+reframing	O
+of	O
+influenza	B-DISO
+vaccination	O
+as	O
+preventing	O
+SARS	B-DISO
+.	O
+
+Nine	O
+of	O
+10	O
+epidemiological	O
+studies	O
+reviewed	O
+showed	O
+that	O
+handwashing	O
+was	O
+protective	O
+against	O
+SARS	B-DISO
+when	O
+comparing	O
+infected	O
+cases	O
+and	O
+non	O
+-	O
+infected	O
+controls	O
+in	O
+univariate	O
+analysis	O
+,	O
+but	O
+only	O
+in	O
+three	O
+studies	O
+was	O
+this	O
+result	O
+statistically	O
+significant	O
+in	O
+multivariate	O
+analysis	O
+.	O
+
+Phylogenetic	O
+analysis	O
+revealed	O
+that	O
+HCoV	B-SPEC
+-	I-SPEC
+NL63	I-SPEC
+genomes	O
+have	O
+a	O
+mosaic	O
+structure	O
+with	O
+multiple	O
+recombination	B-PROC
+sites	O
+.	O
+
+ABSTRACT	O
+:	O
+Antibodies	B-COMP
+to	O
+SARS	B-DISO
+-	O
+Coronavirus	B-SPEC
+(	O
+SARS	B-DISO
+-	O
+CoV	O
+)-	O
+specific	O
+B	B-ANAT
+cell	I-ANAT
+epitopes	O
+might	O
+recognize	O
+the	O
+pathogen	O
+and	O
+interrupt	O
+its	O
+adherence	O
+to	O
+and	O
+penetration	O
+of	O
+host	B-COMP
+cells	B-COMP
+.	O
+
+Using	O
+the	O
+phage	O
+-	O
+displayed	O
+peptide	B-CHED
+library	O
+screening	O
+method	O
+and	O
+purified	O
+Fab	B-PRGE
+fragments	O
+of	O
+immunoglobulin	B-PRGE
+G	I-PRGE
+(	O
+IgG	B-PRGE
+Fab	I-PRGE
+)	O
+from	O
+normal	O
+human	B-SPEC
+sera	B-COMP
+and	O
+convalescent	O
+sera	B-COMP
+from	O
+SARS	B-DISO
+-	O
+CoV	O
+-	O
+infected	O
+patients	O
+as	O
+targets	O
+,	O
+11	O
+B	B-ANAT
+cell	I-ANAT
+epitopes	O
+of	O
+SARS	B-DISO
+-	O
+CoV	O
+spike	B-PRGE
+glycoprotein	I-PRGE
+(	O
+S	B-PRGE
+protein	I-PRGE
+)	O
+and	O
+membrane	B-PRGE
+protein	B-CHED
+(	O
+M	B-PRGE
+protein	I-PRGE
+)	O
+were	O
+screened	O
+.	O
+
+ABSTRACT	O
+:	O
+As	O
+the	O
+worry	O
+and	O
+pandemic	O
+about	O
+deadest	O
+virus	B-SPEC
+such	O
+as	O
+AIDS	O
+and	O
+bird	B-DISO
+flu	I-DISO
+are	O
+intensified	O
+,	O
+eradical	O
+treatments	O
+for	O
+these	O
+virus	B-SPEC
+-	O
+infected	O
+diseases	O
+are	O
+in	O
+high	O
+demand	O
+.	O
+
+This	O
+might	O
+help	O
+us	O
+to	O
+know	O
+greatly	O
+more	O
+about	O
+the	O
+consequences	O
+of	O
+virus	B-DISO
+infection	I-DISO
+and	O
+achieve	O
+biotherapy	O
+of	O
+specifically	O
+targeted	B-PROC
+in	O
+future	O
+.	O
+
+We	O
+used	O
+laboratory	O
+verified	O
+SARS	B-DISO
+case	O
+data	O
+and	O
+the	O
+detailed	O
+quarantine	O
+data	O
+in	O
+Taiwan	O
+,	O
+where	O
+over	O
+150	O
+,	O
+000	O
+people	O
+were	O
+quarantined	O
+during	O
+the	O
+2003	O
+outbreak	O
+,	O
+to	O
+formulate	O
+a	O
+mathematical	O
+model	O
+which	O
+incorporates	O
+Level	O
+A	O
+quarantine	O
+(	O
+of	O
+potentially	O
+exposed	O
+contacts	O
+of	O
+suspected	O
+SARS	B-DISO
+patients	O
+)	O
+and	O
+Level	O
+B	O
+quarantine	O
+(	O
+of	O
+travelers	O
+arriving	O
+at	O
+borders	O
+from	O
+SARS	B-DISO
+affected	O
+areas	O
+)	O
+implemented	O
+in	O
+Taiwan	O
+during	O
+the	O
+outbreak	O
+.	O
+
+We	O
+have	O
+previously	O
+demonstrated	O
+that	O
+fragment	O
+450	O
+-	O
+650	O
+of	O
+the	O
+S	B-PRGE
+protein	I-PRGE
+(	O
+S450	O
+-	O
+650	O
+)	O
+is	O
+predominantly	O
+recognized	O
+by	O
+convalescent	O
+sera	B-COMP
+of	O
+SARS	B-DISO
+patients	O
+.	O
+
+TITLE	O
+:	O
+SARS	B-DISO
+/	O
+avian	B-SPEC
+coronaviruses	O
+.	O
+
+ABSTRACT	O
+:	O
+In	O
+the	O
+hunt	O
+for	O
+the	O
+aetiology	O
+of	O
+the	O
+SARS	B-DISO
+outbreak	O
+in	O
+2003	O
+,	O
+a	O
+newly	O
+developed	O
+virus	O
+DNA	O
+micro	O
+-	O
+array	O
+was	O
+successfully	O
+used	O
+to	O
+hybridise	O
+PCR	O
+products	O
+obtained	O
+by	O
+random	O
+amplification	B-DISO
+of	O
+nucleic	B-CHED
+acids	I-CHED
+extracted	O
+from	O
+a	O
+cell	B-COMP
+culture	O
+infected	O
+with	O
+material	O
+from	O
+a	O
+SARS	B-DISO
+patient	O
+.	O
+
+Coincident	O
+with	O
+this	O
+publication	O
+came	O
+increasing	O
+reports	O
+of	O
+severe	O
+atypical	B-DISO
+pneumonia	I-DISO
+of	O
+unknown	O
+etiology	O
+among	O
+persons	O
+in	O
+southeast	O
+Asia	O
+.	O
+
+TITLE	O
+:	O
+Evaluation	O
+of	O
+a	O
+novel	O
+vesicular	B-SPEC
+stomatitis	I-SPEC
+virus	I-SPEC
+pseudotype	O
+-	O
+based	O
+assay	O
+for	O
+detection	O
+of	O
+neutralizing	O
+antibody	O
+responses	O
+to	O
+SARS	B-PRGE
+-	I-PRGE
+CoV	I-PRGE
+.	O
+ABSTRACT	O
+:	O
+Severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+(	O
+SARS	B-DISO
+)-	O
+coronavirus	B-SPEC
+(	O
+SARS	B-DISO
+-	O
+CoV	O
+)	O
+is	O
+the	O
+causative	O
+agent	O
+of	O
+SARS	B-DISO
+.	O
+
+Real	O
+-	O
+time	O
+polymerase	O
+chain	O
+reaction	O
+(	O
+PCR	O
+)	O
+in	O
+nasopharyngeal	B-ANAT
+aspirates	B-ANAT
+revealed	O
+HCoV	O
+infection	B-DISO
+in	O
+79	O
+cases	O
+(	O
+3	O
+.	O
+8	O
+%):	O
+33	O
+HCoV	B-SPEC
+-	I-SPEC
+229E	I-SPEC
+(	O
+1	O
+.	O
+6	O
+%),	O
+13	O
+HCoV	B-SPEC
+-	I-SPEC
+NL63	I-SPEC
+(	O
+0	O
+.	O
+6	O
+%),	O
+11	O
+HCoV	B-SPEC
+-	I-SPEC
+OC43	I-SPEC
+(	O
+0	O
+.	O
+5	O
+%),	O
+none	O
+HCoV	O
+-	O
+HKU1	O
+genotype	O
+A	O
+,	O
+and	O
+22	O
+(	O
+1	O
+.	O
+1	O
+%)	O
+co	O
+-	O
+detections	O
+of	O
+a	O
+HCoV	O
+and	O
+another	O
+respiratory	O
+virus	B-SPEC
+.	O
+
+The	O
+HCoVs	O
+were	O
+identified	O
+mainly	O
+in	O
+children	O
+with	O
+upper	B-DISO
+respiratory	I-DISO
+tract	I-DISO
+infection	I-DISO
+;	O
+there	O
+was	O
+no	O
+significant	O
+difference	O
+in	O
+clinical	O
+presentation	O
+between	O
+single	O
+HCoV	O
+infections	B-DISO
+and	O
+HCoV	O
+co	B-DISO
+-	I-DISO
+infections	I-DISO
+.	O
+
+There	O
+were	O
+a	O
+few	O
+cases	O
+of	O
+other	O
+members	O
+of	O
+the	O
+households	O
+of	O
+HCoV	O
+-	O
+positive	O
+children	O
+falling	O
+ill	B-DISO
+during	O
+the	O
+5	O
+-	O
+7	O
+days	O
+following	O
+enrollment	O
+.	O
+
+ABSTRACT	O
+:	O
+To	O
+investigate	O
+the	O
+treatment	O
+strategy	O
+of	O
+early	O
+acute	O
+lung	O
+injury	O
+(	O
+ALI	O
+)	O
+after	O
+liver	B-ANAT
+transplantation	O
+.	O
+
+All	O
+18	O
+patients	O
+were	O
+weaned	B-PROC
+and	O
+extubated	O
+successfully	O
+with	O
+the	O
+survival	O
+rate	O
+of	O
+100	O
+%.	O
+
+The	O
+circulating	O
+toxins	B-CHED
+deriving	O
+from	O
+the	O
+bacterial	O
+wall	O
+can	O
+activate	O
+the	O
+septic	O
+cascade	O
+that	O
+induces	O
+many	O
+systemic	O
+reactions	O
+involving	O
+the	O
+activation	O
+of	O
+the	O
+cellular	B-PROC
+immunity	I-PROC
+,	O
+complement	O
+and	O
+coagulation	B-PROC
+system	O
+.	O
+
+In	O
+this	O
+context	O
+,	O
+local	O
+and	O
+systemic	O
+cytokine	B-PROC
+production	I-PROC
+plays	O
+a	O
+major	O
+role	O
+in	O
+inducing	O
+the	O
+septic	O
+cascade	O
+,	O
+which	O
+although	O
+meant	O
+to	O
+be	O
+a	O
+phlogistic	O
+defense	O
+reaction	O
+,	O
+can	O
+often	O
+become	O
+an	O
+uncontrolled	O
+and	O
+dangerous	O
+inflammatory	B-DISO
+reaction	I-DISO
+.	O
+
+The	O
+sepsis	B-DISO
+-	O
+derived	O
+lesions	O
+can	O
+involve	O
+many	O
+organs	B-ANAT
+and	O
+apparatus	O
+leading	O
+to	O
+the	O
+picture	O
+of	O
+sepsis	B-DISO
+syndrome	I-DISO
+.	O
+
+We	O
+observed	O
+that	O
+the	O
+combination	O
+of	O
+DNA	B-PRGE
+-	I-PRGE
+PKcs	I-PRGE
+deficiency	O
+and	O
+telomere	B-COMP
+dysfunction	O
+resulted	O
+in	O
+a	O
+shortened	O
+lifespan	O
+that	O
+was	O
+reduced	O
+further	O
+following	O
+viral	B-DISO
+infection	I-DISO
+or	O
+experimental	O
+activation	O
+of	O
+the	O
+innate	B-DISO
+immune	I-DISO
+response	I-DISO
+.	O
+
+TITLE	O
+:	O
+Role	O
+of	O
+laboratory	O
+variables	O
+in	O
+differentiating	O
+SARS	B-DISO
+-	O
+coronavirus	B-SPEC
+from	O
+other	O
+causes	O
+of	O
+community	O
+-	O
+acquired	O
+pneumonia	O
+within	O
+the	O
+first	O
+72	O
+h	O
+of	O
+hospitalization	O
+.	O
+
+Routine	O
+hematological	O
+/	O
+biochemical	O
+variables	O
+in	O
+patients	O
+with	O
+laboratory	O
+-	O
+confirmed	O
+SARS	B-DISO
+(	O
+2003	O
+)	O
+were	O
+compared	O
+with	O
+those	O
+in	O
+consecutive	O
+patients	O
+hospitalized	O
+June	O
+-	O
+December	O
+2004	O
+with	O
+radiologically	O
+confirmed	O
+CAP	B-DISO
+.	O
+
+Nasopharyngeal	B-ANAT
+aspiration	B-DISO
+and	O
+antigen	B-CHED
+detection	O
+for	O
+influenza	B-SPEC
+virus	I-SPEC
+and	O
+respiratory	B-SPEC
+syncytial	I-SPEC
+virus	I-SPEC
+using	O
+an	O
+immunofluorescence	O
+assay	O
+(	O
+IFA	O
+)	O
+were	O
+routinely	O
+performed	O
+in	O
+patients	O
+with	O
+CAP	B-DISO
+.	O
+
+Altogether	O
+,	O
+181	O
+patients	O
+with	O
+CAP	B-DISO
+(	O
+who	O
+remained	O
+undiagnosed	O
+by	O
+IFA	O
+)	O
+and	O
+303	O
+patients	O
+with	O
+SARS	B-DISO
+were	O
+studied	O
+.	O
+
+TITLE	O
+:	O
+Baculovirus	B-SPEC
+expression	B-PROC
+of	O
+HCoV	B-PRGE
+-	I-PRGE
+OC43	I-PRGE
+nucleocapsid	B-COMP
+protein	B-CHED
+and	O
+development	B-PROC
+of	O
+a	O
+Western	O
+blot	O
+assay	O
+for	O
+detection	O
+of	O
+human	O
+antibodies	B-COMP
+against	O
+HCoV	B-SPEC
+-	I-SPEC
+OC43	I-SPEC
+.	O
+
+Recombinant	B-PRGE
+N	I-PRGE
+protein	I-PRGE
+was	O
+extracted	O
+from	O
+infected	O
+cells	B-COMP
+,	O
+analysed	O
+by	O
+SDS	B-DISO
+-	O
+PAGE	O
+and	O
+Western	O
+blot	O
+,	O
+and	O
+purified	O
+by	O
+Ni2	O
++	O
+affinity	O
+procedure	O
+.	O
+
+TITLE	O
+:	O
+Replicase	B-PRGE
+genes	O
+of	O
+murine	B-SPEC
+coronavirus	I-SPEC
+strains	O
+A59	O
+and	O
+JHM	O
+are	O
+interchangeable	O
+:	O
+differences	O
+in	O
+pathogenesis	O
+map	O
+to	O
+the	O
+3	O
+'	O
+one	O
+-	O
+third	O
+of	O
+the	O
+genome	O
+.	O
+
+Understanding	O
+of	O
+SARS	B-DISO
+and	O
+development	B-PROC
+of	O
+therapeutic	O
+approaches	O
+have	O
+been	O
+hampered	O
+by	O
+the	O
+absence	O
+of	O
+an	O
+animal	B-SPEC
+model	O
+that	O
+mimics	O
+the	O
+human	B-SPEC
+disease	O
+and	O
+is	O
+reproducible	O
+.	O
+
+We	O
+demonstrate	O
+that	O
+the	O
+ORF7b	B-PRGE
+protein	I-PRGE
+is	O
+expressed	B-PROC
+in	O
+virus	B-SPEC
+-	O
+infected	O
+cell	B-COMP
+lysates	O
+and	O
+from	O
+a	O
+cDNA	O
+encoding	O
+the	O
+gene	B-PRGE
+7	I-PRGE
+coding	I-PRGE
+region	I-PRGE
+,	O
+indicating	O
+that	O
+the	O
+sgRNA7	O
+is	O
+bicistronic	O
+.	O
+
+TITLE	O
+:	O
+Suppression	B-PROC
+of	O
+coronavirus	B-SPEC
+replication	O
+by	O
+inhibition	B-PROC
+of	O
+the	O
+MEK	B-PRGE
+signaling	B-PROC
+pathway	I-PROC
+.	O
+
+Furthermore	O
+,	O
+the	O
+treatment	O
+did	O
+not	O
+affect	O
+the	O
+virus	B-SPEC
+entry	O
+,	O
+as	O
+revealed	O
+by	O
+the	O
+virus	B-SPEC
+internalization	O
+assay	O
+.	O
+
+Metabolic	B-PROC
+labeling	O
+and	O
+reporter	O
+gene	O
+assays	O
+demonstrated	O
+that	O
+translation	B-PROC
+of	O
+cellular	B-COMP
+and	O
+viral	O
+mRNAs	O
+appeared	O
+unaffected	O
+by	O
+UO126	O
+treatment	O
+.	O
+
+Observational	O
+,	O
+retrospective	O
+study	O
+in	O
+a	O
+23	O
+-	O
+bed	B-DISO
+medical	O
+/	O
+surgical	O
+intensive	O
+care	O
+unit	O
+(	O
+ICU	O
+)	O
+in	O
+a	O
+cancer	B-DISO
+hospital	O
+from	O
+January	O
+to	O
+December	O
+2003	O
+.	O
+
+The	O
+median	O
+(	O
+interquartile	O
+range	O
+)	O
+duration	O
+of	O
+mechanical	O
+ventilation	O
+(	O
+10	O
+[	O
+6	O
+-	O
+17	O
+]	O
+vs	O
+.	O
+7	O
+[	O
+2	O
+-	O
+12	O
+]	O
+days	O
+,	O
+p	O
+=	O
+.	O
+017	O
+)	O
+and	O
+duration	O
+of	O
+weaning	B-PROC
+from	O
+mechanical	O
+ventilation	O
+(	O
+41	O
+[	O
+16	O
+-	O
+97	O
+]	O
+vs	O
+.	O
+21	O
+[	O
+7	O
+-	O
+33	O
+.	O
+5	O
+]	O
+hrs	B-DISO
+,	O
+p	O
+=	O
+.	O
+018	O
+)	O
+were	O
+longer	O
+in	O
+AKI	O
+patients	O
+compared	O
+with	O
+control	O
+patients	O
+.	O
+
+Surprisingly	O
+,	O
+although	O
+FAH	O
+sequence	O
+1	O
+-	O
+50	O
+shares	O
+a	O
+high	O
+degree	O
+of	O
+homology	O
+with	O
+various	O
+MHV	B-SPEC
+proteins	B-CHED
+,	O
+the	O
+C	O
+-	O
+terminal	O
+portion	O
+does	O
+not	O
+.	O
+
+Moreover	O
+,	O
+whereas	O
+the	O
+autoAb	O
+reacted	O
+with	O
+homologous	O
+peptides	B-CHED
+surrounding	O
+residues	O
+70	O
+,	O
+160	O
+and	O
+360	O
+,	O
+non	O
+-	O
+similar	O
+sequences	O
+around	O
+residues	O
+130	O
+,	O
+210	O
+,	O
+240	O
+,	O
+250	O
+,	O
+and	O
+300	O
+were	O
+also	O
+recognized	O
+,	O
+indicating	O
+that	O
+autoAb	O
+were	O
+not	O
+restricted	O
+to	O
+epitopes	O
+with	O
+sequence	O
+homologies	O
+.	O
+
+Results	O
+indicated	O
+that	O
+the	O
+induction	O
+of	O
+the	O
+autoAb	O
+is	O
+not	O
+only	O
+related	O
+to	O
+molecular	O
+or	O
+structural	O
+mimicry	B-DISO
+,	O
+but	O
+rather	O
+supports	O
+the	O
+Danger	O
+model	O
+,	O
+in	O
+which	O
+any	O
+aggression	B-DISO
+,	O
+in	O
+this	O
+case	O
+the	O
+MHV	B-SPEC
+infection	B-DISO
+,	O
+is	O
+susceptible	O
+to	O
+trigger	O
+the	O
+production	O
+of	O
+autoAb	O
+.	O
+
+ABSTRACT	O
+:	O
+Nitrogen	O
+oxide	O
+(	O
+NO	O
+)	O
+species	B-SPEC
+are	O
+markers	O
+for	O
+oxidative	B-DISO
+stress	I-DISO
+that	O
+may	O
+be	O
+pathogenic	O
+in	O
+acute	O
+lung	B-ANAT
+injury	O
+(	O
+ALI	O
+).	O
+
+Higher	O
+baseline	O
+levels	O
+of	O
+urine	B-ANAT
+NO	O
+to	O
+Cr	O
+were	O
+associated	O
+with	O
+lower	O
+mortality	O
+(	O
+odds	O
+ratio	O
+,	O
+0	O
+.	O
+43	O
+per	O
+log	O
+(	O
+10	O
+)	O
+increase	O
+in	O
+the	O
+ratio	O
+),	O
+more	O
+ventilator	O
+-	O
+free	O
+days	O
+(	O
+mean	O
+increase	O
+,	O
+1	O
+.	O
+9	O
+d	O
+),	O
+and	O
+more	O
+organ	B-ANAT
+-	O
+failure	O
+-	O
+free	O
+days	O
+(	O
+mean	O
+increase	O
+,	O
+2	O
+.	O
+3	O
+d	O
+)	O
+on	O
+multivariate	O
+analysis	O
+(	O
+p	O
+<	O
+0	O
+.	O
+05	O
+for	O
+all	O
+analyses	O
+).	O
+
+RESULTS	O
+:	O
+Higher	O
+baseline	O
+levels	O
+of	O
+urine	B-ANAT
+NO	O
+to	O
+Cr	O
+were	O
+associated	O
+with	O
+lower	O
+mortality	O
+(	O
+odds	O
+ratio	O
+,	O
+0	O
+.	O
+43	O
+per	O
+log	O
+(	O
+10	O
+)	O
+increase	O
+in	O
+the	O
+ratio	O
+),	O
+more	O
+ventilator	O
+-	O
+free	O
+days	O
+(	O
+mean	O
+increase	O
+,	O
+1	O
+.	O
+9	O
+d	O
+),	O
+and	O
+more	O
+organ	B-ANAT
+-	O
+failure	O
+-	O
+free	O
+days	O
+(	O
+mean	O
+increase	O
+,	O
+2	O
+.	O
+3	O
+d	O
+)	O
+on	O
+multivariate	O
+analysis	O
+(	O
+p	O
+<	O
+0	O
+.	O
+05	O
+for	O
+all	O
+analyses	O
+).	O
+
+The	O
+epitope	B-CHED
+NP366	O
+-	O
+specific	O
+response	O
+is	O
+dominated	O
+by	O
+TCR	B-COMP
+clonotypes	O
+that	O
+are	O
+public	O
+(	O
+shared	O
+by	O
+most	O
+mice	B-SPEC
+),	O
+whereas	O
+the	O
+epitope	B-CHED
+PA224	O
+-	O
+specific	O
+response	O
+is	O
+private	O
+(	O
+unique	O
+within	O
+each	O
+infected	O
+animal	B-SPEC
+).	O
+
+We	O
+calculated	O
+that	O
+50	O
+-	O
+550	O
+clonotypes	O
+recognized	O
+each	O
+epitope	B-CHED
+in	O
+individual	O
+mice	B-SPEC
+.	O
+
+During	O
+the	O
+MD	O
+simulation	O
+of	O
+dimer	O
+,	O
+three	O
+interest	O
+phenomena	O
+of	O
+protomer	O
+A	O
+have	O
+been	O
+observed	O
+:	O
+(	O
+i	O
+)	O
+the	O
+distance	O
+between	O
+NE2	O
+of	O
+His41	O
+and	O
+SG	O
+of	O
+Cys145	O
+averages	O
+3	O
+.	O
+72	O
+A	O
+,	O
+which	O
+agrees	O
+well	O
+with	O
+the	O
+experimental	O
+observations	O
+made	O
+by	O
+X	O
+-	O
+ray	B-SPEC
+crystallography	O
+;	O
+(	O
+ii	O
+)	O
+His163	O
+and	O
+Glu166	O
+form	O
+the	O
+""""	O
+tooth	B-ANAT
+""""	O
+conformational	O
+properties	O
+,	O
+resulting	O
+in	O
+the	O
+specificity	O
+for	O
+glutamine	B-CHED
+at	O
+substrate	O
+P1	O
+site	O
+;	O
+and	O
+(	O
+iii	O
+)	O
+the	O
+substrate	O
+-	O
+binding	O
+pocket	O
+formed	O
+by	O
+loop	O
+140	O
+-	O
+146	O
+and	O
+loop	O
+184	O
+-	O
+197	O
+is	O
+large	O
+enough	O
+to	O
+accommodate	O
+the	O
+substrate	O
+analog	O
+.	O
+
+Furthermore	O
+,	O
+a	O
+water	B-CHED
+-	O
+bridge	O
+has	O
+been	O
+found	O
+between	O
+the	O
+N	O
+-	O
+terminus	O
+of	O
+protomer	O
+B	O
+and	O
+Gly170	O
+,	O
+which	O
+stabilizes	O
+His172	O
+and	O
+avoids	O
+it	O
+moving	B-PROC
+toward	O
+Tyr161	O
+to	O
+disrupt	O
+the	O
+H	O
+-	O
+bond	O
+between	O
+Tyr161	O
+and	O
+His163	O
+,	O
+stabilizing	O
+the	O
+conformation	O
+of	O
+His163	O
+.	O
+
+Nonetheless	O
+,	O
+influenza	B-DISO
+pandemics	O
+are	O
+considered	O
+inevitable	O
+.	O
+
+519	O
+U	O
+/	O
+L	O
+,	O
+PO2	B-PROC
+/	O
+FiO2	O
+was	O
+188	O
++/-	O
+
+The	O
+patients	O
+'	O
+condition	B-DISO
+was	O
+improved	O
+much	O
+as	O
+demonstrated	O
+by	O
+pH	O
+7	O
+.	O
+38	O
++/-	O
+
+375	O
+U	O
+/	O
+L	O
+,	O
+PO2	B-PROC
+/	O
+FiO2	O
+285	O
++/-	O
+
+Mycoplasma	B-SPEC
+bovis	I-SPEC
+was	O
+not	O
+detected	O
+at	O
+all	O
+.	O
+
+M	B-SPEC
+.	I-SPEC
+bovis	I-SPEC
+,	O
+an	O
+emerging	O
+pathogen	O
+in	O
+many	O
+countries	O
+,	O
+was	O
+not	O
+detected	O
+.	O
+
+TITLE	O
+:	O
+Newly	O
+recognized	O
+causes	O
+of	O
+acute	O
+lung	B-ANAT
+injury	O
+:	O
+transfusion	O
+of	O
+blood	B-ANAT
+products	O
+,	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+,	O
+and	O
+avian	B-DISO
+influenza	I-DISO
+.	O
+
+This	O
+article	O
+discusses	O
+the	O
+clinical	O
+importance	O
+,	O
+pathogenesis	B-DISO
+,	O
+diagnosis	O
+,	O
+management	O
+,	O
+and	O
+prevention	O
+of	O
+these	O
+newly	O
+recognized	O
+causes	O
+of	O
+respiratory	B-DISO
+failure	I-DISO
+.	O
+
+ABSTRACT	O
+:	O
+Acute	O
+lung	B-ANAT
+injury	O
+and	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+are	O
+inflammatory	O
+conditions	O
+involving	O
+a	O
+broad	O
+spectrum	O
+of	O
+lung	B-ANAT
+injury	O
+from	O
+mild	O
+respiratory	O
+abnormality	O
+to	O
+severe	O
+respiratory	O
+derangement	O
+.	O
+
+VILI	O
+may	O
+amplify	O
+preexisting	O
+injury	O
+,	O
+delay	O
+lung	B-ANAT
+recovery	O
+,	O
+and	O
+result	O
+in	O
+adverse	O
+outcomes	O
+.	O
+
+This	O
+article	O
+examines	O
+the	O
+evidence	O
+supporting	O
+lung	B-ANAT
+-	O
+protective	O
+ventilation	O
+strategies	O
+and	O
+addresses	O
+the	O
+methods	O
+,	O
+outcomes	O
+,	O
+and	O
+potential	O
+obstacles	O
+to	O
+implementation	O
+of	O
+such	O
+approaches	O
+.	O
+
+ABSTRACT	O
+:	O
+Acute	O
+necrotizing	O
+pancreatitis	O
+leads	O
+to	O
+a	O
+systemic	O
+inflammatory	B-DISO
+response	I-DISO
+characterized	O
+by	O
+widespread	O
+leukocyte	B-PROC
+activation	I-PROC
+and	O
+,	O
+as	O
+a	O
+consequence	O
+,	O
+distant	O
+lung	B-ANAT
+injury	O
+.	O
+
+RESULTS	O
+:	O
+The	O
+blood	B-PROC
+flow	I-PROC
+in	O
+the	O
+P	O
+group	O
+was	O
+significantly	O
+lower	O
+than	O
+that	O
+of	O
+the	O
+C	O
+group	O
+,	O
+while	O
+the	O
+blood	B-PROC
+flow	I-PROC
+in	O
+the	O
+T	O
+group	O
+was	O
+significantly	O
+higher	O
+than	O
+that	O
+of	O
+the	O
+P	O
+group	O
+but	O
+showed	O
+no	O
+significant	O
+difference	O
+from	O
+the	O
+C	O
+group	O
+.	O
+
+The	O
+mice	B-SPEC
+were	O
+divided	O
+into	O
+a	O
+group	O
+receiving	O
+normal	O
+feed	O
+and	O
+another	O
+group	O
+receiving	O
+feed	O
+mixed	O
+with	O
+TJ	O
+-	O
+41	O
+at	O
+a	O
+dose	O
+of	O
+1	O
+g	O
+/	O
+kg	O
+/	O
+day	O
+for	O
+8	O
+weeks	O
+before	O
+LPS	B-DISO
+challenge	O
+.	O
+
+The	O
+fraction	O
+of	O
+neutrophils	B-ANAT
+in	O
+the	O
+bronchoalveolar	B-ANAT
+lavage	I-ANAT
+fluid	I-ANAT
+was	O
+15	O
+.	O
+6	O
+%,	O
+lymphocytes	B-ANAT
+were	O
+33	O
+.	O
+6	O
+%,	O
+eosinophils	B-ANAT
+were	O
+26	O
+.	O
+6	O
+%	O
+and	O
+macrophages	B-ANAT
+were	O
+23	O
+.	O
+6	O
+%.	O
+
+After	O
+admission	O
+,	O
+he	O
+displayed	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+with	O
+severe	O
+hypoxemia	O
+as	O
+dyspnea	B-DISO
+gradually	O
+progressed	O
+.	O
+
+We	O
+commenced	O
+treatment	O
+with	O
+high	O
+-	O
+dose	O
+pulse	B-PROC
+methylprednisolone	B-CHED
+and	O
+neutrophil	B-CHED
+elastase	B-PRGE
+inhibitor	I-CHED
+under	O
+mechanical	O
+ventilation	O
+.	O
+
+TITLE	O
+:	O
+Clinical	O
+features	O
+,	O
+complications	O
+and	O
+atypical	O
+manifestations	O
+of	O
+children	O
+with	O
+severe	O
+forms	O
+of	O
+dengue	B-DISO
+hemorrhagic	I-DISO
+fever	I-DISO
+in	O
+South	O
+India	O
+.	O
+
+RESULTS	O
+:	O
+Of	O
+858	O
+patients	O
+with	O
+dengue	B-DISO
+fever	I-DISO
+/	O
+DHF	O
+admitted	O
+to	O
+the	O
+hospital	O
+during	O
+the	O
+study	O
+period	O
+,	O
+109	O
+cases	O
+with	O
+severe	O
+forms	O
+of	O
+disease	O
+required	O
+PICU	B-SPEC
+admission	O
+,	O
+of	O
+which	O
+9	O
+patients	O
+died	B-PROC
+.	O
+
+TITLE	O
+:	O
+Diffuse	O
+alveolar	B-ANAT
+lesion	O
+in	O
+BALB	O
+/	O
+c	O
+mice	B-SPEC
+induced	O
+with	O
+human	B-PRGE
+reovirus	B-SPEC
+BYD1	I-PRGE
+strain	O
+and	O
+its	O
+potential	O
+relation	O
+with	O
+SARS	O
+.	O
+
+ABSTRACT	O
+:	O
+To	O
+investigate	O
+the	O
+effect	O
+of	O
+continuous	O
+high	O
+volume	O
+hemofiltration	O
+(	O
+HVHF	O
+)	O
+on	O
+respiration	B-PROC
+,	O
+hemodynamics	B-PROC
+,	O
+and	O
+oxygen	B-PROC
+metabolism	I-PROC
+in	O
+severe	B-DISO
+sepsis	I-DISO
+patients	O
+with	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+(	O
+ARDS	B-DISO
+).	O
+
+CONCLUSIONS	O
+:	O
+Continuous	O
+HVHF	O
+shows	O
+significant	O
+beneficial	O
+effects	O
+on	O
+pulmonary	B-PROC
+function	I-PROC
+of	O
+severe	B-DISO
+sepsis	I-DISO
+patients	O
+with	O
+ARDS	B-DISO
+as	O
+a	O
+result	O
+of	O
+removal	O
+of	O
+cytokines	O
+,	O
+decrease	O
+of	O
+TFC	O
+and	O
+amelioration	O
+of	O
+disturbance	O
+in	O
+respiration	B-PROC
+,	O
+hemodynamics	B-PROC
+and	O
+oxygen	B-PROC
+metabolism	I-PROC
+.	O
+
+TITLE	O
+:	O
+Receptor	O
+-	O
+binding	B-FUNC
+domain	O
+of	O
+SARS	B-PRGE
+-	I-PRGE
+CoV	I-PRGE
+spike	I-PRGE
+protein	B-CHED
+induces	O
+long	O
+-	O
+term	O
+protective	O
+immunity	B-PROC
+in	O
+an	O
+animal	O
+model	O
+.	O
+
+Our	O
+previous	O
+studies	O
+have	O
+shown	O
+that	O
+the	O
+receptor	O
+-	O
+binding	B-FUNC
+domain	O
+(	O
+RBD	O
+)	O
+of	O
+SARS	B-DISO
+-	O
+CoV	O
+spike	O
+(	O
+S	O
+)	O
+protein	B-CHED
+elicits	O
+highly	O
+potent	O
+neutralizing	O
+antibody	B-PROC
+responses	I-PROC
+in	O
+the	O
+immunized	O
+animals	B-SPEC
+.	O
+
+Sera	B-COMP
+were	O
+analyzed	O
+for	O
+antibodies	B-COMP
+against	O
+feline	B-SPEC
+immunodeficiency	I-SPEC
+virus	I-SPEC
+(	O
+FIV	B-SPEC
+),	O
+feline	B-SPEC
+calicivirus	I-SPEC
+(	O
+FCV	B-CHED
+),	O
+feline	B-SPEC
+herpesvirus	I-SPEC
+1	I-SPEC
+(	O
+feline	B-SPEC
+rhinotracheitis	B-DISO
+:	O
+FHV1	O
+),	O
+feline	B-SPEC
+/	O
+canine	O
+parvovirus	B-DISO
+(	O
+FPV	B-SPEC
+/	O
+CPV	B-SPEC
+),	O
+feline	B-DISO
+infectious	I-DISO
+peritonitis	I-DISO
+virus	B-SPEC
+(	O
+feline	B-SPEC
+coronavirus	B-SPEC
+:	O
+FIPV	O
+),	O
+and	O
+canine	B-SPEC
+distemper	I-SPEC
+virus	I-SPEC
+(	O
+CDV	B-CHED
+)	O
+or	O
+for	O
+the	O
+presence	O
+of	O
+feline	B-SPEC
+leukemia	I-SPEC
+virus	I-SPEC
+(	O
+FeLV	O
+)	O
+antigens	B-CHED
+.	O
+
+TITLE	O
+:	O
+Discovering	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+coronavirus	B-SPEC
+3CL	O
+protease	B-PROC
+inhibitors	I-PROC
+:	O
+virtual	O
+screening	O
+,	O
+surface	O
+plasmon	O
+resonance	O
+,	O
+and	O
+fluorescence	O
+resonance	O
+energy	O
+transfer	O
+assays	O
+.	O
+
+Using	O
+mouse	B-PRGE
+-	I-PRGE
+feline	B-SPEC
+APN	I-PRGE
+chimeras	I-PRGE
+,	O
+we	O
+identified	O
+three	O
+small	O
+,	O
+discontinuous	O
+regions	O
+,	O
+amino	B-CHED
+acids	I-CHED
+(	O
+aa	O
+)	O
+288	O
+to	O
+290	O
+,	O
+aa	O
+732	O
+to	O
+746	O
+(	O
+called	O
+R1	O
+),	O
+and	O
+aa	O
+764	O
+to	O
+788	O
+(	O
+called	O
+R2	O
+)	O
+in	O
+fAPN	O
+that	O
+determined	O
+the	O
+host	B-COMP
+ranges	O
+of	O
+these	O
+coronaviruses	O
+.	O
+
+Blockade	O
+of	O
+infection	B-DISO
+with	O
+anti	B-PRGE
+-	I-PRGE
+fAPN	I-PRGE
+monoclonal	I-PRGE
+antibody	I-PRGE
+RG4	I-PRGE
+suggested	O
+that	O
+these	O
+three	O
+regions	O
+lie	O
+close	O
+together	O
+on	O
+the	O
+fAPN	O
+surface	O
+.	O
+
+TITLE	O
+:	O
+A	O
+hypervariable	O
+region	O
+within	O
+the	O
+3	O
+'	O
+cis	B-DISO
+-	O
+acting	O
+element	O
+of	O
+the	O
+murine	B-SPEC
+coronavirus	I-SPEC
+genome	O
+is	O
+nonessential	O
+for	O
+RNA	O
+synthesis	O
+but	O
+affects	O
+pathogenesis	B-DISO
+.	O
+
+Our	O
+results	O
+show	O
+that	O
+neither	O
+the	O
+HVR	O
+nor	O
+oct	O
+is	O
+essential	O
+for	O
+the	O
+basic	O
+mechanism	O
+of	O
+MHV	B-PRGE
+RNA	B-PROC
+synthesis	I-PROC
+in	O
+tissue	B-ANAT
+culture	O
+.	O
+
+Cyclical	O
+tidal	O
+volume	O
+recruitment	B-DISO
+of	O
+atelectatic	O
+lung	B-ANAT
+regions	O
+causes	O
+acute	O
+lung	B-ANAT
+injury	O
+,	O
+as	O
+do	O
+large	O
+breaths	O
+during	O
+pneumonectomy	O
+.	O
+
+Positive	O
+end	B-PROC
+-	I-PROC
+expiratory	I-PROC
+pressure	O
+levels	O
+must	O
+be	O
+high	O
+enough	O
+to	O
+minimize	O
+recruitment	B-DISO
+/	O
+derecruitment	O
+cycling	O
+.	O
+
+TITLE	O
+:	O
+[	O
+High	O
+incidence	O
+of	O
+fatal	O
+cytokine	O
+-	O
+related	O
+disease	O
+among	O
+children	O
+with	O
+sequelae	O
+of	O
+perinatal	O
+hypoxic	B-DISO
+-	I-DISO
+ischemic	I-DISO
+encephalopathy	I-DISO
+].	O
+
+ABSTRACT	O
+:	O
+The	O
+SARS	B-DISO
+outbreak	O
+in	O
+2003	O
+has	O
+spawned	O
+a	O
+major	O
+controversy	O
+concerning	O
+protective	O
+performance	O
+facemasks	O
+for	O
+healthcare	O
+workers	O
+.	O
+
+Nano	O
+-	O
+masks	O
+show	O
+stronger	O
+water	B-CHED
+repellency	O
+and	O
+antibacterial	O
+activities	O
+,	O
+but	O
+no	O
+difference	O
+in	O
+usability	O
+,	O
+comparing	O
+with	O
+normal	O
+N95	O
+and	O
+surgical	O
+masks	O
+.	O
+
+RESULTS	O
+:	O
+Tests	O
+on	O
+physical	O
+properties	O
+showed	O
+that	O
+N95	O
+respirators	O
+had	O
+significantly	O
+lower	O
+air	B-CHED
+permeability	O
+and	O
+water	B-CHED
+vapor	O
+permeability	O
+than	O
+surgical	O
+masks	O
+.	O
+
+TITLE	O
+:	O
+Derivation	O
+of	O
+a	O
+novel	O
+SARS	B-DISO
+-	O
+coronavirus	B-SPEC
+replicon	O
+cell	B-ANAT
+line	I-ANAT
+and	O
+its	O
+application	O
+for	O
+anti	O
+-	O
+SARS	B-DISO
+drug	O
+screening	O
+.	O
+
+The	O
+purpose	O
+of	O
+our	O
+study	O
+was	O
+to	O
+determine	O
+characteristics	O
+associated	O
+with	O
+the	O
+transmission	O
+of	O
+SARS	B-DISO
+within	O
+households	O
+.	O
+
+SARS	B-DISO
+transmission	O
+in	O
+households	O
+is	O
+complex	O
+and	O
+increases	O
+with	O
+the	O
+length	O
+of	O
+time	O
+an	O
+ill	B-DISO
+person	O
+spends	O
+at	O
+home	O
+.	O
+
+There	O
+is	O
+also	O
+evidence	O
+stemming	O
+from	O
+newly	O
+presented	O
+C	O
+-	O
+L	O
+follow	O
+-	O
+up	O
+studies	O
+that	O
+the	O
+remarkable	O
+advances	O
+in	O
+intensive	O
+care	O
+treatment	O
+,	O
+organ	B-ANAT
+transplantation	O
+medicine	B-CHED
+and	O
+cardiac	B-ANAT
+surgery	O
+with	O
+cardiopulmonary	B-ANAT
+bypass	O
+within	O
+the	O
+past	O
+decade	O
+have	O
+an	O
+important	O
+impact	O
+on	O
+the	O
+general	O
+hospital	O
+inpatients	O
+;	O
+psychosocial	O
+outcome	O
+.	O
+
+Another	O
+outcome	O
+study	O
+examining	O
+concurrently	O
+psychiatric	O
+morbidity	O
+and	O
+quality	O
+of	O
+life	O
+in	O
+intermediate	O
+-	O
+term	O
+survivors	O
+of	O
+orthotopic	O
+liver	B-ANAT
+transplantation	O
+(	O
+OLT	O
+)	O
+survivors	O
+has	O
+documented	O
+that	O
+5	O
+.	O
+4	O
+%	O
+of	O
+these	O
+patients	O
+had	O
+a	O
+full	O
+PTSD	B-DISO
+,	O
+and	O
+17	O
+.	O
+3	O
+%	O
+of	O
+them	O
+a	O
+sub	O
+-	O
+PTSD	B-DISO
+at	O
+4	O
+year	O
+-	O
+follow	O
+-	O
+up	O
+.	O
+
+The	O
+duration	O
+of	O
+intensive	O
+care	O
+treatment	O
+,	O
+the	O
+number	O
+of	O
+medical	O
+complications	O
+,	O
+and	O
+the	O
+occurrence	O
+of	O
+acute	O
+rejection	O
+were	O
+positively	O
+correlated	O
+with	O
+the	O
+risk	O
+of	O
+PTSD	B-DISO
+symptoms	O
+subsequent	O
+to	O
+OLT	O
+.	O
+
+Postoperative	B-DISO
+delirium	I-DISO
+developed	O
+in	O
+32	O
+.	O
+4	O
+%	O
+of	O
+these	O
+patients	O
+,	O
+however	O
+,	O
+only	O
+in	O
+5	O
+.	O
+9	O
+%	O
+of	O
+them	O
+severe	O
+delirium	B-DISO
+was	O
+noted	O
+.	O
+
+If	O
+they	O
+are	O
+untreated	O
+,	O
+PTSD	B-DISO
+symptoms	O
+such	O
+as	O
+intrusive	O
+recollections	O
+,	O
+avoidance	O
+and	O
+hyper	O
+-	O
+arousal	O
+may	O
+impair	O
+the	O
+patients	O
+;	O
+quality	O
+of	O
+life	O
+more	O
+than	O
+the	O
+primary	B-DISO
+disease	I-DISO
+.	O
+
+TITLE	O
+:	O
+Predictive	O
+models	O
+of	O
+control	O
+strategies	O
+involved	O
+in	O
+containing	O
+indoor	O
+airborne	O
+infections	B-DISO
+.	O
+
+We	O
+examine	O
+mathematically	O
+the	O
+impact	O
+of	O
+engineering	O
+control	O
+measures	O
+such	O
+as	O
+enhanced	O
+air	B-CHED
+exchange	O
+and	O
+air	B-CHED
+filtration	O
+rates	O
+with	O
+personal	O
+masking	O
+combined	O
+with	O
+public	O
+health	O
+interventions	O
+such	O
+as	O
+vaccination	O
+,	O
+isolation	O
+,	O
+and	O
+contact	O
+tracing	O
+in	O
+containing	O
+the	O
+spread	O
+of	O
+indoor	O
+airborne	O
+infections	B-DISO
+including	O
+influenza	B-DISO
+,	O
+chickenpox	B-DISO
+,	O
+measles	B-PATH
+,	O
+and	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+(	O
+SARS	B-DISO
+).	O
+
+Combinations	O
+of	O
+engineering	O
+control	O
+measures	O
+and	O
+public	O
+health	O
+interventions	O
+could	O
+moderately	O
+contain	O
+influenza	B-DISO
+strains	O
+with	O
+an	O
+R0	O
+as	O
+high	O
+as	O
+4	O
+.	O
+
+The	O
+combination	O
+of	O
+enhanced	O
+engineering	O
+control	O
+measures	O
+and	O
+assigned	O
+effective	O
+public	O
+health	O
+interventions	O
+would	O
+have	O
+a	O
+high	O
+probability	O
+for	O
+containing	O
+airborne	O
+infection	B-DISO
+.	O
+
+TITLE	O
+:	O
+Virus	B-SPEC
+associated	O
+hemophagocytic	B-DISO
+syndrome	I-DISO
+accompanied	O
+by	O
+acute	B-DISO
+respiratory	I-DISO
+failure	I-DISO
+caused	O
+by	O
+influenza	B-DISO
+A	I-PATH
+(	O
+H3N2	B-CHED
+).	O
+
+Preliminary	O
+studies	O
+with	O
+mice	B-SPEC
+of	O
+a	O
+second	O
+lineage	O
+,	O
+AC63	O
+,	O
+in	O
+which	O
+the	O
+transgene	O
+expression	B-PROC
+was	O
+considerably	O
+less	O
+abundant	O
+than	O
+that	O
+in	O
+the	O
+AC70	O
+line	O
+,	O
+revealed	O
+that	O
+virus	B-PROC
+replication	I-PROC
+was	O
+largely	O
+restricted	O
+to	O
+the	O
+lungs	B-ANAT
+but	O
+not	O
+the	O
+brain	B-ANAT
+.	O
+
+N	B-PRGE
+protein	I-PRGE
+dramatically	O
+inhibited	O
+expression	B-PROC
+from	O
+an	O
+NF	B-PRGE
+-	I-PRGE
+kappaB	I-PRGE
+-	I-PRGE
+responsive	I-PRGE
+promoter	I-PRGE
+.	O
+
+All	O
+three	O
+proteins	B-CHED
+were	O
+able	O
+to	O
+inhibit	O
+expression	B-PROC
+from	O
+an	O
+interferon	B-PRGE
+-	I-PRGE
+stimulated	I-PRGE
+response	I-PRGE
+element	I-PRGE
+(	O
+ISRE	O
+)	O
+promoter	O
+after	O
+infection	B-DISO
+with	O
+Sendai	B-SPEC
+virus	I-SPEC
+,	O
+while	O
+only	O
+ORF	O
+3b	O
+and	O
+ORF	O
+6	O
+proteins	O
+were	O
+able	O
+to	O
+inhibit	O
+expression	B-PROC
+from	O
+the	O
+ISRE	O
+promoter	O
+after	O
+treatment	O
+with	O
+interferon	B-PRGE
+.	O
+
+ABSTRACT	O
+:	O
+A	O
+deletion	O
+mutant	O
+of	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+coronavirus	B-SPEC
+(	O
+SARS	B-DISO
+-	O
+CoV	O
+)	O
+has	O
+been	O
+engineered	O
+by	O
+deleting	O
+the	O
+structural	O
+E	O
+gene	O
+in	O
+an	O
+infectious	B-DISO
+cDNA	O
+clone	O
+that	O
+was	O
+constructed	O
+as	O
+a	O
+bacterial	O
+artificial	O
+chromosome	B-COMP
+(	O
+BAC	O
+).	O
+
+ABSTRACT	O
+:	O
+Severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+(	O
+SARS	B-DISO
+)	O
+constitutes	O
+the	O
+first	O
+new	O
+infectious	B-DISO
+disease	I-DISO
+of	O
+the	O
+current	O
+millennium	O
+.	O
+
+We	O
+hypothesized	O
+that	O
+a	O
+modified	O
+organ	B-ANAT
+expression	B-PROC
+of	O
+cytokines	O
+and	O
+chemokines	O
+that	O
+occurs	O
+in	O
+transgenic	B-SPEC
+mice	I-SPEC
+may	O
+affect	O
+the	O
+systemic	O
+response	O
+to	O
+severe	O
+acute	B-DISO
+pancreatitis	I-DISO
+.	O
+
+Caerulein	B-PRGE
+-	O
+treated	O
+wild	O
+-	O
+type	O
+mice	B-SPEC
+exhibited	O
+increased	O
+lung	B-ANAT
+injury	O
+score	O
+at	O
+1	O
+through	O
+12	O
+h	O
+,	O
+as	O
+compared	O
+to	O
+saline	O
+controls	O
+.	O
+
+RESULTS	O
+:	O
+Caerulein	B-PRGE
+-	O
+treated	O
+wild	O
+-	O
+type	O
+mice	B-SPEC
+exhibited	O
+increased	O
+lung	B-ANAT
+injury	O
+score	O
+at	O
+1	O
+through	O
+12	O
+h	O
+,	O
+as	O
+compared	O
+to	O
+saline	O
+controls	O
+.	O
+
+ABSTRACT	O
+:	O
+Since	O
+its	O
+introduction	O
+in	O
+1985	O
+by	O
+Ciaglia	O
+et	O
+al	O
+,	O
+percutaneous	O
+dilational	O
+tracheostomy	O
+(	O
+PDT	B-CHED
+)	O
+has	O
+gradually	O
+become	O
+the	O
+procedure	O
+of	O
+choice	O
+in	O
+establishing	O
+a	O
+long	O
+-	O
+term	O
+airway	B-ANAT
+in	O
+many	O
+intensive	O
+care	O
+units	O
+(	O
+ICU	O
+).	O
+
+He	O
+developed	O
+subcutaneous	B-DISO
+emphysema	I-DISO
+and	O
+pneumomediastinum	B-DISO
+as	O
+complications	O
+of	O
+mechanical	O
+ventilation	O
+.	O
+
+ABSTRACT	O
+:	O
+Severe	O
+acute	O
+respiratory	O
+distress	O
+syndrome	O
+(	O
+SARS	B-DISO
+)	O
+caused	O
+by	O
+SARS	B-DISO
+-	I-DISO
+associated	I-DISO
+coronavirus	I-DISO
+(	O
+SARS	B-DISO
+-	O
+CoV	O
+)	O
+is	O
+a	O
+systemic	B-DISO
+infection	I-DISO
+that	O
+clinically	O
+manifests	O
+as	O
+progressive	O
+pneumonia	B-DISO
+.	O
+
+In	O
+this	O
+study	O
+,	O
+we	O
+designed	O
+small	O
+interference	O
+RNAs	O
+(	O
+siRNAs	O
+)	O
+targeting	B-PROC
+sgRNA	O
+2	O
+,	O
+3	O
+and	O
+7	O
+and	O
+tested	O
+their	O
+efficiency	O
+and	O
+specificity	O
+in	O
+silencing	O
+the	O
+protein	B-CHED
+translated	O
+from	O
+the	O
+targeted	B-PROC
+sgRNA	O
+.	O
+
+Fifty	O
+-	O
+six	O
+SARS	B-PRGE
+-	I-PRGE
+CoV	I-PRGE
+S	I-PRGE
+-	I-PRGE
+gene	I-PRGE
+sequences	I-PRGE
+,	O
+obtained	O
+from	O
+patients	O
+who	O
+presented	O
+with	O
+SARS	B-DISO
+to	O
+the	O
+Prince	O
+of	O
+Wales	O
+Hospital	O
+during	O
+March	O
+-	O
+May	O
+2003	O
+,	O
+were	O
+analysed	O
+using	O
+a	O
+maximum	O
+likelihood	O
+(	O
+ML	O
+)	O
+approach	O
+,	O
+together	O
+with	O
+138	O
+other	O
+(	O
+both	O
+human	B-SPEC
+and	O
+animal	B-SPEC
+)	O
+S	O
+-	O
+gene	O
+sequences	O
+downloaded	O
+from	O
+GenBank	O
+.	O
+
+Analysis	O
+with	O
+the	O
+other	O
+sequences	O
+,	O
+showed	O
+three	O
+distinct	O
+SARS	B-DISO
+clusters	B-CHED
+,	O
+closely	O
+correlated	O
+to	O
+previously	O
+defined	O
+early	O
+,	O
+middle	O
+and	O
+late	O
+phases	O
+of	O
+the	O
+2003	O
+international	O
+SARS	B-DISO
+outbreaks	O
+.	O
+
+RESULTS	O
+:	O
+The	O
+maximum	O
+-	O
+likelihood	O
+(	O
+ML	O
+)	O
+trees	O
+showed	O
+little	O
+evolution	B-PROC
+occurring	O
+within	O
+these	O
+56	O
+sequences	O
+.	O
+
+Sputum	B-ANAT
+and	O
+pleural	B-ANAT
+fluid	I-ANAT
+cultures	O
+helped	O
+to	O
+establish	O
+a	O
+diagnosis	O
+in	O
+91	O
+.	O
+7	O
+%	O
+(	O
+22	O
+of	O
+24	O
+)	O
+of	O
+cases	O
+.	O
+
+TITLE	O
+:	O
+Avian	B-SPEC
+influenza	B-PATH
+A	I-PATH
+(	O
+H5N1	B-DISO
+)	O
+infection	B-DISO
+in	O
+a	O
+child	O
+.	O
+
+She	O
+had	O
+a	O
+history	O
+of	O
+close	O
+contact	O
+with	O
+her	O
+domestic	O
+poultry	O
+,	O
+which	O
+was	O
+infected	O
+with	O
+avian	B-DISO
+influenza	B-PATH
+A	I-PATH
+(	O
+H5N1	B-DISO
+).	O
+
+TITLE	O
+:	O
+Public	O
+health	O
+implications	O
+of	O
+using	O
+various	O
+case	O
+definitions	O
+in	O
+The	O
+Netherlands	O
+during	O
+the	O
+worldwide	O
+SARS	B-DISO
+outbreak	O
+.	O
+
+The	O
+patients	O
+referred	O
+for	O
+SARS	B-DISO
+assessment	O
+were	O
+analysed	O
+from	O
+a	O
+public	O
+health	O
+perspective	O
+.	O
+
+None	O
+of	O
+the	O
+patients	O
+referred	O
+had	O
+SARS	B-DISO
+,	O
+based	O
+on	O
+serological	O
+and	O
+virological	O
+criteria	O
+.	O
+
+This	O
+applies	O
+not	O
+only	O
+to	O
+SARS	O
+,	O
+but	O
+also	O
+to	O
+other	O
+public	O
+health	O
+threats	O
+,	O
+such	O
+as	O
+pandemic	O
+influenza	B-DISO
+or	O
+a	O
+bioterrorist	O
+episode	O
+.	O
+
+Phylogenetic	O
+trees	O
+constructed	O
+using	O
+chymotrypsin	B-PRGE
+-	I-PRGE
+like	I-PRGE
+protease	I-PRGE
+,	O
+RNA	B-PRGE
+-	I-PRGE
+dependent	I-PRGE
+RNA	I-PRGE
+polymerase	I-PRGE
+,	O
+helicase	B-PRGE
+,	O
+spike	O
+,	O
+and	O
+nucleocapsid	B-COMP
+all	O
+showed	O
+that	O
+the	O
+group	O
+2a	O
+and	O
+2b	O
+and	O
+putative	O
+group	O
+2c	O
+and	O
+2d	O
+coronaviruses	O
+are	O
+more	O
+closely	O
+related	O
+to	O
+each	O
+other	O
+than	O
+to	O
+group	O
+1	O
+and	O
+3	O
+coronaviruses	O
+.	O
+
+CPV	B-SPEC
+-	O
+2c	O
+has	O
+been	O
+detected	O
+initially	O
+in	O
+Italy	O
+and	O
+subsequently	O
+in	O
+Vietnam	O
+.	O
+
+With	O
+a	O
+view	O
+to	O
+preclinical	O
+candidate	O
+selection	O
+we	O
+carried	O
+out	O
+metabolic	B-PROC
+stability	O
+studies	O
+using	O
+cynomolgus	B-SPEC
+monkey	I-SPEC
+liver	B-ANAT
+and	O
+intestinal	B-ANAT
+S9	O
+fractions	O
+.	O
+
+Oxygen	B-CHED
+supplementation	O
+,	O
+recent	O
+chemotherapy	O
+,	O
+and	O
+presence	O
+of	O
+peripheral	O
+edema	B-DISO
+were	O
+independent	O
+predictors	O
+of	O
+a	O
+combined	O
+outcome	O
+of	O
+ALI	O
+or	O
+severe	O
+hypoxemia	O
+after	O
+VATS	O
+talc	O
+pleurodesis	O
+.	O
+
+Patients	O
+with	O
+these	O
+characteristics	O
+might	O
+be	O
+at	O
+risk	O
+for	O
+adverse	O
+outcomes	O
+of	O
+talc	O
+pleurodesis	O
+and	O
+should	O
+be	O
+considered	O
+for	O
+alternative	O
+therapy	O
+for	O
+their	O
+effusions	B-DISO
+.	O
+
+TITLE	O
+:	O
+Genetic	O
+basis	O
+of	O
+respiratory	B-DISO
+distress	I-DISO
+syndrome	I-DISO
+.	O
+
+Spike	O
+glycoprotein	B-CHED
+of	O
+SARS	B-PRGE
+-	I-PRGE
+CoV	I-PRGE
+was	O
+recombined	O
+by	O
+using	O
+insect	B-SPEC
+-	O
+baculovirus	B-SPEC
+expression	B-PROC
+system	O
+and	O
+Nickel	B-CHED
+affinity	O
+Magnet	O
+Beads	O
+,	O
+and	O
+then	O
+used	O
+to	O
+stimulate	O
+cultured	O
+human	B-SPEC
+umbilical	B-ANAT
+vein	I-ANAT
+endothelial	B-ANAT
+cells	I-ANAT
+(	O
+HUVEC	O
+).	O
+
+212	O
+),	O
+(	O
+1	O
+,	O
+676	O
++/-	O
+199	O
+)	O
+ng	O
+/	O
+L	O
+,	O
+all	O
+P	O
+<	O
+0	O
+.	O
+05	O
+]	O
+was	O
+detected	O
+in	O
+the	O
+HUVEC	O
+12	O
+h	O
+after	O
+Spike	O
+glycoprotein	B-CHED
+(	O
+5	O
+,	O
+20	O
+,	O
+40	O
+mg	O
+/	O
+L	O
+)	O
+stimulation	O
+respectively	O
+,	O
+and	O
+presented	O
+with	O
+a	O
+significant	O
+dose	O
+-	O
+dependent	O
+response	O
+.	O
+
+A	O
+strong	O
+IP	O
+-	O
+10	O
+protein	B-PROC
+expression	B-PROC
+was	O
+also	O
+found	O
+in	O
+SARS	B-DISO
+-	O
+CoV	O
+infected	O
+lung	B-ANAT
+in	O
+autopsy	O
+.	O
+
+(	O
+2	O
+)	O
+The	O
+Spike	O
+glycoprotein	B-CHED
+of	O
+SARS	B-PRGE
+-	I-PRGE
+CoV	I-PRGE
+induced	O
+a	O
+high	O
+level	O
+of	O
+IP	O
+-	O
+10	O
+in	O
+endothelial	B-ANAT
+cells	I-ANAT
+,	O
+which	O
+in	O
+turn	O
+damaged	O
+endothelial	B-ANAT
+cells	I-ANAT
+.	O
+
+132	O
+patients	O
+with	O
+mild	O
+to	O
+moderate	O
+asthma	B-PATH
+who	O
+were	O
+allergic	O
+to	O
+HDM	O
+,	O
+recruited	O
+from	O
+three	O
+hospitals	O
+of	O
+China	O
+(	O
+The	O
+First	O
+Affiliated	O
+Hospital	O
+of	O
+Guangzhou	O
+Medical	O
+College	O
+,	O
+Shenyang	O
+General	O
+Military	O
+Hospital	O
+,	O
+Suzhou	O
+Children	O
+'	O
+s	O
+Hospital	O
+),	O
+were	O
+randomly	O
+allocated	O
+to	O
+the	O
+active	O
+group	O
+(	O
+n	O
+=	O
+66	O
+)	O
+or	O
+the	O
+control	O
+group	O
+(	O
+n	O
+=	O
+66	O
+)	O
+respectively	O
+.	O
+
+ABSTRACT	O
+:	O
+Acute	B-DISO
+pancreatitis	I-DISO
+in	O
+its	O
+severe	O
+form	O
+is	O
+complicated	O
+by	O
+multiple	O
+organ	B-ANAT
+system	I-ANAT
+dysfunction	O
+,	O
+most	O
+importantly	O
+by	O
+pulmonary	B-DISO
+complications	I-DISO
+which	O
+include	O
+hypoxia	B-DISO
+,	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+,	O
+atelectasis	B-DISO
+,	O
+and	O
+pleural	B-DISO
+effusion	I-DISO
+.	O
+
+Mutagenesis	B-PROC
+of	O
+the	O
+cysteine	B-PRGE
+cluster	I-PRGE
+I	I-PRGE
+,	O
+located	O
+immediately	O
+proximal	O
+to	O
+the	O
+predicted	O
+transmembrane	B-COMP
+,	O
+domain	O
+did	O
+not	O
+appreciably	O
+reduce	O
+cell	B-COMP
+-	O
+surface	O
+expression	B-PROC
+,	O
+although	O
+S	O
+-	O
+mediated	O
+cell	B-PROC
+fusion	I-PROC
+was	O
+reduced	O
+by	O
+more	O
+than	O
+50	O
+%	O
+in	O
+comparison	O
+to	O
+the	O
+wild	O
+-	O
+type	O
+S	O
+.	O
+Similarly	O
+,	O
+mutagenesis	B-PROC
+of	O
+the	O
+cysteine	O
+cluster	O
+II	O
+located	O
+adjacent	O
+to	O
+cluster	O
+I	O
+reduced	O
+S	O
+-	O
+mediated	O
+cell	B-PROC
+fusion	I-PROC
+by	O
+more	O
+than	O
+60	O
+%	O
+compared	O
+to	O
+the	O
+wild	O
+-	O
+type	O
+S	O
+,	O
+while	O
+cell	B-COMP
+-	O
+surface	O
+expression	B-PROC
+was	O
+reduced	O
+by	O
+less	O
+than	O
+20	O
+%.	O
+
+S	B-PRGE
+glycoprotein	I-PRGE
+palmitoylation	B-PROC
+was	O
+significantly	O
+reduced	O
+for	O
+mutant	B-DISO
+glycoproteins	B-CHED
+having	O
+cluster	O
+I	O
+and	O
+II	O
+cysteine	B-CHED
+changes	O
+,	O
+but	O
+was	O
+largely	O
+unaffected	O
+for	O
+cysteine	B-CHED
+cluster	O
+III	O
+and	O
+IV	O
+mutants	O
+.	O
+
+Pigs	B-SPEC
+represent	O
+an	O
+important	O
+animal	B-SPEC
+reservoir	O
+for	O
+influenza	B-SPEC
+virus	B-DISO
+infection	I-DISO
+of	O
+human	B-SPEC
+populations	O
+and	O
+are	O
+also	O
+naturally	O
+infected	O
+by	O
+coronaviruses	O
+,	O
+an	O
+important	O
+group	O
+of	O
+viruses	B-SPEC
+,	O
+which	O
+includes	O
+the	O
+recently	O
+emerged	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+(	O
+SARS	B-DISO
+)	O
+virus	B-SPEC
+.	O
+
+To	O
+detect	O
+HCoV	B-SPEC
+-	I-SPEC
+NL63	I-SPEC
+,	O
+previously	O
+described	O
+nested	O
+PCR	O
+assays	O
+for	O
+1a	O
+and	O
+1b	O
+were	O
+used	O
+.	O
+
+PCR	O
+products	O
+of	O
+the	O
+1a	O
+gene	O
+for	O
+HCoV	B-SPEC
+-	I-SPEC
+NL63	I-SPEC
+were	O
+sequenced	O
+.	O
+
+In	O
+this	O
+study	O
+,	O
+we	O
+designed	O
+several	O
+plasmids	O
+that	O
+express	O
+small	O
+hairpin	O
+RNA	O
+molecules	O
+(	O
+shRNA	O
+)	O
+specifically	O
+targeting	B-PROC
+to	O
+the	O
+genes	O
+encoding	O
+for	O
+the	O
+SARS	B-PRGE
+-	I-PRGE
+CoV	I-PRGE
+nucleocapsid	B-COMP
+(	I-PRGE
+N	I-PRGE
+)	I-PRGE
+protein	B-CHED
+and	O
+envelope	B-PRGE
+(	I-PRGE
+E	I-PRGE
+)	I-PRGE
+protein	B-CHED
+,	O
+respectively	O
+.	O
+
+Effective	O
+shRNA	O
+molecules	O
+to	O
+the	O
+viral	O
+genes	O
+were	O
+screened	O
+and	O
+identified	O
+,	O
+and	O
+then	O
+constructed	O
+into	O
+adenovirus	B-DISO
+vectors	O
+.	O
+
+The	O
+molecular	O
+technique	O
+we	O
+applied	O
+to	O
+detect	O
+human	B-SPEC
+coronavirus	I-SPEC
+appears	O
+justified	O
+as	O
+a	O
+valuable	O
+diagnostic	O
+approach	O
+to	O
+elucidate	O
+the	O
+prevalence	O
+,	O
+cause	O
+and	O
+clinical	O
+implications	O
+of	O
+ALRI	O
+among	O
+infants	O
+and	O
+young	O
+children	O
+.	O
+
+All	O
+patients	O
+were	O
+treated	O
+with	O
+intravenous	O
+methylprednisolone	B-CHED
+15	O
+mg	O
+/	O
+kg	O
+/	O
+day	O
+for	O
+three	O
+consecutive	O
+days	O
+and	O
+intravenous	O
+cyclophosphamide	B-CHED
+10	O
+mg	O
+/	O
+kg	O
+/	O
+day	O
+for	O
+two	O
+consecutive	O
+days	O
+,	O
+followed	O
+by	O
+intravenous	O
+dexamethasone	B-CHED
+4	O
+mg	O
+thrice	O
+a	O
+day	O
+until	O
+recovery	O
+or	O
+death	B-PROC
+.	O
+
+Three	O
+died	B-PROC
+because	O
+of	O
+severe	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+and	O
+multiorgan	O
+dysfunction	O
+syndrome	B-DISO
+.	O
+
+Recently	O
+,	O
+the	O
+Corona	B-CHED
+virus	B-SPEC
+responsible	O
+for	O
+SARS	B-DISO
+,	O
+which	O
+caused	O
+an	O
+epidemic	O
+sufficiently	O
+worrisome	O
+to	O
+challenge	O
+crisis	O
+management	O
+concepts	O
+,	O
+was	O
+successfully	O
+isolated	O
+.	O
+
+ABSTRACT	O
+:	O
+Severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+(	O
+SARS	B-DISO
+)	O
+is	O
+characterized	O
+by	O
+rapidly	O
+progressing	O
+respiratory	B-DISO
+failure	I-DISO
+resembling	O
+acute	O
+/	O
+adult	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+(	O
+ARDS	B-DISO
+)	O
+associated	O
+with	O
+uncontrolled	O
+inflammatory	B-DISO
+responses	I-DISO
+.	O
+
+Respiratory	B-DISO
+infections	I-DISO
+may	O
+have	O
+a	O
+human	B-SPEC
+source	O
+such	O
+as	O
+tuberculosis	B-PATH
+or	O
+viral	B-DISO
+diseases	I-DISO
+or	O
+may	O
+originate	O
+in	O
+ventilation	O
+systems	O
+such	O
+as	O
+Legionnaire	O
+'	O
+s	O
+disease	O
+(	O
+Legionella	B-DISO
+pneumophila	I-DISO
+pneumonia	I-DISO
+).	O
+
+Some	O
+pathogens	O
+have	O
+acquired	O
+a	O
+new	O
+epidemiological	O
+role	O
+in	O
+patients	O
+affected	O
+with	O
+immune	O
+deficiencies	O
+:	O
+among	O
+them	O
+P	B-SPEC
+.	I-SPEC
+carinii	I-SPEC
+and	O
+other	O
+bacterial	O
+,	O
+fungal	O
+and	O
+viral	O
+pathogens	O
+.	O
+
+TITLE	O
+:	O
+Participation	O
+of	O
+both	O
+host	B-COMP
+and	O
+virus	B-SPEC
+factors	O
+in	O
+induction	O
+of	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+(	O
+SARS	B-DISO
+)	O
+in	O
+F344	O
+rats	B-SPEC
+infected	O
+with	O
+SARS	B-DISO
+coronavirus	B-SPEC
+.	O
+
+During	O
+in	O
+vivo	O
+passage	O
+of	O
+SARS	B-DISO
+-	O
+CoV	O
+,	O
+a	O
+single	O
+amino	B-CHED
+acid	I-CHED
+substitution	O
+was	O
+introduced	O
+within	O
+the	O
+binding	B-FUNC
+domain	O
+of	O
+the	O
+viral	O
+spike	O
+protein	O
+recognizing	O
+angiotensin	B-PRGE
+-	I-PRGE
+converting	I-PRGE
+enzyme	I-PRGE
+2	I-PRGE
+(	O
+ACE2	B-PRGE
+),	O
+which	O
+is	O
+known	O
+as	O
+a	O
+SARS	B-PRGE
+-	I-PRGE
+CoV	I-PRGE
+receptor	I-PRGE
+.	O
+
+ABSTRACT	O
+:	O
+To	O
+explore	O
+the	O
+awareness	O
+on	O
+sever	O
+acute	O
+respiratory	O
+syndrome	O
+(	O
+SARS	B-DISO
+)	O
+and	O
+public	O
+health	O
+emergencies	B-DISO
+among	O
+general	O
+publics	O
+.	O
+
+It	O
+fits	B-DISO
+into	O
+the	O
+Becker	O
+Health	O
+Belief	O
+Model	O
+,	O
+which	O
+explains	O
+that	O
+behaviour	B-PROC
+change	O
+depends	O
+on	O
+the	O
+balance	B-PROC
+of	O
+perceived	O
+vulnerability	O
+,	O
+severity	O
+,	O
+effectiveness	O
+,	O
+and	O
+barriers	O
+.	O
+
+Malaria	B-PATH
+must	O
+always	O
+be	O
+suspected	O
+in	O
+a	O
+returning	O
+traveler	O
+or	O
+a	O
+visitor	O
+from	O
+a	O
+malaria	B-PATH
+-	O
+endemic	O
+country	O
+with	O
+an	O
+acute	O
+febrile	B-DISO
+illness	I-DISO
+.	O
+
+Malaria	B-PATH
+must	O
+be	O
+treated	O
+with	O
+effective	O
+drugs	O
+,	O
+but	O
+current	O
+choices	O
+are	O
+few	O
+:	O
+e	O
+.	O
+g	O
+.	O
+parenteral	O
+artemisinins	O
+,	O
+intravenous	O
+quinine	B-CHED
+or	O
+quinidine	B-CHED
+(	O
+in	O
+the	O
+US	O
+only	O
+).	O
+
+A	O
+recent	O
+trial	O
+in	O
+adults	O
+has	O
+shown	O
+that	O
+intravenous	O
+artesunate	B-CHED
+reduces	O
+severe	O
+malaria	B-PATH
+mortality	O
+by	O
+a	O
+third	O
+compared	O
+with	O
+adults	O
+treated	O
+with	O
+intravenous	O
+quinine	B-CHED
+.	O
+
+ALI	O
+/	O
+ARDS	B-DISO
+in	O
+pediatric	O
+malaria	B-PATH
+appears	O
+to	O
+be	O
+rare	O
+.	O
+
+This	O
+results	O
+in	O
+diagnostic	O
+confusion	B-DISO
+and	O
+suboptimal	O
+treatment	O
+.	O
+
+TITLE	O
+:	O
+Murine	B-SPEC
+coronavirus	I-SPEC
+-	O
+induced	O
+oligodendrocyte	B-PROC
+apoptosis	B-PATH
+is	O
+mediated	O
+through	O
+the	O
+activation	O
+of	O
+the	O
+Fas	O
+signaling	B-PROC
+pathway	I-PROC
+.	O
+
+Treatment	O
+with	O
+a	O
+Fas	B-DISO
+/	O
+Fc	O
+chimera	B-DISO
+,	O
+which	O
+blocks	O
+Fas	B-DISO
+-	O
+Fas	B-DISO
+ligand	B-PROC
+-	O
+mediated	O
+apoptosis	B-PATH
+,	O
+inhibited	O
+the	O
+formation	B-PROC
+of	O
+the	O
+complexes	O
+and	O
+blocked	O
+the	O
+activation	O
+of	O
+caspase	B-PRGE
+-	I-PRGE
+8	I-PRGE
+and	O
+apoptosis	B-PATH
+in	O
+MHV	B-SPEC
+-	O
+infected	O
+cells	B-COMP
+.	O
+
+The	O
+sensitivity	O
+of	O
+the	O
+system	O
+for	O
+virus	B-SPEC
+detection	O
+reached	O
+10	O
+(	O
+2	O
+)	O
+copies	O
+/	O
+microL	O
+.	O
+With	O
+the	O
+help	O
+of	O
+inner	O
+controls	O
+,	O
+the	O
+system	O
+provided	O
+reliable	O
+results	O
+without	O
+false	O
+negatives	O
+and	O
+false	O
+positives	O
+.	O
+
+The	O
+purpose	O
+of	O
+this	O
+study	O
+was	O
+to	O
+investigate	O
+the	O
+effect	O
+of	O
+AWS	B-DISO
+on	O
+length	O
+of	O
+stay	O
+,	O
+morbidity	O
+,	O
+mortality	O
+,	O
+and	O
+cost	O
+in	O
+low	O
+injury	O
+acuity	O
+trauma	O
+patients	O
+.	O
+
+However	O
+,	O
+the	O
+HI	O
+titers	O
+against	O
+the	O
+antigens	B-CHED
+used	O
+in	O
+this	O
+study	O
+were	O
+relatively	O
+similar	O
+in	O
+10	O
+out	O
+of	O
+the	O
+14	O
+flocks	O
+(	O
+71	O
+%)	O
+and	O
+the	O
+serotype	O
+of	O
+IBV	B-SPEC
+that	O
+these	O
+flocks	O
+were	O
+exposed	O
+to	O
+could	O
+not	O
+be	O
+determined	O
+and	O
+the	O
+possible	O
+causes	O
+of	O
+this	O
+are	O
+discussed	O
+.	O
+
+Utilizing	O
+the	O
+human	B-PRGE
+immunoglobulin	B-PROC
+transgenic	O
+mouse	B-SPEC
+,	O
+XenoMouse	O
+,	O
+we	O
+produced	O
+fully	O
+human	B-SPEC
+SARS	B-DISO
+-	O
+CoV	O
+spike	O
+(	O
+S	O
+)	O
+protein	B-CHED
+specific	O
+antibodies	B-COMP
+.	O
+
+Twenty	O
+-	O
+seven	O
+antibodies	B-COMP
+neutralized	O
+200TCID	O
+(	O
+50	O
+)	O
+SARS	B-DISO
+-	O
+CoV	O
+(	O
+Urbani	O
+).	O
+
+Immunoglobulin	B-PROC
+gene	O
+sequence	O
+analyses	O
+suggested	O
+at	O
+least	O
+8	O
+different	O
+binding	O
+specificities	O
+.	O
+
+First	O
+,	O
+the	O
+receptor	O
+of	O
+HCoV	O
+229E	O
+,	O
+human	B-PRGE
+aminopeptidase	B-ENZY
+N	I-ENZY
+(	O
+hAPN	O
+or	O
+CD13	B-PRGE
+)	O
+is	O
+expressed	B-PROC
+mainly	O
+on	O
+human	B-SPEC
+dendritic	B-ANAT
+cells	B-COMP
+(	O
+DCs	B-DISO
+)	O
+and	O
+macrophages	B-ANAT
+indicating	O
+that	O
+targeting	B-PROC
+of	O
+HCoV	O
+229E	O
+-	O
+based	O
+vectors	O
+to	O
+professional	O
+antigen	B-ANAT
+presenting	I-ANAT
+cells	B-COMP
+can	O
+be	O
+achieved	O
+by	O
+receptor	O
+-	O
+mediated	O
+transduction	B-PROC
+.	O
+
+HCoV	O
+229E	O
+infections	B-DISO
+are	O
+mainly	O
+encountered	O
+in	O
+children	O
+and	O
+re	O
+-	O
+infection	B-DISO
+occurs	O
+frequently	O
+in	O
+adults	O
+.	O
+
+Arterial	B-ANAT
+blood	I-ANAT
+gases	O
+were	O
+measured	O
+immediately	O
+before	O
+treatment	O
+,	O
+and	O
+again	O
+at	O
+3	O
+and	O
+6	O
+hours	O
+post	O
+-	O
+treatment	O
+.	O
+
+Hence	O
+,	O
+such	O
+related	O
+experience	O
+or	O
+clinical	O
+trials	O
+should	O
+be	O
+taken	O
+into	O
+consideration	O
+when	O
+facing	O
+the	O
+possible	O
+outbreak	O
+of	O
+avian	B-DISO
+influenza	I-DISO
+in	O
+the	O
+future	O
+.	O
+
+TITLE	O
+:	O
+Symptom	B-DISO
+combinations	O
+associated	O
+with	O
+outcome	O
+and	O
+therapeutic	O
+effects	O
+in	O
+a	O
+cohort	O
+of	O
+cases	O
+with	O
+SARS	O
+.	O
+
+The	O
+relationships	O
+between	O
+these	O
+sign	B-DISO
+/	I-DISO
+symptom	I-DISO
+complexes	O
+and	O
+outcome	O
+under	O
+two	O
+treatment	O
+protocols	O
+were	O
+evaluated	O
+and	O
+differences	O
+were	O
+noted	O
+.	O
+
+We	O
+found	O
+that	O
+a	O
+ban	B-CHED
+on	O
+journeys	O
+>	O
+50	O
+km	O
+would	O
+drastically	O
+reduce	O
+the	O
+speed	O
+and	O
+geographical	O
+spread	O
+of	O
+outbreaks	O
+,	O
+even	O
+when	O
+compliance	O
+is	O
+<	O
+100	O
+%.	O
+
+ARDS	B-DISO
+model	O
+was	O
+reproduced	O
+by	O
+intraperitoneal	O
+injection	O
+of	O
+E	B-SPEC
+.	I-SPEC
+coli	I-SPEC
+in	O
+piglets	O
+.	O
+
+In	O
+the	O
+latter	O
+two	O
+groups	O
+methylprednisolone	B-CHED
+20	O
+mg	O
+was	O
+intravenously	O
+,	O
+given	O
+every	O
+12	O
+hours	O
+(	O
+4	O
+mg	O
+(-	O
+1	O
+)	O
+xkg	O
+(-	O
+1	O
+)	O
+xd	O
+(-	O
+1	O
+)).	O
+
+Ratio	O
+of	O
+pulmonary	B-ANAT
+wet	O
+and	O
+dry	O
+(	O
+W	O
+/	O
+D	O
+)	O
+weight	O
+was	O
+determined	O
+routinely	O
+,	O
+and	O
+pathological	O
+changes	O
+and	O
+their	O
+severity	O
+were	O
+evaluated	O
+by	O
+optical	O
+microscope	O
+and	O
+Smith	O
+scores	O
+.	O
+
+Collectrin	B-PRGE
+associates	O
+with	O
+multiple	O
+apical	O
+transporters	O
+and	O
+defines	O
+a	O
+novel	O
+group	O
+of	O
+renal	B-PRGE
+amino	B-CHED
+acid	I-CHED
+transporters	I-PRGE
+.	O
+
+These	O
+data	O
+identify	O
+collectrin	B-PRGE
+as	O
+a	O
+key	O
+regulator	O
+of	O
+renal	B-ANAT
+amino	B-PROC
+acid	I-PROC
+uptake	I-PROC
+.	O
+
+TITLE	O
+:	O
+Quaternary	O
+structure	O
+,	O
+substrate	O
+selectivity	O
+and	O
+inhibitor	B-CHED
+design	O
+for	O
+SARS	B-PRGE
+3C	I-PRGE
+-	I-PRGE
+like	I-PRGE
+proteinase	B-PROC
+.	O
+
+TITLE	O
+:	O
+Bioinformatics	O
+research	O
+on	O
+the	O
+SARS	B-DISO
+coronavirus	B-SPEC
+(	O
+SARS_CoV	O
+)	O
+in	O
+China	O
+.	O
+
+ABSTRACT	O
+:	O
+Coronaviruses	O
+(	O
+CoVs	O
+),	O
+a	O
+genus	O
+containing	O
+about	O
+26	O
+known	O
+species	B-SPEC
+to	O
+date	O
+,	O
+cause	O
+highly	O
+prevalent	O
+diseases	O
+and	O
+are	O
+often	O
+severe	O
+or	O
+fatal	O
+in	O
+humans	B-SPEC
+and	O
+animals	B-SPEC
+.	O
+
+No	O
+efficacious	O
+therapy	O
+is	O
+currently	O
+available	O
+,	O
+and	O
+vaccines	O
+and	O
+drugs	O
+are	O
+under	O
+development	B-PROC
+to	O
+prevent	O
+SARS	B-DISO
+-	I-DISO
+CoV	I-DISO
+infection	I-DISO
+in	O
+many	O
+countries	O
+.	O
+
+The	O
+present	O
+mini	O
+review	O
+is	O
+focused	O
+on	O
+the	O
+area	O
+of	O
+computer	O
+-	O
+aided	O
+drug	O
+discovery	O
+,	O
+i	O
+.	O
+e	O
+.,	O
+the	O
+advances	O
+achieved	O
+mainly	O
+from	O
+the	O
+approaches	O
+of	O
+structural	O
+bioinformatics	O
+,	O
+pharmacophore	O
+modeling	O
+,	O
+molecular	O
+docking	B-PROC
+,	O
+peptide	B-CHED
+-	O
+cleavage	B-PROC
+site	O
+prediction	O
+,	O
+and	O
+other	O
+computational	O
+means	O
+.	O
+
+TITLE	O
+:	O
+Comparison	O
+of	O
+a	O
+fimbrial	O
+versus	O
+an	O
+autotransporter	O
+display	O
+system	O
+for	O
+viral	O
+epitopes	O
+on	O
+an	O
+attenuated	O
+Salmonella	B-DISO
+vaccine	O
+vector	O
+.	O
+
+ABSTRACT	O
+:	O
+Small	B-PRGE
+immunoproteins	I-PRGE
+(	O
+SIPs	B-PROC
+)	O
+are	O
+single	O
+-	O
+chain	O
+molecules	O
+comprising	O
+the	O
+variable	O
+regions	O
+of	O
+an	O
+antibody	B-COMP
+assembled	O
+in	O
+a	O
+single	O
+polypeptide	B-CHED
+(	O
+scFv	O
+)	O
+and	O
+joined	O
+to	O
+the	O
+immunoglobulin	B-PRGE
+heavy	I-PRGE
+-	I-PRGE
+chain	I-PRGE
+dimerizing	I-PRGE
+domain	I-PRGE
+.	O
+
+It	O
+has	O
+therefore	O
+been	O
+demonstrated	O
+that	O
+it	O
+is	O
+possible	O
+to	O
+confer	O
+passive	O
+immunization	O
+to	O
+newborn	O
+pigs	B-SPEC
+by	O
+feeding	O
+them	O
+with	O
+recombinant	O
+SIPs	B-PROC
+.	O
+
+TITLE	O
+:	O
+Use	O
+of	O
+prediction	O
+markets	O
+to	O
+forecast	O
+infectious	B-DISO
+disease	I-DISO
+activity	O
+.	O
+
+The	O
+extended	O
+HR	O
+regions	O
+may	O
+therefore	O
+be	O
+required	O
+to	O
+prime	O
+the	O
+group	B-PRGE
+1	I-PRGE
+S	I-PRGE
+glycoproteins	I-PRGE
+for	O
+their	O
+fusion	O
+-	O
+activating	O
+conformational	O
+changes	O
+during	O
+viral	O
+entry	O
+.	O
+
+A	O
+hybrid	O
+interferon	O
+,	O
+interferon	B-PRGE
+alpha	I-PRGE
+(	O
+IFN	O
+-	O
+alpha	O
+)	O
+B	O
+/	O
+D	O
+,	O
+and	O
+a	O
+mismatched	O
+double	O
+-	O
+stranded	O
+(	O
+ds	O
+)	O
+RNA	O
+interferon	B-PRGE
+(	O
+IFN	B-PRGE
+)	O
+inducer	O
+,	O
+Ampligen	O
+(	O
+poly	O
+I	O
+:	O
+poly	O
+C124	O
+),	O
+were	O
+the	O
+only	O
+compounds	O
+that	O
+potently	O
+inhibited	O
+virus	B-SPEC
+titres	O
+in	O
+the	O
+lungs	B-ANAT
+of	O
+infected	O
+mice	B-SPEC
+as	O
+assessed	O
+by	O
+CPE	O
+titration	O
+assays	O
+.	O
+
+When	O
+mice	B-SPEC
+were	O
+dosed	O
+intraperitoneally	O
+(	O
+i	O
+.	O
+p	O
+.)	O
+with	O
+IFN	B-PRGE
+-	I-PRGE
+alpha	I-PRGE
+B	I-PRGE
+/	O
+D	O
+once	O
+daily	O
+for	O
+3	O
+days	O
+beginning	O
+4	O
+h	O
+after	O
+virus	B-SPEC
+exposure	O
+,	O
+SARS	B-DISO
+-	O
+CoV	O
+replication	O
+in	O
+the	O
+lungs	B-ANAT
+of	O
+infected	O
+mice	B-SPEC
+was	O
+reduced	O
+by	O
+1	O
+log10	O
+at	O
+10	O
+,	O
+000	O
+and	O
+32	O
+,	O
+000	O
+IU	O
+;	O
+at	O
+the	O
+highest	O
+dose	O
+of	O
+100	O
+,	O
+000	O
+IU	O
+,	O
+virus	B-SPEC
+lung	B-ANAT
+titres	O
+were	O
+below	O
+detectable	O
+limits	O
+.	O
+
+TITLE	O
+:	O
+Antiviral	B-CHED
+activity	O
+of	O
+nucleoside	B-CHED
+analogues	I-CHED
+against	O
+SARS	B-DISO
+-	O
+coronavirus	B-SPEC
+(	O
+SARS	B-DISO
+-	O
+coV	O
+).	O
+
+S	B-SPEC
+.	I-SPEC
+pneumoniae	I-SPEC
+was	O
+detected	O
+by	O
+an	O
+in	O
+vitro	O
+rapid	O
+immunochromatographic	O
+assay	O
+for	O
+S	B-PRGE
+.	I-PRGE
+pneumoniae	I-PRGE
+antigen	B-CHED
+in	O
+urine	B-ANAT
+on	O
+the	O
+day	O
+of	O
+admission	O
+and	O
+by	O
+blood	B-ANAT
+culture	O
+2	O
+days	O
+after	O
+admission	O
+.	O
+
+Symptoms	O
+and	O
+laboratory	O
+findings	O
+improved	O
+after	O
+treatment	O
+with	O
+sivelestat	O
+sodium	B-CHED
+hydrate	I-CHED
+,	O
+antibiotics	B-CHED
+,	O
+and	O
+mechanical	O
+ventilation	O
+.	O
+
+Treatment	O
+with	O
+sivelestat	O
+sodium	B-CHED
+hydrate	I-CHED
+also	O
+decreased	O
+serum	B-PRGE
+neutrophil	B-ENZY
+elastase	I-ENZY
+activity	O
+.	O
+
+Our	O
+results	O
+suggest	O
+that	O
+thermodynamic	O
+predictions	O
+for	O
+secondary	O
+structure	O
+stability	O
+of	O
+solution	O
+-	O
+phase	O
+MB	O
+can	O
+guide	O
+probe	O
+design	O
+for	O
+nanowire	B-CHED
+-	O
+based	O
+assays	O
+.	O
+
+Buffered	O
+300	O
+-	O
+500	O
+mM	O
+NaCl	B-CHED
+was	O
+selected	O
+after	O
+comparison	O
+of	O
+several	O
+buffers	O
+previously	O
+reported	O
+for	O
+similar	O
+types	O
+of	O
+assays	O
+,	O
+and	O
+200	O
+-	O
+500	O
+mM	O
+NaCl	B-CHED
+was	O
+found	O
+to	O
+be	O
+the	O
+optimal	O
+ionic	O
+strength	O
+for	O
+the	O
+hybridization	O
+temperatures	O
+(	O
+25	O
+and	O
+50	O
+degrees	O
+C	O
+)	O
+and	O
+probe	O
+designs	O
+used	O
+here	O
+.	O
+
+Finally	O
+,	O
+we	O
+demonstrated	O
+that	O
+probe	O
+-	O
+coated	O
+nanowires	O
+retain	O
+their	O
+selectivity	O
+and	O
+sensitivity	O
+in	O
+a	O
+triplexed	O
+assay	O
+after	O
+storage	B-PROC
+for	O
+over	O
+3	O
+months	O
+.	O
+
+ABSTRACT	O
+:	O
+The	O
+outbreak	O
+of	O
+severe	O
+acute	O
+respiratory	O
+syndrome	O
+(	O
+SARS	B-DISO
+)	O
+in	O
+2003	O
+alerted	O
+the	O
+world	O
+to	O
+the	O
+new	O
+face	B-DISO
+of	O
+pandemic	O
+disease	O
+:	O
+highly	O
+contagious	O
+and	O
+fatal	O
+infections	B-DISO
+for	O
+which	O
+no	O
+vaccines	O
+are	O
+available	O
+and	O
+current	O
+drugs	O
+are	O
+largely	O
+ineffective	O
+.	O
+
+TITLE	O
+:	O
+Comparative	O
+histopathology	O
+of	O
+two	O
+serotypes	O
+of	O
+infectious	B-DISO
+bronchitis	B-DISO
+virus	B-SPEC
+(	O
+T	O
+and	O
+n1	O
+/	O
+88	O
+)	O
+in	O
+laying	O
+hens	O
+and	O
+cockerels	O
+.	O
+
+The	O
+nucleocapsid	B-COMP
+(	O
+N	O
+)	O
+gene	O
+rescued	O
+VVDeltaE3L	O
+from	O
+IFN	B-PRGE
+sensitivity	O
+.	O
+
+We	O
+have	O
+now	O
+constructed	O
+an	O
+E	O
+knockout	O
+mutant	B-DISO
+that	O
+confirms	O
+that	O
+the	O
+highly	O
+defective	O
+phenotype	O
+of	O
+the	O
+DeltaE	O
+mutant	B-DISO
+is	O
+due	O
+to	O
+loss	O
+of	O
+the	O
+E	B-PRGE
+gene	I-PRGE
+.	O
+
+However	O
+,	O
+the	O
+E	B-PRGE
+protein	I-PRGE
+of	O
+a	O
+group	O
+1	O
+coronavirus	B-SPEC
+,	O
+transmissible	O
+gastroenteritis	B-DISO
+virus	B-SPEC
+,	O
+became	O
+functional	O
+in	O
+MHV	B-SPEC
+only	O
+after	O
+acquisition	O
+of	O
+particular	O
+mutations	O
+.	O
+
+TITLE	O
+:	O
+The	O
+psychological	B-DISO
+effect	O
+of	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+on	O
+emergency	B-DISO
+department	O
+staff	O
+.	O
+
+The	O
+SARS	B-DISO
+outbreak	O
+was	O
+unique	O
+in	O
+its	O
+rapid	O
+transmission	O
+and	O
+it	O
+resulted	O
+in	O
+heavy	O
+stress	O
+in	O
+first	O
+-	O
+line	O
+healthcare	O
+workers	O
+,	O
+particularly	O
+in	O
+the	O
+emergency	B-DISO
+department	O
+.	O
+:	O
+To	O
+determine	O
+the	O
+influence	O
+of	O
+SARS	B-DISO
+on	O
+the	O
+psychological	B-DISO
+status	O
+,	O
+including	O
+post	B-DISO
+-	I-DISO
+traumatic	I-DISO
+stress	I-DISO
+disorder	I-DISO
+(	O
+PTSD	B-DISO
+)	O
+symptoms	O
+,	O
+of	O
+the	O
+staff	O
+in	O
+the	O
+emergency	B-DISO
+department	O
+.	O
+
+SARS	B-DISO
+was	O
+a	O
+traumatic	O
+experience	O
+for	O
+healthcare	O
+providers	O
+in	O
+Taiwan	O
+.	O
+
+Emergency	B-DISO
+department	O
+staff	O
+had	O
+more	O
+severe	O
+PTSD	B-DISO
+symptoms	O
+than	O
+staff	O
+in	O
+the	O
+psychiatric	O
+ward	O
+.	O
+
+ABSTRACT	O
+:	O
+Infectious	O
+bronchitis	B-DISO
+virus	B-SPEC
+(	O
+IBV	B-SPEC
+)	O
+is	O
+the	O
+prototype	O
+of	O
+the	O
+genus	B-SPEC
+Coronavirus	B-SPEC
+.	O
+
+These	O
+results	O
+show	O
+that	O
+the	O
+rate	O
+of	O
+societal	O
+learning	B-PROC
+can	O
+greatly	O
+affect	O
+the	O
+final	O
+size	O
+of	O
+disease	O
+outbreaks	O
+,	O
+justifying	O
+investment	O
+in	O
+early	O
+warning	O
+systems	O
+and	O
+attentiveness	O
+to	O
+disease	O
+outbreak	O
+by	O
+both	O
+government	O
+authorities	O
+and	O
+the	O
+public	O
+.	O
+
+ABSTRACT	O
+:	O
+Most	O
+of	O
+the	O
+individuals	O
+infected	O
+with	O
+SARS	B-DISO
+coronavirus	B-SPEC
+(	O
+SARS	B-DISO
+-	O
+CoV	O
+)	O
+spontaneously	O
+recovered	O
+without	O
+clinical	O
+intervention	O
+.	O
+
+We	O
+have	O
+found	O
+persistence	O
+of	O
+robust	O
+antibody	B-COMP
+and	O
+CTL	B-ANAT
+responses	O
+in	O
+all	O
+of	O
+the	O
+study	O
+subjects	O
+throughout	O
+the	O
+study	O
+period	O
+,	O
+with	O
+a	O
+moderate	O
+decline	O
+one	O
+year	O
+after	O
+the	O
+onset	O
+of	O
+symptoms	O
+.	O
+
+The	O
+entire	O
+ectodomain	O
+of	O
+S	B-PRGE
+protein	I-PRGE
+was	O
+fused	O
+between	O
+the	O
+gp64	O
+signal	O
+peptide	B-CHED
+and	O
+the	O
+VSV	O
+-	O
+G	O
+membrane	B-COMP
+anchor	O
+and	O
+successfully	O
+displayed	O
+on	O
+the	O
+baculovirus	B-SPEC
+surface	O
+.	O
+
+TITLE	O
+:	O
+Recombinant	B-PRGE
+activated	I-PRGE
+factor	I-PRGE
+VII	I-PRGE
+as	O
+an	O
+adjunctive	O
+therapy	O
+for	O
+bleeding	B-DISO
+control	O
+in	O
+severe	O
+trauma	O
+patients	O
+with	O
+coagulopathy	O
+:	O
+subgroup	O
+analysis	O
+from	O
+two	O
+randomized	O
+trials	O
+.	O
+
+Coagulopathy	B-DISO
+was	O
+retrospectively	O
+defined	O
+as	O
+transfusion	O
+of	O
+fresh	B-ANAT
+frozen	I-ANAT
+plasma	I-ANAT
+(	O
+FFP	B-ANAT
+)	O
+(>	O
+1	O
+unit	O
+of	O
+FFP	B-ANAT
+per	O
+4	O
+units	O
+of	O
+RBCs	B-ANAT
+),	O
+FFP	B-ANAT
+in	O
+addition	O
+to	O
+whole	B-ANAT
+blood	I-ANAT
+,	O
+and	O
+transfusion	O
+of	O
+platelets	B-ANAT
+and	O
+/	O
+or	O
+cryoprecipitate	O
+.	O
+
+rFVIIa	O
+reduced	O
+multi	B-DISO
+-	I-DISO
+organ	I-DISO
+failure	I-DISO
+and	O
+/	O
+or	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+in	O
+the	O
+coagulopathic	O
+patients	O
+(	O
+3	O
+%	O
+versus	O
+20	O
+%,	O
+P	O
+=	O
+0	O
+.	O
+004	O
+),	O
+whereas	O
+thromboembolic	B-DISO
+events	I-DISO
+were	O
+equally	O
+present	O
+in	O
+both	O
+groups	O
+(	O
+3	O
+%	O
+versus	O
+4	O
+%,	O
+P	O
+=	O
+1	O
+.	O
+00	O
+).	O
+
+Paradoxically	O
+,	O
+mechanical	O
+ventilation	O
+can	O
+exacerbate	O
+lung	B-ANAT
+damage	O
+--	O
+a	O
+phenomenon	O
+known	O
+as	O
+ventilator	O
+-	O
+induced	O
+lung	B-ANAT
+injury	O
+.	O
+
+High	O
+-	O
+frequency	O
+oscillatory	O
+ventilation	O
+(	O
+HFOV	O
+)	O
+is	O
+an	O
+unconventional	O
+form	O
+of	O
+ventilation	O
+that	O
+may	O
+improve	O
+oxygenation	B-PROC
+in	O
+patients	O
+with	O
+ARDS	B-DISO
+,	O
+while	O
+limiting	O
+further	O
+lung	B-ANAT
+injury	O
+associated	O
+with	O
+high	O
+ventilatory	O
+pressures	O
+and	O
+volumes	O
+delivered	O
+during	O
+conventional	O
+ventilation	O
+.	O
+
+Several	O
+studies	O
+suggest	O
+that	O
+HFOV	O
+may	O
+improve	O
+outcomes	O
+if	O
+used	O
+early	O
+in	O
+the	O
+course	O
+of	O
+ARDS	B-DISO
+,	O
+or	O
+if	O
+used	O
+in	O
+certain	O
+populations	O
+.	O
+
+TITLE	O
+:	O
+Severe	O
+proctitis	B-DISO
+,	O
+perforation	O
+,	O
+and	O
+fatal	O
+rectal	B-DISO
+bleeding	I-DISO
+secondary	O
+to	O
+cytomegalovirus	B-SPEC
+in	O
+an	O
+immunocompetent	O
+patient	O
+:	O
+report	O
+of	O
+a	O
+case	O
+.	O
+
+We	O
+describe	O
+a	O
+case	O
+of	O
+fatal	O
+CMV	B-SPEC
+proctitis	B-DISO
+in	O
+a	O
+71	O
+-	O
+year	O
+-	O
+old	O
+man	B-CHED
+following	O
+an	O
+Ivor	O
+-	O
+Lewis	O
+esophagectomy	O
+.	O
+
+Nosocomial	B-DISO
+infection	I-DISO
+surveillance	O
+is	O
+usually	O
+performed	O
+on	O
+inpatients	O
+only	O
+.	O
+
+In	O
+cases	O
+of	O
+this	O
+kind	O
+,	O
+in	O
+order	B-SPEC
+to	O
+quickly	O
+detect	O
+the	O
+prevalence	O
+of	O
+such	O
+infections	B-DISO
+,	O
+a	O
+surveillance	O
+system	O
+that	O
+includes	O
+hospital	O
+personnel	O
+is	O
+essential	O
+.	O
+
+TITLE	O
+:	O
+Public	O
+health	O
+awareness	O
+of	O
+emerging	O
+zoonotic	O
+viruses	B-SPEC
+of	O
+bats	B-SPEC
+:	O
+a	O
+European	O
+perspective	O
+.	O
+
+ABSTRACT	O
+:	O
+Bats	O
+classified	O
+in	O
+the	O
+order	B-SPEC
+Chiroptera	I-SPEC
+are	O
+the	O
+most	O
+abundant	O
+and	O
+widely	O
+distributed	O
+non	O
+-	O
+human	B-SPEC
+mammalian	B-SPEC
+species	B-SPEC
+in	O
+the	O
+world	O
+.	O
+
+In	O
+Europe	O
+,	O
+primary	O
+efforts	O
+should	O
+be	O
+focussed	O
+on	O
+the	O
+implementation	O
+of	O
+effective	O
+passive	O
+and	O
+active	O
+surveillance	O
+systems	O
+for	O
+EBLVs	O
+in	O
+the	O
+Serotine	O
+bat	B-ENZY
+,	O
+Eptesicus	B-SPEC
+serotinus	I-SPEC
+,	O
+and	O
+Myotis	B-SPEC
+species	B-SPEC
+(	O
+i	O
+.	O
+e	O
+.,	O
+M	B-SPEC
+.	I-SPEC
+daubentonii	I-SPEC
+and	O
+M	B-SPEC
+.	I-SPEC
+dasycneme	I-SPEC
+).	O
+
+TITLE	O
+:	O
+Expression	B-PROC
+,	O
+purification	O
+and	O
+characterization	O
+of	O
+recombinant	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+coronavirus	B-SPEC
+non	O
+-	O
+structural	O
+protein	B-CHED
+1	O
+.	O
+
+The	O
+mature	O
+SARS	B-PRGE
+-	I-PRGE
+CoV	I-PRGE
+protein	B-CHED
+is	O
+present	O
+in	O
+cells	B-COMP
+several	O
+hours	O
+post	O
+-	O
+infection	B-DISO
+and	O
+co	O
+-	O
+localizes	O
+to	O
+the	O
+viral	B-COMP
+replication	I-COMP
+complex	I-COMP
+,	O
+but	O
+its	O
+function	O
+in	O
+the	O
+viral	B-PROC
+life	I-PROC
+cycle	I-PROC
+remains	O
+unknown	O
+.	O
+
+In	O
+order	B-SPEC
+to	O
+initiate	O
+structural	O
+and	O
+biophysical	O
+studies	O
+of	O
+SARS	B-PRGE
+-	I-PRGE
+CoV	I-PRGE
+nsp1	I-PRGE
+,	O
+a	O
+recombinant	O
+expression	B-PROC
+system	O
+and	O
+a	O
+purification	O
+protocol	O
+have	O
+been	O
+developed	O
+,	O
+yielding	O
+milligram	O
+quantities	O
+of	O
+highly	O
+purified	O
+SARS	B-PRGE
+-	I-PRGE
+CoV	I-PRGE
+nsp1	I-PRGE
+.	O
+
+TITLE	O
+:	O
+Absence	O
+of	O
+surface	O
+expression	B-PROC
+of	O
+feline	B-DISO
+infectious	I-DISO
+peritonitis	I-DISO
+virus	B-SPEC
+(	O
+FIPV	O
+)	O
+antigens	B-CHED
+on	O
+infected	O
+cells	O
+isolated	O
+from	O
+cats	B-SPEC
+with	O
+FIP	B-DISO
+.	O
+
+ABSTRACT	O
+:	O
+Feline	B-DISO
+infectious	I-DISO
+peritonitis	I-DISO
+virus	B-SPEC
+(	O
+FIPV	O
+)	O
+positive	O
+cells	B-COMP
+are	O
+present	O
+in	O
+pyogranulomas	O
+and	O
+exudates	B-ANAT
+from	O
+cats	B-SPEC
+with	O
+FIP	B-DISO
+.	O
+
+No	O
+surface	O
+expression	B-PROC
+of	O
+viral	O
+antigens	B-CHED
+was	O
+detected	O
+on	O
+FIPV	O
+positive	O
+cells	B-COMP
+.	O
+
+In	O
+this	O
+study	O
+,	O
+SARS	B-DISO
+-	O
+CoV	O
+M	O
+(	O
+pro	B-CHED
+)	O
+was	O
+used	O
+to	O
+specifically	O
+remove	O
+the	O
+GST	B-PRGE
+tag	I-PRGE
+in	O
+a	O
+new	O
+fusion	B-DISO
+protein	I-DISO
+expression	B-PROC
+system	O
+.	O
+
+TITLE	O
+:	O
+The	O
+synergistic	O
+interaction	O
+of	O
+interferon	B-PRGE
+types	I-PRGE
+I	I-PRGE
+and	I-PRGE
+II	I-PRGE
+leads	O
+to	O
+marked	O
+reduction	O
+in	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+-	O
+associated	O
+coronavirus	B-SPEC
+replication	O
+and	O
+increase	O
+in	O
+the	O
+expression	B-PROC
+of	O
+mRNAs	O
+for	O
+interferon	B-PRGE
+-	O
+induced	O
+proteins	B-CHED
+.	O
+
+First	O
+,	O
+ATA	B-SPEC
+blocks	O
+the	O
+phosphorylation	B-PROC
+of	O
+extracellular	B-PRGE
+signal	I-PRGE
+-	I-PRGE
+regulated	I-PRGE
+kinase	I-PRGE
+1	I-PRGE
+/	I-PRGE
+2	I-PRGE
+,	O
+an	O
+event	O
+shown	O
+to	O
+be	O
+essential	O
+for	O
+vaccinia	B-SPEC
+virus	B-PROC
+replication	I-PROC
+.	O
+
+TITLE	O
+:	O
+Vaccine	O
+efficacy	O
+in	O
+senescent	O
+mice	B-SPEC
+challenged	O
+with	O
+recombinant	O
+SARS	B-DISO
+-	O
+CoV	O
+bearing	O
+epidemic	O
+and	O
+zoonotic	O
+spike	O
+variants	O
+.	O
+
+All	O
+Dutch	O
+isolates	O
+were	O
+identical	O
+in	O
+the	O
+ORF4a	O
+/	O
+b	O
+region	O
+at	O
+amino	B-CHED
+acid	I-CHED
+level	O
+.	O
+
+Remarkably	O
+,	O
+our	O
+analyses	O
+revealed	O
+that	O
+the	O
+laboratory	O
+adapted	O
+,	O
+prototype	O
+HCoV	B-SPEC
+-	I-SPEC
+229E	I-SPEC
+has	O
+a	O
+2	O
+-	O
+nucleotide	B-CHED
+deletion	O
+in	O
+the	O
+ORF4a	O
+/	O
+b	O
+region	O
+,	O
+whereas	O
+all	O
+clinical	O
+isolates	O
+carry	O
+a	O
+single	O
+ORF	O
+,	O
+660	O
+nt	O
+in	O
+size	O
+,	O
+encoding	O
+a	O
+single	O
+protein	B-CHED
+of	O
+219	O
+amino	B-CHED
+acids	I-CHED
+,	O
+which	O
+is	O
+a	O
+homologue	O
+of	O
+the	O
+ORF3	O
+proteins	B-CHED
+encoded	O
+by	O
+HCoV	B-SPEC
+-	I-SPEC
+NL63	I-SPEC
+and	O
+PEDV	B-SPEC
+.	O
+
+TITLE	O
+:	O
+Acute	O
+and	O
+repeated	O
+inhalation	B-PROC
+lung	B-ANAT
+injury	O
+by	O
+3	O
+-	O
+methoxybutyl	O
+chloroformate	O
+in	O
+rats	B-SPEC
+:	O
+CT	O
+-	O
+pathologic	O
+correlation	O
+.	O
+
+The	O
+CT	O
+findings	O
+include	O
+an	O
+irregular	O
+lung	B-ANAT
+surface	I-ANAT
+,	O
+areas	O
+of	O
+multifocal	O
+,	O
+wedge	O
+-	O
+shaped	O
+increased	O
+density	O
+,	O
+a	O
+heterogeneous	O
+lung	B-ANAT
+density	O
+,	O
+bronchial	B-ANAT
+dilatation	B-DISO
+,	O
+and	O
+axial	O
+peribronchovascular	O
+bundle	O
+thickening	O
+.	O
+
+The	O
+histopathology	O
+examination	O
+revealed	O
+the	O
+development	B-PROC
+of	O
+alveolar	B-ANAT
+interstitial	B-ANAT
+thickening	O
+and	O
+vasculitis	B-DISO
+,	O
+and	O
+an	O
+aggravation	O
+of	O
+the	O
+mainstem	O
+bronchial	B-ANAT
+exudates	B-ANAT
+and	O
+bronchial	B-ANAT
+inflammation	B-DISO
+.	O
+
+In	O
+the	O
+rats	B-SPEC
+exposed	O
+to	O
+lowest	O
+concentration	O
+,	O
+the	O
+pulmonary	B-ANAT
+parenchymal	O
+density	O
+and	O
+pathologic	O
+findings	O
+rapidly	O
+returned	O
+to	O
+normal	O
+within	O
+1	O
+week	O
+.	O
+
+We	O
+identified	O
+6	O
+case	O
+series	O
+reporting	O
+135	O
+pediatric	O
+SARS	B-DISO
+patients	O
+(	O
+80	O
+laboratory	O
+-	O
+confirmed	O
+,	O
+27	O
+probable	O
+and	O
+28	O
+suspect	O
+)	O
+from	O
+Canada	O
+,	O
+Hong	O
+Kong	O
+,	O
+Taiwan	O
+and	O
+Singapore	O
+.	O
+
+However	O
+,	O
+patients	O
+12	O
+years	O
+of	O
+age	O
+or	O
+younger	O
+had	O
+milder	O
+disease	O
+and	O
+were	O
+less	O
+likely	O
+than	O
+older	O
+children	O
+to	O
+be	O
+admitted	O
+to	O
+an	O
+intensive	O
+care	O
+unit	O
+,	O
+receive	O
+supplemental	O
+oxygen	B-CHED
+or	O
+be	O
+treated	O
+with	O
+methylprednisolone	B-CHED
+.	O
+
+There	O
+is	O
+only	O
+1	O
+published	O
+report	O
+of	O
+transmission	O
+of	O
+SARS	B-DISO
+virus	B-SPEC
+from	O
+a	O
+pediatric	O
+patient	O
+.	O
+
+Here	O
+,	O
+we	O
+report	O
+the	O
+crystal	B-ANAT
+structure	O
+of	O
+M	B-PRGE
+(	I-PRGE
+pro	I-PRGE
+)	I-PRGE
+at	O
+a	O
+resolution	O
+of	O
+1	O
+.	O
+82	O
+Angstroms	O
+,	O
+in	O
+space	O
+group	O
+P2	O
+(	O
+1	O
+)	O
+at	O
+pH	O
+6	O
+.	O
+0	O
+.	O
+
+TITLE	O
+:	O
+[	O
+Imported	O
+severe	O
+malaria	B-PATH
+in	O
+adults	O
+:	O
+a	O
+retrospective	O
+study	O
+of	O
+ten	O
+cases	O
+admitted	O
+to	O
+intensive	O
+care	O
+units	O
+in	O
+Casablanca	O
+].	O
+
+AV	O
+-	O
+ECLA	O
+'	O
+s	O
+contribution	O
+to	O
+oxygenation	B-PROC
+during	O
+severe	O
+hypoxemia	O
+was	O
+antagonized	O
+by	O
+a	O
+significant	O
+increase	O
+in	O
+the	O
+pulmonary	B-ANAT
+shunt	O
+fraction	O
+.	O
+
+We	O
+further	O
+characterized	O
+the	O
+full	O
+-	O
+length	O
+179	O
+-	O
+residue	O
+protein	B-CHED
+and	O
+show	O
+that	O
+the	O
+polypeptide	B-CHED
+segments	O
+of	O
+residues	O
+1	O
+to	O
+12	O
+and	O
+129	O
+to	O
+179	O
+are	O
+flexibly	O
+disordered	O
+.	O
+
+The	O
+analysis	O
+indicated	O
+that	O
+Leu296	O
+and	O
+Leu298	O
+are	O
+required	O
+for	O
+efficient	O
+nuclear	B-PROC
+export	I-PROC
+of	O
+the	O
+protein	B-CHED
+.	O
+
+Structural	O
+information	O
+indicated	O
+that	O
+both	O
+of	O
+these	O
+amino	B-CHED
+acids	I-CHED
+are	O
+available	O
+for	O
+interaction	O
+with	O
+protein	B-CHED
+complexes	O
+involved	O
+in	O
+this	O
+process	O
+.	O
+
+However	O
+,	O
+export	O
+of	O
+N	B-PRGE
+protein	I-PRGE
+from	O
+the	O
+nucleus	B-COMP
+/	O
+nucleolus	B-COMP
+was	O
+not	O
+inhibited	O
+by	O
+leptomycin	B-CHED
+B	I-CHED
+treatment	O
+,	O
+indicating	O
+that	O
+N	O
+protein	O
+nuclear	B-PROC
+export	I-PROC
+is	O
+independent	O
+of	O
+the	O
+CRM1	B-PRGE
+-	O
+mediated	O
+export	O
+pathway	B-PROC
+.	O
+
+Our	O
+newly	O
+developed	O
+MAC	B-COMP
+-	O
+ELISA	O
+system	O
+offers	O
+a	O
+new	O
+alternative	O
+for	O
+the	O
+confirmation	O
+of	O
+SARS	B-DISO
+-	I-DISO
+CoV	I-DISO
+infection	I-DISO
+.	O
+
+With	O
+patients	O
+with	O
+minor	O
+trauma	O
+as	O
+control	O
+,	O
+the	O
+data	O
+were	O
+analyzed	O
+according	O
+to	O
+injury	O
+severity	O
+score	O
+(	O
+ISS	B-DISO
+),	O
+revised	O
+trauma	O
+score	O
+(	O
+RTS	B-DISO
+),	O
+acute	O
+physiology	O
+and	O
+chronic	O
+health	O
+evaluation	O
+II	O
+(	O
+APACHE	O
+II	O
+),	O
+trauma	O
+and	O
+injury	O
+severity	O
+score	O
+(	O
+TRISS	O
+(	O
+RTS	B-DISO
+))	O
+methods	O
+for	O
+trauma	O
+and	O
+outcome	O
+study	O
+of	O
+probability	O
+of	O
+survival	O
+(	O
+Ps	O
+).	O
+
+ABSTRACT	O
+:	O
+Viruses	B-SPEC
+have	O
+evolved	O
+a	O
+myriad	O
+of	O
+strategies	O
+for	O
+promoting	O
+viral	B-PROC
+replication	I-PROC
+,	O
+survival	O
+and	O
+spread	O
+.	O
+
+Using	O
+EM	O
+techniques	O
+,	O
+we	O
+found	O
+that	O
+these	O
+putative	O
+viral	B-PROC
+replication	I-PROC
+sites	O
+were	O
+associated	O
+with	O
+characteristic	O
+membrane	B-COMP
+tubules	O
+and	O
+double	O
+membrane	B-COMP
+vesicles	B-COMP
+that	O
+most	O
+probably	O
+originated	O
+from	O
+ER	O
+cisternae	O
+.	O
+
+ABSTRACT	O
+:	O
+The	O
+present	O
+study	O
+was	O
+undertaken	O
+to	O
+study	O
+the	O
+relationship	O
+between	O
+the	O
+time	O
+of	O
+anti	O
+-	O
+snake	O
+venom	O
+(	O
+ASV	O
+)	O
+administration	O
+due	O
+to	O
+late	O
+arrival	O
+of	O
+patient	O
+at	O
+hospital	O
+and	O
+subsequent	O
+development	B-PROC
+of	O
+complications	O
+.	O
+
+The	O
+bite	B-PROC
+to	O
+needle	O
+time	O
+(	O
+time	O
+between	O
+the	O
+bite	B-PROC
+and	O
+start	O
+of	O
+ASV	O
+)	O
+was	O
+noted	O
+.	O
+
+ABSTRACT	O
+:	O
+Malaria	B-PATH
+is	O
+the	O
+tropical	B-DISO
+disease	I-DISO
+most	O
+commonly	O
+imported	O
+into	O
+the	O
+UK	O
+,	O
+with	O
+1500	O
+-	O
+2000	O
+cases	O
+reported	O
+each	O
+year	O
+,	O
+and	O
+10	O
+-	O
+20	O
+deaths	O
+.	O
+
+ALL	O
+patients	O
+treated	O
+for	O
+P	B-SPEC
+.	I-SPEC
+falciparum	I-SPEC
+malaria	O
+should	O
+be	O
+admitted	O
+to	O
+hospital	O
+for	O
+at	O
+least	O
+24	O
+h	O
+,	O
+since	O
+patients	O
+can	O
+deteriorate	O
+suddenly	O
+,	O
+especially	O
+early	O
+in	O
+the	O
+course	O
+of	O
+treatment	O
+.	O
+
+They	O
+may	O
+require	O
+haemodynamic	O
+support	O
+and	O
+management	O
+of	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+,	O
+disseminated	B-DISO
+intravascular	I-DISO
+coagulation	I-DISO
+,	O
+renal	B-DISO
+impairment	I-DISO
+/	O
+failure	O
+,	O
+seizures	B-DISO
+,	O
+and	O
+severe	O
+intercurrent	O
+infections	B-DISO
+including	O
+gram	B-DISO
+-	I-DISO
+negative	I-DISO
+bacteraemia	I-DISO
+/	O
+septicaemia	B-DISO
+.	O
+
+The	O
+treatment	O
+of	O
+choice	O
+for	O
+falciparum	B-DISO
+malaria	I-DISO
+in	O
+pregnancy	O
+is	O
+quinine	B-CHED
+;	O
+doxycycline	B-CHED
+is	O
+contraindicated	O
+in	O
+pregnancy	O
+but	O
+clindamycin	B-CHED
+can	O
+be	O
+substituted	O
+for	O
+it	O
+,	O
+and	O
+is	O
+equally	O
+effective	O
+.	O
+
+Doxycycline	B-CHED
+plus	O
+quinine	B-CHED
+should	O
+not	O
+be	O
+given	O
+to	O
+children	O
+under	O
+12	O
+years	O
+as	O
+doxycycline	B-CHED
+is	O
+contraindicated	O
+in	O
+this	O
+age	O
+group	O
+,	O
+but	O
+clindamycin	B-CHED
+can	O
+be	O
+substituted	O
+for	O
+doxycycline	B-CHED
+,	O
+and	O
+pyrimethamine	B-CHED
+-	O
+sulfadoxine	B-CHED
+(	O
+Fansidar	O
+)	O
+may	O
+also	O
+be	O
+an	O
+effective	O
+substitute	O
+.	O
+
+Among	O
+the	O
+non	O
+-	O
+SARS	B-DISO
+patients	O
+,	O
+235	O
+(	O
+93	O
+%)	O
+were	O
+diagnosed	O
+as	O
+having	O
+influenza	B-DISO
+infections	B-DISO
+(	O
+primarily	O
+H3N2	B-CHED
+subtype	O
+)	O
+and	O
+77	O
+(	O
+30	O
+%)	O
+had	O
+radiological	O
+evidence	O
+of	O
+pneumonia	B-DISO
+.	O
+
+In	O
+the	O
+early	O
+phase	O
+of	O
+the	O
+illness	O
+and	O
+after	O
+adjusting	O
+for	O
+baseline	O
+characteristics	O
+,	O
+SARS	B-DISO
+patients	O
+were	O
+less	O
+likely	O
+to	O
+have	O
+lower	O
+respiratory	B-DISO
+symptoms	I-DISO
+(	O
+e	O
+.	O
+g	O
+.	O
+sputum	B-PROC
+production	I-PROC
+,	O
+shortness	B-DISO
+of	I-DISO
+breath	I-DISO
+,	O
+chest	O
+pain	O
+)	O
+and	O
+more	O
+likely	O
+to	O
+have	O
+myalgia	B-DISO
+(	O
+p	O
+<	O
+0	O
+.	O
+001	O
+).	O
+
+The	O
+area	O
+under	O
+the	O
+receiver	O
+operator	O
+characteristic	O
+curve	O
+for	O
+predicting	O
+SARS	B-DISO
+when	O
+all	O
+variables	O
+except	O
+radiological	O
+change	O
+were	O
+considered	O
+was	O
+0	O
+.	O
+933	O
+.	O
+
+TITLE	O
+:	O
+Pandemic	O
+influenza	B-DISO
+and	O
+the	O
+hospitalist	O
+:	O
+apocalypse	O
+when	O
+?	O
+
+While	O
+the	O
+likelihood	O
+of	O
+such	O
+a	O
+prospect	O
+is	O
+uncertain	O
+,	O
+the	O
+inevitability	O
+of	O
+future	O
+pandemics	O
+of	O
+influenza	B-DISO
+is	O
+clear	O
+.	O
+
+This	O
+review	O
+focuses	O
+on	O
+the	O
+epidemiology	O
+and	O
+the	O
+pathophysiology	O
+of	O
+alcohol	O
+-	O
+induced	O
+lung	B-ANAT
+dysfunction	O
+and	O
+discusses	O
+potential	O
+new	O
+treatments	O
+suggested	O
+by	O
+recent	O
+experimental	O
+findings	O
+.	O
+
+They	O
+are	O
+relatively	O
+inexpensive	O
+and	O
+easily	O
+accessible	O
+,	O
+but	O
+their	O
+use	O
+in	O
+SARS	B-DISO
+research	O
+is	O
+limited	O
+because	O
+they	O
+do	O
+not	O
+develop	O
+illness	O
+following	O
+infection	B-DISO
+.	O
+
+Fifteen	O
+passages	O
+resulted	O
+in	O
+a	O
+virus	B-SPEC
+(	O
+MA15	O
+)	O
+that	O
+is	O
+lethal	O
+for	O
+mice	B-SPEC
+following	O
+intranasal	O
+inoculation	O
+.	O
+
+The	O
+MA15	O
+virus	B-SPEC
+has	O
+six	O
+coding	O
+mutations	O
+associated	O
+with	O
+adaptation	B-PROC
+and	O
+increased	O
+virulence	B-PROC
+;	O
+when	O
+introduced	O
+into	O
+a	O
+recombinant	B-PRGE
+SARS	I-PRGE
+-	I-PRGE
+CoV	I-PRGE
+,	O
+these	O
+mutations	O
+result	O
+in	O
+a	O
+highly	O
+virulent	O
+and	O
+lethal	O
+virus	B-SPEC
+(	O
+rMA15	O
+),	O
+duplicating	O
+the	O
+phenotype	O
+of	O
+the	O
+biologically	O
+derived	O
+MA15	O
+virus	B-SPEC
+.	O
+
+Phylogenetic	O
+analysis	O
+showed	O
+that	O
+four	O
+HKU1	O
+strains	O
+were	O
+genotype	O
+A	O
+and	O
+six	O
+genotype	O
+B	O
+.	O
+In	O
+HKU1	O
+-	O
+infected	O
+patients	O
+,	O
+the	O
+predominant	O
+clinical	O
+symptom	B-DISO
+was	O
+rhinorrhea	B-DISO
+(	O
+nine	O
+patients	O
+).	O
+
+Biochemical	O
+analysis	O
+revealed	O
+that	O
+nsp3	B-PRGE
+is	O
+an	O
+integral	O
+membrane	B-COMP
+protein	B-CHED
+that	O
+is	O
+inserted	O
+into	O
+the	O
+endoplasmic	B-COMP
+reticulum	I-COMP
+(	O
+ER	O
+)	O
+membranes	B-ANAT
+co	O
+-	O
+translationally	O
+and	O
+glycosylated	O
+at	O
+asparagine	B-CHED
+-	O
+2357	O
+.	O
+
+We	O
+show	O
+that	O
+nsp3	O
+-	O
+TM	O
+is	O
+sufficient	O
+in	O
+mediating	O
+ER	B-COMP
+membrane	I-COMP
+association	O
+of	O
+a	O
+cytosolic	B-COMP
+protein	B-CHED
+.	O
+
+TITLE	O
+:	O
+Histoplasmosis	B-DISO
+:	O
+a	O
+clinical	O
+and	O
+laboratory	O
+update	O
+.	O
+
+CSF	B-ANAT
+IgG	B-PRGE
+(	O
+range	O
+of	O
+titers	O
+,	O
+1	O
+:	O
+32	O
+to	O
+1	O
+:	O
+4	O
+,	O
+096	O
+)	O
+was	O
+detected	O
+in	O
+12	O
+cats	B-SPEC
+,	O
+including	O
+6	O
+cats	B-SPEC
+with	O
+neurologic	O
+manifestation	O
+of	O
+FIP	B-DISO
+,	O
+4	O
+cats	B-SPEC
+with	O
+FIP	B-DISO
+not	O
+involving	O
+the	O
+CNS	B-CHED
+,	O
+and	O
+2	O
+cats	O
+with	O
+brain	B-DISO
+tumors	I-DISO
+.	O
+
+Blood	B-ANAT
+contamination	O
+of	O
+CSF	B-ANAT
+resulted	O
+in	O
+<	O
+or	O
+=	O
+333	O
+erythrocytes	B-ANAT
+/	O
+microL	O
+in	O
+cats	B-SPEC
+with	O
+CSF	B-ANAT
+IgG	B-PRGE
+.	O
+
+The	O
+mortality	O
+of	O
+SARS	B-DISO
+-	O
+related	O
+ARDS	B-DISO
+is	O
+similar	O
+to	O
+the	O
+mortality	O
+of	O
+ARDS	B-DISO
+from	O
+other	O
+causes	O
+.	O
+
+Mortality	O
+was	O
+24	O
+%	O
+at	O
+hospital	O
+discharge	B-ANAT
+and	O
+at	O
+1	O
+year	O
+.	O
+
+We	O
+tested	O
+two	O
+preventive	O
+strategies	O
+,	O
+vaccination	O
+and	O
+passive	O
+transfer	O
+of	O
+serum	B-COMP
+antibody	B-COMP
+,	O
+to	O
+determine	O
+the	O
+extent	O
+of	O
+protection	O
+achieved	O
+against	O
+SARS	B-DISO
+-	O
+CoV	O
+challenge	O
+in	O
+this	O
+model	O
+.	O
+
+ABSTRACT	O
+:	O
+Yam	B-SPEC
+bean	O
+is	O
+a	O
+common	O
+food	O
+in	O
+southern	O
+Taiwan	O
+.	O
+
+One	O
+of	O
+them	O
+,	O
+a	O
+54	O
+-	O
+year	O
+-	O
+old	O
+woman	O
+,	O
+had	O
+difficulty	B-DISO
+breathing	I-DISO
+and	O
+lost	B-CHED
+consciousness	O
+.	O
+
+Yam	B-SPEC
+bean	O
+seed	O
+poisoning	O
+can	O
+cause	O
+acute	O
+metabolic	B-DISO
+acidosis	I-DISO
+and	O
+altered	B-DISO
+mental	I-DISO
+status	I-DISO
+,	O
+which	O
+could	O
+be	O
+confused	B-DISO
+with	O
+acute	O
+cyanide	B-CHED
+intoxication	O
+from	O
+a	O
+cyanogenic	B-CHED
+glycoside	I-CHED
+-	O
+containing	O
+plant	B-SPEC
+.	O
+
+Generation	O
+of	O
+viruses	B-SPEC
+with	O
+restored	O
+wild	O
+-	O
+type	O
+helical	O
+pitch	O
+resulted	O
+in	O
+increased	O
+virus	B-SPEC
+production	O
+,	O
+but	O
+some	O
+exhibited	O
+decreased	O
+virus	B-SPEC
+release	B-PATH
+.	O
+
+The	O
+clinical	O
+detection	O
+limit	O
+in	O
+patients	O
+with	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+was	O
+100	O
+copies	O
+/	O
+sample	O
+.	O
+
+TITLE	O
+:	O
+Recombinant	O
+protein	B-CHED
+-	O
+based	O
+assays	O
+for	O
+detection	O
+of	O
+antibodies	B-COMP
+to	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+coronavirus	B-SPEC
+spike	O
+and	O
+nucleocapsid	B-COMP
+proteins	B-CHED
+.	O
+
+Our	O
+assays	O
+demonstrated	O
+high	O
+sensitivity	O
+and	O
+specificity	O
+to	O
+the	O
+SARS	B-DISO
+coronavirus	B-SPEC
+in	O
+sera	B-COMP
+collected	O
+from	O
+patients	O
+as	O
+late	O
+as	O
+2	O
+years	O
+postonset	O
+of	O
+symptoms	O
+.	O
+
+The	O
+Medical	O
+Outcome	O
+Study	O
+Short	O
+-	O
+Form	O
+36	O
+Survey	O
+was	O
+given	O
+to	O
+all	O
+HCWs	O
+immediately	O
+after	O
+caring	O
+for	O
+patients	O
+with	O
+SARS	B-DISO
+and	O
+4	O
+weeks	O
+after	O
+self	O
+-	O
+quarantine	O
+and	O
+off	O
+-	O
+duty	O
+shifts	O
+.	O
+
+The	O
+recombinant	B-PRGE
+core	I-PRGE
+protein	I-PRGE
+fused	O
+with	O
+signal	O
+peptide	B-CHED
+from	O
+the	O
+C	O
+-	O
+terminus	O
+of	O
+p7	B-PRGE
+protein	B-CHED
+,	O
+but	O
+not	O
+those	O
+from	O
+the	O
+C	O
+-	O
+termini	O
+of	O
+E1	O
+and	O
+E2	O
+,	O
+could	O
+be	O
+cleaved	B-ANAT
+by	O
+SPP	B-PRGE
+.	O
+
+These	O
+bacteria	B-SPEC
+and	O
+viruses	B-SPEC
+were	O
+nebulized	O
+in	O
+separate	O
+tests	O
+and	O
+injected	O
+into	O
+the	O
+test	O
+duct	B-ANAT
+of	O
+the	O
+test	O
+facility	O
+upstream	O
+of	O
+a	O
+MERV	O
+14	O
+filter	O
+.	O
+
+The	O
+viruses	B-SPEC
+were	O
+extracted	O
+at	O
+much	O
+lower	O
+efficiencies	O
+(	O
+0	O
+.	O
+7	O
+-	O
+20	O
+%).	O
+
+Our	O
+results	O
+indicate	O
+that	O
+the	O
+airborne	O
+concentration	O
+of	O
+spore	O
+-	O
+forming	O
+bacteria	B-SPEC
+in	O
+building	O
+AHUs	O
+may	O
+be	O
+determined	O
+by	O
+analyzing	O
+the	O
+material	O
+collected	O
+on	O
+HVAC	O
+filter	O
+media	B-ANAT
+,	O
+however	O
+culture	O
+-	O
+based	O
+analytical	O
+techniques	O
+are	O
+impractical	O
+for	O
+virus	B-SPEC
+recovery	O
+.	O
+
+ABSTRACT	O
+:	O
+To	O
+map	O
+risk	O
+of	O
+exposure	O
+to	O
+severe	O
+acute	O
+respiratory	O
+syndrome	O
+(	O
+SARS	B-DISO
+)	O
+in	O
+an	O
+urban	O
+area	O
+and	O
+assess	O
+the	O
+ability	O
+of	O
+traditional	O
+interventions	O
+to	O
+control	O
+dispersion	O
+of	O
+the	O
+disease	O
+.	O
+
+GraphDNA	O
+is	O
+a	O
+new	O
+Java	O
+application	O
+that	O
+provides	O
+a	O
+simple	O
+,	O
+user	O
+-	O
+friendly	O
+interface	O
+for	O
+the	O
+visualization	O
+of	O
+DNA	O
+nucleotide	B-CHED
+composition	O
+.	O
+
+We	O
+illustrate	O
+the	O
+use	O
+of	O
+DNA	O
+skews	O
+for	O
+characterization	O
+of	O
+poxvirus	B-SPEC
+and	O
+coronavirus	B-SPEC
+genomes	O
+.	O
+
+CONCLUSIONS	O
+:	O
+GraphDNA	O
+is	O
+a	O
+platform	O
+-	O
+independent	O
+,	O
+Open	O
+Source	O
+,	O
+tool	O
+for	O
+the	O
+analysis	O
+of	O
+nucleotide	B-CHED
+trends	O
+in	O
+DNA	O
+sequences	O
+.	O
+
+Here	O
+,	O
+we	O
+characterized	O
+the	O
+proteolytic	B-PROC
+processing	I-PROC
+of	O
+the	O
+human	B-SPEC
+coronavirus	I-SPEC
+229E	I-SPEC
+(	O
+HCoV	B-SPEC
+-	I-SPEC
+229E	I-SPEC
+)	O
+amino	O
+-	O
+proximal	O
+pp1a	B-PRGE
+/	O
+pp1ab	O
+region	O
+by	O
+two	O
+paralogous	O
+PLpro	O
+activities	O
+.	O
+
+Functional	O
+and	O
+evolutionary	O
+implications	O
+of	O
+the	O
+differential	O
+amino	O
+-	O
+terminal	O
+polyprotein	O
+-	O
+processing	O
+pathways	B-PROC
+among	O
+the	O
+main	O
+CoV	O
+lineages	O
+are	O
+discussed	O
+.	O
+
+The	O
+application	O
+of	O
+the	O
+so	O
+far	O
+learnt	O
+and	O
+the	O
+continued	O
+development	B-PROC
+of	O
+preventive	O
+strategies	O
+,	O
+efficient	O
+vaccines	O
+,	O
+and	O
+antiviral	B-CHED
+substances	O
+are	O
+besides	O
+worldwide	O
+surveillance	O
+decisive	O
+to	O
+rapidly	O
+detect	O
+the	O
+repeated	O
+,	O
+enforced	O
+,	O
+or	O
+new	O
+appearance	O
+of	O
+viruses	B-SPEC
+like	O
+the	O
+SARS	B-PRGE
+-	I-PRGE
+CoV	I-PRGE
+,	O
+influenza	B-PATH
+A	I-PATH
+-	O
+H5N1	B-DISO
+virus	B-SPEC
+,	O
+or	O
+of	O
+new	O
+viruses	B-SPEC
+,	O
+to	O
+contain	O
+their	O
+spread	O
+,	O
+and	O
+to	O
+defeat	O
+them	O
+.	O
+
+TITLE	O
+:	O
+Canine	O
+coronavirus	B-SPEC
+induces	O
+apoptosis	B-PATH
+in	O
+cultured	B-ANAT
+cells	I-ANAT
+.	O
+
+By	O
+contrast	O
+,	O
+specimen	O
+was	O
+positive	O
+by	O
+reverse	B-PROC
+transcription	I-PROC
+-	O
+polymerase	O
+chain	O
+reaction	O
+and	O
+was	O
+confirmed	O
+by	O
+sequencing	O
+both	O
+genes	O
+(	O
+nucleocapsid	B-COMP
+and	O
+fusion	O
+)	O
+of	O
+human	B-SPEC
+metapneumovirus	I-SPEC
+.	O
+
+Most	O
+panel	O
+members	O
+had	O
+experience	O
+with	O
+research	O
+into	O
+the	O
+2003	O
+SARS	B-DISO
+epidemic	O
+.	O
+
+Ten	O
+of	O
+40	O
+studies	O
+reviewed	O
+were	O
+considered	O
+to	O
+be	O
+conclusive	O
+with	O
+regard	O
+to	O
+the	O
+association	O
+between	O
+building	O
+ventilation	O
+and	O
+the	O
+transmission	O
+of	O
+airborne	O
+infection	B-DISO
+.	O
+
+ABSTRACT	O
+:	O
+In	O
+order	B-SPEC
+to	O
+investigate	O
+immunogenicity	O
+in	O
+the	O
+induction	O
+of	O
+humoral	O
+and	O
+cellular	B-PROC
+immune	I-PROC
+responses	I-PROC
+,	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+associated	O
+coronavirus	B-SPEC
+(	O
+SARS	B-DISO
+-	O
+CoV	O
+)-	O
+N	O
+gene	O
+recombinant	O
+replication	O
+-	O
+defective	O
+adenoviral	B-SPEC
+vector	O
+,	O
+rAd	O
+-	O
+N	O
+,	O
+was	O
+generated	O
+and	O
+immunized	O
+BALB	O
+/	O
+c	O
+mice	B-SPEC
+in	O
+a	O
+pcDNA3	O
+.	O
+1	O
+-	O
+N	O
+prime	O
+-	O
+rAd	O
+-	O
+N	O
+boost	O
+regimen	O
+.	O
+
+TITLE	O
+:	O
+Association	O
+of	O
+bovine	B-SPEC
+respiratory	B-DISO
+disease	I-DISO
+with	O
+clinical	O
+status	O
+and	O
+acute	O
+phase	O
+proteins	B-CHED
+in	O
+calves	O
+.	O
+
+TITLE	O
+:	O
+[	O
+Lessons	O
+from	O
+SARS	B-DISO
+].	O
+
+International	O
+collaboration	O
+by	O
+teams	O
+of	O
+epidemiologists	O
+as	O
+well	O
+as	O
+virologists	O
+was	O
+the	O
+key	O
+to	O
+success	O
+against	O
+SARS	B-DISO
+(	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+).	O
+
+ABSTRACT	O
+:	O
+Infection	B-DISO
+with	O
+the	O
+SARS	B-DISO
+-	I-DISO
+associated	I-DISO
+coronavirus	I-DISO
+(	O
+SARS	B-DISO
+-	O
+CoV	O
+)	O
+induces	O
+an	O
+atypical	O
+pulmonary	B-DISO
+disease	I-DISO
+with	O
+a	O
+high	O
+lethality	O
+rate	O
+.	O
+
+ABSTRACT	O
+:	O
+The	O
+immunological	O
+assays	O
+for	O
+detection	O
+of	O
+antibodies	O
+against	O
+SARS	B-PRGE
+-	I-PRGE
+CoV	I-PRGE
+were	O
+developed	O
+in	O
+-	O
+house	O
+and	O
+some	O
+of	O
+them	O
+are	O
+available	O
+commercially	O
+.	O
+
+The	O
+samples	O
+from	O
+normal	O
+blood	B-ANAT
+donors	O
+were	O
+also	O
+tested	O
+for	O
+antibodies	B-COMP
+against	O
+other	O
+respiratory	O
+virus	B-SPEC
+.	O
+
+ABSTRACT	O
+:	O
+Monoclonal	O
+antibodies	O
+(	O
+mAbs	O
+)	O
+developed	O
+for	O
+either	O
+the	O
+prevention	O
+or	O
+treatment	O
+of	O
+viral	B-DISO
+diseases	I-DISO
+represent	O
+a	O
+small	O
+,	O
+but	O
+valuable	O
+,	O
+class	B-SPEC
+of	O
+products	O
+.	O
+
+However	O
+,	O
+the	O
+ability	O
+of	O
+mAbs	O
+to	O
+bind	B-FUNC
+to	O
+specific	O
+targets	O
+and	O
+utilize	O
+various	O
+anti	O
+-	O
+infective	O
+modes	O
+of	O
+action	O
+would	O
+seem	O
+to	O
+make	O
+them	O
+well	O
+suited	O
+for	O
+the	O
+prevention	O
+and	O
+/	O
+or	O
+treatment	O
+of	O
+a	O
+wider	O
+variety	O
+of	O
+viral	B-DISO
+diseases	I-DISO
+.	O
+
+ABSTRACT	O
+:	O
+Severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+(	O
+SARS	B-DISO
+),	O
+caused	O
+by	O
+the	O
+novel	B-SPEC
+coronavirus	I-SPEC
+SARS	B-DISO
+-	O
+CoV	O
+,	O
+produced	O
+a	O
+scare	O
+when	O
+it	O
+appeared	O
+in	O
+2003	O
+in	O
+China	O
+and	O
+later	O
+quickly	O
+spread	O
+to	O
+other	O
+countries	O
+around	O
+the	O
+world	O
+.	O
+
+It	O
+makes	O
+visible	O
+how	O
+during	O
+SARS	B-DISO
+China	O
+eventually	O
+complied	O
+with	O
+the	O
+spirit	O
+of	O
+the	O
+international	O
+sanitation	O
+regulations	O
+but	O
+the	O
+lack	O
+of	O
+commitment	O
+to	O
+improving	O
+access	O
+to	O
+health	O
+care	O
+for	O
+persons	O
+living	O
+with	O
+HIV	B-DISO
+/	I-DISO
+AIDS	I-DISO
+reflects	O
+a	O
+failure	O
+by	O
+China	O
+to	O
+guarantee	O
+the	O
+right	O
+to	O
+adequate	O
+health	O
+care	O
+.	O
+
+In	O
+all	O
+cases	O
+bronchoalveolar	B-ANAT
+lavage	I-ANAT
+fluid	I-ANAT
+was	O
+positive	O
+for	O
+Aspergillus	B-SPEC
+fumigatus	I-SPEC
+.	O
+
+In	O
+this	O
+study	O
+,	O
+we	O
+identified	O
+another	O
+viral	O
+protein	B-CHED
+,	O
+the	O
+spike	O
+of	O
+SARS	B-PRGE
+-	I-PRGE
+CoV	I-PRGE
+,	O
+which	O
+played	O
+an	O
+important	O
+role	O
+in	O
+virus	B-SPEC
+-	O
+stimulated	O
+COX	B-PRGE
+-	I-PRGE
+2	I-PRGE
+expression	B-PROC
+after	O
+screening	O
+all	O
+genes	O
+from	O
+the	O
+SARS	B-DISO
+-	O
+CoV	O
+genome	O
+.	O
+
+This	O
+pathway	B-PROC
+can	O
+be	O
+blocked	O
+by	O
+PKC	B-PRGE
+epsilon	I-PRGE
+-	I-PRGE
+specific	I-PRGE
+,	I-PRGE
+small	I-PRGE
+interfering	I-PRGE
+RNA	I-PRGE
+,	O
+PI3K	B-FUNC
+/	O
+JNK	B-FUNC
+kinase	O
+-	O
+specific	O
+inhibitors	B-CHED
+as	O
+well	O
+as	O
+dominant	B-PRGE
+negative	I-PRGE
+JNK	B-FUNC
+.	O
+
+Our	O
+results	O
+provide	O
+evidence	O
+that	O
+helps	O
+us	O
+understand	O
+the	O
+function	O
+of	O
+SRAS	B-PRGE
+-	I-PRGE
+CoV	I-PRGE
+spike	I-PRGE
+protein	I-PRGE
+in	O
+SARS	B-DISO
+pathogenesis	B-DISO
+.	O
+
+Our	O
+study	O
+indicates	O
+that	O
+bats	B-SPEC
+harbor	O
+a	O
+much	O
+wider	O
+diversity	O
+of	O
+coronaviruses	O
+than	O
+any	O
+other	O
+animal	B-SPEC
+species	B-SPEC
+.	O
+
+However	O
+,	O
+these	O
+antigens	B-CHED
+are	O
+often	O
+poorly	O
+immunogenic	O
+,	O
+and	O
+thus	O
+require	O
+the	O
+use	O
+of	O
+adjuvants	B-CHED
+to	O
+induce	O
+adequate	O
+immunity	B-PROC
+.	O
+
+These	O
+HIV	B-SPEC
+-	I-SPEC
+1	I-SPEC
+-	O
+capturing	O
+nanospheres	O
+and	O
+protein	B-CHED
+-	O
+loaded	O
+gamma	O
+-	O
+PGA	B-DISO
+nanoparticles	B-CHED
+have	O
+shown	O
+unique	O
+potential	O
+as	O
+vaccine	O
+carriers	O
+.	O
+
+Using	O
+the	O
+N	B-PRGE
+protein	I-PRGE
+gene	I-PRGE
+as	O
+target	O
+,	O
+IBVs	O
+were	O
+analyzed	O
+by	O
+reverse	B-PROC
+transcription	I-PROC
+-	O
+polymerase	O
+chain	O
+reaction	O
+/	O
+restriction	O
+fragment	O
+length	O
+polymorphism	B-PROC
+(	O
+RT	O
+-	O
+PCR	O
+/	O
+RFLP	O
+)	O
+with	O
+the	O
+restriction	O
+enzymes	O
+AvaII	O
+,	O
+HphI	O
+,	O
+Sau96I	O
+,	O
+and	O
+Tsp509I	O
+and	O
+cDNA	O
+sequencing	O
+.	O
+
+In	O
+the	O
+event	O
+of	O
+a	O
+bird	B-SPEC
+-	O
+to	O
+-	O
+human	B-SPEC
+or	O
+human	B-SPEC
+-	O
+to	O
+-	O
+human	B-SPEC
+outbreak	O
+in	O
+Hong	O
+Kong	O
+,	O
+many	O
+anticipated	O
+high	O
+fatality	O
+rates	O
+(	O
+70	O
+.	O
+5	O
+%	O
+and	O
+74	O
+.	O
+4	O
+%,	O
+respectively	O
+),	O
+permanent	O
+physical	O
+damage	O
+(	O
+52	O
+.	O
+0	O
+%	O
+and	O
+54	O
+.	O
+9	O
+%,	O
+respectively	O
+),	O
+inadequate	O
+vaccines	O
+(	O
+50	O
+.	O
+0	O
+%	O
+and	O
+64	O
+.	O
+4	O
+%,	O
+respectively	O
+),	O
+insufficient	O
+medicine	B-CHED
+supplies	O
+(	O
+43	O
+.	O
+7	O
+%	O
+and	O
+54	O
+.	O
+5	O
+%,	O
+respectively	O
+),	O
+inadequate	O
+hospital	B-DISO
+infection	I-DISO
+control	O
+(	O
+35	O
+.	O
+1	O
+%	O
+and	O
+43	O
+.	O
+3	O
+%,	O
+respectively	O
+),	O
+high	O
+susceptibility	O
+of	O
+family	B-PRGE
+members	I-PRGE
+contracting	I-PRGE
+H5N1	B-DISO
+(	O
+13	O
+.	O
+9	O
+%	O
+and	O
+24	O
+.	O
+3	O
+%,	O
+respectively	O
+),	O
+and	O
+impact	O
+on	O
+oneself	O
+/	O
+family	B-SPEC
+worse	O
+than	O
+those	O
+of	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+(	O
+21	O
+.	O
+2	O
+and	O
+25	O
+.	O
+0	O
+%,	O
+respectively	O
+).	O
+
+TITLE	O
+:	O
+How	O
+to	O
+provide	O
+an	O
+effective	O
+primary	O
+health	O
+care	O
+in	O
+fighting	O
+against	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+:	O
+the	O
+experiences	O
+of	O
+two	O
+cities	O
+.	O
+
+A	O
+questionnaire	O
+was	O
+sent	O
+to	O
+family	B-SPEC
+medicine	B-CHED
+tutors	O
+affiliated	O
+with	O
+either	O
+the	O
+Chinese	O
+University	O
+of	O
+Hong	O
+Kong	O
+or	O
+the	O
+University	O
+of	O
+Toronto	O
+in	O
+2003	O
+.	O
+
+ABSTRACT	O
+:	O
+Long	O
+pentraxin	B-PRGE
+3	I-PRGE
+(	O
+PTX3	B-PRGE
+)	O
+is	O
+a	O
+newly	O
+discovered	O
+acute	O
+phase	O
+protein	B-CHED
+produced	O
+at	O
+the	O
+sites	O
+of	O
+infection	B-DISO
+and	O
+inflammation	B-DISO
+by	O
+tissue	B-ANAT
+cells	B-COMP
+,	O
+macrophages	B-ANAT
+,	O
+monocytes	B-ANAT
+,	O
+and	O
+dendritic	B-ANAT
+cells	B-COMP
+.	O
+
+PTX3	B-PRGE
+plays	O
+an	O
+important	O
+role	O
+in	O
+preventing	O
+infection	B-DISO
+of	O
+certain	O
+fungi	B-SPEC
+,	O
+bacteria	B-SPEC
+,	O
+and	O
+viruses	B-SPEC
+in	O
+the	O
+lung	B-ANAT
+.	O
+
+Nasal	B-DISO
+discharge	B-ANAT
+was	O
+collected	O
+from	O
+24	O
+patients	O
+with	O
+PVOD	B-DISO
+.	O
+
+Viral	O
+serotypes	O
+were	O
+identified	O
+to	O
+be	O
+human	B-SPEC
+rhinovirus	I-SPEC
+(	O
+HRV	B-SPEC
+)-	O
+40	O
+,	O
+HRV	B-SPEC
+-	O
+75	O
+,	O
+HRV	B-SPEC
+-	O
+78	O
+,	O
+and	O
+HRV	B-SPEC
+-	O
+80	O
+.	O
+
+One	O
+of	O
+the	O
+four	O
+patients	O
+complained	O
+of	O
+anosmia	B-DISO
+,	O
+whereas	O
+another	O
+complained	O
+of	O
+dysosmia	B-DISO
+.	O
+
+RESULTS	O
+:	O
+Rhinoviruses	B-SPEC
+were	O
+detected	O
+in	O
+10	O
+patients	O
+by	O
+electrophoresis	O
+.	O
+
+Dual	O
+infection	B-DISO
+completely	O
+killed	O
+cells	B-COMP
+and	O
+prevented	O
+the	O
+establishment	O
+of	O
+persistent	O
+SARS	B-DISO
+-	I-DISO
+CoV	I-DISO
+infection	I-DISO
+.	O
+
+Apoptosis	B-PATH
+was	O
+induced	O
+easily	O
+in	O
+M	B-SPEC
+.	I-SPEC
+fermentans	I-SPEC
+-	O
+infected	O
+cells	B-COMP
+,	O
+indicating	O
+that	O
+they	O
+were	O
+primed	O
+for	O
+apoptosis	B-PATH
+.	O
+
+It	O
+briefly	O
+reviews	O
+the	O
+history	O
+of	O
+chiropteran	O
+viruses	B-SPEC
+and	O
+discusses	O
+their	O
+emergence	O
+in	O
+the	O
+context	O
+of	O
+geography	O
+,	O
+phylogeny	O
+,	O
+and	O
+ecology	O
+.	O
+
+Intrapulmonary	O
+expression	B-PROC
+of	O
+Caspase	B-PRGE
+-	I-PRGE
+1	I-PRGE
+,	O
+IL	B-PRGE
+-	I-PRGE
+1beta	I-PRGE
+and	O
+IL	B-PRGE
+-	I-PRGE
+18	I-PRGE
+mRNA	B-CHED
+were	O
+detected	O
+by	O
+semi	O
+-	O
+quantitative	O
+RT	O
+-	O
+PCR	O
+.	O
+
+Caspase	B-PRGE
+-	I-PRGE
+1	I-PRGE
+activation	O
+,	O
+and	O
+overproduction	O
+of	O
+IL	B-PRGE
+-	I-PRGE
+1beta	I-PRGE
+and	O
+IL	B-FUNC
+-	I-FUNC
+18	I-FUNC
+play	O
+an	O
+important	O
+role	O
+in	O
+the	O
+course	O
+of	O
+ALI	O
+,	O
+and	O
+Caspase	B-PRGE
+-	I-PRGE
+1	I-PRGE
+inhibition	B-PROC
+is	O
+effective	O
+for	O
+the	O
+treatment	O
+of	O
+ALI	O
+in	O
+experimental	O
+SAP	O
+.	O
+
+Caspase	B-PRGE
+-	I-PRGE
+1	I-PRGE
+inhibitors	B-CHED
+ameliorated	O
+the	O
+severity	O
+of	O
+ALI	O
+in	O
+SAP	B-PRGE
+.	O
+
+A	O
+similar	O
+differential	O
+effect	O
+is	O
+observed	O
+in	O
+primary	O
+human	B-SPEC
+bronchial	B-ANAT
+epithelial	B-ANAT
+cells	I-ANAT
+and	O
+in	O
+type	B-ANAT
+2	I-ANAT
+pneumocytes	I-ANAT
+although	O
+TNFalpha	B-PRGE
+is	O
+not	O
+induced	O
+in	O
+respiratory	O
+epithelial	B-ANAT
+cells	I-ANAT
+.	O
+
+Preliminary	O
+data	O
+suggest	O
+that	O
+such	O
+differential	O
+signalling	B-PROC
+involves	O
+p38	B-FUNC
+MAP	B-ENZY
+kinase	I-ENZY
+rather	O
+than	O
+NF	B-PRGE
+-	I-PRGE
+kappaB	I-PRGE
+.	O
+SARS	B-DISO
+coronavirus	B-DISO
+infection	I-DISO
+of	O
+primary	O
+human	B-SPEC
+macrophages	B-ANAT
+is	O
+associated	O
+with	O
+a	O
+strong	O
+induction	O
+of	O
+chemokines	O
+without	O
+an	O
+associated	O
+type	O
+1	O
+interferon	O
+response	O
+.	O
+
+Ottawa	O
+family	B-SPEC
+physicians	O
+;	O
+respondents	O
+can	O
+be	O
+considered	O
+a	O
+self	O
+-	O
+selected	O
+sample	O
+.	O
+
+Of	O
+these	O
+,	O
+94	O
+%	O
+would	O
+assist	O
+in	O
+immunization	O
+clinics	O
+,	O
+84	O
+%	O
+in	O
+antibiotic	B-CHED
+clinics	O
+,	O
+58	O
+%	O
+in	O
+assessment	O
+centres	O
+,	O
+52	O
+%	O
+in	O
+treatment	O
+centres	O
+,	O
+41	O
+%	O
+with	O
+declaration	O
+of	O
+death	B-PROC
+,	O
+26	O
+%	O
+with	O
+home	O
+care	O
+,	O
+and	O
+23	O
+%	O
+with	O
+telephone	O
+counseling	O
+.	O
+
+ABSTRACT	O
+:	O
+The	O
+best	O
+way	O
+to	O
+control	O
+the	O
+spread	O
+of	O
+Severe	O
+Acute	O
+Respiratory	O
+Syndrome	O
+(	O
+SARS	B-DISO
+)	O
+is	O
+measuring	O
+the	O
+body	B-ANAT
+temperature	O
+precisely	O
+,	O
+therefore	O
+,	O
+it	O
+is	O
+very	O
+important	O
+to	O
+develop	O
+a	O
+set	O
+of	O
+high	O
+-	O
+precision	O
+infrared	O
+thermodetector	O
+for	O
+Medicine	B-CHED
+.	O
+
+TITLE	O
+:	O
+Computer	O
+Aided	O
+Detection	O
+of	O
+SARS	B-DISO
+Based	O
+on	O
+Radiographs	O
+Data	O
+Mining	O
+.	O
+
+ROC	O
+charts	O
+and	O
+confusion	B-DISO
+matrix	O
+by	O
+all	O
+three	O
+methods	O
+are	O
+given	O
+and	O
+analyzed	O
+.	O
+
+TITLE	O
+:	O
+The	O
+3a	O
+Protein	B-CHED
+of	O
+SARS	B-DISO
+-	O
+coronavirus	B-SPEC
+Induces	O
+Apoptosis	B-PATH
+in	O
+Vero	O
+E6	O
+Cells	B-COMP
+.	O
+
+Here	O
+,	O
+we	O
+report	O
+a	O
+novel	O
+dual	O
+priming	O
+oligonucleotide	B-CHED
+(	O
+DPO	O
+)	O
+which	O
+contains	O
+two	O
+separate	O
+priming	O
+regions	O
+joined	O
+by	O
+a	O
+polydeoxyinosine	O
+linker	O
+.	O
+
+This	O
+DPO	O
+-	O
+based	O
+system	O
+is	O
+a	O
+fundamental	O
+tool	O
+for	O
+blocking	B-DISO
+extension	O
+of	O
+non	O
+-	O
+specifically	O
+primed	O
+templates	O
+,	O
+and	O
+thereby	O
+generates	O
+consistently	O
+high	O
+PCR	O
+specificity	O
+even	O
+under	O
+less	O
+than	O
+optimal	O
+PCR	O
+conditions	O
+.	O
+
+Towards	O
+this	O
+,	O
+we	O
+cloned	O
+ferret	B-SPEC
+cytokines	O
+and	O
+established	O
+semi	O
+-	O
+quantitative	O
+real	O
+-	O
+time	O
+PCR	O
+assays	O
+.	O
+
+The	O
+newly	O
+developed	O
+cytokine	O
+assays	O
+strengthen	O
+and	O
+expand	O
+the	O
+ferret	B-SPEC
+model	O
+not	O
+only	O
+for	O
+Morbillivirus	B-SPEC
+pathogenesis	B-DISO
+studies	O
+but	O
+also	O
+for	O
+several	O
+other	O
+human	B-SPEC
+respiratory	O
+viruses	O
+including	O
+influenza	B-DISO
+and	O
+SARS	B-DISO
+.	O
+
+TITLE	O
+:	O
+Longitudinal	O
+course	O
+and	O
+clinical	O
+significance	O
+of	O
+TGF	B-PRGE
+-	I-PRGE
+beta1	I-PRGE
+,	O
+sL	O
+-	O
+and	O
+sE	O
+-	O
+Selectins	O
+and	O
+sICAM	O
+-	O
+1	O
+levels	O
+during	O
+severe	O
+acute	O
+stress	O
+in	O
+children	O
+.	O
+
+Patients	O
+in	O
+the	O
+control	O
+group	O
+did	O
+not	O
+show	O
+an	O
+elevation	O
+of	O
+sE	O
+-	O
+Selectin	B-PROC
+and	O
+sICAM	O
+-	O
+1	O
+levels	O
+longitudinally	O
+.	O
+
+There	O
+is	O
+increasing	O
+evidence	O
+that	O
+IBV	B-SPEC
+can	O
+infect	O
+species	B-SPEC
+of	O
+bird	B-SPEC
+other	O
+than	O
+the	O
+chicken	B-SPEC
+.	O
+
+ABSTRACT	O
+:	O
+Human	O
+coronavirus	O
+NL63	O
+(	O
+HCoV	B-SPEC
+-	I-SPEC
+NL63	I-SPEC
+)	O
+is	O
+a	O
+global	O
+respiratory	B-ANAT
+tract	I-ANAT
+pathogen	O
+;	O
+however	O
+,	O
+the	O
+epidemiology	O
+of	O
+this	O
+virus	B-SPEC
+in	O
+subtropical	O
+area	O
+is	O
+not	O
+well	O
+known	O
+.	O
+
+Every	O
+enrolled	O
+child	O
+had	O
+a	O
+nasopharyngeal	B-ANAT
+aspirate	I-ANAT
+(	O
+NPA	B-CHED
+)	O
+sample	O
+taken	O
+.	O
+
+The	O
+odds	O
+ratio	O
+of	O
+croup	B-DISO
+in	O
+children	O
+infected	O
+with	O
+HCoV	B-SPEC
+-	I-SPEC
+NL63	I-SPEC
+was	O
+43	O
+.	O
+4	O
+(	O
+95	O
+%	O
+CI	O
+8	O
+.	O
+1	O
+approximately	O
+233	O
+.	O
+1	O
+).	O
+
+Antibody	B-COMP
+prophylaxis	O
+as	O
+supplemental	O
+measure	O
+generally	O
+allows	O
+for	O
+containment	O
+of	O
+higher	O
+R	O
+(	O
+0	O
+)	O
+values	O
+and	O
+restricts	O
+both	O
+the	O
+size	O
+and	O
+duration	O
+of	O
+an	O
+outbreak	O
+.	O
+
+METHODS	O
+:	O
+We	O
+developed	O
+a	O
+mathematical	O
+model	O
+to	O
+investigate	O
+the	O
+effects	O
+of	O
+hospital	O
+admission	O
+and	O
+targeted	B-PROC
+antibody	B-COMP
+prophylaxis	O
+on	O
+the	O
+reproduction	B-PROC
+number	O
+R	O
+,	O
+defined	O
+as	O
+the	O
+number	O
+of	O
+secondary	O
+cases	O
+generated	O
+by	O
+an	O
+index	O
+case	O
+,	O
+during	O
+different	O
+SARS	B-DISO
+outbreak	O
+scenarios	O
+.	O
+
+The	O
+second	O
+series	O
+describes	O
+the	O
+effect	O
+of	O
+administering	O
+30	O
+mg	O
+of	O
+furosemide	B-CHED
+intravenously	O
+along	O
+with	O
+the	O
+albumin	B-PRGE
+in	O
+15	O
+patients	O
+,	O
+exploring	O
+whether	O
+this	O
+would	O
+produce	O
+more	O
+sustained	O
+improvement	O
+in	O
+oxygenation	B-PROC
+than	O
+albumin	B-PRGE
+only	O
+.	O
+
+We	O
+report	O
+the	O
+cases	O
+of	O
+2	O
+pediatric	O
+patients	O
+with	O
+mediastinal	B-ANAT
+masses	O
+who	O
+developed	O
+serious	O
+complications	O
+during	O
+general	B-PROC
+anesthesia	I-PROC
+.	O
+
+Existing	O
+in	O
+non	O
+-	O
+identified	O
+animal	B-SPEC
+reservoirs	O
+,	O
+SARS	B-DISO
+-	O
+CoV	O
+continues	O
+to	O
+represent	O
+a	O
+threat	O
+to	O
+humans	B-SPEC
+because	O
+there	O
+is	O
+no	O
+effective	O
+specific	O
+antiviral	B-CHED
+therapy	O
+for	O
+coronavirus	B-DISO
+infections	I-DISO
+.	O
+
+Antiviral	B-CHED
+efficacy	O
+in	O
+vivo	O
+was	O
+determined	O
+by	O
+evaluating	O
+virus	B-SPEC
+titres	O
+in	O
+CCoV	O
+-	O
+infected	O
+dogs	B-SPEC
+treated	O
+orally	B-ANAT
+with	O
+1	O
+mg	O
+/	O
+kg	O
+body	B-ANAT
+weight	O
+indomethacin	B-CHED
+(	O
+INDO	O
+).	O
+
+Unexpectedly	O
+,	O
+we	O
+found	O
+that	O
+INDO	O
+has	O
+a	O
+potent	O
+direct	O
+antiviral	B-CHED
+activity	O
+against	O
+the	O
+coronaviruses	O
+SARS	B-DISO
+-	O
+CoV	O
+and	O
+CCoV	O
+.	O
+INDO	O
+does	O
+not	O
+affect	O
+coronavirus	B-SPEC
+binding	B-FUNC
+or	O
+entry	B-PROC
+into	I-PROC
+host	I-PROC
+cells	B-COMP
+,	O
+but	O
+acts	O
+by	O
+blocking	B-DISO
+viral	O
+RNA	B-PROC
+synthesis	I-PROC
+at	O
+cytoprotective	O
+doses	O
+.	O
+
+Altogether	O
+,	O
+our	O
+data	O
+show	O
+that	O
+SARS	O
+-	O
+CoV	O
+M	O
+protein	B-CHED
+induces	O
+apoptosis	B-PATH
+through	O
+the	O
+modulation	O
+of	O
+the	O
+cellular	B-COMP
+Akt	O
+pro	B-PROC
+-	I-PROC
+survival	I-PROC
+pathway	B-PROC
+and	O
+mitochondrial	B-PRGE
+cytochrome	B-PROC
+c	I-PROC
+release	B-PATH
+.	O
+
+TITLE	O
+:	O
+Managing	O
+bioterrorism	O
+mass	O
+casualties	O
+in	O
+an	O
+emergency	B-DISO
+department	O
+:	O
+lessons	O
+learned	B-PROC
+from	O
+a	O
+rural	O
+community	O
+hospital	O
+disaster	O
+drill	O
+.	O
+
+RESULTS	O
+:	O
+In	O
+univariate	O
+analyses	O
+,	O
+daily	O
+average	O
+temperature	O
+(	O
+DAT	B-ENZY
+),	O
+daily	O
+average	O
+air	B-CHED
+pressure	O
+(	O
+DAAP	O
+),	O
+and	O
+daily	O
+average	O
+relative	O
+humidity	O
+(	O
+DARH	O
+)	O
+were	O
+inversely	O
+associated	O
+with	O
+secondary	O
+attack	O
+rate	O
+(	O
+P	O
+<	O
+0	O
+.	O
+001	O
+);	O
+a	O
+significant	O
+positive	O
+association	O
+was	O
+found	O
+for	O
+daily	O
+hours	O
+of	O
+sunshine	O
+(	O
+DHS	B-DISO
+)	O
+(	O
+P	O
+<	O
+0	O
+.	O
+001	O
+).	O
+
+Viral	O
+pathogens	O
+were	O
+detected	O
+in	O
+97	O
+samples	O
+(	O
+42	O
+.	O
+7	O
+%),	O
+with	O
+4	O
+.	O
+8	O
+%	O
+of	O
+dual	O
+infections	O
+identified	O
+;	O
+respiratory	B-SPEC
+syncytial	I-SPEC
+virus	I-SPEC
+(	O
+RSV	B-SPEC
+)	O
+was	O
+detected	O
+in	O
+17	O
+.	O
+2	O
+%	O
+of	O
+children	O
+,	O
+followed	O
+by	O
+rhinovirus	B-SPEC
+(	O
+9	O
+.	O
+7	O
+%),	O
+parainfluenza	B-SPEC
+virus	I-SPEC
+type	I-SPEC
+3	I-SPEC
+(	O
+PIV3	O
+)	O
+(	O
+7	O
+.	O
+5	O
+%),	O
+and	O
+influenza	B-DISO
+type	O
+A	O
+(	O
+4	O
+.	O
+4	O
+%).	O
+
+Moreover	O
+,	O
+meningoencephalitis	B-DISO
+was	O
+diagnosed	O
+in	O
+two	O
+patients	O
+--	O
+in	O
+one	O
+of	O
+them	O
+concurrently	O
+with	O
+symptoms	B-DISO
+and	I-DISO
+signs	I-DISO
+of	O
+malaria	B-PATH
+,	O
+while	O
+in	O
+the	O
+other	O
+one	O
+-	O
+3	O
+weeks	O
+after	O
+the	O
+symptoms	O
+subsided	O
+.	O
+
+IgM	B-PRGE
+disappeared	O
+almost	O
+500	O
+days	O
+(	O
+91	O
+.	O
+8	O
+%)	O
+after	O
+the	O
+onset	O
+.	O
+
+When	O
+N	B-PRGE
+-	I-PRGE
+IgG	I-PRGE
+and	O
+S	B-PRGE
+-	I-PRGE
+IgG	I-PRGE
+were	O
+tested	O
+40	O
+days	O
+after	O
+the	O
+onset	O
+of	O
+the	O
+disease	O
+at	O
+three	O
+different	O
+times	O
+,	O
+the	O
+positive	O
+rate	O
+of	O
+N	B-PRGE
+-	I-PRGE
+IgG	I-PRGE
+(	O
+92	O
+.	O
+5	O
+%,	O
+37	O
+/	O
+40	O
+)	O
+was	O
+higher	O
+than	O
+that	O
+of	O
+S	B-PRGE
+-	I-PRGE
+IgG	I-PRGE
+(	O
+67	O
+.	O
+5	O
+%,	O
+27	O
+/	O
+40	O
+),	O
+but	O
+the	O
+two	O
+structure	O
+protein	B-CHED
+antibodies	B-COMP
+were	O
+always	O
+lower	O
+than	O
+the	O
+total	O
+IgG	B-PRGE
+.	O
+
+TITLE	O
+:	O
+Natural	O
+mutations	O
+in	O
+the	O
+receptor	B-FUNC
+binding	I-FUNC
+domain	O
+of	O
+spike	O
+glycoprotein	B-CHED
+determine	O
+the	O
+reactivity	O
+of	O
+cross	O
+-	O
+neutralization	O
+between	O
+palm	O
+civet	B-SPEC
+coronavirus	B-SPEC
+and	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+coronavirus	B-SPEC
+.	O
+
+In	O
+addition	O
+,	O
+blood	B-ANAT
+samples	I-ANAT
+were	O
+obtained	O
+from	O
+two	O
+captive	O
+margays	B-SPEC
+(	O
+Leopardus	B-SPEC
+wiedii	I-SPEC
+).	O
+
+Both	O
+margays	B-SPEC
+were	O
+seropositive	O
+for	O
+feline	O
+coronavirus	B-SPEC
+and	O
+one	O
+was	O
+strongly	O
+seropositive	O
+to	O
+T	B-SPEC
+.	I-SPEC
+gondii	I-SPEC
+.	O
+
+All	O
+animals	B-SPEC
+were	O
+seronegative	O
+for	O
+D	B-SPEC
+.	I-SPEC
+immitis	I-SPEC
+.	O
+
+This	O
+survey	O
+provides	O
+preliminary	O
+information	O
+about	O
+feline	B-DISO
+diseases	I-DISO
+endemic	O
+to	O
+the	O
+Petén	O
+region	O
+.	O
+
+Our	O
+data	O
+indicate	O
+that	O
+shielding	O
+of	O
+viral	O
+RNA	O
+to	O
+host	B-COMP
+cell	I-COMP
+sensors	O
+might	O
+be	O
+the	O
+main	O
+general	O
+mechanism	O
+for	O
+coronaviruses	O
+to	O
+prevent	O
+IFN	B-PRGE
+induction	O
+.	O
+
+TITLE	O
+:	O
+Severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+--	O
+retrospect	O
+and	O
+lessons	O
+of	O
+2004	O
+outbreak	O
+in	O
+China	O
+.	O
+
+Initial	O
+two	O
+cases	O
+were	O
+most	O
+likely	O
+to	O
+be	O
+infected	O
+in	O
+Diarrhea	B-DISO
+Virus	B-SPEC
+Laboratory	O
+of	O
+National	O
+Institute	O
+of	O
+Virology	O
+,	O
+China	O
+Centers	O
+for	O
+Disease	O
+Control	O
+and	O
+Prevention	O
+and	O
+main	O
+mode	O
+of	O
+transmission	O
+was	O
+direct	O
+contact	O
+with	O
+SARS	B-DISO
+patients	O
+.	O
+
+SARS	B-DISO
+outbreak	O
+in	O
+2004	O
+has	O
+yielded	O
+following	O
+lessons	O
+for	O
+public	O
+health	O
+globally	O
+.	O
+
+Platelet	B-PROC
+aggregation	I-PROC
+was	O
+analyzed	O
+by	O
+an	O
+aggregometer	O
+using	O
+laser	B-SPEC
+light	O
+(	O
+PA	O
+-	O
+200	O
+,	O
+laser	B-SPEC
+light	O
+scattering	O
+).	O
+
+China	O
+has	O
+the	O
+world	O
+'	O
+s	O
+second	O
+largest	O
+tuberculosis	O
+epidemic	O
+,	O
+but	O
+progress	O
+in	O
+tuberculosis	B-PATH
+control	O
+was	O
+slow	O
+during	O
+the	O
+1990s	O
+.	O
+
+TITLE	O
+:	O
+Ultrastructural	O
+study	O
+of	O
+infectious	B-DISO
+bronchitis	B-DISO
+virus	B-DISO
+infection	I-DISO
+in	O
+infundibulum	B-ANAT
+and	O
+magnum	O
+of	O
+commercial	O
+laying	O
+hens	O
+.	O
+
+ABSTRACT	O
+:	O
+The	O
+infundibulum	O
+and	O
+magnum	O
+of	O
+the	O
+oviduct	B-ANAT
+were	O
+examined	O
+in	O
+hens	O
+in	O
+full	O
+lay	O
+which	O
+were	O
+infected	O
+with	O
+two	O
+Australian	O
+strains	O
+of	O
+infectious	B-DISO
+bronchitis	B-DISO
+virus	B-SPEC
+(	O
+IBV	B-SPEC
+).	O
+
+Virus	B-COMP
+particles	I-COMP
+were	O
+detected	O
+mostly	O
+in	O
+the	O
+rough	B-COMP
+endoplasmic	I-COMP
+reticulum	I-COMP
+(	O
+RER	B-COMP
+)	O
+and	O
+Golgi	B-COMP
+complex	I-COMP
+between	O
+10	O
+and	O
+12	O
+days	O
+p	O
+.	O
+i	O
+.	O
+
+Eggs	O
+with	O
+watery	O
+whites	B-SPEC
+which	O
+were	O
+laid	O
+by	O
+infected	O
+hens	O
+could	O
+be	O
+attributed	O
+to	O
+cytopathological	O
+changes	O
+in	O
+the	O
+granular	B-ANAT
+epithelial	B-ANAT
+cells	I-ANAT
+and	O
+tubular	O
+gland	B-ANAT
+epithelial	B-ANAT
+cells	I-ANAT
+of	O
+the	O
+magnum	O
+resulting	O
+in	O
+reduced	O
+synthesis	B-PROC
+of	O
+albumen	O
+proteins	B-CHED
+.	O
+
+TITLE	O
+:	O
+Exposure	O
+of	O
+free	O
+-	O
+ranging	O
+maned	O
+wolves	O
+(	O
+Chrysocyon	B-SPEC
+brachyurus	I-SPEC
+)	O
+to	O
+infectious	B-DISO
+and	O
+parasitic	B-DISO
+disease	I-DISO
+agents	O
+in	O
+the	O
+Noël	O
+Kempff	O
+Mercado	O
+National	O
+Park	B-DISO
+,	O
+Bolivia	O
+.	O
+
+ABSTRACT	O
+:	O
+Maned	O
+wolves	O
+(	O
+Chrysocyon	B-SPEC
+brachyurus	I-SPEC
+)	O
+are	O
+neotropic	O
+mammals	B-SPEC
+,	O
+listed	O
+as	O
+a	O
+CITES	O
+Appendix	B-ANAT
+II	O
+species	B-SPEC
+,	O
+with	O
+a	O
+distribution	O
+south	O
+of	O
+the	O
+Amazon	B-SPEC
+forest	O
+from	O
+Bolivia	O
+,	O
+through	O
+northern	O
+Argentina	B-SPEC
+and	O
+Paraguay	O
+and	O
+into	O
+eastern	O
+Brazil	O
+and	O
+northern	O
+Uruguay	O
+.	O
+
+The	O
+company	O
+may	O
+initiate	O
+phase	O
+II	O
+clinical	O
+trials	O
+in	O
+breast	B-DISO
+cancer	B-SPEC
+and	O
+oesophageal	B-DISO
+cancer	I-DISO
+in	O
+2006	O
+.	O
+
+In	O
+April	O
+2006	O
+,	O
+a	O
+total	O
+of	O
+210	O
+events	O
+(	O
+patient	O
+deaths	B-PROC
+)	O
+was	O
+reached	O
+,	O
+representing	O
+two	O
+-	O
+thirds	O
+of	O
+the	O
+required	O
+events	O
+for	O
+the	O
+study	O
+.	O
+
+Alfacell	O
+completed	O
+a	O
+phase	O
+III	O
+trial	O
+of	O
+single	O
+-	O
+agent	O
+ranpirnase	O
+in	O
+patients	O
+with	O
+unresectable	O
+malignant	B-DISO
+mesothelioma	I-DISO
+in	O
+April	O
+1999	O
+.	O
+
+In	O
+preclinical	O
+studies	O
+,	O
+ranpirnase	O
+demonstrated	O
+significant	O
+activity	O
+against	O
+neuroblastoma	B-DISO
+,	O
+rhabdomyosarcoma	B-DISO
+and	O
+chemotherapy	O
+-	O
+resistant	O
+variants	O
+of	O
+these	O
+cancer	B-ANAT
+cells	B-COMP
+.	O
+
+infusion	O
+of	O
+lipopolysaccharide	B-CHED
+(	O
+LPS	B-DISO
+;	O
+Escherichia	B-SPEC
+coli	I-SPEC
+10	O
+mg	O
+/	O
+kg	O
+).	O
+
+Lipopolysaccharide	B-CHED
+produced	O
+systemic	O
+hypotension	O
+and	O
+tachycardia	O
+.	O
+
+TITLE	O
+:	O
+Feline	B-SPEC
+aminopeptidase	B-ENZY
+N	I-ENZY
+is	O
+not	O
+a	O
+functional	O
+receptor	O
+for	O
+avian	B-DISO
+infectious	I-DISO
+bronchitis	I-DISO
+virus	B-SPEC
+.	O
+
+ABSTRACT	O
+:	O
+Coronaviruses	O
+are	O
+an	O
+important	O
+cause	O
+of	O
+infectious	O
+diseases	O
+in	O
+humans	B-SPEC
+,	O
+including	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+(	O
+SARS	B-DISO
+),	O
+and	O
+have	O
+the	O
+continued	O
+potential	O
+for	O
+emergence	O
+from	O
+animal	B-SPEC
+species	B-SPEC
+.	O
+
+However	O
+,	O
+a	O
+notable	O
+exception	O
+is	O
+the	O
+receptor	O
+utilization	O
+by	O
+group	O
+3	O
+coronaviruses	O
+,	O
+including	O
+avian	B-DISO
+infectious	I-DISO
+bronchitis	I-DISO
+virus	B-SPEC
+(	O
+IBV	B-SPEC
+).	O
+
+Here	O
+we	O
+show	O
+that	O
+,	O
+whereas	O
+both	O
+transient	O
+transfection	B-PROC
+and	O
+constitutive	O
+expression	B-PROC
+of	O
+fAPN	O
+on	O
+BHK	O
+-	O
+21	O
+cells	B-COMP
+can	O
+rescue	O
+FIPV	O
+and	O
+TGEV	B-SPEC
+infection	B-DISO
+in	O
+non	O
+-	O
+permissive	O
+BHK	O
+cells	B-COMP
+,	O
+fAPN	O
+expression	B-PROC
+does	O
+not	O
+rescue	O
+infection	B-DISO
+by	O
+the	O
+prototype	O
+IBV	B-SPEC
+strain	O
+Mass41	O
+.	O
+
+We	O
+also	O
+show	O
+that	O
+BHK	O
+-	O
+21	O
+cells	B-COMP
+are	O
+slightly	O
+susceptible	O
+to	O
+certain	O
+IBV	B-SPEC
+strains	O
+,	O
+including	O
+Ark99	O
+,	O
+Ark_DPI	O
+,	O
+CA99	O
+,	O
+and	O
+Iowa97	O
+(<	O
+0	O
+.	O
+01	O
+%	O
+efficiency	O
+),	O
+but	O
+this	O
+level	O
+of	O
+infection	B-DISO
+is	O
+not	O
+increased	O
+by	O
+fAPN	O
+expression	B-PROC
+.	O
+
+In	O
+addition	O
+to	O
+SARS	B-DISO
+-	O
+like	O
+coronaviruses	O
+,	O
+many	O
+other	O
+novel	O
+bat	B-ENZY
+coronaviruses	O
+,	O
+which	O
+belong	O
+to	O
+groups	O
+1	O
+and	O
+2	O
+of	O
+the	O
+3	O
+existing	O
+coronavirus	B-SPEC
+groups	O
+,	O
+have	O
+been	O
+detected	O
+by	O
+PCR	O
+.	O
+
+Toronto	O
+HCWs	O
+reported	O
+significantly	O
+higher	O
+levels	O
+of	O
+burnout	O
+(	O
+p	O
+=	O
+0	O
+.	O
+019	O
+),	O
+psychological	B-DISO
+distress	I-DISO
+(	O
+p	O
+<	O
+0	O
+.	O
+001	O
+),	O
+and	O
+posttraumatic	O
+stress	O
+(	O
+p	O
+<	O
+0	O
+.	O
+001	O
+).	O
+
+It	O
+was	O
+caused	O
+by	O
+a	O
+novel	O
+animal	B-SPEC
+coronavirus	B-SPEC
+,	O
+never	O
+recognized	O
+or	O
+characterized	O
+before	O
+.	O
+
+This	O
+review	O
+will	O
+provide	O
+first	O
+-	O
+hand	O
+information	O
+,	O
+particularly	O
+from	O
+Guangdong	O
+,	O
+China	O
+,	O
+about	O
+the	O
+initial	O
+epidemiology	O
+,	O
+the	O
+identification	O
+of	O
+the	O
+aetiological	O
+agent	O
+of	O
+the	O
+disease	O
+,	O
+the	O
+molecular	O
+evolution	B-PROC
+study	O
+of	O
+the	O
+virus	B-SPEC
+,	O
+the	O
+finding	O
+of	O
+SARS	B-PRGE
+-	I-PRGE
+like	I-PRGE
+CoV	I-PRGE
+in	O
+horseshoe	B-SPEC
+bats	I-SPEC
+and	O
+the	O
+mechanistic	O
+analysis	O
+for	O
+the	O
+cross	O
+-	O
+host	O
+tropism	B-PROC
+transition	B-DISO
+.	O
+
+It	O
+is	O
+aimed	O
+to	O
+appreciate	O
+the	O
+concerted	O
+and	O
+coordinated	O
+global	O
+response	O
+that	O
+controlled	O
+SARS	B-DISO
+within	O
+a	O
+short	O
+period	O
+of	O
+time	O
+as	O
+well	O
+as	O
+the	O
+research	O
+strategy	O
+and	O
+methodology	O
+developed	O
+along	O
+with	O
+this	O
+process	O
+,	O
+which	O
+can	O
+be	O
+applied	O
+in	O
+response	O
+to	O
+other	O
+public	O
+health	O
+challenges	O
+,	O
+particularly	O
+the	O
+future	O
+emerging	O
+/	O
+re	O
+-	O
+merging	O
+infectious	B-DISO
+diseases	I-DISO
+.	O
+
+Viruses	B-SPEC
+with	O
+wild	O
+-	O
+type	O
+phenotype	O
+were	O
+readily	O
+recovered	O
+with	O
+the	O
+K	O
+or	O
+A	O
+substitutions	O
+.	O
+
+An	O
+additional	O
+second	O
+-	O
+site	O
+compensatory	O
+V202I	O
+substitution	O
+was	O
+present	O
+in	O
+some	O
+viruses	B-SPEC
+.	O
+
+The	O
+potential	O
+of	O
+Myt1	B-PRGE
+to	O
+play	O
+a	O
+role	O
+in	O
+OP	O
+responses	O
+leading	O
+to	O
+remyelination	B-PROC
+was	O
+examined	O
+using	O
+murine	B-DISO
+hepatitis	I-DISO
+virus	B-SPEC
+strain	O
+A59	O
+(	O
+MHV	B-SPEC
+)	O
+to	O
+induce	O
+spinal	B-ANAT
+cord	I-ANAT
+demyelination	B-DISO
+and	O
+potential	O
+relevance	O
+to	O
+human	B-SPEC
+pathology	B-DISO
+was	O
+evaluated	O
+in	O
+multiple	B-DISO
+sclerosis	I-DISO
+(	O
+MS	O
+)	O
+lesions	O
+.	O
+
+Cells	B-COMP
+with	O
+nuclear	O
+Myt1	O
+immunoreactivity	B-PROC
+were	O
+mainly	O
+OP	O
+cells	B-COMP
+,	O
+identified	O
+by	O
+co	O
+-	O
+localization	B-PROC
+with	O
+platelet	B-FUNC
+-	I-FUNC
+derived	I-FUNC
+growth	B-PROC
+factor	I-FUNC
+alpha	I-PRGE
+receptor	I-PRGE
+,	O
+with	O
+additional	O
+phenotypes	O
+being	O
+either	O
+oligodendrocytes	O
+or	O
+neural	B-ANAT
+stem	I-ANAT
+cells	I-ANAT
+,	O
+identified	O
+by	O
+CC1	B-PRGE
+antigen	I-PRGE
+and	O
+Musashi1	B-PRGE
+,	O
+respectively	O
+.	O
+
+Although	O
+described	O
+as	O
+a	O
+cause	O
+of	O
+gastroenteritis	B-DISO
+in	O
+HIV	B-DISO
+patients	O
+,	O
+with	O
+the	O
+exception	O
+of	O
+the	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+(	O
+SARS	B-DISO
+),	O
+there	O
+is	O
+little	O
+in	O
+the	O
+literature	O
+about	O
+respiratory	B-DISO
+infection	I-DISO
+in	O
+HIV	B-DISO
+patients	O
+.	O
+
+Here	O
+,	O
+we	O
+demonstrated	O
+that	O
+efficient	O
+expression	B-PROC
+of	O
+S	O
+from	O
+the	O
+wild	O
+-	O
+type	O
+spike	O
+gene	O
+in	O
+cultured	B-ANAT
+cells	I-ANAT
+required	O
+the	O
+use	O
+of	O
+improved	O
+plasmid	O
+vectors	O
+containing	O
+donor	B-CHED
+and	O
+acceptor	B-CHED
+splice	O
+sites	O
+,	O
+as	O
+well	O
+as	O
+heterologous	O
+viral	O
+RNA	O
+export	O
+elements	O
+,	O
+such	O
+as	O
+the	O
+CTE	B-DISO
+of	O
+Mazon	O
+-	O
+Pfizer	O
+monkey	B-SPEC
+virus	B-SPEC
+or	O
+the	O
+PRE	O
+of	O
+Woodchuck	B-SPEC
+hepatitis	I-SPEC
+virus	I-SPEC
+(	O
+WPRE	O
+).	O
+
+TITLE	O
+:	O
+Successful	O
+treatment	O
+of	O
+life	O
+-	O
+threatening	O
+melioidosis	B-DISO
+with	O
+activated	O
+protein	B-CHED
+C	O
+and	O
+meropenem	B-CHED
+.	O
+
+TITLE	O
+:	O
+[	O
+Further	O
+analysis	O
+and	O
+study	O
+based	O
+on	O
+a	O
+visualized	O
+method	O
+for	O
+SARS	B-DISO
+RNA	O
+sequences	O
+].	O
+
+During	O
+the	O
+SARS	B-DISO
+outbreak	O
+in	O
+2003	O
+,	O
+ED	O
+visits	O
+declined	O
+by	O
+21	O
+%	O
+(	O
+95	O
+%	O
+confidence	O
+interval	O
+[	O
+CI	O
+],	O
+18	O
+%-	O
+24	O
+%)	O
+over	O
+the	O
+4	O
+-	O
+week	O
+study	O
+period	O
+.	O
+
+In	O
+2004	O
+,	O
+the	O
+year	O
+following	O
+the	O
+SARS	B-DISO
+outbreak	O
+,	O
+visit	O
+patterns	O
+shifted	O
+toward	O
+baseline	O
+levels	O
+,	O
+but	O
+ED	O
+visits	O
+by	O
+infants	O
+and	O
+toddlers	O
+remained	O
+depressed	O
+.	O
+
+RESULTS	O
+:	O
+During	O
+the	O
+SARS	B-DISO
+outbreak	O
+in	O
+2003	O
+,	O
+ED	O
+visits	O
+declined	O
+by	O
+21	O
+%	O
+(	O
+95	O
+%	O
+confidence	O
+interval	O
+[	O
+CI	O
+],	O
+18	O
+%-	O
+24	O
+%)	O
+over	O
+the	O
+4	O
+-	O
+week	O
+study	O
+period	O
+.	O
+
+TITLE	O
+:	O
+Strong	O
+antiviral	B-CHED
+activity	O
+of	O
+heated	O
+and	O
+hydrated	O
+dolomite	O
+--	O
+preliminary	O
+investigation	O
+.	O
+
+This	O
+research	O
+may	O
+facilitate	O
+those	O
+healthcare	O
+services	O
+planning	O
+to	O
+minimise	O
+the	O
+impact	O
+of	O
+infection	B-DISO
+control	O
+measures	O
+on	O
+patient	O
+care	O
+.	O
+
+TITLE	O
+:	O
+Serum	B-ANAT
+alpha1	I-PRGE
+-	I-PRGE
+acid	I-PRGE
+glycoprotein	B-CHED
+(	O
+AGP	B-PRGE
+)	O
+concentration	O
+in	O
+non	O
+-	O
+symptomatic	O
+cats	B-SPEC
+with	O
+feline	B-SPEC
+coronavirus	B-SPEC
+(	O
+FCoV	O
+)	O
+infection	B-DISO
+.	O
+
+ABSTRACT	O
+:	O
+Coronaviruses	O
+(	O
+CoVs	O
+)	O
+possess	B-DISO
+large	O
+RNA	O
+genomes	O
+and	O
+exist	O
+as	O
+quasispecies	O
+,	O
+which	O
+increases	O
+the	O
+possibility	O
+of	O
+adaptive	O
+mutations	O
+and	O
+interspecies	O
+transmission	O
+.	O
+
+TITLE	O
+:	O
+Severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+coronavirus	B-SPEC
+accessory	O
+protein	B-CHED
+6	O
+is	O
+a	O
+virion	B-COMP
+-	O
+associated	O
+protein	B-CHED
+and	O
+is	O
+released	O
+from	O
+6	O
+protein	B-CHED
+-	O
+expressing	O
+cells	B-COMP
+.	O
+
+TITLE	O
+:	O
+Antiviral	B-CHED
+effects	O
+of	O
+antisense	O
+morpholino	O
+oligomers	O
+in	O
+murine	B-SPEC
+coronavirus	I-SPEC
+infection	O
+models	O
+.	O
+
+We	O
+have	O
+used	O
+several	O
+strains	O
+of	O
+murine	B-DISO
+hepatitis	I-DISO
+virus	B-SPEC
+(	O
+MHV	B-SPEC
+)	O
+in	O
+cell	B-COMP
+culture	O
+and	O
+in	O
+vivo	O
+in	O
+mouse	B-SPEC
+models	O
+to	O
+investigate	O
+the	O
+antiviral	B-CHED
+characteristics	O
+of	O
+peptide	B-CHED
+-	O
+conjugated	O
+antisense	O
+phosphorodiamidate	O
+morpholino	O
+oligomers	O
+(	O
+P	O
+-	O
+PMOs	O
+).	O
+
+This	O
+status	O
+changed	O
+dramatically	O
+with	O
+the	O
+emergence	O
+of	O
+SARS	B-DISO
+-	O
+CoV	O
+in	O
+2002	O
+/	O
+2003	O
+.	O
+
+The	O
+4	O
+human	B-SPEC
+coronaviruses	O
+HCoV	B-SPEC
+-	I-SPEC
+229E	I-SPEC
+,	O
+HCoV	B-SPEC
+-	I-SPEC
+OC43	I-SPEC
+,	O
+HCoV	B-SPEC
+-	I-SPEC
+NL63	I-SPEC
+and	O
+HCoV	O
+-	O
+HKU1	O
+cause	O
+mild	O
+respiratory	O
+illnesses	O
+when	O
+compared	O
+to	O
+SARS	B-DISO
+,	O
+but	O
+these	O
+infections	B-DISO
+are	O
+involved	O
+in	O
+10	O
+-	O
+20	O
+%	O
+of	O
+hospitalizations	O
+of	O
+young	O
+children	O
+and	O
+immunocompromised	O
+adults	O
+with	O
+respiratory	B-ANAT
+tract	I-ANAT
+illness	O
+.	O
+
+ABSTRACT	O
+:	O
+Fragments	O
+within	O
+S1	O
+genes	O
+((	O
+poly100	O
+)	O
+S1	O
+)	O
+of	O
+infectious	B-DISO
+bronchitis	B-DISO
+virus	B-SPEC
+(	O
+IBV	B-SPEC
+)	O
+strains	O
+ZJ971	O
+,	O
+M41	O
+and	O
+SC021202	O
+(	O
+SC	O
+)	O
+were	O
+subcloned	O
+into	O
+a	O
+prokaryotic	O
+expression	B-PROC
+vector	O
+and	O
+expressed	B-PROC
+in	O
+Escherichia	B-SPEC
+coli	I-SPEC
+.	O
+
+The	O
+last	O
+indication	O
+is	O
+generally	O
+more	O
+applicable	O
+in	O
+children	O
+than	O
+adults	O
+,	O
+because	O
+of	O
+differences	O
+in	O
+the	O
+cardiovascular	B-ANAT
+response	O
+to	O
+severe	B-DISO
+sepsis	I-DISO
+seen	O
+across	O
+age	O
+groups	O
+.	O
+
+ECMO	O
+has	O
+a	O
+role	O
+as	O
+rescue	O
+therapy	O
+in	O
+patients	O
+with	O
+severe	B-DISO
+sepsis	I-DISO
+who	O
+would	O
+otherwise	O
+die	O
+of	O
+either	O
+hypoxaemia	O
+or	O
+inadequate	O
+cardiac	B-ANAT
+output	O
+.	O
+
+Avian	B-DISO
+influenza	I-DISO
+(	O
+H5N1	B-DISO
+)	O
+is	O
+a	O
+new	O
+emerging	O
+virus	B-SPEC
+usually	O
+contracted	O
+from	O
+direct	O
+contact	O
+with	O
+diseased	O
+birds	B-SPEC
+.	O
+
+Pregnant	O
+women	O
+should	O
+be	O
+treated	O
+aggressively	O
+with	O
+supportive	O
+care	O
+and	O
+antiviral	O
+medications	O
+,	O
+as	O
+the	O
+significant	O
+risk	O
+of	O
+maternal	O
+mortality	O
+outweighs	O
+the	O
+potential	O
+fetal	B-ANAT
+risks	O
+.	O
+
+Therefore	O
+,	O
+CBAs	O
+qualify	O
+as	O
+potential	O
+microbicide	B-CHED
+drugs	O
+.	O
+
+TITLE	O
+:	O
+Angiogenesis	B-PROC
+in	O
+chronic	B-DISO
+lung	I-DISO
+disease	I-DISO
+.	O
+
+ABSTRACT	O
+:	O
+Severe	O
+acute	B-DISO
+pancreatitis	I-DISO
+has	O
+long	O
+been	O
+known	O
+to	O
+be	O
+a	O
+cause	O
+of	O
+pulmonary	O
+dysfunction	O
+and	O
+multisystem	B-DISO
+organ	I-DISO
+failure	I-DISO
+.	O
+
+Arterial	B-ANAT
+blood	I-ANAT
+gas	O
+analysis	O
+and	O
+chest	B-ANAT
+X	O
+-	O
+rays	B-SPEC
+were	O
+performed	O
+in	O
+all	O
+patients	O
+at	O
+admission	O
+and	O
+at	O
+intervals	O
+,	O
+when	O
+clinically	O
+indicated	O
+.	O
+
+On	O
+logistic	O
+regression	O
+analysis	O
+,	O
+the	O
+development	B-PROC
+of	O
+respiratory	B-DISO
+failure	I-DISO
+and	O
+other	O
+organ	B-ANAT
+dysfunctions	O
+were	O
+independent	O
+risk	O
+factors	O
+for	O
+mortality	O
+.	O
+
+RESULTS	O
+:	O
+The	O
+mean	O
+age	O
+was	O
+42	O
+.	O
+9	O
++/-	O
+15	O
+.	O
+9	O
+years	O
+(	O
+range	O
+:	O
+18	O
+-	O
+80	O
+years	O
+)	O
+and	O
+the	O
+etiology	O
+of	O
+the	O
+pancreatitis	B-DISO
+was	O
+gallstones	B-DISO
+in	O
+29	O
+patients	O
+,	O
+alcohol	O
+in	O
+22	O
+patients	O
+while	O
+no	O
+cause	O
+could	O
+be	O
+ascertained	O
+in	O
+9	O
+.	O
+
+The	O
+patients	O
+who	O
+were	O
+hypoxemic	O
+at	O
+presentation	O
+had	O
+a	O
+higher	O
+incidence	O
+of	O
+organ	B-DISO
+failure	I-DISO
+during	O
+the	O
+course	O
+of	O
+the	O
+disease	O
+.	O
+
+The	O
+public	O
+in	O
+Hong	O
+Kong	O
+is	O
+likely	O
+to	O
+adopt	O
+self	O
+-	O
+protective	O
+behaviors	B-PROC
+(	O
+e	O
+.	O
+g	O
+.,	O
+wearing	O
+face	B-DISO
+mask	O
+in	O
+public	O
+venues	O
+(	O
+73	O
+.	O
+8	O
+%),	O
+increasing	O
+the	O
+frequency	O
+of	O
+handwashing	O
+(	O
+86	O
+.	O
+7	O
+%))	O
+and	O
+behaviors	B-PROC
+that	O
+protect	O
+others	O
+(	O
+e	O
+.	O
+g	O
+.,	O
+wearing	O
+face	B-DISO
+masks	O
+when	O
+experiencing	O
+influenza	B-DISO
+-	I-DISO
+like	I-DISO
+illness	I-DISO
+(	O
+ILI	O
+,	O
+92	O
+.	O
+4	O
+%),	O
+immediately	O
+seeking	O
+medical	O
+consultation	O
+(	O
+94	O
+.	O
+2	O
+%),	O
+making	O
+declarations	O
+when	O
+crossing	O
+the	O
+border	B-ANAT
+with	O
+ILI	O
+(	O
+87	O
+.	O
+1	O
+%),	O
+complying	O
+to	O
+quarantine	O
+policies	O
+(	O
+88	O
+.	O
+3	O
+%)).	O
+
+Multivariate	O
+analyses	O
+indicated	O
+that	O
+factors	O
+related	O
+to	O
+age	O
+,	O
+full	O
+-	O
+time	O
+employment	O
+,	O
+perceived	O
+susceptibility	O
+,	O
+perceived	O
+efficacy	O
+of	O
+preventive	O
+measures	O
+,	O
+perceived	O
+higher	O
+fatality	O
+as	O
+compared	O
+to	O
+SARS	B-DISO
+,	O
+perceived	O
+chance	O
+of	O
+a	O
+major	O
+local	O
+outbreak	O
+,	O
+and	O
+being	O
+worried	O
+about	O
+self	O
+/	O
+family	B-SPEC
+members	O
+contracting	O
+the	O
+virus	B-SPEC
+were	O
+significantly	O
+associated	O
+with	O
+the	O
+inclination	O
+to	O
+adopt	O
+self	O
+-	O
+protective	O
+measures	O
+.	O
+
+CONCLUSIONS	O
+:	O
+In	O
+the	O
+event	O
+of	O
+a	O
+human	B-SPEC
+-	O
+to	O
+-	O
+human	B-SPEC
+H5N1	B-DISO
+outbreak	O
+,	O
+the	O
+public	O
+in	O
+Hong	O
+Kong	O
+is	O
+likely	O
+to	O
+adopt	O
+preventive	O
+measures	O
+that	O
+may	O
+help	O
+contain	O
+the	O
+spread	O
+of	O
+the	O
+virus	B-SPEC
+in	O
+the	O
+community	O
+.	O
+
+ABSTRACT	O
+:	O
+The	O
+positive	O
+strand	O
+RNA	O
+coronavirus	O
+,	O
+infectious	B-DISO
+bronchitis	B-DISO
+virus	B-SPEC
+(	O
+IBV	B-SPEC
+),	O
+induces	O
+a	O
+G2	O
+/	O
+M	B-PROC
+phase	I-PROC
+arrest	I-PROC
+and	O
+reduction	O
+in	O
+the	O
+G1	O
+and	O
+G1	O
+/	O
+S	B-PROC
+phase	I-PROC
+transition	B-DISO
+regulator	O
+cyclin	B-PRGE
+D1	I-PRGE
+.	O
+
+Confocal	O
+microscopy	O
+revealed	O
+that	O
+cyclin	B-PRGE
+D1	I-PRGE
+decreased	O
+in	O
+IBV	B-SPEC
+-	O
+infected	O
+cells	B-COMP
+as	O
+infection	B-DISO
+progressed	O
+and	O
+inhibition	B-PROC
+studies	O
+indicated	O
+that	O
+a	O
+population	O
+of	O
+cyclin	B-PRGE
+D1	I-PRGE
+could	O
+be	O
+targeted	B-PROC
+for	O
+degradation	O
+by	O
+a	O
+virus	B-SPEC
+mediated	O
+pathway	B-PROC
+.	O
+
+ABSTRACT	O
+:	O
+Severe	O
+acute	O
+respiratory	O
+syndrome	O
+(	O
+SARS	B-DISO
+)	O
+is	O
+a	O
+newly	O
+emergent	O
+human	B-SPEC
+disease	O
+,	O
+which	O
+requires	O
+rapid	O
+diagnosis	O
+and	O
+effective	O
+therapy	O
+.	O
+
+Among	O
+antibody	B-COMP
+sources	O
+,	O
+immunoglobulin	B-PRGE
+Y	I-PRGE
+(	O
+IgY	O
+)	O
+is	O
+the	O
+major	O
+antibody	B-COMP
+found	O
+in	O
+chicken	B-SPEC
+eggs	O
+and	O
+can	O
+be	O
+used	O
+as	O
+an	O
+alternative	O
+to	O
+mammalian	B-SPEC
+antibodies	B-COMP
+normally	O
+used	O
+in	O
+research	O
+and	O
+immunotherapy	O
+.	O
+
+Truncated	O
+fragments	O
+of	O
+SARS	B-PRGE
+-	I-PRGE
+CoV	I-PRGE
+spike	I-PRGE
+protein	B-CHED
+were	O
+cloned	O
+in	O
+pET	O
+-	O
+21	O
+vector	O
+and	O
+expressed	B-PROC
+in	O
+BL	O
+-	O
+21	O
+Escherichia	B-SPEC
+coli	I-SPEC
+(	O
+E	B-SPEC
+.	I-SPEC
+coli	I-SPEC
+)	O
+cells	B-COMP
+.	O
+
+A	O
+phage	O
+displaying	O
+scFv	O
+library	O
+was	O
+also	O
+established	O
+from	O
+spleen	B-ANAT
+B	B-ANAT
+cells	I-ANAT
+of	O
+immunized	O
+chicken	B-SPEC
+with	O
+5	O
+x	O
+10	O
+(	O
+7	O
+)	O
+clones	O
+.	O
+
+ABSTRACT	O
+:	O
+Over	O
+the	O
+last	O
+century	O
+,	O
+changes	O
+in	O
+land	B-COMP
+-	O
+use	O
+,	O
+modification	O
+of	O
+agriculture	O
+-	O
+livestock	O
+production	O
+systems	O
+,	O
+disruption	O
+of	O
+wildlife	O
+habitats	O
+,	O
+increase	O
+of	O
+human	B-SPEC
+activities	O
+,	O
+higher	O
+frequency	O
+of	O
+international	O
+and	O
+intercontinental	O
+travels	O
+,	O
+wider	O
+circulation	B-PROC
+of	O
+animals	B-SPEC
+and	O
+animal	B-SPEC
+products	O
+have	O
+contributed	O
+to	O
+alter	O
+the	O
+distribution	O
+,	O
+presence	O
+and	O
+density	O
+of	O
+hosts	B-COMP
+and	O
+vectors	O
+.	O
+
+Some	O
+infectious	B-DISO
+pathogens	O
+,	O
+originated	O
+in	O
+wild	O
+animals	B-SPEC
+and	O
+/	O
+or	O
+maintained	O
+in	O
+sylvatic	O
+environments	O
+,	O
+have	O
+become	O
+increasingly	O
+important	O
+worldwide	O
+for	O
+their	O
+impact	O
+on	O
+wildlife	O
+,	O
+human	B-SPEC
+health	O
+,	O
+livestock	O
+and	O
+agricultural	O
+production	O
+systems	O
+.	O
+
+This	O
+study	O
+found	O
+the	O
+noise	O
+levels	O
+reached	O
+98	O
+.	O
+5	O
+-	O
+107	O
+.	O
+5	O
+dB	O
+in	O
+power	O
+generator	O
+rooms	O
+and	O
+air	O
+-	O
+conditioning	O
+facilities	O
+,	O
+and	O
+suggests	O
+employees	O
+use	O
+ear	B-ANAT
+plugs	O
+.	O
+
+Thus	O
+,	O
+the	O
+anti	O
+-	O
+cancer	B-DISO
+utility	O
+of	O
+suppressing	O
+Bcl	B-PRGE
+-	I-PRGE
+2	I-PRGE
+in	O
+cancer	B-ANAT
+cells	B-COMP
+is	O
+limited	O
+.	O
+
+Comparisons	O
+of	O
+the	O
+enteric	O
+(	O
+jejunum	B-ANAT
+)	O
+and	O
+non	O
+-	O
+enteric	O
+(	O
+liver	B-ANAT
+)	O
+derived	O
+viral	O
+RNA	O
+sequences	O
+revealed	O
+100	O
+%	O
+nucleotide	B-CHED
+identity	O
+,	O
+a	O
+finding	O
+that	O
+questions	O
+the	O
+well	O
+accepted	O
+'	O
+internal	O
+mutation	O
+theory	O
+'	O
+of	O
+FIPV	O
+pathogenicity	O
+.	O
+
+Intracerebral	O
+infection	B-DISO
+of	O
+mice	B-SPEC
+with	O
+mouse	B-DISO
+hepatitis	I-DISO
+virus	B-SPEC
+(	O
+MHV	B-SPEC
+)	O
+results	O
+in	O
+an	O
+acute	O
+encephalomyelitis	B-DISO
+followed	O
+by	O
+an	O
+immune	O
+-	O
+mediated	O
+demyelinating	B-DISO
+disease	I-DISO
+.	O
+
+TITLE	O
+:	O
+Detection	O
+of	O
+turkey	B-SPEC
+coronavirus	B-SPEC
+in	O
+commercial	O
+turkey	B-SPEC
+poults	O
+in	O
+Brazil	O
+.	O
+
+Rutamarin	O
+(	O
+4	O
+)	O
+showed	O
+significant	O
+inhibitory	O
+activities	O
+against	O
+A	O
+-	O
+549	O
+,	O
+Bel	B-PRGE
+-	I-PRGE
+7402	I-PRGE
+,	O
+HepG	O
+-	O
+2	O
+and	O
+HCT	O
+-	O
+8	O
+tumour	B-ANAT
+cell	B-COMP
+lines	O
+with	O
+IC50s	O
+of	O
+1	O
+.	O
+318	O
+,	O
+2	O
+.	O
+082	O
+,	O
+2	O
+.	O
+306	O
+and	O
+2	O
+.	O
+497	O
+microg	O
+/	O
+ml	O
+.	O
+
+TITLE	O
+:	O
+Why	O
+did	O
+outbreaks	O
+of	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+occur	O
+in	O
+some	O
+hospital	O
+wards	O
+but	O
+not	O
+in	O
+others	O
+?	O
+
+Relevant	O
+information	O
+about	O
+host	B-COMP
+factors	O
+was	O
+abstracted	O
+from	O
+the	O
+medical	O
+records	O
+.	O
+
+The	O
+lessons	O
+learned	B-PROC
+from	O
+this	O
+study	O
+remain	O
+very	O
+important	O
+and	O
+highly	O
+relevant	O
+to	O
+the	O
+daily	O
+operation	O
+of	O
+hospital	O
+wards	O
+if	O
+we	O
+are	O
+to	O
+prevent	O
+nosocomial	O
+outbreaks	O
+of	O
+other	O
+respiratory	B-DISO
+infections	I-DISO
+in	O
+the	O
+future	O
+.	O
+
+The	O
+recombinant	B-PRGE
+N	I-PRGE
+protein	I-PRGE
+was	O
+migrated	O
+at	O
+48	O
+kDa	O
+and	O
+reacted	O
+with	O
+six	O
+histidine	B-PRGE
+tag	B-DISO
+specific	I-PRGE
+monoclonal	I-PRGE
+antibody	B-COMP
+by	O
+immunoblotting	O
+.	O
+
+The	O
+main	O
+objective	O
+of	O
+the	O
+network	O
+is	O
+to	O
+establish	O
+permanent	O
+communication	O
+between	O
+European	O
+Union	O
+(	O
+EU	O
+)	O
+Member	O
+States	O
+'	O
+public	O
+health	O
+authorities	O
+,	O
+which	O
+are	O
+responsible	O
+for	O
+determining	O
+the	O
+measures	O
+required	O
+to	O
+control	O
+communicable	B-DISO
+disease	I-DISO
+-	O
+related	O
+events	O
+.	O
+
+ABSTRACT	O
+:	O
+Progressive	O
+immune	O
+-	O
+associated	O
+injury	O
+is	O
+a	O
+hallmark	O
+of	O
+severe	O
+acute	O
+respiratory	O
+syndrome	O
+(	O
+SARS	B-DISO
+).	O
+
+Here	O
+we	O
+review	O
+recent	O
+advances	O
+in	O
+SARS	B-DISO
+immunopathogenesis	O
+research	O
+and	O
+present	O
+a	O
+summary	O
+of	O
+our	O
+findings	O
+regarding	O
+host	O
+responses	O
+in	O
+SARS	B-DISO
+patients	O
+.	O
+
+ABSTRACT	O
+:	O
+The	O
+sequential	O
+determination	O
+of	O
+crystal	B-ANAT
+structures	O
+of	O
+the	O
+SARS	B-PRGE
+coronavirus	B-SPEC
+spike	I-PRGE
+receptor	I-PRGE
+-	I-PRGE
+binding	B-FUNC
+domain	I-PRGE
+(	O
+RBD	O
+)	O
+in	O
+complex	O
+with	O
+its	O
+cellular	B-COMP
+receptor	O
+or	O
+neutralizing	O
+antibody	B-COMP
+opened	O
+a	O
+door	O
+for	O
+the	O
+design	O
+and	O
+development	B-PROC
+of	O
+antiviral	B-CHED
+competitive	O
+inhibitors	B-CHED
+.	O
+
+TITLE	O
+:	O
+Inhaled	B-PROC
+nitric	B-CHED
+oxide	I-CHED
+in	O
+newborns	O
+with	O
+severe	O
+hypoxic	B-DISO
+respiratory	B-DISO
+failure	I-DISO
+.	O
+
+Diagnosis	O
+was	O
+confirmed	O
+by	O
+2	O
+-	O
+D	O
+echocardiogram	O
+visualization	O
+with	O
+right	O
+to	O
+left	O
+shunt	O
+through	O
+the	O
+foramen	B-ANAT
+ovale	I-ANAT
+or	O
+patent	B-DISO
+ductus	B-ANAT
+arteriosus	I-ANAT
+.	O
+
+The	O
+earliest	O
+improvement	O
+in	O
+oxygen	B-CHED
+saturation	O
+was	O
+within	O
+ten	O
+minutes	O
+.	O
+
+Meconium	B-DISO
+aspiration	I-DISO
+syndrome	I-DISO
+was	O
+the	O
+most	O
+common	O
+underlying	O
+cause	O
+of	O
+PPHN	O
+.	O
+
+Sixteen	O
+ventilated	O
+trauma	O
+patients	O
+with	O
+severe	O
+refractory	O
+hypoxemia	O
+(	O
+PaO	B-PROC
+(	O
+2	O
+)/	O
+FIO	O
+(	O
+2	O
+)<	O
+150	O
+mmHg	O
+)	O
+and	O
+lung	B-ANAT
+contusions	O
+.	O
+
+The	O
+surfactant	B-CHED
+group	O
+demonstrated	O
+an	O
+acute	O
+improvement	O
+in	O
+oxygenation	B-PROC
+after	O
+surfactant	B-CHED
+replacement	O
+compared	O
+both	O
+to	O
+control	O
+group	O
+and	O
+to	O
+baseline	O
+values	O
+.	O
+
+The	O
+surfactant	B-CHED
+group	O
+demonstrated	O
+a	O
+higher	O
+response	O
+to	O
+recruitment	B-DISO
+maneuvers	O
+than	O
+the	O
+control	O
+group	O
+at	O
+6	O
+h	O
+.	O
+The	O
+mean	O
+duration	O
+of	O
+ventilatory	O
+support	O
+was	O
+5	O
+.	O
+6	O
++/-	O
+2	O
+.	O
+6	O
+days	O
+in	O
+the	O
+surfactant	B-CHED
+group	O
+and	O
+8	O
+.	O
+1	O
++/-	O
+2	O
+.	O
+4	O
+days	O
+in	O
+the	O
+control	O
+group	O
+.	O
+
+ABSTRACT	O
+:	O
+We	O
+present	O
+the	O
+case	O
+of	O
+4month	O
+old	O
+female	O
+infant	O
+,	O
+who	O
+obviously	O
+suffered	O
+from	O
+a	O
+respiratory	B-DISO
+arrest	I-DISO
+during	O
+bottle	O
+-	O
+feed	O
+ing	O
+.	O
+
+TITLE	O
+:	O
+Early	O
+use	O
+of	O
+terlipressin	O
+in	O
+catecholamine	B-CHED
+-	O
+resistant	O
+shock	O
+improves	O
+cerebral	B-ANAT
+perfusion	O
+pressure	O
+in	O
+severe	O
+traumatic	O
+brain	O
+injury	O
+.	O
+
+ABSTRACT	O
+:	O
+Maintaining	O
+adequate	O
+cerebral	B-ANAT
+perfusion	O
+pressure	O
+is	O
+an	O
+essential	O
+aspect	O
+in	O
+the	O
+treatment	O
+of	O
+severe	O
+acute	O
+brain	B-ANAT
+injury	O
+.	O
+
+A	O
+14	O
+-	O
+year	O
+-	O
+old	O
+male	O
+patient	O
+was	O
+admitted	O
+to	O
+the	O
+emergency	B-DISO
+room	O
+after	O
+a	O
+motorcycle	O
+accident	O
+.	O
+
+Our	O
+previous	O
+studies	O
+using	O
+nuclear	O
+magnetic	O
+resonance	O
+revealed	O
+the	O
+domain	O
+organization	O
+of	O
+the	O
+SARS	B-PRGE
+-	I-PRGE
+CoV	I-PRGE
+nucleocapsid	B-COMP
+protein	B-CHED
+.	O
+
+Residues	O
+248	O
+-	O
+280	O
+form	O
+a	O
+positively	O
+charged	O
+groove	B-ANAT
+similar	O
+to	O
+that	O
+found	O
+in	O
+the	O
+infectious	O
+bronchitis	B-DISO
+virus	B-SPEC
+(	O
+IBV	B-SPEC
+)	O
+nucleocapsid	B-COMP
+protein	B-CHED
+.	O
+
+Both	O
+episodes	O
+were	O
+successfully	O
+treated	O
+with	O
+steroid	B-CHED
+pulse	B-PROC
+therapy	O
+.	O
+
+Metastases	B-DISO
+regressed	O
+after	O
+the	O
+first	O
+episode	O
+and	O
+were	O
+stable	O
+during	O
+these	O
+lung	B-DISO
+disorders	I-DISO
+,	O
+but	O
+he	O
+died	B-PROC
+of	O
+tumor	B-DISO
+progression	I-DISO
+6	O
+months	O
+after	O
+RIST	O
+.	O
+
+ABSTRACT	O
+:	O
+At	O
+the	O
+beginning	O
+of	O
+the	O
+20th	O
+century	O
+,	O
+observations	O
+of	O
+apoplectic	O
+adrenal	O
+glands	O
+in	O
+fatal	O
+meningococcemia	B-DISO
+underlined	O
+their	O
+key	O
+role	O
+in	O
+host	B-PROC
+defence	I-PROC
+against	O
+infection	B-DISO
+.	O
+
+Corticosteroids	B-CHED
+were	O
+introduced	O
+in	O
+the	O
+treatment	O
+of	O
+severe	O
+infection	B-DISO
+as	O
+early	O
+as	O
+in	O
+the	O
+1940s	O
+.	O
+
+The	O
+use	O
+of	O
+high	O
+-	O
+dose	O
+ribavirin	B-CHED
+is	O
+appropriate	O
+only	O
+for	O
+the	O
+treatment	O
+of	O
+infectious	B-DISO
+diseases	I-DISO
+for	O
+which	O
+ribavirin	B-CHED
+has	O
+proven	O
+clinical	O
+efficacy	O
+,	O
+or	O
+in	O
+the	O
+context	O
+of	O
+a	O
+clinical	O
+trial	O
+.	O
+
+We	O
+also	O
+demonstrated	O
+that	O
+the	O
+expression	B-PROC
+level	O
+of	O
+the	O
+FIPV	B-PRGE
+virus	I-PRGE
+receptor	I-PRGE
+,	O
+feline	B-PRGE
+aminopeptidase	B-ENZY
+N	I-ENZY
+(	O
+fAPN	O
+),	O
+was	O
+increased	O
+in	O
+macrophages	B-ANAT
+of	O
+FIP	B-DISO
+cats	B-SPEC
+.	O
+
+ABSTRACT	O
+:	O
+Mediterranean	B-DISO
+spotted	I-DISO
+fever	I-DISO
+is	O
+a	O
+rickettsiosis	B-DISO
+caused	O
+by	O
+Rickettsia	B-SPEC
+conorii	I-SPEC
+.	O
+
+SARS	B-DISO
+-	O
+CoV	O
+detection	O
+rates	O
+in	O
+sera	B-COMP
+were	O
+highest	O
+in	O
+the	O
+first	O
+9	O
+days	O
+of	O
+illness	O
+,	O
+whereas	O
+detection	O
+was	O
+highest	O
+in	O
+throat	B-ANAT
+washes	O
+5	O
+-	O
+14	O
+days	O
+after	O
+onset	O
+of	O
+symptoms	O
+.	O
+
+CONCLUSIONS	O
+:	O
+In	O
+the	O
+context	O
+of	O
+an	O
+extensive	O
+outbreak	O
+with	O
+major	O
+pressure	O
+on	O
+hospital	O
+resources	O
+,	O
+patient	O
+self	O
+-	O
+collected	O
+samples	O
+are	O
+an	O
+alternative	O
+to	O
+nasopharyngeal	B-ANAT
+aspirates	B-ANAT
+for	O
+laboratory	O
+confirmation	O
+of	O
+SARS	B-DISO
+-	I-DISO
+CoV	I-DISO
+infection	I-DISO
+.	O
+
+The	O
+pathogenesis	B-DISO
+of	O
+SARS	B-DISO
+is	O
+highly	O
+complex	O
+,	O
+with	O
+multiple	O
+factors	O
+leading	O
+to	O
+severe	O
+injury	O
+in	O
+the	O
+lungs	B-ANAT
+and	O
+dissemination	O
+of	O
+the	O
+virus	B-SPEC
+to	O
+several	O
+other	O
+organs	B-ANAT
+.	O
+
+Several	O
+organs	B-ANAT
+/	O
+cell	B-COMP
+types	O
+may	O
+be	O
+infected	O
+in	O
+the	O
+course	O
+of	O
+the	O
+illness	O
+,	O
+including	O
+mucosal	B-ANAT
+cells	B-COMP
+of	O
+the	O
+intestines	B-ANAT
+,	O
+tubular	O
+epithelial	B-ANAT
+cells	I-ANAT
+of	O
+the	O
+kidneys	B-ANAT
+,	O
+neurons	B-ANAT
+of	O
+the	O
+brain	B-ANAT
+,	O
+and	O
+several	O
+types	O
+of	O
+immune	O
+cells	B-COMP
+,	O
+and	O
+certain	O
+organs	B-ANAT
+may	O
+suffer	B-DISO
+from	O
+indirect	O
+injury	O
+.	O
+
+TITLE	O
+:	O
+Murine	B-SPEC
+hepatitis	B-PRGE
+virus	I-PRGE
+replicase	I-PRGE
+protein	B-CHED
+nsp10	I-PRGE
+is	O
+a	O
+critical	O
+regulator	O
+of	O
+viral	O
+RNA	B-PROC
+synthesis	I-PROC
+.	O
+
+These	O
+results	O
+demonstrate	O
+that	O
+nsp10	O
+is	O
+a	O
+critical	O
+regulator	O
+of	O
+coronavirus	B-SPEC
+RNA	B-PROC
+synthesis	I-PROC
+and	O
+may	O
+play	O
+an	O
+important	O
+role	O
+in	O
+polyprotein	O
+processing	O
+.	O
+
+Here	O
+,	O
+we	O
+identify	O
+HCoV	B-PRGE
+-	I-PRGE
+NL63	I-PRGE
+replicase	I-PRGE
+gene	I-PRGE
+products	I-PRGE
+and	O
+characterize	O
+two	O
+viral	B-PRGE
+papain	I-PRGE
+-	I-PRGE
+like	I-PRGE
+proteases	I-PRGE
+(	O
+PLPs	O
+),	O
+PLP1	B-PRGE
+and	O
+PLP2	B-PRGE
+,	O
+which	O
+process	O
+the	O
+viral	B-PRGE
+replicase	I-PRGE
+polyprotein	I-PRGE
+.	O
+
+ABSTRACT	O
+:	O
+By	O
+using	O
+a	O
+series	O
+of	O
+overlapping	O
+synthetic	O
+peptides	B-CHED
+covering	O
+98	O
+%	O
+of	O
+the	O
+amino	B-CHED
+acid	I-CHED
+sequence	O
+of	O
+the	O
+nucleocapsid	B-COMP
+protein	B-CHED
+(	O
+NP	O
+)	O
+of	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+coronavirus	B-SPEC
+(	O
+SARS	B-DISO
+-	O
+CoV	O
+),	O
+four	O
+helper	B-ANAT
+T	I-ANAT
+-	I-ANAT
+cell	I-ANAT
+(	O
+Th	O
+)	O
+epitopes	O
+(	O
+NP11	O
+,	O
+residues	O
+11	O
+to	O
+25	O
+;	O
+NP51	O
+,	O
+residues	O
+51	O
+to	O
+65	O
+;	O
+NP61	O
+,	O
+residues	O
+61	O
+to	O
+75	O
+;	O
+and	O
+NP111	O
+,	O
+residues	O
+111	O
+to	O
+125	O
+)	O
+in	O
+C57BL	O
+mice	B-SPEC
+(	O
+H	O
+-	O
+2	O
+(	O
+b	O
+)),	O
+four	O
+(	O
+NP21	O
+,	O
+residues	O
+21	O
+to	O
+35	O
+;	O
+NP91	O
+,	O
+residues	O
+91	O
+to	O
+105	O
+;	O
+NP331	O
+,	O
+residues	O
+331	O
+to	O
+345	O
+;	O
+and	O
+NP351	O
+,	O
+residues	O
+351	O
+to	O
+365	O
+)	O
+in	O
+C3H	O
+mice	B-SPEC
+(	O
+H	O
+-	O
+2	O
+(	O
+k	O
+)),	O
+and	O
+two	O
+(	O
+NP81	O
+,	O
+residues	O
+81	O
+to	O
+95	O
+;	O
+and	O
+NP351	O
+,	O
+residues	O
+351	O
+to	O
+365	O
+)	O
+in	O
+BALB	O
+/	O
+c	O
+mice	B-SPEC
+(	O
+H	O
+-	O
+2	O
+(	O
+d	O
+))	O
+have	O
+been	O
+identified	O
+.	O
+
+When	O
+fused	O
+with	O
+a	O
+conserved	O
+neutralizing	O
+epitope	B-CHED
+(	O
+SP1143	O
+-	O
+1157	O
+)	O
+from	O
+the	O
+spike	O
+protein	B-CHED
+of	O
+SARS	B-PRGE
+-	I-PRGE
+CoV	I-PRGE
+,	O
+NP111	O
+and	O
+NP351	O
+assisted	O
+in	O
+the	O
+production	O
+of	O
+high	O
+-	O
+titer	O
+neutralizing	O
+antibodies	B-COMP
+in	O
+vivo	O
+.	O
+
+We	O
+demonstrate	O
+for	O
+the	O
+first	O
+time	O
+the	O
+utility	O
+of	O
+a	O
+highly	O
+sensitive	O
+and	O
+novel	O
+Alexa488	O
+-	O
+QSY7	O
+FRET	O
+-	O
+based	O
+peptide	B-CHED
+substrate	O
+designed	O
+for	O
+routine	O
+analysis	O
+and	O
+high	O
+-	O
+throughput	O
+screening	O
+,	O
+and	O
+show	O
+that	O
+kinetic	O
+constants	O
+determined	O
+from	O
+FRET	O
+-	O
+based	O
+assays	O
+that	O
+are	O
+uncorrected	O
+for	O
+inner	O
+-	O
+filter	O
+effects	O
+can	O
+lead	O
+to	O
+artifacts	O
+.	O
+
+Thus	O
+,	O
+the	O
+evolution	B-PROC
+of	O
+the	O
+ORF1ab	O
+proteins	B-CHED
+may	O
+be	O
+determined	O
+as	O
+much	O
+by	O
+issues	O
+of	O
+host	O
+range	O
+and	O
+virulence	B-PROC
+as	O
+they	O
+are	O
+by	O
+specific	O
+requirements	O
+for	O
+intracellular	B-COMP
+replication	O
+.	O
+
+TITLE	O
+:	O
+Serological	O
+prevalence	O
+of	O
+canine	O
+respiratory	O
+coronavirus	B-SPEC
+in	O
+southern	O
+Italy	O
+and	O
+epidemiological	O
+relationship	O
+with	O
+canine	O
+enteric	O
+coronavirus	O
+.	O
+
+Of	O
+adult	O
+domestic	O
+dogs	B-SPEC
+,	O
+23	O
+.	O
+3	O
+%	O
+had	O
+antibodies	B-COMP
+to	O
+CRCoV	O
+,	O
+compared	O
+with	O
+86	O
+.	O
+1	O
+%	O
+with	O
+antibodies	B-COMP
+to	O
+CECoV	O
+.	O
+Amongst	O
+a	O
+population	O
+of	O
+kenneled	O
+pups	O
+,	O
+4	O
+.	O
+0	O
+%	O
+had	O
+antibodies	B-COMP
+to	O
+CRCoV	O
+,	O
+and	O
+97	O
+.	O
+0	O
+%	O
+had	O
+antibodies	B-COMP
+to	O
+CECoV	O
+.	O
+
+Stigmatization	O
+of	O
+and	O
+discrimination	O
+against	O
+the	O
+chronically	B-DISO
+ill	I-DISO
+and	O
+the	O
+sense	B-PROC
+of	O
+searching	O
+coping	O
+strategy	O
+during	O
+the	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+outbreak	O
+further	O
+motivated	O
+their	O
+practice	O
+.	O
+
+Immunohistochemical	O
+examination	O
+revealed	O
+that	O
+AE2	O
+cells	B-COMP
+as	O
+well	O
+as	O
+alveolar	B-ANAT
+macrophages	I-ANAT
+were	O
+deleted	O
+via	O
+apoptosis	B-PATH
+in	O
+the	O
+mice	O
+treated	O
+with	O
+DT	O
+.	O
+
+These	O
+results	O
+indicate	O
+that	O
+macrophages	B-ANAT
+play	O
+a	O
+protective	O
+role	O
+in	O
+noninflammatory	O
+lung	B-ANAT
+injury	O
+caused	O
+by	O
+the	O
+selective	O
+ablation	O
+of	O
+AE2	O
+cells	B-COMP
+.	O
+
+If	O
+>	O
+4	O
+cm	O
+(	O
+giant	B-DISO
+hemangioma	I-DISO
+),	O
+it	O
+could	O
+present	O
+symptoms	O
+related	O
+to	O
+bleeding	B-DISO
+,	O
+thrombosis	B-DISO
+,	O
+consumptive	B-DISO
+coagulopathy	I-DISO
+,	O
+or	O
+adjacent	O
+abdominal	B-ANAT
+organ	I-ANAT
+compression	O
+.	O
+
+She	O
+died	B-PROC
+6	O
+months	O
+later	O
+from	O
+respiratory	B-DISO
+insufficiency	I-DISO
+and	O
+hypercapnic	B-DISO
+coma	B-DISO
+.	O
+
+This	O
+perception	O
+is	O
+an	O
+improvement	O
+from	O
+that	O
+described	O
+in	O
+an	O
+earlier	O
+study	O
+,	O
+in	O
+which	O
+more	O
+than	O
+half	O
+of	O
+the	O
+patients	O
+were	O
+concerned	O
+about	O
+contracting	O
+an	O
+infection	B-DISO
+during	O
+dental	O
+treatment	O
+and	O
+perceived	O
+that	O
+the	O
+infection	B-DISO
+control	O
+measures	O
+undertaken	O
+by	O
+the	O
+dental	O
+profession	O
+to	O
+prevent	O
+infectious	B-DISO
+diseases	I-DISO
+were	O
+not	O
+satisfactory	O
+.	O
+
+RESULTS	O
+:	O
+Less	O
+than	O
+one	O
+-	O
+third	O
+(	O
+30	O
+.	O
+0	O
+%)	O
+of	O
+the	O
+463	O
+respondents	O
+said	O
+they	O
+were	O
+not	O
+afraid	O
+of	O
+contracting	O
+the	O
+SARS	B-DISO
+coronavirus	B-SPEC
+from	O
+their	O
+dentists	O
+and	O
+did	O
+not	O
+avoid	O
+dental	O
+treatment	O
+for	O
+that	O
+reason	O
+.	O
+
+ABSTRACT	O
+:	O
+The	O
+pathogenesis	B-DISO
+of	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+coronavirus	B-SPEC
+(	O
+SARS	B-DISO
+CoV	O
+)	O
+is	O
+an	O
+important	O
+issue	O
+for	O
+treatment	O
+and	O
+prevention	O
+of	O
+SARS	B-DISO
+.	O
+
+In	O
+this	O
+study	O
+,	O
+proteome	O
+analysis	O
+of	O
+the	O
+human	B-SPEC
+promonocyte	B-ANAT
+HL	O
+-	O
+CZ	O
+cells	B-COMP
+expressing	O
+SARS	B-PRGE
+CoV	I-PRGE
+3CLpro	I-PRGE
+was	O
+performed	O
+using	O
+2	O
+-	O
+DE	O
+and	O
+nanoscale	O
+capillary	B-ANAT
+LC	O
+/	O
+ESI	O
+quadrupole	O
+-	O
+TOF	B-DISO
+MS	O
+.	O
+
+The	O
+study	O
+provides	O
+system	O
+-	O
+level	O
+insights	O
+into	O
+the	O
+interaction	O
+of	O
+SARS	B-PRGE
+CoV	I-PRGE
+3CLpro	I-PRGE
+with	O
+host	B-COMP
+cells	B-COMP
+,	O
+which	O
+will	O
+be	O
+helpful	O
+in	O
+elucidating	O
+the	O
+molecular	O
+basis	O
+of	O
+SARS	B-DISO
+CoV	O
+pathogenesis	B-DISO
+.	O
+
+As	O
+a	O
+result	O
+,	O
+increases	O
+in	O
+BCoV	O
+-	O
+neutralizing	O
+antibody	B-COMP
+titers	O
+were	O
+confirmed	O
+in	O
+all	O
+pups	O
+in	O
+the	O
+challenged	O
+and	O
+control	O
+groups	O
+.	O
+
+However	O
+,	O
+no	O
+clinical	O
+symptoms	O
+such	O
+as	O
+respiratory	B-DISO
+symptoms	I-DISO
+and	O
+diarrhea	B-DISO
+were	O
+observed	O
+.	O
+
+The	O
+serum	B-PRGE
+collectin	I-PRGE
+,	O
+mannan	B-PRGE
+-	I-PRGE
+binding	B-FUNC
+lectin	I-PRGE
+(	O
+MBL	B-PRGE
+),	O
+exhibited	O
+no	O
+detectable	O
+binding	B-FUNC
+to	O
+the	O
+purified	B-PRGE
+S	I-PRGE
+-	I-PRGE
+protein	I-PRGE
+.	O
+
+ABSTRACT	O
+:	O
+When	O
+public	O
+health	O
+decisionmakers	O
+turned	O
+to	O
+quarantine	O
+during	O
+the	O
+recent	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+(	O
+SARS	B-DISO
+)	O
+epidemic	O
+,	O
+difficult	O
+questions	O
+were	O
+raised	O
+about	O
+the	O
+legitimacy	O
+and	O
+acceptability	O
+of	O
+restrictive	O
+measures	O
+to	O
+attain	O
+public	O
+health	O
+goals	O
+.	O
+
+ABSTRACT	O
+:	O
+Due	O
+to	O
+the	O
+exponential	O
+growth	B-PROC
+of	O
+international	O
+exchange	O
+,	O
+millions	O
+of	O
+travelers	O
+are	O
+exposed	O
+to	O
+respiratory	O
+pathogens	O
+in	O
+the	O
+tropics	O
+and	O
+may	O
+return	O
+ill	O
+.	O
+
+Pulmonary	B-DISO
+hypertension	I-DISO
+has	O
+been	O
+reported	O
+in	O
+Schistosoma	B-SPEC
+hematobium	O
+,	O
+S	B-SPEC
+.	I-SPEC
+mansoni	I-SPEC
+and	O
+S	B-SPEC
+.	I-SPEC
+japonicum	I-SPEC
+infections	B-DISO
+.	O
+
+Studies	O
+are	O
+in	O
+progress	O
+to	O
+develop	O
+vaccines	O
+against	O
+amoebiasis	B-PATH
+,	O
+malaria	B-PATH
+and	O
+hookworm	B-DISO
+infections	I-DISO
+.	O
+
+TITLE	O
+:	O
+Early	O
+unreamed	O
+intramedullary	O
+nailing	O
+of	O
+femoral	B-ANAT
+fractures	O
+is	O
+safe	O
+in	O
+patients	O
+with	O
+severe	O
+thoracic	B-ANAT
+trauma	O
+.	O
+
+ABSTRACT	O
+:	O
+The	O
+timing	O
+of	O
+fixation	O
+of	O
+femoral	B-ANAT
+fractures	O
+in	O
+multiply	O
+injured	O
+patients	O
+with	O
+severe	O
+thoracic	B-DISO
+trauma	O
+is	O
+discussed	O
+controversially	O
+.	O
+
+RESULTS	O
+:	O
+Both	O
+cohorts	O
+were	O
+comparable	O
+with	O
+regard	O
+to	O
+demographic	O
+data	O
+,	O
+ISS	B-DISO
+,	O
+AIS	B-DISO
+score	O
+in	O
+the	O
+thoracic	B-ANAT
+region	I-ANAT
+,	O
+and	O
+incidence	O
+and	O
+severity	O
+of	O
+brain	B-ANAT
+injury	O
+.	O
+
+Rates	O
+of	O
+ARDS	B-DISO
+,	O
+MOFS	O
+,	O
+and	O
+mortality	O
+were	O
+not	O
+negatively	O
+influenced	O
+by	O
+early	O
+unreamed	O
+IMN	O
+.	O
+
+CONCLUSIONS	O
+:	O
+Early	O
+unreamed	O
+IMN	O
+of	O
+femoral	B-ANAT
+fractures	O
+in	O
+multiply	O
+injured	O
+patients	O
+with	O
+severe	O
+thoracic	B-DISO
+trauma	O
+is	O
+a	O
+safe	O
+procedure	O
+and	O
+seems	O
+to	O
+be	O
+justified	O
+to	O
+achieve	O
+early	O
+definitive	O
+care	O
+.	O
+
+We	O
+analyzed	O
+the	O
+expression	B-PROC
+of	O
+neutrophil	B-ANAT
+-	O
+derived	O
+S100A12	B-PRGE
+and	O
+the	O
+proinflammatory	O
+receptor	O
+for	O
+advanced	O
+glycation	O
+end	O
+products	O
+(	O
+RAGE	O
+)	O
+in	O
+patients	O
+with	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+.	O
+
+Informative	O
+papers	O
+emerged	O
+this	O
+past	O
+year	O
+concerning	O
+collateral	B-ANAT
+damage	O
+to	O
+the	O
+liver	B-ANAT
+in	O
+extrahepatic	O
+infections	B-DISO
+,	O
+diabetic	O
+lesions	O
+and	O
+causes	O
+of	O
+liver	B-DISO
+dysfunction	I-DISO
+after	O
+transplantation	O
+,	O
+among	O
+other	O
+topics	O
+.	O
+
+New	O
+vaccines	O
+would	O
+ideally	O
+be	O
+:	O
+genetically	O
+stable	O
+(	O
+i	O
+.	O
+e	O
+.	O
+maintain	O
+a	O
+stable	O
+attenuated	O
+phenotype	O
+);	O
+administered	O
+in	O
+ovo	B-SPEC
+;	O
+and	O
+be	O
+flexible	O
+with	O
+respect	O
+to	O
+the	O
+source	O
+of	O
+the	O
+spike	O
+protein	B-CHED
+gene	O
+.	O
+
+These	O
+data	O
+provide	O
+further	O
+evidence	O
+to	O
+warrant	O
+clinical	O
+studies	O
+of	O
+this	O
+antibody	O
+in	O
+the	O
+treatment	O
+and	O
+prevention	O
+of	O
+SARS	B-DISO
+.	O
+
+TITLE	O
+:	O
+Early	O
+treatment	O
+with	O
+arteriovenous	O
+extracorporeal	O
+lung	B-ANAT
+assist	O
+and	O
+high	O
+-	O
+frequency	O
+oscillatory	O
+ventilation	O
+in	O
+a	O
+case	O
+of	O
+severe	O
+acute	O
+respiratory	O
+distress	O
+syndrome	O
+.	O
+
+ABSTRACT	O
+:	O
+Lung	B-ANAT
+protective	O
+ventilation	O
+can	O
+reduce	O
+mortality	O
+in	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+(	O
+ARDS	B-DISO
+).	O
+
+However	O
+,	O
+many	O
+patients	O
+with	O
+severe	O
+ARDS	B-DISO
+remain	O
+hypoxemic	O
+and	O
+more	O
+aggressive	B-DISO
+ventilation	O
+is	O
+necessary	O
+to	O
+maintain	O
+sufficient	O
+gas	B-ENZY
+exchange	O
+.	O
+
+High	O
+-	O
+frequency	O
+oscillatory	O
+ventilation	O
+(	O
+HFOV	O
+)	O
+is	O
+an	O
+alternative	O
+form	O
+of	O
+ventilation	O
+that	O
+may	O
+improve	O
+oxygenation	B-PROC
+while	O
+limiting	O
+the	O
+risk	O
+of	O
+further	O
+lung	B-ANAT
+injury	O
+by	O
+using	O
+extremely	O
+small	O
+tidal	O
+volumes	O
+(	O
+VT	O
+).	O
+
+TITLE	O
+:	O
+Cell	B-ANAT
+cycle	I-PROC
+dependent	O
+nucleolar	B-ANAT
+localization	B-PROC
+of	O
+the	O
+coronavirus	B-PRGE
+nucleocapsid	B-COMP
+protein	B-CHED
+.	O
+
+This	O
+result	O
+was	O
+reinforced	O
+when	O
+FRAP	B-PRGE
+and	O
+FLIP	B-PRGE
+analysis	O
+indicated	O
+that	O
+N	B-PRGE
+protein	I-PRGE
+was	O
+more	O
+mobile	O
+within	O
+the	O
+nucleoplasm	B-COMP
+and	O
+nucleolus	B-COMP
+in	O
+the	O
+G2	O
+/	O
+M	B-PROC
+phase	I-PROC
+of	O
+the	O
+cell	B-PATH
+cycle	I-PATH
+.	O
+
+Rejection	O
+did	O
+not	O
+precede	O
+any	O
+case	O
+of	O
+post	O
+-	O
+transplant	B-ANAT
+blastomycosis	B-DISO
+.	O
+
+The	O
+overall	O
+mortality	O
+rate	O
+was	O
+36	O
+%;	O
+however	O
+,	O
+this	O
+increased	O
+to	O
+67	O
+%	O
+in	O
+those	O
+with	O
+ARDS	B-DISO
+.	O
+
+A	O
+unique	O
+collection	O
+of	O
+33	O
+plant	B-SPEC
+lectins	O
+with	O
+different	O
+specificities	O
+were	O
+evaluated	O
+.	O
+
+ABSTRACT	O
+:	O
+The	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+coronavirus	B-SPEC
+(	O
+SARS	B-DISO
+-	O
+CoV	O
+)	O
+7a	O
+protein	B-CHED
+,	O
+which	O
+is	O
+not	O
+expressed	B-PROC
+by	O
+other	O
+known	O
+coronaviruses	O
+,	O
+can	O
+induce	O
+apoptosis	B-PATH
+in	O
+various	O
+cell	B-ANAT
+lines	I-ANAT
+.	O
+
+In	O
+addition	O
+,	O
+fractionation	O
+experiments	O
+showed	O
+that	O
+7a	O
+colocalized	O
+with	O
+Bcl	B-PRGE
+-	I-PRGE
+XL	I-PRGE
+at	O
+the	O
+endoplasmic	B-COMP
+reticulum	I-COMP
+as	O
+well	O
+as	O
+the	O
+mitochondria	B-COMP
+,	O
+suggesting	O
+that	O
+they	O
+may	O
+form	O
+complexes	O
+in	O
+different	O
+membranous	B-ANAT
+compartments	B-ANAT
+.	O
+
+The	O
+results	O
+showed	O
+that	O
+the	O
+length	O
+of	O
+the	O
+S1	O
+genes	O
+of	O
+the	O
+isolates	O
+were	O
+quite	O
+different	O
+(	O
+1	O
+,	O
+617	O
+,	O
+1	O
+,	O
+620	O
+,	O
+1	O
+,	O
+623	O
+,	O
+1	O
+,	O
+629	O
+,	O
+and	O
+1	O
+,	O
+632	O
+nucleotides	B-CHED
+,	O
+respectively	O
+).	O
+
+The	O
+variation	O
+in	O
+S1	O
+genes	O
+might	O
+affect	O
+the	O
+antigenicity	O
+and	O
+pathogenicity	O
+of	O
+the	O
+viruses	B-SPEC
+.	O
+
+ABSTRACT	O
+:	O
+To	O
+assess	O
+the	O
+association	O
+of	O
+diagnostic	O
+predictors	O
+available	O
+in	O
+the	O
+emergency	O
+department	O
+(	O
+ED	O
+)	O
+with	O
+the	O
+outcome	O
+diagnosis	O
+of	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+(	O
+SARS	B-DISO
+).	O
+
+This	O
+retrospective	O
+cohort	O
+study	O
+describes	O
+all	O
+patients	O
+from	O
+the	O
+Amoy	O
+Garden	O
+complex	O
+who	O
+presented	O
+to	O
+an	O
+ED	O
+SARS	B-DISO
+screening	O
+clinic	O
+during	O
+a	O
+2	O
+-	O
+month	O
+outbreak	O
+.	O
+
+Associations	O
+of	O
+key	O
+predictors	O
+with	O
+the	O
+final	O
+diagnosis	O
+of	O
+SARS	B-DISO
+were	O
+described	O
+.	O
+
+Emergency	B-DISO
+physicians	O
+should	O
+consider	O
+the	O
+presence	O
+of	O
+diarrhea	B-DISO
+,	O
+chest	B-ANAT
+x	O
+-	O
+ray	B-SPEC
+findings	O
+,	O
+the	O
+absolute	O
+lymphocyte	B-ANAT
+count	O
+and	O
+the	O
+platelet	B-ANAT
+count	O
+as	O
+significant	O
+modifiers	O
+of	O
+disease	O
+likelihood	O
+.	O
+
+In	O
+this	O
+study	O
+,	O
+the	O
+nucleotide	B-CHED
+and	O
+deduced	O
+amino	B-CHED
+acid	I-CHED
+sequences	O
+of	O
+the	O
+partial	B-PRGE
+S	I-PRGE
+glycoprotein	I-PRGE
+genes	I-PRGE
+of	O
+Korean	O
+PEDV	B-SPEC
+isolates	O
+,	O
+including	O
+epitope	B-CHED
+region	O
+that	O
+is	O
+capable	O
+of	O
+inducing	O
+PEDV	B-SPEC
+-	O
+neutralizing	O
+antibodies	B-COMP
+,	O
+were	O
+determined	O
+.	O
+
+The	O
+partial	O
+S	O
+glycoprotein	B-CHED
+genes	O
+were	O
+amplified	O
+by	O
+RT	O
+-	O
+PCR	O
+,	O
+cloned	O
+,	O
+sequenced	O
+,	O
+and	O
+compared	O
+with	O
+each	O
+other	O
+as	O
+well	O
+as	O
+with	O
+reference	O
+PEDV	B-SPEC
+strains	O
+.	O
+
+In	O
+addition	O
+,	O
+the	O
+G1	O
+Korean	O
+PEDV	B-SPEC
+isolates	O
+didn	O
+'	O
+t	O
+had	O
+several	O
+specific	O
+nucleotides	B-CHED
+and	O
+amino	B-CHED
+acids	I-CHED
+which	O
+were	O
+found	O
+in	O
+the	O
+G2	O
+and	O
+G3	O
+Korean	O
+PEDV	B-SPEC
+isolates	O
+,	O
+and	O
+especially	O
+the	O
+G1	O
+-	O
+1	O
+Korean	O
+PEDV	B-SPEC
+isolates	O
+had	O
+specific	O
+nucleotides	B-CHED
+and	O
+amino	B-CHED
+acids	I-CHED
+which	O
+were	O
+not	O
+found	O
+in	O
+the	O
+G1	O
+-	O
+2	O
+,	O
+G1	O
+-	O
+3	O
+,	O
+G2	O
+,	O
+and	O
+G3	O
+Korean	O
+PEDV	B-SPEC
+isolates	O
+.	O
+
+After	O
+confirmed	O
+by	O
+the	O
+restriction	O
+endonuclease	O
+analysis	O
+and	O
+PCR	O
+amplification	B-DISO
+,	O
+the	O
+positive	O
+clone	O
+of	O
+S1	B-PRGE
+gene	I-PRGE
+was	O
+sequenced	O
+and	O
+then	O
+was	O
+transferred	O
+into	O
+eukaryotic	O
+expressing	O
+vector	O
+pVAXI	O
+.	O
+
+The	O
+recombinant	O
+plasmid	O
+pVAX1	O
+-	O
+S1	O
+was	O
+transfected	O
+into	O
+COS	B-ANAT
+-	I-ANAT
+7	I-ANAT
+cells	B-COMP
+.	O
+
+6	O
+-	O
+week	O
+-	O
+old	O
+BALB	O
+/	O
+c	O
+mice	B-SPEC
+were	O
+inoculated	O
+orally	B-ANAT
+with	O
+SL7207	O
+(	O
+pVAX1	O
+-	O
+S1	O
+)	O
+at	O
+dosage	O
+of	O
+5	O
+x	O
+10	O
+(	O
+8	O
+)	O
+CFU	O
+,	O
+1	O
+x	O
+10	O
+(	O
+9	O
+)	O
+CFU	O
+and	O
+2	O
+x	O
+10	O
+(	O
+9	O
+)	O
+CFU	O
+respectively	O
+.	O
+
+The	O
+results	O
+suggested	O
+that	O
+SL7207	O
+(	O
+pVAX1	O
+-	O
+S1	O
+)	O
+was	O
+safe	O
+for	O
+mice	B-SPEC
+after	O
+oral	B-ANAT
+immunization	O
+at	O
+dosage	O
+of	O
+2	O
+x	O
+10	O
+(	O
+9	O
+)	O
+CFU	O
+or	O
+below	O
+.	O
+
+The	O
+recombinant	O
+Salmonella	B-DISO
+SL7207	O
+(	O
+pVAX1	O
+-	O
+S1	O
+)	O
+could	O
+induce	O
+significant	O
+humoral	B-PROC
+immune	I-PROC
+response	I-PROC
+in	O
+mice	B-SPEC
+compared	O
+with	O
+the	O
+control	O
+(	O
+P	O
+<	O
+0	O
+.	O
+05	O
+or	O
+0	O
+.	O
+01	O
+)	O
+at	O
+2	O
+w	O
+post	O
+-	O
+boosting	O
+and	O
+2	O
+w	O
+post	O
+-	O
+three	O
+immunization	O
+.	O
+
+The	O
+aim	O
+of	O
+this	O
+paper	O
+is	O
+to	O
+present	O
+the	O
+first	O
+case	O
+report	O
+of	O
+a	O
+patient	O
+with	O
+Down	B-DISO
+'	I-DISO
+s	I-DISO
+syndrome	I-DISO
+(	O
+DS	O
+)	O
+who	O
+died	B-PROC
+of	O
+a	O
+fulminant	O
+NMO	B-CHED
+.	O
+
+A	O
+severe	O
+destruction	O
+of	O
+medulla	B-ANAT
+and	O
+cervical	B-ANAT
+cord	B-DISO
+with	O
+a	O
+very	O
+high	O
+degree	O
+of	O
+demyelination	B-DISO
+of	O
+the	O
+optic	B-ANAT
+nerves	I-ANAT
+was	O
+typical	O
+of	O
+monophasic	O
+NMO	B-CHED
+(	O
+Devic	B-DISO
+'	I-DISO
+s	I-DISO
+disease	I-DISO
+).	O
+
+Alveolar	B-ANAT
+ventilation	O
+is	O
+improved	O
+by	O
+adding	O
+tracheal	O
+gas	B-ENZY
+insufflation	O
+(	O
+TGI	O
+)	O
+to	O
+CMV	B-SPEC
+.	O
+
+ABSTRACT	O
+:	O
+Clinical	O
+trial	O
+designs	O
+that	O
+randomize	O
+patients	O
+to	O
+fixed	B-ANAT
+treatment	O
+regimens	O
+may	O
+disrupt	O
+preexisting	O
+relationships	O
+between	O
+illness	O
+severity	O
+and	O
+level	O
+of	O
+therapy	O
+.	O
+
+To	O
+illustrate	O
+this	O
+problem	O
+,	O
+the	O
+Transfusion	O
+Requirements	O
+in	O
+Critical	O
+Care	O
+(	O
+TRICC	O
+)	O
+trial	O
+and	O
+the	O
+Acute	B-DISO
+Respiratory	I-DISO
+Distress	I-DISO
+Syndrome	I-DISO
+Network	O
+low	O
+tidal	O
+volume	O
+(	O
+ARMA	B-SPEC
+)	O
+trial	O
+were	O
+analyzed	O
+.	O
+
+Upper	B-ANAT
+gastrointestinal	I-ANAT
+endoscopy	O
+showed	O
+a	O
+foreign	O
+body	B-ANAT
+and	O
+CT	O
+examination	O
+revealed	O
+subcutaneous	B-DISO
+emphysema	I-DISO
+.	O
+
+A	O
+transmural	O
+tear	B-ANAT
+in	O
+the	O
+anterior	O
+wall	O
+of	O
+the	O
+esophagus	B-ANAT
+was	O
+found	O
+and	O
+the	O
+foreign	O
+body	B-ANAT
+(	O
+boiled	O
+meat	O
+)	O
+was	O
+removed	O
+.	O
+
+Sensory	B-ANAT
+neurons	I-ANAT
+play	O
+an	O
+important	O
+role	O
+in	O
+promotion	O
+of	O
+the	O
+endothelial	B-ANAT
+production	O
+of	O
+prostaglandins	B-CHED
+by	O
+releasing	O
+calcitonin	B-PRGE
+gene	I-PRGE
+-	I-PRGE
+related	I-PRGE
+peptide	B-CHED
+.	O
+
+Neutrophils	B-ANAT
+activated	O
+by	O
+TNF	B-PRGE
+release	B-PATH
+a	O
+huge	O
+amount	O
+of	O
+neutrophil	B-PRGE
+elastase	I-PRGE
+that	O
+is	O
+capable	O
+of	O
+decreasing	O
+endothelial	B-ANAT
+prostaglandin	B-PROC
+production	I-PROC
+.	O
+
+The	O
+results	O
+indicate	O
+that	O
+there	O
+were	O
+inverse	O
+association	O
+between	O
+the	O
+number	O
+of	O
+daily	O
+cases	O
+and	O
+maximum	O
+and	O
+/	O
+or	O
+minimum	O
+temperatures	O
+whereas	O
+air	B-CHED
+pressure	O
+was	O
+found	O
+to	O
+be	O
+positively	O
+associated	O
+with	O
+SARS	B-DISO
+transmission	O
+.	O
+
+Diseases	O
+with	O
+a	O
+prominent	O
+reduction	O
+were	O
+respiratory	B-DISO
+diseases	I-DISO
+,	O
+minor	O
+problems	O
+,	O
+and	O
+elective	O
+procedures	O
+.	O
+
+Diseases	O
+with	O
+a	O
+moderate	O
+reduction	O
+were	O
+mainly	O
+chronic	B-DISO
+diseases	I-DISO
+.	O
+
+It	O
+most	O
+commonly	O
+presents	O
+either	O
+as	O
+a	O
+superficial	B-DISO
+ulcer	I-DISO
+on	O
+the	O
+glans	O
+or	O
+around	O
+the	O
+corona	B-CHED
+.	O
+
+In	O
+this	O
+review	O
+,	O
+cell	B-COMP
+entry	O
+mechanism	O
+of	O
+those	O
+two	O
+viruses	B-SPEC
+is	O
+described	O
+,	O
+stressing	O
+on	O
+the	O
+difference	O
+and	O
+similarity	O
+found	O
+between	O
+those	O
+two	O
+viruses	B-SPEC
+.	O
+
+Interestingly	O
+,	O
+twelve	O
+human	B-ANAT
+milk	I-ANAT
+samples	O
+were	O
+positive	O
+for	O
+IgA	B-PRGE
+against	O
+porcine	B-DISO
+transmissible	I-DISO
+gastroenteritis	I-DISO
+coronavirus	B-SPEC
+,	O
+and	O
+this	O
+represented	O
+5	O
+%.	O
+
+ABSTRACT	O
+:	O
+To	O
+investigate	O
+incidence	O
+,	O
+causes	O
+and	O
+mortality	O
+of	O
+acute	O
+respiratory	O
+distress	O
+syndrome	O
+(	O
+ARDS	B-DISO
+)	O
+in	O
+intensive	O
+care	O
+units	O
+(	O
+ICU	O
+)	O
+in	O
+Beijing	O
+.	O
+
+Septic	O
+shock	O
+(	O
+36	O
+.	O
+2	O
+%)	O
+and	O
+heart	B-DISO
+failure	I-DISO
+(	O
+20	O
+.	O
+6	O
+%)	O
+were	O
+major	O
+lethal	O
+causes	O
+,	O
+while	O
+only	O
+14	O
+.	O
+6	O
+%	O
+died	B-PROC
+of	O
+respiratory	B-DISO
+failure	I-DISO
+.	O
+
+Our	O
+data	O
+also	O
+suggest	O
+that	O
+the	O
+46	O
+-	O
+LRLGSQLSL	O
+-	O
+54	O
+amino	B-CHED
+acid	I-CHED
+sequence	O
+of	O
+9b	O
+functions	O
+as	O
+a	O
+nuclear	B-PROC
+export	I-PROC
+signal	O
+(	O
+NES	B-SPEC
+).	O
+
+Indications	O
+for	O
+LTx	O
+were	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+,	O
+(	O
+15	O
+%),	O
+cystic	B-DISO
+fibrosis	I-DISO
+(	O
+15	O
+%),	O
+idiopathic	B-DISO
+pulmonary	I-DISO
+fibrosis	I-DISO
+(	O
+8	O
+%),	O
+primary	B-DISO
+pulmonary	I-DISO
+hypertension	I-DISO
+,	O
+(	O
+10	O
+%),	O
+emphysema	B-DISO
+(	O
+15	O
+%),	O
+acute	O
+lung	B-ANAT
+failure	O
+(	O
+11	O
+%),	O
+other	O
+(	O
+23	O
+%),	O
+and	O
+unknown	O
+(	O
+3	O
+%).	O
+
+Major	O
+complications	O
+during	O
+ECMO	O
+included	O
+hemorrhage	B-DISO
+(	O
+52	O
+%),	O
+hemodialysis	O
+(	O
+42	O
+%),	O
+neurologic	O
+(	O
+12	O
+%),	O
+and	O
+cardiac	B-ANAT
+(	O
+28	O
+%)	O
+complications	O
+,	O
+inotropic	O
+support	O
+(	O
+77	O
+%),	O
+and	O
+sepsis	B-DISO
+(	O
+15	O
+%).	O
+
+TITLE	O
+:	O
+[	O
+The	O
+primordial	O
+reservoir	O
+in	O
+the	O
+infectious	B-DISO
+contagion	O
+cicle	O
+.	O
+
+An	O
+emerging	O
+theme	O
+in	O
+coronavirus	B-SPEC
+pathogenesis	B-DISO
+is	O
+that	O
+the	O
+interaction	O
+between	O
+specific	O
+viral	O
+genes	O
+and	O
+the	O
+host	B-COMP
+immune	B-ANAT
+system	I-ANAT
+,	O
+specifically	O
+the	O
+innate	O
+immune	B-ANAT
+system	I-ANAT
+,	O
+functions	O
+as	O
+a	O
+key	O
+determinant	O
+in	O
+regulating	O
+virulence	B-PROC
+and	O
+disease	O
+outcomes	O
+.	O
+
+Our	O
+data	O
+suggests	O
+that	O
+the	O
+SARS	B-PRGE
+-	I-PRGE
+CoV	I-PRGE
+uses	O
+specific	O
+strategies	O
+to	O
+evade	O
+and	O
+antagonize	O
+the	O
+sensing	O
+and	O
+signaling	B-PROC
+arms	B-DISO
+of	O
+the	O
+interferon	B-PRGE
+pathway	B-PROC
+.	O
+
+We	O
+summarize	O
+by	O
+identifying	O
+future	O
+points	O
+of	O
+consideration	O
+that	O
+will	O
+contribute	O
+greatly	O
+to	O
+our	O
+understanding	O
+of	O
+the	O
+molecular	O
+mechanisms	O
+governing	O
+coronavirus	O
+pathogenesis	B-DISO
+and	O
+virulence	B-PROC
+,	O
+and	O
+the	O
+development	B-PROC
+of	O
+severe	O
+disease	O
+in	O
+humans	B-SPEC
+and	O
+animals	B-SPEC
+.	O
+
+The	O
+first	O
+culture	O
+model	O
+is	O
+a	O
+human	O
+bronchial	B-ANAT
+epithelial	I-ANAT
+cell	I-ANAT
+line	O
+Calu	O
+-	O
+3	O
+that	O
+can	O
+be	O
+inoculated	O
+by	O
+viruses	B-SPEC
+either	O
+as	O
+a	O
+non	O
+-	O
+polarized	O
+monolayer	O
+of	O
+cells	B-COMP
+or	O
+polarized	O
+cells	B-COMP
+with	O
+tight	B-COMP
+junctions	I-COMP
+and	O
+microvilli	B-COMP
+.	O
+
+Preincubation	O
+of	O
+the	O
+apical	O
+surface	O
+of	O
+cultures	O
+with	O
+antisera	O
+directed	O
+against	O
+hACE2	O
+reduced	O
+viral	O
+titers	O
+by	O
+two	O
+logs	O
+while	O
+antisera	O
+against	O
+DC	O
+-	O
+SIGN	O
+/	O
+DC	O
+-	O
+SIGNR	O
+did	O
+not	O
+reduce	O
+viral	B-PROC
+replication	I-PROC
+levels	O
+suggesting	O
+that	O
+hACE2	O
+is	O
+the	O
+primary	O
+receptor	O
+for	O
+entry	O
+of	O
+SARS	B-DISO
+-	O
+CoV	O
+into	O
+the	O
+ciliated	O
+cells	B-COMP
+of	O
+HAE	O
+cultures	O
+.	O
+
+TITLE	O
+:	O
+Multiple	B-DISO
+organ	I-DISO
+failure	I-DISO
+following	O
+lamp	O
+oil	O
+aspiration	B-DISO
+.	O
+
+Many	O
+studies	O
+showed	O
+that	O
+this	O
+inflammatory	O
+process	O
+is	O
+not	O
+restricted	O
+to	O
+the	O
+respiratory	B-ANAT
+system	I-ANAT
+but	O
+might	O
+result	O
+in	O
+non	O
+pulmonary	B-ANAT
+organ	B-DISO
+failure	I-DISO
+and	O
+hemodynamic	B-PROC
+compromise	O
+as	O
+well	O
+.	O
+
+Mechanical	O
+ventilation	O
+is	O
+considered	O
+the	O
+hallmark	O
+treatment	O
+for	O
+ALI	O
+patients	O
+aimed	O
+to	O
+recruit	O
+lung	B-ANAT
+tissue	I-ANAT
+and	O
+thereby	O
+reverse	O
+hypoxemia	O
+without	O
+causing	O
+additional	O
+lung	B-ANAT
+injury	O
+potentially	O
+resulting	O
+from	O
+overdistention	O
+or	O
+cycling	O
+collapse	B-DISO
+during	O
+expiration	B-PROC
+.	O
+
+TITLE	O
+:	O
+Rhinovirus	B-SPEC
+and	O
+coronavirus	B-DISO
+infections	I-DISO
+.	O
+
+ABSTRACT	O
+:	O
+The	O
+global	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+(	O
+SARS	B-DISO
+)	O
+outbreak	O
+was	O
+the	O
+first	O
+pandemic	O
+of	O
+the	O
+21st	O
+century	O
+.	O
+
+This	O
+article	O
+reviews	O
+current	O
+information	O
+in	O
+the	O
+clinical	O
+field	O
+of	O
+community	O
+respiratory	O
+viruses	B-SPEC
+,	O
+including	O
+several	O
+newly	O
+discovered	O
+respiratory	O
+viruses	B-SPEC
+.	O
+
+In	O
+order	B-SPEC
+to	O
+understand	O
+this	O
+infection	B-DISO
+,	O
+one	O
+of	O
+the	O
+coronavirus	B-SPEC
+isolates	O
+was	O
+sequenced	O
+and	O
+analyzed	O
+.	O
+
+This	O
+virus	B-SPEC
+designated	O
+as	O
+ACoV	O
+-	O
+00	O
+-	O
+1381	O
+(	O
+ACoV	O
+)	O
+encodes	O
+all	O
+10	O
+open	O
+reading	O
+frames	O
+(	O
+ORFs	O
+)	O
+characteristic	O
+of	O
+Group	O
+2	O
+bovine	B-SPEC
+coronavirus	B-SPEC
+(	O
+BCoV	O
+).	O
+
+These	O
+results	O
+indicate	O
+that	O
+MHV	B-SPEC
+infection	B-DISO
+causes	O
+an	O
+inhibition	B-PATH
+of	I-PATH
+IFN	B-PRGE
+-	I-PRGE
+beta	I-PRGE
+production	O
+at	O
+a	O
+posttranscriptional	O
+level	O
+,	O
+without	O
+altering	O
+RNA	O
+or	O
+protein	B-CHED
+stability	O
+.	O
+
+Thus	O
+,	O
+rather	O
+than	O
+disarming	O
+the	O
+antiviral	B-CHED
+activity	O
+induced	O
+by	O
+IFN	B-PRGE
+-	I-PRGE
+beta	I-PRGE
+pretreatment	O
+completely	O
+,	O
+MHV	B-SPEC
+may	O
+be	O
+inherently	O
+resistant	O
+to	O
+some	O
+aspects	O
+of	O
+the	O
+antiviral	B-CHED
+state	O
+induced	O
+by	O
+IFN	B-PRGE
+-	I-PRGE
+beta	I-PRGE
+.	O
+
+Continued	O
+virological	O
+surveillance	O
+has	O
+proven	O
+to	O
+be	O
+the	O
+best	O
+way	O
+to	O
+avert	O
+this	O
+infectious	B-DISO
+disease	I-DISO
+at	O
+the	O
+source	O
+.	O
+
+Here	O
+we	O
+provide	O
+the	O
+first	O
+description	O
+of	O
+a	O
+previously	O
+unidentified	O
+coronavirus	B-SPEC
+lineage	O
+detected	O
+from	O
+wild	O
+Asian	O
+leopard	B-SPEC
+cats	I-SPEC
+(	O
+Prionailurus	B-SPEC
+bengalensis	I-SPEC
+)	O
+and	O
+Chinese	O
+ferret	B-SPEC
+badgers	O
+(	O
+Melogale	B-SPEC
+moschata	I-SPEC
+)	O
+during	O
+virological	O
+surveillance	O
+in	O
+southern	O
+China	O
+.	O
+
+ABSTRACT	O
+:	O
+Twenty	O
+-	O
+one	O
+free	O
+-	O
+ranging	O
+Central	O
+Kalahari	O
+lions	O
+(	O
+Panthera	B-SPEC
+leo	I-SPEC
+)	O
+exhibited	O
+a	O
+high	O
+prevalence	O
+rate	O
+of	O
+feline	B-SPEC
+herpesvirus	I-SPEC
+(	O
+100	O
+%)	O
+and	O
+feline	B-SPEC
+immunodeficiency	I-SPEC
+virus	I-SPEC
+(	O
+71	O
+.	O
+4	O
+%).	O
+
+TITLE	O
+:	O
+Severe	B-DISO
+sepsis	I-DISO
+and	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+from	O
+community	O
+-	O
+acquired	O
+legionella	B-SPEC
+pneumonia	I-DISO
+:	O
+case	O
+report	O
+.	O
+
+In	O
+order	B-SPEC
+to	O
+understand	O
+the	O
+acquired	O
+tropism	B-PROC
+of	O
+the	O
+Beaudette	O
+strain	O
+,	O
+we	O
+compared	O
+the	O
+S	O
+protein	B-CHED
+sequences	O
+of	O
+several	O
+IBV	B-SPEC
+strains	O
+.	O
+
+The	O
+media	B-ANAT
+have	O
+the	O
+power	O
+to	O
+sway	O
+public	O
+perception	O
+of	O
+health	O
+issues	O
+by	O
+choosing	O
+what	O
+to	O
+publish	O
+and	O
+the	O
+context	O
+in	O
+which	O
+to	O
+present	O
+information	O
+.	O
+
+TITLE	O
+:	O
+In	O
+silico	O
+prediction	O
+of	O
+SARS	B-PRGE
+protease	B-PROC
+inhibitors	I-PROC
+by	O
+virtual	O
+high	O
+throughput	O
+screening	O
+.	O
+
+First	O
+,	O
+potential	O
+compounds	O
+were	O
+extracted	O
+from	O
+protein	B-CHED
+-	O
+ligand	B-PROC
+complexes	O
+selected	O
+from	O
+Protein	B-CHED
+Data	O
+Bank	O
+database	O
+based	O
+on	O
+structural	O
+similarity	O
+to	O
+the	O
+target	O
+protein	B-CHED
+.	O
+
+Later	O
+,	O
+the	O
+set	O
+of	O
+compounds	O
+was	O
+ranked	O
+by	O
+docking	B-PROC
+scores	O
+using	O
+a	O
+Electronic	O
+High	O
+-	O
+Throughput	O
+Screening	O
+flexible	O
+docking	B-PROC
+procedure	O
+to	O
+select	O
+the	O
+most	O
+promising	O
+molecules	O
+.	O
+
+Info	O
+Meta	B-SPEC
+-	O
+Database	O
+.	O
+
+Selected	O
+molecules	O
+having	O
+close	O
+structural	O
+relationship	O
+to	O
+a	O
+2	B-CHED
+-	I-CHED
+methyl	I-CHED
+-	I-CHED
+2	I-CHED
+,	I-CHED
+4	I-CHED
+-	I-CHED
+pentanediol	I-CHED
+may	O
+provide	O
+candidate	O
+lead	B-CHED
+compounds	I-CHED
+toward	O
+the	O
+development	B-PROC
+of	O
+novel	O
+allosteric	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+protease	B-PROC
+inhibitors	I-PROC
+.	O
+
+METHODS	O
+:	O
+Back	B-ANAT
+-	O
+projection	O
+method	O
+.	O
+
+In	O
+particular	O
+,	O
+the	O
+human	B-PRGE
+homologue	I-PRGE
+of	I-PRGE
+ACE	B-ENZY
+(	O
+ACE2	B-PRGE
+)	O
+has	O
+added	O
+a	O
+higher	O
+level	O
+of	O
+complexity	O
+to	O
+the	O
+RAAS	O
+.	O
+
+ABSTRACT	O
+:	O
+Since	O
+the	O
+prevalence	O
+of	O
+bovine	O
+norovirus	B-SPEC
+(	O
+BNoV	O
+)	O
+and	O
+their	O
+genetic	O
+diversity	O
+have	O
+only	O
+been	O
+reported	O
+in	O
+the	O
+USA	O
+,	O
+England	O
+,	O
+Germany	O
+and	O
+The	O
+Netherlands	O
+,	O
+this	O
+study	O
+examined	O
+the	O
+prevalence	O
+and	O
+genetic	O
+diversity	O
+of	O
+BNoVs	O
+in	O
+diarrheic	O
+calves	O
+in	O
+South	O
+Korea	O
+using	O
+645	O
+diarrheic	O
+fecal	B-ANAT
+specimens	O
+from	O
+calves	O
+by	O
+RT	O
+-	O
+PCR	O
+and	O
+nested	O
+PCR	O
+assays	O
+.	O
+
+TITLE	O
+:	O
+Porcine	B-SPEC
+aminopeptidase	B-ENZY
+N	I-ENZY
+is	O
+a	O
+functional	O
+receptor	O
+for	O
+the	O
+PEDV	B-SPEC
+coronavirus	B-SPEC
+.	O
+
+It	O
+was	O
+reported	O
+that	O
+aminopeptidase	B-PRGE
+N	I-PRGE
+(	O
+APN	B-PRGE
+)	O
+is	O
+the	O
+receptor	O
+for	O
+transmissible	O
+gastroenteritis	B-DISO
+virus	B-SPEC
+(	O
+TGEV	B-SPEC
+),	O
+human	B-SPEC
+coronavirus	I-SPEC
+229E	I-SPEC
+(	O
+HCoV	B-SPEC
+-	I-SPEC
+229E	I-SPEC
+)	O
+and	O
+feline	B-SPEC
+coronavirus	B-SPEC
+(	O
+FeCoV	O
+)	O
+which	O
+all	O
+belong	O
+to	O
+group	O
+I	O
+coronavirus	B-SPEC
+including	O
+as	O
+well	O
+as	O
+PEDV	B-SPEC
+.	O
+
+Moreover	O
+,	O
+the	O
+infection	B-DISO
+was	O
+blocked	O
+by	O
+antibodies	B-COMP
+against	O
+pAPN	O
+,	O
+implies	O
+the	O
+critical	O
+role	O
+of	O
+pAPN	O
+during	O
+virus	B-SPEC
+entry	O
+.	O
+
+Antibody	B-COMP
+titers	O
+against	O
+canine	B-SPEC
+distemper	I-SPEC
+virus	I-SPEC
+(	O
+CDV	B-CHED
+),	O
+canine	O
+parvovirus	B-DISO
+(	O
+CPV	B-SPEC
+),	O
+and	O
+canine	B-SPEC
+adenovirus	I-SPEC
+(	O
+CAV	B-SPEC
+)	O
+in	O
+the	O
+three	O
+facilities	O
+in	O
+which	O
+red	B-SPEC
+pandas	I-SPEC
+were	O
+vaccinated	O
+were	O
+highly	O
+variable	O
+.	O
+
+One	O
+red	B-SPEC
+panda	I-SPEC
+in	O
+each	O
+of	O
+three	O
+locations	O
+was	O
+seropositive	O
+for	O
+Neospora	B-SPEC
+caninum	I-SPEC
+.	O
+
+Only	O
+one	O
+of	O
+the	O
+73	O
+red	B-SPEC
+pandas	I-SPEC
+had	O
+a	O
+weak	O
+positive	O
+influenza	B-PATH
+A	I-PATH
+titer	O
+.	O
+
+TITLE	O
+:	O
+The	O
+molecular	O
+biology	O
+of	O
+SARS	B-DISO
+coronavirus	B-SPEC
+.	O
+
+Through	O
+kinetic	O
+measurements	O
+with	O
+recombinant	O
+PCs	B-DISO
+,	O
+we	O
+observed	O
+that	O
+the	O
+peptide	B-CHED
+was	O
+cleaved	B-ANAT
+efficiently	O
+by	O
+both	O
+furin	B-PRGE
+and	O
+PC5	B-PRGE
+,	O
+but	O
+very	O
+poorly	O
+by	O
+PC7	B-ANAT
+.	O
+
+The	O
+data	O
+suggest	O
+that	O
+the	O
+cleavable	O
+peptide	B-CHED
+bond	O
+is	O
+located	O
+within	O
+the	O
+most	O
+exposed	O
+domain	O
+;	O
+this	O
+is	O
+supported	O
+by	O
+the	O
+nearby	O
+turn	O
+structure	O
+.	O
+
+Several	O
+strong	O
+to	O
+weak	O
+NMR	O
+ROESY	O
+correlations	O
+were	O
+detected	O
+,	O
+and	O
+a	O
+3D	O
+structure	O
+of	O
+the	O
+spike	O
+IQF	O
+peptide	B-CHED
+that	O
+contains	O
+the	O
+crucial	O
+cleavage	B-PROC
+site	O
+R	O
+(	O
+761	O
+)	O
+E	O
+has	O
+been	O
+proposed	O
+.	O
+
+During	O
+the	O
+next	O
+10	O
+months	O
+the	O
+patient	O
+was	O
+stable	O
+with	O
+negative	O
+antibodies	B-COMP
+.	O
+
+The	O
+prognosis	O
+of	O
+anti	B-PRGE
+-	I-PRGE
+GBM	I-PRGE
+glomerulonephritis	B-DISO
+depends	O
+on	O
+serum	B-COMP
+creatinine	B-CHED
+and	O
+the	O
+need	O
+of	O
+dialysis	B-SPEC
+at	O
+initial	O
+presentation	O
+.	O
+
+We	O
+suggest	O
+that	O
+integrated	O
+analysis	O
+to	O
+enhance	O
+modelling	O
+the	O
+impact	O
+of	O
+potential	O
+control	O
+measures	O
+against	O
+airborne	O
+infections	B-DISO
+presents	O
+an	O
+opportunity	O
+to	O
+assess	O
+risks	O
+and	O
+benefits	O
+.	O
+
+Here	O
+,	O
+we	O
+have	O
+analyzed	O
+features	O
+of	O
+the	O
+5	O
+'-	O
+terminal	O
+288	O
+-	O
+nt	O
+portion	O
+of	O
+the	O
+nsp1	B-PRGE
+coding	I-PRGE
+region	I-PRGE
+within	O
+the	O
+continuous	O
+ORF	O
+that	O
+are	O
+required	O
+for	O
+DI	O
+RNA	B-PROC
+replication	I-PROC
+.	O
+
+Serum	B-COMP
+samples	O
+from	O
+100	O
+healthy	O
+blood	B-ANAT
+donors	O
+(	O
+set	O
+3	O
+),	O
+collected	O
+in	O
+2002	O
+,	O
+were	O
+also	O
+included	O
+.	O
+
+In	O
+the	O
+postinfection	O
+period	O
+,	O
+however	O
+,	O
+a	O
+number	O
+of	O
+patients	O
+had	O
+much	O
+lower	O
+serum	B-COMP
+IgG	B-PRGE
+levels	O
+against	O
+S450	O
+-	O
+650	O
+than	O
+against	O
+the	O
+N	B-PRGE
+protein	I-PRGE
+.	O
+
+Women	O
+comprise	O
+the	O
+majority	O
+of	O
+patients	O
+:	O
+an	O
+ascending	O
+genital	B-DISO
+infection	I-DISO
+is	O
+thought	O
+to	O
+be	O
+the	O
+major	O
+portal	B-ANAT
+of	O
+entry	O
+.	O
+
+TITLE	O
+:	O
+How	O
+often	O
+do	O
+you	O
+wash	O
+your	O
+hands	B-ANAT
+?	O
+
+TITLE	O
+:	O
+Body	B-ANAT
+mass	O
+index	O
+and	O
+outcomes	O
+in	O
+critically	O
+injured	O
+blunt	O
+trauma	O
+patients	O
+:	O
+weighing	O
+the	O
+impact	O
+.	O
+
+Morbid	B-DISO
+obesity	I-DISO
+was	O
+not	O
+associated	O
+with	O
+increased	O
+mortality	O
+(	O
+OR	O
+0	O
+.	O
+810	O
+,	O
+95	O
+%	O
+CI	O
+,	O
+0	O
+.	O
+353	O
+to	O
+1	O
+.	O
+856	O
+).	O
+
+Our	O
+approach	O
+was	O
+to	O
+produce	O
+retroviral	B-SPEC
+pseudotypes	O
+that	O
+bear	B-SPEC
+the	O
+type	O
+I	O
+or	O
+type	O
+II	O
+feline	B-SPEC
+coronavirus	B-SPEC
+surface	O
+glycoprotein	B-CHED
+and	O
+to	O
+screen	O
+a	O
+range	O
+of	O
+feline	B-SPEC
+cell	B-ANAT
+lines	I-ANAT
+for	O
+the	O
+expression	B-PROC
+of	O
+a	O
+functional	O
+receptor	O
+for	O
+attachment	O
+and	O
+entry	O
+.	O
+
+Our	O
+results	O
+also	O
+indicate	O
+that	O
+it	O
+should	O
+be	O
+possible	O
+to	O
+use	O
+retroviral	B-SPEC
+pseudotypes	O
+to	O
+identify	O
+and	O
+characterize	O
+the	O
+cellular	B-COMP
+receptor	O
+for	O
+type	O
+I	O
+feline	B-SPEC
+coronaviruses	O
+.	O
+
+TITLE	O
+:	O
+Meningococcal	B-DISO
+disease	I-DISO
+and	O
+meningitis	B-DISO
+.	O
+
+Early	O
+intervention	O
+with	O
+aggressive	B-DISO
+fluid	O
+resuscitation	O
+and	O
+antibiotic	B-CHED
+therapy	O
+can	O
+significantly	O
+improve	O
+outcome	O
+.	O
+
+In	O
+the	O
+pediatric	O
+intensive	O
+care	O
+unit	O
+,	O
+a	O
+large	O
+amount	O
+of	O
+fluids	B-ANAT
+may	O
+be	O
+required	O
+during	O
+the	O
+first	O
+few	O
+days	O
+and	O
+vasoactive	O
+drug	O
+infusions	O
+are	O
+often	O
+needed	O
+.	O
+
+Coagulopathy	B-DISO
+is	O
+frequent	O
+,	O
+but	O
+it	O
+has	O
+no	O
+specific	O
+treatment	O
+.	O
+
+Rescue	O
+therapy	O
+with	O
+extracorporeal	O
+membrane	B-COMP
+oxygenation	B-PROC
+may	O
+be	O
+appropriate	O
+in	O
+cases	O
+complicated	O
+by	O
+severe	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+,	O
+but	O
+not	O
+for	O
+refractory	B-DISO
+shock	I-DISO
+.	O
+
+Seizures	B-DISO
+and	O
+hyponatremia	O
+should	O
+be	O
+aggressively	O
+treated	O
+.	O
+
+ABSTRACT	O
+:	O
+More	O
+than	O
+four	O
+years	O
+have	O
+passed	O
+since	O
+the	O
+outbreak	O
+of	O
+the	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+(	O
+SARS	B-DISO
+)	O
+epidemic	O
+,	O
+and	O
+still	O
+very	O
+little	O
+is	O
+known	O
+about	O
+the	O
+molecular	O
+biology	O
+and	O
+pathogenesis	B-DISO
+of	O
+this	O
+deadly	O
+virus	B-SPEC
+.	O
+
+Further	O
+,	O
+we	O
+have	O
+mapped	O
+the	O
+interaction	O
+domain	O
+of	O
+the	O
+3a	O
+protein	B-CHED
+responsible	O
+for	O
+this	O
+RNA	B-PROC
+-	I-PROC
+protein	I-PROC
+interaction	I-PROC
+using	O
+a	O
+series	O
+of	O
+deletion	O
+mutants	O
+and	O
+defined	O
+it	O
+to	O
+the	O
+central	O
+75	O
+amino	B-CHED
+acid	I-CHED
+region	O
+.	O
+
+They	O
+were	O
+weaned	B-PROC
+from	O
+ECMO	O
+after	O
+a	O
+mean	O
+of	O
+114	O
++/-	O
+
+The	O
+detrimental	O
+effects	O
+of	O
+O2	O
+have	O
+established	O
+hyperoxic	O
+ALI	O
+(	O
+HALI	O
+)	O
+as	O
+a	O
+conventional	O
+model	O
+to	O
+study	O
+neonatal	O
+and	O
+adult	O
+forms	O
+of	O
+respiratory	B-DISO
+distress	I-DISO
+syndromes	B-DISO
+in	O
+experimental	O
+animals	B-SPEC
+.	O
+
+ABSTRACT	O
+:	O
+We	O
+report	O
+an	O
+8	O
+-	O
+year	O
+-	O
+old	O
+boy	O
+with	O
+Mycoplasma	O
+pneumoniae	O
+respiratory	B-DISO
+infection	I-DISO
+complicated	O
+by	O
+pneumomediastinum	B-DISO
+and	O
+severe	O
+oral	B-ANAT
+and	O
+conjunctival	O
+mucositis	B-DISO
+.	O
+
+There	O
+are	O
+no	O
+skin	B-ANAT
+lesions	O
+and	O
+it	O
+improves	O
+promptly	O
+with	O
+antibiotics	B-CHED
+.	O
+
+However	O
+,	O
+MHV	B-SPEC
+replication	O
+per	O
+se	O
+does	O
+not	O
+appear	O
+to	O
+benefit	O
+from	O
+the	O
+inhibition	B-PROC
+of	O
+host	B-COMP
+protein	B-PROC
+synthesis	I-PROC
+,	O
+at	O
+least	O
+in	O
+vitro	O
+,	O
+since	O
+viral	B-PROC
+replication	I-PROC
+was	O
+not	O
+negatively	O
+affected	O
+but	O
+rather	O
+enhanced	O
+in	O
+cells	B-COMP
+with	O
+impaired	B-DISO
+translational	B-PROC
+shutoff	O
+.	O
+
+This	O
+cell	B-PROC
+cycle	I-PROC
+arrest	I-PROC
+was	O
+catalyzed	O
+by	O
+the	O
+modulation	O
+of	O
+various	O
+cell	B-PATH
+cycle	I-PATH
+regulatory	O
+genes	O
+and	O
+the	O
+accumulation	O
+of	O
+hypophosphorylated	O
+RB	O
+,	O
+but	O
+was	O
+independent	O
+of	O
+p53	B-PRGE
+.	O
+
+Index	O
+patients	O
+who	O
+were	O
+aged	O
+60	O
+years	O
+or	O
+older	O
+or	O
+whose	O
+lactate	B-PRGE
+dehydrogenase	I-PRGE
+level	O
+was	O
+elevated	O
+upon	O
+admission	O
+to	O
+the	O
+hospital	O
+(	O
+indicating	O
+higher	O
+viral	O
+loads	O
+)	O
+were	O
+more	O
+likely	O
+to	O
+transmit	O
+SARS	O
+to	O
+their	O
+contacts	O
+.	O
+
+The	O
+cellular	B-COMP
+and	O
+humoral	B-PROC
+immune	I-PROC
+responses	I-PROC
+were	O
+assessed	O
+by	O
+enzyme	O
+-	O
+linked	O
+immunosorbent	O
+assays	O
+,	O
+lymphocyte	B-PROC
+proliferation	B-DISO
+assays	O
+,	O
+enzyme	O
+-	O
+linked	O
+immunospot	O
+assays	O
+,	O
+and	O
+fluorescence	O
+-	O
+activated	O
+cell	B-COMP
+sorter	O
+analyses	O
+.	O
+
+Early	O
+administration	O
+of	O
+rFVIIa	O
+decreased	O
+red	B-ANAT
+blood	I-ANAT
+cell	I-ANAT
+use	O
+by	O
+20	O
+%	O
+in	O
+trauma	O
+patients	O
+requiring	O
+massive	O
+transfusion	O
+.	O
+
+ABSTRACT	O
+:	O
+Infectious	B-DISO
+bronchitis	B-DISO
+virus	B-SPEC
+CK	O
+/	O
+CH	O
+/	O
+LDL	B-CHED
+/	O
+97I	O
+was	O
+attenuated	O
+by	O
+serial	O
+passage	O
+in	O
+chicken	B-SPEC
+embryos	B-ANAT
+.	O
+
+At	O
+necropsy	O
+the	O
+prominent	O
+lesion	O
+was	O
+enteritis	B-DISO
+.	O
+
+A	O
+coronavirus	B-SPEC
+was	O
+detected	O
+by	O
+electron	O
+microscopy	O
+and	O
+reverse	B-PRGE
+transcriptase	I-PRGE
+-	O
+polymerase	O
+chain	O
+reaction	O
+in	O
+the	O
+faeces	B-ANAT
+and	O
+in	O
+the	O
+intestinal	B-ANAT
+content	I-ANAT
+of	O
+the	O
+dead	B-PROC
+quails	O
+.	O
+
+Altogether	O
+,	O
+the	O
+findings	O
+suggest	O
+the	O
+existence	O
+of	O
+a	O
+novel	B-SPEC
+coronavirus	I-SPEC
+genetically	O
+related	O
+to	O
+turkey	B-SPEC
+coronavirus	B-SPEC
+.	O
+
+ABSTRACT	O
+:	O
+Cricopharyngeal	O
+myotomy	O
+for	O
+oropharyngeal	B-DISO
+dysphagia	I-DISO
+is	O
+designed	O
+to	O
+improve	O
+symptoms	O
+,	O
+but	O
+the	O
+operation	O
+can	O
+result	O
+in	O
+significant	O
+morbidity	O
+and	O
+even	O
+death	B-PROC
+.	O
+:	O
+A	O
+retrospective	O
+analysis	O
+was	O
+carried	O
+out	O
+of	O
+all	O
+complications	O
+and	O
+deaths	B-PROC
+among	O
+253	O
+patients	O
+who	O
+had	O
+cricopharyngeal	O
+myotomy	O
+performed	O
+by	O
+a	O
+single	O
+surgeon	O
+.	O
+
+A	O
+single	O
+wound	B-DISO
+infection	I-DISO
+developed	O
+among	O
+15	O
+patients	O
+with	O
+neurological	O
+dysphagia	B-DISO
+.	O
+
+Therefore	O
+,	O
+the	O
+BrSARS	O
+-	O
+N	O
+protein	B-CHED
+may	O
+be	O
+useful	O
+for	O
+the	O
+development	B-PROC
+of	O
+highly	O
+sensitive	O
+and	O
+specific	O
+assays	O
+to	O
+determine	O
+SARS	B-DISO
+infection	B-DISO
+and	O
+for	O
+further	O
+research	O
+of	O
+SARS	B-DISO
+-	O
+N	O
+pathology	B-DISO
+.	O
+
+New	O
+findings	O
+are	O
+reported	O
+on	O
+SARS	B-DISO
+-	O
+CoV	O
+replication	O
+and	O
+associated	O
+pathology	B-DISO
+in	O
+two	O
+additional	O
+strains	O
+(	O
+C57BL	O
+/	O
+6	O
+and	O
+129S6	O
+)	O
+of	O
+aged	O
+mice	B-SPEC
+.	O
+
+SARS	B-DISO
+survivors	O
+had	O
+higher	O
+stress	O
+levels	O
+during	O
+the	O
+outbreak	O
+,	O
+compared	O
+with	O
+control	O
+subjects	O
+(	O
+PSS	B-DISO
+-	O
+10	O
+scores	O
+=	O
+19	O
+.	O
+8	O
+and	O
+17	O
+.	O
+9	O
+,	O
+respectively	O
+;	O
+P	O
+<	O
+0	O
+.	O
+01	O
+),	O
+and	O
+this	O
+persisted	O
+1	O
+year	O
+later	O
+(	O
+PSS	O
+-	O
+10	O
+scores	O
+=	O
+19	O
+.	O
+9	O
+and	O
+17	O
+.	O
+3	O
+,	O
+respectively	O
+;	O
+P	O
+<	O
+0	O
+.	O
+01	O
+)	O
+without	O
+signs	O
+of	O
+decrease	O
+.	O
+
+RESULTS	O
+:	O
+SARS	B-DISO
+survivors	O
+had	O
+higher	O
+stress	O
+levels	O
+during	O
+the	O
+outbreak	O
+,	O
+compared	O
+with	O
+control	O
+subjects	O
+(	O
+PSS	B-DISO
+-	O
+10	O
+scores	O
+=	O
+19	O
+.	O
+8	O
+and	O
+17	O
+.	O
+9	O
+,	O
+respectively	O
+;	O
+P	O
+<	O
+0	O
+.	O
+01	O
+),	O
+and	O
+this	O
+persisted	O
+1	O
+year	O
+later	O
+(	O
+PSS	B-DISO
+-	O
+10	O
+scores	O
+=	O
+19	O
+.	O
+9	O
+and	O
+17	O
+.	O
+3	O
+,	O
+respectively	O
+;	O
+P	O
+<	O
+0	O
+.	O
+01	O
+)	O
+without	O
+signs	O
+of	O
+decrease	O
+.	O
+
+During	O
+the	O
+outbreak	O
+,	O
+health	O
+care	O
+worker	O
+SARS	B-DISO
+survivors	O
+had	O
+stress	O
+levels	O
+similar	O
+to	O
+those	O
+of	O
+non	O
+-	O
+health	O
+care	O
+workers	O
+,	O
+but	O
+health	O
+care	O
+workers	O
+showed	O
+significantly	O
+higher	O
+stress	O
+levels	O
+in	O
+2004	O
+(	O
+PSS	B-DISO
+-	O
+10	O
+score	O
+=	O
+22	O
+.	O
+8	O
+,	O
+compared	O
+with	O
+PSS	B-DISO
+-	O
+10	O
+score	O
+=	O
+18	O
+.	O
+4	O
+;	O
+P	O
+<	O
+0	O
+.	O
+05	O
+)	O
+and	O
+had	O
+higher	O
+depression	B-DISO
+,	O
+anxiety	O
+,	O
+posttraumatic	O
+symptoms	O
+,	O
+and	O
+GHQ	O
+-	O
+12	O
+scores	O
+.	O
+
+TITLE	O
+:	O
+Immediate	O
+and	O
+sustained	O
+psychological	B-DISO
+impact	O
+of	O
+an	O
+emerging	B-DISO
+infectious	I-DISO
+disease	I-DISO
+outbreak	O
+on	O
+health	O
+care	O
+workers	O
+.	O
+
+In	O
+2004	O
+,	O
+the	O
+perceived	O
+stress	O
+levels	O
+in	O
+the	O
+high	O
+-	O
+risk	O
+group	O
+were	O
+associated	O
+with	O
+higher	O
+depression	B-DISO
+,	O
+anxiety	O
+,	O
+and	O
+posttraumatic	O
+stress	O
+scores	O
+(	O
+P	O
+<	O
+0	O
+.	O
+001	O
+).	O
+
+ABSTRACT	O
+:	O
+Acute	O
+tonsillitis	O
+or	O
+pharyngitis	B-DISO
+may	O
+lead	O
+to	O
+suppurative	B-DISO
+thrombophlebitis	I-DISO
+of	O
+the	O
+internal	B-ANAT
+jugular	I-ANAT
+vein	I-ANAT
+.	O
+
+This	O
+complication	B-DISO
+,	O
+also	O
+known	O
+as	O
+Lemierre	B-DISO
+'	I-DISO
+s	I-DISO
+syndrome	I-DISO
+,	O
+remains	O
+,	O
+even	O
+nowadays	O
+,	O
+life	O
+threatening	O
+,	O
+due	O
+to	O
+dissemination	O
+of	O
+septic	O
+thromboemboli	O
+to	O
+various	O
+organs	B-ANAT
+.	O
+
+These	O
+GAGs	B-SPEC
+are	O
+sulfated	O
+to	O
+varying	O
+extents	O
+,	O
+lending	O
+a	O
+negative	O
+charge	O
+,	O
+and	O
+are	O
+used	O
+by	O
+a	O
+large	O
+number	O
+of	O
+viruses	B-SPEC
+to	O
+initiate	O
+infection	B-DISO
+of	O
+immortalized	B-ANAT
+cell	I-ANAT
+lines	O
+.	O
+
+With	O
+this	O
+system	O
+,	O
+many	O
+different	O
+constructs	O
+of	O
+the	O
+S	B-PRGE
+glycoprotein	I-PRGE
+can	O
+be	O
+analyzed	O
+in	O
+parallel	O
+thus	O
+providing	O
+another	O
+method	O
+by	O
+which	O
+to	O
+study	O
+the	O
+functional	O
+domains	O
+of	O
+S	O
+involved	O
+in	O
+membrane	B-PROC
+fusion	I-PROC
+event	O
+that	O
+occurs	O
+during	O
+viral	B-DISO
+infection	I-DISO
+.	O
+
+Our	O
+findings	O
+imply	O
+a	O
+significant	O
+impairment	B-DISO
+of	O
+the	O
+membrane	B-COMP
+'	O
+s	O
+deformability	O
+possibly	O
+due	O
+to	O
+changes	O
+in	O
+its	O
+structure	O
+.	O
+
+With	O
+the	O
+new	O
+century	O
+came	O
+the	O
+discovery	O
+of	O
+a	O
+new	O
+homolog	O
+of	O
+ACE	B-PRGE
+,	O
+called	O
+ACE2	B-PRGE
+,	O
+and	O
+early	O
+studies	O
+suggest	O
+that	O
+it	O
+may	O
+play	O
+a	O
+pivotal	O
+role	O
+in	O
+the	O
+RAS	B-CHED
+by	O
+controlling	O
+the	O
+balance	B-PROC
+between	O
+the	O
+vasoconstrictor	O
+effects	O
+of	O
+angiotensin	B-CHED
+-	O
+II	O
+and	O
+the	O
+vasodilatory	O
+properties	O
+of	O
+the	O
+angiotensin	B-CHED
+(	O
+1	O
+-	O
+7	O
+)	O
+peptide	B-CHED
+.	O
+
+ABSTRACT	O
+:	O
+During	O
+the	O
+last	O
+few	O
+years	O
+a	O
+number	O
+of	O
+previously	O
+undescribed	O
+viruses	O
+,	O
+including	O
+human	B-SPEC
+metapneumovirus	I-SPEC
+,	O
+coronaviruses	O
+SARS	B-DISO
+,	O
+NL63	O
+and	O
+HKU1	O
+,	O
+and	O
+bocavirus	B-SPEC
+,	O
+were	O
+identified	O
+in	O
+nasopharyngeal	B-ANAT
+samples	O
+from	O
+patients	O
+with	O
+signs	O
+of	O
+respiratory	B-DISO
+infections	I-DISO
+.	O
+
+Using	O
+synthetic	O
+biology	O
+and	O
+reverse	O
+genetics	O
+,	O
+we	O
+describe	O
+the	O
+construction	O
+of	O
+a	O
+panel	O
+of	O
+isogenic	O
+SARS	B-DISO
+coronavirus	B-SPEC
+(	O
+SARS	B-DISO
+-	O
+CoV	O
+)	O
+strains	O
+bearing	O
+variant	O
+spike	O
+glycoproteins	B-CHED
+that	O
+are	O
+representative	O
+of	O
+zoonotic	O
+strains	O
+found	O
+in	O
+palm	B-ANAT
+civets	B-SPEC
+and	O
+raccoon	B-SPEC
+dogs	I-SPEC
+,	O
+as	O
+well	O
+as	O
+isolates	O
+spanning	O
+the	O
+early	O
+,	O
+middle	O
+,	O
+and	O
+late	O
+phases	O
+of	O
+the	O
+SARS	B-PRGE
+-	I-PRGE
+CoV	I-PRGE
+epidemic	O
+.	O
+
+The	O
+ResPlex	O
+II	O
+assay	O
+also	O
+differentiated	B-PROC
+RSV	B-PRGE
+-	I-PRGE
+A	I-PRGE
+and	O
+RSV	B-PRGE
+-	I-PRGE
+B	I-PRGE
+and	O
+gave	O
+positive	O
+results	O
+for	O
+RhV	O
+and	O
+EnV	O
+in	O
+31	O
+(	O
+8	O
+.	O
+6	O
+%)	O
+and	O
+19	O
+(	O
+5	O
+.	O
+3	O
+%)	O
+specimens	O
+,	O
+respectively	O
+.	O
+
+PIV	O
+-	O
+2	O
+,	O
+PIV	O
+-	O
+4	O
+,	O
+and	O
+SARS	B-PRGE
+CoV	I-PRGE
+were	O
+not	O
+detected	O
+in	O
+the	O
+specimens	O
+tested	O
+.	O
+
+The	O
+two	O
+systems	O
+can	O
+process	O
+80	O
+(	O
+NGEN	O
+)	O
+and	O
+96	O
+(	O
+ResPlex	O
+II	O
+)	O
+tests	O
+per	O
+run	O
+,	O
+with	O
+a	O
+hands	B-ANAT
+-	O
+on	O
+time	O
+of	O
+approximately	O
+60	O
+min	O
+and	O
+test	O
+turnaround	O
+times	O
+of	O
+6	O
+h	O
+(	O
+ResPlex	O
+II	O
+)	O
+and	O
+9	O
+h	O
+(	O
+NGEN	O
+).	O
+
+TITLE	O
+:	O
+[	O
+Loop	O
+-	O
+mediated	O
+isothermal	O
+amplification	B-DISO
+].	O
+
+This	O
+method	O
+allows	O
+highly	O
+efficient	O
+amplification	B-DISO
+by	O
+a	O
+single	O
+enzyme	O
+at	O
+a	O
+constant	O
+temperature	O
+.	O
+
+Therefore	O
+,	O
+application	O
+to	O
+various	O
+life	O
+sciences	O
+,	O
+such	O
+as	O
+clinical	O
+medicine	B-CHED
+,	O
+is	O
+expected	O
+.	O
+
+TITLE	O
+:	O
+Preparations	O
+and	O
+limitations	O
+for	O
+prevention	O
+of	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+in	O
+a	O
+tertiary	O
+care	O
+centre	O
+of	O
+India	O
+.	O
+
+TITLE	O
+:	O
+Canine	O
+coronavirus	B-SPEC
+inactivation	B-DISO
+with	O
+physical	O
+and	O
+chemical	O
+agents	O
+.	O
+
+ABSTRACT	O
+:	O
+Canine	O
+coronavirus	B-SPEC
+(	O
+CCoV	O
+)	O
+is	O
+responsible	O
+for	O
+mild	O
+or	O
+moderate	O
+enteritis	B-DISO
+in	O
+puppies	O
+.	O
+
+The	O
+virus	B-SPEC
+is	O
+highly	O
+contagious	O
+and	O
+avoiding	O
+contact	O
+with	O
+infected	O
+dogs	B-SPEC
+and	O
+their	O
+excretions	B-PROC
+is	O
+the	O
+only	O
+way	O
+to	O
+ensure	O
+disease	O
+prevention	O
+.	O
+
+CCoV	O
+was	O
+observed	O
+to	O
+be	O
+more	O
+stable	O
+at	O
+pH	O
+6	O
+.	O
+0	O
+-	O
+6	O
+.	O
+5	O
+while	O
+extreme	O
+acidic	O
+conditions	O
+inactivated	O
+the	O
+virus	B-SPEC
+.	O
+
+Interestingly	O
+,	O
+the	O
+UV	O
+-	O
+F	O
+-	O
+V	O
+vaccine	O
+induced	O
+fewer	O
+IgG	O
+(	O
+2a	O
+)	O
+subtype	O
+antibodies	O
+and	O
+higher	O
+interleukin	B-PROC
+-	I-PROC
+4	I-PROC
+production	I-PROC
+in	O
+vaccinated	O
+mice	B-SPEC
+than	O
+did	O
+UV	O
+-	O
+V	O
+.	O
+Thus	O
+,	O
+UV	O
+-	O
+F	O
+-	O
+V	O
+imposes	O
+a	O
+Th2	O
+-	O
+type	O
+bias	B-SPEC
+on	O
+the	O
+immune	B-PROC
+response	I-PROC
+,	O
+unlike	O
+UV	O
+-	O
+V	O
+.	O
+We	O
+propose	O
+here	O
+that	O
+doubly	O
+-	O
+inactivated	O
+SARS	B-DISO
+-	O
+CoV	O
+virions	B-COMP
+by	O
+UV	O
+and	O
+formalin	B-CHED
+constitute	O
+a	O
+safe	O
+vaccine	O
+that	O
+may	O
+effectively	O
+induce	O
+neutralizing	O
+antibodies	B-COMP
+in	O
+humans	B-SPEC
+.	O
+
+The	O
+iLA	O
+was	O
+removed	O
+after	O
+15	O
+and	O
+8	O
+days	O
+of	O
+continuous	O
+operation	O
+,	O
+respectively	O
+,	O
+and	O
+both	O
+soldiers	O
+were	O
+successfully	O
+weaned	B-PROC
+from	O
+mechanical	O
+ventilation	O
+.	O
+
+However	O
+,	O
+more	O
+research	O
+is	O
+needed	O
+to	O
+establish	O
+potential	O
+beneficial	O
+effects	O
+of	O
+surfactant	B-CHED
+administration	O
+in	O
+children	O
+with	O
+lung	B-DISO
+diseases	I-DISO
+other	O
+than	O
+RDS	O
+.	O
+
+The	O
+spike	B-PRGE
+envelope	I-PRGE
+glycoprotein	B-CHED
+of	I-PRGE
+SARS	B-DISO
+-	I-PRGE
+CoV	I-PRGE
+,	O
+the	O
+main	O
+determinant	O
+of	O
+SARS	B-PRGE
+-	I-PRGE
+CoV	I-PRGE
+tropism	B-PROC
+,	O
+was	O
+isolated	O
+and	O
+used	O
+to	O
+pseudotype	O
+a	O
+human	B-DISO
+immunodeficiency	I-DISO
+virus	I-DISO
+(	O
+HIV	B-DISO
+)-	O
+based	O
+vector	O
+.	O
+
+Spike	O
+-	O
+pseudotyped	O
+HIV	B-DISO
+-	O
+based	O
+vector	O
+is	O
+a	O
+novel	O
+lung	B-ANAT
+-	O
+directed	O
+gene	O
+transfer	O
+vehicle	O
+that	O
+holds	O
+promise	O
+for	O
+the	O
+treatment	O
+of	O
+genetic	O
+lung	B-DISO
+diseases	I-DISO
+such	O
+as	O
+cystic	B-DISO
+fibrosis	I-DISO
+or	O
+alpha	B-PRGE
+(	I-PRGE
+1	I-PRGE
+)-	I-PRGE
+antitrypsin	I-PRGE
+deficiency	O
+.	O
+
+TITLE	O
+:	O
+[	O
+Acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+complicating	O
+Ebstein	O
+-	O
+Barr	O
+virus	B-SPEC
+pneumonia	B-DISO
+].	O
+
+ARDS	B-DISO
+can	O
+complicate	O
+EBV	O
+pneumonia	B-DISO
+in	O
+an	O
+immuno	O
+-	O
+competent	O
+subject	O
+.	O
+
+In	O
+order	B-SPEC
+to	O
+gain	O
+more	O
+insight	O
+into	O
+functions	O
+and	O
+modes	O
+of	O
+action	O
+and	O
+interaction	O
+of	O
+the	O
+different	O
+proteins	B-CHED
+,	O
+we	O
+cloned	O
+the	O
+viral	O
+ORFeome	O
+and	O
+performed	O
+a	O
+genome	O
+-	O
+wide	O
+analysis	O
+for	O
+intraviral	O
+protein	B-CHED
+interactions	O
+and	O
+for	O
+intracellular	B-PROC
+localization	I-PROC
+.	O
+
+900	O
+pairwise	O
+interactions	O
+were	O
+tested	O
+by	O
+yeast	B-SPEC
+-	O
+two	O
+-	O
+hybrid	O
+matrix	O
+analysis	O
+,	O
+and	O
+more	O
+than	O
+65	O
+positive	O
+non	O
+-	O
+redundant	O
+interactions	O
+,	O
+including	O
+six	O
+self	O
+interactions	O
+,	O
+were	O
+identified	O
+.	O
+
+Nsp8	O
+interacts	O
+with	O
+replicase	O
+proteins	B-CHED
+nsp2	B-PRGE
+,	O
+nsp5	B-PRGE
+,	O
+nsp6	O
+,	O
+nsp7	O
+,	O
+nsp8	O
+,	O
+nsp9	O
+,	O
+nsp12	O
+,	O
+nsp13	O
+and	O
+nsp14	O
+,	O
+indicating	O
+a	O
+crucial	O
+role	O
+as	O
+a	O
+major	O
+player	O
+within	O
+the	O
+replication	O
+complex	O
+machinery	O
+.	O
+
+In	O
+the	O
+case	O
+of	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+coronavirus	B-SPEC
+(	O
+SARS	B-DISO
+-	O
+CoV	O
+)	O
+infection	B-DISO
+,	O
+viral	O
+entry	O
+is	O
+reported	O
+to	O
+require	O
+a	O
+low	O
+pH	O
+in	O
+intracytoplasmic	O
+vesicles	B-COMP
+;	O
+however	O
+,	O
+little	O
+is	O
+known	O
+about	O
+how	O
+SARS	B-PRGE
+-	I-PRGE
+CoV	I-PRGE
+invades	O
+such	O
+compartments	B-ANAT
+.	O
+
+Furthermore	O
+,	O
+the	O
+SARS	O
+-	O
+CoV	O
+entered	O
+COS7	O
+cells	B-COMP
+transfected	O
+with	O
+the	O
+mutant	B-DISO
+of	O
+ACE2	B-PRGE
+with	O
+the	O
+cytoplasmic	B-ANAT
+tail	I-ANAT
+deleted	O
+,	O
+SARS	B-PRGE
+-	I-PRGE
+CoV	I-PRGE
+receptor	I-PRGE
+,	O
+as	O
+well	O
+as	O
+the	O
+wild	O
+-	O
+type	O
+ACE2	O
+,	O
+and	O
+their	O
+entries	O
+were	O
+significantly	O
+inhibited	O
+by	O
+treatment	O
+with	O
+chlorpromazine	B-CHED
+.	O
+
+Here	O
+we	O
+review	O
+recent	O
+progress	O
+in	O
+characterization	O
+of	O
+the	O
+biochemical	O
+properties	O
+,	O
+membrane	B-COMP
+topology	O
+and	O
+functions	O
+of	O
+the	O
+protein	B-CHED
+.	O
+
+TITLE	O
+:	O
+The	O
+nonstructural	O
+protein	B-CHED
+8	O
+(	O
+nsp8	O
+)	O
+of	O
+the	O
+SARS	B-DISO
+coronavirus	B-SPEC
+interacts	O
+with	O
+its	O
+ORF6	O
+accessory	O
+protein	O
+.	O
+
+The	O
+first	O
+ORF	O
+(	O
+1a	O
+and	O
+1b	O
+)	O
+encodes	O
+a	O
+large	O
+polyprotein	O
+that	O
+is	O
+cleaved	B-ANAT
+into	O
+nonstructural	O
+proteins	B-CHED
+(	O
+nsp	O
+).	O
+
+Finally	O
+,	O
+colocalization	O
+experiments	O
+were	O
+performed	O
+in	O
+SARS	B-DISO
+-	O
+CoV	O
+infected	O
+Vero	O
+E6	O
+mammalian	B-SPEC
+cells	B-COMP
+to	O
+confirm	O
+the	O
+nsp8	B-PRGE
+-	I-PRGE
+ORF6	I-PRGE
+interaction	O
+.	O
+
+This	O
+lays	O
+the	O
+basis	O
+for	O
+using	O
+mammary	B-ANAT
+gland	I-ANAT
+bioreactor	O
+generating	O
+edible	O
+vaccine	O
+.	O
+
+ABSTRACT	O
+:	O
+Acute	B-DISO
+pancreatitis	I-DISO
+begins	O
+with	O
+pancreatic	B-ANAT
+injury	O
+,	O
+elicits	O
+an	O
+acute	B-DISO
+inflammatory	I-DISO
+response	I-DISO
+,	O
+and	O
+encompasses	O
+a	O
+variety	O
+of	O
+potential	O
+complications	O
+in	O
+a	O
+subset	O
+of	O
+patients	O
+.	O
+
+The	O
+severity	O
+of	O
+acute	B-DISO
+pancreatitis	I-DISO
+is	O
+a	O
+function	O
+of	O
+the	O
+amount	O
+of	O
+pancreas	B-ANAT
+that	O
+is	O
+injured	O
+and	O
+the	O
+intensity	O
+of	O
+the	O
+inflammatory	B-DISO
+response	I-DISO
+.	O
+
+This	O
+article	O
+reviews	O
+recent	O
+advancements	O
+in	O
+understanding	O
+the	O
+pathogenesis	B-DISO
+,	O
+immunology	O
+,	O
+and	O
+genetics	O
+of	O
+severe	O
+acute	B-DISO
+pancreatitis	I-DISO
+,	O
+and	O
+the	O
+literature	O
+on	O
+laboratory	O
+-	O
+based	O
+markers	O
+,	O
+which	O
+predict	O
+a	O
+severe	O
+clinical	O
+course	O
+and	O
+pancreatic	B-DISO
+necrosis	B-PROC
+.	O
+
+ABSTRACT	O
+:	O
+Field	O
+canine	O
+coronaviruses	O
+(	O
+CCVs	O
+)	O
+identified	O
+during	O
+a	O
+series	O
+of	O
+outbreaks	O
+of	O
+gastroenteritis	B-DISO
+in	O
+Swedish	O
+dogs	B-SPEC
+were	O
+subjected	O
+to	O
+genetic	O
+analysis	O
+involving	O
+the	O
+open	O
+reading	O
+frame	O
+1b	O
+(	O
+ORF1b	O
+)	O
+and	O
+the	O
+membrane	B-COMP
+(	O
+M	O
+)	O
+and	O
+spike	O
+(	O
+S	O
+)	O
+protein	B-CHED
+genes	O
+.	O
+
+Observational	O
+study	O
+of	O
+death	B-PROC
+registry	O
+data	O
+,	O
+using	O
+Poisson	O
+regression	O
+and	O
+interrupted	O
+time	O
+-	O
+series	O
+analysis	O
+to	O
+examine	O
+all	O
+-	O
+cause	O
+mortality	O
+rates	O
+(	O
+excluding	O
+deaths	B-PROC
+due	O
+to	O
+SARS	B-DISO
+)	O
+before	O
+,	O
+during	O
+,	O
+and	O
+after	O
+the	O
+SARS	B-DISO
+outbreak	O
+.	O
+
+There	O
+was	O
+no	O
+significant	O
+change	O
+in	O
+mortality	O
+in	O
+the	O
+Greater	O
+Toronto	O
+Area	O
+before	O
+,	O
+during	O
+,	O
+and	O
+after	O
+the	O
+period	O
+of	O
+the	O
+SARS	B-DISO
+outbreak	O
+in	O
+2003	O
+compared	O
+to	O
+the	O
+corresponding	O
+time	O
+periods	B-PROC
+in	O
+2002	O
+and	O
+2001	O
+.	O
+
+TITLE	O
+:	O
+Spontaneous	O
+exocrine	B-ANAT
+pancreas	I-ANAT
+hypoplasia	B-DISO
+in	O
+specific	O
+pathogen	O
+-	O
+free	O
+C3HeB	O
+/	O
+FeJ	O
+and	O
+101	O
+/	O
+H	O
+mouse	B-SPEC
+pups	O
+causes	O
+steatorrhea	O
+and	O
+runting	O
+.	O
+
+The	O
+objective	O
+of	O
+this	O
+study	O
+was	O
+to	O
+assess	O
+the	O
+required	O
+dose	O
+and	O
+anticoagulatory	O
+effect	O
+of	O
+argatroban	O
+(	O
+Mitsubishi	O
+,	O
+Pharma	O
+Deutschland	O
+GmbH	O
+,	O
+Düsseldorf	O
+,	O
+Germany	O
+),	O
+a	O
+direct	O
+thrombin	B-CHED
+inhibitor	I-CHED
+approved	O
+for	O
+anticoagulation	B-PROC
+in	O
+patients	O
+with	O
+heparin	B-DISO
+-	I-DISO
+induced	I-DISO
+thrombocytopenia	I-DISO
+(	O
+HIT	O
+)	O
+undergoing	O
+extracorporeal	O
+membrane	B-COMP
+oxygenation	B-PROC
+(	O
+ECMO	O
+).	O
+
+However	O
+,	O
+a	O
+dose	O
+10	O
+-	O
+fold	O
+lower	O
+than	O
+that	O
+recommended	O
+by	O
+the	O
+manufacturer	O
+is	O
+sufficient	O
+to	O
+achieve	O
+appropriate	O
+anticoagulation	B-PROC
+in	O
+critically	B-DISO
+ill	I-DISO
+patients	O
+undergoing	O
+ECMO	O
+.	O
+
+TITLE	O
+:	O
+De	O
+novo	O
+initiation	O
+of	O
+RNA	B-PROC
+synthesis	I-PROC
+by	O
+the	O
+arterivirus	B-SPEC
+RNA	O
+-	O
+dependent	O
+RNA	B-PATH
+polymerase	I-PATH
+.	O
+
+The	O
+EAV	B-SPEC
+nsp9	O
+/	O
+RdRp	B-FUNC
+initiates	O
+RNA	B-PROC
+synthesis	I-PROC
+by	O
+a	O
+de	O
+novo	O
+mechanism	O
+on	O
+homopolymeric	O
+templates	O
+in	O
+a	O
+template	O
+-	O
+specific	O
+manner	O
+.	O
+
+A	O
+novel	O
+signature	O
+of	O
+high	O
+IFN	B-PRGE
+-	I-PRGE
+alpha	I-PRGE
+,	O
+IFN	B-PRGE
+-	I-PRGE
+gamma	I-PRGE
+,	O
+and	O
+IFN	B-PRGE
+-	O
+stimulated	O
+chemokine	O
+levels	O
+,	O
+plus	O
+robust	O
+antiviral	B-CHED
+IFN	B-PRGE
+-	I-PRGE
+stimulated	I-PRGE
+gene	I-PRGE
+(	O
+ISG	O
+)	O
+expression	B-PROC
+,	O
+accompanied	O
+early	O
+SARS	B-DISO
+sequelae	O
+.	O
+
+Second	O
+,	O
+103	O
+nasal	B-ANAT
+-	O
+wash	O
+samples	O
+from	O
+5	O
+-	O
+year	O
+-	O
+old	O
+children	O
+with	O
+asthma	B-PATH
+and	O
+respiratory	B-DISO
+symptoms	I-DISO
+were	O
+analyzed	O
+;	O
+RMA	O
+detected	O
+viruses	B-SPEC
+in	O
+74	O
+specimens	O
+(	O
+71	O
+.	O
+8	O
+%)	O
+compared	O
+to	O
+only	O
+24	O
+(	O
+23	O
+.	O
+3	O
+%)	O
+by	O
+traditional	O
+culture	O
+and	O
+immunofluorescent	O
+-	O
+staining	O
+techniques	O
+.	O
+
+RANTES	O
+-	O
+28	O
+G	O
+allele	O
+was	O
+associated	O
+with	O
+SARS	B-PRGE
+susceptibility	I-PRGE
+in	O
+Hong	O
+Kong	O
+Chinese	O
+(	O
+P	O
+<	O
+0	O
+.	O
+0001	O
+,	O
+OR	O
+=	O
+2	O
+.	O
+80	O
+,	O
+95	O
+%	O
+CI	O
+:	O
+2	O
+.	O
+11	O
+-	O
+3	O
+.	O
+71	O
+).	O
+
+Recent	O
+studies	O
+of	O
+anticoagulants	B-CHED
+have	O
+shown	O
+positive	O
+outcomes	O
+in	O
+patients	O
+with	O
+severe	B-DISO
+sepsis	I-DISO
+.	O
+
+Data	O
+from	O
+experimental	O
+models	O
+of	O
+sepsis	B-DISO
+,	O
+ALI	O
+,	O
+and	O
+ARDS	B-DISO
+indicate	O
+that	O
+some	O
+of	O
+these	O
+agents	O
+improve	O
+lung	O
+function	O
+and	O
+oxygenation	B-PROC
+.	O
+
+Some	O
+approaches	O
+to	O
+dealing	O
+with	O
+these	O
+questions	O
+and	O
+addressing	O
+functional	O
+correlates	O
+of	O
+proteolytic	B-PROC
+activity	O
+at	O
+the	O
+level	O
+of	O
+molecular	O
+cell	B-COMP
+biology	O
+are	O
+provided	O
+in	O
+this	O
+review	O
+focusing	O
+on	O
+two	O
+spheres	O
+of	O
+interest	O
+:	O
+neurodegeneration	B-DISO
+and	O
+cardiovascular	B-ANAT
+regulation	B-PROC
+.	O
+
+16	O
+patients	O
+presented	O
+with	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+(	O
+ARDS	B-DISO
+),	O
+2	O
+patients	O
+had	O
+intractable	O
+cardiac	B-DISO
+failure	I-DISO
+,	O
+and	O
+5	O
+patients	O
+had	O
+combined	O
+respiratory	O
+and	O
+cardiac	B-DISO
+failure	I-DISO
+.	O
+
+ABSTRACT	O
+:	O
+Pulmonary	B-ANAT
+-	O
+renal	B-ANAT
+syndromes	B-DISO
+or	O
+lung	B-ANAT
+-	O
+kidney	B-ANAT
+syndromes	B-DISO
+are	O
+clinical	O
+syndromes	O
+defined	O
+by	O
+a	O
+combination	O
+of	O
+diffuse	O
+alveolar	B-ANAT
+haemorrhage	B-DISO
+(	O
+DAH	O
+)	O
+and	O
+glomerulonephritis	B-DISO
+.	O
+
+The	O
+majority	O
+of	O
+cases	O
+of	O
+pulmonary	B-DISO
+-	I-DISO
+renal	B-ANAT
+syndrome	I-DISO
+are	O
+associated	O
+with	O
+ANCAs	O
+,	O
+either	O
+c	B-PRGE
+-	I-PRGE
+ANCA	I-PRGE
+or	O
+p	B-PRGE
+-	I-PRGE
+ANCA	I-PRGE
+,	O
+due	O
+to	O
+autoantibodies	O
+against	O
+the	O
+target	B-PRGE
+antigens	I-PRGE
+proteinase	B-PROC
+-	I-PRGE
+3	I-PRGE
+and	O
+myeloperoxidase	B-PRGE
+respectively	O
+.	O
+
+Soluble	B-PRGE
+N18	I-PRGE
+antibody	I-PRGE
+was	O
+expressed	B-PROC
+in	O
+Escherichia	B-SPEC
+coli	I-SPEC
+HB2151	O
+,	O
+purified	O
+by	O
+Ni	O
+-	O
+NTA	B-CHED
+affinity	O
+chromatography	O
+and	O
+verified	O
+by	O
+SDS	B-DISO
+-	O
+PAGE	O
+and	O
+Western	O
+blot	O
+.	O
+
+Eligible	O
+men	O
+acknowledged	O
+no	O
+history	O
+of	O
+genital	B-DISO
+warts	I-DISO
+and	O
+had	O
+sexual	B-PROC
+intercourse	I-PROC
+with	O
+a	O
+woman	O
+within	O
+the	O
+past	O
+year	O
+.	O
+
+Rotavirus	O
+was	O
+confirmed	O
+to	O
+be	O
+associated	O
+with	O
+calf	B-ANAT
+diarrhea	B-DISO
+,	O
+but	O
+coronavirus	B-SPEC
+and	O
+Cryptosporidium	B-SPEC
+spp	B-ENZY
+.	O
+
+Even	O
+though	O
+it	O
+is	O
+not	O
+closely	O
+associated	O
+with	O
+death	B-PROC
+in	O
+this	O
+study	O
+,	O
+it	O
+may	O
+be	O
+regarded	O
+as	O
+a	O
+marker	O
+of	O
+injury	O
+severity	O
+.	O
+
+The	O
+multivariate	O
+analysis	O
+showed	O
+that	O
+the	O
+factors	O
+associated	O
+with	O
+an	O
+increased	O
+risk	O
+of	O
+death	B-PROC
+were	O
+presence	O
+of	O
+sodium	O
+disorders	O
+(	O
+OR	O
+=	O
+5	O
+.	O
+56	O
+;	O
+95	O
+%	O
+CI	O
+2	O
+.	O
+90	O
+-	O
+10	O
+.	O
+65	O
+),	O
+hypotension	O
+in	O
+the	O
+intensive	O
+care	O
+unit	O
+(	O
+OR	O
+=	O
+12	O
+.	O
+58	O
+;	O
+95	O
+%	O
+CI	O
+4	O
+.	O
+40	O
+-	O
+35	O
+.	O
+00	O
+)	O
+and	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+(	O
+OR	O
+=	O
+13	O
+.	O
+57	O
+;	O
+95	O
+%	O
+CI	O
+1	O
+.	O
+51	O
+-	O
+121	O
+.	O
+66	O
+).	O
+
+ABSTRACT	O
+:	O
+Glycoprotein	B-CHED
+Si	O
+was	O
+the	O
+major	O
+protein	B-CHED
+to	O
+determine	O
+infection	B-DISO
+and	O
+immunogenicity	O
+of	O
+Infectious	B-DISO
+bronchitis	B-DISO
+virus	B-SPEC
+(	O
+IBV	B-SPEC
+).	O
+
+The	O
+E	B-SPEC
+.	I-SPEC
+coli	I-SPEC
+-	O
+mycobacterium	B-SPEC
+expression	B-PROC
+shuttle	O
+plasmid	O
+pR	O
+-	O
+alpha	O
+-	O
+S1	O
+was	O
+constructed	O
+by	O
+inserting	O
+the	O
+S1	B-PRGE
+gene	I-PRGE
+to	O
+the	O
+pRR3	B-PRGE
+with	O
+human	B-PRGE
+mycobacterium	B-SPEC
+tuberculosis	I-SPEC
+HSP70	I-PRGE
+promoter	I-PRGE
+and	O
+a	O
+signal	O
+peptide	B-CHED
+.	O
+
+It	O
+'	O
+s	O
+typically	O
+clinical	O
+manifestations	O
+consist	O
+of	O
+omitting	O
+,	O
+severe	B-DISO
+diarrhea	I-DISO
+,	O
+loss	O
+water	B-CHED
+and	O
+highly	O
+infectious	B-DISO
+disease	I-DISO
+.	O
+
+All	O
+kinds	O
+and	O
+ages	O
+of	O
+pigs	B-SPEC
+can	O
+be	O
+infected	O
+.	O
+
+The	O
+recombinant	O
+glycoprotein	B-CHED
+S	O
+was	O
+detected	O
+by	O
+SDS	B-DISO
+-	O
+PAGE	O
+and	O
+Western	O
+blot	O
+after	O
+induced	O
+by	O
+1ng	O
+/	O
+mL	O
+nisin	O
+.	O
+
+This	O
+system	O
+was	O
+applied	O
+to	O
+develop	O
+a	O
+quantitative	O
+measurement	O
+of	O
+cell	B-PROC
+-	I-PROC
+cell	B-COMP
+fusion	I-PROC
+using	O
+hepatitis	B-SPEC
+C	I-SPEC
+virus	I-SPEC
+(	O
+HCV	B-SPEC
+)	O
+NS3	B-DISO
+/	O
+4A	O
+protease	O
+and	O
+a	O
+secretion	B-PROC
+-	O
+blocked	O
+EGFP	O
+-	O
+4A	O
+/	O
+4B	O
+-	O
+SEAP	O
+(	O
+EGFP	O
+:	O
+enhanced	O
+green	B-PRGE
+fluorescent	I-PRGE
+protein	I-PRGE
+;	O
+4A	O
+/	O
+4B	O
+:	O
+a	O
+decapeptide	O
+substrate	O
+of	O
+NS3	B-PRGE
+/	I-PRGE
+4A	I-PRGE
+protease	I-PRGE
+;	O
+SEAP	O
+:	O
+secreted	B-PROC
+alkaline	B-PRGE
+phosphatase	I-PRGE
+)	O
+fusion	O
+gene	O
+.	O
+
+Cell	B-PROC
+-	I-PROC
+cell	B-COMP
+fusion	I-PROC
+provides	O
+an	O
+environment	O
+in	O
+which	O
+the	O
+protease	O
+encounters	O
+its	O
+substrate	O
+4A	O
+/	O
+4B	O
+,	O
+thereby	O
+releasing	O
+SEAP	O
+from	O
+the	O
+fusion	O
+protein	B-CHED
+.	O
+
+Computed	O
+tomography	O
+scans	O
+revealed	O
+ground	O
+-	O
+glass	O
+opacity	B-DISO
+and	O
+surrounding	O
+ring	O
+-	O
+shaped	O
+air	B-CHED
+-	O
+space	O
+consolidation	O
+,	O
+the	O
+""""	O
+reversed	O
+halo	B-DISO
+sign	I-DISO
+"""."	O
+
+As	O
+cryptogenic	B-DISO
+organizing	I-DISO
+pneumonia	I-DISO
+was	O
+suspected	O
+,	O
+she	O
+was	O
+then	O
+treated	O
+with	O
+intravenously	O
+pulsed	O
+methylprednisolone	B-CHED
+followed	O
+by	O
+prednisolone	B-CHED
+.	O
+
+Thus	O
+,	O
+COX	B-PRGE
+activity	O
+appears	O
+to	O
+be	O
+required	O
+for	O
+efficient	O
+MHV	B-SPEC
+replication	O
+,	O
+providing	O
+a	O
+potential	O
+target	O
+for	O
+anti	O
+-	O
+coronaviral	O
+therapy	O
+.	O
+
+TITLE	O
+:	O
+Hindsight	O
+:	O
+a	O
+re	O
+-	O
+analysis	O
+of	O
+the	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+outbreak	O
+in	O
+Beijing	O
+.	O
+
+TITLE	O
+:	O
+Interstitial	B-ANAT
+lung	B-ANAT
+disease	I-DISO
+and	O
+anti	O
+-	O
+Jo	O
+-	O
+1	O
+antibodies	B-COMP
+:	O
+difference	O
+between	O
+acute	O
+and	O
+gradual	O
+onset	O
+.	O
+
+ABSTRACT	O
+:	O
+Angiotensin	B-CHED
+-	I-PRGE
+converting	I-PRGE
+enzyme	I-PRGE
+(	O
+ACE	B-PRGE
+)	O
+and	O
+ACE2	B-PRGE
+are	O
+highly	O
+homologous	O
+metalloproteases	O
+that	O
+provide	O
+essential	O
+catalytic	O
+functions	O
+in	O
+the	O
+renin	B-PATH
+-	I-PATH
+angiotensin	B-CHED
+system	I-PATH
+(	O
+RAS	B-PRGE
+).	O
+
+Angiotensin	B-PRGE
+II	I-PRGE
+is	O
+one	O
+key	O
+effector	B-CHED
+peptide	B-CHED
+of	O
+the	O
+RAS	B-PRGE
+,	O
+inducing	O
+vasoconstriction	B-DISO
+and	O
+exerting	B-PROC
+multiple	O
+biological	O
+functions	O
+.	O
+
+Accumulating	O
+evidence	O
+has	O
+demonstrated	O
+a	O
+physiological	O
+and	O
+pathological	O
+role	O
+of	O
+ACE2	B-PRGE
+in	O
+the	O
+cardiovascular	B-ANAT
+systems	I-ANAT
+.	O
+
+We	O
+monitored	O
+the	O
+arterial	B-PROC
+pressure	I-PROC
+(	O
+AP	B-PROC
+)	O
+and	O
+heart	B-ANAT
+rate	O
+(	O
+HR	O
+)	O
+and	O
+analysed	O
+the	O
+AP	B-PROC
+and	O
+HR	O
+variabilities	O
+for	O
+assessment	O
+of	O
+autonomic	B-ANAT
+functions	O
+.	O
+
+Biochemical	O
+determinations	O
+indicated	O
+hypoxia	B-DISO
+,	O
+hyperglycaemia	B-DISO
+,	O
+increased	O
+nitrite	B-CHED
+/	O
+nitrate	B-CHED
+,	O
+methyl	B-CHED
+guanidine	B-CHED
+and	O
+other	O
+factors	O
+.	O
+
+Treatment	O
+guidelines	O
+are	O
+not	O
+evidence	O
+based	O
+in	O
+this	O
+age	O
+group	O
+and	O
+frequently	O
+do	O
+not	O
+appear	O
+to	O
+consider	O
+either	O
+the	O
+likely	O
+pathology	B-DISO
+or	O
+the	O
+different	O
+patterns	O
+of	O
+symptoms	O
+.	O
+
+The	O
+choices	O
+are	O
+oral	B-ANAT
+leukotriene	B-PROC
+receptor	I-PROC
+antagonists	I-PROC
+,	O
+or	O
+inhaled	B-PROC
+corticosteroids	B-CHED
+,	O
+which	O
+should	O
+be	O
+introduced	O
+in	O
+a	O
+three	O
+-	O
+stage	O
+protocol	O
+to	O
+avoid	O
+overtreating	O
+the	O
+child	O
+with	O
+evanescent	O
+symptoms	O
+.	O
+
+CONCLUSIONS	O
+:	O
+Intra	B-DISO
+-	I-DISO
+abdominal	I-DISO
+hypertension	I-DISO
+induced	O
+acute	O
+lung	B-ANAT
+injury	O
+and	O
+MODS	B-DISO
+with	O
+IL	B-FUNC
+-	I-FUNC
+8	I-FUNC
+elevation	O
+,	O
+even	O
+though	O
+AD	O
+improved	O
+hemodynamic	B-PROC
+parameters	O
+in	O
+extensively	O
+burned	O
+patients	O
+.	O
+
+TITLE	O
+:	O
+Dual	O
+enteric	O
+and	O
+respiratory	O
+tropisms	B-PROC
+of	O
+winter	B-DISO
+dysentery	I-DISO
+bovine	B-SPEC
+coronavirus	B-SPEC
+in	O
+calves	O
+.	O
+
+The	O
+WD	O
+-	O
+BCoV	O
+-	O
+inoculated	O
+calves	O
+showed	O
+gradual	O
+villous	O
+atrophy	B-DISO
+in	O
+the	O
+small	B-ANAT
+intestine	I-ANAT
+and	O
+a	O
+gradual	O
+increase	O
+in	O
+the	O
+crypt	B-ANAT
+depth	O
+of	O
+the	O
+large	B-ANAT
+intestine	I-ANAT
+.	O
+
+The	O
+effect	O
+of	O
+1	O
+night	O
+of	O
+CPAP	O
+on	O
+sleep	B-PROC
+architecture	O
+,	O
+AHI	O
+,	O
+arousal	O
+indexes	O
+,	O
+and	O
+nocturnal	O
+oxygenation	B-PROC
+was	O
+assessed	O
+.	O
+
+Extremely	O
+severe	O
+obese	B-DISO
+subjects	O
+(	O
+BMI	O
+>	O
+or	O
+=	O
+50	O
+kg	O
+/	O
+m2	O
+)	O
+with	O
+moderate	O
+-	O
+to	O
+-	O
+severe	O
+OSA	B-DISO
+plus	O
+OHS	B-DISO
+exhibit	O
+severe	O
+oxygen	B-CHED
+desaturation	O
+but	O
+similar	O
+severities	O
+of	O
+AHI	O
+,	O
+arousal	O
+indexes	O
+,	O
+and	O
+sleep	B-PROC
+architecture	O
+abnormalities	O
+when	O
+compared	O
+to	O
+matched	O
+subjects	O
+without	O
+OHS	B-DISO
+.	O
+
+RESULTS	O
+:	O
+Twenty	O
+-	O
+three	O
+subjects	O
+with	O
+moderate	O
+-	O
+to	O
+-	O
+severe	O
+OSA	B-DISO
+and	O
+23	O
+subjects	O
+with	O
+moderate	O
+-	O
+to	O
+-	O
+severe	O
+OSA	B-DISO
+plus	O
+OHS	B-DISO
+underwent	O
+a	O
+1	O
+-	O
+night	O
+trial	O
+of	O
+CPAP	O
+.	O
+
+We	O
+describe	O
+an	O
+autoselection	O
+system	O
+for	O
+recombinant	O
+protein	B-PROC
+expression	B-PROC
+in	O
+Saccharomyces	B-SPEC
+cerevisiae	I-SPEC
+which	O
+increases	O
+yields	O
+5	O
+-	O
+10	O
+-	O
+fold	O
+compared	O
+to	O
+conditional	O
+selection	O
+for	O
+expression	B-PROC
+plasmids	O
+.	O
+
+We	O
+demonstrate	O
+the	O
+versatility	O
+of	O
+this	O
+system	O
+by	O
+expressing	O
+proteins	B-CHED
+from	O
+a	O
+number	O
+of	O
+organisms	O
+and	O
+include	O
+several	O
+large	O
+and	O
+problematic	O
+products	O
+.	O
+
+TITLE	O
+:	O
+Propofol	B-CHED
+infusion	O
+syndrome	B-DISO
+.	O
+
+These	O
+results	O
+indicate	O
+that	O
+the	O
+isolate	O
+in	O
+this	O
+study	O
+was	O
+BToV	O
+and	O
+that	O
+BToV	O
+infection	B-DISO
+might	O
+be	O
+common	O
+in	O
+cattle	B-SPEC
+in	O
+Japan	O
+.	O
+
+All	O
+patients	O
+with	O
+severe	O
+brain	B-ANAT
+injury	O
+(	O
+Glasgow	O
+Coma	B-DISO
+Scale	O
+score	O
+<	O
+9	O
+)	O
+were	O
+studied	O
+for	O
+8	O
+days	O
+from	O
+admission	O
+.	O
+
+Ventilatory	O
+pattern	O
+,	O
+respiratory	B-ANAT
+system	I-ANAT
+compliance	O
+,	O
+blood	B-PROC
+gas	B-ENZY
+analysis	O
+,	O
+and	O
+hemodynamic	B-PROC
+profile	O
+were	O
+recorded	O
+and	O
+entered	O
+in	O
+a	O
+stepwise	O
+regression	O
+model	O
+.	O
+
+TITLE	O
+:	O
+Effectiveness	O
+of	O
+control	O
+measures	O
+during	O
+the	O
+SARS	B-DISO
+epidemic	O
+in	O
+Beijing	O
+:	O
+a	O
+comparison	O
+of	O
+the	O
+Rt	O
+curve	O
+and	O
+the	O
+epidemic	O
+curve	O
+.	O
+
+A	O
+case	O
+-	O
+control	O
+study	O
+based	O
+on	O
+817	O
+patients	O
+with	O
+confirmed	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+(	O
+SARS	B-DISO
+),	O
+307	O
+health	O
+care	O
+worker	O
+control	O
+subjects	O
+,	O
+290	O
+outpatient	O
+control	O
+subjects	O
+,	O
+and	O
+309	O
+household	O
+control	O
+subjects	O
+unaffected	O
+by	O
+SARS	B-DISO
+from	O
+Hong	O
+Kong	O
+was	O
+conducted	O
+to	O
+test	O
+for	O
+genetic	O
+association	O
+.	O
+
+ABSTRACT	O
+:	O
+Epidermal	B-FUNC
+growth	B-PROC
+factor	I-FUNC
+(	O
+EGF	B-FUNC
+)	O
+promotes	O
+gastrointestinal	O
+mucosal	B-ANAT
+recovery	O
+by	O
+stimulating	O
+the	O
+mitogenic	B-PROC
+activity	I-PROC
+of	O
+intestinal	B-ANAT
+crypt	B-ANAT
+epithelial	B-ANAT
+cells	I-ANAT
+.	O
+
+PEDV	B-FUNC
++	I-FUNC
+EGF	I-FUNC
+piglets	O
+had	O
+less	O
+severe	O
+clinical	O
+signs	O
+than	O
+PEDV	B-SPEC
+only	O
+piglets	O
+at	O
+48	O
+and	O
+60	O
+h	O
+post	O
+-	O
+infection	B-DISO
+(	O
+hpi	B-DISO
+).	O
+
+In	O
+conclusion	O
+,	O
+this	O
+survey	O
+clearly	O
+demonstrates	O
+that	O
+several	O
+strains	O
+of	O
+IBV	B-SPEC
+are	O
+prevalent	O
+in	O
+poultry	O
+flocks	O
+in	O
+Pakistan	O
+.	O
+
+TITLE	O
+:	O
+Application	O
+of	O
+a	O
+focus	O
+formation	B-PROC
+assay	O
+for	O
+detection	O
+and	O
+titration	O
+of	O
+porcine	B-SPEC
+epidemic	B-DISO
+diarrhea	I-DISO
+virus	I-SPEC
+.	O
+
+TITLE	O
+:	O
+A	O
+rationale	O
+for	O
+using	O
+steroids	B-CHED
+in	O
+the	O
+treatment	O
+of	O
+severe	O
+cases	O
+of	O
+H5N1	B-DISO
+avian	B-DISO
+influenza	I-DISO
+.	O
+
+Adrenal	B-DISO
+insufficiency	I-DISO
+can	O
+be	O
+overcome	O
+,	O
+however	O
+,	O
+with	O
+prolonged	O
+(	O
+7	O
+-	O
+10	O
+or	O
+more	O
+days	O
+)	O
+supraphysiological	O
+steroid	B-CHED
+treatment	O
+at	O
+a	O
+sufficiently	O
+high	O
+dose	O
+to	O
+address	O
+the	O
+excess	O
+activation	B-PROC
+of	I-PROC
+NF	I-PROC
+-	I-PROC
+kappaB	I-PROC
+,	O
+but	O
+low	O
+enough	O
+to	O
+avoid	O
+immune	B-DISO
+suppression	I-DISO
+.	O
+
+ABSTRACT	O
+:	O
+Multiple	O
+contacts	O
+with	O
+the	O
+infectious	B-DISO
+source	O
+may	O
+cause	O
+inconsistencies	O
+in	O
+determining	O
+the	O
+incubation	O
+period	O
+of	O
+a	O
+patient	O
+and	O
+hence	O
+the	O
+calculation	O
+of	O
+the	O
+mean	O
+and	O
+variance	O
+of	O
+the	O
+incubation	O
+period	O
+.	O
+
+Both	O
+wild	O
+-	O
+type	O
+(	O
+WT	O
+)	O
+and	O
+gamma	O
+-	O
+chain	O
+-	O
+deficient	O
+mice	B-SPEC
+that	O
+lack	O
+receptors	O
+for	O
+immune	O
+complexes	O
+(	O
+FcgammaRs	O
+)	O
+were	O
+studied	O
+.	O
+
+Moreover	O
+,	O
+gamma	O
+-	O
+chain	O
+-	O
+deficient	O
+mice	B-SPEC
+that	O
+lack	O
+receptors	O
+for	O
+immune	O
+complexes	O
+were	O
+protected	O
+from	O
+LPS	B-DISO
+-	O
+induced	O
+pulmonary	B-DISO
+inflammation	I-DISO
+.	O
+
+Our	O
+results	O
+suggest	O
+that	O
+immune	O
+complexes	O
+containing	O
+autoantibodies	O
+contribute	O
+to	O
+development	B-PROC
+of	O
+lung	B-DISO
+inflammation	I-DISO
+in	O
+LPS	B-DISO
+-	O
+treated	O
+mice	B-SPEC
+.	O
+
+Virus	B-PROC
+replication	I-PROC
+was	O
+monitored	O
+by	O
+cytopathic	B-DISO
+effect	I-DISO
+observation	O
+,	O
+electron	O
+microscopy	O
+,	O
+indirect	O
+immunofluorescence	O
+,	O
+and	O
+reverse	B-PROC
+transcription	I-PROC
+polymerase	O
+chain	O
+reaction	O
+(	O
+RT	O
+-	O
+PCR	O
+).	O
+
+Demographic	O
+,	O
+clinical	O
+and	O
+laboratory	O
+data	O
+at	O
+presentation	O
+and	O
+investigative	O
+data	O
+during	O
+the	O
+first	O
+10	O
+days	O
+of	O
+illness	O
+from	O
+the	O
+time	O
+of	O
+symptom	B-DISO
+onset	O
+were	O
+compiled	O
+.	O
+
+A	O
+meta	B-SPEC
+-	O
+analysis	O
+.	O
+
+RESULTS	O
+:	O
+Six	O
+trials	O
+met	B-CHED
+the	O
+inclusion	O
+criteria	O
+;	O
+three	O
+investigated	O
+the	O
+role	O
+of	O
+steroids	B-CHED
+in	O
+early	O
+stage	O
+disease	O
+(	O
+n	O
+=	O
+300	O
+)	O
+and	O
+three	O
+investigated	O
+the	O
+role	O
+of	O
+steroids	B-CHED
+in	O
+late	O
+stage	O
+disease	O
+(	O
+n	O
+=	O
+235	O
+).	O
+
+Blood	B-ANAT
+samples	I-ANAT
+were	O
+obtained	O
+for	O
+the	O
+determination	O
+of	O
+amylase	B-PRGE
+,	O
+lipase	B-PRGE
+,	O
+tumor	B-FUNC
+necrosis	I-FUNC
+factor	I-FUNC
+(	O
+TNF	O
+)-	O
+alpha	O
+,	O
+interleukin	B-PRGE
+(	O
+IL	O
+)-	O
+1beta	O
+,	O
+macrophage	B-ANAT
+inflammatory	O
+peptide	B-CHED
+(	O
+MIP	B-DISO
+)-	O
+2	O
+and	O
+soluble	B-PRGE
+intercellular	I-PRGE
+adhesion	I-PRGE
+molecule	I-PRGE
+(	O
+sICAM	O
+)-	O
+1	O
+levels	O
+,	O
+while	O
+pancreatic	B-ANAT
+and	O
+lung	O
+tissues	O
+were	O
+removed	O
+for	O
+myeloperoxidase	B-PRGE
+(	O
+MPO	B-FUNC
+)	O
+activity	O
+,	O
+nitric	B-CHED
+oxide	I-CHED
+(	O
+NOx	O
+)	O
+level	O
+,	O
+CD40	B-PRGE
+expression	B-PROC
+and	O
+histological	O
+evaluation	O
+.	O
+
+Cerulein	B-CHED
+injection	O
+caused	O
+severe	O
+AP	O
+,	O
+confirmed	O
+by	O
+an	O
+increase	O
+in	O
+serum	B-PRGE
+amylase	I-PRGE
+and	O
+lipase	B-PRGE
+levels	O
+,	O
+histopathological	O
+findings	O
+of	O
+severe	O
+AP	O
+,	O
+and	O
+pancreatic	B-ANAT
+MPO	B-FUNC
+activity	O
+,	O
+compared	O
+to	O
+the	O
+values	O
+obtained	O
+in	O
+the	O
+sham	O
+group	O
+.	O
+
+Research	O
+conducted	O
+during	O
+the	O
+SARS	B-DISO
+outbreak	O
+may	O
+help	O
+inform	O
+research	O
+planning	O
+for	O
+future	O
+public	O
+health	O
+emergencies	B-DISO
+.	O
+
+Using	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+coronavirus	B-SPEC
+(	O
+SARS	B-DISO
+-	O
+CoV	O
+)	O
+as	O
+a	O
+model	O
+,	O
+we	O
+demonstrate	O
+that	O
+SARS	B-PRGE
+-	I-PRGE
+COV	I-PRGE
+ORF6	I-PRGE
+protein	B-CHED
+is	O
+localized	O
+to	O
+the	O
+endoplasmic	B-COMP
+reticulum	I-COMP
+(	O
+ER	O
+)/	O
+Golgi	B-COMP
+membrane	I-COMP
+in	O
+infected	O
+cells	B-COMP
+,	O
+where	O
+it	O
+binds	B-FUNC
+to	O
+and	O
+disrupts	O
+nuclear	B-PROC
+import	I-PROC
+complex	O
+formation	B-PROC
+by	O
+tethering	O
+karyopherin	B-PRGE
+alpha	I-PRGE
+2	I-PRGE
+and	O
+karyopherin	B-PRGE
+beta	I-PRGE
+1	I-PRGE
+to	O
+the	O
+membrane	B-COMP
+.	O
+
+TITLE	O
+:	O
+Development	B-PROC
+of	O
+a	O
+respiratory	O
+virus	B-SPEC
+panel	O
+test	O
+for	O
+detection	O
+of	O
+twenty	O
+human	B-SPEC
+respiratory	O
+viruses	B-SPEC
+by	O
+use	O
+of	O
+multiplex	O
+PCR	O
+and	O
+a	O
+fluid	O
+microbead	O
+-	O
+based	O
+assay	O
+.	O
+
+In	O
+a	O
+prospective	O
+evaluation	O
+using	O
+294	O
+nasopharyngeal	B-ANAT
+swab	I-ANAT
+specimens	O
+,	O
+DFA	B-CHED
+/	O
+culture	O
+detected	O
+119	O
+positives	O
+and	O
+the	O
+respiratory	O
+virus	B-SPEC
+panel	O
+(	O
+RVP	O
+)	O
+test	O
+detected	O
+112	O
+positives	O
+,	O
+for	O
+a	O
+sensitivity	O
+of	O
+97	O
+%.	O
+
+TITLE	O
+:	O
+Type	B-PRGE
+IVB	I-PRGE
+pilus	I-PRGE
+operon	I-PRGE
+promoter	I-PRGE
+controlling	O
+expression	B-PROC
+of	O
+the	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+-	O
+associated	O
+coronavirus	B-SPEC
+nucleocapsid	B-COMP
+gene	O
+in	O
+Salmonella	B-SPEC
+enterica	I-SPEC
+Serovar	O
+Typhi	O
+elicits	O
+full	O
+immune	B-PROC
+response	I-PROC
+by	O
+intranasal	O
+vaccination	O
+.	O
+
+Results	O
+showed	O
+that	O
+the	O
+intranasal	O
+route	O
+caused	O
+the	O
+highest	O
+production	O
+of	O
+specific	O
+immunoglobulin	O
+G	O
+(	O
+IgG	B-PRGE
+),	O
+IgG2a	B-COMP
+,	O
+and	O
+secretory	B-PRGE
+IgA	I-PRGE
+,	O
+where	O
+IgG2a	B-COMP
+was	O
+imprinted	O
+as	O
+a	O
+Th1	B-ANAT
+cell	I-ANAT
+bias	B-SPEC
+.	O
+
+The	O
+virus	B-SPEC
+loads	O
+(	O
+VLs	O
+)	O
+and	O
+cytopathic	B-DISO
+effects	I-DISO
+(	O
+CPEs	O
+)	O
+were	O
+recorded	O
+.	O
+
+siRNA	O
+against	O
+orf8a	O
+significantly	O
+reduced	O
+VLs	B-PRGE
+and	O
+interrupted	O
+the	O
+CPE	O
+.	O
+
+RESULTS	O
+:	O
+Two	O
+(	O
+5	O
+.	O
+4	O
+%)	O
+of	O
+37	O
+patients	O
+with	O
+SARS	B-DISO
+had	O
+anti	O
+-	O
+ORF8a	O
+antibodies	B-COMP
+.	O
+
+ORF8a	O
+was	O
+found	O
+to	O
+be	O
+localized	O
+in	O
+mitochondria	B-COMP
+,	O
+and	O
+overexpression	B-PROC
+resulted	O
+in	O
+increases	O
+in	O
+mitochondrial	B-COMP
+transmembrane	B-PROC
+potential	I-PROC
+,	O
+reactive	B-CHED
+oxygen	I-CHED
+species	I-CHED
+production	O
+,	O
+caspase	B-PRGE
+3	I-PRGE
+activity	O
+,	O
+and	O
+cellular	B-COMP
+apoptosis	B-PATH
+.	O
+
+TITLE	O
+:	O
+Detection	O
+of	O
+viruses	B-SPEC
+identified	O
+recently	O
+in	O
+children	O
+with	O
+acute	O
+wheezing	B-DISO
+.	O
+
+Viral	O
+antigens	B-CHED
+for	O
+common	O
+respiratory	O
+viruses	B-SPEC
+were	O
+detected	O
+by	O
+IFA	O
+or	O
+multiplex	O
+PCR	O
+.	O
+
+PCR	O
+assays	O
+for	O
+hBoV	O
+DNA	O
+were	O
+performed	O
+using	O
+the	O
+primer	O
+sets	O
+for	O
+noncapsid	B-PRGE
+protein	I-PRGE
+(	O
+NP1	B-PRGE
+)	O
+and	O
+nonstructural	O
+protein	B-CHED
+(	O
+NS1	B-DISO
+)	O
+genes	O
+.	O
+
+Interferon	B-PRGE
+(	O
+IFN	O
+)	O
+is	O
+not	O
+recommended	O
+as	O
+standard	O
+therapy	O
+in	O
+SARS	B-DISO
+.	O
+
+Dysfunction	O
+of	O
+the	O
+hypothalamic	B-ANAT
+-	I-ANAT
+pituitary	I-ANAT
+-	I-ANAT
+adrenal	I-ANAT
+axis	I-ANAT
+with	O
+decreased	O
+glucocorticoid	B-CHED
+activity	O
+is	O
+being	O
+increasingly	O
+recognized	O
+in	O
+critically	B-DISO
+ill	I-DISO
+patients	O
+,	O
+particularly	O
+those	O
+with	O
+sepsis	B-DISO
+.	O
+
+Critical	B-DISO
+illness	I-DISO
+-	O
+related	O
+corticosteroid	B-CHED
+insufficiency	O
+may	O
+occur	O
+due	O
+to	O
+dysfunction	O
+at	O
+any	O
+point	O
+in	O
+the	O
+hypothalamic	O
+-	O
+pituitary	O
+-	O
+adrenal	O
+axis	O
+including	O
+tissue	B-ANAT
+glucocorticoid	B-DISO
+resistance	B-PROC
+.	O
+
+ABSTRACT	O
+:	O
+The	O
+3C	B-PRGE
+-	I-PRGE
+like	I-PRGE
+main	I-PRGE
+peptidase	I-PRGE
+3CL	I-PRGE
+(	O
+pro	B-PRGE
+)	O
+is	O
+a	O
+viral	O
+polyprotein	O
+processing	O
+enzyme	O
+essential	O
+for	O
+the	O
+viability	O
+of	O
+the	O
+Severe	B-DISO
+Acute	I-DISO
+Respiratory	I-DISO
+Syndrome	I-DISO
+coronavirus	B-SPEC
+(	O
+SARS	B-DISO
+-	O
+CoV	O
+).	O
+
+Our	O
+data	O
+suggest	O
+that	O
+this	O
+structure	O
+resembles	O
+that	O
+of	O
+the	O
+proposed	O
+tetrahedral	O
+intermediate	O
+during	O
+the	O
+deacylation	O
+step	O
+of	O
+normal	O
+peptidyl	O
+cleavage	B-PROC
+.	O
+
+Class	B-SPEC
+II	O
+was	O
+barely	O
+detectable	O
+on	O
+astrocytes	B-ANAT
+,	O
+in	O
+contrast	O
+to	O
+potent	O
+up	B-PROC
+-	I-PROC
+regulation	I-PROC
+on	O
+microglia	B-ANAT
+.	O
+
+Maximal	O
+MHC	B-PROC
+expression	B-PROC
+in	O
+both	O
+glial	B-ANAT
+cell	I-ANAT
+types	O
+correlated	O
+with	O
+IFN	B-PRGE
+-	I-PRGE
+gamma	I-PRGE
+levels	O
+and	O
+lymphocyte	B-ANAT
+accumulation	O
+.	O
+
+TITLE	O
+:	O
+Calf	B-ANAT
+-	O
+level	O
+risk	O
+factors	O
+for	O
+neonatal	B-DISO
+diarrhea	I-DISO
+and	O
+shedding	O
+of	O
+Cryptosporidium	B-SPEC
+parvum	I-SPEC
+in	O
+Ontario	O
+dairy	O
+calves	O
+.	O
+
+Fecal	B-ANAT
+samples	O
+were	O
+collected	O
+weekly	O
+for	O
+4	O
+weeks	O
+from	O
+each	O
+of	O
+1045	O
+calves	O
+under	O
+30	O
+days	O
+of	O
+age	O
+on	O
+11	O
+dairy	O
+farms	O
+in	O
+south	O
+-	O
+western	O
+Ontario	O
+during	O
+the	O
+summer	O
+of	O
+2003	O
+and	O
+the	O
+winter	O
+of	O
+2004	O
+.	O
+
+Furthermore	O
+,	O
+73	O
+%	O
+of	O
+the	O
+846	O
+calves	O
+for	O
+which	O
+all	O
+four	O
+fecal	B-ANAT
+consistency	O
+scores	O
+had	O
+been	O
+recorded	O
+were	O
+diarrheic	O
+at	O
+the	O
+time	O
+of	O
+collection	O
+of	O
+at	O
+least	O
+one	O
+sample	O
+.	O
+
+The	O
+SARS	B-DISO
+-	I-DISO
+associated	I-DISO
+coronavirus	I-DISO
+(	O
+SARS	B-DISO
+-	O
+CoV	O
+)	O
+has	O
+been	O
+identified	O
+as	O
+the	O
+etiological	O
+agent	O
+of	O
+the	O
+disease	O
+.	O
+
+The	O
+substrate	O
+specificity	O
+data	O
+show	O
+the	O
+expected	O
+P1	O
+-	O
+Gln	B-CHED
+P2	O
+-	O
+Leu	B-CHED
+specificity	O
+and	O
+elucidate	O
+a	O
+novel	O
+preference	O
+for	O
+P1	O
+-	O
+His	O
+containing	O
+substrates	O
+equal	O
+to	O
+the	O
+expected	O
+preference	O
+for	O
+P1	O
+-	O
+Gln	O
+.	O
+
+These	O
+data	O
+provide	O
+the	O
+foundation	O
+for	O
+a	O
+rational	O
+small	O
+-	O
+molecule	O
+inhibitor	B-CHED
+design	O
+effort	B-PROC
+based	O
+upon	O
+the	O
+inhibitor	B-CHED
+scaffold	O
+identified	O
+,	O
+the	O
+crystal	B-ANAT
+structure	O
+of	O
+the	O
+complex	O
+,	O
+and	O
+a	O
+more	O
+complete	O
+understanding	O
+of	O
+P1	O
+-	O
+P4	O
+substrate	O
+specificity	O
+.	O
+
+We	O
+performed	O
+a	O
+multicentre	O
+study	O
+in	O
+GBS	B-DISO
+diagnosed	O
+according	O
+to	O
+international	O
+criteria	O
+.	O
+
+The	O
+first	O
+symptom	B-DISO
+was	O
+usually	O
+a	O
+disturbance	O
+of	O
+gait	O
+or	O
+neuropathic	B-DISO
+pain	I-DISO
+.	O
+
+46	O
+%	O
+showed	O
+cranial	B-ANAT
+nerve	I-ANAT
+involvement	O
+,	O
+and	O
+51	O
+%	O
+autonomous	O
+dysfunction	O
+.	O
+
+Electrophysiological	O
+examination	O
+showed	O
+demyelination	B-DISO
+in	O
+74	O
+%,	O
+and	O
+26	O
+%	O
+of	O
+these	O
+presented	O
+with	O
+very	O
+low	O
+amplitude	O
+compound	O
+action	B-PROC
+potentials	I-PROC
+.	O
+
+Transient	O
+deterioration	O
+after	O
+immunoglobulin	B-PROC
+treatment	O
+occurred	O
+in	O
+seven	O
+patients	O
+,	O
+two	O
+suffered	B-DISO
+relapsing	O
+GBS	B-DISO
+,	O
+and	O
+three	O
+developed	O
+CIDP	B-DISO
+.	O
+
+It	O
+is	O
+concluded	O
+that	O
+SARS	B-DISO
+-	O
+CoV	O
+viral	O
+loads	O
+in	O
+these	O
+organs	B-ANAT
+remain	O
+relatively	O
+stable	O
+,	O
+post	O
+-	O
+mortem	O
+.	O
+
+ABSTRACT	O
+:	O
+Recent	O
+experiences	O
+of	O
+emerging	O
+infections	B-DISO
+,	O
+such	O
+as	O
+severe	O
+acute	O
+respiratory	O
+syndrome	O
+(	O
+SARS	B-DISO
+)	O
+and	O
+avian	B-DISO
+influenza	I-DISO
+(	O
+H5N1	B-DISO
+),	O
+have	O
+highlighted	O
+the	O
+risks	O
+of	O
+serious	O
+pulmonary	B-DISO
+infections	I-DISO
+from	O
+occupational	O
+exposures	O
+.	O
+
+Sensory	O
+and	O
+motor	B-ANAT
+nerve	I-ANAT
+conduction	O
+studies	O
+,	O
+repetitive	O
+nerve	B-ANAT
+stimulation	O
+,	O
+electromyogram	O
+,	O
+blood	B-ANAT
+-	O
+cell	B-COMP
+counts	O
+,	O
+general	O
+chemistry	O
+and	O
+metabolic	B-PROC
+function	O
+tests	O
+,	O
+a	O
+CT	O
+scan	O
+,	O
+an	O
+[(	O
+18	O
+)	O
+F	O
+]	O
+fluorodeoxyglucose	O
+-	O
+PET	O
+scan	O
+,	O
+and	O
+tests	O
+for	O
+serum	B-COMP
+antibodies	B-COMP
+to	O
+acetylcholine	B-CHED
+receptors	O
+,	O
+muscle	B-ANAT
+-	O
+specific	O
+tyrosine	B-PRGE
+kinase	I-PRGE
+,	O
+voltage	B-CHED
+-	O
+gated	O
+potassium	B-CHED
+channels	O
+,	O
+P	O
+/	O
+Q	O
+-	O
+type	O
+voltage	B-CHED
+-	O
+gated	O
+calcium	B-CHED
+channels	O
+,	O
+and	O
+paraneoplastic	O
+antigens	B-CHED
+,	O
+were	O
+carried	O
+out	O
+.	O
+
+Combined	O
+treatment	O
+with	O
+prednisone	B-CHED
+,	O
+intravenous	O
+immunoglobulin	B-PROC
+,	O
+ciclosporin	B-CHED
+,	O
+and	O
+rituximab	O
+.	O
+
+We	O
+hypothesized	O
+that	O
+Hsp90	B-CHED
+inhibitors	I-CHED
+may	O
+ameliorate	O
+the	O
+inflammation	B-DISO
+and	O
+ALI	O
+associated	O
+with	O
+severe	B-DISO
+sepsis	I-DISO
+.	O
+
+Hsp90	B-CHED
+inhibitors	I-CHED
+may	O
+offer	O
+a	O
+new	O
+pharmacological	O
+tool	O
+in	O
+the	O
+management	O
+of	O
+severe	B-DISO
+sepsis	I-DISO
+and	O
+severe	B-DISO
+sepsis	I-DISO
+-	O
+induced	O
+ALI	O
+.	O
+
+ABSTRACT	O
+:	O
+Apart	O
+from	O
+bat	B-PRGE
+-	I-PRGE
+SARS	B-DISO
+-	I-PRGE
+CoV	I-PRGE
+,	O
+we	O
+have	O
+identified	O
+a	O
+novel	O
+group	O
+1	O
+coronavirus	B-SPEC
+,	O
+bat	B-PRGE
+-	I-PRGE
+CoV	I-PRGE
+HKU2	I-PRGE
+,	O
+in	O
+Rhinolophus	B-SPEC
+sinicus	I-SPEC
+(	O
+Chinese	O
+horseshoe	B-SPEC
+bats	I-SPEC
+).	O
+
+Instillation	O
+of	O
+MHV	B-SPEC
+-	O
+CXCL10	O
+into	O
+the	O
+CNS	B-CHED
+of	O
+CXCL10	B-PRGE
+-	O
+deficient	O
+(	O
+CXCL10	B-PRGE
+(-/-))	O
+mice	B-SPEC
+resulted	O
+in	O
+viral	B-DISO
+infection	I-DISO
+and	O
+replication	O
+in	O
+both	O
+brain	B-ANAT
+and	O
+liver	B-ANAT
+.	O
+
+Expression	B-PROC
+of	O
+virally	O
+encoded	O
+CXCL10	O
+within	O
+the	O
+brain	B-ANAT
+protected	O
+mice	B-SPEC
+from	O
+death	B-PROC
+and	O
+correlated	O
+with	O
+increased	O
+infiltration	B-DISO
+of	O
+T	B-ANAT
+lymphocytes	I-ANAT
+,	O
+enhanced	O
+IFN	B-PROC
+-	I-PROC
+gamma	I-PROC
+secretion	B-ANAT
+,	O
+and	O
+accelerated	O
+viral	O
+clearance	O
+when	O
+compared	O
+with	O
+mice	B-SPEC
+infected	O
+with	O
+an	O
+isogenic	O
+control	O
+virus	B-SPEC
+,	O
+MHV	B-SPEC
+.	O
+
+ABSTRACT	O
+:	O
+A	O
+case	O
+of	O
+fatal	O
+systemic	O
+coronavirus	O
+infection	O
+is	O
+described	O
+in	O
+a	O
+53	O
+-	O
+day	O
+-	O
+old	O
+Pekinese	O
+dog	B-SPEC
+.	O
+
+Visceral	O
+lesions	O
+consisted	O
+of	O
+extensive	O
+fibrinopurulent	O
+bronchopneumonia	B-DISO
+,	O
+multiple	O
+renal	B-ANAT
+cortical	B-ANAT
+infarcts	B-DISO
+,	O
+severe	O
+coalescing	O
+centrilobular	O
+hepatic	B-ANAT
+fatty	B-DISO
+change	I-DISO
+with	O
+minimal	O
+random	O
+hepatic	B-DISO
+necrosis	B-PROC
+,	O
+and	O
+multifocal	O
+splenic	B-DISO
+haemorrhage	I-DISO
+with	O
+lymphoid	O
+depletion	O
+.	O
+
+Identification	O
+of	O
+type	O
+I	O
+and	O
+type	O
+II	O
+coronavirus	B-SPEC
+in	O
+this	O
+subject	O
+had	O
+been	O
+previously	O
+confirmed	O
+by	O
+genotype	O
+-	O
+specific	O
+real	O
+-	O
+time	O
+reverse	B-PROC
+transcription	I-PROC
+-	O
+polymerase	O
+chain	O
+reaction	O
+(	O
+RT	O
+-	O
+PCR	O
+)	O
+assays	O
+of	O
+the	O
+intestinal	B-ANAT
+contents	I-ANAT
+,	O
+while	O
+only	O
+Coronavirus	B-SPEC
+type	O
+II	O
+was	O
+detected	O
+in	O
+visceral	O
+organs	B-ANAT
+.	O
+
+A	O
+performance	O
+status	O
+>	O
+or	O
+=	O
+2	O
+[	O
+odds	O
+ratio	O
+(	O
+OR	O
+)=	O
+5	O
+.	O
+17	O
+(	O
+95	O
+%	O
+confidence	O
+interval	O
+,	O
+CI	O
+=	O
+1	O
+.	O
+84	O
+-	O
+14	O
+.	O
+53	O
+)],	O
+advanced	B-DISO
+cancer	I-DISO
+(	O
+TNM	O
+stage	O
+IV	O
+)	O
+[	O
+OR	O
+=	O
+3	O
+.	O
+80	O
+(	O
+95	O
+%	O
+CI	O
+=	O
+1	O
+.	O
+28	O
+-	O
+11	O
+.	O
+28	O
+)],	O
+and	O
+the	O
+number	O
+of	O
+organ	B-ANAT
+failures	O
+[	O
+OR	O
+=	O
+2	O
+.	O
+87	O
+(	O
+95	O
+%	O
+CI	O
+=	O
+1	O
+.	O
+83	O
+-	O
+4	O
+.	O
+50	O
+)]	O
+were	O
+associated	O
+with	O
+increased	O
+mortality	O
+in	O
+multivariate	O
+analysis	O
+.	O
+
+ABSTRACT	O
+:	O
+Bone	B-ANAT
+marrow	I-ANAT
+-	O
+derived	O
+progenitors	O
+for	O
+both	O
+epithelial	O
+and	O
+endothelial	B-ANAT
+cells	I-ANAT
+have	O
+been	O
+observed	O
+in	O
+the	O
+lung	B-ANAT
+.	O
+
+We	O
+therefore	O
+tested	O
+the	O
+hypothesis	O
+whether	O
+homing	O
+of	O
+EPC	O
+in	O
+damaged	O
+lung	B-ANAT
+tissue	I-ANAT
+occurs	O
+after	O
+intravenous	O
+administration	O
+.	O
+
+However	O
+,	O
+few	O
+EPC	O
+were	O
+found	O
+in	O
+subcutaneous	O
+Matrigel	O
+in	O
+transplanted	B-ANAT
+rats	B-SPEC
+.	O
+
+The	O
+presence	O
+of	O
+sialic	B-CHED
+acid	I-CHED
+on	O
+HeLa	B-ANAT
+cells	I-ANAT
+contributed	O
+to	O
+efficient	O
+virus	B-PROC
+replication	I-PROC
+,	O
+while	O
+human	B-PRGE
+aminopeptidase	B-ENZY
+N	I-ENZY
+was	O
+not	O
+involved	O
+in	O
+the	O
+infection	B-DISO
+.	O
+
+Both	O
+antibodies	B-COMP
+competed	O
+with	O
+the	O
+SARS	B-PRGE
+-	I-PRGE
+CoV	I-PRGE
+receptor	I-PRGE
+,	O
+ACE2	B-PRGE
+,	O
+for	O
+binding	B-FUNC
+to	O
+the	O
+receptor	O
+-	O
+binding	B-FUNC
+domain	O
+(	O
+RBD	O
+),	O
+suggesting	O
+a	O
+mechanism	O
+of	O
+neutralization	O
+that	O
+involves	O
+interference	O
+with	O
+the	O
+SARS	O
+-	O
+CoV	O
+-	O
+ACE2	B-PRGE
+interaction	O
+.	O
+
+Whereas	O
+the	O
+role	O
+of	O
+innate	B-PROC
+immunity	I-PROC
+in	O
+acute	O
+lung	B-ANAT
+injury	O
+has	O
+been	O
+broadly	O
+investigated	O
+,	O
+the	O
+immune	B-PROC
+response	I-PROC
+after	O
+blunt	O
+chest	B-ANAT
+trauma	O
+is	O
+still	O
+poorly	O
+understood	O
+.	O
+
+In	O
+parallel	O
+,	O
+white	B-ANAT
+blood	I-ANAT
+cell	I-ANAT
+count	O
+in	O
+bronchioalveolar	O
+lavage	O
+fluids	B-ANAT
+was	O
+increased	O
+as	O
+a	O
+function	O
+of	O
+time	O
+and	O
+was	O
+significantly	O
+decreased	O
+by	O
+anti	B-PRGE
+-	I-PRGE
+C5a	I-PRGE
+treatment	O
+.	O
+
+Trauma	O
+-	O
+induced	O
+lung	B-ANAT
+injury	O
+was	O
+also	O
+associated	O
+with	O
+dramatic	O
+changes	O
+in	O
+neutrophil	B-ANAT
+function	O
+,	O
+namely	O
+early	O
+enhanced	O
+chemotaxis	B-PROC
+and	O
+phagocytosis	B-PROC
+,	O
+followed	O
+by	O
+prolonged	O
+functional	O
+defects	O
+-	O
+all	O
+of	O
+which	O
+were	O
+ameliorated	O
+by	O
+anti	B-PRGE
+-	I-PRGE
+C5a	I-PRGE
+treatment	O
+.	O
+
+Fluorescence	O
+confocal	O
+microscopy	O
+of	O
+labeled	O
+MHV	B-SPEC
+-	O
+A59	O
+confirmed	O
+that	O
+virus	B-SPEC
+is	O
+taken	O
+up	O
+via	O
+endocytosis	O
+.	O
+
+However	O
+,	O
+when	O
+virus	B-SPEC
+was	O
+bound	O
+to	O
+cells	B-COMP
+and	O
+the	O
+pH	O
+was	O
+lowered	O
+to	O
+5	O
+.	O
+0	O
+,	O
+we	O
+observed	O
+a	O
+strong	O
+labeling	O
+of	O
+the	O
+plasma	B-COMP
+membrane	I-COMP
+.	O
+
+The	O
+results	O
+imply	O
+that	O
+endocytosis	B-PATH
+plays	O
+a	O
+major	O
+role	O
+in	O
+MHV	B-SPEC
+-	O
+A59	O
+infection	B-DISO
+and	O
+the	O
+acidic	O
+pH	O
+of	O
+the	O
+endosomal	O
+compartment	B-ANAT
+triggers	O
+a	O
+conformational	B-PROC
+change	I-PROC
+of	O
+the	O
+S	B-PRGE
+protein	I-PRGE
+mediating	O
+fusion	O
+.	O
+
+All	O
+vaccination	O
+groups	O
+were	O
+given	O
+Massachusetts	O
+/	O
+Connecticut	O
+strains	O
+of	O
+infectious	B-DISO
+bronchitis	B-DISO
+virus	B-SPEC
+vaccines	O
+at	O
+age	O
+1	O
+day	O
+followed	O
+by	O
+vaccination	O
+with	O
+either	O
+Holland	O
+/	O
+Arkansas	O
+or	O
+Massachusetts	O
+/	O
+Arkansas	O
+vaccine	O
+strains	O
+at	O
+18	O
+days	O
+of	O
+age	O
+.	O
+
+Chickens	B-SPEC
+vaccinated	O
+with	O
+Holland	O
+/	O
+Arkansas	O
+had	O
+marginally	O
+better	O
+protection	O
+against	O
+CA99	O
+challenge	O
+than	O
+chickens	B-SPEC
+vaccinated	O
+with	O
+Massachusetts	O
+/	O
+Arkansas	O
+,	O
+although	O
+differences	O
+were	O
+not	O
+statistically	O
+significant	O
+.	O
+
+TITLE	O
+:	O
+The	O
+efficacy	O
+of	O
+an	O
+avian	B-SPEC
+metapneumovirus	I-SPEC
+vaccine	O
+applied	O
+simultaneously	O
+with	O
+infectious	B-DISO
+bronchitis	B-DISO
+and	O
+Newcastle	B-SPEC
+disease	I-SPEC
+virus	I-SPEC
+vaccines	O
+to	O
+specific	O
+-	O
+pathogen	O
+-	O
+free	O
+chickens	B-SPEC
+.	O
+
+However	O
+,	O
+the	O
+aMPV	O
+vaccine	O
+did	O
+not	O
+affect	O
+the	O
+serological	O
+response	O
+to	O
+the	O
+IBV	B-SPEC
+and	O
+NDV	O
+vaccines	O
+.	O
+
+This	O
+is	O
+the	O
+first	O
+report	O
+showing	O
+aMPV	O
+,	O
+IBV	B-SPEC
+,	O
+and	O
+NDV	B-SPEC
+vaccines	O
+can	O
+be	O
+codelivered	O
+without	O
+affecting	O
+the	O
+efficacy	O
+of	O
+the	O
+aMPV	O
+vaccine	O
+.	O
+
+TITLE	O
+:	O
+Intratracheally	O
+administered	O
+pathogen	O
+-	O
+associated	O
+molecular	O
+patterns	O
+affect	O
+antibody	B-COMP
+responses	I-PROC
+of	O
+poultry	O
+.	O
+
+1	O
+,	O
+3	O
+beta	B-CHED
+-	I-CHED
+Glucan	I-CHED
+did	O
+not	O
+significantly	O
+affect	O
+Ab	O
+responses	O
+to	O
+HuSA	O
+.	O
+
+All	O
+birds	B-SPEC
+challenged	O
+with	O
+PAMP	O
+showed	O
+a	O
+decreased	O
+BW	O
+.	O
+
+Higher	O
+total	O
+Ab	O
+titers	O
+to	O
+infectious	B-DISO
+bursal	I-DISO
+disease	I-DISO
+and	O
+infectious	B-DISO
+bronchitis	B-DISO
+were	O
+found	O
+in	O
+birds	B-SPEC
+challenged	O
+with	O
+LTA	O
+.	O
+
+Sequence	O
+analysis	O
+revealed	O
+that	O
+KQ6	O
+was	O
+an	O
+avian	B-SPEC
+coronavirus	I-SPEC
+infectious	B-DISO
+bronchitis	B-DISO
+virus	B-SPEC
+(	O
+IBV	B-SPEC
+),	O
+a	O
+member	O
+of	O
+coronavirus	B-SPEC
+in	O
+group	O
+3	O
+.	O
+
+ABSTRACT	O
+:	O
+Current	O
+concerns	O
+about	O
+the	O
+spread	O
+of	O
+infectious	O
+diseases	O
+,	O
+especially	O
+unexpected	O
+"("""	O
+emerging	O
+""")"	O
+infections	B-DISO
+such	O
+as	O
+pandemic	O
+influenza	B-DISO
+or	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+(	O
+SARS	B-DISO
+),	O
+have	O
+renewed	O
+focus	O
+on	O
+the	O
+critical	O
+importance	O
+of	O
+global	O
+early	O
+warning	O
+and	O
+rapid	O
+response	O
+.	O
+
+A	O
+number	O
+of	O
+the	O
+gaps	O
+can	O
+be	O
+addressed	O
+through	O
+increased	O
+political	O
+will	O
+,	O
+resources	O
+for	O
+reporting	O
+,	O
+improved	O
+coordination	B-PROC
+and	O
+sharing	O
+of	O
+information	O
+,	O
+raising	O
+clinicians	O
+'	O
+awareness	O
+,	O
+and	O
+additional	O
+research	O
+to	O
+develop	O
+more	O
+rigorous	O
+triggers	O
+for	O
+action	O
+.	O
+
+However	O
+,	O
+only	O
+one	O
+adult	O
+case	O
+of	O
+TRALI	B-DISO
+after	O
+allogenic	O
+marrow	O
+graft	B-ANAT
+has	O
+been	O
+reported	O
+.	O
+
+ABSTRACT	O
+:	O
+The	O
+cellular	B-COMP
+receptor	O
+for	O
+human	B-PRGE
+coronavirus	I-PRGE
+NL63	I-PRGE
+(	O
+HCoV	B-SPEC
+-	I-SPEC
+NL63	I-SPEC
+),	O
+a	O
+group	O
+I	O
+coronavirus	B-SPEC
+,	O
+is	O
+angiotensin	B-CHED
+-	O
+converting	O
+enzyme2	O
+(	O
+ACE2	B-PRGE
+).	O
+
+Here	O
+we	O
+describe	O
+the	O
+ability	O
+of	O
+HCoV	B-SPEC
+-	I-SPEC
+NL63	I-SPEC
+to	O
+utilize	O
+a	O
+number	O
+of	O
+ACE2	O
+variants	O
+previously	O
+characterized	O
+as	O
+SARS	B-PRGE
+-	I-PRGE
+CoV	I-PRGE
+receptors	I-PRGE
+.	O
+
+TITLE	O
+:	O
+Targeting	B-PROC
+the	O
+glycans	B-CHED
+of	O
+glycoproteins	B-CHED
+:	O
+a	O
+novel	O
+paradigm	O
+for	O
+antiviral	B-CHED
+therapy	O
+.	O
+
+In	O
+this	O
+Review	O
+,	O
+an	O
+original	O
+therapeutic	O
+concept	O
+for	O
+suppressing	O
+enveloped	O
+viruses	B-SPEC
+is	O
+presented	O
+that	O
+is	O
+based	O
+on	O
+a	O
+specific	O
+interaction	O
+of	O
+carbohydrate	B-CHED
+-	O
+binding	B-FUNC
+agents	O
+(	O
+CBAs	O
+)	O
+with	O
+the	O
+glycans	B-CHED
+present	O
+on	O
+viral	B-PRGE
+-	I-PRGE
+envelope	I-PRGE
+glycoproteins	B-CHED
+.	O
+
+We	O
+also	O
+confirmed	O
+the	O
+presence	O
+of	O
+a	O
+second	O
+cleavage	B-PROC
+site	O
+between	O
+nsp7	O
+and	O
+nsp8	O
+.	O
+
+Similarly	O
+,	O
+normal	O
+levels	O
+of	O
+dystrophin	B-PRGE
+expression	B-PROC
+were	O
+restored	O
+in	O
+the	O
+diaphragms	B-ANAT
+of	O
+mdx	B-DISO
+mice	B-SPEC
+,	O
+with	O
+treatment	O
+starting	O
+at	O
+the	O
+neonatal	O
+stage	O
+,	O
+and	O
+protein	B-CHED
+was	O
+still	O
+detecTable	O
+22	O
+weeks	O
+after	O
+the	O
+last	O
+dose	O
+of	O
+an	O
+(	O
+R	B-PRGE
+-	I-PRGE
+Ahx	I-PRGE
+-	I-PRGE
+R	I-PRGE
+)(	O
+4	O
+)	O
+AhxB	O
+-	O
+PMO	O
+conjugate	O
+.	O
+
+ABSTRACT	O
+:	O
+Here	O
+we	O
+report	O
+a	O
+case	O
+of	O
+leptospirosis	O
+without	O
+fever	B-PROC
+during	O
+the	O
+late	O
+stage	O
+of	O
+pregnancy	O
+in	O
+which	O
+the	O
+initial	O
+clinical	O
+presentation	O
+was	O
+more	O
+suggestive	O
+of	O
+a	O
+pregnancy	O
+-	O
+related	O
+liver	B-DISO
+dysfunction	I-DISO
+rather	O
+than	O
+an	O
+infectious	B-DISO
+disease	I-DISO
+.	O
+
+At	O
+this	O
+time	O
+,	O
+an	O
+infectious	B-DISO
+disease	I-DISO
+was	O
+considered	O
+and	O
+leptospirosis	B-DISO
+was	O
+confirmed	O
+by	O
+serological	O
+tests	O
+.	O
+
+ABSTRACT	O
+:	O
+Severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+(	O
+SARS	B-DISO
+)	O
+is	O
+a	O
+newly	O
+emerging	B-DISO
+infectious	I-DISO
+disease	I-DISO
+caused	O
+by	O
+a	O
+novel	B-SPEC
+coronavirus	I-SPEC
+(	O
+SARS	B-DISO
+-	O
+CoV	O
+),	O
+which	O
+has	O
+overwhelmed	O
+more	O
+than	O
+30	O
+countries	O
+claiming	O
+nearly	O
+8400	O
+cases	O
+with	O
+over	O
+800	O
+fatalities	O
+.	O
+
+This	O
+review	O
+intends	O
+to	O
+outline	O
+the	O
+major	O
+progress	O
+in	O
+the	O
+journey	O
+of	O
+SARS	B-DISO
+-	O
+related	O
+exploration	O
+,	O
+by	O
+emphasizing	O
+those	O
+inaugurated	O
+studies	O
+with	O
+milestone	O
+-	O
+like	O
+significance	O
+contributed	O
+by	O
+Chinese	O
+research	O
+groups	O
+.	O
+
+And	O
+a	O
+marked	O
+increase	O
+was	O
+observed	O
+in	O
+the	O
+number	O
+of	O
+spleen	B-ANAT
+CD8	B-PRGE
++	I-PRGE
+T	B-ANAT
+cells	I-ANAT
+.	O
+
+As	O
+of	O
+June	O
+23rd	O
+2003	O
+,	O
+the	O
+disease	O
+had	O
+been	O
+reported	O
+from	O
+32	O
+countries	O
+or	O
+regions	O
+globally	O
+,	O
+affecting	O
+8459	O
+people	O
+;	O
+805	O
+individuals	O
+(	O
+9	O
+.	O
+5	O
+%	O
+of	O
+the	O
+total	O
+affected	O
+)	O
+have	O
+died	B-PROC
+of	O
+the	O
+disease	O
+.	O
+
+In	O
+a	O
+comparison	O
+of	O
+nucleotide	B-CHED
+sequences	O
+with	O
+the	O
+chicken	B-SPEC
+germline	O
+gene	O
+,	O
+we	O
+found	O
+that	O
+all	O
+clones	O
+varied	O
+in	O
+the	O
+complementarity	O
+-	O
+determining	O
+regions	O
+,	O
+that	O
+two	O
+scFv	O
+antibodies	O
+reacted	O
+significantly	O
+with	O
+SARS	B-DISO
+-	O
+CoV	O
+-	O
+infected	O
+Vero	B-ANAT
+cells	I-ANAT
+,	O
+and	O
+that	O
+those	O
+two	O
+specific	O
+scFv	O
+antibodies	B-COMP
+recognized	O
+the	O
+same	O
+region	O
+of	O
+the	O
+spike	O
+protein	B-CHED
+spanning	O
+amino	B-CHED
+acid	I-CHED
+residues	O
+750	O
+-	O
+1000	O
+.	O
+
+ORF8a	O
+and	O
+ORF8b	O
+are	O
+predicted	O
+to	O
+encode	O
+two	O
+small	O
+proteins	B-CHED
+,	O
+8a	O
+and	O
+8b	O
+,	O
+and	O
+ORF8	O
+a	O
+single	O
+protein	B-CHED
+,	O
+8ab	O
+(	O
+a	O
+fusion	O
+form	O
+of	O
+8a	O
+and	O
+8b	O
+).	O
+
+Expression	B-PROC
+of	O
+a	O
+construct	O
+containing	O
+ORF8	O
+generated	O
+the	O
+8ab	O
+fusion	O
+protein	B-CHED
+.	O
+
+More	O
+interestingly	O
+,	O
+the	O
+two	O
+proteins	B-CHED
+could	O
+bind	B-FUNC
+to	O
+monoubiquitin	O
+and	O
+polyubiquitin	B-PROC
+,	O
+suggesting	O
+the	O
+potential	O
+involvement	O
+of	O
+these	O
+proteins	B-CHED
+in	O
+the	O
+pathogenesis	B-DISO
+of	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+coronavirus	B-SPEC
+.	O
+
+Pneumonia	B-DISO
+and	O
+sepsis	B-DISO
+were	O
+the	O
+main	O
+cause	O
+of	O
+ARDS	B-DISO
+.	O
+
+The	O
+main	O
+cause	O
+of	O
+death	B-PROC
+is	O
+multiple	B-DISO
+organ	I-DISO
+failure	I-DISO
+.	O
+
+Analyses	O
+of	O
+the	O
+infectivity	O
+of	O
+the	O
+pseudotype	B-PRGE
+-	I-PRGE
+bearing	I-PRGE
+S	I-PRGE
+protein	I-PRGE
+indicated	O
+that	O
+the	O
+two	O
+substitutions	O
+in	O
+the	O
+S2	O
+region	O
+,	O
+especially	O
+the	O
+S950F	O
+substitution	O
+,	O
+were	O
+responsible	O
+for	O
+efficient	O
+infection	B-DISO
+.	O
+
+Therefore	O
+,	O
+virus	B-SPEC
+adaptation	B-PROC
+to	O
+different	O
+host	B-COMP
+species	B-SPEC
+can	O
+be	O
+induced	O
+by	O
+amino	B-PROC
+acid	I-PROC
+substitutions	I-PROC
+in	O
+the	O
+S2	O
+region	O
+.	O
+
+The	O
+complete	O
+coding	O
+region	O
+is	O
+2418bp	O
+in	O
+length	O
+and	O
+is	O
+the	O
+closest	O
+to	O
+human	B-PRGE
+ACE2	I-PRGE
+among	O
+known	O
+ACE2	B-PRGE
+homologs	I-PRGE
+of	O
+non	O
+-	O
+primate	B-SPEC
+animals	B-SPEC
+.	O
+
+The	O
+protein	B-CHED
+signatures	O
+,	O
+or	O
+biomarkers	O
+,	O
+can	O
+be	O
+used	O
+to	O
+diagnose	O
+infection	B-DISO
+,	O
+predict	O
+disease	O
+states	O
+and	O
+to	O
+inform	O
+on	O
+disease	O
+processes	O
+.	O
+
+Surface	O
+activity	O
+of	O
+the	O
+LA	O
+fraction	O
+was	O
+greatly	O
+impaired	B-DISO
+.	O
+
+TITLE	O
+:	O
+Understanding	O
+,	O
+compliance	O
+and	O
+psychological	B-DISO
+impact	O
+of	O
+the	O
+SARS	B-DISO
+quarantine	O
+experience	O
+.	O
+
+A	O
+mailed	O
+questionnaire	O
+was	O
+administered	O
+to	O
+1912	O
+eligible	O
+adults	O
+and	O
+included	O
+the	O
+Impact	O
+of	O
+Events	O
+Scale	O
+-	O
+Revised	O
+(	O
+IES	B-CHED
+-	O
+R	O
+)	O
+to	O
+assess	O
+symptoms	O
+of	O
+post	B-DISO
+-	I-DISO
+traumatic	I-DISO
+stress	I-DISO
+disorder	I-DISO
+(	O
+PTSD	B-DISO
+).	O
+
+TITLE	O
+:	O
+Optimization	O
+of	O
+a	O
+DNA	O
+vaccine	O
+against	O
+SARS	B-DISO
+.	O
+
+The	O
+authors	O
+report	O
+on	O
+a	O
+case	O
+of	O
+pseudomembranous	O
+necrotizing	O
+form	O
+of	O
+histologically	O
+proven	O
+tracheobronchitis	B-DISO
+,	O
+caused	O
+by	O
+Aspergillus	B-SPEC
+spp	B-ENZY
+in	O
+the	O
+time	O
+of	O
+induction	O
+chemotherapy	O
+in	O
+a	O
+patient	O
+with	O
+acute	B-PATH
+myeloid	I-PATH
+leukemia	I-PATH
+.	O
+
+The	O
+clinical	O
+evolution	B-PROC
+is	O
+gradual	O
+:	O
+from	O
+mild	O
+non	O
+-	O
+specific	O
+manifestations	O
+of	O
+acute	B-DISO
+tracheobronchitis	I-DISO
+against	O
+the	O
+background	O
+of	O
+a	O
+prolonged	O
+fever	B-PROC
+unaffected	O
+by	O
+antibiotic	B-CHED
+therapy	O
+to	O
+the	O
+onset	O
+of	O
+severe	O
+acute	B-DISO
+respiratory	I-DISO
+insufficiency	I-DISO
+and	O
+unilateral	O
+bronchial	B-ANAT
+obstruction	B-DISO
+syndrome	B-DISO
+.	O
+
+The	O
+diagnostic	O
+methods	O
+,	O
+therapeutic	O
+possibilities	O
+and	O
+differential	O
+diagnosis	O
+of	O
+this	O
+rare	O
+infectious	B-DISO
+complication	B-DISO
+in	O
+immunocompromised	O
+patients	O
+are	O
+discussed	O
+.	O
+
+To	O
+investigate	O
+whether	O
+leukocytes	B-ANAT
+could	O
+participate	O
+in	O
+respiratory	O
+pathologies	O
+and	O
+serve	O
+as	O
+vector	O
+for	O
+viral	O
+spread	O
+towards	O
+other	O
+tissues	B-ANAT
+,	O
+the	O
+susceptibility	O
+of	O
+human	B-SPEC
+leukocytic	B-ANAT
+cell	B-ANAT
+lines	I-ANAT
+and	O
+peripheral	B-ANAT
+blood	I-ANAT
+mononuclear	I-ANAT
+cells	I-ANAT
+(	O
+PBMC	O
+)	O
+to	O
+HCoV	B-SPEC
+-	I-SPEC
+229E	I-SPEC
+and	O
+HCoV	B-SPEC
+-	I-SPEC
+OC43	I-SPEC
+infection	B-DISO
+was	O
+investigated	O
+.	O
+
+TITLE	O
+:	O
+Enhancement	O
+of	O
+murine	B-SPEC
+coronavirus	I-SPEC
+replication	O
+by	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+coronavirus	B-SPEC
+protein	B-CHED
+6	O
+requires	O
+the	O
+N	O
+-	O
+terminal	O
+hydrophobic	O
+region	O
+but	O
+not	O
+C	O
+-	O
+terminal	O
+sorting	B-PROC
+motifs	O
+.	O
+
+ABSTRACT	O
+:	O
+Severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+coronavirus	B-SPEC
+encodes	O
+several	O
+accessory	O
+proteins	B-CHED
+of	O
+unknown	O
+function	O
+.	O
+
+TITLE	O
+:	O
+The	O
+coronavirus	B-SPEC
+spike	O
+protein	B-CHED
+induces	O
+endoplasmic	B-COMP
+reticulum	I-COMP
+stress	O
+and	O
+upregulation	B-PROC
+of	O
+intracellular	B-ANAT
+chemokine	O
+mRNA	B-CHED
+concentrations	O
+.	O
+
+Thirty	O
+-	O
+five	O
+children	O
+underwent	O
+lung	B-ANAT
+resections	O
+between	O
+1998	O
+and	O
+2006	O
+,	O
+their	O
+age	O
+ranging	O
+from	O
+8	O
+days	O
+to	O
+12	O
+years	O
+(	O
+mean	O
+3	O
+years	O
+),	O
+with	O
+a	O
+male	O
+:	O
+female	O
+ratio	O
+of	O
+4	O
+:	O
+1	O
+.	O
+
+ABSTRACT	O
+:	O
+New	O
+contemporary	O
+data	O
+about	O
+new	O
+infectious	B-DISO
+diseases	I-DISO
+of	O
+XXI	O
+century	O
+are	O
+presented	O
+.	O
+
+Because	O
+of	O
+the	O
+persistent	O
+hemodynamic	B-DISO
+instability	I-DISO
+,	O
+a	O
+mitral	O
+valvular	O
+replacement	O
+and	O
+tricuspid	B-ANAT
+valve	I-ANAT
+annuloplasty	O
+were	O
+performed	O
+.	O
+
+These	O
+genetic	O
+data	O
+show	O
+that	O
+the	O
+endogenous	O
+peptide	B-CHED
+Apelin	O
+is	O
+crucial	O
+to	O
+maintain	O
+cardiac	B-ANAT
+contractility	O
+in	O
+pressure	O
+overload	O
+and	O
+aging	B-PROC
+.	O
+
+TITLE	O
+:	O
+A	O
+feline	B-SPEC
+case	O
+of	O
+isolated	O
+fourth	B-ANAT
+ventricle	I-ANAT
+with	O
+syringomyelia	B-DISO
+suspected	O
+to	O
+be	O
+related	O
+with	O
+feline	B-SPEC
+infectious	I-DISO
+peritonitis	I-DISO
+.	O
+
+The	O
+cat	B-SPEC
+was	O
+diagnosed	O
+with	O
+an	O
+isolated	O
+fourth	B-ANAT
+ventricle	I-ANAT
+(	O
+IFV	B-SPEC
+)	O
+with	O
+syringomyelia	B-DISO
+.	O
+
+The	O
+serum	B-COMP
+isoantibody	O
+test	O
+for	O
+the	O
+feline	B-DISO
+infectious	I-DISO
+peritonitis	I-DISO
+(	O
+FIP	B-DISO
+)	O
+virus	B-SPEC
+was	O
+1	O
+:	O
+3	O
+,	O
+200	O
+.	O
+
+To	O
+our	O
+knowledge	O
+,	O
+there	O
+has	O
+been	O
+no	O
+report	O
+on	O
+IFV	B-SPEC
+in	O
+veterinary	O
+medicine	B-CHED
+.	O
+
+The	O
+results	O
+of	O
+SARS	B-DISO
+-	O
+CoV	O
+structural	O
+proteomics	O
+initiatives	O
+will	O
+have	O
+several	O
+profound	O
+biological	O
+impacts	O
+,	O
+including	O
+elucidation	O
+of	O
+the	O
+structure	O
+-	O
+function	O
+relationships	O
+of	O
+coronavirus	B-SPEC
+proteins	B-CHED
+;	O
+identification	O
+of	O
+targets	O
+for	O
+the	O
+design	O
+of	O
+anti	O
+-	O
+viral	O
+compounds	O
+against	O
+SARS	B-DISO
+-	O
+CoV	O
+and	O
+other	O
+coronaviruses	O
+;	O
+and	O
+addition	O
+of	O
+new	O
+protein	B-CHED
+folds	O
+to	O
+the	O
+fold	O
+space	O
+,	O
+with	O
+further	O
+understanding	O
+of	O
+the	O
+structure	O
+-	O
+function	O
+relationships	O
+for	O
+several	O
+new	O
+protein	B-CHED
+families	O
+.	O
+
+Electron	O
+microscope	O
+analysis	O
+demonstrated	O
+the	O
+formation	B-PROC
+of	O
+VLPs	B-ANAT
+in	O
+vAcME	O
+and	O
+vAcS	O
+coinfected	O
+insect	B-SPEC
+cells	B-COMP
+.	O
+
+VLPs	B-ANAT
+also	O
+conferred	O
+protective	O
+immunity	B-PROC
+against	O
+the	O
+infection	B-DISO
+of	O
+Spike	O
+protein	B-CHED
+pseudotyped	O
+murine	B-SPEC
+leukaemia	B-DISO
+virus	B-SPEC
+.	O
+
+This	O
+is	O
+the	O
+first	O
+study	O
+describing	O
+the	O
+immunogenicity	O
+of	O
+SARS	O
+CoV	O
+VLPs	B-ANAT
+,	O
+providing	O
+valuable	O
+data	O
+for	O
+developing	O
+a	O
+protective	O
+vaccine	O
+against	O
+SARS	B-DISO
+CoV	O
+infection	B-DISO
+.	O
+
+There	O
+have	O
+been	O
+only	O
+few	O
+scattered	O
+reports	O
+in	O
+the	O
+literature	O
+on	O
+the	O
+association	O
+of	O
+HELLP	B-DISO
+syndrome	I-DISO
+and	O
+APS	B-DISO
+,	O
+which	O
+was	O
+successfully	O
+managed	O
+with	O
+the	O
+combination	O
+of	O
+various	O
+immunosuppressive	O
+and	O
+immunomodulatory	O
+treatment	O
+modalities	O
+.	O
+
+Disruption	O
+of	O
+gene	O
+7	O
+did	O
+not	O
+affect	O
+virus	B-PROC
+replication	I-PROC
+or	O
+morbidity	O
+in	O
+golden	O
+Syrian	B-SPEC
+hamsters	I-SPEC
+,	O
+suggesting	O
+that	O
+the	O
+gene	O
+7	O
+products	O
+are	O
+not	O
+required	O
+for	O
+acute	B-DISO
+infection	I-DISO
+in	O
+vivo	O
+.	O
+
+Using	O
+functional	O
+genomics	O
+,	O
+we	O
+analyzed	O
+early	O
+host	B-COMP
+responses	O
+to	O
+SARS	B-DISO
+-	I-DISO
+CoV	I-DISO
+infection	I-DISO
+in	O
+the	O
+lungs	B-ANAT
+of	O
+adolescent	O
+cynomolgus	O
+macaques	B-SPEC
+(	O
+Macaca	B-SPEC
+fascicularis	I-SPEC
+)	O
+that	O
+show	O
+lung	B-ANAT
+pathology	B-DISO
+similar	O
+to	O
+that	O
+observed	O
+in	O
+human	B-SPEC
+adults	O
+with	O
+SARS	B-DISO
+.	O
+
+Analysis	O
+of	O
+gene	O
+signatures	O
+revealed	O
+induction	O
+of	O
+a	O
+strong	O
+innate	B-DISO
+immune	I-DISO
+response	I-DISO
+characterized	O
+by	O
+the	O
+stimulation	O
+of	O
+various	O
+cytokine	O
+and	O
+chemokine	O
+genes	O
+,	O
+including	O
+interleukin	B-PRGE
+(	O
+IL	O
+)-	O
+6	O
+,	O
+IL	B-FUNC
+-	I-FUNC
+8	I-FUNC
+,	O
+and	O
+IP	O
+-	O
+10	O
+,	O
+which	O
+corresponds	O
+to	O
+the	O
+host	B-PROC
+response	I-PROC
+seen	O
+in	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+.	O
+
+TITLE	O
+:	O
+Multiplex	O
+real	O
+-	O
+time	O
+RT	O
+-	O
+PCR	O
+for	O
+the	O
+simultaneous	O
+detection	O
+and	O
+quantification	O
+of	O
+transmissible	O
+gastroenteritis	B-DISO
+virus	B-SPEC
+and	O
+porcine	B-SPEC
+epidemic	I-SPEC
+diarrhea	I-SPEC
+virus	I-SPEC
+.	O
+
+The	O
+assay	O
+may	O
+also	O
+prove	O
+useful	O
+for	O
+detecting	O
+infections	B-DISO
+,	O
+ultimately	O
+leading	O
+to	O
+better	O
+disease	O
+control	O
+on	O
+farms	O
+.	O
+
+Within	O
+1	O
+h	O
+,	O
+17	O
+particles	O
+were	O
+bound	O
+per	O
+cell	B-COMP
+and	O
+,	O
+within	O
+1	O
+min	O
+,	O
+89	O
+%	O
+of	O
+the	O
+bound	O
+particles	O
+were	O
+internalized	O
+.	O
+
+In	O
+CrFK	O
+cells	B-COMP
+,	O
+attachment	O
+and	O
+internalization	O
+were	O
+less	O
+efficient	O
+,	O
+especially	O
+for	O
+FIPV	O
+I	O
+(	O
+Black	O
+),	O
+so	O
+this	O
+cell	O
+line	O
+is	O
+not	O
+suitable	O
+for	O
+studying	O
+FIPV	O
+entry	O
+.	O
+
+Literature	O
+was	O
+identified	O
+through	O
+MEDLINE	O
+(	O
+1966	O
+-	O
+April	O
+2007	O
+)	O
+using	O
+combinations	O
+of	O
+the	O
+key	O
+words	O
+hydrocortisone	B-CHED
+,	O
+adrenal	B-DISO
+insufficiency	I-DISO
+,	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+,	O
+pneumonia	B-DISO
+,	O
+sepsis	B-DISO
+,	O
+and	O
+cortisol	B-CHED
+.	O
+
+Recent	O
+studies	O
+using	O
+extended	O
+courses	O
+of	O
+low	O
+-	O
+to	O
+-	O
+moderate	O
+doses	O
+of	O
+steroids	B-CHED
+have	O
+found	O
+favorable	O
+results	O
+;	O
+however	O
+,	O
+these	O
+results	O
+must	O
+be	O
+interpreted	O
+with	O
+caution	O
+due	O
+to	O
+limitations	O
+in	O
+the	O
+data	O
+.	O
+
+It	O
+is	O
+logical	O
+to	O
+assume	O
+that	O
+increasing	O
+the	O
+dialysis	B-SPEC
+dosage	O
+would	O
+minimize	O
+uremic	O
+complications	O
+and	O
+improve	O
+outcomes	O
+in	O
+such	O
+patients	O
+.	O
+
+TITLE	O
+:	O
+Coronavirus	B-SPEC
+replication	O
+does	O
+not	O
+require	O
+the	O
+autophagy	B-PRGE
+gene	I-PRGE
+ATG5	I-PRGE
+.	O
+
+TITLE	O
+:	O
+Review	O
+of	O
+retention	B-PROC
+strategies	O
+in	O
+longitudinal	O
+studies	O
+and	O
+application	O
+to	O
+follow	O
+-	O
+up	O
+of	O
+ICU	O
+survivors	O
+.	O
+
+TITLE	O
+:	O
+On	O
+the	O
+role	O
+of	O
+asymptomatic	B-DISO
+infection	I-DISO
+in	O
+transmission	O
+dynamics	O
+of	O
+infectious	B-DISO
+diseases	I-DISO
+.	O
+
+ABSTRACT	O
+:	O
+We	O
+propose	O
+a	O
+compartmental	O
+disease	O
+transmission	O
+model	O
+with	O
+an	O
+asymptomatic	O
+(	O
+or	O
+subclinical	O
+)	O
+infective	O
+class	B-SPEC
+to	O
+study	O
+the	O
+role	O
+of	O
+asymptomatic	B-DISO
+infection	I-DISO
+in	O
+the	O
+transmission	O
+dynamics	O
+of	O
+infectious	B-DISO
+diseases	I-DISO
+with	O
+asymptomatic	O
+infectives	O
+,	O
+e	O
+.	O
+g	O
+.,	O
+influenza	B-DISO
+.	O
+
+All	O
+but	O
+one	O
+of	O
+the	O
+HCoVs	O
+corresponded	O
+to	O
+the	O
+newly	O
+recognized	O
+HCoV	B-SPEC
+-	I-SPEC
+NL63	I-SPEC
+and	O
+HCoV	O
+-	O
+HKU1	O
+viruses	B-SPEC
+,	O
+and	O
+>	O
+20	O
+different	O
+serotypes	O
+of	O
+HRVs	O
+were	O
+detected	O
+,	O
+including	O
+a	O
+set	O
+of	O
+5	O
+divergent	O
+isolates	O
+that	O
+formed	O
+a	O
+distinct	O
+genetic	O
+subgroup	O
+.	O
+
+The	O
+light	O
+,	O
+scanning	O
+,	O
+and	O
+transmission	O
+electron	O
+microscopic	O
+changes	O
+in	O
+infected	O
+shell	B-ANAT
+-	O
+forming	O
+regions	O
+of	O
+the	O
+oviduct	B-ANAT
+were	O
+compared	O
+with	O
+the	O
+control	O
+oviducts	B-ANAT
+at	O
+different	O
+egg	B-ANAT
+positions	O
+.	O
+
+The	O
+T	O
+strain	O
+of	O
+infectious	B-DISO
+bronchitis	B-DISO
+virus	B-SPEC
+was	O
+more	O
+pathogenic	O
+compared	O
+with	O
+the	O
+N1	O
+/	O
+88	O
+strain	O
+.	O
+
+Severe	O
+cytopathology	O
+was	O
+recorded	O
+in	O
+the	O
+shell	O
+-	O
+forming	O
+region	O
+of	O
+hens	O
+that	O
+were	O
+out	O
+of	O
+production	O
+,	O
+and	O
+virus	B-COMP
+particles	I-COMP
+were	O
+observed	O
+in	O
+hens	O
+that	O
+had	O
+stopped	O
+laying	O
+.	O
+
+Inhibition	B-PROC
+of	O
+mannosidases	O
+in	O
+host	B-COMP
+cells	B-COMP
+rendered	O
+the	O
+progeny	O
+viruses	B-SPEC
+more	O
+sensitive	O
+to	O
+the	O
+mannose	B-CHED
+-	O
+binding	B-FUNC
+agents	O
+and	O
+even	O
+to	O
+the	O
+N	B-CHED
+-	I-CHED
+acetylglucosamine	I-CHED
+-	O
+binding	B-FUNC
+UDA	B-CHED
+.	O
+
+In	O
+addition	O
+,	O
+inhibition	B-PROC
+of	O
+coronaviruses	O
+was	O
+shown	O
+to	O
+be	O
+dependent	O
+on	O
+the	O
+cell	B-COMP
+-	O
+type	O
+used	O
+to	O
+grow	O
+the	O
+virus	B-SPEC
+stocks	O
+.	O
+
+All	O
+together	O
+,	O
+these	O
+results	O
+show	O
+that	O
+CBA	B-CHED
+exhibit	O
+promising	O
+capabilities	O
+to	O
+inhibit	O
+coronavirus	B-DISO
+infections	I-DISO
+.	O
+
+Together	O
+,	O
+these	O
+results	O
+indicate	O
+that	O
+SARS	B-PRGE
+-	I-PRGE
+CoV	I-PRGE
+M	I-PRGE
+suppresses	O
+NF	B-PRGE
+-	I-PRGE
+kappaB	I-PRGE
+activity	O
+probably	O
+through	O
+a	O
+direct	O
+interaction	O
+with	O
+IKKbeta	B-PRGE
+,	O
+resulting	O
+in	O
+lower	O
+Cox	O
+-	O
+2	O
+expression	B-PROC
+.	O
+
+ABSTRACT	O
+:	O
+During	O
+the	O
+SARS	O
+crisis	O
+in	O
+China	O
+,	O
+40	O
+-	O
+60	O
+%	O
+infected	O
+patients	O
+,	O
+at	O
+some	O
+stages	O
+of	O
+their	O
+treatment	O
+,	O
+received	O
+Chinese	O
+medicine	B-CHED
+treatment	O
+on	O
+top	O
+of	O
+the	O
+standard	O
+modern	O
+medicine	B-CHED
+treatment	O
+.	O
+
+A	O
+review	O
+of	O
+the	O
+publications	O
+during	O
+and	O
+after	O
+the	O
+SARS	B-DISO
+crisis	O
+enabled	O
+us	O
+to	O
+get	O
+an	O
+objective	O
+view	O
+of	O
+the	O
+true	O
+value	O
+of	O
+the	O
+adjuvant	B-CHED
+therapy	O
+using	O
+Chinese	O
+medicinal	O
+herbs	O
+.	O
+
+Positive	O
+effects	O
+using	O
+adjuvant	B-CHED
+herbal	O
+therapy	O
+included	O
+better	O
+control	O
+of	O
+fever	B-PROC
+,	O
+quicker	O
+clearance	O
+of	O
+chest	B-DISO
+infection	I-DISO
+,	O
+lesser	O
+consumption	O
+of	O
+steroids	B-CHED
+and	O
+other	O
+symptoms	O
+relief	O
+.	O
+
+Identification	O
+of	O
+functional	O
+dominant	O
+epitopes	O
+in	O
+SARS	B-PRGE
+CoV	I-PRGE
+S	I-PRGE
+protein	B-CHED
+for	O
+T	B-ANAT
+cells	I-ANAT
+is	O
+crucial	O
+for	O
+further	O
+understanding	O
+of	O
+cellular	B-PROC
+immune	I-PROC
+responses	I-PROC
+elicited	O
+by	O
+SARS	B-DISO
+CoV	O
+S	O
+DNA	O
+vaccine	O
+.	O
+
+Subsequently	O
+,	O
+a	O
+pool	O
+of	O
+17	O
+-	O
+19	O
+mers	O
+overlapped	O
+SARS	B-PRGE
+CoV	I-PRGE
+S	I-PRGE
+peptides	B-CHED
+,	O
+which	O
+served	O
+as	O
+immunogens	O
+,	O
+were	O
+scanned	O
+to	O
+identify	O
+the	O
+specific	O
+epitopes	O
+for	O
+T	B-ANAT
+cells	I-ANAT
+.	O
+
+The	O
+diverse	O
+cellular	B-COMP
+responses	O
+to	O
+infection	B-DISO
+revealed	O
+the	O
+complex	O
+manner	O
+by	O
+which	O
+coronaviruses	O
+affect	O
+cellular	B-PROC
+homeostasis	I-PROC
+and	O
+modulate	O
+cell	B-PROC
+death	I-PROC
+.	O
+
+However	O
+,	O
+mutant	B-DISO
+virus	B-PROC
+replication	I-PROC
+was	O
+strongly	O
+attenuated	O
+in	O
+cells	B-COMP
+with	O
+an	O
+intact	O
+IFN	B-PRGE
+response	O
+.	O
+
+ABSTRACT	O
+:	O
+Severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+(	O
+SARS	B-DISO
+)	O
+is	O
+caused	O
+by	O
+a	O
+newly	O
+emerged	O
+coronavirus	B-SPEC
+(	O
+CoV	B-SPEC
+)	O
+designated	O
+SARS	B-PRGE
+-	I-PRGE
+CoV	B-SPEC
+.	O
+The	O
+virus	B-SPEC
+utilizes	O
+angiotensin	B-PRGE
+-	I-PRGE
+converting	I-PRGE
+enzyme	I-PRGE
+2	I-PRGE
+(	O
+ACE2	B-PRGE
+)	O
+as	O
+the	O
+primary	O
+receptor	O
+.	O
+
+The	O
+results	O
+of	O
+our	O
+study	O
+clearly	O
+demonstrate	O
+that	O
+both	O
+proteins	B-CHED
+serve	O
+as	O
+receptors	O
+independently	O
+of	O
+ACE2	B-PRGE
+and	O
+that	O
+there	O
+is	O
+a	O
+minimal	O
+level	O
+of	O
+synergy	O
+between	O
+DC	O
+/	O
+L	O
+-	O
+SIGN	O
+and	O
+ACE2	O
+.	O
+
+Site	B-PROC
+-	I-PROC
+directed	I-PROC
+mutagenesis	I-PROC
+analyses	O
+have	O
+identified	O
+seven	O
+glycosylation	B-PROC
+sites	O
+on	O
+the	O
+S	B-PRGE
+protein	I-PRGE
+critical	O
+for	O
+DC	O
+/	O
+L	O
+-	O
+SIGN	O
+-	O
+mediated	O
+virus	B-SPEC
+entry	O
+.	O
+
+Of	O
+240	O
+patients	O
+registered	O
+with	O
+SCD	B-DISO
+,	O
+52	O
+(	O
+22	O
+%)	O
+developed	O
+55	O
+episodes	O
+of	O
+ACS	B-FUNC
+.	O
+
+Fever	B-PROC
+,	O
+cough	B-DISO
+,	O
+chest	B-DISO
+pain	I-DISO
+,	O
+tachypnoea	B-DISO
+,	O
+reduced	O
+breath	B-ANAT
+sounds	O
+,	O
+crackles	B-DISO
+and	O
+chest	B-ANAT
+radiograph	O
+opacities	B-DISO
+were	O
+the	O
+main	O
+manifestations	O
+.	O
+
+ACS	B-FUNC
+is	O
+common	O
+in	O
+SCD	B-DISO
+.	O
+
+The	O
+distribution	O
+of	O
+ACS	B-FUNC
+during	O
+the	O
+year	O
+was	O
+bimodal	O
+,	O
+peaking	O
+in	O
+May	O
+and	O
+September	O
+and	O
+at	O
+its	O
+lowest	O
+in	O
+June	O
+and	O
+December	O
+/	O
+January	O
+.	O
+
+Sedation	B-DISO
+was	O
+usually	O
+administered	O
+as	O
+an	O
+intermittent	O
+intravenous	O
+bolus	O
+,	O
+outside	O
+of	O
+a	O
+protocol	O
+,	O
+and	O
+was	O
+assessed	O
+by	O
+nurses	O
+using	O
+clinical	O
+end	O
+points	O
+rather	O
+than	O
+a	O
+sedation	B-DISO
+scale	O
+.	O
+
+Most	O
+physicians	O
+infrequently	O
+use	O
+sedation	B-DISO
+and	O
+analgesic	B-CHED
+therapy	O
+for	O
+NPPV	O
+to	O
+treat	O
+acute	B-DISO
+respiratory	I-DISO
+failure	I-DISO
+,	O
+but	O
+practices	O
+vary	O
+widely	O
+within	O
+and	O
+between	O
+specialties	O
+and	O
+geographic	O
+regions	O
+.	O
+
+There	O
+are	O
+important	O
+gaps	O
+in	O
+our	O
+understanding	O
+of	O
+the	O
+epidemiology	O
+of	O
+respiratory	O
+virus	O
+infections	B-DISO
+in	O
+tropical	O
+countries	O
+.	O
+
+Between	O
+September	O
+19	O
+and	O
+December	O
+31	O
+,	O
+2003	O
+,	O
+64	O
+suspected	O
+cases	O
+of	O
+ARD	B-ENZY
+were	O
+reported	O
+;	O
+of	O
+these	O
+reported	O
+cases	O
+,	O
+21	O
+(	O
+33	O
+%)	O
+died	B-PROC
+.	O
+
+Individual	O
+cases	O
+were	O
+analyzed	O
+for	O
+sex	O
+,	O
+age	O
+,	O
+race	O
+,	O
+circumstances	O
+of	O
+death	B-PROC
+,	O
+social	O
+background	O
+of	O
+the	O
+deceased	B-PROC
+and	O
+previous	O
+medical	O
+history	O
+,	O
+seasonal	O
+occurrence	O
+of	O
+the	O
+disease	B-DISO
+,	I-DISO
+blood	I-DISO
+alcohol	O
+concentration	O
+at	O
+the	O
+time	O
+of	O
+death	B-PROC
+,	O
+body	B-ANAT
+mass	O
+index	O
+,	O
+autopsy	O
+findings	O
+,	O
+histopathology	O
+,	O
+and	O
+etiology	O
+of	O
+acute	B-DISO
+pancreatitis	I-DISO
+.	O
+
+Data	O
+derived	O
+from	O
+medicolegal	O
+autopsy	O
+studies	O
+should	O
+be	O
+included	O
+in	O
+future	O
+population	O
+-	O
+based	O
+studies	O
+of	O
+acute	B-DISO
+pancreatitis	I-DISO
+.	O
+
+Radiographic	O
+appearances	O
+include	O
+bilateral	O
+patchy	O
+air	B-CHED
+space	O
+and	O
+interstitial	B-ANAT
+opacities	B-DISO
+.	O
+
+TITLE	O
+:	O
+[	O
+Bovine	B-SPEC
+coronavirus	B-SPEC
+reproduction	B-PROC
+in	O
+the	O
+continuous	O
+cell	B-COMP
+cultures	O
+at	O
+a	O
+temperature	O
+of	O
+34	O
+degrees	O
+C	O
+].	O
+
+TITLE	O
+:	O
+[	O
+Acute	B-DISO
+severe	I-DISO
+asthma	I-DISO
+in	O
+infants	O
+.	O
+
+Before	O
+admission	O
+,	O
+corticosteroids	B-CHED
+were	O
+not	O
+instituted	O
+in	O
+84	O
+%	O
+of	O
+the	O
+cases	O
+.	O
+
+All	O
+patients	O
+received	O
+beta2	O
+adrenergic	O
+and	O
+intravenous	O
+corticosteroids	B-CHED
+.	O
+
+There	O
+were	O
+2	O
+deaths	B-PROC
+.	O
+
+The	O
+aim	O
+of	O
+this	O
+study	O
+was	O
+to	O
+determine	O
+the	O
+impact	O
+of	O
+PGAR	O
+co	B-DISO
+-	I-DISO
+infection	I-DISO
+on	O
+PEDV	B-SPEC
+pathogenicity	O
+in	O
+piglets	O
+.	O
+
+Thirty	O
+-	O
+six	O
+colostrum	B-ANAT
+-	O
+deprived	O
+,	O
+one	O
+-	O
+day	O
+old	O
+,	O
+Large	B-SPEC
+White	I-SPEC
+-	O
+Duroc	O
+crossbred	O
+pigs	B-SPEC
+were	O
+randomly	O
+divided	O
+into	O
+four	O
+equal	O
+groups	O
+:	O
+PEDV	B-SPEC
+,	O
+PEDV	B-SPEC
+/	O
+PGAR	B-PRGE
+,	O
+PGAR	B-PRGE
+,	O
+and	O
+control	O
+groups	O
+.	O
+
+RFLP	O
+patterns	O
+in	O
+11	O
+of	O
+13	O
+field	O
+PEDV	B-SPEC
+isolates	O
+were	O
+different	O
+from	O
+the	O
+vaccine	O
+strain	O
+using	O
+AspLEI	O
+,	O
+HgaI	O
+and	O
+MspR9I	O
+.	O
+
+TITLE	O
+:	O
+Nuclear	O
+magnetic	O
+resonance	O
+structure	O
+of	O
+the	O
+N	O
+-	O
+terminal	O
+domain	O
+of	O
+nonstructural	O
+protein	B-CHED
+3	O
+from	O
+the	O
+severe	O
+acute	O
+respiratory	O
+syndrome	O
+coronavirus	B-SPEC
+.	O
+
+TITLE	O
+:	O
+High	O
+dose	O
+N	B-CHED
+-	I-CHED
+acetylcysteine	I-CHED
+to	O
+prevent	O
+pulmonary	B-DISO
+complications	I-DISO
+in	O
+partial	O
+or	O
+total	O
+transthoracic	O
+esophagectomy	O
+:	O
+results	O
+of	O
+a	O
+prospective	O
+observational	O
+study	O
+.	O
+
+However	O
+,	O
+it	O
+is	O
+uncertain	O
+whether	O
+SARS	B-DISO
+-	O
+CoV	O
+evades	O
+host	B-COMP
+detection	O
+or	O
+has	O
+evolved	O
+mechanisms	O
+to	O
+counteract	O
+innate	O
+host	B-COMP
+defenses	O
+.	O
+
+Furthermore	O
+,	O
+SARS	B-DISO
+-	I-DISO
+CoV	I-DISO
+infection	I-DISO
+blocked	O
+the	O
+induction	O
+of	O
+IFN	B-PRGE
+antiviral	B-CHED
+activity	O
+and	O
+the	O
+up	O
+-	O
+regulation	O
+of	O
+protein	O
+expression	O
+of	O
+a	O
+subset	O
+of	O
+IFN	B-PRGE
+-	O
+stimulated	O
+genes	O
+triggered	O
+by	O
+double	O
+-	O
+stranded	O
+RNA	O
+or	O
+an	O
+unrelated	O
+paramyxovirus	O
+.	O
+
+TITLE	O
+:	O
+[	O
+Immunisation	O
+strategies	O
+for	O
+the	O
+management	O
+of	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+(	O
+SARS	B-DISO
+)].	O
+
+On	O
+the	O
+basis	O
+of	O
+results	O
+from	O
+a	O
+pilot	O
+study	O
+using	O
+400	O
+NPAs	O
+from	O
+all	O
+age	O
+groups	O
+,	O
+a	O
+prospective	O
+12	O
+-	O
+month	O
+study	O
+was	O
+conducted	O
+to	O
+detect	O
+HBoV	O
+in	O
+1	O
+,	O
+200	O
+NPAs	O
+and	O
+1	O
+,	O
+435	O
+fecal	B-ANAT
+samples	O
+from	O
+patients	O
+<	O
+18	O
+years	O
+old	O
+by	O
+polymerase	O
+chain	O
+reaction	O
+.	O
+
+Codetection	O
+with	O
+other	O
+pathogens	O
+occurred	O
+in	O
+33	O
+%	O
+and	O
+56	O
+%	O
+of	O
+NPAs	O
+and	O
+fecal	B-ANAT
+samples	O
+,	O
+respectively	O
+,	O
+from	O
+patients	O
+with	O
+HBoV	O
+infection	B-DISO
+.	O
+
+A	O
+single	O
+lineage	O
+of	O
+HBoV	O
+was	O
+associated	O
+with	O
+both	O
+respiratory	B-ANAT
+tract	I-ANAT
+and	O
+enteric	O
+infections	B-DISO
+.	O
+
+Included	O
+studies	O
+must	O
+have	O
+a	O
+comparative	O
+arm	B-ANAT
+of	O
+formula	O
+feeding	O
+or	O
+different	O
+durations	O
+of	O
+breastfeeding	B-PROC
+.	O
+
+Also	O
+,	O
+there	O
+is	O
+a	O
+wide	O
+range	O
+of	O
+quality	O
+of	O
+the	O
+body	B-ANAT
+of	O
+evidence	O
+across	O
+different	O
+health	O
+outcomes	O
+.	O
+
+The	O
+2003	O
+SARS	B-DISO
+outbreak	O
+particularly	O
+presented	O
+propitious	O
+circumstances	O
+for	O
+reconsidering	O
+this	O
+issue	O
+.	O
+
+Status	B-DISO
+epilepticus	I-DISO
+was	O
+observed	O
+in	O
+one	O
+patient	O
+but	O
+seizure	B-DISO
+clusters	B-CHED
+were	O
+not	O
+encountered	O
+.	O
+
+Thus	O
+,	O
+the	O
+occurrence	O
+of	O
+seizures	B-DISO
+in	O
+FIP	B-DISO
+indicates	O
+extensive	O
+brain	B-ANAT
+damage	O
+and	O
+can	O
+,	O
+therefore	O
+,	O
+be	O
+considered	O
+to	O
+be	O
+an	O
+unfavourable	O
+prognostic	O
+sign	O
+.	O
+
+Presently	O
+,	O
+we	O
+hypothesize	O
+two	O
+roles	O
+for	O
+the	O
+5	O
+'-	O
+O	O
+-	O
+masked	O
+analogues	O
+:	O
+One	O
+is	O
+the	O
+role	O
+as	O
+an	O
+anti	O
+-	O
+HCV	B-SPEC
+agent	O
+by	O
+itself	O
+,	O
+and	O
+the	O
+other	O
+is	O
+as	O
+a	O
+prodrug	B-CHED
+of	O
+its	O
+5	O
+'-	O
+O	O
+-	O
+demasked	O
+(	O
+deprotected	O
+)	O
+derivative	O
+.	O
+
+Several	O
+infectious	B-DISO
+agents	O
+have	O
+been	O
+associated	O
+with	O
+the	O
+presence	O
+of	O
+GS	O
+,	O
+but	O
+a	O
+causal	O
+relationship	O
+is	O
+unclear	O
+.	O
+
+The	O
+cats	B-SPEC
+in	O
+this	O
+study	O
+were	O
+housed	O
+together	O
+,	O
+had	O
+a	O
+history	O
+of	O
+flea	B-SPEC
+exposure	O
+,	O
+and	O
+were	O
+vaccinated	O
+with	O
+a	O
+modified	O
+live	O
+FVRCP	O
+product	O
+.	O
+
+Abnormality	O
+rate	O
+of	O
+DLCO	O
+in	O
+the	O
+SARS	B-DISO
+patients	O
+within	O
+three	O
+years	O
+after	O
+discharge	B-ANAT
+was	O
+significantly	O
+decreased	O
+(	O
+32	O
+.	O
+4	O
+%	O
+vs	O
+.	O
+5	O
+.	O
+4	O
+%,	O
+P	O
+<	O
+0	O
+.	O
+05	O
+),	O
+but	O
+no	O
+significant	O
+differences	O
+in	O
+FVC	B-PROC
+,	O
+VC	O
+,	O
+25	O
+%-	O
+75	O
+%	O
+FEF	O
+among	O
+SARS	B-DISO
+patients	O
+discharged	O
+one	O
+month	O
+and	O
+three	O
+years	O
+from	O
+the	O
+hospital	O
+(	O
+all	O
+P	O
+>	O
+0	O
+.	O
+05	O
+).	O
+
+Because	O
+several	O
+viruses	B-SPEC
+induce	O
+IFN	B-PROC
+-	I-PROC
+alpha	I-PROC
+production	I-PROC
+,	O
+severe	O
+courses	O
+of	O
+herpes	B-SPEC
+virus	I-SPEC
+infections	B-DISO
+in	O
+nonimmunocompromised	O
+patients	O
+may	O
+be	O
+related	O
+to	O
+numerical	O
+or	O
+functional	O
+PDC	B-DISO
+deficits	O
+.	O
+
+To	O
+evaluate	O
+this	O
+hypothesis	O
+,	O
+PBMC	O
+and	O
+PDC	B-DISO
+were	O
+repeatedly	O
+isolated	O
+from	O
+nine	O
+patients	O
+with	O
+acute	B-DISO
+retinal	I-DISO
+necrosis	B-PROC
+(	O
+ARN	O
+),	O
+caused	O
+by	O
+herpes	B-DISO
+simplex	I-DISO
+or	O
+varicella	B-SPEC
+zoster	I-SPEC
+virus	I-SPEC
+.	O
+
+The	O
+median	O
+percentage	O
+of	O
+isolated	O
+PDC	B-DISO
+was	O
+significantly	O
+lower	O
+in	O
+patients	O
+compared	O
+with	O
+18	O
+age	O
+-	O
+matched	O
+healthy	O
+controls	O
+(	O
+p	O
+<	O
+0	O
+.	O
+001	O
+),	O
+confirmed	O
+by	O
+FACS	O
+analysis	O
+using	O
+peripheral	O
+blood	O
+,	O
+and	O
+was	O
+extremely	O
+low	O
+during	O
+acute	B-DISO
+disease	I-DISO
+.	O
+
+PDC	B-DISO
+counts	O
+dropped	O
+in	O
+five	O
+controls	O
+suffering	B-DISO
+from	O
+respiratory	B-DISO
+infections	I-DISO
+or	O
+diarrhea	B-DISO
+.	O
+
+TITLE	O
+:	O
+Prevention	O
+and	O
+control	O
+of	O
+emerging	O
+infections	B-DISO
+:	O
+a	O
+challenge	O
+for	O
+the	O
+3rd	O
+millennium	O
+.	O
+
+We	O
+hypothesized	O
+that	O
+mesenchymal	B-ANAT
+stem	I-ANAT
+cells	I-ANAT
+(	O
+MSCs	B-FUNC
+),	O
+with	O
+or	O
+without	O
+transfection	B-PROC
+with	O
+the	O
+vasculoprotective	O
+gene	O
+angiopoietin	B-PRGE
+1	I-PRGE
+(	O
+ANGPT1	B-PRGE
+)	O
+would	O
+have	O
+beneficial	O
+effects	O
+in	O
+experimental	O
+ALI	O
+in	O
+mice	B-SPEC
+.	O
+
+TITLE	O
+:	O
+Detection	O
+and	O
+molecular	O
+characterization	O
+of	O
+calf	B-ANAT
+diarrhoea	B-DISO
+bovine	B-SPEC
+coronaviruses	O
+circulating	O
+in	O
+South	O
+Korea	O
+during	O
+2004	O
+-	O
+2005	O
+.	O
+
+Phylogenetic	O
+analysis	O
+of	O
+the	O
+entire	O
+S	B-PRGE
+gene	I-PRGE
+indicated	O
+that	O
+10	O
+Korean	O
+CD	O
+BCoV	O
+strains	O
+clustered	O
+with	O
+other	O
+Korean	O
+BCoV	O
+strains	O
+with	O
+different	O
+clinical	O
+forms	O
+but	O
+were	O
+different	O
+from	O
+the	O
+American	O
+and	O
+Canadian	O
+BCoV	O
+strains	O
+.	O
+
+TITLE	O
+:	O
+Rat	B-SPEC
+coronaviruses	O
+infect	O
+rat	B-SPEC
+alveolar	B-ANAT
+type	O
+I	O
+epithelial	B-ANAT
+cells	I-ANAT
+and	O
+induce	O
+expression	B-PROC
+of	O
+CXC	O
+chemokines	O
+.	O
+
+Replacement	O
+of	O
+conserved	O
+MHV	B-SPEC
+ExoN	O
+active	O
+-	O
+site	O
+residues	O
+with	O
+alanines	O
+resulted	O
+in	O
+viable	O
+mutant	B-DISO
+viruses	B-SPEC
+with	O
+growth	B-PROC
+and	O
+RNA	B-PROC
+synthesis	I-PROC
+defects	O
+that	O
+during	O
+passage	O
+accumulated	O
+15	O
+-	O
+fold	O
+more	O
+mutations	O
+than	O
+wild	O
+-	O
+type	O
+virus	B-SPEC
+without	O
+changes	O
+in	O
+growth	O
+fitness	O
+.	O
+
+HFOV	O
+did	O
+not	O
+cause	O
+unmanageable	O
+or	O
+sustained	O
+increases	O
+in	O
+ICP	B-DISO
+in	O
+our	O
+series	O
+of	O
+patients	O
+.	O
+
+It	O
+appears	O
+HFOV	O
+may	O
+be	O
+a	O
+relatively	O
+safe	O
+and	O
+effective	O
+means	O
+of	O
+oxygenating	O
+patients	O
+with	O
+severe	O
+ARDS	O
+and	O
+concomitant	O
+hICP	O
+secondary	O
+to	O
+acute	O
+brain	B-ANAT
+injury	O
+.	O
+
+RESULTS	O
+:	O
+We	O
+describe	O
+the	O
+effects	O
+of	O
+HFOV	O
+on	O
+hemodynamics	B-PROC
+,	O
+respiratory	B-PROC
+function	I-PROC
+,	O
+and	O
+intracranial	B-PROC
+pressure	I-PROC
+in	O
+five	O
+patients	O
+with	O
+acute	O
+brain	B-ANAT
+injury	O
+being	O
+treated	O
+for	O
+ARDS	B-DISO
+.	O
+
+Both	O
+the	O
+MS2	O
+and	O
+adenovirus	O
+aerosols	O
+were	O
+very	O
+resistant	O
+to	O
+UV	O
+air	B-CHED
+disinfection	O
+,	O
+with	O
+a	O
+reduction	O
+of	O
+less	O
+than	O
+1	O
+logarithm	O
+in	O
+viable	O
+viral	O
+aerosols	O
+at	O
+a	O
+UV	O
+dose	O
+of	O
+2608	O
+microW	O
+s	O
+/	O
+cm2	B-DISO
+.	O
+
+To	O
+explain	O
+this	O
+phenomenon	O
+,	O
+2	O
+hypotheses	O
+were	O
+formulated	O
+:	O
+1	O
+)	O
+the	O
+presence	O
+of	O
+a	O
+2nd	O
+pathogen	O
+could	O
+be	O
+exacerbating	O
+the	O
+porcine	B-SPEC
+circovirus	I-SPEC
+2	I-SPEC
+(	O
+PCV	B-CHED
+-	O
+2	O
+)	O
+infection	B-DISO
+,	O
+or	O
+2	O
+)	O
+a	O
+new	O
+and	O
+more	O
+virulent	O
+PCV	B-CHED
+-	O
+2	O
+strain	O
+could	O
+be	O
+infecting	O
+swine	B-SPEC
+.	O
+
+The	O
+PCR	O
+detection	O
+results	O
+obtained	O
+for	O
+other	O
+viruses	B-SPEC
+revealed	O
+the	O
+following	O
+:	O
+61	O
+.	O
+5	O
+%	O
+were	O
+positive	O
+for	O
+porcine	B-SPEC
+reproductive	I-SPEC
+and	I-SPEC
+respiratory	I-SPEC
+syndrome	I-SPEC
+virus	I-SPEC
+,	O
+30	O
+.	O
+8	O
+%	O
+for	O
+swine	B-SPEC
+influenza	I-SPEC
+virus	I-SPEC
+,	O
+15	O
+.	O
+4	O
+%	O
+for	O
+porcine	B-SPEC
+parvovirus	I-SPEC
+,	O
+69	O
+.	O
+2	O
+%	O
+for	O
+swine	B-SPEC
+torque	B-SPEC
+teno	I-SPEC
+virus	I-SPEC
+(	O
+swTTV	O
+),	O
+38	O
+.	O
+5	O
+%	O
+for	O
+swine	B-SPEC
+hepatitis	B-SPEC
+E	I-SPEC
+virus	I-SPEC
+(	O
+swHEV	O
+)	O
+and	O
+84	O
+.	O
+6	O
+%	O
+for	O
+Mycoplasma	B-DISO
+hyorhinis	I-SPEC
+;	O
+transmissible	O
+gastroenteritis	O
+virus	B-SPEC
+and	O
+porcine	B-SPEC
+respiratory	O
+coronavirus	B-SPEC
+(	O
+TGEV	B-SPEC
+/	O
+PRCV	O
+)	O
+was	O
+not	O
+detected	O
+.	O
+
+Sequences	O
+of	O
+the	O
+entire	O
+genome	O
+revealed	O
+that	O
+these	O
+PCV	B-CHED
+-	O
+2	O
+strains	O
+belonged	O
+to	O
+a	O
+genotype	O
+(	O
+named	O
+PCV	B-CHED
+-	O
+2b	O
+)	O
+that	O
+has	O
+never	O
+been	O
+reported	O
+in	O
+Canada	O
+.	O
+
+ABSTRACT	O
+:	O
+Severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+(	O
+SARS	B-DISO
+)	O
+is	O
+an	O
+acute	B-DISO
+respiratory	I-DISO
+disease	I-DISO
+with	O
+significant	O
+morbidity	O
+and	O
+mortality	O
+.	O
+
+Direct	O
+injury	O
+is	O
+caused	O
+by	O
+infection	B-DISO
+of	O
+the	O
+target	B-ANAT
+cells	I-ANAT
+by	O
+the	O
+virus	B-SPEC
+.	O
+
+To	O
+investigate	O
+if	O
+mRNA	B-CHED
+secondary	O
+structure	O
+improves	O
+stability	O
+of	O
+the	O
+complex	O
+,	O
+we	O
+tested	O
+a	O
+pseudoknot	O
+,	O
+originating	O
+from	O
+the	O
+genomic	O
+RNA	O
+of	O
+infectious	B-DISO
+bronchitis	B-DISO
+virus	B-SPEC
+(	O
+IBV	B-SPEC
+),	O
+a	O
+member	O
+of	O
+the	O
+positive	O
+-	O
+stranded	O
+coronavirus	B-SPEC
+group	I-SPEC
+.	O
+
+Risk	O
+factors	O
+for	O
+hospital	O
+mortality	O
+included	O
+age	O
+,	O
+chronic	O
+comorbidity	O
+of	O
+malignant	B-DISO
+neoplasm	I-DISO
+,	O
+Gram	B-DISO
+-	I-DISO
+positive	I-DISO
+bacterial	I-DISO
+infection	I-DISO
+,	O
+invasive	O
+fungal	B-DISO
+infection	I-DISO
+,	O
+admission	O
+Acute	O
+Physiology	O
+Score	O
+,	O
+and	O
+admission	O
+Sequential	O
+Organ	B-DISO
+Failure	I-DISO
+Assessment	O
+score	O
+of	O
+respiratory	B-DISO
+dysfunction	I-DISO
+and	O
+cardiovascular	B-ANAT
+dysfunction	O
+.	O
+
+The	O
+SARS	B-PRGE
+-	I-PRGE
+CoV	I-PRGE
+specific	I-PRGE
+antibody	B-COMP
+was	O
+detected	O
+for	O
+all	O
+of	O
+them	O
+by	O
+ELISA	O
+and	O
+neutralized	O
+test	O
+simultaneously	O
+.	O
+
+However	O
+,	O
+neutralizing	O
+antibody	B-COMP
+in	O
+some	O
+of	O
+the	O
+cases	O
+decreased	O
+to	O
+a	O
+lower	O
+level	O
+on	O
+the	O
+35th	O
+month	O
+.	O
+
+RSV	B-PRGE
+,	O
+HMPV	B-SPEC
+,	O
+HCoV	O
+,	O
+and	O
+Influenza	B-DISO
+B	O
+were	O
+detected	O
+in	O
+13	O
+.	O
+9	O
+%	O
+(	O
+n	O
+=	O
+54	O
+),	O
+5	O
+.	O
+1	O
+%	O
+(	O
+n	O
+=	O
+20	O
+),	O
+2	O
+.	O
+6	O
+%	O
+(	O
+n	O
+=	O
+10	O
+),	O
+and	O
+1	O
+.	O
+8	O
+%	O
+(	O
+n	O
+=	O
+7	O
+),	O
+respectively	O
+.	O
+
+In	O
+four	O
+(	O
+36	O
+.	O
+4	O
+%)	O
+patients	O
+at	O
+least	O
+one	O
+other	O
+viral	O
+pathogen	O
+was	O
+found	O
+(	O
+plus	O
+RSV	B-PRGE
+n	I-PRGE
+=	I-PRGE
+3	I-PRGE
+;	O
+27	O
+.	O
+3	O
+%;	O
+Norovirus	B-SPEC
+n	O
+=	O
+1	O
+;	O
+9	O
+.	O
+1	O
+%).	O
+
+The	O
+recent	O
+use	O
+of	O
+more	O
+potent	O
+immunosuppressive	O
+drug	O
+regimens	O
+has	O
+reduced	O
+the	O
+incidence	O
+of	O
+acute	O
+rejection	O
+,	O
+increasing	O
+the	O
+incidence	O
+of	O
+potentially	O
+fatal	O
+infectious	B-DISO
+complications	O
+,	O
+such	O
+as	O
+clinically	O
+important	O
+cytomegalovirus	B-SPEC
+(	O
+CMV	B-SPEC
+)	O
+infection	B-DISO
+.	O
+
+The	O
+risk	O
+of	O
+lethal	O
+CMV	B-DISO
+colitis	I-DISO
+is	O
+increased	O
+in	O
+patients	O
+being	O
+treated	O
+with	O
+anti	O
+-	O
+rejection	O
+therapy	O
+for	O
+severe	O
+acute	O
+rejection	O
+;	O
+the	O
+occurrence	O
+of	O
+simultaneous	O
+infection	B-DISO
+,	O
+such	O
+as	O
+pseudomembranous	B-DISO
+colitis	I-DISO
+,	O
+usually	O
+characterized	O
+by	O
+a	O
+favorable	O
+prognosis	O
+,	O
+increases	O
+the	O
+mortality	O
+rate	O
+in	O
+these	O
+patients	O
+.	O
+
+Both	O
+nsp4	B-PRGE
+proteins	B-CHED
+became	O
+N	O
+glycosylated	O
+,	O
+while	O
+their	O
+amino	O
+and	O
+carboxy	B-CHED
+termini	O
+were	O
+localized	O
+to	O
+the	O
+cytoplasm	B-COMP
+.	O
+
+nsp4	B-PRGE
+present	O
+in	O
+these	O
+complexes	O
+did	O
+not	O
+colocalize	O
+with	O
+markers	O
+of	O
+the	O
+ER	O
+or	O
+Golgi	B-COMP
+apparatus	I-COMP
+,	O
+while	O
+the	O
+susceptibility	O
+of	O
+its	O
+sugars	O
+to	O
+endoglycosidase	O
+H	O
+indicated	O
+that	O
+the	O
+protein	B-CHED
+had	O
+also	O
+not	O
+traveled	O
+trough	O
+the	O
+latter	O
+compartment	B-ANAT
+.	O
+
+nsp4	B-PRGE
+contains	O
+four	O
+predicted	O
+transmembrane	B-COMP
+-	O
+spanning	O
+regions	O
+(	O
+TM1	O
+,	O
+-	O
+2	O
+,	O
+-	O
+3	O
+,	O
+and	O
+-	O
+4	O
+),	O
+demonstrates	O
+characteristics	O
+of	O
+an	O
+integral	O
+membrane	B-COMP
+protein	B-CHED
+,	O
+and	O
+is	O
+thought	O
+to	O
+be	O
+essential	O
+for	O
+the	O
+formation	B-PROC
+and	O
+function	O
+of	O
+viral	B-PROC
+replication	I-PROC
+complexes	O
+on	O
+cellular	B-COMP
+membranes	B-ANAT
+.	O
+
+TITLE	O
+:	O
+COQ2	B-PRGE
+nephropathy	B-DISO
+:	O
+a	O
+newly	O
+described	O
+inherited	O
+mitochondriopathy	O
+with	O
+primary	O
+renal	B-ANAT
+involvement	O
+.	O
+
+ABSTRACT	O
+:	O
+To	O
+retrospectively	O
+evaluate	O
+the	O
+efficacy	O
+of	O
+total	O
+lymphoid	O
+irradiation	O
+(	O
+TLI	O
+)-	O
+based	O
+reconditioning	O
+regimens	O
+in	O
+patients	O
+with	O
+graft	B-DISO
+failure	I-DISO
+or	O
+graft	B-PROC
+rejection	I-PROC
+after	O
+allogeneic	O
+hematopoietic	B-ANAT
+stem	I-ANAT
+cell	I-ANAT
+transplantation	O
+.	O
+
+RESULTS	O
+:	O
+Of	O
+the	O
+14	O
+recipients	O
+,	O
+the	O
+data	O
+from	O
+11	O
+were	O
+evaluable	B-DISO
+for	O
+engraftment	B-PROC
+after	O
+TLI	O
+-	O
+based	O
+reconditioning	O
+because	O
+3	O
+adults	O
+died	B-PROC
+early	O
+(	O
+at	O
+Day	O
+2	O
+,	O
+5	O
+,	O
+and	O
+15	O
+)	O
+after	O
+the	O
+second	O
+transplantation	O
+of	O
+infectious	B-DISO
+complications	O
+.	O
+
+TITLE	O
+:	O
+Parental	O
+response	O
+to	O
+child	O
+'	O
+s	O
+isolation	O
+during	O
+the	O
+SARS	B-DISO
+outbreak	O
+.	O
+
+ABSTRACT	O
+:	O
+To	O
+examine	O
+the	O
+needs	O
+,	O
+uncertainties	O
+,	O
+and	O
+experiences	O
+of	O
+parents	O
+during	O
+their	O
+child	O
+'	O
+s	O
+hospitalization	O
+with	O
+highly	O
+suspected	O
+severe	O
+acute	O
+respiratory	O
+syndrome	O
+(	O
+HSS	B-DISO
+),	O
+and	O
+to	O
+identify	O
+ways	O
+to	O
+improve	O
+their	O
+psychological	B-DISO
+preparedness	O
+and	O
+communication	O
+with	O
+health	O
+care	O
+professionals	O
+and	O
+their	O
+isolated	O
+children	O
+during	O
+future	O
+infectious	B-DISO
+disease	I-DISO
+outbreaks	O
+.	O
+
+ABSTRACT	O
+:	O
+Seven	O
+novel	O
+gammaherpesviruses	O
+(	O
+GHV	O
+)	O
+and	O
+one	O
+novel	O
+betaherpesvirus	O
+were	O
+discovered	O
+in	O
+seven	O
+different	O
+European	O
+bat	O
+species	B-SPEC
+(	O
+order	B-SPEC
+Chiroptera	I-SPEC
+,	O
+family	B-SPEC
+Vespertilionidae	I-SPEC
+)	O
+with	O
+a	O
+pan	B-COMP
+-	O
+herpesvirus	B-SPEC
+PCR	O
+assay	O
+,	O
+targeting	B-PROC
+the	O
+DNA	B-PRGE
+polymerase	I-PRGE
+(	O
+DPOL	O
+)	O
+gene	O
+.	O
+
+Flow	O
+cytometric	O
+analysis	O
+showed	O
+that	O
+both	O
+CD4	B-PRGE
++	I-PRGE
+and	O
+CD8	B-PRGE
++	I-PRGE
+T	B-ANAT
+cells	I-ANAT
+were	O
+involved	O
+in	O
+cellular	B-COMP
+responses	O
+to	O
+SARS	B-PRGE
+-	I-PRGE
+CoV	I-PRGE
+M	I-PRGE
+antigen	B-CHED
+.	O
+
+In	O
+contrast	O
+,	O
+the	O
+majority	O
+of	O
+IFN	B-PRGE
+-	I-PRGE
+gamma	I-PRGE
++	I-PRGE
+CD4	I-PRGE
++	I-PRGE
+T	I-PRGE
+cells	O
+were	O
+central	O
+memory	B-ANAT
+cells	B-COMP
+with	O
+the	O
+expression	B-PROC
+of	O
+CD45RO	B-PRGE
++	I-PRGE
+CCR7	I-PRGE
++	I-PRGE
+CD62L	I-PRGE
+-.	O
+
+This	O
+data	O
+may	O
+have	O
+important	O
+implication	O
+for	O
+developing	O
+SARS	B-DISO
+vaccines	O
+.	O
+
+Differences	O
+in	O
+viral	B-ANAT
+structure	I-ANAT
+and	O
+clinical	O
+outcome	O
+prompted	O
+us	O
+to	O
+postulate	O
+that	O
+innate	O
+mucosal	B-PROC
+immune	I-PROC
+responses	I-PROC
+would	O
+be	O
+markedly	O
+different	O
+following	O
+rotavirus	B-SPEC
+and	O
+coronavirus	B-DISO
+infections	I-DISO
+.	O
+
+Gene	B-PROC
+expression	I-PROC
+was	O
+profiled	O
+at	O
+18	O
+h	O
+post	O
+-	O
+infection	B-DISO
+using	O
+bovine	B-SPEC
+cDNA	O
+microarrays	O
+;	O
+the	O
+majority	O
+of	O
+differentially	O
+expressed	B-PROC
+significant	O
+genes	O
+were	O
+associated	O
+with	O
+the	O
+cell	O
+cycle	O
+and	O
+innate	B-DISO
+immune	I-DISO
+responses	I-DISO
+.	O
+
+Both	O
+viruses	B-SPEC
+also	O
+downregulated	O
+IFN	B-PRGE
+-	O
+and	O
+pro	B-CHED
+-	O
+inflammatory	O
+cytokine	O
+-	O
+associated	O
+pathways	B-PROC
+.	O
+
+Among	O
+the	O
+genes	O
+upregulated	O
+by	O
+ricin	B-FUNC
+and	O
+identified	O
+by	O
+microarray	O
+analysis	O
+were	O
+those	O
+associated	O
+with	O
+transcription	B-PROC
+,	O
+nucleosome	B-PROC
+assembly	I-PROC
+,	O
+inflammation	B-DISO
+,	O
+and	O
+response	B-PROC
+to	I-PROC
+stress	I-PROC
+.	O
+
+Sequence	O
+analysis	O
+of	O
+the	O
+promoters	O
+of	O
+these	O
+genes	O
+identified	O
+NF	B-PRGE
+-	I-PRGE
+kappaB	I-PRGE
+as	O
+one	O
+of	O
+the	O
+transcription	O
+factors	O
+whose	O
+binding	B-FUNC
+sites	O
+were	O
+overrepresented	O
+.	O
+
+ABSTRACT	O
+:	O
+RNA	B-PROC
+interference	I-PROC
+(	O
+RNAi	B-PROC
+)	O
+is	O
+an	O
+evolutionally	O
+conserved	O
+gene	O
+silencing	O
+mechanism	O
+present	O
+in	O
+a	O
+variety	O
+of	O
+eukaryotic	O
+species	B-SPEC
+.	O
+
+The	O
+mechanisms	O
+,	O
+strategies	O
+,	O
+hurdles	O
+and	O
+prospects	O
+of	O
+employing	O
+RNAi	B-PROC
+in	O
+the	O
+pharmaceutical	B-CHED
+industry	O
+are	O
+also	O
+discussed	O
+.	O
+
+Both	O
+vaccinated	O
+and	O
+control	O
+dogs	B-SPEC
+were	O
+challenged	O
+two	O
+weeks	O
+after	O
+the	O
+second	O
+vaccination	O
+with	O
+a	O
+field	O
+canine	O
+coronavirus	B-SPEC
+strain	O
+.	O
+
+Blood	B-ANAT
+samples	I-ANAT
+were	O
+collected	O
+for	O
+serological	O
+tests	O
+before	O
+vaccination	O
+and	O
+at	O
+weekly	O
+intervals	O
+after	O
+vaccinations	O
+and	O
+challenge	O
+.	O
+
+Virus	B-SPEC
+was	O
+not	O
+detected	O
+in	O
+faecal	O
+samples	O
+after	O
+the	O
+first	O
+or	O
+second	O
+vaccinations	O
+by	O
+virus	B-SPEC
+isolation	O
+assays	O
+and	O
+PCR	O
+.	O
+
+Significantly	O
+,	O
+the	O
+vaccinated	O
+dogs	B-SPEC
+did	O
+not	O
+have	O
+clinical	O
+signs	O
+after	O
+challenge	O
+and	O
+no	O
+virus	B-DISO
+shedding	I-DISO
+was	O
+observed	O
+.	O
+
+ABSTRACT	O
+:	O
+This	O
+paper	O
+attempts	O
+to	O
+address	O
+the	O
+global	O
+concern	O
+of	O
+the	O
+possible	O
+pandemic	O
+of	O
+influenza	O
+and	O
+avian	B-DISO
+influenza	I-DISO
+.	O
+
+The	O
+underlying	O
+mechanism	O
+for	O
+the	O
+extreme	O
+codon	O
+usage	O
+bias	B-SPEC
+,	O
+cytosine	B-CHED
+deamination	O
+and	O
+G	O
++	O
+C	O
+content	O
+in	O
+CoV	B-SPEC
+-	I-SPEC
+HKU1	I-SPEC
+warrants	O
+further	O
+studies	O
+.	O
+
+A	O
+self	O
+-	O
+administered	O
+questionnaire	O
+was	O
+delivered	O
+to	O
+nurses	O
+in	O
+Hong	O
+Kong	O
+to	O
+assess	O
+their	O
+attitude	O
+towards	O
+avian	B-DISO
+influenza	I-DISO
+;	O
+risk	O
+perception	O
+,	O
+and	O
+their	O
+relationships	O
+with	O
+previous	O
+level	O
+of	O
+exposure	O
+to	O
+SARS	B-DISO
+patients	O
+.	O
+
+High	O
+exposure	O
+nurses	O
+were	O
+less	O
+likely	O
+to	O
+avoid	O
+patients	O
+,	O
+less	O
+inclined	O
+to	O
+change	O
+their	O
+job	O
+if	O
+they	O
+were	O
+required	O
+to	O
+take	O
+care	O
+of	O
+infected	O
+patients	O
+,	O
+and	O
+had	O
+therefore	O
+a	O
+more	O
+positive	O
+attitude	O
+towards	O
+an	O
+impending	O
+avian	B-SPEC
+influenza	B-DISO
+epidemic	I-DISO
+.	O
+
+Respondents	O
+were	O
+classified	O
+into	O
+two	O
+groups	O
+:	O
+high	O
+exposure	O
+(	O
+44	O
+.	O
+1	O
+%)	O
+and	O
+low	O
+exposure	O
+(	O
+55	O
+.	O
+9	O
+%)	O
+as	O
+defined	O
+by	O
+having	O
+worked	O
+in	O
+SARS	B-DISO
+ward	O
+or	O
+hospitals	O
+.	O
+
+Randomised	O
+,	O
+controlled	O
+trials	O
+are	O
+limited	O
+in	O
+BD	O
+,	O
+but	O
+those	O
+that	O
+have	O
+been	O
+conducted	O
+have	O
+documented	O
+favourable	O
+effects	O
+of	O
+colchicine	B-CHED
+,	O
+ciclosporin	B-CHED
+,	O
+azathioprine	B-CHED
+,	O
+thalidomide	B-CHED
+,	O
+dapsone	B-CHED
+,	O
+depot	O
+methylprednisolone	B-CHED
+,	O
+rebamipide	O
+,	O
+sucralfate	O
+,	O
+benzathine	B-CHED
+benzylpenicillin	I-CHED
+,	O
+interferon	B-PRGE
+-	I-PRGE
+alpha	I-PRGE
+-	I-PRGE
+2a	I-PRGE
+and	O
+etanercept	O
+for	O
+various	O
+BD	O
+manifestations	O
+.	O
+
+Although	O
+no	O
+randomised	O
+,	O
+controlled	O
+trials	O
+are	O
+yet	O
+available	O
+,	O
+results	O
+of	O
+open	O
+studies	O
+with	O
+both	O
+interferon	B-PRGE
+-	I-PRGE
+alpha	I-PRGE
+and	O
+infliximab	O
+are	O
+promising	O
+for	O
+those	O
+patients	O
+with	O
+disease	O
+resistant	O
+to	O
+conventional	O
+immunosuppressive	O
+treatments	O
+.	O
+
+TITLE	O
+:	O
+Antiviral	B-CHED
+effects	O
+of	O
+Glycyrrhiza	B-SPEC
+species	B-SPEC
+.	O
+
+Randomized	O
+controlled	O
+trials	O
+confirmed	O
+that	O
+the	O
+Glycyrrhiza	B-SPEC
+glabra	I-SPEC
+derived	O
+compound	O
+glycyrrhizin	B-CHED
+and	O
+its	O
+derivatives	O
+reduced	O
+hepatocellular	B-DISO
+damage	I-DISO
+in	O
+chronic	B-DISO
+hepatitis	I-DISO
+B	I-DISO
+and	O
+C	O
+.	O
+In	O
+hepatitis	B-SPEC
+C	I-SPEC
+virus	I-SPEC
+-	O
+induced	O
+cirrhosis	B-DISO
+the	O
+risk	O
+of	O
+hepatocellular	B-DISO
+carcinoma	I-DISO
+was	O
+reduced	O
+.	O
+
+Animal	B-SPEC
+studies	O
+demonstrated	O
+a	O
+reduction	O
+of	O
+mortality	O
+and	O
+viral	O
+activity	O
+in	O
+herpes	B-SPEC
+simplex	I-SPEC
+virus	I-SPEC
+encephalitis	B-DISO
+and	O
+influenza	B-SPEC
+A	I-SPEC
+virus	I-SPEC
+pneumonia	B-DISO
+.	O
+
+Prior	O
+to	O
+our	O
+study	O
+,	O
+several	O
+cases	O
+of	O
+neonatal	B-DISO
+infection	I-DISO
+were	O
+observed	O
+in	O
+infants	O
+born	O
+at	O
+our	O
+hospital	O
+.	O
+
+RESULTS	O
+:	O
+For	O
+HCoV	B-SPEC
+-	I-SPEC
+229E	I-SPEC
+,	O
+the	O
+percentages	O
+of	O
+seropositive	O
+individuals	O
+were	O
+57	O
+.	O
+1	O
+%	O
+for	O
+infants	O
+<	O
+2	O
+months	O
+old	O
+;	O
+38	O
+.	O
+9	O
+%	O
+for	O
+infants	O
+2	O
+-	O
+3	O
+months	O
+old	O
+;	O
+4	O
+.	O
+7	O
+%	O
+for	O
+infants	O
+4	O
+-	O
+5	O
+months	O
+old	O
+;	O
+42	O
+.	O
+9	O
+-	O
+50	O
+.	O
+0	O
+%	O
+for	O
+infants	O
+6	O
+-	O
+12	O
+months	O
+old	O
+;	O
+34	O
+.	O
+8	O
+-	O
+62	O
+.	O
+5	O
+%	O
+for	O
+individuals	O
+1	O
+-	O
+20	O
+years	O
+old	O
+.	O
+
+However	O
+,	O
+Devic	B-DISO
+'	I-DISO
+s	I-DISO
+neuromyelitis	I-DISO
+optica	I-DISO
+has	O
+also	O
+been	O
+seen	O
+in	O
+children	O
+.	O
+
+ABSTRACT	O
+:	O
+A	O
+recombinant	O
+vaccinia	O
+virus	O
+(	O
+rWR	O
+-	O
+SARS	B-DISO
+-	O
+S	O
+)	O
+expressing	O
+spike	O
+protein	B-CHED
+of	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+coronavirus	B-SPEC
+was	O
+constructed	O
+.	O
+
+Phylogenetic	O
+tree	O
+based	O
+on	O
+amino	B-CHED
+acid	I-CHED
+sequences	O
+of	O
+M	O
+genes	O
+from	O
+20	O
+Chinese	O
+isolates	O
+and	O
+34	O
+reference	O
+strains	O
+showed	O
+that	O
+they	O
+were	O
+classified	O
+into	O
+five	O
+distinct	O
+clusters	B-CHED
+.	O
+
+Molecular	O
+modeling	O
+demonstrated	O
+that	O
+the	O
+catalytic	O
+residues	O
+of	O
+mNsp15	O
+are	O
+superimposable	O
+with	O
+its	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+coronavirus	B-SPEC
+ortholog	O
+.	O
+
+All	O
+four	O
+mutant	B-DISO
+viruses	B-SPEC
+formed	O
+plaques	B-DISO
+with	O
+diameters	O
+similar	O
+to	O
+that	O
+of	O
+MHV	B-SPEC
+-	O
+A59	O
+1000	O
+(	O
+WT	O
+virus	B-SPEC
+)	O
+on	O
+several	O
+different	O
+cell	O
+lines	O
+.	O
+
+The	O
+expression	B-PROC
+of	O
+mNsp15	O
+in	O
+trans	O
+by	O
+transient	O
+transfection	B-PROC
+partially	O
+restored	O
+RNA	B-PROC
+synthesis	I-PROC
+by	O
+vH262A	O
+.	O
+
+ABSTRACT	O
+:	O
+Severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+(	O
+SARS	B-DISO
+)	O
+is	O
+a	O
+new	O
+human	B-SPEC
+infectious	B-DISO
+disease	I-DISO
+caused	O
+by	O
+coronavirus	B-SPEC
+.	O
+
+Concerning	O
+lymphocyte	B-DISO
+disorder	I-DISO
+,	O
+there	O
+were	O
+some	O
+previous	O
+studies	O
+reported	O
+the	O
+low	O
+lymphocyte	B-ANAT
+in	O
+the	O
+patients	O
+with	O
+SARS	B-DISO
+.	O
+
+Five	O
+available	O
+reports	O
+concerning	O
+the	O
+prevalence	O
+of	O
+lymphopenia	B-DISO
+in	O
+SARS	B-DISO
+among	O
+different	O
+populations	O
+were	O
+selected	O
+for	O
+further	O
+analysis	O
+in	O
+this	O
+study	O
+.	O
+
+According	O
+to	O
+this	O
+study	O
+,	O
+the	O
+overall	O
+prevalence	O
+rate	O
+of	O
+lymphopenia	B-DISO
+in	O
+SARS	B-DISO
+is	O
+77	O
+.	O
+2	O
+%.	O
+
+ABSTRACT	O
+:	O
+Acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+(	O
+ARDS	B-DISO
+)	O
+is	O
+a	O
+serious	O
+disorder	O
+of	O
+intensive	O
+care	O
+unit	O
+patients	O
+.	O
+
+The	O
+levels	O
+of	O
+plasma	B-PRGE
+IL	B-FUNC
+-	I-FUNC
+6	I-FUNC
+concentration	O
+at	O
+enrolment	O
+,	O
+24	O
+hours	O
+and	O
+72	O
+hours	O
+after	O
+enrolment	O
+also	O
+predicted	O
+the	O
+14th	O
+day	O
+mortality	O
+of	O
+all	O
+patients	O
+.	O
+
+Furthermore	O
+,	O
+swaddling	O
+does	O
+not	O
+influence	O
+rickets	B-DISO
+onset	O
+or	O
+bone	B-ANAT
+properties	O
+.	O
+
+TITLE	O
+:	O
+CoVDB	O
+:	O
+a	O
+comprehensive	O
+database	O
+for	O
+comparative	O
+analysis	O
+of	O
+coronavirus	B-SPEC
+genes	O
+and	O
+genomes	O
+.	O
+
+The	O
+number	O
+of	O
+coronavirus	B-SPEC
+species	B-SPEC
+with	O
+complete	O
+genomes	O
+available	O
+has	O
+increased	O
+from	O
+9	O
+in	O
+2003	O
+to	O
+25	O
+in	O
+2007	O
+,	O
+of	O
+which	O
+six	O
+,	O
+including	O
+coronavirus	B-SPEC
+HKU1	O
+,	O
+bat	B-PRGE
+SARS	B-DISO
+coronavirus	B-SPEC
+,	I-PRGE
+group	I-PRGE
+1	I-PRGE
+bat	B-SPEC
+coronavirus	I-SPEC
+HKU2	I-SPEC
+,	O
+groups	O
+2c	O
+and	O
+2d	O
+coronaviruses	O
+,	O
+were	O
+sequenced	O
+by	O
+our	O
+laboratory	O
+.	O
+
+The	O
+N	O
+-	O
+protein	B-CHED
+fragments	O
+comprising	O
+aa	O
+360	O
+to	O
+412	O
+and	O
+aa	O
+1	O
+to	O
+213	O
+reacted	O
+specifically	O
+with	O
+SARS	B-DISO
+convalescent	O
+-	O
+phase	O
+sera	B-COMP
+but	O
+not	O
+with	O
+negative	O
+human	B-SPEC
+sera	B-COMP
+in	O
+ELISA	O
+;	O
+the	O
+fragment	O
+comprising	O
+aa	O
+1	O
+to	O
+213	O
+cross	O
+-	O
+reacted	O
+with	O
+antisera	O
+to	O
+animal	B-SPEC
+CoVs	O
+,	O
+whereas	O
+the	O
+fragment	O
+comprising	O
+aa	O
+360	O
+to	O
+412	O
+did	O
+not	O
+cross	O
+-	O
+react	O
+and	O
+could	O
+be	O
+a	O
+potential	O
+candidate	O
+for	O
+SARS	B-DISO
+diagnosis	O
+.	O
+
+Identification	O
+of	O
+the	O
+cross	B-PROC
+-	I-PROC
+reactive	I-PROC
+and	O
+non	O
+-	O
+cross	B-PROC
+-	I-PROC
+reactive	I-PROC
+N	O
+-	O
+protein	B-CHED
+regions	O
+allows	O
+development	B-PROC
+of	O
+SARS	B-DISO
+-	O
+CoV	O
+-	O
+specific	O
+antibody	B-COMP
+assays	O
+for	O
+screening	O
+animal	B-SPEC
+and	O
+human	B-SPEC
+sera	B-COMP
+.	O
+
+ABSTRACT	O
+:	O
+Mutation	O
+within	O
+virus	B-SPEC
+-	O
+derived	O
+CD8	B-PRGE
+T	I-PRGE
+-	I-PRGE
+cell	I-PRGE
+epitopes	I-PRGE
+can	O
+effectively	O
+abrogate	O
+cytotoxic	B-ANAT
+T	I-ANAT
+-	I-ANAT
+lymphocyte	I-ANAT
+(	O
+CTL	B-ANAT
+)	O
+recognition	O
+and	O
+impede	O
+virus	B-SPEC
+clearance	O
+in	O
+infected	O
+hosts	B-COMP
+.	O
+
+ABSTRACT	O
+:	O
+To	O
+investigate	O
+whether	O
+genetic	O
+factors	O
+of	O
+innate	B-PROC
+immunity	I-PROC
+might	O
+influence	O
+susceptibility	O
+and	O
+/	O
+or	O
+progression	O
+in	O
+individuals	O
+infected	O
+with	O
+SARS	B-DISO
+,	O
+we	O
+evaluated	O
+the	O
+CD14	B-PRGE
+gene	I-PRGE
+polymorphism	O
+in	O
+198	O
+Hong	O
+Kong	O
+blood	B-ANAT
+donors	O
+and	O
+152	O
+Hong	O
+Kong	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+(	O
+SARS	B-DISO
+)	O
+patients	O
+who	O
+were	O
+previously	O
+genotyped	O
+for	O
+FcgammaRIIA	O
+polymorphisms	B-PROC
+.	O
+
+TITLE	O
+:	O
+Biological	O
+and	O
+genetic	O
+analysis	O
+of	O
+a	O
+bovine	B-SPEC
+-	O
+like	O
+coronavirus	B-SPEC
+isolated	O
+from	O
+water	B-SPEC
+buffalo	I-SPEC
+(	O
+Bubalus	B-SPEC
+bubalis	I-SPEC
+)	O
+calves	O
+.	O
+
+By	O
+conventional	O
+and	O
+real	O
+-	O
+time	O
+RT	O
+-	O
+PCR	O
+assays	O
+,	O
+the	O
+virus	B-SPEC
+was	O
+demonstrated	O
+in	O
+the	O
+intestinal	B-ANAT
+contents	I-ANAT
+of	O
+two	O
+20	O
+-	O
+day	O
+-	O
+old	O
+buffalo	O
+calves	O
+dead	B-PROC
+of	O
+a	O
+severe	O
+form	O
+of	O
+enteritis	B-DISO
+and	O
+in	O
+the	O
+feces	B-ANAT
+of	O
+additional	O
+17	O
+buffalo	O
+calves	O
+with	O
+diarrhea	B-DISO
+.	O
+
+Moreover	O
+,	O
+the	O
+genetic	O
+distance	O
+between	O
+BuCoV	O
+and	O
+BCoV	O
+was	O
+proven	O
+to	O
+be	O
+the	O
+same	O
+or	O
+even	O
+higher	O
+than	O
+the	O
+distance	O
+between	O
+other	O
+ruminant	B-SPEC
+coronaviruses	O
+and	O
+BCoV	O
+.	O
+In	O
+conclusion	O
+,	O
+our	O
+data	O
+support	O
+the	O
+existence	O
+of	O
+a	O
+host	B-COMP
+-	O
+range	O
+variant	O
+of	O
+BCoV	O
+associated	O
+with	O
+enteritis	B-DISO
+in	O
+buffaloes	O
+.	O
+
+ABSTRACT	O
+:	O
+Infection	B-DISO
+of	O
+mice	B-SPEC
+with	O
+variants	O
+of	O
+mouse	B-DISO
+hepatitis	I-DISO
+virus	B-SPEC
+,	O
+strain	O
+JHM	O
+(	O
+MHV	B-SPEC
+-	O
+JHM	O
+),	O
+provide	O
+models	O
+of	O
+acute	O
+and	O
+chronic	O
+viral	B-DISO
+infection	I-DISO
+of	O
+the	O
+central	B-ANAT
+nervous	I-ANAT
+system	I-ANAT
+(	O
+CNS	B-CHED
+).	O
+
+However	O
+,	O
+the	O
+association	O
+of	O
+S	B-PRGE
+gene	I-PRGE
+variation	O
+and	O
+neurovirulence	O
+with	O
+host	B-COMP
+ability	O
+to	O
+generate	O
+anti	O
+-	O
+viral	O
+CD8	O
+T	B-ANAT
+cell	I-ANAT
+responses	O
+is	O
+not	O
+completely	O
+clear	O
+.	O
+
+TITLE	O
+:	O
+Fatal	O
+winter	B-DISO
+dysentery	I-DISO
+with	O
+severe	B-DISO
+anemia	I-DISO
+in	O
+an	O
+adult	O
+cow	B-SPEC
+.	O
+
+TITLE	O
+:	O
+The	O
+presence	O
+of	O
+the	O
+adult	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+does	O
+not	O
+worsen	O
+mortality	O
+or	O
+discharge	B-ANAT
+disability	O
+in	O
+blunt	O
+trauma	O
+patients	O
+with	O
+severe	O
+traumatic	O
+brain	B-ANAT
+injury	O
+.	O
+
+Among	O
+362	O
+TBI	O
+patients	O
+,	O
+28	O
+(	O
+7	O
+.	O
+7	O
+%)	O
+developed	O
+ARDS	B-DISO
+.	O
+
+We	O
+developed	O
+a	O
+real	O
+-	O
+time	O
+reverse	O
+-	O
+transcription	B-PROC
+polymerase	O
+chain	O
+reaction	O
+(	O
+RT	O
+-	O
+PCR	O
+)	O
+assay	O
+panel	O
+for	O
+the	O
+recognized	O
+HCoV	O
+types	O
+and	O
+compared	O
+HCoV	O
+infections	B-DISO
+in	O
+patients	O
+hospitalized	O
+with	O
+pneumonia	B-DISO
+,	O
+outpatients	O
+with	O
+influenza	B-DISO
+-	I-DISO
+like	I-DISO
+illness	I-DISO
+,	O
+and	O
+asymptomatic	O
+control	O
+patients	O
+between	O
+September	O
+2003	O
+and	O
+August	O
+2005	O
+.	O
+
+HCoV	O
+infections	B-DISO
+were	O
+infrequently	O
+detected	O
+in	O
+rural	O
+Thailand	O
+by	O
+use	O
+of	O
+sensitive	O
+real	O
+-	O
+time	O
+RT	O
+-	O
+PCR	O
+assays	O
+.	O
+
+TITLE	O
+:	O
+The	O
+utility	O
+of	O
+preemptive	O
+mass	O
+influenza	B-DISO
+vaccination	O
+in	O
+controlling	O
+a	O
+sars	B-DISO
+outbreak	O
+during	O
+flu	B-DISO
+season	O
+.	O
+
+ABSTRACT	O
+:	O
+During	O
+flu	B-DISO
+season	O
+,	O
+respiratory	B-DISO
+infections	I-DISO
+can	O
+cause	O
+non	O
+-	O
+specific	O
+influenza	B-DISO
+-	O
+like	O
+-	O
+illnesses	O
+(	O
+ILIs	O
+)	O
+in	O
+up	O
+to	O
+one	O
+-	O
+half	O
+of	O
+the	O
+general	O
+population	O
+.	O
+
+Between	O
+January	O
+1998	O
+and	O
+December	O
+2006	O
+,	O
+we	O
+studied	O
+42	O
+ARDS	B-DISO
+patients	O
+treated	O
+by	O
+PP	O
+to	O
+correct	O
+severe	O
+oxygenation	B-PROC
+impairment	B-DISO
+(	O
+Pao2	O
+/	O
+fraction	O
+of	O
+inspired	B-PROC
+oxygen	B-CHED
+ratio	O
+,	O
+<	O
+100	O
+mm	O
+Hg	O
+).	O
+
+RV	O
+enlargement	B-DISO
+was	O
+measured	O
+by	O
+RV	O
+/	O
+left	O
+ventricular	B-ANAT
+(	O
+LV	O
+)	O
+end	O
+-	O
+diastolic	O
+area	O
+ratio	O
+in	O
+the	O
+long	O
+axis	B-SPEC
+.	O
+
+In	O
+group	O
+1	O
+,	O
+this	O
+produced	O
+a	O
+significant	O
+decrease	O
+in	O
+mean	O
+(+/-	O
+SD	O
+)	O
+RV	O
+enlargement	B-DISO
+(	O
+from	O
+0	O
+.	O
+91	O
++/-	O
+0	O
+.	O
+22	O
+to	O
+0	O
+.	O
+61	O
++/-	O
+0	O
+.	O
+21	O
+)	O
+after	O
+18	O
+h	O
+of	O
+PP	O
+(	O
+p	O
+=	O
+0	O
+.	O
+000	O
+)	O
+and	O
+a	O
+significant	O
+reduction	O
+in	O
+mean	O
+septal	O
+dyskinesia	B-DISO
+(	O
+from	O
+1	O
+.	O
+5	O
++/-	O
+0	O
+.	O
+2	O
+to	O
+1	O
+.	O
+1	O
++/-	O
+0	O
+.	O
+1	O
+)	O
+after	O
+18	O
+h	O
+of	O
+PP	O
+(	O
+p	O
+=	O
+0	O
+.	O
+000	O
+).	O
+
+ABSTRACT	O
+:	O
+Lung	O
+involvement	O
+is	O
+rarely	O
+observed	O
+in	O
+the	O
+DRESS	B-DISO
+syndrome	I-DISO
+(	O
+Drug	B-DISO
+rash	I-DISO
+with	I-DISO
+eosinophilia	I-DISO
+and	I-DISO
+systemic	I-DISO
+symptoms	I-DISO
+).	O
+
+We	O
+report	O
+here	O
+a	O
+severe	O
+minocycline	B-CHED
+induced	O
+hypersensitivity	B-DISO
+syndrome	I-DISO
+with	O
+initial	O
+respiratory	B-DISO
+distress	I-DISO
+.	O
+
+A	O
+19	O
+year	O
+old	O
+man	B-CHED
+was	O
+admitted	O
+to	O
+the	O
+intensive	O
+care	O
+unit	O
+for	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+with	O
+fever	B-PROC
+(	O
+400C	O
+),	O
+lymph	B-ANAT
+node	I-ANAT
+enlargement	B-DISO
+,	O
+hepatomegaly	B-DISO
+,	O
+splenomegaly	O
+and	O
+eosinophilia	B-DISO
+(	O
+1640	O
+/	O
+mm3	O
+).	O
+
+Skin	B-ANAT
+lesions	O
+were	O
+delayed	O
+and	O
+appeared	O
+3	O
+days	O
+later	O
+.	O
+
+ABSTRACT	O
+:	O
+To	O
+assess	O
+factors	O
+associated	O
+with	O
+adherence	O
+to	O
+recommended	O
+barrier	O
+precautions	O
+among	O
+healthcare	O
+workers	O
+(	O
+HCWs	O
+)	O
+providing	O
+care	O
+to	O
+critically	B-DISO
+ill	I-DISO
+patients	O
+with	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+(	O
+SARS	B-DISO
+).	O
+
+TITLE	O
+:	O
+Information	O
+control	O
+in	O
+time	O
+of	O
+crisis	O
+:	O
+the	O
+framing	O
+of	O
+SARS	B-DISO
+in	O
+China	O
+-	O
+based	O
+newspapers	O
+and	O
+Internet	O
+sources	O
+.	O
+
+In	O
+both	O
+lines	O
+of	O
+birds	B-SPEC
+,	O
+IL	B-PRGE
+-	I-PRGE
+6	I-PRGE
+mRNA	B-CHED
+levels	O
+were	O
+elevated	O
+in	O
+the	O
+kidneys	B-ANAT
+at	O
+4	O
+d	O
+postinfection	O
+.	O
+
+In	O
+this	O
+study	O
+,	O
+we	O
+established	O
+a	O
+new	O
+animal	B-SPEC
+model	O
+,	O
+the	O
+Chinese	B-SPEC
+hamster	I-SPEC
+,	O
+susceptible	O
+to	O
+SARS	B-DISO
+-	I-DISO
+CoV	I-DISO
+infection	I-DISO
+.	O
+
+Kinetic	O
+analysis	O
+of	O
+RNA	B-FUNC
+binding	I-FUNC
+indicated	O
+that	O
+the	O
+C	O
+-	O
+terminal	O
+phosphorylation	B-PROC
+cluster	O
+was	O
+involved	O
+in	O
+the	O
+recognition	O
+of	O
+viral	O
+RNA	O
+from	O
+non	O
+-	O
+viral	O
+RNA	O
+.	O
+
+Rescue	O
+experiments	O
+indicated	O
+that	O
+phosphorylated	O
+N	O
+protein	B-CHED
+recovered	O
+infectious	B-DISO
+IBV	B-SPEC
+more	O
+efficiently	O
+when	O
+compared	O
+to	O
+modified	O
+N	O
+proteins	B-CHED
+either	O
+partially	O
+or	O
+non	O
+-	O
+phosphorylated	O
+.	O
+
+They	O
+also	O
+establish	O
+a	O
+structural	O
+basis	O
+for	O
+the	O
+'	O
+core	O
+design	O
+'	O
+of	O
+these	O
+inhibitors	O
+by	O
+showing	O
+that	O
+the	O
+3	O
+-	O
+chloropyridine	B-CHED
+functions	O
+common	O
+to	O
+all	O
+of	O
+the	O
+present	O
+inhibitors	B-CHED
+tend	O
+to	O
+cluster	O
+in	O
+the	O
+S1	O
+specificity	O
+pocket	O
+.	O
+
+TITLE	O
+:	O
+Cloning	O
+and	O
+further	O
+sequence	O
+analysis	O
+of	O
+the	O
+ORF3	O
+gene	O
+of	O
+wild	O
+-	O
+and	O
+attenuated	O
+-	O
+type	O
+porcine	B-SPEC
+epidemic	B-DISO
+diarrhea	I-DISO
+viruses	B-SPEC
+.	O
+
+The	O
+coding	O
+region	O
+of	O
+the	O
+ORF3	O
+gene	O
+of	O
+attenuated	O
+-	O
+type	O
+PEDVs	O
+including	O
+attenuated	O
+DR13	O
+,	O
+KPED	O
+-	O
+9	O
+,	O
+and	O
+P	O
+-	O
+5V	O
+had	O
+51	O
+nucleotide	B-CHED
+deletions	O
+that	O
+were	O
+not	O
+found	O
+in	O
+the	O
+ORF3	O
+genes	O
+of	O
+wild	O
+-	O
+type	O
+PEDVs	O
+including	O
+CV777	O
+,	O
+Br1	O
+/	O
+87	O
+,	O
+LZC	O
+,	O
+parent	O
+DR13	O
+,	O
+and	O
+12	O
+field	O
+samples	O
+.	O
+
+Therefore	O
+,	O
+51	O
+nucleotide	B-CHED
+deletions	O
+appear	O
+to	O
+be	O
+meaningful	O
+and	O
+may	O
+be	O
+significant	O
+for	O
+PEDV	B-SPEC
+pathogenicity	O
+,	O
+because	O
+they	O
+lead	O
+to	O
+changes	O
+in	O
+the	O
+predicted	O
+amino	B-CHED
+acid	I-CHED
+sequences	O
+of	O
+attenuated	O
+-	O
+type	O
+PEDVs	O
+.	O
+
+Since	O
+avian	B-PRGE
+influenza	I-PRGE
+virus	I-PRGE
+A	I-PRGE
+(	O
+H5N1	B-DISO
+)	O
+produces	O
+human	B-SPEC
+infections	B-DISO
+with	O
+high	O
+morbidity	O
+and	O
+mortality	O
+rates	O
+,	O
+the	O
+probability	O
+of	O
+human	B-SPEC
+-	O
+to	O
+-	O
+human	B-SPEC
+transmission	O
+and	O
+its	O
+consequences	O
+attract	O
+a	O
+great	O
+deal	O
+of	O
+attention	O
+,	O
+recently	O
+.	O
+
+According	O
+to	O
+World	O
+Health	O
+Organization	O
+data	O
+up	O
+until	O
+January	O
+2007	O
+,	O
+the	O
+number	O
+of	O
+confirmed	O
+human	B-SPEC
+cases	O
+was	O
+270	O
+(	O
+164	O
+death	B-PROC
+).	O
+
+The	O
+transmission	O
+of	O
+H5N1	B-DISO
+virus	B-SPEC
+to	O
+humans	B-SPEC
+is	O
+by	O
+direct	O
+contact	O
+with	O
+infected	O
+birds	B-SPEC
+and	O
+poultry	O
+,	O
+close	O
+contact	O
+with	O
+their	O
+secretions	B-ANAT
+or	O
+contaminated	O
+fomites	O
+.	O
+
+In	O
+this	O
+review	O
+article	O
+influenza	B-SPEC
+virus	I-SPEC
+A	O
+(	O
+H5N1	B-DISO
+)	O
+infections	B-DISO
+,	O
+epidemiology	O
+and	O
+protection	O
+have	O
+been	O
+discussed	O
+.	O
+
+TITLE	O
+:	O
+Severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+coronavirus	B-SPEC
+as	O
+an	O
+agent	O
+of	O
+emerging	O
+and	O
+reemerging	O
+infection	B-DISO
+.	O
+
+CD11c	B-PRGE
+(+)	O
+macrophages	B-ANAT
+in	O
+the	O
+infected	O
+CNS	B-CHED
+exhibit	O
+variable	O
+properties	O
+of	O
+immature	O
+antigen	B-ANAT
+-	I-ANAT
+presenting	I-ANAT
+cells	B-COMP
+(	O
+APCs	B-DISO
+),	O
+with	O
+modestly	O
+increased	O
+CD40	B-PRGE
+and	O
+MHC	B-PROC
+expression	B-PROC
+,	O
+and	O
+equivalent	O
+potent	O
+antigen	B-CHED
+uptake	O
+when	O
+compared	O
+with	O
+CD11c	O
+(-)	O
+macrophages	B-ANAT
+.	O
+
+These	O
+results	O
+suggest	O
+that	O
+chronic	O
+CNS	B-DISO
+infection	I-DISO
+results	O
+in	O
+the	O
+appearance	O
+of	O
+CD11c	B-PRGE
+-	O
+expressing	O
+macrophages	B-ANAT
+from	O
+the	O
+blood	B-ANAT
+that	O
+exhibit	O
+properties	O
+of	O
+immature	O
+APCs	B-DISO
+,	O
+are	O
+closely	O
+associated	O
+with	O
+areas	O
+of	O
+demyelination	B-DISO
+,	O
+and	O
+may	O
+act	O
+as	O
+final	O
+effectors	O
+of	O
+myelin	B-COMP
+destruction	O
+.	O
+
+TITLE	O
+:	O
+Co	O
+-	O
+circulation	B-PROC
+of	O
+human	B-SPEC
+metapneumovirus	I-SPEC
+and	O
+SARS	B-DISO
+-	I-DISO
+associated	I-DISO
+coronavirus	I-DISO
+during	O
+a	O
+major	O
+nosocomial	O
+SARS	O
+outbreak	O
+in	O
+Hong	O
+Kong	O
+.	O
+
+ABSTRACT	O
+:	O
+The	O
+clinico	O
+-	O
+epidemiological	O
+significance	O
+of	O
+human	B-SPEC
+metapneumovirus	I-SPEC
+(	O
+hMPV	B-SPEC
+)	O
+detected	O
+during	O
+the	O
+SARS	B-DISO
+outbreak	O
+is	O
+unknown	O
+.	O
+
+ABSTRACT	O
+:	O
+The	O
+peptides	B-CHED
+derived	O
+from	O
+the	O
+heptad	O
+repeat	O
+(	O
+HRP	O
+)	O
+of	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+coronavirus	B-SPEC
+(	O
+SCoV	B-SPEC
+)	O
+spike	O
+protein	B-CHED
+(	O
+sHRPs	O
+)	O
+are	O
+known	O
+to	O
+inhibit	O
+SCoV	B-SPEC
+infection	B-DISO
+,	O
+yet	O
+their	O
+efficacies	O
+are	O
+fairly	O
+low	O
+.	O
+
+The	O
+incremental	O
+effect	O
+of	O
+adding	O
+virucidals	O
+or	O
+antiseptics	O
+to	O
+normal	O
+handwashing	O
+to	O
+decrease	O
+respiratory	B-DISO
+disease	I-DISO
+remains	O
+uncertain	O
+.	O
+
+TITLE	O
+:	O
+Human	B-SPEC
+coronaviruses	O
+:	O
+what	O
+do	O
+they	O
+cause	O
+?	O
+
+TITLE	O
+:	O
+VII	O
+International	O
+Symposium	O
+on	O
+Respiratory	O
+Viral	B-DISO
+Infections	I-DISO
+.	O
+
+Our	O
+effort	B-PROC
+is	O
+to	O
+draft	O
+our	O
+guidelines	O
+of	O
+combining	O
+traditional	O
+Chinese	O
+medicine	B-CHED
+and	O
+western	O
+medicine	B-CHED
+as	O
+a	O
+supplement	O
+to	O
+SSC	O
+guidelines	O
+.	O
+
+These	O
+include	O
+the	O
+Asian	O
+tsunami	O
+which	O
+devastated	O
+many	O
+of	O
+the	O
+countries	O
+around	O
+the	O
+rim	O
+of	O
+the	O
+Indian	O
+Ocean	O
+in	O
+December	O
+2004	O
+,	O
+extensive	O
+flooding	O
+in	O
+many	O
+parts	O
+of	O
+Europe	O
+in	O
+August	O
+2005	O
+,	O
+hurricane	O
+katrina	O
+(	O
+September	O
+2005	O
+),	O
+the	O
+outbreak	O
+of	O
+severe	O
+acute	O
+respiratory	O
+syndrome	O
+(	O
+SARS	B-DISO
+)	O
+in	O
+many	O
+regions	O
+of	O
+Asia	O
+and	O
+Canada	O
+in	O
+2003	O
+and	O
+the	O
+Pakistan	O
+earthquake	O
+(	O
+towards	O
+the	O
+end	O
+of	O
+2005	O
+).	O
+
+Three	O
+potential	O
+caveolin	B-PRGE
+-	I-PRGE
+1	I-PRGE
+-	I-PRGE
+binding	I-PRGE
+sites	I-PRGE
+were	O
+reported	O
+to	O
+be	O
+present	O
+in	O
+the	O
+3a	O
+protein	B-CHED
+.	O
+
+Studies	O
+have	O
+shown	O
+potential	O
+for	O
+benefit	O
+of	O
+inhaled	B-PROC
+nitric	B-CHED
+oxide	I-CHED
+in	O
+newborns	O
+with	O
+hypoxemic	O
+respiratory	B-DISO
+failure	I-DISO
+and	O
+pulmonary	B-DISO
+hypertension	I-DISO
+,	O
+surfactant	B-CHED
+in	O
+respiratory	B-DISO
+distress	I-DISO
+syndrome	I-DISO
+in	O
+preterm	O
+neonates	O
+and	O
+heliox	O
+in	O
+severe	O
+upper	O
+airway	O
+obstruction	O
+.	O
+
+The	O
+findings	O
+indicate	O
+that	O
+ARDS	B-DISO
+might	O
+occur	O
+more	O
+frequently	O
+in	O
+patients	O
+with	O
+TBRF	O
+than	O
+previously	O
+recognized	O
+.	O
+
+Laboratory	O
+examinations	O
+showed	O
+increased	O
+serum	B-COMP
+protein	B-CHED
+content	O
+and	O
+decreased	O
+albumin	B-PRGE
+/	O
+globulin	O
+ratio	O
+.	O
+
+Serum	B-COMP
+electrophoresis	O
+revealed	O
+increased	O
+alpha	B-PRGE
+2	I-PRGE
+-	I-PRGE
+and	I-PRGE
+gamma	I-PRGE
+-	I-PRGE
+globulin	I-PRGE
+content	O
+.	O
+
+FIP	B-PRGE
+antigen	B-CHED
+was	O
+demonstrated	O
+immunohistochemically	O
+in	O
+penile	B-ANAT
+tissue	B-ANAT
+.	O
+
+Differences	O
+in	O
+sperm	B-ANAT
+analysis	O
+among	O
+treatment	O
+groups	O
+were	O
+limited	O
+.	O
+
+TITLE	O
+:	O
+[	O
+Ischemic	O
+rhabdomyolysis	B-DISO
+and	O
+acute	B-DISO
+renal	I-DISO
+failure	I-DISO
+].	O
+
+Furthermore	O
+,	O
+our	O
+results	O
+show	O
+that	O
+receptor	O
+binding	O
+and	O
+subsequent	O
+membrane	B-PROC
+fusion	I-PROC
+are	O
+distinct	O
+steps	O
+,	O
+and	O
+that	O
+each	O
+spike	O
+can	O
+bind	B-FUNC
+up	O
+to	O
+three	O
+ACE2	B-PRGE
+molecules	O
+.	O
+
+We	O
+are	O
+interested	O
+in	O
+understanding	O
+the	O
+mechanisms	O
+controlling	O
+the	O
+impact	O
+of	O
+coronavirus	B-DISO
+infection	I-DISO
+on	O
+host	B-COMP
+cells	B-COMP
+.	O
+
+ABSTRACT	O
+:	O
+We	O
+have	O
+previously	O
+demonstrated	O
+that	O
+over	O
+-	O
+expression	B-PROC
+of	O
+spike	O
+protein	B-CHED
+(	O
+S	O
+)	O
+of	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+coronavirus	B-SPEC
+(	O
+SARS	B-DISO
+-	O
+CoV	O
+)	O
+or	O
+its	O
+C	O
+-	O
+terminal	O
+subunit	O
+(	O
+S2	O
+)	O
+is	O
+sufficient	O
+to	O
+induce	O
+apoptosis	B-PATH
+in	O
+vitro	O
+.	O
+
+Inhibition	B-PROC
+of	O
+Bcl	B-PRGE
+-	I-PRGE
+2	I-PRGE
+-	O
+related	O
+anti	O
+-	O
+apoptotic	O
+pathway	B-PROC
+was	O
+further	O
+supported	O
+by	O
+the	O
+diminution	O
+of	O
+S2	O
+-	O
+induced	O
+apoptosis	B-PATH
+in	O
+Vero	O
+E6	O
+cells	B-COMP
+over	O
+-	O
+expressing	O
+Bcl	B-PRGE
+-	I-PRGE
+xL	I-PRGE
+.	O
+In	O
+addition	O
+,	O
+modulation	O
+of	O
+CCN	B-CHED
+E2	O
+and	O
+CDKN	O
+1A	O
+implied	O
+the	O
+possible	O
+control	O
+of	O
+cell	B-PROC
+cycle	I-PROC
+arrest	I-PROC
+at	O
+G1	O
+/	O
+S	B-PROC
+phase	I-PROC
+.	O
+
+ABSTRACT	O
+:	O
+Clostridium	B-SPEC
+difficile	I-SPEC
+was	O
+investigated	O
+as	O
+a	O
+possible	O
+cause	O
+of	O
+enteritis	B-DISO
+in	O
+calves	O
+.	O
+
+Salmonella	B-DISO
+sp	O
+.	O
+was	O
+isolated	O
+from	O
+both	O
+diarrheic	O
+and	O
+nondiarrheic	O
+calves	O
+,	O
+but	O
+large	O
+numbers	O
+of	O
+E	B-SPEC
+.	I-SPEC
+coli	I-SPEC
+were	O
+found	O
+more	O
+commonly	O
+in	O
+diarrheic	O
+calves	O
+than	O
+in	O
+nondiarrheic	O
+animals	B-SPEC
+.	O
+
+Prevalence	O
+rates	O
+for	O
+coronavirus	B-SPEC
+and	O
+Cryptosporidium	B-SPEC
+sp	O
+.	O
+were	O
+substantially	O
+higher	O
+in	O
+nondiarrheic	O
+calves	O
+than	O
+in	O
+diarrheic	O
+,	O
+but	O
+rates	O
+of	O
+detection	O
+of	O
+rotavirus	B-SPEC
+and	O
+Giardia	B-DISO
+sp	O
+.	O
+were	O
+more	O
+nearly	O
+equal	O
+between	O
+groups	O
+.	O
+
+Diagn	O
+.,	O
+St	O
+.	O
+Louis	O
+,	O
+MO	O
+,	O
+U	O
+.	O
+S	O
+.	O
+A	O
+.]	O
+and	O
+add	B-DISO
+strength	O
+to	O
+a	O
+working	O
+hypothesis	O
+that	O
+C	B-SPEC
+.	I-SPEC
+difficile	I-SPEC
+infection	B-DISO
+and	O
+the	O
+accompanying	O
+intoxication	O
+can	O
+manifest	O
+as	O
+diarrhea	B-DISO
+in	O
+calves	O
+.	O
+
+ABSTRACT	O
+:	O
+The	O
+contribution	O
+of	O
+DRAK2	O
+[	O
+death	B-PRGE
+-	I-PRGE
+associated	I-PRGE
+protein	B-ENZY
+kinase	I-ENZY
+(	O
+DAPK	B-PRGE
+)-	O
+related	O
+apoptosis	B-PATH
+-	O
+inducing	O
+kinase	O
+2	O
+]	O
+to	O
+anti	O
+-	O
+viral	O
+memory	B-PROC
+T	B-ANAT
+cell	I-ANAT
+responses	O
+following	O
+infection	B-DISO
+with	O
+mouse	B-DISO
+hepatitis	I-DISO
+virus	B-SPEC
+(	O
+MHV	B-SPEC
+)	O
+was	O
+examined	O
+.	O
+
+A	O
+vector	O
+containing	O
+a	O
+fused	O
+5	O
+'	O
+UTR	O
+and	O
+enhanced	O
+green	O
+fluorescent	O
+protein	O
+(	O
+eGFP	O
+)	O
+was	O
+co	O
+-	O
+transfected	O
+with	O
+the	O
+DNAzyme	O
+into	O
+E6	O
+cells	B-COMP
+and	O
+the	O
+cells	B-COMP
+expressing	O
+eGFP	O
+were	O
+visualized	O
+with	O
+fluorescence	O
+microscopy	O
+and	O
+analyzed	O
+by	O
+fluorescence	O
+-	O
+activated	O
+cell	B-COMP
+sorting	B-PROC
+(	O
+FACS	O
+).	O
+
+ABSTRACT	O
+:	O
+Negative	O
+air	B-CHED
+pressure	O
+ventilation	O
+has	O
+been	O
+used	O
+to	O
+maintain	O
+adequate	O
+functional	B-PROC
+residual	I-PROC
+capacity	I-PROC
+in	O
+patients	O
+with	O
+chronic	O
+muscular	B-DISO
+disease	I-DISO
+and	O
+to	O
+decrease	O
+transpulmonary	O
+pressure	O
+and	O
+improve	O
+cardiac	B-ANAT
+output	O
+during	O
+right	B-ANAT
+heart	I-ANAT
+surgery	O
+.	O
+
+Physiological	O
+and	O
+blood	B-PROC
+gas	B-ENZY
+data	O
+were	O
+compared	O
+among	O
+groups	O
+using	O
+analysis	O
+of	O
+variance	O
+.	O
+
+RESULTS	O
+:	O
+Group	O
+1	O
+showed	O
+significantly	O
+higher	O
+oxygenation	B-PROC
+than	O
+Group	O
+2	O
+,	O
+and	O
+the	O
+same	O
+oxygenation	B-PROC
+with	O
+significantly	O
+higher	O
+mean	O
+blood	B-PROC
+pressure	I-PROC
+compared	O
+to	O
+Group	O
+3	O
+.	O
+
+CONCLUSIONS	O
+:	O
+Adequate	O
+CNEP	O
+combined	O
+with	O
+HFO	O
+improves	O
+oxygenation	B-PROC
+with	O
+less	O
+impact	O
+on	O
+blood	B-PROC
+pressure	I-PROC
+than	O
+high	O
+-	O
+frequency	O
+oscillation	O
+alone	O
+in	O
+an	O
+animal	B-SPEC
+model	O
+of	O
+respiratory	B-DISO
+failure	I-DISO
+.	O
+
+At	O
+days	O
+3	O
+and	O
+7	O
+postinoculation	O
+,	O
+SARS	B-PRGE
+-	I-PRGE
+CoV	I-PRGE
+replicated	O
+more	O
+efficiently	O
+in	O
+the	O
+lungs	B-ANAT
+of	O
+transgenic	B-SPEC
+mice	I-SPEC
+than	O
+in	O
+those	O
+of	O
+wild	O
+-	O
+type	O
+mice	B-SPEC
+.	O
+
+Therefore	O
+,	O
+transgenic	B-SPEC
+mice	I-SPEC
+were	O
+more	O
+susceptible	O
+to	O
+SARS	B-DISO
+-	O
+CoV	O
+than	O
+were	O
+wild	O
+-	O
+type	O
+mice	B-SPEC
+,	O
+and	O
+susceptibility	O
+was	O
+associated	O
+with	O
+severe	O
+pathologic	O
+changes	O
+that	O
+resembled	O
+human	B-SPEC
+SARS	B-DISO
+infection	B-DISO
+.	O
+
+ABSTRACT	O
+:	O
+Caused	O
+by	O
+a	O
+new	O
+coronavirus	O
+,	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+(	O
+SARS	B-DISO
+)	O
+is	O
+a	O
+highly	O
+contagious	B-DISO
+disease	I-DISO
+associated	O
+with	O
+significant	O
+fatality	O
+that	O
+emerged	O
+in	O
+2003	O
+.	O
+
+A	O
+few	O
+such	O
+segments	O
+are	O
+present	O
+in	O
+the	O
+SARS	B-DISO
+-	O
+CoV	O
+genome	O
+,	O
+but	O
+also	O
+in	O
+mRNAs	O
+of	O
+host	B-COMP
+proteins	B-CHED
+involved	O
+in	O
+the	O
+regulation	B-PROC
+of	I-PROC
+signaling	I-PROC
+pathways	B-PROC
+.	O
+
+Five	O
+patients	O
+out	O
+of	O
+ten	O
+experienced	O
+seven	O
+DLTs	O
+(	O
+severe	O
+esophagitis	B-DISO
+,	O
+asthenia	B-DISO
+,	O
+vomiting	B-DISO
+:	O
+5	O
+/	O
+1	O
+/	O
+1	O
+)	O
+at	O
+any	O
+dose	O
+-	O
+level	O
+.	O
+
+TITLE	O
+:	O
+Structural	O
+basis	O
+of	O
+mercury	B-CHED
+-	O
+and	O
+zinc	B-CHED
+-	O
+conjugated	O
+complexes	O
+as	O
+SARS	B-PRGE
+-	I-PRGE
+CoV	I-PRGE
+3C	I-PRGE
+-	I-PRGE
+like	I-PRGE
+protease	B-CHED
+inhibitors	I-CHED
+.	O
+
+ABSTRACT	O
+:	O
+Although	O
+mucosal	B-PROC
+immune	I-PROC
+responses	I-PROC
+are	O
+critical	O
+for	O
+protection	O
+of	O
+hosts	B-COMP
+from	O
+clinical	O
+illness	O
+and	O
+even	O
+mortality	O
+caused	O
+by	O
+mucosal	B-ANAT
+pathogens	O
+,	O
+the	O
+molecular	O
+mechanism	O
+of	O
+mucosal	B-PROC
+immunity	I-PROC
+,	O
+which	O
+is	O
+independent	O
+of	O
+systemic	O
+immunity	B-PROC
+,	O
+remains	O
+elusive	O
+.	O
+
+This	O
+was	O
+accompanied	O
+or	O
+immediately	O
+followed	O
+by	O
+a	O
+potent	O
+Th1	O
+adaptive	O
+immunity	O
+as	O
+evidenced	O
+by	O
+the	O
+activation	O
+of	O
+T	B-ANAT
+-	I-ANAT
+cell	I-ANAT
+signaling	O
+molecules	O
+,	O
+surface	O
+markers	O
+,	O
+and	O
+effector	B-CHED
+molecules	O
+.	O
+
+ABSTRACT	O
+:	O
+For	O
+many	O
+centuries	O
+,	O
+man	B-CHED
+is	O
+fascinated	O
+by	O
+bats	B-SPEC
+,	O
+the	O
+only	O
+flying	O
+mammals	B-SPEC
+.	O
+
+Qualitative	O
+content	O
+analysis	O
+of	O
+12	O
+emergency	B-DISO
+plans	O
+from	O
+national	O
+,	O
+provincial	O
+and	O
+municipal	O
+levels	O
+were	O
+conducted	O
+using	O
+NVIVO	O
+software	O
+.	O
+
+While	O
+support	O
+mechanisms	O
+for	O
+HCWs	O
+are	O
+included	O
+in	O
+this	O
+sample	O
+of	O
+emergency	B-DISO
+plans	O
+,	O
+content	O
+analysis	O
+revealed	O
+few	O
+emotional	O
+or	O
+social	O
+supports	O
+planned	O
+for	O
+critical	O
+personnel	O
+;	O
+particularly	O
+for	O
+those	O
+who	O
+will	O
+be	O
+required	O
+to	O
+work	O
+in	O
+extremely	O
+stressful	O
+conditions	O
+under	O
+significant	O
+personal	O
+risk	O
+.	O
+
+Dot	O
+blot	O
+analysis	O
+showed	O
+that	O
+SARS	B-PRGE
+-	I-PRGE
+CoV	I-PRGE
+spike	I-PRGE
+protein	B-CHED
+,	O
+which	O
+was	O
+expressed	B-PROC
+and	O
+purified	O
+from	O
+mammal	B-SPEC
+cells	B-COMP
+,	O
+can	O
+be	O
+detected	O
+by	O
+anti	B-PRGE
+-	I-PRGE
+Z	I-PRGE
+sera	I-PRGE
+from	O
+rabbit	B-SPEC
+.	O
+
+We	O
+conclude	O
+that	O
+iNO	B-PRGE
+therapy	O
+leads	O
+to	O
+an	O
+improvement	O
+in	O
+oxygenation	B-PROC
+without	O
+short	O
+-	O
+term	O
+side	O
+effects	O
+(	O
+such	O
+as	O
+pulmonary	B-ANAT
+hemorrhage	B-DISO
+,	I-DISO
+intracranial	I-DISO
+hemorrhage	B-DISO
+,	O
+pneumothorax	B-DISO
+or	O
+acute	O
+deterioration	O
+)	O
+in	O
+premature	O
+infants	O
+with	O
+severe	O
+RDS	O
+and	O
+respiratory	B-DISO
+failure	I-DISO
+.	O
+
+ABSTRACT	O
+:	O
+A	O
+longitudinal	O
+survey	O
+to	O
+detect	O
+enteric	O
+viruses	B-SPEC
+in	O
+intestinal	B-ANAT
+contents	I-ANAT
+collected	O
+from	O
+turkeys	B-SPEC
+in	O
+eight	O
+commercial	O
+operations	O
+and	O
+one	O
+research	O
+facility	O
+was	O
+performed	O
+using	O
+molecular	O
+detection	O
+methods	O
+.	O
+
+The	O
+samples	O
+were	O
+screened	O
+for	O
+astrovirus	O
+,	O
+rotavirus	B-SPEC
+,	O
+reovirus	B-SPEC
+,	O
+and	O
+turkey	B-SPEC
+coronavirus	B-SPEC
+(	O
+TCoV	O
+)	O
+by	O
+a	O
+reverse	B-PRGE
+transcriptase	I-PRGE
+and	O
+polymerase	O
+chain	O
+reaction	O
+(	O
+RT	O
+-	O
+PCR	O
+),	O
+and	O
+for	O
+groups	O
+1	O
+and	O
+2	O
+adenovirus	B-DISO
+by	O
+PCR	O
+.	O
+
+Comparison	O
+of	O
+infected	O
+birds	B-SPEC
+with	O
+one	O
+group	O
+of	O
+turkeys	B-SPEC
+that	O
+were	O
+negative	O
+for	O
+enteric	O
+viruses	B-SPEC
+by	O
+the	O
+methods	O
+used	O
+here	O
+suggests	O
+that	O
+astrovirus	O
+and	O
+/	O
+or	O
+rotavirus	B-SPEC
+may	O
+affect	O
+production	O
+.	O
+
+Additional	O
+chickens	B-SPEC
+of	O
+both	O
+genotypes	O
+served	O
+as	O
+unvaccinated	O
+/	O
+challenged	O
+and	O
+unvaccinated	O
+/	O
+nonchallenged	O
+controls	O
+.	O
+
+With	O
+respect	O
+to	O
+the	O
+deduced	O
+amino	B-CHED
+acid	I-CHED
+sequence	O
+,	O
+the	O
+Korean	O
+IBV	B-SPEC
+isolates	O
+had	O
+71	O
+.	O
+5	O
+-	O
+99	O
+.	O
+3	O
+%	O
+similarity	O
+with	O
+each	O
+other	O
+and	O
+44	O
+.	O
+9	O
+-	O
+80	O
+.	O
+3	O
+%	O
+similarity	O
+with	O
+non	O
+-	O
+Korean	O
+IBV	B-SPEC
+strains	O
+.	O
+
+ABSTRACT	O
+:	O
+Alterations	O
+in	O
+coagulation	O
+,	O
+including	O
+elevated	O
+pulmonary	B-ANAT
+and	O
+systemic	O
+concentrations	O
+of	O
+urokinase	B-PRGE
+,	O
+are	O
+frequent	O
+in	O
+patients	O
+with	O
+acute	O
+lung	B-ANAT
+injury	O
+(	O
+ALI	O
+).	O
+
+These	O
+results	O
+identify	O
+a	O
+specific	O
+urokinase	B-PRGE
+haplotype	O
+as	O
+a	O
+genetic	O
+risk	O
+factor	O
+for	O
+higher	O
+mortality	O
+and	O
+more	O
+severe	O
+clinical	O
+outcome	O
+in	O
+patients	O
+with	O
+infection	B-DISO
+-	O
+associated	O
+ALI	O
+.	O
+
+In	O
+this	O
+study	O
+,	O
+we	O
+evaluated	O
+the	O
+pharmacokinetics	B-PROC
+,	O
+tolerance	B-DISO
+and	O
+immunity	B-PROC
+of	O
+this	O
+kind	O
+of	O
+antibody	B-COMP
+in	O
+macaques	B-SPEC
+and	O
+rats	B-SPEC
+.	O
+
+The	O
+antibody	B-COMP
+titring	O
+from	O
+1	O
+:	O
+100	O
+to	O
+400	O
+against	O
+the	O
+equine	B-PRGE
+anti	I-PRGE
+-	I-PRGE
+SARS	B-DISO
+-	I-PRGE
+CoV	I-PRGE
+F	I-PRGE
+(	O
+ab	O
+')(	O
+2	O
+)	O
+in	O
+the	O
+inoculated	O
+hosts	B-COMP
+could	O
+be	O
+detected	O
+at	O
+week	O
+2	O
+during	O
+the	O
+successive	O
+injections	O
+of	O
+the	O
+equine	O
+F	O
+(	O
+ab	O
+')(	O
+2	O
+).	O
+
+This	O
+study	O
+attempted	O
+to	O
+identify	O
+the	O
+stage	O
+-	O
+specific	O
+difficulties	O
+encountered	O
+by	O
+Taiwan	O
+'	O
+s	O
+surviving	O
+frontline	O
+nurses	O
+during	O
+the	O
+anti	O
+-	O
+SARS	B-DISO
+process	O
+.	O
+
+TITLE	O
+:	O
+Human	B-SPEC
+(	O
+non	O
+-	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+)	O
+coronavirus	B-DISO
+infections	I-DISO
+in	O
+hospitalised	O
+children	O
+in	O
+France	O
+.	O
+
+We	O
+previously	O
+showed	O
+that	O
+Ceacam1a	O
+(-/-)	O
+mice	B-SPEC
+are	O
+completely	O
+resistant	O
+to	O
+MHV	B-SPEC
+-	O
+A59	O
+infection	B-DISO
+(	O
+E	O
+.	O
+Hemmila	O
+et	O
+al	O
+.,	O
+J	O
+.	O
+Virol	O
+.	O
+
+Although	O
+Ceacam1a	O
+(-/-)	O
+mice	B-SPEC
+were	O
+completely	O
+resistant	O
+to	O
+i	O
+.	O
+c	O
+.	O
+
+TITLE	O
+:	O
+Cloning	O
+,	O
+expression	B-PROC
+and	O
+characterization	O
+of	O
+ferret	B-PRGE
+CXCL10	I-PRGE
+.	O
+
+The	O
+inactivated	O
+vaccine	O
+was	O
+safe	O
+and	O
+well	O
+tolerated	O
+and	O
+can	O
+elicit	O
+SARS	B-PRGE
+-	I-PRGE
+CoV	I-PRGE
+-	I-PRGE
+specific	I-PRGE
+neutralizing	I-PRGE
+antibodies	B-COMP
+.	O
+
+CONCLUSIONS	O
+:	O
+The	O
+inactivated	O
+vaccine	O
+was	O
+safe	O
+and	O
+well	O
+tolerated	O
+and	O
+can	O
+elicit	O
+SARS	B-PRGE
+-	I-PRGE
+CoV	I-PRGE
+-	I-PRGE
+specific	I-PRGE
+neutralizing	I-PRGE
+antibodies	B-COMP
+.	O
+
+Concerns	O
+about	O
+SARS	B-DISO
+adversely	O
+affected	O
+the	O
+willingness	O
+of	O
+respondents	O
+to	O
+perform	O
+SCPR	O
+or	O
+CCPR	O
+on	O
+strangers	O
+and	O
+to	O
+perform	O
+SCPR	O
+on	O
+family	B-SPEC
+members	O
+.	O
+
+Consequences	O
+of	O
+the	O
+LFA	B-PRGE
+-	I-PRGE
+1	I-PRGE
+interaction	O
+with	O
+7a	O
+are	O
+discussed	O
+.	O
+
+In	O
+an	O
+initial	O
+experiment	O
+,	O
+the	O
+effect	O
+of	O
+coinfection	B-DISO
+of	O
+PRCV	O
+and	O
+B	B-SPEC
+.	I-SPEC
+bronchiseptica	I-SPEC
+was	O
+examined	O
+in	O
+thirty	O
+,	O
+4	O
+-	O
+week	O
+-	O
+old	O
+pigs	B-SPEC
+(	O
+10	O
+pigs	B-SPEC
+/	O
+group	O
+)	O
+that	O
+were	O
+infected	O
+with	O
+either	O
+PRCV	O
+or	O
+B	B-SPEC
+.	I-SPEC
+bronchiseptica	I-SPEC
+,	O
+or	O
+both	O
+PRCV	O
+and	O
+B	B-SPEC
+.	I-SPEC
+bronchiseptica	I-SPEC
+.	O
+
+Thus	O
+,	O
+there	O
+appears	O
+to	O
+be	O
+a	O
+synergistic	O
+effect	O
+between	O
+PRCV	O
+and	O
+B	B-SPEC
+.	I-SPEC
+bronchiseptica	I-SPEC
+with	O
+regards	O
+to	O
+proinflammatory	O
+cytokine	O
+transcription	B-PROC
+that	O
+may	O
+partially	O
+explain	O
+the	O
+increased	O
+severity	O
+of	O
+pneumonia	B-DISO
+in	O
+coinfected	O
+pigs	B-SPEC
+.	O
+
+The	O
+other	O
+cell	B-COMP
+type	I-COMP
+was	O
+composed	O
+of	O
+spindle	B-COMP
+-	O
+shaped	O
+cells	B-COMP
+that	O
+were	O
+positive	O
+for	O
+vimentin	B-COMP
+and	O
+collagen	B-PRGE
+III	I-PRGE
+and	O
+likely	O
+fibroblasts	B-ANAT
+.	O
+
+Its	O
+catalytic	O
+capability	O
+is	O
+similar	O
+to	O
+those	O
+of	O
+TVMV	B-SPEC
+and	O
+TEV	B-PRGE
+NIa	B-SPEC
+protease	I-PRGE
+.	O
+
+The	O
+patient	O
+'	O
+s	O
+serum	B-COMP
+creatinine	B-CHED
+level	O
+was	O
+301	O
+micromol	O
+/	O
+l	O
+and	O
+her	O
+liver	B-PROC
+function	I-PROC
+tests	O
+were	O
+normal	O
+.	O
+
+Type	B-PRGE
+B	I-PRGE
+insulin	I-PRGE
+resistance	B-PROC
+syndrome	O
+.	O
+
+Plasmapheresis	O
+was	O
+initiated	O
+,	O
+inducing	O
+a	O
+striking	O
+acute	O
+decline	O
+in	O
+insulin	B-PRGE
+needs	O
+.	O
+
+TITLE	O
+:	O
+Amniotic	B-ANAT
+fluid	I-ANAT
+embolism	I-DISO
+managed	O
+with	O
+success	O
+during	O
+labour	B-PROC
+:	O
+report	O
+of	O
+a	O
+severe	O
+clinical	O
+case	O
+and	O
+review	O
+of	O
+literature	O
+.	O
+
+We	O
+sought	O
+to	O
+understand	O
+how	O
+and	O
+why	O
+this	O
+apparently	O
+surprising	O
+policy	O
+evolution	B-PROC
+took	O
+place	O
+.	O
+
+These	O
+included	O
+the	O
+emergence	O
+of	O
+effective	O
+'	O
+champions	O
+'	O
+for	O
+such	O
+policies	O
+,	O
+an	O
+ethos	O
+of	O
+pragmatism	O
+and	O
+receptivity	O
+to	O
+evidence	O
+,	O
+growing	O
+collaboration	O
+across	O
+public	O
+health	O
+,	O
+police	O
+and	O
+other	O
+sectors	O
+,	O
+the	O
+influence	O
+of	O
+contingent	O
+events	O
+such	O
+as	O
+the	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+(	O
+SARS	B-DISO
+)	O
+epidemic	O
+and	O
+pressure	O
+from	O
+donors	O
+and	O
+international	O
+organizations	O
+to	O
+adopt	O
+best	O
+practice	O
+in	O
+HIV	B-DISO
+prevention	O
+.	O
+
+ABSTRACT	O
+:	O
+This	O
+study	O
+was	O
+conducted	O
+to	O
+evaluate	O
+the	O
+effects	O
+of	O
+4	O
+Chinese	O
+herbal	O
+polysaccharides	B-CHED
+on	O
+the	O
+production	O
+of	O
+serum	B-COMP
+antibodies	B-COMP
+and	O
+the	O
+proliferation	B-DISO
+of	O
+peripheral	O
+T	B-ANAT
+lymphocytes	I-ANAT
+,	O
+including	O
+subpopulations	O
+in	O
+vaccinated	O
+chickens	B-SPEC
+.	O
+
+On	O
+d	O
+10	O
+,	O
+20	O
+,	O
+30	O
+,	O
+40	O
+,	O
+and	O
+50	O
+after	O
+the	O
+first	O
+vaccination	O
+,	O
+the	O
+proliferation	B-DISO
+of	O
+peripheral	B-ANAT
+blood	I-ANAT
+mononuclear	I-ANAT
+cells	I-ANAT
+in	O
+response	O
+to	O
+concanavalin	O
+A	O
+stimulation	O
+as	O
+well	O
+as	O
+the	O
+proportions	O
+of	O
+CD3	B-PRGE
+(+),	I-PRGE
+CD4	B-PRGE
+(+),	O
+and	O
+CD8	B-PRGE
+(+)	O
+peripheral	B-ANAT
+blood	I-ANAT
+mononuclear	I-ANAT
+cells	I-ANAT
+were	O
+determined	O
+by	O
+the	O
+3	B-CHED
+-(	I-CHED
+4	I-CHED
+,	I-CHED
+5	I-CHED
+-	I-CHED
+dimethylthiazol	I-CHED
+-	I-CHED
+2	I-CHED
+-	I-CHED
+yl	I-CHED
+)-	I-CHED
+2	I-CHED
+,	I-CHED
+5	I-CHED
+-	I-CHED
+diphenyltetrazolium	I-CHED
+bromide	I-CHED
+method	O
+and	O
+flow	O
+cytometry	O
+,	O
+respectively	O
+.	O
+
+TITLE	O
+:	O
+SARS	B-DISO
+and	O
+health	O
+worker	O
+safety	O
+:	O
+lessons	O
+for	O
+influenza	B-DISO
+pandemic	O
+planning	O
+and	O
+response	O
+.	O
+
+ABSTRACT	O
+:	O
+The	O
+global	O
+spread	O
+of	O
+the	O
+severe	O
+acute	O
+respiratory	O
+syndrome	O
+(	O
+SARS	B-DISO
+)	O
+epidemic	O
+has	O
+clearly	O
+shown	O
+the	O
+importance	O
+of	O
+considering	O
+the	O
+long	O
+-	O
+range	O
+transportation	O
+networks	O
+in	O
+the	O
+understanding	O
+of	O
+emerging	O
+diseases	O
+outbreaks	O
+.	O
+
+The	O
+level	O
+of	O
+predictability	O
+offered	O
+by	O
+the	O
+model	O
+can	O
+be	O
+quantitatively	O
+analyzed	O
+and	O
+related	O
+to	O
+the	O
+appearance	O
+of	O
+robust	O
+epidemic	O
+pathways	B-PROC
+that	O
+represent	O
+the	O
+most	O
+probable	O
+routes	O
+for	O
+the	O
+spread	O
+of	O
+the	O
+disease	O
+.	O
+
+RESULTS	O
+:	O
+In	O
+order	B-SPEC
+to	O
+assess	O
+the	O
+predictive	O
+power	O
+of	O
+the	O
+model	O
+,	O
+the	O
+case	O
+study	O
+of	O
+the	O
+global	O
+spread	O
+of	O
+SARS	B-DISO
+is	O
+considered	O
+.	O
+
+We	O
+report	O
+the	O
+clinical	O
+,	O
+virological	O
+and	O
+serological	O
+findings	O
+in	O
+dogs	B-SPEC
+experimentally	O
+infected	O
+with	O
+strain	O
+CB	O
+/	O
+05	O
+.	O
+
+The	O
+dogs	B-SPEC
+,	O
+three	O
+2	O
+.	O
+5	O
+-	O
+month	O
+-	O
+old	O
+and	O
+two	O
+6	O
+-	O
+month	O
+-	O
+old	O
+pups	O
+,	O
+were	O
+successfully	O
+infected	O
+,	O
+shedding	O
+viral	O
+RNA	O
+with	O
+their	O
+faeces	B-ANAT
+for	O
+the	O
+entire	O
+observation	O
+period	O
+(	O
+21	O
+days	O
+)	O
+and	O
+displaying	O
+systemic	O
+clinical	O
+signs	O
+resembling	O
+those	O
+observed	O
+during	O
+the	O
+course	O
+of	O
+natural	O
+infection	B-DISO
+.	O
+
+This	O
+subgroup	O
+maps	O
+to	O
+two	O
+previously	O
+identified	O
+domains	O
+within	O
+S2	O
+,	O
+a	O
+putative	O
+fusion	O
+peptide	B-CHED
+and	O
+a	O
+heptad	O
+repeat	O
+,	O
+both	O
+conserved	O
+features	O
+of	O
+class	O
+I	O
+fusion	O
+proteins	B-CHED
+.	O
+
+Interestingly	O
+,	O
+a	O
+recombinant	O
+with	O
+S1	O
+from	O
+A59	O
+and	O
+S2	O
+from	O
+V51	O
+was	O
+severely	O
+debilitated	O
+in	O
+its	O
+ability	O
+to	O
+productively	O
+infect	O
+cells	B-COMP
+via	O
+CEACAM1a	O
+,	O
+while	O
+the	O
+inverse	O
+recombinant	O
+was	O
+not	O
+.	O
+
+This	O
+result	O
+suggests	O
+that	O
+the	O
+S2	O
+substitutions	O
+exert	B-PROC
+powerful	O
+effects	O
+on	O
+the	O
+fusion	O
+trigger	O
+that	O
+normally	O
+passes	O
+from	O
+S1	O
+to	O
+S2	O
+.	O
+
+These	O
+novel	O
+findings	O
+play	O
+against	O
+the	O
+existing	O
+data	O
+that	O
+suggest	O
+that	O
+MHV	B-SPEC
+host	B-COMP
+range	O
+determinants	O
+are	O
+located	O
+in	O
+the	O
+S1	B-PRGE
+subunit	I-PRGE
+,	O
+which	O
+harbors	O
+the	O
+receptor	B-FUNC
+binding	I-FUNC
+domain	O
+,	O
+or	O
+involve	O
+coordinating	O
+changes	O
+in	O
+both	O
+S1	O
+and	O
+S2	O
+.	O
+
+Mounting	O
+evidence	O
+also	O
+suggests	O
+that	O
+the	O
+class	B-SPEC
+I	O
+fusion	O
+mechanism	O
+may	O
+possess	B-DISO
+some	O
+innate	O
+plasticity	O
+that	O
+regulates	O
+viral	O
+host	B-COMP
+range	O
+.	O
+
+Members	O
+of	O
+one	O
+class	B-SPEC
+of	O
+suppressor	O
+were	O
+mapped	O
+to	O
+the	O
+portions	O
+of	O
+gene	O
+1	O
+that	O
+encode	O
+nsp8	O
+and	O
+nsp9	O
+,	O
+thereby	O
+providing	O
+the	O
+first	O
+evidence	O
+for	O
+specific	O
+interactions	O
+between	O
+coronavirus	O
+replicase	O
+gene	O
+products	O
+and	O
+a	O
+cis	B-DISO
+-	O
+acting	O
+genomic	O
+RNA	O
+element	O
+.	O
+
+We	O
+strongly	O
+recommend	O
+BC	O
+as	O
+a	O
+useful	O
+virucidal	O
+agent	O
+,	O
+especially	O
+in	O
+the	O
+manufacture	O
+of	O
+vaccines	O
+for	O
+these	O
+viruses	B-SPEC
+.	O
+
+In	O
+addition	O
+,	O
+we	O
+will	O
+discuss	O
+how	O
+the	O
+formation	B-PROC
+of	O
+these	O
+large	O
+vesicles	B-COMP
+might	O
+be	O
+induced	O
+.	O
+
+TITLE	O
+:	O
+Stevens	B-DISO
+-	I-DISO
+Johnson	I-DISO
+syndrome	I-DISO
+without	O
+skin	B-ANAT
+lesions	O
+.	O
+
+Results	O
+indicate	O
+that	O
+human	B-SPEC
+resources	O
+play	O
+an	O
+important	O
+role	O
+in	O
+this	O
+issue	O
+.	O
+
+ABSTRACT	O
+:	O
+Canine	O
+coronavirus	B-SPEC
+(	O
+CCoV	O
+)	O
+is	O
+responsible	O
+for	O
+enteric	O
+disease	O
+in	O
+pups	O
+.	O
+
+In	O
+general	O
+,	O
+virus	B-SPEC
+inactivation	B-DISO
+implies	O
+a	O
+permanent	O
+loss	O
+of	O
+infectivity	O
+which	O
+can	O
+be	O
+evaluated	O
+in	O
+suspensions	O
+and	O
+hand	O
+disinfection	O
+tests	O
+.	O
+
+TITLE	O
+:	O
+In	O
+vitro	O
+inhibition	B-PROC
+of	O
+coronavirus	B-SPEC
+replications	O
+by	O
+the	O
+traditionally	O
+used	O
+medicinal	O
+herbal	O
+extracts	O
+,	O
+Cimicifuga	O
+rhizoma	O
+,	O
+Meliae	O
+cortex	B-ANAT
+,	O
+Coptidis	O
+rhizoma	O
+,	O
+and	O
+Phellodendron	B-SPEC
+cortex	B-ANAT
+.	O
+
+These	O
+extracts	O
+also	O
+significantly	O
+decreased	O
+PEDV	B-SPEC
+production	O
+and	O
+less	O
+dramatically	O
+decreased	O
+vesicular	B-SPEC
+stomatitis	I-SPEC
+virus	I-SPEC
+(	O
+VSV	O
+)	O
+production	O
+in	O
+vitro	O
+.	O
+
+These	O
+extracts	O
+also	O
+significantly	O
+decreased	O
+PEDV	B-SPEC
+production	O
+and	O
+less	O
+dramatically	O
+decreased	O
+vesicular	B-SPEC
+stomatitis	I-SPEC
+virus	I-SPEC
+(	O
+VSV	O
+)	O
+production	O
+in	O
+vitro	O
+.	O
+
+Findings	O
+with	O
+regard	O
+to	O
+the	O
+administration	O
+of	O
+the	O
+stress	O
+hormone	B-CHED
+cortisol	B-CHED
+were	O
+more	O
+complex	O
+,	O
+however	O
+.	O
+
+Several	O
+studies	O
+from	O
+our	O
+group	O
+have	O
+demonstrated	O
+that	O
+the	O
+administration	O
+of	O
+stress	O
+doses	O
+of	O
+cortisol	B-CHED
+to	O
+critically	B-DISO
+ill	I-DISO
+patients	O
+resulted	O
+in	O
+a	O
+significant	O
+reduction	O
+of	O
+PTSD	B-DISO
+symptoms	O
+measured	O
+after	O
+recovery	O
+without	O
+influencing	O
+the	O
+number	O
+of	O
+categories	O
+of	O
+traumatic	O
+memory	B-PROC
+.	O
+
+Retinal	B-DISO
+degeneration	I-DISO
+resistant	O
+CD	O
+-	O
+1	O
+mice	B-SPEC
+do	O
+not	O
+develop	O
+the	O
+late	O
+phase	O
+.	O
+
+The	O
+process	O
+of	O
+temperature	O
+regulation	B-PROC
+can	O
+be	O
+altered	O
+by	O
+drugs	O
+such	O
+as	O
+succinylcholine	O
+,	O
+phenothiazines	B-CHED
+,	O
+monoamine	B-PROC
+oxidase	I-PROC
+inhibitors	I-PROC
+,	O
+atropine	B-CHED
+,	O
+benztropine	B-CHED
+,	O
+antihistamines	B-CHED
+,	O
+cocaine	B-CHED
+,	O
+Ecstasy	O
+,	O
+amphetamines	B-CHED
+,	O
+and	O
+haloperidol	B-CHED
+.	O
+
+She	O
+eventually	O
+responded	O
+to	O
+high	O
+-	O
+dose	O
+methylprednisolone	B-CHED
+.	O
+
+The	O
+incremental	O
+effect	O
+of	O
+adding	O
+virucidals	O
+or	O
+antiseptics	O
+to	O
+normal	O
+handwashing	O
+to	O
+decrease	O
+the	O
+spread	O
+of	O
+respiratory	B-DISO
+disease	I-DISO
+remains	O
+uncertain	O
+.	O
+
+Routine	O
+long	O
+term	O
+implementation	O
+of	O
+some	O
+physical	O
+measures	O
+to	O
+interrupt	O
+or	O
+reduce	O
+the	O
+spread	O
+of	O
+respiratory	O
+viruses	B-SPEC
+might	O
+be	O
+difficult	O
+but	O
+many	O
+simple	O
+and	O
+low	O
+cost	O
+interventions	O
+could	O
+be	O
+useful	O
+in	O
+reducing	O
+the	O
+spread	O
+.	O
+
+TITLE	O
+:	O
+Structural	O
+and	O
+functional	O
+analyses	O
+of	O
+the	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+coronavirus	B-SPEC
+endoribonuclease	O
+Nsp15	O
+.	O
+
+Alanine	B-CHED
+substitution	O
+of	O
+several	O
+residues	O
+in	O
+the	O
+RNA	O
+-	O
+contacting	O
+portion	O
+of	O
+Nsp15	O
+did	O
+not	O
+affect	O
+hexamer	O
+formation	B-PROC
+but	O
+decreased	O
+the	O
+affinity	O
+of	O
+RNA	B-FUNC
+binding	I-FUNC
+and	O
+reduced	B-PRGE
+endonuclease	I-PRGE
+activity	O
+.	O
+
+The	O
+3	O
+'	O
+7	O
+.	O
+5	O
+kb	O
+of	O
+the	O
+genomes	O
+of	O
+17	O
+Australian	O
+IBV	B-SPEC
+strains	O
+were	O
+sequenced	O
+,	O
+and	O
+growth	B-PROC
+properties	O
+of	O
+6	O
+of	O
+the	O
+strains	O
+were	O
+compared	O
+.	O
+
+Although	O
+the	O
+novel	O
+IBVs	O
+induced	O
+histopathological	O
+lesions	O
+in	O
+the	O
+tracheas	B-ANAT
+of	O
+infected	O
+chicks	O
+that	O
+were	O
+comparable	O
+to	O
+those	O
+induced	O
+by	O
+classical	O
+strains	O
+,	O
+they	O
+did	O
+not	O
+induce	O
+lesions	O
+in	O
+the	O
+kidneys	B-ANAT
+.	O
+
+ABSTRACT	O
+:	O
+The	O
+etiology	O
+,	O
+pathogenesis	B-DISO
+,	O
+and	O
+prognosis	O
+for	O
+a	O
+newly	O
+emerging	O
+disease	O
+are	O
+generally	O
+unknown	O
+to	O
+clinicians	O
+.	O
+
+The	O
+ratio	O
+of	O
+recombinant	O
+proteins	B-CHED
+of	O
+PUPs	O
+to	O
+total	O
+proteins	O
+is	O
+as	O
+follows	O
+:	O
+X4	O
+,	O
+20	O
+%;	O
+X5	O
+,	O
+27	O
+.	O
+8	O
+%;	O
+ORF10	O
+,	O
+68	O
+.	O
+5	O
+%	O
+under	O
+the	O
+optimum	O
+conditions	O
+.	O
+
+TITLE	O
+:	O
+[	O
+A	O
+case	O
+of	O
+miliary	B-DISO
+tuberculosis	I-DISO
+showing	O
+acute	B-DISO
+respiratory	I-DISO
+failure	I-DISO
+during	O
+pregnancy	O
+].	O
+
+We	O
+treated	O
+her	O
+with	O
+antituberculosis	O
+chemotherapy	O
+,	O
+corticosteroid	B-CHED
+,	O
+sivelestat	O
+sodium	B-CHED
+hydrate	I-CHED
+,	O
+direct	O
+hemoperfusion	O
+using	O
+a	O
+polymyxin	B-CHED
+B	I-CHED
+immobilized	O
+column	B-ANAT
+,	O
+and	O
+mechanical	O
+ventilation	O
+,	O
+but	O
+she	O
+died	B-PROC
+due	O
+to	O
+respiratory	B-DISO
+failure	I-DISO
+.	O
+
+We	O
+emphasize	O
+that	O
+in	O
+this	O
+case	O
+pregnancy	O
+has	O
+the	O
+risk	O
+of	O
+to	O
+causing	O
+disease	B-DISO
+progression	I-DISO
+of	O
+miliary	B-DISO
+tuberculosis	I-DISO
+and	O
+we	O
+should	O
+treat	O
+immediately	O
+and	O
+intensively	O
+for	O
+miliary	O
+tuberculosis	O
+complicated	O
+with	O
+ARDS	B-DISO
+.	O
+
+Across	O
+worldwide	O
+efforts	O
+in	O
+Asia	O
+,	O
+Europe	O
+and	O
+America	O
+,	O
+the	O
+international	O
+research	O
+teams	O
+working	O
+on	O
+SARS	B-PRGE
+-	I-PRGE
+CoV	I-PRGE
+have	O
+now	O
+determined	O
+experimental	O
+structural	O
+information	O
+for	O
+45	O
+%	O
+of	O
+the	O
+SARS	O
+-	O
+CoV	O
+proteins	B-CHED
+and	O
+53	O
+%	O
+of	O
+all	O
+its	O
+soluble	O
+proteins	B-CHED
+.	O
+
+TITLE	O
+:	O
+Surface	O
+-	O
+displayed	O
+porcine	B-SPEC
+epidemic	B-DISO
+diarrhea	I-DISO
+viral	O
+(	O
+PEDV	B-SPEC
+)	O
+antigens	B-CHED
+on	O
+lactic	B-CHED
+acid	I-CHED
+bacteria	B-SPEC
+.	O
+
+These	O
+results	O
+indicate	O
+that	O
+mucosal	B-ANAT
+immunization	O
+with	O
+recombinant	O
+L	B-SPEC
+.	I-SPEC
+casei	I-SPEC
+expressing	O
+PEDV	B-SPEC
+N	O
+protein	B-CHED
+(	O
+neucleoprotein	O
+of	O
+PEDV	B-SPEC
+)	O
+on	O
+its	O
+surface	O
+elicited	O
+high	O
+levels	O
+of	O
+mucosal	B-PRGE
+IgA	I-PRGE
+and	I-PRGE
+circulation	B-PROC
+IgG	I-PRGE
+immune	B-PROC
+responses	I-PROC
+against	O
+the	O
+antigen	B-CHED
+N	O
+of	O
+PEDV	B-SPEC
+.	O
+
+However	O
+,	O
+previous	O
+studies	O
+suggested	O
+that	O
+none	O
+of	O
+the	O
+currently	O
+sampled	O
+bat	B-ENZY
+SLCoVs	O
+is	O
+the	O
+descendant	O
+of	O
+the	O
+direct	O
+ancestor	O
+of	O
+SCoV	O
+,	O
+based	O
+on	O
+their	O
+relatively	O
+distant	O
+phylogenetic	O
+relationship	O
+.	O
+
+In	O
+this	O
+study	O
+,	O
+evidence	O
+of	O
+the	O
+recombinant	O
+origin	O
+of	O
+the	O
+genome	O
+of	O
+a	O
+bat	B-ENZY
+SLCoV	O
+is	O
+demonstrated	O
+.	O
+
+Key	O
+recommendations	O
+,	O
+listed	O
+by	O
+category	O
+,	O
+include	O
+:	O
+early	O
+goal	O
+-	O
+directed	O
+resuscitation	O
+of	O
+the	O
+septic	O
+patient	O
+during	O
+the	O
+first	O
+6	O
+hrs	B-DISO
+after	O
+recognition	O
+(	O
+1C	O
+);	O
+blood	B-ANAT
+cultures	O
+prior	O
+to	O
+antibiotic	B-CHED
+therapy	O
+(	O
+1C	O
+);	O
+imaging	O
+studies	O
+performed	O
+promptly	O
+to	O
+confirm	O
+potential	O
+source	O
+of	O
+infection	B-DISO
+(	O
+1C	O
+);	O
+administration	O
+of	O
+broad	O
+-	O
+spectrum	O
+antibiotic	B-CHED
+therapy	O
+within	O
+1	O
+hr	O
+of	O
+diagnosis	O
+of	O
+septic	B-DISO
+shock	I-DISO
+(	O
+1B	O
+)	O
+and	O
+severe	B-DISO
+sepsis	I-DISO
+without	I-DISO
+septic	I-DISO
+shock	I-DISO
+(	O
+1D	O
+);	O
+reassessment	O
+of	O
+antibiotic	B-CHED
+therapy	O
+with	O
+microbiology	O
+and	O
+clinical	O
+data	O
+to	O
+narrow	O
+coverage	O
+,	O
+when	O
+appropriate	O
+(	O
+1C	O
+);	O
+a	O
+usual	O
+7	O
+-	O
+10	O
+days	O
+of	O
+antibiotic	B-CHED
+therapy	O
+guided	O
+by	O
+clinical	O
+response	O
+(	O
+1D	O
+);	O
+source	O
+control	O
+with	O
+attention	O
+to	O
+the	O
+balance	B-PROC
+of	O
+risks	O
+and	O
+benefits	O
+of	O
+the	O
+chosen	O
+method	O
+(	O
+1C	O
+);	O
+administration	O
+of	O
+either	O
+crystalloid	B-COMP
+or	O
+colloid	B-ANAT
+fluid	O
+resuscitation	O
+(	O
+1B	O
+);	O
+fluid	O
+challenge	O
+to	O
+restore	O
+mean	O
+circulating	O
+filling	O
+pressure	O
+(	O
+1C	O
+);	O
+reduction	O
+in	O
+rate	O
+of	O
+fluid	O
+administration	O
+with	O
+rising	O
+filing	O
+pressures	O
+and	O
+no	O
+improvement	O
+in	O
+tissue	B-ANAT
+perfusion	O
+(	O
+1D	O
+);	O
+vasopressor	O
+preference	O
+for	O
+norepinephrine	B-CHED
+or	O
+dopamine	B-CHED
+to	O
+maintain	O
+an	O
+initial	O
+target	O
+of	O
+mean	O
+arterial	B-PROC
+pressure	I-PROC
+>	O
+or	O
+=	O
+65	O
+mm	O
+Hg	O
+(	O
+1C	O
+);	O
+dobutamine	B-CHED
+inotropic	O
+therapy	O
+when	O
+cardiac	B-ANAT
+output	O
+remains	O
+low	O
+despite	O
+fluid	O
+resuscitation	O
+and	O
+combined	O
+inotropic	O
+/	O
+vasopressor	O
+therapy	O
+(	O
+1C	O
+);	O
+stress	O
+-	O
+dose	O
+steroid	B-CHED
+therapy	O
+given	O
+only	O
+in	O
+septic	B-DISO
+shock	I-DISO
+after	O
+blood	B-PROC
+pressure	I-PROC
+is	O
+identified	O
+to	O
+be	O
+poorly	O
+responsive	O
+to	O
+fluid	O
+and	O
+vasopressor	O
+therapy	O
+(	O
+2C	O
+);	O
+recombinant	B-PRGE
+activated	I-PRGE
+protein	I-PRGE
+C	I-PRGE
+in	O
+patients	O
+with	O
+severe	B-DISO
+sepsis	I-DISO
+and	O
+clinical	O
+assessment	O
+of	O
+high	O
+risk	O
+for	O
+death	B-PROC
+(	O
+2B	O
+except	O
+2C	O
+for	O
+post	O
+-	O
+operative	O
+patients	O
+).	O
+
+Recommendations	O
+specific	O
+to	O
+pediatric	O
+severe	B-DISO
+sepsis	I-DISO
+include	O
+:	O
+greater	O
+use	O
+of	O
+physical	O
+examination	O
+therapeutic	O
+end	O
+points	O
+(	O
+2C	O
+);	O
+dopamine	B-CHED
+as	O
+the	O
+first	O
+drug	O
+of	O
+choice	O
+for	O
+hypotension	O
+(	O
+2C	O
+);	O
+steroids	B-CHED
+only	O
+in	O
+children	O
+with	O
+suspected	O
+or	O
+proven	O
+adrenal	B-DISO
+insufficiency	I-DISO
+(	O
+2C	O
+);	O
+a	O
+recommendation	O
+against	O
+the	O
+use	O
+of	O
+recombinant	B-PRGE
+activated	I-PRGE
+protein	I-PRGE
+C	I-PRGE
+in	O
+children	O
+(	O
+1B	O
+).	O
+
+CONCLUSIONS	O
+:	O
+There	O
+was	O
+strong	O
+agreement	O
+among	O
+a	O
+large	O
+cohort	O
+of	O
+international	O
+experts	O
+regarding	O
+many	O
+level	O
+1	O
+recommendations	O
+for	O
+the	O
+best	O
+current	O
+care	O
+of	O
+patients	O
+with	O
+severe	B-DISO
+sepsis	I-DISO
+.	O
+
+TITLE	O
+:	O
+Differential	B-PROC
+gene	I-PROC
+expression	I-PROC
+profiles	O
+in	O
+acute	B-DISO
+hepatic	I-DISO
+failure	I-DISO
+model	O
+in	O
+mice	B-SPEC
+infected	O
+with	O
+MHV	B-SPEC
+-	O
+3	O
+virus	B-SPEC
+intervened	O
+by	O
+anti	O
+-	O
+hepatic	B-DISO
+failure	I-DISO
+compound	O
+.	O
+
+TITLE	O
+:	O
+Angiotensin	B-CHED
+-	I-PRGE
+converting	I-PRGE
+enzyme	I-PRGE
+insertion	O
+/	O
+deletion	O
+polymorphism	B-PROC
+is	O
+not	O
+associated	O
+with	O
+susceptibility	O
+and	O
+outcome	O
+in	O
+sepsis	O
+and	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+.	O
+
+ABSTRACT	O
+:	O
+The	O
+insertion	O
+/	O
+deletion	O
+(	O
+I	O
+/	O
+D	O
+)	O
+of	O
+a	O
+289	O
+base	B-FUNC
+pair	I-FUNC
+Alu	O
+repeat	O
+sequence	O
+polymorphism	B-PROC
+in	O
+the	O
+angiotensin	B-PRGE
+-	I-PRGE
+converting	I-PRGE
+enzyme	I-PRGE
+gene	I-PRGE
+(	O
+ACE	B-PRGE
+)	O
+has	O
+been	O
+shown	O
+to	O
+predict	O
+susceptibility	O
+and	O
+outcome	O
+in	O
+the	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+(	O
+ARDS	B-DISO
+).	O
+
+TITLE	O
+:	O
+Human	B-SPEC
+monoclonal	O
+antibodies	B-COMP
+by	O
+immortalization	O
+of	O
+memory	B-PROC
+B	B-ANAT
+cells	I-ANAT
+.	O
+
+Retrospectively	O
+,	O
+74	O
+patients	O
+with	O
+acute	O
+traumatic	O
+aortic	B-DISO
+rupture	I-DISO
+were	O
+analyzed	O
+.	O
+
+Ten	O
+surgical	O
+complications	O
+occurred	O
+in	O
+5	O
+patients	O
+:	O
+respiratory	B-DISO
+insufficiency	I-DISO
+(	O
+n	O
+=	O
+3	O
+),	O
+pulmonary	B-DISO
+infection	I-DISO
+(	O
+n	O
+=	O
+2	O
+),	O
+recurrent	O
+nerve	B-DISO
+palsy	I-DISO
+(	O
+n	O
+=	O
+2	O
+),	O
+repeat	O
+thoracotomy	O
+(	O
+n	O
+=	O
+2	O
+),	O
+and	O
+compartment	B-DISO
+syndrome	I-DISO
+(	O
+n	O
+=	O
+1	O
+).	O
+
+Except	O
+for	O
+one	O
+case	O
+,	O
+which	O
+required	O
+conversion	O
+to	O
+conventional	O
+surgery	O
+,	O
+stent	O
+-	O
+graft	B-ANAT
+implantation	B-PROC
+was	O
+successful	O
+in	O
+all	O
+cases	O
+,	O
+without	O
+peri	O
+-	O
+interventional	O
+complications	O
+or	O
+procedure	O
+-	O
+induced	O
+paraplegia	B-DISO
+.	O
+
+Two	O
+patients	O
+underwent	O
+surgical	O
+repair	B-PROC
+15	O
+days	O
+and	O
+4	O
+months	O
+after	O
+endografting	O
+because	O
+of	O
+injury	O
+of	O
+the	O
+aortic	B-ANAT
+wall	I-ANAT
+by	O
+the	O
+stent	O
+and	O
+development	B-PROC
+of	O
+a	O
+spurious	B-DISO
+aneurysm	I-DISO
+,	O
+respectively	O
+.	O
+
+Benefits	O
+in	O
+recognizing	O
+mild	O
+cases	O
+of	O
+TRALI	B-DISO
+include	O
+quantifying	O
+the	O
+true	O
+incidence	O
+of	O
+TRALI	B-DISO
+,	O
+understanding	O
+the	O
+physiology	O
+of	O
+mild	O
+versus	O
+severe	O
+TRALI	O
+,	O
+and	O
+preventing	O
+subsequent	O
+cases	O
+of	O
+TRALI	B-DISO
+due	O
+to	O
+donors	O
+found	O
+to	O
+have	O
+HLA	B-PRGE
+antibodies	B-COMP
+.	O
+
+TITLE	O
+:	O
+Comparison	O
+of	O
+acute	O
+non	O
+-	O
+haemolytic	O
+transfusion	B-DISO
+reactions	I-DISO
+in	O
+female	O
+and	O
+male	O
+patients	O
+receiving	O
+female	O
+or	O
+male	O
+blood	O
+components	O
+.	O
+
+The	O
+patients	O
+and	O
+196	O
+donors	O
+of	O
+suspect	O
+blood	O
+products	O
+were	O
+screened	O
+for	O
+antibodies	B-COMP
+to	O
+HLA	B-PRGE
+Class	B-SPEC
+I	I-PRGE
+,	O
+HLA	B-PRGE
+Class	B-SPEC
+II	O
+,	O
+granulocytes	B-ANAT
+,	O
+and	O
+platelets	B-ANAT
+.	O
+
+Non	O
+-	O
+HLA	B-PRGE
+antibodies	B-COMP
+were	O
+significantly	O
+associated	O
+with	O
+severe	O
+reactions	O
+in	O
+females	O
+.	O
+
+Here	O
+,	O
+the	O
+immunogenicity	O
+of	O
+a	O
+novel	O
+antigenic	O
+domain	O
+found	O
+on	O
+the	O
+carboxy	B-CHED
+-	O
+terminal	O
+of	O
+the	O
+spike	O
+protein	B-CHED
+characterized	O
+by	O
+the	O
+peptide	B-CHED
+motif	O
+GPRLQPY	O
+,	O
+was	O
+evaluated	O
+.	O
+
+The	O
+maximal	O
+radiographic	O
+score	O
+correlated	O
+best	O
+with	O
+the	O
+percentage	O
+of	O
+lymphocytes	B-ANAT
+in	O
+a	O
+leukocyte	B-ANAT
+count	O
+(	O
+p	O
+<	O
+0	O
+.	O
+001	O
+),	O
+while	O
+the	O
+second	O
+most	O
+significant	O
+factor	O
+was	O
+the	O
+number	O
+of	O
+hospitalized	O
+days	O
+(	O
+p	O
+<	O
+0	O
+.	O
+001	O
+)	O
+and	O
+the	O
+third	O
+most	O
+significant	O
+factor	O
+was	O
+the	O
+absolute	O
+lymphocyte	B-ANAT
+count	O
+(	O
+p	O
+=	O
+0	O
+.	O
+013	O
+).	O
+
+The	O
+mean	O
+radiographic	O
+scores	O
+of	O
+the	O
+patients	O
+who	O
+died	B-PROC
+,	O
+with	O
+comorbidities	O
+and	O
+without	O
+a	O
+comorbidity	O
+were	O
+11	O
+.	O
+1	O
+,	O
+6	O
+.	O
+3	O
+and	O
+2	O
+.	O
+9	O
+,	O
+respectively	O
+(	O
+p	O
+=	O
+0	O
+.	O
+032	O
+).	O
+
+Intravenous	O
+gasoline	O
+injection	O
+causes	O
+major	O
+injury	O
+to	O
+the	O
+lungs	B-ANAT
+,	O
+the	O
+organ	B-ANAT
+bearing	O
+the	O
+first	O
+capillary	B-ANAT
+bed	I-ANAT
+encountered	O
+.	O
+
+ABSTRACT	O
+:	O
+To	O
+analyze	O
+antigenic	O
+structure	O
+of	O
+the	O
+spike	O
+(	O
+S	O
+)	O
+protein	B-CHED
+of	O
+Porcine	B-SPEC
+epidemic	I-SPEC
+diarrhea	I-SPEC
+virus	I-SPEC
+(	O
+PEDV	B-SPEC
+),	O
+the	O
+gene	O
+encoding	O
+its	O
+major	O
+immunodominant	O
+region	O
+S1	O
+was	O
+amplified	O
+by	O
+PCR	O
+.	O
+
+The	O
+monkeys	B-SPEC
+were	O
+inoculated	O
+into	O
+the	O
+trachea	B-DISO
+with	O
+NS	O
+-	O
+I	O
+strain	O
+of	O
+SARS	B-DISO
+-	O
+CoV	O
+and	O
+the	O
+clinical	O
+manifestation	O
+of	O
+the	O
+illness	O
+was	O
+monitored	O
+.	O
+
+The	O
+results	O
+showed	O
+that	O
+the	O
+monkeys	B-SPEC
+infected	O
+with	O
+SARS	B-DISO
+-	O
+CoV	O
+developed	O
+the	O
+typical	O
+SARS	B-DISO
+according	O
+to	O
+clinical	O
+,	O
+virological	O
+,	O
+and	O
+pathological	O
+findings	O
+.	O
+
+In	O
+addition	O
+to	O
+full	O
+-	O
+length	O
+S	O
+of	O
+SL	O
+-	O
+CoV	O
+and	O
+SARS	B-DISO
+-	O
+CoV	O
+,	O
+a	O
+series	O
+of	O
+S	O
+chimeras	O
+was	O
+constructed	O
+by	O
+inserting	O
+different	O
+sequences	O
+of	O
+the	O
+SARS	B-DISO
+-	O
+CoV	O
+S	O
+into	O
+the	O
+SL	O
+-	O
+CoV	O
+S	O
+backbone	B-ANAT
+.	O
+
+First	O
+,	O
+the	O
+SL	O
+-	O
+CoV	O
+S	O
+was	O
+unable	O
+to	O
+use	O
+any	O
+of	O
+the	O
+three	O
+ACE2	B-PRGE
+molecules	I-PRGE
+as	O
+its	O
+receptor	O
+.	O
+
+Second	O
+,	O
+the	O
+SARS	B-PRGE
+-	I-PRGE
+CoV	I-PRGE
+S	I-PRGE
+failed	O
+to	O
+enter	O
+cells	B-COMP
+expressing	O
+the	O
+bat	B-PRGE
+ACE2	I-PRGE
+.	O
+
+Third	O
+,	O
+the	O
+chimeric	O
+S	O
+covering	O
+the	O
+previously	O
+defined	O
+receptor	O
+-	O
+binding	B-FUNC
+domain	O
+gained	O
+its	O
+ability	O
+to	O
+enter	O
+cells	B-COMP
+via	O
+human	B-PRGE
+ACE2	I-PRGE
+,	O
+albeit	O
+with	O
+different	O
+efficiencies	O
+for	O
+different	O
+constructs	O
+.	O
+
+Fourth	O
+,	O
+a	O
+minimal	O
+insert	O
+region	O
+(	O
+amino	B-CHED
+acids	I-CHED
+310	O
+to	O
+518	O
+)	O
+was	O
+found	O
+to	O
+be	O
+sufficient	O
+to	O
+convert	O
+the	O
+SL	O
+-	O
+CoV	O
+S	O
+from	O
+non	O
+-	O
+ACE2	B-PRGE
+binding	B-FUNC
+to	O
+human	B-PRGE
+ACE2	I-PRGE
+binding	B-FUNC
+,	O
+indicating	O
+that	O
+the	O
+SL	O
+-	O
+CoV	O
+S	O
+is	O
+largely	O
+compatible	O
+with	O
+SARS	B-PRGE
+-	I-PRGE
+CoV	I-PRGE
+S	I-PRGE
+protein	B-CHED
+both	O
+in	O
+structure	O
+and	O
+in	O
+function	O
+.	O
+
+ABSTRACT	O
+:	O
+Two	O
+main	O
+types	O
+of	O
+safety	O
+procedures	O
+must	O
+be	O
+applied	O
+to	O
+biological	O
+products	O
+,	O
+including	O
+plasma	O
+derivatives	O
+:	O
+(	O
+i	O
+)	O
+preventive	O
+procedures	O
+and	O
+(	O
+ii	O
+)	O
+elimination	B-PROC
+procedures	O
+.	O
+
+Other	O
+inactivation	B-DISO
+procedures	O
+such	O
+as	O
+pasteurization	O
+,	O
+dry	O
+-	O
+heat	O
+or	O
+nanofiltration	O
+may	O
+prove	O
+equally	O
+effective	O
+.	O
+
+ABSTRACT	O
+:	O
+Immunocompetent	O
+,	O
+but	O
+not	O
+RAG1	B-PRGE
+(-/-)	O
+mice	B-SPEC
+infected	O
+with	O
+MHV	B-SPEC
+-	O
+JHM	O
+develop	O
+demyelination	B-DISO
+.	O
+
+TITLE	O
+:	O
+Isolation	O
+of	O
+inhibitory	O
+RNA	O
+aptamers	O
+against	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+(	O
+SARS	B-DISO
+)	O
+coronavirus	B-SPEC
+NTPase	B-PRGE
+/	O
+Helicase	B-PRGE
+.	O
+
+ABSTRACT	O
+:	O
+Recent	O
+outbreak	O
+of	O
+Severe	B-DISO
+Acute	I-DISO
+Respiratory	I-DISO
+Syndrome	I-DISO
+(	O
+SARS	B-DISO
+)	O
+that	O
+caused	O
+almost	O
+800	O
+victims	O
+requires	O
+a	O
+development	B-PROC
+of	O
+efficient	O
+inhibitor	B-CHED
+against	O
+SARS	B-DISO
+coronavirus	B-SPEC
+(	O
+SCV	B-SPEC
+).	O
+
+We	O
+believe	O
+this	O
+to	O
+be	O
+the	O
+first	O
+report	O
+suggesting	O
+a	O
+role	O
+for	O
+caesarean	O
+section	O
+,	O
+performed	O
+with	O
+the	O
+aim	O
+of	O
+an	O
+improvement	O
+in	O
+maternal	O
+respiratory	B-PROC
+function	I-PROC
+,	O
+at	O
+such	O
+an	O
+early	O
+point	O
+in	O
+pregnancy	O
+.	O
+
+Parvovirus	B-DISO
+was	O
+only	O
+detected	O
+in	O
+one	O
+healthy	O
+dog	B-SPEC
+(	O
+0	O
+.	O
+5	O
+per	O
+cent	O
+),	O
+thus	O
+with	O
+a	O
+prevalence	O
+that	O
+was	O
+significantly	O
+lower	O
+than	O
+16	O
+.	O
+0	O
+per	O
+cent	O
+detected	O
+in	O
+the	O
+dogs	B-SPEC
+with	O
+acute	O
+haemorrhagic	B-DISO
+diarrhoea	I-DISO
+(	O
+P	O
+<	O
+0	O
+.	O
+001	O
+).	O
+
+ABSTRACT	O
+:	O
+Pneumocystis	B-DISO
+pneumonia	I-DISO
+usually	O
+occurs	O
+in	O
+immunosuppressed	O
+individuals	O
+,	O
+generally	O
+those	O
+with	O
+underlying	O
+T	B-ANAT
+-	I-ANAT
+lymphocyte	I-ANAT
+disorders	O
+.	O
+
+Six	O
+patients	O
+received	O
+corticotherapy	O
+for	O
+alcoholic	B-DISO
+hepatitis	I-DISO
+treatment	O
+before	O
+the	O
+diagnosis	O
+of	O
+Pneumocystis	B-DISO
+pneumonia	I-DISO
+.	O
+
+Chronic	B-DISO
+alcoholism	I-DISO
+and	O
+alcoholic	B-DISO
+liver	I-DISO
+disease	I-DISO
+are	O
+both	O
+associated	O
+with	O
+an	O
+important	O
+degree	O
+of	O
+immunosuppression	B-PROC
+.	O
+
+The	O
+preliminary	O
+and	O
+yet	O
+alarming	O
+conclusion	O
+may	O
+be	O
+that	O
+,	O
+in	O
+high	O
+-	O
+rise	O
+buildings	O
+,	O
+windows	O
+flush	B-DISO
+with	O
+a	O
+flat	O
+façade	O
+can	O
+be	O
+a	O
+major	O
+route	O
+for	O
+the	O
+vertical	O
+spread	O
+of	O
+pathogen	O
+-	O
+containing	O
+aerosols	O
+.	O
+
+The	O
+structure	O
+-	O
+based	O
+optimization	O
+of	O
+N3	O
+has	O
+yielded	O
+two	O
+more	O
+efficacious	O
+lead	B-CHED
+compounds	I-CHED
+,	O
+N27	O
+and	O
+H16	O
+,	O
+with	O
+potent	O
+inhibition	B-PROC
+against	O
+SARS	B-PRGE
+-	I-PRGE
+CoV	I-PRGE
+M	I-PRGE
+(	I-PRGE
+pro	B-CHED
+).	I-PRGE
+
+TITLE	O
+:	O
+The	O
+spike	O
+protein	B-CHED
+of	O
+infectious	B-DISO
+bronchitis	B-DISO
+virus	B-SPEC
+is	O
+retained	O
+intracellularly	O
+by	O
+a	O
+tyrosine	B-CHED
+motif	O
+.	O
+
+Deletion	O
+of	O
+a	O
+dilysine	O
+motif	O
+that	O
+has	O
+previously	O
+been	O
+suggested	O
+to	O
+function	O
+as	O
+a	O
+retrieval	O
+signal	O
+did	O
+not	O
+abolish	O
+intracellular	B-PROC
+retention	I-PROC
+.	O
+
+Treatment	O
+of	O
+the	O
+S	O
+proteins	B-CHED
+with	O
+endoglycosidases	O
+did	O
+not	O
+reveal	O
+any	O
+differences	O
+between	O
+the	O
+parental	O
+and	O
+the	O
+mutant	B-DISO
+proteins	B-CHED
+.	O
+
+Taken	O
+together	O
+,	O
+these	O
+results	O
+indicate	O
+that	O
+the	O
+S	B-PRGE
+protein	I-PRGE
+of	O
+IBV	B-SPEC
+is	O
+retained	O
+at	O
+a	O
+late	B-COMP
+Golgi	I-COMP
+compartment	B-ANAT
+.	O
+
+However	O
+,	O
+NKG2D	B-PRGE
+neutralization	O
+increased	O
+viral	O
+titers	O
+within	O
+the	O
+liver	B-ANAT
+,	O
+suggesting	O
+a	O
+protective	O
+role	O
+for	O
+NKG2D	B-PRGE
+signaling	B-PROC
+in	O
+this	O
+organ	B-ANAT
+.	O
+
+These	O
+data	O
+indicate	O
+that	O
+(	O
+i	O
+)	O
+CXCL10	B-PRGE
+enhances	O
+innate	B-DISO
+immune	I-DISO
+responses	I-DISO
+,	O
+resulting	O
+in	O
+protection	O
+from	O
+MHV	B-SPEC
+-	O
+induced	O
+neurological	O
+and	O
+liver	B-DISO
+disease	I-DISO
+;	O
+(	O
+ii	O
+)	O
+elevated	O
+NK	B-PRGE
+cell	I-PRGE
+IFN	I-PRGE
+-	I-PRGE
+gamma	I-PRGE
+expression	B-PROC
+in	O
+the	O
+brain	B-ANAT
+of	O
+MHV	B-SPEC
+-	O
+CXCL10	O
+-	O
+infected	O
+mice	B-SPEC
+occurs	O
+independently	O
+of	O
+NKG2D	B-PRGE
+;	O
+and	O
+(	O
+iii	O
+)	O
+NKG2D	B-PRGE
+signaling	B-PROC
+promotes	O
+antiviral	B-CHED
+activity	O
+within	O
+the	O
+livers	B-ANAT
+of	O
+MHV	B-SPEC
+-	O
+infected	O
+mice	B-SPEC
+that	O
+is	O
+not	O
+dependent	O
+on	O
+IFN	B-PRGE
+-	I-PRGE
+gamma	I-PRGE
+and	O
+tumor	B-PRGE
+necrosis	I-PRGE
+factor	I-PRGE
+alpha	I-PRGE
+secretion	B-PROC
+.	O
+
+CD4	B-PRGE
+(+)	O
+T	B-ANAT
+cells	I-ANAT
+provide	O
+an	O
+auxiliary	O
+function	O
+(	O
+s	O
+)	O
+for	O
+CD8	B-PRGE
+(+)	O
+T	B-ANAT
+-	I-ANAT
+cell	I-ANAT
+survival	O
+;	O
+however	O
+,	O
+their	O
+direct	O
+contribution	O
+to	O
+control	O
+of	O
+virus	B-PROC
+replication	I-PROC
+and	O
+pathology	B-DISO
+is	O
+unclear	O
+.	O
+
+Local	O
+release	B-PATH
+of	O
+IFN	B-PRGE
+-	I-PRGE
+gamma	I-PRGE
+was	O
+evident	O
+by	O
+up	B-PROC
+-	I-PROC
+regulation	I-PROC
+of	O
+class	B-SPEC
+II	O
+molecules	O
+on	O
+microglia	B-ANAT
+in	O
+recipients	O
+of	O
+IFN	B-PRGE
+-	I-PRGE
+gamma	I-PRGE
+producing	O
+CD4	B-PRGE
+(+)	O
+T	B-ANAT
+cells	I-ANAT
+.	O
+
+ABSTRACT	O
+:	O
+In	O
+2003	O
+,	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+coronavirus	B-SPEC
+(	O
+SARS	B-DISO
+-	O
+CoV	O
+)	O
+emerged	O
+and	O
+caused	O
+over	O
+8	O
+,	O
+000	O
+human	B-SPEC
+cases	O
+of	O
+infection	B-DISO
+and	O
+more	O
+than	O
+700	O
+deaths	B-PROC
+worldwide	O
+.	O
+
+Using	O
+synthetic	O
+biology	O
+,	O
+we	O
+engineered	O
+the	O
+spike	O
+protein	B-CHED
+(	O
+S	O
+)	O
+from	O
+a	O
+civet	B-SPEC
+strain	O
+,	O
+SZ16	O
+,	O
+into	O
+our	O
+epidemic	O
+strain	O
+infectious	B-DISO
+clone	O
+,	O
+creating	O
+the	O
+chimeric	O
+virus	B-SPEC
+icSZ16	O
+-	O
+S	O
+,	O
+which	O
+was	O
+infectious	B-DISO
+but	O
+yielded	O
+progeny	O
+viruses	B-SPEC
+incapable	O
+of	O
+propagating	O
+in	O
+vitro	O
+.	O
+
+TITLE	O
+:	O
+[	O
+Techniques	O
+used	O
+for	O
+the	O
+diagnostic	O
+of	O
+upper	O
+and	O
+lower	B-ANAT
+respiratory	I-ANAT
+tract	I-ANAT
+viral	B-DISO
+infections	I-DISO
+].	O
+
+To	O
+look	O
+for	O
+viruses	B-SPEC
+which	O
+are	O
+non	O
+detectable	O
+by	O
+antigen	B-CHED
+detection	O
+assays	O
+(	O
+rhinovirus	B-SPEC
+,	O
+coronavirus	B-SPEC
+,	O
+bocavirus	B-SPEC
+,	O
+polyomavirus	B-SPEC
+...)	O
+or	O
+in	O
+severe	O
+or	O
+complicated	O
+respiratory	O
+lower	O
+infections	B-DISO
+,	O
+the	O
+use	O
+of	O
+molecular	O
+tools	O
+is	O
+highly	O
+indicated	O
+.	O
+
+RESULTS	O
+:	O
+Our	O
+heuristic	O
+staging	O
+model	O
+provides	O
+valuable	O
+information	O
+about	O
+the	O
+features	O
+of	O
+a	O
+biological	O
+event	O
+that	O
+can	O
+be	O
+used	O
+to	O
+determine	O
+the	O
+level	O
+of	O
+concern	O
+warranted	O
+,	O
+such	O
+as	O
+whether	O
+the	O
+pathogen	O
+in	O
+question	O
+is	O
+responding	O
+to	O
+established	O
+public	O
+health	O
+disease	O
+control	O
+measures	O
+,	O
+including	O
+the	O
+use	O
+of	O
+antimicrobials	B-CHED
+or	O
+vaccines	O
+;	O
+whether	O
+the	O
+public	O
+health	O
+and	O
+medical	O
+infrastructure	O
+of	O
+the	O
+country	O
+involved	O
+is	O
+adequate	O
+to	O
+mount	O
+the	O
+necessary	O
+response	O
+;	O
+whether	O
+the	O
+country	O
+'	O
+s	O
+officials	O
+are	O
+providing	O
+an	O
+appropriate	O
+level	O
+of	O
+information	O
+to	O
+international	O
+public	O
+health	O
+authorities	O
+;	O
+and	O
+whether	O
+the	O
+event	O
+poses	O
+a	O
+international	O
+threat	O
+.	O
+
+TITLE	O
+:	O
+Retrospective	O
+study	O
+of	O
+severe	O
+cases	O
+of	O
+leptospirosis	B-DISO
+admitted	O
+in	O
+the	O
+intensive	O
+care	O
+unit	O
+.	O
+
+These	O
+results	O
+suggested	O
+that	O
+HNA	B-PRGE
+-	I-PRGE
+2a	I-PRGE
+salvaged	O
+the	O
+inhibition	B-PROC
+process	O
+of	O
+natural	O
+phagocytosis	B-PROC
+by	O
+anti	B-PRGE
+-	I-PRGE
+FcgammaRIII	I-PRGE
+antibodies	I-PRGE
+.	O
+
+TITLE	O
+:	O
+Extrapulmonary	O
+ventilation	O
+for	O
+unresponsive	O
+severe	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+after	O
+pulmonary	O
+resection	O
+.	O
+
+2	O
+.	O
+5	O
+days	O
+,	O
+and	O
+replaced	O
+only	O
+once	O
+for	O
+massive	O
+clotting	B-PROC
+.	O
+
+0	O
+.	O
+36	O
+L	O
+/	O
+min	O
+of	O
+the	O
+cardiac	B-ANAT
+output	O
+perfused	O
+the	O
+device	O
+,	O
+without	O
+hemodynamic	B-PROC
+impairment	B-DISO
+.	O
+
+All	O
+but	O
+1	O
+patient	O
+(	O
+14	O
+%)	O
+who	O
+died	B-PROC
+of	O
+multiorgan	B-DISO
+failure	I-DISO
+were	O
+weaned	B-PROC
+from	O
+mechanical	O
+ventilation	O
+8	O
++/-	O
+
+These	O
+findings	O
+document	O
+that	O
+TB	O
+contains	O
+multiple	O
+lipids	B-CHED
+that	O
+can	O
+directly	O
+impair	O
+the	O
+biophysical	O
+function	O
+of	O
+endogenous	O
+and	O
+exogenous	O
+lung	B-ANAT
+surfactants	B-CHED
+.	O
+
+TITLE	O
+:	O
+Cell	B-ANAT
+type	I-ANAT
+-	O
+specific	O
+cleavage	B-PROC
+of	O
+nucleocapsid	B-PRGE
+protein	B-CHED
+by	O
+effector	B-CHED
+caspases	O
+during	O
+SARS	B-DISO
+coronavirus	B-SPEC
+infection	I-DISO
+.	O
+
+In	O
+Caco	O
+-	O
+2	O
+and	O
+N2a	O
+cells	B-COMP
+,	O
+almost	O
+no	O
+N	O
+-	O
+processing	O
+was	O
+detectable	O
+.	O
+
+Our	O
+purpose	O
+is	O
+not	O
+to	O
+defend	O
+or	O
+criticise	O
+this	O
+account	O
+,	O
+but	O
+to	O
+show	O
+that	O
+it	O
+needs	O
+to	O
+be	O
+developed	O
+in	O
+order	B-SPEC
+to	O
+address	O
+three	O
+important	O
+issues	O
+.	O
+
+In	O
+this	O
+review	O
+,	O
+some	O
+of	O
+the	O
+notable	O
+achievements	O
+made	O
+by	O
+SARS	B-DISO
+structural	O
+biology	O
+projects	O
+worldwide	O
+are	O
+examined	O
+and	O
+strategies	O
+for	O
+therapeutic	O
+intervention	O
+are	O
+discussed	O
+based	O
+on	O
+available	O
+SARS	B-PRGE
+-	I-PRGE
+CoV	I-PRGE
+protein	B-CHED
+structures	O
+.	O
+
+Recommendations	O
+specific	O
+to	O
+pediatric	O
+severe	B-DISO
+sepsis	I-DISO
+include	O
+greater	O
+use	O
+of	O
+physical	O
+examination	O
+therapeutic	O
+end	O
+points	O
+(	O
+2C	O
+);	O
+dopamine	B-CHED
+as	O
+the	O
+first	O
+drug	O
+of	O
+choice	O
+for	O
+hypotension	O
+(	O
+2C	O
+);	O
+steroids	B-CHED
+only	O
+in	O
+children	O
+with	O
+suspected	O
+or	O
+proven	O
+adrenal	B-DISO
+insufficiency	I-DISO
+(	O
+2C	O
+);	O
+and	O
+a	O
+recommendation	O
+against	O
+the	O
+use	O
+of	O
+recombinant	B-PRGE
+activated	I-PRGE
+protein	I-PRGE
+C	I-PRGE
+in	O
+children	O
+(	O
+1B	O
+).	O
+
+TITLE	O
+:	O
+Mannan	B-CHED
+-	I-PRGE
+binding	B-FUNC
+lectin	I-PRGE
+(	O
+MBL	B-PRGE
+)	O
+serum	B-COMP
+concentration	O
+in	O
+relation	O
+to	O
+propagation	O
+of	O
+infectious	B-DISO
+bronchitis	B-DISO
+virus	B-SPEC
+(	O
+IBV	B-SPEC
+)	O
+in	O
+chickens	B-SPEC
+.	O
+
+In	O
+addition	O
+,	O
+macrophage	B-ANAT
+infiltration	B-DISO
+into	O
+the	O
+CNS	B-CHED
+was	O
+unaffected	O
+in	O
+MHV	B-SPEC
+-	O
+infected	O
+CCR1	B-PRGE
+-/-	O
+mice	B-SPEC
+when	O
+compared	O
+to	O
+CCR1	O
++/+	O
+mice	B-SPEC
+.	O
+
+TITLE	O
+:	O
+Innovation	O
+and	O
+challenges	O
+in	O
+funding	O
+rapid	O
+research	O
+responses	O
+to	O
+emerging	B-DISO
+infectious	I-DISO
+diseases	I-DISO
+:	O
+Lessons	O
+learned	B-PROC
+from	O
+the	O
+outbreak	O
+of	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+.	O
+
+DPO	B-PRGE
+-	O
+based	O
+mRT	B-ANAT
+-	O
+PCR	O
+was	O
+found	O
+as	O
+a	O
+sensitive	O
+tool	O
+for	O
+the	O
+detection	O
+of	O
+the	O
+viruses	B-SPEC
+that	O
+cause	O
+childhood	O
+respiratory	B-DISO
+infections	I-DISO
+.	O
+
+A	O
+total	O
+of	O
+129	O
+viruses	B-SPEC
+were	O
+identified	O
+:	O
+respiratory	B-SPEC
+syncytial	I-SPEC
+virus	I-SPEC
+A	O
+/	O
+B	O
+(	O
+38	O
+.	O
+0	O
+%/	O
+7	O
+.	O
+8	O
+%),	O
+influenza	B-SPEC
+virus	I-SPEC
+A	O
+/	O
+B	O
+(	O
+10	O
+.	O
+1	O
+%/	O
+5	O
+.	O
+4	O
+%),	O
+parainfluenza	B-DISO
+virus	B-SPEC
+1	O
+/	O
+2	O
+/	O
+3	O
+(	O
+7	O
+.	O
+0	O
+%/	O
+3	O
+.	O
+1	O
+%/	O
+7	O
+.	O
+8	O
+%),	O
+coronavirus	B-SPEC
+229E	O
+or	O
+NL63	O
+(	O
+6	O
+.	O
+2	O
+%),	O
+human	B-SPEC
+metapneumovirus	I-SPEC
+(	O
+4	O
+.	O
+7	O
+%),	O
+adenovirus	B-DISO
+(	O
+4	O
+.	O
+7	O
+%),	O
+rhinovirus	B-SPEC
+(	O
+3	O
+.	O
+9	O
+%),	O
+and	O
+coronavirus	B-SPEC
+OC43	O
+(	O
+1	O
+.	O
+6	O
+%).	O
+
+ABSTRACT	O
+:	O
+Gemcitabine	B-CHED
+is	O
+a	O
+new	O
+important	O
+drug	O
+used	O
+to	O
+treat	O
+solid	B-DISO
+tumors	I-DISO
+including	O
+non	B-PATH
+-	I-PATH
+small	I-PATH
+cell	I-PATH
+lung	B-ANAT
+cancer	B-SPEC
+,	O
+pancreatic	B-ANAT
+,	O
+bladder	B-ANAT
+and	O
+breast	B-DISO
+cancers	I-DISO
+.	O
+
+TITLE	O
+:	O
+Comparison	O
+of	O
+effectiveness	O
+of	O
+whole	O
+viral	O
+,	O
+N	O
+and	O
+N199	O
+proteins	B-CHED
+by	O
+ELISA	O
+for	O
+the	O
+rapid	O
+diagnosis	O
+of	O
+severe	O
+acute	O
+respiratory	O
+syndrome	O
+coronavirus	B-SPEC
+.	O
+
+CONCLUSIONS	O
+:	O
+N199	O
+protein	B-CHED
+is	O
+feasible	O
+in	O
+both	O
+clinical	O
+diagnosis	O
+and	O
+SARS	B-DISO
+-	O
+CoV	O
+reservoir	O
+screening	O
+.	O
+
+DMSO	B-CHED
+,	O
+the	O
+solvent	B-CHED
+for	O
+the	O
+ethylene	B-CHED
+vinyl	B-CHED
+alcohol	O
+copolymer	B-CHED
+,	O
+is	O
+excreted	O
+via	O
+the	O
+lungs	B-ANAT
+after	O
+administration	O
+and	O
+we	O
+postulate	O
+that	O
+DMSO	B-CHED
+was	O
+the	O
+possible	O
+cause	O
+of	O
+ARDS	B-DISO
+in	O
+this	O
+patient	O
+.	O
+
+Monitoring	O
+of	O
+haemodynamic	O
+parameters	O
+(	O
+invasive	O
+blood	B-PROC
+pressure	I-PROC
+,	O
+electrocardiography	O
+)	O
+and	O
+ventilatory	O
+parameters	O
+(	O
+ETCO2	O
+,	O
+SpO2	O
+,	O
+airway	B-ANAT
+pressure	O
+monitoring	O
+)	O
+are	O
+important	O
+in	O
+the	O
+recognition	O
+of	O
+this	O
+possible	O
+event	O
+.	O
+
+In	O
+phylogenetic	O
+analysis	O
+of	O
+the	O
+ORF	O
+7	O
+gene	O
+,	O
+Korean	O
+TGEV	B-SPEC
+strains	O
+were	O
+clustered	O
+into	O
+two	O
+groups	O
+.	O
+
+The	O
+KT2	B-PRGE
+-	I-PRGE
+H	I-PRGE
+strain	O
+exhibited	O
+a	O
+higher	O
+replication	O
+rate	O
+than	O
+KT2	O
+-	O
+L	O
+and	O
+produced	O
+a	O
+CPE	O
+distinctly	O
+different	O
+from	O
+that	O
+of	O
+the	O
+KT2	B-PRGE
+-	I-PRGE
+L	I-PRGE
+strain	O
+.	O
+
+Participants	O
+experienced	O
+a	O
+5	O
+-	O
+stage	O
+process	O
+of	O
+protecting	O
+self	O
+,	O
+family	B-SPEC
+,	O
+and	O
+others	O
+,	O
+responding	O
+according	O
+to	O
+the	O
+perceived	O
+threat	O
+of	O
+SARS	B-DISO
+.	O
+
+However	O
+,	O
+a	O
+small	O
+number	O
+of	O
+rare	O
+and	O
+highly	O
+contagious	O
+agents	O
+can	O
+initially	O
+present	O
+as	O
+febrile	B-PROC
+respiratory	O
+illnesses	O
+,	O
+which	O
+can	O
+lead	O
+to	O
+an	O
+epidemic	O
+that	O
+can	O
+greatly	O
+impact	O
+the	O
+health	O
+care	O
+system	O
+.	O
+
+Acute	B-DISO
+respiratory	I-DISO
+failure	I-DISO
+and	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+occur	O
+with	O
+these	O
+agents	O
+,	O
+so	O
+a	O
+lung	B-ANAT
+-	O
+protective	O
+(	O
+low	O
+tidal	O
+volume	O
+)	O
+ventilation	O
+strategy	O
+is	O
+indicated	O
+.	O
+
+TITLE	O
+:	O
+Pulmonary	B-ANAT
+hypertension	I-DISO
+and	O
+cor	B-DISO
+pulmonale	I-DISO
+during	O
+severe	O
+acute	B-DISO
+chest	B-ANAT
+syndrome	I-DISO
+in	I-DISO
+sickle	B-ANAT
+cell	I-ANAT
+disease	I-DISO
+.	O
+
+The	O
+aim	O
+of	O
+the	O
+present	O
+study	O
+was	O
+to	O
+evaluate	O
+changes	O
+in	O
+pulmonary	B-ANAT
+pressures	O
+and	O
+cardiac	B-ANAT
+biomarkers	O
+during	O
+severe	O
+acute	B-DISO
+chest	I-DISO
+syndrome	I-DISO
+and	O
+their	O
+associations	O
+with	O
+mortality	O
+.	O
+
+Pulmonary	B-ANAT
+pressures	O
+increase	O
+during	O
+severe	O
+acute	B-DISO
+chest	I-DISO
+syndrome	I-DISO
+,	O
+and	O
+pulmonary	B-DISO
+hypertension	I-DISO
+is	O
+associated	O
+with	O
+cardiac	B-ANAT
+biomarker	B-CHED
+elevation	O
+and	O
+a	O
+higher	O
+risk	O
+of	O
+death	B-PROC
+.	O
+
+Together	O
+rhinoviruses	B-SPEC
+,	O
+coronaviruses	O
+,	O
+HMPV	B-SPEC
+,	O
+and	O
+HBoV	O
+accounted	O
+for	O
+60	O
+%	O
+(	O
+65	O
+of	O
+109	O
+)	O
+of	O
+viruses	B-SPEC
+.	O
+
+Rhinoviruses	B-SPEC
+,	O
+coronaviruses	O
+,	O
+HMPV	B-SPEC
+,	O
+and	O
+HBoV	O
+are	O
+common	O
+pathogens	O
+associated	O
+with	O
+respiratory	B-DISO
+symptoms	I-DISO
+in	O
+otherwise	O
+healthy	O
+infants	O
+.	O
+
+RESULTS	O
+:	O
+All	O
+112	O
+infants	O
+who	O
+had	O
+an	O
+ARI	B-CHED
+had	O
+cough	B-DISO
+,	O
+and	O
+39	O
+(	O
+35	O
+%)	O
+had	O
+wheeze	B-DISO
+.	O
+
+vaccination	O
+elicited	O
+stronger	O
+systemic	O
+and	O
+local	O
+specific	O
+cytotoxic	B-ANAT
+T	I-ANAT
+cell	I-ANAT
+responses	O
+than	O
+the	O
+i	O
+.	O
+m	O
+.	O
+
+TITLE	O
+:	O
+Learning	B-PROC
+from	O
+the	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+(	O
+SARS	B-DISO
+)	O
+epidemic	O
+.	O
+
+In	O
+examining	O
+nursing	B-PROC
+practice	O
+models	O
+within	O
+complex	O
+clinical	O
+situations	O
+,	O
+the	O
+significance	O
+lies	O
+not	O
+only	O
+in	O
+the	O
+model	O
+'	O
+s	O
+effects	O
+but	O
+also	O
+in	O
+other	O
+operational	O
+outcomes	O
+.	O
+
+Positive	O
+correlations	O
+were	O
+found	O
+for	O
+nurses	O
+'	O
+perceived	O
+infection	B-DISO
+control	O
+practice	O
+competence	O
+and	O
+their	O
+perceived	O
+caring	O
+attributes	O
+.	O
+
+Guided	O
+by	O
+the	O
+crystal	B-ANAT
+structure	O
+and	O
+molecular	B-PROC
+dynamics	I-PROC
+simulations	O
+,	O
+we	O
+performed	O
+systematic	O
+mutation	O
+analyses	O
+to	O
+identify	O
+residues	O
+critical	O
+for	O
+3CL	O
+pro	B-CHED
+dimerization	O
+and	O
+activity	O
+in	O
+this	O
+study	O
+.	O
+
+TITLE	O
+:	O
+Respiratory	B-DISO
+disease	I-DISO
+associated	O
+with	O
+bovine	B-SPEC
+coronavirus	B-DISO
+infection	I-DISO
+in	O
+cattle	B-SPEC
+herds	O
+in	O
+Southern	O
+Italy	O
+.	O
+
+A	O
+recently	O
+established	O
+real	O
+-	O
+time	O
+RT	O
+-	O
+PCR	O
+assay	O
+showed	O
+that	O
+viral	O
+RNA	O
+loads	O
+in	O
+nasal	B-ANAT
+secretions	B-ANAT
+ranged	O
+between	O
+3	O
+.	O
+10	O
+x	O
+10	O
+(	O
+2	O
+)	O
+and	O
+7	O
+.	O
+50	O
+x	O
+10	O
+(	O
+7	O
+)	O
+RNA	O
+copies	O
+/	O
+microl	O
+of	O
+template	O
+.	O
+
+New	O
+episodes	O
+of	O
+psychiatric	B-DISO
+disorders	I-DISO
+were	O
+directly	O
+associated	O
+with	O
+a	O
+history	O
+of	O
+having	O
+a	O
+psychiatric	B-DISO
+disorder	I-DISO
+before	O
+the	O
+SARS	B-DISO
+outbreak	O
+(	O
+p	O
+=.	O
+02	O
+)	O
+and	O
+inversely	O
+associated	O
+with	O
+years	O
+of	O
+health	O
+care	O
+experience	O
+(	O
+p	O
+=.	O
+03	O
+)	O
+and	O
+the	O
+perceived	O
+adequacy	O
+of	O
+training	O
+and	O
+support	O
+(	O
+p	O
+=.	O
+03	O
+).	O
+
+TITLE	O
+:	O
+An	O
+evaluation	O
+of	O
+the	O
+safety	O
+and	O
+efficacy	O
+of	O
+an	O
+anti	O
+-	O
+inflammatory	O
+,	O
+pulmonary	B-ANAT
+enteral	O
+formula	O
+in	O
+the	O
+treatment	O
+of	O
+pediatric	O
+burn	O
+patients	O
+with	O
+respiratory	O
+failure	O
+.	O
+
+Recently	O
+,	O
+a	O
+specialized	O
+pulmonary	B-ANAT
+enteral	O
+formula	O
+(	O
+SPEF	O
+)	O
+was	O
+commercially	O
+introduced	O
+as	O
+an	O
+adjunct	O
+intervention	O
+in	O
+acute	O
+lung	B-ANAT
+injury	O
+management	O
+.	O
+
+In	O
+this	O
+study	O
+,	O
+we	O
+confirmed	O
+that	O
+mouse	B-PRGE
+hepatitis	I-PRGE
+coronavirus	B-SPEC
+A59	I-PRGE
+E	I-PRGE
+protein	B-CHED
+is	O
+palmitoylated	O
+.	O
+
+Double	O
+-	O
+and	O
+triple	O
+-	O
+mutant	B-DISO
+E	O
+proteins	B-CHED
+resulted	O
+in	O
+decreased	O
+virus	B-COMP
+-	I-COMP
+like	I-COMP
+particle	I-COMP
+output	O
+when	O
+coexpressed	O
+with	O
+the	O
+membrane	B-COMP
+(	O
+M	O
+)	O
+protein	B-CHED
+.	O
+
+ABSTRACT	O
+:	O
+The	O
+coronavirus	O
+assembly	O
+process	O
+encloses	O
+a	O
+ribonucleoprotein	B-COMP
+genome	O
+into	O
+vesicles	B-COMP
+containing	O
+the	O
+lipid	B-CHED
+-	O
+embedded	O
+proteins	B-CHED
+S	O
+(	O
+spike	O
+),	O
+E	O
+(	O
+envelope	B-COMP
+),	O
+and	O
+M	O
+(	O
+membrane	B-COMP
+).	O
+
+The	O
+samples	O
+comprised	O
+95	O
+cases	O
+of	O
+recovered	O
+SARS	B-DISO
+patients	O
+and	O
+403	O
+unrelated	O
+healthy	O
+controls	O
+.	O
+
+ABSTRACT	O
+:	O
+Most	O
+coronaviruses	O
+infecting	O
+humans	B-SPEC
+cause	O
+mild	O
+diseases	O
+,	O
+whereas	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+(	O
+SARS	B-DISO
+)-	O
+associated	O
+coronavirus	B-SPEC
+is	O
+an	O
+extremely	O
+dangerous	O
+pathogen	O
+.	O
+
+Here	O
+,	O
+we	O
+report	O
+the	O
+development	B-PROC
+of	O
+a	O
+serologic	O
+assay	O
+for	O
+detection	O
+of	O
+antibodies	B-COMP
+to	O
+human	B-SPEC
+coronaviruses	O
+(	O
+HCoVs	O
+)	O
+based	O
+on	O
+recombinant	O
+nucleocapsid	B-COMP
+(	O
+N	O
+)	O
+proteins	B-CHED
+of	O
+all	O
+known	O
+pathogenic	O
+strains	O
+(	O
+229E	O
+,	O
+NL63	O
+,	O
+OC43	O
+,	O
+HKU1	O
+,	O
+SARS	B-DISO
+).	O
+
+The	O
+novel	O
+immunoassay	O
+is	O
+highly	O
+useful	O
+for	O
+epidemiologic	O
+surveys	O
+,	O
+where	O
+use	O
+of	O
+nucleic	B-CHED
+acid	I-CHED
+diagnostics	O
+often	O
+is	O
+limited	O
+.	O
+
+For	O
+assay	O
+evaluation	O
+,	O
+serum	B-COMP
+samples	O
+from	O
+persons	O
+infected	O
+with	O
+229E	O
+or	O
+OC43	O
+(	O
+acute	O
+/	O
+convalescent	O
+),	O
+recovered	O
+SARS	B-DISO
+patients	O
+and	O
+healthy	O
+donors	O
+were	O
+analyzed	O
+.	O
+
+Feline	B-DISO
+infectious	I-DISO
+peritonitis	I-DISO
+was	O
+confirmed	O
+by	O
+histology	O
+or	O
+immunostaining	O
+of	O
+feline	B-SPEC
+coronavirus	B-SPEC
+(	O
+FCoV	O
+)	O
+antigen	B-CHED
+in	O
+effusion	B-DISO
+or	O
+tissue	B-ANAT
+macrophages	B-ANAT
+or	O
+both	O
+.	O
+
+There	O
+was	O
+only	O
+1	O
+long	O
+-	O
+term	O
+survivor	O
+(>	O
+3	O
+months	O
+),	O
+and	O
+the	O
+cat	B-SPEC
+was	O
+in	O
+the	O
+FeIFN	B-PRGE
+-	I-PRGE
+omega	I-PRGE
+group	I-PRGE
+.	O
+
+The	O
+expression	B-PROC
+of	O
+viral	O
+genes	O
+in	O
+Vero	O
+-	O
+E6	O
+cells	B-COMP
+was	O
+detected	O
+by	O
+real	O
+-	O
+time	O
+PCR	O
+.	O
+
+Obtained	O
+results	O
+indicated	O
+that	O
+the	O
+majority	O
+of	O
+siRNAs	O
+could	O
+effectively	O
+inhibit	O
+the	O
+expression	B-PROC
+of	O
+viral	O
+genes	O
+.	O
+
+Amoxapine	B-CHED
+was	O
+stopped	O
+,	O
+resulting	O
+in	O
+complete	O
+resolution	O
+of	O
+the	O
+pulmonary	B-DISO
+infiltrates	I-DISO
+.	O
+
+We	O
+concluded	O
+that	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+may	O
+be	O
+associated	O
+with	O
+amoxapine	B-CHED
+treatment	O
+.	O
+
+ABSTRACT	O
+:	O
+White	O
+smoke	O
+inhalation	O
+is	O
+an	O
+uncommon	O
+but	O
+potentially	O
+deadly	O
+cause	O
+of	O
+acute	O
+lung	B-ANAT
+injury	O
+.	O
+
+The	O
+purpose	O
+of	O
+this	O
+research	O
+was	O
+to	O
+evaluate	O
+an	O
+emergency	B-DISO
+preparedness	O
+training	O
+programme	O
+and	O
+to	O
+develop	O
+a	O
+participatory	O
+training	O
+approach	O
+for	O
+emergency	B-DISO
+response	O
+.	O
+
+Seventy	O
+-	O
+six	O
+public	O
+health	O
+staff	O
+completed	O
+the	O
+emergency	B-DISO
+preparedness	O
+training	O
+programme	O
+.	O
+
+The	O
+spike	B-PRGE
+(	I-PRGE
+S	I-PRGE
+)	I-PRGE
+glycoprotein	I-PRGE
+has	O
+been	O
+identified	O
+as	O
+a	O
+major	O
+component	O
+of	O
+protective	O
+immunity	B-PROC
+,	O
+and	O
+23	O
+different	O
+amino	B-CHED
+acid	I-CHED
+changes	O
+were	O
+noted	O
+during	O
+the	O
+expanding	O
+epidemic	O
+.	O
+
+ABSTRACT	O
+:	O
+Paramyxoviruses	O
+belong	O
+to	O
+the	O
+Paramyxoviridae	O
+family	B-SPEC
+of	O
+the	O
+order	B-SPEC
+Mononegavirales	I-SPEC
+.	O
+
+The	O
+rescued	O
+viruses	B-SPEC
+grew	O
+well	O
+and	O
+were	O
+stable	O
+in	O
+embryonated	O
+chicken	B-SPEC
+eggs	O
+over	O
+multiple	O
+passages	O
+.	O
+
+We	O
+were	O
+able	O
+to	O
+detect	O
+the	O
+expression	B-PROC
+of	O
+both	O
+reporter	O
+genes	O
+in	O
+the	O
+same	O
+cell	B-COMP
+infected	O
+with	O
+the	O
+virus	B-SPEC
+possessing	O
+a	O
+segmented	O
+genome	O
+,	O
+and	O
+viral	O
+particles	O
+can	O
+contain	O
+either	O
+one	O
+or	O
+two	O
+types	O
+of	O
+RNA	O
+segments	O
+.	O
+
+However	O
+,	O
+hACE2	O
+-	O
+dependent	O
+entry	O
+of	O
+trypsin	B-PRGE
+-	O
+treated	O
+retrovirus	B-SPEC
+pseudotyped	O
+viruses	B-SPEC
+expressing	O
+JMD	O
+mutant	B-DISO
+S	O
+Delta19	O
+proteins	B-CHED
+was	O
+greatly	O
+reduced	O
+.	O
+
+S	O
+Delta19	O
+proteins	B-CHED
+with	O
+other	O
+double	O
+alanine	B-CHED
+substitutions	O
+reduced	O
+cell	B-PROC
+-	I-PROC
+cell	B-COMP
+fusion	I-PROC
+further	O
+,	O
+from	O
+40	O
+%	O
+to	O
+less	O
+than	O
+20	O
+%	O
+of	O
+wild	O
+-	O
+type	O
+levels	O
+.	O
+
+The	O
+infection	B-DISO
+rate	O
+(	O
+7	O
+.	O
+9	O
+%	O
+vs	O
+26	O
+.	O
+3	O
+%,	O
+P	O
+<	O
+0	O
+.	O
+05	O
+),	O
+operation	O
+rate	O
+(	O
+13	O
+.	O
+2	O
+%	O
+vs	O
+34	O
+.	O
+2	O
+%,	O
+P	O
+<	O
+0	O
+.	O
+05	O
+)	O
+and	O
+mortality	O
+(	O
+5	O
+.	O
+3	O
+%	O
+vs	O
+21	O
+.	O
+1	O
+%,	O
+P	O
+<	O
+0	O
+.	O
+05	O
+)	O
+in	O
+the	O
+early	O
+treatment	O
+group	O
+were	O
+lower	O
+than	O
+in	O
+the	O
+late	O
+treatment	O
+group	O
+.	O
+
+In	O
+contrast	O
+to	O
+microglia	B-ANAT
+,	O
+oligodendroglia	B-ANAT
+are	O
+resistant	O
+to	O
+CD8	B-PRGE
+T	I-PRGE
+cell	I-PRGE
+perforin	I-PRGE
+-	O
+mediated	O
+viral	O
+control	O
+in	O
+the	O
+absence	O
+of	O
+IFN	B-PRGE
+gamma	I-PRGE
+.	O
+
+TITLE	O
+:	O
+Infectious	B-DISO
+diseases	I-DISO
+and	O
+governance	O
+of	O
+global	O
+risks	O
+through	O
+public	O
+communication	O
+and	O
+participation	O
+.	O
+
+The	O
+membrane	B-COMP
+(	O
+M	O
+)	O
+protein	B-CHED
+genes	O
+of	O
+six	O
+PEDV	B-SPEC
+isolates	O
+were	O
+amplified	O
+by	O
+reverse	B-PRGE
+transcriptase	I-PRGE
+-	O
+polymerase	O
+chain	O
+reaction	O
+(	O
+RT	O
+-	O
+PCR	O
+),	O
+then	O
+cloned	O
+,	O
+sequenced	O
+,	O
+and	O
+compared	O
+with	O
+each	O
+other	O
+as	O
+well	O
+as	O
+those	O
+ten	O
+PEDV	B-SPEC
+reference	O
+strains	O
+.	O
+
+The	O
+nucleotide	B-CHED
+and	O
+amino	B-CHED
+acid	I-CHED
+identity	O
+of	O
+M	B-PRGE
+protein	I-PRGE
+genes	O
+between	O
+the	O
+six	O
+PEDV	B-SPEC
+isolates	O
+and	O
+ten	O
+reference	O
+PEDV	B-SPEC
+strains	O
+varied	O
+from	O
+97	O
+.	O
+2	O
+to	O
+99	O
+.	O
+4	O
+%	O
+and	O
+96	O
+.	O
+9	O
+to	O
+100	O
+%,	O
+respectively	O
+.	O
+
+These	O
+results	O
+demonstrated	O
+that	O
+there	O
+was	O
+a	O
+new	O
+genotype	O
+of	O
+PEDV	B-SPEC
+prevailing	O
+in	O
+China	O
+.	O
+
+A	O
+drastic	O
+virus	B-SPEC
+population	O
+shift	O
+was	O
+demonstrated	O
+along	O
+time	O
+and	O
+the	O
+novel	O
+Italy	O
+02	O
+serotype	O
+was	O
+shown	O
+to	O
+have	O
+displaced	O
+the	O
+previous	O
+predominant	O
+serotype	O
+4	O
+/	O
+91	O
+in	O
+the	O
+field	O
+.	O
+
+During	O
+the	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+epidemic	O
+in	O
+Toronto	O
+,	O
+airway	B-ANAT
+manipulation	O
+was	O
+clearly	O
+identified	O
+as	O
+the	O
+procedure	O
+most	O
+associated	O
+with	O
+risk	O
+to	O
+health	O
+care	O
+workers	O
+.	O
+
+Briefly	O
+,	O
+SARS	B-DISO
+patients	O
+'	O
+serum	B-COMP
+samples	O
+were	O
+first	O
+fractionated	O
+in	O
+Q	O
+Ceramic	O
+HyperD	O
+ion	B-PROC
+exchange	I-PROC
+sorbent	O
+beads	O
+by	O
+buffers	O
+at	O
+different	O
+pH	O
+.	O
+Serum	B-COMP
+protein	B-CHED
+fractions	O
+thus	O
+obtained	O
+were	O
+then	O
+bound	O
+onto	O
+a	O
+copper	B-CHED
+(	O
+II	O
+)	O
+immobilized	O
+metal	B-CHED
+affinity	O
+capture	O
+(	O
+IMAC30	O
+Cu	O
+[	O
+II	O
+])	O
+ProteinChip	O
+Array	O
+or	O
+a	O
+weak	O
+cation	B-CHED
+-	O
+exchange	O
+(	O
+CM10	O
+)	O
+ProteinChip	O
+Array	O
+.	O
+
+After	O
+washing	O
+and	O
+addition	O
+of	O
+sinapinic	B-CHED
+acid	I-CHED
+,	O
+the	O
+chips	O
+were	O
+read	O
+in	O
+a	O
+Protein	B-CHED
+Biological	O
+System	O
+(	O
+PBS	B-DISO
+)	O
+IIc	O
+mass	O
+spectrometer	O
+.	O
+
+The	O
+remaining	O
+biomarkers	O
+could	O
+also	O
+be	O
+useful	O
+in	O
+the	O
+study	O
+of	O
+other	O
+clinical	O
+parameters	O
+in	O
+SARS	B-DISO
+patients	O
+.	O
+
+However	O
+,	O
+the	O
+epidemiology	O
+and	O
+pathogenesis	B-DISO
+of	O
+SARS	B-DISO
+remain	O
+poorly	O
+understood	O
+and	O
+there	O
+is	O
+currently	O
+no	O
+effective	O
+treatment	O
+.	O
+
+To	O
+date	O
+,	O
+considerable	O
+research	O
+has	O
+been	O
+done	O
+on	O
+detection	O
+,	O
+prevention	O
+and	O
+treatment	O
+of	O
+SARS	B-DISO
+.	O
+
+HCWs	O
+in	O
+a	O
+Toronto	O
+hospital	O
+who	O
+worked	O
+in	O
+high	O
+-	O
+risk	O
+areas	O
+completed	O
+a	O
+questionnaire	O
+regarding	O
+their	O
+attitude	O
+toward	O
+the	O
+SARS	B-DISO
+crisis	O
+along	O
+with	O
+the	O
+Impact	O
+of	O
+Event	O
+Scale	O
+-	O
+Revised	O
+,	O
+which	O
+screens	O
+for	O
+PTSS	O
+.	O
+
+In	O
+addition	O
+,	O
+HCWs	O
+who	O
+cared	O
+for	O
+only	O
+one	O
+SARS	B-DISO
+patient	O
+in	O
+comparison	O
+to	O
+those	O
+caring	O
+for	O
+multiple	O
+SARS	B-DISO
+patients	O
+experienced	O
+more	O
+PTSS	O
+.	O
+
+The	O
+literature	O
+was	O
+searched	O
+for	O
+clinical	O
+studies	O
+on	O
+lung	B-ANAT
+-	O
+protective	O
+mechanical	O
+ventilation	O
+using	O
+lower	O
+tidal	O
+volumes	O
+in	O
+patients	O
+not	O
+suffering	B-DISO
+from	O
+ALI	O
+/	O
+ARDS	B-DISO
+.	O
+
+Others	O
+were	O
+6	O
+cases	O
+of	O
+acute	O
+membrane	B-COMP
+laryngotracheobronchitis	B-DISO
+,	O
+3	O
+cases	O
+of	O
+congenital	O
+main	O
+respiratory	B-ANAT
+tract	I-ANAT
+stenosis	B-DISO
+,	O
+2	O
+cases	O
+of	O
+congenital	O
+laryngeal	B-DISO
+webs	I-DISO
+,	O
+2	O
+cases	O
+of	O
+vocal	B-DISO
+cord	I-DISO
+paralysis	I-DISO
+,	O
+3	O
+cases	O
+of	O
+Pierre	B-DISO
+Robin	I-DISO
+syndrome	I-DISO
+,	O
+2	O
+cases	O
+of	O
+Cri	B-DISO
+-	I-DISO
+du	I-DISO
+-	I-DISO
+chat	I-DISO
+syndrome	I-DISO
+.	O
+
+Congenital	B-DISO
+disease	I-DISO
+is	O
+the	O
+main	O
+cause	O
+of	O
+severe	O
+upper	B-ANAT
+respiratory	I-ANAT
+tract	I-ANAT
+obstruction	B-DISO
+.	O
+
+Serologic	O
+antibody	B-COMP
+titers	O
+against	O
+canine	B-SPEC
+distemper	I-SPEC
+virus	I-SPEC
+(	O
+CDV	B-CHED
+),	O
+canine	O
+parvovirus	B-DISO
+(	O
+CPV	B-SPEC
+),	O
+canine	B-SPEC
+adenovirus	I-SPEC
+(	O
+CAV	B-SPEC
+),	O
+canine	O
+coronavirus	B-SPEC
+(	O
+CCV	B-DISO
+),	O
+canine	B-SPEC
+herpesvirus	I-SPEC
+,	O
+canine	B-SPEC
+parainfluenza	I-SPEC
+virus	I-SPEC
+(	O
+CPIV	O
+),	O
+Toxoplasma	B-SPEC
+gondii	I-SPEC
+,	O
+Neospora	B-SPEC
+caninum	I-SPEC
+,	O
+and	O
+Leptospira	B-SPEC
+interrogans	I-SPEC
+were	O
+measured	O
+in	O
+44	O
+samples	O
+taken	O
+from	O
+19	O
+giant	B-SPEC
+pandas	B-DISO
+between	O
+1998	O
+and	O
+2003	O
+at	O
+the	O
+Chengdu	O
+Research	O
+Base	O
+of	O
+Giant	B-SPEC
+Panda	I-SPEC
+Breeding	B-PROC
+in	O
+Sichuan	O
+,	O
+China	O
+.	O
+
+Positive	O
+antibody	B-COMP
+titers	O
+were	O
+found	O
+only	O
+against	O
+CDV	B-CHED
+,	O
+CPV	B-SPEC
+,	O
+and	O
+T	B-SPEC
+.	I-SPEC
+gondii	I-SPEC
+.	O
+
+TITLE	O
+:	O
+Transverse	O
+laparostomy	O
+is	O
+feasible	O
+and	O
+effective	O
+in	O
+the	O
+treatment	O
+of	O
+abdominal	B-ANAT
+compartment	I-ANAT
+syndrome	I-DISO
+in	O
+severe	O
+acute	O
+pancreatitis	O
+.	O
+
+At	O
+29	O
+d	O
+.	O
+p	O
+.	O
+i	O
+.,	O
+one	O
+group	O
+was	O
+challenged	O
+with	O
+10	O
+(	O
+3	O
+)	O
+TCID50	O
+SARS	B-DISO
+-	O
+CoV	O
+,	O
+and	O
+an	O
+anamnestic	B-PROC
+response	I-PROC
+in	O
+neutralizing	O
+antibodies	B-COMP
+was	O
+evident	O
+with	O
+no	O
+detectable	O
+virus	B-SPEC
+.	O
+
+TITLE	O
+:	O
+[	O
+Acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+in	O
+infants	O
+at	O
+term	O
+and	O
+near	O
+term	O
+about	O
+23	O
+cases	O
+].	O
+
+Retrospective	O
+study	O
+of	O
+the	O
+medical	O
+records	O
+of	O
+infants	O
+admitted	O
+in	O
+the	O
+paediatric	O
+intensive	O
+care	O
+unit	O
+for	O
+ARDS	B-DISO
+along	O
+a	O
+period	O
+of	O
+4	O
+years	O
+.	O
+
+1	O
+.	O
+1	O
+weeks	O
+of	O
+gestation	B-PROC
+;	O
+birth	B-PROC
+weight	O
+=	O
+2756	O
++/-	O
+
+ARDS	B-DISO
+represents	O
+6	O
+.	O
+8	O
+%	O
+of	O
+etiology	O
+of	O
+respiratory	B-DISO
+distress	I-DISO
+in	O
+infants	O
+at	O
+term	O
+and	O
+near	O
+term	O
+.	O
+
+Finally	O
+,	O
+the	O
+pH	O
+-	O
+inactivation	B-DISO
+profile	O
+of	O
+3CLpro	O
+with	O
+iodoacetamide	O
+is	O
+indicative	O
+of	O
+an	O
+ion	O
+-	O
+pair	O
+mechanism	O
+.	O
+
+TITLE	O
+:	O
+Genetic	O
+diversity	O
+-	O
+independent	O
+neutralization	O
+of	O
+pandemic	O
+viruses	B-SPEC
+(	O
+e	O
+.	O
+g	O
+.	O
+HIV	B-DISO
+),	O
+potentially	O
+pandemic	O
+(	O
+e	O
+.	O
+g	O
+.	O
+H5N1	O
+strain	O
+of	O
+influenza	B-DISO
+)	O
+and	O
+carcinogenic	O
+(	O
+e	O
+.	O
+g	O
+.	O
+HBV	B-DISO
+and	O
+HCV	B-SPEC
+)	O
+viruses	B-SPEC
+and	O
+possible	O
+agents	O
+of	O
+bioterrorism	O
+(	O
+variola	B-DISO
+)	O
+by	O
+enveloped	O
+virus	B-SPEC
+neutralizing	O
+compounds	O
+(	O
+EVNCs	O
+).	O
+
+Also	O
+the	O
+difficulty	O
+in	O
+predicting	O
+the	O
+next	O
+pandemic	O
+strain	O
+of	O
+influenza	B-DISO
+may	O
+make	O
+it	O
+difficult	O
+to	O
+respond	O
+rapidly	O
+should	O
+there	O
+be	O
+an	O
+outbreak	O
+.	O
+
+Broad	O
+spectrum	O
+agents	O
+that	O
+can	O
+serve	O
+as	O
+disrafters	O
+or	O
+neutralize	O
+the	O
+viral	O
+infectivity	O
+by	O
+binding	B-FUNC
+to	O
+the	O
+envelope	B-COMP
+lipid	B-CHED
+or	O
+sugar	O
+moieties	O
+will	O
+not	O
+be	O
+affected	O
+by	O
+the	O
+vagaries	O
+of	O
+hypermutation	O
+of	O
+surface	O
+antigens	B-CHED
+.	O
+
+ABSTRACT	O
+:	O
+Neurological	O
+conditions	O
+such	O
+as	O
+stroke	B-DISO
+,	O
+subarachnoid	B-DISO
+haemorrhage	I-DISO
+and	O
+seizure	B-DISO
+activity	O
+,	O
+amongst	O
+others	O
+,	O
+have	O
+been	O
+associated	O
+with	O
+the	O
+development	B-PROC
+of	O
+pulmonary	B-DISO
+oedema	I-DISO
+.	O
+
+Unilateral	O
+pulmonary	B-DISO
+oedema	I-DISO
+is	O
+also	O
+a	O
+very	O
+rare	O
+occurrence	O
+,	O
+and	O
+has	O
+not	O
+,	O
+to	O
+our	O
+knowledge	O
+,	O
+been	O
+reported	O
+in	O
+acute	O
+MS	O
+exacerbation	O
+in	O
+the	O
+past	O
+.	O
+
+Mapping	O
+studies	O
+localized	O
+the	O
+critical	O
+N	O
+sequences	O
+for	O
+this	O
+interaction	O
+to	O
+amino	B-CHED
+acid	I-CHED
+residues	O
+175	O
+-	O
+210	O
+,	O
+which	O
+included	O
+a	O
+serine	B-CHED
+/	O
+arginine	B-CHED
+(	O
+SR	O
+)-	O
+rich	O
+domain	O
+.	O
+
+However	O
+,	O
+experiments	O
+in	O
+which	O
+RNA	O
+extracted	O
+from	O
+FCoV	O
+-	O
+infected	O
+cell	B-COMP
+culture	O
+supernatants	O
+was	O
+combined	O
+with	O
+RNA	O
+extracted	O
+from	O
+faecal	B-ANAT
+suspensions	O
+revealed	O
+the	O
+presence	O
+of	O
+faecal	B-ANAT
+factors	O
+that	O
+significantly	O
+inhibited	O
+the	O
+reverse	B-PROC
+transcription	I-PROC
+reaction	O
+.	O
+
+TITLE	O
+:	O
+[	O
+Procalcitonin	O
+-	O
+marker	O
+of	O
+severe	O
+infection	B-DISO
+and	O
+sepsis	B-DISO
+].	O
+
+TITLE	O
+:	O
+Orchitis	B-DISO
+in	O
+roosters	O
+with	O
+reduced	O
+fertility	B-DISO
+associated	O
+with	O
+avian	B-DISO
+infectious	I-DISO
+bronchitis	I-DISO
+virus	B-SPEC
+and	O
+avian	B-SPEC
+metapneumovirus	I-SPEC
+infections	B-DISO
+.	O
+
+Sequence	O
+analysis	O
+of	O
+the	O
+amplified	O
+fragment	O
+revealed	O
+a	O
+close	O
+relationship	O
+with	O
+European	O
+IBV	B-SPEC
+genotype	O
+D274	O
+,	O
+previously	O
+unreported	O
+in	O
+Brazil	O
+.	O
+
+These	O
+results	O
+indicate	O
+that	O
+IBV	B-SPEC
+and	O
+perhaps	O
+aMPV	O
+are	O
+likely	O
+to	O
+have	O
+played	O
+a	O
+role	O
+in	O
+the	O
+pathogenesis	B-DISO
+of	O
+the	O
+testicular	B-DISO
+disease	I-DISO
+described	O
+and	O
+should	O
+be	O
+regarded	O
+as	O
+factors	O
+that	O
+can	O
+influence	O
+male	O
+fertility	B-DISO
+disease	O
+in	O
+chickens	B-SPEC
+.	O
+
+The	O
+vaccine	O
+strains	O
+of	O
+IBV	B-SPEC
+tested	O
+were	O
+Massachusetts	O
+(	O
+Mass	O
+)	O
+and	O
+Arkansas	O
+(	O
+Ark	B-PRGE
+).	O
+
+TITLE	O
+:	O
+Molecular	O
+characterization	O
+of	O
+infectious	B-DISO
+bronchitis	B-DISO
+virus	B-SPEC
+strains	O
+isolated	O
+from	O
+the	O
+enteric	O
+contents	O
+of	O
+Brazilian	O
+laying	O
+hens	O
+and	O
+broilers	O
+.	O
+
+However	O
+,	O
+the	O
+role	O
+of	O
+IBV	B-SPEC
+as	O
+an	O
+enteric	O
+pathogen	O
+in	O
+still	O
+controversial	O
+.	O
+
+For	O
+the	O
+5	O
+European	O
+and	O
+3	O
+Asian	O
+regions	O
+that	O
+had	O
+been	O
+affected	O
+by	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+,	O
+the	O
+pattern	O
+of	O
+reported	O
+precautionary	O
+action	O
+was	O
+broadly	O
+similar	O
+across	O
+the	O
+regions	O
+;	O
+approximately	O
+75	O
+%	O
+of	O
+respondents	O
+reported	O
+that	O
+they	O
+would	O
+avoid	O
+public	O
+transportation	O
+and	O
+20	O
+%-	O
+30	O
+%	O
+would	O
+try	O
+to	O
+stay	O
+indoors	O
+.	O
+
+Effective	O
+HPAI	O
+(	O
+H5N1	B-DISO
+)	O
+surveillance	O
+,	O
+containment	O
+response	O
+,	O
+and	O
+field	O
+evaluation	O
+are	O
+essential	O
+to	O
+monitor	O
+and	O
+contain	O
+potential	O
+pandemic	O
+strains	O
+.	O
+
+Moreover	O
+,	O
+it	O
+strongly	O
+stimulates	O
+pro	O
+-	O
+inflammatory	O
+activation	O
+of	O
+the	O
+macrophages	B-ANAT
+and	O
+the	O
+release	B-PATH
+of	O
+vasoactive	O
+substances	O
+,	O
+such	O
+as	O
+prostaglandins	B-CHED
+and	O
+thromboxanes	B-CHED
+.	O
+
+The	O
+inflammatory	B-DISO
+response	I-DISO
+is	O
+triggered	O
+by	O
+cascade	O
+systems	O
+(	O
+such	O
+as	O
+the	O
+complement	O
+,	O
+coagulation	B-PROC
+,	O
+kinins	O
+,	O
+fibrinolysis	B-PROC
+),	O
+cell	B-COMP
+elements	O
+(	O
+endothelium	B-ANAT
+,	O
+leukocytes	B-ANAT
+,	O
+macrophages	B-ANAT
+,	O
+monocytes	B-ANAT
+,	O
+mast	B-ANAT
+cells	I-ANAT
+)	O
+and	O
+the	O
+release	B-PATH
+of	O
+mediators	O
+(	O
+cytokines	O
+,	O
+proteolytic	B-PROC
+enzymes	O
+,	O
+histamine	B-CHED
+,	O
+etc	O
+.)	O
+and	O
+others	O
+interacting	O
+factors	O
+.	O
+
+ABSTRACT	O
+:	O
+Many	O
+genetic	O
+and	O
+mechanistic	O
+features	O
+distinguish	O
+the	O
+coronavirus	O
+replication	O
+machinery	O
+from	O
+that	O
+encoded	O
+by	O
+most	O
+other	O
+RNA	O
+viruses	B-SPEC
+.	O
+
+The	O
+viral	B-ANAT
+components	I-ANAT
+of	O
+the	O
+complex	O
+are	O
+encoded	O
+by	O
+the	O
+giant	B-PRGE
+replicase	I-PRGE
+gene	I-PRGE
+,	O
+which	O
+is	O
+expressed	B-PROC
+in	O
+the	O
+form	O
+of	O
+two	O
+polyproteins	O
+(	O
+pp1a	B-PRGE
+and	O
+pp1ab	O
+)	O
+that	O
+are	O
+processed	O
+into	O
+16	O
+cleavage	B-PROC
+products	O
+(	O
+nonstructural	O
+proteins	B-CHED
+1	O
+-	O
+16	O
+).	O
+
+Using	O
+the	O
+combination	O
+of	O
+yeast	B-SPEC
+two	O
+-	O
+hybrid	O
+screening	O
+and	O
+GST	B-PRGE
+pull	O
+-	O
+down	O
+assays	O
+,	O
+we	O
+have	O
+now	O
+analyzed	O
+all	O
+potential	O
+interactions	O
+between	O
+SARS	B-DISO
+-	O
+Coronavirus	B-SPEC
+nonstructural	O
+proteins	B-CHED
+,	O
+which	O
+may	O
+contribute	O
+to	O
+the	O
+structure	O
+and	O
+/	O
+or	O
+function	O
+of	O
+the	O
+viral	B-PROC
+replication	I-PROC
+/	O
+transcription	B-PROC
+complex	O
+.	O
+
+TITLE	O
+:	O
+Duration	O
+of	O
+antibody	B-PROC
+responses	I-PROC
+after	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+.	O
+
+The	O
+quadroma	O
+culture	O
+supernatant	O
+was	O
+initially	O
+processed	O
+on	O
+a	O
+Protein	B-CHED
+-	O
+G	O
+column	B-ANAT
+to	O
+isolate	O
+all	O
+the	O
+species	B-SPEC
+of	O
+immunoglobulins	O
+.	O
+
+ABSTRACT	O
+:	O
+ALI	O
+/	O
+ARDS	B-DISO
+(	O
+acute	O
+lung	B-ANAT
+injury	O
+/	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+)	O
+is	O
+a	O
+severe	O
+inflammatory	O
+lung	B-DISO
+disease	I-DISO
+associated	O
+with	O
+very	O
+high	O
+mortality	O
+.	O
+
+Importantly	O
+,	O
+no	O
+effective	O
+therapy	O
+has	O
+been	O
+developed	O
+to	O
+date	O
+for	O
+ALI	O
+/	O
+ARDS	B-DISO
+.	O
+
+These	O
+complexes	O
+are	O
+present	O
+in	O
+various	O
+human	B-ANAT
+tissues	I-ANAT
+,	O
+including	O
+the	O
+lung	B-ANAT
+,	O
+as	O
+they	O
+have	O
+been	O
+detected	O
+in	O
+lung	B-ANAT
+fluids	B-ANAT
+from	O
+patients	O
+with	O
+ALI	O
+/	O
+ARDS	B-DISO
+.	O
+
+In	O
+this	O
+review	O
+,	O
+the	O
+significance	O
+of	O
+the	O
+latter	O
+findings	O
+are	O
+explored	O
+,	O
+and	O
+the	O
+possible	O
+involvement	O
+of	O
+anti	O
+-	O
+IL	B-FUNC
+-	I-FUNC
+8	I-FUNC
+autoantibody	O
+:	O
+IL	B-FUNC
+-	I-FUNC
+8	I-FUNC
+immune	O
+complexes	O
+in	O
+pathogenesis	B-DISO
+of	O
+ALI	O
+/	O
+ARDS	B-DISO
+is	O
+discussed	O
+.	O
+
+The	O
+unusual	O
+manifestation	O
+of	O
+pulmonary	B-ANAT
+hemorrhagic	O
+syndrome	B-DISO
+in	O
+these	O
+cases	O
+camouflaged	O
+the	O
+cardiovascular	B-ANAT
+involvement	O
+.	O
+
+RESULTS	O
+:	O
+Forty	O
+-	O
+four	O
+cases	O
+of	O
+leptospirosis	B-DISO
+in	O
+the	O
+year	O
+2005	O
+formed	O
+3	O
+.	O
+52	O
+%	O
+of	O
+the	O
+autopsies	O
+performed	O
+.	O
+
+To	O
+our	O
+knowledge	O
+,	O
+this	O
+is	O
+the	O
+first	O
+report	O
+showing	O
+selection	O
+of	O
+a	O
+more	O
+fit	O
+virus	B-SPEC
+subpopulation	O
+as	O
+well	O
+as	O
+mutations	O
+associated	O
+with	O
+replication	O
+of	O
+modified	O
+live	O
+IBV	B-SPEC
+vaccine	O
+viruses	B-SPEC
+in	O
+chickens	B-SPEC
+.	O
+
+ABSTRACT	O
+:	O
+Severe	O
+and	O
+recurrent	O
+acute	O
+vascular	O
+rejection	O
+of	O
+the	O
+pulmonary	B-ANAT
+allograft	O
+is	O
+an	O
+accepted	O
+major	O
+risk	O
+factor	O
+for	O
+obliterative	B-DISO
+bronchiolitis	I-DISO
+.	O
+
+Retrospective	O
+analysis	O
+of	O
+341	O
+90	O
+-	O
+day	O
+survivors	O
+of	O
+lung	B-ANAT
+transplant	B-ANAT
+performed	O
+in	O
+1995	O
+-	O
+2005	O
+who	O
+underwent	O
+1	O
+,	O
+770	O
+transbronchial	O
+lung	B-ANAT
+biopsy	O
+procedures	O
+.	O
+
+A	O
+total	O
+of	O
+182	O
+transbronchial	O
+biopsies	O
+were	O
+ungraded	O
+(	O
+8	O
+inadequate	O
+,	O
+142	O
+cytomegalovirus	B-SPEC
+,	O
+32	O
+other	O
+diagnoses	O
+).	O
+
+The	O
+condition	B-DISO
+was	O
+progressive	O
+and	O
+fatal	O
+in	O
+all	O
+the	O
+cases	O
+.	O
+
+ABSTRACT	O
+:	O
+Hypophosphatemia	O
+is	O
+an	O
+unusual	O
+cause	O
+of	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+(	O
+ARDS	B-DISO
+).	O
+
+The	O
+patient	O
+was	O
+managed	O
+with	O
+supplemental	O
+potassium	O
+,	O
+octreotide	B-CHED
+,	O
+and	O
+oxygen	B-CHED
+therapy	O
+.	O
+
+ECMO	O
+and	O
+iLA	B-PRGE
+might	O
+be	O
+associated	O
+with	O
+serious	O
+complications	O
+(	O
+bleeding	B-DISO
+,	O
+ischaemia	B-DISO
+),	O
+thus	O
+further	O
+randomised	O
+prospective	O
+studies	O
+are	O
+warranted	O
+to	O
+elucidate	O
+specific	O
+indications	O
+.	O
+
+TITLE	O
+:	O
+Glucose	B-CHED
+-	I-ENZY
+6	I-ENZY
+-	I-ENZY
+phosphate	B-CHED
+dehydrogenase	I-ENZY
+deficiency	I-DISO
+enhances	O
+human	B-SPEC
+coronavirus	I-SPEC
+229E	I-SPEC
+infection	B-DISO
+.	O
+
+ABSTRACT	O
+:	O
+The	O
+host	O
+cellular	B-COMP
+environment	O
+is	O
+a	O
+key	O
+determinant	O
+of	O
+pathogen	O
+infectivity	O
+.	O
+
+ABSTRACT	O
+:	O
+Abstract	O
+:	O
+Candidate	O
+IBV	O
+vaccines	O
+should	O
+elicit	O
+cellular	B-COMP
+responses	O
+as	O
+well	O
+as	O
+humoral	O
+responses	O
+.	O
+
+Plasmids	O
+were	O
+transfected	O
+into	O
+the	O
+Vero	B-ANAT
+cells	I-ANAT
+by	O
+lipofectamine	O
+,	O
+and	O
+the	O
+expressed	B-PROC
+products	O
+were	O
+detected	O
+by	O
+RT	O
+-	O
+PCR	O
+and	O
+indirect	O
+immunofluorescence	O
+assay	O
+.	O
+
+Two	O
+weeks	O
+after	O
+boosting	O
+,	O
+chickens	B-SPEC
+were	O
+challenged	O
+by	O
+virulent	O
+IBV	B-SPEC
+strain	O
+.	O
+
+These	O
+results	O
+demonstrate	O
+that	O
+bicistronic	O
+DNA	O
+vaccine	O
+containing	O
+IL	B-FUNC
+-	I-FUNC
+2	I-FUNC
+elicit	O
+remarkably	O
+immune	B-PROC
+responses	I-PROC
+and	O
+suggest	O
+that	O
+optimal	O
+humoral	O
+and	O
+cellular	B-COMP
+responses	O
+priming	O
+requires	O
+the	O
+precise	O
+temporal	O
+and	O
+spatial	O
+codelivery	O
+of	O
+Ag	O
+and	O
+IL	B-FUNC
+-	I-FUNC
+2	I-FUNC
+.	O
+
+TITLE	O
+:	O
+The	O
+beneficial	O
+effects	O
+of	O
+inhaled	B-PROC
+nitric	B-CHED
+oxide	I-CHED
+in	O
+patients	O
+with	O
+severe	O
+traumatic	O
+brain	B-ANAT
+injury	O
+complicated	O
+by	O
+acute	O
+respiratory	O
+distress	O
+syndrome	O
+:	O
+a	O
+hypothesis	O
+.	O
+
+The	O
+hypothesis	O
+may	O
+be	O
+confirmed	O
+by	O
+:	O
+(	O
+1	O
+)	O
+demonstrating	O
+an	O
+improvement	O
+in	O
+physiologic	O
+parameters	O
+,	O
+intracranial	B-PROC
+pressure	I-PROC
+,	O
+and	O
+brain	B-ANAT
+oxygenation	B-PROC
+with	O
+inhaled	B-PROC
+nitric	B-CHED
+oxide	I-CHED
+use	O
+in	O
+severely	O
+head	B-ANAT
+injured	O
+patients	O
+,	O
+and	O
+(	O
+2	O
+)	O
+demonstrating	O
+a	O
+decrease	O
+in	O
+biochemical	O
+serum	B-COMP
+markers	O
+in	O
+such	O
+patients	O
+;	O
+specifically	O
+,	O
+glial	B-COMP
+fibrillary	I-COMP
+acidic	I-COMP
+protein	I-COMP
+,	O
+inflammatory	O
+cytokines	O
+,	O
+and	O
+biomarkers	O
+of	O
+the	O
+hypothalamic	B-ANAT
+-	I-ANAT
+pituitary	I-ANAT
+-	I-ANAT
+adrenal	I-ANAT
+axis	I-ANAT
+,	O
+and	O
+(	O
+3	O
+)	O
+documentation	O
+of	O
+outcomes	O
+.	O
+
+Detailed	O
+analysis	O
+of	O
+the	O
+point	O
+mutants	O
+of	O
+these	O
+two	O
+amino	B-CHED
+acid	I-CHED
+residues	O
+and	O
+their	O
+nearby	O
+hydrogen	B-CHED
+bond	O
+partner	O
+Ser	B-COMP
+-	O
+123	O
+and	O
+Ser	B-COMP
+-	O
+139	O
+revealed	O
+a	O
+strong	O
+correlation	O
+between	O
+the	O
+enzyme	B-FUNC
+activity	I-FUNC
+loss	O
+and	O
+dimer	O
+dissociation	O
+.	O
+
+ABSTRACT	O
+:	O
+The	O
+common	O
+cold	O
+or	O
+upper	B-DISO
+respiratory	I-DISO
+infection	I-DISO
+(	O
+URI	O
+)	O
+is	O
+highly	O
+prevalent	O
+among	O
+young	O
+children	O
+and	O
+often	O
+results	O
+in	O
+otitis	B-DISO
+media	I-DISO
+(	O
+OM	O
+).	O
+
+Virus	B-SPEC
+studies	O
+were	O
+performed	O
+for	O
+864	O
+URI	O
+episodes	O
+;	O
+63	O
+%	O
+were	O
+virus	B-SPEC
+positive	O
+.	O
+
+The	O
+overall	O
+incidence	O
+of	O
+OM	O
+that	O
+complicated	O
+URI	O
+was	O
+61	O
+%,	O
+including	O
+a	O
+37	O
+%	O
+incidence	O
+of	O
+AOM	B-DISO
+and	O
+a	O
+24	O
+%	O
+incidence	O
+of	O
+OME	O
+.	O
+
+TITLE	O
+:	O
+[	O
+Evaluation	O
+of	O
+the	O
+efficacy	O
+and	O
+safety	O
+of	O
+corticosteroid	B-CHED
+in	O
+the	O
+treatment	O
+of	O
+severe	O
+SARS	B-DISO
+in	O
+Guangdong	O
+province	O
+with	O
+multi	O
+-	O
+factor	O
+regression	O
+analysis	O
+].	O
+
+The	O
+detail	O
+data	O
+of	O
+1	O
+278	O
+SARS	B-DISO
+patients	O
+and	O
+borderline	O
+cases	O
+were	O
+collected	O
+.	O
+
+Subjects	O
+who	O
+received	O
+steroid	B-CHED
+(	O
+which	O
+was	O
+converted	O
+into	O
+methylprednisolone	B-CHED
+)	O
+treatment	O
+were	O
+further	O
+divided	O
+into	O
+three	O
+groups	O
+:	O
+small	O
+dose	O
+group	O
+(<	O
+80	O
+mg	O
+/	O
+day	O
+);	O
+moderate	O
+dose	O
+group	O
+(	O
+80	O
+-	O
+320	O
+mg	O
+/	O
+day	O
+);	O
+high	O
+dose	O
+group	O
+(>	O
+or	O
+=	O
+320	O
+mg	O
+/	O
+day	O
+).	O
+
+(	O
+2	O
+)	O
+COX	O
+regression	O
+revealed	O
+that	O
+steroid	B-CHED
+was	O
+not	O
+related	O
+to	O
+instant	O
+mortality	O
+rate	O
+.	O
+
+(	O
+4	O
+)	O
+Incidence	O
+of	O
+infections	B-DISO
+in	O
+patients	O
+with	O
+steroid	B-CHED
+was	O
+3	O
+.	O
+095	O
+times	O
+higher	O
+than	O
+in	O
+patients	O
+without	O
+steroid	B-CHED
+(	O
+chi	B-CHED
+(	O
+2	O
+)=	O
+4	O
+.	O
+289	O
+,	O
+P	O
+=	O
+0	O
+.	O
+038	O
+).	O
+
+Here	O
+,	O
+we	O
+report	O
+that	O
+lipid	B-COMP
+rafts	I-COMP
+in	O
+Vero	O
+E6	O
+cells	B-COMP
+are	O
+involved	O
+in	O
+the	O
+entry	O
+of	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+coronavirus	B-SPEC
+(	O
+SARS	B-DISO
+-	O
+CoV	O
+).	O
+
+At	O
+discharge	B-ANAT
+,	O
+no	O
+major	O
+neurological	O
+deficits	O
+were	O
+present	O
+.	O
+
+Prompt	O
+antidote	B-CHED
+treatment	O
+and	O
+aggressive	B-DISO
+supportive	O
+emergency	B-DISO
+and	O
+intensive	O
+care	O
+unit	O
+therapy	O
+contribute	O
+to	O
+improved	O
+survival	O
+after	O
+acute	O
+organophosphate	O
+poisoning	O
+.	O
+
+Symptoms	O
+always	O
+improve	O
+with	O
+corticosteroids	B-CHED
+.	O
+
+But	O
+relapses	O
+are	O
+frequent	O
+after	O
+stopping	O
+corticosteroid	B-CHED
+treatment	O
+,	O
+as	O
+well	O
+as	O
+the	O
+occurrence	O
+of	O
+severe	O
+asthma	B-PATH
+.	O
+
+TITLE	O
+:	O
+Epidemiology	O
+of	O
+AKI	B-PRGE
+in	O
+the	O
+ICU	O
+.	O
+
+This	O
+classification	O
+was	O
+adapted	O
+and	O
+modified	O
+by	O
+the	O
+Acute	O
+Kidney	B-ANAT
+Injury	O
+Network	O
+into	O
+the	O
+AKI	O
+staging	O
+system	O
+.	O
+
+The	O
+incidence	O
+of	O
+AKI	O
+in	O
+ICU	O
+patients	O
+is	O
+increasing	O
+;	O
+severe	O
+AKI	O
+,	O
+treated	O
+by	O
+renal	B-ANAT
+replacement	O
+therapy	O
+(	O
+RRT	O
+),	O
+has	O
+now	O
+an	O
+incidence	O
+comparable	O
+to	O
+that	O
+of	O
+acute	O
+lung	B-ANAT
+injury	O
+/	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+(	O
+ALI	O
+/	O
+ARDS	B-DISO
+),	O
+and	O
+less	O
+severe	O
+AKI	O
+has	O
+an	O
+incidence	O
+comparable	O
+to	O
+that	O
+of	O
+sepsis	B-DISO
+.	O
+
+The	O
+prognosis	O
+of	O
+patients	O
+with	O
+AKI	O
+treated	O
+with	O
+RRT	O
+is	O
+still	O
+dim	B-CHED
+,	O
+with	O
+mortality	O
+rates	O
+between	O
+50	O
+%	O
+and	O
+60	O
+%.	O
+
+The	O
+prevalence	O
+of	O
+any	O
+HPV	O
+infection	B-DISO
+in	O
+the	O
+glans	O
+/	O
+corona	B-CHED
+was	O
+significantly	O
+higher	O
+in	O
+uncircumcised	O
+men	O
+(	O
+46	O
+%)	O
+than	O
+in	O
+circumcised	O
+men	O
+(	O
+29	O
+%)	O
+(	O
+odds	O
+ratio	O
+[	O
+OR	O
+],	O
+1	O
+.	O
+96	O
+[	O
+95	O
+%	O
+confidence	O
+interval	O
+(	O
+CI	O
+),	O
+1	O
+.	O
+02	O
+-	O
+3	O
+.	O
+75	O
+],	O
+adjusted	O
+for	O
+demographic	O
+characteristics	O
+and	O
+sexual	O
+history	O
+).	O
+
+We	O
+treated	O
+porcine	B-SPEC
+respiratory	O
+coronavirus	B-SPEC
+(	O
+PRCV	O
+)-	O
+infected	O
+conventional	O
+pigs	B-SPEC
+with	O
+the	O
+corticosteroid	B-CHED
+dexamethasone	B-CHED
+(	O
+DEX	O
+)	O
+as	O
+a	O
+model	O
+for	O
+SARS	B-DISO
+.	O
+
+PRCV	O
+infection	B-DISO
+increased	O
+T	B-ANAT
+-	I-ANAT
+cell	I-ANAT
+frequencies	O
+in	O
+BAL	B-ENZY
+,	O
+but	O
+DEX	O
+treatment	O
+of	O
+PRCV	O
+-	O
+infected	O
+pigs	B-SPEC
+reduced	O
+frequencies	O
+of	O
+T	B-ANAT
+cells	I-ANAT
+;	O
+interestingly	O
+B	O
+and	O
+SWC3a	O
+(+)	O
+(	O
+monocytes	B-ANAT
+/	O
+macrophages	B-ANAT
+/	O
+granulocytes	B-ANAT
+)	O
+cell	B-COMP
+frequencies	O
+were	O
+increased	O
+.	O
+
+Ninety	O
+-	O
+five	O
+dogs	B-SPEC
+and	O
+52	O
+cats	B-SPEC
+presented	O
+during	O
+a	O
+neutering	O
+campaign	O
+.	O
+
+(	O
+1	O
+%),	O
+and	O
+Mycoplasma	B-SPEC
+haemocanis	I-SPEC
+(	O
+1	O
+%)	O
+observed	O
+.	O
+
+Antibodies	B-COMP
+against	O
+panleukopenia	O
+virus	B-SPEC
+(	O
+67	O
+%),	O
+Toxoplasma	B-SPEC
+gondii	I-SPEC
+(	O
+63	O
+%),	O
+calicivirus	O
+(	O
+44	O
+%),	O
+and	O
+herpesvirus	B-SPEC
+1	O
+(	O
+10	O
+%)	O
+were	O
+detected	O
+in	O
+cats	B-SPEC
+.	O
+
+In	O
+the	O
+absence	O
+of	O
+vaccination	O
+,	O
+a	O
+reservoir	O
+of	O
+susceptible	O
+animals	B-SPEC
+remains	O
+vulnerable	O
+to	O
+new	O
+disease	O
+introductions	O
+.	O
+
+Data	O
+were	O
+collected	O
+for	O
+patient	O
+age	O
+,	O
+neurological	O
+diagnosis	O
+,	O
+associated	O
+comorbidities	O
+,	O
+index	O
+of	O
+respiratory	B-DISO
+insufficiency	I-DISO
+in	O
+the	O
+immediate	O
+postoperative	O
+period	O
+and	O
+period	O
+of	O
+hospitalization	O
+.	O
+
+All	O
+of	O
+the	O
+children	O
+that	O
+developed	O
+ARI	B-CHED
+presented	O
+quadriplegia	B-DISO
+.	O
+
+ARI	B-CHED
+increased	O
+the	O
+period	O
+of	O
+hospitalization	O
+;	O
+these	O
+children	O
+had	O
+an	O
+average	O
+length	O
+of	O
+stay	O
+of	O
+7	O
+days	O
+versus	O
+1	O
+.	O
+5	O
+days	O
+for	O
+those	O
+that	O
+did	O
+not	O
+develop	O
+complications	O
+.	O
+
+Comparison	O
+of	O
+the	O
+growth	B-PROC
+ability	O
+in	O
+embryos	B-ANAT
+and	O
+replication	O
+and	O
+pathogenicity	O
+in	O
+chickens	O
+with	O
+IBV	B-SPEC
+carrying	O
+the	O
+normal	O
+3a	O
+gene	O
+indicated	O
+that	O
+this	O
+deleted	O
+sequence	O
+in	O
+the	O
+3a	O
+gene	O
+of	O
+CK	O
+/	O
+CH	O
+/	O
+LSD	B-PRGE
+/	O
+03I	O
+was	O
+not	O
+necessary	O
+for	O
+viral	B-DISO
+pathogenesis	I-DISO
+and	O
+replication	O
+either	O
+in	O
+vitro	O
+or	O
+in	O
+vivo	O
+.	O
+
+Occurrence	O
+of	O
+a	O
+mutation	O
+at	O
+the	O
+corresponding	O
+position	O
+of	O
+the	O
+CK	O
+/	O
+CH	O
+/	O
+LLN	O
+/	O
+98I	O
+start	O
+codon	O
+in	O
+the	O
+3a	O
+gene	O
+led	O
+to	O
+the	O
+absence	O
+of	O
+ORF	B-PRGE
+3a	I-PRGE
+in	O
+this	O
+virus	B-SPEC
+,	O
+resulting	O
+in	O
+a	O
+novel	O
+genomic	O
+organization	O
+at	O
+the	O
+3	O
+'-	O
+encoding	O
+regions	O
+:	O
+S	O
+-	O
+3b	O
+,	O
+3c	O
+-	O
+M	O
+-	O
+5a	O
+,	O
+5b	O
+-	O
+N	O
+.	O
+Comparison	O
+with	O
+other	O
+viruses	B-SPEC
+carrying	O
+the	O
+normal	O
+3a	O
+gene	O
+revealed	O
+that	O
+CK	O
+/	O
+CH	O
+/	O
+LLN	O
+/	O
+98I	O
+had	O
+replication	O
+and	O
+pathogenicity	O
+abilities	O
+in	O
+vivo	O
+similar	O
+to	O
+those	O
+of	O
+other	O
+IBVs	O
+;	O
+however	O
+,	O
+its	O
+growth	B-PROC
+ability	O
+in	O
+embryos	B-ANAT
+was	O
+lower	O
+,	O
+although	O
+the	O
+relationship	O
+between	O
+the	O
+lower	O
+growth	B-PROC
+ability	O
+and	O
+the	O
+ORF	O
+3a	O
+defect	O
+requires	O
+further	O
+confirmation	O
+.	O
+
+This	O
+enzyme	O
+is	O
+a	O
+target	O
+for	O
+the	O
+design	O
+of	O
+potential	O
+anti	O
+-	O
+SARS	B-DISO
+drugs	O
+.	O
+
+The	O
+presence	O
+of	O
+respiratory	O
+syncitial	O
+virus	B-SPEC
+(	O
+RSV	B-SPEC
+),	O
+human	B-SPEC
+Metapneumoviruses	B-SPEC
+(	O
+hMPVs	O
+),	O
+human	B-SPEC
+Bocaviruses	B-SPEC
+(	O
+hBoVs	O
+),	O
+and	O
+human	B-SPEC
+Coronaviruses	O
+(	O
+hCoVs	O
+)	O
+was	O
+assayed	O
+by	O
+molecular	O
+detection	O
+and	O
+clinical	O
+symptoms	O
+evaluated	O
+.	O
+
+TITLE	O
+:	O
+Chemokine	O
+expression	B-PROC
+during	O
+mouse	B-SPEC
+-	O
+hepatitis	B-DISO
+-	O
+virus	B-SPEC
+-	O
+induced	O
+encephalitis	B-DISO
+:	O
+contributions	O
+of	O
+the	O
+spike	O
+and	O
+background	O
+genes	O
+.	O
+
+To	O
+determine	O
+if	O
+chemokine	O
+expression	B-PROC
+corresponds	O
+with	O
+the	O
+cellular	B-DISO
+infiltrate	I-DISO
+,	O
+chemokine	O
+protein	B-CHED
+and	O
+RNA	O
+levels	O
+from	O
+the	O
+brains	B-ANAT
+of	O
+infected	O
+mice	B-SPEC
+were	O
+quantified	O
+.	O
+
+Thus	O
+,	O
+chemokine	O
+patterns	O
+correspond	O
+with	O
+the	O
+cellular	B-DISO
+infiltrate	I-DISO
+,	O
+and	O
+the	O
+spike	O
+protein	B-CHED
+influences	O
+levels	O
+of	O
+macrophage	B-ANAT
+,	O
+but	O
+not	O
+T	B-ANAT
+-	I-ANAT
+cell	I-ANAT
+,	O
+chemokines	O
+.	O
+
+This	O
+review	O
+will	O
+first	O
+describe	O
+the	O
+rationale	O
+for	O
+developing	O
+safe	O
+and	O
+effective	O
+SARS	B-DISO
+vaccines	O
+,	O
+followed	O
+by	O
+elucidating	O
+viral	O
+antigens	B-CHED
+that	O
+could	O
+be	O
+used	O
+as	O
+potential	O
+vaccine	O
+components	O
+.	O
+
+This	O
+suggests	O
+that	O
+recombinant	O
+protein	O
+/	O
+peptide	B-CHED
+-	O
+based	O
+subunit	O
+vaccines	O
+containing	O
+the	O
+spike	O
+protein	B-CHED
+,	O
+especially	O
+the	O
+receptor	O
+-	O
+bind	B-FUNC
+domain	O
+of	O
+SARS	B-PRGE
+-	I-PRGE
+CoV	I-PRGE
+,	O
+could	O
+be	O
+developed	O
+as	O
+safe	O
+and	O
+effective	O
+SARS	B-DISO
+vaccines	O
+.	O
+
+TITLE	O
+:	O
+Without	O
+its	O
+N	O
+-	O
+finger	B-ANAT
+,	O
+the	O
+main	O
+protease	O
+of	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+coronavirus	B-SPEC
+can	O
+form	O
+a	O
+novel	O
+dimer	O
+through	O
+its	O
+C	O
+-	O
+terminal	O
+domain	O
+.	O
+
+Therefore	O
+,	O
+the	O
+N	B-PRGE
+-	I-PRGE
+finger	I-PRGE
+of	I-PRGE
+SARS	B-DISO
+-	I-PRGE
+CoV	I-PRGE
+M	I-PRGE
+(	I-PRGE
+pro	B-CHED
+)	I-PRGE
+is	O
+not	O
+only	O
+critical	O
+for	O
+its	O
+dimerization	O
+but	O
+also	O
+essential	O
+for	O
+the	O
+enzyme	O
+to	O
+form	O
+the	O
+enzymatically	O
+active	O
+dimer	O
+.	O
+
+In	O
+conclusion	O
+,	O
+the	O
+approach	O
+we	O
+used	O
+for	O
+armored	O
+L	O
+-	O
+RNA	O
+preparation	O
+is	O
+practical	O
+and	O
+could	O
+reduce	O
+the	O
+labor	B-PROC
+and	O
+cost	O
+of	O
+quality	O
+control	O
+in	O
+multiplex	O
+RNA	O
+virus	B-SPEC
+assays	O
+.	O
+
+TITLE	O
+:	O
+Acute	O
+pulmonary	B-DISO
+capillary	I-DISO
+leak	I-DISO
+syndrome	I-DISO
+during	O
+elective	O
+surgery	O
+under	O
+general	B-PROC
+anesthesia	I-PROC
+.	O
+
+His	O
+condition	B-DISO
+was	O
+well	O
+controlled	O
+before	O
+the	O
+operation	O
+.	O
+
+Elevated	O
+concentrations	O
+of	O
+the	O
+proinflammatory	O
+cytokines	O
+,	O
+interleukin	B-PRGE
+(	O
+IL	O
+)-	O
+6	O
+and	O
+IL	B-FUNC
+-	I-FUNC
+8	I-FUNC
+,	O
+in	O
+both	O
+plasma	B-ANAT
+and	O
+the	O
+pulmonary	B-DISO
+edema	I-DISO
+fluid	O
+,	O
+suggested	O
+a	O
+possible	O
+role	O
+of	O
+systemic	O
+and	O
+pulmonary	B-DISO
+inflammation	I-DISO
+in	O
+the	O
+development	B-PROC
+of	O
+this	O
+acute	O
+pulmonary	B-ANAT
+capillary	I-ANAT
+leak	O
+.	O
+
+ABSTRACT	O
+:	O
+In	O
+the	O
+past	O
+few	O
+years	O
+,	O
+the	O
+classical	O
+concept	O
+of	O
+the	O
+renin	O
+-	O
+angiotensin	B-CHED
+system	O
+(	O
+RAS	B-PRGE
+)	O
+has	O
+experienced	O
+substantial	O
+conceptual	O
+changes	O
+.	O
+
+This	O
+study	O
+was	O
+to	O
+investigate	O
+the	O
+relationship	O
+between	O
+tumor	B-FUNC
+necrosis	I-FUNC
+factor	I-FUNC
+(	O
+TNF	O
+)-	O
+alpha	O
+gene	B-PROC
+polymorphisms	I-PROC
+with	O
+the	O
+occurrence	O
+of	O
+SARS	B-DISO
+-	I-DISO
+CoV	I-DISO
+infection	I-DISO
+and	O
+its	O
+role	O
+in	O
+prognosis	O
+of	O
+patients	O
+with	O
+lung	B-ANAT
+interstitial	B-DISO
+fibrosis	I-DISO
+and	O
+femoral	B-ANAT
+head	I-ANAT
+osteonecrosis	B-DISO
+.	O
+
+At	O
+the	O
+same	O
+time	O
+,	O
+the	O
+-	O
+863	O
+AC	O
+genotype	O
+was	O
+manifested	O
+as	O
+another	O
+risk	O
+effect	O
+associated	O
+with	O
+femoral	B-ANAT
+head	I-ANAT
+necrosis	B-PROC
+with	O
+OR	O
+(	O
+95	O
+%	O
+CI	O
+)	O
+of	O
+6	O
+.	O
+42	O
+(	O
+1	O
+.	O
+53	O
+-	O
+26	O
+.	O
+88	O
+)	O
+and	O
+the	O
+adjusted	O
+OR	O
+was	O
+8	O
+.	O
+40	O
+(	O
+95	O
+%	O
+CI	O
+1	O
+.	O
+76	O
+-	O
+40	O
+.	O
+02	O
+)	O
+in	O
+cured	O
+SARS	B-DISO
+patients	O
+compared	O
+to	O
+CC	O
+genotype	O
+.	O
+
+SNPs	O
+of	O
+TNF	B-PRGE
+-	I-PRGE
+alpha	I-PRGE
+gene	I-PRGE
+of	I-PRGE
+promoter	I-PRGE
+region	I-PRGE
+may	O
+not	O
+associate	O
+with	O
+SARS	B-DISO
+-	I-DISO
+CoV	I-DISO
+infection	I-DISO
+.	O
+
+CONCLUSIONS	O
+:	O
+SNPs	O
+of	O
+TNF	B-PRGE
+-	I-PRGE
+alpha	I-PRGE
+gene	I-PRGE
+of	I-PRGE
+promoter	I-PRGE
+region	I-PRGE
+may	O
+not	O
+associate	O
+with	O
+SARS	B-DISO
+-	I-DISO
+CoV	I-DISO
+infection	I-DISO
+.	O
+
+In	O
+the	O
+experiment	O
+to	O
+determine	O
+whether	O
+SARS	B-DISO
+-	O
+CoV	O
+can	O
+directly	O
+infect	O
+hematopoietic	B-ANAT
+stem	I-ANAT
+cells	I-ANAT
+and	O
+megakaryocytic	B-ANAT
+cells	B-COMP
+,	O
+incubation	O
+of	O
+the	O
+cells	B-COMP
+with	O
+SARS	B-PRGE
+-	I-PRGE
+CoV	I-PRGE
+did	O
+not	O
+show	O
+active	O
+infection	B-DISO
+.	O
+
+ABSTRACT	O
+:	O
+Amiodarone	O
+interferes	O
+with	O
+the	O
+endocytic	O
+pathway	B-PROC
+,	O
+inhibits	O
+proteolysis	B-PROC
+,	O
+and	O
+causes	O
+the	O
+formation	B-PROC
+of	O
+vacuoles	B-COMP
+,	O
+but	O
+uptake	O
+and	O
+intracellular	B-COMP
+distribution	O
+of	O
+the	O
+drug	O
+,	O
+origin	O
+of	O
+vacuoles	B-COMP
+,	O
+and	O
+functional	O
+consequences	O
+of	O
+amiodarone	B-CHED
+accumulation	O
+remain	O
+unclear	O
+.	O
+
+ABSTRACT	O
+:	O
+Acute	O
+lung	B-ANAT
+injury	O
+results	O
+in	O
+a	O
+severe	O
+inflammatory	B-DISO
+response	I-DISO
+,	O
+which	O
+leads	O
+to	O
+priming	O
+and	O
+activation	O
+of	O
+leucocytes	B-ANAT
+,	O
+release	B-PATH
+of	O
+reactive	O
+oxygen	B-CHED
+and	O
+reactive	B-CHED
+nitrogen	I-CHED
+species	I-CHED
+,	O
+destruction	O
+of	O
+pulmonary	B-ANAT
+endothelium	B-ANAT
+,	O
+extravasation	B-DISO
+of	O
+protein	B-CHED
+-	O
+rich	O
+fluid	O
+into	O
+the	O
+interstitium	B-ANAT
+and	O
+formation	B-PROC
+of	O
+oedema	B-DISO
+.	O
+
+Additionally	O
+,	O
+H2S	B-CHED
+administration	O
+attenuated	O
+protein	B-PROC
+oxidation	B-PROC
+following	O
+injury	O
+and	O
+improved	O
+the	O
+histological	O
+condition	B-DISO
+of	O
+the	O
+lung	B-ANAT
+.	O
+
+ABSTRACT	O
+:	O
+The	O
+significance	O
+of	O
+endotoxemia	O
+in	O
+man	O
+is	O
+controversial	O
+,	O
+induces	O
+cytokine	O
+release	B-PATH
+and	O
+stimulates	O
+the	O
+immune	B-ANAT
+system	I-ANAT
+.	O
+
+ALI	O
+/	O
+ARDS	B-DISO
+was	O
+defined	O
+according	O
+to	O
+the	O
+American	O
+-	O
+European	O
+Consensus	O
+Conference	O
+on	O
+ARDS	B-DISO
+.	O
+
+ARDS	B-DISO
+(	O
+P	O
+(	O
+a	O
+)	O
+O	O
+(	O
+2	O
+)/	O
+F	O
+(	O
+i	O
+)	O
+O	O
+(	O
+2	O
+)	O
+<	O
+200	O
+)	O
+revealed	O
+higher	O
+endotoxemia	O
+(	O
+0	O
+.	O
+22	O
+-	O
+0	O
+.	O
+46	O
+[	O
+0	O
+.	O
+06	O
+-	O
+1	O
+.	O
+15	O
+]	O
+EU	O
+/	O
+mL	O
+vs	O
+0	O
+.	O
+05	O
+-	O
+0	O
+.	O
+14	O
+[	O
+0	O
+.	O
+02	O
+-	O
+0	O
+.	O
+63	O
+]	O
+EU	O
+/	O
+mL	O
+)	O
+than	O
+ALI	O
+(	O
+P	O
+(	O
+a	O
+)	O
+O	O
+(	O
+2	O
+)/	O
+F	O
+(	O
+i	O
+)	O
+O	O
+(	O
+2	O
+)	O
+>	O
+200	O
+)	O
+but	O
+lower	O
+DeltaIL	O
+-	O
+6	O
+(	O
+124	O
+-	O
+209	O
+[	O
+10	O
+-	O
+1214	O
+]	O
+pg	O
+/	O
+mL	O
+vs	O
+298	O
+-	O
+746	O
+[	O
+5	O
+-	O
+1797	O
+]	O
+pg	O
+/	O
+mL	O
+),	O
+DeltaTNFalpha	O
+(	O
+50	O
+-	O
+100	O
+[	O
+6	O
+-	O
+660	O
+]	O
+pg	O
+/	O
+mL	O
+vs	O
+143	O
+-	O
+243	O
+[	O
+12	O
+-	O
+2795	O
+]	O
+pg	O
+/	O
+mL	O
+),	O
+and	O
+DeltaIL	O
+-	O
+1	O
+(	O
+2	O
+-	O
+3	O
+[	O
+0	O
+-	O
+26	O
+]	O
+pg	O
+/	O
+mL	O
+vs	O
+2	O
+-	O
+14	O
+[	O
+0	O
+-	O
+99	O
+]	O
+pg	O
+/	O
+mL	O
+).	O
+
+All	O
+patients	O
+presented	O
+antibodies	O
+to	O
+lipopolysaccharides	B-CHED
+and	O
+alpha	B-PRGE
+-	I-PRGE
+hemolysin	I-PRGE
+,	O
+but	O
+the	O
+level	O
+did	O
+not	O
+correlate	O
+with	O
+P	O
+(	O
+a	O
+)	O
+O	O
+(	O
+2	O
+)/	O
+F	O
+(	O
+i	O
+)	O
+O	O
+(	O
+2	O
+).	O
+
+The	O
+more	O
+severe	O
+the	O
+disease	O
+,	O
+the	O
+more	O
+intense	O
+is	O
+endotoxemia	O
+but	O
+the	O
+lower	O
+is	O
+the	O
+capacity	O
+of	O
+mononuclear	B-ANAT
+cells	I-ANAT
+to	O
+release	B-PATH
+cytokines	O
+(	O
+tolerance	B-DISO
+).	O
+
+TITLE	O
+:	O
+Structural	O
+and	O
+biological	O
+basis	O
+of	O
+CTL	B-ANAT
+escape	O
+in	O
+coronavirus	B-SPEC
+-	O
+infected	O
+mice	B-SPEC
+.	O
+
+ABSTRACT	O
+:	O
+Cytotoxic	B-ANAT
+T	I-ANAT
+lymphocyte	I-ANAT
+escape	O
+occurs	O
+in	O
+many	O
+human	B-SPEC
+infections	B-DISO
+,	O
+as	O
+well	O
+as	O
+mice	B-SPEC
+infected	O
+with	O
+the	O
+JHM	O
+strain	O
+of	O
+mouse	B-DISO
+hepatitis	I-DISO
+virus	B-SPEC
+,	O
+which	O
+exhibit	O
+CTL	B-ANAT
+escape	O
+variants	O
+with	O
+mutations	O
+in	O
+a	O
+single	O
+epitope	B-CHED
+from	O
+the	O
+spike	O
+glycoprotein	B-CHED
+(	O
+S510	O
+).	O
+
+Three	O
+phylogenetic	O
+groups	O
+were	O
+identified	O
+,	O
+including	O
+reassortant	O
+strains	O
+-	O
+group	O
+1	O
+(	O
+Victoria	B-SPEC
+lineage	O
+of	O
+HA	O
+,	O
+Yamagata	O
+lineage	O
+of	O
+NA	O
+,	O
+clade	O
+A	O
+of	O
+NS	O
+),	O
+group	O
+2	O
+(	O
+Yamagata	O
+lineage	O
+of	O
+HA	O
+,	O
+Yamagata	O
+lineage	O
+of	O
+NA	O
+,	O
+clade	O
+A	O
+of	O
+NS	O
+),	O
+and	O
+group	O
+3	O
+(	O
+Yamagata	O
+lineage	O
+of	O
+HA	O
+,	O
+Yamagata	O
+lineage	O
+of	O
+NA	O
+,	O
+clade	O
+B	O
+of	O
+NS	O
+).	O
+
+The	O
+goal	O
+of	O
+treatment	O
+is	O
+to	O
+prevent	O
+the	O
+development	B-PROC
+of	O
+multiply	O
+organ	B-ANAT
+dysfunctions	O
+.	O
+
+Indications	O
+for	O
+laparocentesis	O
+and	O
+peritoneal	O
+transudate	B-ANAT
+evacuation	O
+are	O
+discussed	O
+.	O
+
+However	O
+,	O
+compared	O
+to	O
+conventional	O
+vaccines	O
+,	O
+DNA	O
+vaccines	O
+usually	O
+induce	O
+poor	O
+antibody	B-PROC
+responses	I-PROC
+.	O
+
+These	O
+results	O
+demonstrated	O
+that	O
+bicistronic	O
+DNA	O
+vaccine	O
+is	O
+an	O
+effective	O
+approach	O
+to	O
+increase	O
+IBV	B-SPEC
+DNA	O
+vaccine	O
+immunogenicity	O
+.	O
+
+One	O
+of	O
+the	O
+inhibitors	B-CHED
+showed	O
+a	O
+time	O
+-	O
+dependent	O
+inhibition	B-PROC
+,	O
+with	O
+a	O
+K	O
+(	O
+i	O
+)	O
+value	O
+of	O
+0	O
+.	O
+3	O
+microM	O
+after	O
+4h	O
+incubation	O
+.	O
+
+TITLE	O
+:	O
+[	O
+Clinical	O
+study	O
+of	O
+Yihuo	O
+Qingxia	O
+method	O
+in	O
+treating	O
+hyperlipoidemia	O
+-	O
+related	O
+severe	O
+acute	B-DISO
+pancreatitis	I-DISO
+in	O
+early	O
+stage	O
+].	O
+
+One	O
+hundred	O
+and	O
+four	O
+patients	O
+with	O
+hyperlipoidemia	B-PRGE
+-	I-PRGE
+related	I-PRGE
+SAP	I-PRGE
+were	O
+divided	O
+into	O
+two	O
+groups	O
+:	O
+early	O
+group	O
+(	O
+admitted	O
+to	O
+hospital	O
+within	O
+3	O
+days	O
+after	O
+onset	O
+)	O
+and	O
+late	O
+group	O
+(	O
+admitted	O
+to	O
+hospital	O
+from	O
+3	O
+days	O
+to	O
+7	O
+days	O
+after	O
+onset	O
+).	O
+
+Yihuo	O
+Qingxia	O
+method	O
+has	O
+a	O
+good	O
+efficacy	O
+in	O
+treating	O
+hyperlipoidemia	B-PRGE
+-	I-PRGE
+related	I-PRGE
+SAP	I-PRGE
+in	O
+early	O
+stage	O
+.	O
+
+ABSTRACT	O
+:	O
+Human	B-SPEC
+coronavirus	I-SPEC
+229E	I-SPEC
+(	O
+HCoV	O
+)	O
+has	O
+been	O
+recently	O
+recognized	O
+as	O
+a	O
+potential	O
+agent	O
+of	O
+nosocomial	O
+viral	O
+respiratory	B-DISO
+infections	I-DISO
+(	O
+NRVI	O
+)	O
+in	O
+high	O
+-	O
+risk	O
+infants	O
+.	O
+
+Nasal	B-ANAT
+samples	O
+obtained	O
+at	O
+admission	O
+and	O
+weekly	O
+thereafter	O
+for	O
+all	O
+hospitalised	O
+children	O
+,	O
+as	O
+well	O
+as	O
+monthly	O
+nasal	B-ANAT
+samples	O
+from	O
+staff	O
+,	O
+were	O
+analysed	O
+using	O
+immunofluorescence	O
+for	O
+respiratory	B-SPEC
+syncytial	I-SPEC
+virus	I-SPEC
+(	O
+RSV	B-SPEC
+),	O
+influenza	B-SPEC
+viruses	I-SPEC
+A	O
+and	O
+B	O
+,	O
+paramyxoviruses	O
+1	O
+,	O
+2	O
+,	O
+3	O
+and	O
+adenoviruses	B-SPEC
+.	O
+
+Risk	O
+factors	O
+for	O
+NRVI	O
+in	O
+neonates	O
+were	O
+birth	B-PROC
+weight	O
+,	O
+gestational	O
+age	O
+,	O
+ventilation	O
+,	O
+oxygenation	B-PROC
+and	O
+hospitalisation	O
+length	O
+.	O
+
+TITLE	O
+:	O
+Pulmonary	B-ANAT
+coagulopathy	B-DISO
+as	O
+a	O
+new	O
+target	O
+in	O
+lung	B-ANAT
+injury	O
+--	O
+a	O
+review	O
+of	O
+available	O
+pre	O
+-	O
+clinical	O
+models	O
+.	O
+
+Recent	O
+animal	B-SPEC
+studies	O
+have	O
+demonstrated	O
+that	O
+administration	O
+of	O
+heparins	B-CHED
+,	O
+activated	B-PRGE
+protein	B-CHED
+C	I-PRGE
+(	O
+APC	B-COMP
+),	O
+Antithrombin	B-PRGE
+(	O
+AT	O
+),	O
+Tissue	B-PRGE
+factor	I-PRGE
+-	I-PRGE
+Factor	I-PRGE
+VIIa	I-PRGE
+(	O
+TF	O
+-	O
+FVIIa	O
+)	O
+pathway	B-PROC
+inhibitors	B-CHED
+,	O
+plasminogen	B-PROC
+activators	I-PROC
+(	O
+PA	O
+)	O
+and	O
+thrombomodulin	B-PRGE
+(	O
+TM	O
+)	O
+can	O
+attenuate	O
+pulmonary	B-ANAT
+coagulopathy	B-DISO
+and	O
+reduce	O
+lung	B-ANAT
+injury	O
+and	O
+/	O
+or	O
+improve	O
+oxygenation	B-PROC
+.	O
+
+TITLE	O
+:	O
+Intrahepatic	O
+endothelial	B-ANAT
+and	O
+Kupffer	B-ANAT
+cells	I-ANAT
+involved	O
+in	O
+immunosuppressive	O
+cytokines	O
+and	O
+natural	O
+killer	O
+(	O
+NK	O
+)/	O
+NK	O
+T	O
+cell	O
+disorders	O
+in	O
+viral	O
+acute	B-DISO
+hepatitis	I-DISO
+.	O
+
+ABSTRACT	O
+:	O
+During	O
+acute	B-DISO
+viral	I-DISO
+hepatitis	I-DISO
+,	O
+the	O
+intrahepatic	O
+tolerance	B-DISO
+sustained	O
+by	O
+immunosuppressive	O
+cytokines	O
+such	O
+as	O
+interleukin	B-PRGE
+(	O
+IL	O
+)-	O
+4	O
+,	O
+IL	B-FUNC
+-	I-FUNC
+10	I-FUNC
+,	O
+transforming	B-PRGE
+growth	I-PRGE
+factor	I-PRGE
+(	O
+TGF	O
+)-	O
+beta	O
+and	O
+prostaglandin	B-CHED
+E2	I-CHED
+(	O
+PGE2	B-CHED
+),	O
+produced	O
+by	O
+Kupffer	B-ANAT
+cells	I-ANAT
+(	O
+KC	O
+),	O
+liver	B-ANAT
+sinusoidal	O
+endothelial	B-ANAT
+cells	I-ANAT
+(	O
+LSEC	O
+),	O
+natural	O
+killer	O
+(	O
+NK	O
+)	O
+T	B-ANAT
+cells	I-ANAT
+and	O
+natural	O
+regulatory	B-ANAT
+T	I-ANAT
+cells	I-ANAT
+may	O
+be	O
+disturbed	O
+.	O
+
+Tracheal	O
+swabs	O
+from	O
+175	O
+broiler	O
+flocks	O
+at	O
+the	O
+acute	O
+phase	O
+of	O
+respiratory	B-DISO
+disease	I-DISO
+were	O
+collected	O
+.	O
+
+ACE	B-PRGE
+cleaves	O
+angiotensin	B-PRGE
+I	I-PRGE
+to	O
+generate	O
+angiotensin	B-PRGE
+II	I-PRGE
+that	O
+is	O
+a	O
+key	O
+effector	B-CHED
+peptide	B-CHED
+of	O
+the	O
+system	O
+and	O
+exerts	B-PROC
+multiple	O
+biological	O
+functions	O
+,	O
+whereas	O
+ACE2	B-PRGE
+reduces	O
+angiotensin	B-PRGE
+II	I-PRGE
+levels	O
+and	O
+thus	O
+is	O
+a	O
+negative	O
+regulator	O
+of	O
+the	O
+system	O
+.	O
+
+SARS	B-PRGE
+-	I-PRGE
+3CL	I-PRGE
+(	I-PRGE
+pro	B-CHED
+)	I-PRGE
+is	O
+a	O
+viral	B-PRGE
+cysteine	I-PRGE
+protease	I-PRGE
+critical	O
+to	O
+the	O
+pathogen	O
+'	O
+s	O
+life	O
+cycle	O
+and	O
+hence	O
+a	O
+therapeutic	O
+target	O
+of	O
+importance	O
+.	O
+
+To	O
+identify	O
+residues	O
+in	O
+the	O
+spike	O
+protein	B-CHED
+of	O
+NL63	O
+that	O
+are	O
+important	O
+for	O
+hACE2	O
+binding	B-FUNC
+,	O
+this	O
+study	O
+first	O
+generated	O
+a	O
+series	O
+of	O
+S1	O
+-	O
+truncated	O
+variants	O
+,	O
+examined	O
+their	O
+associations	O
+with	O
+the	O
+hACE2	B-PRGE
+receptor	I-PRGE
+and	O
+subsequently	O
+mapped	O
+a	O
+minimal	O
+receptor	O
+-	O
+binding	B-FUNC
+domain	O
+(	O
+RBD	O
+)	O
+that	O
+consisted	O
+of	O
+141	O
+residues	O
+(	O
+aa	O
+476	O
+-	O
+616	O
+)	O
+towards	O
+the	O
+C	O
+terminus	O
+of	O
+the	O
+S1	B-PRGE
+domain	I-PRGE
+.	O
+
+These	O
+results	O
+may	O
+help	O
+to	O
+delineate	O
+the	O
+molecular	O
+interactions	O
+between	O
+the	O
+S	B-PRGE
+protein	I-PRGE
+of	O
+NL63	O
+and	O
+the	O
+hACE2	B-PRGE
+receptor	I-PRGE
+,	O
+and	O
+may	O
+also	O
+enhance	O
+our	O
+understanding	O
+of	O
+the	O
+pathogenesis	B-DISO
+of	O
+NL63	O
+and	O
+SARS	B-DISO
+-	O
+CoV	O
+.	O
+
+The	O
+pre	O
+-	O
+existence	O
+of	O
+anti	O
+-	O
+MV	O
+antibodies	B-COMP
+induced	O
+by	O
+the	O
+initial	O
+immunisation	O
+dose	O
+did	O
+not	O
+inhibit	O
+boost	O
+of	O
+anti	O
+-	O
+S	O
+and	O
+anti	O
+-	O
+N	O
+antibodies	B-COMP
+.	O
+
+Immunisations	O
+comprising	O
+a	O
+mixture	O
+of	O
+rMV	O
+-	O
+S	O
+and	O
+rMV	O
+-	O
+N	O
+induced	O
+immune	B-PROC
+responses	I-PROC
+similar	O
+in	O
+magnitude	O
+to	O
+that	O
+of	O
+vaccine	O
+components	O
+administered	O
+separately	O
+.	O
+
+These	O
+data	O
+support	O
+the	O
+suitability	O
+of	O
+MV	O
+as	O
+a	O
+bivalent	O
+candidate	O
+vaccine	O
+vector	O
+against	O
+MV	O
+and	O
+emerging	O
+viruses	B-SPEC
+such	O
+as	O
+SARS	B-DISO
+-	O
+CoV	O
+.	O
+
+TITLE	O
+:	O
+Homelessness	O
+and	O
+the	O
+response	O
+to	O
+emerging	B-DISO
+infectious	I-DISO
+disease	I-DISO
+outbreaks	O
+:	O
+lessons	O
+from	O
+SARS	B-DISO
+.	O
+
+We	O
+conducted	O
+key	O
+informant	O
+interviews	O
+with	O
+homeless	O
+service	O
+providers	O
+and	O
+public	O
+health	O
+officials	O
+(	O
+n	O
+=	O
+17	O
+)	O
+and	O
+identified	O
+challenges	O
+specific	O
+to	O
+the	O
+homeless	O
+population	O
+in	O
+the	O
+areas	O
+of	O
+communication	O
+,	O
+infection	B-DISO
+control	O
+,	O
+isolation	O
+and	O
+quarantine	O
+,	O
+and	O
+resource	O
+allocation	O
+.	O
+
+TITLE	O
+:	O
+A	O
+survey	O
+of	O
+rodent	B-SPEC
+-	O
+borne	O
+pathogens	O
+carried	O
+by	O
+wild	O
+-	O
+caught	O
+Norway	B-SPEC
+rats	I-SPEC
+:	O
+a	O
+potential	O
+threat	O
+to	O
+laboratory	O
+rodent	O
+colonies	O
+.	O
+
+Antibodies	B-COMP
+against	O
+rat	B-SPEC
+coronavirus	B-SPEC
+/	O
+sialodacryoadenitis	O
+virus	B-SPEC
+(	O
+91	O
+.	O
+7	O
+%),	O
+Mycoplasma	B-SPEC
+pulmonis	I-SPEC
+(	O
+72	O
+.	O
+9	O
+%),	O
+cilia	B-SPEC
+-	I-SPEC
+associated	I-SPEC
+respiratory	I-SPEC
+bacillus	I-SPEC
+(	O
+52	O
+.	O
+1	O
+%),	O
+rat	B-SPEC
+parvovirus	B-DISO
+/	O
+rat	B-SPEC
+minute	O
+virus	B-SPEC
+(	O
+29	O
+.	O
+2	O
+%),	O
+Kilham	B-SPEC
+rat	I-SPEC
+virus	I-SPEC
+(	O
+10	O
+.	O
+4	O
+%),	O
+Toolan	O
+'	O
+s	O
+H	B-SPEC
+-	I-SPEC
+1	I-SPEC
+virus	I-SPEC
+(	O
+10	O
+.	O
+4	O
+%),	O
+Sendai	B-SPEC
+virus	I-SPEC
+(	O
+4	O
+.	O
+2	O
+%)	O
+and	O
+Theiler	B-DISO
+'	I-DISO
+s	I-DISO
+mouse	I-DISO
+encephalomyelitis	I-DISO
+virus	B-SPEC
+(	O
+4	O
+.	O
+2	O
+%),	O
+were	O
+detected	O
+in	O
+wild	O
+-	O
+caught	O
+Norway	B-SPEC
+rats	I-SPEC
+.	O
+
+Endoparasites	O
+,	O
+including	O
+Nippostrongylus	B-SPEC
+braziliensis	O
+(	O
+71	O
+.	O
+6	O
+%),	O
+Rodentolepis	B-SPEC
+nana	O
+or	O
+Hymenolepis	B-SPEC
+diminuta	I-SPEC
+(	O
+34	O
+.	O
+4	O
+%),	O
+Hetarakis	O
+spumosa	O
+(	O
+24	O
+.	O
+1	O
+%)	O
+and	O
+Trichuris	B-SPEC
+muris	I-SPEC
+(	O
+14	O
+.	O
+8	O
+%),	O
+as	O
+well	O
+as	O
+ectoparasites	O
+(	O
+14	O
+.	O
+8	O
+%),	O
+were	O
+identified	O
+in	O
+wild	O
+-	O
+caught	O
+rats	B-SPEC
+.	O
+
+In	O
+smoke	O
+inhalation	B-PROC
+victims	O
+,	O
+tracheobronchial	O
+IL	B-PRGE
+-	I-PRGE
+1beta	I-PRGE
+and	O
+IL	B-FUNC
+-	I-FUNC
+8	I-FUNC
+increase	O
+rapidly	O
+and	O
+high	O
+initial	O
+IL	B-FUNC
+-	I-FUNC
+8	I-FUNC
+may	O
+predict	O
+improved	O
+oxygenation	B-PROC
+.	O
+
+TITLE	O
+:	O
+Effects	O
+of	O
+different	O
+immunization	O
+protocols	O
+and	O
+adjuvant	B-CHED
+on	O
+antibody	B-PROC
+responses	I-PROC
+to	O
+inactivated	O
+SARS	O
+-	O
+CoV	O
+vaccine	O
+.	O
+
+We	O
+attempted	O
+to	O
+investigate	O
+the	O
+effects	O
+of	O
+different	O
+immunization	O
+protocols	O
+and	O
+adjuvant	B-CHED
+on	O
+the	O
+antibody	B-PROC
+responses	I-PROC
+to	O
+inactivated	O
+SARS	B-DISO
+-	O
+CoV	O
+vaccine	O
+.	O
+
+ABSTRACT	O
+:	O
+Snakebite	O
+envenoming	O
+is	O
+an	O
+important	O
+medical	O
+emergency	B-DISO
+in	O
+Kerala	O
+,	O
+but	O
+the	O
+factors	O
+leading	O
+to	O
+complications	O
+have	O
+not	O
+been	O
+well	O
+studied	O
+.	O
+
+To	O
+study	O
+the	O
+clinical	O
+characteristics	O
+,	O
+factors	O
+involved	O
+in	O
+complications	O
+and	O
+the	O
+outcomes	O
+in	O
+relation	O
+to	O
+timing	O
+of	O
+polyvalent	O
+snake	B-SPEC
+antivenom	O
+(	O
+SAV	O
+)	O
+administration	O
+in	O
+patients	O
+with	O
+snakebite	O
+envenoming	O
+.	O
+
+Capillary	B-DISO
+leak	I-DISO
+syndrome	I-DISO
+,	O
+respiratory	O
+paralysis	O
+and	O
+intracerebral	O
+bleeding	B-DISO
+were	O
+the	O
+risk	O
+factors	O
+for	O
+mortality	O
+.	O
+
+Between	O
+November	O
+2003	O
+and	O
+November	O
+2006	O
+,	O
+59	O
+bronchoalveolar	O
+episodes	O
+from	O
+55	O
+HIV	B-DISO
+-	O
+infected	O
+patients	O
+were	O
+analysed	O
+.	O
+
+We	O
+describe	O
+the	O
+case	O
+of	O
+a	O
+64	O
+-	O
+year	O
+-	O
+old	O
+patient	O
+who	O
+had	O
+developed	O
+an	O
+acute	B-DISO
+respiratory	I-DISO
+insufficiency	I-DISO
+due	O
+to	O
+right	O
+-	O
+to	O
+-	O
+left	O
+shunt	O
+in	O
+a	O
+patent	B-DISO
+foramen	I-DISO
+ovale	I-DISO
+one	O
+month	O
+after	O
+right	O
+intrapericardiac	O
+pneumonectomy	O
+.	O
+
+The	O
+patient	O
+was	O
+initially	O
+treated	O
+unsuccessfully	O
+with	O
+bronchodilators	O
+,	O
+corticosteroids	B-CHED
+and	O
+oxygen	B-CHED
+therapy	O
+.	O
+
+The	O
+presence	O
+of	O
+a	O
+right	O
+-	O
+to	O
+-	O
+left	O
+interatrial	O
+shunt	O
+through	O
+a	O
+patent	B-DISO
+foramen	I-DISO
+ovale	I-DISO
+was	O
+documented	O
+by	O
+transesophageal	O
+echocardiography	O
+24	O
+h	O
+after	O
+admission	O
+to	O
+intensive	O
+care	O
+.	O
+
+TITLE	O
+:	O
+Phytochemical	O
+analysis	O
+and	O
+in	O
+vitro	O
+antiviral	B-CHED
+activities	O
+of	O
+the	O
+essential	O
+oils	O
+of	O
+seven	O
+Lebanon	O
+species	O
+.	O
+
+Essential	O
+oils	O
+have	O
+been	O
+evaluated	O
+for	O
+their	O
+inhibitory	O
+activity	O
+against	O
+SARS	B-DISO
+-	O
+CoV	O
+and	O
+HSV	B-SPEC
+-	I-SPEC
+1	I-SPEC
+replication	O
+in	O
+vitro	O
+by	O
+visually	O
+scoring	O
+of	O
+the	O
+virus	B-SPEC
+-	O
+induced	O
+cytopathogenic	O
+effect	O
+post	O
+-	O
+infection	B-DISO
+.	O
+
+ABSTRACT	O
+:	O
+We	O
+developed	O
+a	O
+new	O
+system	O
+for	O
+detection	O
+of	O
+viral	O
+nucleic	O
+acids	O
+because	O
+rapid	O
+detection	O
+of	O
+pathogens	O
+is	O
+necessary	O
+to	O
+prevent	O
+potential	O
+outbreaks	O
+of	O
+infectious	B-DISO
+diseases	I-DISO
+.	O
+
+This	O
+system	O
+,	O
+named	O
+rapid	O
+determination	O
+of	O
+viral	O
+RNA	O
+sequences	O
+(	O
+RDV	B-SPEC
+),	O
+involves	O
+whole	O
+-	O
+genome	O
+amplification	B-DISO
+and	O
+a	O
+new	O
+direct	O
+sequencing	O
+technique	O
+.	O
+
+A	O
+PBS	B-DISO
+control	O
+and	O
+E	B-SPEC
+.	I-SPEC
+coli	I-SPEC
+group	O
+without	O
+previous	O
+virus	B-SPEC
+inoculation	O
+were	O
+also	O
+included	O
+.	O
+
+From	O
+1	O
+to	O
+4dpi	O
+,	O
+NO	O
+production	O
+by	O
+PBMC	O
+from	O
+all	O
+E	B-SPEC
+.	I-SPEC
+coli	I-SPEC
+-	O
+inoculated	O
+animals	B-SPEC
+was	O
+elevated	O
+compared	O
+to	O
+PBS	B-DISO
+birds	B-SPEC
+.	O
+
+The	O
+mRNA	B-CHED
+of	O
+human	B-PRGE
+ACE2	I-PRGE
+was	O
+expressed	B-PROC
+efficiently	O
+in	O
+the	O
+normal	O
+lung	B-ANAT
+tissue	I-ANAT
+,	O
+but	O
+not	O
+in	O
+the	O
+cartilage	B-ANAT
+and	O
+cancellous	B-ANAT
+bone	I-ANAT
+under	O
+the	O
+weight	O
+-	O
+bearing	O
+area	O
+of	O
+the	O
+femoral	B-ANAT
+head	I-ANAT
+.	O
+
+ABSTRACT	O
+:	O
+The	O
+role	O
+of	O
+the	O
+novel	O
+respiratory	O
+viruses	B-SPEC
+,	O
+human	B-PRGE
+metapneumovirus	I-PRGE
+(	O
+hMPV	B-SPEC
+),	O
+human	B-PRGE
+coronavirus	I-PRGE
+NL63	I-PRGE
+(	O
+HCoV	O
+NL63	O
+)	O
+and	O
+human	B-SPEC
+bocavirus	I-SPEC
+(	O
+HBoV	O
+),	O
+in	O
+wheezing	B-DISO
+illness	O
+in	O
+children	O
+has	O
+not	O
+been	O
+well	O
+studied	O
+,	O
+especially	O
+in	O
+Africa	O
+.	O
+
+TITLE	O
+:	O
+Reduced	O
+incorporation	O
+of	O
+SARS	B-PRGE
+-	I-PRGE
+CoV	I-PRGE
+spike	I-PRGE
+protein	B-CHED
+into	O
+viral	B-COMP
+particles	I-COMP
+due	O
+to	O
+amino	B-CHED
+acid	I-CHED
+substitutions	I-PROC
+within	O
+the	O
+receptor	O
+binding	O
+domain	O
+.	O
+
+Carbon	B-CHED
+monoxide	I-CHED
+poisoning	O
+from	O
+such	O
+a	O
+source	O
+,	O
+however	O
+,	O
+is	O
+extremely	O
+rare	O
+.	O
+
+The	O
+53	O
+-	O
+year	O
+-	O
+old	O
+father	O
+performed	O
+cardiopulmonary	B-ANAT
+resuscitation	O
+on	O
+his	O
+son	O
+but	O
+soon	O
+lost	B-CHED
+consciousness	O
+.	O
+
+Her	O
+symptoms	O
+improved	O
+after	O
+oxygen	B-CHED
+therapy	O
+.	O
+
+Acardiac	O
+twinning	O
+is	O
+the	O
+most	O
+extreme	O
+manifestation	O
+of	O
+the	O
+twin	B-DISO
+-	I-DISO
+twin	I-DISO
+transfusion	I-DISO
+syndrome	I-DISO
+.	O
+
+This	O
+occurs	O
+in	O
+1	O
+in	O
+100	O
+monozygotic	O
+twin	O
+pregnancies	B-PROC
+and	O
+1	O
+in	O
+35	O
+,	O
+000	O
+births	B-PROC
+.	O
+
+We	O
+report	O
+a	O
+case	O
+of	O
+diamnionic	O
+monochorionic	O
+female	O
+twins	O
+in	O
+which	O
+the	O
+acardiac	B-DISO
+twin	I-DISO
+demonstrated	O
+severe	O
+hydrops	B-DISO
+fetalis	I-DISO
+and	O
+bilateral	O
+talipes	O
+varus	B-DISO
+deformity	I-DISO
+.	O
+
+The	O
+acardiac	O
+fetus	B-ANAT
+had	O
+a	O
+two	O
+-	O
+vessel	B-ANAT
+umbilical	B-ANAT
+cord	I-ANAT
+measuring	O
+43	O
+.	O
+5	O
+cm	O
+in	O
+length	O
+and	O
+0	O
+.	O
+8	O
+cm	O
+in	O
+diameter	O
+.	O
+
+The	O
+fetus	B-ANAT
+was	O
+severely	O
+hydropic	O
+.	O
+
+It	O
+was	O
+found	O
+that	O
+:	O
+(	O
+1	O
+)	O
+there	O
+was	O
+an	O
+overall	O
+increase	O
+in	O
+knowledge	O
+of	O
+bioevent	O
+preparedness	O
+;	O
+(	O
+2	O
+)	O
+participants	O
+gave	O
+high	O
+ratings	O
+for	O
+the	O
+effectiveness	O
+of	O
+the	O
+PBL	O
+process	O
+;	O
+(	O
+3	O
+)	O
+participants	O
+found	O
+value	O
+in	O
+the	O
+multidisciplinary	O
+group	O
+process	O
+;	O
+and	O
+(	O
+4	O
+)	O
+participants	O
+strongly	O
+agreed	O
+that	O
+they	O
+preferred	O
+the	O
+PBL	O
+process	O
+to	O
+the	O
+traditional	O
+lecture	O
+format	O
+for	O
+learning	B-PROC
+about	O
+bioevent	O
+preparedness	O
+.	O
+
+The	O
+other	O
+40	O
+%	O
+will	O
+develop	O
+symptomatic	O
+disease	O
+that	O
+manifests	O
+with	O
+variable	O
+signs	B-DISO
+and	I-DISO
+symptoms	I-DISO
+,	O
+predominantly	O
+an	O
+influenza	B-DISO
+-	O
+like	O
+syndrome	B-DISO
+,	O
+pneumonia	B-DISO
+,	O
+or	O
+pleural	B-DISO
+effusion	I-DISO
+.	O
+
+In	O
+this	O
+review	O
+we	O
+highlight	O
+the	O
+similarities	O
+and	O
+differences	O
+of	O
+SARS	B-DISO
+and	O
+H5N1	B-DISO
+,	O
+and	O
+emphasize	O
+the	O
+importance	O
+of	O
+appropriate	O
+sampling	O
+for	O
+laboratory	O
+diagnosis	O
+of	O
+the	O
+latter	O
+.	O
+
+ABSTRACT	O
+:	O
+There	O
+were	O
+three	O
+events	O
+of	O
+severe	O
+acute	O
+respiratory	O
+syndrome	O
+(	O
+SARS	B-DISO
+)	O
+in	O
+China	O
+from	O
+2003	O
+to	O
+2004	O
+.	O
+
+TITLE	O
+:	O
+Proteomics	O
+analysis	O
+unravels	O
+the	O
+functional	O
+repertoire	O
+of	O
+coronavirus	B-SPEC
+nonstructural	O
+protein	B-CHED
+3	O
+.	O
+
+ABSTRACT	O
+:	O
+Severe	O
+acute	O
+respiratory	O
+syndrome	O
+(	O
+SARS	B-DISO
+)	O
+coronavirus	B-DISO
+infection	I-DISO
+and	O
+growth	B-PROC
+are	O
+dependent	O
+on	O
+initiating	O
+signaling	B-PROC
+and	O
+enzyme	O
+actions	O
+upon	O
+viral	O
+entry	O
+into	O
+the	O
+host	B-COMP
+cell	I-COMP
+.	O
+
+Mass	O
+spectrometry	O
+and	O
+kinase	O
+profiling	O
+techniques	O
+identified	O
+nearly	O
+200	O
+incorporated	O
+host	B-COMP
+and	O
+viral	O
+proteins	B-CHED
+.	O
+
+One	O
+of	O
+these	O
+domains	O
+is	O
+located	O
+within	O
+the	O
+previously	O
+described	O
+SARS	B-DISO
+-	O
+unique	O
+domain	O
+,	O
+and	O
+there	O
+is	O
+a	O
+nucleic	B-CHED
+acid	I-CHED
+chaperone	O
+-	O
+like	O
+domain	O
+located	O
+immediately	O
+downstream	O
+of	O
+the	O
+papain	B-PRGE
+-	I-PRGE
+like	I-PRGE
+proteinase	B-PROC
+domain	I-PRGE
+.	O
+
+ABSTRACT	O
+:	O
+Severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+(	O
+SARS	B-DISO
+)	O
+is	O
+a	O
+systemic	B-DISO
+disease	I-DISO
+characterized	O
+by	O
+both	O
+lung	B-ANAT
+pathology	B-DISO
+and	O
+widespread	O
+extrapulmonary	O
+virus	B-SPEC
+dissemination	O
+causing	O
+multiple	O
+organ	B-ANAT
+injuries	O
+.	O
+
+Immortalized	O
+cultures	O
+of	O
+differentiated	B-PROC
+proximal	O
+tubular	O
+epithelial	B-ANAT
+cells	I-ANAT
+(	O
+PTEC	O
+),	O
+glomerular	B-ANAT
+mesangial	I-ANAT
+cells	I-ANAT
+(	O
+MC	O
+),	O
+and	O
+glomerular	B-ANAT
+epithelial	B-ANAT
+cells	I-ANAT
+(	O
+podocytes	O
+)	O
+were	O
+found	O
+to	O
+express	O
+the	O
+SARS	O
+-	O
+CoV	O
+receptor	O
+angiotensin	B-PRGE
+-	I-PRGE
+converting	I-PRGE
+enzyme	I-PRGE
+2	I-PRGE
+on	O
+their	O
+surface	O
+.	O
+
+This	O
+SARS	B-PRGE
+-	I-PRGE
+CoV	I-PRGE
+variant	O
+acquired	O
+a	O
+single	O
+nonconservative	O
+amino	B-CHED
+acid	I-CHED
+change	O
+from	O
+glutamic	B-CHED
+acid	I-CHED
+(	O
+E	O
+)	O
+to	O
+alanine	B-CHED
+(	O
+A	O
+)	O
+at	O
+position	O
+11	O
+in	O
+the	O
+viral	B-COMP
+membrane	I-COMP
+(	O
+M	O
+)	O
+protein	B-CHED
+.	O
+
+The	O
+analysis	O
+shows	O
+no	O
+consistent	O
+correlation	O
+between	O
+frameshifting	O
+efficiency	O
+and	O
+global	O
+stability	O
+of	O
+the	O
+downstream	O
+mRNA	B-CHED
+structure	O
+.	O
+
+The	O
+study	O
+also	O
+illustrates	O
+the	O
+capability	O
+of	O
+siRNA	O
+to	O
+enable	O
+a	O
+massive	O
+reduction	O
+in	O
+development	B-PROC
+time	O
+for	O
+novel	O
+targeted	B-PROC
+therapeutic	O
+agents	O
+.	O
+
+We	O
+detail	O
+a	O
+representative	O
+example	O
+of	O
+large	O
+-	O
+mammal	B-SPEC
+siRNA	O
+use	O
+.	O
+
+Fluorescence	O
+from	O
+CFP	O
+and	O
+YFP	O
+was	O
+in	O
+each	O
+case	O
+observed	O
+in	O
+separate	O
+areas	O
+in	O
+both	O
+inoculated	O
+and	O
+upper	O
+uninoculated	O
+leaves	O
+,	O
+indicating	O
+that	O
+populations	O
+of	O
+identical	O
+,	O
+but	O
+differently	O
+labeled	O
+viruses	B-SPEC
+were	O
+replicated	O
+and	O
+distributed	O
+in	O
+discrete	O
+areas	O
+of	O
+infected	O
+leaves	O
+.	O
+
+TITLE	O
+:	O
+Materno	O
+-	O
+fetal	B-ANAT
+transmission	O
+of	O
+human	B-SPEC
+coronaviruses	O
+:	O
+a	O
+prospective	O
+pilot	O
+study	O
+.	O
+
+Possible	O
+vertical	B-DISO
+transmission	I-DISO
+of	O
+HCoV	O
+was	O
+hypothesized	O
+in	O
+this	O
+pilot	O
+study	O
+and	O
+requires	O
+further	O
+investigation	O
+on	O
+a	O
+larger	O
+scale	O
+.	O
+
+ABSTRACT	O
+:	O
+Based	O
+on	O
+a	O
+five	O
+-	O
+letter	O
+model	O
+of	O
+the	O
+20	O
+amino	O
+acids	O
+,	O
+we	O
+propose	O
+a	O
+new	O
+2	O
+-	O
+D	O
+graphical	O
+representation	O
+of	O
+protein	B-CHED
+sequence	O
+.	O
+
+Then	O
+we	O
+transform	O
+the	O
+2	O
+-	O
+D	O
+graphical	O
+representation	O
+into	O
+a	O
+numerical	O
+characterization	O
+that	O
+will	O
+facilitate	O
+quantitative	O
+comparisons	O
+of	O
+protein	B-CHED
+sequences	O
+.	O
+
+TITLE	O
+:	O
+Emerging	O
+zoonoses	B-DISO
+:	O
+the	O
+challenge	O
+for	O
+public	O
+health	O
+and	O
+biodefense	O
+.	O
+
+Models	O
+that	O
+strive	O
+to	O
+predict	O
+the	O
+dynamics	O
+of	O
+agents	O
+may	O
+be	O
+useful	O
+but	O
+can	O
+also	O
+blind	B-DISO
+us	O
+to	O
+increasing	O
+disease	O
+risks	O
+if	O
+it	O
+does	O
+not	O
+match	O
+a	O
+specific	O
+model	O
+.	O
+
+Zoonoses	B-DISO
+must	O
+be	O
+dealt	O
+with	O
+at	O
+the	O
+interface	O
+of	O
+human	B-SPEC
+and	O
+animal	B-SPEC
+health	O
+by	O
+all	O
+available	O
+information	O
+.	O
+
+25	O
+kg	O
+,	O
+and	O
+had	O
+failed	O
+conventional	O
+lung	B-ANAT
+-	O
+protective	O
+ventilation	O
+due	O
+to	O
+refractory	O
+hypoxia	B-DISO
+or	O
+respiratory	B-DISO
+acidosis	I-DISO
+and	O
+high	O
+plateau	O
+airway	B-ANAT
+pressures	O
+.	O
+
+Most	O
+adults	O
+can	O
+maintain	O
+adequate	O
+gas	B-ENZY
+exchange	O
+using	O
+HFO	O
+frequencies	O
+well	O
+above	O
+5	O
+-	O
+6	O
+Hz	O
+.	O
+
+Use	O
+of	O
+higher	O
+frequencies	O
+should	O
+minimize	O
+tidal	O
+volume	O
+and	O
+we	O
+speculate	O
+might	O
+thereby	O
+reduce	O
+ventilator	O
+-	O
+associated	O
+lung	B-ANAT
+injury	O
+.	O
+
+TITLE	O
+:	O
+Protective	O
+effects	O
+of	O
+propofol	B-CHED
+on	O
+acute	O
+lung	B-ANAT
+injury	O
+induced	O
+by	O
+oleic	B-CHED
+acid	I-CHED
+in	O
+conscious	O
+rats	B-SPEC
+.	O
+
+Histopathological	O
+examination	O
+of	O
+the	O
+lung	B-ANAT
+was	O
+performed	O
+.	O
+
+In	O
+addition	O
+,	O
+oleic	B-CHED
+acid	I-CHED
+significantly	O
+increased	O
+inflammatory	O
+mediators	O
+and	O
+neutrophil	B-ANAT
+-	O
+derived	O
+factors	O
+but	O
+depressed	O
+Na	B-PRGE
++-	I-PRGE
+K	I-PRGE
++-	I-PRGE
+ATPase	I-PRGE
+.	O
+
+As	O
+no	O
+effective	O
+vaccines	O
+or	O
+antiviral	B-CHED
+agents	I-CHED
+are	O
+available	O
+,	O
+the	O
+most	O
+effective	O
+measure	O
+to	O
+prevent	O
+the	O
+expansion	O
+of	O
+a	O
+SARS	B-DISO
+epidemic	O
+is	O
+the	O
+rapid	O
+diagnosis	O
+and	O
+isolation	O
+of	O
+SARS	B-DISO
+patients	O
+.	O
+
+The	O
+information	O
+about	O
+binding	B-FUNC
+sites	O
+and	O
+epitopes	O
+of	O
+monoclonal	O
+antibodies	B-COMP
+may	O
+be	O
+useful	O
+for	O
+the	O
+development	B-PROC
+of	O
+new	O
+diagnostic	O
+methods	O
+for	O
+SARS	B-DISO
+and	O
+for	O
+analyzing	O
+the	O
+function	O
+of	O
+N	B-PRGE
+protein	I-PRGE
+of	O
+SARS	B-PRGE
+-	I-PRGE
+CoV	I-PRGE
+.	O
+
+ABSTRACT	O
+:	O
+SARS	B-DISO
+-	O
+CoV	O
+grows	O
+in	O
+a	O
+variety	O
+of	O
+tissues	B-ANAT
+that	O
+express	O
+its	O
+receptor	O
+,	O
+although	O
+the	O
+mechanism	O
+for	O
+high	O
+replication	O
+in	O
+the	O
+lungs	B-ANAT
+and	O
+severe	O
+respiratory	O
+illness	O
+is	O
+not	O
+well	O
+understood	O
+.	O
+
+TITLE	O
+:	O
+Evidence	O
+-	O
+based	O
+therapy	O
+of	O
+severe	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+:	O
+an	O
+algorithm	O
+-	O
+guided	O
+approach	O
+.	O
+
+Criteria	O
+for	O
+administration	O
+,	O
+weaning	B-PROC
+and	O
+discontinuation	O
+of	O
+these	O
+supportive	O
+interventions	O
+have	O
+never	O
+been	O
+described	O
+in	O
+detail	O
+.	O
+
+The	O
+introduction	O
+of	O
+the	O
+T10651C	O
+mutation	O
+into	O
+the	O
+infectious	B-DISO
+MHV	B-SPEC
+clone	O
+resulted	O
+in	O
+the	O
+recovery	O
+of	O
+a	O
+mutant	B-DISO
+virus	B-SPEC
+,	O
+the	O
+nsp5	B-PRGE
+/	I-PRGE
+V148A	I-PRGE
+virus	B-SPEC
+,	O
+that	O
+demonstrated	O
+reduced	O
+growth	B-PROC
+and	O
+nsp5	B-PRGE
+proteinase	I-PRGE
+activity	O
+identical	O
+to	O
+that	O
+of	O
+Alb	B-PRGE
+/	O
+ts	O
+/	O
+nsp5	B-PRGE
+/	O
+V148A	O
+at	O
+the	O
+nonpermissive	O
+temperature	O
+.	O
+
+Sequence	O
+analysis	O
+of	O
+40	O
+degrees	O
+C	O
+revertants	O
+of	O
+Alb	B-PRGE
+/	O
+ts	O
+/	O
+nsp5	B-PRGE
+/	O
+V148A	O
+identified	O
+primary	O
+reversion	O
+to	O
+Ala148Val	O
+in	O
+nsp5	O
+,	O
+as	O
+well	O
+as	O
+two	O
+independent	O
+second	O
+-	O
+site	O
+mutations	O
+resulting	O
+in	O
+Ser133Asn	O
+and	O
+His134Tyr	O
+substitutions	O
+in	O
+nsp5	B-PRGE
+.	O
+
+Modeling	O
+of	O
+the	O
+nsp5	B-PRGE
+structure	O
+of	O
+Alb	B-PRGE
+/	O
+ts	O
+/	O
+nsp5	B-PRGE
+/	O
+V148A	O
+predicted	O
+that	O
+the	O
+Val148Ala	O
+mutation	O
+alters	O
+residue	O
+148	O
+interactions	O
+with	O
+residues	O
+of	O
+the	O
+substrate	O
+binding	B-FUNC
+S1	O
+subsite	O
+of	O
+the	O
+nsp5	B-PRGE
+active	O
+-	O
+site	O
+cavity	B-DISO
+.	O
+
+This	O
+study	O
+identifies	O
+novel	O
+residues	O
+in	O
+nsp5	B-PRGE
+that	O
+may	O
+be	O
+important	O
+for	O
+regulating	O
+substrate	O
+specificity	O
+and	O
+nsp5	B-PRGE
+proteinase	I-PRGE
+activity	O
+.	O
+
+Here	O
+we	O
+demonstrate	O
+that	O
+these	O
+strains	O
+also	O
+differ	O
+in	O
+their	O
+abilities	O
+to	O
+infect	O
+a	O
+particular	O
+cell	B-COMP
+type	I-COMP
+(	O
+s	O
+)	O
+in	O
+the	O
+brain	B-ANAT
+.	O
+
+Overall	O
+,	O
+these	O
+observations	O
+suggest	O
+that	O
+isogenic	O
+demyelinating	O
+and	O
+nondemyelinating	O
+strains	O
+of	O
+MHV	B-SPEC
+,	O
+differing	O
+in	O
+the	O
+spike	O
+protein	B-CHED
+expressed	B-PROC
+,	O
+infect	O
+neurons	B-ANAT
+and	O
+glial	B-ANAT
+cells	I-ANAT
+in	O
+different	O
+proportions	O
+and	O
+that	O
+differential	O
+tropism	B-PROC
+to	O
+a	O
+particular	O
+CNS	B-CHED
+cell	B-COMP
+type	I-COMP
+may	O
+play	O
+a	O
+significant	O
+role	O
+in	O
+mediating	O
+the	O
+onset	O
+and	O
+mechanisms	O
+of	O
+demyelination	B-DISO
+.	O
+
+The	O
+results	O
+were	O
+that	O
+the	O
+majority	O
+(	O
+53	O
+%)	O
+of	O
+bronchiolites	O
+in	O
+children	O
+had	O
+like	O
+etiology	O
+RSV	B-SPEC
+and	O
+a	O
+lot	O
+of	O
+these	O
+infections	B-DISO
+had	O
+double	O
+viral	O
+etiology	O
+(	O
+26	O
+%	O
+RSV	O
++	O
+Rhinovirus	B-SPEC
+;	O
+2	O
+,	O
+7	O
+%	O
+RSV	B-SPEC
++	I-SPEC
+HMPV	I-SPEC
+and	O
+1	O
+%	O
+RSV	B-SPEC
++	I-SPEC
+Coronavirus	I-SPEC
+229E	O
+).	O
+
+ABSTRACT	O
+:	O
+Bovine	O
+coronavirus	B-SPEC
+(	O
+BCoV	O
+)	O
+causes	O
+severe	B-DISO
+diarrhea	I-DISO
+in	O
+newborn	O
+calves	O
+,	O
+is	O
+associated	O
+with	O
+winter	B-DISO
+dysentery	I-DISO
+in	O
+adult	O
+cattle	B-SPEC
+and	O
+respiratory	B-DISO
+infections	I-DISO
+in	O
+calves	O
+and	O
+feedlot	O
+cattle	B-SPEC
+.	O
+
+The	O
+present	O
+study	O
+describes	O
+a	O
+strategy	O
+for	O
+the	O
+sequencing	O
+of	O
+the	O
+BCoV	B-PRGE
+S1	I-PRGE
+gene	I-PRGE
+directly	O
+from	O
+fecal	B-ANAT
+diarrheic	O
+specimens	O
+that	O
+were	O
+previously	O
+identified	O
+as	O
+BCoV	O
+positive	O
+by	O
+RT	O
+-	O
+PCR	O
+assay	O
+for	O
+N	O
+gene	O
+detection	O
+.	O
+
+Based	O
+on	O
+the	O
+phylogenetic	O
+analysis	O
+of	O
+the	O
+hypervariable	O
+region	O
+of	O
+the	O
+S1	B-PRGE
+subunit	I-PRGE
+,	O
+these	O
+strains	O
+clustered	O
+with	O
+the	O
+American	O
+(	O
+BCoV	O
+-	O
+ENT	B-ANAT
+,	O
+182NS	O
+)	O
+and	O
+Canadian	O
+(	O
+BCQ20	O
+,	O
+BCQ2070	O
+,	O
+BCQ9	O
+,	O
+BCQ571	O
+,	O
+BCQ1523	O
+)	O
+calf	B-ANAT
+diarrhea	B-DISO
+and	O
+the	O
+Canadian	O
+winter	B-DISO
+dysentery	I-DISO
+(	O
+BCQ7373	O
+,	O
+BCQ2590	O
+)	O
+strains	O
+,	O
+but	O
+clustered	O
+on	O
+a	O
+separate	O
+branch	B-ANAT
+of	I-ANAT
+the	O
+Korean	O
+and	O
+respiratory	O
+BCoV	O
+strains	O
+.	O
+
+Some	O
+veterinarians	O
+prescribe	O
+immune	O
+modulators	O
+to	O
+treat	O
+cats	B-SPEC
+with	O
+FIP	B-DISO
+with	O
+no	O
+documented	O
+controlled	O
+evidence	O
+of	O
+efficacy	O
+.	O
+
+The	O
+internal	O
+control	O
+primers	O
+and	O
+probe	O
+target	O
+a	O
+region	O
+in	O
+the	O
+coat	B-PRGE
+protein	B-CHED
+gene	I-PRGE
+of	O
+the	O
+E	B-PRGE
+.	I-PRGE
+coli	I-PRGE
+F	I-PRGE
+-	I-PRGE
+specific	I-PRGE
+bacteriophage	B-SPEC
+ms2	I-PRGE
+,	O
+which	O
+is	O
+contained	O
+within	O
+the	O
+aRNA	B-SPEC
+.	O
+
+Because	O
+it	O
+is	O
+difficult	O
+to	O
+obtain	O
+regulatory	O
+approval	O
+of	O
+vaccine	O
+based	O
+on	O
+live	O
+viruses	B-SPEC
+,	O
+we	O
+constructed	O
+a	O
+replication	O
+-	O
+defective	O
+single	O
+-	O
+cycle	O
+VSV	O
+vector	O
+in	O
+which	O
+we	O
+replaced	O
+the	O
+VSV	O
+glycoprotein	B-CHED
+(	O
+G	O
+)	O
+gene	O
+with	O
+the	O
+SARS	B-PRGE
+-	I-PRGE
+CoV	I-PRGE
+S	I-PRGE
+gene	I-PRGE
+.	O
+
+Our	O
+results	O
+,	O
+along	O
+with	O
+earlier	O
+studies	O
+showing	O
+potent	O
+induction	O
+of	O
+T	B-ANAT
+-	I-ANAT
+cell	I-ANAT
+responses	O
+by	O
+single	O
+-	O
+cycle	O
+vectors	O
+,	O
+indicate	O
+that	O
+these	O
+vectors	O
+are	O
+excellent	O
+alternatives	O
+to	O
+live	O
+-	O
+attenuated	O
+VSV	O
+.	O
+
+Inhibition	O
+of	O
+ciliostasis	O
+was	O
+also	O
+observed	O
+when	O
+TOCs	O
+were	O
+pretreated	O
+with	O
+an	O
+alpha2	B-PRGE
+,	I-PRGE
+3	I-PRGE
+-	I-PRGE
+specific	I-PRGE
+neuraminidase	I-PRGE
+.	O
+
+These	O
+results	O
+indicate	O
+that	O
+alpha2	O
+,	O
+3	O
+-	O
+linked	O
+sialic	B-CHED
+acid	I-CHED
+plays	O
+an	O
+important	O
+role	O
+for	O
+infection	B-DISO
+of	O
+the	O
+respiratory	B-ANAT
+epithelium	I-ANAT
+by	O
+IBV	B-SPEC
+.	O
+
+TITLE	O
+:	O
+[	O
+Prospective	O
+,	O
+multicenter	O
+study	O
+of	O
+mortality	O
+and	O
+risk	O
+factors	O
+in	O
+children	O
+with	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+in	O
+25	O
+pediatric	O
+intensive	O
+care	O
+units	O
+in	O
+China	O
+].	O
+
+ARDS	B-DISO
+was	O
+diagnosed	O
+according	O
+to	O
+the	O
+1994	O
+American	O
+-	O
+European	O
+Consensus	O
+Conference	O
+criteria	O
+.	O
+
+ABSTRACT	O
+:	O
+This	O
+study	O
+was	O
+designated	O
+to	O
+investigate	O
+whether	O
+extravascular	O
+lung	O
+water	B-CHED
+index	O
+(	O
+EVLI	O
+)	O
+is	O
+an	O
+independent	O
+predictor	O
+for	O
+mortality	O
+outcome	O
+in	O
+patients	O
+with	O
+severe	B-DISO
+sepsis	I-DISO
+.	O
+
+ABSTRACT	O
+:	O
+SARS	B-DISO
+-	I-PRGE
+CoV	I-PRGE
+M	I-PRGE
+gene	I-PRGE
+fragment	I-PRGE
+was	O
+cloned	O
+and	O
+expressed	O
+as	O
+a	O
+recombinant	O
+protein	B-CHED
+fused	O
+with	O
+a	O
+V5	B-PRGE
+tag	I-PRGE
+at	O
+the	O
+C	O
+-	O
+terminus	O
+in	O
+Vero	O
+E6	O
+cells	B-COMP
+.	O
+
+Translation	B-PROC
+initiated	O
+in	O
+-	O
+frame	O
+from	O
+the	O
+third	O
+Met	B-CHED
+is	O
+unusual	O
+since	O
+the	O
+sequence	O
+around	O
+the	O
+first	O
+Met	B-CHED
+of	O
+SARS	B-PRGE
+-	I-PRGE
+CoV	I-PRGE
+M	I-PRGE
+protein	B-CHED
+contains	O
+the	O
+optimal	O
+consensus	O
+Kozak	O
+sequence	O
+.	O
+
+TITLE	O
+:	O
+Detection	O
+and	O
+prevalence	O
+patterns	O
+of	O
+group	O
+I	O
+coronaviruses	O
+in	O
+bats	B-SPEC
+,	O
+northern	O
+Germany	O
+.	O
+
+The	O
+lineages	O
+formed	O
+a	O
+monophyletic	O
+clade	O
+of	O
+bat	B-ENZY
+coronaviruses	O
+found	O
+in	O
+northern	O
+Germany	O
+.	O
+
+These	O
+mini	O
+-	O
+GST	B-PRGE
+fusion	O
+proteins	B-CHED
+were	O
+scanned	O
+by	O
+ELISA	O
+and	O
+Western	O
+blotting	O
+with	O
+the	O
+six	O
+McAbs	O
+,	O
+and	O
+the	O
+result	O
+showed	O
+that	O
+S1D5	O
+(	O
+residues	O
+744	O
+-	O
+759	O
+)	O
+and	O
+S1D6	O
+(	O
+residues	O
+756	O
+-	O
+771	O
+)	O
+are	O
+two	O
+linear	O
+epitopes	O
+of	O
+the	O
+PEDV	B-PRGE
+S	I-PRGE
+protein	B-CHED
+.	O
+
+The	O
+anticomplementary	O
+activity	O
+was	O
+evaluated	O
+from	O
+hemolytic	O
+assays	O
+through	O
+the	O
+classical	O
+pathway	B-PROC
+(	O
+CP	O
+)	O
+and	O
+the	O
+alternative	O
+pathway	B-PROC
+(	O
+AP	O
+)	O
+of	O
+complement	O
+system	O
+in	O
+vitro	O
+.	O
+
+Vascular	B-DISO
+lesions	I-DISO
+,	O
+e	O
+.	O
+g	O
+.	O
+degeneration	B-DISO
+of	O
+endothelial	B-ANAT
+cells	I-ANAT
+,	O
+perivascular	O
+and	O
+intramural	O
+oedema	B-DISO
+,	O
+fibrinoid	B-DISO
+necrosis	I-DISO
+,	O
+vasculitis	B-DISO
+,	O
+perivasculitis	B-DISO
+,	O
+and	O
+vascular	B-ANAT
+thrombi	B-DISO
+were	O
+observed	O
+in	O
+all	O
+cases	O
+,	O
+associated	O
+with	O
+the	O
+presence	O
+of	O
+PCV2	B-PRGE
+antigen	I-PRGE
+.	O
+
+Twelve	O
+of	O
+17	O
+(	O
+70	O
+.	O
+6	O
+%)	O
+nursing	B-PROC
+staff	O
+who	O
+developed	O
+SARS	B-DISO
+worked	O
+with	O
+another	O
+nursing	B-PROC
+staff	O
+who	O
+was	O
+symptomatic	O
+for	O
+SARS	B-DISO
+.	O
+
+These	O
+relaxations	O
+of	O
+precautions	O
+were	O
+temporally	O
+associated	O
+with	O
+the	O
+nosocomial	O
+transmission	O
+of	O
+SARS	B-DISO
+to	O
+hospital	O
+staff	O
+,	O
+other	O
+patients	O
+and	O
+visitors	O
+at	O
+Hospital	O
+X	O
+.	O
+As	O
+a	O
+result	O
+of	O
+this	O
+outbreak	O
+significant	O
+changes	O
+have	O
+been	O
+made	O
+with	O
+respect	O
+to	O
+infection	B-DISO
+-	O
+control	O
+practices	O
+within	O
+Canada	O
+.	O
+
+Multivariate	O
+logistic	O
+regression	O
+analysis	O
+showed	O
+that	O
+ARDS	B-DISO
+and	O
+hyperglycosemia	O
+were	O
+high	O
+risk	O
+factors	O
+.	O
+
+The	O
+angiotensin	B-PRGE
+-	I-PRGE
+converting	I-PRGE
+enzyme	I-PRGE
+2	I-PRGE
+(	O
+ACE	B-PRGE
+-	I-PRGE
+2	I-PRGE
+)	O
+has	O
+been	O
+identified	O
+as	O
+a	O
+functional	O
+receptor	O
+for	O
+SARS	B-PRGE
+-	I-PRGE
+CoV	I-PRGE
+.	O
+ACE	B-PRGE
+-	I-PRGE
+2	I-PRGE
+has	O
+been	O
+shown	O
+to	O
+be	O
+expressed	B-PROC
+at	O
+the	O
+apical	O
+domain	O
+of	O
+polarized	O
+Calu	O
+-	O
+3	O
+cells	B-COMP
+.	O
+
+The	O
+data	O
+might	O
+provide	O
+an	O
+important	O
+insight	O
+into	O
+the	O
+mechanism	O
+of	O
+pathogenesis	B-DISO
+of	O
+SARS	B-DISO
+-	O
+CoV	O
+allowing	O
+further	O
+development	B-PROC
+of	O
+antiviral	B-CHED
+therapies	O
+for	O
+treating	O
+SARS	B-DISO
+infections	B-DISO
+.	O
+
+ABSTRACT	O
+:	O
+The	O
+related	O
+3C	O
+and	O
+3C	O
+-	O
+like	O
+proteinase	O
+(	O
+3C	O
+(	O
+pro	B-CHED
+)	O
+and	O
+3CL	O
+(	O
+pro	B-PRGE
+))	O
+of	O
+picornaviruses	B-SPEC
+and	O
+coronaviruses	O
+,	O
+respectively	O
+,	O
+are	O
+good	O
+drug	O
+targets	O
+.	O
+
+As	O
+part	O
+of	O
+an	O
+effort	B-PROC
+to	O
+generate	O
+broad	O
+-	O
+spectrum	O
+inhibitors	B-CHED
+of	O
+these	O
+enzymes	O
+,	O
+we	O
+screened	O
+a	O
+library	O
+of	O
+inhibitors	B-CHED
+based	O
+on	O
+a	O
+halopyridinyl	O
+ester	B-CHED
+from	O
+a	O
+previous	O
+study	O
+of	O
+the	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+(	O
+SARS	B-DISO
+)	O
+3CL	O
+proteinase	B-PROC
+against	O
+Hepatitis	B-SPEC
+A	I-SPEC
+virus	I-SPEC
+(	O
+HAV	B-DISO
+)	O
+3C	O
+(	O
+pro	B-CHED
+).	O
+
+Modeling	O
+studies	O
+indicated	O
+that	O
+the	O
+halopyridinyl	O
+moiety	O
+of	O
+the	O
+inhibitor	B-CHED
+fits	B-DISO
+tightly	O
+into	O
+the	O
+S1	O
+-	O
+binding	O
+pocket	O
+,	O
+consistent	O
+with	O
+the	O
+lack	O
+of	O
+tolerance	B-DISO
+of	O
+the	O
+inhibitors	B-CHED
+to	O
+modification	O
+in	O
+this	O
+portion	O
+of	O
+the	O
+molecule	O
+.	O
+
+TITLE	O
+:	O
+[	O
+Emerging	B-DISO
+infectious	I-DISO
+diseases	I-DISO
+among	O
+swine	B-SPEC
+workers	O
+].	O
+
+Workers	O
+at	O
+risk	O
+include	O
+those	O
+who	O
+are	O
+in	O
+contact	O
+with	O
+live	O
+or	O
+dead	B-PROC
+infected	O
+animals	B-SPEC
+,	O
+with	O
+aerosols	O
+,	O
+dust	O
+or	O
+surfaces	O
+contaminated	O
+by	O
+animal	B-SPEC
+secretions	B-ANAT
+,	O
+persons	O
+engaged	O
+in	O
+animal	B-SPEC
+breeding	B-PROC
+and	O
+trade	O
+,	O
+veterinaries	O
+,	O
+and	O
+others	O
+.	O
+
+TITLE	O
+:	O
+Respiratory	O
+viruses	B-SPEC
+in	O
+laryngeal	B-ANAT
+croup	B-DISO
+of	O
+young	O
+children	O
+.	O
+
+Acute	O
+laryngeal	B-ANAT
+croup	B-DISO
+is	O
+most	O
+often	O
+associated	O
+with	O
+PIV	O
+,	O
+RSV	B-SPEC
+,	O
+rhinovirus	B-SPEC
+,	O
+and	O
+enterovirus	B-SPEC
+.	O
+
+Long	O
+-	O
+standing	B-PROC
+mechanical	O
+ventilation	O
+should	O
+be	O
+constrained	O
+because	O
+it	O
+is	O
+likely	O
+to	O
+cause	O
+severe	O
+refractory	O
+complications	O
+.	O
+
+Anti	B-PRGE
+-	I-PRGE
+HLA	I-PRGE
+and	I-PRGE
+antigranulocyte	I-PRGE
+antibodies	B-COMP
+were	O
+detected	O
+in	O
+the	O
+donated	O
+blood	B-ANAT
+products	O
+.	O
+
+Furthermore	O
+,	O
+residues	O
+Y29	O
+and	O
+F173	O
+of	O
+FCoV	O
+nsp16	O
+,	O
+which	O
+may	O
+be	O
+the	O
+functional	O
+counterparts	O
+of	O
+aromatic	O
+residues	O
+involved	O
+in	O
+substrate	O
+recognition	O
+by	O
+the	O
+vaccinia	B-PRGE
+virus	I-PRGE
+MTase	I-PRGE
+VP39	I-PRGE
+,	O
+were	O
+found	O
+to	O
+be	O
+essential	O
+for	O
+both	O
+substrate	O
+binding	B-FUNC
+and	O
+2	B-PRGE
+'	I-PRGE
+O	I-PRGE
+-	I-PRGE
+MTase	I-PRGE
+activity	O
+.	O
+
+ABSTRACT	O
+:	O
+We	O
+previously	O
+reported	O
+the	O
+detection	O
+of	O
+bat	B-ENZY
+coronaviruses	O
+(	O
+bat	B-PRGE
+CoVs	I-PRGE
+1A	I-PRGE
+,	O
+1B	O
+,	O
+HKU7	O
+,	O
+HKU8	O
+and	O
+bat	B-ENZY
+-	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+coronavirus	B-SPEC
+)	O
+in	O
+Miniopterus	B-SPEC
+spp	B-ENZY
+.	O
+
+However	O
+,	O
+despite	O
+these	O
+treatments	O
+,	O
+he	O
+developed	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+(	O
+ARDS	B-DISO
+).	O
+
+He	O
+was	O
+administered	O
+the	O
+combination	O
+of	O
+intravenous	O
+pazufloxacin	O
+and	O
+erythromycin	B-CHED
+,	O
+corticosteroid	B-CHED
+,	O
+and	O
+sivelestat	O
+for	O
+two	O
+weeks	O
+.	O
+
+This	O
+study	O
+evaluated	O
+the	O
+role	O
+of	O
+PCT	B-DISO
+in	O
+predicting	O
+the	O
+outcome	O
+of	O
+patients	O
+with	O
+ARDS	B-DISO
+caused	O
+by	O
+severe	O
+CAP	B-DISO
+.	O
+
+It	O
+is	O
+well	O
+accepted	O
+that	O
+mechanical	O
+ventilation	O
+can	O
+worsen	O
+lung	B-ANAT
+injury	O
+,	O
+potentially	O
+worsening	O
+systemic	O
+organ	B-ANAT
+function	O
+,	O
+and	O
+can	O
+thus	O
+impact	O
+on	O
+mortality	O
+in	O
+acute	O
+lung	B-ANAT
+injury	O
+(	O
+ALI	O
+)/	O
+ARDS	B-DISO
+.	O
+
+Imai	O
+et	O
+al	O
+.	O
+(	O
+2008	O
+)	O
+now	O
+report	O
+that	O
+ALI	O
+is	O
+triggered	O
+by	O
+the	O
+signaling	B-PROC
+of	O
+oxidized	B-CHED
+phospholipids	I-CHED
+through	O
+Toll	B-PRGE
+-	I-PRGE
+like	I-PRGE
+receptor	I-PRGE
+4	I-PRGE
+(	O
+TLR4	B-PRGE
+)	O
+and	O
+the	O
+adaptor	B-PRGE
+protein	I-PRGE
+TRIF	I-PRGE
+.	O
+
+Various	O
+substitutions	O
+in	O
+the	O
+basic	O
+phenothiazine	B-CHED
+structure	O
+did	O
+not	O
+promote	O
+efficacy	O
+.	O
+
+HCl	B-CHED
+(	O
+IC	O
+(	O
+50	O
+)=	O
+195	O
++/-	O
+71	O
+.	O
+2	O
+microM	O
+).	O
+
+Herein	O
+is	O
+described	O
+a	O
+readily	O
+quantifiable	O
+novel	O
+isopeptidase	O
+assay	O
+platform	O
+consisting	O
+of	O
+Ub	O
+or	O
+UBL	O
+fused	O
+to	O
+the	O
+reporter	B-PRGE
+enzyme	I-PRGE
+phospholipase	I-PRGE
+A	I-PRGE
+(	I-PRGE
+2	I-PRGE
+)	I-PRGE
+(	O
+PLA	B-CHED
+(	O
+2	O
+)).	O
+
+Taken	O
+together	O
+,	O
+these	O
+studies	O
+illustrate	O
+the	O
+utility	O
+of	O
+the	O
+reporter	O
+-	O
+based	O
+approach	O
+to	O
+measuring	O
+isopeptidase	B-FUNC
+activity	I-FUNC
+.	O
+
+A	O
+competitive	B-PROC
+inhibition	I-PROC
+enzyme	O
+-	O
+linked	O
+immunosorbent	O
+assay	O
+showed	O
+that	O
+the	O
+2	O
+recognized	O
+epitopes	O
+are	O
+distinct	O
+.	O
+
+TITLE	O
+:	O
+Clinicopathologic	O
+features	O
+of	O
+a	O
+systemic	O
+coronavirus	B-SPEC
+-	O
+associated	O
+disease	O
+resembling	O
+feline	B-SPEC
+infectious	I-DISO
+peritonitis	I-DISO
+in	O
+the	O
+domestic	O
+ferret	O
+(	O
+Mustela	B-SPEC
+putorius	I-SPEC
+).	O
+
+Immunohistochemically	O
+,	O
+all	O
+cases	O
+were	O
+positive	O
+for	O
+coronavirus	B-PRGE
+antigen	B-CHED
+using	I-PRGE
+monoclonal	I-PRGE
+antibody	B-COMP
+FIPV3	I-PRGE
+-	I-PRGE
+70	I-PRGE
+.	O
+
+In	O
+6	O
+trials	O
+(	O
+n	O
+=	O
+504	O
+),	O
+prone	O
+positioning	O
+was	O
+associated	O
+with	O
+an	O
+increased	O
+risk	O
+of	O
+pressure	B-DISO
+ulcers	I-DISO
+(	O
+RR	O
+1	O
+.	O
+36	O
+,	O
+95	O
+%	O
+CI	O
+1	O
+.	O
+07	O
+-	O
+1	O
+.	O
+71	O
+;	O
+p	O
+=	O
+0	O
+.	O
+01	O
+).	O
+
+The	O
+lack	O
+of	O
+effect	O
+of	O
+ventilation	O
+in	O
+the	O
+prone	O
+position	O
+on	O
+mortality	O
+was	O
+similar	O
+in	O
+trials	O
+of	O
+prolonged	O
+prone	O
+positioning	O
+and	O
+in	O
+patients	O
+with	O
+acute	O
+lung	B-ANAT
+injury	O
+.	O
+
+Healthcare	O
+workers	O
+should	O
+take	O
+adequate	O
+respiratory	O
+protection	O
+in	O
+addition	O
+to	O
+strict	O
+contact	O
+and	O
+droplet	O
+precautions	O
+when	O
+managing	O
+patients	O
+with	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+.	O
+
+The	O
+most	O
+promising	O
+compounds	O
+include	O
+carbohydrate	B-CHED
+-	O
+binding	B-FUNC
+agents	O
+,	O
+neutralizing	O
+antibodies	B-COMP
+and	O
+drugs	O
+targeting	B-PROC
+a	O
+coronaviral	B-PRGE
+envelope	I-PRGE
+protein	B-CHED
+.	O
+
+Histopathological	O
+and	O
+immunohistochemical	O
+stains	O
+were	O
+employed	O
+using	O
+specific	O
+antibody	B-COMP
+for	O
+O	B-SPEC
+.	I-SPEC
+tsutsugamushi	I-SPEC
+and	O
+inducible	B-PRGE
+nitric	I-PRGE
+oxide	I-PRGE
+synthase	I-PRGE
+(	O
+iNOS	B-PRGE
+).	O
+
+Gross	O
+inspection	O
+revealed	O
+oedematous	B-DISO
+and	O
+haemorrhagic	O
+lungs	B-ANAT
+.	O
+
+Scrub	B-DISO
+typhus	I-DISO
+is	O
+usually	O
+a	O
+mild	O
+infectious	B-DISO
+disease	I-DISO
+.	O
+
+The	O
+clinical	O
+investigation	O
+and	O
+analysis	O
+suggest	O
+direct	O
+endothelial	B-ANAT
+cell	I-ANAT
+invasion	O
+of	O
+the	O
+organism	O
+and	O
+marked	O
+iNOS	O
+expression	B-PROC
+may	O
+be	O
+involved	O
+in	O
+the	O
+pathogenesis	B-DISO
+of	O
+ARDS	B-DISO
+associated	O
+with	O
+scrub	B-DISO
+typhus	I-DISO
+.	O
+
+ABSTRACT	O
+:	O
+A	O
+novel	O
+gene	O
+was	O
+previously	O
+isolated	O
+from	O
+a	O
+cDNA	O
+library	O
+of	O
+human	B-ANAT
+embryo	I-ANAT
+lung	B-ANAT
+tissue	I-ANAT
+by	O
+its	O
+encoded	O
+protein	B-CHED
+,	O
+which	O
+interacts	O
+with	O
+non	O
+-	O
+structural	O
+protein	B-CHED
+10	O
+(	O
+nsp	O
+-	O
+10	O
+)	O
+of	O
+the	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+coronavirus	B-SPEC
+(	O
+SARS	B-DISO
+-	O
+CoV	O
+).	O
+
+In	O
+the	O
+present	O
+study	O
+,	O
+we	O
+demonstrated	O
+that	O
+HEPIS	O
+was	O
+capable	O
+of	O
+suppressing	O
+chloramphenicol	B-PRGE
+acetyltransferase	I-PRGE
+(	O
+CAT	B-PRGE
+)	O
+gene	B-PROC
+expression	I-PROC
+controlled	O
+by	O
+different	O
+enhancerelements	O
+in	O
+a	O
+transcription	B-PROC
+assay	O
+.	O
+
+Eligible	O
+studies	O
+reported	O
+data	O
+on	O
+psychiatric	O
+morbidity	O
+at	O
+least	O
+once	O
+after	O
+intensive	O
+care	O
+treatment	O
+of	O
+ALI	O
+/	O
+ARDS	B-DISO
+.	O
+
+All	O
+four	O
+studies	O
+that	O
+examined	O
+relationships	O
+between	O
+psychiatric	B-DISO
+symptoms	I-DISO
+and	O
+quality	O
+of	O
+life	O
+found	O
+significant	O
+negative	O
+associations	O
+.	O
+
+TITLE	O
+:	O
+The	O
+economic	O
+impact	O
+of	O
+SARS	B-DISO
+:	O
+how	O
+does	O
+the	O
+reality	O
+match	O
+the	O
+predictions	O
+?	O
+
+TITLE	O
+:	O
+[	O
+Refractory	O
+infectious	B-DISO
+ARDS	B-DISO
+:	O
+place	O
+of	O
+extracorporeal	O
+membrane	B-COMP
+oxygenation	B-PROC
+].	O
+
+ABSTRACT	O
+:	O
+Acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+(	O
+ARDS	B-DISO
+)	O
+is	O
+a	O
+frequent	O
+cause	O
+of	O
+admission	O
+in	O
+intensive	O
+care	O
+unit	O
+.	O
+
+One	O
+patient	O
+died	B-PROC
+of	O
+progressive	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+(	O
+ARDS	B-DISO
+)	O
+and	O
+pulmonary	B-DISO
+hemorrhage	I-DISO
+.	O
+
+ABSTRACT	O
+:	O
+Progressive	B-DISO
+supranuclear	I-DISO
+palsy	I-DISO
+(	O
+PSP	B-DISO
+)	O
+is	O
+classically	O
+characterized	O
+by	O
+supranuclear	B-DISO
+ophthalmoplegia	I-DISO
+,	O
+paroxysmal	O
+imbalance	B-DISO
+with	O
+backward	O
+falling	O
+,	O
+axial	O
+dystonia	B-DISO
+,	O
+rigidity	B-DISO
+,	O
+pseudobulbar	B-DISO
+palsy	I-DISO
+and	O
+cognitive	B-DISO
+dysfunction	I-DISO
+.	O
+
+However	O
+,	O
+incomplete	O
+or	O
+atypical	O
+clinical	O
+presentation	O
+has	O
+been	O
+previously	O
+reported	O
+,	O
+but	O
+in	O
+all	O
+these	O
+cases	O
+,	O
+the	O
+patients	O
+had	O
+at	O
+least	O
+one	O
+of	O
+the	O
+main	O
+clinical	O
+features	O
+of	O
+the	O
+disease	O
+(	O
+ophthalmoplegia	B-DISO
+,	O
+parkinsonian	B-DISO
+syndrome	I-DISO
+or	O
+cognitive	B-DISO
+dysfunction	I-DISO
+).	O
+
+A	O
+few	O
+months	O
+later	O
+she	O
+developed	O
+severe	O
+swallowing	B-DISO
+disorders	I-DISO
+,	O
+caused	O
+by	O
+achalasia	B-DISO
+of	O
+the	O
+upper	B-ANAT
+esophageal	I-ANAT
+sphincter	I-ANAT
+,	O
+and	O
+responsible	O
+for	O
+recurrent	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+and	O
+pneumonia	B-DISO
+,	O
+prevailing	O
+to	O
+tracheotomy	O
+and	O
+gastrostomy	B-DISO
+.	O
+
+Statistical	O
+analysis	O
+indicated	O
+that	O
+there	O
+was	O
+a	O
+positive	O
+relationship	O
+(	O
+R2	O
+=	O
+0	O
+.	O
+88	O
+)	O
+between	O
+organic	O
+matter	O
+and	O
+total	O
+PAHs	B-CHED
+thus	O
+it	O
+has	O
+the	O
+potential	O
+to	O
+be	O
+used	O
+as	O
+an	O
+indicator	B-CHED
+for	O
+PAHs	B-CHED
+in	O
+HW	O
+ashes	O
+.	O
+
+The	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+outbreak	O
+exposed	O
+the	O
+vulnerability	O
+of	O
+health	O
+care	O
+workers	O
+and	O
+highlighted	O
+the	O
+importance	O
+of	O
+establishing	O
+stringent	O
+infection	B-DISO
+control	O
+and	O
+crisis	O
+management	O
+protocols	O
+.	O
+
+In	O
+this	O
+study	O
+,	O
+three	O
+fragments	O
+[	O
+N1	O
+(	O
+residues	O
+:	O
+1	O
+-	O
+422	O
+);	O
+N2	O
+(	O
+residues	O
+:	O
+1	O
+-	O
+109	O
+);	O
+N3	O
+(	O
+residues	O
+:	O
+110	O
+-	O
+422	O
+)]	O
+of	O
+N	B-PRGE
+protein	I-PRGE
+of	O
+SARS	B-PRGE
+-	I-PRGE
+CoV	I-PRGE
+were	O
+expressed	B-PROC
+in	O
+Escherichia	B-SPEC
+coli	I-SPEC
+and	O
+analyzed	O
+by	O
+pooled	O
+sera	B-COMP
+of	O
+convalescence	O
+phase	O
+of	O
+SARS	B-DISO
+patients	O
+.	O
+
+Specific	O
+humoral	O
+and	O
+cellular	B-PROC
+immunity	I-PROC
+in	O
+mice	B-SPEC
+could	O
+be	O
+induced	O
+significantly	O
+by	O
+inoculating	O
+SARS	B-DISO
+-	O
+CoV	O
+N1	O
+and	O
+N3	O
+DNA	O
+vaccine	O
+.	O
+
+In	O
+addition	O
+,	O
+the	O
+immune	B-PROC
+response	I-PROC
+levels	O
+in	O
+N3	O
+were	O
+significantly	O
+higher	O
+for	O
+antibody	B-PROC
+responses	I-PROC
+(	O
+IgG	B-PRGE
+and	O
+IgG1	B-COMP
+but	O
+not	O
+IgG2a	B-COMP
+)	O
+and	O
+cell	B-PROC
+proliferation	B-DISO
+but	O
+not	O
+in	O
+CD4	B-PRGE
+(+):	O
+CD8	B-PRGE
+(+)	O
+assay	O
+compared	O
+to	O
+N1	O
+vaccine	O
+.	O
+
+TITLE	O
+:	O
+Data	O
+-	O
+driven	O
+exploration	O
+of	O
+'	O
+spatial	O
+pattern	O
+-	O
+time	O
+process	O
+-	O
+driving	O
+forces	O
+'	O
+associations	O
+of	O
+SARS	B-DISO
+epidemic	O
+in	O
+Beijing	O
+,	O
+China	O
+.	O
+
+ABSTRACT	O
+:	O
+Severe	B-DISO
+Acute	I-DISO
+Respiratory	I-DISO
+Syndrome	I-DISO
+(	O
+SARS	B-DISO
+)	O
+was	O
+first	O
+reported	O
+in	O
+November	O
+2002	O
+in	O
+China	O
+,	O
+and	O
+spreads	O
+to	O
+about	O
+30	O
+countries	O
+over	O
+the	O
+next	O
+few	O
+months	O
+.	O
+
+RESULTS	O
+:	O
+The	O
+study	O
+of	O
+associations	O
+between	O
+important	O
+SARS	B-DISO
+characteristics	O
+considerably	O
+enhanced	O
+the	O
+mainstream	O
+epidemic	O
+analysis	O
+and	O
+improved	O
+the	O
+understanding	O
+of	O
+the	O
+relationships	O
+between	O
+the	O
+observed	O
+epidemic	O
+determinants	O
+.	O
+
+The	O
+response	O
+of	O
+SARS	B-DISO
+transmission	O
+to	O
+various	O
+epidemic	O
+control	O
+factors	O
+was	O
+simulated	O
+,	O
+target	O
+areas	O
+were	O
+detected	O
+,	O
+critical	O
+time	O
+and	O
+relevant	O
+factors	O
+were	O
+determined	O
+.	O
+
+In	O
+a	O
+parallel	O
+experiment	O
+,	O
+we	O
+employed	O
+a	O
+HIV	B-DISO
+-	O
+luc	O
+/	O
+SARS	B-DISO
+pseudotyped	O
+virus	B-SPEC
+entry	O
+inhibition	B-PROC
+assay	O
+to	O
+screen	O
+for	O
+potent	O
+inhibitory	O
+activities	O
+on	O
+HR	O
+peptides	O
+derived	O
+from	O
+the	O
+SARS	B-PRGE
+-	I-PRGE
+CoV	I-PRGE
+S	I-PRGE
+protein	B-CHED
+HR	O
+regions	O
+and	O
+a	O
+series	O
+of	O
+other	O
+small	O
+-	O
+molecule	O
+drugs	O
+.	O
+
+ADS	B-PRGE
+-	I-PRGE
+J1	I-PRGE
+,	O
+which	O
+has	O
+been	O
+used	O
+to	O
+interfere	O
+with	O
+the	O
+fusogenesis	O
+of	O
+HIV	B-SPEC
+-	I-SPEC
+1	I-SPEC
+onto	O
+CD4	B-PRGE
++	I-PRGE
+cells	B-COMP
+,	O
+demonstrated	O
+the	O
+highest	O
+HIV	B-DISO
+-	O
+luc	O
+/	O
+SARS	B-DISO
+pseudotyped	O
+virus	B-SPEC
+-	O
+entry	O
+inhibition	B-PROC
+activity	O
+among	O
+the	O
+other	O
+small	O
+-	O
+molecule	O
+drugs	O
+.	O
+
+Acute	O
+lung	B-ANAT
+injury	O
+was	O
+induced	O
+successfully	O
+by	O
+intratracheal	O
+administration	O
+of	O
+LPS	B-DISO
+(	O
+0	O
+.	O
+5	O
+mg	O
+/	O
+kg	O
+)	O
+in	O
+male	O
+BALB	O
+/	O
+c	O
+mice	B-SPEC
+.	O
+
+TITLE	O
+:	O
+Ethyl	B-CHED
+pyruvate	B-CHED
+.	O
+
+Treatment	O
+with	O
+ethyl	B-CHED
+pyruvate	B-CHED
+has	O
+been	O
+shown	O
+to	O
+improve	O
+survival	O
+and	O
+ameliorate	O
+organ	B-ANAT
+dysfunction	O
+in	O
+a	O
+wide	O
+variety	O
+of	O
+preclinical	O
+models	O
+of	O
+critical	B-DISO
+illnesses	I-DISO
+,	O
+such	O
+as	O
+severe	B-DISO
+sepsis	I-DISO
+,	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+,	O
+burn	O
+injury	O
+,	O
+acute	B-DISO
+pancreatitis	I-DISO
+and	O
+stroke	B-DISO
+.	O
+
+Ethyl	B-CHED
+pyruvate	B-CHED
+is	O
+a	O
+simple	O
+molecule	O
+that	O
+has	O
+been	O
+shown	O
+to	O
+have	O
+salutary	O
+effects	O
+in	O
+numerous	O
+large	O
+and	O
+small	O
+animal	B-SPEC
+models	O
+of	O
+critical	B-DISO
+illness	I-DISO
+.	O
+
+We	O
+classified	O
+patients	O
+as	O
+having	O
+confirmed	O
+cases	O
+of	O
+Nipah	B-DISO
+virus	I-DISO
+infection	I-DISO
+if	O
+they	O
+had	O
+antibodies	B-COMP
+reactive	O
+with	O
+Nipah	B-PRGE
+virus	I-PRGE
+antigen	B-CHED
+.	O
+
+Among	O
+patients	O
+with	O
+Nipah	B-DISO
+virus	I-DISO
+infection	I-DISO
+who	O
+had	O
+well	O
+-	O
+defined	O
+exposure	O
+to	O
+another	O
+patient	O
+infected	O
+with	O
+Nipah	B-SPEC
+virus	I-SPEC
+,	O
+the	O
+median	O
+incubation	O
+period	O
+was	O
+9	O
+days	O
+(	O
+range	O
+,	O
+6	O
+-	O
+11	O
+days	O
+).	O
+
+Nipah	B-DISO
+virus	I-DISO
+infection	I-DISO
+produced	O
+rapidly	O
+progressive	O
+severe	O
+illness	O
+affecting	O
+the	O
+central	O
+nervous	B-DISO
+and	O
+respiratory	B-ANAT
+systems	I-ANAT
+.	O
+
+HFOV	O
+was	O
+used	O
+as	O
+a	O
+rescue	O
+after	O
+conventional	O
+mechanical	O
+ventilation	O
+(	O
+CMV	B-SPEC
+)	O
+for	O
+4	O
+.	O
+4	O
++/-	O
+
+CONCLUSIONS	O
+:	O
+As	O
+a	O
+relatively	O
+late	O
+rescue	O
+therapy	O
+after	O
+failure	O
+of	O
+CMV	B-SPEC
+,	O
+HFOV	O
+may	O
+improve	O
+PaCO2	O
+and	O
+PaO2	O
+/	O
+FiO2	O
+in	O
+children	O
+with	O
+respiratory	B-DISO
+failure	I-DISO
+.	O
+
+Further	O
+studies	O
+are	O
+warranted	O
+to	O
+consider	O
+other	O
+animal	B-SPEC
+species	B-SPEC
+in	O
+efforts	O
+to	O
+find	O
+better	O
+animal	B-SPEC
+models	O
+for	O
+the	O
+evaluation	O
+of	O
+SARS	B-DISO
+-	O
+CoV	O
+vaccines	O
+and	O
+antiviral	B-CHED
+drugs	I-CHED
+.	O
+
+ABSTRACT	O
+:	O
+Extracorporeal	O
+Membrane	B-COMP
+Oxygenation	B-PROC
+(	O
+ECMO	O
+)	O
+is	O
+a	O
+technology	O
+used	O
+in	O
+treatment	O
+of	O
+patients	O
+with	O
+severe	O
+but	O
+potentially	O
+reversible	O
+respiratory	B-DISO
+failure	I-DISO
+.	O
+
+TITLE	O
+:	O
+The	O
+nucleocapsid	B-COMP
+protein	B-CHED
+of	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+coronavirus	B-SPEC
+inhibits	O
+cell	B-COMP
+cytokinesis	B-PROC
+and	O
+proliferation	B-DISO
+by	O
+interacting	O
+with	O
+translation	B-PRGE
+elongation	I-PRGE
+factor	I-PRGE
+1alpha	I-PRGE
+.	O
+
+Using	O
+a	O
+yeast	B-SPEC
+two	O
+-	O
+hybrid	O
+screen	O
+with	O
+the	O
+nucleocapsid	B-COMP
+(	O
+N	O
+)	O
+protein	B-CHED
+of	O
+SARS	B-PRGE
+-	I-PRGE
+CoV	I-PRGE
+as	O
+a	O
+bait	O
+,	O
+the	O
+C	O
+terminus	O
+(	O
+amino	B-CHED
+acids	I-CHED
+251	O
+to	O
+422	O
+)	O
+of	O
+the	O
+N	B-PRGE
+protein	I-PRGE
+was	O
+found	O
+to	O
+interact	O
+with	O
+human	B-SPEC
+elongation	B-PRGE
+factor	I-PRGE
+1	O
+-	O
+alpha	O
+(	O
+EF1alpha	B-PRGE
+),	O
+an	O
+essential	O
+component	O
+of	O
+the	O
+translational	B-PROC
+machinery	O
+with	O
+an	O
+important	O
+role	O
+in	O
+cytokinesis	B-PROC
+,	O
+promoting	O
+the	O
+bundling	O
+of	O
+filamentous	B-COMP
+actin	I-COMP
+(	O
+F	B-COMP
+-	I-COMP
+actin	I-COMP
+).	O
+
+Proliferation	O
+of	O
+human	B-SPEC
+peripheral	B-ANAT
+blood	I-ANAT
+lymphocytes	B-ANAT
+and	O
+other	O
+human	B-SPEC
+cell	B-ANAT
+lines	I-ANAT
+was	O
+significantly	O
+inhibited	O
+by	O
+the	O
+infection	B-DISO
+of	O
+recombinant	O
+retrovirus	B-SPEC
+expressing	O
+SARS	B-DISO
+-	O
+CoV	O
+N	O
+protein	B-CHED
+.	O
+
+ABSTRACT	O
+:	O
+The	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+coronavirus	B-SPEC
+(	O
+SARS	B-DISO
+-	O
+CoV	O
+)	O
+encodes	O
+numerous	O
+accessory	O
+proteins	B-CHED
+whose	O
+importance	O
+in	O
+the	O
+natural	O
+infection	B-DISO
+process	O
+is	O
+currently	O
+unclear	O
+.	O
+
+In	O
+this	O
+study	O
+,	O
+protein	B-CHED
+6	O
+was	O
+expressed	B-PROC
+from	O
+plasmid	O
+DNAs	O
+and	O
+accumulated	O
+in	O
+cells	B-COMP
+prior	O
+to	O
+infection	B-DISO
+by	O
+wild	O
+-	O
+type	O
+MHV	B-SPEC
+.	O
+
+In	O
+this	O
+study	O
+a	O
+chimeric	O
+ACE2	B-PRGE
+bearing	O
+the	O
+critical	O
+N	O
+-	O
+terminal	O
+helix	O
+from	O
+civet	B-SPEC
+and	O
+the	O
+remaining	O
+peptidase	B-PRGE
+domain	I-PRGE
+from	O
+human	B-SPEC
+was	O
+constructed	O
+,	O
+and	O
+it	O
+was	O
+shown	O
+that	O
+this	O
+construct	O
+has	O
+the	O
+same	O
+receptor	B-FUNC
+activity	I-FUNC
+as	O
+civet	B-SPEC
+ACE2	O
+.	O
+
+In	O
+addition	O
+,	O
+crystal	B-ANAT
+structures	O
+of	O
+the	O
+chimeric	O
+ACE2	B-PRGE
+complexed	O
+with	O
+RBDs	O
+from	O
+various	O
+human	B-SPEC
+and	O
+civet	B-SPEC
+SARS	B-DISO
+-	O
+CoV	O
+strains	O
+were	O
+determined	O
+.	O
+
+These	O
+structures	O
+,	O
+combined	O
+with	O
+a	O
+previously	O
+determined	O
+structure	O
+of	O
+human	O
+ACE2	O
+complexed	O
+with	O
+the	O
+RBD	O
+from	O
+a	O
+human	B-SPEC
+SARS	B-DISO
+-	O
+CoV	O
+strain	O
+,	O
+have	O
+revealed	O
+a	O
+structural	O
+basis	O
+for	O
+understanding	O
+the	O
+major	O
+species	B-SPEC
+barriers	O
+between	O
+humans	B-SPEC
+and	O
+civets	B-SPEC
+for	O
+SARS	B-DISO
+-	O
+CoV	O
+infections	B-DISO
+.	O
+
+TITLE	O
+:	O
+The	O
+discovery	O
+of	O
+angiotensin	B-PRGE
+-	I-PRGE
+converting	I-PRGE
+enzyme	I-PRGE
+2	I-PRGE
+and	O
+its	O
+role	O
+in	O
+acute	O
+lung	B-ANAT
+injury	O
+in	O
+mice	B-SPEC
+.	O
+
+Interestingly	O
+,	O
+a	O
+novel	O
+homologue	O
+of	O
+angiotensin	B-PRGE
+-	I-PRGE
+converting	I-PRGE
+enzyme	I-PRGE
+,	O
+termed	O
+angiotensin	B-PRGE
+-	I-PRGE
+converting	I-PRGE
+enzyme	I-PRGE
+2	I-PRGE
+(	O
+ACE2	B-PRGE
+),	O
+has	O
+been	O
+identified	O
+as	O
+a	O
+receptor	O
+for	O
+SARS	B-PRGE
+-	I-PRGE
+CoV	I-PRGE
+.	O
+Angiotensin	B-PRGE
+-	I-PRGE
+converting	I-PRGE
+enzyme	I-PRGE
+and	O
+ACE2	B-PRGE
+share	O
+homology	O
+in	O
+their	O
+catalytic	O
+domain	O
+and	O
+provide	O
+different	O
+key	O
+functions	O
+in	O
+the	O
+renin	B-PATH
+-	I-PATH
+angiotensin	B-CHED
+system	I-PATH
+(	O
+RAS	B-PRGE
+).	O
+
+Notably	O
+,	O
+injection	O
+of	O
+SARS	B-DISO
+-	O
+CoV	O
+Spike	O
+into	O
+mice	B-SPEC
+worsens	O
+acute	O
+lung	B-ANAT
+failure	O
+in	O
+vivo	O
+,	O
+which	O
+can	O
+be	O
+attenuated	O
+by	O
+blocking	B-DISO
+the	O
+renin	B-PRGE
+-	O
+angiotensin	B-CHED
+pathway	B-PROC
+,	O
+suggesting	O
+that	O
+the	O
+activation	O
+of	O
+the	O
+pulmonary	B-ANAT
+RAS	B-CHED
+influences	O
+the	O
+pathogenesis	B-DISO
+of	O
+ALI	O
+/	O
+ARDS	B-DISO
+and	O
+SARS	B-DISO
+.	O
+
+They	O
+comprise	O
+obstructive	O
+ventilatory	O
+defects	O
+due	O
+to	O
+the	O
+inhalation	B-PROC
+syndrome	B-DISO
+and	O
+restrictive	O
+defects	O
+secondary	O
+to	O
+ARDS	B-DISO
+or	O
+to	O
+dermal	O
+injury	O
+.	O
+
+We	O
+report	O
+the	O
+case	O
+of	O
+a	O
+female	O
+patient	O
+,	O
+extensively	O
+burnt	O
+2	O
+years	O
+previously	O
+,	O
+admitted	O
+to	O
+hospital	O
+with	O
+severe	O
+acute	B-DISO
+respiratory	I-DISO
+failure	I-DISO
+complicating	O
+COPD	B-DISO
+.	O
+
+Our	O
+data	O
+establish	O
+a	O
+vital	O
+functional	O
+dependence	B-DISO
+of	O
+SARS	B-PRGE
+-	I-PRGE
+CoV	I-PRGE
+RNA	B-PROC
+synthesis	I-PROC
+on	O
+virus	B-SPEC
+-	O
+induced	O
+membrane	B-COMP
+structures	O
+.	O
+
+Viruses	B-SPEC
+lacking	O
+E	B-PRGE
+protein	I-PRGE
+were	O
+highly	O
+attenuated	O
+in	O
+the	O
+highly	O
+sensitive	O
+hACE	O
+-	O
+2	O
+Tg	O
+mice	B-SPEC
+,	O
+in	O
+contrast	O
+to	O
+the	O
+minimal	O
+rSARS	O
+-	O
+CoV	O
+-	O
+Delta	O
+[	O
+6	O
+-	O
+9b	O
+]	O
+and	O
+wt	O
+viruses	B-SPEC
+.	O
+
+Multiple	O
+-	O
+factor	O
+Logistic	O
+regression	O
+analysis	O
+indicated	O
+that	O
+the	O
+MODS	B-DISO
+(	O
+OR	O
+=	O
+67	O
+.	O
+358	O
+,	O
+P	O
+<	O
+0	O
+.	O
+01	O
+),	O
+APACHE	O
+II	O
+score	O
+(	O
+OR	O
+=	O
+9	O
+.	O
+716	O
+,	O
+P	O
+<	O
+0	O
+.	O
+01	O
+)	O
+and	O
+ACS	B-FUNC
+(	O
+OR	O
+=	O
+5	O
+.	O
+775	O
+,	O
+P	O
+<	O
+0	O
+.	O
+05	O
+)	O
+were	O
+the	O
+independent	O
+risk	O
+factors	O
+affecting	O
+the	O
+prognosis	O
+of	O
+SAP	B-PRGE
+during	O
+its	O
+early	O
+stage	O
+,	O
+whereas	O
+pancreatic	B-DISO
+infection	I-DISO
+(	O
+OR	O
+=	O
+9	O
+.	O
+652	O
+,	O
+P	O
+<	O
+0	O
+.	O
+01	O
+),	O
+MODS	B-DISO
+(	O
+OR	O
+=	O
+5	O
+.	O
+212	O
+,	O
+P	O
+<	O
+0	O
+.	O
+05	O
+)	O
+and	O
+celiac	O
+hemorrhage	B-DISO
+(	O
+OR	O
+=	O
+4	O
+.	O
+707	O
+,	O
+P	O
+<	O
+0	O
+.	O
+05	O
+)	O
+were	O
+the	O
+independent	O
+risk	O
+factors	O
+during	O
+the	O
+advanced	O
+stage	O
+of	O
+SAP	B-PRGE
+.	O
+
+The	O
+aim	O
+of	O
+this	O
+study	O
+was	O
+to	O
+report	O
+our	O
+experience	O
+with	O
+three	O
+patients	O
+who	O
+underwent	O
+total	O
+hepatectomy	O
+and	O
+protocaval	O
+shunt	O
+,	O
+followed	O
+by	O
+liver	B-ANAT
+transplantation	O
+(	O
+two	O
+-	O
+stage	O
+procedure	O
+).	O
+
+TITLE	O
+:	O
+Appraisal	O
+of	O
+recommended	O
+respiratory	B-DISO
+infection	I-DISO
+control	O
+practices	O
+in	O
+primary	O
+care	O
+and	O
+emergency	B-DISO
+department	O
+settings	O
+.	O
+
+Use	O
+of	O
+recommended	O
+measures	O
+was	O
+generally	O
+higher	O
+among	O
+nursing	B-PROC
+staff	O
+than	O
+medical	O
+practitioners	O
+.	O
+
+CONCLUSIONS	O
+:	O
+This	O
+study	O
+found	O
+significant	O
+gaps	O
+in	O
+adherence	O
+to	O
+CDC	O
+recommendations	O
+for	O
+the	O
+control	O
+of	O
+respiratory	B-DISO
+infections	I-DISO
+in	O
+ambulatory	O
+care	O
+clinical	O
+settings	O
+.	O
+
+Toward	O
+this	O
+end	O
+,	O
+lessons	O
+learned	B-PROC
+from	O
+previous	O
+outbreaks	O
+merit	O
+consideration	O
+and	O
+may	O
+inform	O
+future	O
+epidemics	O
+.	O
+
+These	O
+included	O
+the	O
+development	B-PROC
+of	O
+communication	O
+strategies	O
+for	O
+responding	O
+to	O
+SARS	B-DISO
+;	O
+easing	O
+vulnerability	O
+among	O
+all	O
+stakeholders	O
+;	O
+and	O
+the	O
+rapid	O
+development	B-PROC
+of	O
+practice	O
+guidelines	O
+.	O
+
+CONCLUSIONS	O
+:	O
+Given	O
+the	O
+continuing	O
+threat	O
+of	O
+current	O
+and	O
+future	O
+airborne	O
+viruses	B-SPEC
+with	O
+potential	O
+for	O
+epidemic	O
+spread	O
+and	O
+devastating	O
+outcomes	O
+,	O
+preparedness	O
+strategies	O
+are	O
+certainly	O
+needed	O
+.	O
+
+Five	O
+coronaviruses	O
+currently	O
+infect	O
+humans	B-SPEC
+:	O
+HCoVs	O
+229E	O
+and	O
+OC43	O
+,	O
+identified	O
+in	O
+the	O
+1960s	O
+,	O
+SARS	B-DISO
+-	O
+CoV	O
+identified	O
+in	O
+March	O
+2003	O
+during	O
+the	O
+SARS	B-DISO
+epidemic	O
+,	O
+and	O
+the	O
+HCoVs	O
+NL63	O
+and	O
+HKU1	O
+,	O
+identified	O
+in	O
+2004	O
+and	O
+2005	O
+respectively	O
+.	O
+
+The	O
+genome	O
+of	O
+the	O
+coronaviruses	O
+is	O
+a	O
+linear	O
+,	O
+non	O
+-	O
+segmented	O
+,	O
+positive	O
+-	O
+sense	B-PROC
+single	O
+-	O
+stranded	O
+RNA	O
+molecule	O
+of	O
+approximately	O
+30kb	O
+.	O
+
+Human	B-SPEC
+coronaviruses	O
+may	O
+be	O
+also	O
+involved	O
+in	O
+enteric	O
+and	O
+neurologic	B-DISO
+diseases	I-DISO
+.	O
+
+TITLE	O
+:	O
+[	O
+Evaluation	O
+of	O
+Seeplex	O
+RV	O
+detection	O
+kit	B-FUNC
+for	O
+detecting	O
+rhinovirus	B-SPEC
+,	O
+human	B-SPEC
+metapneumovirus	I-SPEC
+,	O
+and	O
+coronavirus	O
+].	O
+
+The	O
+early	O
+development	B-PROC
+of	O
+SARS	B-DISO
+-	O
+CoV	O
+diagnostics	O
+is	O
+now	O
+being	O
+replaced	O
+by	O
+refinement	O
+and	O
+optimization	O
+of	O
+these	O
+assays	O
+.	O
+
+TITLE	O
+:	O
+Severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+:	O
+clinical	O
+and	O
+laboratory	O
+manifestations	O
+.	O
+
+The	O
+aetiological	O
+agent	O
+is	O
+a	O
+new	O
+coronavirus	B-SPEC
+spread	O
+by	O
+droplet	O
+transmission	O
+.	O
+
+We	O
+investigated	O
+serum	B-COMP
+LD	O
+isoenzymes	O
+and	O
+blood	B-ANAT
+lymphocyte	B-ANAT
+subsets	O
+of	O
+SARS	B-DISO
+patients	O
+,	O
+and	O
+found	O
+LD1	O
+activity	O
+as	O
+the	O
+best	O
+biochemical	O
+prognostic	O
+indicator	B-CHED
+for	O
+death	B-PROC
+,	O
+while	O
+CD3	B-PRGE
++,	I-PRGE
+CD4	B-PRGE
++,	I-PRGE
+CD8	B-PRGE
++	I-PRGE
+and	O
+natural	B-ANAT
+killer	I-ANAT
+cell	I-ANAT
+counts	O
+were	O
+promising	O
+predictors	O
+for	O
+intensive	O
+care	O
+unit	O
+(	O
+ICU	O
+)	O
+admission	O
+.	O
+
+ABSTRACT	O
+:	O
+A	O
+variety	O
+of	O
+intervention	O
+measures	O
+exist	O
+to	O
+prevent	O
+and	O
+control	O
+diseases	O
+with	O
+pandemic	O
+potential	O
+like	O
+SARS	O
+or	O
+pandemic	O
+influenza	B-DISO
+.	O
+
+Mitral	B-ANAT
+valve	I-ANAT
+plasty	O
+was	O
+performed	O
+successfully	O
+.	O
+
+Although	O
+SARS	B-DISO
+is	O
+etiologically	O
+linked	O
+to	O
+a	O
+new	O
+coronavirus	B-SPEC
+(	O
+SARS	B-DISO
+-	O
+CoV	O
+)	O
+and	O
+functional	O
+cell	B-COMP
+receptor	O
+has	O
+been	O
+identified	O
+,	O
+the	O
+pathogenesis	B-DISO
+of	O
+the	O
+virus	B-DISO
+infection	I-DISO
+is	O
+largely	O
+unclear	O
+.	O
+
+A	O
+type	O
+of	O
+medium	O
+or	O
+low	O
+titer	O
+anti	B-PRGE
+-	I-PRGE
+lung	I-PRGE
+tissue	I-PRGE
+antibodies	B-COMP
+were	O
+found	O
+in	O
+the	O
+sera	B-COMP
+of	O
+SARS	B-DISO
+patients	O
+at	O
+the	O
+early	O
+stage	O
+of	O
+the	O
+disease	O
+.	O
+
+Anti	O
+-	O
+EN	O
+antibody	B-COMP
+was	O
+positive	O
+in	O
+the	O
+sera	B-COMP
+of	O
+40	O
+.	O
+9	O
+%	O
+of	O
+SARS	B-DISO
+patients	O
+.	O
+
+Adult	O
+murine	B-SPEC
+lungs	B-ANAT
+,	O
+which	O
+had	O
+significantly	O
+higher	O
+interleukin	B-PRGE
+(	O
+IL	O
+)-	O
+4	O
+and	O
+lower	O
+IL	B-FUNC
+-	I-FUNC
+10	I-FUNC
+and	O
+IL	B-FUNC
+-	I-FUNC
+13	I-FUNC
+levels	O
+before	O
+infection	B-DISO
+than	O
+young	O
+murine	B-SPEC
+lungs	B-ANAT
+,	O
+rapidly	O
+produced	O
+high	O
+levels	O
+of	O
+proinflammatory	O
+chemokines	O
+and	O
+cytokines	O
+known	O
+to	O
+induce	O
+macrophage	B-ANAT
+and	O
+neutrophil	B-ANAT
+infiltration	B-DISO
+and	O
+activation	O
+(	O
+eg	O
+,	O
+tumor	B-PRGE
+necrosis	I-PRGE
+factor	I-PRGE
+-	I-PRGE
+alpha	I-PRGE
+).	O
+
+Intravenous	O
+injection	O
+with	O
+anti	B-PRGE
+-	I-PRGE
+tumor	I-PRGE
+necrosis	I-PRGE
+factor	I-PRGE
+-	I-PRGE
+alpha	I-PRGE
+antibody	B-COMP
+3	O
+hours	O
+after	O
+infection	B-DISO
+had	O
+no	O
+effect	O
+on	O
+SARS	B-DISO
+-	I-DISO
+CoV	I-DISO
+infection	I-DISO
+.	O
+
+This	O
+study	O
+describes	O
+a	O
+method	O
+for	O
+the	O
+detection	O
+of	O
+SARS	B-DISO
+associated	O
+coronavirus	B-SPEC
+gene	O
+by	O
+the	O
+combination	O
+of	O
+functionalized	O
+nanoparticles	B-CHED
+and	O
+PCR	O
+-	O
+based	O
+assay	O
+.	O
+
+TITLE	O
+:	O
+Complete	O
+genomic	O
+sequence	O
+of	O
+turkey	B-SPEC
+coronavirus	B-SPEC
+.	O
+
+The	O
+TCoV	O
+genome	O
+is	O
+organized	O
+as	O
+follows	O
+:	O
+5	O
+'	O
+UTR	O
+--	O
+replicase	B-PRGE
+(	O
+ORFs	B-PRGE
+1a	I-PRGE
+,	I-PRGE
+1b	I-PRGE
+)--	I-PRGE
+spike	I-PRGE
+(	I-PRGE
+S	I-PRGE
+)	I-PRGE
+protein	B-CHED
+--	I-PRGE
+ORF3	I-PRGE
+(	I-PRGE
+ORFs	I-PRGE
+3a	I-PRGE
+,	I-PRGE
+3b	I-PRGE
+)--	I-PRGE
+small	I-PRGE
+envelop	I-PRGE
+(	I-PRGE
+E	I-PRGE
+or	I-PRGE
+3c	I-PRGE
+)	I-PRGE
+protein	B-CHED
+--	I-PRGE
+membrane	I-PRGE
+(	I-PRGE
+M	I-PRGE
+)	I-PRGE
+protein	B-CHED
+--	I-PRGE
+ORF5	I-PRGE
+(	I-PRGE
+ORFs	I-PRGE
+X	I-PRGE
+,	O
+5a	O
+,	O
+5b	O
+)--	O
+nucleocapsid	B-COMP
+(	O
+N	O
+)	O
+protein	B-CHED
+--	O
+3	O
+'	O
+UTR	O
+--	O
+poly	O
+(	O
+A	O
+).	O
+
+The	O
+genotypes	O
+of	O
+4SNPs	O
+on	O
+IL	B-PRGE
+-	I-PRGE
+12	I-PRGE
+RB1	I-PRGE
+gene	I-PRGE
+,	O
++	O
+705A	O
+/	O
+G	O
+,+	O
+1158T	O
+/	O
+C	O
+,	O
++	B-PRGE
+1196G	I-PRGE
+/	I-PRGE
+C	I-PRGE
+and	I-PRGE
++	I-PRGE
+1664	I-PRGE
+C	I-PRGE
+/	O
+T	O
+,	O
+were	O
+determined	O
+by	O
+PCR	O
+-	O
+RFLP	O
+.	O
+
+Our	O
+data	O
+indicate	O
+that	O
+genetic	O
+variants	O
+of	O
+IL12RB1confer	O
+genetic	O
+susceptibility	O
+to	O
+SARS	B-DISO
+infection	B-DISO
+,	O
+but	O
+not	O
+necessary	O
+associated	O
+with	O
+the	O
+progression	O
+of	O
+the	O
+disease	O
+in	O
+Chinese	O
+population	O
+.	O
+
+Additionally	O
+,	O
+estimation	O
+of	O
+the	O
+frequencies	O
+of	O
+multiple	O
+-	O
+locus	O
+haplotypes	O
+revealed	O
+potential	O
+risk	O
+haplotypes	O
+(	O
+GCCT	O
+)	O
+for	O
+SARS	B-DISO
+infection	B-DISO
+.	O
+
+We	O
+also	O
+demonstrate	O
+that	O
+the	O
+removal	O
+of	O
+vRNA	O
+from	O
+total	O
+RNA	O
+samples	O
+,	O
+by	O
+means	O
+of	O
+virus	B-SPEC
+-	O
+specific	O
+oligonucleotide	B-CHED
+capturing	O
+,	O
+significantly	O
+reduced	O
+the	O
+number	O
+of	O
+false	O
+-	O
+positive	O
+hits	O
+and	O
+increased	O
+the	O
+sensitivity	O
+of	O
+the	O
+method	O
+as	O
+tested	O
+on	O
+different	O
+array	O
+platforms	O
+.	O
+
+By	O
+flow	O
+cytometry	O
+,	O
+it	O
+was	O
+revealed	O
+that	O
+HC	O
+increased	O
+the	O
+proportion	O
+of	O
+CD4	B-PRGE
+(+)	O
+and	O
+CD8	B-PRGE
+(+)	O
+T	B-ANAT
+cells	I-ANAT
+.	O
+
+In	O
+the	O
+anti	O
+-	O
+viral	O
+aspect	O
+,	O
+HC	O
+exhibited	O
+significant	O
+inhibitory	O
+effects	O
+on	O
+SARS	B-PRGE
+-	I-PRGE
+CoV	I-PRGE
+3C	I-PRGE
+-	I-PRGE
+like	I-PRGE
+protease	I-PRGE
+(	O
+3CL	O
+(	O
+pro	B-CHED
+))	O
+and	O
+RNA	B-PRGE
+-	I-PRGE
+dependent	I-PRGE
+RNA	I-PRGE
+polymerase	I-PRGE
+(	O
+RdRp	B-FUNC
+).	O
+
+This	O
+study	O
+used	O
+bronchoalveolar	O
+lavage	O
+(	O
+BAL	B-ENZY
+),	O
+histopathology	O
+and	O
+gene	B-PROC
+expression	I-PROC
+analysis	O
+to	O
+examine	O
+the	O
+development	B-PROC
+of	O
+ALI	O
+in	O
+mice	B-SPEC
+infected	O
+with	O
+Plasmodium	B-SPEC
+berghei	I-SPEC
+ANKA	O
+(	O
+PbA	B-CHED
+).	O
+
+In	O
+contrast	O
+to	O
+sepsis	B-DISO
+-	O
+induced	O
+ALI	O
+,	O
+BAL	B-ENZY
+fluid	O
+cell	B-COMP
+counts	O
+remained	O
+constant	O
+with	O
+no	O
+infiltration	B-DISO
+of	O
+neutrophils	B-ANAT
+.	O
+
+No	O
+similar	O
+comprehensive	O
+studies	O
+of	O
+the	O
+brain	B-ANAT
+have	O
+been	O
+reported	O
+in	O
+bovine	B-SPEC
+fetuses	B-ANAT
+.	O
+
+Hospital	O
+emergency	B-DISO
+planning	O
+could	O
+be	O
+more	O
+robust	O
+by	O
+including	O
+additional	O
+organizational	O
+supports	O
+such	O
+as	O
+emotional	O
+/	O
+psychological	B-DISO
+support	O
+services	O
+,	O
+delineating	O
+management	O
+responsibilities	O
+,	O
+human	B-SPEC
+resources	O
+,	O
+vaccine	O
+/	O
+anti	O
+-	O
+viral	O
+planning	O
+,	O
+recognition	O
+/	O
+compensation	B-PROC
+,	O
+media	B-ANAT
+strategies	O
+,	O
+and	O
+professional	O
+development	B-PROC
+.	O
+
+The	O
+authors	O
+provide	O
+a	O
+number	O
+of	O
+recommendations	O
+for	O
+consideration	O
+in	O
+infectious	B-DISO
+disease	I-DISO
+pandemic	O
+plan	B-DISO
+development	B-PROC
+to	O
+better	O
+support	O
+the	O
+healthcare	O
+workers	O
+in	O
+their	O
+roles	O
+as	O
+first	O
+responders	O
+.	O
+
+Intriguingly	O
+,	O
+viral	B-DISO
+infection	I-DISO
+,	O
+judged	O
+by	O
+real	O
+-	O
+time	O
+RT	O
+-	O
+PCR	O
+analysis	O
+of	O
+SARS	O
+-	O
+CoV	O
+mRNA	B-PROC
+expression	B-PROC
+,	O
+was	O
+significantly	O
+attenuated	O
+by	O
+deletion	O
+of	O
+the	O
+cytoplasmic	B-ANAT
+tail	I-ANAT
+of	O
+ACE2	O
+or	O
+knock	O
+-	O
+down	O
+of	O
+TACE	B-PRGE
+expression	B-PROC
+by	O
+siRNA	O
+.	O
+
+TITLE	O
+:	O
+Severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+coronavirus	B-DISO
+infection	I-DISO
+causes	O
+neuronal	O
+death	B-PROC
+in	O
+the	O
+absence	O
+of	O
+encephalitis	O
+in	O
+mice	B-SPEC
+transgenic	O
+for	O
+human	B-SPEC
+ACE2	O
+.	O
+
+HCoV	B-SPEC
+-	I-SPEC
+229E	I-SPEC
+is	O
+a	O
+close	O
+relative	O
+of	O
+HCoV	B-SPEC
+-	I-SPEC
+NL63	I-SPEC
+,	O
+and	O
+infection	B-DISO
+with	O
+either	O
+virus	B-SPEC
+can	O
+lead	O
+to	O
+the	O
+hospitalization	O
+of	O
+young	O
+children	O
+,	O
+immunocompromised	O
+persons	O
+,	O
+and	O
+the	O
+elderly	O
+.	O
+
+The	O
+longitudinal	O
+serum	B-COMP
+samples	O
+were	O
+collected	O
+from	O
+13	O
+newborns	O
+,	O
+and	O
+data	O
+for	O
+those	O
+newborns	O
+were	O
+available	O
+from	O
+multiple	O
+time	O
+points	O
+spanning	O
+a	O
+period	O
+of	O
+at	O
+least	O
+18	O
+months	O
+.	O
+
+The	O
+adrenocorticotrophic	O
+hormone	B-CHED
+stimulation	O
+test	O
+should	O
+not	O
+be	O
+used	O
+to	O
+identify	O
+those	O
+patients	O
+with	O
+septic	B-DISO
+shock	I-DISO
+or	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+who	O
+should	O
+receive	O
+glucocorticoids	B-CHED
+.	O
+
+Mean	O
+EVLW	O
+indexed	O
+to	O
+ActBW	O
+was	O
+12	O
+.	O
+7	O
+mg	O
+/	O
+kg	O
+for	O
+ARDS	B-DISO
+patients	O
+and	O
+7	O
+.	O
+8	O
+mg	O
+/	O
+kg	O
+for	O
+non	O
+-	O
+ARDS	B-DISO
+sepsis	B-DISO
+patients	O
+(	O
+p	O
+<	O
+.	O
+0001	O
+).	O
+
+Based	O
+on	O
+the	O
+Coroners	O
+'	O
+suicide	O
+death	B-PROC
+records	O
+,	O
+overall	O
+severity	O
+of	O
+illness	O
+,	O
+level	O
+of	O
+dependency	O
+and	O
+worrying	O
+of	O
+having	O
+sickness	O
+among	O
+the	O
+older	O
+adult	O
+suicides	O
+were	O
+found	O
+to	O
+be	O
+significantly	O
+different	O
+in	O
+the	O
+pre	O
+-	O
+SARS	B-DISO
+,	O
+peri	O
+-	O
+SARS	B-DISO
+and	O
+post	O
+-	O
+SARS	B-DISO
+periods	B-PROC
+.	O
+
+TITLE	O
+:	O
+Canine	O
+respiratory	O
+coronavirus	B-SPEC
+:	O
+an	O
+emerging	O
+pathogen	O
+in	O
+the	O
+canine	O
+infectious	B-DISO
+respiratory	B-DISO
+disease	I-DISO
+complex	O
+.	O
+
+TITLE	O
+:	O
+Human	B-SPEC
+rhinoviruses	B-SPEC
+:	O
+the	O
+cold	B-DISO
+wars	O
+resume	O
+.	O
+
+CONCLUSIONS	O
+:	O
+The	O
+finding	O
+of	O
+many	O
+divergent	O
+and	O
+previously	O
+unrecognized	O
+HRV	O
+strains	O
+has	O
+drawn	O
+attention	O
+and	O
+resources	O
+back	B-ANAT
+to	O
+the	O
+most	O
+widespread	O
+and	O
+frequent	O
+infectious	B-DISO
+agent	O
+of	O
+humans	B-SPEC
+;	O
+providing	O
+us	O
+the	O
+chance	O
+to	O
+seize	O
+the	O
+advantage	O
+in	O
+a	O
+decades	O
+-	O
+long	O
+cold	B-DISO
+war	O
+.	O
+
+To	O
+the	O
+best	O
+of	O
+our	O
+knowledge	O
+,	O
+this	O
+is	O
+the	O
+first	O
+case	O
+of	O
+YNS	B-DISO
+who	O
+underwent	O
+LRLT	O
+for	O
+FHF	B-DISO
+.	O
+
+Mortality	O
+rates	O
+were	O
+comparable	O
+regardless	O
+of	O
+whether	O
+patients	O
+were	O
+PaO	B-PROC
+(	O
+2	O
+)/	O
+F	O
+(	O
+I	O
+)	O
+O	O
+(	O
+2	O
+)	O
+responders	O
+or	O
+their	O
+PaCO	O
+(	O
+2	O
+)	O
+decreased	O
+by	O
+>	O
+or	O
+=	O
+1	O
+mmHg	O
+.	O
+
+Measures	O
+to	O
+prevent	O
+pressure	B-DISO
+sores	I-DISO
+are	O
+mandatory	O
+.	O
+
+Coronavirus	B-SPEC
+antibody	B-COMP
+was	O
+detected	O
+in	O
+2	O
+out	O
+of	O
+the	O
+55	O
+bat	B-ENZY
+serum	B-COMP
+samples	O
+.	O
+
+In	O
+spite	O
+of	O
+the	O
+lack	O
+of	O
+solid	O
+scientific	O
+support	O
+for	O
+our	O
+diagnosis	O
+,	O
+we	O
+conclude	O
+that	O
+our	O
+patient	O
+suffered	B-DISO
+an	O
+uncommon	O
+type	O
+of	O
+amniotic	B-DISO
+fluid	I-DISO
+embolism	I-DISO
+syndrome	B-DISO
+and	O
+we	O
+believe	O
+that	O
+this	O
+report	O
+highlights	O
+the	O
+need	O
+for	O
+extreme	O
+vigilance	O
+and	O
+a	O
+high	O
+index	O
+of	O
+suspicion	O
+for	O
+such	O
+a	O
+diagnosis	O
+in	O
+any	O
+pregnant	O
+individual	O
+.	O
+
+Rotavirus	B-SPEC
+also	O
+has	O
+marked	O
+environmental	O
+resistance	B-PROC
+,	O
+but	O
+periodic	O
+reintroduction	O
+into	O
+facilities	O
+,	O
+possibly	O
+on	O
+bags	O
+of	O
+feed	O
+,	O
+bedding	O
+,	O
+or	O
+other	O
+supplies	O
+or	O
+equipment	O
+,	O
+also	O
+seems	O
+likely	O
+.	O
+
+Pinworm	B-DISO
+infestations	B-DISO
+continue	O
+because	O
+of	O
+prolonged	O
+infections	B-DISO
+,	O
+inefficient	O
+diagnosis	O
+,	O
+and	O
+the	O
+survivability	O
+of	O
+eggs	O
+of	O
+some	O
+species	B-SPEC
+in	O
+the	O
+environment	O
+.	O
+
+The	O
+main	O
+causes	O
+of	O
+death	B-PROC
+were	O
+hemorrhagic	B-DISO
+shock	I-DISO
+and	O
+associated	O
+injuries	O
+.	O
+
+TITLE	O
+:	O
+The	O
+role	O
+of	O
+programmed	O
+-	O
+1	O
+ribosomal	B-PROC
+frameshifting	I-PROC
+in	O
+coronavirus	B-SPEC
+propagation	O
+.	O
+
+Fever	B-PROC
+of	O
+more	O
+then	O
+38	O
+degrees	O
+C	O
+,	O
+lasting	O
+more	O
+then	O
+24	O
+hours	O
+,	O
+is	O
+the	O
+most	O
+frequently	O
+encountered	O
+symptom	B-DISO
+.	O
+
+Infants	O
+born	O
+to	O
+pregnant	O
+women	O
+with	O
+SARS	B-DISO
+did	O
+not	O
+appear	O
+to	O
+have	O
+acquired	O
+the	O
+infection	B-DISO
+through	O
+vertical	B-DISO
+transmission	I-DISO
+.	O
+
+The	O
+DeltaE1	O
+/	O
+DeltaE2A	O
+-	O
+vector	O
+backbones	B-ANAT
+were	O
+rescued	O
+on	O
+a	O
+PER	O
+.	O
+C6	O
+cell	B-ANAT
+line	I-ANAT
+engineered	O
+to	O
+constitutively	O
+over	O
+express	O
+the	O
+Ad5	B-PRGE
+E2A	I-PRGE
+protein	B-CHED
+.	O
+
+None	O
+of	O
+the	O
+rats	B-SPEC
+received	O
+antibiotics	B-CHED
+during	O
+the	O
+experimental	O
+procedures	O
+.	O
+
+The	O
+lung	B-ANAT
+tissues	I-ANAT
+were	O
+removed	O
+for	O
+analysis	O
+of	O
+biochemical	O
+parameters	O
+and	O
+light	O
+microscopic	O
+investigation	O
+.	O
+
+Our	O
+findings	O
+suggested	O
+that	O
+leflunomide	B-CHED
+attenuated	O
+the	O
+lung	B-ANAT
+injury	O
+after	O
+CLP	O
+-	O
+induced	O
+sepsis	B-DISO
+by	O
+inhibition	B-PROC
+of	O
+neutrophils	B-ANAT
+accumulation	O
+and	O
+increasing	O
+endogenous	O
+antioxidant	B-CHED
+capacity	O
+.	O
+
+Although	O
+ceftriaxone	B-CHED
+was	O
+given	O
+to	O
+him	O
+,	O
+his	O
+symptoms	O
+did	O
+not	O
+improve	O
+.	O
+
+Abdominal	O
+compartment	O
+syndrome	O
+was	O
+defined	O
+as	O
+IAP	B-PRGE
+>	O
+or	O
+=	O
+20	O
+mm	O
+Hg	O
+plus	O
+>	O
+or	O
+=	O
+1	O
+new	O
+organ	B-DISO
+failure	I-DISO
+.	O
+
+Of	O
+83	O
+patients	O
+,	O
+considering	O
+IAP	O
+(	O
+max	O
+),	O
+31	O
+%	O
+had	O
+intra	B-DISO
+-	I-DISO
+abdominal	I-DISO
+hypertension	I-DISO
+on	O
+admission	O
+and	O
+another	O
+33	O
+%	O
+developed	O
+it	O
+after	O
+(	O
+23	O
+%	O
+and	O
+31	O
+%	O
+with	O
+IAP	O
+(	O
+mean	O
+)).	O
+
+Nonsurvivors	O
+had	O
+higher	O
+IAP	B-PRGE
+(	O
+max	B-PRGE
+),	O
+IAP	O
+(	O
+mean	O
+),	O
+and	O
+fluid	O
+balances	O
+and	O
+lower	O
+abdominal	B-ANAT
+perfusion	O
+pressure	O
+.	O
+
+TITLE	O
+:	O
+Prevalence	O
+and	O
+clinical	O
+characterisation	O
+of	O
+patients	O
+with	O
+severe	O
+partial	O
+respiratory	B-DISO
+failure	I-DISO
+admitted	O
+to	O
+an	O
+intensive	O
+care	O
+unit	O
+.	O
+
+In	O
+16	O
+-	O
+bed	B-DISO
+ICU	O
+of	O
+a	O
+central	O
+Hospital	O
+in	O
+Lisbon	O
+,	O
+patients	O
+admitted	O
+in	O
+the	O
+year	O
+2004	O
+were	O
+analysed	O
+.	O
+
+By	O
+multivariate	O
+analysis	O
+the	O
+mortality	O
+of	O
+patients	O
+with	O
+SRPF	O
+correlated	O
+with	O
+older	O
+age	O
+and	O
+the	O
+presence	O
+of	O
+circulatory	B-DISO
+failure	I-DISO
+(	O
+p	O
+<	O
+0	O
+.	O
+001	O
+).	O
+
+By	O
+multivariate	O
+analysis	O
+the	O
+mortality	O
+of	O
+patients	O
+with	O
+SRPF	O
+correlated	O
+with	O
+older	O
+age	O
+and	O
+the	O
+presence	O
+of	O
+circulatory	B-DISO
+failure	I-DISO
+(	O
+p	O
+<	O
+0	O
+.	O
+001	O
+).	O
+
+In	O
+this	O
+study	O
+,	O
+we	O
+identified	O
+four	O
+B	B-ANAT
+cell	I-ANAT
+epitopes	O
+from	O
+the	O
+spike	O
+(	O
+S	O
+)	O
+and	O
+membrane	B-COMP
+(	O
+M	O
+)	O
+protein	B-CHED
+through	O
+bioinformatics	O
+analysis	O
+and	O
+constructed	O
+a	O
+multi	O
+-	O
+epitope	B-CHED
+DNA	O
+vaccine	O
+.	O
+
+In	O
+control	O
+cats	B-SPEC
+,	O
+CSF	B-PRGE
+-	I-PRGE
+TP	I-PRGE
+concentration	O
+ranged	O
+from	O
+0	O
+.	O
+06	O
+to	O
+0	O
+.	O
+36	O
+g	O
+/	O
+L	O
+,	O
+Q	O
+(	O
+alb	O
+)	O
+ranged	O
+from	O
+0	O
+.	O
+6	O
+to	O
+5	O
+.	O
+7	O
+x	O
+10	O
+(-	O
+3	O
+),	O
+and	O
+IgG	B-PRGE
+index	O
+ranged	O
+from	O
+0	O
+.	O
+3	O
+to	O
+0	O
+.	O
+6	O
+.	O
+
+This	O
+study	O
+evaluated	O
+17	O
+risk	O
+factors	O
+potentially	O
+associated	O
+with	O
+the	O
+conversion	O
+from	O
+ALI	O
+to	O
+ARDS	B-DISO
+in	O
+severe	O
+multiple	O
+trauma	O
+.	O
+
+Fecal	B-ANAT
+shedding	O
+,	O
+as	O
+determined	O
+by	O
+real	O
+-	O
+time	O
+polymerase	O
+chain	O
+reaction	O
+(	O
+RT	O
+-	O
+PCR	O
+)	O
+from	O
+rectal	O
+swabs	O
+,	O
+appeared	O
+within	O
+a	O
+week	O
+and	O
+was	O
+significantly	O
+higher	O
+in	O
+kittens	O
+than	O
+older	O
+cats	B-SPEC
+.	O
+
+Cats	B-SPEC
+with	O
+higher	O
+feline	B-SPEC
+coronavirus	B-SPEC
+(	O
+FCoV	O
+)	O
+antibody	B-COMP
+titers	O
+were	O
+significantly	O
+more	O
+likely	O
+to	O
+shed	O
+virus	B-SPEC
+,	O
+while	O
+cats	B-SPEC
+with	O
+lower	O
+titers	O
+were	O
+significantly	O
+less	O
+likely	O
+to	O
+be	O
+shedding	O
+.	O
+
+ABSTRACT	O
+:	O
+Viral	O
+upper	O
+respiratory	O
+tract	O
+infection	O
+(	O
+vURI	O
+)	O
+may	O
+or	O
+may	O
+not	O
+present	O
+with	O
+a	O
+cold	B-DISO
+/	O
+flu	B-DISO
+-	I-DISO
+like	I-DISO
+illness	I-DISO
+(	O
+CFLI	O
+).	O
+
+The	O
+frequency	O
+of	O
+PCR	O
+virus	B-SPEC
+detection	O
+without	O
+CFLI	O
+was	O
+different	O
+among	O
+viruses	B-SPEC
+.	O
+
+This	O
+introduces	O
+virus	B-SPEC
+-	O
+specific	O
+biases	O
+to	O
+estimating	O
+the	O
+frequencies	O
+of	O
+specific	O
+complications	O
+attributable	O
+to	O
+a	O
+vURI	O
+when	O
+ascertained	O
+by	O
+CFLI	O
+identification	O
+.	O
+
+Here	O
+,	O
+the	O
+crystal	B-ANAT
+structure	O
+of	O
+HLA	B-PRGE
+-	I-PRGE
+B	I-PRGE
+*	I-PRGE
+1501	I-PRGE
+in	O
+complex	O
+with	O
+a	O
+SARS	B-DISO
+coronavirus	B-SPEC
+-	O
+derived	O
+nonapeptide	O
+(	O
+VQQESSFVM	O
+)	O
+has	O
+been	O
+determined	O
+at	O
+high	O
+resolution	O
+(	O
+1	O
+.	O
+87	O
+A	O
+).	O
+
+The	O
+peptide	B-CHED
+is	O
+deeply	O
+anchored	O
+in	O
+the	O
+B	O
+and	O
+F	O
+pockets	O
+,	O
+but	O
+with	O
+the	O
+Glu4	O
+residue	O
+pointing	O
+away	O
+from	O
+the	O
+floor	O
+in	O
+the	O
+peptide	B-CHED
+-	O
+binding	B-FUNC
+groove	B-ANAT
+,	O
+making	O
+it	O
+available	O
+for	O
+interactions	O
+with	O
+a	O
+potential	O
+T	B-PRGE
+-	I-PRGE
+cell	I-PRGE
+receptor	I-PRGE
+.	O
+
+After	O
+stabilization	O
+,	O
+pigs	B-SPEC
+belonging	O
+to	O
+group	O
+II	O
+were	O
+observed	O
+only	O
+,	O
+whereas	O
+in	O
+those	O
+belonging	O
+to	O
+groups	O
+III	O
+to	O
+V	O
+,	O
+a	O
+surfactant	B-CHED
+-	O
+depletion	O
+severe	O
+(	O
+Pao	B-PROC
+(	O
+2	O
+)/	O
+Fio	O
+(	O
+2	O
+)	O
+<	O
+100	O
+)	O
+postpneumonectomy	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+was	O
+induced	O
+.	O
+
+In	O
+group	O
+V	O
+pigs	B-SPEC
+,	O
+the	O
+iLA	O
+Novalung	O
+device	O
+diverted	O
+17	O
+%	O
++/-	O
+
+Imported	O
+diseases	O
+at	O
+risk	O
+of	O
+secondary	B-DISO
+transmission	I-DISO
+were	O
+also	O
+diagnosed	O
+,	O
+including	O
+pulmonary	B-DISO
+tuberculosis	B-PATH
+(	O
+n	O
+=	O
+8	O
+),	O
+viral	B-DISO
+hepatitis	I-DISO
+(	O
+n	O
+=	O
+8	O
+),	O
+typhoid	B-DISO
+fever	I-DISO
+(	O
+n	O
+=	O
+6	O
+),	O
+human	B-DISO
+immunodeficiency	I-DISO
+virus	I-DISO
+(	O
+HIV	B-DISO
+)	O
+(	O
+six	O
+new	O
+diagnosis	O
+),	O
+non	O
+-	O
+typhoid	B-DISO
+salmonellosis	B-DISO
+(	O
+n	O
+=	O
+5	O
+),	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+,	O
+and	O
+Crimean	B-DISO
+-	I-DISO
+Congo	I-DISO
+hemorrhagic	I-DISO
+fever	I-DISO
+.	O
+
+Thirty	O
+-	O
+two	O
+New	B-SPEC
+Zealand	I-SPEC
+rabbits	I-SPEC
+were	O
+randomly	O
+divided	O
+into	O
+four	O
+groups	O
+,	O
+and	O
+acute	B-DISO
+respiratory	I-DISO
+failure	I-DISO
+model	O
+was	O
+reproduced	O
+by	O
+severe	O
+steam	O
+inhalation	B-PROC
+injury	O
+.	O
+
+Caspase	B-PRGE
+-	I-PRGE
+3	I-PRGE
+and	O
+p73	B-PRGE
+mRNA	I-PRGE
+expression	B-PROC
+in	O
+lung	B-ANAT
+tissue	I-ANAT
+in	O
+groups	O
+with	O
+exogenous	O
+PS	O
+group	O
+were	O
+significantly	O
+lower	O
+than	O
+those	O
+of	O
+the	O
+corresponding	O
+group	O
+without	O
+exogenous	O
+PS	O
+(	O
+all	O
+P	O
+<	O
+0	O
+.	O
+05	O
+).	O
+
+CONCLUSIONS	O
+:	O
+Compared	O
+with	O
+CMV	B-SPEC
+or	O
+CMV	O
++	O
+PS	O
+,	O
+HFOV	O
+or	O
+HFOV	O
++	O
+PS	O
+can	O
+decrease	O
+the	O
+concentration	O
+of	O
+caspase	B-PRGE
+-	I-PRGE
+3	I-PRGE
+and	O
+p73	B-PRGE
+,	O
+reduce	O
+the	O
+mRNA	B-PROC
+expression	B-PROC
+of	O
+caspase	B-PRGE
+-	I-PRGE
+3	I-PRGE
+and	O
+p73	B-PRGE
+in	O
+the	O
+lung	B-ANAT
+homogenates	O
+,	O
+as	O
+a	O
+result	O
+lung	B-ANAT
+tissue	I-ANAT
+apoptosis	B-PATH
+in	O
+inhalation	B-PROC
+injury	O
+may	O
+be	O
+suppressed	O
+.	O
+
+We	O
+report	O
+the	O
+identification	O
+of	O
+novel	O
+groups	O
+of	O
+astroviruses	O
+in	O
+apparently	O
+healthy	O
+insectivorous	O
+bats	B-SPEC
+found	O
+in	O
+Hong	O
+Kong	O
+,	O
+in	O
+particular	O
+,	O
+bats	B-SPEC
+belonging	O
+to	O
+the	O
+genera	O
+Miniopterus	B-SPEC
+and	O
+Myotis	B-SPEC
+.	O
+
+Many	O
+of	O
+the	O
+bat	B-ENZY
+astroviruses	O
+form	O
+distinct	O
+phylogenetic	O
+clusters	B-CHED
+in	O
+the	O
+genus	B-SPEC
+Mamastrovirus	I-SPEC
+within	O
+the	O
+family	B-SPEC
+Astroviridae	I-SPEC
+.	O
+
+Related	O
+HEs	B-DISO
+occur	O
+in	O
+influenza	B-DISO
+C	O
+,	O
+toro	O
+-,	O
+and	O
+coronaviruses	O
+,	O
+apparently	O
+as	O
+a	O
+result	O
+of	O
+relatively	O
+recent	O
+lateral	B-PROC
+gene	I-PROC
+transfer	I-PROC
+events	O
+.	O
+
+ABSTRACT	O
+:	O
+Coronaviruses	O
+induce	O
+in	O
+infected	O
+cells	O
+the	O
+formation	B-PROC
+of	O
+double	O
+membrane	B-COMP
+vesicles	B-COMP
+,	O
+which	O
+are	O
+the	O
+sites	O
+of	O
+RNA	B-PROC
+replication	I-PROC
+.	O
+
+Not	O
+much	O
+is	O
+known	O
+about	O
+the	O
+formation	B-PROC
+of	O
+these	O
+vesicles	B-COMP
+,	O
+although	O
+recent	O
+observations	O
+indicate	O
+an	O
+important	O
+role	O
+for	O
+the	O
+endoplasmic	B-COMP
+reticulum	I-COMP
+in	O
+the	O
+formation	B-PROC
+of	O
+the	O
+mouse	B-DISO
+hepatitis	I-DISO
+coronavirus	B-SPEC
+(	O
+MHV	B-SPEC
+)	O
+replication	O
+complexes	O
+(	O
+RCs	O
+).	O
+
+Accordingly	O
+,	O
+individual	O
+knockdown	O
+of	O
+the	O
+Golgi	O
+-	O
+resident	O
+targets	O
+of	O
+BFA	O
+by	O
+transfection	B-PROC
+of	O
+small	O
+interfering	O
+RNAs	O
+(	O
+siRNAs	O
+)	O
+showed	O
+that	O
+GBF1	B-PRGE
+,	O
+but	O
+not	O
+BIG1	B-PRGE
+or	O
+BIG2	B-PRGE
+,	O
+was	O
+critically	O
+involved	O
+in	O
+MHV	B-SPEC
+RNA	B-PROC
+replication	I-PROC
+.	O
+
+The	O
+GBP	O
+-	O
+fusion	O
+method	O
+allows	O
+immobilization	O
+of	O
+proteins	B-CHED
+in	O
+bioactive	O
+forms	O
+onto	O
+the	O
+gold	B-CHED
+surface	O
+without	O
+surface	O
+modification	O
+suitable	O
+for	O
+studying	O
+antigen	B-PROC
+-	I-PROC
+antibody	B-COMP
+interaction	I-PROC
+.	O
+
+Elevated	O
+intra	O
+-	O
+abdominal	B-ANAT
+pressure	O
+due	O
+to	O
+whatever	O
+mechanism	O
+affects	O
+all	O
+intra	O
+-	O
+abdominal	B-ANAT
+viscera	I-ANAT
+,	O
+including	O
+the	O
+abdominal	B-ANAT
+wall	I-ANAT
+.	O
+
+Elevated	B-DISO
+intracranial	I-DISO
+pressure	I-DISO
+causes	O
+encephalopathy	O
+and	O
+the	O
+risk	O
+of	O
+neuronal	O
+damage	O
+due	O
+to	O
+the	O
+sharp	O
+decrease	O
+in	O
+cerebral	B-ANAT
+perfusion	O
+pressure	O
+.	O
+
+Decompressive	O
+laparotomy	O
+leads	O
+to	O
+a	O
+rapid	O
+improvement	O
+in	O
+pulmonary	B-ANAT
+parameters	O
+and	O
+oxygen	B-CHED
+delivery	O
+.	O
+
+TITLE	O
+:	O
+[	O
+Detection	O
+of	O
+coronavirus	B-SPEC
+in	O
+experimental	O
+pneumocystic	O
+pneumonia	B-DISO
+].	O
+
+The	O
+material	O
+was	O
+found	O
+to	O
+contain	O
+pneumocysts	O
+,	O
+bacteria	B-SPEC
+,	O
+and	O
+coronaviruses	O
+.	O
+
+Injury	O
+characteristics	O
+and	O
+pathophysiological	O
+state	O
+upon	O
+emergency	B-DISO
+room	O
+arrival	O
+were	O
+comparable	O
+between	O
+groups	O
+.	O
+
+Viral	O
+antibody	B-COMP
+titers	O
+to	O
+eight	O
+respiratory	O
+viruses	B-SPEC
+(	O
+influenza	B-PATH
+A	I-PATH
+and	O
+B	O
+,	O
+respiratory	B-SPEC
+syncytial	I-SPEC
+virus	I-SPEC
+(	O
+RSV	B-SPEC
+),	O
+parainfluenza	B-DISO
+virus	B-SPEC
+serotype	O
+three	O
+(	O
+PIV	O
+-	O
+3	O
+),	O
+PIV	O
+-	O
+2	O
+,	O
+human	B-SPEC
+metapneumovirus	I-SPEC
+(	O
+hMPV	B-SPEC
+),	O
+and	O
+coronaviruses	O
+229E	O
+and	O
+OC43	O
+)	O
+were	O
+measured	O
+using	O
+enzyme	O
+immunoassay	O
+at	O
+baseline	O
+and	O
+53	O
+weeks	O
+.	O
+
+A	O
+total	O
+of	O
+204	O
+viral	B-DISO
+infections	I-DISO
+were	O
+documented	O
+in	O
+157	O
+subjects	O
+.	O
+
+TITLE	O
+:	O
+A	O
+structural	O
+view	O
+of	O
+the	O
+inactivation	B-DISO
+of	O
+the	O
+SARS	B-PRGE
+coronavirus	B-SPEC
+main	I-PRGE
+proteinase	B-PROC
+by	O
+benzotriazole	B-CHED
+esters	B-CHED
+.	O
+
+ABSTRACT	O
+:	O
+The	O
+main	O
+proteinase	B-PROC
+(	O
+M	O
+(	O
+pro	B-CHED
+))	O
+of	O
+the	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+(	O
+SARS	B-DISO
+)	O
+coronavirus	B-SPEC
+is	O
+a	O
+principal	O
+target	O
+for	O
+the	O
+design	O
+of	O
+anticoronaviral	O
+compounds	O
+.	O
+
+In	O
+one	O
+of	O
+the	O
+structures	O
+,	O
+the	O
+thioester	B-CHED
+product	O
+has	O
+been	O
+hydrolyzed	O
+and	O
+benzoic	B-CHED
+acid	I-CHED
+is	O
+observed	O
+to	O
+bind	B-FUNC
+to	O
+the	O
+hydrophobic	O
+S2	O
+pocket	O
+.	O
+
+TITLE	O
+:	O
+Potent	O
+in	O
+vitro	O
+activity	O
+of	O
+the	O
+albumin	B-PRGE
+fusion	I-PRGE
+type	I-PRGE
+1	I-PRGE
+interferons	I-PRGE
+(	O
+albumin	B-PRGE
+-	O
+interferon	B-PRGE
+-	I-PRGE
+alpha	I-PRGE
+and	O
+albumin	O
+-	O
+interferon	B-PRGE
+-	O
+beta	O
+)	O
+against	O
+RNA	O
+viral	O
+agents	O
+of	O
+bioterrorism	O
+and	O
+the	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+(	O
+SARS	B-DISO
+)	O
+virus	B-SPEC
+.	O
+
+ABSTRACT	O
+:	O
+The	O
+type	B-PRGE
+1	I-PRGE
+interferons	I-PRGE
+(	O
+INF	B-PRGE
+-	I-PRGE
+alpha	I-PRGE
+and	O
+INF	B-PRGE
+-	I-PRGE
+beta	I-PRGE
+)	O
+are	O
+potent	O
+antiviral	B-CHED
+agents	I-CHED
+.	O
+
+The	O
+in	O
+vitro	O
+antiviral	B-CHED
+activity	O
+of	O
+albumin	B-PRGE
+-	O
+IFN	B-PRGE
+-	I-PRGE
+alpha	I-PRGE
+was	O
+evaluated	O
+against	O
+representative	O
+bioterrorism	O
+viral	O
+agents	O
+and	O
+the	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+virus	B-SPEC
+.	O
+
+Albumin	B-PRGE
+-	O
+IFN	B-PRGE
+-	I-PRGE
+beta	I-PRGE
+showed	O
+75	O
+-	O
+and	O
+360	O
+-	O
+fold	O
+greater	O
+in	O
+vitro	O
+activity	O
+than	O
+albumin	B-PRGE
+-	O
+IFN	B-PRGE
+-	I-PRGE
+alpha	I-PRGE
+against	O
+Ebola	B-SPEC
+virus	I-SPEC
+and	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+,	O
+respectively	O
+.	O
+
+So	O
+far	O
+,	O
+the	O
+structure	O
+determination	O
+of	O
+the	O
+SARS	B-PRGE
+-	I-PRGE
+CoV	I-PRGE
+NP	I-PRGE
+CTD	I-PRGE
+in	O
+solution	O
+has	O
+been	O
+impeded	O
+by	O
+the	O
+poor	O
+quality	O
+of	O
+NMR	O
+spectra	O
+,	O
+especially	O
+for	O
+aromatic	O
+resonances	O
+.	O
+
+The	O
+NMR	O
+structure	O
+is	O
+almost	O
+identical	O
+with	O
+the	O
+previously	O
+solved	O
+crystal	B-ANAT
+structure	O
+,	O
+except	O
+for	O
+a	O
+disordered	O
+putative	O
+RNA	O
+-	O
+binding	B-FUNC
+domain	O
+at	O
+the	O
+N	O
+-	O
+terminus	O
+.	O
+
+Thirteen	O
+severely	O
+burned	O
+children	O
+with	O
+inhalation	B-PROC
+injury	O
+who	O
+did	O
+not	O
+survive	O
+and	O
+15	O
+severely	O
+burned	O
+pediatric	O
+patients	O
+with	O
+inhalation	B-PROC
+injury	O
+who	O
+survived	O
+were	O
+enrolled	O
+in	O
+the	O
+study	O
+.	O
+
+RESULTS	O
+:	O
+Significantly	O
+altered	O
+levels	O
+of	O
+IL	B-FUNC
+-	I-FUNC
+4	I-FUNC
+,	O
+IL	B-FUNC
+-	I-FUNC
+6	I-FUNC
+,	O
+IL	B-FUNC
+-	I-FUNC
+7	I-FUNC
+,	O
+IL	B-FUNC
+-	I-FUNC
+10	I-FUNC
+,	O
+and	O
+IL	B-FUNC
+-	I-FUNC
+13	I-FUNC
+were	O
+detected	O
+within	O
+the	O
+first	O
+7	O
+days	O
+after	O
+admission	O
+in	O
+serum	B-COMP
+from	O
+burn	O
+pediatric	O
+patients	O
+with	O
+concomitant	O
+inhalation	B-PROC
+injury	O
+who	O
+did	O
+not	O
+survive	O
+when	O
+compared	O
+with	O
+similar	O
+patients	O
+who	O
+did	O
+(	O
+P	O
+<	O
+0	O
+.	O
+05	O
+).	O
+
+CONCLUSIONS	O
+:	O
+Early	O
+alterations	O
+in	O
+serum	B-COMP
+levels	O
+of	O
+IL	B-FUNC
+-	I-FUNC
+6	I-FUNC
+,	O
+IL	B-FUNC
+-	I-FUNC
+7	I-FUNC
+and	O
+IL	B-FUNC
+-	I-FUNC
+10	I-FUNC
+may	O
+constitute	O
+useful	O
+predictive	O
+markers	O
+for	O
+identifying	O
+patients	O
+those	O
+who	O
+have	O
+sustained	O
+a	O
+burn	O
+with	O
+concomitant	O
+inhalation	B-PROC
+injury	O
+and	O
+who	O
+have	O
+high	O
+mortality	O
+.	O
+
+Plasma	B-PRGE
+protein	B-CHED
+C	I-PRGE
+levels	O
+are	O
+decreased	O
+in	O
+patients	O
+with	O
+acute	O
+lung	B-ANAT
+injury	O
+and	O
+are	O
+associated	O
+with	O
+higher	O
+mortality	O
+and	O
+fewer	O
+ventilator	O
+-	O
+free	O
+days	O
+.	O
+
+To	O
+test	O
+the	O
+efficacy	O
+of	O
+activated	B-PRGE
+protein	I-PRGE
+C	I-PRGE
+(	O
+APC	B-COMP
+)	O
+as	O
+a	O
+therapy	O
+for	O
+patients	O
+with	O
+ALI	O
+.	O
+
+The	O
+disease	O
+is	O
+characterized	O
+by	O
+uncontrolled	O
+replication	O
+of	O
+the	O
+virus	O
+and	O
+a	O
+prominent	O
+pro	B-CHED
+-	O
+inflammatory	B-DISO
+response	I-DISO
+.	O
+
+Reports	O
+using	O
+historical	O
+matched	O
+controls	O
+have	O
+suggested	O
+that	O
+treatment	O
+with	O
+interferon	B-PRGE
+alfacon	I-PRGE
+-	I-PRGE
+1	I-PRGE
+(	O
+a	O
+synthetic	O
+interferon	O
+)	O
+combined	O
+with	O
+steroid	B-CHED
+,	O
+protease	B-PROC
+inhibitors	I-PROC
+together	O
+with	O
+ribavirin	B-CHED
+,	O
+or	O
+convalescent	O
+plasma	B-ANAT
+containing	O
+neutralizing	O
+antibody	B-COMP
+,	O
+could	O
+be	O
+useful	O
+.	O
+
+In	O
+addition	O
+,	O
+similar	O
+with	O
+experimental	O
+results	O
+,	O
+the	O
+complex	O
+between	O
+N3	O
+and	O
+3CL	O
+(	O
+Pro	B-CHED
+)	O
+is	O
+578	O
+kcal	O
+/	O
+mol	O
+more	O
+stable	O
+than	O
+N1	O
+-	O
+3CL	O
+(	O
+Pro	B-CHED
+)	O
+using	O
+Own	O
+N	O
+-	O
+layer	B-ANAT
+Integrated	O
+molecular	O
+Orbital	O
+molecular	O
+Mechanics	O
+(	O
+ONIOM	O
+)	O
+approach	O
+.	O
+
+We	O
+suggest	O
+3CL	O
+(	O
+Pro	B-CHED
+)	O
+inhibitors	B-CHED
+need	O
+small	O
+polar	O
+groups	O
+to	O
+decrease	O
+the	O
+energy	O
+barrier	O
+for	O
+alkylation	O
+reaction	O
+.	O
+
+A	O
+32	O
+-	O
+year	O
+-	O
+old	O
+woman	O
+presented	O
+with	O
+severe	O
+cholinergic	B-DISO
+crisis	I-DISO
+after	O
+ingestion	O
+of	O
+an	O
+unknown	O
+amount	O
+of	O
+dichlorvos	B-CHED
+in	O
+a	O
+suicide	B-DISO
+attempt	I-DISO
+.	O
+
+Her	O
+vocal	B-ANAT
+cord	I-ANAT
+movements	B-PROC
+were	O
+restored	O
+to	O
+near	O
+normal	O
+with	O
+time	O
+and	O
+she	O
+was	O
+discharged	O
+on	O
+the	O
+20th	O
+day	O
+after	O
+admission	O
+.	O
+
+Instillation	O
+of	O
+mouse	B-DISO
+hepatitis	I-DISO
+virus	B-SPEC
+(	O
+MHV	B-SPEC
+,	O
+a	O
+positive	O
+-	O
+strand	O
+RNA	O
+virus	B-SPEC
+)	O
+into	O
+the	O
+CNS	B-CHED
+of	O
+mice	B-SPEC
+results	O
+in	O
+acute	O
+encephalitis	B-DISO
+followed	O
+by	O
+a	O
+chronic	O
+immune	O
+-	O
+mediated	O
+demyelinating	B-DISO
+disease	I-DISO
+.	O
+
+TITLE	O
+:	O
+Distinct	O
+signature	O
+type	B-PRGE
+I	I-PRGE
+interferon	I-PRGE
+responses	O
+are	O
+determined	O
+by	O
+the	O
+infecting	O
+virus	B-SPEC
+and	O
+the	O
+target	O
+cell	O
+.	O
+
+The	O
+promoter	O
+regions	O
+of	O
+the	O
+IFN	B-PRGE
+-	I-PRGE
+alpha	I-PRGE
+genes	I-PRGE
+,	O
+however	O
+,	O
+have	O
+different	O
+transcription	B-FUNC
+factor	I-FUNC
+binding	I-FUNC
+sites	O
+,	O
+implying	O
+differential	O
+transcriptional	B-PROC
+activation	I-PROC
+.	O
+
+These	O
+data	O
+suggest	O
+that	O
+the	O
+infecting	O
+virus	B-SPEC
+and	O
+the	O
+target	B-ANAT
+cell	I-ANAT
+type	O
+dictate	O
+the	O
+extent	O
+and	O
+signature	O
+of	O
+inducible	O
+type	B-PRGE
+I	I-PRGE
+IFN	I-PRGE
+gene	I-PRGE
+expression	O
+.	O
+
+The	O
+objective	O
+of	O
+the	O
+present	O
+study	O
+was	O
+to	O
+develop	O
+and	O
+apply	O
+the	O
+direct	O
+immunohistochemistry	O
+(	O
+D	O
+-	O
+IHC	O
+)	O
+assay	O
+to	O
+search	O
+for	O
+turkey	O
+coronavirus	B-SPEC
+(	O
+TCoV	O
+)	O
+antigens	B-CHED
+in	O
+formalin	B-CHED
+-	O
+fixed	B-ANAT
+embedded	O
+-	O
+paraffin	O
+tissues	B-ANAT
+by	O
+the	O
+use	O
+of	O
+biotin	B-CHED
+-	O
+labeled	O
+polyclonal	O
+antibody	B-COMP
+.	O
+
+(	O
+Correction	O
+added	O
+after	O
+online	O
+publication	O
+5	O
+June	O
+2008	O
+:	O
+The	O
+denominators	O
+112	O
+pregnancies	B-PROC
+,	O
+labours	O
+,	O
+and	O
+labour	B-PROC
+/	O
+deliveries	O
+,	O
+and	O
+16	O
+and	O
+68	O
+neonates	O
+were	O
+included	O
+;	O
+and	O
+9	O
+%	O
+of	O
+labours	O
+was	O
+corrected	O
+to	O
+10	O
+%.)	O
+
+Interventions	O
+to	O
+lower	O
+stillbirths	B-DISO
+and	O
+neonatal	O
+deaths	B-PROC
+should	O
+focus	O
+on	O
+improving	O
+the	O
+quality	O
+of	O
+medical	O
+care	O
+for	O
+important	O
+obstetric	O
+complications	O
+and	O
+newborn	O
+illnesses	O
+.	O
+
+TITLE	O
+:	O
+Detection	O
+of	O
+bovine	B-SPEC
+coronavirus	B-SPEC
+using	O
+a	O
+TaqMan	O
+-	O
+based	O
+real	O
+-	O
+time	O
+RT	O
+-	O
+PCR	O
+assay	O
+.	O
+
+The	O
+rapidity	O
+and	O
+high	O
+throughput	O
+of	O
+the	O
+BCoV	O
+TaqMan	O
+assay	O
+makes	O
+this	O
+method	O
+a	O
+powerful	O
+tool	O
+for	O
+a	O
+sensitive	O
+and	O
+specific	O
+diagnosis	O
+of	O
+BCoV	O
+infection	B-DISO
+in	O
+cattle	B-SPEC
+.	O
+
+TITLE	O
+:	O
+Experimental	O
+optic	B-DISO
+neuritis	I-DISO
+induced	O
+by	O
+a	O
+demyelinating	O
+strain	O
+of	O
+mouse	B-DISO
+hepatitis	I-DISO
+virus	B-SPEC
+.	O
+
+ABSTRACT	O
+:	O
+Zoonotic	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+coronavirus	B-SPEC
+(	O
+SARS	B-PRGE
+-	I-PRGE
+CoV	I-PRGE
+)	O
+likely	O
+evolved	O
+to	O
+infect	O
+humans	B-SPEC
+by	O
+a	O
+series	O
+of	O
+transmission	O
+events	O
+between	O
+humans	B-SPEC
+and	O
+animals	B-SPEC
+in	O
+markets	O
+in	O
+China	O
+.	O
+
+Virus	B-SPEC
+sequence	O
+data	O
+suggest	O
+that	O
+the	O
+palm	B-ANAT
+civet	B-SPEC
+served	O
+as	O
+an	O
+amplification	B-DISO
+host	B-COMP
+in	O
+which	O
+civet	B-SPEC
+and	O
+human	B-SPEC
+interaction	O
+fostered	O
+the	O
+evolution	B-PROC
+of	O
+the	O
+epidemic	O
+SARS	B-DISO
+Urbani	O
+strain	O
+.	O
+
+TITLE	O
+:	O
+C3d	B-DISO
+and	O
+C4d	O
+deposition	O
+early	O
+after	O
+lung	B-ANAT
+transplantation	O
+.	O
+
+Significant	O
+C3d	B-DISO
+and	O
+C4d	O
+staining	O
+(	O
+i	O
+.	O
+e	O
+.,	O
+Grade	O
+>	O
+or	O
+=	O
+2	O
+on	O
+more	O
+than	O
+one	O
+occasion	O
+)	O
+was	O
+observed	O
+in	O
+20	O
+and	O
+11	O
+LTRs	O
+,	O
+respectively	O
+.	O
+
+Complement	O
+staining	O
+was	O
+increased	O
+in	O
+LTRs	O
+with	O
+severe	O
+primary	B-DISO
+graft	I-DISO
+dysfunction	I-DISO
+or	O
+airway	B-ANAT
+infection	B-DISO
+,	O
+but	O
+was	O
+not	O
+associated	O
+with	O
+acute	O
+cellular	B-COMP
+or	O
+chronic	O
+rejection	O
+,	O
+or	O
+with	O
+morphologic	O
+features	O
+of	O
+AMR	O
+.	O
+
+We	O
+sought	O
+to	O
+evaluate	O
+the	O
+significance	O
+of	O
+MBL	B-DISO
+deficiency	I-DISO
+(	O
+O	O
+/	O
+O	O
+genotypes	O
+)	O
+and	O
+insufficiency	O
+(	O
+O	O
+/	O
+O	O
+plus	O
+XA	O
+/	O
+O	O
+genotypes	O
+),	O
+as	O
+well	O
+as	O
+MASP	B-PRGE
+-	I-PRGE
+2	I-PRGE
+deficiency	O
+(	O
+D105G	O
+mutation	O
+),	O
+in	O
+the	O
+susceptibility	O
+to	O
+and	O
+severity	O
+and	O
+outcome	O
+of	O
+CAP	B-DISO
+in	O
+adults	O
+.	O
+
+ABSTRACT	O
+:	O
+The	O
+causative	O
+agent	O
+of	O
+severe	O
+acute	O
+respiratory	O
+syndrome	O
+(	O
+SARS	B-DISO
+)	O
+has	O
+been	O
+identified	O
+as	O
+a	O
+novel	B-SPEC
+coronavirus	I-SPEC
+,	O
+SARS	B-DISO
+-	O
+CoV	O
+.	O
+The	O
+development	B-PROC
+of	O
+rapid	O
+screening	O
+assays	O
+is	O
+essential	O
+for	O
+antiviral	B-CHED
+drug	I-CHED
+discovery	O
+.	O
+
+By	O
+using	O
+a	O
+cell	B-ANAT
+line	I-ANAT
+expressing	O
+a	O
+SARS	B-DISO
+-	O
+CoV	O
+subgenomic	O
+replicon	O
+,	O
+we	O
+developed	O
+a	O
+high	O
+-	O
+throughput	O
+assay	O
+and	O
+used	O
+it	O
+to	O
+screen	O
+small	O
+molecule	O
+compounds	O
+for	O
+inhibitors	B-CHED
+of	O
+SARS	B-DISO
+-	O
+CoV	O
+replication	O
+in	O
+the	O
+absence	O
+of	O
+live	O
+virus	B-SPEC
+.	O
+
+TITLE	O
+:	O
+Pathology	B-DISO
+of	O
+experimental	O
+SARS	B-DISO
+coronavirus	B-DISO
+infection	I-DISO
+in	O
+cats	B-SPEC
+and	O
+ferrets	B-SPEC
+.	O
+
+All	O
+fatalities	O
+caused	O
+by	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+.	O
+
+A	O
+28	O
+-	O
+yr	O
+-	O
+old	O
+man	B-CHED
+involved	O
+in	O
+a	O
+motor	O
+vehicle	O
+collision	O
+sustained	O
+multiple	O
+injuries	O
+,	O
+including	O
+T6	O
+-	O
+T7	O
+thoracic	B-ANAT
+vertebrae	I-ANAT
+fracture	O
+.	O
+
+The	O
+cerebrospinal	B-ANAT
+fluid	I-ANAT
+protein	B-CHED
+concentration	O
+was	O
+5	O
+.	O
+03	O
+g	O
+.	O
+
+According	O
+to	O
+further	O
+analysis	O
+,	O
+HIV	B-SPEC
+-	I-SPEC
+1	I-SPEC
+NC	O
+replacement	O
+with	O
+N	O
+residues	O
+2	O
+-	O
+213	O
+,	O
+215	O
+-	O
+421	O
+,	O
+or	O
+234	O
+-	O
+421	O
+resulted	O
+in	O
+efficient	O
+VLP	O
+production	O
+at	O
+levels	O
+comparable	O
+to	O
+that	O
+of	O
+wt	O
+HIV	B-SPEC
+-	I-SPEC
+1	I-SPEC
+,	O
+but	O
+replacement	O
+with	O
+residues	O
+215	O
+-	O
+359	O
+,	O
+302	O
+-	O
+421	O
+,	O
+2	O
+-	O
+168	O
+,	O
+or	O
+2	O
+-	O
+86	O
+failed	O
+to	O
+restore	O
+VLP	B-COMP
+production	O
+to	O
+wild	O
+-	O
+type	O
+levels	O
+.	O
+
+TITLE	O
+:	O
+Renal	B-ANAT
+failure	I-DISO
+in	O
+malaria	B-PATH
+.	O
+
+Currently	O
+,	O
+high	O
+quality	O
+intensive	O
+care	O
+,	O
+early	O
+institution	O
+of	O
+renal	B-ANAT
+replacement	O
+therapy	O
+,	O
+and	O
+avoidance	O
+of	O
+nephrotoxic	O
+drugs	O
+are	O
+standard	O
+practice	O
+of	O
+the	O
+prevention	O
+and	O
+management	O
+of	O
+ARF	B-DISO
+.	O
+
+Plasma	B-PRGE
+IL	B-FUNC
+-	I-FUNC
+6	I-FUNC
+levels	O
+are	O
+influenced	O
+mainly	O
+by	O
+genetic	O
+determinants	O
+,	O
+and	O
+a	O
+-	O
+174G	O
+/	O
+C	O
+polymorphism	B-PROC
+of	O
+the	O
+gene	O
+has	O
+been	O
+recently	O
+associated	O
+with	O
+susceptibility	O
+to	O
+ALI	O
+.	O
+
+DNA	O
+was	O
+isolated	O
+from	O
+67	O
+consecutive	O
+patients	O
+who	O
+fulfilled	O
+international	O
+criteria	O
+for	O
+severe	B-DISO
+sepsis	I-DISO
+and	O
+for	O
+ALI	O
+and	O
+96	O
+population	O
+-	O
+based	O
+controls	O
+drawn	O
+from	O
+the	O
+general	O
+population	O
+.	O
+
+TITLE	O
+:	O
+[	O
+Role	O
+of	O
+coagulation	B-PROC
+in	O
+acute	O
+pulmonary	B-ANAT
+lesion	O
+physiopathology	O
+.	O
+
+Acute	O
+lung	B-ANAT
+injury	O
+/	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+are	O
+associated	O
+with	O
+increased	O
+procoagulant	O
+and	O
+reduced	O
+fibrinolytic	O
+activities	O
+mainly	O
+in	O
+alveoli	B-ANAT
+and	O
+interstitial	B-ANAT
+spaces	I-ANAT
+in	O
+the	O
+lung	B-ANAT
+.	O
+
+Fibrin	O
+deposits	O
+,	O
+which	O
+are	O
+the	O
+hallmark	O
+of	O
+early	O
+phase	O
+acute	O
+lung	B-ANAT
+injury	O
+,	O
+stimulate	O
+fibroblast	B-ANAT
+aggregation	O
+and	O
+collagen	B-COMP
+secretion	B-PROC
+,	O
+participating	O
+to	O
+the	O
+constitution	O
+of	O
+pulmonary	B-DISO
+fibrosis	I-DISO
+.	O
+
+HCoV	B-SPEC
+-	I-SPEC
+NL63	I-SPEC
+was	O
+detected	O
+in	O
+10	O
+patients	O
+(	O
+2	O
+.	O
+0	O
+%)	O
+with	O
+symptomatic	O
+respiratory	B-DISO
+diseases	I-DISO
+,	O
+mainly	O
+during	O
+winter	O
+.	O
+
+We	O
+immunized	O
+mice	B-SPEC
+with	O
+UV	O
+-	O
+inactivated	O
+SARS	B-PRGE
+-	I-PRGE
+CoV	I-PRGE
+to	O
+generate	O
+three	O
+anti	B-PRGE
+-	I-PRGE
+S	I-PRGE
+monoclonal	I-PRGE
+antibodies	I-PRGE
+,	O
+and	O
+established	O
+several	O
+neutralization	O
+escape	O
+mutants	O
+with	O
+S	B-PRGE
+protein	I-PRGE
+.	O
+
+FCoV	O
+biotypes	O
+that	O
+cause	O
+FIP	B-DISO
+are	O
+designated	O
+feline	B-DISO
+infectious	I-DISO
+peritonitis	I-DISO
+virus	B-SPEC
+(	O
+FIPV	O
+),	O
+and	O
+are	O
+distinguished	O
+by	O
+their	O
+ability	O
+to	O
+infect	O
+macrophages	B-ANAT
+and	O
+monocytes	B-ANAT
+.	O
+
+TITLE	O
+:	O
+Development	B-PROC
+of	O
+broad	O
+-	O
+spectrum	O
+halomethyl	O
+ketone	B-CHED
+inhibitors	B-CHED
+against	O
+coronavirus	B-SPEC
+main	I-PRGE
+protease	I-PRGE
+3CL	I-PRGE
+(	O
+pro	O
+).	O
+
+ABSTRACT	O
+:	O
+Coronaviruses	O
+comprise	O
+a	O
+large	O
+group	O
+of	O
+RNA	O
+viruses	B-SPEC
+with	O
+diverse	O
+host	B-COMP
+specificity	O
+.	O
+
+Here	O
+3CL	O
+(	O
+pro	B-CHED
+)	O
+derived	O
+from	O
+the	O
+SARS	B-PRGE
+-	I-PRGE
+CoV	I-PRGE
+was	O
+used	O
+as	O
+the	O
+primary	O
+target	O
+to	O
+identify	O
+a	O
+new	O
+class	B-SPEC
+of	O
+inhibitors	B-CHED
+containing	O
+a	O
+halomethyl	O
+ketone	B-CHED
+warhead	O
+.	O
+
+It	O
+can	O
+be	O
+related	O
+to	O
+infectious	B-DISO
+condition	B-DISO
+,	O
+surgery	O
+,	O
+or	O
+treatment	O
+changes	O
+.	O
+
+A	O
+discrete	O
+time	O
+stochastic	O
+model	O
+that	O
+uses	O
+a	O
+back	B-ANAT
+-	O
+projection	O
+approach	O
+is	O
+proposed	O
+.	O
+
+Applying	O
+the	O
+method	O
+to	O
+SARS	B-DISO
+data	O
+from	O
+Hong	O
+Kong	O
+,	O
+a	O
+value	O
+of	O
+3	O
+.	O
+88	O
+with	O
+a	O
+posterior	O
+standard	O
+deviation	O
+of	O
+0	O
+.	O
+09	O
+was	O
+estimated	O
+for	O
+the	O
+basic	O
+reproduction	B-PROC
+number	O
+.	O
+
+Therefore	O
+,	O
+we	O
+have	O
+carried	O
+out	O
+a	O
+study	O
+of	O
+the	O
+binding	B-FUNC
+and	O
+interaction	O
+with	O
+model	O
+membranes	B-ANAT
+of	O
+a	O
+peptide	B-CHED
+corresponding	O
+to	O
+segment	O
+873	O
+-	O
+888	O
+of	O
+the	O
+SARS	B-PRGE
+-	I-PRGE
+CoV	I-PRGE
+S	I-PRGE
+glycoprotein	B-CHED
+,	O
+peptide	B-CHED
+SARS	B-DISO
+IFP	O
+,	O
+as	O
+well	O
+as	O
+the	O
+structural	O
+changes	O
+taking	O
+place	O
+in	O
+both	O
+the	O
+phospholipid	B-CHED
+and	O
+the	O
+peptide	B-CHED
+induced	O
+by	O
+the	O
+binding	B-FUNC
+of	O
+the	O
+peptide	B-CHED
+to	O
+the	O
+membrane	B-COMP
+.	O
+
+To	O
+achieve	O
+better	O
+outcomes	O
+of	O
+ECLS	O
+in	O
+this	O
+high	O
+risk	O
+group	O
+,	O
+an	O
+understanding	O
+of	O
+the	O
+real	O
+impact	O
+of	O
+preexisting	O
+organ	B-ANAT
+dysfunction	O
+on	O
+ECLS	O
+-	O
+associated	O
+mortality	O
+is	O
+necessary	O
+.	O
+
+Multivariate	O
+analysis	O
+revealed	O
+that	O
+the	O
+necessity	O
+of	O
+renal	B-ANAT
+dialysis	B-SPEC
+was	O
+an	O
+independent	O
+risk	O
+factor	O
+associated	O
+with	O
+failure	O
+to	O
+wean	B-PROC
+and	O
+non	O
+-	O
+survival	O
+,	O
+and	O
+the	O
+necessity	O
+of	O
+cardiopulmonary	B-ANAT
+resuscitation	O
+(	O
+CPR	B-ENZY
+)	O
+before	O
+ECLS	O
+was	O
+an	O
+independent	O
+risk	O
+factor	O
+for	O
+non	O
+-	O
+survival	O
+.	O
+
+TITLE	O
+:	O
+Preparing	O
+for	O
+an	O
+influenza	B-DISO
+pandemic	O
+in	O
+Singapore	O
+.	O
+
+Based	O
+on	O
+the	O
+infectious	B-DISO
+cDNA	O
+clone	O
+of	O
+rSARS	O
+-	O
+CoV	O
+-	O
+DeltaE	O
+,	O
+in	O
+which	O
+the	O
+E	B-PRGE
+gene	I-PRGE
+has	O
+been	O
+deleted	O
+,	O
+a	O
+safe	O
+non	O
+-	O
+infectious	B-DISO
+replicon	O
+was	O
+constructed	O
+by	O
+replacing	O
+the	O
+S	B-PRGE
+gene	I-PRGE
+with	O
+the	O
+enhanced	B-PRGE
+green	I-PRGE
+fluorescent	I-PRGE
+protein	I-PRGE
+(	O
+eGFP	O
+)	O
+gene	O
+.	O
+
+Polyclonal	O
+IgY	O
+-	O
+based	O
+immunoswabs	O
+detected	O
+an	O
+NP	O
+concentration	O
+of	O
+10	O
+pg	O
+/	O
+mL	O
+in	O
+pig	B-SPEC
+nasopharyngeal	B-ANAT
+aspirate	I-ANAT
+providing	O
+the	O
+most	O
+sensitive	O
+SARS	B-DISO
+point	O
+of	O
+care	O
+assay	O
+.	O
+
+Interstitial	B-DISO
+nephritis	I-DISO
+is	O
+the	O
+principal	O
+feature	O
+of	O
+the	O
+disease	O
+.	O
+
+-	O
+1	O
+PRF	O
+is	O
+programmed	O
+by	O
+a	O
+bipartite	O
+signal	O
+embedded	O
+in	O
+the	O
+mRNA	B-CHED
+and	O
+includes	O
+a	O
+heptanucleotide	O
+""""	O
+slip	O
+site	O
+""""	O
+over	O
+which	O
+the	O
+paused	O
+ribosome	B-COMP
+""""	O
+backs	B-ANAT
+up	O
+""""	O
+by	O
+one	O
+nucleotide	B-CHED
+,	O
+and	O
+a	O
+downstream	O
+stimulatory	O
+element	O
+,	O
+either	O
+an	O
+RNA	O
+pseudoknot	O
+or	O
+a	O
+very	O
+stable	O
+RNA	O
+stem	B-ANAT
+-	O
+loop	O
+.	O
+
+The	O
+precise	O
+mechanism	O
+by	O
+which	O
+the	O
+downstream	O
+RNA	O
+stimulates	O
+-	O
+1	O
+PRF	O
+by	O
+the	O
+translocating	O
+ribosome	B-COMP
+remains	O
+unclear	O
+.	O
+
+There	O
+was	O
+no	O
+significant	O
+change	O
+in	O
+the	O
+tumor	B-DISO
+type	O
+or	O
+reason	O
+for	O
+referral	O
+.	O
+
+TITLE	O
+:	O
+Virus	B-SPEC
+-	I-ANAT
+like	I-ANAT
+particles	I-ANAT
+of	O
+SARS	B-DISO
+-	O
+like	O
+coronavirus	B-SPEC
+formed	O
+by	O
+membrane	B-COMP
+proteins	B-CHED
+from	O
+different	O
+origins	O
+demonstrate	O
+stimulating	O
+activity	O
+in	O
+human	O
+dendritic	B-ANAT
+cells	B-COMP
+.	O
+
+ABSTRACT	O
+:	O
+Intermediate	B-DISO
+syndrome	I-DISO
+(	O
+IMS	O
+)	O
+is	O
+a	O
+major	O
+cause	O
+of	O
+death	B-PROC
+from	O
+respiratory	B-DISO
+failure	I-DISO
+following	O
+acute	O
+organophosphate	O
+poisoning	O
+.	O
+
+All	O
+ten	O
+patients	O
+showed	O
+progressive	O
+RNS	B-DISO
+changes	O
+correlating	O
+with	O
+the	O
+severity	O
+of	O
+IMS	O
+.	O
+
+Characteristic	O
+changes	O
+in	O
+RNS	B-DISO
+,	O
+preceding	O
+the	O
+development	B-PROC
+of	O
+IMS	O
+,	O
+help	O
+to	O
+identify	O
+a	O
+subgroup	O
+of	O
+patients	O
+at	O
+high	O
+risk	O
+of	O
+developing	O
+respiratory	B-DISO
+failure	I-DISO
+.	O
+
+RNS	B-DISO
+changes	O
+are	O
+objective	O
+and	O
+precede	O
+the	O
+diagnosis	O
+and	O
+complications	O
+of	O
+IMS	O
+.	O
+
+In	O
+the	O
+present	O
+study	O
+,	O
+we	O
+demonstrate	O
+that	O
+the	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+coronavirus	B-SPEC
+nucleocapsid	B-COMP
+protein	B-CHED
+is	O
+phosphorylated	O
+primarily	O
+within	O
+the	O
+RS	O
+-	O
+rich	O
+region	O
+in	O
+cells	B-COMP
+and	O
+by	O
+SR	B-PRGE
+protein	I-PRGE
+kinase	I-PRGE
+1	I-PRGE
+in	O
+vitro	O
+.	O
+
+When	O
+the	O
+TMD	B-DISO
+of	O
+human	B-SPEC
+CD4	B-PRGE
+was	O
+replaced	O
+with	O
+the	O
+ORF7b	O
+TMD	B-DISO
+,	O
+the	O
+resulting	O
+chimeric	O
+protein	B-CHED
+localized	O
+to	O
+the	O
+Golgi	O
+complex	O
+.	O
+
+ABSTRACT	O
+:	O
+The	O
+relationship	O
+between	O
+immunosenescence	B-DISO
+and	O
+the	O
+host	B-COMP
+response	B-PROC
+to	I-PROC
+virus	I-PROC
+infection	O
+is	O
+poorly	O
+understood	O
+at	O
+the	O
+molecular	O
+level	O
+.	O
+
+We	O
+provide	O
+insight	O
+into	O
+gene	B-PROC
+expression	I-PROC
+profiles	O
+and	O
+molecular	O
+signatures	O
+underlying	O
+immunosenescence	B-DISO
+in	O
+the	O
+context	O
+of	O
+the	O
+host	B-PROC
+response	I-PROC
+to	O
+viral	B-DISO
+infection	I-DISO
+.	O
+
+Activation	O
+of	O
+caspase	B-PRGE
+-	I-PRGE
+8	I-PRGE
+through	O
+extrinsic	O
+signal	O
+(	O
+s	O
+)	O
+caused	O
+Bid	B-PRGE
+activation	O
+.	O
+
+In	O
+the	O
+intrinsic	O
+pathway	B-PROC
+,	O
+there	O
+was	O
+activation	O
+of	O
+caspase	B-PRGE
+-	I-PRGE
+9	I-PRGE
+and	O
+cytochrome	B-PRGE
+c	I-PRGE
+release	B-PATH
+from	O
+the	O
+mitochondria	B-COMP
+.	O
+
+A	O
+block	O
+in	O
+nuclear	B-PROC
+translocation	I-PROC
+of	O
+the	O
+STAT3	B-PRGE
+transcription	B-PROC
+factor	O
+in	O
+cells	B-COMP
+expressing	O
+the	O
+3a	O
+protein	B-CHED
+was	O
+also	O
+observed	O
+.	O
+
+RESULTS	O
+:	O
+Main	O
+underlying	O
+lung	B-DISO
+diseases	I-DISO
+were	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+(	O
+70	O
+.	O
+4	O
+%)	O
+and	O
+pneumonia	B-DISO
+(	O
+28	O
+.	O
+3	O
+%).	O
+
+ABSTRACT	O
+:	O
+Recently	O
+,	O
+the	O
+existence	O
+of	O
+a	O
+relationship	O
+was	O
+reported	O
+between	O
+the	O
+severity	O
+of	O
+lung	B-ANAT
+injury	O
+and	O
+the	O
+serum	B-COMP
+level	O
+of	O
+F2	O
+-	O
+isoprostane	O
+,	O
+a	O
+known	O
+oxidative	B-DISO
+stress	I-DISO
+marker	O
+.	O
+
+Four	O
+patients	O
+survived	O
+and	O
+9	O
+died	B-PROC
+.	O
+
+ABSTRACT	O
+:	O
+Poult	O
+enteritis	B-DISO
+(	O
+PE	O
+)	O
+is	O
+one	O
+of	O
+the	O
+most	O
+common	O
+diseases	O
+seen	O
+in	O
+young	O
+turkey	B-SPEC
+flocks	O
+.	O
+
+Rotaviruses	B-SPEC
+were	O
+present	O
+in	O
+46	O
+.	O
+5	O
+%	O
+of	O
+the	O
+chicken	B-SPEC
+flocks	O
+tested	O
+and	O
+in	O
+69	O
+.	O
+7	O
+%	O
+of	O
+the	O
+turkey	B-SPEC
+flocks	O
+tested	O
+.	O
+
+Coronaviruses	O
+were	O
+detected	O
+in	O
+the	O
+intestinal	B-ANAT
+contents	I-ANAT
+of	O
+chickens	B-SPEC
+,	O
+but	O
+not	O
+turkeys	B-SPEC
+.	O
+
+Most	O
+flocks	O
+were	O
+positive	O
+for	O
+two	O
+or	O
+more	O
+of	O
+the	O
+viruses	B-SPEC
+,	O
+and	O
+overall	O
+no	O
+clear	O
+pattern	O
+of	O
+virus	B-SPEC
+geographic	O
+distribution	O
+was	O
+evident	O
+.	O
+
+TITLE	O
+:	O
+Identification	O
+of	O
+a	O
+newly	O
+isolated	O
+avian	B-DISO
+infectious	I-DISO
+bronchitis	I-DISO
+coronavirus	B-SPEC
+variant	O
+in	O
+China	O
+exhibiting	O
+affinity	O
+for	O
+the	O
+respiratory	O
+tract	O
+.	O
+
+ABSTRACT	O
+:	O
+Twelve	O
+infectious	B-DISO
+bronchitis	B-DISO
+virus	B-SPEC
+(	O
+IBV	B-SPEC
+)	O
+isolates	O
+obtained	O
+from	O
+commercial	O
+chickens	B-SPEC
+in	O
+China	O
+between	O
+2005	O
+and	O
+2006	O
+were	O
+characterized	O
+by	O
+reverse	B-PRGE
+transcriptase	I-PRGE
+-	O
+polymerase	O
+chain	O
+reaction	O
+(	O
+RT	O
+-	O
+PCR	O
+)	O
+and	O
+the	O
+sequencing	O
+of	O
+the	O
+entire	O
+S1	B-PRGE
+gene	I-PRGE
+.	O
+
+ABSTRACT	O
+:	O
+Thirty	O
+-	O
+three	O
+field	O
+isolates	O
+of	O
+avian	O
+infectious	O
+bronchitis	O
+virus	B-SPEC
+(	O
+IBV	B-SPEC
+)	O
+were	O
+recovered	O
+from	O
+commercial	O
+chicken	B-SPEC
+flocks	O
+in	O
+Korea	O
+between	O
+2003	O
+and	O
+2006	O
+and	O
+were	O
+characterized	O
+phylogenetically	O
+by	O
+nucleotide	B-CHED
+sequence	O
+analysis	O
+of	O
+the	O
+IBV	B-PRGE
+S1	I-PRGE
+gene	I-PRGE
+hyper	I-PRGE
+-	I-PRGE
+variable	I-PRGE
+region	I-PRGE
+.	O
+
+ABSTRACT	O
+:	O
+Antiphospholipid	B-DISO
+syndrome	I-DISO
+(	O
+APS	B-DISO
+)	O
+is	O
+a	O
+systemic	O
+autoimmune	B-DISO
+disorder	I-DISO
+characterized	O
+by	O
+a	O
+combination	O
+of	O
+arterial	B-ANAT
+or	O
+venous	B-DISO
+thrombosis	I-DISO
+and	O
+recurrent	O
+fetal	B-ANAT
+loss	O
+,	O
+accompanied	O
+by	O
+elevated	O
+titers	O
+of	O
+antiphospholipid	O
+antibodies	B-COMP
+(	O
+aPL	B-DISO
+).	O
+
+Catastrophic	O
+antiphospholipid	B-DISO
+syndrome	I-DISO
+(	O
+CAPS	O
+)	O
+is	O
+a	O
+small	O
+subset	O
+of	O
+APS	B-DISO
+characterized	O
+by	O
+widespread	O
+systemic	O
+thrombotic	O
+disease	O
+with	O
+multiorgan	B-DISO
+failure	I-DISO
+.	O
+
+Our	O
+case	O
+is	O
+interesting	O
+in	O
+that	O
+severe	O
+respiratory	B-DISO
+failure	I-DISO
+due	O
+to	O
+ARDS	B-DISO
+was	O
+the	O
+initial	O
+presentation	O
+of	O
+CAPS	O
+.	O
+
+To	O
+explore	O
+mechanistic	O
+participation	O
+of	O
+PBEF	O
+in	O
+ALI	O
+and	O
+ventilator	O
+-	O
+induced	O
+lung	B-ANAT
+injury	O
+(	O
+VILI	O
+).	O
+
+Gene	B-PROC
+expression	I-PROC
+profiling	O
+identified	O
+induction	O
+of	O
+ALI	B-PRGE
+-	I-PRGE
+and	I-PRGE
+VILI	I-PRGE
+-	I-PRGE
+associated	I-PRGE
+gene	I-PRGE
+modules	I-PRGE
+(	O
+nuclear	B-PRGE
+factor	I-PRGE
+-	I-PRGE
+kappaB	I-PRGE
+,	O
+leukocyte	B-ANAT
+extravasation	B-DISO
+,	O
+apoptosis	B-PATH
+,	O
+Toll	B-PRGE
+receptor	I-PRGE
+pathways	B-PROC
+).	O
+
+Finally	O
+,	O
+strategies	O
+to	O
+reduce	O
+PBEF	O
+availability	O
+(	O
+neutralizing	O
+antibody	B-COMP
+)	O
+resulted	O
+in	O
+significant	O
+protection	O
+from	O
+VILI	O
+.	O
+
+TITLE	O
+:	O
+Structural	O
+flexibility	O
+of	O
+the	O
+pentameric	O
+SARS	B-DISO
+coronavirus	B-SPEC
+envelope	B-COMP
+protein	B-CHED
+ion	O
+channel	O
+.	O
+
+This	O
+study	O
+aimed	O
+to	O
+analyze	O
+the	O
+clinical	O
+and	O
+laboratory	O
+characteristics	O
+of	O
+systemic	O
+-	O
+onset	O
+juvenile	B-DISO
+idiopathic	I-DISO
+arthritis	I-DISO
+(	O
+SoJIA	O
+)	O
+with	O
+macrophage	B-DISO
+activation	I-DISO
+syndrome	I-DISO
+(	O
+MAS	B-COMP
+)	O
+in	O
+13	O
+patients	O
+.	O
+
+The	O
+perforin	B-PRGE
+A91V	I-PRGE
+(	O
+NCBI	O
+:	O
+SNP	O
+rs35947132	O
+)	O
+gene	O
+in	O
+6	O
+patients	O
+was	O
+normal	O
+.	O
+
+The	O
+characteristics	O
+of	O
+revealed	O
+pneumonia	B-DISO
+among	O
+pregnant	O
+women	O
+show	O
+that	O
+it	O
+is	O
+has	O
+acute	O
+and	O
+severe	O
+clinical	O
+course	O
+,	O
+with	O
+simultaneous	O
+infectious	B-DISO
+toxic	B-DISO
+shock	I-DISO
+,	O
+acute	O
+respiratory	O
+compromise	O
+and	O
+respiratory	B-DISO
+distress	I-DISO
+syndrome	I-DISO
+,	O
+which	O
+occasionally	O
+results	O
+in	O
+lethal	O
+outcome	O
+.	O
+
+ABSTRACT	O
+:	O
+Emerging	O
+viral	B-DISO
+diseases	I-DISO
+are	O
+nothing	O
+new	O
+.	O
+
+Smallpox	O
+probably	O
+reached	O
+Europe	O
+from	O
+Asia	O
+in	O
+the	O
+5th	O
+century	O
+,	O
+and	O
+yellow	B-DISO
+fever	I-DISO
+emerged	O
+in	O
+the	O
+Americas	O
+during	O
+the	O
+16th	O
+century	O
+as	O
+a	O
+consequence	O
+of	O
+the	O
+African	O
+slave	O
+trade	O
+.	O
+
+Dengue	B-DISO
+fever	I-DISO
+arose	O
+simultaneously	O
+in	O
+South	O
+-	O
+East	O
+Asia	O
+,	O
+Africa	O
+,	O
+and	O
+North	O
+America	O
+during	O
+the	O
+18th	O
+century	O
+.	O
+
+MHV	B-SPEC
+infection	B-DISO
+of	O
+primary	O
+cell	B-COMP
+cultures	O
+indicates	O
+that	O
+hepatocytes	B-ANAT
+are	O
+not	O
+responsible	O
+for	O
+the	O
+IFN	B-PROC
+-	I-PROC
+beta	I-PROC
+production	I-PROC
+in	O
+the	O
+liver	B-ANAT
+during	O
+MHV	B-SPEC
+infection	B-DISO
+.	O
+
+This	O
+has	O
+been	O
+shown	O
+in	O
+one	O
+small	O
+randomised	O
+controlled	O
+study	O
+,	O
+terminated	O
+prematurely	O
+due	O
+to	O
+0	O
+%	O
+mortality	O
+in	O
+the	O
+intervention	O
+arm	B-ANAT
+.	O
+
+ABSTRACT	O
+:	O
+Viral	O
+infections	O
+are	O
+common	O
+causes	O
+of	O
+respiratory	B-DISO
+tract	I-DISO
+disease	I-DISO
+in	O
+the	O
+outpatient	O
+setting	O
+but	O
+much	O
+less	O
+common	O
+in	O
+the	O
+intensive	O
+care	O
+unit	O
+.	O
+
+However	O
+,	O
+a	O
+finite	O
+number	O
+of	O
+viral	O
+agents	O
+cause	O
+respiratory	B-DISO
+tract	I-DISO
+disease	I-DISO
+in	O
+the	O
+intensive	O
+care	O
+unit	O
+.	O
+
+This	O
+review	O
+discusses	O
+the	O
+basic	O
+pathophysiology	O
+leading	O
+to	O
+clinical	O
+presentations	O
+in	O
+a	O
+few	O
+common	O
+and	O
+rare	O
+,	O
+but	O
+important	O
+,	O
+viruses	O
+found	O
+in	O
+the	O
+intensive	O
+care	O
+unit	O
+:	O
+influenza	B-DISO
+,	O
+RSV	B-PRGE
+,	O
+SARS	B-DISO
+,	O
+VZV	B-SPEC
+,	O
+adenovirus	B-DISO
+,	O
+CMV	B-SPEC
+,	O
+VHF	O
+,	O
+and	O
+Hantavirus	B-SPEC
+.	O
+
+The	O
+authors	O
+study	O
+the	O
+problem	O
+of	O
+allocating	O
+limited	O
+control	O
+resources	O
+(	O
+e	O
+.	O
+g	O
+.	O
+quarantine	O
+or	O
+recovery	O
+resources	O
+)	O
+in	O
+these	O
+networks	O
+in	O
+a	O
+way	O
+that	O
+exploits	O
+the	O
+topological	O
+structure	O
+,	O
+so	O
+as	O
+to	O
+maximise	O
+the	O
+speed	O
+at	O
+which	O
+the	O
+virus	B-SPEC
+is	O
+eliminated	O
+.	O
+
+Viral	B-DISO
+infections	I-DISO
+are	O
+common	O
+in	O
+adults	O
+with	O
+pneumonia	B-DISO
+.	O
+
+To	O
+identify	O
+specific	O
+patient	O
+subgroups	O
+for	O
+future	O
+study	O
+,	O
+we	O
+performed	O
+an	O
+exploratory	O
+post	O
+hoc	O
+analysis	O
+of	O
+clinical	O
+trials	O
+of	O
+recombinant	B-PRGE
+surfactant	I-PRGE
+protein	B-CHED
+-	I-PRGE
+C	I-PRGE
+(	O
+rSP	B-PRGE
+-	I-PRGE
+C	I-PRGE
+)	O
+surfactant	B-CHED
+(	O
+Venticute	O
+;	O
+Nycomed	O
+GmbH	O
+;	O
+Konstanz	O
+,	O
+Germany	O
+).	O
+
+We	O
+performed	O
+a	O
+pooled	O
+analysis	O
+of	O
+all	O
+five	O
+multicenter	O
+studies	O
+in	O
+which	O
+patients	O
+with	O
+ARDS	B-DISO
+due	O
+to	O
+various	O
+predisposing	O
+events	O
+were	O
+treated	O
+with	O
+rSP	B-PRGE
+-	I-PRGE
+C	I-PRGE
+surfactant	B-CHED
+.	O
+
+We	O
+tested	O
+sera	B-COMP
+collected	O
+from	O
+12	O
+ocelots	B-SPEC
+(	O
+Leopardus	B-SPEC
+pardalis	I-SPEC
+)	O
+native	O
+to	O
+Barro	O
+Colorado	O
+Island	O
+,	O
+Panama	B-SPEC
+,	O
+which	O
+is	O
+free	O
+of	O
+domestic	O
+animals	B-SPEC
+,	O
+for	O
+antibodies	B-COMP
+to	O
+feline	B-SPEC
+herpes	B-SPEC
+virus	I-SPEC
+,	O
+feline	B-SPEC
+calicivirus	I-SPEC
+,	O
+feline	B-SPEC
+corona	B-CHED
+virus	B-SPEC
+,	O
+feline	B-SPEC
+panleukopenia	I-SPEC
+virus	I-SPEC
+,	O
+canine	B-SPEC
+distemper	I-SPEC
+virus	I-SPEC
+,	O
+and	O
+feline	B-SPEC
+immunodeficiency	I-SPEC
+virus	I-SPEC
+(	O
+FIV	B-SPEC
+),	O
+typically	O
+a	O
+species	B-SPEC
+-	O
+specific	O
+infection	B-DISO
+.	O
+
+TITLE	O
+:	O
+Pharmacotherapy	O
+of	O
+acute	O
+lung	B-ANAT
+injury	O
+and	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+.	O
+
+The	O
+complex	O
+lung	B-ANAT
+injury	O
+pathophysiology	O
+of	O
+ALI	O
+/	O
+ARDS	B-DISO
+offers	O
+an	O
+array	O
+of	O
+possible	O
+targets	O
+for	O
+drug	O
+therapy	O
+,	O
+including	O
+inflammation	O
+,	O
+cell	B-COMP
+and	O
+tissue	B-ANAT
+injury	O
+,	O
+vascular	B-ANAT
+dysfunction	O
+,	O
+surfactant	B-CHED
+dysfunction	O
+,	O
+and	O
+oxidant	B-CHED
+injury	O
+.	O
+
+Added	O
+targets	O
+for	O
+pharmacotherapy	O
+outside	O
+the	O
+lungs	B-ANAT
+may	O
+also	O
+be	O
+present	O
+,	O
+since	O
+multiorgan	O
+or	O
+systemic	O
+pathology	B-DISO
+is	O
+common	O
+in	O
+ALI	O
+/	O
+ARDS	B-DISO
+.	O
+
+TITLE	O
+:	O
+Synthesis	B-PROC
+and	O
+in	O
+vitro	O
+anti	O
+-	O
+HIV	B-DISO
+evaluation	O
+of	O
+a	O
+new	O
+series	O
+of	O
+6	O
+-	O
+arylmethyl	O
+-	O
+substituted	O
+S	O
+-	O
+DABOs	O
+as	O
+potential	O
+non	O
+-	O
+nucleoside	O
+HIV	B-CHED
+-	I-CHED
+1	I-CHED
+reverse	B-PROC
+transcriptase	I-PROC
+inhibitors	I-PROC
+.	O
+
+We	O
+will	O
+perform	O
+numerous	O
+real	O
+world	O
+tests	O
+with	O
+our	O
+tools	O
+with	O
+both	O
+Avian	B-DISO
+Influenza	I-DISO
+and	O
+Coronaviruses	O
+.	O
+
+The	O
+versatility	O
+of	O
+the	O
+system	O
+was	O
+demonstrated	O
+by	O
+successful	O
+detection	O
+of	O
+SARS	B-DISO
+viral	O
+DNA	O
+and	O
+ATP	B-CHED
+.	O
+
+The	O
+crystal	B-ANAT
+structure	O
+of	O
+Nsp9	O
+of	O
+human	B-SPEC
+coronavirus	I-SPEC
+(	O
+HCoV	O
+)	O
+229E	O
+reveals	O
+a	O
+novel	O
+disulfide	B-CHED
+-	O
+linked	O
+homodimer	O
+,	O
+which	O
+is	O
+very	O
+different	O
+from	O
+the	O
+previously	O
+reported	O
+Nsp9	O
+dimer	O
+of	O
+SARS	B-DISO
+coronavirus	B-SPEC
+.	O
+
+The	O
+objective	O
+of	O
+this	O
+report	O
+is	O
+to	O
+examine	O
+the	O
+impact	O
+of	O
+HFOV	O
+on	O
+blunt	O
+trauma	O
+patients	O
+with	O
+severe	O
+pulmonary	B-ANAT
+contusions	O
+who	O
+failed	O
+or	O
+were	O
+at	O
+a	O
+high	O
+risk	O
+of	O
+failing	O
+conventional	O
+mechanical	O
+ventilation	O
+.	O
+
+Baseline	O
+demographic	O
+data	O
+including	O
+injury	O
+severity	O
+score	O
+(	O
+ISS	B-DISO
+),	O
+length	O
+of	O
+time	O
+requiring	O
+HFOV	O
+,	O
+total	O
+ventilator	O
+days	O
+,	O
+and	O
+inhospital	O
+mortality	O
+were	O
+collected	O
+.	O
+
+Demonstrated	O
+by	O
+flow	O
+cytometry	O
+and	O
+confocal	O
+microscopy	O
+,	O
+A	O
+-	O
+431	O
+,	O
+MCF	O
+-	O
+7	O
+,	O
+MDA	B-PRGE
+-	I-PRGE
+MB	I-PRGE
+-	I-PRGE
+453	I-PRGE
+,	O
+MDA	B-PRGE
+-	I-PRGE
+MB	I-PRGE
+-	O
+468	O
+and	O
+Capan	O
+-	O
+1	O
+cells	B-COMP
+internalized	O
+fluorophore	O
+-	O
+conjugated	O
+cystatin	B-PRGE
+C	I-PRGE
+when	O
+exposed	O
+to	O
+physiological	O
+concentrations	O
+(	O
+1	O
+microm	O
+).	O
+
+The	O
+chest	B-ANAT
+radiograph	O
+and	O
+chest	B-ANAT
+CT	O
+scan	O
+showed	O
+diffuse	O
+ground	O
+-	O
+glass	O
+-	O
+opacities	B-DISO
+and	O
+reticular	O
+shadows	O
+in	O
+both	O
+lung	B-ANAT
+fields	O
+.	O
+
+The	O
+pulmonary	B-DISO
+infiltration	I-DISO
+seen	O
+on	O
+chest	B-ANAT
+radiograph	O
+diminished	O
+gradually	O
+after	O
+pulse	B-PROC
+methylprednisolone	B-CHED
+and	O
+cyclophosphamide	B-CHED
+therapy	O
+.	O
+
+This	O
+case	O
+has	O
+been	O
+followed	O
+but	O
+no	O
+myositis	B-DISO
+or	O
+recurrence	B-DISO
+of	O
+interstitial	B-DISO
+pneumonia	I-DISO
+has	O
+been	O
+recognized	O
+.	O
+
+TITLE	O
+:	O
+Association	O
+between	O
+faecal	B-ANAT
+shedding	O
+of	O
+feline	B-SPEC
+coronavirus	B-SPEC
+and	O
+serum	B-PRGE
+alpha1	I-PRGE
+-	I-PRGE
+acid	I-PRGE
+glycoprotein	B-CHED
+sialylation	O
+.	O
+
+TITLE	O
+:	O
+Disaster	O
+and	O
+emergency	B-DISO
+management	O
+:	O
+Canadian	O
+nurses	O
+'	O
+perceptions	O
+of	O
+preparedness	O
+on	O
+hospital	O
+front	O
+lines	O
+.	O
+
+Using	O
+a	O
+peptide	B-CHED
+library	O
+derived	O
+from	O
+N	O
+,	O
+we	O
+found	O
+that	O
+amino	B-CHED
+acids	I-CHED
+101	O
+-	O
+115	O
+constituted	O
+a	O
+novel	O
+binding	B-FUNC
+site	O
+for	O
+M	O
+.	O
+We	O
+examined	O
+the	O
+ability	O
+of	O
+N	O
+mutants	O
+to	O
+interact	O
+with	O
+M	O
+and	O
+form	O
+pseudoparticles	O
+,	O
+and	O
+our	O
+observations	O
+indicated	O
+that	O
+M	O
+bound	O
+to	O
+NDelta	O
+(	O
+101	O
+-	O
+115	O
+),	O
+N1	O
+-	O
+150	O
+,	O
+N151	O
+-	O
+300	O
+,	O
+and	O
+N301	O
+-	O
+422	O
+,	O
+but	O
+not	O
+to	O
+N1	O
+-	O
+150Delta	O
+(	O
+101	O
+-	O
+115	O
+).	O
+
+TITLE	O
+:	O
+Risk	O
+factors	O
+of	O
+mortality	O
+in	O
+road	O
+traffic	O
+injury	O
+patients	O
+with	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+.	O
+
+TITLE	O
+:	O
+Molecular	B-PROC
+dynamic	I-PROC
+simulations	O
+analysis	O
+of	O
+ritonavir	B-CHED
+and	O
+lopinavir	O
+as	O
+SARS	B-PRGE
+-	I-PRGE
+CoV	I-PRGE
+3CL	I-PRGE
+(	I-PRGE
+pro	B-CHED
+)	I-PRGE
+inhibitors	B-CHED
+.	O
+
+The	O
+binding	B-FUNC
+affinities	O
+of	O
+LPV	O
+and	O
+RTV	O
+to	O
+SARS	B-PRGE
+-	I-PRGE
+CoV	I-PRGE
+3CL	I-PRGE
+(	I-PRGE
+pro	B-CHED
+)	I-PRGE
+do	O
+not	O
+show	O
+any	O
+significant	O
+difference	O
+.	O
+
+Furthermore	O
+,	O
+it	O
+was	O
+identified	O
+that	O
+budded	O
+virus	B-SPEC
+(	O
+BV	O
+)	O
+can	O
+induce	O
+antiviral	B-CHED
+effects	O
+in	O
+HD	O
+11	O
+cells	B-COMP
+contrary	O
+to	O
+occlusion	B-DISO
+-	O
+derived	O
+virus	B-SPEC
+(	O
+ODV	O
+).	O
+
+TITLE	O
+:	O
+A	O
+SARS	B-DISO
+-	I-PRGE
+CoV	I-PRGE
+protein	B-CHED
+,	I-PRGE
+ORF	I-PRGE
+-	I-PRGE
+6	I-PRGE
+,	O
+induces	O
+caspase	B-PRGE
+-	I-PRGE
+3	I-PRGE
+mediated	O
+,	O
+ER	O
+stress	O
+and	O
+JNK	B-FUNC
+-	O
+dependent	O
+apoptosis	B-PATH
+.	O
+
+Tag	B-DISO
+single	O
+nucleotide	B-CHED
+polymorphisms	B-PROC
+(	O
+SNP	O
+;	O
+n	O
+=	O
+37	O
+)	O
+selected	O
+across	O
+the	O
+entire	O
+coding	O
+and	O
+putative	O
+regulatory	O
+regions	O
+of	O
+CSA	B-DISO
+and	O
+CSB	B-DISO
+based	O
+on	O
+a	O
+high	O
+-	O
+density	O
+SNP	O
+database	O
+were	O
+genotyped	O
+by	O
+the	O
+Illumina	O
+Golden	O
+Gate	O
+assay	O
+.	O
+
+Major	O
+principal	O
+components	O
+of	O
+CSA	O
+and	O
+CSB	B-DISO
+that	O
+captured	O
+the	O
+linkage	B-PROC
+disequilibrium	B-DISO
+from	O
+multiple	O
+SNPs	O
+were	O
+globally	O
+associated	O
+with	O
+the	O
+number	O
+of	O
+breaks	O
+per	O
+cell	B-COMP
+at	O
+the	O
+threshold	O
+of	O
+80	O
+%	O
+(	O
+P	O
+<	O
+or	O
+=	O
+0	O
+.	O
+02	O
+for	O
+both	O
+genes	O
+).	O
+
+TITLE	O
+:	O
+Molecular	O
+and	O
+genetic	O
+characterisation	O
+of	O
+the	O
+SARS	B-PRGE
+coronavirus	B-SPEC
+auxiliary	I-PRGE
+protein	B-CHED
+X1	I-PRGE
+in	O
+Drosophila	B-SPEC
+.	O
+
+We	O
+have	O
+established	O
+and	O
+characterised	O
+an	O
+in	O
+-	O
+vivo	O
+3a	O
+transgenic	O
+Drosophila	B-SPEC
+model	O
+,	O
+and	O
+demonstrated	O
+its	O
+usefulness	O
+in	O
+studying	O
+SARS	B-PRGE
+-	I-PRGE
+CoV	I-PRGE
+3a	I-PRGE
+gene	B-PROC
+function	I-PROC
+.	O
+
+Subclinical	O
+SARS	B-DISO
+coronavirus	B-DISO
+infection	I-DISO
+is	O
+rare	O
+in	O
+children	O
+.	O
+
+A	O
+novel	O
+HLA	B-PRGE
+-	I-PRGE
+A2	I-PRGE
+.	I-PRGE
+1	I-PRGE
+-	I-PRGE
+specific	I-PRGE
+SARS	B-DISO
+coronavirus	B-SPEC
+(	I-PRGE
+SARS	B-DISO
+-	I-PRGE
+CoV	I-PRGE
+)	I-PRGE
+nucleocapsid	B-COMP
+(	I-PRGE
+N	I-PRGE
+)	I-PRGE
+protein	B-CHED
+epitope	B-CHED
+(	O
+N220	O
+-	O
+N228	O
+LALLLLDRL	O
+)	O
+able	O
+to	O
+activate	O
+cytotoxic	B-ANAT
+T	I-ANAT
+cells	I-ANAT
+in	O
+vitro	O
+has	O
+been	O
+identified	O
+.	O
+
+In	O
+contrast	O
+,	O
+homozygous	O
+L	O
+-	O
+SIGN	O
+demonstrated	O
+lower	O
+binding	B-FUNC
+capacity	O
+for	O
+HIV1	B-PRGE
+-	I-PRGE
+gp120	I-PRGE
+.	I-PRGE
+3	I-PRGE
+.	O
+
+We	O
+have	O
+shown	O
+that	O
+these	O
+compounds	O
+can	O
+inhibit	O
+SARS	B-PRGE
+-	I-PRGE
+CoV	I-PRGE
+helicase	B-FUNC
+activity	I-FUNC
+and	O
+viral	O
+growth	B-PROC
+in	O
+cell	B-COMP
+culture	O
+systems	O
+.	O
+
+TITLE	O
+:	O
+An	O
+evaluation	O
+of	O
+SARS	B-DISO
+and	O
+droplet	O
+infection	B-DISO
+control	O
+practices	O
+in	O
+acute	O
+and	O
+rehabilitation	O
+hospitals	O
+in	O
+Hong	O
+Kong	O
+.	O
+
+Compliance	O
+with	O
+infection	B-DISO
+control	O
+guidelines	O
+is	O
+satisfactory	O
+and	O
+has	O
+increased	O
+compared	O
+with	O
+previous	O
+studies	O
+.	O
+
+ABSTRACT	O
+:	O
+31	O
+samples	O
+of	O
+blood	O
+serum	O
+of	O
+pregnant	O
+women	O
+with	O
+acute	O
+respiratory	B-DISO
+virus	I-DISO
+infection	I-DISO
+and	O
+pneumonia	B-DISO
+symptoms	O
+who	O
+had	O
+been	O
+administered	O
+into	O
+hospital	O
+were	O
+analyzed	O
+.	O
+
+ABSTRACT	O
+:	O
+Four	O
+new	O
+infectious	B-DISO
+bronchitis	B-DISO
+virus	B-SPEC
+(	O
+IBV	B-SPEC
+)	O
+strains	O
+(	O
+T6	O
+,	O
+K32	O
+,	O
+K43	O
+,	O
+and	O
+K87	O
+)	O
+were	O
+isolated	O
+from	O
+clinically	O
+infected	O
+chickens	B-SPEC
+in	O
+New	O
+Zealand	O
+.	O
+
+These	O
+strains	O
+were	O
+compared	O
+with	O
+four	O
+strains	O
+(	O
+A	O
+,	O
+B	O
+,	O
+C	O
+,	O
+and	O
+D	O
+),	O
+which	O
+had	O
+circulated	O
+25	O
+years	O
+previously	O
+,	O
+by	O
+sequencing	O
+the	O
+gene	O
+coding	O
+for	O
+the	O
+S1	O
+subunit	O
+of	O
+the	O
+spike	O
+glycoprotein	B-CHED
+.	O
+
+ILI	O
+was	O
+reported	O
+for	O
+240	O
+/	O
+420	O
+patients	O
+(	O
+57	O
+.	O
+1	O
+%),	O
+with	O
+influenza	B-DISO
+and	O
+rhinovirus	B-SPEC
+etiologies	O
+accounting	O
+for	O
+30	O
+.	O
+9	O
+%	O
+and	O
+19	O
+.	O
+6	O
+%,	O
+respectively	O
+.	O
+
+In	O
+the	O
+past	O
+,	O
+enteroviruses	B-SPEC
+(	O
+EV	O
+)	O
+were	O
+considered	O
+the	O
+most	O
+common	O
+cause	O
+of	O
+myocarditis	B-DISO
+in	O
+all	O
+age	O
+groups	O
+.	O
+
+Parvovirus	B-DISO
+B19	I-DISO
+infection	I-DISO
+is	O
+associated	O
+sometimes	O
+with	O
+myocarditis	B-DISO
+.	O
+
+TITLE	O
+:	O
+RNA	O
+viruses	B-SPEC
+and	O
+the	O
+mitogenic	O
+Raf	B-PRGE
+/	O
+MEK	B-PRGE
+/	O
+ERK	B-FUNC
+signal	B-PROC
+transduction	I-PROC
+cascade	O
+.	O
+
+As	O
+these	O
+pathogens	O
+partly	O
+use	O
+the	O
+DNA	B-PROC
+synthesis	I-PROC
+machinery	O
+for	O
+their	O
+replication	O
+,	O
+they	O
+aim	O
+to	O
+drive	O
+cells	B-COMP
+into	O
+a	O
+proliferative	B-DISO
+state	O
+.	O
+
+Two	O
+18	O
+year	O
+-	O
+old	O
+patients	O
+were	O
+admitted	O
+to	O
+a	O
+tertiary	O
+liver	B-ANAT
+unit	O
+with	O
+features	O
+of	O
+acute	B-DISO
+liver	I-DISO
+failure	I-DISO
+,	O
+cardio	O
+-	O
+respiratory	O
+collapse	B-DISO
+and	O
+pancytopenia	B-DISO
+.	O
+
+The	O
+clinical	O
+spectrum	O
+,	O
+diagnostic	O
+features	O
+and	O
+current	O
+evidence	O
+based	O
+recommendations	O
+for	O
+treatment	O
+of	O
+this	O
+condition	B-DISO
+are	O
+explored	O
+.	O
+
+Pulmonary	B-ANAT
+histopathology	O
+showed	O
+acute	B-DISO
+interstitial	I-DISO
+pneumonia	I-DISO
+in	O
+40	O
+%	O
+(	O
+99	O
+),	O
+diffuse	B-DISO
+alveolar	I-DISO
+damage	I-DISO
+in	O
+36	O
+%	O
+(	O
+89	O
+),	O
+pulmonary	B-DISO
+edema	I-DISO
+in	O
+13	O
+%	O
+(	O
+33	O
+),	O
+and	O
+alveolar	B-ANAT
+hemorrhage	B-DISO
+in	O
+12	O
+%	O
+(	O
+29	O
+)	O
+of	O
+patients	O
+.	O
+
+Multivariate	O
+analysis	O
+showed	O
+a	O
+significant	O
+and	O
+positive	O
+association	O
+between	O
+Pneumocystis	B-DISO
+jiroveci	I-DISO
+pneumonia	I-DISO
+and	O
+acute	B-DISO
+interstitial	I-DISO
+pneumonia	I-DISO
+(	O
+Odds	O
+ratio	O
+,	O
+4	O
+.	O
+51	O
+;	O
+95	O
+%	O
+CI	O
+,	O
+2	O
+.	O
+46	O
+-	O
+8	O
+.	O
+24	O
+;	O
+p	O
+<	O
+0	O
+.	O
+001	O
+),	O
+severe	B-DISO
+sepsis	I-DISO
+and	O
+/	O
+or	O
+septic	B-DISO
+shock	I-DISO
+and	O
+diffuse	B-DISO
+alveolar	I-DISO
+damage	I-DISO
+(	O
+Odds	O
+ratio	O
+,	O
+3	O
+.	O
+60	O
+;	O
+95	O
+%	O
+CI	O
+,	O
+1	O
+.	O
+78	O
+-	O
+7	O
+.	O
+27	O
+;	O
+p	O
+<	O
+0	O
+.	O
+001	O
+),	O
+and	O
+cytomegalovirus	B-SPEC
+and	O
+acute	B-DISO
+interstitial	I-DISO
+pneumonia	I-DISO
+(	O
+Odds	O
+ratio	O
+,	O
+2	O
+.	O
+22	O
+;	O
+95	O
+%	O
+CI	O
+,	O
+1	O
+.	O
+01	O
+-	O
+4	O
+.	O
+93	O
+;	O
+p	O
+=	O
+0	O
+.	O
+05	O
+).	O
+
+Further	O
+studies	O
+are	O
+necessary	O
+to	O
+elucidate	O
+the	O
+complete	O
+pulmonary	B-ANAT
+physiopathological	O
+mechanism	O
+involved	O
+with	O
+each	O
+HIV	B-DISO
+/	I-DISO
+AIDS	I-DISO
+-	O
+associated	O
+disease	O
+.	O
+
+Recent	O
+studies	O
+have	O
+identified	O
+three	O
+membrane	B-COMP
+-	O
+active	O
+regions	O
+in	O
+the	O
+S2	O
+domain	O
+of	O
+SARS	B-PRGE
+-	I-PRGE
+CoV	I-PRGE
+glycoprotein	B-CHED
+,	O
+one	O
+situated	O
+downstream	O
+of	O
+the	O
+minimum	O
+furin	B-ENZY
+cleavage	B-PROC
+,	O
+which	O
+is	O
+considered	O
+the	O
+fusion	O
+peptide	B-CHED
+(	O
+SARSFP	O
+),	O
+an	O
+internal	O
+fusion	O
+peptide	B-CHED
+located	O
+immediately	O
+upstream	O
+of	O
+the	O
+HR1	O
+region	O
+(	O
+SARSIFP	O
+)	O
+and	O
+the	O
+pre	O
+-	O
+transmembrane	B-COMP
+domain	O
+(	O
+SARSPTM	O
+).	O
+
+TITLE	O
+:	O
+Endothelial	B-ANAT
+pathomechanisms	O
+in	O
+acute	O
+lung	B-ANAT
+injury	O
+.	O
+
+The	O
+pulmonary	B-ANAT
+endothelium	B-ANAT
+is	O
+a	O
+major	O
+metabolic	B-PROC
+organ	B-ANAT
+promoting	O
+adequate	O
+pulmonary	B-ANAT
+and	O
+systemic	O
+vascular	B-ANAT
+homeostasis	B-PROC
+,	O
+and	O
+a	O
+main	O
+target	O
+of	O
+circulating	O
+cells	B-COMP
+and	O
+humoral	O
+mediators	O
+under	O
+injury	O
+;	O
+pulmonary	B-ANAT
+endothelium	B-ANAT
+is	O
+therefore	O
+critically	O
+involved	O
+in	O
+the	O
+pathogenesis	B-DISO
+of	O
+ALI	O
+.	O
+
+We	O
+screened	O
+a	O
+phage	O
+displaying	O
+library	O
+of	O
+human	B-SPEC
+single	O
+-	O
+chain	O
+antibodies	B-COMP
+(	O
+ScFv	B-COMP
+)	O
+against	O
+the	O
+predicted	O
+epitopes	O
+and	O
+obtained	O
+a	O
+human	B-SPEC
+ScFv	B-COMP
+which	O
+can	O
+recognize	O
+the	O
+SARS	B-DISO
+virus	B-SPEC
+in	O
+vitro	O
+.	O
+
+TITLE	O
+:	O
+Health	O
+impact	O
+of	O
+hospital	O
+restrictions	O
+on	O
+seriously	O
+ill	B-DISO
+hospitalized	O
+patients	O
+:	O
+lessons	O
+from	O
+the	O
+Toronto	O
+SARS	O
+outbreak	O
+.	O
+
+Short	O
+-	O
+term	O
+mortality	O
+,	O
+overall	O
+readmissions	O
+,	O
+cardiac	B-ANAT
+readmissions	O
+for	O
+acute	B-DISO
+myocardial	I-DISO
+infarction	I-DISO
+patients	O
+,	O
+serious	O
+complications	O
+for	O
+very	O
+low	O
+birth	B-PROC
+weight	O
+babies	O
+,	O
+and	O
+quality	O
+of	O
+care	O
+measures	O
+,	O
+comparing	O
+adjusted	O
+rates	O
+across	O
+time	O
+periods	B-PROC
+within	O
+regions	O
+.	O
+
+Recent	O
+studies	O
+have	O
+shown	O
+that	O
+SARS	B-PRGE
+-	I-PRGE
+CoV	I-PRGE
+VLP	B-COMP
+formation	B-PROC
+depends	O
+on	O
+either	O
+M	O
+and	O
+E	O
+proteins	B-CHED
+or	O
+M	O
+and	O
+N	O
+proteins	B-CHED
+.	O
+
+TITLE	O
+:	O
+Severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+vaccine	O
+efficacy	O
+in	O
+ferrets	B-SPEC
+:	O
+whole	O
+killed	O
+virus	B-SPEC
+and	O
+adenovirus	B-SPEC
+-	O
+vectored	O
+vaccines	O
+.	O
+
+TITLE	O
+:	O
+Clathrin	B-PRGE
+-	O
+and	O
+caveolae	B-COMP
+-	O
+independent	O
+entry	O
+of	O
+feline	B-DISO
+infectious	I-DISO
+peritonitis	I-DISO
+virus	B-SPEC
+in	O
+monocytes	B-ANAT
+depends	O
+on	O
+dynamin	O
+.	O
+
+In	O
+this	O
+study	O
+,	O
+the	O
+pathway	B-PROC
+of	O
+internalization	O
+is	O
+characterized	O
+by	O
+evaluating	O
+the	O
+effect	O
+of	O
+chemical	O
+inhibitors	B-CHED
+and	O
+/	O
+or	O
+expression	B-PROC
+of	O
+dominant	O
+-	O
+negative	O
+(	O
+DN	O
+)	O
+proteins	B-CHED
+on	O
+the	O
+percentage	O
+of	O
+internalized	O
+virions	B-COMP
+per	O
+cell	B-COMP
+and	O
+infection	B-DISO
+.	O
+
+Further	O
+,	O
+co	O
+-	O
+localization	B-PROC
+studies	O
+were	O
+performed	O
+to	O
+determine	O
+the	O
+involvement	O
+of	O
+certain	O
+cellular	B-COMP
+internalization	O
+proteins	B-CHED
+.	O
+
+Insertion	O
+of	O
+arbidol	O
+,	O
+arbidol	O
+mesylate	O
+,	O
+and	O
+ribavirin	B-CHED
+into	O
+the	O
+nutrient	B-CHED
+medium	O
+2	O
+hours	O
+after	O
+infection	B-DISO
+of	O
+porcine	B-SPEC
+embryonic	B-ANAT
+renal	B-ANAT
+cells	B-COMP
+caused	O
+a	O
+reduction	O
+in	O
+the	O
+accumulation	O
+of	O
+the	O
+pathogen	O
+by	O
+2	O
+.	O
+5	O
+,	O
+2	O
+.	O
+1	O
+,	O
+and	O
+2	O
+.	O
+6	O
+Ig	O
+,	O
+respectively	O
+.	O
+
+Infection	B-DISO
+with	O
+recombinant	O
+SARS	B-DISO
+-	O
+CoV	O
+viruses	B-SPEC
+bearing	O
+disruptions	O
+in	O
+the	O
+gene	O
+7	O
+coding	O
+region	O
+showed	O
+no	O
+significant	O
+change	O
+in	O
+replication	O
+kinetics	O
+,	O
+tissue	B-PROC
+tropism	B-PROC
+,	O
+morbidity	O
+,	O
+or	O
+mortality	O
+suggesting	O
+that	O
+the	O
+ORF7a	O
+(	O
+7a	O
+)	O
+and	O
+ORF7b	O
+(	O
+7b	O
+)	O
+proteins	B-CHED
+are	O
+not	O
+required	O
+for	O
+virus	B-PROC
+replication	I-PROC
+in	O
+immunosuppressed	O
+hamsters	B-SPEC
+.	O
+
+Understanding	O
+the	O
+spillover	O
+from	O
+bats	B-SPEC
+to	O
+humans	B-SPEC
+and	O
+other	O
+animals	B-SPEC
+,	O
+and	O
+the	O
+associated	O
+health	O
+risks	O
+requires	O
+an	O
+analysis	O
+of	O
+the	O
+disease	O
+dynamics	O
+in	O
+bat	B-ENZY
+populations	O
+.	O
+
+The	O
+resultant	O
+recombinant	O
+protein	B-CHED
+was	O
+produced	O
+and	O
+used	O
+in	O
+antibody	B-COMP
+detection	O
+assays	O
+via	O
+western	O
+blot	O
+analysis	O
+of	O
+serum	B-COMP
+samples	O
+.	O
+
+Seropositivity	O
+for	O
+this	O
+protein	B-CHED
+was	O
+not	O
+specific	O
+for	O
+the	O
+FCoV	O
+virulent	O
+biotype	O
+or	O
+a	O
+diagnosis	O
+of	O
+FIP	B-DISO
+.	O
+
+The	O
+gene	O
+segment	O
+encoding	O
+the	O
+IBV	B-PRGE
+nsp3	I-PRGE
+ADRP	I-PRGE
+domain	I-PRGE
+has	O
+been	O
+cloned	O
+and	O
+expressed	B-PROC
+in	O
+Escherichia	B-SPEC
+coli	I-SPEC
+.	O
+
+TITLE	O
+:	O
+Practice	O
+and	O
+perception	O
+--	O
+a	O
+nationwide	O
+survey	O
+of	O
+therapy	O
+habits	O
+in	O
+sepsis	B-DISO
+.	O
+
+Practice	O
+recommendations	O
+were	O
+selected	O
+by	O
+German	O
+Sepsis	B-DISO
+Competence	O
+Network	O
+(	O
+SepNet	O
+)	O
+investigators	O
+.	O
+
+A	O
+total	O
+of	O
+17	O
+.	O
+1	O
+%	O
+patients	O
+had	O
+tidal	O
+volume	O
+between	O
+6	O
+and	O
+8	O
+mL	O
+/	O
+kg	O
+predicted	O
+body	B-ANAT
+weight	O
+and	O
+80	O
+.	O
+3	O
+%	O
+>	O
+8	O
+mL	O
+/	O
+kg	O
+predicted	O
+body	B-ANAT
+weight	O
+.	O
+
+To	O
+evaluate	O
+the	O
+prevalence	O
+and	O
+epidemiological	O
+features	O
+of	O
+newer	O
+and	O
+traditional	O
+respiratory	O
+viruses	B-SPEC
+in	O
+infants	O
+and	O
+young	O
+children	O
+with	O
+recurrent	O
+wheeze	B-DISO
+.	O
+
+On	O
+admission	O
+a	O
+respiratory	B-ANAT
+sample	I-ANAT
+was	O
+obtained	O
+through	O
+a	O
+nasopharyngeal	B-ANAT
+aspirate	I-ANAT
+.	O
+
+Fifty	O
+five	O
+percent	O
+of	O
+the	O
+viruses	B-SPEC
+were	O
+detected	O
+by	O
+Immunofluorescence	O
+and	O
+45	O
+%	O
+by	O
+Polymerase	O
+Chain	O
+Reaction	O
+.	O
+
+In	O
+the	O
+study	O
+,	O
+the	O
+complete	O
+genome	O
+sequence	O
+of	O
+strain	O
+A2	O
+was	O
+sequenced	O
+and	O
+analyzed	O
+,	O
+which	O
+was	O
+a	O
+predominant	O
+IBV	B-SPEC
+strain	O
+in	O
+China	O
+.	O
+
+The	O
+results	O
+of	O
+this	O
+study	O
+suggest	O
+that	O
+strain	O
+A2	O
+may	O
+play	O
+an	O
+important	O
+role	O
+in	O
+IBV	B-SPEC
+'	O
+s	O
+evolution	B-PROC
+and	O
+A2	O
+-	O
+like	O
+IBVs	O
+are	O
+predominant	O
+strains	O
+in	O
+China	O
+.	O
+
+Of	O
+the	O
+18	O
+E	B-SPEC
+.	I-SPEC
+coli	I-SPEC
+isolated	O
+from	O
+healthy	O
+calves	O
+,	O
+K99	O
+(	O
+16	O
+.	O
+6	O
+%)	O
+and	O
+intimin	O
+(	O
+55	O
+.	O
+5	O
+%)	O
+genes	O
+were	O
+identified	O
+by	O
+PCR	O
+.	O
+
+TITLE	O
+:	O
+Viral	O
+nucleolar	B-ANAT
+localisation	B-PROC
+signals	O
+determine	O
+dynamic	O
+trafficking	B-PROC
+within	O
+the	O
+nucleolus	B-COMP
+.	O
+
+ABSTRACT	O
+:	O
+Localisation	O
+of	O
+both	O
+viral	O
+and	O
+cellular	B-COMP
+proteins	B-CHED
+to	O
+the	O
+nucleolus	B-COMP
+is	O
+determined	O
+by	O
+a	O
+variety	O
+of	O
+factors	O
+including	O
+nucleolar	B-ANAT
+localisation	B-PROC
+signals	O
+(	O
+NoLSs	O
+),	O
+but	O
+how	O
+these	O
+signals	O
+operate	O
+is	O
+not	O
+clearly	O
+understood	O
+.	O
+
+In	O
+addition	O
+,	O
+we	O
+have	O
+examined	O
+different	O
+size	O
+samples	O
+based	O
+on	O
+largest	O
+flight	B-PROC
+volume	O
+and	O
+largest	O
+metropolitan	O
+populations	O
+.	O
+
+TITLE	O
+:	O
+[	O
+Development	B-PROC
+and	O
+comparison	O
+of	O
+real	O
+-	O
+time	O
+and	O
+conventional	O
+RT	O
+-	O
+PCR	O
+assay	O
+for	O
+detection	O
+of	O
+human	B-SPEC
+coronavirus	I-SPEC
+NL63	I-SPEC
+and	O
+HKU1	O
+].	O
+
+All	O
+pathogens	O
+were	O
+detected	O
+in	O
+swabs	O
+of	O
+the	O
+upper	B-ANAT
+respiratory	I-ANAT
+tract	I-ANAT
+,	O
+but	O
+only	O
+M	B-SPEC
+.	I-SPEC
+hyopneumoniae	I-SPEC
+and	O
+B	B-SPEC
+.	I-SPEC
+bronchiseptica	I-SPEC
+were	O
+detected	O
+in	O
+expired	B-ANAT
+air	I-ANAT
+from	O
+individually	O
+sampled	O
+,	O
+acutely	O
+infected	O
+pigs	B-SPEC
+.	O
+
+TITLE	O
+:	O
+Spinal	O
+cryptococcoma	O
+in	O
+an	O
+immunocompetent	O
+cat	B-SPEC
+.	O
+
+At	O
+necropsy	O
+,	O
+the	O
+only	O
+lesion	O
+detected	O
+was	O
+a	O
+malacic	O
+area	O
+,	O
+4cm	O
+in	O
+length	O
+,	O
+in	O
+the	O
+spinal	B-ANAT
+cord	I-ANAT
+.	O
+
+Both	O
+antibody	B-COMP
+-	O
+displaying	O
+human	B-SPEC
+cells	B-COMP
+and	O
+virus	B-COMP
+particles	I-COMP
+bound	O
+antigen	B-CHED
+specifically	O
+.	O
+
+The	O
+aim	O
+of	O
+the	O
+study	O
+was	O
+to	O
+describe	O
+the	O
+frequency	O
+of	O
+viral	O
+pathogens	O
+and	O
+relative	O
+frequency	O
+of	O
+co	O
+-	O
+infections	O
+in	O
+nasal	B-ANAT
+specimens	O
+obtained	O
+from	O
+young	O
+children	O
+with	O
+bronchiolitis	B-DISO
+receiving	O
+care	O
+at	O
+a	O
+children	O
+'	O
+s	O
+hospital	O
+.	O
+
+Viruses	B-SPEC
+were	O
+detected	O
+in	O
+168	O
+(	O
+93	O
+%)	O
+of	O
+the	O
+180	O
+children	O
+with	O
+bronchiolitis	B-DISO
+.	O
+
+Respiratory	B-SPEC
+syncytial	I-SPEC
+virus	I-SPEC
+(	O
+RSV	B-SPEC
+)	O
+was	O
+the	O
+most	O
+common	O
+virus	B-SPEC
+detected	O
+(	O
+77	O
+%),	O
+followed	O
+by	O
+adenovirus	B-DISO
+(	O
+15	O
+%),	O
+human	B-SPEC
+metapneumovirus	I-SPEC
+(	O
+11	O
+%),	O
+coronavirus	B-SPEC
+(	O
+8	O
+%),	O
+parainfluenza	B-DISO
+(	O
+6	O
+%)	O
+and	O
+influenza	B-DISO
+(	O
+1	O
+%).	O
+
+Molecular	O
+diagnostic	O
+techniques	O
+identified	O
+a	O
+high	O
+frequency	O
+of	O
+viruses	B-SPEC
+and	O
+viral	O
+co	B-DISO
+-	I-DISO
+infections	I-DISO
+among	O
+children	O
+evaluated	O
+for	O
+bronchiolitis	B-DISO
+.	O
+
+RESULTS	O
+:	O
+Viruses	B-SPEC
+were	O
+detected	O
+in	O
+168	O
+(	O
+93	O
+%)	O
+of	O
+the	O
+180	O
+children	O
+with	O
+bronchiolitis	B-DISO
+.	O
+
+TITLE	O
+:	O
+Entry	O
+from	O
+the	O
+cell	B-COMP
+surface	I-COMP
+of	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+coronavirus	B-SPEC
+with	O
+cleaved	B-ANAT
+S	B-PRGE
+protein	B-CHED
+as	O
+revealed	O
+by	O
+pseudotype	O
+virus	B-SPEC
+bearing	O
+cleaved	B-ANAT
+S	B-PRGE
+protein	I-PRGE
+.	O
+
+Furthermore	O
+,	O
+a	O
+phylogenetic	O
+tree	O
+based	O
+on	O
+these	O
+M	O
+DNA	O
+sequences	O
+was	O
+generated	O
+,	O
+and	O
+the	O
+tree	O
+topology	O
+suggests	O
+that	O
+some	O
+Chinese	O
+IBV	B-SPEC
+strains	O
+may	O
+have	O
+a	O
+common	O
+ancestor	O
+;	O
+however	O
+,	O
+HH06	O
+is	O
+a	O
+new	O
+local	O
+IBV	B-SPEC
+isolate	O
+that	O
+is	O
+responsible	O
+for	O
+the	O
+field	O
+outbreak	O
+of	O
+nephritis	B-DISO
+.	O
+
+TITLE	O
+:	O
+Interactions	O
+between	O
+M	B-PRGE
+protein	I-PRGE
+and	O
+other	O
+structural	O
+proteins	B-CHED
+of	O
+severe	O
+,	O
+acute	O
+respiratory	O
+syndrome	B-DISO
+-	O
+associated	O
+coronavirus	B-SPEC
+.	O
+
+This	O
+study	O
+helps	O
+us	O
+better	O
+understand	O
+protein	B-CHED
+-	O
+protein	B-CHED
+interactions	O
+during	O
+viral	B-PROC
+assembly	I-PROC
+of	O
+SARS	B-DISO
+-	O
+CoV	O
+.	O
+
+ABSTRACT	O
+:	O
+Nosocomial	O
+infection	O
+represents	O
+an	O
+important	O
+indicator	B-CHED
+of	O
+healthcare	O
+quality	O
+and	O
+patient	O
+safety	O
+.	O
+
+Anticipation	O
+of	O
+a	O
+bird	B-SPEC
+-	O
+to	O
+-	O
+human	B-SPEC
+H5N1	B-DISO
+outbreak	O
+,	O
+perceptions	O
+that	O
+such	O
+an	O
+outbreak	O
+would	O
+be	O
+worse	O
+than	O
+SARS	B-DISO
+,	O
+that	O
+IV	O
+was	O
+efficacious	O
+in	O
+preventing	O
+bird	B-SPEC
+-	O
+to	O
+-	O
+human	B-SPEC
+avian	B-DISO
+influenza	I-DISO
+transmission	O
+were	O
+associated	O
+with	O
+the	O
+studied	O
+IV	O
+behavior	O
+(	O
+OR	O
+=	O
+2	O
+.	O
+64	O
+-	O
+3	O
+.	O
+97	O
+,	O
+p	O
+<	O
+0	O
+.	O
+05	O
+).	O
+
+Exposure	O
+to	O
+live	O
+birds	B-SPEC
+,	O
+perceived	O
+similar	O
+symptoms	O
+between	O
+influenza	B-DISO
+and	O
+bird	B-SPEC
+-	O
+to	O
+-	O
+human	B-SPEC
+H5N1	B-DISO
+avian	B-DISO
+influenza	I-DISO
+,	O
+that	O
+bird	B-SPEC
+-	O
+to	O
+-	O
+human	B-SPEC
+avian	B-DISO
+influenza	I-DISO
+was	O
+more	O
+lethal	O
+than	O
+SARS	B-DISO
+were	O
+predictive	O
+use	O
+of	O
+face	B-DISO
+mask	O
+when	O
+having	O
+ILI	O
+symptoms	O
+(	O
+OR	O
+=	O
+4	O
+.	O
+25	O
+-	O
+8	O
+.	O
+34	O
+,	O
+p	O
+<	O
+0	O
+.	O
+05	O
+).	O
+
+Perceptions	O
+related	O
+to	O
+human	B-SPEC
+avian	B-DISO
+influenza	I-DISO
+were	O
+associated	O
+with	O
+IV	O
+and	O
+mask	O
+use	O
+behaviors	B-PROC
+.	O
+
+TITLE	O
+:	O
+Design	O
+,	O
+synthesis	B-PROC
+and	O
+antiviral	B-CHED
+efficacy	O
+of	O
+a	O
+series	O
+of	O
+potent	O
+chloropyridyl	O
+ester	B-CHED
+-	O
+derived	O
+SARS	B-DISO
+-	I-PRGE
+CoV	I-PRGE
+3CLpro	I-PRGE
+inhibitors	B-CHED
+.	O
+
+Position	O
+of	O
+the	O
+carboxylate	B-CHED
+functionality	O
+is	O
+critical	O
+to	O
+potency	O
+.	O
+
+Pulmonary	B-DISO
+infections	I-DISO
+in	O
+the	O
+maintenance	O
+phase	O
+of	O
+the	O
+therapy	O
+were	O
+frequently	O
+treated	O
+with	O
+oral	B-ANAT
+antibiotics	B-CHED
+,	O
+and	O
+they	O
+were	O
+generally	O
+rapidly	O
+taken	O
+under	O
+control	O
+.	O
+
+In	O
+conclusion	O
+,	O
+pulmonary	B-DISO
+complications	I-DISO
+are	O
+frequent	O
+in	O
+children	O
+with	O
+acute	B-DISO
+leukemia	I-DISO
+,	O
+and	O
+early	O
+diagnosis	O
+and	O
+appropriate	O
+management	O
+are	O
+important	O
+to	O
+avoid	O
+mortality	O
+owing	O
+to	O
+pulmonary	B-DISO
+complications	I-DISO
+,	O
+especially	O
+in	O
+neutropenic	O
+patients	O
+receiving	O
+induction	O
+or	O
+consolidation	O
+phase	O
+of	O
+chemotherapy	O
+.	O
+
+In	O
+broilers	O
+,	O
+replication	O
+of	O
+the	O
+challenge	O
+virus	B-SPEC
+was	O
+not	O
+prevented	O
+but	O
+was	O
+significantly	O
+reduced	O
+.	O
+
+ABSTRACT	O
+:	O
+Positive	O
+-	O
+strand	O
+RNA	O
+viruses	B-SPEC
+,	O
+a	O
+large	O
+group	O
+including	O
+human	B-SPEC
+pathogens	O
+such	O
+as	O
+SARS	B-DISO
+-	O
+coronavirus	B-SPEC
+(	O
+SARS	B-DISO
+-	O
+CoV	O
+),	O
+replicate	O
+in	O
+the	O
+cytoplasm	B-COMP
+of	O
+infected	O
+host	B-COMP
+cells	B-COMP
+.	O
+
+Generally	O
+,	O
+their	O
+ultrastructure	O
+,	O
+morphogenesis	B-PROC
+,	O
+and	O
+exact	O
+role	O
+in	O
+viral	B-PROC
+replication	I-PROC
+remain	O
+to	O
+be	O
+defined	O
+.	O
+
+Since	O
+we	O
+could	O
+not	O
+discern	O
+a	O
+connection	O
+between	O
+DMV	O
+interior	O
+and	O
+cytosol	B-COMP
+,	O
+our	O
+analysis	O
+raises	O
+several	O
+questions	O
+about	O
+the	O
+mechanism	O
+of	O
+DMV	O
+formation	B-PROC
+and	O
+the	O
+actual	O
+site	O
+of	O
+SARS	B-PRGE
+-	I-PRGE
+CoV	I-PRGE
+RNA	B-PROC
+synthesis	I-PROC
+.	O
+
+Our	O
+data	O
+document	O
+the	O
+extensive	O
+virus	B-SPEC
+-	O
+induced	O
+reorganization	O
+of	O
+host	O
+cell	B-COMP
+membranes	I-COMP
+into	O
+a	O
+network	O
+that	O
+is	O
+used	O
+to	O
+organize	O
+viral	B-PROC
+replication	I-PROC
+and	O
+possibly	O
+hide	B-ANAT
+replicating	O
+RNA	O
+from	O
+antiviral	B-CHED
+defense	O
+mechanisms	O
+.	O
+
+The	O
+mESCs	O
+replicated	O
+MHV	B-SPEC
+-	O
+A59	O
+but	O
+not	O
+MMVp	O
+,	O
+MHV	B-SPEC
+-	O
+A59	O
+being	O
+cytolytic	O
+for	O
+mESCs	O
+.	O
+
+To	O
+determine	O
+the	O
+role	O
+of	O
+rh	B-PRGE
+-	I-PRGE
+ACE2	I-PRGE
+in	O
+early	O
+lung	B-ANAT
+pathogenesis	B-DISO
+in	O
+vivo	O
+,	O
+we	O
+studied	O
+eleven	O
+Chinese	O
+rhesus	B-SPEC
+monkeys	I-SPEC
+experimentally	O
+infected	O
+with	O
+a	O
+pathogenic	O
+SARS	B-DISO
+-	O
+CoV	O
+(	O
+PUMC01	O
+)	O
+strain	O
+.	O
+
+Many	O
+natural	O
+non	O
+-	O
+synonymous	O
+(	O
+NS	O
+)	O
+changes	O
+were	O
+found	O
+in	O
+rh	B-PRGE
+-	I-PRGE
+ACE2	I-PRGE
+genes	I-PRGE
+.	O
+
+Of	O
+the	O
+146	O
+subjects	O
+who	O
+came	O
+into	O
+contact	O
+with	O
+SARS	B-DISO
+patients	O
+at	O
+Hospital	O
+A	O
+,	O
+43	O
+(	O
+29	O
+.	O
+5	O
+%)	O
+developed	O
+SARS	B-DISO
+,	O
+and	O
+an	O
+additional	O
+16	O
+(	O
+11	O
+%)	O
+were	O
+asymptomatic	O
+but	O
+SARS	B-DISO
+-	O
+coronavirus	B-SPEC
+(	O
+CoV	O
+)	O
+seropositive	O
+.	O
+
+Early	O
+diagnosis	O
+,	O
+institution	O
+of	O
+specific	O
+antimalarial	B-CHED
+treatment	O
+and	O
+assisted	O
+ventilation	O
+can	O
+be	O
+life	O
+-	O
+saving	O
+.	O
+
+TITLE	O
+:	O
+Comparative	O
+sequence	O
+analyses	O
+of	O
+a	O
+new	O
+mammalian	B-SPEC
+reovirus	B-SPEC
+genome	O
+and	O
+the	O
+mammalian	B-SPEC
+reovirus	B-SPEC
+S1	O
+genes	O
+from	O
+six	O
+new	O
+serotype	O
+2	O
+human	O
+isolates	O
+.	O
+
+ABSTRACT	O
+:	O
+Right	B-DISO
+ventricular	I-DISO
+failure	I-DISO
+may	O
+result	O
+from	O
+an	O
+newly	O
+developed	O
+disease	O
+(	O
+e	O
+.	O
+g	O
+.	O
+as	O
+a	O
+consequence	O
+of	O
+acute	O
+respiratory	O
+distress	O
+syndrome	O
+[	O
+ARDS	B-DISO
+]	O
+or	O
+of	O
+severe	O
+pulmonary	B-DISO
+embolism	I-DISO
+)	O
+or	O
+of	O
+already	O
+present	O
+pulmonary	B-DISO
+hypertension	I-DISO
+(	O
+PHT	B-DISO
+).	O
+
+Furthermore	O
+an	O
+increase	O
+in	O
+right	O
+ventricular	B-ANAT
+contractility	O
+by	O
+inodilators	O
+is	O
+aimed	O
+at	O
+.	O
+
+The	O
+central	O
+goal	O
+in	O
+the	O
+treatment	O
+of	O
+right	B-DISO
+heart	I-DISO
+failure	I-DISO
+as	O
+part	O
+of	O
+PHT	B-PRGE
+is	O
+to	O
+lower	O
+pulmonary	B-PROC
+vascular	B-ANAT
+resistance	I-PROC
+and	O
+thus	O
+decrease	O
+right	O
+ventricular	B-ANAT
+afterload	O
+.	O
+
+This	O
+result	O
+suggests	O
+that	O
+optimal	O
+infection	B-DISO
+requires	O
+a	O
+multivalent	O
+interaction	O
+between	O
+viral	O
+attachment	O
+protein	B-CHED
+and	O
+cellular	B-COMP
+receptors	O
+.	O
+
+ABSTRACT	O
+:	O
+Historically	O
+,	O
+coronaviruses	O
+were	O
+predominantly	O
+associated	O
+with	O
+mild	O
+upper	O
+respiratory	O
+disease	O
+in	O
+humans	B-SPEC
+.	O
+
+TITLE	O
+:	O
+Inhibition	B-PROC
+of	O
+the	O
+interaction	O
+between	O
+the	O
+SARS	B-PRGE
+-	I-PRGE
+CoV	I-PRGE
+spike	I-PRGE
+protein	B-CHED
+and	O
+its	O
+cellular	B-COMP
+receptor	O
+by	O
+anti	O
+-	O
+histo	O
+-	O
+blood	O
+group	O
+antibodies	B-COMP
+.	O
+
+We	O
+observed	O
+that	O
+the	O
+S	B-PRGE
+protein	I-PRGE
+/	O
+angiotensin	B-PRGE
+-	I-PRGE
+converting	I-PRGE
+enzyme	I-PRGE
+2	I-PRGE
+-	O
+dependent	O
+adhesion	B-DISO
+of	O
+these	O
+cells	B-COMP
+to	O
+an	O
+angiotensin	B-PRGE
+-	I-PRGE
+converting	I-PRGE
+enzyme	I-PRGE
+2	I-PRGE
+expressing	O
+cell	B-ANAT
+line	I-ANAT
+was	O
+specifically	O
+inhibited	O
+by	O
+either	O
+a	O
+monoclonal	O
+or	O
+human	B-PRGE
+natural	I-PRGE
+anti	I-PRGE
+-	I-PRGE
+A	I-PRGE
+antibodies	B-COMP
+,	O
+indicating	O
+that	O
+these	O
+antibodies	B-COMP
+may	O
+block	O
+the	O
+interaction	O
+between	O
+the	O
+virus	B-SPEC
+and	O
+its	O
+receptor	O
+,	O
+thereby	O
+providing	O
+protection	O
+.	O
+
+The	O
+model	O
+indicated	O
+that	O
+the	O
+ABO	O
+polymorphism	B-PROC
+could	O
+contribute	O
+to	O
+substantially	O
+reduce	O
+the	O
+virus	B-SPEC
+transmission	O
+,	O
+affecting	O
+both	O
+the	O
+number	O
+of	O
+infected	O
+individuals	O
+and	O
+the	O
+kinetics	O
+of	O
+the	O
+epidemic	O
+.	O
+
+Not	O
+only	O
+viruses	B-SPEC
+were	O
+discovered	O
+that	O
+must	O
+have	O
+been	O
+with	O
+humans	B-SPEC
+for	O
+many	O
+decades	O
+or	O
+centuries	O
+,	O
+such	O
+as	O
+human	B-SPEC
+metapneumovirus	I-SPEC
+and	O
+2	O
+different	O
+human	B-SPEC
+coronaviruses	O
+,	O
+but	O
+also	O
+viruses	B-SPEC
+that	O
+are	O
+truly	O
+new	O
+for	O
+humans	B-SPEC
+and	O
+have	O
+emerged	O
+as	O
+a	O
+result	O
+of	O
+recent	O
+interspecies	O
+transmissions	O
+from	O
+other	O
+mammalian	B-SPEC
+or	O
+avian	B-SPEC
+reservoirs	O
+.	O
+
+Throat	B-ANAT
+swab	I-ANAT
+specimens	O
+from	O
+242	O
+adults	O
+admitted	O
+to	O
+hospital	O
+with	O
+CAP	B-DISO
+were	O
+tested	O
+.	O
+
+L	B-SPEC
+.	I-SPEC
+pneumophila	I-SPEC
+PCR	O
+was	O
+positive	O
+in	O
+only	O
+3	O
+out	O
+of	O
+11	O
+cases	O
+(	O
+27	O
+%)	O
+of	O
+Legionnaires	B-DISO
+'	I-DISO
+disease	I-DISO
+(	O
+LD	O
+).	O
+
+TITLE	O
+:	O
+[	O
+The	O
+functions	O
+of	O
+liver	B-ANAT
+natural	B-ANAT
+killer	I-ANAT
+cells	I-ANAT
+in	O
+murine	B-SPEC
+fulminant	B-DISO
+hepatitis	I-DISO
+induced	O
+by	O
+murine	B-SPEC
+hepatitis	I-DISO
+virus	O
+strain	O
+3	O
+].	O
+
+ABSTRACT	O
+:	O
+To	O
+investigate	O
+the	O
+role	O
+of	O
+liver	B-ANAT
+natural	B-ANAT
+killer	I-ANAT
+cells	I-ANAT
+(	O
+NK	B-ANAT
+cells	I-ANAT
+)	O
+in	O
+murine	B-DISO
+hepatitis	I-DISO
+virus	B-SPEC
+strain	O
+3	O
+(	O
+MHV	B-SPEC
+-	O
+3	O
+)	O
+induced	O
+murine	B-SPEC
+fulminant	B-DISO
+hepatitis	I-DISO
+.	O
+
+Psychological	B-DISO
+and	O
+physical	O
+functioning	O
+at	O
+each	O
+time	O
+point	O
+was	O
+measured	O
+using	O
+the	O
+12	O
+-	O
+item	O
+Medical	O
+Outcome	O
+Study	O
+Short	O
+-	O
+Form	O
+Health	O
+Survey	O
+(	O
+SF	O
+-	O
+12	O
+).	O
+
+TITLE	O
+:	O
+Respiratory	O
+pathogens	O
+in	O
+children	O
+with	O
+and	O
+without	O
+respiratory	B-DISO
+symptoms	I-DISO
+.	O
+
+Immune	B-PROC
+response	I-PROC
+was	O
+assessed	O
+by	O
+intracellular	B-COMP
+cytokine	O
+staining	O
+(	O
+ICS	B-DISO
+),	O
+ELISpot	O
+,	O
+ELISA	O
+,	O
+and	O
+neutralization	O
+assays	O
+.	O
+
+SARS	O
+-	O
+CoV	O
+-	O
+specific	O
+CD4	B-PRGE
++	I-PRGE
+T	B-ANAT
+-	I-ANAT
+cell	I-ANAT
+responses	O
+were	O
+detected	O
+in	O
+all	O
+vaccinees	O
+,	O
+and	O
+CD8	B-PRGE
++	I-PRGE
+T	B-ANAT
+-	I-ANAT
+cell	I-ANAT
+responses	O
+in	O
+approximately	O
+20	O
+%	O
+of	O
+individuals	O
+.	O
+
+The	O
+VRC	O
+SARS	B-DISO
+DNA	O
+vaccine	O
+was	O
+well	O
+tolerated	O
+and	O
+produced	O
+cellular	B-PROC
+immune	I-PROC
+responses	I-PROC
+and	O
+neutralizing	O
+antibody	B-COMP
+in	O
+healthy	O
+adults	O
+.	O
+
+Efficiency	O
+of	O
+bovine	B-SPEC
+antibody	B-PROC
+production	I-PROC
+could	O
+be	O
+enhanced	O
+using	O
+cholera	B-PRGE
+toxin	I-PRGE
+subunit	I-PRGE
+b	I-PRGE
+,	O
+and	O
+milk	O
+production	O
+could	O
+be	O
+rapidly	O
+accelerated	O
+using	O
+recombinant	B-PRGE
+bovine	I-PRGE
+somatotropin	I-PRGE
+hormone	B-CHED
+.	O
+
+There	O
+is	O
+substantial	O
+evidence	O
+for	O
+heritable	O
+predispositions	O
+to	O
+severe	O
+infections	B-DISO
+and	O
+an	O
+emerging	O
+body	B-ANAT
+of	O
+literature	O
+implicating	O
+genetic	O
+factors	O
+in	O
+ALI	O
+pathogenesis	B-DISO
+.	O
+
+ABSTRACT	O
+:	O
+Analyses	O
+of	O
+viral	O
+protein	B-CHED
+-	O
+protein	B-CHED
+interactions	O
+are	O
+an	O
+important	O
+step	O
+to	O
+understand	O
+viral	O
+protein	B-CHED
+functions	O
+and	O
+their	O
+underlying	O
+molecular	O
+mechanisms	O
+.	O
+
+Three	O
+informative	O
+MYLK	O
+coding	O
+single	O
+nucleotide	B-CHED
+polymorphisms	B-PROC
+were	O
+individually	O
+associated	O
+with	O
+acute	O
+lung	B-ANAT
+injury	O
+,	O
+with	O
+two	O
+informative	O
+risk	O
+-	O
+conferring	O
+genotypes	O
+His21Pro	O
+(	O
+CC	O
+genotype	O
+,	O
+odds	O
+ratio	O
+=	O
+1	O
+.	O
+87	O
+,	O
+95	O
+%	O
+confidence	O
+interval	O
+1	O
+.	O
+06	O
+-	O
+3	O
+.	O
+33	O
+;	O
+p	O
+=	O
+0	O
+.	O
+022	O
+)	O
+and	O
+Pro147Ser	O
+(	O
+TT	O
+,	O
+odds	O
+ratio	O
+=	O
+2	O
+.	O
+13	O
+,	O
+95	O
+%	O
+confidence	O
+interval	O
+1	O
+.	O
+14	O
+-	O
+4	O
+.	O
+10	O
+;	O
+p	O
+=	O
+0	O
+.	O
+011	O
+)	O
+more	O
+frequent	O
+than	O
+the	O
+noninformative	O
+Thr335Thr	O
+CC	O
+genotype	O
+(	O
+odds	O
+ratio	O
+=	O
+0	O
+.	O
+42	O
+,	O
+95	O
+%	O
+confidence	O
+interval	O
+0	O
+.	O
+20	O
+-	O
+0	O
+.	O
+85	O
+;	O
+p	O
+=	O
+0	O
+.	O
+010	O
+).	O
+
+Finally	O
+,	O
+haplotype	O
+analyses	O
+revealed	O
+strong	O
+acute	O
+lung	B-ANAT
+injury	O
+associations	O
+with	O
+2	O
+-	O
+4	O
+single	O
+nucleotide	B-CHED
+polymorphism	B-PROC
+haplotypes	O
+,	O
+all	O
+involving	O
+His21Pro	O
+(	O
+p	O
+<	O
+0	O
+.	O
+008	O
+).	O
+
+RESULTS	O
+:	O
+Ninety	O
+-	O
+one	O
+of	O
+the	O
+273	O
+subjects	O
+(	O
+33	O
+%)	O
+met	B-CHED
+criteria	O
+for	O
+acute	O
+lung	B-ANAT
+injury	O
+within	O
+5	O
+days	O
+of	O
+traumatic	O
+insult	O
+.	O
+
+TITLE	O
+:	O
+T	B-ANAT
+cell	B-COMP
+responses	O
+to	O
+whole	O
+SARS	B-DISO
+coronavirus	B-SPEC
+in	O
+humans	B-SPEC
+.	O
+
+Approximately	O
+50	O
+%	O
+of	O
+convalescent	O
+SARS	B-DISO
+patients	O
+were	O
+positive	O
+for	O
+T	B-ANAT
+cell	I-ANAT
+responses	O
+,	O
+and	O
+90	O
+%	O
+possessed	B-DISO
+strongly	O
+neutralizing	O
+Abs	B-PRGE
+.	O
+
+Strong	O
+T	B-ANAT
+cell	I-ANAT
+responses	O
+correlated	O
+significantly	O
+(	O
+p	O
+<	O
+0	O
+.	O
+05	O
+)	O
+with	O
+higher	O
+neutralizing	O
+Ab	O
+.	O
+
+Increased	O
+Th2	O
+cytokines	O
+were	O
+observed	O
+in	O
+patients	O
+with	O
+fatal	O
+infection	B-DISO
+.	O
+
+Methicillin	B-DISO
+-	I-DISO
+resistant	I-DISO
+Staphylococcus	B-SPEC
+aureus	I-SPEC
+(	O
+MRSA	B-DISO
+)	O
+rates	O
+increased	O
+from	O
+1999	O
+to	O
+2005	O
+(	O
+F	O
+=	O
+9	O
+.	O
+4	O
+,	O
+P	O
+=	O
+.	O
+003	O
+).	O
+
+However	O
+,	O
+the	O
+proportion	O
+of	O
+ICPs	O
+in	O
+hospitals	O
+certified	O
+by	O
+the	O
+Certification	O
+Board	O
+of	O
+Infection	B-DISO
+Control	O
+decreased	O
+from	O
+53	O
+%	O
+(	O
+SD	O
+,	O
+46	O
+)	O
+in	O
+1999	O
+to	O
+38	O
+%	O
+(	O
+SD	O
+,	O
+36	O
+)	O
+in	O
+2005	O
+(	O
+F	O
+=	O
+8	O
+.	O
+7	O
+,	O
+P	O
+=	O
+.	O
+004	O
+).	O
+
+The	O
+antibody	B-COMP
+prevalence	O
+was	O
+high	O
+at	O
+both	O
+sampling	O
+times	O
+with	O
+approximately	O
+85	O
+%	O
+and	O
+80	O
+%	O
+of	O
+animals	B-SPEC
+positive	O
+for	O
+antibodies	B-COMP
+to	O
+BCV	B-SPEC
+and	O
+to	O
+BRSV	B-SPEC
+,	O
+respectively	O
+.	O
+
+The	O
+increasing	O
+virulence	B-PROC
+of	O
+dengue	B-DISO
+fever	I-DISO
+with	O
+dengue	B-DISO
+hemorrhagic	I-DISO
+fever	I-DISO
+and	O
+dengue	B-DISO
+shock	I-DISO
+syndrome	I-DISO
+disproved	O
+the	O
+theory	O
+of	O
+the	O
+evolution	B-PROC
+toward	O
+commensalism	B-PROC
+,	O
+and	O
+the	O
+discovery	O
+of	O
+the	O
+microbial	O
+origins	O
+of	O
+peptic	B-DISO
+ulcer	I-DISO
+demonstrated	O
+the	O
+reach	B-PROC
+of	O
+infectious	B-DISO
+diseases	I-DISO
+.	O
+
+ABSTRACT	O
+:	O
+To	O
+determine	O
+whether	O
+the	O
+variable	O
+nucleotide	B-CHED
+tandem	O
+repeat	O
+polymorphism	B-PROC
+in	O
+intron	O
+2	O
+of	O
+the	O
+interleukin	B-PRGE
+-	I-PRGE
+1	I-PRGE
+receptor	I-PRGE
+antagonist	B-PROC
+gene	O
+is	O
+associated	O
+with	O
+lung	B-ANAT
+injury	O
+in	O
+children	O
+with	O
+community	O
+-	O
+acquired	O
+pneumonia	B-DISO
+.	O
+
+ABSTRACT	O
+:	O
+Epitope	O
+-	O
+based	O
+vaccines	O
+designed	O
+to	O
+induce	O
+cellular	B-PROC
+immune	I-PROC
+response	I-PROC
+and	O
+antibody	B-PROC
+responses	I-PROC
+specific	O
+for	O
+infectious	B-DISO
+bronchitis	B-DISO
+virus	B-SPEC
+(	O
+IBV	B-SPEC
+)	O
+are	O
+being	O
+developed	O
+as	O
+a	O
+means	O
+for	O
+increasing	O
+vaccine	O
+potency	O
+.	O
+
+The	O
+7	O
+-	O
+day	O
+-	O
+old	O
+chickens	B-SPEC
+were	O
+immunized	O
+intramuscularly	O
+with	O
+multi	O
+-	O
+epitope	B-CHED
+DNA	O
+vaccine	O
+encapsulated	O
+by	O
+liposome	O
+and	O
+boosted	O
+two	O
+weeks	O
+later	O
+,	O
+and	O
+were	O
+challenged	O
+by	O
+virulent	O
+IBV	B-SPEC
+strain	O
+five	O
+weeks	O
+post	O
+booster	O
+.	O
+
+The	O
+results	O
+showed	O
+that	O
+multi	O
+-	O
+epitope	B-CHED
+DNA	O
+vaccine	O
+led	O
+to	O
+a	O
+dramatic	O
+augmentation	O
+of	O
+humoral	O
+and	O
+cellular	B-COMP
+responses	O
+,	O
+and	O
+provided	O
+up	O
+to	O
+80	O
+.	O
+0	O
+%	O
+rate	O
+of	O
+immune	O
+protection	O
+.	O
+
+The	O
+novel	O
+immunogenic	O
+chimeric	O
+multi	O
+-	O
+epitope	B-CHED
+DNA	O
+vaccine	O
+revealed	O
+in	O
+this	O
+study	O
+provided	O
+a	O
+new	O
+candidate	O
+target	O
+for	O
+IBV	B-SPEC
+vaccine	O
+development	B-PROC
+.	O
+
+Among	O
+the	O
+farms	O
+,	O
+Farm	O
+A	O
+showed	O
+a	O
+high	O
+antibody	B-COMP
+incidence	O
+.	O
+
+ABSTRACT	O
+:	O
+Nitric	B-CHED
+acid	I-CHED
+(	O
+HNO	O
+(	O
+3	O
+))	O
+is	O
+a	O
+solution	O
+of	O
+nitrogen	B-CHED
+dioxide	I-CHED
+(	O
+NO	O
+(	O
+2	O
+))	O
+in	O
+water	B-CHED
+commonly	O
+used	O
+as	O
+an	O
+industrial	O
+chemical	O
+and	O
+cleaner	O
+.	O
+
+The	O
+coexistence	O
+of	O
+HNO	O
+(	O
+3	O
+)	O
+with	O
+varying	O
+oxides	B-CHED
+of	I-CHED
+nitrogen	I-CHED
+likely	O
+results	O
+in	O
+the	O
+large	O
+continuum	O
+of	O
+symptoms	O
+related	O
+to	O
+HNO	O
+(	O
+3	O
+)	O
+exposure	O
+and	O
+varying	O
+times	O
+of	O
+onset	O
+--	O
+acute	O
+,	O
+subacute	O
+,	O
+and	O
+delayed	O
+.	O
+
+As	O
+a	O
+consequence	O
+,	O
+the	O
+proteinase	B-PROC
+domains	O
+present	O
+in	O
+nsp3	B-PRGE
+and	O
+nsp5	B-PRGE
+would	O
+be	O
+separated	O
+from	O
+their	O
+target	O
+sequences	O
+by	O
+the	O
+lipid	B-ANAT
+bilayer	I-ANAT
+.	O
+
+Subsequently	O
+,	O
+we	O
+verified	O
+that	O
+in	O
+nsp4	B-PRGE
+,	O
+all	O
+four	O
+hydrophobic	O
+domains	O
+span	O
+the	O
+lipid	B-ANAT
+bilayer	I-ANAT
+.	O
+
+High	O
+nucleotide	B-CHED
+identities	O
+(	O
+99	O
+.	O
+4	O
+to	O
+99	O
+.	O
+6	O
+%)	O
+among	O
+the	O
+wild	O
+-	O
+ruminant	B-SPEC
+strains	O
+and	O
+recent	O
+BCoV	O
+strains	O
+(	O
+BCoV	O
+-	O
+LUN	B-PRGE
+and	O
+BCoV	B-PRGE
+-	I-PRGE
+ENT	I-PRGE
+,	O
+isolated	O
+in	O
+1998	O
+)	O
+further	O
+confirm	O
+the	O
+close	O
+relatedness	O
+.	O
+
+TITLE	O
+:	O
+Neuroprotective	O
+effect	O
+of	O
+apolipoprotein	B-PRGE
+D	I-PRGE
+against	O
+human	B-PRGE
+coronavirus	I-PRGE
+OC43	I-PRGE
+-	O
+induced	O
+encephalitis	B-DISO
+in	O
+mice	B-SPEC
+.	O
+
+While	O
+best	O
+described	O
+in	O
+patients	O
+with	O
+IPF	O
+,	O
+they	O
+have	O
+also	O
+been	O
+reported	O
+in	O
+patients	O
+with	O
+other	O
+forms	O
+of	O
+interstitial	B-DISO
+lung	B-ANAT
+disease	I-DISO
+.	O
+
+ABSTRACT	O
+:	O
+Acute	O
+rhabdomyolysis	B-DISO
+is	O
+a	O
+syndrome	O
+characterized	O
+by	O
+the	O
+lesion	O
+of	O
+skeletal	B-ANAT
+muscle	I-ANAT
+resulting	O
+in	O
+subsequent	O
+release	B-PATH
+of	O
+intracellular	B-COMP
+contents	O
+into	O
+the	O
+circulatory	B-ANAT
+system	I-ANAT
+,	O
+which	O
+can	O
+cause	O
+potentially	O
+lethal	O
+complications	O
+.	O
+
+Laboratory	O
+findings	O
+showed	O
+high	O
+levels	O
+of	O
+creatine	B-CHED
+phosphokinase	O
+as	O
+the	O
+most	O
+sensitive	O
+marker	O
+of	O
+muscular	B-ANAT
+damage	O
+.	O
+
+The	O
+peak	O
+of	O
+creatine	B-CHED
+phosphokinase	O
+(	O
+186	O
+.	O
+080	O
+U	O
+/	O
+L	O
+;	O
+normal	O
+range	O
+0	O
+-	O
+177	O
+)	O
+was	O
+recorded	O
+at	O
+12	O
+hours	O
+of	O
+admission	O
+.	O
+
+Other	O
+pertinent	O
+laboratory	O
+results	O
+such	O
+as	O
+urea	B-CHED
+,	O
+creatinine	B-CHED
+,	O
+prothrombin	B-PRGE
+time	O
+,	O
+alanine	B-PRGE
+aminotransferase	I-PRGE
+and	O
+aspartate	B-PRGE
+aminotransferase	I-PRGE
+were	O
+also	O
+changed	O
+significantly	O
+.	O
+
+On	O
+admission	O
+the	O
+patient	O
+also	O
+had	O
+oliguria	B-DISO
+with	O
+dark	O
+brown	O
+pigment	O
+in	O
+his	O
+urine	B-ANAT
+.	O
+
+The	O
+patient	O
+was	O
+hypovolemic	O
+and	O
+IV	O
+rehydratation	O
+with	O
+crystalloids	O
+,	O
+sodium	B-CHED
+bicarbonate	I-CHED
+and	O
+mannitol	B-CHED
+started	O
+immediately	O
+upon	O
+admission	O
+.	O
+
+Other	O
+laboratory	O
+findings	O
+can	O
+help	O
+identify	O
+common	O
+complications	O
+of	O
+rhabdomyolysis	B-DISO
+such	O
+as	O
+acute	B-DISO
+renal	I-DISO
+failure	I-DISO
+,	O
+metabolic	B-PROC
+derangements	O
+and	O
+disseminated	O
+intravascular	O
+coagulopathy	B-DISO
+.	O
+
+ABSTRACT	O
+:	O
+The	O
+3C	B-PRGE
+-	I-PRGE
+like	I-PRGE
+(	I-PRGE
+3CL	I-PRGE
+)	I-PRGE
+protease	I-PRGE
+of	O
+the	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+(	O
+SARS	B-DISO
+)	O
+coronavirus	B-SPEC
+is	O
+a	O
+key	O
+enzyme	O
+for	O
+the	O
+virus	B-PROC
+maturation	B-PROC
+.	O
+
+We	O
+found	O
+for	O
+the	O
+first	O
+time	O
+that	O
+the	O
+mature	B-PRGE
+SARS	I-PRGE
+3CL	I-PRGE
+protease	I-PRGE
+is	O
+subject	O
+to	O
+degradation	O
+at	O
+188Arg	O
+/	O
+189Gln	O
+.	O
+
+The	O
+results	O
+indicated	O
+for	O
+the	O
+first	O
+time	O
+that	O
+the	O
+tetrapeptide	B-CHED
+sequence	O
+is	O
+enough	O
+for	O
+inhibitory	O
+activities	O
+of	O
+peptide	B-CHED
+-	O
+aldehyde	B-CHED
+derivatives	O
+.	O
+
+TITLE	O
+:	O
+DIHYDROPYRIMIDINE	B-DISO
+DEHYDROGENASE	I-DISO
+DEFICIENCY	I-DISO
+(	O
+DPD	B-FUNC
+)	O
+IN	O
+GI	O
+MALIGNANCIES	B-DISO
+:	O
+EXPERIENCE	O
+OF	O
+4	O
+-	O
+YEARS	O
+.	O
+
+Screening	O
+patients	O
+for	O
+DPD	B-DISO
+deficiency	I-DISO
+prior	O
+to	O
+administration	O
+of	O
+5	B-CHED
+-	I-CHED
+FU	I-CHED
+or	O
+capecitabine	B-CHED
+using	O
+UraBT	O
+could	O
+potentially	O
+lower	O
+risk	O
+of	O
+toxicity	O
+.	O
+
+MRI	O
+in	O
+this	O
+patient	O
+showed	O
+widespread	O
+T2	O
+-	O
+hyperintensity	O
+along	O
+the	O
+cerebral	B-ANAT
+cortical	B-ANAT
+gray	B-ANAT
+matter	I-ANAT
+from	O
+day	O
+3	O
+to	O
+day	O
+22	O
+.	O
+
+These	O
+MRI	O
+findings	O
+provide	O
+radiologic	O
+evidence	O
+for	O
+damage	O
+to	O
+the	O
+cortical	B-ANAT
+gray	B-ANAT
+matter	I-ANAT
+in	O
+AEFCSE	O
+.	O
+
+TITLE	O
+:	O
+[	O
+Outcome	O
+for	O
+adults	O
+with	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+].	O
+
+ABSTRACT	O
+:	O
+Acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+in	O
+adults	O
+(	O
+ARDS	B-DISO
+)	O
+is	O
+a	O
+relatively	O
+frequent	O
+disease	O
+,	O
+the	O
+mortality	O
+of	O
+which	O
+has	O
+diminished	O
+considerably	O
+in	O
+recent	O
+years	O
+.	O
+
+Secondary	O
+deterioration	O
+of	O
+respiratory	B-PROC
+function	I-PROC
+is	O
+not	O
+part	O
+of	O
+the	O
+natural	O
+history	O
+of	O
+ARDS	B-DISO
+and	O
+should	O
+suggest	O
+other	O
+diagnoses	O
+.	O
+
+The	O
+various	O
+studies	O
+find	O
+a	O
+clear	O
+diminution	O
+in	O
+quality	O
+of	O
+life	O
+after	O
+ARDS	B-DISO
+(	O
+compared	O
+with	O
+the	O
+general	O
+population	O
+),	O
+essentially	O
+related	O
+to	O
+neuromuscular	O
+deficiencies	O
+associated	O
+with	O
+the	O
+neuromyopathies	B-DISO
+of	O
+resuscitation	O
+or	O
+to	O
+neuropsychological	O
+damage	O
+combining	O
+cognitive	B-DISO
+disorders	I-DISO
+and	O
+symptoms	O
+of	O
+posttraumatic	O
+stress	O
+.	O
+
+Immunofluorescence	O
+analysis	O
+visualized	O
+S	O
+along	O
+the	O
+secretory	B-PROC
+pathway	I-PROC
+from	O
+endoplasmic	B-COMP
+reticulum	I-COMP
+to	O
+plasma	B-COMP
+membrane	I-COMP
+.	O
+
+ABSTRACT	O
+:	O
+We	O
+report	O
+the	O
+discovery	O
+and	O
+optimization	O
+of	O
+a	O
+potent	O
+inhibitor	O
+against	O
+the	O
+papain	B-PRGE
+-	I-PRGE
+like	I-PRGE
+protease	I-PRGE
+(	O
+PLpro	O
+)	O
+from	O
+the	O
+coronavirus	B-SPEC
+that	O
+causes	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+(	O
+SARS	B-DISO
+-	O
+CoV	O
+).	O
+
+The	O
+X	O
+-	O
+ray	B-SPEC
+structure	O
+of	O
+PLpro	O
+in	O
+complex	O
+with	O
+GRL0617	O
+indicates	O
+that	O
+the	O
+compound	O
+has	O
+a	O
+unique	O
+mode	O
+of	O
+inhibition	O
+whereby	O
+it	O
+binds	B-FUNC
+within	O
+the	O
+S4	O
+-	O
+S3	O
+subsites	O
+of	O
+the	O
+enzyme	O
+and	O
+induces	O
+a	O
+loop	O
+closure	O
+that	O
+shuts	O
+down	O
+catalysis	O
+at	O
+the	O
+active	O
+site	O
+.	O
+
+They	O
+are	O
+extremely	O
+common	O
+causes	O
+of	O
+morbidity	O
+in	O
+the	O
+competent	O
+hosts	B-COMP
+and	O
+some	O
+are	O
+associated	O
+with	O
+significant	O
+mortality	O
+in	O
+the	O
+compromised	O
+individuals	O
+.	O
+
+Some	O
+of	O
+these	O
+emerging	O
+pathogens	O
+may	O
+have	O
+the	O
+potential	O
+to	O
+cause	O
+pandemics	O
+or	O
+global	O
+spread	O
+of	O
+a	O
+severe	O
+disease	O
+,	O
+as	O
+exemplified	O
+by	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+and	O
+avian	B-DISO
+influenza	I-DISO
+.	O
+
+Systolic	O
+blood	B-PROC
+pressure	I-PROC
+,	O
+respiratory	O
+rate	O
+,	O
+degree	O
+of	O
+dyspnea	B-DISO
+,	O
+blood	B-PROC
+oxygen	B-CHED
+saturation	I-PROC
+,	O
+and	O
+heart	B-ANAT
+rate	O
+were	O
+measured	O
+immediately	O
+before	O
+and	O
+at	O
+10	O
+-	O
+15	O
+min	O
+intervals	O
+after	O
+challenge	O
+until	O
+terminal	O
+apnea	O
+occurred	O
+or	O
+until	O
+euthanasia	O
+at	O
+140	O
+min	O
+after	O
+challenge	O
+.	O
+
+The	O
+model	O
+demonstrated	O
+that	O
+the	O
+physical	O
+form	O
+of	O
+heartworm	O
+Ag	O
+used	O
+for	O
+IV	O
+challenge	O
+in	O
+D	B-SPEC
+.	I-SPEC
+immitis	I-SPEC
+-	O
+sensitized	O
+cats	B-SPEC
+is	O
+an	O
+important	O
+factor	O
+for	O
+determining	O
+the	O
+characteristics	O
+of	O
+the	O
+post	O
+-	O
+challenge	O
+reaction	O
+,	O
+and	O
+the	O
+amount	O
+of	O
+exposed	O
+internal	O
+filarial	B-SPEC
+Ag	O
+presented	O
+to	O
+the	O
+feline	B-SPEC
+immune	B-ANAT
+system	I-ANAT
+may	O
+influence	O
+the	O
+severity	O
+of	O
+the	O
+response	O
+to	O
+challenge	O
+.	O
+
+TITLE	O
+:	O
+Delayed	O
+recognition	O
+of	O
+Guillain	O
+-	O
+Barré	O
+syndrome	B-DISO
+in	O
+a	O
+child	O
+:	O
+a	O
+misleading	O
+respiratory	B-DISO
+distress	I-DISO
+.	O
+
+ABSTRACT	O
+:	O
+Guillain	O
+-	O
+Barré	O
+syndrome	O
+(	O
+GBS	B-DISO
+)	O
+is	O
+the	O
+most	O
+common	O
+cause	O
+of	O
+acute	O
+flaccid	B-DISO
+paralysis	I-DISO
+in	O
+childhood	O
+.	O
+
+We	O
+found	O
+that	O
+the	O
+mutant	B-DISO
+virus	B-SPEC
+replicated	O
+to	O
+slightly	O
+reduced	O
+titers	O
+in	O
+livers	B-ANAT
+but	O
+,	O
+strikingly	O
+,	O
+did	O
+not	O
+induce	O
+liver	B-DISO
+disease	I-DISO
+.	O
+
+Collectively	O
+,	O
+our	O
+data	O
+demonstrate	O
+that	O
+the	O
+MHV	B-SPEC
+X	O
+domain	O
+exacerbates	O
+MHV	B-SPEC
+-	O
+induced	O
+liver	B-ANAT
+pathology	B-DISO
+,	O
+most	O
+likely	O
+through	O
+the	O
+induction	O
+of	O
+excessive	O
+inflammatory	O
+cytokine	O
+expression	B-PROC
+.	O
+
+A	O
+certain	O
+number	O
+of	O
+viruses	B-SPEC
+are	O
+able	O
+to	O
+incorporate	O
+their	O
+nucleic	B-CHED
+acid	I-CHED
+into	O
+the	O
+genome	O
+of	O
+the	O
+host	B-COMP
+-	O
+cell	B-COMP
+,	O
+leading	O
+to	O
+rearrangement	B-PROC
+of	O
+the	O
+cell	B-COMP
+genes	O
+and	O
+formation	B-PROC
+of	O
+malignant	B-DISO
+tumors	I-DISO
+.	O
+
+Viral	O
+persistence	O
+can	O
+cause	O
+manifestations	O
+of	O
+latent	O
+or	O
+chronic	B-DISO
+infections	I-DISO
+,	O
+as	O
+well	O
+as	O
+prion	O
+-	O
+caused	O
+slow	O
+infections	B-DISO
+of	O
+the	O
+central	B-ANAT
+nervous	I-ANAT
+system	I-ANAT
+.	O
+
+Data	O
+from	O
+the	O
+National	O
+Hospital	O
+Discharge	B-ANAT
+Survey	O
+between	O
+1990	O
+and	O
+2004	O
+on	O
+patients	O
+who	O
+underwent	O
+primary	O
+or	O
+revision	O
+THA	O
+/	O
+TKA	O
+in	O
+the	O
+United	O
+States	O
+were	O
+analysed	O
+.	O
+
+Three	O
+different	O
+PEEP	B-CHED
+levels	O
+of	O
+0	O
+(	O
+ZEEP	O
+),	O
+10	O
+(	O
+PEEP10	O
+)	O
+and	O
+20	O
+cm	O
+H2O	B-CHED
+(	O
+PEEP20	O
+,	O
+1	O
+cm	O
+H2O	O
+=	O
+0	O
+.	O
+098	O
+kPa	O
+)	O
+were	O
+applied	O
+to	O
+each	O
+group	O
+one	O
+after	O
+another	O
+.	O
+
+Hemodynamics	B-PROC
+,	O
+respiratory	B-PROC
+mechanics	I-PROC
+and	O
+gas	B-ENZY
+exchange	O
+were	O
+measured	O
+15	O
+minutes	O
+after	O
+each	O
+PEEP	B-CHED
+level	O
+was	O
+applied	O
+,	O
+and	O
+lung	B-ANAT
+specimens	O
+for	O
+pathological	O
+examination	O
+were	O
+harvested	O
+after	O
+sacrifice	O
+of	O
+the	O
+animals	B-SPEC
+.	O
+
+The	O
+identification	O
+of	O
+papules	O
+in	O
+well	O
+-	O
+haired	O
+skin	B-ANAT
+was	O
+difficult	O
+,	O
+and	O
+clipping	O
+of	O
+the	O
+fur	O
+facilitated	O
+their	O
+detection	O
+.	O
+
+ABSTRACT	O
+:	O
+Infection	B-DISO
+with	O
+feline	B-DISO
+infectious	I-DISO
+peritonitis	I-DISO
+virus	B-SPEC
+(	O
+FIPV	O
+),	O
+a	O
+feline	B-SPEC
+coronavirus	B-SPEC
+,	O
+frequently	O
+leads	O
+to	O
+death	B-PROC
+in	O
+spite	O
+of	O
+a	O
+strong	O
+humoral	B-PROC
+immune	I-PROC
+response	I-PROC
+.	O
+
+As	O
+the	O
+cell	B-COMP
+surface	I-COMP
+is	O
+cleared	O
+from	O
+viral	O
+proteins	B-CHED
+,	O
+internalization	O
+might	O
+offer	O
+protection	O
+against	O
+antibody	B-COMP
+-	O
+dependent	O
+cell	B-COMP
+lysis	B-DISO
+.	O
+
+Between	O
+30	O
+and	O
+60	O
+min	O
+after	O
+antibody	B-COMP
+addition	O
+,	O
+the	O
+complexes	O
+left	O
+the	O
+late	O
+endosomes	O
+but	O
+were	O
+not	O
+degraded	O
+in	O
+the	O
+lysosomes	B-COMP
+.	O
+
+This	O
+study	O
+reveals	O
+what	O
+is	O
+probably	O
+a	O
+new	O
+internalization	O
+pathway	B-PROC
+into	O
+primary	O
+monocytes	B-ANAT
+,	O
+confirming	O
+once	O
+more	O
+the	O
+complexity	O
+of	O
+endocytic	O
+processes	O
+.	O
+
+ABSTRACT	O
+:	O
+The	O
+avian	O
+influenza	B-PATH
+A	I-PATH
+(	O
+A	O
+/	O
+H5N1	B-DISO
+)	O
+virus	B-SPEC
+has	O
+attracted	O
+the	O
+attention	O
+of	O
+governments	O
+and	O
+health	O
+organizations	O
+throughout	O
+the	O
+world	O
+because	O
+of	O
+its	O
+pandemic	O
+potential	O
+.	O
+
+In	O
+vitro	O
+study	O
+on	O
+human	B-SPEC
+gastric	B-ANAT
+juice	I-ANAT
+and	O
+randomized	O
+controlled	O
+animal	B-SPEC
+study	O
+.	O
+
+Male	O
+New	O
+-	O
+Zealand	O
+white	O
+rabbits	B-SPEC
+.	O
+
+Proinflammatory	O
+activity	O
+of	O
+gastric	B-ANAT
+juice	I-ANAT
+from	O
+17	O
+intensive	O
+care	O
+unit	O
+patients	O
+and	O
+12	O
+controls	O
+undergoing	O
+elective	O
+surgery	O
+was	O
+measured	O
+based	O
+on	O
+a	O
+target	B-ANAT
+cell	I-ANAT
+activation	O
+assay	O
+.	O
+
+Gastric	B-ANAT
+juice	I-ANAT
+from	O
+intensive	O
+care	O
+unit	O
+patients	O
+,	O
+even	O
+buffered	O
+at	O
+pH	O
+7	O
+.	O
+4	O
+,	O
+stimulated	O
+human	B-SPEC
+type	O
+II	O
+-	O
+like	O
+A549	O
+epithelial	B-ANAT
+cells	I-ANAT
+to	O
+up	O
+-	O
+regulate	O
+intercellular	B-PRGE
+adhesion	I-PRGE
+molecule	I-PRGE
+-	I-PRGE
+1	I-PRGE
+and	O
+interleukin	B-PRGE
+-	I-PRGE
+8	I-PRGE
+,	O
+significantly	O
+more	O
+than	O
+juice	O
+obtained	O
+in	O
+controls	O
+.	O
+
+A	O
+human	B-SPEC
+gastric	B-ANAT
+juice	I-ANAT
+with	O
+high	O
+proinflammatory	O
+activity	O
+is	O
+more	O
+""""	O
+toxic	O
+""""	O
+to	O
+the	O
+lung	B-ANAT
+than	O
+one	O
+with	O
+low	O
+proinflammatory	O
+activity	O
+in	O
+a	O
+ventilated	O
+rabbit	B-SPEC
+model	O
+,	O
+an	O
+effect	O
+that	O
+is	O
+independent	O
+of	O
+pH	O
+and	O
+particulate	O
+matter	O
+content	O
+.	O
+
+Since	O
+its	O
+discovery	O
+,	O
+many	O
+trials	O
+have	O
+been	O
+executed	O
+to	O
+establish	O
+the	O
+prophylactic	O
+and	O
+therapeutics	O
+toward	O
+SARS	B-DISO
+using	O
+laboratory	O
+animals	B-SPEC
+.	O
+
+Nasal	B-DISO
+discharge	B-ANAT
+was	O
+recorded	O
+,	O
+and	O
+antibody	B-PROC
+response	I-PROC
+and	O
+virus	B-DISO
+shedding	I-DISO
+were	O
+measured	O
+.	O
+
+Both	O
+LC16mOrVV	O
+-	O
+N	O
+-	O
+immunized	O
+mice	B-SPEC
+and	O
+LC16mOrVV	O
+-	O
+N	O
++	O
+LC16mOrVV	O
+-	O
+S	O
+-	O
+immunized	O
+mice	B-SPEC
+exhibited	O
+severe	O
+pneumonia	B-DISO
+.	O
+
+This	O
+article	O
+attempts	O
+to	O
+address	O
+the	O
+key	O
+respiratory	O
+issues	O
+in	O
+these	O
+respiratory	B-DISO
+infections	I-DISO
+unique	O
+to	O
+Asia	O
+and	O
+highlight	O
+the	O
+important	O
+diagnostic	O
+and	O
+management	O
+issues	O
+faced	O
+by	O
+practising	O
+respirologists	O
+.	O
+
+Four	O
+human	B-SPEC
+and	O
+one	O
+feline	B-PRGE
+coronavirus	B-SPEC
+antigen	B-CHED
+were	O
+cloned	O
+into	O
+baculoviruses	O
+expressed	B-PROC
+in	O
+insect	B-SPEC
+cells	B-COMP
+and	O
+recovered	O
+proteins	B-CHED
+bound	O
+in	O
+the	O
+solid	O
+phase	O
+of	O
+an	O
+enzyme	O
+-	O
+linked	O
+immunosorbent	O
+assay	O
+-	O
+based	O
+system	O
+.	O
+
+Demographic	O
+factors	O
+,	O
+such	O
+as	O
+race	O
+,	O
+smoking	O
+status	O
+,	O
+and	O
+socioeconomic	O
+status	O
+,	O
+may	O
+confer	O
+an	O
+increased	O
+risk	O
+of	O
+susceptibility	O
+to	O
+these	O
+viruses	B-SPEC
+.	O
+
+Septic	B-DISO
+shock	I-DISO
+and	O
+multiple	B-DISO
+organ	I-DISO
+failure	I-DISO
+are	O
+uncommon	O
+but	O
+are	O
+of	O
+markedly	O
+bad	O
+prognostic	O
+significance	O
+.	O
+
+Septic	B-DISO
+shock	I-DISO
+is	O
+an	O
+infrequent	O
+complication	B-DISO
+of	O
+disseminated	B-DISO
+tuberculosis	I-DISO
+.	O
+
+TITLE	O
+:	O
+[	O
+A	O
+rare	O
+cause	O
+of	O
+stridor	B-DISO
+in	O
+a	O
+59	O
+year	O
+old	O
+woman	O
+in	O
+intensive	O
+care	O
+].	O
+
+TITLE	O
+:	O
+Association	O
+of	O
+a	O
+history	O
+of	O
+varicella	B-DISO
+virus	B-DISO
+infection	I-DISO
+with	O
+multiple	B-DISO
+sclerosis	I-DISO
+.	O
+
+Subjects	O
+were	O
+divided	O
+into	O
+subgroups	O
+according	O
+to	O
+MS	O
+subtype	O
+and	O
+the	O
+history	O
+of	O
+varicella	B-DISO
+virus	B-DISO
+infection	I-DISO
+along	O
+with	O
+other	O
+variables	O
+was	O
+assessed	O
+.	O
+
+Epitope	B-CHED
+enhancement	O
+can	O
+elicit	O
+more	O
+potent	O
+T	B-ANAT
+cell	I-ANAT
+responses	O
+and	O
+can	O
+subsequently	O
+lead	O
+to	O
+a	O
+stronger	O
+memory	B-PROC
+pool	O
+;	O
+however	O
+,	O
+the	O
+molecular	O
+basis	O
+of	O
+such	O
+enhancement	O
+is	O
+unclear	O
+.	O
+
+The	O
+virus	B-SPEC
+was	O
+also	O
+detectable	O
+in	O
+the	O
+oviduct	B-ANAT
+of	O
+vaccinated	O
+,	O
+challenged	O
+hens	O
+although	O
+the	O
+viral	O
+load	O
+was	O
+much	O
+lower	O
+compared	O
+to	O
+the	O
+viral	O
+load	O
+in	O
+the	O
+oviduct	B-ANAT
+of	O
+unvaccinated	O
+,	O
+challenged	O
+hens	O
+.	O
+
+This	O
+indicates	O
+that	O
+rearing	O
+phase	O
+vaccination	O
+can	O
+offer	O
+significant	O
+protection	O
+of	O
+the	O
+fully	O
+functional	O
+oviduct	B-ANAT
+against	O
+a	O
+pathogenic	O
+strain	O
+of	O
+IBV	B-SPEC
+.	O
+
+ABSTRACT	O
+:	O
+Severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+(	O
+SARS	B-DISO
+)	O
+is	O
+a	O
+lifethreatening	O
+emerging	O
+respiratory	B-DISO
+disease	I-DISO
+caused	O
+by	O
+the	O
+coronavirus	B-SPEC
+,	O
+SARS	B-PRGE
+-	I-PRGE
+CoV	I-PRGE
+.	O
+The	O
+nucleocapsid	B-COMP
+(	O
+N	O
+)	O
+protein	B-CHED
+of	O
+SARS	B-PRGE
+-	I-PRGE
+CoV	I-PRGE
+is	O
+highly	O
+antigenic	O
+and	O
+may	O
+be	O
+a	O
+suitable	O
+candidate	O
+for	O
+diagnostic	O
+applications	O
+.	O
+
+In	O
+addition	O
+,	O
+we	O
+show	O
+that	O
+wild	O
+-	O
+type	O
+PLP2	B-PRGE
+but	O
+not	O
+the	O
+mutant	B-DISO
+PLP2	O
+lacking	O
+the	O
+deubiquitinase	B-PROC
+(	O
+DUB	O
+)	O
+activity	O
+can	O
+reduce	O
+IFN	B-PRGE
+induction	O
+and	O
+promote	O
+viral	O
+growth	B-PROC
+in	O
+cells	B-COMP
+infected	O
+with	O
+VSV	O
+.	O
+
+Postoperatively	O
+both	O
+patients	O
+suffered	O
+from	O
+severe	O
+complication	B-DISO
+including	O
+septic	B-DISO
+shock	I-DISO
+and	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+.	O
+
+TITLE	O
+:	O
+Review	O
+of	O
+ECMO	O
+(	O
+extra	O
+corporeal	O
+membrane	B-COMP
+oxygenation	B-PROC
+)	O
+support	O
+in	O
+critically	B-DISO
+ill	I-DISO
+adult	O
+patients	O
+.	O
+
+Complication	B-DISO
+rates	O
+and	O
+outcomes	O
+are	O
+reviewed	O
+and	O
+our	O
+experience	O
+at	O
+The	O
+Epworth	O
+Hospital	O
+is	O
+summarized	O
+.	O
+
+ABSTRACT	O
+:	O
+In	O
+this	O
+paper	O
+,	O
+an	O
+improved	O
+recovery	O
+method	O
+for	O
+target	O
+ssDNA	O
+using	O
+amino	O
+-	O
+modified	O
+silica	B-CHED
+-	O
+coated	O
+magnetic	O
+nanoparticles	B-CHED
+(	O
+ASMNPs	O
+)	O
+is	O
+reported	O
+.	O
+
+The	O
+purpose	O
+of	O
+our	O
+study	O
+was	O
+to	O
+survey	O
+the	O
+prevalence	O
+of	O
+the	O
+SARS	B-DISO
+coronavirus	B-SPEC
+(	O
+CoV	B-SPEC
+)	O
+in	O
+a	O
+community	O
+adjacent	O
+to	O
+Kaohsiung	O
+CGMH	O
+and	O
+collect	O
+demographic	O
+data	O
+,	O
+including	O
+basic	O
+information	O
+about	O
+health	O
+status	O
+,	O
+household	O
+,	O
+and	O
+possible	O
+risk	O
+factors	O
+for	O
+SARS	B-DISO
+-	I-DISO
+CoV	I-DISO
+infection	I-DISO
+.	O
+
+The	O
+SARS	B-DISO
+outbreak	O
+in	O
+Taiwan	O
+was	O
+primarily	O
+limited	O
+to	O
+hospital	O
+settings	O
+.	O
+
+Both	O
+confirmed	O
+cases	O
+were	O
+under	O
+19	O
+years	O
+of	O
+age	O
+and	O
+had	O
+no	O
+known	O
+SARS	B-DISO
+-	O
+related	O
+risk	O
+factors	O
+.	O
+
+We	O
+also	O
+found	O
+229E	O
+virion	B-COMP
+S	O
+protein	B-CHED
+to	O
+be	O
+cleaved	B-ANAT
+by	O
+CPL	B-DISO
+.	O
+
+ABSTRACT	O
+:	O
+In	O
+this	O
+territory	O
+-	O
+wide	O
+molecular	O
+epidemiology	O
+study	O
+of	O
+coronaviruses	O
+(	O
+CoVs	O
+)	O
+in	O
+Hong	O
+Kong	O
+involving	O
+1	O
+,	O
+541	O
+dead	B-PROC
+wild	O
+birds	B-SPEC
+,	O
+three	O
+novel	O
+CoVs	O
+were	O
+identified	O
+in	O
+three	O
+different	O
+bird	B-SPEC
+families	O
+(	O
+bulbul	B-PRGE
+CoV	I-PRGE
+HKU11	I-PRGE
+[	I-PRGE
+BuCoV	I-PRGE
+HKU11	I-PRGE
+],	I-PRGE
+thrush	B-DISO
+CoV	I-PRGE
+HKU12	I-PRGE
+[	I-PRGE
+ThCoV	I-PRGE
+HKU12	I-PRGE
+],	I-PRGE
+and	I-PRGE
+munia	I-PRGE
+CoV	I-PRGE
+HKU13	I-PRGE
+[	I-PRGE
+MuCoV	I-PRGE
+HKU13	I-PRGE
+]).	I-PRGE
+
+TITLE	O
+:	O
+Development	B-PROC
+and	O
+evaluation	O
+of	O
+a	O
+leadership	O
+training	O
+program	O
+for	O
+public	O
+health	O
+emergency	B-DISO
+response	O
+:	O
+results	O
+from	O
+a	O
+Chinese	O
+study	O
+.	O
+
+Forty	O
+-	O
+one	O
+public	O
+health	O
+leaders	O
+(	O
+N	O
+=	O
+41	O
+)	O
+from	O
+five	O
+provinces	O
+completed	O
+the	O
+entire	O
+emergency	B-DISO
+preparedness	O
+training	O
+program	O
+in	O
+China	O
+.	O
+
+Moreover	O
+,	O
+the	O
+response	O
+of	O
+participants	O
+in	O
+the	O
+program	O
+to	O
+the	O
+avian	B-DISO
+influenza	I-DISO
+outbreak	O
+,	O
+as	O
+well	O
+as	O
+the	O
+planned	O
+evaluations	O
+for	O
+this	O
+leadership	O
+training	O
+program	O
+,	O
+further	O
+demonstrated	O
+both	O
+the	O
+successful	O
+approaches	O
+and	O
+methods	O
+and	O
+the	O
+positive	O
+impact	O
+of	O
+this	O
+integrated	O
+leadership	O
+training	O
+initiative	O
+.	O
+
+A	O
+56	O
+-	O
+year	O
+-	O
+old	O
+women	O
+admitted	O
+for	O
+high	O
+-	O
+fever	B-PROC
+,	O
+dyspnea	B-DISO
+,	O
+and	O
+disturbance	B-DISO
+of	I-DISO
+consciousness	I-DISO
+on	O
+September	O
+11	O
+,	O
+2006	O
+,	O
+was	O
+found	O
+in	O
+chest	B-ANAT
+computed	O
+tomography	O
+(	O
+CT	O
+)	O
+on	O
+admission	O
+to	O
+have	O
+diffuse	O
+infiltration	B-DISO
+with	O
+bilateral	B-DISO
+pleural	I-DISO
+effusion	I-DISO
+.	O
+
+Abdominal	B-ANAT
+CT	O
+on	O
+admission	O
+showed	O
+left	O
+hydronephrosis	B-DISO
+complicated	O
+with	O
+ureteral	O
+stones	O
+.	O
+
+Because	O
+Escherichia	B-SPEC
+coli	I-SPEC
+was	O
+isolated	O
+from	O
+urine	B-ANAT
+and	O
+blood	B-ANAT
+cultures	O
+,	O
+she	O
+was	O
+diagnosed	O
+with	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+(	O
+ARDS	B-DISO
+)	O
+caused	O
+by	O
+E	B-SPEC
+.	I-SPEC
+coli	I-SPEC
+inducing	O
+septic	B-DISO
+shock	I-DISO
+.	O
+
+After	O
+therapy	O
+,	O
+her	O
+condition	B-DISO
+improved	O
+,	O
+and	O
+she	O
+was	O
+extubated	O
+on	O
+hospital	O
+day	O
+9	O
+.	O
+
+Broilers	O
+were	O
+inoculated	O
+with	O
+IBV	B-SPEC
+H120	O
+vaccine	O
+virus	B-SPEC
+or	O
+virulent	O
+M41	O
+and	O
+challenged	O
+5	O
+days	O
+later	O
+with	O
+E	B-SPEC
+.	I-SPEC
+coli	I-SPEC
+506	O
+.	O
+
+In	O
+the	O
+lungs	B-ANAT
+and	O
+the	O
+airsacs	O
+the	O
+macrophages	B-ANAT
+were	O
+more	O
+numerous	O
+in	O
+the	O
+IBV	B-SPEC
+/	O
+E	B-SPEC
+.	I-SPEC
+coli	I-SPEC
+and	O
+the	O
+E	B-SPEC
+.	I-SPEC
+coli	I-SPEC
+groups	O
+than	O
+in	O
+the	O
+PBS	B-DISO
+group	O
+.	O
+
+Canine	O
+respiratory	O
+coronavirus	B-SPEC
+(	O
+CRCoV	O
+)	O
+has	O
+previously	O
+been	O
+shown	O
+to	O
+have	O
+a	O
+widespread	O
+international	O
+presence	O
+and	O
+has	O
+been	O
+implicated	O
+in	O
+outbreaks	O
+of	O
+canine	O
+infectious	B-DISO
+respiratory	B-DISO
+disease	I-DISO
+(	O
+CIRD	O
+).	O
+
+This	O
+study	O
+aimed	O
+to	O
+quantify	O
+pro	B-CHED
+-	O
+inflammatory	O
+cytokine	O
+mRNAs	O
+following	O
+infection	B-DISO
+of	O
+canine	O
+air	B-CHED
+-	O
+interface	O
+tracheal	O
+cultures	O
+with	O
+CRCoV	O
+.	O
+Within	O
+this	O
+system	O
+,	O
+immunohistochemistry	O
+identified	O
+ciliated	O
+epithelial	O
+and	O
+goblet	B-ANAT
+cells	I-ANAT
+as	O
+positive	O
+for	O
+CRCoV	O
+,	O
+identical	O
+to	O
+naturally	O
+infected	O
+cases	O
+,	O
+thus	O
+the	O
+data	O
+obtained	O
+would	O
+be	O
+fully	O
+transferable	O
+to	O
+the	O
+situation	O
+in	O
+vivo	O
+.	O
+
+TITLE	O
+:	O
+Patterns	O
+of	O
+brain	B-ANAT
+injury	O
+and	O
+outcome	O
+in	O
+term	O
+neonates	O
+presenting	O
+with	O
+postnatal	O
+collapse	B-DISO
+.	O
+
+Infants	O
+born	O
+at	O
+>	O
+or	O
+=	O
+36	O
+weeks	O
+'	O
+gestation	B-PROC
+with	O
+early	O
+(<	O
+72	O
+h	O
+)	O
+PNC	O
+.	O
+
+Ten	O
+were	O
+born	O
+vaginally	O
+(	O
+including	O
+occipitoposterior	O
+(	O
+1	O
+),	O
+breech	O
+(	O
+2	O
+),	O
+water	B-CHED
+birth	B-PROC
+(	O
+2	O
+),	O
+ventouse	O
+/	O
+forceps	O
+(	O
+3	O
+)),	O
+and	O
+two	O
+by	O
+emergency	B-DISO
+caesarean	O
+section	O
+.	O
+
+RESULTS	O
+:	O
+Twelve	O
+infants	O
+were	O
+studied	O
+;	O
+median	O
+gestation	B-PROC
+39	O
+weeks	O
+(	O
+36	O
+-	O
+41	O
+),	O
+birth	B-PROC
+weight	O
+3150	O
+g	O
+(	O
+1930	O
+-	O
+4010	O
+).	O
+
+TITLE	O
+:	O
+Identification	O
+of	O
+a	O
+minimal	O
+peptide	B-CHED
+derived	O
+from	O
+heptad	O
+repeat	O
+(	O
+HR	O
+)	O
+2	O
+of	O
+spike	O
+protein	B-CHED
+of	O
+SARS	B-DISO
+-	I-PRGE
+CoV	I-PRGE
+and	O
+combination	O
+of	O
+HR1	O
+-	O
+derived	O
+peptides	B-CHED
+as	O
+fusion	O
+inhibitors	B-CHED
+.	O
+
+A549	O
+cells	B-COMP
+were	O
+shown	O
+to	O
+bind	B-FUNC
+purified	O
+soluble	O
+HCoV	O
+-	O
+HKU1	O
+S	O
+(	O
+1	O
+-	O
+600	O
+)	O
+glycopeptide	B-CHED
+.	O
+
+To	O
+search	O
+for	O
+the	O
+functional	O
+receptor	O
+for	O
+HCoV	O
+-	O
+HKU1	O
+,	O
+an	O
+A549	O
+cDNA	O
+expression	B-PROC
+library	O
+was	O
+constructed	O
+and	O
+transduced	O
+into	O
+the	O
+nonpermissive	O
+,	O
+baby	O
+hamster	O
+kidney	B-ANAT
+cells	B-ANAT
+line	I-ANAT
+BHK	O
+-	O
+21	O
+.	O
+
+The	O
+structures	O
+were	O
+individually	O
+solved	O
+to	O
+elucidate	O
+the	O
+structural	O
+similarities	O
+and	O
+differences	O
+of	O
+the	O
+ADRP	O
+domains	O
+among	O
+various	O
+coronavirus	B-SPEC
+species	B-SPEC
+.	O
+
+ABSTRACT	O
+:	O
+Vaccine	O
+development	B-PROC
+for	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+coronavirus	B-SPEC
+(	O
+SARS	B-DISO
+-	O
+CoV	O
+)	O
+has	O
+mainly	O
+focused	O
+on	O
+the	O
+spike	O
+(	O
+S	O
+)	O
+protein	B-CHED
+.	O
+
+Furthermore	O
+,	O
+a	O
+strong	O
+Th1	O
+-	O
+based	O
+cellular	B-PROC
+immune	I-PROC
+response	I-PROC
+was	O
+stimulated	O
+by	O
+both	O
+DNA	O
+vaccines	O
+.	O
+
+The	O
+vaccines	O
+stimulated	O
+gamma	O
+interferon	O
+production	O
+mainly	O
+by	O
+CD8	B-PRGE
+(+)	O
+T	B-ANAT
+cells	I-ANAT
+and	O
+interleukin	B-PRGE
+-	I-PRGE
+2	I-PRGE
+(	O
+IL	B-FUNC
+-	I-FUNC
+2	I-FUNC
+)	O
+mainly	O
+by	O
+CD4	B-PRGE
+(+)	O
+T	B-ANAT
+cells	I-ANAT
+.	O
+
+The	O
+strategies	O
+investigated	O
+in	O
+this	O
+study	O
+,	O
+in	O
+particular	O
+the	O
+use	O
+of	O
+structural	O
+information	O
+in	O
+combination	O
+of	O
+chain	O
+-	O
+shuffling	O
+as	O
+well	O
+as	O
+hot	O
+-	O
+spot	B-SPEC
+CDR	B-ENZY
+mutagenesis	B-PROC
+,	O
+can	O
+be	O
+exploited	O
+to	O
+broaden	O
+neutralization	O
+activity	O
+,	O
+to	O
+improve	O
+anti	O
+-	O
+viral	O
+nAb	O
+therapies	O
+,	O
+and	O
+directly	O
+manipulate	O
+virus	B-SPEC
+evolution	B-PROC
+.	O
+
+The	O
+ARIMA	O
+model	O
+of	O
+outpatient	O
+volume	O
+in	O
+the	O
+pre	O
+-	O
+SARS	B-DISO
+year	O
+was	O
+developed	O
+.	O
+
+The	O
+findings	O
+of	O
+this	O
+study	O
+identify	O
+subspecialties	O
+that	O
+are	O
+particularly	O
+vulnerable	O
+in	O
+an	O
+infectious	B-DISO
+disease	I-DISO
+designated	O
+hospital	O
+and	O
+such	O
+hospitals	O
+need	O
+to	O
+consider	O
+which	O
+subspecialties	O
+should	O
+be	O
+included	O
+in	O
+their	O
+medical	O
+structure	O
+.	O
+
+CONCLUSIONS	O
+:	O
+This	O
+study	O
+demonstrates	O
+that	O
+if	O
+a	O
+hospital	O
+is	O
+completely	O
+shut	O
+down	O
+due	O
+to	O
+SARS	B-DISO
+or	O
+a	O
+similar	O
+disease	O
+,	O
+the	O
+impact	O
+is	O
+longer	O
+than	O
+previous	O
+reported	O
+and	O
+different	O
+departments	O
+may	O
+experience	O
+different	O
+recover	B-PROC
+periods	B-PROC
+.	O
+
+TITLE	O
+:	O
+Chemical	O
+properties	O
+of	O
+heavy	O
+metals	B-CHED
+in	O
+typical	O
+hospital	O
+waste	O
+incinerator	O
+ashes	O
+in	O
+China	O
+.	O
+
+Chemical	O
+analysis	O
+indicated	O
+that	O
+the	O
+HW	O
+ashes	O
+contained	O
+large	O
+amounts	O
+of	O
+metal	B-CHED
+salts	B-CHED
+of	O
+Al	O
+,	O
+Ca	O
+,	O
+Fe	O
+,	O
+K	O
+,	O
+Mg	O
+,	O
+Na	O
+with	O
+a	O
+concentration	O
+range	O
+of	O
+1	O
+.	O
+8	O
+-	O
+315gkg	O
+(-	O
+1	O
+).	O
+
+HIV	B-DISO
+/	I-DISO
+AIDS	I-DISO
+,	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+,	O
+H5N1	B-DISO
+avian	B-DISO
+influenza	I-DISO
+,	O
+and	O
+many	O
+other	O
+emerging	O
+diseases	O
+have	O
+either	O
+proved	O
+fatal	O
+or	O
+caused	O
+international	O
+alarm	O
+.	O
+
+ABSTRACT	O
+:	O
+Porcine	O
+epidemic	O
+diarrhea	O
+virus	O
+(	O
+PEDV	B-SPEC
+)	O
+is	O
+the	O
+predominant	O
+cause	O
+of	O
+severe	O
+entero	O
+-	O
+pathogenic	O
+diarrhea	B-DISO
+in	O
+swine	B-SPEC
+.	O
+
+Single	O
+E	B-SPEC
+.	I-SPEC
+coli	I-SPEC
+inoculation	O
+induced	O
+pneumonia	B-DISO
+and	O
+airsacculitis	B-DISO
+;	O
+in	O
+case	O
+it	O
+was	O
+preceded	O
+by	O
+IBV	B-SPEC
+infection	B-DISO
+,	O
+the	O
+same	O
+macroscopical	O
+lesions	O
+and	O
+also	O
+viral	O
+tracheitis	O
+were	O
+found	O
+.	O
+
+In	O
+the	O
+airsacs	O
+,	O
+a	O
+few	O
+bacteria	B-SPEC
+were	O
+found	O
+from	O
+0	O
+.	O
+5	O
+hpi	B-DISO
+up	O
+to	O
+4	O
+dpi	O
+in	O
+E	B-SPEC
+.	I-SPEC
+coli	I-SPEC
+and	O
+IBV	B-SPEC
+-	O
+E	B-SPEC
+.	I-SPEC
+coli	I-SPEC
+inoculated	O
+birds	B-SPEC
+.	O
+
+Although	O
+both	O
+pathogens	O
+were	O
+cleared	O
+beyond	O
+detection	O
+at	O
+7	O
+dpi	O
+,	O
+in	O
+IBV	B-SPEC
+-	O
+E	B-SPEC
+.	I-SPEC
+coli	I-SPEC
+inoculated	O
+birds	B-SPEC
+lesions	O
+in	O
+the	O
+airsac	O
+persisted	O
+,	O
+in	O
+contrast	O
+to	O
+broilers	O
+inoculated	O
+with	O
+E	B-SPEC
+.	I-SPEC
+coli	I-SPEC
+only	O
+.	O
+
+TITLE	O
+:	O
+Severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+(	O
+SARS	B-DISO
+)	O
+coronavirus	B-SPEC
+-	O
+induced	O
+lung	B-ANAT
+epithelial	O
+cytokines	O
+exacerbate	O
+SARS	O
+pathogenesis	B-DISO
+by	O
+modulating	O
+intrinsic	O
+functions	O
+of	O
+monocyte	B-ANAT
+-	I-ANAT
+derived	I-ANAT
+macrophages	I-ANAT
+and	O
+dendritic	B-ANAT
+cells	B-COMP
+.	O
+
+We	O
+also	O
+identified	O
+interleukin	B-PRGE
+-	I-PRGE
+6	I-PRGE
+(	O
+IL	B-FUNC
+-	I-FUNC
+6	I-FUNC
+)	O
+and	O
+IL	B-FUNC
+-	I-FUNC
+8	I-FUNC
+as	O
+key	O
+SARS	B-DISO
+-	O
+CoV	O
+-	O
+induced	O
+epithelial	O
+cytokines	O
+capable	O
+of	O
+inhibiting	O
+the	O
+T	B-ANAT
+-	I-ANAT
+cell	I-ANAT
+-	O
+priming	O
+ability	O
+of	O
+DC	O
+.	O
+
+The	O
+OPHL	O
+plan	B-DISO
+includes	O
+:	O
+(	O
+1	O
+)	O
+an	O
+aggressive	B-DISO
+restructuring	O
+of	O
+the	O
+overall	O
+molecular	O
+microbiology	O
+testing	O
+capacity	O
+of	O
+the	O
+OPHL	O
+;	O
+(	O
+2	O
+)	O
+the	O
+ability	O
+to	O
+shift	O
+influenza	B-DISO
+testing	O
+of	O
+samples	O
+between	O
+designated	O
+OPHL	O
+laboratories	O
+;	O
+and	O
+(	O
+3	O
+)	O
+the	O
+development	O
+of	O
+screening	O
+tools	O
+for	O
+pandemic	O
+influenza	B-DISO
+diagnostic	O
+tests	O
+.	O
+
+The	O
+present	O
+study	O
+sought	O
+to	O
+evaluate	O
+the	O
+factors	O
+determining	O
+the	O
+efficacy	O
+of	O
+iLA	B-PRGE
+and	O
+calculate	O
+its	O
+contribution	O
+to	O
+gas	B-ENZY
+exchange	O
+.	O
+
+TITLE	O
+:	O
+Field	O
+strain	O
+feline	B-SPEC
+coronaviruses	O
+with	O
+small	O
+deletions	O
+in	O
+ORF7b	O
+associated	O
+with	O
+both	O
+enteric	O
+infection	O
+and	O
+feline	B-DISO
+infectious	I-DISO
+peritonitis	I-DISO
+.	O
+
+These	O
+results	O
+show	O
+that	O
+deletions	O
+in	O
+the	O
+ORF7b	O
+gene	O
+are	O
+not	O
+constrained	O
+to	O
+low	O
+pathogenicity	O
+/	O
+enteric	O
+biotypes	O
+but	O
+also	O
+associated	O
+with	O
+pathogenicity	O
+/	O
+FIP	B-DISO
+biotypes	O
+of	O
+FCoV	O
+.	O
+
+Of	O
+the	O
+enteric	O
+tissues	B-ANAT
+,	O
+only	O
+one	O
+mesenteric	B-ANAT
+lymph	I-ANAT
+node	I-ANAT
+sample	O
+was	O
+positive	O
+.	O
+
+The	O
+CRCoV	O
+real	O
+-	O
+time	O
+PCR	O
+assay	O
+has	O
+proved	O
+to	O
+be	O
+a	O
+highly	O
+specific	O
+and	O
+sensitive	O
+assay	O
+that	O
+can	O
+be	O
+applied	O
+for	O
+diagnostic	O
+purposes	O
+as	O
+well	O
+as	O
+to	O
+investigate	O
+further	O
+the	O
+tissue	B-PROC
+tropism	B-PROC
+of	O
+CRCoV	O
+.	O
+
+Human	B-PRGE
+coronavirus	I-PRGE
+(	O
+hCoV	O
+)	O
+NL63	O
+is	O
+associated	O
+with	O
+up	O
+to	O
+10	O
+%	O
+of	O
+common	B-DISO
+colds	I-DISO
+.	O
+
+Human	B-SPEC
+colon	B-DISO
+carcinoma	I-DISO
+cells	B-COMP
+(	O
+CaCo	O
+-	O
+2	O
+)	O
+replicated	O
+virus	B-SPEC
+more	O
+than	O
+100	O
+fold	O
+more	O
+efficiently	O
+than	O
+commonly	O
+used	O
+African	B-SPEC
+green	I-SPEC
+monkey	I-SPEC
+kidney	B-ANAT
+cells	B-COMP
+(	O
+LLC	B-COMP
+-	O
+MK2	O
+).	O
+
+The	O
+utility	O
+of	O
+plaque	B-DISO
+assays	O
+with	O
+agrose	O
+overlay	O
+was	O
+demonstrated	O
+for	O
+purifying	O
+virus	B-SPEC
+,	O
+thereby	O
+increasing	O
+viral	O
+infectivity	O
+by	O
+1	O
+log	O
+10	O
+PFU	B-CHED
+/	O
+mL	O
+.	O
+CaCo	O
+-	O
+2	O
+cells	B-COMP
+support	O
+hCoV	B-SPEC
+-	I-SPEC
+NL63	I-SPEC
+better	O
+than	O
+LLC	B-COMP
+-	O
+MK2	O
+cells	B-COMP
+and	O
+enable	O
+cytopathogenic	O
+plaque	B-DISO
+assays	O
+.	O
+
+Avicel	O
+overlay	O
+is	O
+favourable	O
+for	O
+plaque	B-DISO
+quantification	O
+,	O
+and	O
+agarose	B-CHED
+overlay	O
+is	O
+preferred	O
+for	O
+plaque	B-DISO
+purification	O
+.	O
+
+TITLE	O
+:	O
+Avian	B-SPEC
+Influenza	I-DISO
+:	O
+a	O
+global	O
+threat	O
+needing	O
+a	O
+global	O
+solution	O
+.	O
+
+Such	O
+birds	B-SPEC
+often	O
+live	O
+in	O
+close	O
+proximity	O
+to	O
+humans	B-SPEC
+and	O
+this	O
+increases	O
+the	O
+chance	O
+of	O
+genetic	O
+re	O
+-	O
+assortment	O
+between	O
+avian	B-SPEC
+and	O
+human	B-DISO
+influenza	B-SPEC
+viruses	I-SPEC
+which	O
+may	O
+produce	O
+a	O
+mutant	B-DISO
+strain	O
+that	O
+is	O
+easily	O
+transmitted	B-DISO
+between	O
+humans	B-SPEC
+.	O
+
+The	O
+application	O
+of	O
+inhaled	B-PROC
+nitric	B-CHED
+oxide	I-CHED
+(	O
+iNO	O
+)	O
+is	O
+a	O
+therapeutic	O
+option	O
+to	O
+selectively	O
+influence	O
+pulmonary	B-ANAT
+blood	B-PROC
+flow	I-PROC
+in	O
+order	B-SPEC
+to	O
+improve	O
+arterial	B-ANAT
+oxygenation	B-PROC
+and	O
+to	O
+decrease	O
+pulmonary	B-ANAT
+artery	I-ANAT
+pressure	O
+without	O
+relevant	O
+systemic	O
+side	O
+effects	O
+.	O
+
+Certain	O
+experimental	O
+lentiviral	O
+vaccines	O
+even	O
+proved	O
+to	O
+be	O
+counterproductive	O
+:	O
+they	O
+rendered	O
+vaccinated	O
+subjects	O
+more	O
+susceptible	O
+to	O
+infection	B-DISO
+rather	O
+than	O
+protecting	O
+them	O
+.	O
+
+Other	O
+mechanisms	O
+may	O
+,	O
+either	O
+in	O
+the	O
+absence	O
+of	O
+or	O
+in	O
+combination	O
+with	O
+ADE	B-CHED
+,	O
+be	O
+involved	O
+.	O
+
+Also	O
+recent	O
+failures	O
+in	O
+the	O
+development	B-PROC
+of	O
+a	O
+vaccine	O
+against	O
+HIV	B-DISO
+may	O
+at	O
+least	O
+in	O
+part	O
+be	O
+attributed	O
+to	O
+induction	O
+of	O
+enhanced	O
+susceptibility	O
+to	O
+infection	B-DISO
+.	O
+
+ABSTRACT	O
+:	O
+Coronaviruses	O
+devote	O
+more	O
+than	O
+three	O
+quarters	O
+of	O
+their	O
+coding	O
+capacity	O
+to	O
+encode	O
+two	O
+large	O
+polyproteins	O
+(	O
+1a	O
+and	O
+1ab	O
+polyproteins	O
+),	O
+which	O
+are	O
+proteolytically	O
+processed	O
+into	O
+15	O
+-	O
+16	O
+mature	O
+,	O
+nonstructural	O
+replicase	B-PRGE
+proteins	I-PRGE
+(	O
+nsp1	B-PRGE
+to	O
+16	O
+).	O
+
+Introduction	O
+of	O
+the	O
+mutation	O
+into	O
+the	O
+IBV	B-SPEC
+infectious	B-DISO
+clone	O
+system	O
+showed	O
+recovery	O
+of	O
+a	O
+mutant	B-DISO
+virus	B-SPEC
+with	O
+severe	O
+growth	B-PROC
+defects	O
+,	O
+supporting	O
+that	O
+dimerization	O
+is	O
+critical	O
+for	O
+the	O
+function	O
+of	O
+this	O
+replicase	B-PRGE
+protein	I-PRGE
+.	O
+
+The	O
+TCoV	O
+nsp15	O
+cleaved	B-ANAT
+single	O
+-	O
+stranded	O
+(	O
+ss	O
+)	O
+RNA	O
+at	O
+the	O
+uridylate	B-CHED
+site	O
+.	O
+
+TITLE	O
+:	O
+The	O
+SARS	B-DISO
+(	O
+Severe	B-DISO
+Acute	I-DISO
+Respiratory	I-DISO
+Syndrome	I-DISO
+)	O
+pandemic	O
+in	O
+Hong	O
+Kong	O
+:	O
+effects	O
+on	O
+the	O
+subjective	O
+wellbeing	O
+of	O
+elderly	O
+and	O
+younger	O
+people	O
+.	O
+
+The	O
+PWI	O
+demonstrated	O
+good	O
+psychometric	O
+performance	O
+and	O
+also	O
+more	O
+robustness	O
+with	O
+elderly	O
+people	O
+,	O
+including	O
+its	O
+sensitivity	O
+to	O
+the	O
+sense	B-PROC
+of	O
+population	O
+threat	O
+.	O
+
+This	O
+improved	O
+within	O
+a	O
+few	O
+days	O
+and	O
+,	O
+after	O
+five	O
+days	O
+,	O
+she	O
+was	O
+transferred	O
+to	O
+the	O
+nursing	B-PROC
+department	O
+.	O
+
+Here	O
+,	O
+we	O
+have	O
+isolated	O
+DNA	O
+aptamers	O
+against	O
+the	O
+SARS	B-PRGE
+-	I-PRGE
+CoV	I-PRGE
+helicase	I-PRGE
+from	O
+a	O
+combinatorial	O
+DNA	O
+library	O
+.	O
+
+TITLE	O
+:	O
+Identification	O
+of	O
+viral	O
+and	O
+atypical	O
+bacterial	O
+pathogens	O
+in	O
+children	O
+hospitalized	O
+with	O
+acute	B-DISO
+respiratory	I-DISO
+infections	I-DISO
+in	O
+Hong	O
+Kong	O
+by	O
+multiplex	O
+PCR	O
+assays	O
+.	O
+
+ABSTRACT	O
+:	O
+Acute	B-DISO
+respiratory	I-DISO
+tract	I-DISO
+infection	I-DISO
+is	O
+a	O
+leading	O
+cause	O
+of	O
+hospital	O
+admission	O
+of	O
+children	O
+.	O
+
+Most	O
+RSV	B-DISO
+infections	I-DISO
+were	O
+found	O
+between	O
+February	O
+and	O
+September	O
+.	O
+
+Adenovirus	B-DISO
+had	O
+multiple	O
+peaks	O
+,	O
+whereas	O
+rhinovirus	B-SPEC
+and	O
+coronavirus	B-SPEC
+OC43	O
+were	O
+detected	O
+mainly	O
+in	O
+winter	O
+and	O
+early	O
+spring	O
+.	O
+
+These	O
+surface	O
+deposits	O
+of	O
+PMP	B-CHED
+MO	O
+after	O
+removal	O
+were	O
+studied	O
+with	O
+scanning	O
+electron	O
+and	O
+fluorescence	O
+microscopy	O
+techniques	O
+.	O
+
+A	O
+membranous	B-ANAT
+structure	O
+composed	O
+of	O
+single	O
+cells	B-COMP
+and	O
+clusters	B-CHED
+of	O
+cells	B-COMP
+covered	O
+large	O
+areas	O
+of	O
+the	O
+PMP	B-CHED
+fibers	O
+.	O
+
+We	O
+assume	O
+that	O
+these	O
+cellular	B-COMP
+deposits	O
+lower	O
+the	O
+efficacy	O
+of	O
+ECMO	O
+.	O
+
+Later	O
+posttransplant	O
+,	O
+infection	B-DISO
+with	O
+viruses	B-SPEC
+circulating	O
+in	O
+the	O
+community	O
+can	O
+occur	O
+with	O
+a	O
+number	O
+of	O
+pathogens	O
+,	O
+including	O
+some	O
+vaccine	O
+-	O
+preventable	O
+illnesses	O
+such	O
+as	O
+measles	B-PATH
+and	O
+mumps	B-DISO
+.	O
+
+This	O
+article	O
+reviews	O
+some	O
+of	O
+the	O
+emerging	O
+and	O
+reemerging	O
+viral	O
+pathogens	O
+infecting	O
+solid	B-ANAT
+organ	I-ANAT
+and	O
+hematopoietic	O
+stem	B-ANAT
+-	O
+cell	B-COMP
+recipients	O
+,	O
+including	O
+adenovirus	B-DISO
+,	O
+bocavirus	B-SPEC
+,	O
+coronavirus	B-SPEC
+,	O
+human	B-SPEC
+herpesvirus	I-SPEC
+-	O
+6	O
+,	O
+lymphocytic	B-SPEC
+choriomeningitis	I-SPEC
+virus	I-SPEC
+,	O
+measles	B-PATH
+,	O
+mumps	B-DISO
+,	O
+metapneumovirus	B-SPEC
+,	O
+parainfluenza	B-DISO
+,	O
+rotavirus	B-SPEC
+,	O
+respiratory	B-SPEC
+syncytial	I-SPEC
+virus	I-SPEC
+,	O
+and	O
+West	B-DISO
+Nile	I-DISO
+virus	I-DISO
+.	O
+
+Of	O
+the	O
+43	O
+patients	O
+,	O
+19	O
+had	O
+Jeune	B-DISO
+syndrome	I-DISO
+and	O
+24	O
+had	O
+Jarcho	O
+-	O
+Levin	O
+syndrome	O
+.	O
+
+ABSTRACT	O
+:	O
+To	O
+seek	O
+differentially	O
+expressed	B-PROC
+serum	B-COMP
+proteins	B-CHED
+in	O
+recovered	O
+SARS	B-DISO
+patients	O
+complicating	O
+avascular	B-DISO
+necrosis	I-DISO
+of	I-DISO
+femoral	B-ANAT
+head	I-ANAT
+(	O
+AVNFH	O
+).	O
+
+42	O
+respectively	O
+,	O
+and	O
+the	O
+matching	O
+rate	O
+of	O
+protein	B-CHED
+points	O
+was	O
+ranged	O
+from	O
+85	O
+%	O
+to	O
+95	O
+%;	O
+eighteen	O
+differentially	O
+expressed	B-PROC
+proteins	B-CHED
+were	O
+discovered	O
+including	O
+transthyretin	B-PRGE
+,	O
+serpin	B-PRGE
+peptidase	I-PRGE
+inhibitor	O
+,	O
+alpha	B-PRGE
+-	I-PRGE
+1	I-PRGE
+-	I-PRGE
+antitrypsin	I-PRGE
+precursor	I-PRGE
+,	O
+serum	B-COMP
+amyloid	B-DISO
+P	O
+components	O
+,	O
+etc	O
+.	O
+
+Compared	O
+to	O
+healthy	O
+group	O
+and	O
+SARS	B-DISO
+non	O
+-	O
+AVNFH	O
+group	O
+,	O
+transthyretin	B-PRGE
+,	O
+C4B3	O
+,	O
+fibrinogen	B-PRGE
+gamma	I-PRGE
+,	O
+apolipoprotein	B-PRGE
+L	I-PRGE
+,	O
+apolipoprotein	B-PRGE
+A	I-PRGE
+-	I-PRGE
+IV	I-PRGE
+precursor	I-PRGE
+,	O
+albumin	B-PRGE
+and	O
+prealbumin	B-PRGE
+showed	O
+lower	O
+expression	B-PROC
+,	O
+inversely	O
+serpin	B-PRGE
+peptidase	I-PRGE
+inhibitor	O
+,	O
+alpha	B-PRGE
+-	I-PRGE
+1	I-PRGE
+-	I-PRGE
+antitrypsin	I-PRGE
+precursor	I-PRGE
+and	O
+serum	B-COMP
+amyloid	B-DISO
+P	O
+components	O
+showed	O
+higher	O
+expression	B-PROC
+in	O
+serum	B-COMP
+in	O
+the	O
+SARS	B-PRGE
+AVNFH	I-PRGE
+necrosis	B-PROC
+group	I-PRGE
+.	O
+
+There	O
+were	O
+differentially	O
+expressed	B-PROC
+serum	B-COMP
+proteins	B-CHED
+in	O
+three	O
+groups	O
+.	O
+
+The	O
+areas	O
+under	O
+the	O
+ROC	O
+curve	O
+on	O
+serum	B-COMP
+amyloid	B-DISO
+P	O
+component	O
+was	O
+0	O
+.	O
+854	O
+,	O
+the	O
+specificity	O
+was	O
+77	O
+.	O
+8	O
+%	O
+and	O
+the	O
+sensitivity	O
+was	O
+85	O
+.	O
+2	O
+%.	O
+
+CONCLUSIONS	O
+:	O
+There	O
+were	O
+differentially	O
+expressed	B-PROC
+serum	B-COMP
+proteins	B-CHED
+in	O
+three	O
+groups	O
+.	O
+
+The	O
+length	O
+of	O
+complete	O
+genome	O
+was	O
+28590	O
+nucletides	O
+,	O
+and	O
+was	O
+composed	O
+of	O
+7	O
+ORFs	O
+,	O
+which	O
+was	O
+flanked	O
+by	O
+untranslated	O
+regions	O
+(	O
+UTRs	O
+)	O
+with	O
+315	O
+bases	B-CHED
+at	O
+the	O
+5	O
+'-	O
+end	O
+and	O
+277	O
+bases	B-CHED
+at	O
+the	O
+3	O
+'-	O
+end	O
+.	O
+
+The	O
+CCoV	O
+-	O
+II	O
+strains	O
+were	O
+strictly	O
+related	O
+to	O
+porcine	B-DISO
+transmissible	I-DISO
+gastroenteritis	I-DISO
+virus	B-SPEC
+(	O
+TGEV	B-SPEC
+)	O
+in	O
+the	O
+N	O
+-	O
+terminal	O
+domain	O
+of	O
+the	O
+spike	O
+protein	B-CHED
+,	O
+whereas	O
+in	O
+the	O
+other	O
+parts	O
+of	O
+the	O
+genome	O
+,	O
+a	O
+higher	O
+genetic	O
+relatedness	O
+to	O
+recent	O
+CCoV	O
+-	O
+II	O
+isolates	O
+was	O
+observed	O
+.	O
+
+Here	O
+,	O
+we	O
+report	O
+the	O
+design	O
+,	O
+synthesis	B-PROC
+,	O
+and	O
+recovery	O
+of	O
+the	O
+largest	O
+synthetic	O
+replicating	O
+life	O
+form	O
+,	O
+a	O
+29	O
+.	O
+7	O
+-	O
+kb	O
+bat	B-ENZY
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+(	O
+SARS	B-DISO
+)-	O
+like	O
+coronavirus	B-SPEC
+(	O
+Bat	B-ENZY
+-	O
+SCoV	O
+),	O
+a	O
+likely	O
+progenitor	O
+to	O
+the	O
+SARS	B-PRGE
+-	I-PRGE
+CoV	I-PRGE
+epidemic	O
+.	O
+
+To	O
+test	O
+a	O
+possible	O
+route	O
+of	O
+emergence	O
+from	O
+the	O
+noncultivable	O
+Bat	O
+-	O
+SCoV	O
+to	O
+human	B-PRGE
+SARS	B-DISO
+-	I-PRGE
+CoV	I-PRGE
+,	O
+we	O
+designed	O
+a	O
+consensus	O
+Bat	B-ENZY
+-	O
+SCoV	O
+genome	O
+and	O
+replaced	O
+the	O
+Bat	B-PRGE
+-	I-PRGE
+SCoV	I-PRGE
+Spike	I-PRGE
+receptor	I-PRGE
+-	I-PRGE
+binding	B-FUNC
+domain	I-PRGE
+(	O
+RBD	O
+)	O
+with	O
+the	O
+SARS	B-PRGE
+-	I-PRGE
+CoV	I-PRGE
+RBD	I-PRGE
+(	O
+Bat	B-PRGE
+-	I-PRGE
+SRBD	I-PRGE
+).	O
+
+Serological	O
+results	O
+showed	O
+that	O
+the	O
+diagnostic	O
+sensitivity	O
+and	O
+specificity	O
+of	O
+the	O
+truncated	O
+S	O
+-	O
+N	O
+fusion	O
+protein	B-CHED
+derived	O
+the	O
+SARS	B-DISO
+virus	B-SPEC
+were	O
+>	O
+99	O
+%	O
+(	O
+457	O
+/	O
+460	O
+)	O
+and	O
+100	O
+.	O
+00	O
+%	O
+(	O
+650	O
+/	O
+650	O
+),	O
+respectively	O
+.	O
+
+Fluorescent	O
+quantitative	O
+RT	O
+-	O
+PCR	O
+showed	O
+that	O
+BALB	O
+/	O
+c	O
+mice	B-SPEC
+challenged	O
+intranasally	O
+with	O
+SARSCoV	O
+at	O
+day	O
+33	O
+post	O
+injection	O
+were	O
+completely	O
+protected	O
+from	O
+virus	B-PROC
+replication	I-PROC
+.	O
+
+The	O
+truncated	O
+S	B-PRGE
+-	I-PRGE
+N	I-PRGE
+fusion	I-PRGE
+protein	I-PRGE
+is	O
+a	O
+suitable	O
+immunodiagnostic	O
+antigen	B-CHED
+and	O
+vaccine	O
+candidate	O
+.	O
+
+These	O
+recombinant	O
+fragments	O
+were	O
+designed	O
+as	O
+parts	O
+of	O
+two	O
+different	O
+structural	O
+proteins	B-CHED
+from	O
+SARS	B-DISO
+-	I-DISO
+associated	I-DISO
+coronavirus	I-DISO
+(	O
+SARS	B-DISO
+-	O
+CoV	O
+).	O
+
+One	O
+recombinant	O
+polypeptide	B-CHED
+,	O
+S251	O
+-	O
+683	O
+,	O
+was	O
+designed	O
+as	O
+part	O
+of	O
+the	O
+spike	O
+glycoprotein	B-CHED
+,	O
+and	O
+the	O
+other	O
+three	O
+polypeptides	B-CHED
+comprised	O
+almost	O
+the	O
+whole	B-PRGE
+nucleocapsid	I-PRGE
+protein	B-CHED
+,	O
+avoiding	O
+the	O
+last	O
+25	O
+C	O
+-	O
+terminal	O
+amino	B-CHED
+acids	I-CHED
+.	O
+
+The	O
+degree	O
+of	O
+discomfort	B-DISO
+reported	O
+was	O
+2	O
+.	O
+54	O
+for	O
+swabs	O
+,	O
+2	O
+.	O
+63	O
+for	O
+washes	O
+,	O
+2	O
+.	O
+68	O
+for	O
+aspirates	B-ANAT
+and	O
+3	O
+.	O
+61	O
+for	O
+brushings	O
+.	O
+
+ABSTRACT	O
+:	O
+It	O
+has	O
+been	O
+suggested	O
+that	O
+antibody	B-COMP
+overproduction	O
+plays	O
+a	O
+role	O
+in	O
+the	O
+pathogenesis	B-DISO
+of	O
+feline	B-DISO
+infectious	I-DISO
+peritonitis	I-DISO
+(	O
+FIP	B-DISO
+).	O
+
+The	O
+present	O
+study	O
+shows	O
+that	O
+:	O
+(	O
+1	O
+)	O
+the	O
+ratio	O
+of	O
+peripheral	B-ANAT
+blood	I-ANAT
+sIg	O
+(+)	O
+CD21	O
+(-)	O
+B	B-ANAT
+-	I-ANAT
+cells	I-ANAT
+was	O
+higher	O
+in	O
+cats	B-SPEC
+with	O
+FIP	B-DISO
+than	O
+in	O
+SPF	O
+cats	B-SPEC
+,	O
+(	O
+2	O
+)	O
+the	O
+albumin	B-PRGE
+-	I-PRGE
+to	I-PRGE
+-	I-PRGE
+globulin	I-PRGE
+ratio	O
+has	O
+negative	O
+correlation	O
+with	O
+the	O
+ratio	O
+of	O
+peripheral	B-ANAT
+blood	I-ANAT
+sIg	O
+(+)	O
+CD21	O
+(-)	O
+B	B-ANAT
+-	I-ANAT
+cell	I-ANAT
+,	O
+(	O
+3	O
+)	O
+cells	B-COMP
+strongly	O
+expressing	O
+mRNA	B-CHED
+of	O
+the	O
+plasma	B-ANAT
+cell	I-ANAT
+master	O
+gene	O
+,	O
+B	B-ANAT
+-	I-ANAT
+lymphocyte	I-ANAT
+-	O
+induced	O
+maturation	B-PROC
+protein	B-CHED
+1	O
+(	O
+Blimp	O
+-	O
+1	O
+),	O
+were	O
+increased	O
+in	O
+peripheral	B-ANAT
+blood	I-ANAT
+in	O
+cats	B-SPEC
+with	O
+FIP	B-DISO
+,	O
+(	O
+4	O
+)	O
+mRNA	B-PROC
+expression	B-PROC
+of	O
+B	B-PROC
+-	I-PROC
+cell	I-PROC
+differentiation	I-PROC
+/	O
+survival	O
+factors	O
+,	O
+IL	B-FUNC
+-	I-FUNC
+6	I-FUNC
+,	O
+CD40	B-PRGE
+ligand	I-PRGE
+,	O
+and	O
+B	B-ANAT
+-	I-ANAT
+cell	I-ANAT
+-	O
+activating	O
+factor	O
+belonging	O
+to	O
+the	O
+tumor	B-PRGE
+necrosis	I-PRGE
+factor	I-PRGE
+family	B-SPEC
+(	O
+BAFF	B-PRGE
+),	O
+was	O
+enhanced	O
+in	O
+macrophages	B-ANAT
+in	O
+cats	B-SPEC
+with	O
+FIP	B-DISO
+,	O
+and	O
+(	O
+5	O
+)	O
+mRNAs	O
+of	O
+these	O
+B	B-PROC
+-	I-PROC
+cell	I-PROC
+differentiation	I-PROC
+/	O
+survival	O
+factors	O
+were	O
+overexpressed	O
+in	O
+antibody	B-COMP
+-	O
+dependent	O
+enhancement	O
+(	O
+ADE	B-CHED
+)-	O
+induced	O
+macrophages	B-ANAT
+.	O
+
+These	O
+data	O
+suggest	O
+that	O
+virus	B-SPEC
+-	O
+infected	O
+macrophages	B-ANAT
+overproduce	O
+B	B-PROC
+-	I-PROC
+cell	I-PROC
+differentiation	I-PROC
+/	O
+survival	O
+factors	O
+,	O
+and	O
+these	O
+factors	O
+act	O
+on	O
+B	B-ANAT
+-	I-ANAT
+cells	I-ANAT
+and	O
+promote	O
+B	B-PROC
+-	I-PROC
+cell	I-PROC
+differentiation	I-PROC
+into	O
+plasma	B-ANAT
+cells	I-ANAT
+in	O
+FIPV	O
+-	O
+infected	O
+cats	B-SPEC
+.	O
+
+ABSTRACT	O
+:	O
+Neutrophil	B-PRGE
+elastase	I-PRGE
+is	O
+believed	O
+to	O
+play	O
+an	O
+important	O
+role	O
+in	O
+acute	O
+lung	B-ANAT
+injury	O
+(	O
+ALI	O
+).	O
+
+Treatment	O
+with	O
+antibiotics	B-CHED
+and	O
+corticosteroids	B-CHED
+resulted	O
+in	O
+improvement	O
+of	O
+the	O
+clinical	B-DISO
+findings	I-DISO
+and	O
+successful	O
+weaning	B-PROC
+from	O
+mechanical	O
+ventilation	O
+.	O
+
+Phylogenetic	O
+analysis	O
+of	O
+the	O
+RNA	B-PRGE
+-	I-PRGE
+dependent	I-PRGE
+RNA	I-PRGE
+polymerase	I-PRGE
+gene	I-PRGE
+and	O
+helicase	B-PRGE
+confirmed	O
+them	O
+as	O
+group	O
+1	O
+coronaviruses	O
+.	O
+
+A	O
+38	O
+-	O
+year	O
+-	O
+old	O
+male	O
+who	O
+presented	O
+progressive	O
+symptoms	O
+of	O
+dysphagia	B-DISO
+,	O
+dysphonia	O
+and	O
+weakness	B-DISO
+hindering	O
+movement	B-PROC
+of	O
+the	O
+upper	B-ANAT
+limbs	I-ANAT
+.	O
+
+ABSTRACT	O
+:	O
+Over	O
+10	O
+mo	O
+,	O
+287	O
+mouse	B-SPEC
+litters	O
+were	O
+cross	O
+-	O
+fostered	O
+by	O
+using	O
+1	O
+of	O
+2	O
+paradigms	O
+to	O
+eliminate	O
+murine	B-SPEC
+norovirus	I-SPEC
+(	O
+MNV	O
+),	O
+Helicobacter	B-SPEC
+spp	B-ENZY
+.,	O
+murine	B-DISO
+hepatitis	I-DISO
+virus	B-SPEC
+(	O
+MHV	B-SPEC
+),	O
+and	O
+Syphacia	B-SPEC
+obvelata	I-SPEC
+.	O
+
+TITLE	O
+:	O
+Searching	O
+immunodominant	O
+epitopes	O
+prior	O
+to	O
+epidemic	O
+:	O
+HLA	B-ANAT
+class	B-SPEC
+II	O
+-	O
+restricted	O
+SARS	B-DISO
+-	I-PRGE
+CoV	I-PRGE
+spike	I-PRGE
+protein	B-CHED
+epitopes	I-PRGE
+in	O
+unexposed	O
+individuals	O
+.	O
+
+Small	O
+-	O
+angle	O
+X	O
+-	O
+ray	B-SPEC
+scattering	O
+data	O
+show	O
+that	O
+the	O
+protein	B-CHED
+is	O
+in	O
+an	O
+extended	O
+conformation	O
+and	O
+that	O
+the	O
+two	O
+structural	O
+domains	O
+of	O
+the	O
+SARS	B-PRGE
+-	I-PRGE
+CoV	I-PRGE
+N	I-PRGE
+protein	B-CHED
+are	O
+far	O
+apart	O
+.	O
+
+Although	O
+the	O
+N	O
+proteins	B-CHED
+of	O
+different	O
+coronaviruses	O
+share	O
+very	O
+low	O
+sequence	O
+homology	O
+,	O
+the	O
+physicochemical	O
+features	O
+described	O
+above	O
+may	O
+be	O
+conserved	O
+across	O
+different	O
+groups	O
+of	O
+Coronaviridae	B-SPEC
+.	O
+
+ABSTRACT	O
+:	O
+The	O
+nuclear	O
+magnetic	O
+resonance	O
+(	O
+NMR	O
+)	O
+structure	O
+of	O
+a	O
+central	O
+segment	O
+of	O
+the	O
+previously	O
+annotated	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+(	O
+SARS	B-DISO
+)-	O
+unique	O
+domain	O
+(	O
+SUD	O
+-	O
+M	O
+,	O
+for	O
+""""	O
+middle	O
+of	O
+the	O
+SARS	B-DISO
+-	O
+unique	O
+domain	O
+""")"	O
+in	O
+SARS	B-DISO
+coronavirus	B-SPEC
+(	O
+SARS	B-DISO
+-	O
+CoV	O
+)	O
+nonstructural	B-PRGE
+protein	I-PRGE
+3	I-PRGE
+(	O
+nsp3	B-PRGE
+)	O
+has	O
+been	O
+determined	O
+.	O
+
+SUD	O
+-	O
+M	O
+(	O
+527	O
+-	O
+651	O
+)	O
+also	O
+shows	O
+three	O
+-	O
+dimensional	O
+structure	O
+homology	O
+with	O
+several	O
+helicases	B-PRGE
+and	I-PRGE
+nucleoside	I-PRGE
+triphosphate	I-PRGE
+-	I-PRGE
+binding	B-FUNC
+proteins	B-CHED
+,	O
+but	O
+it	O
+does	O
+not	O
+contain	O
+the	O
+motifs	O
+of	O
+catalytic	O
+residues	O
+found	O
+in	O
+these	O
+structural	O
+homologues	O
+.	O
+
+These	O
+studies	O
+are	O
+revealing	O
+a	O
+rich	O
+set	O
+of	O
+novel	O
+viral	O
+proteins	B-CHED
+that	O
+engage	O
+,	O
+modify	O
+,	O
+and	O
+/	O
+or	O
+disrupt	O
+host	B-COMP
+cell	I-COMP
+signaling	O
+and	O
+nuclear	B-PROC
+import	I-PROC
+machinery	O
+for	O
+the	O
+benefit	O
+of	O
+virus	B-PROC
+replication	I-PROC
+.	O
+
+TITLE	O
+:	O
+Characteristic	O
+features	O
+and	O
+outcomes	O
+of	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+found	O
+in	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+intensive	O
+care	O
+unit	O
+patients	O
+.	O
+
+In	O
+a	O
+SARS	B-DISO
+ICU	O
+,	O
+patients	O
+with	O
+a	O
+confirmed	O
+diagnosis	O
+of	O
+SARS	B-DISO
+had	O
+significantly	O
+different	O
+clinical	O
+features	O
+and	O
+timing	O
+of	O
+mortality	O
+from	O
+those	O
+of	O
+the	O
+control	O
+group	O
+.	O
+
+RESULTS	O
+:	O
+Of	O
+the	O
+50	O
+patients	O
+,	O
+14	O
+had	O
+confirmed	O
+SARS	B-DISO
+.	O
+
+TITLE	O
+:	O
+Titration	O
+of	O
+human	B-SPEC
+coronaviruses	O
+,	O
+HcoV	B-SPEC
+-	I-SPEC
+229E	I-SPEC
+and	O
+HCoV	B-SPEC
+-	I-SPEC
+OC43	I-SPEC
+,	O
+by	O
+an	O
+indirect	O
+immunoperoxidase	O
+assay	O
+.	O
+
+After	O
+viral	O
+growth	B-PROC
+,	O
+viral	O
+detection	O
+by	O
+IPA	B-CHED
+yields	O
+the	O
+infectious	B-DISO
+virus	B-SPEC
+titer	O
+,	O
+expressed	B-PROC
+as	O
+""""	O
+Tissue	B-ANAT
+Culture	O
+Infectious	B-DISO
+Dose	O
+""""	O
+(	O
+TCID50	O
+).	O
+
+In	O
+this	O
+chapter	O
+we	O
+describe	O
+a	O
+two	O
+-	O
+step	O
+conventional	O
+RT	O
+-	O
+PCR	O
+and	O
+a	O
+one	O
+-	O
+step	O
+quantitative	O
+RT	O
+-	O
+PCR	O
+that	O
+were	O
+used	O
+routinely	O
+in	O
+our	O
+laboratories	O
+during	O
+the	O
+SARS	B-DISO
+outbreak	O
+.	O
+
+ABSTRACT	O
+:	O
+Group	O
+2a	O
+of	O
+the	O
+Coronaviridae	B-SPEC
+family	B-SPEC
+contains	O
+human	B-SPEC
+and	O
+animal	B-SPEC
+pathogens	O
+that	O
+include	O
+mouse	B-DISO
+hepatitis	I-DISO
+virus	B-SPEC
+,	O
+rat	B-SPEC
+coronavirus	B-SPEC
+,	O
+human	B-SPEC
+respiratory	O
+coronaviruses	O
+OC43	O
+and	O
+the	O
+recently	O
+identified	O
+HKU1	O
+strain	O
+,	O
+a	O
+newly	O
+recognized	O
+canine	O
+respiratory	O
+coronavirus	B-SPEC
+,	O
+porcine	B-SPEC
+hemagglutinating	O
+encephalomyelitis	B-DISO
+virus	B-SPEC
+,	O
+equine	B-SPEC
+coronavirus	B-SPEC
+,	O
+bovine	B-SPEC
+coronavirus	B-SPEC
+(	O
+BCoV	O
+),	O
+and	O
+wild	O
+-	O
+ruminant	B-SPEC
+coronaviruses	O
+.	O
+
+We	O
+have	O
+developed	O
+and	O
+optimized	O
+laboratory	O
+diagnostic	O
+techniques	O
+,	O
+including	O
+virus	B-SPEC
+isolation	O
+in	O
+HRT	O
+-	O
+18	O
+cell	B-COMP
+cultures	O
+,	O
+antibody	B-COMP
+and	O
+antigen	B-CHED
+ELISA	O
+,	O
+and	O
+RT	O
+-	O
+PCR	O
+,	O
+for	O
+rapid	O
+,	O
+sensitive	O
+,	O
+and	O
+reliable	O
+diagnosis	O
+of	O
+BCoV	O
+and	O
+related	O
+wild	O
+ruminant	B-SPEC
+coronaviruses	O
+.	O
+
+The	O
+gene	O
+1	O
+primer	O
+pair	O
+enabled	O
+the	O
+detection	O
+of	O
+a	O
+new	O
+coronavirus	B-SPEC
+in	O
+a	O
+green	O
+-	O
+checked	O
+Amazon	B-SPEC
+parrot	I-SPEC
+(	O
+Amazon	B-SPEC
+viridigenalis	O
+Cassin	O
+).	O
+
+Transmissible	O
+gastroenteritis	B-DISO
+virus	B-SPEC
+(	O
+TGEV	B-SPEC
+),	O
+a	O
+group	O
+1	O
+coronavirus	B-SPEC
+,	O
+infects	O
+the	O
+porcine	B-SPEC
+small	B-ANAT
+intestine	I-ANAT
+.	O
+
+Because	O
+of	O
+the	O
+reactivity	O
+with	O
+specific	O
+lectins	O
+we	O
+assume	O
+that	O
+the	O
+recognized	O
+glycoprotein	B-CHED
+has	O
+the	O
+characteristics	O
+of	O
+a	O
+mucin	B-PRGE
+.	O
+
+TITLE	O
+:	O
+Engineering	O
+infectious	B-DISO
+cDNAs	O
+of	O
+coronavirus	B-SPEC
+as	O
+bacterial	O
+artificial	O
+chromosomes	B-COMP
+.	O
+
+ABSTRACT	O
+:	O
+The	O
+construction	O
+of	O
+coronavirus	O
+(	O
+CoV	B-SPEC
+)	O
+infectious	B-DISO
+clones	O
+had	O
+been	O
+hampered	O
+by	O
+the	O
+large	O
+size	O
+of	O
+the	O
+viral	B-COMP
+genome	I-COMP
+(	O
+around	O
+30kb	O
+)	O
+and	O
+the	O
+instability	O
+of	O
+plasmids	O
+carrying	O
+CoV	B-PRGE
+replicase	I-PRGE
+sequences	I-PRGE
+in	O
+Escherichia	B-SPEC
+coli	I-SPEC
+.	O
+
+ABSTRACT	O
+:	O
+Coronavirus	B-SPEC
+reverse	O
+genetic	O
+systems	O
+have	O
+become	O
+valuable	O
+tools	O
+for	O
+studying	O
+the	O
+molecular	O
+biology	O
+of	O
+coronavirus	B-DISO
+infections	I-DISO
+.	O
+
+Here	O
+we	O
+provide	O
+a	O
+collection	O
+of	O
+protocols	O
+for	O
+the	O
+generation	O
+,	O
+cloning	O
+,	O
+and	O
+modification	O
+of	O
+full	O
+-	O
+length	O
+coronavirus	B-SPEC
+cDNA	O
+using	O
+vaccinia	B-SPEC
+virus	I-SPEC
+as	O
+a	O
+cloning	O
+vector	O
+.	O
+
+Additional	O
+mutations	O
+created	O
+in	O
+the	O
+donor	B-CHED
+RNA	O
+can	O
+be	O
+co	O
+-	O
+incorporated	O
+into	O
+the	O
+recombinant	O
+virus	B-SPEC
+in	O
+order	B-SPEC
+to	O
+generate	O
+mutant	B-DISO
+viruses	B-SPEC
+.	O
+
+ABSTRACT	O
+:	O
+Immunological	O
+detection	O
+of	O
+viruses	O
+and	O
+their	O
+components	O
+by	O
+monoclonal	O
+antibodies	B-COMP
+is	O
+a	O
+powerful	O
+method	O
+for	O
+studying	O
+the	O
+structure	O
+and	O
+function	O
+of	O
+viral	O
+molecules	O
+.	O
+
+In	O
+addition	O
+to	O
+this	O
+role	O
+,	O
+IBV	B-SPEC
+E	O
+may	O
+also	O
+function	O
+as	O
+a	O
+viroporin	O
+,	O
+although	O
+no	O
+data	O
+from	O
+infected	O
+cells	B-COMP
+have	O
+confirmed	O
+this	O
+possibility	O
+definitively	O
+.	O
+
+This	O
+chapter	O
+details	O
+methods	O
+for	O
+generating	O
+and	O
+screening	O
+antibodies	B-COMP
+to	O
+these	O
+gene	B-PRGE
+3	I-PRGE
+proteins	I-PRGE
+.	O
+
+TITLE	O
+:	O
+Production	O
+of	O
+coronavirus	B-SPEC
+nonstructural	O
+proteins	B-CHED
+in	O
+soluble	O
+form	O
+for	O
+crystallization	O
+.	O
+
+However	O
+,	O
+to	O
+work	O
+with	O
+highly	O
+contagious	O
+pathogens	O
+,	O
+it	O
+is	O
+necessary	O
+to	O
+take	O
+precautions	O
+against	O
+laboratory	O
+-	O
+acquired	O
+infection	B-DISO
+.	O
+
+In	O
+general	O
+,	O
+the	O
+potency	O
+of	O
+new	O
+ATCs	B-DISO
+was	O
+better	O
+than	O
+that	O
+of	O
+the	O
+first	O
+series	O
+and	O
+O	O
+-[	O
+2	O
+-	O
+phthalimidoethyl	O
+]	O
+4	O
+-	O
+chlorophenyl	O
+(	O
+3	O
+-	O
+nitrobenzoyl	O
+)	O
+thiocarbamate	O
+turned	O
+out	O
+to	O
+be	O
+the	O
+most	O
+potent	O
+ATC	O
+so	O
+far	O
+synthesized	O
+(	O
+EC	O
+(	O
+50	O
+)=	O
+1	O
+.	O
+5nM	O
+).	O
+
+Also	O
+,	O
+greater	O
+amounts	O
+of	O
+collagen	B-COMP
+had	O
+accumulated	O
+in	O
+lung	B-ANAT
+tissue	I-ANAT
+in	O
+the	O
+Gln	B-CHED
+group	O
+.	O
+
+These	O
+results	O
+were	O
+consistent	O
+with	O
+the	O
+histopathological	O
+findings	O
+that	O
+Gln	B-CHED
+supplementation	O
+causes	O
+more	O
+severe	O
+interstitial	B-DISO
+inflammation	I-DISO
+and	O
+fibrosis	B-DISO
+in	O
+a	O
+model	O
+of	O
+ALI	O
+induced	O
+by	O
+LPS	B-DISO
+.	O
+
+Burned	O
+patients	O
+with	O
+ARDS	B-DISO
+but	O
+without	O
+inhalation	B-PROC
+injury	O
+had	O
+significant	O
+temporal	O
+improvement	O
+in	O
+the	O
+oxygenation	B-PROC
+index	O
+from	O
+27	O
++/-	O
+
+Delivery	O
+of	O
+nebulized	O
+bronchodilators	O
+,	O
+heparin	B-CHED
+and	O
+n	O
+-	O
+acetyl	B-CHED
+cysteine	B-CHED
+,	O
+normally	O
+mainstays	O
+of	O
+smoke	O
+inhalation	B-PROC
+therapy	O
+,	O
+was	O
+impossible	O
+during	O
+HFOV	O
+.	O
+
+Severe	O
+hypercapnia	B-DISO
+tended	O
+to	O
+be	O
+more	O
+frequent	O
+during	O
+HFOV	O
+among	O
+patients	O
+with	O
+smoke	O
+inhalation	B-PROC
+.	O
+
+TITLE	O
+:	O
+Acute	B-DISO
+respiratory	I-DISO
+failure	I-DISO
+due	O
+to	O
+refeeding	B-DISO
+syndrome	I-DISO
+and	O
+hypophosphatemia	B-DISO
+induced	O
+by	O
+hypocaloric	O
+enteral	O
+nutrition	O
+.	O
+
+In	O
+chronically	O
+malnourished	B-DISO
+patients	O
+undergoing	O
+nutritional	O
+support	O
+,	O
+even	O
+hypocaloric	O
+feeding	O
+should	O
+be	O
+considered	O
+a	O
+risk	O
+factor	O
+for	O
+developing	O
+refeeding	O
+syndrome	O
+leading	O
+to	O
+severe	O
+and	O
+acute	O
+electrolyte	O
+fluid	O
+-	O
+balance	B-PROC
+and	O
+metabolic	B-PROC
+abnormalities	O
+.	O
+
+This	O
+study	O
+evaluated	O
+a	O
+new	O
+multiplex	O
+PCR	O
+assay	O
+(	O
+Seegene	O
+Inc	O
+.,	O
+Seoul	O
+,	O
+Korea	O
+)	O
+for	O
+simultaneous	O
+detection	O
+and	O
+identification	O
+of	O
+12	O
+respiratory	O
+viruses	B-SPEC
+using	O
+two	O
+primer	O
+mixes	O
+.	O
+
+We	O
+determined	O
+the	O
+malnutrition	B-DISO
+-	O
+attributable	O
+fractions	O
+among	O
+children	O
+admitted	O
+to	O
+a	O
+rural	O
+district	O
+hospital	O
+in	O
+Kenya	O
+,	O
+among	O
+inpatient	O
+deaths	B-PROC
+and	O
+among	O
+children	O
+with	O
+the	O
+major	O
+causes	O
+of	O
+severe	O
+disease	O
+.	O
+
+This	O
+contribution	O
+is	O
+underestimated	O
+by	O
+using	O
+conventional	O
+clinical	O
+definitions	O
+of	O
+severe	B-DISO
+malnutrition	I-DISO
+.	O
+
+Two	O
+-	O
+hundred	O
+and	O
+ninety	O
+-	O
+four	O
+specimens	O
+from	O
+42	O
+men	O
+who	O
+tested	O
+positive	O
+for	O
+HPV	O
+-	O
+16	O
+at	O
+one	O
+or	O
+more	O
+anatomic	B-ANAT
+sites	I-ANAT
+were	O
+evaluated	O
+.	O
+
+HPV	O
+-	O
+16	O
+viral	O
+load	O
+was	O
+positively	O
+correlated	O
+between	O
+proximal	O
+anatomic	B-ANAT
+sites	I-ANAT
+:	O
+perianal	B-ANAT
+and	O
+anal	B-ANAT
+canal	I-ANAT
+(	O
+P	O
+=	O
+0	O
+.	O
+003	O
+),	O
+perianal	B-ANAT
+and	O
+scrotum	B-ANAT
+(	O
+P	O
+=	O
+0	O
+.	O
+011	O
+),	O
+scrotum	B-ANAT
+and	O
+glans	O
+/	O
+corona	B-CHED
+(	O
+P	O
+=	O
+0	O
+.	O
+045	O
+),	O
+and	O
+scrotum	B-ANAT
+and	O
+penile	B-ANAT
+shaft	O
+(	O
+P	O
+=	O
+0	O
+.	O
+037	O
+).	O
+
+In	O
+conclusion	O
+,	O
+the	O
+penile	B-ANAT
+shaft	O
+seemed	O
+to	O
+be	O
+the	O
+preferred	O
+site	O
+for	O
+HPV	O
+-	O
+16	O
+viral	B-PROC
+replication	I-PROC
+.	O
+
+TITLE	O
+:	O
+SCHOOL	O
+model	O
+and	O
+new	O
+targeting	B-PROC
+strategies	O
+.	O
+
+Thus	O
+,	O
+an	O
+important	O
+application	O
+of	O
+the	O
+SCHOOL	O
+model	O
+is	O
+that	O
+global	O
+therapeutic	O
+strategies	O
+targeting	B-PROC
+key	O
+protein	B-CHED
+-	O
+protein	B-CHED
+interactions	O
+involved	O
+in	O
+MIRR	O
+triggering	O
+and	O
+transmembrane	B-COMP
+signal	B-PROC
+transduction	I-PROC
+may	O
+be	O
+used	O
+to	O
+treat	O
+a	O
+diverse	O
+set	O
+of	O
+immune	O
+-	O
+mediated	O
+diseases	O
+.	O
+
+It	O
+also	O
+demonstrates	O
+how	O
+the	O
+lessons	O
+learned	B-PROC
+from	O
+viral	B-DISO
+pathogenesis	I-DISO
+can	O
+be	O
+used	O
+practically	O
+for	O
+rational	O
+drug	O
+design	O
+.	O
+
+From	O
+launching	O
+the	O
+SARS	B-DISO
+Supporting	O
+Line	O
+,	O
+distributing	O
+health	O
+promotional	O
+material	O
+,	O
+disseminating	O
+SARS	B-DISO
+related	O
+information	O
+,	O
+paying	O
+tribute	O
+to	O
+frontline	O
+health	O
+workers	O
+,	O
+and	O
+promoting	O
+local	O
+business	O
+,	O
+to	O
+fundraising	O
+for	O
+SARS	B-DISO
+related	O
+research	O
+;	O
+they	O
+played	O
+an	O
+active	O
+role	O
+in	O
+easing	O
+the	O
+public	O
+'	O
+s	O
+anxiety	O
+,	O
+especially	O
+for	O
+the	O
+Chinese	O
+-	O
+Canadians	O
+in	O
+the	O
+great	O
+Toronto	O
+area	O
+.	O
+
+The	O
+Chinese	O
+-	O
+Canadian	O
+community	O
+organizations	O
+'	O
+activities	O
+during	O
+the	O
+SARS	B-DISO
+outbreak	O
+demonstrate	O
+that	O
+ethnic	O
+minority	O
+organizations	O
+can	O
+play	O
+an	O
+important	O
+role	O
+in	O
+public	O
+health	O
+,	O
+especially	O
+in	O
+a	O
+public	O
+health	O
+crisis	O
+,	O
+and	O
+beyond	O
+.	O
+
+ABSTRACT	O
+:	O
+Infectious	B-DISO
+Bronchitis	B-DISO
+Virus	B-SPEC
+,	O
+a	O
+member	O
+of	O
+the	O
+Coronaviridae	B-SPEC
+,	O
+is	O
+a	O
+respiratory	O
+pathogen	O
+in	O
+poultry	O
+.	O
+
+We	O
+found	O
+that	O
+in	O
+vitro	O
+stimulation	O
+with	O
+IBV	B-SPEC
+resulted	O
+in	O
+ChIFN	B-PRGE
+-	I-PRGE
+gamma	I-PRGE
+production	O
+in	O
+splenocytes	O
+of	O
+both	O
+infected	O
+birds	B-SPEC
+and	O
+uninfected	O
+birds	B-SPEC
+.	O
+
+The	O
+aim	O
+of	O
+the	O
+present	O
+study	O
+was	O
+to	O
+examine	O
+the	O
+2003	O
+severe	O
+acute	O
+respiratory	O
+syndrome	O
+(	O
+SARS	B-DISO
+)	O
+crisis	O
+in	O
+relation	O
+to	O
+the	O
+degree	O
+of	O
+knowledge	O
+sharing	O
+and	O
+professional	O
+commitment	O
+,	O
+as	O
+perceived	O
+by	O
+the	O
+current	O
+nursing	B-PROC
+staff	O
+in	O
+Taiwan	O
+.	O
+
+Hospitals	O
+and	O
+healthcare	O
+services	O
+can	O
+enhance	O
+retention	B-PROC
+of	O
+medical	O
+personnel	O
+by	O
+encouraging	O
+knowledge	O
+sharing	O
+,	O
+which	O
+enhances	O
+professional	O
+commitment	O
+and	O
+alleviates	O
+the	O
+impact	O
+of	O
+newly	O
+introduced	O
+contagious	B-DISO
+diseases	I-DISO
+.	O
+
+RESULTS	O
+:	O
+The	O
+results	O
+showed	O
+that	O
+knowledge	O
+sharing	O
+correlated	O
+positively	O
+with	O
+professional	O
+commitment	O
+but	O
+negatively	O
+with	O
+the	O
+impact	O
+of	O
+SARS	B-DISO
+.	O
+
+CONCLUSIONS	O
+:	O
+This	O
+cross	O
+-	O
+sectional	O
+study	O
+provides	O
+preliminary	O
+evidence	O
+that	O
+knowledge	O
+sharing	O
+is	O
+significantly	O
+correlated	O
+with	O
+impact	O
+of	O
+SARS	B-DISO
+and	O
+professional	O
+commitment	O
+of	O
+nursing	B-PROC
+personnel	O
+.	O
+
+Despite	O
+increased	O
+viral	O
+loads	O
+,	O
+the	O
+expression	B-PROC
+of	O
+multiple	O
+proinflammatory	O
+cytokines	O
+and	O
+chemokines	O
+within	O
+lung	B-ANAT
+tissue	I-ANAT
+and	O
+recruitment	B-DISO
+of	O
+inflammatory	O
+monocytes	B-ANAT
+/	O
+macrophages	B-ANAT
+to	O
+the	O
+lung	B-ANAT
+was	O
+severely	O
+impaired	B-DISO
+in	O
+MyD88	O
+(-/-)	O
+mice	B-SPEC
+compared	O
+to	O
+wild	O
+-	O
+type	O
+mice	B-SPEC
+.	O
+
+Furthermore	O
+,	O
+mice	B-SPEC
+deficient	O
+in	O
+chemokine	O
+receptors	O
+that	O
+contribute	O
+to	O
+monocyte	B-ANAT
+recruitment	B-DISO
+to	O
+the	O
+lung	B-ANAT
+were	O
+more	O
+susceptible	O
+to	O
+rMA15	O
+-	O
+induced	O
+disease	O
+and	O
+exhibited	O
+severe	O
+lung	B-ANAT
+pathology	B-DISO
+similar	O
+to	O
+that	O
+seen	O
+in	O
+MyD88	O
+(-/-)	O
+mice	B-SPEC
+.	O
+
+ABSTRACT	O
+:	O
+Fulminant	O
+viral	B-DISO
+hepatitis	I-DISO
+(	O
+FH	O
+)	O
+remains	O
+an	O
+important	O
+clinical	O
+problem	O
+in	O
+which	O
+the	O
+underlying	O
+pathogenesis	B-DISO
+is	O
+not	O
+well	O
+understood	O
+.	O
+
+The	O
+objective	O
+of	O
+this	O
+study	O
+was	O
+to	O
+determine	O
+the	O
+pathogenicity	O
+of	O
+5	O
+nonvaccine	O
+-	O
+related	O
+IBV	B-SPEC
+isolates	O
+recovered	O
+from	O
+the	O
+sentinel	O
+birds	B-SPEC
+.	O
+
+Based	O
+on	O
+sequences	O
+of	O
+part	O
+of	O
+the	O
+S1	B-PRGE
+gene	I-PRGE
+IBV	I-PRGE
+-	I-PRGE
+ON2	I-PRGE
+,	O
+IBV	B-SPEC
+-	O
+ON3	O
+,	O
+and	O
+IBV	B-SPEC
+-	O
+ON5	O
+formed	O
+a	O
+cluster	O
+and	O
+they	O
+were	O
+closely	O
+related	O
+to	O
+strain	O
+CU	O
+-	O
+82792	O
+.	O
+
+ABSTRACT	O
+:	O
+We	O
+have	O
+developed	O
+a	O
+real	O
+-	O
+time	O
+reverse	B-PROC
+transcription	I-PROC
+-	O
+PCR	O
+(	O
+RT	O
+-	O
+PCR	O
+)	O
+method	O
+to	O
+detect	O
+13	O
+respiratory	O
+viruses	B-SPEC
+:	O
+influenza	B-SPEC
+virus	I-SPEC
+A	O
+and	O
+B	O
+;	O
+respiratory	B-SPEC
+syncytial	I-SPEC
+virus	I-SPEC
+(	O
+RSV	B-SPEC
+)	O
+subgroup	O
+A	O
+and	O
+B	O
+;	O
+parainfluenza	B-DISO
+virus	B-SPEC
+(	O
+PIV	O
+)	O
+1	O
+,	O
+2	O
+,	O
+and	O
+3	O
+;	O
+adenovirus	B-DISO
+;	O
+rhinovirus	B-SPEC
+(	O
+RV	O
+);	O
+enterovirus	B-SPEC
+;	O
+coronavirus	B-SPEC
+(	O
+OC43	O
+);	O
+human	B-SPEC
+metapneumovirus	I-SPEC
+(	O
+hMPV	B-SPEC
+);	O
+and	O
+human	B-SPEC
+bocavirus	I-SPEC
+(	O
+HBoV	O
+).	O
+
+The	O
+new	O
+method	O
+for	O
+detection	O
+of	O
+these	O
+viruses	B-SPEC
+was	O
+applied	O
+simultaneously	O
+with	O
+real	O
+-	O
+time	O
+PCR	O
+for	O
+the	O
+detection	O
+of	O
+six	O
+bacterial	O
+pathogens	O
+in	O
+clinical	O
+samples	O
+from	O
+1700	O
+pediatric	O
+patients	O
+with	O
+community	O
+-	O
+acquired	O
+pneumonia	B-DISO
+(	O
+CAP	B-DISO
+).	O
+
+She	O
+died	B-PROC
+two	O
+weeks	O
+after	O
+hospital	O
+admission	O
+due	O
+to	O
+acute	B-DISO
+respiratory	I-DISO
+failure	I-DISO
+.	O
+
+After	O
+dechallenge	O
+of	O
+minocyclin	O
+,	O
+neurological	B-DISO
+symptoms	I-DISO
+quickly	O
+subsided	O
+.	O
+
+The	O
+IBV	B-SPEC
+strains	O
+in	O
+Taiwan	O
+were	O
+clustered	O
+into	O
+two	O
+groups	O
+,	O
+Taiwan	O
+group	O
+I	O
+and	O
+Taiwan	O
+group	O
+II	O
+,	O
+based	O
+on	O
+the	O
+S1	B-PRGE
+gene	I-PRGE
+.	O
+
+IL	B-FUNC
+-	I-FUNC
+15	I-FUNC
+deficiency	O
+also	O
+had	O
+no	O
+affect	O
+on	O
+IL	B-PRGE
+-	I-PRGE
+7	I-PRGE
+receptor	I-PRGE
+(	O
+CD127	B-PRGE
+)	O
+expression	B-PROC
+,	O
+Bcl	B-PRGE
+-	I-PRGE
+2	I-PRGE
+upregulation	B-PROC
+,	O
+granzyme	B-PRGE
+B	I-PRGE
+expression	B-PROC
+,	O
+or	O
+IFN	B-PROC
+-	I-PROC
+gamma	I-PROC
+secretion	B-ANAT
+in	O
+CNS	B-CHED
+persisting	O
+CD8	O
+(+)	O
+T	B-ANAT
+cells	I-ANAT
+.	O
+
+Finally	O
+,	O
+GSK	B-PRGE
+-	I-PRGE
+3	I-PRGE
+inhibitor	B-CHED
+was	O
+found	O
+to	O
+reduce	O
+N	O
+phosphorylation	B-PROC
+in	O
+the	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+CoV	O
+-	O
+infected	O
+VeroE6	O
+cells	B-COMP
+and	O
+decrease	O
+the	O
+viral	O
+titer	O
+and	O
+cytopathic	B-DISO
+effects	I-DISO
+.	O
+
+ECMO	O
+allowed	O
+epinephrine	B-CHED
+and	O
+norepinephrine	B-CHED
+to	O
+be	O
+progressively	O
+discontinued	O
+,	O
+and	O
+protective	O
+mechanical	O
+ventilation	O
+.	O
+
+ECMO	O
+withdrawal	B-DISO
+was	O
+possible	O
+at	O
+D9	O
+,	O
+with	O
+milrinone	B-CHED
+as	O
+the	O
+sole	B-ANAT
+inotropic	O
+agent	O
+.	O
+
+These	O
+findings	O
+indicate	O
+that	O
+lung	B-DISO
+edema	I-DISO
+in	O
+SARS	B-DISO
+infection	B-DISO
+may	O
+be	O
+due	O
+at	O
+least	O
+in	O
+part	O
+to	O
+activation	O
+of	O
+PKC	B-DISO
+by	O
+SARS	B-DISO
+proteins	B-CHED
+,	O
+leading	O
+to	O
+decreasing	O
+levels	O
+and	O
+activity	O
+of	O
+ENaC	B-PRGE
+at	O
+the	O
+apical	O
+surfaces	O
+of	O
+lung	B-ANAT
+epithelial	B-ANAT
+cells	I-ANAT
+.	O
+
+Mild	O
+-	O
+risk	O
+(	O
+hazard	O
+ratio	O
+[	O
+HR	O
+]	O
+1	O
+.	O
+8	O
+;	O
+95	O
+%	O
+confidence	O
+interval	O
+[	O
+CI	O
+]	O
+1	O
+.	O
+1	O
+-	O
+2	O
+.	O
+9	O
+;	O
+p	O
+<	O
+0	O
+.	O
+05	O
+),	O
+high	O
+-	O
+risk	O
+(	O
+HR	O
+3	O
+.	O
+1	O
+;	O
+95	O
+%	O
+CI	O
+=	O
+2	O
+.	O
+0	O
+-	O
+4	O
+.	O
+7	O
+;	O
+p	O
+<	O
+0	O
+.	O
+001	O
+),	O
+and	O
+very	O
+high	O
+risk	O
+levels	O
+(	O
+HR	O
+6	O
+.	O
+3	O
+;	O
+95	O
+%	O
+CI	O
+=	O
+4	O
+.	O
+2	O
+-	O
+9	O
+.	O
+4	O
+;	O
+p	O
+<	O
+0	O
+.	O
+001	O
+)	O
+were	O
+significantly	O
+associated	O
+with	O
+higher	O
+risk	O
+of	O
+death	B-PROC
+in	O
+Cox	O
+proportional	O
+hazards	O
+regression	O
+analysis	O
+.	O
+
+Furthermore	O
+,	O
+PIRO	O
+score	O
+also	O
+is	O
+associated	O
+with	O
+increased	O
+healthcare	O
+resource	O
+utilization	O
+in	O
+CAP	B-DISO
+patients	O
+admitted	O
+in	O
+the	O
+ICU	O
+.	O
+
+To	O
+explore	O
+the	O
+correlation	O
+between	O
+different	O
+types	O
+of	O
+FCoV	O
+and	O
+FIP	B-DISO
+,	O
+clinical	O
+specimens	O
+collected	O
+from	O
+363	O
+naturally	O
+infected	O
+cats	B-SPEC
+during	O
+2003	O
+-	O
+2007	O
+were	O
+analyzed	O
+.	O
+
+Irrespective	O
+of	O
+the	O
+predominance	O
+of	O
+type	O
+I	O
+FCoV	O
+infection	B-DISO
+in	O
+Taiwan	O
+,	O
+type	O
+II	O
+FCoV	O
+demonstrated	O
+a	O
+significantly	O
+higher	O
+correlation	O
+with	O
+FIP	B-DISO
+(	O
+p	O
+<	O
+0	O
+.	O
+01	O
+).	O
+
+Accordingly	O
+,	O
+a	O
+preliminary	O
+report	O
+of	O
+our	O
+experience	O
+of	O
+suspected	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+-	O
+associated	O
+coronavirus	B-DISO
+infections	I-DISO
+in	O
+children	O
+was	O
+published	O
+without	O
+microbiological	O
+findings	O
+.	O
+
+To	O
+investigate	O
+the	O
+mechanism	O
+of	O
+SARS	B-DISO
+-	O
+CoV	O
+assembly	O
+,	O
+we	O
+cloned	O
+the	O
+genes	O
+encoding	O
+these	O
+four	O
+proteins	B-CHED
+into	O
+the	O
+eukaryotic	O
+expression	B-PROC
+vector	O
+pCAGGS	O
+and	O
+transfected	O
+them	O
+into	O
+293T	O
+cells	B-COMP
+.	O
+
+TITLE	O
+:	O
+Existence	O
+of	O
+avian	B-DISO
+infectious	I-DISO
+bronchitis	I-DISO
+virus	B-SPEC
+with	O
+a	O
+European	O
+-	O
+prevalent	O
+4	O
+/	O
+91	O
+genotype	O
+in	O
+Japan	O
+.	O
+
+These	O
+IBV	B-SPEC
+isolates	O
+were	O
+classified	O
+into	O
+three	O
+genetic	O
+groups	O
+,	O
+including	O
+two	O
+that	O
+have	O
+already	O
+been	O
+reported	O
+(	O
+JP	O
+-	O
+I	O
+and	O
+JP	B-PRGE
+-	I-PRGE
+III	I-PRGE
+).	O
+
+TITLE	O
+:	O
+Induction	O
+of	O
+proinflammatory	O
+cytokines	O
+in	O
+primary	O
+human	B-SPEC
+macrophages	B-ANAT
+by	O
+influenza	B-SPEC
+A	I-SPEC
+virus	I-SPEC
+(	O
+H5N1	B-DISO
+)	O
+is	O
+selectively	O
+regulated	O
+by	O
+IFN	B-PRGE
+regulatory	I-PRGE
+factor	I-PRGE
+3	I-PRGE
+and	O
+p38	B-PRGE
+MAPK	B-FUNC
+.	O
+
+In	O
+comparison	O
+with	O
+human	B-DISO
+influenza	I-DISO
+(	O
+H1N1	O
+),	O
+the	O
+H5N1	B-DISO
+virus	B-SPEC
+more	O
+strongly	O
+activated	O
+IFN	B-PRGE
+regulatory	I-PRGE
+factor	I-PRGE
+3	I-PRGE
+(	O
+IRF3	B-PRGE
+).	O
+
+Generation	O
+of	O
+bone	B-ANAT
+marrow	I-ANAT
+-	O
+chimeric	O
+mice	B-SPEC
+expressing	O
+the	O
+type	B-PRGE
+I	I-PRGE
+IFN	I-PRGE
+receptor	I-PRGE
+(	O
+IFNAR	B-PRGE
+)	O
+on	O
+either	O
+hemopoietic	O
+or	O
+non	O
+-	O
+bone	B-ANAT
+marrow	I-ANAT
+-	O
+derived	O
+cells	B-COMP
+revealed	O
+that	O
+the	O
+early	O
+control	O
+of	O
+MHV	B-SPEC
+depended	O
+mainly	O
+on	O
+IFNAR	B-PRGE
+expression	B-PROC
+on	O
+hemopoietic	O
+cells	B-COMP
+.	O
+
+This	O
+genetic	O
+analysis	O
+revealed	O
+that	O
+IFNAR	B-PRGE
+expression	B-PROC
+on	O
+LysM	O
++	O
+macrophages	B-ANAT
+and	O
+CD11c	O
++	O
+dendritic	B-ANAT
+cells	B-COMP
+was	O
+most	O
+important	O
+for	O
+the	O
+early	O
+containment	O
+of	O
+MHV	B-SPEC
+within	O
+secondary	B-ANAT
+lymphoid	I-ANAT
+organs	I-ANAT
+and	O
+to	O
+prevent	O
+lethal	O
+liver	B-DISO
+disease	I-DISO
+.	O
+
+Here	O
+we	O
+report	O
+the	O
+3D	O
+virion	B-COMP
+structure	O
+of	O
+coronaviruses	O
+obtained	O
+by	O
+cryo	O
+-	O
+electron	O
+tomography	O
+.	O
+
+MHV	B-SPEC
+particles	O
+have	O
+a	O
+distinctly	O
+spherical	O
+shape	O
+and	O
+a	O
+relatively	O
+homogenous	O
+size	O
+(	O
+approximately	O
+85	O
+nm	O
+envelope	B-COMP
+diameter	O
+).	O
+
+Instead	O
+,	O
+the	O
+ribonucleoprotein	B-COMP
+seems	O
+to	O
+be	O
+extensively	O
+folded	O
+onto	O
+itself	O
+,	O
+assuming	O
+a	O
+compact	O
+structure	O
+that	O
+tends	O
+to	O
+closely	O
+follow	O
+the	O
+envelope	B-COMP
+at	O
+a	O
+distance	O
+of	O
+approximately	O
+4	O
+nm	O
+.	O
+
+The	O
+questionnaire	O
+focused	O
+on	O
+perceived	O
+threat	O
+,	O
+vulnerability	O
+,	O
+severity	O
+,	O
+response	O
+efficacy	O
+,	O
+and	O
+self	O
+-	O
+efficacy	O
+related	O
+to	O
+SARS	B-DISO
+and	O
+eight	O
+other	O
+diseases	O
+.	O
+
+Response	O
+efficacy	O
+and	O
+self	O
+-	O
+efficacy	O
+for	O
+SARS	B-DISO
+were	O
+higher	O
+in	O
+Asia	O
+compared	O
+to	O
+Europe	O
+.	O
+
+One	O
+patient	O
+with	O
+coma	B-DISO
+died	B-PROC
+due	O
+to	O
+ventilator	B-DISO
+-	I-DISO
+associated	I-DISO
+pneumonia	I-DISO
+(	O
+mortality	O
+=	O
+2	O
+.	O
+3	O
+%).	O
+
+RESULTS	O
+:	O
+In	O
+the	O
+Emergency	B-DISO
+Department	O
+two	O
+patients	O
+were	O
+comatose	B-DISO
+and	O
+required	O
+intubation	O
+.	O
+
+Further	O
+,	O
+a	O
+relative	O
+paucity	O
+of	O
+Tregs	O
+characterizes	O
+lethal	O
+infection	B-DISO
+because	O
+adoptive	O
+transfer	O
+of	O
+Tregs	O
+into	O
+rJ	O
+-	O
+infected	O
+mice	O
+increases	O
+survival	O
+from	O
+0	O
+%	O
+to	O
+50	O
+%.	O
+
+SARS	B-DISO
+was	O
+associated	O
+with	O
+significant	O
+long	O
+-	O
+term	O
+stress	O
+in	O
+healthcare	O
+workers	O
+,	O
+but	O
+not	O
+with	O
+increased	O
+mental	B-DISO
+illness	I-DISO
+.	O
+
+Applicable	O
+models	O
+to	O
+improve	O
+adaptation	B-PROC
+in	O
+individuals	O
+include	O
+Folkman	O
+and	O
+Greer	O
+'	O
+s	O
+framework	O
+for	O
+stress	O
+appraisal	O
+and	O
+coping	O
+along	O
+with	O
+psychological	B-DISO
+first	O
+aid	O
+.	O
+
+Resilience	O
+is	O
+supported	O
+at	O
+an	O
+organizational	O
+level	O
+by	O
+effective	O
+training	O
+and	O
+support	O
+,	O
+development	B-PROC
+of	O
+material	O
+and	O
+relational	O
+reserves	O
+,	O
+effective	O
+leadership	O
+,	O
+the	O
+effects	O
+of	O
+the	O
+characteristics	O
+of	O
+""""	O
+magnet	O
+hospitals	O
+","""	O
+and	O
+a	O
+culture	O
+of	O
+organizational	O
+justice	O
+.	O
+
+Although	O
+the	O
+severity	O
+of	O
+a	O
+pandemic	O
+is	O
+unpredictable	O
+,	O
+this	O
+effort	B-PROC
+is	O
+not	O
+likely	O
+to	O
+be	O
+wasted	B-DISO
+because	O
+it	O
+will	O
+also	O
+support	O
+the	O
+health	O
+of	O
+both	O
+patients	O
+and	O
+staff	O
+in	O
+normal	O
+times	O
+.	O
+
+While	O
+there	O
+have	O
+been	O
+no	O
+recent	O
+outbreaks	O
+of	O
+the	O
+disease	O
+,	O
+the	O
+threat	O
+remains	O
+as	O
+SARS	B-DISO
+coronavirus	B-SPEC
+(	O
+SARS	B-DISO
+-	O
+CoV	O
+)	O
+like	O
+strains	O
+still	O
+exist	O
+in	O
+animal	B-SPEC
+reservoirs	O
+.	O
+
+Biophysical	O
+analyses	O
+with	O
+circular	O
+dichroism	O
+,	O
+transmission	O
+electron	O
+microscopy	O
+and	O
+dynamic	O
+light	O
+scattering	O
+confirmed	O
+the	O
+computational	O
+design	O
+showing	O
+alpha	O
+-	O
+helcial	O
+nanoparticles	B-CHED
+with	O
+sizes	O
+of	O
+about	O
+25	O
+nm	O
+.	O
+
+Immunization	O
+experiments	O
+with	O
+no	O
+adjuvants	B-CHED
+were	O
+performed	O
+with	O
+BALB	O
+/	O
+c	O
+mice	B-SPEC
+.	O
+
+An	O
+investigation	O
+of	O
+the	O
+binding	O
+properties	O
+of	O
+the	O
+elicited	O
+antibodies	B-COMP
+showed	O
+that	O
+they	O
+were	O
+highly	O
+conformation	O
+specific	O
+for	O
+the	O
+coiled	O
+-	O
+coil	O
+epitope	B-CHED
+because	O
+they	O
+specifically	O
+recognized	O
+the	O
+native	O
+trimeric	O
+conformation	O
+of	O
+C	O
+-	O
+terminal	O
+heptad	O
+repeat	O
+region	O
+.	O
+
+TITLE	O
+:	O
+Severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+coronavirus	B-SPEC
+nsp9	O
+dimerization	O
+is	O
+essential	O
+for	O
+efficient	O
+viral	O
+growth	O
+.	O
+
+The	O
+G104V	O
+mutant	B-DISO
+produced	O
+highly	O
+debilitated	O
+virus	B-SPEC
+and	O
+eventually	O
+reverted	O
+back	B-ANAT
+to	O
+the	O
+wild	B-PRGE
+-	I-PRGE
+type	I-PRGE
+protein	I-PRGE
+sequence	I-PRGE
+through	O
+a	O
+codon	O
+transversion	B-DISO
+.	O
+
+ABSTRACT	O
+:	O
+To	O
+estimate	O
+the	O
+coincidence	O
+of	O
+new	O
+otitis	O
+media	O
+(	O
+OM	O
+)	O
+for	O
+first	O
+nasopharyngeal	B-ANAT
+detections	O
+of	O
+the	O
+more	O
+common	O
+viruses	B-SPEC
+by	O
+polymerase	O
+chain	O
+reaction	O
+(	O
+PCR	O
+).	O
+
+A	O
+total	O
+of	O
+176	O
+children	O
+(	O
+81	O
+%)	O
+had	O
+isolated	O
+PCR	O
+detection	O
+of	O
+at	O
+least	O
+1	O
+virus	B-SPEC
+.	O
+
+The	O
+OM	O
+coincidence	O
+rates	O
+were	O
+62	O
+of	O
+144	O
+(	O
+44	O
+%)	O
+for	O
+rhinovirus	B-SPEC
+,	O
+15	O
+of	O
+27	O
+(	O
+56	O
+%)	O
+for	O
+respiratory	B-SPEC
+syncytial	I-SPEC
+virus	I-SPEC
+,	O
+8	O
+of	O
+11	O
+(	O
+73	O
+%)	O
+and	O
+1	O
+of	O
+5	O
+(	O
+20	O
+%)	O
+for	O
+influenza	B-PATH
+A	I-PATH
+and	O
+B	O
+,	O
+respectively	O
+,	O
+6	O
+of	O
+12	O
+(	O
+50	O
+%)	O
+for	O
+adenovirus	B-DISO
+,	O
+7	O
+of	O
+18	O
+(	O
+39	O
+%)	O
+for	O
+coronavirus	B-SPEC
+,	O
+and	O
+4	O
+of	O
+11	O
+(	O
+36	O
+%)	O
+for	O
+parainfluenza	B-DISO
+virus	B-SPEC
+detections	O
+(	O
+P	O
+=	O
+.	O
+37	O
+).	O
+
+On	O
+the	O
+other	O
+hand	O
+,	O
+wishful	O
+thinking	O
+was	O
+associated	O
+with	O
+those	O
+behaviours	O
+that	O
+may	O
+potentially	O
+lead	O
+to	O
+economic	O
+hardship	O
+in	O
+afflicted	O
+areas	O
+,	O
+such	O
+as	O
+avoiding	O
+people	O
+perceived	O
+to	O
+be	O
+at	O
+risk	O
+for	O
+an	O
+infectious	B-DISO
+agent	O
+.	O
+
+Although	O
+its	O
+cost	O
+and	O
+technological	O
+availability	O
+make	O
+it	O
+unlikely	O
+that	O
+this	O
+system	O
+will	O
+very	O
+soon	O
+be	O
+the	O
+diagnostic	O
+standard	O
+worldwide	O
+,	O
+this	O
+system	O
+could	O
+be	O
+useful	O
+for	O
+the	O
+earlier	O
+discovery	O
+of	O
+novel	O
+emerging	O
+viruses	B-SPEC
+and	O
+bioterrorism	O
+,	O
+which	O
+are	O
+difficult	O
+to	O
+detect	O
+with	O
+conventional	O
+procedures	O
+.	O
+
+We	O
+demonstrate	O
+that	O
+sialic	B-FUNC
+acid	I-FUNC
+binding	I-FUNC
+is	O
+important	O
+for	O
+the	O
+infection	B-DISO
+of	O
+primary	O
+chicken	B-SPEC
+kidney	B-ANAT
+cells	B-COMP
+and	O
+the	O
+tracheal	B-ANAT
+epithelium	I-ANAT
+by	O
+all	O
+four	O
+strains	O
+.	O
+
+Moreover	O
+,	O
+pre	O
+-	O
+exposure	O
+to	O
+the	O
+wild	O
+-	O
+type	O
+VTT	O
+via	O
+intranasal	O
+or	O
+intraoral	O
+route	O
+impaired	B-DISO
+the	O
+Nab	O
+response	O
+via	O
+the	O
+same	O
+routes	O
+of	O
+MVTT	O
+-	O
+S	O
+vaccination	O
+probably	O
+due	O
+to	O
+the	O
+pre	O
+-	O
+existing	O
+anti	O
+-	O
+VTT	O
+Nab	O
+response	O
+.	O
+
+Interestingly	O
+,	O
+although	O
+the	O
+structural	O
+proteins	B-CHED
+show	O
+the	O
+same	O
+features	O
+of	O
+CRCoV	O
+4182	O
+,	O
+the	O
+genomic	O
+region	O
+between	O
+the	O
+spike	O
+and	O
+the	O
+envelope	O
+protein	B-CHED
+genes	O
+of	O
+CRCoV	O
+240	O
+/	O
+05	O
+encodes	O
+for	O
+three	O
+distinct	O
+products	O
+,	O
+including	O
+the	O
+equivalent	O
+bovine	B-PRGE
+4	I-PRGE
+.	I-PRGE
+9	I-PRGE
+kDa	I-PRGE
+non	I-PRGE
+-	I-PRGE
+structural	I-PRGE
+protein	B-CHED
+and	O
+a	O
+truncated	O
+form	O
+of	O
+the	O
+4	O
+.	O
+8	O
+kDa	O
+protein	B-CHED
+,	O
+whereas	O
+CRCoV	O
+4182	O
+has	O
+a	O
+unique	O
+8	O
+.	O
+8	O
+kDa	O
+protein	B-CHED
+.	O
+
+Seven	O
+samples	O
+were	O
+positive	O
+for	O
+CCoV	O
+while	O
+all	O
+samples	O
+were	O
+negative	O
+for	O
+CRCoV	O
+.	O
+Sequence	O
+analysis	O
+of	O
+five	O
+CCoV	O
+strains	O
+showed	O
+a	O
+high	O
+similarity	O
+with	O
+transmissible	O
+gastroenteritis	B-DISO
+virus	B-SPEC
+(	O
+TGEV	B-SPEC
+)	O
+at	O
+the	O
+N	O
+-	O
+terminus	O
+of	O
+the	O
+spike	O
+protein	B-CHED
+.	O
+
+We	O
+identified	O
+a	O
+reference	O
+data	O
+set	O
+of	O
+624	O
+mechanically	O
+-	O
+ventilated	O
+patients	O
+in	O
+the	O
+MIMIC	O
+-	O
+II	O
+intensive	O
+care	O
+database	O
+with	O
+and	O
+without	O
+low	O
+PaO	B-PROC
+(	O
+2	O
+)/	O
+FiO	O
+(	O
+2	O
+)	O
+ratios	O
+(	O
+termed	O
+respiratory	O
+instability	O
+),	O
+and	O
+developed	O
+prediction	O
+algorithms	O
+for	O
+distinguishing	O
+these	O
+patients	O
+prior	O
+to	O
+the	O
+critical	O
+event	O
+.	O
+
+ABSTRACT	O
+:	O
+Angiotensin	O
+-	O
+converting	O
+enzyme	O
+(	O
+ACE	B-PRGE
+)-	O
+2	O
+is	O
+a	O
+homolog	O
+of	O
+the	O
+well	O
+-	O
+characterized	O
+plasma	B-COMP
+membrane	I-COMP
+-	O
+bound	O
+angiotensin	B-PRGE
+-	I-PRGE
+converting	I-PRGE
+enzyme	I-PRGE
+.	O
+
+These	O
+4	O
+/	O
+91	O
+isolates	O
+were	O
+neutralized	O
+with	O
+serum	B-COMP
+from	O
+birds	B-SPEC
+immunized	O
+with	O
+4	O
+/	O
+91	O
+vaccine	O
+.	O
+
+TITLE	O
+:	O
+Delivery	O
+to	O
+the	O
+lower	B-ANAT
+respiratory	I-ANAT
+tract	I-ANAT
+is	O
+required	O
+for	O
+effective	O
+immunization	O
+with	O
+Newcastle	B-DISO
+disease	I-DISO
+virus	I-SPEC
+-	O
+vectored	O
+vaccines	O
+intended	O
+for	O
+humans	B-SPEC
+.	O
+
+Furthermore	O
+,	O
+direct	O
+comparison	O
+of	O
+a	O
+vaccine	O
+based	O
+on	O
+an	O
+NDV	B-SPEC
+mesogenic	O
+strain	O
+(	O
+NDV	B-SPEC
+-	O
+BC	O
+)	O
+with	O
+a	O
+similarly	O
+designed	O
+NDV	B-SPEC
+vector	O
+based	O
+on	O
+a	O
+modified	O
+lentogenic	O
+strain	O
+carrying	O
+a	O
+polybasic	O
+F	O
+cleavage	O
+site	O
+(	O
+NDV	B-SPEC
+-	O
+VF	O
+)	O
+suggested	O
+that	O
+the	O
+two	O
+NDV	B-SPEC
+strains	O
+were	O
+similar	O
+in	O
+immunogenicity	O
+and	O
+were	O
+equally	O
+protective	O
+.	O
+
+TITLE	O
+:	O
+Effects	O
+of	O
+infectious	B-DISO
+bronchitis	B-DISO
+virus	B-SPEC
+vaccine	O
+on	O
+the	O
+oviduct	B-ANAT
+of	O
+hens	O
+.	O
+
+Cilia	B-COMP
+loss	O
+was	O
+not	O
+observed	O
+in	O
+any	O
+region	O
+of	O
+the	O
+oviduct	B-ANAT
+using	O
+scanning	O
+electron	O
+microscopy	O
+.	O
+
+ABSTRACT	O
+:	O
+Lung	B-ANAT
+contusion	O
+is	O
+a	O
+common	O
+problem	O
+from	O
+blunt	O
+chest	B-ANAT
+trauma	O
+caused	O
+by	O
+mechanical	O
+forces	O
+and	O
+by	O
+exposure	O
+to	O
+blast	B-ANAT
+overpressure	O
+,	O
+often	O
+with	O
+fatal	O
+consequences	O
+.	O
+
+No	O
+changes	O
+were	O
+detected	O
+in	O
+the	O
+lung	B-ANAT
+manganase	B-PRGE
+superoxide	I-PRGE
+dismutase	I-PRGE
+(	O
+MnSOD	B-PRGE
+)	O
+or	O
+glutathione	B-PRGE
+reductase	I-PRGE
+(	O
+GR	O
+)	O
+mRNA	B-PROC
+expression	B-PROC
+after	O
+blast	B-ANAT
+.	O
+
+N	B-CHED
+-	I-CHED
+Acetylcysteine	I-CHED
+amide	B-CHED
+significantly	O
+reduced	O
+infiltration	B-DISO
+of	O
+neutrophils	B-ANAT
+and	O
+CD11b	B-PRGE
+mRNA	I-PRGE
+activation	O
+in	O
+lungs	B-ANAT
+,	O
+and	O
+completely	O
+blocked	O
+activation	O
+of	O
+MIP	B-PRGE
+-	I-PRGE
+1	I-PRGE
+,	O
+MCP	B-PRGE
+-	I-PRGE
+1	I-PRGE
+and	O
+CINC	B-PRGE
+-	I-PRGE
+1	I-PRGE
+mRNA	B-CHED
+.	O
+
+The	O
+relatively	O
+higher	O
+inhibition	B-PROC
+of	O
+chemokine	O
+mRNAs	O
+compared	O
+with	O
+reduction	O
+in	O
+MPO	B-FUNC
+activity	O
+and	O
+CD11b	B-PRGE
+is	O
+in	O
+accordance	O
+with	O
+an	O
+antioxidant	B-PROC
+effect	I-PROC
+of	O
+NACA	B-COMP
+on	O
+reactive	B-CHED
+oxygen	I-CHED
+species	I-CHED
+(	O
+ROS	B-CHED
+)	O
+accumulation	O
+,	O
+rather	O
+than	O
+by	O
+an	O
+effect	O
+on	O
+neutrophil	B-ANAT
+sequestration	O
+.	O
+
+ABSTRACT	O
+:	O
+The	O
+Murine	B-DISO
+hepatitis	I-DISO
+virus	B-SPEC
+(	O
+MHV	B-SPEC
+)	O
+strain	O
+A59	O
+ns2	B-DISO
+protein	B-CHED
+is	O
+a	O
+30	O
+-	O
+kDa	O
+nonstructural	O
+protein	B-CHED
+that	O
+is	O
+expressed	B-PROC
+from	O
+a	O
+subgenomic	O
+mRNA	B-CHED
+in	O
+the	O
+cytoplasm	B-COMP
+of	O
+virus	B-SPEC
+-	O
+infected	O
+cells	B-COMP
+.	O
+
+Its	O
+homologs	O
+are	O
+also	O
+encoded	O
+in	O
+other	O
+closely	O
+related	O
+group	O
+2a	O
+coronaviruses	O
+and	O
+more	O
+distantly	O
+related	O
+toroviruses	B-SPEC
+.	O
+
+Interestingly	O
+,	O
+none	O
+of	O
+the	O
+mutant	B-DISO
+viruses	B-SPEC
+were	O
+attenuated	O
+for	O
+replication	O
+in	O
+mouse	B-ANAT
+brain	I-ANAT
+following	O
+intracranial	B-ANAT
+inoculation	O
+.	O
+
+ABSTRACT	O
+:	O
+We	O
+report	O
+on	O
+recent	O
+advances	O
+and	O
+achievements	O
+on	O
+the	O
+use	O
+of	O
+extracorporeal	O
+gas	O
+exchange	O
+for	O
+long	O
+-	O
+term	O
+application	O
+in	O
+the	O
+therapy	O
+of	O
+critically	B-DISO
+ill	I-DISO
+patients	O
+with	O
+various	O
+forms	O
+of	O
+respiratory	B-DISO
+failure	I-DISO
+.	O
+
+Although	O
+not	O
+yet	O
+formally	O
+published	O
+,	O
+the	O
+results	O
+of	O
+this	O
+study	O
+,	O
+if	O
+confirmed	O
+,	O
+represent	O
+the	O
+first	O
+positive	O
+randomized	O
+clinical	O
+trial	O
+on	O
+adult	O
+extracorporeal	O
+membrane	B-COMP
+oxygenation	B-PROC
+application	O
+in	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+patients	O
+.	O
+
+Other	O
+important	O
+results	O
+come	O
+from	O
+the	O
+clinical	O
+application	O
+of	O
+interventional	O
+lung	B-ANAT
+assist	O
+,	O
+a	O
+pumpless	O
+arteriovenous	O
+extracorporeal	O
+technique	O
+,	O
+in	O
+different	O
+clinical	O
+conditions	O
+(	O
+acute	O
+respiratory	O
+distress	O
+syndrome	O
+,	O
+bridge	O
+to	O
+transplantation	O
+,	O
+asthma	B-PATH
+,	O
+and	O
+trauma	O
+).	O
+
+Recently	O
+,	O
+several	O
+studies	O
+have	O
+reported	O
+that	O
+AE	O
+also	O
+occurred	O
+in	O
+interstitial	B-DISO
+pneumonias	I-DISO
+other	O
+than	O
+IPF	O
+,	O
+such	O
+as	O
+collagen	B-DISO
+vascular	B-ANAT
+disease	I-DISO
+-	O
+associated	O
+interstitial	B-DISO
+pneumonia	I-DISO
+(	O
+CVD	B-DISO
+-	O
+IP	O
+).	O
+
+This	O
+study	O
+was	O
+conducted	O
+to	O
+elucidate	O
+cumulative	O
+incidence	O
+of	O
+AE	O
+in	O
+CVD	B-DISO
+-	O
+IP	O
+and	O
+its	O
+clinical	O
+features	O
+.	O
+
+Underlying	O
+CVDs	O
+included	O
+rheumatoid	B-PATH
+arthritis	I-PATH
+(	O
+RA	O
+)	O
+(	O
+n	O
+=	O
+5	O
+;	O
+overall	O
+incidence	O
+,	O
+20	O
+.	O
+0	O
+%)	O
+and	O
+primary	O
+Sjögren	O
+syndrome	B-DISO
+(	O
+n	O
+=	O
+1	O
+;	O
+overall	O
+incidence	O
+,	O
+5	O
+.	O
+9	O
+%).	O
+
+RESULTS	O
+:	O
+Among	O
+83	O
+CVD	B-DISO
+-	O
+IP	O
+patients	O
+,	O
+six	O
+patients	O
+with	O
+a	O
+mean	O
+age	O
+of	O
+65	O
+.	O
+7	O
+years	O
+developed	O
+AE	O
+(	O
+overall	O
+incidence	O
+,	O
+7	O
+.	O
+2	O
+%;	O
+1	O
+-	O
+year	O
+incidence	O
+,	O
+1	O
+.	O
+25	O
+%).	O
+
+In	O
+the	O
+present	O
+pilot	O
+study	O
+we	O
+tested	O
+the	O
+hypothesis	O
+that	O
+timely	O
+initiation	O
+of	O
+iLA	O
+using	O
+clear	O
+algorithms	O
+and	O
+an	O
+improved	O
+cannulation	O
+technique	O
+will	O
+positively	O
+influence	O
+complication	B-DISO
+rates	O
+and	O
+management	O
+of	O
+lung	B-ANAT
+protective	O
+ventilation	O
+.	O
+
+Patients	O
+with	O
+cardiac	B-DISO
+insufficiency	I-DISO
+or	O
+severe	O
+peripheral	O
+vascular	O
+disease	O
+were	O
+not	O
+considered	O
+suitable	O
+for	O
+iLA	B-PRGE
+.	O
+
+The	O
+use	O
+of	O
+an	O
+indication	O
+algorithm	O
+for	O
+iLA	B-PRGE
+in	O
+early	O
+ARDS	B-DISO
+,	O
+combined	O
+with	O
+a	O
+refined	O
+application	O
+technique	O
+was	O
+associated	O
+with	O
+efficient	O
+carbon	B-CHED
+dioxide	I-CHED
+removal	O
+and	O
+a	O
+reduced	O
+incidence	O
+of	O
+adverse	O
+events	O
+.	O
+
+RESULTS	O
+:	O
+Initiation	O
+of	O
+iLA	B-PRGE
+resulted	O
+in	O
+a	O
+marked	O
+removal	O
+in	O
+arterial	B-ANAT
+carbon	B-CHED
+dioxide	I-CHED
+allowing	O
+a	O
+rapid	O
+reduction	O
+in	O
+tidal	O
+volume	O
+(<	O
+or	O
+=	O
+6	O
+ml	O
+/	O
+kg	O
+)	O
+and	O
+inspiratory	B-PROC
+plateau	O
+pressure	O
+.	O
+
+Gas	B-PRGE
+exchange	O
+,	O
+tidal	O
+volumes	O
+,	O
+airway	B-ANAT
+pressures	O
+,	O
+breathing	B-PROC
+patterns	O
+and	O
+sedation	B-DISO
+requirements	O
+before	O
+(	O
+baseline	O
+)	O
+and	O
+after	O
+(	O
+2	O
+-	O
+4	O
+days	O
+)	O
+initiation	O
+of	O
+treatment	O
+with	O
+p	O
+-	O
+ECLA	O
+were	O
+analysed	O
+.	O
+
+Their	O
+knowledge	O
+of	O
+SARS	B-DISO
+was	O
+high	O
+.	O
+
+They	O
+had	O
+a	O
+lower	O
+perceived	O
+threat	O
+than	O
+general	O
+populations	O
+with	O
+regard	O
+to	O
+SARS	B-DISO
+and	O
+avian	B-DISO
+flu	I-DISO
+due	O
+to	O
+a	O
+lower	O
+perceived	O
+severity	O
+.	O
+
+Previous	O
+studies	O
+indicated	O
+that	O
+TCoV	O
+was	O
+closely	O
+related	O
+to	O
+bovine	B-SPEC
+coronavirus	B-SPEC
+and	O
+other	O
+group	O
+2	O
+mammalian	B-SPEC
+coronaviruses	O
+,	O
+but	O
+more	O
+recent	O
+antigenic	O
+and	O
+genome	O
+sequence	O
+analyses	O
+contradict	O
+these	O
+findings	O
+and	O
+,	O
+instead	O
+,	O
+provide	O
+evidence	O
+that	O
+TCoV	O
+is	O
+closely	O
+related	O
+to	O
+avian	B-SPEC
+infectious	I-DISO
+bronchitis	I-DISO
+virus	B-SPEC
+(	O
+IBV	B-SPEC
+).	O
+
+TITLE	O
+:	O
+A	O
+nomenclature	O
+for	O
+avian	B-SPEC
+coronavirus	I-SPEC
+isolates	O
+and	O
+the	O
+question	O
+of	O
+species	B-SPEC
+status	O
+.	O
+
+Representatives	O
+of	O
+avian	B-SPEC
+coronaviruses	O
+from	O
+turkey	B-SPEC
+and	O
+pheasant	O
+would	O
+include	O
+turkey	B-SPEC
+/	O
+United	O
+States	O
+(	O
+Nc	O
+)/	O
+NC95	O
+/	O
+95	O
+and	O
+pheasant	O
+/	O
+UK	O
+/	O
+750	O
+/	O
+83	O
+.	O
+
+If	O
+the	O
+serotype	O
+of	O
+an	O
+isolate	O
+has	O
+been	O
+clearly	O
+established	O
+,	O
+this	O
+might	O
+be	O
+included	O
+in	O
+the	O
+name	B-SPEC
+at	O
+end	O
+,	O
+like	O
+the	O
+serotype	O
+designation	O
+of	O
+AIVs	O
+,	O
+e	O
+.	O
+g	O
+.	O
+chicken	B-SPEC
+/	O
+China	O
+/	O
+NRZ	O
+/	O
+91	O
+(	O
+Mass	O
+.)	O
+for	O
+the	O
+Chinese	O
+isolate	O
+of	O
+the	O
+Massachusetts	O
+serotype	O
+.	O
+
+Adenovirus	B-DISO
+-	O
+like	O
+particles	O
+were	O
+detected	O
+by	O
+electron	O
+microscopy	O
+,	O
+and	O
+the	O
+virus	B-SPEC
+isolated	O
+from	O
+the	O
+trachea	B-DISO
+and	O
+the	O
+lungs	B-ANAT
+was	O
+identified	O
+as	O
+egg	B-DISO
+drop	I-DISO
+syndrome	I-DISO
+(	O
+EDS	B-DISO
+)	O
+virus	B-SPEC
+by	O
+serological	O
+and	O
+genomic	O
+examination	O
+.	O
+
+Histological	O
+examination	O
+of	O
+tissues	B-ANAT
+was	O
+largely	O
+unremarkable	O
+,	O
+apart	O
+from	O
+some	O
+sections	O
+that	O
+showed	O
+crypt	B-ANAT
+dilation	B-DISO
+and	O
+flattened	O
+epithelia	O
+.	O
+
+This	O
+gene	O
+order	B-SPEC
+is	O
+unlike	O
+that	O
+of	O
+any	O
+known	O
+mammalian	B-SPEC
+coronavirus	B-SPEC
+,	O
+which	O
+does	O
+not	O
+have	O
+a	O
+gene	O
+analogous	O
+to	O
+the	O
+gene	O
+5	O
+of	O
+IBV	B-SPEC
+.	O
+The	O
+gene	O
+5	O
+of	O
+the	O
+turkey	B-SPEC
+virus	B-SPEC
+had	O
+two	O
+open	O
+reading	O
+frames	O
+,	O
+5a	O
+and	O
+5b	O
+,	O
+as	O
+in	O
+IBV	B-SPEC
+and	O
+the	O
+coronaviruses	O
+isolated	O
+from	O
+turkeys	B-SPEC
+in	O
+North	O
+America	O
+.	O
+
+These	O
+results	O
+demonstrate	O
+,	O
+for	O
+the	O
+first	O
+time	O
+,	O
+that	O
+a	O
+coronavirus	B-SPEC
+was	O
+associated	O
+with	O
+disease	O
+in	O
+turkeys	B-SPEC
+outside	O
+of	O
+North	O
+America	O
+and	O
+that	O
+it	O
+is	O
+a	O
+Group	O
+3	O
+coronavirus	B-SPEC
+,	O
+like	O
+IBV	B-SPEC
+.	O
+
+The	O
+PCRs	O
+,	O
+or	O
+reverse	B-PRGE
+transcriptase	I-PRGE
+-	O
+PCRs	O
+,	O
+may	O
+be	O
+general	O
+,	O
+designed	O
+to	O
+detect	O
+all	O
+or	O
+most	O
+variants	O
+of	O
+a	O
+pathogen	O
+,	O
+or	O
+to	O
+be	O
+serotype	O
+,	O
+genotype	O
+or	O
+pathotype	O
+specific	O
+.	O
+
+Progress	O
+is	O
+being	O
+made	O
+with	O
+respect	O
+to	O
+making	O
+nucleic	B-CHED
+acid	I-CHED
+approaches	O
+more	O
+suitable	O
+for	O
+use	O
+in	O
+diagnostic	O
+laboratories	O
+.	O
+
+We	O
+examined	O
+inflammatory	O
+gene	O
+mRNA	B-CHED
+abundances	O
+found	O
+in	O
+S	O
+protein	B-CHED
+-	O
+treated	O
+PBMC	O
+using	O
+gene	O
+arrays	O
+.	O
+
+Also	O
+,	O
+titration	O
+of	O
+S	B-PRGE
+protein	I-PRGE
+-	O
+specific	O
+production	O
+and	O
+secretion	B-PROC
+of	O
+IL	B-FUNC
+-	I-FUNC
+8	I-FUNC
+by	O
+ELISA	O
+showed	O
+that	O
+the	O
+dose	O
+of	O
+5	O
+.	O
+6nM	O
+of	O
+S	O
+produced	O
+a	O
+significant	O
+increase	O
+in	O
+IL	O
+-	O
+8	O
+(	O
+p	O
+=	O
+0	O
+.	O
+003	O
+)	O
+compared	O
+to	O
+mock	O
+-	O
+treated	O
+controls	O
+.	O
+
+Activation	O
+and	O
+translocation	B-DISO
+of	O
+NF	B-PRGE
+-	I-PRGE
+kappaB	I-PRGE
+was	O
+shown	O
+to	O
+occur	O
+rapidly	O
+following	O
+exposure	O
+of	O
+PBMC	O
+or	O
+THP	B-CHED
+-	O
+1	O
+cells	B-COMP
+to	O
+S	B-PRGE
+protein	I-PRGE
+using	O
+a	O
+highly	O
+sensitive	O
+assay	O
+for	O
+active	O
+nuclear	O
+NF	B-PRGE
+-	I-PRGE
+kappaB	I-PRGE
+p65	B-PRGE
+transcription	I-PRGE
+factor	I-PRGE
+.	O
+
+BRSV	B-SPEC
+was	O
+detected	O
+in	O
+diseased	O
+calves	O
+in	O
+two	O
+herds	O
+but	O
+not	O
+in	O
+the	O
+clinically	O
+healthy	O
+animals	B-SPEC
+.	O
+
+Recent	O
+studies	O
+suggest	O
+a	O
+beneficial	O
+effect	O
+of	O
+early	O
+use	O
+of	O
+NMBAs	O
+on	O
+oxygenation	O
+and	O
+inflammation	B-DISO
+.	O
+
+The	O
+role	O
+of	O
+NMBAs	O
+in	O
+the	O
+occurrence	O
+of	O
+ICU	O
+-	O
+acquired	O
+neuromyopathies	B-DISO
+and	O
+lung	B-ANAT
+atelectasis	B-DISO
+in	O
+ARDS	B-DISO
+patients	O
+remains	O
+largely	O
+questioned	O
+.	O
+
+ABSTRACT	O
+:	O
+Sepsis	B-DISO
+induced	O
+acute	O
+lung	B-ANAT
+injury	O
+(	O
+ALI	O
+)	O
+as	O
+a	O
+common	O
+syndrome	B-DISO
+in	O
+clinical	O
+practice	O
+has	O
+a	O
+high	O
+mortality	O
+.	O
+
+Recombinant	O
+human	B-SPEC
+activated	B-PRGE
+protein	I-PRGE
+C	I-PRGE
+(	O
+APC	B-COMP
+)	O
+can	O
+significantly	O
+reduce	O
+the	O
+mortality	O
+of	O
+patients	O
+with	O
+severe	B-DISO
+sepsis	I-DISO
+.	O
+
+In	O
+comparison	O
+with	O
+nontreatment	O
+in	O
+the	O
+control	O
+group	O
+,	O
+the	O
+infusion	O
+of	O
+APC	B-COMP
+significantly	O
+reduced	O
+the	O
+increase	O
+of	O
+thrombomodulin	B-PRGE
+level	I-PRGE
+(	O
+TM	O
+;	O
+control	O
+group	O
+was	O
+(	O
+0	O
+.	O
+68	O
++/-	O
+0	O
+.	O
+06	O
+)	O
+ng	O
+/	O
+ml	O
+,	O
+vs	O
+APC	B-COMP
+group	O
+of	O
+(	O
+0	O
+.	O
+62	O
++/-	O
+
+APC	B-COMP
+-	O
+treated	O
+rabbits	B-SPEC
+showed	O
+no	O
+significant	O
+difference	O
+in	O
+platelet	B-ANAT
+count	O
+and	O
+antithrombin	B-PRGE
+but	O
+exhibited	O
+less	O
+D	O
+-	O
+dimer	O
+production	O
+than	O
+did	O
+the	O
+controls	O
+.	O
+
+0	O
+.	O
+6	O
+in	O
+APC	B-COMP
+group	O
+,	O
+P	O
+<	O
+0	O
+.	O
+01	O
+).	O
+
+Anti	B-PRGE
+-	I-PRGE
+coagulation	I-PRGE
+and	I-PRGE
+pro	B-CHED
+-	I-PRGE
+fibrinolysis	B-PROC
+activity	O
+may	O
+be	O
+two	O
+of	O
+the	O
+possible	O
+mechanisms	O
+by	O
+which	O
+activated	O
+protein	B-CHED
+C	O
+attenuated	O
+endotoxin	O
+-	O
+induced	O
+ALI	O
+.	O
+
+CONCLUSIONS	O
+:	O
+Anti	B-PRGE
+-	I-PRGE
+coagulation	I-PRGE
+and	I-PRGE
+pro	B-CHED
+-	I-PRGE
+fibrinolysis	B-PROC
+activity	O
+may	O
+be	O
+two	O
+of	O
+the	O
+possible	O
+mechanisms	O
+by	O
+which	O
+activated	O
+protein	B-CHED
+C	O
+attenuated	O
+endotoxin	O
+-	O
+induced	O
+ALI	O
+.	O
+
+Of	O
+1	O
+,	O
+091	O
+patients	O
+with	O
+malaria	B-PATH
+,	O
+635	O
+had	O
+P	B-SPEC
+.	I-SPEC
+falciparum	I-SPEC
+malaria	O
+and	O
+456	O
+had	O
+P	B-SPEC
+.	I-SPEC
+vivax	I-SPEC
+malaria	O
+.	O
+
+Further	O
+large	O
+-	O
+scale	O
+multicentric	O
+epidemiologic	O
+studies	O
+are	O
+needed	O
+to	O
+define	O
+the	O
+basic	O
+pathology	B-DISO
+of	O
+this	O
+less	O
+known	O
+entity	O
+.	O
+
+The	O
+study	O
+population	O
+consisted	O
+of	O
+hospitalized	O
+patients	O
+under	O
+the	O
+age	O
+of	O
+5	O
+years	O
+with	O
+bronchiolitis	B-DISO
+,	O
+pneumonia	B-DISO
+,	O
+croup	B-DISO
+,	O
+or	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+.	O
+
+Respiratory	O
+viruses	B-SPEC
+were	O
+identified	O
+in	O
+49	O
+.	O
+6	O
+%	O
+of	O
+296	O
+patients	O
+.	O
+
+Using	O
+our	O
+methods	O
+to	O
+detect	O
+viral	O
+causes	O
+seemed	O
+to	O
+be	O
+acceptable	O
+for	O
+the	O
+national	O
+surveillance	O
+of	O
+severe	O
+acute	B-DISO
+respiratory	I-DISO
+infections	I-DISO
+in	O
+infants	O
+and	O
+children	O
+.	O
+
+Multivariate	O
+analysis	O
+showed	O
+that	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+,	O
+pulmonary	B-ANAT
+artery	I-ANAT
+catheter	O
+placement	O
+,	O
+comorbidities	O
+,	O
+hospital	O
+-	O
+acquired	O
+infection	B-DISO
+,	O
+APACHE	O
+II	O
+score	O
+and	O
+maximum	O
+LOD	B-FUNC
+score	O
+,	O
+were	O
+independent	O
+risk	O
+factors	O
+for	O
+hospital	O
+mortality	O
+.	O
+
+The	O
+general	O
+condition	B-DISO
+,	O
+serum	B-COMP
+total	O
+bilirubin	B-CHED
+,	O
+albumin	B-PRGE
+,	O
+creatinine	B-CHED
+,	O
+and	O
+prothrombin	B-PRGE
+activity	O
+,	O
+Child	O
+-	O
+Turcotte	O
+-	O
+Pugh	O
+(	O
+CTP	B-CHED
+)	O
+score	O
+,	O
+and	O
+model	O
+for	O
+end	O
+-	O
+stage	O
+liver	B-DISO
+disease	I-DISO
+(	O
+MELD	O
+)	O
+score	O
+48	O
+h	O
+before	O
+operation	O
+were	O
+recorded	O
+.	O
+
+Logistic	O
+stepwise	O
+regression	O
+analysis	O
+screened	O
+out	O
+serum	B-COMP
+total	O
+bilirubin	B-CHED
+as	O
+an	O
+independent	O
+predictor	O
+for	O
+ALI	O
+following	O
+OLT	O
+.	O
+
+The	O
+widespread	O
+incorporation	O
+of	O
+molecular	O
+methods	O
+into	O
+clinical	O
+microbiology	O
+laboratories	O
+has	O
+not	O
+only	O
+led	O
+to	O
+notable	O
+advances	O
+in	O
+the	O
+etiological	O
+diagnosis	O
+of	O
+viral	O
+respiratory	B-DISO
+infections	I-DISO
+but	O
+has	O
+also	O
+increased	O
+insight	O
+into	O
+the	O
+pathology	B-DISO
+and	O
+epidemiological	O
+profiles	O
+of	O
+the	O
+causative	O
+viruses	B-SPEC
+.	O
+
+Using	O
+IHC	O
+,	O
+antigens	B-CHED
+of	O
+IBV	B-SPEC
+were	O
+detected	O
+in	O
+nasal	B-ANAT
+epithelium	I-ANAT
+,	O
+trachea	B-DISO
+,	O
+lung	B-ANAT
+,	O
+spleen	B-ANAT
+,	O
+myocardial	O
+vasculature	B-ANAT
+,	O
+liver	B-ANAT
+,	O
+gastrointestinal	B-ANAT
+tract	I-ANAT
+,	O
+kidney	B-ANAT
+,	O
+skin	B-ANAT
+,	O
+sclera	B-ANAT
+of	O
+the	O
+eye	B-ANAT
+,	O
+spinal	B-ANAT
+cord	I-ANAT
+,	O
+as	O
+well	O
+as	O
+in	O
+brain	B-ANAT
+neurons	B-ANAT
+of	O
+the	O
+inoculated	O
+embryos	B-ANAT
+.	O
+
+ABSTRACT	O
+:	O
+Severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+(	O
+SARS	B-DISO
+)	O
+is	O
+a	O
+newly	O
+emerging	B-DISO
+infectious	I-DISO
+disease	I-DISO
+caused	O
+by	O
+a	O
+novel	B-SPEC
+coronavirus	I-SPEC
+,	O
+SARS	B-DISO
+-	O
+coronavirus	B-SPEC
+(	O
+SARS	B-DISO
+-	O
+CoV	O
+).	O
+
+The	O
+SARS	B-PRGE
+-	I-PRGE
+CoV	I-PRGE
+spike	I-PRGE
+(	I-PRGE
+S	I-PRGE
+)	I-PRGE
+protein	B-CHED
+is	O
+composed	O
+of	O
+two	O
+subunits	O
+;	O
+the	O
+S1	O
+subunit	O
+contains	O
+a	O
+receptor	O
+-	O
+binding	B-FUNC
+domain	O
+that	O
+engages	O
+with	O
+the	O
+host	B-COMP
+cell	I-COMP
+receptor	O
+angiotensin	B-PRGE
+-	I-PRGE
+converting	I-PRGE
+enzyme	I-PRGE
+2	I-PRGE
+and	O
+the	O
+S2	B-PRGE
+subunit	I-PRGE
+mediates	O
+fusion	O
+between	O
+the	O
+viral	O
+and	O
+host	O
+cell	B-COMP
+membranes	I-COMP
+.	O
+
+During	O
+the	O
+period	O
+March	O
+-	O
+May	O
+2004	O
+,	O
+all	O
+hospital	O
+staff	O
+completed	O
+a	O
+mandatory	O
+infection	B-DISO
+control	O
+education	O
+program	O
+,	O
+including	O
+the	O
+receipt	O
+of	O
+hospital	O
+-	O
+specific	O
+MRSA	B-DISO
+data	O
+and	O
+case	O
+-	O
+based	O
+practice	O
+with	O
+additional	O
+precautions	O
+.	O
+
+RESULTS	O
+:	O
+The	O
+rate	O
+of	O
+nosocomial	O
+acquisition	O
+of	O
+MRSA	B-DISO
+colonization	O
+or	O
+infection	B-DISO
+was	O
+8	O
+.	O
+8	O
+cases	O
+per	O
+100	O
+admission	O
+MRSA	B-DISO
+exposure	O
+-	O
+days	O
+for	O
+the	O
+period	O
+before	O
+SARS	B-DISO
+,	O
+3	O
+.	O
+8	O
+cases	O
+per	O
+100	O
+admission	O
+MRSA	B-DISO
+exposure	O
+-	O
+days	O
+for	O
+the	O
+period	O
+after	O
+SARS	B-DISO
+(	O
+P	O
+<.	O
+001	O
+for	O
+before	O
+SARS	B-DISO
+vs	O
+after	O
+SARS	B-DISO
+),	O
+and	O
+1	O
+.	O
+9	O
+cases	O
+per	O
+100	O
+admission	O
+MRSA	B-DISO
+exposure	O
+-	O
+days	O
+for	O
+the	O
+period	O
+after	O
+education	O
+(	O
+P	O
+=.	O
+02	O
+for	O
+after	O
+education	O
+vs	O
+before	O
+education	O
+).	O
+
+The	O
+subsequent	O
+needle	O
+core	O
+biopsy	O
+was	O
+diagnostic	O
+for	O
+a	O
+mixed	B-DISO
+germ	I-DISO
+cell	I-DISO
+tumor	I-DISO
+comprising	O
+immature	B-DISO
+teratoma	I-DISO
+and	O
+seminoma	B-DISO
+.	O
+
+The	O
+right	O
+-	O
+sided	O
+pneumonectomy	O
+revealed	O
+an	O
+intrapulmonary	O
+tumor	B-DISO
+with	O
+cystic	O
+and	O
+solid	O
+components	O
+,	O
+hemorrhage	B-DISO
+,	O
+and	O
+necrosis	B-PROC
+with	O
+a	O
+tumor	B-DISO
+diameter	O
+of	O
+18cm	O
+.	O
+
+In	O
+two	O
+recent	O
+randomized	O
+,	O
+controlled	O
+studies	O
+,	O
+the	O
+fish	B-SPEC
+oil	O
+formula	O
+that	O
+was	O
+previously	O
+shown	O
+to	O
+be	O
+effective	O
+was	O
+administered	O
+to	O
+patients	O
+with	O
+ARDS	O
+/	O
+acute	O
+lung	B-ANAT
+injury	O
+(	O
+in	O
+which	O
+hypoxia	B-DISO
+is	O
+less	O
+severe	O
+)	O
+and	O
+to	O
+patients	O
+with	O
+severe	B-DISO
+sepsis	I-DISO
+and	O
+hypoxia	B-DISO
+,	O
+respectively	O
+.	O
+
+ABSTRACT	O
+:	O
+Human	B-SPEC
+health	O
+threats	O
+posed	O
+by	O
+airborne	O
+pathogens	O
+are	O
+difficult	O
+to	O
+handle	O
+for	O
+healthcare	O
+responders	O
+due	O
+to	O
+the	O
+fact	O
+that	O
+the	O
+contaminated	O
+area	O
+is	O
+not	O
+immediately	O
+recognizable	O
+.	O
+
+By	O
+means	O
+of	O
+wind	B-DISO
+dispersion	O
+modeling	O
+,	O
+it	O
+is	O
+possible	O
+to	O
+estimate	O
+the	O
+extent	O
+and	O
+geographical	O
+position	O
+of	O
+hazardous	O
+areas	O
+and	O
+health	O
+impact	O
+.	O
+
+As	O
+per	O
+the	O
+World	O
+Health	O
+Organization	O
+(	O
+WHO	O
+),	O
+the	O
+continual	O
+lack	O
+of	O
+a	O
+rapid	O
+laboratory	O
+test	O
+to	O
+aid	O
+the	O
+early	O
+diagnosis	O
+of	O
+suspected	O
+cases	O
+of	O
+SARS	B-DISO
+makes	O
+this	O
+area	O
+a	O
+priority	O
+for	O
+future	O
+research	O
+.	O
+
+The	O
+genetically	O
+engineered	O
+attenuated	O
+form	O
+of	O
+the	O
+virus	B-SPEC
+or	O
+viral	O
+vector	O
+vaccine	O
+encoding	O
+for	O
+the	O
+SARS	B-PRGE
+-	I-PRGE
+CoV	I-PRGE
+spike	I-PRGE
+glycoprotein	B-CHED
+has	O
+been	O
+shown	O
+to	O
+elicit	O
+protective	O
+immunity	B-PROC
+in	O
+vaccinated	O
+animals	B-SPEC
+.	O
+
+NP	O
+is	O
+the	O
+preferred	O
+target	O
+for	O
+routine	O
+detection	O
+of	O
+SARS	B-DISO
+-	I-DISO
+CoV	I-DISO
+infection	I-DISO
+by	O
+ELISA	O
+which	O
+is	O
+an	O
+economical	O
+method	O
+compared	O
+to	O
+other	O
+methods	O
+.	O
+
+TITLE	O
+:	O
+A	O
+case	O
+of	O
+Boerhaave	B-DISO
+'	I-DISO
+s	I-DISO
+syndrome	I-DISO
+presenting	O
+after	O
+a	O
+trial	O
+of	O
+non	O
+-	O
+invasive	O
+ventilation	O
+.	O
+
+Within	O
+20	O
+h	O
+,	O
+she	O
+deteriorated	O
+and	O
+progressed	O
+to	O
+severe	O
+type	B-DISO
+2	I-DISO
+respiratory	I-DISO
+failure	I-DISO
+.	O
+
+After	O
+initiation	O
+of	O
+first	O
+non	O
+-	O
+invasive	O
+and	O
+then	O
+invasive	O
+ventilation	O
+,	O
+a	O
+tension	B-DISO
+pneumothorax	I-DISO
+developed	O
+.	O
+
+Subsequent	O
+management	O
+included	O
+a	O
+thoracotomy	O
+,	O
+defunctioning	O
+oesophagectomy	O
+,	O
+and	O
+gastrostomy	B-DISO
+with	O
+ventilatory	O
+and	O
+inotropic	O
+support	O
+.	O
+
+Five	O
+stages	O
+arose	O
+in	O
+the	O
+participants	O
+'	O
+involvement	O
+against	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+over	O
+12	O
+weeks	O
+:	O
+facing	O
+shock	O
+and	O
+chaos	B-SPEC
+;	O
+searching	O
+for	O
+reliable	O
+sources	O
+to	O
+clarify	O
+myths	O
+;	O
+developing	O
+and	O
+adjusting	O
+nursing	B-PROC
+care	O
+;	O
+supporting	O
+nurses	O
+and	O
+their	O
+clients	O
+;	O
+and	O
+rewarding	O
+nurses	O
+.	O
+
+Five	O
+stages	O
+arose	O
+in	O
+the	O
+participants	O
+'	O
+involvement	O
+against	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+over	O
+12	O
+weeks	O
+:	O
+facing	O
+shock	O
+and	O
+chaos	B-SPEC
+;	O
+searching	O
+for	O
+reliable	O
+sources	O
+to	O
+clarify	O
+myths	O
+;	O
+developing	O
+and	O
+adjusting	O
+nursing	B-PROC
+care	O
+;	O
+supporting	O
+nurses	O
+and	O
+their	O
+clients	O
+;	O
+and	O
+rewarding	O
+nurses	O
+.	O
+
+Such	O
+combination	O
+of	O
+the	O
+2	O
+functional	O
+domains	O
+in	O
+coronavirus	B-SPEC
+nsp14	O
+suggests	O
+that	O
+it	O
+may	O
+represent	O
+a	O
+novel	O
+form	O
+of	O
+RNA	O
+-	O
+processing	O
+enzymes	O
+.	O
+
+Mutational	O
+analysis	O
+in	O
+a	O
+replicon	O
+system	O
+showed	O
+that	O
+the	O
+N7	B-PRGE
+-	I-PRGE
+MTase	I-PRGE
+activity	O
+was	O
+important	O
+for	O
+SARS	B-DISO
+virus	B-PROC
+replication	I-PROC
+/	O
+transcription	B-PROC
+and	O
+can	O
+thus	O
+be	O
+used	O
+as	O
+an	O
+attractive	O
+drug	O
+target	O
+to	O
+develop	O
+antivirals	B-CHED
+for	O
+control	O
+of	O
+coronaviruses	O
+including	O
+the	O
+deadly	O
+SARS	B-DISO
+virus	B-SPEC
+.	O
+
+The	O
+conventional	O
+identification	O
+methods	O
+require	O
+time	O
+-	O
+consuming	O
+culturing	O
+,	O
+and	O
+/	O
+or	O
+detection	O
+of	O
+antibodies	B-COMP
+,	O
+which	O
+are	O
+not	O
+very	O
+sensitive	O
+and	O
+specific	O
+.	O
+
+Individuals	O
+with	O
+psychological	B-DISO
+disorders	O
+were	O
+classified	O
+on	O
+the	O
+basis	O
+of	O
+scores	O
+on	O
+the	O
+30	O
+-	O
+item	O
+General	O
+Health	O
+Questionnaire	O
+during	O
+the	O
+recovery	O
+period	O
+.	O
+
+Until	O
+now	O
+information	O
+on	O
+newly	O
+identified	O
+respiratory	O
+viruses	B-SPEC
+in	O
+immunosuppressed	O
+adult	O
+patients	O
+is	O
+limited	O
+.	O
+
+ABSTRACT	O
+:	O
+Critically	O
+ill	O
+patients	O
+with	O
+severe	O
+systemic	O
+inflammation	B-DISO
+can	O
+develop	O
+critical	B-DISO
+illness	I-DISO
+-	O
+related	O
+corticosteroid	B-CHED
+insufficiency	O
+(	O
+CIRCI	O
+),	O
+which	O
+is	O
+associated	O
+with	O
+a	O
+poor	O
+outcome	O
+.	O
+
+The	O
+results	O
+of	O
+large	O
+scale	O
+multi	O
+-	O
+centre	O
+trials	O
+gave	O
+partially	O
+conflicting	O
+results	O
+arguing	O
+against	O
+the	O
+broad	O
+use	O
+of	O
+corticosteroids	B-CHED
+in	O
+stress	O
+doses	O
+.	O
+
+The	O
+kinetics	O
+of	O
+virus	B-SPEC
+spread	O
+to	O
+and	O
+clearance	O
+from	O
+the	O
+brain	B-ANAT
+appeared	O
+to	O
+depend	O
+on	O
+the	O
+inoculation	O
+dose	O
+.	O
+
+Our	O
+results	O
+provide	O
+new	O
+insights	O
+in	O
+coronavirus	B-SPEC
+pathogenesis	B-DISO
+and	O
+demonstrate	O
+the	O
+potential	O
+of	O
+BLI	O
+to	O
+study	O
+coronavirus	B-SPEC
+-	O
+host	B-COMP
+interactions	O
+in	O
+vivo	O
+.	O
+
+ABSTRACT	O
+:	O
+Recently	O
+,	O
+several	O
+potently	O
+neutralizing	O
+fully	O
+human	O
+monoclonal	O
+antibodies	B-COMP
+(	O
+hmAbs	O
+)	O
+targeting	B-PROC
+the	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+-	O
+associated	O
+coronavirus	B-SPEC
+(	O
+SARS	B-PRGE
+CoV	I-PRGE
+)	O
+S	B-PRGE
+glycoprotein	I-PRGE
+,	O
+and	O
+the	O
+G	B-PRGE
+glycoprotein	I-PRGE
+of	O
+the	O
+paramyxoviruses	O
+Hendra	B-SPEC
+virus	I-SPEC
+(	O
+HeV	B-SPEC
+)	O
+and	O
+Nipah	B-SPEC
+virus	I-SPEC
+(	O
+NiV	O
+)	O
+have	O
+been	O
+discovered	O
+[	O
+corrected	O
+].	O
+
+ABSTRACT	O
+:	O
+Use	O
+of	O
+inhaled	B-PROC
+nitric	B-CHED
+oxide	I-CHED
+in	O
+humans	B-SPEC
+with	O
+traumatic	O
+brain	B-ANAT
+injury	O
+and	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+has	O
+twice	O
+previously	O
+been	O
+reported	O
+to	O
+be	O
+beneficial	O
+.	O
+
+Out	O
+of	O
+the	O
+seven	O
+positive	O
+clones	O
+observed	O
+by	O
+yeast	B-SPEC
+two	O
+-	O
+hybrid	O
+assay	O
+,	O
+only	O
+the	O
+Ddx5	B-PRGE
+(	I-PRGE
+Asp	I-PRGE
+-	I-PRGE
+Glu	B-CHED
+-	I-PRGE
+Ala	B-CHED
+-	I-PRGE
+Asp	B-CHED
+box	I-PRGE
+polypeptide	B-CHED
+5	I-PRGE
+)	I-PRGE
+protein	B-CHED
+showed	O
+specific	O
+interaction	O
+with	O
+SARS	B-PRGE
+-	I-PRGE
+CoV	I-PRGE
+helicase	I-PRGE
+.	O
+
+TITLE	O
+:	O
+ECMO	O
+in	O
+ARDS	B-DISO
+:	O
+a	O
+long	O
+-	O
+term	O
+follow	O
+-	O
+up	O
+study	O
+regarding	O
+pulmonary	B-ANAT
+morphology	O
+and	O
+function	O
+and	O
+health	O
+-	O
+related	O
+quality	O
+of	O
+life	O
+.	O
+
+The	O
+majority	O
+of	O
+ECMO	O
+-	O
+treated	O
+ARDS	B-DISO
+patients	O
+have	O
+good	O
+physical	O
+and	O
+social	O
+functioning	O
+.	O
+
+We	O
+retrospectively	O
+collected	O
+demographic	O
+,	O
+clinical	O
+,	O
+laboratory	O
+,	O
+and	O
+outcomes	O
+data	O
+,	O
+and	O
+we	O
+compared	O
+the	O
+5	O
+cases	O
+in	O
+lung	B-ANAT
+transplant	B-ANAT
+recipients	O
+with	O
+20	O
+cases	O
+in	O
+other	O
+solid	O
+organ	B-ANAT
+transplant	I-ANAT
+recipients	O
+(	O
+heart	B-ANAT
+,	O
+2	O
+;	O
+kidney	B-ANAT
+,	O
+13	O
+;	O
+liver	B-ANAT
+,	O
+5	O
+).	O
+
+Our	O
+study	O
+supports	O
+the	O
+observation	O
+that	O
+adult	O
+mice	B-SPEC
+do	O
+have	O
+progressively	O
+greater	O
+immune	O
+reactions	O
+than	O
+weanling	O
+and	O
+adolescent	O
+ones	O
+over	O
+time	O
+.	O
+
+RESULTS	O
+:	O
+Histopathological	O
+analysis	O
+of	O
+adult	O
+male	O
+BALB	O
+/	O
+C	O
+mice	B-SPEC
+after	O
+N	O
+-	O
+protein	B-CHED
+infection	B-DISO
+showed	O
+progressive	O
+inflammatory	O
+reactions	O
+,	O
+especially	O
+pulmonary	B-DISO
+edema	I-DISO
+,	O
+in	O
+accordance	O
+with	O
+a	O
+moderately	O
+(	O
+approximately	O
+13	O
+%)	O
+elevated	O
+level	O
+of	O
+W	O
+/	O
+D	O
+ratio	O
+at	O
+24	O
+h	O
+.	O
+Although	O
+adult	O
+groups	O
+underwent	O
+a	O
+progressive	O
+lung	B-DISO
+inflammation	I-DISO
+in	O
+the	O
+acute	O
+phase	O
+accompanied	O
+by	O
+raised	O
+levels	O
+of	O
+TNF	B-PRGE
+-	I-PRGE
+alpha	I-PRGE
+in	O
+serum	B-COMP
+,	O
+no	O
+significant	O
+changes	O
+in	O
+lung	B-PRGE
+TNF	I-PRGE
+-	I-PRGE
+alpha	I-PRGE
+level	O
+were	O
+reported	O
+simultaneously	O
+.	O
+
+ABSTRACT	O
+:	O
+Impact	O
+of	O
+recently	O
+discovered	O
+viruses	O
+on	O
+epidemiology	O
+of	O
+acute	O
+respiratory	B-DISO
+tract	I-DISO
+infections	I-DISO
+(	O
+ARTI	O
+)	O
+is	O
+still	O
+unclear	O
+.	O
+
+Polyclonal	O
+antibody	B-COMP
+of	O
+this	O
+protein	B-CHED
+was	O
+obtained	O
+,	O
+and	O
+Western	O
+blotting	O
+assay	O
+indicated	O
+that	O
+the	O
+X5	B-PRGE
+protein	I-PRGE
+has	O
+the	O
+strong	O
+property	O
+of	O
+antigen	B-CHED
+.	O
+
+In	O
+multivariate	O
+logistic	O
+regression	O
+analysis	O
+,	O
+myalgia	B-DISO
+was	O
+less	O
+likely	O
+with	O
+HCoV	O
+infection	B-DISO
+than	O
+with	O
+LDI	O
+(	O
+OR	O
+,	O
+0	O
+.	O
+27	O
+[	O
+95	O
+%	O
+confidence	O
+limit	O
+,	O
+0	O
+.	O
+13	O
+-	O
+0	O
+.	O
+58	O
+]).	O
+
+There	O
+are	O
+no	O
+treatment	O
+guidelines	O
+for	O
+hip	O
+necrosis	B-PROC
+in	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+(	O
+SARS	B-DISO
+)	O
+patients	O
+.	O
+
+MRI	O
+showed	O
+a	O
+trend	O
+of	O
+reduction	O
+in	O
+bone	B-DISO
+marrow	I-DISO
+edema	I-DISO
+and	O
+the	O
+size	O
+of	O
+the	O
+lesion	O
+,	O
+but	O
+no	O
+changes	O
+in	O
+the	O
+stage	O
+of	O
+the	O
+lesion	O
+.	O
+
+Cocktail	O
+therapy	O
+seems	O
+promising	O
+in	O
+delaying	O
+the	O
+disease	B-DISO
+progression	I-DISO
+of	O
+SARS	B-DISO
+-	O
+associated	O
+femoral	B-ANAT
+head	I-ANAT
+necrosis	B-PROC
+in	O
+the	O
+short	O
+-	O
+term	O
+.	O
+
+RESULTS	O
+:	O
+At	O
+the	O
+4	O
+-	O
+year	O
+follow	O
+-	O
+up	O
+,	O
+significant	O
+improvements	O
+in	O
+pain	O
+score	O
+and	O
+Harris	O
+hip	B-ANAT
+score	O
+were	O
+observed	O
+in	O
+all	O
+cases	O
+(	O
+p	O
+<	O
+0	O
+.	O
+001	O
+).	O
+
+TITLE	O
+:	O
+Sequence	O
+and	O
+phylogenetic	O
+analysis	O
+of	O
+S1	O
+,	O
+S2	O
+,	O
+M	O
+,	O
+and	O
+N	O
+genes	O
+of	O
+infectious	B-DISO
+bronchitis	B-DISO
+virus	B-SPEC
+isolates	O
+from	O
+Malaysia	O
+.	O
+
+The	O
+patient	O
+underwent	O
+surgical	O
+debridement	O
+with	O
+stabilization	O
+of	O
+the	O
+anterior	O
+column	B-ANAT
+from	O
+T6	O
+-	O
+T9	O
+using	O
+an	O
+expandable	O
+titanium	B-CHED
+cage	O
+,	O
+autologous	O
+bone	O
+graft	B-ANAT
+,	O
+and	O
+an	O
+anterolateral	O
+locking	O
+plate	O
+.	O
+
+The	O
+patient	O
+recovered	O
+well	O
+under	O
+adjunctive	O
+antibiotic	B-CHED
+treatment	O
+.	O
+
+She	O
+presented	O
+again	O
+to	O
+the	O
+emergency	B-DISO
+department	O
+6	O
+months	O
+later	O
+,	O
+secondary	O
+to	O
+a	O
+repeat	O
+fall	O
+,	O
+with	O
+acute	B-DISO
+paraplegia	I-DISO
+of	O
+the	O
+lower	B-ANAT
+extremities	I-ANAT
+and	O
+radiographic	O
+evidence	O
+of	O
+failure	O
+of	O
+fixation	O
+of	O
+the	O
+anterior	O
+T	O
+-	O
+spine	B-COMP
+.	O
+
+CONCLUSIONS	O
+:	O
+This	O
+catastrophic	O
+example	O
+of	O
+a	O
+lethal	O
+outcome	O
+secondary	O
+to	O
+failure	O
+of	O
+anterior	O
+column	B-ANAT
+fixation	O
+for	O
+pyogenic	O
+thoracic	B-DISO
+spondylodiscitis	B-DISO
+underlines	O
+the	O
+notion	O
+that	O
+surgical	O
+strategies	O
+for	O
+the	O
+infected	O
+spine	B-COMP
+must	O
+be	O
+aimed	O
+at	O
+achieving	O
+absolute	O
+stability	O
+by	O
+a	O
+360	O
+degrees	O
+fusion	O
+.	O
+
+This	O
+study	O
+evaluated	O
+survival	O
+of	O
+two	O
+surrogate	O
+coronaviruses	O
+,	O
+transmissible	O
+gastroenteritis	B-DISO
+(	O
+TGEV	B-SPEC
+)	O
+and	O
+mouse	B-DISO
+hepatitis	I-DISO
+(	O
+MHV	B-SPEC
+).	O
+
+TITLE	O
+:	O
+Mental	B-DISO
+Symptoms	I-DISO
+in	O
+Different	O
+Health	O
+Professionals	O
+During	O
+the	O
+SARS	B-DISO
+Attack	O
+:	O
+A	O
+Follow	O
+-	O
+up	O
+Study	O
+.	O
+
+Then	O
+arterial	B-ANAT
+oxygen	B-PROC
+partial	I-PROC
+pressure	I-PROC
+(	O
+PaO2	O
+),	O
+lung	B-ANAT
+histology	O
+,	O
+lung	B-ANAT
+tissue	I-ANAT
+nitric	B-CHED
+oxide	I-CHED
+(	O
+NO	O
+)	O
+production	O
+and	O
+expression	B-PROC
+of	O
+nitric	B-CHED
+oxide	I-CHED
+synthases	O
+(	O
+NOS	B-PRGE
+)	O
+were	O
+detected	O
+at	O
+0	O
+.	O
+5	O
+,	O
+1	O
+,	O
+2	O
+,	O
+3	O
+or	O
+4	O
+h	O
+after	O
+LPS	B-DISO
+injection	O
+.	O
+
+Dexamethasone	B-CHED
+could	O
+ameliorate	O
+PaO2	O
+and	O
+lung	B-ANAT
+damage	O
+evidently	O
+,	O
+which	O
+were	O
+paralleled	O
+by	O
+significant	O
+decreases	O
+in	O
+the	O
+production	O
+of	O
+NO	O
+and	O
+in	O
+the	O
+expression	B-PROC
+of	O
+iNOS	B-PRGE
+mRNA	I-PRGE
+.	O
+
+ABSTRACT	O
+:	O
+Interest	O
+in	O
+the	O
+potential	O
+of	O
+monoclonal	O
+antibodies	O
+(	O
+mAbs	O
+)	O
+to	O
+serve	O
+as	O
+therapeutic	O
+agents	O
+has	O
+surged	O
+in	O
+the	O
+past	O
+decade	O
+with	O
+a	O
+major	O
+emphasis	O
+on	O
+human	B-SPEC
+viral	B-DISO
+diseases	I-DISO
+.	O
+
+Rats	B-SPEC
+were	O
+intravenously	O
+injected	O
+with	O
+oleic	B-CHED
+acid	I-CHED
+(	O
+OA	O
+)	O
+to	O
+induce	O
+ALI	O
+and	O
+30	O
+minutes	O
+later	O
+they	O
+were	O
+divided	O
+into	O
+five	O
+groups	O
+:	O
+model	O
+(	O
+injury	O
+only	O
+),	O
+PPS	B-PRGE
+aerosol	I-PRGE
+(	O
+PPS	B-PRGE
+-	I-PRGE
+aer	B-COMP
+),	O
+saline	O
+aerosol	O
+(	O
+saline	O
+-	O
+aer	B-COMP
+),	O
+PPS	B-DISO
+instillation	O
+(	O
+PPS	B-DISO
+-	O
+inst	O
+),	O
+and	O
+saline	O
+instillation	O
+(	O
+Saline	O
+-	O
+Inst	O
+).	O
+
+Those	O
+results	O
+show	O
+that	O
+liver	B-ANAT
+injury	O
+after	O
+viral	B-DISO
+infection	I-DISO
+may	O
+lead	O
+to	O
+the	O
+spreading	O
+of	O
+the	O
+immune	B-PROC
+response	I-PROC
+and	O
+to	O
+an	O
+increase	O
+of	O
+serum	B-COMP
+IgG	B-PRGE
+,	O
+suggesting	O
+that	O
+the	O
+procedure	O
+used	O
+herein	O
+could	O
+simulate	O
+the	O
+onset	O
+of	O
+autoimmune	B-DISO
+hepatitis	I-DISO
+.	O
+
+TITLE	O
+:	O
+Roles	O
+of	O
+spike	O
+protein	B-CHED
+in	O
+the	O
+pathogenesis	B-DISO
+of	O
+SARS	B-DISO
+coronavirus	B-SPEC
+.	O
+
+Two	O
+new	O
+aspects	O
+of	O
+the	O
+interaction	O
+between	O
+SARS	B-PRGE
+-	I-PRGE
+CoV	I-PRGE
+S	I-PRGE
+protein	B-CHED
+and	O
+the	O
+cell	B-COMP
+have	O
+been	O
+defined	O
+.	O
+
+These	O
+have	O
+important	O
+implications	O
+in	O
+the	O
+pathogenesis	B-DISO
+of	O
+SARS	B-DISO
+,	O
+providing	O
+opportunities	O
+for	O
+developing	O
+vaccines	O
+and	O
+antivirals	B-CHED
+against	O
+SARS	B-DISO
+-	O
+CoV	O
+.	O
+4	O
+.	O
+
+ABSTRACT	O
+:	O
+Direct	O
+hemoperfusion	O
+with	O
+polymyxin	O
+B	O
+-	O
+immobilized	O
+fibers	O
+(	O
+PMX	O
+-	O
+DHP	O
+)	O
+has	O
+been	O
+widely	O
+regarded	O
+as	O
+a	O
+treatment	O
+modality	O
+for	O
+septic	B-DISO
+shock	I-DISO
+in	O
+Japan	O
+.	O
+
+It	O
+was	O
+suggested	O
+that	O
+early	O
+introduction	O
+of	O
+PMX	O
+-	O
+DHP	O
+for	O
+severe	B-DISO
+sepsis	I-DISO
+may	O
+improve	O
+oxygenation	B-PROC
+.	O
+
+ABSTRACT	O
+:	O
+SARS	B-DISO
+coronavirus	B-SPEC
+(	O
+SARS	B-DISO
+-	O
+CoV	O
+)	O
+was	O
+identified	O
+as	O
+the	O
+etiological	O
+agent	O
+of	O
+SARS	B-DISO
+,	O
+and	O
+extensive	O
+investigations	O
+indicated	O
+that	O
+it	O
+originated	O
+from	O
+an	O
+animal	B-SPEC
+source	O
+(	O
+probably	O
+bats	B-SPEC
+)	O
+and	O
+was	O
+recently	O
+introduced	O
+into	O
+the	O
+human	B-SPEC
+population	O
+via	O
+wildlife	O
+animals	B-SPEC
+from	O
+wet	O
+markets	O
+in	O
+southern	O
+China	O
+.	O
+
+In	O
+addition	O
+,	O
+the	O
+replicase	B-PRGE
+experienced	O
+positive	O
+selection	O
+only	O
+in	O
+human	B-SPEC
+patients	O
+,	O
+whereas	O
+assembly	O
+proteins	B-CHED
+experienced	O
+positive	O
+selection	O
+mainly	O
+in	O
+the	O
+middle	O
+and	O
+late	O
+phases	O
+.	O
+
+TITLE	O
+:	O
+Comparison	O
+of	O
+vesicular	B-SPEC
+stomatitis	I-SPEC
+virus	I-SPEC
+pseudotyped	O
+with	O
+the	O
+S	O
+proteins	B-CHED
+from	O
+a	O
+porcine	B-SPEC
+and	O
+a	O
+human	O
+coronavirus	O
+.	O
+
+Higher	O
+infectivity	O
+values	O
+were	O
+obtained	O
+with	O
+the	O
+SARS	B-PRGE
+-	I-PRGE
+CoV	I-PRGE
+S	I-PRGE
+protein	B-CHED
+than	O
+with	O
+the	O
+TGEV	B-PRGE
+S	I-PRGE
+protein	B-CHED
+.	O
+
+In	O
+the	O
+case	O
+of	O
+the	O
+SARS	B-PRGE
+-	I-PRGE
+CoV	I-PRGE
+S	I-PRGE
+protein	B-CHED
+,	O
+truncation	B-DISO
+of	O
+the	O
+cytoplasmic	B-ANAT
+tail	I-ANAT
+resulted	O
+in	O
+increased	O
+infectivity	O
+.	O
+
+Spinal	B-ANAT
+cord	I-ANAT
+trauma	O
+was	O
+suspected	O
+and	O
+high	O
+doses	O
+of	O
+dexamethasone	B-CHED
+were	O
+administered	O
+.	O
+
+TITLE	O
+:	O
+Suppression	B-PROC
+of	O
+host	B-COMP
+gene	B-PROC
+expression	I-PROC
+by	O
+nsp1	B-PRGE
+proteins	I-PRGE
+of	O
+group	O
+2	O
+bat	B-ENZY
+coronaviruses	O
+.	O
+
+The	O
+host	B-COMP
+mRNA	B-PROC
+degradation	I-PROC
+and	O
+translational	B-PROC
+suppression	B-DISO
+activities	O
+of	O
+nsp1	B-PRGE
+of	O
+SARS	B-PRGE
+-	I-PRGE
+CoV	I-PRGE
+and	O
+Rm1	B-PRGE
+nsp1	I-PRGE
+were	O
+similar	O
+and	O
+stronger	O
+than	O
+the	O
+activities	O
+of	O
+the	O
+nsp1	B-PRGE
+proteins	I-PRGE
+of	O
+133	O
+and	O
+HKU9	O
+-	O
+1	O
+.	O
+
+The	O
+results	O
+of	O
+our	O
+studies	O
+suggested	O
+a	O
+conserved	O
+function	O
+among	O
+nsp1	B-PRGE
+proteins	I-PRGE
+of	O
+SARS	B-DISO
+-	I-PRGE
+CoV	I-PRGE
+and	I-PRGE
+group	I-PRGE
+2	I-PRGE
+bat	B-ENZY
+CoVs	I-PRGE
+.	O
+
+ABSTRACT	O
+:	O
+Wide	O
+variation	O
+between	O
+hospitals	O
+in	O
+the	O
+quality	O
+of	O
+critical	O
+care	O
+lead	O
+to	O
+many	O
+potentially	O
+avoidable	O
+deaths	B-PROC
+.	O
+
+Within	O
+hours	O
+of	O
+initiation	O
+increase	O
+,	O
+ICP	B-DISO
+improved	O
+and	O
+normalized	O
+.	O
+
+For	O
+the	O
+most	O
+part	O
+,	O
+the	O
+major	O
+plagues	B-DISO
+of	O
+antiquity	O
+remain	O
+historical	O
+footnotes	O
+,	O
+yet	O
+,	O
+despite	O
+many	O
+advances	O
+,	O
+there	O
+is	O
+clear	O
+evidence	O
+that	O
+major	O
+pandemic	O
+illness	O
+is	O
+always	O
+just	O
+one	O
+outbreak	O
+away	O
+.	O
+
+In	O
+addition	O
+to	O
+the	O
+HIV	B-DISO
+pandemic	O
+,	O
+the	O
+smaller	O
+epidemic	O
+outbreaks	O
+of	O
+Legionnaire	B-DISO
+'	I-DISO
+s	I-DISO
+disease	I-DISO
+,	O
+hantavirus	B-DISO
+pulmonary	B-ANAT
+syndrome	I-DISO
+,	O
+and	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+,	O
+among	O
+many	O
+others	O
+,	O
+points	O
+out	O
+the	O
+potential	O
+risk	O
+associated	O
+with	O
+a	O
+lack	O
+of	O
+preplanning	O
+and	O
+preparedness	O
+.	O
+
+TITLE	O
+:	O
+A	O
+child	O
+with	O
+benign	O
+acute	O
+childhood	O
+myositis	B-DISO
+after	O
+influenza	B-DISO
+.	O
+
+The	O
+URI	B-PRGE
+symptoms	I-PRGE
+that	O
+precede	O
+BACM	O
+are	O
+consistent	O
+with	O
+an	O
+uncomplicated	O
+viral	O
+influenza	B-PATH
+infection	B-DISO
+and	O
+include	O
+fever	B-PROC
+,	O
+malaise	B-DISO
+,	O
+cough	B-DISO
+,	O
+sore	B-DISO
+throat	I-DISO
+,	O
+headache	B-DISO
+,	O
+and	O
+rhinitis	B-DISO
+.	O
+
+TITLE	O
+:	O
+Lung	B-ANAT
+abscesses	I-DISO
+:	O
+review	O
+of	O
+60	O
+cases	O
+.	O
+
+One	O
+case	O
+with	O
+transitional	B-DISO
+cell	I-DISO
+carcinoma	I-DISO
+of	I-DISO
+the	I-DISO
+urinary	B-ANAT
+bladder	I-ANAT
+developed	O
+acute	O
+episode	O
+of	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+(	O
+ARDS	B-DISO
+).	O
+
+Chronic	O
+hypercalcemia	B-DISO
+results	O
+in	O
+severe	O
+metastatic	B-DISO
+calcification	I-DISO
+.	O
+
+An	O
+increase	O
+in	O
+plasma	B-ANAT
+calcium	B-CHED
+above	O
+5	O
+mM	O
+is	O
+a	O
+risk	O
+factor	O
+for	O
+developing	O
+ARDS	B-DISO
+and	O
+ALI	O
+.	O
+
+Our	O
+recent	O
+experiment	O
+in	O
+conscious	O
+rats	B-SPEC
+and	O
+isolated	O
+rat	B-SPEC
+'	O
+s	O
+lungs	B-ANAT
+supported	O
+this	O
+contention	O
+.	O
+
+TITLE	O
+:	O
+The	O
+current	O
+infectious	B-DISO
+risks	O
+of	O
+transfusions	O
+.	O
+
+RESULTS	O
+:	O
+Transmission	O
+of	O
+infectious	B-DISO
+agents	O
+from	O
+blood	B-ANAT
+transfusion	O
+is	O
+rare	O
+.	O
+
+ABSTRACT	O
+:	O
+Coronavirus	B-SPEC
+M	O
+protein	B-CHED
+is	O
+an	O
+essential	O
+component	O
+of	O
+virion	B-COMP
+and	O
+plays	O
+pivotal	O
+roles	O
+in	O
+virion	B-PROC
+assembly	I-PROC
+,	O
+budding	B-PATH
+and	O
+maturation	B-PROC
+.	O
+
+We	O
+modeled	O
+a	O
+generic	O
+disease	O
+caused	O
+by	O
+a	O
+pathogen	O
+apparently	O
+transmitted	B-DISO
+by	O
+close	O
+interpersonal	O
+contact	O
+,	O
+but	O
+about	O
+which	O
+little	O
+else	O
+is	O
+known	O
+.	O
+
+We	O
+derived	O
+an	O
+expression	B-PROC
+for	O
+Re	O
+,	O
+the	O
+reproduction	B-PROC
+number	O
+,	O
+took	O
+its	O
+partial	O
+derivatives	O
+with	O
+respect	O
+to	O
+control	O
+parameters	O
+,	O
+and	O
+encoded	O
+these	O
+analytical	O
+results	O
+in	O
+a	O
+user	O
+-	O
+friendly	O
+Mathematica	O
+notebook	O
+.	O
+
+TITLE	O
+:	O
+[	O
+Treatment	O
+of	O
+severe	B-DISO
+sepsis	I-DISO
+].	O
+
+Today	O
+,	O
+the	O
+multidisciplinary	O
+treatment	O
+of	O
+severe	B-DISO
+sepsis	I-DISO
+includes	O
+haemodynamic	O
+,	O
+respiratory	O
+,	O
+endocrine	B-CHED
+,	O
+immune	O
+,	O
+and	O
+coagulation	B-PROC
+aspects	O
+besides	O
+the	O
+control	O
+of	O
+the	O
+underlying	B-DISO
+infection	I-DISO
+.	O
+
+AAV1	O
+-	O
+hrGFP	O
+infusions	O
+resulted	O
+in	O
+approximately	O
+550	O
+,	O
+700	O
+,	O
+and	O
+73	O
+mm	O
+(	O
+3	O
+)	O
+coverage	O
+after	O
+infusion	O
+into	O
+corona	B-ANAT
+radiata	I-ANAT
+,	O
+striatum	B-ANAT
+,	O
+and	O
+basal	B-ANAT
+forebrain	I-ANAT
+,	O
+respectively	O
+.	O
+
+TITLE	O
+:	O
+Differential	O
+virological	O
+and	O
+immunological	O
+outcome	O
+of	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+coronavirus	B-SPEC
+infection	I-DISO
+in	O
+susceptible	O
+and	O
+resistant	O
+transgenic	B-SPEC
+mice	I-SPEC
+expressing	O
+human	B-SPEC
+angiotensin	B-PRGE
+-	I-PRGE
+converting	I-PRGE
+enzyme	I-PRGE
+2	I-PRGE
+.	O
+
+ABSTRACT	O
+:	O
+Nidoviruses	O
+(	O
+arteriviruses	B-SPEC
+,	O
+coronaviruses	O
+,	O
+and	O
+roniviruses	O
+)	O
+are	O
+a	O
+phylogenetically	O
+compact	O
+but	O
+diverse	O
+group	O
+of	O
+positive	O
+-	O
+strand	O
+RNA	O
+viruses	B-SPEC
+that	O
+includes	O
+important	O
+human	B-SPEC
+and	O
+animal	B-SPEC
+pathogens	O
+.	O
+
+NendoU	O
+activity	O
+was	O
+previously	O
+verified	O
+in	O
+vitro	O
+for	O
+the	O
+coronavirus	B-SPEC
+nsp15	O
+,	O
+but	O
+not	O
+for	O
+any	O
+of	O
+its	O
+distantly	O
+related	O
+orthologs	O
+from	O
+other	O
+nidovirus	B-SPEC
+lineages	O
+,	O
+like	O
+the	O
+arterivirus	B-SPEC
+nsp11	O
+.	O
+
+The	O
+newly	O
+developed	O
+RT	O
+-	O
+PCR	O
+/	O
+HRM	O
+curve	O
+analysis	O
+model	O
+could	O
+detect	O
+and	O
+rapidly	O
+identify	O
+novel	O
+and	O
+vaccine	O
+-	O
+related	O
+IBV	B-SPEC
+strains	O
+,	O
+as	O
+confirmed	O
+by	O
+S1	B-PRGE
+gene	I-PRGE
+and	O
+3	B-PRGE
+'	I-PRGE
+UTR	I-PRGE
+nucleotide	I-PRGE
+sequences	I-PRGE
+.	O
+
+Some	O
+investigators	O
+have	O
+suggested	O
+early	O
+and	O
+aggressive	B-DISO
+treatment	O
+of	O
+the	O
+trauma	O
+-	O
+induced	O
+coagulopathy	B-DISO
+by	O
+transfusion	O
+of	O
+fresh	B-ANAT
+-	O
+frozen	O
+plasma	B-ANAT
+(	O
+FFP	O
+)	O
+and	O
+packed	O
+red	B-ANAT
+blood	I-ANAT
+cells	I-ANAT
+(	O
+PRBC	O
+)	O
+in	O
+a	O
+1	O
+:	O
+1	O
+ratio	O
+.	O
+
+ABSTRACT	O
+:	O
+The	O
+8ab	O
+protein	B-CHED
+of	O
+SARS	B-PRGE
+-	I-PRGE
+CoV	I-PRGE
+is	O
+a	O
+group	O
+-	O
+specific	O
+accessory	O
+protein	B-CHED
+,	O
+which	O
+is	O
+lost	B-CHED
+when	O
+the	O
+virus	B-SPEC
+was	O
+transmitted	B-DISO
+from	O
+animals	B-SPEC
+to	O
+humans	B-SPEC
+due	O
+to	O
+a	O
+29	O
+-	O
+nucleotide	B-CHED
+deletion	O
+in	O
+the	O
+ORF8ab	O
+region	O
+.	O
+
+When	O
+ectopically	O
+expressed	B-PROC
+in	O
+mammalian	B-SPEC
+cells	B-COMP
+,	O
+8ab	O
+induced	O
+the	O
+proteolysis	B-PROC
+of	O
+ATF6	B-PRGE
+and	O
+the	O
+translocation	B-DISO
+of	O
+its	O
+cleaved	B-ANAT
+DNA	O
+-	O
+binding	B-FUNC
+and	O
+transcription	B-PROC
+-	O
+activation	O
+domains	O
+from	O
+the	O
+ER	O
+to	O
+the	O
+nucleus	B-COMP
+.	O
+
+ABSTRACT	O
+:	O
+To	O
+construct	O
+the	O
+expression	B-PROC
+plasmid	O
+of	O
+S2	B-PRGE
+extracellular	I-PRGE
+domain	I-PRGE
+(	O
+S2ED	O
+)	O
+of	O
+SARS	B-DISO
+-	O
+coronavirus	B-SPEC
+(	O
+SARS	B-DISO
+-	O
+Cov	O
+)	O
+spike	B-PRGE
+protein	I-PRGE
+(	O
+S	B-PRGE
+protein	I-PRGE
+)	O
+and	O
+enhanced	B-PRGE
+green	I-PRGE
+fluorescent	I-PRGE
+protein	I-PRGE
+(	O
+EGFP	O
+)	O
+to	O
+obtain	O
+the	O
+fusion	O
+protein	B-CHED
+expressed	B-PROC
+in	O
+prokaryotic	O
+cells	B-COMP
+.	O
+
+When	O
+incubated	O
+with	O
+Hela	B-ANAT
+cells	I-ANAT
+,	O
+the	O
+purified	O
+protein	B-CHED
+could	O
+not	O
+internalize	O
+through	O
+membrane	B-PROC
+fusion	I-PROC
+.	O
+
+ABSTRACT	O
+:	O
+Lemierre	B-DISO
+'	I-DISO
+s	I-DISO
+syndrome	I-DISO
+is	O
+characterized	O
+by	O
+a	O
+primary	O
+oropharyngeal	B-ANAT
+infection	B-DISO
+in	O
+a	O
+young	O
+healthy	O
+person	O
+who	O
+subsequently	O
+develops	O
+septic	B-DISO
+thrombophlebitis	I-DISO
+of	O
+the	O
+internal	B-ANAT
+jugular	I-ANAT
+vein	I-ANAT
+and	O
+metastatic	O
+abscesses	B-DISO
+.	O
+
+TITLE	O
+:	O
+Pandemic	O
+threats	O
+and	O
+the	O
+need	O
+for	O
+new	O
+emergency	B-DISO
+public	O
+health	O
+legislation	O
+in	O
+Canada	O
+.	O
+
+Intermediate	B-DISO
+syndrome	I-DISO
+.	O
+
+Various	O
+pre	O
+-	O
+and	O
+postnatal	O
+factors	O
+,	O
+-	O
+such	O
+as	O
+exposure	O
+to	O
+chorioamnionitis	B-DISO
+,	O
+pneumonia	B-DISO
+,	O
+fluid	O
+lung	B-ANAT
+,	O
+sepsis	B-DISO
+and	O
+asphyxia	B-DISO
+-	O
+can	O
+induce	O
+an	O
+injurious	O
+inflammatory	B-DISO
+response	I-DISO
+in	O
+the	O
+lung	B-ANAT
+which	O
+may	O
+subsequently	O
+affect	O
+surfactant	B-CHED
+function	O
+,	O
+synthesis	B-PROC
+and	O
+alveolar	B-ANAT
+stability	O
+.	O
+
+TITLE	O
+:	O
+C	O
+-	O
+terminal	O
+domain	O
+of	O
+SARS	B-PRGE
+-	I-PRGE
+CoV	I-PRGE
+main	I-PRGE
+protease	I-PRGE
+can	O
+form	O
+a	O
+3D	O
+domain	O
+-	O
+swapped	O
+dimer	O
+.	O
+
+ABSTRACT	O
+:	O
+SARS	B-DISO
+coronavirus	B-SPEC
+main	O
+protease	O
+(	O
+M	O
+(	O
+pro	B-CHED
+))	O
+plays	O
+an	O
+essential	O
+role	O
+in	O
+the	O
+extensive	O
+proteolytic	B-PROC
+processing	I-PROC
+of	O
+the	O
+viral	O
+polyproteins	O
+(	O
+pp1a	B-PRGE
+and	O
+pp1ab	O
+),	O
+and	O
+it	O
+is	O
+an	O
+important	O
+target	O
+for	O
+anti	O
+-	O
+SARS	B-DISO
+drug	O
+development	B-PROC
+.	O
+
+TITLE	O
+:	O
+Coronavirus	B-SPEC
+infection	I-DISO
+and	O
+hospitalizations	O
+for	O
+acute	O
+respiratory	O
+illness	O
+in	O
+young	O
+children	O
+.	O
+
+TITLE	O
+:	O
+Activation	O
+of	O
+the	O
+SARS	B-PRGE
+coronavirus	B-SPEC
+spike	I-PRGE
+protein	B-CHED
+via	O
+sequential	O
+proteolytic	B-PROC
+cleavage	B-PROC
+at	O
+two	O
+distinct	O
+sites	O
+.	O
+
+In	O
+some	O
+cases	O
+,	O
+the	O
+S	B-PRGE
+protein	I-PRGE
+is	O
+proteolytically	O
+cleaved	B-ANAT
+at	O
+the	O
+S1	O
+-	O
+S2	O
+boundary	O
+.	O
+
+In	O
+the	O
+case	O
+of	O
+the	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+coronavirus	B-SPEC
+(	O
+SARS	B-DISO
+-	O
+CoV	O
+),	O
+it	O
+has	O
+been	O
+shown	O
+that	O
+virus	B-SPEC
+entry	O
+requires	O
+the	O
+endosomal	B-PRGE
+protease	I-PRGE
+cathepsin	I-PRGE
+L	I-PRGE
+;	O
+however	O
+,	O
+it	O
+was	O
+also	O
+found	O
+that	O
+infection	B-DISO
+of	O
+SARS	B-PRGE
+-	I-PRGE
+CoV	I-PRGE
+could	O
+be	O
+strongly	O
+induced	O
+by	O
+trypsin	B-PRGE
+treatment	O
+.	O
+
+Overall	O
+,	O
+in	O
+terms	O
+of	O
+how	O
+cleavage	B-PROC
+might	O
+activate	O
+membrane	B-PROC
+fusion	I-PROC
+,	O
+proteolytic	B-PROC
+processing	I-PROC
+of	O
+the	O
+SARS	B-PRGE
+-	I-PRGE
+CoV	I-PRGE
+S	I-PRGE
+protein	B-CHED
+remains	O
+unclear	O
+.	O
+
+Taken	O
+together	O
+,	O
+these	O
+data	O
+suggest	O
+a	O
+novel	O
+priming	O
+mechanism	O
+for	O
+a	O
+viral	O
+fusion	O
+protein	B-CHED
+,	O
+with	O
+a	O
+critical	O
+proteolytic	B-PROC
+cleavage	B-PROC
+event	O
+on	O
+the	O
+SARS	B-PRGE
+-	I-PRGE
+CoV	I-PRGE
+S	I-PRGE
+protein	B-CHED
+at	O
+position	O
+797	O
+(	O
+S2	O
+'),	O
+acting	O
+in	O
+concert	O
+with	O
+the	O
+S1	O
+-	O
+S2	O
+cleavage	B-PROC
+site	O
+to	O
+mediate	O
+membrane	B-PROC
+fusion	I-PROC
+and	O
+virus	B-SPEC
+infectivity	O
+.	O
+
+Similar	O
+to	O
+other	O
+N	O
+-	O
+glycosylated	O
+proteins	B-CHED
+,	O
+the	O
+glycosylation	B-PROC
+of	O
+SARS	B-PRGE
+-	I-PRGE
+CoV	I-PRGE
+E	I-PRGE
+protein	B-CHED
+occurred	O
+co	O
+-	O
+translationally	O
+in	O
+the	O
+presence	O
+of	O
+microsomes	B-ANAT
+.	O
+
+11	O
+-	O
+33	O
+and	O
+37	O
+-	O
+59	O
+)	O
+are	O
+predicted	O
+to	O
+be	O
+alpha	O
+-	O
+helices	B-SPEC
+,	O
+which	O
+penetrate	O
+into	O
+membranes	B-ANAT
+by	O
+themselves	O
+.	O
+
+The	O
+other	O
+Argentinean	O
+isolates	O
+formed	O
+three	O
+separate	O
+clusters	B-CHED
+(	O
+A	O
+,	O
+B	O
+and	O
+C	O
+),	O
+distant	O
+from	O
+the	O
+vaccine	O
+serotypes	O
+,	O
+with	O
+no	O
+correlation	O
+between	O
+the	O
+generated	O
+clusters	O
+and	O
+a	O
+geographic	O
+pattern	O
+.	O
+
+ABSTRACT	O
+:	O
+The	O
+spike	O
+(	O
+S	O
+)	O
+protein	B-CHED
+of	O
+the	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+coronavirus	B-SPEC
+(	O
+SARS	B-DISO
+-	O
+CoV	O
+)	O
+is	O
+responsible	O
+for	O
+host	O
+cell	B-COMP
+attachment	I-COMP
+and	O
+fusion	O
+of	O
+the	O
+viral	O
+and	O
+host	O
+cell	B-COMP
+membranes	I-COMP
+.	O
+
+Both	O
+S	O
+and	O
+the	O
+RBD	O
+are	O
+highly	O
+immunogenic	O
+and	O
+both	O
+have	O
+been	O
+found	O
+to	O
+elicit	O
+neutralizing	O
+antibodies	B-COMP
+.	O
+
+ABSTRACT	O
+:	O
+Clinical	O
+use	O
+of	O
+bone	O
+marrow	O
+mesenchymal	B-ANAT
+stem	I-ANAT
+cells	I-ANAT
+(	O
+BMMSCs	O
+)	O
+holds	O
+great	O
+promise	O
+for	O
+regenerative	O
+medicine	B-CHED
+in	O
+intractable	O
+lung	B-DISO
+diseases	I-DISO
+,	O
+such	O
+as	O
+lung	B-DISO
+fibrosis	I-DISO
+or	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+.	O
+
+In	O
+order	B-SPEC
+to	O
+evaluate	O
+the	O
+clinical	O
+applicability	O
+of	O
+BMMSC	O
+transplantation	O
+,	O
+we	O
+tested	O
+whether	O
+engraftment	B-PROC
+of	O
+minimally	O
+cultured	O
+BMMSCs	O
+ameliorates	O
+progressive	O
+fibrotic	O
+lung	B-ANAT
+injury	O
+.	O
+
+2	O
+-	O
+h	O
+adherent	O
+BMMSCs	O
+were	O
+smaller	O
+,	O
+less	O
+granular	O
+,	O
+possessed	B-DISO
+higher	O
+proliferative	B-DISO
+capacity	O
+and	O
+expressed	B-PROC
+higher	O
+levels	O
+of	O
+several	O
+stem	B-ANAT
+cell	I-ANAT
+markers	O
+and	O
+chemokine	O
+receptors	O
+than	O
+9	O
+-	O
+day	O
+cultured	O
+BMMSCs	O
+,	O
+but	O
+lower	O
+type	B-PRGE
+I	I-PRGE
+procollagen	I-PRGE
+,	O
+alpha	B-PRGE
+-	I-PRGE
+smooth	I-PRGE
+muscle	I-PRGE
+actin	I-PRGE
+,	O
+tumour	B-PRGE
+necrosis	I-PRGE
+factor	I-PRGE
+-	I-PRGE
+beta	I-PRGE
+and	O
+oncogenic	B-PRGE
+transcription	I-PRGE
+factor	I-PRGE
+c	I-PRGE
+-	I-PRGE
+Myc	I-PRGE
+,	O
+suggesting	O
+that	O
+they	O
+may	O
+be	O
+advantageous	O
+for	O
+cell	B-COMP
+-	O
+based	O
+therapy	O
+compared	O
+with	O
+9	O
+-	O
+day	O
+cultured	O
+BMMSCs	O
+.	O
+
+This	O
+study	O
+was	O
+to	O
+determine	O
+whether	O
+the	O
+damage	O
+was	O
+correlated	O
+with	O
+expression	B-PROC
+of	O
+the	O
+SARS	B-PRGE
+coronavirus	B-SPEC
+receptor	I-PRGE
+,	O
+angiotensin	B-PRGE
+converting	I-PRGE
+enzyme	I-PRGE
+2	I-PRGE
+(	O
+ACE2	B-PRGE
+),	O
+in	O
+different	O
+organs	B-ANAT
+,	O
+especially	O
+in	O
+the	O
+endocrine	B-CHED
+tissues	B-ANAT
+of	O
+the	O
+pancreas	B-ANAT
+,	O
+and	O
+to	O
+elucidate	O
+the	O
+pathogenesis	B-DISO
+of	O
+glucose	B-DISO
+intolerance	B-PROC
+in	O
+SARS	B-DISO
+patients	O
+.	O
+
+The	O
+pattern	O
+of	O
+SARS	B-PRGE
+coronavirus	B-SPEC
+receptor	I-PRGE
+-	I-PRGE
+ACE2	I-PRGE
+proteins	B-CHED
+in	O
+different	O
+human	B-SPEC
+organs	B-ANAT
+was	O
+also	O
+studied	O
+.	O
+
+The	O
+analysis	O
+of	O
+cell	B-COMP
+surface	I-COMP
+markers	O
+demonstrated	O
+that	O
+the	O
+CD4	B-PRGE
+-	O
+CD8	B-PRGE
+-	O
+T	B-ANAT
+cells	I-ANAT
+are	O
+a	O
+completely	O
+new	O
+T	B-ANAT
+cell	B-COMP
+subset	I-ANAT
+.	O
+
+It	O
+was	O
+previously	O
+demonstrated	O
+that	O
+patients	O
+with	O
+activated	O
+PMNs	O
+in	O
+the	O
+lungs	B-ANAT
+have	O
+PMNs	O
+in	O
+the	O
+peripheral	O
+circulation	B-PROC
+with	O
+a	O
+reduced	O
+active	O
+FcgammaRII	O
+up	O
+-	O
+regulating	O
+capacity	O
+.	O
+
+In	O
+addition	O
+,	O
+decreasing	O
+responsiveness	O
+of	O
+active	O
+FcgammaRII	O
+on	O
+PMNs	O
+was	O
+found	O
+in	O
+patients	O
+who	O
+developed	O
+systemic	B-DISO
+inflammatory	I-DISO
+response	I-DISO
+syndrome	I-DISO
+(	O
+SIRS	B-DISO
+)	O
+or	O
+acute	O
+lung	B-ANAT
+injury	O
+(	O
+ALI	O
+)/	O
+ARDS	B-DISO
+.	O
+
+In	O
+addition	O
+,	O
+decreasing	O
+responsiveness	O
+of	O
+active	O
+FcgammaRII	O
+on	O
+PMNs	O
+was	O
+found	O
+in	O
+patients	O
+who	O
+developed	O
+systemic	B-DISO
+inflammatory	I-DISO
+response	I-DISO
+syndrome	I-DISO
+(	O
+SIRS	B-DISO
+)	O
+or	O
+acute	O
+lung	B-ANAT
+injury	O
+(	O
+ALI	O
+)/	O
+ARDS	B-DISO
+.	O
+
+TITLE	O
+:	O
+Interleukin	B-PRGE
+-	I-PRGE
+12	I-PRGE
+(	O
+IL	B-FUNC
+-	I-FUNC
+12	I-FUNC
+),	O
+but	O
+not	O
+IL	B-FUNC
+-	I-FUNC
+23	I-FUNC
+,	O
+deficiency	O
+ameliorates	O
+viral	B-DISO
+encephalitis	I-DISO
+without	O
+affecting	O
+viral	O
+control	O
+.	O
+
+These	O
+data	O
+suggest	O
+that	O
+IL	B-FUNC
+-	I-FUNC
+12	I-FUNC
+does	O
+not	O
+contribute	O
+to	O
+antiviral	B-CHED
+function	O
+within	O
+the	O
+CNS	B-CHED
+but	O
+enhances	O
+morbidity	O
+associated	O
+with	O
+viral	B-DISO
+encephalitis	I-DISO
+by	O
+increasing	O
+the	O
+ratio	O
+of	O
+IFN	B-PRGE
+-	I-PRGE
+gamma	I-PRGE
+to	O
+protective	O
+IL	B-FUNC
+-	I-FUNC
+10	I-FUNC
+.	O
+
+ABSTRACT	O
+:	O
+Ethyl	O
+pyruvate	B-CHED
+(	O
+EtP	B-CHED
+)	O
+may	O
+prolong	O
+survival	O
+and	O
+ameliorate	O
+organ	B-ANAT
+dysfunction	O
+in	O
+a	O
+variety	O
+of	O
+models	O
+of	O
+critical	B-DISO
+illness	I-DISO
+,	O
+e	O
+.	O
+g	O
+.	O
+severe	B-DISO
+sepsis	I-DISO
+and	O
+acute	O
+respiratory	O
+syndrome	B-DISO
+,	O
+by	O
+modulation	O
+of	O
+the	O
+expression	B-PROC
+of	O
+inflammatory	O
+mediators	O
+.	O
+
+Here	O
+,	O
+we	O
+studied	O
+the	O
+effects	O
+of	O
+EtP	B-CHED
+on	O
+the	O
+reactions	O
+in	O
+and	O
+between	O
+human	B-SPEC
+neutrophils	B-ANAT
+and	O
+lung	B-ANAT
+epithelial	O
+(	O
+A549	O
+)	O
+cells	B-COMP
+in	O
+vitro	O
+.	O
+
+Likewise	O
+,	O
+treatment	O
+with	O
+2	O
+.	O
+5	O
+-	O
+10	O
+mM	O
+EtP	B-CHED
+(	O
+but	O
+not	O
+NaP	B-PROC
+)	O
+reduced	O
+ICAM	B-PRGE
+-	I-PRGE
+1	I-PRGE
+and	O
+VCAM	B-PRGE
+-	I-PRGE
+1	I-PRGE
+expression	B-PROC
+in	O
+a	O
+dose	O
+-	O
+dependent	O
+fashion	O
+.	O
+
+TITLE	O
+:	O
+Genetic	O
+diversity	O
+of	O
+avian	B-DISO
+infectious	I-DISO
+bronchitis	I-DISO
+viruses	B-SPEC
+in	O
+Japan	O
+based	O
+on	O
+analysis	O
+of	O
+s2	B-PRGE
+glycoprotein	B-CHED
+gene	I-PRGE
+.	O
+
+TITLE	O
+:	O
+[	O
+A	O
+case	O
+of	O
+miliary	B-DISO
+tuberculosis	I-DISO
+presenting	O
+with	O
+acute	O
+resiratory	O
+distress	O
+syndrome	B-DISO
+].	O
+
+PaO2	O
+/	O
+FiO2	O
+ratio	O
+improved	O
+but	O
+X	O
+-	O
+ray	B-SPEC
+findings	O
+showed	O
+no	O
+improvement	O
+and	O
+a	O
+blood	B-ANAT
+test	O
+revealed	O
+pancytopenia	B-DISO
+.	O
+
+Therefore	O
+,	O
+we	O
+diagnosed	O
+miliary	B-DISO
+tuberculosis	I-DISO
+and	O
+transferred	O
+the	O
+patient	O
+to	O
+an	O
+infectious	B-DISO
+disease	I-DISO
+hospital	O
+.	O
+
+TITLE	O
+:	O
+Intra	B-DISO
+-	I-DISO
+abdominal	I-DISO
+hypertension	I-DISO
+in	O
+acute	B-DISO
+pancreatitis	I-DISO
+.	O
+
+ABSTRACT	O
+:	O
+The	O
+incidence	O
+of	O
+intra	B-DISO
+-	I-DISO
+abdominal	B-ANAT
+hypertension	I-DISO
+(	O
+IAH	B-FUNC
+)	O
+in	O
+patients	O
+with	O
+severe	O
+acute	B-DISO
+pancreatitis	I-DISO
+(	O
+SAP	O
+)	O
+is	O
+approximately	O
+60	O
+-	O
+80	O
+%.	O
+
+It	O
+is	O
+usually	O
+an	O
+early	O
+phenomenon	O
+,	O
+partly	O
+related	O
+to	O
+the	O
+effects	O
+of	O
+the	O
+inflammatory	O
+process	O
+,	O
+causing	O
+retroperitoneal	B-DISO
+edema	I-DISO
+,	O
+fluid	O
+collections	O
+,	O
+ascites	O
+,	O
+and	O
+ileus	B-DISO
+,	O
+and	O
+partly	O
+iatrogenic	O
+,	O
+resulting	O
+from	O
+aggressive	B-DISO
+fluid	O
+resuscitation	O
+.	O
+
+IAH	B-FUNC
+is	O
+associated	O
+with	O
+impaired	B-DISO
+organ	B-ANAT
+dysfunction	O
+,	O
+especially	O
+of	O
+the	O
+cardiovascular	B-ANAT
+,	O
+respiratory	O
+,	O
+and	O
+renal	B-ANAT
+systems	O
+.	O
+
+It	O
+can	O
+be	O
+achieved	O
+with	O
+full	O
+-	O
+thickness	O
+laparostomy	O
+(	O
+midline	B-COMP
+or	O
+transverse	O
+subcostal	B-ANAT
+)	O
+or	O
+through	O
+a	O
+subcutaneous	O
+linea	B-ANAT
+alba	I-ANAT
+fasciotomy	O
+.	O
+
+In	O
+three	O
+trials	O
+,	O
+the	O
+effect	O
+of	O
+different	O
+levels	O
+of	O
+PEEP	B-CHED
+was	O
+compared	O
+in	O
+groups	O
+receiving	O
+comparable	O
+tidal	O
+volumes	O
+.	O
+
+Toll	B-PRGE
+-	I-PRGE
+like	I-PRGE
+receptor	I-PRGE
+-	I-PRGE
+3	I-PRGE
+(	O
+TLR	O
+-	O
+3	O
+)	O
+is	O
+an	O
+integral	O
+part	O
+of	O
+the	O
+host	B-COMP
+'	O
+s	O
+innate	O
+immune	B-ANAT
+system	I-ANAT
+and	O
+serves	O
+as	O
+an	O
+important	O
+signaling	B-PROC
+pathway	I-PROC
+for	O
+the	O
+recognition	O
+of	O
+dsRNA	B-CHED
+for	O
+the	O
+triggering	O
+of	O
+antiviral	B-CHED
+and	O
+inflammatory	B-DISO
+responses	I-DISO
+to	O
+combat	B-CHED
+viral	B-DISO
+infections	I-DISO
+.	O
+
+Increase	O
+in	O
+the	O
+concentrations	O
+of	O
+adhesion	B-DISO
+molecules	O
+preceded	O
+the	O
+development	B-PROC
+of	O
+pulmonary	B-DISO
+infiltration	I-DISO
+with	O
+respiratory	B-DISO
+failure	I-DISO
+symptoms	O
+,	O
+which	O
+provoked	O
+endothelial	B-DISO
+dysfunction	I-DISO
+and	O
+determined	O
+the	O
+capillary	B-ANAT
+surface	O
+permeability	O
+for	O
+neutrophils	B-ANAT
+and	O
+monocytes	B-ANAT
+.	O
+
+At	O
+IL	B-FUNC
+-	I-FUNC
+18	I-FUNC
+concentrations	O
+>	O
+650	O
+pg	O
+/	O
+ml	O
+,	O
+AP	O
+patients	O
+are	O
+likely	O
+to	O
+develop	O
+pulmonary	B-ANAT
+dysfunction	O
+(	O
+sensitivity	O
+58	O
+%,	O
+specificity	O
+100	O
+%,	O
+LR	O
+-	O
+positive	O
+>	O
+58	O
+)	O
+which	O
+allows	O
+us	O
+to	O
+use	O
+it	O
+as	O
+a	O
+screening	O
+test	O
+.	O
+
+Recently	O
+,	O
+a	O
+30	O
+-	O
+nucleotide	B-CHED
+(	O
+nt	O
+)	O
+cis	B-DISO
+-	O
+replication	O
+stem	B-ANAT
+-	O
+loop	O
+VI	O
+(	O
+SLVI	O
+)	O
+has	O
+been	O
+mapped	O
+at	O
+nt	O
+101	O
+to	O
+130	O
+within	O
+a	O
+288	O
+-	O
+nt	O
+5	O
+'-	O
+terminal	O
+segment	O
+of	O
+the	O
+738	O
+-	O
+nt	O
+nsp1	B-PRGE
+cistron	O
+in	O
+a	O
+BCoV	O
+defective	O
+interfering	O
+(	O
+DI	O
+)	O
+RNA	O
+.	O
+
+ABSTRACT	O
+:	O
+Several	O
+instances	O
+of	O
+emerging	O
+diseases	O
+in	O
+humans	O
+appear	O
+to	O
+be	O
+caused	O
+by	O
+the	O
+spillover	O
+of	O
+viruses	B-SPEC
+endemic	O
+to	O
+bats	B-SPEC
+,	O
+either	O
+directly	O
+or	O
+through	O
+other	O
+animal	B-SPEC
+intermediaries	O
+.	O
+
+We	O
+also	O
+screened	O
+bat	O
+tissues	B-ANAT
+by	O
+PCR	O
+using	O
+primers	O
+designed	O
+to	O
+amplify	O
+nucleic	B-CHED
+acids	I-CHED
+from	O
+members	O
+of	O
+certain	O
+families	O
+of	O
+viruses	B-SPEC
+.	O
+
+Our	O
+data	O
+suggest	O
+an	O
+intrinsic	O
+mechanism	O
+operated	O
+by	O
+free	O
+CEACAM1	O
+for	O
+surveillance	O
+of	O
+pathogens	O
+and	O
+maintenance	O
+of	O
+homeostasis	O
+in	O
+the	O
+intestine	B-ANAT
+.	O
+
+ABSTRACT	O
+:	O
+Critical	O
+Care	O
+Air	B-CHED
+Transport	B-PROC
+Teams	O
+(	O
+CCATTs	O
+)	O
+are	O
+an	O
+integral	O
+component	O
+of	O
+modern	O
+casualty	O
+care	O
+,	O
+allowing	O
+early	O
+transport	B-PROC
+of	O
+critically	B-DISO
+ill	I-DISO
+and	O
+injured	O
+patients	O
+.	O
+
+The	O
+United	O
+States	O
+TRANSCOM	O
+Regulation	B-PROC
+and	O
+Command	O
+/	O
+Control	O
+Evacuation	O
+System	O
+and	O
+the	O
+United	O
+States	O
+Army	O
+Institute	O
+of	O
+Surgical	O
+Research	O
+Joint	B-ANAT
+Theater	O
+Trauma	O
+Registry	O
+databases	O
+were	O
+reviewed	O
+for	O
+all	O
+critical	O
+patients	O
+transported	O
+out	O
+of	O
+theater	O
+between	O
+November	O
+2005	O
+and	O
+March	O
+2007	O
+.	O
+
+ALRT	O
+missions	O
+comprised	O
+0	O
+.	O
+6	O
+%	O
+of	O
+all	O
+critical	O
+patient	O
+movements	B-PROC
+out	O
+of	O
+the	O
+combat	B-CHED
+theater	O
+and	O
+1	O
+%	O
+of	O
+ventilator	O
+transports	O
+.	O
+
+No	O
+significant	O
+correlation	O
+was	O
+found	O
+between	O
+complexity	O
+of	O
+5	O
+'-	O
+UTR	O
+and	O
+the	O
+sequence	O
+context	O
+of	O
+AUG	O
+codon	O
+with	O
+the	O
+level	O
+of	O
+translation	O
+of	O
+SARS	B-PRGE
+-	I-PRGE
+CoV	I-PRGE
+sgRNAs	I-PRGE
+.	O
+
+These	O
+results	O
+will	O
+be	O
+helpful	O
+for	O
+further	O
+studies	O
+to	O
+reveal	O
+the	O
+biological	O
+functions	O
+and	O
+translation	B-PROC
+regulatory	O
+mechanisms	O
+of	O
+sgRNAs	O
+in	O
+the	O
+coronavirus	B-SPEC
+life	O
+cycle	O
+and	O
+pathogenesis	B-DISO
+.	O
+
+HCoV	B-SPEC
+-	I-SPEC
+229E	I-SPEC
+is	O
+a	O
+proven	O
+common	B-DISO
+cold	I-DISO
+virus	B-SPEC
+in	O
+healthy	O
+adults	O
+,	O
+so	O
+it	O
+is	O
+probable	O
+that	O
+both	O
+viruses	B-SPEC
+induce	O
+comparable	O
+symptoms	O
+in	O
+adults	O
+,	O
+even	O
+though	O
+their	O
+mode	O
+of	O
+infection	B-DISO
+differs	O
+.	O
+
+TITLE	O
+:	O
+Detection	O
+of	O
+respiratory	O
+viruses	B-SPEC
+with	O
+a	O
+multiplex	O
+polymerase	O
+chain	O
+reaction	O
+assay	O
+(	O
+MultiCode	O
+-	O
+PLx	O
+Respiratory	O
+Virus	O
+Panel	O
+)	O
+in	O
+patients	O
+with	O
+hematologic	B-DISO
+malignancies	I-DISO
+.	O
+
+Sensitive	O
+molecular	O
+assays	O
+have	O
+increased	O
+the	O
+detection	O
+of	O
+common	O
+respiratory	O
+viruses	B-SPEC
+and	O
+expanded	O
+the	O
+panel	O
+of	O
+detectable	O
+viruses	B-SPEC
+.	O
+
+TITLE	O
+:	O
+Thiopurine	B-CHED
+analogue	O
+inhibitors	B-CHED
+of	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+-	O
+coronavirus	B-SPEC
+papain	B-ENZY
+-	I-PRGE
+like	I-PRGE
+protease	I-PRGE
+,	O
+a	O
+deubiquitinating	O
+and	O
+deISGylating	O
+enzyme	O
+.	O
+
+6MP	O
+and	O
+6TG	O
+have	O
+long	O
+been	O
+used	O
+in	O
+cancer	B-DISO
+chemotherapy	O
+for	O
+treatment	O
+of	O
+acute	O
+lymphoblastic	B-ANAT
+or	O
+myeloblastic	B-DISO
+leukaemia	I-DISO
+.	O
+
+So	O
+far	O
+,	O
+several	O
+crystal	B-ANAT
+structures	O
+of	O
+cellular	B-COMP
+DUBs	O
+have	O
+been	O
+solved	O
+.	O
+
+Since	O
+plant	B-SPEC
+transformation	B-DISO
+and	O
+regeneration	B-PROC
+of	O
+stable	O
+transformants	O
+require	O
+considerable	O
+time	O
+,	O
+we	O
+initially	O
+used	O
+a	O
+green	B-PRGE
+fluorescent	I-PRGE
+protein	I-PRGE
+(	O
+GFP	O
+)	O
+to	O
+tag	B-DISO
+the	O
+antigen	B-CHED
+in	O
+transient	O
+expression	B-PROC
+.	O
+
+The	O
+surface	O
+glycoproteins	B-CHED
+of	O
+SARS	B-PRGE
+-	I-PRGE
+CoV	I-PRGE
+and	I-PRGE
+HIV	B-SPEC
+-	I-SPEC
+1	I-SPEC
+were	O
+used	O
+as	O
+model	O
+proteins	B-CHED
+.	O
+
+The	O
+random	O
+dissection	O
+approach	O
+described	O
+here	O
+should	O
+be	O
+applicable	O
+to	O
+other	O
+viral	O
+proteins	B-CHED
+for	O
+isolating	O
+soluble	O
+viral	O
+surface	O
+protein	B-CHED
+fragments	O
+,	O
+and	O
+may	O
+provide	O
+alternatives	O
+to	O
+the	O
+full	O
+-	O
+length	O
+proteins	O
+(	O
+subunits	O
+)	O
+or	O
+linear	O
+short	O
+peptides	B-CHED
+in	O
+search	O
+for	O
+antigen	B-CHED
+or	O
+vaccine	O
+candidates	O
+.	O
+
+ABSTRACT	O
+:	O
+Severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+(	O
+SARS	B-DISO
+)	O
+coronavirus	B-SPEC
+is	O
+highly	O
+pathogenic	O
+in	O
+humans	B-SPEC
+and	O
+evades	O
+innate	B-PROC
+immunity	I-PROC
+at	O
+multiple	O
+levels	O
+.	O
+
+M	B-PRGE
+protein	I-PRGE
+potently	O
+antagonizes	O
+the	O
+activation	O
+of	O
+interferon	B-PRGE
+-	O
+stimulated	O
+response	O
+element	O
+-	O
+dependent	O
+transcription	B-PROC
+by	O
+double	O
+-	O
+stranded	O
+RNA	O
+,	O
+RIG	B-PRGE
+-	I-PRGE
+I	I-PRGE
+,	O
+MDA5	B-PRGE
+,	O
+TBK1	B-FUNC
+,	O
+IKKepsilon	B-PRGE
+,	O
+and	O
+virus	B-SPEC
+-	O
+induced	O
+signaling	B-PROC
+adaptor	O
+(	O
+VISA	B-DISO
+)	O
+but	O
+has	O
+no	O
+influence	O
+on	O
+the	O
+transcriptional	B-PROC
+activity	O
+of	O
+this	O
+element	O
+when	O
+IRF3	B-PRGE
+or	O
+IRF7	B-PRGE
+is	O
+overexpressed	O
+.	O
+
+M	B-PRGE
+protein	I-PRGE
+physically	O
+associates	O
+with	O
+RIG	B-PRGE
+-	I-PRGE
+I	I-PRGE
+,	O
+TBK1	B-FUNC
+,	O
+IKKepsilon	B-PRGE
+,	O
+and	O
+TRAF3	B-PRGE
+and	O
+likely	O
+sequesters	O
+some	O
+of	O
+them	O
+in	O
+membrane	O
+-	O
+associated	O
+cytoplasmic	B-COMP
+compartments	B-ANAT
+.	O
+
+Moreover	O
+,	O
+despite	O
+control	O
+of	O
+infectious	B-DISO
+virus	B-SPEC
+,	O
+CD8	B-PRGE
+T	I-PRGE
+cells	O
+within	O
+the	O
+CNS	B-CHED
+of	O
+persistently	O
+infected	O
+mice	B-SPEC
+maintained	O
+high	O
+PD	O
+-	O
+1	O
+expression	B-PROC
+.	O
+
+Proper	O
+anaesthetic	O
+management	O
+of	O
+patients	O
+with	O
+mediastinal	B-ANAT
+mass	B-DISO
+syndrome	I-DISO
+begins	O
+with	O
+an	O
+assessment	O
+of	O
+the	O
+preoperative	O
+status	O
+,	O
+directed	O
+foremost	O
+at	O
+establishing	O
+the	O
+localization	B-PROC
+of	O
+the	O
+tumour	B-DISO
+and	O
+on	O
+the	O
+basis	O
+of	O
+the	O
+clinical	O
+and	O
+radiological	O
+findings	O
+,	O
+discerning	O
+whether	O
+any	O
+vital	O
+mediastinal	B-ANAT
+structures	O
+are	O
+affected	O
+.	O
+
+A	O
+GBL	O
+withdrawal	B-DISO
+syndrome	I-DISO
+was	O
+diagnosed	O
+.	O
+
+TITLE	O
+:	O
+The	O
+cat	B-SPEC
+with	O
+neurological	O
+manifestations	O
+of	O
+systemic	B-DISO
+disease	I-DISO
+.	O
+
+TITLE	O
+:	O
+From	O
+lab	O
+to	O
+bedside	O
+:	O
+emerging	O
+clinical	O
+applications	O
+of	O
+thymosin	B-PRGE
+alpha	I-PRGE
+1	I-PRGE
+.	O
+
+Talpha	O
+(	O
+1	O
+)	O
+is	O
+approved	O
+in	O
+over	O
+35	O
+countries	O
+for	O
+the	O
+treatment	O
+of	O
+hepatitis	B-DISO
+B	I-DISO
+and	O
+C	O
+,	O
+and	O
+as	O
+an	O
+immune	O
+stimulant	O
+and	O
+adjuvant	B-CHED
+.	O
+
+This	O
+outcome	O
+suggests	O
+that	O
+drotrecogin	O
+alfa	O
+(	O
+activated	O
+)	O
+may	O
+be	O
+useful	O
+therapy	O
+for	O
+transplant	B-ANAT
+recipients	O
+who	O
+develop	O
+severe	B-DISO
+sepsis	I-DISO
+or	O
+septic	B-DISO
+shock	I-DISO
+secondary	O
+to	O
+potentially	O
+lethal	O
+opportunistic	B-DISO
+infections	I-DISO
+.	O
+
+In	O
+a	O
+systematic	O
+review	O
+of	O
+the	O
+literature	O
+on	O
+nine	O
+respiratory	O
+viral	B-DISO
+infections	I-DISO
+of	O
+public	O
+-	O
+health	O
+importance	O
+,	O
+we	O
+identified	O
+436	O
+articles	O
+with	O
+statements	O
+of	O
+incubation	O
+period	O
+and	O
+38	O
+with	O
+data	O
+for	O
+pooled	O
+analysis	O
+.	O
+
+Further	O
+analysis	O
+shows	O
+that	O
+sufficient	O
+incorporation	O
+of	O
+9b	O
+protein	B-CHED
+into	O
+VLPs	B-ANAT
+is	O
+dependent	O
+upon	O
+the	O
+co	O
+-	O
+expression	B-PROC
+of	O
+E	O
+and	O
+M	O
+proteins	B-CHED
+,	O
+but	O
+not	O
+upon	O
+the	O
+presence	O
+of	O
+either	O
+S	O
+or	O
+N	O
+protein	B-CHED
+.	O
+
+Our	O
+data	O
+indicate	O
+that	O
+9b	O
+protein	B-CHED
+of	O
+SARS	B-PRGE
+-	I-PRGE
+CoV	I-PRGE
+is	O
+another	O
+virion	B-COMP
+-	O
+associated	O
+accessory	O
+protein	O
+.	O
+
+TITLE	O
+:	O
+Fatal	O
+pulmonary	B-DISO
+fibrosis	I-DISO
+after	O
+rituximab	O
+administration	O
+.	O
+
+We	O
+previously	O
+showed	O
+that	O
+caspase	B-PRGE
+pathways	B-PROC
+are	O
+involved	O
+in	O
+3a	O
+-	O
+induced	O
+apoptosis	B-PATH
+.	O
+
+It	O
+was	O
+previously	O
+reported	O
+that	O
+3a	O
+possesses	B-DISO
+potassium	B-CHED
+ion	I-CHED
+channel	O
+activity	O
+.	O
+
+Surfactant	B-CHED
+inactivation	B-DISO
+--	O
+and	O
+dysfunction	O
+--	O
+is	O
+also	O
+a	O
+hallmark	O
+in	O
+newborns	O
+with	O
+meconium	B-DISO
+aspiration	I-DISO
+syndrome	I-DISO
+(	O
+MAS	B-COMP
+),	O
+pneumonia	B-DISO
+and	O
+other	O
+disorders	O
+affecting	O
+the	O
+pulmonary	B-PROC
+function	I-PROC
+.	O
+
+This	O
+study	O
+describes	O
+a	O
+novel	O
+role	O
+for	O
+MAVS	B-PRGE
+in	O
+controlling	O
+viral	O
+infections	O
+through	O
+the	O
+induction	B-PROC
+of	I-PROC
+apoptosis	I-PROC
+,	O
+and	O
+identifies	O
+viral	O
+proteins	B-CHED
+which	O
+inhibit	O
+this	O
+host	B-PROC
+response	I-PROC
+.	O
+
+Tag	B-PRGE
+single	I-PRGE
+nucleotide	B-CHED
+polymorphisms	B-PROC
+(	O
+tagSNPs	O
+)	O
+were	O
+chosen	O
+using	O
+pairwise	O
+tagging	O
+algorithms	O
+.	O
+
+Our	O
+data	O
+do	O
+not	O
+suggest	O
+a	O
+role	O
+for	O
+MASP2	B-PRGE
+polymorphisms	B-PROC
+in	O
+SARS	B-PRGE
+susceptibility	I-PRGE
+in	O
+northern	O
+and	O
+southern	O
+China	O
+.	O
+
+In	O
+those	O
+with	O
+acute	O
+lung	B-ANAT
+injury	O
+(	O
+ALI	O
+)/	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+(	O
+ARDS	B-DISO
+),	O
+there	O
+was	O
+a	O
+significant	O
+increase	O
+from	O
+baseline	O
+in	O
+the	O
+partial	O
+pressure	O
+of	O
+arterial	B-ANAT
+oxygen	B-CHED
+(	O
+PaO2	O
+)	O
+to	O
+fraction	O
+of	O
+inspired	B-PROC
+oxygen	B-CHED
+(	O
+FiO2	O
+)	O
+ratio	O
+at	O
+24	O
+hours	O
+in	O
+the	O
+CVVH	O
+group	O
+(	O
+n	O
+=	O
+16	O
+,	O
+174	O
++/-	O
+
+The	O
+application	O
+of	O
+CVVH	O
+in	O
+adult	O
+patients	O
+with	O
+severe	O
+burns	O
+and	O
+AKI	O
+was	O
+associated	O
+with	O
+a	O
+decrease	O
+in	O
+28	O
+-	O
+day	O
+and	O
+hospital	O
+mortality	O
+when	O
+compared	O
+with	O
+a	O
+historical	O
+control	O
+group	O
+,	O
+which	O
+largely	O
+did	O
+not	O
+receive	O
+any	O
+form	O
+of	O
+renal	B-ANAT
+replacement	O
+.	O
+
+TITLE	O
+:	O
+Towards	O
+construction	O
+of	O
+viral	O
+vectors	O
+based	O
+on	O
+avian	B-SPEC
+coronavirus	I-SPEC
+infectious	B-DISO
+bronchitis	B-DISO
+virus	B-SPEC
+for	O
+gene	O
+delivery	O
+and	O
+vaccine	O
+development	B-PROC
+.	O
+
+By	O
+using	O
+an	O
+infectious	B-DISO
+cloning	O
+system	O
+developed	O
+recently	O
+for	O
+the	O
+avian	B-SPEC
+coronavirus	I-SPEC
+infectious	B-DISO
+bronchitis	B-DISO
+virus	B-SPEC
+(	O
+IBV	B-SPEC
+),	O
+the	O
+enhanced	B-PRGE
+green	I-PRGE
+fluorescent	I-PRGE
+protein	I-PRGE
+(	O
+EGFP	O
+)	O
+gene	O
+,	O
+the	O
+firefly	B-PRGE
+luciferase	I-PRGE
+gene	I-PRGE
+and	O
+several	O
+host	B-COMP
+and	O
+viral	O
+genes	O
+(	O
+eIF3f	B-PRGE
+,	O
+SARS	B-PRGE
+ORF6	I-PRGE
+,	I-PRGE
+Dengue	B-SPEC
+virus	I-SPEC
+1	I-PRGE
+core	I-PRGE
+protein	B-CHED
+gene	I-PRGE
+)	O
+were	O
+inserted	O
+into	O
+various	O
+positions	O
+of	O
+the	O
+IBV	B-SPEC
+genome	O
+,	O
+and	O
+the	O
+effects	O
+on	O
+gene	B-PROC
+expression	I-PROC
+,	O
+virus	B-SPEC
+recovery	O
+,	O
+and	O
+stability	O
+in	O
+cell	B-COMP
+culture	O
+were	O
+studied	O
+.	O
+
+Loss	O
+of	O
+ACE2	B-PRGE
+function	O
+is	O
+implicated	O
+in	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+(	O
+SARS	B-DISO
+)	O
+pathogenesis	B-DISO
+,	O
+but	O
+little	O
+is	O
+known	O
+about	O
+ACE2	B-PRGE
+biogenesis	B-PROC
+and	O
+activity	O
+in	O
+the	O
+airways	O
+.	O
+
+Phorbol	B-CHED
+ester	I-CHED
+,	O
+ionomycin	B-CHED
+,	O
+endotoxin	O
+,	O
+and	O
+IL	B-PRGE
+-	I-PRGE
+1beta	I-PRGE
+and	O
+TNFalpha	B-PRGE
+acutely	O
+induced	O
+ACE2	B-PRGE
+release	B-PATH
+,	O
+further	O
+supporting	O
+that	O
+ADAM17	B-PRGE
+and	O
+ADAM10	B-PRGE
+regulate	O
+ACE2	B-PRGE
+cleavage	B-PROC
+.	O
+
+In	O
+the	O
+case	O
+of	O
+the	O
+S2	B-PRGE
+domain	I-PRGE
+of	O
+protein	B-PRGE
+S	I-PRGE
+,	O
+it	O
+has	O
+been	O
+found	O
+a	O
+highly	O
+hydrophobic	O
+and	O
+interfacial	O
+domain	O
+flanked	O
+by	O
+the	O
+heptad	O
+repeat	O
+1	O
+and	O
+2	O
+regions	O
+;	O
+significantly	O
+,	O
+different	O
+peptides	B-CHED
+pertaining	O
+to	O
+this	O
+domain	O
+have	O
+shown	O
+a	O
+significant	O
+leakage	B-DISO
+effect	O
+and	O
+an	O
+important	O
+plaque	B-DISO
+formation	B-PROC
+inhibition	B-PROC
+,	O
+which	O
+,	O
+similarly	O
+to	O
+HIV	B-SPEC
+-	I-SPEC
+1	I-SPEC
+gp41	O
+,	O
+support	O
+the	O
+role	O
+of	O
+this	O
+region	O
+in	O
+the	O
+fusion	O
+process	O
+.	O
+
+The	O
+aim	O
+of	O
+the	O
+present	O
+study	O
+was	O
+to	O
+carry	O
+out	O
+molecular	O
+epidemiological	O
+investigation	O
+on	O
+enterotoxigenic	O
+Escherichia	O
+coli	O
+(	O
+ETEC	O
+)	O
+K99	O
+and	O
+Salmonella	B-PRGE
+spp	B-ENZY
+.	O
+
+The	O
+results	O
+of	O
+the	O
+present	O
+study	O
+indicate	O
+the	O
+importance	O
+of	O
+PCR	O
+as	O
+rapid	O
+,	O
+effective	O
+and	O
+reliable	O
+tool	O
+for	O
+screening	O
+of	O
+ETEC	O
+and	O
+Salmonella	B-DISO
+spp	B-ENZY
+.	O
+
+SARS	B-DISO
+-	I-DISO
+CoV	I-DISO
+infection	I-DISO
+induced	O
+a	O
+range	O
+of	O
+interferon	B-PRGE
+,	O
+cytokine	O
+,	O
+and	O
+pulmonary	B-ANAT
+wound	O
+-	O
+healing	B-PROC
+genes	O
+,	O
+as	O
+well	O
+as	O
+several	O
+genes	O
+associated	O
+with	O
+the	O
+onset	O
+of	O
+ARDS	B-DISO
+.	O
+
+Common	O
+causes	O
+of	O
+ALI	O
+/	O
+ARDS	B-DISO
+are	O
+sepsis	B-DISO
+,	O
+pneumonia	B-DISO
+,	O
+trauma	O
+,	O
+aspiration	B-DISO
+pneumonia	I-DISO
+,	O
+pancreatitis	B-DISO
+,	O
+and	O
+so	O
+on	O
+.	O
+
+TITLE	O
+:	O
+Analysis	O
+of	O
+the	O
+properties	O
+of	O
+neutralizing	O
+monoclonal	O
+antibodies	B-COMP
+against	O
+the	O
+hemagglutinating	O
+encephalomyelitis	O
+virus	B-SPEC
+and	O
+inhibition	B-PROC
+of	O
+HEV	B-SPEC
+infection	B-DISO
+by	O
+specific	O
+MAb	O
+.	O
+
+ABSTRACT	O
+:	O
+Eleven	O
+monoclonal	O
+antibodies	B-COMP
+(	O
+MAbs	O
+)	O
+that	O
+were	O
+reactive	O
+against	O
+the	O
+hemagglutinating	O
+encephalomyelitis	B-DISO
+virus	B-SPEC
+(	O
+HEV	B-SPEC
+),	O
+as	O
+seen	O
+in	O
+the	O
+enzyme	O
+-	O
+linked	O
+immunosorbent	O
+assay	O
+,	O
+were	O
+obtained	O
+.	O
+
+They	O
+also	O
+showed	O
+hemagglutination	B-PROC
+inhibition	B-PROC
+activity	O
+(	O
+1	O
+:	O
+400	O
+to	O
+1	O
+:	O
+409	O
+,	O
+600	O
+).	O
+
+The	O
+synthetic	O
+ribozyme	O
+cleaved	B-ANAT
+the	O
+synthetic	O
+target	O
+MHV	B-SPEC
+and	O
+SARS	B-DISO
+-	O
+CoV	O
+RNA	O
+into	O
+fragments	O
+of	O
+predicted	O
+length	O
+.	O
+
+Effects	O
+of	O
+the	O
+chimeric	O
+ribozyme	O
+on	O
+expression	B-PROC
+of	O
+SARS	B-DISO
+-	O
+CoV	O
+were	O
+evaluated	O
+in	O
+cultured	O
+3T3	O
+cells	B-COMP
+.	O
+
+Furthermore	O
+,	O
+the	O
+binding	B-FUNC
+constant	O
+of	O
+the	O
+AMP	O
+to	O
+Fn	O
+was	O
+determined	O
+from	O
+the	O
+concentration	O
+dependence	B-DISO
+of	O
+the	O
+response	O
+of	O
+our	O
+biosensors	O
+.	O
+
+These	O
+results	O
+suggest	O
+that	O
+the	O
+recombinant	O
+RBD	O
+produced	O
+in	O
+an	O
+established	O
+stable	O
+cell	O
+line	O
+maintains	O
+strong	O
+immunogenicity	O
+with	O
+high	O
+potential	O
+for	O
+use	O
+as	O
+an	O
+effective	O
+and	O
+economic	O
+subunit	O
+SARS	B-DISO
+vaccine	O
+.	O
+
+N	B-PRGE
+protein	I-PRGE
+is	O
+thought	O
+to	O
+dysregulate	O
+cell	B-COMP
+signalling	B-PROC
+and	O
+the	O
+transcription	B-PROC
+of	O
+cellular	B-COMP
+genes	O
+,	O
+including	O
+FGL2	B-PRGE
+,	O
+which	O
+encodes	O
+a	O
+prothrombinase	B-PRGE
+implicated	O
+in	O
+vascular	B-ANAT
+thrombosis	B-DISO
+,	O
+fibrin	B-DISO
+deposition	I-DISO
+and	O
+pneumocyte	B-ANAT
+necrosis	B-PROC
+.	O
+
+However	O
+,	O
+the	O
+expression	B-PROC
+of	O
+N	B-PRGE
+protein	I-PRGE
+did	O
+not	O
+influence	O
+the	O
+transcription	B-PROC
+from	O
+the	O
+FGL2	B-PRGE
+promoter	I-PRGE
+.	O
+
+ABSTRACT	O
+:	O
+Permeability	O
+edema	O
+is	O
+a	O
+life	O
+-	O
+threatening	O
+complication	B-DISO
+accompanying	O
+acute	O
+lung	B-ANAT
+injury	O
+(	O
+ALI	O
+),	O
+severe	O
+pneumonia	B-DISO
+and	O
+the	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+(	O
+ARDS	B-DISO
+),	O
+which	O
+can	O
+be	O
+associated	O
+with	O
+a	O
+reduced	O
+alveolar	B-ANAT
+liquid	O
+clearance	O
+(	O
+ALC	O
+)	O
+capacity	O
+,	O
+a	O
+disruption	O
+of	O
+the	O
+alveolar	B-ANAT
+epithelial	O
+barrier	O
+,	O
+and	O
+an	O
+increased	O
+capillary	B-ANAT
+endothelial	B-ANAT
+permeability	O
+.	O
+
+Apart	O
+from	O
+ventilation	O
+strategies	O
+,	O
+no	O
+standard	O
+treatment	O
+exists	O
+for	O
+permeability	O
+edema	B-DISO
+,	O
+making	O
+the	O
+search	O
+for	O
+novel	O
+regulators	O
+of	O
+endothelial	B-ANAT
+and	O
+epithelial	O
+hyperpermeability	O
+and	O
+dysfunction	O
+important	O
+.	O
+
+CC	O
+/	O
+Fr	O
+.	O
+2	O
+inhibited	O
+the	O
+internalization	O
+of	O
+TfR	B-PRGE
+but	O
+the	O
+procyanidins	O
+did	O
+not	O
+.	O
+
+ABSTRACT	O
+:	O
+Porcine	B-PRGE
+aminopeptidase	B-ENZY
+N	I-ENZY
+(	O
+pAPN	O
+)	O
+is	O
+a	O
+cellular	B-COMP
+membrane	I-COMP
+protein	B-CHED
+and	O
+a	O
+functional	O
+receptor	O
+for	O
+porcine	B-SPEC
+coronaviruses	O
+.	O
+
+Because	O
+of	O
+the	O
+high	O
+mortality	O
+which	O
+is	O
+up	O
+to	O
+100	O
+%	O
+in	O
+suckling	O
+piglets	O
+,	O
+PED	B-PRGE
+is	O
+an	O
+important	O
+porcine	B-SPEC
+disease	O
+in	O
+Korea	O
+.	O
+
+After	O
+the	O
+confirmation	O
+of	O
+PEDV	B-SPEC
+neutralizing	O
+activity	O
+of	O
+purified	O
+recombinant	O
+scFvs	O
+by	O
+VN	O
+test	O
+,	O
+scFvs	O
+were	O
+expressed	B-PROC
+on	O
+the	O
+surface	O
+of	O
+E	B-SPEC
+.	I-SPEC
+coli	I-SPEC
+cells	B-COMP
+.	O
+
+ABSTRACT	O
+:	O
+Isatis	B-SPEC
+indigotica	I-SPEC
+(	O
+I	B-SPEC
+.	I-SPEC
+indigotica	I-SPEC
+),	O
+Cruciferae	B-SPEC
+,	O
+has	O
+been	O
+used	O
+in	O
+Chinese	O
+medicine	B-CHED
+for	O
+anti	O
+-	O
+leukemia	B-DISO
+and	O
+anti	O
+-	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+(	O
+SARS	B-DISO
+).	O
+
+The	O
+cytotoxic	O
+effect	O
+of	O
+extracts	O
+on	O
+swine	B-SPEC
+peripheral	B-ANAT
+blood	I-ANAT
+mononuclear	I-ANAT
+cells	I-ANAT
+(	O
+PBMCs	O
+)	O
+and	O
+HL	B-ANAT
+-	I-ANAT
+60	I-ANAT
+was	O
+assessed	O
+by	O
+MTT	B-CHED
+method	O
+.	O
+
+It	O
+also	O
+highlights	O
+the	O
+recent	O
+identification	O
+of	O
+numerous	O
+novel	O
+coronaviruses	O
+and	O
+the	O
+propensity	O
+of	O
+this	O
+virus	B-SPEC
+family	B-SPEC
+to	O
+cross	O
+species	B-SPEC
+barriers	O
+.	O
+
+The	O
+aims	O
+of	O
+this	O
+study	O
+were	O
+to	O
+validate	O
+a	O
+colorimetric	O
+method	O
+to	O
+measure	O
+total	O
+sialic	B-CHED
+acid	I-CHED
+(	O
+TSA	B-FUNC
+)	O
+in	O
+feline	B-SPEC
+serum	B-COMP
+and	O
+to	O
+investigate	O
+the	O
+serum	B-COMP
+concentration	O
+of	O
+TSA	B-FUNC
+in	O
+clinically	O
+healthy	O
+cats	B-SPEC
+seronegative	O
+(	O
+n	O
+=	O
+9	O
+)	O
+and	O
+seropositive	O
+(	O
+n	O
+=	O
+48	O
+)	O
+for	O
+feline	B-SPEC
+coronavirus	B-SPEC
+(	O
+FCoV	O
+),	O
+and	O
+in	O
+cats	B-SPEC
+affected	O
+by	O
+feline	B-DISO
+infectious	I-DISO
+peritonitis	I-DISO
+(	O
+FIP	B-DISO
+,	O
+n	O
+=	O
+28	O
+),	O
+tumors	B-DISO
+(	O
+n	O
+=	O
+20	O
+),	O
+or	O
+inflammation	B-DISO
+(	O
+n	O
+=	O
+16	O
+).	O
+
+Compared	O
+with	O
+seropositive	O
+controls	O
+,	O
+the	O
+concentration	O
+of	O
+TSA	B-FUNC
+was	O
+higher	O
+in	O
+cats	B-SPEC
+with	O
+FIP	B-DISO
+(	O
+556	O
+.	O
+7	O
++/-	O
+
+Consequently	O
+,	O
+TSA	B-FUNC
+could	O
+support	O
+a	O
+diagnosis	O
+of	O
+FIP	B-DISO
+only	O
+at	O
+extremely	O
+high	O
+serum	B-COMP
+concentration	O
+(>	O
+800	O
+mg	O
+/	O
+L	O
+)	O
+or	O
+when	O
+the	O
+pre	O
+-	O
+test	O
+probability	O
+of	O
+FIP	B-DISO
+is	O
+high	O
+.	O
+
+TITLE	O
+:	O
+The	O
+SARS	B-DISO
+-	O
+unique	O
+domain	O
+(	O
+SUD	O
+)	O
+of	O
+SARS	B-DISO
+coronavirus	B-SPEC
+contains	O
+two	O
+macrodomains	O
+that	O
+bind	B-FUNC
+G	O
+-	O
+quadruplexes	O
+.	O
+
+SP	B-PRGE
+-	I-PRGE
+D	I-PRGE
+is	O
+recognized	O
+to	O
+bind	B-FUNC
+the	O
+S	B-PRGE
+protein	I-PRGE
+of	O
+SARS	B-PRGE
+-	I-PRGE
+CoV	I-PRGE
+and	O
+enhance	O
+phagocytosis	B-PROC
+.	O
+
+The	O
+possible	O
+re	O
+-	O
+emergence	O
+of	O
+SARS	O
+or	O
+SARS	B-DISO
+-	O
+like	O
+infections	B-DISO
+suggests	O
+a	O
+need	O
+for	O
+minimal	O
+traumatic	O
+techniques	O
+for	O
+following	O
+the	O
+alveolar	B-ANAT
+compartment	B-ANAT
+,	O
+e	O
+.	O
+g	O
+.	O
+during	O
+testing	O
+of	O
+antivirals	B-CHED
+.	O
+
+The	O
+resulting	O
+recombinant	O
+MHV	B-SPEC
+was	O
+viable	O
+and	O
+had	O
+indeed	O
+acquired	O
+the	O
+ability	O
+to	O
+infect	O
+all	O
+glioblastoma	B-DISO
+cell	B-ANAT
+lines	I-ANAT
+tested	O
+in	O
+vitro	O
+.	O
+
+We	O
+show	O
+that	O
+the	O
+residues	O
+immediately	O
+C	O
+-	O
+terminal	O
+to	O
+the	O
+SARS	B-PRGE
+-	I-PRGE
+CoV	I-PRGE
+S2	I-PRGE
+cleavage	B-PROC
+site	O
+SFIEDLLFNKVTLADAGF	O
+are	O
+very	O
+highly	O
+conserved	O
+across	O
+all	O
+CoVs	O
+.	O
+
+Before	O
+(	O
+normal	O
+condition	B-DISO
+)	O
+and	O
+after	O
+(	O
+pseudo	O
+-	O
+infection	B-DISO
+condition	B-DISO
+)	O
+exercise	O
+,	O
+a	O
+significant	O
+linear	O
+discriminant	O
+function	O
+(	O
+p50	O
+.	O
+001	O
+)	O
+was	O
+determined	O
+to	O
+distinguish	O
+the	O
+pseudo	O
+-	O
+infection	O
+condition	B-DISO
+from	O
+the	O
+normal	O
+condition	B-DISO
+(	O
+Mahalanobis	O
+D	O
+-	O
+square	O
+1	O
+/	O
+4	O
+20	O
+.	O
+3	O
+,	O
+classification	O
+error	O
+rate55	O
+%).	O
+
+TITLE	O
+:	O
+Review	O
+of	O
+new	O
+and	O
+newly	O
+discovered	O
+respiratory	B-ANAT
+tract	I-ANAT
+viruses	B-SPEC
+in	O
+children	O
+.	O
+
+ABSTRACT	O
+:	O
+Respiratory	B-ANAT
+tract	I-ANAT
+viral	B-DISO
+infection	I-DISO
+continues	O
+to	O
+be	O
+among	O
+the	O
+most	O
+common	O
+reasons	O
+for	O
+emergency	B-DISO
+department	O
+visits	O
+and	O
+hospitalization	O
+of	O
+children	O
+,	O
+particularly	O
+infants	O
+younger	O
+than	O
+1	O
+year	O
+,	O
+in	O
+the	O
+United	O
+States	O
+.	O
+
+Throughout	O
+the	O
+years	O
+,	O
+clinicians	O
+have	O
+considered	O
+respiratory	B-SPEC
+syncytial	I-SPEC
+virus	I-SPEC
+followed	O
+by	O
+influenza	B-DISO
+as	O
+the	O
+most	O
+common	O
+pathogens	O
+responsible	O
+.	O
+
+This	O
+includes	O
+human	B-SPEC
+metapneumovirus	I-SPEC
+,	O
+which	O
+leads	O
+to	O
+similar	O
+but	O
+often	O
+epidemiologically	O
+more	O
+severe	O
+clinical	O
+symptoms	O
+than	O
+respiratory	B-SPEC
+syncytial	I-SPEC
+virus	I-SPEC
+.	O
+
+This	O
+lead	O
+to	O
+an	O
+improvement	O
+in	O
+arterial	B-ANAT
+oxygenation	B-PROC
+and	O
+reduction	O
+in	O
+respiratory	O
+rate	O
+of	O
+the	O
+patient	O
+and	O
+gradual	O
+disappearance	O
+of	O
+fetal	B-DISO
+distress	I-DISO
+.	O
+
+Our	O
+results	O
+and	O
+accumulated	O
+data	O
+on	O
+HLA	B-ANAT
+in	O
+the	O
+Asian	O
+populations	O
+would	O
+help	O
+in	O
+the	O
+understanding	O
+of	O
+associations	O
+with	O
+emerging	B-DISO
+infectious	I-DISO
+diseases	I-DISO
+.	O
+
+It	O
+is	O
+used	O
+to	O
+help	O
+prevent	O
+influenza	B-PATH
+infection	B-DISO
+as	O
+long	O
+as	O
+necessary	O
+with	O
+little	O
+risk	O
+for	O
+influenza	B-DISO
+mutation	O
+rendering	O
+it	O
+less	O
+effective	O
+.	O
+
+Of	O
+the	O
+viral	O
+-	O
+entry	O
+inhibitors	B-CHED
+,	O
+monoclonal	O
+antibodies	B-COMP
+have	O
+demonstrated	O
+efficacy	O
+,	O
+clinical	O
+application	O
+in	O
+other	O
+viral	B-DISO
+infections	I-DISO
+,	O
+and	O
+the	O
+potential	O
+to	O
+impact	O
+a	O
+future	O
+epidemic	O
+.	O
+
+ABSTRACT	O
+:	O
+Human	O
+coronavirus	O
+NL63	O
+(	O
+HCoV	B-SPEC
+-	I-SPEC
+NL63	I-SPEC
+)	O
+is	O
+a	O
+novel	O
+respiratory	O
+virus	B-SPEC
+which	O
+is	O
+associated	O
+with	O
+respiratory	B-DISO
+tract	I-DISO
+infections	I-DISO
+in	O
+children	O
+.	O
+
+To	O
+determine	O
+the	O
+role	O
+of	O
+HCoV	B-SPEC
+-	I-SPEC
+NL63	I-SPEC
+in	O
+infants	O
+and	O
+young	O
+children	O
+hospitalised	O
+with	O
+acute	O
+respiratory	B-DISO
+tract	I-DISO
+infections	I-DISO
+(	O
+ARI	B-CHED
+)	O
+in	O
+Cape	O
+Town	O
+,	O
+South	O
+Africa	O
+.	O
+
+Most	O
+patients	O
+had	O
+a	O
+diagnosis	O
+of	O
+pneumonia	B-DISO
+or	O
+lower	B-ANAT
+respiratory	I-ANAT
+tract	I-ANAT
+infection	I-DISO
+(	O
+6	O
+/	O
+9	O
+;	O
+67	O
+%).	O
+
+ABSTRACT	O
+:	O
+Angiotensin	B-PRGE
+converting	I-PRGE
+enzyme	I-PRGE
+2	I-PRGE
+(	O
+ACE2	B-PRGE
+),	O
+a	O
+monocarboxylase	O
+that	O
+degrades	O
+angiotensin	B-PRGE
+II	I-PRGE
+to	O
+angiotensin	B-CHED
+1	O
+-	O
+7	O
+,	O
+is	O
+also	O
+the	O
+functional	O
+receptor	O
+for	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+(	O
+SARS	B-DISO
+)	O
+coronavirus	B-SPEC
+(	O
+SARS	B-DISO
+-	O
+CoV	O
+)	O
+and	O
+is	O
+highly	O
+expressed	B-PROC
+in	O
+the	O
+lungs	B-ANAT
+and	O
+heart	B-ANAT
+.	O
+
+Autopsy	O
+heart	B-ANAT
+samples	O
+from	O
+patients	O
+who	O
+succumbed	O
+to	O
+the	O
+SARS	B-DISO
+crisis	O
+in	O
+Toronto	O
+(	O
+Canada	O
+)	O
+were	O
+used	O
+to	O
+investigate	O
+the	O
+impact	O
+of	O
+SARS	B-DISO
+on	O
+myocardial	O
+structure	O
+,	O
+inflammation	B-DISO
+and	O
+ACE2	B-PRGE
+protein	I-PRGE
+expression	B-PROC
+.	O
+
+ABSTRACT	O
+:	O
+The	O
+case	O
+fatality	O
+rate	O
+is	O
+an	O
+important	O
+indicator	O
+of	O
+the	O
+severity	O
+of	O
+a	O
+disease	O
+,	O
+and	O
+unbiased	O
+and	O
+accurate	O
+estimates	O
+of	O
+it	O
+during	O
+an	O
+outbreak	O
+are	O
+important	O
+in	O
+the	O
+study	O
+of	O
+epidemic	O
+diseases	O
+,	O
+including	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+(	O
+SARS	B-DISO
+).	O
+
+The	O
+method	O
+was	O
+applied	O
+to	O
+summary	O
+SARS	B-DISO
+data	O
+obtained	O
+from	O
+Hong	O
+Kong	O
+and	O
+Singapore	O
+.	O
+
+The	O
+overview	O
+discusses	O
+whether	O
+serially	O
+Vero	B-ANAT
+cell	I-ANAT
+propagated	O
+PED	O
+virus	B-SPEC
+strains	O
+may	O
+be	O
+used	O
+as	O
+live	O
+vaccines	O
+.	O
+
+TITLE	O
+:	O
+Surveillance	O
+of	O
+human	B-DISO
+papilloma	I-DISO
+virus	I-DISO
+infection	I-DISO
+and	O
+cervical	B-DISO
+cancer	B-SPEC
+in	O
+kidney	B-ANAT
+transplant	I-ANAT
+recipients	O
+:	O
+preliminary	O
+data	O
+.	O
+
+We	O
+report	O
+the	O
+preliminary	O
+findings	O
+of	O
+a	O
+prospective	O
+study	O
+that	O
+evaluated	O
+the	O
+incidence	O
+of	O
+HPV	O
+infection	B-DISO
+and	O
+cervical	B-DISO
+carcinoma	I-DISO
+in	O
+a	O
+population	O
+of	O
+kidney	B-ANAT
+transplant	I-ANAT
+recipients	O
+.	O
+
+Failing	O
+to	O
+account	O
+for	O
+dynamic	O
+molecular	O
+evolution	B-PROC
+can	O
+affect	O
+greatly	O
+estimating	O
+index	O
+case	O
+dates	O
+,	O
+resulting	O
+in	O
+an	O
+overestimated	O
+age	O
+for	O
+the	O
+SARS	B-DISO
+-	O
+CoV	O
+-	O
+human	B-SPEC
+infection	B-DISO
+,	O
+for	O
+instance	O
+.	O
+
+Infection	B-DISO
+with	O
+equine	B-DISO
+influenza	B-PATH
+A	I-PATH
+(	O
+H3N8	O
+)	O
+or	O
+a	O
+highly	O
+related	O
+influenza	B-SPEC
+virus	I-SPEC
+can	O
+cause	O
+severe	O
+respiratory	B-DISO
+disease	I-DISO
+and	O
+mortality	O
+in	O
+greyhounds	O
+and	O
+other	O
+dogs	B-SPEC
+.	O
+
+Impairment	B-DISO
+of	O
+the	O
+protein	B-CHED
+C	O
+system	O
+plays	O
+an	O
+important	O
+role	O
+in	O
+acute	O
+lung	O
+injury	O
+/	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+and	O
+severe	B-DISO
+sepsis	I-DISO
+.	O
+
+She	O
+also	O
+required	O
+vigorous	O
+inotropic	O
+support	O
+(	O
+dopamine	B-CHED
++	O
+noradrenaline	B-CHED
+).	O
+
+Aspergillus	B-SPEC
+DNA	O
+was	O
+detected	O
+in	O
+bronchoalveolar	O
+lavage	O
+,	O
+and	O
+in	O
+blood	B-COMP
+serum	I-COMP
+(	O
+PCR	O
+).	O
+
+These	O
+theoretical	O
+results	O
+should	O
+be	O
+kept	O
+in	O
+mind	O
+when	O
+analyzing	O
+data	O
+for	O
+emerging	O
+vector	O
+-	O
+borne	O
+diseases	O
+(	O
+West	O
+-	O
+Nile	O
+,	O
+dengue	B-DISO
+,	O
+chikungunya	B-DISO
+)	O
+or	O
+air	B-CHED
+-	O
+borne	O
+diseases	O
+(	O
+SARS	O
+,	O
+pandemic	O
+influenza	B-DISO
+);	O
+all	O
+these	O
+diseases	O
+being	O
+influenced	O
+by	O
+seasonality	O
+.	O
+
+ABSTRACT	O
+:	O
+Human	B-ANAT
+embryonic	I-ANAT
+stem	I-ANAT
+cell	B-COMP
+-	O
+derived	O
+oligodendrocyte	B-ANAT
+progenitors	O
+(	O
+OPCs	O
+)	O
+were	O
+transplanted	B-ANAT
+into	O
+mice	B-SPEC
+persistently	O
+infected	O
+with	O
+the	O
+neurotropic	O
+JHM	O
+strain	O
+of	O
+mouse	B-DISO
+hepatitis	I-DISO
+virus	B-SPEC
+with	O
+established	O
+demyelination	B-DISO
+.	O
+
+These	O
+data	O
+suggest	O
+that	O
+remyelination	B-PROC
+was	O
+initiated	O
+by	O
+the	O
+local	O
+response	O
+to	O
+xenograft	O
+transplantation	O
+.	O
+
+ABSTRACT	O
+:	O
+Feline	B-SPEC
+coronavirus	B-DISO
+infection	I-DISO
+is	O
+ubiquitous	O
+in	O
+domestic	B-SPEC
+cats	I-SPEC
+,	O
+and	O
+is	O
+particularly	O
+common	O
+where	O
+conditions	O
+are	O
+crowded	O
+.	O
+
+The	O
+clinical	O
+picture	O
+of	O
+FIP	B-DISO
+is	O
+highly	O
+variable	O
+,	O
+depending	O
+on	O
+the	O
+distribution	O
+of	O
+the	O
+vasculitis	B-DISO
+and	O
+pyogranulomatous	O
+lesions	O
+.	O
+
+At	O
+present	O
+,	O
+only	O
+one	O
+(	O
+intranasal	O
+)	O
+FIP	B-DISO
+vaccine	O
+is	O
+available	O
+,	O
+which	O
+is	O
+considered	O
+as	O
+being	O
+non	O
+-	O
+core	O
+.	O
+
+ABSTRACT	O
+:	O
+Feline	B-DISO
+infectious	I-DISO
+peritonitis	I-DISO
+(	O
+FIP	B-DISO
+)	O
+is	O
+considered	O
+a	O
+fatal	O
+disease	O
+.	O
+
+A	O
+total	O
+of	O
+23	O
+emm	O
+types	O
+were	O
+identified	O
+in	O
+1	O
+,	O
+218	O
+S	B-SPEC
+.	I-SPEC
+pyogenes	I-SPEC
+isolates	O
+.	O
+
+In	O
+2003	O
+,	O
+the	O
+dramatic	O
+drop	O
+in	O
+scarlet	B-DISO
+fever	I-DISO
+cases	O
+in	O
+central	O
+Taiwan	O
+and	O
+throughout	O
+the	O
+whole	O
+country	O
+was	O
+associated	O
+with	O
+the	O
+occurrence	O
+of	O
+a	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+(	O
+SARS	B-DISO
+)	O
+outbreak	O
+that	O
+occurred	O
+between	O
+late	O
+-	O
+February	O
+and	O
+mid	O
+-	O
+June	O
+in	O
+Taiwan	O
+.	O
+
+The	O
+occurrences	O
+of	O
+scarlet	B-DISO
+fever	I-DISO
+in	O
+central	O
+Taiwan	O
+in	O
+2000	O
+-	O
+2006	O
+were	O
+primarily	O
+caused	O
+by	O
+five	O
+emm	O
+types	O
+,	O
+which	O
+accounted	O
+for	O
+96	O
+.	O
+8	O
+%	O
+of	O
+the	O
+isolates	O
+collected	O
+.	O
+
+Corticosteroid	B-CHED
+was	O
+administered	O
+systemically	O
+in	O
+all	O
+cases	O
+except	O
+one	O
+case	O
+of	O
+TEN	O
+which	O
+developed	O
+methicillin	B-CHED
+resistant	O
+staphylococcus	B-SPEC
+aureus	I-SPEC
+(	O
+MRSA	B-DISO
+)	O
+pneumoniae	O
+before	O
+the	O
+onset	O
+of	O
+the	O
+eruption	B-DISO
+.	O
+
+ABSTRACT	O
+:	O
+Prenatal	O
+influenza	O
+exposure	O
+increases	O
+the	O
+risk	O
+for	O
+schizophrenia	B-DISO
+and	O
+brings	O
+to	O
+question	O
+how	O
+other	O
+respiratory	O
+viruses	B-SPEC
+may	O
+contribute	O
+to	O
+neuropsychiatric	O
+disease	O
+etiopathology	O
+.	O
+
+Naphtol	O
+-	O
+AS	O
+-	O
+D	O
+-	O
+chloroacetate	O
+esterase	O
+staining	O
+was	O
+used	O
+to	O
+determine	O
+pulmonary	B-ANAT
+PMN	B-PROC
+infiltration	B-DISO
+.	O
+
+3	O
+.	O
+68	O
+ng	O
+/	O
+ml	O
+;	O
+p	O
+<	O
+0	O
+.	O
+05	O
+)	O
+and	O
+as	O
+a	O
+result	O
+decreased	O
+pulmonary	B-DISO
+infiltration	I-DISO
+of	O
+PMNs	O
+(	O
+21	O
+.	O
+2	O
++/-	O
+5	O
+.	O
+1	O
+vs	O
+.	O
+32	O
+.	O
+5	O
++/-	O
+
+Histological	O
+evaluation	O
+revealed	O
+decreased	O
+pulmonary	B-DISO
+edema	I-DISO
+(	O
+1	O
+.	O
+83	O
++/-	O
+0	O
+.	O
+41	O
+vs	O
+.	O
+2	O
+.	O
+33	O
++/-	O
+
+Doxycycline	B-CHED
+reduced	O
+PMN	B-PROC
+migration	B-PROC
+in	O
+vitro	O
+and	O
+in	O
+vivo	O
+and	O
+therefore	O
+might	O
+represent	O
+a	O
+novel	O
+strategy	O
+for	O
+the	O
+prevention	O
+of	O
+secondary	O
+pulmonary	B-DISO
+complications	I-DISO
+in	O
+acute	B-DISO
+pancreatitis	I-DISO
+.	O
+
+The	O
+S	B-COMP
+-	I-COMP
+layer	I-COMP
+fusion	O
+proteins	B-CHED
+produced	O
+in	O
+a	O
+500	O
+-	O
+l	O
+fermentor	O
+were	O
+likely	O
+to	O
+be	O
+stable	O
+in	O
+the	O
+range	O
+of	O
+pH	O
+5	O
+to	O
+8	O
+and	O
+0	O
+degree	O
+to	O
+40	O
+degrees	O
+.	O
+
+(	O
+III	B-PRGE
+-	I-PRGE
+C	I-PRGE
+)	O
+2	O
+.	O
+
+(	O
+III	B-PRGE
+-	I-PRGE
+C	I-PRGE
+)	O
+6	O
+.	O
+
+Staff	O
+caring	O
+for	O
+pregnant	O
+SARS	B-DISO
+patients	O
+should	O
+be	O
+actively	O
+monitored	O
+for	O
+fever	B-PROC
+and	O
+other	O
+symptoms	O
+of	O
+SARS	B-DISO
+.	O
+
+All	O
+health	O
+care	O
+personnel	O
+,	O
+trainees	O
+,	O
+and	O
+support	O
+staff	O
+should	O
+be	O
+trained	O
+in	O
+infection	B-DISO
+control	O
+management	O
+and	O
+containment	O
+to	O
+prevent	O
+spread	O
+of	O
+the	O
+SARS	B-DISO
+virus	B-SPEC
+.	O
+
+TITLE	O
+:	O
+Pheochromocytoma	B-DISO
+presenting	O
+as	O
+massive	O
+hemoptysis	B-DISO
+and	O
+acute	B-DISO
+respiratory	I-DISO
+failure	I-DISO
+.	O
+
+On	O
+the	O
+other	O
+hand	O
+,	O
+the	O
+S1	O
+gene	O
+of	O
+JP	O
+/	O
+Wakayama	O
+-	O
+2	O
+/	O
+2004	O
+revealed	O
+high	O
+sequence	O
+similarity	O
+with	O
+that	O
+of	O
+the	O
+4	O
+/	O
+91	O
+vaccine	O
+strain	O
+and	O
+appeared	O
+to	O
+be	O
+a	O
+vaccine	O
+-	O
+like	O
+virus	B-SPEC
+derived	O
+from	O
+a	O
+vaccine	O
+.	O
+
+Furthermore	O
+,	O
+the	O
+4	O
+/	O
+91	O
+vaccine	O
+strain	O
+and	O
+vaccine	O
+-	O
+like	O
+isolate	O
+(	O
+JP	O
+/	O
+Wakayama	O
+-	O
+2	O
+/	O
+2004	O
+)	O
+could	O
+be	O
+differentiated	B-PROC
+from	O
+the	O
+other	O
+field	O
+isolates	O
+by	O
+Bgl	B-PRGE
+II	I-PRGE
+digestion	B-PROC
+.	O
+
+TITLE	O
+:	O
+Comparison	O
+of	O
+enzyme	O
+-	O
+linked	O
+immunosorbent	O
+assay	O
+and	O
+RT	O
+-	O
+PCR	O
+for	O
+the	O
+detection	O
+of	O
+porcine	B-SPEC
+epidemic	B-DISO
+diarrhoea	I-DISO
+virus	I-SPEC
+.	O
+
+A	O
+double	O
+antibody	B-COMP
+sandwich	O
+enzyme	O
+-	O
+linked	O
+immunosorbent	O
+assay	O
+(	O
+DAS	O
+-	O
+ELISA	O
+)	O
+based	O
+on	O
+the	O
+use	O
+of	O
+monoclonal	O
+antibodies	B-COMP
+was	O
+developed	O
+for	O
+the	O
+detection	O
+of	O
+porcine	B-SPEC
+epidemic	I-SPEC
+diarrhoea	I-SPEC
+virus	I-SPEC
+(	O
+PEDV	B-SPEC
+).	O
+
+The	O
+DAS	O
+-	O
+ELISA	O
+was	O
+compared	O
+with	O
+RT	O
+-	O
+PCR	O
+in	O
+the	O
+examination	O
+of	O
+506	O
+specimens	O
+collected	O
+during	O
+2006	O
+-	O
+2007	O
+from	O
+pigs	B-SPEC
+originating	O
+from	O
+different	O
+farms	O
+located	O
+in	O
+the	O
+Po	O
+valley	O
+.	O
+
+The	O
+results	O
+of	O
+rapid	O
+diagnostic	O
+test	O
+for	O
+malaria	B-PATH
+(	O
+OptiMAL	O
+test	O
+,	O
+Diamed	O
+AG	O
+,	O
+Switzerland	O
+)	O
+were	O
+correlated	O
+with	O
+the	O
+peripheral	B-ANAT
+blood	I-ANAT
+smear	O
+findings	O
+in	O
+the	O
+patients	O
+in	O
+whom	O
+it	O
+was	O
+requested	O
+.	O
+
+The	O
+peak	O
+incidence	O
+of	O
+malaria	B-PATH
+was	O
+seen	O
+in	O
+September	O
+2005	O
+and	O
+August	O
+2006	O
+.	O
+
+One	O
+patient	O
+went	O
+into	O
+acute	B-DISO
+renal	I-DISO
+failure	I-DISO
+following	O
+quinine	B-CHED
+therapy	O
+and	O
+showed	O
+red	B-ANAT
+cell	I-ANAT
+fragments	O
+in	O
+the	O
+peripheral	B-ANAT
+blood	I-ANAT
+.	O
+
+CONCLUSIONS	O
+:	O
+This	O
+paper	O
+is	O
+presented	O
+to	O
+highlight	O
+that	O
+P	B-SPEC
+.	I-SPEC
+vivax	I-SPEC
+malaria	O
+though	O
+considered	O
+to	O
+be	O
+a	O
+benign	O
+entity	O
+can	O
+also	O
+have	O
+a	O
+severe	O
+and	O
+complicated	O
+course	O
+which	O
+is	O
+usually	O
+associated	O
+with	O
+P	B-SPEC
+.	I-SPEC
+falciparum	I-SPEC
+malaria	O
+.	O
+
+ABSTRACT	O
+:	O
+Respiratory	O
+virus	O
+infections	B-DISO
+are	O
+the	O
+most	O
+important	O
+trigger	O
+of	O
+respiratory	O
+illnesses	O
+in	O
+childhood	O
+.	O
+
+In	O
+a	O
+prospective	O
+birth	B-PROC
+cohort	O
+study	O
+,	O
+infants	O
+were	O
+followed	O
+from	O
+birth	B-PROC
+through	O
+the	O
+first	O
+year	O
+of	O
+life	O
+with	O
+daily	O
+questionnaires	O
+about	O
+respiratory	B-DISO
+symptoms	I-DISO
+.	O
+
+Infections	B-DISO
+with	O
+RSV	B-SPEC
+were	O
+associated	O
+with	O
+more	O
+physician	O
+visits	O
+than	O
+HRV	O
+infections	B-DISO
+(	O
+P	O
+=	O
+0	O
+.	O
+06	O
+).	O
+
+There	O
+was	O
+also	O
+strong	O
+induction	O
+of	O
+TNF	B-PRGE
+-	O
+related	O
+apoptosis	B-PATH
+-	O
+inducing	O
+ligand	B-PROC
+(	O
+TRAIL	O
+),	O
+but	O
+not	O
+Fas	B-PRGE
+ligand	B-PROC
+gene	B-PROC
+expression	I-PROC
+in	O
+SARS	B-DISO
+-	O
+CoV	O
+infected	O
+DCs	B-DISO
+.	O
+
+Interestingly	O
+,	O
+the	O
+expressions	O
+of	O
+most	O
+genes	O
+studied	O
+were	O
+higher	O
+in	O
+CB	O
+DCs	O
+than	O
+adult	O
+DCs	B-DISO
+.	O
+
+The	O
+upregulation	B-PROC
+of	O
+chemokines	O
+and	O
+CCRs	O
+may	O
+facilitate	O
+DC	O
+migration	B-PROC
+from	O
+the	O
+infection	B-DISO
+site	I-DISO
+to	O
+the	O
+lymph	B-ANAT
+nodes	I-ANAT
+,	O
+whereas	O
+the	O
+increase	O
+of	O
+TRAIL	B-PRGE
+may	O
+induce	O
+lymphocyte	B-PROC
+apoptosis	B-PATH
+.	O
+
+This	O
+study	O
+examines	O
+the	O
+effect	O
+of	O
+shifting	O
+childbirth	B-PROC
+services	O
+from	O
+advanced	O
+hospitals	O
+(	O
+i	O
+.	O
+e	O
+.,	O
+medical	O
+centers	O
+and	O
+regional	O
+hospitals	O
+)	O
+to	O
+local	O
+community	O
+hospitals	O
+(	O
+i	O
+.	O
+e	O
+.,	O
+clinics	O
+and	O
+district	O
+hospitals	O
+).	O
+
+The	O
+highest	O
+survival	O
+rate	O
+(	O
+98	O
+.	O
+6	O
+%)	O
+of	O
+the	O
+pups	O
+was	O
+found	O
+when	O
+mother	O
+mice	B-SPEC
+were	O
+treated	O
+daily	O
+with	O
+a	O
+concentration	O
+of	O
+15	O
+mg	O
+of	O
+chloroquine	B-CHED
+per	O
+kg	O
+of	O
+body	B-ANAT
+weight	O
+.	O
+
+TITLE	O
+:	O
+Mathematical	O
+modelling	O
+of	O
+SARS	B-DISO
+and	O
+other	B-DISO
+infectious	I-DISO
+diseases	I-DISO
+in	O
+China	O
+:	O
+a	O
+review	O
+.	O
+
+ABSTRACT	O
+:	O
+To	O
+give	O
+an	O
+overview	O
+of	O
+the	O
+recent	O
+history	O
+of	O
+publications	O
+on	O
+mathematical	O
+modelling	O
+of	O
+infectious	O
+diseases	O
+in	O
+the	O
+Chinese	O
+literature	O
+,	O
+and	O
+a	O
+more	O
+detailed	O
+review	O
+of	O
+the	O
+models	O
+on	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+(	O
+SARS	B-DISO
+).	O
+
+Spatial	O
+analyses	O
+including	O
+kernel	O
+density	O
+estimation	O
+,	O
+and	O
+spatial	O
+statistical	O
+and	O
+tracking	O
+analyses	O
+were	O
+performed	O
+to	O
+characterise	O
+the	O
+spatiotemporal	O
+distribution	O
+of	O
+SARS	B-DISO
+cases	O
+based	O
+on	O
+onset	O
+location	O
+/	O
+date	O
+.	O
+
+The	O
+SARS	B-DISO
+epidemic	O
+in	O
+mainland	O
+China	O
+spanned	O
+a	O
+large	O
+geographical	O
+extent	O
+but	O
+clustered	O
+in	O
+two	O
+areas	O
+:	O
+first	O
+in	O
+Guangdong	O
+Province	O
+,	O
+and	O
+about	O
+3	O
+months	O
+later	O
+in	O
+Beijing	O
+with	O
+its	O
+surrounding	O
+areas	O
+in	O
+Shanxi	O
+Province	O
+,	O
+Inner	O
+Mongolia	O
+Autonomic	O
+Region	O
+,	O
+Hebei	O
+Province	O
+and	O
+Tianjin	O
+.	O
+
+This	O
+knowledge	O
+may	O
+be	O
+important	O
+for	O
+the	O
+control	O
+of	O
+re	O
+-	O
+emerging	O
+SARS	B-DISO
+,	O
+or	O
+other	O
+future	O
+emerging	O
+human	B-SPEC
+-	O
+to	O
+-	O
+human	B-SPEC
+transmittable	O
+infections	B-DISO
+.	O
+
+RESULTS	O
+:	O
+The	O
+SARS	B-DISO
+epidemic	O
+in	O
+mainland	O
+China	O
+spanned	O
+a	O
+large	O
+geographical	O
+extent	O
+but	O
+clustered	O
+in	O
+two	O
+areas	O
+:	O
+first	O
+in	O
+Guangdong	O
+Province	O
+,	O
+and	O
+about	O
+3	O
+months	O
+later	O
+in	O
+Beijing	O
+with	O
+its	O
+surrounding	O
+areas	O
+in	O
+Shanxi	O
+Province	O
+,	O
+Inner	O
+Mongolia	O
+Autonomic	B-ANAT
+Region	O
+,	O
+Hebei	O
+Province	O
+and	O
+Tianjin	O
+.	O
+
+ABSTRACT	O
+:	O
+To	O
+describe	O
+and	O
+analyse	O
+factors	O
+associated	O
+with	O
+the	O
+duration	O
+of	O
+disease	O
+onset	O
+to	O
+hospital	O
+admission	O
+,	O
+admission	O
+to	O
+discharge	O
+and	O
+admission	O
+to	O
+death	B-PROC
+for	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+(	O
+SARS	B-DISO
+),	O
+using	O
+the	O
+recently	O
+developed	O
+comprehensive	O
+database	O
+covering	O
+all	O
+regions	O
+of	O
+mainland	O
+China	O
+,	O
+and	O
+compare	O
+the	O
+results	O
+within	O
+and	O
+outside	O
+China	O
+.	O
+
+Linear	O
+regression	O
+(	O
+uni	O
+-	O
+and	O
+multivariate	O
+analysis	O
+)	O
+was	O
+performed	O
+for	O
+all	O
+three	O
+durations	O
+to	O
+test	O
+the	O
+impact	O
+of	O
+the	O
+following	O
+variables	O
+:	O
+sex	O
+,	O
+age	O
+,	O
+occupation	O
+,	O
+geographic	O
+location	O
+and	O
+period	O
+of	O
+the	O
+SARS	B-DISO
+epidemic	O
+(	O
+time	O
+since	O
+the	O
+first	O
+case	O
+,	O
+i	O
+.	O
+e	O
+.	O
+16	O
+November	O
+2002	O
+).	O
+
+RESULTS	O
+:	O
+The	O
+average	O
+duration	O
+of	O
+onset	O
+of	O
+symptoms	O
+to	O
+hospital	O
+admission	O
+was	O
+3	O
+.	O
+8	O
+days	O
+,	O
+of	O
+admission	O
+to	O
+discharge	B-ANAT
+for	O
+those	O
+who	O
+survived	O
+was	O
+29	O
+.	O
+7	O
+days	O
+,	O
+while	O
+admission	O
+to	O
+death	B-PROC
+for	O
+casualties	O
+was	O
+17	O
+.	O
+4	O
+days	O
+.	O
+
+SARS	B-DISO
+became	O
+a	O
+notifiable	O
+disease	O
+in	O
+China	O
+in	O
+mid	O
+-	O
+April	O
+2003	O
+,	O
+after	O
+which	O
+introduction	O
+of	O
+efficient	O
+nationwide	O
+control	O
+measures	O
+led	O
+to	O
+containment	O
+within	O
+2	O
+months	O
+.	O
+
+To	O
+optimise	O
+future	O
+data	O
+collection	O
+during	O
+large	O
+-	O
+scale	O
+outbreaks	O
+of	O
+emerging	O
+or	O
+re	O
+-	O
+emerging	O
+infectious	O
+disease	O
+,	O
+China	O
+must	O
+further	O
+improve	O
+the	O
+infectious	B-DISO
+diseases	I-DISO
+reporting	O
+system	O
+,	O
+enhance	O
+collaboration	O
+between	O
+all	O
+levels	O
+of	O
+disease	O
+control	O
+,	O
+health	O
+departments	O
+,	O
+hospitals	O
+and	O
+institutes	O
+nationally	O
+and	O
+globally	O
+,	O
+and	O
+train	O
+specialized	O
+staff	O
+working	O
+at	O
+county	O
+centres	O
+of	O
+disease	O
+control	O
+.	O
+
+TITLE	O
+:	O
+Construction	O
+of	O
+plasmids	O
+expressing	O
+Sars	B-PRGE
+-	I-PRGE
+CoV	I-PRGE
+encoding	I-PRGE
+proteins	B-CHED
+and	O
+their	O
+effects	O
+on	O
+transcription	B-PROC
+of	O
+hfgl2	B-PRGE
+prothrombinase	I-PRGE
+.	O
+
+This	O
+study	O
+tests	O
+the	O
+hypothesis	O
+that	O
+concurrent	O
+gastric	B-ANAT
+aspiration	B-DISO
+(	O
+combined	O
+acid	O
+and	O
+small	O
+gastric	B-ANAT
+particles	O
+,	O
+CASP	O
+)	O
+at	O
+the	O
+time	O
+of	O
+trauma	O
+significantly	O
+increases	O
+permeability	O
+injury	O
+and	O
+inflammation	B-DISO
+compared	O
+with	O
+LC	O
+alone	O
+,	O
+and	O
+also	O
+modifies	O
+the	O
+inflammatory	B-DISO
+response	I-DISO
+to	O
+include	O
+distinct	O
+features	O
+compared	O
+with	O
+the	O
+aspiration	B-DISO
+component	O
+of	O
+injury	O
+.	O
+
+Rats	B-SPEC
+with	O
+LC	O
++	O
+CASP	O
+versus	O
+LC	O
+had	O
+more	O
+severe	O
+inflammation	B-DISO
+based	O
+on	O
+higher	O
+levels	O
+of	O
+PMN	B-PROC
+in	O
+BAL	B-ENZY
+at	O
+5	O
+h	O
+,	O
+increased	O
+whole	O
+lung	B-ANAT
+myeloperoxidase	B-PRGE
+(	O
+MPO	B-FUNC
+)	O
+activity	O
+at	O
+5	O
+and	O
+24	O
+h	O
+,	O
+and	O
+increased	O
+levels	O
+of	O
+inflammatory	O
+mediators	O
+in	O
+BAL	B-PRGE
+(	O
+TNFalpha	B-PRGE
+,	O
+IL	B-PRGE
+-	I-PRGE
+1beta	I-PRGE
+,	O
+and	O
+MCP	B-PRGE
+-	I-PRGE
+1	I-PRGE
+at	O
+5	O
+and	O
+24	O
+h	O
+;	O
+IL	B-FUNC
+-	I-FUNC
+10	I-FUNC
+,	O
+MIP	B-PRGE
+-	I-PRGE
+2	I-PRGE
+,	O
+and	O
+CINC	B-CHED
+-	O
+1	O
+at	O
+5	O
+h	O
+).	O
+
+Rats	B-SPEC
+with	O
+LC	O
++	O
+CASP	O
+also	O
+had	O
+distinct	O
+aspects	O
+of	O
+inflammation	B-DISO
+compared	O
+with	O
+CASP	O
+alone	O
+,	O
+i	O
+.	O
+e	O
+.,	O
+significantly	O
+higher	O
+levels	O
+of	O
+IL	B-FUNC
+-	I-FUNC
+10	I-FUNC
+(	O
+5	O
+and	O
+24	O
+h	O
+),	O
+IL	B-PRGE
+-	I-PRGE
+1beta	I-PRGE
+(	O
+24	O
+h	O
+),	O
+CINC	B-CHED
+-	O
+1	O
+(	O
+24	O
+h	O
+),	O
+and	O
+MCP	B-FUNC
+-	O
+1	O
+(	O
+24	O
+h	O
+),	O
+and	O
+significantly	O
+lower	O
+levels	O
+of	O
+MPO	B-FUNC
+(	O
+5	O
+h	O
+),	O
+MIP	B-DISO
+-	O
+2	O
+(	O
+5	O
+h	O
+),	O
+and	O
+CINC	B-CHED
+-	O
+1	O
+(	O
+5	O
+h	O
+).	O
+
+In	O
+addition	O
+to	O
+detecting	O
+the	O
+current	O
+swine	B-SPEC
+flu	I-DISO
+the	O
+xTAG	O
+RVP	O
+test	O
+detected	O
+the	O
+H5N1	B-DISO
+A	O
+/	O
+Vietnam	O
+/	O
+1203	O
+/	O
+2004	O
+high	O
+pathogenicity	O
+avian	B-SPEC
+influenza	I-SPEC
+virus	I-SPEC
+that	O
+circulated	O
+in	O
+South	O
+East	O
+Asia	O
+in	O
+2003	O
+as	O
+well	O
+as	O
+17	O
+out	O
+of	O
+17	O
+influenza	B-PATH
+A	I-PATH
+viruses	B-SPEC
+representing	O
+11	O
+HA	O
+subtypes	O
+isolated	O
+from	O
+birds	B-SPEC
+,	O
+swine	B-SPEC
+and	O
+horses	B-SPEC
+not	O
+yet	O
+seen	O
+in	O
+the	O
+human	B-SPEC
+population	O
+.	O
+
+The	O
+injury	O
+results	O
+in	O
+a	O
+fall	O
+in	O
+arterial	B-ANAT
+oxygenation	B-PROC
+as	O
+a	O
+result	O
+of	O
+airway	B-DISO
+obstruction	I-DISO
+,	O
+increased	O
+pulmonary	B-ANAT
+transvascular	O
+fluid	O
+flux	O
+and	O
+loss	O
+of	O
+hypoxic	B-DISO
+pulmonary	B-ANAT
+vasoconstriction	B-DISO
+.	O
+
+The	O
+changes	O
+in	O
+cardiopulmonary	B-ANAT
+function	O
+are	O
+mediated	O
+by	O
+reactive	O
+oxygen	B-CHED
+and	O
+nitrogen	B-CHED
+species	B-SPEC
+.	O
+
+Current	O
+data	O
+suggest	O
+that	O
+cytotoxins	O
+and	O
+activated	O
+cells	B-COMP
+are	O
+formed	O
+in	O
+the	O
+airway	B-ANAT
+and	O
+carried	O
+to	O
+the	O
+parenchyma	B-ANAT
+.	O
+
+TITLE	O
+:	O
+Innovative	O
+in	O
+silico	O
+approaches	O
+to	O
+address	O
+avian	B-DISO
+flu	I-DISO
+using	O
+grid	O
+technology	O
+.	O
+
+TITLE	O
+:	O
+Transient	O
+mutism	B-DISO
+and	O
+pathologic	O
+laughter	O
+in	O
+the	O
+course	O
+of	O
+cerebellitis	B-DISO
+.	O
+
+Cytometry	O
+analysis	O
+indicated	O
+that	O
+the	O
+majority	O
+of	O
+memory	B-PROC
+CD8	B-PRGE
+(+)	O
+T	B-ANAT
+cells	I-ANAT
+produced	O
+IFN	B-PRGE
+-	I-PRGE
+gamma	I-PRGE
+,	O
+whereas	O
+memory	B-PROC
+CD4	B-PRGE
+(+)	O
+T	B-ANAT
+cells	I-ANAT
+produced	O
+IFN	B-PRGE
+-	I-PRGE
+gamma	I-PRGE
+,	O
+IL	B-FUNC
+-	I-FUNC
+2	I-FUNC
+or	O
+TNF	B-PRGE
+-	I-PRGE
+alpha	I-PRGE
+.	O
+
+4	O
+.	O
+3	O
+scores	O
+,	O
+P	O
+<	O
+0	O
+.	O
+01	O
+);	O
+the	O
+incidence	O
+of	O
+shock	O
+was	O
+lesser	O
+(	O
+1	O
+/	O
+20	O
+vs	O
+7	O
+/	O
+19	O
+);	O
+the	O
+duration	O
+of	O
+ARDS	B-DISO
+,	O
+renal	B-DISO
+failure	I-DISO
+,	O
+cardiac	B-ANAT
+insufficiency	B-DISO
+,	I-DISO
+hepatic	I-DISO
+dysfunction	O
+,	O
+cerebropathy	O
+and	O
+enteroplegia	O
+,	O
+as	O
+well	O
+as	O
+the	O
+duration	O
+in	O
+hospital	O
+and	O
+the	O
+requirement	O
+of	O
+operation	O
+shifting	O
+were	O
+all	O
+shorter	O
+significantly	O
+(	O
+P	O
+<	O
+0	O
+.	O
+05	O
+)	O
+in	O
+the	O
+ET	O
+group	O
+than	O
+those	O
+in	O
+the	O
+LT	O
+group	O
+,	O
+but	O
+no	O
+statistical	O
+difference	O
+(	O
+P	O
+>	O
+0	O
+.	O
+05	O
+)	O
+was	O
+shown	O
+in	O
+terms	O
+of	O
+the	O
+infection	B-DISO
+incidence	O
+and	O
+the	O
+mortality	O
+.	O
+
+CONCLUSIONS	O
+:	O
+An	O
+early	O
+application	O
+of	O
+CQCQD	O
+in	O
+the	O
+treatment	O
+of	O
+SAP	B-PRGE
+could	O
+shorten	O
+the	O
+duration	O
+of	O
+complications	O
+and	O
+the	O
+couse	O
+of	O
+disease	O
+,	O
+lower	O
+the	O
+requirement	O
+of	O
+operation	O
+shifting	O
+.	O
+
+Prone	O
+positioning	O
+,	O
+bronchodilators	O
+,	O
+inhaled	B-PROC
+nitric	B-CHED
+oxide	I-CHED
+,	O
+tight	O
+glucose	B-CHED
+control	O
+,	O
+and	O
+high	O
+-	O
+flow	O
+nasal	B-ANAT
+cannula	B-SPEC
+(	O
+HFNC	O
+)	O
+oxygen	B-CHED
+are	O
+therapies	O
+that	O
+require	O
+further	O
+study	O
+before	O
+they	O
+can	O
+be	O
+recommended	O
+for	O
+children	O
+with	O
+ALI	O
+/	O
+ARDS	B-DISO
+.	O
+
+Overall	O
+,	O
+the	O
+lesion	O
+volume	O
+was	O
+reduced	O
+by	O
+>	O
+15	O
+%	O
+in	O
+80	O
+hips	B-ANAT
+,	O
+and	O
+only	O
+four	O
+hips	B-ANAT
+with	O
+relatively	O
+larger	O
+lesion	O
+volumes	O
+showed	O
+no	O
+apparent	O
+reductions	O
+.	O
+
+TITLE	O
+:	O
+Studies	O
+on	O
+membrane	B-COMP
+topology	O
+,	O
+N	O
+-	O
+glycosylation	B-PROC
+and	O
+functionality	O
+of	O
+SARS	B-PRGE
+-	I-PRGE
+CoV	I-PRGE
+membrane	B-COMP
+protein	B-CHED
+.	O
+
+The	O
+G	O
+/	O
+CTAAAAA	O
+/	O
+GT	O
+sequence	O
+downstream	O
+of	O
+the	O
+recombination	B-PROC
+site	O
+may	O
+represent	O
+a	O
+specific	O
+recombination	B-PROC
+signal	O
+in	O
+CCoVs	O
+.	O
+
+This	O
+study	O
+indicated	O
+that	O
+the	O
+similarity	O
+of	O
+CCoVs	O
+in	O
+virulence	B-PROC
+and	O
+tropism	B-PROC
+was	O
+mostly	O
+acquired	O
+by	O
+the	O
+homologous	O
+RNA	O
+recombination	B-PROC
+and	O
+not	O
+only	O
+by	O
+simple	O
+mutation	O
+and	O
+selection	O
+.	O
+
+TITLE	O
+:	O
+[	O
+Effect	O
+on	O
+mRNA	B-CHED
+and	O
+secretion	B-PROC
+levels	O
+of	O
+proinflammatory	O
+cytokines	O
+in	O
+DC	O
+infected	O
+by	O
+SARS	B-DISO
+-	O
+CoV	O
+N	O
+gene	O
+recombinant	O
+adenovirus	O
+].	O
+
+The	O
+present	O
+study	O
+was	O
+designed	O
+to	O
+determine	O
+whether	O
+the	O
+administration	O
+of	O
+dobutamine	B-CHED
+decreases	O
+pulmonary	B-DISO
+edema	I-DISO
+and	O
+stimulates	O
+AFC	O
+in	O
+a	O
+rat	B-SPEC
+model	O
+of	O
+lipopolysaccharide	B-CHED
+-	O
+induced	O
+lung	B-ANAT
+injury	O
+.	O
+
+Our	O
+study	O
+indicates	O
+that	O
+dobutamine	B-CHED
+may	O
+enhance	O
+alveolar	B-ANAT
+fluid	O
+reabsorption	O
+by	O
+increasing	O
+the	O
+expression	B-PROC
+of	O
+aquaporin	B-PRGE
+-	I-PRGE
+1	I-PRGE
+and	O
+aquaporin	B-PRGE
+-	I-PRGE
+5	I-PRGE
+.	O
+
+The	O
+patients	O
+studied	O
+were	O
+those	O
+who	O
+were	O
+admitted	O
+to	O
+the	O
+Goa	O
+Medical	O
+College	O
+with	O
+a	O
+diagnosis	O
+of	O
+acute	B-DISO
+pancreatitis	I-DISO
+based	O
+on	O
+a	O
+serum	B-COMP
+amylase	B-PRGE
+of	O
+greater	O
+than	O
+180	O
+Somogyii	O
+units	O
+with	O
+appropriate	O
+clinical	O
+and	O
+radiographic	O
+evidence	O
+.	O
+
+TITLE	O
+:	O
+Proteolytic	B-PROC
+activation	O
+of	O
+the	O
+spike	O
+protein	B-CHED
+at	O
+a	O
+novel	O
+RRRR	O
+/	O
+S	O
+motif	O
+is	O
+implicated	O
+in	O
+furin	B-PRGE
+-	O
+dependent	O
+entry	O
+,	O
+syncytium	O
+formation	O
+,	O
+and	O
+infectivity	O
+of	O
+coronavirus	B-SPEC
+infectious	B-DISO
+bronchitis	B-DISO
+virus	B-SPEC
+in	O
+cultured	B-ANAT
+cells	I-ANAT
+.	O
+
+In	O
+this	O
+study	O
+,	O
+we	O
+observe	O
+that	O
+the	O
+S2	O
+subunit	O
+of	O
+the	O
+IBV	B-SPEC
+Beaudette	O
+strain	O
+is	O
+additionally	O
+cleaved	B-ANAT
+at	O
+the	O
+second	O
+furin	B-PRGE
+site	I-PRGE
+(	O
+RRRR	O
+(	O
+690	O
+)/	O
+S	O
+)	O
+in	O
+cells	B-COMP
+expressing	O
+S	O
+constructs	O
+and	O
+in	O
+virus	B-SPEC
+-	O
+infected	O
+cells	B-COMP
+.	O
+
+Site	B-PROC
+-	I-PROC
+directed	I-PROC
+mutagenesis	I-PROC
+studies	O
+revealed	O
+that	O
+the	O
+S1	O
+/	O
+S2	O
+cleavage	B-PROC
+by	O
+furin	B-PRGE
+was	O
+not	O
+necessary	O
+for	O
+,	O
+but	O
+could	O
+promote	O
+,	O
+syncytium	B-PROC
+formation	I-PROC
+by	O
+and	O
+infectivity	O
+of	O
+IBV	B-SPEC
+in	O
+Vero	B-ANAT
+cells	I-ANAT
+.	O
+
+Virus	B-PROC
+replication	I-PROC
+and	O
+distribution	O
+did	O
+not	O
+correlate	O
+with	O
+the	O
+relative	O
+susceptibilities	O
+of	O
+A	O
+/	O
+J	O
+,	O
+BALB	O
+/	O
+c	O
+,	O
+C3H	O
+/	O
+HeJ	O
+,	O
+and	O
+C57BL	O
+/	O
+6	O
+mice	O
+.	O
+
+C3H	O
+/	O
+HeJ	O
+mice	B-SPEC
+harbor	O
+a	O
+natural	O
+mutation	O
+in	O
+the	O
+gene	O
+that	O
+encodes	O
+Toll	B-PRGE
+-	I-PRGE
+like	I-PRGE
+receptor	I-PRGE
+4	I-PRGE
+(	O
+TLR4	B-PRGE
+)	O
+that	O
+disrupts	O
+TLR4	B-PRGE
+signaling	B-PROC
+.	O
+
+ABSTRACT	O
+:	O
+3	O
+-	O
+Chlorobenzofuran	O
+-	O
+2	O
+-	O
+carbaldehyde	B-CHED
+was	O
+condensed	B-PROC
+with	O
+substituted	O
+acetophenone	B-CHED
+by	O
+using	O
+the	O
+Claisen	O
+-	O
+Schmidt	O
+condensation	B-DISO
+to	O
+obtain	O
+3	O
+-(	O
+3	O
+-	O
+chlorobenzofuran	O
+-	O
+2	O
+-	O
+yl	O
+)-	O
+1	O
+-(	O
+substituted	O
+phenyl	B-CHED
+)-	O
+2	O
+-	O
+propen	O
+-	O
+1	O
+-	O
+one	O
+(	O
+2a	O
+-	O
+m	O
+)	O
+which	O
+upon	O
+further	O
+treatment	O
+with	O
+hydrazine	B-CHED
+hydrate	I-CHED
+gave	O
+2	O
+-[	O
+3	O
+-(	O
+substituted	O
+phenyl	B-CHED
+)-	O
+4	O
+,	O
+5	O
+-	O
+dihydro	O
+-	O
+1H	O
+-	O
+5	O
+-	O
+pyrazolyl	O
+)	O
+benzofuran	B-CHED
+-	O
+3	O
+-	O
+yl	O
+chloride	B-CHED
+derivatives	O
+(	O
+3a	O
+-	O
+m	O
+).	O
+
+RESULTS	O
+:	O
+Wheezing	B-DISO
+children	O
+had	O
+a	O
+higher	O
+[	O
+chi	B-CHED
+(	O
+2	O
+)=	O
+5	O
+.	O
+561	O
+,	O
+p	O
+=	O
+0	O
+.	O
+018	O
+]	O
+prevalence	O
+of	O
+respiratory	O
+viruses	B-SPEC
+compared	O
+with	O
+stabilized	O
+asthmatics	B-DISO
+(	O
+34	O
+.	O
+3	O
+%	O
+(	O
+24	O
+)	O
+versus	O
+(	O
+vs	O
+.)	O
+17	O
+.	O
+5	O
+%	O
+(	O
+14	O
+)).	O
+
+CONCLUSIONS	O
+:	O
+Emergent	O
+wheezing	B-DISO
+illnesses	O
+during	O
+childhood	O
+can	O
+be	O
+linked	O
+to	O
+infection	B-DISO
+with	O
+rhinovirus	B-SPEC
+in	O
+Trinidad	O
+'	O
+s	O
+tropical	O
+environment	O
+.	O
+
+TITLE	O
+:	O
+A	O
+test	O
+of	O
+syndromic	O
+surveillance	O
+using	O
+a	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+model	O
+.	O
+
+Records	O
+from	O
+42	O
+patients	O
+(	O
+95	O
+%)	O
+were	O
+successfully	O
+transmitted	B-DISO
+to	O
+the	O
+NYC	O
+-	O
+DOHMH	O
+.	O
+
+TITLE	O
+:	O
+Long	O
+-	O
+term	O
+psychiatric	O
+morbidities	O
+among	O
+SARS	B-DISO
+survivors	O
+.	O
+
+ABSTRACT	O
+:	O
+Alcohol	B-DISO
+withdrawal	I-DISO
+syndrome	I-DISO
+(	O
+AWS	B-DISO
+)	O
+is	O
+a	O
+major	O
+cause	O
+of	O
+morbidity	O
+and	O
+mortality	O
+in	O
+the	O
+acute	O
+care	O
+setting	O
+.	O
+
+We	O
+describe	O
+a	O
+28	O
+-	O
+year	O
+-	O
+old	O
+man	B-CHED
+who	O
+was	O
+brought	O
+to	O
+the	O
+emergency	B-DISO
+department	O
+with	O
+a	O
+new	O
+-	O
+onset	O
+seizure	B-DISO
+and	O
+clinical	O
+signs	B-DISO
+and	I-DISO
+symptoms	I-DISO
+consistent	O
+with	O
+advanced	O
+delirium	B-DISO
+tremens	I-DISO
+.	O
+
+A	O
+symptom	B-DISO
+-	O
+triggered	O
+intensive	O
+care	O
+unit	O
+treatment	O
+protocol	O
+consisting	O
+of	O
+a	O
+benzodiazepine	B-CHED
+and	O
+antiadrenergic	O
+agents	O
+was	O
+started	O
+.	O
+
+ABSTRACT	O
+:	O
+The	O
+use	O
+of	O
+metered	O
+-	O
+dose	O
+inhaler	O
+(	O
+MDI	B-DISO
+)	O
+with	O
+spacer	O
+instead	O
+of	O
+nebulizer	O
+may	O
+be	O
+important	O
+during	O
+an	O
+outbreak	O
+of	O
+an	O
+airborne	O
+infection	B-DISO
+.	O
+
+However	O
+,	O
+there	O
+is	O
+a	O
+paucity	O
+of	O
+data	O
+on	O
+patients	O
+'	O
+and	O
+nurses	O
+'	O
+abilities	O
+and	O
+perspectives	O
+on	O
+MDI	B-DISO
+with	O
+spacer	O
+for	O
+the	O
+treatment	O
+of	O
+acute	O
+airway	B-DISO
+obstruction	I-DISO
+during	O
+such	O
+an	O
+outbreak	O
+.	O
+
+Fifty	O
+-	O
+eight	O
+percent	O
+of	O
+the	O
+patients	O
+thought	O
+MDI	B-DISO
+with	O
+spacer	O
+was	O
+easier	O
+to	O
+use	O
+than	O
+nebulizer	O
+,	O
+and	O
+34	O
+%	O
+thought	O
+MDI	B-DISO
+was	O
+as	O
+easy	O
+to	O
+use	O
+as	O
+nebulizer	O
+.	O
+
+Forty	O
+-	O
+two	O
+nurses	O
+(	O
+84	O
+%)	O
+thought	O
+that	O
+nebulizer	O
+was	O
+more	O
+effective	O
+for	O
+treating	O
+acute	O
+airflow	B-PROC
+obstruction	B-DISO
+in	O
+the	O
+hospital	O
+.	O
+
+ABSTRACT	O
+:	O
+A	O
+surface	O
+plasmon	O
+resonance	O
+(	O
+SPR	O
+)-	O
+based	O
+biosensor	O
+was	O
+developed	O
+for	O
+simple	O
+diagnosis	O
+of	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+(	O
+SARS	B-DISO
+)	O
+using	O
+a	O
+protein	B-CHED
+created	O
+by	O
+genetically	O
+fusing	O
+gold	B-CHED
+binding	B-FUNC
+polypeptides	B-CHED
+(	O
+GBPs	O
+)	O
+to	O
+a	O
+SARS	B-PRGE
+coronaviral	I-PRGE
+surface	I-PRGE
+antigen	B-CHED
+(	O
+SCVme	O
+).	O
+
+The	O
+study	O
+was	O
+performed	O
+on	O
+100	O
+sera	B-COMP
+collected	O
+from	O
+cats	B-SPEC
+belonging	O
+to	O
+catteries	O
+or	O
+community	O
+shelters	O
+and	O
+to	O
+households	O
+.	O
+
+Gel	O
+-	O
+based	O
+polymerase	O
+chain	O
+reaction	O
+(	O
+PCR	O
+)	O
+assays	O
+were	O
+4	O
+.	O
+6	O
+%	O
+positive	O
+for	O
+Bovine	B-SPEC
+respiratory	I-SPEC
+syncytial	I-SPEC
+virus	I-SPEC
+and	O
+10	O
+.	O
+8	O
+%	O
+positive	O
+for	O
+Bovine	B-SPEC
+coronavirus	B-SPEC
+.	O
+
+TITLE	O
+:	O
+Pneumonia	B-DISO
+and	O
+respiratory	B-DISO
+failure	I-DISO
+from	O
+swine	B-SPEC
+-	O
+origin	O
+influenza	B-PATH
+A	I-PATH
+(	O
+H1N1	O
+)	O
+in	O
+Mexico	O
+.	O
+
+RESULTS	O
+:	O
+From	O
+March	O
+24	O
+through	O
+April	O
+24	O
+,	O
+2009	O
+,	O
+a	O
+total	O
+of	O
+18	O
+cases	O
+of	O
+pneumonia	B-DISO
+and	O
+confirmed	O
+S	O
+-	O
+OIV	O
+infection	B-DISO
+were	O
+identified	O
+among	O
+98	O
+patients	O
+hospitalized	O
+for	O
+acute	O
+respiratory	O
+illness	O
+at	O
+the	O
+National	O
+Institute	O
+of	O
+Respiratory	B-DISO
+Diseases	I-DISO
+in	O
+Mexico	O
+City	O
+.	O
+
+Initial	O
+recovery	O
+was	O
+observed	O
+but	O
+70	O
+days	O
+after	O
+onset	O
+the	O
+child	O
+suffered	B-DISO
+severe	O
+relapse	B-DISO
+and	O
+died	B-PROC
+from	O
+respiratory	B-DISO
+arrest	I-DISO
+.	O
+
+Feces	B-ANAT
+samples	O
+were	O
+available	O
+for	O
+44	O
+animals	B-SPEC
+,	O
+including	O
+one	O
+L	B-SPEC
+.	I-SPEC
+geoffroyi	I-SPEC
+,	O
+eight	O
+L	B-SPEC
+.	I-SPEC
+pardalis	I-SPEC
+,	O
+14	O
+L	B-SPEC
+.	I-SPEC
+wiedii	I-SPEC
+,	O
+20	O
+L	B-SPEC
+.	I-SPEC
+tigrinus	I-SPEC
+,	O
+and	O
+one	O
+P	O
+.	O
+yagouaroundi	O
+.	O
+
+Blood	B-ANAT
+DNA	O
+samples	O
+were	O
+evaluated	O
+by	O
+polymerase	O
+chain	O
+reaction	O
+(	O
+PCR	O
+)	O
+for	O
+feline	B-SPEC
+leukemia	I-SPEC
+virus	I-SPEC
+(	O
+FeLV	O
+)	O
+proviral	O
+DNA	O
+,	O
+whereas	O
+reverse	B-PRGE
+transcriptase	I-PRGE
+-	O
+PCR	O
+was	O
+run	O
+on	O
+fecal	B-ANAT
+samples	O
+for	O
+detection	O
+of	O
+coronavirus	B-SPEC
+RNA	O
+.	O
+
+Results	O
+showed	O
+that	O
+Penn	O
+-	O
+98	O
+-	O
+1	O
+behaved	O
+like	O
+MHV	B-SPEC
+-	O
+2	O
+,	O
+thus	O
+establishing	O
+a	O
+role	O
+for	O
+the	O
+spike	O
+protein	B-CHED
+in	O
+viral	O
+growth	B-PROC
+.	O
+
+Interestingly	O
+,	O
+when	O
+the	O
+genomic	O
+RNAs	O
+were	O
+delivered	O
+directly	O
+into	O
+the	O
+cells	O
+via	O
+transfection	B-PROC
+,	O
+the	O
+levels	O
+of	O
+gene	B-PROC
+expression	I-PROC
+for	O
+these	O
+viruses	B-SPEC
+were	O
+similar	O
+.	O
+
+Avian	B-SPEC
+coronavirus	I-SPEC
+infectious	B-DISO
+bronchitis	B-DISO
+(	O
+IBV	B-SPEC
+)	O
+has	O
+been	O
+adapted	O
+to	O
+embryonated	O
+chicken	B-SPEC
+eggs	O
+,	O
+primary	O
+chicken	B-SPEC
+kidney	B-ANAT
+(	O
+CK	O
+)	O
+cells	B-COMP
+,	O
+monkey	B-SPEC
+kidney	B-ANAT
+cell	I-ANAT
+line	O
+Vero	O
+,	O
+and	O
+other	O
+human	B-SPEC
+and	O
+animal	B-SPEC
+cells	B-COMP
+.	O
+
+ABSTRACT	O
+:	O
+Attenuated	O
+Salmonella	B-DISO
+typhimurium	O
+was	O
+selected	O
+as	O
+a	O
+transgenic	O
+vehicle	O
+for	O
+the	O
+development	B-PROC
+of	O
+live	O
+mucosal	B-ANAT
+vaccines	O
+against	O
+transmissible	O
+gastroenteritis	B-DISO
+virus	B-SPEC
+(	O
+TGEV	B-SPEC
+).	O
+
+A	O
+2	O
+.	O
+2kb	O
+DNA	O
+fragment	O
+,	O
+encoding	O
+for	O
+N	O
+-	O
+terminal	O
+domain	O
+glycoprotein	B-CHED
+S	O
+of	O
+TGEV	B-SPEC
+,	O
+was	O
+amplified	O
+by	O
+RT	O
+-	O
+PCR	O
+and	O
+cloned	O
+into	O
+eukaryotic	O
+expression	B-PROC
+vector	O
+pVAX1	O
+.	O
+
+Cellular	B-COMP
+and	O
+humoral	B-PROC
+immune	I-PROC
+responses	I-PROC
+were	O
+assessed	O
+by	O
+indirect	O
+ELISA	O
+,	O
+lymphocyte	B-PROC
+proliferation	B-DISO
+assays	O
+,	O
+ELISPOT	O
+and	O
+FACS	O
+.	O
+
+This	O
+process	O
+requires	O
+the	O
+specific	O
+recognition	O
+of	O
+RNA	O
+cis	B-DISO
+-	O
+acting	O
+signals	O
+located	O
+at	O
+the	O
+ends	O
+of	O
+the	O
+viral	B-COMP
+genome	I-COMP
+.	O
+
+Nine	O
+of	O
+them	O
+,	O
+including	O
+members	O
+of	O
+the	O
+heterogeneous	B-PRGE
+ribonucleoprotein	I-PRGE
+family	B-SPEC
+of	I-PRGE
+proteins	B-CHED
+(	O
+hnRNPs	O
+),	O
+the	O
+poly	B-PRGE
+(	I-PRGE
+A	I-PRGE
+)-	I-PRGE
+binding	I-PRGE
+protein	B-CHED
+(	O
+PABP	B-PRGE
+),	O
+the	O
+p100	B-PRGE
+transcriptional	B-PROC
+co	B-PRGE
+-	I-PRGE
+activator	I-PRGE
+protein	I-PRGE
+and	O
+two	O
+aminoacyl	B-CHED
+-	I-CHED
+tRNA	I-CHED
+synthetases	O
+,	O
+showed	O
+a	O
+preferential	O
+binding	B-FUNC
+to	O
+the	O
+3	O
+'	O
+end	O
+of	O
+the	O
+genome	O
+,	O
+whereas	O
+only	O
+the	O
+polypyrimidine	O
+tract	O
+-	O
+binding	O
+protein	B-CHED
+(	O
+PTB	B-PRGE
+)	O
+was	O
+preferentially	O
+pulled	O
+down	O
+with	O
+the	O
+5	O
+'	O
+end	O
+of	O
+the	O
+genome	O
+.	O
+
+The	O
+potential	O
+function	O
+of	O
+the	O
+3	O
+'	O
+end	O
+-	O
+interacting	O
+proteins	B-CHED
+in	O
+virus	B-PROC
+replication	I-PROC
+was	O
+studied	O
+by	O
+analyzing	O
+the	O
+effect	O
+of	O
+their	O
+silencing	O
+using	O
+a	O
+TGEV	B-SPEC
+-	O
+derived	O
+replicon	O
+and	O
+the	O
+infectious	B-DISO
+virus	B-SPEC
+.	O
+
+These	O
+data	O
+suggest	O
+that	O
+PABP	B-PRGE
+,	O
+hnRNP	B-PRGE
+Q	I-PRGE
+,	O
+and	O
+EPRS	O
+play	O
+a	O
+positive	O
+role	O
+in	O
+virus	B-DISO
+infection	I-DISO
+that	O
+could	O
+be	O
+mediated	O
+through	O
+their	O
+interaction	O
+with	O
+the	O
+viral	O
+3	O
+'	O
+end	O
+,	O
+and	O
+that	O
+GAPDH	B-PRGE
+has	O
+a	O
+negative	O
+effect	O
+on	O
+viral	B-DISO
+infection	I-DISO
+.	O
+
+Moreover	O
+,	O
+a	O
+new	O
+IBV	B-SPEC
+strain	O
+was	O
+isolated	O
+and	O
+identified	O
+in	O
+a	O
+layer	B-ANAT
+hen	O
+.	O
+
+TITLE	O
+:	O
+Single	O
+-	O
+dose	O
+etomidate	B-CHED
+for	O
+rapid	O
+sequence	O
+intubation	O
+may	O
+impact	O
+outcome	O
+after	O
+severe	O
+injury	O
+.	O
+
+ABSTRACT	O
+:	O
+Etomidate	O
+is	O
+an	O
+induction	O
+agent	O
+used	O
+for	O
+the	O
+rapid	O
+sequence	O
+intubation	O
+(	O
+RSI	B-DISO
+)	O
+of	O
+trauma	O
+patients	O
+because	O
+of	O
+its	O
+favorable	O
+hemodynamic	B-PROC
+profile	O
+and	O
+rapid	O
+onset	O
+.	O
+
+However	O
+,	O
+recent	O
+studies	O
+have	O
+shown	O
+etomidate	B-CHED
+to	O
+decrease	O
+circulating	O
+cortisol	B-CHED
+concentrations	O
+,	O
+potentially	O
+influencing	O
+inflammation	B-DISO
+.	O
+
+RESULTS	O
+:	O
+Over	O
+a	O
+2	O
+-	O
+year	O
+period	O
+,	O
+94	O
+study	O
+patients	O
+underwent	O
+RSI	B-DISO
+,	O
+of	O
+which	O
+35	O
+received	O
+etomidate	B-CHED
+(	O
+37	O
+%).	O
+
+TITLE	O
+:	O
+Impact	O
+of	O
+obesity	B-DISO
+in	O
+damage	O
+control	O
+laparotomy	O
+patients	O
+.	O
+
+The	O
+novel	O
+modeling	O
+approach	O
+proposed	O
+,	O
+which	O
+does	O
+not	O
+require	O
+sizable	O
+case	O
+and	O
+control	O
+gene	O
+datasets	O
+,	O
+could	O
+have	O
+important	O
+future	O
+public	O
+health	O
+implications	O
+in	O
+swiftly	O
+identifying	O
+potential	O
+high	O
+-	O
+risk	O
+groups	O
+associated	O
+with	O
+being	O
+highly	O
+susceptible	O
+to	O
+a	O
+particular	O
+infectious	B-DISO
+disease	I-DISO
+.	O
+
+ABSTRACT	O
+:	O
+A	O
+clinical	O
+picture	O
+of	O
+patients	O
+with	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+(	O
+ARDS	B-DISO
+)	O
+induced	O
+by	O
+highly	O
+pathogenic	O
+avian	B-DISO
+influenza	B-PATH
+A	I-PATH
+(	O
+H5N1	B-DISO
+)	O
+has	O
+been	O
+reported	O
+.	O
+
+We	O
+reviewed	O
+37	O
+sets	O
+of	O
+clinical	O
+data	O
+for	O
+pediatric	O
+patients	O
+with	O
+ARDS	B-DISO
+at	O
+the	O
+National	O
+Hospital	O
+of	O
+Pediatrics	O
+(	O
+Hanoi	O
+,	O
+Vietnam	O
+);	O
+12	O
+patients	O
+with	O
+H5N1	B-DISO
+-	O
+positive	O
+and	O
+25	O
+with	O
+H5N1	B-DISO
+-	O
+negative	O
+ARDS	B-DISO
+were	O
+enrolled	O
+.	O
+
+However	O
+,	O
+the	O
+H5N1	B-DISO
+-	O
+positive	O
+patients	O
+had	O
+ARDS	B-DISO
+with	O
+normal	O
+ventilation	O
+capacity	O
+at	O
+the	O
+time	O
+of	O
+hospital	O
+admission	O
+,	O
+then	O
+rapidly	O
+proceeded	O
+to	O
+severe	O
+respiratory	B-DISO
+failure	I-DISO
+.	O
+
+TITLE	O
+:	O
+Systemic	O
+and	O
+bronchoalveolar	O
+cytokines	O
+as	O
+predictors	O
+of	O
+in	O
+-	O
+hospital	O
+mortality	O
+in	O
+severe	O
+community	O
+-	O
+acquired	O
+pneumonia	B-DISO
+.	O
+
+This	O
+was	O
+a	O
+prospective	O
+study	O
+with	O
+bronchoalveolar	O
+lavage	O
+(	O
+BAL	B-ENZY
+)	O
+and	O
+blood	B-ANAT
+sampling	O
+.	O
+
+This	O
+study	O
+was	O
+carried	O
+out	O
+in	O
+a	O
+44	O
+-	O
+bed	B-DISO
+medical	O
+ICU	O
+of	O
+a	O
+1700	O
+-	O
+bed	B-DISO
+university	O
+hospital	O
+.	O
+
+We	O
+performed	O
+a	O
+retrospective	O
+cohort	O
+study	O
+on	O
+46	O
+,	O
+858	O
+patients	O
+who	O
+sustained	O
+blunt	O
+liver	B-ANAT
+or	O
+spleen	B-ANAT
+injury	O
+utilizing	O
+the	O
+2002	O
+National	O
+Trauma	O
+Data	O
+Bank	O
+(	O
+NTDB	O
+).	O
+
+We	O
+have	O
+determined	O
+the	O
+crystal	B-ANAT
+structures	O
+of	O
+the	O
+C	O
+-	O
+terminal	O
+hydrophilic	O
+domain	O
+of	O
+nsp4	B-PRGE
+(	O
+nsp4C	O
+)	O
+from	O
+MHV	B-SPEC
+strain	O
+A59	O
+and	O
+a	O
+C425S	O
+site	O
+-	O
+directed	O
+mutant	B-DISO
+.	O
+
+This	O
+structure	O
+may	O
+serve	O
+as	O
+a	O
+basis	O
+for	O
+further	O
+functional	O
+studies	O
+of	O
+nsp4	B-PRGE
+.	O
+
+ABSTRACT	O
+:	O
+To	O
+discuss	O
+the	O
+potential	O
+mechanisms	O
+and	O
+the	O
+role	O
+of	O
+adrenalitis	B-DISO
+with	O
+extensive	O
+hemorrhage	B-DISO
+and	O
+necrosis	B-PROC
+in	O
+acute	O
+critical	O
+infectious	B-DISO
+diseases	I-DISO
+.	O
+
+Our	O
+aim	O
+was	O
+to	O
+assess	O
+the	O
+clinical	O
+and	O
+nutritional	O
+efficacy	O
+of	O
+a	O
+probiotic	O
+and	O
+prebiotic	O
+functional	O
+food	O
+for	O
+the	O
+treatment	O
+of	O
+severe	O
+acute	O
+malnutrition	B-DISO
+in	O
+a	O
+HIV	B-DISO
+-	O
+prevalent	O
+setting	O
+.	O
+
+In	O
+Malawi	O
+,	O
+Synbiotic2000	O
+Forte	O
+did	O
+not	O
+improve	O
+severe	O
+acute	O
+malnutrition	B-DISO
+outcomes	O
+.	O
+
+North	O
+and	O
+South	O
+America	O
+,	O
+Europe	O
+and	O
+Australia	O
+also	O
+have	O
+infections	B-DISO
+which	O
+are	O
+geographically	O
+concentrated	O
+.	O
+
+ABSTRACT	O
+:	O
+SARS	B-DISO
+-	O
+like	O
+coronavirus	B-SPEC
+(	O
+SL	O
+-	O
+CoV	O
+)	O
+in	O
+bats	B-SPEC
+have	O
+a	O
+similar	O
+genomic	O
+organization	O
+to	O
+the	O
+human	B-PRGE
+SARS	B-DISO
+-	I-PRGE
+CoV	I-PRGE
+.	O
+Their	O
+cognate	O
+gene	O
+products	O
+are	O
+highly	O
+conserved	O
+with	O
+the	O
+exception	O
+of	O
+the	O
+N	O
+-	O
+terminal	O
+region	O
+of	O
+the	O
+S	O
+proteins	B-CHED
+,	O
+which	O
+have	O
+only	O
+63	O
+-	O
+64	O
+%	O
+sequence	O
+identity	O
+.	O
+
+This	O
+work	O
+provides	O
+useful	O
+information	O
+for	O
+future	O
+development	B-PROC
+of	O
+differential	O
+serologic	O
+diagnosis	O
+and	O
+vaccines	O
+for	O
+coronaviruses	O
+with	O
+different	O
+S	O
+protein	B-CHED
+sequences	O
+.	O
+
+TITLE	O
+:	O
+[	O
+A	O
+case	O
+of	O
+Legionella	B-DISO
+pneumonia	I-DISO
+with	O
+diabetic	B-DISO
+ketoacidosis	I-DISO
+rescued	O
+despite	O
+the	O
+development	B-PROC
+of	O
+acute	O
+renal	O
+failure	O
+and	O
+ARDS	B-DISO
+].	O
+
+ABSTRACT	O
+:	O
+A	O
+57	O
+-	O
+year	O
+-	O
+old	O
+man	B-CHED
+was	O
+admitted	O
+to	O
+our	O
+hospital	O
+complaining	O
+of	O
+general	O
+fatigue	B-DISO
+and	O
+appetite	B-DISO
+loss	I-DISO
+.	O
+
+In	O
+addition	O
+,	O
+he	O
+developed	O
+adult	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+on	O
+the	O
+6th	O
+hospital	O
+day	O
+,	O
+therefore	O
+siveletat	O
+sodium	O
+was	O
+given	O
+.	O
+
+ABSTRACT	O
+:	O
+In	O
+April	O
+2009	O
+,	O
+CDC	O
+reported	O
+the	O
+first	O
+two	O
+cases	O
+in	O
+the	O
+United	O
+States	O
+of	O
+human	O
+infection	B-DISO
+with	O
+a	O
+novel	O
+influenza	B-PATH
+A	I-PATH
+(	O
+H1N1	O
+)	O
+virus	B-SPEC
+.	O
+
+We	O
+hypothesized	O
+that	O
+biomimetic	O
+polymers	B-CHED
+could	O
+be	O
+used	O
+to	O
+enhance	O
+passive	O
+barrier	O
+function	O
+by	O
+reducing	O
+the	O
+porosity	O
+of	O
+the	O
+endothelial	B-ANAT
+glycocalyx	B-COMP
+and	O
+attenuate	O
+mechanotransduction	O
+by	O
+restricting	O
+the	O
+motion	O
+of	O
+the	O
+glycoproteins	B-CHED
+implicated	O
+in	O
+signal	B-PROC
+transduction	I-PROC
+.	O
+
+Understanding	O
+how	O
+nurses	O
+perceive	O
+disaster	O
+and	O
+the	O
+likelihood	O
+of	O
+disastrous	O
+events	O
+is	O
+the	O
+initial	O
+step	O
+for	O
+disaster	O
+planning	O
+and	O
+the	O
+development	B-PROC
+of	O
+a	O
+disaster	O
+nursing	B-PROC
+curriculum	O
+in	O
+Hong	O
+Kong	O
+.	O
+
+The	O
+large	O
+coronavirus	B-SPEC
+genome	O
+(	O
+26	O
+-	O
+31	O
+kb	O
+)	O
+encodes	O
+15	O
+-	O
+16	O
+nonstructural	O
+proteins	B-CHED
+(	O
+nsps	O
+)	O
+that	O
+are	O
+derived	O
+from	O
+two	O
+replicase	B-PRGE
+polyproteins	I-PRGE
+by	O
+autoproteolytic	O
+processing	O
+.	O
+
+Two	O
+gerbils	B-SPEC
+from	O
+both	O
+groups	O
+were	O
+necropsied	O
+weekly	O
+,	O
+pathological	O
+changes	O
+were	O
+recorded	O
+and	O
+tissue	B-ANAT
+samples	O
+collected	O
+for	O
+further	O
+investigation	O
+.	O
+
+Research	O
+results	O
+demonstrated	O
+that	O
+Mongolian	B-SPEC
+gerbils	I-SPEC
+in	O
+Group	O
+1	O
+were	O
+successfully	O
+infected	O
+with	O
+HEV	B-ANAT
+.	O
+
+Sequence	O
+analysis	O
+showed	O
+some	O
+viruses	B-SPEC
+to	O
+be	O
+related	O
+to	O
+IBV	B-SPEC
+.	O
+
+TITLE	O
+:	O
+Chinese	O
+-	O
+like	O
+strain	O
+of	O
+porcine	B-SPEC
+epidemic	I-SPEC
+diarrhea	I-SPEC
+virus	I-SPEC
+,	O
+Thailand	O
+.	O
+
+TITLE	O
+:	O
+Angiotensin	B-CHED
+-	I-PRGE
+converting	I-PRGE
+enzyme	I-PRGE
+2	I-PRGE
+(	O
+ACE2	B-PRGE
+)	O
+from	O
+raccoon	B-SPEC
+dog	I-SPEC
+can	O
+serve	O
+as	O
+an	O
+efficient	O
+receptor	O
+for	O
+the	O
+spike	O
+protein	O
+of	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+coronavirus	B-SPEC
+.	O
+
+Human	B-DISO
+immunodeficiency	I-DISO
+virus	I-DISO
+-	O
+backboned	O
+pseudoviruses	O
+expressing	O
+spike	O
+proteins	B-CHED
+derived	O
+from	O
+human	B-PRGE
+SARS	B-DISO
+-	I-PRGE
+CoV	I-PRGE
+or	O
+SARS	B-PRGE
+-	I-PRGE
+CoV	I-PRGE
+-	I-PRGE
+like	I-PRGE
+viruses	B-SPEC
+of	O
+masked	B-SPEC
+palm	I-SPEC
+civets	I-SPEC
+and	O
+raccoon	B-SPEC
+dogs	I-SPEC
+were	O
+tested	O
+for	O
+their	O
+entry	O
+efficiency	O
+into	O
+these	O
+cell	B-ANAT
+lines	I-ANAT
+.	O
+
+The	O
+results	O
+showed	O
+that	O
+rdACE2	O
+is	O
+a	O
+more	O
+efficient	O
+receptor	O
+for	O
+human	B-PRGE
+SARS	B-DISO
+-	I-PRGE
+CoV	I-PRGE
+,	O
+but	O
+not	O
+for	O
+SARS	B-DISO
+-	O
+CoV	O
+-	O
+like	O
+viruses	B-SPEC
+of	O
+masked	B-SPEC
+palm	I-SPEC
+civets	I-SPEC
+and	O
+raccoon	B-SPEC
+dogs	I-SPEC
+,	O
+than	O
+huACE2	O
+or	O
+pcACE2	O
+.	O
+
+This	O
+study	O
+provides	O
+useful	O
+data	O
+to	O
+elucidate	O
+the	O
+role	O
+of	O
+raccoon	B-SPEC
+dog	I-SPEC
+in	O
+SARS	B-DISO
+outbreaks	O
+.	O
+
+ABSTRACT	O
+:	O
+Between	O
+2002	O
+and	O
+2007	O
+,	O
+more	O
+than	O
+1000	O
+chickens	O
+from	O
+commercial	O
+farms	O
+,	O
+live	O
+bird	B-SPEC
+markets	O
+and	O
+backyard	O
+farms	O
+in	O
+Nigeria	O
+and	O
+Niger	B-SPEC
+were	O
+tested	O
+for	O
+the	O
+presence	O
+of	O
+the	O
+infectious	B-DISO
+bronchitis	B-DISO
+virus	B-SPEC
+(	O
+IBV	B-SPEC
+)	O
+genome	O
+.	O
+
+TITLE	O
+:	O
+CXCL10	B-PRGE
+and	O
+trafficking	B-PROC
+of	O
+virus	B-SPEC
+-	O
+specific	O
+T	B-ANAT
+cells	I-ANAT
+during	O
+coronavirus	B-SPEC
+-	O
+induced	O
+demyelination	B-DISO
+.	O
+
+HCoVs	O
+are	O
+associated	O
+with	O
+a	O
+small	O
+,	O
+but	O
+significant	O
+number	O
+(	O
+at	O
+least	O
+2	O
+.	O
+4	O
+%	O
+of	O
+total	O
+samples	O
+submitted	O
+),	O
+of	O
+both	O
+upper	O
+and	O
+lower	B-ANAT
+respiratory	I-ANAT
+tract	I-ANAT
+illnesses	O
+in	O
+children	O
+in	O
+Colorado	O
+.	O
+
+Our	O
+data	O
+raise	O
+the	O
+possibility	O
+that	O
+HCoV	O
+may	O
+play	O
+a	O
+role	O
+in	O
+gastrointestinal	O
+and	O
+CNS	B-DISO
+disease	I-DISO
+.	O
+
+The	O
+induced	O
+antibodies	B-COMP
+demonstrated	O
+neutralizing	O
+effects	O
+on	O
+TGEV	B-SPEC
+infection	B-DISO
+.	O
+
+These	O
+data	O
+indicated	O
+that	O
+the	O
+recombinant	O
+L	O
+.	O
+lactis	O
+could	O
+be	O
+a	O
+valuable	O
+tool	O
+in	O
+the	O
+development	B-PROC
+of	O
+future	O
+vaccines	O
+against	O
+TGEV	B-SPEC
+.	O
+
+This	O
+allowed	O
+us	O
+to	O
+detect	O
+vaccine	O
+virus	B-SPEC
+in	O
+as	O
+few	O
+as	O
+3	O
+%	O
+of	O
+the	O
+birds	B-SPEC
+in	O
+a	O
+flock	O
+of	O
+20	O
+,	O
+000	O
+birds	B-SPEC
+with	O
+a	O
+95	O
+%	O
+confidence	O
+level	O
+.	O
+
+Our	O
+findings	O
+show	O
+that	O
+introduction	O
+of	O
+IBV	B-SPEC
+vaccines	O
+into	O
+a	O
+commercial	O
+broiler	O
+flock	O
+do	O
+not	O
+necessarily	O
+follow	O
+a	O
+seemingly	O
+logical	O
+pattern	O
+of	O
+a	O
+high	O
+number	O
+of	O
+birds	B-SPEC
+infected	O
+followed	O
+by	O
+clearance	O
+from	O
+the	O
+trachea	B-DISO
+,	O
+but	O
+resembled	O
+either	O
+a	O
+parabolic	O
+curve	O
+or	O
+a	O
+sinusoidal	O
+-	O
+type	O
+wave	O
+.	O
+
+It	O
+was	O
+also	O
+confirmed	O
+previously	O
+that	O
+porcine	B-PRGE
+aminopeptidase	B-ENZY
+N	I-ENZY
+(	O
+pAPN	O
+)	O
+could	O
+bind	B-FUNC
+to	O
+PEDV	B-SPEC
+,	O
+and	O
+anti	O
+-	O
+pAPN	O
+antibodies	B-COMP
+could	O
+inhibit	O
+the	O
+combination	O
+.	O
+
+ABSTRACT	O
+:	O
+Acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+(	O
+ARDS	B-DISO
+)	O
+is	O
+a	O
+severe	O
+form	O
+of	O
+acute	O
+lung	B-ANAT
+injury	O
+.	O
+
+Other	O
+genes	O
+unassociated	O
+to	O
+date	O
+with	O
+ARDS	B-DISO
+/	O
+SARS	B-DISO
+include	O
+C1Qb	B-PRGE
+,	O
+C5R1	B-PRGE
+,	O
+CASP3	B-PRGE
+,	O
+CASP9	B-PRGE
+,	O
+CD14	B-PRGE
+,	O
+CD68	B-PRGE
+,	O
+FGF7	B-PRGE
+,	O
+HLA	B-PRGE
+-	I-PRGE
+DRA	I-PRGE
+,	O
+IGF1	B-PRGE
+,	O
+IRF3	B-PRGE
+,	O
+MALAT	O
+-	O
+1	O
+,	O
+MSR1	B-PRGE
+,	O
+NFIL3	B-PRGE
+,	O
+SLPI	B-PRGE
+,	O
+USP33	B-PRGE
+,	O
+CLC	B-PRGE
+,	O
+GBP1	B-PRGE
+and	O
+TAC1	B-PRGE
+.	O
+
+Pus	B-CHED
+was	O
+detected	O
+in	O
+the	O
+peritoneal	B-ANAT
+cavity	I-ANAT
+by	O
+abdominal	B-ANAT
+paracentesis	O
+in	O
+a	O
+27	O
+-	O
+year	O
+-	O
+old	O
+woman	O
+who	O
+had	O
+no	O
+predisposing	O
+features	O
+for	O
+severe	O
+peritonitis	B-DISO
+.	O
+
+TITLE	O
+:	O
+[	O
+Severe	O
+complications	O
+and	O
+their	O
+outcomes	O
+in	O
+65	O
+patients	O
+with	O
+Legionella	B-DISO
+pneumonia	I-DISO
+].	O
+
+Six	O
+deaths	B-PROC
+occurred	O
+(	O
+mortality	O
+rate	O
+9	O
+.	O
+2	O
+%),	O
+4	O
+of	O
+which	O
+were	O
+due	O
+to	O
+septic	B-DISO
+shock	I-DISO
+/	O
+multiple	B-DISO
+organ	I-DISO
+dysfunction	I-DISO
+syndrome	I-DISO
+(	O
+MODS	B-DISO
+)	O
+(	O
+2	O
+patients	O
+)	O
+or	O
+interstitial	B-DISO
+pneumonia	I-DISO
+/	O
+pulmonary	B-DISO
+fibrosis	I-DISO
+after	O
+Legionella	B-DISO
+pneumonia	I-DISO
+(	O
+2	O
+patients	O
+),	O
+whereas	O
+the	O
+other	O
+2	O
+deaths	B-PROC
+were	O
+due	O
+to	O
+causes	O
+unrelated	O
+to	O
+Legionella	B-DISO
+pneumonia	I-DISO
+.	O
+
+To	O
+the	O
+best	O
+of	O
+our	O
+knowledge	O
+,	O
+RS3PE	B-DISO
+syndrome	I-DISO
+complicated	O
+by	O
+pulmonary	B-ANAT
+lesions	O
+and	O
+accompanied	O
+by	O
+severe	O
+acute	B-DISO
+respiratory	I-DISO
+failure	I-DISO
+requiring	O
+noninvasive	O
+positive	O
+-	O
+pressure	O
+ventilation	O
+has	O
+not	O
+previously	O
+been	O
+reported	O
+,	O
+and	O
+this	O
+rare	O
+case	O
+is	O
+discussed	O
+with	O
+reference	O
+to	O
+the	O
+literature	O
+.	O
+
+Eleven	O
+different	O
+viruses	B-SPEC
+were	O
+identified	O
+in	O
+91	O
+nasopharyngeal	B-ANAT
+swabs	O
+of	O
+children	O
+with	O
+acute	B-DISO
+respiratory	I-DISO
+infection	I-DISO
+,	O
+influenza	B-PATH
+A	I-PATH
+(	O
+IAV	O
+)	O
+and	O
+B	O
+,	O
+respiratory	B-SPEC
+syncytial	I-SPEC
+virus	I-SPEC
+(	O
+RSV	B-SPEC
+),	O
+human	B-SPEC
+rhinovirus	I-SPEC
+(	O
+hRhV	O
+),	O
+human	B-SPEC
+echovirus	B-SPEC
+,	O
+parainfluenza	B-DISO
+viruses	B-SPEC
+(	O
+PIV	O
+)	O
+1	O
+,	O
+2	O
+,	O
+3	O
+and	O
+4	O
+,	O
+human	B-SPEC
+metapneumovirus	I-SPEC
+(	O
+hMPV	B-SPEC
+),	O
+and	O
+human	B-SPEC
+coronavirus	I-SPEC
+NL63	I-SPEC
+.	O
+
+ABSTRACT	O
+:	O
+Viruses	O
+that	O
+infect	O
+the	O
+lung	B-ANAT
+are	O
+a	O
+significant	O
+cause	O
+of	O
+morbidity	O
+and	O
+mortality	O
+in	O
+animals	B-SPEC
+and	O
+humans	B-SPEC
+worldwide	O
+.	O
+
+Alveolar	B-ANAT
+epithelial	B-ANAT
+cells	I-ANAT
+are	O
+an	O
+important	O
+target	O
+for	O
+coronavirus	B-DISO
+infection	I-DISO
+in	O
+the	O
+lung	B-ANAT
+,	O
+and	O
+infected	O
+cells	B-COMP
+can	O
+initiate	O
+innate	B-DISO
+immune	I-DISO
+responses	I-DISO
+to	O
+viral	B-DISO
+infection	I-DISO
+.	O
+
+We	O
+have	O
+shown	O
+that	O
+rat	B-SPEC
+coronavirus	B-DISO
+infection	I-DISO
+of	O
+rat	B-SPEC
+alveolar	B-ANAT
+type	O
+I	O
+epithelial	B-ANAT
+cells	I-ANAT
+in	O
+vitro	O
+induces	O
+expression	B-PROC
+of	O
+CXC	O
+chemokines	O
+,	O
+which	O
+may	O
+recruit	O
+and	O
+activate	O
+neutrophils	B-ANAT
+.	O
+
+Although	O
+several	O
+nsp	O
+'	O
+s	O
+exhibit	O
+catalytic	O
+activities	O
+that	O
+are	O
+important	O
+for	O
+viral	B-PROC
+replication	I-PROC
+and	O
+transcription	B-PROC
+,	O
+other	O
+nsp	O
+'	O
+s	O
+have	O
+less	O
+clearly	O
+defined	O
+roles	O
+during	O
+an	O
+infection	B-DISO
+.	O
+
+In	O
+order	B-SPEC
+to	O
+gain	O
+a	O
+better	O
+understanding	O
+of	O
+their	O
+functions	O
+,	O
+we	O
+attempted	O
+to	O
+identify	O
+host	B-COMP
+proteins	B-CHED
+that	O
+interact	O
+with	O
+nsp	O
+'	O
+s	O
+during	O
+SARS	B-DISO
+-	O
+CoV	O
+infections	B-DISO
+.	O
+
+In	O
+chronic	B-DISO
+respiratory	I-DISO
+disease	I-DISO
+(	O
+CRD	B-DISO
+)	O
+PH	O
+is	O
+""""	O
+pre	O
+-	O
+capillary	B-ANAT
+","""	O
+due	O
+to	O
+an	O
+increase	O
+of	O
+pulmonary	B-PROC
+vascular	B-ANAT
+resistance	I-PROC
+(	O
+PVR	B-DISO
+).	O
+
+The	O
+first	O
+cause	O
+of	O
+increased	O
+PVR	B-DISO
+is	O
+chronic	O
+long	O
+-	O
+standing	B-PROC
+alveolar	B-ANAT
+hypoxia	B-DISO
+which	O
+induces	O
+pulmonary	B-ANAT
+vascular	B-ANAT
+remodeling	O
+.	O
+
+These	O
+acute	O
+increases	O
+in	O
+afterload	O
+can	O
+favor	O
+the	O
+development	B-PROC
+of	O
+RHF	O
+.	O
+
+ABSTRACT	O
+:	O
+Although	O
+low	O
+-	O
+tidal	O
+ventilation	O
+may	O
+reduce	O
+mortality	O
+in	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+(	O
+ARDS	B-DISO
+),	O
+it	O
+can	O
+also	O
+result	O
+in	O
+severe	O
+respiratory	B-DISO
+acidosis	I-DISO
+and	O
+lung	B-ANAT
+derecruitment	O
+.	O
+
+This	O
+study	O
+tested	O
+the	O
+hypothesis	O
+that	O
+combining	O
+""""	O
+open	O
+-	O
+lung	B-ANAT
+""""	O
+ventilation	O
+and	O
+arteriovenous	O
+extracorporeal	O
+lung	B-ANAT
+assist	O
+(	O
+av	O
+-	O
+ECLA	O
+)	O
+allows	O
+for	O
+maximal	O
+tidal	O
+volume	O
+(	O
+VT	O
+)	O
+reduction	O
+without	O
+the	O
+development	B-PROC
+of	O
+decompensated	O
+respiratory	B-DISO
+acidosis	I-DISO
+and	O
+impairment	B-DISO
+of	O
+oxygenation	B-PROC
+.	O
+
+After	O
+lung	B-ANAT
+recruitment	B-DISO
+,	O
+oxygenation	B-PROC
+remained	O
+significantly	O
+improved	O
+although	O
+VTs	O
+were	O
+minimized	O
+to	O
+0	O
+ml	O
+/	O
+kg	O
+(	O
+p	O
+<	O
+0	O
+.	O
+05	O
+).	O
+
+PaO2	O
+was	O
+significantly	O
+improved	O
+during	O
+PCV	B-CHED
+and	O
+av	O
+-	O
+ECLA	O
+compared	O
+with	O
+PCV	B-CHED
+alone	O
+at	O
+VTs	O
+<	O
+4	O
+ml	O
+/	O
+kg	O
+(	O
+p	O
+<	O
+0	O
+.	O
+05	O
+).	O
+
+With	O
+VT	O
+<	O
+6	O
+ml	O
+/	O
+kg	O
+,	O
+severe	O
+acidosis	B-DISO
+could	O
+only	O
+be	O
+avoided	O
+if	O
+PCV	B-CHED
+was	O
+combined	O
+with	O
+av	O
+-	O
+ECLA	O
+.	O
+
+We	O
+have	O
+carried	O
+out	O
+computational	O
+docking	B-PROC
+studies	O
+and	O
+generated	O
+a	O
+predictive	O
+3D	O
+-	O
+QSAR	O
+model	O
+for	O
+SARS	B-PRGE
+-	I-PRGE
+CoV	I-PRGE
+PLpro	I-PRGE
+inhibitors	B-CHED
+.	O
+
+ABSTRACT	O
+:	O
+In	O
+order	O
+to	O
+determine	O
+the	O
+prevalence	O
+of	O
+canine	O
+enteric	B-SPEC
+coronavirus	I-SPEC
+(	O
+CECoV	O
+)	O
+in	O
+the	O
+general	O
+dog	B-SPEC
+population	O
+,	O
+faecal	B-ANAT
+samples	O
+were	O
+obtained	O
+in	O
+a	O
+cross	O
+-	O
+sectional	O
+study	O
+of	O
+249	O
+dogs	B-SPEC
+presenting	O
+for	O
+any	O
+reason	O
+at	O
+veterinary	O
+practices	O
+randomly	O
+selected	O
+from	O
+across	O
+the	O
+UK	O
+.	O
+
+TITLE	O
+:	O
+Two	O
+forms	O
+of	O
+diffuse	B-DISO
+alveolar	I-DISO
+damage	I-DISO
+in	O
+the	O
+lungs	B-ANAT
+of	O
+patients	O
+with	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+.	O
+
+Immunohistochemical	O
+staining	O
+for	O
+types	B-PRGE
+I	I-PRGE
+and	I-PRGE
+IV	I-PRGE
+collagen	I-PRGE
+,	O
+alpha	B-PRGE
+-	I-PRGE
+smooth	I-PRGE
+muscle	I-PRGE
+actin	I-PRGE
+,	O
+and	O
+Ki	B-PRGE
+-	I-PRGE
+67	I-PRGE
+was	O
+carried	O
+out	O
+,	O
+and	O
+the	O
+sites	O
+of	O
+myofibroblast	B-ANAT
+proliferation	B-DISO
+and	O
+type	B-PRGE
+I	I-PRGE
+collagen	I-PRGE
+production	O
+were	O
+examined	O
+.	O
+
+All	O
+diffuse	B-DISO
+alveolar	I-DISO
+damage	I-DISO
+cases	O
+in	O
+the	O
+proliferative	O
+phase	O
+showed	O
+intra	O
+-	O
+alveolar	B-ANAT
+myofibroblast	B-ANAT
+proliferation	B-DISO
+.	O
+
+Increased	O
+awareness	O
+of	O
+NTPE	O
+as	O
+an	O
+underestimated	O
+cause	O
+of	O
+acute	O
+and	O
+chronic	O
+embolism	B-DISO
+,	O
+which	O
+may	O
+result	O
+in	O
+acute	O
+and	O
+chronic	O
+pulmonary	B-DISO
+hypertension	I-DISO
+,	O
+is	O
+needed	O
+.	O
+
+Three	O
+different	O
+mouse	B-SPEC
+strains	O
+,	O
+differing	O
+in	O
+their	O
+susceptibility	O
+to	O
+infection	B-DISO
+with	O
+MHV	B-SPEC
+,	O
+were	O
+used	O
+.	O
+
+129SvEv	O
+mice	B-SPEC
+lacking	O
+the	O
+type	B-PRGE
+I	I-PRGE
+interferon	I-PRGE
+receptor	I-PRGE
+(	O
+IFNAR	B-PRGE
+-/-),	O
+however	O
+,	O
+were	O
+not	O
+able	O
+to	O
+control	O
+the	O
+infection	B-DISO
+.	O
+
+Overall	O
+,	O
+this	O
+study	O
+broadens	O
+our	O
+present	O
+knowledge	O
+of	O
+the	O
+type	O
+I	O
+and	O
+II	O
+IFN	B-PRGE
+-	O
+mediated	O
+effector	B-CHED
+responses	O
+during	O
+CoV	O
+infection	B-DISO
+in	O
+vivo	O
+.	O
+
+The	O
+new	O
+assays	O
+did	O
+not	O
+cross	O
+react	O
+with	O
+samples	O
+containing	O
+other	O
+viruses	O
+including	O
+parainfluenza	B-DISO
+1	O
+,	O
+2	O
+,	O
+and	O
+4	O
+;	O
+human	B-SPEC
+metapnuemovirus	O
+;	O
+coronavirus	B-SPEC
+229E	O
+,	O
+NL63	O
+,	O
+OC43	O
+;	O
+rhinovirus	B-SPEC
+;	O
+adenovirus	B-DISO
+;	O
+bocavirus	B-SPEC
+and	O
+had	O
+a	O
+specificity	O
+of	O
+100	O
+%	O
+and	O
+a	O
+sensitivity	O
+of	O
+98	O
+.	O
+2	O
+%	O
+for	O
+RSV	B-SPEC
+and	O
+96	O
+.	O
+5	O
+%	O
+for	O
+influenza	B-DISO
+respectively	O
+.	O
+
+In	O
+one	O
+series	O
+only	O
+children	O
+with	O
+RSV	B-DISO
+infection	I-DISO
+experienced	O
+recurrent	O
+wheezing	B-DISO
+and	O
+in	O
+another	O
+only	O
+RSV	B-DISO
+infection	I-DISO
+was	O
+associated	O
+with	O
+respiratory	B-DISO
+complications	I-DISO
+(	O
+hypoxia	B-DISO
+correlated	O
+with	O
+prolonged	O
+hospitalisation	O
+).	O
+
+TITLE	O
+:	O
+Expression	B-PROC
+,	O
+crystallization	O
+and	O
+preliminary	O
+X	O
+-	O
+ray	B-SPEC
+diffraction	O
+analysis	O
+of	O
+the	O
+N	O
+-	O
+terminal	O
+domain	O
+of	O
+nsp2	O
+from	O
+avian	B-DISO
+infectious	I-DISO
+bronchitis	I-DISO
+virus	B-SPEC
+.	O
+
+ABSTRACT	O
+:	O
+Avian	B-DISO
+infectious	I-DISO
+bronchitis	I-DISO
+virus	B-SPEC
+(	O
+IBV	B-SPEC
+)	O
+is	O
+a	O
+prototype	O
+of	O
+the	O
+group	O
+III	O
+coronaviruses	O
+and	O
+encodes	O
+15	O
+nonstructural	O
+proteins	B-CHED
+which	O
+make	O
+up	O
+the	O
+transcription	B-PROC
+/	O
+replication	O
+machinery	O
+.	O
+
+TITLE	O
+:	O
+Serological	O
+studies	O
+of	O
+infectious	B-DISO
+bronchitis	B-DISO
+vaccines	O
+against	O
+Japanese	O
+field	O
+isolates	O
+of	O
+homologous	O
+and	O
+heterologous	O
+genotypes	O
+.	O
+
+Field	O
+isolates	O
+have	O
+mainly	O
+been	O
+classified	O
+into	O
+three	O
+major	O
+genotypes	O
+,	O
+JP	O
+-	O
+I	O
+,	O
+JP	O
+-	O
+II	O
+and	O
+JP	B-PRGE
+-	I-PRGE
+III	I-PRGE
+,	O
+since	O
+2003	O
+;	O
+however	O
+,	O
+the	O
+4	O
+/	O
+91	O
+genotype	O
+was	O
+detected	O
+from	O
+recent	O
+field	O
+isolates	O
+in	O
+Japan	O
+.	O
+
+A	O
+quantile	O
+regression	O
+model	O
+was	O
+applied	O
+to	O
+estimate	O
+reference	O
+ranges	O
+of	O
+normal	O
+oral	B-ANAT
+temperatures	O
+for	O
+students	O
+with	O
+adjustment	O
+for	O
+potential	O
+confounding	O
+factors	O
+.	O
+
+ABSTRACT	O
+:	O
+To	O
+evaluate	O
+the	O
+effects	O
+of	O
+acute	O
+hypercapnia	B-DISO
+induced	O
+by	O
+positive	O
+end	B-PROC
+-	I-PROC
+expiratory	I-PROC
+pressure	O
+(	O
+PEEP	B-CHED
+)	O
+variations	O
+at	O
+constant	O
+plateau	O
+pressure	O
+(	O
+P	O
+(	O
+plat	O
+))	O
+in	O
+patients	O
+with	O
+severe	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+(	O
+ARDS	B-DISO
+)	O
+on	O
+right	O
+ventricular	B-ANAT
+(	O
+RV	O
+)	O
+function	O
+.	O
+
+We	O
+compared	O
+three	O
+ventilatory	O
+strategies	O
+,	O
+each	O
+used	O
+for	O
+1	O
+h	O
+,	O
+with	O
+P	O
+(	O
+plat	O
+)	O
+at	O
+22	O
+(	O
+20	O
+-	O
+25	O
+)	O
+cmH	B-DISO
+(	O
+2	O
+)	O
+O	O
+:	O
+low	O
+PEEP	B-CHED
+(	O
+5	O
+.	O
+4	O
+cmH	B-DISO
+(	O
+2	O
+)	O
+O	O
+)	O
+or	O
+high	O
+PEEP	B-CHED
+(	O
+11	O
+.	O
+0	O
+cmH	B-DISO
+(	O
+2	O
+)	O
+O	O
+)	O
+with	O
+compensation	B-PROC
+of	O
+the	O
+tidal	O
+volume	O
+reduction	O
+by	O
+either	O
+a	O
+high	O
+respiratory	O
+rate	O
+(	O
+high	O
+PEEP	B-CHED
+/	O
+high	O
+rate	O
+)	O
+or	O
+instrumental	O
+dead	B-PROC
+space	O
+decrease	O
+(	O
+high	O
+PEEP	B-CHED
+/	O
+low	O
+rate	O
+).	O
+
+This	O
+study	O
+provides	O
+new	O
+insights	O
+into	O
+host	B-COMP
+-	O
+pathogen	O
+interactions	O
+related	O
+to	O
+co	B-DISO
+-	I-DISO
+infection	I-DISO
+by	O
+CoVs	O
+and	O
+other	O
+respiratory	O
+viruses	B-SPEC
+.	O
+
+TITLE	O
+:	O
+Lack	O
+of	O
+evidence	O
+of	O
+avian	B-SPEC
+adenovirus	I-SPEC
+infection	O
+among	O
+turkey	B-SPEC
+workers	O
+.	O
+
+Although	O
+there	O
+are	O
+many	O
+animal	B-SPEC
+-	O
+specific	O
+adenoviruses	B-SPEC
+and	O
+occasionally	O
+they	O
+have	O
+been	O
+noted	O
+to	O
+infect	O
+man	B-CHED
+,	O
+rarely	O
+have	O
+they	O
+been	O
+studied	O
+as	O
+potential	O
+zoonotic	O
+pathogens	O
+.	O
+
+Multivariate	O
+modeling	O
+revealed	O
+no	O
+statistical	O
+difference	O
+in	O
+elevated	O
+antibody	B-COMP
+titers	O
+against	O
+HEV	B-SPEC
+between	O
+the	O
+two	O
+groups	O
+.	O
+
+In	O
+comparison	O
+with	O
+conventional	O
+enzyme	O
+linked	O
+immunosorbent	O
+assay	O
+(	O
+ELISA	O
+),	O
+the	O
+detection	O
+limit	O
+of	O
+the	O
+LSPCF	O
+fiber	O
+-	O
+optic	B-ANAT
+biosensor	O
+for	O
+the	O
+GST	B-PRGE
+-	I-PRGE
+N	I-PRGE
+protein	I-PRGE
+was	O
+improved	O
+at	O
+least	O
+10	O
+(	O
+4	O
+)-	O
+fold	O
+using	O
+the	O
+same	O
+monoclonal	O
+antibodies	B-COMP
+.	O
+
+TITLE	O
+:	O
+Large	O
+Arf1	B-PRGE
+guanine	I-PRGE
+nucleotide	I-PRGE
+exchange	I-PRGE
+factors	I-PRGE
+:	O
+evolution	B-PROC
+,	O
+domain	O
+structure	O
+,	O
+and	O
+roles	O
+in	O
+membrane	B-ANAT
+trafficking	B-PROC
+and	O
+human	B-SPEC
+disease	O
+.	O
+
+TITLE	O
+:	O
+Safety	O
+and	O
+tolerability	O
+of	O
+ribosome	B-COMP
+-	O
+component	O
+immune	O
+modulator	O
+in	O
+adults	O
+and	O
+children	O
+.	O
+
+These	O
+aptamer	O
+-	O
+antibody	O
+hybrid	O
+immunoassays	O
+may	O
+be	O
+useful	O
+for	O
+rapid	O
+,	O
+sensitive	O
+detection	O
+of	O
+SARS	B-PRGE
+-	I-PRGE
+CoV	I-PRGE
+N	I-PRGE
+protein	B-CHED
+.	O
+
+Furthermore	O
+,	O
+human	B-SPEC
+epithelial	O
+A549	O
+cells	B-COMP
+expressed	B-PROC
+ACE2	B-PRGE
+,	O
+and	O
+expression	B-PROC
+of	O
+3a	O
+/	O
+X1	O
+in	O
+these	O
+cells	B-COMP
+up	O
+-	O
+regulated	O
+TNF	B-PRGE
+-	I-PRGE
+alpha	I-PRGE
+,	O
+which	O
+is	O
+known	O
+to	O
+accelerate	O
+osteoclastogenesis	O
+.	O
+
+ABSTRACT	O
+:	O
+Hyperinfection	O
+syndrome	B-DISO
+with	O
+Strongyloides	B-SPEC
+stercoralis	I-SPEC
+is	O
+not	O
+uncommon	O
+in	O
+immunocompromised	O
+patients	O
+.	O
+
+TITLE	O
+:	O
+Avian	B-DISO
+influenza	I-DISO
+virus	I-SPEC
+,	O
+Streptococcus	B-SPEC
+suis	I-SPEC
+serotype	O
+2	O
+,	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+-	O
+coronavirus	B-SPEC
+and	O
+beyond	O
+:	O
+molecular	O
+epidemiology	O
+,	O
+ecology	O
+and	O
+the	O
+situation	O
+in	O
+China	O
+.	O
+
+Even	O
+the	O
+'	O
+well	O
+-	O
+known	O
+'	O
+reservoir	O
+animals	B-SPEC
+for	O
+influenza	B-SPEC
+virus	I-SPEC
+,	O
+migratory	O
+birds	B-SPEC
+,	O
+became	O
+victims	O
+of	O
+the	O
+highly	O
+pathogenic	O
+H5N1	B-DISO
+virus	B-SPEC
+.	O
+
+Phylogenetic	O
+analysis	O
+based	O
+on	O
+that	O
+region	O
+revealed	O
+that	O
+these	O
+viruses	B-SPEC
+were	O
+separated	O
+into	O
+two	O
+groups	O
+(	O
+I	O
+and	O
+II	O
+).	O
+
+ABSTRACT	O
+:	O
+Acute	O
+lung	B-ANAT
+injury	O
+(	O
+ALI	O
+)	O
+is	O
+an	O
+inflammatory	B-DISO
+disorder	I-DISO
+associated	O
+with	O
+reduced	O
+alveolar	B-ANAT
+-	O
+capillary	B-ANAT
+barrier	O
+function	O
+,	O
+increased	O
+pulmonary	B-ANAT
+vascular	B-PROC
+permeability	I-PROC
+,	O
+and	O
+infiltration	B-DISO
+of	O
+leukocytes	B-ANAT
+into	O
+the	O
+alveolar	B-ANAT
+space	O
+.	O
+
+Surface	O
+plasmon	O
+resonance	O
+(	O
+SPR	O
+)	O
+experiments	O
+showed	O
+that	O
+the	O
+affinity	O
+of	O
+HCoV	B-PRGE
+-	I-PRGE
+OC43	I-PRGE
+N	I-PRGE
+protein	B-CHED
+for	O
+RNA	O
+was	O
+approximately	O
+fivefold	O
+higher	O
+than	O
+that	O
+of	O
+N	B-PRGE
+protein	I-PRGE
+for	O
+DNA	O
+.	O
+
+SPR	O
+experiments	O
+demonstrated	O
+that	O
+the	O
+C	O
+-	O
+terminal	O
+region	O
+(	O
+residues	O
+301	O
+-	O
+448	O
+)	O
+of	O
+HCoV	B-PRGE
+-	I-PRGE
+OC43	I-PRGE
+N	I-PRGE
+protein	B-CHED
+lacks	O
+RNA	O
+-	O
+binding	B-PROC
+activity	I-PROC
+,	O
+while	O
+crosslinking	O
+and	O
+gel	O
+filtration	O
+analyses	O
+revealed	O
+that	O
+the	O
+C	O
+-	O
+terminal	O
+region	O
+is	O
+mainly	O
+involved	O
+in	O
+the	O
+oligomerization	O
+of	O
+the	O
+HCoV	B-PRGE
+-	I-PRGE
+OC43	I-PRGE
+N	I-PRGE
+protein	B-CHED
+.	O
+
+TITLE	O
+:	O
+Mechanisms	O
+of	O
+primary	O
+axonal	O
+damage	O
+in	O
+a	O
+viral	O
+model	O
+of	O
+multiple	B-DISO
+sclerosis	I-DISO
+.	O
+
+ABSTRACT	O
+:	O
+Multiple	B-DISO
+sclerosis	I-DISO
+(	O
+MS	O
+)	O
+is	O
+an	O
+inflammatory	O
+demyelinating	B-DISO
+disease	I-DISO
+of	O
+the	O
+CNS	B-CHED
+.	O
+
+He	O
+died	B-PROC
+after	O
+12	O
+days	O
+of	O
+septic	O
+multiple	B-DISO
+organ	I-DISO
+failure	I-DISO
+.	O
+
+Postoperative	O
+neutropenia	O
+may	O
+be	O
+a	O
+warning	O
+sign	O
+of	O
+severe	O
+infection	B-DISO
+even	O
+in	O
+survivable	O
+burns	O
+.	O
+
+In	O
+particular	O
+,	O
+estimates	O
+of	O
+daily	O
+reproduction	B-PROC
+numbers	O
+were	O
+provided	O
+for	O
+each	O
+subpopulation	O
+.	O
+
+This	O
+observation	O
+suggests	O
+that	O
+public	O
+health	O
+measures	O
+and	O
+possible	O
+changes	O
+in	O
+individual	O
+behaviors	B-PROC
+effectively	O
+reduced	O
+transmission	O
+,	O
+especially	O
+in	O
+hospitals	O
+.	O
+
+In	O
+the	O
+meantime	O
+,	O
+the	O
+Severe	B-DISO
+Acute	I-DISO
+Respiratory	I-DISO
+Syndrome	I-DISO
+(	O
+SARS	B-DISO
+)	O
+outbreak	O
+and	O
+the	O
+concern	O
+over	O
+pandemic	O
+influenza	B-DISO
+have	O
+stimulated	O
+considerable	O
+government	O
+and	O
+healthcare	O
+institutional	O
+efforts	O
+to	O
+improve	O
+infection	B-DISO
+control	O
+systems	O
+in	O
+Canada	O
+.	O
+
+The	O
+proportion	O
+of	O
+hospitals	O
+that	O
+reported	O
+having	O
+new	O
+nosocomial	O
+Vancomycin	B-CHED
+-	O
+resistant	O
+Enterococcus	B-SPEC
+(	O
+VRE	O
+)	O
+cases	O
+was	O
+greater	O
+in	O
+2005	O
+than	O
+in	O
+1999	O
+(	O
+X	O
+=	O
+10	O
+.	O
+5	O
+,	O
+P	O
+=	O
+0	O
+.	O
+001	O
+).	O
+
+ICP	B-DISO
+full	O
+time	O
+equivalents	O
+(	O
+FTEs	O
+)	O
+per	O
+100	O
+beds	O
+increased	O
+from	O
+0	O
+.	O
+5	O
+(	O
+SD	O
+0	O
+.	O
+2	O
+)	O
+in	O
+1999	O
+to	O
+0	O
+.	O
+8	O
+(	O
+SD	O
+0	O
+.	O
+3	O
+)	O
+in	O
+2005	O
+(	O
+F	O
+=	O
+90	O
+.	O
+8	O
+,	O
+P	O
+<	O
+0	O
+.	O
+0001	O
+).	O
+
+Although	O
+A	B-SPEC
+.	I-SPEC
+baumannii	I-SPEC
+is	O
+considered	O
+the	O
+causative	O
+agent	O
+in	O
+nosocomical	O
+pneumonia	B-DISO
+,	O
+community	O
+-	O
+acquired	O
+pneumonia	B-DISO
+due	O
+to	O
+A	B-SPEC
+.	I-SPEC
+baumannii	I-SPEC
+is	O
+very	O
+rare	O
+.	O
+
+ABSTRACT	O
+:	O
+The	O
+coronaviruses	O
+mouse	B-DISO
+hepatitis	B-PRGE
+virus	I-PRGE
+type	I-PRGE
+2	I-PRGE
+(	O
+MHV	B-SPEC
+-	O
+2	O
+)	O
+and	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+coronavirus	B-SPEC
+(	O
+SARS	B-PRGE
+-	I-PRGE
+CoV	I-PRGE
+)	O
+utilize	O
+proteases	O
+to	O
+enter	O
+host	B-COMP
+cells	B-COMP
+.	O
+
+This	O
+trypsin	B-PRGE
+-	O
+or	O
+CPL	B-DISO
+-	O
+mediated	O
+conversion	O
+to	O
+6HB	O
+can	O
+be	O
+blocked	O
+by	O
+a	O
+heptad	O
+repeat	O
+peptide	B-CHED
+known	O
+to	O
+block	O
+the	O
+formation	B-PROC
+of	O
+6HB	O
+.	O
+
+Interestingly	O
+,	O
+consecutive	O
+treatment	O
+with	O
+CPL	B-DISO
+and	O
+then	O
+chlorpromazine	B-CHED
+enabled	O
+a	O
+portion	O
+of	O
+the	O
+virus	B-SPEC
+to	O
+enter	O
+from	O
+cell	B-COMP
+surface	I-COMP
+.	O
+
+ABSTRACT	O
+:	O
+We	O
+report	O
+on	O
+a	O
+4	O
+month	O
+old	O
+male	O
+infant	O
+with	O
+respiratory	O
+syncytial	O
+virus	O
+(	O
+RSV	B-SPEC
+)	O
+infection	B-DISO
+leading	O
+to	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+(	O
+ARDS	B-DISO
+).	O
+
+This	O
+case	O
+report	O
+describes	O
+severe	O
+maxillary	B-ANAT
+and	O
+mandibular	B-ANAT
+necrotizing	O
+stomatitis	B-DISO
+and	O
+osteomyelitis	B-DISO
+in	O
+a	O
+young	O
+female	O
+patient	O
+after	O
+chemotherapy	O
+for	O
+acute	B-DISO
+leukaemia	I-DISO
+.	O
+
+Thirty	O
+-	O
+two	O
+months	O
+after	O
+presentation	O
+of	O
+the	O
+initial	O
+symptoms	O
+,	O
+the	O
+patient	O
+died	B-PROC
+due	O
+to	O
+complications	O
+related	O
+to	O
+leukaemia	B-DISO
+recurrence	B-DISO
+(	O
+haemorrhage	B-DISO
+,	O
+sepsis	B-DISO
+and	O
+respiratory	B-DISO
+distress	I-DISO
+syndrome	I-DISO
+).	O
+
+Dental	O
+monitoring	O
+during	O
+cancer	B-DISO
+treatment	O
+is	O
+imperative	O
+in	O
+order	B-SPEC
+to	O
+emphasize	O
+the	O
+importance	O
+of	O
+dental	B-DISO
+plaque	I-DISO
+control	O
+and	O
+the	O
+maintenance	O
+of	O
+a	O
+healthy	O
+periodontal	O
+condition	B-DISO
+throughout	O
+medical	O
+treatment	O
+.	O
+
+We	O
+reveal	O
+correlations	O
+with	O
+specific	O
+cellular	B-COMP
+states	O
+that	O
+are	O
+defined	O
+by	O
+the	O
+population	O
+context	O
+of	O
+a	O
+cell	B-COMP
+,	O
+and	O
+we	O
+derive	O
+probabilistic	O
+models	O
+that	O
+can	O
+explain	O
+and	O
+predict	O
+most	O
+cellular	B-COMP
+heterogeneity	O
+of	O
+these	O
+activities	O
+,	O
+solely	O
+on	O
+the	O
+basis	O
+of	O
+each	O
+cell	B-COMP
+'	O
+s	O
+population	O
+context	O
+.	O
+
+Finally	O
+,	O
+we	O
+reveal	O
+that	O
+synergy	O
+between	O
+two	O
+molecular	O
+components	O
+,	O
+focal	B-COMP
+adhesion	I-COMP
+kinase	O
+and	O
+the	O
+sphingolipid	B-CHED
+GM1	B-CHED
+,	O
+enhances	O
+the	O
+population	O
+-	O
+determined	O
+pattern	O
+of	O
+simian	B-SPEC
+virus	I-SPEC
+40	I-SPEC
+(	O
+SV40	B-SPEC
+)	O
+infection	B-DISO
+.	O
+
+Septic	B-DISO
+shock	I-DISO
+is	O
+a	O
+major	O
+cause	O
+of	O
+admission	O
+to	O
+the	O
+ICU	O
+during	O
+Hajj	O
+and	O
+carries	O
+a	O
+poor	O
+outcome	O
+.	O
+
+ABSTRACT	O
+:	O
+The	O
+S2	O
+domain	O
+of	O
+the	O
+coronavirus	B-SPEC
+spike	O
+(	O
+S	O
+)	O
+protein	B-CHED
+is	O
+known	O
+to	O
+be	O
+responsible	O
+for	O
+mediating	O
+membrane	B-PROC
+fusion	I-PROC
+.	O
+
+In	O
+addition	O
+to	O
+a	O
+well	O
+-	O
+recognized	O
+cleavage	B-PROC
+site	O
+at	O
+the	O
+S1	O
+-	O
+S2	O
+boundary	O
+,	O
+a	O
+second	O
+proteolytic	B-PROC
+cleavage	B-PROC
+site	O
+has	O
+been	O
+identified	O
+in	O
+the	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+coronavirus	B-SPEC
+(	O
+SARS	B-DISO
+-	O
+CoV	O
+)	O
+S2	O
+domain	O
+(	O
+R797	O
+).	O
+
+ABSTRACT	O
+:	O
+There	O
+is	O
+a	O
+need	O
+for	O
+biomarkers	O
+insuring	O
+identification	O
+of	O
+septic	O
+patients	O
+at	O
+high	O
+-	O
+risk	O
+for	O
+death	B-PROC
+.	O
+
+We	O
+performed	O
+a	O
+prospective	O
+,	O
+multicenter	O
+,	O
+observational	O
+study	O
+to	O
+investigate	O
+the	O
+time	O
+-	O
+course	O
+of	O
+lipopolysaccharide	B-PRGE
+binding	I-PRGE
+protein	B-CHED
+(	O
+LBP	B-DISO
+)	O
+serum	B-COMP
+levels	O
+in	O
+patients	O
+with	O
+severe	B-DISO
+sepsis	I-DISO
+and	O
+examined	O
+whether	O
+serial	O
+serum	B-COMP
+levels	O
+of	O
+LBP	B-DISO
+could	O
+be	O
+used	O
+as	O
+a	O
+marker	O
+of	O
+outcome	O
+.	O
+
+LBP	B-DISO
+serum	B-COMP
+levels	O
+at	O
+study	O
+entry	O
+,	O
+at	O
+48	O
+hours	O
+and	O
+at	O
+day	O
+-	O
+7	O
+were	O
+measured	O
+in	O
+180	O
+patients	O
+with	O
+severe	B-DISO
+sepsis	I-DISO
+.	O
+
+LBP	B-DISO
+serum	B-COMP
+levels	O
+were	O
+similar	O
+in	O
+survivors	O
+and	O
+non	O
+-	O
+survivors	O
+at	O
+study	O
+entry	O
+(	O
+117	O
+.	O
+4	O
++/-	O
+75	O
+.	O
+7	O
+microg	O
+/	O
+mL	O
+vs	O
+.	O
+129	O
+.	O
+8	O
++/-	O
+71	O
+.	O
+3	O
+microg	O
+/	O
+mL	O
+,	O
+P	O
+=	O
+0	O
+.	O
+249	O
+)	O
+but	O
+there	O
+were	O
+significant	O
+differences	O
+at	O
+48	O
+hours	O
+(	O
+77	O
+.	O
+2	O
++/-	O
+57	O
+.	O
+0	O
+vs	O
+.	O
+121	O
+.	O
+2	O
++/-	O
+73	O
+.	O
+4	O
+microg	O
+/	O
+mL	O
+,	O
+P	O
+<	O
+0	O
+.	O
+0001	O
+)	O
+and	O
+at	O
+day	O
+-	O
+7	O
+(	O
+64	O
+.	O
+7	O
++/-	O
+45	O
+.	O
+8	O
+vs	O
+.	O
+89	O
+.	O
+7	O
++/-	O
+61	O
+.	O
+1	O
+microg	O
+/	O
+ml	O
+,	O
+p	O
+=	O
+0	O
+.	O
+017	O
+).	O
+
+Nevertheless	O
+,	O
+carnivores	B-SPEC
+remain	O
+the	O
+most	O
+critical	O
+vectors	O
+for	O
+public	O
+health	O
+,	O
+in	O
+particular	O
+dogs	B-SPEC
+that	O
+are	O
+originating	O
+55	O
+.	O
+000	O
+rabies	B-DISO
+deaths	B-PROC
+per	O
+year	O
+,	O
+essentially	O
+in	O
+developing	O
+countries	O
+.	O
+
+These	O
+experiments	O
+proof	O
+that	O
+FIPV	O
+can	O
+employ	O
+another	O
+immune	B-PROC
+evasion	I-PROC
+strategy	O
+against	O
+ADCML	O
+(	O
+besides	O
+preventing	O
+surface	O
+expression	B-PROC
+):	O
+the	O
+inhibition	B-PROC
+of	O
+complement	O
+-	O
+mediated	O
+lysis	B-DISO
+.	O
+
+The	O
+selective	O
+forces	O
+underlying	O
+HE	O
+diversity	O
+and	O
+the	O
+molecular	O
+basis	O
+for	O
+Sia	B-PRGE
+specificity	O
+are	O
+poorly	O
+understood	O
+.	O
+
+Our	O
+findings	O
+shed	O
+light	O
+on	O
+HE	O
+evolution	B-PROC
+and	O
+provide	O
+fundamental	O
+insight	O
+into	O
+mechanisms	O
+of	O
+substrate	O
+binding	B-FUNC
+,	O
+substrate	O
+recognition	O
+,	O
+and	O
+receptor	O
+selection	O
+in	O
+this	O
+important	O
+class	B-SPEC
+of	O
+virion	B-COMP
+proteins	B-CHED
+.	O
+
+ABSTRACT	O
+:	O
+Corticosteroids	O
+are	O
+widely	O
+used	O
+to	O
+treat	O
+a	O
+diversity	O
+of	O
+pathological	O
+conditions	O
+including	O
+allergic	O
+,	O
+autoimmune	B-DISO
+and	O
+some	O
+infectious	B-DISO
+diseases	I-DISO
+.	O
+
+These	O
+drugs	O
+have	O
+complex	O
+mechanisms	O
+of	O
+action	O
+involving	O
+both	O
+genomic	O
+and	O
+non	O
+-	O
+genomic	O
+mechanisms	O
+and	O
+interfere	O
+with	O
+different	O
+signal	B-PROC
+transduction	I-PROC
+pathways	I-PROC
+in	O
+the	O
+cell	B-COMP
+.	O
+
+According	O
+to	O
+the	O
+changes	O
+of	O
+CD4	B-PRGE
+(+)	O
+T	B-ANAT
+cell	I-ANAT
+,	O
+immunosuppressive	B-CHED
+agents	I-CHED
+(	O
+CsA	B-DISO
+/	O
+FK506	O
++	O
+MMF	O
++	O
+Pred	O
+)	O
+were	O
+adjusted	O
+,	O
+and	O
+the	O
+effects	O
+of	O
+CMV	B-SPEC
+pneumonia	B-DISO
+occurring	O
+were	O
+investigated	O
+.	O
+
+Of	O
+the	O
+133	O
+recipients	O
+,	O
+12	O
+(	O
+9	O
+.	O
+0	O
+%,	O
+12	O
+/	O
+133	O
+)	O
+had	O
+severe	O
+pneumonia	B-DISO
+,	O
+during	O
+58	O
+-	O
+118	O
+days	O
+after	O
+operation	O
+,	O
+including	O
+7	O
+with	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+(	O
+ARDS	B-DISO
+);	O
+4	O
+patients	O
+(	O
+33	O
+.	O
+3	O
+%,	O
+4	O
+/	O
+12	O
+)	O
+died	B-PROC
+and	O
+8	O
+(	O
+66	O
+.	O
+7	O
+%,	O
+8	O
+/	O
+12	O
+)	O
+were	O
+cured	O
+.	O
+
+Determination	O
+of	O
+CD4	B-PRGE
+(+)	O
+T	B-ANAT
+cell	I-ANAT
+could	O
+reflect	O
+the	O
+status	O
+of	O
+cellular	B-PROC
+immunity	I-PROC
+and	O
+give	O
+directions	O
+of	O
+the	O
+withdrawal	B-DISO
+.	O
+
+RESULTS	O
+:	O
+In	O
+the	O
+period	O
+of	O
+45	O
+-	O
+72	O
+day	O
+after	O
+renal	B-ANAT
+transplantation	O
+,	O
+36	O
+cases	O
+were	O
+found	O
+to	O
+have	O
+significantly	O
+lower	O
+number	O
+of	O
+CD4	B-PRGE
+(+)	O
+T	B-ANAT
+cells	I-ANAT
+than	O
+that	O
+before	O
+operation	O
+.	O
+
+All	O
+the	O
+fecal	B-ANAT
+samples	O
+which	O
+tested	O
+positive	O
+for	O
+TGEV	O
+by	O
+the	O
+nested	O
+RT	O
+-	O
+PCR	O
+assay	O
+also	O
+tested	O
+positive	O
+by	O
+the	O
+TaqMan	O
+assay	O
+.	O
+
+Stroke	B-DISO
+volume	O
+variation	O
+and	O
+pulse	B-PROC
+pressure	I-PROC
+variation	O
+related	O
+to	O
+changes	O
+in	O
+stroke	B-DISO
+volume	O
+during	O
+positive	O
+pressure	O
+ventilation	O
+predict	O
+fluid	O
+responsiveness	O
+and	O
+represent	O
+an	O
+evolving	O
+practice	O
+for	O
+volume	O
+management	O
+in	O
+the	O
+intensive	O
+care	O
+unit	O
+(	O
+ICU	O
+)	O
+or	O
+operating	O
+room	O
+.	O
+
+SARS	B-DISO
+-	O
+CoV	O
+N	O
+greatly	O
+increased	O
+the	O
+amount	O
+of	O
+MAP19	B-PRGE
+.	O
+
+TITLE	O
+:	O
+Macrophage	B-ANAT
+interleukin	B-PRGE
+-	I-PRGE
+6	I-PRGE
+and	O
+tumour	B-PRGE
+necrosis	I-PRGE
+factor	I-PRGE
+-	I-PRGE
+alpha	I-PRGE
+are	O
+induced	O
+by	O
+coronavirus	B-SPEC
+fixation	O
+to	O
+Toll	O
+-	O
+like	O
+receptor	O
+2	O
+/	O
+heparan	O
+sulphate	O
+receptors	O
+but	O
+not	O
+carcinoembryonic	B-PRGE
+cell	I-PRGE
+adhesion	B-DISO
+antigen	B-CHED
+1a	I-PRGE
+.	O
+
+ABSTRACT	O
+:	O
+A	O
+rapid	O
+antiviral	B-CHED
+immune	B-PROC
+response	I-PROC
+may	O
+be	O
+related	O
+to	O
+viral	O
+interaction	O
+with	O
+the	O
+host	B-COMP
+cell	I-COMP
+leading	O
+to	O
+activation	O
+of	O
+macrophages	B-ANAT
+via	O
+pattern	O
+recognition	O
+receptors	O
+(	O
+PPRs	B-PRGE
+)	O
+or	O
+specific	O
+viral	O
+receptors	O
+.	O
+
+TITLE	O
+:	O
+A	O
+synergistic	O
+interferon	B-PROC
+-	I-PROC
+gamma	I-PROC
+production	I-PROC
+is	O
+induced	O
+by	O
+mouse	B-DISO
+hepatitis	I-DISO
+virus	B-SPEC
+in	O
+interleukin	B-PRGE
+-	I-PRGE
+12	I-PRGE
+(	O
+IL	B-FUNC
+-	I-FUNC
+12	I-FUNC
+)/	O
+IL	B-FUNC
+-	I-FUNC
+18	I-FUNC
+-	O
+activated	O
+natural	B-ANAT
+killer	I-ANAT
+cells	I-ANAT
+and	O
+modulated	O
+by	O
+carcinoembryonic	O
+antigen	B-CHED
+-	O
+related	O
+cell	B-PROC
+adhesion	B-DISO
+molecules	O
+(	O
+CEACAM	O
+)	O
+1a	O
+receptor	O
+.	O
+
+Immunofluorescent	O
+staining	O
+showed	O
+that	O
+four	O
+cell	B-COMP
+types	O
+supported	O
+SDAV	O
+virus	B-PROC
+replication	I-PROC
+in	O
+the	O
+lower	B-ANAT
+respiratory	I-ANAT
+tract	I-ANAT
+,	O
+namely	O
+Clara	O
+cells	B-COMP
+,	O
+ciliated	O
+cells	B-COMP
+in	O
+the	O
+bronchial	B-ANAT
+airway	B-ANAT
+and	O
+alveolar	B-ANAT
+type	O
+I	O
+and	O
+type	O
+II	O
+cells	B-COMP
+in	O
+the	O
+lung	B-ANAT
+parenchyma	I-ANAT
+.	O
+
+The	O
+messages	O
+give	O
+voice	B-PROC
+to	O
+the	O
+Chinese	O
+nursing	B-PROC
+experience	O
+and	O
+when	O
+synthesised	O
+with	O
+reports	O
+from	O
+other	O
+international	O
+nurses	O
+,	O
+they	O
+enable	O
+specific	O
+direction	O
+to	O
+enhance	O
+potential	O
+for	O
+a	O
+well	O
+-	O
+prepared	O
+nursing	B-PROC
+workforce	O
+and	O
+quality	O
+patient	O
+care	O
+in	O
+future	O
+epidemics	O
+.	O
+
+The	O
+preparation	O
+of	O
+a	O
+knowledgeable	O
+,	O
+cared	O
+-	O
+for	O
+nursing	B-PROC
+workforce	O
+promises	O
+optimal	O
+outcomes	O
+with	O
+the	O
+emergence	O
+of	O
+the	O
+next	O
+global	O
+infection	B-DISO
+.	O
+
+ABSTRACT	O
+:	O
+Stem	O
+-	O
+loop	O
+2	O
+(	O
+SL2	B-PRGE
+)	O
+of	O
+the	O
+5	O
+'-	O
+untranslated	O
+region	O
+of	O
+the	O
+mouse	B-DISO
+hepatitis	I-DISO
+virus	B-SPEC
+(	O
+MHV	B-SPEC
+)	O
+contains	O
+a	O
+highly	O
+conserved	O
+pentaloop	O
+(	O
+C47	O
+-	O
+U48	O
+-	O
+U49	O
+-	O
+G50	O
+-	O
+U51	O
+)	O
+stacked	O
+on	O
+a	O
+5	O
+-	O
+bp	O
+stem	B-ANAT
+.	O
+
+These	O
+studies	O
+suggest	O
+that	O
+SL2	B-PRGE
+functions	O
+as	O
+an	O
+important	O
+,	O
+but	O
+rather	O
+plastic	O
+,	O
+structural	O
+element	O
+in	O
+stimulating	O
+subgenomic	O
+RNA	B-PROC
+synthesis	I-PROC
+in	O
+coronaviruses	O
+.	O
+
+HCoV	B-SPEC
+-	I-SPEC
+NL63	I-SPEC
+infection	B-DISO
+was	O
+more	O
+common	O
+in	O
+2006	O
+-	O
+2007	O
+than	O
+2005	O
+-	O
+2006	O
+(	O
+1	O
+.	O
+2	O
+%	O
+and	O
+0	O
+.	O
+3	O
+%,	O
+respectively	O
+;	O
+P	O
+=	O
+0	O
+.	O
+006	O
+).	O
+
+With	O
+new	O
+information	O
+surfacing	O
+from	O
+public	O
+health	O
+investigations	O
+of	O
+recent	O
+cases	O
+of	O
+swine	B-DISO
+influenza	I-DISO
+in	O
+the	O
+United	O
+States	O
+,	O
+here	O
+we	O
+discuss	O
+putative	O
+links	O
+between	O
+the	O
+outbreak	O
+of	O
+SRI	O
+in	O
+Mexico	O
+and	O
+the	O
+emergence	O
+of	O
+a	O
+novel	O
+swine	B-DISO
+influenza	B-PATH
+A	I-PATH
+(	O
+H1N1	O
+)	O
+strain	O
+in	O
+several	O
+southwestern	O
+U	O
+.	O
+S	O
+.	O
+states	O
+.	O
+
+The	O
+135	O
+participating	O
+herds	O
+were	O
+randomly	O
+selected	O
+from	O
+those	O
+in	O
+The	O
+Norwegian	O
+Dairy	O
+Herd	O
+Recording	O
+System	O
+that	O
+had	O
+at	O
+least	O
+15	O
+cow	B-SPEC
+-	O
+years	O
+.	O
+
+Potential	O
+risk	O
+factors	O
+for	O
+diarrhea	B-DISO
+were	O
+analyzed	O
+by	O
+using	O
+Cox	O
+regression	O
+analysis	O
+adjusted	O
+for	O
+herd	O
+frailty	O
+effect	O
+.	O
+
+Other	O
+factors	O
+found	O
+to	O
+increase	O
+the	O
+risk	O
+of	O
+diarrhea	B-DISO
+were	O
+use	O
+of	O
+slatted	O
+concrete	O
+floor	O
+in	O
+group	O
+pens	O
+versus	O
+other	O
+floor	O
+types	O
+[	O
+hazard	O
+ratio	O
+(	O
+HR	O
+)	O
+=	O
+8	O
+.	O
+9	O
+],	O
+housing	O
+of	O
+calves	O
+in	O
+free	O
+-	O
+stalls	O
+compared	O
+with	O
+tie	O
+-	O
+stalls	O
+(	O
+HR	O
+=	O
+3	O
+.	O
+7	O
+),	O
+purchasing	O
+of	O
+calves	O
+into	O
+the	O
+herd	O
+versus	O
+not	O
+purchasing	O
+calves	O
+(	O
+HR	O
+=	O
+4	O
+.	O
+1	O
+),	O
+and	O
+calves	O
+being	O
+born	O
+during	O
+winter	O
+compared	O
+with	O
+other	O
+seasons	O
+of	O
+the	O
+year	O
+(	O
+HR	O
+=	O
+1	O
+.	O
+5	O
+).	O
+
+No	O
+calves	O
+were	O
+antibody	B-COMP
+positive	O
+for	O
+M	B-SPEC
+.	I-SPEC
+bovis	I-SPEC
+.	O
+
+In	O
+a	O
+multi	O
+-	O
+variate	O
+logistic	O
+regression	O
+model	O
+,	O
+pre	O
+-	O
+ECMO	O
+factors	O
+including	O
+increasing	O
+age	O
+,	O
+decreased	O
+weight	O
+,	O
+days	O
+on	O
+mechanical	O
+ventilation	O
+before	O
+ECMO	O
+,	O
+arterial	B-ANAT
+blood	I-ANAT
+pH	O
+<	O
+or	O
+=	O
+7	O
+.	O
+18	O
+,	O
+and	O
+Hispanic	O
+and	O
+Asian	O
+race	O
+compared	O
+to	O
+white	O
+race	O
+were	O
+associated	O
+with	O
+increased	O
+odds	O
+of	O
+death	B-PROC
+.	O
+
+The	O
+two	O
+diagnostic	O
+categories	O
+acute	B-DISO
+respiratory	I-DISO
+failure	I-DISO
+and	O
+asthma	B-PATH
+compared	O
+to	O
+ARDS	B-DISO
+were	O
+associated	O
+with	O
+decreased	O
+odds	O
+of	O
+mortality	O
+as	O
+was	O
+venovenous	O
+compared	O
+to	O
+venoarterial	O
+mode	O
+.	O
+
+CPR	B-ENZY
+and	O
+complications	O
+while	O
+on	O
+ECMO	O
+including	O
+circuit	O
+rupture	O
+,	O
+central	B-ANAT
+nervous	I-ANAT
+system	I-ANAT
+infarction	B-DISO
+or	O
+hemorrhage	B-DISO
+,	I-DISO
+gastrointestinal	I-DISO
+or	O
+pulmonary	B-DISO
+hemorrhage	I-DISO
+,	O
+and	O
+arterial	B-ANAT
+blood	I-ANAT
+pH	O
+<	O
+7	O
+.	O
+2	O
+or	O
+>	O
+7	O
+.	O
+6	O
+were	O
+associated	O
+with	O
+increased	O
+odds	O
+of	O
+death	B-PROC
+.	O
+
+For	O
+the	O
+most	O
+recent	O
+years	O
+(	O
+n	O
+=	O
+600	O
+),	O
+age	O
+and	O
+PaCO	O
+(	O
+2	O
+)	O
+>	O
+or	O
+=	O
+70	O
+compared	O
+to	O
+PaCO	O
+(	O
+2	O
+)	O
+<	O
+or	O
+=	O
+44	O
+were	O
+also	O
+associated	O
+with	O
+increased	O
+odds	O
+of	O
+death	B-PROC
+.	O
+
+TITLE	O
+:	O
+[	O
+Influenza	B-DISO
+A	I-PATH
+(	O
+H1N1	O
+)	O
+epidemic	O
+in	O
+Argentina	B-SPEC
+.	O
+
+ICU	O
+:	O
+28	O
+severe	O
+pneumonia	B-DISO
+patients	O
+were	O
+admitted	O
+(	O
+21	O
+with	O
+associated	O
+conditions	O
+);	O
+24	O
+with	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+received	O
+mechanical	O
+ventilation	O
+,	O
+21	O
+of	O
+them	O
+had	O
+shock	O
+;	O
+8	O
+/	O
+9	O
+acute	B-DISO
+renal	I-DISO
+failure	I-DISO
+cases	O
+required	O
+hemodialysis	O
+.	O
+
+TITLE	O
+:	O
+The	O
+making	O
+of	O
+a	O
+Chinese	O
+head	B-ANAT
+of	O
+the	O
+WHO	O
+:	O
+a	O
+study	O
+of	O
+the	O
+media	B-ANAT
+discourse	O
+on	O
+Margaret	O
+Chan	O
+'	O
+s	O
+contest	O
+for	O
+the	O
+WHO	O
+director	O
+-	O
+generalship	O
+and	O
+its	O
+implications	O
+for	O
+the	O
+collective	O
+memory	O
+of	O
+SARS	B-DISO
+.	O
+
+It	O
+maps	O
+the	O
+political	O
+context	O
+of	O
+the	O
+media	B-ANAT
+discourse	O
+and	O
+explores	O
+the	O
+construction	O
+of	O
+a	O
+collective	O
+past	O
+to	O
+foster	O
+national	O
+cohesion	O
+in	O
+postcolonial	O
+Hong	O
+Kong	O
+.	O
+
+Risk	O
+of	O
+bias	B-SPEC
+of	O
+randomised	O
+studies	O
+was	O
+assessed	O
+for	O
+generation	O
+of	O
+the	O
+allocation	O
+sequence	O
+,	O
+allocation	O
+concealment	O
+,	O
+blinding	O
+,	O
+and	O
+follow	O
+-	O
+up	O
+.	O
+
+However	O
+,	O
+many	O
+simple	O
+and	O
+low	O
+cost	O
+interventions	O
+reduce	O
+the	O
+transmission	O
+of	O
+epidemic	O
+respiratory	O
+viruses	B-SPEC
+.	O
+
+ABSTRACT	O
+:	O
+Some	O
+highly	O
+pathogenic	O
+viruses	B-SPEC
+,	O
+such	O
+as	O
+Chikungunya	B-SPEC
+virus	I-SPEC
+,	O
+Japanese	B-SPEC
+encephalitis	I-SPEC
+virus	I-SPEC
+,	O
+Yellow	B-SPEC
+fever	I-SPEC
+virus	I-SPEC
+,	O
+Dengue	B-SPEC
+virus	I-SPEC
+,	O
+Hanta	O
+virus	B-SPEC
+,	O
+SARS	B-DISO
+-	O
+CoV	O
+,	O
+and	O
+H5N1	B-DISO
+avian	B-SPEC
+influenza	I-SPEC
+virus	I-SPEC
+can	O
+cause	O
+severe	O
+infectious	B-DISO
+diseases	I-DISO
+.	O
+
+However	O
+,	O
+the	O
+consensus	O
+method	O
+for	O
+detecting	O
+these	O
+viruses	B-SPEC
+has	O
+not	O
+been	O
+well	O
+established	O
+.	O
+
+70	O
+-	O
+mer	O
+oligonucleotides	B-CHED
+were	O
+used	O
+at	O
+the	O
+genus	B-SPEC
+level	O
+and	O
+50	O
+-	O
+mer	O
+oligonucleotides	B-CHED
+were	O
+at	O
+the	O
+species	B-SPEC
+level	O
+,	O
+respectively	O
+.	O
+
+This	O
+method	O
+may	O
+have	O
+an	O
+important	O
+potential	O
+application	O
+for	O
+the	O
+diagnosis	O
+of	O
+virus	B-DISO
+infection	I-DISO
+.	O
+
+Using	O
+inhibitors	B-CHED
+specific	O
+for	O
+three	O
+mitogen	B-PRGE
+-	I-PRGE
+activated	I-PRGE
+protein	B-CHED
+kinases	I-PRGE
+,	O
+we	O
+showed	O
+that	O
+induction	O
+of	O
+TNF	B-PRGE
+-	I-PRGE
+alpha	I-PRGE
+and	O
+IL	B-FUNC
+-	I-FUNC
+6	I-FUNC
+by	O
+MHV	B-SPEC
+-	O
+A59	O
+infection	B-DISO
+was	O
+mediated	O
+through	O
+activation	O
+of	O
+the	O
+Janus	B-PRGE
+N	I-PRGE
+-	I-PRGE
+terminal	I-PRGE
+kinase	I-PRGE
+signaling	B-PROC
+pathway	I-PROC
+,	O
+but	O
+not	O
+through	O
+the	O
+extracellular	B-PRGE
+signal	I-PRGE
+-	I-PRGE
+regulated	I-PRGE
+kinase	I-PRGE
+or	O
+p38	B-FUNC
+signaling	B-PROC
+pathway	I-PROC
+.	O
+
+TITLE	O
+:	O
+[	O
+Induction	O
+of	O
+immune	B-PROC
+response	I-PROC
+after	O
+oral	B-ANAT
+inoculation	O
+of	O
+mice	B-SPEC
+with	O
+Lactobacillus	B-SPEC
+casei	I-SPEC
+surface	O
+-	O
+displayed	O
+porcine	O
+epidemic	B-DISO
+diarrhea	I-DISO
+viral	O
+N	O
+protein	B-CHED
+].	O
+
+Statistical	O
+significant	O
+difference	O
+was	O
+observed	O
+among	O
+the	O
+spleen	B-ANAT
+lymphocyte	B-PROC
+proliferation	B-DISO
+index	O
+(	O
+LPI	B-DISO
+)	O
+among	O
+the	O
+immunization	O
+groups	O
+of	O
+mice	B-SPEC
+and	O
+control	O
+groups	O
+.	O
+
+TITLE	O
+:	O
+Development	B-PROC
+of	O
+a	O
+real	O
+-	O
+time	O
+TaqMan	O
+RT	O
+-	O
+PCR	O
+assay	O
+for	O
+the	O
+detection	O
+of	O
+infectious	B-DISO
+bronchitis	B-DISO
+virus	B-SPEC
+in	O
+chickens	B-SPEC
+,	O
+and	O
+comparison	O
+of	O
+RT	O
+-	O
+PCR	O
+and	O
+virus	B-SPEC
+isolation	O
+.	O
+
+For	O
+IS	O
+/	O
+885	O
+/	O
+00	O
+,	O
+real	O
+-	O
+time	O
+RT	O
+-	O
+PCR	O
+was	O
+more	O
+sensitive	O
+by	O
+tenfold	O
+than	O
+virus	B-SPEC
+isolation	O
+and	O
+30	O
+-	O
+or	O
+40	O
+-	O
+fold	O
+than	O
+by	O
+N	B-PRGE
+gene	I-PRGE
+or	O
+S1	B-PRGE
+gene	I-PRGE
+RT	O
+-	O
+PCR	O
+,	O
+respectively	O
+.	O
+
+Furthermore	O
+,	O
+CCoV	O
+-	O
+II	O
+infection	B-DISO
+resulted	O
+in	O
+truncated	O
+bid	O
+(	O
+tbid	O
+)	O
+translocation	B-DISO
+from	O
+the	O
+cytosolic	B-COMP
+to	O
+the	O
+mitochondrial	B-COMP
+fraction	O
+,	O
+the	O
+cytochrome	B-PRGE
+c	I-PRGE
+release	B-PATH
+from	I-PRGE
+mitochondria	B-COMP
+,	O
+and	O
+alterations	O
+in	O
+the	O
+pro	B-CHED
+-	O
+and	O
+anti	O
+-	O
+apoptotic	O
+proteins	B-CHED
+of	O
+bcl	B-PRGE
+-	I-PRGE
+2	I-PRGE
+family	I-PRGE
+.	O
+
+Mutation	O
+of	O
+the	O
+solvent	B-CHED
+-	O
+exposed	O
+Y127	O
+,	O
+positioned	O
+on	O
+the	O
+beta	O
+-	O
+platform	O
+surface	O
+of	O
+our	O
+1	O
+.	O
+75	O
+A	O
+structure	O
+,	O
+binds	O
+the	O
+TRS	B-DISO
+far	O
+less	O
+tightly	O
+and	O
+is	O
+severely	O
+crippled	O
+in	O
+its	O
+RNA	O
+unwinding	O
+activity	O
+.	O
+
+It	O
+is	O
+not	O
+known	O
+whether	O
+these	O
+cells	B-COMP
+are	O
+maintained	O
+by	O
+proliferation	B-DISO
+of	O
+T	B-ANAT
+cells	I-ANAT
+that	O
+entered	O
+the	O
+CNS	B-CHED
+during	O
+acute	B-DISO
+infection	I-DISO
+or	O
+are	O
+newly	O
+recruited	O
+from	O
+Ag	O
+-	O
+experienced	O
+or	O
+naive	O
+T	B-ANAT
+cell	I-ANAT
+pools	O
+.	O
+
+The	O
+total	O
+number	O
+of	O
+patients	O
+included	O
+in	O
+the	O
+surgery	O
+and	O
+PCD	B-DISO
+groups	O
+was	O
+sixteen	O
+and	O
+thirteen	O
+,	O
+respectively	O
+.	O
+
+The	O
+GhanaBt	O
+-	O
+CoVGrp2	O
+shared	O
+an	O
+old	O
+ancestor	O
+(	O
+approximately	O
+2	O
+,	O
+400	O
+years	O
+)	O
+with	O
+the	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+-	O
+like	O
+group	O
+of	O
+CoV	O
+.	O
+
+We	O
+also	O
+demonstrate	O
+that	O
+glycosaminoglycan	B-CHED
+had	O
+no	O
+effect	O
+on	O
+infection	B-DISO
+of	O
+the	O
+cells	B-COMP
+by	O
+IBV	B-SPEC
+.	O
+
+ABSTRACT	O
+:	O
+Infectious	B-DISO
+bronchitis	B-DISO
+(	O
+IB	O
+)	O
+is	O
+an	O
+economically	O
+important	O
+viral	B-DISO
+disease	I-DISO
+with	O
+worldwide	O
+distribution	O
+.	O
+
+CONCLUSIONS	O
+:	O
+Human	B-PRGE
+A	I-PRGE
+/	O
+H5N1	B-DISO
+infection	B-DISO
+is	O
+a	O
+severe	O
+and	O
+rapidly	O
+progressive	B-DISO
+disease	I-DISO
+mostly	O
+manifested	O
+as	O
+ARDS	B-DISO
+.	O
+
+Bronchopleural	B-DISO
+fistula	I-DISO
+was	O
+an	O
+intractable	O
+complication	B-DISO
+for	O
+patient	O
+with	O
+A	O
+/	O
+H5N1	B-DISO
+infection	B-DISO
+.	O
+
+Severe	B-DISO
+Acute	I-DISO
+Respiratory	I-DISO
+Syndrome	I-DISO
+coronavirus	B-SPEC
+(	O
+SARS	B-DISO
+-	O
+CoV	O
+)	O
+belongs	O
+to	O
+the	O
+family	B-SPEC
+Coronaviridae	I-SPEC
+,	O
+was	O
+first	O
+identified	O
+during	O
+2002	O
+-	O
+2003	O
+.	O
+
+Mortality	O
+in	O
+SARS	B-DISO
+patients	O
+ranges	O
+from	O
+between	O
+6	O
+to	O
+55	O
+%.	O
+
+Firstly	O
+,	O
+NO	O
+or	O
+its	O
+derivatives	O
+cause	O
+a	O
+reduction	O
+in	O
+the	O
+palmitoylation	B-PROC
+of	O
+nascently	O
+expressed	B-PROC
+spike	O
+(	O
+S	O
+)	O
+protein	B-CHED
+which	O
+affects	O
+the	O
+fusion	O
+between	O
+the	O
+S	B-PRGE
+protein	I-PRGE
+and	O
+its	O
+cognate	O
+receptor	O
+,	O
+angiotensin	B-PRGE
+converting	I-PRGE
+enzyme	I-PRGE
+2	I-PRGE
+.	O
+
+Chest	B-ANAT
+CT	O
+may	O
+be	O
+warranted	O
+in	O
+complicated	O
+cases	O
+of	O
+severe	O
+pneumonia	B-DISO
+and	O
+in	O
+febrile	B-PROC
+neutropenic	O
+patients	O
+with	O
+normal	O
+or	O
+nonspecific	O
+chest	B-ANAT
+radiographic	O
+findings	O
+.	O
+
+TITLE	O
+:	O
+Role	O
+of	O
+spike	O
+protein	B-CHED
+endodomains	O
+in	O
+regulating	O
+coronavirus	B-SPEC
+entry	O
+.	O
+
+This	O
+slower	O
+refolding	O
+was	O
+also	O
+reflected	O
+in	O
+the	O
+paucity	O
+of	O
+postfusion	O
+six	O
+-	O
+helix	O
+bundle	O
+configurations	O
+among	O
+the	O
+mutant	B-DISO
+S	O
+proteins	B-CHED
+.	O
+
+ABSTRACT	O
+:	O
+Hantavirus	B-SPEC
+pulmonary	B-ANAT
+syndrome	I-DISO
+(	O
+HPS	B-DISO
+)	O
+is	O
+an	O
+emerging	O
+rodent	B-SPEC
+-	O
+borne	O
+disease	O
+in	O
+the	O
+American	O
+continent	O
+,	O
+characterized	O
+by	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+and	O
+a	O
+high	O
+case	O
+-	O
+fatality	O
+ratio	O
+.	O
+
+The	O
+present	O
+work	O
+describes	O
+a	O
+case	O
+of	O
+HPS	B-DISO
+,	O
+with	O
+favorable	O
+outcome	O
+,	O
+whose	O
+initial	O
+features	O
+were	O
+mistaken	O
+for	O
+leptospirosis	B-DISO
+or	O
+other	O
+less	O
+severe	O
+acute	B-DISO
+infections	I-DISO
+.	O
+
+Young	O
+dogs	B-SPEC
+are	O
+less	O
+likely	O
+to	O
+be	O
+seropositive	O
+than	O
+older	O
+dogs	B-SPEC
+,	O
+probably	O
+due	O
+to	O
+increased	O
+opportunity	O
+for	O
+exposure	O
+to	O
+CRCoV	O
+over	O
+time	O
+.	O
+
+Serum	B-COMP
+antibodies	B-COMP
+to	O
+CIV	B-SPEC
+were	O
+not	O
+detected	O
+in	O
+any	O
+of	O
+the	O
+dogs	O
+sampled	O
+,	O
+suggesting	O
+that	O
+this	O
+virus	B-SPEC
+is	O
+unlikely	O
+to	O
+be	O
+present	O
+in	O
+dogs	B-SPEC
+in	O
+New	O
+Zealand	O
+.	O
+
+None	O
+was	O
+seropositive	O
+for	O
+CIV	B-SPEC
+.	O
+
+ABSTRACT	O
+:	O
+Ascaris	B-SPEC
+lumbricoides	I-SPEC
+infects	O
+an	O
+estimated	O
+1	O
+.	O
+2	O
+billion	O
+people	O
+worldwide	O
+,	O
+but	O
+is	O
+usually	O
+asymptomatic	O
+.	O
+
+The	O
+nature	O
+of	O
+work	O
+-	O
+family	B-SPEC
+and	O
+family	B-SPEC
+-	O
+work	O
+conflict	O
+perceived	O
+and	O
+experienced	O
+by	O
+nurses	O
+during	O
+infectious	B-DISO
+disease	I-DISO
+outbreaks	O
+,	O
+as	O
+well	O
+as	O
+the	O
+supports	O
+needed	O
+to	O
+enable	O
+them	O
+to	O
+balance	B-PROC
+their	O
+social	O
+roles	O
+during	O
+this	O
+type	O
+of	O
+heightened	O
+stress	O
+,	O
+are	O
+explored	O
+.	O
+
+ABSTRACT	O
+:	O
+A	O
+review	O
+of	O
+the	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+outbreak	O
+in	O
+Ontario	O
+in	O
+2003	O
+found	O
+that	O
+there	O
+had	O
+been	O
+several	O
+faults	O
+in	O
+healthcare	O
+services	O
+and	O
+that	O
+these	O
+had	O
+contributed	O
+to	O
+the	O
+spread	O
+of	O
+infection	B-DISO
+and	O
+the	O
+deaths	B-PROC
+of	O
+two	O
+nurses	O
+.	O
+
+ABSTRACT	O
+:	O
+In	O
+some	O
+cases	O
+of	O
+severe	O
+acute	O
+respiratory	O
+distress	O
+syndrome	O
+,	O
+hypoxemia	O
+occurs	O
+despite	O
+optimized	O
+conservative	O
+therapy	O
+;	O
+however	O
+,	O
+extracorporeal	O
+membrane	B-COMP
+oxygenation	B-PROC
+(	O
+ECMO	O
+)	O
+can	O
+assure	O
+sufficient	O
+gas	B-ENZY
+exchange	O
+.	O
+
+Another	O
+approach	O
+is	O
+the	O
+use	O
+of	O
+an	O
+arterio	B-ANAT
+-	I-ANAT
+venous	I-ANAT
+pumpless	O
+extracorporeal	O
+lung	B-ANAT
+assist	O
+(	O
+pECLA	O
+)	O
+using	O
+an	O
+oxygenator	O
+with	O
+reduced	O
+pressure	O
+drop	O
+to	O
+simplify	O
+management	O
+and	O
+to	O
+avoid	O
+pump	O
+-	O
+related	O
+complications	O
+.	O
+
+TITLE	O
+:	O
+New	O
+simulation	O
+-	O
+based	O
+airway	B-ANAT
+management	O
+training	O
+program	O
+for	O
+junior	O
+physicians	O
+:	O
+Advanced	O
+Airway	B-ANAT
+Life	O
+Support	O
+.	O
+
+TITLE	O
+:	O
+No	O
+evidence	O
+of	O
+over	O
+-	O
+reporting	O
+of	O
+SARS	B-DISO
+in	O
+mainland	O
+China	O
+.	O
+
+Differences	O
+in	O
+clinical	O
+symptoms	O
+between	O
+probable	O
+and	O
+suspected	O
+SARS	B-DISO
+cases	O
+were	O
+tested	O
+by	O
+Fisher	B-SPEC
+'	O
+s	O
+exact	O
+test	O
+.	O
+
+These	O
+cases	O
+resulted	O
+in	O
+33	O
+deaths	B-PROC
+,	O
+five	O
+of	O
+which	O
+occurred	O
+in	O
+hospital	O
+staff	O
+.	O
+
+The	O
+recombinant	O
+IBV	B-SPEC
+was	O
+in	O
+effect	O
+a	O
+chimaeric	O
+virus	B-SPEC
+with	O
+the	O
+replicase	B-PRGE
+gene	I-PRGE
+derived	O
+from	O
+Beaudette	O
+and	O
+the	O
+rest	B-FUNC
+of	O
+the	O
+genome	O
+from	O
+M41	O
+.	O
+
+This	O
+demonstrated	O
+that	O
+it	O
+is	O
+possible	O
+to	O
+exchange	O
+a	O
+large	O
+region	O
+of	O
+the	O
+IBV	B-SPEC
+genome	O
+,	O
+approximately	O
+8	O
+.	O
+4	O
+kb	O
+,	O
+using	O
+our	O
+transient	O
+dominant	O
+selection	O
+method	O
+.	O
+
+Analysis	O
+of	O
+the	O
+chimaeric	O
+virus	B-SPEC
+showed	O
+that	O
+it	O
+was	O
+avirulent	O
+indicating	O
+that	O
+none	O
+of	O
+the	O
+structural	O
+or	O
+accessory	O
+genes	O
+derived	O
+from	O
+a	O
+virulent	O
+isolate	O
+of	O
+IBV	B-SPEC
+were	O
+able	O
+to	O
+restore	O
+virulence	B-PROC
+and	O
+that	O
+therefore	O
+,	O
+the	O
+loss	O
+of	O
+virulence	B-PROC
+associated	O
+with	O
+the	O
+Beaudette	O
+strain	O
+resides	O
+in	O
+the	O
+replicase	B-PRGE
+gene	I-PRGE
+.	O
+
+Comparison	O
+of	O
+the	O
+deduced	O
+amino	B-CHED
+acid	I-CHED
+sequences	O
+of	O
+the	O
+spike	O
+protein	B-CHED
+in	O
+the	O
+CRCoV	O
+and	O
+bovine	B-SPEC
+coronavirus	B-SPEC
+(	O
+BCoV	O
+)	O
+strains	O
+revealed	O
+twenty	O
+sequence	O
+variations	O
+.	O
+
+TITLE	O
+:	O
+Dynamics	O
+of	O
+SARS	B-DISO
+-	O
+coronavirus	B-SPEC
+HR2	O
+domain	O
+in	O
+the	O
+prefusion	O
+and	O
+transition	B-DISO
+states	O
+.	O
+
+TITLE	O
+:	O
+Prevalence	O
+,	O
+prediction	O
+and	O
+risk	O
+factors	O
+of	O
+enteropathogens	O
+in	O
+normal	O
+and	O
+non	O
+-	O
+normal	O
+faeces	B-ANAT
+of	O
+young	O
+Dutch	O
+dairy	O
+calves	O
+.	O
+
+Fifty	O
+-	O
+seven	O
+percent	O
+of	O
+calves	O
+had	O
+faeces	O
+of	O
+normal	O
+colour	O
+(	O
+brownish	O
+)	O
+and	O
+consistency	O
+(	O
+firm	O
+),	O
+23	O
+.	O
+8	O
+%	O
+(	O
+95	O
+%	O
+CI	O
+:	O
+19	O
+.	O
+8	O
+-	O
+28	O
+.	O
+2	O
+%)	O
+had	O
+'	O
+custard	O
+-	O
+like	O
+'	O
+faeces	B-ANAT
+and	O
+19	O
+.	O
+1	O
+%	O
+(	O
+95	O
+%	O
+CI	O
+:	O
+15	O
+.	O
+5	O
+-	O
+23	O
+.	O
+2	O
+%)	O
+had	O
+diarrhoea	B-DISO
+.	O
+
+No	O
+animal	B-SPEC
+or	O
+managerial	O
+factors	O
+were	O
+associated	O
+with	O
+shedding	O
+of	O
+Cl	O
+.	O
+
+Hemocompatibility	O
+of	O
+devices	O
+depends	O
+on	O
+the	O
+size	O
+and	O
+modification	O
+of	O
+blood	B-ANAT
+contacting	O
+surfaces	O
+as	O
+well	O
+as	O
+blood	B-PROC
+flow	I-PROC
+rates	O
+.	O
+
+Scanning	O
+electron	O
+microscopy	O
+of	O
+oxygenator	O
+fibers	O
+showed	O
+significantly	O
+increased	O
+binding	B-FUNC
+and	O
+shape	O
+change	O
+of	O
+platelets	B-ANAT
+after	O
+interventional	O
+lung	B-ANAT
+assist	O
+.	O
+
+Interleukin	B-PRGE
+8	I-PRGE
+and	O
+tumor	B-PRGE
+necrosis	I-PRGE
+factor	I-PRGE
+-	I-PRGE
+alpha	I-PRGE
+concentration	O
+as	O
+well	O
+as	O
+leukocyte	B-ANAT
+count	O
+remained	O
+unchanged	O
+.	O
+
+Infants	O
+with	O
+RV	O
+infection	B-DISO
+had	O
+higher	O
+blood	B-ANAT
+eosinophil	I-ANAT
+counts	O
+than	O
+infants	O
+with	O
+bronchiolitis	B-DISO
+from	O
+RSV	B-SPEC
+and	O
+hBoV	O
+(	O
+307	O
++/-	O
+436	O
+vs	O
+138	O
++/-	O
+168	O
+vs	O
+89	O
++/-	O
+19	O
+n	O
+/	O
+mm	O
+(	O
+3	O
+);	O
+p	O
+<	O
+0	O
+.	O
+05	O
+).	O
+
+The	O
+population	O
+and	O
+health	O
+care	O
+system	O
+in	O
+Mexico	O
+City	O
+experienced	O
+the	O
+first	O
+and	O
+greatest	O
+early	O
+burden	O
+of	O
+critical	B-DISO
+illness	I-DISO
+.	O
+
+By	O
+60	O
+days	O
+,	O
+24	O
+patients	O
+had	O
+died	B-PROC
+(	O
+41	O
+.	O
+4	O
+%;	O
+95	O
+%	O
+confidence	O
+interval	O
+,	O
+28	O
+.	O
+9	O
+%-	O
+55	O
+.	O
+0	O
+%).	O
+
+Patients	O
+who	O
+died	B-PROC
+had	O
+greater	O
+initial	O
+severity	O
+of	O
+illness	O
+,	O
+worse	O
+hypoxemia	O
+,	O
+higher	O
+creatine	B-PRGE
+kinase	I-PRGE
+levels	O
+,	O
+higher	O
+creatinine	B-CHED
+levels	O
+,	O
+and	O
+ongoing	O
+organ	B-ANAT
+dysfunction	O
+.	O
+
+Among	O
+the	O
+168	O
+patients	O
+with	O
+confirmed	O
+or	O
+probable	O
+2009	O
+influenza	B-PATH
+A	I-PATH
+(	O
+H1N1	O
+),	O
+the	O
+mean	O
+(	O
+SD	O
+)	O
+age	O
+was	O
+32	O
+.	O
+3	O
+(	O
+21	O
+.	O
+4	O
+)	O
+years	O
+;	O
+113	O
+were	O
+female	O
+(	O
+67	O
+.	O
+3	O
+%)	O
+and	O
+50	O
+were	O
+children	O
+(	O
+29	O
+.	O
+8	O
+%).	O
+
+Shock	O
+and	O
+nonpulmonary	O
+acute	O
+organ	B-ANAT
+dysfunction	O
+was	O
+common	O
+(	O
+Sequential	O
+Organ	B-DISO
+Failure	I-DISO
+Assessment	O
+mean	O
+[	O
+SD	O
+]	O
+score	O
+of	O
+6	O
+.	O
+8	O
+[	O
+3	O
+.	O
+6	O
+]	O
+on	O
+day	O
+1	O
+).	O
+
+Overall	O
+mortality	O
+among	O
+critically	B-DISO
+ill	I-DISO
+patients	O
+at	O
+90	O
+days	O
+was	O
+17	O
+.	O
+3	O
+%	O
+(	O
+95	O
+%	O
+confidence	O
+interval	O
+,	O
+12	O
+.	O
+0	O
+%-	O
+24	O
+.	O
+0	O
+%;	O
+n	O
+=	O
+29	O
+).	O
+
+Overall	O
+mortality	O
+among	O
+critically	B-DISO
+ill	I-DISO
+patients	O
+at	O
+90	O
+days	O
+was	O
+17	O
+.	O
+3	O
+%	O
+(	O
+95	O
+%	O
+confidence	O
+interval	O
+,	O
+12	O
+.	O
+0	O
+%-	O
+24	O
+.	O
+0	O
+%;	O
+n	O
+=	O
+29	O
+).	O
+
+To	O
+describe	O
+the	O
+characteristics	O
+of	O
+all	O
+patients	O
+with	O
+2009	O
+influenza	B-PATH
+A	I-PATH
+(	O
+H1N1	O
+)-	O
+associated	O
+ARDS	B-DISO
+treated	O
+with	O
+ECMO	O
+and	O
+to	O
+report	O
+incidence	O
+,	O
+resource	O
+utilization	O
+,	O
+and	O
+patient	O
+outcomes	O
+.	O
+
+Before	O
+ECMO	O
+,	O
+patients	O
+had	O
+severe	O
+respiratory	B-DISO
+failure	I-DISO
+despite	O
+advanced	O
+mechanical	O
+ventilatory	O
+support	O
+with	O
+a	O
+median	O
+(	O
+IQR	O
+)	O
+Pao	B-PROC
+(	O
+2	O
+)/	O
+fraction	O
+of	O
+inspired	B-PROC
+oxygen	B-CHED
+(	O
+Fio	O
+(	O
+2	O
+))	O
+ratio	O
+of	O
+56	O
+(	O
+48	O
+-	O
+63	O
+),	O
+positive	O
+end	B-PROC
+-	I-PROC
+expiratory	I-PROC
+pressure	O
+of	O
+18	O
+(	O
+15	O
+-	O
+20	O
+)	O
+cm	O
+H	O
+(	O
+2	O
+)	O
+O	O
+,	O
+and	O
+an	O
+acute	O
+lung	B-ANAT
+injury	O
+score	O
+of	O
+3	O
+.	O
+8	O
+(	O
+3	O
+.	O
+5	O
+-	O
+4	O
+.	O
+0	O
+).	O
+
+Viruses	B-SPEC
+were	O
+detected	O
+by	O
+either	O
+virus	B-SPEC
+isolation	O
+or	O
+PCR	O
+methods	O
+significantly	O
+more	O
+frequently	O
+in	O
+conjunctival	O
+samples	O
+from	O
+dogs	O
+with	O
+conjunctivitis	B-DISO
+(	O
+7	O
+/	O
+30	O
+[	O
+23	O
+.	O
+3	O
+%])	O
+than	O
+dogs	B-SPEC
+without	O
+conjunctivitis	B-DISO
+(	O
+0	O
+/	O
+30	O
+[	O
+0	O
+%]).	O
+
+Canine	B-SPEC
+herpesvirus	I-SPEC
+-	O
+1	O
+was	O
+isolated	O
+from	O
+2	O
+conjunctival	O
+samples	O
+and	O
+detected	O
+by	O
+use	O
+of	O
+PCR	O
+assay	O
+in	O
+5	O
+conjunctival	O
+samples	O
+.	O
+
+Specimens	O
+(	O
+n	O
+=	O
+1	O
+,	O
+108	O
+)	O
+from	O
+244	O
+suspected	O
+respiratory	O
+virus	B-SPEC
+outbreaks	O
+in	O
+2006	O
+and	O
+2007	O
+in	O
+Alberta	B-SPEC
+,	O
+Canada	O
+,	O
+were	O
+included	O
+in	O
+the	O
+study	O
+.	O
+
+ABSTRACT	O
+:	O
+Type	O
+II	O
+mixed	O
+cryoglobulin	O
+syndrome	B-DISO
+is	O
+a	O
+systematic	O
+vasculitis	B-DISO
+mainly	O
+linked	O
+to	O
+immune	O
+complex	O
+deposition	O
+in	O
+several	O
+organs	B-ANAT
+and	O
+to	O
+hepatitis	B-SPEC
+C	I-SPEC
+virus	B-DISO
+infection	I-DISO
+.	O
+
+Therapeutic	O
+strategies	O
+can	O
+target	O
+either	O
+the	O
+viral	O
+trigger	O
+hepatitis	B-SPEC
+C	I-SPEC
+virus	I-SPEC
+if	O
+present	O
+,	O
+or	O
+pathogenic	O
+events	O
+downstream	O
+the	O
+triggering	O
+infection	B-DISO
+,	O
+e	O
+.	O
+g	O
+,	O
+the	O
+proliferation	B-DISO
+B	B-ANAT
+-	I-ANAT
+cells	I-ANAT
+directly	O
+.	O
+
+Antiviral	B-CHED
+therapy	O
+should	O
+be	O
+considered	O
+as	O
+a	O
+first	O
+-	O
+line	O
+treatment	O
+in	O
+many	O
+HCV	B-SPEC
+-	O
+positive	O
+patients	O
+.	O
+
+TITLE	O
+:	O
+A	O
+rare	O
+case	O
+of	O
+neuroleptic	B-DISO
+malignant	I-DISO
+syndrome	I-DISO
+presenting	O
+with	O
+serious	O
+hyperthermia	B-PROC
+treated	O
+with	O
+a	O
+non	O
+-	O
+invasive	O
+cooling	O
+device	O
+:	O
+a	O
+case	O
+report	O
+.	O
+
+Because	O
+of	O
+other	O
+different	O
+life	O
+-	O
+threatening	O
+diseases	O
+matching	O
+the	O
+various	O
+clinical	B-DISO
+findings	I-DISO
+,	O
+the	O
+correct	O
+diagnosis	O
+can	O
+sometimes	O
+be	O
+hard	O
+to	O
+make	O
+.	O
+
+CONCLUSIONS	O
+:	O
+Numerous	O
+case	O
+reports	O
+have	O
+been	O
+published	O
+about	O
+patients	O
+who	O
+developed	O
+neuroleptic	B-DISO
+malignant	I-DISO
+syndrome	I-DISO
+due	O
+to	O
+Olanzapin	O
+(	O
+Zyprexa	B-CHED
+(	O
+R	O
+))	O
+medication	O
+.	O
+
+The	O
+prolonged	O
+immunosuppression	B-PROC
+following	O
+specific	O
+treatment	O
+may	O
+be	O
+associated	O
+with	O
+a	O
+high	O
+risk	O
+of	O
+developing	O
+severe	O
+infections	B-DISO
+.	O
+
+We	O
+describe	O
+the	O
+case	O
+of	O
+an	O
+8	O
+-	O
+month	O
+-	O
+old	O
+Caucasian	O
+girl	O
+affected	O
+by	O
+a	O
+severe	O
+form	O
+of	O
+autoimmune	B-DISO
+hemolytic	I-DISO
+anemia	I-DISO
+,	O
+which	O
+required	O
+continuous	O
+steroid	B-CHED
+treatment	O
+for	O
+16	O
+months	O
+.	O
+
+The	O
+pathophysiology	O
+of	O
+MAS	B-COMP
+is	O
+multifactorial	O
+and	O
+complex	O
+.	O
+
+In	O
+this	O
+article	O
+,	O
+we	O
+discuss	O
+the	O
+mechanical	O
+and	O
+chemical	O
+effects	O
+of	O
+meconium	B-ANAT
+on	O
+a	O
+newborn	O
+'	O
+s	O
+airway	B-ANAT
+,	O
+meconium	B-ANAT
+-	O
+induced	O
+inflammation	B-DISO
+,	O
+mediated	O
+by	O
+proinflammatory	O
+cytokines	O
+and	O
+chemokines	O
+,	O
+the	O
+complement	O
+system	O
+and	O
+the	O
+proinflammatory	O
+enzyme	O
+phospholipase	B-PRGE
+A2	I-PRGE
+.	O
+
+Finally	O
+,	O
+risk	O
+factors	O
+for	O
+MAS	B-COMP
+development	B-PROC
+to	O
+identify	O
+those	O
+newborns	O
+that	O
+develop	O
+MAS	B-COMP
+and	O
+those	O
+who	O
+do	O
+not	O
+are	O
+discussed	O
+.	O
+
+TITLE	O
+:	O
+Reverse	B-PROC
+transcription	I-PROC
+loop	O
+-	O
+mediated	O
+isothermal	O
+amplification	B-DISO
+for	O
+the	O
+rapid	O
+detection	O
+of	O
+infectious	B-DISO
+bronchitis	B-DISO
+virus	B-SPEC
+in	O
+infected	O
+chicken	B-SPEC
+tissues	B-ANAT
+.	O
+
+The	O
+sensitivity	O
+of	O
+RT	B-PRGE
+-	I-PRGE
+LAMP	I-PRGE
+and	O
+RT	O
+-	O
+PCR	O
+assays	O
+for	O
+detecting	O
+IBV	B-SPEC
+RNA	O
+in	O
+clinical	O
+specimens	O
+was	O
+99	O
+.	O
+5	O
+%	O
+and	O
+98	O
+.	O
+4	O
+%,	O
+respectively	O
+.	O
+
+TITLE	O
+:	O
+[	O
+Prophylactic	O
+ventilation	O
+of	O
+severely	O
+injured	O
+patients	O
+with	O
+thoracic	B-DISO
+trauma	O
+--	O
+does	O
+it	O
+always	O
+make	O
+sense	O
+?].	O
+
+The	O
+development	B-PROC
+and	O
+progression	O
+of	O
+ALI	O
+/	O
+ARDS	B-DISO
+may	O
+be	O
+triggered	O
+by	O
+various	O
+intrahospital	O
+exposures	O
+including	O
+but	O
+not	O
+limited	O
+to	O
+transfusion	O
+,	O
+aspiration	B-DISO
+,	O
+mechanical	O
+ventilation	O
+,	O
+certain	O
+medications	O
+and	O
+delayed	O
+treatment	O
+of	O
+shock	O
+and	O
+infection	B-DISO
+.	O
+
+NL63	O
+productively	O
+infects	O
+LLCMK2	O
+cells	B-COMP
+and	O
+ciliated	O
+epithelial	B-ANAT
+cells	I-ANAT
+of	O
+human	B-SPEC
+airway	B-ANAT
+cell	B-COMP
+cultures	O
+.	O
+
+Virus	B-PROC
+replication	I-PROC
+predominantly	O
+occurs	O
+on	O
+the	O
+rough	B-COMP
+endoplasmic	I-COMP
+reticulum	I-COMP
+(	O
+RER	B-COMP
+),	O
+both	O
+perinuclear	O
+and	O
+cytoplasmic	B-COMP
+,	O
+and	O
+the	O
+Golgi	B-COMP
+.	O
+
+Pleomorphic	O
+double	O
+membrane	B-COMP
+-	O
+bound	O
+vesicles	B-COMP
+(	O
+DMV	O
+),	O
+measuring	O
+roughly	O
+140	O
+to	O
+210	O
+nm	O
+in	O
+diameter	O
+,	O
+were	O
+observed	O
+.	O
+
+In	O
+summary	O
+,	O
+we	O
+report	O
+the	O
+key	O
+morphologic	O
+characteristics	O
+of	O
+NL63	O
+infection	B-DISO
+observed	O
+by	O
+TEM	B-COMP
+analysis	O
+.	O
+
+We	O
+now	O
+report	O
+that	O
+an	O
+HCoV	B-SPEC
+-	I-SPEC
+OC43	I-SPEC
+mutant	B-DISO
+harboring	O
+two	O
+persistence	O
+-	O
+associated	O
+S	O
+glycoprotein	B-CHED
+point	B-PROC
+mutations	I-PROC
+(	O
+H183R	O
+and	O
+Y241H	O
+),	O
+induced	O
+a	O
+stronger	O
+unfolded	O
+protein	B-CHED
+response	O
+(	O
+UPR	O
+)	O
+and	O
+translation	B-PROC
+attenuation	O
+in	O
+infected	O
+human	B-SPEC
+neurons	B-ANAT
+.	O
+
+There	O
+was	O
+a	O
+major	O
+contribution	O
+of	O
+the	O
+IRE1	B-PRGE
+/	O
+XBP1	B-PRGE
+pathway	B-PROC
+,	O
+followed	O
+by	O
+caspase	B-PRGE
+-	I-PRGE
+3	I-PRGE
+activation	O
+and	O
+nuclear	O
+fragmentation	B-DISO
+,	O
+with	O
+no	O
+significant	O
+role	O
+of	O
+the	O
+ATF6	B-PRGE
+and	O
+eIF2	B-PRGE
+-	I-PRGE
+alpha	I-PRGE
+/	O
+ATF4	B-PRGE
+pathways	B-PROC
+.	O
+
+The	O
+N176A	O
+,	O
+N237A	O
+,	O
+and	O
+N176A	O
+/	O
+N237A	O
+mutant	B-DISO
+viruses	B-SPEC
+were	O
+viable	O
+,	O
+and	O
+N176	O
+and	O
+N237	O
+were	O
+glycosylated	O
+during	O
+infection	B-DISO
+of	O
+wild	O
+-	O
+type	O
+(	O
+wt	O
+)	O
+and	O
+mutant	B-DISO
+viruses	B-SPEC
+.	O
+
+The	O
+results	O
+also	O
+support	O
+the	O
+conclusion	O
+that	O
+the	O
+structure	O
+of	O
+DMVs	O
+is	O
+essential	O
+for	O
+efficient	O
+RNA	B-PROC
+synthesis	I-PROC
+and	O
+optimal	O
+replication	O
+of	O
+coronaviruses	O
+.	O
+
+The	O
+disease	O
+is	O
+an	O
+acute	O
+,	O
+highly	O
+contagious	O
+enteric	O
+disease	O
+that	O
+is	O
+characterized	O
+by	O
+depression	B-DISO
+,	O
+anorexia	B-DISO
+,	O
+diarrhea	B-DISO
+,	O
+and	O
+high	O
+mortality	O
+in	O
+commercial	O
+turkey	B-SPEC
+flocks	O
+.	O
+
+TITLE	O
+:	O
+Characterization	O
+of	O
+new	O
+variants	O
+of	O
+avian	B-DISO
+infectious	I-DISO
+bronchitis	I-DISO
+virus	B-SPEC
+in	O
+Tunisia	O
+.	O
+
+Thereafter	O
+,	O
+six	O
+animals	B-SPEC
+were	O
+assigned	O
+randomly	O
+into	O
+angiotensin	B-PRGE
+-	I-PRGE
+converting	I-PRGE
+enzyme	I-PRGE
+2	I-PRGE
+group	O
+,	O
+whereas	O
+another	O
+six	O
+animals	B-SPEC
+served	O
+as	O
+control	O
+.	O
+
+Furthermore	O
+,	O
+angiotensin	B-PRGE
+II	I-PRGE
+and	O
+tumor	B-PRGE
+necrosis	I-PRGE
+factor	I-PRGE
+-	I-PRGE
+alpha	I-PRGE
+levels	O
+,	O
+both	O
+of	O
+which	O
+were	O
+substantially	O
+increased	O
+,	O
+returned	O
+to	O
+basal	O
+values	O
+.	O
+
+Here	O
+,	O
+we	O
+show	O
+that	O
+severe	O
+disease	O
+is	O
+correlated	O
+with	O
+slow	O
+kinetics	O
+of	O
+virus	B-SPEC
+clearance	O
+and	O
+delayed	O
+activation	O
+and	O
+transit	O
+of	O
+respiratory	O
+dendritic	B-ANAT
+cells	B-COMP
+(	O
+rDC	B-DISO
+)	O
+to	O
+the	O
+draining	O
+lymph	B-ANAT
+nodes	I-ANAT
+(	O
+DLN	O
+)	O
+with	O
+a	O
+consequent	O
+deficient	O
+virus	B-SPEC
+-	O
+specific	O
+T	B-ANAT
+cell	I-ANAT
+response	O
+.	O
+
+Inhibitory	O
+AMs	B-DISO
+are	O
+believed	O
+to	O
+prevent	O
+the	O
+development	B-PROC
+of	O
+immune	B-PROC
+responses	I-PROC
+to	O
+environmental	O
+antigens	B-CHED
+and	O
+allergic	O
+responses	O
+by	O
+interacting	O
+with	O
+lung	B-ANAT
+dendritic	B-COMP
+cells	I-ANAT
+and	O
+T	B-ANAT
+cells	I-ANAT
+.	O
+
+The	O
+inhibitory	O
+effects	O
+of	O
+AM	O
+can	O
+also	O
+be	O
+nullified	O
+if	O
+mice	B-SPEC
+or	O
+AMs	B-DISO
+are	O
+pretreated	O
+with	O
+poly	O
+I	O
+:	O
+C	O
+,	O
+which	O
+directly	O
+activate	O
+AMs	B-DISO
+and	O
+rDCs	O
+through	O
+toll	O
+-	O
+like	O
+receptors	O
+3	O
+(	O
+TLR3	B-PRGE
+).	O
+
+The	O
+infection	B-DISO
+largely	O
+mimicked	O
+human	B-SPEC
+disease	O
+,	O
+but	O
+lung	B-ANAT
+pathology	B-DISO
+lacked	O
+hyaline	B-DISO
+membrane	B-COMP
+formation	B-PROC
+.	O
+
+In	O
+vitro	O
+efficacy	O
+against	O
+v2163	O
+was	O
+shown	O
+with	O
+known	O
+inhibitors	B-CHED
+of	O
+SARS	B-DISO
+-	O
+CoV	O
+replication	O
+.	O
+
+In	O
+v2163	O
+-	O
+infected	O
+mice	B-SPEC
+,	O
+Ampligen	O
+was	O
+fully	O
+protective	O
+,	O
+stinging	B-PRGE
+nettle	I-PRGE
+lectin	I-PRGE
+(	O
+UDA	B-CHED
+)	O
+was	O
+partially	O
+protective	O
+,	O
+ribavirin	B-CHED
+was	O
+disputable	O
+and	O
+possibly	O
+exacerbated	O
+disease	O
+,	O
+and	O
+EP128533	O
+was	O
+inactive	O
+.	O
+
+Ribavirin	O
+,	O
+UDA	B-CHED
+,	O
+and	O
+Ampligen	O
+decreased	O
+IL	B-FUNC
+-	I-FUNC
+6	I-FUNC
+expression	B-PROC
+.	O
+
+TITLE	O
+:	O
+[	O
+Pneumonia	B-DISO
+and	O
+the	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+due	O
+to	O
+influenza	B-PATH
+A	I-PATH
+(	O
+H1N1	O
+)	O
+virus	B-SPEC
+].	O
+
+We	O
+present	O
+a	O
+case	O
+of	O
+ARDS	B-DISO
+secondary	O
+to	O
+infection	B-DISO
+with	O
+the	O
+influenza	B-PATH
+A	I-PATH
+(	O
+H1N1	O
+)	O
+virus	B-SPEC
+.	O
+
+By	O
+comparing	O
+and	O
+contrasting	O
+the	O
+outcomes	O
+of	O
+an	O
+emerging	O
+infection	B-DISO
+with	O
+those	O
+of	O
+closely	O
+related	O
+pathogens	O
+in	O
+different	O
+but	O
+related	O
+host	B-COMP
+species	B-SPEC
+,	O
+we	O
+can	O
+further	O
+delineate	O
+the	O
+various	O
+host	B-COMP
+pathways	B-PROC
+determining	O
+the	O
+outcome	O
+of	O
+zoonotic	O
+transmission	O
+and	O
+adaptation	B-PROC
+to	O
+the	O
+newly	O
+invaded	O
+species	B-SPEC
+.	O
+
+Thus	O
+,	O
+young	O
+piglets	O
+,	O
+growing	O
+16	O
+-	O
+20	O
+-	O
+week	O
+-	O
+old	O
+finisher	O
+pigs	B-SPEC
+,	O
+and	O
+mature	O
+third	O
+parity	O
+sows	O
+were	O
+infected	O
+with	O
+virulent	O
+or	O
+attenuated	O
+PRRSV	B-SPEC
+,	O
+and	O
+the	O
+dynamics	O
+of	O
+viral	B-DISO
+infection	I-DISO
+,	O
+disease	O
+,	O
+and	O
+immune	B-PROC
+response	I-PROC
+were	O
+monitored	O
+over	O
+time	O
+.	O
+
+Prolonged	O
+infection	B-DISO
+was	O
+not	O
+due	O
+to	O
+IL	B-FUNC
+-	I-FUNC
+10	I-FUNC
+-	O
+mediated	O
+immunosuppression	B-PROC
+,	O
+and	O
+PRRSV	B-SPEC
+did	O
+not	O
+elicit	O
+a	O
+specific	O
+IFN	B-PRGE
+gamma	I-PRGE
+response	O
+,	O
+especially	O
+in	O
+non	O
+-	O
+adult	O
+animals	B-SPEC
+.	O
+
+While	O
+mAb	O
+341C	O
+binds	B-FUNC
+to	O
+a	O
+mostly	O
+linear	O
+epitope	B-CHED
+composed	O
+of	O
+residues	O
+(	O
+507	O
+)	O
+PAT	B-DISO
+(	O
+509	O
+)	O
+and	O
+V	O
+(	O
+349	O
+),	O
+mAb	O
+240C	O
+binds	O
+to	O
+an	O
+epitope	B-CHED
+that	O
+partially	O
+overlaps	O
+the	O
+former	O
+by	O
+at	O
+least	O
+two	O
+residues	O
+(	O
+P	O
+(	O
+507	O
+)	O
+and	O
+A	O
+(	O
+508	O
+)).	O
+
+TITLE	O
+:	O
+Differential	O
+downregulation	B-PROC
+of	O
+ACE2	B-PRGE
+by	O
+the	O
+spike	O
+proteins	B-CHED
+of	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+coronavirus	B-SPEC
+and	O
+human	B-SPEC
+coronavirus	I-SPEC
+NL63	I-SPEC
+.	O
+
+However	O
+,	O
+the	O
+experiences	O
+of	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+survivors	O
+have	O
+not	O
+been	O
+reported	O
+.	O
+
+Caregivers	O
+'	O
+interviews	O
+revealed	O
+substantial	O
+strain	O
+from	O
+caregiving	O
+responsibilities	O
+as	O
+well	O
+as	O
+frequent	O
+symptom	B-DISO
+minimization	O
+by	O
+patients	O
+.	O
+
+Usually	O
+,	O
+RdRp	B-FUNC
+domains	O
+are	O
+readily	O
+identifiable	O
+by	O
+comparative	O
+sequence	O
+analysis	O
+,	O
+but	O
+biochemical	O
+confirmation	O
+and	O
+characterization	O
+can	O
+be	O
+hampered	O
+by	O
+intrinsic	O
+protein	B-CHED
+properties	O
+and	O
+technical	O
+complications	O
+.	O
+
+ABSTRACT	O
+:	O
+To	O
+unscramble	O
+the	O
+relationship	O
+between	O
+protein	O
+function	O
+and	O
+protein	B-CHED
+structure	O
+,	O
+it	O
+is	O
+essential	O
+to	O
+assess	O
+the	O
+protein	B-CHED
+similarity	O
+from	O
+different	O
+aspects	O
+.	O
+
+TITLE	O
+:	O
+Acute	B-DISO
+post	I-DISO
+-	I-DISO
+streptococcal	I-DISO
+glomerulonephritis	I-DISO
+in	O
+children	O
+of	O
+French	O
+Polynesia	O
+:	O
+a	O
+3	O
+-	O
+year	O
+retrospective	O
+study	O
+.	O
+
+Acute	B-DISO
+post	I-DISO
+-	I-DISO
+streptococcal	I-DISO
+glomerulonephritis	I-DISO
+is	O
+endemic	O
+among	O
+French	O
+Polynesians	O
+,	O
+and	O
+they	O
+can	O
+be	O
+considered	O
+to	O
+be	O
+a	O
+high	O
+-	O
+risk	O
+population	O
+.	O
+
+TITLE	O
+:	O
+An	O
+ELISA	O
+based	O
+on	O
+recombinant	O
+spike	O
+protein	B-CHED
+S	O
+for	O
+the	O
+detection	O
+of	O
+antibodies	B-COMP
+to	O
+transmissible	O
+gastroenteritis	O
+virus	B-SPEC
+of	O
+swine	B-SPEC
+-	O
+like	O
+canine	O
+coronaviruses	O
+.	O
+
+However	O
+,	O
+female	O
+and	O
+male	O
+mice	B-SPEC
+that	O
+received	O
+the	O
+high	O
+dose	O
+experienced	O
+a	O
+16	O
+%	O
+and	O
+8	O
+%	O
+incidence	O
+,	O
+respectively	O
+,	O
+of	O
+fatal	O
+pulmonary	B-DISO
+hemorrhage	I-DISO
+.	O
+
+This	O
+study	O
+established	O
+a	O
+safe	O
+dose	O
+range	O
+and	O
+demonstrated	O
+the	O
+feasibility	O
+of	O
+prolonged	O
+,	O
+repeated	O
+dosing	O
+of	O
+pf	O
+-	O
+tPA	B-FUNC
+.	O
+
+High	O
+doses	O
+(>	O
+or	O
+=	O
+1mg	O
+/	O
+kg	O
+/	O
+d	O
+)	O
+were	O
+associated	O
+with	O
+pulmonary	B-DISO
+hemorrhage	I-DISO
+that	O
+may	O
+be	O
+due	O
+,	O
+in	O
+part	O
+,	O
+to	O
+accumulation	O
+of	O
+drug	O
+in	O
+the	O
+lungs	B-ANAT
+.	O
+
+The	O
+use	O
+of	O
+NIPPV	O
+in	O
+vivax	O
+-	O
+malaria	B-PATH
+related	O
+ARDS	B-DISO
+was	O
+associated	O
+with	O
+a	O
+good	O
+outcome	O
+.	O
+
+In	O
+patients	O
+with	O
+cirrhosis	B-DISO
+and	O
+spontaneous	B-DISO
+bacterial	I-DISO
+peritonitis	I-DISO
+(	O
+SBP	O
+),	O
+early	O
+use	O
+of	O
+antibiotics	B-CHED
+and	O
+intravenous	O
+albumin	B-PRGE
+administration	O
+decreases	O
+the	O
+risk	O
+for	O
+developing	O
+renal	B-DISO
+failure	I-DISO
+and	O
+improves	O
+survival	O
+.	O
+
+These	O
+treatments	O
+include	O
+recombinant	O
+human	B-SPEC
+activated	O
+C	B-PRGE
+protein	I-PRGE
+and	O
+protective	O
+-	O
+ventilation	O
+strategy	O
+for	O
+respiratory	B-DISO
+failure	I-DISO
+.	O
+
+Other	O
+treatments	O
+should	O
+be	O
+evaluated	O
+in	O
+the	O
+cirrhotic	O
+population	O
+with	O
+severe	B-DISO
+sepsis	I-DISO
+including	O
+the	O
+early	O
+use	O
+of	O
+antibiotics	B-CHED
+in	O
+""""	O
+non	O
+-	O
+SBP	O
+""""	O
+infections	B-DISO
+,	O
+vasopressor	O
+therapy	O
+,	O
+hydrocortisone	B-CHED
+,	O
+renal	B-ANAT
+-	O
+replacement	O
+therapy	O
+and	O
+liver	B-ANAT
+support	O
+systems	O
+,	O
+and	O
+selective	O
+decontamination	O
+of	O
+the	O
+digestive	B-ANAT
+tract	I-ANAT
+or	O
+oropharynx	B-ANAT
+.	O
+
+TITLE	O
+:	O
+The	O
+open	O
+reading	O
+frame	O
+3a	O
+protein	B-CHED
+of	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+-	O
+associated	O
+coronavirus	B-SPEC
+promotes	O
+membrane	B-COMP
+rearrangement	B-PROC
+and	O
+cell	B-PROC
+death	I-PROC
+.	O
+
+We	O
+investigated	O
+the	O
+functions	O
+of	O
+the	O
+largest	O
+of	O
+the	O
+accessory	O
+proteins	B-CHED
+,	O
+the	O
+ORF	B-PRGE
+3a	I-PRGE
+protein	I-PRGE
+,	O
+using	O
+a	O
+3a	O
+-	O
+deficient	O
+strain	O
+of	O
+SARS	B-DISO
+-	O
+CoV	O
+.	O
+Cell	B-PROC
+death	I-PROC
+of	O
+Vero	B-ANAT
+cells	I-ANAT
+after	O
+infection	B-DISO
+with	O
+SARS	B-DISO
+-	O
+CoV	O
+was	O
+reduced	O
+upon	O
+deletion	O
+of	O
+ORF	B-PRGE
+3a	I-PRGE
+.	O
+
+In	O
+addition	O
+,	O
+we	O
+report	O
+that	O
+ORF	B-PRGE
+3a	I-PRGE
+is	O
+both	O
+necessary	O
+and	O
+sufficient	O
+for	O
+SARS	B-DISO
+-	O
+CoV	O
+-	O
+induced	O
+Golgi	B-COMP
+fragmentation	B-DISO
+and	O
+that	O
+the	O
+3a	O
+protein	B-CHED
+accumulates	O
+and	O
+localizes	O
+to	O
+vesicles	O
+containing	O
+markers	O
+for	O
+late	O
+endosomes	O
+.	O
+
+Most	O
+cats	B-SPEC
+with	O
+FIP	B-DISO
+had	O
+no	O
+detectable	O
+intestinal	B-ANAT
+feline	B-SPEC
+coronaviruses	O
+(	O
+FCoVs	O
+)	O
+and	O
+had	O
+seemingly	O
+cleared	O
+the	O
+primary	O
+FECV	B-SPEC
+infection	B-DISO
+.	O
+
+However	O
+,	O
+human	B-SPEC
+migration	B-PROC
+has	O
+occurred	O
+for	O
+centuries	O
+and	O
+will	O
+continue	O
+,	O
+despite	O
+the	O
+threats	O
+posed	O
+by	O
+microbes	O
+.	O
+
+Other	O
+medical	O
+concerns	O
+include	O
+recurrent	O
+oral	B-ANAT
+staphylococcal	B-DISO
+infections	I-DISO
+,	O
+otitis	B-DISO
+media	I-DISO
+,	O
+ocular	B-DISO
+herpes	B-SPEC
+simplex	I-SPEC
+virus	I-SPEC
+keratitis	B-DISO
+,	O
+asthma	B-PATH
+,	O
+steroid	B-CHED
+-	O
+induced	O
+gastritis	B-DISO
+,	O
+steroid	B-CHED
+-	O
+induced	O
+cataracts	B-DISO
+,	O
+recurrent	O
+upper	B-DISO
+respiratory	I-DISO
+infections	I-DISO
+,	O
+and	O
+acute	B-DISO
+pharyngitis	I-DISO
+.	O
+
+DNA	O
+sequencing	O
+showed	O
+a	O
+novel	O
+signal	B-PRGE
+transducer	I-PRGE
+and	I-PRGE
+activator	I-PRGE
+of	I-PRGE
+transcription	I-PRGE
+3	I-PRGE
+(	O
+STAT3	B-PRGE
+)	O
+gene	B-PROC
+mutation	I-PROC
+within	O
+intron	O
+12	O
+,	O
+specifically	O
+adenine	O
+to	O
+cytosine	B-CHED
+,	O
+two	O
+base	B-FUNC
+pairs	I-FUNC
+upstream	O
+of	O
+exon	O
+13	O
+.	O
+
+PTSD	B-DISO
+occurs	O
+in	O
+a	O
+significant	O
+percentage	O
+of	O
+subjects	O
+who	O
+recover	B-PROC
+from	O
+SARS	B-DISO
+,	O
+and	O
+the	O
+occurrence	O
+of	O
+PTSD	B-DISO
+predicts	O
+persistent	O
+psychological	B-DISO
+distress	I-DISO
+and	O
+diminished	O
+social	O
+functioning	O
+in	O
+the	O
+4	O
+years	O
+after	O
+SARS	B-DISO
+treatment	O
+.	O
+
+TITLE	O
+:	O
+Community	O
+-	O
+acquired	O
+methicillin	B-DISO
+-	I-DISO
+resistant	I-DISO
+Staphylococcus	B-SPEC
+aureus	I-SPEC
+pneumonia	B-DISO
+and	O
+ARDS	B-DISO
+:	O
+1	O
+-	O
+year	O
+follow	O
+-	O
+up	O
+.	O
+
+Migration	B-PROC
+of	O
+PMNs	O
+to	O
+the	O
+CNS	B-CHED
+coincided	O
+with	O
+increased	O
+expression	B-PROC
+of	O
+transcripts	O
+specific	O
+for	O
+the	O
+CXCR2	B-PRGE
+ELR	I-PRGE
+-	O
+positive	O
+chemokine	O
+ligands	O
+CXCL1	B-PRGE
+,	O
+CXCL2	B-PRGE
+,	O
+and	O
+CXCL5	B-PRGE
+within	O
+the	O
+brain	B-ANAT
+.	O
+
+Treatment	O
+of	O
+JHMV	O
+-	O
+infected	O
+mice	B-SPEC
+with	O
+anti	B-PRGE
+-	I-PRGE
+CXCR2	I-PRGE
+blocking	I-PRGE
+antibody	B-COMP
+reduced	O
+PMN	B-PROC
+trafficking	B-PROC
+into	O
+the	O
+CNS	B-CHED
+by	O
+>	O
+95	O
+%,	O
+dampened	O
+MMP	B-PROC
+-	I-PROC
+9	I-PROC
+activity	I-PROC
+,	O
+and	O
+abrogated	O
+blood	B-ANAT
+-	O
+brain	B-ANAT
+-	O
+barrier	O
+(	O
+BBB	B-CHED
+)	O
+breakdown	B-DISO
+.	O
+
+We	O
+then	O
+investigate	O
+the	O
+novel	O
+and	O
+exciting	O
+possibilities	O
+of	O
+targeting	B-PROC
+tetraspanins	O
+for	O
+the	O
+treatment	O
+of	O
+infectious	B-DISO
+disease	I-DISO
+,	O
+using	O
+specific	O
+antibodies	B-COMP
+,	O
+recombinant	O
+EC2	O
+domains	O
+,	O
+small	O
+-	O
+molecule	O
+mimetics	O
+,	O
+and	O
+small	O
+interfering	O
+RNA	O
+.	O
+
+TITLE	O
+:	O
+Corticosteroid	B-CHED
+therapy	O
+for	O
+acute	O
+lung	B-ANAT
+injury	O
+,	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+,	O
+and	O
+severe	O
+pneumonia	O
+:	O
+a	O
+meta	B-SPEC
+-	O
+analysis	O
+of	O
+randomized	O
+controlled	O
+trials	O
+.	O
+
+For	O
+each	O
+outcome	O
+,	O
+we	O
+used	O
+Grading	O
+of	O
+Recommendations	O
+Assessments	O
+,	O
+Development	B-PROC
+and	O
+Evaluation	O
+(	O
+GRADE	O
+)	O
+criteria	O
+to	O
+evaluate	O
+the	O
+quality	O
+of	O
+the	O
+underlying	O
+evidence	O
+.	O
+
+The	O
+drowning	O
+especially	O
+took	O
+place	O
+in	O
+fresh	B-ANAT
+water	B-CHED
+(	O
+71	O
+%),	O
+particularly	O
+in	O
+swimming	B-PROC
+pools	O
+(	O
+51	O
+.	O
+8	O
+%).	O
+
+ABSTRACT	O
+:	O
+We	O
+analyzed	O
+antibody	B-PROC
+responses	I-PROC
+in	O
+sera	B-COMP
+from	O
+feline	B-SPEC
+immunodeficiency	I-SPEC
+virus	I-SPEC
+(	O
+FIV	B-SPEC
+)-	O
+infected	O
+and	O
+uninfected	O
+cats	B-SPEC
+.	O
+
+ABSTRACT	O
+:	O
+Persistent	B-DISO
+infection	I-DISO
+of	O
+domestic	B-SPEC
+cats	I-SPEC
+with	O
+feline	B-SPEC
+coronaviruses	O
+(	O
+FCoVs	O
+)	O
+can	O
+lead	O
+to	O
+a	O
+highly	O
+lethal	O
+,	O
+immunopathological	O
+disease	O
+termed	O
+feline	B-DISO
+infectious	I-DISO
+peritonitis	I-DISO
+(	O
+FIP	B-DISO
+).	O
+
+Type	O
+II	O
+FCoVs	O
+can	O
+be	O
+propagated	O
+to	O
+high	O
+titers	O
+by	O
+employing	O
+feline	B-PRGE
+aminopeptidase	B-ENZY
+N	I-ENZY
+(	O
+fAPN	O
+)	O
+as	O
+a	O
+cellular	B-COMP
+receptor	O
+,	O
+whereas	O
+the	O
+propagation	O
+of	O
+type	B-PRGE
+I	I-PRGE
+FCoVs	I-PRGE
+is	O
+usually	O
+difficult	O
+,	O
+and	O
+the	O
+involvement	O
+of	O
+fAPN	B-PRGE
+as	I-PRGE
+a	I-PRGE
+receptor	I-PRGE
+is	O
+controversial	O
+.	O
+
+We	O
+also	O
+observed	O
+that	O
+recombinant	O
+FCoVs	O
+display	O
+a	O
+large	O
+-	O
+plaque	B-DISO
+phenotype	O
+and	O
+,	O
+unexpectedly	O
+,	O
+accelerated	O
+growth	B-PROC
+kinetics	O
+indistinguishable	O
+from	O
+that	O
+of	O
+type	B-PRGE
+II	I-PRGE
+FCoV	I-PRGE
+strain	O
+79	O
+-	O
+1146	O
+.	O
+
+By	O
+day	O
+7	O
+,	O
+histopathologic	O
+evidence	O
+of	O
+pneumonitis	B-DISO
+was	O
+seen	O
+in	O
+the	O
+lungs	B-ANAT
+when	O
+viral	O
+clearance	O
+occurred	O
+.	O
+
+ABSTRACT	O
+:	O
+Over	O
+the	O
+past	O
+30	O
+years	O
+,	O
+several	O
+cross	O
+-	O
+species	O
+transmission	O
+events	O
+,	O
+as	O
+well	O
+as	O
+changes	O
+in	O
+virus	B-SPEC
+tropism	B-PROC
+,	O
+have	O
+mediated	O
+significant	O
+animal	B-SPEC
+and	O
+human	B-SPEC
+diseases	O
+.	O
+
+TITLE	O
+:	O
+Pulmonary	B-ANAT
+fibrosis	I-DISO
+induced	O
+by	O
+H5N1	B-DISO
+viral	B-DISO
+infection	I-DISO
+in	O
+mice	B-SPEC
+.	O
+
+At	O
+acute	O
+stage	O
+,	O
+infected	O
+-	O
+mice	B-SPEC
+showed	O
+typical	O
+diffuse	O
+pneumonia	B-DISO
+with	O
+inflammatory	O
+cellular	B-PROC
+infiltration	B-DISO
+,	O
+alveolar	B-ANAT
+and	O
+interstitial	B-DISO
+edema	I-DISO
+and	O
+hemorrhage	B-DISO
+on	O
+day	O
+7	O
+postinoculation	O
+.	O
+
+At	O
+restoration	O
+stage	O
+,	O
+most	O
+infected	O
+-	O
+mice	B-SPEC
+developed	O
+PF	O
+of	O
+different	O
+severities	O
+on	O
+day	O
+30	O
+postinoculation	O
+,	O
+and	O
+18	O
+%	O
+of	O
+the	O
+survived	O
+mice	B-SPEC
+underwent	O
+severe	O
+interstitial	B-ANAT
+and	O
+intra	O
+-	O
+alveolar	B-ANAT
+fibrosis	B-DISO
+with	O
+thickened	O
+alveolar	B-ANAT
+walls	O
+,	O
+collapsed	O
+alveoli	B-ANAT
+and	O
+large	O
+fibrotic	O
+areas	O
+.	O
+
+The	O
+dry	O
+lung	B-ANAT
+-	O
+to	O
+-	O
+body	B-ANAT
+weight	O
+ratio	O
+was	O
+significantly	O
+increased	O
+in	O
+infected	O
+group	O
+,	O
+which	O
+might	O
+be	O
+associated	O
+with	O
+the	O
+formation	B-PROC
+of	O
+PF	O
+in	O
+H5N1	B-DISO
+-	O
+infected	O
+mice	B-SPEC
+.	O
+
+Treatment	O
+of	O
+the	O
+rabbits	B-SPEC
+with	O
+a	O
+humanized	B-PRGE
+anti	I-PRGE
+-	I-PRGE
+CXCL8	I-PRGE
+antibody	I-PRGE
+prevented	O
+neutrophil	B-ANAT
+infiltration	B-DISO
+in	O
+the	O
+lung	B-ANAT
+in	O
+association	O
+with	O
+alleviated	O
+ALI	O
+syndrome	B-DISO
+.	O
+
+Many	O
+intrahospital	O
+exposures	O
+,	O
+including	O
+aspiration	B-DISO
+,	O
+delayed	O
+resuscitation	O
+,	O
+high	O
+tidal	O
+volume	O
+mechanical	O
+ventilation	O
+and	O
+non	O
+critical	O
+use	O
+of	O
+transfusions	O
+may	O
+contribute	O
+or	O
+worsen	O
+ARDS	B-DISO
+.	O
+
+TITLE	O
+:	O
+Serosurvey	O
+of	O
+selected	O
+viruses	B-SPEC
+in	O
+captive	O
+giant	B-SPEC
+pandas	B-DISO
+(	O
+Ailuropoda	B-SPEC
+melanoleuca	I-SPEC
+)	O
+in	O
+China	O
+.	O
+
+ABSTRACT	O
+:	O
+Serum	O
+samples	O
+from	O
+92	O
+giant	B-SPEC
+pandas	B-DISO
+in	O
+three	O
+captive	O
+facilities	O
+were	O
+tested	O
+for	O
+antibodies	B-COMP
+against	O
+five	O
+viruses	B-SPEC
+of	O
+carnivores	B-SPEC
+.	O
+
+ABSTRACT	O
+:	O
+Severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+(	O
+SARS	B-DISO
+),	O
+caused	O
+by	O
+the	O
+coronavirus	B-SPEC
+SARS	B-DISO
+-	O
+CoV	O
+,	O
+is	O
+an	O
+acute	B-DISO
+infectious	I-DISO
+disease	I-DISO
+with	O
+significant	O
+mortality	O
+.	O
+
+A	O
+typical	O
+clinical	O
+feature	O
+associated	O
+with	O
+SARS	B-DISO
+is	O
+pulmonary	B-DISO
+fibrosis	I-DISO
+and	O
+associated	O
+lung	B-ANAT
+failure	O
+.	O
+
+A	O
+specific	O
+one	O
+-	O
+step	O
+real	O
+-	O
+time	O
+reverse	B-PROC
+transcription	I-PROC
+-	O
+polymerase	O
+chain	O
+reaction	O
+(	O
+RRT	O
+-	O
+PCR	O
+)	O
+assay	O
+for	O
+detection	O
+and	O
+quantitation	O
+of	O
+TCoV	O
+in	O
+the	O
+turkey	B-SPEC
+tissues	B-ANAT
+was	O
+developed	O
+using	O
+a	O
+dual	O
+-	O
+labeled	O
+fluorescent	B-CHED
+probe	I-CHED
+.	O
+
+The	O
+assay	O
+was	O
+highly	O
+sensitive	O
+and	O
+could	O
+quantitate	O
+between	O
+10	O
+(	O
+2	O
+)	O
+and	O
+10	O
+(	O
+10	O
+)	O
+copies	O
+/	O
+microl	O
+of	O
+viral	B-COMP
+genome	I-COMP
+.	O
+
+TITLE	O
+:	O
+[	O
+Dose	O
+of	O
+glucocorticosteroids	O
+in	O
+the	O
+treatment	O
+of	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+].	O
+
+Glococoticostecoids	O
+were	O
+used	O
+in	O
+59	O
+.	O
+56	O
+%	O
+of	O
+the	O
+SARS	B-DISO
+cases	O
+.	O
+
+In	O
+order	B-SPEC
+to	O
+gain	O
+insight	O
+into	O
+the	O
+molecular	O
+basis	O
+of	O
+protease	O
+cleavage	B-PROC
+and	O
+its	O
+impact	O
+on	O
+the	O
+efficiency	O
+of	O
+viral	O
+entry	O
+,	O
+we	O
+investigated	O
+the	O
+susceptibility	O
+of	O
+a	O
+recombinant	O
+native	O
+full	O
+-	O
+length	O
+S	O
+-	O
+protein	B-CHED
+trimer	O
+(	O
+triSpike	O
+)	O
+of	O
+the	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+coronavirus	B-SPEC
+(	O
+SARS	B-DISO
+-	O
+CoV	O
+)	O
+to	O
+cleavage	B-PROC
+by	O
+various	O
+airway	B-ANAT
+proteases	O
+.	O
+
+The	O
+R667A	O
+SARS	B-DISO
+-	O
+CoVpp	O
+mutant	B-DISO
+exhibited	O
+a	O
+lack	O
+of	O
+virus	B-SPEC
+entry	O
+enhancement	O
+following	O
+protease	O
+treatment	O
+.	O
+
+TITLE	O
+:	O
+H1N1	B-DISO
+influenza	I-DISO
+A	O
+virus	O
+-	O
+associated	O
+acute	O
+lung	B-ANAT
+injury	O
+:	O
+response	O
+to	O
+combination	O
+oseltamivir	B-CHED
+and	O
+prolonged	O
+corticosteroid	O
+treatment	O
+.	O
+
+RESULTS	O
+:	O
+Patients	O
+with	O
+and	O
+without	O
+confirmed	O
+H1N1	B-DISO
+influenza	I-DISO
+had	O
+similar	O
+disease	O
+severity	O
+at	O
+presentation	O
+and	O
+a	O
+comparable	O
+response	O
+to	O
+treatment	O
+.	O
+
+At	O
+auscultation	O
+of	O
+the	O
+chest	B-ANAT
+fine	O
+rales	B-DISO
+were	O
+heard	O
+over	O
+both	O
+lungs	B-ANAT
+with	O
+diminished	O
+percussion	O
+sounds	O
+basal	O
+.	O
+
+An	O
+antifungal	B-CHED
+and	O
+antiviral	B-CHED
+treatment	O
+(	O
+voriconazol	O
+,	O
+oseltamivir	B-CHED
+)	O
+was	O
+started	O
+and	O
+a	O
+cortisone	B-CHED
+pulse	B-PROC
+was	O
+attempted	O
+.	O
+
+This	O
+syndrome	B-DISO
+is	O
+most	O
+frequently	O
+associated	O
+with	O
+hematopoietic	B-DISO
+malignancies	I-DISO
+with	O
+a	O
+high	O
+growth	B-PROC
+fraction	O
+,	O
+including	O
+acute	B-DISO
+leukemias	I-DISO
+and	O
+lymphomas	B-DISO
+,	O
+but	O
+can	O
+be	O
+encountered	O
+in	O
+patients	O
+with	O
+nonhematopoietic	O
+solid	B-DISO
+tumors	I-DISO
+.	O
+
+Recombinant	B-PRGE
+urate	I-PRGE
+oxidase	I-PRGE
+(	O
+rasburicase	O
+)	O
+is	O
+a	O
+newer	O
+agent	O
+that	O
+directly	O
+cleaves	O
+uric	O
+acid	O
+.	O
+
+In	O
+dogs	B-SPEC
+,	O
+infectious	B-DISO
+respiratory	B-DISO
+disease	I-DISO
+is	O
+a	O
+common	O
+problem	O
+,	O
+particularly	O
+in	O
+housed	O
+animals	B-SPEC
+.	O
+
+TITLE	O
+:	O
+Update	O
+on	O
+cutaneous	O
+manifestations	O
+of	O
+infectious	B-DISO
+diseases	I-DISO
+.	O
+
+Real	O
+-	O
+time	O
+reverse	B-PRGE
+transcriptase	I-PRGE
+-	O
+polymerase	O
+chain	O
+reaction	O
+of	O
+respiratory	B-ANAT
+sample	I-ANAT
+for	O
+novel	O
+H1N1	O
+virus	B-SPEC
+revealed	O
+positive	O
+results	O
+.	O
+
+The	O
+ICU	O
+cohort	O
+of	O
+47	O
+influenza	B-DISO
+patients	O
+had	O
+a	O
+median	O
+age	O
+of	O
+34	O
+years	O
+,	O
+Acute	O
+Physiology	O
+and	O
+Chronic	O
+Health	O
+Evaluation	O
+II	O
+score	O
+of	O
+21	O
+,	O
+and	O
+BMI	O
+of	O
+35	O
+kg	O
+/	O
+m2	O
+.	O
+
+All	O
+eight	O
+deaths	B-PROC
+occurred	O
+among	O
+the	O
+64	O
+%	O
+of	O
+patients	O
+(	O
+n	O
+=	O
+30	O
+)	O
+with	O
+ARDS	B-DISO
+,	O
+26	O
+(	O
+87	O
+%)	O
+of	O
+whom	O
+also	O
+developed	O
+multiorgan	B-DISO
+failure	I-DISO
+.	O
+
+Severe	O
+ARDS	B-DISO
+with	O
+multiorgan	O
+dysfunction	O
+in	O
+the	O
+absence	O
+of	O
+bacterial	B-DISO
+infection	I-DISO
+was	O
+a	O
+common	O
+clinical	O
+presentation	O
+.	O
+
+In	O
+this	O
+study	O
+,	O
+we	O
+assessed	O
+the	O
+pathogenic	O
+and	O
+antigenic	O
+characteristics	O
+of	O
+a	O
+K	O
+-	O
+IIb	O
+type	O
+field	O
+strain	O
+of	O
+IBV	B-SPEC
+that	O
+emerged	O
+in	O
+Korea	O
+since	O
+2003	O
+,	O
+such	O
+as	O
+Kr	O
+/	O
+Q43	O
+/	O
+06	O
+.	O
+
+This	O
+report	O
+is	O
+the	O
+first	O
+to	O
+document	O
+the	O
+emergence	O
+of	O
+a	O
+new	O
+antigenic	O
+variant	O
+of	O
+nephropathogenic	O
+IBV	O
+in	O
+chicken	B-SPEC
+from	O
+Korea	O
+.	O
+
+Fluid	O
+management	O
+optimization	O
+and	O
+prevention	O
+of	O
+inflammation	O
+and	O
+lung	B-ANAT
+stretching	O
+are	O
+currently	O
+recommended	O
+for	O
+the	O
+treatment	O
+of	O
+acute	O
+lung	B-ANAT
+and	O
+renal	B-ANAT
+injury	O
+.	O
+
+It	O
+can	O
+be	O
+concluded	O
+from	O
+the	O
+present	O
+study	O
+that	O
+vaccination	O
+with	O
+a	O
+live	O
+M	B-SPEC
+.	I-SPEC
+synoviae	I-SPEC
+vaccine	O
+reduces	O
+the	O
+occurrence	O
+of	O
+M	B-SPEC
+.	I-SPEC
+synoviae	I-SPEC
+-	O
+induced	O
+EAA	O
+significantly	O
+.	O
+
+The	O
+resultant	O
+subset	O
+was	O
+greater	O
+than	O
+98	O
+%	O
+homogeneous	O
+in	O
+regards	O
+to	O
+the	O
+selected	O
+phenotype	O
+and	O
+contained	O
+the	O
+preponderance	O
+of	O
+individuals	O
+secreting	B-PROC
+IFN	B-PRGE
+-	I-PRGE
+alpha	I-PRGE
+after	O
+exposure	O
+to	O
+a	O
+known	O
+stimulant	O
+,	O
+transmissible	O
+gastroenteritis	B-DISO
+virus	B-SPEC
+(	O
+TGEV	B-SPEC
+).	O
+
+While	O
+a	O
+substantial	O
+IFN	B-PRGE
+-	I-PRGE
+alpha	I-PRGE
+response	O
+was	O
+also	O
+elicited	O
+from	O
+the	O
+porcine	B-SPEC
+pDCs	O
+by	O
+pseudorabies	B-SPEC
+virus	I-SPEC
+(	O
+PrV	B-DISO
+),	O
+swine	B-SPEC
+influenza	I-SPEC
+virus	I-SPEC
+(	O
+SIV	B-DISO
+),	O
+and	O
+TLR7	O
+and	O
+9	O
+agonists	B-CHED
+,	O
+there	O
+was	O
+an	O
+agent	O
+-	O
+dependent	O
+induction	O
+of	O
+varying	O
+amounts	O
+of	O
+IL	B-FUNC
+-	I-FUNC
+2	I-FUNC
+,	O
+IL	B-FUNC
+-	I-FUNC
+6	I-FUNC
+,	O
+IL	B-FUNC
+-	I-FUNC
+8	I-FUNC
+,	O
+IL	B-FUNC
+-	I-FUNC
+12	I-FUNC
+,	O
+IFN	B-PRGE
+-	I-PRGE
+gamma	I-PRGE
+,	O
+and	O
+TNF	B-PRGE
+-	I-PRGE
+alpha	I-PRGE
+.	O
+
+TITLE	O
+:	O
+Evidence	O
+lost	B-CHED
+to	O
+treatment	O
+of	O
+critically	O
+-	O
+ill	B-DISO
+patients	O
+?	O
+
+Along	O
+with	O
+grading	O
+the	O
+available	O
+evidence	O
+,	O
+implementing	O
+new	O
+therapies	O
+and	O
+strategies	O
+in	O
+daily	O
+practice	O
+is	O
+another	O
+important	O
+but	O
+frequently	O
+forgotten	O
+step	O
+in	O
+improving	O
+care	O
+for	O
+critically	O
+-	O
+ill	B-DISO
+patients	O
+.	O
+
+TITLE	O
+:	O
+Lung	B-ANAT
+parenchyma	I-ANAT
+remodeling	O
+in	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+.	O
+
+Factors	O
+influencing	O
+progression	O
+to	O
+fibroproliferative	O
+ARDS	B-DISO
+versus	O
+resolution	O
+and	O
+reconstitution	O
+of	O
+the	O
+normal	O
+pulmonary	B-ANAT
+parenchymal	O
+architecture	O
+are	O
+poorly	O
+understood	O
+.	O
+
+Abnormal	O
+repair	B-PROC
+and	O
+remodeling	O
+may	O
+be	O
+profoundly	O
+affected	O
+by	O
+both	O
+environmental	O
+and	O
+genetic	O
+factors	O
+.	O
+
+In	O
+this	O
+review	O
+,	O
+we	O
+explore	O
+recent	O
+advances	O
+in	O
+the	O
+field	O
+of	O
+fibroproliferative	O
+ARDS	B-DISO
+/	O
+ALI	O
+,	O
+with	O
+special	O
+emphasis	O
+on	O
+1	O
+)	O
+the	O
+physiological	O
+properties	O
+of	O
+the	O
+extracellular	B-COMP
+matrix	I-COMP
+,	O
+2	O
+)	O
+the	O
+mechanisms	O
+of	O
+remodeling	O
+,	O
+3	O
+)	O
+the	O
+impact	O
+of	O
+mechanical	O
+ventilation	O
+on	O
+lung	B-ANAT
+fibrotic	O
+response	O
+,	O
+and	O
+(	O
+4	O
+)	O
+therapeutic	O
+interventions	O
+in	O
+the	O
+remodeling	O
+process	O
+.	O
+
+Recent	O
+epidemiological	O
+evidence	O
+has	O
+pointed	O
+to	O
+viral	B-DISO
+infection	I-DISO
+as	O
+a	O
+trigger	O
+to	O
+initiating	O
+white	B-ANAT
+matter	I-ANAT
+damage	O
+in	O
+humans	B-SPEC
+.	O
+
+Clinically	O
+it	O
+is	O
+characterized	O
+by	O
+spiking	O
+fever	B-PROC
+,	O
+arthritis	B-DISO
+,	O
+rash	B-DISO
+,	O
+and	O
+impairment	B-DISO
+of	O
+multiple	O
+organs	B-ANAT
+.	O
+
+Treatment	O
+includes	O
+the	O
+use	O
+of	O
+non	O
+-	O
+steroid	B-CHED
+antirheumatic	B-CHED
+drugs	I-CHED
+and	O
+corticosteroids	B-CHED
+.	O
+
+We	O
+report	O
+a	O
+46	O
+-	O
+year	O
+-	O
+old	O
+man	B-CHED
+withARDS	O
+after	O
+cardiac	B-ANAT
+surgery	O
+whose	O
+arterial	B-ANAT
+oxygenation	B-PROC
+was	O
+surprisingly	O
+improved	O
+1	O
+hour	O
+after	O
+using	O
+volume	O
+-	O
+controlled	O
+inverse	O
+ratio	O
+ventilation	O
+(	O
+VC	O
+-	O
+IRV	B-PROC
+).	O
+
+TITLE	O
+:	O
+Antibody	B-FUNC
+binding	B-FUNC
+site	O
+mapping	O
+of	O
+SARS	B-PRGE
+-	I-PRGE
+CoV	I-PRGE
+spike	I-PRGE
+protein	B-CHED
+receptor	I-PRGE
+-	I-PRGE
+binding	B-FUNC
+domain	I-PRGE
+by	O
+a	O
+combination	O
+of	O
+yeast	O
+surface	O
+display	O
+and	O
+phage	O
+peptide	B-CHED
+library	O
+screening	O
+.	O
+
+Using	O
+these	O
+monoclonal	O
+antibodies	B-COMP
+in	O
+phage	O
+peptide	B-CHED
+library	O
+screening	O
+identified	O
+10	O
+distinct	O
+mimotopes	O
+12	O
+amino	B-CHED
+acids	I-CHED
+in	O
+length	O
+.	O
+
+Yeast	B-SPEC
+surface	O
+display	O
+combined	O
+with	O
+phage	O
+peptide	B-CHED
+library	O
+screening	O
+provides	O
+a	O
+convenient	O
+strategy	O
+for	O
+the	O
+identification	O
+of	O
+epitope	B-CHED
+peptides	B-CHED
+from	O
+certain	O
+antigenic	O
+proteins	B-CHED
+.	O
+
+ABSTRACT	O
+:	O
+Pulmonary	B-ANAT
+manifestations	O
+in	O
+leptospirosis	B-DISO
+are	O
+considered	O
+a	O
+major	O
+complication	B-DISO
+,	O
+and	O
+are	O
+related	O
+to	O
+a	O
+poor	O
+prognosis	O
+.	O
+
+Severe	O
+pulmonary	B-DISO
+involvement	I-DISO
+was	O
+defined	O
+by	O
+evidence	O
+of	O
+acute	B-DISO
+respiratory	I-DISO
+failure	I-DISO
+.	O
+
+We	O
+performed	O
+a	O
+multivariate	O
+analysis	O
+to	O
+assess	O
+independent	O
+factors	O
+related	O
+to	O
+mortality	O
+and	O
+found	O
+:	O
+Mechanical	O
+ventilation	O
+requirement	O
+(	O
+OR	O
+27	O
+.	O
+85	O
+,	O
+p	O
+<	O
+0	O
+.	O
+0001	O
+)	O
+and	O
+ASAT	B-DISO
+>	O
+150	O
+UI	O
+/	O
+L	O
+(	O
+OR	O
+4	O
+.	O
+57	O
+,	O
+p	O
+<	O
+0	O
+.	O
+02	O
+).	O
+
+Severe	O
+pulmonary	B-DISO
+involvement	I-DISO
+in	O
+leptospirosis	B-DISO
+is	O
+associated	O
+with	O
+extensive	B-DISO
+disease	I-DISO
+involving	O
+other	O
+organs	B-ANAT
+.	O
+
+RESULTS	O
+:	O
+169	O
+patients	O
+with	O
+a	O
+laboratory	O
+-	O
+confirmed	O
+diagnosis	O
+of	O
+leptospirosis	B-DISO
+were	O
+investigated	O
+.	O
+
+CONCLUSIONS	O
+:	O
+Severe	O
+pulmonary	B-DISO
+involvement	I-DISO
+in	O
+leptospirosis	B-DISO
+is	O
+associated	O
+with	O
+extensive	B-DISO
+disease	I-DISO
+involving	O
+other	O
+organs	B-ANAT
+.	O
+
+TITLE	O
+:	O
+[	O
+Exogenous	O
+pulmonary	B-ANAT
+surfactant	B-CHED
+replacement	O
+combined	O
+with	O
+recruitment	B-DISO
+maneuver	O
+in	O
+prevention	O
+of	O
+alveolar	O
+derecruitment	O
+in	O
+rabbits	B-SPEC
+with	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+].	O
+
+PS	O
+replacement	O
+combined	O
+with	O
+RM	O
+therapy	O
+can	O
+alleviate	O
+VALI	O
+and	O
+is	O
+more	O
+effective	O
+in	O
+improving	O
+oxygenation	B-PROC
+and	O
+lung	B-ANAT
+mechanics	O
+.	O
+
+TITLE	O
+:	O
+The	O
+treatment	O
+of	O
+bleeding	B-DISO
+is	O
+to	O
+stop	O
+the	O
+bleeding	B-DISO
+!	O
+
+Treatment	O
+of	O
+trauma	O
+-	O
+related	O
+hemorrhage	B-DISO
+.	O
+
+Analysis	O
+of	O
+data	O
+for	O
+the	O
+117	O
+blunt	O
+trauma	O
+patients	O
+who	O
+survived	O
+at	O
+least	O
+48	O
+hours	O
+after	O
+receiving	O
+study	O
+treatment	O
+shows	O
+that	O
+,	O
+in	O
+addition	O
+to	O
+reducing	O
+RBC	B-ANAT
+requirement	O
+,	O
+rFVIIa	O
+significantly	O
+reduced	O
+the	O
+need	O
+for	O
+massive	O
+transfusion	O
+over	O
+48	O
+hours	O
+(>	O
+20	O
+RBC	B-ANAT
+units	O
+)	O
+(	O
+relative	O
+risk	O
+reduction	O
+of	O
+56	O
+%	O
+[	O
+95	O
+%	O
+confidence	O
+interval	O
+:	O
+9	O
+%-	O
+79	O
+%];	O
+p	O
+=	O
+0	O
+.	O
+03	O
+),	O
+and	O
+the	O
+fresh	B-ANAT
+-	O
+frozen	O
+plasma	B-ANAT
+(	O
+p	O
+=	O
+0	O
+.	O
+036	O
+),	O
+platelet	B-ANAT
+(	O
+p	O
+=	O
+0	O
+.	O
+023	O
+),	O
+and	O
+cryoprecipitate	O
+(	O
+p	O
+=	O
+0	O
+.	O
+053	O
+)	O
+requirements	O
+within	O
+48	O
+hours	O
+,	O
+and	O
+was	O
+associated	O
+with	O
+a	O
+significant	O
+reduction	O
+in	O
+the	O
+30	O
+-	O
+day	O
+risk	O
+of	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+(	O
+ARDS	B-DISO
+)	O
+(	O
+p	O
+=	O
+0	O
+.	O
+05	O
+)	O
+and	O
+multiple	B-DISO
+organ	I-DISO
+failure	I-DISO
+and	O
+/	O
+or	O
+ARDS	B-DISO
+(	O
+p	O
+=	O
+0	O
+.	O
+05	O
+).	O
+
+RESULTS	O
+:	O
+In	O
+patients	O
+with	O
+blunt	O
+trauma	O
+alive	O
+at	O
+48	O
+hours	O
+,	O
+treatment	O
+with	O
+rFVIIa	O
+effected	O
+a	O
+significant	O
+reduction	O
+in	O
+the	O
+primary	O
+endpoint	O
+of	O
+48	O
+-	O
+hour	O
+red	B-ANAT
+blood	I-ANAT
+cell	I-ANAT
+(	O
+RBC	B-ANAT
+)	O
+transfusion	O
+requirement	O
+(	O
+p	O
+=	O
+0	O
+.	O
+02	O
+),	O
+and	O
+the	O
+safety	O
+of	O
+the	O
+dosing	O
+regimen	O
+was	O
+established	O
+.	O
+
+Seroprevalences	O
+of	O
+the	O
+free	O
+-	O
+ranging	O
+cheetahs	B-SPEC
+were	O
+below	O
+5	O
+%	O
+for	O
+all	O
+nine	O
+viruses	B-SPEC
+,	O
+which	O
+is	O
+significantly	O
+lower	O
+than	O
+seroprevalences	O
+in	O
+nonvaccinated	O
+captive	O
+cheetahs	B-SPEC
+and	O
+those	O
+for	O
+five	O
+of	O
+seven	O
+viruses	B-SPEC
+in	O
+previously	O
+studied	O
+free	O
+-	O
+ranging	O
+cheetahs	B-SPEC
+from	O
+north	O
+-	O
+central	O
+Namibia	B-SPEC
+(	O
+L	O
+.	O
+Munson	O
+,	O
+L	O
+.	O
+Marker	O
+,	O
+E	O
+.	O
+Dubovi	O
+,	O
+J	O
+.	O
+A	O
+.	O
+Spencer	O
+,	O
+J	O
+.	O
+F	O
+.	O
+Evermann	O
+,	O
+and	O
+S	O
+.	O
+J	O
+.	O
+O	O
+'	O
+Brien	O
+,	O
+J	O
+.	O
+Wildl	O
+.	O
+
+The	O
+results	O
+suggest	O
+that	O
+while	O
+free	O
+-	O
+ranging	O
+wild	O
+carnivores	B-SPEC
+may	O
+be	O
+a	O
+source	O
+of	O
+pathogens	O
+,	O
+the	O
+distribution	O
+of	O
+seroprevalences	O
+across	O
+studies	O
+mirrored	O
+local	O
+human	B-SPEC
+population	O
+density	O
+and	O
+factors	O
+associated	O
+with	O
+human	B-SPEC
+habitation	O
+,	O
+probably	O
+reflecting	O
+contact	O
+opportunities	O
+with	O
+(	O
+nonvaccinated	O
+)	O
+domestic	O
+and	O
+feral	O
+cats	B-SPEC
+and	O
+dogs	B-SPEC
+.	O
+
+TITLE	O
+:	O
+Comprehensive	O
+detection	O
+and	O
+identification	O
+of	O
+seven	O
+animal	B-SPEC
+coronaviruses	O
+and	O
+human	B-SPEC
+respiratory	O
+coronavirus	O
+229E	O
+with	O
+a	O
+microarray	O
+hybridization	B-PROC
+assay	O
+.	O
+
+The	O
+results	O
+showed	O
+that	O
+extensive	O
+cross	B-PROC
+-	I-PROC
+reaction	I-PROC
+existed	O
+between	O
+CCoV	O
+,	O
+FCoV	O
+,	O
+FIPV	O
+,	O
+TGEV	B-SPEC
+and	O
+PRCoV	O
+,	O
+while	O
+there	O
+was	O
+no	O
+cross	B-PROC
+-	I-PROC
+reaction	I-PROC
+between	O
+BCoV	O
+,	O
+TCoV	O
+and	O
+HRCoV	O
+.	O
+The	O
+ultimate	O
+specific	O
+gene	O
+chip	O
+was	O
+developed	O
+with	O
+DNA	O
+fragments	O
+reamplified	O
+from	O
+the	O
+chosen	O
+recombinant	O
+plasmids	O
+without	O
+cross	B-PROC
+-	I-PROC
+reaction	I-PROC
+between	O
+different	O
+coronaviruses	O
+.	O
+
+Here	O
+,	O
+we	O
+describe	O
+a	O
+study	O
+that	O
+leads	O
+to	O
+the	O
+identification	O
+of	O
+a	O
+novel	O
+HLA	B-PRGE
+-	I-PRGE
+A	I-PRGE
+*	I-PRGE
+0201	I-PRGE
+-	O
+restricted	O
+epitope	B-CHED
+from	O
+conserved	O
+regions	O
+of	O
+S	B-PRGE
+protein	I-PRGE
+.	O
+
+We	O
+assessed	O
+the	O
+effectiveness	O
+of	O
+ribavirin	B-CHED
+and	O
+corticosteroids	B-CHED
+as	O
+the	O
+initial	O
+treatment	O
+for	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+using	O
+propensity	O
+score	O
+analysis	O
+.	O
+
+Our	O
+results	O
+add	B-DISO
+strength	O
+to	O
+the	O
+hypothesis	O
+that	O
+the	O
+combination	O
+of	O
+ribavirin	O
+and	O
+corticosteroids	B-CHED
+has	O
+no	O
+therapeutic	O
+benefit	O
+when	O
+given	O
+early	O
+during	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+infection	B-DISO
+.	O
+
+ABSTRACT	O
+:	O
+Feline	B-SPEC
+gingivostomatitis	B-DISO
+(	O
+FGS	B-DISO
+)	O
+is	O
+a	O
+common	O
+syndrome	B-DISO
+in	O
+cats	B-SPEC
+;	O
+feline	B-SPEC
+calicivirus	I-SPEC
+(	O
+FCV	B-CHED
+),	O
+feline	B-SPEC
+herpesvirus	I-SPEC
+1	I-SPEC
+(	O
+FHV	O
+-	O
+1	O
+),	O
+and	O
+Bartonella	B-SPEC
+species	B-SPEC
+are	O
+common	O
+differential	O
+diagnoses	O
+.	O
+
+RESULTS	O
+:	O
+The	O
+majority	O
+of	O
+physicians	O
+agreed	O
+that	O
+home	O
+quarantine	O
+of	O
+contacts	O
+of	O
+patients	O
+with	O
+probable	O
+SARS	O
+was	O
+warranted	O
+(	O
+95	O
+%),	O
+government	O
+'	O
+s	O
+public	O
+education	O
+effort	B-PROC
+was	O
+effective	O
+(	O
+83	O
+%),	O
+and	O
+the	O
+overall	O
+Singapore	O
+'	O
+s	O
+response	O
+was	O
+commendable	O
+(	O
+82	O
+%).	O
+
+Protection	O
+measures	O
+targeting	B-PROC
+only	O
+infected	O
+patients	O
+yielded	O
+lowest	O
+incremental	O
+cost	O
+/	O
+death	B-PROC
+averted	O
+of	O
+23	O
+,	O
+000	O
+(	O
+US	O
+dollars	O
+)	O
+for	O
+pandemic	O
+(	O
+H1N1	O
+)	O
+2009	O
+.	O
+
+We	O
+demonstrated	O
+our	O
+methods	O
+have	O
+better	O
+classification	O
+capability	O
+when	O
+comparing	O
+with	O
+conventional	O
+methods	O
+including	O
+Fisher	B-SPEC
+linear	O
+discriminant	O
+(	O
+FLD	O
+),	O
+K	O
+-	O
+nearest	O
+neighborhood	O
+(	O
+KNN	O
+),	O
+linear	O
+support	O
+vector	O
+machines	O
+(	O
+linSVM	O
+)	O
+and	O
+radial	O
+basis	O
+function	O
+based	O
+support	O
+vector	O
+machines	O
+(	O
+rbfSVM	O
+).	O
+
+ABSTRACT	O
+:	O
+Few	O
+infectious	B-DISO
+diseases	I-DISO
+are	O
+entirely	O
+human	O
+-	O
+specific	O
+:	O
+Most	O
+human	B-SPEC
+pathogens	O
+also	O
+circulate	O
+in	O
+animals	B-SPEC
+or	O
+else	O
+originated	O
+in	O
+nonhuman	O
+hosts	B-COMP
+.	O
+
+The	O
+multihost	O
+ecology	O
+of	O
+zoonoses	B-DISO
+leads	O
+to	O
+complex	O
+dynamics	O
+,	O
+and	O
+analytical	O
+tools	O
+,	O
+such	O
+as	O
+mathematical	O
+modeling	O
+,	O
+are	O
+vital	O
+to	O
+the	O
+development	B-PROC
+of	O
+effective	O
+control	O
+policies	O
+and	O
+research	O
+agendas	O
+.	O
+
+Much	O
+attention	O
+has	O
+focused	O
+on	O
+modeling	O
+pathogens	O
+with	O
+simpler	O
+life	O
+cycles	O
+and	O
+immediate	O
+global	O
+urgency	O
+,	O
+such	O
+as	O
+influenza	B-DISO
+and	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+.	O
+
+The	O
+structure	O
+of	O
+the	O
+FCoV	O
+X	O
+domain	O
+had	O
+the	O
+expected	O
+macro	O
+-	O
+domain	O
+fold	O
+and	O
+is	O
+the	O
+first	O
+structure	O
+of	O
+this	O
+domain	O
+from	O
+a	O
+coronavirus	B-SPEC
+belonging	O
+to	O
+subgroup	O
+1a	O
+.	O
+
+TITLE	O
+:	O
+[	O
+Acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+induced	O
+by	O
+hydrogen	B-CHED
+fluoride	I-CHED
+gas	B-ENZY
+inhalation	B-PROC
+].	O
+
+ABSTRACT	O
+:	O
+A	O
+21	O
+-	O
+year	O
+old	O
+man	O
+was	O
+referred	O
+to	O
+our	O
+hospital	O
+with	O
+severe	O
+respiratory	B-DISO
+distress	I-DISO
+and	O
+diffuse	O
+infiltrative	O
+shadows	O
+on	O
+chest	B-ANAT
+radiograph	O
+.	O
+
+TITLE	O
+:	O
+TACE	B-ENZY
+antagonists	B-CHED
+blocking	B-DISO
+ACE2	O
+shedding	O
+caused	O
+by	O
+the	O
+spike	O
+protein	B-CHED
+of	O
+SARS	B-DISO
+-	O
+CoV	O
+are	O
+candidate	O
+antiviral	O
+compounds	O
+.	O
+
+In	O
+vitro	O
+and	O
+in	O
+vivo	O
+data	O
+revealed	O
+that	O
+the	O
+TACE	B-PRGE
+inhibitor	B-CHED
+TAPI	O
+-	O
+2	O
+attenuated	O
+entry	O
+of	O
+both	O
+pseudotyped	O
+virus	B-SPEC
+expressing	O
+the	O
+SARS	B-PRGE
+-	I-PRGE
+S	I-PRGE
+protein	B-CHED
+in	O
+a	O
+lentiviral	O
+vector	O
+backbone	B-ANAT
+and	O
+infectious	B-DISO
+SARS	B-DISO
+-	O
+CoV	O
+.	O
+TAPI	O
+-	O
+2	O
+blocked	O
+both	O
+the	O
+SARS	B-PRGE
+-	I-PRGE
+S	I-PRGE
+protein	B-CHED
+-	O
+induced	O
+shedding	O
+of	O
+angiotensin	B-PRGE
+-	I-PRGE
+converting	I-PRGE
+enzyme	I-PRGE
+2	I-PRGE
+(	O
+ACE2	B-PRGE
+),	O
+a	O
+receptor	O
+of	O
+SARS	B-PRGE
+-	I-PRGE
+CoV	I-PRGE
+,	O
+and	O
+TNF	B-PROC
+-	I-PROC
+alpha	I-PROC
+production	I-PROC
+in	O
+lung	B-ANAT
+tissues	I-ANAT
+.	O
+
+Body	B-ANAT
+weight	O
+was	O
+measured	O
+,	O
+and	O
+fecal	B-ANAT
+and	O
+blood	B-ANAT
+samples	I-ANAT
+were	O
+collected	O
+from	O
+the	O
+dogs	B-SPEC
+during	O
+the	O
+experiment	O
+for	O
+the	O
+measurement	O
+of	O
+hematology	O
+,	O
+fecal	O
+immunoglobulin	B-PROC
+(	O
+Ig	O
+)	O
+A	O
+and	O
+IgG	B-PRGE
+,	O
+circulating	O
+IgA	B-PRGE
+and	O
+IgG	B-PRGE
+,	O
+and	O
+canine	O
+corona	B-CHED
+virus	B-SPEC
+(	O
+CCV	B-DISO
+)-	O
+specific	O
+IgG	B-PRGE
+.	O
+There	O
+were	O
+no	O
+differences	O
+in	O
+body	B-ANAT
+weights	O
+among	O
+the	O
+groups	O
+,	O
+but	O
+monocyte	B-ANAT
+counts	O
+in	O
+hematology	O
+and	O
+serum	B-COMP
+IgA	B-PRGE
+were	O
+higher	O
+in	O
+the	O
+group	O
+receiving	O
+L	B-SPEC
+.	I-SPEC
+casei	I-SPEC
+expressing	O
+cGMCSF	O
+than	O
+in	O
+the	O
+other	O
+two	O
+groups	O
+.	O
+
+It	O
+has	O
+been	O
+found	O
+that	O
+in	O
+2	O
+s	O
+,	O
+most	O
+of	O
+the	O
+recruitable	O
+lung	B-ANAT
+regions	O
+may	O
+be	O
+open	O
+when	O
+a	O
+proper	O
+pressure	O
+is	O
+applied	O
+.	O
+
+A	O
+large	O
+outcome	O
+study	O
+showed	O
+that	O
+higher	O
+PEEP	B-CHED
+might	O
+provide	O
+survival	O
+benefit	O
+in	O
+a	O
+subgroup	O
+of	O
+more	O
+severe	O
+patients	O
+as	O
+compared	O
+with	O
+lower	O
+PEEP	B-CHED
+.	O
+
+To	O
+set	O
+PEEP	O
+in	O
+each	O
+individual	O
+patient	O
+,	O
+the	O
+use	O
+of	O
+the	O
+expiratory	B-PROC
+limb	B-ANAT
+of	O
+the	O
+pressure	O
+-	O
+volume	O
+curve	O
+has	O
+been	O
+suggested	O
+.	O
+
+Setting	O
+PEEP	B-CHED
+according	O
+to	O
+transpulmonary	O
+pressure	O
+has	O
+a	O
+robust	O
+physiological	O
+background	O
+,	O
+although	O
+it	O
+requires	O
+confirmatory	O
+study	O
+.	O
+
+Policies	O
+of	O
+school	O
+closure	O
+,	O
+vaccination	O
+and	O
+antivirals	B-CHED
+,	O
+together	O
+with	O
+prophylactic	O
+absence	O
+from	O
+work	O
+are	O
+evaluated	O
+and	O
+their	O
+cost	O
+impacts	O
+are	O
+estimated	O
+.	O
+
+TITLE	O
+:	O
+Bovine	B-SPEC
+respiratory	B-DISO
+disease	I-DISO
+research	O
+(	O
+1983	O
+-	O
+2009	O
+).	O
+
+Bovine	B-SPEC
+immunology	O
+research	O
+has	O
+provided	O
+more	O
+specific	O
+information	O
+on	O
+immune	O
+responses	O
+,	O
+T	B-ANAT
+cell	I-ANAT
+subsets	I-ANAT
+and	O
+cytokines	O
+.	O
+
+This	O
+review	O
+focuses	O
+on	O
+the	O
+pathogenesis	B-DISO
+of	O
+BHV	O
+-	O
+1	O
+and	O
+BRSV	B-SPEC
+,	O
+two	O
+very	O
+different	O
+agents	O
+that	O
+primarily	O
+cause	O
+disease	O
+in	O
+the	O
+upper	O
+and	O
+lower	B-ANAT
+respiratory	I-ANAT
+tract	I-ANAT
+,	O
+respectively	O
+.	O
+
+Apparently	O
+,	O
+nsp2	B-PRGE
+,	O
+once	O
+recruited	O
+to	O
+the	O
+RTCs	O
+,	O
+is	O
+not	O
+exchanged	O
+with	O
+nsp2	B-PRGE
+present	O
+in	O
+the	O
+cytoplasm	B-COMP
+or	O
+at	O
+other	O
+DMVs	O
+.	O
+
+ABSTRACT	O
+:	O
+The	O
+murine	B-SPEC
+coronavirus	I-SPEC
+,	O
+mouse	B-DISO
+hepatitis	I-DISO
+virus	B-SPEC
+(	O
+MHV	B-SPEC
+)	O
+strain	O
+A59	O
+,	O
+causes	O
+acute	O
+encephalitis	B-DISO
+and	O
+chronic	O
+demyelinating	B-DISO
+disease	I-DISO
+as	O
+well	O
+as	O
+hepatitis	B-DISO
+in	O
+mice	B-SPEC
+.	O
+
+Previous	O
+analysis	O
+of	O
+chimeric	O
+recombinant	O
+MHVs	O
+in	O
+which	O
+the	O
+spike	O
+gene	O
+,	O
+encoding	O
+the	O
+protein	B-CHED
+that	O
+mediates	O
+viral	O
+entry	O
+and	O
+cell	B-COMP
+-	O
+to	O
+-	O
+cell	B-PROC
+fusion	I-PROC
+,	O
+was	O
+exchanged	O
+between	O
+JHM	O
+and	O
+A59	O
+showed	O
+that	O
+the	O
+spike	O
+plays	O
+a	O
+major	O
+role	O
+in	O
+determining	O
+organ	B-ANAT
+tropism	B-PROC
+and	O
+neurovirulence	O
+but	O
+that	O
+other	O
+genes	O
+also	O
+play	O
+important	O
+roles	O
+in	O
+pathogenic	O
+outcome	O
+.	O
+
+TITLE	O
+:	O
+Mental	O
+morbidities	O
+and	O
+chronic	O
+fatigue	B-DISO
+in	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+survivors	O
+:	O
+long	O
+-	O
+term	O
+follow	O
+-	O
+up	O
+.	O
+
+We	O
+investigated	O
+long	O
+-	O
+term	O
+psychiatric	O
+morbidities	O
+and	O
+chronic	O
+fatigue	B-DISO
+among	O
+SARS	B-DISO
+survivors	O
+.	O
+
+ABSTRACT	O
+:	O
+Bats	B-SPEC
+are	O
+the	O
+suspected	O
+natural	O
+reservoir	O
+hosts	B-COMP
+for	O
+a	O
+number	O
+of	O
+new	O
+and	O
+emerging	O
+zoonotic	O
+viruses	B-SPEC
+including	O
+Nipah	B-SPEC
+virus	I-SPEC
+,	O
+Hendra	B-SPEC
+virus	I-SPEC
+,	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+coronavirus	B-SPEC
+and	O
+Ebola	B-SPEC
+virus	I-SPEC
+.	O
+
+TITLE	O
+:	O
+Annexin	B-PRGE
+A2	O
+on	O
+lung	B-ANAT
+epithelial	B-ANAT
+cell	I-ANAT
+surface	I-ANAT
+is	O
+recognized	O
+by	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+-	O
+associated	O
+coronavirus	B-SPEC
+spike	O
+domain	O
+2	O
+antibodies	B-COMP
+.	O
+
+We	O
+previously	O
+showed	O
+that	O
+antibodies	B-COMP
+against	O
+SARS	B-DISO
+-	O
+CoV	O
+spike	B-PRGE
+domain	I-PRGE
+2	I-PRGE
+(	O
+S2	O
+)	O
+in	O
+the	O
+patient	O
+sera	B-COMP
+can	O
+cross	O
+-	O
+react	O
+with	O
+human	B-SPEC
+lung	B-ANAT
+epithelial	B-ANAT
+cells	I-ANAT
+;	O
+however	O
+,	O
+the	O
+autoantigen	O
+is	O
+not	O
+yet	O
+identified	O
+.	O
+
+Neither	O
+admission	O
+lactate	B-CHED
+nor	O
+glucose	B-CHED
+was	O
+able	O
+to	O
+predict	O
+outcome	O
+.	O
+
+Gas	B-PRGE
+exchange	O
+capacity	O
+of	O
+the	O
+device	O
+averaged	O
+155	O
+(	O
+116	O
+to	O
+182	O
+)	O
+mL	O
+/	O
+min	O
+for	O
+oxygen	B-CHED
+and	O
+210	O
+(	O
+164	O
+to	O
+251	O
+)	O
+mL	O
+/	O
+min	O
+for	O
+carbon	B-CHED
+dioxide	I-CHED
+.	O
+
+Effective	O
+management	O
+of	O
+severe	O
+malaria	B-PATH
+includes	O
+early	O
+suspicion	O
+,	O
+prompt	O
+diagnosis	O
+,	O
+early	O
+institution	O
+of	O
+appropriate	O
+antimalarial	B-CHED
+chemotherapy	O
+,	O
+and	O
+supportive	O
+care	O
+,	O
+preferably	O
+in	O
+an	O
+intensive	O
+care	O
+unit	O
+.	O
+
+The	O
+3a	O
+protein	B-CHED
+was	O
+found	O
+to	O
+induce	O
+serine	B-CHED
+phosphorylation	B-PROC
+within	O
+the	O
+IFN	B-PRGE
+alpha	O
+-	O
+receptor	O
+subunit	O
+1	O
+(	O
+IFNAR1	B-PRGE
+)	O
+degradation	O
+motif	O
+and	O
+to	O
+increase	O
+IFNAR1	B-PRGE
+ubiquitination	B-PROC
+.	O
+
+We	O
+sought	O
+to	O
+compare	O
+a	O
+protocol	O
+for	O
+DPA	B-CHED
+against	O
+a	O
+protocol	O
+for	O
+diversion	O
+in	O
+severely	O
+ill	B-DISO
+critical	O
+patients	O
+with	O
+intra	O
+-	O
+abdominal	B-DISO
+sepsis	B-SPEC
+.	O
+
+A	O
+retrospective	O
+cohort	O
+study	O
+was	O
+performed	O
+examining	O
+112	O
+patients	O
+admitted	O
+through	O
+an	O
+ICU	O
+between	O
+2002	O
+and	O
+2006	O
+,	O
+with	O
+diagnosis	O
+of	O
+secondary	B-DISO
+peritonitis	I-DISO
+and	O
+managed	O
+with	O
+staged	O
+laparotomies	O
+whom	O
+required	O
+small	O
+-	O
+or	O
+large	O
+-	O
+bowel	B-ANAT
+segment	O
+resections	O
+.	O
+
+Patients	O
+were	O
+categorized	O
+and	O
+compared	O
+according	O
+to	O
+the	O
+surgical	O
+treatment	O
+necessitated	O
+to	O
+resolve	O
+the	O
+secondary	B-DISO
+peritonitis	I-DISO
+(	O
+DPA	B-CHED
+versus	O
+diversion	O
+).	O
+
+There	O
+were	O
+30	O
+patients	O
+(	O
+88	O
+.	O
+2	O
+%)	O
+with	O
+DPA	B-CHED
+and	O
+65	O
+patients	O
+(	O
+83	O
+.	O
+3	O
+%)	O
+with	O
+diversion	O
+discharged	O
+alive	O
+(	O
+p	O
+=	O
+0	O
+.	O
+51	O
+).	O
+
+TITLE	O
+:	O
+Picornaviral	B-PRGE
+3C	I-PRGE
+protease	I-PRGE
+inhibitors	O
+and	O
+the	O
+dual	O
+3C	B-PRGE
+protease	I-PRGE
+/	I-PRGE
+coronaviral	I-PRGE
+3C	I-PRGE
+-	I-PRGE
+like	I-PRGE
+protease	B-CHED
+inhibitors	I-CHED
+.	O
+
+TITLE	O
+:	O
+Emergence	O
+of	O
+a	O
+group	O
+3	O
+coronavirus	B-SPEC
+through	O
+recombination	B-PROC
+.	O
+
+This	O
+is	O
+the	O
+first	O
+evidence	O
+that	O
+recombination	B-PROC
+can	O
+directly	O
+lead	O
+to	O
+the	O
+emergence	O
+of	O
+new	O
+coronaviruses	O
+and	O
+new	O
+coronaviral	O
+diseases	O
+,	O
+emphasizing	O
+the	O
+importance	O
+of	O
+limiting	O
+exposure	O
+to	O
+reservoirs	O
+of	O
+coronaviruses	O
+that	O
+can	O
+serve	O
+as	O
+a	O
+source	O
+of	O
+genetic	O
+material	O
+for	O
+emerging	O
+viruses	O
+.	O
+
+ABSTRACT	O
+:	O
+Twenty	O
+-	O
+seven	O
+strains	O
+of	O
+avian	B-DISO
+infectious	I-DISO
+bronchitis	I-DISO
+virus	B-SPEC
+(	O
+IBV	B-SPEC
+)	O
+were	O
+isolated	O
+from	O
+dead	B-PROC
+or	O
+diseased	O
+chickens	B-SPEC
+at	O
+different	O
+chicken	B-SPEC
+farms	O
+in	O
+South	O
+China	O
+during	O
+2004	O
+-	O
+2008	O
+,	O
+of	O
+which	O
+the	O
+S1	B-PRGE
+gene	I-PRGE
+was	O
+sequenced	O
+.	O
+
+The	O
+study	O
+of	O
+the	O
+protease	O
+cleavage	B-PROC
+motif	O
+within	O
+the	O
+S1	O
+protein	B-CHED
+found	O
+12	O
+different	O
+cleavage	B-PROC
+motifs	O
+,	O
+of	O
+which	O
+3	O
+motifs	O
+are	O
+shared	O
+by	O
+both	O
+isolated	O
+and	O
+published	O
+strains	O
+,	O
+2	O
+motifs	O
+unique	O
+to	O
+isolated	O
+strains	O
+,	O
+and	O
+7	O
+motifs	O
+unique	O
+to	O
+published	O
+strains	O
+,	O
+further	O
+bolstering	O
+the	O
+notion	O
+of	O
+no	O
+new	O
+predominant	O
+strains	O
+.	O
+
+Use	O
+of	O
+systemic	O
+steroids	B-CHED
+was	O
+associated	O
+with	O
+delayed	O
+viral	O
+clearance	O
+in	O
+severe	O
+acute	O
+respiratory	O
+syndrome	O
+and	O
+H3N2	B-CHED
+infection	B-DISO
+.	O
+
+Such	O
+knowledge	O
+is	O
+however	O
+critical	O
+,	O
+notably	O
+for	O
+predicting	O
+population	O
+compliance	O
+with	O
+non	O
+pharmaceutical	B-CHED
+interventions	O
+.	O
+
+We	O
+demonstrate	O
+for	O
+the	O
+first	O
+time	O
+that	O
+early	O
+enteral	O
+feeding	O
+is	O
+a	O
+protective	O
+factor	O
+for	O
+EOVAP	O
+,	O
+and	O
+this	O
+result	O
+could	O
+have	O
+clinical	O
+implications	O
+for	O
+the	O
+prevention	O
+of	O
+EOVAP	O
+after	O
+traumatic	O
+brain	B-ANAT
+injury	O
+.	O
+
+Among	O
+hospitalizations	O
+with	O
+myocardial	O
+disorders	O
+,	O
+the	O
+rate	O
+of	O
+severe	O
+complications	O
+ranged	O
+from	O
+13	O
+.	O
+2	O
+for	O
+acute	B-DISO
+myocardial	I-DISO
+infarction	I-DISO
+to	O
+128	O
+.	O
+6	O
+for	O
+adult	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+and	O
+from	O
+10	O
+.	O
+7	O
+for	O
+pulmonary	B-DISO
+edema	I-DISO
+to	O
+193	O
+.	O
+0	O
+for	O
+fluid	O
+and	O
+electrolyte	O
+disorders	O
+per	O
+1	O
+,	O
+000	O
+delivery	O
+and	O
+postpartum	O
+hospitalizations	O
+,	O
+respectively	O
+.	O
+
+TITLE	O
+:	O
+Vitamin	B-CHED
+K3	I-CHED
+attenuates	O
+lipopolysaccharide	B-CHED
+-	O
+induced	O
+acute	O
+lung	B-ANAT
+injury	O
+through	O
+inhibition	B-PROC
+of	O
+nuclear	B-PRGE
+factor	I-PRGE
+-	I-PRGE
+kappaB	I-PRGE
+activation	O
+.	O
+
+In	O
+this	O
+study	O
+,	O
+we	O
+investigated	O
+the	O
+anti	O
+-	O
+inflammatory	O
+effects	O
+of	O
+vitamin	B-CHED
+K3	I-CHED
+in	O
+in	O
+vitro	O
+cultured	B-ANAT
+cell	I-ANAT
+experiments	O
+and	O
+in	O
+vivo	O
+animal	B-SPEC
+experiments	O
+.	O
+
+In	O
+human	B-SPEC
+embryonic	B-ANAT
+kidney	B-ANAT
+(	O
+HEK	O
+)	O
+293	O
+cells	B-COMP
+,	O
+vitamin	B-CHED
+K3	I-CHED
+inhibited	O
+the	O
+tumour	B-DISO
+necrosis	I-DISO
+factor	O
+(	O
+TNF	O
+)-	O
+alpha	O
+-	O
+evoked	O
+translocation	B-DISO
+of	O
+nuclear	B-PRGE
+factor	I-PRGE
+(	O
+NF	O
+)-	O
+kappaB	O
+into	O
+the	O
+nucleus	B-COMP
+,	O
+although	O
+vitamins	B-CHED
+K1	O
+and	O
+K2	O
+did	O
+not	O
+.	O
+
+Sequence	O
+and	O
+phylogenetic	O
+analyses	O
+showed	O
+that	O
+the	O
+CCoV	B-PRGE
+-	I-PRGE
+IIb	I-PRGE
+strains	O
+were	O
+related	O
+to	O
+prototype	O
+TGEV	B-SPEC
+-	O
+like	O
+strains	O
+in	O
+the	O
+5	O
+'	O
+and	O
+the	O
+3	O
+'	O
+ends	O
+of	O
+the	O
+spike	O
+protein	B-CHED
+gene	O
+.	O
+
+TITLE	O
+:	O
+Broad	O
+-	O
+spectrum	O
+in	O
+vitro	O
+activity	O
+and	O
+in	O
+vivo	O
+efficacy	O
+of	O
+the	O
+antiviral	B-CHED
+protein	B-CHED
+griffithsin	O
+against	O
+emerging	O
+viruses	O
+of	O
+the	O
+family	B-SPEC
+Coronaviridae	I-SPEC
+.	O
+
+With	O
+this	O
+greater	O
+understanding	O
+of	O
+SARS	B-DISO
+-	O
+CoV	O
+biology	O
+,	O
+many	O
+researchers	O
+have	O
+sought	O
+to	O
+identify	O
+agents	O
+for	O
+the	O
+treatment	O
+of	O
+SARS	B-DISO
+.	O
+
+The	O
+risk	O
+of	O
+catching	B-DISO
+H1N1	O
+will	O
+essentially	O
+be	O
+confined	O
+to	O
+passengers	O
+travelling	O
+in	O
+the	O
+same	O
+cabin	O
+as	O
+the	O
+source	O
+case	O
+.	O
+
+RESULTS	O
+:	O
+The	O
+risk	O
+of	O
+catching	B-DISO
+H1N1	O
+will	O
+essentially	O
+be	O
+confined	O
+to	O
+passengers	O
+travelling	O
+in	O
+the	O
+same	O
+cabin	O
+as	O
+the	O
+source	O
+case	O
+.	O
+
+RESULTS	O
+:	O
+Our	O
+estimated	O
+SCCD	B-DISO
+was	O
+0	O
+.	O
+133	O
+fewer	O
+secondary	O
+cases	O
+per	O
+quarantined	O
+versus	O
+non	O
+-	O
+quarantined	O
+index	O
+case	O
+;	O
+and	O
+a	O
+NNQ	O
+of	O
+7	O
+.	O
+5	O
+exposed	O
+individuals	O
+to	O
+be	O
+placed	O
+in	O
+community	O
+quarantine	O
+to	O
+prevent	O
+one	O
+additional	O
+case	O
+of	O
+transmission	O
+in	O
+the	O
+community	O
+.	O
+
+ABSTRACT	O
+:	O
+Severe	O
+respiratory	B-DISO
+failure	I-DISO
+(	O
+including	O
+acute	O
+lung	B-ANAT
+injury	O
+and	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+)	O
+caused	O
+by	O
+2009	O
+H1N1	B-DISO
+influenza	I-DISO
+infection	O
+has	O
+been	O
+reported	O
+worldwide	O
+.	O
+
+Most	O
+of	O
+the	O
+knowledge	O
+about	O
+the	O
+pathogenesis	B-DISO
+of	O
+MS	O
+has	O
+been	O
+derived	O
+from	O
+murine	B-SPEC
+models	O
+,	O
+such	O
+as	O
+experimental	O
+autoimmune	B-DISO
+encephalomyelitis	B-DISO
+and	O
+viral	O
+encephalomyelitis	B-DISO
+.	O
+
+Overall	O
+,	O
+our	O
+study	O
+supports	O
+the	O
+development	B-PROC
+of	O
+therapeutic	O
+strategies	O
+based	O
+on	O
+nitroxides	B-CHED
+to	O
+manage	O
+neuroinflammatory	O
+diseases	O
+,	O
+including	O
+MS	O
+.	O
+
+A	O
+total	O
+of	O
+17	O
+children	O
+died	B-PROC
+.	O
+
+If	O
+corticosteroids	B-CHED
+are	O
+administered	O
+,	O
+infection	B-DISO
+surveillance	O
+,	O
+avoidance	O
+of	O
+neuromuscular	O
+blockers	O
+,	O
+and	O
+gradual	O
+taper	O
+of	O
+corticosteroids	B-CHED
+are	O
+recommended	O
+.	O
+
+ABSTRACT	O
+:	O
+A	O
+3C	B-PRGE
+-	I-PRGE
+like	I-PRGE
+protease	I-PRGE
+(	O
+3CLpro	O
+)	O
+from	O
+the	O
+severe	O
+acute	O
+respiratory	O
+syndrome	O
+-	O
+coronavirus	B-SPEC
+(	O
+SARS	B-DISO
+-	O
+CoV	O
+)	O
+is	O
+required	O
+for	O
+viral	B-PROC
+replication	I-PROC
+,	O
+cleaving	O
+the	O
+replicase	B-PRGE
+polyproteins	I-PRGE
+at	O
+11	O
+sites	O
+with	O
+the	O
+conserved	O
+Gln	B-CHED
+[	O
+downward	O
+arrow	O
+](	O
+Ser	B-COMP
+,	O
+Ala	B-CHED
+,	O
+Gly	B-CHED
+)	O
+sequences	O
+.	O
+
+TITLE	O
+:	O
+Gamma	B-PRGE
+interferon	I-PRGE
+signaling	O
+in	O
+oligodendrocytes	B-ANAT
+is	O
+critical	O
+for	O
+protection	O
+from	O
+neurotropic	O
+coronavirus	B-SPEC
+infection	I-DISO
+.	O
+
+These	O
+data	O
+indicate	O
+that	O
+IFN	B-PRGE
+-	I-PRGE
+gamma	I-PRGE
+signaling	B-PROC
+by	O
+oligodendroglia	B-ANAT
+reduces	O
+viral	B-PROC
+replication	I-PROC
+but	O
+affects	O
+both	O
+demyelination	B-DISO
+and	O
+tissue	B-ANAT
+destruction	O
+in	O
+a	O
+host	B-COMP
+-	O
+specific	O
+manner	O
+.	O
+
+We	O
+report	O
+the	O
+case	O
+of	O
+a	O
+12	O
+-	O
+year	O
+-	O
+old	O
+boy	O
+with	O
+history	O
+of	O
+congenital	B-DISO
+heart	I-DISO
+disease	I-DISO
+who	O
+was	O
+transplanted	B-ANAT
+in	O
+June	O
+2001	O
+.	O
+
+Three	O
+expression	B-PROC
+plasmids	O
+each	O
+targeting	B-PRGE
+spike	I-PRGE
+protein	B-CHED
+(	O
+S1	O
+),	O
+nucleocapsid	B-COMP
+protein	B-CHED
+(	O
+N	O
+),	O
+and	O
+membrane	B-COMP
+protein	B-CHED
+(	O
+M	O
+)	O
+of	O
+IBV	B-SPEC
+were	O
+prepared	O
+.	O
+
+TITLE	O
+:	O
+[	O
+Application	O
+of	O
+bioactive	O
+mutant	B-PRGE
+TNF	I-PRGE
+alpha	I-PRGE
+to	O
+a	O
+mucosal	B-ANAT
+vaccine	O
+adjuvant	B-CHED
+].	O
+
+Mucosal	B-ANAT
+vaccines	O
+administered	O
+either	O
+orally	B-ANAT
+or	O
+nasally	O
+have	O
+been	O
+shown	O
+to	O
+be	O
+effective	O
+in	O
+inducing	O
+antigen	B-CHED
+-	O
+specific	O
+immune	B-PROC
+responses	I-PROC
+at	O
+both	O
+systemic	O
+and	O
+mucosal	B-ANAT
+compartments	B-ANAT
+.	O
+
+At	O
+SHC	B-PRGE
+,	O
+if	O
+ATR	O
+>	O
+or	O
+=	O
+5	O
+degrees	O
+,	O
+postero	O
+-	O
+anterior	O
+radiograph	O
+of	O
+the	O
+spine	B-COMP
+was	O
+done	O
+.	O
+
+Of	O
+the	O
+3186	O
+female	O
+students	O
+in	O
+the	O
+primary	O
+level	O
+,	O
+aged	O
+between	O
+9	O
+and	O
+13	O
+years	O
+old	O
+who	O
+were	O
+referred	O
+to	O
+SHC	B-PRGE
+for	O
+the	O
+second	O
+-	O
+tier	O
+screening	O
+,	O
+2438	O
+attended	O
+,	O
+and	O
+for	O
+secondary	O
+students	O
+aged	O
+between	O
+12	O
+and	O
+13	O
+years	O
+old	O
+,	O
+1587	O
+out	O
+of	O
+1720	O
+students	O
+attended	O
+.	O
+
+The	O
+sequence	O
+comparison	O
+revealed	O
+that	O
+the	O
+field	O
+isolates	O
+had	O
+96	O
+%	O
+homology	O
+with	O
+a	O
+few	O
+point	B-PROC
+mutations	I-PROC
+.	O
+
+GeneOrder	O
+,	O
+CoreGenes	O
+and	O
+CGUG	O
+are	O
+web	B-DISO
+-	O
+based	O
+'	O
+on	O
+-	O
+the	O
+-	O
+fly	B-SPEC
+'	O
+tools	O
+that	O
+examine	O
+gene	O
+order	B-SPEC
+and	O
+synteny	B-PROC
+,	O
+as	O
+well	O
+as	O
+proteomes	O
+for	O
+comparative	O
+genomics	O
+and	O
+for	O
+drug	O
+discovery	O
+and	O
+design	O
+targets	O
+.	O
+
+Multivariate	O
+analysis	O
+showed	O
+that	O
+respiratory	B-DISO
+viral	I-DISO
+infection	I-DISO
+early	O
+after	O
+HSCT	O
+is	O
+an	O
+important	O
+predictor	O
+for	O
+the	O
+development	B-PROC
+of	O
+allo	O
+-	O
+LS	O
+(	O
+P	O
+<.	O
+0001	O
+).	O
+
+We	O
+hypothesize	O
+that	O
+early	O
+infection	B-DISO
+of	O
+the	O
+respiratory	B-ANAT
+tract	I-ANAT
+with	O
+a	O
+common	B-DISO
+cold	I-DISO
+virus	B-SPEC
+makes	O
+the	O
+lungs	B-ANAT
+a	O
+target	O
+for	O
+alloimmunity	B-PROC
+.	O
+
+During	O
+the	O
+containment	O
+and	O
+early	O
+mitigation	O
+phases	O
+of	O
+the	O
+swine	B-SPEC
+-	O
+origin	O
+influenza	B-SPEC
+virus	I-SPEC
+(	O
+S	O
+-	O
+OIV	O
+)	O
+A	O
+H1N1	O
+pandemic	O
+,	O
+an	O
+infection	B-DISO
+control	O
+bundle	O
+consisting	O
+of	O
+multiple	O
+coherent	O
+measures	O
+was	O
+organised	O
+by	O
+our	O
+infection	B-DISO
+control	O
+team	O
+to	O
+minimise	O
+nosocomial	O
+transmission	O
+.	O
+
+All	O
+patients	O
+had	O
+flu	B-DISO
+like	I-DISO
+symptoms	I-DISO
+and	O
+most	O
+presented	O
+with	O
+respiratory	B-DISO
+distress	I-DISO
+and	O
+tachycardia	O
+.	O
+
+Such	O
+frequent	O
+recombination	B-PROC
+,	O
+coupled	O
+with	O
+rapid	O
+evolution	B-PROC
+especially	O
+in	O
+ORF7b	B-PRGE
+/	I-PRGE
+ORF8	I-PRGE
+region	I-PRGE
+,	O
+in	O
+these	O
+animals	B-SPEC
+may	O
+have	O
+accounted	O
+for	O
+the	O
+cross	O
+-	O
+species	B-SPEC
+transmission	O
+and	O
+emergence	O
+of	O
+SARS	B-DISO
+.	O
+
+Remarkably	O
+,	O
+it	O
+was	O
+found	O
+that	O
+they	O
+utilize	O
+distinct	O
+cultured	B-ANAT
+cell	I-ANAT
+lines	O
+for	O
+in	O
+vitro	O
+virus	B-SPEC
+propagation	O
+,	O
+since	O
+PEDV	B-SPEC
+could	O
+not	O
+be	O
+replicated	O
+in	O
+swine	B-SPEC
+testis	B-ANAT
+(	O
+ST	O
+)	O
+cells	B-COMP
+expressing	O
+native	O
+porcine	B-SPEC
+APN	O
+(	O
+pAPN	O
+),	O
+which	O
+are	O
+highly	O
+susceptible	O
+to	O
+TGEV	B-SPEC
+.	O
+
+In	O
+contrast	O
+,	O
+in	O
+the	O
+engineered	O
+stable	O
+cell	B-ANAT
+lines	I-ANAT
+,	O
+a	O
+high	O
+level	O
+of	O
+recombinant	O
+pAPN	O
+expression	B-PROC
+was	O
+demonstrated	O
+.	O
+
+Of	O
+the	O
+intestinal	B-ANAT
+contents	I-ANAT
+collected	O
+from	O
+43	O
+PES	B-ANAT
+cases	O
+,	O
+25	O
+were	O
+positive	O
+for	O
+rotavirus	B-SPEC
+and	O
+13	O
+for	O
+small	O
+round	O
+viruses	B-SPEC
+by	O
+electron	O
+microscopy	O
+(	O
+EM	O
+).	O
+
+Of	O
+the	O
+enteric	O
+virus	B-SPEC
+-	O
+positive	O
+cases	O
+by	O
+EM	O
+(	O
+n	O
+=	O
+27	O
+),	O
+16	O
+cases	O
+had	O
+rotavirus	B-SPEC
+or	O
+small	O
+round	O
+viruses	B-SPEC
+alone	O
+and	O
+the	O
+remaining	O
+11	O
+cases	O
+had	O
+both	O
+viruses	B-SPEC
+.	O
+
+Thus	O
+,	O
+8	O
+(	O
+19	O
+%)	O
+cases	O
+were	O
+positive	O
+for	O
+a	O
+single	O
+virus	O
+,	O
+whereas	O
+a	O
+combination	O
+of	O
+viruses	B-SPEC
+was	O
+detected	O
+in	O
+the	O
+remaining	O
+35	O
+(	O
+81	O
+%)	O
+cases	O
+.	O
+
+Fifteen	O
+cases	O
+were	O
+positive	O
+for	O
+all	O
+3	O
+viruses	B-SPEC
+.	O
+
+The	O
+second	O
+case	O
+is	O
+a	O
+15	O
+years	O
+old	O
+woman	O
+with	O
+26	O
+.	O
+5	O
+weeks	O
+of	O
+pregnancy	O
+,	O
+who	O
+suffers	B-DISO
+a	O
+generalized	O
+paralysis	O
+with	O
+blood	B-PRGE
+potassium	B-CHED
+of	I-PRGE
+2	I-PRGE
+.	I-PRGE
+7	I-PRGE
+meq	I-PRGE
+/	I-PRGE
+L	I-PRGE
+,	O
+requiring	O
+also	O
+mechanical	O
+ventilation	O
+for	O
+respiratory	O
+paralysis	O
+;	O
+the	O
+final	O
+diagnosis	O
+was	O
+Barterr	O
+syndrome	B-DISO
+,	O
+and	O
+the	O
+medical	O
+profile	O
+remited	O
+after	O
+potassium	B-CHED
+supplement	O
+.	O
+
+In	O
+-	O
+silico	O
+analysis	O
+of	O
+the	O
+225	O
+amino	B-CHED
+acid	I-CHED
+sequence	O
+of	O
+hCoV	B-PRGE
+-	I-PRGE
+NL63	I-PRGE
+ORF	I-PRGE
+3	I-PRGE
+predicted	O
+a	O
+triple	O
+membrane	B-COMP
+-	O
+spanning	O
+protein	B-CHED
+.	O
+
+The	O
+protein	B-CHED
+was	O
+detected	O
+within	O
+the	O
+endoplasmatic	O
+reticulum	B-ANAT
+/	O
+Golgi	B-COMP
+intermediate	O
+compartment	B-ANAT
+(	O
+ERGIC	B-COMP
+)	O
+where	O
+coronavirus	B-SPEC
+assembly	O
+and	O
+budding	B-PATH
+takes	O
+place	O
+.	O
+
+RESULTS	O
+:	O
+In	O
+-	O
+silico	O
+analysis	O
+of	O
+the	O
+225	O
+amino	B-CHED
+acid	I-CHED
+sequence	O
+of	O
+hCoV	B-PRGE
+-	I-PRGE
+NL63	I-PRGE
+ORF	I-PRGE
+3	I-PRGE
+predicted	O
+a	O
+triple	O
+membrane	B-COMP
+-	O
+spanning	O
+protein	B-CHED
+.	O
+
+TITLE	O
+:	O
+Inhibition	B-PROC
+of	O
+porcine	B-DISO
+transmissible	I-DISO
+gastroenteritis	I-DISO
+virus	B-SPEC
+(	O
+TGEV	B-SPEC
+)	O
+replication	O
+in	O
+mini	O
+-	O
+pigs	B-SPEC
+by	O
+shRNA	O
+.	O
+
+ABSTRACT	O
+:	O
+The	O
+first	O
+influenza	B-DISO
+pandemic	O
+of	O
+the	O
+xxist	O
+century	O
+is	O
+due	O
+to	O
+a	O
+novel	O
+A	O
+(	O
+H1N1	O
+)	O
+strain	O
+.	O
+
+During	O
+winter	O
+2009	O
+-	O
+2010	O
+,	O
+an	O
+inflow	O
+of	O
+flu	O
+-	O
+related	O
+ARDS	B-DISO
+cases	O
+is	O
+expected	O
+in	O
+French	O
+ICUs	O
+.	O
+
+TITLE	O
+:	O
+Genetic	O
+variation	O
+in	O
+MYLK	O
+and	O
+lung	B-ANAT
+injury	O
+in	O
+children	O
+and	O
+adults	O
+with	O
+community	O
+-	O
+acquired	O
+pneumonia	B-DISO
+.	O
+
+No	O
+associations	O
+were	O
+observed	O
+between	O
+the	O
+myosin	B-PRGE
+light	I-PRGE
+chain	I-PRGE
+kinase	I-PRGE
+gene	I-PRGE
+single	O
+nucleotide	B-CHED
+polymorphisms	B-PROC
+genotyped	O
+in	O
+children	O
+with	O
+community	O
+-	O
+acquired	O
+pneumonia	B-DISO
+and	O
+increased	O
+severity	O
+of	O
+lung	B-ANAT
+injury	O
+.	O
+
+ABSTRACT	O
+:	O
+From	O
+March	O
+to	O
+July	O
+2009	O
+,	O
+influenza	B-PATH
+A	I-PATH
+(	O
+H1N1	B-PATH
+)	O
+2009	O
+(	O
+H1N1	B-PATH
+-	O
+2009	O
+)	O
+virus	B-SPEC
+emerged	O
+as	O
+a	O
+major	O
+cause	O
+of	O
+respiratory	B-DISO
+failure	I-DISO
+that	O
+required	O
+mechanical	O
+ventilation	O
+.	O
+
+A	O
+small	O
+proportion	O
+of	O
+patients	O
+who	O
+had	O
+this	O
+condition	B-DISO
+developed	O
+severe	O
+respiratory	B-DISO
+failure	I-DISO
+that	O
+was	O
+unresponsive	O
+to	O
+conventional	O
+therapeutic	O
+interventions	O
+.	O
+
+Four	O
+patients	O
+were	O
+treated	O
+with	O
+veno	O
+-	O
+venous	B-ANAT
+pump	O
+-	O
+driven	O
+extracorporeal	O
+membrane	B-COMP
+oxygenation	B-PROC
+(	O
+vv	O
+-	O
+ECMO	O
+),	O
+and	O
+two	O
+patients	O
+were	O
+treated	O
+with	O
+pumpless	O
+lung	B-ANAT
+assist	O
+(	O
+NovaLung	O
+iLA	O
+).	O
+
+RESULTS	O
+:	O
+During	O
+the	O
+study	O
+period	O
+,	O
+168	O
+patients	O
+in	O
+Canada	O
+were	O
+admitted	O
+to	O
+ICUs	O
+for	O
+severe	O
+respiratory	B-DISO
+failure	I-DISO
+due	O
+to	O
+confirmed	O
+H1N1	O
+-	O
+2009	O
+infection	B-DISO
+.	O
+
+TITLE	O
+:	O
+Lessons	O
+learned	B-PROC
+from	O
+the	O
+anti	O
+-	O
+SARS	B-DISO
+quarantine	O
+experience	O
+in	O
+a	O
+hospital	O
+-	O
+based	O
+fever	B-PROC
+screening	O
+station	O
+in	O
+Taiwan	O
+.	O
+
+We	O
+conducted	O
+a	O
+phenomenologic	O
+,	O
+qualitative	O
+study	O
+using	O
+semistructured	O
+telephone	O
+interviews	O
+during	O
+the	O
+SARS	B-DISO
+outbreak	O
+in	O
+Taiwan	O
+.	O
+
+Seventeen	O
+patients	O
+with	O
+fever	B-PROC
+who	O
+were	O
+quarantined	O
+in	O
+the	O
+fever	B-PROC
+screening	O
+station	O
+of	O
+a	O
+hospital	O
+emergency	B-DISO
+department	O
+for	O
+at	O
+least	O
+2	O
+hours	O
+were	O
+recruited	O
+into	O
+this	O
+study	O
+.	O
+
+These	O
+immune	O
+complexes	O
+associate	O
+with	O
+FcgammaRIIa	O
+(	O
+Fcgamma	O
+IIa	O
+receptor	O
+)	O
+in	O
+lungs	B-ANAT
+of	O
+patients	O
+with	O
+ARDS	B-DISO
+.	O
+
+It	O
+is	O
+a	O
+low	O
+-	O
+affinity	O
+receptor	O
+for	O
+IgG	B-PRGE
+that	O
+preferentially	O
+binds	B-FUNC
+aggregated	O
+immunoglobulins	O
+and	O
+immune	O
+complexes	O
+.	O
+
+To	O
+shed	O
+further	O
+light	O
+on	O
+these	O
+structures	O
+,	O
+we	O
+have	O
+performed	O
+a	O
+time	O
+-	O
+course	O
+experiment	O
+in	O
+which	O
+the	O
+mouse	B-DISO
+hepatitis	I-DISO
+virus	B-SPEC
+(	O
+MHV	B-SPEC
+)-	O
+induced	O
+membrane	B-COMP
+rearrangements	O
+were	O
+examined	O
+qualitatively	O
+and	O
+quantitatively	O
+by	O
+(	O
+immuno	O
+)-	O
+electron	O
+microscopy	O
+.	O
+
+With	O
+our	O
+approach	O
+we	O
+were	O
+able	O
+to	O
+confirm	O
+the	O
+appearance	O
+of	O
+6	O
+,	O
+previously	O
+reported	O
+,	O
+membranous	B-ANAT
+structures	O
+during	O
+the	O
+course	O
+of	O
+a	O
+complete	O
+infection	B-DISO
+cycle	O
+.	O
+
+We	O
+have	O
+characterized	O
+the	O
+LVCVs	O
+,	O
+TBs	B-DISO
+and	O
+CMSs	O
+,	O
+and	O
+found	O
+that	O
+the	O
+CoV	O
+-	O
+induced	O
+structures	O
+appear	O
+in	O
+a	O
+strict	O
+order	B-SPEC
+.	O
+
+ABSTRACT	O
+:	O
+Viral	O
+epidemics	O
+or	O
+pandemics	O
+of	O
+acute	O
+respiratory	O
+infections	O
+like	O
+influenza	B-DISO
+or	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+pose	O
+a	O
+world	O
+-	O
+wide	O
+threat	O
+.	O
+
+The	O
+risk	O
+of	O
+bias	B-SPEC
+for	O
+the	O
+four	O
+RCTs	O
+,	O
+and	O
+most	O
+cluster	O
+RCTs	O
+,	O
+was	O
+high	O
+.	O
+
+TITLE	O
+:	O
+Sudden	B-DISO
+death	I-DISO
+of	O
+a	O
+patient	O
+with	O
+pandemic	O
+influenza	B-DISO
+(	O
+A	O
+/	O
+H1N1pdm	O
+)	O
+virus	B-DISO
+infection	I-DISO
+by	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+.	O
+
+A	O
+41	O
+-	O
+year	O
+-	O
+old	O
+female	O
+visited	O
+our	O
+hospital	O
+with	O
+a	O
+fever	B-PROC
+of	O
+38	O
+.	O
+7C	O
+.	O
+
+She	O
+was	O
+a	O
+public	O
+health	O
+nurse	O
+with	O
+no	O
+underlying	O
+disease	O
+and	O
+had	O
+had	O
+contact	O
+with	O
+a	O
+group	O
+of	O
+elementary	O
+school	O
+students	O
+who	O
+had	O
+been	O
+infected	O
+with	O
+the	O
+influenza	B-DISO
+(	O
+A	O
+/	O
+H1N1pdm	O
+)	O
+virus	B-SPEC
+1	O
+week	O
+earlier	O
+.	O
+
+She	O
+was	O
+prescribed	O
+oseltamivir	B-CHED
+and	O
+returned	O
+to	O
+the	O
+hotel	O
+where	O
+she	O
+was	O
+staying	O
+alone	O
+.	O
+
+The	O
+next	O
+day	O
+,	O
+she	O
+was	O
+found	O
+dead	B-PROC
+in	O
+her	O
+hotel	O
+room	O
+.	O
+
+TITLE	O
+:	O
+Severe	O
+influenza	B-SPEC
+A	I-SPEC
+virus	I-SPEC
+(	O
+H1N1	O
+)	O
+infection	B-DISO
+in	O
+pregnancy	O
+.	O
+
+ABSTRACT	O
+:	O
+H1N1	B-DISO
+influenza	I-DISO
+is	O
+an	O
+emerging	O
+threat	O
+that	O
+is	O
+life	O
+threatening	O
+to	O
+pregnant	O
+women	O
+in	O
+the	O
+third	O
+trimester	O
+.	O
+
+After	O
+delivery	O
+,	O
+she	O
+developed	O
+ARDS	B-DISO
+,	O
+requiring	O
+prolonged	O
+mechanical	O
+ventilation	O
+,	O
+yet	O
+she	O
+survived	O
+and	O
+has	O
+recovered	O
+.	O
+
+Four	O
+scientific	O
+search	O
+engines	O
+using	O
+12	O
+search	O
+sequences	O
+identified	O
+21	O
+mask	O
+studies	O
+in	O
+healthcare	O
+settings	O
+for	O
+the	O
+prevention	O
+of	O
+transmission	O
+of	O
+respiratory	B-SPEC
+syncytial	I-SPEC
+virus	I-SPEC
+,	O
+Bordetella	B-SPEC
+pertussis	I-SPEC
+,	O
+and	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+.	O
+
+ABSTRACT	O
+:	O
+Legionnaires	B-DISO
+'	I-DISO
+disease	I-DISO
+(	O
+LD	O
+)	O
+is	O
+a	O
+pneumonia	B-DISO
+caused	O
+by	O
+Legionella	B-SPEC
+pneumophila	I-SPEC
+(	O
+LP	O
+).	O
+
+Immunocompetent	O
+patient	O
+,	O
+male	O
+,	O
+53	O
+-	O
+year	O
+old	O
+,	O
+with	O
+severe	O
+form	O
+of	O
+LB	O
+had	O
+fever	B-PROC
+,	O
+cough	B-DISO
+,	O
+weakness	B-DISO
+and	O
+diarrhea	B-DISO
+as	O
+the	O
+initial	O
+symptoms	O
+of	O
+the	O
+disease	O
+.	O
+
+CONCLUSIONS	O
+:	O
+In	O
+severe	O
+pneumonias	B-DISO
+it	O
+is	O
+necessary	O
+to	O
+consider	O
+LD	O
+in	O
+differential	O
+diagnosis	O
+,	O
+perform	O
+tests	O
+with	O
+aim	O
+of	O
+detecting	O
+LP	O
+and	O
+apply	O
+adequate	O
+antibiotic	B-CHED
+treatment	O
+in	O
+order	B-SPEC
+to	O
+accomplish	O
+positive	O
+outcome	O
+of	O
+the	O
+therapy	O
+and	O
+prevent	O
+complications	O
+.	O
+
+Pumpless	O
+systems	O
+treat	O
+lung	B-ANAT
+failure	O
+only	O
+;	O
+they	O
+require	O
+adequate	O
+cardiac	B-ANAT
+output	O
+.	O
+
+Anticoagulation	B-PROC
+,	O
+hemodynamic	B-PROC
+,	O
+and	O
+respiratory	O
+variables	O
+were	O
+analyzed	O
+.	O
+
+Initial	O
+serum	B-COMP
+lactate	B-CHED
+was	O
+51	O
++/-	O
+
+43	O
+mg	O
+/	O
+dL	O
+.	O
+The	O
+sequential	O
+organ	B-DISO
+failure	I-DISO
+assessment	O
+score	O
+averaged	O
+11	O
+.	O
+8	O
++/-	O
+
+Respiratory	O
+support	O
+by	O
+an	O
+extracorporeal	O
+device	O
+used	O
+as	O
+last	O
+resort	O
+therapy	O
+allows	O
+rapid	O
+stabilization	O
+of	O
+patients	O
+with	O
+acute	O
+lung	B-ANAT
+failure	O
+.	O
+
+RESULTS	O
+:	O
+All	O
+patients	O
+exhibited	O
+severe	O
+cardiopulmonary	B-DISO
+failure	I-DISO
+with	O
+a	O
+mean	O
+oxygenation	B-PROC
+ratio	O
+(	O
+partial	B-PROC
+pressure	I-PROC
+of	I-PROC
+oxygen	I-PROC
+to	O
+fraction	O
+of	O
+inspired	B-PROC
+oxygen	B-CHED
+ratio	O
+)	O
+of	O
+74	O
++/-	O
+
+The	O
+SARS	B-PRGE
+-	I-PRGE
+CoV	I-PRGE
+3CL	I-PRGE
+protease	I-PRGE
+was	O
+purified	O
+from	O
+a	O
+colon	B-ANAT
+bacillus	B-SPEC
+recombinant	O
+.	O
+
+Therefore	O
+it	O
+seemed	O
+natural	O
+to	O
+expect	O
+that	O
+theoreticians	O
+would	O
+immediately	O
+proceed	O
+to	O
+expand	O
+this	O
+mathematical	O
+framework	O
+both	O
+because	O
+the	O
+need	O
+to	O
+handle	O
+recurrent	O
+single	O
+infectious	B-DISO
+disease	I-DISO
+outbreaks	O
+has	O
+always	O
+been	O
+a	O
+priority	O
+for	O
+public	O
+health	O
+officials	O
+and	O
+because	O
+theoreticians	O
+often	O
+try	O
+to	O
+push	O
+the	O
+limits	O
+of	O
+exiting	O
+theories	O
+.	O
+
+Randomized	O
+controlled	O
+trials	O
+of	O
+INO	O
+in	O
+the	O
+treatment	O
+of	O
+ARDS	B-DISO
+have	O
+shown	O
+short	O
+-	O
+term	O
+physiologic	O
+benefits	O
+,	O
+but	O
+no	O
+benefit	O
+in	O
+long	O
+-	O
+term	O
+outcomes	O
+.	O
+
+It	O
+was	O
+conducted	O
+on	O
+individuals	O
+attending	O
+community	O
+polyclinics	O
+in	O
+Singapore	O
+within	O
+the	O
+first	O
+week	O
+of	O
+July	O
+2003	O
+,	O
+16	O
+weeks	O
+after	O
+the	O
+first	O
+national	O
+outbreak	O
+of	O
+SARS	B-DISO
+.	O
+
+ABSTRACT	O
+:	O
+This	O
+study	O
+aimed	O
+to	O
+examine	O
+the	O
+potential	O
+antiviral	B-CHED
+activity	O
+of	O
+lactic	B-CHED
+acid	I-CHED
+bacteria	B-SPEC
+(	O
+LAB	O
+)	O
+using	O
+animal	B-SPEC
+and	O
+human	B-SPEC
+intestinal	B-ANAT
+and	O
+macrophage	B-ANAT
+cell	B-ANAT
+line	I-ANAT
+models	O
+of	O
+non	O
+tumor	B-DISO
+origin	O
+.	O
+
+Highest	O
+protection	O
+effects	O
+were	O
+recorded	O
+with	O
+the	O
+known	O
+probiotics	O
+Lactobacillus	B-SPEC
+rhamnosus	I-SPEC
+GG	O
+and	O
+Lactobacillus	B-SPEC
+casei	I-SPEC
+Shirota	O
+against	O
+both	O
+RV	O
+and	O
+TGEV	O
+,	O
+while	O
+notable	O
+antiviral	B-CHED
+activity	O
+was	O
+also	O
+attributed	O
+to	O
+Enterococcus	B-SPEC
+faecium	I-SPEC
+PCK38	O
+,	O
+Lactobacillus	B-SPEC
+fermentum	I-SPEC
+ACA	B-ANAT
+-	O
+DC179	O
+,	O
+Lactobacillus	B-SPEC
+pentosus	I-SPEC
+PCA227	O
+and	O
+Lactobacillus	B-SPEC
+plantarum	I-SPEC
+PCA236	O
+and	O
+PCS22	O
+,	O
+depending	O
+on	O
+the	O
+cell	B-ANAT
+line	I-ANAT
+and	O
+virus	B-SPEC
+combination	O
+used	O
+.	O
+
+A	O
+variable	O
+increase	O
+(	O
+of	O
+up	O
+to	O
+50	O
+%)	O
+on	O
+the	O
+release	B-PATH
+of	O
+NO	O
+(-)	O
+and	O
+H	O
+(	O
+2	O
+)	O
+O	O
+(	O
+2	O
+)	O
+(	O
+ROS	B-CHED
+)	O
+was	O
+obtained	O
+when	O
+LAB	O
+strains	O
+were	O
+co	O
+-	O
+incubated	O
+with	O
+the	O
+cell	B-ANAT
+lines	I-ANAT
+,	O
+but	O
+the	O
+results	O
+were	O
+found	O
+to	O
+be	O
+LAB	B-PRGE
+strain	O
+and	O
+cell	B-ANAT
+line	I-ANAT
+specific	O
+,	O
+apart	O
+from	O
+a	O
+small	O
+number	O
+of	O
+strains	O
+which	O
+were	O
+able	O
+to	O
+induce	O
+strong	O
+ROS	B-CHED
+release	B-PATH
+in	O
+more	O
+than	O
+one	O
+cell	B-ANAT
+line	I-ANAT
+.	O
+
+TITLE	O
+:	O
+[	O
+Acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+due	O
+to	O
+Influenza	B-PATH
+A	I-PATH
+(	O
+H1N1	O
+)	O
+S	O
+-	O
+OIV	O
+and	O
+extracorporeal	O
+oxygenation	B-PROC
+:	O
+the	O
+benefit	O
+of	O
+a	O
+multidisciplinary	O
+care	O
+network	O
+].	O
+
+We	O
+report	O
+the	O
+following	O
+case	O
+:	O
+a	O
+23	O
+-	O
+year	O
+-	O
+old	O
+female	O
+patient	O
+with	O
+no	O
+prior	O
+medical	O
+history	O
+presented	O
+a	O
+severe	O
+respiratory	B-DISO
+distress	I-DISO
+that	O
+required	O
+high	O
+frequency	O
+oscillation	O
+ventilation	O
+and	O
+finally	O
+Extracorporeal	O
+Membrane	B-COMP
+Oxygenation	B-PROC
+(	O
+ECMO	O
+).	O
+
+Ticks	B-SPEC
+are	O
+among	O
+the	O
+most	O
+competent	O
+and	O
+versatile	O
+arthropod	B-SPEC
+vectors	O
+of	O
+infectious	B-DISO
+diseases	I-DISO
+because	O
+ticks	B-SPEC
+of	O
+all	O
+ages	O
+and	O
+both	O
+sexes	O
+remain	O
+infectious	B-DISO
+for	O
+generations	O
+without	O
+having	O
+to	O
+reacquire	O
+infections	B-DISO
+from	O
+reservoir	O
+hosts	B-COMP
+.	O
+
+Today	O
+,	O
+ticks	B-SPEC
+transmit	O
+the	O
+most	O
+common	O
+arthropod	B-DISO
+-	I-DISO
+borne	I-DISO
+infectious	I-DISO
+disease	I-DISO
+in	O
+the	O
+United	O
+States	O
+(	O
+US	O
+),	O
+Lyme	B-DISO
+disease	I-DISO
+(	O
+LD	O
+);	O
+and	O
+the	O
+most	O
+lethal	O
+arthropod	B-DISO
+-	I-DISO
+borne	I-DISO
+infectious	I-DISO
+disease	I-DISO
+in	O
+the	O
+US	O
+,	O
+Rocky	B-DISO
+Mountain	I-DISO
+spotted	I-DISO
+fever	I-DISO
+(	O
+RMSF	O
+).	O
+
+Ticks	B-SPEC
+have	O
+also	O
+become	O
+frequent	O
+vectors	O
+of	O
+emerging	O
+zoonotic	O
+diseases	O
+in	O
+the	O
+Gulf	O
+South	O
+,	O
+including	O
+southern	B-DISO
+tick	I-DISO
+-	I-DISO
+associated	I-DISO
+rash	I-DISO
+illness	I-DISO
+(	O
+STARI	O
+),	O
+transmitted	B-DISO
+by	O
+the	O
+lone	B-SPEC
+star	I-SPEC
+tick	I-SPEC
+,	O
+and	O
+Maculatum	O
+disease	O
+,	O
+transmitted	O
+by	O
+the	O
+Gulf	O
+Coast	O
+tick	B-SPEC
+.	O
+
+An	O
+increasing	O
+incidence	O
+of	O
+emerging	O
+and	O
+re	O
+-	O
+emerging	O
+,	O
+endemic	O
+infectious	B-DISO
+diseases	I-DISO
+transmitted	B-DISO
+by	O
+existing	O
+and	O
+unanticipated	O
+tick	B-SPEC
+vectors	O
+may	O
+be	O
+expected	O
+.	O
+
+Web	B-DISO
+of	O
+Science	O
+and	O
+PubMed	O
+databases	O
+were	O
+searched	O
+for	O
+references	O
+to	O
+papers	O
+on	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+,	O
+avian	B-DISO
+influenza	I-DISO
+/	O
+flu	B-DISO
+,	O
+H5N1	B-DISO
+,	O
+swine	B-DISO
+influenza	I-DISO
+/	O
+flu	B-DISO
+,	O
+H1N1	O
+,	O
+and	O
+pandemics	O
+.	O
+
+These	O
+results	O
+suggest	O
+that	O
+rSARS	O
+-	O
+CoV	O
+-	O
+DeltaE	O
+is	O
+an	O
+efficacious	O
+vaccine	O
+candidate	O
+that	O
+might	O
+be	O
+useful	O
+if	O
+SARS	B-DISO
+recurred	O
+.	O
+
+Most	O
+patients	O
+were	O
+considered	O
+quite	O
+healthy	O
+but	O
+the	O
+majority	O
+had	O
+risk	O
+factors	O
+such	O
+as	O
+smoking	O
+,	O
+obesity	B-DISO
+or	O
+hypertension	B-DISO
+.	O
+
+Key	O
+words	O
+:	O
+influenza	B-PATH
+A	I-PATH
+,	O
+pneumonia	B-DISO
+,	O
+multiple	B-DISO
+organ	I-DISO
+failure	I-DISO
+,	O
+death	B-PROC
+rate	O
+,	O
+intensive	O
+care	O
+,	O
+ventilator	O
+therapy	O
+,	O
+ECMO	O
+.	O
+
+RESULTS	O
+:	O
+During	O
+a	O
+six	O
+week	O
+period	O
+in	O
+the	O
+fall	O
+of	O
+2009	O
+,	O
+16	O
+patients	O
+were	O
+admitted	O
+to	O
+intensive	O
+care	O
+in	O
+Iceland	O
+with	O
+confirmed	O
+H1N1	O
+infection	B-DISO
+.	O
+
+Progressive	O
+azotemia	B-DISO
+and	O
+oliguria	B-DISO
+then	O
+developed	O
+,	O
+and	O
+he	O
+required	O
+temporary	O
+hemodialysis	O
+.	O
+
+His	O
+partial	O
+oxygen	B-CHED
+level	O
+gradually	O
+increased	O
+after	O
+continuous	O
+heparin	B-CHED
+and	O
+steroid	B-CHED
+administration	O
+.	O
+
+Although	O
+several	O
+studies	O
+have	O
+demonstrated	O
+the	O
+superiority	O
+of	O
+Artesunate	B-CHED
+,	O
+this	O
+drug	O
+is	O
+not	O
+licensed	O
+in	O
+many	O
+countries	O
+.	O
+
+ABSTRACT	O
+:	O
+N	B-CHED
+-	I-CHED
+glycans	I-CHED
+were	O
+released	O
+from	O
+the	O
+SARS	B-DISO
+coronavirus	B-SPEC
+(	O
+SARS	B-DISO
+-	O
+CoV	O
+)	O
+spike	O
+glycoprotein	B-CHED
+produced	O
+in	O
+Vero	O
+E6	O
+cells	B-COMP
+and	O
+their	O
+structures	O
+were	O
+determined	O
+by	O
+a	O
+combination	O
+of	O
+matrix	O
+-	O
+assisted	O
+laser	B-SPEC
+desorption	O
+/	O
+ionization	O
+(	O
+MALDI	O
+)	O
+mass	O
+spectrometry	O
+,	O
+negative	O
+ion	O
+electrospray	O
+collision	O
+-	O
+induced	O
+dissociation	B-DISO
+time	O
+-	O
+of	O
+-	O
+flight	B-PROC
+mass	O
+spectrometry	O
+and	O
+normal	O
+-	O
+phase	O
+high	O
+-	O
+performance	O
+liquid	O
+chromatography	O
+with	O
+exoglycosidase	O
+digestion	B-PROC
+.	O
+
+TITLE	O
+:	O
+Effect	O
+on	O
+tuberculosis	B-PATH
+outcomes	O
+of	O
+educational	O
+outreach	O
+to	O
+South	O
+African	O
+clinics	O
+during	O
+two	O
+randomised	O
+trials	O
+.	O
+
+In	O
+the	O
+present	O
+study	O
+,	O
+we	O
+determined	O
+the	O
+complete	O
+nucleotide	B-CHED
+sequences	O
+of	O
+the	O
+spike	O
+(	O
+S	O
+)	O
+glycoprotein	B-CHED
+genes	O
+of	O
+seven	O
+Korean	O
+PEDV	B-SPEC
+isolates	O
+.	O
+
+In	O
+addition	O
+,	O
+the	O
+largest	O
+number	O
+of	O
+amino	B-CHED
+acid	I-CHED
+variations	O
+was	O
+accumulated	O
+in	O
+the	O
+S1	O
+N	O
+-	O
+terminal	O
+region	O
+,	O
+leading	O
+to	O
+the	O
+presence	O
+of	O
+hypervariability	O
+in	O
+the	O
+isolates	O
+.	O
+
+ABSTRACT	O
+:	O
+Angiotensin	B-CHED
+-	I-PRGE
+converting	I-PRGE
+enzyme	I-PRGE
+2	I-PRGE
+(	O
+ACE2	O
+),	O
+a	O
+first	O
+homolog	O
+of	O
+ACE	B-PRGE
+,	O
+regulates	O
+the	O
+renin	B-PATH
+-	I-PATH
+angiotensin	B-CHED
+system	I-PATH
+by	O
+counterbalancing	O
+ACE	B-PRGE
+activity	O
+.	O
+
+Accumulating	O
+evidence	O
+in	O
+recent	O
+years	O
+has	O
+demonstrated	O
+a	O
+physiological	O
+and	O
+pathological	O
+role	O
+of	O
+ACE2	B-PRGE
+in	O
+the	O
+cardiovascular	B-ANAT
+,	O
+renal	B-ANAT
+and	O
+respiratory	B-ANAT
+systems	I-ANAT
+.	O
+
+TITLE	O
+:	O
+Delayed	O
+clearance	O
+of	O
+viral	O
+load	O
+and	O
+marked	O
+cytokine	B-PROC
+activation	I-PROC
+in	O
+severe	O
+cases	O
+of	O
+pandemic	O
+H1N1	O
+2009	O
+influenza	O
+virus	B-DISO
+infection	I-DISO
+.	O
+
+Here	O
+,	O
+we	O
+show	O
+that	O
+SARS	B-DISO
+-	O
+CoV	O
+-	O
+infected	O
+aged	O
+macaques	B-SPEC
+develop	O
+more	O
+severe	O
+pathology	B-DISO
+than	O
+young	O
+adult	O
+animals	B-SPEC
+,	O
+even	O
+though	O
+viral	B-PROC
+replication	I-PROC
+levels	O
+are	O
+similar	O
+.	O
+
+Telomere	B-COMP
+-	O
+poor	O
+or	O
+telomere	B-COMP
+-	O
+free	O
+'	B-ANAT
+ghost	I-ANAT
+'	O
+nuclei	B-CHED
+were	O
+a	O
+regular	O
+finding	O
+in	O
+these	O
+RS	O
+cells	O
+.	O
+
+TITLE	O
+:	O
+Hexokinase	B-ENZY
+II	O
+gene	O
+transfer	O
+protects	O
+against	O
+neurodegeneration	B-DISO
+in	O
+the	O
+rotenone	B-CHED
+and	O
+MPTP	B-CHED
+mouse	B-SPEC
+models	O
+of	O
+Parkinson	B-PATH
+'	I-PATH
+s	I-PATH
+disease	I-PATH
+.	O
+
+The	O
+placHK2	O
+amplicon	O
+vector	O
+was	O
+injected	O
+into	O
+substantia	B-ANAT
+nigra	I-ANAT
+of	O
+mice	B-SPEC
+that	O
+were	O
+subsequently	O
+administered	O
+rotenone	B-CHED
+or	O
+MPTP	B-CHED
+.	O
+
+The	O
+spike	B-PRGE
+(	I-PRGE
+S	I-PRGE
+)	I-PRGE
+glycoprotein	I-PRGE
+has	O
+been	O
+identified	O
+as	O
+a	O
+major	O
+target	O
+of	O
+protective	O
+immunity	B-PROC
+and	O
+contains	O
+3	O
+regions	O
+that	O
+are	O
+targeted	B-PROC
+by	O
+neutralizing	O
+antibodies	B-COMP
+in	O
+the	O
+S1	O
+and	O
+S2	O
+domains	O
+.	O
+
+We	O
+also	O
+identified	O
+possible	O
+interactions	O
+between	O
+the	O
+S1	O
+and	O
+S2	O
+domains	O
+of	O
+the	O
+SARS	B-PRGE
+-	I-PRGE
+CoV	I-PRGE
+S	I-PRGE
+glycoprotein	B-CHED
+.	O
+
+These	O
+data	O
+provide	O
+a	O
+mechanism	O
+for	O
+overcoming	O
+neutralization	O
+escape	O
+by	O
+use	O
+of	O
+broadly	O
+cross	B-PROC
+-	I-PROC
+reactive	I-PROC
+cocktails	O
+of	O
+cross	O
+-	O
+neutralizing	O
+MAbs	O
+that	O
+recognize	O
+residues	O
+within	O
+the	O
+receptor	O
+-	O
+binding	B-FUNC
+domain	O
+that	O
+are	O
+critical	O
+for	O
+virus	B-PROC
+replication	I-PROC
+and	O
+virulence	B-PROC
+.	O
+
+TITLE	O
+:	O
+Novel	O
+influenza	B-DISO
+H1N1	O
+in	O
+pregnancy	O
+:	O
+a	O
+report	O
+of	O
+two	O
+cases	O
+.	O
+
+We	O
+hypothesized	O
+that	O
+free	O
+thyroxine	B-CHED
+(	O
+T	O
+(	O
+4	O
+))	O
+levels	O
+in	O
+term	O
+and	O
+late	O
+preterm	O
+infants	O
+with	O
+respiratory	B-DISO
+distress	I-DISO
+would	O
+be	O
+inversely	O
+related	O
+to	O
+severity	O
+of	O
+illness	O
+Eligible	O
+infants	O
+included	O
+those	O
+had	O
+>	O
+or	O
+=	O
+35	O
+weeks	O
+of	O
+gestation	B-PROC
+requiring	O
+mechanical	O
+ventilation	O
+or	O
+nasal	B-ANAT
+continuous	O
+positive	O
+airway	B-ANAT
+pressure	O
+.	O
+
+There	O
+was	O
+an	O
+inverse	O
+correlation	O
+between	O
+SNAP	B-FUNC
+at	O
+birth	B-PROC
+and	O
+fT	O
+(	O
+4	O
+.)	O
+
+The	O
+purpose	O
+of	O
+this	O
+study	O
+was	O
+to	O
+define	O
+the	O
+clinical	O
+phenotype	O
+of	O
+GBS	B-DISO
+and	O
+the	O
+relation	O
+with	O
+preceding	O
+C	O
+jejuni	O
+infections	B-DISO
+in	O
+Bangladesh	O
+.	O
+
+We	O
+performed	O
+a	O
+prospective	O
+matched	O
+case	O
+-	O
+control	O
+hospital	O
+surveillance	O
+including	O
+100	O
+patients	O
+fulfilling	O
+the	O
+National	O
+Institute	O
+of	O
+Neurological	B-DISO
+Disorders	I-DISO
+and	O
+Stroke	B-DISO
+criteria	O
+for	O
+GBS	B-DISO
+from	O
+2006	O
+to	O
+2007	O
+in	O
+the	O
+Dhaka	O
+area	O
+of	O
+Bangladesh	O
+.	O
+
+GBS	B-DISO
+affected	O
+predominantly	O
+young	O
+adult	O
+males	O
+living	O
+in	O
+rural	O
+areas	O
+.	O
+
+The	O
+majority	O
+of	O
+patients	O
+had	O
+a	O
+pure	B-FUNC
+motor	O
+variant	O
+of	O
+GBS	B-DISO
+(	O
+92	O
+%)	O
+with	O
+relatively	O
+infrequent	O
+cranial	B-ANAT
+nerve	I-ANAT
+involvement	O
+(	O
+30	O
+%).	O
+
+Based	O
+on	O
+our	O
+homology	O
+model	O
+of	O
+the	O
+kinase	O
+domain	O
+of	O
+MLK3	B-PRGE
+,	O
+the	O
+region	O
+containing	O
+the	O
+cleavage	B-PROC
+site	O
+is	O
+predicted	O
+to	O
+reside	O
+on	O
+a	O
+flexible	O
+solvent	B-CHED
+-	O
+accessible	O
+loop	O
+.	O
+
+Plasma	B-ANAT
+levels	O
+of	O
+CC16	B-PRGE
+and	O
+KL	O
+-	O
+6	O
+were	O
+higher	O
+in	O
+ALI	O
+/	O
+ARDS	B-DISO
+patients	O
+at	O
+baseline	O
+as	O
+compared	O
+to	O
+patients	O
+without	O
+lung	B-ANAT
+injury	O
+.	O
+
+Plasma	B-ANAT
+levels	O
+of	O
+SP	B-PRGE
+-	I-PRGE
+D	I-PRGE
+and	O
+KL	O
+-	O
+6	O
+rise	O
+with	O
+potentially	O
+injurious	O
+ventilator	O
+settings	O
+,	O
+and	O
+thus	O
+may	O
+serve	O
+as	O
+biological	O
+markers	O
+of	O
+VALI	O
+in	O
+patients	O
+with	O
+ALI	O
+/	O
+ARDS	B-DISO
+.	O
+
+The	O
+Delphi	O
+panel	O
+consisted	O
+of	O
+38	O
+experts	O
+from	O
+22	O
+countries	O
+,	O
+who	O
+highlighted	O
+the	O
+necessity	O
+to	O
+test	O
+plans	O
+and	O
+stressed	O
+the	O
+importance	O
+of	O
+surveillance	O
+measures	O
+for	O
+the	O
+swift	B-SPEC
+containment	O
+of	O
+communicable	B-DISO
+disease	I-DISO
+outbreaks	O
+and	O
+the	O
+inclusion	O
+of	O
+detailed	O
+triage	O
+plans	O
+in	O
+national	O
+pandemic	O
+plans	O
+.	O
+
+Viral	O
+RNA	O
+corresponding	O
+to	O
+the	O
+spike	O
+gene	O
+region	O
+(	O
+1178	O
+-	O
+2073	O
+genome	O
+position	O
+)	O
+was	O
+amplified	O
+from	O
+the	O
+upper	O
+respiratory	O
+tract	O
+of	O
+chickens	B-SPEC
+and	O
+from	O
+the	O
+intestinal	B-ANAT
+tract	I-ANAT
+of	O
+poults	O
+and	O
+phylogenetic	O
+analysis	O
+confirmed	O
+the	O
+identity	O
+as	O
+TCoV	O
+.	O
+This	O
+is	O
+the	O
+first	O
+description	O
+of	O
+TCoV	O
+antigens	B-CHED
+and	O
+mRNA	B-CHED
+in	O
+upper	O
+respiratory	O
+tissues	B-ANAT
+in	O
+experimentally	O
+infected	O
+chickens	B-SPEC
+.	O
+
+ABSTRACT	O
+:	O
+Adult	O
+Respiratory	O
+Distress	O
+Syndrome	O
+results	O
+from	O
+a	O
+variety	O
+of	O
+different	O
+initial	O
+insults	O
+,	O
+including	O
+trauma	O
+,	O
+sepsis	B-DISO
+,	O
+pneumonia	B-DISO
+and	O
+aspiration	B-DISO
+,	O
+and	O
+represents	O
+a	O
+severe	O
+form	O
+of	O
+acute	O
+lung	B-ANAT
+injury	O
+.	O
+
+The	O
+findings	O
+of	O
+these	O
+analyses	O
+all	O
+support	O
+a	O
+""""	O
+golden	O
+mean	O
+""""	O
+model	O
+in	O
+which	O
+viruses	B-SPEC
+use	O
+both	O
+programmed	O
+ribosomal	B-PROC
+frameshifting	I-PROC
+and	O
+translational	B-PROC
+attenuation	I-PROC
+to	O
+control	O
+the	O
+relative	O
+ratios	O
+of	O
+their	O
+encoded	O
+proteins	B-CHED
+.	O
+
+In	O
+addition	O
+,	O
+viral	O
+proteases	O
+can	O
+be	O
+involved	O
+in	O
+further	O
+processes	O
+relevant	O
+for	O
+viral	B-PROC
+replication	I-PROC
+.	O
+
+Our	O
+data	O
+show	O
+that	O
+the	O
+neutralizing	O
+mAbs	O
+bind	B-FUNC
+to	O
+the	O
+angiotensin	B-PRGE
+-	I-PRGE
+converting	I-PRGE
+enzyme	I-PRGE
+2	I-PRGE
+(	O
+ACE2	B-PRGE
+)	O
+receptor	O
+-	O
+binding	B-FUNC
+domain	O
+(	O
+RBD	O
+)	O
+of	O
+the	O
+SARS	B-PRGE
+S	I-PRGE
+protein	B-CHED
+.	O
+
+Three	O
+of	O
+the	O
+chimeric	O
+mAbs	O
+retain	O
+their	O
+binding	O
+specificity	O
+while	O
+one	O
+conformational	O
+mAb	O
+,	O
+F26G19	O
+,	O
+lost	B-CHED
+its	O
+ability	O
+to	O
+bind	B-FUNC
+the	O
+S	B-PRGE
+protein	I-PRGE
+despite	O
+high	O
+level	O
+expression	B-PROC
+.	O
+
+In	O
+cases	O
+like	O
+this	O
+,	O
+the	O
+dominance	O
+of	O
+a	O
+compact	O
+RBD	O
+antigenic	O
+domain	O
+and	O
+the	O
+central	O
+role	O
+of	O
+the	O
+S	B-PRGE
+protein	I-PRGE
+in	O
+pathogenesis	B-DISO
+may	O
+inherently	O
+create	O
+immunoselection	O
+pressure	O
+on	O
+viruses	B-SPEC
+to	O
+evolve	O
+more	O
+complex	O
+evasion	O
+strategies	O
+or	O
+die	O
+out	O
+of	O
+a	O
+host	B-COMP
+species	B-SPEC
+.	O
+
+Dual	O
+infections	B-DISO
+with	O
+PEDV	B-SPEC
+and	O
+PRV	B-DISO
+-	O
+A	O
+were	O
+identified	O
+in	O
+seven	O
+specimens	O
+(	O
+4	O
+%)	O
+(	O
+n	O
+=	O
+6	O
+).	O
+
+ABSTRACT	O
+:	O
+The	O
+main	O
+cause	O
+of	O
+death	O
+in	O
+lung	B-ANAT
+transplantation	O
+patients	O
+is	O
+chronic	O
+rejection	O
+,	O
+known	O
+as	O
+bronchiolitis	B-DISO
+obliterans	I-DISO
+syndrome	B-DISO
+(	O
+BOS	B-DISO
+).	O
+
+Among	O
+the	O
+factors	O
+analyzed	O
+,	O
+13	O
+patients	O
+(	O
+72	O
+%)	O
+displayed	O
+acute	B-PROC
+cellular	I-PROC
+rejection	I-PROC
+and	O
+nine	O
+(	O
+50	O
+%)	O
+gastroesophageal	B-DISO
+reflux	I-DISO
+disease	I-DISO
+(	O
+GERD	B-DISO
+)	O
+diagnosed	O
+by	O
+pHmetry	O
+,	O
+both	O
+of	O
+which	O
+were	O
+significantly	O
+associated	O
+with	O
+BOS	B-DISO
+(	O
+P	O
+=	O
+.	O
+005	O
+).	O
+
+To	O
+date	O
+,	O
+21	O
+randomised	O
+-	O
+controlled	O
+trials	O
+have	O
+enrolled	O
+3	O
+336	O
+preterm	O
+infants	O
+<	O
+34	O
+weeks	O
+of	O
+gestation	B-PROC
+for	O
+iNO	B-PRGE
+treatment	O
+.	O
+
+Overall	O
+,	O
+iNO	B-PRGE
+treatment	O
+does	O
+not	O
+reduce	O
+the	O
+rate	O
+of	O
+bronchopulmonary	B-DISO
+dysplasia	I-DISO
+(	O
+BPD	B-DISO
+)	O
+or	O
+death	B-PROC
+compared	O
+to	O
+controls	O
+.	O
+
+A	O
+complex	O
+interaction	O
+between	O
+the	O
+coronavirus	B-SPEC
+and	O
+the	O
+feline	B-SPEC
+immune	B-ANAT
+system	I-ANAT
+causes	O
+disseminated	O
+vasculitis	B-DISO
+,	O
+which	O
+is	O
+the	O
+hallmark	O
+of	O
+FIP	B-DISO
+.	O
+
+Minimizing	O
+exposure	O
+is	O
+the	O
+best	O
+method	O
+of	O
+preventing	O
+infection	B-DISO
+.	O
+
+Key	O
+recommendations	O
+included	O
+specific	O
+policies	O
+and	O
+guidelines	O
+concerning	O
+psychosocial	O
+care	O
+,	O
+infection	B-DISO
+control	O
+,	O
+communication	O
+strategies	O
+and	O
+the	O
+management	O
+of	O
+various	O
+resources	O
+.	O
+
+ABSTRACT	O
+:	O
+Respiratory	O
+infections	O
+are	O
+among	O
+the	O
+most	O
+important	O
+diseases	O
+of	O
+growing	O
+pigs	B-SPEC
+.	O
+
+There	O
+was	O
+a	O
+broad	O
+range	O
+of	O
+microscopical	O
+lesions	O
+and	O
+the	O
+cases	O
+were	O
+characterized	O
+as	O
+acute	O
+(	O
+n	O
+=	O
+10	O
+),	O
+subacute	O
+(	O
+n	O
+=	O
+24	O
+)	O
+or	O
+chronic	O
+(	O
+n	O
+=	O
+114	O
+)	O
+bronchopneumonia	B-DISO
+.	O
+
+Here	O
+we	O
+characterized	O
+the	O
+DUB	B-PRGE
+and	O
+IFN	B-PRGE
+antagonism	O
+activities	O
+of	O
+the	O
+PLP	B-PRGE
+domains	I-PRGE
+of	O
+human	B-SPEC
+coronavirus	I-SPEC
+NL63	I-SPEC
+and	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+(	O
+SARS	B-DISO
+)	O
+coronavirus	B-SPEC
+to	O
+determine	O
+if	O
+DUB	B-PRGE
+activity	O
+mediates	O
+interferon	B-PRGE
+antagonism	O
+.	O
+
+We	O
+found	O
+that	O
+NL63	B-PRGE
+PLP2	I-PRGE
+deconjugated	O
+ubiquitin	B-PROC
+(	O
+Ub	B-PROC
+)	O
+and	O
+the	O
+Ub	B-PROC
+-	O
+line	O
+molecule	O
+ISG15	O
+from	O
+cellular	B-COMP
+substrates	O
+and	O
+processed	O
+both	O
+lysine	B-CHED
+-	O
+48	O
+-	O
+and	O
+lysine	B-CHED
+-	O
+63	O
+-	O
+linked	O
+polyubiquitin	B-PRGE
+chains	I-PRGE
+.	O
+
+ABSTRACT	O
+:	O
+Avian	B-SPEC
+coronavirus	I-SPEC
+infectious	B-DISO
+bronchitis	B-DISO
+virus	B-SPEC
+(	O
+IBV	B-SPEC
+)	O
+poses	O
+a	O
+major	O
+threat	O
+to	O
+the	O
+global	O
+poultry	O
+industry	O
+.	O
+
+However	O
+,	O
+no	O
+positive	O
+selection	O
+pressures	O
+were	O
+related	O
+to	O
+those	O
+variations	O
+in	O
+the	O
+S1	O
+genes	O
+among	O
+Taiwan	O
+IBV	B-SPEC
+.	O
+
+To	O
+assess	O
+the	O
+in	O
+vitro	O
+antiviral	B-CHED
+activity	O
+of	O
+swine	B-SPEC
+intestine	B-ANAT
+antimicrobial	B-CHED
+peptides	B-CHED
+(	O
+SIAMP	O
+)	O
+against	O
+IBV	B-SPEC
+,	O
+45	O
+chick	B-ANAT
+embryos	I-ANAT
+were	O
+randomly	O
+assigned	O
+into	O
+3	O
+groups	O
+,	O
+15	O
+for	O
+each	O
+group	O
+.	O
+
+TITLE	O
+:	O
+Inhaled	B-PROC
+prostacyclin	B-CHED
+in	O
+combination	O
+with	O
+high	O
+-	O
+frequency	O
+percussive	O
+ventilation	O
+.	O
+
+ABSTRACT	O
+:	O
+We	O
+report	O
+a	O
+case	O
+of	O
+severe	O
+neonatal	B-DISO
+infection	I-DISO
+on	O
+day	O
+6	O
+of	O
+life	O
+due	O
+to	O
+Toxoplasma	B-SPEC
+gondii	I-SPEC
+mimicking	O
+septic	O
+shock	B-DISO
+syndrome	I-DISO
+associated	O
+with	O
+multiple	B-DISO
+organ	I-DISO
+failure	I-DISO
+such	O
+as	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+with	O
+persistent	B-DISO
+pulmonary	I-DISO
+hypertension	I-DISO
+,	O
+neurological	O
+distress	O
+,	O
+thrombocytopenia	O
+with	O
+disseminated	O
+intravascular	O
+coagulopathy	B-DISO
+and	O
+transaminitis	O
+.	O
+
+We	O
+propose	O
+that	O
+administering	O
+inhalable	O
+insulin	B-PRGE
+to	O
+hyperglycemic	O
+ALI	O
+/	O
+ARDS	B-DISO
+patients	O
+could	O
+directly	O
+reduce	O
+alveolar	B-ANAT
+inflammation	B-DISO
+while	O
+reducing	O
+circulating	O
+glucose	B-CHED
+levels	O
+.	O
+
+TITLE	O
+:	O
+Social	O
+support	O
+and	O
+psychological	B-DISO
+adjustment	O
+to	O
+SARS	B-DISO
+:	O
+the	O
+mediating	O
+role	O
+of	O
+self	O
+-	O
+care	O
+self	O
+-	O
+efficacy	O
+.	O
+
+Based	O
+on	O
+structural	O
+equation	O
+modeling	O
+,	O
+findings	O
+showed	O
+that	O
+self	O
+-	O
+care	O
+self	O
+-	O
+efficacy	O
+completely	O
+mediated	O
+the	O
+effects	O
+of	O
+perceived	O
+medical	O
+staff	O
+support	O
+and	O
+perceived	O
+family	B-SPEC
+/	O
+friends	O
+support	O
+on	O
+mental	O
+health	O
+status	O
+.	O
+
+The	O
+model	O
+achieved	O
+a	O
+satisfactory	O
+fit	B-DISO
+,	O
+CFI	B-FUNC
+=	O
+0	O
+.	O
+98	O
+,	O
+NNFI	O
+=	O
+0	O
+.	O
+98	O
+,	O
+RMSEA	O
+=	O
+0	O
+.	O
+06	O
+,	O
+and	O
+explained	O
+75	O
+.	O
+2	O
+%	O
+of	O
+the	O
+variance	O
+in	O
+mental	O
+health	O
+status	O
+.	O
+
+Excessive	O
+inflammatory	B-DISO
+response	I-DISO
+to	O
+necrotic	B-ANAT
+debris	I-ANAT
+might	O
+contribute	O
+to	O
+the	O
+development	B-PROC
+of	O
+ARDS	B-DISO
+.	O
+
+Despite	O
+these	O
+measures	O
+,	O
+3	O
+patients	O
+(	O
+43	O
+%)	O
+ultimately	O
+died	B-PROC
+.	O
+
+Clinicians	O
+should	O
+be	O
+vigilant	O
+for	O
+the	O
+potential	O
+of	O
+H1N1	O
+infection	B-DISO
+to	O
+progress	O
+to	O
+severe	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+in	O
+a	O
+variety	O
+of	O
+patient	O
+demographics	O
+,	O
+including	O
+younger	O
+patients	O
+without	O
+baseline	O
+cardiopulmonary	B-DISO
+disease	I-DISO
+.	O
+
+A	O
+high	O
+degree	O
+of	O
+suspicion	O
+is	O
+critical	O
+,	O
+especially	O
+with	O
+the	O
+relative	O
+insensitivity	O
+of	O
+rapid	O
+testing	O
+,	O
+and	O
+should	O
+prompt	O
+empiric	O
+antiviral	B-CHED
+therapy	O
+.	O
+
+When	O
+the	O
+host	B-COMP
+population	O
+is	O
+vaccinated	O
+,	O
+the	O
+virus	B-SPEC
+escapes	O
+from	O
+passive	B-PROC
+immunity	I-PROC
+by	O
+mutations	O
+in	O
+the	O
+antibody	B-COMP
+-	O
+binding	B-FUNC
+region	O
+on	O
+the	O
+surface	O
+of	O
+the	O
+target	O
+protein	B-CHED
+.	O
+
+Using	O
+population	O
+genetic	O
+theory	O
+,	O
+we	O
+evaluated	O
+the	O
+probability	O
+that	O
+a	O
+mutant	B-DISO
+is	O
+fixed	B-ANAT
+in	O
+a	O
+host	B-COMP
+population	O
+.	O
+
+We	O
+simulate	O
+the	O
+adaptive	O
+evolution	B-PROC
+of	O
+coronavirus	B-SPEC
+,	O
+the	O
+etiological	O
+agent	O
+of	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+,	O
+and	O
+show	O
+that	O
+some	O
+of	O
+mutations	O
+in	O
+the	O
+RBD	O
+may	O
+have	O
+high	O
+fixation	O
+probabilities	O
+in	O
+the	O
+vaccinated	O
+host	B-COMP
+population	O
+.	O
+
+15	O
+.	O
+6	O
+years	O
+;	O
+75	O
+%	O
+men	O
+)	O
+with	O
+severe	O
+ARDS	B-DISO
+(	O
+PaO	B-PROC
+(	O
+2	O
+)/	O
+FiO2	O
+<	O
+or	O
+=	O
+150	O
+mmHg	O
+)	O
+admitted	O
+to	O
+a	O
+medical	O
+intensive	O
+care	O
+unit	O
+(	O
+MICU	O
+).	O
+
+TITLE	O
+:	O
+[	O
+What	O
+degree	O
+of	O
+hypoxemia	O
+is	O
+tolerable	O
+for	O
+human	B-SPEC
+beings	O
+?].	O
+
+Seven	O
+patients	O
+(	O
+20	O
+.	O
+6	O
+%)	O
+required	O
+partial	O
+PA	O
+reconstruction	O
+with	O
+autologous	O
+pericardium	B-ANAT
+patch	O
+.	O
+
+Five	O
+patients	O
+(	O
+14	O
+.	O
+7	O
+%)	O
+with	O
+a	O
+lower	O
+lobe	B-ANAT
+tumor	B-DISO
+required	O
+PA	O
+reconstruction	O
+with	O
+artery	B-ANAT
+flap	B-ANAT
+.	O
+
+The	O
+perioperative	O
+mortality	O
+was	O
+2	O
+.	O
+9	O
+%,	O
+and	O
+1	O
+patient	O
+died	B-PROC
+on	O
+postoperative	O
+day	O
+13	O
+because	O
+of	O
+severe	O
+bronchopleural	B-DISO
+fistula	I-DISO
+.	O
+
+Quantum	O
+dots	O
+(	O
+QDs	O
+)	O
+posses	O
+unique	O
+fluorescence	O
+properties	O
+that	O
+have	O
+also	O
+been	O
+explored	O
+for	O
+their	O
+application	O
+to	O
+virus	B-SPEC
+detection	O
+when	O
+combined	O
+with	O
+direct	O
+antibody	B-COMP
+conjugation	B-PROC
+or	O
+streptavidin	O
+-	O
+biotin	B-FUNC
+binding	I-FUNC
+systems	O
+.	O
+
+ABSTRACT	O
+:	O
+To	O
+describe	O
+the	O
+clinical	O
+manifestations	O
+laboratory	O
+findings	O
+and	O
+frequency	O
+of	O
+complications	O
+in	O
+adult	O
+chickenpox	B-DISO
+patients	O
+admitted	O
+in	O
+the	O
+hospital	O
+.	O
+
+Full	O
+blood	B-ANAT
+count	O
+,	O
+urea	B-CHED
+,	O
+electrolytes	O
+and	O
+blood	B-ANAT
+sugar	O
+were	O
+done	O
+for	O
+all	O
+the	O
+patients	O
+,	O
+whereas	O
+,	O
+other	O
+tests	O
+were	O
+carried	O
+out	O
+when	O
+and	O
+where	O
+it	O
+was	O
+indicated	O
+.	O
+
+Children	O
+usually	O
+have	O
+mild	O
+-	O
+to	O
+-	O
+severe	O
+respiratory	B-DISO
+symptoms	I-DISO
+and	O
+occasionally	O
+die	O
+of	O
+respiratory	B-DISO
+failure	I-DISO
+.	O
+
+Pathologically	O
+,	O
+the	O
+lungs	B-ANAT
+had	O
+grossly	O
+visible	O
+emphysematous	O
+changes	O
+with	O
+""""	O
+cysts	B-DISO
+""""	O
+up	O
+to	O
+2	O
+mm	O
+in	O
+diameter	O
+.	O
+
+Ultrastructurally	O
+,	O
+type	B-ANAT
+II	I-ANAT
+pneumocytes	I-ANAT
+had	O
+numerous	O
+lamellar	O
+bodies	O
+,	O
+and	O
+alveolar	B-ANAT
+spaces	O
+contained	O
+fragments	O
+of	O
+type	B-ANAT
+II	I-ANAT
+pneumocytes	I-ANAT
+and	O
+extruded	O
+lamellar	O
+bodies	O
+.	O
+
+Linear	O
+regression	O
+analyses	O
+between	O
+the	O
+average	O
+polarities	O
+and	O
+the	O
+folding	O
+rates	O
+of	O
+peptide	B-CHED
+chains	O
+were	O
+performed	O
+for	O
+alpha	O
+-	O
+helices	B-SPEC
+and	O
+beta	O
+-	O
+strands	O
+respectively	O
+.	O
+
+ABSTRACT	O
+:	O
+A	O
+joint	B-ANAT
+study	O
+group	O
+on	O
+cow	O
+'	O
+s	O
+milk	O
+allergy	B-PROC
+was	O
+convened	O
+by	O
+the	O
+Emilia	B-SPEC
+-	O
+Romagna	O
+Working	O
+Group	O
+for	O
+Paediatric	O
+Allergy	B-DISO
+and	O
+by	O
+the	O
+Emilia	B-SPEC
+-	O
+Romagna	O
+Working	O
+Group	O
+for	O
+Paediatric	O
+Gastroenterology	O
+to	O
+focus	O
+best	O
+practice	O
+for	O
+diagnosis	O
+,	O
+management	O
+and	O
+follow	O
+-	O
+up	O
+of	O
+cow	B-DISO
+'	I-DISO
+s	I-DISO
+milk	I-DISO
+allergy	B-PROC
+in	O
+children	O
+and	O
+to	O
+offer	O
+a	O
+common	O
+approach	O
+for	O
+allergologists	O
+,	O
+gastroenterologists	O
+,	O
+general	O
+paediatricians	O
+and	O
+primary	O
+care	O
+physicians	O
+.	O
+
+Late	O
+reactions	O
+due	O
+to	O
+cow	B-DISO
+'	I-DISO
+s	I-DISO
+milk	I-DISO
+allergy	B-PROC
+are	O
+atopic	B-DISO
+dermatitis	I-DISO
+,	O
+chronic	B-DISO
+diarrhoea	I-DISO
+,	O
+blood	B-ANAT
+in	O
+the	O
+stools	B-ANAT
+,	O
+iron	B-DISO
+deficiency	I-DISO
+anaemia	I-DISO
+,	O
+gastroesophageal	B-DISO
+reflux	I-DISO
+disease	I-DISO
+,	O
+constipation	B-DISO
+,	I-DISO
+chronic	I-DISO
+vomiting	B-DISO
+,	O
+colic	B-DISO
+,	O
+poor	O
+growth	B-PROC
+(	O
+food	O
+refusal	O
+),	O
+enterocolitis	B-DISO
+syndrome	B-DISO
+,	O
+protein	B-DISO
+-	I-DISO
+losing	I-DISO
+enteropathy	I-DISO
+with	O
+hypoalbuminemia	O
+,	O
+eosinophilic	O
+oesophagogastroenteropathy	O
+.	O
+
+TITLE	O
+:	O
+A	O
+comparative	O
+epidemiologic	O
+analysis	O
+of	O
+SARS	B-DISO
+in	O
+Hong	O
+Kong	O
+,	O
+Beijing	O
+and	O
+Taiwan	O
+.	O
+
+ABSTRACT	O
+:	O
+Mice	B-SPEC
+infected	O
+with	O
+the	O
+neurotropic	O
+JHM	O
+strain	O
+of	O
+mouse	B-DISO
+hepatitis	I-DISO
+virus	B-SPEC
+(	O
+JHMV	O
+)	O
+develop	O
+acute	O
+and	O
+chronic	O
+demyelinating	B-DISO
+diseases	I-DISO
+with	O
+histopathological	O
+similarities	O
+to	O
+multiple	B-DISO
+sclerosis	I-DISO
+.	O
+
+By	O
+extension	O
+,	O
+decreasing	O
+inflammation	B-DISO
+,	O
+whether	O
+by	O
+Treg	O
+transfer	O
+or	O
+by	O
+otherwise	O
+enhancing	O
+the	O
+anti	O
+-	O
+inflammatory	O
+milieu	O
+,	O
+could	O
+contribute	O
+to	O
+improved	O
+clinical	O
+outcomes	O
+in	O
+patients	O
+with	O
+virus	B-SPEC
+-	O
+induced	O
+demyelination	B-DISO
+.	O
+
+This	O
+study	O
+further	O
+shows	O
+that	O
+an	O
+imperfect	O
+SARS	O
+vaccine	O
+with	O
+infection	B-DISO
+-	O
+blocking	B-DISO
+efficacy	O
+is	O
+always	O
+beneficial	O
+in	O
+reducing	O
+disease	O
+spread	O
+within	O
+the	O
+community	O
+,	O
+although	O
+its	O
+overall	O
+impact	O
+increases	O
+with	O
+increasing	O
+efficacy	O
+and	O
+coverage	O
+.	O
+
+ABSTRACT	O
+:	O
+To	O
+observe	O
+the	O
+effect	O
+of	O
+Qingyi	O
+Decoction	O
+(	O
+QYD	O
+)	O
+in	O
+treating	O
+severe	O
+acute	B-DISO
+pancreatitis	I-DISO
+(	O
+SAP	O
+)	O
+and	O
+its	O
+impacts	O
+on	O
+blood	B-ANAT
+levels	O
+of	O
+tumor	B-PRGE
+necrosis	I-PRGE
+factor	I-PRGE
+-	I-PRGE
+alpha	I-PRGE
+(	O
+TNF	B-PRGE
+-	I-PRGE
+alpha	I-PRGE
+),	O
+interleukin	B-PRGE
+6	I-PRGE
+and	O
+8	O
+(	O
+IL	B-FUNC
+-	I-FUNC
+6	I-FUNC
+and	O
+IL	B-FUNC
+-	I-FUNC
+8	I-FUNC
+).	O
+
+The	O
+incidences	O
+of	O
+the	O
+two	O
+severe	O
+complications	O
+,	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+and	O
+intestinal	B-DISO
+paralysis	I-DISO
+,	O
+in	O
+the	O
+treated	O
+group	O
+was	O
+3	O
+.	O
+6	O
+%	O
+and	O
+5	O
+.	O
+4	O
+%	O
+respectively	O
+,	O
+while	O
+in	O
+the	O
+control	O
+group	O
+,	O
+12	O
+.	O
+7	O
+%	O
+and	O
+18	O
+.	O
+2	O
+%,	O
+showing	O
+statistical	O
+significance	O
+between	O
+groups	O
+(	O
+P	O
+<	O
+0	O
+.	O
+05	O
+).	O
+
+Reference	O
+sera	B-COMP
+against	O
+newcastle	B-SPEC
+disease	I-SPEC
+virus	I-SPEC
+,	O
+infectious	B-DISO
+bursal	I-DISO
+disease	I-DISO
+,	O
+avian	B-SPEC
+influenza	I-SPEC
+virus	I-SPEC
+H5	O
+and	O
+H9	O
+subtypes	O
+were	O
+all	O
+negatives	O
+for	O
+anti	O
+-	O
+IBV	B-SPEC
+antibodies	B-COMP
+using	O
+the	O
+GICA	O
+.	O
+
+The	O
+GICA	O
+test	O
+strip	O
+is	O
+a	O
+reliable	O
+and	O
+useful	O
+tool	O
+for	O
+the	O
+on	O
+-	O
+site	O
+surveillance	O
+of	O
+anti	O
+-	O
+IBV	B-SPEC
+antibodies	B-COMP
+.	O
+
+Immunoglobulins	O
+A	O
+,	O
+G	B-PRGE
+and	I-PRGE
+M	I-PRGE
+(	O
+IgA	B-PRGE
+,	O
+G	O
+and	O
+M	O
+)	O
+types	O
+of	O
+anticardiolipin	O
+antibodies	B-COMP
+were	O
+examined	O
+by	O
+enzyme	O
+-	O
+linked	O
+immunosorbent	O
+assay	O
+.	O
+
+The	O
+routine	O
+examinations	O
+of	O
+prothrombin	B-PRGE
+time	O
+,	O
+thrombin	B-PRGE
+time	O
+,	O
+prothrombin	B-PRGE
+activity	O
+,	O
+and	O
+international	O
+normalized	O
+ratio	O
+were	O
+also	O
+performed	O
+.	O
+
+The	O
+titers	O
+of	O
+specific	O
+IgA	B-PRGE
+,	O
+IgG	B-PRGE
+,	O
+and	O
+IgM	B-PRGE
+were	O
+11	O
+.	O
+33	O
++/-	O
+
+Coronaviruses	O
+were	O
+detected	O
+by	O
+RT	O
+-	O
+PCR	O
+in	O
+14	O
+out	O
+of	O
+36	O
+horseshoe	B-SPEC
+bat	I-SPEC
+(	O
+Rhinolophus	B-SPEC
+hipposideros	I-SPEC
+)	O
+fecal	B-ANAT
+samples	O
+,	O
+with	O
+38	O
+.	O
+8	O
+%	O
+virus	B-SPEC
+prevalence	O
+.	O
+
+The	O
+most	O
+closely	O
+related	O
+virus	O
+sequence	O
+in	O
+GenBank	O
+was	O
+SARS	B-DISO
+bat	B-ENZY
+isolate	O
+Rp3	B-DISO
+/	O
+2004	O
+(	O
+DQ071615	O
+)	O
+within	O
+the	O
+SARS	B-DISO
+-	O
+like	O
+CoV	O
+cluster	O
+,	O
+sharing	O
+85	O
+%	O
+nucleotide	B-CHED
+identity	O
+and	O
+95	O
+.	O
+6	O
+%	O
+amino	B-CHED
+acid	I-CHED
+identity	O
+.	O
+
+Spike	O
+(	O
+S	O
+)	O
+protein	B-CHED
+of	O
+coronavirus	B-SPEC
+(	O
+CoV	O
+)	O
+is	O
+responsible	O
+for	O
+entry	O
+events	O
+.	O
+
+The	O
+entry	O
+pathway	B-PROC
+of	O
+SARS	B-DISO
+-	O
+CoV	O
+could	O
+influence	O
+the	O
+severity	O
+of	O
+the	O
+disease	O
+.	O
+
+Here	O
+an	O
+outline	O
+is	O
+provided	O
+of	O
+basic	O
+concepts	O
+and	O
+approaches	O
+used	O
+in	O
+mathematical	O
+modeling	O
+and	O
+parameterization	O
+of	O
+disease	B-DISO
+transmission	I-DISO
+.	O
+
+ABSTRACT	O
+:	O
+In	O
+ovo	B-SPEC
+vaccination	O
+remains	O
+an	O
+attractive	O
+option	O
+for	O
+a	O
+cost	O
+effective	O
+,	O
+uniform	O
+and	O
+mass	O
+application	O
+of	O
+vaccines	O
+for	O
+commercial	O
+poultry	O
+.	O
+
+In	O
+this	O
+study	O
+,	O
+a	O
+recombinant	O
+adenovirus	B-DISO
+expressing	O
+the	O
+S1	B-PRGE
+gene	I-PRGE
+of	O
+nephropathogenic	O
+IBV	B-SPEC
+(	O
+rAd	B-PRGE
+-	I-PRGE
+S1	I-PRGE
+)	O
+was	O
+constructed	O
+and	O
+the	O
+immune	B-PROC
+responses	I-PROC
+and	O
+protective	O
+efficacy	O
+against	O
+homologous	O
+challenge	O
+were	O
+evaluated	O
+after	O
+in	O
+ovo	B-SPEC
+vaccination	O
+.	O
+
+The	O
+construction	O
+of	O
+non	O
+-	O
+replicating	O
+human	B-SPEC
+adenovirus	B-DISO
+vector	O
+encoding	O
+S1	B-PRGE
+gene	I-PRGE
+of	O
+IBV	B-SPEC
+and	O
+its	O
+in	O
+ovo	B-SPEC
+delivery	O
+demonstrated	O
+the	O
+potential	O
+of	O
+an	O
+alternative	O
+vaccination	O
+strategy	O
+against	O
+IBV	B-SPEC
+.	O
+
+Furthermore	O
+,	O
+MHV	B-SPEC
+is	O
+relatively	O
+resistant	O
+to	O
+the	O
+antiviral	B-CHED
+effects	O
+of	O
+IFN	B-PRGE
+-	I-PRGE
+alpha	I-PRGE
+/	I-PRGE
+beta	I-PRGE
+in	O
+mouse	B-SPEC
+fibroblast	I-ANAT
+cell	B-ANAT
+lines	I-ANAT
+and	O
+in	O
+human	B-SPEC
+293T	O
+cells	B-COMP
+.	O
+
+Canine	O
+coronavirus	B-SPEC
+type	O
+II	O
+was	O
+detected	O
+by	O
+reverse	B-PROC
+transcription	I-PROC
+nested	O
+polymerase	O
+chain	O
+reaction	O
+in	O
+all	O
+11	O
+puppies	O
+,	O
+whereas	O
+1	O
+puppy	O
+presented	O
+dual	O
+infection	B-DISO
+with	O
+CCoV	O
+type	O
+II	O
+and	O
+canine	O
+parvovirus	B-DISO
+2	O
+.	O
+
+It	O
+involves	O
+scoring	O
+the	O
+severity	O
+of	O
+clinical	O
+signs	O
+,	O
+the	O
+transmission	O
+of	O
+the	O
+infection	B-DISO
+,	O
+the	O
+number	O
+of	O
+cases	O
+,	O
+and	O
+the	O
+infection	B-DISO
+source	O
+.	O
+
+The	O
+use	O
+of	O
+surrogate	O
+viruses	B-SPEC
+has	O
+the	O
+potential	O
+to	O
+overcome	O
+the	O
+challenges	O
+of	O
+working	O
+with	O
+SARS	B-DISO
+-	O
+CoV	O
+and	O
+to	O
+increase	O
+the	O
+available	O
+data	O
+on	O
+coronavirus	B-SPEC
+survival	O
+on	O
+surfaces	O
+.	O
+
+The	O
+results	O
+show	O
+that	O
+when	O
+high	O
+numbers	O
+of	O
+viruses	B-SPEC
+are	O
+deposited	O
+,	O
+TGEV	B-SPEC
+and	O
+MHV	B-SPEC
+may	O
+survive	O
+for	O
+days	O
+on	O
+surfaces	O
+at	O
+ATs	B-DISO
+and	O
+RHs	B-DISO
+typical	O
+of	O
+indoor	O
+environments	O
+.	O
+
+Strain	O
+H165	O
+has	O
+been	O
+proven	O
+to	O
+be	O
+safe	O
+in	O
+piglets	O
+and	O
+pregnant	O
+sows	O
+and	O
+displays	O
+efficacy	O
+against	O
+TGEV	B-SPEC
+infection	B-DISO
+.	O
+
+The	O
+genomes	O
+were	O
+28	O
+,	O
+569	O
+nucleotides	B-CHED
+in	O
+length	O
+,	O
+including	O
+the	O
+poly	O
+(	O
+A	O
+)	O
+tail	O
+.	O
+
+Our	O
+findings	O
+from	O
+phylogenetic	O
+analysis	O
+may	O
+enhance	O
+our	O
+understanding	O
+of	O
+the	O
+evolution	B-PROC
+of	O
+TGEV	B-SPEC
+,	O
+as	O
+well	O
+as	O
+the	O
+other	O
+coronaviruses	O
+.	O
+
+Finally	O
+,	O
+the	O
+events	O
+surrounding	O
+the	O
+pneumonic	B-DISO
+plague	I-DISO
+outbreak	O
+of	O
+1994	O
+in	O
+Surat	O
+,	O
+India	O
+,	O
+highlighted	O
+the	O
+need	O
+for	O
+the	O
+public	O
+to	O
+be	O
+kept	O
+adequately	O
+informed	O
+about	O
+an	O
+incident	O
+.	O
+
+TITLE	O
+:	O
+Induction	O
+of	O
+interferon	B-FUNC
+-	I-FUNC
+gamma	I-FUNC
+-	O
+inducible	O
+protein	B-CHED
+10	O
+by	O
+SARS	B-DISO
+-	I-DISO
+CoV	I-DISO
+infection	I-DISO
+,	O
+interferon	B-PRGE
+alfacon	I-PRGE
+1	I-PRGE
+and	O
+interferon	B-CHED
+inducer	I-CHED
+in	O
+human	B-SPEC
+bronchial	B-ANAT
+epithelial	O
+Calu	O
+-	O
+3	O
+cells	B-COMP
+and	O
+BALB	O
+/	O
+c	O
+mice	B-SPEC
+.	O
+
+Several	O
+mechanisms	O
+involving	O
+both	O
+direct	O
+effects	O
+on	O
+target	B-ANAT
+cells	I-ANAT
+and	O
+indirect	O
+effects	O
+via	O
+the	O
+immune	B-ANAT
+system	I-ANAT
+might	O
+exist	O
+.	O
+
+To	O
+find	O
+out	O
+if	O
+HCoVs	O
+can	O
+be	O
+found	O
+in	O
+stools	B-ANAT
+of	O
+children	O
+with	O
+acute	B-DISO
+gastroenteritis	I-DISO
+and	O
+to	O
+assess	O
+the	O
+significance	O
+of	O
+HCoVs	O
+in	O
+the	O
+etiology	O
+of	O
+acute	B-DISO
+gastroenteritis	I-DISO
+in	O
+children	O
+.	O
+
+This	O
+study	O
+shows	O
+that	O
+all	O
+known	O
+non	O
+-	O
+SARS	B-DISO
+HCoVs	O
+can	O
+be	O
+found	O
+in	O
+stools	B-ANAT
+of	O
+children	O
+with	O
+acute	B-DISO
+gastroenteritis	I-DISO
+.	O
+
+On	O
+the	O
+basis	O
+of	O
+this	O
+study	O
+,	O
+the	O
+significance	O
+of	O
+coronaviruses	O
+as	O
+gastrointestinal	O
+pathogens	O
+in	O
+children	O
+appears	O
+minor	O
+,	O
+since	O
+most	O
+of	O
+the	O
+coronavirus	B-SPEC
+findings	O
+were	O
+co	B-DISO
+-	I-DISO
+infections	I-DISO
+with	O
+known	O
+gastroenteritis	B-DISO
+viruses	B-SPEC
+.	O
+
+Therefore	O
+,	O
+widening	O
+indications	O
+with	O
+the	O
+aim	O
+of	O
+reducing	O
+ventilator	O
+induced	O
+lung	B-ANAT
+injury	O
+(	O
+VILI	O
+)	O
+is	O
+still	O
+controversial	O
+.	O
+
+In	O
+some	O
+infected	O
+cats	B-SPEC
+,	O
+virulent	O
+virus	B-SPEC
+mutants	O
+induce	O
+feline	B-DISO
+infectious	I-DISO
+peritonitis	I-DISO
+(	O
+FIP	B-DISO
+),	O
+a	O
+fatal	O
+systemic	B-DISO
+disease	I-DISO
+that	O
+can	O
+develop	O
+in	O
+association	O
+with	O
+viraemia	B-DISO
+.	O
+
+Phylogenetic	O
+analysis	O
+of	O
+all	O
+non	O
+-	O
+structural	O
+and	O
+most	O
+structural	O
+genes	O
+shows	O
+that	O
+TW	O
+IBV	B-SPEC
+is	O
+genetically	O
+distinct	O
+from	O
+the	O
+US	O
+strain	O
+and	O
+more	O
+similar	O
+to	O
+Chinese	O
+(	O
+CH	O
+)	O
+IBV	B-SPEC
+.	O
+
+In	O
+contrast	O
+,	O
+the	O
+nucleocapsid	B-COMP
+(	O
+N	O
+)	O
+gene	O
+of	O
+TW	O
+IBV	B-SPEC
+presents	O
+phylogenetic	O
+incongruence	O
+.	O
+
+Occasionally	O
+the	O
+mother	O
+has	O
+a	O
+substantial	O
+proportion	O
+of	O
+abnormal	O
+mtDNA	B-COMP
+and	O
+develops	O
+severe	O
+symptoms	O
+in	O
+adulthood	O
+.	O
+
+Outcomes	O
+were	O
+kidney	B-ANAT
+injury	O
+and	O
+kidney	B-DISO
+failure	I-DISO
+defined	O
+using	O
+RIFLE	O
+(	O
+risk	O
+,	O
+injury	O
+,	O
+failure	O
+,	O
+loss	O
+,	O
+end	O
+-	O
+stage	O
+disease	O
+)	O
+criteria	O
+or	O
+need	O
+for	O
+dialysis	B-SPEC
+therapy	O
+.	O
+
+A	O
+chronic	O
+treatment	O
+with	O
+corticosterone	B-CHED
+downregulates	O
+proinflammatory	O
+cytokines	O
+and	O
+chemokines	O
+,	O
+suggesting	O
+that	O
+the	O
+delayed	O
+effects	O
+of	O
+chronic	O
+stress	O
+can	O
+suppress	O
+the	O
+immune	B-PROC
+response	I-PROC
+.	O
+
+Viroporins	O
+E	O
+from	O
+mouse	B-PRGE
+hepatitis	I-PRGE
+virus	B-SPEC
+,	I-PRGE
+6K	I-PRGE
+from	I-PRGE
+Sindbis	B-SPEC
+virus	I-SPEC
+and	I-PRGE
+NS4A	I-PRGE
+protein	B-CHED
+from	O
+hepatitis	B-SPEC
+C	I-SPEC
+virus	I-SPEC
+were	O
+also	O
+able	O
+to	O
+permeabilize	O
+neighbouring	O
+cells	B-COMP
+to	O
+different	O
+extents	O
+.	O
+
+TITLE	O
+:	O
+[	O
+New	O
+influenza	B-SPEC
+virus	I-SPEC
+(	O
+H1N1	O
+)	O
+related	O
+pneumonia	B-DISO
+with	O
+fatal	O
+outcome	O
+].	O
+
+A	O
+retrospective	O
+analysis	O
+of	O
+the	O
+post	O
+-	O
+operative	O
+clinical	O
+data	O
+was	O
+conducted	O
+in	O
+128	O
+surgical	O
+patients	O
+with	O
+chronic	B-DISO
+constrictive	I-DISO
+pericarditis	I-DISO
+.	O
+
+ABSTRACT	O
+:	O
+Virus	B-SPEC
+-	O
+infected	O
+cells	B-COMP
+secrete	B-PROC
+a	O
+broad	O
+range	O
+of	O
+interferons	O
+(	O
+IFN	B-PRGE
+)	O
+which	O
+confer	O
+resistance	B-PROC
+to	O
+yet	O
+uninfected	O
+cells	B-COMP
+by	O
+triggering	O
+the	O
+synthesis	B-PROC
+of	O
+antiviral	B-CHED
+factors	O
+.	O
+
+These	O
+viruses	B-SPEC
+were	O
+more	O
+pathogenic	O
+and	O
+replicated	O
+to	O
+higher	O
+titers	O
+in	O
+the	O
+lungs	B-ANAT
+of	O
+mice	B-SPEC
+lacking	O
+both	O
+IFN	B-PRGE
+receptors	I-PRGE
+than	O
+in	O
+mice	B-SPEC
+with	O
+single	O
+IFN	B-PRGE
+receptor	I-PRGE
+defects	O
+.	O
+
+ABSTRACT	O
+:	O
+The	O
+live	O
+replication	O
+-	O
+competent	O
+modified	O
+vaccinia	B-SPEC
+virus	I-SPEC
+Tiantan	O
+(	O
+MVTT	O
+)	O
+is	O
+an	O
+attractive	O
+vaccine	O
+vector	O
+,	O
+yet	O
+little	O
+is	O
+known	O
+about	O
+its	O
+tissue	B-PROC
+tropism	B-PROC
+and	O
+pathology	B-DISO
+in	O
+vivo	O
+.	O
+
+Contactors	O
+with	O
+SARS	B-DISO
+patients	O
+and	O
+those	O
+with	O
+symptom	B-DISO
+development	B-PROC
+following	O
+the	O
+contacts	O
+were	O
+investigated	O
+via	O
+questionnaire	O
+.	O
+
+Serum	B-COMP
+samples	O
+were	O
+collected	O
+from	O
+32	O
+highly	O
+-	O
+exposed	O
+individuals	O
+,	O
+of	O
+whom	O
+13	O
+developing	O
+SARS	B-DISO
+symptoms	O
+after	O
+contact	O
+had	O
+serum	B-COMP
+samples	O
+positive	O
+for	O
+SARS	B-PRGE
+-	I-PRGE
+CoV	I-PRGE
+antibody	B-COMP
+.	O
+
+In	O
+24	O
+pigs	B-SPEC
+with	O
+ALI	O
+,	O
+effects	O
+of	O
+10	O
+ppm	O
+iNO	O
+were	O
+evaluated	O
+during	O
+controlled	O
+mechanical	O
+ventilation	O
+(	O
+CMV	B-SPEC
+)	O
+and	O
+SB	O
+in	O
+random	O
+order	B-SPEC
+.	O
+
+Statistical	O
+analysis	O
+did	O
+not	O
+reveal	O
+gas	B-ENZY
+exchange	O
+improvements	O
+due	O
+to	O
+SB	O
+alone	O
+.	O
+
+The	O
+authors	O
+conclude	O
+that	O
+effectiveness	O
+of	O
+iNO	B-PRGE
+may	O
+be	O
+improved	O
+by	O
+unassisted	O
+SB	O
+during	O
+BIPAP	O
+but	O
+not	O
+by	O
+assisted	O
+SB	O
+.	O
+
+Thus	O
+combined	O
+iNO	O
+and	O
+unassisted	O
+SB	O
+is	O
+possibly	O
+most	O
+effective	O
+to	O
+improve	O
+gas	B-ENZY
+exchange	O
+in	O
+severe	O
+hypoxemic	O
+ARDS	B-DISO
+.	O
+
+ABSTRACT	O
+:	O
+To	O
+assess	O
+the	O
+economic	O
+impact	O
+of	O
+bovine	B-SPEC
+coronavirus	B-SPEC
+(	O
+BCV	B-SPEC
+)	O
+and	O
+bovine	B-SPEC
+respiratory	I-SPEC
+syncytial	I-SPEC
+virus	I-SPEC
+(	O
+BRSV	B-SPEC
+)	O
+infections	B-DISO
+,	O
+accurate	O
+estimates	O
+of	O
+their	O
+associated	O
+effects	O
+on	O
+animal	B-SPEC
+performance	O
+are	O
+needed	O
+.	O
+
+This	O
+study	O
+aimed	O
+to	O
+quantify	O
+the	O
+variation	O
+in	O
+individual	O
+test	O
+-	O
+day	O
+milk	O
+yield	O
+and	O
+somatic	B-ANAT
+cell	I-ANAT
+count	O
+,	O
+risk	O
+of	O
+reproductive	B-PROC
+failure	O
+after	O
+first	O
+service	O
+of	O
+dairy	O
+cows	B-SPEC
+,	O
+and	O
+risk	O
+of	O
+death	B-PROC
+of	O
+calves	O
+and	O
+heifers	O
+according	O
+to	O
+the	O
+BCV	B-SPEC
+and	O
+BRSV	B-SPEC
+status	O
+of	O
+the	O
+herd	O
+.	O
+
+For	O
+this	O
+purpose	O
+,	O
+serial	O
+10	O
+-	O
+fold	O
+dilutions	O
+of	O
+the	O
+respective	O
+inactivated	O
+vaccines	O
+were	O
+prepared	O
+and	O
+groups	O
+of	O
+SPF	B-PRGE
+chickens	I-PRGE
+were	O
+vaccinated	O
+with	O
+a	O
+double	O
+dose	O
+of	O
+the	O
+vaccine	O
+dilutions	O
+.	O
+
+ABSTRACT	O
+:	O
+The	O
+disease	O
+burden	O
+caused	O
+by	O
+recently	O
+identified	O
+respiratory	O
+viruses	O
+like	O
+HCoV	B-SPEC
+-	I-SPEC
+NL63	I-SPEC
+is	O
+unknown	O
+.	O
+
+This	O
+number	O
+reflects	O
+522	O
+HCoV	B-SPEC
+-	I-SPEC
+NL63	I-SPEC
+children	O
+in	O
+Germany	O
+per	O
+year	O
+.	O
+
+RSV	B-SPEC
+detection	O
+in	O
+serum	B-COMP
+was	O
+associated	O
+with	O
+high	O
+viral	O
+load	O
+in	O
+BAL	B-ENZY
+samples	O
+(	O
+p	O
+=	O
+.	O
+05	O
+),	O
+and	O
+viral	O
+RNA	O
+detection	O
+in	O
+serum	B-COMP
+was	O
+significantly	O
+associated	O
+with	O
+death	B-PROC
+(	O
+adjusted	O
+rate	O
+ratio	O
+,	O
+1	O
+.	O
+8	O
+;	O
+(	O
+p	O
+=	O
+.	O
+02	O
+).	O
+
+Significant	O
+positive	O
+correlations	O
+exist	O
+between	O
+sPLA2	B-PRGE
+,	O
+TNF	B-PRGE
+-	I-PRGE
+α	I-PRGE
+and	O
+oxygen	B-CHED
+need	O
+,	O
+mean	O
+airway	B-ANAT
+pressure	O
+,	O
+ventilatory	O
+index	O
+,	O
+and	O
+the	O
+Murray	O
+'	O
+s	O
+lung	B-ANAT
+injury	O
+score	O
+.	O
+
+Negative	O
+correlations	O
+were	O
+also	O
+found	O
+between	O
+sPLA2	B-PRGE
+,	O
+TNF	B-PRGE
+-	I-PRGE
+α	I-PRGE
+,	O
+and	O
+Pao2	B-PRGE
+/	O
+Fio2	O
+ratio	O
+.	O
+
+To	O
+confront	O
+emerging	O
+viral	O
+threats	O
+,	O
+nations	O
+have	O
+implemented	O
+strategies	O
+to	O
+prepare	O
+for	O
+pandemics	O
+and	O
+to	O
+control	O
+virus	B-SPEC
+spread	O
+.	O
+
+We	O
+offer	O
+examples	O
+from	O
+influenza	B-SPEC
+virus	I-SPEC
+research	O
+,	O
+as	O
+well	O
+as	O
+from	O
+research	O
+on	O
+other	O
+pandemics	O
+of	O
+our	O
+time	O
+-	O
+HIV	O
+/	O
+AIDS	O
+and	O
+HCV	B-SPEC
+-	O
+to	O
+demonstrate	O
+that	O
+systems	O
+biology	O
+offers	O
+one	O
+possible	O
+key	O
+to	O
+stopping	O
+the	O
+cycle	O
+of	O
+viral	O
+pandemics	O
+.	O
+
+Control	O
+pigs	B-SPEC
+received	O
+a	O
+saline	O
+infusion	O
+,	O
+whereas	O
+ALF	O
+pigs	B-SPEC
+received	O
+acetaminophen	B-CHED
+intravenously	O
+for	O
+12	O
+hours	O
+to	O
+maintain	O
+blood	B-ANAT
+concentrations	O
+between	O
+200	O
+-	O
+300	O
+mg	O
+/	O
+l	O
+.	O
+
+Of	O
+nine	O
+pigs	B-SPEC
+that	O
+received	O
+acetaminophen	B-CHED
+,	O
+four	O
+survived	O
+20	O
+hours	O
+and	O
+two	O
+survived	O
+28	O
+hours	O
+.	O
+
+A	O
+marked	O
+increase	O
+in	O
+serum	B-COMP
+AST	B-ENZY
+(	O
+471	O
+.	O
+5	O
++/-	O
+
+1	O
+g	O
+/	O
+dL	O
+)	O
+in	O
+injured	O
+animals	B-SPEC
+.	O
+
+The	O
+ability	O
+of	O
+MHV	B-SPEC
+to	O
+delay	O
+SeV	O
+-	O
+mediated	O
+ISG	O
+production	O
+may	O
+partially	O
+involve	O
+limiting	O
+the	O
+ability	O
+of	O
+IFN	B-PRGE
+regulatory	I-PRGE
+factor	I-PRGE
+3	I-PRGE
+(	O
+IRF	B-PRGE
+-	I-PRGE
+3	I-PRGE
+)	O
+to	O
+function	O
+as	O
+a	O
+transcription	B-PROC
+factor	O
+.	O
+
+Transcription	B-PROC
+from	O
+an	O
+IRF	B-PRGE
+-	I-PRGE
+3	I-PRGE
+-	I-PRGE
+responsive	I-PRGE
+promoter	I-PRGE
+was	O
+partially	O
+inhibited	O
+by	O
+MHV	B-SPEC
+;	O
+however	O
+,	O
+IRF	B-PRGE
+-	I-PRGE
+3	I-PRGE
+was	O
+transported	O
+to	O
+the	O
+nucleus	B-COMP
+and	O
+bound	O
+DNA	O
+in	O
+MHV	B-SPEC
+-	O
+infected	O
+cells	B-COMP
+superinfected	O
+with	O
+SeV	O
+.	O
+
+Consequently	O
+,	O
+left	B-DISO
+ventricular	I-DISO
+failure	I-DISO
+as	O
+evidenced	O
+by	O
+dramatic	O
+decline	O
+in	O
+aortic	B-ANAT
+flow	O
+with	O
+a	O
+slow	O
+decrease	O
+in	O
+pulmonary	B-ANAT
+flow	O
+resulted	O
+in	O
+pressure	O
+and	O
+volume	O
+loading	O
+in	O
+the	O
+pulmonary	O
+circulation	B-PROC
+.	O
+
+Genetic	O
+association	O
+analysis	O
+of	O
+this	O
+SNP	O
+with	O
+clinico	O
+-	O
+pathologic	O
+outcomes	O
+in	O
+824	O
+serologic	O
+confirmed	O
+SARS	B-DISO
+patients	O
+showed	O
+that	O
+the	O
+-	O
+336AG	O
+/	O
+GG	O
+genotype	O
+SARS	B-DISO
+patients	O
+was	O
+associated	O
+with	O
+lower	O
+standardized	O
+lactate	B-PRGE
+-	I-PRGE
+dehydrogenase	I-PRGE
+(	O
+LDH	B-PRGE
+)	O
+levels	O
+compared	O
+with	O
+the	O
+-	O
+336AA	O
+patients	O
+(	O
+p	O
+=	O
+0	O
+.	O
+014	O
+,	O
+odds	O
+ratio	O
+=	O
+0	O
+.	O
+40	O
+).	O
+
+The	O
+relevance	O
+of	O
+these	O
+findings	O
+for	O
+other	B-DISO
+infectious	I-DISO
+diseases	I-DISO
+and	O
+inflammatory	O
+conditions	O
+would	O
+be	O
+worth	O
+investigating	O
+.	O
+
+ABSTRACT	O
+:	O
+This	O
+study	O
+aimed	O
+to	O
+develop	O
+a	O
+visual	O
+protein	B-CHED
+chip	O
+that	O
+can	O
+differentiate	O
+the	O
+antibodies	B-COMP
+induced	O
+by	O
+avian	B-SPEC
+influenza	I-SPEC
+virus	I-SPEC
+,	O
+Newcastle	B-SPEC
+disease	I-SPEC
+virus	I-SPEC
+,	O
+infectious	B-DISO
+bronchitis	B-DISO
+virus	B-SPEC
+and	O
+infectious	B-SPEC
+bursal	I-SPEC
+disease	I-SPEC
+virus	I-SPEC
+,	O
+simultaneously	O
+.	O
+
+The	O
+protein	B-CHED
+chip	O
+was	O
+used	O
+to	O
+test	O
+known	O
+serum	O
+samples	O
+of	O
+the	O
+four	O
+poultry	B-DISO
+diseases	I-DISO
+and	O
+field	O
+serum	B-COMP
+samples	O
+.	O
+
+To	O
+investigate	O
+the	O
+frequency	O
+of	O
+coronaviruses	O
+in	O
+stool	B-ANAT
+samples	O
+from	O
+children	O
+and	O
+adults	O
+with	O
+gastrointestinal	O
+illness	O
+by	O
+RT	O
+-	O
+PCR	O
+.	O
+
+Clinical	O
+samples	O
+submitted	O
+for	O
+infectious	B-DISO
+diarrhea	I-DISO
+testing	O
+were	O
+collected	O
+from	O
+December	O
+2007	O
+through	O
+March	O
+2008	O
+.	O
+
+Coronaviruses	O
+as	O
+a	O
+group	O
+are	O
+not	O
+commonly	O
+identified	O
+in	O
+stool	B-ANAT
+samples	O
+of	O
+patients	O
+presenting	O
+with	O
+gastrointestinal	O
+illness	O
+.	O
+
+No	O
+stool	B-ANAT
+samples	O
+screened	O
+positive	O
+for	O
+HCoV	B-SPEC
+-	I-SPEC
+NL63	I-SPEC
+,	O
+HCoV	B-SPEC
+-	I-SPEC
+229E	I-SPEC
+,	O
+or	O
+HCoV	B-SPEC
+-	I-SPEC
+OC43	I-SPEC
+.	O
+
+Based	O
+on	O
+ethnographic	O
+data	O
+from	O
+participant	O
+observation	O
+in	O
+a	O
+chronic	B-DISO
+renal	I-DISO
+disease	I-DISO
+patient	O
+self	O
+-	O
+help	O
+alliance	O
+and	O
+semistructured	O
+interviews	O
+with	O
+its	O
+30	O
+members	O
+,	O
+I	O
+demonstrate	O
+that	O
+the	O
+participants	O
+'	O
+knowledge	O
+perceptions	O
+of	O
+and	O
+the	O
+adoption	O
+of	O
+the	O
+preventive	O
+health	O
+behaviors	B-PROC
+against	O
+H1N1	O
+were	O
+greatly	O
+influenced	O
+by	O
+their	O
+past	O
+experiences	O
+of	O
+being	O
+stigmatized	O
+in	O
+the	O
+2003	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+(	O
+SARS	B-DISO
+)	O
+outbreak	O
+.	O
+
+Patients	O
+who	O
+died	B-PROC
+had	O
+higher	O
+acute	O
+physiology	O
+and	O
+chronic	O
+health	O
+evaluation	O
+II	O
+score	O
+compared	O
+to	O
+survivors	O
+(	O
+29	O
+.	O
+2	O
++	O
+or	O
+-	O
+7	O
+.	O
+3	O
+vs	O
+.	O
+18	O
+.	O
+6	O
++	O
+or	O
+-	O
+6	O
+.	O
+4	O
+,	O
+P	O
+=	O
+0	O
+.	O
+02	O
+).	O
+
+TITLE	O
+:	O
+[	O
+Clinical	O
+analysis	O
+of	O
+75	O
+patients	O
+with	O
+severe	O
+influenza	B-PATH
+A	I-PATH
+H1N1	O
+in	O
+Qinghai	O
+Province	O
+].	O
+
+In	O
+8	O
+patients	O
+with	O
+fungal	B-DISO
+infection	I-DISO
+anti	O
+-	O
+fungal	O
+therapy	O
+was	O
+given	O
+.	O
+
+Patients	O
+suffering	B-DISO
+from	O
+influenza	B-PATH
+A	I-PATH
+H1N1	O
+are	O
+susceptible	O
+to	O
+pulmonary	B-DISO
+complications	I-DISO
+.	O
+
+RESULTS	O
+:	O
+The	O
+first	O
+case	O
+with	O
+severe	O
+influenza	B-PATH
+A	I-PATH
+H1N1	O
+was	O
+diagnosed	O
+on	O
+October	O
+14	O
+,	O
+and	O
+up	O
+to	O
+75	O
+patients	O
+(	O
+47	O
+.	O
+78	O
+%)	O
+on	O
+December	O
+31	O
+.	O
+
+ABSTRACT	O
+:	O
+Murine	B-SPEC
+coronavirus	I-SPEC
+(	O
+mouse	B-DISO
+hepatitis	I-DISO
+virus	B-SPEC
+,	O
+MHV	B-SPEC
+)	O
+is	O
+a	O
+collection	O
+of	O
+strains	O
+that	O
+induce	O
+disease	O
+in	O
+several	O
+organ	B-ANAT
+systems	I-ANAT
+of	O
+mice	B-SPEC
+.	O
+
+Studies	O
+of	O
+host	B-COMP
+responses	O
+to	O
+MHV	B-SPEC
+indicate	O
+that	O
+both	O
+innate	O
+and	O
+adaptive	O
+responses	O
+are	O
+crucial	O
+to	O
+antiviral	B-CHED
+defense	O
+.	O
+
+CD8	B-PRGE
+T	B-ANAT
+cells	I-ANAT
+,	O
+with	O
+the	O
+help	O
+of	O
+CD4	B-PRGE
+T	I-PRGE
+cells	O
+,	O
+are	O
+crucial	O
+for	O
+viral	O
+clearance	O
+during	O
+acute	B-DISO
+disease	I-DISO
+and	O
+persist	O
+in	O
+the	O
+CNS	B-CHED
+during	O
+chronic	B-DISO
+disease	I-DISO
+.	O
+
+TITLE	O
+:	O
+[	O
+Diabetes	B-DISO
+mellitus	I-DISO
+as	O
+a	O
+rare	O
+complication	B-DISO
+of	O
+hemolytic	B-DISO
+uremic	I-DISO
+syndrome	I-DISO
+--	O
+case	O
+report	O
+].	O
+
+Routine	O
+blood	B-ANAT
+tests	O
+showed	O
+microangiopathic	O
+anaemia	B-DISO
+,	O
+thrombocytopenia	O
+(	O
+52000	O
+/	O
+ul	O
+.)	O
+and	O
+uremia	B-DISO
+.	O
+
+Additional	O
+factor	O
+prone	O
+to	O
+thrombotic	O
+events	O
+was	O
+the	O
+4G	O
+/	O
+4G	O
+genotype	O
+responsible	O
+for	O
+increased	O
+PAI	B-PRGE
+-	I-PRGE
+1	I-PRGE
+blood	B-ANAT
+concentration	O
+,	O
+which	O
+may	O
+result	O
+in	O
+intensified	O
+fibrinolysis	B-PROC
+inhibition	B-PROC
+.	O
+
+The	O
+use	O
+of	O
+oseltamivir	B-CHED
+for	O
+treatment	O
+and	O
+prophylaxis	O
+of	O
+infection	B-DISO
+is	O
+recommended	O
+and	O
+its	O
+use	O
+has	O
+climbed	O
+steeply	O
+although	O
+there	O
+is	O
+little	O
+data	O
+available	O
+on	O
+its	O
+benefit	O
+in	O
+critically	O
+unwell	B-DISO
+patients	O
+with	O
+H1N1	B-DISO
+influenza	I-DISO
+.	O
+
+TITLE	O
+:	O
+Plasmapheresis	O
+treatment	O
+in	O
+Guillain	O
+-	O
+Barré	O
+syndrome	B-DISO
+:	O
+potential	O
+benefit	O
+over	O
+intravenous	O
+immunoglobulin	B-PRGE
+.	O
+
+Despite	O
+potent	O
+antiviral	B-CHED
+T	B-ANAT
+-	I-ANAT
+lymphocyte	I-ANAT
+activity	O
+,	O
+sterile	B-DISO
+immunity	B-PROC
+is	O
+not	O
+achieved	O
+,	O
+and	O
+MHV	B-SPEC
+chronically	O
+persists	O
+within	O
+oligodendrocytes	B-ANAT
+.	O
+
+Continued	O
+infiltration	B-DISO
+and	O
+activation	O
+of	O
+the	O
+immune	B-ANAT
+system	I-ANAT
+,	O
+a	O
+result	O
+of	O
+the	O
+lingering	O
+viral	O
+antigen	B-CHED
+and	O
+RNA	O
+within	O
+oligodendrocytes	B-ANAT
+,	O
+lead	O
+directly	O
+to	O
+the	O
+development	B-PROC
+of	O
+an	O
+immune	O
+-	O
+mediated	O
+demyelination	B-DISO
+that	O
+bears	B-SPEC
+remarkable	O
+similarities	O
+,	O
+both	O
+clinically	O
+and	O
+histologically	O
+,	O
+to	O
+the	O
+human	B-SPEC
+demyelinating	B-DISO
+disease	I-DISO
+multiple	B-DISO
+sclerosis	I-DISO
+.	O
+
+We	O
+conclude	O
+that	O
+protein	B-CHED
+-	O
+ligand	B-PROC
+and	O
+protein	B-CHED
+-	O
+protein	B-CHED
+interactions	O
+are	O
+closely	O
+correlated	O
+in	O
+Mpro	O
+.	O
+
+ABSTRACT	O
+:	O
+The	O
+mechanisms	O
+responsible	O
+for	O
+virulence	B-PROC
+of	O
+influenza	B-SPEC
+viruses	I-SPEC
+in	O
+humans	B-SPEC
+remain	O
+poorly	O
+understood	O
+.	O
+
+The	O
+linear	O
+motif	O
+(	O
+11	O
+)	O
+DSPAPIIKLGG	O
+(	O
+21	O
+),	O
+located	O
+at	O
+the	O
+N	O
+-	O
+terminus	O
+of	O
+the	O
+N	B-PRGE
+protein	I-PRGE
+,	O
+was	O
+identified	O
+as	O
+the	O
+epitope	B-CHED
+bound	O
+by	O
+2D2	O
+.	O
+
+The	O
+results	O
+showed	O
+that	O
+this	O
+recombinant	O
+protein	B-CHED
+was	O
+correctly	O
+folded	O
+,	O
+being	O
+able	O
+to	O
+maintain	O
+intact	O
+conformation	O
+and	O
+authentic	O
+antigenicity	O
+.	O
+
+These	O
+results	O
+suggest	O
+that	O
+the	O
+recombinant	B-PRGE
+RBD219	I-PRGE
+-	I-PRGE
+CHO	I-PRGE
+protein	B-CHED
+has	O
+great	O
+potential	O
+for	O
+the	O
+development	B-PROC
+of	O
+an	O
+effective	O
+and	O
+safe	O
+SARS	B-DISO
+subunit	O
+vaccine	O
+.	O
+
+Vaccination	O
+against	O
+influenza	B-DISO
+(	O
+including	O
+H1N1	O
+)	O
+is	O
+effective	O
+and	O
+strongly	O
+recommended	O
+for	O
+healthcare	O
+workers	O
+.	O
+
+Damage	O
+control	O
+orthopedics	O
+(	O
+DCO	B-DISO
+)	O
+is	O
+defined	O
+as	O
+the	O
+minimally	O
+-	O
+traumatic	O
+interventions	O
+intended	O
+to	O
+provide	O
+quick	O
+stabilization	O
+of	O
+orthopedic	O
+injuries	O
+to	O
+minimize	O
+the	O
+systemic	O
+inflammatory	B-DISO
+response	I-DISO
+.	O
+
+The	O
+method	O
+was	O
+useful	O
+,	O
+convenient	O
+and	O
+efficient	O
+for	O
+rapid	O
+identification	O
+of	O
+CTL	B-ANAT
+epitopes	O
+derived	O
+from	O
+SARS	B-PRGE
+-	I-PRGE
+CoV	I-PRGE
+proteins	B-CHED
+and	O
+will	O
+be	O
+possibly	O
+applicable	O
+for	O
+other	O
+pathogens	O
+to	O
+develop	O
+a	O
+peptide	B-CHED
+-	O
+based	O
+vaccine	O
+.	O
+
+The	O
+emergency	B-DISO
+preparedness	O
+training	O
+programme	O
+was	O
+effective	O
+and	O
+feasible	O
+in	O
+improving	O
+the	O
+performance	O
+of	O
+rural	O
+public	O
+health	O
+personnel	O
+on	O
+emergency	B-DISO
+response	O
+.	O
+
+Extracorporeal	O
+membrane	B-COMP
+oxygenation	B-PROC
+(	O
+ECMO	O
+)	O
+can	O
+be	O
+effective	O
+in	O
+severe	O
+cardiopulmonary	B-DISO
+failure	I-DISO
+,	O
+but	O
+preexisting	O
+bleeding	B-DISO
+is	O
+still	O
+a	O
+contraindication	O
+for	O
+its	O
+use	O
+.	O
+
+We	O
+used	O
+a	O
+new	O
+miniaturised	O
+ECMO	O
+device	O
+(	O
+PLS	O
+-	O
+Set	O
+,	O
+MAQUET	O
+Cardiopulmonary	B-ANAT
+AG	O
+,	O
+Hechingen	O
+,	O
+Germany	O
+)	O
+and	O
+performed	O
+initially	O
+heparin	B-CHED
+-	O
+free	O
+ECMO	O
+.	O
+
+The	O
+present	O
+report	O
+is	O
+,	O
+to	O
+our	O
+knowledge	O
+,	O
+the	O
+first	O
+on	O
+a	O
+heart	B-ANAT
+transplant	B-ANAT
+patient	O
+who	O
+developed	O
+H1N1	B-DISO
+virus	I-DISO
+infection	I-DISO
+and	O
+had	O
+a	O
+favorable	O
+outcome	O
+,	O
+thus	O
+generating	O
+discussion	O
+on	O
+the	O
+real	O
+role	O
+of	O
+immunosuppressive	O
+therapy	O
+as	O
+a	O
+risk	O
+factor	O
+for	O
+the	O
+severe	O
+form	O
+of	O
+the	O
+disease	O
+.	O
+
+Four	O
+cohorts	O
+of	O
+arterial	O
+blood	O
+gases	O
+(	O
+ABGs	O
+)	O
+were	O
+identified	O
+with	O
+P	O
+/	O
+F	O
+>	O
+300	O
+,	O
+300	O
+>	O
+or	O
+=	O
+P	O
+/	O
+F	O
+>	O
+200	O
+,	O
+200	O
+>	O
+or	O
+=	O
+P	O
+/	O
+F	O
+>	O
+100	O
+,	O
+100	O
+>	O
+or	O
+=	O
+P	O
+/	O
+F	O
+.	O
+Using	O
+the	O
+standard	O
+predicted	O
+body	B-ANAT
+weight	O
+(	O
+PBW	O
+)	O
+equation	O
+,	O
+we	O
+calculated	O
+the	O
+milliliters	O
+per	O
+kilogram	O
+(	O
+mL	O
+/	O
+kg	O
+PBW	O
+)	O
+with	O
+which	O
+the	O
+patient	O
+'	O
+s	O
+lungs	B-ANAT
+were	O
+being	O
+ventilated	O
+.	O
+
+Tidal	O
+volumes	O
+ranged	O
+between	O
+8	O
+.	O
+64	O
+and	O
+9	O
+.	O
+16	O
+and	O
+the	O
+average	O
+PEEP	B-CHED
+varied	O
+from	O
+2	O
+.	O
+5	O
+to	O
+5	O
+.	O
+5	O
+cm	O
+H	O
+(	O
+2	O
+)	O
+O	O
+.	O
+There	O
+were	O
+substantial	O
+differences	O
+in	O
+the	O
+average	O
+Fio	O
+(	O
+2	O
+)	O
+and	O
+PIP	B-CHED
+among	O
+the	O
+groups	O
+,	O
+59	O
+%	O
+to	O
+91	O
+%	O
+and	O
+22	O
+to	O
+29	O
+cm	O
+H	O
+(	O
+2	O
+)	O
+O	O
+,	O
+respectively	O
+.	O
+
+This	O
+suggests	O
+that	O
+type	O
+I	O
+,	O
+II	O
+and	O
+III	O
+interferon	O
+signaling	B-PROC
+play	O
+minor	O
+roles	O
+in	O
+regulating	O
+SARS	B-DISO
+pathogenesis	B-DISO
+in	O
+mouse	B-SPEC
+models	O
+.	O
+
+There	O
+might	O
+have	O
+a	O
+local	O
+outbreak	O
+of	O
+HCoV	B-SPEC
+-	I-SPEC
+229E	I-SPEC
+infection	B-DISO
+in	O
+Beijing	O
+,	O
+Oct	B-PRGE
+-	I-PRGE
+Dec	I-PRGE
+,	O
+2007	O
+.	O
+
+TITLE	O
+:	O
+[	O
+A	O
+case	O
+of	O
+severe	O
+pulmonary	B-DISO
+tuberculosis	B-PATH
+with	O
+septic	B-DISO
+shock	I-DISO
+and	O
+ARDS	B-DISO
+].	O
+
+Intensive	O
+care	O
+resulted	O
+in	O
+the	O
+improvement	O
+of	O
+his	O
+general	O
+condition	B-DISO
+and	O
+the	O
+reduction	O
+of	O
+his	O
+chest	B-ANAT
+abnormal	O
+shadows	O
+,	O
+and	O
+he	O
+was	O
+discharged	O
+8	O
+months	O
+after	O
+admission	O
+.	O
+
+ABSTRACT	O
+:	O
+4	O
+-[(	O
+1	O
+,	O
+2	O
+-	O
+dihydro	O
+-	O
+2	O
+-	O
+oxo	B-CHED
+-	O
+3H	O
+-	O
+indol	B-CHED
+-	O
+3	O
+-	O
+ylidene	O
+)	O
+amino	O
+]-	O
+N	O
+(	O
+4	O
+,	O
+6	O
+-	O
+dimethyl	B-CHED
+-	O
+2	O
+-	O
+pyrimidiny	O
+)	O
+benzene	B-CHED
+sulphonamide	O
+and	O
+its	O
+derivatives	O
+were	O
+evaluated	O
+for	O
+antiviral	B-CHED
+activity	O
+against	O
+Pathogenic	O
+viruses	B-SPEC
+such	O
+as	O
+Hepatitis	B-SPEC
+C	I-SPEC
+Virus	I-SPEC
+and	O
+SARS	B-DISO
+-	O
+CoV	O
+in	O
+Vero	O
+and	O
+Huh	O
+5	O
+-	O
+2	O
+cells	B-COMP
+,	O
+respectively	O
+.	O
+
+TITLE	O
+:	O
+Detection	O
+and	O
+molecular	O
+characterization	O
+of	O
+enteric	O
+viruses	B-SPEC
+in	O
+breeder	O
+turkeys	B-SPEC
+.	O
+
+Faecal	B-ANAT
+samples	O
+were	O
+collected	O
+from	O
+all	O
+flocks	O
+at	O
+1	O
+week	O
+of	O
+age	O
+and	O
+then	O
+every	O
+other	O
+week	O
+until	O
+the	O
+poults	O
+reached	O
+9	O
+weeks	O
+of	O
+age	O
+.	O
+
+Most	O
+groups	O
+of	O
+broilers	O
+with	O
+a	O
+low	O
+level	O
+of	O
+IgM	B-PRGE
+ELISA	O
+positives	O
+had	O
+a	O
+low	O
+or	O
+moderate	O
+level	O
+of	O
+protection	O
+against	O
+challenge	O
+.	O
+
+TITLE	O
+:	O
+Viral	O
+respiratory	B-DISO
+diseases	I-DISO
+(	O
+ILT	O
+,	O
+aMPV	O
+infections	B-DISO
+,	O
+IB	O
+):	O
+are	O
+they	O
+ever	O
+under	O
+control	O
+?	O
+
+The	O
+use	O
+of	O
+vaccines	O
+is	O
+the	O
+main	O
+approach	O
+to	O
+control	O
+of	O
+the	O
+economically	O
+important	O
+poultry	O
+viral	O
+respiratory	O
+diseases	O
+infectious	B-DISO
+laryngotracheitis	B-DISO
+(	O
+ILT	O
+),	O
+avian	B-SPEC
+metapneumovirus	I-SPEC
+(	O
+aMPV	O
+)	O
+infections	B-DISO
+and	O
+infectious	B-DISO
+bronchitis	B-DISO
+(	O
+IB	O
+).	O
+
+Avian	B-SPEC
+metapneumoviruses	B-SPEC
+,	O
+the	O
+cause	O
+of	O
+turkey	B-SPEC
+rhinotracheitis	I-DISO
+and	O
+respiratory	O
+disease	O
+in	O
+chickens	B-SPEC
+exists	O
+as	O
+4	O
+subtypes	O
+,	O
+A	O
+,	O
+B	O
+,	O
+C	O
+and	O
+D	O
+.	O
+A	O
+and	O
+B	O
+are	O
+widespread	O
+and	O
+vaccines	O
+work	O
+well	O
+provided	O
+that	O
+accurate	O
+doses	O
+are	O
+given	O
+.	O
+
+TITLE	O
+:	O
+Prevalence	O
+of	O
+SARS	B-PRGE
+-	I-PRGE
+CoV	I-PRGE
+antibody	B-COMP
+in	O
+all	O
+Hong	O
+Kong	O
+patient	O
+contacts	O
+.	O
+
+ABSTRACT	O
+:	O
+The	O
+near	O
+absence	O
+of	O
+transmission	O
+(	O
+seroprevalence	O
+=	O
+0	O
+.	O
+19	O
+%)	O
+resulting	O
+in	O
+asymptomatic	O
+infection	O
+in	O
+this	O
+representative	O
+high	O
+-	O
+risk	O
+group	O
+of	O
+close	O
+contacts	O
+indicates	O
+that	O
+the	O
+prevailing	O
+SARS	B-DISO
+-	O
+CoV	O
+strains	O
+in	O
+Hong	O
+Kong	O
+almost	O
+always	O
+led	O
+to	O
+clinically	O
+apparent	O
+disease	O
+.	O
+
+A	O
+general	O
+anesthetic	O
+consisting	O
+of	O
+ketamine	B-CHED
+and	O
+etomidate	B-CHED
+and	O
+an	O
+intravenous	O
+infusion	O
+of	O
+remifentanil	B-CHED
+were	O
+used	O
+to	O
+provide	O
+stable	O
+anesthesia	B-DISO
+and	O
+analgesia	B-DISO
+for	O
+a	O
+successful	O
+delivery	O
+.	O
+
+By	O
+recombinant	B-PRGE
+expression	I-PRGE
+and	I-PRGE
+purification	I-PRGE
+of	I-PRGE
+secretory	B-PROC
+HE	I-PRGE
+(	O
+recHE	O
+)	O
+proteins	B-CHED
+,	O
+receptor	O
+-	O
+binding	B-FUNC
+and	O
+quantitative	O
+analyses	O
+of	O
+enzymatic	O
+activities	O
+displayed	O
+by	O
+ISAV	B-SPEC
+HE	O
+molecules	O
+are	O
+presented	O
+for	O
+the	O
+first	O
+time	O
+.	O
+
+The	O
+three	O
+amino	B-CHED
+acid	I-CHED
+differences	O
+between	O
+the	O
+high	O
+and	O
+low	O
+virulent	O
+variants	O
+,	O
+of	O
+which	O
+two	O
+localized	O
+to	O
+the	O
+putative	O
+receptor	O
+-	O
+binding	B-FUNC
+domain	O
+and	O
+one	O
+in	O
+the	O
+esterase	B-PRGE
+domain	I-PRGE
+,	O
+had	O
+no	O
+impact	O
+on	O
+receptor	O
+-	O
+binding	B-FUNC
+or	O
+-	O
+release	B-PATH
+activities	O
+.	O
+
+Phenyl	B-CHED
+and	O
+methyl	B-CHED
+substituents	O
+at	O
+the	O
+Michael	O
+system	O
+decrease	O
+the	O
+reactivity	O
+of	O
+the	O
+electrophilic	O
+compound	O
+,	O
+but	O
+chlorophenyl	O
+substituents	O
+partly	O
+recover	O
+the	O
+reactivity	O
+.	O
+
+TITLE	O
+:	O
+The	O
+history	O
+of	O
+ultraviolet	O
+germicidal	O
+irradiation	O
+for	O
+air	B-CHED
+disinfection	O
+.	O
+
+Both	O
+immunizations	O
+induced	O
+SARS	O
+-	O
+CoV	O
+-	O
+specific	O
+IgG	B-PRGE
+,	O
+although	O
+the	O
+levels	O
+of	O
+IgG	B-PRGE
+in	O
+groups	O
+immunized	O
+via	O
+the	O
+intraperitoneal	O
+(	O
+i	O
+.	O
+p	O
+.)	O
+route	O
+were	O
+higher	O
+.	O
+
+sIgA	B-PRGE
+was	O
+detected	O
+in	O
+saliva	B-ANAT
+in	O
+groups	O
+immunized	O
+intranasally	O
+but	O
+not	O
+in	O
+groups	O
+immunized	O
+intraperitoneally	O
+.	O
+
+CpG	O
+had	O
+an	O
+adjuvant	B-CHED
+effect	O
+on	O
+IgA	B-PRGE
+production	O
+in	O
+genital	B-ANAT
+tract	O
+washes	O
+when	O
+administered	O
+intranasally	O
+but	O
+only	O
+affected	O
+IgA	B-PRGE
+production	O
+in	O
+faeces	B-ANAT
+samples	O
+when	O
+administered	O
+intraperitoneally	O
+.	O
+
+Secretions	B-ANAT
+in	O
+genital	B-ANAT
+tract	O
+washes	O
+from	O
+the	O
+i	O
+.	O
+n	O
+.	O
+
+Using	O
+this	O
+virus	B-SPEC
+,	O
+complexes	O
+of	O
+SARS	B-PRGE
+-	I-PRGE
+CoV	I-PRGE
+E	I-PRGE
+and	O
+other	O
+proteins	B-CHED
+were	O
+purified	O
+using	O
+a	O
+tandem	O
+affinity	O
+purification	O
+system	O
+.	O
+
+TITLE	O
+:	O
+Nitric	B-CHED
+oxide	I-CHED
+is	O
+elicited	O
+and	O
+inhibits	O
+viral	B-PROC
+replication	I-PROC
+in	O
+pigs	B-SPEC
+infected	O
+with	O
+porcine	B-SPEC
+respiratory	O
+coronavirus	O
+but	O
+not	O
+porcine	B-SPEC
+reproductive	I-SPEC
+and	I-SPEC
+respiratory	I-SPEC
+syndrome	I-SPEC
+virus	I-SPEC
+.	O
+
+Moreover	O
+,	O
+NO	O
+levels	O
+in	O
+cell	B-COMP
+culture	O
+medium	O
+of	O
+PRRSV	B-SPEC
+-	O
+infected	O
+alveolar	B-ANAT
+macrophages	I-ANAT
+(	O
+AMs	B-DISO
+)	O
+did	O
+not	O
+differ	O
+from	O
+that	O
+of	O
+mock	O
+-	O
+infected	O
+AMs	O
+.	O
+
+The	O
+objective	O
+of	O
+this	O
+study	O
+was	O
+to	O
+assess	O
+if	O
+lipoteichoic	B-CHED
+acid	I-CHED
+(	O
+LTA	O
+),	O
+produced	O
+by	O
+Staphylococcus	B-SPEC
+aureus	I-SPEC
+,	O
+exacerbates	O
+respiratory	B-DISO
+disease	I-DISO
+in	O
+porcine	B-SPEC
+respiratory	O
+coronavirus	B-SPEC
+(	O
+PRCV	O
+)-	O
+infected	O
+pigs	B-SPEC
+,	O
+as	O
+has	O
+previously	O
+been	O
+shown	O
+with	O
+lipopolysaccharide	B-CHED
+.	O
+
+Given	O
+that	O
+Gram	B-SPEC
+-	I-SPEC
+positive	I-SPEC
+bacteria	I-SPEC
+,	O
+capable	O
+of	O
+producing	O
+LTA	O
+,	O
+are	O
+commonly	O
+found	O
+in	O
+pig	B-SPEC
+accommodation	O
+,	O
+the	O
+role	O
+of	O
+this	O
+compound	O
+in	O
+the	O
+development	B-PROC
+of	O
+the	O
+porcine	B-SPEC
+respiratory	B-DISO
+disease	I-DISO
+complex	O
+requires	O
+further	O
+investigation	O
+.	O
+
+ABSTRACT	O
+:	O
+Although	O
+most	O
+inbred	O
+mouse	B-SPEC
+strains	O
+are	O
+highly	O
+susceptible	O
+to	O
+mouse	B-DISO
+hepatitis	I-DISO
+virus	B-SPEC
+(	O
+MHV	B-SPEC
+)	O
+infection	B-DISO
+,	O
+the	O
+inbred	O
+SJL	O
+line	O
+of	O
+mice	B-SPEC
+is	O
+highly	O
+resistant	O
+to	O
+its	O
+infection	B-DISO
+.	O
+
+mCEACAM1a	O
+(	O
+1a	O
+)	O
+has	O
+a	O
+10	O
+-	O
+to	O
+100	O
+-	O
+fold	O
+-	O
+higher	O
+receptor	B-FUNC
+activity	I-FUNC
+than	O
+does	O
+mCEACAM1b	O
+(	O
+1b	O
+).	O
+
+No	O
+infectious	B-DISO
+virus	B-SPEC
+or	O
+viral	O
+RNA	O
+was	O
+detected	O
+in	O
+the	O
+organs	B-ANAT
+of	O
+cB61ba	O
+mice	B-SPEC
+,	O
+while	O
+viral	O
+RNA	O
+and	O
+infectious	B-DISO
+virus	B-SPEC
+were	O
+detected	O
+in	O
+target	O
+organs	B-ANAT
+of	O
+SJL	O
+mice	B-SPEC
+.	O
+
+These	O
+results	O
+strongly	O
+support	O
+the	O
+hypothesis	O
+that	O
+although	O
+alleles	O
+of	O
+mCEACAM1	O
+are	O
+the	O
+principal	O
+determinants	O
+of	O
+mouse	B-SPEC
+susceptibility	O
+to	O
+MHV	B-SPEC
+-	O
+A59	O
+,	O
+other	O
+as	O
+-	O
+yet	O
+-	O
+unidentified	O
+murine	B-SPEC
+genes	O
+may	O
+also	O
+play	O
+a	O
+role	O
+in	O
+susceptibility	O
+to	O
+MHV	B-SPEC
+.	O
+
+Nineteen	O
+animals	B-SPEC
+were	O
+seropositive	O
+for	O
+CIV	B-SPEC
+by	O
+ELISA	O
+out	O
+of	O
+the	O
+385	O
+samples	O
+tested	O
+.	O
+
+Serum	B-COMP
+antibodies	B-COMP
+for	O
+both	O
+viruses	B-SPEC
+were	O
+detected	O
+in	O
+6	O
+of	O
+the	O
+483	O
+dogs	B-SPEC
+sampled	O
+,	O
+suggesting	O
+that	O
+these	O
+viruses	B-SPEC
+are	O
+present	O
+in	O
+dogs	B-SPEC
+in	O
+Korea	O
+.	O
+
+TITLE	O
+:	O
+Transmission	O
+of	O
+zoonoses	B-DISO
+through	O
+immigration	O
+and	O
+tourism	O
+.	O
+
+Tourism	O
+constitutes	O
+a	O
+small	O
+fraction	O
+of	O
+overall	O
+movements	B-PROC
+of	O
+humans	B-SPEC
+but	O
+a	O
+point	O
+worthy	O
+of	O
+note	O
+is	O
+the	O
+number	O
+of	O
+international	O
+travellers	O
+has	O
+increased	O
+by	O
+more	O
+than	O
+1	O
+300	O
+%	O
+over	O
+the	O
+last	O
+50	O
+years	O
+.	O
+
+ABSTRACT	O
+:	O
+Ventilator	O
+-	O
+induced	O
+lung	O
+injury	O
+(	O
+VILI	O
+)	O
+significantly	O
+contributes	O
+to	O
+mortality	O
+in	O
+patients	O
+with	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+,	O
+the	O
+most	O
+severe	O
+form	O
+of	O
+acute	O
+lung	B-ANAT
+injury	O
+.	O
+
+The	O
+expression	B-PROC
+of	O
+stretch	O
+-	O
+responsive	O
+genes	O
+containing	O
+putative	O
+ATF3	B-PRGE
+cis	B-DISO
+-	O
+regulatory	O
+regions	O
+was	O
+significantly	O
+altered	O
+in	O
+ATF3	B-PRGE
+-	O
+deficient	O
+mice	B-SPEC
+.	O
+
+Nucleoprotein	O
+(	O
+N	O
+)	O
+sequences	O
+of	O
+the	O
+virus	B-SPEC
+at	O
+passages	O
+155	O
+and	O
+165	O
+were	O
+aligned	O
+and	O
+compared	O
+using	O
+a	O
+computer	O
+software	O
+program	O
+.	O
+
+Picorna	O
+was	O
+the	O
+most	O
+common	O
+virus	B-SPEC
+detected	O
+in	O
+Western	O
+countries	O
+whereas	O
+influenza	B-DISO
+was	O
+most	O
+common	O
+in	O
+Asia	O
+.	O
+
+TITLE	O
+:	O
+The	O
+impact	O
+of	O
+epidemic	O
+outbreak	O
+:	O
+the	O
+case	O
+of	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+(	O
+SARS	B-DISO
+)	O
+and	O
+suicide	O
+among	O
+older	O
+adults	O
+in	O
+Hong	O
+Kong	O
+.	O
+
+We	O
+recommend	O
+that	O
+the	O
+mental	O
+and	O
+psychological	B-DISO
+well	O
+-	O
+being	O
+of	O
+the	O
+community	O
+,	O
+in	O
+particular	O
+older	O
+adults	O
+,	O
+be	O
+taken	O
+into	O
+careful	O
+account	O
+when	O
+developing	O
+epidemic	O
+control	O
+measures	O
+to	O
+combat	B-CHED
+the	O
+future	O
+outbreak	O
+of	O
+diseases	O
+in	O
+the	O
+community	O
+.	O
+
+TITLE	O
+:	O
+Detection	O
+of	O
+novel	O
+respiratory	O
+viruses	B-SPEC
+from	O
+influenza	B-DISO
+-	I-DISO
+like	I-DISO
+illness	I-DISO
+in	O
+the	O
+Philippines	O
+.	O
+
+The	O
+crystallographic	O
+structure	O
+of	O
+the	O
+N28A	O
+mutant	B-DISO
+determined	O
+at	O
+2	O
+.	O
+35	O
+A	O
+resolution	O
+reveals	O
+the	O
+critical	O
+role	O
+of	O
+Asn28	O
+in	O
+maintaining	O
+the	O
+structural	O
+integrity	O
+of	O
+the	O
+active	O
+site	O
+and	O
+in	O
+orienting	O
+key	O
+residues	O
+involved	O
+in	O
+binding	B-FUNC
+at	O
+the	O
+dimer	O
+interface	O
+and	O
+substrate	O
+catalysis	O
+.	O
+
+We	O
+report	O
+the	O
+first	O
+47	O
+fatal	O
+cases	O
+of	O
+2009	O
+H1N1	B-DISO
+influenza	I-DISO
+in	O
+New	O
+York	O
+City	O
+.	O
+
+Many	O
+(	O
+79	O
+%)	O
+had	O
+underlying	O
+risk	O
+conditions	O
+for	O
+severe	O
+seasonal	O
+influenza	O
+,	O
+and	O
+58	O
+%	O
+were	O
+obese	B-DISO
+according	O
+to	O
+their	O
+body	B-ANAT
+mass	O
+index	O
+.	O
+
+With	O
+community	O
+-	O
+wide	O
+transmission	O
+of	O
+2009	O
+H1N1	B-DISO
+influenza	I-DISO
+A	O
+virus	O
+,	O
+timely	O
+medical	O
+care	O
+and	O
+antiviral	B-CHED
+therapy	O
+should	O
+be	O
+considered	O
+for	O
+patients	O
+with	O
+severe	O
+influenza	B-DISO
+-	I-DISO
+like	I-DISO
+illness	I-DISO
+or	O
+with	O
+underlying	O
+risk	O
+conditions	O
+for	O
+complications	O
+from	O
+influenza	B-DISO
+.	O
+
+This	O
+may	O
+be	O
+particularly	O
+true	O
+when	O
+severe	B-DISO
+sepsis	I-DISO
+is	O
+the	O
+cause	O
+of	O
+ARDS	B-DISO
+.	O
+
+We	O
+repeatedly	O
+measured	O
+V	O
+(	O
+D	O
+)/	O
+V	O
+(	O
+T	O
+)	O
+in	O
+a	O
+29	O
+-	O
+year	O
+-	O
+old	O
+man	B-CHED
+with	O
+sepsis	B-DISO
+-	O
+induced	O
+ARDS	B-DISO
+over	O
+the	O
+course	O
+of	O
+activated	O
+protein	B-CHED
+C	O
+therapy	O
+.	O
+
+When	O
+the	O
+measurement	O
+was	O
+repeated	O
+29	O
+h	O
+after	O
+therapy	O
+was	O
+discontinued	O
+,	O
+V	O
+(	O
+D	O
+)/	O
+V	O
+(	O
+T	O
+)	O
+had	O
+increased	O
+modestly	O
+,	O
+to	O
+0	O
+.	O
+34	O
+,	O
+whereas	O
+alveolar	B-ANAT
+V	O
+(	O
+D	O
+)	O
+had	O
+increased	O
+to	O
+71	O
+mL	O
+,	O
+or	O
+43	O
+%	O
+of	O
+the	O
+pre	O
+-	O
+activated	O
+-	O
+protein	B-CHED
+-	O
+C	O
+baseline	O
+measurement	O
+.	O
+
+Over	O
+the	O
+course	O
+of	O
+activated	O
+protein	B-CHED
+C	O
+therapy	O
+there	O
+was	O
+a	O
+persistent	O
+decrease	O
+in	O
+alveolar	B-ANAT
+V	O
+(	O
+D	O
+)	O
+and	O
+increase	O
+in	O
+alveolar	B-ANAT
+V	O
+(	O
+T	O
+),	O
+even	O
+while	O
+positive	O
+end	B-PROC
+-	I-PROC
+expiratory	I-PROC
+pressure	O
+was	O
+reduced	O
+and	O
+respiratory	O
+-	O
+system	O
+compliance	O
+decreased	O
+.	O
+
+Knockdown	O
+of	O
+another	O
+cytoplasmic	O
+receptor	O
+,	O
+the	O
+melanoma	B-PATH
+-	O
+differentiation	B-PROC
+-	O
+associated	O
+gene	B-PRGE
+5	I-PRGE
+(	O
+MDA5	B-PRGE
+),	O
+by	O
+small	O
+interfering	O
+RNAs	O
+also	O
+blocked	O
+IFN	B-PRGE
+-	I-PRGE
+beta	I-PRGE
+induction	O
+.	O
+
+Murine	B-DISO
+hepatitis	I-DISO
+virus	B-SPEC
+(	O
+MHV	B-SPEC
+)	O
+PLP2	O
+and	O
+orthologs	O
+recognize	O
+and	O
+cleave	O
+at	O
+a	O
+position	O
+following	O
+a	O
+p4	O
+-	O
+Leu	B-CHED
+-	O
+X	O
+-	O
+Gly	B-CHED
+-	I-CHED
+Gly	I-CHED
+-	O
+p1	O
+tetrapeptide	B-CHED
+,	O
+but	O
+it	O
+is	O
+unknown	O
+whether	O
+these	O
+residues	O
+are	O
+sufficient	O
+to	O
+result	O
+in	O
+processing	O
+by	O
+PLP2	B-PRGE
+at	O
+sites	O
+normally	O
+cleaved	B-ANAT
+by	O
+PLP1	B-PRGE
+.	O
+
+TITLE	O
+:	O
+Extracorporeal	O
+CO2	B-CHED
+removal	O
+.	O
+
+Due	O
+to	O
+the	O
+negative	O
+results	O
+of	O
+a	O
+clinical	O
+trial	O
+,	O
+the	O
+extensive	O
+resources	O
+required	O
+and	O
+the	O
+high	O
+incidence	O
+of	O
+side	O
+effects	O
+,	O
+low	O
+frequency	O
+positive	O
+pressure	O
+ventilation	O
+ECCO	O
+(	O
+2	O
+)	O
+R	O
+was	O
+restricted	O
+to	O
+a	O
+'	O
+rescue	O
+'	O
+therapy	O
+for	O
+the	O
+most	O
+severe	O
+case	O
+of	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+(	O
+ARDS	B-DISO
+).	O
+
+TITLE	O
+:	O
+Acute	O
+kidney	B-ANAT
+injury	O
+and	O
+2009	O
+H1N1	B-DISO
+influenza	I-DISO
+-	O
+related	O
+critical	B-DISO
+illness	I-DISO
+.	O
+
+This	O
+pandemic	O
+was	O
+responsible	O
+for	O
+thousands	O
+of	O
+deaths	B-PROC
+worldwide	O
+,	O
+many	O
+more	O
+hospital	O
+admissions	O
+,	O
+and	O
+thousands	O
+of	O
+admissions	O
+to	O
+intensive	O
+care	O
+units	O
+(	O
+ICUs	O
+).	O
+
+All	O
+patients	O
+with	O
+severe	O
+falciparum	B-DISO
+malaria	I-DISO
+above	O
+the	O
+age	O
+of	O
+14	O
+years	O
+admitted	O
+to	O
+the	O
+ICU	O
+were	O
+included	O
+in	O
+this	O
+study	O
+.	O
+
+Most	O
+patients	O
+(	O
+66	O
+.	O
+9	O
+percent	O
+)	O
+had	O
+a	O
+history	O
+of	O
+fever	B-PROC
+for	O
+less	O
+than	O
+seven	O
+days	O
+.	O
+
+RESULTS	O
+:	O
+Most	O
+patients	O
+(	O
+66	O
+.	O
+9	O
+percent	O
+)	O
+had	O
+a	O
+history	O
+of	O
+fever	B-PROC
+for	O
+less	O
+than	O
+seven	O
+days	O
+.	O
+
+TITLE	O
+:	O
+Acute	O
+motor	O
+axonal	B-DISO
+neuropathy	I-DISO
+associated	O
+with	O
+pandemic	O
+H1N1	B-DISO
+influenza	I-DISO
+A	O
+infection	B-DISO
+.	O
+
+28	O
+-	O
+year	O
+-	O
+old	O
+white	O
+female	O
+was	O
+admitted	O
+to	O
+our	O
+Intensive	O
+Care	O
+Unit	O
+during	O
+the	O
+influenza	B-DISO
+pandemic	O
+because	O
+of	O
+severe	O
+ARDS	B-DISO
+due	O
+to	O
+bilateral	B-DISO
+pneumonia	I-DISO
+.	O
+
+The	O
+course	O
+of	O
+the	O
+disease	O
+was	O
+complicated	O
+with	O
+the	O
+new	O
+onset	O
+tetraplegia	B-DISO
+due	O
+to	O
+the	O
+AMAN	O
+variant	O
+of	O
+GBS	B-DISO
+.	O
+
+RESULTS	O
+:	O
+28	O
+-	O
+year	O
+-	O
+old	O
+white	O
+female	O
+was	O
+admitted	O
+to	O
+our	O
+Intensive	O
+Care	O
+Unit	O
+during	O
+the	O
+influenza	B-DISO
+pandemic	O
+because	O
+of	O
+severe	O
+ARDS	B-DISO
+due	O
+to	O
+bilateral	B-DISO
+pneumonia	I-DISO
+.	O
+
+ABSTRACT	O
+:	O
+Animal	B-DISO
+diseases	I-DISO
+impact	O
+food	O
+supplies	O
+,	O
+trade	O
+and	O
+commerce	O
+,	O
+and	O
+human	O
+health	O
+and	O
+well	O
+-	O
+being	O
+in	O
+every	O
+part	O
+of	O
+the	O
+world	O
+.	O
+
+This	O
+was	O
+demonstrated	O
+by	O
+the	O
+2000	O
+-	O
+2001	O
+foot	B-DISO
+and	I-DISO
+mouth	B-ANAT
+disease	I-DISO
+(	O
+FMD	B-DISO
+)	O
+outbreaks	O
+that	O
+occurred	O
+in	O
+Europe	O
+,	O
+South	O
+America	O
+,	O
+Asia	O
+and	O
+Africa	O
+and	O
+by	O
+the	O
+recent	O
+increased	O
+occurrence	O
+of	O
+emerging	O
+diseases	O
+transmitted	B-DISO
+from	O
+animals	B-SPEC
+to	O
+humans	B-SPEC
+.	O
+
+PICU	B-SPEC
+in	O
+a	O
+university	O
+-	O
+affiliated	O
+,	O
+tertiary	O
+-	O
+care	O
+,	O
+pediatric	O
+hospital	O
+.	O
+
+We	O
+identified	O
+30	O
+patients	O
+with	O
+acute	O
+LRTI	B-DISO
+due	O
+to	O
+influenza	B-PATH
+A	I-PATH
+pH1N1	O
+virus	B-SPEC
+(	O
+group	O
+1	O
+)	O
+and	O
+62	O
+patients	O
+with	O
+LRTI	B-DISO
+due	O
+to	O
+other	O
+viral	O
+pathogens	O
+(	O
+group	O
+2	O
+).	O
+
+Median	O
+length	O
+of	O
+PICU	B-SPEC
+stay	O
+was	O
+15	O
+days	O
+.	O
+
+A	O
+pair	O
+of	O
+primers	O
+(	O
+P1	O
+and	O
+P4	O
+)	O
+specific	O
+for	O
+CDV	B-CHED
+corresponding	O
+to	O
+the	O
+highly	O
+conserved	O
+region	O
+of	O
+the	O
+CDV	B-CHED
+genome	O
+were	O
+used	O
+as	O
+a	O
+common	O
+primer	O
+pair	O
+in	O
+the	O
+first	O
+-	O
+round	O
+PCR	O
+of	O
+the	O
+nested	O
+PCR	O
+.	O
+
+ABSTRACT	O
+:	O
+Respiratory	O
+viruses	O
+frequently	O
+are	O
+recovered	O
+in	O
+the	O
+upper	O
+-	O
+respiratory	B-ANAT
+tract	I-ANAT
+during	O
+acute	O
+exacerbations	O
+of	O
+COPD	B-DISO
+(	O
+AECOPD	O
+),	O
+but	O
+their	O
+role	O
+as	O
+contributing	O
+pathogens	O
+remains	O
+unclear	O
+.	O
+
+The	O
+study	O
+was	O
+of	O
+a	O
+prospective	O
+cohort	O
+of	O
+patients	O
+with	O
+COPD	B-DISO
+admitted	O
+to	O
+the	O
+ED	O
+for	O
+AECOPD	O
+.	O
+
+In	O
+five	O
+of	O
+these	O
+patients	O
+,	O
+no	O
+virus	B-SPEC
+had	O
+been	O
+identified	O
+during	O
+the	O
+initial	O
+exacerbation	O
+,	O
+thus	O
+suggesting	O
+a	O
+new	O
+viral	B-DISO
+infection	I-DISO
+acquired	O
+during	O
+follow	O
+-	O
+up	O
+.	O
+
+During	O
+AECOPD	O
+,	O
+procalcitonin	O
+and	O
+C	B-PRGE
+-	I-PRGE
+reactive	I-PRGE
+protein	I-PRGE
+levels	O
+did	O
+not	O
+differ	O
+significantly	O
+between	O
+patients	O
+with	O
+or	O
+without	O
+a	O
+proven	O
+viral	B-DISO
+infection	I-DISO
+.	O
+
+Sixteen	O
+cases	O
+were	O
+included	O
+in	O
+the	O
+study	O
+from	O
+a	O
+review	O
+of	O
+medical	O
+records	O
+at	O
+two	O
+academic	O
+institutions	O
+;	O
+inclusion	O
+was	O
+based	O
+either	O
+on	O
+necropsy	O
+lesions	O
+(	O
+n	O
+=	O
+13	O
+)	O
+or	O
+a	O
+combination	O
+of	O
+histopathological	O
+,	O
+cytological	O
+,	O
+and	O
+clinicopathological	O
+findings	O
+highly	O
+suggestive	O
+of	O
+FIPV	O
+infection	B-DISO
+(	O
+n	O
+=	O
+3	O
+).	O
+
+The	O
+liver	B-ANAT
+was	O
+judged	O
+to	O
+be	O
+normal	O
+in	O
+echogenicity	O
+in	O
+11	O
+(	O
+69	O
+%)	O
+cats	B-SPEC
+,	O
+diffusely	O
+hypoechoic	O
+in	O
+three	O
+cats	B-SPEC
+,	O
+focally	O
+hyperechoic	O
+in	O
+one	O
+cat	B-SPEC
+,	O
+and	O
+focally	O
+hypoechoic	O
+in	O
+one	O
+cat	B-SPEC
+.	O
+
+This	O
+may	O
+not	O
+be	O
+optimal	O
+because	O
+it	O
+may	O
+present	O
+an	O
+excessive	O
+supply	O
+of	O
+linoleic	B-CHED
+acid	I-CHED
+.	O
+
+This	O
+has	O
+been	O
+associated	O
+with	O
+alterations	O
+in	O
+patterns	O
+of	O
+inflammatory	O
+mediators	O
+and	O
+in	O
+immune	B-PROC
+function	I-PROC
+and	O
+,	O
+in	O
+some	O
+studies	O
+,	O
+a	O
+reduction	O
+in	O
+length	O
+of	O
+intensive	O
+care	O
+unit	O
+(	O
+ICU	O
+)	O
+and	O
+hospital	O
+stay	O
+.	O
+
+In	O
+post	O
+-	O
+surgical	O
+patients	O
+and	O
+in	O
+those	O
+with	O
+mild	O
+sepsis	B-DISO
+or	O
+trauma	O
+,	O
+there	O
+is	O
+clinical	O
+benefit	O
+from	O
+a	O
+formula	O
+including	O
+fish	B-SPEC
+oil	O
+and	O
+arginine	B-CHED
+.	O
+
+Our	O
+results	O
+demonstrated	O
+that	O
+a	O
+P1	O
+-	O
+Asn	B-CHED
+substitution	O
+at	O
+the	O
+nsp4	B-PRGE
+-	I-PRGE
+5	I-PRGE
+/	O
+Q2779	O
+,	O
+nsp5	B-PRGE
+-	I-PRGE
+6	I-PRGE
+/	O
+Q3086	O
+,	O
+nsp7	O
+-	O
+8	O
+/	O
+Q3462	O
+,	O
+nsp8	O
+-	O
+9	O
+/	O
+Q3672	O
+,	O
+and	O
+nsp9	O
+-	O
+10	O
+/	O
+Q3783	O
+sites	O
+,	O
+a	O
+P1	O
+-	O
+Glu	B-CHED
+substitution	O
+at	O
+the	O
+nsp8	O
+-	O
+9	O
+/	O
+Q3672	O
+site	O
+,	O
+and	O
+a	O
+P1	O
+-	O
+His	O
+substitution	O
+at	O
+the	O
+nsp15	O
+-	O
+16	O
+/	O
+Q6327	O
+site	O
+were	O
+tolerated	O
+and	O
+allowed	O
+recovery	O
+of	O
+infectious	O
+mutant	B-DISO
+viruses	B-SPEC
+,	O
+albeit	O
+with	O
+variable	O
+degrees	O
+of	O
+growth	B-PROC
+defects	O
+.	O
+
+Analysis	O
+of	O
+the	O
+effects	O
+of	O
+these	O
+lethal	O
+mutations	O
+on	O
+RNA	B-PROC
+synthesis	I-PROC
+suggested	O
+that	O
+processing	O
+intermediates	O
+,	O
+such	O
+as	O
+the	O
+nsp6	O
+-	O
+7	O
+,	O
+nsp12	O
+-	O
+13	O
+,	O
+nsp13	O
+-	O
+14	O
+,	O
+nsp14	O
+-	O
+15	O
+,	O
+and	O
+nsp15	O
+-	O
+16	O
+precursors	O
+,	O
+may	O
+function	O
+in	O
+negative	O
+-	O
+stranded	O
+genomic	O
+RNA	B-PROC
+replication	I-PROC
+,	O
+whereas	O
+mature	O
+proteins	B-CHED
+may	O
+be	O
+required	O
+for	O
+subgenomic	O
+RNA	O
+(	O
+sgRNA	O
+)	O
+transcription	B-PROC
+.	O
+
+It	O
+indicated	O
+that	O
+SNH	O
+could	O
+enhance	O
+immune	B-PROC
+responses	I-PROC
+and	O
+increase	O
+protection	O
+against	O
+virulent	O
+IBV	B-SPEC
+challenge	O
+in	O
+chickens	B-SPEC
+.	O
+
+In	O
+this	O
+small	O
+series	O
+of	O
+patients	O
+with	O
+H1N1	O
+/	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+and	O
+hemodynamic	B-PROC
+compromise	O
+,	O
+therapeutic	O
+plasma	B-ANAT
+exchange	O
+appeared	O
+to	O
+benefit	O
+as	O
+a	O
+method	O
+of	O
+mitigating	O
+the	O
+associated	O
+cytokine	B-DISO
+storm	I-DISO
+.	O
+
+We	O
+compared	O
+the	O
+SARS	B-DISO
+-	O
+case	O
+and	O
+matched	O
+-	O
+control	O
+non	O
+-	O
+SARS	B-DISO
+articles	O
+published	O
+according	O
+to	O
+the	O
+timeline	O
+of	O
+submission	O
+,	O
+acceptance	O
+,	O
+and	O
+publication	O
+.	O
+
+The	O
+impact	O
+factors	O
+of	O
+the	O
+publishing	O
+journals	O
+were	O
+examined	O
+according	O
+to	O
+the	O
+time	O
+of	O
+publication	O
+of	O
+SARS	O
+articles	O
+,	O
+and	O
+the	O
+numbers	O
+of	O
+citations	O
+received	O
+by	O
+SARS	B-DISO
+-	O
+case	O
+and	O
+matched	O
+-	O
+control	O
+articles	O
+submitted	O
+during	O
+and	O
+after	O
+the	O
+epidemic	O
+were	O
+compared	O
+.	O
+
+The	O
+median	O
+numbers	O
+of	O
+citations	O
+of	O
+the	O
+SARS	B-DISO
+articles	O
+submitted	O
+during	O
+the	O
+epidemic	O
+and	O
+over	O
+the	O
+2	O
+y	O
+thereafter	O
+were	O
+17	O
+(	O
+interquartile	O
+range	O
+[	O
+IQR	O
+]	O
+8	O
+.	O
+0	O
+-	O
+52	O
+.	O
+0	O
+)	O
+and	O
+8	O
+(	O
+IQR	O
+3	O
+.	O
+2	O
+-	O
+21	O
+.	O
+8	O
+),	O
+respectively	O
+,	O
+significantly	O
+higher	O
+than	O
+the	O
+median	O
+numbers	O
+of	O
+control	O
+article	O
+citations	O
+(	O
+15	O
+,	O
+IQR	O
+8	O
+.	O
+5	O
+-	O
+16	O
+.	O
+5	O
+,	O
+p	O
+<	O
+0	O
+.	O
+05	O
+,	O
+and	O
+7	O
+,	O
+IQR	O
+3	O
+.	O
+0	O
+-	O
+12	O
+.	O
+0	O
+,	O
+p	O
+<	O
+0	O
+.	O
+01	O
+,	O
+respectively	O
+).	O
+
+This	O
+condition	B-DISO
+is	O
+often	O
+lethal	O
+,	O
+usually	O
+requiring	O
+mechanical	O
+ventilation	O
+and	O
+admission	O
+to	O
+an	O
+intensive	O
+care	O
+unit	O
+.	O
+
+TITLE	O
+:	O
+Image	O
+findings	O
+of	O
+patients	O
+with	O
+H1N1	O
+virus	B-SPEC
+pneumonia	B-DISO
+and	O
+acute	B-DISO
+respiratory	I-DISO
+failure	I-DISO
+.	O
+
+The	O
+aim	O
+of	O
+this	O
+study	O
+was	O
+to	O
+assess	O
+the	O
+findings	O
+of	O
+chest	O
+radiography	O
+and	O
+high	O
+-	O
+resolution	O
+computed	O
+tomography	O
+in	O
+patients	O
+requiring	O
+intensive	O
+care	O
+unit	O
+treatment	O
+for	O
+severe	O
+H1N1	O
+virus	B-SPEC
+pneumonia	B-DISO
+.	O
+
+In	O
+2009	O
+,	O
+10	O
+patients	O
+required	O
+treatment	O
+in	O
+an	O
+intensive	O
+care	O
+unit	O
+for	O
+confirmed	O
+H1N1	O
+pneumonia	B-DISO
+.	O
+
+Four	O
+patients	O
+underwent	O
+extracorporeal	O
+membrane	B-COMP
+oxygenation	B-PROC
+(	O
+ECMO	O
+)	O
+therapy	O
+.	O
+
+Pleural	B-DISO
+effusion	I-DISO
+was	O
+present	O
+in	O
+three	O
+of	O
+four	O
+patients	O
+undergoing	O
+ECMO	O
+therapy	O
+.	O
+
+Reverse	B-PROC
+transcription	I-PROC
+-	O
+PCR	O
+coupled	O
+with	O
+direct	O
+nucleotide	B-CHED
+sequencing	O
+and	O
+GenBank	O
+BLAST	B-ANAT
+database	O
+analysis	O
+of	O
+the	O
+hypervariable	O
+region	O
+of	O
+the	O
+S1	O
+subunit	O
+of	O
+the	O
+virus	B-SPEC
+spike	O
+gene	O
+showed	O
+that	O
+these	O
+isolates	O
+are	O
+genetically	O
+very	O
+different	O
+from	O
+the	O
+previously	O
+known	O
+IBV	B-SPEC
+genotypes	O
+in	O
+Japan	O
+.	O
+
+These	O
+results	O
+suggest	O
+that	O
+the	O
+isolates	O
+are	O
+a	O
+novel	O
+IBV	B-SPEC
+genotype	O
+in	O
+Japan	O
+(	O
+designated	O
+JP	O
+-	O
+IV	O
+).	O
+
+In	O
+developing	O
+countries	O
+of	O
+Asia	O
+,	O
+there	O
+is	O
+a	O
+continuous	O
+and	O
+close	O
+contact	O
+between	O
+animals	B-SPEC
+and	O
+humans	B-SPEC
+,	O
+especially	O
+in	O
+rural	O
+settings	O
+.	O
+
+ABSTRACT	O
+:	O
+Blastomycosis	B-DISO
+is	O
+an	O
+endemic	O
+mycosis	B-DISO
+that	O
+occurs	O
+predominantly	O
+in	O
+North	O
+America	O
+in	O
+the	O
+north	O
+central	O
+United	O
+States	O
+and	O
+provinces	O
+of	O
+Canada	O
+,	O
+southern	O
+states	O
+,	O
+and	O
+those	O
+midwestern	O
+states	O
+that	O
+border	O
+the	O
+Mississippi	O
+River	O
+basin	O
+.	O
+
+However	O
+,	O
+the	O
+vast	O
+majority	O
+of	O
+infected	O
+persons	O
+are	O
+asymptomatic	O
+or	O
+have	O
+mild	O
+respiratory	B-DISO
+symptoms	I-DISO
+that	O
+are	O
+not	O
+diagnosed	O
+as	O
+being	O
+caused	O
+by	O
+a	O
+fungal	B-DISO
+infection	I-DISO
+.	O
+
+Further	O
+,	O
+the	O
+limits	O
+of	O
+replication	O
+infidelity	O
+during	O
+replication	O
+of	O
+large	O
+RNA	O
+genomes	O
+and	O
+how	O
+decreased	O
+fidelity	O
+impacts	O
+virus	B-SPEC
+fitness	O
+over	O
+time	O
+are	O
+not	O
+known	O
+.	O
+
+High	O
+anti	B-PRGE
+-	I-PRGE
+TNF	I-PRGE
+-	I-PRGE
+alpha	I-PRGE
+activity	O
+was	O
+detected	O
+in	O
+bronchoalveolar	O
+lavage	O
+(	O
+BAL	B-ENZY
+)	O
+fluids	B-ANAT
+,	I-ANAT
+peritoneal	I-ANAT
+lavage	O
+fluids	B-ANAT
+and	O
+serum	B-COMP
+of	O
+all	O
+animals	B-SPEC
+for	O
+at	O
+least	O
+8h	O
+post	O
+-	O
+inoculation	O
+(	O
+HPI	B-DISO
+).	O
+
+No	O
+significant	O
+differences	O
+in	O
+disease	O
+severity	O
+,	O
+lung	B-ANAT
+lesions	O
+,	O
+virus	B-PROC
+replication	I-PROC
+,	O
+lung	B-ANAT
+cell	B-COMP
+infiltration	B-DISO
+or	O
+levels	O
+of	O
+IFN	B-PRGE
+-	I-PRGE
+alpha	I-PRGE
+,	O
+IL	B-FUNC
+-	I-FUNC
+1	I-FUNC
+,	O
+IL	B-FUNC
+-	I-FUNC
+6	I-FUNC
+and	O
+IL	B-PRGE
+-	I-PRGE
+12	I-PRGE
+/	I-PRGE
+IL	B-FUNC
+-	I-FUNC
+23	I-FUNC
+were	O
+observed	O
+between	O
+the	O
+two	O
+groups	O
+.	O
+
+The	O
+compound	O
+also	O
+displayed	O
+cathepsin	B-PRGE
+L	I-PRGE
+/	I-PRGE
+B	I-PRGE
+selectivity	O
+of	O
+>	O
+700	O
+-	O
+fold	O
+and	O
+was	O
+nontoxic	O
+to	O
+human	B-SPEC
+aortic	B-ANAT
+endothelial	B-ANAT
+cells	I-ANAT
+at	O
+100	O
+muM	B-SPEC
+.	O
+The	O
+oxocarbazate	O
+and	O
+a	O
+related	O
+thiocarbazate	O
+(	O
+PubChem	O
+CID	O
+16725315	O
+)	O
+were	O
+tested	O
+in	O
+a	O
+SARS	O
+coronavirus	B-SPEC
+(	O
+CoV	B-SPEC
+)	O
+and	O
+Ebola	B-SPEC
+virus	I-SPEC
+-	O
+pseudotype	O
+infection	B-DISO
+assay	O
+with	O
+the	O
+oxocarbazate	O
+but	O
+not	O
+the	O
+thiocarbazate	O
+,	O
+demonstrating	O
+activity	O
+in	O
+blocking	B-DISO
+both	O
+SARS	B-PRGE
+-	I-PRGE
+CoV	B-SPEC
+(	O
+IC	O
+(	O
+50	O
+)	O
+=	O
+273	O
++/-	O
+
+TITLE	O
+:	O
+Quantitative	O
+proteomics	O
+using	O
+stable	O
+isotope	O
+labeling	O
+with	O
+amino	B-CHED
+acids	I-CHED
+in	O
+cell	B-COMP
+culture	O
+reveals	O
+changes	O
+in	O
+the	O
+cytoplasmic	O
+,	O
+nuclear	O
+,	O
+and	O
+nucleolar	B-ANAT
+proteomes	O
+in	O
+Vero	B-ANAT
+cells	I-ANAT
+infected	O
+with	O
+the	O
+coronavirus	B-SPEC
+infectious	B-DISO
+bronchitis	B-DISO
+virus	B-SPEC
+.	O
+
+ABSTRACT	O
+:	O
+Virus	B-SPEC
+-	O
+host	B-COMP
+interactions	O
+involve	O
+complex	O
+interplay	O
+between	O
+viral	O
+and	O
+host	B-COMP
+factors	O
+,	O
+rendering	O
+them	O
+an	O
+ideal	O
+target	O
+for	O
+proteomic	O
+analysis	O
+.	O
+
+Fractionation	O
+of	O
+cells	B-COMP
+into	O
+cytoplasmic	B-COMP
+,	O
+nuclear	O
+,	O
+and	O
+nucleolar	B-ANAT
+extracts	O
+was	O
+used	O
+to	O
+reduce	O
+sample	O
+complexity	O
+and	O
+provide	O
+information	O
+on	O
+the	O
+trafficking	B-PROC
+of	O
+proteins	B-CHED
+between	O
+the	O
+different	O
+compartments	B-ANAT
+.	O
+
+A	O
+luciferase	B-ENZY
+-	O
+based	O
+reporter	O
+gene	O
+assay	O
+was	O
+used	O
+to	O
+validate	O
+the	O
+up	B-PROC
+-	I-PROC
+regulation	I-PROC
+of	O
+AP	B-PRGE
+-	I-PRGE
+1	I-PRGE
+-	O
+and	O
+NF	B-PRGE
+-	I-PRGE
+kappaB	I-PRGE
+-	O
+dependent	O
+transcription	B-PROC
+in	O
+IBV	B-SPEC
+-	O
+infected	O
+cells	B-COMP
+and	O
+confirmed	O
+using	O
+immunofluorescence	O
+.	O
+
+Blood	B-ANAT
+cultures	O
+grew	O
+gram	O
+-	O
+positive	O
+cocci	B-SPEC
+,	O
+which	O
+later	O
+proved	O
+to	O
+be	O
+Streptococcus	B-SPEC
+agalactiae	I-SPEC
+(	O
+GBS	B-DISO
+).	O
+
+Such	O
+patients	O
+hence	O
+present	O
+most	O
+commonly	O
+to	O
+rheumatologists	O
+and	O
+nephrologists	O
+but	O
+usually	O
+require	O
+input	O
+from	O
+a	O
+number	O
+of	O
+specialties	O
+,	O
+respiratory	O
+and	O
+critical	O
+care	O
+medicine	B-CHED
+in	O
+particular	O
+.	O
+
+By	O
+the	O
+end	O
+of	O
+September	O
+2009	O
+,	O
+it	O
+was	O
+estimated	O
+that	O
+at	O
+least	O
+270	O
+,	O
+000	O
+persons	O
+had	O
+been	O
+infected	O
+by	O
+pandemic	O
+influenza	B-PATH
+A	I-PATH
+(	O
+H1N1	O
+)	O
+in	O
+Singapore	O
+.	O
+
+In	O
+addition	O
+,	O
+one	O
+-	O
+fifth	O
+of	O
+cases	O
+with	O
+severe	O
+illness	O
+had	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+.	O
+
+Exciting	O
+new	O
+studies	O
+reveal	O
+that	O
+the	O
+alcoholic	O
+lung	O
+is	O
+characterized	O
+by	O
+discrete	O
+changes	O
+in	O
+cellular	B-PROC
+function	I-PROC
+within	O
+the	O
+lower	O
+airways	O
+,	O
+mediated	O
+via	O
+oxidant	B-CHED
+stress	O
+and	O
+altered	O
+signaling	B-PROC
+pathways	B-PROC
+and	O
+,	O
+in	O
+experimental	O
+models	O
+,	O
+is	O
+highly	O
+amenable	O
+to	O
+targeted	B-PROC
+therapies	O
+.	O
+
+The	O
+co	O
+-	O
+localization	B-PROC
+signal	O
+of	O
+SARS	B-PRGE
+-	I-PRGE
+CoV	I-PRGE
+NP	I-PRGE
+and	I-PRGE
+proteasome	B-PATH
+subunit	I-PRGE
+p42	I-PRGE
+in	O
+2BS	O
+cells	B-COMP
+was	O
+detected	O
+using	O
+indirect	O
+immunofluorescence	O
+and	O
+confocal	O
+microscopy	O
+.	O
+
+p42	B-PRGE
+is	O
+a	O
+subunit	O
+of	O
+the	O
+26S	B-COMP
+proteasome	I-COMP
+;	O
+this	O
+large	O
+,	O
+multi	B-PRGE
+-	I-PRGE
+protein	I-PRGE
+complex	I-PRGE
+is	O
+a	O
+component	O
+of	O
+the	O
+ubiquitin	B-PROC
+-	O
+proteasome	B-PROC
+pathway	I-PROC
+,	O
+which	O
+is	O
+involved	O
+in	O
+a	O
+variety	O
+of	O
+basic	O
+cellular	B-COMP
+processes	O
+and	O
+inflammatory	B-DISO
+responses	I-DISO
+.	O
+
+TITLE	O
+:	O
+Detection	O
+of	O
+a	O
+virus	B-SPEC
+related	O
+to	O
+betacoronaviruses	O
+in	O
+Italian	O
+greater	B-SPEC
+horseshoe	I-SPEC
+bats	I-SPEC
+.	O
+
+ABSTRACT	O
+:	O
+The	O
+association	O
+between	O
+coronaviruses	O
+and	O
+bats	O
+is	O
+a	O
+worldwide	O
+phenomenon	O
+and	O
+bats	B-SPEC
+belonging	O
+to	O
+genus	B-SPEC
+Rhinolophus	I-SPEC
+are	O
+the	O
+reservoir	O
+host	B-COMP
+for	O
+several	O
+coronaviruses	O
+,	O
+including	O
+a	O
+large	O
+number	O
+of	O
+viruses	B-SPEC
+closely	O
+related	O
+genetically	O
+to	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+-	O
+coronavirus	B-SPEC
+(	O
+SARS	B-DISO
+-	O
+CoV	O
+).	O
+
+We	O
+focus	O
+on	O
+their	O
+function	O
+and	O
+mechanisms	O
+,	O
+and	O
+also	O
+discuss	O
+viral	O
+ion	O
+channel	O
+protein	B-CHED
+serving	O
+as	O
+a	O
+potential	O
+drug	O
+target	O
+.	O
+
+Exposure	O
+of	O
+NSCLC	B-DISO
+cells	B-COMP
+to	O
+TSL	B-PRGE
+-	I-PRGE
+1	I-PRGE
+caused	O
+cell	B-COMP
+-	O
+cycle	O
+arrest	O
+in	O
+subG1	O
+phase	O
+and	O
+caused	O
+apoptosis	O
+.	O
+
+Improving	O
+alveolar	B-ANAT
+ventilation	O
+and	O
+oxygenation	B-PROC
+may	O
+improve	O
+the	O
+outcome	O
+of	O
+acute	B-DISO
+chest	I-DISO
+syndrome	I-DISO
+(	O
+ACS	B-FUNC
+).	O
+
+On	O
+day	O
+3	O
+,	O
+the	O
+groups	O
+did	O
+not	O
+differ	O
+regarding	O
+the	O
+proportion	O
+of	O
+episodes	O
+with	O
+normal	O
+PaO2	O
+(	O
+35	O
+%	O
+with	O
+NIV	O
+and	O
+25	O
+%	O
+with	O
+oxygen	B-CHED
+;	O
+P	O
+=	O
+0	O
+.	O
+5	O
+)	O
+or	O
+A	O
+-	O
+a	O
+).	O
+
+We	O
+have	O
+experienced	O
+a	O
+67	O
+-	O
+year	O
+-	O
+old	O
+male	O
+patient	O
+with	O
+ARDS	B-DISO
+associated	O
+with	O
+a	O
+severe	O
+type	O
+of	O
+ulcerative	B-DISO
+colitis	I-DISO
+(	O
+UC	O
+).	O
+
+Severe	O
+dyspnea	B-DISO
+symptoms	O
+occurred	O
+during	O
+the	O
+treatment	O
+of	O
+UC	O
+in	O
+a	O
+previous	O
+hospital	O
+and	O
+the	O
+patient	O
+was	O
+transferred	O
+to	O
+our	O
+hospital	O
+on	O
+June	O
+27	O
+,	O
+2007	O
+.	O
+
+Our	O
+case	O
+report	O
+suggests	O
+that	O
+a	O
+severe	O
+type	O
+of	O
+ulcerative	B-DISO
+colitis	I-DISO
+might	O
+be	O
+taken	O
+into	O
+consideration	O
+as	O
+one	O
+of	O
+the	O
+predisposing	O
+factors	O
+of	O
+ARDS	B-DISO
+.	O
+
+ABSTRACT	O
+:	O
+The	O
+apparent	O
+association	O
+between	O
+varicella	O
+zoster	O
+virus	O
+(	O
+VZV	B-SPEC
+)	O
+and	O
+multiple	B-DISO
+sclerosis	I-DISO
+(	O
+MS	O
+)	O
+has	O
+been	O
+described	O
+.	O
+
+In	O
+patients	O
+with	O
+relapse	B-DISO
+/	O
+remission	B-DISO
+(	O
+R	O
+/	O
+R	O
+)	O
+MS	O
+we	O
+have	O
+found	O
+high	O
+loads	O
+of	O
+VZV	B-SPEC
+DNA	O
+in	O
+lymphocytes	B-ANAT
+and	O
+in	O
+cerebrospinal	B-ANAT
+fluid	I-ANAT
+(	O
+CSF	B-ANAT
+),	O
+as	O
+well	O
+as	O
+abundant	O
+viral	B-COMP
+particles	I-COMP
+in	O
+CSF	B-ANAT
+visualized	O
+by	O
+electron	O
+microscopy	O
+at	O
+the	O
+time	O
+of	O
+relapse	B-DISO
+.	O
+
+In	O
+the	O
+present	O
+study	O
+we	O
+analyzed	O
+the	O
+presence	O
+of	O
+VZV	B-SPEC
+in	O
+patients	O
+with	O
+progressive	O
+forms	O
+of	O
+MS	O
+;	O
+DNA	O
+from	O
+VZV	B-SPEC
+was	O
+searched	O
+by	O
+real	O
+-	O
+time	O
+PCR	O
+in	O
+blood	B-ANAT
+lymphocytes	B-ANAT
+and	O
+in	O
+CSF	B-ANAT
+of	O
+20	O
+patients	O
+with	O
+progressive	O
+MS	O
+.	O
+
+Ultrastructural	O
+study	O
+searching	O
+for	O
+viral	B-PRGE
+particles	I-PRGE
+in	I-PRGE
+CSF	B-ANAT
+was	O
+made	O
+with	O
+transmission	O
+electron	O
+microscopy	O
+.	O
+
+Nonetheless	O
+,	O
+the	O
+amount	O
+of	O
+DNA	O
+and	O
+the	O
+number	O
+of	O
+viral	O
+particles	O
+were	O
+lower	O
+than	O
+those	O
+that	O
+have	O
+been	O
+found	O
+in	O
+MS	O
+patients	O
+with	O
+R	O
+/	O
+R	O
+at	O
+the	O
+time	O
+of	O
+relapse	B-DISO
+,	O
+but	O
+higher	O
+than	O
+those	O
+found	O
+during	O
+remission	B-DISO
+.	O
+
+Similar	O
+to	O
+findings	O
+in	O
+patients	O
+with	O
+R	O
+/	O
+R	O
+MS	O
+,	O
+VZV	B-SPEC
+might	O
+be	O
+associated	O
+to	O
+progressive	O
+MS	O
+,	O
+but	O
+in	O
+minor	O
+quantity	O
+.	O
+
+CONCLUSIONS	O
+:	O
+Similar	O
+to	O
+findings	O
+in	O
+patients	O
+with	O
+R	O
+/	O
+R	O
+MS	O
+,	O
+VZV	B-SPEC
+might	O
+be	O
+associated	O
+to	O
+progressive	O
+MS	O
+,	O
+but	O
+in	O
+minor	O
+quantity	O
+.	O
+
+To	O
+understand	O
+the	O
+pathogenesis	B-DISO
+of	O
+SARS	B-PRGE
+-	I-PRGE
+CoV	I-PRGE
+,	O
+human	B-SPEC
+type	B-ANAT
+II	I-ANAT
+pneumocyte	I-ANAT
+(	O
+A549	O
+)	O
+cells	B-COMP
+were	O
+incubated	O
+with	O
+the	O
+viral	B-PRGE
+spike	I-PRGE
+protein	I-PRGE
+or	O
+with	O
+SARS	B-PRGE
+-	I-PRGE
+CoV	I-PRGE
+virus	B-ANAT
+-	I-ANAT
+like	I-ANAT
+particles	I-ANAT
+containing	O
+the	O
+viral	O
+spike	O
+protein	B-CHED
+to	O
+examine	O
+cytokine	O
+modulation	O
+in	O
+lung	B-ANAT
+cells	B-COMP
+.	O
+
+Inhibition	B-PROC
+of	O
+the	O
+proteasome	B-PATH
+by	O
+different	O
+chemical	O
+compounds	O
+(	O
+i	O
+.	O
+e	O
+.,	O
+MG132	O
+,	O
+epoxomicin	B-CHED
+,	O
+and	O
+Velcade	B-CHED
+)	O
+appeared	O
+to	O
+not	O
+only	O
+impair	O
+entry	O
+but	O
+also	O
+RNA	B-PROC
+synthesis	I-PROC
+and	O
+subsequent	O
+protein	B-PROC
+expression	B-PROC
+of	O
+different	O
+CoVs	O
+(	O
+i	O
+.	O
+e	O
+.,	O
+mouse	B-DISO
+hepatitis	I-DISO
+virus	B-SPEC
+[	O
+MHV	B-SPEC
+],	O
+feline	B-DISO
+infectious	I-DISO
+peritonitis	I-DISO
+virus	B-SPEC
+,	O
+and	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+CoV	O
+).	O
+
+The	O
+inhibitory	O
+effect	O
+on	O
+CoV	B-PRGE
+protein	I-PRGE
+expression	B-PROC
+did	O
+not	O
+appear	O
+to	O
+result	O
+from	O
+a	O
+general	O
+inhibition	B-PROC
+of	O
+translation	B-PROC
+due	O
+to	O
+induction	O
+of	O
+a	O
+cellular	B-DISO
+stress	B-PATH
+response	I-PATH
+by	O
+the	O
+inhibitors	B-CHED
+.	O
+
+Viral	O
+protein	B-PROC
+expression	B-PROC
+was	O
+reduced	O
+in	O
+cells	B-COMP
+expressing	O
+a	O
+temperature	O
+-	O
+sensitive	O
+ubiquitin	B-ENZY
+-	I-ENZY
+activating	I-ENZY
+enzyme	I-ENZY
+E1	O
+at	O
+the	O
+restrictive	O
+temperature	O
+,	O
+as	O
+well	O
+as	O
+in	O
+cells	B-COMP
+in	O
+which	O
+ubiquitin	B-PROC
+was	O
+depleted	O
+by	O
+using	O
+small	O
+interfering	O
+RNAs	O
+.	O
+
+More	O
+detailed	O
+characterization	O
+of	O
+these	O
+virus	B-SPEC
+-	O
+cell	B-PROC
+interactions	I-PROC
+may	O
+facilitate	O
+the	O
+development	B-PROC
+of	O
+new	O
+treatments	O
+active	O
+against	O
+HCV	B-SPEC
+and	O
+other	O
+RNA	O
+viruses	B-SPEC
+that	O
+are	O
+dependent	O
+on	O
+newly	O
+synthesized	O
+cellular	B-COMP
+membranes	B-ANAT
+for	O
+replication	O
+.	O
+
+TITLE	O
+:	O
+Extracorporeal	O
+life	O
+support	O
+for	O
+management	O
+of	O
+refractory	O
+cardiac	B-ANAT
+or	O
+respiratory	B-DISO
+failure	I-DISO
+:	O
+initial	O
+experience	O
+in	O
+a	O
+tertiary	O
+centre	O
+.	O
+
+ECMO	O
+support	O
+was	O
+applied	O
+in	O
+case	O
+of	O
+severe	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+(	O
+ARDS	B-DISO
+)	O
+not	O
+responsive	O
+to	O
+conventional	O
+treatments	O
+.	O
+
+TITLE	O
+:	O
+Live	O
+attenuated	O
+Salmonella	B-SPEC
+enterica	I-SPEC
+serovar	O
+Typhimurium	O
+expressing	O
+swine	B-SPEC
+interferon	B-PRGE
+-	I-PRGE
+alpha	I-PRGE
+has	O
+antiviral	O
+activity	O
+and	O
+alleviates	O
+clinical	O
+signs	O
+induced	O
+by	O
+infection	B-DISO
+with	O
+transmissible	O
+gastroenteritis	B-DISO
+virus	B-SPEC
+in	O
+piglets	O
+.	O
+
+ABSTRACT	O
+:	O
+Enhancing	O
+innate	O
+and	O
+acquired	B-PROC
+immunity	I-PROC
+by	O
+cytokines	O
+such	O
+as	O
+IFN	B-PRGE
+-	I-PRGE
+alpha	I-PRGE
+appears	O
+to	O
+be	O
+useful	O
+as	O
+a	O
+first	O
+line	O
+of	O
+defense	O
+against	O
+viral	B-DISO
+infection	I-DISO
+.	O
+
+In	O
+this	O
+study	O
+,	O
+we	O
+tested	O
+the	O
+efficacy	O
+of	O
+live	O
+attenuated	O
+Salmonella	B-SPEC
+enterica	I-SPEC
+serovar	O
+Typhimurium	O
+designed	O
+to	O
+secrete	B-PROC
+swine	B-PRGE
+IFN	I-PRGE
+-	I-PRGE
+alpha	I-PRGE
+(	O
+swIFN	B-PRGE
+-	I-PRGE
+alpha	I-PRGE
+)	O
+protein	B-CHED
+for	O
+preventing	O
+the	O
+clinical	O
+signs	O
+caused	O
+by	O
+infection	B-DISO
+with	O
+transmissible	O
+gastroenteritis	B-DISO
+virus	B-SPEC
+(	O
+TGEV	B-SPEC
+),	O
+one	O
+of	O
+the	O
+diarrhea	B-DISO
+-	O
+causing	O
+viruses	B-SPEC
+in	O
+the	O
+swine	B-SPEC
+industry	O
+.	O
+
+TITLE	O
+:	O
+Spatial	O
+patterns	O
+of	O
+bovine	B-SPEC
+corona	B-CHED
+virus	B-SPEC
+and	O
+bovine	B-SPEC
+respiratory	I-SPEC
+syncytial	I-SPEC
+virus	I-SPEC
+in	O
+the	O
+Swedish	O
+beef	O
+cattle	O
+population	O
+.	O
+
+In	O
+the	O
+Swedish	O
+beef	O
+cattle	B-SPEC
+population	O
+however	O
+,	O
+no	O
+investigations	O
+have	O
+yet	O
+been	O
+performed	O
+regarding	O
+the	O
+prevalence	O
+and	O
+geographical	O
+distribution	O
+of	O
+BCV	B-SPEC
+and	O
+BRSV	B-SPEC
+.	O
+
+BCV	B-SPEC
+and	O
+BRSV	B-SPEC
+appeared	O
+to	O
+be	O
+spatially	O
+related	O
+:	O
+two	O
+areas	O
+in	O
+southern	O
+Sweden	O
+(	O
+Skaraborg	O
+and	O
+Skåne	O
+)	O
+had	O
+a	O
+significantly	O
+higher	O
+prevalence	O
+of	O
+BCV	B-SPEC
+(	O
+72	O
+.	O
+5	O
+and	O
+65	O
+.	O
+5	O
+%	O
+respectively	O
+);	O
+almost	O
+the	O
+same	O
+two	O
+areas	O
+were	O
+identified	O
+as	O
+being	O
+high	O
+-	O
+prevalence	O
+clusters	B-CHED
+for	O
+BRSV	B-SPEC
+(	O
+69	O
+.	O
+2	O
+and	O
+66	O
+.	O
+8	O
+%	O
+respectively	O
+).	O
+
+Areas	O
+with	O
+beef	O
+herd	O
+density	O
+>	O
+10	O
+per	O
+100	O
+km	O
+(	O
+2	O
+)	O
+were	O
+found	O
+to	O
+be	O
+at	O
+significantly	O
+higher	O
+risk	O
+of	O
+being	O
+part	O
+of	O
+high	O
+-	O
+prevalence	O
+clusters	B-CHED
+.	O
+
+With	O
+the	O
+exponential	O
+model	O
+,	O
+the	O
+infectivity	O
+of	O
+SARS	B-DISO
+-	O
+CoV	O
+was	O
+calculated	O
+and	O
+compared	O
+with	O
+those	O
+of	O
+other	O
+coronaviruses	O
+.	O
+
+Its	O
+estimated	O
+infectivity	O
+was	O
+comparable	O
+to	O
+that	O
+of	O
+HCoV	B-SPEC
+-	I-SPEC
+229E	I-SPEC
+,	O
+known	O
+as	O
+an	O
+agent	O
+of	O
+human	B-SPEC
+common	B-DISO
+cold	I-DISO
+,	O
+and	O
+also	O
+similar	O
+to	O
+those	O
+of	O
+some	O
+animal	B-SPEC
+coronaviruses	O
+belonging	O
+to	O
+the	O
+same	O
+genetic	O
+group	O
+.	O
+
+Serum	B-COMP
+levels	O
+of	O
+ET	B-PRGE
+-	I-PRGE
+1	I-PRGE
+and	O
+NO	O
+increased	O
+after	O
+ALI	O
+models	O
+were	O
+established	O
+and	O
+slightly	O
+decreased	O
+after	O
+a	O
+6	O
+-	O
+hour	O
+ventilation	O
+in	O
+both	O
+the	O
+VT6	O
+group	O
+and	O
+the	O
+VT20	O
+group	O
+.	O
+
+RESULTS	O
+:	O
+PaO2	O
+was	O
+increased	O
+after	O
+mechanical	O
+ventilation	O
+,	O
+but	O
+hypercapnia	B-DISO
+occurred	O
+in	O
+the	O
+VT6	O
+group	O
+.	O
+
+TITLE	O
+:	O
+[	O
+Clinical	O
+manifestations	O
+,	O
+diagnosis	O
+and	O
+treatment	O
+of	O
+swine	B-DISO
+flu	I-DISO
+(	O
+A	O
+/	O
+H1N1	O
+)	O
+infection	B-DISO
+among	O
+patients	O
+hospitalized	O
+in	O
+the	O
+Hospital	O
+of	O
+Infectious	O
+Diseases	O
+in	O
+Warsaw	O
+in	O
+2009	O
+].	O
+
+We	O
+have	O
+observed	O
+infection	B-DISO
+A	O
+/	O
+H1N1	O
+occurrence	O
+in	O
+109	O
+patients	O
+(	O
+Female	O
+-	O
+64	O
+,	O
+Male	O
+-	O
+45	O
+,	O
+aged	O
+17	O
+-	O
+71	O
+y	O
+),	O
+hospitalized	O
+between	O
+August	O
+and	O
+December	O
+2009	O
+.	O
+
+Among	O
+multiple	O
+acute	O
+symptoms	O
+we	O
+observed	O
+high	B-PROC
+temperature	I-PROC
+,	O
+cough	B-DISO
+,	O
+myalgia	B-DISO
+and	O
+neurological	O
+manifestations	O
+,	O
+very	O
+frequent	O
+.	O
+
+We	O
+observed	O
+bacterial	O
+superinfections	B-DISO
+associated	O
+with	O
+swine	B-DISO
+flu	I-DISO
+,	O
+ARDS	B-DISO
+and	O
+shock	B-DISO
+syndrome	I-DISO
+,	O
+secondary	B-DISO
+bacterial	I-DISO
+pneumonia	I-DISO
+and	O
+neurological	O
+complications	O
+.	O
+
+Three	O
+of	O
+them	O
+developed	O
+interstitial	B-DISO
+pneumonia	I-DISO
+.	O
+
+45	O
+laboratory	O
+-	O
+confirmed	O
+intubated	O
+SARS	B-DISO
+patients	O
+were	O
+identified	O
+.	O
+
+In	O
+multivariate	O
+GEE	O
+logistic	O
+regression	O
+models	O
+,	O
+presence	O
+in	O
+the	O
+room	O
+during	O
+fiberoptic	O
+intubation	O
+(	O
+OR	O
+=	O
+2	O
+.	O
+79	O
+,	O
+p	O
+=	O
+.	O
+004	O
+)	O
+or	O
+ECG	O
+(	O
+OR	O
+=	O
+3	O
+.	O
+52	O
+,	O
+p	O
+=	O
+.	O
+002	O
+),	O
+unprotected	O
+eye	B-ANAT
+contact	O
+with	O
+secretions	B-ANAT
+(	O
+OR	O
+=	O
+7	O
+.	O
+34	O
+,	O
+p	O
+=	O
+.	O
+001	O
+),	O
+patient	O
+APACHE	O
+II	O
+score	O
+>	O
+or	O
+=	O
+20	O
+(	O
+OR	O
+=	O
+17	O
+.	O
+05	O
+,	O
+p	O
+=	O
+.	O
+009	O
+)	O
+and	O
+patient	O
+Pa0	O
+(	O
+2	O
+)/	O
+Fi0	O
+(	O
+2	O
+)	O
+ratio	O
+<	O
+or	O
+=	O
+59	O
+(	O
+OR	O
+=	O
+8	O
+.	O
+65	O
+,	O
+p	O
+=	O
+.	O
+001	O
+)	O
+were	O
+associated	O
+with	O
+increased	O
+risk	O
+of	O
+transmission	O
+of	O
+SARS	B-DISO
+-	O
+CoV	O
+.	O
+In	O
+CART	O
+analyses	O
+,	O
+the	O
+four	O
+covariates	O
+which	O
+explained	O
+the	O
+greatest	O
+amount	O
+of	O
+variation	O
+in	O
+SARS	B-DISO
+-	O
+CoV	O
+transmission	O
+were	O
+covariates	O
+representing	O
+individual	O
+patients	O
+.	O
+
+Close	O
+contact	O
+with	O
+the	O
+airway	B-ANAT
+of	O
+severely	O
+ill	B-DISO
+patients	O
+and	O
+failure	O
+of	O
+infection	B-DISO
+control	O
+practices	O
+to	O
+prevent	O
+exposure	O
+to	O
+respiratory	O
+secretions	B-ANAT
+were	O
+associated	O
+with	O
+transmission	O
+of	O
+SARS	B-DISO
+-	O
+CoV	O
+.	O
+Rates	O
+of	O
+transmission	O
+of	O
+SARS	B-DISO
+-	O
+CoV	O
+varied	O
+widely	O
+among	O
+patients	O
+.	O
+
+CONCLUSIONS	O
+:	O
+Close	O
+contact	O
+with	O
+the	O
+airway	B-ANAT
+of	O
+severely	O
+ill	B-DISO
+patients	O
+and	O
+failure	O
+of	O
+infection	B-DISO
+control	O
+practices	O
+to	O
+prevent	O
+exposure	O
+to	O
+respiratory	O
+secretions	B-ANAT
+were	O
+associated	O
+with	O
+transmission	O
+of	O
+SARS	B-DISO
+-	O
+CoV	O
+.	O
+Rates	O
+of	O
+transmission	O
+of	O
+SARS	B-DISO
+-	O
+CoV	O
+varied	O
+widely	O
+among	O
+patients	O
+.	O
+
+Malaria	B-PATH
+-	O
+associated	O
+ALI	O
+correlated	O
+with	O
+high	O
+levels	O
+of	O
+circulating	O
+VEGF	B-PRGE
+,	O
+produced	O
+de	O
+novo	O
+in	O
+the	O
+spleen	B-ANAT
+,	O
+and	O
+its	O
+blockage	O
+led	O
+to	O
+protection	O
+of	O
+mice	O
+from	O
+this	O
+syndrome	B-DISO
+.	O
+
+TITLE	O
+:	O
+The	O
+highly	O
+cited	O
+SARS	B-DISO
+research	O
+literature	O
+.	O
+
+TITLE	O
+:	O
+Case	O
+report	O
+:	O
+Sanjad	O
+--	O
+Sakati	B-DISO
+syndrome	I-DISO
+:	O
+dental	O
+findings	O
+and	O
+treatment	O
+.	O
+
+The	O
+child	O
+was	O
+observed	O
+after	O
+one	O
+year	O
+,	O
+plaque	B-DISO
+removal	O
+was	O
+carried	O
+out	O
+and	O
+fluoride	B-CHED
+varnish	O
+was	O
+placed	O
+on	O
+all	O
+teeth	B-ANAT
+.	O
+
+The	O
+prevalence	O
+of	O
+avoidance	O
+behaviors	B-PROC
+was	O
+very	O
+high	O
+.	O
+
+Significant	O
+complications	O
+due	O
+to	O
+nasojejunal	O
+feeding	O
+tube	O
+placement	O
+,	O
+such	O
+as	O
+hydrothorax	B-DISO
+,	O
+duodenal	B-DISO
+perforation	I-DISO
+and	O
+retroperitoneal	B-ANAT
+emphysema	B-DISO
+,	O
+are	O
+very	O
+rare	O
+.	O
+
+Half	O
+a	O
+month	O
+later	O
+,	O
+she	O
+had	O
+a	O
+high	O
+fever	B-PROC
+and	O
+abdominal	B-ANAT
+distension	B-DISO
+.	O
+
+CONCLUSIONS	O
+:	O
+When	O
+a	O
+nasojejunal	O
+feeding	O
+tube	O
+is	O
+placed	O
+through	O
+the	O
+transnasal	O
+endoscopic	O
+technique	O
+,	O
+an	O
+abdominal	B-ANAT
+radiography	O
+should	O
+be	O
+used	O
+to	O
+confirm	O
+the	O
+tube	O
+'	O
+s	O
+position	O
+and	O
+indicate	O
+if	O
+it	O
+is	O
+kinking	O
+or	O
+beyond	O
+the	O
+ligament	B-ANAT
+of	I-ANAT
+Treitz	I-ANAT
+.	O
+
+ABSTRACT	O
+:	O
+Severe	O
+Acute	O
+Respiratory	O
+Syndrome	O
+(	O
+SARS	B-DISO
+)	O
+had	O
+an	O
+enormous	O
+effect	O
+on	O
+Taiwan	O
+'	O
+s	O
+public	O
+health	O
+and	O
+the	O
+nation	O
+'	O
+s	O
+economy	O
+.	O
+
+TITLE	O
+:	O
+Patients	O
+with	O
+acute	B-DISO
+pancreatitis	I-DISO
+complicated	O
+by	O
+organ	B-DISO
+failure	I-DISO
+show	O
+highly	O
+aberrant	O
+monocyte	B-ANAT
+signaling	B-PROC
+profiles	O
+assessed	O
+by	O
+phospho	O
+-	O
+specific	O
+flow	O
+cytometry	O
+.	O
+
+Phosphorylation	B-PROC
+levels	O
+induced	O
+by	O
+interleukin	B-PRGE
+-	I-PRGE
+6	I-PRGE
+in	O
+STAT1	B-PRGE
+and	O
+STAT3	B-PRGE
+and	O
+by	O
+combination	O
+of	O
+phorbol	B-CHED
+12	I-CHED
+-	I-CHED
+myristate	I-CHED
+13	I-CHED
+-	I-CHED
+acetate	I-CHED
+and	O
+calcium	B-CHED
+ionophore	I-CHED
+A23187	O
+in	O
+extracellular	B-PRGE
+signal	I-PRGE
+-	I-PRGE
+regulated	I-PRGE
+kinases	I-PRGE
+1	I-PRGE
+/	I-PRGE
+2	I-PRGE
+,	O
+members	O
+of	O
+a	O
+mitogen	B-PRGE
+-	I-PRGE
+activated	I-PRGE
+protein	B-CHED
+kinase	I-PRGE
+family	B-SPEC
+,	O
+were	O
+depressed	O
+in	O
+patients	O
+'	O
+monocytes	B-ANAT
+,	O
+whereas	O
+phosphorylation	B-PROC
+levels	O
+induced	O
+by	O
+granulocyte	B-PRGE
+-	I-PRGE
+macrophage	B-ANAT
+colony	I-PRGE
+-	I-PRGE
+stimulating	I-PRGE
+factor	I-PRGE
+in	O
+STAT5	B-PRGE
+was	O
+normal	O
+.	O
+
+Extracellular	B-PRGE
+signal	I-PRGE
+-	I-PRGE
+regulated	I-PRGE
+kinases	I-PRGE
+1	I-PRGE
+/	I-PRGE
+2	I-PRGE
+activation	O
+is	O
+impaired	B-DISO
+,	O
+which	O
+may	O
+depress	O
+monocytes	B-ANAT
+'	O
+transmigration	O
+and	O
+may	O
+consequently	O
+increase	O
+risk	O
+of	O
+infection	B-DISO
+.	O
+
+These	O
+patients	O
+have	O
+less	O
+left	B-DISO
+heart	I-DISO
+failure	I-DISO
+than	O
+expected	O
+on	O
+the	O
+basis	O
+of	O
+prior	O
+descriptions	O
+of	O
+influenza	B-DISO
+myopericarditis	B-DISO
+or	O
+of	O
+general	O
+populations	O
+of	O
+septic	O
+patients	O
+.	O
+
+Here	O
+,	O
+the	O
+expression	B-PROC
+and	O
+crystallization	O
+of	O
+the	O
+MHV	B-PRGE
+nucleocapsid	B-COMP
+protein	B-CHED
+C	I-PRGE
+-	I-PRGE
+terminal	I-PRGE
+domain	I-PRGE
+are	O
+reported	O
+.	O
+
+The	O
+gene	O
+segment	O
+encoding	O
+IBV	B-SPEC
+nsp9	O
+has	O
+been	O
+cloned	O
+and	O
+expressed	B-PROC
+in	O
+Escherichia	B-SPEC
+coli	I-SPEC
+.	O
+
+A	O
+32	O
+-	O
+year	O
+-	O
+old	O
+man	B-CHED
+,	O
+injured	O
+in	O
+a	O
+motorcycle	O
+accident	O
+,	O
+was	O
+referred	O
+to	O
+a	O
+trauma	O
+center	O
+in	O
+a	O
+state	O
+of	O
+shock	O
+.	O
+
+Sequence	O
+analysis	O
+revealed	O
+that	O
+the	O
+major	O
+difference	O
+between	O
+the	O
+two	O
+strains	O
+in	O
+this	O
+region	O
+is	O
+the	O
+absence	O
+of	O
+gene	B-PRGE
+5a	I-PRGE
+from	O
+MHV	B-SPEC
+-	O
+S	O
+.	O
+Creation	O
+of	O
+a	O
+gene	O
+5a	O
+knockout	O
+mutant	B-DISO
+of	O
+MHV	B-SPEC
+-	O
+A59	O
+demonstrated	O
+that	O
+a	O
+major	O
+component	O
+of	O
+IFN	O
+resistance	B-PROC
+maps	O
+to	O
+gene	O
+5a	O
+.	O
+
+This	O
+is	O
+the	O
+first	O
+demonstration	O
+of	O
+a	O
+coronavirus	B-SPEC
+gene	O
+product	O
+that	O
+can	O
+protect	O
+that	O
+same	O
+virus	B-SPEC
+from	O
+the	O
+antiviral	B-CHED
+state	O
+induced	O
+by	O
+IFN	B-PRGE
+.	O
+
+TITLE	O
+:	O
+The	O
+relationship	O
+between	O
+antibody	B-COMP
+status	O
+to	O
+bovine	B-SPEC
+corona	B-CHED
+virus	B-SPEC
+and	O
+bovine	B-SPEC
+respiratory	I-SPEC
+syncytial	I-SPEC
+virus	I-SPEC
+and	O
+disease	O
+incidence	O
+,	O
+reproduction	B-PROC
+and	O
+herd	O
+characteristics	O
+in	O
+dairy	O
+herds	O
+.	O
+
+Our	O
+objective	O
+was	O
+to	O
+evaluate	O
+the	O
+effects	O
+of	O
+these	O
+infections	B-DISO
+on	O
+general	O
+health	O
+and	O
+reproduction	B-PROC
+parameters	O
+measurable	O
+on	O
+herd	O
+level	O
+and	O
+to	O
+explore	O
+the	O
+association	O
+between	O
+antibody	B-COMP
+status	O
+and	O
+some	O
+herd	O
+characteristics	O
+.	O
+
+The	O
+samples	O
+were	O
+analysed	O
+for	O
+immunoglobulin	B-PRGE
+G	I-PRGE
+antibodies	B-COMP
+to	O
+BCV	B-SPEC
+and	O
+BRSV	B-SPEC
+with	O
+indirect	O
+enzyme	O
+-	O
+linked	O
+immunosorbent	O
+assays	O
+.	O
+
+Positive	O
+herds	O
+had	O
+a	O
+higher	O
+(	O
+P	O
+=	O
+0	O
+.	O
+001	O
+)	O
+bulk	O
+tank	O
+milk	O
+somatic	B-ANAT
+cell	I-ANAT
+count	O
+(	O
+BMSCC	O
+)	O
+compared	O
+with	O
+negative	O
+herds	O
+.	O
+
+Our	O
+result	O
+shows	O
+that	O
+herds	O
+that	O
+were	O
+antibody	B-COMP
+positive	O
+to	O
+BCV	B-SPEC
+and	O
+/	O
+or	O
+BRSV	B-SPEC
+had	O
+a	O
+higher	O
+BMSCC	O
+compared	O
+with	O
+herds	O
+negative	O
+to	O
+BCV	B-SPEC
+and	O
+BRSV	B-SPEC
+.	O
+
+Negative	O
+herds	O
+were	O
+located	O
+in	O
+close	O
+proximity	O
+to	O
+positive	O
+herds	O
+,	O
+indicating	O
+that	O
+local	O
+spread	O
+and	O
+airborne	O
+transmission	O
+between	O
+herds	O
+might	O
+not	O
+be	O
+of	O
+great	O
+importance	O
+and	O
+that	O
+herds	O
+can	O
+stay	O
+free	O
+from	O
+these	O
+infection	B-DISO
+transmission	I-DISO
+although	O
+virus	B-SPEC
+is	O
+circulating	O
+in	O
+the	O
+area	O
+.	O
+
+A	O
+higher	O
+proportion	O
+(	O
+P	O
+=	O
+0	O
+.	O
+01	O
+)	O
+of	O
+herds	O
+used	O
+professional	O
+technicians	O
+for	O
+artificial	O
+insemination	B-PROC
+,	O
+rather	O
+than	O
+farm	O
+personnel	O
+,	O
+amongst	O
+the	O
+33	O
+herds	O
+negative	O
+to	O
+BCV	B-SPEC
+compared	O
+with	O
+the	O
+46	O
+positive	O
+herds	O
+.	O
+
+TITLE	O
+:	O
+Severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+coronavirus	B-SPEC
+papain	B-ENZY
+-	O
+like	O
+novel	O
+protease	B-PROC
+inhibitors	I-PROC
+:	O
+design	O
+,	O
+synthesis	O
+,	O
+protein	B-CHED
+-	O
+ligand	B-PROC
+X	O
+-	O
+ray	B-SPEC
+structure	O
+and	O
+biological	O
+evaluation	O
+.	O
+
+A	O
+protein	B-CHED
+-	O
+ligand	B-PROC
+X	O
+-	O
+ray	B-SPEC
+structure	O
+of	O
+15	O
+g	O
+-	O
+bound	O
+SARS	O
+-	O
+CoV	O
+PLpro	O
+and	O
+a	O
+corresponding	O
+model	O
+of	O
+15	O
+h	O
+docked	O
+to	O
+PLpro	O
+provide	O
+intriguing	O
+molecular	O
+insight	O
+into	O
+the	O
+ligand	B-PROC
+-	O
+binding	B-FUNC
+site	O
+interactions	O
+.	O
+
+TITLE	O
+:	O
+Proteomic	O
+analysis	O
+of	O
+purified	O
+coronavirus	B-SPEC
+infectious	B-DISO
+bronchitis	B-DISO
+virus	B-COMP
+particles	I-COMP
+.	O
+
+TITLE	O
+:	O
+Migration	B-PROC
+of	O
+engrafted	O
+neural	B-ANAT
+stem	I-ANAT
+cells	I-ANAT
+is	O
+mediated	O
+by	O
+CXCL12	B-PRGE
+signaling	B-PROC
+through	O
+CXCR4	B-FUNC
+in	O
+a	O
+viral	O
+model	O
+of	O
+multiple	O
+sclerosis	O
+.	O
+
+Although	O
+successful	O
+transplantation	O
+of	O
+rodent	B-SPEC
+-	O
+derived	O
+glial	B-ANAT
+cell	I-ANAT
+types	O
+into	O
+models	O
+of	O
+MS	O
+has	O
+been	O
+performed	O
+,	O
+the	O
+mechanisms	O
+by	O
+which	O
+these	O
+cells	B-COMP
+navigate	O
+within	O
+an	O
+inflammatory	O
+environment	O
+created	O
+by	O
+a	O
+persistent	O
+virus	B-SPEC
+has	O
+not	O
+been	O
+defined	O
+.	O
+
+Infection	B-DISO
+of	O
+the	O
+mouse	B-SPEC
+CNS	B-CHED
+with	O
+the	O
+neurotropic	O
+JHM	O
+strain	O
+of	O
+mouse	O
+hepatitis	O
+virus	B-SPEC
+(	O
+JHMV	O
+)	O
+results	O
+in	O
+an	O
+immune	O
+-	O
+mediated	O
+demyelinating	B-DISO
+disease	I-DISO
+with	O
+clinical	O
+and	O
+histologic	O
+similarities	O
+to	O
+MS	O
+.	O
+
+The	O
+number	O
+of	O
+stories	O
+published	O
+in	O
+10	O
+newspapers	O
+containing	O
+the	O
+words	O
+,	O
+'	B-DISO
+SARS	I-DISO
+,'	O
+'	B-DISO
+Bovine	I-DISO
+Spongiform	I-DISO
+Encephalopathy	I-DISO
+,'	O
+'	B-DISO
+Avian	I-DISO
+Influenza	I-DISO
+,'	O
+and	O
+'	B-SPEC
+Influenza	I-SPEC
+A	I-SPEC
+virus	I-SPEC
+'	O
+was	O
+compared	O
+with	O
+the	O
+number	O
+of	O
+stories	O
+on	O
+chronic	O
+or	O
+well	O
+-	O
+known	O
+diseases	O
+.	O
+
+Also	O
+,	O
+media	B-ANAT
+coverage	O
+of	O
+'	B-DISO
+pneumonia	I-DISO
+'	O
+and	O
+'	B-PATH
+tuberculosis	I-PATH
+'	O
+did	O
+not	O
+vary	O
+in	O
+accordance	O
+with	O
+changes	O
+in	O
+the	O
+mortality	O
+of	O
+each	O
+disease	O
+.	O
+
+We	O
+demonstrate	O
+that	O
+IBV	B-SPEC
+strains	O
+4	O
+/	O
+91	O
+,	O
+Italy02	O
+,	O
+and	O
+QX	O
+infect	O
+ciliated	O
+and	O
+mucus	B-ANAT
+-	O
+producing	O
+cells	B-COMP
+of	O
+the	O
+bronchial	B-ANAT
+epithelium	I-ANAT
+,	O
+whereas	O
+cells	B-COMP
+of	O
+the	O
+parabronchial	O
+tissue	B-ANAT
+are	O
+resistant	O
+to	O
+infection	B-DISO
+.	O
+
+TITLE	O
+:	O
+Attachment	O
+of	O
+mouse	B-DISO
+hepatitis	I-DISO
+virus	B-SPEC
+to	O
+O	B-CHED
+-	I-CHED
+acetylated	I-CHED
+sialic	I-CHED
+acid	I-CHED
+is	O
+mediated	O
+by	O
+hemagglutinin	B-PRGE
+-	I-PRGE
+esterase	I-PRGE
+and	O
+not	O
+by	O
+the	O
+spike	O
+protein	B-CHED
+.	O
+
+ABSTRACT	O
+:	O
+The	O
+members	O
+of	O
+Betacoronavirus	B-SPEC
+phylocluster	O
+A	O
+possess	B-DISO
+two	O
+types	O
+of	O
+surface	O
+projections	O
+,	O
+one	O
+comprised	O
+of	O
+the	O
+spike	O
+protein	B-CHED
+(	O
+S	O
+)	O
+and	O
+the	O
+other	O
+of	O
+hemagglutinin	B-PRGE
+-	I-PRGE
+esterase	I-PRGE
+(	O
+HE	O
+).	O
+
+MHV	B-SPEC
+infection	B-DISO
+causes	O
+accumulation	O
+of	O
+EDEM1	O
+and	O
+OS	O
+-	O
+9	O
+,	O
+another	O
+short	O
+-	O
+living	O
+ER	B-PRGE
+chaperone	I-PRGE
+,	O
+in	O
+the	O
+DMVs	O
+.	O
+
+ABSTRACT	O
+:	O
+In	O
+the	O
+present	O
+study	O
+we	O
+describe	O
+the	O
+rapid	O
+development	O
+of	O
+an	O
+attenuated	O
+live	O
+vaccine	O
+for	O
+GA08	O
+,	O
+a	O
+new	O
+serotype	O
+of	O
+infectious	B-DISO
+bronchitis	B-DISO
+virus	B-SPEC
+,	O
+using	O
+a	O
+heat	O
+-	O
+treatment	O
+method	O
+.	O
+
+ABSTRACT	O
+:	O
+Among	O
+the	O
+most	O
+severe	O
+complications	O
+caused	O
+by	O
+the	O
+influenza	O
+A	O
+virus	O
+H1N1	O
+pandemic	O
+is	O
+the	O
+Acute	B-DISO
+Respiratory	I-DISO
+Distress	I-DISO
+Syndrome	I-DISO
+(	O
+ARDS	B-DISO
+).	O
+
+Patients	O
+admitted	O
+to	O
+the	O
+ICU	O
+with	O
+a	O
+diagnosis	O
+of	O
+severe	O
+pneumonia	B-DISO
+,	O
+ARDS	B-DISO
+,	O
+and	O
+high	O
+suspicion	O
+of	O
+influenza	B-PATH
+A	I-PATH
+H1N1	O
+.	O
+
+24	O
+patients	O
+were	O
+studied	O
+,	O
+100	O
+%	O
+with	O
+a	O
+diagnosis	O
+of	O
+ARDS	B-DISO
+,	O
+mean	O
+age	O
+41	O
+.	O
+1	O
+(+/-	O
+14	O
+.	O
+8	O
+).	O
+
+Existing	O
+sources	O
+of	O
+advice	O
+on	O
+these	O
+issues	O
+in	O
+Australia	O
+,	O
+by	O
+way	O
+of	O
+statements	O
+of	O
+medical	O
+ethics	O
+and	O
+other	O
+sources	O
+of	O
+advice	O
+,	O
+are	O
+shown	O
+to	O
+be	O
+in	O
+need	O
+of	O
+further	O
+amplification	B-DISO
+if	O
+health	O
+workers	O
+are	O
+to	O
+be	O
+provided	O
+with	O
+the	O
+certainty	O
+and	O
+guidance	O
+required	O
+.	O
+
+However	O
+,	O
+adverse	B-DISO
+effects	I-DISO
+,	O
+especially	O
+potentially	O
+fatal	O
+and	O
+non	O
+-	O
+reversible	O
+acute	O
+and	O
+chronic	O
+pulmonary	B-DISO
+toxicity	I-DISO
+,	O
+continue	O
+to	O
+be	O
+observed	O
+.	O
+
+Three	O
+different	O
+and	O
+intertwined	O
+mechanisms	O
+of	O
+lung	B-ANAT
+toxicity	O
+have	O
+been	O
+suggested	O
+:	O
+(	O
+i	O
+)	O
+a	O
+direct	O
+toxic	O
+effect	O
+;	O
+(	O
+ii	O
+)	O
+an	O
+immune	O
+-	O
+mediated	O
+mechanism	O
+;	O
+and	O
+(	O
+iii	O
+)	O
+the	O
+angiotensin	B-CHED
+enzyme	O
+system	O
+activation	O
+.	O
+
+TITLE	O
+:	O
+T	B-ANAT
+cell	B-COMP
+epitope	B-CHED
+specificity	O
+and	O
+pathogenesis	B-DISO
+of	O
+mouse	B-DISO
+hepatitis	I-DISO
+virus	B-SPEC
+-	O
+1	O
+-	O
+induced	O
+disease	O
+in	O
+susceptible	O
+and	O
+resistant	O
+hosts	O
+.	O
+
+hRSV	B-SPEC
+acute	B-DISO
+bronchiolitis	I-DISO
+increased	O
+from	O
+261	O
+cases	O
+in	O
+epidemics	O
+from	O
+1999	O
+-	O
+2003	O
+to	O
+341	O
+cases	O
+from	O
+2004	O
+-	O
+2009	O
+.	O
+
+ABSTRACT	O
+:	O
+To	O
+assess	O
+the	O
+characteristics	O
+,	O
+treatment	O
+and	O
+outcome	O
+of	O
+patients	O
+with	O
+crush	O
+syndrome	O
+caused	O
+by	O
+prolonged	O
+limb	B-ANAT
+compression	O
+longer	O
+than	O
+24	O
+h	O
+in	O
+the	O
+Sichuan	O
+earthquake	O
+.	O
+
+The	O
+medical	O
+records	O
+of	O
+nine	O
+severe	O
+crush	B-DISO
+syndrome	I-DISO
+patients	O
+were	O
+retrospectively	O
+reviewed	O
+.	O
+
+The	O
+major	O
+associated	O
+injuries	O
+were	O
+in	O
+the	O
+lower	B-ANAT
+extremities	I-ANAT
+.	O
+
+Multiple	O
+organ	O
+failure	O
+and	O
+sepsis	B-DISO
+developed	O
+in	O
+eight	O
+patients	O
+,	O
+but	O
+no	O
+patients	O
+died	B-PROC
+.	O
+
+TITLE	O
+:	O
+Alternative	B-PROC
+splicing	I-PROC
+of	O
+CD200	B-PRGE
+is	O
+regulated	O
+by	O
+an	O
+exonic	B-PRGE
+splicing	I-PRGE
+enhancer	I-PRGE
+and	O
+SF2	B-PRGE
+/	O
+ASF	B-DISO
+.	O
+
+TITLE	O
+:	O
+Pulmonary	B-ANAT
+vascular	B-ANAT
+dysfunction	O
+is	O
+associated	O
+with	O
+poor	O
+outcomes	O
+in	O
+patients	O
+with	O
+acute	O
+lung	B-ANAT
+injury	O
+.	O
+
+A	O
+total	O
+of	O
+501	O
+patients	O
+who	O
+received	O
+a	O
+PA	O
+catheter	O
+were	O
+evaluated	O
+for	O
+associations	O
+between	O
+increases	O
+in	O
+transpulmonary	O
+gradient	O
+(	O
+TPG	O
+)	O
+(	O
+PA	O
+mean	O
+pressure	O
+-	O
+PA	O
+occlusion	B-DISO
+pressure	O
+)	O
+or	O
+pulmonary	B-PROC
+vascular	B-ANAT
+resistance	I-PROC
+index	O
+(	O
+PVRi	O
+)	O
+and	O
+60	O
+-	O
+day	O
+mortality	O
+,	O
+ventilator	O
+-,	O
+intensive	O
+care	O
+unit	O
+(	O
+ICU	O
+)-,	O
+and	O
+cardiovascular	B-ANAT
+-	O
+free	O
+days	O
+(	O
+days	O
+with	O
+mean	O
+arterial	B-PROC
+pressure	I-PROC
+≥	O
+60	O
+mm	O
+Hg	O
+off	O
+vasopressor	O
+support	O
+).	O
+
+Only	O
+13	O
+.	O
+3	O
+%	O
+of	O
+the	O
+respondents	O
+planned	O
+to	O
+receive	O
+the	O
+H1N1	O
+vaccine	O
+,	O
+compared	O
+with	O
+37	O
+.	O
+5	O
+%	O
+for	O
+the	O
+seasonal	O
+influenza	B-DISO
+vaccine	O
+.	O
+
+Vaccination	O
+against	O
+seasonal	O
+influenza	B-DISO
+in	O
+the	O
+preceding	O
+season	O
+strongly	O
+predicted	O
+the	O
+likelihood	O
+of	O
+H1N1	O
+vaccination	O
+.	O
+
+Efforts	O
+are	O
+needed	O
+to	O
+address	O
+concerns	O
+about	O
+vaccination	O
+risk	O
+and	O
+to	O
+incorporate	O
+H1N1	O
+vaccination	O
+in	O
+standard	O
+infection	B-DISO
+control	O
+practice	O
+with	O
+policy	O
+support	O
+.	O
+
+For	O
+this	O
+high	O
+-	O
+risk	O
+group	O
+,	O
+there	O
+is	O
+an	O
+increased	O
+incidence	O
+of	O
+severe	B-DISO
+anemia	I-DISO
+,	O
+as	O
+well	O
+as	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+and	O
+pulmonary	B-DISO
+edema	I-DISO
+.	O
+
+By	O
+August	O
+2003	O
+,	O
+there	O
+were	O
+8422	O
+SARS	B-DISO
+cases	O
+and	O
+916	O
+deaths	B-PROC
+reported	O
+from	O
+29	O
+countries	O
+.	O
+
+These	O
+data	O
+suggest	O
+that	O
+M	B-SPEC
+.	I-SPEC
+daubentoni	I-SPEC
+and	O
+R	B-SPEC
+.	I-SPEC
+sinicus	I-SPEC
+are	O
+likely	O
+to	O
+be	O
+susceptible	O
+to	O
+SARS	B-PRGE
+-	I-PRGE
+CoV	I-PRGE
+and	O
+may	O
+be	O
+candidates	O
+as	O
+the	O
+natural	O
+host	B-COMP
+of	O
+the	O
+SARS	B-DISO
+-	O
+CoV	O
+progenitor	O
+viruses	B-SPEC
+.	O
+
+TITLE	O
+:	O
+Nursing	B-PROC
+students	O
+'	O
+knowledge	O
+and	O
+practice	O
+of	O
+infection	B-DISO
+control	O
+precautions	O
+:	O
+an	O
+educational	O
+intervention	O
+.	O
+
+While	O
+many	O
+in	O
+-	O
+service	O
+education	O
+sessions	O
+were	O
+arranged	O
+by	O
+institutions	O
+in	O
+response	O
+to	O
+the	O
+outbreak	O
+,	O
+preservice	O
+nursing	B-PROC
+education	O
+has	O
+overlooked	O
+preparation	O
+for	O
+handling	O
+such	O
+infectious	B-DISO
+disease	I-DISO
+epidemics	O
+.	O
+
+Following	O
+the	O
+education	O
+programme	O
+,	O
+students	O
+in	O
+the	O
+intervention	O
+group	O
+showed	O
+a	O
+statistically	O
+significant	O
+improvement	O
+across	O
+time	O
+in	O
+their	O
+knowledge	O
+of	O
+these	O
+precautions	O
+[	O
+F	O
+(	O
+2	O
+,	O
+180	O
+)	O
+=	O
+13	O
+.	O
+53	O
+,	O
+P	O
+<	O
+0	O
+.	O
+001	O
+]	O
+and	O
+confidence	O
+in	O
+resolving	O
+infection	B-DISO
+-	O
+related	O
+issues	O
+[	O
+F	O
+(	O
+1	O
+.	O
+79	O
+,	O
+168	O
+.	O
+95	O
+)	O
+=	O
+3	O
+.	O
+24	O
+]	O
+when	O
+compared	O
+with	O
+those	O
+in	O
+the	O
+control	O
+group	O
+.	O
+
+ABSTRACT	O
+:	O
+We	O
+report	O
+a	O
+case	O
+of	O
+severe	O
+sand	O
+aspiration	O
+in	O
+association	O
+with	O
+near	O
+-	O
+drowning	O
+,	O
+which	O
+led	O
+to	O
+respiratory	B-DISO
+failure	I-DISO
+secondary	O
+to	O
+the	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+,	O
+necessitating	O
+mechanical	O
+ventilation	O
+,	O
+repeated	O
+therapeutic	O
+bronchoscopic	O
+lavage	O
+,	O
+and	O
+a	O
+stay	O
+in	O
+the	O
+intensive	O
+care	O
+unit	O
+that	O
+exceeded	O
+one	O
+month	O
+.	O
+
+TITLE	O
+:	O
+[	O
+Acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+due	O
+to	O
+Toxocara	B-DISO
+cati	I-DISO
+infection	I-DISO
+].	O
+
+Dry	B-DISO
+cough	I-DISO
+and	O
+chest	B-DISO
+discomfort	I-DISO
+are	O
+the	O
+most	O
+common	O
+respiratory	B-DISO
+symptoms	I-DISO
+.	O
+
+A	O
+few	O
+cases	O
+of	O
+acute	O
+pneumonia	O
+requiring	O
+mechanical	O
+ventilation	O
+due	O
+to	O
+toxocara	B-SPEC
+have	O
+been	O
+published	O
+but	O
+this	O
+is	O
+,	O
+to	O
+our	O
+knowledge	O
+,	O
+is	O
+the	O
+first	O
+reported	O
+case	O
+of	O
+ARDS	B-DISO
+with	O
+multi	B-DISO
+-	I-DISO
+organ	I-DISO
+failure	I-DISO
+.	O
+
+The	O
+objective	O
+of	O
+this	O
+study	O
+was	O
+to	O
+assess	O
+the	O
+interactions	O
+between	O
+MBL	O
+and	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+-	O
+coronavirus	B-SPEC
+(	O
+SARS	B-DISO
+-	O
+CoV	O
+)	O
+spike	O
+(	O
+S	O
+)	O
+glycoprotein	B-CHED
+(	O
+SARS	B-DISO
+-	O
+S	O
+).	O
+
+In	O
+the	O
+present	O
+study	O
+,	O
+the	O
+3	O
+'	O
+terminal	O
+7	O
+.	O
+2	O
+kb	O
+of	O
+the	O
+genome	O
+of	O
+a	O
+recently	O
+isolated	O
+variant	O
+of	O
+IBV	B-SPEC
+(	O
+N1	O
+/	O
+03	O
+)	O
+was	O
+sequenced	O
+and	O
+compared	O
+with	O
+the	O
+sequences	O
+of	O
+classical	O
+and	O
+novel	O
+strains	O
+of	O
+IBV	B-SPEC
+,	O
+the	O
+two	O
+main	O
+groups	O
+of	O
+these	O
+viruses	B-SPEC
+in	O
+Australia	O
+.	O
+
+TITLE	O
+:	O
+Light	O
+whole	O
+genome	O
+sequence	O
+for	O
+SNP	O
+discovery	O
+across	O
+domestic	B-SPEC
+cat	I-SPEC
+breeds	B-PROC
+.	O
+
+ABSTRACT	O
+:	O
+The	O
+domestic	B-SPEC
+cat	I-SPEC
+has	O
+offered	O
+enormous	O
+genomic	O
+potential	O
+in	O
+the	O
+veterinary	O
+description	O
+of	O
+over	O
+250	O
+hereditary	B-DISO
+disease	I-DISO
+models	O
+as	O
+well	O
+as	O
+the	O
+occurrence	O
+of	O
+several	O
+deadly	O
+feline	B-SPEC
+viruses	B-SPEC
+(	O
+feline	B-SPEC
+leukemia	I-SPEC
+virus	I-SPEC
+--	O
+FeLV	O
+,	O
+feline	B-SPEC
+coronavirus	B-SPEC
+--	O
+FECV	B-SPEC
+,	O
+feline	B-SPEC
+immunodeficiency	I-SPEC
+virus	I-SPEC
+--	O
+FIV	B-SPEC
+)	O
+that	O
+are	O
+homologues	O
+to	O
+human	B-SPEC
+scourges	O
+(	O
+cancer	B-DISO
+,	O
+SARS	B-DISO
+,	O
+and	O
+AIDS	O
+respectively	O
+).	O
+
+To	O
+remedy	O
+this	O
+,	O
+we	O
+generated	O
+3	O
+,	O
+178	O
+,	O
+297	O
+paired	O
+fosmid	O
+-	O
+end	O
+Sanger	O
+sequence	O
+reads	O
+from	O
+seven	O
+cats	B-SPEC
+,	O
+and	O
+combined	O
+these	O
+data	O
+with	O
+the	O
+publicly	O
+available	O
+2X	O
+cat	B-SPEC
+whole	O
+genome	O
+sequence	O
+.	O
+
+The	O
+SARS	B-PRGE
+-	I-PRGE
+CoV	I-PRGE
+spike	I-PRGE
+(	I-PRGE
+S	I-PRGE
+)	I-PRGE
+protein	B-CHED
+mediates	O
+virus	B-SPEC
+entry	O
+by	O
+binding	B-FUNC
+cellular	B-COMP
+receptors	O
+and	O
+inducing	O
+fusion	O
+between	O
+the	O
+viral	B-COMP
+envelope	I-COMP
+and	O
+the	O
+host	B-COMP
+cell	I-COMP
+membrane	I-COMP
+.	O
+
+Here	O
+,	O
+we	O
+created	O
+a	O
+non	O
+-	O
+palmitoylated	O
+SARS	B-DISO
+-	O
+CoV	O
+S	O
+protein	B-CHED
+by	O
+mutating	O
+all	O
+nine	O
+cytoplasmic	B-COMP
+cysteine	B-CHED
+residues	O
+.	O
+
+Given	O
+a	O
+hypothetical	O
+scenario	O
+that	O
+two	O
+to	O
+three	O
+new	O
+human	B-SPEC
+-	O
+to	O
+-	O
+human	B-SPEC
+H5N1	B-DISO
+cases	O
+had	O
+been	O
+reported	O
+in	O
+Hong	O
+Kong	O
+,	O
+the	O
+trends	O
+of	O
+the	O
+respondents	O
+in	O
+various	O
+H5N1	B-DISO
+-	O
+related	O
+risk	O
+perceptions	O
+,	O
+anticipated	O
+personal	O
+psychological	B-DISO
+responses	O
+,	O
+and	O
+anticipated	O
+personal	O
+preventive	O
+behaviors	B-PROC
+were	O
+investigated	O
+.	O
+
+The	O
+public	O
+'	O
+s	O
+general	O
+preparedness	O
+was	O
+still	O
+relatively	O
+good	O
+and	O
+rational	O
+,	O
+even	O
+though	O
+individual	O
+preventive	O
+behaviors	B-PROC
+were	O
+less	O
+common	O
+.	O
+
+RESULTS	O
+:	O
+Over	O
+time	O
+,	O
+a	O
+decreased	O
+proportion	O
+of	O
+the	O
+respondents	O
+(	O
+1	O
+)	O
+felt	O
+susceptible	O
+to	O
+contracting	O
+H5N1	B-DISO
+,	O
+(	O
+2	O
+)	O
+expected	O
+a	O
+large	O
+outbreak	O
+would	O
+eventually	O
+occur	O
+,	O
+(	O
+3	O
+)	O
+believed	O
+that	O
+the	O
+impacts	O
+of	O
+H5N1	B-DISO
+were	O
+worse	O
+than	O
+those	O
+of	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+(	O
+SARS	B-DISO
+),	O
+and	O
+(	O
+4	O
+)	O
+anticipated	O
+adopting	O
+more	O
+types	O
+of	O
+preventive	O
+measures	O
+and	O
+experiencing	O
+mental	O
+distress	O
+in	O
+the	O
+case	O
+of	O
+a	O
+small	O
+-	O
+scale	O
+outbreak	O
+in	O
+Hong	O
+Kong	O
+(	O
+AOR	B-FUNC
+from	O
+0	O
+.	O
+27	O
+to	O
+0	O
+.	O
+43	O
+,	O
+p	O
+<	O
+0	O
+.	O
+001	O
+),	O
+but	O
+the	O
+public	O
+remained	O
+vigilant	O
+on	O
+public	O
+health	O
+behaviors	B-PROC
+,	O
+such	O
+as	O
+hand	O
+-	O
+washing	O
+.	O
+
+To	O
+determine	O
+role	O
+of	O
+the	O
+combination	O
+of	O
+Systemic	B-DISO
+Inflammatory	I-DISO
+Response	I-DISO
+Syndrome	I-DISO
+(	O
+SIRS	B-DISO
+)	O
+score	O
+and	O
+serum	B-COMP
+Interleukin	B-PRGE
+-	I-PRGE
+6	I-PRGE
+(	O
+IL	B-FUNC
+-	I-FUNC
+6	I-FUNC
+)	O
+level	O
+on	O
+admission	O
+as	O
+predictor	O
+of	O
+illness	O
+severity	O
+and	O
+outcome	O
+of	O
+Severe	O
+Acute	B-DISO
+Pancreatitis	I-DISO
+(	O
+SAP	O
+).	O
+
+In	O
+105	O
+patients	O
+with	O
+SIRS	B-DISO
+score	O
+3	O
+and	O
+higher	O
+,	O
+initial	O
+measured	O
+IL	B-FUNC
+-	I-FUNC
+6	I-FUNC
+levels	O
+were	O
+significantly	O
+higher	O
+than	O
+in	O
+the	O
+group	O
+of	O
+remaining	O
+129	O
+patients	O
+(	O
+72	O
++/-	O
+
+TITLE	O
+:	O
+Telbivudine	B-CHED
+preserves	O
+T	O
+-	O
+helper	O
+1	O
+cytokine	B-PROC
+production	I-PROC
+and	O
+downregulates	O
+programmed	O
+death	B-PROC
+ligand	B-CHED
+1	O
+in	O
+a	O
+mouse	B-SPEC
+model	O
+of	O
+viral	B-DISO
+hepatitis	I-DISO
+.	O
+
+The	O
+results	O
+demonstrate	O
+the	O
+immunomodulatory	O
+properties	O
+of	O
+telbivudine	B-CHED
+,	O
+independent	O
+of	O
+its	O
+antiviral	B-CHED
+activity	O
+,	O
+in	O
+a	O
+mouse	B-SPEC
+model	O
+of	O
+MHV	B-SPEC
+-	O
+3	O
+-	O
+induced	O
+hepatitis	B-DISO
+.	O
+
+To	O
+further	O
+delineate	O
+the	O
+structure	O
+-	O
+function	O
+relationships	O
+of	O
+the	O
+domain	O
+III	O
+and	O
+the	O
+long	O
+loop	O
+,	O
+we	O
+generated	O
+some	O
+truncated	O
+and	O
+mutated	O
+M	O
+(	O
+pro	B-CHED
+)	O
+forms	O
+bearing	O
+various	O
+combinations	O
+of	O
+the	O
+loop	O
+with	O
+other	O
+structural	O
+parts	O
+of	O
+the	O
+enzyme	O
+.	O
+
+TITLE	O
+:	O
+Genome	O
+informatics	O
+of	O
+influenza	B-PATH
+A	I-PATH
+:	O
+from	O
+data	O
+sharing	O
+to	O
+shared	O
+analytical	O
+capabilities	O
+.	O
+
+Importantly	O
+,	O
+all	O
+three	O
+excess	O
+mortalities	O
+were	O
+at	O
+their	O
+highest	O
+in	O
+May	O
+,	O
+2003	O
+,	O
+when	O
+inter	O
+-	O
+hospital	O
+nosocomial	B-DISO
+infections	I-DISO
+were	O
+peaking	O
+.	O
+
+JHMV	O
+infection	B-DISO
+induced	I-DISO
+the	O
+rapid	O
+and	O
+sustained	O
+expression	B-PROC
+of	O
+transcripts	O
+specific	O
+for	O
+the	O
+ELR	B-PRGE
++	I-PRGE
+chemokine	I-PRGE
+ligands	O
+CXCL1	B-PRGE
+and	O
+CXCL2	B-PRGE
+,	O
+as	O
+well	O
+as	O
+their	O
+binding	B-FUNC
+receptor	O
+CXCR2	B-PRGE
+,	O
+which	O
+was	O
+enriched	O
+within	O
+the	O
+spinal	B-ANAT
+cord	I-ANAT
+during	O
+chronic	B-DISO
+infection	I-DISO
+.	O
+
+Inclusion	O
+of	O
+CXCL1	B-PRGE
+within	O
+JHMV	O
+infected	O
+cultures	O
+restricted	O
+caspase	B-PRGE
+3	I-PRGE
+cleavage	B-PROC
+and	O
+increased	O
+Bcl	B-PRGE
+-	I-PRGE
+2	I-PRGE
+expression	B-PROC
+that	O
+was	O
+associated	O
+with	O
+a	O
+significant	O
+(	O
+p	O
+<	O
+0	O
+.	O
+001	O
+)	O
+decrease	O
+in	O
+apoptosis	B-PATH
+.	O
+
+Compared	O
+with	O
+mice	B-SPEC
+treated	O
+with	O
+HB	B-PRGE
+-	I-PRGE
+EGF	I-PRGE
+(	O
+I	B-PRGE
+/	I-PRGE
+R	I-PRGE
++	I-PRGE
+HB	I-PRGE
+-	I-PRGE
+EGF	I-PRGE
+),	O
+the	O
+I	O
+/	O
+R	O
+group	O
+had	O
+more	O
+severe	O
+acute	O
+lung	B-ANAT
+injury	O
+,	O
+and	O
+decreased	O
+survival	O
+.	O
+
+ABSTRACT	O
+:	O
+Angiotensin	B-PRGE
+-	I-PRGE
+converting	I-PRGE
+enzyme	I-PRGE
+(	O
+ACE	B-PRGE
+)	O
+2	O
+is	O
+a	O
+homolog	O
+to	O
+the	O
+carboxypeptidase	B-PRGE
+ACE	I-PRGE
+,	O
+which	O
+generates	O
+angiotensin	B-PRGE
+II	I-PRGE
+,	O
+the	O
+main	O
+active	O
+peptide	B-CHED
+of	O
+renin	B-PATH
+-	I-PATH
+angiotensin	B-CHED
+system	I-PATH
+(	O
+RAS	B-PRGE
+).	O
+
+TITLE	O
+:	O
+Vectored	O
+vaccines	O
+to	O
+protect	O
+against	O
+PRRSV	B-SPEC
+.	O
+
+A	O
+TGEV	B-SPEC
+derived	O
+vector	O
+(	O
+rTGEV	O
+)	O
+was	O
+generated	O
+,	O
+expressing	O
+PRRSV	B-SPEC
+wild	O
+type	O
+or	O
+modified	O
+GP5	B-PRGE
+and	O
+M	O
+proteins	B-CHED
+,	O
+described	O
+as	O
+the	O
+main	O
+inducers	O
+of	O
+neutralizing	O
+antibodies	B-COMP
+and	O
+cellular	B-PROC
+immune	I-PROC
+response	I-PROC
+,	O
+respectively	O
+.	O
+
+Since	O
+the	O
+ratios	O
+of	O
+these	O
+sequences	O
+generally	O
+remained	O
+constant	O
+in	O
+the	O
+quasispecies	O
+population	O
+during	O
+replication	O
+,	O
+factors	O
+that	O
+could	O
+affect	O
+the	O
+balance	B-PROC
+of	O
+virulent	O
+to	O
+avirulent	O
+sequences	O
+during	O
+viral	B-PROC
+infection	I-PROC
+of	O
+birds	B-SPEC
+were	O
+investigated	O
+.	O
+
+The	O
+effect	O
+of	O
+a	O
+prior	O
+infection	B-DISO
+of	O
+the	O
+host	B-COMP
+by	O
+infectious	B-DISO
+bronchitis	B-DISO
+virus	B-SPEC
+or	O
+infectious	B-SPEC
+bursal	I-SPEC
+disease	I-SPEC
+virus	I-SPEC
+on	O
+the	O
+subsequent	O
+emergence	O
+of	O
+virulent	O
+Newcastle	B-SPEC
+disease	I-SPEC
+virus	I-SPEC
+was	O
+examined	O
+.	O
+
+ABSTRACT	O
+:	O
+In	O
+Hong	O
+Kong	O
+during	O
+the	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+outbreak	O
+of	O
+2003	O
+,	O
+sustained	O
+uncertainty	O
+caused	O
+daily	O
+stress	O
+for	O
+residents	O
+for	O
+>	O
+3	O
+months	O
+.	O
+
+However	O
+,	O
+nsp1	B-PRGE
+may	O
+not	O
+be	O
+the	O
+key	O
+determinant	O
+of	O
+viral	O
+pathogenicity	O
+,	O
+or	O
+the	O
+factor	O
+used	O
+by	O
+the	O
+SARS	B-DISO
+coronavirus	B-SPEC
+to	O
+evade	O
+host	B-COMP
+innate	B-PROC
+immunity	I-PROC
+.	O
+
+However	O
+,	O
+we	O
+recently	O
+showed	O
+that	O
+inefficient	O
+immune	O
+activation	O
+and	O
+a	O
+poor	O
+virus	B-SPEC
+-	O
+specific	O
+T	B-ANAT
+cell	I-ANAT
+response	O
+underlie	O
+severe	O
+disease	O
+in	O
+SARS	B-DISO
+-	O
+CoV	O
+-	O
+infected	O
+mice	B-SPEC
+.	O
+
+Here	O
+,	O
+we	O
+extend	O
+these	O
+results	O
+to	O
+show	O
+that	O
+virus	B-SPEC
+-	O
+specific	O
+T	B-ANAT
+cells	I-ANAT
+,	O
+in	O
+the	O
+absence	O
+of	O
+activation	O
+of	O
+the	O
+innate	B-DISO
+immune	I-DISO
+response	I-DISO
+,	O
+were	O
+sufficient	O
+to	O
+significantly	O
+enhance	O
+survival	O
+and	O
+diminish	O
+clinical	O
+disease	O
+.	O
+
+Infection	B-DISO
+was	O
+not	O
+associated	O
+with	O
+evidence	O
+of	O
+hepatitis	B-DISO
+or	O
+hepatic	B-DISO
+dysfunction	I-DISO
+.	O
+
+It	O
+is	O
+quite	O
+possible	O
+that	O
+mass	O
+casualties	O
+from	O
+a	O
+terrorist	O
+incident	O
+or	O
+major	O
+industrial	O
+accident	O
+involving	O
+the	O
+release	B-PATH
+of	O
+large	O
+quantities	O
+of	O
+inhaled	B-PROC
+TICs	B-DISO
+would	O
+place	O
+a	O
+severe	O
+burden	O
+on	O
+already	O
+scarce	O
+intensive	O
+care	O
+facilities	O
+.	O
+
+Thus	O
+,	O
+despite	O
+improvements	O
+in	O
+ventilation	O
+strategies	O
+,	O
+pharmacological	O
+intervention	O
+for	O
+ALI	O
+/	O
+ARDS	B-DISO
+remains	O
+problematical	O
+.	O
+
+Hepatocyte	B-PROC
+growth	B-PROC
+factor	I-PROC
+(	O
+HGF	B-DISO
+)	O
+does	O
+not	O
+have	O
+epithelial	O
+specificity	O
+for	O
+lung	B-ANAT
+tissue	I-ANAT
+.	O
+
+This	O
+retrospective	O
+case	O
+series	O
+spans	O
+December	O
+2002	O
+to	O
+January	O
+2009	O
+of	O
+survivors	O
+transferred	O
+to	O
+an	O
+echelon	O
+IV	O
+military	O
+trauma	O
+center	O
+in	O
+Europe	O
+serving	O
+as	O
+the	O
+primary	O
+evacuation	O
+hub	O
+for	O
+ongoing	O
+combat	B-CHED
+operations	O
+.	O
+
+TITLE	O
+:	O
+Clinical	O
+pathological	O
+characteristics	O
+and	O
+management	O
+of	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+resulting	O
+from	O
+influenza	O
+A	O
+(	O
+H1N1	O
+)	O
+virus	B-SPEC
+.	O
+
+Supernatants	O
+of	O
+these	O
+strains	O
+inhibited	O
+TGE	B-DISO
+coronavirus	B-SPEC
+in	O
+vitro	O
+in	O
+ST	O
+cells	B-COMP
+,	O
+without	O
+any	O
+cytopathic	B-DISO
+effect	I-DISO
+even	O
+after	O
+72	O
+h	O
+of	O
+incubation	O
+.	O
+
+TITLE	O
+:	O
+Cell	B-ANAT
+replacement	O
+therapies	O
+to	O
+promote	O
+remyelination	B-PROC
+in	O
+a	O
+viral	O
+model	O
+of	O
+demyelination	B-DISO
+.	O
+
+In	O
+this	O
+study	O
+,	O
+surface	O
+-	O
+enhanced	O
+Raman	O
+spectroscopy	O
+(	O
+SERS	O
+)	O
+coupled	O
+with	O
+gold	B-CHED
+SERS	O
+-	O
+active	O
+substrates	O
+was	O
+used	O
+to	O
+detect	O
+and	O
+discriminate	O
+7	O
+food	O
+-	O
+and	O
+waterborne	O
+viruses	B-SPEC
+,	O
+including	O
+norovirus	B-SPEC
+,	O
+adenovirus	B-DISO
+,	O
+parvovirus	B-DISO
+,	O
+rotavirus	B-SPEC
+,	O
+coronavirus	B-SPEC
+,	O
+paramyxovirus	O
+,	O
+and	O
+herpersvirus	O
+.	O
+
+After	O
+capturing	O
+the	O
+characteristic	O
+SERS	O
+spectral	O
+patterns	O
+,	O
+multivariate	O
+statistical	O
+analyses	O
+,	O
+including	O
+soft	O
+independent	O
+modeling	O
+of	O
+class	B-SPEC
+analogy	O
+(	O
+SIMCA	O
+)	O
+and	O
+principal	O
+component	O
+analysis	O
+(	O
+PCA	B-DISO
+),	O
+were	O
+employed	O
+to	O
+analyze	O
+SERS	O
+spectral	O
+data	O
+for	O
+characterization	O
+and	O
+identification	O
+of	O
+viruses	O
+.	O
+
+The	O
+results	O
+show	O
+that	O
+SIMCA	O
+was	O
+able	O
+to	O
+differentiate	O
+viruses	B-SPEC
+with	O
+and	O
+without	O
+envelope	B-COMP
+with	O
+>	O
+95	O
+%	O
+of	O
+classification	O
+accuracy	O
+,	O
+while	O
+PCA	B-DISO
+presented	O
+clear	O
+spectral	O
+data	O
+segregations	O
+between	O
+different	O
+virus	B-SPEC
+strains	O
+.	O
+
+Here	O
+,	O
+we	O
+have	O
+identified	O
+an	O
+RSS	B-DISO
+from	O
+a	O
+medically	O
+important	O
+positive	O
+-	O
+sense	B-PROC
+mammalian	B-SPEC
+virus	B-SPEC
+,	O
+Severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+coronavirus	B-SPEC
+.	O
+
+Sequencing	O
+of	O
+the	O
+3	O
+'	O
+one	O
+-	O
+third	O
+of	O
+the	O
+MHV	B-SPEC
+-	O
+1	O
+genome	O
+demonstrated	O
+that	O
+the	O
+genetic	O
+organization	O
+of	O
+MHV	B-PRGE
+-	I-PRGE
+1	I-PRGE
+was	O
+similar	O
+to	O
+that	O
+of	O
+other	O
+strains	O
+of	O
+MHV	B-SPEC
+.	O
+
+These	O
+data	O
+suggest	O
+that	O
+important	O
+determinants	O
+of	O
+pneumopathogenicity	O
+are	O
+contained	O
+within	O
+the	O
+3	O
+'	O
+one	O
+-	O
+third	O
+of	O
+the	O
+MHV	B-SPEC
+-	O
+1	O
+genome	O
+,	O
+but	O
+additional	O
+important	O
+virulence	B-PROC
+factors	O
+must	O
+be	O
+encoded	O
+in	O
+the	O
+genome	O
+upstream	O
+of	O
+the	O
+S	B-PRGE
+gene	I-PRGE
+.	O
+
+ABSTRACT	O
+:	O
+Hens	O
+were	O
+vaccinated	O
+during	O
+the	O
+rearing	O
+phase	O
+with	O
+infectious	O
+bronchitis	B-DISO
+virus	B-SPEC
+(	O
+IBV	B-SPEC
+)	O
+vaccines	O
+commercially	O
+available	O
+in	O
+Australia	O
+(	O
+Vic	O
+S	O
+and	O
+A3	O
+)	O
+or	O
+left	O
+unvaccinated	O
+and	O
+then	O
+challenged	O
+with	O
+the	O
+N1	O
+/	O
+88	O
+strain	O
+of	O
+IBV	B-SPEC
+at	O
+30	O
+wk	O
+of	O
+age	O
+.	O
+
+The	O
+loss	O
+of	O
+influenza	B-DISO
+infectivity	O
+was	O
+frequently	O
+accompanied	O
+by	O
+loss	O
+of	O
+hemagglutinating	O
+activity	O
+.	O
+
+ABSTRACT	O
+:	O
+Acute	O
+lung	B-ANAT
+injury	O
+(	O
+ALI	O
+)	O
+and	O
+its	O
+severe	O
+form	O
+,	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+(	O
+ARDS	B-DISO
+),	O
+are	O
+major	O
+causes	O
+of	O
+acute	B-DISO
+respiratory	I-DISO
+failure	I-DISO
+with	O
+high	O
+rates	O
+of	O
+morbidity	O
+and	O
+mortality	O
+.	O
+
+In	O
+the	O
+present	O
+study	O
+,	O
+we	O
+induced	O
+indirect	O
+lung	B-ANAT
+injury	O
+by	O
+intraperitoneal	O
+injection	O
+of	O
+LPS	B-DISO
+and	O
+direct	O
+lung	B-ANAT
+injury	O
+by	O
+intratracheal	O
+injection	O
+of	O
+LPS	B-DISO
+in	O
+wild	O
+-	O
+type	O
+and	O
+Sftpd	O
+(-/-)	O
+mice	B-SPEC
+to	O
+elucidate	O
+the	O
+role	O
+of	O
+SP	B-PRGE
+-	I-PRGE
+D	I-PRGE
+during	O
+ALI	O
+/	O
+ARDS	B-DISO
+.	O
+
+In	O
+19	O
+of	O
+the	O
+37	O
+patients	O
+,	O
+weaning	B-PROC
+and	O
+extubation	O
+became	O
+possible	O
+within	O
+the	O
+first	O
+24	O
+hours	O
+.	O
+
+We	O
+have	O
+previously	O
+shown	O
+that	O
+the	O
+prototype	O
+OC43	O
+strain	O
+of	O
+the	O
+common	B-DISO
+cold	I-DISO
+-	O
+associated	O
+human	B-SPEC
+respiratory	O
+coronavirus	B-SPEC
+has	O
+the	O
+capacity	O
+to	O
+infect	O
+human	B-SPEC
+neuronal	O
+and	O
+glial	B-ANAT
+cells	I-ANAT
+and	O
+does	O
+persist	O
+in	O
+human	B-SPEC
+brains	B-ANAT
+.	O
+
+ABSTRACT	O
+:	O
+It	O
+is	O
+known	O
+that	O
+severe	O
+acute	O
+respiratory	O
+syndrome	O
+(	O
+SARS	B-DISO
+),	O
+a	O
+severe	O
+infectious	B-DISO
+illness	O
+,	O
+which	O
+caused	O
+an	O
+epidemic	O
+in	O
+Asia	O
+in	O
+2003	O
+,	O
+has	O
+extensive	O
+and	O
+complex	O
+effects	O
+on	O
+human	B-SPEC
+organ	B-ANAT
+systems	I-ANAT
+.	O
+
+RESULTS	O
+:	O
+About	O
+9	O
+.	O
+2	O
+%	O
+of	O
+the	O
+participants	O
+reported	O
+that	O
+their	O
+perceptions	O
+of	O
+life	O
+became	O
+more	O
+pessimistic	O
+following	O
+the	O
+SARS	B-DISO
+crisis	O
+.	O
+
+TITLE	O
+:	O
+Serum	B-ANAT
+protein	B-CHED
+electrophoresis	O
+in	O
+155	O
+cats	B-SPEC
+.	O
+
+ABSTRACT	O
+:	O
+All	O
+serum	B-COMP
+protein	B-CHED
+electrophoresis	O
+(	O
+SPE	O
+)	O
+results	O
+obtained	O
+between	O
+2002	O
+and	O
+2009	O
+from	O
+clinical	O
+cases	O
+presented	O
+to	O
+the	O
+University	O
+of	O
+Bristol	O
+Feline	O
+Centre	O
+were	O
+examined	O
+retrospectively	O
+.	O
+
+One	O
+hundred	O
+and	O
+fifty	O
+-	O
+five	O
+results	O
+met	B-CHED
+the	O
+inclusion	O
+criteria	O
+.	O
+
+A	O
+monoclonal	B-DISO
+gammopathy	I-DISO
+occurred	O
+in	O
+four	O
+cats	B-SPEC
+;	O
+one	O
+with	O
+feline	B-DISO
+infectious	I-DISO
+peritonitis	I-DISO
+(	O
+FIP	B-DISO
+),	O
+one	O
+with	O
+lymphoma	B-DISO
+and	O
+two	O
+cases	O
+of	O
+splenic	B-ANAT
+plasmacytoma	B-DISO
+(	O
+one	O
+suspected	O
+,	O
+one	O
+confirmed	O
+).	O
+
+The	O
+clinical	O
+presentation	O
+varied	O
+with	O
+the	O
+age	O
+of	O
+the	O
+affected	O
+animals	B-SPEC
+with	O
+a	O
+bovine	B-SPEC
+-	O
+respiratory	O
+-	O
+complex	O
+-	O
+like	O
+syndrome	B-DISO
+in	O
+young	O
+stock	O
+,	O
+and	O
+diarrhea	B-DISO
+and	O
+dysentery	B-DISO
+only	O
+in	O
+the	O
+lactating	O
+stock	O
+.	O
+
+The	O
+route	O
+of	O
+introduction	O
+of	O
+BVDV	B-SPEC
+-	I-SPEC
+2	I-SPEC
+into	O
+Israel	O
+could	O
+not	O
+be	O
+elucidated	O
+.	O
+
+Most	O
+cases	O
+appeared	O
+to	O
+be	O
+primary	O
+viral	B-DISO
+pneumonia	I-DISO
+,	O
+but	O
+only	O
+one	O
+case	O
+was	O
+positive	O
+for	O
+a	O
+urinary	O
+pneumococcal	B-PRGE
+antigen	I-PRGE
+.	O
+
+This	O
+was	O
+a	O
+retrospective	O
+chart	O
+review	O
+of	O
+H1N1	O
+patients	O
+with	O
+ARDS	B-DISO
+who	O
+were	O
+admitted	O
+to	O
+our	O
+intensive	O
+care	O
+unit	O
+(	O
+ICU	O
+)	O
+between	O
+July	O
+and	O
+September	O
+2009	O
+.	O
+
+However	O
+,	O
+such	O
+a	O
+strategy	O
+may	O
+result	O
+in	O
+alveolar	B-ANAT
+collapse	B-DISO
+,	O
+leading	O
+to	O
+cyclic	O
+opening	O
+and	O
+closing	O
+of	O
+atelectatic	O
+alveoli	B-ANAT
+and	O
+distal	O
+airways	O
+.	O
+
+The	O
+most	O
+commonly	O
+used	O
+RM	O
+is	O
+conventional	O
+sustained	O
+inflation	O
+,	O
+associated	O
+with	O
+respiratory	O
+and	O
+cardiovascular	B-ANAT
+side	O
+effects	O
+,	O
+which	O
+may	O
+be	O
+minimized	O
+by	O
+newly	O
+proposed	O
+strategies	O
+:	O
+prolonged	O
+or	O
+incremental	O
+PEEP	O
+elevation	O
+;	O
+pressure	O
+-	O
+controlled	O
+ventilation	O
+with	O
+fixed	B-ANAT
+PEEP	B-CHED
+and	O
+increased	O
+driving	O
+pressure	O
+;	O
+pressure	O
+-	O
+controlled	O
+ventilation	O
+applied	O
+with	O
+escalating	O
+PEEP	B-CHED
+and	O
+constant	O
+driving	O
+pressure	O
+;	O
+and	O
+long	O
+and	O
+slow	O
+increase	O
+in	O
+pressure	O
+.	O
+
+Current	O
+evidence	O
+suggests	O
+that	O
+RMs	O
+can	O
+be	O
+used	O
+before	O
+setting	O
+PEEP	B-CHED
+,	O
+after	O
+ventilator	O
+circuit	O
+disconnection	O
+or	O
+as	O
+a	O
+rescue	O
+maneuver	O
+to	O
+overcome	O
+severe	O
+hypoxemia	O
+;	O
+however	O
+,	O
+their	O
+routine	O
+use	O
+does	O
+not	O
+seem	O
+to	O
+be	O
+justified	O
+at	O
+present	O
+.	O
+
+ABSTRACT	O
+:	O
+The	O
+coronavirus	B-SPEC
+nucleocapsid	B-COMP
+(	O
+N	O
+)	O
+protein	B-CHED
+plays	O
+an	O
+essential	O
+role	O
+in	O
+virion	B-PROC
+assembly	I-PROC
+via	O
+interactions	O
+with	O
+the	O
+large	O
+,	O
+positive	O
+-	O
+strand	O
+RNA	B-COMP
+viral	I-COMP
+genome	I-COMP
+and	O
+the	O
+carboxy	B-CHED
+-	O
+terminal	O
+endodomain	O
+of	O
+the	O
+membrane	B-COMP
+protein	B-CHED
+(	O
+M	O
+).	O
+
+The	O
+resulting	O
+viral	O
+mutant	B-DISO
+was	O
+severely	O
+defective	O
+,	O
+even	O
+though	O
+individual	O
+domains	O
+of	O
+the	O
+N	O
+protein	B-CHED
+responsible	O
+for	O
+N	O
+-	O
+RNA	O
+,	O
+N	O
+-	O
+M	O
+,	O
+or	O
+N	O
+-	O
+N	O
+interactions	O
+were	O
+completely	O
+interchangeable	O
+between	O
+BCoV	O
+and	O
+MHV	B-SPEC
+.	O
+
+The	O
+lesion	O
+in	O
+the	O
+BCoV	O
+N	O
+substitution	O
+mutant	B-DISO
+could	O
+be	O
+compensated	O
+for	O
+by	O
+reverting	O
+mutations	O
+in	O
+the	O
+central	O
+,	O
+serine	B-CHED
+-	O
+and	O
+arginine	B-CHED
+-	O
+rich	O
+(	O
+SR	O
+)	O
+domain	O
+of	O
+the	O
+N	B-PRGE
+protein	I-PRGE
+.	O
+
+Thenar	B-ANAT
+oxygen	B-CHED
+saturation	O
+(	O
+StO	O
+(	O
+2	O
+))	O
+was	O
+also	O
+measured	O
+with	O
+near	O
+-	O
+infrared	O
+spectroscopy	O
+(	O
+NIRS	O
+)	O
+during	O
+a	O
+vascular	B-DISO
+occlusion	B-PROC
+test	O
+.	O
+
+RESULTS	O
+:	O
+All	O
+patients	O
+received	O
+invasive	O
+mechanical	O
+ventilation	O
+and	O
+at	O
+least	O
+one	O
+of	O
+the	O
+following	O
+adjuvant	B-CHED
+therapies	O
+:	O
+inhaled	B-PROC
+nitric	B-CHED
+oxide	I-CHED
+(	O
+n	O
+=	O
+4	O
+),	O
+extracorporeal	O
+membrane	B-COMP
+oxygenation	B-PROC
+(	O
+n	O
+=	O
+1	O
+),	O
+prone	O
+position	O
+(	O
+n	O
+=	O
+4	O
+),	O
+recruitment	B-DISO
+maneuver	O
+(	O
+n	O
+=	O
+3	O
+),	O
+and	O
+hydrocortisone	B-CHED
+50	O
+mg	O
+·	O
+hr	O
+(-	O
+6	O
+)	O
+(	O
+n	O
+=	O
+6	O
+).	O
+
+To	O
+test	O
+this	O
+hypothesis	O
+,	O
+an	O
+in	O
+vitro	O
+model	O
+of	O
+dual	O
+infection	B-DISO
+with	O
+cell	B-COMP
+culture	O
+-	O
+adapted	O
+PEDV	B-SPEC
+and	O
+Chlamydia	B-SPEC
+abortus	I-SPEC
+or	O
+Chlamydia	B-SPEC
+pecorum	I-SPEC
+in	O
+Vero	B-ANAT
+cells	I-ANAT
+was	O
+established	O
+.	O
+
+Dual	O
+infections	B-DISO
+with	O
+Chlamydia	B-SPEC
+abortus	I-SPEC
+revealed	O
+a	O
+heterogenous	O
+mix	O
+of	O
+inclusion	O
+types	O
+including	O
+small	O
+inclusions	O
+consisting	O
+of	O
+aberrant	O
+bodies	O
+(	O
+ABs	O
+),	O
+medium	O
+-	O
+sized	O
+inclusions	O
+consisting	O
+of	O
+ABs	O
+and	O
+reticulate	O
+bodies	O
+and	O
+normal	O
+inclusions	O
+.	O
+
+In	O
+the	O
+present	O
+study	O
+we	O
+confirm	O
+that	O
+PEDV	B-SPEC
+co	B-DISO
+-	I-DISO
+infection	I-DISO
+alters	O
+the	O
+developmental	O
+cycle	O
+of	O
+member	O
+species	B-SPEC
+of	O
+the	O
+family	B-SPEC
+Chlamydiaceae	I-SPEC
+,	O
+in	O
+a	O
+similar	O
+manner	O
+to	O
+other	O
+well	O
+-	O
+described	O
+persistence	O
+induction	O
+methods	O
+.	O
+
+The	O
+survey	O
+included	O
+questions	O
+regarding	O
+individual	O
+perceptions	O
+,	O
+motivating	O
+factors	O
+,	O
+and	O
+behaviors	B-PROC
+associated	O
+with	O
+hand	O
+washing	O
+for	O
+the	O
+prevention	O
+of	O
+H1N1	B-DISO
+influenza	I-DISO
+transmission	O
+.	O
+
+Study	O
+participants	O
+who	O
+were	O
+female	O
+(	O
+OR	O
+:	O
+1	O
+.	O
+79	O
+-	O
+3	O
+.	O
+90	O
+)	O
+who	O
+perceived	O
+of	O
+hand	O
+washing	O
+to	O
+be	O
+effective	O
+(	O
+OR	O
+:	O
+1	O
+.	O
+34	O
+-	O
+12	O
+.	O
+15	O
+)	O
+and	O
+illness	O
+severity	O
+to	O
+be	O
+greater	O
+(	O
+OR	O
+:	O
+1	O
+.	O
+00	O
+-	O
+3	O
+.	O
+12	O
+)	O
+washed	O
+their	O
+hands	B-ANAT
+more	O
+frequently	O
+.	O
+
+ABSTRACT	O
+:	O
+Feline	O
+coronaviruses	O
+(	O
+FCoV	O
+)	O
+comprise	O
+two	O
+biotypes	O
+:	O
+feline	B-SPEC
+enteric	O
+coronaviruses	O
+(	O
+FECV	B-SPEC
+)	O
+and	O
+feline	B-DISO
+infectious	I-DISO
+peritonitis	I-DISO
+viruses	B-SPEC
+(	O
+FIPV	O
+).	O
+
+FECV	B-SPEC
+is	O
+associated	O
+with	O
+asymptomatic	O
+persistent	O
+enteric	O
+infections	B-DISO
+,	O
+while	O
+FIPV	O
+causes	O
+feline	B-DISO
+infectious	I-DISO
+peritonitis	I-DISO
+(	O
+FIP	B-DISO
+),	O
+a	O
+usually	O
+fatal	O
+systemic	B-DISO
+disease	I-DISO
+in	O
+domestic	B-SPEC
+cats	I-SPEC
+and	O
+some	O
+wild	O
+Felidae	B-SPEC
+.	O
+
+TITLE	O
+:	O
+Studies	O
+of	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+coronavirus	B-SPEC
+pathology	B-DISO
+in	O
+human	B-SPEC
+cases	O
+and	O
+animal	B-SPEC
+models	O
+.	O
+
+TITLE	O
+:	O
+SARS	B-DISO
+spike	O
+protein	B-CHED
+induces	O
+phenotypic	O
+conversion	O
+of	O
+human	B-SPEC
+B	B-ANAT
+cells	I-ANAT
+to	O
+macrophage	B-ANAT
+-	O
+like	O
+cells	B-COMP
+.	O
+
+Here	O
+,	O
+we	O
+investigated	O
+whether	O
+spike	O
+protein	B-CHED
+of	O
+SARS	B-DISO
+-	O
+CoV	O
+can	O
+act	O
+as	O
+a	O
+ligand	B-PROC
+to	O
+trigger	O
+the	O
+conversion	O
+of	O
+B	B-ANAT
+cells	I-ANAT
+to	O
+macrophages	B-ANAT
+.	O
+
+TITLE	O
+:	O
+Papain	B-ENZY
+-	I-PRGE
+like	I-PRGE
+protease	I-PRGE
+1	I-PRGE
+from	O
+transmissible	O
+gastroenteritis	B-DISO
+virus	B-SPEC
+:	O
+crystal	B-ANAT
+structure	O
+and	O
+enzymatic	B-PROC
+activity	I-PROC
+toward	O
+viral	O
+and	O
+cellular	B-COMP
+substrates	O
+.	O
+
+These	O
+enzymes	O
+mediate	O
+the	O
+processing	O
+of	O
+the	O
+two	O
+precursor	O
+polyproteins	O
+of	O
+the	O
+viral	B-PRGE
+replicase	I-PRGE
+and	O
+are	O
+also	O
+thought	O
+to	O
+modulate	O
+host	B-COMP
+cell	I-COMP
+functions	O
+to	O
+facilitate	O
+infection	B-DISO
+.	O
+
+TITLE	O
+:	O
+Quantification	O
+of	O
+circulating	O
+cell	B-COMP
+-	O
+free	O
+DNA	O
+in	O
+the	O
+serum	B-COMP
+of	O
+patients	O
+with	O
+obstructive	B-DISO
+sleep	B-PROC
+apnea	I-DISO
+-	O
+hypopnea	O
+syndrome	O
+.	O
+
+The	O
+aim	O
+of	O
+this	O
+study	O
+was	O
+to	O
+examine	O
+whether	O
+serum	B-COMP
+DNA	O
+concentrations	O
+were	O
+elevated	O
+in	O
+patients	O
+with	O
+obstructive	B-DISO
+sleep	I-DISO
+apnea	I-DISO
+-	O
+hypopnea	B-DISO
+syndrome	I-DISO
+(	O
+OSAHS	B-DISO
+).	O
+
+Univariate	O
+analysis	O
+showed	O
+that	O
+serum	B-COMP
+DNA	O
+correlated	O
+positively	O
+with	O
+AHI	O
+,	O
+oxygen	B-CHED
+desaturation	O
+index	O
+(	O
+ODI	O
+),	O
+IL	B-FUNC
+-	I-FUNC
+6	I-FUNC
+,	O
+and	O
+MDA	B-CHED
+,	O
+and	O
+negatively	O
+correlated	O
+with	O
+minimal	O
+oxygen	B-CHED
+saturation	O
+(	O
+miniSaO	O
+(	O
+2	O
+))	O
+(	O
+all	O
+p	O
+<	O
+0	O
+.	O
+05	O
+).	O
+
+In	O
+stepwise	O
+multiple	O
+regression	O
+analysis	O
+,	O
+only	O
+MDA	B-CHED
+and	O
+miniSaO	O
+(	O
+2	O
+)	O
+were	O
+suggested	O
+as	O
+significant	O
+independent	O
+predictors	O
+for	O
+the	O
+serum	B-COMP
+DNA	O
+concentrations	O
+.	O
+
+TITLE	O
+:	O
+Treating	O
+Infectious	B-DISO
+Diseases	I-DISO
+in	O
+a	O
+Microbial	O
+World	O
+:	O
+Report	O
+of	O
+Two	O
+Workshops	O
+on	O
+Novel	O
+Antimicrobial	B-CHED
+Therapeutics	O
+ABSTRACT	O
+:	O
+At	O
+the	O
+request	O
+of	O
+the	O
+National	O
+Institute	O
+of	O
+Allergy	B-DISO
+and	O
+Infectious	B-DISO
+Diseases	I-DISO
+,	O
+two	O
+committees	O
+established	O
+by	O
+the	O
+National	O
+Research	O
+Council	O
+organized	O
+workshops	O
+to	O
+identify	O
+promising	O
+new	O
+approaches	O
+to	O
+the	O
+development	B-PROC
+of	O
+antimicrobial	B-CHED
+therapeutics	O
+(	O
+Appendix	B-ANAT
+A	O
+).	O
+
+ABSTRACT	O
+:	O
+The	O
+species	B-SPEC
+barrier	O
+is	O
+not	O
+perfect	O
+for	O
+Influenza	O
+A	O
+and	O
+numerous	O
+transmissions	O
+of	O
+the	O
+virus	B-SPEC
+from	O
+pigs	B-SPEC
+or	O
+poultry	O
+to	O
+humans	B-SPEC
+have	O
+been	O
+described	O
+these	O
+years	O
+.	O
+
+In	O
+addition	O
+,	O
+enhanced	O
+DNA	B-PROC
+unwinding	I-PROC
+was	O
+observed	O
+for	O
+gapped	O
+DNA	O
+substrates	O
+that	O
+had	O
+a	O
+5	O
+'-	O
+overhang	O
+,	O
+indicating	O
+that	O
+the	O
+translocated	O
+nsP13	O
+molecules	O
+pile	B-DISO
+up	O
+and	O
+the	O
+preceding	O
+helicase	B-PRGE
+facilitate	O
+DNA	B-PROC
+unwinding	I-PROC
+.	O
+
+Together	O
+with	O
+the	O
+propensity	O
+of	O
+oligomer	O
+formation	B-PROC
+of	O
+nsP13	O
+molecules	O
+,	O
+we	O
+propose	O
+that	O
+the	O
+cooperative	O
+translocation	B-DISO
+by	O
+the	O
+functionally	O
+interacting	O
+oligomers	O
+of	O
+the	O
+helicase	B-PRGE
+molecules	I-PRGE
+loaded	O
+onto	O
+the	O
+5	O
+'-	O
+overhang	O
+account	O
+for	O
+the	O
+observed	O
+enhanced	O
+processivity	O
+of	O
+DNA	B-PROC
+unwinding	I-PROC
+.	O
+
+Among	O
+compounds	O
+tested	O
+,	O
+the	O
+fluorene	B-CHED
+compound	O
+4b	O
+was	O
+found	O
+to	O
+possess	B-DISO
+the	O
+most	O
+potent	O
+activity	O
+(	O
+EC	O
+(	O
+50	O
+)=	O
+0	O
+.	O
+3	O
+microM	O
+),	O
+lower	O
+cytotoxicity	B-DISO
+(	O
+CC	O
+(	O
+50	O
+)>	O
+50	O
+microM	O
+),	O
+and	O
+significantly	O
+better	O
+pharmacokinetic	O
+properties	O
+compared	O
+to	O
+its	O
+corresponding	O
+fluorenone	B-CHED
+compound	O
+4c	O
+.	O
+
+The	O
+data	O
+indicated	O
+that	O
+forsythoside	O
+A	O
+has	O
+the	O
+potential	O
+to	O
+prevent	O
+IBV	B-SPEC
+infection	B-DISO
+in	O
+vitro	O
+.	O
+
+The	O
+overall	O
+prevalence	O
+of	O
+virus	B-SPEC
+RNA	O
+was	O
+55	O
+.	O
+8	O
+%.	O
+
+Phylogenetic	O
+analysis	O
+of	O
+the	O
+RNA	B-PRGE
+-	I-PRGE
+dependent	I-PRGE
+RNA	I-PRGE
+polymerase	I-PRGE
+gene	I-PRGE
+showed	O
+that	O
+groups	O
+1	O
+and	O
+2	O
+CoVs	O
+were	O
+similar	O
+to	O
+Bat	B-PRGE
+-	I-PRGE
+CoV	I-PRGE
+/	O
+China	O
+/	O
+A515	O
+/	O
+2005	O
+(	O
+95	O
+%	O
+nt	O
+sequence	O
+identity	O
+)	O
+and	O
+Bat	B-PRGE
+-	I-PRGE
+CoV	I-PRGE
+/	O
+HKU9	O
+-	O
+1	O
+/	O
+China	O
+/	O
+2007	O
+(	O
+83	O
+%	O
+identity	O
+),	O
+respectively	O
+.	O
+
+Fruit	O
+bats	O
+infected	O
+with	O
+virus	B-SPEC
+did	O
+not	O
+show	O
+clinical	O
+signs	O
+of	O
+infection	B-DISO
+.	O
+
+This	O
+new	O
+systemic	B-DISO
+disease	I-DISO
+resembles	O
+the	O
+dry	O
+form	O
+of	O
+feline	B-DISO
+infectious	I-DISO
+peritonitis	I-DISO
+(	O
+FIP	B-DISO
+)	O
+and	O
+has	O
+been	O
+reported	O
+in	O
+the	O
+United	O
+States	O
+and	O
+Europe	O
+.	O
+
+This	O
+article	O
+addresses	O
+the	O
+clinical	O
+signs	O
+,	O
+pathology	B-DISO
+,	O
+pathogenesis	B-DISO
+,	O
+diagnosis	O
+,	O
+treatment	O
+,	O
+and	O
+prevention	O
+of	O
+this	O
+ferret	B-SPEC
+FIP	B-DISO
+-	O
+like	O
+disease	O
+.	O
+
+Surface	O
+expression	B-PROC
+of	O
+spike	O
+and	O
+staining	O
+with	O
+sera	B-COMP
+of	O
+SARS	B-DISO
+survivors	O
+suggested	O
+low	O
+antigenic	O
+overlap	O
+with	O
+SARS	B-DISO
+CoV	O
+.	O
+However	O
+,	O
+the	O
+receptor	B-FUNC
+binding	I-FUNC
+domain	O
+of	O
+SARS	B-PRGE
+CoV	I-PRGE
+showed	O
+higher	O
+similarity	O
+with	O
+that	O
+of	O
+BtCoV	O
+/	O
+BM48	O
+-	O
+31	O
+/	O
+Bulgaria	B-SPEC
+/	O
+2008	O
+than	O
+with	O
+that	O
+of	O
+any	O
+Chinese	O
+bat	B-ENZY
+-	O
+borne	O
+CoV	O
+.	O
+Critical	O
+spike	O
+domains	O
+472	O
+and	O
+487	O
+were	O
+identical	O
+and	O
+similar	O
+,	O
+respectively	O
+.	O
+
+TITLE	O
+:	O
+Loop	O
+-	O
+mediated	O
+isothermal	O
+amplification	B-DISO
+for	O
+rapid	O
+detection	O
+and	O
+differentiation	B-PROC
+of	O
+wild	O
+-	O
+type	O
+pseudorabies	B-DISO
+and	O
+gene	O
+-	O
+deleted	O
+virus	B-SPEC
+vaccines	O
+.	O
+
+One	O
+group	O
+of	O
+primers	O
+was	O
+designed	O
+to	O
+detect	O
+wild	O
+-	O
+type	O
+strains	O
+(	O
+i	O
+.	O
+e	O
+.,	O
+strains	O
+with	O
+the	O
+gE	B-PRGE
+gene	I-PRGE
+)	O
+and	O
+the	O
+other	O
+group	O
+of	O
+primers	O
+was	O
+designed	O
+to	O
+detect	O
+both	O
+PRV	B-DISO
+gE	O
+-	O
+vaccine	O
+and	O
+wild	O
+-	O
+type	O
+strains	O
+(	O
+i	O
+.	O
+e	O
+.,	O
+strains	O
+with	O
+the	O
+gG	B-PRGE
+gene	I-PRGE
+and	O
+with	O
+or	O
+without	O
+the	O
+gE	B-PRGE
+gene	I-PRGE
+).	O
+
+The	O
+prevalence	O
+of	O
+CPV	B-SPEC
+was	O
+58	O
+per	O
+cent	O
+(	O
+95	O
+per	O
+cent	O
+confidence	O
+interval	O
+[	O
+CI	O
+]	O
+52	O
+to	O
+63	O
+per	O
+cent	O
+),	O
+with	O
+some	O
+evidence	O
+for	O
+regional	O
+variation	O
+.	O
+
+Large	O
+herd	O
+size	O
+,	O
+being	O
+located	O
+in	O
+southern	O
+Sweden	O
+,	O
+and	O
+not	O
+providing	O
+boots	O
+for	O
+visitors	O
+were	O
+found	O
+to	O
+be	O
+associated	O
+with	O
+being	O
+antibody	B-COMP
+-	O
+positive	O
+to	O
+BCV	B-SPEC
+and	O
+BRSV	B-SPEC
+.	O
+
+This	O
+indicates	O
+that	O
+local	O
+factors	O
+such	O
+as	O
+daily	O
+visiting	O
+milk	O
+trucks	O
+and	O
+wild	O
+animals	B-SPEC
+were	O
+unlikely	O
+to	O
+be	O
+important	O
+sources	O
+of	O
+infection	B-DISO
+in	O
+this	O
+area	O
+.	O
+
+ARDS	B-DISO
+-	O
+like	O
+syndrome	B-DISO
+was	O
+produced	O
+by	O
+lung	B-ANAT
+lavage	O
+in	O
+eight	O
+pigs	B-SPEC
+(	O
+ARDS	B-DISO
+group	O
+).	O
+
+RESULTS	O
+:	O
+After	O
+bleeding	B-DISO
+,	O
+in	O
+the	O
+control	O
+group	O
+ventilated	O
+with	O
+a	O
+VT	O
+of	O
+10	O
+ml	O
+/	O
+kg	O
+,	O
+DeltaPP	O
+increased	O
+from	O
+8	O
+.	O
+5	O
+(	O
+95	O
+%	O
+confidence	O
+interval	O
+[	O
+CI	O
+],	O
+7	O
+.	O
+1	O
+to	O
+9	O
+.	O
+9	O
+%)	O
+to	O
+18	O
+.	O
+5	O
+%	O
+(	O
+CI	O
+,	O
+15	O
+.	O
+3	O
+to	O
+21	O
+.	O
+7	O
+%;	O
+P	O
+<	O
+0	O
+.	O
+05	O
+).	O
+
+Two	O
+of	O
+6	O
+cats	B-SPEC
+with	O
+FIP	B-DISO
+had	O
+increased	O
+macro	O
+-	O
+CK1	B-PRGE
+and	O
+increased	O
+CK	B-FUNC
+-	I-FUNC
+BB	I-FUNC
+activity	O
+.	O
+
+TITLE	O
+:	O
+Molecular	O
+mapping	O
+of	O
+the	O
+RNA	B-PRGE
+Cap	I-PRGE
+2	I-PRGE
+'-	I-PRGE
+O	I-PRGE
+-	I-PRGE
+methyltransferase	I-PRGE
+activation	O
+interface	O
+between	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+coronavirus	B-SPEC
+nsp10	O
+and	O
+nsp16	O
+.	O
+
+Alanine	B-CHED
+-	O
+scanning	O
+mutagenesis	B-PROC
+,	O
+bioinformatics	O
+,	O
+and	O
+molecular	O
+modeling	O
+were	O
+used	O
+to	O
+identify	O
+several	O
+""""	O
+hot	B-DISO
+spots	I-DISO
+","""	O
+such	O
+as	O
+Val	B-CHED
+(	O
+42	O
+),	O
+Met	B-CHED
+(	O
+44	O
+),	O
+Ala	B-CHED
+(	O
+71	O
+),	O
+Lys	B-CHED
+(	O
+93	O
+),	O
+Gly	B-CHED
+(	O
+94	O
+),	O
+and	O
+Tyr	B-CHED
+(	O
+96	O
+),	O
+forming	O
+a	O
+continuous	O
+protein	B-CHED
+-	O
+protein	B-CHED
+surface	O
+of	O
+about	O
+830	O
+Å	O
+(	O
+2	O
+),	O
+bearing	O
+very	O
+conserved	O
+amino	B-CHED
+acids	I-CHED
+among	O
+coronaviruses	O
+.	O
+
+Thus	O
+,	O
+the	O
+nsp10	O
+-	O
+nsp16	O
+interface	O
+may	O
+represent	O
+an	O
+attractive	O
+target	O
+for	O
+antivirals	B-CHED
+against	O
+human	B-SPEC
+and	O
+animal	B-SPEC
+pathogenic	O
+coronaviruses	O
+.	O
+
+Despite	O
+a	O
+deletion	O
+of	O
+the	O
+type	B-PRGE
+I	I-PRGE
+interferon	I-PRGE
+receptor	I-PRGE
+,	O
+strong	O
+expression	B-PROC
+of	O
+interferon	B-PRGE
+-	O
+stimulated	O
+genes	O
+was	O
+observed	O
+in	O
+the	O
+lungs	B-ANAT
+of	O
+IFNAR1	B-PRGE
+-/-	O
+mice	B-SPEC
+,	O
+contributing	O
+to	O
+clearance	O
+of	O
+the	O
+virus	O
+.	O
+
+Among	O
+10	O
+bats	B-SPEC
+with	O
+complete	O
+RNA	B-PRGE
+-	I-PRGE
+dependent	I-PRGE
+RNA	I-PRGE
+polymerase	I-PRGE
+(	O
+RdRp	B-FUNC
+),	O
+spike	O
+(	O
+S	O
+),	O
+and	O
+nucleocapsid	B-COMP
+(	O
+N	O
+)	O
+genes	O
+sequenced	O
+,	O
+three	O
+and	O
+two	O
+sequence	O
+clades	O
+for	O
+all	O
+three	O
+genes	O
+were	O
+codetected	O
+in	O
+two	O
+and	O
+five	O
+bats	B-SPEC
+,	O
+respectively	O
+,	O
+suggesting	O
+the	O
+coexistence	O
+of	O
+two	O
+or	O
+three	O
+distinct	O
+genotypes	O
+of	O
+Ro	O
+-	O
+BatCoV	O
+HKU9	O
+in	O
+the	O
+same	O
+bat	B-ENZY
+.	O
+
+ABSTRACT	O
+:	O
+We	O
+report	O
+a	O
+case	O
+of	O
+H1N1	O
+2009	O
+influenza	B-PATH
+A	I-PATH
+,	O
+in	O
+a	O
+previously	O
+fit	B-DISO
+woman	O
+at	O
+24	O
+weeks	O
+of	O
+gestation	B-PROC
+,	O
+who	O
+presented	O
+atypically	O
+with	O
+abdominal	B-DISO
+pain	I-DISO
+.	O
+
+ABSTRACT	O
+:	O
+ORF8a	O
+protein	O
+is	O
+39	O
+residues	O
+long	O
+and	O
+contains	O
+a	O
+single	O
+transmembrane	B-COMP
+domain	O
+.	O
+
+A	O
+plaque	B-DISO
+assay	O
+was	O
+used	O
+to	O
+evaluate	O
+the	O
+effects	O
+of	O
+19	O
+extracts	O
+,	O
+and	O
+the	O
+concentration	O
+of	O
+extract	O
+required	O
+to	O
+inhibit	O
+50	O
+%	O
+of	O
+the	O
+replication	O
+(	O
+EC	O
+(	O
+50	O
+))	O
+of	O
+mouse	B-DISO
+hepatitis	I-DISO
+virus	B-SPEC
+(	O
+MHV	B-SPEC
+)	O
+A59	O
+strain	O
+(	O
+MHV	B-SPEC
+-	O
+A59	O
+)	O
+was	O
+determined	O
+.	O
+
+Little	O
+information	O
+is	O
+available	O
+on	O
+the	O
+management	O
+of	O
+patients	O
+with	O
+Panton	O
+-	O
+Valentine	O
+leukocidin	O
+expressing	O
+S	B-SPEC
+.	I-SPEC
+aureus	I-SPEC
+pneumonia	B-DISO
+with	O
+extracorporeal	O
+membrane	B-COMP
+oxygenation	B-PROC
+support	O
+.	O
+
+As	O
+a	O
+large	O
+extracorporeal	O
+membrane	B-COMP
+oxygenation	B-PROC
+center	O
+,	O
+we	O
+reviewed	O
+our	O
+experience	O
+and	O
+outcomes	O
+with	O
+Panton	O
+-	O
+Valentine	O
+Leukocidin	O
+expressing	O
+S	B-SPEC
+.	I-SPEC
+aureus	I-SPEC
+pneumonia	B-DISO
+.	O
+
+Locally	O
+held	O
+register	O
+of	O
+all	O
+extracorporeal	O
+membrane	B-COMP
+oxygenation	B-PROC
+patients	O
+at	O
+Glenfield	O
+Hospital	O
+.	O
+
+After	O
+varying	O
+periods	B-PROC
+on	O
+extracorporeal	O
+membrane	B-COMP
+oxygenation	B-PROC
+with	O
+appropriate	O
+antibiotic	B-CHED
+and	O
+ancillary	O
+care	O
+,	O
+all	O
+four	O
+patients	O
+were	O
+discharged	O
+home	O
+.	O
+
+The	O
+virus	B-SPEC
+titer	O
+of	O
+25V16G	O
+in	O
+the	O
+liver	B-ANAT
+was	O
+50	O
+-	O
+and	O
+250	O
+-	O
+fold	O
+higher	O
+than	O
+that	O
+of	O
+JHMV	O
+at	O
+5	O
+and	O
+7	O
+d	O
+post	O
+-	O
+infection	B-DISO
+,	O
+respectively	O
+.	O
+
+One	O
+explanation	O
+for	O
+the	O
+greater	O
+pathogenicity	O
+of	O
+25V16G	O
+is	O
+that	O
+25V16G	O
+escapes	O
+CTL	B-ANAT
+-	O
+mediated	O
+protection	O
+in	O
+B6	O
+-	O
+GKO	O
+mice	B-SPEC
+.	O
+
+This	O
+experimental	O
+model	O
+may	O
+be	O
+used	O
+to	O
+assess	O
+the	O
+role	O
+of	O
+IFN	B-PRGE
+-	I-PRGE
+gamma	I-PRGE
+in	O
+viral	O
+persistence	O
+in	O
+vivo	O
+.	O
+
+Significantly	O
+better	O
+oxygenation	B-PROC
+with	O
+higher	O
+PaO	B-PROC
+(	O
+2	O
+)	O
+and	O
+alveolar	B-ANAT
+-	O
+arterial	B-ANAT
+oxygen	B-CHED
+difference	O
+was	O
+noted	O
+in	O
+the	O
+Surf	O
+and	O
+Bude	O
++	O
+Surf	O
+groups	O
+,	O
+compared	O
+with	O
+the	O
+control	O
+group	O
+(	O
+p	O
+<	O
+0	O
+.	O
+05	O
+),	O
+but	O
+there	O
+were	O
+no	O
+significant	O
+differences	O
+between	O
+the	O
+Surf	O
+and	O
+Bude	O
++	O
+Surf	O
+groups	O
+.	O
+
+TITLE	O
+:	O
+Microbiological	O
+and	O
+pathological	O
+examination	O
+of	O
+fatal	O
+calf	B-ANAT
+pneumonia	B-DISO
+cases	O
+induced	O
+by	O
+bacterial	O
+and	O
+viral	O
+respiratory	O
+pathogens	O
+.	O
+
+ABSTRACT	O
+:	O
+The	O
+infectious	O
+origin	O
+of	O
+fatal	O
+cases	O
+of	O
+calf	B-ANAT
+pneumonia	B-DISO
+was	O
+studied	O
+in	O
+48	O
+calves	O
+from	O
+27	O
+different	O
+herds	O
+on	O
+postmortem	O
+examination	O
+.	O
+
+The	O
+presence	O
+of	O
+multiple	O
+respiratory	O
+pathogens	O
+in	O
+23	O
+/	O
+40	O
+(	O
+57	O
+.	O
+5	O
+%)	O
+cases	O
+indicated	O
+the	O
+complex	O
+origin	O
+of	O
+fatal	O
+calf	B-ANAT
+pneumonia	B-DISO
+.	O
+
+ABSTRACT	O
+:	O
+In	O
+patients	O
+with	O
+severe	O
+acute	O
+pancreatitis	O
+and	O
+abdominal	B-DISO
+compartment	I-DISO
+syndrome	I-DISO
+,	O
+establishment	O
+of	O
+the	O
+indications	O
+and	O
+optimal	O
+time	O
+for	O
+surgical	O
+decompression	O
+may	O
+avoid	O
+exacerbation	O
+of	O
+multiple	O
+-	O
+organ	B-DISO
+dysfunction	I-DISO
+syndrome	I-DISO
+.	O
+
+Surgical	O
+decompression	O
+of	O
+the	O
+abdomen	B-ANAT
+.	O
+
+Diarrhoea	B-DISO
+was	O
+more	O
+common	O
+in	O
+case	O
+herd	O
+calves	O
+.	O
+
+The	O
+immunoreactivity	B-PROC
+of	O
+the	O
+MAb	O
+to	O
+TGEV	B-PRGE
+S	I-PRGE
+protein	B-CHED
+was	O
+confirmed	O
+by	O
+Western	O
+blot	O
+analysis	O
+.	O
+
+TITLE	O
+:	O
+A	O
+conserved	O
+domain	O
+in	O
+the	O
+coronavirus	B-SPEC
+membrane	B-COMP
+protein	B-CHED
+tail	O
+is	O
+important	O
+for	O
+virus	B-PROC
+assembly	I-PROC
+.	O
+
+E121Q	O
+and	O
+E121L	O
+M	O
+proteins	B-CHED
+were	O
+capable	O
+of	O
+forming	O
+virus	B-ANAT
+-	I-ANAT
+like	I-ANAT
+particles	I-ANAT
+(	O
+VLPs	B-ANAT
+)	O
+when	O
+coexpressed	O
+with	O
+E	O
+,	O
+whereas	O
+E121R	B-PRGE
+and	I-PRGE
+E121K	I-PRGE
+proteins	I-PRGE
+were	O
+not	O
+.	O
+
+HCoV	O
+-	O
+HKU1	O
+,	O
+a	O
+human	B-SPEC
+coronavirus	I-SPEC
+identified	O
+in	O
+a	O
+clinical	O
+sample	O
+from	O
+a	O
+patient	O
+with	O
+severe	O
+pneumonia	B-DISO
+,	O
+has	O
+been	O
+a	O
+major	O
+challenge	O
+for	O
+successful	O
+propagation	O
+on	O
+all	O
+immortalized	O
+cells	B-COMP
+tested	O
+to	O
+date	O
+.	O
+
+Nasopharyngeal	B-ANAT
+aspirates	B-ANAT
+were	O
+prospectively	O
+collected	O
+from	O
+182	O
+children	O
+hospitalized	O
+with	O
+croup	B-DISO
+at	O
+Seoul	O
+National	O
+University	O
+Bundang	O
+Hospital	O
+from	O
+January	O
+2005	O
+to	O
+June	O
+2009	O
+.	O
+
+Agreement	O
+with	O
+reference	O
+tests	O
+was	O
+optimal	O
+for	O
+BCoV	O
+(	O
+kappa	O
+=	O
+0	O
+.	O
+833	O
+)	O
+and	O
+substantial	O
+for	O
+rotavirus	B-SPEC
+detection	O
+(	O
+kappa	O
+=	O
+0	O
+.	O
+648	O
+).	O
+
+the	O
+internal	O
+control	O
+,	O
+ND5	B-PRGE
+mRNA	I-PRGE
+,	O
+was	O
+detected	O
+successfully	O
+in	O
+all	O
+reactions	O
+.	O
+
+TITLE	O
+:	O
+Synthesis	B-PROC
+,	O
+antiviral	B-CHED
+activity	O
+and	O
+cytotoxicity	B-DISO
+evaluation	O
+of	O
+Schiff	B-CHED
+bases	I-CHED
+of	O
+some	O
+2	O
+-	O
+phenyl	B-CHED
+quinazoline	B-CHED
+-	O
+4	O
+(	O
+3	O
+)	O
+H	O
+-	O
+ones	O
+.	O
+
+Cytotoxicity	B-DISO
+and	O
+antiviral	B-CHED
+activity	O
+were	O
+evaluated	O
+against	O
+herpes	B-SPEC
+simplex	I-SPEC
+virus	I-SPEC
+-	O
+1	O
+(	O
+KOS	O
+),	O
+herpes	B-SPEC
+simplex	I-SPEC
+virus	I-SPEC
+-	O
+2	O
+(	O
+G	O
+),	O
+vaccinia	B-SPEC
+virus	I-SPEC
+,	O
+vesicular	B-SPEC
+stomatitis	I-SPEC
+virus	I-SPEC
+,	O
+herpes	B-SPEC
+simplex	I-SPEC
+virus	I-SPEC
+-	O
+1	O
+TK	B-PRGE
+-	I-PRGE
+KOS	I-PRGE
+ACVr	I-PRGE
+,	O
+para	B-PRGE
+influenza	I-PRGE
+-	I-PRGE
+3	I-PRGE
+virus	B-SPEC
+,	I-PRGE
+reovirus	B-SPEC
+-	I-PRGE
+1	I-PRGE
+,	I-PRGE
+Sindbis	B-SPEC
+virus	I-SPEC
+,	I-PRGE
+Coxsackie	B-DISO
+virus	I-DISO
+B4	I-PRGE
+,	O
+Punta	B-SPEC
+Toro	I-SPEC
+virus	I-SPEC
+,	O
+feline	B-SPEC
+corona	B-CHED
+virus	B-SPEC
+(	O
+FIPV	O
+),	O
+feline	B-SPEC
+herpes	B-SPEC
+virus	I-SPEC
+,	O
+respiratory	B-SPEC
+syncytial	I-SPEC
+virus	I-SPEC
+,	O
+influenza	B-PATH
+A	I-PATH
+H1N1	O
+subtype	O
+,	O
+influenza	B-PATH
+A	I-PATH
+H3N2	B-CHED
+subtype	O
+,	O
+and	O
+influenza	B-SPEC
+B	I-SPEC
+virus	I-SPEC
+.	O
+
+TITLE	O
+:	O
+Impact	O
+of	O
+porcine	B-SPEC
+epidemic	I-SPEC
+diarrhea	I-SPEC
+virus	B-DISO
+infection	I-DISO
+at	O
+different	O
+periods	B-PROC
+of	O
+pregnancy	O
+on	O
+subsequent	O
+reproductive	O
+performance	O
+in	O
+gilts	O
+and	O
+sows	O
+.	O
+
+It	O
+was	O
+found	O
+that	O
+the	O
+impact	O
+of	O
+PEDV	B-SPEC
+infection	B-DISO
+on	O
+the	O
+reproductive	B-PROC
+performance	O
+of	O
+gilts	O
+and	O
+sows	O
+depended	O
+on	O
+the	O
+period	O
+of	O
+pregnancy	O
+when	O
+the	O
+females	O
+were	O
+exposed	O
+to	O
+the	O
+pathogen	O
+,	O
+and	O
+parity	O
+number	O
+.	O
+
+PEDV	B-SPEC
+infection	B-DISO
+during	O
+the	O
+first	O
+30	O
+days	O
+of	O
+pregnancy	O
+resulted	O
+in	O
+a	O
+decrease	O
+of	O
+TB	O
+by	O
+1	O
+.	O
+4	O
+(	O
+11	O
+.	O
+7	O
+vs	O
+.	O
+10	O
+.	O
+3	O
+piglets	O
+/	O
+litter	O
+,	O
+P	O
+<	O
+0	O
+.	O
+001	O
+)	O
+and	O
+a	O
+decrease	O
+of	O
+BA	O
+by	O
+2	O
+.	O
+2	O
+(	O
+10	O
+.	O
+7	O
+vs	O
+.	O
+8	O
+.	O
+5	O
+piglets	O
+/	O
+litter	O
+,	O
+P	O
+<	O
+0	O
+.	O
+001	O
+)	O
+in	O
+the	O
+gilts	O
+'	O
+litters	O
+,	O
+while	O
+the	O
+influence	O
+of	O
+PEDV	B-SPEC
+infection	B-DISO
+on	O
+TB	O
+and	O
+BA	O
+was	O
+not	O
+significant	O
+in	O
+sows	O
+(	O
+P	O
+>	O
+0	O
+.	O
+05	O
+).	O
+
+TITLE	O
+:	O
+Atrial	B-ANAT
+natriuretic	O
+peptide	B-CHED
+attenuates	O
+LPS	B-DISO
+-	O
+induced	O
+lung	B-ANAT
+vascular	B-ANAT
+leak	O
+:	O
+role	O
+of	O
+PAK1	B-PRGE
+.	O
+
+The	O
+current	O
+study	O
+examined	O
+involvement	O
+of	O
+the	O
+Rac	B-PRGE
+effector	I-PRGE
+p21	I-PRGE
+-	I-PRGE
+activated	I-PRGE
+kinase	I-PRGE
+(	O
+PAK1	B-PRGE
+)	O
+in	O
+ANP	B-PRGE
+-	O
+protective	O
+effects	O
+in	O
+the	O
+model	O
+of	O
+lung	B-ANAT
+vascular	B-PROC
+permeability	I-PROC
+induced	O
+by	O
+bacterial	O
+wall	O
+LPS	B-DISO
+.	O
+
+C57BL	O
+/	O
+6J	O
+mice	B-SPEC
+or	O
+ANP	O
+knockout	O
+mice	B-SPEC
+(	O
+Nppa	O
+(-/-))	O
+were	O
+treated	O
+with	O
+LPS	B-DISO
+(	O
+0	O
+.	O
+63	O
+mg	O
+/	O
+kg	O
+intratracheal	O
+)	O
+with	O
+or	O
+without	O
+ANP	O
+(	O
+2	O
+μg	O
+/	O
+kg	O
+iv	O
+).	O
+
+Endothelial	B-ANAT
+barrier	O
+properties	O
+were	O
+assessed	O
+by	O
+morphological	O
+analysis	O
+and	O
+measurements	O
+of	O
+transendothelial	O
+electrical	O
+resistance	O
+.	O
+
+ANP	B-PRGE
+treatment	O
+stimulated	O
+Rac	B-PRGE
+-	O
+dependent	O
+PAK1	B-PRGE
+phosphorylation	B-PROC
+,	O
+attenuated	O
+endothelial	B-ANAT
+permeability	O
+caused	O
+by	O
+LPS	B-DISO
+,	O
+TNF	B-PRGE
+-	I-PRGE
+α	I-PRGE
+,	O
+and	O
+IL	B-FUNC
+-	I-FUNC
+6	I-FUNC
+,	O
+decreased	O
+LPS	B-DISO
+-	O
+induced	O
+cell	B-COMP
+and	O
+protein	B-CHED
+accumulation	O
+in	O
+bronchoalveolar	B-ANAT
+lavage	I-ANAT
+fluid	I-ANAT
+,	O
+and	O
+suppressed	O
+Evans	O
+blue	O
+extravasation	B-DISO
+in	O
+the	O
+murine	B-SPEC
+model	O
+of	O
+acute	O
+lung	B-ANAT
+injury	O
+.	O
+
+ABSTRACT	O
+:	O
+A	O
+sensitive	O
+reverse	O
+-	O
+transcription	B-PROC
+loop	O
+-	O
+mediated	O
+isothermal	O
+amplification	B-DISO
+(	O
+RT	O
+-	O
+LAMP	O
+)	O
+assay	O
+was	O
+developed	O
+for	O
+the	O
+rapid	O
+visual	O
+detection	O
+of	O
+turkey	B-SPEC
+coronavirus	B-SPEC
+(	O
+TCoV	O
+)	O
+infection	B-DISO
+.	O
+
+The	O
+role	O
+of	O
+antivirals	B-CHED
+in	O
+the	O
+management	O
+of	O
+severe	O
+EBV	B-DISO
+infections	I-DISO
+is	O
+debatable	O
+.	O
+
+45	O
+patients	O
+with	O
+severe	O
+manifestations	O
+of	O
+infectious	B-DISO
+mononucleosis	I-DISO
+received	O
+antivirals	B-CHED
+(	O
+as	O
+an	O
+adjunct	O
+to	O
+steroids	B-CHED
+in	O
+26	O
+of	O
+them	O
+).	O
+
+However	O
+,	O
+physicians	O
+may	O
+consider	O
+using	O
+antiviral	B-CHED
+agents	I-CHED
+in	O
+severe	O
+manifestations	O
+of	O
+EBV	B-DISO
+infections	I-DISO
+in	O
+immunocompetent	O
+patients	O
+as	O
+an	O
+adjunct	O
+to	O
+steroid	B-CHED
+treatment	O
+.	O
+
+In	O
+addition	O
+,	O
+while	O
+neurons	B-ANAT
+are	O
+the	O
+predominant	O
+CNS	B-CHED
+cell	B-COMP
+type	I-COMP
+infected	O
+in	O
+vivo	O
+,	O
+the	O
+canonical	O
+receptor	O
+for	O
+MHV	B-SPEC
+,	O
+the	O
+carcinoembryonic	B-PRGE
+antigen	I-PRGE
+family	B-SPEC
+member	I-PRGE
+CEACAM1a	O
+,	O
+has	O
+been	O
+demonstrated	O
+only	O
+on	O
+endothelial	B-ANAT
+cells	I-ANAT
+and	O
+microglia	B-ANAT
+.	O
+
+In	O
+order	B-SPEC
+to	O
+investigate	O
+whether	O
+CEACAM1a	O
+is	O
+also	O
+expressed	B-PROC
+in	O
+other	O
+cell	B-COMP
+types	O
+,	O
+ceacam1a	B-PRGE
+mRNA	I-PRGE
+expression	B-PROC
+was	O
+quantified	O
+in	O
+murine	B-SPEC
+tissues	B-ANAT
+and	O
+primary	O
+cells	B-COMP
+.	O
+
+Infection	O
+with	O
+FCoV	O
+can	O
+result	O
+in	O
+a	O
+diverse	O
+range	O
+of	O
+signs	O
+from	O
+clinically	O
+inapparent	O
+infections	B-DISO
+to	O
+a	O
+highly	O
+fatal	O
+disease	O
+called	O
+feline	B-DISO
+infectious	I-DISO
+peritonitis	I-DISO
+(	O
+FIP	B-DISO
+).	O
+
+At	O
+present	O
+,	O
+a	O
+definitive	O
+diagnosis	O
+of	O
+FIP	B-DISO
+can	O
+be	O
+established	O
+only	O
+by	O
+histopathological	O
+examination	O
+of	O
+biopsies	O
+.	O
+
+ABSTRACT	O
+:	O
+A	O
+conserved	O
+nucleic	B-CHED
+acid	I-CHED
+fragment	O
+of	O
+the	O
+nucleocapsid	B-COMP
+gene	O
+of	O
+Swine	B-DISO
+Transmissible	I-DISO
+Gastroenteritis	I-DISO
+Coronavirus	B-SPEC
+(	O
+TGEV	B-SPEC
+)	O
+was	O
+chosen	O
+as	O
+the	O
+target	O
+,	O
+six	O
+special	O
+primers	O
+were	O
+designed	O
+successfully	O
+.	O
+
+TITLE	O
+:	O
+SARS	B-DISO
+-	O
+coronavirus	B-SPEC
+protein	B-CHED
+6	O
+conformations	O
+required	O
+to	O
+impede	O
+protein	B-PROC
+import	I-PROC
+into	O
+the	O
+nucleus	B-COMP
+.	O
+
+Protein	B-CHED
+6	O
+is	O
+minimally	O
+bifunctional	O
+,	O
+with	O
+an	O
+N	O
+-	O
+terminal	O
+lipophilic	O
+part	O
+implicated	O
+in	O
+accelerating	O
+viral	O
+growth	B-PROC
+and	O
+a	O
+C	O
+-	O
+terminal	O
+hydrophilic	O
+part	O
+interfering	O
+with	O
+general	O
+protein	B-PROC
+import	I-PROC
+into	O
+the	O
+nucleus	B-COMP
+.	O
+
+ABSTRACT	O
+:	O
+The	O
+authors	O
+describe	O
+here	O
+the	O
+use	O
+of	O
+foam	O
+sclerotherapy	O
+under	O
+C	O
+-	O
+arm	O
+computed	O
+tomography	O
+(	O
+CT	O
+)	O
+guidance	O
+for	O
+the	O
+treatment	O
+of	O
+gastric	B-DISO
+varices	I-DISO
+via	O
+balloon	O
+-	O
+occluded	B-DISO
+retrograde	O
+transvenous	O
+obliteration	O
+in	O
+seven	O
+patients	O
+and	O
+percutaneous	O
+transhepatic	O
+obliteration	O
+in	O
+one	O
+patient	O
+.	O
+
+All	O
+gastric	B-DISO
+varices	I-DISO
+were	O
+occluded	B-DISO
+successfully	O
+after	O
+replacement	O
+of	O
+blood	B-ANAT
+by	O
+foam	O
+,	O
+which	O
+was	O
+trapped	O
+in	O
+the	O
+gastric	B-DISO
+varices	I-DISO
+as	O
+shown	O
+by	O
+C	O
+-	O
+arm	B-ANAT
+CT	O
+.	O
+
+It	O
+also	O
+helped	O
+reduce	O
+the	O
+amount	O
+of	O
+sclerosant	O
+,	O
+an	O
+issue	O
+that	O
+is	O
+associated	O
+with	O
+severe	O
+complications	O
+,	O
+such	O
+as	O
+hemolysis	B-DISO
+,	O
+allergy	B-DISO
+,	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+,	O
+and	O
+others	O
+.	O
+
+Patients	O
+with	O
+severe	O
+Clostridium	B-DISO
+difficile	I-DISO
+infection	I-DISO
+(	O
+CDI	B-DISO
+)	O
+are	O
+at	O
+increased	O
+risk	O
+for	O
+IAH	B-FUNC
+and	O
+ACS	B-FUNC
+.	O
+
+The	O
+patient	O
+was	O
+not	O
+considered	O
+a	O
+surgical	O
+candidate	O
+,	O
+was	O
+refractory	O
+to	O
+escalating	O
+non	O
+-	O
+surgical	O
+support	O
+,	O
+and	O
+died	B-PROC
+following	O
+withdrawal	B-DISO
+of	O
+life	O
+support	O
+.	O
+
+There	O
+are	O
+few	O
+data	O
+about	O
+the	O
+epidemiology	O
+of	O
+H1N1	B-DISO
+influenza	I-DISO
+among	O
+HCWs	O
+.	O
+
+During	O
+6	O
+months	O
+of	O
+surveillance	O
+,	O
+526	O
+HCWs	O
+were	O
+confirmed	O
+positive	O
+for	O
+H1N1	B-DISO
+influenza	I-DISO
+.	O
+
+Among	O
+all	O
+PCR	O
+-	O
+confirmed	O
+cases	O
+,	O
+the	O
+attack	O
+rate	O
+was	O
+significantly	O
+higher	O
+in	O
+clinical	O
+HCWs	O
+than	O
+in	O
+nonclinical	O
+HCWs	O
+(	O
+6	O
+.	O
+0	O
+%	O
+vs	O
+4	O
+.	O
+3	O
+%;	O
+P	O
+<	O
+.	O
+001	O
+)	O
+and	O
+in	O
+HCWs	O
+in	O
+emergency	B-DISO
+departments	O
+than	O
+in	O
+HCWs	O
+in	O
+other	O
+hospital	O
+locations	O
+(	O
+17	O
+.	O
+4	O
+%	O
+vs	O
+5	O
+.	O
+0	O
+%,	O
+P	O
+<	O
+.	O
+001	O
+).	O
+
+These	O
+results	O
+indicate	O
+that	O
+GHRP	B-PRGE
+-	I-PRGE
+2	I-PRGE
+attenuated	O
+LPS	B-DISO
+-	O
+induced	O
+ALI	O
+.	O
+
+ABSTRACT	O
+:	O
+Acute	O
+lung	O
+injury	O
+(	O
+ALI	O
+)	O
+and	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+(	O
+ARDS	B-DISO
+)	O
+represent	O
+a	O
+spectrum	O
+of	O
+acute	B-DISO
+respiratory	I-DISO
+failure	I-DISO
+with	O
+diffuse	O
+,	O
+bilateral	O
+lung	B-ANAT
+injury	O
+and	O
+severe	O
+hypoxemia	O
+caused	O
+by	O
+non	B-DISO
+-	I-DISO
+cardiogenic	I-DISO
+pulmonary	I-DISO
+edema	I-DISO
+.	O
+
+Status	O
+dystonicus	O
+describes	O
+the	O
+episodes	O
+of	O
+acute	O
+and	O
+life	O
+-	O
+threatening	O
+generalized	O
+dystonia	O
+,	O
+which	O
+occasionally	O
+manifest	O
+themselves	O
+in	O
+patients	O
+with	O
+dystonic	O
+syndromes	B-DISO
+.	O
+
+The	O
+similarity	O
+between	O
+the	O
+clinical	O
+features	O
+of	O
+the	O
+case	O
+we	O
+present	O
+and	O
+those	O
+reported	O
+in	O
+connection	O
+to	O
+abrupt	O
+withdrawal	B-DISO
+of	O
+intrathecal	B-ANAT
+baclofen	B-CHED
+is	O
+emphasized	O
+.	O
+
+The	O
+clinical	O
+similarities	O
+between	O
+the	O
+intrathecal	B-ANAT
+baclofen	B-CHED
+withdrawal	B-DISO
+syndrome	I-DISO
+and	O
+status	O
+dystonicus	O
+have	O
+not	O
+previously	O
+been	O
+highlighted	O
+.	O
+
+These	O
+results	O
+confirm	O
+that	O
+the	O
+IRES	O
+-	O
+driven	O
+dhfr	B-PRGE
+promoter	I-PRGE
+generates	O
+greater	O
+gene	B-DISO
+amplification	I-DISO
+,	O
+which	O
+in	O
+turn	O
+enhances	O
+S	O
+(	O
+TR2	O
+)	O
+expression	B-PROC
+.	O
+
+The	O
+S	O
+(	O
+TR2	O
+)	O
+glycoform	O
+did	O
+not	O
+change	O
+between	O
+suspension	O
+and	O
+serum	B-COMP
+-	O
+free	O
+cultures	O
+,	O
+suggesting	O
+that	O
+the	O
+stable	O
+and	O
+amplified	O
+cell	B-ANAT
+clones	I-ANAT
+analyzed	O
+in	O
+this	O
+study	O
+have	O
+potential	O
+for	O
+producing	O
+homologous	O
+S	O
+(	O
+TR2	B-PRGE
+)	O
+on	O
+a	O
+large	O
+scale	O
+.	O
+
+Questionnaire	O
+results	O
+were	O
+reviewed	O
+in	O
+workshops	O
+,	O
+analysing	O
+how	O
+differences	O
+between	O
+national	O
+laws	O
+might	O
+support	O
+or	O
+hinder	O
+regional	O
+responses	O
+to	O
+pandemic	O
+influenza	B-DISO
+.	O
+
+Respondents	O
+examined	O
+the	O
+impact	O
+of	O
+national	O
+laws	O
+on	O
+the	O
+movements	B-PROC
+of	O
+information	O
+,	O
+goods	O
+,	O
+services	O
+and	O
+people	O
+across	O
+borders	O
+in	O
+a	O
+time	O
+of	O
+pandemic	O
+,	O
+the	O
+capacity	O
+for	O
+surveillance	O
+,	O
+case	O
+detection	O
+,	O
+case	O
+management	O
+and	O
+community	O
+control	O
+,	O
+the	O
+deployment	O
+of	O
+strategies	O
+of	O
+prevention	O
+,	O
+containment	O
+,	O
+mitigation	O
+and	O
+recovery	O
+and	O
+the	O
+identification	O
+of	O
+commonalities	O
+and	O
+disconnects	O
+across	O
+states	O
+.	O
+
+Some	O
+states	O
+propose	O
+use	O
+of	O
+emergency	B-DISO
+powers	O
+that	O
+might	O
+potentially	O
+override	O
+human	B-SPEC
+rights	O
+protections	O
+while	O
+other	O
+states	O
+propose	O
+to	O
+limit	O
+interventions	O
+to	O
+those	O
+authorized	O
+by	O
+public	O
+health	O
+laws	O
+.	O
+
+TITLE	O
+:	O
+Management	O
+of	O
+acute	O
+lung	B-ANAT
+injury	O
+/	O
+ARDS	B-DISO
+.	O
+
+Management	O
+includes	O
+ventilatory	O
+therapy	O
+including	O
+lower	O
+tidal	O
+volume	O
+,	O
+relatively	O
+high	O
+PEEP	B-CHED
+and	O
+supportive	O
+care	O
+.	O
+
+Without	O
+a	O
+major	O
+change	O
+in	O
+bed	O
+occupancy	O
+rate	O
+,	O
+nursing	B-PROC
+workforce	O
+,	O
+or	O
+the	O
+protocol	O
+of	O
+environmental	O
+cleansing	O
+throughout	O
+the	O
+study	O
+period	O
+,	O
+a	O
+stepwise	O
+reduction	O
+in	O
+ICU	O
+onset	O
+nonbacteraemic	O
+MRSA	B-DISO
+infection	I-DISO
+was	O
+observed	O
+:	O
+from	O
+3	O
+.	O
+54	O
+(	O
+phase	O
+1	O
+)	O
+to	O
+2	O
+.	O
+26	O
+(	O
+phase	O
+2	O
+,	O
+p	O
+=	O
+0	O
+.	O
+042	O
+)	O
+and	O
+1	O
+.	O
+02	O
+(	O
+phase	O
+3	O
+,	O
+p	O
+=	O
+0	O
+.	O
+006	O
+)	O
+per	O
+1000	O
+-	O
+patient	O
+-	O
+days	O
+.	O
+
+Infection	B-DISO
+due	O
+to	O
+ESBL	O
+-	O
+producing	O
+organisms	O
+did	O
+not	O
+show	O
+a	O
+corresponding	O
+reduction	O
+.	O
+
+However	O
+a	O
+significant	O
+trend	O
+improvement	O
+of	O
+ICU	O
+onset	O
+MRSA	B-DISO
+infection	I-DISO
+by	O
+segmented	O
+regression	O
+analysis	O
+can	O
+only	O
+be	O
+demonstrated	O
+when	O
+comparison	O
+was	O
+made	O
+before	O
+and	O
+after	O
+the	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+(	O
+SARS	B-DISO
+)	O
+epidemic	O
+.	O
+
+However	O
+compliance	O
+with	O
+infection	B-DISO
+control	O
+measures	O
+relies	O
+largely	O
+on	O
+a	O
+personal	O
+commitment	O
+,	O
+which	O
+may	O
+increase	O
+when	O
+personal	O
+safety	O
+is	O
+threatened	O
+.	O
+
+Using	O
+known	O
+kinetic	O
+rate	O
+constants	O
+,	O
+the	O
+individual	O
+contributions	O
+of	O
+different	O
+steps	O
+of	O
+the	O
+translation	B-PROC
+elongation	I-PROC
+cycle	O
+to	O
+-	O
+1	O
+PRF	O
+and	O
+the	O
+ratio	O
+between	O
+two	O
+types	O
+of	O
+frameshift	B-DISO
+products	O
+were	O
+evaluated	O
+.	O
+
+A	O
+more	O
+detailed	O
+understanding	O
+of	O
+the	O
+mechanisms	O
+underlying	O
+-	O
+1	O
+PRF	O
+may	O
+provide	O
+insight	O
+into	O
+developing	O
+antiviral	B-CHED
+therapeutics	O
+.	O
+
+Both	O
+patients	O
+developed	O
+acute	B-DISO
+renal	I-DISO
+failure	I-DISO
+,	O
+necessitating	O
+CVVHDF	O
+.	O
+
+We	O
+determined	O
+peak	O
+and	O
+trough	O
+serum	B-COMP
+TMP	B-CHED
+and	O
+SMX	B-CHED
+concentrations	O
+and	O
+the	O
+extent	O
+of	O
+TMP	B-CHED
+/	O
+SMX	B-CHED
+CVVHDF	O
+clearance	O
+at	O
+steady	O
+-	O
+state	O
+while	O
+the	O
+patients	O
+were	O
+still	O
+anuric	O
+and	O
+oliguric	O
+.	O
+
+In	O
+both	O
+patients	O
+,	O
+CVVHDF	O
+clearance	O
+of	O
+TMP	B-CHED
+ranged	O
+from	O
+21	O
+.	O
+5	O
+to	O
+28	O
+.	O
+9	O
+mL	O
+/	O
+min	O
+,	O
+corresponding	O
+with	O
+normal	O
+renal	B-PROC
+clearance	I-PROC
+(	O
+20	O
+-	O
+80	O
+mL	O
+/	O
+min	O
+).	O
+
+Overall	O
+,	O
+endotracheal	O
+tube	O
+(	O
+ETT	O
+)	O
+ventilation	O
+was	O
+required	O
+in	O
+108	O
+(	O
+29	O
+%),	O
+nasal	B-ANAT
+CPAP	O
+in	O
+166	O
+(	O
+45	O
+%)	O
+and	O
+cot	O
+oxygen	B-CHED
+in	O
+95	O
+(	O
+26	O
+%)	O
+patients	O
+.	O
+
+TITLE	O
+:	O
+Enhanced	O
+cell	B-PROC
+fusion	I-PROC
+activity	O
+in	O
+porcine	B-SPEC
+epidemic	I-SPEC
+diarrhea	I-SPEC
+virus	I-SPEC
+adapted	O
+to	O
+suckling	O
+mice	B-SPEC
+.	O
+
+The	O
+spike	O
+(	O
+S	O
+)	O
+protein	B-CHED
+of	O
+MK	B-PRGE
+-	I-PRGE
+p10	I-PRGE
+had	O
+four	O
+amino	B-PROC
+acid	I-PROC
+substitutions	I-PROC
+relative	O
+to	O
+the	O
+original	O
+strain	O
+.	O
+
+In	O
+this	O
+study	O
+,	O
+the	O
+avian	B-SPEC
+nucleolar	B-ANAT
+proteome	O
+was	O
+defined	O
+in	O
+the	O
+absence	O
+and	O
+presence	O
+of	O
+virus	O
+,	O
+in	O
+this	O
+case	O
+the	O
+positive	O
+strand	O
+RNA	O
+virus	B-SPEC
+,	O
+avian	B-SPEC
+coronavirus	I-SPEC
+infectious	B-DISO
+bronchitis	B-DISO
+virus	B-SPEC
+.	O
+
+Data	O
+sets	O
+,	O
+potential	O
+protein	B-CHED
+changes	O
+and	O
+the	O
+functional	O
+consequences	O
+of	O
+virus	B-DISO
+infection	I-DISO
+were	O
+validated	O
+using	O
+independent	O
+assays	O
+.	O
+
+TITLE	O
+:	O
+Use	O
+of	O
+a	O
+multiplex	O
+PCR	O
+/	O
+RT	O
+-	O
+PCR	O
+approach	O
+to	O
+assess	O
+the	O
+viral	O
+causes	O
+of	O
+influenza	B-DISO
+-	O
+like	O
+illnesses	O
+in	O
+Cambodia	O
+during	O
+three	O
+consecutive	O
+dry	O
+seasons	O
+.	O
+
+Ninety	O
+apparently	O
+healthy	O
+individuals	O
+were	O
+included	O
+as	O
+controls	O
+and	O
+10	O
+%	O
+of	O
+these	O
+samples	O
+tested	O
+positive	O
+for	O
+one	O
+or	O
+more	O
+respiratory	O
+viruses	B-SPEC
+.	O
+
+Membrane	B-COMP
+(	O
+M	O
+)	O
+and	O
+envelope	B-PRGE
+(	I-PRGE
+E	I-PRGE
+)	I-PRGE
+proteins	B-CHED
+are	O
+major	O
+structural	O
+proteins	B-CHED
+of	O
+the	O
+SARS	B-DISO
+-	O
+CoV	O
+.	O
+The	O
+M	B-PRGE
+protein	I-PRGE
+has	O
+been	O
+determined	O
+as	O
+a	O
+protective	O
+antigen	B-CHED
+in	O
+humoral	O
+responses	O
+.	O
+
+Additionally	O
+,	O
+the	O
+transmembrane	B-COMP
+domain	O
+of	O
+the	O
+M	B-PRGE
+protein	I-PRGE
+may	O
+contain	O
+a	O
+T	B-ANAT
+cell	I-ANAT
+epitope	B-CHED
+cluster	O
+revealed	O
+by	O
+the	O
+immunogenic	O
+and	O
+structural	O
+analysis	O
+of	O
+a	O
+panel	O
+of	O
+truncated	O
+peptides	B-CHED
+overlapping	O
+with	O
+Mn2	O
+and	O
+Md3	O
+.	O
+
+Among	O
+patients	O
+who	O
+developed	O
+ALI	O
+/	O
+ARDS	B-DISO
+,	O
+there	O
+was	O
+no	O
+evidence	O
+to	O
+support	O
+a	O
+difference	O
+in	O
+partial	B-PROC
+pressure	I-PROC
+of	I-PROC
+oxygen	I-PROC
+in	O
+arterial	B-ANAT
+blood	I-ANAT
+to	O
+fraction	O
+of	O
+inspired	B-PROC
+oxygen	B-CHED
+(	O
+Pao	B-PROC
+(	O
+2	O
+)/	O
+Fio	O
+(	O
+2	O
+))	O
+(	O
+P	O
+=	O
+.	O
+33	O
+),	O
+lung	B-ANAT
+injury	O
+score	O
+(	O
+P	O
+=	O
+.	O
+67	O
+),	O
+or	O
+mortality	O
+(	O
+P	O
+=	O
+.	O
+78	O
+)	O
+by	O
+race	O
+.	O
+
+Collectively	O
+,	O
+these	O
+data	O
+indicate	O
+that	O
+the	O
+inability	O
+to	O
+control	O
+viral	B-PROC
+replication	I-PROC
+following	O
+SCI	O
+is	O
+not	O
+level	O
+dependent	O
+and	O
+that	O
+increased	O
+susceptibility	O
+to	O
+infection	B-DISO
+is	O
+due	O
+to	O
+suppression	B-DISO
+of	O
+both	O
+innate	O
+and	O
+adaptive	B-PROC
+immune	I-PROC
+responses	I-PROC
+.	O
+
+ABSTRACT	O
+:	O
+Antineutrophil	O
+cytoplasmic	O
+antibody	B-COMP
+-	O
+associated	O
+vasculitis	B-DISO
+is	O
+a	O
+life	O
+-	O
+threatening	O
+disorder	O
+for	O
+which	O
+medical	O
+therapy	O
+has	O
+greatly	O
+improved	O
+survival	O
+.	O
+
+The	O
+co	O
+-	O
+circulation	B-PROC
+of	O
+multiple	O
+IBV	B-SPEC
+types	O
+and	O
+the	O
+ongoing	O
+emergence	O
+of	O
+IBV	B-SPEC
+variants	O
+are	O
+the	O
+epidemiological	O
+challenges	O
+in	O
+China	O
+.	O
+
+ABSTRACT	O
+:	O
+Inhalation	B-PROC
+injury	O
+contributes	O
+to	O
+the	O
+morbidity	O
+and	O
+mortality	O
+of	O
+burn	O
+victims	O
+.	O
+
+The	O
+study	O
+consisted	O
+of	O
+six	O
+groups	O
+:	O
+a	O
+sham	O
+group	O
+(	O
+n	O
+=	O
+4	O
+,	O
+instrumented	O
+noninjured	O
+),	O
+a	O
+control	O
+group	O
+(	O
+n	O
+=	O
+6	O
+,	O
+injured	O
+and	O
+not	O
+treated	O
+),	O
+and	O
+tiotropium	O
+bromide	B-CHED
+-	O
+treated	O
+groups	O
+,	O
+including	O
+both	O
+preinjury	O
+and	O
+postinjury	O
+nebulization	O
+protocols	O
+.	O
+
+EMBASE	O
+-	O
+PubMed	O
+,	O
+MEDLINE	O
+(	O
+OVID	O
+),	O
+SCI	B-PRGE
+/	O
+Web	B-DISO
+of	O
+Science	O
+,	O
+the	O
+Cochrane	O
+Library	O
+,	O
+Google	O
+Scholar	O
+,	O
+and	O
+personal	O
+files	O
+.	O
+
+To	O
+report	O
+a	O
+case	O
+of	O
+brachial	B-DISO
+neuritis	I-DISO
+with	O
+bilateral	O
+phrenic	B-ANAT
+nerve	I-ANAT
+involvement	O
+and	O
+diaphragmatic	B-DISO
+weakness	I-DISO
+.	O
+
+We	O
+evaluated	O
+clinical	O
+outcomes	O
+after	O
+2	O
+days	O
+of	O
+therapy	O
+with	O
+neuromuscular	O
+blocking	B-DISO
+agents	O
+in	O
+patients	O
+with	O
+early	O
+,	O
+severe	O
+ARDS	B-DISO
+.	O
+
+(	O
+Funded	O
+by	O
+Assistance	O
+Publique	O
+-	O
+Hôpitaux	O
+de	O
+Marseille	O
+and	O
+the	O
+Programme	O
+Hospitalier	O
+de	O
+Recherche	O
+Clinique	O
+Régional	O
+2004	O
+-	O
+26	O
+of	O
+the	O
+French	O
+Ministry	O
+of	O
+Health	O
+;	O
+ClinicalTrials	O
+.	O
+gov	O
+number	O
+,	O
+NCT00299650	O
+.)	O
+RESULTS	O
+:	O
+The	O
+hazard	O
+ratio	O
+for	O
+death	B-PROC
+at	O
+90	O
+days	O
+in	O
+the	O
+cisatracurium	O
+group	O
+,	O
+as	O
+compared	O
+with	O
+the	O
+placebo	O
+group	O
+,	O
+was	O
+0	O
+.	O
+68	O
+(	O
+95	O
+%	O
+confidence	O
+interval	O
+[	O
+CI	O
+],	O
+0	O
+.	O
+48	O
+to	O
+0	O
+.	O
+98	O
+;	O
+P	O
+=	O
+0	O
+.	O
+04	O
+),	O
+after	O
+adjustment	O
+for	O
+both	O
+the	O
+baseline	O
+PaO2	O
+:	O
+FIO2	O
+and	O
+plateau	O
+pressure	O
+and	O
+the	O
+Simplified	O
+Acute	O
+Physiology	O
+II	O
+score	O
+.	O
+
+The	O
+rate	O
+of	O
+ICU	O
+-	O
+acquired	O
+paresis	B-DISO
+did	O
+not	O
+differ	O
+significantly	O
+between	O
+the	O
+two	O
+groups	O
+.	O
+
+Single	O
+application	O
+of	O
+only	O
+low	O
+vector	O
+doses	O
+elicited	O
+strong	O
+and	O
+long	O
+-	O
+lasting	O
+cytotoxic	O
+T	B-ANAT
+-	I-ANAT
+cell	B-COMP
+responses	O
+,	O
+providing	O
+protective	O
+antiviral	B-CHED
+and	O
+antitumor	O
+immunity	B-PROC
+.	O
+
+Furthermore	O
+,	O
+human	B-SPEC
+DCs	B-DISO
+transduced	O
+with	O
+Melan	O
+-	O
+A	O
+-	O
+recombinant	O
+human	B-SPEC
+coronavirus	I-SPEC
+229E	I-SPEC
+efficiently	O
+activated	O
+tumor	B-DISO
+-	O
+specific	O
+CD8	B-PRGE
+(+)	O
+T	B-ANAT
+cells	I-ANAT
+.	O
+
+ABSTRACT	O
+:	O
+Fifteen	O
+infectious	O
+bronchitis	B-DISO
+viruses	B-SPEC
+(	O
+IBV	B-SPEC
+)	O
+isolated	O
+from	O
+broiler	O
+and	O
+broiler	O
+breeder	O
+flocks	O
+in	O
+Slovenia	O
+between	O
+1990	O
+and	O
+2005	O
+were	O
+molecularly	O
+characterised	O
+.	O
+
+The	O
+typical	O
+manifestation	O
+of	O
+severe	O
+diseases	O
+was	O
+diffuse	O
+viral	B-DISO
+pneumonia	I-DISO
+complicated	O
+with	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+.	O
+
+In	O
+the	O
+present	O
+report	O
+,	O
+the	O
+recombinant	O
+adenoviruses	B-SPEC
+expressing	O
+chicken	B-PRGE
+granulocyte	B-ANAT
+-	I-PRGE
+macrophage	B-ANAT
+colony	I-PRGE
+stimulating	I-PRGE
+factor	I-PRGE
+(	O
+GM	B-PRGE
+-	I-PRGE
+CSF	I-PRGE
+)	O
+and	O
+S1	B-PRGE
+gene	I-PRGE
+of	O
+nephropathogenic	O
+IBV	B-SPEC
+were	O
+constructed	O
+and	O
+characterized	O
+.	O
+
+The	O
+results	O
+showed	O
+that	O
+the	O
+chickens	B-SPEC
+vaccinated	O
+in	O
+ovo	B-SPEC
+with	O
+rAd	B-PRGE
+-	I-PRGE
+S1	I-PRGE
+,	O
+rAd	B-PRGE
+-	I-PRGE
+GM	I-PRGE
+-	I-PRGE
+S1	I-PRGE
+(	O
+GM	B-PRGE
+-	I-PRGE
+CSF	I-PRGE
+fused	O
+with	O
+S1	O
+using	O
+glycine	B-CHED
+linkers	O
+)	O
+and	O
+rAd	B-PRGE
+-	I-PRGE
+GM	I-PRGE
+-	I-PRGE
+CSF	I-PRGE
+plus	O
+rAd	B-PRGE
+-	I-PRGE
+S1	I-PRGE
+(	O
+co	O
+-	O
+administered	O
+)	O
+developed	O
+specific	O
+anti	O
+-	O
+IBV	B-SPEC
+HI	O
+antibodies	B-COMP
+.	O
+
+TITLE	O
+:	O
+[	O
+Acute	B-DISO
+heart	I-DISO
+failure	I-DISO
+in	O
+patients	O
+over	O
+70	O
+years	O
+of	O
+age	O
+:	O
+Precipitating	O
+factors	O
+of	O
+decompensation	O
+].	O
+
+There	O
+is	O
+limited	O
+information	O
+on	O
+the	O
+prevalence	O
+of	O
+precipitating	O
+factors	O
+of	O
+heart	B-DISO
+failure	I-DISO
+decompensation	O
+in	O
+this	O
+population	O
+.	O
+
+We	O
+identified	O
+one	O
+or	O
+more	O
+precipitating	O
+factors	O
+of	O
+heart	B-DISO
+failure	I-DISO
+decompensation	O
+in	O
+89	O
+.	O
+6	O
+%	O
+of	O
+the	O
+patients	O
+.	O
+
+The	O
+most	O
+common	O
+were	O
+atrial	B-ANAT
+tachyarrhythmia	O
+(	O
+22	O
+.	O
+3	O
+%),	O
+respiratory	B-DISO
+infection	I-DISO
+(	O
+21	O
+.	O
+2	O
+%),	O
+severe	B-DISO
+anemia	I-DISO
+(	O
+17	O
+.	O
+1	O
+%),	O
+acute	B-DISO
+renal	I-DISO
+failure	I-DISO
+(	O
+12	O
+.	O
+7	O
+%),	O
+severe	O
+hypoalbuminemia	O
+(	O
+11	O
+.	O
+4	O
+%)	O
+and	O
+acute	B-DISO
+coronary	I-DISO
+syndrome	I-DISO
+(	O
+9	O
+.	O
+1	O
+%).	O
+
+In	O
+most	O
+patients	O
+over	O
+70	O
+years	O
+of	O
+age	O
+hospitalized	O
+with	O
+acute	B-DISO
+heart	I-DISO
+failure	I-DISO
+it	O
+is	O
+possible	O
+to	O
+identify	O
+one	O
+or	O
+more	O
+precipitating	O
+factors	O
+of	O
+decompensation	O
+,	O
+some	O
+of	O
+which	O
+are	O
+independently	O
+associated	O
+with	O
+hospital	O
+mortality	O
+.	O
+
+The	O
+variables	O
+independently	O
+associated	O
+with	O
+hospital	O
+mortality	O
+were	O
+acute	B-DISO
+renal	I-DISO
+failure	I-DISO
+,	O
+severe	O
+hypoalbuminemia	O
+,	O
+systolic	O
+blood	B-PROC
+pressure	I-PROC
+<	O
+110mmHg	O
+,	O
+white	B-ANAT
+blood	I-ANAT
+cell	I-ANAT
+count	O
+>	O
+10	O
+.	O
+000	O
+per	O
+mm³	O
+and	O
+valvular	B-DISO
+heart	I-DISO
+disease	I-DISO
+.	O
+
+Analysis	O
+of	O
+the	O
+3	O
+'	O
+UTR	O
+and	O
+S1	O
+gene	O
+nucleotide	B-CHED
+sequences	O
+for	O
+the	O
+five	O
+IB	O
+virus	B-SPEC
+strains	O
+that	O
+could	O
+not	O
+be	O
+classified	O
+indicated	O
+that	O
+four	O
+belonged	O
+to	O
+one	O
+of	O
+the	O
+subgroups	O
+,	O
+and	O
+one	O
+was	O
+a	O
+potential	O
+recombinant	O
+strain	O
+(	O
+between	O
+strains	O
+from	O
+subgroups	O
+2	O
+and	O
+3	O
+).	O
+
+CONCLUSIONS	O
+:	O
+HRM	O
+curve	O
+analysis	O
+can	O
+rapidly	O
+assign	O
+the	O
+majority	O
+of	O
+IB	O
+viruses	B-SPEC
+present	O
+in	O
+field	O
+submissions	O
+to	O
+known	O
+subgroups	O
+.	O
+
+The	O
+sPLA	B-PRGE
+(	I-PRGE
+2	I-PRGE
+)-	I-PRGE
+II	I-PRGE
+mRNA	I-PRGE
+and	O
+sPLA	B-PRGE
+(	I-PRGE
+2	I-PRGE
+)-	I-PRGE
+II	I-PRGE
+protein	B-CHED
+expression	B-PROC
+in	O
+lung	B-ANAT
+were	O
+detected	O
+by	O
+reverse	B-PROC
+transcription	I-PROC
+-	O
+polymerase	O
+chain	O
+reaction	O
+(	O
+RT	O
+-	O
+PCR	O
+)	O
+and	O
+Western	O
+blotting	O
+.	O
+
+Administration	O
+of	O
+QYT	O
+can	O
+reduce	O
+the	O
+injury	O
+of	O
+lung	B-ANAT
+by	O
+decreasing	O
+the	O
+expression	B-PROC
+of	O
+sPLA	B-PRGE
+(	I-PRGE
+2	I-PRGE
+)-	I-PRGE
+II	I-PRGE
+in	O
+transcriptional	B-PROC
+level	O
+and	O
+thus	O
+protecting	O
+pulmonary	B-PROC
+function	I-PROC
+.	O
+
+In	O
+the	O
+case	O
+of	O
+the	O
+Coronaviridae	B-SPEC
+this	O
+family	B-SPEC
+is	O
+now	O
+recognized	O
+as	O
+including	O
+potent	O
+human	B-SPEC
+pathogens	O
+causing	O
+upper	O
+and	O
+lower	B-DISO
+respiratory	I-DISO
+tract	I-DISO
+infections	I-DISO
+as	O
+well	O
+as	O
+nosocomial	O
+ones	O
+.	O
+
+Within	O
+the	O
+purpose	O
+of	O
+developing	O
+new	O
+antiseptics	O
+molecules	O
+,	O
+the	O
+antiseptic	O
+virucidal	O
+activity	O
+of	O
+two	O
+calix	B-CHED
+[	I-CHED
+4	I-CHED
+]	I-CHED
+arene	I-CHED
+derivatives	O
+,	O
+the	O
+tetra	B-CHED
+-	O
+para	B-CHED
+-	O
+sulfonato	B-CHED
+-	O
+calix	B-CHED
+[	I-CHED
+4	I-CHED
+]	I-CHED
+arene	I-CHED
+(	O
+C	O
+[	O
+4	O
+]	O
+S	O
+)	O
+and	O
+the	O
+1	O
+,	O
+3	O
+-	O
+bis	B-FUNC
+(	O
+bithiazolyl	O
+)-	O
+tetra	B-CHED
+-	O
+para	B-CHED
+-	O
+sulfonato	B-CHED
+-	O
+calix	B-CHED
+[	I-CHED
+4	I-CHED
+]	I-CHED
+arene	I-CHED
+(	O
+C	O
+[	O
+4	O
+]	O
+S	O
+-	O
+BTZ	O
+)	O
+were	O
+evaluated	O
+toward	O
+the	O
+human	B-SPEC
+coronavirus	I-SPEC
+229E	I-SPEC
+(	O
+HCoV	O
+229E	O
+).	O
+
+In	O
+vitro	O
+,	O
+the	O
+pretreatment	O
+of	O
+peritoneal	B-ANAT
+macrophages	I-ANAT
+with	O
+inhibitors	B-CHED
+of	O
+the	O
+proteasome	B-PATH
+(	O
+pyrrolidine	B-CHED
+dithiocarbamate	O
+[	O
+PDTC	O
+],	O
+MG132	O
+,	O
+and	O
+PS	B-CHED
+-	I-CHED
+341	I-CHED
+)	O
+markedly	O
+inhibited	O
+MHV	B-SPEC
+-	O
+1	O
+replication	O
+at	O
+an	O
+early	O
+step	O
+in	O
+its	O
+replication	O
+cycle	O
+,	O
+as	O
+evidenced	O
+by	O
+inhibition	B-PROC
+of	O
+viral	O
+RNA	O
+production	O
+.	O
+
+The	O
+results	O
+further	O
+suggest	O
+that	O
+targeting	B-PROC
+the	O
+proteasome	B-PATH
+may	O
+be	O
+an	O
+effective	O
+new	O
+treatment	O
+for	O
+severe	O
+coronavirus	B-DISO
+infections	I-DISO
+.	O
+
+After	O
+tracheostomy	O
+,	O
+the	O
+patient	O
+was	O
+treated	O
+with	O
+antibiotic	B-CHED
+therapy	O
+guided	O
+by	O
+serial	O
+surveillance	O
+cultures	O
+of	O
+endotracheal	O
+aspirates	B-ANAT
+.	O
+
+We	O
+identified	O
+Neural	B-PRGE
+Cell	I-PRGE
+Adhesion	I-PRGE
+Molecule	I-PRGE
+(	O
+NCAM	B-PRGE
+)	O
+as	O
+a	O
+novel	O
+interacting	O
+partner	O
+of	O
+the	O
+PHE	B-PRGE
+-	I-PRGE
+CoV	I-PRGE
+S	I-PRGE
+protein	B-CHED
+.	O
+
+We	O
+found	O
+that	O
+a	O
+soluble	O
+form	O
+of	O
+anti	B-PRGE
+-	I-PRGE
+NCAM	I-PRGE
+antibody	I-PRGE
+blocked	O
+association	O
+of	O
+the	O
+PHE	B-CHED
+-	O
+CoV	O
+with	O
+N2a	O
+cells	B-COMP
+.	O
+
+Furthermore	O
+,	O
+double	O
+-	O
+stranded	O
+siRNA	O
+targeted	B-PROC
+against	O
+NCAM	O
+inhibited	O
+PHE	B-CHED
+-	O
+CoV	O
+infection	B-DISO
+.	O
+
+A	O
+novel	O
+interaction	O
+was	O
+identified	O
+between	O
+NCAM	O
+and	O
+spike	O
+protein	B-CHED
+and	O
+this	O
+association	O
+is	O
+critical	O
+during	O
+PHE	O
+-	O
+CoV	O
+infection	B-DISO
+.	O
+
+Furthermore	O
+,	O
+double	O
+-	O
+stranded	O
+siRNA	O
+targeted	B-PROC
+against	O
+NCAM	O
+inhibited	O
+PHE	B-CHED
+-	O
+CoV	O
+infection	B-DISO
+.	O
+
+The	O
+scoring	O
+functionality	O
+that	O
+evaluates	O
+the	O
+fitness	O
+of	O
+the	O
+docking	B-PROC
+result	O
+is	O
+one	O
+of	O
+the	O
+major	O
+challenges	O
+in	O
+virtual	O
+screening	O
+.	O
+
+TITLE	O
+:	O
+Acute	O
+undifferentiated	O
+febrile	B-DISO
+illness	I-DISO
+in	O
+adult	O
+hospitalized	O
+patients	O
+:	O
+the	O
+disease	O
+spectrum	O
+and	O
+diagnostic	O
+predictors	O
+-	O
+an	O
+experience	O
+from	O
+a	O
+tertiary	O
+care	O
+hospital	O
+in	O
+South	O
+India	O
+.	O
+
+An	O
+1	O
+-	O
+year	O
+prospective	O
+,	O
+observational	O
+study	O
+was	O
+conducted	O
+in	O
+adults	O
+(	O
+age	O
+>	O
+16	O
+years	O
+)	O
+who	O
+presented	O
+with	O
+an	O
+undifferentiated	O
+febrile	B-DISO
+illness	I-DISO
+of	O
+duration	O
+5	O
+-	O
+21	O
+days	O
+,	O
+requiring	O
+hospitalization	O
+.	O
+
+Normal	O
+leukocyte	B-ANAT
+counts	O
+,	O
+moderate	O
+to	O
+severe	O
+thrombocytopenia	O
+,	O
+renal	B-DISO
+failure	I-DISO
+,	O
+splenomegaly	O
+and	O
+hyperbilirubinaemia	B-DISO
+with	O
+mildly	O
+elevated	O
+serum	B-PRGE
+transaminases	I-PRGE
+were	O
+associated	O
+with	O
+malaria	B-PATH
+.	O
+
+Rash	B-DISO
+,	O
+overt	O
+bleeding	B-DISO
+manifestations	O
+,	O
+normal	O
+to	O
+low	O
+leukocyte	B-ANAT
+counts	O
+,	O
+moderate	O
+to	O
+severe	O
+thrombocytopenia	O
+and	O
+significantly	O
+elevated	O
+hepatic	B-ANAT
+transaminases	O
+were	O
+associated	O
+with	O
+dengue	B-DISO
+.	O
+
+ABSTRACT	O
+:	O
+The	O
+World	O
+Health	O
+Organization	O
+(	O
+WHO	O
+)	O
+is	O
+central	O
+to	O
+the	O
+international	O
+community	O
+'	O
+s	O
+efforts	O
+to	O
+control	O
+infectious	B-DISO
+disease	I-DISO
+outbreaks	O
+.	O
+
+This	O
+ubiquitous	O
+trimethylxanthine	O
+,	O
+pervasively	O
+used	O
+in	O
+the	O
+human	B-SPEC
+diet	O
+and	O
+beverages	O
+,	O
+significantly	O
+impacts	O
+on	O
+major	O
+acute	O
+neonatal	O
+morbidities	O
+including	O
+apnea	B-DISO
+of	I-DISO
+prematurity	I-DISO
+,	O
+bronchopulmonary	B-DISO
+dysplasia	I-DISO
+,	O
+patent	O
+ductus	O
+arteriousus	O
+with	O
+or	O
+without	O
+surgical	O
+ligation	O
+and	O
+post	O
+-	O
+operative	O
+apnea	B-DISO
+.	O
+
+Potential	O
+uses	O
+in	O
+respiratory	B-DISO
+distress	I-DISO
+syndrome	I-DISO
+as	O
+suggested	O
+by	O
+improved	O
+lung	B-PROC
+function	I-PROC
+in	O
+primate	B-SPEC
+models	O
+is	O
+supported	O
+by	O
+the	O
+decreased	O
+time	O
+on	O
+mechanical	O
+ventilation	O
+and	O
+need	O
+for	O
+oxygen	B-CHED
+therapy	O
+.	O
+
+Increased	O
+effector	B-CHED
+function	O
+at	O
+the	O
+single	O
+-	O
+cell	O
+level	O
+was	O
+also	O
+evident	O
+by	O
+elevated	O
+granzyme	B-PRGE
+B	I-PRGE
+expression	B-PROC
+specifically	O
+in	O
+virus	B-SPEC
+-	O
+specific	O
+CNS	B-CHED
+CD8	O
+T	B-ANAT
+cells	I-ANAT
+.	O
+
+Although	O
+enhanced	O
+T	B-ANAT
+cell	I-ANAT
+activity	O
+accelerated	O
+virus	B-SPEC
+control	O
+,	O
+50	O
+%	O
+of	O
+mice	B-SPEC
+succumbed	O
+to	O
+infection	B-DISO
+.	O
+
+B7	B-PRGE
+-	I-PRGE
+H1	I-PRGE
+(-/-)	O
+mice	B-SPEC
+exhibited	O
+extensive	O
+loss	O
+of	O
+axonal	O
+integrity	O
+,	O
+although	O
+demyelination	B-DISO
+,	O
+a	O
+hallmark	O
+of	O
+virus	B-SPEC
+-	O
+induced	O
+tissue	B-ANAT
+damage	O
+,	O
+was	O
+not	O
+increased	O
+.	O
+
+TITLE	O
+:	O
+Detection	O
+and	O
+characterization	O
+of	O
+bovine	B-SPEC
+-	O
+like	O
+coronaviruses	O
+from	O
+four	O
+species	B-SPEC
+of	O
+zoo	O
+ruminants	B-SPEC
+.	O
+
+Comparison	O
+of	O
+the	O
+entire	O
+deduced	O
+aa	O
+sequences	O
+of	O
+the	O
+S	B-PRGE
+and	I-PRGE
+HE	I-PRGE
+glycoproteins	I-PRGE
+revealed	O
+no	O
+specific	O
+differences	O
+that	O
+would	O
+account	O
+for	O
+discrimination	O
+between	O
+bovine	B-PRGE
+-	I-PRGE
+like	I-PRGE
+CoV	I-PRGE
+strains	O
+from	O
+zoo	O
+ruminants	B-SPEC
+and	O
+BcoVs	O
+strains	O
+.	O
+
+These	O
+emerging	O
+sublineages	O
+display	O
+varying	O
+levels	O
+of	O
+drug	B-PROC
+resistance	I-PROC
+and	O
+in	O
+some	O
+cases	O
+an	O
+increased	O
+preference	O
+for	O
+binding	B-FUNC
+to	O
+human	B-SPEC
+α2	O
+,	O
+6	O
+-	O
+linked	O
+sialic	B-CHED
+acid	I-CHED
+cellular	B-COMP
+receptors	O
+.	O
+
+Here	O
+we	O
+review	O
+the	O
+epidemiology	O
+,	O
+host	B-COMP
+range	O
+,	O
+clinical	O
+features	O
+,	O
+prophylaxis	O
+and	O
+treatment	O
+options	O
+,	O
+and	O
+preventative	O
+measures	O
+recommended	O
+for	O
+AIV	O
+with	O
+an	O
+emphasis	O
+on	O
+H5N1	B-DISO
+.	O
+
+Causes	O
+of	O
+cardiac	B-ANAT
+shock	O
+were	O
+:	O
+myocarditis	B-DISO
+(	O
+28	O
+.	O
+1	O
+%),	O
+acute	B-DISO
+heart	I-DISO
+failure	I-DISO
+of	O
+unknown	O
+aetiology	O
+(	O
+21	O
+.	O
+9	O
+%),	O
+drug	O
+-	O
+induced	O
+cardiovascular	B-ANAT
+failure	O
+(	O
+18	O
+.	O
+8	O
+%),	O
+post	O
+-	O
+infarction	B-DISO
+cardiac	B-DISO
+failure	I-DISO
+(	O
+12	O
+.	O
+5	O
+%),	O
+post	O
+-	O
+cardiac	B-ANAT
+surgery	O
+(	O
+12	O
+.	O
+5	O
+%)	O
+and	O
+refractory	O
+cardiac	B-DISO
+arrest	I-DISO
+(	O
+6	O
+.	O
+2	O
+%).	O
+
+The	O
+M	O
+gene	O
+of	O
+PEDV	B-SPEC
+was	O
+expressed	B-PROC
+in	O
+Escherichia	B-SPEC
+coli	I-SPEC
+.	O
+
+51	O
+%	O
+of	O
+these	O
+patients	O
+required	O
+ventilatory	O
+support	O
+,	O
+45	O
+%	O
+received	O
+systemic	O
+corticosteroids	B-CHED
+,	O
+and	O
+91	O
+%	O
+received	O
+initial	O
+broad	O
+spectrum	O
+antibiotic	B-CHED
+coverage	O
+.	O
+
+Pigs	B-SPEC
+were	O
+either	O
+mock	O
+-	O
+infected	O
+or	O
+infected	O
+with	O
+porcine	B-SPEC
+reproductive	I-SPEC
+and	I-SPEC
+respiratory	I-SPEC
+syndrome	I-SPEC
+virus	I-SPEC
+(	O
+PRRSV	B-SPEC
+),	O
+a	O
+virus	B-SPEC
+known	O
+to	O
+cause	O
+immunosuppressive	O
+respiratory	B-DISO
+disease	I-DISO
+,	O
+and	O
+then	O
+pigs	B-SPEC
+were	O
+co	O
+-	O
+infected	O
+with	O
+PRCV	O
+,	O
+which	O
+normally	O
+causes	O
+subclinical	O
+respiratory	B-DISO
+infection	I-DISO
+.	O
+
+We	O
+evaluated	O
+the	O
+effect	O
+of	O
+vaccine	O
+dose	O
+and	O
+each	O
+adjuvant	B-CHED
+on	O
+immunogenicity	O
+and	O
+efficacy	O
+in	O
+mice	B-SPEC
+,	O
+and	O
+the	O
+effect	O
+of	O
+vaccine	O
+dose	O
+with	O
+or	O
+without	O
+the	O
+AS01	O
+(	O
+B	O
+)	O
+adjuvant	B-CHED
+on	O
+the	O
+immunogenicity	O
+and	O
+efficacy	O
+in	O
+hamsters	B-SPEC
+.	O
+
+Vaccine	O
+with	O
+adjuvant	B-CHED
+provided	O
+better	O
+protection	O
+than	O
+non	O
+-	O
+adjuvanted	O
+WI	O
+-	O
+SARS	B-DISO
+vaccine	O
+at	O
+this	O
+later	O
+time	O
+point	O
+.	O
+
+These	O
+results	O
+show	O
+that	O
+in	O
+early	O
+phase	O
+,	O
+the	O
+inflammatory	O
+cytokines	O
+in	O
+plasma	B-ANAT
+might	O
+affect	O
+iNOS	O
+expression	B-PROC
+and	O
+cytokines	O
+.	O
+
+ABSTRACT	O
+:	O
+In	O
+the	O
+present	O
+study	O
+,	O
+anti	O
+-	O
+IBV	B-SPEC
+(	O
+infectious	B-DISO
+bronchitis	B-DISO
+virus	B-SPEC
+)	O
+activity	O
+of	O
+1	B-CHED
+,	I-CHED
+8	I-CHED
+-	I-CHED
+cineole	I-CHED
+was	O
+studied	O
+by	O
+MTT	B-CHED
+assay	O
+,	O
+as	O
+well	O
+as	O
+docking	B-PROC
+and	O
+molecular	B-PROC
+dynamic	I-PROC
+(	O
+MD	O
+)	O
+simulations	O
+.	O
+
+Lymphopenia	B-DISO
+and	O
+increased	O
+creatine	B-PRGE
+kinase	I-PRGE
+levels	O
+were	O
+frequently	O
+observed	O
+(	O
+83	O
+%	O
+and	O
+65	O
+%	O
+among	O
+PCR	O
++	O
+and	O
+PCR	O
+-	O
+respectively	O
+).	O
+
+H1N1	O
+infection	B-DISO
+was	O
+associated	O
+with	O
+severe	O
+respiratory	O
+illness	O
+and	O
+ARDS	B-DISO
+.	O
+
+TITLE	O
+:	O
+U	O
+.	O
+S	O
+.	O
+attitudes	O
+and	O
+perceived	O
+practice	O
+for	O
+noninvasive	O
+ventilation	O
+in	O
+pediatric	O
+acute	B-DISO
+respiratory	I-DISO
+failure	I-DISO
+.	O
+
+TITLE	O
+:	O
+Evolved	O
+variants	O
+of	O
+the	O
+membrane	B-COMP
+protein	B-CHED
+can	O
+partially	O
+replace	O
+the	O
+envelope	B-COMP
+protein	B-CHED
+in	O
+murine	B-SPEC
+coronavirus	I-SPEC
+assembly	O
+.	O
+
+TITLE	O
+:	O
+Efficient	O
+activation	O
+of	O
+the	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+coronavirus	B-SPEC
+spike	O
+protein	B-CHED
+by	O
+the	O
+transmembrane	O
+protease	O
+TMPRSS2	O
+.	O
+
+To	O
+test	O
+this	O
+,	O
+the	O
+TMPRSS2	B-PRGE
+and	O
+S	O
+proteins	B-CHED
+were	O
+expressed	B-PROC
+in	O
+cells	B-COMP
+labeled	O
+with	O
+fluorescent	O
+probes	O
+of	O
+different	O
+colors	O
+,	O
+and	O
+the	O
+cell	B-PROC
+-	I-PROC
+cell	B-COMP
+fusion	I-PROC
+between	O
+these	O
+cells	B-COMP
+was	O
+tested	O
+.	O
+
+ABSTRACT	O
+:	O
+Effective	O
+prediction	O
+of	O
+future	O
+viral	O
+zoonoses	B-DISO
+requires	O
+an	O
+in	O
+-	O
+depth	O
+understanding	O
+of	O
+the	O
+heterologous	O
+viral	O
+population	O
+in	O
+key	O
+animal	B-SPEC
+species	B-SPEC
+that	O
+will	O
+likely	O
+serve	O
+as	O
+reservoir	O
+hosts	B-COMP
+or	O
+intermediates	O
+during	O
+the	O
+next	O
+viral	O
+epidemic	O
+.	O
+
+ABSTRACT	O
+:	O
+Five	O
+monoclonal	O
+antibodies	B-COMP
+(	O
+MAbs	O
+)	O
+against	O
+recombinant	O
+nucleocapsid	B-PRGE
+protein	B-CHED
+(	O
+NP	O
+)	O
+of	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+(	O
+SARS	B-DISO
+)-	O
+causing	O
+coronavirus	B-SPEC
+(	O
+CoV	O
+)	O
+were	O
+developed	O
+by	O
+hybridoma	B-ANAT
+technology	O
+.	O
+
+ABSTRACT	O
+:	O
+Little	O
+is	O
+known	O
+about	O
+the	O
+impact	O
+of	O
+community	O
+-	O
+acquired	O
+respiratory	O
+coinfection	B-DISO
+in	O
+patients	O
+with	O
+pandemic	O
+2009	O
+influenza	B-PATH
+A	I-PATH
+(	O
+H1N1	O
+)	O
+virus	B-DISO
+infection	I-DISO
+.	O
+
+ABSTRACT	O
+:	O
+In	O
+this	O
+study	O
+,	O
+we	O
+analyzed	O
+the	O
+respiratory	O
+status	O
+and	O
+the	O
+prognosis	O
+of	O
+patients	O
+,	O
+including	O
+adults	O
+with	O
+acute	B-DISO
+respiratory	I-DISO
+failure	I-DISO
+requiring	O
+venovenous	O
+extracorporeal	O
+membrane	B-COMP
+oxygenation	B-PROC
+(	O
+VV	O
+ECMO	O
+)	O
+to	O
+maintain	O
+respiratory	O
+status	O
+.	O
+
+The	O
+pre	O
+-	O
+ECMO	O
+ventilator	O
+time	O
+was	O
+shorter	O
+in	O
+group	O
+A	O
+than	O
+in	O
+group	B-DISO
+B	I-DISO
+.	O
+Significant	O
+differences	O
+were	O
+found	O
+between	O
+the	O
+two	O
+groups	O
+in	O
+the	O
+P	O
+/	O
+F	O
+ratio	O
+and	O
+LIS	B-FUNC
+from	O
+pre	O
+-	O
+ECMO	O
+introduction	O
+to	O
+72	O
+hours	O
+after	O
+.	O
+
+ECMO	O
+flow	O
+in	O
+group	O
+A	O
+could	O
+be	O
+weaned	B-PROC
+for	O
+48	O
+hours	O
+after	O
+introduction	O
+,	O
+significantly	O
+different	O
+compared	O
+with	O
+group	B-DISO
+B	I-DISO
+.	O
+CONCLUSIONS	O
+:	O
+The	O
+early	O
+introduction	O
+of	O
+ECMO	O
+may	O
+be	O
+desirable	O
+if	O
+the	O
+causes	O
+of	O
+respiratory	B-DISO
+failure	I-DISO
+are	O
+recoverable	O
+.	O
+
+Tendon	B-ANAT
+reflexes	B-PROC
+were	O
+reduced	O
+in	O
+eight	O
+and	O
+brisk	O
+in	O
+four	O
+patients	O
+.	O
+
+The	O
+lung	B-ANAT
+injury	O
+is	O
+caused	O
+primarily	O
+by	O
+neutrophil	B-ANAT
+-	O
+dependent	O
+and	O
+platelet	B-ANAT
+-	O
+dependent	O
+damage	O
+to	O
+the	O
+endothelial	B-ANAT
+and	O
+epithelial	O
+barriers	O
+of	O
+the	O
+lung	B-ANAT
+.	O
+
+Resolution	O
+is	O
+delayed	O
+because	O
+of	O
+injury	O
+to	O
+the	O
+lung	B-ANAT
+epithelial	O
+barrier	O
+,	O
+which	O
+prevents	O
+removal	O
+of	O
+alveolar	B-DISO
+edema	I-DISO
+fluid	O
+and	O
+deprives	O
+the	O
+lung	B-ANAT
+of	O
+adequate	O
+quantities	O
+of	O
+surfactant	B-CHED
+.	O
+
+Thus	O
+,	O
+using	O
+a	O
+low	O
+tidal	O
+volume	O
+prevents	O
+added	O
+lung	B-ANAT
+damage	O
+by	O
+the	O
+same	O
+mechanical	O
+ventilation	O
+that	O
+is	O
+essential	O
+for	O
+life	O
+support	O
+.	O
+
+However	O
+,	O
+adaptation	B-PROC
+is	O
+difficult	O
+to	O
+distinguish	O
+conclusively	O
+from	O
+the	O
+other	O
+processes	O
+that	O
+generate	O
+genetic	B-DISO
+change	I-DISO
+.	O
+
+ABSTRACT	O
+:	O
+Perioperative	O
+red	O
+blood	O
+cell	O
+transfusion	O
+is	O
+commonly	O
+used	O
+to	O
+address	O
+anemia	B-DISO
+,	O
+an	O
+independent	O
+risk	O
+factor	O
+for	O
+morbidity	O
+and	O
+mortality	O
+after	O
+cardiac	B-ANAT
+operations	O
+;	O
+however	O
+,	O
+evidence	O
+regarding	O
+optimal	O
+blood	B-ANAT
+transfusion	O
+practice	O
+in	O
+patients	O
+undergoing	O
+cardiac	B-ANAT
+surgery	O
+is	O
+lacking	O
+.	O
+
+The	O
+Transfusion	O
+Requirements	O
+After	O
+Cardiac	B-ANAT
+Surgery	O
+(	O
+TRACS	O
+)	O
+study	O
+,	O
+a	O
+prospective	O
+,	O
+randomized	O
+,	O
+controlled	O
+clinical	O
+noninferiority	O
+trial	O
+conducted	O
+between	O
+February	O
+2009	O
+and	O
+February	O
+2010	O
+in	O
+an	O
+intensive	O
+care	O
+unit	O
+at	O
+a	O
+university	O
+hospital	O
+cardiac	B-ANAT
+surgery	O
+referral	O
+center	O
+in	O
+Brazil	O
+.	O
+
+Composite	O
+end	O
+point	O
+of	O
+30	O
+-	O
+day	O
+all	O
+-	O
+cause	O
+mortality	O
+and	O
+severe	O
+morbidity	O
+(	O
+cardiogenic	B-DISO
+shock	I-DISO
+,	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+,	O
+or	O
+acute	O
+renal	B-ANAT
+injury	O
+requiring	O
+dialysis	B-SPEC
+or	O
+hemofiltration	O
+)	O
+occurring	O
+during	O
+the	O
+hospital	O
+stay	O
+.	O
+
+Independent	O
+of	O
+transfusion	O
+strategy	O
+,	O
+the	O
+number	O
+of	O
+transfused	O
+red	B-ANAT
+blood	I-ANAT
+cell	I-ANAT
+units	O
+was	O
+an	O
+independent	O
+risk	O
+factor	O
+for	O
+clinical	O
+complications	O
+or	O
+death	B-PROC
+at	O
+30	O
+days	O
+(	O
+hazard	O
+ratio	O
+for	O
+each	O
+additional	O
+unit	O
+transfused	O
+,	O
+1	O
+.	O
+2	O
+[	O
+95	O
+%	O
+CI	O
+,	O
+1	O
+.	O
+1	O
+-	O
+1	O
+.	O
+4	O
+];	O
+P	O
+=	O
+.	O
+002	O
+).	O
+
+TITLE	O
+:	O
+[	O
+Extracorporeal	O
+life	O
+support	O
+given	O
+to	O
+a	O
+16	O
+-	O
+year	O
+-	O
+old	O
+girl	O
+with	O
+cystic	B-DISO
+fibrosis	I-DISO
+,	O
+candida	B-SPEC
+pneumonia	I-DISO
+and	O
+acute	O
+respiratory	O
+distress	O
+syndrome	O
+].	O
+
+ABSTRACT	O
+:	O
+Small	B-ANAT
+bowel	I-ANAT
+resection	O
+had	O
+to	O
+be	O
+performed	O
+because	O
+of	O
+an	O
+acute	O
+ileus	B-DISO
+in	O
+a	O
+16	O
+-	O
+year	O
+old	O
+girl	O
+with	O
+mucoviscidosis	B-DISO
+.	O
+
+CONCLUSIONS	O
+:	O
+ECMO	O
+is	O
+a	O
+another	O
+treatment	O
+option	O
+for	O
+serious	O
+ARDS	B-DISO
+in	O
+infection	B-DISO
+-	O
+related	O
+worsening	O
+of	O
+pulmonary	B-DISO
+cystic	I-DISO
+fibrosis	I-DISO
+.	O
+
+Most	O
+patients	O
+(	O
+95	O
+[	O
+90	O
+%])	O
+had	O
+at	O
+least	O
+one	O
+more	O
+chronic	B-DISO
+disease	I-DISO
+.	O
+
+More	O
+patients	O
+had	O
+serum	B-COMP
+antibody	B-COMP
+to	O
+each	O
+HCoV	O
+strain	O
+(	O
+104	O
+[	O
+99	O
+%]	O
+had	O
+antibody	B-COMP
+to	O
+HCoV	B-SPEC
+-	I-SPEC
+229E	I-SPEC
+,	O
+105	O
+[	O
+100	O
+%]	O
+had	O
+antibody	B-COMP
+to	O
+HCoV	B-SPEC
+-	I-SPEC
+OC43	I-SPEC
+,	O
+103	O
+[	O
+98	O
+%]	O
+had	O
+antibody	B-COMP
+to	O
+HCoV	B-SPEC
+-	I-SPEC
+NL63	I-SPEC
+,	O
+and	O
+96	O
+[	O
+91	O
+%]	O
+had	O
+antibody	B-COMP
+to	O
+HCoV	O
+-	O
+HKU1	O
+)	O
+than	O
+had	O
+antibody	B-COMP
+to	O
+each	O
+HCoV	O
+strain	O
+in	O
+nasal	B-ANAT
+wash	O
+specimens	O
+(	O
+12	O
+[	O
+11	O
+%]	O
+had	O
+antibody	B-COMP
+to	O
+HCoV	B-SPEC
+-	I-SPEC
+229E	I-SPEC
+,	O
+22	O
+[	O
+22	O
+%]	O
+had	O
+antibody	B-COMP
+to	O
+HCoV	B-SPEC
+-	I-SPEC
+OC43	I-SPEC
+,	O
+8	O
+[	O
+8	O
+%]	O
+had	O
+antibody	B-FUNC
+to	O
+HCoV	B-SPEC
+-	I-SPEC
+NL63	I-SPEC
+,	O
+and	O
+31	O
+[	O
+31	O
+%]	O
+had	O
+antibody	B-COMP
+to	O
+HCoV	O
+-	O
+HKU1	O
+),	O
+respectively	O
+(	O
+P	O
+<	O
+0	O
+.	O
+0001	O
+).	O
+
+The	O
+rapid	O
+induction	O
+of	O
+autoantibodies	O
+in	O
+ARDS	B-DISO
+and	O
+severe	B-DISO
+sepsis	I-DISO
+suggests	O
+that	O
+ongoing	O
+systemic	O
+inflammation	B-DISO
+and	O
+associated	O
+tissue	B-ANAT
+destruction	O
+mediate	O
+the	O
+break	O
+in	O
+tolerance	B-DISO
+against	O
+these	O
+self	O
+proteins	B-CHED
+.	O
+
+ABSTRACT	O
+:	O
+A	O
+series	O
+of	O
+pyrazolone	O
+compounds	O
+as	O
+possible	O
+SARS	B-PRGE
+-	I-PRGE
+CoV	I-PRGE
+3CL	I-PRGE
+protease	B-PROC
+inhibitors	I-PROC
+were	O
+designed	O
+,	O
+synthesized	O
+,	O
+and	O
+evaluated	O
+by	O
+in	O
+vitro	O
+protease	O
+assay	O
+using	O
+fluorogenic	O
+substrate	O
+peptide	B-CHED
+in	O
+which	O
+several	O
+showed	O
+potent	O
+inhibition	B-PROC
+against	O
+the	O
+3CL	B-PRGE
+protease	I-PRGE
+.	O
+
+P5	O
+and	O
+P3	O
+positions	O
+prefer	O
+residues	O
+with	O
+high	O
+β	O
+-	O
+sheet	O
+propensity	O
+;	O
+P4	O
+prefers	O
+small	O
+hydrophobic	O
+residues	O
+;	O
+P2	O
+prefers	O
+hydrophobic	O
+residues	O
+without	O
+β	O
+-	O
+branch	B-ANAT
+.	O
+
+Gln	B-CHED
+is	O
+the	O
+best	O
+residue	O
+at	O
+P1	O
+position	O
+,	O
+but	O
+observable	O
+cleavage	B-PROC
+can	O
+be	O
+detected	O
+with	O
+His	O
+and	O
+Met	O
+substitutions	O
+.	O
+
+Cholesterol	B-DISO
+depletion	I-DISO
+from	O
+viral	B-COMP
+membrane	I-COMP
+may	O
+not	O
+affect	O
+the	O
+adsorption	O
+process	O
+as	O
+neither	O
+the	O
+sialic	B-FUNC
+acid	I-FUNC
+binding	B-PROC
+activity	I-PROC
+nor	O
+the	O
+binding	B-FUNC
+to	O
+aminopeptidase	B-PRGE
+N	I-PRGE
+was	O
+reduced	O
+post	O
+-	O
+MβCD	O
+treatment	O
+.	O
+
+Reduced	O
+infectivity	O
+of	O
+cholesterol	B-CHED
+-	O
+depleted	O
+TGEV	B-SPEC
+was	O
+observed	O
+only	O
+when	O
+the	O
+adsorption	O
+process	O
+occurred	O
+at	O
+37	O
+°	O
+C	O
+but	O
+not	O
+when	O
+the	O
+virus	O
+was	O
+applied	O
+at	O
+4	O
+°	O
+C	O
+.	O
+
+Recombinant	B-PRGE
+plasmid	I-PRGE
+pSY	I-PRGE
+-	I-PRGE
+S1	I-PRGE
+/	O
+IL18	B-PRGE
+was	O
+constructed	O
+by	O
+cloning	O
+chicken	B-PRGE
+IL	B-FUNC
+-	I-FUNC
+18	I-FUNC
+into	O
+fowlpox	B-SPEC
+virus	I-SPEC
+transfer	O
+plasmid	O
+containing	O
+S1	B-PRGE
+gene	I-PRGE
+and	O
+transfected	O
+into	O
+the	O
+chicken	B-SPEC
+embryo	B-ANAT
+fibroblasts	B-ANAT
+cell	B-COMP
+pre	O
+-	O
+infected	O
+with	O
+S	O
+-	O
+FPV	B-SPEC
+-	O
+017	O
+to	O
+generate	O
+rFPV	O
+-	O
+S1	O
+/	O
+IL18	B-PRGE
+.	O
+
+Expression	B-PROC
+of	O
+the	O
+recombinant	O
+proteins	B-CHED
+was	O
+confirmed	O
+by	O
+RT	O
+-	O
+PCR	O
+and	O
+IFA	O
+.	O
+
+ABSTRACT	O
+:	O
+Small	O
+interfering	O
+RNA	O
+(	O
+siRNA	O
+)	O
+is	O
+a	O
+class	B-SPEC
+of	O
+duplex	O
+RNA	O
+molecules	O
+of	O
+21	O
+-	O
+25	O
+nt	O
+nucleotides	B-CHED
+in	O
+length	O
+functioning	O
+post	O
+-	O
+transcriptionally	O
+to	O
+downregulate	O
+targeted	B-PROC
+gene	B-PROC
+expression	I-PROC
+.	O
+
+Real	O
+time	O
+quantitative	O
+RT	O
+-	O
+PCR	O
+(	O
+qRT	O
+-	O
+PCR	O
+)	O
+revealed	O
+that	O
+siRNA	O
+targeting	B-PROC
+the	O
+3	O
+'	O
+half	O
+of	O
+the	O
+M	B-PRGE
+gene	I-PRGE
+(	O
+si	O
+-	O
+M2	O
+)	O
+induced	O
+more	O
+potent	O
+inhibition	B-PROC
+than	O
+that	O
+targeting	B-PROC
+the	O
+5	O
+'	O
+half	O
+(	O
+si	O
+-	O
+M1	O
+).	O
+
+TITLE	O
+:	O
+Immunogenicity	O
+of	O
+the	O
+spike	O
+glycoprotein	B-CHED
+of	O
+bat	B-ENZY
+SARS	B-DISO
+-	O
+like	O
+coronavirus	B-SPEC
+.	O
+
+Our	O
+results	O
+showed	O
+that	O
+immunized	O
+mice	B-SPEC
+generated	O
+strong	O
+humoral	B-PROC
+immune	I-PROC
+responses	I-PROC
+against	O
+the	O
+SL	B-PRGE
+-	I-PRGE
+CoV	I-PRGE
+S	I-PRGE
+protein	I-PRGE
+.	O
+
+The	O
+mTNFR1shRNA	O
+plasmid	O
+significantly	O
+reduced	O
+mTNFR1	O
+expression	B-PROC
+in	O
+vivo	O
+,	O
+markedly	O
+ameliorates	O
+inflammatory	B-DISO
+infiltration	I-DISO
+,	O
+prolonged	O
+the	O
+survival	O
+time	O
+period	O
+and	O
+elevated	O
+the	O
+survival	O
+rate	O
+from	O
+0	O
+up	O
+to	O
+13	O
+.	O
+3	O
+%	O
+in	O
+Balb	O
+/	O
+cJ	O
+mice	B-SPEC
+with	O
+MHV	B-SPEC
+-	O
+3	O
+induced	O
+fulminant	B-DISO
+hepatitis	I-DISO
+.	O
+
+The	O
+disease	O
+continued	O
+to	O
+progress	O
+for	O
+2	O
+-	O
+3	O
+days	O
+and	O
+X	O
+-	O
+ray	B-SPEC
+showed	O
+that	O
+all	O
+29	O
+patients	O
+had	O
+increased	O
+solid	O
+lesions	O
+with	O
+the	O
+existence	O
+of	O
+interstitial	B-ANAT
+lesions	O
+.	O
+
+ABSTRACT	O
+:	O
+We	O
+report	O
+the	O
+first	O
+documented	O
+case	O
+of	O
+morbillivirus	O
+infection	O
+in	O
+a	O
+wild	O
+,	O
+free	O
+-	O
+ranging	O
+Siberian	O
+tiger	B-SPEC
+(	O
+Panthera	B-SPEC
+tigris	I-SPEC
+altaica	I-SPEC
+).	O
+
+Her	O
+condition	B-DISO
+progressed	O
+rapidly	O
+with	O
+neurological	O
+signs	O
+,	O
+anorexia	B-DISO
+,	O
+and	O
+ultimately	O
+death	B-PROC
+.	O
+
+The	O
+animal	B-SPEC
+also	O
+was	O
+antibody	B-COMP
+-	O
+positive	O
+for	O
+canine	B-SPEC
+distemper	I-SPEC
+virus	I-SPEC
+,	O
+feline	B-DISO
+panleukopenia	I-DISO
+,	O
+and	O
+feline	B-SPEC
+coronavirus	B-SPEC
+.	O
+
+The	O
+pandemic	O
+was	O
+caused	O
+by	O
+an	O
+H1N1	O
+virus	B-SPEC
+that	O
+represents	O
+a	O
+quadruple	O
+reassortment	O
+of	O
+2	O
+swine	B-SPEC
+strains	O
+,	O
+1	O
+human	B-SPEC
+strain	O
+,	O
+and	O
+1	O
+avian	B-SPEC
+strain	O
+of	O
+influenza	B-DISO
+.	O
+
+Until	O
+February	O
+1	O
+,	O
+2010	O
+,	O
+a	O
+total	O
+of	O
+47	O
+cases	O
+of	O
+influenza	B-PATH
+A	I-PATH
+(	O
+Inf	O
+A	O
+)	O
+were	O
+recorded	O
+by	O
+the	O
+Spanish	O
+Society	O
+of	O
+Nephrology	O
+in	O
+kidney	B-ANAT
+transplant	I-ANAT
+recipients	O
+.	O
+
+In	O
+these	O
+cases	O
+we	O
+determined	O
+H1N1	O
+Inf	O
+A	O
+pandemic	O
+variant	O
+by	O
+detection	O
+of	O
+Inf	B-PRGE
+A	I-PRGE
+Matrix	I-PRGE
+Protein	I-PRGE
+2	I-PRGE
+gene	I-PRGE
+M2	I-PRGE
+and	O
+the	O
+specific	O
+H1	B-PRGE
+gene	I-PRGE
+for	O
+influenza	B-DISO
+pandemic	O
+H1N1	O
+2009	O
+with	O
+reverse	B-PRGE
+transcriptase	I-PRGE
+polymerase	I-PRGE
+chain	I-PRGE
+reaction	I-PRGE
+Inf	I-PRGE
+A	O
+/	O
+H1N1	O
+(	O
+Roche	O
+).	O
+
+Antimalarial	B-CHED
+treatment	O
+was	O
+continued	O
+for	O
+a	O
+total	O
+of	O
+7	O
+days	O
+followed	O
+by	O
+primaquine	B-CHED
+for	O
+14	O
+days	O
+once	O
+the	O
+blood	B-ANAT
+smear	O
+results	O
+revealed	O
+Plasmodium	B-SPEC
+ovale	I-SPEC
+infection	I-DISO
+.	O
+
+At	O
+the	O
+same	O
+time	O
+,	O
+virus	B-DISO
+infection	I-DISO
+models	O
+provide	O
+a	O
+unique	O
+platform	O
+for	O
+studying	O
+the	O
+biology	O
+and	O
+regulation	B-PROC
+of	O
+ncRNAs	O
+.	O
+
+ABSTRACT	O
+:	O
+Permissive	O
+hypoxemia	O
+is	O
+a	O
+lung	O
+-	O
+protective	O
+strategy	O
+that	O
+aims	O
+to	O
+provide	O
+a	O
+patient	O
+with	O
+severe	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+(	O
+ARDS	B-DISO
+)	O
+a	O
+level	O
+of	O
+oxygen	B-CHED
+delivery	O
+that	O
+is	O
+adequate	O
+to	O
+avoid	O
+tissue	B-ANAT
+hypoxia	B-DISO
+while	O
+minimizing	O
+the	O
+detrimental	O
+effects	O
+of	O
+the	O
+often	O
+toxic	O
+ventilatory	O
+support	O
+required	O
+to	O
+maintain	O
+normal	O
+arterial	B-ANAT
+oxygenation	B-PROC
+.	O
+
+Although	O
+it	O
+has	O
+not	O
+yet	O
+been	O
+studied	O
+,	O
+this	O
+approach	O
+is	O
+theorized	O
+to	O
+improve	O
+clinical	O
+outcomes	O
+of	O
+critically	O
+ill	O
+patients	O
+with	O
+severe	O
+ARDS	B-DISO
+.	O
+
+Eleven	O
+of	O
+the	O
+15	O
+patients	O
+had	O
+increased	O
+serum	B-COMP
+lactate	B-PRGE
+dehydrogenase	I-PRGE
+levels	O
+,	O
+which	O
+were	O
+above	O
+245	O
+U	O
+/	O
+L	O
+.	O
+Three	O
+patients	O
+had	O
+elevated	O
+creatine	B-PRGE
+kinase	I-PRGE
+levels	O
+at	O
+admission	O
+.	O
+
+Findings	O
+on	O
+chest	B-ANAT
+radiographs	O
+were	O
+consistent	O
+with	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+in	O
+all	O
+patients	O
+requiring	O
+mechanical	O
+ventilation	O
+.	O
+
+The	O
+superior	O
+protection	O
+for	O
+the	O
+aged	O
+observed	O
+with	O
+VRP	O
+(	O
+3000	O
+)-	O
+based	O
+vaccines	O
+was	O
+confirmed	O
+in	O
+a	O
+lethal	O
+influenza	B-SPEC
+virus	I-SPEC
+challenge	O
+model	O
+.	O
+
+Exploration	O
+into	O
+the	O
+mechanism	O
+(	O
+s	O
+)	O
+of	O
+successful	O
+vaccination	O
+in	O
+the	O
+immunosenescent	O
+should	O
+aid	O
+in	O
+the	O
+development	B-PROC
+of	O
+successful	O
+vaccine	O
+strategies	O
+for	O
+other	O
+viral	B-DISO
+diseases	I-DISO
+disproportionately	O
+affecting	O
+the	O
+elderly	O
+,	O
+like	O
+West	B-DISO
+Nile	I-DISO
+virus	I-DISO
+,	O
+influenza	B-SPEC
+virus	I-SPEC
+,	O
+norovirus	B-SPEC
+,	O
+or	O
+other	O
+emerging	O
+viruses	B-SPEC
+of	O
+the	O
+future	O
+.	O
+
+Influenza	B-PATH
+A	I-PATH
+,	O
+B	O
+and	O
+coronavirus	B-SPEC
+antibody	B-COMP
+titers	O
+were	O
+measured	O
+in	O
+257	O
+subjects	O
+with	O
+recurrent	O
+unipolar	O
+and	O
+bipolar	B-DISO
+disorder	I-DISO
+and	O
+healthy	O
+controls	O
+,	O
+by	O
+SCID	B-DISO
+.	O
+
+ACoRN	O
+Respiratory	O
+Score	O
+was	O
+correlated	O
+with	O
+Score	O
+for	O
+Neonatal	O
+Acute	O
+Physiology	O
+-	O
+Version	O
+II	O
+(	O
+SNAP	B-PRGE
+-	I-PRGE
+II	I-PRGE
+)	O
+(	O
+P	O
+<	O
+0	O
+.	O
+01	O
+).	O
+
+The	O
+main	O
+cause	O
+of	O
+death	B-PROC
+is	O
+severe	O
+infection	B-DISO
+complicating	O
+of	O
+MOSF	O
+and	O
+most	O
+patients	O
+require	O
+prolonged	O
+mechanical	O
+ventilation	O
+.	O
+
+RESULTS	O
+:	O
+(	O
+1	O
+)	O
+The	O
+125	O
+cases	O
+included	O
+94	O
+male	O
+and	O
+31	O
+female	O
+infants	O
+,	O
+vaginal	B-ANAT
+delivery	O
+occurred	O
+in	O
+80	O
+cases	O
+and	O
+cesarean	O
+section	O
+in	O
+45	O
+cases	O
+.	O
+
+ABSTRACT	O
+:	O
+Infection	B-DISO
+of	O
+mouse	B-SPEC
+oligodendrocytes	B-ANAT
+with	O
+a	O
+recombinant	O
+mouse	B-DISO
+hepatitis	I-DISO
+virus	B-SPEC
+(	O
+MHV	B-SPEC
+)	O
+expressing	O
+a	O
+green	B-PRGE
+fluorescence	I-PRGE
+protein	I-PRGE
+facilitated	O
+specific	O
+selection	O
+of	O
+virus	B-SPEC
+-	O
+infected	O
+cells	B-COMP
+and	O
+subsequent	O
+establishment	O
+of	O
+persistence	O
+.	O
+
+TITLE	O
+:	O
+SARS	B-DISO
+coronavirus	B-SPEC
+8b	O
+reduces	O
+viral	B-PROC
+replication	I-PROC
+by	O
+down	O
+-	O
+regulating	O
+E	O
+via	O
+an	O
+ubiquitin	B-PROC
+-	O
+independent	O
+proteasome	O
+pathway	O
+.	O
+
+By	O
+using	O
+Vero	O
+E6	O
+cells	B-COMP
+stably	O
+expressing	O
+green	B-PRGE
+fluorescence	I-PRGE
+protein	I-PRGE
+-	O
+tagged	O
+8b	O
+,	O
+ectopic	B-PROC
+expression	I-PROC
+of	O
+8b	O
+was	O
+shown	O
+to	O
+significantly	O
+reduce	O
+the	O
+production	O
+of	O
+progeny	O
+virus	B-SPEC
+and	O
+down	O
+-	O
+regulate	O
+E	O
+expression	B-PROC
+.	O
+
+Of	O
+the	O
+study	O
+patients	O
+,	O
+878	O
+(	O
+42	O
+.	O
+3	O
+%)	O
+had	O
+elevated	O
+cTnT	O
+and	O
+1200	O
+patients	O
+(	O
+57	O
+.	O
+7	O
+%)	O
+had	O
+undetectable	O
+cTnT	O
+.	O
+During	O
+hospitalization	O
+,	O
+1	O
+.	O
+1	O
+%	O
+of	O
+the	O
+patients	O
+with	O
+troponin	O
+T	O
+<	O
+0	O
+.	O
+01	O
+ng	O
+/	O
+mL	O
+died	O
+compared	O
+to	O
+21	O
+%	O
+of	O
+those	O
+with	O
+troponin	B-PRGE
+T	I-PRGE
+≥	O
+0	O
+.	O
+01	O
+ng	O
+/	O
+mL	O
+(	O
+P	O
+<.	O
+0001	O
+).	O
+
+TITLE	O
+:	O
+Antiviral	B-CHED
+activities	O
+of	O
+ISG20	B-PRGE
+in	O
+positive	O
+-	O
+strand	O
+RNA	B-DISO
+virus	I-DISO
+infections	I-DISO
+.	O
+
+ABSTRACT	O
+:	O
+ISG20	B-PRGE
+is	O
+an	O
+interferon	O
+-	O
+inducible	O
+3	O
+'-	O
+5	O
+'	O
+exonuclease	O
+that	O
+inhibits	O
+replication	O
+of	O
+several	O
+human	B-SPEC
+and	O
+animal	B-SPEC
+RNA	O
+viruses	B-SPEC
+.	O
+
+Therefore	O
+,	O
+antiviral	B-CHED
+effects	O
+may	O
+contribute	O
+to	O
+the	O
+beneficial	O
+effects	O
+exerted	B-PROC
+by	O
+EPs	O
+®	O
+7630	O
+in	O
+acute	B-DISO
+bronchitis	I-DISO
+patients	O
+.	O
+
+TITLE	O
+:	O
+Clinical	O
+features	O
+of	O
+children	O
+hospitalized	O
+with	O
+malaria	B-PATH
+--	O
+a	O
+study	O
+from	O
+Bikaner	O
+,	O
+northwest	O
+India	O
+.	O
+
+This	O
+prospective	O
+study	O
+was	O
+done	O
+on	O
+303	O
+admitted	O
+children	O
+of	O
+malaria	B-PATH
+.	O
+
+Severe	O
+disease	O
+was	O
+present	O
+in	O
+49	O
+.	O
+5	O
+%	O
+(	O
+150	O
+/	O
+303	O
+)	O
+children	O
+with	O
+malaria	B-PATH
+,	O
+with	O
+the	O
+risk	O
+greatest	O
+among	O
+P	B-SPEC
+.	I-SPEC
+vivax	I-SPEC
+monoinfection	O
+(	O
+63	O
+.	O
+1	O
+%	O
+[	O
+65	O
+/	O
+103	O
+])	O
+compared	O
+with	O
+P	B-SPEC
+.	I-SPEC
+falciparum	I-SPEC
+,	O
+either	O
+alone	O
+(	O
+42	O
+.	O
+7	O
+%	O
+[	O
+79	O
+/	O
+185	O
+];	O
+odds	O
+ratio	O
+[	O
+OR	O
+]	O
+=	O
+2	O
+.	O
+3	O
+[	O
+95	O
+%	O
+confidence	O
+interval	O
+(	O
+CI	O
+)	O
+=	O
+1	O
+.	O
+40	O
+-	O
+3	O
+.	O
+76	O
+],	O
+P	O
+=	O
+0	O
+.	O
+001	O
+)	O
+or	O
+mixed	B-DISO
+infections	I-DISO
+(	O
+40	O
+%	O
+[	O
+6	O
+/	O
+15	O
+];	O
+OR	O
+=	O
+2	O
+.	O
+57	O
+[	O
+95	O
+%	O
+CI	O
+=	O
+0	O
+.	O
+88	O
+-	O
+7	O
+.	O
+48	O
+]).	O
+
+Two	O
+international	O
+infection	B-DISO
+control	O
+teams	O
+responsible	O
+for	O
+healthcare	O
+worker	O
+safety	O
+during	O
+the	O
+Severe	O
+Acute	O
+Respiratory	O
+Syndrome	O
+outbreak	O
+reviewed	O
+the	O
+evidence	O
+-	O
+based	O
+algorithms	O
+.	O
+
+Despite	O
+strong	O
+evidence	O
+for	O
+vaccination	O
+and	O
+antiviral	B-CHED
+prophylaxis	O
+providing	O
+significant	O
+protection	O
+,	O
+clinicians	O
+believed	O
+they	O
+required	O
+the	O
+additional	O
+combinations	O
+of	O
+both	O
+masks	O
+and	O
+face	B-DISO
+shields	O
+.	O
+
+ALI	O
+/	O
+ARDS	B-DISO
+are	O
+characterized	O
+by	O
+lung	B-DISO
+edema	I-DISO
+due	O
+to	O
+increased	O
+permeability	O
+of	O
+the	O
+alveolar	B-ANAT
+-	O
+capillary	B-ANAT
+barrier	O
+and	O
+subsequent	O
+impairment	B-DISO
+of	O
+arterial	B-ANAT
+oxygenation	B-PROC
+.	O
+
+ABSTRACT	O
+:	O
+The	O
+spike	O
+(	O
+S	O
+)	O
+protein	B-CHED
+of	O
+SARS	B-PRGE
+-	I-PRGE
+CoV	I-PRGE
+not	O
+only	O
+mediates	O
+receptor	O
+-	O
+binding	B-FUNC
+but	O
+also	O
+induces	O
+neutralizing	O
+antibodies	B-COMP
+.	O
+
+Furthermore	O
+,	O
+affinity	O
+purified	O
+anti	O
+-	O
+RBD	O
+antibodies	B-COMP
+possessed	B-DISO
+robust	O
+neutralizing	O
+activity	O
+.	O
+
+Our	O
+data	O
+suggested	O
+that	O
+HeLa	O
+cell	B-ANAT
+extracts	I-ANAT
+and	O
+cultured	O
+host	B-COMP
+cells	B-COMP
+,	O
+but	O
+not	O
+RRL	O
+,	O
+contain	O
+a	O
+host	B-COMP
+factor	O
+(	O
+s	O
+)	O
+that	O
+is	O
+essential	O
+for	O
+TGEV	B-PRGE
+nsp1	I-PRGE
+-	O
+induced	O
+translational	B-PROC
+suppression	B-DISO
+.	O
+
+TITLE	O
+:	O
+The	O
+hydrophobic	O
+domain	O
+of	O
+infectious	B-DISO
+bronchitis	B-PRGE
+virus	B-SPEC
+E	I-PRGE
+protein	B-CHED
+alters	O
+the	O
+host	B-COMP
+secretory	B-PROC
+pathway	I-PROC
+and	O
+is	O
+important	O
+for	O
+release	O
+of	O
+infectious	B-DISO
+virus	B-SPEC
+.	O
+
+The	O
+E	B-PRGE
+protein	I-PRGE
+is	O
+made	O
+in	O
+excess	O
+during	O
+infection	B-DISO
+and	O
+has	O
+been	O
+shown	O
+to	O
+have	O
+ion	B-FUNC
+channel	I-FUNC
+activity	I-FUNC
+in	O
+planar	O
+lipid	B-ANAT
+bilayers	I-ANAT
+.	O
+
+However	O
+,	O
+a	O
+role	O
+in	O
+infection	B-DISO
+for	O
+the	O
+unincorporated	O
+E	O
+or	O
+its	O
+ion	B-FUNC
+channel	I-FUNC
+activity	I-FUNC
+has	O
+not	O
+been	O
+described	O
+.	O
+
+The	O
+phenotype	O
+of	O
+IBV	B-SPEC
+-	O
+EG3	O
+suggested	O
+that	O
+the	O
+hydrophobic	O
+domain	O
+of	O
+IBV	B-SPEC
+E	O
+may	O
+be	O
+important	O
+for	O
+the	O
+forward	O
+trafficking	B-PROC
+of	O
+cargo	O
+,	O
+so	O
+we	O
+determined	O
+whether	O
+IBV	B-SPEC
+E	O
+facilitated	O
+the	O
+delivery	O
+of	O
+cargo	O
+to	O
+the	O
+plasma	B-COMP
+membrane	I-COMP
+.	O
+
+The	O
+ResPlex	O
+II	O
+additionally	O
+detects	O
+coronavirus	B-SPEC
+(	O
+229E	O
+,	O
+OC43	O
+,	O
+NL63	O
+,	O
+HKU1	O
+),	O
+coxsackie	O
+/	O
+echo	B-SPEC
+virus	B-SPEC
+,	O
+bocavirus	B-SPEC
+and	O
+differentiates	O
+adenoviruses	B-SPEC
+(	O
+B	O
+,	O
+E	O
+).	O
+
+While	O
+the	O
+ResPlex	O
+II	O
+and	O
+MultiCode	O
+-	O
+PLx	O
+offer	O
+a	O
+broader	O
+virus	B-SPEC
+detection	O
+range	O
+and	O
+greater	O
+ease	O
+of	O
+use	O
+,	O
+the	O
+xTAG	O
+PRV	B-DISO
+showed	O
+increased	O
+sensitivity	O
+to	O
+common	O
+viral	O
+targets	O
+represented	O
+in	O
+the	O
+assays	O
+,	O
+and	O
+also	O
+had	O
+the	O
+ability	O
+to	O
+differentiate	O
+human	B-SPEC
+from	O
+non	O
+-	O
+human	B-DISO
+influenza	B-PATH
+A	I-PATH
+H1	O
+.	O
+
+The	O
+clinical	O
+manifestations	O
+,	O
+radiologic	O
+features	O
+,	O
+reasons	O
+of	O
+misdiagnosis	O
+,	O
+experiences	O
+in	O
+treatment	O
+and	O
+prognosis	O
+of	O
+4	O
+children	O
+with	O
+lymphoma	B-DISO
+complicated	O
+with	O
+pneumonia	B-DISO
+due	O
+to	O
+novel	O
+influenza	B-PATH
+A	I-PATH
+(	O
+H1N1	O
+)	O
+virus	B-SPEC
+during	O
+chemotherapy	O
+were	O
+analyzed	O
+retrospectively	O
+.	O
+
+Two	O
+of	O
+them	O
+developed	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+(	O
+ARDS	B-DISO
+).	O
+
+All	O
+the	O
+4	O
+patients	O
+were	O
+treated	O
+with	O
+oseltamivir	B-CHED
+phosphate	I-CHED
+.	O
+
+Methylprednisolone	B-CHED
+was	O
+used	O
+in	O
+3	O
+patients	O
+.	O
+
+The	O
+patients	O
+might	O
+be	O
+easily	O
+misdiagnosed	O
+as	O
+sepsis	B-DISO
+at	O
+early	O
+stage	O
+.	O
+
+During	O
+H1N1	O
+prevalent	O
+season	O
+when	O
+high	O
+fever	B-PROC
+occurred	O
+,	O
+H1N1	O
+infection	B-DISO
+should	O
+be	O
+considered	O
+.	O
+
+Early	O
+detection	O
+of	O
+the	O
+virus	B-SPEC
+and	O
+use	O
+of	O
+oseltamivir	B-CHED
+phosphate	I-CHED
+and	O
+high	O
+-	O
+dose	O
+IVIG	O
+and	O
+methylprednisolone	B-CHED
+might	O
+reduce	O
+the	O
+mortality	O
+.	O
+
+TITLE	O
+:	O
+Coronavirus	B-SPEC
+causes	O
+lower	B-DISO
+respiratory	I-DISO
+tract	I-DISO
+infections	I-DISO
+less	O
+frequently	O
+than	O
+RSV	B-SPEC
+in	O
+hospitalized	O
+Norwegian	O
+children	O
+.	O
+
+Coronavirus	B-SPEC
+was	O
+found	O
+in	O
+68	O
+(	O
+12	O
+.	O
+7	O
+%):	O
+HCoV	B-SPEC
+-	I-SPEC
+OC43	I-SPEC
+,	O
+n	O
+=	O
+44	O
+(	O
+8	O
+.	O
+2	O
+%),	O
+and	O
+HCoV	B-SPEC
+-	I-SPEC
+NL63	I-SPEC
+,	O
+n	O
+=	O
+24	O
+(	O
+4	O
+.	O
+5	O
+%).	O
+
+HCoV	B-SPEC
+-	I-SPEC
+OC43	I-SPEC
+and	O
+HCoV	B-SPEC
+-	I-SPEC
+NL63	I-SPEC
+are	O
+common	O
+among	O
+hospitalized	O
+Norwegian	O
+children	O
+with	O
+RTI	B-DISO
+.	O
+
+Children	O
+with	O
+HCoV	B-SPEC
+-	I-SPEC
+OC43	I-SPEC
+and	O
+HCoV	B-SPEC
+-	I-SPEC
+NL63	I-SPEC
+have	O
+LRTI	B-DISO
+less	O
+frequently	O
+and	O
+may	O
+need	O
+a	O
+shorter	O
+hospital	O
+stay	O
+than	O
+children	O
+with	O
+RSV	B-SPEC
+.	O
+
+After	O
+adjusting	O
+for	O
+age	O
+,	O
+chronic	B-DISO
+disease	I-DISO
+,	O
+LRTI	B-DISO
+,	O
+and	O
+co	O
+-	O
+detection	O
+of	O
+other	O
+viruses	B-SPEC
+in	O
+a	O
+multiple	O
+logistic	O
+regression	O
+analysis	O
+,	O
+HCoV	O
+was	O
+associated	O
+with	O
+a	O
+shorter	O
+fever	B-PROC
+period	O
+and	O
+shorter	O
+hospitalization	O
+time	O
+than	O
+RSV	B-SPEC
+.	O
+
+RESULTS	O
+:	O
+In	O
+the	O
+nvA	B-CHED
+(	O
+H1N1	O
+)-	O
+ARDS	B-DISO
+group	O
+,	O
+obesity	B-DISO
+and	O
+lymphocytopenia	B-DISO
+were	O
+more	O
+common	O
+and	O
+IP	B-PRGE
+-	I-PRGE
+10	I-PRGE
+,	O
+interleukin	B-PRGE
+(	O
+IL	O
+)-	O
+12	O
+,	O
+IL	B-FUNC
+-	I-FUNC
+15	I-FUNC
+,	O
+tumor	B-FUNC
+necrosis	I-FUNC
+factor	I-FUNC
+(	O
+TNF	O
+)	O
+α	O
+,	O
+IL	B-FUNC
+-	I-FUNC
+6	I-FUNC
+,	O
+IL	B-FUNC
+-	I-FUNC
+8	I-FUNC
+and	O
+IL	B-FUNC
+-	I-FUNC
+9	I-FUNC
+were	O
+significantly	O
+increased	O
+versus	O
+control	O
+.	O
+
+Perceived	O
+sufficiency	O
+of	O
+information	O
+about	O
+several	O
+aspects	O
+of	O
+the	O
+A	O
+/	O
+H1N1	B-DISO
+influenza	I-DISO
+was	O
+moderately	O
+high	O
+,	O
+and	O
+the	O
+overall	O
+information	O
+about	O
+the	O
+A	O
+/	O
+H1N1	B-DISO
+influenza	I-DISO
+was	O
+considered	O
+clear	O
+(	O
+median	O
+7	O
+.	O
+4	O
+/	O
+9	O
+).	O
+
+Also	O
+,	O
+perceived	O
+sufficiency	O
+of	O
+information	O
+for	O
+the	O
+prognosis	O
+of	O
+the	O
+infection	B-DISO
+was	O
+significantly	O
+independently	O
+associated	O
+with	O
+the	O
+degree	O
+of	O
+worry	O
+about	O
+the	O
+pandemic	O
+(	O
+p	O
+=	O
+0	O
+.	O
+008	O
+).	O
+
+ABSTRACT	O
+:	O
+Severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+(	O
+SARS	O
+)	O
+caused	O
+thousands	O
+of	O
+human	B-SPEC
+infections	B-DISO
+worldwide	O
+and	O
+hundreds	O
+of	O
+deaths	B-PROC
+in	O
+just	O
+a	O
+few	O
+months	O
+.	O
+
+This	O
+possibility	O
+has	O
+focused	O
+continuous	O
+action	O
+on	O
+SARS	B-DISO
+vaccine	O
+research	O
+.	O
+
+Inactivated	O
+vaccines	O
+,	O
+viral	O
+and	O
+bacterial	O
+vector	O
+vaccines	O
+,	O
+recombinant	O
+protein	B-CHED
+vaccines	O
+,	O
+subunit	O
+vaccines	O
+,	O
+DNA	O
+vaccines	O
+,	O
+and	O
+live	O
+-	O
+attenuated	O
+virus	B-SPEC
+vaccines	O
+have	O
+been	O
+studied	O
+in	O
+different	O
+animal	B-SPEC
+models	O
+.	O
+
+Moreover	O
+,	O
+potential	O
+vaccine	O
+enhancement	O
+of	O
+SARS	B-DISO
+have	O
+also	O
+been	O
+shown	O
+in	O
+some	O
+studies	O
+.	O
+
+The	O
+primary	O
+receptor	O
+for	O
+the	O
+human	B-SPEC
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+CoV	O
+(	O
+SARS	B-DISO
+)	O
+CoV	O
+is	O
+angiotensin	B-PRGE
+-	I-PRGE
+converting	I-PRGE
+enzyme	I-PRGE
+2	I-PRGE
+(	O
+ACE2	B-PRGE
+).	O
+
+ACE2	B-PRGE
+immunoprecipitation	O
+captured	O
+transmembrane	B-COMP
+protease	O
+/	O
+serine	B-CHED
+subfamily	B-SPEC
+member	O
+2	O
+(	O
+TMPRSS2	B-PRGE
+),	O
+a	O
+known	O
+human	B-SPEC
+airway	B-ANAT
+and	O
+alveolar	B-ANAT
+protease	O
+.	O
+
+ACE2	B-PRGE
+and	O
+TMPRSS2	B-PRGE
+colocalized	O
+on	O
+cell	B-COMP
+surfaces	O
+and	O
+enhanced	O
+the	O
+cell	B-COMP
+entry	O
+of	O
+both	O
+SARS	B-DISO
+S	O
+-	O
+pseudotyped	O
+HIV	B-DISO
+and	O
+authentic	O
+SARS	B-DISO
+-	O
+CoV	O
+.	O
+Enhanced	O
+entry	O
+correlated	O
+with	O
+TMPRSS2	O
+-	O
+mediated	O
+proteolysis	O
+of	O
+both	O
+S	O
+and	O
+ACE2	O
+.	O
+
+These	O
+findings	O
+indicate	O
+that	O
+a	O
+cell	B-COMP
+surface	I-COMP
+complex	O
+comprising	O
+a	O
+primary	O
+receptor	O
+and	O
+a	O
+separate	O
+endoprotease	O
+operates	O
+as	O
+a	O
+portal	B-ANAT
+for	O
+activation	O
+of	O
+SARS	B-DISO
+-	O
+CoV	O
+cell	B-COMP
+entry	O
+.	O
+
+TITLE	O
+:	O
+Erythropoetin	O
+as	O
+a	O
+novel	O
+agent	O
+with	O
+pleiotropic	O
+effects	O
+against	O
+acute	O
+lung	B-ANAT
+injury	O
+.	O
+
+Taken	O
+together	O
+,	O
+this	O
+treatment	O
+strategy	O
+is	O
+not	O
+a	O
+single	O
+mediator	O
+approach	O
+,	O
+but	O
+it	O
+rather	O
+provides	O
+protection	O
+by	O
+modulating	O
+multiple	O
+levels	O
+of	O
+early	O
+signaling	B-PROC
+pathways	B-PROC
+involved	O
+in	O
+apoptosis	B-PATH
+,	O
+inflammation	B-DISO
+,	O
+and	O
+peroxidation	O
+,	O
+potentially	O
+restoring	O
+overall	O
+homeostasis	B-PROC
+.	O
+
+Levofloxacin	B-CHED
+treatment	O
+caused	O
+the	O
+occurrence	O
+of	O
+acute	O
+eosinophilic	O
+infiltrate	B-DISO
+.	O
+
+Local	O
+and	O
+systemic	O
+inflammatory	B-DISO
+responses	I-DISO
+were	O
+assessed	O
+by	O
+measuring	O
+cytokines	O
+in	O
+the	O
+lung	B-ANAT
+and	O
+plasma	B-ANAT
+.	O
+
+TITLE	O
+:	O
+Murine	B-SPEC
+coronavirus	I-SPEC
+neuropathogenesis	B-DISO
+:	O
+determinants	O
+of	O
+virulence	B-PROC
+.	O
+
+In	O
+addition	O
+,	O
+JHM	O
+.	O
+SD	O
+induces	O
+only	O
+a	O
+minimal	O
+T	B-ANAT
+-	I-ANAT
+cell	I-ANAT
+response	O
+,	O
+whereas	O
+the	O
+strong	O
+T	B-ANAT
+-	I-ANAT
+cell	I-ANAT
+response	O
+and	O
+the	O
+concomitant	O
+interferon	B-PRGE
+-	I-PRGE
+γ	I-PRGE
+(	O
+IFN	B-PRGE
+-	I-PRGE
+γ	I-PRGE
+)	O
+induced	O
+by	O
+the	O
+less	O
+neurovirulent	O
+A59	O
+is	O
+protective	O
+.	O
+
+NATs	O
+provide	O
+fast	B-FUNC
+,	O
+accurate	O
+and	O
+sensitive	O
+detection	O
+of	O
+respiratory	O
+viruses	B-SPEC
+and	O
+have	O
+significantly	O
+increased	O
+our	O
+understanding	O
+of	O
+the	O
+epidemiology	O
+of	O
+these	O
+viruses	B-SPEC
+.	O
+
+TITLE	O
+:	O
+Advances	O
+in	O
+perioperative	O
+pain	O
+management	O
+:	O
+use	O
+of	O
+medications	O
+with	O
+dual	O
+analgesic	B-CHED
+mechanisms	O
+,	O
+tramadol	O
+&	O
+tapentadol	O
+.	O
+
+The	O
+development	B-PROC
+of	O
+effective	O
+analgesic	B-CHED
+regimens	O
+for	O
+the	O
+management	O
+of	O
+postoperative	B-DISO
+pain	I-DISO
+is	O
+a	O
+priority	O
+especially	O
+in	O
+patients	O
+with	O
+impaired	B-DISO
+cardiorespiratory	O
+,	O
+hepatic	B-ANAT
+,	O
+or	O
+renal	B-PROC
+function	I-PROC
+.	O
+
+In	O
+contrast	O
+to	O
+pure	B-FUNC
+opioid	B-PROC
+agonists	I-PROC
+,	O
+both	O
+drugs	O
+are	O
+believed	O
+to	O
+have	O
+lower	O
+risks	O
+of	O
+respiratory	B-DISO
+depression	I-DISO
+,	O
+tolerance	B-DISO
+,	O
+and	O
+dependence	B-DISO
+.	O
+
+ABSTRACT	O
+:	O
+Human	B-SPEC
+coronaviruses	O
+(	O
+HCoVs	O
+)	O
+are	O
+responsible	O
+for	O
+respiratory	B-DISO
+tract	I-DISO
+infections	I-DISO
+ranging	O
+from	O
+common	B-DISO
+colds	I-DISO
+to	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+.	O
+
+Globally	O
+,	O
+approximately	O
+5	O
+%	O
+of	O
+all	O
+upper	O
+and	O
+lower	B-DISO
+respiratory	I-DISO
+tract	I-DISO
+infections	I-DISO
+in	O
+hospitalized	O
+children	O
+are	O
+caused	O
+by	O
+HCoV	B-SPEC
+-	I-SPEC
+229E	I-SPEC
+and	O
+HCoV	B-SPEC
+-	I-SPEC
+NL63	I-SPEC
+.	O
+
+The	O
+aim	O
+of	O
+this	O
+study	O
+was	O
+to	O
+develop	O
+a	O
+double	O
+-	O
+antibody	B-COMP
+sandwich	O
+enzyme	O
+-	O
+linked	O
+immunosorbent	O
+assay	O
+(	O
+DAS	O
+-	O
+ELISA	O
+)	O
+as	O
+a	O
+potential	O
+tool	O
+for	O
+identification	O
+and	O
+differentiation	O
+between	O
+HCoV	B-SPEC
+-	I-SPEC
+NL63	I-SPEC
+and	O
+HCoV	B-SPEC
+-	I-SPEC
+229E	I-SPEC
+.	O
+
+ABSTRACT	O
+:	O
+Total	O
+liquid	O
+ventilation	O
+(	O
+TLV	O
+)	O
+has	O
+the	O
+potential	O
+to	O
+provide	O
+respiratory	O
+support	O
+superior	O
+to	O
+conventional	O
+mechanical	O
+ventilation	O
+(	O
+CMV	B-SPEC
+)	O
+in	O
+the	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+(	O
+ARDS	B-DISO
+).	O
+
+Ten	O
+sheep	B-SPEC
+weighing	O
+53	O
+±	O
+4	O
+(	O
+SD	O
+)	O
+kg	O
+were	O
+anesthetized	O
+and	O
+ventilated	O
+with	O
+100	O
+%	O
+oxygen	B-CHED
+.	O
+
+Oleic	B-CHED
+acid	I-CHED
+was	O
+injected	O
+into	O
+the	O
+pulmonary	B-PROC
+circulation	B-PROC
+until	O
+PaO2	O
+:	O
+FiO2	O
+≤	O
+60	O
+mm	O
+Hg	O
+,	O
+followed	O
+by	O
+transition	B-DISO
+to	O
+a	O
+protective	O
+CMV	B-SPEC
+protocol	O
+(	O
+n	O
+=	O
+5	O
+)	O
+or	O
+TLV	O
+(	O
+n	O
+=	O
+5	O
+)	O
+for	O
+24	O
+hours	O
+.	O
+
+Differential	O
+methylation	B-PROC
+of	O
+cytoplasmic	B-COMP
+RNA	O
+probably	O
+serves	O
+as	O
+an	O
+example	O
+for	O
+pattern	O
+recognition	O
+and	O
+restriction	O
+of	O
+propagation	O
+of	O
+foreign	O
+viral	O
+RNA	O
+in	O
+host	B-COMP
+cells	B-COMP
+.	O
+
+It	O
+is	O
+caused	O
+due	O
+to	O
+release	B-PATH
+of	O
+nitrogen	B-CHED
+gas	B-ENZY
+bubbles	O
+that	O
+impinge	O
+the	O
+blood	B-ANAT
+vessels	I-ANAT
+of	O
+the	O
+spinal	B-ANAT
+cord	I-ANAT
+and	O
+brain	B-ANAT
+and	O
+result	O
+in	O
+severe	O
+neurodeficit	O
+.	O
+
+Kinetic	O
+determinations	O
+of	O
+the	O
+monomer	O
+dimer	O
+dissociation	B-DISO
+constant	O
+(	O
+K	O
+(	O
+d	O
+))	O
+indicated	O
+that	O
+activation	O
+was	O
+a	O
+result	O
+of	O
+a	O
+more	O
+active	O
+dimer	O
+,	O
+without	O
+significant	O
+changes	O
+in	O
+K	O
+(	O
+d	O
+)	O
+values	O
+.	O
+
+TITLE	O
+:	O
+Preparation	O
+and	O
+characterization	O
+of	O
+polyclonal	O
+antibody	B-COMP
+against	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+-	O
+associated	O
+coronavirus	B-SPEC
+spike	O
+protein	B-CHED
+.	O
+
+The	O
+gene	O
+was	O
+cloned	O
+into	O
+prokaryotic	O
+expression	B-PROC
+vector	O
+pGEX	O
+-	O
+6P	O
+-	O
+1	O
+,	O
+resulting	O
+in	O
+a	O
+recombinant	O
+plasmid	O
+pGEX	O
+-	O
+SARS	B-DISO
+-	O
+S1	O
+.	O
+
+ELISA	O
+indicated	O
+that	O
+the	O
+antibody	B-COMP
+against	O
+SARS	B-PRGE
+-	I-PRGE
+CoV	I-PRGE
+S1	I-PRGE
+protein	B-CHED
+had	O
+no	O
+cross	B-PROC
+reaction	I-PROC
+with	O
+S1	O
+proteins	B-CHED
+of	O
+transmissible	O
+gastroenteritis	B-DISO
+virus	B-SPEC
+,	O
+a	O
+porcine	B-SPEC
+coronavirus	B-SPEC
+,	O
+and	O
+infectious	B-DISO
+bronchitis	B-DISO
+virus	B-SPEC
+,	O
+an	O
+avian	B-SPEC
+coronavirus	I-SPEC
+.	O
+
+During	O
+this	O
+same	O
+period	O
+the	O
+rate	O
+of	O
+postpartum	O
+hospitalisations	O
+with	O
+chronic	B-DISO
+heart	I-DISO
+disease	I-DISO
+tripled	O
+(	O
+P	O
+<	O
+0	O
+.	O
+01	O
+).	O
+
+Severe	O
+complications	O
+during	O
+hospitalisations	O
+for	O
+delivery	O
+among	O
+women	O
+with	O
+chronic	B-DISO
+heart	I-DISO
+disease	I-DISO
+were	O
+more	O
+common	O
+in	O
+2004	O
+-	O
+2006	O
+than	O
+in	O
+1995	O
+-	O
+1997	O
+.	O
+
+Three	O
+kinds	O
+of	O
+protein	B-CHED
+derived	O
+from	O
+the	O
+C	O
+-	O
+terminal	O
+S2	O
+domain	O
+of	O
+S	B-PRGE
+protein	I-PRGE
+of	O
+the	O
+FIPV	O
+KU	O
+-	O
+2	O
+strain	O
+were	O
+developed	O
+using	O
+a	O
+baculovirus	B-SPEC
+expression	B-PROC
+system	O
+.	O
+
+It	O
+isn	B-CHED
+'	O
+t	O
+every	O
+day	O
+that	O
+a	O
+doctor	O
+becomes	O
+a	O
+patient	O
+.	O
+
+When	O
+status	O
+epileptics	B-DISO
+or	O
+prolonged	O
+coma	B-DISO
+manifests	O
+even	O
+in	O
+patients	O
+with	O
+severe	O
+brain	B-DISO
+disorders	I-DISO
+,	O
+we	O
+must	O
+consider	O
+encephalopathy	B-DISO
+in	O
+the	O
+differential	O
+diagnosis	O
+.	O
+
+TITLE	O
+:	O
+[	O
+Construction	O
+of	O
+MHV	B-SPEC
+-	O
+A59	O
+damp	B-CHED
+-	O
+heat	O
+mouse	B-SPEC
+model	O
+and	O
+analysis	O
+of	O
+the	O
+relevant	O
+indices	O
+].	O
+
+The	O
+mouse	B-SPEC
+model	O
+established	O
+using	O
+MHV	B-SPEC
+-	O
+A59	O
+virus	B-SPEC
+and	O
+the	O
+damp	B-CHED
+-	O
+heat	O
+factors	O
+can	O
+mimic	O
+damp	B-CHED
+-	O
+heat	O
+syndrome	B-DISO
+described	O
+in	O
+traditional	O
+Chinese	O
+medicine	B-CHED
+theory	O
+.	O
+
+Compared	O
+with	O
+the	O
+control	O
+group	O
+,	O
+the	O
+model	O
+group	O
+showed	O
+a	O
+significantly	O
+higher	O
+ratio	O
+of	O
+IFN	B-PRGE
+-	I-PRGE
+γ	I-PRGE
+/	I-PRGE
+IL	I-PRGE
+-	I-PRGE
+4	I-PRGE
+.	O
+
+ALI	O
+and	O
+its	O
+severe	O
+form	O
+,	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+(	O
+ARDS	B-DISO
+),	O
+are	O
+responsible	O
+for	O
+significant	O
+morbidity	O
+and	O
+mortality	O
+in	O
+intensive	O
+care	O
+units	O
+,	O
+despite	O
+improvement	O
+in	O
+ventilation	O
+strategies	O
+.	O
+
+All	O
+relevant	O
+meta	B-SPEC
+-	O
+analyses	O
+were	O
+identified	O
+by	O
+a	O
+computerized	O
+search	O
+of	O
+PubMed	O
+using	O
+combinations	O
+of	O
+the	O
+following	O
+terms	O
+:	O
+acute	O
+lung	B-ANAT
+injury	O
+,	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+,	O
+positive	O
+end	B-PROC
+-	I-PROC
+expiratory	I-PROC
+pressure	O
+,	O
+mechanical	O
+ventilation	O
+,	O
+prone	O
+position	O
+,	O
+drotrecogin	O
+,	O
+activated	B-PRGE
+protein	I-PRGE
+C	I-PRGE
+,	O
+sepsis	B-DISO
+,	O
+and	O
+septic	O
+patients	O
+.	O
+
+TITLE	O
+:	O
+Fisher	B-SPEC
+syndrome	I-DISO
+.	O
+
+The	O
+acute	O
+phase	O
+of	O
+Fisher	B-DISO
+syndrome	I-DISO
+should	O
+be	O
+carefully	O
+observed	O
+to	O
+see	O
+if	O
+it	O
+occurs	O
+concomitantly	O
+with	O
+Guillain	O
+-	O
+Barré	O
+syndrome	B-DISO
+or	O
+if	O
+there	O
+is	O
+development	B-PROC
+to	O
+Bickerstaff	B-DISO
+brainstem	I-DISO
+encephalitis	I-DISO
+,	O
+as	O
+these	O
+require	O
+specific	O
+immune	O
+treatments	O
+.	O
+
+Large	O
+retrospective	O
+studies	O
+have	O
+suggested	O
+that	O
+neither	O
+plasmapheresis	O
+nor	O
+IVIg	O
+alters	O
+the	O
+clinical	O
+outcome	O
+of	O
+patients	O
+with	O
+Fisher	B-DISO
+syndrome	I-DISO
+,	O
+probably	O
+because	O
+of	O
+the	O
+good	O
+spontaneous	B-PROC
+recovery	I-PROC
+in	O
+these	O
+patients	O
+.	O
+
+To	O
+evaluate	O
+the	O
+efficacy	O
+of	O
+immunotherapies	O
+used	O
+to	O
+treat	O
+Fisher	B-DISO
+syndrome	I-DISO
+,	O
+large	O
+prospective	O
+studies	O
+are	O
+required	O
+.	O
+
+Prospective	O
+,	O
+observational	O
+,	O
+multicenter	O
+study	O
+from	O
+23	O
+June	O
+2009	O
+through	O
+11	O
+February	O
+2010	O
+,	O
+reported	O
+in	O
+the	O
+European	O
+Society	O
+of	O
+Intensive	O
+Care	O
+Medicine	B-CHED
+(	O
+ESICM	O
+)	O
+H1N1	O
+registry	O
+.	O
+
+Patients	O
+who	O
+received	O
+corticosteroids	B-CHED
+were	O
+significantly	O
+older	O
+and	O
+were	O
+more	O
+likely	O
+to	O
+have	O
+coexisting	O
+asthma	B-PATH
+,	O
+chronic	B-DISO
+obstructive	I-DISO
+pulmonary	I-DISO
+disease	I-DISO
+(	O
+COPD	B-DISO
+),	O
+and	O
+chronic	O
+steroid	B-CHED
+use	O
+.	O
+
+TITLE	O
+:	O
+Detection	O
+and	O
+genetic	O
+characterization	O
+of	O
+canine	O
+parvoviruses	B-SPEC
+and	O
+coronaviruses	O
+in	O
+southern	O
+Ireland	O
+.	O
+
+TITLE	O
+:	O
+[	O
+Intra	B-DISO
+-	I-DISO
+alveolar	I-DISO
+hemorrhage	I-DISO
+:	O
+rare	O
+presentation	O
+of	O
+fat	O
+pulmonary	B-DISO
+embolism	I-DISO
+].	O
+
+Angio	O
+-	O
+CT	O
+-	O
+scan	O
+didn	O
+'	O
+t	O
+show	O
+any	O
+proximal	O
+vascular	B-DISO
+obstruction	I-DISO
+,	O
+but	O
+parenchymal	O
+sections	O
+showed	O
+diffuse	O
+,	O
+bilateral	O
+and	O
+multifocal	O
+hyperdensities	O
+predominating	O
+at	O
+the	O
+periphery	O
+.	O
+
+Broncho	B-ANAT
+-	I-ANAT
+alveolar	I-ANAT
+lavage	O
+brought	O
+a	O
+hemorrhagic	O
+liquid	O
+,	O
+with	O
+a	O
+high	O
+macrophage	B-ANAT
+content	O
+and	O
+lipid	B-CHED
+inclusions	O
+in	O
+macrophages	B-ANAT
+.	O
+
+CONCLUSIONS	O
+:	O
+The	O
+occurrence	O
+of	O
+intra	B-DISO
+-	I-DISO
+alveolar	I-DISO
+hemorrhage	I-DISO
+in	O
+the	O
+course	O
+fat	B-DISO
+embolism	I-DISO
+is	O
+rarely	O
+reported	O
+.	O
+
+Multivariate	O
+logistic	O
+regression	O
+analysis	O
+showed	O
+that	O
+female	O
+gender	O
+as	O
+well	O
+as	O
+the	O
+presence	O
+of	O
+chronic	O
+medical	O
+illnesses	O
+diagnosed	O
+before	O
+the	O
+onset	O
+of	O
+SARS	B-DISO
+and	O
+avascular	B-DISO
+necrosis	I-DISO
+were	O
+independent	O
+predictors	O
+of	O
+PTSD	B-DISO
+at	O
+30	O
+months	O
+post	O
+-	O
+SARS	B-DISO
+.	O
+
+The	O
+study	O
+of	O
+PTSD	B-DISO
+at	O
+30	O
+months	O
+post	O
+-	O
+SARS	B-DISO
+showed	O
+that	O
+the	O
+predictive	O
+value	O
+of	O
+acute	O
+medical	O
+variables	O
+may	O
+fade	O
+out	O
+.	O
+
+On	O
+the	O
+contrary	O
+,	O
+the	O
+adversity	O
+both	O
+before	O
+and	O
+after	O
+the	O
+SARS	B-DISO
+outbreak	O
+may	O
+be	O
+more	O
+important	O
+in	O
+hindering	O
+recovery	O
+from	O
+PTSD	B-DISO
+.	O
+
+RESULTS	O
+:	O
+The	O
+plasma	B-ANAT
+NEP	O
+activity	O
+was	O
+significantly	O
+lower	O
+in	O
+patients	O
+presenting	O
+with	O
+ALI	O
+/	O
+ARDS	B-DISO
+than	O
+in	O
+controls	O
+.	O
+
+With	O
+the	O
+combination	O
+of	O
+target	O
+-	O
+enriched	O
+multiplexing	O
+PCR	O
+amplification	B-DISO
+and	O
+Luminex	O
+suspension	O
+array	O
+identification	O
+,	O
+12	O
+common	O
+respiratory	O
+viruses	B-SPEC
+,	O
+including	O
+RSV	B-SPEC
+A	O
+and	O
+B	O
+,	O
+influenza	B-SPEC
+virus	I-SPEC
+A	O
+and	O
+B	O
+,	O
+parainfluenza	B-DISO
+virus	B-SPEC
+1	O
+,	O
+2	O
+,	O
+3	O
+,	O
+and	O
+4	O
+,	O
+human	B-SPEC
+metapneumovirus	I-SPEC
+,	O
+rhinoviruses	B-SPEC
+,	O
+enteroviruses	B-SPEC
+,	O
+and	O
+SARS	B-DISO
+coronavirus	B-SPEC
+,	O
+are	O
+detected	O
+and	O
+differentiated	B-PROC
+simultaneously	O
+within	O
+five	O
+hours	O
+.	O
+
+Existing	O
+continuous	O
+infusions	O
+of	O
+midazolam	O
+,	O
+opioids	O
+,	O
+and	O
+neuromuscular	O
+blockers	O
+were	O
+continued	O
+during	O
+surgery	O
+and	O
+were	O
+augmented	O
+by	O
+a	O
+variety	O
+of	O
+parenteral	O
+agents	O
+,	O
+including	O
+propofol	B-CHED
+,	O
+fentanyl	B-CHED
+,	O
+and	O
+ketamine	B-CHED
+during	O
+surgery	O
+.	O
+
+Subanalysis	O
+of	O
+the	O
+prone	O
+cases	O
+showed	O
+no	O
+significant	O
+changes	O
+in	O
+the	O
+PaO₂	B-PRGE
+/	O
+FiO₂	O
+ratio	O
+or	O
+oxygenation	B-PROC
+index	O
+but	O
+again	O
+showed	O
+a	O
+significant	O
+but	O
+temporary	O
+increase	O
+in	O
+intraoperative	O
+PaCO₂	O
+.	O
+HFOV	O
+was	O
+aborted	O
+for	O
+conventional	O
+mechanical	O
+ventilation	O
+in	O
+three	O
+cases	O
+due	O
+to	O
+respiratory	O
+deterioration	O
+(	O
+2	O
+cases	O
+)	O
+and	O
+hemodynamic	B-DISO
+instability	I-DISO
+(	O
+1	O
+case	O
+).	O
+
+ABSTRACT	O
+:	O
+Administer	O
+chest	O
+compressions	O
+(	O
+minimum	O
+100	O
+/	O
+min	O
+,	O
+minimum	O
+5	O
+cm	O
+depth	O
+)	O
+at	O
+a	O
+ratio	O
+of	O
+30	O
+:	O
+2	O
+with	O
+ventilation	O
+(	O
+tidal	O
+volume	O
+500	O
+-	O
+600	O
+ml	O
+,	O
+inspiration	B-PROC
+time	O
+1	O
+s	O
+,	O
+F	O
+(	O
+I	O
+)	O
+O₂	O
+if	O
+possible	O
+1	O
+.	O
+0	O
+).	O
+
+If	O
+heart	B-ANAT
+rate	O
+remains	O
+<	O
+60	O
+/	O
+min	O
+,	O
+start	O
+chest	B-ANAT
+compressions	O
+(	O
+120	O
+chest	B-ANAT
+compressions	O
+/	O
+min	O
+)	O
+and	O
+ventilation	O
+with	O
+a	O
+ratio	O
+3	O
+:	O
+1	O
+.	O
+
+ACUTE	B-DISO
+CORONARY	I-DISO
+SYNDROME	I-DISO
+:	O
+Even	O
+if	O
+only	O
+a	O
+weak	O
+suspicion	O
+of	O
+an	O
+acute	B-DISO
+coronary	I-DISO
+syndrome	I-DISO
+is	O
+present	O
+,	O
+record	O
+a	O
+prehospital	O
+12	O
+-	O
+lead	O
+ECG	O
+.	O
+
+In	O
+parallel	O
+to	O
+pain	O
+therapy	O
+,	O
+administer	O
+aspirin	B-CHED
+(	O
+160	O
+-	O
+325	O
+mg	O
+p	O
+.	O
+o	O
+.	O
+
+Aggressive	B-DISO
+fluid	O
+resuscitation	O
+,	O
+hyperventilation	O
+and	O
+excessive	O
+ventilation	O
+pressure	O
+may	O
+impair	O
+outcome	O
+in	O
+patients	O
+with	O
+severe	O
+hemorrhagic	B-DISO
+shock	I-DISO
+.	O
+
+In	O
+addition	O
+,	O
+CD20	B-PRGE
++	I-PRGE
+B	I-PRGE
+-	O
+cell	O
+infiltration	B-DISO
+into	O
+the	O
+fascia	B-ANAT
+was	O
+also	O
+detected	O
+in	O
+all	O
+of	O
+the	O
+cases	O
+,	O
+indicating	O
+further	O
+transition	B-DISO
+to	O
+DM	O
+.	O
+
+The	O
+other	O
+2	O
+cases	O
+also	O
+required	O
+glucocorticoids	B-CHED
+to	O
+achieve	O
+remission	B-DISO
+.	O
+
+The	O
+possibility	O
+of	O
+co	B-DISO
+-	I-DISO
+infection	I-DISO
+especially	O
+with	O
+scrub	B-DISO
+typhus	I-DISO
+must	O
+be	O
+considered	O
+in	O
+cases	O
+with	O
+atypical	O
+presentation	O
+and	O
+severe	O
+illness	O
+.	O
+
+There	O
+was	O
+no	O
+mortality	O
+and	O
+main	O
+complication	B-DISO
+was	O
+Weil	O
+'	O
+s	O
+syndrome	B-DISO
+in	O
+77	O
+percent	O
+.	O
+
+In	O
+this	O
+article	O
+,	O
+reverse	B-PROC
+transcription	I-PROC
+-	O
+loop	O
+-	O
+mediated	O
+isothermal	O
+amplification	B-DISO
+(	O
+RT	O
+-	O
+LAMP	O
+)	O
+was	O
+developed	O
+to	O
+detect	O
+TGEV	B-SPEC
+.	O
+
+In	O
+addition	O
+,	O
+the	O
+established	O
+RT	O
+-	O
+LAMP	O
+differentiated	B-PROC
+TGEV	B-SPEC
+from	O
+porcine	B-SPEC
+epidemic	I-SPEC
+diarrhea	I-SPEC
+virus	I-SPEC
+,	O
+porcine	B-SPEC
+rotavirus	B-SPEC
+,	O
+porcine	B-SPEC
+pseudorabies	B-SPEC
+virus	I-SPEC
+,	O
+porcine	B-SPEC
+reproductive	I-SPEC
+and	I-SPEC
+respiratory	I-SPEC
+syndrome	I-SPEC
+virus	I-SPEC
+,	O
+and	O
+avian	B-DISO
+infectious	I-DISO
+bronchitis	I-DISO
+virus	B-SPEC
+.	O
+
+TITLE	O
+:	O
+Early	O
+opioid	O
+infusion	O
+and	O
+neonatal	O
+outcomes	O
+in	O
+preterm	O
+neonates	O
+≤	O
+28	O
+weeks	O
+'	O
+gestation	B-PROC
+.	O
+
+The	O
+unmodified	O
+peptide	B-CHED
+takes	O
+on	O
+an	O
+orientation	O
+within	O
+lipid	B-ANAT
+bilayers	I-ANAT
+that	O
+is	O
+tilted	O
+approximately	O
+30	O
+°	O
+away	O
+from	O
+an	O
+in	O
+-	O
+plane	O
+position	O
+.	O
+
+Myasthenic	B-DISO
+crisis	I-DISO
+is	O
+characterized	O
+by	O
+respiratory	B-DISO
+failure	I-DISO
+requiring	O
+mechanical	O
+ventilation	O
+.	O
+
+On	O
+admission	O
+,	O
+she	O
+presented	O
+with	O
+severe	O
+mid	O
+-	O
+sternal	O
+chest	B-DISO
+pain	I-DISO
+and	O
+shortness	B-DISO
+of	I-DISO
+breath	I-DISO
+shortly	O
+after	O
+a	O
+personally	O
+significant	O
+stressful	O
+life	O
+event	O
+.	O
+
+CONCLUSIONS	O
+:	O
+This	O
+is	O
+the	O
+first	O
+reported	O
+case	O
+of	O
+the	O
+simultaneous	O
+triggering	O
+of	O
+both	O
+takotsubo	B-DISO
+cardiomyopathy	I-DISO
+and	O
+myasthenic	B-DISO
+crisis	I-DISO
+by	O
+the	O
+physiologic	O
+consequences	O
+of	O
+a	O
+state	O
+of	O
+severe	O
+emotional	B-DISO
+stress	I-DISO
+.	O
+
+The	O
+vanadium	B-CHED
+concentration	O
+was	O
+6	O
+.	O
+22	O
+mg	O
+/	O
+L	O
+,	O
+corresponding	O
+to	O
+6000	O
+times	O
+higher	O
+than	O
+normal	O
+concentration	O
+in	O
+the	O
+general	O
+population	O
+.	O
+
+TITLE	O
+:	O
+A	O
+structural	O
+analysis	O
+of	O
+M	B-PRGE
+protein	I-PRGE
+in	O
+coronavirus	B-SPEC
+assembly	O
+and	O
+morphology	O
+.	O
+
+The	O
+S259	O
+/	O
+L	O
+mutation	O
+of	O
+SARS	B-PRGE
+-	I-PRGE
+CoV	I-PRGE
+helicase	I-PRGE
+is	O
+always	O
+found	O
+in	O
+all	O
+the	O
+identified	O
+bananin	O
+-	O
+resistant	O
+variants	O
+,	O
+suggesting	O
+a	O
+primary	O
+role	O
+of	O
+this	O
+mutation	O
+site	O
+for	O
+bananin	O
+activity	O
+.	O
+
+TITLE	O
+:	O
+Rapid	O
+and	O
+sensitive	O
+detection	O
+of	O
+bovine	B-SPEC
+coronavirus	B-SPEC
+and	O
+group	O
+a	O
+bovine	B-SPEC
+rotavirus	B-SPEC
+from	O
+fecal	B-ANAT
+samples	O
+by	O
+using	O
+one	O
+-	O
+step	O
+duplex	O
+RT	O
+-	O
+PCR	O
+assay	O
+.	O
+
+Reverse	B-PROC
+transcription	I-PROC
+-	O
+polymerase	O
+chain	O
+reaction	O
+targeting	B-PROC
+the	O
+3	O
+'	O
+untranslated	O
+region	O
+was	O
+used	O
+to	O
+detect	O
+CoV	B-PRGE
+RNA	I-PRGE
+,	O
+and	O
+positive	O
+samples	O
+were	O
+submitted	O
+for	O
+sequence	O
+analysis	O
+.	O
+
+However	O
+,	O
+CEACAM1a	O
+is	O
+poorly	O
+expressed	B-PROC
+in	O
+neurons	B-ANAT
+,	O
+and	O
+the	O
+extremely	O
+neurotropic	O
+MHV	B-SPEC
+strain	O
+JHM	O
+.	O
+SD	O
+infects	O
+ceacam1a	O
+(-/-)	O
+mice	B-SPEC
+and	O
+spreads	O
+among	O
+ceacam1a	O
+(-/-)	O
+neurons	B-ANAT
+.	O
+
+TITLE	O
+:	O
+Structure	O
+-	O
+activity	O
+relationships	O
+study	O
+of	O
+6	O
+-	O
+chloro	B-CHED
+-	O
+4	O
+-(	O
+2	O
+-	O
+chlorophenyl	O
+)-	O
+3	O
+-(	O
+2	B-CHED
+-	I-CHED
+hydroxyethyl	I-CHED
+)	O
+quinolin	B-CHED
+-	I-CHED
+2	I-CHED
+(	I-CHED
+1H	I-CHED
+)-	I-CHED
+one	I-CHED
+derivatives	O
+as	O
+novel	O
+non	O
+-	O
+nucleoside	B-CHED
+anti	B-CHED
+-	I-CHED
+hepatitis	I-CHED
+B	I-CHED
+virus	I-CHED
+agents	I-CHED
+.	O
+
+Preliminary	O
+mechanism	O
+study	O
+suggested	O
+compound	O
+44	O
+could	O
+mainly	O
+enhance	O
+the	O
+transcript	O
+activity	O
+of	O
+HBV	B-DISO
+ENI	O
+(	O
+enhancer	O
+I	O
+),	O
+EN	O
+-	O
+II	O
+(	O
+enhancer	O
+II	O
+).	O
+
+We	O
+show	O
+that	O
+the	O
+problem	O
+of	O
+finding	O
+such	O
+a	O
+cut	O
+is	O
+NP	O
+-	O
+hard	O
+and	O
+APX	O
+-	O
+hard	O
+but	O
+is	O
+fixed	B-ANAT
+-	O
+parameter	O
+tractable	O
+,	O
+which	O
+indicates	O
+that	O
+although	O
+the	O
+problem	O
+is	O
+unlikely	O
+to	O
+have	O
+a	O
+polynomial	O
+time	O
+algorithm	O
+(	O
+even	O
+for	O
+approximation	O
+),	O
+exact	O
+parameterized	O
+and	O
+local	O
+search	O
+based	O
+techniques	O
+may	O
+produce	O
+workable	O
+algorithms	O
+.	O
+
+This	O
+plant	B-SPEC
+expression	B-PROC
+vector	O
+was	O
+transformed	O
+into	O
+lettuce	O
+(	O
+Lactuca	B-SPEC
+sativa	I-SPEC
+L	O
+.)	O
+using	O
+the	O
+Agrobacterium	B-SPEC
+-	O
+mediated	O
+transformation	B-DISO
+method	O
+.	O
+
+Stable	O
+integration	B-PROC
+and	O
+transcriptional	B-PROC
+expression	B-PROC
+of	O
+the	O
+sCTB	B-PRGE
+-	I-PRGE
+sCOE	I-PRGE
+fusion	I-PRGE
+gene	I-PRGE
+was	O
+confirmed	O
+using	O
+genomic	O
+DNA	O
+PCR	O
+analysis	O
+and	O
+northern	O
+blot	O
+analysis	O
+,	O
+respectively	O
+.	O
+
+Severe	O
+disease	O
+was	O
+noted	O
+to	O
+occur	O
+more	O
+commonly	O
+in	O
+younger	O
+patients	O
+than	O
+those	O
+typically	O
+affected	O
+by	O
+seasonal	O
+influenza	B-DISO
+and	O
+obesity	B-DISO
+and	O
+pregnancy	O
+were	O
+associated	O
+with	O
+severe	O
+disease	O
+.	O
+
+TITLE	O
+:	O
+[	O
+Two	O
+adult	O
+cases	O
+of	O
+influenza	B-PATH
+A	I-PATH
+/	O
+H1N1v	O
+virus	B-SPEC
+pneumonia	B-DISO
+hospitalized	O
+in	O
+the	O
+Intensive	O
+Care	O
+Unit	O
+of	O
+the	O
+Reims	O
+University	O
+Medical	O
+Centre	O
+].	O
+
+The	O
+nucleocapsid	B-COMP
+antibody	B-COMP
+titer	O
+was	O
+between	O
+1	O
+/	O
+156	O
+and	O
+1	O
+/	O
+210	O
+in	O
+3	O
+cases	O
+,	O
+and	O
+2	O
+cases	O
+were	O
+normal	O
+.	O
+
+All	O
+cats	B-SPEC
+had	O
+severe	O
+hyperproteinemia	B-DISO
+due	O
+to	O
+hyperglobulinemia	O
+.	O
+
+In	O
+the	O
+past	O
+few	O
+decades	O
+,	O
+there	O
+has	O
+been	O
+a	O
+consistent	O
+scientific	O
+and	O
+technologic	O
+effort	B-PROC
+to	O
+develop	O
+alternative	O
+strategies	O
+to	O
+avoid	O
+the	O
+need	O
+for	O
+mechanical	O
+ventilation	O
+.	O
+
+Therefore	O
+,	O
+further	O
+development	O
+in	O
+this	O
+direction	O
+will	O
+occur	O
+only	O
+with	O
+a	O
+permanent	O
+integration	B-PROC
+and	O
+exchange	O
+of	O
+knowledge	O
+among	O
+industry	O
+,	O
+clinicians	O
+,	O
+and	O
+scientific	O
+investigators	O
+.	O
+
+A	O
+3	O
+-	O
+day	O
+-	O
+old	O
+Thoroughbred	O
+foal	O
+presented	O
+with	O
+a	O
+24	O
+-	O
+hour	O
+history	O
+of	O
+diarrhea	B-DISO
+and	O
+depression	B-DISO
+.	O
+
+During	O
+hospitalization	O
+the	O
+foal	O
+developed	O
+hyperglycemia	B-DISO
+concomitantly	O
+with	O
+low	O
+insulin	B-PRGE
+concentration	O
+and	O
+an	O
+adequate	O
+response	O
+to	O
+exogenous	O
+insulin	B-PRGE
+therapy	O
+supported	O
+a	O
+diagnosis	O
+of	O
+Type	B-DISO
+1	I-DISO
+diabetes	I-DISO
+mellitus	I-DISO
+.	O
+
+This	O
+study	O
+was	O
+conducted	O
+to	O
+identify	O
+preceding	O
+events	O
+,	O
+demographic	O
+,	O
+clinical	O
+characteristics	O
+and	O
+prognostic	O
+factors	O
+of	O
+childhood	O
+Guillain	O
+-	O
+Barré	O
+syndrome	B-DISO
+after	O
+post	O
+-	O
+poliomyelitis	B-DISO
+eradication	O
+era	B-CHED
+in	O
+Egypt	O
+.	O
+
+Several	O
+successive	O
+reports	O
+confirmed	O
+retrospectively	O
+that	O
+this	O
+new	O
+human	B-SPEC
+coronavirus	I-SPEC
+was	O
+circulating	O
+in	O
+different	O
+countries	O
+worldwide	O
+.	O
+
+METHODS	O
+:	O
+Nasopharyngeal	B-ANAT
+aspiration	B-DISO
+(	O
+NPA	B-CHED
+)	O
+samples	O
+were	O
+collected	O
+from	O
+301	O
+children	O
+with	O
+ARTI	O
+at	O
+the	O
+First	O
+Hospital	O
+of	O
+Lanzhou	O
+University	O
+,	O
+Gansu	O
+Province	O
+,	O
+China	O
+,	O
+between	O
+November	O
+2007	O
+and	O
+October	O
+2008	O
+.	O
+
+Here	O
+,	O
+the	O
+peptides	B-CHED
+capable	O
+of	O
+binding	B-FUNC
+the	O
+pAPN	O
+were	O
+,	O
+for	O
+the	O
+first	O
+time	O
+,	O
+identified	O
+by	O
+biopanning	O
+using	O
+a	O
+random	O
+12	O
+-	O
+mer	O
+peptide	B-CHED
+library	O
+to	O
+the	O
+immobilized	O
+protein	B-CHED
+.	O
+
+We	O
+recently	O
+demonstrated	O
+that	O
+minute	O
+amounts	O
+of	O
+IFN	B-PRGE
+applied	O
+before	O
+infection	B-DISO
+(	O
+IFN	B-PRGE
+priming	O
+)	O
+can	O
+ameliorate	O
+the	O
+IFN	B-PRGE
+response	O
+of	O
+tissue	B-ANAT
+cells	B-COMP
+to	O
+SARS	B-PRGE
+-	I-PRGE
+CoV	I-PRGE
+.	O
+IFN	B-PRGE
+priming	O
+of	O
+SARS	B-DISO
+-	O
+CoV	O
+-	O
+infected	O
+cells	B-COMP
+activated	O
+genes	O
+for	O
+IFN	B-PRGE
+transcription	B-PROC
+,	O
+IFN	B-PRGE
+signaling	B-PROC
+,	O
+antiviral	B-CHED
+effector	B-CHED
+proteins	B-CHED
+,	O
+ubiquitinylation	B-PROC
+and	O
+ISGylation	O
+,	O
+antigen	B-PROC
+presentation	I-PROC
+,	O
+and	O
+other	O
+cytokines	O
+and	O
+chemokines	O
+,	O
+whereas	O
+IFN	B-PRGE
+treatment	O
+or	O
+infection	B-DISO
+alone	O
+had	O
+no	O
+major	O
+effect	O
+.	O
+
+TITLE	O
+:	O
+Hospitalized	O
+children	O
+with	O
+2009	O
+pandemic	O
+influenza	B-PATH
+A	I-PATH
+(	O
+H1N1	O
+):	O
+comparison	O
+to	O
+seasonal	O
+influenza	B-DISO
+and	O
+risk	O
+factors	O
+for	O
+admission	O
+to	O
+the	O
+ICU	O
+.	O
+
+Children	O
+under	O
+the	O
+age	O
+of	O
+2	O
+hospitalized	O
+with	O
+2009	O
+H1N1	B-DISO
+influenza	I-DISO
+were	O
+significantly	O
+less	O
+likely	O
+to	O
+require	O
+ICU	O
+care	O
+compared	O
+to	O
+older	O
+hospitalized	O
+children	O
+.	O
+
+Here	O
+,	O
+we	O
+reported	O
+the	O
+NMR	O
+assignments	O
+of	O
+the	O
+SARS	B-PRGE
+-	I-PRGE
+CoV	I-PRGE
+M	I-PRGE
+(	I-PRGE
+pro	B-CHED
+)	I-PRGE
+N	I-PRGE
+-	I-PRGE
+terminal	I-PRGE
+domain	I-PRGE
+alone	O
+,	O
+which	O
+are	O
+essential	O
+for	O
+its	O
+solution	O
+structure	O
+determination	O
+.	O
+
+Enterovirus	B-SPEC
+,	O
+rhinovirus	B-SPEC
+,	O
+and	O
+parainfluenza	B-SPEC
+virus	I-SPEC
+type	I-SPEC
+3	I-SPEC
+were	O
+the	O
+most	O
+common	O
+viruses	B-SPEC
+found	O
+in	O
+patients	O
+with	O
+HCoV	O
+infections	B-DISO
+.	O
+
+A	O
+typical	O
+experimental	O
+infection	B-DISO
+,	O
+molecular	O
+characterization	O
+,	O
+and	O
+serological	O
+analysis	O
+were	O
+also	O
+carried	O
+out	O
+to	O
+further	O
+characterize	O
+and	O
+to	O
+evaluate	O
+any	O
+significant	O
+difference	O
+between	O
+strains	O
+.	O
+
+The	O
+sequence	O
+analysis	O
+showed	O
+two	O
+amino	B-CHED
+acid	I-CHED
+deletions	O
+and	O
+loss	O
+of	O
+an	O
+N	O
+-	O
+glycosylation	B-PROC
+site	O
+in	O
+transmissible	O
+gastroenteritis	O
+virus	B-SPEC
+S	O
+protein	B-CHED
+after	O
+passages	O
+in	O
+piglets	O
+.	O
+
+Moreover	O
+,	O
+both	O
+APRIL	B-PRGE
+and	O
+BAFF	O
+were	O
+predominantly	O
+localized	O
+to	O
+astrocytes	B-ANAT
+.	O
+
+We	O
+show	O
+that	O
+IL	B-PROC
+-	I-PROC
+17	I-PROC
+levels	O
+in	O
+serum	B-COMP
+are	O
+rapidly	O
+elevated	O
+and	O
+positively	O
+correlated	O
+to	O
+liver	B-DISO
+damage	I-DISO
+and	O
+death	B-PROC
+of	O
+the	O
+mice	B-SPEC
+.	O
+
+The	O
+results	O
+demonstrate	O
+an	O
+essential	O
+role	O
+of	O
+Th17	O
+cells	B-COMP
+in	O
+MHV	B-SPEC
+-	O
+induced	O
+immunopathology	B-DISO
+and	O
+the	O
+importance	O
+of	O
+IFN	B-PRGE
+-	I-PRGE
+γ	I-PRGE
+in	O
+maintaining	O
+immune	O
+balance	B-PROC
+between	O
+Th1	O
+and	O
+Th17	O
+responses	O
+during	O
+acute	O
+viral	B-DISO
+infection	I-DISO
+.	O
+
+The	O
+replacement	O
+of	O
+the	O
+MHV	B-SPEC
+2a	O
+/	O
+haemagglutinin	O
+-	O
+esterase	B-PRGE
+gene	O
+with	O
+a	O
+membrane	B-COMP
+-	O
+anchored	O
+protein	B-CHED
+hook	O
+(	O
+HK	O
+)	O
+and	O
+replacement	O
+of	O
+gene	B-PRGE
+4	I-PRGE
+with	O
+EGFP	O
+did	O
+not	O
+change	O
+the	O
+adaptability	O
+and	O
+cytopathology	O
+of	O
+recombinant	O
+viruses	B-SPEC
+in	O
+these	O
+cells	B-COMP
+.	O
+
+ABSTRACT	O
+:	O
+Infectious	O
+bronchitis	B-DISO
+virus	B-SPEC
+(	O
+IBV	B-SPEC
+)	O
+infection	B-DISO
+has	O
+been	O
+a	O
+major	O
+threat	O
+to	O
+the	O
+poultry	O
+industry	O
+worldwide	O
+.	O
+
+The	O
+b	O
+-	O
+ELISA	O
+specifically	O
+detected	O
+Taiwan	O
+IBV	O
+serotypes	O
+but	O
+not	O
+three	O
+non	O
+-	O
+Taiwan	O
+IBV	B-SPEC
+serotypes	O
+nor	O
+sera	B-COMP
+against	O
+other	O
+avian	B-SPEC
+pathogens	O
+.	O
+
+It	O
+has	O
+the	O
+potential	O
+to	O
+serve	O
+as	O
+a	O
+rapid	O
+and	O
+reliable	O
+diagnostic	O
+method	O
+for	O
+IBV	B-SPEC
+clinical	B-DISO
+infections	I-DISO
+in	O
+the	O
+field	O
+in	O
+Taiwan	O
+.	O
+
+The	O
+size	O
+of	O
+the	O
+PEI	B-CHED
+/	O
+pci	B-PRGE
+-	O
+S	O
+nanoparticles	B-CHED
+appeared	O
+to	O
+be	O
+around	O
+194	O
+.	O
+7	O
+±	O
+99	O
+.	O
+3	O
+nm	O
+,	O
+and	O
+the	O
+expression	B-PROC
+of	O
+the	O
+S	B-PRGE
+mRNA	I-PRGE
+and	O
+protein	B-CHED
+was	O
+confirmed	O
+in	O
+vitro	O
+.	O
+
+PEI	B-CHED
+/	O
+pci	B-PRGE
+-	O
+S	O
+nanoparticles	B-CHED
+produced	O
+significantly	O
+(	O
+P	O
+<	O
+0	O
+.	O
+05	O
+)	O
+higher	O
+S	O
+-	O
+specific	O
+IgG1	B-COMP
+in	O
+the	O
+sera	B-COMP
+and	O
+mucosal	B-PRGE
+secretory	B-PROC
+IgA	I-PRGE
+in	O
+the	O
+lung	B-ANAT
+wash	O
+than	O
+those	O
+in	O
+mice	B-SPEC
+treated	O
+with	O
+pci	B-PRGE
+-	I-PRGE
+S	I-PRGE
+alone	O
+.	O
+
+TEE	O
+can	O
+be	O
+performed	O
+safely	O
+and	O
+efficiently	O
+in	O
+severe	O
+ARDS	B-DISO
+patients	O
+in	O
+PP	O
+.	O
+
+In	O
+coronaviruses	O
+,	O
+the	O
+structural	O
+protein	B-CHED
+N	O
+(	O
+nucleocapsid	B-COMP
+protein	B-CHED
+)	O
+associates	O
+with	O
+the	O
+viral	O
+RNA	O
+to	O
+form	O
+the	O
+filamentous	O
+nucleocapsid	B-COMP
+and	O
+plays	O
+a	O
+crucial	O
+role	O
+in	O
+genome	O
+replication	O
+and	O
+transcription	B-PROC
+.	O
+
+The	O
+structure	O
+of	O
+N	O
+-	O
+terminal	O
+domain	O
+of	O
+MHV	B-PRGE
+N	I-PRGE
+protein	B-CHED
+also	O
+implicated	O
+its	O
+specific	O
+affinity	O
+with	O
+transcriptional	B-PROC
+regulatory	O
+sequence	O
+(	O
+TRS	B-DISO
+)	O
+RNA	O
+.	O
+
+Compared	O
+with	O
+the	O
+previously	O
+well	O
+characterized	O
+form	O
+of	O
+M	O
+(	O
+pro	B-CHED
+),	O
+in	O
+equilibrium	B-PROC
+between	O
+inactive	O
+monomer	O
+and	O
+active	O
+dimer	O
+,	O
+the	O
+stable	O
+AO	O
+-	O
+M	O
+(	O
+pro	B-CHED
+)	O
+exhibits	O
+much	O
+higher	O
+proteolytic	B-PROC
+activity	O
+at	O
+low	O
+concentration	O
+.	O
+
+As	O
+all	O
+eight	O
+active	O
+sites	O
+are	O
+bound	O
+with	O
+inhibitors	B-CHED
+,	O
+the	O
+polyvalent	O
+nature	O
+of	O
+the	O
+interaction	O
+between	O
+AO	B-PRGE
+-	I-PRGE
+M	I-PRGE
+(	I-PRGE
+pro	I-PRGE
+)	I-PRGE
+and	O
+its	O
+polyprotein	O
+substrates	O
+with	O
+multiple	O
+cleavage	B-PROC
+sites	O
+,	O
+would	O
+make	O
+AO	O
+-	O
+M	O
+(	O
+pro	B-CHED
+)	O
+functionally	O
+much	O
+more	O
+superior	O
+than	O
+the	O
+M	O
+(	O
+pro	B-CHED
+)	O
+active	O
+dimer	O
+for	O
+polyprotein	O
+processing	O
+.	O
+
+Surprisingly	O
+,	O
+all	O
+three	O
+mutants	O
+still	O
+perform	O
+N	O
+-	O
+terminal	O
+autocleavage	O
+,	O
+while	O
+the	O
+dimerization	O
+of	O
+mature	O
+protease	O
+and	O
+trans	O
+-	O
+cleavage	B-PROC
+activity	O
+following	O
+auto	O
+-	O
+processing	O
+are	O
+completely	O
+inhibited	O
+by	O
+the	O
+E290R	O
+and	O
+R298E	O
+mutations	O
+and	O
+partially	O
+so	O
+by	O
+the	O
+R4E	O
+mutation	O
+.	O
+
+Sequence	O
+and	O
+phylogenetic	O
+analysis	O
+showed	O
+that	O
+recent	O
+,	O
+prevalent	O
+Korean	O
+PEDV	B-SPEC
+field	O
+isolates	O
+have	O
+close	O
+relationships	O
+to	O
+Chinese	O
+field	O
+strains	O
+and	O
+differ	O
+genetically	O
+from	O
+European	O
+strains	O
+and	O
+vaccine	O
+strains	O
+used	O
+in	O
+Korea	O
+.	O
+
+Soluble	B-PRGE
+RAGE	I-PRGE
+(	O
+sRAGE	O
+)	O
+level	O
+is	O
+elevated	O
+in	O
+patients	O
+with	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+(	O
+ARDS	B-DISO
+).	O
+
+This	O
+study	O
+demonstrated	O
+that	O
+sRAGE	O
+was	O
+independently	O
+associated	O
+with	O
+death	O
+in	O
+ARDS	B-DISO
+patients	O
+.	O
+
+TITLE	O
+:	O
+Mutation	O
+of	O
+neutralizing	O
+/	O
+antibody	B-COMP
+-	O
+dependent	O
+enhancing	O
+epitope	B-CHED
+on	O
+spike	O
+protein	B-CHED
+and	O
+7b	O
+gene	O
+of	O
+feline	O
+infectious	O
+peritonitis	O
+virus	B-SPEC
+:	O
+influences	O
+of	O
+viral	B-PROC
+replication	I-PROC
+in	O
+monocytes	B-ANAT
+/	O
+macrophages	B-ANAT
+and	O
+virulence	B-PROC
+in	O
+cats	B-SPEC
+.	O
+
+We	O
+also	O
+demonstrated	O
+that	O
+the	O
+mutation	O
+or	O
+deletion	O
+of	O
+two	O
+nucleotides	O
+in	O
+7b	O
+gene	O
+abrogate	O
+the	O
+virulence	B-PROC
+of	O
+strain	O
+FIPV	O
+79	O
+-	O
+1146	O
+.	O
+
+TITLE	O
+:	O
+Screening	O
+and	O
+identification	O
+of	O
+T	O
+helper	O
+1	O
+and	O
+linear	O
+immunodominant	O
+antibody	B-COMP
+-	O
+binding	B-FUNC
+epitopes	O
+in	O
+the	O
+spike	O
+2	O
+domain	O
+and	O
+the	O
+nucleocapsid	O
+protein	B-CHED
+of	O
+feline	B-DISO
+infectious	I-DISO
+peritonitis	I-DISO
+virus	B-SPEC
+.	O
+
+In	O
+the	O
+S2	O
+domain	O
+of	O
+type	B-PRGE
+I	I-PRGE
+FIPV	I-PRGE
+,	I-PRGE
+3	I-PRGE
+and	I-PRGE
+7	I-PRGE
+peptides	I-PRGE
+containing	O
+linear	O
+immunodominant	O
+antibody	B-COMP
+-	O
+binding	B-FUNC
+epitopes	O
+were	O
+identified	O
+in	O
+the	O
+IH	O
+and	O
+HR2	O
+regions	O
+,	O
+respectively	O
+.	O
+
+ABSTRACT	O
+:	O
+A	O
+recombinant	O
+fowlpox	B-SPEC
+virus	I-SPEC
+(	O
+rFPV	O
+-	O
+IFNγS1	O
+)	O
+that	O
+co	O
+-	O
+expressed	B-PROC
+the	O
+infectious	B-DISO
+bronchitis	B-DISO
+virus	B-SPEC
+(	O
+IBV	B-SPEC
+)	O
+S1	O
+gene	O
+and	O
+the	O
+chicken	B-PRGE
+interferon	I-PRGE
+-	I-PRGE
+γ	I-PRGE
+gene	I-PRGE
+has	O
+been	O
+constructed	O
+.	O
+
+These	O
+results	O
+indicate	O
+that	O
+the	O
+rFPV	O
+-	O
+IFNγS1	O
+protected	O
+chickens	B-SPEC
+against	O
+challenge	O
+with	O
+homotypic	O
+IBV	B-SPEC
+strain	O
+LX4	O
+and	O
+heterotypic	O
+strains	O
+LHLJ04XI	O
+and	O
+LHB	B-PRGE
+.	O
+
+Highly	O
+significant	O
+decreases	O
+in	O
+haematocrit	O
+and	O
+albumin	B-PRGE
+levels	O
+and	O
+an	O
+increase	O
+in	O
+total	O
+bilirubin	B-CHED
+level	O
+were	O
+noted	O
+in	O
+both	O
+effusive	O
+and	O
+non	O
+-	O
+effusive	O
+FIP	B-DISO
+,	O
+at	O
+first	O
+presentation	O
+and	O
+before	O
+death	B-PROC
+.	O
+
+The	O
+packed	O
+cell	B-COMP
+volume	O
+,	O
+bilirubin	B-CHED
+,	O
+AST	B-PRGE
+,	O
+potassium	B-CHED
+,	O
+and	O
+sodium	O
+levels	O
+were	O
+established	O
+to	O
+predict	O
+disease	O
+staging	O
+and	O
+survival	O
+time	O
+.	O
+
+However	O
+,	O
+a	O
+defined	O
+biological	B-CHED
+role	I-CHED
+for	O
+2	O
+'-	O
+O	O
+-	O
+methylation	B-PROC
+of	O
+mRNA	B-CHED
+remains	O
+elusive	O
+.	O
+
+A	O
+total	O
+of	O
+64	O
+consecutive	O
+subjects	O
+,	O
+divided	O
+into	O
+four	O
+groups	O
+:	O
+acute	O
+lung	B-ANAT
+injury	O
+/	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+(	O
+n	O
+=	O
+15	O
+);	O
+acute	O
+lung	B-ANAT
+injury	O
+/	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+plus	O
+severe	B-DISO
+sepsis	I-DISO
+/	O
+septic	B-DISO
+shock	I-DISO
+(	O
+n	O
+=	O
+18	O
+);	O
+severe	B-DISO
+sepsis	I-DISO
+/	O
+septic	B-DISO
+shock	I-DISO
+(	O
+n	O
+=	O
+16	O
+);	O
+and	O
+mechanically	O
+ventilated	O
+controls	O
+(	O
+n	O
+=	O
+15	O
+).	O
+
+Plasma	O
+sRAGE	O
+levels	O
+were	O
+measured	O
+at	O
+baseline	O
+and	O
+on	O
+days	O
+3	O
+,	O
+6	O
+,	O
+and	O
+28	O
+(	O
+or	O
+at	O
+intensive	O
+care	O
+unit	O
+discharge	B-ANAT
+,	O
+whichever	O
+occurred	O
+first	O
+).	O
+
+TITLE	O
+:	O
+Characterization	O
+and	O
+utility	O
+of	O
+monoclonal	O
+antibodies	B-COMP
+against	O
+spike	O
+protein	B-CHED
+of	O
+transmissible	O
+gastroenteritis	O
+virus	B-SPEC
+.	O
+
+These	O
+mAbs	O
+were	O
+capable	O
+of	O
+reacting	O
+with	O
+the	O
+TGEV	B-PRGE
+S1	I-PRGE
+protein	B-CHED
+analysed	O
+by	O
+ELISA	O
+and	O
+Western	O
+blot	O
+.	O
+
+These	O
+mAbs	O
+were	O
+able	O
+to	O
+detect	O
+the	O
+TGEV	B-SPEC
+-	O
+infected	O
+cells	B-COMP
+in	O
+immunofluorescence	O
+assays	O
+and	O
+Western	O
+blot	O
+.	O
+
+Here	O
+,	O
+we	O
+report	O
+a	O
+fatal	O
+case	O
+of	O
+acute	O
+interstitial	B-DISO
+myocarditis	I-DISO
+associated	O
+with	O
+novel	B-DISO
+influenza	I-DISO
+A	I-DISO
+/	I-DISO
+H1N1	I-DISO
+infection	B-DISO
+in	O
+an	O
+immunocompetent	O
+young	O
+woman	O
+.	O
+
+All	O
+patients	O
+presented	O
+with	O
+severe	O
+cardiac	B-ANAT
+dysfunction	O
+(	O
+acute	B-DISO
+heart	I-DISO
+failure	I-DISO
+,	O
+cardiogenic	B-DISO
+shock	I-DISO
+or	O
+cardiac	B-DISO
+arrest	I-DISO
+due	O
+to	O
+ventricular	B-DISO
+fibrillation	I-DISO
+)	O
+as	O
+the	O
+leading	O
+symptom	B-DISO
+of	O
+influenza	B-PATH
+A	I-PATH
+(	O
+H1N1	O
+)	O
+infection	B-DISO
+.	O
+
+Except	O
+for	O
+one	O
+patient	O
+who	O
+died	B-PROC
+before	O
+influenza	B-PATH
+A	I-PATH
+(	O
+H1N1	O
+)	O
+infection	B-DISO
+had	O
+been	O
+diagnosed	O
+,	O
+all	O
+patients	O
+received	O
+antiviral	B-CHED
+therapy	O
+with	O
+oseltamivir	B-CHED
+and	O
+supportive	O
+critical	O
+care	O
+.	O
+
+An	O
+RT	O
+-	O
+PCR	O
+/	O
+ESI	O
+-	O
+MS	O
+respiratory	O
+virus	B-SPEC
+surveillance	O
+kit	B-FUNC
+designed	O
+to	O
+detect	O
+respiratory	B-SPEC
+syncytial	I-SPEC
+virus	I-SPEC
+,	O
+influenza	B-PATH
+A	I-PATH
+and	O
+B	O
+,	O
+parainfluenza	B-DISO
+types	O
+1	O
+-	O
+4	O
+,	O
+Adenoviridae	B-SPEC
+types	O
+A	O
+-	O
+F	O
+,	O
+Coronaviridae	B-SPEC
+,	O
+human	B-SPEC
+bocavirus	I-SPEC
+,	O
+and	O
+human	B-SPEC
+metapneumovirus	I-SPEC
+was	O
+evaluated	O
+using	O
+both	O
+mock	O
+-	O
+ups	O
+and	O
+frozen	O
+archived	O
+NPA	B-CHED
+(	O
+N	O
+=	O
+280	O
+),	O
+95	O
+of	O
+which	O
+were	O
+positive	O
+by	O
+clinical	O
+virology	O
+methods	O
+.	O
+
+ABSTRACT	O
+:	O
+Leukotriene	O
+B4	O
+(	O
+LTB4	B-CHED
+)	O
+recruits	O
+and	O
+activates	O
+neutrophils	B-ANAT
+.	O
+
+Symptoms	O
+were	O
+scored	O
+and	O
+nasal	B-ANAT
+lavages	O
+carried	O
+out	O
+.	O
+
+Supernatants	O
+from	O
+neutrophils	B-ANAT
+activated	O
+by	O
+LTB4	B-CHED
+in	O
+vitro	O
+were	O
+assayed	O
+for	O
+virucidal	O
+activity	O
+against	O
+respiratory	O
+viruses	B-SPEC
+.	O
+
+ABSTRACT	O
+:	O
+Due	O
+to	O
+their	O
+different	O
+virulence	B-PROC
+and	O
+infectivity	O
+,	O
+both	O
+severe	O
+acute	O
+respiratory	O
+syndrome	O
+(	O
+SARS	B-DISO
+)	O
+and	O
+H1N1	O
+09	O
+revealed	O
+different	O
+strengths	O
+and	O
+weaknesses	B-DISO
+in	O
+our	O
+ability	O
+to	O
+contain	O
+new	O
+viral	O
+threats	O
+over	O
+the	O
+past	O
+decade	O
+.	O
+
+Here	O
+we	O
+show	O
+that	O
+IFITM	O
+proteins	B-CHED
+restricted	O
+infection	B-DISO
+mediated	O
+by	O
+the	O
+entry	O
+glycoproteins	B-CHED
+(	O
+GP	O
+(	O
+1	O
+,	O
+2	O
+))	O
+of	O
+Marburg	O
+and	O
+Ebola	O
+filoviruses	O
+(	O
+MARV	O
+,	O
+EBOV	O
+).	O
+
+Only	O
+ethanol	B-CHED
+reduced	O
+infectivity	O
+of	O
+the	O
+2	O
+coronaviruses	O
+by	O
+>	O
+3	O
+-	O
+log	O
+(	O
+10	O
+)	O
+after	O
+1	O
+minute	O
+.	O
+
+Similarly	O
+,	O
+the	O
+herd	O
+status	O
+regarding	O
+clinical	O
+respiratory	B-DISO
+disease	I-DISO
+in	O
+calves	O
+and	O
+history	O
+of	O
+respiratory	O
+virus	O
+exposure	O
+was	O
+evaluated	O
+based	O
+on	O
+lung	B-ANAT
+auscultations	O
+and	O
+blood	B-ANAT
+samplings	O
+of	O
+calves	O
+60	O
+-	O
+90	O
+days	O
+old	O
+.	O
+
+The	O
+median	O
+calf	B-ANAT
+mortality	O
+risk	O
+(	O
+in	O
+calves	O
+1	O
+-	O
+90	O
+days	O
+of	O
+age	O
+)	O
+among	O
+HM	O
+herds	O
+was	O
+9	O
+%	O
+(	O
+Range	O
+:	O
+6	O
+-	O
+24	O
+%)	O
+and	O
+among	O
+LM	O
+herds	O
+1	O
+%	O
+(	O
+Range	O
+:	O
+0	O
+-	O
+2	O
+%).	O
+
+The	O
+median	O
+age	O
+at	O
+death	B-PROC
+of	O
+calves	O
+in	O
+the	O
+age	O
+interval	O
+1	O
+-	O
+90	O
+days	O
+that	O
+died	B-PROC
+during	O
+a	O
+one	O
+-	O
+year	O
+period	O
+was	O
+significantly	O
+lower	O
+among	O
+HM	O
+herds	O
+(	O
+13	O
+days	O
+)	O
+than	O
+in	O
+LM	O
+herds	O
+(	O
+24	O
+days	O
+)	O
+(	O
+p	O
+=	O
+0	O
+.	O
+0013	O
+)	O
+The	O
+results	O
+indicate	O
+that	O
+gastrointestinal	B-DISO
+disorders	I-DISO
+may	O
+be	O
+an	O
+important	O
+cause	O
+of	O
+calf	B-ANAT
+mortality	O
+in	O
+large	O
+Swedish	O
+dairy	O
+herds	O
+.	O
+
+Eighty	O
+-	O
+three	O
+children	O
+with	O
+confirmed	O
+infection	B-DISO
+attributable	O
+to	O
+pandemic	O
+influenza	B-DISO
+detected	O
+by	O
+reverse	O
+-	O
+transcriptase	B-PROC
+polymerase	O
+chain	O
+reaction	O
+assay	O
+between	O
+November	O
+1	O
+and	O
+December	O
+31	O
+,	O
+2009	O
+who	O
+were	O
+admitted	O
+to	O
+critical	O
+care	O
+units	O
+.	O
+
+Severe	O
+disease	O
+and	O
+high	O
+mortality	O
+rates	O
+were	O
+seen	O
+in	O
+children	O
+with	O
+pandemic	O
+influenza	B-DISO
+.	O
+
+ABSTRACT	O
+:	O
+Different	O
+isoforms	O
+of	O
+nitric	B-CHED
+oxide	I-CHED
+(	O
+NO	O
+)	O
+synthase	O
+are	O
+critically	O
+involved	O
+in	O
+the	O
+development	B-PROC
+of	O
+pulmonary	B-DISO
+failure	I-DISO
+secondary	O
+to	O
+acute	O
+lung	B-ANAT
+injury	O
+.	O
+
+Chronically	O
+instrumented	O
+sheep	B-SPEC
+were	O
+allocated	O
+to	O
+a	O
+sham	O
+-	O
+injured	O
+group	O
+(	O
+n	O
+=	O
+6	O
+),	O
+an	O
+injured	O
+and	O
+untreated	O
+group	O
+(	O
+n	O
+=	O
+6	O
+),	O
+or	O
+an	O
+injured	O
+group	O
+treated	O
+with	O
+simultaneous	O
+infusion	O
+of	O
+selective	O
+inducible	O
+and	O
+neuronal	B-PRGE
+NO	I-PRGE
+synthase	I-PRGE
+inhibitors	B-CHED
+(	O
+n	O
+=	O
+5	O
+).	O
+
+The	O
+treatment	O
+fully	O
+prevented	O
+the	O
+elevations	O
+in	O
+lymph	B-ANAT
+and	O
+plasma	B-ANAT
+nitrate	B-CHED
+/	O
+nitrite	B-CHED
+levels	O
+,	O
+pulmonary	B-ANAT
+shunting	O
+,	O
+ventilatory	O
+pressures	O
+,	O
+lung	B-ANAT
+lymph	B-PROC
+flow	I-PROC
+,	O
+and	O
+wet	O
+/	O
+dry	O
+weight	O
+ratio	O
+and	O
+significantly	O
+attenuated	O
+the	O
+decline	O
+in	O
+PaO2	O
+/	O
+FiO2	O
+ratio	O
+.	O
+
+In	O
+conclusion	O
+,	O
+simultaneous	O
+blockade	O
+of	O
+inducible	O
+and	O
+neuronal	B-PRGE
+NO	I-PRGE
+synthase	I-PRGE
+exerts	B-PROC
+beneficial	O
+pulmonary	B-PROC
+effects	I-PROC
+in	O
+an	O
+ovine	O
+model	O
+of	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+secondary	O
+to	O
+combined	O
+burn	O
+and	O
+smoke	O
+inhalation	B-PROC
+injury	O
+.	O
+
+The	O
+regional	O
+challenges	O
+in	O
+control	O
+of	O
+emerging	B-DISO
+infectious	I-DISO
+diseases	I-DISO
+are	O
+formidable	O
+and	O
+range	O
+from	O
+influencing	O
+the	O
+factors	O
+that	O
+drive	O
+disease	O
+emergence	O
+,	O
+to	O
+making	O
+surveillance	O
+systems	O
+fit	B-DISO
+for	O
+purpose	O
+,	O
+and	O
+ensuring	O
+that	O
+regional	O
+governance	O
+mechanisms	O
+work	O
+effectively	O
+to	O
+improve	O
+control	O
+interventions	O
+.	O
+
+The	O
+Virochip	O
+also	O
+successfully	O
+detected	O
+porcine	B-PRGE
+circovirus	I-PRGE
+type	I-PRGE
+2	I-PRGE
+(	O
+PCV2	O
+)	O
+in	O
+serum	B-COMP
+containing	O
+2	O
+.	O
+50	O
+×	O
+10	O
+(	O
+8	O
+)	O
+viral	O
+copies	O
+per	O
+microliter	O
+and	O
+porcine	B-SPEC
+respiratory	O
+coronavirus	B-SPEC
+(	O
+PRCV	O
+)	O
+in	O
+turbinate	B-ANAT
+tissue	B-ANAT
+homogenate	O
+.	O
+
+TITLE	O
+:	O
+Severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+coronavirus	B-SPEC
+papain	B-PRGE
+-	I-PRGE
+like	I-PRGE
+protease	I-PRGE
+suppressed	O
+alpha	B-PRGE
+interferon	I-PRGE
+-	O
+induced	O
+responses	O
+through	O
+downregulation	B-PROC
+of	O
+extracellular	B-PRGE
+signal	I-PRGE
+-	I-PRGE
+regulated	I-PRGE
+kinase	I-PRGE
+1	I-PRGE
+-	O
+mediated	O
+signalling	B-PROC
+pathways	B-PROC
+.	O
+
+Poly	O
+-	O
+ubiquitination	B-PROC
+of	O
+ERK1	B-FUNC
+showed	O
+a	O
+relationship	O
+between	O
+ERK1	B-FUNC
+and	O
+ubiquitin	B-PROC
+proteasome	B-PATH
+signalling	B-PROC
+pathways	B-PROC
+associated	O
+with	O
+IFN	B-PRGE
+antagonism	I-PRGE
+by	O
+PLpro	O
+.	O
+
+However	O
+,	O
+administration	O
+of	O
+surfactant	B-CHED
+is	O
+currently	O
+not	O
+advised	O
+in	O
+adult	O
+respiratory	B-DISO
+failure	I-DISO
+.	O
+
+Faecal	B-ANAT
+shedding	O
+of	O
+the	O
+challenge	O
+virus	B-SPEC
+occurred	O
+in	O
+both	O
+treatment	O
+groups	O
+,	O
+but	O
+vaccinated	O
+dogs	B-SPEC
+were	O
+found	O
+to	O
+shed	O
+very	O
+low	O
+viral	O
+titres	O
+in	O
+comparison	O
+to	O
+controls	O
+.	O
+
+ABSTRACT	O
+:	O
+A	O
+new	O
+equine	O
+coronavirus	B-SPEC
+was	O
+isolated	O
+from	O
+the	O
+feces	B-ANAT
+of	O
+adult	O
+horses	B-SPEC
+with	O
+pyrogenic	O
+and	O
+enteric	O
+disease	O
+.	O
+
+TITLE	O
+:	O
+The	O
+influence	O
+of	O
+severe	B-DISO
+obesity	I-DISO
+on	O
+non	O
+-	O
+invasive	O
+ventilation	O
+(	O
+NIV	O
+)	O
+strategies	O
+and	O
+responses	O
+in	O
+patients	O
+with	O
+acute	O
+hypercapnic	O
+respiratory	O
+failure	O
+attacks	O
+in	O
+the	O
+ICU	O
+.	O
+
+Patients	O
+were	O
+divided	O
+into	O
+two	O
+groups	O
+:	O
+obese	B-DISO
+(	O
+BMI	O
+>	O
+35	O
+kg	O
+/	O
+m2	O
+)	O
+and	O
+non	O
+-	O
+obese	B-DISO
+(	O
+BMI	O
+<	O
+35	O
+kg	O
+/	O
+m2	O
+),	O
+and	O
+the	O
+differences	O
+between	O
+these	O
+two	O
+groups	O
+in	O
+necessary	O
+pressure	O
+,	O
+volume	O
+,	O
+mode	O
+,	O
+ventilator	O
+and	O
+time	O
+to	O
+reduce	O
+PaCO2	O
+<	O
+50	O
+mmHg	O
+were	O
+investigated	O
+.	O
+
+With	O
+anticonvulsant	B-CHED
+therapy	O
+and	O
+antibiotics	B-CHED
+there	O
+was	O
+complete	O
+resolution	O
+of	O
+neurological	B-DISO
+symptoms	I-DISO
+.	O
+
+The	O
+very	O
+preliminary	O
+data	O
+of	O
+this	O
+ongoing	O
+study	O
+suggest	O
+that	O
+in	O
+'	O
+late	O
+-	O
+preterm	O
+'	O
+infants	O
+some	O
+individual	O
+/	O
+environmental	O
+characteristics	O
+of	O
+the	O
+infants	O
+play	O
+a	O
+relevant	O
+role	O
+in	O
+determining	O
+the	O
+risk	O
+of	O
+severe	O
+RSV	B-DISO
+infection	I-DISO
+.	O
+
+Babies	O
+of	O
+33	O
+(+	O
+0d	O
+)-	O
+34	O
+(+	O
+6d	O
+)	O
+wGA	O
+were	O
+more	O
+frequently	O
+conceived	O
+through	O
+assisted	O
+fertilization	B-PROC
+technologies	O
+,	O
+born	O
+from	O
+cesarean	O
+delivery	O
+had	O
+more	O
+frequently	O
+acute	O
+perinatal	O
+risk	O
+factors	O
+and	O
+were	O
+more	O
+frequently	O
+twins	O
+.	O
+
+These	O
+results	O
+clearly	O
+suggested	O
+that	O
+increased	O
+oxidant	B-CHED
+levels	O
+led	O
+to	O
+oxidative	B-DISO
+stress	I-DISO
+,	O
+antioxidant	B-CHED
+deficiency	O
+attenuating	O
+lung	B-DISO
+inflammation	I-DISO
+and	O
+tissue	B-ANAT
+damage	O
+.	O
+
+Multivariable	O
+analysis	O
+indicated	O
+that	O
+both	O
+of	O
+these	O
+single	O
+nucleotide	B-CHED
+polymorphisms	B-PROC
+are	O
+independently	O
+associated	O
+with	O
+need	O
+for	O
+mechanical	O
+ventilation	O
+(	O
+p	O
+=	O
+.	O
+040	O
+and	O
+p	O
+=	O
+.	O
+012	O
+,	O
+respectively	O
+)	O
+as	O
+was	O
+rs7316	O
+when	O
+its	O
+interaction	O
+with	O
+age	O
+was	O
+considered	O
+(	O
+p	O
+=	O
+.	O
+015	O
+).	O
+
+Antibody	B-PROC
+responses	I-PROC
+to	O
+antigens	B-CHED
+H1N1	O
+,	O
+H3N2	B-CHED
+,	O
+and	O
+B	O
+were	O
+measured	O
+in	O
+blood	B-ANAT
+samples	I-ANAT
+at	O
+vaccination	O
+(	O
+T0	O
+)	O
+and	O
+after	O
+1	O
+month	O
+(	O
+T1	O
+).	O
+
+One	O
+month	O
+after	O
+vaccination	O
+(	O
+T1	O
+),	O
+both	O
+groups	O
+showed	O
+significant	O
+increases	O
+in	O
+the	O
+antibody	B-COMP
+geometric	O
+mean	O
+titers	O
+(	O
+GMTs	O
+)	O
+for	O
+all	O
+antigens	B-CHED
+.	O
+
+TITLE	O
+:	O
+Epithelial	B-ANAT
+cells	I-ANAT
+lining	O
+salivary	B-ANAT
+gland	I-ANAT
+ducts	B-ANAT
+are	O
+early	O
+target	B-ANAT
+cells	I-ANAT
+of	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+coronavirus	B-DISO
+infection	I-DISO
+in	O
+the	O
+upper	O
+respiratory	B-ANAT
+tracts	I-ANAT
+of	O
+rhesus	B-SPEC
+macaques	I-SPEC
+.	O
+
+The	O
+source	O
+of	O
+high	O
+viral	O
+loads	O
+in	O
+saliva	B-ANAT
+,	O
+however	O
+,	O
+remains	O
+elusive	O
+.	O
+
+It	O
+has	O
+enabled	O
+us	O
+to	O
+determine	O
+the	O
+structures	O
+of	O
+two	O
+coronavirus	B-SPEC
+receptor	O
+-	O
+binding	B-FUNC
+domains	O
+each	O
+complexed	O
+with	O
+their	O
+receptor	O
+at	O
+moderate	O
+resolutions	O
+.	O
+
+TITLE	O
+:	O
+Development	B-PROC
+of	O
+anti	B-CHED
+-	I-CHED
+viral	I-CHED
+agents	I-CHED
+using	O
+molecular	O
+modeling	O
+and	O
+virtual	O
+screening	O
+techniques	O
+.	O
+
+The	O
+most	O
+obvious	O
+example	O
+is	O
+anti	O
+-	O
+AIDS	O
+research	O
+,	O
+where	O
+HIV	B-PRGE
+protease	I-PRGE
+and	O
+reverse	B-PRGE
+transcriptase	I-PRGE
+have	O
+triggered	O
+enormous	O
+efforts	O
+in	O
+developing	O
+and	O
+improving	O
+computational	O
+methods	O
+.	O
+
+From	O
+2006	O
+to	O
+2008	O
+,	O
+30	O
+patients	O
+received	O
+ECMO	O
+for	O
+severe	O
+ARDS	B-DISO
+.	O
+
+Patients	O
+were	O
+divided	O
+into	O
+three	O
+groups	O
+according	O
+to	O
+the	O
+configuration	O
+:	O
+veno	O
+-	O
+venous	B-ANAT
+(	O
+vv	O
+;	O
+n	O
+=	O
+11	O
+),	O
+venoarterial	O
+(	O
+va	O
+;	O
+n	O
+=	O
+8	O
+)	O
+or	O
+veno	O
+-	O
+venoarterial	O
+(	O
+vva	O
+;	O
+n	O
+=	O
+11	O
+).	O
+
+All	O
+patients	O
+presented	O
+with	O
+a	O
+mixture	B-CHED
+of	O
+bilateral	O
+patchy	O
+consolidations	O
+and	O
+ground	O
+glass	O
+opacities	B-DISO
+.	O
+
+Here	O
+we	O
+demonstrate	O
+that	O
+FMDV	B-PRGE
+Lb	I-PRGE
+(	I-PRGE
+pro	B-CHED
+),	I-PRGE
+a	O
+shorter	O
+form	O
+of	O
+L	O
+(	O
+pro	B-CHED
+),	O
+has	O
+deubiquitinating	B-PROC
+activity	O
+.	O
+
+Mutations	O
+in	O
+Lb	O
+(	O
+pro	B-CHED
+)	O
+that	O
+ablate	O
+the	O
+catalytic	B-FUNC
+activity	I-FUNC
+(	O
+C51A	O
+or	O
+D163N	O
+/	O
+D164N	O
+)	O
+or	O
+disrupt	O
+the	O
+SAP	O
+(	O
+for	O
+SAF	B-PRGE
+-	I-PRGE
+A	I-PRGE
+/	I-PRGE
+B	I-PRGE
+,	O
+Acinus	B-ANAT
+,	O
+and	O
+PIAS	O
+)	O
+domain	O
+(	O
+I83A	O
+/	O
+L86A	O
+)	O
+abrogated	O
+the	O
+DUB	O
+activity	O
+of	O
+Lb	B-PRGE
+(	I-PRGE
+pro	I-PRGE
+)	I-PRGE
+as	O
+well	O
+as	O
+its	O
+ability	O
+to	O
+block	O
+signaling	B-PROC
+to	O
+the	O
+IFN	B-PRGE
+-	I-PRGE
+β	I-PRGE
+promoter	I-PRGE
+.	O
+
+From	O
+December	O
+1989	O
+to	O
+December	O
+2008	O
+,	O
+102	O
+consecutive	O
+patients	O
+with	O
+pure	B-FUNC
+DAI	O
+were	O
+admitted	O
+to	O
+our	O
+neurosurgical	O
+intensive	O
+care	O
+unit	O
+.	O
+
+Age	O
+,	O
+gender	O
+,	O
+Acute	O
+Physiology	O
+and	O
+Chronic	O
+Health	O
+Evaluation	O
+score	O
+,	O
+Glasgow	O
+Coma	B-DISO
+Score	O
+(	O
+GCS	O
+),	O
+pupillary	O
+light	O
+reactivity	O
+on	O
+admission	O
+,	O
+brain	B-ANAT
+magnetic	O
+resonance	O
+imaging	O
+(	O
+MRI	O
+)	O
+24	O
+hours	O
+to	O
+72	O
+hours	O
+after	O
+trauma	O
+and	O
+sepsis	B-DISO
+,	O
+shock	O
+,	O
+adult	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+,	O
+renal	B-DISO
+failure	I-DISO
+,	O
+neurosurgery	O
+,	O
+high	O
+intracranial	B-PROC
+pressure	I-PROC
+during	O
+the	O
+6	O
+months	O
+posttrauma	O
+were	O
+studied	O
+with	O
+multiple	O
+logistic	O
+regression	O
+,	O
+and	O
+Cox	O
+'	O
+s	O
+proportional	O
+hazards	O
+,	O
+respectively	O
+,	O
+considering	O
+the	O
+Glasgow	O
+Outcome	O
+Scale	O
+and	O
+the	O
+time	O
+to	O
+recovery	O
+of	O
+consciousness	O
+as	O
+outcome	O
+variables	O
+.	O
+
+All	O
+18	O
+patients	O
+had	O
+acute	O
+lung	B-ANAT
+injury	O
+(	O
+ALI	O
+)	O
+or	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+(	O
+ARDS	B-DISO
+).	O
+
+The	O
+most	O
+common	O
+clinical	O
+presentation	O
+was	O
+ALI	O
+/	O
+ARDS	B-DISO
+in	O
+H1N1	O
+patients	O
+who	O
+needed	O
+intensive	O
+care	O
+.	O
+
+Multiple	O
+sequence	O
+alignment	O
+of	O
+deduced	O
+amino	B-CHED
+acid	I-CHED
+sequences	O
+with	O
+commonly	O
+used	O
+vaccine	O
+strains	O
+revealed	O
+that	O
+most	O
+substitutions	O
+occurred	O
+in	O
+the	O
+53	O
+-	O
+148	O
+amino	B-CHED
+acid	I-CHED
+region	O
+.	O
+
+Also	O
+analyzed	O
+were	O
+six	O
+swab	O
+samples	O
+(	O
+tracheal	O
+and	O
+cloacal	B-ANAT
+)	O
+from	O
+asymptomatic	O
+pigeons	B-SPEC
+(	O
+Columba	B-SPEC
+livia	I-SPEC
+),	O
+caught	O
+in	O
+an	O
+urbanized	O
+region	O
+in	O
+southeastern	O
+Brazil	O
+.	O
+
+In	O
+this	O
+respect	O
+,	O
+one	O
+could	O
+also	O
+expect	O
+benefits	O
+in	O
+the	O
+management	O
+of	O
+other	O
+bird	B-SPEC
+species	B-SPEC
+that	O
+may	O
+act	O
+as	O
+avian	B-SPEC
+coronavirus	I-SPEC
+reservoirs	O
+.	O
+
+With	O
+the	O
+experience	O
+acquired	O
+in	O
+the	O
+2009	O
+AH1	O
+/	O
+N1	O
+influenza	B-DISO
+pandemic	O
+,	O
+virological	O
+diagnosis	O
+of	O
+pneumonia	B-DISO
+by	O
+rapid	O
+polymerase	O
+chain	O
+reaction	O
+techniques	O
+has	O
+recently	O
+begun	O
+to	O
+be	O
+used	O
+.	O
+
+Just	O
+as	O
+the	O
+use	O
+of	O
+antibiotics	B-CHED
+to	O
+treat	O
+infections	B-DISO
+radically	O
+changed	O
+their	O
+prognosis	O
+and	O
+treatment	O
+,	O
+reports	O
+in	O
+the	O
+literature	O
+have	O
+progressively	O
+began	O
+to	O
+appear	O
+of	O
+the	O
+immunomodulatory	O
+effect	O
+of	O
+drugs	O
+that	O
+were	O
+not	O
+initially	O
+designed	O
+for	O
+the	O
+treatment	O
+of	O
+pneumonia	B-DISO
+,	O
+leading	O
+to	O
+hope	O
+for	O
+the	O
+potential	O
+modification	O
+of	O
+outcome	O
+in	O
+these	O
+patients	O
+.	O
+
+This	O
+proof	O
+of	O
+concept	O
+study	O
+supports	O
+further	O
+development	B-PROC
+and	O
+design	O
+modifications	O
+to	O
+increase	O
+performance	O
+and	O
+to	O
+reduce	O
+coagulation	B-PROC
+activation	O
+for	O
+potential	O
+long	O
+-	O
+term	O
+application	O
+.	O
+
+TITLE	O
+:	O
+The	O
+Fcγ	B-PRGE
+receptor	I-PRGE
+IIA	I-PRGE
+-	I-PRGE
+H	I-PRGE
+/	I-PRGE
+H131	I-PRGE
+genotype	I-PRGE
+is	O
+associated	O
+with	O
+bacteremia	B-DISO
+in	O
+pneumococcal	O
+community	O
+-	O
+acquired	O
+pneumonia	O
+.	O
+
+FCGR2A	B-PRGE
+-	O
+H131R	O
+polymorphism	B-PROC
+was	O
+determined	O
+in	O
+1	O
+,	O
+262	O
+patients	O
+with	O
+CAP	B-DISO
+and	O
+in	O
+1	O
+,	O
+224	O
+in	O
+the	O
+subject	O
+control	O
+group	O
+.	O
+
+Patients	O
+with	O
+bacteremic	O
+PCAP	B-DISO
+(	O
+B	O
+-	O
+PCAP	B-DISO
+)	O
+had	O
+significantly	O
+higher	O
+frequencies	O
+of	O
+FCGR2A	B-PRGE
+-	I-PRGE
+H	I-PRGE
+/	O
+H131	O
+genotypes	O
+than	O
+those	O
+with	O
+nonbacteremic	O
+PCAP	B-DISO
+(	O
+p	O
+=	O
+.	O
+00016	O
+,	O
+odds	O
+ratio	O
+=	O
+2	O
+.	O
+9	O
+,	O
+95	O
+%	O
+confidence	O
+interval	O
+1	O
+.	O
+58	O
+-	O
+5	O
+.	O
+3	O
+).	O
+
+Thirty	O
+third	O
+-	O
+year	O
+and	O
+fourth	O
+-	O
+year	O
+nursing	B-PROC
+students	O
+were	O
+first	O
+taught	O
+the	O
+procedure	O
+and	O
+then	O
+given	O
+both	O
+an	O
+anxious	O
+-	O
+mood	O
+and	O
+a	O
+calm	O
+-	O
+mood	O
+induction	O
+in	O
+a	O
+randomly	O
+assigned	O
+counterbalanced	O
+order	B-SPEC
+.	O
+
+This	O
+study	O
+investigated	O
+how	O
+the	O
+3CLpro	O
+affected	O
+the	O
+secretion	B-PROC
+of	O
+cytokines	O
+in	O
+the	O
+gene	O
+-	O
+transfected	O
+cells	B-COMP
+.	O
+
+Furthermore	O
+,	O
+the	O
+protein	B-CHED
+levels	O
+of	O
+NF	B-PRGE
+-	I-PRGE
+kB	I-PRGE
+decreased	O
+in	O
+3CLpro	O
+-	O
+transfected	O
+A549	O
+cells	B-COMP
+when	O
+compared	O
+to	O
+EGFP	O
+transfected	O
+cells	B-COMP
+.	O
+
+Inflammatory	O
+cytokines	O
+,	O
+such	O
+as	O
+interleukin	B-PRGE
+1β	I-PRGE
+(	O
+IL	O
+-	O
+1β	O
+),	O
+IL	B-FUNC
+-	I-FUNC
+8	I-FUNC
+,	O
+and	O
+IL	B-FUNC
+-	I-FUNC
+6	I-FUNC
+,	O
+play	O
+a	O
+major	O
+role	O
+in	O
+mediating	O
+and	O
+amplifying	O
+ALI	O
+/	O
+ARDS	B-DISO
+by	O
+stimulating	O
+chemotaxis	B-PROC
+and	O
+activation	O
+of	O
+neutrophils	B-ANAT
+.	O
+
+ABSTRACT	O
+:	O
+The	O
+severe	O
+acute	O
+respiratory	O
+syndrome	O
+(	O
+SARS	B-DISO
+)	O
+leads	O
+to	O
+severe	O
+injury	O
+in	O
+the	O
+lungs	B-ANAT
+with	O
+multiple	O
+factors	O
+,	O
+though	O
+the	O
+pathogenesis	B-DISO
+is	O
+still	O
+largely	O
+unclear	O
+.	O
+
+Among	O
+these	O
+,	O
+13	O
+loci	O
+were	O
+never	O
+reported	O
+to	O
+be	O
+transcriptional	B-PROC
+by	O
+other	O
+detection	O
+methods	O
+such	O
+as	O
+gene	O
+chips	O
+,	O
+tiling	O
+arrays	O
+,	O
+and	O
+paired	O
+-	O
+end	O
+ditags	O
+(	O
+PETs	O
+).	O
+
+The	O
+result	O
+showed	O
+that	O
+random	O
+-	O
+priming	O
+cDNA	O
+library	O
+is	O
+valid	O
+for	O
+the	O
+investigation	O
+of	O
+transcript	O
+diversity	O
+in	O
+the	O
+virus	B-SPEC
+-	O
+infected	O
+tissue	B-ANAT
+.	O
+
+The	O
+EST	O
+data	O
+could	O
+be	O
+a	O
+useful	O
+supplemental	O
+source	O
+for	O
+SARS	B-DISO
+pathology	B-DISO
+researches	O
+.	O
+
+We	O
+report	O
+a	O
+case	O
+of	O
+successfully	O
+treated	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+complicating	O
+imported	O
+P	O
+falciparum	B-DISO
+malaria	I-DISO
+at	O
+a	O
+large	O
+teaching	O
+hospital	O
+in	O
+Washington	O
+,	O
+DC	O
+.	O
+
+TITLE	O
+:	O
+Phylogenetic	O
+analysis	O
+of	O
+infectious	B-DISO
+bronchitis	B-DISO
+coronaviruses	O
+newly	O
+isolated	O
+in	O
+China	O
+,	O
+and	O
+pathogenicity	O
+and	O
+evaluation	O
+of	O
+protection	O
+induced	O
+by	O
+Massachusetts	O
+serotype	O
+H120	O
+vaccine	O
+against	O
+QX	O
+-	O
+like	O
+strains	O
+.	O
+
+TITLE	O
+:	O
+Efficacy	O
+and	O
+safety	O
+of	O
+an	O
+attenuated	O
+live	O
+QX	O
+-	O
+like	O
+infectious	B-DISO
+bronchitis	B-DISO
+virus	B-SPEC
+strain	O
+as	O
+a	O
+vaccine	O
+for	O
+chickens	O
+.	O
+
+There	O
+was	O
+a	O
+clear	O
+decrease	O
+in	O
+pathogenicity	O
+for	O
+the	O
+respiratory	B-ANAT
+tract	I-ANAT
+and	O
+kidneys	B-ANAT
+when	O
+the	O
+virus	B-SPEC
+had	O
+undergone	O
+a	O
+large	O
+number	O
+of	O
+passages	O
+.	O
+
+Both	O
+passage	O
+levels	O
+were	O
+tested	O
+for	O
+efficacy	O
+in	O
+SPF	B-PRGE
+chickens	I-PRGE
+and	O
+passage	O
+level	O
+85	O
+was	O
+tested	O
+for	O
+efficacy	O
+in	O
+commercial	O
+chickens	B-SPEC
+with	O
+maternally	O
+derived	O
+antibodies	B-COMP
+(	O
+MDA	B-CHED
+)	O
+against	O
+a	O
+challenge	O
+with	O
+QX	O
+-	O
+like	O
+strain	O
+IB	O
+D388	O
+.	O
+
+TITLE	O
+:	O
+Successful	O
+extracorporeal	O
+membrane	B-COMP
+oxygenation	B-PROC
+for	O
+respiratory	B-DISO
+failure	I-DISO
+in	O
+an	O
+infant	O
+with	O
+DiGeorge	B-DISO
+anomaly	I-DISO
+,	O
+following	O
+thymus	B-SPEC
+transplantation	O
+.	O
+
+This	O
+case	O
+demonstrates	O
+the	O
+complex	O
+decision	O
+making	O
+process	O
+regarding	O
+initiation	O
+of	O
+ECMO	O
+in	O
+patients	O
+with	O
+severe	O
+immunodeficiency	B-DISO
+.	O
+
+ABSTRACT	O
+:	O
+Since	O
+the	O
+early	O
+1970s	O
+there	O
+has	O
+been	O
+an	O
+ongoing	O
+debate	O
+regarding	O
+the	O
+wisdom	O
+of	O
+promoting	O
+unassisted	O
+spontaneous	O
+breathing	B-PROC
+throughout	O
+the	O
+course	O
+of	O
+critical	B-DISO
+illness	I-DISO
+in	O
+patients	O
+with	O
+severe	O
+respiratory	B-DISO
+failure	I-DISO
+.	O
+
+Use	O
+of	O
+mechanical	O
+ventilation	O
+modes	O
+in	O
+a	O
+manner	O
+that	O
+induces	O
+spontaneous	O
+breathing	B-PROC
+effort	B-PROC
+,	O
+while	O
+simultaneously	O
+reducing	O
+the	O
+work	O
+load	O
+on	O
+the	O
+respiratory	B-ANAT
+muscles	I-ANAT
+,	O
+is	O
+probably	O
+sufficient	O
+to	O
+minimize	O
+both	O
+problems	O
+.	O
+
+ABSTRACT	O
+:	O
+Airway	B-ANAT
+pressure	O
+release	B-PATH
+ventilation	O
+(	O
+APRV	O
+)	O
+and	O
+bi	O
+-	O
+level	O
+positive	O
+airway	B-ANAT
+pressure	O
+(	O
+BIPAP	O
+)	O
+are	O
+proposed	O
+to	O
+reduce	O
+patient	O
+work	B-PROC
+of	I-PROC
+breathing	I-PROC
+(	O
+WOB	O
+)	O
+sufficiently	O
+and	O
+to	O
+obviate	O
+issues	O
+related	O
+to	O
+patient	O
+-	O
+ventilator	O
+synchrony	O
+,	O
+so	O
+that	O
+spontaneous	O
+breathing	B-PROC
+can	O
+be	O
+maintained	O
+throughout	O
+the	O
+course	O
+of	O
+acute	O
+lung	B-ANAT
+injury	O
+(	O
+ALI	O
+).	O
+
+TITLE	O
+:	O
+Development	B-PROC
+of	O
+monoclonal	O
+antibodies	B-COMP
+(	O
+MAbs	O
+)	O
+to	O
+feline	B-SPEC
+interferon	O
+(	O
+fIFN	O
+)-	O
+γ	O
+as	O
+tools	O
+to	O
+evaluate	O
+cellular	O
+immune	O
+responses	O
+to	O
+feline	B-DISO
+infectious	I-DISO
+peritonitis	I-DISO
+virus	B-SPEC
+(	O
+FIPV	O
+).	O
+
+The	O
+antibody	B-COMP
+-	O
+dependent	O
+enhancement	O
+(	O
+ADE	B-CHED
+)	O
+of	O
+FIPV	O
+infection	B-DISO
+has	O
+been	O
+recognised	O
+in	O
+experimentally	O
+infected	O
+cats	B-SPEC
+,	O
+and	O
+cellular	B-PROC
+immunity	I-PROC
+is	O
+considered	O
+to	O
+play	O
+an	O
+important	O
+role	O
+in	O
+preventing	O
+the	O
+onset	O
+of	O
+FIP	B-DISO
+.	O
+
+Especially	O
+,	O
+CD8	B-PRGE
+(+)	I-PRGE
+fIFN	I-PRGE
+-	I-PRGE
+γ	I-PRGE
+(+)	O
+cells	B-COMP
+,	O
+but	O
+not	O
+CD4	B-PRGE
+(+)	I-PRGE
+fIFN	I-PRGE
+-	I-PRGE
+γ	I-PRGE
+(+)	O
+cells	B-COMP
+,	O
+were	O
+increased	O
+.	O
+
+These	O
+results	O
+suggest	O
+that	O
+cellular	B-PROC
+immunity	I-PROC
+plays	O
+an	O
+important	O
+role	O
+in	O
+preventing	O
+the	O
+development	B-PROC
+of	O
+FIP	B-DISO
+.	O
+
+To	O
+validate	O
+the	O
+immune	O
+-	O
+related	O
+assays	O
+,	O
+hamsters	B-SPEC
+were	O
+infected	O
+with	O
+vesicular	B-SPEC
+stomatitis	I-SPEC
+virus	I-SPEC
+(	O
+VSV	O
+),	O
+Indiana	O
+species	B-SPEC
+,	O
+or	O
+treated	O
+with	O
+lipopolysaccharide	B-CHED
+(	O
+LPS	B-DISO
+)	O
+and	O
+host	B-COMP
+immune	B-PROC
+responses	I-PROC
+were	O
+monitored	O
+in	O
+selected	O
+organs	B-ANAT
+.	O
+
+Ribosomal	B-PRGE
+protein	B-CHED
+L18	I-PRGE
+was	O
+identified	O
+as	O
+the	O
+most	O
+stable	O
+internal	O
+reference	O
+gene	O
+.	O
+
+Secondary	O
+analysis	O
+of	O
+multicentered	O
+,	O
+randomized	O
+,	O
+controlled	O
+trial	O
+data	O
+from	O
+the	O
+National	O
+Heart	B-ANAT
+,	O
+Lung	B-ANAT
+,	O
+and	O
+Blood	B-ANAT
+Institute	O
+Acute	B-DISO
+Respiratory	I-DISO
+Distress	I-DISO
+Syndrome	I-DISO
+Clinical	O
+Trials	O
+Network	O
+.	O
+
+One	O
+hundred	O
+sixty	O
+-	O
+six	O
+of	O
+2632	O
+(	O
+6	O
+.	O
+3	O
+%)	O
+subjects	O
+received	O
+rescue	O
+therapy	O
+,	O
+defined	O
+as	O
+prone	O
+positioning	O
+(	O
+97	O
+of	O
+166	O
+[	O
+58	O
+%]),	O
+inhaled	B-PROC
+vasodilators	O
+(	O
+47	O
+of	O
+166	O
+[	O
+28	O
+%]),	O
+high	O
+-	O
+frequency	O
+ventilation	O
+(	O
+12	O
+of	O
+166	O
+[	O
+7	O
+%]),	O
+or	O
+extracorporeal	O
+membrane	B-COMP
+oxygenation	B-PROC
+(	O
+10	O
+of	O
+166	O
+[	O
+6	O
+%]).	O
+
+Within	O
+the	O
+limits	O
+of	O
+an	O
+observational	O
+study	O
+design	O
+,	O
+we	O
+did	O
+not	O
+find	O
+evidence	O
+of	O
+a	O
+survival	O
+benefit	O
+with	O
+use	O
+of	O
+rescue	O
+therapies	O
+in	O
+acute	O
+lung	B-ANAT
+injury	O
+.	O
+
+The	O
+repeated	O
+computed	O
+tomography	O
+angiogram	O
+of	O
+chest	B-ANAT
+demonstrated	O
+remission	B-DISO
+of	O
+ruptured	O
+ICA	B-CHED
+.	O
+
+It	O
+is	O
+difficult	O
+to	O
+distinguish	O
+between	O
+them	O
+,	O
+especially	O
+in	O
+cases	O
+such	O
+as	O
+our	O
+uremic	O
+SLE	B-DISO
+patient	O
+with	O
+a	O
+calamitous	O
+disease	B-DISO
+progression	I-DISO
+.	O
+
+TITLE	O
+:	O
+Eosinophils	B-ANAT
+:	O
+collection	O
+,	O
+separation	B-DISO
+,	O
+and	O
+activation	O
+.	O
+
+ABSTRACT	O
+:	O
+Feline	O
+infectious	O
+peritonitis	O
+(	O
+FIP	B-DISO
+)	O
+can	O
+be	O
+difficult	O
+to	O
+diagnose	O
+.	O
+
+Clinical	B-DISO
+findings	I-DISO
+,	O
+serum	B-COMP
+protein	B-CHED
+electrophoresis	O
+(	O
+SPE	O
+),	O
+analysis	O
+of	O
+the	O
+effusions	B-DISO
+(	O
+AE	O
+),	O
+antifeline	O
+coronavirus	B-SPEC
+serology	O
+,	O
+serum	B-COMP
+concentration	O
+of	O
+α1	B-PRGE
+-	I-PRGE
+acid	I-PRGE
+glycoprotein	I-PRGE
+(	O
+AGP	B-PRGE
+)	O
+and	O
+histopathology	O
+were	O
+classified	O
+as	O
+consistent	O
+,	O
+doubtful	O
+or	O
+non	O
+-	O
+consistent	O
+with	O
+FIP	B-DISO
+.	O
+
+In	O
+the	O
+current	O
+study	O
+,	O
+we	O
+first	O
+examined	O
+the	O
+efficacy	O
+of	O
+UDA	B-CHED
+on	O
+the	O
+replication	O
+of	O
+different	O
+SARS	B-DISO
+-	O
+CoV	O
+strains	O
+in	O
+Vero	O
+76	O
+cells	B-COMP
+.	O
+
+BALB	O
+/	O
+c	O
+mice	B-SPEC
+were	O
+infected	O
+with	O
+two	O
+LD50	O
+(	O
+575	O
+PFU	B-CHED
+)	O
+of	O
+virus	B-SPEC
+for	O
+4	O
+h	O
+before	O
+the	O
+mice	B-SPEC
+were	O
+treated	O
+intraperitoneally	O
+with	O
+UDA	B-CHED
+at	O
+20	O
+,	O
+10	O
+,	O
+5	O
+or	O
+0	O
+mg	O
+/	O
+kg	O
+/	O
+day	O
+for	O
+4	O
+days	O
+.	O
+
+Treatment	O
+with	O
+UDA	B-CHED
+at	O
+5	O
+mg	O
+/	O
+kg	O
+significantly	O
+protected	O
+the	O
+mice	B-SPEC
+against	O
+a	O
+lethal	O
+infection	B-DISO
+with	O
+mouse	B-SPEC
+-	O
+adapted	O
+SARS	B-DISO
+-	O
+CoV	O
+(	O
+p	O
+<	O
+0	O
+.	O
+001	O
+),	O
+but	O
+did	O
+not	O
+significantly	O
+reduce	O
+virus	O
+lung	B-ANAT
+titers	O
+.	O
+
+When	O
+UDA	B-CHED
+was	O
+exposed	O
+to	O
+N	B-CHED
+-	I-CHED
+acetylglucosamine	I-CHED
+and	O
+then	O
+UDA	B-CHED
+was	O
+added	O
+to	O
+cells	B-COMP
+just	O
+prior	O
+to	O
+adsorption	O
+,	O
+UDA	B-CHED
+did	O
+not	O
+inhibit	O
+the	O
+virus	B-DISO
+infection	I-DISO
+.	O
+
+ABSTRACT	O
+:	O
+Green	B-PRGE
+fluorescent	I-PRGE
+protein	I-PRGE
+(	O
+GFP	O
+)-	O
+tagged	O
+mouse	B-DISO
+hepatitis	I-DISO
+coronavirus	B-SPEC
+nonstructural	B-PRGE
+protein	I-PRGE
+4	I-PRGE
+(	O
+nsp4	B-PRGE
+)	O
+was	O
+shown	O
+to	O
+localize	O
+to	O
+the	O
+endoplasmic	B-COMP
+reticulum	I-COMP
+(	O
+ER	O
+)	O
+and	O
+to	O
+be	O
+recruited	O
+to	O
+the	O
+coronavirus	B-SPEC
+replicative	O
+structures	O
+.	O
+
+The	O
+molecular	O
+data	O
+presented	O
+in	O
+this	O
+study	O
+provide	O
+the	O
+first	O
+genetic	O
+evidence	O
+for	O
+a	O
+new	O
+coronavirus	O
+associated	O
+with	O
+epizootic	O
+catarrhal	O
+gastroenteritis	B-DISO
+outbreaks	O
+in	O
+mink	B-SPEC
+and	O
+demonstrate	O
+that	O
+MCoVs	O
+possess	B-DISO
+high	O
+genomic	O
+variability	O
+and	O
+relatively	O
+low	O
+overall	O
+nucleotide	B-CHED
+sequence	O
+identities	O
+(	O
+91	O
+.	O
+7	O
+%)	O
+between	O
+contemporary	O
+strains	O
+.	O
+
+ABSTRACT	O
+:	O
+Acute	O
+lung	O
+injury	O
+(	O
+ALI	O
+)	O
+and	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+(	O
+ARDS	B-DISO
+)	O
+are	O
+severe	O
+inflammatory	O
+lung	B-DISO
+diseases	I-DISO
+associated	O
+with	O
+very	O
+high	O
+mortality	O
+,	O
+and	O
+are	O
+the	O
+most	O
+common	O
+and	O
+earliest	O
+organ	B-ANAT
+dysfunctions	O
+in	O
+the	O
+development	B-PROC
+of	O
+multiple	B-DISO
+organ	I-DISO
+dysfunction	I-DISO
+syndrome	I-DISO
+.	O
+
+In	O
+this	O
+study	O
+,	O
+several	O
+alizarine	O
+derivatives	O
+were	O
+synthesized	O
+and	O
+tested	O
+for	O
+both	O
+HIV	B-SPEC
+-	I-SPEC
+1	I-SPEC
+RT	O
+-	O
+associated	O
+activities	O
+.	O
+
+With	O
+some	O
+improvements	O
+in	O
+the	O
+expression	B-PROC
+system	O
+,	O
+it	O
+could	O
+be	O
+used	O
+to	O
+induce	O
+a	O
+targeted	B-PROC
+immune	B-PROC
+response	I-PROC
+against	O
+specific	O
+mucosal	B-ANAT
+pathogens	O
+,	O
+and	O
+co	O
+-	O
+expression	B-PROC
+of	O
+several	O
+antigens	B-CHED
+would	O
+allow	O
+development	B-PROC
+of	O
+a	O
+novel	O
+multivalent	O
+vaccine	O
+.	O
+
+The	O
+aims	O
+of	O
+this	O
+review	O
+are	O
+to	O
+summarize	O
+the	O
+definitions	O
+,	O
+causes	O
+,	O
+and	O
+clinical	O
+course	O
+as	O
+well	O
+as	O
+the	O
+current	O
+understanding	O
+of	O
+the	O
+genetic	O
+background	O
+,	O
+mechanism	O
+of	O
+disease	O
+,	O
+and	O
+therapy	O
+of	O
+toxic	O
+epidermal	O
+necrolysis	O
+and	O
+Stevens	B-DISO
+-	I-DISO
+Johnson	I-DISO
+syndrome	I-DISO
+.	O
+
+Toxic	B-DISO
+epidermal	I-DISO
+necrolysis	I-DISO
+and	O
+Stevens	B-DISO
+-	I-DISO
+Johnson	I-DISO
+syndrome	I-DISO
+are	O
+acute	O
+inflammatory	O
+skin	B-ANAT
+reactions	O
+.	O
+
+TITLE	O
+:	O
+Retrieval	O
+of	O
+critically	B-DISO
+ill	I-DISO
+adults	O
+using	O
+extracorporeal	O
+membrane	B-COMP
+oxygenation	B-PROC
+:	O
+an	O
+Australian	O
+experience	O
+.	O
+
+The	O
+indications	O
+for	O
+retrieval	O
+were	O
+respiratory	O
+in	O
+38	O
+patients	O
+(	O
+of	O
+whom	O
+16	O
+were	O
+confirmed	O
+or	O
+suspected	O
+H1N1	O
+cases	O
+)	O
+and	O
+cardiac	B-ANAT
+in	O
+2	O
+patients	O
+.	O
+
+Thirty	O
+-	O
+four	O
+patients	O
+(	O
+85	O
+%)	O
+survived	O
+to	O
+hospital	O
+discharge	B-ANAT
+.	O
+
+We	O
+have	O
+previously	O
+shown	O
+that	O
+papain	B-PRGE
+-	I-PRGE
+like	I-PRGE
+protease	I-PRGE
+domain	I-PRGE
+2	I-PRGE
+(	O
+PLP2	B-PRGE
+),	O
+a	O
+catalytic	O
+domain	O
+of	O
+the	O
+nonstructural	B-PRGE
+protein	I-PRGE
+3	I-PRGE
+(	O
+nsp3	B-PRGE
+)	O
+of	O
+MHV	B-SPEC
+-	O
+A59	O
+,	O
+encodes	O
+a	O
+deubiquitinase	B-PROC
+(	O
+DUB	B-PRGE
+)	O
+and	O
+inactivates	O
+IFN	B-PRGE
+regulatory	I-PRGE
+factor	I-PRGE
+3	I-PRGE
+(	O
+IRF3	B-PRGE
+)	O
+thereby	O
+the	O
+type	O
+I	O
+interferon	B-PRGE
+(	O
+IFN	B-PRGE
+)	O
+response	O
+.	O
+
+TITLE	O
+:	O
+Routine	O
+prone	O
+positioning	O
+in	O
+patients	O
+with	O
+severe	O
+ARDS	B-DISO
+:	O
+feasibility	O
+and	O
+impact	O
+on	O
+prognosis	O
+.	O
+
+The	O
+lung	B-ANAT
+injury	O
+score	O
+was	O
+3	O
+.	O
+13	O
+±	O
+0	O
+.	O
+15	O
+.	O
+
+CONCLUSIONS	O
+:	O
+We	O
+demonstrate	O
+the	O
+clinical	O
+feasibility	O
+of	O
+routine	O
+PP	O
+in	O
+patients	O
+with	O
+a	O
+PaO	B-PROC
+(	O
+2	O
+)/	O
+FiO	O
+(	O
+2	O
+)	O
+below	O
+100	O
+mmHg	O
+after	O
+24	O
+-	O
+48	O
+h	O
+and	O
+suggest	O
+that	O
+,	O
+when	O
+combined	O
+with	O
+a	O
+low	O
+stretch	O
+ventilation	O
+strategy	O
+,	O
+it	O
+is	O
+protective	O
+with	O
+a	O
+high	O
+survival	O
+rate	O
+.	O
+
+Currently	O
+,	O
+the	O
+longitudinal	O
+profiles	O
+of	O
+antibody	B-PROC
+responses	I-PROC
+in	O
+recovered	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+(	O
+SARS	B-DISO
+)	O
+patients	O
+have	O
+not	O
+been	O
+fully	O
+characterized	O
+.	O
+
+For	O
+IgG	B-PRGE
+antibodies	I-PRGE
+in	O
+the	O
+3rd	O
+y	O
+,	O
+the	O
+positive	O
+rate	O
+of	O
+whole	O
+-	O
+virus	B-SPEC
+-	O
+specific	O
+antibodies	B-COMP
+was	O
+42	O
+%,	O
+which	O
+was	O
+tested	O
+with	O
+commercial	O
+kits	O
+at	O
+1	O
+/	O
+10	O
+dilution	O
+of	O
+the	O
+sera	B-COMP
+.	O
+
+In	O
+comparison	O
+,	O
+the	O
+positive	O
+rate	O
+of	O
+spike	O
+(	O
+S	O
+)	O
+protein	B-CHED
+-	O
+specific	O
+antibodies	B-COMP
+was	O
+100	O
+%,	O
+which	O
+was	O
+tested	O
+by	O
+spike	O
+protein	B-CHED
+-	O
+based	O
+ELISA	O
+at	O
+1	O
+/	O
+100	O
+dilution	O
+;	O
+4	O
+samples	O
+at	O
+month	O
+60	O
+were	O
+included	O
+.	O
+
+ABSTRACT	O
+:	O
+Virus	B-SPEC
+-	O
+associated	O
+hemophagocytic	B-DISO
+syndrome	I-DISO
+(	O
+VAHS	O
+)	O
+is	O
+a	O
+severe	O
+complication	B-DISO
+of	O
+various	O
+viral	B-DISO
+infections	I-DISO
+often	O
+resulting	O
+in	O
+multiorgan	B-DISO
+failure	I-DISO
+and	O
+death	B-PROC
+.	O
+
+All	O
+25	O
+patients	O
+received	O
+mechanical	O
+ventilation	O
+for	O
+severe	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+and	O
+refractory	O
+hypoxemia	O
+,	O
+with	O
+a	O
+median	O
+duration	O
+of	O
+mechanical	O
+ventilation	O
+of	O
+19	O
+days	O
+(	O
+IQR	O
+,	O
+13	O
+to	O
+26	O
+days	O
+).	O
+
+TITLE	O
+:	O
+Views	O
+of	O
+GPs	B-DISO
+and	O
+practice	O
+nurses	O
+on	O
+support	O
+needed	O
+to	O
+respond	O
+to	O
+pandemic	O
+influenza	B-DISO
+:	O
+a	O
+qualitative	O
+study	O
+.	O
+
+The	O
+two	O
+most	O
+effective	O
+siRNAs	O
+,	O
+targeting	B-PROC
+the	O
+untranslated	O
+5	O
+'	O
+leader	O
+sequence	O
+(	O
+L2	O
+)	O
+and	O
+the	O
+nucleocapsid	O
+gene	O
+(	O
+N1	O
+),	O
+resulted	O
+in	O
+a	O
+>	O
+95	O
+%	O
+reduction	O
+in	O
+extracellular	B-COMP
+viral	O
+titre	O
+.	O
+
+TITLE	O
+:	O
+In	O
+vitro	O
+inhibition	B-PROC
+of	O
+porcine	B-SPEC
+hemagglutinating	O
+encephalomyelitis	B-DISO
+virus	B-PROC
+replication	I-PROC
+with	O
+siRNAs	O
+targeting	O
+the	O
+spike	O
+glycoprotein	B-CHED
+and	O
+replicase	B-PRGE
+polyprotein	O
+genes	O
+.	O
+
+ABSTRACT	O
+:	O
+The	O
+specific	O
+effect	O
+of	O
+rna	B-PROC
+interference	I-PROC
+on	O
+the	O
+replication	O
+of	O
+porcine	B-SPEC
+hemagglutinating	O
+encephalomyelitis	B-DISO
+virus	B-SPEC
+(	O
+phe	B-CHED
+-	O
+cov	O
+)	O
+was	O
+explored	O
+.	O
+
+Examination	O
+of	O
+CPE	O
+demonstrated	O
+that	O
+the	O
+four	O
+siRNAs	O
+were	O
+capable	O
+of	O
+protecting	O
+cells	B-COMP
+against	O
+PHE	B-CHED
+-	O
+CoV	O
+invasion	B-DISO
+with	O
+very	O
+high	O
+specificity	O
+and	O
+efficiency	O
+.	O
+
+Transfection	B-PROC
+with	O
+siRNAs	O
+also	O
+suppressed	O
+the	O
+production	O
+of	O
+infectious	B-DISO
+virus	B-SPEC
+by	O
+up	O
+to	O
+18	O
+-	O
+to	O
+32	O
+-	O
+fold	O
+as	O
+assessed	O
+by	O
+a	O
+HA	O
+test	O
+and	O
+93	O
+-	O
+to	O
+494	O
+-	O
+fold	O
+as	O
+assessed	O
+by	O
+TCID	O
+(	O
+50	O
+)	O
+assay	O
+.	O
+
+Furthermore	O
+,	O
+treatment	O
+with	O
+siRNAs	O
+caused	O
+a	O
+53	O
+-	O
+91	O
+%	O
+reduction	O
+in	O
+the	O
+viral	B-COMP
+genome	I-COMP
+copy	O
+number	O
+as	O
+assessed	O
+by	O
+real	O
+-	O
+time	O
+RT	O
+-	O
+PCR	O
+.	O
+
+The	O
+patient	O
+had	O
+an	O
+acute	O
+unilateral	O
+hydrops	B-DISO
+,	O
+with	O
+a	O
+monolateral	O
+keratoconus	B-DISO
+.	O
+
+Many	O
+cellular	B-COMP
+proteins	B-CHED
+interacting	O
+with	O
+regulatory	O
+CoV	B-PRGE
+RNA	I-PRGE
+sequences	I-PRGE
+are	O
+members	O
+of	O
+the	O
+heterogeneous	B-PRGE
+nuclear	I-PRGE
+ribonucleoprotein	I-PRGE
+(	O
+hnRNP	B-ANAT
+)	O
+family	B-SPEC
+of	O
+RNA	O
+-	O
+binding	B-FUNC
+proteins	B-CHED
+,	O
+involved	O
+in	O
+mRNA	B-PROC
+processing	I-PROC
+and	O
+transport	B-PROC
+,	O
+which	O
+shuttle	O
+between	O
+the	O
+nucleus	B-COMP
+and	O
+the	O
+cytoplasm	B-COMP
+.	O
+
+TITLE	O
+:	O
+[	O
+Encephalomyelitis	B-DISO
+caused	O
+by	O
+enterovirus	B-SPEC
+type	O
+71	O
+in	O
+children	O
+].	O
+
+ABSTRACT	O
+:	O
+The	O
+transcription	O
+and	O
+replication	O
+of	O
+the	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+(	O
+SARS	B-DISO
+)	O
+coronavirus	B-SPEC
+(	O
+SARS	B-DISO
+-	O
+CoV	O
+)	O
+is	O
+regulated	O
+by	O
+specific	O
+viral	B-COMP
+genome	I-COMP
+sequences	O
+within	O
+5	O
+'-	O
+and	O
+3	O
+'-	O
+untranslated	O
+regions	O
+(	O
+5	O
+'-	O
+UTR	O
+and	O
+3	O
+'-	O
+UTR	O
+).	O
+
+The	O
+highly	O
+conserved	O
+pentaloop	O
+of	O
+SL2	B-PRGE
+is	O
+stacked	O
+on	O
+5	O
+-	O
+bp	O
+stem	B-ANAT
+and	O
+adopts	O
+a	O
+canonical	O
+CUYG	O
+tetraloop	O
+fold	O
+with	O
+the	O
+3	O
+'	O
+nucleotide	B-CHED
+(	O
+U51	O
+)	O
+flipped	O
+out	O
+of	O
+the	O
+stack	O
+.	O
+
+17	O
+differentially	O
+expressed	B-PROC
+proteins	B-CHED
+from	O
+tracheal	O
+tissues	B-ANAT
+and	O
+19	O
+differentially	O
+expressed	B-PROC
+proteins	B-CHED
+from	O
+kidney	B-ANAT
+tissues	B-ANAT
+were	O
+identified	O
+.	O
+
+Moreover	O
+,	O
+western	O
+blotting	O
+analysis	O
+further	O
+confirmed	O
+the	O
+changes	O
+of	O
+annexin	B-PRGE
+A5	I-PRGE
+and	O
+HSPB1	B-PRGE
+during	O
+IBV	B-SPEC
+infection	B-DISO
+.	O
+
+To	O
+study	O
+whether	O
+the	O
+TRS	B-DISO
+-	O
+L	O
+is	O
+structured	O
+and	O
+to	O
+determine	O
+whether	O
+this	O
+structure	O
+has	O
+a	O
+functional	O
+impact	O
+on	O
+genomic	O
+and	O
+subgenomic	O
+viral	O
+RNA	B-PROC
+synthesis	I-PROC
+,	O
+we	O
+have	O
+used	O
+a	O
+combination	O
+of	O
+nuclear	O
+magnetic	O
+resonance	O
+(	O
+NMR	O
+)	O
+spectroscopy	O
+and	O
+UV	O
+thermal	O
+denaturation	B-PROC
+approaches	O
+together	O
+with	O
+site	B-PROC
+-	I-PROC
+directed	I-PROC
+mutagenesis	I-PROC
+and	O
+in	O
+vivo	O
+transcriptional	B-PROC
+analyses	O
+.	O
+
+TRS	B-DISO
+-	O
+L	O
+mutations	O
+altering	O
+the	O
+structure	O
+and	O
+the	O
+stability	O
+of	O
+the	O
+TRS	B-DISO
+-	O
+L	O
+hairpin	O
+affected	O
+replication	O
+and	O
+transcription	B-PROC
+,	O
+indicating	O
+the	O
+requirement	O
+of	O
+a	O
+functional	O
+RNA	O
+hairpin	O
+structure	O
+in	O
+these	O
+processes	O
+.	O
+
+Overall	O
+influenza	B-SPEC
+virus	I-SPEC
+A	O
+(	O
+27	O
+.	O
+3	O
+%)	O
+was	O
+the	O
+most	O
+common	O
+virus	B-SPEC
+followed	O
+by	O
+rhinovirus	B-SPEC
+(	O
+24	O
+.	O
+8	O
+%),	O
+RSV	B-SPEC
+(	O
+21	O
+.	O
+2	O
+%),	O
+adenovirus	O
+(	O
+6	O
+.	O
+1	O
+%),	O
+coronavirus	B-SPEC
+OC43	O
+(	O
+6	O
+.	O
+1	O
+%),	O
+influenza	B-SPEC
+virus	I-SPEC
+B	O
+(	O
+3	O
+.	O
+9	O
+%),	O
+parainfluenza	B-DISO
+virus	B-SPEC
+-	O
+3	O
+(	O
+2	O
+.	O
+9	O
+%),	O
+and	O
+parainfluenza	B-DISO
+virus	B-SPEC
+-	O
+1	O
+(	O
+2	O
+.	O
+3	O
+%).	O
+
+Thus	O
+,	O
+we	O
+conducted	O
+30	O
+-	O
+ns	O
+molecular	B-PROC
+dynamics	I-PROC
+(	O
+MD	O
+)	O
+simulations	O
+for	O
+N214A	O
+,	O
+WT	O
+,	O
+and	O
+R298A	O
+which	O
+we	O
+previously	O
+characterized	O
+to	O
+be	O
+a	O
+monomer	O
+with	O
+the	O
+collapsed	O
+catalytic	O
+machinery	O
+.	O
+
+Remarkably	O
+,	O
+three	O
+proteases	O
+display	O
+distinctive	O
+dynamical	O
+behaviors	B-PROC
+.	O
+
+Consequently	O
+,	O
+mediating	O
+the	O
+dynamics	O
+may	O
+offer	O
+a	O
+potential	O
+avenue	O
+to	O
+inhibit	O
+the	O
+SARS	B-PRGE
+-	I-PRGE
+CoV	I-PRGE
+3CLpro	I-PRGE
+.	O
+
+A	O
+total	O
+of	O
+81	O
+patients	O
+diagnosed	O
+as	O
+SAP	B-PRGE
+were	O
+randomly	O
+assigned	O
+to	O
+a	O
+control	O
+group	O
+or	O
+treatment	O
+group	O
+according	O
+to	O
+a	O
+random	O
+number	O
+table	O
+generated	O
+from	O
+an	O
+SPSS	O
+software	O
+.	O
+
+Dx	O
+combined	O
+with	O
+DCQD	O
+could	O
+decrease	O
+the	O
+risk	O
+of	O
+developing	O
+ARDS	B-DISO
+in	O
+SAP	O
+patients	O
+with	O
+SIRS	B-DISO
+and	O
+shorten	O
+their	O
+length	O
+of	O
+hospitalization	O
+.	O
+
+CONCLUSIONS	O
+:	O
+Dx	O
+combined	O
+with	O
+DCQD	O
+could	O
+decrease	O
+the	O
+risk	O
+of	O
+developing	O
+ARDS	B-DISO
+in	O
+SAP	O
+patients	O
+with	O
+SIRS	B-DISO
+and	O
+shorten	O
+their	O
+length	O
+of	O
+hospitalization	O
+.	O
+
+Knowledge	O
+on	O
+the	O
+ecology	O
+of	O
+reservoir	O
+-	O
+borne	O
+viruses	B-SPEC
+is	O
+critical	O
+for	O
+preventive	O
+approaches	O
+against	O
+zoonotic	O
+epidemics	O
+.	O
+
+Nsp16	O
+is	O
+an	O
+RNA	B-PRGE
+-	I-PRGE
+cap	I-PRGE
+AdoMet	B-CHED
+-	I-PRGE
+dependent	I-PRGE
+(	I-PRGE
+nucleoside	B-CHED
+-	I-PRGE
+2	I-PRGE
+'-	I-PRGE
+O	I-PRGE
+-)-	I-PRGE
+methyltransferase	I-PRGE
+that	O
+is	O
+only	O
+active	O
+in	O
+the	O
+presence	O
+of	O
+nsp10	O
+.	O
+
+The	O
+crystals	B-ANAT
+diffracted	O
+to	O
+a	O
+resolution	O
+of	O
+1	O
+.	O
+9	O
+Å	O
+resolution	O
+and	O
+crystal	B-ANAT
+structure	O
+determination	O
+is	O
+in	O
+progress	O
+.	O
+
+Frog	O
+,	O
+snake	B-SPEC
+,	O
+hare	B-SPEC
+,	O
+and	O
+pheasant	O
+were	O
+the	O
+wild	O
+meats	O
+most	O
+frequently	O
+eaten	O
+by	O
+local	O
+people	O
+.	O
+
+Storage	B-PROC
+of	O
+the	O
+strips	O
+at	O
+room	O
+temperature	O
+for	O
+6	O
+months	O
+or	O
+at	O
+4	O
+°	O
+C	O
+for	O
+12	O
+months	O
+did	O
+not	O
+change	O
+their	O
+sensitivity	O
+and	O
+specificity	O
+.	O
+
+TITLE	O
+:	O
+Porcine	B-SPEC
+teschovirus	I-SPEC
+polioencephalomyelitis	B-DISO
+in	O
+western	O
+Canada	O
+.	O
+
+Necropsies	O
+revealed	O
+no	O
+gross	O
+lesions	O
+,	O
+but	O
+microscopic	O
+lesions	O
+consisted	O
+of	O
+a	O
+nonsuppurative	O
+polioencephalomyelitis	B-DISO
+,	O
+most	O
+severe	O
+in	O
+the	O
+brain	B-ANAT
+stem	I-ANAT
+and	O
+spinal	B-ANAT
+cord	I-ANAT
+.	O
+
+Tests	O
+for	O
+circovirus	B-SPEC
+,	O
+Porcine	B-SPEC
+reproductive	I-SPEC
+and	I-SPEC
+respiratory	I-SPEC
+syndrome	I-SPEC
+virus	I-SPEC
+,	O
+coronavirus	B-SPEC
+,	O
+Rabies	B-SPEC
+virus	I-SPEC
+,	O
+and	O
+Pseudorabies	B-SPEC
+virus	I-SPEC
+were	O
+negative	O
+.	O
+
+Using	O
+immunohistochemistry	O
+,	O
+virus	B-PROC
+neutralization	I-PROC
+,	O
+fluorescent	O
+antibody	B-COMP
+test	O
+,	O
+and	O
+nested	O
+reverse	B-PROC
+transcription	I-PROC
+polymerase	O
+chain	O
+reaction	O
+,	O
+Porcine	B-SPEC
+teschovirus	I-SPEC
+was	O
+identified	O
+in	O
+tissues	B-ANAT
+from	O
+affected	O
+individuals	O
+.	O
+
+The	O
+results	O
+indicated	O
+that	O
+Korean	O
+bovine	O
+kobuvirus	O
+has	O
+diverse	O
+lineages	O
+regardless	O
+of	O
+disease	O
+status	O
+and	O
+species	B-SPEC
+.	O
+
+A	O
+general	O
+shell	B-ANAT
+vial	O
+culture	O
+using	O
+a	O
+pool	O
+of	O
+monoclonal	O
+antibodies	B-COMP
+was	O
+used	O
+to	O
+detect	O
+other	O
+common	O
+respiratory	O
+viruses	B-SPEC
+on	O
+26	O
+%	O
+of	O
+samples	O
+.	O
+
+Infection	B-DISO
+with	O
+other	O
+respiratory	O
+viruses	B-SPEC
+occurred	O
+in	O
+20	O
+/	O
+128	O
+(	O
+16	O
+%)	O
+of	O
+HRV	O
+-	O
+positive	O
+children	O
+and	O
+in	O
+26	O
+/	O
+92	O
+(	O
+28	O
+%)	O
+of	O
+HRV	O
+-	O
+negative	O
+samples	O
+.	O
+
+Treatment	O
+is	O
+mainly	O
+supportive	O
+combining	O
+oxygen	B-CHED
+supplementation	O
+adequate	O
+hydration	O
+analgesia	B-DISO
+and	O
+sedation	B-DISO
+.	O
+
+Patients	O
+usually	O
+present	O
+with	O
+chronic	O
+recurrent	O
+rhinosinusitis	B-DISO
+,	O
+otitis	B-DISO
+media	I-DISO
+,	O
+pneumonia	B-DISO
+,	O
+and	O
+bronchiectasis	B-DISO
+caused	O
+by	O
+pseudomonal	O
+infection	B-DISO
+.	O
+
+TITLE	O
+:	O
+How	O
+I	O
+treat	O
+acute	B-DISO
+chest	I-DISO
+syndrome	I-DISO
+in	O
+children	O
+with	O
+sickle	B-DISO
+cell	I-DISO
+disease	I-DISO
+.	O
+
+PTB	B-PRGE
+was	O
+detected	O
+in	O
+these	O
+modified	O
+stress	O
+granules	O
+in	O
+TGEV	B-SPEC
+-	O
+infected	O
+swine	B-SPEC
+testis	B-ANAT
+cells	B-COMP
+but	O
+not	O
+in	O
+stress	O
+granules	O
+induced	O
+by	O
+oxidative	B-DISO
+stress	I-DISO
+.	O
+
+We	O
+recently	O
+determined	O
+the	O
+crystal	B-ANAT
+structures	O
+of	O
+NL63	O
+coronavirus	B-SPEC
+(	O
+NL63	O
+-	O
+CoV	O
+)	O
+and	O
+SARS	B-DISO
+coronavirus	B-SPEC
+(	O
+SARS	B-DISO
+-	O
+CoV	O
+)	O
+receptor	O
+-	O
+binding	B-FUNC
+domains	O
+(	O
+RBDs	O
+),	O
+each	O
+complexed	O
+with	O
+their	O
+common	O
+receptor	O
+,	O
+human	B-PRGE
+angiotensin	B-PRGE
+-	I-PRGE
+converting	I-PRGE
+enzyme	I-PRGE
+2	I-PRGE
+(	O
+hACE2	O
+),	O
+and	O
+proposed	O
+the	O
+existence	O
+of	O
+a	O
+virus	B-SPEC
+-	O
+binding	B-FUNC
+hot	B-DISO
+spot	I-DISO
+on	O
+hACE2	O
+.	O
+
+TITLE	O
+:	O
+Comparison	O
+of	O
+the	O
+Luminex	O
+xTAG	O
+respiratory	O
+viral	O
+panel	O
+with	O
+xTAG	O
+respiratory	O
+viral	O
+panel	O
+fast	B-FUNC
+for	O
+diagnosis	O
+of	O
+respiratory	O
+virus	B-SPEC
+infections	B-DISO
+.	O
+
+We	O
+recently	O
+reported	O
+that	O
+the	O
+initial	O
+expressions	O
+of	O
+viral	O
+antigens	B-CHED
+in	O
+the	O
+brain	B-ANAT
+are	O
+detected	O
+in	O
+the	O
+infiltrating	B-DISO
+monocyte	B-ANAT
+lineage	O
+and	O
+in	O
+ependymal	B-ANAT
+cells	I-ANAT
+.	O
+
+Their	O
+histopathological	O
+changes	O
+were	O
+similar	O
+to	O
+those	O
+symptoms	O
+observed	O
+in	O
+the	O
+piglets	O
+,	O
+exhibiting	O
+typical	O
+changes	O
+for	O
+non	O
+-	O
+suppurative	O
+encephalitis	B-DISO
+.	O
+
+The	O
+assay	O
+was	O
+highly	O
+specific	O
+since	O
+all	O
+negative	O
+controls	O
+and	O
+other	O
+viruses	B-SPEC
+of	O
+clinical	O
+and	O
+structural	O
+relevance	O
+failed	O
+to	O
+develop	O
+any	O
+positive	O
+results	O
+.	O
+
+Using	O
+the	O
+candidate	O
+gene	O
+approach	O
+,	O
+genetic	O
+variants	O
+associated	O
+with	O
+immune	B-PROC
+response	I-PROC
+and	O
+inflammatory	O
+pathways	B-PROC
+have	O
+been	O
+identified	O
+and	O
+implicated	O
+in	O
+ALI	O
+.	O
+
+ABSTRACT	O
+:	O
+Respiratory	B-SPEC
+syncytial	I-SPEC
+virus	I-SPEC
+(	O
+RSV	B-SPEC
+)	O
+infection	B-DISO
+-	O
+induced	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+(	O
+ARDS	B-DISO
+)	O
+in	O
+previously	O
+healthy	O
+adults	O
+is	O
+rare	O
+,	O
+but	O
+the	O
+overall	O
+mortality	O
+rate	O
+is	O
+40	O
+-	O
+60	O
+%.	O
+
+We	O
+present	O
+the	O
+case	O
+of	O
+an	O
+adult	O
+female	O
+with	O
+RSV	B-SPEC
+pneumonia	B-DISO
+-	O
+induced	O
+ARDS	B-DISO
+who	O
+was	O
+successfully	O
+treated	O
+with	O
+inhaled	B-PROC
+ribavirin	B-CHED
+and	O
+whose	O
+pulmonary	B-PROC
+function	I-PROC
+was	O
+restored	O
+to	O
+near	O
+normal	O
+.	O
+
+Influenza	B-DISO
+,	O
+for	O
+example	O
+,	O
+recurs	O
+annually	O
+and	O
+has	O
+been	O
+modeled	O
+more	O
+thoroughly	O
+than	O
+any	O
+other	B-DISO
+infectious	I-DISO
+disease	I-DISO
+.	O
+
+Moreover	O
+,	O
+models	O
+were	O
+integrated	O
+into	O
+preparedness	O
+exercises	O
+,	O
+during	O
+which	O
+working	O
+relationships	O
+were	O
+established	O
+that	O
+bore	B-CHED
+fruit	O
+during	O
+the	O
+2009	O
+A	O
+/	O
+H1N1	O
+pandemic	O
+.	O
+
+Accordingly	O
+,	O
+we	O
+illustrate	O
+the	O
+increasingly	O
+timely	O
+care	O
+-	O
+seeking	O
+by	O
+which	O
+,	O
+together	O
+with	O
+increasingly	O
+accurate	O
+diagnoses	O
+and	O
+effective	O
+isolation	O
+,	O
+SARS	B-DISO
+was	O
+controlled	O
+via	O
+heuristic	O
+arguments	O
+and	O
+descriptive	O
+analyses	O
+of	O
+familiar	O
+observations	O
+.	O
+
+The	O
+aim	O
+of	O
+this	O
+study	O
+was	O
+to	O
+compare	O
+the	O
+early	O
+progression	O
+of	O
+air	B-ANAT
+sac	B-COMP
+lesions	O
+in	O
+birds	B-SPEC
+receiving	O
+a	O
+vaccine	O
+strain	O
+of	O
+the	O
+virus	B-SPEC
+or	O
+a	O
+more	O
+virulent	O
+field	O
+strain	O
+.	O
+
+TITLE	O
+:	O
+Fulminant	O
+myocarditis	B-DISO
+in	O
+an	O
+adult	O
+with	O
+2009	O
+pandemic	O
+influenza	B-PATH
+A	I-PATH
+(	O
+H1N1	B-DISO
+influenza	I-DISO
+)	O
+infection	B-DISO
+.	O
+
+To	O
+prevent	O
+circuit	O
+thrombosis	B-DISO
+or	O
+thromboembolic	O
+complications	O
+during	O
+ECMO	O
+systemic	O
+anticoagulation	B-PROC
+is	O
+recommended	O
+.	O
+
+Drawing	O
+on	O
+what	O
+we	O
+learned	B-PROC
+from	O
+the	O
+impact	O
+of	O
+SARS	B-DISO
+on	O
+our	O
+hospital	O
+,	O
+we	O
+had	O
+the	O
+opportunity	O
+to	O
+improve	O
+our	O
+organization	O
+'	O
+s	O
+preparedness	O
+for	O
+the	O
+pandemic	O
+.	O
+
+Ten	O
+key	O
+themes	O
+emerged	O
+from	O
+our	O
+qualitative	O
+analysis	O
+of	O
+written	O
+comments	O
+,	O
+including	O
+family	B-SPEC
+-	O
+work	O
+balance	B-PROC
+,	O
+antiviral	B-CHED
+prophylaxis	O
+,	O
+and	O
+mistrust	O
+or	O
+fear	O
+towards	O
+health	O
+care	O
+workers	O
+.	O
+
+Laboratory	O
+data	O
+revealed	O
+severe	O
+renal	B-DISO
+insufficiency	I-DISO
+and	O
+positive	O
+titers	O
+for	O
+the	O
+myeloperoxidase	B-PRGE
+anti	I-PRGE
+-	I-PRGE
+neutrophil	B-ANAT
+cytoplasmic	B-COMP
+and	I-PRGE
+anti	I-PRGE
+-	I-PRGE
+glomerular	B-ANAT
+basement	I-ANAT
+membrane	I-ANAT
+antibodies	B-COMP
+.	O
+
+The	O
+deterioration	O
+of	O
+her	O
+general	O
+status	O
+did	O
+not	O
+allow	O
+us	O
+to	O
+perform	O
+the	O
+renal	B-ANAT
+biopsy	O
+.	O
+
+Although	O
+corticosteroid	B-CHED
+therapy	O
+,	O
+hemodialysis	O
+,	O
+and	O
+plasma	B-ANAT
+exchange	O
+were	O
+concomitantly	O
+initiated	O
+,	O
+pulmonary	B-DISO
+hemorrhage	I-DISO
+occurred	O
+several	O
+days	O
+after	O
+admission	O
+.	O
+
+Mechanical	O
+ventilation	O
+support	O
+was	O
+provided	O
+and	O
+continuous	O
+hemodiafiltration	O
+was	O
+carried	O
+out	O
+,	O
+following	O
+which	O
+the	O
+respiratory	B-DISO
+failure	I-DISO
+improved	O
+immediately	O
+.	O
+
+Thereafter	O
+,	O
+severe	O
+and	O
+serious	O
+systemic	B-DISO
+infection	I-DISO
+due	O
+to	O
+various	O
+pathogens	O
+including	O
+Staphylococcus	B-SPEC
+aureus	I-SPEC
+,	O
+Cytomegalovirus	B-SPEC
+,	O
+Pneumocystis	B-SPEC
+jiroveci	I-SPEC
+,	O
+Pseudomonas	B-SPEC
+aeruginosa	I-SPEC
+,	O
+and	O
+Bacteroides	B-SPEC
+recurred	O
+,	O
+and	O
+she	O
+died	B-PROC
+from	O
+systemic	O
+invasive	B-DISO
+aspergillosis	I-DISO
+(	O
+IA	O
+).	O
+
+TITLE	O
+:	O
+Development	B-PROC
+and	O
+RNA	O
+-	O
+synthesizing	O
+activity	O
+of	O
+coronavirus	B-SPEC
+replication	O
+structures	O
+in	O
+the	O
+absence	O
+of	O
+protein	O
+synthesis	O
+.	O
+
+Using	O
+cycloheximide	B-CHED
+and	O
+puromycin	B-CHED
+,	O
+we	O
+have	O
+studied	O
+the	O
+effect	O
+of	O
+translation	B-PROC
+inhibition	B-PROC
+on	O
+the	O
+RNA	B-PROC
+synthesis	I-PROC
+of	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+coronavirus	B-SPEC
+and	O
+mouse	B-DISO
+hepatitis	I-DISO
+virus	B-SPEC
+.	O
+
+The	O
+MFI	O
+was	O
+evaluated	O
+for	O
+its	O
+diagnostic	O
+power	O
+,	O
+with	O
+panels	O
+of	O
+mouse	B-SPEC
+sera	B-COMP
+classified	O
+as	O
+positive	O
+or	O
+negative	O
+for	O
+anti	O
+-	O
+MHV	B-SPEC
+antibodies	B-COMP
+by	O
+enzyme	O
+-	O
+linked	O
+immunosorbent	O
+assay	O
+(	O
+ELISA	O
+)	O
+using	O
+MHV	B-PRGE
+virion	B-COMP
+antigen	B-CHED
+and	O
+indirect	O
+fluorescent	O
+antibody	B-COMP
+assay	O
+.	O
+
+The	O
+aim	O
+of	O
+our	O
+study	O
+was	O
+to	O
+compare	O
+the	O
+demographic	O
+characteristics	O
+,	O
+clinical	O
+presentation	O
+,	O
+and	O
+mortality	O
+of	O
+critically	B-DISO
+ill	I-DISO
+patients	O
+with	O
+(	O
+H1N1	O
++)	O
+and	O
+without	O
+H1N1	O
+infection	B-DISO
+(	O
+H1N1	O
+-).	O
+
+We	O
+retrospectively	O
+analyzed	O
+medical	O
+charts	O
+of	O
+patients	O
+admitted	O
+in	O
+""""	O
+Swine	B-DISO
+Flu	I-DISO
+ICU	O
+""""	O
+with	O
+ARDS	B-DISO
+from	O
+August	O
+2009	O
+to	O
+May	O
+2010	O
+.	O
+
+The	O
+reduction	O
+of	O
+a	O
+given	O
+social	O
+network	O
+was	O
+described	O
+like	O
+an	O
+involution	B-PROC
+of	O
+the	O
+algebraic	O
+complexity	O
+of	O
+the	O
+associated	O
+Tutte	O
+polynomial	O
+.	O
+
+This	O
+report	O
+describes	O
+a	O
+modified	O
+technique	O
+of	O
+insertion	O
+for	O
+dual	O
+lumen	B-ANAT
+bicaval	O
+cannulae	O
+.	O
+
+The	O
+Global	O
+Outbreak	O
+Alert	O
+and	O
+Response	O
+Network	O
+was	O
+activated	O
+,	O
+and	O
+international	O
+experts	O
+were	O
+brought	O
+together	O
+to	O
+implement	O
+enhanced	O
+global	O
+surveillance	O
+systems	O
+for	O
+SARS	O
+.	O
+The	O
+international	O
+community	O
+has	O
+learned	B-PROC
+a	O
+lot	O
+of	O
+lessons	O
+from	O
+the	O
+SARS	B-DISO
+outbreak	O
+.	O
+
+Within	O
+and	O
+between	O
+hospitals	O
+,	O
+movement	B-PROC
+by	O
+healthcare	O
+workers	O
+,	O
+patients	O
+and	O
+visitors	O
+were	O
+restricted	O
+,	O
+as	O
+was	O
+the	O
+number	O
+of	O
+hospital	O
+visitors	O
+.	O
+
+They	O
+,	O
+as	O
+well	O
+as	O
+all	O
+outgoing	O
+travellers	O
+from	O
+Singapore	O
+,	O
+were	O
+monitored	O
+for	O
+fever	B-PROC
+.	O
+
+Because	O
+of	O
+their	O
+clinical	O
+similarities	O
+to	O
+patients	O
+with	O
+fibromyalgia	B-DISO
+syndrome	I-DISO
+(	O
+FMS	B-DISO
+)	O
+these	O
+post	O
+-	O
+SARS	B-DISO
+subjects	O
+were	O
+similarly	O
+compared	O
+to	O
+21	O
+drug	O
+free	O
+female	O
+patients	O
+,	O
+(	O
+mean	O
+age	O
+42	O
+.	O
+4	O
++/-	O
+
+The	O
+clinical	O
+and	O
+sleep	B-PROC
+features	O
+of	O
+chronic	O
+post	O
+-	O
+SARS	B-DISO
+form	O
+a	O
+syndrome	B-DISO
+of	O
+chronic	O
+fatigue	B-DISO
+,	O
+pain	O
+,	O
+weakness	B-DISO
+,	O
+depression	B-DISO
+and	O
+sleep	B-DISO
+disturbance	I-DISO
+,	O
+which	O
+overlaps	O
+with	O
+the	O
+clinical	O
+and	O
+sleep	B-PROC
+features	O
+of	O
+FMS	B-DISO
+and	O
+chronic	B-DISO
+fatigue	I-DISO
+syndrome	I-DISO
+.	O
+
+Afterwards	O
+,	O
+the	O
+discrete	O
+Fourier	O
+transform	O
+is	O
+applied	O
+to	O
+these	O
+indicator	B-CHED
+sequences	O
+to	O
+calculate	O
+spectra	O
+of	O
+the	O
+nucleotides	B-CHED
+.	O
+
+In	O
+this	O
+study	O
+,	O
+we	O
+demonstrated	O
+that	O
+two	O
+bacterial	O
+pathogens	O
+(	O
+Fusobacterium	B-SPEC
+necrophorum	I-SPEC
+and	O
+Acinetobacter	B-SPEC
+baumannii	I-SPEC
+)	O
+causing	O
+sepsis	B-DISO
+were	O
+detected	O
+by	O
+DNA	O
+-	O
+probe	O
+hybridization	B-PROC
+and	O
+a	O
+severe	O
+acute	O
+respiratory	O
+syndrome	O
+coronavirus	B-SPEC
+was	O
+detected	O
+by	O
+antigen	B-PROC
+-	I-PROC
+antibody	B-COMP
+interaction	I-PROC
+using	O
+the	O
+functional	O
+PCs	B-DISO
+.	O
+
+Optical	O
+readout	O
+with	O
+the	O
+integrated	O
+sensor	O
+detecting	O
+the	O
+signals	O
+from	O
+PCs	B-DISO
+,	O
+allows	O
+for	O
+low	O
+cost	O
+and	O
+robust	O
+readout	O
+of	O
+resonance	O
+peak	O
+shift	O
+.	O
+
+Virological	O
+diagnosis	O
+using	O
+virus	B-SPEC
+culture	O
+,	O
+antigen	B-CHED
+detection	O
+,	O
+and	O
+polymerase	O
+chain	O
+reaction	O
+methods	O
+on	O
+nasal	B-ANAT
+swab	O
+specimens	O
+would	O
+be	O
+attempted	O
+for	O
+all	O
+these	O
+visits	O
+irrespective	O
+of	O
+triggers	O
+.	O
+
+Although	O
+newly	O
+discovered	O
+respiratory	O
+viruses	B-SPEC
+were	O
+identified	O
+in	O
+these	O
+episodes	O
+,	O
+rhinovirus	B-SPEC
+was	O
+the	O
+commonest	O
+organism	O
+associated	O
+with	O
+both	O
+asthma	B-PATH
+exacerbations	O
+and	O
+non	O
+-	O
+asthma	B-PATH
+related	O
+episodes	O
+.	O
+
+This	O
+motif	O
+is	O
+conserved	O
+in	O
+E	O
+proteins	B-CHED
+of	O
+beta	O
+and	O
+gamma	O
+coronaviruses	O
+(	O
+formerly	O
+referred	O
+to	O
+as	O
+group	O
+2	O
+and	O
+3	O
+coronaviruses	O
+),	O
+where	O
+it	O
+also	O
+functions	O
+as	O
+a	O
+Golgi	B-COMP
+complex	I-COMP
+-	O
+targeting	B-PROC
+signal	O
+.	O
+
+ABSTRACT	O
+:	O
+Ebola	B-SPEC
+virus	I-SPEC
+(	O
+EboV	O
+)	O
+and	O
+Marburg	O
+virus	O
+(	O
+MarV	O
+)	O
+(	O
+filoviruses	O
+)	O
+are	O
+the	O
+causative	O
+agents	O
+of	O
+severe	O
+hemorrhagic	B-DISO
+fever	I-DISO
+.	O
+
+Infection	B-DISO
+begins	O
+with	O
+uptake	O
+of	O
+particles	O
+into	O
+cellular	B-COMP
+endosomes	O
+,	O
+where	O
+the	O
+viral	B-COMP
+envelope	I-COMP
+glycoprotein	B-PRGE
+(	O
+GP	O
+)	O
+catalyzes	O
+fusion	O
+between	O
+the	O
+viral	O
+and	O
+host	O
+cell	B-COMP
+membranes	I-COMP
+.	O
+
+There	O
+have	O
+been	O
+cases	O
+of	O
+vasculitis	B-DISO
+following	O
+influenza	B-DISO
+vaccination	O
+,	O
+and	O
+rash	B-DISO
+and	O
+acute	O
+purpura	B-DISO
+may	O
+occur	O
+in	O
+certain	O
+viral	B-DISO
+infections	I-DISO
+.	O
+
+Notably	O
+,	O
+the	O
+patient	O
+had	O
+fever	B-PROC
+,	O
+severe	O
+abdominal	B-DISO
+pain	I-DISO
+,	O
+hematuria	O
+,	O
+arthritis	B-DISO
+,	O
+and	O
+purpuric	O
+manifestations	O
+associated	O
+with	O
+a	O
+normal	O
+platelet	B-ANAT
+count	O
+.	O
+
+Henoch	O
+-	O
+Schönlein	O
+purpura	B-DISO
+triggered	O
+by	O
+the	O
+novel	O
+influenza	B-SPEC
+virus	B-DISO
+infection	I-DISO
+could	O
+be	O
+an	O
+attractive	O
+pathogenetic	O
+hypothesis	O
+.	O
+
+All	O
+the	O
+PCR	O
+products	O
+were	O
+ligated	O
+into	O
+pMD19	O
+-	O
+T	O
+vector	O
+and	O
+sequenced	O
+,	O
+and	O
+the	O
+ORF5a	O
+open	O
+reading	O
+frame	O
+in	O
+the	O
+pMDTM9	O
+plasmid	O
+was	O
+replaced	O
+by	O
+an	O
+enhanced	B-PRGE
+green	I-PRGE
+fluorescent	I-PRGE
+protein	I-PRGE
+(	O
+EGFP	O
+)	O
+gene	O
+.	O
+
+Recombinant	O
+virus	B-SPEC
+expressing	O
+the	O
+green	B-PRGE
+fluorescent	I-PRGE
+protein	B-CHED
+was	O
+rescued	O
+and	O
+identified	O
+by	O
+RT	O
+-	O
+PCR	O
+and	O
+sequencing	O
+.	O
+
+TITLE	O
+:	O
+Perioperative	O
+use	O
+of	O
+metformin	B-CHED
+in	O
+cardiac	B-ANAT
+surgery	O
+.	O
+
+However	O
+,	O
+in	O
+the	O
+majority	O
+of	O
+cases	O
+,	O
+lactic	B-DISO
+acidosis	I-DISO
+is	O
+diagnosed	O
+in	O
+patients	O
+with	O
+severe	O
+acute	B-DISO
+renal	I-DISO
+failure	I-DISO
+,	O
+which	O
+itself	O
+can	O
+cause	O
+lactic	B-DISO
+acidosis	I-DISO
+.	O
+
+TITLE	O
+:	O
+PIKA	B-SPEC
+provides	O
+an	O
+adjuvant	B-CHED
+effect	O
+to	O
+induce	O
+strong	O
+mucosal	B-ANAT
+and	O
+systemic	O
+humoral	B-PROC
+immunity	I-PROC
+against	O
+SARS	O
+-	O
+CoV	O
+.	O
+ABSTRACT	O
+:	O
+Severe	B-DISO
+Acute	I-DISO
+Respiratory	I-DISO
+Syndrome	I-DISO
+(	O
+SARS	B-DISO
+)	O
+is	O
+a	O
+deadly	O
+infectious	B-DISO
+disease	I-DISO
+caused	O
+by	O
+SARS	B-DISO
+Coronavirus	B-SPEC
+(	O
+SARS	B-DISO
+-	O
+CoV	O
+).	O
+
+Although	O
+intraperitoneal	O
+immunization	O
+of	O
+inactivated	O
+SARS	B-DISO
+-	O
+CoV	O
+vaccine	O
+alone	O
+could	O
+induce	O
+a	O
+certain	O
+level	O
+of	O
+neutralizing	O
+activity	O
+in	O
+serum	B-COMP
+as	O
+well	O
+as	O
+in	O
+mucosal	B-ANAT
+sites	O
+,	O
+co	O
+-	O
+administration	O
+of	O
+inactivated	O
+SARS	B-PRGE
+-	I-PRGE
+CoV	I-PRGE
+vaccine	O
+with	O
+PIKA	B-SPEC
+as	O
+adjuvant	B-CHED
+could	O
+induce	O
+a	O
+much	O
+higher	O
+neutralizing	O
+activity	O
+.	O
+
+At	O
+each	O
+visit	O
+,	O
+patients	O
+were	O
+interviewed	O
+and	O
+examined	O
+;	O
+underwent	O
+pulmonary	B-ANAT
+-	O
+function	O
+tests	O
+,	O
+the	O
+6	O
+-	O
+minute	O
+walk	O
+test	O
+,	O
+resting	B-ANAT
+and	O
+exercise	O
+oximetry	O
+,	O
+chest	B-ANAT
+imaging	O
+,	O
+and	O
+a	O
+quality	O
+-	O
+of	O
+-	O
+life	O
+evaluation	O
+;	O
+and	O
+reported	O
+their	O
+use	O
+of	O
+health	O
+care	O
+services	O
+.	O
+
+Seven	O
+of	O
+the	O
+53	O
+compounds	O
+were	O
+selected	O
+;	O
+their	O
+IC	O
+(	O
+50	O
+)	O
+ranged	O
+from	O
+38	O
+.	O
+57	O
+±	O
+2	O
+.	O
+41	O
+to	O
+101	O
+.	O
+38	O
+±	O
+3	O
+.	O
+27	O
+μM	O
+.	O
+Two	O
+strong	O
+3CL	B-PRGE
+(	I-PRGE
+pro	I-PRGE
+)	I-PRGE
+inhibitors	B-CHED
+were	O
+further	O
+identified	O
+as	O
+competitive	O
+inhibitors	B-CHED
+of	O
+3CL	O
+(	O
+pro	B-CHED
+)	O
+with	O
+K	O
+(	O
+i	O
+)	O
+values	O
+of	O
+9	O
+.	O
+11	O
+±	O
+1	O
+.	O
+6	O
+and	O
+9	O
+.	O
+93	O
+±	O
+0	O
+.	O
+44	O
+μM	O
+.	O
+Hydrophobic	O
+and	O
+hydrogen	B-CHED
+bond	O
+interactions	O
+of	O
+compound	O
+with	O
+amino	B-CHED
+acid	I-CHED
+residues	O
+in	O
+the	O
+active	O
+site	O
+of	O
+3CL	B-PRGE
+(	I-PRGE
+pro	I-PRGE
+)	I-PRGE
+were	O
+also	O
+identified	O
+.	O
+
+Survival	O
+to	O
+hospital	O
+discharge	B-ANAT
+was	O
+analyzed	O
+using	O
+Cox	O
+regression	O
+,	O
+accounting	O
+for	O
+the	O
+time	O
+to	O
+administration	O
+of	O
+steroids	B-CHED
+,	O
+and	O
+after	O
+adjustment	O
+on	O
+the	O
+propensity	O
+for	O
+receiving	O
+steroid	B-CHED
+therapy	O
+.	O
+
+The	O
+survival	O
+rate	O
+and	O
+its	O
+resulting	O
+pathological	O
+changes	O
+were	O
+observed	O
+and	O
+patho	O
+physiological	O
+indexes	O
+and	O
+lung	B-ANAT
+fluid	O
+content	O
+were	O
+determined	O
+at	O
+sequential	O
+time	O
+points	O
+post	O
+explosion	O
+.	O
+
+In	O
+an	O
+airtight	O
+environment	O
+,	O
+rabbit	B-SPEC
+ARDS	B-DISO
+model	O
+can	O
+be	O
+reproduced	O
+successfully	O
+by	O
+blast	B-ANAT
+injury	O
+with	O
+1	O
+917	O
+.	O
+3	O
+mm	O
+Hg	O
+explosion	O
+pressure	O
+;	O
+TNF	B-PRGE
+-	I-PRGE
+α	I-PRGE
+and	O
+IL	B-FUNC
+-	I-FUNC
+6	I-FUNC
+are	O
+involved	O
+in	O
+the	O
+pathogenesis	B-DISO
+and	O
+development	B-PROC
+of	O
+ARDS	B-DISO
+in	O
+blast	B-ANAT
+injury	O
+.	O
+
+ABSTRACT	O
+:	O
+Two	O
+tests	O
+were	O
+developed	O
+that	O
+allow	O
+the	O
+detection	O
+and	O
+genotyping	O
+of	O
+infectious	B-DISO
+bronchitis	B-DISO
+virus	B-SPEC
+(	O
+IBV	B-SPEC
+)	O
+and	O
+other	O
+closely	O
+related	O
+gammacoronaviruses	O
+.	O
+
+The	O
+first	O
+test	O
+employs	O
+a	O
+one	O
+-	O
+step	O
+,	O
+reverse	B-PROC
+transcription	I-PROC
+-	O
+polymerase	O
+chain	O
+reaction	O
+(	O
+RT	O
+-	O
+PCR	O
+)	O
+assay	O
+in	O
+which	O
+the	O
+amplification	B-DISO
+is	O
+monitored	O
+in	O
+real	O
+time	O
+using	O
+a	O
+TaqMan	O
+(®)	O
+probe	O
+.	O
+
+In	O
+the	O
+present	O
+study	O
+,	O
+two	O
+CCoV	B-PRGE
+-	I-PRGE
+IIb	I-PRGE
+strains	O
+were	O
+detected	O
+in	O
+the	O
+faeces	B-ANAT
+and	O
+internal	O
+organs	B-ANAT
+of	O
+two	O
+puppies	O
+,	O
+which	O
+died	B-PROC
+after	O
+presenting	O
+gastrointestinal	B-DISO
+symptoms	I-DISO
+.	O
+
+ARDS	B-DISO
+was	O
+associated	O
+with	O
+high	O
+but	O
+comparable	O
+mortality	O
+.	O
+
+The	O
+non	O
+-	O
+survivors	O
+had	O
+significantly	O
+lower	O
+oxygenation	B-PROC
+,	O
+pH	O
+,	O
+and	O
+higher	O
+SOFA	O
+scores	O
+.	O
+
+Factors	O
+significantly	O
+associated	O
+with	O
+mortality	O
+were	O
+PaO2	O
+/	O
+FiO2	O
+on	O
+day	O
+3	O
+,	O
+pH	O
+and	O
+SOFA	O
+score	O
+;	O
+and	O
+SOFA	O
+score	O
+of	O
+13	O
+or	O
+above	O
+was	O
+predictive	O
+of	O
+death	B-PROC
+.	O
+
+I	O
+also	O
+use	O
+the	O
+example	O
+of	O
+HIV	B-DISO
+and	O
+CMV	B-SPEC
+to	O
+illustrate	O
+how	O
+two	O
+unrelated	O
+enveloped	O
+viruses	B-SPEC
+use	O
+a	O
+similar	O
+SCHOOL	O
+mechanism	O
+to	O
+modulate	O
+the	O
+host	B-COMP
+immune	B-PROC
+response	I-PROC
+mediated	O
+by	O
+two	O
+functionally	O
+different	O
+receptors	O
+:	O
+T	B-PRGE
+cell	I-PRGE
+antigen	B-CHED
+receptor	I-PRGE
+and	O
+natural	B-PRGE
+killer	I-PRGE
+cell	I-PRGE
+receptor	I-PRGE
+,	O
+NKp30	B-PRGE
+.	O
+
+ABSTRACT	O
+:	O
+Neuralgic	B-DISO
+amyotrophy	I-DISO
+(	O
+brachial	B-ANAT
+plexus	I-ANAT
+neuropathy	B-DISO
+,	I-DISO
+brachial	I-DISO
+plexus	I-DISO
+neuritis	B-DISO
+,	O
+or	O
+Parsonage	B-DISO
+-	I-DISO
+Turner	I-DISO
+syndrome	I-DISO
+)	O
+is	O
+an	O
+uncommon	O
+inflammatory	O
+condition	B-DISO
+typically	O
+characterized	O
+by	O
+acute	O
+and	O
+severe	O
+shoulder	B-DISO
+pain	I-DISO
+followed	O
+by	O
+paresis	B-DISO
+with	O
+muscle	B-DISO
+weakness	I-DISO
+and	O
+atrophy	B-DISO
+of	O
+the	O
+upper	B-ANAT
+limb	I-ANAT
+or	O
+shoulder	B-ANAT
+girdle	I-ANAT
+.	O
+
+Nasal	B-ANAT
+/	O
+throat	B-ANAT
+swabs	O
+were	O
+obtained	O
+for	O
+polymerase	O
+chain	O
+reaction	O
+test	O
+from	O
+315	O
+hospitalized	O
+patients	O
+and	O
+20	O
+non	O
+-	O
+hospitalized	O
+patients	O
+,	O
+and	O
+145	O
+(	O
+46	O
+%)	O
+and	O
+15	O
+(	O
+75	O
+%)	O
+specimens	O
+,	O
+respectively	O
+,	O
+tested	O
+positive	O
+on	O
+A	O
+(	O
+H1N1	O
+)	O
+v	O
+.	O
+
+CONCLUSIONS	O
+:	O
+Sentinel	O
+influenza	B-DISO
+-	I-DISO
+like	I-DISO
+illness	I-DISO
+and	O
+SARI	O
+surveillance	O
+,	O
+both	O
+followed	O
+with	O
+virological	O
+surveillance	O
+,	O
+seem	O
+to	O
+be	O
+the	O
+optimal	O
+method	O
+to	O
+monitor	O
+the	O
+full	O
+scope	O
+of	O
+the	O
+influenza	B-DISO
+pandemic	O
+(	O
+from	O
+mild	O
+to	O
+severe	O
+influenza	B-DISO
+)	O
+in	O
+Vojvodina	O
+.	O
+
+using	O
+selective	O
+enrichment	O
+faecal	B-ANAT
+culture	O
+,	O
+and	O
+for	O
+enterotoxigenic	O
+Escherichia	B-SPEC
+coli	I-SPEC
+(	O
+K99	O
+)	O
+and	O
+Cryptosporidium	B-SPEC
+parvum	I-SPEC
+using	O
+a	O
+commercial	O
+enzyme	O
+-	O
+linked	O
+immunosorbent	O
+assay	O
+.	O
+
+Most	O
+outbreaks	O
+of	O
+calf	B-ANAT
+diarrhoea	B-DISO
+in	O
+dairy	O
+and	O
+dairy	O
+beef	O
+operations	O
+involve	O
+multiple	O
+pathogens	O
+.	O
+
+CONCLUSIONS	O
+:	O
+Most	O
+outbreaks	O
+of	O
+calf	B-ANAT
+diarrhoea	B-DISO
+in	O
+dairy	O
+and	O
+dairy	O
+beef	O
+operations	O
+involve	O
+multiple	O
+pathogens	O
+.	O
+
+TITLE	O
+:	O
+Viral	B-PROC
+infections	I-PROC
+in	O
+workers	O
+in	O
+hospital	O
+and	O
+research	O
+laboratory	O
+settings	O
+:	O
+a	O
+comparative	O
+review	O
+of	O
+infection	O
+modes	O
+and	O
+respective	O
+biosafety	O
+aspects	O
+.	O
+
+For	O
+airborne	O
+viruses	B-SPEC
+,	O
+81	O
+%	O
+of	O
+the	O
+infections	B-DISO
+occurred	O
+in	O
+laboratories	O
+,	O
+with	O
+hantavirus	B-SPEC
+the	O
+leading	O
+causative	O
+agent	O
+.	O
+
+Current	O
+standard	O
+precaution	O
+practices	O
+are	O
+insufficient	O
+to	O
+prevent	O
+most	O
+of	O
+the	O
+unconventional	O
+infections	B-DISO
+in	O
+hospitals	O
+analyzed	O
+in	O
+this	O
+study	O
+;	O
+it	O
+is	O
+recommended	O
+that	O
+special	O
+attention	O
+be	O
+given	O
+to	O
+flaviviruses	B-SPEC
+in	O
+these	O
+settings	O
+.	O
+
+A	O
+high	O
+prevalence	O
+of	O
+IBV	B-SPEC
+variants	O
+was	O
+found	O
+and	O
+the	O
+sequence	O
+analysis	O
+of	O
+41	O
+samples	O
+revealed	O
+a	O
+high	O
+molecular	O
+similarity	O
+among	O
+the	O
+Brazilian	O
+isolates	O
+(	O
+from	O
+90	O
+.	O
+2	O
+to	O
+100	O
+%	O
+and	O
+from	O
+85	O
+.	O
+3	O
+to	O
+100	O
+%	O
+nucleotide	B-CHED
+and	O
+amino	B-CHED
+acid	I-CHED
+identity	O
+,	O
+respectively	O
+).	O
+
+The	O
+full	O
+-	O
+length	O
+spike	O
+(	O
+S	O
+)	O
+gene	O
+of	O
+these	O
+viruses	B-SPEC
+was	O
+amplified	O
+,	O
+cloned	O
+and	O
+sequenced	O
+from	O
+three	O
+samples	O
+.	O
+
+ABSTRACT	O
+:	O
+Fourteen	O
+infectious	O
+bronchitis	B-DISO
+viruses	B-SPEC
+(	O
+IBVs	O
+)	O
+detected	O
+in	O
+broiler	O
+,	O
+broiler	O
+breeder	O
+,	O
+and	O
+layer	B-ANAT
+flocks	O
+in	O
+Slovenia	O
+between	O
+2007	O
+and	O
+2009	O
+were	O
+molecularly	O
+analyzed	O
+by	O
+reverse	B-PROC
+transcription	I-PROC
+-	O
+PCR	O
+and	O
+direct	O
+sequencing	O
+of	O
+the	O
+S1	B-PRGE
+gene	I-PRGE
+.	O
+
+The	O
+results	O
+of	O
+phylogenetic	O
+analyses	O
+and	O
+epidemiologic	O
+investigations	O
+revealed	O
+that	O
+the	O
+genetic	O
+classification	O
+correlates	O
+with	O
+the	O
+geographic	O
+origins	O
+of	O
+the	O
+IBV	B-SPEC
+strains	O
+.	O
+
+TITLE	O
+:	O
+Repeated	O
+virus	B-SPEC
+identification	O
+in	O
+the	O
+airways	O
+of	O
+patients	O
+with	O
+mild	O
+and	O
+severe	O
+asthma	B-PATH
+during	O
+prospective	O
+follow	O
+-	O
+up	O
+.	O
+
+All	O
+subjects	O
+underwent	O
+spirometry	O
+and	O
+completed	O
+a	O
+written	O
+questionnaire	O
+on	O
+asthma	B-PATH
+symptoms	O
+at	O
+baseline	O
+.	O
+
+RESULTS	O
+:	O
+Thirty	O
+-	O
+two	O
+of	O
+525	O
+patient	O
+assessments	O
+(	O
+6	O
+%)	O
+showed	O
+a	O
+virus	B-SPEC
+-	O
+positive	O
+sample	O
+.	O
+
+Bacterial	O
+isolates	O
+from	O
+specimens	O
+recovered	O
+from	O
+our	O
+patient	O
+before	O
+and	O
+after	O
+his	O
+death	B-PROC
+were	O
+analyzed	O
+using	O
+microarray	O
+DNA	O
+analysis	O
+and	O
+spa	O
+typing	O
+,	O
+and	O
+the	O
+results	O
+revealed	O
+that	O
+the	O
+S	B-SPEC
+.	I-SPEC
+aureus	I-SPEC
+isolates	O
+belonged	O
+to	O
+clonal	B-ANAT
+complex	O
+8	O
+,	O
+were	O
+methicillin	B-CHED
+-	O
+susceptible	O
+and	O
+positive	O
+for	O
+Panton	O
+-	O
+Valentine	O
+leukocidin	O
+.	O
+
+Rapid	O
+identification	O
+of	O
+Panton	O
+-	O
+Valentine	O
+leukocidin	O
+in	O
+methicillin	B-CHED
+-	O
+sensitive	O
+S	B-SPEC
+.	I-SPEC
+aureus	I-SPEC
+isolates	O
+causing	O
+severe	O
+infections	B-DISO
+is	O
+necessary	O
+so	O
+as	O
+not	O
+to	O
+miss	O
+their	O
+potentially	O
+devastating	O
+consequences	O
+.	O
+
+Among	O
+843	O
+cases	O
+,	O
+90	O
+were	O
+HboV	O
+positive	O
+(	O
+10	O
+.	O
+7	O
+%),	O
+131	O
+were	O
+respiratory	B-SPEC
+syncytial	I-SPEC
+virus	I-SPEC
+(	O
+RSV	B-SPEC
+)	O
+positive	O
+(	O
+15	O
+.	O
+5	O
+%),	O
+117	O
+were	O
+influenza	B-SPEC
+virus	I-SPEC
+positive	O
+(	O
+13	O
+.	O
+9	O
+%),	O
+84	O
+were	O
+parainfluenza	B-DISO
+virus	B-SPEC
+positive	O
+(	O
+10	O
+.	O
+0	O
+%),	O
+55	O
+were	O
+rhinovirus	B-SPEC
+positive	O
+(	O
+6	O
+.	O
+5	O
+%),	O
+48	O
+were	O
+coronavirus	B-SPEC
+positive	O
+(	O
+5	O
+.	O
+7	O
+%),	O
+and	O
+33	O
+were	O
+human	B-SPEC
+metapneumovirus	I-SPEC
+positive	O
+(	O
+3	O
+.	O
+7	O
+%).	O
+
+Of	O
+the	O
+90	O
+HBoV	O
+infected	O
+patients	O
+,	O
+45	O
+(	O
+50	O
+%)	O
+showed	O
+a	O
+co	B-DISO
+-	I-DISO
+infection	I-DISO
+with	O
+other	O
+respiratory	B-ANAT
+tract	I-ANAT
+viruses	B-SPEC
+.	O
+
+There	O
+were	O
+no	O
+significant	O
+differences	O
+in	O
+the	O
+frequency	O
+of	O
+wheezing	B-DISO
+between	O
+HBoV	O
+and	O
+RSV	B-SPEC
+infected	O
+patients	O
+.	O
+
+HBoV	O
+positive	O
+rate	O
+detected	O
+from	O
+children	O
+with	O
+wheezing	B-DISO
+is	O
+higher	O
+than	O
+from	O
+children	O
+without	O
+wheezing	B-DISO
+,	O
+suggesting	O
+that	O
+apart	O
+from	O
+RSV	B-SPEC
+,	O
+HBoV	O
+is	O
+another	O
+virus	B-SPEC
+causing	O
+wheezing	B-DISO
+in	O
+children	O
+with	O
+respiratory	B-DISO
+tract	I-DISO
+infection	I-DISO
+.	O
+
+TITLE	O
+:	O
+Public	O
+health	O
+crises	O
+:	O
+the	O
+development	B-PROC
+of	O
+a	O
+consensus	O
+document	O
+on	O
+their	O
+management	O
+in	O
+Spain	O
+.	O
+
+This	O
+inhibitor	B-CHED
+significantly	O
+decreased	O
+human	B-SPEC
+coronavirus	I-SPEC
+229E	I-SPEC
+(	O
+HCoV	B-SPEC
+-	I-SPEC
+229E	I-SPEC
+)	O
+replication	O
+,	O
+reducing	O
+the	O
+percentage	O
+of	O
+infected	O
+cells	B-COMP
+and	O
+intra	O
+-	O
+and	O
+extracellular	B-COMP
+infectious	B-DISO
+virus	B-SPEC
+titers	O
+.	O
+
+Expansion	O
+of	O
+CXCR3	B-PRGE
+-	O
+expressing	O
+ASC	O
+in	O
+draining	O
+lymph	B-ANAT
+nodes	I-ANAT
+prior	O
+to	O
+accumulation	O
+within	O
+the	O
+CNS	B-CHED
+was	O
+consistent	O
+with	O
+their	O
+recruitment	B-DISO
+by	O
+sustained	O
+expression	B-PROC
+of	O
+CXCR3	B-PRGE
+ligands	O
+during	O
+viral	O
+persistence	O
+.	O
+
+Both	O
+total	O
+and	O
+virus	B-SPEC
+-	O
+specific	O
+ASC	O
+were	O
+reduced	O
+greater	O
+than	O
+80	O
+%	O
+in	O
+the	O
+CNS	B-CHED
+of	O
+infected	O
+CXCR3	B-PRGE
+(-/-)	O
+mice	B-SPEC
+.	O
+
+Furthermore	O
+,	O
+in	O
+contrast	O
+to	O
+the	O
+reduction	O
+of	O
+ASC	O
+in	O
+the	O
+CNS	O
+,	O
+neither	O
+virus	B-SPEC
+-	O
+specific	O
+ASC	O
+trafficking	B-PROC
+to	O
+bone	B-ANAT
+marrow	I-ANAT
+nor	O
+antiviral	B-PRGE
+serum	B-COMP
+antibody	B-COMP
+was	O
+reduced	O
+relative	O
+to	O
+levels	O
+in	O
+control	O
+mice	B-SPEC
+.	O
+
+TITLE	O
+:	O
+[	O
+Severe	O
+cases	O
+of	O
+A	O
+(	O
+H1N1	O
+)	O
+v2009	O
+infection	B-DISO
+in	O
+Réunion	O
+Island	O
+in	O
+2009	O
+and	O
+2010	O
+].	O
+
+Our	O
+data	O
+may	O
+contribute	O
+toward	O
+better	O
+management	O
+of	O
+influenza	B-SPEC
+virus	I-SPEC
+pandemics	O
+in	O
+the	O
+future	O
+.	O
+
+However	O
+,	O
+lung	B-ANAT
+-	O
+protective	O
+ventilation	O
+is	O
+the	O
+only	O
+confirmed	O
+option	O
+in	O
+ARDS	O
+management	O
+improving	O
+survival	O
+,	O
+and	O
+few	O
+other	O
+therapies	O
+have	O
+translated	O
+into	O
+improved	O
+oxygenation	B-PROC
+or	O
+reduced	O
+ventilation	O
+time	O
+.	O
+
+His	O
+-	O
+tagged	O
+RdRp	B-FUNC
+was	O
+expressed	B-PROC
+in	O
+baculovirus	B-SPEC
+,	O
+purified	O
+and	O
+used	O
+as	O
+immunogen	B-CHED
+to	O
+produce	O
+mAbs	O
+.	O
+
+The	O
+availability	O
+of	O
+TGEV	O
+RdRp	B-FUNC
+mAbs	O
+will	O
+be	O
+instrumental	O
+to	O
+study	O
+coronavirus	B-SPEC
+replication	O
+and	O
+to	O
+analyze	O
+the	O
+function	O
+of	O
+RdRp	B-FUNC
+in	O
+pathogenesis	B-DISO
+.	O
+
+This	O
+study	O
+examined	O
+the	O
+use	O
+of	O
+ammonia	B-CHED
+at	O
+different	O
+concentrations	O
+and	O
+temperatures	O
+to	O
+disinfect	O
+hatchery	O
+waste	O
+.	O
+
+ABSTRACT	O
+:	O
+Consider	O
+a	O
+data	O
+collection	O
+setup	O
+during	O
+a	O
+spread	O
+of	O
+an	O
+infectious	B-DISO
+disease	I-DISO
+.	O
+
+The	O
+statistical	O
+properties	O
+of	O
+the	O
+spinned	O
+Poisson	O
+distribution	O
+are	O
+developed	O
+and	O
+illustrated	O
+using	O
+infectious	B-DISO
+smallpox	B-DISO
+incidence	O
+in	O
+Abakaliki	O
+,	O
+Nigeria	O
+.	O
+
+We	O
+conducted	O
+a	O
+review	O
+of	O
+the	O
+literature	O
+examining	O
+the	O
+clinical	O
+relationship	O
+between	O
+viral	B-DISO
+respiratory	I-DISO
+infection	I-DISO
+and	O
+graft	B-DISO
+complications	I-DISO
+.	O
+
+Our	O
+review	O
+confirms	O
+a	O
+causal	O
+relationship	O
+between	O
+respiratory	O
+viruses	B-SPEC
+and	O
+respiratory	B-DISO
+symptoms	I-DISO
+,	O
+but	O
+cannot	O
+confirm	O
+a	O
+link	O
+between	O
+respiratory	O
+viruses	B-SPEC
+and	O
+acute	O
+lung	B-ANAT
+rejection	O
+.	O
+
+In	O
+all	O
+the	O
+patients	O
+we	O
+registered	O
+the	O
+basic	O
+demographic	O
+data	O
+,	O
+risk	O
+factors	O
+for	O
+severe	O
+disease	O
+,	O
+symptoms	B-DISO
+and	I-DISO
+signs	I-DISO
+of	O
+influenza	B-DISO
+,	O
+laboratory	O
+tests	O
+and	O
+chest	B-ANAT
+radiography	O
+.	O
+
+A	O
+total	O
+of	O
+67	O
+(	O
+68	O
+.	O
+4	O
+%)	O
+patients	O
+received	O
+oseltamivir	B-CHED
+,	O
+89	O
+(	O
+90	O
+.	O
+1	O
+%)	O
+was	O
+applied	O
+to	O
+antibiotics	B-CHED
+and	O
+64	O
+(	O
+65	O
+.	O
+3	O
+%)	O
+were	O
+treated	O
+with	O
+a	O
+combined	O
+therapy	O
+.	O
+
+Patients	O
+seem	O
+to	O
+have	O
+benefit	O
+from	O
+antiviral	B-CHED
+therapy	O
+especially	O
+in	O
+first	O
+48	O
+hours	O
+.	O
+
+ABSTRACT	O
+:	O
+A	O
+series	O
+of	O
+sialosides	O
+modified	O
+at	O
+the	O
+4	O
+-	O
+and	O
+9	O
+-	O
+hydroxy	O
+group	O
+were	O
+synthesised	O
+and	O
+tested	O
+for	O
+inhibition	B-PROC
+of	O
+the	O
+viral	O
+haemagglutinin	O
+-	O
+esterase	B-FUNC
+activity	I-FUNC
+from	O
+various	O
+Orthomyxoviruses	B-SPEC
+and	O
+Coronaviruses	O
+.	O
+
+RSV	B-SPEC
+was	O
+the	O
+most	O
+common	O
+pathogen	O
+(	O
+41	O
+.	O
+7	O
+%),	O
+followed	O
+by	O
+hMPV	B-SPEC
+(	O
+27	O
+.	O
+1	O
+%),	O
+hBoV	O
+,	O
+and	O
+enterovirus	B-SPEC
+(	O
+both	O
+6	O
+.	O
+3	O
+%).	O
+
+The	O
+hMPV	B-SPEC
+group	O
+had	O
+higher	O
+mixed	B-DISO
+infection	I-DISO
+rate	O
+than	O
+RSV	B-SPEC
+group	O
+.	O
+
+ABSTRACT	O
+:	O
+Severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+(	O
+SARS	B-DISO
+)	O
+coronavirus	B-SPEC
+(	O
+CoV	O
+)	O
+envelope	B-COMP
+(	O
+E	O
+)	O
+protein	B-CHED
+is	O
+a	O
+transmembrane	B-COMP
+protein	B-CHED
+.	O
+
+Patients	O
+with	O
+H1N1	O
+associated	O
+with	O
+ARDS	B-DISO
+may	O
+be	O
+given	O
+a	O
+trial	O
+of	O
+IV	O
+IgG	B-PRGE
+.	O
+More	O
+case	O
+reports	O
+and	O
+trials	O
+are	O
+required	O
+to	O
+ascertain	O
+the	O
+efficacy	O
+of	O
+IV	O
+IgG	B-PRGE
+and	O
+the	O
+best	O
+dosage	O
+and	O
+timing	O
+of	O
+starting	O
+IV	O
+IgG	B-PRGE
+in	O
+relation	O
+to	O
+antiviral	B-CHED
+therapy	O
+.	O
+
+These	O
+domains	O
+possess	B-DISO
+ADP	B-CHED
+-	O
+ribose	B-CHED
+-	O
+1	B-PRGE
+″-	I-PRGE
+phosphatase	I-PRGE
+(	O
+ADRP	B-PRGE
+)	O
+activity	O
+and	O
+/	O
+or	O
+bind	B-FUNC
+poly	O
+(	O
+ADP	B-CHED
+-	O
+ribose	B-CHED
+),	O
+poly	O
+(	O
+A	O
+)	O
+or	O
+poly	O
+(	O
+G	O
+).	O
+
+Overall	O
+,	O
+the	O
+majority	O
+of	O
+IL	B-PRGE
+-	I-PRGE
+10	I-PRGE
+-	I-PRGE
+producing	I-PRGE
+CD8	I-PRGE
+(+)	O
+T	B-ANAT
+cells	I-ANAT
+were	O
+specific	O
+for	O
+the	O
+immunodominant	O
+major	B-PROC
+histocompatibility	I-PROC
+complex	I-PROC
+(	O
+MHC	B-PROC
+)	O
+class	B-SPEC
+I	O
+epitope	B-CHED
+.	O
+
+Unexpectedly	O
+,	O
+we	O
+found	O
+a	O
+positive	O
+correlation	O
+between	O
+duration	O
+of	O
+MV	O
+and	O
+survival	O
+although	O
+two	O
+patients	O
+,	O
+who	O
+were	O
+on	O
+MV	O
+for	O
+the	O
+longest	O
+period	O
+of	O
+time	O
+(	O
+43	O
+and	O
+39	O
+days	O
+,	O
+respectively	O
+),	O
+developed	O
+,	O
+as	O
+a	O
+complication	B-DISO
+,	O
+secondary	B-DISO
+bacterial	I-DISO
+pneumonia	I-DISO
+.	O
+
+TITLE	O
+:	O
+European	O
+risk	O
+assessment	O
+guidance	O
+for	O
+infectious	B-DISO
+diseases	I-DISO
+transmitted	B-DISO
+on	O
+aircraft	O
+--	O
+the	O
+RAGIDA	O
+project	O
+.	O
+
+Herein	O
+,	O
+we	O
+explore	O
+whether	O
+inflammation	B-DISO
+induced	O
+via	O
+viral	B-DISO
+infection	I-DISO
+,	O
+compared	O
+with	O
+inflammation	B-DISO
+induced	O
+via	O
+bacterial	O
+lipopolysaccharide	B-CHED
+,	O
+modulates	O
+AD	O
+-	O
+like	O
+pathological	O
+features	O
+in	O
+the	O
+3xTg	O
+-	O
+AD	O
+mouse	B-SPEC
+model	O
+and	O
+provide	O
+evidence	O
+to	O
+support	O
+the	O
+hypothesis	O
+that	O
+infectious	B-DISO
+agents	O
+may	O
+act	O
+as	O
+a	O
+comorbidity	O
+for	O
+AD	O
+.	O
+
+Our	O
+study	O
+shows	O
+that	O
+infection	O
+-	O
+induced	O
+acute	O
+or	O
+chronic	B-DISO
+inflammation	I-DISO
+significantly	O
+exacerbates	O
+tau	B-CHED
+pathological	O
+characteristics	O
+,	O
+with	O
+chronic	B-DISO
+inflammation	I-DISO
+leading	O
+to	O
+impairments	O
+in	O
+spatial	O
+memory	B-PROC
+.	O
+
+Tau	B-CHED
+phosphorylation	B-PROC
+was	O
+increased	O
+via	O
+a	O
+glycogen	B-PRGE
+synthase	I-PRGE
+kinase	I-PRGE
+-	I-PRGE
+3β	I-PRGE
+-	O
+dependent	O
+mechanism	O
+,	O
+and	O
+there	O
+was	O
+a	O
+prominent	O
+shift	O
+of	O
+tau	B-CHED
+from	O
+the	O
+detergent	B-CHED
+-	O
+soluble	O
+to	O
+the	O
+detergent	B-CHED
+-	O
+insoluble	B-ANAT
+fraction	I-ANAT
+.	O
+
+Only	O
+1	O
+.	O
+3	O
+%	O
+of	O
+patients	O
+enrolled	O
+in	O
+Acute	B-DISO
+Respiratory	I-DISO
+Distress	I-DISO
+Syndrome	I-DISO
+Network	O
+trials	O
+had	O
+baseline	O
+positive	O
+end	B-PROC
+-	I-PROC
+expiratory	I-PROC
+pressure	O
+<	O
+5	O
+cm	O
+H₂O	O
+,	O
+and	O
+50	O
+%	O
+had	O
+baseline	O
+positive	O
+end	B-PROC
+-	I-PROC
+expiratory	I-PROC
+pressure	O
+≥	O
+10	O
+cm	O
+H₂O	O
+.	O
+Baseline	O
+PaO₂	B-PRGE
+/	O
+Fio₂	O
+predicted	O
+mortality	O
+,	O
+but	O
+after	O
+controlling	O
+for	O
+PaO₂	B-PRGE
+/	O
+Fio₂	O
+,	O
+baseline	O
+positive	O
+end	B-PROC
+-	I-PROC
+expiratory	I-PROC
+pressure	O
+did	O
+not	O
+predict	O
+mortality	O
+.	O
+
+TITLE	O
+:	O
+Comparative	O
+pathogenesis	B-DISO
+of	O
+three	O
+human	B-SPEC
+and	O
+zoonotic	O
+SARS	B-DISO
+-	O
+CoV	O
+strains	O
+in	O
+cynomolgus	O
+macaques	B-SPEC
+.	O
+
+Viral	B-PROC
+replication	I-PROC
+was	O
+higher	O
+in	O
+animals	B-SPEC
+infected	O
+with	O
+a	O
+late	O
+human	B-SPEC
+phase	O
+isolate	O
+compared	O
+to	O
+a	O
+zoonotic	O
+isolate	O
+.	O
+
+TITLE	O
+:	O
+Activation	O
+and	O
+maturation	B-PROC
+of	O
+SARS	B-PRGE
+-	I-PRGE
+CoV	I-PRGE
+main	I-PRGE
+protease	I-PRGE
+.	O
+
+TITLE	O
+:	O
+[	O
+Extracorporeal	O
+membrane	B-COMP
+oxygenation	B-PROC
+in	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+after	O
+a	O
+liver	B-ANAT
+transplant	B-ANAT
+].	O
+
+TITLE	O
+:	O
+Combination	O
+of	O
+extracorporeal	O
+membrane	B-COMP
+oxygenation	B-PROC
+and	O
+high	O
+-	O
+frequency	O
+oscillatory	O
+ventilation	O
+saved	O
+a	O
+child	O
+with	O
+severe	O
+ARDS	O
+after	O
+pulmonary	B-ANAT
+resection	O
+.	O
+
+ABSTRACT	O
+:	O
+We	O
+report	O
+a	O
+case	O
+in	O
+which	O
+a	O
+2	O
+-	O
+year	O
+-	O
+old	O
+girl	O
+who	O
+underwent	O
+a	O
+right	O
+middle	O
+and	O
+lower	O
+lung	B-ANAT
+lobectomy	O
+for	O
+congenital	B-DISO
+cystic	I-DISO
+adenomatoid	I-DISO
+malformation	I-DISO
+suffered	B-DISO
+massive	B-DISO
+bleeding	I-DISO
+and	O
+developed	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+(	O
+ARDS	B-DISO
+)	O
+during	O
+the	O
+operation	O
+.	O
+
+We	O
+introduced	O
+venovenous	O
+(	O
+V	O
+-	O
+V	O
+)	O
+extracorporeal	O
+membrane	B-COMP
+oxygenation	B-PROC
+(	O
+ECMO	B-PROC
+)	O
+to	O
+rest	B-FUNC
+the	O
+lung	B-ANAT
+,	O
+and	O
+V	O
+-	O
+V	O
+ECMO	B-PROC
+was	O
+changed	O
+to	O
+right	O
+and	O
+left	O
+atrial	B-ANAT
+ECMO	B-PROC
+because	O
+of	O
+unsatisfactory	O
+oxygen	B-CHED
+support	O
+on	O
+POD	O
+23	O
+.	O
+
+The	O
+collapsed	B-DISO
+lung	I-DISO
+was	O
+then	O
+gradually	O
+recruited	O
+,	O
+and	O
+pulmonary	B-ANAT
+oxygenation	B-PROC
+improved	O
+(	O
+P	O
+/	O
+F	O
+ratio	O
+=	O
+434	O
+).	O
+
+TITLE	O
+:	O
+LocaPep	O
+:	O
+localization	B-PROC
+of	O
+epitopes	O
+on	O
+protein	B-CHED
+surfaces	O
+using	O
+peptides	B-CHED
+from	O
+phage	O
+display	O
+libraries	O
+.	O
+
+TITLE	O
+:	O
+In	O
+silico	O
+investigations	O
+of	O
+possible	O
+routes	O
+of	O
+assembly	O
+of	O
+ORF	B-PRGE
+3a	I-PRGE
+from	O
+SARS	B-DISO
+-	O
+CoV	O
+.	O
+ABSTRACT	O
+:	O
+ORF	O
+3a	O
+of	O
+human	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+corona	B-CHED
+virus	B-SPEC
+(	O
+SARS	B-DISO
+-	O
+CoV	O
+)	O
+has	O
+been	O
+identified	O
+as	O
+a	O
+274	O
+amino	B-CHED
+acid	I-CHED
+membrane	B-COMP
+protein	B-CHED
+.	O
+
+Optimization	O
+of	O
+a	O
+manufacturing	O
+process	O
+for	O
+diagnostic	O
+agents	O
+and	O
+vaccines	O
+has	O
+been	O
+achieved	O
+while	O
+applying	O
+a	O
+roll	O
+tube	O
+method	O
+for	O
+both	O
+RBT	O
+cell	B-COMP
+cultivation	O
+and	O
+coronavirus	B-SPEC
+reproduction	B-PROC
+.	O
+
+ABSTRACT	O
+:	O
+Human	B-PRGE
+coronavirus	I-PRGE
+NL63	I-PRGE
+was	O
+identified	O
+in	O
+2004	O
+in	O
+the	O
+Netherlands	O
+.	O
+
+The	O
+ribosomal	B-PROC
+frameshifting	I-PROC
+was	O
+inhibited	O
+by	O
+the	O
+PNA	B-CHED
+,	O
+which	O
+bound	O
+sequence	O
+-	O
+specifically	O
+a	O
+pseudoknot	O
+structure	O
+in	O
+the	O
+-	O
+1	O
+PRF	O
+signal	O
+,	O
+in	O
+cell	B-ANAT
+lines	I-ANAT
+as	O
+assessed	O
+using	O
+a	O
+dual	O
+luciferase	B-ENZY
+-	O
+based	O
+reporter	O
+plasmid	O
+containing	O
+the	O
+-	O
+1	O
+PRF	O
+signal	O
+.	O
+
+This	O
+study	O
+was	O
+undertaken	O
+to	O
+determine	O
+the	O
+utility	O
+of	O
+sampling	O
+used	O
+ventilation	O
+filters	O
+to	O
+assess	O
+the	O
+types	O
+and	O
+concentrations	O
+of	O
+virus	B-SPEC
+aerosols	O
+present	O
+in	O
+buildings	O
+.	O
+
+Two	O
+passages	O
+of	O
+eluates	O
+in	O
+cell	B-COMP
+cultures	O
+or	O
+these	O
+eggs	O
+did	O
+not	O
+reveal	O
+the	O
+presence	O
+of	O
+any	O
+live	O
+virus	B-SPEC
+.	O
+
+Lung	B-ANAT
+rest	B-FUNC
+,	O
+achieved	O
+by	O
+extracorporeal	O
+carbon	B-CHED
+dioxide	I-CHED
+removal	O
+(	O
+ECCO₂R	O
+),	O
+allowed	O
+weaning	B-PROC
+from	O
+mechanical	O
+ventilation	O
+,	O
+closure	O
+of	O
+BPF	O
+,	O
+and	O
+resumption	O
+of	O
+spontaneous	O
+breathing	B-PROC
+.	O
+
+The	O
+Virochip	O
+has	O
+also	O
+been	O
+used	O
+to	O
+identify	O
+novel	O
+viruses	B-SPEC
+,	O
+including	O
+the	O
+SARS	B-DISO
+coronavirus	B-SPEC
+,	O
+a	O
+novel	O
+rhinovirus	O
+clade	O
+,	O
+XMRV	O
+(	O
+a	O
+retrovirus	B-SPEC
+linked	O
+to	O
+prostate	B-PATH
+cancer	B-SPEC
+),	O
+avian	B-SPEC
+bornavirus	I-SPEC
+(	O
+the	O
+cause	O
+of	O
+a	O
+wasting	B-DISO
+disease	I-DISO
+in	O
+parrots	B-SPEC
+),	O
+and	O
+a	O
+novel	O
+cardiovirus	B-SPEC
+in	O
+children	O
+with	O
+respiratory	O
+and	O
+diarrheal	O
+illness	O
+.	O
+
+The	O
+current	O
+version	O
+of	O
+the	O
+Virochip	O
+has	O
+been	O
+ported	O
+to	O
+an	O
+Agilent	O
+microarray	O
+platform	O
+and	O
+consists	O
+of	O
+~	O
+36	O
+,	O
+000	O
+probes	O
+derived	O
+from	O
+over	O
+~	O
+1	O
+,	O
+500	O
+viruses	B-SPEC
+in	O
+GenBank	O
+as	O
+of	O
+December	O
+of	O
+2009	O
+.	O
+
+Sequence	O
+analyses	O
+revealed	O
+a	O
+strong	O
+selection	O
+for	O
+the	O
+S	B-PRGE
+gene	I-PRGE
+of	O
+83P	O
+-	O
+5	O
+in	O
+Vero	B-ANAT
+cells	I-ANAT
+,	O
+and	O
+virtually	O
+all	O
+mutations	O
+occurring	O
+at	O
+the	O
+34th	O
+and	O
+61st	O
+passages	O
+had	O
+been	O
+carried	O
+over	O
+to	O
+the	O
+100th	O
+-	O
+passaged	O
+virus	B-SPEC
+.	O
+
+Eight	O
+accessory	O
+proteins	B-CHED
+of	O
+SARS	B-DISO
+coronavirus	B-SPEC
+were	O
+the	O
+suspected	O
+players	O
+in	O
+the	O
+pathogenesis	B-DISO
+of	O
+the	O
+virus	B-SPEC
+.	O
+
+Among	O
+them	O
+,	O
+protein	B-PRGE
+3b	I-PRGE
+localizes	O
+to	O
+the	O
+nucleus	B-COMP
+and	O
+behaves	O
+as	O
+an	O
+interferon	B-PRGE
+antagonist	B-PROC
+by	O
+inhibiting	O
+IRF3	B-PRGE
+activation	O
+.	O
+
+However	O
+,	O
+the	O
+effect	O
+of	O
+3b	O
+on	O
+the	O
+activity	O
+of	O
+other	O
+common	O
+host	B-COMP
+transcription	B-PROC
+factors	O
+remains	O
+unexplored	O
+.	O
+
+A	O
+series	O
+of	O
+peptide	B-CHED
+analogues	O
+were	O
+also	O
+synthesized	O
+,	O
+showing	O
+that	O
+glutamate	B-CHED
+subtitution	O
+at	O
+Arg	B-CHED
+(	O
+708	O
+)	O
+and	O
+/	O
+or	O
+Arg	B-CHED
+(	O
+710	O
+)	O
+attenuated	O
+the	O
+cleavage	B-PROC
+process	O
+,	O
+while	O
+alanine	B-CHED
+substitution	O
+at	O
+Arg	B-CHED
+(	O
+708	O
+)	O
+and	O
+/	O
+or	O
+Ser	B-COMP
+(	O
+709	O
+)	O
+did	O
+not	O
+inhibit	O
+peptide	B-CHED
+cleavage	B-PROC
+by	O
+recombinant	O
+ADAM17	O
+.	O
+
+Thus	O
+,	O
+optic	B-DISO
+neuritis	I-DISO
+was	O
+dependent	O
+on	O
+a	O
+spike	O
+glycoprotein	B-CHED
+-	O
+mediated	O
+mechanism	O
+of	O
+viral	B-PRGE
+antigen	I-PRGE
+transport	B-PROC
+along	O
+retinal	B-ANAT
+ganglion	B-DISO
+cell	B-COMP
+axons	B-COMP
+.	O
+
+ABSTRACT	O
+:	O
+Nuclear	O
+factor	O
+-	O
+κB	O
+(	O
+NF	O
+-	O
+κB	O
+)	O
+is	O
+required	O
+for	O
+transcription	B-PROC
+of	O
+many	O
+pro	B-CHED
+-	O
+inflammatory	O
+genes	O
+and	O
+has	O
+been	O
+implicated	O
+in	O
+the	O
+pathogenesis	B-DISO
+of	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+(	O
+ARDS	B-DISO
+).	O
+
+RESULTS	O
+:	O
+Patients	O
+homozygous	O
+for	O
+the	O
+4	O
+base	B-FUNC
+pair	I-FUNC
+deletion	O
+in	O
+the	O
+promoter	O
+of	O
+NFKB1	B-PRGE
+(	O
+del	B-PRGE
+/	O
+del	B-PRGE
+)	O
+did	O
+not	O
+have	O
+an	O
+increased	O
+odds	O
+ratio	O
+(	O
+OR	O
+)	O
+of	O
+developing	O
+ARDS	B-DISO
+in	O
+unadjusted	O
+analysis	O
+but	O
+were	O
+more	O
+likely	O
+to	O
+develop	O
+ARDS	B-DISO
+in	O
+the	O
+presence	O
+of	O
+a	O
+significant	O
+interaction	O
+between	O
+the	O
+del	O
+/	O
+del	O
+genotype	O
+and	O
+age	O
+(	O
+OR	O
+5	O
+.	O
+21	O
+,	O
+95	O
+%	O
+CI	O
+1	O
+.	O
+35	O
+-	O
+20	O
+.	O
+0	O
+).	O
+
+The	O
+inhibition	B-PROC
+of	O
+TGEV	B-SPEC
+infection	B-DISO
+in	O
+vitro	O
+by	O
+LiCl	B-CHED
+was	O
+observed	O
+at	O
+different	O
+virus	B-SPEC
+doses	O
+and	O
+with	O
+different	O
+cell	B-ANAT
+lines	I-ANAT
+.	O
+
+The	O
+inhibitory	O
+effect	O
+of	O
+LiCl	B-CHED
+was	O
+also	O
+observed	O
+with	O
+porcine	B-SPEC
+epidemic	B-DISO
+diarrhea	I-DISO
+coronavirus	B-SPEC
+.	O
+
+Together	O
+with	O
+other	O
+reports	O
+concerning	O
+the	O
+inhibitory	O
+effect	O
+of	O
+lithium	B-CHED
+salts	I-CHED
+on	O
+IBV	B-SPEC
+in	O
+cell	B-COMP
+culture	O
+,	O
+our	O
+results	O
+indicate	O
+that	O
+LiCl	B-CHED
+may	O
+be	O
+a	O
+potent	O
+agent	O
+against	O
+porcine	B-SPEC
+and	O
+avian	B-SPEC
+coronaviruses	O
+.	O
+
+Regression	O
+analyses	O
+suggested	O
+that	O
+the	O
+number	O
+of	O
+stressors	O
+and	O
+use	O
+of	O
+avoidant	O
+coping	O
+strategies	O
+positively	O
+predicted	O
+psychological	B-DISO
+symptoms	I-DISO
+.	O
+
+In	O
+both	O
+groups	O
+recruitment	B-DISO
+maneuvers	O
+(	O
+RM	O
+)	O
+were	O
+performed	O
+every	O
+2	O
+hours	O
+,	O
+increasing	O
+PEEP	B-CHED
+to	O
+20	O
+cmH2O	O
+.	O
+
+The	O
+PEEP	B-CHED
+levels	O
+set	O
+in	O
+the	O
+FOT	O
+group	O
+were	O
+significantly	O
+higher	O
+compared	O
+to	O
+those	O
+set	O
+in	O
+the	O
+ARDSNet	O
+group	O
+during	O
+the	O
+whole	O
+trial	O
+.	O
+
+These	O
+higher	O
+values	O
+of	O
+PEEP	B-CHED
+resulted	O
+in	O
+improved	O
+lung	B-ANAT
+mechanics	O
+,	O
+reduced	O
+driving	O
+pressure	O
+,	O
+improved	O
+oxygenation	B-PROC
+,	O
+with	O
+a	O
+trend	O
+for	O
+higher	O
+PaCO2	O
+and	O
+lower	O
+systemic	O
+and	O
+pulmonary	B-ANAT
+pressure	O
+.	O
+
+After	O
+12	O
+hours	O
+of	O
+ventilation	O
+,	O
+histopathological	O
+analysis	O
+showed	O
+a	O
+significantly	O
+lower	O
+score	O
+of	O
+lung	B-ANAT
+injury	O
+in	O
+the	O
+FOT	O
+group	O
+compared	O
+to	O
+the	O
+ARDSNet	O
+group	O
+.	O
+
+TITLE	O
+:	O
+Lack	O
+of	O
+peripheral	O
+memory	B-ANAT
+B	I-ANAT
+cell	B-COMP
+responses	O
+in	O
+recovered	O
+patients	O
+with	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+:	O
+a	O
+six	O
+-	O
+year	O
+follow	O
+-	O
+up	O
+study	O
+.	O
+
+SARS	B-DISO
+-	O
+specific	O
+IgG	B-PRGE
+Ab	O
+may	O
+eventually	O
+vanish	O
+and	O
+peripheral	O
+memory	B-ANAT
+B	I-ANAT
+cell	B-COMP
+responses	O
+are	O
+undetectable	O
+in	O
+recovered	O
+SARS	B-DISO
+patients	O
+.	O
+
+In	O
+the	O
+most	O
+severe	O
+cases	O
+of	O
+primary	O
+pneumonia	B-DISO
+,	O
+patients	O
+develop	O
+refractory	O
+hypoxemic	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+(	O
+ARDS	B-DISO
+)	O
+with	O
+typical	O
+computed	O
+tomographic	O
+findings	O
+of	O
+multi	O
+-	O
+lobar	O
+alveolar	B-ANAT
+opacities	B-DISO
+and	O
+extremely	O
+reduced	O
+pulmonary	B-ANAT
+airspace	O
+.	O
+
+Although	O
+no	O
+new	O
+cases	O
+of	O
+SARS	B-DISO
+have	O
+been	O
+reported	O
+since	O
+2004	O
+,	O
+future	O
+outbreaks	O
+are	O
+a	O
+constant	O
+threat	O
+;	O
+therefore	O
+,	O
+the	O
+development	B-PROC
+of	O
+vaccines	O
+against	O
+SARS	B-PRGE
+-	I-PRGE
+CoV	I-PRGE
+is	O
+a	O
+prudent	O
+preventive	O
+step	O
+and	O
+should	O
+be	O
+carried	O
+out	O
+.	O
+
+To	O
+discover	O
+ligands	O
+for	O
+the	O
+SARS	B-DISO
+-	O
+pseudoknot	O
+by	O
+virtual	O
+screening	O
+,	O
+we	O
+constructed	O
+a	O
+3D	O
+structural	O
+model	O
+of	O
+the	O
+SARS	B-DISO
+-	O
+pseudoknot	O
+and	O
+conducted	O
+a	O
+computational	O
+screening	O
+of	O
+the	O
+chemical	O
+database	O
+.	O
+
+TITLE	O
+:	O
+The	O
+rumouring	O
+of	O
+SARS	B-DISO
+during	O
+the	O
+2003	O
+epidemic	O
+in	O
+China	O
+.	O
+
+ABSTRACT	O
+:	O
+A	O
+number	O
+of	O
+different	O
+modalities	O
+have	O
+been	O
+employed	O
+in	O
+addition	O
+to	O
+conventional	O
+ventilation	O
+to	O
+improve	O
+oxygenation	B-PROC
+in	O
+patients	O
+with	O
+severe	O
+2009	O
+pandemic	O
+influenza	B-PATH
+A	I-PATH
+(	O
+H1N1	O
+)	O
+pneumonia	B-DISO
+.	O
+
+Virus	B-SPEC
+attachment	O
+and	O
+entry	O
+into	O
+the	O
+cell	B-COMP
+occurred	O
+15	O
+h	O
+post	O
+-	O
+infection	B-DISO
+(	O
+pi	O
+),	O
+and	O
+the	O
+myriad	O
+of	O
+virus	B-COMP
+particles	I-COMP
+were	O
+observed	O
+both	O
+extracellularly	O
+and	O
+intracellularly	O
+after	O
+48	O
+h	O
+pi	O
+.	O
+
+Thereafter	O
+,	O
+intracellular	B-COMP
+virus	B-COMP
+particles	I-COMP
+were	O
+observed	O
+to	O
+be	O
+present	O
+in	O
+vacuoles	B-COMP
+or	O
+present	O
+freely	O
+in	O
+the	O
+cytoplasm	B-COMP
+.	O
+
+Chickens	B-SPEC
+were	O
+then	O
+challenged	O
+with	O
+IBV	B-SPEC
+strain	O
+M41	O
+by	O
+the	O
+nasal	B-ANAT
+-	O
+ocular	B-PROC
+route	O
+3	O
+weeks	O
+after	O
+boosting	O
+.	O
+
+Several	O
+virus	B-SPEC
+families	O
+in	O
+the	O
+order	B-SPEC
+Nidovirales	I-SPEC
+,	O
+such	O
+as	O
+the	O
+coronaviruses	O
+(	O
+CoVs	O
+)	O
+must	O
+achieve	O
+these	O
+objectives	O
+with	O
+the	O
+largest	O
+and	O
+most	O
+complex	O
+replicating	O
+RNA	O
+genomes	O
+known	O
+,	O
+up	O
+to	O
+32	O
+kb	O
+of	O
+positive	O
+-	O
+sense	B-PROC
+RNA	O
+.	O
+
+Polyclonal	O
+antibodies	B-COMP
+raised	O
+against	O
+expressed	B-PROC
+S1	O
+(	O
+amino	B-CHED
+acid	I-CHED
+position	O
+1	O
+to	O
+573	O
+from	O
+start	O
+codon	O
+of	O
+S	B-PRGE
+protein	I-PRGE
+),	O
+4F	O
+/	O
+4R	O
+(	O
+482	O
+-	O
+678	O
+),	O
+6F	O
+/	O
+6R	O
+(	O
+830	O
+-	O
+1071	O
+),	O
+or	O
+Mod4F	O
+/	O
+Epi4R	O
+(	O
+476	O
+-	O
+520	O
+)	O
+S	O
+fragment	O
+recognized	O
+native	O
+S1	B-PRGE
+protein	I-PRGE
+and	O
+TCoV	O
+in	O
+the	O
+intestines	B-ANAT
+of	O
+TCoV	O
+-	O
+infected	O
+turkey	B-SPEC
+embryos	B-ANAT
+.	O
+
+Mortality	O
+,	O
+(	O
+multi	O
+)	O
+organ	B-DISO
+failure	I-DISO
+during	O
+admission	O
+were	O
+observed	O
+,	O
+blood	B-ANAT
+samples	I-ANAT
+for	O
+laboratory	O
+analysis	O
+were	O
+drawn	O
+on	O
+admission	O
+,	O
+on	O
+Days	O
+3	O
+,	O
+7	O
+,	O
+and	O
+14	O
+of	O
+the	O
+treatment	O
+.	O
+
+TITLE	O
+:	O
+Intriguing	O
+interplay	O
+between	O
+feline	B-DISO
+infectious	I-DISO
+peritonitis	I-DISO
+virus	B-SPEC
+and	O
+its	O
+receptors	O
+during	O
+entry	O
+in	O
+primary	O
+feline	O
+monocytes	B-ANAT
+.	O
+
+Secondly	O
+,	O
+the	O
+level	O
+of	O
+co	O
+-	O
+localization	B-PROC
+of	O
+FIPV	O
+and	O
+the	O
+receptors	O
+was	O
+determined	O
+.	O
+
+Blocking	B-DISO
+fAPN	O
+reduced	O
+FIPV	O
+II	O
+binding	B-FUNC
+by	O
+53	O
+%	O
+and	O
+infection	B-DISO
+by	O
+80	O
+%.	O
+
+Furthermore	O
+,	O
+we	O
+assessed	O
+cell	B-COMP
+toxicity	O
+and	O
+possible	O
+targets	O
+for	O
+the	O
+peptides	B-CHED
+,	O
+thereby	O
+strengthening	O
+the	O
+notion	O
+that	O
+HR2	O
+is	O
+an	O
+attractive	O
+site	O
+for	O
+therapeutic	O
+intervention	O
+.	O
+
+Treatment	O
+was	O
+ineffective	O
+and	O
+the	O
+ferrets	B-SPEC
+died	B-PROC
+2	O
+-	O
+5	O
+days	O
+later	O
+.	O
+
+ABSTRACT	O
+:	O
+We	O
+have	O
+shown	O
+that	O
+mice	B-SPEC
+infected	O
+with	O
+mouse	B-DISO
+hepatitis	I-DISO
+virus	B-SPEC
+A59	O
+develop	O
+autoantibodies	O
+(	O
+autoAb	O
+)	O
+to	O
+liver	B-ANAT
+and	O
+kidney	B-ANAT
+fumarylacetoacetate	B-PRGE
+hydrolase	I-PRGE
+(	O
+FAH	B-PRGE
+).	O
+
+TITLE	O
+:	O
+Crush	B-DISO
+syndrome	I-DISO
+and	O
+acute	O
+kidney	B-ANAT
+injury	O
+in	O
+the	O
+Wenchuan	O
+Earthquake	O
+.	O
+
+We	O
+report	O
+the	O
+characteristics	O
+of	O
+crush	B-DISO
+syndrome	I-DISO
+(	O
+CS	O
+)	O
+and	O
+acute	O
+kidney	B-ANAT
+injury	O
+(	O
+AKI	O
+)	O
+brought	O
+by	O
+the	O
+earthquake	O
+,	O
+which	O
+took	O
+place	O
+in	O
+a	O
+mountainous	O
+area	O
+.	O
+
+They	O
+had	O
+various	O
+complications	O
+,	O
+including	O
+different	O
+kinds	O
+of	O
+infection	B-DISO
+or	O
+sepsis	B-DISO
+,	O
+AKI	B-PRGE
+,	O
+hematological	O
+abnormality	O
+,	O
+adult	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+,	O
+congestive	B-DISO
+heart	I-DISO
+failure	I-DISO
+,	O
+multiple	O
+organs	B-ANAT
+dysfunction	O
+syndrome	B-DISO
+,	O
+etc	O
+.	O
+
+Complication	B-DISO
+of	O
+acute	O
+lung	B-ANAT
+injury	O
+(	O
+ALI	O
+)/	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+(	O
+ARDS	B-DISO
+)	O
+by	O
+pneumonia	B-DISO
+makes	O
+patients	O
+very	O
+ill	B-DISO
+due	O
+to	O
+severe	O
+respiratory	B-DISO
+failure	I-DISO
+.	O
+
+Among	O
+these	O
+patients	O
+,	O
+six	O
+had	O
+ALI	O
+or	O
+a	O
+condition	B-DISO
+that	O
+was	O
+clinically	O
+comparable	O
+to	O
+ALI	O
+(	O
+cALI	O
+).	O
+
+RESULTS	O
+:	O
+Circulating	O
+sES	B-PRGE
+levels	O
+were	O
+elevated	O
+in	O
+pneumonia	B-DISO
+patients	O
+with	O
+ALI	O
+/	O
+cALI	O
+,	O
+and	O
+sES	O
+levels	O
+decreased	O
+following	O
+treatment	O
+of	O
+their	O
+pneumonia	B-DISO
+.	O
+
+Under	O
+electron	O
+microscopy	O
+,	O
+PEDV	B-SPEC
+-	O
+infected	O
+Vero	B-ANAT
+cells	I-ANAT
+,	O
+as	O
+well	O
+as	O
+PEDV	B-SPEC
+-	O
+infected	O
+Vero	O
+/	O
+TMPRSS2	O
+cells	B-COMP
+treated	O
+with	O
+leupeptin	O
+,	O
+retained	O
+huge	O
+clusters	B-CHED
+of	O
+virions	B-COMP
+on	O
+their	O
+surfaces	O
+,	O
+while	O
+such	O
+clusters	B-CHED
+were	O
+rarely	O
+seen	O
+in	O
+the	O
+presence	O
+of	O
+trypsin	B-PRGE
+and	O
+the	O
+absence	O
+of	O
+leupeptin	O
+in	O
+Vero	O
+and	O
+Vero	O
+/	O
+TMPRSS2	O
+cells	B-COMP
+,	O
+respectively	O
+.	O
+
+We	O
+observed	O
+that	O
+all	O
+kinds	O
+of	O
+splenic	B-ANAT
+cells	B-COMP
+examined	O
+were	O
+infected	O
+,	O
+including	O
+B220	O
+(+)	O
+Ly	O
+-	O
+6C	O
+(+)	O
+plasmacytoid	B-ANAT
+dendritic	I-ANAT
+cells	B-COMP
+.	O
+
+ABSTRACT	O
+:	O
+Pulmonary	B-DISO
+tuberculosis	B-PATH
+can	O
+lead	O
+to	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+(	O
+ARDS	B-DISO
+)	O
+which	O
+is	O
+associated	O
+with	O
+high	O
+mortality	O
+.	O
+
+Substances	O
+produced	O
+in	O
+the	O
+lungs	B-ANAT
+can	O
+be	O
+translocated	O
+into	O
+the	O
+systemic	O
+circulation	B-PROC
+as	O
+a	O
+result	O
+of	O
+injury	O
+to	O
+the	O
+pulmonary	B-ANAT
+epithelium	B-ANAT
+and	O
+to	O
+the	O
+capillary	B-ANAT
+endothelium	I-ANAT
+.	O
+
+ABSTRACT	O
+:	O
+Hepatitis	B-SPEC
+B	I-SPEC
+virus	I-SPEC
+core	O
+antibody	B-COMP
+(	O
+HBcAb	O
+)-	O
+positive	O
+organ	B-ANAT
+donors	O
+have	O
+the	O
+potential	O
+to	O
+transmit	O
+infection	B-DISO
+to	O
+transplant	B-ANAT
+recipients	O
+.	O
+
+Effective	O
+antiviral	B-CHED
+agents	I-CHED
+are	O
+lacking	O
+that	O
+specifically	O
+target	O
+RNA	O
+viruses	B-SPEC
+such	O
+as	O
+measles	B-PATH
+,	O
+SARS	B-DISO
+-	O
+CoV	O
+and	O
+influenza	B-DISO
+H5N1	B-DISO
+viruses	B-SPEC
+,	O
+and	O
+available	O
+vaccinations	O
+have	O
+demonstrated	O
+variable	O
+efficacy	O
+.	O
+
+Surprisingly	O
+,	O
+we	O
+found	O
+that	O
+the	O
+antiviral	B-CHED
+activities	O
+of	O
+mucroporin	O
+-	O
+M1	O
+against	O
+measles	B-PATH
+,	O
+SARS	B-DISO
+-	O
+CoV	O
+and	O
+influenza	B-DISO
+H5N1	B-DISO
+viruses	B-SPEC
+were	O
+notably	O
+increased	O
+with	O
+an	O
+EC₅₀	O
+of	O
+7	O
+.	O
+15	O
+μg	O
+/	O
+ml	O
+(	O
+3	O
+.	O
+52	O
+μM	O
+)	O
+and	O
+a	O
+CC₅₀	O
+of	O
+70	O
+.	O
+46	O
+μg	O
+/	O
+ml	O
+(	O
+34	O
+.	O
+70	O
+μM	O
+)	O
+against	O
+measles	B-SPEC
+virus	I-SPEC
+,	O
+an	O
+EC₅₀	O
+of	O
+14	O
+.	O
+46	O
+μg	O
+/	O
+ml	O
+(	O
+7	O
+.	O
+12	O
+μM	O
+)	O
+against	O
+SARS	B-DISO
+-	O
+CoV	O
+and	O
+an	O
+EC₅₀	O
+of	O
+2	O
+.	O
+10	O
+μg	O
+/	O
+ml	O
+(	O
+1	O
+.	O
+03	O
+μM	O
+)	O
+against	O
+H5N1	B-DISO
+,	O
+while	O
+the	O
+original	O
+peptide	B-CHED
+mucroporin	O
+showed	O
+no	O
+antiviral	B-CHED
+activity	O
+against	O
+any	O
+of	O
+these	O
+three	O
+viruses	B-SPEC
+.	O
+
+We	O
+studied	O
+13	O
+adults	O
+with	O
+early	O
+-	O
+phase	O
+acute	O
+lung	B-ANAT
+injury	O
+/	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+(	O
+ALI	O
+/	O
+ARDS	B-DISO
+).	O
+
+The	O
+PEEP	B-CHED
+was	O
+then	O
+progressively	O
+reduced	O
+until	O
+the	O
+PaO	B-PROC
+(	O
+2	O
+)	O
+decreased	O
+by	O
+more	O
+than	O
+10	O
+%	O
+of	O
+the	O
+maximum	O
+PaO	B-PROC
+(	O
+2	O
+);	O
+the	O
+PEEP	B-CHED
+was	O
+subsequently	O
+set	O
+to	O
+2	O
+cmH	B-DISO
+(	O
+2	O
+)	O
+O	O
+above	O
+this	O
+level	O
+.	O
+
+ABSTRACT	O
+:	O
+To	O
+describe	O
+the	O
+clinical	O
+presentation	O
+,	O
+case	O
+management	O
+,	O
+and	O
+outcome	O
+in	O
+2	O
+foals	O
+with	O
+Rhodococcus	O
+equi	O
+infection	O
+associated	O
+with	O
+presumptive	O
+severe	O
+immune	O
+-	O
+mediated	O
+hemolytic	B-DISO
+anemia	I-DISO
+.	O
+
+Following	O
+admission	O
+to	O
+the	O
+intensive	O
+care	O
+unit	O
+,	O
+hypoxia	B-DISO
+became	O
+critical	O
+,	O
+with	O
+a	O
+PaO	B-PROC
+(	O
+2	O
+)/	O
+F	O
+(	O
+I	O
+)	O
+O	O
+(	O
+2	O
+)	O
+value	O
+of	O
+52	O
+even	O
+after	O
+recruitment	B-DISO
+maneuvers	O
+.	O
+
+Inhaled	B-PROC
+nitric	B-CHED
+oxide	I-CHED
+(	O
+NO	O
+10	O
+ppm	O
+)	O
+was	O
+administered	O
+to	O
+the	O
+patient	O
+as	O
+a	O
+rescue	O
+treatment	O
+,	O
+resulting	O
+in	O
+a	O
+gradual	O
+but	O
+dramatic	O
+improvement	O
+in	O
+pulmonary	B-ANAT
+oxygenation	B-PROC
+.	O
+
+Accordingly	O
+,	O
+C57BL	O
+/	O
+6	O
+mice	B-SPEC
+were	O
+chosen	O
+,	O
+because	O
+these	O
+animals	B-SPEC
+respond	O
+to	O
+PADRE	O
+better	O
+than	O
+other	O
+mouse	B-SPEC
+strains	O
+.	O
+
+Furthermore	O
+,	O
+PADRE	O
+administration	O
+amplified	O
+the	O
+MHV	B-SPEC
+effect	O
+,	O
+extending	O
+the	O
+duration	O
+of	O
+hypergammaglobulinemia	O
+and	O
+increasing	O
+the	O
+binding	B-FUNC
+of	O
+autoAb	O
+as	O
+well	O
+as	O
+the	O
+degree	O
+of	O
+hepatic	B-ANAT
+infiltrates	B-DISO
+.	O
+
+The	O
+classical	O
+post	O
+-	O
+diarrhoeal	O
+form	O
+associated	O
+with	O
+Escherichia	B-SPEC
+coli	I-SPEC
+(	O
+O157	O
+:	O
+H7	O
+)	O
+infection	B-DISO
+was	O
+not	O
+seen	O
+.	O
+
+One	O
+patient	O
+died	B-PROC
+of	O
+acute	B-DISO
+respiratory	I-DISO
+failure	I-DISO
+.	O
+
+Further	O
+,	O
+we	O
+found	O
+that	O
+9b	O
+interacts	O
+with	O
+the	O
+cellular	B-COMP
+protein	B-CHED
+Crm1	B-PRGE
+and	O
+gets	O
+exported	O
+out	O
+of	O
+the	O
+nucleus	B-COMP
+using	O
+an	O
+active	O
+NES	B-SPEC
+.	O
+
+ABSTRACT	O
+:	O
+Cellular	O
+and	O
+viral	B-PRGE
+S	I-PRGE
+-	I-PRGE
+adenosylmethionine	I-PRGE
+-	I-PRGE
+dependent	I-PRGE
+methyltransferases	I-PRGE
+are	O
+involved	O
+in	O
+many	O
+regulated	O
+processes	O
+such	O
+as	O
+metabolism	B-PROC
+,	O
+detoxification	B-PROC
+,	O
+signal	B-PROC
+transduction	I-PROC
+,	O
+chromatin	B-PROC
+remodeling	I-PROC
+,	O
+nucleic	B-CHED
+acid	I-CHED
+processing	O
+,	O
+and	O
+mRNA	B-PROC
+capping	B-PROC
+.	O
+
+The	O
+method	O
+of	O
+virus	B-SPEC
+inoculation	O
+requires	O
+careful	O
+consideration	O
+in	O
+the	O
+design	O
+of	O
+ferret	B-SPEC
+experiments	O
+as	O
+a	O
+model	O
+for	O
+influenza	B-DISO
+A	I-DISO
+/	I-DISO
+H5N1	I-DISO
+in	O
+humans	B-SPEC
+.	O
+
+A	O
+clinical	O
+diagnosis	O
+of	O
+ACS	B-FUNC
+was	O
+made	O
+.	O
+
+Exploration	O
+of	O
+the	O
+retroperitoneal	B-ANAT
+hematoma	B-DISO
+showed	O
+an	O
+actively	O
+bleeding	B-DISO
+ligated	O
+ileocolic	O
+vessel	B-ANAT
+.	O
+
+Unfortunately	O
+,	O
+little	O
+is	O
+known	O
+about	O
+maintenance	O
+mechanisms	O
+for	O
+any	O
+pathogen	O
+in	O
+bat	B-ENZY
+populations	O
+.	O
+
+We	O
+propose	O
+that	O
+life	O
+history	O
+patterns	O
+of	O
+many	O
+species	B-SPEC
+of	O
+temperate	O
+-	O
+zone	O
+bats	B-SPEC
+,	O
+coupled	O
+with	O
+sufficiently	O
+long	O
+incubation	O
+periods	O
+,	O
+allows	O
+for	O
+rabies	B-SPEC
+virus	I-SPEC
+maintenance	O
+.	O
+
+Seasonal	O
+variability	O
+in	O
+bat	B-ENZY
+mortality	O
+rates	O
+,	O
+specifically	O
+low	O
+mortality	O
+during	O
+hibernation	B-PROC
+,	O
+allows	O
+long	O
+-	O
+term	O
+bat	B-ENZY
+population	O
+viability	O
+.	O
+
+Within	O
+viable	O
+bat	B-ENZY
+populations	O
+,	O
+sufficiently	O
+long	O
+incubation	O
+periods	B-PROC
+allow	O
+enough	O
+infected	O
+individuals	O
+to	O
+enter	O
+hibernation	B-PROC
+and	O
+survive	O
+until	O
+the	O
+following	O
+year	O
+,	O
+and	O
+hence	O
+avoid	O
+an	O
+epizootic	O
+fadeout	O
+of	O
+rabies	B-SPEC
+virus	I-SPEC
+.	O
+
+Five	O
+patients	O
+had	O
+full	O
+or	O
+nearly	O
+complete	O
+recoveries	O
+;	O
+one	O
+still	O
+requires	O
+nocturnal	O
+ventilation	O
+;	O
+and	O
+one	O
+died	B-PROC
+(	O
+14	O
+%)	O
+of	O
+myocardial	B-DISO
+infarction	I-DISO
+while	O
+still	O
+requiring	O
+mechanical	O
+ventilation	O
+.	O
+
+Our	O
+hypothesis	O
+is	O
+that	O
+antecedent	O
+respiratory	B-DISO
+viral	I-DISO
+infection	I-DISO
+increases	O
+bacterial	O
+density	O
+and	O
+progression	O
+to	O
+perforation	O
+.	O
+
+Data	O
+are	O
+reported	O
+by	O
+clinical	O
+ear	B-ANAT
+state	O
+.	O
+
+M	B-SPEC
+.	I-SPEC
+catarrhalis	I-SPEC
+(	O
+96	O
+%),	O
+H	B-SPEC
+.	I-SPEC
+influenzae	I-SPEC
+(	O
+91	O
+%),	O
+S	B-SPEC
+.	I-SPEC
+pneumoniae	I-SPEC
+(	O
+89	O
+%)	O
+and	O
+respiratory	O
+viruses	B-SPEC
+(	O
+59	O
+%)	O
+were	O
+common	O
+;	O
+including	O
+rhinovirus	B-SPEC
+(	O
+HRV	O
+)	O
+(	O
+38	O
+%),	O
+polyomavirus	B-SPEC
+(	O
+HPyV	O
+)	O
+(	O
+14	O
+%),	O
+adenovirus	B-SPEC
+(	O
+HAdV	O
+)	O
+(	O
+13	O
+%),	O
+bocavirus	B-SPEC
+(	O
+HBoV	O
+)	O
+(	O
+8	O
+%)	O
+and	O
+coronavirus	B-SPEC
+(	O
+HCoV	O
+)	O
+(	O
+4	O
+%).	O
+
+Children	O
+infected	O
+with	O
+HAdV	O
+were	O
+3	O
+times	O
+more	O
+likely	O
+(	O
+p	O
+<	O
+0	O
+.	O
+001	O
+)	O
+to	O
+have	O
+AOM	B-DISO
+with	O
+or	O
+without	O
+perforation	O
+.	O
+
+In	O
+cases	O
+where	O
+intranuclear	B-COMP
+inclusions	I-COMP
+are	O
+missing	O
+but	O
+clinical	O
+and	O
+histological	O
+findings	O
+are	O
+compatible	O
+with	O
+FHV	O
+-	O
+1	O
+dermatitis	B-DISO
+,	O
+immunohistochemistry	O
+(	O
+IHC	O
+)	O
+and	O
+PCRs	O
+have	O
+been	O
+used	O
+.	O
+
+If	O
+clinical	O
+signs	O
+and	O
+histopathology	O
+suggest	O
+FHV	O
+-	O
+1	O
+infection	B-DISO
+in	O
+the	O
+absence	O
+of	O
+typical	O
+inclusion	B-COMP
+bodies	I-COMP
+,	O
+IHC	O
+is	O
+the	O
+preferred	O
+diagnostic	O
+test	O
+;	O
+PCR	O
+may	O
+be	O
+useful	O
+for	O
+initial	O
+screening	O
+,	O
+but	O
+due	O
+to	O
+false	O
+positives	O
+is	O
+not	O
+sufficient	O
+for	O
+a	O
+definitive	O
+diagnosis	O
+.	O
+
+We	O
+prospectively	O
+describe	O
+baseline	O
+characteristics	O
+,	O
+treatment	O
+and	O
+outcomes	O
+of	O
+consecutive	O
+critically	B-DISO
+ill	I-DISO
+patients	O
+with	O
+confirmed	O
+2009	O
+influenza	B-PATH
+A	I-PATH
+(	O
+H1N1	O
+)	O
+in	O
+the	O
+intensive	O
+care	O
+unit	O
+(	O
+ICU	O
+)	O
+of	O
+Sfax	O
+hospital	O
+.	O
+
+We	O
+prospectively	O
+analysed	O
+data	O
+and	O
+outcomes	O
+of	O
+these	O
+patients	O
+and	O
+compared	O
+survivors	O
+and	O
+dead	B-PROC
+patients	O
+to	O
+identify	O
+any	O
+predictors	O
+of	O
+death	B-PROC
+.	O
+
+In	O
+our	O
+experience	O
+,	O
+respiratory	B-DISO
+dysfunction	I-DISO
+can	O
+remain	O
+isolated	O
+but	O
+may	O
+also	O
+be	O
+associated	O
+with	O
+other	O
+dysfunctions	O
+or	O
+complications	O
+,	O
+such	O
+as	O
+,	O
+septic	B-DISO
+shock	I-DISO
+,	O
+seizures	B-DISO
+,	O
+myasthenia	B-DISO
+gravis	I-DISO
+exacerbation	O
+,	O
+Guillan	O
+-	O
+Barre	O
+syndrome	B-DISO
+,	O
+acute	B-DISO
+renal	I-DISO
+failure	I-DISO
+,	O
+nosocomial	B-DISO
+infections	I-DISO
+and	O
+biological	O
+disturbances	O
+.	O
+
+CONCLUSIONS	O
+:	O
+Critical	B-DISO
+illness	I-DISO
+from	O
+the	O
+2009	O
+influenza	B-PATH
+A	I-PATH
+(	O
+H1N1	O
+)	O
+in	O
+Sfax	O
+occurred	O
+in	O
+young	O
+individuals	O
+and	O
+was	O
+associated	O
+with	O
+severe	O
+acute	O
+respiratory	O
+and	O
+additional	O
+organ	B-ANAT
+system	I-ANAT
+failure	O
+.	O
+
+TITLE	O
+:	O
+Transesophageal	O
+echocardiography	O
+-	O
+guided	O
+technique	O
+for	O
+extracorporeal	O
+membrane	B-COMP
+oxygenation	B-PROC
+dual	O
+-	O
+lumen	O
+catheter	O
+placement	O
+.	O
+
+ABSTRACT	O
+:	O
+Sickle	B-ANAT
+cell	B-COMP
+disease	I-DISO
+is	O
+the	O
+commonest	O
+haemoglobinopathy	B-DISO
+within	O
+the	O
+United	O
+Kingdom	B-SPEC
+.	O
+
+No	O
+significant	O
+differences	O
+in	O
+28	O
+-	O
+day	O
+all	O
+-	O
+cause	O
+mortality	O
+were	O
+observed	O
+(	O
+ITT	O
+patients	O
+:	O
+26	O
+.	O
+2	O
+%	O
+EPA	B-CHED
+/	O
+GLA	B-CHED
+diet	O
+versus	O
+27	O
+.	O
+6	O
+%	O
+control	O
+diet	O
+,	O
+respectively	O
+;	O
+P	O
+=	O
+0	O
+.	O
+72	O
+;	O
+evaluable	B-DISO
+:	O
+26	O
+.	O
+4	O
+EPA	B-CHED
+/	O
+GLA	B-CHED
+diet	O
+versus	O
+30	O
+.	O
+18	O
+control	O
+diet	O
+,	O
+respectively	O
+;	O
+P	O
+=	O
+0	O
+.	O
+79	O
+).	O
+
+Whereas	O
+D	O
+-	O
+2	O
+exhibited	O
+high	O
+cytotoxicity	O
+in	O
+MT	O
+-	O
+4	O
+cell	B-ANAT
+lines	I-ANAT
+,	O
+L	O
+-	O
+2	O
+did	O
+not	O
+show	O
+any	O
+discernible	O
+cytotoxicity	B-DISO
+in	O
+all	O
+cell	B-ANAT
+lines	I-ANAT
+tested	O
+,	O
+reflecting	O
+that	O
+L	O
+-	O
+2	O
+may	O
+be	O
+a	O
+good	O
+candidate	O
+for	O
+an	O
+anti	O
+-	O
+AIDS	O
+drug	O
+.	O
+
+L	O
+-	O
+2	O
+also	O
+showed	O
+weak	O
+anti	O
+-	O
+HSV	B-SPEC
+-	O
+2	O
+activity	O
+without	O
+cytotoxicity	B-DISO
+.	O
+
+Due	O
+to	O
+severe	O
+hypoxemia	O
+and	O
+hypercarbia	B-DISO
+,	O
+the	O
+patient	O
+required	O
+mechanical	O
+ventilation	O
+and	O
+later	O
+emergent	O
+blood	B-ANAT
+oxygenation	B-PROC
+with	O
+extracorporeal	O
+support	O
+.	O
+
+It	O
+seems	O
+to	O
+be	O
+an	O
+effective	O
+and	O
+useful	O
+ultimate	O
+therapeutic	O
+strategy	O
+for	O
+preventing	O
+death	B-PROC
+and	O
+furthermore	O
+permitting	O
+near	O
+-	O
+full	O
+pulmonary	B-PROC
+function	B-DISO
+recovery	I-DISO
+.	O
+
+ABSTRACT	O
+:	O
+Pericardial	B-DISO
+effusion	I-DISO
+is	O
+a	O
+common	O
+finding	O
+in	O
+everyday	O
+clinical	O
+practice	O
+.	O
+
+Epidemiologic	O
+considerations	O
+are	O
+very	O
+important	O
+,	O
+as	O
+in	O
+developed	O
+countries	O
+acute	O
+idiopathic	O
+pericarditis	O
+and	O
+idiopathic	O
+pericardial	B-DISO
+effusion	I-DISO
+are	O
+the	O
+most	O
+common	O
+etiologies	O
+,	O
+but	O
+in	O
+some	O
+underdeveloped	O
+geographic	O
+areas	O
+tuberculous	B-DISO
+pericarditis	I-DISO
+is	O
+the	O
+leading	O
+cause	O
+of	O
+pericardial	B-DISO
+effusion	I-DISO
+.	O
+
+Pericardial	B-ANAT
+drainage	B-ANAT
+is	O
+mandatory	O
+when	O
+clinical	O
+tamponade	O
+is	O
+present	O
+.	O
+
+ABSTRACT	O
+:	O
+Porcine	B-SPEC
+epidemic	I-SPEC
+diarrhea	I-SPEC
+virus	I-SPEC
+(	O
+PEDV	B-SPEC
+)	O
+infection	B-DISO
+in	O
+Vero	B-ANAT
+cells	I-ANAT
+is	O
+facilitated	O
+by	O
+trypsin	B-PRGE
+through	O
+an	O
+undefined	O
+mechanism	O
+.	O
+
+TITLE	O
+:	O
+Crystal	B-ANAT
+structure	O
+of	O
+mouse	B-PRGE
+coronavirus	B-SPEC
+receptor	I-PRGE
+-	I-PRGE
+binding	B-FUNC
+domain	I-PRGE
+complexed	O
+with	O
+its	O
+murine	B-SPEC
+receptor	O
+.	O
+
+Mouse	B-DISO
+hepatitis	I-DISO
+coronavirus	B-SPEC
+(	O
+MHV	B-SPEC
+)	O
+uses	O
+the	O
+N	O
+-	O
+terminal	O
+domain	O
+(	O
+NTD	O
+)	O
+of	O
+its	O
+spike	O
+protein	B-CHED
+as	O
+its	O
+receptor	O
+-	O
+binding	B-FUNC
+domain	O
+.	O
+
+Despite	O
+its	O
+galectin	O
+fold	O
+,	O
+MHV	B-SPEC
+NTD	O
+does	O
+not	O
+bind	B-FUNC
+sugars	O
+,	O
+but	O
+instead	O
+binds	B-FUNC
+mCEACAM1a	O
+through	O
+exclusive	O
+protein	B-CHED
+-	O
+protein	B-CHED
+interactions	O
+.	O
+
+Sugar	O
+-	O
+binding	B-FUNC
+assays	O
+reveal	O
+that	O
+galectin	B-PRGE
+-	I-PRGE
+like	I-PRGE
+NTDs	I-PRGE
+of	O
+some	O
+coronaviruses	O
+such	O
+as	O
+human	B-SPEC
+coronavirus	I-SPEC
+OC43	O
+and	O
+bovine	B-SPEC
+coronavirus	B-SPEC
+bind	B-FUNC
+sugars	O
+.	O
+
+Yet	O
+,	O
+ACS	B-FUNC
+in	O
+hemoglobin	B-DISO
+SC	I-DISO
+disease	I-DISO
+is	O
+not	O
+well	O
+characterized	O
+.	O
+
+We	O
+retrospectively	O
+reviewed	O
+71	O
+inpatient	O
+episodes	O
+of	O
+ACS	B-FUNC
+in	O
+patients	O
+with	O
+hemoglobin	B-DISO
+SC	I-DISO
+disease	I-DISO
+over	O
+a	O
+20	O
+-	O
+year	O
+period	O
+.	O
+
+Neurohumoral	O
+-	O
+mediated	O
+cardiorenal	O
+dysfunction	O
+and	O
+congestion	B-DISO
+may	O
+contribute	O
+to	O
+these	O
+high	O
+event	O
+rates	O
+.	O
+
+ABSTRACT	O
+:	O
+Reversible	O
+cerebral	O
+vasoconstriction	B-PROC
+syndrome	B-DISO
+(	O
+RCVS	O
+)	O
+has	O
+reversible	O
+multifocal	O
+narrowing	O
+of	O
+the	O
+cerebral	B-ANAT
+arteries	I-ANAT
+.	O
+
+Sudden	O
+severe	B-DISO
+headache	I-DISO
+had	O
+progressed	O
+and	O
+developed	O
+bilateral	O
+lower	O
+visual	O
+fields	O
+defect	O
+along	O
+with	O
+mild	O
+weakness	B-DISO
+of	O
+her	O
+right	B-ANAT
+leg	I-ANAT
+on	O
+the	O
+next	O
+day	O
+.	O
+
+To	O
+address	O
+this	O
+,	O
+children	O
+less	O
+than	O
+5	O
+years	O
+of	O
+age	O
+with	O
+respiratory	B-DISO
+infections	I-DISO
+from	O
+3	O
+public	O
+sector	O
+hospitals	O
+,	O
+Pretoria	O
+South	O
+Africa	O
+were	O
+screened	O
+for	O
+14	O
+respiratory	O
+viruses	B-SPEC
+,	O
+by	O
+PCR	O
+over	O
+2	O
+years	O
+.	O
+
+A	O
+pulmonary	B-PROC
+function	I-PROC
+test	O
+showed	O
+moderate	O
+obstructive	B-DISO
+ventilatory	I-DISO
+defect	I-DISO
+and	O
+chest	B-ANAT
+high	O
+resolution	O
+CT	O
+scan	O
+disclosed	O
+some	O
+dilated	O
+vessels	B-ANAT
+over	O
+the	O
+left	O
+lower	O
+lung	B-ANAT
+.	O
+
+A	O
+germicide	O
+can	O
+be	O
+considered	O
+to	O
+have	O
+an	O
+efficient	O
+ATS	B-DISO
+-	O
+D	O
+antiviral	B-CHED
+activity	O
+if	O
+it	O
+induces	O
+a	O
+>	O
+3	O
+or	O
+>	O
+4	O
+log	O
+(	O
+10	O
+)	O
+reduction	O
+(	O
+American	O
+and	O
+European	O
+regulatory	O
+agency	O
+requirements	O
+,	O
+respectively	O
+)	O
+in	O
+viral	O
+titers	O
+in	O
+a	O
+defined	O
+contact	O
+time	O
+.	O
+
+Therefore	O
+,	O
+the	O
+acquisition	O
+of	O
+gene	O
+7	O
+by	O
+the	O
+TGEV	B-SPEC
+genome	O
+most	O
+likely	O
+has	O
+provided	O
+a	O
+selective	O
+advantage	O
+to	O
+the	O
+virus	B-SPEC
+.	O
+
+TITLE	O
+:	O
+Establishment	O
+of	O
+a	O
+novel	O
+ovine	O
+kidney	B-ANAT
+cell	I-ANAT
+line	O
+for	O
+isolation	O
+and	O
+propagation	O
+of	O
+viruses	B-SPEC
+infecting	O
+domestic	O
+cloven	O
+-	O
+hoofed	O
+animal	B-SPEC
+species	B-SPEC
+.	O
+
+In	O
+conclusion	O
+,	O
+our	O
+data	O
+demonstrate	O
+that	O
+the	O
+attachment	O
+patterns	O
+of	O
+the	O
+IBV	B-SPEC
+S	O
+proteins	B-CHED
+correlate	O
+with	O
+the	O
+tropisms	B-PROC
+and	O
+pathogenicities	O
+of	O
+the	O
+corresponding	O
+viruses	B-SPEC
+.	O
+
+This	O
+brief	O
+article	O
+is	O
+based	O
+on	O
+the	O
+hypothesis	O
+that	O
+neonatal	O
+RDS	O
+has	O
+a	O
+complex	O
+and	O
+multifactorial	O
+pathogenesis	B-DISO
+characterized	O
+by	O
+an	O
+injurious	O
+inflammatory	O
+sequence	O
+in	O
+the	O
+immature	O
+lung	B-ANAT
+.	O
+
+The	O
+mortality	O
+rate	O
+of	O
+ARDS	B-DISO
+/	O
+DAD	B-PRGE
+is	O
+extremely	O
+high	O
+,	O
+at	O
+approximately	O
+60	O
+%,	O
+and	O
+no	O
+effective	O
+treatment	O
+for	O
+ARDS	B-DISO
+/	O
+DAD	O
+has	O
+been	O
+established	O
+.	O
+
+We	O
+examined	O
+serial	O
+pathological	O
+changes	O
+in	O
+the	O
+lungs	B-ANAT
+of	O
+mice	B-SPEC
+infected	O
+with	O
+influenza	B-SPEC
+virus	I-SPEC
+to	O
+determine	O
+the	O
+progress	O
+from	O
+viral	B-DISO
+pneumonia	I-DISO
+to	O
+ARDS	B-DISO
+/	O
+DAD	B-PRGE
+.	O
+
+The	O
+present	O
+study	O
+indicates	O
+that	O
+DAD	B-PRGE
+with	O
+severe	O
+alveolar	B-ANAT
+collapse	B-DISO
+is	O
+associated	O
+with	O
+death	B-PROC
+in	O
+this	O
+mouse	B-SPEC
+infection	B-DISO
+model	O
+of	O
+influenza	B-SPEC
+virus	I-SPEC
+.	O
+
+Safety	O
+advisories	O
+from	O
+the	O
+FDA	O
+,	O
+CDC	O
+,	O
+and	O
+the	O
+relevant	O
+pharmaceutical	B-CHED
+manufacturers	O
+were	O
+ambiguous	O
+in	O
+their	O
+description	O
+in	O
+""""	O
+black	O
+box	O
+""""	O
+warning	O
+sections	O
+of	O
+package	O
+inserts	O
+describing	O
+these	O
+serious	O
+and	O
+potentially	O
+fatal	O
+toxicities	O
+.	O
+
+RESULTS	O
+:	O
+Adverse	O
+event	O
+reports	O
+identified	O
+three	O
+health	O
+care	O
+workers	O
+who	O
+developed	O
+nevirapine	B-CHED
+-	O
+associated	O
+Stevens	B-DISO
+-	I-DISO
+Johnson	I-DISO
+syndrome	I-DISO
+following	O
+occupational	O
+exposure	O
+to	O
+HIV	B-DISO
+-	O
+infected	O
+blood	B-ANAT
+or	O
+blood	B-ANAT
+products	O
+;	O
+four	O
+persons	O
+with	O
+localized	O
+hypersensitivity	B-DISO
+and	O
+fatal	O
+cardiac	B-DISO
+events	I-DISO
+associated	O
+with	O
+rapamycin	B-CHED
+-	O
+or	O
+paclitaxel	B-CHED
+-	O
+coated	O
+coronary	B-ANAT
+artery	I-ANAT
+stent	O
+placements	O
+;	O
+and	O
+six	O
+persons	O
+with	O
+breast	B-DISO
+cancer	B-SPEC
+who	O
+developed	O
+severe	O
+or	O
+fatal	O
+anaphylaxis	B-DISO
+after	O
+receiving	O
+adjuvant	B-CHED
+chemotherapy	O
+with	O
+Cremophor	O
+-	O
+EL	O
+containing	O
+paclitaxel	B-CHED
+.	O
+
+It	O
+is	O
+also	O
+an	O
+important	O
+immune	O
+target	O
+for	O
+the	O
+host	B-COMP
+in	O
+neutralizing	O
+the	O
+virus	B-SPEC
+.	O
+
+Of	O
+these	O
+,	O
+the	O
+region	O
+encoding	O
+antigenic	O
+sites	O
+A	O
+and	O
+to	O
+a	O
+lesser	O
+extent	O
+D	O
+,	O
+herein	O
+defined	O
+as	O
+S	O
+-	O
+AD	O
+,	O
+are	O
+most	O
+critical	O
+in	O
+eliciting	O
+host	B-COMP
+neutralizing	O
+antibodies	B-COMP
+.	O
+
+We	O
+compared	O
+the	O
+effects	O
+of	O
+airway	B-ANAT
+pressure	O
+release	B-PATH
+ventilation	O
+and	O
+conventional	O
+mechanical	O
+ventilation	O
+on	O
+oxygenation	B-PROC
+in	O
+a	O
+porcine	B-SPEC
+model	O
+of	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+induced	O
+by	O
+wood	O
+smoke	O
+inhalation	B-PROC
+.	O
+
+Before	O
+injury	O
+,	O
+the	O
+pigs	B-SPEC
+were	O
+randomized	O
+to	O
+receive	O
+conventional	O
+mechanical	O
+ventilation	O
+(	O
+n	O
+=	O
+15	O
+)	O
+or	O
+airway	B-ANAT
+pressure	O
+release	B-PATH
+ventilation	O
+(	O
+n	O
+=	O
+12	O
+)	O
+for	O
+48	O
+hrs	B-DISO
+after	O
+smoke	O
+inhalation	B-PROC
+.	O
+
+At	O
+other	O
+time	O
+points	O
+,	O
+PaO2	O
+/	O
+Fio2	O
+ratio	O
+was	O
+not	O
+different	O
+between	O
+conventional	O
+mechanical	O
+ventilation	O
+and	O
+airway	B-ANAT
+pressure	O
+release	B-PATH
+ventilation	O
+.	O
+
+The	O
+results	O
+indicated	O
+that	O
+the	O
+recombination	O
+events	O
+occurred	O
+in	O
+the	O
+S1	B-PRGE
+gene	I-PRGE
+between	O
+the	O
+field	O
+strains	O
+.	O
+
+They	O
+also	O
+suggest	O
+two	O
+mechanisms	O
+by	O
+which	O
+TNFR1	B-PRGE
+mediates	O
+TNF	B-PRGE
+-	I-PRGE
+α	I-PRGE
+-	O
+driven	O
+DC	O
+maturation	B-PROC
+,	O
+as	O
+follows	O
+:	O
+a	O
+direct	O
+effect	O
+through	O
+TNFR1	B-PRGE
+expressed	B-PROC
+on	O
+immature	O
+DCs	B-DISO
+and	O
+an	O
+indirect	O
+effect	O
+through	O
+TNFR1	B-PRGE
+expressed	B-PROC
+on	O
+naive	O
+T	B-ANAT
+cells	I-ANAT
+.	O
+
+Specifically	O
+,	O
+we	O
+review	O
+the	O
+effects	O
+of	O
+hypercapnia	O
+and	O
+acidosis	B-DISO
+on	O
+the	O
+attenuation	O
+of	O
+pulmonary	B-DISO
+inflammation	I-DISO
+,	O
+reduction	O
+of	O
+apoptosis	B-PATH
+in	O
+alveolar	B-ANAT
+epithelial	B-ANAT
+cells	I-ANAT
+,	O
+improvement	O
+in	O
+sepsis	B-DISO
+-	O
+induced	O
+ALI	O
+and	O
+the	O
+therapeutic	O
+effects	O
+on	O
+other	O
+organ	B-ANAT
+systems	I-ANAT
+,	O
+as	O
+well	O
+as	O
+the	O
+potentially	O
+harmful	O
+effects	O
+of	O
+these	O
+strategies	O
+.	O
+
+However	O
+,	O
+future	O
+research	O
+should	O
+focus	O
+on	O
+the	O
+intracellular	B-COMP
+signaling	B-PROC
+pathways	B-PROC
+that	O
+mediate	O
+ALI	O
+development	B-PROC
+,	O
+potentially	O
+focusing	O
+on	O
+the	O
+role	O
+of	O
+reactive	O
+biological	O
+species	B-SPEC
+in	O
+ALI	O
+pathogenesis	B-DISO
+.	O
+
+Future	O
+research	O
+can	O
+also	O
+elucidate	O
+how	O
+such	O
+pathways	B-PROC
+may	O
+be	O
+targeted	B-PROC
+by	O
+hypercapnia	B-DISO
+and	O
+hypercapnic	B-DISO
+acidosis	I-DISO
+to	O
+attenuate	O
+lung	B-ANAT
+injury	O
+.	O
+
+ABSTRACT	O
+:	O
+The	O
+history	O
+,	O
+current	O
+situation	O
+and	O
+control	O
+measures	O
+for	O
+infectious	O
+bronchitis	B-DISO
+virus	B-SPEC
+(	O
+IBV	B-SPEC
+)	O
+variants	O
+are	O
+reviewed	O
+.	O
+
+Six	O
+adjoining	O
+12	O
+.	O
+1	O
+-	O
+ha	O
+pastures	O
+bisected	O
+by	O
+a	O
+stream	O
+in	O
+central	O
+Iowa	O
+were	O
+divided	O
+into	O
+three	O
+treatments	O
+:	O
+continuous	O
+stocking	O
+with	O
+unrestricted	O
+stream	O
+access	O
+(	O
+CSU	O
+),	O
+continuous	O
+stocking	O
+with	O
+restricted	O
+stream	O
+access	O
+(	O
+CSR	B-DISO
+),	O
+and	O
+rotational	O
+stocking	O
+(	O
+RS	O
+).	O
+
+Bovine	B-SPEC
+enterovirus	I-SPEC
+was	O
+shed	O
+by	O
+an	O
+average	O
+of	O
+24	O
+.	O
+3	O
+%	O
+of	O
+cows	O
+during	O
+the	O
+study	O
+period	O
+and	O
+was	O
+collected	O
+in	O
+the	O
+runoff	O
+of	O
+8	O
+.	O
+3	O
+and	O
+16	O
+.	O
+7	O
+%	O
+of	O
+runoff	O
+simulations	O
+on	O
+bare	O
+sites	O
+in	O
+CSU	O
+pastures	O
+in	O
+June	O
+and	O
+October	O
+of	O
+2008	O
+,	O
+respectively	O
+,	O
+and	O
+from	O
+8	O
+.	O
+3	O
+%	O
+of	O
+runoff	O
+simulations	O
+on	O
+vegetated	O
+sites	O
+in	O
+CSU	O
+pastures	O
+in	O
+April	O
+2009	O
+.	O
+
+ABSTRACT	O
+:	O
+In	O
+fulminant	O
+blastomycosis	B-DISO
+with	O
+multiorgan	B-DISO
+failure	I-DISO
+,	O
+the	O
+earliest	O
+diagnosis	O
+possible	O
+is	O
+crucial	O
+for	O
+successful	O
+treatment	O
+.	O
+
+TITLE	O
+:	O
+High	O
+-	O
+frequency	O
+oscillatory	O
+ventilation	O
+in	O
+patients	O
+with	O
+acute	O
+exacerbation	O
+of	O
+chronic	B-DISO
+obstructive	I-DISO
+pulmonary	I-DISO
+disease	I-DISO
+.	O
+
+ABSTRACT	O
+:	O
+High	O
+-	O
+frequency	O
+oscillatory	O
+ventilation	O
+(	O
+HFOV	O
+)	O
+is	O
+usually	O
+considered	O
+not	O
+indicated	O
+for	O
+treatment	O
+of	O
+patients	O
+with	O
+chronic	B-DISO
+obstructive	I-DISO
+pulmonary	I-DISO
+disease	I-DISO
+(	O
+COPD	B-DISO
+)	O
+because	O
+of	O
+the	O
+theoretical	O
+risk	O
+of	O
+air	B-DISO
+trapping	I-DISO
+and	O
+hyperinflation	B-DISO
+.	O
+
+Ventilation	O
+was	O
+more	O
+homogeneously	O
+distributed	O
+during	O
+HFOV	O
+than	O
+during	O
+initial	O
+CMV	B-SPEC
+.	O
+
+Higher	O
+respiratory	B-ANAT
+system	I-ANAT
+compliance	O
+and	O
+tidal	O
+volume	O
+were	O
+found	O
+during	O
+CMV	B-SPEC
+after	O
+24	O
+hours	O
+of	O
+HFOV	O
+.	O
+
+ABSTRACT	O
+:	O
+The	O
+5	O
+'	O
+140	O
+nucleotides	B-CHED
+of	O
+the	O
+mouse	B-DISO
+hepatitis	I-DISO
+virus	B-SPEC
+(	O
+MHV	B-SPEC
+)	O
+5	O
+'	O
+untranslated	O
+region	O
+(	O
+5	O
+'	O
+UTR	O
+)	O
+are	O
+predicted	O
+to	O
+contain	O
+three	O
+secondary	O
+structures	O
+,	O
+stem	B-ANAT
+-	O
+loop	O
+1	O
+(	O
+SL1	B-PRGE
+),	O
+SL2	B-PRGE
+,	O
+and	O
+SL4	O
+.	O
+
+However	O
+,	O
+deletion	O
+of	O
+SL4	O
+is	O
+lethal	O
+,	O
+and	O
+genomes	O
+carrying	O
+this	O
+deletion	O
+are	O
+defective	O
+in	O
+directing	O
+subgenomic	O
+RNA	B-PROC
+synthesis	I-PROC
+.	O
+
+The	O
+second	O
+-	O
+site	O
+mutations	O
+are	O
+predicted	O
+to	O
+change	O
+either	O
+the	O
+spacing	O
+between	O
+SL1	B-PRGE
+and	O
+SL2	B-PRGE
+or	O
+that	O
+between	O
+SL2	B-PRGE
+and	O
+SL4	O
+or	O
+to	O
+destabilize	O
+the	O
+proximal	O
+portion	O
+of	O
+SL4a	O
+in	O
+our	O
+model	O
+.	O
+
+The	O
+therapeutic	O
+potential	O
+of	O
+P2Y	B-PRGE
+receptors	I-PRGE
+is	O
+rapidly	O
+expanding	O
+field	O
+in	O
+pharmacology	O
+and	O
+some	O
+selective	O
+agonists	B-CHED
+became	O
+recently	O
+available	O
+.	O
+
+Clinical	O
+and	O
+experimental	O
+studies	O
+point	O
+to	O
+the	O
+involvement	O
+of	O
+immunological	O
+mechanisms	O
+in	O
+the	O
+physiopathology	O
+of	O
+lung	B-ANAT
+damage	O
+caused	O
+by	O
+leptospirosis	B-DISO
+.	O
+
+Lung	B-ANAT
+involvement	O
+in	O
+leptospirosis	B-DISO
+is	O
+a	O
+serious	O
+manifestation	O
+,	O
+with	O
+a	O
+high	O
+and	O
+variable	O
+mortality	O
+rate	O
+.	O
+
+During	O
+a	O
+1	O
+-	O
+year	O
+period	O
+,	O
+this	O
+protocol	O
+management	O
+was	O
+used	O
+in	O
+5	O
+patients	O
+with	O
+refractory	O
+respiratory	O
+failure	O
+associated	O
+with	O
+bronchial	B-DISO
+fistula	I-DISO
+after	O
+thoracic	B-DISO
+operations	O
+.	O
+
+It	O
+may	O
+be	O
+possible	O
+that	O
+viral	O
+dynamics	O
+from	O
+both	O
+hypotheses	O
+are	O
+at	O
+play	O
+in	O
+the	O
+occurrence	O
+of	O
+FIP	B-DISO
+.	O
+
+In	O
+Hluhluwe	O
+-	O
+iMfolozi	O
+Park	B-DISO
+(	O
+HiP	B-PRGE
+),	O
+a	O
+small	O
+,	O
+enclosed	O
+reserve	O
+in	O
+South	O
+Africa	O
+,	O
+a	O
+large	O
+lion	B-SPEC
+(	O
+Panthera	B-SPEC
+leo	I-SPEC
+)	O
+population	O
+arose	O
+from	O
+a	O
+small	O
+founder	B-DISO
+group	O
+in	O
+the	O
+1960s	O
+and	O
+started	O
+showing	O
+conspicuous	O
+signs	O
+of	O
+inbreeding	B-PROC
+.	O
+
+Antibodies	B-COMP
+to	O
+feline	B-SPEC
+herpesvirus	I-SPEC
+,	O
+feline	B-SPEC
+calicivirus	I-SPEC
+,	O
+feline	B-SPEC
+parvovirus	I-SPEC
+,	O
+and	O
+feline	B-SPEC
+coronavirus	B-SPEC
+were	O
+present	O
+in	O
+the	O
+lion	B-SPEC
+population	O
+,	O
+but	O
+there	O
+was	O
+no	O
+significant	O
+difference	O
+in	O
+antibody	B-COMP
+prevalence	O
+between	O
+native	O
+and	O
+translocated	O
+lions	B-SPEC
+and	O
+their	O
+offspring	O
+,	O
+and	O
+these	O
+feline	B-SPEC
+viruses	B-SPEC
+did	O
+not	O
+appear	O
+to	O
+have	O
+an	O
+effect	O
+on	O
+the	O
+clinical	O
+health	O
+of	O
+HiP	B-ANAT
+lions	B-SPEC
+.	O
+
+Early	O
+recognition	O
+and	O
+aggressive	B-DISO
+therapeutic	O
+treatment	O
+could	O
+prevent	O
+fatal	O
+cardiac	B-DISO
+complications	I-DISO
+.	O
+
+ABSTRACT	O
+:	O
+Right	B-DISO
+ventricular	I-DISO
+dysfunction	I-DISO
+(	O
+RVD	B-PROC
+)	O
+is	O
+common	O
+in	O
+critically	O
+ill	O
+patients	O
+and	O
+the	O
+presence	O
+of	O
+this	O
+condition	B-DISO
+affects	O
+patients	O
+'	O
+outcomes	O
+.	O
+
+The	O
+mean	O
+body	B-ANAT
+mass	O
+index	O
+was	O
+25	O
+.	O
+0	O
++/-	O
+
+Although	O
+similar	O
+proportions	O
+of	O
+both	O
+group	O
+received	O
+ventilatory	O
+support	O
+,	O
+the	O
+RVD	B-PROC
+patients	O
+had	O
+lower	O
+tidal	O
+volume	O
+and	O
+had	O
+higher	O
+peak	O
+airway	B-ANAT
+pressure	O
+.	O
+
+TITLE	O
+:	O
+Quasi	O
+-	O
+life	O
+self	O
+-	O
+organizing	O
+systems	O
+:	O
+based	O
+on	O
+ensembles	O
+of	O
+succinylated	O
+derivatives	O
+of	O
+interferon	B-PRGE
+-	I-PRGE
+gamma	I-PRGE
+.	O
+
+pECLA	O
+is	O
+an	O
+effective	O
+and	O
+manageable	O
+technique	O
+to	O
+support	O
+gas	B-ENZY
+exchange	O
+in	O
+ARDS	B-DISO
+patients	O
+.	O
+
+CONCLUSIONS	O
+:	O
+pECLA	O
+is	O
+an	O
+effective	O
+and	O
+manageable	O
+technique	O
+to	O
+support	O
+gas	B-ENZY
+exchange	O
+in	O
+ARDS	B-DISO
+patients	O
+.	O
+
+ABSTRACT	O
+:	O
+This	O
+review	O
+summarizes	O
+knowledge	O
+and	O
+evidence	O
+on	O
+the	O
+use	O
+of	O
+positive	O
+end	O
+-	O
+expiratory	O
+pressure	O
+(	O
+PEEP	B-CHED
+)	O
+in	O
+patients	O
+with	O
+severely	O
+hypoxemic	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+(	O
+ARDS	B-DISO
+).	O
+
+More	O
+specifically	O
+,	O
+it	O
+documents	O
+the	O
+current	O
+evidence	O
+on	O
+the	O
+effects	O
+of	O
+higher	O
+PEEP	B-CHED
+in	O
+preventing	O
+(	O
+or	O
+attenuating	O
+)	O
+lung	B-ANAT
+damage	O
+during	O
+the	O
+ventilatory	O
+management	O
+of	O
+patients	O
+with	O
+severely	O
+hypoxemic	O
+ARDS	B-DISO
+.	O
+
+In	O
+this	O
+review	O
+,	O
+those	O
+variables	O
+are	O
+defined	O
+as	O
+PaO	B-PROC
+(	O
+2	O
+)/	O
+F	O
+(	O
+I	O
+)	O
+O	O
+(	O
+2	O
+)	O
+≤	O
+100	O
+mm	O
+Hg	O
+and	O
+≥	O
+15	O
+cm	O
+H	O
+(	O
+2	O
+)	O
+O	O
+,	O
+respectively	O
+.	O
+
+In	O
+ARDS	B-DISO
+,	O
+the	O
+primary	O
+objective	O
+of	O
+PEEP	B-CHED
+is	O
+to	O
+increase	O
+the	O
+amount	O
+of	O
+non	O
+-	O
+aerated	O
+lung	B-ANAT
+at	O
+the	O
+end	O
+of	O
+expiration	B-PROC
+.	O
+
+RESULTS	O
+:	O
+WNv	B-PRGE
+antigen	B-CHED
+was	O
+detected	O
+in	O
+brain	B-ANAT
+,	O
+spleen	B-ANAT
+,	O
+heart	B-ANAT
+,	O
+kidney	B-ANAT
+,	O
+liver	B-ANAT
+,	O
+gonads	B-ANAT
+,	O
+intestine	B-ANAT
+,	O
+lung	B-ANAT
+,	O
+and	O
+pancreas	B-ANAT
+.	O
+
+These	O
+AER	B-COMP
+/	O
+AED	B-CHED
+mice	B-SPEC
+developed	O
+life	O
+-	O
+threatening	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+(	O
+ARDS	B-DISO
+),	O
+displayed	O
+by	O
+diffuse	B-DISO
+alveolar	I-DISO
+damage	I-DISO
+(	O
+DAD	O
+)	O
+resulting	O
+from	O
+i	O
+)	O
+dramatic	O
+interstitial	B-ANAT
+alveolar	B-ANAT
+septa	O
+-	O
+thickening	O
+with	O
+mononuclear	B-ANAT
+cells	I-ANAT
+,	O
+ii	O
+)	O
+some	O
+hyperplasia	B-DISO
+of	O
+alveolar	B-ANAT
+type	B-ANAT
+-	I-ANAT
+II	I-ANAT
+pneumocytes	I-ANAT
+,	O
+iii	O
+)	O
+copious	O
+intra	O
+-	O
+alveolar	B-ANAT
+protein	B-PROC
+secretion	B-ANAT
+,	O
+iv	O
+)	O
+some	O
+hyaline	B-DISO
+membrane	B-COMP
+-	O
+covered	O
+alveolar	B-ANAT
+walls	O
+,	O
+and	O
+v	O
+)	O
+DENV	O
+-	O
+2	O
+antigen	B-CHED
+-	O
+positive	O
+alveolar	B-ANAT
+macrophages	I-ANAT
+.	O
+
+These	O
+results	O
+imply	O
+a	O
+potential	O
+hazard	O
+of	O
+DENV	B-PRGE
+NS1	I-PRGE
+glycoprotein	B-CHED
+-	O
+based	O
+vaccines	O
+,	O
+particularly	O
+against	O
+DENV	O
+strains	O
+that	O
+contain	O
+multiple	O
+mutations	O
+or	O
+genetic	B-PROC
+recombination	I-PROC
+within	O
+or	O
+between	O
+their	O
+DENV	O
+E	O
+and	O
+NS1	B-PRGE
+glycoprotein	B-CHED
+-	I-PRGE
+encoding	I-PRGE
+genes	I-PRGE
+.	O
+
+TITLE	O
+:	O
+The	O
+Italian	O
+ECMO	O
+network	O
+experience	O
+during	O
+the	O
+2009	O
+influenza	B-PATH
+A	I-PATH
+(	O
+H1N1	O
+)	O
+pandemic	O
+:	O
+preparation	O
+for	O
+severe	O
+respiratory	O
+emergency	O
+outbreaks	O
+.	O
+
+Lithium	B-CHED
+poisoning	O
+results	O
+in	O
+multisystem	O
+toxicity	O
+,	O
+and	O
+characteristic	O
+clinical	O
+manifestations	O
+are	O
+directly	O
+correlated	O
+to	O
+serum	B-COMP
+lithium	B-CHED
+concentration	O
+.	O
+
+She	O
+was	O
+referred	O
+for	O
+generalized	B-DISO
+weakness	I-DISO
+,	O
+found	O
+in	O
+hemodynamic	B-PROC
+compromise	O
+,	O
+and	O
+had	O
+laboratory	O
+data	O
+significant	O
+for	O
+a	O
+lithium	B-CHED
+level	O
+of	O
+3	O
+.	O
+3	O
+mmole	O
+/	O
+L	O
+,	O
+needing	O
+emergent	O
+hemodialysis	O
+.	O
+
+Subsequently	O
+,	O
+she	O
+developed	O
+hypoxic	B-DISO
+respiratory	B-DISO
+failure	I-DISO
+requiring	O
+intubation	O
+.	O
+
+We	O
+included	O
+67	O
+studies	O
+including	O
+randomised	O
+controlled	O
+trials	O
+and	O
+observational	O
+studies	O
+with	O
+a	O
+mixed	O
+risk	O
+of	O
+bias	B-SPEC
+.	O
+
+Simple	O
+and	O
+low	O
+-	O
+cost	O
+interventions	O
+would	O
+be	O
+useful	O
+for	O
+reducing	O
+transmission	O
+of	O
+epidemic	O
+respiratory	O
+viruses	B-SPEC
+.	O
+
+This	O
+empirical	O
+rule	O
+was	O
+shown	O
+to	O
+govern	O
+inter	O
+-	O
+individual	O
+transmission	O
+dynamics	O
+for	O
+many	O
+pathogens	O
+in	O
+several	O
+species	B-SPEC
+,	O
+and	O
+individuals	O
+who	O
+infect	O
+disproportionately	O
+more	O
+secondary	O
+contacts	O
+,	O
+as	O
+compared	O
+to	O
+most	O
+others	O
+,	O
+became	O
+known	O
+as	O
+super	O
+-	O
+spreaders	O
+.	O
+
+Gag	B-PRGE
+proteins	B-CHED
+,	O
+encoded	O
+by	O
+retroviruses	B-SPEC
+,	O
+orchestrate	O
+the	O
+assembly	O
+of	O
+virus	B-COMP
+particles	I-COMP
+in	O
+close	O
+collaboration	O
+with	O
+host	B-COMP
+cell	I-COMP
+machinery	O
+.	O
+
+Similarly	O
+,	O
+nuclear	O
+trafficking	B-PROC
+of	O
+the	O
+RSV	B-PRGE
+Gag	B-SPEC
+protein	B-CHED
+is	O
+required	O
+for	O
+efficient	O
+encapsidation	O
+of	O
+the	O
+viral	O
+genomic	O
+RNA	O
+(	O
+gRNA	O
+)	O
+into	O
+assembling	O
+virus	B-COMP
+particles	I-COMP
+.	O
+19	O
+Recently	O
+,	O
+we	O
+reported	O
+that	O
+the	O
+viral	O
+RNA	O
+itself	O
+appears	O
+to	O
+be	O
+a	O
+key	O
+factor	O
+in	O
+controlling	O
+the	O
+nucleus	B-COMP
+/	O
+cytosol	B-COMP
+distribution	O
+of	O
+RSV	B-PRGE
+Gag	B-PRGE
+.	O
+22	O
+Our	O
+data	O
+demonstrate	O
+that	O
+binding	B-FUNC
+of	O
+RSV	B-SPEC
+RNA	O
+to	O
+the	O
+Gag	B-PRGE
+protein	B-CHED
+promotes	O
+Gag	B-PRGE
+-	O
+CRM1	B-PRGE
+-	O
+RanGTP	O
+binding	B-FUNC
+,	O
+resulting	O
+in	O
+export	O
+of	O
+the	O
+retroviral	B-SPEC
+RNP	B-COMP
+from	O
+the	O
+nucleus	B-COMP
+.	O
+
+Hospitals	O
+are	O
+often	O
+the	O
+epicentres	O
+of	O
+newly	O
+circulating	O
+infections	B-DISO
+.	O
+
+HCWs	O
+perceived	O
+risk	O
+factors	O
+for	O
+occupationally	O
+acquired	O
+infectious	B-DISO
+diseases	I-DISO
+to	O
+be	O
+1	O
+.)	O
+exposure	O
+to	O
+patients	O
+with	O
+undiagnosed	O
+infections	B-DISO
+2	O
+.)	O
+
+Demographic	O
+data	O
+,	O
+symptoms	O
+,	O
+comorbidities	O
+,	O
+disease	B-DISO
+progression	I-DISO
+,	O
+treatments	O
+,	O
+and	O
+clinical	O
+outcomes	O
+were	O
+collected	O
+for	O
+analysis	O
+.	O
+
+Sixty	O
+-	O
+two	O
+severe	O
+or	O
+critically	B-DISO
+ill	I-DISO
+patients	O
+were	O
+admitted	O
+to	O
+the	O
+hospital	O
+with	O
+confirmed	O
+2009	O
+influenza	B-PATH
+A	I-PATH
+(	O
+H1N1	O
+)	O
+infection	B-DISO
+.	O
+
+All	O
+patients	O
+presented	O
+with	O
+fever	B-PROC
+and	O
+respiratory	B-DISO
+symptoms	I-DISO
+.	O
+
+Four	O
+death	B-PROC
+reports	O
+(	O
+6	O
+.	O
+5	O
+%)	O
+were	O
+filed	O
+within	O
+the	O
+first	O
+14	O
+days	O
+from	O
+the	O
+onset	O
+of	O
+critical	B-DISO
+illness	I-DISO
+with	O
+the	O
+primary	O
+causes	O
+of	O
+severe	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+,	O
+hypoxemia	O
+,	O
+or	O
+complications	O
+,	O
+secondary	B-DISO
+infection	I-DISO
+and	O
+sepsis	B-DISO
+,	O
+pyopneumothorax	B-DISO
+and	O
+stroke	B-DISO
+.	O
+
+Homozygosity	O
+mapping	O
+was	O
+performed	O
+by	O
+50K	O
+SNP	O
+genotyping	O
+and	O
+candidate	O
+genes	O
+were	O
+successively	O
+analyzed	O
+by	O
+direct	O
+sequencing	O
+on	O
+genomic	O
+DNA	O
+of	O
+the	O
+family	B-SPEC
+members	O
+.	O
+
+SNP	O
+genotyping	O
+detected	O
+several	O
+regions	O
+of	O
+homozygosity	O
+in	O
+which	O
+we	O
+focused	O
+our	O
+attention	O
+to	O
+genes	O
+involved	O
+in	O
+mitochondrial	B-PROC
+translation	B-PROC
+.	O
+
+All	O
+studies	O
+with	O
+the	O
+prone	O
+position	O
+document	O
+an	O
+improvement	O
+in	O
+systemic	O
+oxygenation	B-PROC
+in	O
+70	O
+%	O
+to	O
+80	O
+%	O
+of	O
+patients	O
+with	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+(	O
+ARDS	B-DISO
+),	O
+with	O
+maximal	O
+improvement	O
+seen	O
+in	O
+the	O
+most	O
+hypoxemic	O
+patients	O
+.	O
+
+Referral	O
+to	O
+a	O
+specialized	O
+center	O
+with	O
+ECMO	O
+experience	O
+should	O
+be	O
+considered	O
+early	O
+after	O
+the	O
+initiation	O
+of	O
+high	O
+-	O
+level	O
+ventilator	O
+support	O
+in	O
+adult	O
+patients	O
+with	O
+severe	O
+ARDS	B-DISO
+.	O
+
+TITLE	O
+:	O
+[	O
+Acute	B-DISO
+interstitial	I-DISO
+pneumonia	I-DISO
+:	O
+diagnostic	O
+approach	O
+and	O
+management	O
+].	O
+
+The	O
+onset	O
+of	O
+respiratory	B-DISO
+symptoms	I-DISO
+is	O
+acute	O
+,	O
+most	O
+often	O
+within	O
+two	O
+weeks	O
+.	O
+
+Underlying	O
+aetiologies	O
+are	O
+numerous	O
+and	O
+variable	O
+,	O
+particularly	O
+in	O
+relation	O
+to	O
+the	O
+underlying	O
+immune	B-PROC
+status	I-PROC
+of	O
+the	O
+host	B-COMP
+.	O
+
+We	O
+document	O
+two	O
+young	O
+adults	O
+suffering	B-DISO
+from	O
+H1N1	O
+-	O
+associated	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+and	O
+renal	B-DISO
+failure	I-DISO
+who	O
+developed	O
+cerebral	B-DISO
+edema	I-DISO
+.	O
+
+These	O
+results	O
+show	O
+that	O
+pathogen	O
+epitope	B-CHED
+-	O
+specific	O
+Foxp3	B-PRGE
+(+)	O
+T	B-ANAT
+reg	I-ANAT
+cells	B-COMP
+can	O
+be	O
+identified	O
+on	O
+the	O
+basis	O
+of	O
+cytokine	B-PROC
+production	I-PROC
+.	O
+
+TITLE	O
+:	O
+Severe	O
+H1N1	O
+-	O
+infection	B-DISO
+during	O
+pregnancy	O
+.	O
+
+We	O
+report	O
+the	O
+case	O
+of	O
+a	O
+24	O
+-	O
+year	O
+gravida	O
+4	O
+para	O
+2	O
+with	O
+singleton	O
+pregnancy	O
+admitted	O
+to	O
+obstetrical	O
+unit	O
+for	O
+fever	B-PROC
+up	O
+to	O
+38	O
+°	O
+C	O
+during	O
+the	O
+20th	O
+week	O
+of	O
+a	O
+so	O
+far	O
+uncomplicated	O
+pregnancy	O
+.	O
+
+Coincidentally	O
+,	O
+progressive	O
+pancytopenia	B-DISO
+and	O
+increased	O
+inflammatory	O
+activity	O
+was	O
+recorded	O
+.	O
+
+Recent	O
+human	B-DISO
+immunodeficiency	I-DISO
+virus	I-DISO
+,	O
+cytomegalic	O
+virus	B-SPEC
+,	O
+herpes	B-SPEC
+simplex	I-SPEC
+virus	I-SPEC
+,	O
+classical	O
+influenza	B-DISO
+and	O
+parainfluenza	B-DISO
+infections	B-DISO
+were	O
+excluded	O
+.	O
+
+TITLE	O
+:	O
+Use	O
+of	O
+a	O
+novel	O
+virus	B-SPEC
+detection	O
+assay	O
+to	O
+identify	O
+coronavirus	B-SPEC
+HKU1	O
+in	O
+the	O
+lungs	B-ANAT
+of	O
+a	O
+hematopoietic	B-ANAT
+stem	I-ANAT
+cell	I-ANAT
+transplant	B-ANAT
+recipient	O
+with	O
+fatal	O
+pneumonia	B-DISO
+.	O
+
+ABSTRACT	O
+:	O
+A	O
+38	O
+-	O
+year	O
+-	O
+old	O
+female	O
+patient	O
+with	O
+systemic	B-PATH
+lupus	I-PATH
+erythematosus	I-PATH
+presented	O
+with	O
+pulmonary	B-DISO
+infiltrates	I-DISO
+and	O
+hypoxemia	O
+for	O
+several	O
+months	O
+following	O
+immunodepleting	O
+autologous	O
+hematopoietic	B-ANAT
+stem	I-ANAT
+cell	I-ANAT
+transplantation	O
+.	O
+
+She	O
+was	O
+treated	O
+for	O
+influenza	B-DISO
+,	O
+which	O
+was	O
+isolated	O
+repeatedly	O
+from	O
+oropharynx	B-ANAT
+and	O
+bronchoalveolar	O
+lavage	O
+(	O
+BAL	B-ENZY
+)	O
+fluids	B-ANAT
+,	O
+and	O
+later	O
+empirically	O
+for	O
+lupus	B-DISO
+pneumonitis	I-DISO
+,	O
+but	O
+died	B-PROC
+6	O
+months	O
+after	O
+transplant	B-ANAT
+.	O
+
+As	O
+a	O
+result	O
+,	O
+more	O
+severe	O
+tissue	B-ANAT
+damage	O
+was	O
+produced	O
+and	O
+mortality	O
+rates	O
+were	O
+higher	O
+.	O
+
+Thus	O
+,	O
+the	O
+up	B-PROC
+-	I-PROC
+regulation	I-PROC
+of	O
+FGL2	B-PRGE
+in	O
+PD	B-PRGE
+-	I-PRGE
+1	I-PRGE
+-	O
+deficient	O
+mice	B-SPEC
+was	O
+determined	O
+to	O
+be	O
+mediated	O
+by	O
+IFN	B-PRGE
+-	I-PRGE
+γ	I-PRGE
+and	O
+TNF	B-PRGE
+-	I-PRGE
+α	I-PRGE
+.	O
+
+Here	O
+we	O
+show	O
+that	O
+replication	O
+of	O
+ns2	B-DISO
+mutant	B-DISO
+viruses	B-SPEC
+is	O
+attenuated	O
+in	O
+bone	B-ANAT
+marrow	I-ANAT
+-	I-ANAT
+derived	I-ANAT
+macrophages	I-ANAT
+(	O
+BMM	B-ANAT
+)	O
+generated	O
+from	O
+wild	O
+-	O
+type	O
+(	O
+wt	O
+)	O
+mice	B-SPEC
+but	O
+not	O
+in	O
+L2	O
+fibroblasts	B-ANAT
+,	O
+primary	O
+astrocytes	B-ANAT
+,	O
+or	O
+BMM	B-ANAT
+generated	O
+from	O
+type	B-PRGE
+I	I-PRGE
+interferon	I-PRGE
+receptor	I-PRGE
+-	O
+deficient	O
+(	O
+IFNAR	B-PRGE
+(-/-))	O
+mice	B-SPEC
+.	O
+
+The	O
+AAV	O
+vector	O
+encoding	O
+EC	O
+-	O
+SOD	B-FUNC
+increased	O
+lung	B-ANAT
+EC	O
+-	O
+SOD	B-FUNC
+concentrations	O
+,	O
+and	O
+enhanced	O
+the	O
+antioxidant	B-CHED
+capacity	O
+of	O
+the	O
+lung	B-ANAT
+.	O
+
+EC	B-PRGE
+-	I-PRGE
+SOD	I-PRGE
+attenuated	O
+pulmonary	B-DISO
+inflammation	I-DISO
+,	O
+decreased	O
+bronchoalveolar	O
+lavage	O
+neutrophil	B-ANAT
+counts	O
+,	O
+and	O
+reduced	O
+interleukin	B-PRGE
+-	I-PRGE
+6	I-PRGE
+and	O
+CINC	B-PRGE
+-	I-PRGE
+1	I-PRGE
+concentrations	O
+.	O
+
+TITLE	O
+:	O
+Local	O
+renin	B-PRGE
+-	O
+angiotensin	B-PRGE
+II	I-PRGE
+systems	O
+,	O
+angiotensin	B-PRGE
+-	I-PRGE
+converting	I-PRGE
+enzyme	I-PRGE
+and	O
+its	O
+homologue	O
+ACE2	B-PRGE
+:	O
+their	O
+potential	O
+role	O
+in	O
+the	O
+pathogenesis	O
+of	O
+chronic	O
+obstructive	B-DISO
+pulmonary	I-DISO
+diseases	I-DISO
+,	O
+pulmonary	B-DISO
+hypertension	I-DISO
+and	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+.	O
+
+In	O
+the	O
+present	O
+paper	O
+,	O
+we	O
+review	O
+data	O
+from	O
+studies	O
+of	O
+the	O
+past	O
+decade	O
+that	O
+implicate	O
+AngII	B-PRGE
+and	O
+functional	O
+polymorphisms	B-PROC
+of	O
+the	O
+ACE	B-PRGE
+gene	I-PRGE
+that	O
+increase	O
+ACE	B-PRGE
+activity	O
+with	O
+increased	O
+susceptibility	O
+for	O
+asthma	B-PATH
+and	O
+chronic	B-DISO
+obstructive	I-DISO
+pulmonary	I-DISO
+disease	I-DISO
+(	O
+COPD	B-DISO
+)	O
+and	O
+for	O
+pulmonary	B-DISO
+hypertension	I-DISO
+.	O
+
+This	O
+review	O
+introduces	O
+these	O
+new	O
+viruses	B-SPEC
+and	O
+reviews	O
+their	O
+clinical	O
+significance	O
+,	O
+especially	O
+with	O
+regard	O
+to	O
+the	O
+elderly	O
+population	O
+.	O
+
+TITLE	O
+:	O
+Severe	O
+Plasmodium	B-SPEC
+knowlesi	I-SPEC
+malaria	B-PATH
+in	O
+a	O
+tertiary	O
+care	O
+hospital	O
+,	O
+Sabah	O
+,	O
+Malaysia	O
+.	O
+
+Twenty	O
+-	O
+two	O
+(	O
+39	O
+%)	O
+had	O
+severe	O
+malaria	B-PATH
+;	O
+of	O
+these	O
+,	O
+6	O
+(	O
+27	O
+%)	O
+died	B-PROC
+.	O
+
+None	O
+experienced	O
+coma	B-DISO
+.	O
+
+Parasite	O
+clearance	O
+times	O
+were	O
+1	O
+-	O
+2	O
+days	O
+shorter	O
+with	O
+either	O
+artemether	B-CHED
+-	O
+lumefantrine	B-CHED
+or	O
+artesunate	B-CHED
+treatment	O
+.	O
+
+Artemisinin	B-CHED
+derivatives	I-CHED
+rapidly	O
+clear	O
+parasitemia	B-DISO
+and	O
+are	O
+efficacious	O
+in	O
+treating	O
+uncomplicated	O
+and	O
+severe	O
+knowlesi	O
+malaria	B-PATH
+.	O
+
+Likewise	O
+,	O
+the	O
+SARS	B-DISO
+VLP	B-COMP
+vaccine	O
+,	O
+containing	O
+4	O
+μg	O
+of	O
+S	B-PRGE
+protein	I-PRGE
+without	O
+adjuvant	B-CHED
+,	O
+reduced	O
+lung	B-ANAT
+virus	B-SPEC
+titer	O
+to	O
+below	O
+detectable	O
+level	O
+,	O
+protected	O
+mice	B-SPEC
+from	O
+weight	O
+loss	O
+,	O
+and	O
+elicited	O
+a	O
+high	O
+level	O
+of	O
+neutralizing	O
+antibodies	B-COMP
+against	O
+SARS	B-DISO
+-	O
+CoV	O
+.	O
+Sf9	B-PRGE
+cell	I-PRGE
+-	I-PRGE
+produced	I-PRGE
+full	I-PRGE
+length	I-PRGE
+purified	I-PRGE
+SARS	B-DISO
+S	I-PRGE
+protein	B-CHED
+was	O
+also	O
+an	O
+effective	O
+vaccine	O
+against	O
+SARS	B-DISO
+-	O
+CoV	O
+but	O
+only	O
+when	O
+co	O
+-	O
+administered	O
+IM	O
+with	O
+aluminum	B-CHED
+hydroxide	I-CHED
+.	O
+
+All	O
+evidence	O
+charge	O
+venlafaxine	B-CHED
+as	O
+the	O
+only	O
+possible	O
+causal	O
+factor	O
+.	O
+
+TITLE	O
+:	O
+SARS	B-DISO
+-	O
+Coronavirus	B-SPEC
+ancestor	O
+'	O
+s	O
+foot	B-ANAT
+-	O
+prints	O
+in	O
+South	O
+-	O
+East	O
+Asian	O
+bat	B-ENZY
+colonies	O
+and	O
+the	O
+refuge	O
+theory	O
+.	O
+
+To	O
+this	O
+end	O
+,	O
+RdRp	B-FUNC
+sequence	O
+of	O
+Coronavirinae	B-SPEC
+was	O
+targeted	B-PROC
+by	O
+RT	O
+-	O
+PCR	O
+in	O
+non	O
+-	O
+invasive	O
+samples	O
+from	O
+bats	B-SPEC
+collected	O
+in	O
+Thailand	O
+.	O
+
+One	O
+hundred	O
+and	O
+twenty	O
+-	O
+eight	O
+of	O
+189	O
+patients	O
+died	B-PROC
+in	O
+hospital	O
+.	O
+
+Thus	O
+,	O
+it	O
+seems	O
+prudent	O
+to	O
+continue	O
+to	O
+explore	O
+and	O
+develop	O
+antiviral	B-CHED
+chemotherapies	O
+to	O
+treat	O
+SARS	B-DISO
+-	O
+CoV	O
+infections	B-DISO
+.	O
+
+In	O
+addition	O
+,	O
+compounds	O
+that	O
+have	O
+been	O
+tested	O
+in	O
+various	O
+animal	B-SPEC
+models	O
+and	O
+were	O
+found	O
+to	O
+reduce	O
+virus	B-SPEC
+lung	B-ANAT
+titers	O
+and	O
+/	O
+or	O
+were	O
+protective	O
+against	O
+death	B-PROC
+in	O
+lethal	O
+models	O
+of	O
+disease	O
+,	O
+or	O
+otherwise	O
+have	O
+been	O
+shown	O
+to	O
+ameliorate	O
+the	O
+effects	O
+of	O
+viral	B-DISO
+infection	I-DISO
+,	O
+are	O
+also	O
+reported	O
+.	O
+
+To	O
+determine	O
+the	O
+presence	O
+and	O
+distribution	O
+of	O
+CoV	O
+in	O
+Iberian	O
+bats	B-SPEC
+,	O
+576	O
+individuals	O
+of	O
+26	O
+different	O
+bat	B-ENZY
+species	B-SPEC
+were	O
+captured	O
+in	O
+13	O
+locations	O
+in	O
+Spain	O
+.	O
+
+We	O
+detected	O
+anti	O
+-	O
+HCoV	B-SPEC
+-	I-SPEC
+NL63	I-SPEC
+antibodies	B-COMP
+among	O
+50	O
+sera	B-COMP
+samples	O
+collected	O
+from	O
+adult	O
+for	O
+health	O
+-	O
+examination	O
+by	O
+WBLA	O
+.	O
+
+Their	O
+expression	B-PROC
+location	O
+in	O
+cell	B-COMP
+and	O
+level	O
+were	O
+characterized	O
+using	O
+indirect	O
+immune	O
+fluorescence	O
+assay	O
+(	O
+IFA	O
+)	O
+and	O
+Western	O
+-	O
+Blot	O
+,	O
+respectively	O
+.	O
+
+The	O
+expressions	O
+of	O
+four	O
+segments	O
+of	O
+spike	O
+proteins	B-CHED
+in	O
+recombinant	O
+vaccinia	B-DISO
+viruses	B-SPEC
+were	O
+showed	O
+at	O
+appropriate	O
+level	O
+and	O
+with	O
+posttranslational	B-PROC
+modification	I-PROC
+(	O
+glycosylation	B-PROC
+),	O
+and	O
+S1	O
+,	O
+RL	O
+and	O
+RS	O
+were	O
+mainly	O
+distributed	O
+in	O
+the	O
+cell	O
+membrane	O
+,	O
+while	O
+the	O
+S2	O
+was	O
+mainly	O
+distributed	O
+in	O
+the	O
+cytoplasm	B-COMP
+.	O
+
+TITLE	O
+:	O
+Emerging	O
+theme	O
+:	O
+cellular	B-COMP
+PDZ	O
+proteins	B-CHED
+as	O
+common	O
+targets	O
+of	O
+pathogenic	O
+viruses	B-SPEC
+.	O
+
+Recent	O
+studies	O
+have	O
+shown	O
+that	O
+many	O
+other	O
+viruses	B-SPEC
+also	O
+encode	O
+PBM	O
+-	O
+containing	O
+proteins	B-CHED
+that	O
+bind	B-FUNC
+to	O
+cellular	B-COMP
+PDZ	O
+proteins	B-CHED
+.	O
+
+Examination	O
+of	O
+the	O
+cellular	B-COMP
+PDZ	O
+proteins	B-CHED
+that	O
+are	O
+targets	O
+of	O
+viral	O
+PBMs	O
+reveals	O
+that	O
+the	O
+viral	O
+proteins	B-CHED
+often	O
+interact	O
+with	O
+the	O
+same	O
+or	O
+similar	O
+types	O
+of	O
+PDZ	O
+proteins	O
+,	O
+most	O
+notably	O
+Dlg1	B-PRGE
+and	O
+other	O
+members	O
+of	O
+the	O
+membrane	B-PRGE
+-	I-PRGE
+associated	I-PRGE
+guanylate	B-ENZY
+kinase	I-ENZY
+protein	B-CHED
+family	B-SPEC
+,	O
+as	O
+well	O
+as	O
+Scribble	O
+.	O
+
+The	O
+inhibition	B-PROC
+or	O
+perturbation	O
+of	O
+the	O
+function	O
+of	O
+cellular	B-COMP
+PDZ	O
+proteins	B-CHED
+appears	O
+to	O
+be	O
+a	O
+widely	O
+used	O
+strategy	O
+for	O
+viruses	B-SPEC
+to	O
+enhance	O
+their	O
+replication	O
+,	O
+disseminate	O
+in	O
+the	O
+host	B-COMP
+,	O
+and	O
+transmit	O
+to	O
+new	O
+hosts	B-COMP
+.	O
+
+ABSTRACT	O
+:	O
+Public	O
+health	O
+measures	O
+successfully	O
+contained	O
+outbreaks	O
+of	O
+the	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+coronavirus	B-SPEC
+(	O
+SARS	B-DISO
+-	O
+CoV	O
+)	O
+infection	B-DISO
+.	O
+
+TITLE	O
+:	O
+Surgical	O
+transplantation	O
+of	O
+mouse	B-SPEC
+neural	B-ANAT
+stem	I-ANAT
+cells	I-ANAT
+into	O
+the	O
+spinal	B-ANAT
+cords	I-ANAT
+of	O
+mice	B-SPEC
+infected	O
+with	O
+neurotropic	O
+mouse	O
+hepatitis	O
+virus	B-SPEC
+.	O
+
+ABSTRACT	O
+:	O
+Mice	B-SPEC
+infected	O
+with	O
+the	O
+neurotropic	O
+JHM	O
+strain	O
+of	O
+mouse	B-DISO
+hepatitis	I-DISO
+virus	B-SPEC
+(	O
+MHV	B-SPEC
+)	O
+develop	O
+pathological	O
+and	O
+clinical	O
+outcomes	O
+similar	O
+to	O
+patients	O
+with	O
+the	O
+demyelinating	B-DISO
+disease	I-DISO
+Multiple	B-DISO
+Sclerosis	I-DISO
+(	O
+MS	O
+).	O
+
+In	O
+brief	O
+,	O
+we	O
+provide	O
+a	O
+procedure	O
+for	O
+i	O
+)	O
+preparation	O
+of	O
+NSCs	O
+prior	O
+to	O
+transplant	B-ANAT
+,	O
+ii	O
+)	O
+pre	O
+-	O
+operative	O
+care	O
+of	O
+mice	B-SPEC
+,	O
+iii	O
+)	O
+exposure	O
+of	O
+the	O
+spinal	B-ANAT
+cord	I-ANAT
+via	O
+laminectomy	O
+,	O
+iv	O
+)	O
+stereotactic	O
+injection	O
+of	O
+NSCs	O
+,	O
+and	O
+iv	O
+)	O
+post	O
+-	O
+operative	O
+care	O
+.	O
+
+ABSTRACT	O
+:	O
+From	O
+the	O
+emergence	O
+of	O
+Hendra	B-SPEC
+virus	I-SPEC
+and	O
+Menangle	B-SPEC
+virus	I-SPEC
+in	O
+Australia	O
+to	O
+the	O
+global	O
+pandemics	O
+of	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+and	O
+influenza	B-SPEC
+viruses	I-SPEC
+(	O
+both	O
+H5N1	B-DISO
+and	O
+H1N1	O
+),	O
+there	O
+has	O
+been	O
+a	O
+surge	O
+of	O
+zoonotic	O
+virus	B-SPEC
+outbreaks	O
+in	O
+the	O
+last	O
+two	O
+decades	O
+.	O
+
+Only	O
+6	O
+(	O
+14	O
+.	O
+3	O
+%)	O
+of	O
+the	O
+schools	O
+with	O
+influenza	B-DISO
+specific	O
+Web	B-DISO
+sites	O
+had	O
+information	O
+for	O
+parents	O
+,	O
+with	O
+23	O
+(	O
+54	O
+.	O
+8	O
+%)	O
+providing	O
+information	O
+specifically	O
+for	O
+faculty	O
+and	O
+staff	O
+,	O
+and	O
+24	O
+(	O
+57	O
+.	O
+1	O
+%)	O
+providing	O
+information	O
+specifically	O
+to	O
+students	O
+.	O
+
+We	O
+found	O
+no	O
+guidelines	O
+for	O
+maximizing	O
+the	O
+access	O
+to	O
+and	O
+effectiveness	O
+of	O
+online	O
+pandemic	O
+communications	O
+at	O
+institutions	O
+of	O
+higher	O
+learning	B-PROC
+.	O
+
+1165	O
+nasopharyngeal	B-ANAT
+aspirates	B-ANAT
+(	O
+NPA	B-CHED
+)	O
+specimens	O
+were	O
+collected	O
+from	O
+hospitalized	O
+children	O
+with	O
+ARTI	O
+between	O
+September	O
+2007	O
+and	O
+August	O
+2008	O
+in	O
+Changsha	O
+.	O
+
+Coronavirus	B-SPEC
+HKU1	O
+may	O
+be	O
+important	O
+pathogens	O
+in	O
+children	O
+with	O
+acute	O
+lower	O
+respiratory	O
+tract	O
+infection	O
+.	O
+
+There	O
+is	O
+no	O
+significant	O
+difference	O
+in	O
+the	O
+infectious	B-DISO
+rate	O
+between	O
+the	O
+boys	O
+and	O
+the	O
+girls	O
+.	O
+
+RESULTS	O
+:	O
+Coronavirus	B-SPEC
+HKU1	O
+were	O
+detected	O
+in	O
+12	O
+patients	O
+(	O
+1	O
+.	O
+03	O
+%)	O
+out	O
+of	O
+the	O
+1165	O
+children	O
+.	O
+
+TITLE	O
+:	O
+Infectious	B-DISO
+bronchitis	B-DISO
+virus	B-SPEC
+in	O
+testicles	B-ANAT
+and	O
+venereal	O
+transmission	O
+.	O
+
+We	O
+first	O
+assessed	O
+the	O
+effect	O
+of	O
+IBV	B-SPEC
+replication	O
+in	O
+the	O
+chicken	B-SPEC
+testes	B-ANAT
+.	O
+
+TITLE	O
+:	O
+Expression	B-PROC
+,	O
+crystallization	O
+and	O
+preliminary	O
+crystallographic	O
+study	O
+of	O
+the	O
+C	O
+-	O
+terminal	O
+half	O
+of	O
+nsp2	O
+from	O
+SARS	B-DISO
+coronavirus	B-SPEC
+.	O
+
+Our	O
+results	O
+support	O
+previous	O
+findings	O
+which	O
+suggest	O
+that	O
+high	O
+levels	O
+of	O
+IL	B-FUNC
+-	I-FUNC
+6	I-FUNC
+and	O
+IL	B-FUNC
+-	I-FUNC
+8	I-FUNC
+in	O
+serum	B-COMP
+somehow	O
+participate	O
+in	O
+the	O
+inflammatory	B-DISO
+response	I-DISO
+in	O
+severe	O
+cases	O
+of	O
+pandemic	O
+influenza	B-DISO
+pneumonia	I-DISO
+.	O
+
+TITLE	O
+:	O
+Characterization	O
+of	O
+the	O
+spike	O
+protein	B-CHED
+of	O
+human	B-PRGE
+coronavirus	I-PRGE
+NL63	I-PRGE
+in	I-PRGE
+receptor	B-FUNC
+binding	I-FUNC
+and	O
+pseudotype	O
+virus	O
+entry	O
+.	O
+
+Here	O
+,	O
+we	O
+further	O
+characterized	O
+the	O
+S	B-PRGE
+protein	I-PRGE
+by	O
+investigating	O
+the	O
+roles	O
+of	O
+the	O
+cytoplasmic	B-ANAT
+tail	I-ANAT
+and	O
+19	O
+residues	O
+located	O
+in	O
+the	O
+RBD	O
+in	O
+protein	B-CHED
+accumulation	O
+,	O
+receptor	B-FUNC
+binding	I-FUNC
+,	O
+and	O
+pseudotype	O
+virus	B-SPEC
+entry	O
+.	O
+
+Base	B-PRGE
+-	O
+pairing	O
+to	O
+create	O
+the	O
+pseudoknot	O
+-	O
+forming	O
+stem	B-ANAT
+(	O
+P1	O
+(	O
+pk	O
+))	O
+is	O
+mutually	O
+exclusive	O
+with	O
+formation	B-PROC
+of	O
+stem	B-ANAT
+P0a	O
+at	O
+the	O
+base	O
+of	O
+the	O
+bulged	O
+stem	B-ANAT
+-	O
+loop	O
+;	O
+as	O
+a	O
+result	O
+,	O
+the	O
+two	O
+structures	O
+cannot	O
+be	O
+present	O
+simultaneously	O
+.	O
+
+These	O
+multiple	O
+-	O
+spanning	O
+transmembrane	B-COMP
+proteins	B-CHED
+located	O
+to	O
+the	O
+endoplasmic	B-COMP
+reticulum	I-COMP
+(	O
+ER	O
+)	O
+where	O
+they	O
+generated	O
+Atg5	O
+and	O
+LC3II	O
+-	O
+positive	O
+vesicles	B-COMP
+,	O
+and	O
+vesicle	B-PROC
+formation	I-PROC
+was	O
+dependent	O
+on	O
+Atg5	B-PRGE
+and	O
+class	B-PRGE
+III	I-PRGE
+PI3	I-PRGE
+kinase	I-PRGE
+.	O
+
+Omegasomes	O
+induced	O
+by	O
+viral	O
+nsp6	O
+matured	O
+into	O
+autophagosomes	O
+that	O
+delivered	O
+LC3	O
+to	O
+lysosomes	B-COMP
+and	O
+therefore	O
+recruited	O
+and	O
+recycled	O
+the	O
+proteins	B-CHED
+needed	O
+for	O
+autophagosome	B-COMP
+nucleation	O
+,	O
+expansion	O
+,	O
+cellular	B-COMP
+trafficking	B-PROC
+and	O
+delivery	O
+of	O
+cargo	O
+to	O
+lysosomes	B-COMP
+.	O
+
+ABSTRACT	O
+:	O
+The	O
+global	O
+spread	O
+of	O
+infectious	B-DISO
+diseases	I-DISO
+is	O
+facilitated	O
+by	O
+the	O
+ability	O
+of	O
+infected	O
+humans	B-SPEC
+to	O
+travel	O
+thousands	O
+of	O
+miles	O
+in	O
+short	O
+time	O
+spans	O
+,	O
+rapidly	O
+transporting	O
+pathogens	O
+to	O
+distant	O
+locations	O
+.	O
+
+These	O
+data	O
+demonstrate	O
+that	O
+neutrophil	B-ANAT
+-	O
+derived	O
+MMP9	B-PRGE
+is	O
+not	O
+the	O
+sole	B-ANAT
+mediator	O
+facilitating	O
+parenchymal	O
+leukocyte	B-ANAT
+entry	O
+via	O
+BBB	B-CHED
+disruption	O
+during	O
+viral	O
+encephalomyelitis	B-DISO
+.	O
+
+ABSTRACT	O
+:	O
+To	O
+elucidate	O
+the	O
+co	O
+-	O
+localization	B-PROC
+characteristic	O
+between	O
+porcine	B-SPEC
+epidemic	I-SPEC
+diarrhea	I-SPEC
+virus	I-SPEC
+(	O
+PEDV	B-SPEC
+)	O
+N	O
+protein	B-CHED
+and	O
+B23	O
+.	O
+1	O
+phosphoprotein	O
+.	O
+
+The	O
+fusion	O
+proteins	B-CHED
+successfully	O
+expressed	B-PROC
+in	O
+transfected	O
+Vero	O
+E6	O
+cells	B-COMP
+by	O
+western	O
+blot	O
+analysis	O
+,	O
+and	O
+the	O
+PEDV	B-PRGE
+N	I-PRGE
+protein	B-CHED
+and	O
+the	O
+B23	O
+.	O
+1	O
+phosphoprotein	O
+showed	O
+co	O
+-	O
+localization	O
+features	O
+in	O
+co	O
+-	O
+transfected	O
+cells	B-COMP
+through	O
+confocal	O
+microscopy	O
+analysis	O
+.	O
+
+ABSTRACT	O
+:	O
+Human	B-SPEC
+coronaviruses	O
+are	O
+one	O
+of	O
+the	O
+main	O
+causes	O
+of	O
+upper	B-DISO
+respiratory	I-DISO
+tract	I-DISO
+infections	I-DISO
+in	O
+humans	B-SPEC
+.	O
+
+To	O
+evaluate	O
+the	O
+clinical	O
+utility	O
+of	O
+the	O
+ELISA	O
+,	O
+serum	B-COMP
+samples	O
+collected	O
+from	O
+patients	O
+during	O
+an	O
+outbreak	O
+of	O
+HCoV	B-SPEC
+-	I-SPEC
+OC43	I-SPEC
+infection	B-DISO
+and	O
+previously	O
+identified	O
+as	O
+positive	O
+by	O
+HCoV	B-SPEC
+-	I-SPEC
+OC43	I-SPEC
+whole	O
+N	O
+ELISA	O
+were	O
+screened	O
+resulting	O
+in	O
+100	O
+%	O
+diagnosis	O
+agreement	O
+between	O
+the	O
+testing	O
+methods	O
+.	O
+
+TITLE	O
+:	O
+Identification	O
+of	O
+small	O
+-	O
+molecule	O
+inhibitors	B-CHED
+of	O
+the	O
+XendoU	B-PRGE
+endoribonucleases	I-PRGE
+family	I-PRGE
+.	O
+
+ABSTRACT	O
+:	O
+The	O
+XendoU	O
+family	O
+of	O
+enzymes	O
+includes	O
+several	O
+proteins	B-CHED
+displaying	O
+high	O
+sequence	O
+homology	O
+.	O
+
+ABSTRACT	O
+:	O
+Influenza	B-DISO
+(	O
+H1N1	O
+)	O
+2009	O
+occurred	O
+in	O
+Mexico	O
+in	O
+April	O
+2009	O
+,	O
+quickly	O
+spread	O
+around	O
+the	O
+world	O
+,	O
+and	O
+was	O
+found	O
+in	O
+Japan	O
+in	O
+May	O
+.	O
+Many	O
+pediatric	O
+patients	O
+experienced	O
+encephalopathy	B-DISO
+,	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+,	O
+and	O
+severe	O
+pneumonia	B-DISO
+.	O
+
+The	O
+diagnosis	O
+of	O
+influenza	B-DISO
+(	O
+H1N1	O
+)	O
+2009	O
+infection	B-DISO
+was	O
+based	O
+on	O
+positive	O
+results	O
+of	O
+a	O
+real	O
+-	O
+time	O
+polymerase	O
+chain	O
+reaction	O
+.	O
+
+No	O
+patient	O
+was	O
+diagnosed	O
+as	O
+having	O
+a	O
+bacterial	B-DISO
+infection	I-DISO
+.	O
+
+The	O
+2003	O
+outbreak	O
+of	O
+Severe	B-DISO
+Acute	I-DISO
+Respiratory	I-DISO
+Syndrome	I-DISO
+(	O
+SARS	B-DISO
+)	O
+changed	O
+government	O
+epidemic	O
+prevention	O
+policies	O
+and	O
+marked	O
+a	O
+renewed	O
+focus	O
+on	O
+preventing	O
+and	O
+controlling	O
+communicable	B-DISO
+diseases	I-DISO
+.	O
+
+Our	O
+data	O
+suggest	O
+that	O
+wheezing	B-DISO
+in	O
+SCD	B-DISO
+may	O
+occur	O
+independently	O
+of	O
+asthma	B-PATH
+and	O
+is	O
+a	O
+marker	O
+of	O
+disease	O
+severity	O
+.	O
+
+To	O
+develop	O
+an	O
+antigen	B-CHED
+that	O
+is	O
+more	O
+specific	O
+,	O
+more	O
+sensitive	O
+,	O
+and	O
+easier	O
+to	O
+prepare	O
+for	O
+serological	O
+diagnosis	O
+,	O
+the	O
+antigenic	O
+sites	O
+in	O
+the	O
+MHV	B-PRGE
+-	I-PRGE
+nucleocapsid	B-COMP
+(	I-PRGE
+N	I-PRGE
+)	I-PRGE
+protein	B-CHED
+were	O
+screened	O
+in	O
+this	O
+study	O
+.	O
+
+Sixteen	O
+antigenic	O
+linear	O
+sequences	O
+in	O
+the	O
+N	B-PRGE
+protein	I-PRGE
+were	O
+found	O
+using	O
+antisera	O
+obtained	O
+from	O
+mice	B-SPEC
+infected	O
+naturally	O
+with	O
+MHV	B-SPEC
+and	O
+a	O
+peptide	B-CHED
+array	O
+containing	O
+overlapping	O
+10	O
+-	O
+mer	O
+peptides	B-CHED
+covering	O
+the	O
+entire	O
+N	B-PRGE
+protein	I-PRGE
+.	O
+
+From	O
+these	O
+antigenic	O
+sequences	O
+,	O
+two	O
+synthesized	O
+peptides	B-CHED
+,	O
+ILKKTTWADQTERGL	O
+and	O
+RFDSTLPGFETIMKVL	O
+,	O
+which	O
+were	O
+consistent	O
+with	O
+positions	O
+24	O
+-	O
+38	O
+and	O
+357	O
+-	O
+372	O
+of	O
+the	O
+N	O
+protein	O
+respectively	O
+,	O
+were	O
+used	O
+as	O
+antigens	B-CHED
+in	O
+ELISA	O
+.	O
+
+One	O
+of	O
+the	O
+least	O
+understood	O
+prognosticators	O
+is	O
+generalised	O
+status	O
+myoclonus	B-DISO
+(	O
+GSM	B-DISO
+),	O
+with	O
+case	O
+reports	O
+confusing	O
+GSM	B-DISO
+,	O
+isolated	O
+myoclonic	B-DISO
+jerks	I-DISO
+and	O
+post	O
+-	O
+hypoxic	B-DISO
+intention	B-DISO
+myoclonus	I-DISO
+(	O
+Lance	B-DISO
+Adams	I-DISO
+syndrome	I-DISO
+[	O
+LAS	O
+]).	O
+
+Although	O
+FE	O
+has	O
+been	O
+described	O
+in	O
+other	O
+animal	B-SPEC
+models	O
+,	O
+this	O
+study	O
+represents	O
+the	O
+first	O
+reported	O
+cases	O
+of	O
+FE	O
+and	O
+bone	B-ANAT
+marrow	I-ANAT
+embolism	O
+in	O
+nonhuman	O
+primates	B-SPEC
+.	O
+
+Histopathologic	O
+findings	O
+from	O
+cynomolgus	O
+macaques	B-SPEC
+(	O
+Macaca	B-SPEC
+fascicularis	I-SPEC
+)	O
+indicated	O
+that	O
+in	O
+all	O
+5	O
+cases	O
+,	O
+fat	O
+and	O
+bone	B-ANAT
+marrow	I-ANAT
+embolization	O
+occurred	O
+subsequent	O
+to	O
+multiple	O
+bone	B-ANAT
+marrow	I-ANAT
+biopsies	O
+.	O
+
+However	O
+,	O
+the	O
+up	B-PROC
+-	I-PROC
+regulation	I-PROC
+of	O
+AQP1	B-PRGE
+and	O
+AQP5	B-PRGE
+was	O
+suppressed	O
+by	O
+the	O
+administration	O
+of	O
+E2	O
+,	O
+resulting	O
+in	O
+an	O
+attenuation	O
+of	O
+lung	B-DISO
+edema	I-DISO
+.	O
+
+The	O
+assay	O
+system	O
+employs	O
+a	O
+novel	O
+dual	O
+envelope	B-COMP
+strategy	O
+,	O
+using	O
+lentiviral	O
+pseudovirions	O
+as	O
+targets	O
+whose	O
+entry	O
+is	O
+driven	O
+by	O
+the	O
+SARS	B-PRGE
+-	I-PRGE
+CoV	I-PRGE
+Spike	I-PRGE
+glycoprotein	B-CHED
+.	O
+
+As	O
+an	O
+example	O
+of	O
+the	O
+power	O
+of	O
+this	O
+assay	O
+a	O
+class	O
+of	O
+inhibitors	B-CHED
+is	O
+reported	O
+with	O
+the	O
+potential	O
+to	O
+inhibit	O
+SARS	B-PRGE
+-	I-PRGE
+CoV	I-PRGE
+at	O
+two	O
+steps	O
+of	O
+the	O
+replication	O
+cycle	O
+,	O
+viral	O
+entry	O
+and	O
+particle	O
+assembly	O
+.	O
+
+A	O
+Cesarean	O
+delivery	O
+was	O
+performed	O
+under	O
+deep	O
+general	B-PROC
+anesthesia	I-PROC
+with	O
+high	O
+-	O
+dose	O
+opioid	O
+administration	O
+to	O
+avoid	O
+tachycardia	O
+and	O
+hypertension	B-DISO
+during	O
+tracheal	O
+intubation	O
+and	O
+obstetric	O
+surgery	O
+.	O
+
+Delivery	O
+took	O
+place	O
+less	O
+than	O
+five	O
+minutes	O
+after	O
+induction	O
+of	O
+anesthesia	B-DISO
+,	O
+and	O
+tracheal	O
+intubation	O
+of	O
+the	O
+newborn	O
+was	O
+required	O
+due	O
+to	O
+opioid	O
+-	O
+induced	O
+hypoventilation	B-DISO
+.	O
+
+Bleeding	B-DISO
+because	O
+of	O
+absent	O
+synthesis	B-PROC
+of	O
+various	O
+coagulation	B-PROC
+factors	O
+and	O
+disseminated	B-DISO
+intravascular	I-DISO
+coagulation	I-DISO
+,	O
+acute	O
+kidney	B-ANAT
+failure	B-DISO
+,	I-DISO
+circulatory	I-DISO
+failure	O
+with	O
+vasopressor	O
+dependence	B-DISO
+,	O
+respiratory	B-DISO
+failure	I-DISO
+with	O
+adult	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+,	O
+neurological	O
+failure	O
+up	O
+to	O
+coma	B-DISO
+because	O
+of	O
+hepatic	B-DISO
+encephalopathy	I-DISO
+,	O
+and	O
+a	O
+very	O
+high	O
+risk	O
+of	O
+infection	B-DISO
+and	O
+sepsis	B-DISO
+frequently	O
+result	O
+from	O
+the	O
+initial	O
+state	O
+of	O
+isolated	O
+liver	B-DISO
+failure	I-DISO
+.	O
+
+High	O
+urgency	O
+liver	B-ANAT
+transplantation	O
+is	O
+a	O
+highly	O
+efficient	O
+therapy	O
+if	O
+performed	O
+in	O
+time	O
+.	O
+
+A	O
+prospective	O
+study	O
+in	O
+88	O
+patients	O
+with	O
+acute	B-DISO
+liver	I-DISO
+failure	I-DISO
+has	O
+shown	O
+a	O
+nonsignificant	O
+trend	O
+in	O
+improvement	O
+of	O
+survival	O
+after	O
+acute	B-DISO
+liver	I-DISO
+failure	I-DISO
+by	O
+multipass	O
+albumin	B-PRGE
+dialysis	B-SPEC
+and	O
+filtering	O
+.	O
+
+With	O
+regional	O
+citrate	B-CHED
+anticoagulation	B-PROC
+for	O
+multipass	O
+albumin	B-PRGE
+dialysis	B-SPEC
+and	O
+filtering	O
+,	O
+the	O
+need	O
+for	O
+systemic	O
+anticoagulation	B-PROC
+-	O
+a	O
+potentially	O
+very	O
+harmful	O
+measure	O
+in	O
+these	O
+patients	O
+-	O
+can	O
+be	O
+eliminated	O
+and	O
+the	O
+rate	O
+of	O
+filter	O
+clotting	B-PROC
+can	O
+extremely	O
+effectively	O
+be	O
+reduced	O
+.	O
+
+In	O
+a	O
+randomized	O
+controlled	O
+trial	O
+,	O
+referral	O
+of	O
+ARDS	B-DISO
+patients	O
+in	O
+a	O
+center	O
+with	O
+experience	O
+on	O
+ECMO	O
+was	O
+associated	O
+with	O
+an	O
+improved	O
+survival	O
+rate	O
+.	O
+
+Pharmacological	O
+treatments	O
+such	O
+as	O
+neuromuscular	O
+blocking	B-DISO
+and	O
+intravenous	O
+β2	O
+agonist	B-CHED
+may	O
+be	O
+effective	O
+in	O
+specific	O
+times	O
+and	O
+subsets	O
+of	O
+patients	O
+.	O
+
+New	O
+techniques	O
+and	O
+drugs	O
+that	O
+should	O
+facilitate	O
+prevention	O
+or	O
+healing	B-PROC
+of	O
+lung	B-ANAT
+injury	O
+are	O
+under	O
+investigation	O
+.	O
+
+These	O
+results	O
+warrant	O
+a	O
+controlled	O
+trial	O
+of	O
+dexamethasone	B-CHED
+versus	O
+placebo	O
+in	O
+AML	B-DISO
+FAB	O
+-	O
+M5	O
+patients	O
+with	O
+noninfectious	O
+pulmonary	B-DISO
+infiltrates	I-DISO
+.	O
+
+ABSTRACT	O
+:	O
+To	O
+summarize	O
+literature	O
+describing	O
+use	O
+of	O
+neuromuscular	O
+blocking	B-DISO
+agents	O
+(	O
+NMBAs	O
+)	O
+for	O
+common	O
+critical	O
+care	O
+indications	O
+and	O
+provide	O
+a	O
+review	O
+of	O
+NMBA	O
+pharmacology	O
+,	O
+pharmacokinetics	B-PROC
+,	O
+dosing	O
+,	O
+drug	B-PROC
+interactions	I-PROC
+,	O
+monitoring	O
+,	O
+complications	O
+,	O
+and	O
+reversal	O
+.	O
+
+Clinical	O
+applications	O
+of	O
+NMBAs	O
+in	O
+intensive	O
+care	O
+include	O
+,	O
+but	O
+are	O
+not	O
+limited	O
+to	O
+,	O
+immobilizing	O
+patients	O
+for	O
+procedural	O
+interventions	O
+,	O
+decreasing	O
+oxygen	O
+consumption	O
+,	O
+facilitating	O
+mechanical	O
+ventilation	O
+,	O
+reducing	O
+intracranial	B-PROC
+pressure	I-PROC
+,	O
+preventing	O
+shivering	O
+,	O
+and	O
+management	O
+of	O
+tetanus	B-DISO
+.	O
+
+In	O
+each	O
+case	O
+study	O
+,	O
+this	O
+goal	O
+is	O
+complicated	O
+by	O
+limited	O
+data	O
+,	O
+spatiotemporal	O
+variability	O
+in	O
+pathogen	B-DISO
+transmission	I-DISO
+and	O
+impact	O
+,	O
+and	O
+often	O
+,	O
+insufficient	O
+biological	O
+understanding	O
+.	O
+
+To	O
+gain	O
+a	O
+better	O
+understanding	O
+of	O
+the	O
+structure	O
+-	O
+activity	O
+relationships	O
+(	O
+SARs	B-DISO
+),	O
+herein	O
+we	O
+report	O
+the	O
+design	O
+and	O
+microwave	O
+-	O
+assisted	O
+synthesis	B-PROC
+of	O
+a	O
+novel	O
+series	O
+of	O
+1	O
+-	O
+H	O
+-	O
+benzylindole	O
+derivatives	O
+.	O
+
+Expression	B-PROC
+of	O
+l	B-PRGE
+-	I-PRGE
+selectin	I-PRGE
+,	O
+CXCR2	B-PRGE
+and	O
+C5aR	B-PRGE
+was	O
+partially	O
+restored	O
+at	O
+24	O
+h	O
+after	O
+injury	O
+.	O
+
+None	O
+of	O
+the	O
+patients	O
+developed	O
+ARDS	B-DISO
+.	O
+
+This	O
+study	O
+aimed	O
+to	O
+determine	O
+the	O
+distribution	O
+of	O
+several	O
+respiratory	O
+viruses	B-SPEC
+in	O
+children	O
+diagnosed	O
+as	O
+having	O
+influenza	B-DISO
+-	I-DISO
+like	I-DISO
+illness	I-DISO
+,	O
+over	O
+the	O
+winter	O
+period	O
+of	O
+2005	O
+-	O
+2008	O
+.	O
+
+Simultaneous	O
+presence	O
+of	O
+two	O
+or	O
+three	O
+viruses	O
+was	O
+observed	O
+in	O
+173	O
+of	O
+the	O
+above	O
+positive	O
+cases	O
+,	O
+21	O
+%	O
+of	O
+which	O
+included	O
+influenza	B-SPEC
+virus	I-SPEC
+and	O
+rhinovirus	B-SPEC
+.	O
+
+We	O
+collected	O
+paired	O
+tracheal	O
+and	O
+cloacal	B-ANAT
+swabs	O
+from	O
+283	O
+birds	B-SPEC
+including	O
+278	O
+domestic	O
+and	O
+five	O
+wild	O
+birds	B-SPEC
+(	O
+three	O
+vultures	O
+,	O
+one	O
+sparrowhawk	O
+and	O
+one	O
+Western	B-SPEC
+Grey	I-SPEC
+Plantain	I-SPEC
+-	I-SPEC
+eater	I-SPEC
+)	O
+in	O
+the	O
+Central	O
+Region	O
+(	O
+Ouagadougou	O
+)	O
+and	O
+the	O
+Western	O
+Region	O
+(	O
+Bobo	O
+-	O
+Dioulasso	O
+and	O
+Sokoroni	O
+)	O
+of	O
+Burkina	O
+Faso	O
+.	O
+
+Total	O
+RNA	O
+extracted	O
+from	O
+samples	O
+were	O
+subjected	O
+to	O
+reverse	B-PROC
+transcription	I-PROC
+and	O
+resulting	O
+cDNA	O
+amplified	O
+by	O
+PCR	O
+using	O
+specific	O
+primers	O
+for	O
+detection	O
+of	O
+Avian	B-SPEC
+Influenza	I-SPEC
+Virus	I-SPEC
+(	O
+AIV	O
+mainly	O
+highly	O
+pathogenic	O
+H5N1	B-DISO
+),	O
+Infectious	B-DISO
+Bronchitis	B-DISO
+Virus	B-SPEC
+(	O
+IBV	B-SPEC
+),	O
+and	O
+Newcastle	O
+Disease	O
+Virus	O
+(	O
+NDV	B-SPEC
+)	O
+for	O
+the	O
+first	O
+time	O
+in	O
+Burkina	O
+Faso	O
+.	O
+
+None	O
+of	O
+the	O
+283	O
+birds	B-SPEC
+were	O
+co	O
+-	O
+infected	O
+by	O
+AIV	O
+,	O
+IBV	B-SPEC
+and	O
+/	O
+or	O
+NDV	B-SPEC
+in	O
+our	O
+study	O
+areas	O
+.	O
+
+S1	B-PRGE
+glycoprotein	I-PRGE
+genes	O
+of	O
+these	O
+strains	O
+were	O
+sequenced	O
+and	O
+analyzed	O
+with	O
+38	O
+strains	O
+published	O
+in	O
+GenBank	O
+.	O
+
+S1	O
+genes	O
+of	O
+these	O
+isolated	O
+strains	O
+and	O
+the	O
+vaccine	O
+strains	O
+showed	O
+nucleotide	B-CHED
+homologies	O
+ranging	O
+from	O
+65	O
+.	O
+2	O
+to	O
+82	O
+%	O
+and	O
+amino	B-CHED
+acid	I-CHED
+homologies	O
+ranging	O
+from	O
+58	O
+.	O
+4	O
+to	O
+81	O
+.	O
+9	O
+%.	O
+
+ABSTRACT	O
+:	O
+An	O
+overview	O
+of	O
+available	O
+literature	O
+on	O
+the	O
+use	O
+of	O
+protective	O
+facemasks	O
+by	O
+children	O
+for	O
+protection	O
+from	O
+respiratory	O
+infectious	O
+agents	O
+reveals	O
+relatively	O
+few	O
+articles	O
+dealing	O
+specifically	O
+with	O
+the	O
+topic	O
+,	O
+despite	O
+their	O
+use	O
+during	O
+recent	O
+outbreaks	O
+(	O
+eg	O
+,	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+,	O
+pandemic	O
+influenza	B-DISO
+).	O
+
+Little	O
+is	O
+known	O
+about	O
+the	O
+physiological	O
+and	O
+psychological	B-DISO
+burdens	O
+imposed	O
+by	O
+these	O
+devices	O
+and	O
+a	O
+child	O
+'	O
+s	O
+ability	O
+to	O
+correctly	O
+use	O
+and	O
+tolerate	O
+them	O
+.	O
+
+In	O
+turn	O
+,	O
+stigmatization	O
+during	O
+the	O
+SARS	B-DISO
+crisis	O
+facilitated	O
+a	O
+moral	O
+panic	O
+of	O
+sorts	B-PROC
+in	O
+which	O
+racism	O
+at	O
+a	O
+cultural	O
+level	O
+was	O
+expressed	B-PROC
+and	O
+rationalized	O
+on	O
+the	O
+basis	O
+of	O
+a	O
+rhetoric	O
+of	O
+the	O
+new	O
+public	O
+health	O
+and	O
+anti	O
+-	O
+globalization	O
+sentiments	O
+.	O
+
+ABSTRACT	O
+:	O
+Avian	B-DISO
+infectious	I-DISO
+bronchitis	I-DISO
+virus	B-SPEC
+(	O
+IBV	B-SPEC
+),	O
+a	O
+coronavirus	B-SPEC
+,	O
+causes	O
+infectious	B-DISO
+bronchitis	B-DISO
+leading	O
+to	O
+enormous	O
+economic	O
+loss	O
+in	O
+the	O
+poultry	O
+industry	O
+worldwide	O
+.	O
+
+Houttuynia	B-SPEC
+cordata	I-SPEC
+(	O
+Saururaceae	B-SPEC
+)	O
+(	O
+HC	O
+)	O
+is	O
+a	O
+traditional	O
+Chinese	O
+medicine	B-CHED
+used	O
+in	O
+China	O
+.	O
+
+During	O
+the	O
+study	O
+period	O
+178	O
+patients	O
+with	O
+diffuse	O
+viral	B-DISO
+pneumonitis	I-DISO
+requiring	O
+MV	O
+were	O
+admitted	O
+.	O
+
+Lack	O
+of	O
+recovery	O
+of	O
+platelet	B-ANAT
+count	O
+and	O
+persistence	O
+of	O
+leukocytosis	B-DISO
+were	O
+characteristic	O
+of	O
+non	O
+-	O
+survivors	O
+.	O
+
+Persistence	O
+of	O
+thrombocytopenia	O
+,	O
+acidosis	B-DISO
+and	O
+leukocytosis	B-DISO
+,	O
+and	O
+high	O
+LDH	B-PRGE
+levels	O
+found	O
+in	O
+non	O
+-	O
+survivors	O
+during	O
+the	O
+course	O
+of	O
+the	O
+disease	O
+might	O
+be	O
+novel	O
+prognostic	O
+findings	O
+.	O
+
+The	O
+IBV	B-SPEC
+genome	O
+was	O
+detected	O
+in	O
+202	O
+out	O
+of	O
+605	O
+field	O
+samples	O
+from	O
+chickens	B-SPEC
+with	O
+various	O
+clinical	O
+signs	O
+.	O
+
+ABSTRACT	O
+:	O
+Despite	O
+increasing	O
+attention	O
+to	O
+the	O
+long	O
+-	O
+term	O
+risks	O
+of	O
+radiation	O
+exposure	O
+and	O
+contrast	O
+-	O
+induced	O
+nephropathy	B-DISO
+(	O
+CIN	B-DISO
+),	O
+institutional	O
+guidelines	O
+and	O
+patient	O
+consent	O
+procedures	O
+for	O
+contrast	O
+-	O
+enhanced	O
+computed	O
+tomography	O
+(	O
+CECT	O
+)	O
+imaging	O
+in	O
+the	O
+emergency	B-DISO
+department	O
+(	O
+ED	O
+)	O
+setting	O
+have	O
+focused	O
+primarily	O
+on	O
+more	O
+immediate	O
+complications	O
+,	O
+directly	O
+attributable	O
+to	O
+the	O
+administration	O
+of	O
+intravenous	O
+(	O
+IV	O
+)	O
+iodinated	O
+contrast	O
+administration	O
+.	O
+
+TITLE	O
+:	O
+Update	O
+on	O
+rhinovirus	B-SPEC
+and	O
+coronavirus	B-DISO
+infections	I-DISO
+.	O
+
+However	O
+,	O
+RVIs	O
+are	O
+increasingly	O
+recognized	O
+as	O
+a	O
+cause	O
+of	O
+morbidity	O
+and	O
+mortality	O
+in	O
+recipients	O
+of	O
+hematopoietic	B-PRGE
+stem	I-PRGE
+cell	I-PRGE
+transplants	B-ANAT
+(	O
+HSCT	O
+)	O
+and	O
+solid	O
+organ	B-ANAT
+transplants	I-ANAT
+(	O
+SOTs	O
+).	O
+
+However	O
+,	O
+mortality	O
+secondary	O
+to	O
+neonatal	O
+lung	B-ANAT
+failure	O
+has	O
+been	O
+decreased	O
+substantially	O
+by	O
+the	O
+improvements	O
+in	O
+the	O
+whole	O
+field	O
+of	O
+perinatal	O
+medicine	B-CHED
+.	O
+
+TITLE	O
+:	O
+Design	O
+and	O
+validation	O
+of	O
+consensus	O
+-	O
+degenerate	B-DISO
+hybrid	O
+oligonucleotide	B-CHED
+primers	O
+for	O
+broad	O
+and	O
+sensitive	O
+detection	O
+of	O
+corona	O
+-	O
+and	O
+toroviruses	B-SPEC
+.	O
+
+They	O
+were	O
+evaluated	O
+initially	O
+on	O
+RNA	O
+templates	O
+from	O
+virus	B-SPEC
+-	O
+infected	O
+cells	B-COMP
+using	O
+a	O
+two	O
+-	O
+step	O
+RT	O
+-	O
+PCR	O
+protocol	O
+that	O
+was	O
+further	O
+advanced	O
+to	O
+a	O
+one	O
+-	O
+step	O
+assay	O
+.	O
+
+Operation	O
+conditions	O
+were	O
+as	O
+follows	O
+:	O
+blood	B-PROC
+flow	I-PROC
+rate	O
+150	O
+ml	O
+/	O
+min	O
+,	O
+filtration	O
+rate	O
+1	O
+,	O
+500	O
+ml	O
+/	O
+h	O
+(	O
+post	O
+-	O
+dilution	O
+),	O
+and	O
+dialysate	O
+flow	O
+rate	O
+300	O
+-	O
+500	O
+ml	O
+/	O
+min	O
+over	O
+8	O
+-	O
+12	O
+h	O
+daily	O
+.	O
+
+Nerves	B-ANAT
+were	O
+harvested	O
+for	O
+morphometric	O
+analysis	O
+on	O
+postoperative	O
+day	O
+18	O
+after	O
+an	O
+SDAV	O
+outbreak	O
+occurred	O
+that	O
+affected	O
+the	O
+12	O
+experimental	O
+animals	B-SPEC
+.	O
+
+The	O
+number	O
+of	O
+proteins	B-CHED
+bound	O
+to	O
+lipoplexes	O
+was	O
+double	O
+that	O
+of	O
+those	O
+identified	O
+in	O
+the	O
+corona	B-CHED
+of	O
+CLs	B-DISO
+(	O
+208	O
+vs	O
+105	O
+),	O
+while	O
+77	O
+proteins	B-CHED
+were	O
+common	O
+to	O
+both	O
+coronas	O
+.	O
+
+TITLE	O
+:	O
+Safe	O
+transport	B-PROC
+of	O
+critically	B-DISO
+ill	I-DISO
+adult	O
+patients	O
+on	O
+extracorporeal	O
+membrane	B-COMP
+oxygenation	B-PROC
+support	O
+to	O
+a	O
+regional	O
+extracorporeal	O
+membrane	O
+oxygenation	B-PROC
+center	O
+.	O
+
+Fourteen	O
+patients	O
+with	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+(	O
+ARDS	B-DISO
+)	O
+were	O
+placed	O
+on	O
+venovenous	O
+(	O
+VV	O
+)	O
+ECMO	O
+.	O
+
+ABSTRACT	O
+:	O
+Caspase	B-PRGE
+-	I-PRGE
+8	I-PRGE
+(	O
+casp8	B-PRGE
+)	O
+is	O
+required	O
+for	O
+extrinsic	B-PROC
+apoptosis	I-PROC
+,	O
+and	O
+mice	B-SPEC
+deficient	O
+in	O
+casp8	B-PRGE
+fail	O
+to	O
+develop	O
+and	O
+die	O
+in	O
+utero	B-ANAT
+while	O
+ultimately	O
+failing	O
+to	O
+maintain	O
+the	O
+proliferation	B-DISO
+of	O
+T	B-ANAT
+cells	I-ANAT
+,	O
+B	B-ANAT
+cells	I-ANAT
+,	O
+and	O
+a	O
+host	B-COMP
+of	O
+other	O
+cell	B-COMP
+types	O
+.	O
+
+Paradoxically	O
+,	O
+these	O
+failures	O
+are	O
+not	O
+caused	O
+by	O
+a	O
+defect	O
+in	O
+apoptosis	B-PATH
+,	O
+but	O
+by	O
+a	O
+presumed	O
+proliferative	B-DISO
+function	O
+of	O
+this	O
+protease	O
+.	O
+
+Finally	O
+,	O
+we	O
+demonstrate	O
+that	O
+caspase	B-PRGE
+-	O
+mediated	O
+cleavage	B-PROC
+of	O
+RIPK1	B-PRGE
+-	O
+containing	O
+necrosis	B-PROC
+inducing	O
+complexes	O
+(	O
+necrosomes	O
+)	O
+is	O
+sufficient	O
+to	O
+prevent	O
+necroptosis	B-DISO
+in	O
+the	O
+face	B-DISO
+of	O
+death	B-PRGE
+receptor	B-PROC
+signaling	I-PROC
+.	O
+
+These	O
+studies	O
+highlight	O
+the	O
+""""	O
+two	O
+-	O
+faced	O
+""""	O
+nature	O
+of	O
+casp8	B-PRGE
+activity	O
+,	O
+promoting	O
+clonal	B-DISO
+expansion	I-DISO
+in	O
+some	O
+situations	O
+and	O
+apoptotic	O
+demise	O
+in	O
+others	O
+.	O
+
+TITLE	O
+:	O
+Detection	O
+of	O
+bat	B-ENZY
+coronaviruses	O
+from	O
+Miniopterus	B-SPEC
+fuliginosus	I-SPEC
+in	O
+Japan	O
+.	O
+
+In	O
+this	O
+study	O
+,	O
+bat	B-ENZY
+coronaviruses	O
+(	O
+BtCoVs	O
+)	O
+were	O
+detected	O
+by	O
+RT	O
+-	O
+PCR	O
+from	O
+intestinal	B-ANAT
+and	O
+fecal	B-ANAT
+specimens	O
+of	O
+Miniopterus	B-SPEC
+fuliginosus	I-SPEC
+breeding	B-PROC
+colonies	O
+in	O
+Wakayama	O
+Prefecture	O
+caves	O
+,	O
+where	O
+we	O
+previously	O
+identified	O
+bat	B-PRGE
+betaherpesvirus	I-PRGE
+2	I-PRGE
+.	O
+
+These	O
+data	O
+suggest	O
+that	O
+BtCoV	O
+is	O
+endemic	O
+in	O
+M	B-SPEC
+.	I-SPEC
+fuliginosus	I-SPEC
+in	O
+Japan	O
+.	O
+
+Laboratory	O
+investigations	O
+of	O
+blood	B-ANAT
+and	O
+urine	B-ANAT
+revealed	O
+elevations	O
+in	O
+dopamine	B-CHED
+,	O
+metanephrines	O
+,	O
+and	O
+epinephrines	O
+,	O
+as	O
+well	O
+as	O
+trazodone	B-CHED
+and	O
+risperidone	B-CHED
+.	O
+
+It	O
+is	O
+mainly	O
+characterized	O
+by	O
+hyperthermia	B-PROC
+,	O
+altered	O
+mental	O
+state	O
+,	O
+hemodynamic	B-PROC
+dysregulation	O
+,	O
+elevated	O
+serum	B-PRGE
+creatine	B-ENZY
+kinase	I-ENZY
+,	O
+and	O
+rigors	B-DISO
+.	O
+
+Although	O
+the	O
+exact	O
+mechanisms	O
+in	O
+the	O
+etiology	O
+of	O
+FHF	B-DISO
+are	O
+not	O
+understood	O
+,	O
+elevated	O
+levels	O
+of	O
+brain	B-ANAT
+ammonia	B-CHED
+have	O
+been	O
+consistently	O
+reported	O
+.	O
+
+In	O
+the	O
+present	O
+study	O
+we	O
+have	O
+examined	O
+the	O
+role	O
+of	O
+cerebral	B-ANAT
+electron	B-PROC
+transport	I-PROC
+chain	I-PROC
+complexes	O
+,	O
+including	O
+complex	B-COMP
+I	I-COMP
+,	O
+II	O
+,	O
+III	O
+IV	O
+,	O
+and	O
+pyruvate	B-PATH
+dehydrogenase	I-PATH
+in	O
+the	O
+non	O
+-	O
+synaptic	O
+mitochondria	B-COMP
+isolated	O
+from	O
+the	O
+cortex	B-ANAT
+of	O
+the	O
+thioacetamide	B-CHED
+-	O
+induced	O
+FHF	O
+rats	B-SPEC
+.	O
+
+Our	O
+results	O
+also	O
+suggest	O
+mitochondrial	B-PROC
+swelling	B-DISO
+in	O
+FHF	B-DISO
+induced	O
+rats	B-SPEC
+.	O
+
+Disease	O
+burden	O
+caused	O
+by	O
+respiratory	O
+viruses	B-SPEC
+in	O
+hospitalized	O
+patients	O
+was	O
+quantified	O
+using	O
+the	O
+World	O
+Health	O
+Organization	O
+endorsed	O
+DALY	O
+model	O
+.	O
+
+However	O
+,	O
+oxygenation	B-PROC
+and	O
+lung	B-ANAT
+protection	O
+were	O
+maintained	O
+at	O
+extremely	O
+low	O
+tidal	O
+volumes	O
+in	O
+association	O
+with	O
+very	O
+severe	O
+hypercapnia	B-DISO
+and	O
+no	O
+adverse	O
+hemodynamic	B-PROC
+effects	O
+were	O
+observed	O
+with	O
+this	O
+strategy	O
+.	O
+
+Our	O
+results	O
+reveal	O
+that	O
+LF	O
+inhibits	O
+SARS	B-DISO
+pseudovirus	O
+infection	B-DISO
+in	O
+a	O
+dose	O
+-	O
+dependent	O
+manner	O
+.	O
+
+LF	O
+may	O
+play	O
+a	O
+protective	O
+role	O
+in	O
+host	B-PROC
+defense	I-PROC
+against	O
+SARS	B-DISO
+-	I-DISO
+CoV	I-DISO
+infection	I-DISO
+through	O
+binding	B-FUNC
+to	O
+HSPGs	O
+and	O
+blocking	B-DISO
+the	O
+preliminary	O
+interaction	O
+between	O
+SARS	B-DISO
+-	O
+CoV	O
+and	O
+host	B-COMP
+cells	B-COMP
+.	O
+
+The	O
+reproductive	B-PROC
+risk	O
+perceptions	O
+voiced	O
+by	O
+Canadian	O
+nurses	O
+generally	O
+were	O
+consistent	O
+with	O
+reported	O
+case	O
+reports	O
+of	O
+pregnant	O
+women	O
+infected	O
+with	O
+SARS	B-DISO
+or	O
+emerging	O
+influenza	B-DISO
+strains	O
+.	O
+
+We	O
+calculated	O
+a	O
+composite	O
+neurological	B-DISO
+symptom	I-DISO
+score	O
+(	O
+lowest	O
+score	O
+was	O
+best	O
+)	O
+every	O
+day	O
+and	O
+assessed	O
+changes	O
+before	O
+and	O
+after	O
+immunoadsorption	O
+.	O
+
+We	O
+enrolled	O
+12	O
+patients	O
+who	O
+initially	O
+presented	O
+with	O
+enteritis	B-DISO
+and	O
+subsequent	O
+renal	B-DISO
+failure	I-DISO
+;	O
+10	O
+(	O
+83	O
+%)	O
+of	O
+12	O
+patients	O
+needed	O
+renal	B-ANAT
+replacement	O
+therapy	O
+by	O
+a	O
+median	O
+of	O
+8	O
+·	O
+0	O
+days	O
+(	O
+range	O
+5	O
+-	O
+12	O
+).	O
+
+A	O
+mutation	O
+in	O
+tRNA	B-FUNC
+(	O
+Lys	B-CHED
+)	O
+that	O
+causes	O
+myoclonic	B-DISO
+epilepsy	I-DISO
+with	O
+ragged	O
+-	O
+red	O
+fibers	O
+(	O
+MERRF	B-DISO
+)	O
+is	O
+also	O
+reported	O
+to	O
+prevent	O
+modification	O
+of	O
+the	O
+wobble	O
+U	O
+.	O
+Here	O
+we	O
+show	O
+that	O
+mitochondrial	B-PROC
+translation	B-PROC
+is	O
+unaffected	O
+in	O
+fibroblasts	B-ANAT
+from	O
+an	O
+MTU1	O
+patient	O
+,	O
+in	O
+which	O
+MTU1	B-PRGE
+is	O
+undetectable	O
+by	O
+immunoblotting	O
+,	O
+despite	O
+the	O
+severe	O
+reduction	O
+in	O
+the	O
+2	O
+-	O
+thiolation	O
+of	O
+mitochondrial	B-ANAT
+tRNA	B-FUNC
+(	O
+Lys	B-CHED
+),	O
+tRNA	B-FUNC
+(	O
+Glu	B-CHED
+)	O
+and	O
+tRNA	B-FUNC
+(	O
+Gln	B-CHED
+).	O
+
+Further	O
+,	O
+the	O
+mitochondrial	B-PROC
+translation	B-PROC
+deficiencies	O
+present	O
+in	O
+myoblasts	B-ANAT
+from	O
+mitochondrial	B-DISO
+encephalomyopathy	I-DISO
+,	O
+lactic	B-DISO
+acidosis	I-DISO
+and	O
+stroke	B-DISO
+-	O
+like	O
+episode	O
+and	O
+MERRF	B-DISO
+patients	O
+,	O
+which	O
+are	O
+associated	O
+with	O
+defects	O
+in	O
+post	O
+-	O
+transcriptional	B-PROC
+modification	O
+of	O
+mitochondrial	B-COMP
+tRNAs	O
+,	O
+did	O
+not	O
+worsen	O
+following	O
+knockdown	O
+of	O
+MTU1	B-PRGE
+in	O
+these	O
+cells	B-COMP
+.	O
+
+ABSTRACT	O
+:	O
+Infectious	B-DISO
+bronchitis	B-DISO
+is	O
+one	O
+of	O
+the	O
+most	O
+important	O
+diseases	O
+in	O
+poultry	O
+and	O
+it	O
+causes	O
+major	O
+economic	O
+losses	O
+.	O
+
+There	O
+was	O
+also	O
+an	O
+average	O
+reduction	O
+of	O
+37	O
+%	O
+in	O
+air	B-CHED
+exchange	O
+volume	O
+with	O
+the	O
+use	O
+of	O
+N95	O
+respirators	O
+.	O
+
+ABSTRACT	O
+:	O
+Genetic	O
+background	O
+may	O
+play	O
+an	O
+important	O
+role	O
+in	O
+the	O
+process	O
+of	O
+SARS	B-DISO
+-	I-DISO
+CoV	I-DISO
+infection	I-DISO
+and	O
+SARS	B-DISO
+development	B-PROC
+.	O
+
+α	O
+-	O
+2	O
+-	O
+Heremans	O
+-	O
+Schmid	O
+Glycoprotein	B-CHED
+(	O
+AHSG	O
+),	O
+which	O
+is	O
+required	O
+for	O
+macrophage	B-ANAT
+deactivation	O
+by	O
+endogenous	O
+cations	B-CHED
+,	O
+is	O
+associated	O
+with	O
+inflammatory	O
+regulation	B-PROC
+.	O
+
+We	O
+investigated	O
+the	O
+association	O
+between	O
+the	O
+polymorphisms	B-PROC
+of	O
+these	O
+two	O
+inflammation	B-DISO
+-	O
+associated	O
+genes	O
+and	O
+SARS	B-DISO
+development	B-PROC
+.	O
+
+The	O
+linkage	B-PROC
+disequilibrium	B-DISO
+(	O
+LD	O
+)	O
+maps	O
+of	O
+these	O
+two	O
+genes	O
+were	O
+built	O
+with	O
+Haploview	O
+using	O
+data	O
+on	O
+CHB	O
++	O
+JPT	O
+(	O
+version	O
+2	O
+)	O
+from	O
+the	O
+HapMap	O
+.	O
+
+Several	O
+different	O
+methods	O
+have	O
+been	O
+used	O
+to	O
+generate	O
+SARS	B-PRGE
+-	I-PRGE
+CoV	I-PRGE
+specific	I-PRGE
+neutralizing	I-PRGE
+hmAbs	I-PRGE
+including	O
+the	O
+immunization	O
+of	O
+transgenic	B-SPEC
+mice	I-SPEC
+,	O
+cloning	O
+of	O
+small	O
+chain	O
+variable	O
+regions	O
+from	O
+naïve	O
+and	O
+convalescent	O
+patients	O
+,	O
+and	O
+the	O
+immortalization	O
+of	O
+convalescent	O
+B	B-ANAT
+cells	I-ANAT
+.	O
+
+Prenatal	O
+exposure	O
+to	O
+polychlorinated	O
+biphenyls	B-CHED
+(	O
+PCB	B-CHED
+)	O
+and	O
+related	O
+toxicants	O
+results	O
+in	O
+cognitive	O
+and	O
+motor	O
+deficits	O
+.	O
+
+The	O
+meta	B-SPEC
+-	O
+analytic	O
+pooled	O
+risk	O
+estimate	O
+for	O
+SIDS	B-DISO
+based	O
+on	O
+15	O
+studies	O
+is	O
+2	O
+.	O
+94	O
+(	O
+95	O
+%	O
+confidence	O
+interval	O
+:	O
+2	O
+.	O
+43	O
+-	O
+3	O
+.	O
+57	O
+).	O
+
+Serologic	O
+evidence	O
+of	O
+exposure	O
+to	O
+Ehrlichia	B-SPEC
+spp	B-ENZY
+.,	O
+Feline	B-SPEC
+immunodeficiency	I-SPEC
+virus	I-SPEC
+,	O
+and	O
+Feline	B-SPEC
+leukemia	I-SPEC
+virus	I-SPEC
+(	O
+FeLV	B-SPEC
+)	O
+was	O
+detected	O
+rarely	O
+,	O
+and	O
+infections	B-DISO
+with	O
+FeLV	B-SPEC
+,	O
+Ehrlichia	B-SPEC
+spp	B-ENZY
+.,	O
+and	O
+Cytauxzoon	B-SPEC
+spp	B-ENZY
+.	O
+were	O
+found	O
+infrequently	O
+.	O
+
+TITLE	O
+:	O
+Changes	O
+in	O
+nonstructural	O
+protein	B-CHED
+3	O
+are	O
+associated	O
+with	O
+attenuation	O
+in	O
+avian	B-SPEC
+coronavirus	I-SPEC
+infectious	B-DISO
+bronchitis	B-DISO
+virus	B-SPEC
+.	O
+
+The	O
+dependence	B-DISO
+on	I-DISO
+the	O
+sialic	B-FUNC
+acid	I-FUNC
+binding	B-PROC
+activity	I-PROC
+for	O
+an	O
+efficient	O
+infection	B-DISO
+differs	O
+in	O
+the	O
+analyzed	O
+TGEV	B-SPEC
+strains	O
+.	O
+
+ABSTRACT	O
+:	O
+We	O
+have	O
+shown	O
+previously	O
+that	O
+replacement	O
+of	O
+the	O
+spike	O
+(	O
+S	O
+)	O
+gene	O
+of	O
+the	O
+apathogenic	O
+IBV	O
+strain	O
+Beau	O
+-	O
+R	O
+with	O
+that	O
+from	O
+the	O
+pathogenic	O
+strain	O
+of	O
+the	O
+same	O
+serotype	O
+,	O
+M41	O
+,	O
+resulted	O
+in	O
+an	O
+apathogenic	O
+virus	B-SPEC
+,	O
+BeauR	O
+-	O
+M41	O
+(	O
+S	O
+),	O
+that	O
+conferred	O
+protection	O
+against	O
+challenge	O
+with	O
+M41	O
+.	O
+
+TITLE	O
+:	O
+Community	O
+-	O
+acquired	O
+polymicrobial	O
+pneumonia	B-DISO
+in	O
+the	O
+intensive	O
+care	O
+unit	O
+:	O
+aetiology	O
+and	O
+prognosis	O
+.	O
+
+ABSTRACT	O
+:	O
+The	O
+frequency	O
+and	O
+clinical	O
+significance	O
+of	O
+polymicrobial	O
+aetiology	O
+in	O
+community	O
+-	O
+acquired	O
+pneumonia	O
+(	O
+CAP	B-DISO
+)	O
+patients	O
+admitted	O
+to	O
+the	O
+ICU	O
+have	O
+been	O
+poorly	O
+studied	O
+.	O
+
+The	O
+prospective	O
+observational	O
+study	O
+included	O
+362	O
+consecutive	O
+adult	O
+patients	O
+with	O
+CAP	B-DISO
+admitted	O
+to	O
+the	O
+ICU	O
+within	O
+24	O
+hours	O
+of	O
+presentation	O
+;	O
+196	O
+(	O
+54	O
+%)	O
+patients	O
+had	O
+an	O
+established	O
+aetiology	O
+.	O
+
+Use	O
+of	O
+a	O
+PAC	B-DISO
+during	O
+CABG	O
+surgery	O
+was	O
+associated	O
+with	O
+increased	O
+mortality	O
+and	O
+a	O
+higher	O
+risk	O
+of	O
+severe	O
+end	O
+-	O
+organ	B-ANAT
+complications	O
+in	O
+this	O
+propensity	O
+-	O
+matched	O
+observational	O
+study	O
+.	O
+
+IBV	B-SPEC
+infection	B-DISO
+was	O
+shown	O
+to	O
+induce	O
+cell	B-PROC
+cycle	I-PROC
+arrest	I-PROC
+at	O
+both	O
+S	O
+and	O
+G	O
+(	O
+2	O
+)/	O
+M	B-PROC
+phases	I-PROC
+for	O
+the	O
+enhancement	O
+of	O
+viral	B-PROC
+replication	I-PROC
+and	O
+progeny	O
+production	O
+.	O
+
+In	O
+this	O
+study	O
+we	O
+show	O
+that	O
+activation	O
+of	O
+cellular	B-PROC
+DNA	B-PATH
+damage	I-PATH
+response	I-PATH
+is	O
+one	O
+of	O
+the	O
+mechanisms	O
+exploited	O
+by	O
+Coronavirus	B-SPEC
+to	O
+induce	O
+cell	B-PROC
+cycle	I-PROC
+arrest	I-PROC
+.	O
+
+An	O
+influenza	B-DISO
+-	O
+like	O
+syndrome	B-DISO
+was	O
+the	O
+presenting	O
+diagnosis	O
+in	O
+99	O
+%	O
+of	O
+the	O
+cases	O
+.	O
+
+Here	O
+,	O
+we	O
+identified	O
+ANXA2	B-PRGE
+as	O
+a	O
+RNA	B-PRGE
+binding	I-PRGE
+protein	B-CHED
+(	O
+RBP	B-PRGE
+)	O
+that	O
+binds	B-FUNC
+IBV	B-SPEC
+(	O
+Infectious	B-DISO
+Bronchitis	B-DISO
+Virus	B-SPEC
+)	O
+pseudoknot	O
+RNA	O
+.	O
+
+Therefore	O
+,	O
+we	O
+believe	O
+that	O
+the	O
+selected	O
+ssDNA	O
+aptamer	O
+may	O
+be	O
+a	O
+good	O
+alternative	O
+detection	O
+probe	O
+for	O
+the	O
+rapid	O
+and	O
+sensitive	O
+detection	O
+of	O
+SARS	B-DISO
+.	O
+
+ABSTRACT	O
+:	O
+In	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+coronavirus	B-SPEC
+,	O
+the	O
+envelope	B-COMP
+heptad	O
+repeat	O
+2	O
+(	O
+HR2	B-PRGE
+)	O
+plays	O
+a	O
+critical	O
+role	O
+in	O
+viral	O
+entry	O
+.	O
+
+ABSTRACT	O
+:	O
+In	O
+this	O
+study	O
+,	O
+as	O
+a	O
+bioisosteric	O
+alternative	O
+scaffold	O
+of	O
+the	O
+antiviral	B-CHED
+aryl	O
+diketoacids	O
+(	O
+ADKs	O
+),	O
+we	O
+used	O
+5	O
+-	O
+hydroxychromone	O
+on	O
+which	O
+two	O
+arylmethyloxy	O
+substituents	O
+were	O
+installed	O
+.	O
+
+The	O
+5	O
+-	O
+hydroxychromones	O
+(	O
+5b	O
+-	O
+5g	O
+)	O
+thus	O
+prepared	O
+showed	O
+anti	O
+-	O
+HCV	B-SPEC
+activity	O
+and	O
+,	O
+depending	O
+on	O
+the	O
+aromatic	O
+substituents	O
+on	O
+the	O
+2	O
+-	O
+arylmethyloxy	O
+moiety	O
+,	O
+some	O
+of	O
+the	O
+derivatives	O
+(	O
+5b	O
+-	O
+5f	O
+)	O
+were	O
+also	O
+active	O
+against	O
+SCV	B-SPEC
+.	O
+
+TITLE	O
+:	O
+[	O
+Causes	O
+,	O
+complications	O
+and	O
+risk	O
+factors	O
+of	O
+severe	O
+influenza	B-PATH
+A	I-PATH
+(	O
+H1N1	O
+)].	O
+
+ABSTRACT	O
+:	O
+Analysis	O
+of	O
+35	O
+deaths	O
+from	O
+A	O
+(	O
+H1N1	O
+)	O
+influenza	B-SPEC
+virus	B-DISO
+infection	I-DISO
+in	O
+the	O
+Transbaikal	O
+region	O
+(	O
+autumn	O
+2009	O
+)	O
+is	O
+reported	O
+.	O
+
+Under	O
+the	O
+pseudo	O
+-	O
+steady	O
+concentration	O
+environment	O
+,	O
+facemask	O
+protection	O
+was	O
+found	O
+to	O
+be	O
+45	O
+per	O
+cent	O
+,	O
+while	O
+under	O
+expiratory	B-PROC
+emissions	B-ANAT
+,	O
+protection	O
+varied	O
+from	O
+33	O
+to	O
+100	O
+per	O
+cent	O
+.	O
+
+In	O
+the	O
+absence	O
+of	O
+alum	O
+,	O
+DIV	O
+vaccine	O
+performed	O
+poorly	O
+in	O
+young	O
+animals	B-SPEC
+challenged	O
+with	O
+lethal	O
+homologous	O
+or	O
+heterologous	O
+strains	O
+.	O
+
+Importantly	O
+,	O
+aged	O
+animals	B-SPEC
+displayed	O
+increased	O
+eosinophilic	O
+immune	O
+pathology	B-DISO
+in	O
+the	O
+lungs	B-ANAT
+and	O
+were	O
+not	O
+protected	O
+against	O
+significant	O
+virus	B-PROC
+replication	I-PROC
+.	O
+
+Patients	O
+were	O
+diagnosed	O
+through	O
+genetic	O
+screening	O
+and	O
+identification	O
+of	O
+mutations	O
+shown	O
+to	O
+cause	O
+fast	B-FUNC
+channel	O
+syndrome	B-DISO
+.	O
+
+Fast	B-FUNC
+channel	O
+syndrome	B-DISO
+contrasted	O
+with	O
+AChR	B-PRGE
+deficiency	O
+in	O
+the	O
+occurrence	O
+of	O
+severe	O
+respiratory	O
+crises	O
+in	O
+infancy	O
+and	O
+childhood	O
+.	O
+
+Measured	O
+carboxyhemoglobin	O
+levels	O
+increased	O
+significantly	O
+with	O
+higher	O
+AIS	B-DISO
+grade	O
+.	O
+
+After	O
+adjustment	O
+for	O
+age	O
+,	O
+%	O
+TBSA	O
+burn	O
+,	O
+and	O
+full	O
+-	O
+thickness	O
+component	O
+,	O
+severe	O
+inhalation	B-PROC
+injury	O
+(	O
+grades	O
+2	O
+and	O
+3	O
+)	O
+was	O
+associated	O
+with	O
+an	O
+increased	O
+risk	O
+of	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+at	O
+24	O
+and	O
+72	O
+hours	O
+,	O
+as	O
+well	O
+as	O
+ventilator	O
+days	O
+>	O
+21	O
+days	O
+,	O
+and	O
+a	O
+trend	O
+toward	O
+multiple	B-DISO
+organ	I-DISO
+dysfunction	I-DISO
+syndrome	I-DISO
+and	O
+mortality	O
+.	O
+
+The	O
+bronchoscopic	O
+grading	O
+of	O
+inhalation	B-PROC
+injury	O
+moderately	O
+correlates	O
+with	O
+early	O
+indices	O
+of	O
+impaired	B-DISO
+gas	I-DISO
+exchange	I-DISO
+in	O
+this	O
+cohort	O
+and	O
+may	O
+be	O
+a	O
+promising	O
+tool	O
+for	O
+staging	O
+lower	O
+airway	B-ANAT
+injury	O
+.	O
+
+He	O
+was	O
+admitted	O
+to	O
+intensive	O
+care	O
+with	O
+acute	B-DISO
+dyspnoea	I-DISO
+.	O
+
+A	O
+CT	O
+scan	O
+showed	O
+bilateral	O
+,	O
+diffuse	O
+alveolar	B-ANAT
+shadowing	O
+.	O
+
+These	O
+acids	O
+have	O
+a	O
+double	O
+effect	O
+on	O
+the	O
+lungs	B-ANAT
+:	O
+a	O
+direct	O
+toxicity	O
+with	O
+severe	O
+inflammation	B-DISO
+of	O
+the	O
+mucosa	B-ANAT
+leading	O
+to	O
+alveolar	B-ANAT
+haemorrhage	B-DISO
+and	O
+subsequently	O
+the	O
+acid	B-CHED
+anhydrides	I-CHED
+may	O
+lead	O
+to	O
+the	O
+syndrome	B-DISO
+of	O
+intra	B-DISO
+-	I-DISO
+alveolar	I-DISO
+haemorrhage	I-DISO
+and	O
+anaemia	B-DISO
+described	O
+in	O
+occupational	O
+lung	B-DISO
+diseases	I-DISO
+by	O
+Herbert	O
+in	O
+Oxford	O
+in	O
+1979	O
+.	O
+
+It	O
+manifests	O
+itself	O
+by	O
+haemoptysis	B-DISO
+and	O
+intravascular	B-DISO
+haemolysis	I-DISO
+.	O
+
+We	O
+draw	O
+attention	O
+to	O
+the	O
+extremely	O
+serious	O
+potential	O
+consequences	O
+of	O
+new	O
+methods	O
+of	O
+using	O
+cannabis	B-DISO
+,	O
+particularly	O
+the	O
+use	O
+of	O
+""""	O
+bang	O
+""""	O
+in	O
+homemade	O
+plastic	O
+materials	O
+.	O
+
+ABSTRACT	O
+:	O
+Guillain	O
+-	O
+Barre	O
+Syndrome	O
+(	O
+GBS	B-DISO
+)	O
+is	O
+an	O
+acute	O
+polyradidulonevritis	O
+which	O
+is	O
+primitive	O
+inflammatory	O
+and	O
+demyelinisant	O
+.	O
+
+The	O
+prodromic	O
+infectious	B-DISO
+manifestations	O
+were	O
+observed	O
+in	O
+54	O
+.	O
+5	O
+%	O
+of	O
+cases	O
+.	O
+
+Acute	O
+Respiratory	B-DISO
+disorder	I-DISO
+is	O
+the	O
+most	O
+severe	O
+complication	B-DISO
+this	O
+syndrome	B-DISO
+can	O
+lead	O
+to	O
+in	O
+5	O
+%	O
+of	O
+cases	O
+.	O
+
+A	O
+retrospective	O
+study	O
+was	O
+performed	O
+of	O
+all	O
+hospitalized	O
+patients	O
+at	O
+the	O
+peak	O
+of	O
+the	O
+pH1N1	O
+season	O
+in	O
+whom	O
+a	O
+single	O
+respiratory	O
+virus	B-SPEC
+was	O
+detected	O
+by	O
+a	O
+molecular	O
+assay	O
+targeting	B-PROC
+18	O
+viruses	B-SPEC
+/	O
+subtypes	O
+(	O
+RVP	O
+,	O
+Luminex	O
+xTAG	O
+).	O
+
+No	O
+seasonal	O
+influenza	B-PATH
+A	I-PATH
+or	O
+B	O
+was	O
+detected	O
+.	O
+
+Here	O
+we	O
+show	O
+that	O
+a	O
+hot	O
+water	B-CHED
+extract	O
+of	O
+H	B-SPEC
+.	I-SPEC
+cordata	I-SPEC
+(	O
+HCWE	O
+)	O
+inhibits	O
+HSV	B-SPEC
+-	O
+2	O
+infection	B-DISO
+through	O
+inhibition	B-PROC
+of	O
+NF	O
+-	O
+κB	O
+activation	O
+.	O
+
+Furthermore	O
+,	O
+we	O
+show	O
+that	O
+treatment	O
+with	O
+quercetin	B-CHED
+,	O
+quercitrin	B-CHED
+or	O
+isoquercitrin	B-CHED
+,	O
+major	O
+water	B-CHED
+extractable	O
+flavonoids	B-CHED
+from	O
+H	B-SPEC
+.	I-SPEC
+cordata	I-SPEC
+,	O
+significantly	O
+blocked	O
+HSV	B-SPEC
+-	O
+2	O
+infection	B-DISO
+.	O
+
+These	O
+results	O
+together	O
+demonstrated	O
+that	O
+H	B-SPEC
+.	I-SPEC
+cordata	I-SPEC
+blocks	O
+HSV	B-SPEC
+-	O
+2	O
+infection	B-DISO
+through	O
+inhibition	B-PROC
+of	O
+NF	O
+-	O
+κB	O
+activation	O
+.	O
+
+Fourteen	O
+cats	B-SPEC
+were	O
+FCoV	O
+-	O
+positive	O
+,	O
+including	O
+infections	B-DISO
+with	O
+type	O
+I	O
+FCoV	O
+(	O
+n	O
+=	O
+8	O
+),	O
+type	O
+II	O
+FCoV	O
+(	O
+n	O
+=	O
+4	O
+),	O
+and	O
+types	O
+I	O
+and	O
+II	O
+co	B-DISO
+-	I-DISO
+infection	I-DISO
+(	O
+n	O
+=	O
+2	O
+).	O
+
+The	O
+prediction	O
+of	O
+single	O
+-	O
+organ	B-ANAT
+and	O
+multiorgan	B-DISO
+failure	I-DISO
+from	O
+the	O
+cytokine	O
+profiles	O
+was	O
+evaluated	O
+by	O
+receiver	O
+operating	O
+characteristic	O
+analyses	O
+.	O
+
+The	O
+fact	O
+that	O
+all	O
+of	O
+the	O
+cytokines	O
+were	O
+particularly	O
+elevated	O
+in	O
+patients	O
+with	O
+organ	B-ANAT
+failures	O
+calls	O
+for	O
+evaluation	O
+of	O
+agents	O
+modifying	O
+the	O
+severe	O
+inflammatory	B-DISO
+response	I-DISO
+in	O
+patients	O
+with	O
+AP	O
+.	O
+
+Expression	B-PROC
+of	O
+the	O
+glial	B-PRGE
+glutamate	B-CHED
+transporter	I-PRGE
+GLT	I-PRGE
+-	I-PRGE
+1	I-PRGE
+,	O
+responsible	O
+for	O
+glutamate	B-PROC
+homeostasis	I-PROC
+,	O
+was	O
+downregulated	O
+following	O
+infection	B-DISO
+,	O
+and	O
+GYKI	O
+-	O
+52466	O
+also	O
+significantly	O
+restored	O
+its	O
+steady	O
+-	O
+state	O
+expression	B-PROC
+level	O
+.	O
+
+A	O
+51	O
+-	O
+year	O
+-	O
+old	O
+man	B-CHED
+with	O
+a	O
+five	O
+-	O
+year	O
+history	O
+of	O
+alcoholic	B-DISO
+cirrhosis	I-DISO
+was	O
+admitted	O
+for	O
+acute	B-DISO
+respiratory	I-DISO
+failure	I-DISO
+,	O
+platypnoea	B-DISO
+and	O
+severe	O
+hypoxaemia	O
+requiring	O
+emergency	B-DISO
+tracheal	O
+intubation	O
+.	O
+
+Three	O
+months	O
+after	O
+hospital	O
+discharge	B-ANAT
+,	O
+the	O
+patient	O
+recovered	O
+a	O
+correct	O
+physical	O
+autonomy	O
+status	O
+without	O
+supplemental	O
+O2	O
+.	O
+
+RESULTS	O
+:	O
+A	O
+51	O
+-	O
+year	O
+-	O
+old	O
+man	B-CHED
+with	O
+a	O
+five	O
+-	O
+year	O
+history	O
+of	O
+alcoholic	B-DISO
+cirrhosis	I-DISO
+was	O
+admitted	O
+for	O
+acute	B-DISO
+respiratory	I-DISO
+failure	I-DISO
+,	O
+platypnoea	B-DISO
+and	O
+severe	O
+hypoxaemia	O
+requiring	O
+emergency	B-DISO
+tracheal	O
+intubation	O
+.	O
+
+The	O
+results	O
+showed	O
+that	O
+IBV	B-SPEC
+infection	B-DISO
+of	O
+cultured	O
+human	B-SPEC
+and	O
+animal	B-SPEC
+cells	B-COMP
+activated	O
+the	O
+p38	B-FUNC
+mitogen	B-PRGE
+-	I-PRGE
+activated	I-PRGE
+protein	B-CHED
+kinase	I-PRGE
+(	O
+MAPK	B-FUNC
+)	O
+pathway	B-PROC
+and	O
+induced	O
+the	O
+expression	B-PROC
+of	O
+IL	B-FUNC
+-	I-FUNC
+6	I-FUNC
+and	O
+IL	B-FUNC
+-	I-FUNC
+8	I-FUNC
+.	O
+
+Feedback	O
+from	O
+family	B-SPEC
+medicine	B-CHED
+and	O
+public	O
+health	O
+educator	O
+-	O
+practitioners	O
+regarding	O
+the	O
+set	O
+of	O
+proposed	O
+""""	O
+essential	O
+""""	O
+competencies	O
+indicated	O
+the	O
+need	O
+for	O
+a	O
+more	O
+limited	O
+,	O
+feasible	O
+set	O
+of	O
+""""	O
+priority	O
+""""	O
+areas	O
+to	O
+be	O
+highlighted	O
+during	O
+residency	O
+training	O
+.	O
+
+Costimulation	O
+of	O
+primary	O
+human	B-SPEC
+fibroblasts	B-ANAT
+with	O
+IL	B-PROC
+-	I-PROC
+17	I-PROC
+greatly	O
+enhanced	O
+respiratory	B-SPEC
+syncytial	I-SPEC
+virus	I-SPEC
+-	O
+induced	O
+or	O
+synthetic	O
+dsRNA	B-CHED
+-	O
+based	O
+viral	O
+mimic	O
+polyinosinic	O
+:	O
+polycytidylic	O
+acid	O
+-	O
+induced	O
+expression	B-PROC
+of	O
+proinflammatory	O
+genes	O
+without	O
+affecting	O
+expression	B-PROC
+of	O
+IFN	B-PRGE
+-	I-PRGE
+β	I-PRGE
+-	O
+stimulated	O
+or	O
+IFN	B-PRGE
+-	I-PRGE
+stimulated	I-PRGE
+genes	I-PRGE
+.	O
+
+Knockdown	O
+of	O
+expression	B-PROC
+of	O
+known	O
+mediators	O
+of	O
+the	O
+antiviral	B-CHED
+signaling	B-PROC
+pathway	I-PROC
+revealed	O
+that	O
+the	O
+IL	B-PRGE
+-	I-PRGE
+17	I-PRGE
+-	I-PRGE
+poly	I-PRGE
+(	O
+I	O
+:	O
+C	O
+)	O
+synergy	O
+depends	O
+on	O
+the	O
+presence	O
+of	O
+the	O
+transcriptional	B-PROC
+factors	O
+RelA	B-PRGE
+and	O
+IFN	B-PRGE
+regulatory	I-PRGE
+factor	I-PRGE
+3	I-PRGE
+and	O
+IκB	O
+kinases	O
+.	O
+
+ABSTRACT	O
+:	O
+We	O
+systematically	O
+reviewed	O
+the	O
+evidence	O
+for	O
+an	O
+association	O
+between	O
+male	O
+circumcision	O
+and	O
+Human	O
+Papillomavirus	O
+(	O
+HPV	O
+)	O
+infection	B-DISO
+and	O
+genital	B-DISO
+warts	I-DISO
+in	O
+men	O
+.	O
+
+There	O
+was	O
+weak	O
+evidence	O
+that	O
+circumcision	O
+was	O
+associated	O
+with	O
+decreased	O
+HPV	O
+incidence	O
+(	O
+summary	O
+RR	O
+,	O
+0	O
+.	O
+75	O
+,	O
+95	O
+%	O
+CI	O
+,	O
+0	O
+.	O
+57	O
+-	O
+0	O
+.	O
+99	O
+;	O
+3	O
+studies	O
+)	O
+and	O
+increased	O
+HPV	O
+clearance	O
+(	O
+summary	O
+RR	O
+,	O
+1	O
+.	O
+33	O
+;	O
+95	O
+%	O
+CI	O
+,	O
+0	O
+.	O
+89	O
+-	O
+1	O
+.	O
+98	O
+;	O
+3	O
+studies	O
+)	O
+but	O
+no	O
+evidence	O
+of	O
+an	O
+association	O
+with	O
+prevalent	O
+genital	B-DISO
+warts	I-DISO
+(	O
+OR	O
+,	O
+0	O
+.	O
+93	O
+,	O
+95	O
+%	O
+CI	O
+,	O
+0	O
+.	O
+65	O
+-	O
+1	O
+.	O
+33	O
+;	O
+15	O
+studies	O
+).	O
+
+We	O
+concluded	O
+that	O
+the	O
+inhibition	B-PROC
+of	O
+PEDV	B-SPEC
+production	O
+by	O
+Q7R	O
+is	O
+not	O
+simply	O
+due	O
+to	O
+a	O
+general	O
+action	O
+as	O
+an	O
+antioxidants	B-CHED
+and	O
+is	O
+highly	O
+specific	O
+,	O
+as	O
+several	O
+other	O
+antioxidants	B-CHED
+(	O
+NAC	B-COMP
+,	O
+PDTC	O
+,	O
+trolox	O
+)	O
+are	O
+inactive	O
+against	O
+PEDV	B-SPEC
+infection	B-DISO
+.	O
+
+ABSTRACT	O
+:	O
+This	O
+study	O
+reports	O
+the	O
+value	O
+of	O
+accurate	O
+pulmonary	B-ANAT
+contusion	O
+(	O
+PC	O
+)	O
+volume	O
+measurement	O
+with	O
+3	O
+-	O
+dimensional	O
+computed	O
+tomography	O
+(	O
+CT	O
+)	O
+in	O
+predicting	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+(	O
+ARDS	B-DISO
+)	O
+development	B-PROC
+.	O
+
+The	O
+study	O
+enrolled	O
+all	O
+patients	O
+who	O
+were	O
+diagnosed	O
+with	O
+PC	O
+on	O
+admission	O
+by	O
+CT	O
+and	O
+had	O
+a	O
+chest	B-ANAT
+Abbreviated	O
+Injury	O
+Score	O
+(	O
+AIS	B-DISO
+)	O
+exceeding	O
+2	O
+between	O
+January	O
+1	O
+,	O
+2010	O
+,	O
+and	O
+October	O
+31	O
+,	O
+2010	O
+.	O
+
+ARDS	B-DISO
+was	O
+diagnosed	O
+in	O
+26	O
+patients	O
+(	O
+43	O
+.	O
+3	O
+%)	O
+and	O
+pneumonia	B-DISO
+in	O
+21	O
+(	O
+35	O
+.	O
+0	O
+%).	O
+
+The	O
+partial	B-PROC
+pressure	I-PROC
+of	I-PROC
+oxygen	I-PROC
+/	O
+fraction	O
+of	O
+inspired	B-PROC
+oxygen	B-CHED
+ratio	O
+,	O
+the	O
+needed	O
+maximal	O
+positive	O
+end	B-PROC
+-	I-PROC
+expiratory	I-PROC
+pressure	O
+level	O
+,	O
+and	O
+ARDS	B-DISO
+incidence	O
+between	O
+the	O
+severe	O
+group	O
+and	O
+the	O
+general	O
+group	O
+was	O
+significantly	O
+different	O
+(	O
+p	O
+<.	O
+05	O
+).	O
+
+TITLE	O
+:	O
+RNA	O
+-	O
+cleaving	O
+properties	O
+of	O
+human	B-PRGE
+apurinic	I-PRGE
+/	I-PRGE
+apyrimidinic	I-PRGE
+endonuclease	I-PRGE
+1	I-PRGE
+(	O
+APE1	B-PRGE
+).	O
+
+APE1	B-PRGE
+is	O
+able	O
+to	O
+cleave	O
+CD44	B-PRGE
+mRNA	I-PRGE
+,	O
+microRNAs	O
+(	O
+miR	O
+-	O
+21	O
+,	O
+miR	B-PRGE
+-	I-PRGE
+10b	I-PRGE
+),	O
+and	O
+three	O
+RNA	O
+components	O
+of	O
+SARS	B-DISO
+-	O
+corona	B-CHED
+virus	B-SPEC
+(	O
+orf1b	O
+,	O
+orf3	B-PRGE
+,	O
+spike	O
+)	O
+suggesting	O
+that	O
+,	O
+when	O
+challenged	O
+,	O
+it	O
+can	O
+cleave	O
+any	O
+RNAs	O
+in	O
+vitro	O
+.	O
+
+TITLE	O
+:	O
+Gross	O
+vulva	B-ANAT
+odema	O
+complicating	O
+severe	B-DISO
+pre	I-DISO
+-	I-DISO
+eclampsia	I-DISO
+/	O
+eclampsia	B-DISO
+:	O
+a	O
+case	O
+series	O
+.	O
+
+A	O
+clinical	O
+case	O
+series	O
+of	O
+four	O
+patients	O
+with	O
+Pre	B-DISO
+-	I-DISO
+eclampsia	I-DISO
+that	O
+presented	O
+with	O
+gross	O
+vulva	B-ANAT
+edema	B-DISO
+.	O
+
+The	O
+presence	O
+of	O
+gross	O
+vulva	B-ANAT
+oedema	B-DISO
+in	O
+pre	B-DISO
+-	I-DISO
+eclampsia	I-DISO
+may	O
+be	O
+an	O
+indicator	B-CHED
+of	O
+severity	O
+of	O
+disease	O
+and	O
+or	O
+deteriorating	O
+fetomaternal	O
+condition	B-DISO
+.	O
+
+CONCLUSIONS	O
+:	O
+The	O
+presence	O
+of	O
+gross	O
+vulva	O
+oedema	B-DISO
+in	O
+pre	B-DISO
+-	I-DISO
+eclampsia	I-DISO
+may	O
+be	O
+an	O
+indicator	B-CHED
+of	O
+severity	O
+of	O
+disease	O
+and	O
+or	O
+deteriorating	O
+fetomaternal	O
+condition	B-DISO
+.	O
+
+For	O
+patients	O
+with	O
+H1N1	O
+-	O
+related	O
+ARDS	B-DISO
+,	O
+referral	O
+and	O
+transfer	O
+to	O
+an	O
+ECMO	O
+center	O
+was	O
+associated	O
+with	O
+lower	O
+hospital	O
+mortality	O
+compared	O
+with	O
+matched	O
+non	O
+-	O
+ECMO	O
+-	O
+referred	O
+patients	O
+.	O
+
+HCoV	B-SPEC
+-	I-SPEC
+NL63	I-SPEC
+may	O
+be	O
+a	O
+causative	O
+agent	O
+of	O
+previously	O
+unexplained	O
+respiratory	O
+illnesses	O
+.	O
+
+ABSTRACT	O
+:	O
+CH	O
+/	O
+S	O
+is	O
+a	O
+virulent	O
+porcine	O
+epidemic	O
+diarrhea	O
+virus	O
+(	O
+PEDV	B-SPEC
+)	O
+strain	O
+and	O
+is	O
+used	O
+as	O
+the	O
+virulent	O
+strain	O
+to	O
+evaluate	O
+the	O
+protection	O
+rates	O
+of	O
+vaccines	O
+against	O
+PEDV	B-SPEC
+infection	B-DISO
+in	O
+China	O
+.	O
+
+This	O
+conference	O
+illuminated	O
+the	O
+constantly	O
+evolving	O
+field	O
+of	O
+antiviral	O
+chemotherapy	O
+by	O
+providing	O
+a	O
+forum	O
+to	O
+present	O
+and	O
+discuss	O
+new	O
+antiviral	B-CHED
+compounds	O
+,	O
+new	O
+uses	O
+for	O
+old	O
+compounds	O
+and	O
+exciting	O
+clinical	O
+results	O
+.	O
+
+This	O
+ICAR	O
+was	O
+a	O
+fitting	B-DISO
+testament	O
+to	O
+the	O
+'	O
+father	O
+of	O
+antiviral	B-CHED
+chemotherapy	O
+',	O
+Bill	B-ANAT
+Prusoff	O
+,	O
+who	O
+died	B-PROC
+aged	O
+90	O
+in	O
+April	O
+2011	O
+.	O
+
+ABSTRACT	O
+:	O
+Toxic	O
+epidermal	O
+necrolysis	O
+(	O
+TEN	O
+),	O
+also	O
+known	O
+as	O
+Lyell	B-DISO
+'	I-DISO
+s	I-DISO
+syndrome	I-DISO
+,	O
+is	O
+a	O
+severe	O
+drug	O
+reaction	O
+characterized	O
+by	O
+extensive	O
+destruction	O
+of	O
+the	O
+epidermis	B-ANAT
+and	O
+mucosal	B-ANAT
+epithelia	O
+.	O
+
+The	O
+most	O
+serious	O
+chronic	O
+complication	B-DISO
+was	O
+the	O
+presence	O
+of	O
+significant	O
+opacity	B-DISO
+of	O
+the	O
+corneal	B-ANAT
+epithelium	I-ANAT
+,	O
+causing	O
+almost	O
+complete	O
+loss	B-DISO
+of	I-DISO
+vision	I-DISO
+.	O
+
+HAT	B-PRGE
+cleaved	B-ANAT
+SARS	B-DISO
+-	O
+S	O
+at	O
+R667	O
+,	O
+as	O
+determined	O
+by	O
+mutagenesis	B-PROC
+and	O
+mass	O
+spectrometry	O
+,	O
+and	O
+activated	O
+SARS	O
+-	O
+S	O
+for	O
+cell	B-PROC
+-	I-PROC
+cell	B-COMP
+fusion	I-PROC
+in	O
+cis	B-DISO
+and	O
+trans	O
+,	O
+while	O
+the	O
+related	B-PRGE
+pulmonary	I-PRGE
+protease	I-PRGE
+TMPRSS2	I-PRGE
+cleaved	B-ANAT
+SARS	B-DISO
+-	O
+S	O
+at	O
+multiple	O
+sites	O
+and	O
+activated	O
+SARS	B-DISO
+-	O
+S	O
+only	O
+in	O
+trans	O
+.	O
+
+All	O
+HCoV	O
+-	O
+HKU1	O
+genomes	O
+contain	O
+unique	O
+tandem	O
+copies	O
+of	O
+a	O
+30	O
+-	O
+base	O
+acidic	O
+tandem	O
+repeat	O
+of	O
+unknown	O
+function	O
+at	O
+the	O
+N	O
+-	O
+terminus	O
+of	O
+nsp3	B-PRGE
+inside	O
+the	O
+acidic	O
+domain	O
+upstream	O
+of	O
+papain	B-PRGE
+-	I-PRGE
+like	I-PRGE
+protease	I-PRGE
+1	I-PRGE
+.	O
+
+Similar	O
+to	O
+other	O
+human	B-SPEC
+coronaviruses	O
+,	O
+HCoV	O
+-	O
+HKU1	O
+infections	B-DISO
+have	O
+been	O
+reported	O
+globally	O
+,	O
+with	O
+a	O
+median	O
+(	O
+range	O
+)	O
+incidence	O
+of	O
+0	O
+.	O
+9	O
+(	O
+0	O
+-	O
+4	O
+.	O
+4	O
+)	O
+%.	O
+
+SNPs	O
+and	O
+deletions	O
+causing	O
+a	O
+truncation	B-DISO
+of	O
+the	O
+3c	O
+gene	O
+product	O
+were	O
+found	O
+in	O
+almost	O
+all	O
+isolates	O
+from	O
+the	O
+diseased	O
+tissues	B-ANAT
+of	O
+the	O
+eight	O
+cats	B-SPEC
+suffering	B-DISO
+from	O
+FIP	B-DISO
+,	O
+whereas	O
+most	O
+,	O
+but	O
+not	O
+all	O
+fecal	B-ANAT
+isolates	O
+from	O
+these	O
+same	O
+cats	B-SPEC
+had	O
+intact	O
+3c	O
+genes	O
+.	O
+
+Compartmentalization	O
+of	O
+the	O
+parental	O
+and	O
+mutant	O
+forms	O
+was	O
+not	O
+absolute	O
+;	O
+virus	B-SPEC
+of	O
+lesional	O
+type	O
+was	O
+sometimes	O
+found	O
+in	O
+feces	B-ANAT
+of	O
+affected	O
+cats	B-SPEC
+and	O
+virus	B-SPEC
+identical	O
+to	O
+fecal	B-ANAT
+type	O
+was	O
+occasionally	O
+identified	O
+in	O
+diseased	O
+tissues	B-ANAT
+.	O
+
+Laboratory	O
+cats	B-SPEC
+inoculated	O
+with	O
+a	O
+mixture	B-CHED
+of	O
+two	O
+closely	O
+related	O
+variants	O
+from	O
+the	O
+same	O
+FIP	B-DISO
+cat	B-SPEC
+developed	O
+disease	O
+from	O
+one	O
+or	O
+the	O
+other	O
+variant	O
+,	O
+but	O
+not	O
+both	O
+.	O
+
+TITLE	O
+:	O
+Recombination	B-PROC
+in	O
+avian	B-SPEC
+gamma	O
+-	O
+coronavirus	B-SPEC
+infectious	B-DISO
+bronchitis	B-DISO
+virus	B-SPEC
+.	O
+
+The	O
+extent	O
+of	O
+the	O
+recombination	B-PROC
+observed	O
+,	O
+suggests	O
+that	O
+this	O
+may	O
+be	O
+one	O
+of	O
+the	O
+principal	O
+mechanisms	O
+for	O
+generating	O
+genetic	O
+and	O
+antigenic	B-PROC
+diversity	I-PROC
+within	O
+IBV	B-SPEC
+.	O
+
+This	O
+population	O
+-	O
+based	O
+observational	O
+cohort	O
+from	O
+January	O
+1	O
+to	O
+December	O
+31	O
+,	O
+2006	O
+,	O
+in	O
+Olmsted	O
+County	O
+,	O
+Minnesota	O
+,	O
+included	O
+all	O
+consecutive	O
+critically	B-DISO
+ill	I-DISO
+adult	O
+residents	O
+admitted	O
+to	O
+the	O
+ICU	O
+.	O
+
+Main	O
+outcomes	O
+were	O
+incidence	O
+of	O
+critical	O
+care	O
+syndromes	B-DISO
+,	O
+life	O
+-	O
+support	O
+interventions	O
+,	O
+and	O
+organ	B-ANAT
+failures	O
+as	O
+defined	O
+by	O
+standard	O
+criteria	O
+.	O
+
+Of	O
+the	O
+cohort	O
+,	O
+1	O
+,	O
+330	O
+patients	O
+(	O
+91	O
+%)	O
+survived	O
+to	O
+hospital	O
+discharge	B-ANAT
+.	O
+
+Short	O
+-	O
+and	O
+long	O
+-	O
+term	O
+survival	O
+decreased	O
+by	O
+the	O
+number	O
+of	O
+failing	O
+organs	B-ANAT
+.	O
+
+ABSTRACT	O
+:	O
+We	O
+compared	O
+the	O
+diagnostic	O
+performance	O
+and	O
+overall	O
+respiratory	O
+pathogen	O
+detection	O
+rate	O
+of	O
+the	O
+premarket	O
+version	O
+of	O
+the	O
+FilmArray	O
+Respiratory	O
+Panel	O
+(	O
+RP	O
+)	O
+multiplex	O
+PCR	O
+assay	O
+(	O
+Idaho	O
+Technology	O
+,	O
+Inc	O
+.,	O
+Salt	B-CHED
+Lake	B-SPEC
+City	O
+,	O
+UT	O
+)	O
+with	O
+those	O
+of	O
+the	O
+Food	O
+and	O
+Drug	O
+Administration	O
+(	O
+FDA	O
+)-	O
+cleared	O
+Prodesse	O
+ProFlu	O
++,	O
+ProFAST	O
++,	O
+ProParaflu	O
++,	O
+Pro	B-CHED
+hMPV	O
++,	O
+and	O
+ProAdeno	O
++	O
+real	O
+-	O
+time	O
+PCR	O
+assays	O
+(	O
+Gen	O
+-	O
+Probe	O
+,	O
+San	O
+Diego	O
+,	O
+CA	O
+).	O
+
+The	O
+assays	O
+were	O
+performed	O
+on	O
+a	O
+panel	O
+of	O
+192	O
+nasopharyngeal	B-ANAT
+-	O
+secretion	B-PROC
+specimens	O
+collected	O
+from	O
+81	O
+children	O
+under	O
+1	O
+year	O
+of	O
+age	O
+with	O
+upper	B-ANAT
+respiratory	I-ANAT
+tract	I-ANAT
+symptoms	O
+.	O
+
+However	O
+,	O
+GBS	B-DISO
+has	O
+rarely	O
+reported	O
+to	O
+be	O
+a	O
+neurological	B-DISO
+complication	I-DISO
+of	O
+the	O
+recent	O
+pandemic	O
+influenza	B-PATH
+A	I-PATH
+(	O
+H1N1	O
+)	O
+2009	O
+virus	B-SPEC
+infections	B-DISO
+.	O
+
+Here	O
+,	O
+the	O
+authors	O
+report	O
+a	O
+case	O
+series	O
+of	O
+seven	O
+severely	O
+burned	O
+pediatric	O
+patients	O
+who	O
+received	O
+surfactant	B-CHED
+for	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+and	O
+severe	O
+hypoxemia	O
+.	O
+
+Seven	O
+cases	O
+were	O
+reviewed	O
+of	O
+pediatric	O
+patients	O
+who	O
+received	O
+surfactant	B-CHED
+for	O
+severe	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+.	O
+
+Four	O
+patients	O
+had	O
+reduced	O
+oxygen	O
+requirements	O
+following	O
+surfactant	B-CHED
+administration	O
+(	O
+FiO	O
+(	O
+2	O
+):	O
+0	O
+.	O
+66	O
+±	O
+0	O
+.	O
+23	O
+-	O
+0	O
+.	O
+48	O
+±	O
+0	O
+.	O
+025	O
+).	O
+
+Three	O
+patients	O
+showed	O
+no	O
+reduction	O
+in	O
+oxygen	B-CHED
+requirements	O
+(	O
+FiO	O
+(	O
+2	O
+):	O
+0	O
+.	O
+95	O
+±	O
+0	O
+.	O
+09	O
+-	O
+0	O
+.	O
+90	O
+±	O
+0	O
+.	O
+0	O
+).	O
+
+We	O
+used	O
+the	O
+SARS	B-DISO
+-	O
+CoV	O
+apo	B-PRGE
+X	I-PRGE
+-	O
+ray	B-SPEC
+structure	O
+to	O
+develop	O
+a	O
+model	O
+of	O
+the	O
+NL63	B-PRGE
+-	I-PRGE
+PLP2	I-PRGE
+catalytic	I-PRGE
+site	I-PRGE
+.	O
+
+ABSTRACT	O
+:	O
+Infectious	B-DISO
+bronchitis	B-DISO
+virus	B-SPEC
+(	O
+IBV	B-SPEC
+)	O
+causes	O
+avian	B-DISO
+infectious	I-DISO
+bronchitis	I-DISO
+,	O
+an	O
+important	O
+disease	O
+that	O
+produces	O
+severe	O
+economic	O
+losses	O
+in	O
+the	O
+poultry	O
+industry	O
+worldwide	O
+.	O
+
+TITLE	O
+:	O
+Modification	O
+of	O
+a	O
+high	O
+frequency	O
+oscillator	O
+circuit	O
+with	O
+a	O
+heated	O
+expiratory	B-PROC
+filter	O
+to	O
+prevent	O
+infectious	O
+pathogen	B-DISO
+transmission	I-DISO
+:	O
+a	O
+bench	O
+study	O
+.	O
+
+Filter	O
+efficacy	O
+was	O
+tested	O
+through	O
+an	O
+independent	O
+laboratory	O
+,	O
+and	O
+expiratory	B-PROC
+resistance	B-PROC
+measurements	O
+were	O
+taken	O
+after	O
+prolonged	O
+use	O
+with	O
+humidification	O
+.	O
+
+Frequency	O
+of	O
+ACE	B-PRGE
+I	I-PRGE
+/	I-PRGE
+D	I-PRGE
+genotype	I-PRGE
+was	O
+similar	O
+in	O
+ARDS	B-DISO
+and	O
+control	O
+groups	O
+(	O
+p	O
+=	O
+0	O
+.	O
+18	O
+).	O
+
+TITLE	O
+:	O
+A	O
+polyclonal	O
+antibody	B-COMP
+against	O
+the	O
+C	O
+subunit	O
+of	O
+porcine	B-PRGE
+aminopeptidase	B-ENZY
+N	I-ENZY
+expressed	B-PROC
+in	O
+Escherichia	B-SPEC
+coli	I-SPEC
+.	O
+
+In	O
+Western	O
+blot	O
+analysis	O
+,	O
+the	O
+antibody	B-COMP
+elicited	O
+by	O
+the	O
+recombinant	B-PRGE
+protein	I-PRGE
+pAPN	I-PRGE
+-	I-PRGE
+C	I-PRGE
+could	O
+recognize	O
+the	O
+native	O
+pAPN	O
+.	O
+
+BALB	O
+/	O
+c	O
+mice	B-SPEC
+were	O
+immunized	O
+with	O
+the	O
+purified	O
+recombinant	O
+proteins	B-CHED
+to	O
+prepare	O
+MAbs	O
+by	O
+hybridoma	B-ANAT
+technique	O
+.	O
+
+ABSTRACT	O
+:	O
+Mannose	B-PRGE
+-	I-PRGE
+binding	B-FUNC
+lectin	I-PRGE
+(	O
+MBL	B-PRGE
+),	O
+a	O
+C	B-PRGE
+-	I-PRGE
+type	I-PRGE
+collectin	I-PRGE
+with	O
+structural	O
+similarities	O
+to	O
+C1q	B-PRGE
+,	O
+is	O
+an	O
+innate	O
+pattern	O
+-	O
+recognition	O
+molecule	O
+that	O
+is	O
+sequestered	O
+to	O
+sites	O
+of	O
+inflammation	B-DISO
+and	O
+infections	B-DISO
+.	O
+
+Immediately	O
+before	O
+the	O
+transfer	O
+,	O
+she	O
+suffered	B-DISO
+two	O
+cardiac	B-DISO
+arrest	I-DISO
+episodes	O
+.	O
+
+ABSTRACT	O
+:	O
+Human	B-SPEC
+coronaviruses	O
+(	O
+HCoV	O
+)	O
+are	O
+recognized	O
+respiratory	O
+pathogens	O
+.	O
+
+We	O
+have	O
+previously	O
+reported	O
+that	O
+HCoV	B-SPEC
+-	I-SPEC
+OC43	I-SPEC
+infection	B-DISO
+of	O
+human	B-SPEC
+neurons	B-ANAT
+activates	O
+the	O
+unfolded	O
+-	O
+protein	B-CHED
+response	O
+and	O
+caspase	B-PRGE
+-	I-PRGE
+3	I-PRGE
+and	O
+induces	O
+cell	B-PROC
+death	I-PROC
+and	O
+that	O
+the	O
+viral	B-PRGE
+spike	I-PRGE
+(	I-PRGE
+S	I-PRGE
+)	I-PRGE
+glycoprotein	I-PRGE
+is	O
+involved	O
+in	O
+the	O
+process	O
+.	O
+
+ABSTRACT	O
+:	O
+The	O
+design	O
+and	O
+evaluation	O
+of	O
+low	O
+molecular	O
+weight	O
+peptide	B-CHED
+-	O
+based	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+(	O
+SARS	B-DISO
+)	O
+chymotrypsin	B-PRGE
+-	I-PRGE
+like	I-PRGE
+protease	I-PRGE
+(	B-PRGE
+3CL	I-PRGE
+)	I-PRGE
+protease	I-PRGE
+inhibitors	I-PRGE
+are	O
+described	O
+.	O
+
+A	O
+substrate	O
+-	O
+based	O
+peptide	B-CHED
+aldehyde	B-CHED
+was	O
+selected	O
+as	O
+a	O
+starting	O
+compound	O
+,	O
+and	O
+optimum	O
+side	O
+-	O
+chain	O
+structures	O
+were	O
+determined	O
+,	O
+based	O
+on	O
+a	O
+comparison	O
+of	O
+inhibitory	O
+activities	O
+with	O
+Michael	O
+type	O
+inhibitors	B-CHED
+.	O
+
+Respiratory	O
+rate	O
+and	O
+inspiratory	B-PROC
+pressure	O
+became	O
+extremely	O
+variable	O
+,	O
+varying	O
+at	O
+each	O
+cycle	O
+,	O
+while	O
+children	O
+were	O
+breathing	B-PROC
+easily	O
+and	O
+smoothly	O
+.	O
+
+In	O
+one	O
+child	O
+,	O
+NAVA	O
+facilitated	O
+the	O
+management	O
+of	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+with	O
+extensive	O
+subcutaneous	B-DISO
+emphysema	I-DISO
+.	O
+
+Our	O
+findings	O
+highlight	O
+the	O
+feasibility	O
+and	O
+benefit	O
+of	O
+NAVA	O
+in	O
+children	O
+with	O
+severe	O
+RSV	B-SPEC
+-	O
+related	O
+bronchiolitis	B-DISO
+.	O
+
+NAVA	O
+provides	O
+a	O
+less	O
+aggressive	B-DISO
+ventilation	O
+requiring	O
+lower	O
+inspiratory	B-PROC
+pressures	O
+with	O
+good	O
+results	O
+for	O
+oxygenation	B-PROC
+and	O
+more	O
+comfort	O
+for	O
+the	O
+children	O
+.	O
+
+Each	O
+mishandling	O
+treatment	O
+was	O
+experimentally	O
+applied	O
+under	O
+laboratory	O
+conditions	O
+and	O
+then	O
+samples	O
+were	O
+assayed	O
+for	O
+antibodies	B-COMP
+against	O
+IBV	B-SPEC
+,	O
+AEV	O
+and	O
+CAV	B-SPEC
+using	O
+commercial	O
+ELISA	O
+kits	O
+.	O
+
+Severe	O
+haemolysis	B-DISO
+had	O
+the	O
+most	O
+consistent	O
+detrimental	O
+effect	O
+on	O
+ELISA	O
+performance	O
+,	O
+producing	O
+results	O
+that	O
+were	O
+significantly	O
+different	O
+from	O
+the	O
+reference	O
+standard	O
+in	O
+all	O
+three	O
+ELISAs	O
+,	O
+although	O
+the	O
+direction	O
+of	O
+the	O
+effect	O
+varied	O
+(	O
+less	O
+positive	O
+for	O
+the	O
+IBV	O
+and	O
+CAV	B-SPEC
+assays	O
+;	O
+more	O
+positive	O
+for	O
+the	O
+AEV	O
+assay	O
+).	O
+
+ABSTRACT	O
+:	O
+Infectious	O
+bronchitis	B-DISO
+virus	B-SPEC
+(	O
+IBV	B-SPEC
+)	O
+Cal99	O
+variant	O
+was	O
+isolated	O
+from	O
+the	O
+kidneys	B-ANAT
+of	O
+seven	O
+2	B-PRGE
+-	I-PRGE
+5	I-PRGE
+-	I-PRGE
+mo	I-PRGE
+-	I-PRGE
+old	I-PRGE
+game	I-PRGE
+chickens	I-PRGE
+with	O
+nephritis	B-DISO
+and	O
+respiratory	B-DISO
+disease	I-DISO
+.	O
+
+Sequencing	O
+of	O
+the	O
+hypervariable	O
+region	O
+of	O
+the	O
+S1	B-PRGE
+gene	I-PRGE
+of	O
+the	O
+kidney	B-ANAT
+IBV	B-SPEC
+isolate	O
+,	O
+designated	O
+IBV	B-SPEC
+/	O
+CA99variant	O
+/	O
+07	O
+,	O
+revealed	O
+that	O
+the	O
+virus	B-SPEC
+was	O
+98	O
+%	O
+homologous	O
+to	O
+the	O
+Cal99	O
+serotype	O
+of	O
+IBV	B-SPEC
+.	O
+
+SPECIAL	O
+ARTICLE	O
+:	O
+Five	O
+case	O
+scenarios	O
+that	O
+we	O
+confronted	O
+at	O
+the	O
+pediatric	O
+ward	O
+of	O
+the	O
+field	O
+hospital	O
+are	O
+presented	O
+:	O
+two	O
+children	O
+with	O
+respiratory	O
+compromise	O
+due	O
+to	O
+pulmonary	B-DISO
+infection	I-DISO
+,	O
+one	O
+premature	O
+baby	O
+with	O
+respiratory	B-DISO
+distress	I-DISO
+syndrome	I-DISO
+,	O
+an	O
+asphyxiated	O
+neonate	O
+,	O
+and	O
+a	O
+baby	O
+with	O
+severe	B-DISO
+sepsis	I-DISO
+of	O
+a	O
+probable	O
+abdominal	B-ANAT
+origin	O
+.	O
+
+TITLE	O
+:	O
+Post	O
+-	O
+ARDS	B-DISO
+pulmonary	B-DISO
+fibrosis	I-DISO
+in	O
+patients	O
+with	O
+H1N1	O
+pneumonia	B-DISO
+:	O
+role	O
+of	O
+follow	O
+-	O
+up	O
+CT	O
+.	O
+
+Twenty	O
+-	O
+five	O
+percent	O
+of	O
+patients	O
+(	O
+5	O
+/	O
+20	O
+)	O
+developed	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+(	O
+ARDS	B-DISO
+),	O
+which	O
+progressed	O
+to	O
+predominantly	O
+peripheral	O
+pulmonary	B-DISO
+fibrosis	I-DISO
+in	O
+10	O
+%	O
+(	O
+2	O
+/	O
+20	O
+;	O
+one	O
+died	B-PROC
+and	O
+one	O
+had	O
+late	O
+-	O
+onset	O
+pulmonary	B-DISO
+fibrosis	I-DISO
+,	O
+documented	O
+on	O
+day	O
+68	O
+).	O
+
+SARS	B-DISO
+coronavirus	B-SPEC
+(	O
+SARS	B-PRGE
+-	I-PRGE
+CoV	I-PRGE
+)	O
+encodes	O
+two	O
+S	B-CHED
+-	I-CHED
+adenosyl	I-CHED
+-	I-CHED
+L	I-CHED
+-	I-CHED
+methionine	I-CHED
+(	O
+SAM	B-DISO
+)-	O
+dependent	O
+methyltransferases	O
+(	O
+MTase	B-PRGE
+)	O
+which	O
+sequentially	O
+methylate	O
+the	O
+RNA	O
+cap	B-DISO
+at	O
+guanosine	B-CHED
+-	O
+N7	O
+and	O
+ribose	B-CHED
+2	O
+'-	O
+O	O
+positions	O
+,	O
+catalyzed	O
+by	O
+nsp14	B-PRGE
+N7	I-PRGE
+-	I-PRGE
+MTase	I-PRGE
+and	O
+nsp16	B-PRGE
+2	I-PRGE
+'-	I-PRGE
+O	I-PRGE
+-	I-PRGE
+MTase	I-PRGE
+,	O
+respectively	O
+.	O
+
+A	O
+unique	O
+feature	O
+for	O
+SARS	B-DISO
+-	O
+CoV	O
+is	O
+that	O
+nsp16	O
+requires	O
+non	O
+-	O
+structural	O
+protein	B-CHED
+nsp10	O
+as	O
+a	O
+stimulatory	O
+factor	O
+to	O
+execute	O
+its	O
+MTase	B-PRGE
+activity	O
+.	O
+
+TITLE	O
+:	O
+Diagnostic	O
+value	O
+of	O
+urine	B-ANAT
+sTREM	O
+-	O
+1	O
+for	O
+sepsis	B-DISO
+and	O
+relevant	O
+acute	O
+kidney	B-ANAT
+injuries	O
+:	O
+a	O
+prospective	O
+study	O
+.	O
+
+We	O
+enrolled	O
+104	O
+subjects	O
+admitted	O
+to	O
+the	O
+ICU	O
+:	O
+16	O
+cases	O
+with	O
+systemic	B-DISO
+inflammatory	I-DISO
+response	I-DISO
+syndrome	I-DISO
+(	O
+SIRS	B-DISO
+);	O
+35	O
+with	O
+sepsis	B-DISO
+and	O
+53	O
+with	O
+severe	B-DISO
+sepsis	I-DISO
+.	O
+
+Results	O
+for	O
+urine	B-ANAT
+sTREM	O
+-	O
+1	O
+,	O
+WBC	B-ANAT
+,	O
+serum	B-PRGE
+CRP	I-PRGE
+and	O
+serum	B-COMP
+PCT	B-DISO
+were	O
+recorded	O
+on	O
+days	O
+1	O
+,	O
+3	O
+,	O
+5	O
+,	O
+7	O
+,	O
+10	O
+,	O
+and	O
+14	O
+.	O
+
+Logistic	O
+regression	O
+analysis	O
+showed	O
+that	O
+urine	B-ANAT
+sTREM	O
+-	O
+1	O
+and	O
+severity	O
+were	O
+risk	O
+factors	O
+related	O
+to	O
+AKI	B-PRGE
+occurrence	O
+.	O
+
+RESULTS	O
+:	O
+On	O
+the	O
+day	O
+of	O
+admission	O
+to	O
+the	O
+ICU	O
+,	O
+and	O
+compared	O
+with	O
+the	O
+SIRS	B-DISO
+group	O
+,	O
+the	O
+sepsis	B-DISO
+group	O
+exhibited	O
+higher	O
+levels	O
+of	O
+urine	B-ANAT
+sTREM	O
+-	O
+1	O
+and	O
+Acute	O
+Physiologic	O
+Assessment	O
+and	O
+Chronic	O
+Health	O
+Evaluation	O
+II	O
+(	O
+APACHE	O
+II	O
+)	O
+scores	O
+(	O
+P	O
+<	O
+0	O
+.	O
+05	O
+).	O
+
+By	O
+combining	O
+quantitative	O
+real	O
+-	O
+time	O
+PCR	O
+and	O
+transient	O
+transfection	B-PROC
+system	O
+,	O
+a	O
+simple	O
+and	O
+safe	O
+method	O
+is	O
+established	O
+to	O
+measure	O
+ORF6	O
+'	O
+s	O
+ability	O
+to	O
+suppress	O
+the	O
+expression	B-PROC
+of	O
+co	O
+-	O
+transfected	O
+myc	B-PRGE
+-	I-PRGE
+nsp8	I-PRGE
+.	O
+
+RESULTS	O
+:	O
+Using	O
+a	O
+transient	O
+transfection	B-PROC
+system	O
+,	O
+ORF6	O
+'	O
+s	O
+ability	O
+to	O
+suppress	O
+the	O
+expression	B-PROC
+of	O
+co	O
+-	O
+transfected	O
+expression	B-PROC
+constructs	O
+was	O
+measured	O
+in	O
+a	O
+quantitative	O
+manner	O
+.	O
+
+The	O
+alanine	B-CHED
+substitution	O
+of	O
+the	O
+diacidic	O
+cluster	O
+motif	O
+also	O
+altered	O
+the	O
+subcellular	O
+localization	B-PROC
+of	O
+the	O
+ORF6	B-PRGE
+protein	I-PRGE
+,	O
+indicating	O
+a	O
+potential	O
+relationship	O
+between	O
+the	O
+subcellular	O
+localization	B-PROC
+of	O
+the	O
+ORF6	B-PRGE
+protein	I-PRGE
+and	O
+its	O
+ability	O
+to	O
+suppress	O
+the	O
+expression	B-PROC
+of	O
+co	O
+-	O
+transfected	O
+expression	B-PROC
+constructs	O
+.	O
+
+The	O
+indication	O
+for	O
+HFOV	O
+was	O
+severe	O
+oxygenation	B-PROC
+failure	O
+(	O
+PaO2	O
+/	O
+FiO2	O
+<	O
+120	O
+mm	O
+Hg	O
+)	O
+while	O
+receiving	O
+aggressive	B-DISO
+CV	O
+support	O
+(	O
+defined	O
+by	O
+either	O
+PaO2	O
+≤	O
+65	O
+mm	O
+Hg	O
+with	O
+FiO2	O
+≥	O
+0	O
+.	O
+6	O
+when	O
+positive	O
+end	B-PROC
+-	I-PROC
+expiratory	I-PROC
+pressures	O
+>	O
+10	O
+cmH2O	O
+or	O
+plateau	O
+airway	B-ANAT
+pressure	O
+≥	O
+35	O
+cm	O
+H2O	B-CHED
+).	O
+
+Additional	O
+outcome	O
+measures	O
+included	O
+HFOV	O
+successful	O
+weaning	O
+rate	O
+,	O
+cause	O
+of	O
+failure	O
+,	O
+complications	O
+,	O
+survival	O
+rate	O
+,	O
+and	O
+cause	O
+of	O
+death	B-PROC
+.	O
+
+TITLE	O
+:	O
+Epidemiology	O
+and	O
+immunoprotection	O
+of	O
+nephropathogenic	O
+avian	B-DISO
+infectious	I-DISO
+bronchitis	I-DISO
+virus	B-SPEC
+in	O
+southern	O
+China	O
+.	O
+
+Severe	O
+AH	O
+appears	O
+common	O
+and	O
+its	O
+prevalence	O
+varies	O
+by	O
+underlying	O
+clinical	O
+condition	B-DISO
+.	O
+
+TITLE	O
+:	O
+The	O
+SARS	B-PRGE
+-	I-PRGE
+coronavirus	B-SPEC
+nsp7	I-PRGE
++	I-PRGE
+nsp8	I-PRGE
+complex	I-PRGE
+is	O
+a	O
+unique	O
+multimeric	B-PRGE
+RNA	I-PRGE
+polymerase	I-PRGE
+capable	O
+of	O
+both	O
+de	O
+novo	O
+initiation	O
+and	O
+primer	O
+extension	O
+.	O
+
+The	O
+first	O
+is	O
+primer	O
+-	O
+dependent	O
+and	O
+associated	O
+with	O
+the	O
+106	B-PRGE
+-	I-PRGE
+kDa	I-PRGE
+non	I-PRGE
+-	I-PRGE
+structural	I-PRGE
+protein	I-PRGE
+12	I-PRGE
+(	O
+nsp12	O
+),	O
+whereas	O
+the	O
+second	O
+is	O
+catalysed	O
+by	O
+the	O
+22	O
+-	O
+kDa	O
+nsp8	O
+.	O
+
+TITLE	O
+:	O
+Physiologic	O
+effect	O
+and	O
+safety	O
+of	O
+the	O
+pumpless	O
+extracorporeal	O
+interventional	O
+lung	B-ANAT
+assist	O
+system	O
+in	O
+patients	O
+with	O
+acute	O
+respiratory	O
+failure	O
+--	O
+a	O
+pilot	O
+study	O
+.	O
+
+We	O
+evaluated	O
+the	O
+physiologic	O
+effect	O
+and	O
+safety	O
+of	O
+the	O
+iLA	O
+device	O
+in	O
+patients	O
+with	O
+acute	B-DISO
+respiratory	I-DISO
+failure	I-DISO
+from	O
+various	O
+causes	O
+.	O
+
+This	O
+review	O
+summarizes	O
+interdisciplinary	O
+current	O
+knowledge	O
+in	O
+regard	O
+to	O
+virology	O
+,	O
+immunology	O
+,	O
+pathology	B-DISO
+,	O
+diagnostics	O
+,	O
+and	O
+treatment	O
+options	O
+in	O
+the	O
+context	O
+of	O
+multicat	O
+environments	O
+.	O
+
+ABSTRACT	O
+:	O
+Acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+(	O
+ARDS	B-DISO
+)	O
+is	O
+defined	O
+as	O
+severe	O
+hypoxemic	O
+respiratory	B-DISO
+failure	I-DISO
+resulting	O
+from	O
+diffuse	O
+lung	B-ANAT
+injury	O
+and	O
+secondary	O
+to	O
+direct	O
+and	O
+indirect	O
+insults	O
+.	O
+
+The	O
+primary	O
+outcome	O
+was	O
+death	B-PROC
+before	O
+hospital	O
+discharge	B-ANAT
+and	O
+within	O
+90	O
+days	O
+of	O
+study	O
+enrolment	O
+.	O
+
+Secondary	O
+outcomes	O
+included	O
+28	O
+-	O
+day	O
+mortality	O
+,	O
+number	O
+of	O
+ventilator	O
+-	O
+free	O
+days	O
+,	O
+number	O
+of	O
+days	O
+outside	O
+of	O
+ICU	O
+,	O
+number	O
+of	O
+days	O
+without	O
+organ	B-ANAT
+system	I-ANAT
+failure	O
+,	O
+rate	O
+of	O
+barotrauma	O
+,	O
+and	O
+rate	O
+of	O
+ICU	O
+-	O
+acquired	O
+paresis	B-DISO
+(	O
+as	O
+defined	O
+by	O
+a	O
+Medical	O
+Research	O
+Council	O
+[	O
+MRC	O
+]	O
+score	O
+<	O
+48	O
+)	O
+on	O
+day	O
+28	O
+and	O
+at	O
+ICU	O
+discharge	B-ANAT
+.	O
+
+Pneumonia	B-DISO
+is	O
+the	O
+most	O
+common	O
+complication	B-DISO
+(	O
+43	O
+.	O
+2	O
+%);	O
+other	O
+complications	O
+include	O
+bronchiolitis	B-DISO
+,	O
+hemoptysis	B-DISO
+,	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+(	O
+ARDS	B-DISO
+)	O
+and	O
+encephalitis	B-DISO
+.	O
+
+Apart	O
+from	O
+oseltamivir	B-CHED
+the	O
+other	O
+antibiotics	B-CHED
+included	O
+ceftriaxone	B-CHED
+,	O
+cefotaxime	B-CHED
+,	O
+amplicillin	O
+and	O
+azithromycin	B-CHED
+,	O
+were	O
+added	O
+for	O
+pneumonia	B-DISO
+.	O
+
+However	O
+,	O
+in	O
+some	O
+instances	O
+,	O
+especially	O
+if	O
+syringomyelia	B-DISO
+is	O
+associated	O
+,	O
+an	O
+abrupt	O
+clinical	O
+onset	O
+is	O
+reported	O
+and	O
+is	O
+accompanied	O
+by	O
+an	O
+acknowledged	O
+risk	O
+of	O
+potentially	O
+severe	O
+clinical	O
+signs	O
+or	O
+even	O
+sudden	B-DISO
+death	I-DISO
+.	O
+
+All	O
+3	O
+patients	O
+showed	O
+a	O
+CM	O
+-	O
+I	O
+/	O
+syringomyelia	B-DISO
+complex	O
+at	O
+diagnosis	O
+,	O
+and	O
+all	O
+of	O
+them	O
+had	O
+a	O
+good	O
+neurological	O
+outcome	O
+after	O
+surgery	O
+despite	O
+the	O
+ominous	O
+clinical	O
+presentation	O
+.	O
+
+Recombinant	B-PRGE
+human	I-PRGE
+EC	I-PRGE
+-	I-PRGE
+SOD	B-FUNC
+(	O
+rhEC	B-PRGE
+-	I-PRGE
+SOD	I-PRGE
+)	O
+was	O
+produced	O
+from	O
+a	O
+synthetic	O
+cassette	O
+constructed	O
+in	O
+the	O
+methylotrophic	O
+yeast	B-SPEC
+Pichia	B-SPEC
+pastoris	I-SPEC
+.	O
+
+In	O
+1969	O
+,	O
+electron	O
+microcopy	O
+was	O
+used	O
+to	O
+show	O
+,	O
+for	O
+the	O
+first	O
+time	O
+,	O
+the	O
+responsibility	O
+of	O
+a	O
+virus	B-SPEC
+in	O
+a	O
+case	O
+of	O
+calf	B-ANAT
+diarrhea	B-DISO
+.	O
+
+Noroviruses	B-SPEC
+,	O
+and	O
+particularly	O
+the	O
+human	B-SPEC
+virus	B-SPEC
+Norwalk	O
+,	O
+were	O
+subsequently	O
+discovered	O
+,	O
+followed	O
+by	O
+coronavirus	B-SPEC
+,	O
+sapovirus	B-SPEC
+,	O
+pestivirus	B-SPEC
+,	O
+astrovirus	O
+,	O
+enteric	O
+adenoviruses	B-SPEC
+,	O
+torovirus	B-SPEC
+,	O
+and	O
+picobirnavirus	B-SPEC
+.	O
+
+TITLE	O
+:	O
+Quinoline	B-CHED
+tricyclic	O
+derivatives	O
+.	O
+
+Title	O
+compounds	O
+were	O
+tested	O
+in	O
+cell	B-COMP
+-	O
+based	O
+assays	O
+for	O
+cytotoxicity	B-DISO
+and	O
+antiviral	B-CHED
+activity	O
+against	O
+RNA	O
+viruses	B-SPEC
+representative	O
+of	O
+the	O
+three	O
+genera	O
+of	O
+the	O
+Flaviviridae	B-SPEC
+family	B-SPEC
+,	O
+that	O
+is	O
+BVDV	B-SPEC
+(	O
+Pestivirus	B-SPEC
+),	O
+YFV	B-SPEC
+(	O
+Flavivirus	B-SPEC
+)	O
+and	O
+HCV	B-SPEC
+(	O
+Hepacivirus	B-SPEC
+).	O
+
+In	O
+enzyme	O
+assays	O
+,	O
+1m	O
+,	O
+2h	O
+,	O
+5m	O
+and	O
+5n	O
+proved	O
+to	O
+be	O
+potent	O
+inhibitors	B-CHED
+of	O
+the	O
+BVDV	B-PRGE
+RNA	I-PRGE
+-	I-PRGE
+dependent	I-PRGE
+RNA	B-PATH
+polymerase	I-PATH
+(	O
+RdRp	B-FUNC
+),	O
+while	O
+only	O
+2h	O
+also	O
+inhibited	O
+the	O
+recombinant	O
+HCV	B-SPEC
+enzyme	O
+.	O
+
+The	O
+2003	O
+SARS	B-DISO
+outbreak	O
+exposed	O
+weaknesses	B-DISO
+in	O
+global	O
+governance	O
+that	O
+caused	O
+uncoordinated	B-DISO
+public	O
+health	O
+and	O
+economic	O
+responses	O
+.	O
+
+Acute	O
+lung	B-ANAT
+injury	O
+/	O
+ARDS	B-DISO
+is	O
+characterized	O
+by	O
+breakdown	B-DISO
+of	O
+the	O
+air	B-ANAT
+-	I-ANAT
+blood	I-ANAT
+barrier	I-ANAT
+,	O
+with	O
+the	O
+accumulation	O
+of	O
+proteinaceous	O
+fluid	O
+and	O
+influx	O
+of	O
+inflammatory	B-ANAT
+cells	I-ANAT
+into	O
+the	O
+alveolar	B-ANAT
+airspace	O
+,	O
+all	O
+of	O
+which	O
+are	O
+likely	O
+mediated	O
+by	O
+endothelial	O
+dysfunction	O
+and	O
+disruption	O
+of	O
+the	O
+pulmonary	B-ANAT
+endothelial	B-ANAT
+barrier	O
+.	O
+
+Based	O
+on	O
+this	O
+study	O
+we	O
+suggest	O
+that	O
+hospital	O
+emergency	B-DISO
+management	O
+research	O
+in	O
+China	O
+should	O
+make	O
+efforts	O
+to	O
+(	O
+1	O
+)	O
+establish	O
+a	O
+universally	O
+accepted	O
+theory	O
+framework	O
+and	O
+terminology	O
+,	O
+(	O
+2	O
+)	O
+create	O
+a	O
+structure	O
+for	O
+further	O
+studies	O
+,	O
+(	O
+3	O
+)	O
+integrate	O
+research	O
+of	O
+different	O
+disciplines	O
+,	O
+and	O
+(	O
+4	O
+)	O
+avoid	O
+or	O
+minimise	O
+confusion	B-DISO
+.	O
+
+A	O
+retrospective	O
+chart	O
+review	O
+was	O
+conducted	O
+on	O
+the	O
+medical	O
+records	O
+of	O
+400	O
+intensive	O
+care	O
+patients	O
+who	O
+were	O
+admitted	O
+to	O
+the	O
+ICU	O
+three	O
+months	O
+before	O
+and	O
+during	O
+the	O
+2003	O
+SARS	B-DISO
+outbreak	O
+.	O
+
+RESULTS	O
+:	O
+The	O
+rate	O
+of	O
+HAIs	O
+was	O
+higher	O
+in	O
+the	O
+pre	O
+-	O
+SARS	B-DISO
+period	O
+than	O
+the	O
+SARS	B-DISO
+period	O
+.	O
+
+Several	O
+lymphocyte	O
+subsets	O
+vary	O
+naturally	O
+with	O
+aging	B-PROC
+,	O
+so	O
+the	O
+interpretation	O
+of	O
+results	O
+using	O
+animals	B-SPEC
+of	O
+different	O
+age	O
+ranges	O
+must	O
+proceed	O
+with	O
+care	O
+.	O
+
+Nearly	O
+one	O
+-	O
+third	O
+to	O
+one	O
+-	O
+half	O
+of	O
+these	O
+cases	O
+may	O
+be	O
+infectious	B-DISO
+in	O
+origin	O
+.	O
+
+Specific	O
+recommendations	O
+are	O
+made	O
+regarding	O
+ventilator	O
+capacity	O
+,	O
+including	O
+the	O
+potential	O
+use	O
+of	O
+high	O
+-	O
+frequency	O
+oscillatory	O
+ventilation	O
+and	O
+extracorporeal	O
+membrane	B-COMP
+oxygenation	B-PROC
+.	O
+
+This	O
+likely	O
+stems	B-ANAT
+from	O
+the	O
+ability	O
+of	O
+Staphylococcal	O
+enterotoxins	O
+to	O
+elicit	O
+powerful	O
+episodes	O
+of	O
+T	B-ANAT
+cell	I-ANAT
+stimulation	O
+resulting	O
+in	O
+release	B-PATH
+of	O
+pro	B-CHED
+-	O
+inflammatory	O
+cytokines	O
+.	O
+
+ABSTRACT	O
+:	O
+Plasmodium	B-SPEC
+falciparum	I-SPEC
+and	O
+to	O
+some	O
+extent	O
+malaria	B-DISO
+caused	O
+by	O
+other	O
+species	B-SPEC
+of	O
+Plasmodia	O
+can	O
+quickly	O
+lead	O
+to	O
+cerebral	B-DISO
+malaria	B-PATH
+,	O
+acute	B-DISO
+renal	I-DISO
+failure	I-DISO
+,	O
+or	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+.	O
+
+TITLE	O
+:	O
+Molecular	O
+determinants	O
+of	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+coronavirus	B-SPEC
+pathogenesis	B-DISO
+and	O
+virulence	B-PROC
+in	O
+young	O
+and	O
+aged	O
+mouse	B-SPEC
+models	O
+of	O
+human	B-SPEC
+disease	O
+.	O
+
+Since	O
+young	O
+and	O
+aged	O
+(	O
+1	O
+-	O
+year	O
+-	O
+old	O
+)	O
+mice	B-SPEC
+do	O
+not	O
+develop	O
+severe	O
+clinical	O
+disease	O
+following	O
+infection	B-DISO
+with	O
+wild	O
+-	O
+type	O
+SARS	B-DISO
+-	O
+CoV	O
+,	O
+a	O
+mouse	B-SPEC
+-	O
+adapted	O
+strain	O
+of	O
+SARS	B-DISO
+-	O
+CoV	O
+(	O
+called	O
+MA15	O
+)	O
+was	O
+developed	O
+and	O
+was	O
+shown	O
+to	O
+cause	O
+lethal	O
+infection	B-DISO
+in	O
+these	O
+animals	B-SPEC
+.	O
+
+The	O
+compounds	O
+were	O
+tested	O
+for	O
+antiparasitic	O
+activities	O
+against	O
+Leishmania	B-SPEC
+major	I-SPEC
+and	O
+Trypanosoma	B-SPEC
+brucei	I-SPEC
+,	O
+and	O
+for	O
+protease	O
+inhibition	B-PROC
+against	O
+several	O
+cysteine	B-PRGE
+proteases	I-PRGE
+such	O
+as	O
+falcipain	O
+,	O
+rhodesain	O
+,	O
+cathepsin	B-PRGE
+L	I-PRGE
+,	O
+cathepsin	B-PRGE
+B	I-PRGE
+,	O
+and	O
+viral	B-PRGE
+proteases	I-PRGE
+SARS	I-PRGE
+-	I-PRGE
+CoV	I-PRGE
+M	I-PRGE
+(	I-PRGE
+pro	B-CHED
+),	I-PRGE
+and	O
+PL	O
+(	O
+pro	B-CHED
+).	O
+
+TITLE	O
+:	O
+Acute	B-DISO
+Respiratory	I-DISO
+Distress	I-DISO
+Syndrome	I-DISO
+as	O
+a	O
+presenting	O
+manifestation	O
+in	O
+young	O
+patients	O
+infected	O
+with	O
+H1N1	O
+influenza	O
+virus	O
+.	O
+
+Prone	O
+positioning	O
+may	O
+also	O
+minimize	O
+secondary	O
+lung	B-ANAT
+injury	O
+induced	O
+by	O
+mechanical	O
+ventilation	O
+,	O
+although	O
+this	O
+benefit	O
+has	O
+not	O
+been	O
+investigated	O
+as	O
+extensively	O
+,	O
+despite	O
+its	O
+potential	O
+.	O
+
+Chickens	B-SPEC
+that	O
+were	O
+challenged	O
+by	O
+LPS	B-DISO
+or	O
+CPM	O
+had	O
+a	O
+lower	O
+ileal	B-ANAT
+CP	O
+digestibility	O
+than	O
+that	O
+of	O
+the	O
+control	O
+group	O
+(	O
+P	O
+<	O
+0	O
+.	O
+01	O
+).	O
+
+Only	O
+5	O
+clusters	B-CHED
+were	O
+identified	O
+at	O
+42	O
+d	O
+of	O
+age	O
+.	O
+
+The	O
+ERIC	O
+-	O
+PCR	O
+fingerprints	O
+of	O
+the	O
+microbial	O
+flora	O
+of	O
+the	O
+cecal	B-ANAT
+contents	O
+revealed	O
+the	O
+potential	O
+effects	O
+of	O
+immune	O
+stress	O
+on	O
+the	O
+microbial	O
+populations	O
+of	O
+treated	O
+birds	B-SPEC
+.	O
+
+A	O
+large	O
+number	O
+of	O
+SARS	B-DISO
+patients	O
+experienced	O
+large	O
+joint	B-ANAT
+arthralgia	B-DISO
+,	O
+although	O
+this	O
+was	O
+,	O
+for	O
+the	O
+most	O
+part	O
+,	O
+not	O
+associated	O
+with	O
+any	O
+abnormality	O
+on	O
+magnetic	O
+resonance	O
+imaging	O
+.	O
+
+Prevalence	O
+of	O
+osteonecrosis	B-DISO
+in	O
+SARS	B-DISO
+patients	O
+treated	O
+with	O
+steroids	B-CHED
+ranged	O
+from	O
+5	O
+%	O
+to	O
+58	O
+%.	O
+
+Osteonecrosis	B-DISO
+risk	O
+was	O
+<	O
+1	O
+%	O
+in	O
+patients	O
+receiving	O
+<	O
+3	O
+g	O
+and	O
+13	O
+%	O
+in	O
+patients	O
+receiving	O
+>	O
+3	O
+g	O
+cumulative	O
+prednisolone	O
+-	O
+equivalent	O
+dose	O
+.	O
+
+ABSTRACT	O
+:	O
+Acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+is	O
+a	O
+severe	O
+form	O
+of	O
+respiratory	B-DISO
+failure	I-DISO
+characterized	O
+by	O
+acute	O
+onset	O
+of	O
+significant	O
+hypoxaemia	O
+(	O
+PaO2	O
+:	O
+FiO2	O
+<	O
+200mmHg	O
+)	O
+with	O
+diffuse	O
+bilateral	O
+pulmonary	B-ANAT
+air	B-CHED
+-	O
+space	O
+shadowing	O
+on	O
+chest	B-ANAT
+X	O
+-	O
+ray	B-SPEC
+,	O
+without	O
+clinical	O
+signs	O
+of	O
+heart	B-DISO
+failure	I-DISO
+(	O
+Bernard	O
+et	O
+al	O
+,	O
+1994	O
+).	O
+
+We	O
+observed	O
+differential	O
+expression	B-PROC
+of	O
+over	O
+200	O
+small	O
+RNAs	O
+of	O
+diverse	O
+classes	O
+during	O
+infection	B-DISO
+.	O
+
+An	O
+integrative	O
+sequencing	O
+analysis	O
+of	O
+both	O
+small	O
+RNAs	O
+and	O
+long	O
+transcripts	O
+from	O
+the	O
+same	O
+samples	O
+showed	O
+that	O
+the	O
+results	O
+revealing	O
+differential	O
+expression	B-PROC
+of	O
+miRNAs	O
+during	O
+infection	B-DISO
+were	O
+largely	O
+due	O
+to	O
+transcriptional	B-PROC
+regulation	I-PROC
+and	O
+that	O
+the	O
+predicted	O
+miRNA	O
+-	O
+mRNA	B-CHED
+network	O
+could	O
+modulate	O
+global	O
+host	B-COMP
+responses	O
+to	O
+virus	B-DISO
+infection	I-DISO
+in	O
+a	O
+combinatorial	O
+fashion	O
+.	O
+
+Most	O
+studies	O
+examining	O
+the	O
+host	B-COMP
+transcriptional	B-PROC
+response	O
+to	O
+infection	B-DISO
+focus	O
+only	O
+on	O
+protein	B-CHED
+-	O
+coding	O
+genes	O
+.	O
+
+We	O
+demonstrated	O
+that	O
+virus	B-DISO
+infection	I-DISO
+also	O
+altered	O
+expression	B-PROC
+of	O
+many	O
+short	O
+ncRNAs	O
+of	O
+diverse	O
+classes	O
+.	O
+
+TITLE	O
+:	O
+Acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+after	O
+gastrointestinal	O
+surgery	O
+.	O
+
+Management	O
+of	O
+this	O
+condition	B-DISO
+has	O
+been	O
+difficult	O
+and	O
+effective	O
+therapies	O
+have	O
+not	O
+yet	O
+been	O
+established	O
+.	O
+
+A	O
+total	O
+of	O
+15	O
+patients	O
+developed	O
+ARDS	B-DISO
+after	O
+gastrointestinal	O
+operations	O
+performed	O
+in	O
+our	O
+institution	O
+.	O
+
+Longitudinal	O
+fluctuation	B-DISO
+in	O
+PaO2	O
+/	O
+FiO2	O
+ratio	O
+after	O
+starting	O
+treatment	O
+appears	O
+to	O
+offer	O
+a	O
+prognostic	O
+factor	O
+for	O
+ARDS	B-DISO
+.	O
+
+In	O
+addition	O
+,	O
+CCoV	O
+-	O
+II	O
+induces	O
+a	O
+remarkable	O
+increase	O
+in	O
+the	O
+expression	O
+of	O
+TNF	B-PRGE
+-	O
+related	O
+apoptosis	B-PATH
+-	O
+inducing	O
+ligand	B-PROC
+(	O
+TRAIL	O
+),	O
+while	O
+we	O
+observed	O
+a	O
+slight	O
+up	B-PROC
+-	I-PROC
+regulation	I-PROC
+of	O
+FasL	B-PRGE
+/	O
+Fas	B-DISO
+at	O
+36	O
+p	O
+.	O
+i	O
+.	O
+
+Furthermore	O
+,	O
+we	O
+found	O
+that	O
+virus	B-DISO
+infection	I-DISO
+increased	O
+both	O
+bax	B-PRGE
+translocation	B-DISO
+into	O
+mitochondria	B-COMP
+and	O
+decreased	O
+bcl	B-PRGE
+-	I-PRGE
+2	I-PRGE
+expression	B-PROC
+in	O
+cytosol	B-COMP
+in	O
+a	O
+time	O
+-	O
+dependent	O
+manner	O
+.	O
+
+These	O
+data	O
+suggest	O
+that	O
+FOXO	B-PRGE
+transcription	I-PRGE
+factors	I-PRGE
+mediate	O
+pro	B-CHED
+-	O
+apoptotic	O
+effects	O
+of	O
+CCoV	O
+-	O
+II	O
+,	O
+in	O
+part	O
+due	O
+to	O
+activation	O
+of	O
+extrinsic	B-PROC
+apoptosis	I-PROC
+pathway	B-PROC
+,	O
+while	O
+some	O
+Sirtuin	B-PRGE
+family	I-PRGE
+members	I-PRGE
+(	O
+such	O
+as	O
+SIRT3	B-PRGE
+and	O
+SIRT4	B-PRGE
+)	O
+may	O
+be	O
+involved	O
+in	O
+intrinsic	B-PROC
+apoptotic	I-PROC
+pathway	I-PROC
+.	O
+
+Twenty	O
+-	O
+one	O
+sheep	B-SPEC
+(	O
+37	O
+±	O
+2	O
+kg	O
+)	O
+were	O
+operatively	O
+prepared	O
+and	O
+randomly	O
+allocated	O
+to	O
+either	O
+the	O
+sham	O
+,	O
+control	O
+,	O
+or	O
+treatment	O
+group	O
+(	O
+n	O
+=	O
+7	O
+each	O
+).	O
+
+The	O
+animals	O
+were	O
+fluid	O
+resuscitated	O
+with	O
+Ringer	O
+'	O
+s	O
+lactate	B-CHED
+to	O
+maintain	O
+hematocrit	O
+at	O
+baseline	O
+.	O
+
+Fluorescent	O
+antibody	B-COMP
+staining	O
+indicated	O
+that	O
+HCoV	B-SPEC
+-	I-SPEC
+229E	I-SPEC
+could	O
+readily	O
+infect	O
+AMs	B-DISO
+,	O
+but	O
+no	O
+evidence	O
+was	O
+found	O
+for	O
+infection	B-DISO
+in	O
+differentiated	B-PROC
+alveolar	B-ANAT
+epithelial	O
+type	O
+II	O
+cells	B-COMP
+and	O
+only	O
+a	O
+very	O
+low	O
+level	O
+of	O
+infection	B-DISO
+in	O
+type	O
+II	O
+cells	B-COMP
+transitioning	O
+to	O
+the	O
+type	B-PRGE
+I	I-PRGE
+-	I-PRGE
+like	I-PRGE
+cell	B-COMP
+phenotype	O
+.	O
+
+AMs	B-DISO
+secreted	B-PROC
+significant	O
+amounts	O
+of	O
+tumour	B-DISO
+necrosis	B-PROC
+factor	I-PRGE
+alpha	I-PRGE
+(	O
+TNF	B-PRGE
+-	I-PRGE
+α	I-PRGE
+),	O
+regulated	O
+on	O
+activation	O
+normal	O
+T	B-ANAT
+-	I-ANAT
+cell	I-ANAT
+expressed	B-PROC
+and	O
+secreted	B-PROC
+(	O
+RANTES	B-PRGE
+/	O
+CCL5	B-PRGE
+)	O
+and	O
+macrophage	B-PRGE
+inflammatory	I-PRGE
+protein	B-CHED
+1β	I-PRGE
+(	O
+MIP	B-PRGE
+-	I-PRGE
+1β	I-PRGE
+/	O
+CCL4	B-PRGE
+)	O
+in	O
+response	O
+to	O
+HCoV	B-SPEC
+-	I-SPEC
+229E	I-SPEC
+infection	B-DISO
+,	O
+but	O
+these	O
+cells	B-COMP
+exhibited	O
+no	O
+detectable	O
+increase	O
+in	O
+IFN	B-PRGE
+-	I-PRGE
+β	I-PRGE
+or	O
+interleukin	B-PRGE
+-	I-PRGE
+29	I-PRGE
+in	O
+mRNA	B-CHED
+levels	O
+.	O
+
+AMs	B-DISO
+from	O
+smokers	O
+had	O
+reduced	O
+secretion	B-PROC
+of	O
+TNF	B-PRGE
+-	I-PRGE
+α	I-PRGE
+compared	O
+with	O
+non	O
+-	O
+smokers	O
+in	O
+response	O
+to	O
+HCoV	B-SPEC
+-	I-SPEC
+229E	I-SPEC
+infection	B-DISO
+.	O
+
+The	O
+most	O
+common	O
+thoracic	B-DISO
+CT	O
+findings	O
+in	O
+pandemic	O
+H1N1	O
+were	O
+patchy	O
+infiltration	B-DISO
+,	O
+lobar	O
+consolidation	O
+,	O
+and	O
+interstitial	B-ANAT
+infiltration	B-DISO
+with	O
+airbronchogram	O
+and	O
+bilateral	O
+distribution	O
+.	O
+
+Only	O
+one	O
+patient	O
+(	O
+3	O
+.	O
+8	O
+%)	O
+showed	O
+ground	O
+-	O
+glass	O
+opacity	B-DISO
+,	O
+predominant	O
+radiographic	O
+finding	O
+in	O
+the	O
+previous	O
+reports	O
+and	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+(	O
+SARS	B-DISO
+).	O
+
+There	O
+was	O
+neither	O
+a	O
+difference	O
+in	O
+quality	O
+of	O
+life	O
+(	O
+day	O
+7	O
+,	O
+P	O
+=	O
+.	O
+892	O
+),	O
+in	O
+the	O
+amount	O
+of	O
+effusion	B-DISO
+(	O
+day	O
+7	O
+,	O
+P	O
+=	O
+.	O
+710	O
+),	O
+the	O
+tumor	B-PRGE
+necrosis	I-PRGE
+factor	I-PRGE
+-	I-PRGE
+alpha	I-PRGE
+(	O
+TNF	B-PRGE
+-	I-PRGE
+α	I-PRGE
+)	O
+concentration	O
+(	O
+day	O
+7	O
+,	O
+P	O
+=	O
+.	O
+355	O
+),	O
+nor	O
+in	O
+any	O
+other	O
+variable	O
+investigated	O
+in	O
+this	O
+study	O
+,	O
+including	O
+a	O
+complete	O
+blood	B-ANAT
+count	O
+,	O
+and	O
+a	O
+small	O
+animal	B-SPEC
+biochemistry	O
+profile	O
+.	O
+
+TITLE	O
+:	O
+Comprehensive	O
+systematic	O
+review	O
+of	O
+healthcare	O
+workers	O
+'	O
+perceptions	O
+of	O
+risk	O
+and	O
+use	O
+of	O
+coping	O
+strategies	O
+towards	O
+emerging	O
+respiratory	O
+infectious	B-DISO
+diseases	I-DISO
+.	O
+
+ABSTRACT	O
+:	O
+To	O
+determine	O
+healthcare	O
+workers	O
+'	O
+perceptions	O
+of	O
+risk	O
+from	O
+exposure	O
+to	O
+emerging	O
+acute	O
+respiratory	O
+infectious	B-DISO
+diseases	I-DISO
+and	O
+the	O
+perceived	O
+effectiveness	O
+of	O
+strategies	O
+used	O
+to	O
+facilitate	O
+healthy	O
+coping	O
+in	O
+acute	O
+hospital	O
+and	O
+community	O
+healthcare	O
+settings	O
+.	O
+
+This	O
+review	O
+focuses	O
+primarily	O
+on	O
+the	O
+pathogenesis	B-DISO
+of	O
+murine	B-SPEC
+coronavirus	I-SPEC
+mouse	B-DISO
+hepatitis	I-DISO
+virus	B-SPEC
+(	O
+MHV	B-SPEC
+)	O
+and	O
+severe	O
+acute	O
+respiratory	O
+coronavirus	B-SPEC
+(	O
+SARS	B-DISO
+-	O
+CoV	O
+).	O
+
+SARS	B-DISO
+-	O
+CoV	O
+emerged	O
+in	O
+the	O
+human	B-SPEC
+population	O
+in	O
+China	O
+in	O
+2002	O
+,	O
+causing	O
+a	O
+worldwide	O
+epidemic	O
+with	O
+severe	O
+morbidity	O
+and	O
+high	O
+mortality	O
+rates	O
+,	O
+particularly	O
+in	O
+older	O
+individuals	O
+.	O
+
+Among	O
+the	O
+respiratory	O
+viruses	B-SPEC
+that	O
+can	O
+affect	O
+the	O
+lung	B-ANAT
+and	O
+cause	O
+ARDS	B-DISO
+,	O
+pandemic	O
+viruses	B-SPEC
+head	B-ANAT
+the	O
+list	O
+,	O
+with	O
+influenza	B-SPEC
+viruses	I-SPEC
+H5N1	B-DISO
+and	O
+H1N1	O
+2009	O
+being	O
+the	O
+most	O
+recently	O
+identified	O
+.	O
+
+TITLE	O
+:	O
+Human	B-SPEC
+coronavirus	I-SPEC
+in	O
+young	O
+children	O
+hospitalized	O
+for	O
+acute	O
+respiratory	O
+illness	O
+and	O
+asymptomatic	O
+controls	O
+.	O
+
+From	O
+December	O
+2003	O
+to	O
+April	O
+2004	O
+and	O
+October	O
+2004	O
+to	O
+April	O
+2005	O
+,	O
+we	O
+conducted	O
+prospective	O
+,	O
+population	O
+-	O
+based	O
+surveillance	O
+of	O
+children	O
+<	O
+5	O
+years	O
+of	O
+age	O
+hospitalized	O
+for	O
+ARI	B-CHED
+/	O
+fever	B-PROC
+in	O
+3	O
+US	O
+counties	O
+.	O
+
+The	O
+prevalence	O
+of	O
+HCoV	O
+or	O
+individual	O
+species	B-SPEC
+was	O
+not	O
+significantly	O
+higher	O
+among	O
+hospitalized	O
+children	O
+than	O
+controls	O
+.	O
+
+ABSTRACT	O
+:	O
+Antibody	B-COMP
+repertoires	O
+for	O
+library	O
+construction	O
+are	O
+conventionally	O
+harvested	O
+from	O
+mRNAs	O
+of	O
+immune	O
+cells	B-COMP
+.	O
+
+TITLE	O
+:	O
+Varicella	B-DISO
+zoster	I-DISO
+virus	I-SPEC
+and	O
+relapsing	B-DISO
+remitting	I-DISO
+multiple	I-DISO
+sclerosis	I-DISO
+.	O
+
+From	O
+April	O
+2002	O
+to	O
+February	O
+2011	O
+,	O
+14	O
+patients	O
+aged	O
+19	O
+days	O
+to	O
+20	O
+years	O
+old	O
+(	O
+average	O
+44	O
+months	O
+),	O
+with	O
+body	B-ANAT
+weight	O
+2	O
+.	O
+6	O
+kg	O
+to	O
+71	O
+kg	O
+(	O
+median	O
+14	O
+.	O
+1	O
+kg	O
+),	O
+underwent	O
+ECMO	O
+support	O
+for	O
+failing	O
+cardiac	B-PROC
+function	I-PROC
+,	O
+hypoxemia	O
+,	O
+and	O
+low	B-DISO
+cardiac	I-DISO
+output	I-DISO
+syndrome	I-DISO
+.	O
+
+In	O
+one	O
+patient	O
+,	O
+ECMO	O
+was	O
+introduced	O
+after	O
+partial	O
+pulmonary	B-ANAT
+resection	O
+for	O
+congenital	B-DISO
+cystic	I-DISO
+adenomatoid	I-DISO
+malformation	I-DISO
+because	O
+of	O
+respiratory	B-DISO
+failure	I-DISO
+.	O
+
+Although	O
+management	O
+of	O
+the	O
+ECMO	O
+circuit	O
+,	O
+including	O
+anticoagulation	B-PROC
+(	O
+activated	O
+clotting	B-PROC
+time	O
+:	O
+150	O
+-	O
+250	O
+),	O
+was	O
+conducted	O
+following	O
+the	O
+institutional	O
+practice	O
+guidelines	O
+,	O
+it	O
+was	O
+difficult	O
+to	O
+control	O
+the	O
+bleeding	B-DISO
+.	O
+
+Fifty	O
+-	O
+three	O
+wasted	B-DISO
+pigs	B-SPEC
+and	O
+seven	O
+specific	O
+pathogen	O
+free	O
+(	O
+SPF	O
+)	O
+pigs	B-SPEC
+were	O
+postmortem	O
+examined	O
+.	O
+
+TITLE	O
+:	O
+Age	O
+-	O
+related	O
+increases	O
+in	O
+PGD	B-CHED
+(	O
+2	O
+)	O
+expression	B-PROC
+impair	O
+respiratory	O
+DC	O
+migration	B-PROC
+,	O
+resulting	O
+in	O
+diminished	O
+T	O
+cell	O
+responses	O
+upon	O
+respiratory	B-DISO
+virus	I-DISO
+infection	I-DISO
+in	O
+mice	B-SPEC
+.	O
+
+However	O
+,	O
+the	O
+development	B-PROC
+of	O
+robust	O
+T	B-ANAT
+cell	I-ANAT
+responses	O
+in	O
+the	O
+lung	B-ANAT
+also	O
+requires	O
+respiratory	O
+DCs	B-DISO
+(	O
+rDCs	O
+),	O
+which	O
+must	O
+process	O
+antigen	B-CHED
+and	O
+migrate	O
+to	O
+draining	O
+LNs	B-DISO
+(	O
+DLNs	O
+),	O
+and	O
+little	O
+is	O
+known	O
+about	O
+age	O
+-	O
+related	O
+defects	O
+in	O
+these	O
+T	B-ANAT
+cell	I-ANAT
+-	O
+extrinsic	O
+functions	O
+.	O
+
+Decision	O
+support	O
+systems	O
+(	O
+DSS	B-DISO
+)	O
+may	O
+support	O
+clinicians	O
+in	O
+finding	O
+the	O
+correct	O
+balance	B-PROC
+.	O
+
+The	O
+DSS	B-DISO
+was	O
+retrospectively	O
+evaluated	O
+in	O
+16	O
+intensive	O
+care	O
+patient	O
+cases	O
+,	O
+with	O
+physiological	O
+models	O
+fitted	B-DISO
+to	O
+the	O
+retrospective	O
+data	O
+and	O
+then	O
+used	O
+to	O
+simulate	O
+patient	O
+response	O
+to	O
+changes	O
+in	O
+therapy	O
+.	O
+
+Changes	O
+in	O
+advice	O
+with	O
+CO	O
+variation	O
+of	O
+about	O
+20	O
+%	O
+were	O
+negligible	O
+except	O
+in	O
+cases	O
+of	O
+high	O
+oxygen	B-CHED
+consumption	O
+.	O
+
+India	O
+'	O
+s	O
+pandemic	O
+plan	B-DISO
+suffers	B-DISO
+from	O
+a	O
+glaring	O
+omission	O
+in	O
+this	O
+aspect	O
+.	O
+
+Although	O
+the	O
+survey	O
+response	O
+rate	O
+was	O
+relatively	O
+low	O
+,	O
+some	O
+clues	O
+for	O
+further	O
+study	O
+were	O
+discovered	O
+,	O
+and	O
+suggestions	O
+to	O
+the	O
+health	O
+authority	O
+for	O
+hospital	O
+emergency	B-DISO
+management	O
+improvement	O
+were	O
+revealed	O
+.	O
+
+Clinically	O
+,	O
+DS	O
+is	O
+characterized	O
+by	O
+weight	O
+gain	O
+,	O
+fever	B-PROC
+not	O
+attributable	O
+to	O
+infection	B-DISO
+,	O
+respiratory	B-DISO
+distress	I-DISO
+,	O
+cardiac	B-ANAT
+involvement	O
+,	O
+hypotension	O
+,	O
+and	O
+/	O
+or	O
+acute	B-DISO
+renal	I-DISO
+failure	I-DISO
+.	O
+
+At	O
+the	O
+histological	O
+point	O
+of	O
+view	O
+,	O
+there	O
+is	O
+an	O
+extensive	O
+interstitial	B-ANAT
+and	O
+intra	O
+-	O
+alveolar	B-ANAT
+pulmonary	B-DISO
+infiltration	I-DISO
+by	O
+maturing	O
+myeloid	O
+cells	B-ANAT
+,	I-ANAT
+endothelial	I-ANAT
+cell	B-DISO
+damage	I-DISO
+,	O
+intra	O
+-	O
+alveolar	B-DISO
+edema	I-DISO
+,	O
+inter	O
+-	O
+alveolar	B-ANAT
+hemorrhage	B-DISO
+,	O
+and	O
+fibrinous	O
+exsudates	O
+.	O
+
+The	O
+objective	O
+of	O
+this	O
+study	O
+was	O
+to	O
+measure	O
+healthcare	O
+utilization	O
+patterns	O
+in	O
+Guatemala	O
+to	O
+inform	O
+the	O
+establishment	O
+of	O
+a	O
+sentinel	O
+surveillance	O
+system	O
+for	O
+influenza	B-DISO
+and	O
+other	O
+respiratory	B-DISO
+infections	I-DISO
+,	O
+and	O
+allow	O
+estimation	O
+of	O
+disease	O
+burden	O
+.	O
+
+TITLE	O
+:	O
+Potential	O
+clinical	O
+application	O
+of	O
+KGF	B-PRGE
+-	I-PRGE
+2	I-PRGE
+(	O
+FGF	B-PRGE
+-	I-PRGE
+10	I-PRGE
+)	O
+for	O
+acute	O
+lung	B-ANAT
+injury	O
+/	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+.	O
+
+Dysfunction	O
+of	O
+endothelial	B-ANAT
+and	O
+epithelial	O
+barriers	O
+is	O
+one	O
+of	O
+the	O
+most	O
+important	O
+mechanisms	O
+in	O
+hypoxia	B-DISO
+-	O
+associated	O
+ALI	O
+/	O
+ARDS	B-DISO
+.	O
+
+After	O
+examination	O
+at	O
+rest	B-FUNC
+,	O
+all	O
+subjects	O
+performed	O
+a	O
+maximal	O
+cycling	O
+exercise	O
+test	O
+.	O
+
+These	O
+abnormalities	O
+are	O
+not	O
+exclusively	O
+seen	O
+in	O
+habitual	O
+users	O
+or	O
+cases	O
+of	O
+overdose	O
+,	O
+and	O
+may	O
+sometimes	O
+cause	O
+confusion	B-DISO
+as	O
+to	O
+the	O
+underlying	O
+pathology	B-DISO
+.	O
+
+During	O
+this	O
+re	O
+-	O
+cloning	O
+,	O
+we	O
+obtained	O
+the	O
+mutant	B-DISO
+viruses	B-SPEC
+,	O
+Mu	B-PRGE
+-	I-PRGE
+1	I-PRGE
+,	O
+Mu	B-PRGE
+-	I-PRGE
+2	I-PRGE
+,	O
+and	O
+Br	O
+-	O
+1	O
+which	O
+was	O
+isolated	O
+from	O
+the	O
+mice	B-SPEC
+brain	B-ANAT
+infected	O
+with	O
+srr7	O
+(	O
+Mix	B-PRGE
+).	O
+
+ABSTRACT	O
+:	O
+In	O
+cases	O
+of	O
+hypoxia	O
+,	O
+oxygen	B-CHED
+can	O
+be	O
+supplied	O
+via	O
+a	O
+number	O
+of	O
+methods	O
+including	O
+face	B-DISO
+masks	O
+,	O
+nasal	B-ANAT
+cannulae	O
+,	O
+hyperoxygenated	O
+oxygen	B-CHED
+chambers	O
+and	O
+mechanical	O
+ventilation	O
+.	O
+
+Treatment	O
+was	O
+changed	O
+to	O
+veno	O
+-	O
+arterial	B-ANAT
+extracorporeal	O
+membrane	B-COMP
+oxygenation	B-PROC
+(	O
+ECMO	O
+)	O
+on	O
+the	O
+third	O
+day	O
+.	O
+
+ABSTRACT	O
+:	O
+This	O
+paper	O
+summarizes	O
+results	O
+obtained	O
+by	O
+multiplex	O
+PCR	O
+screening	O
+of	O
+human	B-SPEC
+clinical	O
+samples	O
+for	O
+respiratory	O
+viruses	B-SPEC
+and	O
+corresponding	O
+data	O
+obtained	O
+after	O
+passaging	O
+of	O
+virus	B-SPEC
+-	O
+positive	O
+samples	O
+in	O
+MDCK	O
+33016PF	O
+cells	B-COMP
+.	O
+
+These	O
+results	O
+demonstrate	O
+that	O
+,	O
+under	O
+practical	O
+conditions	O
+as	O
+applied	O
+to	O
+grow	O
+influenza	B-SPEC
+viruses	I-SPEC
+,	O
+contaminating	O
+viruses	B-SPEC
+can	O
+be	O
+effectively	O
+removed	O
+by	O
+passages	O
+in	O
+MDCK	B-ANAT
+cells	I-ANAT
+.	O
+
+Additionally	O
+,	O
+compound	O
+1	O
+also	O
+shows	O
+high	O
+anti	B-PRGE
+-	I-PRGE
+SARS	I-PRGE
+activity	O
+at	O
+an	O
+EC	O
+(	O
+50	O
+)	O
+of	O
+7	O
+.	O
+08μM	O
+and	O
+toxicity	O
+with	O
+a	O
+CC	O
+(	O
+50	O
+)	O
+of	O
+118	O
+.	O
+6μM	O
+against	O
+MDCK	B-ANAT
+cells	I-ANAT
+.	O
+
+MassTag	B-PRGE
+polymerase	I-PRGE
+chain	I-PRGE
+reaction	O
+for	O
+influenza	B-PATH
+A	I-PATH
+and	O
+B	O
+,	O
+respiratory	B-SPEC
+syncytial	I-SPEC
+virus	I-SPEC
+groups	O
+A	O
+and	O
+B	O
+,	O
+human	B-SPEC
+coronavirus	I-SPEC
+-	O
+229E	O
+and	O
+human	B-SPEC
+coronavirus	I-SPEC
+-	O
+OC43	O
+,	O
+human	B-SPEC
+metapneumovirus	I-SPEC
+,	O
+enterovirus	B-SPEC
+,	O
+human	B-SPEC
+parainfluenza	B-DISO
+viruses	B-SPEC
+2	O
+,	O
+3	O
+,	O
+and	O
+4a	O
+,	O
+human	B-SPEC
+adenovirus	B-DISO
+,	O
+Haemophilus	B-SPEC
+influenzae	I-SPEC
+,	O
+Neisseria	B-SPEC
+meningitidis	I-SPEC
+,	O
+Streptococcus	B-SPEC
+pneumoniae	I-SPEC
+,	O
+Legionella	B-DISO
+pneumonia	I-DISO
+,	O
+and	O
+Mycoplasma	B-DISO
+pneumonia	I-DISO
+was	O
+done	O
+on	O
+respiratory	O
+specimens	O
+.	O
+
+Taken	O
+together	O
+,	O
+Lc	O
+-	O
+expressed	B-PROC
+N	B-PRGE
+protein	I-PRGE
+as	O
+molecular	O
+adjuvant	B-CHED
+or	O
+immunoenhancer	O
+was	O
+able	O
+to	O
+effectively	O
+facilitate	O
+the	O
+induction	O
+of	O
+mucosal	B-ANAT
+and	O
+systemic	O
+immune	B-PROC
+responses	I-PROC
+by	O
+Lc	O
+-	O
+expressing	O
+S1	O
+region	O
+.	O
+
+Cell	B-PRGE
+adhesion	B-DISO
+molecules	I-PRGE
+were	O
+expressed	B-PROC
+at	O
+higher	O
+levels	O
+in	O
+FXR	B-PRGE
+-/-	O
+mice	B-SPEC
+as	O
+compared	O
+with	O
+control	O
+mice	B-SPEC
+.	O
+
+Approximately	O
+81	O
+%	O
+of	O
+investigations	O
+were	O
+responses	O
+to	O
+infectious	B-DISO
+disease	I-DISO
+outbreaks	O
+,	O
+but	O
+the	O
+proportion	O
+of	O
+investigations	O
+related	O
+to	O
+chronic	O
+and	O
+other	O
+noninfectious	O
+conditions	O
+increased	O
+7	O
+-	O
+fold	O
+(	O
+6	O
+%-	O
+45	O
+%).	O
+
+Indirect	O
+methods	O
+have	O
+been	O
+developed	O
+to	O
+quantify	O
+inflammation	O
+in	O
+correlation	O
+with	O
+a	O
+bacterial	O
+or	O
+not	O
+infection	B-DISO
+.	O
+
+All	O
+of	O
+the	O
+patients	O
+received	O
+a	O
+single	O
+dose	O
+of	O
+the	O
+MF59	O
+-	O
+adjuvanted	O
+seasonal	O
+influenza	B-DISO
+vaccine	O
+(	O
+Fluad	O
+,	O
+Siena	O
+,	O
+Italy	O
+).	O
+
+The	O
+analysis	O
+of	O
+cytopathic	O
+effects	O
+(	O
+CPE	O
+)	O
+demonstrated	O
+that	O
+shN2	B-PRGE
+-	I-PRGE
+1	I-PRGE
+and	O
+shN2	B-PRGE
+-	I-PRGE
+2	I-PRGE
+were	O
+capable	O
+of	O
+protecting	O
+cells	B-COMP
+against	O
+PHEV	O
+infection	B-DISO
+with	O
+high	O
+specificity	O
+and	O
+efficiency	O
+.	O
+
+TITLE	O
+:	O
+Protein	B-CHED
+catabolism	I-PROC
+and	O
+requirements	O
+in	O
+severe	O
+illness	O
+.	O
+
+Nutritional	O
+support	O
+limits	O
+but	O
+does	O
+not	O
+stop	O
+the	O
+loss	O
+of	O
+total	O
+body	B-ANAT
+protein	B-CHED
+mass	O
+occurring	O
+in	O
+acute	O
+severe	O
+illness	O
+.	O
+
+In	O
+contrast	O
+,	O
+protein	B-CHED
+intakes	O
+between	O
+1	O
+.	O
+2	O
+and	O
+1	O
+.	O
+5	O
+g	O
+/	O
+kg	O
+body	O
+weight	O
+/	O
+day	O
+with	O
+neutral	O
+energy	B-PROC
+balance	I-PROC
+minimize	O
+total	O
+body	B-ANAT
+protein	B-CHED
+mass	O
+loss	O
+.	O
+
+TITLE	O
+:	O
+Contemporary	O
+extracorporeal	O
+membrane	B-COMP
+oxygenation	B-PROC
+for	O
+adult	O
+respiratory	B-DISO
+failure	I-DISO
+:	O
+life	O
+support	O
+in	O
+the	O
+new	O
+era	O
+.	O
+
+After	O
+approval	O
+by	O
+the	O
+Institutional	O
+Review	O
+Board	O
+,	O
+40	O
+severely	O
+brain	B-ANAT
+-	O
+injured	O
+patients	O
+were	O
+included	O
+.	O
+
+On	O
+cessation	O
+of	O
+midazolam	O
+infusion	O
+,	O
+patients	O
+were	O
+given	O
+clorazepate	B-CHED
+for	O
+3	O
+days	O
+.	O
+
+Of	O
+40	O
+patients	O
+,	O
+there	O
+were	O
+10	O
+who	O
+did	O
+not	O
+require	O
+buprenorphine	B-CHED
+.	O
+
+An	O
+agitation	B-DISO
+occurred	O
+5	O
+hours	O
+(	O
+1	O
+-	O
+21	O
+)	O
+after	O
+cessation	O
+of	O
+opioid	O
+,	O
+associated	O
+with	O
+tachycardia	O
+,	O
+arterial	B-DISO
+hypertension	I-DISO
+,	O
+and	O
+tachypnea	B-DISO
+.	O
+
+It	O
+also	O
+highlights	O
+the	O
+fact	O
+that	O
+the	O
+virus	B-SPEC
+is	O
+still	O
+very	O
+virulent	O
+and	O
+will	O
+pose	O
+a	O
+major	O
+annual	O
+health	O
+risk	O
+along	O
+with	O
+the	O
+seasonal	O
+influenza	B-DISO
+for	O
+at	O
+least	O
+the	O
+next	O
+few	O
+years	O
+.	O
+
+The	O
+use	O
+of	O
+surfactant	B-CHED
+and	O
+inhaled	B-PROC
+nitric	B-CHED
+oxide	I-CHED
+(	O
+iNO	O
+)	O
+has	O
+led	O
+to	O
+the	O
+decreased	O
+mortality	O
+and	O
+the	O
+need	O
+for	O
+extracorporeal	O
+membrane	B-COMP
+oxygenation	B-PROC
+(	O
+ECMO	O
+)	O
+use	O
+.	O
+
+Induction	O
+of	O
+the	O
+slow	O
+-	O
+growth	B-PROC
+phenotype	O
+was	O
+shown	O
+to	O
+take	O
+place	O
+over	O
+a	O
+60	O
+-	O
+hour	O
+time	O
+course	O
+,	O
+providing	O
+the	O
+basis	O
+for	O
+conducting	B-PROC
+a	O
+screen	O
+for	O
+small	O
+molecules	O
+that	O
+restore	O
+growth	B-PROC
+by	O
+inhibiting	O
+the	O
+function	O
+of	O
+PLP	B-PRGE
+.	O
+
+One	O
+of	O
+these	O
+,	O
+NSC158362	O
+,	O
+potently	O
+inhibited	O
+SARS	O
+-	O
+CoV	O
+replication	O
+in	O
+cell	B-COMP
+culture	O
+without	O
+toxic	O
+effects	O
+on	O
+cells	B-COMP
+,	O
+and	O
+it	O
+specifically	O
+inhibited	O
+SARS	B-DISO
+-	O
+CoV	O
+replication	O
+but	O
+not	O
+influenza	B-SPEC
+virus	B-PROC
+replication	I-PROC
+.	O
+
+ABSTRACT	O
+:	O
+Bovine	B-SPEC
+torovirus	I-SPEC
+(	O
+BToV	O
+)	O
+is	O
+recognized	O
+as	O
+an	O
+enteric	O
+pathogen	O
+of	O
+calves	O
+,	O
+but	O
+its	O
+etiological	O
+role	O
+in	O
+diarrhea	B-DISO
+and	O
+epidemiological	O
+characterization	O
+in	O
+adult	O
+cows	B-SPEC
+remain	O
+unclear	O
+.	O
+
+Nucleotide	O
+sequence	O
+analysis	O
+of	O
+the	O
+BToV	O
+nucleocapsid	B-COMP
+,	O
+spike	O
+,	O
+and	O
+hemagglutinin	B-PRGE
+-	I-PRGE
+esterase	I-PRGE
+(	O
+HE	O
+)	O
+genes	O
+revealed	O
+a	O
+close	O
+relatedness	O
+among	O
+the	O
+detected	O
+BToV	O
+strains	O
+from	O
+each	O
+outbreak	O
+and	O
+those	O
+of	O
+Japanese	O
+BToV	O
+strain	O
+Aichi	O
+/	O
+2004	O
+.	O
+
+Sequence	O
+analysis	O
+of	O
+this	O
+isolate	O
+and	O
+Aichi	O
+/	O
+2004	O
+indicated	O
+that	O
+both	O
+strains	O
+have	O
+truncated	O
+HE	O
+genes	O
+with	O
+deletions	O
+in	O
+the	O
+3	O
+'	O
+region	O
+that	O
+occurred	O
+through	O
+cell	B-COMP
+culture	O
+-	O
+adaptation	B-PROC
+.	O
+
+The	O
+short	O
+projections	O
+that	O
+are	O
+believed	O
+to	O
+be	O
+formed	O
+by	O
+the	O
+HE	O
+protein	B-CHED
+on	O
+virus	B-COMP
+particles	I-COMP
+were	O
+not	O
+observed	O
+in	O
+these	O
+cultured	O
+strains	O
+by	O
+electron	O
+microscopy	O
+.	O
+
+Despite	O
+being	O
+one	O
+of	O
+the	O
+predominant	O
+IB	O
+virus	B-SPEC
+(	O
+IBV	B-SPEC
+)	O
+serotype	O
+in	O
+several	O
+European	O
+countries	O
+,	O
+slightly	O
+is	O
+known	O
+about	O
+pathogenesis	B-DISO
+and	O
+pathogenicity	O
+of	O
+Italy	O
+02	O
+serotype	O
+.	O
+
+Furthermore	O
+,	O
+new	O
+data	O
+about	O
+IBV	B-SPEC
+pathogenesis	B-DISO
+essential	O
+in	O
+field	O
+control	O
+is	O
+afforded	O
+.	O
+
+The	O
+nsp1	B-PRGE
+-	O
+induced	O
+RNA	O
+cleavage	B-PROC
+of	O
+template	O
+mRNAs	O
+exhibited	O
+no	O
+apparent	O
+preference	O
+for	O
+a	O
+specific	O
+nucleotide	B-CHED
+sequence	O
+at	O
+the	O
+RNA	O
+cleavage	B-PROC
+sites	O
+.	O
+
+RSV	B-SPEC
+was	O
+the	O
+main	O
+pathogen	O
+of	O
+ARI	B-CHED
+,	O
+and	O
+the	O
+new	O
+-	O
+found	O
+virus	B-SPEC
+MPV	B-SPEC
+was	O
+also	O
+another	O
+crucial	O
+pathogen	O
+.	O
+
+The	O
+incidence	O
+rate	O
+of	O
+HPIV	O
+and	O
+HRV	O
+showed	O
+no	O
+obvious	O
+seasonal	O
+features	O
+;	O
+while	O
+the	O
+prevalence	O
+of	O
+FluA	O
+,	O
+FluB	O
+,	O
+RSV	B-SPEC
+,	O
+ADV	O
+,	O
+MPV	B-SPEC
+and	O
+HCoV	O
+changed	O
+significantly	O
+in	O
+different	O
+seasons	O
+.	O
+22	O
+.	O
+2	O
+%	O
+(	O
+227	O
+/	O
+1024	O
+)	O
+ARI	B-CHED
+patients	O
+co	O
+-	O
+infected	O
+other	O
+respiratory	O
+virus	B-SPEC
+.	O
+90	O
+.	O
+1	O
+%	O
+(	O
+163	O
+/	O
+181	O
+)	O
+FluA	O
+patients	O
+,	O
+88	O
+.	O
+9	O
+%	O
+(	O
+88	O
+/	O
+99	O
+)	O
+FluB	O
+patients	O
+and	O
+92	O
+.	O
+7	O
+%	O
+(	O
+51	O
+/	O
+55	O
+)	O
+ADV	O
+patients	O
+had	O
+high	O
+fever	B-PROC
+symptoms	O
+.	O
+
+As	O
+a	O
+consequence	O
+attenuated	O
+viruses	B-SPEC
+have	O
+only	O
+a	O
+few	O
+mutations	O
+responsible	O
+for	O
+the	O
+loss	O
+of	O
+virulence	B-PROC
+,	O
+which	O
+will	O
+differ	O
+between	O
+vaccines	O
+affecting	O
+virulence	B-PROC
+and	O
+/	O
+or	O
+immunogenicity	O
+and	O
+can	O
+revert	O
+to	O
+virulence	B-PROC
+.	O
+
+A	O
+new	O
+generation	O
+of	O
+vaccines	O
+is	O
+called	O
+for	O
+and	O
+one	O
+means	O
+of	O
+controlling	O
+IBV	B-SPEC
+involves	O
+the	O
+development	O
+of	O
+new	O
+and	O
+safer	O
+vaccines	O
+by	O
+precisely	O
+modifying	O
+the	O
+IBV	B-SPEC
+genome	O
+using	O
+reverse	O
+genetics	O
+for	O
+the	O
+production	O
+of	O
+rationally	O
+attenuated	O
+IBVs	O
+in	O
+order	B-SPEC
+to	O
+obtain	O
+an	O
+optimum	O
+balance	B-PROC
+between	O
+loss	O
+of	O
+virulence	B-PROC
+and	O
+capacity	O
+to	O
+induce	O
+immunity	B-PROC
+.	O
+
+TITLE	O
+:	O
+SARS	B-DISO
+-	O
+CoV	O
+and	O
+emergent	O
+coronaviruses	O
+:	O
+viral	O
+determinants	O
+of	O
+interspecies	O
+transmission	O
+.	O
+
+TITLE	O
+:	O
+The	O
+dependence	B-DISO
+of	O
+viral	O
+RNA	B-PROC
+replication	I-PROC
+on	O
+co	O
+-	O
+opted	O
+host	B-COMP
+factors	O
+.	O
+
+ABSTRACT	O
+:	O
+Transfer	O
+of	O
+severely	O
+hypoxic	B-DISO
+patients	O
+is	O
+a	O
+high	O
+-	O
+risk	O
+procedure	O
+.	O
+
+New	B-PRGE
+cluster	I-PRGE
+1	I-PRGE
+IBV	B-SPEC
+strains	O
+represented	O
+recombinants	O
+between	O
+Korean	O
+nephropathogenic	O
+strain	O
+KM91	O
+and	O
+the	O
+QXIBV	O
+strain	O
+.	O
+
+ABSTRACT	O
+:	O
+The	O
+appearance	O
+of	O
+eight	O
+new	O
+respiratory	O
+viruses	O
+,	O
+including	O
+the	O
+SARS	B-DISO
+coronavirus	B-SPEC
+in	O
+2003	O
+and	O
+swine	B-SPEC
+-	O
+origin	O
+influenza	B-PATH
+A	I-PATH
+/	O
+H1N1	O
+in	O
+2009	O
+,	O
+in	O
+the	O
+human	B-SPEC
+population	O
+in	O
+the	O
+past	O
+nine	O
+years	O
+has	O
+tested	O
+the	O
+ability	O
+of	O
+virology	O
+laboratories	O
+to	O
+develop	O
+diagnostic	O
+tests	O
+to	O
+identify	O
+these	O
+viruses	B-SPEC
+.	O
+
+These	O
+resistance	B-PROC
+assays	O
+,	O
+together	O
+with	O
+viral	O
+load	O
+assays	O
+,	O
+will	O
+enable	O
+clinical	O
+laboratories	O
+to	O
+provide	O
+physicians	O
+with	O
+new	O
+and	O
+important	O
+information	O
+for	O
+optimal	O
+treatment	O
+of	O
+respiratory	O
+virus	B-SPEC
+infections	B-DISO
+.	O
+
+Dr	O
+.	O
+Yin	O
+started	O
+his	O
+research	O
+on	O
+infectious	B-DISO
+disease	I-DISO
+prevention	O
+in	O
+the	O
+1980s	O
+.	O
+
+Led	O
+by	O
+Dr	O
+.	O
+Yin	O
+,	O
+Sinovac	O
+successfully	O
+developed	O
+the	O
+vaccine	O
+prducts	O
+against	O
+SARS	B-DISO
+,	O
+H5N1	B-DISO
+,	O
+H1N1	O
+,	O
+hepatitis	B-DISO
+A	I-DISO
+and	O
+B	O
+and	O
+infleunza	O
+.	O
+
+Currently	O
+,	O
+Sinovac	O
+is	O
+working	O
+on	O
+the	O
+R	O
+&	O
+D	O
+of	O
+EV71	O
+vaccine	O
+against	O
+hand	B-DISO
+,	I-DISO
+foot	I-DISO
+and	I-DISO
+mouth	B-ANAT
+disease	I-DISO
+,	O
+and	O
+pneumococcal	O
+conjugate	O
+vaccine	O
+.	O
+
+The	O
+encouraging	O
+results	O
+of	O
+the	O
+efficacy	O
+and	O
+economic	O
+assessment	O
+of	O
+conventional	O
+ventilatory	O
+support	O
+versus	O
+ECMO	O
+for	O
+severe	O
+adult	O
+respiratory	B-DISO
+failure	I-DISO
+(	O
+CESAR	O
+)	O
+trial	O
+performed	O
+in	O
+the	O
+United	O
+Kingdom	B-SPEC
+and	O
+good	O
+outcomes	O
+of	O
+patients	O
+who	O
+received	O
+ECMO	O
+as	O
+rescue	O
+therapy	O
+during	O
+the	O
+recent	O
+H1N1	B-DISO
+influenza	I-DISO
+pandemic	O
+,	O
+in	O
+which	O
+the	O
+latest	O
+generation	O
+of	O
+ECMO	O
+technology	O
+was	O
+used	O
+,	O
+reignited	O
+interest	O
+in	O
+ECMO	O
+for	O
+severe	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+(	O
+ARDS	B-DISO
+).	O
+
+Frequencies	O
+of	O
+infections	B-DISO
+are	O
+only	O
+known	O
+for	O
+hospitalized	O
+children	O
+.	O
+
+Notably	O
+,	O
+HCoV	O
+-	O
+HKU1	O
+seroconversion	O
+was	O
+absent	O
+after	O
+HCoV	B-SPEC
+-	I-SPEC
+OC43	I-SPEC
+infection	B-DISO
+.	O
+
+TITLE	O
+:	O
+The	O
+use	O
+of	O
+masks	O
+and	O
+respirators	O
+to	O
+prevent	O
+transmission	O
+of	O
+influenza	B-DISO
+:	O
+a	O
+systematic	O
+review	O
+of	O
+the	O
+scientific	O
+evidence	O
+.	O
+
+A	O
+systematic	O
+review	O
+was	O
+undertaken	O
+to	O
+help	O
+inform	O
+pandemic	O
+influenza	B-DISO
+guidance	O
+in	O
+the	O
+United	O
+Kingdom	B-SPEC
+.	O
+
+From	O
+a	O
+compendium	O
+of	O
+12	O
+studies	O
+that	O
+included	O
+responses	O
+to	O
+influenza	B-PATH
+A	I-PATH
+subtype	O
+H5N1	B-DISO
+,	O
+reconstructed	O
+1918	O
+influenza	B-SPEC
+A	I-SPEC
+virus	I-SPEC
+,	O
+and	O
+SARS	B-DISO
+coronavirus	B-SPEC
+,	O
+we	O
+used	O
+meta	B-SPEC
+-	O
+analysis	O
+to	O
+derive	O
+multiple	O
+gene	B-PROC
+expression	I-PROC
+signatures	O
+.	O
+
+Highly	O
+pathogenic	O
+viruses	B-SPEC
+elicit	O
+expression	B-PROC
+of	O
+many	O
+of	O
+the	O
+same	O
+key	O
+genes	O
+as	O
+lower	O
+pathogenic	O
+viruses	B-SPEC
+but	O
+to	O
+a	O
+higher	O
+degree	O
+.	O
+
+After	O
+the	O
+Hajj	O
+,	O
+participants	O
+reported	O
+high	O
+rates	O
+of	O
+maintaining	O
+hand	O
+hygiene	O
+(	O
+98	O
+%),	O
+cough	O
+etiquette	O
+(	O
+89	O
+%),	O
+and	O
+wearing	O
+a	O
+face	B-DISO
+mask	O
+(	O
+90	O
+%).	O
+
+Since	O
+no	O
+specific	O
+pharmacologic	O
+intervention	O
+exists	O
+for	O
+ARDS	B-DISO
+,	O
+our	O
+objective	O
+was	O
+to	O
+determine	O
+the	O
+effect	O
+of	O
+treatment	O
+with	O
+ergothioneine	B-CHED
+-	O
+a	O
+safe	O
+agent	O
+with	O
+multiple	O
+anti	O
+-	O
+inflammatory	O
+and	O
+antioxidant	B-CHED
+properties	O
+on	O
+the	O
+development	B-PROC
+of	O
+lung	B-ANAT
+injury	O
+and	O
+inflammation	B-DISO
+in	O
+rats	B-SPEC
+insufflated	O
+with	O
+cytokines	O
+found	O
+in	O
+lung	B-ANAT
+lavages	O
+of	O
+ARDS	B-DISO
+patients	O
+.	O
+
+METHODS	O
+:	O
+Sprague	B-SPEC
+-	I-SPEC
+Dawley	I-SPEC
+rats	I-SPEC
+(	O
+3	O
+-	O
+10	O
+/	O
+group	O
+)	O
+were	O
+given	O
+15	O
+mg	O
+/	O
+kg	O
+or	O
+150	O
+mg	O
+/	O
+kg	O
+l	B-CHED
+-	I-CHED
+ergothioneine	I-CHED
+intravenously	O
+1h	O
+before	O
+or	O
+18	O
+h	O
+after	O
+cytokine	O
+(	O
+IL	B-FUNC
+-	I-FUNC
+1	I-FUNC
+and	O
+IFNγ	O
+)	O
+insufflation	O
+.	O
+
+Lung	B-ANAT
+injury	O
+(	O
+lavage	O
+LDH	B-PRGE
+levels	O
+)	O
+and	O
+lung	B-DISO
+inflammation	I-DISO
+(	O
+lavage	O
+neutrophil	B-ANAT
+numbers	O
+)	O
+were	O
+measured	O
+24h	O
+after	O
+cytokine	O
+insufflation	O
+.	O
+
+TITLE	O
+:	O
+Overview	O
+of	O
+plant	B-SPEC
+-	O
+derived	O
+vaccine	O
+antigens	B-CHED
+:	O
+Dengue	B-SPEC
+virus	I-SPEC
+.	O
+
+Recently	O
+,	O
+these	O
+issues	O
+were	O
+addressed	O
+by	O
+showing	O
+a	O
+very	O
+good	O
+response	O
+to	O
+inducing	O
+neutralizing	O
+antibodies	B-COMP
+by	O
+plant	B-SPEC
+-	O
+derived	O
+dengue	B-DISO
+vaccine	O
+antigens	B-CHED
+.	O
+
+This	O
+indicates	O
+the	O
+feasibility	O
+of	O
+using	O
+plant	B-SPEC
+-	O
+derived	O
+vaccine	O
+antigens	B-CHED
+as	O
+a	O
+low	O
+-	O
+cost	O
+method	O
+to	O
+combat	B-CHED
+dengue	B-DISO
+and	O
+other	B-DISO
+infectious	I-DISO
+diseases	I-DISO
+.	O
+
+CD4	B-PRGE
+T	B-ANAT
+cell	I-ANAT
+depletion	O
+subsequent	O
+to	O
+CD4	B-PRGE
+T	I-PRGE
+cell	O
+CNS	B-CHED
+migration	B-PROC
+restored	O
+CD8	B-PRGE
+T	I-PRGE
+cell	O
+activity	O
+and	O
+virus	B-SPEC
+control	O
+.	O
+
+The	O
+results	O
+also	O
+increase	O
+understanding	O
+of	O
+the	O
+structures	O
+and	O
+functions	O
+of	O
+coronavirus	B-SPEC
+S1	O
+domains	O
+whose	O
+tertiary	O
+structures	O
+are	O
+currently	O
+unknown	O
+.	O
+
+TITLE	O
+:	O
+Spatial	O
+dynamics	O
+of	O
+airborne	O
+infectious	B-DISO
+diseases	I-DISO
+.	O
+
+A	O
+diagnosis	O
+of	O
+IgA	B-PRGE
+and	O
+IgG2	B-DISO
+deficiency	I-DISO
+and	O
+SLE	B-DISO
+was	O
+made	O
+on	O
+the	O
+basis	O
+of	O
+severe	O
+proteinuria	O
+,	O
+hematuria	O
+,	O
+hypocomplementemia	B-DISO
+,	O
+high	B-PRGE
+anti	I-PRGE
+-	I-PRGE
+DNA	I-PRGE
+antibody	I-PRGE
+and	O
+antinuclear	O
+antibody	B-COMP
+(	O
+ANA	O
+)	O
+titers	O
+,	O
+and	O
+malar	B-ANAT
+rash	B-DISO
+.	O
+
+However	O
+,	O
+these	O
+clinical	O
+signs	B-DISO
+and	I-DISO
+symptoms	I-DISO
+and	O
+laboratory	O
+features	O
+disappeared	O
+after	O
+the	O
+administration	O
+of	O
+methylprednisolone	B-CHED
+pulse	B-PROC
+therapy	O
+and	O
+prednisolone	B-CHED
+.	O
+
+Lesions	O
+indicative	O
+of	O
+respiratory	B-DISO
+disease	I-DISO
+in	O
+pig	B-SPEC
+lungs	B-ANAT
+at	O
+slaughter	O
+e	O
+.	O
+g	O
+.	O
+pneumonia	B-DISO
+and	O
+pleuritis	B-DISO
+are	O
+frequently	O
+recorded	O
+to	O
+assess	O
+herd	O
+health	O
+or	O
+provide	O
+data	O
+for	O
+epidemiological	O
+studies	O
+.	O
+
+ABSTRACT	O
+:	O
+This	O
+study	O
+investigated	O
+bovine	O
+coronavirus	B-SPEC
+(	O
+BCV	B-SPEC
+)	O
+in	O
+both	O
+beef	O
+calves	O
+direct	O
+from	O
+the	O
+ranch	O
+and	O
+commingled	O
+,	O
+mixed	O
+-	O
+source	O
+calves	O
+obtained	O
+from	O
+an	O
+auction	O
+market	O
+.	O
+
+TITLE	O
+:	O
+Contribution	O
+of	O
+neutrophil	B-ANAT
+-	O
+derived	O
+myeloperoxidase	B-PRGE
+in	O
+the	O
+early	O
+phase	O
+of	O
+fulminant	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+induced	O
+by	O
+influenza	B-SPEC
+virus	B-DISO
+infection	I-DISO
+.	O
+
+In	O
+addition	O
+to	O
+interferon	B-PRGE
+(	O
+IFN	O
+)-	O
+α	O
+,	O
+plenty	O
+of	O
+keratinocyte	B-ANAT
+-	O
+derived	O
+chemokines	O
+(	O
+KC	O
+),	O
+macrophage	B-PRGE
+inflammatory	I-PRGE
+protein	B-CHED
+2	I-PRGE
+(	O
+MIP	B-PRGE
+-	I-PRGE
+2	I-PRGE
+),	O
+regulated	O
+on	O
+activation	O
+normal	O
+T	B-ANAT
+-	I-ANAT
+cell	I-ANAT
+expressed	B-PROC
+and	O
+secreted	B-PROC
+(	O
+RANTES	O
+),	O
+and	O
+monocyte	B-PRGE
+chemotactic	I-PRGE
+protein	B-CHED
+1	I-PRGE
+(	O
+MCP	B-PRGE
+-	I-PRGE
+1	I-PRGE
+)	O
+were	O
+significantly	O
+released	O
+into	O
+bronchoalveolar	B-ANAT
+lavage	I-ANAT
+fluid	I-ANAT
+(	O
+BALF	O
+)	O
+of	O
+the	O
+model	O
+.	O
+
+MPO	B-FUNC
+(-/-)	O
+mice	B-SPEC
+also	O
+suppressed	O
+viral	O
+load	O
+in	O
+the	O
+lung	B-ANAT
+.	O
+
+The	O
+present	O
+study	O
+suggests	O
+that	O
+MPO	B-FUNC
+-	O
+mediated	O
+OCl	B-CHED
+(-)	O
+generation	O
+affects	O
+claudin	O
+molecules	O
+and	O
+leads	O
+to	O
+protein	B-CHED
+leakage	B-DISO
+and	O
+viral	O
+spread	O
+as	O
+a	O
+damage	O
+factor	O
+in	O
+influenza	B-DISO
+-	O
+induced	O
+ARDS	B-DISO
+.	O
+
+Thrombocytopenia	O
+,	O
+chest	B-ANAT
+x	O
+-	O
+rays	B-SPEC
+with	O
+suggestive	O
+signs	O
+,	O
+and	O
+receiving	O
+supplemental	O
+oxygenation	B-PROC
+were	O
+highly	O
+sensitive	O
+(>	O
+95	O
+%),	O
+while	O
+elevated	O
+hematocrit	O
+was	O
+highly	O
+specific	O
+(	O
+83	O
+%)	O
+in	O
+detecting	O
+HPS	B-DISO
+.	O
+
+Combining	O
+increased	O
+EVLW	O
+and	O
+a	O
+diagnosis	O
+of	O
+ALI	O
+,	O
+ARDS	B-DISO
+or	O
+sLI	B-PRGE
+increases	O
+the	O
+posttest	O
+odds	O
+of	O
+ICU	O
+mortality	O
+.	O
+
+EVLW	O
+was	O
+associated	O
+with	O
+degree	O
+of	O
+lung	B-ANAT
+injury	O
+and	O
+mortality	O
+,	O
+regardless	O
+of	O
+the	O
+index	O
+used	O
+,	O
+confirming	O
+that	O
+it	O
+may	O
+be	O
+used	O
+as	O
+a	O
+bedside	O
+indicator	B-CHED
+of	O
+disease	O
+severity	O
+.	O
+
+The	O
+use	O
+of	O
+EVLW	O
+as	O
+a	O
+bedside	O
+test	O
+conferred	O
+added	O
+diagnostic	O
+value	O
+for	O
+the	O
+identification	O
+of	O
+patients	O
+with	O
+lung	B-ANAT
+injury	O
+.	O
+
+In	O
+conclusion	O
+,	O
+the	O
+clinical	O
+course	O
+of	O
+H1N1	O
+infection	B-DISO
+may	O
+be	O
+fatal	O
+in	O
+rare	O
+cases	O
+of	O
+leukemic	O
+children	O
+receiving	O
+chemotherapy	O
+.	O
+
+We	O
+discussed	O
+the	O
+potential	O
+advantages	O
+of	O
+extracorporeal	O
+oxygenation	B-PROC
+as	O
+the	O
+main	O
+support	O
+in	O
+this	O
+particular	O
+clinical	O
+setting	O
+.	O
+
+Pyruvate	B-PRGE
+kinase	I-PRGE
+(	O
+liver	B-ANAT
+)	O
+was	O
+found	O
+to	O
+interact	O
+with	O
+SARS	B-PRGE
+-	I-PRGE
+CoV	I-PRGE
+nucleocapsid	B-COMP
+protein	B-CHED
+in	O
+this	O
+experiment	O
+.	O
+
+PK	B-DISO
+deficiency	I-DISO
+in	O
+red	B-ANAT
+blood	I-ANAT
+cells	I-ANAT
+is	O
+known	O
+to	O
+result	O
+in	O
+human	O
+hereditary	O
+non	O
+-	O
+spherocytic	B-DISO
+hemolytic	I-DISO
+anemia	I-DISO
+.	O
+
+After	O
+three	O
+immunizations	O
+,	O
+rS1	B-PRGE
+glycoprotein	I-PRGE
+induced	O
+40	O
+%	O
+protection	O
+,	O
+while	O
+vaccination	O
+with	O
+rN	O
+provided	O
+no	O
+protection	O
+.	O
+
+Vaccination	O
+with	O
+H120	O
+,	O
+and	O
+to	O
+a	O
+lesser	O
+extent	O
+rS1	O
+,	O
+induced	O
+HI	O
+and	O
+virus	B-SPEC
+-	O
+specific	O
+IgG	B-COMP
+antibody	I-COMP
+production	O
+.	O
+
+These	O
+findings	O
+indicate	O
+that	O
+recombinant	O
+viral	O
+proteins	B-CHED
+administered	O
+through	O
+the	O
+mucosal	B-ANAT
+route	O
+can	O
+evoke	O
+an	O
+immune	B-PROC
+response	I-PROC
+without	O
+the	O
+assistance	O
+of	O
+a	O
+vector	O
+.	O
+
+Non	O
+-	O
+aerated	O
+parenchyma	B-ANAT
+decreased	O
+significantly	O
+from	O
+53	O
+.	O
+6	O
+%	O
+(	O
+interquartile	O
+range	O
+(	O
+IQR	O
+):	O
+42	O
+.	O
+5	O
+to	O
+62	O
+.	O
+4	O
+)	O
+to	O
+12	O
+.	O
+7	O
+%	O
+(	O
+IQR	O
+:	O
+4	O
+.	O
+9	O
+to	O
+24	O
+.	O
+2	O
+)	O
+(	O
+P	O
+<	O
+0	O
+.	O
+0001	O
+)	O
+after	O
+MRS	B-DISO
+.	O
+
+TITLE	O
+:	O
+Characterization	O
+of	O
+germline	O
+antibody	B-COMP
+libraries	O
+from	O
+human	B-SPEC
+umbilical	B-ANAT
+cord	I-ANAT
+blood	I-ANAT
+and	O
+selection	O
+of	O
+monoclonal	O
+antibodies	O
+to	O
+viral	B-PRGE
+envelope	I-PRGE
+glycoproteins	B-CHED
+:	O
+Implications	O
+for	O
+mechanisms	O
+of	O
+immune	B-PROC
+evasion	I-PROC
+and	O
+design	O
+of	O
+vaccine	O
+immunogens	O
+.	O
+
+ABSTRACT	O
+:	O
+To	O
+describe	O
+the	O
+most	O
+recent	O
+advances	O
+and	O
+clinical	O
+applications	O
+of	O
+adjunctive	O
+techniques	O
+in	O
+mechanical	O
+ventilation	O
+,	O
+focusing	O
+on	O
+their	O
+overall	O
+impact	O
+on	O
+mortality	O
+and	O
+their	O
+potential	O
+indications	O
+in	O
+critically	B-DISO
+ill	I-DISO
+patients	O
+.	O
+
+TITLE	O
+:	O
+Enveloped	O
+virus	B-SPEC
+but	O
+not	O
+bacteria	B-SPEC
+block	O
+IL	B-FUNC
+-	I-FUNC
+13	I-FUNC
+responses	O
+in	O
+human	B-SPEC
+cord	B-ANAT
+blood	I-ANAT
+T	B-ANAT
+cells	I-ANAT
+in	O
+vitro	O
+.	O
+
+Instead	O
+,	O
+Th1	O
+responses	O
+were	O
+correlated	O
+with	O
+the	O
+capacity	O
+to	O
+induce	O
+IFN	B-PRGE
+-	I-PRGE
+α	I-PRGE
+secretion	B-PROC
+,	O
+which	O
+in	O
+cord	B-DISO
+cells	B-COMP
+were	O
+induced	O
+by	O
+S	B-SPEC
+.	I-SPEC
+aureus	I-SPEC
+and	O
+influenza	B-SPEC
+virus	I-SPEC
+alone	O
+.	O
+
+ABSTRACT	O
+:	O
+The	O
+resurgence	O
+of	O
+the	O
+malaria	O
+eradication	O
+agenda	O
+and	O
+the	O
+increasing	O
+number	O
+of	O
+severe	O
+manifestation	O
+reports	O
+has	O
+contributed	O
+to	O
+a	O
+renewed	O
+interested	O
+in	O
+the	O
+Plasmodium	B-DISO
+vivax	I-DISO
+infection	I-DISO
+.	O
+
+TITLE	O
+:	O
+Acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+induced	O
+by	O
+a	O
+swine	B-SPEC
+2009	O
+H1N1	O
+variant	O
+in	O
+mice	B-SPEC
+.	O
+
+ABSTRACT	O
+:	O
+Acute	O
+respiratory	O
+distress	O
+syndrome	O
+(	O
+ARDS	B-DISO
+)	O
+induced	O
+by	O
+pandemic	O
+2009	O
+H1N1	B-DISO
+influenza	I-DISO
+virus	O
+has	O
+been	O
+widely	O
+reported	O
+and	O
+was	O
+considered	O
+the	O
+main	O
+cause	O
+of	O
+death	B-PROC
+in	O
+critically	B-DISO
+ill	I-DISO
+patients	O
+with	O
+2009	O
+H1N1	O
+infection	B-DISO
+.	O
+
+Depalmitylation	O
+of	O
+mouse	B-DISO
+hepatitis	I-DISO
+virus	B-SPEC
+S	O
+proteins	B-CHED
+abolished	O
+this	O
+interaction	O
+,	O
+resulting	O
+in	O
+the	O
+failure	O
+of	O
+S	O
+incorporation	O
+into	O
+virions	B-COMP
+.	O
+
+ABSTRACT	O
+:	O
+Acute	O
+Respiratory	O
+Distress	O
+Syndrome	O
+(	O
+ARDS	B-DISO
+)	O
+constitutes	O
+a	O
+spectrum	O
+of	O
+severe	O
+acute	B-DISO
+respiratory	I-DISO
+failure	I-DISO
+in	O
+response	O
+to	O
+a	O
+variety	O
+of	O
+inciting	O
+stimuli	O
+that	O
+is	O
+the	O
+leading	O
+cause	O
+of	O
+death	B-PROC
+and	O
+disability	O
+in	O
+the	O
+critically	B-DISO
+ill	I-DISO
+.	O
+
+However	O
+,	O
+pathogen	B-DISO
+transmission	I-DISO
+within	O
+threatened	O
+host	B-COMP
+populations	O
+may	O
+also	O
+be	O
+important	O
+,	O
+and	O
+may	O
+not	O
+be	O
+controllable	O
+by	O
+managing	O
+another	O
+host	B-COMP
+species	B-SPEC
+.	O
+
+These	O
+are	O
+denoted	O
+N	O
+-	O
+terminal	O
+domain	O
+(	O
+NTD	O
+)	O
+and	O
+C	O
+-	O
+terminal	O
+domain	O
+and	O
+are	O
+joined	O
+by	O
+a	O
+charged	O
+linker	O
+region	O
+rich	O
+in	O
+serine	B-CHED
+and	O
+arginine	B-CHED
+residues	O
+(	O
+SR	O
+linker	O
+).	O
+
+We	O
+reviewed	O
+all	O
+patients	O
+with	O
+osteolysis	B-DISO
+of	O
+lymphatic	B-ANAT
+origin	O
+and	O
+treated	O
+in	O
+our	O
+department	O
+who	O
+had	O
+died	B-PROC
+in	O
+the	O
+last	O
+15	O
+years	O
+,	O
+and	O
+we	O
+reviewed	O
+all	O
+published	O
+cases	O
+of	O
+death	B-PROC
+with	O
+this	O
+disease	O
+since	O
+the	O
+1950	O
+'	O
+s	O
+.	O
+
+The	O
+respiratory	B-ANAT
+sample	I-ANAT
+(	O
+nasal	B-ANAT
+or	O
+pharyngeal	B-ANAT
+exudate	B-ANAT
+or	O
+deeper	O
+sample	O
+in	O
+intubated	O
+patients	O
+)	O
+should	O
+be	O
+obtained	O
+as	O
+soon	O
+as	O
+possible	O
+,	O
+with	O
+the	O
+immediate	O
+start	O
+of	O
+empirical	O
+antiviral	B-CHED
+treatment	O
+.	O
+
+The	O
+centralization	O
+of	O
+extracorporeal	O
+membrane	B-COMP
+oxygenation	B-PROC
+in	O
+referral	O
+hospitals	O
+is	O
+recommended	O
+.	O
+
+Clinical	B-DISO
+findings	I-DISO
+show	O
+50	O
+-	O
+60	O
+%	O
+survival	O
+rates	O
+in	O
+patients	O
+treated	O
+with	O
+this	O
+technique	O
+.	O
+
+Early	O
+diagnosis	O
+and	O
+adequate	O
+monitoring	O
+allow	O
+the	O
+start	O
+of	O
+effective	O
+treatment	O
+,	O
+and	O
+in	O
+severe	O
+cases	O
+help	O
+decide	O
+the	O
+use	O
+of	O
+circulatory	B-PROC
+support	O
+systems	O
+.	O
+
+Fourteen	O
+to	O
+16	O
+-	O
+week	O
+-	O
+old	O
+ACE2	O
+knockout	O
+mice	B-SPEC
+-	O
+male	O
+(	O
+ACE2	O
+(-/	O
+y	O
+))	O
+and	O
+female	O
+(	O
+ACE2	O
+(-/-))-	O
+and	O
+age	O
+-	O
+matched	O
+wild	O
+-	O
+type	O
+(	O
+WT	O
+)	O
+male	O
+mice	B-SPEC
+received	O
+intratracheal	O
+BLM	B-DISO
+(	O
+1	O
+.	O
+5U	O
+/	O
+kg	O
+).	O
+
+Male	O
+ACE2	O
+(-/	O
+y	O
+)	O
+BLM	B-DISO
+injured	O
+mice	B-SPEC
+exhibited	O
+poorer	O
+exercise	O
+capacity	O
+,	O
+worse	O
+lung	B-PROC
+function	I-PROC
+and	O
+exacerbated	O
+lung	B-DISO
+fibrosis	I-DISO
+and	O
+collagen	B-COMP
+deposition	O
+compared	O
+with	O
+WT	O
+.	O
+
+In	O
+agreement	O
+with	O
+the	O
+high	O
+viral	O
+load	O
+,	O
+the	O
+lung	O
+specimens	O
+from	O
+this	O
+patient	O
+,	O
+but	O
+not	O
+the	O
+other	O
+three	O
+patients	O
+,	O
+showed	O
+a	O
+high	O
+expression	B-PROC
+of	O
+α	O
+-	O
+2	O
+,	O
+6	O
+-	O
+linked	O
+sialic	B-CHED
+acid	I-CHED
+by	O
+lectin	B-PRGE
+staining	O
+.	O
+
+The	O
+data	O
+indicated	O
+overexpression	B-PROC
+of	O
+the	O
+viral	B-PRGE
+receptor	I-PRGE
+as	O
+a	O
+potential	O
+mechanism	O
+for	O
+severe	O
+disease	O
+in	O
+some	O
+patients	O
+.	O
+
+During	O
+the	O
+same	O
+period	O
+,	O
+the	O
+prevalence	O
+of	O
+PCV2	O
+,	O
+PRRSV	B-SPEC
+,	O
+and	O
+PRCV	O
+was	O
+lower	O
+(	O
+P	O
+<	O
+0	O
+.	O
+05	O
+).	O
+
+TITLE	O
+:	O
+Serosurvey	O
+of	O
+free	O
+-	O
+ranging	O
+Amur	B-SPEC
+tigers	I-SPEC
+in	O
+the	O
+Russian	O
+Far	O
+East	O
+.	O
+
+No	O
+differences	O
+were	O
+detected	O
+in	O
+antibody	B-COMP
+prevalence	O
+estimates	O
+between	O
+tigers	B-SPEC
+captured	O
+as	O
+part	O
+of	O
+a	O
+research	O
+program	O
+and	O
+those	O
+captured	O
+to	O
+mitigate	O
+human	B-SPEC
+-	O
+tiger	B-SPEC
+conflicts	O
+.	O
+
+It	O
+is	O
+not	O
+clearly	O
+understood	O
+how	O
+this	O
+virus	B-SPEC
+is	O
+replicated	O
+within	O
+and	O
+released	O
+from	O
+the	O
+sensory	B-ANAT
+neurons	I-ANAT
+,	O
+and	O
+it	O
+remains	O
+to	O
+know	O
+how	O
+satellite	O
+cells	B-COMP
+response	O
+to	O
+the	O
+HEV	B-SPEC
+invasion	B-DISO
+.	O
+
+Released	O
+HEV	B-SPEC
+particles	O
+were	O
+subsequently	O
+taken	O
+up	O
+by	O
+the	O
+adjacent	O
+satellite	O
+cells	B-COMP
+.	O
+
+TITLE	O
+:	O
+First	O
+experience	O
+with	O
+the	O
+new	O
+portable	O
+extracorporeal	O
+membrane	B-COMP
+oxygenation	B-PROC
+system	O
+Cardiohelp	O
+for	O
+severe	O
+respiratory	O
+failure	O
+in	O
+adults	O
+.	O
+
+Cardiohelp	O
+support	O
+resulted	O
+in	O
+immediate	O
+improvement	O
+of	O
+gas	B-ENZY
+exchange	O
+and	O
+highly	O
+protective	O
+ventilation	O
+.	O
+
+TITLE	O
+:	O
+Phosphatidylinositol	B-CHED
+4	I-ENZY
+-	I-ENZY
+kinase	I-ENZY
+IIIβ	I-PRGE
+is	O
+required	O
+for	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+coronavirus	B-SPEC
+spike	O
+-	O
+mediated	O
+cell	B-COMP
+entry	O
+.	O
+
+Thus	O
+,	O
+we	O
+believe	O
+that	O
+3b	O
+might	O
+play	O
+an	O
+important	O
+role	O
+in	O
+SARS	B-DISO
+-	O
+CoV	O
+pathogenesis	B-DISO
+and	O
+therefore	O
+is	O
+of	O
+considerable	O
+interest	O
+.	O
+
+These	O
+results	O
+were	O
+further	O
+confirmed	O
+both	O
+in	O
+vivo	O
+and	O
+in	O
+vitro	O
+,	O
+in	O
+IBV	B-SPEC
+-	O
+infected	O
+embryonated	O
+chicken	B-SPEC
+eggs	O
+,	O
+chicken	B-SPEC
+fibroblast	B-ANAT
+cells	B-COMP
+and	O
+mammalian	B-SPEC
+cells	B-COMP
+at	O
+transcriptional	B-PROC
+and	O
+translational	B-PROC
+levels	O
+,	O
+respectively	O
+.	O
+
+A	O
+""""	O
+2	O
+-	O
+hit	O
+""""	O
+injury	O
+was	O
+induced	O
+:	O
+(	O
+a	O
+)	O
+peritoneal	B-ANAT
+sepsis	B-DISO
+-	O
+by	O
+placement	O
+of	O
+a	O
+fecal	B-ANAT
+clot	B-DISO
+in	O
+the	O
+peritoneum	B-ANAT
+,	O
+and	O
+(	O
+b	O
+)	O
+ischemia	B-DISO
+/	O
+reperfusion	O
+-	O
+by	O
+clamping	O
+the	O
+superior	B-ANAT
+mesenteric	I-ANAT
+artery	I-ANAT
+for	O
+30	O
+min	O
+.	O
+
+Animals	B-SPEC
+were	O
+randomized	O
+into	O
+two	O
+groups	O
+:	O
+CMT	O
+-	O
+3	O
+group	O
+(	O
+n	O
+=	O
+7	O
+)	O
+received	O
+CMT	O
+-	O
+3	O
+(	O
+200	O
+mg	O
+/	O
+kg	O
+);	O
+placebo	O
+group	O
+(	O
+n	O
+=	O
+9	O
+)	O
+received	O
+the	O
+same	O
+dose	O
+of	O
+a	O
+CMT	O
+-	O
+3	O
+vehicle	O
+(	O
+carboxymethylcellulose	O
+).	O
+
+It	O
+improved	O
+all	O
+histological	O
+lesions	O
+of	O
+ARDS	B-DISO
+(	O
+P	O
+<	O
+0	O
+.	O
+05	O
+vs	O
+.	O
+placebo	O
+).	O
+
+Chemically	O
+modified	O
+tetracycline	B-CHED
+3	O
+treatment	O
+prevented	O
+coagulopathy	B-DISO
+and	O
+protected	O
+against	O
+bowel	B-ANAT
+injury	O
+.	O
+
+Treatment	O
+of	O
+sepsis	B-DISO
+patients	O
+with	O
+CMT	O
+-	O
+3	O
+could	O
+significantly	O
+reduce	O
+progression	O
+from	O
+sepsis	B-DISO
+into	O
+ARDS	B-DISO
+.	O
+
+ABSTRACT	O
+:	O
+Global	O
+travel	O
+and	O
+transport	O
+play	O
+a	O
+critical	O
+role	O
+in	O
+the	O
+spread	O
+of	O
+infections	B-DISO
+.	O
+
+We	O
+see	O
+this	O
+clearly	O
+in	O
+the	O
+first	O
+two	O
+pandemics	O
+of	O
+the	O
+21st	O
+century	O
+:	O
+SARS	B-DISO
+and	O
+influenza	B-DISO
+H1N1	O
+-	O
+2009	O
+.	O
+
+Seasonal	O
+,	O
+pandemic	O
+,	O
+and	O
+avian	B-DISO
+influenza	I-DISO
+have	O
+some	O
+important	O
+differences	O
+with	O
+regards	O
+to	O
+exposure	O
+risks	O
+,	O
+infectivity	O
+,	O
+and	O
+severity	O
+.	O
+
+To	O
+date	O
+,	O
+avian	B-DISO
+influenza	I-DISO
+has	O
+low	O
+human	B-SPEC
+-	O
+to	O
+-	O
+human	B-SPEC
+transmission	O
+;	O
+infection	B-DISO
+typically	O
+requires	O
+close	O
+contact	O
+with	O
+poultry	O
+,	O
+but	O
+presents	O
+with	O
+severe	O
+disease	O
+and	O
+a	O
+high	O
+fatality	O
+rate	O
+.	O
+
+Environmental	O
+studies	O
+have	O
+shown	O
+that	O
+animal	B-SPEC
+coronaviruses	O
+remain	O
+infectious	B-DISO
+in	O
+water	B-CHED
+and	O
+sewage	O
+for	O
+up	O
+to	O
+a	O
+year	O
+depending	O
+on	O
+the	O
+temperature	O
+and	O
+humidity	O
+.	O
+
+UV	O
+and	O
+confocal	O
+microscopic	O
+observation	O
+indicated	O
+attachment	O
+of	O
+residual	O
+labeled	O
+virions	B-COMP
+to	O
+the	O
+lettuce	O
+surface	O
+after	O
+the	O
+elution	O
+procedure	O
+,	O
+suggesting	O
+that	O
+rates	O
+of	O
+inactivation	B-DISO
+or	O
+detection	O
+of	O
+the	O
+virus	B-SPEC
+may	O
+be	O
+underestimated	O
+.	O
+
+For	O
+BCV	B-SPEC
+,	O
+this	O
+association	O
+was	O
+significant	O
+also	O
+when	O
+accounting	O
+for	O
+herd	O
+size	O
+and	O
+regional	O
+cattle	O
+density	O
+,	O
+but	O
+not	O
+for	O
+BRSV	B-SPEC
+.	O
+
+TITLE	O
+:	O
+A	O
+hexapeptide	O
+of	O
+the	O
+receptor	O
+-	O
+binding	B-FUNC
+domain	O
+of	O
+SARS	B-PRGE
+corona	B-CHED
+virus	B-SPEC
+spike	I-PRGE
+protein	B-CHED
+blocks	O
+viral	O
+entry	O
+into	O
+host	O
+cells	B-COMP
+via	O
+the	O
+human	B-PRGE
+receptor	I-PRGE
+ACE2	I-PRGE
+.	O
+
+TITLE	O
+:	O
+Porcine	B-SPEC
+epidemic	I-SPEC
+diarrhoea	I-SPEC
+virus	I-SPEC
+:	O
+a	O
+comprehensive	O
+review	O
+of	O
+molecular	O
+epidemiology	O
+,	O
+diagnosis	O
+,	O
+and	O
+vaccines	O
+.	O
+
+The	O
+economic	O
+impacts	O
+of	O
+the	O
+PEDV	B-SPEC
+are	O
+substantial	O
+,	O
+given	O
+that	O
+it	O
+results	O
+in	O
+significant	O
+morbidity	O
+and	O
+mortality	O
+in	O
+neonatal	O
+piglets	O
+and	O
+is	O
+associated	O
+with	O
+increased	O
+costs	O
+related	O
+to	O
+vaccination	O
+and	O
+disinfection	O
+.	O
+
+ABSTRACT	O
+:	O
+Public	O
+and	O
+political	O
+awareness	O
+of	O
+emerging	B-DISO
+infectious	I-DISO
+diseases	I-DISO
+is	O
+growing	O
+,	O
+as	O
+animal	B-SPEC
+and	O
+human	B-SPEC
+health	O
+specialists	O
+work	O
+closer	O
+together	O
+to	O
+avert	O
+potential	O
+outbreaks	O
+.	O
+
+TITLE	O
+:	O
+Incidence	O
+of	O
+influenza	B-DISO
+-	I-DISO
+like	I-DISO
+illness	I-DISO
+and	O
+severe	O
+acute	B-DISO
+respiratory	I-DISO
+infection	I-DISO
+during	O
+three	O
+influenza	B-DISO
+seasons	O
+in	O
+Bangladesh	O
+,	O
+2008	O
+-	O
+2010	O
+.	O
+
+No	O
+specific	O
+therapies	O
+are	O
+currently	O
+available	O
+to	O
+treat	O
+or	O
+decrease	O
+the	O
+risk	O
+of	O
+ARDS	B-DISO
+in	O
+patients	O
+with	O
+alcoholism	B-DISO
+.	O
+
+A	O
+chest	B-ANAT
+radiograph	O
+demonstrated	O
+worsening	O
+pulmonary	B-DISO
+infiltrates	I-DISO
+.	O
+
+TITLE	O
+:	O
+Alphacoronavirus	B-SPEC
+detected	O
+in	O
+bats	B-SPEC
+in	O
+the	O
+United	O
+Kingdom	B-SPEC
+.	O
+
+Alphacoronavirus	B-SPEC
+strains	O
+were	O
+detected	O
+in	O
+two	O
+of	O
+seven	O
+bat	B-ENZY
+species	B-SPEC
+,	O
+namely	O
+Myotis	B-SPEC
+nattereri	I-SPEC
+and	O
+M	B-SPEC
+.	I-SPEC
+daubentonii	I-SPEC
+.	O
+
+Virus	B-SPEC
+prevalence	O
+was	O
+particularly	O
+high	O
+in	O
+the	O
+previously	O
+unrecognized	O
+host	B-COMP
+M	B-SPEC
+.	I-SPEC
+nattereri	I-SPEC
+,	O
+which	O
+can	O
+live	O
+in	O
+close	O
+proximity	O
+to	O
+humans	B-SPEC
+.	O
+
+ABSTRACT	O
+:	O
+Recently	O
+,	O
+we	O
+reported	O
+the	O
+discovery	O
+of	O
+three	O
+novel	O
+coronaviruses	O
+,	O
+bulbul	B-SPEC
+coronavirus	B-SPEC
+HKU11	O
+,	O
+thrush	B-PRGE
+coronavirus	B-SPEC
+HKU12	I-PRGE
+,	I-PRGE
+and	I-PRGE
+munia	I-PRGE
+coronavirus	B-SPEC
+HKU13	I-PRGE
+,	O
+which	O
+were	O
+identified	O
+as	O
+representatives	O
+of	O
+a	O
+novel	O
+genus	B-SPEC
+,	O
+Deltacoronavirus	O
+,	O
+in	O
+the	O
+subfamily	B-SPEC
+Coronavirinae	B-SPEC
+.	O
+
+TITLE	O
+:	O
+Feline	B-SPEC
+infectious	I-DISO
+peritonitis	I-DISO
+:	O
+role	O
+of	O
+the	O
+feline	B-PRGE
+coronavirus	B-SPEC
+3c	I-PRGE
+gene	I-PRGE
+in	O
+intestinal	B-ANAT
+tropism	B-PROC
+and	O
+pathogenicity	O
+based	O
+upon	O
+isolates	O
+from	O
+resident	O
+and	O
+adopted	O
+shelter	O
+cats	O
+.	O
+
+However	O
+,	O
+a	O
+recent	O
+study	O
+found	O
+that	O
+one	O
+-	O
+third	O
+of	O
+FIPV	O
+isolates	O
+have	O
+an	O
+intact	O
+3c	O
+and	O
+suggested	O
+that	O
+it	O
+is	O
+not	O
+solely	O
+involved	O
+in	O
+FIP	B-DISO
+but	O
+is	O
+essential	O
+for	O
+intestinal	B-ANAT
+replication	O
+.	O
+
+Therefore	O
+,	O
+an	O
+intact	O
+3c	O
+appears	O
+to	O
+be	O
+essential	O
+for	O
+intestinal	B-ANAT
+replication	O
+.	O
+
+The	O
+underlying	O
+mechanisms	O
+that	O
+involve	O
+canonical	O
+inflammatory	O
+pathways	B-PROC
+such	O
+as	O
+MAP	B-PRGE
+kinases	I-PRGE
+,	O
+CXCR2	B-PRGE
+chemokines	I-PRGE
+,	O
+PAF	B-DISO
+,	O
+leukotrienes	B-CHED
+,	O
+adhesions	B-DISO
+molecules	O
+(	O
+CD18	B-PRGE
+,	O
+ICAM	O
+-	O
+1	O
+)	O
+and	O
+elastase	O
+have	O
+been	O
+defined	O
+relatively	O
+well	O
+.	O
+
+There	O
+were	O
+no	O
+significant	O
+differences	O
+between	O
+hemodynamic	B-PROC
+and	O
+respiratory	O
+variables	O
+before	O
+and	O
+after	O
+the	O
+procedure	O
+.	O
+
+ABSTRACT	O
+:	O
+Many	O
+chronic	B-DISO
+rhinosinusitis	I-DISO
+(	O
+CRS	B-DISO
+)	O
+patients	O
+recall	O
+an	O
+upper	B-DISO
+respiratory	I-DISO
+tract	I-DISO
+infection	I-DISO
+as	O
+the	O
+inciting	O
+event	O
+of	O
+their	O
+chronic	B-DISO
+illness	I-DISO
+.	O
+
+Viral	B-DISO
+infections	I-DISO
+have	O
+been	O
+shown	O
+to	O
+cause	O
+obstruction	B-DISO
+of	O
+the	O
+osteomeatal	O
+complex	O
+,	O
+which	O
+is	O
+likely	O
+to	O
+be	O
+a	O
+critical	O
+step	O
+in	O
+the	O
+development	B-PROC
+of	O
+CRS	B-DISO
+.	O
+
+Viral	B-DISO
+infections	I-DISO
+in	O
+established	O
+asthmatics	B-DISO
+are	O
+associated	O
+with	O
+acute	O
+exacerbations	O
+.	O
+
+PCR	O
+was	O
+used	O
+to	O
+look	O
+for	O
+common	O
+respiratory	O
+viruses	B-SPEC
+(	O
+parainfluenza	B-DISO
+1	O
+,	O
+2	O
+,	O
+and	O
+3	O
+;	O
+respiratory	B-SPEC
+syncytial	I-SPEC
+virus	I-SPEC
+[	O
+RSV	B-SPEC
+];	O
+human	B-SPEC
+metapneumovirus	I-SPEC
+[	O
+hMPV	B-SPEC
+];	O
+adenovirus	B-DISO
+[	O
+ADV	O
+];	O
+rhinovirus	B-SPEC
+;	O
+coronavirus	B-SPEC
+;	O
+bocavirus	B-SPEC
+[	O
+BoV	O
+];	O
+cytomegalovirus	B-SPEC
+[	O
+CMV	B-SPEC
+];	O
+and	O
+influenza	B-PATH
+A	I-PATH
+and	O
+B	O
+).	O
+
+ABSTRACT	O
+:	O
+The	O
+severe	O
+acute	O
+respiratory	O
+syndrome	O
+coronavirus	B-SPEC
+(	O
+SARS	B-DISO
+-	O
+CoV	O
+)	O
+from	O
+palm	B-ANAT
+civets	B-SPEC
+has	O
+twice	O
+evolved	O
+the	O
+capacity	O
+to	O
+infect	O
+humans	B-SPEC
+by	O
+gaining	O
+binding	B-FUNC
+affinity	O
+for	O
+human	B-PRGE
+receptor	I-PRGE
+angiotensin	B-CHED
+-	I-PRGE
+converting	I-PRGE
+enzyme	I-PRGE
+2	I-PRGE
+(	O
+ACE2	B-PRGE
+).	O
+
+TITLE	O
+:	O
+The	O
+murine	B-PRGE
+coronavirus	I-PRGE
+hemagglutinin	I-PRGE
+-	I-PRGE
+esterase	I-PRGE
+receptor	I-PRGE
+-	I-PRGE
+binding	B-FUNC
+site	I-PRGE
+:	O
+a	O
+major	O
+shift	O
+in	O
+ligand	B-PROC
+specificity	O
+through	O
+modest	O
+changes	O
+in	O
+architecture	O
+.	O
+
+ABSTRACT	O
+:	O
+The	O
+hemagglutinin	O
+-	O
+esterases	O
+(	O
+HEs	B-DISO
+),	O
+envelope	B-COMP
+glycoproteins	B-CHED
+of	O
+corona	B-CHED
+-,	O
+toro	O
+-	O
+and	O
+orthomyxoviruses	B-SPEC
+,	O
+mediate	O
+reversible	O
+virion	B-COMP
+attachment	O
+to	O
+O	O
+-	O
+acetylated	O
+sialic	B-CHED
+acids	I-CHED
+(	O
+O	O
+-	O
+Ac	O
+-	O
+Sias	O
+).	O
+
+They	O
+do	O
+so	O
+through	O
+concerted	O
+action	O
+of	O
+distinct	O
+receptor	O
+-	O
+binding	B-FUNC
+"("""	O
+lectin	B-PRGE
+""")"	I-PRGE
+and	O
+receptor	O
+-	O
+destroying	O
+sialate	B-PRGE
+O	I-PRGE
+-	I-PRGE
+acetylesterase	I-PRGE
+"("""	O
+esterase	B-PRGE
+""")"	I-PRGE
+domains	O
+.	O
+
+Here	O
+we	O
+present	O
+the	O
+crystal	B-ANAT
+structure	O
+of	O
+the	O
+lectin	B-PRGE
+domain	O
+of	O
+mouse	B-DISO
+hepatitis	I-DISO
+virus	B-SPEC
+(	O
+MHV	B-SPEC
+)	O
+strain	O
+S	O
+HE	O
+,	O
+resolved	O
+both	O
+in	O
+its	O
+native	O
+state	O
+and	O
+in	O
+complex	O
+with	O
+a	O
+receptor	O
+analogue	O
+.	O
+
+Antibodies	B-COMP
+to	O
+CRCoV	O
+,	O
+CPIV	O
+,	O
+or	O
+B	B-SPEC
+.	I-SPEC
+bronchiseptica	I-SPEC
+on	O
+arrival	O
+were	O
+not	O
+significantly	O
+(	O
+P	O
+>	O
+0	O
+.	O
+05	O
+)	O
+associated	O
+with	O
+disease	O
+-	O
+sparing	O
+after	O
+entry	O
+into	O
+the	O
+shelter	O
+.	O
+
+Chest	B-ANAT
+X	O
+-	O
+ray	B-SPEC
+abnormality	O
+in	O
+11	O
+.	O
+5	O
+%	O
+patients	O
+,	O
+7	O
+%	O
+had	O
+bilateral	O
+infiltrates	B-DISO
+,	O
+1	O
+.	O
+5	O
+%	O
+had	O
+inflammatory	O
+patch	O
+and	O
+3	O
+%	O
+had	O
+findings	O
+suggestive	O
+of	O
+bronchitis	B-DISO
+.	O
+
+All	O
+the	O
+patients	O
+with	O
+ARDS	B-DISO
+had	O
+poor	O
+disease	O
+outcome	O
+.	O
+
+A	O
+natural	O
+flavonoid	B-CHED
+quercetin	B-CHED
+has	O
+a	O
+3	O
+,	O
+5	O
+-	O
+dihydroxychromone	O
+pharmacophore	O
+which	O
+is	O
+in	O
+bioisosteric	O
+relationship	O
+with	O
+the	O
+1	O
+,	O
+3	O
+-	O
+diketoacid	O
+moiety	O
+of	O
+the	O
+ADK	O
+.	O
+
+Thus	O
+,	O
+it	O
+was	O
+of	O
+our	O
+interest	O
+to	O
+test	O
+the	O
+antiviral	B-CHED
+activity	O
+of	O
+the	O
+quercetin	B-CHED
+derivatives	O
+with	O
+an	O
+arylmethyl	O
+group	O
+attached	O
+.	O
+
+In	O
+this	O
+study	O
+,	O
+we	O
+prepared	O
+a	O
+series	O
+of	O
+the	O
+7	O
+-	O
+O	O
+-	O
+arylmethylquercetin	O
+derivatives	O
+with	O
+various	O
+aromatic	O
+substituents	O
+and	O
+evaluated	O
+their	O
+antiviral	B-CHED
+activity	O
+against	O
+the	O
+SARS	B-DISO
+-	I-DISO
+associated	I-DISO
+coronavirus	I-DISO
+(	O
+SARS	B-DISO
+-	O
+CoV	O
+,	O
+SCV	B-SPEC
+)	O
+as	O
+well	O
+as	O
+hepatitis	B-SPEC
+C	I-SPEC
+virus	I-SPEC
+(	O
+HCV	B-SPEC
+).	O
+
+Expression	B-PROC
+of	O
+the	O
+sNsp15	O
+in	O
+cells	B-COMP
+resulted	O
+in	O
+an	O
+increased	O
+abundance	O
+of	O
+pRb	B-PRGE
+in	O
+the	O
+cytoplasm	B-COMP
+,	O
+decreased	O
+overall	O
+levels	O
+of	O
+pRb	B-PRGE
+,	O
+an	O
+increased	O
+proportion	O
+of	O
+cells	B-COMP
+in	O
+the	O
+S	B-PROC
+phase	I-PROC
+of	O
+the	O
+cell	B-PATH
+cycle	I-PATH
+,	O
+and	O
+an	O
+enhanced	O
+expression	B-PROC
+from	O
+a	O
+promoter	O
+normally	O
+repressed	O
+by	O
+pRb	O
+.	O
+
+Oral	B-ANAT
+vaccination	O
+of	O
+an	O
+attenuated	O
+Salmonella	B-DISO
+typhimurium	O
+strain	O
+transformed	O
+with	O
+plasmids	O
+encoding	O
+CEA	B-PRGE
+-	O
+SARS	B-DISO
+-	O
+CoV	O
+fusion	O
+gene	O
+into	O
+BALB	O
+/	O
+c	O
+mice	B-SPEC
+elicited	O
+significant	O
+increases	O
+in	O
+TNF	B-PRGE
+-	I-PRGE
+α	I-PRGE
+and	O
+IL	B-FUNC
+-	I-FUNC
+10	I-FUNC
+in	O
+the	O
+serum	B-COMP
+.	O
+
+Paediatric	O
+cases	O
+of	O
+survival	O
+after	O
+H2S	B-CHED
+intoxication	O
+have	O
+been	O
+rarely	O
+reported	O
+.	O
+
+Hypothermia	O
+and	O
+other	O
+metabolic	B-PROC
+abnormalities	O
+are	O
+now	O
+better	O
+explained	O
+thanks	O
+to	O
+actual	O
+knowledge	O
+about	O
+endogenous	O
+H2S	B-CHED
+function	O
+.	O
+
+However	O
+,	O
+a	O
+comparison	O
+of	O
+the	O
+difference	O
+in	O
+the	O
+HTS	B-DISO
+results	O
+based	O
+on	O
+the	O
+choice	O
+of	O
+reducing	B-CHED
+agent	I-CHED
+used	O
+and	O
+potency	O
+comparisons	O
+of	O
+selected	O
+inhibitors	B-CHED
+has	O
+not	O
+been	O
+done	O
+with	O
+the	O
+physiological	O
+reducing	B-CHED
+agent	I-CHED
+reduced	B-CHED
+glutathione	I-CHED
+(	O
+GSH	B-DISO
+).	O
+
+TITLE	O
+:	O
+Epidemiology	O
+of	O
+coronavirus	B-SPEC
+-	O
+associated	O
+respiratory	B-DISO
+tract	I-DISO
+infections	I-DISO
+and	O
+the	O
+role	O
+of	O
+rapid	O
+diagnostic	O
+tests	O
+:	O
+a	O
+prospective	O
+study	O
+.	O
+
+HCoV	B-SPEC
+-	I-SPEC
+OC43	I-SPEC
+was	O
+the	O
+most	O
+common	O
+coronavirus	B-SPEC
+detected	O
+,	O
+followed	O
+by	O
+HCoV	B-SPEC
+-	I-SPEC
+NL63	I-SPEC
+,	O
+CoVHKU1	O
+,	O
+and	O
+HCoV	B-SPEC
+-	I-SPEC
+229E	I-SPEC
+.	O
+
+Complete	O
+genome	O
+sequencing	O
+and	O
+phylogenetic	O
+analysis	O
+showed	O
+that	O
+bat	B-PRGE
+-	I-PRGE
+SARS	B-DISO
+-	I-PRGE
+CoV	I-PRGE
+formed	O
+a	O
+distinct	O
+cluster	O
+with	O
+SARS	B-PRGE
+-	I-PRGE
+CoV	I-PRGE
+as	O
+group	O
+2b	O
+coronaviruses	O
+,	O
+distantly	O
+related	O
+to	O
+known	O
+group	O
+2	O
+coronaviruses	O
+.	O
+
+Most	O
+differences	O
+between	O
+the	O
+bat	B-ENZY
+-	O
+SARS	B-DISO
+-	O
+CoV	O
+and	O
+SARS	B-DISO
+-	O
+CoV	O
+genomes	O
+were	O
+observed	O
+in	O
+the	O
+spike	O
+gene	O
+.	O
+
+The	O
+presence	O
+of	O
+a29	O
+-	O
+bp	O
+insertion	O
+in	O
+ORF	O
+8	O
+of	O
+bat	B-ENZY
+-	O
+SARS	B-DISO
+-	O
+CoV	O
+genome	O
+,	O
+not	O
+in	O
+most	O
+human	B-SPEC
+SARS	B-DISO
+-	O
+CoV	O
+genomes	O
+,	O
+suggests	O
+that	O
+it	O
+has	O
+a	O
+common	O
+ancestor	O
+with	O
+civet	B-SPEC
+SARS	B-DISO
+-	O
+CoV	O
+.	O
+4	O
+.	O
+
+Antibody	B-COMP
+-	O
+mediated	O
+enhancement	O
+of	O
+SARS	B-DISO
+-	I-DISO
+CoV	I-DISO
+infection	I-DISO
+with	O
+anti	B-PRGE
+-	I-PRGE
+SARS	I-PRGE
+-	I-PRGE
+CoV	I-PRGE
+Spike	I-PRGE
+immune	O
+-	O
+serum	B-COMP
+was	O
+observed	O
+in	O
+vitro	O
+.	O
+
+The	O
+antibody	B-COMP
+-	O
+mediated	O
+enhancement	O
+phenomenon	O
+is	O
+not	O
+a	O
+mandatory	O
+component	O
+of	O
+the	O
+humoral	B-PROC
+immune	I-PROC
+response	I-PROC
+elicited	O
+by	O
+SARS	B-DISO
+vaccines	O
+,	O
+as	O
+pure	B-FUNC
+neutralising	O
+antibody	B-COMP
+only	O
+could	O
+be	O
+obtained	O
+.	O
+
+TITLE	O
+:	O
+Feline	B-SPEC
+and	O
+canine	O
+coronaviruses	O
+:	O
+common	O
+genetic	O
+and	O
+pathobiological	O
+features	O
+.	O
+
+ABSTRACT	O
+:	O
+A	O
+new	O
+human	O
+coronavirus	O
+responsible	O
+for	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+(	O
+SARS	B-DISO
+)	O
+was	O
+identified	O
+in	O
+2003	O
+,	O
+which	O
+raised	O
+concern	O
+about	O
+coronaviruses	O
+as	O
+agents	O
+of	O
+serious	O
+infectious	B-DISO
+disease	I-DISO
+.	O
+
+The	O
+stability	O
+of	O
+the	O
+virus	B-SPEC
+at	O
+different	O
+temperatures	O
+and	O
+relative	O
+humidity	O
+on	O
+smooth	O
+surfaces	O
+were	O
+studied	O
+.	O
+
+The	O
+approach	O
+and	O
+methods	O
+developed	O
+can	O
+easily	O
+be	O
+implemented	O
+in	O
+other	O
+enclosed	O
+spaces	O
+such	O
+as	O
+buildings	O
+,	O
+trains	O
+,	O
+and	O
+buses	O
+to	O
+assess	O
+the	O
+infection	B-DISO
+risk	O
+.	O
+
+ABSTRACT	O
+:	O
+Feline	O
+coronavirus	B-SPEC
+(	O
+FCoV	O
+)	O
+causes	O
+feline	B-DISO
+infectious	I-DISO
+peritonitis	I-DISO
+(	O
+FIP	B-DISO
+).	O
+
+The	O
+FCoV	O
+/	O
+FIP	O
+-	O
+free	O
+status	O
+of	O
+the	O
+Falkland	O
+Islands	O
+cats	B-SPEC
+should	O
+be	O
+maintained	O
+by	O
+FCoV	O
+testing	O
+incoming	O
+cats	B-SPEC
+.	O
+
+ABSTRACT	O
+:	O
+Infections	B-DISO
+with	O
+persistent	O
+viruses	B-SPEC
+are	O
+a	O
+frequent	O
+cause	O
+of	O
+immunosuppression	B-PROC
+,	O
+autoimmune	B-DISO
+sequelae	O
+,	O
+and	O
+/	O
+or	O
+neoplastic	B-DISO
+disease	I-DISO
+.	O
+
+The	O
+profound	O
+impact	O
+of	O
+pDC	B-DISO
+deficiency	O
+on	O
+innate	O
+antiviral	B-CHED
+responses	O
+was	O
+revealed	O
+by	O
+the	O
+failure	O
+to	O
+control	O
+acute	B-DISO
+infection	I-DISO
+with	O
+the	O
+cytopathic	O
+mouse	B-DISO
+hepatitis	I-DISO
+virus	B-SPEC
+.	O
+
+Furthermore	O
+,	O
+pDC	B-DISO
+-	O
+deficient	O
+animals	B-SPEC
+failed	O
+to	O
+clear	O
+lymphocytic	B-SPEC
+choriomeningitis	I-SPEC
+virus	I-SPEC
+(	O
+LCMV	B-SPEC
+)	O
+from	O
+hematopoietic	O
+organs	B-ANAT
+during	O
+persistent	O
+LCMV	B-SPEC
+infection	B-DISO
+.	O
+
+This	O
+failure	O
+was	O
+associated	O
+with	O
+reduced	O
+numbers	O
+and	O
+functionality	O
+of	O
+LCMV	B-SPEC
+-	O
+specific	O
+CD4	B-PRGE
+(+)	O
+helper	B-ANAT
+T	I-ANAT
+cells	I-ANAT
+and	O
+impaired	B-DISO
+antiviral	B-CHED
+CD8	B-PRGE
+(+)	O
+T	B-ANAT
+-	I-ANAT
+cell	I-ANAT
+responses	O
+.	O
+
+Adoptive	O
+transfer	O
+of	O
+LCMV	B-SPEC
+-	O
+specific	O
+T	B-ANAT
+cells	I-ANAT
+revealed	O
+that	O
+both	O
+CD4	B-PRGE
+(+)	O
+and	O
+CD8	B-PRGE
+(+)	O
+T	B-ANAT
+cells	I-ANAT
+required	O
+IFN	B-PRGE
+-	I-PRGE
+I	I-PRGE
+for	O
+expansion	O
+,	O
+but	O
+only	O
+CD4	B-PRGE
+(+)	O
+T	B-ANAT
+cells	I-ANAT
+required	O
+the	O
+presence	O
+of	O
+pDCs	O
+.	O
+
+Thus	O
+pDCs	O
+provide	O
+an	O
+essential	O
+link	O
+between	O
+innate	O
+and	O
+adaptive	O
+immunity	B-PROC
+to	O
+chronic	O
+viral	B-DISO
+infection	I-DISO
+,	O
+likely	O
+through	O
+the	O
+secretion	B-PROC
+of	O
+IFN	B-PRGE
+-	I-PRGE
+I	I-PRGE
+and	O
+other	O
+cytokines	O
+.	O
+
+Considering	O
+the	O
+widespread	O
+nature	O
+of	O
+CCoV	O
+infections	B-DISO
+among	O
+dog	B-SPEC
+populations	O
+,	O
+several	O
+studies	O
+have	O
+been	O
+carried	O
+out	O
+,	O
+focusing	O
+upon	O
+the	O
+epidemiological	O
+relevance	O
+of	O
+these	O
+viruses	B-SPEC
+and	O
+underlining	O
+the	O
+need	O
+for	O
+further	O
+investigation	O
+into	O
+the	O
+biology	O
+of	O
+CCoVs	O
+and	O
+into	O
+the	O
+pathogenetic	O
+role	O
+of	O
+the	O
+infections	B-DISO
+.	O
+
+ABSTRACT	O
+:	O
+Recruitment	B-DISO
+maneuvers	O
+and	O
+the	O
+application	O
+of	O
+high	O
+levels	O
+of	O
+positive	O
+end	B-PROC
+-	I-PROC
+expiratory	I-PROC
+pressure	O
+combined	O
+with	O
+lung	B-ANAT
+protective	O
+mechanical	O
+ventilation	O
+strategies	O
+have	O
+been	O
+proposed	O
+to	O
+improve	O
+pulmonary	B-PROC
+function	I-PROC
+in	O
+patients	O
+with	O
+severe	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+.	O
+
+However	O
+,	O
+the	O
+optimal	O
+way	O
+to	O
+achieve	O
+and	O
+maintain	O
+alveolar	B-ANAT
+recruitment	B-DISO
+is	O
+still	O
+under	O
+debate	O
+.	O
+
+ECMO	O
+could	O
+improve	O
+gas	B-ENZY
+exchange	O
+,	O
+oxygenation	B-PROC
+and	O
+partially	O
+replace	O
+pulmonary	B-PROC
+function	I-PROC
+.	O
+
+Patients	O
+with	O
+ARDS	B-DISO
+should	O
+be	O
+treated	O
+with	O
+ECMO	O
+early	O
+if	O
+artificial	O
+ventilation	O
+treatment	O
+was	O
+unresponsive	O
+.	O
+
+TITLE	O
+:	O
+[	O
+Use	O
+of	O
+extracorporeal	O
+membrane	B-COMP
+oxygenation	B-PROC
+in	O
+adults	O
+with	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+:	O
+a	O
+meta	B-SPEC
+-	O
+analysis	O
+].	O
+
+There	O
+is	O
+no	O
+evidence	O
+to	O
+prove	O
+that	O
+ECMO	O
+is	O
+beneficial	O
+in	O
+adult	O
+patients	O
+with	O
+ARDS	B-DISO
+,	O
+therefore	O
+further	O
+investigation	O
+with	O
+a	O
+large	O
+sample	O
+of	O
+high	O
+quality	O
+RCT	O
+is	O
+warranted	O
+.	O
+
+CONCLUSIONS	O
+:	O
+There	O
+is	O
+no	O
+evidence	O
+to	O
+prove	O
+that	O
+ECMO	O
+is	O
+beneficial	O
+in	O
+adult	O
+patients	O
+with	O
+ARDS	B-DISO
+,	O
+therefore	O
+further	O
+investigation	O
+with	O
+a	O
+large	O
+sample	O
+of	O
+high	O
+quality	O
+RCT	O
+is	O
+warranted	O
+.	O
+
+The	O
+setting	O
+of	O
+ventilator	O
+support	O
+were	O
+significantly	O
+decreased	O
+,	O
+and	O
+arterial	B-PROC
+oxygen	B-CHED
+saturation	I-PROC
+[	O
+SaO	O
+(	O
+2	O
+)],	O
+arterial	B-ANAT
+blood	I-ANAT
+carbon	B-CHED
+dioxide	I-CHED
+partial	O
+pressure	O
+[	O
+PaCO	O
+(	O
+2	O
+)]	O
+and	O
+blood	B-ANAT
+pH	O
+value	O
+were	O
+improved	O
+significantly	O
+after	O
+the	O
+V	O
+-	O
+V	O
+mode	O
+ECMO	O
+.	O
+
+TITLE	O
+:	O
+[	O
+A	O
+study	O
+of	O
+the	O
+clinical	O
+features	O
+and	O
+the	O
+effect	O
+of	O
+therapy	O
+on	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+patients	O
+as	O
+a	O
+result	O
+of	O
+severe	O
+triphosgene	O
+poisoning	O
+].	O
+
+We	O
+assessed	O
+the	O
+characteristics	O
+and	O
+predictors	O
+of	O
+outcome	O
+of	O
+patients	O
+with	O
+CAP	B-DISO
+and	O
+severe	O
+ARF	B-DISO
+treated	O
+with	O
+NIV	O
+.	O
+
+If	O
+predictors	O
+for	O
+NIV	O
+failure	O
+are	O
+present	O
+,	O
+avoiding	O
+delayed	O
+intubation	O
+of	O
+patients	O
+with	O
+""""	O
+de	O
+novo	O
+""""	O
+ARF	B-DISO
+would	O
+potentially	O
+minimise	O
+mortality	O
+.	O
+
+ABSTRACT	O
+:	O
+A	O
+male	O
+ferret	B-SPEC
+,	O
+which	O
+was	O
+purchased	O
+from	O
+abroad	O
+at	O
+9	O
+months	O
+of	O
+age	O
+,	O
+had	O
+shown	O
+significant	O
+weight	O
+loss	O
+starting	O
+at	O
+13	O
+months	O
+of	O
+age	O
+.	O
+
+At	O
+necropsy	O
+,	O
+a	O
+white	O
+,	O
+quail	O
+egg	B-ANAT
+-	O
+sized	O
+mass	O
+was	O
+found	O
+in	O
+the	O
+mesentery	B-ANAT
+.	O
+
+Electron	O
+microscopically	O
+,	O
+the	O
+cytoplasm	B-COMP
+of	O
+the	O
+macrophages	B-ANAT
+contained	O
+viral	B-ANAT
+particles	I-ANAT
+,	O
+which	O
+were	O
+identified	O
+as	O
+coronavirus	B-SPEC
+.	O
+
+The	O
+histopathological	O
+features	O
+in	O
+this	O
+ferret	B-SPEC
+were	O
+similar	O
+to	O
+those	O
+in	O
+cats	B-SPEC
+with	O
+feline	B-DISO
+infectious	I-DISO
+peritonitis	I-DISO
+(	O
+FIP	B-DISO
+).	O
+
+This	O
+was	O
+the	O
+first	O
+case	O
+in	O
+ferrets	B-SPEC
+in	O
+Japan	O
+.	O
+
+These	O
+patients	O
+were	O
+hospitalized	O
+patients	O
+in	O
+department	O
+of	O
+internal	O
+medicine	B-CHED
+or	O
+outpatients	O
+in	O
+emergency	B-DISO
+department	O
+in	O
+Beijing	O
+Children	O
+'	O
+s	O
+Hospital	O
+.	O
+
+The	O
+top	O
+three	O
+viruses	B-SPEC
+were	O
+RSV	B-SPEC
+,	O
+HRV	O
+and	O
+PIV	O
+;	O
+and	O
+the	O
+positive	O
+rates	O
+were	O
+50	O
+.	O
+9	O
+%,	O
+36	O
+.	O
+2	O
+%	O
+and	O
+12	O
+.	O
+0	O
+%	O
+respectively	O
+in	O
+group	O
+of	O
+<	O
+1	O
+year	O
+old	O
+.	O
+
+ABSTRACT	O
+:	O
+The	O
+study	O
+evaluated	O
+which	O
+viruses	B-SPEC
+can	O
+be	O
+detected	O
+in	O
+dogs	B-SPEC
+with	O
+acute	O
+hemorrhagic	B-DISO
+diarrhea	I-DISO
+and	O
+compared	O
+signalment	O
+,	O
+clinical	O
+signs	O
+,	O
+and	O
+laboratory	O
+abnormalities	O
+among	O
+groups	O
+of	O
+dogs	B-SPEC
+infected	O
+with	O
+different	O
+viruses	B-SPEC
+and	O
+those	O
+that	O
+tested	O
+virus	B-SPEC
+-	O
+negative	O
+.	O
+
+TITLE	O
+:	O
+[	O
+Synthesis	B-PROC
+of	O
+A	O
+-	O
+secomethylenamino	O
+-	O
+and	O
+substituted	O
+amidoximotriterpenoids	O
+].	O
+
+ABSTRACT	O
+:	O
+Development	B-PROC
+of	O
+the	O
+functionalization	O
+of	O
+triterpenoids	B-CHED
+to	O
+A	O
+-	O
+secoamidoximes	O
+,	O
+A	O
+-	O
+secomethylenamines	O
+and	O
+branched	B-ANAT
+3	O
+-(	O
+3	O
+-	O
+aminopropylamino	O
+)-	O
+3	O
+-(	O
+3	O
+-	O
+aminopropoxy	O
+)	O
+amidoximes	B-CHED
+is	O
+illustrated	O
+by	O
+the	O
+betulonic	O
+acid	O
+ketoxime	B-CHED
+.	O
+
+TITLE	O
+:	O
+[	O
+Extracorporeal	O
+membrane	B-COMP
+oxygenation	B-PROC
+for	O
+severe	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+caused	O
+by	O
+novel	O
+2009	O
+influenza	O
+A	O
+(	O
+H1N1	O
+)	O
+virus	B-SPEC
+].	O
+
+Eight	O
+were	O
+complicated	O
+with	O
+pulmonary	B-ANAT
+barotraumas	O
+(	O
+6	O
+of	O
+pneumothorax	B-DISO
+).	O
+
+One	O
+patient	O
+stayed	O
+in	O
+ICU	O
+and	O
+2	O
+died	B-PROC
+in	O
+ICU	O
+.	O
+
+TITLE	O
+:	O
+Diagnostics	O
+of	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+-	O
+associated	O
+coronavirus	B-SPEC
+(	O
+SARS	B-DISO
+-	O
+CoV	O
+)	O
+nucleocapsid	B-ANAT
+antigen	B-CHED
+using	O
+chicken	B-PRGE
+immunoglobulin	B-PROC
+Y	I-PRGE
+.	O
+ABSTRACT	O
+:	O
+
+Furthermore	O
+,	O
+the	O
+immunoassay	O
+of	O
+SARS	B-PRGE
+-	I-PRGE
+CoV	I-PRGE
+NP	I-PRGE
+antigen	B-CHED
+developed	O
+could	O
+be	O
+an	O
+effective	O
+and	O
+sensitive	O
+method	O
+of	O
+diagnosing	O
+SARS	B-DISO
+-	O
+suspected	O
+individuals	O
+during	O
+a	O
+future	O
+SARS	B-DISO
+-	O
+CoV	O
+outbreak	O
+.	O
+
+Phylogenetic	O
+analysis	O
+of	O
+VP3	O
+/	O
+VP1	B-PRGE
+region	O
+was	O
+performed	O
+on	O
+the	O
+positive	O
+samples	O
+.	O
+
+pH	O
+,	O
+arterial	B-ANAT
+partial	O
+pressure	O
+of	O
+O2	O
+(	O
+PaO2	O
+),	O
+PaO2	O
+/	O
+inspired	B-PROC
+O2	O
+fraction	O
+(	O
+FiO2	O
+)	O
+and	O
+lung	B-PROC
+compliance	I-PROC
+decreased	O
+,	O
+while	O
+PaCO2	O
+and	O
+airway	B-ANAT
+pressure	O
+increased	O
+in	O
+comparison	O
+with	O
+baseline	O
+(	O
+P	O
+<	O
+0	O
+.	O
+05	O
+).	O
+
+However	O
+,	O
+the	O
+mechanisms	O
+underlying	O
+TGEV	B-SPEC
+-	O
+induced	O
+apoptosis	B-PATH
+are	O
+still	O
+unclear	O
+.	O
+
+ECMO	O
+was	O
+initiated	O
+when	O
+ARDS	B-DISO
+proved	O
+refractory	O
+to	O
+standard	O
+treatment	O
+.	O
+
+ABSTRACT	O
+:	O
+When	O
+pandemics	O
+lead	O
+to	O
+a	O
+higher	O
+workload	O
+in	O
+the	O
+healthcare	O
+sector	O
+,	O
+the	O
+attitude	O
+of	O
+healthcare	O
+staff	O
+and	O
+,	O
+more	O
+importantly	O
+,	O
+the	O
+ability	O
+to	O
+predict	O
+the	O
+rate	O
+of	O
+absence	O
+due	O
+to	O
+sickness	O
+are	O
+crucial	O
+factors	O
+in	O
+emergency	B-DISO
+preparedness	O
+and	O
+resource	O
+allocation	O
+.	O
+
+Also	O
+,	O
+the	O
+linear	O
+relation	O
+between	O
+the	O
+tested	O
+subject	O
+'	O
+s	O
+height	O
+and	O
+their	O
+coughing	B-DISO
+and	O
+speaking	O
+velocity	O
+was	O
+shown	O
+in	O
+this	O
+study	O
+.	O
+
+Using	O
+reverse	O
+genetic	O
+mutagenesis	B-PROC
+of	O
+the	O
+CoV	O
+murine	B-DISO
+hepatitis	I-DISO
+virus	B-SPEC
+(	O
+MHV	B-SPEC
+)	O
+nsp5	O
+,	O
+we	O
+identified	O
+a	O
+new	O
+temperature	O
+-	O
+sensitive	O
+(	O
+ts	O
+)	O
+mutation	O
+in	O
+D2	O
+of	O
+nsp5	B-PRGE
+(	O
+Ser133Ala	O
+)	O
+and	O
+confirmed	O
+a	O
+ts	O
+residue	O
+in	O
+D3	O
+(	O
+Phe219Leu	O
+).	O
+
+Surprisingly	O
+,	O
+the	O
+30	O
+-	O
+nt	O
+inter	O
+-	O
+stem	B-ANAT
+-	O
+loop	O
+domain	O
+in	O
+the	O
+MHV	B-SPEC
+genome	O
+can	O
+be	O
+deleted	O
+and	O
+viral	O
+progeny	O
+,	O
+although	O
+debilitated	O
+,	O
+are	O
+still	O
+produced	O
+.	O
+
+Here	O
+,	O
+an	O
+African	B-SPEC
+green	I-SPEC
+monkey	I-SPEC
+(	O
+AGM	O
+)	O
+model	O
+was	O
+used	O
+to	O
+elucidate	O
+immune	O
+mechanisms	O
+that	O
+facilitate	O
+viral	O
+clearance	O
+but	O
+may	O
+also	O
+contribute	O
+to	O
+persistent	O
+lung	B-DISO
+inflammation	I-DISO
+following	O
+SARS	B-DISO
+-	I-DISO
+CoV	I-DISO
+infection	I-DISO
+.	O
+
+During	O
+primary	B-DISO
+infection	I-DISO
+,	O
+SARS	B-DISO
+-	O
+CoV	O
+replicated	O
+in	O
+the	O
+AGM	O
+lung	B-ANAT
+for	O
+up	O
+to	O
+10	O
+days	O
+.	O
+
+Among	O
+these	O
+reads	O
+,	O
+13	O
+,	O
+541	O
+(	O
+0	O
+.	O
+15	O
+%)	O
+had	O
+similarity	O
+to	O
+phage	O
+sequences	O
+and	O
+9	O
+,	O
+170	O
+(	O
+0	O
+.	O
+1	O
+%)	O
+had	O
+similarity	O
+to	O
+eukaryotic	O
+virus	B-SPEC
+sequences	O
+.	O
+
+Some	O
+of	O
+these	O
+also	O
+had	O
+strong	O
+antibacterial	O
+and	O
+antifungal	B-CHED
+activity	O
+.	O
+
+The	O
+peptides	B-CHED
+strongly	O
+increased	O
+neutrophil	B-ANAT
+and	O
+macrophage	B-ANAT
+uptake	O
+of	O
+IAV	O
+,	O
+while	O
+inhibiting	O
+monocyte	B-ANAT
+cytokine	O
+generation	O
+.	O
+
+At	O
+onset	O
+,	O
+sensory	O
+symptoms	O
+(	O
+pain	O
+and	O
+paresthesia	B-DISO
+)	O
+were	O
+noted	O
+in	O
+59	O
+%	O
+of	O
+the	O
+cases	O
+and	O
+limb	B-DISO
+weakness	I-DISO
+in	O
+77	O
+%.	O
+
+NIV	O
+may	O
+reduce	O
+the	O
+need	O
+for	O
+endotracheal	O
+mechanical	O
+ventilation	O
+and	O
+improve	O
+clinical	O
+outcome	O
+in	O
+patients	O
+with	O
+acute	B-DISO
+respiratory	I-DISO
+failure	I-DISO
+after	O
+lung	B-ANAT
+resection	O
+,	O
+avoiding	O
+complications	O
+related	O
+to	O
+intubation	O
+.	O
+
+ABSTRACT	O
+:	O
+Recent	O
+research	O
+has	O
+shown	O
+that	O
+Coronavirus	B-SPEC
+(	O
+CoV	O
+)	O
+replication	O
+depends	O
+on	O
+active	O
+immunophilin	B-PROC
+pathways	B-PROC
+.	O
+
+As	O
+shown	O
+by	O
+plaque	B-DISO
+titration	O
+,	O
+qPCR	O
+,	O
+Luciferase	B-ENZY
+-	O
+and	O
+green	B-PRGE
+fluorescent	I-PRGE
+protein	I-PRGE
+(	O
+GFP	O
+)	O
+reporter	O
+gene	B-PROC
+expression	I-PROC
+,	O
+replication	O
+was	O
+diminished	O
+by	O
+several	O
+orders	O
+of	O
+magnitude	O
+.	O
+
+This	O
+technology	O
+was	O
+chosen	O
+since	O
+PriProET	O
+is	O
+very	O
+robust	O
+to	O
+tolerate	O
+the	O
+nucleotide	B-CHED
+substitutions	O
+in	O
+the	O
+target	O
+area	O
+.	O
+
+Purified	B-PRGE
+3CL	I-PRGE
+(	I-PRGE
+pro	I-PRGE
+)	I-PRGE
+was	O
+used	O
+for	O
+inhibition	B-PROC
+and	O
+kinetic	O
+assays	O
+with	O
+seven	O
+flavonoid	B-CHED
+compounds	O
+.	O
+
+Bronchial	B-ANAT
+lavage	I-ANAT
+on	O
+day	O
+10	O
+showed	O
+blood	B-ANAT
+-	O
+tinged	O
+fluid	O
+and	O
+hemosiderin	O
+-	O
+laden	O
+macrophages	B-ANAT
+,	O
+but	O
+no	O
+bacteria	B-SPEC
+or	O
+fungi	B-SPEC
+.	O
+
+We	O
+believed	O
+that	O
+this	O
+clinical	O
+exacerbation	O
+might	O
+have	O
+occurred	O
+due	O
+to	O
+the	O
+re	O
+-	O
+exacerbation	O
+of	O
+pandemic	O
+influenza	B-PATH
+A	I-PATH
+(	O
+H1N1	O
+)	O
+pneumonia	B-DISO
+due	O
+to	O
+the	O
+cessation	O
+of	O
+corticosteroids	B-CHED
+.	O
+
+Currently	O
+,	O
+the	O
+use	O
+of	O
+corticosteroid	B-CHED
+therapy	O
+for	O
+severe	O
+pandemic	O
+influenza	B-PATH
+A	I-PATH
+(	O
+H1N1	O
+)	O
+pneumonia	B-DISO
+is	O
+controversial	O
+,	O
+but	O
+even	O
+the	O
+late	O
+administration	O
+of	O
+corticosteroid	B-CHED
+therapy	O
+may	O
+be	O
+effective	O
+.	O
+
+However	O
+,	O
+this	O
+case	O
+also	O
+suggests	O
+that	O
+the	O
+early	O
+administration	O
+of	O
+corticosteroid	B-CHED
+therapy	O
+as	O
+immunomodulation	B-PROC
+might	O
+be	O
+effective	O
+in	O
+selected	O
+cases	O
+,	O
+and	O
+that	O
+cessation	O
+of	O
+such	O
+therapy	O
+during	O
+the	O
+early	O
+phase	O
+of	O
+ARDS	B-DISO
+may	O
+cause	O
+exacerbation	O
+of	O
+clinical	O
+symptoms	O
+.	O
+
+In	O
+rare	O
+cases	O
+,	O
+some	O
+patients	O
+develop	O
+influenza	B-DISO
+-	O
+associated	O
+multiple	B-DISO
+organ	I-DISO
+failures	I-DISO
+,	O
+requiring	O
+rescue	O
+therapies	O
+such	O
+as	O
+extracorporeal	O
+membrane	B-COMP
+oxygenation	B-PROC
+(	O
+ECMO	O
+)	O
+or	O
+continuous	O
+venovenous	O
+hemodiafiltration	O
+(	O
+CVVHDF	O
+).	O
+
+OC	O
+,	O
+the	O
+active	O
+form	O
+of	O
+oseltamivir	O
+,	O
+was	O
+quantified	O
+in	O
+plasma	B-ANAT
+,	O
+and	O
+main	O
+pharmacokinetic	O
+parameters	O
+were	O
+determined	O
+.	O
+
+PEDVs	O
+were	O
+detected	O
+in	O
+samples	O
+(	O
+feces	B-ANAT
+or	O
+small	B-ANAT
+intestines	I-ANAT
+)	O
+from	O
+most	O
+farms	O
+.	O
+
+The	O
+induction	O
+of	O
+antigen	B-CHED
+-	O
+specific	O
+mucosal	B-ANAT
+and	O
+systemic	O
+immune	B-PROC
+response	I-PROC
+at	O
+the	O
+site	O
+of	O
+virus	B-SPEC
+entry	O
+is	O
+a	O
+major	O
+challenge	O
+for	O
+vaccine	O
+design	O
+.	O
+
+Here	O
+,	O
+we	O
+designed	O
+a	O
+strategy	O
+for	O
+noninvasive	O
+receptor	O
+mediated	O
+gene	B-PROC
+delivery	I-PROC
+to	O
+nasal	B-ANAT
+resident	O
+DCs	B-DISO
+.	O
+
+Our	O
+results	O
+suggest	O
+that	O
+targeted	B-PROC
+pDNA	O
+delivery	O
+through	O
+a	O
+noninvasive	O
+intranasal	O
+route	O
+can	O
+be	O
+a	O
+strategy	O
+for	O
+designing	O
+low	O
+-	O
+dose	O
+vaccines	O
+.	O
+
+TITLE	O
+:	O
+Trends	O
+in	O
+notifiable	O
+infectious	B-DISO
+diseases	I-DISO
+in	O
+China	O
+:	O
+implications	O
+for	O
+surveillance	O
+and	O
+population	O
+health	O
+policy	O
+.	O
+
+Zoonotic	O
+infections	B-DISO
+,	O
+such	O
+as	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+(	O
+SARS	B-DISO
+),	O
+rabies	B-DISO
+and	O
+influenza	B-DISO
+,	O
+pose	O
+constant	O
+threats	O
+to	O
+Chinese	O
+residents	O
+and	O
+remain	O
+the	O
+most	O
+deadly	O
+disease	O
+type	O
+among	O
+the	O
+infected	O
+individuals	O
+.	O
+
+TITLE	O
+:	O
+[	O
+Experience	O
+with	O
+empirical	O
+treatment	O
+of	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+due	O
+to	O
+coronavirus	B-SPEC
+,	O
+genotype	O
+IV	O
+].	O
+
+In	O
+a	O
+screen	O
+based	O
+on	O
+a	O
+yeast	B-SPEC
+three	O
+-	O
+hybrid	O
+system	O
+using	O
+the	O
+5	O
+'-	O
+untranslated	O
+region	O
+(	O
+5	O
+'-	O
+UTR	O
+)	O
+of	O
+SARS	B-DISO
+coronavirus	B-SPEC
+(	O
+SARS	B-DISO
+-	O
+CoV	O
+)	O
+RNA	O
+as	O
+bait	O
+against	O
+a	O
+human	B-SPEC
+cDNA	O
+library	O
+derived	O
+from	O
+HeLa	B-ANAT
+cells	I-ANAT
+,	O
+we	O
+found	O
+a	O
+positive	O
+candidate	O
+cellular	B-COMP
+protein	B-CHED
+,	O
+zinc	B-PRGE
+finger	B-ANAT
+CCHC	I-PRGE
+-	I-PRGE
+type	I-PRGE
+and	I-PRGE
+RNA	I-PRGE
+-	I-PRGE
+binding	B-FUNC
+motif	I-PRGE
+1	I-PRGE
+(	O
+MADP1	B-PRGE
+),	O
+to	O
+be	O
+able	O
+to	O
+interact	O
+with	O
+this	O
+region	O
+of	O
+the	O
+SARS	B-DISO
+-	O
+CoV	O
+genome	O
+.	O
+
+The	O
+primers	O
+were	O
+designed	O
+to	O
+target	O
+the	O
+highly	O
+conserved	O
+fragment	O
+of	O
+BCoV	B-PRGE
+-	I-PRGE
+1	I-PRGE
+nucleocapsid	I-PRGE
+gene	I-PRGE
+.	O
+
+She	O
+was	O
+successfully	O
+treated	O
+with	O
+extraordinary	O
+life	O
+support	O
+measures	O
+,	O
+which	O
+included	O
+extracorporeal	O
+membrane	B-COMP
+oxygenation	B-PROC
+,	O
+double	O
+lumen	B-ANAT
+lung	B-ANAT
+ventilation	O
+for	O
+management	O
+of	O
+hemoptysis	B-DISO
+,	O
+and	O
+lung	B-ANAT
+assist	O
+membrane	B-COMP
+ventilation	O
+.	O
+
+In	O
+each	O
+of	O
+these	O
+patients	O
+,	O
+a	O
+PD	O
+catheter	O
+was	O
+placed	O
+for	O
+severe	O
+abdominal	O
+distension	B-DISO
+and	O
+proven	O
+/	O
+suspected	O
+ACS	B-FUNC
+.	O
+
+There	O
+was	O
+dramatic	O
+improvement	O
+in	O
+venous	B-ANAT
+return	O
+after	O
+drainage	B-ANAT
+of	O
+peritoneal	B-ANAT
+fluid	I-ANAT
+.	O
+
+ABSTRACT	O
+:	O
+A	O
+decade	O
+of	O
+high	O
+-	O
+throughput	O
+screenings	O
+for	O
+intraviral	O
+and	O
+virus	O
+-	O
+host	B-COMP
+protein	B-CHED
+-	O
+protein	B-CHED
+interactions	O
+led	O
+to	O
+the	O
+accumulation	O
+of	O
+data	O
+and	O
+to	O
+the	O
+development	B-PROC
+of	O
+theories	O
+on	O
+laws	O
+governing	O
+interactome	O
+organization	O
+for	O
+many	O
+viruses	B-SPEC
+.	O
+
+During	O
+a	O
+one	O
+-	O
+year	O
+period	O
+throat	B-ANAT
+swab	I-ANAT
+samples	O
+were	O
+collected	O
+from	O
+370	O
+previously	O
+healthy	O
+children	O
+,	O
+aged	O
+14	O
+days	O
+to	O
+13	O
+years	O
+,	O
+admitted	O
+to	O
+two	O
+different	O
+paediatric	O
+wards	O
+because	O
+of	O
+respiratory	B-DISO
+tract	I-DISO
+infection	I-DISO
+.	O
+
+ABSTRACT	O
+:	O
+Mycoplasma	B-SPEC
+pneumoniae	I-SPEC
+(	O
+MP	O
+),	O
+the	O
+smallest	O
+self	O
+-	O
+replicating	O
+biological	O
+system	O
+,	O
+is	O
+a	O
+common	O
+cause	O
+of	O
+upper	O
+and	O
+lower	O
+respiratory	O
+tract	O
+infections	O
+,	O
+leading	O
+to	O
+a	O
+wide	O
+range	O
+of	O
+pulmonary	B-ANAT
+and	O
+extra	O
+-	O
+pulmonary	B-ANAT
+manifestations	O
+.	O
+
+TITLE	O
+:	O
+Acute	B-DISO
+renal	I-DISO
+failure	I-DISO
+in	O
+falciparum	B-DISO
+malaria	I-DISO
+:	O
+clinical	O
+characteristics	O
+,	O
+demonstration	O
+of	O
+oxidative	B-DISO
+stress	I-DISO
+,	O
+and	O
+prognostication	O
+.	O
+
+The	O
+average	O
+duration	O
+of	O
+renal	B-DISO
+failure	I-DISO
+was	O
+10	O
+.	O
+53	O
+±	O
+4	O
+.	O
+0	O
+days	O
+.	O
+
+ARDS	B-DISO
+;	O
+Pathophysiology	O
+;	O
+Treatment	O
+.	O
+
+Among	O
+176	O
+pediatric	O
+HSCT	O
+recipients	O
+,	O
+84	O
+with	O
+respiratory	B-DISO
+symptoms	I-DISO
+within	O
+one	O
+yr	O
+after	O
+HSCT	O
+were	O
+tested	O
+by	O
+viral	O
+culture	O
+or	O
+multiplex	O
+PCR	O
+.	O
+
+However	O
+,	O
+one	O
+patient	O
+died	B-PROC
+of	O
+adenovirus	B-DISO
+(	O
+AdV	O
+)	O
+pneumonia	B-DISO
+with	O
+pulmonary	B-DISO
+hemorrhage	I-DISO
+;	O
+the	O
+mortality	O
+rate	O
+of	O
+RV	O
+infection	B-DISO
+within	O
+28	O
+d	O
+after	O
+HSCT	O
+was	O
+0	O
+.	O
+57	O
+%.	O
+
+In	O
+the	O
+present	O
+report	O
+,	O
+we	O
+describe	O
+the	O
+experience	O
+of	O
+a	O
+referral	O
+ECMO	O
+center	O
+using	O
+portable	O
+miniaturized	O
+ECMO	O
+systems	O
+for	O
+H1N1	O
+-	O
+related	O
+severe	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+(	O
+ARDS	B-DISO
+).	O
+
+In	O
+our	O
+experience	O
+,	O
+ECMO	O
+support	O
+was	O
+a	O
+valuable	O
+therapeutic	O
+option	O
+for	O
+H1N1	O
+-	O
+related	O
+severe	O
+ARDS	B-DISO
+.	O
+
+The	O
+use	O
+of	O
+portable	O
+miniaturized	O
+systems	O
+allowed	O
+urgent	O
+rescue	O
+of	O
+patients	O
+from	O
+referring	O
+hospitals	O
+and	O
+safe	O
+interhospital	O
+and	O
+intrahospital	O
+transport	B-PROC
+during	O
+ECMO	O
+support	O
+.	O
+
+RESULTS	O
+:	O
+Ten	O
+adult	O
+patients	O
+with	O
+severe	O
+ARDS	B-DISO
+secondary	O
+to	O
+H1N1	O
+infection	B-DISO
+(	O
+Pao	B-PROC
+(	O
+2	O
+)/	O
+fraction	O
+of	O
+inspired	B-PROC
+oxygen	B-CHED
+,	O
+69	O
+mm	O
+Hg	O
+[	O
+56	O
+-	O
+84	O
+];	O
+Murray	O
+score	O
+,	O
+3	O
+.	O
+5	O
+[	O
+3	O
+.	O
+5	O
+-	O
+3	O
+.	O
+8	O
+])	O
+were	O
+included	O
+,	O
+and	O
+60	O
+%	O
+survived	O
+to	O
+hospital	O
+discharge	B-ANAT
+.	O
+
+Of	O
+the	O
+4	O
+deaths	B-PROC
+,	O
+2	O
+were	O
+caused	O
+by	O
+hemorrhagic	B-DISO
+shock	I-DISO
+;	O
+1	O
+,	O
+by	O
+irreversible	O
+multiple	B-DISO
+organ	I-DISO
+failure	I-DISO
+;	O
+and	O
+1	O
+,	O
+by	O
+refractory	O
+septic	B-DISO
+shock	I-DISO
+.	O
+
+ABSTRACT	O
+:	O
+Acute	O
+respiratory	B-DISO
+tract	I-DISO
+infections	I-DISO
+(	O
+ARTIs	O
+)	O
+represent	O
+a	O
+serious	O
+global	O
+health	O
+burden	O
+.	O
+
+To	O
+date	O
+,	O
+few	O
+reports	O
+have	O
+addressed	O
+the	O
+prevalence	O
+of	O
+respiratory	O
+viruses	B-SPEC
+(	O
+RVs	O
+)	O
+in	O
+adults	O
+with	O
+ARTIs	O
+attending	O
+an	O
+emergency	B-DISO
+department	O
+(	O
+ED	O
+).	O
+
+Therefore	O
+,	O
+the	O
+potential	O
+impact	O
+of	O
+respiratory	O
+virus	B-SPEC
+infections	B-DISO
+on	O
+such	O
+patients	O
+remains	O
+unknown	O
+.	O
+
+To	O
+determine	O
+the	O
+epidemiological	O
+and	O
+clinical	O
+profiles	O
+of	O
+common	O
+and	O
+recently	O
+discovered	O
+respiratory	O
+viruses	B-SPEC
+in	O
+adults	O
+with	O
+ARTIs	O
+attending	O
+an	O
+ED	O
+in	O
+Beijing	O
+,	O
+a	O
+1	O
+-	O
+year	O
+consecutive	O
+study	O
+was	O
+conducted	O
+from	O
+May	O
+,	O
+2010	O
+,	O
+to	O
+April	O
+,	O
+2011	O
+.	O
+
+TITLE	O
+:	O
+Differential	O
+domain	O
+structure	O
+stability	O
+of	O
+the	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+coronavirus	B-SPEC
+papain	O
+-	O
+like	O
+protease	O
+.	O
+
+Here	O
+we	O
+report	O
+the	O
+sensitivity	O
+of	O
+PLpro	O
+to	O
+denaturant	O
+urea	B-CHED
+.	O
+
+A	O
+retrospective	O
+comparison	O
+of	O
+the	O
+signalment	O
+between	O
+cats	B-SPEC
+with	O
+confirmed	O
+FIP	B-DISO
+and	O
+the	O
+general	O
+cat	B-SPEC
+population	O
+was	O
+designed	O
+.	O
+
+Domestic	O
+crossbred	O
+,	O
+Persian	O
+and	O
+Himalayan	O
+cats	B-SPEC
+were	O
+significantly	O
+under	O
+-	O
+represented	O
+in	O
+the	O
+FIP	B-DISO
+cohort	O
+,	O
+while	O
+several	O
+breeds	B-PROC
+were	O
+over	O
+-	O
+represented	O
+,	O
+including	O
+British	O
+Shorthair	O
+,	O
+Devon	O
+Rex	B-FUNC
+and	O
+Abyssinian	O
+.	O
+
+An	O
+overview	O
+of	O
+the	O
+prevalence	O
+and	O
+pathogenesis	B-DISO
+of	O
+the	O
+disorder	O
+,	O
+clinical	O
+diagnosis	O
+,	O
+and	O
+treatment	O
+are	O
+presented	O
+.	O
+
+People	O
+might	O
+not	O
+be	O
+aware	O
+of	O
+the	O
+possibility	O
+of	O
+scrub	B-DISO
+typhus	I-DISO
+because	O
+it	O
+had	O
+been	O
+a	O
+more	O
+common	O
+disease	O
+in	O
+the	O
+past	O
+.	O
+
+ABSTRACT	O
+:	O
+In	O
+2009	O
+,	O
+during	O
+the	O
+influenza	O
+A	O
+(	O
+H1N1	O
+)	O
+epidemic	O
+,	O
+there	O
+were	O
+many	O
+reported	O
+cases	O
+of	O
+pulmonary	B-DISO
+infection	I-DISO
+with	O
+severe	O
+hypoxemia	O
+that	O
+was	O
+refractory	O
+to	O
+the	O
+ventilatory	O
+strategies	O
+and	O
+rescue	O
+therapies	O
+commonly	O
+used	O
+to	O
+treat	O
+patients	O
+with	O
+severe	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+.	O
+
+The	O
+detection	O
+limit	O
+of	O
+the	O
+one	O
+-	O
+step	O
+multiplex	O
+RT	O
+-	O
+PCR	O
+for	O
+GAR	B-FUNC
+,	O
+GCR	O
+,	O
+BCV	B-SPEC
+,	O
+and	O
+BToV	O
+was	O
+10	O
+(	O
+2	O
+),	O
+10	O
+(	O
+0	O
+),	O
+10	O
+(	O
+1	O
+),	O
+and	O
+10	O
+(	O
+2	O
+)	O
+TCID	O
+(	O
+50	O
+)/	O
+ml	O
+,	O
+respectively	O
+,	O
+and	O
+that	O
+for	O
+GBR	O
+was	O
+10	O
+(	O
+6	O
+)	O
+copies	O
+/	O
+ml	O
+.	O
+
+Taken	O
+together	O
+,	O
+our	O
+results	O
+indicate	O
+that	O
+the	O
+one	O
+-	O
+step	O
+multiplex	O
+RT	O
+-	O
+PCR	O
+developed	O
+here	O
+for	O
+the	O
+detection	O
+of	O
+GAR	B-FUNC
+,	O
+GBR	O
+,	O
+GCR	B-PRGE
+,	O
+BCV	B-SPEC
+,	O
+and	O
+BToV	O
+can	O
+be	O
+expected	O
+to	O
+be	O
+a	O
+useful	O
+tool	O
+for	O
+the	O
+rapid	O
+and	O
+cost	O
+-	O
+effective	O
+diagnosis	O
+and	O
+surveillance	O
+of	O
+viral	B-DISO
+diarrhea	I-DISO
+in	O
+adult	O
+cattle	B-SPEC
+.	O
+
+During	O
+viral	B-DISO
+CNS	I-DISO
+infections	I-DISO
+,	O
+however	O
+,	O
+an	O
+indiscriminate	O
+maintenance	O
+of	O
+CNS	B-CHED
+immune	O
+privilege	O
+through	O
+Treg	O
+-	O
+mediated	O
+negative	O
+regulation	B-PROC
+could	O
+prevent	O
+autoimmune	B-DISO
+sequelae	O
+but	O
+impair	O
+the	O
+control	O
+of	O
+viral	B-PROC
+replication	I-PROC
+.	O
+
+However	O
+,	O
+Treg	O
+depletion	O
+led	O
+to	O
+a	O
+more	O
+severe	O
+CNS	O
+inflammation	B-DISO
+associated	O
+with	O
+neuronal	O
+damage	O
+.	O
+
+Loss	O
+of	O
+cardiolipin	B-CHED
+in	O
+the	O
+inner	B-COMP
+mitochondrial	I-COMP
+membrane	I-COMP
+results	O
+in	O
+respiratory	B-COMP
+chain	I-COMP
+dysfunction	O
+.	O
+
+Initial	O
+metabolic	B-PROC
+screening	O
+was	O
+normal	O
+,	O
+except	O
+for	O
+a	O
+cyclic	B-DISO
+neutropenia	I-DISO
+.	O
+
+Respiratory	B-COMP
+chain	I-COMP
+analysis	O
+performed	O
+on	O
+skin	B-ANAT
+fibroblasts	B-ANAT
+revealed	O
+a	O
+decreased	B-DISO
+activity	I-DISO
+of	O
+complexes	O
+I	O
+,	O
+III	O
+and	O
+IV	O
+.	O
+
+This	O
+support	O
+should	O
+alleviate	O
+the	O
+catabolic	B-PROC
+effects	O
+of	O
+the	O
+disease	O
+,	O
+avoid	O
+calorie	B-DISO
+overload	I-DISO
+and	O
+,	O
+in	O
+selected	O
+patients	O
+,	O
+to	O
+use	O
+omega	B-CHED
+-	I-CHED
+3	I-CHED
+fatty	I-CHED
+acid	I-CHED
+and	O
+antioxidant	B-CHED
+-	O
+enriched	O
+diets	O
+,	O
+which	O
+could	O
+improve	O
+outcome	O
+.	O
+
+ABSTRACT	O
+:	O
+Severe	O
+acute	O
+respiratory	O
+syndrome	O
+(	O
+SARS	B-DISO
+)	O
+is	O
+a	O
+zoonotic	O
+disease	O
+caused	O
+by	O
+SARS	B-DISO
+-	O
+related	O
+coronavirus	B-SPEC
+(	O
+SARS	B-DISO
+-	O
+CoV	O
+)	O
+that	O
+emerged	O
+in	O
+2002	O
+to	O
+become	O
+a	O
+global	O
+health	O
+concern	O
+.	O
+
+Even	O
+in	O
+severe	O
+bleeding	B-DISO
+DAH	O
+has	O
+been	O
+shown	O
+to	O
+respond	O
+promptly	O
+without	O
+thromboembolic	O
+complication	B-DISO
+when	O
+FVIIa	O
+was	O
+administered	O
+locally	O
+via	O
+the	O
+air	B-CHED
+side	O
+,	O
+because	O
+the	O
+FVIIa	O
+does	O
+not	O
+penetrate	O
+the	O
+alveolo	O
+-	O
+capillary	B-ANAT
+membrane	B-COMP
+to	O
+the	O
+blood	B-ANAT
+-	O
+side	O
+.	O
+
+The	O
+incidence	O
+of	O
+DAH	O
+(	O
+in	O
+the	O
+US	O
+and	O
+Europe	O
+is	O
+100	O
+,	O
+000	O
+-	O
+150	O
+,	O
+000	O
+,	O
+and	O
+50	O
+,	O
+000	O
+patients	O
+annually	O
+are	O
+at	O
+risk	O
+of	O
+developing	O
+DAH	O
+following	O
+hematopoietic	B-ANAT
+stem	I-ANAT
+cell	I-ANAT
+transplant	B-ANAT
+(	O
+HSCT	O
+)	O
+and	O
+autoimmune	B-DISO
+diseases	I-DISO
+.	O
+
+The	O
+diagnosis	O
+of	O
+DAH	O
+is	O
+simple	O
+,	O
+a	O
+series	O
+of	O
+broncho	B-ANAT
+-	I-ANAT
+alveolar	I-ANAT
+washes	O
+which	O
+become	O
+increasingly	O
+bloody	O
+.	O
+
+Intrapulmonary	O
+administration	O
+of	O
+rFVIIa	O
+is	O
+recommended	O
+as	O
+the	O
+treatment	O
+of	O
+choice	O
+for	O
+DAH	O
+and	O
+blast	B-ANAT
+lung	B-ANAT
+injury	O
+(	O
+BLI	O
+)	O
+because	O
+the	O
+treatment	O
+has	O
+been	O
+shown	O
+to	O
+be	O
+successful	O
+and	O
+uncomplicated	O
+in	O
+spite	O
+of	O
+the	O
+fact	O
+that	O
+only	O
+a	O
+small	O
+series	O
+of	O
+DAH	O
+has	O
+been	O
+documented	O
+.	O
+
+Levels	O
+of	O
+MMP	B-PRGE
+-	I-PRGE
+2	I-PRGE
+and	O
+MMP	B-PROC
+-	I-PROC
+9	I-PROC
+activity	I-PROC
+,	O
+T1	O
+-	O
+α	O
+and	O
+thrombomodulin	B-PRGE
+were	O
+also	O
+diminished	O
+in	O
+the	O
+DOX	O
+-	O
+treated	O
+group	O
+.	O
+
+These	O
+findings	O
+were	O
+corroborated	O
+by	O
+histopathologic	O
+analyses	O
+,	O
+which	O
+demonstrated	O
+significant	O
+reduction	O
+in	O
+lung	B-ANAT
+damage	O
+.	O
+
+In	O
+order	B-SPEC
+to	O
+expand	O
+the	O
+knowledge	O
+of	O
+the	O
+molecular	O
+features	O
+of	O
+these	O
+viruses	B-SPEC
+,	O
+we	O
+have	O
+sequenced	O
+and	O
+characterized	O
+the	O
+complete	O
+genome	O
+of	O
+European	O
+QX	O
+-	O
+like	O
+IBV	B-SPEC
+strain	O
+CK	O
+/	O
+SWE	O
+/	O
+0658946	O
+/	O
+10	O
+,	O
+which	O
+was	O
+isolated	O
+in	O
+2010	O
+in	O
+Sweden	O
+.	O
+
+TITLE	O
+:	O
+Clinical	O
+experience	O
+of	O
+extracorporeal	O
+membrane	B-COMP
+oxygenation	B-PROC
+for	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+associated	O
+with	O
+pneumonia	B-DISO
+in	O
+children	O
+.	O
+
+Application	O
+of	O
+ECMO	O
+in	O
+pediatric	O
+patients	O
+with	O
+severe	O
+ARDS	B-DISO
+seems	O
+effective	O
+in	O
+improving	O
+survival	O
+,	O
+even	O
+under	O
+the	O
+conditions	O
+of	O
+pneumonia	B-DISO
+with	O
+septic	B-DISO
+shock	I-DISO
+.	O
+
+CONCLUSIONS	O
+:	O
+Application	O
+of	O
+ECMO	O
+in	O
+pediatric	O
+patients	O
+with	O
+severe	O
+ARDS	B-DISO
+seems	O
+effective	O
+in	O
+improving	O
+survival	O
+,	O
+even	O
+under	O
+the	O
+conditions	O
+of	O
+pneumonia	B-DISO
+with	O
+septic	B-DISO
+shock	I-DISO
+.	O
+
+TITLE	O
+:	O
+Replication	O
+of	O
+murine	B-SPEC
+coronavirus	I-SPEC
+requires	O
+multiple	O
+cysteines	O
+in	O
+the	O
+endodomain	O
+of	O
+spike	O
+protein	B-CHED
+.	O
+
+ABSTRACT	O
+:	O
+To	O
+determine	O
+the	O
+presence	O
+of	O
+viral	O
+pathogens	O
+in	O
+natural	O
+areas	O
+a	O
+survey	O
+was	O
+conducted	O
+on	O
+an	O
+opportunistic	O
+sample	O
+of	O
+fifty	O
+eight	O
+wild	O
+(	O
+Felis	O
+silvestris	O
+silvestris	O
+)	O
+and	O
+feral	O
+cats	B-SPEC
+(	O
+F	O
+.	O
+s	B-SPEC
+.	I-SPEC
+catus	I-SPEC
+).	O
+
+TITLE	O
+:	O
+Acute	O
+lung	B-ANAT
+inflammatory	B-DISO
+response	I-DISO
+and	O
+injury	O
+after	O
+hemorrhagic	B-DISO
+shock	I-DISO
+are	O
+more	O
+severe	O
+in	O
+postpartum	O
+rabbits	O
+.	O
+
+ABSTRACT	O
+:	O
+The	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+may	O
+complicate	O
+postpartum	O
+hemorrhagic	B-DISO
+shock	I-DISO
+and	O
+resuscitation	O
+,	O
+but	O
+its	O
+mechanisms	O
+are	O
+not	O
+yet	O
+well	O
+defined	O
+.	O
+
+We	O
+studied	O
+the	O
+lung	B-ANAT
+inflammatory	B-DISO
+response	I-DISO
+to	O
+postpartum	O
+hemorrhagic	B-DISO
+shock	I-DISO
+and	O
+resuscitation	O
+in	O
+a	O
+rabbit	B-SPEC
+model	O
+and	O
+the	O
+role	O
+of	O
+the	O
+nuclear	O
+factor	O
+-	O
+κB	O
+pathway	B-PROC
+.	O
+
+TITLE	O
+:	O
+Is	O
+benign	B-DISO
+tertian	I-DISO
+malaria	I-DISO
+actually	O
+benign	O
+?	O
+
+The	O
+availability	O
+of	O
+large	O
+-	O
+scale	O
+genomic	O
+datasets	O
+focused	O
+on	O
+host	B-COMP
+-	O
+pathogen	O
+interactions	O
+can	O
+be	O
+used	O
+to	O
+discover	O
+novel	O
+drug	O
+targets	O
+as	O
+well	O
+as	O
+potential	O
+opportunities	O
+for	O
+drug	O
+repositioning	O
+.	O
+
+In	O
+this	O
+study	O
+,	O
+we	O
+performed	O
+a	O
+large	O
+-	O
+scale	O
+analysis	O
+of	O
+microarray	O
+datasets	O
+involving	O
+host	B-PROC
+response	I-PROC
+to	O
+infections	B-DISO
+by	O
+influenza	B-SPEC
+A	I-SPEC
+virus	I-SPEC
+,	O
+respiratory	B-SPEC
+syncytial	I-SPEC
+virus	I-SPEC
+,	O
+rhinovirus	B-SPEC
+,	O
+SARS	B-DISO
+-	O
+coronavirus	B-SPEC
+,	O
+metapneumonia	O
+virus	B-SPEC
+,	O
+coxsackievirus	B-SPEC
+and	O
+cytomegalovirus	B-SPEC
+.	O
+
+TITLE	O
+:	O
+[	O
+KCTD9	B-PRGE
+,	O
+a	O
+novel	O
+potassium	B-CHED
+channel	O
+related	O
+gene	O
+,	O
+was	O
+highly	O
+expressed	B-PROC
+in	O
+hepatic	B-ANAT
+NK	B-ANAT
+cells	I-ANAT
+and	O
+T	O
+cells	O
+of	O
+fulminant	B-DISO
+hepatitis	I-DISO
+mice	B-SPEC
+induced	O
+by	O
+MHV	B-SPEC
+-	O
+3	O
+].	O
+
+75	O
+C3H	O
+/	O
+HeJ	O
+female	O
+mice	B-SPEC
+were	O
+done	O
+into	O
+two	O
+groups	O
+,	O
+39	O
+for	O
+model	O
+group	O
+of	O
+chronic	B-DISO
+hepatitis	I-DISO
+induced	O
+by	O
+MHV3	O
+,	O
+36	O
+for	O
+control	O
+.	O
+
+Basal	O
+expression	B-PROC
+was	O
+also	O
+investigated	O
+and	O
+showed	O
+constitutive	O
+expression	B-PROC
+of	O
+KCTD9	B-PRGE
+in	O
+brain	B-ANAT
+,	O
+thymus	B-SPEC
+and	O
+other	O
+organs	B-ANAT
+in	O
+BALB	O
+/	O
+cJ	O
+mice	B-SPEC
+.	O
+
+RESULTS	O
+:	O
+Increased	O
+expressions	O
+of	O
+KCTD9	B-PRGE
+mRNA	I-PRGE
+was	O
+observed	O
+in	O
+livers	B-ANAT
+of	O
+both	O
+model	O
+mice	B-SPEC
+of	O
+fulminant	O
+viral	B-DISO
+hepatitis	I-DISO
+and	O
+chronic	B-DISO
+hepatitis	I-DISO
+.	O
+
+Another	O
+significant	O
+finding	O
+of	O
+this	O
+study	O
+is	O
+that	O
+the	O
+government	O
+'	O
+s	O
+,	O
+organizations	O
+'	O
+and	O
+nurses	O
+'	O
+perceptions	O
+of	O
+new	O
+emerging	O
+respiratory	O
+infectious	B-DISO
+diseases	I-DISO
+were	O
+influenced	O
+by	O
+their	O
+previous	O
+experience	O
+with	O
+SARS	B-DISO
+.	O
+
+ABSTRACT	O
+:	O
+Pneumonia	B-DISO
+was	O
+a	O
+common	O
+complication	B-DISO
+among	O
+hospitalized	O
+patients	O
+with	O
+2009	O
+pandemic	O
+influenza	B-PATH
+A	I-PATH
+H1N1	O
+[	O
+pH1N1	O
+]	O
+in	O
+the	O
+United	O
+States	O
+in	O
+2009	O
+.	O
+
+We	O
+describe	O
+two	O
+patients	O
+,	O
+both	O
+with	O
+H1N1	O
+pneumonia	B-DISO
+complicated	O
+by	O
+invasive	B-DISO
+Aspergillosis	I-DISO
+,	O
+who	O
+required	O
+ECMO	O
+support	O
+significantly	O
+longer	O
+at	O
+45	O
+and	O
+52	O
+days	O
+,	O
+but	O
+eventually	O
+made	O
+a	O
+full	O
+recovery	O
+.	O
+
+However	O
+,	O
+as	O
+pores	O
+connecting	O
+the	O
+DMV	O
+interior	O
+with	O
+the	O
+cytoplasm	B-COMP
+have	O
+not	O
+been	O
+detected	O
+,	O
+it	O
+is	O
+unclear	O
+whether	O
+RNA	B-PROC
+synthesis	I-PROC
+occurs	O
+at	O
+these	O
+same	O
+sites	O
+.	O
+
+These	O
+results	O
+demonstrate	O
+the	O
+feasibility	O
+of	O
+detecting	O
+viral	O
+RNA	B-PROC
+synthesis	I-PROC
+by	O
+using	O
+click	O
+chemistry	O
+and	O
+indicate	O
+that	O
+dsRNA	B-CHED
+dots	O
+do	O
+not	O
+necessarily	O
+correspond	O
+with	O
+sites	O
+of	O
+active	O
+viral	O
+RNA	B-PROC
+synthesis	I-PROC
+.	O
+
+ABSTRACT	O
+:	O
+Viruses	B-SPEC
+enter	O
+the	O
+host	O
+cell	O
+by	O
+binding	B-FUNC
+cellular	B-COMP
+receptors	O
+that	O
+allow	O
+appropriate	O
+delivery	O
+of	O
+the	O
+viral	B-COMP
+genome	I-COMP
+.	O
+
+ABSTRACT	O
+:	O
+Animals	B-SPEC
+were	O
+immunized	O
+with	O
+transmissible	O
+gastroenteritis	B-DISO
+virus	B-SPEC
+conjugated	O
+with	O
+gold	B-CHED
+nanoparticles	B-CHED
+.	O
+
+Transplantation	O
+of	O
+Olig1	B-PRGE
+-/-	O
+and	O
+Olig1	O
++/+	O
+NPCs	O
+into	O
+JHMV	O
+-	O
+infected	O
+mice	O
+resulted	O
+in	O
+similar	O
+cell	B-PROC
+survival	I-PROC
+,	O
+proliferation	B-DISO
+,	O
+and	O
+selective	O
+migration	B-PROC
+to	O
+areas	O
+of	O
+demyelination	B-DISO
+.	O
+
+Further	O
+,	O
+these	O
+findings	O
+reveal	O
+that	O
+Olig1function	O
+is	O
+required	O
+for	O
+the	O
+remyelination	B-PROC
+potential	O
+of	O
+NPCs	O
+after	O
+transplant	B-ANAT
+,	O
+through	O
+specification	O
+and	O
+/	O
+or	O
+maintenance	O
+of	O
+oligodendroglial	O
+identity	O
+.	O
+
+Extracorporeal	O
+membrane	B-COMP
+oxygenation	B-PROC
+(	O
+ECMO	O
+)	O
+has	O
+been	O
+aggressively	O
+introduced	O
+for	O
+such	O
+patients	O
+,	O
+although	O
+in	O
+only	O
+a	O
+few	O
+institutions	O
+.	O
+
+Outcomes	O
+such	O
+as	O
+need	O
+for	O
+ventilation	O
+and	O
+development	B-PROC
+of	O
+intermediate	B-DISO
+syndrome	I-DISO
+(	O
+IMS	O
+)	O
+were	O
+noted	O
+.	O
+
+They	O
+had	O
+no	O
+electrophysiological	O
+abnormalities	O
+at	O
+median	O
+and	O
+ulnar	B-ANAT
+nerves	I-ANAT
+before	O
+intubation	O
+.	O
+
+Further	O
+studies	O
+are	O
+needed	O
+to	O
+quantify	O
+CNS	B-CHED
+and	O
+muscarinic	O
+dysfunction	O
+to	O
+assist	O
+in	O
+the	O
+development	B-PROC
+of	O
+better	O
+treatments	O
+for	O
+the	O
+severe	O
+and	O
+early	O
+OP	O
+poisoning	O
+.	O
+
+ABSTRACT	O
+:	O
+We	O
+investigated	O
+the	O
+clinical	O
+impact	O
+of	O
+human	B-PRGE
+coronaviruses	I-PRGE
+(	O
+HCoV	O
+)	O
+OC43	O
+,	O
+229E	O
+,	O
+HKU1	O
+and	O
+NL63	O
+in	O
+pediatric	O
+patients	O
+with	O
+cystic	B-DISO
+fibrosis	I-DISO
+(	O
+CF	O
+)	O
+during	O
+routine	O
+and	O
+exacerbation	O
+visits	O
+.	O
+
+The	O
+mRNA	B-PROC
+expression	B-PROC
+of	O
+local	O
+pulmonary	B-ANAT
+inflammatory	O
+markers	O
+was	O
+compared	O
+to	O
+protein	B-CHED
+levels	O
+of	O
+systemic	O
+inflammatory	O
+markers	O
+.	O
+
+The	O
+most	O
+severe	O
+pulmonary	B-ANAT
+lesions	O
+were	O
+observed	O
+in	O
+animals	B-SPEC
+receiving	O
+the	O
+high	O
+S	B-SPEC
+.	I-SPEC
+aureus	I-SPEC
+concentration	O
+,	O
+indicating	O
+that	O
+severity	O
+of	O
+lesions	O
+is	O
+dependent	O
+on	O
+inoculum	O
+concentration	O
+rather	O
+than	O
+total	O
+numbers	O
+of	O
+bacteria	B-SPEC
+.	O
+
+Furthermore	O
+,	O
+local	O
+mRNA	B-PROC
+expression	B-PROC
+of	O
+inflammatory	O
+cytokines	O
+appeared	O
+to	O
+be	O
+dependent	O
+on	O
+the	O
+magnitude	O
+and	O
+severity	O
+of	O
+tissue	B-ANAT
+destruction	O
+,	O
+including	O
+the	O
+ability	O
+to	O
+confine	O
+the	O
+lesions	O
+.	O
+
+In	O
+addition	O
+,	O
+the	O
+dynamic	O
+transcriptional	B-PROC
+alterations	O
+of	O
+12	O
+selected	O
+proteins	B-CHED
+were	O
+analyzed	O
+by	O
+the	O
+real	O
+-	O
+time	O
+RT	O
+-	O
+PCR	O
+,	O
+and	O
+western	O
+blot	O
+analysis	O
+confirmed	O
+the	O
+change	O
+in	O
+abundance	O
+of	O
+heat	B-PROC
+shock	I-PROC
+proteins	B-CHED
+(	O
+HSP	B-DISO
+)	O
+beta	O
+-	O
+1	O
+,	O
+annexin	B-PRGE
+A2	I-PRGE
+,	O
+and	O
+annexin	B-PRGE
+A5	I-PRGE
+.	O
+
+Anti	B-CHED
+-	I-CHED
+inflammatory	I-CHED
+drugs	I-CHED
+cannot	O
+be	O
+considered	O
+as	O
+an	O
+alternative	O
+for	O
+antibiotic	B-CHED
+treatment	O
+.	O
+
+TITLE	O
+:	O
+Vitamin	B-CHED
+D	I-CHED
+deficiency	I-DISO
+and	O
+comorbidities	O
+in	O
+children	O
+with	O
+sickle	B-DISO
+cell	I-DISO
+anemia	B-SPEC
+.	O
+
+ABSTRACT	O
+:	O
+Vitamin	B-CHED
+D	I-CHED
+deficiency	I-DISO
+is	O
+known	O
+to	O
+be	O
+common	O
+among	O
+patients	O
+with	O
+sickle	B-DISO
+cell	I-DISO
+anemia	B-SPEC
+(	O
+SCA	B-ANAT
+).	O
+
+This	O
+syndrome	B-DISO
+is	O
+characterized	O
+by	O
+noncardiogenic	O
+pulmonary	B-DISO
+edema	I-DISO
+,	O
+diffuse	O
+pulmonary	B-DISO
+infiltrates	I-DISO
+,	O
+and	O
+hypoxemia	O
+refractory	O
+to	O
+oxygen	B-CHED
+delivery	O
+.	O
+
+Recent	O
+studies	O
+in	O
+our	O
+laboratory	O
+and	O
+others	O
+have	O
+revealed	O
+a	O
+hitherto	O
+unknown	O
+correlation	O
+between	O
+chemokine	O
+CXCL10	B-PRGE
+/	O
+CXCR3	B-PRGE
+,	O
+Heme	B-PRGE
+/	O
+HO	B-PRGE
+-	I-PRGE
+1	I-PRGE
+and	O
+STAT3	B-PRGE
+and	O
+cerebral	B-DISO
+malaria	B-PATH
+severity	O
+and	O
+mortality	O
+.	O
+
+Then	O
+,	O
+we	O
+further	O
+determined	O
+the	O
+mechanisms	O
+how	O
+STAT3	B-PRGE
+regulates	O
+HO	B-PRGE
+-	I-PRGE
+1	I-PRGE
+and	O
+CXCL10	B-PRGE
+as	O
+well	O
+as	O
+mutual	O
+regulation	B-PROC
+among	O
+them	O
+in	O
+CRL	O
+-	O
+2581	O
+,	O
+a	O
+murine	B-SPEC
+endothelial	B-ANAT
+cell	I-ANAT
+line	O
+.	O
+
+The	O
+results	O
+demonstrate	O
+that	O
+(	O
+1	O
+)	O
+STAT3	B-PRGE
+is	O
+activated	O
+by	O
+P	B-SPEC
+.	I-SPEC
+berghei	I-SPEC
+ANKA	O
+(	O
+PBA	B-CHED
+)	O
+infection	B-DISO
+in	O
+vivo	O
+and	O
+Heme	B-CHED
+in	O
+vitro	O
+.	O
+
+Our	O
+ultimate	O
+goal	O
+is	O
+to	O
+develop	O
+novel	O
+therapies	O
+targeting	B-PROC
+Heme	B-CHED
+or	O
+CXCL10	O
+-	O
+related	O
+biological	B-PROC
+signaling	I-PROC
+molecules	O
+associated	O
+with	O
+development	B-PROC
+of	O
+fatal	O
+malaria	B-PATH
+.	O
+
+(	O
+4	O
+)	O
+HO	B-PRGE
+-	I-PRGE
+1	I-PRGE
+regulates	O
+STAT3	B-PRGE
+signaling	B-PROC
+.	O
+
+We	O
+assessed	O
+the	O
+role	O
+of	O
+extracorporeal	O
+membrane	B-COMP
+oxygenation	B-PROC
+(	O
+ECMO	O
+)	O
+support	O
+in	O
+adult	O
+recipients	O
+facing	O
+acute	O
+pulmonary	B-DISO
+failure	I-DISO
+and	O
+refractory	O
+to	O
+conventional	O
+mechanical	O
+ventilation	O
+and	O
+concurrent	O
+nitric	B-CHED
+oxide	I-CHED
+gas	B-ENZY
+inhalation	B-PROC
+.	O
+
+Eight	O
+patients	O
+(	O
+44	O
+.	O
+4	O
+%)	O
+were	O
+successfully	O
+weaned	B-PROC
+from	O
+ECMO	O
+upon	O
+the	O
+first	O
+attempt	O
+after	O
+a	O
+mean	O
+support	O
+of	O
+11	O
+.	O
+9	O
+±	O
+6	O
+.	O
+1	O
+days	O
+,	O
+but	O
+the	O
+other	O
+10	O
+died	B-PROC
+due	O
+to	O
+overwhelming	O
+infection	B-DISO
+.	O
+
+Univariate	O
+analysis	O
+revealed	O
+no	O
+significant	O
+pre	O
+-	O
+ECMO	O
+risk	O
+factor	O
+for	O
+treatment	O
+failure	O
+but	O
+C	B-PRGE
+-	I-PRGE
+reactive	I-PRGE
+protein	I-PRGE
+concentration	O
+at	O
+the	O
+time	O
+of	O
+ECMO	O
+differed	O
+significantly	O
+among	O
+patients	O
+who	O
+did	O
+versus	O
+did	O
+not	O
+survive	O
+after	O
+ECMO	O
+.	O
+
+ECMO	O
+as	O
+rescue	O
+therapy	O
+may	O
+be	O
+a	O
+final	O
+therapeutic	O
+option	O
+for	O
+OLT	O
+recipients	O
+with	O
+refractory	O
+pulmonary	B-ANAT
+dysfunction	O
+who	O
+would	O
+otherwise	O
+die	O
+due	O
+to	O
+hypoxemia	O
+from	O
+severe	O
+pneumonia	B-DISO
+or	O
+adult	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+.	O
+
+Similarly	O
+,	O
+the	O
+mean	O
+IBV	B-SPEC
+ELISA	O
+antibody	B-COMP
+titres	O
+in	O
+the	O
+toxin	O
+fed	O
+groups	O
+were	O
+significantly	O
+(	O
+P	O
+<	O
+0	O
+.	O
+01	O
+)	O
+reduced	O
+as	O
+compared	O
+with	O
+the	O
+IBV	B-SPEC
+ELISA	O
+antibody	B-COMP
+titres	O
+of	O
+IBV	B-SPEC
+infected	O
+but	O
+not	O
+toxin	O
+fed	O
+group	O
+,	O
+at	O
+all	O
+intervals	O
+.	O
+
+ABSTRACT	O
+:	O
+Wound	O
+control	O
+in	O
+laparostomy	O
+for	O
+the	O
+treatment	O
+of	O
+intra	B-DISO
+-	I-DISO
+abdominal	I-DISO
+hypertension	I-DISO
+remains	O
+challenging	O
+and	O
+numerous	O
+techniques	O
+have	O
+been	O
+described	O
+.	O
+
+This	O
+was	O
+successfully	O
+managed	O
+by	O
+performing	O
+a	O
+laparostomy	O
+and	O
+using	O
+an	O
+ABThera	O
+™	O
+Open	O
+Abdomen	B-ANAT
+Negative	O
+Pressure	O
+Therapy	O
+System	O
+(	O
+KCI	O
+,	O
+San	O
+Antonio	O
+,	O
+TX	O
+).	O
+
+ABSTRACT	O
+:	O
+Acute	O
+lung	O
+injury	O
+(	O
+ALI	O
+)	O
+and	O
+its	O
+more	O
+severe	O
+form	O
+,	O
+the	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+(	O
+ARDS	B-DISO
+),	O
+are	O
+common	O
+complications	O
+of	O
+acute	B-DISO
+pancreatitis	I-DISO
+(	O
+AP	O
+).	O
+
+Because	O
+of	O
+the	O
+persistent	O
+threat	O
+from	O
+the	O
+A	O
+/	O
+H5N1	B-DISO
+virus	B-SPEC
+since	O
+1997	O
+and	O
+the	O
+outbreak	O
+of	O
+the	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+(	O
+SARS	B-DISO
+)	O
+coronavirus	B-SPEC
+in	O
+2003	O
+,	O
+medical	O
+and	O
+scientific	O
+communities	O
+have	O
+been	O
+more	O
+prepared	O
+in	O
+mindset	O
+and	O
+infrastructure	O
+.	O
+
+TITLE	O
+:	O
+Simultaneous	O
+treatment	O
+of	O
+human	B-SPEC
+bronchial	B-ANAT
+epithelial	B-ANAT
+cells	I-ANAT
+with	O
+serine	B-CHED
+and	O
+cysteine	B-PRGE
+protease	I-PRGE
+inhibitors	I-CHED
+prevents	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+coronavirus	B-SPEC
+entry	O
+.	O
+
+The	O
+use	O
+of	O
+veno	O
+-	O
+arterial	B-ANAT
+(	O
+VA	O
+)	O
+ECMO	O
+support	O
+was	O
+reserved	O
+for	O
+cases	O
+of	O
+cardiac	B-ANAT
+shock	O
+refractory	O
+to	O
+standard	O
+treatment	O
+and	O
+cardiac	B-ANAT
+arrests	O
+not	O
+responding	O
+to	O
+conventional	O
+resuscitation	O
+.	O
+
+Eight	O
+of	O
+these	O
+received	O
+VV	O
+ECMO	O
+for	O
+ARDS	B-DISO
+of	O
+various	O
+etiologies	O
+,	O
+with	O
+a	O
+survival	O
+rate	O
+of	O
+63	O
+%.	O
+
+Typical	O
+complications	O
+include	O
+coagulation	B-DISO
+disorder	I-DISO
+,	O
+acute	B-DISO
+respiratory	I-DISO
+failure	I-DISO
+,	O
+acute	B-DISO
+renal	I-DISO
+failure	I-DISO
+,	O
+infections	B-DISO
+,	I-DISO
+central	I-DISO
+nervous	I-DISO
+system	I-DISO
+symptoms	O
+,	O
+hepatic	B-DISO
+failure	I-DISO
+and	O
+bleeding	B-DISO
+,	O
+and	O
+premature	O
+ablation	O
+of	O
+the	O
+placenta	B-ANAT
+.	O
+
+After	O
+the	O
+2003	O
+SARS	B-DISO
+epidemic	O
+,	O
+the	O
+pressure	O
+in	O
+Shenzhen	O
+to	O
+contain	O
+infectious	B-DISO
+disease	I-DISO
+has	O
+been	O
+considerable	O
+.	O
+
+TITLE	O
+:	O
+Prevalence	O
+of	O
+and	O
+risk	O
+factors	O
+associated	O
+with	O
+viral	O
+and	O
+bacterial	O
+pathogens	O
+in	O
+farmed	O
+European	O
+wild	B-SPEC
+boar	I-SPEC
+.	O
+
+Serological	O
+screening	O
+was	O
+carried	O
+out	O
+on	O
+303	O
+samples	O
+from	O
+animals	B-SPEC
+slaughtered	O
+between	O
+2005	O
+and	O
+2008	O
+,	O
+and	O
+random	O
+-	O
+effect	O
+logistic	O
+regression	O
+models	O
+were	O
+developed	O
+for	O
+pathogens	O
+with	O
+a	O
+'	O
+non	O
+-	O
+zero	O
+'	O
+prevalence	O
+.	O
+
+Here	O
+we	O
+use	O
+a	O
+murine	B-SPEC
+model	O
+for	O
+evaluation	O
+of	O
+the	O
+induction	O
+of	O
+humoral	O
+and	O
+cellular	B-PROC
+immune	I-PROC
+responses	I-PROC
+by	O
+inactivated	O
+and	O
+PHE	B-CHED
+-	O
+CoV	O
+DNA	O
+vaccines	O
+in	O
+order	B-SPEC
+to	O
+define	O
+the	O
+immune	O
+correlates	O
+for	O
+protection	O
+against	O
+PHE	B-CHED
+-	O
+CoV	O
+.	O
+The	O
+inactivated	O
+vaccine	O
+was	O
+composed	O
+of	O
+purified	O
+PHE	B-CHED
+-	O
+CoV	O
+and	O
+aluminum	B-CHED
+hydroxide	I-CHED
+gel	O
+(	O
+alum	O
+),	O
+which	O
+was	O
+chosen	O
+as	O
+an	O
+adjuvant	B-CHED
+because	O
+of	O
+its	O
+long	O
+history	O
+of	O
+safety	O
+for	O
+human	B-SPEC
+use	O
+.	O
+
+This	O
+response	O
+may	O
+activate	O
+both	O
+B	O
+and	O
+T	B-ANAT
+cells	I-ANAT
+to	O
+mount	O
+a	O
+specific	O
+humoral	O
+and	O
+cellular	B-PROC
+immune	I-PROC
+response	I-PROC
+that	O
+could	O
+,	O
+in	O
+turn	O
+,	O
+elicit	O
+a	O
+phagocyte	B-ANAT
+-	O
+mediated	O
+defense	O
+against	O
+PHE	B-CHED
+-	O
+CoV	O
+infections	B-DISO
+to	O
+achieve	O
+viral	O
+clearance	O
+.	O
+
+The	O
+fecal	B-ANAT
+score	O
+regarded	O
+as	O
+pathological	O
+was	O
+the	O
+highest	O
+score	O
+associated	O
+with	O
+a	O
+significant	O
+reduction	O
+in	O
+average	O
+daily	O
+gain	O
+(	O
+ADG	O
+).	O
+
+The	O
+quality	O
+of	O
+feces	B-ANAT
+was	O
+affected	O
+by	O
+both	O
+age	O
+and	O
+breed	B-PROC
+size	O
+.	O
+
+ABSTRACT	O
+:	O
+Fifty	O
+-	O
+seven	O
+derivatives	O
+of	O
+glycyrrhetinic	B-CHED
+acid	I-CHED
+(	O
+GA	O
+)	O
+were	O
+synthesized	O
+,	O
+and	O
+their	O
+anti	O
+-	O
+hepatitis	B-SPEC
+B	I-SPEC
+virus	I-SPEC
+(	O
+HBV	B-DISO
+)	O
+activity	O
+was	O
+evaluated	O
+in	O
+HepG	B-PRGE
+2	I-PRGE
+.	I-PRGE
+2	I-PRGE
+.	O
+15	O
+cells	B-COMP
+.	O
+
+The	O
+structure	O
+-	O
+activity	O
+relationships	O
+(	O
+SARs	B-DISO
+)	O
+of	O
+GA	O
+derivatives	O
+were	O
+discussed	O
+for	O
+exploring	O
+novel	O
+anti	B-CHED
+-	I-CHED
+HBV	I-CHED
+agents	I-CHED
+.	O
+
+Ninety	O
+-	O
+eight	O
+(	O
+28	O
+.	O
+9	O
+%)	O
+patients	O
+had	O
+at	O
+least	O
+one	O
+episode	O
+of	O
+microbiologically	O
+documented	O
+bacterial	O
+VAP	O
+,	O
+including	O
+41	O
+(	O
+41	O
+.	O
+8	O
+%)	O
+who	O
+died	B-PROC
+in	O
+the	O
+ICU	O
+,	O
+compared	O
+with	O
+74	O
+(	O
+30	O
+.	O
+7	O
+%)	O
+of	O
+the	O
+241	O
+patients	O
+without	O
+VAP	O
+(	O
+P	O
+=	O
+0	O
+.	O
+05	O
+).	O
+
+Tracheostomy	O
+,	O
+enteral	O
+nutrition	B-PROC
+,	O
+and	O
+the	O
+use	O
+of	O
+a	O
+subglottic	B-ANAT
+secretion	B-PROC
+-	O
+drainage	B-ANAT
+device	O
+were	O
+protective	O
+.	O
+
+After	O
+adjustment	O
+,	O
+age	O
+and	O
+severity	O
+at	O
+baseline	O
+,	O
+but	O
+not	O
+VAP	O
+,	O
+were	O
+associated	O
+with	O
+ICU	O
+death	B-PROC
+.	O
+
+The	O
+findings	O
+allow	O
+adaption	B-PROC
+of	O
+treatment	O
+to	O
+milder	O
+forms	O
+of	O
+acute	O
+lung	B-ANAT
+injury	O
+and	O
+severe	O
+forms	O
+.	O
+
+Phylogenetic	O
+analysis	O
+of	O
+the	O
+complete	O
+M	O
+gene	O
+showed	O
+that	O
+all	O
+south	O
+China	O
+PEDV	B-SPEC
+strains	O
+have	O
+a	O
+close	O
+relationship	O
+with	O
+most	O
+of	O
+the	O
+strains	O
+in	O
+Korea	O
+and	O
+Thailand	O
+,	O
+but	O
+differ	O
+genetically	O
+from	O
+the	O
+vaccine	O
+strain	O
+(	O
+CV777	O
+).	O
+
+ABSTRACT	O
+:	O
+Recently	O
+a	O
+commercial	O
+antigen	O
+-	O
+capture	O
+enzyme	O
+-	O
+linked	O
+immunosorbent	O
+assay	O
+kit	B-FUNC
+in	O
+the	O
+form	O
+of	O
+a	O
+dipstick	O
+(	O
+Bovine	B-SPEC
+Enterichek	O
+,	O
+Biovet	O
+Inc	O
+.)	O
+was	O
+made	O
+available	O
+to	O
+bovine	B-SPEC
+practitioners	O
+and	O
+producers	O
+for	O
+the	O
+rapid	O
+detection	O
+of	O
+Betacoronavirus	B-SPEC
+1	I-SPEC
+(	O
+BCV	B-SPEC
+-	O
+1	O
+),	O
+Rotavirus	B-SPEC
+A	I-SPEC
+(	O
+RV	O
+-	O
+A	O
+),	O
+Escherichia	B-SPEC
+coli	I-SPEC
+K99	O
+(+),	O
+and	O
+Cryptosporidium	B-SPEC
+parvum	I-SPEC
+in	O
+feces	B-ANAT
+from	O
+diarrheic	O
+calves	O
+.	O
+
+Specifically	O
+,	O
+sigma	B-PRGE
+(	I-PRGE
+σ	I-PRGE
+)	I-PRGE
+C	I-PRGE
+protein	I-PRGE
+of	O
+avian	B-SPEC
+reovirus	I-SPEC
+(	O
+ARV	O
+),	O
+a	O
+functional	O
+homolog	O
+of	O
+mammalian	B-PRGE
+reovirus	B-SPEC
+σ1	I-PRGE
+protein	B-CHED
+and	O
+responsible	O
+for	O
+M	B-ANAT
+-	I-ANAT
+cell	I-ANAT
+targeting	B-PROC
+,	O
+was	O
+administered	O
+together	O
+with	O
+a	O
+subfragment	O
+of	O
+the	O
+spike	O
+protein	B-CHED
+of	O
+infectious	B-DISO
+bronchitis	B-DISO
+virus	B-SPEC
+(	O
+IBV	B-SPEC
+).	O
+
+IN	O
+immunization	O
+produced	O
+antigen	O
+specific	O
+IgA	B-PRGE
+both	O
+systemically	O
+and	O
+in	O
+the	O
+lungs	B-ANAT
+.	O
+
+Our	O
+results	O
+indicate	O
+that	O
+ARV	B-PRGE
+σC	I-PRGE
+protein	I-PRGE
+delivered	O
+by	O
+LAB	O
+via	O
+the	O
+IN	O
+route	O
+elicits	O
+strong	O
+mucosal	B-PROC
+immunity	I-PROC
+.	O
+
+Evaluations	O
+of	O
+an	O
+inactivated	O
+whole	O
+virus	B-SPEC
+vaccine	O
+in	O
+ferrets	B-SPEC
+and	O
+nonhuman	O
+primates	B-SPEC
+and	O
+a	O
+virus	B-SPEC
+-	O
+like	O
+-	O
+particle	O
+vaccine	O
+in	O
+mice	B-SPEC
+induced	O
+protection	O
+against	O
+infection	B-DISO
+but	O
+challenged	O
+animals	B-SPEC
+exhibited	O
+an	O
+immunopathologic	O
+-	O
+type	O
+lung	B-DISO
+disease	I-DISO
+.	O
+
+on	O
+day	O
+0	O
+and	O
+28	O
+and	O
+sacrificed	O
+for	O
+serum	B-COMP
+antibody	B-COMP
+measurements	O
+or	O
+challenged	O
+with	O
+live	O
+virus	B-SPEC
+on	O
+day	O
+56	O
+.	O
+
+RESULTS	O
+:	O
+All	O
+vaccines	O
+induced	O
+serum	B-COMP
+neutralizing	O
+antibody	B-COMP
+with	O
+increasing	O
+dosages	O
+and	O
+/	O
+or	O
+alum	O
+significantly	O
+increasing	O
+responses	O
+.	O
+
+The	O
+pathologic	O
+changes	O
+seen	O
+in	O
+all	O
+control	O
+groups	O
+lacked	O
+the	O
+eosinophil	B-ANAT
+prominence	O
+.	O
+
+ABSTRACT	O
+:	O
+Prior	O
+to	O
+the	O
+availability	O
+of	O
+the	O
+specific	O
+pandemic	O
+vaccine	O
+,	O
+strategies	O
+to	O
+mitigate	O
+the	O
+impact	O
+of	O
+the	O
+disease	O
+typically	O
+involved	O
+antiviral	B-CHED
+treatment	O
+and	O
+""""	O
+non	O
+-	O
+pharmaceutical	B-CHED
+""""	O
+community	O
+interventions	O
+.	O
+
+While	O
+avian	B-DISO
+flu	I-DISO
+or	O
+SARS	B-DISO
+were	O
+mistaken	O
+as	O
+examples	O
+of	O
+past	O
+pandemics	O
+,	O
+almost	O
+all	O
+participants	O
+were	O
+able	O
+to	O
+associate	O
+the	O
+recent	O
+""""	O
+swine	B-DISO
+flu	I-DISO
+""""	O
+situation	O
+as	O
+an	O
+example	O
+of	O
+a	O
+pandemic	O
+event	O
+.	O
+
+It	O
+may	O
+be	O
+necessary	O
+to	O
+emphasize	O
+that	O
+pandemic	O
+influenza	B-DISO
+could	O
+pose	O
+a	O
+real	O
+threat	O
+to	O
+them	O
+,	O
+that	O
+it	O
+is	O
+important	O
+to	O
+protect	O
+oneself	O
+from	O
+infection	B-DISO
+and	O
+that	O
+infection	B-DISO
+control	O
+measures	O
+can	O
+be	O
+effective	O
+.	O
+
+At	O
+the	O
+genetic	O
+level	O
+,	O
+this	O
+virus	B-SPEC
+was	O
+strictly	O
+related	O
+to	O
+the	O
+prototype	O
+strain	O
+CB	O
+/	O
+05	O
+,	O
+but	O
+displayed	O
+some	O
+unique	O
+features	O
+.	O
+
+After	O
+experimental	O
+infection	B-DISO
+with	O
+the	O
+new	O
+pantropic	O
+isolate	O
+,	O
+most	O
+inoculated	O
+dogs	B-SPEC
+showed	O
+diarrhoea	B-DISO
+and	O
+acute	O
+lymphopenia	B-DISO
+.	O
+
+Gross	O
+lesions	O
+and	O
+histological	O
+changes	O
+were	O
+mainly	O
+evident	O
+in	O
+the	O
+gut	B-ANAT
+and	O
+lymphoid	B-ANAT
+tissues	I-ANAT
+,	O
+although	O
+some	O
+animals	B-SPEC
+showed	O
+remarkable	O
+changed	O
+also	O
+in	O
+parenchymatous	O
+organs	B-ANAT
+.	O
+
+ABSTRACT	O
+:	O
+Fifty	O
+-	O
+six	O
+isolates	O
+of	O
+avian	O
+infectious	O
+bronchitis	O
+virus	B-SPEC
+(	O
+IBV	B-SPEC
+)	O
+were	O
+obtained	O
+from	O
+different	O
+field	O
+outbreaks	O
+in	O
+China	O
+in	O
+2010	O
+,	O
+and	O
+they	O
+were	O
+genotyped	O
+by	O
+comparison	O
+with	O
+19	O
+reference	O
+strains	O
+in	O
+the	O
+present	O
+study	O
+.	O
+
+The	O
+results	O
+showed	O
+that	O
+LX4	O
+-	O
+type	O
+isolates	O
+are	O
+still	O
+the	O
+predominant	O
+IBVs	O
+circulating	O
+in	O
+chicken	B-SPEC
+flocks	O
+in	O
+China	O
+,	O
+and	O
+these	O
+isolates	O
+could	O
+be	O
+grouped	O
+further	O
+into	O
+two	O
+clusters	B-CHED
+.	O
+
+TITLE	O
+:	O
+A	O
+novel	O
+case	O
+of	O
+transient	O
+right	B-DISO
+ventricular	I-DISO
+failure	I-DISO
+in	O
+a	O
+patient	O
+with	O
+respiratory	B-DISO
+distress	I-DISO
+.	O
+
+Over	O
+the	O
+next	O
+6	O
+days	O
+,	O
+the	O
+patient	O
+'	O
+s	O
+cardiac	B-ANAT
+and	O
+respiratory	B-PROC
+function	I-PROC
+improved	O
+,	O
+and	O
+a	O
+repeat	O
+echocardiogram	O
+demonstrated	O
+complete	O
+normalization	O
+of	O
+RV	O
+function	O
+.	O
+
+Finally	O
+,	O
+the	O
+functional	O
+consequences	O
+of	O
+palmitoylation	B-PROC
+are	O
+discussed	O
+regarding	O
+binding	B-FUNC
+of	O
+proteins	B-CHED
+to	O
+membranes	B-ANAT
+or	O
+membrane	B-COMP
+rafts	O
+,	O
+entry	O
+of	O
+enveloped	O
+viruses	B-SPEC
+into	O
+target	B-ANAT
+cells	I-ANAT
+by	O
+spike	O
+-	O
+mediated	O
+membrane	B-PROC
+fusion	I-PROC
+as	O
+well	O
+as	O
+assembly	O
+and	O
+release	O
+of	O
+virus	B-COMP
+particles	I-COMP
+from	O
+infected	O
+cells	B-COMP
+.	O
+
+ABSTRACT	O
+:	O
+The	O
+type	B-PRGE
+II	I-PRGE
+transmembrane	I-PRGE
+serine	B-CHED
+proteases	I-PRGE
+TMPRSS2	B-PRGE
+and	O
+HAT	B-PRGE
+activate	O
+influenza	B-SPEC
+viruses	I-SPEC
+and	O
+the	O
+SARS	B-DISO
+-	O
+coronavirus	B-SPEC
+(	O
+TMPRSS2	O
+)	O
+in	O
+cell	B-COMP
+culture	O
+and	O
+may	O
+play	O
+an	O
+important	O
+role	O
+in	O
+viral	O
+spread	O
+and	O
+pathogenesis	B-DISO
+in	O
+the	O
+infected	O
+host	B-COMP
+.	O
+
+A	O
+recombinant	O
+Marek	B-SPEC
+'	I-SPEC
+s	I-SPEC
+disease	I-SPEC
+virus	I-SPEC
+(	O
+MDV	B-SPEC
+),	O
+rMDV	O
+-	O
+S1	O
+,	O
+that	O
+expresses	O
+the	O
+S1	O
+subunit	O
+of	O
+the	O
+spike	O
+(	O
+S	O
+)	O
+protein	B-CHED
+from	O
+the	O
+QX	O
+-	O
+like	O
+infectious	B-DISO
+bronchitis	B-DISO
+virus	B-SPEC
+(	O
+IBV	B-SPEC
+)	O
+was	O
+constructed	O
+by	O
+inserting	O
+the	O
+IBV	B-PRGE
+S1	I-PRGE
+gene	I-PRGE
+into	O
+the	O
+genome	O
+of	O
+the	O
+CVI988	O
+/	O
+Rispens	O
+strain	O
+of	O
+MDV	B-SPEC
+.	O
+
+As	O
+a	O
+result	O
+,	O
+15	O
+-	O
+16kb	O
+nucleotide	B-CHED
+sequences	O
+encoding	O
+complete	O
+RNA	B-PRGE
+dependent	I-PRGE
+RNA	I-PRGE
+polymerase	I-PRGE
+,	O
+spike	O
+,	O
+envelope	B-COMP
+,	O
+membrane	B-COMP
+,	O
+and	O
+nucleocapsid	B-COMP
+proteins	B-CHED
+plus	O
+other	O
+open	O
+reading	O
+frames	O
+(	O
+ORFs	O
+)	O
+were	O
+generated	O
+.	O
+
+Furthermore	O
+,	O
+the	O
+CoVs	O
+BtKY22	O
+,	O
+BtKY41	O
+,	O
+and	O
+BtKY43	O
+in	O
+Alphacoronavirus	B-SPEC
+genus	B-SPEC
+and	O
+BtKY24	O
+in	O
+Betacoronavirus	B-SPEC
+genus	B-SPEC
+are	O
+likely	O
+representatives	O
+of	O
+4	O
+novel	O
+CoV	O
+species	B-SPEC
+.	O
+
+TITLE	O
+:	O
+Aerosol	O
+generating	O
+procedures	O
+and	O
+risk	O
+of	O
+transmission	O
+of	O
+acute	B-DISO
+respiratory	I-DISO
+infections	I-DISO
+to	O
+healthcare	O
+workers	O
+:	O
+a	O
+systematic	O
+review	O
+.	O
+
+Other	O
+intubation	O
+associated	O
+procedures	O
+,	O
+endotracheal	O
+aspiration	B-DISO
+,	O
+suction	O
+of	O
+body	B-ANAT
+fluids	I-ANAT
+,	O
+bronchoscopy	O
+,	O
+nebulizer	O
+treatment	O
+,	O
+administration	O
+of	O
+O2	O
+,	O
+high	O
+flow	O
+O2	O
+,	O
+manipulation	O
+of	O
+O2	B-PRGE
+mask	I-PRGE
+or	O
+BiPAP	O
+mask	O
+,	O
+defibrillation	O
+,	O
+chest	B-ANAT
+compressions	O
+,	O
+insertion	O
+of	O
+nasogastric	B-ANAT
+tube	O
+,	O
+and	O
+collection	O
+of	O
+sputum	B-ANAT
+were	O
+not	O
+significant	O
+.	O
+
+The	O
+samples	O
+from	O
+various	O
+tissues	B-ANAT
+were	O
+collected	O
+at1	B-DISO
+,	O
+2	O
+,	O
+3	O
+,	O
+5	O
+,	O
+7	O
+,	O
+11	O
+,	O
+13	O
+,	O
+15	O
+,	O
+and	O
+20	O
+days	O
+postinoculation	O
+.	O
+
+Chickens	B-SPEC
+exhibited	O
+mild	O
+respiratory	O
+signs	O
+and	O
+depression	B-DISO
+.	O
+
+The	O
+most	O
+remarkable	O
+clinical	O
+signs	O
+and	O
+virus	B-SPEC
+detection	O
+appeared	O
+on	O
+day	O
+1	O
+PI	O
+.	O
+
+TITLE	O
+:	O
+Transmission	O
+electron	O
+microscopy	O
+studies	O
+of	O
+cellular	B-COMP
+responses	O
+to	O
+entry	O
+of	O
+virions	B-COMP
+:	O
+one	O
+kind	O
+of	O
+natural	O
+nanobiomaterial	O
+.	O
+
+ABSTRACT	O
+:	O
+Virions	O
+are	O
+one	O
+kind	O
+of	O
+nanoscale	O
+pathogen	O
+and	O
+are	O
+able	O
+to	O
+infect	O
+living	O
+cells	B-COMP
+of	O
+animals	B-SPEC
+,	O
+plants	B-SPEC
+,	O
+and	O
+bacteria	B-SPEC
+.	O
+
+The	O
+infection	B-DISO
+is	O
+an	O
+intrinsic	O
+property	O
+of	O
+the	O
+virions	B-COMP
+,	O
+and	O
+the	O
+biological	B-PROC
+process	I-PROC
+provides	O
+a	O
+good	O
+model	O
+for	O
+studying	O
+how	O
+these	O
+nanoparticles	B-CHED
+enter	O
+into	O
+cells	B-COMP
+.	O
+
+For	O
+this	O
+paper	O
+,	O
+we	O
+chose	O
+Bombyx	B-SPEC
+mori	I-SPEC
+cypovirus	B-SPEC
+1	I-SPEC
+(	O
+BmCPV	O
+-	O
+1	O
+)	O
+interactions	O
+with	O
+midgut	B-ANAT
+cells	B-COMP
+from	O
+silkworm	B-SPEC
+,	O
+and	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+(	O
+SARS	B-DISO
+)	O
+associated	O
+coronavirus	B-SPEC
+interactions	O
+with	O
+Vero	O
+E6	O
+cells	B-COMP
+,	O
+as	O
+examples	O
+to	O
+demonstrate	O
+the	O
+response	O
+of	O
+eukaryotic	B-ANAT
+cells	I-ANAT
+to	O
+two	O
+different	O
+types	O
+of	O
+virus	B-SPEC
+from	O
+our	O
+previous	O
+studies	O
+.	O
+
+With	O
+a	O
+diagnosis	O
+of	O
+complicate	O
+sigmoid	B-DISO
+volvulus	I-DISO
+she	O
+was	O
+underwent	O
+to	O
+the	O
+laparotomy	O
+where	O
+we	O
+found	O
+necrosis	B-PROC
+of	O
+all	O
+descending	B-ANAT
+colon	I-ANAT
+due	O
+to	O
+double	O
+twist	B-PROC
+volvulus	B-DISO
+of	O
+the	O
+sigmoid	B-ANAT
+.	O
+
+This	O
+case	O
+suggests	O
+that	O
+severe	O
+pericardial	B-DISO
+effusion	I-DISO
+and	O
+pericardial	B-DISO
+tamponade	I-DISO
+may	O
+be	O
+life	O
+-	O
+threatening	O
+complications	O
+of	O
+transient	O
+leukemia	B-DISO
+of	O
+Down	B-DISO
+syndrome	I-DISO
+and	O
+also	O
+it	O
+may	O
+be	O
+managed	O
+successfully	O
+with	O
+appropriate	O
+treatments	O
+.	O
+
+ABSTRACT	O
+:	O
+The	O
+coronavirus	B-SPEC
+E	O
+protein	B-CHED
+is	O
+a	O
+small	O
+membrane	B-COMP
+protein	B-CHED
+with	O
+a	O
+single	O
+predicted	O
+hydrophobic	O
+domain	O
+(	O
+HD	O
+),	O
+and	O
+has	O
+a	O
+poorly	O
+defined	O
+role	O
+in	O
+infection	B-DISO
+.	O
+
+ABSTRACT	O
+:	O
+Since	O
+first	O
+described	O
+in	O
+1946	O
+by	O
+Mendelson	O
+,	O
+aspiration	O
+of	O
+gastric	B-ANAT
+content	I-ANAT
+resulting	O
+in	O
+severe	O
+pulmonary	B-DISO
+complications	I-DISO
+is	O
+a	O
+known	O
+hazard	O
+of	O
+general	O
+anaesthesia	B-DISO
+.	O
+
+Gene	B-PROC
+transcription	I-PROC
+signatures	O
+unique	O
+to	O
+SARS	B-DISO
+-	O
+CoV	O
+disease	O
+states	O
+have	O
+been	O
+identified	O
+,	O
+but	O
+host	B-COMP
+factors	O
+that	O
+regulate	O
+exacerbated	O
+disease	O
+phenotypes	O
+still	O
+remain	O
+largely	O
+undetermined	O
+.	O
+
+Our	O
+study	O
+demonstrates	O
+for	O
+the	O
+first	O
+time	O
+that	O
+selected	O
+naturally	O
+-	O
+occurring	O
+flavonoids	B-CHED
+,	O
+including	O
+myricetin	B-CHED
+and	O
+scultellarein	O
+might	O
+serve	O
+as	O
+SARS	B-PRGE
+-	I-PRGE
+CoV	I-PRGE
+chemical	O
+inhibitors	B-CHED
+.	O
+
+TITLE	O
+:	O
+Weaning	B-PROC
+from	O
+venovenous	O
+extracorporeal	O
+membrane	B-COMP
+oxygenation	B-PROC
+without	O
+anticoagulation	B-PROC
+:	O
+is	O
+it	O
+possible	O
+?	O
+
+ABSTRACT	O
+:	O
+A	O
+19	O
+-	O
+year	O
+-	O
+old	O
+man	O
+affected	O
+with	O
+severe	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+that	O
+was	O
+unresponsive	O
+to	O
+medical	O
+treatment	O
+was	O
+successfully	O
+weaned	B-PROC
+without	O
+anticoagulation	B-PROC
+therapy	O
+from	O
+venovenous	O
+extracorporeal	O
+membrane	B-COMP
+oxygenation	B-PROC
+(	O
+ECMO	O
+)	O
+because	O
+of	O
+life	O
+-	O
+threatening	O
+bleeding	B-DISO
+.	O
+
+The	O
+patient	O
+was	O
+discontinued	O
+from	O
+ECMO	O
+and	O
+extubated	O
+after	O
+pulmonary	B-PROC
+function	I-PROC
+improved	O
+.	O
+
+Based	O
+on	O
+this	O
+single	O
+experience	O
+,	O
+management	O
+and	O
+weaning	B-PROC
+without	O
+any	O
+anticoagulant	B-CHED
+agent	O
+might	O
+be	O
+possible	O
+.	O
+
+TITLE	O
+:	O
+NOX	O
+enzymes	O
+:	O
+potential	O
+target	O
+for	O
+the	O
+treatment	O
+of	O
+acute	O
+lung	B-ANAT
+injury	O
+.	O
+
+ABSTRACT	O
+:	O
+Inoculation	O
+of	O
+the	O
+neurotropic	O
+JHM	O
+strain	O
+of	O
+mouse	O
+hepatitis	O
+virus	B-SPEC
+(	O
+JHMV	O
+)	O
+into	O
+the	O
+central	B-ANAT
+nervous	I-ANAT
+system	I-ANAT
+(	O
+CNS	B-CHED
+)	O
+of	O
+susceptible	O
+strains	O
+of	O
+mice	B-SPEC
+results	O
+in	O
+wide	O
+-	O
+spread	O
+replication	O
+within	O
+glial	B-ANAT
+cells	I-ANAT
+accompanied	O
+by	O
+infiltration	B-DISO
+of	O
+virus	B-SPEC
+-	O
+specific	O
+T	B-ANAT
+lymphocytes	I-ANAT
+that	O
+control	O
+virus	B-SPEC
+through	O
+cytokine	B-PROC
+secretion	I-PROC
+and	O
+cytolytic	O
+activity	O
+.	O
+
+ABSTRACT	O
+:	O
+Since	O
+late	O
+2010	O
+,	O
+porcine	O
+epidemic	O
+diarrhea	O
+virus	O
+(	O
+PEDV	B-SPEC
+)	O
+has	O
+been	O
+re	O
+-	O
+emerging	O
+in	O
+immunized	O
+swine	B-SPEC
+herds	O
+with	O
+devastating	O
+impact	O
+in	O
+the	O
+Hebei	O
+province	O
+of	O
+China	O
+.	O
+
+ILI	O
+could	O
+not	O
+distinguish	O
+A	O
+/	O
+H1N1p	O
+infection	B-DISO
+from	O
+that	O
+due	O
+to	O
+other	O
+respiratory	O
+viruses	B-SPEC
+.	O
+
+The	O
+data	O
+on	O
+the	O
+in	O
+vivo	O
+activity	O
+of	O
+pharmacological	O
+drugs	O
+with	O
+respect	O
+to	O
+TOPC	O
+virus	B-SPEC
+are	O
+rather	O
+scanty	O
+and	O
+it	O
+is	O
+difficult	O
+to	O
+predetermine	O
+their	O
+efficacy	O
+.	O
+
+The	O
+lesser	O
+degree	O
+of	O
+anxiety	O
+expressed	B-PROC
+by	O
+phase	O
+II	O
+senior	O
+students	O
+may	O
+be	O
+due	O
+in	O
+part	O
+,	O
+to	O
+a	O
+more	O
+realistic	O
+assessment	O
+of	O
+SARS	B-DISO
+risk	O
+brought	O
+about	O
+by	O
+maturity	O
+,	O
+time	O
+spent	O
+in	O
+hospital	O
+and	O
+interaction	O
+with	O
+clinical	O
+lecturers	O
+and	O
+medical	O
+staff	O
+.	O
+
+TITLE	O
+:	O
+The	O
+coronavirus	B-PRGE
+E	I-PRGE
+protein	B-CHED
+:	O
+assembly	O
+and	O
+beyond	O
+.	O
+
+TITLE	O
+:	O
+Co	O
+-	O
+circulation	B-PROC
+of	O
+four	O
+human	B-SPEC
+coronaviruses	O
+(	O
+HCoVs	O
+)	O
+in	O
+Queensland	O
+children	O
+with	O
+acute	O
+respiratory	B-ANAT
+tract	I-ANAT
+illnesses	O
+in	O
+2004	O
+.	O
+
+Screening	O
+of	O
+888	O
+inpatient	O
+and	O
+outpatient	O
+respiratory	O
+specimens	O
+spanning	O
+late	O
+autumn	O
+through	O
+to	O
+early	O
+spring	O
+,	O
+2004	O
+,	O
+identified	O
+the	O
+presence	O
+of	O
+a	O
+human	B-SPEC
+coronavirus	I-SPEC
+(	O
+HCoV	O
+)	O
+on	O
+74	O
+occasions	O
+(	O
+8	O
+.	O
+3	O
+%	O
+of	O
+all	O
+specimens	O
+and	O
+26	O
+.	O
+3	O
+%	O
+of	O
+all	O
+respiratory	O
+virus	B-SPEC
+detections	O
+).	O
+
+HCoV	O
+-	O
+HKU1	O
+and	O
+HCoV	B-SPEC
+-	I-SPEC
+OC43	I-SPEC
+comprised	O
+82	O
+.	O
+4	O
+%	O
+of	O
+all	O
+HCoVs	O
+detected	O
+.	O
+
+TITLE	O
+:	O
+Acquired	B-DISO
+haemophilia	I-DISO
+secondary	O
+to	O
+ivabradine	O
+presenting	O
+with	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+.	O
+
+Chest	B-ANAT
+radiography	O
+showed	O
+bilateral	O
+infiltrates	B-DISO
+mainly	O
+in	O
+the	O
+lower	O
+lobes	B-ANAT
+.	O
+
+However	O
+,	O
+the	O
+activated	O
+partial	O
+thromboplastin	B-PRGE
+time	O
+showed	O
+a	O
+prolongation	O
+that	O
+was	O
+not	O
+reversed	O
+on	O
+a	O
+correction	O
+study	O
+.	O
+
+He	O
+presented	O
+with	O
+a	O
+2	O
+-	O
+week	O
+history	O
+of	O
+increasing	O
+abdominal	B-DISO
+pain	I-DISO
+,	O
+nausea	B-DISO
+,	O
+diminished	O
+appetite	B-PROC
+and	O
+longstanding	O
+encopresis	B-DISO
+.	O
+
+Although	O
+ACS	B-FUNC
+secondary	O
+to	O
+constipation	B-DISO
+is	O
+extremely	O
+unusual	O
+,	O
+this	O
+case	O
+illustrates	O
+the	O
+need	O
+to	O
+actively	O
+treat	O
+constipation	B-DISO
+and	O
+what	O
+can	O
+happen	O
+if	O
+it	O
+is	O
+not	O
+.	O
+
+Most	O
+compounds	O
+presented	O
+selective	O
+inhibitory	O
+properties	O
+in	O
+the	O
+10	O
+-	O
+20	O
+μM	O
+range	O
+against	O
+HIV	B-SPEC
+-	I-SPEC
+1	I-SPEC
+reverse	B-PRGE
+transcriptase	I-PRGE
+associated	O
+ribonuclease	B-FUNC
+H	I-FUNC
+activity	I-FUNC
+,	O
+without	O
+affecting	O
+the	O
+integrase	B-PRGE
+and	O
+reverse	B-PRGE
+transcriptase	I-PRGE
+DNA	I-PRGE
+polymerase	I-PRGE
+activities	O
+.	O
+
+Unfortunately	O
+all	O
+tested	O
+compounds	O
+exhibited	O
+high	O
+cellular	B-PROC
+cytotoxicity	B-DISO
+in	O
+cell	B-COMP
+culture	O
+which	O
+limited	O
+their	O
+applications	O
+as	O
+antiviral	B-CHED
+agents	I-CHED
+.	O
+
+A	O
+total	O
+of	O
+1128	O
+CSF	B-ANAT
+samples	O
+were	O
+retrospectively	O
+tested	O
+using	O
+the	O
+Parechovirus	B-SPEC
+-	O
+Rgene	O
+™	O
+real	O
+-	O
+time	O
+RT	O
+-	O
+PCR	O
+assay	O
+.	O
+
+Over	O
+a	O
+3	O
+-	O
+year	O
+period	O
+,	O
+33	O
+/	O
+1128	O
+(	O
+2	O
+.	O
+9	O
+%)	O
+CSF	B-ANAT
+samples	O
+were	O
+found	O
+to	O
+be	O
+HPeV	O
+-	O
+positive	O
+.	O
+
+Routine	O
+screening	O
+for	O
+HPeV	B-PRGE
+in	I-PRGE
+CSF	I-PRGE
+and	O
+blood	B-ANAT
+should	O
+thus	O
+be	O
+performed	O
+more	O
+extensively	O
+and	O
+could	O
+improve	O
+clinical	O
+management	O
+.	O
+
+Some	O
+of	O
+them	O
+developed	O
+shortness	B-DISO
+of	I-DISO
+breath	I-DISO
+or	O
+severe	O
+dyspnea	B-DISO
+on	O
+6	O
+days	O
+after	O
+disease	O
+onset	O
+.	O
+
+The	O
+gammacoronaviruses	O
+primarily	O
+infect	O
+avian	B-SPEC
+hosts	B-COMP
+.	O
+
+Recombination	B-PROC
+also	O
+generates	O
+new	O
+haplotype	O
+diversity	O
+by	O
+recombining	O
+existing	O
+variants	O
+.	O
+
+Efficient	O
+replication	O
+of	O
+CCoV	O
+-	O
+A76	O
+is	O
+restricted	O
+to	O
+canine	O
+cell	B-ANAT
+lines	I-ANAT
+,	O
+in	O
+contrast	O
+to	O
+the	O
+prototypical	O
+type	O
+II	O
+strain	O
+CCoV	O
+-	O
+1	O
+-	O
+71	O
+that	O
+more	O
+efficiently	O
+replicates	O
+in	O
+feline	B-SPEC
+cells	B-COMP
+.	O
+
+This	O
+approach	O
+uses	O
+a	O
+right	O
+lateral	O
+mini	O
+-	O
+thoracotomy	O
+and	O
+femoral	B-ANAT
+cannulation	O
+for	O
+cardiopulmonary	B-ANAT
+bypass	O
+.	O
+
+The	O
+main	O
+reasons	O
+for	O
+conversion	O
+were	O
+as	O
+follows	O
+:	O
+major	O
+bleeding	B-DISO
+in	O
+18	O
+patients	O
+(	O
+52	O
+.	O
+9	O
+%);	O
+severe	O
+pulmonary	B-ANAT
+adhesions	B-DISO
+in	O
+six	O
+patients	O
+(	O
+17	O
+.	O
+6	O
+%);	O
+and	O
+aortic	B-DISO
+dissection	I-DISO
+in	O
+five	O
+patients	O
+(	O
+14	O
+.	O
+7	O
+%).	O
+
+In	O
+the	O
+discipline	O
+of	O
+medical	O
+microbiology	O
+,	O
+there	O
+is	O
+no	O
+definitive	O
+theoretical	O
+answer	O
+to	O
+this	O
+question	O
+:	O
+there	O
+,	O
+the	O
+conditions	O
+of	O
+aetiological	O
+possibility	O
+exist	O
+in	O
+a	O
+curious	O
+tension	B-DISO
+.	O
+
+We	O
+studied	O
+the	O
+influence	O
+of	O
+the	O
+inhibitory	O
+CD200	B-PRGE
+-	O
+CD200R	B-PRGE
+axis	B-SPEC
+on	O
+clearance	O
+and	O
+pathology	B-DISO
+in	O
+two	O
+different	O
+virus	B-DISO
+infection	I-DISO
+models	O
+.	O
+
+We	O
+therefore	O
+hypothesize	O
+that	O
+CD200R	B-PRGE
+ligation	O
+suppresses	O
+TLR7	B-PRGE
+responses	O
+and	O
+that	O
+release	B-PATH
+of	O
+this	O
+inhibition	B-PROC
+enlarges	O
+sex	O
+differences	O
+in	O
+TLR7	B-PRGE
+signaling	B-PROC
+.	O
+
+ABSTRACT	O
+:	O
+The	O
+non	O
+-	O
+structural	O
+protein	B-CHED
+13	O
+(	O
+nsp13	O
+)	O
+of	O
+Severe	B-DISO
+Acute	I-DISO
+Respiratory	I-DISO
+Syndrome	I-DISO
+Coronavirus	B-SPEC
+(	O
+SARS	B-DISO
+-	O
+CoV	O
+)	O
+is	O
+a	O
+helicase	B-PRGE
+that	O
+separates	O
+double	O
+-	O
+stranded	O
+RNA	O
+(	O
+dsRNA	B-CHED
+)	O
+or	O
+DNA	O
+(	O
+dsDNA	O
+)	O
+with	O
+a	O
+5	O
+'	O
+→	O
+3	O
+'	O
+polarity	O
+,	O
+using	O
+the	O
+energy	O
+of	O
+nucleotide	B-CHED
+hydrolysis	O
+.	O
+
+To	O
+elucidate	O
+the	O
+nature	O
+of	O
+the	O
+intermediates	O
+we	O
+carried	O
+out	O
+transient	O
+kinetic	O
+analysis	O
+of	O
+the	O
+nsp13	B-PRGE
+helicase	I-PRGE
+activity	O
+.	O
+
+This	O
+effect	O
+is	O
+specific	O
+for	O
+SARS	B-PRGE
+-	I-PRGE
+CoV	I-PRGE
+nsp12	I-PRGE
+,	O
+as	O
+no	O
+change	O
+in	O
+nsp13	O
+activity	O
+was	O
+observed	O
+when	O
+foot	B-ANAT
+-	O
+and	O
+-	O
+mouth	B-ANAT
+-	O
+disease	O
+virus	B-SPEC
+RdRp	B-FUNC
+was	O
+used	O
+in	O
+place	O
+of	O
+nsp12	O
+.	O
+
+With	O
+a	O
+few	O
+vaccine	O
+antigens	B-CHED
+,	O
+it	O
+also	O
+promoted	O
+a	O
+Th1	O
+-	O
+biased	O
+response	O
+based	O
+on	O
+pronounced	O
+induction	O
+of	O
+Th1	B-PRGE
+-	I-PRGE
+associated	I-PRGE
+IgG2a	I-PRGE
+and	O
+IgG2b	B-COMP
+antibody	I-COMP
+responses	O
+and	O
+the	O
+upregulated	O
+production	O
+of	O
+Th1	B-PRGE
+cytokines	I-PRGE
+,	O
+including	O
+IL	B-FUNC
+-	I-FUNC
+2	I-FUNC
+,	O
+IFN	B-PRGE
+-	I-PRGE
+γ	I-PRGE
+,	O
+TNF	B-PRGE
+-	I-PRGE
+α	I-PRGE
+and	O
+IL	B-FUNC
+-	I-FUNC
+6	I-FUNC
+.	O
+
+In	O
+this	O
+study	O
+,	O
+we	O
+have	O
+established	O
+rOv	B-PRGE
+-	I-PRGE
+ASP	I-PRGE
+-	I-PRGE
+1	I-PRGE
+'	O
+s	O
+adjuvanticity	B-PROC
+in	O
+mice	B-SPEC
+during	O
+the	O
+course	O
+of	O
+two	O
+sequential	O
+vaccinations	O
+using	O
+two	O
+vaccine	O
+model	O
+systems	O
+:	O
+the	O
+receptor	O
+-	O
+binding	B-FUNC
+domain	O
+(	O
+RBD	O
+)	O
+of	O
+SARS	B-PRGE
+-	I-PRGE
+CoV	I-PRGE
+spike	I-PRGE
+protein	B-CHED
+and	O
+a	O
+commercial	O
+influenza	B-SPEC
+virus	I-SPEC
+hemagglutinin	O
+(	O
+HA	O
+)	O
+vaccine	O
+comprised	O
+of	O
+three	O
+virus	B-SPEC
+strains	O
+.	O
+
+TITLE	O
+:	O
+A	O
+facile	O
+inhibitor	B-CHED
+screening	O
+of	O
+SARS	B-DISO
+coronavirus	B-SPEC
+N	O
+protein	B-CHED
+using	O
+nanoparticle	B-CHED
+-	O
+based	O
+RNA	O
+oligonucleotide	B-CHED
+.	O
+
+TITLE	O
+:	O
+Application	O
+of	O
+purified	O
+recombinant	O
+antigenic	O
+spike	O
+fragments	O
+to	O
+the	O
+diagnosis	O
+of	O
+avian	B-SPEC
+infectious	I-DISO
+bronchitis	I-DISO
+virus	O
+infection	O
+.	O
+
+ABSTRACT	O
+:	O
+The	O
+spike	O
+(	O
+S	O
+)	O
+protein	B-CHED
+,	O
+containing	O
+two	O
+subunits	O
+,	O
+S1	O
+and	O
+S2	O
+,	O
+is	O
+the	O
+major	O
+immunity	B-PROC
+-	O
+eliciting	O
+antigen	B-CHED
+of	O
+avian	B-DISO
+infectious	I-DISO
+bronchitis	I-DISO
+virus	B-SPEC
+(	O
+IBV	B-SPEC
+),	O
+a	O
+highly	O
+contagious	B-DISO
+disease	I-DISO
+of	O
+chickens	B-SPEC
+.	O
+
+Nonetheless	O
+,	O
+these	O
+immune	O
+-	O
+dominant	O
+regions	O
+were	O
+defined	O
+using	O
+selected	O
+monoclonal	O
+antibodies	B-COMP
+or	O
+using	O
+a	O
+short	O
+peptide	B-CHED
+approach	O
+that	O
+involves	O
+only	O
+certain	O
+limited	O
+regions	O
+of	O
+the	O
+S	B-PRGE
+protein	I-PRGE
+.	O
+
+This	O
+indicated	O
+that	O
+,	O
+among	O
+the	O
+five	O
+antigenic	O
+recombinant	O
+proteins	B-CHED
+,	O
+the	O
+region	O
+S	O
+-	O
+E	O
+showed	O
+the	O
+highest	O
+specificity	O
+and	O
+sensitivity	O
+,	O
+namely	O
+95	O
+.	O
+38	O
+%	O
+and	O
+96	O
+.	O
+29	O
+%,	O
+respectively	O
+.	O
+
+The	O
+κ	O
+value	O
+for	O
+the	O
+in	O
+-	O
+house	O
+ELISA	O
+using	O
+the	O
+S	O
+-	O
+E	O
+fragment	O
+compared	O
+to	O
+a	O
+commercial	O
+kit	B-FUNC
+was	O
+0	O
+.	O
+9172	O
+,	O
+indicating	O
+a	O
+high	O
+agreement	O
+between	O
+these	O
+two	O
+methods	O
+.	O
+
+This	O
+raises	O
+ERAD	B-PROC
+activity	O
+in	O
+the	O
+absence	O
+of	O
+UPR	O
+-	O
+induction	O
+.	O
+
+The	O
+mouse	B-DISO
+hepatitis	I-DISO
+virus	B-SPEC
+(	O
+MHV	B-SPEC
+)	O
+subverts	O
+ERAD	B-PROC
+tuning	O
+for	O
+replication	O
+.	O
+
+A	O
+total	O
+of	O
+30	O
+samples	O
+collected	O
+between	O
+2009	O
+and	O
+2011	O
+were	O
+used	O
+for	O
+PCR	O
+amplification	B-DISO
+and	O
+direct	O
+sequencing	O
+of	O
+partial	O
+or	O
+full	O
+S	B-PRGE
+gene	I-PRGE
+.	O
+
+It	O
+could	O
+not	O
+be	O
+verified	O
+whether	O
+being	O
+overweight	B-DISO
+was	O
+a	O
+factor	O
+of	O
+higher	O
+mortality	O
+due	O
+to	O
+influenza	B-PATH
+A	I-PATH
+(	O
+H1N1	O
+)	O
+amongst	O
+pregnant	O
+women	O
+in	O
+the	O
+state	O
+of	O
+Mexico	O
+.	O
+
+The	O
+nsp14	O
+ExoN	O
+activity	O
+ensures	O
+a	O
+yet	O
+-	O
+uncharacterized	O
+function	O
+in	O
+the	O
+virus	B-SPEC
+life	O
+cycle	O
+and	O
+must	O
+be	O
+regulated	O
+to	O
+avoid	O
+nonspecific	O
+RNA	B-PATH
+degradation	I-PATH
+.	O
+
+In	O
+this	O
+work	O
+,	O
+we	O
+show	O
+that	O
+the	O
+association	O
+of	O
+nsp10	O
+with	O
+nsp14	O
+stimulates	O
+>	O
+35	O
+-	O
+fold	O
+the	O
+ExoN	O
+activity	O
+of	O
+the	O
+latter	O
+while	O
+playing	O
+no	O
+effect	O
+on	O
+N7	B-PRGE
+-	I-PRGE
+MTase	I-PRGE
+activity	O
+.	O
+
+TITLE	O
+:	O
+Expression	B-PROC
+of	O
+B	O
+and	O
+T	B-ANAT
+lymphocyte	I-ANAT
+attenuator	O
+(	O
+BTLA	O
+)	O
+in	O
+macrophages	B-ANAT
+contributes	O
+to	O
+the	O
+fulminant	B-DISO
+hepatitis	I-DISO
+caused	O
+by	O
+murine	B-DISO
+hepatitis	I-DISO
+virus	B-SPEC
+strain	O
+-	O
+3	O
+.	O
+
+BTLA	B-PRGE
+-	O
+deficient	O
+(	O
+BTLA	B-PRGE
+-/-)	O
+mice	B-SPEC
+and	O
+their	O
+wild	O
+-	O
+type	O
+littermates	O
+were	O
+infected	O
+with	O
+murine	B-DISO
+hepatitis	I-DISO
+virus	B-SPEC
+strain	O
+-	O
+3	O
+(	O
+MHV	B-SPEC
+-	O
+3	O
+),	O
+and	O
+the	O
+levels	O
+of	O
+tissue	B-ANAT
+damage	O
+,	O
+cell	B-COMP
+apoptosis	B-PATH
+,	O
+serum	B-COMP
+liver	B-ANAT
+enzymes	O
+,	O
+fibrinogen	B-PRGE
+-	I-PRGE
+like	I-PRGE
+protein	B-CHED
+2	I-PRGE
+(	O
+FGL2	B-PRGE
+)	O
+and	O
+cytokine	B-PROC
+production	I-PROC
+were	O
+measured	O
+and	O
+compared	O
+.	O
+
+Survival	O
+rate	O
+was	O
+studied	O
+after	O
+MHV	B-SPEC
+-	O
+3	O
+infection	B-DISO
+with	O
+or	O
+without	O
+adoptive	O
+transferring	O
+macrophages	B-ANAT
+.	O
+
+This	O
+effect	O
+is	O
+due	O
+to	O
+rapid	O
+,	O
+TRAIL	B-PRGE
+(	O
+TNF	B-PRGE
+-	O
+related	O
+apoptosis	B-PATH
+-	O
+inducing	O
+ligand	B-PROC
+)-	O
+dependent	O
+apoptosis	B-PATH
+of	O
+MHV	B-SPEC
+-	O
+3	O
+-	O
+infected	O
+macrophages	B-ANAT
+in	O
+BTLA	O
+-/-	O
+mice	B-SPEC
+.	O
+
+The	O
+early	O
+loss	O
+of	O
+macrophages	B-ANAT
+resulted	O
+in	O
+reduced	O
+pathogenic	O
+tumour	B-DISO
+necrosis	I-DISO
+factor	O
+α	O
+(	O
+TNFα	O
+)	O
+and	O
+FGL2	B-PRGE
+levels	O
+and	O
+lower	O
+viral	O
+titres	O
+.	O
+
+ABSTRACT	O
+:	O
+The	O
+interplay	O
+between	O
+IFN	O
+-	O
+γ	O
+,	O
+IL	B-PROC
+-	I-PROC
+17	I-PROC
+and	O
+neutrophils	B-ANAT
+during	O
+CNS	B-CHED
+inflammatory	B-DISO
+disease	I-DISO
+is	O
+complex	O
+due	O
+to	O
+cross	O
+-	O
+regulatory	O
+factors	O
+affecting	O
+both	O
+positive	O
+and	O
+negative	O
+feedback	O
+loops	O
+.	O
+
+Kunming	O
+mice	B-SPEC
+were	O
+injected	O
+separately	O
+with	O
+each	O
+of	O
+these	O
+constructs	O
+or	O
+with	O
+a	O
+pVAX1	O
+-(	O
+PEDV	B-SPEC
+-	O
+S1	O
+)/	O
+pVAX1	O
+-(	O
+IL	B-FUNC
+-	I-FUNC
+18	I-FUNC
+)	O
+combination	O
+,	O
+an	O
+attenuated	O
+PEDV	B-SPEC
+vaccine	O
+,	O
+or	O
+vector	O
+only	O
+control	O
+.	O
+
+Animals	B-SPEC
+were	O
+examined	O
+for	O
+T	O
+lymphocyte	O
+proliferation	B-DISO
+,	O
+anti	O
+-	O
+PEDV	B-SPEC
+antibodies	B-COMP
+,	O
+IFN	B-PRGE
+-	I-PRGE
+γ	I-PRGE
+and	O
+IL	B-PRGE
+-	I-PRGE
+4	I-PRGE
+protein	B-CHED
+levels	O
+,	O
+and	O
+cytotoxic	B-ANAT
+T	I-ANAT
+cell	I-ANAT
+function	O
+in	O
+mouse	B-SPEC
+peripheral	B-ANAT
+blood	I-ANAT
+and	O
+spleen	B-ANAT
+.	O
+
+ECLS	O
+may	O
+have	O
+a	O
+role	O
+to	O
+play	O
+in	O
+the	O
+acute	O
+support	O
+of	O
+children	O
+with	O
+cardiorespiratory	B-DISO
+failure	I-DISO
+as	O
+a	O
+result	O
+of	O
+malignancy	B-DISO
+or	O
+the	O
+required	O
+treatment	O
+.	O
+
+Drugs	O
+can	O
+induce	O
+all	O
+types	O
+of	O
+immunological	O
+reactions	O
+described	O
+by	O
+Gell	O
+and	O
+Coombs	O
+;	O
+however	O
+,	O
+most	O
+reactions	O
+in	O
+immune	O
+-	O
+mediated	O
+DILD	O
+may	O
+be	O
+T	B-ANAT
+cell	I-ANAT
+-	O
+mediated	O
+.	O
+
+Identifying	O
+the	O
+causative	O
+drug	O
+that	O
+induces	O
+an	O
+allergy	B-DISO
+or	O
+cytotoxicity	B-DISO
+is	O
+essential	O
+for	O
+preventing	O
+secondary	O
+reactions	O
+.	O
+
+Numerous	O
+studies	O
+have	O
+been	O
+carried	O
+out	O
+to	O
+identify	O
+new	O
+bat	B-ENZY
+viruses	B-SPEC
+related	O
+to	O
+SARS	B-DISO
+-	O
+coronavirus	B-SPEC
+(	O
+bat	B-ENZY
+-	O
+SARS	B-DISO
+-	O
+like	O
+CoVs	O
+)	O
+using	O
+a	O
+reverse	O
+-	O
+transcribed	O
+-	O
+polymerase	O
+chain	O
+reaction	O
+assay	O
+.	O
+
+ABSTRACT	O
+:	O
+The	O
+case	O
+is	O
+presented	O
+of	O
+a	O
+38	O
+year	O
+-	O
+old	O
+patient	O
+who	O
+was	O
+admitted	O
+in	O
+the	O
+Emergency	O
+Department	O
+due	O
+to	O
+a	O
+severe	O
+acute	B-DISO
+respiratory	I-DISO
+failure	I-DISO
+and	O
+who	O
+was	O
+transferred	O
+to	O
+the	O
+Critical	O
+Care	O
+Unit	O
+with	O
+a	O
+suspected	O
+initial	O
+diagnosis	O
+of	O
+community	B-DISO
+acquired	I-DISO
+pneumonia	I-DISO
+caused	O
+by	O
+an	O
+atypical	O
+microorganism	O
+,	O
+which	O
+was	O
+complicated	O
+with	O
+an	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+.	O
+
+The	O
+interaction	O
+between	O
+nonstructural	O
+protein	B-CHED
+(	O
+nsp	O
+)	O
+10	O
+and	O
+nsp16	O
+has	O
+been	O
+demonstrated	O
+and	O
+the	O
+crystal	B-ANAT
+structure	O
+of	O
+SARS	B-PRGE
+-	I-PRGE
+CoV	I-PRGE
+nsp16	I-PRGE
+/	I-PRGE
+10	I-PRGE
+complex	I-PRGE
+has	O
+been	O
+revealed	O
+.	O
+
+TITLE	O
+:	O
+[	O
+Acute	B-DISO
+respiratory	I-DISO
+failure	I-DISO
+after	O
+metoclopramide	B-CHED
+for	O
+methemoglobinemia	B-DISO
+-	O
+a	O
+rare	O
+and	O
+potentially	O
+life	O
+-	O
+threatening	O
+side	O
+effect	O
+].	O
+
+On	O
+physical	O
+exam	O
+the	O
+patient	O
+showed	O
+tachycardia	O
+,	O
+dyspnoea	B-DISO
+and	O
+progressive	O
+somnolence	O
+.	O
+
+Blood	B-PROC
+gas	B-ENZY
+analysis	O
+(	O
+BGA	O
+)	O
+however	O
+showed	O
+a	O
+massive	O
+increase	O
+in	O
+methemoglobinemia	B-DISO
+from	O
+0	O
+.	O
+5	O
+%	O
+just	O
+prior	O
+to	O
+MCP	B-FUNC
+injection	O
+to	O
+53	O
+.	O
+1	O
+%	O
+after	O
+MCP	B-FUNC
+injection	O
+;	O
+simultaneously	O
+the	O
+pO2	B-PROC
+decreased	O
+from	O
+74	O
+auf	O
+54	O
+mmHg	O
+and	O
+the	O
+pCO2	O
+from	O
+37	O
+.	O
+7	O
+to	O
+34	O
+.	O
+1	O
+mmHg	O
+.	O
+
+CONCLUSIONS	O
+:	O
+The	O
+development	B-PROC
+of	O
+a	O
+severe	O
+and	O
+acute	O
+methemoglobinemia	B-DISO
+following	O
+the	O
+administration	O
+of	O
+MCP	B-FUNC
+is	O
+described	O
+in	O
+this	O
+case	O
+report	O
+.	O
+
+In	O
+this	O
+patient	O
+,	O
+risk	O
+factors	O
+for	O
+invasive	O
+fungal	B-DISO
+disease	I-DISO
+included	O
+a	O
+combination	O
+of	O
+severe	O
+and	O
+prolonged	O
+H1N1	O
+-	O
+influenza	B-SPEC
+virus	B-DISO
+infection	I-DISO
+,	O
+corticosteroid	B-CHED
+therapy	O
+and	O
+broad	O
+-	O
+spectrum	O
+antibiotics	B-CHED
+.	O
+
+The	O
+authors	O
+suggest	O
+that	O
+deeper	O
+excision	O
+of	O
+necrotic	B-PROC
+tissue	B-ANAT
+and	O
+skin	B-ANAT
+grafting	I-ANAT
+as	O
+well	O
+as	O
+appropriate	O
+antibiotics	B-CHED
+are	O
+principal	O
+measures	O
+to	O
+counteract	O
+systemic	B-DISO
+inflammatory	I-DISO
+response	I-DISO
+syndrome	I-DISO
+.	O
+
+VIGOR	O
+accurately	O
+detects	O
+the	O
+complex	O
+gene	O
+features	O
+like	O
+ribonucleicacid	O
+editing	O
+,	O
+stop	O
+codon	O
+leakage	B-DISO
+and	O
+ribosomal	B-COMP
+shunting	O
+.	O
+
+To	O
+describe	O
+the	O
+characteristics	O
+of	O
+ICU	O
+patients	O
+with	O
+pH1N1	O
+virus	B-DISO
+infection	I-DISO
+in	O
+the	O
+United	O
+States	O
+during	O
+the	O
+spring	O
+and	O
+fall	O
+of	O
+2009	O
+and	O
+to	O
+describe	O
+the	O
+factors	O
+associated	O
+with	O
+severe	O
+complications	O
+including	O
+ARDS	B-DISO
+and	O
+death	B-PROC
+.	O
+
+The	O
+majority	O
+(	O
+77	O
+%)	O
+of	O
+154	O
+patients	O
+hospitalized	O
+in	O
+an	O
+ICU	O
+were	O
+<	O
+50	O
+years	O
+of	O
+age	O
+,	O
+and	O
+65	O
+%	O
+had	O
+at	O
+least	O
+one	O
+underlying	O
+medical	O
+condition	B-DISO
+.	O
+
+Patients	O
+with	O
+ARDS	B-DISO
+were	O
+more	O
+likely	O
+to	O
+be	O
+morbidly	O
+obese	B-DISO
+(	O
+36	O
+%	O
+versus	O
+19	O
+%,	O
+P	O
+=	O
+0	O
+.	O
+04	O
+)	O
+and	O
+patients	O
+who	O
+died	B-PROC
+were	O
+less	O
+likely	O
+to	O
+have	O
+asthma	B-PATH
+(	O
+11	O
+%	O
+versus	O
+28	O
+%,	O
+P	O
+=	O
+0	O
+.	O
+05	O
+).	O
+
+Compared	O
+with	O
+patients	O
+who	O
+received	O
+treatment	O
+≥	O
+6	O
+days	O
+after	O
+illness	O
+onset	O
+,	O
+patients	O
+treated	O
+≤	O
+2	O
+days	O
+after	O
+illness	O
+onset	O
+were	O
+less	O
+likely	O
+to	O
+develop	O
+ARDS	B-DISO
+(	O
+17	O
+%	O
+versus	O
+37	O
+%,	O
+P	O
+<	O
+0	O
+.	O
+01	O
+)	O
+or	O
+die	O
+(	O
+7	O
+%	O
+versus	O
+35	O
+%,	O
+P	O
+<	O
+0	O
+.	O
+01	O
+).	O
+
+However	O
+,	O
+systemic	O
+anticoagulation	B-PROC
+during	O
+ECMO	O
+is	O
+recommended	O
+and	O
+thus	O
+traumatic	O
+brain	B-ANAT
+injury	O
+(	O
+TBI	O
+)	O
+and	O
+intracranial	B-DISO
+bleeding	I-DISO
+are	O
+well	O
+-	O
+accepted	O
+contraindications	O
+for	O
+ECMO	O
+therapy	O
+.	O
+
+We	O
+compared	O
+two	O
+of	O
+the	O
+Japanese	O
+isolates	O
+with	O
+the	O
+ATCC	O
+-	O
+VR740	O
+strain	O
+by	O
+using	O
+virus	B-SPEC
+-	O
+neutralizing	O
+assays	O
+consisting	O
+of	O
+infectious	B-DISO
+HCoV	B-SPEC
+-	I-SPEC
+229E	I-SPEC
+particles	O
+and	O
+vesicular	B-SPEC
+stomatitis	I-SPEC
+virus	I-SPEC
+(	O
+VSV	O
+)-	O
+pseudotyped	O
+virus	B-SPEC
+carrying	O
+the	O
+HCoV	B-PRGE
+-	I-PRGE
+229E	I-PRGE
+S	I-PRGE
+protein	B-CHED
+.	O
+
+TITLE	O
+:	O
+Organ	B-ANAT
+tropism	B-PROC
+of	O
+murine	B-SPEC
+coronavirus	I-SPEC
+does	O
+not	O
+correlate	O
+with	O
+the	O
+expression	B-PROC
+levels	O
+of	O
+the	O
+membrane	B-ANAT
+-	O
+anchored	O
+or	O
+secreted	B-PROC
+isoforms	O
+of	O
+the	O
+carcinoembryonic	B-PRGE
+antigen	I-PRGE
+-	I-PRGE
+related	I-PRGE
+cell	B-PROC
+adhesion	B-DISO
+molecule	I-PRGE
+1	I-PRGE
+receptor	I-PRGE
+.	O
+
+TITLE	O
+:	O
+Acute	B-DISO
+pancreatitis	I-DISO
+and	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+complicating	O
+dengue	B-DISO
+haemorrhagic	I-DISO
+fever	B-PROC
+.	O
+
+To	O
+our	O
+knowledge	O
+,	O
+this	O
+is	O
+the	O
+first	O
+reported	O
+case	O
+of	O
+dengue	B-DISO
+haemorrhagic	I-DISO
+fever	I-DISO
+complicated	O
+with	O
+acute	B-DISO
+pancreatitis	I-DISO
+and	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+.	O
+
+All	O
+patients	O
+underwent	O
+MDCT	O
+of	O
+the	O
+thorax	B-ANAT
+due	O
+to	O
+respiratory	B-DISO
+distress	I-DISO
+.	O
+
+Adverse	O
+outcome	O
+measures	O
+were	O
+defined	O
+as	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+with	O
+the	O
+need	O
+for	O
+mechanical	O
+ventilation	O
+,	O
+extracorporeal	O
+membrane	O
+oxygenation	B-PROC
+or	O
+death	B-PROC
+.	O
+
+The	O
+ability	O
+of	O
+A77	O
+-	O
+1726	O
+to	O
+improve	O
+cardiopulmonary	B-ANAT
+function	O
+in	O
+influenza	B-DISO
+-	O
+infected	O
+mice	B-SPEC
+and	O
+to	O
+reduce	O
+the	O
+severity	O
+of	O
+ongoing	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+late	O
+in	O
+infection	B-DISO
+suggests	O
+that	O
+pyrimidine	B-CHED
+synthesis	I-CHED
+inhibitors	I-CHED
+are	O
+promising	O
+therapeutic	O
+candidates	O
+for	O
+the	O
+management	O
+of	O
+severe	O
+influenza	B-DISO
+.	O
+
+TITLE	O
+:	O
+Purification	O
+,	O
+crystallization	O
+and	O
+preliminary	O
+X	O
+-	O
+ray	B-SPEC
+analysis	O
+of	O
+nonstructural	B-PRGE
+protein	I-PRGE
+2	I-PRGE
+(	O
+nsp2	B-PRGE
+)	O
+from	O
+avian	B-DISO
+infectious	I-DISO
+bronchitis	I-DISO
+virus	B-SPEC
+.	O
+
+ABSTRACT	O
+:	O
+Avian	B-DISO
+infectious	I-DISO
+bronchitis	I-DISO
+virus	B-SPEC
+(	O
+IBV	B-SPEC
+)	O
+is	O
+a	O
+member	O
+of	O
+the	O
+group	O
+III	O
+coronaviruses	O
+,	O
+which	O
+differ	O
+from	O
+the	O
+other	O
+groups	O
+of	O
+coronaviruses	O
+in	O
+that	O
+they	O
+do	O
+not	O
+encode	O
+the	O
+essential	O
+pathogenic	O
+factor	O
+nonstructural	B-PRGE
+protein	I-PRGE
+1	I-PRGE
+(	O
+nsp1	B-PRGE
+)	O
+and	O
+instead	O
+start	O
+with	O
+nsp2	B-PRGE
+.	O
+
+In	O
+order	B-SPEC
+to	O
+better	O
+understand	O
+the	O
+structural	O
+details	O
+and	O
+functional	O
+mechanism	O
+of	O
+IBV	B-SPEC
+nsp2	B-PRGE
+,	O
+the	O
+recombinant	O
+protein	B-CHED
+was	O
+cloned	O
+,	O
+overexpressed	O
+in	O
+Escherichia	B-SPEC
+coli	I-SPEC
+,	O
+purified	O
+and	O
+crystallized	O
+.	O
+
+The	O
+crystals	B-ANAT
+diffracted	O
+to	O
+2	O
+.	O
+8	O
+Å	O
+resolution	O
+and	O
+belonged	O
+to	O
+space	O
+group	O
+P2	O
+(	O
+1	O
+),	O
+with	O
+unit	O
+-	O
+cell	B-COMP
+parameters	O
+a	O
+=	O
+57	O
+.	O
+0	O
+,	O
+b	O
+=	O
+192	O
+.	O
+3	O
+,	O
+c	O
+=	O
+105	O
+.	O
+7	O
+Å	O
+,	O
+β	O
+=	O
+90	O
+.	O
+8	O
+°.	O
+
+Bone	B-ANAT
+fractures	O
+were	O
+diagnosed	O
+in	O
+1	O
+,	O
+431	O
+(	O
+55	O
+.	O
+08	O
+%)	O
+patients	O
+and	O
+crush	B-DISO
+syndrome	I-DISO
+was	O
+observed	O
+in	O
+23	O
+(	O
+0	O
+.	O
+89	O
+%).	O
+
+PP	O
+improves	O
+oxygenation	B-PROC
+in	O
+burn	O
+patients	O
+with	O
+severe	O
+ARDS	B-DISO
+and	O
+was	O
+safely	O
+implemented	O
+in	O
+a	O
+burn	O
+intensive	O
+care	O
+unit	O
+.	O
+
+Overall	O
+,	O
+14	O
+survived	O
+48	O
+hours	O
+(	O
+78	O
+%),	O
+12	O
+survived	O
+28	O
+days	O
+(	O
+67	O
+%),	O
+and	O
+six	O
+survived	O
+to	O
+hospital	O
+discharge	B-ANAT
+(	O
+33	O
+%).	O
+
+During	O
+the	O
+2010s	O
+,	O
+the	O
+military	O
+surgeons	O
+promoted	O
+the	O
+use	O
+of	O
+a	O
+hemostatic	B-PROC
+regimen	O
+which	O
+consists	O
+of	O
+platelets	B-ANAT
+,	O
+RBC	B-ANAT
+,	O
+and	O
+FFP	O
+in	O
+a	O
+1	O
+:	O
+1	O
+:	O
+1	O
+ratio	O
+.	O
+
+This	O
+syndrome	B-DISO
+was	O
+typically	O
+seen	O
+after	O
+treatment	O
+of	O
+HS	O
+and	O
+was	O
+associated	O
+with	O
+abnormal	B-DISO
+bleeding	I-DISO
+plus	O
+respiratory	B-DISO
+failure	I-DISO
+and	O
+renal	B-DISO
+failure	I-DISO
+thought	O
+to	O
+be	O
+caused	O
+by	O
+a	O
+combination	O
+of	O
+micro	O
+-	O
+and	O
+macrothromboses	O
+.	O
+
+ABSTRACT	O
+:	O
+Even	O
+though	O
+the	O
+effect	O
+of	O
+antibody	B-COMP
+affinity	O
+on	O
+neutralization	O
+potency	O
+is	O
+well	O
+documented	O
+,	O
+surprisingly	O
+,	O
+its	O
+impact	O
+on	O
+neutralization	O
+breadth	O
+and	O
+escape	O
+has	O
+not	O
+been	O
+systematically	O
+determined	O
+.	O
+
+Here	O
+,	O
+random	O
+mutagenesis	B-PROC
+and	O
+DNA	O
+shuffling	O
+of	O
+the	O
+single	O
+-	O
+chain	O
+variable	O
+fragment	O
+of	O
+the	O
+neutralizing	O
+antibody	B-COMP
+80R	O
+followed	O
+by	O
+bacterial	O
+display	O
+screening	O
+using	O
+anchored	O
+periplasmic	B-COMP
+expression	B-PROC
+(	O
+APEx	O
+)	O
+were	O
+used	O
+to	O
+generate	O
+a	O
+number	O
+of	O
+higher	O
+-	O
+affinity	O
+variants	O
+of	O
+the	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+coronavirus	B-SPEC
+(	O
+SARS	B-DISO
+-	O
+CoV	O
+)-	O
+neutralizing	O
+antibody	B-COMP
+80R	O
+with	O
+equilibrium	B-PROC
+dissociation	B-DISO
+constants	O
+(	O
+K	O
+(	O
+D	O
+))	O
+as	O
+low	O
+as	O
+37	O
+pM	O
+,	O
+a	O
+>	O
+270	O
+-	O
+fold	O
+improvement	O
+relative	O
+to	O
+that	O
+of	O
+the	O
+parental	O
+80R	O
+single	O
+-	O
+chain	O
+variable	O
+fragment	O
+(	O
+scFv	O
+).	O
+
+Escape	O
+from	O
+the	O
+highest	O
+-	O
+affinity	O
+variant	O
+required	O
+reduced	O
+selective	O
+pressure	O
+and	O
+multiple	O
+substitutions	O
+in	O
+the	O
+binding	B-FUNC
+epitope	B-CHED
+.	O
+
+Collectively	O
+,	O
+these	O
+results	O
+support	O
+the	O
+hypothesis	O
+that	O
+engineered	O
+antibodies	B-COMP
+with	O
+picomolar	O
+dissociation	B-DISO
+constants	O
+for	O
+a	O
+neutralizing	O
+epitope	B-CHED
+can	O
+confer	O
+escape	O
+-	O
+resistant	O
+protection	O
+.	O
+
+TITLE	O
+:	O
+The	O
+long	O
+view	O
+:	O
+40	O
+years	O
+of	O
+infectious	B-DISO
+bronchitis	B-DISO
+research	O
+.	O
+
+The	O
+remit	O
+of	O
+this	O
+review	O
+is	O
+to	O
+provide	O
+the	O
+non	O
+-	O
+specialist	O
+reader	O
+of	O
+Avian	O
+Pathology	B-DISO
+with	O
+an	O
+overview	O
+of	O
+research	O
+carried	O
+out	O
+on	O
+infectious	B-DISO
+bronchitis	B-DISO
+over	O
+the	O
+40	O
+years	O
+since	O
+the	O
+journal	O
+was	O
+first	O
+published	O
+.	O
+
+However	O
+,	O
+the	O
+quantitative	O
+and	O
+qualitative	O
+measures	O
+of	O
+protein	B-CHED
+intrinsic	O
+disorder	O
+in	O
+species	B-SPEC
+with	O
+known	O
+genomes	O
+are	O
+still	O
+not	O
+available	O
+.	O
+
+Furthermore	O
+,	O
+although	O
+the	O
+correlation	O
+between	O
+high	O
+fraction	O
+of	O
+disordered	O
+residues	O
+and	O
+advanced	O
+species	B-SPEC
+has	O
+been	O
+reported	O
+,	O
+the	O
+details	O
+of	O
+this	O
+correlation	O
+and	O
+the	O
+connection	O
+between	O
+the	O
+disorder	O
+content	O
+and	O
+proteome	O
+complexity	O
+have	O
+not	O
+been	O
+reported	O
+as	O
+of	O
+yet	O
+.	O
+
+We	O
+are	O
+showing	O
+here	O
+that	O
+viruses	B-SPEC
+are	O
+characterized	O
+by	O
+the	O
+widest	O
+spread	O
+of	O
+the	O
+proteome	O
+disorder	O
+content	O
+(	O
+the	O
+percentage	O
+of	O
+disordered	O
+residues	O
+ranges	O
+from	O
+7	O
+.	O
+3	O
+%	O
+in	O
+human	O
+coronavirus	O
+NL63	O
+to	O
+77	O
+.	O
+3	O
+%	O
+in	O
+Avian	B-SPEC
+carcinoma	I-SPEC
+virus	I-SPEC
+).	O
+
+This	O
+suggests	O
+that	O
+the	O
+increased	O
+disorder	O
+content	O
+in	O
+eukaryotic	O
+proteomes	O
+might	O
+be	O
+used	O
+by	O
+nature	O
+to	O
+deal	O
+with	O
+the	O
+increased	O
+cell	B-COMP
+complexity	O
+due	O
+to	O
+the	O
+appearance	O
+of	O
+the	O
+various	O
+cellular	B-COMP
+compartments	B-ANAT
+.	O
+
+The	O
+murine	B-SPEC
+coronavirus	I-SPEC
+,	O
+mouse	B-DISO
+hepatitis	I-DISO
+virus	B-SPEC
+(	O
+MHV	B-SPEC
+),	O
+causes	O
+acute	B-DISO
+hepatitis	I-DISO
+in	O
+its	O
+natural	O
+host	B-COMP
+and	O
+provides	O
+a	O
+useful	O
+model	O
+for	O
+understanding	O
+virus	B-SPEC
+interaction	O
+with	O
+liver	B-ANAT
+cells	I-ANAT
+.	O
+
+Without	O
+concrete	O
+metrics	O
+,	O
+IHR	O
+may	O
+waste	O
+its	O
+considerable	O
+promise	O
+as	O
+an	O
+instrument	O
+for	O
+global	O
+health	O
+security	O
+against	O
+public	O
+health	O
+emergencies	B-DISO
+.	O
+
+TITLE	O
+:	O
+National	O
+survey	O
+of	O
+pandemic	O
+influenza	B-PATH
+A	I-PATH
+(	O
+H1N1	O
+)	O
+2009	O
+-	O
+associated	O
+encephalopathy	B-DISO
+in	O
+Japanese	O
+children	O
+.	O
+
+Febrile	B-DISO
+convulsion	I-DISO
+was	O
+noted	O
+at	O
+a	O
+higher	O
+rate	O
+in	O
+medical	O
+past	O
+-	O
+history	O
+in	O
+cases	O
+without	O
+sequelae	O
+(	O
+40	O
+of	O
+the	O
+149	O
+cases	O
+;	O
+27	O
+%)	O
+than	O
+in	O
+serious	O
+cases	O
+.	O
+
+In	O
+contrast	O
+,	O
+pre	O
+-	O
+existing	O
+epilepsy	O
+and	O
+mental	B-DISO
+retardation	I-DISO
+were	O
+observed	O
+more	O
+frequently	O
+in	O
+serious	O
+cases	O
+.	O
+
+SARS	B-DISO
+-	I-DISO
+CoV	I-DISO
+infection	I-DISO
+causes	O
+robust	O
+downregulation	B-PROC
+of	O
+cellular	B-PRGE
+ACE2	I-PRGE
+expression	B-PROC
+levels	O
+and	O
+it	O
+has	O
+been	O
+suggested	O
+that	O
+the	O
+SARS	B-PRGE
+-	I-PRGE
+CoV	I-PRGE
+effect	O
+on	O
+ACE2	B-PRGE
+is	O
+involved	O
+in	O
+the	O
+severity	O
+of	O
+disease	O
+.	O
+
+This	O
+deletion	O
+is	O
+similar	O
+to	O
+that	O
+observed	O
+in	O
+porcine	B-SPEC
+respiratory	O
+coronavirus	B-SPEC
+(	O
+PRCoV	O
+)	O
+when	O
+compared	O
+to	O
+transmissible	O
+gastroenteritis	B-DISO
+virus	B-SPEC
+,	O
+which	O
+correlates	O
+with	O
+reduced	O
+virulence	B-PROC
+.	O
+
+All	O
+specimens	O
+were	O
+also	O
+tested	O
+for	O
+the	O
+presence	O
+of	O
+other	O
+common	O
+respiratory	O
+viruses	B-SPEC
+and	O
+newly	O
+identified	O
+viruses	B-SPEC
+,	O
+human	B-SPEC
+metapneumovirus	I-SPEC
+(	O
+hMPV	B-SPEC
+)	O
+and	O
+human	B-SPEC
+bocavirus	I-SPEC
+(	O
+HBoV	O
+).	O
+
+All	O
+4	O
+non	O
+-	O
+SARS	B-DISO
+-	O
+associated	O
+HCoVs	O
+were	O
+more	O
+frequently	O
+detected	O
+by	O
+real	O
+-	O
+time	O
+RT	O
+-	O
+PCR	O
+assay	O
+in	O
+adults	O
+with	O
+URTI	B-DISO
+in	O
+Beijing	O
+and	O
+HCoV	B-SPEC
+-	I-SPEC
+229E	I-SPEC
+led	O
+to	O
+the	O
+most	O
+prevalent	O
+infection	B-DISO
+.	O
+
+TITLE	O
+:	O
+DNA	O
+block	B-CHED
+copolymers	I-CHED
+:	O
+functional	O
+materials	O
+for	O
+nanoscience	O
+and	O
+biomedicine	O
+.	O
+
+Synthetic	O
+macromolecules	B-CHED
+have	O
+changed	O
+the	O
+world	O
+and	O
+currently	O
+play	O
+a	O
+major	O
+role	O
+in	O
+all	O
+aspects	O
+of	O
+daily	O
+life	O
+.	O
+
+To	O
+fulfill	O
+the	O
+requirements	O
+of	O
+modern	O
+life	O
+,	O
+polymers	B-CHED
+and	O
+their	O
+composites	O
+have	O
+become	O
+increasingly	O
+complex	O
+.	O
+
+The	O
+microphase	O
+separation	B-DISO
+of	O
+the	O
+individual	O
+polymer	B-CHED
+components	O
+and	O
+the	O
+resulting	O
+formation	B-PROC
+of	O
+well	O
+defined	O
+nanosized	O
+domains	O
+provide	O
+a	O
+broad	O
+range	O
+of	O
+new	O
+materials	O
+with	O
+various	O
+properties	O
+.	O
+
+TITLE	O
+:	O
+Chinese	B-SPEC
+hamster	I-SPEC
+ovary	I-ANAT
+cell	B-COMP
+lines	O
+selected	O
+for	O
+resistance	B-PROC
+to	O
+ebolavirus	B-SPEC
+glycoprotein	B-CHED
+mediated	O
+infection	O
+are	O
+defective	O
+for	O
+NPC1	B-DISO
+expression	B-PROC
+.	O
+
+ABSTRACT	O
+:	O
+Ebolavirus	B-SPEC
+causes	O
+severe	O
+hemorrhagic	B-DISO
+fever	I-DISO
+in	O
+humans	B-SPEC
+and	O
+non	O
+-	O
+human	B-SPEC
+primates	B-SPEC
+.	O
+
+Susceptibility	O
+to	O
+vectors	O
+carrying	O
+SARS	B-PRGE
+coronavirus	B-SPEC
+S	I-PRGE
+or	O
+VSV	O
+-	O
+G	O
+glycoproteins	B-CHED
+suggests	O
+that	O
+endocytic	O
+and	O
+processing	O
+pathways	B-PROC
+utilized	O
+by	O
+other	O
+viruses	B-SPEC
+are	O
+intact	O
+in	O
+these	O
+cells	B-COMP
+.	O
+
+ABSTRACT	O
+:	O
+This	O
+paper	O
+describes	O
+the	O
+molecular	O
+detection	O
+of	O
+respiratory	O
+viruses	B-SPEC
+from	O
+nasopharyngeal	B-ANAT
+flocked	O
+swabs	O
+(	O
+flocked	O
+swabs	O
+)	O
+and	O
+nasopharyngeal	B-ANAT
+washes	O
+(	O
+washes	O
+)	O
+in	O
+a	O
+clinical	O
+setting	O
+.	O
+
+A	O
+better	O
+understanding	O
+of	O
+the	O
+formation	B-PROC
+,	O
+function	O
+,	O
+and	O
+relevance	O
+of	O
+MPs	O
+may	O
+give	O
+rise	O
+to	O
+new	O
+promising	O
+therapeutic	O
+strategies	O
+to	O
+modulate	O
+coagulation	B-PROC
+,	O
+inflammation	B-DISO
+,	O
+endothelial	B-ANAT
+function	O
+,	O
+and	O
+permeability	O
+either	O
+through	O
+removal	O
+or	O
+inhibition	B-PROC
+of	O
+""""	O
+detrimental	O
+""""	O
+MPs	O
+or	O
+through	O
+administration	O
+or	O
+stimulation	O
+of	O
+""""	O
+favorable	O
+""""	O
+MPs	O
+.	O
+
+ABSTRACT	O
+:	O
+Human	O
+coronavirus	O
+(	O
+HCoV	O
+)	O
+NL63	O
+,	O
+a	O
+newly	O
+discovered	O
+coronavirus	B-SPEC
+,	O
+has	O
+been	O
+associated	O
+with	O
+acute	O
+lower	B-DISO
+respiratory	I-DISO
+tract	I-DISO
+infections	I-DISO
+(	O
+ALRTI	O
+).	O
+
+The	O
+underlying	O
+mechanisms	O
+of	O
+SARS	B-DISO
+are	O
+still	O
+largely	O
+undefined	O
+.	O
+
+Effects	O
+of	O
+PTX3	B-PRGE
+on	O
+viral	O
+binding	B-FUNC
+and	O
+infectivity	O
+were	O
+determined	O
+in	O
+vitro	O
+.	O
+
+PTX3	B-PRGE
+deficiency	O
+enhanced	O
+early	O
+infiltration	B-DISO
+of	O
+neutrophils	B-ANAT
+and	O
+macrophages	B-ANAT
+in	O
+the	O
+lung	B-ANAT
+.	O
+
+TITLE	O
+:	O
+Severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+coronavirus	B-SPEC
+replication	O
+inhibitor	B-CHED
+that	O
+interferes	O
+with	O
+the	O
+nucleic	O
+acid	O
+unwinding	O
+of	O
+the	O
+viral	B-PRGE
+helicase	I-PRGE
+.	O
+
+SSYA10	O
+-	O
+001	O
+did	O
+not	O
+inhibit	O
+hepatitis	B-SPEC
+C	I-SPEC
+virus	I-SPEC
+(	O
+HCV	B-SPEC
+)	O
+helicase	O
+,	O
+other	O
+bacterial	O
+and	O
+viral	O
+RNA	O
+-	O
+dependent	O
+RNA	B-PRGE
+polymerases	I-PRGE
+,	O
+or	O
+reverse	B-PRGE
+transcriptase	I-PRGE
+.	O
+
+These	O
+results	O
+suggest	O
+that	O
+SSYA10	O
+-	O
+001	O
+specifically	O
+blocks	O
+nsp13	O
+through	O
+a	O
+novel	O
+mechanism	O
+and	O
+is	O
+less	O
+likely	O
+to	O
+interfere	O
+with	O
+the	O
+functions	O
+of	O
+cellular	B-COMP
+enzymes	O
+that	O
+process	O
+nucleic	B-CHED
+acids	I-CHED
+or	O
+ATP	B-CHED
+.	O
+
+Hence	O
+,	O
+it	O
+is	O
+possible	O
+that	O
+SSYA10	O
+-	O
+001	O
+inhibits	O
+unwinding	O
+by	O
+nsp13	O
+by	O
+affecting	O
+conformational	O
+changes	O
+during	O
+the	O
+course	O
+of	O
+the	O
+reaction	O
+or	O
+translocation	B-DISO
+on	O
+the	O
+nucleic	B-CHED
+acid	I-CHED
+.	O
+
+In	O
+all	O
+patients	O
+,	O
+foam	O
+was	O
+observed	O
+in	O
+the	O
+target	O
+vessels	B-ANAT
+at	O
+C	O
+-	O
+arm	B-ANAT
+CT	O
+.	O
+
+Although	O
+being	O
+extremely	O
+rare	O
+,	O
+scrub	B-DISO
+typhus	I-DISO
+can	O
+be	O
+life	O
+-	O
+threatening	O
+in	O
+an	O
+infant	O
+;	O
+therefore	O
+,	O
+physicians	O
+in	O
+endemic	O
+countries	O
+should	O
+be	O
+aware	O
+of	O
+the	O
+necessity	O
+for	O
+early	O
+recognition	O
+and	O
+prompt	O
+treatment	O
+of	O
+suspected	O
+cases	O
+.	O
+
+ABSTRACT	O
+:	O
+Type	O
+I	O
+interferons	O
+(	O
+IFNα	O
+/	O
+β	O
+)	O
+provide	O
+a	O
+primary	O
+defense	O
+against	O
+infection	B-DISO
+.	O
+
+Compared	O
+with	O
+microglia	B-ANAT
+,	O
+oligodendroglia	B-ANAT
+were	O
+characterized	O
+by	O
+low	O
+basal	O
+expression	B-PROC
+of	O
+mRNA	B-CHED
+encoding	O
+viral	O
+RNA	O
+sensing	O
+pattern	O
+recognition	O
+receptors	O
+(	O
+PRRs	B-DISO
+),	O
+IFNα	B-PRGE
+/	I-PRGE
+β	I-PRGE
+receptor	I-PRGE
+chains	I-PRGE
+,	O
+interferon	B-PRGE
+sensitive	I-PRGE
+genes	I-PRGE
+(	O
+ISG	O
+),	O
+as	O
+well	O
+as	O
+kinases	O
+and	O
+transcription	B-PROC
+factors	O
+critical	O
+in	O
+IFNα	O
+/	O
+β	O
+signaling	B-PROC
+.	O
+
+Although	O
+PRRs	B-DISO
+and	O
+ISGs	O
+were	O
+upregulated	O
+by	O
+infection	B-DISO
+in	O
+both	O
+cell	B-COMP
+types	O
+,	O
+the	O
+repertoire	O
+and	O
+absolute	O
+mRNA	B-CHED
+levels	O
+were	O
+more	O
+limited	O
+in	O
+oligodendroglia	B-ANAT
+.	O
+
+ABSTRACT	O
+:	O
+In	O
+leptospirosis	O
+,	O
+severe	O
+pulmonary	B-ANAT
+hemorrhagic	O
+syndrome	B-DISO
+has	O
+replaced	O
+Weil	B-DISO
+'	I-DISO
+s	I-DISO
+disease	I-DISO
+as	O
+the	O
+main	O
+cause	O
+of	O
+mortality	O
+,	O
+with	O
+rates	O
+of	O
+up	O
+to	O
+75	O
+%.	O
+
+Four	O
+men	O
+,	O
+all	O
+farmers	O
+,	O
+were	O
+admitted	O
+to	O
+the	O
+intensive	O
+care	O
+unit	O
+between	O
+August	O
+2009	O
+and	O
+July	O
+2010	O
+with	O
+a	O
+diagnosis	O
+of	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+.	O
+
+Data	O
+of	O
+20	O
+SARS	B-DISO
+-	O
+associated	O
+serum	B-COMP
+proteomic	O
+features	O
+and	O
+ten	O
+serological	O
+variables	O
+from	O
+38	O
+SARS	B-DISO
+adult	O
+patients	O
+before	O
+treatment	O
+were	O
+subjected	O
+to	O
+multivariate	O
+logistic	O
+regression	O
+.	O
+
+After	O
+purification	O
+by	O
+cation	B-CHED
+-	O
+exchange	O
+chromatography	O
+and	O
+gel	O
+electrophoresis	O
+,	O
+proteomic	O
+features	O
+of	O
+m	O
+/	O
+z	O
+7769	O
+and	O
+m	O
+/	O
+z	O
+8865	O
+were	O
+found	O
+to	O
+be	O
+platelet	B-PRGE
+factor	I-PRGE
+4	I-PRGE
+(	O
+PF4	B-PRGE
+)	O
+and	O
+beta	O
+-	O
+thromboglobulin	O
+(	O
+beta	B-PRGE
+-	I-PRGE
+TG	I-PRGE
+)	O
+by	O
+tandem	O
+mass	O
+spectrometry	O
+,	O
+respectively	O
+.	O
+
+The	O
+proportion	O
+of	O
+TCRγδ	O
+(+)	O
+DN	O
+T	B-ANAT
+cells	I-ANAT
+in	O
+liver	B-ANAT
+CD3	B-PRGE
+(+)	O
+T	B-ANAT
+cells	I-ANAT
+was	O
+markedly	O
+increased	O
+after	O
+MHV	B-SPEC
+-	O
+3	O
+infection	B-DISO
+.	O
+
+Adoptive	O
+transfer	O
+of	O
+TCRγδ	O
+(+)	O
+DN	O
+T	B-ANAT
+cells	I-ANAT
+led	O
+to	O
+dramatically	O
+decreased	O
+survival	O
+in	O
+MHV	B-SPEC
+-	O
+3	O
+-	O
+infected	O
+mice	B-SPEC
+,	O
+accompanied	O
+by	O
+deteriorated	O
+histopathology	O
+and	O
+elevated	O
+ALT	B-FUNC
+and	O
+AST	B-PRGE
+levels	O
+.	O
+
+These	O
+results	O
+indicate	O
+that	O
+liver	B-ANAT
+TCRγδ	O
+(+)	O
+DN	O
+T	B-ANAT
+cells	I-ANAT
+play	O
+a	O
+critical	O
+role	O
+in	O
+the	O
+liver	B-ANAT
+injury	O
+in	O
+MHV	B-SPEC
+-	O
+3	O
+-	O
+induced	O
+hepatitis	B-DISO
+,	O
+via	O
+a	O
+TNF	B-PRGE
+-	I-PRGE
+α	I-PRGE
+dependent	O
+pathway	B-PROC
+.	O
+
+TITLE	O
+:	O
+Tracing	O
+the	O
+transmission	O
+of	O
+bovine	B-SPEC
+coronavirus	B-DISO
+infections	I-DISO
+in	O
+cattle	B-SPEC
+herds	O
+based	O
+on	O
+S	B-PRGE
+gene	I-PRGE
+diversity	O
+.	O
+
+In	O
+order	B-SPEC
+to	O
+investigate	O
+the	O
+molecular	O
+epidemiology	O
+of	O
+BCoV	O
+,	O
+27	O
+reverse	B-PROC
+transcription	I-PROC
+polymerase	O
+chain	O
+reaction	O
+(	O
+RT	O
+-	O
+PCR	O
+)	O
+positive	O
+samples	O
+from	O
+25	O
+cattle	B-SPEC
+herds	O
+in	O
+different	O
+parts	O
+of	O
+Sweden	O
+were	O
+analysed	O
+.	O
+
+ABSTRACT	O
+:	O
+Porcine	B-SPEC
+reproductive	I-SPEC
+and	I-SPEC
+respiratory	I-SPEC
+syndrome	I-SPEC
+virus	I-SPEC
+(	O
+PRRSV	B-SPEC
+)	O
+is	O
+not	O
+only	O
+a	O
+poor	O
+inducer	O
+of	O
+type	O
+I	O
+interferon	B-PRGE
+but	O
+also	O
+inhibits	O
+the	O
+efficient	O
+induction	O
+of	O
+type	B-PRGE
+I	I-PRGE
+interferon	I-PRGE
+by	O
+porcine	B-DISO
+transmissible	I-DISO
+gastroenteritis	I-DISO
+virus	B-SPEC
+(	O
+TGEV	B-SPEC
+)	O
+and	O
+synthetic	O
+dsRNA	B-CHED
+molecules	O
+,	O
+Poly	O
+I	O
+:	O
+C	O
+.	O
+However	O
+,	O
+the	O
+mechanistic	O
+basis	O
+by	O
+which	O
+PRRSV	B-SPEC
+interferes	O
+with	O
+the	O
+induction	O
+of	O
+type	B-PRGE
+I	I-PRGE
+interferon	I-PRGE
+in	O
+its	O
+natural	O
+host	B-COMP
+cells	B-COMP
+remains	O
+less	O
+well	O
+defined	O
+.	O
+
+Atypical	O
+T	O
+(	O
+regs	O
+)	O
+express	O
+FoxP3	B-PRGE
+and	O
+CD4	B-PRGE
+but	O
+have	O
+no	O
+surface	O
+expression	B-PROC
+of	O
+CD25	B-PRGE
+.	O
+
+The	O
+function	O
+of	O
+inducible	O
+T	O
+(	O
+regs	O
+)	O
+is	O
+presumably	O
+to	O
+maintain	O
+immune	O
+homeostasis	O
+,	O
+especially	O
+in	O
+the	O
+context	O
+of	O
+chronic	O
+inflammation	B-DISO
+or	I-DISO
+infection	I-DISO
+.	O
+
+Nineteen	O
+deaths	B-PROC
+occurred	O
+,	O
+13	O
+of	O
+which	O
+had	O
+a	O
+cytomegalovirus	B-SPEC
+viral	O
+load	O
+≥	O
+log	O
+4	O
+.	O
+
+The	O
+objective	O
+was	O
+to	O
+assess	O
+the	O
+effectiveness	O
+of	O
+HFNC	O
+oxygen	B-CHED
+therapy	O
+in	O
+adult	O
+patients	O
+with	O
+SARI	O
+by	O
+confirmed	O
+2009	O
+influenza	B-PATH
+A	I-PATH
+/	O
+H1N1v	O
+infection	B-DISO
+(	O
+by	O
+real	O
+-	O
+time	O
+reverse	B-PROC
+transcription	I-PROC
+polymerase	O
+chain	O
+reaction	O
+testing	O
+).	O
+
+Many	O
+,	O
+if	O
+not	O
+most	O
+,	O
+of	O
+all	O
+important	O
+zoonoses	O
+relate	O
+in	O
+some	O
+way	O
+to	O
+animals	B-SPEC
+in	O
+the	O
+food	O
+production	O
+chain	O
+.	O
+
+Examples	O
+range	O
+from	O
+BSE	B-DISO
+and	O
+E	B-SPEC
+.	I-SPEC
+coli	I-SPEC
+outbreaks	O
+over	O
+dioxin	B-CHED
+crises	O
+to	O
+intentional	O
+melamine	B-CHED
+contamination	O
+.	O
+
+Food	O
+related	O
+zoonoses	B-DISO
+can	O
+be	O
+separated	O
+in	O
+three	O
+major	O
+classes	O
+:	O
+parasites	O
+,	O
+bacteria	B-SPEC
+,	O
+and	O
+viruses	B-SPEC
+.	O
+
+While	O
+parasites	O
+often	O
+relate	O
+to	O
+very	O
+specific	O
+animal	B-SPEC
+hosts	B-COMP
+and	O
+contribute	O
+significantly	O
+to	O
+the	O
+human	B-SPEC
+disease	O
+burden	O
+,	O
+virus	B-SPEC
+have	O
+often	O
+been	O
+related	O
+to	O
+major	O
+,	O
+well	O
+-	O
+published	O
+global	O
+outbreaks	O
+,	O
+e	O
+.	O
+g	O
+.	O
+SARS	B-DISO
+and	O
+avian	B-SPEC
+-	O
+and	O
+swine	B-SPEC
+-	O
+influenza	B-DISO
+.	O
+
+ABSTRACT	O
+:	O
+Due	O
+to	O
+the	O
+progress	O
+of	O
+targeted	O
+recombination	B-PROC
+and	O
+reverse	O
+genetics	O
+technique	O
+,	O
+it	O
+is	O
+possible	O
+to	O
+express	O
+foreign	O
+genes	O
+using	O
+coronaviruses	O
+as	O
+a	O
+vector	O
+via	O
+its	O
+unique	O
+transcription	B-PROC
+mechanism	O
+.	O
+
+By	O
+modification	O
+of	O
+the	O
+infectious	B-DISO
+cDNA	O
+of	O
+the	O
+genome	O
+of	O
+coronaviruse	O
+,	O
+it	O
+has	O
+led	O
+to	O
+an	O
+efficient	O
+(>	O
+50	O
+microg	O
+/	O
+10	O
+(	O
+6	O
+)	O
+cells	B-COMP
+)	O
+and	O
+stable	O
+(>	O
+30	O
+passages	O
+)	O
+expression	B-PROC
+of	O
+the	O
+foreign	O
+gene	O
+.	O
+
+Of	O
+17	O
+autopsies	O
+,	O
+13	O
+revealed	O
+that	O
+death	B-PROC
+could	O
+be	O
+attributed	O
+to	O
+P	B-SPEC
+.	I-SPEC
+vivax	I-SPEC
+infection	B-DISO
+;	O
+in	O
+the	O
+remaining	O
+4	O
+,	O
+acute	B-DISO
+diseases	I-DISO
+other	O
+than	O
+malaria	B-PATH
+were	O
+found	O
+to	O
+be	O
+the	O
+cause	O
+of	O
+death	B-PROC
+.	O
+
+The	O
+primary	O
+complication	B-DISO
+in	O
+patients	O
+in	O
+which	O
+malaria	B-PATH
+contributed	O
+to	O
+death	B-PROC
+was	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+(	O
+ARDS	B-DISO
+)	O
+and	O
+pulmonary	B-DISO
+edema	I-DISO
+associated	O
+with	O
+the	O
+accumulation	O
+of	O
+neutrophils	B-ANAT
+in	O
+the	O
+interalveolar	O
+space	O
+(	O
+6	O
+cases	O
+).	O
+
+Experts	O
+say	O
+that	O
+the	O
+number	O
+of	O
+animal	B-SPEC
+to	O
+human	B-SPEC
+""""	O
+species	B-SPEC
+jumps	O
+""""	O
+is	O
+bound	O
+to	O
+increase	O
+as	O
+populations	O
+increase	O
+and	O
+the	O
+speed	O
+of	O
+travel	O
+between	O
+continents	O
+accelerates	O
+.	O
+
+Typical	O
+pandemic	O
+timelines	O
+no	O
+longer	O
+apply	O
+.(	O
+1	O
+)	O
+Pandemic	O
+H1N1	O
+traveled	O
+the	O
+world	O
+in	O
+just	O
+weeks	O
+,	O
+as	O
+did	O
+SARS	B-DISO
+,	O
+despite	O
+major	O
+efforts	O
+to	O
+contain	O
+both	O
+outbreaks	O
+.	O
+
+TITLE	O
+:	O
+Pleural	B-ANAT
+effusion	I-ANAT
+following	O
+ovarian	B-DISO
+hyperstimulation	I-DISO
+.	O
+
+TITLE	O
+:	O
+Cleistanthus	B-SPEC
+collinus	O
+poisoning	O
+.	O
+
+MEDLINE	O
+(	O
+PUBMED	O
+)	O
+and	O
+Google	O
+were	O
+searched	O
+for	O
+published	O
+papers	O
+using	O
+the	O
+search	O
+/	O
+MeSH	O
+terms	O
+""""	O
+Cleistanthus	B-SPEC
+collinus	O
+","""	O
+""""	O
+Euphorbiaceae	B-SPEC
+","""	O
+""""	O
+Diphyllin	O
+","""	O
+""""	O
+Cleistanthin	O
+A	O
+","""	O
+Cleistanthin	O
+B	O
+""""	O
+and	O
+""""	O
+Oduvanthalai	O
+.	O
+
+Human	B-SPEC
+toxicity	O
+results	O
+in	O
+renal	B-DISO
+tubular	I-DISO
+dysfunction	I-DISO
+,	O
+commonly	O
+dRTA	O
+,	O
+with	O
+resultant	O
+hypokalemia	O
+and	O
+normal	O
+anion	B-CHED
+gap	O
+metabolic	B-DISO
+acidosis	I-DISO
+.	O
+
+Acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+(	O
+ARDS	B-DISO
+)	O
+is	O
+seen	O
+in	O
+severe	O
+cases	O
+.	O
+
+ABSTRACT	O
+:	O
+A	O
+few	O
+months	O
+into	O
+the	O
+2009	O
+influenza	O
+pandemic	O
+,	O
+nine	O
+European	O
+countries	O
+implemented	O
+case	O
+-	O
+based	O
+surveillance	O
+of	O
+hospitalised	O
+severe	O
+influenza	B-DISO
+infections	B-DISO
+.	O
+
+In	O
+the	O
+present	O
+study	O
+,	O
+we	O
+assess	O
+the	O
+association	O
+between	O
+patient	O
+characteristics	O
+,	O
+in	O
+particular	O
+underlying	O
+conditions	O
+,	O
+and	O
+the	O
+severity	O
+level	O
+of	O
+influenza	B-PATH
+A	I-PATH
+(	O
+H1N1	O
+)	O
+pdm09	O
+infection	B-DISO
+during	O
+the	O
+2010	O
+-	O
+2011	O
+season	O
+.	O
+
+The	O
+nsp12	O
+preferentially	O
+copied	O
+homopolymeric	O
+pyrimidine	B-CHED
+RNA	O
+templates	O
+in	O
+the	O
+absence	O
+of	O
+an	O
+added	O
+oligonucleotide	B-CHED
+primer	O
+.	O
+
+In	O
+a	O
+fibrotic	O
+cell	B-COMP
+model	O
+with	O
+transforming	B-PRGE
+growth	I-PRGE
+factor	I-PRGE
+beta	I-PRGE
+-	I-PRGE
+1	I-PRGE
+induction	O
+,	O
+the	O
+human	B-SPEC
+lung	B-ANAT
+epithelial	O
+A549	O
+acquired	O
+a	O
+mesenchymal	O
+phenotype	O
+and	O
+an	O
+increase	O
+of	O
+vimentin	B-COMP
+expression	B-PROC
+with	O
+a	O
+concomitant	O
+decrease	O
+of	O
+E	B-PRGE
+-	I-PRGE
+cadherin	I-PRGE
+.	O
+
+The	O
+clinical	O
+outcome	O
+measures	O
+included	O
+the	O
+mortality	O
+rate	O
+at	O
+28th	O
+day	O
+,	O
+respiratory	O
+index	O
+(	O
+FiO2	O
+/	O
+PO2	B-PROC
+),	O
+dynamic	O
+lung	B-PROC
+compliance	I-PROC
+(	O
+Cdyn	O
+),	O
+arterial	B-ANAT
+partial	B-PROC
+pressure	I-PROC
+of	I-PROC
+oxygen	I-PROC
+(	O
+PaO2	O
+),	O
+arterial	B-ANAT
+partial	O
+pressure	O
+of	O
+carbon	B-CHED
+dioxide	I-CHED
+(	O
+PaCO2	O
+),	O
+mechanical	O
+ventilation	O
+parameters	O
+,	O
+vasoactive	O
+drug	O
+dose	O
+and	O
+lung	O
+X	O
+-	O
+ray	B-SPEC
+changes	O
+.	O
+
+Death	B-PROC
+occurred	O
+in	O
+54	O
+cases	O
+,	O
+the	O
+total	O
+mortality	O
+was	O
+36	O
+.	O
+7	O
+%.	O
+
+PaO2	O
+/	O
+FiO2	O
+and	O
+Cdyn	O
+were	O
+improved	O
+after	O
+2	O
+hours	O
+CBP	O
+treatment	O
+compared	O
+with	O
+those	O
+before	O
+CBP	O
+treatment	O
+(	O
+P	O
+<	O
+0	O
+.	O
+05	O
+),	O
+mechanical	O
+ventilation	O
+parameters	O
+including	O
+fraction	O
+of	O
+inspired	B-PROC
+oxygen	B-CHED
+(	O
+FiO2	O
+),	O
+peak	O
+inspiratory	B-PROC
+pressure	O
+(	O
+PiP	B-CHED
+)	O
+and	O
+positive	O
+end	O
+expiratory	B-PROC
+pressure	O
+(	O
+PEEP	B-CHED
+)	O
+were	O
+reduced	O
+.	O
+
+The	O
+mortality	O
+on	O
+CBP	B-PRGE
+treatment	O
+group	O
+and	O
+non	O
+-	O
+treatment	O
+group	O
+were	O
+37	O
+.	O
+5	O
+%	O
+and	O
+36	O
+.	O
+5	O
+%,	O
+respectively	O
+,	O
+the	O
+difference	O
+was	O
+not	O
+significant	O
+(	O
+P	O
+>	O
+0	O
+.	O
+05	O
+).	O
+
+Twenty	O
+-	O
+three	O
+infants	O
+with	O
+ventricular	B-DISO
+septal	I-DISO
+defect	I-DISO
+(	O
+VSD	B-DISO
+)	O
+were	O
+enrolled	O
+in	O
+the	O
+study	O
+.	O
+
+Ten	O
+infant	O
+patients	O
+in	O
+the	O
+treatment	O
+group	O
+were	O
+given	O
+pulmonary	B-ANAT
+surfactant	B-CHED
+by	O
+tracheal	O
+instillation	O
+during	O
+mechanical	O
+ventilating	O
+postoperatively	O
+.	O
+
+In	O
+the	O
+first	O
+24	O
+hours	O
+after	O
+heart	B-ANAT
+surgery	O
+,	O
+compared	O
+with	O
+the	O
+control	O
+group	O
+,	O
+a	O
+more	O
+increased	O
+oxygenation	B-PROC
+index	O
+(	O
+from	O
+89	O
+.	O
+36	O
+±	O
+12	O
+.	O
+69	O
+to	O
+285	O
+±	O
+16	O
+.	O
+51	O
+)	O
+was	O
+observed	O
+in	O
+treatment	O
+group	O
+,	O
+and	O
+it	O
+was	O
+from	O
+93	O
+.	O
+71	O
+±	O
+11	O
+.	O
+82	O
+to	O
+133	O
+±	O
+19	O
+.	O
+62	O
+in	O
+the	O
+control	O
+group	O
+.	O
+
+ICU	O
+stay	O
+time	O
+of	O
+treatment	O
+group	O
+(	O
+3	O
+.	O
+90	O
+±	O
+1	O
+.	O
+34	O
+)	O
+d	O
+was	O
+shorter	O
+than	O
+that	O
+of	O
+control	O
+group	O
+[(	O
+6	O
+.	O
+18	O
+±	O
+1	O
+.	O
+90	O
+)	O
+d	O
+,	O
+P	O
+<	O
+0	O
+.	O
+05	O
+].	O
+Two	O
+infants	O
+of	O
+the	O
+control	O
+group	O
+died	B-PROC
+,	O
+but	O
+none	O
+in	O
+treatment	O
+group	O
+died	B-PROC
+.	O
+
+CONCLUSIONS	O
+:	O
+In	O
+this	O
+study	O
+,	O
+a	O
+satisfactory	O
+curative	O
+effect	O
+was	O
+observed	O
+for	O
+the	O
+treatment	O
+of	O
+acute	O
+lung	B-ANAT
+injury	O
+with	O
+PS	O
+intratracheal	O
+instillation	O
+after	O
+heart	B-ANAT
+surgery	O
+under	O
+cardiopulmonary	B-ANAT
+bypass	O
+in	O
+infant	O
+patients	O
+.	O
+
+Improved	O
+outcome	O
+from	O
+using	O
+ECMO	O
+for	O
+respiratory	B-DISO
+failure	I-DISO
+has	O
+been	O
+reported	O
+worldwide	O
+,	O
+ranging	O
+from	O
+15	O
+%	O
+to	O
+over	O
+50	O
+%	O
+in	O
+recent	O
+reviews	O
+.(	O
+1	O
+,	O
+2	O
+)	O
+The	O
+rationale	O
+of	O
+this	O
+therapy	O
+is	O
+to	O
+allow	O
+time	O
+for	O
+the	O
+lungs	B-ANAT
+to	O
+heal	B-PROC
+,	O
+minimizing	O
+further	O
+lung	B-ANAT
+injury	O
+from	O
+positive	O
+pressure	O
+ventilation	O
+.(	O
+3	O
+,	O
+4	O
+)	O
+We	O
+describe	O
+a	O
+case	O
+of	O
+severe	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+(	O
+ARDS	B-DISO
+)	O
+with	O
+extensive	O
+barotrauma	O
+supported	O
+by	O
+VV	O
+-	O
+ECMO	O
+for	O
+96	O
+days	O
+in	O
+a	O
+resource	O
+-	O
+limited	O
+center	O
+.	O
+
+Therefore	O
+,	O
+when	O
+the	O
+prevalence	O
+of	O
+FIP	B-DISO
+is	O
+low	O
+,	O
+the	O
+A	O
+:	O
+G	O
+ratio	O
+is	O
+useful	O
+to	O
+rule	O
+out	O
+FIP	B-DISO
+but	O
+is	O
+not	O
+helpful	O
+in	O
+making	O
+a	O
+positive	O
+diagnosis	O
+of	O
+FIP	B-DISO
+.	O
+
+Timely	O
+intervention	O
+and	O
+administration	O
+of	O
+Oseltamivir	B-CHED
+may	O
+need	O
+to	O
+be	O
+modified	O
+.	O
+
+Infection	B-DISO
+and	O
+malignant	O
+involvement	O
+are	O
+the	O
+most	O
+common	O
+causes	O
+of	O
+pleural	B-DISO
+effusion	I-DISO
+in	O
+patients	O
+with	O
+acute	B-DISO
+leukemia	I-DISO
+or	O
+MDS	B-DISO
+.	O
+
+TITLE	O
+:	O
+Enteropathogens	O
+identified	O
+in	O
+cats	B-SPEC
+entering	O
+a	O
+Florida	O
+animal	B-SPEC
+shelter	O
+with	O
+normal	O
+feces	B-ANAT
+or	O
+diarrhea	B-DISO
+.	O
+
+ABSTRACT	O
+:	O
+To	O
+determine	O
+the	O
+frequency	O
+of	O
+enteropathogens	O
+in	O
+cats	B-SPEC
+entering	O
+an	O
+animal	B-SPEC
+shelter	O
+with	O
+normal	O
+feces	B-ANAT
+or	O
+diarrhea	B-DISO
+.	O
+
+In	O
+the	O
+present	O
+study	O
+,	O
+cats	B-SPEC
+entered	O
+the	O
+shelter	O
+with	O
+a	O
+variety	O
+of	O
+enteropathogens	O
+,	O
+many	O
+of	O
+which	O
+are	O
+pathogenic	O
+or	O
+zoonotic	O
+.	O
+
+Dogs	B-SPEC
+entered	O
+the	O
+shelter	O
+with	O
+a	O
+variety	O
+of	O
+enteropathogens	O
+,	O
+many	O
+of	O
+which	O
+are	O
+pathogenic	O
+or	O
+zoonotic	O
+.	O
+
+ABSTRACT	O
+:	O
+Respiratory	O
+virus	O
+infections	B-DISO
+cause	O
+significant	O
+morbidity	O
+and	O
+mortality	O
+in	O
+immunocompromised	O
+patients	O
+.	O
+
+This	O
+review	O
+discusses	O
+recent	O
+progress	O
+in	O
+studies	O
+of	O
+virus	B-SPEC
+-	O
+host	B-COMP
+interactions	O
+during	O
+animal	B-SPEC
+and	O
+human	B-SPEC
+coronavirus	I-SPEC
+and	O
+arterivirus	B-DISO
+infections	I-DISO
+,	O
+with	O
+emphasis	O
+on	O
+IBV	B-SPEC
+-	O
+host	B-COMP
+cell	I-COMP
+interactions	O
+.	O
+
+ABSTRACT	O
+:	O
+Coronaviruses	O
+are	O
+enveloped	O
+positive	O
+-	O
+stranded	O
+RNA	O
+viruses	O
+that	O
+replicate	O
+in	O
+the	O
+cytoplasm	B-COMP
+.	O
+
+We	O
+describe	O
+the	O
+clinical	O
+and	O
+epidemiologic	O
+features	O
+of	O
+hospitalized	O
+patients	O
+who	O
+survived	O
+and	O
+patients	O
+who	O
+died	B-PROC
+because	O
+of	O
+pandemic	O
+2009	O
+influenza	B-PATH
+A	I-PATH
+(	O
+H1N1	O
+)	O
+infection	B-DISO
+reported	O
+in	O
+Santa	O
+Fe	O
+,	O
+Argentina	B-SPEC
+,	O
+from	O
+May	O
+to	O
+July	O
+2009	O
+.	O
+
+During	O
+the	O
+study	O
+period	O
+,	O
+there	O
+were	O
+242	O
+cases	O
+of	O
+hospitalization	O
+or	O
+death	B-PROC
+.	O
+
+The	O
+mean	O
+age	O
+was	O
+27	O
+·	O
+8	O
+years	O
+for	O
+surviving	O
+and	O
+39	O
+·	O
+6	O
+for	O
+those	O
+who	O
+died	B-PROC
+.	O
+
+Of	O
+the	O
+242	O
+patients	O
+,	O
+68	O
+%	O
+had	O
+findings	O
+consistent	O
+with	O
+pneumonia	B-DISO
+.	O
+
+TITLE	O
+:	O
+Antiviral	B-CHED
+activity	O
+of	O
+zinc	B-CHED
+salts	B-CHED
+against	O
+transmissible	O
+gastroenteritis	B-DISO
+virus	B-SPEC
+in	O
+vitro	O
+.	O
+
+ABSTRACT	O
+:	O
+Shortly	O
+after	O
+the	O
+advent	O
+of	O
+severe	O
+acute	O
+respiratory	O
+syndrome	O
+and	O
+the	O
+avian	B-DISO
+influenza	I-DISO
+,	O
+the	O
+emergence	O
+of	O
+the	O
+influenza	B-PATH
+A	I-PATH
+(	O
+H1N1	O
+)	O
+2009	O
+pandemic	O
+caused	O
+significant	O
+vibrations	O
+to	O
+the	O
+public	O
+health	O
+authorities	O
+and	O
+stressed	O
+the	O
+health	O
+systems	O
+worldwide	O
+.	O
+
+To	O
+further	O
+analyze	O
+this	O
+functions	O
+,	O
+the	O
+interaction	O
+of	O
+SARS	B-PRGE
+-	I-PRGE
+CoV	I-PRGE
+protein	B-CHED
+6	I-PRGE
+with	O
+other	O
+viral	O
+and	O
+/	O
+or	O
+cellular	B-COMP
+factors	O
+has	O
+been	O
+analyzed	O
+during	O
+SARS	B-DISO
+-	O
+CoV	O
+infective	O
+cycle	O
+.	O
+
+Risk	O
+of	O
+mortality	O
+in	O
+vivax	B-DISO
+malaria	I-DISO
+was	O
+highest	O
+in	O
+patients	O
+with	O
+ARDS	B-DISO
+followed	O
+by	O
+MODS	B-DISO
+and	O
+shock	O
+.	O
+
+METHODS	O
+:	O
+A	O
+retrospective	O
+chart	O
+review	O
+of	O
+patients	O
+admitted	O
+with	O
+parasitologically	O
+confirmed	O
+malaria	B-PATH
+between	O
+January	O
+and	O
+December	O
+2010	O
+.	O
+
+Our	O
+outcome	O
+measures	O
+for	O
+this	O
+study	O
+included	O
+survival	O
+to	O
+discharge	B-ANAT
+,	O
+length	O
+of	O
+ECLS	O
+run	O
+,	O
+days	O
+undergoing	O
+mechanical	O
+ventilation	O
+,	O
+days	O
+in	O
+an	O
+intensive	O
+care	O
+unit	O
+,	O
+total	O
+length	O
+of	O
+hospital	O
+stay	O
+,	O
+adjunct	O
+therapies	O
+and	O
+procedures	O
+,	O
+and	O
+complications	O
+.	O
+
+Compared	O
+with	O
+controls	O
+,	O
+the	O
+proportion	O
+of	O
+patients	O
+with	O
+positive	O
+granulocytes	B-ANAT
+and	O
+monocytes	B-ANAT
+was	O
+higher	O
+among	O
+sick	O
+cats	B-SPEC
+(	O
+especially	O
+cats	B-SPEC
+with	O
+diseases	O
+other	O
+than	O
+FIP	B-DISO
+)	O
+and	O
+cats	B-SPEC
+with	O
+high	O
+serum	B-COMP
+AGP	O
+concentration	O
+,	O
+but	O
+not	O
+in	O
+cats	B-SPEC
+with	O
+leucocytosis	B-DISO
+or	O
+that	O
+were	O
+FCoV	O
+-	O
+seropositive	O
+.	O
+
+CONCLUSIONS	O
+:	O
+AGP	O
+-	O
+positive	O
+leucocytes	B-ANAT
+can	O
+be	O
+found	O
+in	O
+feline	B-SPEC
+blood	B-ANAT
+,	O
+especially	O
+during	O
+inflammation	B-DISO
+.	O
+
+TITLE	O
+:	O
+Comparison	O
+of	O
+three	O
+multiplex	O
+PCR	O
+assays	O
+for	O
+the	O
+detection	O
+of	O
+respiratory	O
+viral	B-DISO
+infections	I-DISO
+:	O
+evaluation	O
+of	O
+xTAG	O
+respiratory	O
+virus	O
+panel	O
+fast	B-FUNC
+assay	O
+,	O
+RespiFinder	O
+19	O
+assay	O
+and	O
+RespiFinder	O
+SMART	O
+22	O
+assay	O
+.	O
+
+Multiple	O
+infections	B-DISO
+were	O
+detected	O
+in	O
+16	O
+TS	O
+samples	O
+(	O
+32	O
+%)	O
+by	O
+RespiFinder	O
+-	O
+19	O
+.	O
+
+RESULTS	O
+:	O
+To	O
+compare	O
+the	O
+analytical	O
+sensitivity	O
+of	O
+the	O
+multiplex	O
+assays	O
+,	O
+samples	O
+were	O
+inoculated	O
+with	O
+13	O
+different	O
+quantified	O
+viruses	B-SPEC
+in	O
+the	O
+range	O
+of	O
+10	O
+(	O
+1	O
+)	O
+to	O
+10	O
+(	O
+5	O
+)	O
+copies	O
+/	O
+ml	O
+.	O
+
+TITLE	O
+:	O
+Genomic	O
+and	O
+serological	O
+detection	O
+of	O
+bat	B-ENZY
+coronavirus	B-SPEC
+from	O
+bats	B-SPEC
+in	O
+the	O
+Philippines	O
+.	O
+
+TITLE	O
+:	O
+[	O
+Clinical	O
+signs	O
+of	O
+endothelial	B-ANAT
+disorders	O
+in	O
+patients	O
+with	O
+severe	B-DISO
+sepsis	I-DISO
+].	O
+
+TITLE	O
+:	O
+Infectious	B-DISO
+bronchitis	B-DISO
+virus	B-SPEC
+nucleoprotein	O
+specific	O
+CTL	B-ANAT
+response	O
+is	O
+generated	O
+prior	O
+to	O
+serum	B-COMP
+IgG	B-PRGE
+.	O
+ABSTRACT	O
+:	O
+Infectious	B-DISO
+bronchitis	B-DISO
+(	O
+IB	O
+)	O
+is	O
+an	O
+acute	O
+and	O
+highly	O
+contagious	O
+viral	O
+respiratory	B-DISO
+disease	I-DISO
+of	O
+chickens	B-SPEC
+.	O
+
+However	O
+,	O
+serum	B-PRGE
+IgG	I-PRGE
+dramatically	O
+increased	O
+after	O
+M41	O
+challenge	O
+.	O
+
+However	O
+,	O
+chickens	B-SPEC
+vaccinated	O
+with	O
+H52	O
+did	O
+not	O
+demonstrate	O
+clinical	O
+signs	O
+or	O
+histological	O
+changes	O
+post	O
+challenge	O
+with	O
+M41	O
+.	O
+
+ABSTRACT	O
+:	O
+Clinicians	O
+often	O
+do	O
+not	O
+consider	O
+the	O
+presence	O
+of	O
+more	O
+than	O
+one	O
+viral	O
+etiologic	O
+agent	O
+in	O
+respiratory	O
+infection	O
+,	O
+and	O
+in	O
+many	O
+cases	O
+they	O
+order	B-SPEC
+diagnostics	O
+for	O
+influenza	B-SPEC
+viruses	I-SPEC
+or	O
+recently	O
+even	O
+only	O
+for	O
+A	O
+(	O
+H1N1	O
+)	O
+2009	O
+virus	B-SPEC
+.	O
+
+However	O
+,	O
+in	O
+a	O
+substantial	O
+number	O
+of	O
+patients	O
+with	O
+a	O
+respiratory	B-DISO
+tract	I-DISO
+disease	I-DISO
+,	O
+co	B-DISO
+-	I-DISO
+infection	I-DISO
+with	O
+various	O
+viral	O
+pathogens	O
+has	O
+been	O
+confirmed	O
+.	O
+
+ABSTRACT	O
+:	O
+This	O
+study	O
+compared	O
+the	O
+complete	O
+genome	O
+sequences	O
+of	O
+16	O
+NL63	O
+strain	O
+human	B-SPEC
+coronaviruses	O
+(	O
+hCoVs	O
+)	O
+from	O
+respiratory	O
+specimens	O
+of	O
+paediatric	O
+patients	O
+with	O
+respiratory	B-DISO
+disease	I-DISO
+in	O
+Colorado	O
+,	O
+USA	O
+,	O
+and	O
+characterized	O
+the	O
+epidemiology	O
+and	O
+clinical	O
+characteristics	O
+associated	O
+with	O
+circulating	O
+NL63	O
+viruses	B-SPEC
+over	O
+a	O
+3	O
+-	O
+year	O
+period	O
+.	O
+
+Perinatal	O
+risk	O
+factors	O
+for	O
+ROP	B-DISO
+were	O
+assessed	O
+using	O
+univariate	O
+and	O
+multivariate	O
+analysis	O
+.	O
+
+Infants	O
+who	O
+progressed	O
+to	O
+stage	O
+3	O
+ROP	B-DISO
+were	O
+given	O
+laser	B-SPEC
+therapy	O
+.	O
+
+Univariate	O
+analysis	O
+showed	O
+that	O
+there	O
+was	O
+a	O
+significant	O
+relationship	O
+between	O
+the	O
+occurrence	O
+of	O
+ROP	B-DISO
+and	O
+gestational	O
+age	O
+(	O
+P	O
+=	O
+0	O
+.	O
+000	O
+),	O
+sepsis	B-DISO
+(	O
+P	O
+=	O
+0	O
+.	O
+004	O
+),	O
+oxygen	B-CHED
+therapy	O
+(	O
+P	O
+=	O
+0	O
+.	O
+018	O
+),	O
+and	O
+frequency	O
+of	O
+blood	B-ANAT
+transfusions	O
+(	O
+P	O
+=	O
+0	O
+.	O
+030	O
+).	O
+
+TITLE	O
+:	O
+Protective	O
+ventilation	O
+in	O
+experimental	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+after	O
+ventilator	O
+-	O
+induced	O
+lung	O
+injury	O
+:	O
+a	O
+randomized	O
+controlled	O
+trial	O
+.	O
+
+The	O
+protective	O
+ventilation	O
+strategy	O
+of	O
+adequate	O
+pH	O
+or	O
+PaCO2	O
+with	O
+minimal	O
+V	O
+(	O
+T	O
+),	O
+and	O
+high	O
+/	O
+safe	O
+P	O
+(	O
+PLAT	O
+)	O
+resulting	O
+in	O
+high	O
+PEEP	B-CHED
+was	O
+based	O
+on	O
+the	O
+avoidance	O
+of	O
+known	O
+lung	B-ANAT
+-	O
+damaging	O
+phenomena	O
+.	O
+
+Furthermore	O
+,	O
+the	O
+impact	O
+of	O
+the	O
+appearance	O
+of	O
+new	O
+hosts	B-COMP
+in	O
+paediatric	O
+-	O
+very	O
+low	O
+birthweight	O
+infants	O
+,	O
+immunosuppressed	O
+patients	O
+-	O
+is	O
+evaluated	O
+.	O
+
+The	O
+nsp1	B-PRGE
+-	I-PRGE
+40S	I-PRGE
+ribosome	I-PRGE
+complex	I-PRGE
+further	O
+induces	O
+an	O
+endonucleolytic	O
+cleavage	B-PROC
+near	O
+the	O
+5	O
+'	O
+UTR	O
+of	O
+host	B-COMP
+mRNA	B-CHED
+.	O
+
+TITLE	O
+:	O
+Implications	O
+of	O
+altered	O
+replication	O
+fidelity	O
+on	O
+the	O
+evolution	B-PROC
+and	O
+pathogenesis	B-DISO
+of	O
+coronaviruses	O
+.	O
+
+Recent	O
+studies	O
+support	O
+the	O
+hypothesis	O
+that	O
+coronavirus	B-SPEC
+replication	O
+fidelity	O
+may	O
+result	O
+from	O
+a	O
+multi	O
+-	O
+protein	B-COMP
+complex	I-COMP
+,	O
+suggesting	O
+multiple	O
+pathways	B-PROC
+to	O
+disrupt	O
+or	O
+alter	O
+virus	B-SPEC
+fidelity	O
+and	O
+diversity	O
+,	O
+and	O
+attenuate	O
+pathogenesis	B-DISO
+.	O
+
+Impaired	B-DISO
+gas	I-DISO
+exchange	I-DISO
+in	O
+influenza	B-DISO
+-	O
+infected	O
+mice	B-SPEC
+was	O
+accompanied	O
+by	O
+progressive	O
+hemoglobin	B-PRGE
+desaturation	O
+,	O
+hypercapnia	B-DISO
+,	O
+uncompensated	O
+respiratory	B-DISO
+acidosis	I-DISO
+,	O
+hyperkalemia	O
+,	O
+and	O
+polycythemia	B-DISO
+.	O
+
+Postnatal	O
+period	O
+is	O
+critical	O
+to	O
+the	O
+development	B-PROC
+of	O
+neuro	O
+--	O
+hypothalamic	B-ANAT
+circuits	O
+involved	O
+in	O
+appetite	B-PROC
+control	I-PROC
+--	O
+nutritional	O
+programming	O
+--	O
+in	O
+which	O
+leptin	B-PRGE
+,	O
+present	O
+in	O
+breast	B-ANAT
+milk	I-ANAT
+,	O
+appears	O
+to	O
+have	O
+a	O
+decisive	O
+role	O
+.	O
+
+An	O
+indirect	O
+ELISA	O
+using	O
+recombinant	B-PRGE
+N	I-PRGE
+protein	I-PRGE
+as	O
+antigen	B-CHED
+was	O
+established	O
+to	O
+screen	O
+antibody	B-COMP
+-	O
+producing	O
+hybridoma	B-ANAT
+cell	B-ANAT
+lines	I-ANAT
+.	O
+
+In	O
+those	O
+patients	O
+tracheobronchial	O
+toilette	O
+is	O
+crucial	O
+in	O
+preventing	O
+or	O
+treating	O
+airways	O
+obstructed	O
+by	O
+secretions	B-ANAT
+and	O
+deterioration	O
+of	O
+oxygenation	B-PROC
+.	O
+
+Bacteremia	B-DISO
+and	O
+hospital	O
+-	O
+acquired	O
+pneumonia	B-DISO
+can	O
+complicate	O
+severe	O
+malaria	B-PATH
+and	O
+may	O
+contribute	O
+to	O
+ALI	O
+/	O
+ARDS	B-DISO
+.	O
+
+Two	O
+British	O
+siblings	O
+in	O
+the	O
+mid	O
+-	O
+1980s	O
+showed	O
+nearly	O
+constant	O
+fecal	B-ANAT
+viral	B-DISO
+shedding	I-DISO
+.	O
+
+A	O
+subset	O
+of	O
+CoVs	O
+uses	O
+the	O
+cell	B-COMP
+surface	I-COMP
+aminopeptidase	B-PRGE
+N	I-PRGE
+(	O
+APN	B-PRGE
+),	O
+a	O
+membrane	B-COMP
+-	O
+bound	O
+metalloprotease	B-PRGE
+,	O
+as	O
+a	O
+cell	B-COMP
+entry	O
+receptor	O
+.	O
+
+In	O
+these	O
+viruses	B-SPEC
+,	O
+the	O
+envelope	B-PRGE
+spike	I-PRGE
+glycoprotein	B-CHED
+(	I-PRGE
+S	I-PRGE
+)	I-PRGE
+mediates	O
+the	O
+attachment	O
+of	O
+the	O
+virus	B-COMP
+particles	I-COMP
+to	O
+APN	O
+and	O
+subsequent	O
+cell	B-COMP
+entry	O
+,	O
+which	O
+can	O
+be	O
+blocked	O
+by	O
+neutralizing	O
+antibodies	B-COMP
+.	O
+
+Our	O
+results	O
+provide	O
+a	O
+compelling	O
+view	O
+on	O
+CoV	O
+cell	B-COMP
+entry	O
+and	O
+immune	O
+neutralization	O
+,	O
+and	O
+may	O
+aid	O
+the	O
+design	O
+of	O
+antivirals	B-CHED
+or	O
+CoV	O
+vaccines	O
+.	O
+
+TITLE	O
+:	O
+Origin	O
+,	O
+diversity	O
+,	O
+and	O
+maturation	B-PROC
+of	O
+human	B-PRGE
+antiviral	B-CHED
+antibodies	B-COMP
+analyzed	O
+by	O
+high	O
+-	O
+throughput	O
+sequencing	O
+.	O
+
+TITLE	O
+:	O
+Toxic	B-DISO
+megacolon	I-DISO
+from	O
+fulminant	O
+Clostridium	B-DISO
+difficile	I-DISO
+infection	I-DISO
+induced	O
+by	O
+topical	O
+silver	B-CHED
+sulphadiazine	I-CHED
+.	O
+
+Here	O
+,	O
+we	O
+present	O
+an	O
+unusual	O
+case	O
+of	O
+TM	O
+from	O
+C	O
+difficile	O
+infection	B-DISO
+induced	I-DISO
+by	O
+topical	O
+silver	B-CHED
+sulphadiazine	I-CHED
+in	O
+a	O
+60	O
+-	O
+year	O
+-	O
+old	O
+man	B-CHED
+with	O
+immune	O
+-	O
+bullous	O
+pemphigus	B-DISO
+vulgaris	I-DISO
+.	O
+
+Influenza	B-SPEC
+virus	B-DISO
+infection	I-DISO
+is	O
+treated	O
+worldwide	O
+mainly	O
+by	O
+neuraminidase	B-PROC
+inhibitors	I-PROC
+(	O
+NAIs	B-SPEC
+).	O
+
+Mouse	B-SPEC
+survival	O
+,	O
+body	B-ANAT
+weight	O
+and	O
+general	O
+condition	B-DISO
+were	O
+observed	O
+for	O
+up	O
+to	O
+20	O
+days	O
+after	O
+inoculation	O
+.	O
+
+Viral	O
+titer	O
+and	O
+cytokine	O
+/	O
+chemokine	O
+levels	O
+in	O
+the	O
+lungs	B-ANAT
+,	O
+lung	B-ANAT
+weight	O
+,	O
+pathological	O
+analysis	O
+,	O
+and	O
+blood	B-ANAT
+O	O
+(	O
+2	O
+)	O
+and	O
+CO	O
+(	O
+2	O
+)	O
+pressures	O
+were	O
+evaluated	O
+.	O
+
+However	O
+,	O
+virus	B-SPEC
+titer	O
+,	O
+lung	B-ANAT
+weight	O
+and	O
+cytokine	O
+/	O
+chemokine	O
+responses	O
+were	O
+not	O
+different	O
+between	O
+the	O
+groups	O
+.	O
+
+TITLE	O
+:	O
+[	O
+The	O
+response	O
+of	O
+intensive	O
+care	O
+medicine	B-CHED
+in	O
+situations	O
+of	O
+multiple	O
+victims	O
+and	O
+catastrophe	O
+].	O
+
+A	O
+literature	O
+search	O
+for	O
+studies	O
+involving	O
+the	O
+seven	O
+isolated	O
+tanshinone	O
+hits	O
+showed	O
+that	O
+at	O
+present	O
+,	O
+none	O
+have	O
+been	O
+identified	O
+as	O
+coronaviral	O
+protease	B-PROC
+inhibitors	I-PROC
+.	O
+
+All	O
+isolated	O
+compounds	O
+(	O
+1	O
+-	O
+7	O
+)	O
+act	O
+as	O
+time	O
+dependent	O
+inhibitors	B-CHED
+of	O
+PL	O
+(	O
+pro	B-CHED
+),	O
+but	O
+no	O
+improved	O
+inhibition	B-PROC
+was	O
+observed	O
+following	O
+preincubation	O
+with	O
+the	O
+3CL	O
+(	O
+pro	B-CHED
+).	O
+
+These	O
+findings	O
+provide	O
+potential	O
+inhibitors	B-CHED
+for	O
+SARS	B-DISO
+-	O
+CoV	O
+viral	B-DISO
+infection	I-DISO
+and	O
+replication	O
+.	O
+
+Th17	O
+associated	O
+cytokines	O
+,	O
+IL	B-FUNC
+-	I-FUNC
+6	I-FUNC
+,	O
+IL	B-FUNC
+-	I-FUNC
+21	I-FUNC
+and	O
+IL	B-FUNC
+-	I-FUNC
+22	I-FUNC
+,	O
+were	O
+also	O
+increased	O
+significantly	O
+at	O
+72	O
+h	O
+post	O
+-	O
+infection	B-DISO
+.	O
+
+Finally	O
+,	O
+we	O
+introduce	O
+a	O
+constraint	O
+in	O
+Richards	O
+model	O
+to	O
+address	O
+over	O
+fitting	B-DISO
+problem	O
+observed	O
+in	O
+the	O
+existing	O
+studies	O
+and	O
+then	O
+apply	O
+our	O
+method	O
+with	O
+constraint	O
+to	O
+conduct	B-PROC
+some	O
+validation	O
+analysis	O
+using	O
+the	O
+data	O
+of	O
+recent	O
+outbreaks	O
+of	O
+prototype	O
+infectious	B-DISO
+diseases	I-DISO
+such	O
+as	O
+Canada	O
+2009	O
+H1N1	O
+outbreak	O
+,	O
+GTA	O
+2003	O
+SARS	B-DISO
+outbreak	O
+,	O
+Singapore	O
+2005	O
+dengue	B-DISO
+outbreak	O
+,	O
+and	O
+Taiwan	O
+2003	O
+SARS	B-DISO
+outbreak	O
+.	O
+
+TITLE	O
+:	O
+Sequence	O
+alignment	O
+of	O
+viral	O
+channel	O
+proteins	B-CHED
+with	O
+cellular	B-COMP
+ion	B-FUNC
+channels	I-FUNC
+.	O
+
+TITLE	O
+:	O
+Effects	O
+of	O
+chicken	B-SPEC
+anaemia	I-SPEC
+virus	I-SPEC
+and	O
+infectious	B-SPEC
+bursal	I-SPEC
+disease	I-SPEC
+virus	I-SPEC
+-	O
+induced	O
+immunodeficiency	B-DISO
+on	O
+infectious	B-DISO
+bronchitis	B-DISO
+virus	B-PROC
+replication	I-PROC
+and	O
+genotypic	O
+drift	O
+.	O
+
+The	O
+IBV	B-SPEC
+-	O
+Ark	O
+vaccine	O
+was	O
+applied	O
+ocularly	O
+and	O
+tears	B-ANAT
+were	O
+collected	O
+from	O
+infected	O
+chickens	B-SPEC
+for	O
+subsequent	O
+ocular	B-PROC
+inoculation	O
+in	O
+later	O
+passages	O
+.	O
+
+The	O
+area	O
+under	O
+the	O
+receiver	O
+operating	O
+characteristic	O
+curve	O
+for	O
+serum	B-COMP
+CC16	O
+and	O
+pneumonia	B-DISO
+was	O
+0	O
+.	O
+79	O
+(	O
+0	O
+.	O
+62	O
+-	O
+0	O
+.	O
+97	O
+;	O
+p	O
+=	O
+0	O
+.	O
+0011	O
+).	O
+
+TITLE	O
+:	O
+Emergence	O
+of	O
+a	O
+novel	O
+genotype	O
+of	O
+avian	B-DISO
+infectious	I-DISO
+bronchitis	I-DISO
+virus	B-SPEC
+in	O
+Egypt	O
+.	O
+
+TITLE	O
+:	O
+One	O
+health	O
+:	O
+the	O
+Hong	O
+Kong	O
+experience	O
+with	O
+avian	B-DISO
+influenza	I-DISO
+.	O
+
+Surveillance	O
+of	O
+influenza	B-DISO
+in	O
+swine	B-SPEC
+has	O
+provided	O
+insights	O
+into	O
+the	O
+emergence	O
+of	O
+the	O
+2009	O
+pandemic	O
+,	O
+to	O
+the	O
+reverse	O
+zoonosis	B-DISO
+of	O
+the	O
+pandemic	O
+virus	B-SPEC
+from	O
+humans	B-SPEC
+to	O
+swine	B-SPEC
+and	O
+to	O
+the	O
+emergence	O
+of	O
+novel	O
+reassortant	O
+viruses	B-SPEC
+within	O
+swine	B-SPEC
+.	O
+
+TITLE	O
+:	O
+Prevalence	O
+of	O
+acute	O
+respiratory	B-DISO
+symptoms	I-DISO
+in	O
+breath	B-ANAT
+-	O
+hold	O
+divers	O
+.	O
+
+ABSTRACT	O
+:	O
+After	O
+repetitive	O
+deep	O
+dives	O
+,	O
+breath	B-ANAT
+-	O
+hold	O
+divers	O
+are	O
+often	O
+affected	O
+by	O
+a	O
+syndrome	B-DISO
+characterized	O
+by	O
+typical	O
+symptoms	O
+such	O
+as	O
+cough	B-DISO
+,	O
+sensation	B-PROC
+of	O
+chest	B-ANAT
+constriction	B-COMP
+,	O
+blood	B-ANAT
+-	O
+striated	O
+expectorate	B-PROC
+(	O
+hemoptysis	B-DISO
+)	O
+and	O
+,	O
+rarely	O
+,	O
+an	O
+overt	O
+acute	B-DISO
+pulmonary	I-DISO
+edema	I-DISO
+syndrome	B-DISO
+,	O
+often	O
+together	O
+with	O
+various	O
+degrees	O
+of	O
+dyspnea	B-DISO
+.	O
+
+TITLE	O
+:	O
+[	O
+Epidemiological	O
+profile	O
+of	O
+pandemic	O
+influenza	B-PATH
+A	I-PATH
+cases	O
+in	O
+the	O
+south	O
+of	O
+Santa	O
+Catarina	O
+state	O
+,	O
+Brazil	O
+,	O
+in	O
+2009	O
+].	O
+
+H1N1	O
+cases	O
+were	O
+confirmed	O
+by	O
+laboratory	O
+testing	O
+(	O
+positive	O
+RT	O
+-	O
+PCR	O
+)	O
+or	O
+signs	B-DISO
+and	I-DISO
+symptoms	I-DISO
+characteristic	O
+of	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+.	O
+
+H1N1	O
+cases	O
+were	O
+confirmed	O
+by	O
+laboratory	O
+testing	O
+(	O
+positive	O
+RT	O
+-	O
+PCR	O
+)	O
+or	O
+signs	B-DISO
+and	I-DISO
+symptoms	I-DISO
+characteristic	O
+of	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+.	O
+
+TITLE	O
+:	O
+Diagnostic	O
+accuracy	O
+of	O
+the	O
+Rivalta	O
+test	O
+for	O
+feline	B-DISO
+infectious	I-DISO
+peritonitis	I-DISO
+.	O
+
+The	O
+prevalence	O
+of	O
+FIP	B-DISO
+in	O
+this	O
+population	O
+was	O
+determined	O
+,	O
+and	O
+sensitivity	O
+,	O
+specificity	O
+,	O
+and	O
+PPV	B-CHED
+and	O
+NPV	O
+of	O
+the	O
+Rivalta	O
+test	O
+were	O
+calculated	O
+.	O
+
+Of	O
+851	O
+cats	O
+with	O
+effusions	B-DISO
+,	O
+782	O
+had	O
+conclusively	O
+positive	O
+or	O
+negative	O
+results	O
+for	O
+the	O
+Rivalta	O
+test	O
+.	O
+
+Increased	O
+effusion	B-DISO
+cholesterol	B-CHED
+concentration	O
+and	O
+specific	O
+gravity	O
+as	O
+well	O
+as	O
+decreased	O
+serum	B-PRGE
+albumin	I-PRGE
+:	I-PRGE
+globulin	I-PRGE
+ratio	O
+and	O
+hyperbilirubinemia	B-DISO
+were	O
+positively	O
+correlated	O
+with	O
+positive	O
+Rivalta	O
+test	O
+results	O
+.	O
+
+Sensitivity	O
+,	O
+specificity	O
+,	O
+and	O
+PPV	B-CHED
+of	O
+the	O
+Rivalta	O
+test	O
+for	O
+the	O
+diagnosis	O
+of	O
+FIP	B-DISO
+were	O
+lower	O
+than	O
+previously	O
+reported	O
+except	O
+when	O
+used	O
+in	O
+young	O
+cats	B-SPEC
+.	O
+
+Increased	O
+effusion	B-DISO
+cholesterol	B-CHED
+concentration	O
+and	O
+specific	O
+gravity	O
+as	O
+well	O
+as	O
+decreased	O
+serum	B-PRGE
+albumin	I-PRGE
+:	I-PRGE
+globulin	I-PRGE
+ratio	O
+and	O
+hyperbilirubinemia	B-DISO
+were	O
+positively	O
+correlated	O
+with	O
+positive	O
+Rivalta	O
+test	O
+results	O
+.	O
+
+A	O
+workflow	O
+was	O
+developed	O
+consisting	O
+of	O
+an	O
+optimized	O
+fecal	B-ANAT
+nucleic	B-CHED
+acid	I-CHED
+purification	O
+and	O
+multiplex	O
+reverse	B-PROC
+transcription	I-PROC
+quantitative	O
+polymerase	O
+chain	O
+reaction	O
+(	O
+RT	O
+-	O
+qPCR	O
+)	O
+for	O
+single	O
+tube	O
+concurrent	O
+detection	O
+of	O
+BCV	O
+,	O
+BRV	B-DISO
+,	O
+and	O
+Cryptosporidium	B-SPEC
+spp	B-ENZY
+.,	O
+and	O
+an	O
+internal	O
+control	O
+to	O
+monitor	O
+nucleic	B-CHED
+acid	I-CHED
+purification	O
+efficacy	O
+and	O
+PCR	O
+reagent	B-CHED
+functionality	O
+.	O
+
+Analytical	O
+specificity	O
+was	O
+confirmed	O
+using	O
+Canine	O
+and	O
+Feline	B-SPEC
+coronavirus	B-SPEC
+,	O
+Giardia	B-DISO
+spp	B-ENZY
+.,	O
+and	O
+noninfected	O
+bovine	B-SPEC
+purified	O
+nucleic	B-CHED
+acid	I-CHED
+.	O
+
+We	O
+report	O
+herein	O
+the	O
+broad	O
+-	O
+spectrum	O
+antiviral	B-CHED
+activities	O
+of	O
+three	O
+compounds	O
+possessing	O
+a	O
+common	O
+dipeptidyl	O
+residue	O
+with	O
+different	O
+warheads	O
+,	O
+i	O
+.	O
+e	O
+.,	O
+an	O
+aldehyde	B-CHED
+(	O
+GC373	O
+),	O
+a	O
+bisulfite	O
+adduct	O
+(	O
+GC376	O
+),	O
+and	O
+an	O
+α	O
+-	O
+ketoamide	O
+(	O
+GC375	O
+),	O
+against	O
+viruses	B-SPEC
+that	O
+belong	O
+to	O
+the	O
+supercluster	O
+.	O
+
+TITLE	O
+:	O
+Monitoring	O
+of	O
+S	B-PRGE
+protein	I-PRGE
+maturation	B-PROC
+in	O
+the	O
+endoplasmic	B-COMP
+reticulum	I-COMP
+by	O
+calnexin	O
+is	O
+important	O
+for	O
+the	O
+infectivity	O
+of	O
+severe	O
+acute	O
+respiratory	O
+syndrome	O
+coronavirus	B-SPEC
+.	O
+
+We	O
+found	O
+that	O
+SARS	B-DISO
+-	O
+CoV	O
+spike	B-PRGE
+glycoprotein	I-PRGE
+(	O
+S	B-PRGE
+protein	I-PRGE
+),	O
+a	O
+key	O
+molecule	O
+for	O
+viral	O
+entry	O
+,	O
+binds	B-FUNC
+to	O
+calnexin	B-PRGE
+,	O
+a	O
+molecular	O
+chaperone	O
+in	O
+the	O
+endoplasmic	B-COMP
+reticulum	I-COMP
+(	O
+ER	O
+),	O
+but	O
+not	O
+to	O
+calreticulin	B-PRGE
+,	O
+a	O
+homolog	O
+of	O
+calnexin	B-PRGE
+.	O
+
+Treatment	O
+with	O
+peptide	B-CHED
+-	O
+N	O
+-	O
+glycosidase	O
+F	O
+(	O
+PNGase	B-FUNC
+F	I-FUNC
+),	O
+which	O
+removes	O
+all	O
+types	O
+of	O
+N	B-CHED
+-	I-CHED
+glycan	I-CHED
+side	O
+chains	O
+from	O
+glycoproteins	B-CHED
+,	O
+eliminated	O
+the	O
+infectivity	O
+of	O
+S	O
+-	O
+pseudovirus	O
+.	O
+
+Greater	O
+than	O
+90	O
+%	O
+of	O
+all	O
+deaths	B-PROC
+from	O
+influenza	B-SPEC
+A	I-SPEC
+virus	I-SPEC
+(	O
+IAV	O
+)	O
+occur	O
+in	O
+the	O
+elderly	O
+(>	O
+65	O
+years	O
+of	O
+age	O
+).	O
+
+We	O
+also	O
+identified	O
+a	O
+potential	O
+cellular	B-COMP
+target	O
+for	O
+poly	O
+(	O
+I	O
+·	O
+C	O
+)	O
+by	O
+showing	O
+that	O
+treatment	O
+inhibited	O
+virus	B-PROC
+replication	I-PROC
+in	O
+primary	O
+human	B-SPEC
+airway	B-ANAT
+epithelial	B-ANAT
+cells	I-ANAT
+.	O
+
+30	O
+kb	O
+as	O
+a	O
+genome	O
+,	O
+which	O
+is	O
+wrapped	O
+by	O
+the	O
+envelope	B-COMP
+,	O
+and	O
+constitute	O
+Nidovirales	B-SPEC
+together	O
+with	O
+Arteriviridae	B-SPEC
+.	O
+
+Those	O
+proteins	B-CHED
+exhibit	O
+different	O
+functions	O
+,	O
+such	O
+as	O
+RNA	B-PRGE
+-	I-PRGE
+dependent	I-PRGE
+RNA	I-PRGE
+polymerase	I-PRGE
+,	O
+helicase	B-PRGE
+,	O
+proteases	O
+and	O
+proteins	O
+that	O
+regulate	O
+cellular	B-COMP
+functions	O
+,	O
+mRNAs	O
+smaller	O
+than	O
+mRNA	B-CHED
+-	O
+2	O
+translate	O
+in	O
+general	O
+the	O
+structural	O
+proteins	B-CHED
+,	O
+nucleocapsid	B-COMP
+(	O
+N	O
+)	O
+protein	B-CHED
+,	O
+spike	O
+(	O
+S	O
+)	O
+protein	B-CHED
+,	O
+integrated	O
+membrane	B-COMP
+(	O
+M	O
+)	O
+protein	B-CHED
+and	O
+envelope	B-PRGE
+(	I-PRGE
+E	I-PRGE
+)	I-PRGE
+proteins	B-CHED
+.	O
+
+CONCLUSIONS	O
+:	O
+Truncated	B-PRGE
+N	I-PRGE
+protein	I-PRGE
+PN185	I-PRGE
+and	O
+PN155b	O
+expressed	B-PROC
+in	O
+E	O
+.	O
+Coli	O
+are	O
+better	O
+antigen	B-CHED
+candidates	O
+used	O
+for	O
+detection	O
+of	O
+SARS	B-PRGE
+-	I-PRGE
+CoV	I-PRGE
+specific	I-PRGE
+antibody	B-COMP
+.	O
+
+The	O
+immunochromatographic	O
+strip	O
+was	O
+capable	O
+of	O
+specifically	O
+detecting	O
+PHE	B-CHED
+-	O
+CoV	O
+with	O
+a	O
+HA	O
+unit	O
+of	O
+2	O
+within	O
+10	O
+min	O
+.	O
+
+Based	O
+on	O
+its	O
+high	O
+specificity	O
+,	O
+sensitivity	O
+,	O
+and	O
+stability	O
+,	O
+the	O
+immunochromatographic	O
+strip	O
+would	O
+be	O
+suitable	O
+for	O
+on	O
+-	O
+site	O
+detection	O
+of	O
+PHE	B-CHED
+-	O
+CoV	O
+for	O
+surveillance	O
+and	O
+epidemiological	O
+purposes	O
+.	O
+
+Lipopolysaccharide	B-CHED
+(	O
+LPS	B-DISO
+)-	O
+induced	O
+acute	O
+lung	B-ANAT
+injury	O
+(	O
+ALI	O
+)	O
+in	O
+rat	B-SPEC
+models	O
+is	O
+considered	O
+similar	O
+to	O
+adult	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+(	O
+ARDS	B-DISO
+)	O
+in	O
+humans	B-SPEC
+.	O
+
+TITLE	O
+:	O
+No	O
+serologic	O
+evidence	O
+for	O
+zoonotic	O
+canine	O
+respiratory	O
+coronavirus	B-DISO
+infections	I-DISO
+among	O
+immunocompetent	O
+adults	O
+.	O
+
+The	O
+objectives	O
+of	O
+this	O
+study	O
+were	O
+to	O
+determine	O
+whether	O
+people	O
+with	O
+occupational	O
+contact	O
+with	O
+dogs	B-SPEC
+were	O
+more	O
+likely	O
+to	O
+have	O
+antibodies	B-COMP
+against	O
+canine	O
+respiratory	O
+coronavirus	B-SPEC
+(	O
+CRCoV	O
+)	O
+compared	O
+to	O
+persons	O
+with	O
+no	O
+dog	B-SPEC
+exposure	O
+.	O
+
+We	O
+enrolled	O
+1006	O
+children	O
+less	O
+than	O
+5	O
+years	O
+of	O
+age	O
+of	O
+whom	O
+423	O
+(	O
+42	O
+%),	O
+428	O
+(	O
+42	O
+%)	O
+and	O
+155	O
+(	O
+16	O
+%)	O
+had	O
+pneumonia	B-DISO
+,	O
+bronchiolitis	B-DISO
+and	O
+unclassified	O
+lower	B-DISO
+respiratory	I-DISO
+tract	I-DISO
+infections	I-DISO
+,	O
+respectively	O
+.	O
+
+Our	O
+objective	O
+was	O
+to	O
+revise	O
+the	O
+definition	O
+of	O
+acute	O
+respiratory	O
+distress	O
+syndrome	O
+(	O
+ARDS	B-DISO
+)	O
+using	O
+a	O
+conceptual	O
+model	O
+incorporating	O
+reliability	O
+and	O
+validity	O
+,	O
+and	O
+a	O
+novel	O
+iterative	O
+approach	O
+with	O
+formal	B-CHED
+evaluation	O
+of	O
+the	O
+definition	O
+.	O
+
+RESULTS	O
+:	O
+Four	O
+theoretically	O
+effective	O
+sequences	O
+of	O
+TGEV	B-PRGE
+ORF	I-PRGE
+7	I-PRGE
+gene	I-PRGE
+were	O
+designed	O
+and	O
+selected	O
+for	O
+construction	O
+of	O
+shRNA	O
+expression	B-PROC
+plasmids	O
+.	O
+
+ABSTRACT	O
+:	O
+Critical	B-DISO
+illness	I-DISO
+due	O
+to	O
+2009	O
+H1N1	B-DISO
+influenza	I-DISO
+has	O
+been	O
+characterized	O
+by	O
+respiratory	B-DISO
+complications	I-DISO
+,	O
+including	O
+acute	O
+lung	B-ANAT
+injury	O
+(	O
+ALI	O
+)	O
+or	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+(	O
+ARDS	B-DISO
+),	O
+and	O
+associated	O
+with	O
+high	O
+mortality	O
+.	O
+
+The	O
+noninfluenza	O
+group	O
+tended	O
+to	O
+have	O
+higher	O
+overall	O
+charges	O
+,	O
+including	O
+significantly	O
+higher	O
+cost	O
+of	O
+blood	B-ANAT
+products	O
+in	O
+the	O
+ICU	O
+.	O
+
+TITLE	O
+:	O
+Human	B-SPEC
+herpes	B-SPEC
+virus	I-SPEC
+co	B-DISO
+-	I-DISO
+infection	I-DISO
+is	O
+associated	O
+with	O
+mortality	O
+in	O
+HIV	B-DISO
+-	O
+negative	O
+patients	O
+with	O
+Pneumocystis	B-DISO
+jirovecii	I-SPEC
+pneumonia	B-DISO
+.	O
+
+The	O
+levels	O
+of	O
+creatine	B-PRGE
+kinase	I-PRGE
+(	O
+CK	B-ENZY
+),	O
+creatine	B-PRGE
+kinase	I-PRGE
+-	I-PRGE
+MB	I-PRGE
+(	O
+CK	B-FUNC
+-	I-FUNC
+MB	I-FUNC
+)	O
+and	O
+cardiac	B-PRGE
+troponin	I-PRGE
+I	I-PRGE
+(	O
+cTnI	B-PRGE
+)	O
+in	O
+milder	O
+,	O
+moderate	O
+and	O
+severe	O
+poisoning	O
+groups	O
+were	O
+significantly	O
+elevated	O
+compared	O
+by	O
+the	O
+healthy	O
+control	O
+group	O
+(	O
+P	O
+<	O
+0	O
+.	O
+05	O
+).	O
+
+Notably	O
+,	O
+the	O
+rapid	O
+adaptive	O
+genetic	B-DISO
+change	I-DISO
+in	O
+BatCoV	B-PRGE
+HKU10	I-PRGE
+spike	I-PRGE
+protein	I-PRGE
+by	O
+~	O
+40	O
+%	O
+amino	B-CHED
+acid	I-CHED
+divergence	O
+after	O
+recent	O
+interspecies	O
+transmission	O
+was	O
+even	O
+greater	O
+than	O
+the	O
+~	O
+20	O
+%	O
+amino	B-CHED
+acid	I-CHED
+divergence	O
+between	O
+spike	O
+proteins	B-CHED
+of	O
+severe	O
+acute	O
+respiratory	O
+
+We	O
+also	O
+discuss	O
+the	O
+recent	O
+progress	O
+in	O
+the	O
+identification	O
+of	O
+novel	O
+chemical	O
+inhibitors	B-CHED
+of	O
+nsP13	O
+in	O
+the	O
+context	O
+of	O
+our	O
+recent	O
+discovery	O
+of	O
+the	O
+strong	O
+inhibition	B-PROC
+of	O
+the	O
+SARS	B-PRGE
+helicase	I-PRGE
+by	O
+natural	O
+flavonoids	B-CHED
+,	O
+myricetin	B-CHED
+and	O
+scutellarein	B-CHED
+.	O
+
+These	O
+compounds	O
+will	O
+serve	O
+as	O
+important	O
+resources	O
+for	O
+the	O
+future	O
+development	O
+of	O
+anti	O
+-	O
+SARS	B-DISO
+medications	O
+.	O
+
+ABSTRACT	O
+:	O
+Severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+(	O
+SARS	B-DISO
+)	O
+coronavirus	B-SPEC
+(	O
+SARS	B-PRGE
+-	I-PRGE
+CoV	I-PRGE
+)	O
+papain	B-PRGE
+-	I-PRGE
+like	I-PRGE
+protease	I-PRGE
+(	O
+PLpro	O
+),	O
+a	O
+deubiquitinating	B-PROC
+enzyme	I-PROC
+,	O
+demonstrates	O
+inactivation	B-DISO
+of	O
+interferon	B-PRGE
+(	O
+IFN	O
+)	O
+regulatory	O
+factor	O
+3	O
+and	O
+NF	O
+-	O
+κB	O
+,	O
+reduction	O
+of	O
+IFN	B-PRGE
+induction	O
+,	O
+and	O
+suppression	B-DISO
+of	O
+type	B-PRGE
+I	I-PRGE
+IFN	I-PRGE
+signaling	B-PROC
+pathway	I-PROC
+.	O
+
+ABSTRACT	O
+:	O
+Zoonoses	B-DISO
+represent	O
+a	O
+public	O
+health	O
+risk	O
+recently	O
+pointed	O
+out	O
+by	O
+the	O
+spreading	O
+of	O
+previously	O
+unknown	O
+human	O
+infectious	B-DISO
+diseases	I-DISO
+emerging	O
+from	O
+animal	B-SPEC
+reservoirs	O
+such	O
+as	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+and	O
+avian	B-DISO
+influenza	I-DISO
+caused	O
+by	O
+H5N1	B-DISO
+-	O
+virus	B-SPEC
+.	O
+
+An	O
+early	O
+extensive	O
+clinical	O
+,	O
+laboratory	O
+,	O
+and	O
+imaging	O
+evaluation	O
+of	O
+""""	O
+at	O
+risk	O
+patients	O
+""""	O
+allows	O
+a	O
+correct	O
+diagnosis	O
+of	O
+ARDS	B-DISO
+,	O
+assessment	O
+of	O
+comorbidities	O
+,	O
+and	O
+calculation	O
+of	O
+prognostic	O
+indices	O
+,	O
+so	O
+that	O
+a	O
+careful	O
+treatment	O
+can	O
+be	O
+planned	O
+.	O
+
+Revaluation	O
+of	O
+ARDS	B-DISO
+patients	O
+on	O
+the	O
+third	O
+day	O
+of	O
+evolution	B-PROC
+(	O
+Sequential	O
+Organ	B-DISO
+Failure	I-DISO
+Assessment	O
+(	O
+SOFA	O
+),	O
+biomarkers	O
+and	O
+response	O
+to	O
+infection	B-DISO
+therapy	O
+)	O
+allows	O
+changes	O
+in	O
+the	O
+initial	O
+treatment	O
+plans	O
+and	O
+can	O
+help	O
+decrease	O
+ARDS	B-DISO
+mortality	O
+.	O
+
+Thus	O
+,	O
+he	O
+was	O
+treated	O
+with	O
+infusions	O
+of	O
+anti	B-PRGE
+-	I-PRGE
+CD20	I-PRGE
+therapy	O
+(	O
+rituximab	O
+):	O
+his	O
+clinical	O
+conditions	O
+improved	O
+very	O
+rapidly	O
+and	O
+a	O
+significant	O
+decrease	O
+in	O
+the	O
+activity	O
+of	O
+pulmonary	B-DISO
+disease	I-DISO
+was	O
+detected	O
+using	O
+high	O
+-	O
+resolution	O
+computerized	O
+tomography	O
+(	O
+HRCT	O
+)	O
+of	O
+the	O
+thorax	B-ANAT
+and	O
+pulmonary	B-PROC
+function	I-PROC
+tests	O
+.	O
+
+TITLE	O
+:	O
+Impact	O
+of	O
+a	O
+hospital	O
+-	O
+wide	O
+hand	O
+hygiene	O
+promotion	O
+strategy	O
+on	O
+healthcare	O
+-	O
+associated	O
+infections	B-DISO
+.	O
+
+However	O
+,	O
+the	O
+post	O
+-	O
+SARS	B-DISO
+period	O
+confirmed	O
+that	O
+this	O
+practice	O
+was	O
+not	O
+sustainable	O
+.	O
+
+ABSTRACT	O
+:	O
+The	O
+whey	O
+acidic	O
+protein	B-CHED
+family	B-SPEC
+member	O
+,	O
+WFDC1	B-PRGE
+/	O
+ps20	B-PRGE
+is	O
+a	O
+permissivity	O
+factor	O
+in	O
+HIV	B-PATH
+infection	I-PATH
+.	O
+
+TITLE	O
+:	O
+Complete	O
+viral	O
+RNA	O
+genome	O
+sequencing	O
+of	O
+ultra	O
+-	O
+low	O
+copy	O
+samples	O
+by	O
+sequence	O
+-	O
+independent	O
+amplification	B-DISO
+.	O
+
+We	O
+demonstrated	O
+that	O
+N50	O
+could	O
+induce	O
+significant	O
+IFN	B-PRGE
+-	I-PRGE
+gamma	I-PRGE
+response	O
+from	O
+SARS	B-DISO
+-	O
+CoV	O
+S	O
+DNA	O
+immunized	O
+mice	B-SPEC
+splenocytes	O
+by	O
+the	O
+means	O
+of	O
+ELISA	O
+,	O
+ELISPOT	O
+and	O
+FACS	O
+.	O
+
+This	O
+allows	O
+a	O
+target	O
+tidal	O
+volume	O
+to	O
+be	O
+set	O
+based	O
+on	O
+automatic	O
+changes	O
+in	O
+inspiratory	B-PROC
+positive	O
+airway	B-ANAT
+pressure	O
+.	O
+
+In	O
+cases	O
+such	O
+as	O
+this	O
+,	O
+in	O
+which	O
+patients	O
+with	O
+severe	O
+acute	B-DISO
+respiratory	I-DISO
+failure	I-DISO
+requiring	O
+full	O
+-	O
+time	O
+noninvasive	O
+positive	O
+pressure	O
+ventilation	O
+therapy	O
+also	O
+show	O
+sleep	B-DISO
+-	I-DISO
+disordered	I-DISO
+breathing	B-PROC
+,	O
+different	O
+ventilator	O
+settings	O
+must	O
+be	O
+used	O
+for	O
+waking	B-PROC
+and	O
+sleeping	B-PROC
+.	O
+
+CONCLUSIONS	O
+:	O
+Henoch	B-DISO
+-	I-DISO
+Schonlein	I-DISO
+purpura	I-DISO
+is	O
+a	O
+mild	O
+disease	O
+in	O
+the	O
+eastern	O
+province	O
+of	O
+Saudi	O
+Arabia	O
+and	O
+with	O
+no	O
+significant	O
+differences	O
+in	O
+the	O
+epidemic	O
+and	O
+clinical	O
+profile	O
+than	O
+that	O
+reported	O
+elsewhere	O
+.	O
+
+In	O
+the	O
+context	O
+of	O
+disease	O
+emergence	O
+from	O
+wildlife	O
+,	O
+wildlife	O
+and	O
+habitat	O
+should	O
+be	O
+conserved	O
+,	O
+which	O
+in	O
+turn	O
+will	O
+preserve	O
+vital	O
+ecosystem	O
+structure	O
+and	O
+function	O
+,	O
+which	O
+has	O
+broader	O
+implications	O
+for	O
+human	B-SPEC
+wellbeing	O
+and	O
+environmental	O
+sustainability	O
+,	O
+while	O
+simultaneously	O
+minimizing	O
+the	O
+spillover	O
+of	O
+pathogens	O
+from	O
+wild	O
+animals	O
+into	O
+human	B-SPEC
+beings	O
+.	O
+
+We	O
+report	O
+here	O
+the	O
+complete	O
+genome	O
+sequence	O
+of	O
+PEDV	B-SPEC
+strain	O
+AJ1102	O
+isolated	O
+from	O
+a	O
+suckling	O
+piglet	O
+with	O
+acute	B-DISO
+diarrhea	I-DISO
+,	O
+which	O
+will	O
+help	O
+toward	O
+understanding	O
+the	O
+molecular	O
+and	O
+evolutionary	O
+characteristics	O
+of	O
+the	O
+epidemic	O
+PEDV	B-SPEC
+in	O
+China	O
+.	O
+
+Phylogenetic	O
+analyses	O
+based	O
+on	O
+the	O
+whole	O
+genome	O
+revealed	O
+that	O
+CHGD	O
+-	O
+01	O
+shared	O
+nucleotide	B-CHED
+sequence	O
+identities	O
+of	O
+98	O
+.	O
+2	O
+-	O
+98	O
+.	O
+4	O
+%	O
+with	O
+two	O
+other	O
+Chinese	O
+isolates	O
+reported	O
+in	O
+the	O
+same	O
+year	O
+,	O
+thus	O
+constituting	O
+a	O
+new	O
+cluster	O
+.	O
+
+Its	O
+ORF3	O
+and	O
+nucleoprotein	O
+genes	O
+,	O
+however	O
+,	O
+were	O
+divergent	O
+from	O
+all	O
+other	O
+sequenced	O
+PEDV	B-SPEC
+isolate	O
+clusters	B-CHED
+and	O
+therefore	O
+formed	O
+a	O
+new	O
+group	O
+,	O
+suggesting	O
+a	O
+new	O
+variant	O
+PEDV	B-SPEC
+isolate	O
+in	O
+China	O
+.	O
+
+Daily	O
+fluid	O
+intake	O
+of	O
+patients	O
+showed	O
+a	O
+tendency	O
+of	O
+decrease	O
+in	O
+both	O
+groups	O
+from	O
+PBD	B-DISO
+3	O
+to	O
+10	O
+.	O
+
+Daily	O
+fluid	O
+output	O
+of	O
+patients	O
+showed	O
+a	O
+tendency	O
+of	O
+increase	O
+in	O
+both	O
+groups	O
+from	O
+PBD	B-DISO
+3	O
+to	O
+10	O
+.	O
+
+Fluid	B-PROC
+balance	I-PROC
+was	O
+lower	O
+in	O
+treatment	O
+group	O
+than	O
+in	O
+control	O
+group	O
+from	O
+PBD	B-DISO
+3	O
+to	O
+7	O
+,	O
+and	O
+it	O
+showed	O
+statistically	O
+significant	O
+differences	O
+on	O
+PBD	B-DISO
+4	O
+,	O
+5	O
+,	O
+and	O
+6	O
+(	O
+with	O
+F	O
+values	O
+from	O
+4	O
+.	O
+799	O
+to	O
+8	O
+.	O
+031	O
+,	O
+P	O
+values	O
+below	O
+0	O
+.	O
+05	O
+).	O
+
+Lung	B-DISO
+infection	I-DISO
+and	O
+blood	B-ANAT
+stream	O
+infection	B-DISO
+were	O
+respectively	O
+observed	O
+in	O
+1	O
+and	O
+4	O
+patient	O
+(	O
+s	O
+)	O
+in	O
+treatment	O
+group	O
+,	O
+and	O
+9	O
+and	O
+11	O
+patients	O
+in	O
+control	O
+group	O
+from	O
+PBD	B-DISO
+7	O
+to	O
+14	O
+.	O
+
+This	O
+strategy	O
+may	O
+be	O
+also	O
+beneficial	O
+for	O
+the	O
+prevention	O
+of	O
+organ	B-ANAT
+complications	O
+as	O
+well	O
+as	O
+a	O
+better	O
+prognosis	O
+in	O
+severely	O
+burned	O
+patients	O
+.	O
+
+ABSTRACT	O
+:	O
+Transplantation	O
+of	O
+syngeneic	O
+neural	O
+progenitor	B-ANAT
+cells	I-ANAT
+(	O
+NPCs	O
+)	O
+into	O
+mice	B-SPEC
+persistently	O
+infected	O
+with	O
+the	O
+JHM	O
+strain	O
+of	O
+mouse	B-DISO
+hepatitis	I-DISO
+virus	B-SPEC
+(	O
+JHMV	O
+)	O
+results	O
+in	O
+enhanced	O
+differentiation	B-PROC
+into	O
+oligodendrocyte	B-ANAT
+progenitor	B-ANAT
+cells	I-ANAT
+that	O
+is	O
+associated	O
+with	O
+remyelination	B-PROC
+,	O
+axonal	O
+sparing	O
+,	O
+and	O
+clinical	O
+improvement	O
+.	O
+
+Cultured	O
+NPCs	O
+constitutively	O
+expressed	B-PROC
+the	O
+costimulatory	O
+molecules	O
+CD80	B-PRGE
+/	O
+CD86	B-PRGE
+,	O
+and	O
+IFN	B-PRGE
+-	I-PRGE
+γ	I-PRGE
+treatment	O
+induced	O
+expression	B-PROC
+of	O
+MHC	B-PRGE
+class	B-SPEC
+I	I-PRGE
+and	I-PRGE
+II	I-PRGE
+antigens	B-CHED
+.	O
+
+Our	O
+findings	O
+strongly	O
+demonstrated	O
+that	O
+PGRN	O
+could	O
+effectively	O
+ameliorate	O
+the	O
+LPS	B-DISO
+-	O
+induced	O
+ALI	O
+in	O
+mice	B-SPEC
+,	O
+suggesting	O
+a	O
+potential	O
+application	O
+for	O
+PGRN	O
+-	O
+based	O
+therapy	O
+to	O
+treat	O
+clinical	O
+ARDS	B-DISO
+.	O
+
+ABSTRACT	O
+:	O
+Upper	O
+respiratory	O
+tract	O
+infection	O
+(	O
+URTI	B-DISO
+)	O
+is	O
+a	O
+major	O
+reason	O
+for	O
+hospitalization	O
+in	O
+childhood	O
+.	O
+
+Viruses	B-SPEC
+were	O
+detected	O
+in	O
+84	O
+(	O
+51	O
+.	O
+2	O
+%)	O
+patients	O
+by	O
+VRDAL	O
+multiplex	O
+PCR	O
+,	O
+and	O
+8	O
+(	O
+4	O
+.	O
+9	O
+%)	O
+of	O
+cases	O
+were	O
+mixed	B-DISO
+infections	I-DISO
+.	O
+
+RESULTS	O
+:	O
+Viruses	B-SPEC
+were	O
+detected	O
+in	O
+84	O
+(	O
+51	O
+.	O
+2	O
+%)	O
+patients	O
+by	O
+VRDAL	O
+multiplex	O
+PCR	O
+,	O
+and	O
+8	O
+(	O
+4	O
+.	O
+9	O
+%)	O
+of	O
+cases	O
+were	O
+mixed	B-DISO
+infections	I-DISO
+.	O
+
+ABSTRACT	O
+:	O
+A	O
+multiplex	O
+reverse	B-PROC
+transcription	I-PROC
+polymerase	O
+chain	O
+reaction	O
+(	O
+mRT	B-ANAT
+-	O
+PCR	O
+)	O
+assay	O
+was	O
+developed	O
+for	O
+the	O
+simultaneous	O
+detection	O
+of	O
+canine	B-SPEC
+distemper	I-SPEC
+virus	I-SPEC
+(	O
+CDV	B-CHED
+),	O
+canine	O
+respiratory	O
+coronavirus	B-SPEC
+(	O
+CRCoV	O
+)	O
+and	O
+canine	O
+influenza	B-SPEC
+virus	I-SPEC
+(	O
+CIV	B-SPEC
+).	O
+
+Therefore	O
+,	O
+this	O
+assay	O
+could	O
+be	O
+a	O
+better	O
+alternative	O
+for	O
+the	O
+definitive	O
+and	O
+simultaneous	O
+ante	O
+-	O
+mortem	O
+detection	O
+of	O
+the	O
+three	O
+viral	O
+pathogens	O
+that	O
+cause	O
+CIRD	O
+by	O
+using	O
+nasal	B-ANAT
+swabs	O
+.	O
+
+ABSTRACT	O
+:	O
+The	O
+papain	B-PRGE
+-	I-PRGE
+like	I-PRGE
+protease	I-PRGE
+(	O
+PL	O
+(	O
+pro	B-CHED
+)),	O
+which	O
+controls	O
+replication	O
+of	O
+the	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+coronavirus	B-SPEC
+(	O
+SARS	B-DISO
+-	O
+CoV	O
+),	O
+has	O
+been	O
+identified	O
+as	O
+a	O
+potential	O
+drug	O
+target	O
+for	O
+the	O
+treatment	O
+of	O
+SARS	B-DISO
+.	O
+
+In	O
+this	O
+study	O
+,	O
+diarylheptanoids	O
+1	O
+-	O
+9	O
+were	O
+isolated	O
+from	O
+Alnus	B-SPEC
+japonica	I-SPEC
+,	O
+and	O
+the	O
+inhibitory	O
+activities	O
+of	O
+these	O
+compounds	O
+against	O
+PL	O
+(	O
+pro	B-CHED
+)	O
+were	O
+determined	O
+.	O
+
+Animals	B-SPEC
+were	O
+divided	O
+into	O
+eight	O
+groups	O
+:	O
+sham	O
+(	O
+n	O
+=	O
+10	O
+);	O
+model	O
+(	O
+injury	O
+only	O
+,	O
+n	O
+=	O
+10	O
+);	O
+normal	O
+saline	O
+(	O
+NS	O
+)	O
+aerosol	O
+driven	O
+by	O
+compressed	O
+air	B-CHED
+(	O
+air	B-CHED
+-	O
+NS	O
+,	O
+n	O
+=	O
+13	O
+);	O
+PS	O
+aerosol	O
+driven	O
+by	O
+compressed	O
+air	B-CHED
+(	O
+air	B-CHED
+-	O
+PS	O
+,	O
+n	O
+=	O
+13	O
+);	O
+NS	O
+aerosol	O
+driven	O
+by	O
+O2	O
+(	O
+O2	O
+-	O
+NS	O
+,	O
+n	O
+=	O
+13	O
+);	O
+PS	O
+aerosol	O
+driven	O
+by	O
+O2	O
+(	O
+O2	O
+-	O
+PS	O
+,	O
+n	O
+=	O
+13	O
+);	O
+Dex	O
+aerosol	O
+driven	O
+by	O
+O2	O
+(	O
+O2	O
+-	O
+Dex	O
+,	O
+n	O
+=	O
+13	O
+);	O
+and	O
+PS	O
+and	O
+Dex	O
+aerosol	O
+driven	O
+by	O
+O2	O
+(	O
+O2	O
+-	O
+PS	O
+-	O
+Dex	O
+,	O
+n	O
+=	O
+13	O
+).	O
+
+Animals	B-SPEC
+treated	O
+with	O
+air	B-CHED
+-	O
+PS	O
+for	O
+20	O
+minutes	O
+had	O
+significantly	O
+improved	O
+lung	B-PROC
+function	I-PROC
+,	O
+reduced	O
+pulmonary	B-DISO
+edema	I-DISO
+,	O
+decreased	O
+concentration	O
+of	O
+total	O
+protein	B-CHED
+and	O
+proinflammatory	O
+cytokines	O
+in	O
+BALF	O
+,	O
+ameliorated	O
+lung	B-ANAT
+injury	O
+,	O
+and	O
+improved	O
+animal	B-SPEC
+survival	O
+.	O
+
+CONCLUSIONS	O
+:	O
+Inhalation	B-PROC
+of	O
+aerosolized	O
+PS	O
+generated	O
+by	O
+the	O
+noninvasive	O
+apparatus	B-ANAT
+could	O
+significantly	O
+reduce	O
+lung	B-ANAT
+injury	O
+,	O
+while	O
+using	O
+oxygen	B-CHED
+line	O
+available	O
+in	O
+the	O
+clinical	O
+wards	O
+to	O
+generate	O
+PS	O
+aerosol	O
+is	O
+more	O
+convenient	O
+and	O
+adds	O
+further	O
+benefits	O
+.	O
+
+These	O
+steroids	B-CHED
+may	O
+cause	O
+increased	O
+viral	B-PROC
+replication	I-PROC
+and	O
+promote	O
+parenchymal	O
+involvement	O
+and	O
+the	O
+development	B-PROC
+of	O
+ARDS	B-DISO
+.	O
+
+In	O
+this	O
+review	O
+,	O
+we	O
+discuss	O
+the	O
+utility	O
+of	O
+animal	B-SPEC
+models	O
+for	O
+studies	O
+of	O
+influenza	B-PATH
+A	I-PATH
+viruses	B-SPEC
+,	O
+HIV	B-DISO
+and	O
+SARS	B-DISO
+-	O
+CoV	O
+in	O
+light	O
+of	O
+viral	O
+emergence	O
+,	O
+assessment	O
+of	O
+infection	B-DISO
+and	O
+transmission	O
+risks	O
+,	O
+and	O
+regulatory	O
+decision	O
+making	O
+.	O
+
+the	O
+SARS	B-PRGE
+-	I-PRGE
+CoV	I-PRGE
+N	I-PRGE
+gene	I-PRGE
+was	O
+cloned	O
+into	O
+pQE	O
+-	O
+80L	O
+vector	O
+,	O
+and	O
+the	O
+constructs	O
+were	O
+transformed	O
+into	O
+Escherichia	B-SPEC
+coli	I-SPEC
+BL21	B-ANAT
+.	O
+
+CONCLUSIONS	O
+:	O
+the	O
+specificity	O
+of	O
+the	O
+SARS	B-PRGE
+-	I-PRGE
+CoV	I-PRGE
+N	I-PRGE
+protein	B-CHED
+-	O
+based	O
+IgG	B-PRGE
+ELISA	O
+assay	O
+for	O
+the	O
+detection	O
+of	O
+the	O
+SARS	B-PRGE
+-	I-PRGE
+CoV	I-PRGE
+N	I-PRGE
+specific	I-PRGE
+IgG	I-PRGE
+in	O
+plasma	B-ANAT
+samples	O
+from	O
+IDUs	O
+with	O
+HIV	B-SPEC
+-	I-SPEC
+1	I-SPEC
+positive	O
+is	O
+,	O
+therefore	O
+,	O
+questionable	O
+.	O
+
+All	O
+urinary	O
+samples	O
+were	O
+negative	O
+for	O
+FCV	B-CHED
+and	O
+FCoV	O
+.	O
+One	O
+(	O
+1	O
+%)	O
+of	O
+the	O
+FLUTD	O
+cats	B-SPEC
+was	O
+found	O
+to	O
+be	O
+positive	O
+for	O
+FHV	O
+-	O
+1	O
+.	O
+
+The	O
+results	O
+did	O
+not	O
+indicate	O
+an	O
+association	O
+between	O
+the	O
+viral	B-DISO
+infections	I-DISO
+examined	O
+and	O
+signs	O
+of	O
+FLUTD	O
+in	O
+the	O
+study	O
+sample	O
+.	O
+
+To	O
+investigate	O
+the	O
+epidemiological	O
+and	O
+genetic	O
+variation	O
+of	O
+HBoV	O
+in	O
+Guangzhou	O
+,	O
+South	O
+China	O
+,	O
+we	O
+screened	O
+3460	O
+throat	B-ANAT
+swab	I-ANAT
+samples	O
+from	O
+1686	O
+children	O
+and	O
+1774	O
+adults	O
+with	O
+acute	B-DISO
+respiratory	I-DISO
+infection	I-DISO
+symptoms	O
+for	O
+HBoV	O
+between	O
+March	O
+2010	O
+and	O
+February	O
+2011	O
+,	O
+and	O
+analyzed	O
+the	O
+complete	O
+genome	O
+sequence	O
+of	O
+2	O
+HBoV	O
+strains	O
+.	O
+
+Recombination	B-PROC
+analysis	O
+confirmed	O
+that	O
+HBoV	O
+strain	O
+GZ9081	O
+was	O
+an	O
+intra	O
+-	O
+genotype	O
+recombinant	O
+strain	O
+among	O
+HBoV1	O
+variants	O
+.	O
+
+The	O
+purpose	O
+of	O
+this	O
+pilot	O
+study	O
+was	O
+to	O
+determine	O
+the	O
+inclusion	O
+of	O
+disaster	O
+medicine	B-CHED
+in	O
+the	O
+required	O
+course	O
+work	O
+of	O
+medical	O
+students	O
+at	O
+AAMC	O
+schools	O
+in	O
+the	O
+United	O
+States	O
+,	O
+and	O
+to	O
+identify	O
+the	O
+content	O
+areas	O
+addressed	O
+.	O
+
+TITLE	O
+:	O
+Programmed	O
+-	O
+1	O
+frameshifting	O
+efficiency	O
+correlates	O
+with	O
+RNA	O
+pseudoknot	O
+conformational	O
+plasticity	O
+,	O
+not	O
+resistance	B-PROC
+to	O
+mechanical	O
+unfolding	O
+.	O
+
+Previous	O
+work	O
+has	O
+suggested	O
+that	O
+frameshifting	O
+efficiency	O
+is	O
+related	O
+to	O
+the	O
+resistance	B-PROC
+of	O
+the	O
+pseudoknot	O
+against	O
+mechanical	O
+unfolding	O
+.	O
+
+We	O
+found	O
+that	O
+neither	O
+the	O
+average	O
+unfolding	O
+force	O
+,	O
+nor	O
+the	O
+unfolding	O
+kinetics	O
+,	O
+nor	O
+the	O
+parameters	O
+describing	O
+the	O
+energy	O
+landscape	O
+for	O
+mechanical	O
+unfolding	O
+of	O
+the	O
+pseudoknot	O
+(	O
+energy	O
+barrier	O
+height	O
+and	O
+distance	O
+to	O
+the	O
+transition	B-DISO
+state	O
+)	O
+could	O
+be	O
+correlated	O
+to	O
+frameshifting	O
+efficiency	O
+.	O
+
+TITLE	O
+:	O
+Incidence	O
+of	O
+viral	O
+respiratory	O
+pathogens	O
+causing	O
+exacerbations	O
+in	O
+adult	O
+cystic	B-DISO
+fibrosis	I-DISO
+patients	O
+.	O
+
+The	O
+spike	O
+glycoprotein	B-CHED
+of	O
+IBV	B-SPEC
+is	O
+essential	O
+for	O
+host	O
+cell	B-COMP
+attachment	I-COMP
+,	O
+neutralization	O
+,	O
+and	O
+is	O
+involved	O
+in	O
+the	O
+induction	O
+of	O
+protective	O
+immunity	B-PROC
+.	O
+
+On	O
+analysis	O
+of	O
+potential	O
+phosphorylation	B-PROC
+sites	O
+,	O
+the	O
+Ser542	O
+and	O
+Ser563	O
+sites	O
+were	O
+not	O
+present	O
+in	O
+Massachusetts	O
+strains	O
+,	O
+while	O
+QX	O
+-	O
+like	O
+isolates	O
+did	O
+not	O
+have	O
+the	O
+Ser534	O
+site	O
+.	O
+
+Massachusetts	O
+and	O
+QX	O
+-	O
+like	O
+strains	O
+showed	O
+different	O
+cleavage	B-PROC
+site	O
+motifs	O
+.	O
+
+Moreover	O
+,	O
+there	O
+are	O
+very	O
+few	O
+bat	B-ENZY
+cell	B-ANAT
+lines	I-ANAT
+or	O
+reagents	B-CHED
+available	O
+for	O
+investigating	O
+CoV	O
+replication	O
+in	O
+bat	B-ENZY
+cells	B-COMP
+or	O
+for	O
+isolating	O
+bat	B-ENZY
+CoVs	O
+adapted	O
+to	O
+specific	O
+bat	B-ENZY
+species	B-SPEC
+.	O
+
+immunization	O
+with	O
+rADV	O
+-	O
+S	O
+is	O
+safe	O
+and	O
+effective	O
+in	O
+induction	O
+of	O
+a	O
+broad	O
+spectrum	O
+of	O
+immune	B-PROC
+responses	I-PROC
+and	O
+presumably	O
+protection	O
+against	O
+infection	B-DISO
+with	O
+SARS	B-DISO
+-	O
+CoV	O
+.	O
+RESULTS	O
+:	O
+Here	O
+,	O
+we	O
+show	O
+that	O
+s	O
+.	O
+l	O
+.	O
+
+ABSTRACT	O
+:	O
+The	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+coronavirus	B-SPEC
+(	O
+SARS	B-DISO
+-	O
+CoV	O
+)	O
+spike	O
+protein	B-CHED
+is	O
+known	O
+to	O
+mediate	O
+receptor	O
+interaction	O
+and	O
+immune	O
+recognition	O
+and	O
+thus	O
+it	O
+is	O
+considered	O
+as	O
+a	O
+major	O
+target	O
+for	O
+vaccine	O
+design	O
+.	O
+
+The	O
+spike	O
+protein	B-CHED
+plays	O
+an	O
+important	O
+role	O
+in	O
+virus	B-SPEC
+entry	O
+,	O
+virus	B-SPEC
+receptor	B-PROC
+interactions	I-PROC
+,	O
+and	O
+virus	B-SPEC
+tropism	B-PROC
+.	O
+
+In	O
+conclusion	O
+,	O
+the	O
+method	O
+described	O
+in	O
+this	O
+study	O
+allows	O
+sensitive	O
+detection	O
+of	O
+a	O
+recombinant	B-PRGE
+SARS	I-PRGE
+spike	I-PRGE
+protein	B-CHED
+by	O
+sandwich	O
+ELISA	O
+with	O
+bi	O
+-	O
+specific	O
+monoclonal	O
+antibody	B-COMP
+and	O
+could	O
+be	O
+used	O
+for	O
+the	O
+diagnosis	O
+of	O
+patients	O
+suspected	O
+with	O
+SARS	B-DISO
+.	O
+
+The	O
+literature	O
+data	O
+demonstrate	O
+the	O
+multifaceted	O
+clinical	O
+picture	O
+of	O
+this	O
+disease	O
+attributable	O
+to	O
+genetic	O
+variability	O
+of	O
+the	O
+virus	B-SPEC
+and	O
+the	O
+immune	B-PROC
+response	I-PROC
+to	O
+infection	B-DISO
+.	O
+
+TITLE	O
+:	O
+[	O
+Peculiarities	O
+of	O
+clinical	O
+and	O
+X	O
+-	O
+ray	B-SPEC
+picture	O
+of	O
+pneumonia	B-DISO
+in	O
+patients	O
+with	O
+influenza	B-PATH
+A	I-PATH
+(	O
+H1N1	O
+)].	O
+
+The	O
+final	O
+X	O
+-	O
+ray	B-SPEC
+examination	O
+revealed	O
+normalization	O
+of	O
+the	O
+lung	B-ANAT
+structure	I-ANAT
+only	O
+in	O
+15	O
+.	O
+5	O
+%	O
+of	O
+the	O
+cases	O
+mostly	O
+the	O
+patients	O
+with	O
+mild	O
+pneumonia	B-DISO
+.	O
+
+Pulmonary	B-ANAT
+CT	O
+is	O
+believed	O
+to	O
+be	O
+the	O
+most	O
+informative	O
+method	O
+for	O
+diagnostics	O
+of	O
+pneumonia	B-DISO
+and	O
+its	O
+complications	O
+during	O
+influenza	B-PATH
+A	I-PATH
+(	O
+H1N1	O
+).	O
+
+At	O
+48	O
+h	O
+post	O
+transfection	B-PROC
+,	O
+the	O
+medium	O
+to	O
+culture	O
+the	O
+transfected	O
+BHK	O
+-	O
+21	O
+cells	B-COMP
+was	O
+harvested	O
+and	O
+inoculated	O
+into	O
+10	O
+-	O
+days	O
+old	O
+SPF	O
+embryonated	O
+chicken	B-SPEC
+eggs	O
+(	O
+ECE	O
+)	O
+to	O
+replicate	O
+the	O
+rescued	O
+virus	B-SPEC
+.	O
+
+Because	O
+of	O
+the	O
+expanding	O
+size	O
+and	O
+density	O
+of	O
+its	O
+population	O
+and	O
+the	O
+frequent	O
+interaction	O
+of	O
+people	O
+with	O
+animals	B-SPEC
+,	O
+China	O
+is	O
+a	O
+hotspot	O
+for	O
+the	O
+emergence	O
+and	O
+spread	O
+of	O
+new	O
+microbial	O
+threats	O
+and	O
+is	O
+a	O
+major	O
+contributor	O
+to	O
+the	O
+worldwide	O
+infectious	B-DISO
+disease	I-DISO
+burden	O
+.	O
+
+This	O
+review	O
+examines	O
+antibiotic	B-CHED
+misuse	O
+and	O
+the	O
+status	O
+of	O
+antibiotic	B-CHED
+resistance	B-PROC
+in	O
+the	O
+Chinese	O
+healthcare	O
+system	O
+.	O
+
+Tuberculosis	B-DISO
+remains	O
+a	O
+serious	O
+problem	O
+in	O
+China	O
+,	O
+with	O
+a	O
+high	O
+prevalence	O
+of	O
+multidrug	O
+-	O
+resistant	O
+and	O
+extensively	O
+drug	O
+-	O
+resistant	O
+strains	O
+.	O
+
+There	O
+is	O
+a	O
+need	O
+for	O
+effective	O
+infection	B-DISO
+prevention	O
+and	O
+control	O
+measures	O
+and	O
+strict	O
+use	O
+of	O
+antibiotics	B-CHED
+in	O
+China	O
+to	O
+control	O
+the	O
+rise	O
+and	O
+spread	O
+of	O
+antibiotic	B-CHED
+resistance	B-PROC
+in	O
+the	O
+country	O
+.	O
+
+Nasopharyngeal	B-ANAT
+aspirates	B-ANAT
+(	O
+NPA	B-CHED
+)	O
+samples	O
+were	O
+collected	O
+from	O
+1185	O
+hospitalized	O
+children	O
+with	O
+ALRTI	O
+at	O
+the	O
+People	O
+'	O
+s	O
+Hospital	O
+of	O
+Hunan	O
+province	O
+,	O
+between	O
+September	O
+2008	O
+and	O
+October	O
+2010	O
+.	O
+
+The	O
+overall	O
+frequency	O
+of	O
+coronavirus	B-SPEC
+NL63	O
+infection	B-DISO
+was	O
+0	O
+.	O
+8	O
+%,	O
+6	O
+(	O
+60	O
+%)	O
+out	O
+of	O
+the	O
+coronavirus	B-SPEC
+NL63	O
+positive	O
+patients	O
+were	O
+detected	O
+in	O
+summer	O
+,	O
+2	O
+in	O
+autumn	O
+,	O
+1	O
+in	O
+spring	O
+and	O
+winter	O
+,	O
+respectively	O
+.	O
+
+Four	O
+of	O
+the	O
+10	O
+cases	O
+had	O
+critical	B-DISO
+illness	I-DISO
+,	O
+4	O
+cases	O
+had	O
+underlying	O
+diseases	O
+,	O
+and	O
+7	O
+cases	O
+had	O
+mixed	B-DISO
+infection	I-DISO
+with	O
+other	O
+viruses	B-SPEC
+.	O
+
+Coronavirus	B-SPEC
+NL63	O
+infections	B-DISO
+are	O
+common	O
+in	O
+children	O
+under	O
+3	O
+years	O
+of	O
+age	O
+.	O
+
+There	O
+was	O
+serological	O
+evidence	O
+of	O
+previous	O
+exposure	O
+to	O
+bovine	B-DISO
+viral	I-DISO
+diarrhoea	I-DISO
+virus	B-SPEC
+,	O
+bovine	B-SPEC
+respiratory	I-SPEC
+syncytial	I-SPEC
+virus	I-SPEC
+and	O
+bovine	B-SPEC
+parainfluenza	I-SPEC
+virus	I-SPEC
+type	I-SPEC
+3	I-SPEC
+,	O
+but	O
+not	O
+to	O
+bovine	B-SPEC
+herpesvirus	I-SPEC
+type	I-SPEC
+1	I-SPEC
+.	O
+
+We	O
+report	O
+three	O
+cases	O
+of	O
+sigmoid	B-ANAT
+perforation	O
+in	O
+burn	O
+patients	O
+appearing	O
+late	O
+during	O
+hospitalization	O
+.	O
+
+The	O
+common	O
+aetiological	O
+factor	O
+was	O
+a	O
+state	O
+of	O
+septic	B-DISO
+shock	I-DISO
+treated	O
+with	O
+infusion	O
+of	O
+vasopressors	O
+.	O
+
+Two	O
+patients	O
+also	O
+received	O
+corticosteroids	B-CHED
+as	O
+treatment	O
+for	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+.	O
+
+These	O
+cases	O
+underline	O
+the	O
+necessity	O
+to	O
+maintain	O
+adequate	O
+organ	B-ANAT
+perfusion	O
+and	O
+to	O
+prevent	O
+intestinal	B-DISO
+ischaemia	I-DISO
+in	O
+severe	O
+burns	O
+.	O
+
+On	O
+the	O
+day	O
+of	O
+ICU	O
+admission	O
+,	O
+the	O
+sepsis	B-DISO
+group	O
+exhibited	O
+higher	O
+levels	O
+of	O
+urine	B-ANAT
+sCD163	O
+(	O
+74	O
+.	O
+8	O
+ng	O
+/	O
+ml	O
+;	O
+range	O
+:	O
+47	O
+.	O
+9	O
+-	O
+148	O
+.	O
+3	O
+ng	O
+/	O
+ml	O
+)	O
+compared	O
+with	O
+those	O
+in	O
+the	O
+SIRS	B-DISO
+group	O
+(	O
+31	O
+.	O
+9	O
+ng	O
+/	O
+ml	O
+;	O
+16	O
+.	O
+8	O
+-	O
+48	O
+.	O
+0	O
+,	O
+P	O
+<	O
+0	O
+.	O
+001	O
+).	O
+
+RESULTS	O
+:	O
+On	O
+the	O
+day	O
+of	O
+ICU	O
+admission	O
+,	O
+the	O
+sepsis	B-DISO
+group	O
+exhibited	O
+higher	O
+levels	O
+of	O
+urine	B-ANAT
+sCD163	O
+(	O
+74	O
+.	O
+8	O
+ng	O
+/	O
+ml	O
+;	O
+range	O
+:	O
+47	O
+.	O
+9	O
+-	O
+148	O
+.	O
+3	O
+ng	O
+/	O
+ml	O
+)	O
+compared	O
+with	O
+those	O
+in	O
+the	O
+SIRS	B-DISO
+group	O
+(	O
+31	O
+.	O
+9	O
+ng	O
+/	O
+ml	O
+;	O
+16	O
+.	O
+8	O
+-	O
+48	O
+.	O
+0	O
+,	O
+P	O
+<	O
+0	O
+.	O
+001	O
+).	O
+
+ABSTRACT	O
+:	O
+Infection	B-DISO
+with	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+coronavirus	B-SPEC
+(	O
+SARS	B-DISO
+-	O
+CoV	O
+)	O
+causes	O
+acute	O
+lung	B-ANAT
+injury	O
+(	O
+ALI	O
+)	O
+that	O
+often	O
+leads	O
+to	O
+severe	O
+lung	B-DISO
+disease	I-DISO
+.	O
+
+Mice	B-SPEC
+lacking	O
+STAT1	B-PRGE
+have	O
+greater	O
+weight	O
+loss	O
+,	O
+severe	O
+lung	B-ANAT
+pathology	B-DISO
+with	O
+pre	O
+-	O
+pulmonary	B-ANAT
+-	O
+fibrosis	B-DISO
+-	O
+like	O
+lesions	O
+,	O
+and	O
+an	O
+altered	O
+immune	B-PROC
+response	I-PROC
+following	O
+infection	B-DISO
+with	O
+SARS	B-DISO
+-	O
+CoV	O
+.	O
+We	O
+hypothesized	O
+that	O
+STAT1	B-PRGE
+plays	O
+a	O
+role	O
+in	O
+the	O
+polarization	O
+of	O
+the	O
+immune	B-PROC
+response	I-PROC
+,	O
+specifically	O
+in	O
+macrophages	B-ANAT
+,	O
+resulting	O
+in	O
+a	O
+worsened	O
+outcome	O
+.	O
+
+We	O
+evaluated	O
+the	O
+benefits	O
+of	O
+inhaled	B-PROC
+epoprostenol	B-CHED
+as	O
+a	O
+less	O
+expensive	O
+alternative	O
+to	O
+nitric	B-CHED
+oxide	I-CHED
+in	O
+ventilated	O
+surgical	O
+intensive	O
+care	O
+patients	O
+with	O
+severe	O
+hypoxemia	O
+.	O
+
+One	O
+-	O
+way	O
+repeated	O
+-	O
+measures	O
+analysis	O
+of	O
+variance	O
+compared	O
+improvements	O
+in	O
+oxygenation	B-PROC
+.	O
+
+TITLE	O
+:	O
+Fourth	O
+European	O
+Conference	O
+on	O
+Infections	B-DISO
+in	O
+Leukaemia	B-DISO
+(	O
+ECIL	O
+-	O
+4	O
+):	O
+guidelines	O
+for	O
+diagnosis	O
+and	O
+treatment	O
+of	O
+human	O
+respiratory	O
+syncytial	O
+virus	O
+,	O
+parainfluenza	B-DISO
+virus	B-SPEC
+,	O
+metapneumovirus	B-SPEC
+,	O
+rhinovirus	B-SPEC
+,	O
+and	O
+coronavirus	B-SPEC
+.	O
+
+Identification	O
+of	O
+epitopes	O
+on	O
+the	O
+PEDV	B-PRGE
+M	I-PRGE
+protein	B-CHED
+will	O
+be	O
+helpful	O
+in	O
+the	O
+elucidation	O
+of	O
+the	O
+antigenic	O
+properties	O
+of	O
+this	O
+protein	B-CHED
+.	O
+
+ABSTRACT	O
+:	O
+The	O
+first	O
+decade	O
+of	O
+the	O
+21st	O
+century	O
+has	O
+witnessed	O
+three	O
+major	O
+influenza	B-DISO
+public	O
+health	O
+emergencies	B-DISO
+:	O
+(	O
+1	O
+)	O
+the	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+of	O
+2002	O
+-	O
+2003	O
+;	O
+(	O
+2	O
+)	O
+the	O
+avian	B-DISO
+flu	I-DISO
+of	O
+2006	O
+;	O
+and	O
+(	O
+3	O
+)	O
+the	O
+2009	O
+H1N1	O
+pandemic	O
+influenza	B-DISO
+.	O
+
+Use	O
+of	O
+corticosteroids	O
+to	O
+attenuate	O
+inflammation	B-DISO
+remains	O
+controversial	O
+.	O
+
+We	O
+provide	O
+evidence	O
+for	O
+a	O
+novel	O
+mode	O
+of	O
+action	O
+of	O
+nsp1	B-PRGE
+.	O
+
+nsp1	B-PRGE
+inhibited	O
+the	O
+translation	B-PROC
+initiation	I-PROC
+step	O
+by	O
+targeting	B-PROC
+at	O
+least	O
+two	O
+separate	O
+stages	O
+:	O
+48S	O
+initiation	O
+complex	O
+formation	B-PROC
+and	O
+the	O
+steps	O
+involved	O
+in	O
+the	O
+formation	B-PROC
+of	O
+the	O
+80S	B-PRGE
+initiation	I-PRGE
+complex	I-PRGE
+from	O
+the	O
+48S	B-PRGE
+complex	I-PRGE
+.	O
+
+nsp1	B-PRGE
+had	O
+a	O
+differential	O
+,	O
+mRNA	B-CHED
+template	O
+-	O
+dependent	O
+,	O
+inhibitory	O
+effect	O
+on	O
+48S	O
+and	O
+80S	O
+initiation	O
+complex	O
+formation	B-PROC
+.	O
+
+A	O
+total	O
+of	O
+120	O
+viruses	B-SPEC
+were	O
+detected	O
+from	O
+113	O
+children	O
+.	O
+
+ABSTRACT	O
+:	O
+The	O
+avian	B-DISO
+infectious	I-DISO
+bronchitis	I-DISO
+virus	B-SPEC
+(	O
+IBV	B-SPEC
+)	O
+multi	O
+-	O
+epitope	B-CHED
+based	O
+peptide	B-CHED
+EpiC	O
+was	O
+found	O
+to	O
+be	O
+effective	O
+in	O
+inducing	O
+strong	O
+humoral	O
+and	O
+cellular	B-COMP
+responses	O
+against	O
+IBV	B-SPEC
+.	O
+
+SDS	B-DISO
+-	O
+PAGE	O
+and	O
+Western	O
+blot	O
+results	O
+indicated	O
+that	O
+EpiC	O
+was	O
+successfully	O
+expressed	B-PROC
+and	O
+had	O
+good	O
+immunoreactivity	B-PROC
+with	O
+chicken	B-PRGE
+anti	I-PRGE
+-	I-PRGE
+IBV	B-SPEC
+serum	B-COMP
+.	O
+
+Fusion	O
+of	O
+the	O
+signal	O
+pepitide	O
+gene	O
+SPusp45	O
+and	O
+the	O
+nine	O
+-	O
+peptide	B-CHED
+LEISSTCDA	O
+encoding	O
+oligonucleotide	B-CHED
+to	O
+EpiC	O
+increased	O
+the	O
+secretion	B-PROC
+of	O
+EpiC	O
+,	O
+but	O
+reduced	O
+the	O
+total	O
+yields	O
+of	O
+EpiC	O
+.	O
+Oral	B-ANAT
+immunization	O
+to	O
+specific	O
+-	O
+pathogen	O
+-	O
+free	O
+(	O
+SPF	O
+)	O
+chickens	B-SPEC
+with	O
+recombinant	O
+strains	O
+induced	O
+significantly	O
+higher	O
+levels	O
+of	O
+humoral	B-PROC
+immune	I-PROC
+responses	I-PROC
+,	O
+and	O
+provided	O
+protection	O
+against	O
+lethal	O
+dose	O
+challenge	O
+by	O
+the	O
+IBV	O
+SAIBk	O
+strain	O
+.	O
+
+These	O
+results	O
+indicate	O
+that	O
+it	O
+is	O
+feasible	O
+to	O
+use	O
+L	B-SPEC
+.	I-SPEC
+lactis	I-SPEC
+as	O
+an	O
+antigen	B-CHED
+delivery	O
+vehicle	O
+in	O
+developing	O
+oral	B-ANAT
+vaccines	O
+against	O
+IBV	B-SPEC
+infection	B-DISO
+.	O
+
+ABSTRACT	O
+:	O
+Conventional	O
+and	O
+molecular	O
+epidemiologic	O
+studies	O
+have	O
+confirmed	O
+the	O
+ability	O
+of	O
+infectious	O
+bronchitis	B-DISO
+virus	B-SPEC
+(	O
+IBV	B-SPEC
+)	O
+to	O
+rapidly	O
+evolve	O
+and	O
+successfully	O
+circumvent	O
+extensive	O
+vaccination	O
+programs	O
+implemented	O
+since	O
+the	O
+early	O
+1950s	O
+.	O
+
+However	O
+,	O
+the	O
+mechanisms	O
+regulating	O
+the	O
+evolution	B-PROC
+of	O
+IBV	B-SPEC
+include	O
+both	O
+the	O
+generation	O
+of	O
+genetic	O
+diversity	O
+and	O
+the	O
+selection	O
+process	O
+.	O
+
+IBV	B-SPEC
+'	O
+s	O
+generation	O
+of	O
+genetic	O
+diversity	O
+has	O
+been	O
+extensively	O
+investigated	O
+and	O
+ultimately	O
+involves	O
+mutations	O
+and	O
+recombination	B-PROC
+events	O
+occurring	O
+during	O
+viral	B-PROC
+replication	I-PROC
+.	O
+
+The	O
+relevance	O
+of	O
+the	O
+selection	O
+process	O
+has	O
+been	O
+further	O
+understood	O
+more	O
+recently	O
+by	O
+identifying	O
+genetic	O
+and	O
+phenotypic	O
+differences	O
+between	O
+IBV	B-SPEC
+populations	O
+prior	O
+to	O
+,	O
+and	O
+during	O
+,	O
+replication	O
+in	O
+the	O
+natural	O
+host	B-COMP
+.	O
+
+Some	O
+scientists	O
+have	O
+used	O
+or	O
+adopted	O
+the	O
+related	O
+quasispecies	O
+frame	O
+to	O
+explain	O
+IBV	B-SPEC
+evolution	B-PROC
+.	O
+
+Understanding	O
+the	O
+mechanisms	O
+underlying	O
+the	O
+evolution	B-PROC
+of	O
+IBV	B-SPEC
+is	O
+of	O
+basic	O
+relevance	O
+and	O
+,	O
+without	O
+doubt	O
+,	O
+essential	O
+to	O
+appropriately	O
+control	O
+and	O
+prevent	O
+the	O
+disease	O
+.	O
+
+The	O
+first	O
+patient	O
+,	O
+a	O
+man	B-CHED
+aged	O
+60	O
+years	O
+from	O
+Saudi	O
+Arabia	O
+,	O
+was	O
+hospitalized	O
+in	O
+June	O
+2012	O
+and	O
+died	B-PROC
+;	O
+the	O
+second	O
+patient	O
+,	O
+a	O
+man	B-CHED
+aged	O
+49	O
+years	O
+from	O
+Qatar	O
+with	O
+onset	O
+of	O
+symptoms	O
+in	O
+September	O
+2012	O
+was	O
+transported	O
+to	O
+the	O
+United	O
+Kingdom	B-SPEC
+for	O
+intensive	O
+care	O
+.	O
+
+He	O
+remains	O
+hospitalized	O
+on	O
+life	O
+support	O
+with	O
+both	O
+pulmonary	B-ANAT
+and	O
+renal	B-DISO
+failure	I-DISO
+.	O
+
+Updates	O
+on	O
+the	O
+investigation	O
+and	O
+the	O
+WHO	O
+case	O
+definition	O
+are	O
+available	O
+at	O
+http	O
+://	O
+www	O
+.	O
+who	O
+.	O
+int	O
+/	O
+csr	B-DISO
+/	O
+don	B-PRGE
+/	O
+en	O
+/	O
+index	O
+.	O
+html	O
+.	O
+
+Subsequently	O
+,	O
+infections	B-DISO
+with	O
+this	O
+genotype	O
+were	O
+found	O
+in	O
+several	O
+other	O
+European	O
+countries	O
+such	O
+as	O
+France	O
+,	O
+Italy	O
+,	O
+Germany	O
+,	O
+United	O
+Kingdom	B-SPEC
+,	O
+Slovenia	O
+,	O
+and	O
+Sweden	O
+.	O
+
+In	O
+such	O
+potentially	O
+dangerous	O
+situations	O
+,	O
+we	O
+advocate	O
+a	O
+method	O
+of	O
+clamping	O
+and	O
+severing	O
+the	O
+pulmonary	B-ANAT
+lobar	O
+root	B-ANAT
+structure	O
+en	O
+masse	O
+.	O
+
+Seven	O
+patients	O
+had	O
+inflammatory	O
+lung	B-DISO
+disease	I-DISO
+,	O
+four	O
+had	O
+primary	O
+pulmonary	B-DISO
+carcinoma	I-DISO
+,	O
+and	O
+one	O
+had	O
+suffered	B-DISO
+blunt	O
+chest	B-ANAT
+trauma	O
+.	O
+
+They	O
+are	O
+most	O
+well	O
+studied	O
+in	O
+their	O
+effects	O
+on	O
+the	O
+immune	B-ANAT
+system	I-ANAT
+and	O
+their	O
+integral	O
+role	O
+in	O
+mediating	O
+inflammation	B-DISO
+.	O
+
+The	O
+common	B-DISO
+cold	I-DISO
+and	O
+otitis	B-DISO
+media	I-DISO
+are	O
+two	O
+such	O
+disease	O
+states	O
+,	O
+and	O
+much	O
+has	O
+been	O
+learned	B-PROC
+about	O
+the	O
+various	O
+effects	O
+of	O
+cytokines	O
+in	O
+each	O
+disease	O
+.	O
+
+One	O
+hundred	O
+nine	O
+pediatric	O
+patients	O
+having	O
+respiratory	B-DISO
+tract	I-DISO
+infections	I-DISO
+were	O
+included	O
+in	O
+this	O
+study	O
+.	O
+
+Virus	B-SPEC
+was	O
+detected	O
+in	O
+43	O
+cases	O
+from	O
+larynx	B-DISO
+swabs	O
+(	O
+43	O
+/	O
+109	O
+,	O
+39	O
+.	O
+4	O
+%).	O
+
+Specificity	O
+of	O
+the	O
+PCR	O
+and	O
+DFA	B-CHED
+methods	O
+for	O
+RSV	B-DISO
+infections	I-DISO
+were	O
+detected	O
+as	O
+97	O
+%	O
+and	O
+100	O
+%	O
+respectively	O
+.	O
+
+Metapneumovirus	B-SPEC
+was	O
+also	O
+frequent	O
+(	O
+3	O
+.	O
+6	O
+%).	O
+
+C	B-SPEC
+.	I-SPEC
+pneumoniae	I-SPEC
+was	O
+not	O
+found	O
+to	O
+be	O
+a	O
+common	O
+agent	O
+for	O
+acute	B-DISO
+respiratory	I-DISO
+disease	I-DISO
+in	O
+children	O
+.	O
+
+TITLE	O
+:	O
+Long	O
+-	O
+distance	O
+RNA	O
+-	O
+RNA	O
+interactions	O
+in	O
+the	O
+coronavirus	B-SPEC
+genome	O
+form	O
+high	O
+-	O
+order	B-SPEC
+structures	O
+promoting	O
+discontinuous	O
+RNA	O
+synthesis	O
+during	O
+transcription	B-PROC
+.	O
+
+Furthermore	O
+,	O
+the	O
+template	O
+switch	O
+requires	O
+the	O
+physical	O
+proximity	O
+of	O
+RNA	O
+genome	O
+domains	O
+located	O
+between	O
+20	O
+,	O
+000	O
+and	O
+30	O
+,	O
+000	O
+nucleotides	B-CHED
+apart	O
+.	O
+
+The	O
+same	O
+could	O
+be	O
+observed	O
+comparing	O
+the	O
+group	O
+of	O
+patients	O
+with	O
+acute	O
+inflammation	B-DISO
+and	O
+non	O
+-	O
+COPD	B-DISO
+healthy	O
+smokers	O
+(	O
+P	O
+=	O
+0	O
+.	O
+007	O
+).	O
+
+Tissue	B-ANAT
+detection	O
+of	O
+the	O
+protein	B-CHED
+showed	O
+that	O
+it	O
+was	O
+significantly	O
+overexpressed	O
+in	O
+COPD	B-DISO
+smokers	O
+in	O
+comparison	O
+to	O
+COPD	B-DISO
+nonsmokers	O
+and	O
+was	O
+only	O
+slightly	O
+expressed	B-PROC
+in	O
+patients	O
+with	O
+age	O
+-	O
+related	O
+emphysema	B-DISO
+.	O
+
+As	O
+αB	B-PRGE
+-	I-PRGE
+crystallin	I-PRGE
+is	O
+a	O
+regulator	O
+of	O
+innate	B-PROC
+immunity	I-PROC
+and	O
+a	O
+therapeutic	O
+anti	B-CHED
+-	I-CHED
+inflammatory	I-CHED
+agent	I-CHED
+,	O
+its	O
+exact	O
+role	O
+in	O
+COPD	B-DISO
+pathogenesis	B-DISO
+and	O
+therapy	O
+should	O
+be	O
+explored	O
+further	O
+.	O
+
+CONCLUSIONS	O
+:	O
+αB	B-PRGE
+-	I-PRGE
+crystallin	I-PRGE
+is	O
+increased	O
+in	O
+patients	O
+with	O
+inflammatory	O
+lung	B-DISO
+diseases	I-DISO
+.	O
+
+Because	O
+of	O
+increased	O
+overlap	O
+and	O
+potential	O
+contact	O
+with	O
+domestic	O
+species	B-SPEC
+,	O
+we	O
+conducted	O
+a	O
+retrospective	O
+serosurvey	O
+for	O
+11	O
+common	O
+carnivore	O
+pathogens	O
+in	O
+40	O
+Geoffroy	B-SPEC
+'	I-SPEC
+s	I-SPEC
+cats	I-SPEC
+(	O
+Leopardus	B-SPEC
+geoffroyi	I-SPEC
+)	O
+sampled	O
+between	O
+2000	O
+and	O
+2008	O
+within	O
+or	O
+near	O
+two	O
+protected	O
+areas	O
+in	O
+central	O
+Argentina	B-SPEC
+(	O
+Lihué	O
+Calel	O
+National	O
+Park	B-DISO
+,	O
+La	O
+Pampa	O
+,	O
+and	O
+Campos	O
+del	O
+Tuyú	O
+National	O
+Park	B-DISO
+,	O
+Buenos	O
+Aires	O
+),	O
+as	O
+well	O
+as	O
+five	O
+domestic	B-SPEC
+cats	I-SPEC
+and	O
+11	O
+domestic	O
+dogs	B-SPEC
+from	O
+catde	O
+ranches	O
+adjacent	O
+to	O
+Lihué	O
+Calel	O
+Park	B-DISO
+.	O
+
+Domestic	O
+dogs	B-SPEC
+had	O
+antibodies	B-COMP
+to	O
+CDV	B-CHED
+,	O
+canine	B-SPEC
+adenovirus	I-SPEC
+,	O
+canine	B-SPEC
+herpesvirus	I-SPEC
+,	O
+and	O
+canine	O
+parvovirus	B-DISO
+.	O
+
+TITLE	O
+:	O
+Pathogens	O
+of	O
+wild	O
+maned	O
+wolves	O
+(	O
+Chrysocyon	B-SPEC
+brachyurus	I-SPEC
+)	O
+in	O
+Brazil	O
+.	O
+
+ABSTRACT	O
+:	O
+To	O
+better	O
+understand	O
+the	O
+molecular	O
+epidemiology	O
+of	O
+infectious	O
+bronchitis	B-DISO
+virus	B-SPEC
+(	O
+IBV	B-SPEC
+)	O
+in	O
+the	O
+United	O
+States	O
+following	O
+the	O
+introduction	O
+of	O
+commercial	O
+IBV	B-SPEC
+vaccines	O
+,	O
+we	O
+sequenced	O
+the	O
+S1	O
+and	O
+N	O
+structural	O
+protein	B-CHED
+genes	O
+of	O
+thirteen	O
+IBV	B-SPEC
+field	O
+isolates	O
+collected	O
+in	O
+the	O
+1960s	O
+.	O
+
+In	O
+addition	O
+,	O
+the	O
+Mass	O
+-	O
+type	O
+isolates	O
+had	O
+high	O
+levels	O
+of	O
+sequence	O
+identity	O
+in	O
+the	O
+S1	B-PRGE
+gene	I-PRGE
+compared	O
+with	O
+widely	O
+used	O
+modified	O
+live	O
+vaccines	O
+(	O
+Mass41	O
+,	O
+Ma5	B-PRGE
+and	O
+H120	O
+)	O
+and	O
+modern	O
+field	O
+strains	O
+from	O
+the	O
+USA	O
+and	O
+other	O
+countries	O
+,	O
+suggesting	O
+a	O
+common	O
+ancestor	O
+.	O
+
+The	O
+active	O
+site	O
+anchors	O
+the	O
+N	O
+-	O
+terminal	O
+neutral	O
+residue	O
+of	O
+peptides	B-CHED
+/	O
+proteins	B-CHED
+,	O
+and	O
+the	O
+peptide	B-CHED
+-	O
+binding	B-FUNC
+channel	O
+binds	B-FUNC
+the	O
+remainder	O
+of	O
+the	O
+peptides	O
+/	O
+proteins	B-CHED
+in	O
+a	O
+sequence	O
+-	O
+independent	O
+fashion	O
+.	O
+
+For	O
+decades	O
+,	O
+this	O
+method	O
+has	O
+been	O
+used	O
+to	O
+support	O
+critically	B-DISO
+ill	I-DISO
+patients	O
+in	O
+respiratory	B-DISO
+failure	I-DISO
+.	O
+
+The	O
+application	O
+of	O
+these	O
+technologies	O
+in	O
+primary	B-DISO
+graft	I-DISO
+dysfunction	I-DISO
+(	O
+PGD	B-CHED
+)	O
+after	O
+LTx	O
+is	O
+beyond	O
+the	O
+scope	O
+of	O
+this	O
+review	O
+and	O
+is	O
+not	O
+discussed	O
+.	O
+
+CLINICAL	O
+APPLICATIONS	O
+OF	O
+EXTRACORPOREAL	O
+LUNG	B-ANAT
+SUPPORT	O
+:	O
+Extracorporeal	O
+lung	B-ANAT
+support	O
+technologies	O
+[	O
+i	O
+.	O
+e	O
+.,	O
+Interventional	O
+Lung	B-ANAT
+Assist	O
+(	O
+ILA	O
+)	O
+and	O
+extracorporeal	O
+membrane	B-COMP
+oxygenation	B-PROC
+(	O
+ECMO	O
+)]	O
+have	O
+been	O
+advocated	O
+for	O
+use	O
+in	O
+the	O
+treatment	O
+of	O
+patients	O
+with	O
+respiratory	B-DISO
+failure	I-DISO
+.	O
+
+As	O
+a	O
+bridge	O
+to	O
+LTx	O
+-	O
+for	O
+patients	O
+with	O
+irreversible	O
+end	O
+stage	O
+lung	B-DISO
+disease	I-DISO
+requiring	O
+LTx	O
+.	O
+
+EX	O
+-	O
+VIVO	O
+LUNG	B-ANAT
+PERFUSION	O
+AND	O
+ASSESSMENT	O
+:	O
+Recently	O
+,	O
+the	O
+evaluation	O
+and	O
+reconditioning	O
+of	O
+donor	B-CHED
+lungs	B-ANAT
+ex	O
+-	O
+vivo	O
+has	O
+been	O
+introduced	O
+into	O
+clinical	O
+practice	O
+as	O
+a	O
+method	O
+of	O
+improving	O
+the	O
+rate	O
+of	O
+donor	B-CHED
+lung	B-ANAT
+utilization	O
+.	O
+
+Problems	O
+associated	O
+with	O
+cannulation	O
+during	O
+the	O
+procedure	O
+include	O
+bleeding	B-DISO
+around	O
+the	O
+cannulation	O
+site	O
+and	O
+limb	B-ANAT
+ischemia	B-DISO
+distal	O
+to	O
+the	O
+cannulation	O
+site	O
+.	O
+
+In	O
+their	O
+study	O
+,	O
+12	O
+patients	O
+at	O
+high	O
+urgency	O
+status	O
+for	O
+LTx	O
+,	O
+who	O
+also	O
+had	O
+severe	O
+ventilation	O
+refractory	O
+hypercapnea	O
+and	O
+respiratory	B-DISO
+acidosis	I-DISO
+,	O
+were	O
+connected	O
+to	O
+ILA	B-PRGE
+prior	O
+to	O
+LTx	O
+.	O
+
+Airborne	O
+transmission	O
+is	O
+the	O
+spread	O
+of	O
+infectious	B-DISO
+pathogens	O
+over	O
+large	O
+distances	O
+through	O
+the	O
+air	B-CHED
+.	O
+
+The	O
+effectiveness	O
+of	O
+an	O
+in	O
+-	O
+room	O
+air	B-CHED
+cleaner	O
+to	O
+remove	O
+airborne	O
+pathogens	O
+from	O
+room	O
+air	B-CHED
+depends	O
+on	O
+several	O
+factors	O
+,	O
+including	O
+the	O
+airflow	B-PROC
+rate	O
+through	O
+the	O
+unit	O
+'	O
+s	O
+filter	O
+and	O
+the	O
+airflow	B-PROC
+patterns	O
+in	O
+the	O
+room	O
+.	O
+
+Importantly	O
+,	O
+the	O
+use	O
+of	O
+an	O
+in	O
+-	O
+room	O
+air	B-CHED
+cleaner	O
+does	O
+not	O
+preclude	O
+either	O
+the	O
+need	O
+for	O
+health	O
+care	O
+workers	O
+and	O
+visitors	O
+to	O
+use	O
+personal	O
+protective	O
+equipment	O
+(	O
+N95	O
+mask	O
+or	O
+equivalent	O
+)	O
+when	O
+entering	O
+AII	O
+rooms	O
+or	O
+health	O
+care	O
+facilities	O
+from	O
+meeting	O
+current	O
+regulatory	O
+requirements	O
+for	O
+airflow	B-PROC
+rates	O
+(	O
+ventilation	O
+rates	O
+)	O
+in	O
+buildings	O
+and	O
+airflow	B-PROC
+differentials	O
+for	O
+effective	O
+negative	O
+-	O
+pressure	O
+rooms	O
+.	O
+
+The	O
+cluster	O
+ion	O
+surrounds	O
+the	O
+airborne	O
+particle	O
+,	O
+and	O
+the	O
+positive	O
+and	O
+negative	O
+ions	B-CHED
+react	O
+to	O
+form	O
+hydroxyls	O
+.	O
+
+The	O
+objective	O
+of	O
+the	O
+systematic	O
+review	O
+was	O
+to	O
+determine	O
+the	O
+effectiveness	O
+of	O
+in	O
+-	O
+room	O
+air	B-CHED
+cleaners	O
+with	O
+built	O
+in	O
+UVGI	O
+lights	O
+and	O
+HEPA	O
+filtration	O
+compared	O
+with	O
+those	O
+using	O
+HEPA	O
+filtration	O
+only	O
+.	O
+
+There	O
+were	O
+no	O
+existing	O
+health	O
+technology	O
+assessments	O
+on	O
+air	B-CHED
+cleaning	O
+technology	O
+located	O
+during	O
+the	O
+literature	O
+review	O
+.	O
+
+At	O
+least	O
+one	O
+underlying	O
+medical	O
+condition	B-DISO
+was	O
+reported	O
+in	O
+70	O
+.	O
+7	O
+%	O
+(	O
+for	O
+pandemic	O
+influenza	B-DISO
+strain	O
+)	O
+and	O
+96	O
+%	O
+(	O
+for	O
+influenza	B-DISO
+type	O
+B	O
+)	O
+of	O
+deaths	B-PROC
+.	O
+
+Predominating	O
+preexisting	O
+condition	B-DISO
+was	O
+coronary	B-DISO
+heart	B-ANAT
+disease	I-DISO
+.	O
+
+TITLE	O
+:	O
+Severe	B-DISO
+sepsis	I-DISO
+and	O
+septic	B-DISO
+shock	I-DISO
+in	O
+pregnancy	O
+:	O
+indications	O
+for	O
+delivery	O
+and	O
+maternal	O
+and	O
+perinatal	O
+outcomes	O
+.	O
+
+All	O
+patients	O
+with	O
+septic	B-DISO
+shock	I-DISO
+were	O
+delivered	O
+during	O
+hospitalization	O
+vs	O
+.	O
+40	O
+%	O
+with	O
+severe	B-DISO
+sepsis	I-DISO
+.	O
+
+ARDS	B-DISO
+is	O
+frequently	O
+found	O
+in	O
+critically	B-DISO
+ill	I-DISO
+obstetric	O
+patients	O
+with	O
+severe	B-DISO
+sepsis	I-DISO
+/	O
+septic	B-DISO
+shock	I-DISO
+and	O
+is	O
+associated	O
+with	O
+a	O
+high	O
+risk	O
+of	O
+emergent	O
+cesarean	O
+delivery	O
+.	O
+
+RESULTS	O
+:	O
+Pyelonephritis	B-DISO
+was	O
+the	O
+most	O
+common	O
+etiology	O
+overall	O
+(	O
+37	O
+%)	O
+and	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+(	O
+ARDS	B-DISO
+)	O
+was	O
+the	O
+most	O
+common	O
+organ	B-ANAT
+injury	O
+in	O
+both	O
+severe	B-DISO
+sepsis	I-DISO
+(	O
+50	O
+%)	O
+and	O
+septic	B-DISO
+shock	I-DISO
+(	O
+80	O
+%).	O
+
+ABSTRACT	O
+:	O
+On	O
+22	O
+September	O
+2012	O
+,	O
+a	O
+novel	B-SPEC
+coronavirus	I-SPEC
+,	O
+very	O
+closely	O
+related	O
+to	O
+that	O
+from	O
+a	O
+fatal	O
+case	O
+in	O
+Saudi	O
+Arabia	O
+three	O
+months	O
+previously	O
+,	O
+was	O
+detected	O
+in	O
+a	O
+previously	O
+well	O
+adult	O
+transferred	O
+to	O
+intensive	O
+care	O
+in	O
+London	O
+from	O
+Qatar	O
+with	O
+severe	O
+respiratory	O
+illness	O
+.	O
+
+The	O
+novel	B-SPEC
+coronavirus	I-SPEC
+was	O
+not	O
+detected	O
+in	O
+10	O
+of	O
+10	O
+symptomatic	O
+contacts	O
+tested	O
+.	O
+
+We	O
+recently	O
+determined	O
+the	O
+crystal	B-ANAT
+structure	O
+of	O
+MHV	B-SPEC
+NTD	O
+complexed	O
+with	O
+its	O
+protein	B-CHED
+receptor	O
+murine	B-SPEC
+carcinoembryonic	O
+antigen	B-CHED
+-	O
+related	O
+cell	B-PROC
+adhesion	B-DISO
+molecule	O
+1	O
+(	O
+CEACAM1	B-PRGE
+),	O
+which	O
+surprisingly	O
+revealed	O
+a	O
+human	B-PRGE
+galectin	I-PRGE
+(	O
+galactose	B-PRGE
+-	I-PRGE
+binding	B-FUNC
+lectin	I-PRGE
+)	O
+fold	O
+in	O
+MHV	B-SPEC
+NTD	O
+.	O
+
+So	O
+far	O
+,	O
+no	O
+drugs	O
+are	O
+available	O
+for	O
+the	O
+inhibition	B-PROC
+of	O
+the	O
+RT	B-PRGE
+associated	I-PRGE
+ribonuclease	I-PRGE
+H	I-PRGE
+function	O
+(	O
+RNase	B-PRGE
+H	I-PRGE
+),	O
+which	O
+plays	O
+an	O
+essential	O
+role	O
+in	O
+the	O
+HIV	B-DISO
+replication	O
+cycle	O
+.	O
+
+TITLE	O
+:	O
+Steroid	B-CHED
+modulation	O
+of	O
+cytokine	O
+release	B-PATH
+and	O
+desmosine	B-CHED
+levels	O
+in	O
+bilateral	O
+total	O
+knee	B-ANAT
+replacement	O
+:	O
+a	O
+prospective	O
+,	O
+double	O
+-	O
+blind	O
+,	O
+randomized	O
+controlled	O
+trial	O
+.	O
+
+We	O
+had	O
+found	O
+a	O
+significant	O
+decrease	O
+in	O
+IL	B-FUNC
+-	I-FUNC
+6	I-FUNC
+in	O
+patients	O
+having	O
+bilateral	O
+total	O
+knee	B-ANAT
+replacement	O
+who	O
+received	O
+two	O
+doses	O
+of	O
+100	O
+mg	O
+of	O
+hydrocortisone	B-CHED
+eight	O
+hours	O
+apart	O
+;	O
+however	O
+,	O
+by	O
+twenty	O
+-	O
+four	O
+hours	O
+,	O
+IL	B-FUNC
+-	I-FUNC
+6	I-FUNC
+levels	O
+were	O
+equal	O
+to	O
+those	O
+in	O
+the	O
+group	O
+that	O
+received	O
+a	O
+placebo	O
+.	O
+
+Pain	O
+scores	O
+at	O
+twenty	O
+-	O
+four	O
+hours	O
+were	O
+significantly	O
+lower	O
+in	O
+the	O
+study	O
+group	O
+(	O
+1	O
+.	O
+4	O
+±	O
+0	O
+.	O
+9	O
+versus	O
+2	O
+.	O
+4	O
+±	O
+1	O
+.	O
+2	O
+;	O
+p	O
+=	O
+0	O
+.	O
+01	O
+)	O
+as	O
+was	O
+the	O
+presence	O
+of	O
+fever	B-PROC
+(	O
+11	O
+.	O
+8	O
+%	O
+versus	O
+47	O
+.	O
+1	O
+%;	O
+p	O
+=	O
+0	O
+.	O
+03	O
+).	O
+
+The	O
+significantly	O
+lower	O
+values	O
+of	O
+desmosine	B-CHED
+in	O
+the	O
+study	O
+group	O
+suggest	O
+that	O
+this	O
+treatment	O
+may	O
+be	O
+protective	O
+against	O
+lung	B-ANAT
+injury	O
+.	O
+
+Nowadays	O
+the	O
+ECMO	O
+-	O
+systems	O
+are	O
+heparin	B-CHED
+-	O
+coated	O
+,	O
+so	O
+that	O
+there	O
+is	O
+no	O
+need	O
+of	O
+therapeutic	O
+systemic	O
+anticoagulation	B-PROC
+,	O
+and	O
+thus	O
+bleeding	B-DISO
+complications	O
+are	O
+less	O
+frequent	O
+.	O
+
+ABSTRACT	O
+:	O
+Highly	O
+virulent	O
+pantropic	O
+canine	O
+coronavirus	O
+(	O
+CCoV	O
+)	O
+strains	O
+belonging	O
+to	O
+subtype	O
+IIa	O
+were	O
+recently	O
+identified	O
+in	O
+dogs	B-SPEC
+.	O
+
+In	O
+humans	B-SPEC
+the	O
+number	O
+of	O
+cases	O
+infected	O
+with	O
+this	O
+virus	B-SPEC
+is	O
+few	O
+but	O
+the	O
+mortality	O
+has	O
+been	O
+about	O
+60	O
+%.	O
+
+In	O
+October	O
+2011	O
+,	O
+Xigris	O
+(	O
+drotrecogin	O
+alfa	O
+,	O
+a	O
+recombinant	B-PRGE
+activated	I-PRGE
+protein	I-PRGE
+C	I-PRGE
+)	O
+was	O
+withdrawn	B-DISO
+from	O
+the	O
+market	O
+following	O
+the	O
+failure	O
+of	O
+its	O
+worldwide	O
+trial	O
+that	O
+had	O
+attempted	O
+to	O
+demonstrate	O
+improved	O
+outcome	O
+.	O
+
+ABSTRACT	O
+:	O
+Acute	B-DISO
+respiratory	I-DISO
+infections	I-DISO
+are	O
+a	O
+major	O
+cause	O
+of	O
+morbidity	O
+in	O
+children	O
+both	O
+in	O
+developed	O
+and	O
+developing	O
+countries	O
+.	O
+
+ABSTRACT	O
+:	O
+Epstein	B-SPEC
+-	I-SPEC
+Barr	I-SPEC
+virus	I-SPEC
+-	O
+induced	O
+gene	B-PRGE
+3	I-PRGE
+(	O
+EBI3	B-COMP
+)	O
+associates	O
+with	O
+p28	B-COMP
+and	O
+p35	B-COMP
+to	O
+form	O
+the	O
+immunomodulatory	O
+cytokines	B-PRGE
+IL	I-PRGE
+-	I-PRGE
+27	I-PRGE
+and	I-PRGE
+IL	B-FUNC
+-	I-FUNC
+35	I-FUNC
+,	O
+respectively	O
+.	O
+
+TITLE	O
+:	O
+The	O
+heptide	O
+repeat	O
+2	O
+and	O
+upstream	O
+region	O
+of	O
+TGEV	B-SPEC
+induces	O
+potent	O
+cross	O
+-	O
+neutralizing	O
+antibodies	B-COMP
+against	O
+group	O
+I	O
+coronaviruses	O
+.	O
+
+Our	O
+study	O
+provides	O
+evidence	O
+that	O
+malaria	B-PATH
+-	O
+induced	O
+immune	B-PROC
+responses	I-PROC
+impair	O
+host	B-COMP
+resistance	B-PROC
+to	O
+Mycobacterium	B-SPEC
+tuberculosis	I-SPEC
+.	O
+
+However	O
+,	O
+some	O
+patients	O
+developed	O
+severe	O
+illness	O
+and	O
+some	O
+died	B-PROC
+.	O
+
+TITLE	O
+:	O
+Mortality	O
+,	O
+severe	O
+acute	B-DISO
+respiratory	I-DISO
+infection	I-DISO
+,	O
+and	O
+influenza	B-DISO
+-	I-DISO
+like	I-DISO
+illness	I-DISO
+associated	O
+with	O
+influenza	B-DISO
+A	I-PATH
+(	O
+H1N1	O
+)	O
+pdm09	O
+in	O
+Argentina	B-SPEC
+,	O
+2009	O
+.	O
+
+During	O
+April	O
+to	O
+December	O
+2009	O
+,	O
+we	O
+actively	O
+searched	O
+for	O
+persons	O
+with	O
+severe	O
+acute	B-DISO
+respiratory	I-DISO
+infection	I-DISO
+and	O
+influenza	B-DISO
+-	I-DISO
+like	I-DISO
+illness	I-DISO
+(	O
+ILI	O
+)	O
+in	O
+three	O
+sentinel	O
+cities	O
+.	O
+
+Sixteen	O
+naturally	O
+infected	O
+FIV	B-SPEC
+/	O
+FeLV	O
+cats	B-SPEC
+were	O
+followed	O
+during	O
+rFeIFNω	O
+therapy	O
+in	O
+order	B-SPEC
+to	O
+monitor	O
+clinical	O
+signs	O
+and	O
+to	O
+correlate	O
+with	O
+excretion	B-PROC
+of	O
+concomitant	O
+viruses	B-SPEC
+(	O
+FCV	B-CHED
+,	O
+FHV	O
+-	O
+1	O
+,	O
+feline	B-SPEC
+coronavirus	B-SPEC
+(	O
+FCoV	O
+)	O
+and	O
+parvovirus	B-DISO
+(	O
+FPV	B-SPEC
+)).	O
+
+Of	O
+the	O
+11	O
+FCoV	O
+positive	O
+cats	B-SPEC
+,	O
+9	O
+reduced	O
+viral	O
+loads	O
+.	O
+
+In	O
+conclusion	O
+,	O
+rFeIFNω	O
+improves	O
+clinical	O
+signs	O
+and	O
+reduces	O
+concurrent	O
+viral	O
+excretion	B-PROC
+in	O
+naturally	O
+infected	O
+retroviral	B-SPEC
+cats	B-SPEC
+.	O
+
+RT	O
+-	O
+LAMP	O
+assays	O
+would	O
+be	O
+suitable	O
+for	O
+monitoring	O
+active	O
+MHV	B-SPEC
+infection	B-DISO
+in	O
+mouse	B-SPEC
+colonies	O
+.	O
+
+TITLE	O
+:	O
+Emerging	O
+outbreaks	O
+associated	O
+with	O
+equine	B-SPEC
+coronavirus	B-SPEC
+in	O
+adult	O
+horses	B-SPEC
+.	O
+
+Following	O
+the	O
+molecular	O
+detection	O
+of	O
+ECoV	O
+in	O
+the	O
+feces	B-ANAT
+from	O
+the	O
+initial	O
+index	O
+cases	O
+,	O
+the	O
+remaining	O
+herdmates	O
+were	O
+closely	O
+observed	O
+for	O
+the	O
+development	B-PROC
+of	O
+clinical	O
+signs	O
+.	O
+
+Fecal	B-ANAT
+samples	O
+were	O
+collected	O
+from	O
+sick	O
+and	O
+healthy	O
+horses	B-SPEC
+for	O
+the	O
+PCR	O
+detection	O
+of	O
+ECoV	O
+.	O
+All	O
+four	O
+outbreaks	O
+involved	O
+primarily	O
+adult	O
+horses	B-SPEC
+.	O
+
+In	O
+this	O
+study	O
+,	O
+we	O
+generated	O
+two	O
+monoclonal	O
+antibodies	B-COMP
+(	O
+mAbs	O
+),	O
+designated	O
+as	O
+6D10	O
+and	O
+4F10	O
+,	O
+which	O
+were	O
+directed	O
+against	O
+the	O
+N	B-PRGE
+protein	I-PRGE
+of	O
+IBV	B-SPEC
+using	O
+the	O
+whole	O
+viral	B-COMP
+particles	I-COMP
+as	O
+immunogens	O
+.	O
+
+After	O
+screening	O
+a	O
+phage	O
+display	O
+peptide	B-CHED
+library	O
+and	O
+peptide	B-CHED
+scanning	O
+,	O
+we	O
+identified	O
+two	O
+linear	O
+B	B-ANAT
+-	I-ANAT
+cell	I-ANAT
+epitopes	O
+that	O
+were	O
+recognized	O
+by	O
+the	O
+mAbs	O
+6D10	O
+and	O
+4F10	O
+,	O
+which	O
+corresponded	O
+to	O
+the	O
+amino	B-CHED
+acid	I-CHED
+sequences	O
+(	O
+242	O
+)	O
+FGPRTK	O
+(	O
+247	O
+)	O
+and	O
+(	O
+195	O
+)	O
+DLIARAAKI	O
+(	O
+203	O
+),	O
+respectively	O
+,	O
+in	O
+the	O
+IBV	B-SPEC
+N	O
+protein	B-CHED
+.	O
+
+Moreover	O
+,	O
+SARS	B-PRGE
+-	I-PRGE
+CoV	I-PRGE
+ssRNA	I-PRGE
+was	O
+able	O
+to	O
+cause	O
+acute	O
+lung	O
+injury	O
+in	O
+mice	B-SPEC
+with	O
+a	O
+high	O
+mortality	O
+rate	O
+in	O
+vivo	O
+experiment	O
+.	O
+
+It	O
+suggests	O
+that	O
+SARS	B-DISO
+-	O
+CoV	O
+specific	O
+GU	O
+-	O
+rich	O
+ssRNA	O
+plays	O
+a	O
+very	O
+important	O
+role	O
+in	O
+the	O
+cytokine	B-DISO
+storm	I-DISO
+associated	O
+with	O
+a	O
+dysregulation	O
+of	O
+the	O
+innate	B-PROC
+immunity	I-PROC
+.	O
+
+Stricture	B-DISO
+was	O
+significantly	O
+associated	O
+with	O
+hematemesis	B-DISO
+(	O
+p	O
+<	O
+0	O
+.	O
+001	O
+)	O
+and	O
+melena	B-DISO
+(	O
+p	O
+<	O
+0	O
+.	O
+001	O
+).	O
+
+CONCLUSIONS	O
+:	O
+This	O
+study	O
+highlights	O
+the	O
+magnitude	O
+and	O
+ill	B-DISO
+-	O
+effects	O
+of	O
+self	O
+-	O
+harm	O
+caused	O
+by	O
+a	O
+strong	O
+corrosive	O
+,	O
+readily	O
+available	O
+due	O
+to	O
+very	O
+few	O
+restrictions	O
+in	O
+its	O
+distribution	O
+.	O
+
+ABSTRACT	O
+:	O
+The	O
+degradative	O
+activity	O
+of	O
+the	O
+human	B-SPEC
+immunodeficiency	I-SPEC
+virus	I-SPEC
+type	I-SPEC
+1	I-SPEC
+(	O
+HIV	B-SPEC
+-	I-SPEC
+1	I-SPEC
+)	O
+reverse	B-PRGE
+transcriptase	I-PRGE
+(	O
+RT	O
+),	O
+termed	O
+ribonuclease	B-PRGE
+H	I-PRGE
+(	O
+RNase	B-PRGE
+H	I-PRGE
+),	O
+which	O
+hydrolyzes	O
+the	O
+RNA	O
+component	O
+of	O
+the	O
+heteroduplex	O
+RNA	O
+:	O
+DNA	B-PATH
+replication	I-PATH
+intermediate	O
+,	O
+is	O
+an	O
+excellent	O
+target	O
+for	O
+drug	O
+discovery	O
+.	O
+
+Anthraquinones	B-CHED
+(	O
+AQs	O
+)	O
+and	O
+their	O
+derivatives	O
+,	O
+which	O
+are	O
+common	O
+secondary	B-CHED
+metabolites	I-CHED
+occurring	O
+in	O
+bacteria	B-SPEC
+,	O
+fungi	B-SPEC
+,	O
+lichens	O
+and	O
+a	O
+large	O
+number	O
+of	O
+families	O
+in	O
+higher	B-SPEC
+plants	I-SPEC
+,	O
+have	O
+been	O
+reported	O
+to	O
+have	O
+several	O
+biological	O
+activities	O
+including	O
+that	O
+of	O
+inhibiting	O
+HIV	B-SPEC
+-	I-SPEC
+1	I-SPEC
+RT	O
+activities	O
+in	O
+biochemical	O
+assays	O
+.	O
+
+She	O
+was	O
+brought	O
+to	O
+our	O
+emergency	B-DISO
+department	O
+by	O
+air	B-CHED
+ambulance	O
+for	O
+assessment	O
+.	O
+
+Prevention	O
+strategies	O
+and	O
+current	O
+and	O
+future	O
+therapies	O
+need	O
+to	O
+be	O
+implemented	O
+to	O
+avoid	O
+and	O
+treat	O
+the	O
+development	B-PROC
+of	O
+these	O
+life	O
+-	O
+threatening	O
+medical	O
+complications	O
+.	O
+
+TITLE	O
+:	O
+Bortezomib	B-CHED
+-	O
+induced	O
+bronchiolitis	B-DISO
+obliterans	I-DISO
+organizing	I-DISO
+pneumonia	I-DISO
+.	O
+
+Systemic	O
+corticotherapy	O
+led	O
+to	O
+a	O
+rapid	O
+improvement	O
+in	O
+the	O
+patient	O
+'	O
+s	O
+condition	B-DISO
+.	O
+
+Faced	O
+with	O
+severe	O
+respiratory	B-DISO
+symptoms	I-DISO
+in	O
+the	O
+absence	O
+of	O
+other	O
+etiologies	O
+,	O
+complications	O
+due	O
+to	O
+bortezomid	O
+treatment	O
+should	O
+be	O
+evoked	O
+and	O
+corticotherapy	O
+considered	O
+.	O
+
+ABSTRACT	O
+:	O
+To	O
+evaluate	O
+the	O
+predictors	O
+of	O
+mortality	O
+in	O
+critically	O
+ill	O
+patients	O
+receiving	O
+initial	O
+antibiotic	B-CHED
+therapy	O
+(	O
+IAT	O
+;	O
+<	O
+48	O
+h	O
+after	O
+admission	O
+).	O
+
+Patients	O
+with	O
+IAT	O
+were	O
+significantly	O
+older	O
+(	O
+67	O
+±	O
+14	O
+vs	O
+.	O
+64	O
+±	O
+14	O
+years	O
+;	O
+p	O
+=	O
+0	O
+.	O
+006	O
+)	O
+and	O
+had	O
+a	O
+higher	O
+prevalence	O
+of	O
+chronic	B-DISO
+renal	I-DISO
+failure	I-DISO
+(	O
+33	O
+vs	O
+.	O
+23	O
+%;	O
+p	O
+=	O
+0	O
+.	O
+015	O
+),	O
+chronic	B-DISO
+obstructive	I-DISO
+pulmonary	I-DISO
+disease	I-DISO
+(	O
+COPD	B-DISO
+;	O
+27	O
+vs	O
+.	O
+16	O
+%;	O
+p	O
+=	O
+0	O
+.	O
+002	O
+),	O
+malignoma	O
+(	O
+17	O
+vs	O
+.	O
+9	O
+%;	O
+p	O
+=	O
+0	O
+.	O
+007	O
+),	O
+acute	O
+renal	O
+failure	O
+(	O
+11	O
+vs	O
+.	O
+4	O
+%;	O
+p	O
+=	O
+0	O
+.	O
+001	O
+),	O
+respiratory	B-DISO
+failure	I-DISO
+(	O
+22	O
+vs	O
+.	O
+7	O
+%;	O
+p	O
+<	O
+0	O
+.	O
+001	O
+),	O
+and	O
+a	O
+shock	O
+index	O
+<	O
+1	O
+.	O
+0	O
+(	O
+21	O
+vs	O
+.	O
+8	O
+%;	O
+p	O
+<	O
+0	O
+.	O
+001	O
+).	O
+
+We	O
+show	O
+here	O
+that	O
+both	O
+proteins	B-CHED
+can	O
+associate	O
+with	O
+membranes	B-ANAT
+co	O
+-	O
+but	O
+not	O
+posttranslationally	O
+,	O
+and	O
+we	O
+perform	O
+a	O
+structure	O
+function	O
+analysis	O
+of	O
+A14	O
+and	O
+A17	O
+using	O
+inducible	O
+recombinants	O
+.	O
+
+In	O
+the	O
+absence	O
+of	O
+A14	O
+,	O
+electron	O
+-	O
+dense	O
+virosomes	O
+and	O
+distinct	O
+clusters	B-CHED
+of	O
+small	O
+vesicles	B-COMP
+accumulate	O
+;	O
+in	O
+the	O
+absence	O
+of	O
+A17	O
+,	O
+small	O
+vesicles	B-COMP
+form	O
+a	O
+corona	B-CHED
+around	O
+the	O
+virosomes	O
+.	O
+
+TITLE	O
+:	O
+¹H	O
+,	O
+¹³C	O
+,	O
+¹⁵N	O
+resonance	O
+assignments	O
+of	O
+murine	B-DISO
+hepatitis	I-DISO
+virus	B-SPEC
+nonstructural	O
+protein	B-CHED
+3a	O
+.	O
+
+The	O
+incidence	O
+of	O
+severe	O
+intoxication	O
+was	O
+3	O
+.	O
+7	O
+%	O
+with	O
+axillary	B-ANAT
+brachial	B-ANAT
+plexus	I-ANAT
+block	O
+and	O
+3	O
+.	O
+0	O
+%	O
+with	O
+modified	O
+interscalene	O
+brachial	B-ANAT
+plexus	I-ANAT
+block	O
+.	O
+
+There	O
+was	O
+no	O
+nerve	B-ANAT
+injury	O
+related	O
+complication	B-DISO
+after	O
+withdrawing	O
+the	O
+external	O
+indwelling	O
+catheter	O
+.	O
+
+ABSTRACT	O
+:	O
+Live	O
+,	O
+attenuated	O
+RNA	O
+virus	O
+vaccines	O
+are	O
+efficacious	O
+but	O
+subject	O
+to	O
+reversion	O
+to	O
+virulence	B-PROC
+.	O
+
+TITLE	O
+:	O
+CXCL10	B-PRGE
+-	O
+CXCR3	B-PRGE
+enhances	O
+the	O
+development	B-PROC
+of	O
+neutrophil	B-ANAT
+-	O
+mediated	O
+fulminant	O
+lung	B-ANAT
+injury	O
+of	O
+viral	O
+and	O
+nonviral	O
+origin	O
+.	O
+
+CXCL10	B-PRGE
+-	O
+CXCR3	B-PRGE
+signaling	B-PROC
+appears	O
+to	O
+be	O
+a	O
+critical	O
+factor	O
+for	O
+the	O
+exacerbation	O
+of	O
+the	O
+pathology	B-DISO
+of	O
+ARDS	B-DISO
+.	O
+
+TITLE	O
+:	O
+Construction	O
+of	O
+recombinant	O
+lactobacilli	O
+expressing	O
+the	O
+core	O
+neutralizing	O
+epitope	B-CHED
+(	O
+COE	B-CHED
+)	O
+of	O
+porcine	B-SPEC
+epidemic	I-SPEC
+diarrhea	I-SPEC
+virus	I-SPEC
+and	O
+a	O
+fusion	O
+protein	B-CHED
+consisting	O
+of	O
+COE	B-CHED
+and	O
+Escherichia	B-SPEC
+coli	I-SPEC
+heat	O
+-	O
+labile	O
+enterotoxin	O
+B	O
+,	O
+and	O
+comparison	O
+of	O
+the	O
+immune	B-PROC
+responses	I-PROC
+by	O
+orogastric	O
+immunization	O
+.	O
+
+Moreover	O
+,	O
+higher	O
+levels	O
+of	O
+interleukin	B-PRGE
+-	I-PRGE
+4	I-PRGE
+and	O
+gamma	B-PRGE
+interferon	I-PRGE
+were	O
+also	O
+exhibited	O
+compared	O
+with	O
+negative	O
+control	O
+.	O
+
+Ochroconis	B-SPEC
+gallopavum	O
+is	O
+a	O
+neurotropic	O
+dematiaceous	O
+mold	B-CHED
+responsible	O
+for	O
+life	O
+-	O
+threatening	O
+respiratory	O
+and	O
+central	B-DISO
+nervous	I-DISO
+system	I-DISO
+infections	I-DISO
+in	O
+domestic	O
+poultry	O
+and	O
+in	O
+immunologically	O
+compromised	O
+humans	B-SPEC
+.	O
+
+No	O
+brain	B-ANAT
+involvement	O
+was	O
+observed	O
+.	O
+
+Thirty	O
+-	O
+five	O
+participants	O
+enrolled	O
+and	O
+were	O
+randomly	O
+assigned	O
+into	O
+either	O
+a	O
+treatment	O
+condition	B-DISO
+(	O
+n	O
+=	O
+17	O
+,	O
+treated	O
+with	O
+CQCQD	O
+)	O
+or	O
+a	O
+control	O
+condition	B-DISO
+(	O
+n	O
+=	O
+18	O
+,	O
+treated	O
+with	O
+placebo	O
+)	O
+24	O
+hours	O
+following	O
+the	O
+onset	O
+of	O
+the	O
+disease	O
+.	O
+
+RESULTS	O
+:	O
+The	O
+duration	O
+of	O
+acute	O
+respiratory	B-DISO
+distress	I-DISO
+syndrome	I-DISO
+,	I-DISO
+acute	I-DISO
+hepatitis	B-DISO
+,	O
+acute	B-DISO
+renal	I-DISO
+failure	I-DISO
+,	O
+gastrointestinal	B-DISO
+failure	I-DISO
+and	O
+blood	B-PROC
+coagulation	I-PROC
+dysfunction	O
+were	O
+shorter	O
+in	O
+the	O
+treatment	O
+group	O
+than	O
+in	O
+those	O
+in	O
+the	O
+control	O
+group	O
+(	O
+P	O
+<	O
+0	O
+.	O
+05	O
+).	O
+
+Our	O
+findings	O
+suggest	O
+that	O
+a	O
+novel	O
+PEDV	B-SPEC
+with	O
+a	O
+characteristic	O
+variant	B-PRGE
+S	I-PRGE
+gene	I-PRGE
+is	O
+responsible	O
+for	O
+recent	O
+outbreaks	O
+of	O
+clinical	O
+diarrhea	B-DISO
+in	O
+piglets	O
+in	O
+China	O
+.	O
+
+The	O
+IBV	B-SPEC
+was	O
+detected	O
+by	O
+RT	O
+-	O
+PCR	O
+directly	O
+in	O
+muscle	B-ANAT
+samples	O
+.	O
+
+ABSTRACT	O
+:	O
+Many	O
+patients	O
+with	O
+severe	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+(	O
+ARDS	B-DISO
+)	O
+caused	O
+by	O
+influenza	B-PATH
+A	I-PATH
+(	O
+H1N1	O
+)	O
+infection	B-DISO
+receive	O
+extracorporeal	O
+membrane	B-COMP
+oxygenation	B-PROC
+(	O
+ECMO	O
+)	O
+as	O
+a	O
+rescue	O
+therapy	O
+.	O
+
+The	O
+participants	O
+self	O
+-	O
+collected	O
+an	O
+anterior	O
+nasal	B-ANAT
+swab	O
+from	O
+one	O
+nostril	B-ANAT
+,	O
+and	O
+trained	O
+study	O
+personnel	O
+collected	O
+one	O
+from	O
+the	O
+other	O
+nostril	B-ANAT
+.	O
+
+The	O
+amount	O
+of	O
+β	B-PRGE
+-	I-PRGE
+actin	I-PRGE
+DNA	O
+per	O
+swab	O
+was	O
+higher	O
+in	O
+the	O
+self	O
+-	O
+than	O
+in	O
+the	O
+staff	O
+-	O
+collected	O
+swabs	O
+(	O
+p	O
+=	O
+0	O
+.	O
+008	O
+).	O
+
+It	O
+is	O
+also	O
+connected	O
+to	O
+damages	O
+of	O
+different	O
+organic	O
+systems	O
+and	O
+it	O
+often	O
+leads	O
+to	O
+appearance	O
+of	O
+multiple	B-DISO
+organ	I-DISO
+failure	I-DISO
+.	O
+
+Initial	O
+examination	O
+of	O
+the	O
+patient	O
+revealed	O
+swelling	B-DISO
+and	O
+paleness	B-DISO
+of	O
+the	O
+right	B-ANAT
+lower	I-ANAT
+leg	I-ANAT
+,	O
+signs	O
+of	O
+gangrene	B-DISO
+of	O
+the	O
+right	B-ANAT
+foot	I-ANAT
+and	O
+the	O
+1st	O
+and	O
+the	O
+4th	O
+toes	B-ANAT
+of	O
+the	O
+left	B-ANAT
+foot	I-ANAT
+.	O
+
+The	O
+patient	O
+refused	O
+the	O
+suggested	O
+surgical	O
+treatment	O
+(	O
+fasciotomy	O
+,	O
+foot	B-ANAT
+amputation	O
+).	O
+
+TITLE	O
+:	O
+[	O
+Case	O
+report	O
+of	O
+anesthesia	B-DISO
+with	O
+veno	O
+-	O
+veno	O
+extracorporeal	O
+membrane	B-COMP
+oxygenation	B-PROC
+(	O
+V	O
+-	O
+V	O
+ECMO	O
+)	O
+during	O
+one	O
+-	O
+lung	O
+ventilation	O
+for	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+(	O
+ARDS	B-DISO
+)	O
+complicated	O
+with	O
+severe	B-DISO
+sepsis	I-DISO
+due	O
+to	O
+spontaneous	O
+esophageal	O
+rupture	O
+].	O
+
+Infection	B-DISO
+was	O
+documented	O
+in	O
+3	O
+cases	O
+,	O
+hyperbilirubinemia	B-DISO
+in	O
+2	O
+cases	O
+,	O
+lower	B-DISO
+limb	I-DISO
+ischemia	I-DISO
+in	O
+1	O
+case	O
+,	O
+hyperglycemia	B-DISO
+in	O
+3	O
+cases	O
+,	O
+disseminated	B-DISO
+intravascular	I-DISO
+coagulation	I-DISO
+in	O
+1	O
+case	O
+,	O
+membrane	B-COMP
+lung	B-ANAT
+leakage	B-DISO
+in	O
+2	O
+cases	O
+,	O
+systemic	O
+hemolysis	B-DISO
+in	O
+3	O
+cases	O
+,	O
+oxygenator	O
+failure	O
+in	O
+2	O
+cases	O
+and	O
+oxygenator	O
+thrombosis	B-DISO
+in	O
+one	O
+case	O
+.	O
+
+TITLE	O
+:	O
+Evolution	B-PROC
+of	O
+infectious	B-DISO
+bronchitis	B-DISO
+virus	B-SPEC
+in	O
+Taiwan	O
+:	O
+positively	O
+selected	O
+sites	O
+in	O
+the	O
+nucleocapsid	B-ANAT
+protein	B-CHED
+and	O
+their	O
+effects	O
+on	O
+RNA	O
+-	O
+binding	B-PROC
+activity	I-PROC
+.	O
+
+We	O
+have	O
+demonstrated	O
+that	O
+RNA	O
+recombination	B-PROC
+can	O
+give	O
+rise	O
+to	O
+a	O
+new	O
+viral	O
+population	O
+,	O
+supported	O
+by	O
+the	O
+finding	O
+that	O
+most	O
+isolated	O
+Taiwanese	O
+(	O
+TW	O
+)	O
+IBVs	O
+,	O
+similar	O
+to	O
+Chinese	O
+(	O
+CH	O
+)	O
+IBVs	O
+,	O
+exhibit	O
+a	O
+genetic	O
+rearrangement	B-PROC
+with	O
+the	O
+American	O
+(	O
+US	O
+)	O
+IBV	B-SPEC
+at	O
+the	O
+5	O
+'	O
+end	O
+of	O
+the	O
+nucleocapsid	B-COMP
+(	O
+N	O
+)	O
+gene	O
+.	O
+
+Based	O
+on	O
+the	O
+crystal	B-ANAT
+structure	O
+of	O
+the	O
+NTD	O
+,	O
+the	O
+stereographic	O
+positions	O
+of	O
+both	O
+predicted	O
+selected	O
+sites	O
+do	O
+not	O
+fall	O
+close	O
+to	O
+the	O
+RNA	O
+-	O
+binding	B-FUNC
+groove	B-ANAT
+.	O
+
+The	O
+Authors	O
+reviewed	O
+the	O
+most	O
+significant	O
+(	O
+Table	O
+I	O
+,	O
+II	O
+)	O
+clinical	O
+,	O
+laboratory	O
+,	O
+radiological	O
+and	O
+pathologic	O
+findings	O
+,	O
+surgical	O
+procedure	O
+,	O
+and	O
+early	O
+and	O
+long	O
+-	O
+term	O
+results	O
+in	O
+5	O
+children	O
+,	O
+2	O
+males	O
+and	O
+3	O
+females	O
+,	O
+suffering	B-DISO
+from	O
+sacrococcygeal	O
+teratomas	B-DISO
+.	O
+
+Two	O
+patients	O
+were	O
+also	O
+suffering	B-DISO
+from	O
+the	O
+Currarino	B-DISO
+syndrome	I-DISO
+associated	O
+with	O
+Hirschsprung	B-DISO
+'	I-DISO
+s	I-DISO
+disease	I-DISO
+and	O
+other	O
+,	O
+multiple	O
+malformations	B-DISO
+and	O
+a	O
+cloacal	B-ANAT
+anomaly	O
+with	O
+anal	B-ANAT
+imperforation	O
+,	O
+respectively	O
+.	O
+
+All	O
+patients	O
+underwent	O
+emergency	B-DISO
+surgical	O
+management	O
+,	O
+in	O
+accordance	O
+with	O
+recommended	O
+practice	O
+,	O
+consisting	O
+of	O
+complete	O
+exeresis	O
+of	O
+the	O
+tumor	B-DISO
+,	O
+including	O
+coccygectomy	O
+,	O
+in	O
+3	O
+of	O
+the	O
+5	O
+children	O
+.	O
+
+Being	O
+congenital	O
+tumors	B-DISO
+,	O
+prenatal	O
+diagnosis	O
+by	O
+US	O
+scan	O
+is	O
+extremely	O
+important	O
+in	O
+order	B-SPEC
+to	O
+decide	O
+either	O
+for	O
+an	O
+anticipated	O
+delivery	O
+or	O
+to	O
+perform	O
+,	O
+in	O
+critical	O
+fetuses	B-ANAT
+,	O
+prenatal	O
+treatment	O
+within	O
+highly	O
+specialized	O
+facilities	O
+,	O
+or	O
+to	O
+organize	O
+proper	O
+perinatal	O
+care	O
+,	O
+always	O
+in	O
+appropriate	O
+facilities	O
+where	O
+it	O
+is	O
+possible	O
+to	O
+define	O
+the	O
+diagnosis	O
+and	O
+carry	O
+out	O
+emergency	B-DISO
+surgery	O
+.	O
+
+Some	O
+sacrococcygeal	O
+teratomas	B-DISO
+can	O
+hide	B-ANAT
+more	O
+or	O
+less	O
+extensive	O
+islands	O
+of	O
+immaturity	O
+or	O
+signs	O
+of	O
+malignant	B-DISO
+transformation	I-DISO
+that	O
+are	O
+clinically	O
+evident	O
+.	O
+
+The	O
+UKCCSG	O
+II	O
+(	O
+Children	O
+UK	O
+Cancer	B-DISO
+Study	O
+Group	O
+)	O
+and	O
+the	O
+SFOP	O
+(	O
+Société	O
+Française	O
+d	O
+'	O
+Oncologie	O
+Pédiatrique	O
+)	O
+indicated	O
+AFP	O
+values	O
+exceeding	O
+10	O
+,	O
+000	O
+ng	O
+/	O
+ml	O
+as	O
+the	O
+threshold	O
+identifying	O
+a	O
+group	O
+of	O
+patients	O
+with	O
+severe	O
+prognosis	O
+.	O
+
+In	O
+newborns	O
+or	O
+infants	O
+suffering	B-DISO
+from	O
+congenital	B-DISO
+malformations	I-DISO
+associated	O
+with	O
+teratomas	B-DISO
+,	O
+definitive	O
+surgical	O
+correction	O
+,	O
+if	O
+indicated	O
+,	O
+must	O
+obviously	O
+be	O
+postponed	O
+to	O
+a	O
+proper	O
+time	O
+,	O
+especially	O
+in	O
+patients	O
+with	O
+multiple	O
+malformations	B-DISO
+or	O
+needing	O
+adjuvant	B-CHED
+chemotherapy	O
+,	O
+unless	O
+a	O
+complication	B-DISO
+arises	O
+or	O
+the	O
+repair	B-PROC
+cannot	O
+be	O
+delayed	O
+.	O
+
+RESULTS	O
+:	O
+Of	O
+the	O
+5	O
+patients	O
+,	O
+the	O
+female	O
+newborn	O
+affected	O
+by	O
+the	O
+Currarino	B-DISO
+syndrome	I-DISO
+,	O
+associated	O
+with	O
+persistence	O
+of	O
+the	O
+common	O
+cloacal	B-ANAT
+canal	B-ANAT
+and	O
+anal	B-ANAT
+imperforation	O
+,	O
+died	B-PROC
+two	O
+days	O
+after	O
+surgery	O
+,	O
+of	O
+cardiovascular	B-ANAT
+and	O
+respiratory	B-DISO
+complications	I-DISO
+.	O
+
+The	O
+predictive	O
+values	O
+of	O
+ΔPP	O
+and	O
+static	O
+variables	O
+[	O
+right	O
+atrial	B-ANAT
+pressure	O
+(	O
+RAP	O
+)	O
+and	O
+pulmonary	B-ANAT
+artery	I-ANAT
+occlusion	O
+pressure	O
+(	O
+PAOP	O
+)]	O
+were	O
+evaluated	O
+through	O
+a	O
+receiver	O
+operating	O
+characteristic	O
+(	O
+ROC	O
+)	O
+curve	O
+analysis	O
+.	O
+
+RESULTS	O
+:	O
+Thirty	O
+-	O
+four	O
+patients	O
+had	O
+characteristics	O
+consistent	O
+with	O
+acute	O
+lung	B-ANAT
+injury	O
+or	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+and	O
+were	O
+ventilated	O
+with	O
+high	O
+levels	O
+of	O
+PEEP	B-CHED
+[	O
+median	O
+(	O
+inter	O
+-	O
+quartile	O
+range	O
+)	O
+10	O
+.	O
+0	O
+(	O
+10	O
+.	O
+0	O
+-	O
+13	O
+.	O
+5	O
+)].	O
+
+Both	O
+genotypes	O
+A	O
+and	O
+B	O
+were	O
+detected	O
+but	O
+no	O
+recombination	B-PROC
+between	O
+them	O
+was	O
+found	O
+.	O
+
+ABSTRACT	O
+:	O
+Recently	O
+,	O
+nephropathogenic	O
+infectious	O
+bronchitis	B-DISO
+virus	B-SPEC
+(	O
+IBV	B-SPEC
+)	O
+outbreaks	O
+have	O
+occurred	O
+in	O
+commercial	O
+broiler	O
+flocks	O
+and	O
+have	O
+been	O
+associated	O
+with	O
+a	O
+high	O
+incidence	O
+and	O
+morbidity	O
+in	O
+China	O
+.	O
+
+In	O
+this	O
+study	O
+,	O
+a	O
+virulent	O
+PEDV	B-SPEC
+strain	O
+,	O
+GD	O
+-	O
+1	O
+,	O
+was	O
+obtained	O
+from	O
+fecal	B-ANAT
+samples	O
+from	O
+suckling	O
+piglets	O
+that	O
+suffered	B-DISO
+from	O
+severe	B-DISO
+diarrhea	I-DISO
+in	O
+2011	O
+in	O
+Guangdong	O
+,	O
+China	O
+.	O
+
+TITLE	O
+:	O
+Complete	O
+genome	O
+sequence	O
+of	O
+a	O
+Vero	B-ANAT
+cell	I-ANAT
+-	O
+adapted	O
+isolate	O
+of	O
+porcine	B-SPEC
+epidemic	I-SPEC
+diarrhea	I-SPEC
+virus	I-SPEC
+in	O
+eastern	O
+China	O
+.	O
+
+ABSTRACT	O
+:	O
+To	O
+date	O
+,	O
+multiple	O
+serotypes	O
+and	O
+genotypes	O
+of	O
+infectious	O
+bronchitis	B-DISO
+virus	B-SPEC
+(	O
+IBV	B-SPEC
+)	O
+have	O
+been	O
+isolated	O
+and	O
+identified	O
+.	O
+
+Overall	O
+,	O
+4	O
+%	O
+(	O
+57	O
+)	O
+of	O
+specimens	O
+were	O
+positive	O
+for	O
+influenza	B-DISO
+.	O
+
+The	O
+specimens	O
+were	O
+tested	O
+using	O
+real	O
+-	O
+time	O
+and	O
+multiplex	O
+reverse	O
+-	O
+transcription	B-PROC
+polymerase	O
+chain	O
+reaction	O
+methods	O
+for	O
+the	O
+detection	O
+of	O
+15	O
+RNA	O
+respiratory	O
+viruses	B-SPEC
+.	O
+
+TITLE	O
+:	O
+Genomic	O
+characterization	O
+of	O
+a	O
+newly	O
+discovered	O
+coronavirus	B-SPEC
+associated	O
+with	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+in	O
+humans	B-SPEC
+.	O
+
+HCoV	O
+-	O
+EMC	B-COMP
+/	O
+2012	O
+may	O
+be	O
+most	O
+closely	O
+related	O
+to	O
+a	O
+coronavirus	B-SPEC
+detected	O
+in	O
+Pipistrellus	B-SPEC
+pipistrellus	I-SPEC
+in	O
+The	O
+Netherlands	O
+,	O
+but	O
+because	O
+only	O
+a	O
+short	O
+sequence	O
+from	O
+the	O
+most	O
+conserved	O
+part	O
+of	O
+the	O
+RNA	B-PRGE
+-	I-PRGE
+dependent	I-PRGE
+RNA	I-PRGE
+polymerase	I-PRGE
+-	O
+encoding	O
+region	O
+of	O
+the	O
+genome	O
+was	O
+reported	O
+for	O
+this	O
+bat	B-ENZY
+virus	B-SPEC
+,	O
+its	O
+genetic	O
+distance	O
+from	O
+HCoV	O
+-	O
+EMC	B-COMP
+remains	O
+uncertain	O
+.	O
+
+ABSTRACT	O
+:	O
+The	O
+clinical	O
+manifestations	O
+of	O
+severe	O
+malaria	O
+are	O
+several	O
+and	O
+occur	O
+in	O
+different	O
+anatomical	B-ANAT
+sites	I-ANAT
+.	O
+
+Cytoadherence	O
+of	O
+infected	O
+red	B-ANAT
+blood	I-ANAT
+cells	I-ANAT
+to	O
+the	O
+vascular	B-ANAT
+endothelium	I-ANAT
+of	O
+different	O
+organs	B-ANAT
+and	O
+rosetting	B-PROC
+are	O
+unique	O
+features	O
+of	O
+malaria	B-PATH
+parasites	O
+which	O
+are	O
+likely	O
+to	O
+contribute	O
+to	O
+the	O
+vascular	B-ANAT
+damage	O
+and	O
+the	O
+consequent	O
+excessive	O
+inflammatory	O
+/	O
+immune	B-PROC
+response	I-PROC
+of	O
+the	O
+host	B-COMP
+.	O
+
+In	O
+addition	O
+to	O
+cerebral	B-DISO
+malaria	B-PATH
+or	O
+severe	O
+anaemia	B-DISO
+,	O
+which	O
+are	O
+quite	O
+common	O
+manifestation	O
+of	O
+severe	O
+malaria	B-PATH
+,	O
+clinical	O
+evidences	O
+of	O
+thrombocytopenia	O
+,	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+(	O
+ARDS	B-DISO
+),	O
+liver	B-ANAT
+and	O
+kidney	B-DISO
+disease	I-DISO
+,	O
+are	O
+reported	O
+.	O
+
+Surfactant	B-CHED
+dysfunction	O
+with	O
+quantitative	O
+and	O
+qualitative	O
+abnormalities	O
+of	O
+both	O
+phospholipids	B-CHED
+and	O
+proteins	B-CHED
+are	O
+characteristic	O
+of	O
+patients	O
+with	O
+ARDS	B-DISO
+.	O
+
+Phylogenetic	O
+analysis	O
+showed	O
+that	O
+YN	O
+and	O
+most	O
+of	O
+the	O
+previously	O
+characterized	O
+IBV	B-SPEC
+isolates	O
+found	O
+in	O
+China	O
+were	O
+phylogenetically	O
+classified	O
+into	O
+2	O
+main	O
+genetic	O
+clusters	B-CHED
+.	O
+
+The	O
+YN	O
+isolate	O
+caused	O
+severe	O
+lesions	O
+and	O
+resulted	O
+in	O
+deaths	B-PROC
+of	O
+65	O
+%	O
+in	O
+experimental	O
+infections	B-DISO
+of	O
+30	O
+-	O
+day	O
+-	O
+old	O
+specific	O
+-	O
+pathogen	O
+-	O
+free	O
+chickens	B-SPEC
+.	O
+
+TITLE	O
+:	O
+Isolation	O
+and	O
+molecular	O
+characterization	O
+of	O
+type	O
+I	O
+and	O
+type	O
+II	O
+feline	B-SPEC
+coronavirus	B-SPEC
+in	O
+Malaysia	O
+.	O
+
+Differentiation	B-PROC
+of	O
+FCoV	O
+biotypes	O
+using	O
+RT	O
+-	O
+PCR	O
+assay	O
+revealed	O
+that	O
+,	O
+97	O
+.	O
+5	O
+%	O
+and	O
+2	O
+.	O
+5	O
+%	O
+of	O
+local	O
+isolates	O
+were	O
+type	O
+I	O
+and	O
+type	O
+II	O
+FCoV	O
+,	O
+respectively	O
+.	O
+
+Patients	O
+with	O
+vWD	B-PRGE
+are	O
+exposed	O
+to	O
+Transfuse	O
+Related	O
+Acute	O
+Lung	B-ANAT
+Injury	O
+(	O
+TRALI	B-DISO
+)	O
+when	O
+they	O
+become	O
+recipients	O
+of	O
+multiple	O
+blood	B-ANAT
+products	O
+and	O
+repeated	O
+transfusions	O
+.	O
+
+Concluding	O
+,	O
+patients	O
+with	O
+vWd	O
+who	O
+received	O
+recurrent	O
+transfusions	O
+have	O
+an	O
+increased	O
+risk	O
+of	O
+TRALI	B-DISO
+.	O
+
+To	O
+identify	O
+the	O
+immunoreactivities	O
+of	O
+the	O
+three	O
+structural	O
+regions	O
+of	O
+the	O
+NP	O
+that	O
+are	O
+recognised	O
+by	O
+the	O
+rabbit	B-SPEC
+polyclonal	O
+antibody	B-COMP
+and	O
+human	B-SPEC
+serum	B-COMP
+,	O
+the	O
+antigenicities	O
+of	O
+three	O
+protein	B-CHED
+fragments	O
+,	O
+including	O
+the	O
+N	O
+-	O
+terminal	O
+domain	O
+(	O
+aa	O
+1	O
+-	O
+173	O
+),	O
+the	O
+central	O
+-	O
+linker	O
+region	O
+(	O
+aa	O
+174	O
+-	O
+300	O
+),	O
+and	O
+the	O
+C	O
+-	O
+terminal	O
+domain	O
+(	O
+aa	O
+301	O
+-	O
+448	O
+),	O
+were	O
+evaluated	O
+by	O
+Western	O
+blot	O
+.	O
+
+The	O
+rabbit	B-SPEC
+polyclonal	O
+antibody	B-COMP
+demonstrated	O
+greater	O
+immunoreactivity	B-PROC
+to	O
+the	O
+central	O
+-	O
+linker	O
+region	O
+and	O
+the	O
+C	O
+-	O
+terminal	O
+domain	O
+than	O
+to	O
+the	O
+N	O
+-	O
+terminal	O
+domain	O
+.	O
+
+In	O
+addition	O
+,	O
+molecular	O
+markers	O
+have	O
+been	O
+identified	O
+that	O
+distinguish	O
+between	O
+field	O
+and	O
+vaccine	O
+(	O
+or	O
+vaccine	O
+-	O
+like	O
+)	O
+Mass	O
+-	O
+type	O
+viruses	B-SPEC
+,	O
+which	O
+may	O
+be	O
+able	O
+to	O
+differentiate	O
+between	O
+field	O
+and	O
+vaccine	O
+strains	O
+for	O
+diagnostic	O
+purposes	O
+.	O
+
+ABSTRACT	O
+:	O
+The	O
+mechanisms	O
+by	O
+which	O
+viruses	O
+induce	O
+asthma	B-PATH
+exacerbations	O
+are	O
+not	O
+well	O
+understood	O
+.	O
+
+mRNA	B-PROC
+expression	B-PROC
+for	O
+selected	O
+markers	O
+of	O
+viral	B-DISO
+infection	I-DISO
+was	O
+measured	O
+using	O
+RT	O
+-	O
+PCR	O
+.	O
+
+Viral	B-DISO
+infections	I-DISO
+were	O
+detected	O
+in	O
+3	O
+of	O
+the	O
+'	O
+well	O
+'	O
+weeks	O
+and	O
+17	O
+of	O
+the	O
+'	O
+sick	O
+'	O
+weeks	O
+(	O
+10	O
+rhinovirus	B-SPEC
+,	O
+three	O
+coronavirus	B-SPEC
+,	O
+two	O
+influenza	B-PATH
+A	I-PATH
+,	O
+two	O
+influenza	B-DISO
+B	O
+,	O
+two	O
+respiratory	B-SPEC
+syncytial	I-SPEC
+virus	I-SPEC
+,	O
+one	O
+parainfluenza	B-DISO
+).	O
+
+Phylogenetic	O
+analysis	O
+confirmed	O
+that	O
+ck	O
+/	O
+CH	O
+/	O
+LZJ	O
+/	O
+111113	O
+is	O
+of	O
+the	O
+4	O
+/	O
+91	O
+type	O
+;	O
+however	O
+,	O
+further	O
+extensive	O
+analyses	O
+of	O
+full	O
+-	O
+length	O
+genomes	O
+identified	O
+occurrence	O
+of	O
+recombination	B-PROC
+events	O
+.	O
+
+This	O
+recombination	B-PROC
+event	O
+took	O
+place	O
+at	O
+the	O
+3	O
+'	O
+end	O
+of	O
+the	O
+N	B-PRGE
+gene	I-PRGE
+and	O
+the	O
+3	O
+'	O
+untranslated	O
+region	O
+may	O
+account	O
+for	O
+differences	O
+in	O
+replication	O
+efficiency	O
+in	O
+tissues	B-ANAT
+of	O
+chickens	B-SPEC
+inoculated	O
+by	O
+the	O
+two	O
+viruses	B-SPEC
+.	O
+
+The	O
+accessory	O
+proteins	B-CHED
+of	O
+feline	B-SPEC
+coronaviruses	O
+have	O
+been	O
+speculated	O
+to	O
+play	O
+a	O
+prominent	O
+role	O
+in	O
+virulence	B-PROC
+as	O
+deletions	O
+were	O
+found	O
+to	O
+be	O
+associated	O
+with	O
+attenuated	O
+viruses	B-SPEC
+.	O
+
+In	O
+order	B-SPEC
+to	O
+investigate	O
+if	O
+the	O
+accessory	O
+proteins	B-CHED
+of	O
+FIPV	O
+are	O
+important	O
+for	O
+sustaining	O
+its	O
+replication	O
+in	O
+monocytes	B-ANAT
+,	O
+replication	O
+kinetics	O
+were	O
+determined	O
+for	O
+FIPV	O
+79	O
+-	O
+1146	O
+and	O
+its	O
+deletion	O
+mutants	O
+,	O
+lacking	O
+either	O
+accessory	O
+protein	B-CHED
+open	O
+reading	O
+frame	O
+3abc	O
+(	O
+FIPV	O
+-	O
+Δ3	O
+),	O
+7ab	O
+(	O
+FIPV	O
+-	O
+Δ7	O
+)	O
+or	O
+both	O
+(	O
+FIPV	O
+-	O
+Δ3Δ7	O
+).	O
+
+Genome	O
+replication	O
+of	O
+EAV	B-SPEC
+has	O
+been	O
+associated	O
+with	O
+modified	O
+intracellular	B-COMP
+membranes	B-ANAT
+that	O
+are	O
+shaped	O
+into	O
+double	O
+-	O
+membrane	B-COMP
+vesicles	B-COMP
+(	O
+DMVs	O
+).	O
+
+Nevertheless	O
+,	O
+colocalization	O
+of	O
+DMVs	O
+and	O
+LC3	O
+was	O
+still	O
+observed	O
+in	O
+these	O
+knockout	O
+cells	B-COMP
+,	O
+which	O
+only	O
+contain	O
+the	O
+nonlipidated	O
+form	O
+of	O
+LC3	O
+.	O
+
+EAV	B-SPEC
+replication	O
+could	O
+be	O
+fully	O
+restored	O
+in	O
+these	O
+cells	B-COMP
+by	O
+expression	B-PROC
+of	O
+a	O
+nonlipidated	O
+form	O
+of	O
+LC3	O
+.	O
+
+Expression	B-PROC
+of	O
+the	O
+ezrin	B-PRGE
+dominant	B-DISO
+negative	I-DISO
+FERM	B-DISO
+domain	O
+enhanced	O
+cell	B-COMP
+susceptibility	O
+to	O
+infection	B-DISO
+by	O
+SARS	B-DISO
+-	O
+CoV	O
+and	O
+S	O
+-	O
+pseudotyped	O
+particles	O
+and	O
+potentiated	O
+S	O
+-	O
+dependent	O
+membrane	B-PROC
+fusion	I-PROC
+.	O
+
+Ezrin	B-PRGE
+interacts	O
+with	O
+SARS	B-PRGE
+-	I-PRGE
+CoV	I-PRGE
+S	I-PRGE
+endodomain	I-PRGE
+and	O
+limits	O
+virus	B-SPEC
+entry	O
+and	O
+fusion	O
+.	O
+
+TITLE	O
+:	O
+Human	B-SPEC
+monoclonal	O
+antibodies	B-COMP
+against	O
+highly	O
+conserved	O
+HR1	O
+and	O
+HR2	O
+domains	O
+of	O
+the	O
+SARS	B-DISO
+-	I-PRGE
+CoV	I-PRGE
+spike	I-PRGE
+protein	I-PRGE
+are	O
+more	O
+broadly	O
+neutralizing	O
+.	O
+
+ABSTRACT	O
+:	O
+The	O
+enteropathogenic	O
+coronavirus	B-SPEC
+transmissible	O
+gastroenteritis	B-DISO
+virus	B-SPEC
+(	O
+TGEV	B-SPEC
+)	O
+causes	O
+severe	O
+disease	O
+in	O
+young	O
+piglets	O
+.	O
+
+Virus	B-SPEC
+yields	O
+of	O
+the	O
+E	B-SPEC
+.	I-SPEC
+faecium	I-SPEC
+-	O
+treated	O
+cultures	O
+were	O
+reduced	O
+by	O
+up	O
+to	O
+three	O
+log10	O
+units	O
+.	O
+
+Increased	O
+production	O
+of	O
+nitric	B-CHED
+oxide	I-CHED
+in	O
+the	O
+cells	B-COMP
+treated	O
+with	O
+E	B-SPEC
+.	I-SPEC
+faecium	I-SPEC
+and	O
+elevated	O
+expression	B-PROC
+of	O
+interleukin	B-PRGE
+6	I-PRGE
+and	O
+8	O
+pointed	O
+to	O
+stimulated	O
+cellular	B-COMP
+defense	O
+as	O
+a	O
+mechanism	O
+to	O
+fight	O
+TGEV	B-SPEC
+infection	B-DISO
+.	O
+
+A	O
+respiratory	O
+virus	B-SPEC
+was	O
+detected	O
+in	O
+193	O
+(	O
+76	O
+%)	O
+patients	O
+;	O
+156	O
+(	O
+81	O
+%)	O
+patients	O
+had	O
+upper	B-DISO
+respiratory	I-DISO
+tract	I-DISO
+infection	I-DISO
+.	O
+
+Leukemia	B-DISO
+or	O
+lymphoma	B-DISO
+was	O
+the	O
+most	O
+common	O
+underlying	O
+diagnosis	O
+in	O
+95	O
+(	O
+49	O
+%)	O
+patients	O
+followed	O
+by	O
+solid	B-DISO
+tumor	I-DISO
+47	O
+(	O
+24	O
+%),	O
+posthematopoietic	B-PRGE
+stem	I-PRGE
+cell	I-PRGE
+transplant	I-PRGE
+28	I-PRGE
+(	O
+15	O
+%)	O
+and	O
+brain	B-DISO
+tumor	I-DISO
+in	O
+23	O
+(	O
+12	O
+%)	O
+patients	O
+.	O
+
+Coinfection	B-DISO
+with	O
+>	O
+1	O
+virus	B-SPEC
+was	O
+present	O
+in	O
+47	O
+(	O
+24	O
+%)	O
+patients	O
+,	O
+and	O
+did	O
+not	O
+increase	O
+the	O
+risk	O
+for	O
+LRTI	B-DISO
+.	O
+
+C	B-SPEC
+.	I-SPEC
+pneumoniae	I-SPEC
+and	O
+M	B-SPEC
+.	I-SPEC
+pneumoniae	I-SPEC
+were	O
+detected	O
+in	O
+4	O
+and	O
+3	O
+patients	O
+,	O
+respectively	O
+.	O
+:	O
+Human	B-SPEC
+rhinovirus	I-SPEC
+was	O
+the	O
+most	O
+common	O
+virus	B-SPEC
+detected	O
+in	O
+children	O
+with	O
+cancer	B-DISO
+and	O
+posthematopoietic	O
+stem	O
+cell	B-ANAT
+transplant	I-ANAT
+hospitalized	O
+with	O
+an	O
+acute	O
+respiratory	O
+illness	O
+,	O
+and	O
+was	O
+not	O
+associated	O
+with	O
+increased	O
+morbidity	O
+.	O
+
+C	B-SPEC
+.	I-SPEC
+pneumoniae	I-SPEC
+and	O
+M	B-SPEC
+.	I-SPEC
+pneumoniae	I-SPEC
+were	O
+detected	O
+in	O
+4	O
+and	O
+3	O
+patients	O
+,	O
+respectively	O
+.	O
+
+We	O
+randomly	O
+tested	O
+(	O
+30	O
+min	O
+)	O
+while	O
+recording	O
+EAdi	O
+:	O
+(	O
+1	O
+)	O
+PSV30	O
+(	O
+PSV	B-PRGE
+with	I-PRGE
+an	O
+expiratory	B-PROC
+trigger	O
+at	O
+30	O
+%	O
+of	O
+flow	O
+peak	O
+value	O
+);	O
+(	O
+2	O
+)	O
+PSV1	O
+(	O
+PSV	O
+with	O
+expiratory	B-PROC
+trigger	O
+at	O
+1	O
+%);	O
+(	O
+3	O
+)	O
+NAVA	O
+.	O
+
+TITLE	O
+:	O
+Communicable	B-DISO
+disease	I-DISO
+control	O
+in	O
+China	O
+:	O
+From	O
+Mao	B-PROC
+to	O
+now	O
+.	O
+
+ABSTRACT	O
+:	O
+China	O
+'	O
+s	O
+progress	O
+on	O
+communicable	B-DISO
+disease	I-DISO
+control	O
+(	O
+CDC	O
+)	O
+in	O
+the	O
+30	O
+years	O
+after	O
+establishment	O
+of	O
+the	O
+People	O
+'	O
+s	O
+Republic	O
+in	O
+1949	O
+is	O
+widely	O
+regarded	O
+as	O
+remarkable	O
+.	O
+
+TITLE	O
+:	O
+Development	B-PROC
+of	O
+novel	O
+entry	O
+inhibitors	B-CHED
+targeting	B-PROC
+emerging	O
+viruses	B-SPEC
+.	O
+
+A	O
+retrospective	O
+chart	O
+review	O
+was	O
+conducted	O
+on	O
+8	O
+patients	O
+with	O
+H5N1	B-DISO
+infection	B-DISO
+(	O
+aged	O
+2	O
+-	O
+30	O
+years	O
+;	O
+3	O
+fatal	O
+)	O
+who	O
+were	O
+hospitalized	O
+in	O
+Bach	O
+Mai	B-SPEC
+Hospital	O
+(	O
+BMH	B-DISO
+),	O
+Vietnam	O
+,	O
+or	O
+in	O
+affiliated	O
+hospitals	O
+with	O
+consultation	O
+by	O
+physicians	O
+in	O
+BMH	B-DISO
+between	O
+2007	O
+and	O
+2010	O
+.	O
+
+TITLE	O
+:	O
+Prediction	O
+and	O
+prevention	O
+of	O
+the	O
+next	O
+pandemic	O
+zoonosis	B-DISO
+.	O
+
+We	O
+lay	O
+out	O
+a	O
+series	O
+of	O
+research	O
+and	O
+surveillance	O
+opportunities	O
+and	O
+goals	O
+that	O
+could	O
+help	O
+to	O
+overcome	O
+these	O
+challenges	O
+and	O
+move	B-PROC
+the	O
+global	O
+pandemic	O
+strategy	O
+from	O
+response	O
+to	O
+pre	O
+-	O
+emption	O
+.	O
+
+ABSTRACT	O
+:	O
+The	O
+human	B-SPEC
+coronavirus	I-SPEC
+NL63	I-SPEC
+is	O
+generally	O
+classified	O
+as	O
+a	O
+common	O
+cold	O
+pathogen	O
+,	O
+though	O
+the	O
+infection	B-DISO
+may	O
+also	O
+result	O
+in	O
+severe	O
+lower	B-ANAT
+respiratory	I-ANAT
+tract	I-ANAT
+diseases	O
+,	O
+especially	O
+in	O
+children	O
+,	O
+patients	O
+with	O
+underlying	O
+disease	O
+,	O
+and	O
+elderly	O
+.	O
+
+In	O
+the	O
+current	O
+manuscript	O
+we	O
+developed	O
+a	O
+set	O
+of	O
+polymer	B-CHED
+-	O
+based	O
+compounds	O
+showing	O
+prominent	O
+anticoronaviral	O
+activity	O
+.	O
+
+ABSTRACT	O
+:	O
+The	O
+K	O
+-	O
+I	O
+and	O
+nephropathogenic	O
+K	O
+-	O
+II	O
+genotypes	O
+of	O
+infectious	B-DISO
+bronchitis	B-DISO
+virus	B-SPEC
+(	O
+IBV	B-SPEC
+)	O
+have	O
+been	O
+isolated	O
+since	O
+1995	O
+and	O
+1990	O
+,	O
+respectively	O
+,	O
+in	O
+Korea	O
+and	O
+commercial	O
+inactivated	O
+oil	O
+-	O
+emulsion	O
+vaccines	O
+containing	O
+KM91	O
+(	O
+K	O
+-	O
+II	O
+type	O
+)	O
+and	O
+Massachusetts	O
+41	O
+strains	O
+have	O
+been	O
+used	O
+in	O
+the	O
+field	O
+.	O
+
+In	O
+the	O
+present	O
+study	O
+,	O
+comparative	O
+genomics	O
+of	O
+SNU8067	O
+(	O
+K	O
+-	O
+I	O
+type	O
+)	O
+and	O
+KM91	O
+IBVs	O
+was	O
+performed	O
+,	O
+and	O
+an	O
+animal	B-SPEC
+model	O
+to	O
+test	O
+the	O
+pathogenicity	O
+of	O
+SNU8067	O
+was	O
+established	O
+and	O
+applied	O
+to	O
+vaccine	O
+efficacy	O
+test	O
+.	O
+
+Using	O
+the	O
+Data	O
+Integration	B-PROC
+for	O
+Alberta	B-SPEC
+Laboratories	O
+(	O
+DIAL	O
+)	O
+platform	O
+,	O
+26	O
+,	O
+226	O
+respiratory	O
+specimens	O
+at	O
+ProvLab	O
+between	O
+1	O
+July	O
+2009	O
+and	O
+30	O
+June	O
+2012	O
+were	O
+selected	O
+and	O
+included	O
+in	O
+the	O
+study	O
+.	O
+
+hMPV	B-SPEC
+was	O
+significantly	O
+more	O
+likely	O
+to	O
+be	O
+identified	O
+in	O
+mono	B-DISO
+infection	B-DISO
+as	O
+compared	O
+with	O
+ADV	O
+,	O
+CRV	B-DISO
+,	O
+PIV	O
+,	O
+and	O
+RSV	B-SPEC
+with	O
+the	O
+exception	O
+of	O
+ERV	B-PROC
+[	O
+p	O
+<	O
+0	O
+.	O
+05	O
+].	O
+
+This	O
+review	O
+will	O
+summarize	O
+current	O
+knowledge	O
+on	O
+the	O
+capacity	O
+of	O
+human	B-SPEC
+coronaviruses	O
+to	O
+survive	O
+in	O
+the	O
+environment	O
+and	O
+the	O
+efficacy	O
+of	O
+well	O
+-	O
+known	O
+antiseptic	O
+-	O
+disinfectants	B-CHED
+against	O
+them	O
+,	O
+with	O
+particular	O
+focus	O
+on	O
+the	O
+development	B-PROC
+of	O
+new	O
+methodologies	O
+to	O
+evaluate	O
+the	O
+activity	O
+of	O
+new	O
+antiseptic	O
+-	O
+disinfectants	B-CHED
+on	O
+viruses	B-SPEC
+.	O
+
+TITLE	O
+:	O
+Virus	B-SPEC
+pathogen	O
+database	O
+and	O
+analysis	O
+resource	O
+(	O
+ViPR	O
+):	O
+a	O
+comprehensive	O
+bioinformatics	O
+database	O
+and	O
+analysis	O
+resource	O
+for	O
+the	O
+coronavirus	B-SPEC
+research	O
+community	O
+.	O
+
+Records	O
+returned	O
+from	O
+these	O
+queries	O
+can	O
+then	O
+be	O
+subjected	O
+to	O
+web	B-DISO
+-	O
+based	O
+analyses	O
+including	O
+:	O
+multiple	O
+sequence	O
+alignment	O
+,	O
+phylogenetic	O
+inference	O
+,	O
+sequence	O
+variation	O
+determination	O
+,	O
+BLAST	B-ANAT
+comparison	O
+,	O
+and	O
+metadata	O
+-	O
+driven	O
+comparative	O
+genomics	O
+statistical	O
+analysis	O
+.	O
+
+ABSTRACT	O
+:	O
+Coronaviruses	O
+are	O
+positive	O
+-	O
+strand	O
+RNA	O
+viruses	O
+that	O
+are	O
+important	O
+infectious	B-DISO
+agents	O
+of	O
+both	O
+animals	B-SPEC
+and	O
+humans	B-SPEC
+.	O
+
+Upon	O
+infection	B-DISO
+,	O
+coronaviruses	O
+extensively	O
+rearrange	O
+cellular	B-COMP
+membranes	B-ANAT
+into	O
+organelle	B-COMP
+-	O
+like	O
+replicative	O
+structures	O
+that	O
+consist	O
+of	O
+double	O
+-	O
+membrane	B-COMP
+vesicles	B-COMP
+and	O
+convoluted	O
+membranes	B-ANAT
+to	O
+which	O
+the	O
+nonstructural	O
+proteins	B-CHED
+involved	O
+in	O
+RNA	B-PROC
+synthesis	I-PROC
+localize	O
+.	O
+
+By	O
+nature	O
+of	O
+their	O
+double	O
+membrane	B-COMP
+,	O
+these	O
+vesicles	B-COMP
+resemble	O
+cellular	B-COMP
+autophagosomes	O
+,	O
+generated	O
+during	O
+the	O
+cellular	B-PROC
+autophagy	I-PROC
+pathway	B-PROC
+.	O
+
+TITLE	O
+:	O
+Sequencing	O
+,	O
+phylogenetic	O
+analysis	O
+,	O
+and	O
+potential	O
+recombination	B-PROC
+events	O
+of	O
+infectious	B-DISO
+bronchitis	B-DISO
+viruses	B-SPEC
+isolated	O
+in	O
+Korea	O
+.	O
+
+ABSTRACT	O
+:	O
+The	O
+S2	B-PRGE
+glycoprotein	I-PRGE
+and	O
+membrane	B-COMP
+(	O
+M	O
+)	O
+protein	B-CHED
+genes	O
+and	O
+S1	B-PRGE
+glycoprotein	I-PRGE
+and	O
+nucleocapsid	B-COMP
+(	O
+N	O
+)	O
+genes	O
+of	O
+11	O
+Korean	O
+infectious	B-DISO
+bronchitis	B-DISO
+virus	B-SPEC
+(	O
+IBV	B-SPEC
+)	O
+isolates	O
+were	O
+amplified	O
+by	O
+RT	O
+-	O
+PCR	O
+,	O
+cloned	O
+,	O
+and	O
+sequenced	O
+.	O
+
+The	O
+determination	O
+of	O
+patient	O
+subgroups	O
+should	O
+be	O
+explored	O
+to	O
+improve	O
+the	O
+management	O
+of	O
+this	O
+condition	B-DISO
+.	O
+
+This	O
+case	O
+illustrates	O
+that	O
+interstitial	B-DISO
+lung	B-ANAT
+diseases	I-DISO
+,	O
+specifically	O
+AFOP	O
+,	O
+should	O
+be	O
+included	O
+in	O
+the	O
+differential	O
+diagnosis	O
+of	O
+diffuse	O
+lung	B-DISO
+diseases	I-DISO
+in	O
+patients	O
+with	O
+respiratory	B-DISO
+failure	I-DISO
+with	O
+or	O
+without	O
+shock	O
+.	O
+
+TITLE	O
+:	O
+Characteristics	O
+and	O
+outcome	O
+of	O
+critically	B-DISO
+ill	I-DISO
+patients	O
+with	O
+2009	O
+H1N1	B-DISO
+influenza	I-DISO
+infection	O
+in	O
+Syria	O
+.	O
+
+ABSTRACT	O
+:	O
+To	O
+describe	O
+the	O
+epidemiologic	O
+characteristics	O
+,	O
+clinical	O
+features	O
+,	O
+and	O
+outcome	O
+of	O
+severe	O
+cases	O
+of	O
+2009	O
+H1N1	O
+influenza	O
+A	O
+infections	B-DISO
+who	O
+were	O
+admitted	O
+to	O
+the	O
+intensive	O
+care	O
+units	O
+(	O
+ICUs	O
+)	O
+in	O
+Damascus	O
+,	O
+Syria	O
+.	O
+
+Anon	O
+-	O
+cardiogenic	O
+pulmonar	O
+edema	B-DISO
+progressing	O
+to	O
+clinico	O
+-	O
+physiological	O
+ARDS	B-DISO
+criteria	O
+was	O
+diagnosed	O
+.	O
+
+ABSTRACT	O
+:	O
+Knowledge	O
+of	O
+coronaviruses	O
+in	O
+wild	O
+carnivores	B-SPEC
+is	O
+limited	O
+.	O
+
+This	O
+report	O
+describes	O
+coronavirus	B-SPEC
+genetic	O
+diversity	O
+,	O
+species	B-SPEC
+specificity	O
+and	O
+infection	B-DISO
+prevalence	O
+in	O
+three	O
+wild	O
+African	O
+carnivores	B-SPEC
+.	O
+
+ABSTRACT	O
+:	O
+Feline	B-SPEC
+coronavirus	B-DISO
+infection	I-DISO
+is	O
+common	O
+among	O
+domestic	O
+and	O
+exotic	O
+felid	B-SPEC
+species	B-SPEC
+and	O
+usually	O
+associated	O
+with	O
+mild	O
+or	O
+asymptomatic	O
+enteritis	B-DISO
+;	O
+however	O
+,	O
+feline	B-DISO
+infectious	I-DISO
+peritonitis	I-DISO
+(	O
+FIP	B-DISO
+)	O
+is	O
+a	O
+fatal	O
+disease	O
+of	O
+cats	B-SPEC
+that	O
+is	O
+caused	O
+by	O
+systemic	B-DISO
+infection	I-DISO
+with	O
+a	O
+feline	B-DISO
+infectious	I-DISO
+peritonitis	I-DISO
+virus	B-SPEC
+(	O
+FIPV	O
+),	O
+a	O
+variant	O
+of	O
+feline	B-SPEC
+enteric	B-SPEC
+coronavirus	I-SPEC
+(	O
+FECV	B-SPEC
+).	O
+
+During	O
+the	O
+replication	B-PROC
+process	I-PROC
+,	O
+coronavirus	B-SPEC
+produces	O
+viral	O
+polyproteins	O
+that	O
+are	O
+processed	O
+into	O
+mature	O
+proteins	B-CHED
+by	O
+viral	O
+proteases	O
+,	O
+the	O
+main	O
+protease	O
+(	O
+3C	O
+-	O
+like	O
+[	O
+3CL	O
+]	O
+protease	O
+)	O
+and	O
+the	O
+papain	B-PRGE
+-	I-PRGE
+like	I-PRGE
+protease	I-PRGE
+.	O
+
+The	O
+recognition	O
+of	O
+the	O
+target	O
+sequence	O
+by	O
+the	O
+oligonucleotides	B-CHED
+is	O
+mediated	O
+by	O
+short	O
+(	O
+6	O
+-	O
+8	O
+nt	O
+)	O
+conserved	O
+regions	O
+,	O
+which	O
+facilitates	O
+development	B-PROC
+of	O
+broad	O
+-	O
+spectrum	O
+assays	O
+.	O
+
+However	O
+,	O
+five	O
+samples	O
+were	O
+negative	O
+by	O
+RT	B-PRGE
+-	I-PRGE
+PCR	I-PRGE
+,	O
+so	O
+the	O
+presence	O
+of	O
+virus	B-SPEC
+alone	O
+may	O
+not	O
+explain	O
+all	O
+cases	O
+of	O
+false	O
+-	O
+negative	O
+FCoV	O
+antibody	O
+tests	O
+,	O
+although	O
+it	O
+is	O
+a	O
+possible	O
+explanation	O
+in	O
+71	O
+%	O
+of	O
+discordant	O
+samples	O
+.	O
+
+TITLE	O
+:	O
+Circulating	O
+histones	O
+are	O
+mediators	O
+of	O
+trauma	O
+-	O
+associated	O
+lung	B-ANAT
+injury	O
+.	O
+
+Circulating	O
+histone	B-PRGE
+levels	O
+in	O
+patients	O
+with	O
+severe	O
+trauma	O
+were	O
+determined	O
+and	O
+correlated	O
+with	O
+respiratory	B-DISO
+failure	I-DISO
+and	O
+Sequential	O
+Organ	B-DISO
+Failure	I-DISO
+Assessment	O
+(	O
+SOFA	O
+)	O
+scores	O
+.	O
+
+Pathological	O
+examinations	O
+showed	O
+that	O
+lungs	B-ANAT
+were	O
+the	O
+predominantly	O
+affected	O
+organ	B-ANAT
+with	O
+edema	B-DISO
+,	O
+hemorrhage	B-DISO
+,	O
+microvascular	O
+thrombosis	B-DISO
+,	O
+and	O
+neutrophil	B-ANAT
+congestion	B-DISO
+.	O
+
+This	O
+study	O
+has	O
+resolved	O
+an	O
+issue	O
+concerning	O
+the	O
+number	O
+of	O
+ORFs	O
+expressed	B-PROC
+by	O
+members	O
+of	O
+the	O
+Gammacoronavirus	B-SPEC
+genus	B-SPEC
+and	O
+proposes	O
+the	O
+existence	O
+of	O
+a	O
+fifth	O
+IBV	B-SPEC
+accessory	O
+protein	B-CHED
+.	O
+
+We	O
+hereby	O
+report	O
+case	O
+of	O
+a	O
+child	O
+who	O
+had	O
+successfully	O
+undergone	O
+gastric	B-ANAT
+pull	O
+-	O
+up	O
+approximately	O
+18	O
+months	O
+before	O
+and	O
+presented	O
+with	O
+gradually	O
+progressing	O
+dyspnea	B-DISO
+due	O
+to	O
+aerophagia	B-DISO
+from	O
+excessive	O
+crying	O
+.	O
+
+TITLE	O
+:	O
+Characteristics	O
+of	O
+critically	B-DISO
+ill	I-DISO
+patients	O
+in	O
+ICUs	O
+in	O
+mainland	O
+China	O
+.	O
+
+Specific	O
+primers	O
+were	O
+carefully	O
+selected	O
+from	O
+articles	O
+published	O
+for	O
+each	O
+of	O
+the	O
+following	O
+three	O
+viruses	B-SPEC
+:	O
+porcine	B-SPEC
+circovirus	I-SPEC
+type	I-SPEC
+II	I-SPEC
+(	O
+PCV2	O
+),	O
+porcine	B-SPEC
+teschovirus	I-SPEC
+(	O
+PTV	B-SPEC
+)	O
+and	O
+porcine	B-DISO
+transmissible	I-DISO
+gastroenteritis	I-DISO
+virus	B-SPEC
+(	O
+TGEV	B-SPEC
+).	O
+
+Outcome	O
+was	O
+better	O
+when	O
+the	O
+time	O
+of	O
+severe	O
+deoxygenation	O
+(	O
+Pao2	O
+<	O
+70	O
+mm	O
+Hg	O
+)	O
+despite	O
+maximally	O
+invasive	O
+respiratory	O
+support	O
+to	O
+ECMO	O
+implantation	B-PROC
+was	O
+less	O
+than	O
+6	O
+hours	O
+(	O
+odds	O
+ratio	O
+:	O
+2	O
+.	O
+4	O
+;	O
+p	O
+=	O
+0	O
+.	O
+05	O
+).	O
+
+ARDS	B-DISO
+associated	O
+with	O
+H1N1	O
+remains	O
+a	O
+devastating	O
+clinical	O
+picture	O
+.	O
+
+RESULTS	O
+:	O
+Successful	O
+ECMO	O
+weaning	B-PROC
+was	O
+possible	O
+in	O
+44	O
+%	O
+(	O
+n	O
+=	O
+8	O
+)	O
+of	O
+patients	O
+and	O
+overall	O
+mortality	O
+was	O
+61	O
+%	O
+(	O
+n	O
+=	O
+11	O
+).	O
+
+The	O
+patient	O
+was	O
+successfully	O
+weaned	B-PROC
+from	O
+the	O
+ventilator	O
+after	O
+the	O
+percutaneous	O
+closure	O
+of	O
+PFO	B-CHED
+through	O
+a	O
+catheter	O
+-	O
+deployed	O
+double	O
+-	O
+umbrella	O
+device	O
+,	O
+presenting	O
+a	O
+full	O
+recovery	O
+.	O
+
+ABSTRACT	O
+:	O
+A	O
+high	O
+-	O
+throughput	O
+screen	O
+of	O
+the	O
+NIH	O
+molecular	O
+libraries	O
+sample	O
+collection	O
+and	O
+subsequent	O
+optimization	O
+of	O
+a	O
+lead	O
+dipeptide	B-CHED
+-	O
+like	O
+series	O
+of	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+(	O
+SARS	B-DISO
+)	O
+main	O
+protease	O
+(	O
+3CLpro	O
+)	O
+inhibitors	B-CHED
+led	O
+to	O
+the	O
+identification	O
+of	O
+probe	O
+compound	O
+ML188	O
+(	O
+16	O
+-(	O
+R	O
+),	O
+(	O
+R	O
+)-	O
+N	O
+-(	O
+4	O
+-(	O
+tert	B-CHED
+-	I-CHED
+butyl	I-CHED
+)	O
+phenyl	B-CHED
+)-	O
+N	O
+-(	O
+2	O
+-(	O
+tert	O
+-	O
+butylamino	O
+)-	O
+2	O
+-	O
+oxo	B-CHED
+-	O
+1	O
+-(	O
+pyridin	B-CHED
+-	I-CHED
+3	I-CHED
+-	I-CHED
+yl	I-CHED
+)	O
+ethyl	B-CHED
+)	O
+furan	B-CHED
+-	O
+2	O
+-	O
+carboxamide	B-CHED
+,	O
+Pubchem	O
+CID	O
+:	O
+46897844	O
+).	O
+
+TITLE	O
+:	O
+Assays	O
+for	O
+laboratory	O
+confirmation	O
+of	O
+novel	O
+human	B-SPEC
+coronavirus	I-SPEC
+(	O
+hCoV	O
+-	O
+EMC	B-COMP
+)	O
+infections	B-DISO
+.	O
+
+TITLE	O
+:	O
+Laboratory	O
+capability	O
+for	O
+molecular	O
+detection	O
+and	O
+confirmation	O
+of	O
+novel	B-SPEC
+coronavirus	I-SPEC
+in	O
+Europe	O
+,	O
+November	O
+2012	O
+.	O
+
+HCoV	B-PRGE
+-	I-PRGE
+EMC	I-PRGE
+is	O
+a	O
+member	O
+of	O
+the	O
+same	O
+virus	B-SPEC
+genus	B-SPEC
+as	O
+SARS	B-DISO
+-	O
+CoV	O
+but	O
+constitutes	O
+a	O
+sister	O
+species	B-SPEC
+.	O
+
+Here	O
+we	O
+investigated	O
+whether	O
+it	O
+might	O
+utilize	O
+angiotensin	B-PRGE
+-	I-PRGE
+converting	I-PRGE
+enzyme	I-PRGE
+2	I-PRGE
+(	O
+ACE2	B-PRGE
+),	O
+the	O
+SARS	B-PRGE
+-	I-PRGE
+CoV	I-PRGE
+receptor	I-PRGE
+.	O
+
+TITLE	O
+:	O
+[	O
+Myasthenic	B-DISO
+crisis	I-DISO
+and	O
+Takotsubo	B-DISO
+syndrome	I-DISO
+:	O
+a	O
+non	O
+-	O
+chance	O
+relationship	O
+].	O
+
+Takotsubo	O
+syndrome	O
+(	O
+TTS	O
+)	O
+is	O
+a	O
+rare	O
+condition	B-DISO
+that	O
+mimics	O
+an	O
+acute	B-DISO
+myocardial	I-DISO
+infarction	I-DISO
+.	O
+
+The	O
+antiviral	B-CHED
+efficacy	O
+of	O
+amantadine	B-CHED
+congeners	O
+can	O
+be	O
+chemically	O
+modified	O
+,	O
+resulting	O
+in	O
+re	O
+-	O
+constitution	O
+,	O
+improvement	O
+and	O
+/	O
+or	O
+extension	O
+of	O
+antiviral	B-CHED
+activities	O
+mediated	O
+by	O
+amino	O
+-	O
+adamantyls	O
+.	O
+
+One	O
+N	O
+-	O
+phenacyl	O
+amantadine	B-CHED
+derivative	O
+was	O
+investigated	O
+for	O
+inhibiting	O
+the	O
+in	O
+vitro	O
+replication	O
+of	O
+respiratory	O
+viruses	B-SPEC
+(	O
+influenza	B-PATH
+A	I-PATH
+viruses	B-SPEC
+,	O
+influenza	B-SPEC
+B	I-SPEC
+virus	I-SPEC
+,	O
+human	B-SPEC
+parainfluenza	I-SPEC
+virus	I-SPEC
+type	I-SPEC
+3	I-SPEC
+and	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+coronavirus	B-SPEC
+).	O
+
+Their	O
+structure	O
+was	O
+proved	O
+by	O
+determining	O
+the	O
+X	O
+-	O
+ray	B-SPEC
+single	O
+crystal	B-ANAT
+structure	O
+of	O
+one	O
+hydrolytic	O
+elaboration	O
+product	O
+.	O
+
+Clinical	O
+judgment	O
+for	O
+characterizing	O
+hydrostatic	O
+pulmonary	B-DISO
+edema	I-DISO
+suffices	O
+,	O
+unless	O
+there	O
+is	O
+no	O
+apparent	O
+ARDS	B-DISO
+risk	O
+factor	O
+,	O
+in	O
+which	O
+case	O
+an	O
+objective	O
+evaluation	O
+is	O
+required	O
+;	O
+the	O
+category	O
+of	O
+acute	O
+lung	B-ANAT
+injury	O
+was	O
+removed	O
+,	O
+and	O
+ARDS	B-DISO
+was	O
+divided	O
+into	O
+three	O
+categories	O
+of	O
+severity	O
+based	O
+on	O
+the	O
+P	O
+/	O
+F	O
+ratio	O
+-	O
+mild	O
+(	O
+from	O
+201	O
+to	O
+300	O
+),	O
+moderate	O
+(	O
+from	O
+101	O
+to	O
+200	O
+),	O
+and	O
+severe	O
+(≤	O
+100	O
+mmHg	O
+).	O
+
+The	O
+results	O
+highlight	O
+the	O
+need	O
+to	O
+strengthen	O
+,	O
+amongst	O
+the	O
+health	O
+staff	O
+,	O
+the	O
+knowledge	O
+of	O
+the	O
+guidelines	O
+for	O
+the	O
+clinical	O
+care	O
+of	O
+malaria	B-PATH
+patients	O
+,	O
+in	O
+order	B-SPEC
+to	O
+make	O
+a	O
+correct	O
+clinical	O
+diagnosis	O
+and	O
+provide	O
+appropriate	O
+treatment	O
+.	O
+
+However	O
+,	O
+little	O
+is	O
+known	O
+about	O
+the	O
+biogenesis	B-PROC
+and	O
+three	O
+-	O
+dimensional	O
+structure	O
+of	O
+the	O
+MW	O
+.	O
+
+TITLE	O
+:	O
+Enhanced	O
+CD8	B-PRGE
+T	B-ANAT
+-	I-ANAT
+cell	I-ANAT
+anti	O
+-	O
+viral	O
+function	O
+and	O
+clinical	O
+disease	O
+in	O
+B7	B-PRGE
+-	I-PRGE
+H1	I-PRGE
+-	O
+deficient	O
+mice	B-SPEC
+requires	O
+CD4	O
+T	B-ANAT
+cells	I-ANAT
+during	O
+encephalomyelitis	B-DISO
+.	O
+
+However	O
+,	O
+the	O
+relative	O
+contribution	O
+of	O
+CD4	B-PRGE
+T	I-PRGE
+cells	O
+to	O
+CD8	B-PRGE
+function	O
+in	O
+the	O
+CNS	B-CHED
+,	O
+in	O
+the	O
+absence	O
+of	O
+B7	B-PRGE
+-	I-PRGE
+H1	I-PRGE
+,	O
+remains	O
+unclear	O
+.	O
+
+Wild	O
+-	O
+type	O
+(	O
+WT	O
+)	O
+and	O
+B7	B-PRGE
+-	I-PRGE
+H1	I-PRGE
+-/-	O
+mice	B-SPEC
+were	O
+infected	O
+with	O
+a	O
+gliatropic	O
+coronavirus	B-SPEC
+and	O
+CD4	B-PRGE
+T	I-PRGE
+cells	O
+depleted	O
+to	O
+specifically	O
+block	O
+T	O
+helper	O
+function	O
+in	O
+the	O
+CNS	B-CHED
+.	O
+
+Increased	O
+anti	O
+-	O
+viral	O
+activity	O
+by	O
+CD8	B-PRGE
+T	I-PRGE
+cells	O
+in	O
+the	O
+CNS	B-CHED
+of	O
+B7	B-PRGE
+-	I-PRGE
+H1	I-PRGE
+-/-	O
+mice	B-SPEC
+was	O
+lost	B-CHED
+upon	O
+depletion	O
+of	O
+CD4	B-PRGE
+T	I-PRGE
+cells	O
+;	O
+however	O
+,	O
+despite	O
+concomitant	O
+loss	O
+of	O
+viral	O
+control	O
+,	O
+the	O
+clinical	O
+disease	O
+was	O
+less	O
+severe	O
+.	O
+
+High	O
+-	O
+frequency	O
+oscillatory	O
+ventilation	O
+(	O
+HFOV	O
+)	O
+has	O
+been	O
+used	O
+to	O
+treat	O
+pediatric	O
+patients	O
+with	O
+severe	O
+ARDS	B-DISO
+.	O
+
+However	O
+,	O
+there	O
+is	O
+little	O
+research	O
+that	O
+has	O
+rigorously	O
+evaluated	O
+the	O
+association	O
+between	O
+domain	O
+swapping	O
+and	O
+protein	B-PROC
+folding	I-PROC
+/	O
+unfolding	O
+.	O
+
+With	O
+an	O
+exchange	O
+of	O
+nearly	O
+one	O
+-	O
+third	O
+of	O
+the	O
+genome	O
+with	O
+other	O
+members	O
+of	O
+alphacoronaviruses	O
+,	O
+the	O
+new	O
+emerging	O
+virus	B-SPEC
+could	O
+gain	O
+new	O
+antigenicity	O
+,	O
+posing	O
+a	O
+threat	O
+to	O
+cats	B-SPEC
+that	O
+either	O
+have	O
+been	O
+infected	O
+with	O
+a	O
+type	O
+I	O
+virus	B-SPEC
+before	O
+or	O
+never	O
+have	O
+been	O
+infected	O
+with	O
+FCoV	O
+.	O
+
+hMPV	B-SPEC
+can	O
+cause	O
+morbidity	O
+in	O
+hematopoietic	B-ANAT
+stem	I-ANAT
+cell	I-ANAT
+transplant	B-ANAT
+recipients	O
+and	O
+recent	O
+research	O
+has	O
+demonstrated	O
+that	O
+it	O
+is	O
+an	O
+important	O
+virus	B-SPEC
+in	O
+patients	O
+admitted	O
+to	O
+hospital	O
+with	O
+respiratory	B-DISO
+infections	I-DISO
+and	O
+suspected	O
+of	O
+having	O
+pandemic	O
+2009	O
+influenza	B-PATH
+A	I-PATH
+(	O
+H1N1pdm09	O
+)	O
+virus	B-SPEC
+.	O
+
+The	O
+purpose	O
+of	O
+this	O
+study	O
+was	O
+to	O
+investigate	O
+infections	B-DISO
+caused	O
+by	O
+hMPV	B-SPEC
+in	O
+two	O
+groups	O
+of	O
+patients	O
+admitted	O
+to	O
+hospital	O
+:	O
+Immunocompromized	O
+patients	O
+with	O
+a	O
+potential	O
+risk	O
+of	O
+severe	O
+outcomes	O
+and	O
+immunocompetent	O
+patients	O
+with	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+.	O
+
+Amplification	B-DISO
+of	O
+the	O
+hMPV	B-SPEC
+genes	O
+was	O
+performed	O
+by	O
+polymerase	O
+chain	O
+reaction	O
+.	O
+
+In	O
+contrast	O
+,	O
+IFN	B-PRGE
+-	I-PRGE
+γ	I-PRGE
+production	O
+in	O
+blood	B-ANAT
+was	O
+highest	O
+at	O
+1	O
+dpi	O
+and	O
+decreased	O
+over	O
+time	O
+down	O
+to	O
+levels	O
+comparable	O
+to	O
+uninfected	O
+birds	B-SPEC
+at	O
+4	O
+dpi	O
+.	O
+
+TITLE	O
+:	O
+Design	O
+and	O
+synthesis	B-PROC
+of	O
+new	O
+tripeptide	B-PRGE
+-	I-PRGE
+type	I-PRGE
+SARS	B-DISO
+-	I-PRGE
+CoV	I-PRGE
+3CL	I-PRGE
+protease	B-PROC
+inhibitors	I-PROC
+containing	O
+an	O
+electrophilic	O
+arylketone	O
+moiety	O
+.	O
+
+TITLE	O
+:	O
+Bovine	B-SPEC
+coronaviruses	O
+from	O
+the	O
+respiratory	B-ANAT
+tract	I-ANAT
+:	O
+antigenic	O
+and	O
+genetic	O
+diversity	O
+.	O
+
+Forty	O
+-	O
+one	O
+percent	O
+were	O
+viral	O
+coinfections	B-DISO
+,	O
+which	O
+were	O
+significantly	O
+younger	O
+than	O
+virus	B-SPEC
+negative	O
+patients	O
+,	O
+had	O
+a	O
+higher	O
+leukocyte	B-ANAT
+count	O
+and	O
+were	O
+hospitalized	O
+for	O
+a	O
+longer	O
+time	O
+.	O
+
+This	O
+vaccine	O
+is	O
+comprised	O
+of	O
+a	O
+recombinant	B-PRGE
+receptor	I-PRGE
+-	I-PRGE
+binding	I-PRGE
+domain	I-PRGE
+(	O
+RBD	O
+)	O
+of	O
+the	O
+SARS	B-PRGE
+-	I-PRGE
+CoV	I-PRGE
+spike	I-PRGE
+(	I-PRGE
+S	I-PRGE
+)	I-PRGE
+protein	B-CHED
+and	O
+formulated	O
+on	O
+alum	O
+,	O
+together	O
+with	O
+a	O
+synthetic	O
+glucopyranosyl	O
+lipid	B-CHED
+A	I-CHED
+.	O
+The	O
+vaccine	O
+would	O
+induce	O
+neutralizing	O
+antibodies	B-COMP
+without	O
+causing	O
+Th2	O
+-	O
+type	O
+immunopathology	B-DISO
+.	O
+
+A	O
+step	O
+-	O
+wise	O
+RM	O
+and	O
+decremental	O
+PEEP	B-CHED
+trial	O
+were	O
+performed	O
+.	O
+
+A	O
+>	O
+25	O
+%	O
+improvement	O
+in	O
+lung	B-PROC
+function	I-PROC
+(	O
+Cdyn	O
+or	O
+PaO2	O
+/	O
+FIO2	O
+)	O
+was	O
+observed	O
+after	O
+90	O
+%	O
+of	O
+the	O
+RM	O
+procedures	O
+.	O
+
+Gas	B-PRGE
+exchange	O
+worsening	O
+over	O
+the	O
+next	O
+24	O
+hr	O
+resulted	O
+in	O
+HFOV	O
+use	O
+in	O
+36	O
+%	O
+of	O
+patients	O
+,	O
+while	O
+the	O
+remaining	O
+subjects	O
+sustained	O
+improvements	O
+in	O
+oxygenation	B-PROC
+at	O
+12	O
+and	O
+24	O
+hr	O
+.	O
+
+TITLE	O
+:	O
+Mechanical	O
+ventilation	O
+and	O
+intra	B-DISO
+-	I-DISO
+abdominal	I-DISO
+hypertension	I-DISO
+:	O
+'	O
+Beyond	O
+Good	O
+and	O
+Evil	O
+'.	O
+
+In	O
+the	O
+presence	O
+of	O
+alveolar	B-ANAT
+capillary	B-ANAT
+damage	O
+,	O
+which	O
+occurs	O
+in	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+(	O
+ARDS	B-DISO
+),	O
+intra	B-DISO
+-	I-DISO
+abdominal	I-DISO
+hypertension	I-DISO
+promotes	O
+lung	B-ANAT
+injury	O
+as	O
+well	O
+as	O
+edema	B-DISO
+,	O
+impedes	O
+the	O
+pulmonary	B-ANAT
+lymphatic	B-ANAT
+drainage	B-ANAT
+,	O
+and	O
+increases	O
+intra	O
+-	O
+thoracic	B-DISO
+pressures	O
+,	O
+leading	O
+to	O
+atelectasis	B-DISO
+,	O
+airway	B-ANAT
+closure	O
+,	O
+and	O
+deterioration	O
+of	O
+respiratory	B-PROC
+mechanics	I-PROC
+and	O
+gas	B-ENZY
+exchange	O
+.	O
+
+TITLE	O
+:	O
+Comparative	O
+analysis	O
+of	O
+bat	B-ENZY
+genomes	O
+provides	O
+insight	O
+into	O
+the	O
+evolution	B-PROC
+of	O
+flight	B-PROC
+and	O
+immunity	B-PROC
+.	O
+
+KIOM	O
+198	O
+and	O
+KIOM	O
+124	O
+were	O
+identified	O
+as	O
+Epimedium	B-SPEC
+koreanum	I-SPEC
+Nakai	I-SPEC
+and	O
+Lonicera	B-SPEC
+japonica	I-SPEC
+Thunberg	O
+,	O
+respectively	O
+.	O
+
+TITLE	O
+:	O
+Multiplex	O
+nested	O
+RT	O
+-	O
+PCR	O
+for	O
+detecting	O
+avian	B-SPEC
+influenza	I-SPEC
+virus	I-SPEC
+,	O
+infectious	B-DISO
+bronchitis	B-DISO
+virus	B-SPEC
+and	O
+Newcastle	O
+disease	O
+virus	O
+.	O
+
+The	O
+delicate	O
+balance	B-PROC
+of	O
+multiple	O
+effects	O
+of	O
+DN	O
+T	B-ANAT
+cells	I-ANAT
+may	O
+lead	O
+to	O
+viral	O
+persistence	O
+in	O
+MHV	B-SPEC
+-	O
+3	O
+induced	O
+hepatitis	B-DISO
+.	O
+
+In	O
+short	O
+,	O
+our	O
+study	O
+identified	O
+DN	O
+T	B-ANAT
+cells	I-ANAT
+contributing	O
+to	O
+viral	O
+persistence	O
+in	O
+MHV	B-SPEC
+-	O
+3	O
+induced	O
+hepatitis	B-DISO
+in	O
+C3H	O
+/	O
+HeJ	O
+mice	O
+,	O
+which	O
+provides	O
+a	O
+rationale	O
+for	O
+modulating	O
+DN	O
+T	B-ANAT
+cells	I-ANAT
+for	O
+the	O
+management	O
+of	O
+viral	B-DISO
+hepatitis	I-DISO
+.	O
+
+We	O
+searched	O
+PubMed	O
+for	O
+references	O
+to	O
+""""	O
+permissive	O
+hypoxemia	O
+/	O
+hypoxaemia	O
+""""	O
+and	O
+""""	O
+precise	O
+control	O
+of	O
+arterial	B-ANAT
+oxygenation	B-PROC
+""""	O
+as	O
+well	O
+as	O
+reference	O
+to	O
+""""	O
+profound	O
+hypoxemia	O
+/	O
+hypoxaemia	O
+/	O
+hypoxia	B-DISO
+","""	O
+""""	O
+severe	O
+hypoxemia	O
+/	O
+hypoxaemia	O
+/	O
+hypoxia	B-DISO
+.	O
+
+Incorporation	O
+of	O
+in	O
+situ	O
+soft	O
+X	O
+-	O
+ray	B-SPEC
+irradiation	O
+at	O
+low	O
+-	O
+intensity	O
+corona	B-CHED
+conditions	O
+resulted	O
+in	O
+(	O
+i	O
+)	O
+2	O
+-	O
+fold	O
+to	O
+9	O
+-	O
+fold	O
+increase	O
+in	O
+capture	O
+efficiency	O
+of	O
+200	O
+-	O
+to	O
+600	O
+-	O
+nm	O
+particles	O
+and	O
+(	O
+ii	O
+)	O
+a	O
+considerable	O
+delay	O
+in	O
+the	O
+mean	O
+day	O
+of	O
+death	B-PROC
+as	O
+well	O
+as	O
+lower	O
+overall	O
+mortality	O
+rates	O
+in	O
+ectromelia	B-SPEC
+virus	I-SPEC
+(	O
+ECTV	O
+)	O
+cohorts	O
+.	O
+
+TITLE	O
+:	O
+Bats	B-SPEC
+and	O
+their	O
+virome	O
+:	O
+an	O
+important	O
+source	O
+of	O
+emerging	O
+viruses	B-SPEC
+capable	O
+of	O
+infecting	O
+humans	B-SPEC
+.	O
+
+C	O
+(	O
+57	O
+)	O
+BL	O
+/	O
+6	O
+mice	B-SPEC
+were	O
+randomly	O
+assigned	O
+to	O
+control	O
+group	O
+,	O
+high	O
+-	O
+fat	O
+diet	O
+group	O
+,	O
+mouse	B-DISO
+hepatitis	I-DISO
+virus	B-SPEC
+strain	O
+A59	O
+(	O
+MHV	B-SPEC
+-	O
+A59	O
+)	O
+virus	B-DISO
+infection	I-DISO
+group	O
+,	O
+and	O
+high	O
+-	O
+fat	O
+diet	O
+plus	O
+virus	B-DISO
+infection	I-DISO
+group	O
+.	O
+
+This	O
+amino	B-CHED
+acid	I-CHED
+constitutes	O
+a	O
+neutralization	O
+epitope	B-CHED
+of	O
+BCoV	O
+,	O
+which	O
+is	O
+distinct	O
+from	O
+aa	O
+528	O
+of	O
+the	O
+Quebec	O
+strain	O
+.	O
+
+Therefore	O
+,	O
+PEDV	B-SPEC
+exhibits	O
+rapid	O
+variation	O
+and	O
+genetic	O
+evolution	B-PROC
+,	O
+and	O
+the	O
+currently	O
+prevailing	O
+PEDV	B-SPEC
+strains	O
+in	O
+central	O
+China	O
+are	O
+a	O
+new	O
+genotype	O
+.	O
+
+Infection	B-DISO
+of	O
+wild	O
+-	O
+type	O
+mice	B-SPEC
+with	O
+rJ2	O
+.	O
+2	O
+results	O
+in	O
+mild	O
+acute	O
+encephalitis	B-DISO
+,	O
+followed	O
+by	O
+a	O
+nonlethal	O
+,	O
+chronic	O
+demyelinating	B-DISO
+disease	I-DISO
+.	O
+
+Proinflammatory	O
+innate	O
+and	O
+adaptive	B-PROC
+immune	I-PROC
+responses	I-PROC
+mediate	O
+virus	B-SPEC
+clearance	O
+.	O
+
+TITLE	O
+:	O
+Structure	O
+of	O
+alphacoronavirus	B-SPEC
+transmissible	O
+gastroenteritis	B-DISO
+virus	B-SPEC
+nsp1	B-PRGE
+has	O
+implications	O
+for	O
+coronavirus	B-SPEC
+nsp1	B-PRGE
+function	O
+and	O
+evolution	B-PROC
+.	O
+
+Here	O
+we	O
+present	O
+the	O
+first	O
+nsp1	B-PRGE
+structure	I-PRGE
+from	O
+an	O
+alphacoronavirus	B-SPEC
+,	O
+transmissible	O
+gastroenteritis	B-DISO
+virus	B-SPEC
+(	O
+TGEV	B-SPEC
+)	O
+nsp1	B-PRGE
+.	O
+
+Contrary	O
+to	O
+previous	O
+speculation	O
+,	O
+the	O
+TGEV	B-PRGE
+nsp1	I-PRGE
+structure	O
+suggests	O
+that	O
+coronavirus	B-SPEC
+nsp1s	O
+have	O
+a	O
+common	O
+origin	O
+,	O
+despite	O
+the	O
+lack	O
+of	O
+sequence	O
+homology	O
+.	O
+
+However	O
+,	O
+comparisons	O
+of	O
+surface	O
+electrostatics	O
+,	O
+shape	O
+,	O
+and	O
+amino	O
+acid	O
+conservation	O
+between	O
+the	O
+alpha	O
+-	O
+and	O
+betacoronaviruses	O
+lead	O
+us	O
+to	O
+speculate	O
+that	O
+the	O
+mechanism	O
+for	O
+nsp1	B-PRGE
+-	O
+induced	O
+suppression	B-DISO
+of	O
+host	B-COMP
+gene	B-PROC
+expression	I-PROC
+might	O
+be	O
+different	O
+in	O
+these	O
+two	O
+genera	O
+.	O
+
+ABSTRACT	O
+:	O
+The	O
+FilmArray	O
+respiratory	O
+virus	B-SPEC
+panel	O
+detects	O
+15	O
+viral	O
+agents	O
+in	O
+respiratory	O
+specimens	O
+using	O
+polymerase	O
+chain	O
+reaction	O
+.	O
+
+By	O
+the	O
+early	O
+1970s	O
+P	O
+(	O
+aO	O
+(	O
+2	O
+))	O
+had	O
+become	O
+the	O
+gold	B-CHED
+standard	O
+for	O
+clinically	O
+assessing	O
+oxygenation	B-PROC
+in	O
+the	O
+body	B-ANAT
+.	O
+
+ABSTRACT	O
+:	O
+The	O
+non	O
+—	O
+structural	O
+protein	B-CHED
+13	O
+(	O
+nsp13	O
+)	O
+of	O
+Severe	B-DISO
+Acute	I-DISO
+Respiratory	I-DISO
+Syndrome	I-DISO
+Coronavirus	B-SPEC
+(	O
+SARS	O
+—	O
+CoV	O
+)	O
+is	O
+a	O
+helicase	B-PRGE
+that	O
+separates	O
+double	O
+—	O
+stranded	O
+RNA	O
+or	O
+DNA	O
+with	O
+a	O
+5	O
+'—	O
+3	O
+'	O
+polarity	O
+,	O
+using	O
+the	O
+energy	O
+of	O
+nucleotide	B-CHED
+hydrolysis	O
+.	O
+
+GST	B-PRGE
+—	I-PRGE
+nsp13	I-PRGE
+showed	O
+much	O
+more	O
+efficient	O
+nucleic	B-CHED
+acid	I-CHED
+unwinding	O
+than	O
+the	O
+H6	O
+—	O
+tagged	O
+counterpart	O
+.	O
+
+We	O
+uncovered	O
+RNA	O
+dimerization	O
+through	O
+a	O
+palindromic	O
+sequence	O
+embedded	O
+in	O
+the	O
+SARS	B-PRGE
+-	I-PRGE
+CoV	I-PRGE
+Stem	B-ANAT
+3	I-PRGE
+.	O
+
+The	O
+median	O
+duration	O
+of	O
+the	O
+ECMO	O
+runs	O
+was	O
+215	O
+(	O
+1	O
+-	O
+578	O
+)	O
+h	O
+.	O
+Ninety	O
+-	O
+seven	O
+(	O
+78	O
+%)	O
+of	O
+the	O
+patients	O
+could	O
+be	O
+weaned	B-PROC
+from	O
+ECMO	O
+.	O
+
+High	O
+SAPS	B-PRGE
+-	I-PRGE
+II	I-PRGE
+,	O
+SOFA	O
+and	O
+Murray	O
+scores	O
+were	O
+associated	O
+with	O
+a	O
+high	O
+mortality	O
+.	O
+
+The	O
+pathogenesis	B-DISO
+of	O
+five	O
+geographically	O
+unrelated	O
+canine	O
+respiratory	O
+coronavirus	B-SPEC
+(	O
+CRCoV	O
+)	O
+isolates	O
+was	O
+investigated	O
+.	O
+
+Following	O
+experimental	O
+infection	B-DISO
+in	O
+dogs	B-SPEC
+,	O
+all	O
+five	O
+CRCoV	O
+isolates	O
+gave	O
+rise	O
+to	O
+clinical	O
+signs	O
+of	O
+respiratory	B-DISO
+disease	I-DISO
+consistent	O
+with	O
+that	O
+observed	O
+during	O
+natural	O
+infection	B-DISO
+.	O
+
+ABSTRACT	O
+:	O
+Conditional	O
+ligands	O
+have	O
+enabled	O
+the	O
+high	O
+-	O
+throughput	O
+production	O
+of	O
+human	B-PRGE
+leukocyte	B-ANAT
+antigen	B-CHED
+(	O
+HLA	B-PRGE
+)	O
+libraries	O
+that	O
+present	O
+defined	O
+peptides	B-CHED
+.	O
+
+Unique	O
+ligands	O
+for	O
+all	O
+16	B-PRGE
+HLA	I-PRGE
+types	O
+were	O
+constructed	O
+to	O
+provide	O
+the	O
+desired	O
+soluble	O
+HLA	B-PRGE
+product	I-PRGE
+in	O
+sufficient	O
+yield	O
+.	O
+
+Main	O
+risk	O
+factors	O
+are	O
+represented	O
+by	O
+tobacco	B-SPEC
+smoking	O
+and	O
+exposure	O
+to	O
+biomass	O
+fuel	B-CHED
+.	O
+
+Smoking	O
+prevention	O
+and	O
+standardized	O
+management	O
+programs	O
+for	O
+asthma	B-PATH
+and	O
+COPD	B-DISO
+are	O
+now	O
+available	O
+but	O
+prompt	O
+actions	O
+are	O
+needed	O
+to	O
+make	O
+them	O
+more	O
+effective	O
+in	O
+this	O
+region	O
+and	O
+thus	O
+avoid	O
+an	O
+adverse	O
+impact	O
+on	O
+national	O
+economic	O
+development	O
+.	O
+
+Indeed	O
+,	O
+after	O
+transfecting	O
+BHK	O
+-	O
+21	O
+cells	B-COMP
+with	O
+various	O
+cDNA	O
+infectious	B-DISO
+clones	O
+of	O
+HCoV	B-SPEC
+-	I-SPEC
+OC43	I-SPEC
+,	O
+either	O
+lacking	O
+the	O
+HE	B-PRGE
+protein	I-PRGE
+or	O
+bearing	O
+an	O
+HE	O
+protein	O
+with	O
+a	O
+nonfunctional	O
+acetyl	B-PRGE
+-	I-PRGE
+esterase	I-PRGE
+enzymatic	B-PROC
+activity	I-PROC
+,	O
+we	O
+were	O
+reproducibly	O
+unable	O
+to	O
+detect	O
+recombinant	O
+infectious	B-DISO
+viruses	B-SPEC
+compared	O
+to	O
+the	O
+reference	O
+infectious	B-DISO
+HCoV	B-SPEC
+-	I-SPEC
+OC43	I-SPEC
+clone	O
+pBAC	O
+-	O
+OC43	O
+(	O
+FL	O
+).	O
+
+Complementation	O
+experiments	O
+,	O
+using	O
+BHK	O
+-	O
+21	O
+cells	B-COMP
+expressing	O
+wild	O
+-	O
+type	O
+HE	O
+,	O
+either	O
+transiently	O
+or	O
+in	O
+a	O
+stable	O
+ectopic	B-PROC
+expression	I-PROC
+,	O
+demonstrate	O
+that	O
+this	O
+protein	B-CHED
+plays	O
+a	O
+very	O
+significant	O
+role	O
+in	O
+the	O
+production	O
+of	O
+infectious	B-DISO
+recombinant	O
+coronaviral	O
+particles	O
+that	O
+can	O
+subsequently	O
+more	O
+efficiently	O
+infect	O
+susceptible	O
+epithelial	O
+and	O
+neuronal	O
+cells	B-COMP
+.	O
+
+The	O
+proportion	O
+of	O
+subject	O
+swabs	O
+with	O
+multiple	O
+viruses	B-SPEC
+detected	O
+changed	O
+as	O
+respiratory	O
+illnesses	O
+progressed	O
+from	O
+week	O
+to	O
+week	O
+,	O
+as	O
+did	O
+the	O
+prevalence	O
+of	O
+individual	O
+viruses	B-SPEC
+.	O
+
+Children	O
+with	O
+multiple	O
+viruses	B-SPEC
+detected	O
+at	O
+the	O
+time	O
+of	O
+illness	O
+onset	O
+had	O
+less	O
+frequent	O
+fever	B-PROC
+(	O
+odds	O
+ratio	O
+[	O
+OR	O
+],	O
+0	O
+.	O
+56	O
+;	O
+95	O
+%	O
+confidence	O
+interval	O
+[	O
+CI	O
+],	O
+0	O
+.	O
+35	O
+,	O
+0	O
+.	O
+90	O
+),	O
+however	O
+,	O
+these	O
+children	O
+more	O
+often	O
+had	O
+illness	O
+symptoms	O
+lasting	O
+over	O
+7	O
+days	O
+(	O
+OR	O
+,	O
+1	O
+.	O
+94	O
+;	O
+95	O
+%	O
+CI	O
+,	O
+1	O
+.	O
+20	O
+,	O
+3	O
+.	O
+14	O
+).	O
+
+Children	O
+with	O
+multiple	O
+viruses	B-SPEC
+detected	O
+at	O
+the	O
+time	O
+of	O
+illness	O
+onset	O
+had	O
+less	O
+frequent	O
+fever	B-PROC
+(	O
+odds	O
+ratio	O
+[	O
+OR	O
+],	O
+0	O
+.	O
+56	O
+;	O
+95	O
+%	O
+confidence	O
+interval	O
+[	O
+CI	O
+],	O
+0	O
+.	O
+35	O
+,	O
+0	O
+.	O
+90	O
+),	O
+however	O
+,	O
+these	O
+children	O
+more	O
+often	O
+had	O
+illness	O
+symptoms	O
+lasting	O
+over	O
+7	O
+days	O
+(	O
+OR	O
+,	O
+1	O
+.	O
+94	O
+;	O
+95	O
+%	O
+CI	O
+,	O
+1	O
+.	O
+20	O
+,	O
+3	O
+.	O
+14	O
+).	O
+
+ABSTRACT	O
+:	O
+To	O
+summarize	O
+the	O
+experience	O
+of	O
+extracorporeal	O
+membrane	O
+oxygenation	B-PROC
+(	O
+ECMO	O
+)	O
+for	O
+patients	O
+with	O
+severe	O
+acute	B-DISO
+respiratory	I-DISO
+failure	I-DISO
+in	O
+adults	O
+and	O
+to	O
+investigate	O
+the	O
+factors	O
+associated	O
+with	O
+death	B-PROC
+.	O
+
+The	O
+clinical	O
+data	O
+of	O
+patients	O
+with	O
+severe	O
+acute	B-DISO
+respiratory	I-DISO
+failure	I-DISO
+supported	O
+with	O
+ECMO	O
+in	O
+respiratory	O
+intensive	O
+care	O
+unit	O
+of	O
+Beijing	O
+Chaoyang	O
+Hospital	O
+from	O
+November	O
+2009	O
+to	O
+December	O
+2011	O
+were	O
+prospectively	O
+collected	O
+and	O
+analyzed	O
+.	O
+
+Twenty	O
+-	O
+five	O
+patients	O
+with	O
+severe	O
+respiratory	B-DISO
+failure	I-DISO
+received	O
+ECMO	O
+treatment	O
+,	O
+of	O
+which	O
+16	O
+patients	O
+were	O
+analyzed	O
+.	O
+
+The	O
+mean	O
+PaO2	O
+/	O
+fraction	O
+of	O
+inspired	B-PROC
+oxygenation	B-PROC
+(	O
+FiO2	O
+)	O
+ratio	O
+was	O
+(	O
+54	O
+±	O
+18	O
+)	O
+mm	O
+Hg	O
+(	O
+1	O
+mm	O
+Hg	O
+=	O
+0	O
+.	O
+133	O
+kPa	O
+),	O
+positive	O
+end	B-PROC
+-	I-PROC
+expiratory	I-PROC
+pressure	O
+(	O
+PEEP	B-CHED
+)	O
+was	O
+(	O
+11	O
+±	O
+6	O
+)	O
+cm	O
+H2O	B-CHED
+(	O
+1	O
+cm	O
+H2O	B-CHED
+=	O
+0	O
+.	O
+098	O
+kPa	O
+),	O
+Murray	O
+lung	B-ANAT
+injury	O
+score	O
+was	O
+3	O
+.	O
+6	O
+±	O
+0	O
+.	O
+5	O
+,	O
+serum	B-COMP
+lactate	B-CHED
+was	O
+(	O
+2	O
+.	O
+5	O
+±	O
+2	O
+.	O
+0	O
+)	O
+mmol	O
+/	O
+L	O
+,	O
+serum	B-COMP
+white	B-ANAT
+blood	I-ANAT
+cell	I-ANAT
+count	O
+was	O
+(	O
+16	O
+±	O
+6	O
+)×	O
+10	O
+(	O
+9	O
+)/	O
+L	O
+,	O
+and	O
+APACHEII	O
+score	O
+was	O
+17	O
+±	O
+8	O
+.	O
+
+PaO2	O
+/	O
+FiO2	O
+and	O
+white	B-ANAT
+blood	I-ANAT
+cell	I-ANAT
+count	O
+pre	O
+-	O
+ECMO	O
+may	O
+be	O
+the	O
+risk	O
+factors	O
+for	O
+poor	O
+outcome	O
+.	O
+
+Patients	O
+had	O
+severe	O
+respiratory	B-DISO
+failure	I-DISO
+despite	O
+advanced	O
+mechanical	O
+ventilator	O
+support	O
+.	O
+
+Twenty	O
+-	O
+five	O
+adult	O
+patients	O
+with	O
+severe	O
+ARDS	B-DISO
+admitted	O
+to	O
+Intensive	O
+Care	O
+Unit	O
+of	O
+Wuxi	O
+People	O
+'	O
+s	O
+Hospital	O
+from	O
+January	O
+2008	O
+to	O
+June	O
+2011	O
+were	O
+retrospectively	O
+studied	O
+.	O
+
+All	O
+the	O
+cases	O
+met	B-CHED
+the	O
+ECMO	O
+criteria	O
+.	O
+
+In	O
+survivor	O
+group	O
+,	O
+serum	B-COMP
+lactate	B-CHED
+levels	O
+and	O
+norepinephrin	O
+doses	O
+decreased	O
+significantly	O
+(	O
+t	O
+=	O
+4	O
+.	O
+679	O
+-	O
+23	O
+.	O
+397	O
+,	O
+all	O
+P	O
+<	O
+0	O
+.	O
+05	O
+),	O
+while	O
+the	O
+serum	B-COMP
+lactate	B-CHED
+levels	O
+and	O
+norepinephrin	O
+doses	O
+increased	O
+in	O
+non	O
+-	O
+survivor	O
+group	O
+(	O
+t	O
+=	O
+4	O
+.	O
+325	O
+-	O
+29	O
+.	O
+729	O
+,	O
+all	O
+P	O
+<	O
+0	O
+.	O
+05	O
+).	O
+
+Mean	O
+artery	B-ANAT
+pressure	O
+(	O
+mAP	O
+)	O
+increased	O
+gradually	O
+(	O
+P	O
+<	O
+0	O
+.	O
+05	O
+)	O
+in	O
+the	O
+hemofiltration	O
+group	O
+than	O
+in	O
+the	O
+control	O
+group	O
+.	O
+
+It	O
+may	O
+become	O
+one	O
+of	O
+the	O
+important	O
+therapies	O
+for	O
+SAP	B-PRGE
+.	O
+
+We	O
+also	O
+noted	O
+respiratory	B-DISO
+distress	I-DISO
+(	O
+3	O
+/	O
+10	O
+),	O
+cardiac	B-DISO
+arrhythmia	I-DISO
+(	O
+4	O
+/	O
+10	O
+),	O
+hyperkaleamia	O
+,	O
+impaired	B-DISO
+renal	I-DISO
+function	I-DISO
+(	O
+2	O
+/	O
+10	O
+),	O
+hepatic	B-ANAT
+toxicity	O
+(	O
+1	O
+/	O
+10	O
+)	O
+and	O
+altered	B-DISO
+consciousness	I-DISO
+(	O
+3	O
+/	O
+10	O
+).	O
+
+ABSTRACT	O
+:	O
+This	O
+study	O
+was	O
+designed	O
+to	O
+optimize	O
+the	O
+latest	O
+generation	O
+venovenous	O
+(	O
+vv	O
+)-	O
+extracorporeal	O
+membrane	B-COMP
+oxygenation	B-PROC
+(	O
+ECMO	O
+)-	O
+circuit	O
+configuration	O
+and	O
+settings	O
+based	O
+on	O
+the	O
+evaluation	O
+of	O
+blood	B-ANAT
+oxygenation	B-PROC
+and	O
+CO2	B-CHED
+removal	O
+determinants	O
+in	O
+patients	O
+with	O
+severe	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+(	O
+ARDS	B-DISO
+)	O
+on	O
+ultraprotective	O
+mechanical	O
+ventilation	O
+.	O
+
+TITLE	O
+:	O
+The	O
+new	O
+age	O
+of	O
+virus	B-SPEC
+discovery	O
+:	O
+genomic	O
+analysis	O
+of	O
+a	O
+novel	O
+human	B-SPEC
+betacoronavirus	B-SPEC
+isolated	O
+from	O
+a	O
+fatal	O
+case	O
+of	O
+pneumonia	O
+.	O
+
+ABSTRACT	O
+:	O
+A	O
+new	O
+human	B-SPEC
+betacoronavirus	B-SPEC
+in	O
+lineage	O
+c	O
+,	O
+tentatively	O
+called	O
+HCoV	O
+-	O
+EMC	B-COMP
+,	O
+was	O
+isolated	O
+from	O
+a	O
+patient	O
+from	O
+the	O
+Kingdom	B-SPEC
+of	O
+Saudi	O
+Arabia	O
+who	O
+died	B-PROC
+from	O
+acute	O
+severe	O
+pneumonia	B-DISO
+and	O
+renal	B-DISO
+failure	I-DISO
+.	O
+
+A	O
+positive	O
+RT	O
+-	O
+PCR	O
+for	O
+currently	O
+epidemic	O
+respiratory	O
+viruses	B-SPEC
+should	O
+not	O
+be	O
+used	O
+as	O
+an	O
+evidence	O
+against	O
+the	O
+diagnosis	O
+of	O
+KD	O
+.	O
+
+Moreover	O
+,	O
+the	O
+few	O
+ASC	O
+recruited	O
+to	O
+the	O
+CNS	B-CHED
+in	O
+CXCL10	O
+(-/-)	O
+mice	B-SPEC
+were	O
+confined	O
+to	O
+the	O
+vasculature	B-ANAT
+,	O
+distinct	O
+from	O
+the	O
+parenchymal	O
+localization	B-PROC
+in	O
+wild	O
+-	O
+type	O
+and	O
+CXCL9	O
+(-/-)	O
+mice	O
+.	O
+
+TITLE	O
+:	O
+Solution	O
+structure	O
+of	O
+mouse	B-DISO
+hepatitis	I-DISO
+virus	B-SPEC
+(	O
+MHV	B-SPEC
+)	O
+nsp3a	O
+and	O
+determinants	O
+of	O
+the	O
+interaction	O
+with	O
+MHV	O
+nucleocapsid	B-COMP
+(	O
+N	O
+)	O
+protein	B-CHED
+.	O
+
+ABSTRACT	O
+:	O
+Coronaviruses	O
+(	O
+CoVs	O
+)	O
+are	O
+positive	O
+-	O
+sense	B-PROC
+,	O
+single	O
+-	O
+stranded	O
+,	O
+enveloped	O
+RNA	O
+viruses	B-SPEC
+that	O
+infect	O
+a	O
+variety	O
+of	O
+vertebrate	B-SPEC
+hosts	B-COMP
+.	O
+
+Seventy	O
+-	O
+nine	O
+patients	O
+were	O
+enrolled	O
+after	O
+a	O
+'	O
+stabilization	O
+period	O
+'	O
+(	O
+24	O
+h	O
+with	O
+optimized	O
+therapy	O
+and	O
+high	O
+PEEP	B-CHED
+).	O
+
+The	O
+use	O
+of	O
+very	O
+low	O
+V	O
+(	O
+T	O
+)	O
+combined	O
+with	O
+extracorporeal	O
+CO2	B-CHED
+removal	O
+has	O
+the	O
+potential	O
+to	O
+further	O
+reduce	O
+VILI	O
+compared	O
+with	O
+a	O
+'	O
+normal	O
+'	O
+lung	B-ANAT
+protective	O
+management	O
+.	O
+
+TITLE	O
+:	O
+The	O
+role	O
+of	O
+viral	O
+population	O
+diversity	O
+in	O
+adaptation	B-PROC
+of	O
+bovine	B-SPEC
+coronavirus	B-SPEC
+to	O
+new	O
+host	B-COMP
+environments	O
+.	O
+
+Multiple	O
+new	O
+coronaviruses	O
+,	O
+including	O
+SARS	B-DISO
+,	O
+have	O
+been	O
+identified	O
+in	O
+human	B-SPEC
+samples	O
+just	O
+within	O
+the	O
+last	O
+ten	O
+years	O
+,	O
+demonstrating	O
+the	O
+potential	O
+of	O
+coronaviruses	O
+as	O
+emergent	O
+human	B-SPEC
+pathogens	O
+.	O
+
+Deep	O
+sequencing	O
+was	O
+used	O
+to	O
+characterize	O
+genomic	O
+changes	O
+in	O
+coronavirus	B-SPEC
+quasispecies	O
+during	O
+simulated	O
+host	B-COMP
+-	O
+switching	O
+.	O
+
+Three	O
+bovine	B-SPEC
+nasal	B-ANAT
+samples	O
+infected	O
+with	O
+bovine	B-SPEC
+coronavirus	B-SPEC
+were	O
+used	O
+to	O
+infect	O
+human	B-SPEC
+and	O
+bovine	B-SPEC
+macrophage	B-ANAT
+and	O
+lung	B-ANAT
+cell	B-ANAT
+lines	I-ANAT
+.	O
+
+The	O
+insert	O
+coded	O
+for	O
+three	O
+arginine	B-CHED
+residues	O
+,	O
+occurred	O
+in	O
+a	O
+region	O
+associated	O
+with	O
+fusion	O
+entry	B-PROC
+into	I-PROC
+host	I-PROC
+cells	B-COMP
+,	O
+and	O
+may	O
+allow	O
+infection	B-DISO
+of	O
+new	O
+cell	B-COMP
+types	O
+via	O
+heparin	B-CHED
+sulfate	I-CHED
+binding	O
+.	O
+
+ABSTRACT	O
+:	O
+By	O
+using	O
+a	O
+fragment	O
+-	O
+assembly	O
+strategy	O
+and	O
+bioisosteric	O
+-	O
+replacement	O
+principle	O
+,	O
+a	O
+series	O
+of	O
+novel	O
+piperazine	O
+derivatives	O
+were	O
+designed	O
+,	O
+synthesized	O
+,	O
+and	O
+evaluated	O
+for	O
+their	O
+cellular	B-COMP
+target	O
+-	O
+effector	B-CHED
+fusion	O
+activities	O
+and	O
+in	O
+vitro	O
+antiviral	B-CHED
+activities	O
+against	O
+HIV	B-SPEC
+-	I-SPEC
+1	I-SPEC
+.	O
+
+Preliminary	O
+structure	O
+-	O
+activity	O
+relationships	O
+(	O
+SARs	B-DISO
+)	O
+of	O
+target	O
+compounds	O
+were	O
+concluded	O
+in	O
+this	O
+study	O
+,	O
+and	O
+five	O
+compounds	O
+were	O
+found	O
+to	O
+exhibited	O
+medium	O
+to	O
+potent	O
+CCR5	B-PRGE
+fusion	O
+activities	O
+with	O
+IC	O
+(	O
+50	O
+)	O
+values	O
+in	O
+low	O
+micromolar	O
+level	O
+.	O
+
+To	O
+determine	O
+the	O
+occurrence	O
+of	O
+refeeding	B-DISO
+syndrome	I-DISO
+in	O
+adults	O
+commenced	O
+on	O
+artificial	O
+nutrition	B-PROC
+support	O
+.	O
+
+Tertiary	O
+outcome	O
+:	O
+mortality	O
+due	O
+to	O
+refeeding	B-DISO
+syndrome	I-DISO
+and	O
+all	O
+-	O
+cause	O
+mortality	O
+.	O
+
+This	O
+prospective	O
+cohort	O
+study	O
+included	O
+children	O
+hospitalized	O
+with	O
+SARI	O
+(	O
+according	O
+to	O
+the	O
+World	O
+Health	O
+Organization	O
+definition	O
+)	O
+and	O
+whose	O
+laboratory	O
+results	O
+proved	O
+RSV	B-DISO
+infection	I-DISO
+during	O
+the	O
+period	O
+from	O
+February	O
+2010	O
+to	O
+May	O
+2011	O
+.	O
+
+Early	O
+recognition	O
+of	O
+risk	O
+factors	O
+for	O
+complicated	O
+RSV	B-SPEC
+disease	O
+on	O
+admission	O
+prompts	O
+early	O
+interventions	O
+and	O
+early	O
+ICU	O
+admissions	O
+for	O
+these	O
+children	O
+.	O
+
+After	O
+a	O
+long	O
+period	O
+of	O
+very	O
+severe	O
+respiratory	O
+impairment	B-DISO
+,	O
+the	O
+evolution	B-PROC
+was	O
+progressively	O
+favourable	O
+and	O
+the	O
+patient	O
+was	O
+discharged	O
+from	O
+ICU	O
+with	O
+full	O
+respiratory	O
+recovery	O
+43	O
+days	O
+after	O
+admission	O
+.	O
+
+Polymorphonuclear	O
+leucocytes	B-ANAT
+(	O
+PMNs	O
+)	O
+are	O
+activated	O
+after	O
+trauma	O
+and	O
+there	O
+is	O
+substantial	O
+evidence	O
+of	O
+their	O
+involvement	O
+in	O
+the	O
+development	B-PROC
+of	O
+ARDS	B-DISO
+.	O
+
+We	O
+found	O
+,	O
+however	O
+,	O
+a	O
+correlation	O
+between	O
+HBP	B-DISO
+levels	O
+and	O
+development	B-PROC
+of	O
+ARDS	B-DISO
+(	O
+P	O
+=	O
+0	O
+.	O
+026	O
+,	O
+n	O
+=	O
+47	O
+),	O
+but	O
+not	O
+to	O
+severe	B-DISO
+sepsis	I-DISO
+.	O
+
+HBP	B-DISO
+is	O
+a	O
+potential	O
+biomarker	B-CHED
+candidate	O
+for	O
+early	O
+detection	O
+of	O
+ARDS	B-DISO
+development	B-PROC
+after	O
+trauma	O
+.	O
+
+CONCLUSIONS	O
+:	O
+HBP	B-DISO
+is	O
+a	O
+potential	O
+biomarker	B-CHED
+candidate	O
+for	O
+early	O
+detection	O
+of	O
+ARDS	B-DISO
+development	B-PROC
+after	O
+trauma	O
+.	O
+
+Identification	O
+of	O
+the	O
+receptor	O
+will	O
+provide	O
+insight	O
+into	O
+the	O
+pathogenesis	O
+of	O
+pulmonary	B-ANAT
+and	O
+renal	B-DISO
+disease	I-DISO
+and	O
+may	O
+also	O
+suggest	O
+novel	O
+therapeutic	O
+interventions	O
+.	O
+
+TITLE	O
+:	O
+Activation	O
+of	O
+the	O
+heat	B-PROC
+shock	I-PROC
+response	I-PROC
+attenuates	O
+the	O
+interleukin	B-PRGE
+1β	I-PRGE
+-	O
+mediated	O
+inhibition	B-PROC
+of	O
+the	O
+amiloride	O
+-	O
+sensitive	O
+alveolar	B-ANAT
+epithelial	O
+ion	B-PROC
+transport	I-PROC
+.	O
+
+Further	O
+analysis	O
+demonstrates	O
+prolonged	O
+preservation	O
+of	O
+αENaC	O
+expression	B-PROC
+by	O
+the	O
+activation	O
+of	O
+the	O
+heat	B-PROC
+shock	I-PROC
+response	I-PROC
+that	O
+involves	O
+inducible	O
+Hsp70	B-PRGE
+.	O
+
+We	O
+did	O
+this	O
+study	O
+to	O
+find	O
+the	O
+clinical	O
+characteristics	O
+and	O
+risk	O
+factors	O
+associated	O
+with	O
+severe	O
+adenovirus	B-DISO
+infection	I-DISO
+.	O
+
+The	O
+clinical	O
+diagnosis	O
+included	O
+pneumonia	B-DISO
+in	O
+40	O
+(	O
+89	O
+%)	O
+patients	O
+,	O
+bronchopneumonia	B-DISO
+in	O
+5	O
+(	O
+11	O
+%),	O
+and	O
+encephalitis	B-DISO
+in	O
+7	O
+(	O
+16	O
+%).	O
+
+ABSTRACT	O
+:	O
+The	O
+role	O
+of	O
+nitric	B-PRGE
+oxide	I-PRGE
+synthase	I-PRGE
+(	O
+NOS	B-PRGE
+)	O
+in	O
+the	O
+pathophysiology	O
+of	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+(	O
+ARDS	B-DISO
+)	O
+is	O
+not	O
+well	O
+understood	O
+.	O
+
+Accumulating	O
+evidence	O
+indicates	O
+that	O
+the	O
+enzymatic	B-PROC
+activity	I-PROC
+of	O
+ACE2	B-PRGE
+has	O
+a	O
+protective	O
+role	O
+in	O
+cardiovascular	B-DISO
+diseases	I-DISO
+.	O
+
+Loss	O
+of	O
+ACE2	B-PRGE
+can	O
+be	O
+detrimental	O
+,	O
+as	O
+it	O
+leads	O
+to	O
+functional	O
+deterioration	O
+of	O
+the	O
+heart	B-ANAT
+and	O
+progression	O
+of	O
+cardiac	B-ANAT
+,	O
+renal	B-ANAT
+,	O
+and	O
+vascular	B-ANAT
+pathologies	O
+.	O
+
+ACE2	B-PRGE
+is	O
+a	O
+multifunctional	O
+enzyme	O
+and	O
+thus	O
+potentially	O
+acts	O
+on	O
+other	O
+vasoactive	O
+peptides	B-CHED
+,	O
+such	O
+as	O
+Apelin	B-PRGE
+,	O
+a	O
+vital	O
+regulator	O
+of	O
+blood	B-PROC
+pressure	I-PROC
+and	O
+myocardium	B-ANAT
+contractility	O
+.	O
+
+TITLE	O
+:	O
+Visualizing	O
+the	O
+autophagy	B-PROC
+pathway	B-PROC
+in	O
+avian	B-SPEC
+cells	B-COMP
+and	O
+its	O
+application	O
+to	O
+studying	O
+infectious	B-DISO
+bronchitis	B-DISO
+virus	B-SPEC
+.	O
+
+Here	O
+we	O
+report	O
+the	O
+cloning	O
+of	O
+avian	B-SPEC
+LC3	O
+paralogs	O
+A	O
+,	O
+B	O
+and	O
+C	O
+from	O
+the	O
+domestic	O
+chicken	B-SPEC
+,	O
+Gallus	B-PRGE
+gallus	I-PRGE
+domesticus	I-PRGE
+,	O
+and	O
+the	O
+production	O
+of	O
+replication	O
+-	O
+deficient	O
+,	O
+recombinant	O
+adenovirus	B-DISO
+vectors	O
+expressing	O
+these	O
+avian	B-SPEC
+LC3s	O
+tagged	O
+with	O
+EGFP	O
+and	O
+FLAG	B-PRGE
+-	O
+mCherry	O
+.	O
+
+Previous	O
+studies	O
+suggest	O
+that	O
+the	O
+PEDV	B-PRGE
+E	I-PRGE
+protein	B-CHED
+plays	O
+an	O
+important	O
+role	O
+in	O
+the	O
+viral	B-PROC
+assembly	I-PROC
+process	O
+.	O
+
+In	O
+addition	O
+,	O
+the	O
+PEDV	B-PRGE
+E	I-PRGE
+protein	B-CHED
+is	O
+able	O
+to	O
+up	O
+-	O
+regulate	O
+IL	B-FUNC
+-	I-FUNC
+8	I-FUNC
+and	O
+Bcl	B-PRGE
+-	I-PRGE
+2	I-PRGE
+expression	B-PROC
+.	O
+
+TITLE	O
+:	O
+Interferon	B-PRGE
+alpha	I-PRGE
+-	O
+armed	O
+nanoparticles	B-CHED
+trigger	O
+rapid	O
+and	O
+sustained	O
+STAT1	B-PRGE
+-	I-PRGE
+dependent	O
+anti	O
+-	O
+viral	O
+cellular	B-ANAT
+responses	O
+.	O
+
+Notably	O
+,	O
+comprehensive	O
+experimental	O
+approaches	O
+ensure	O
+that	O
+formation	B-PROC
+of	O
+the	O
+IFNα	O
+NP	O
+-	O
+corona	B-CHED
+does	O
+not	O
+affect	O
+the	O
+biological	O
+activity	O
+of	O
+the	O
+cytokine	O
+,	O
+as	O
+STAT1	B-PRGE
+signaling	B-PROC
+was	O
+efficiently	O
+activated	O
+.	O
+
+These	O
+findings	O
+demonstrate	O
+that	O
+the	O
+protein	B-CHED
+sequence	O
+is	O
+not	O
+the	O
+primary	O
+cause	O
+of	O
+altered	O
+genomic	O
+and	O
+subgenomic	O
+RNA	O
+production	O
+.	O
+
+In	O
+adults	O
+with	O
+moderate	O
+-	O
+to	O
+-	O
+severe	O
+ARDS	B-DISO
+,	O
+early	O
+application	O
+of	O
+HFOV	O
+,	O
+as	O
+compared	O
+with	O
+a	O
+ventilation	O
+strategy	O
+of	O
+low	O
+tidal	O
+volume	O
+and	O
+high	O
+positive	O
+end	B-PROC
+-	I-PROC
+expiratory	I-PROC
+pressure	O
+,	O
+does	O
+not	O
+reduce	O
+,	O
+and	O
+may	O
+increase	O
+,	O
+in	O
+-	O
+hospital	O
+mortality	O
+.	O
+
+TITLE	O
+:	O
+[	O
+Systemic	O
+hantavirus	B-SPEC
+-	O
+infection	B-DISO
+in	O
+a	O
+comatose	B-DISO
+HIV	B-DISO
+patient	O
+].	O
+
+Laboratory	O
+analyses	O
+showed	O
+elevated	O
+infection	B-DISO
+parameters	O
+,	O
+azotemia	B-DISO
+,	O
+proteinuria	O
+and	O
+thrombopenia	O
+.	O
+
+An	O
+early	O
+-	O
+goal	O
+-	O
+directed	O
+therapy	O
+and	O
+antibiotic	B-CHED
+treatment	O
+with	O
+Piperacillin	B-CHED
+and	O
+Tazobactam	O
+was	O
+initiated	O
+.	O
+
+Multiplex	O
+reverse	O
+-	O
+transcription	B-PROC
+polymerase	O
+chain	O
+reactions	O
+were	O
+performed	O
+for	O
+rhinovirus	B-SPEC
+,	O
+respiratory	B-SPEC
+syncytial	I-SPEC
+virus	I-SPEC
+(	O
+RSV	B-SPEC
+),	O
+parainfluenza	B-DISO
+viruses	B-SPEC
+(	O
+PIVs	O
+),	O
+adenovirus	B-DISO
+,	O
+human	B-SPEC
+coronavirus	I-SPEC
+(	O
+hCoV	O
+),	O
+influenza	B-SPEC
+viruses	I-SPEC
+and	O
+human	B-SPEC
+metapneumovirus	I-SPEC
+.	O
+
+Respiratory	O
+viral	B-DISO
+infections	I-DISO
+in	O
+pediatric	O
+patients	O
+who	O
+have	O
+undergone	O
+HSCT	O
+are	O
+common	O
+and	O
+are	O
+frequently	O
+acquired	O
+during	O
+hospitalization	O
+.	O
+
+Continuous	O
+monitoring	O
+is	O
+required	O
+to	O
+determine	O
+the	O
+role	O
+of	O
+respiratory	O
+viruses	B-SPEC
+in	O
+immunocompromised	O
+children	O
+and	O
+the	O
+importance	O
+of	O
+preventive	O
+strategies	O
+.	O
+
+Alcohol	O
+-	O
+induced	O
+GSH	B-DISO
+depletion	O
+or	O
+oxidation	B-PROC
+was	O
+associated	O
+with	O
+impaired	B-DISO
+functions	O
+of	O
+alveolar	B-ANAT
+type	O
+II	O
+cells	B-COMP
+and	O
+alveolar	B-ANAT
+macrophages	I-ANAT
+but	O
+could	O
+be	O
+reversed	O
+by	O
+restoring	O
+GSH	B-DISO
+pools	O
+in	O
+the	O
+alveolar	B-ANAT
+lining	O
+fluid	O
+.	O
+
+This	O
+technique	O
+is	O
+also	O
+proposed	O
+for	O
+hypoxemic	O
+respiratory	B-DISO
+failure	I-DISO
+,	O
+with	O
+more	O
+various	O
+results	O
+.	O
+
+These	O
+results	O
+represent	O
+the	O
+most	O
+complete	O
+description	O
+of	O
+human	B-SPEC
+virus	B-SPEC
+diversity	O
+in	O
+any	O
+wastewater	O
+sample	O
+to	O
+date	O
+,	O
+provide	O
+engineers	O
+and	O
+environmental	O
+scientists	O
+with	O
+critical	O
+information	O
+on	O
+important	O
+viral	O
+agents	O
+and	O
+routes	O
+of	O
+infection	B-DISO
+from	O
+exposure	O
+to	O
+wastewater	O
+and	O
+sewage	O
+sludge	B-ANAT
+,	O
+and	O
+represent	O
+a	O
+significant	O
+leap	O
+forward	O
+in	O
+understanding	O
+the	O
+pathogen	O
+content	O
+of	O
+class	B-SPEC
+B	O
+biosolids	O
+.	O
+
+Supplemental	O
+oxygen	B-CHED
+is	O
+often	O
+necessary	O
+in	O
+both	O
+mild	O
+and	O
+severe	O
+lung	B-DISO
+disease	I-DISO
+.	O
+
+We	O
+determined	O
+the	O
+specific	O
+effects	O
+of	O
+myeloid	O
+ADORA2A	O
+,	O
+using	O
+chimera	B-DISO
+experiments	O
+.	O
+
+Chest	B-ANAT
+X	O
+-	O
+ray	B-SPEC
+revealed	O
+diffuse	O
+reticulonodular	O
+shadows	O
+and	O
+high	O
+-	O
+resolution	O
+computed	O
+tomography	O
+showed	O
+randomly	O
+distributed	O
+small	O
+nodules	B-DISO
+.	O
+
+Recommendations	O
+specific	O
+to	O
+pediatric	O
+severe	B-DISO
+sepsis	I-DISO
+include	O
+:	O
+therapy	O
+with	O
+face	B-DISO
+mask	O
+oxygen	B-CHED
+,	O
+high	O
+flow	O
+nasal	B-ANAT
+cannula	B-SPEC
+oxygen	B-CHED
+,	O
+or	O
+nasopharyngeal	B-ANAT
+continuous	O
+PEEP	B-CHED
+in	O
+the	O
+presence	O
+of	O
+respiratory	B-DISO
+distress	I-DISO
+and	O
+hypoxemia	O
+(	O
+2C	O
+),	O
+use	O
+of	O
+physical	O
+examination	O
+therapeutic	O
+endpoints	O
+such	O
+as	O
+capillary	B-PROC
+refill	I-PROC
+(	O
+2C	O
+);	O
+for	O
+septic	B-DISO
+shock	I-DISO
+associated	O
+with	O
+hypovolemia	O
+,	O
+the	O
+use	O
+of	O
+crystalloids	O
+or	O
+albumin	B-PRGE
+to	O
+deliver	O
+a	O
+bolus	O
+of	O
+20	O
+mL	O
+/	O
+kg	O
+of	O
+crystalloids	O
+(	O
+or	O
+albumin	B-PRGE
+equivalent	O
+)	O
+over	O
+5	O
+to	O
+10	O
+mins	O
+(	O
+2C	O
+);	O
+more	O
+common	O
+use	O
+of	O
+inotropes	O
+and	O
+vasodilators	O
+for	O
+low	O
+cardiac	B-ANAT
+output	O
+septic	B-DISO
+shock	I-DISO
+associated	O
+with	O
+elevated	O
+systemic	B-PROC
+vascular	I-PROC
+resistance	I-PROC
+(	O
+2C	O
+);	O
+and	O
+use	O
+of	O
+hydrocortisone	B-CHED
+only	O
+in	O
+children	O
+with	O
+suspected	O
+or	O
+proven	O
+""""	O
+absolute	O
+"""'"	O
+adrenal	B-DISO
+insufficiency	I-DISO
+(	O
+2C	O
+).	O
+
+Sequence	O
+comparisons	O
+demonstrated	O
+that	O
+the	O
+Sczy3	O
+genome	O
+had	O
+the	O
+highest	O
+nt	O
+sequence	O
+identity	O
+with	O
+QX	B-PRGE
+-	I-PRGE
+like	I-PRGE
+IBVs	I-PRGE
+and	O
+was	O
+most	O
+dissimilar	O
+to	O
+the	O
+Massachusetts	O
+type	O
+IBV	B-SPEC
+.	O
+
+Of	O
+nasopharyngeal	B-ANAT
+swabs	O
+or	O
+aspirates	B-ANAT
+and	O
+bronchoalveolar	B-ANAT
+lavage	I-ANAT
+fluid	I-ANAT
+samples	O
+submitted	O
+for	O
+RV15	O
+testing	O
+,	O
+199	O
+retrospectively	O
+collected	O
+positive	O
+specimens	O
+and	O
+283	O
+prospectively	O
+collected	O
+specimens	O
+were	O
+further	O
+tested	O
+with	O
+RV16	O
+and	O
+xTAG	O
+.	O
+
+RV16	O
+was	O
+more	O
+sensitive	O
+than	O
+xTAG	O
+for	O
+coronavirus	O
+OC43	O
+/	O
+HKU1	O
+(	O
+100	O
+%	O
+versus	O
+26	O
+.	O
+1	O
+%;	O
+P	O
+<	O
+0	O
+.	O
+0001	O
+)	O
+and	O
+adenovirus	B-DISO
+(	O
+100	O
+%	O
+versus	O
+79	O
+.	O
+5	O
+%;	O
+P	O
+<	O
+0	O
+.	O
+01	O
+)	O
+but	O
+was	O
+less	O
+sensitive	O
+than	O
+xTAG	O
+for	O
+rhinovirus	B-SPEC
+/	O
+enterovirus	B-SPEC
+(	O
+89	O
+.	O
+4	O
+%	O
+versus	O
+97	O
+.	O
+9	O
+%;	O
+P	O
+<	O
+0	O
+.	O
+05	O
+).	O
+
+However	O
+,	O
+improvement	O
+of	O
+the	O
+sensitivity	O
+for	O
+rhinovirus	B-SPEC
+is	O
+required	O
+.	O
+
+The	O
+objective	O
+of	O
+this	O
+study	O
+was	O
+to	O
+analyze	O
+the	O
+association	O
+between	O
+candidate	O
+gene	O
+polymorphisms	O
+and	O
+susceptibility	O
+to	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+(	O
+ARDS	B-DISO
+)	O
+in	O
+patients	O
+with	O
+severe	B-DISO
+sepsis	I-DISO
+.	O
+
+Results	O
+were	O
+confirmed	O
+by	O
+proteomic	O
+and	O
+chromatin	B-COMP
+immunoprecipitation	O
+assay	O
+analyses	O
+and	O
+in	O
+parallel	O
+microarray	O
+studies	O
+using	O
+infected	O
+primary	O
+human	B-SPEC
+airway	B-ANAT
+epithelial	B-ANAT
+cell	I-ANAT
+cultures	O
+.	O
+
+ABSTRACT	O
+:	O
+Monovalent	O
+antisera	O
+of	O
+3	O
+vaccine	O
+strains	O
+and	O
+7	O
+representative	O
+field	O
+isolates	O
+were	O
+prepared	O
+based	O
+on	O
+the	O
+comparison	O
+of	O
+genetic	O
+diversity	O
+of	O
+the	O
+hypervariable	O
+region	O
+I	O
+of	O
+S1	O
+gene	O
+(	O
+HVR	O
+I	O
+from	O
+3	O
+infectious	B-DISO
+bronchitis	B-DISO
+(	O
+IB	B-DISO
+)	O
+vaccine	O
+strains	O
+(	O
+H120	O
+,	O
+Ma5	O
+and	O
+4	O
+/	O
+91	O
+)	O
+,	O
+one	O
+reference	O
+strain	O
+M41	O
+and	O
+26	O
+IB	B-DISO
+field	O
+isolates	O
+.	O
+
+The	O
+objective	O
+was	O
+to	O
+compare	O
+characteristics	O
+of	O
+hospitalized	O
+pH1N1	O
+patients	O
+with	O
+and	O
+without	O
+asthma	B-PATH
+and	O
+assess	O
+factors	O
+associated	O
+with	O
+severity	O
+among	O
+asthma	B-PATH
+patients	O
+.	O
+
+Influenza	B-DISO
+antiviral	B-CHED
+agents	I-CHED
+should	O
+be	O
+started	O
+early	O
+in	O
+hospitalized	O
+patients	O
+with	O
+suspected	O
+influenza	B-DISO
+,	O
+including	O
+those	O
+with	O
+asthma	B-PATH
+.	O
+
+Using	O
+this	O
+ventilatory	O
+setting	O
+,	O
+patients	O
+in	O
+the	O
+validation	O
+cohort	O
+were	O
+reclassified	O
+as	O
+having	O
+mild	O
+ARDS	B-DISO
+(	O
+n	O
+=	O
+47	O
+,	O
+mortality	O
+17	O
+%),	O
+moderate	O
+ARDS	B-DISO
+(	O
+n	O
+=	O
+149	O
+,	O
+mortality	O
+40	O
+.	O
+9	O
+%),	O
+and	O
+severe	O
+ARDS	B-DISO
+(	O
+n	O
+=	O
+86	O
+,	O
+mortality	O
+58	O
+.	O
+1	O
+%)	O
+(	O
+p	O
+=	O
+0	O
+.	O
+00001	O
+).	O
+
+There	O
+is	O
+consistent	O
+evidence	O
+that	O
+downregulation	B-PROC
+of	O
+systemic	O
+inflammation	B-DISO
+with	O
+prolonged	O
+low	O
+-	O
+dose	O
+glucocorticoid	B-CHED
+treatment	O
+in	O
+patients	O
+with	O
+severe	B-DISO
+sepsis	I-DISO
+and	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+improves	O
+cardiovascular	B-ANAT
+and	O
+pulmonary	B-ANAT
+organ	B-ANAT
+physiology	O
+.	O
+
+The	O
+objective	O
+of	O
+our	O
+study	O
+was	O
+to	O
+assess	O
+the	O
+significance	O
+of	O
+HCoVs	O
+in	O
+the	O
+etiology	O
+of	O
+acute	B-DISO
+gastroenteritis	I-DISO
+(	O
+AGE	O
+)	O
+in	O
+children	O
+<	O
+6	O
+years	O
+of	O
+age	O
+.	O
+
+All	O
+four	O
+HCoVs	O
+species	B-SPEC
+were	O
+detected	O
+in	O
+stool	B-ANAT
+and	O
+NP	O
+samples	O
+.	O
+
+The	O
+number	O
+of	O
+potential	O
+phosphorylation	B-PROC
+sites	O
+in	O
+the	O
+N	O
+protein	B-CHED
+varied	O
+from	O
+5	O
+to	O
+12	O
+.	O
+
+ABSTRACT	O
+:	O
+Corticosteroids	B-CHED
+have	O
+been	O
+widely	O
+administered	O
+in	O
+critically	O
+ill	O
+patients	O
+for	O
+various	O
+indications	O
+.	O
+
+But	O
+use	O
+of	O
+corticosteroids	B-CHED
+carries	O
+the	O
+risk	O
+of	O
+severe	O
+adverse	B-DISO
+effects	I-DISO
+,	O
+partly	O
+because	O
+of	O
+their	O
+anti	O
+-	O
+infammatory	O
+effects	O
+.	O
+
+TITLE	O
+:	O
+Protection	O
+of	O
+chickens	B-SPEC
+against	O
+infectious	B-DISO
+bronchitis	B-DISO
+virus	B-SPEC
+with	O
+a	O
+multivalent	O
+DNA	O
+vaccine	O
+and	O
+boosting	O
+with	O
+an	O
+inactivated	O
+vaccine	O
+.	O
+
+A	O
+prime	O
+-	O
+boost	O
+immunization	O
+protocol	O
+against	O
+IBV	B-SPEC
+was	O
+developed	O
+.	O
+
+The	O
+serum	B-PRGE
+antibody	B-COMP
+titers	O
+in	O
+the	O
+prime	O
+-	O
+boost	O
+birds	B-SPEC
+were	O
+significantly	O
+higher	O
+than	O
+those	O
+of	O
+the	O
+multivalent	O
+DNA	O
+vaccine	O
+group	O
+(	O
+p	O
+<	O
+0	O
+.	O
+01	O
+)	O
+but	O
+not	O
+significantly	O
+different	O
+compared	O
+to	O
+the	O
+inactivated	O
+vaccine	O
+group	O
+at	O
+49	O
+days	O
+of	O
+age	O
+.	O
+
+Since	O
+the	O
+nucleocapsid	B-PRGE
+(	I-PRGE
+N	I-PRGE
+)	I-PRGE
+protein	B-CHED
+is	O
+highly	O
+conserved	O
+,	O
+it	O
+is	O
+a	O
+candidate	O
+protein	B-CHED
+for	O
+early	O
+diagnosis	O
+and	O
+vaccine	O
+development	B-PROC
+.	O
+
+The	O
+nucleotide	B-CHED
+sequences	O
+of	O
+the	O
+N	B-PRGE
+gene	I-PRGE
+of	O
+the	O
+Chinese	O
+PEDV	B-SPEC
+strains	O
+consist	O
+of	O
+1326	O
+nucleotides	B-CHED
+and	O
+encode	O
+a	O
+441	O
+-	O
+aa	O
+-	O
+long	O
+peptide	B-CHED
+.	O
+
+To	O
+obtain	O
+data	O
+that	O
+would	O
+facilitate	O
+this	O
+estimation	O
+,	O
+a	O
+meta	B-SPEC
+-	O
+analysis	O
+was	O
+performed	O
+on	O
+the	O
+data	O
+from	O
+18	O
+infectious	B-DISO
+bronchitis	B-DISO
+virus	B-SPEC
+(	O
+IBV	B-SPEC
+)	O
+vaccination	O
+-	O
+challenge	O
+experiments	O
+performed	O
+at	O
+the	O
+Dutch	O
+Animal	B-SPEC
+Health	O
+Service	O
+Deventer	O
+,	O
+the	O
+Netherlands	O
+(	O
+GD	O
+)	O
+in	O
+order	B-SPEC
+to	O
+determine	O
+and	O
+quantify	O
+the	O
+source	O
+of	O
+variation	O
+in	O
+the	O
+mean	O
+level	O
+of	O
+protection	O
+of	O
+different	O
+groups	O
+.	O
+
+Angiogenic	B-PROC
+factors	O
+and	O
+their	O
+receptors	O
+,	O
+including	O
+vascular	B-PROC
+endothelial	B-ANAT
+growth	B-PROC
+factor	I-PROC
+(	O
+VEGF	B-PROC
+)/	O
+VEGF	B-PRGE
+-	I-PRGE
+receptor	I-PRGE
+(	O
+VEGFR	B-PRGE
+)	O
+and	O
+the	O
+angiopoietin	O
+(	O
+Ang	O
+)/	O
+Tie2	B-PRGE
+signaling	B-PROC
+pathways	B-PROC
+,	O
+play	O
+pivotal	O
+roles	O
+in	O
+both	O
+angiogenesis	B-PROC
+and	O
+microvascular	B-PROC
+permeability	I-PROC
+.	O
+
+TITLE	O
+:	O
+Plasma	B-ANAT
+kallistatin	I-PRGE
+levels	O
+in	O
+patients	O
+with	O
+severe	O
+community	O
+-	O
+acquired	O
+pneumonia	B-DISO
+.	O
+
+Plasma	B-PRGE
+kallistatin	I-PRGE
+,	O
+kallikrein	B-PRGE
+,	O
+and	O
+other	O
+biomarkers	O
+of	O
+inflammation	B-DISO
+(	O
+tumor	B-PRGE
+necrosis	I-PRGE
+factor	I-PRGE
+-	I-PRGE
+α	I-PRGE
+(	O
+TNF	B-PRGE
+-	I-PRGE
+α	I-PRGE
+),	O
+interleukin	B-PRGE
+(	I-PRGE
+IL	I-PRGE
+)-	I-PRGE
+1β	I-PRGE
+,	O
+IL	B-FUNC
+-	I-FUNC
+6	I-FUNC
+,	O
+IL	B-FUNC
+-	I-FUNC
+8	I-FUNC
+,	O
+C	B-PRGE
+-	I-PRGE
+reactive	I-PRGE
+protein	I-PRGE
+(	O
+CRP	B-PRGE
+)),	O
+and	O
+anti	O
+-	O
+coagulation	B-PROC
+(	O
+protein	B-CHED
+C	O
+,	O
+anti	B-PRGE
+-	I-PRGE
+thrombin	I-PRGE
+III	I-PRGE
+)	O
+were	O
+measured	O
+on	O
+days	O
+1	O
+and	O
+4	O
+of	O
+ICU	O
+admission	O
+.	O
+
+TITLE	O
+:	O
+[	O
+Atrial	B-ANAT
+chaotic	O
+tachycardia	O
+during	O
+a	O
+respiratory	B-DISO
+tract	I-DISO
+infection	I-DISO
+due	O
+to	O
+NL63	O
+coronavirus	B-SPEC
+].	O
+
+TITLE	O
+:	O
+Review	O
+of	O
+infectious	B-DISO
+bronchitis	B-DISO
+virus	B-SPEC
+around	O
+the	O
+world	O
+.	O
+
+The	O
+purpose	O
+of	O
+this	O
+review	O
+is	O
+to	O
+give	O
+an	O
+update	O
+on	O
+the	O
+strains	O
+of	O
+IBV	B-SPEC
+currently	O
+circulating	O
+in	O
+commercial	O
+chickens	B-SPEC
+worldwide	O
+and	O
+hopefully	O
+to	O
+present	O
+a	O
+clear	O
+picture	O
+of	O
+the	O
+relationship	O
+between	O
+many	O
+of	O
+these	O
+viruses	B-SPEC
+.	O
+
+ABSTRACT	O
+:	O
+Protein	B-PROC
+ubiquitination	B-PROC
+regulates	O
+important	O
+innate	B-DISO
+immune	I-DISO
+responses	I-DISO
+.	O
+
+This	O
+enzyme	O
+is	O
+essential	O
+for	O
+arterivirus	B-SPEC
+replication	O
+by	O
+cleaving	O
+a	O
+site	O
+within	O
+the	O
+viral	B-PRGE
+replicase	I-PRGE
+polyproteins	I-PRGE
+and	O
+also	O
+removes	O
+ubiquitin	B-PROC
+from	O
+cellular	B-COMP
+proteins	B-CHED
+.	O
+
+To	O
+dissect	O
+this	O
+dual	O
+specificity	O
+,	O
+which	O
+relies	O
+on	O
+a	O
+single	O
+catalytic	O
+site	O
+,	O
+we	O
+determined	O
+the	O
+crystal	B-ANAT
+structure	O
+of	O
+equine	B-SPEC
+arteritis	I-SPEC
+virus	I-SPEC
+PLP2	B-PRGE
+in	O
+complex	O
+with	O
+ubiquitin	B-PROC
+(	O
+1	O
+.	O
+45	O
+Å	O
+).	O
+
+PLP2	B-PRGE
+binds	B-FUNC
+ubiquitin	B-PROC
+using	O
+a	O
+zinc	B-CHED
+finger	B-ANAT
+that	O
+is	O
+uniquely	O
+integrated	O
+into	O
+an	O
+exceptionally	O
+compact	O
+OTU	O
+-	O
+domain	O
+fold	O
+that	O
+represents	O
+a	O
+new	O
+subclass	O
+of	O
+zinc	B-CHED
+-	O
+dependent	O
+OTU	B-PRGE
+DUBs	I-PRGE
+.	O
+
+Notably	O
+,	O
+the	O
+ubiquitin	B-PROC
+-	O
+binding	B-FUNC
+surface	O
+is	O
+distant	O
+from	O
+the	O
+catalytic	O
+site	O
+,	O
+which	O
+allowed	O
+us	O
+to	O
+mutate	B-PROC
+this	O
+surface	O
+to	O
+significantly	O
+reduce	O
+DUB	O
+activity	O
+without	O
+affecting	O
+polyprotein	O
+cleavage	B-PROC
+.	O
+
+Fluid	O
+accumulation	O
+into	O
+alveoli	B-ANAT
+is	O
+a	O
+general	O
+finding	O
+in	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+(	O
+ARDS	B-DISO
+).	O
+
+Severe	O
+acute	B-DISO
+respiratory	I-DISO
+failure	I-DISO
+with	O
+ARDS	B-DISO
+is	O
+a	O
+complication	B-DISO
+of	O
+influenza	B-PATH
+A	I-PATH
+(	O
+H1N1	O
+)	O
+infection	B-DISO
+.	O
+
+Compared	O
+with	O
+normal	B-ANAT
+plasma	I-ANAT
+levels	O
+,	O
+the	O
+HBP	B-DISO
+concentrations	O
+were	O
+highly	O
+elevated	O
+at	O
+baseline	O
+and	O
+at	O
+day	O
+2	O
+:	O
+98	O
+ng	O
+/	O
+mL	O
+(	O
+62	O
+-	O
+183	O
+ng	O
+/	O
+mL	O
+)	O
+and	O
+93	O
+ng	O
+/	O
+mL	O
+(	O
+62	O
+-	O
+271	O
+ng	O
+/	O
+mL	O
+)	O
+(	O
+p	O
+0	O
+.	O
+876	O
+),	O
+respectively	O
+.	O
+
+ABSTRACT	O
+:	O
+Postpneumonectomy	O
+syndrome	O
+is	O
+a	O
+rare	O
+condition	B-DISO
+that	O
+is	O
+characterized	O
+by	O
+dyspnea	B-DISO
+resulting	O
+from	O
+an	O
+extreme	O
+mediastinal	B-ANAT
+shift	O
+and	O
+bronchial	B-DISO
+compression	I-DISO
+of	O
+the	O
+residual	O
+lung	B-ANAT
+following	O
+surgical	O
+pneumonectomy	O
+.	O
+
+The	O
+patient	O
+developed	O
+cor	B-DISO
+pulmonale	I-DISO
+due	O
+to	O
+his	O
+extensive	O
+lung	B-DISO
+disease	I-DISO
+and	O
+as	O
+a	O
+consequence	O
+was	O
+not	O
+a	O
+suitable	O
+candidate	O
+for	O
+surgical	O
+intervention	O
+.	O
+
+CONCLUSIONS	O
+:	O
+We	O
+present	O
+a	O
+rare	O
+case	O
+of	O
+postpneumonectomy	O
+-	O
+like	O
+syndrome	B-DISO
+as	O
+sequelae	O
+of	O
+severe	O
+pulmonary	B-ANAT
+parenchymal	O
+tuberculosis	B-DISO
+infection	I-DISO
+along	O
+with	O
+a	O
+review	O
+of	O
+literature	O
+,	O
+in	O
+the	O
+hopes	O
+of	O
+aiding	O
+clinicians	O
+to	O
+include	O
+the	O
+differential	O
+of	O
+postpneumonectomy	O
+-	O
+like	O
+syndrome	B-DISO
+in	O
+patients	O
+presenting	O
+with	O
+worsening	O
+dyspnea	B-DISO
+without	O
+a	O
+history	O
+of	O
+surgical	O
+lung	B-ANAT
+resection	O
+.	O
+
+The	O
+sporadic	O
+nature	O
+of	O
+these	O
+infections	B-DISO
+hampers	O
+our	O
+understanding	O
+of	O
+these	O
+diseases	O
+and	O
+limits	O
+the	O
+opportunities	O
+to	O
+design	O
+appropriate	O
+medical	O
+countermeasures	O
+against	O
+them	O
+.	O
+
+SF	O
+-	O
+aero	O
+induced	O
+less	O
+alveolar	B-ANAT
+hemorrhage	B-DISO
+and	O
+inflammation	B-DISO
+.	O
+
+Its	O
+genome	O
+was	O
+analyzed	O
+by	O
+nucleotide	B-CHED
+sequencing	O
+and	O
+was	O
+determined	O
+to	O
+have	O
+31	O
+,	O
+029	O
+bp	O
+.	O
+
+ABSTRACT	O
+:	O
+Intra	B-DISO
+-	I-DISO
+abdominal	I-DISO
+hypertension	I-DISO
+(	O
+IAH	O
+)	O
+contributes	O
+to	O
+organ	B-ANAT
+dysfunction	O
+and	O
+leads	O
+to	O
+the	O
+development	B-PROC
+of	O
+the	O
+abdominal	B-DISO
+compartment	I-DISO
+syndrome	I-DISO
+(	O
+ACS	B-FUNC
+).	O
+
+There	O
+is	O
+an	O
+accumulating	O
+evidence	O
+in	O
+human	B-SPEC
+and	O
+animal	B-SPEC
+studies	O
+that	O
+changes	O
+of	O
+perfusion	O
+,	O
+particularly	O
+to	O
+the	O
+microvasculature	B-PROC
+,	O
+are	O
+crucial	O
+events	O
+in	O
+the	O
+progression	O
+of	O
+acute	B-DISO
+pancreatitis	I-DISO
+(	O
+AP	O
+).	O
+
+TITLE	O
+:	O
+Canine	O
+coronavirus	B-SPEC
+,	O
+Greece	O
+.	O
+
+Mild	O
+disease	O
+or	O
+asymptomatic	O
+carriage	O
+are	O
+probably	O
+in	O
+many	O
+cases	O
+common	O
+outcomes	O
+of	O
+infection	B-DISO
+.	O
+
+Of	O
+the	O
+5	O
+,	O
+318	O
+submitted	O
+clinical	O
+samples	O
+,	O
+3	O
+,	O
+350	O
+(	O
+63	O
+.	O
+0	O
+%)	O
+specimens	O
+were	O
+positive	O
+for	O
+at	O
+least	O
+one	O
+respiratory	O
+virus	B-SPEC
+.	O
+
+Human	B-SPEC
+respiratory	I-SPEC
+syncytial	I-SPEC
+virus	I-SPEC
+was	O
+the	O
+most	O
+common	O
+virus	B-SPEC
+in	O
+children	O
+under	O
+5	O
+years	O
+of	O
+age	O
+,	O
+and	O
+the	O
+influenza	B-SPEC
+A	I-SPEC
+virus	I-SPEC
+was	O
+the	O
+most	O
+prevalent	O
+virus	B-SPEC
+in	O
+children	O
+over	O
+5	O
+years	O
+of	O
+age	O
+.	O
+
+TITLE	O
+:	O
+Osteonecrosis	B-DISO
+of	O
+the	O
+femoral	B-ANAT
+head	I-ANAT
+in	O
+SARS	B-DISO
+patients	O
+:	O
+seven	O
+years	O
+later	O
+.	O
+
+The	O
+structure	O
+activity	O
+relationships	O
+(	O
+SARs	B-DISO
+)	O
+were	O
+discussed	O
+and	O
+rationalized	O
+by	O
+docking	B-PROC
+simulations	O
+.	O
+
+Beginning	O
+in	O
+April	O
+2010	O
+,	O
+we	O
+conducted	O
+an	O
+observational	O
+cohort	O
+study	O
+at	O
+five	O
+hospitals	O
+in	O
+Mexico	O
+City	O
+,	O
+enrolling	O
+subjects	O
+who	O
+met	B-CHED
+the	O
+criteria	O
+for	O
+ILI	O
+.	O
+
+Six	O
+percent	O
+of	O
+subjects	O
+died	B-PROC
+,	O
+and	O
+of	O
+those	O
+,	O
+54	O
+%	O
+had	O
+no	O
+pathogen	O
+identified	O
+.	O
+
+One	O
+of	O
+the	O
+major	O
+cell	B-COMP
+types	O
+to	O
+be	O
+infected	O
+is	O
+the	O
+alveolar	B-ANAT
+type	I-ANAT
+II	I-ANAT
+cell	I-ANAT
+.	O
+
+ABSTRACT	O
+:	O
+A	O
+series	O
+of	O
+trans	O
+-	O
+3	O
+-	O
+aryl	O
+acrylic	O
+acids	O
+1	O
+-	O
+27	O
+and	O
+their	O
+derivatives	O
+28	O
+-	O
+34	O
+were	O
+prepared	O
+and	O
+evaluated	O
+for	O
+their	O
+antiviral	B-CHED
+activity	O
+against	O
+tobacco	B-SPEC
+mosaic	I-SPEC
+virus	I-SPEC
+(	O
+TMV	B-SPEC
+)	O
+for	O
+the	O
+first	O
+time	O
+.	O
+
+Guillain	O
+-	O
+Barré	O
+syndrome	B-DISO
+is	O
+believed	O
+to	O
+result	O
+from	O
+an	O
+aberrant	O
+immune	B-PROC
+response	I-PROC
+that	O
+attacks	O
+nerve	B-ANAT
+tissue	I-ANAT
+.	O
+
+Supportive	O
+therapy	O
+includes	O
+controlling	O
+pain	O
+with	O
+nonsteroidal	O
+anti	B-CHED
+-	I-CHED
+inflammatory	I-CHED
+drugs	I-CHED
+,	O
+carbamazepine	B-CHED
+,	O
+or	O
+gabapentin	B-CHED
+;	O
+monitoring	O
+for	O
+respiratory	O
+and	O
+autonomic	B-ANAT
+complications	O
+;	O
+and	O
+preventing	O
+venous	B-DISO
+thrombosis	I-DISO
+,	O
+skin	B-ANAT
+breakdown	B-DISO
+,	O
+and	O
+deconditioning	O
+.	O
+
+For	O
+future	O
+pandemics	O
+,	O
+this	O
+study	O
+identified	O
+the	O
+need	O
+for	O
+all	O
+staff	O
+to	O
+have	O
+a	O
+basic	O
+understanding	O
+of	O
+extracorporeal	O
+membrane	B-COMP
+oxygenation	B-PROC
+;	O
+strengthen	O
+inter	O
+-	O
+professional	O
+collaboration	O
+and	O
+communication	O
+;	O
+provision	O
+for	O
+more	O
+support	O
+and	O
+recognition	O
+of	O
+these	O
+highly	O
+specialized	O
+nurses	O
+,	O
+along	O
+with	O
+providing	O
+regular	O
+pandemic	O
+updates	O
+and	O
+offering	O
+counselling	O
+services	O
+.	O
+
+Like	O
+SARS	B-PRGE
+-	I-PRGE
+CoV	I-PRGE
+,	O
+HCoV	B-PRGE
+-	I-PRGE
+EMC	I-PRGE
+is	O
+of	O
+zoonotic	O
+origin	O
+and	O
+closely	O
+related	O
+to	O
+bat	B-ENZY
+coronaviruses	O
+.	O
+
+AKI	O
+occurred	O
+in	O
+63	O
+patients	O
+(	O
+32	O
+%),	O
+with	O
+maximum	O
+RIFLE	O
+class	B-SPEC
+R	O
+(	O
+Risk	O
+),	O
+class	B-SPEC
+I	O
+(	O
+Injury	O
+)	O
+and	O
+class	B-SPEC
+F	O
+(	O
+Failure	O
+)	O
+in	O
+27	O
+(	O
+43	O
+%),	O
+23	O
+(	O
+37	O
+%)	O
+and	O
+13	O
+(	O
+21	O
+%)	O
+patients	O
+,	O
+respectively	O
+.	O
+
+Poor	O
+prognostic	O
+factors	O
+were	O
+delayed	O
+diagnosis	O
+,	O
+anaemia	B-DISO
+,	O
+severe	O
+AKI	O
+,	O
+shock	O
+,	O
+ARDS	B-DISO
+,	O
+need	O
+for	O
+ventilatory	O
+support	O
+,	O
+raised	O
+serum	B-PRGE
+transaminases	I-PRGE
+and	O
+metabolic	B-DISO
+acidosis	I-DISO
+.	O
+
+TITLE	O
+:	O
+Bronchiolitis	B-DISO
+obliterans	I-DISO
+syndrome	B-DISO
+and	O
+restrictive	O
+allograft	O
+syndrome	B-DISO
+:	O
+do	O
+risk	O
+factors	O
+differ	O
+?	O
+
+Once	O
+cultured	O
+in	O
+Transwells	O
+,	O
+Calu	O
+-	O
+3	O
+LCC	B-DISO
+must	O
+be	O
+handled	O
+with	O
+care	O
+.	O
+
+ABSTRACT	O
+:	O
+The	O
+human	B-SPEC
+airway	B-ANAT
+epithelium	B-ANAT
+(	O
+HAE	O
+)	O
+represents	O
+the	O
+entry	O
+port	O
+of	O
+many	O
+human	B-SPEC
+respiratory	O
+viruses	B-SPEC
+,	O
+including	O
+human	B-SPEC
+coronaviruses	O
+(	O
+HCoVs	O
+).	O
+
+TCoV	O
+viral	O
+RNA	O
+loads	O
+measured	O
+by	O
+quantitative	O
+real	O
+-	O
+time	O
+reverse	B-PROC
+transcription	I-PROC
+-	O
+PCR	O
+were	O
+lower	O
+in	O
+vaccinated	O
+turkeys	B-SPEC
+than	O
+those	O
+in	O
+challenge	O
+control	O
+turkeys	B-SPEC
+.	O
+
+Severe	O
+ARDS	B-DISO
+was	O
+defined	O
+as	O
+acute	O
+-	O
+onset	O
+pulmonary	B-DISO
+failure	I-DISO
+with	O
+bilateral	B-DISO
+pulmonary	I-DISO
+infiltrates	I-DISO
+and	O
+an	O
+oxygenation	B-PROC
+index	O
+(	O
+OI	O
+)	O
+higher	O
+than	O
+13	O
+despite	O
+maximal	O
+ventilator	O
+settings	O
+.	O
+
+Nearly	O
+10	O
+,	O
+843	O
+patients	O
+underwent	O
+surgery	O
+during	O
+the	O
+study	O
+period	O
+,	O
+and	O
+the	O
+ARDS	B-DISO
+incidence	O
+rate	O
+was	O
+0	O
+.	O
+76	O
+%	O
+(	O
+83	O
+/	O
+10	O
+,	O
+843	O
+),	O
+with	O
+64	O
+patients	O
+(	O
+77	O
+%,	O
+64	O
+/	O
+83	O
+)	O
+receiving	O
+HFOV	O
+.	O
+
+Pulmonary	B-DISO
+hypertension	I-DISO
+and	O
+RRTIs	O
+before	O
+surgery	O
+were	O
+risk	O
+factors	O
+for	O
+in	O
+-	O
+hospital	O
+mortality	O
+.	O
+
+Phenotypic	O
+analysis	O
+of	O
+blood	B-ANAT
+-	O
+derived	O
+NK	B-ANAT
+cells	I-ANAT
+in	O
+FIP	B-DISO
+cats	B-SPEC
+revealed	O
+an	O
+upregulation	B-PROC
+of	O
+activation	O
+markers	O
+(	O
+CD16	O
+and	O
+CD25	B-PRGE
+)	O
+and	O
+migration	B-PROC
+markers	O
+(	O
+CD11b	B-PRGE
+and	O
+CD62L	B-PRGE
+)	O
+while	O
+LN	O
+-	O
+derived	O
+NK	B-ANAT
+cells	I-ANAT
+showed	O
+upregulation	B-PROC
+of	O
+only	O
+CD16	B-PRGE
+and	O
+CD62L	B-PRGE
+.	O
+
+ABSTRACT	O
+:	O
+The	O
+nucleotide	O
+sequences	O
+of	O
+a	O
+region	O
+including	O
+S1	O
+,	O
+S2	O
+,	O
+3a	O
+,	O
+3b	O
+and	O
+E	O
+genes	O
+of	O
+twenty	O
+-	O
+seven	O
+infectious	B-DISO
+bronchitis	B-DISO
+virus	B-SPEC
+(	O
+IBV	B-SPEC
+)	O
+isolates	O
+in	O
+Korea	O
+between	O
+1990	O
+-	O
+2011	O
+were	O
+determined	O
+and	O
+phylogenetic	O
+and	O
+computational	O
+recombination	B-PROC
+analyses	O
+were	O
+conducted	O
+.	O
+
+In	O
+conclusion	O
+,	O
+multiple	O
+IBV	B-SPEC
+genotypes	O
+have	O
+co	O
+-	O
+circulated	O
+;	O
+QX	O
+-	O
+like	O
+viruses	B-SPEC
+have	O
+recurred	O
+and	O
+new	O
+recombinants	O
+have	O
+emerged	O
+in	O
+Korea	O
+.	O
+
+Immunoreactivity	B-PROC
+was	O
+only	O
+completely	O
+lost	B-CHED
+in	O
+light	O
+-	O
+exposed	O
+sections	O
+and	O
+as	O
+early	O
+as	O
+1	O
+month	O
+for	O
+CD45	B-PRGE
+.	O
+
+Other	O
+markers	O
+with	O
+complete	O
+loss	O
+of	O
+immunoreactivity	B-PROC
+were	O
+bovine	B-PRGE
+viral	I-PRGE
+diarrhea	I-PRGE
+virus	I-PRGE
+,	I-PRGE
+CD18	I-PRGE
+(	O
+only	O
+with	O
+fluorescent	O
+light	O
+),	O
+CD31	B-PRGE
+,	O
+CD68	B-PRGE
+,	O
+canine	O
+parvovirus	B-DISO
+,	O
+chromogranins	O
+,	O
+and	O
+thyroid	B-ANAT
+transcription	B-PROC
+factor	O
+-	O
+1	O
+.	O
+
+A	O
+repeat	O
+CXR	O
+confirmed	O
+correct	O
+positioning	O
+of	O
+the	O
+chest	O
+tube	O
+and	O
+reexpansion	O
+of	O
+the	O
+right	B-ANAT
+lung	I-ANAT
+.	O
+
+The	O
+first	O
+9	O
+cases	O
+were	O
+in	O
+individuals	O
+resident	O
+in	O
+the	O
+Middle	O
+East	O
+,	O
+while	O
+the	O
+most	O
+recent	O
+3	O
+cases	O
+were	O
+in	O
+family	B-SPEC
+members	O
+resident	O
+in	O
+the	O
+UK	O
+.	O
+
+CONCLUSIONS	O
+:	O
+Heterogeneity	O
+in	O
+the	O
+number	O
+of	O
+secondary	O
+cases	O
+caused	O
+per	O
+infectious	B-DISO
+individual	O
+is	O
+a	O
+plausible	O
+explanation	O
+for	O
+the	O
+observed	O
+skewness	O
+in	O
+genotypic	O
+cluster	O
+size	O
+distribution	O
+of	O
+TB	O
+.	O
+
+Results	O
+of	O
+a	O
+skin	B-ANAT
+biopsy	O
+were	O
+compatible	O
+with	O
+TEN	O
+.	O
+
+TITLE	O
+:	O
+Acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+due	O
+to	O
+exposure	O
+to	O
+high	O
+-	O
+concentration	O
+mixture	B-CHED
+of	O
+ethenone	B-CHED
+and	O
+crotonaldehyde	B-CHED
+.	O
+
+This	O
+report	O
+is	O
+the	O
+first	O
+one	O
+to	O
+present	O
+a	O
+patient	O
+with	O
+ARDS	B-DISO
+in	O
+relation	O
+to	O
+long	O
+-	O
+standing	B-PROC
+exposure	O
+to	O
+a	O
+high	O
+-	O
+concentration	O
+mixture	B-CHED
+of	O
+ethenone	B-CHED
+and	O
+crotonaldehyde	B-CHED
+.	O
+
+CONCLUSIONS	O
+:	O
+Exposure	O
+to	O
+mixtures	O
+of	O
+ethenone	B-CHED
+and	O
+crotonaldehyde	B-CHED
+can	O
+cause	O
+severe	O
+pulmonary	B-ANAT
+injury	O
+leading	O
+to	O
+delayed	O
+ARDS	B-DISO
+.	O
+
+ABSTRACT	O
+:	O
+Coronaviruses	O
+selectively	O
+package	O
+genomic	O
+RNA	O
+into	O
+assembled	O
+virions	O
+,	O
+despite	O
+the	O
+great	O
+molar	B-ANAT
+excess	O
+of	O
+subgenomic	O
+RNA	O
+species	B-SPEC
+that	O
+is	O
+present	O
+in	O
+infected	O
+cells	B-COMP
+.	O
+
+We	O
+demonstrate	O
+that	O
+HCoV	O
+-	O
+EMC	B-COMP
+resembles	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+coronavirus	B-SPEC
+(	O
+SARS	B-DISO
+-	O
+CoV	O
+)	O
+in	O
+productively	O
+infecting	O
+primary	O
+and	O
+continuous	O
+cells	B-COMP
+of	O
+the	O
+human	B-SPEC
+airways	O
+and	O
+in	O
+preventing	O
+the	O
+induction	O
+of	O
+interferon	B-PRGE
+regulatory	I-PRGE
+factor	I-PRGE
+3	I-PRGE
+(	O
+IRF	B-PRGE
+-	I-PRGE
+3	I-PRGE
+)-	O
+mediated	O
+antiviral	B-CHED
+alpha	B-PRGE
+/	I-PRGE
+beta	I-PRGE
+interferon	I-PRGE
+(	O
+IFN	B-PRGE
+-	I-PRGE
+α	I-PRGE
+/	I-PRGE
+β	I-PRGE
+)	O
+responses	O
+.	O
+
+Thus	O
+,	O
+HCoV	O
+-	O
+EMC	B-COMP
+can	O
+utilize	O
+a	O
+broad	O
+range	O
+of	O
+human	B-SPEC
+cell	B-COMP
+substrates	O
+and	O
+suppress	O
+IFN	B-PRGE
+induction	O
+,	O
+but	O
+it	O
+does	O
+not	O
+reach	B-PROC
+the	O
+IFN	B-PRGE
+resistance	I-PRGE
+of	I-PRGE
+SARS	B-DISO
+-	I-PRGE
+CoV	I-PRGE
+.	O
+
+In	O
+this	O
+updated	O
+review	O
+,	O
+we	O
+searched	O
+the	O
+Cochrane	O
+Central	O
+Register	O
+of	O
+Controlled	O
+Trials	O
+(	O
+CENTRAL	O
+)	O
+(	O
+The	O
+Cochrane	O
+Library	O
+2011	O
+,	O
+Issue	O
+11	O
+);	O
+CINAHL	O
+(	O
+Cumulative	O
+Index	O
+to	O
+Nursing	B-PROC
+&	O
+Allied	O
+Health	O
+Literature	O
+)	O
+via	O
+Ovid	O
+(	O
+1982	O
+to	O
+November	O
+2011	O
+);	O
+Ovid	O
+MEDLINE	O
+(	O
+1950	O
+to	O
+November	O
+2011	O
+);	O
+and	O
+Ovid	O
+EMBASE	O
+(	O
+1982	O
+to	O
+November	O
+2011	O
+).	O
+
+Clinically	O
+relevant	O
+outcome	O
+measures	O
+should	O
+be	O
+assessed	O
+(	O
+mortality	O
+at	O
+discharge	B-ANAT
+and	O
+later	O
+,	O
+duration	O
+of	O
+both	O
+respiratory	O
+support	O
+and	O
+hospital	O
+stay	O
+,	O
+and	O
+long	O
+-	O
+term	O
+neurodevelopmental	O
+outcomes	O
+).	O
+
+It	O
+is	O
+important	O
+to	O
+investigate	O
+the	O
+autoprocessing	O
+mechanism	O
+of	O
+these	O
+proteases	O
+from	O
+the	O
+point	O
+of	O
+view	O
+of	O
+anti	O
+-	O
+SARS	B-DISO
+-	O
+CoV	O
+drug	O
+design	O
+.	O
+
+Such	O
+cleavage	B-PROC
+mainly	O
+occurs	O
+in	O
+a	O
+trans	O
+manner	O
+;	O
+i	O
+.	O
+e	O
+.	O
+the	O
+pro	B-CHED
+-	O
+form	O
+dimer	O
+cleaves	O
+the	O
+monomeric	O
+form	O
+.	O
+
+The	O
+stimulation	O
+by	O
+N	O
+-	O
+terminal	O
+pro	B-CHED
+-	O
+sequence	O
+removal	O
+is	O
+due	O
+to	O
+the	O
+cis	B-DISO
+(	O
+intra	O
+-	O
+dimer	O
+and	O
+inter	O
+-	O
+protomer	O
+)	O
+effect	O
+of	O
+formation	B-PROC
+of	O
+the	O
+new	O
+N	O
+-	O
+terminus	O
+,	O
+whereas	O
+that	O
+by	O
+C	O
+-	O
+terminal	O
+cleavage	B-PROC
+is	O
+due	O
+to	O
+removal	O
+of	O
+its	O
+trans	O
+(	O
+inter	O
+-	O
+dimer	O
+)	O
+inhibitory	O
+effect	O
+.	O
+
+The	O
+main	O
+target	O
+damage	O
+during	O
+severe	B-DISO
+sepsis	I-DISO
+is	O
+the	O
+endothelium	B-ANAT
+.	O
+
+In	O
+this	O
+study	O
+,	O
+the	O
+hypothesis	O
+that	O
+low	O
+levels	O
+of	O
+endocan	O
+may	O
+result	O
+from	O
+proteolysis	B-PROC
+was	O
+tested	O
+.	O
+
+TITLE	O
+:	O
+Epidemiological	O
+and	O
+clinical	O
+features	O
+of	O
+human	B-SPEC
+coronavirus	I-SPEC
+infections	O
+among	O
+different	O
+subsets	O
+of	O
+patients	O
+.	O
+
+Phylogenetic	O
+analysis	O
+showed	O
+that	O
+recent	O
+prevalent	O
+Korean	O
+PEDV	B-SPEC
+field	O
+isolates	O
+are	O
+closely	O
+related	O
+to	O
+the	O
+Chinese	O
+field	O
+strains	O
+and	O
+differ	O
+genetically	O
+from	O
+the	O
+European	O
+strains	O
+and	O
+the	O
+vaccine	O
+strains	O
+used	O
+in	O
+Korea	O
+,	O
+which	O
+raises	O
+questions	O
+of	O
+whether	O
+a	O
+new	O
+-	O
+type	O
+PEDV	B-SPEC
+vaccine	O
+may	O
+be	O
+necessary	O
+for	O
+preventing	O
+PEDV	B-SPEC
+infection	B-DISO
+more	O
+effectively	O
+in	O
+Korea	O
+.	O
+
+TITLE	O
+:	O
+[	O
+Granulomatous	O
+lung	B-ANAT
+and	O
+systemic	O
+diseases	O
+].	O
+
+Granulomatous	O
+lung	B-DISO
+diseases	I-DISO
+are	O
+often	O
+accompanied	O
+by	O
+severe	O
+,	O
+systemic	O
+inflammation	B-DISO
+.	O
+
+Sarcoidosis	B-DISO
+is	O
+the	O
+most	O
+common	O
+granulomatous	B-DISO
+lung	I-DISO
+disease	I-DISO
+.	O
+
+Pulmonary	B-DISO
+granuloma	I-DISO
+also	O
+evolve	O
+in	O
+the	O
+context	O
+of	O
+autoimmune	B-DISO
+diseases	I-DISO
+such	O
+as	O
+rheumatoid	B-PATH
+arthritis	I-PATH
+,	O
+granulomatosis	B-DISO
+with	O
+polyangiitis	O
+(	O
+GBA	O
+,	O
+Wegener	O
+'	O
+s	O
+)	O
+and	O
+eosinophilic	O
+granulomatosis	B-DISO
+with	O
+polyangiitis	O
+(	O
+EGPA	O
+,	O
+Churg	O
+-	O
+Strauss	O
+syndrome	O
+).	O
+
+Furthermore	O
+,	O
+immunodeficiencies	B-DISO
+such	O
+as	O
+common	B-DISO
+variable	I-DISO
+immunodeficiency	I-DISO
+(	O
+CVID	B-DISO
+)	O
+and	O
+immune	B-DISO
+reconstitution	I-DISO
+syndrome	I-DISO
+in	O
+HIV	B-DISO
+can	O
+be	O
+associated	O
+with	O
+systemic	O
+granulomatous	B-DISO
+inflammation	I-DISO
+.	O
+
+ABSTRACT	O
+:	O
+Streptococcus	B-SPEC
+agalactiae	I-SPEC
+(	O
+Group	B-SPEC
+B	I-SPEC
+streptococcus	I-SPEC
+,	O
+GBS	B-DISO
+)	O
+has	O
+emerged	O
+as	O
+an	O
+important	O
+pathogen	O
+that	O
+affects	O
+humans	B-SPEC
+and	O
+animals	B-SPEC
+,	O
+including	O
+aquatic	O
+species	B-SPEC
+.	O
+
+To	O
+our	O
+knowledge	O
+,	O
+this	O
+is	O
+the	O
+first	O
+report	O
+on	O
+S	O
+.	O
+agalactiae	O
+natural	O
+infection	B-DISO
+in	O
+domestic	B-SPEC
+rabbits	I-SPEC
+.	O
+
+We	O
+found	O
+that	O
+the	O
+spike	O
+protein	B-CHED
+of	O
+hCoV	O
+-	O
+EMC	B-COMP
+(	O
+EMC	B-COMP
+-	O
+S	O
+)	O
+is	O
+incorporated	O
+into	O
+lentiviral	O
+particles	O
+and	O
+mediates	O
+transduction	B-PROC
+of	O
+human	B-SPEC
+cell	B-ANAT
+lines	I-ANAT
+derived	O
+from	O
+different	O
+organs	B-ANAT
+,	O
+including	O
+the	O
+lungs	B-ANAT
+,	O
+kidneys	B-ANAT
+,	O
+and	O
+colon	B-ANAT
+,	O
+as	O
+well	O
+as	O
+primary	O
+human	B-SPEC
+macrophages	B-ANAT
+.	O
+
+Intestinal	B-ANAT
+samples	O
+from	O
+76	O
+turkey	B-SPEC
+flocks	O
+from	O
+different	O
+Brazilian	O
+states	O
+affected	O
+or	O
+not	O
+with	O
+intestinal	B-DISO
+disorders	I-DISO
+were	O
+evaluated	O
+for	O
+the	O
+presence	O
+of	O
+adenovirus	B-DISO
+groups	O
+1	O
+and	O
+2	O
+(	O
+TAV	B-SPEC
+),	O
+astrovirus	O
+types	O
+1	O
+and	O
+2	O
+(	O
+TAstV	O
+-	O
+1	O
+and	O
+TAstV	O
+-	O
+2	O
+),	O
+turkey	B-SPEC
+coronavirus	B-SPEC
+(	O
+TCoV	O
+),	O
+reovirus	B-SPEC
+,	O
+rotavirus	B-SPEC
+,	O
+and	O
+avian	B-SPEC
+nephritis	B-DISO
+virus	B-SPEC
+(	O
+ANV	O
+)	O
+using	O
+PCR	O
+.	O
+
+An	O
+increase	O
+in	O
+lymphocyte	B-ANAT
+percentage	O
+coincided	O
+with	O
+a	O
+decreased	O
+heterophil	B-ANAT
+percentage	O
+and	O
+heterophil	B-ANAT
+to	O
+lymphocyte	B-ANAT
+ratio	O
+(	O
+d	O
+14	O
+)	O
+in	O
+the	O
+HYPER	O
+group	O
+.	O
+
+Independent	O
+of	O
+T4	O
+treatment	O
+,	O
+cold	B-DISO
+exposure	O
+was	O
+generally	O
+associated	O
+with	O
+decreased	O
+immune	O
+functions	O
+at	O
+early	O
+stages	O
+.	O
+
+The	O
+data	O
+suggested	O
+that	O
+oral	B-ANAT
+exposure	O
+of	O
+broiler	O
+breeder	O
+hens	O
+to	O
+1	O
+mg	O
+/	O
+L	O
+of	O
+T4	O
+not	O
+only	O
+had	O
+no	O
+adverse	B-DISO
+effect	I-DISO
+on	O
+immune	B-PROC
+function	I-PROC
+,	O
+but	O
+also	O
+modulated	O
+early	O
+adaptive	B-PROC
+immune	I-PROC
+responses	I-PROC
+in	O
+progeny	O
+chicks	O
+for	O
+which	O
+the	O
+causal	O
+mechanisms	O
+remain	O
+to	O
+be	O
+unraveled	O
+.	O
+
+The	O
+objective	O
+of	O
+the	O
+present	O
+study	O
+was	O
+to	O
+determine	O
+the	O
+seroprevalence	O
+of	O
+T	B-SPEC
+.	I-SPEC
+gondii	I-SPEC
+infection	B-DISO
+in	O
+bats	B-SPEC
+in	O
+China	O
+.	O
+
+Studies	O
+with	O
+hamsters	B-SPEC
+demonstrated	O
+that	O
+in	O
+leptospirosis	B-DISO
+a	O
+noncardiogenic	O
+pulmonary	B-DISO
+edema	I-DISO
+occurs	O
+consequently	O
+to	O
+a	O
+decrease	O
+in	O
+the	O
+clearance	O
+of	O
+alveolar	B-ANAT
+fluid	O
+,	O
+due	O
+to	O
+a	O
+decrease	O
+in	O
+sodium	O
+transporter	O
+in	O
+the	O
+luminal	B-ANAT
+membrane	B-COMP
+(	O
+ENaC	O
+)	O
+and	O
+an	O
+increase	O
+in	O
+the	O
+NKCC1	B-PRGE
+basolateral	I-PRGE
+membrane	I-PRGE
+transporter	I-PRGE
+.	O
+
+Clinical	B-DISO
+findings	I-DISO
+revealed	O
+severe	O
+cardiac	B-DISO
+failure	I-DISO
+with	O
+development	B-PROC
+of	O
+cardiogenic	B-DISO
+shock	I-DISO
+and	O
+need	O
+for	O
+adrenergic	B-CHED
+drug	I-CHED
+therapy	O
+for	O
+circulatory	B-PROC
+support	O
+.	O
+
+The	O
+immediate	O
+initiation	O
+of	O
+a	O
+mechanical	O
+circulatory	B-PROC
+support	O
+by	O
+an	O
+Extracorporal	O
+Membrane	B-COMP
+Oxygenator	O
+(	O
+ECMO	O
+)	O
+facilitated	O
+rapid	O
+hemodynamic	B-PROC
+stabilization	O
+and	O
+recovery	O
+of	O
+organ	B-ANAT
+function	O
+.	O
+
+In	O
+the	O
+presence	O
+of	O
+nonphysiological	O
+concentration	O
+of	O
+Ca	O
+-	O
+ions	B-CHED
+the	O
+channel	O
+develops	O
+channel	B-FUNC
+activity	I-FUNC
+.	O
+
+However	O
+,	O
+this	O
+can	O
+be	O
+similar	O
+to	O
+other	O
+diseases	O
+causing	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+or	O
+severe	O
+community	O
+-	O
+acquired	O
+pneumonia	B-DISO
+,	O
+so	O
+the	O
+diagnosis	O
+can	O
+be	O
+delayed	O
+.	O
+
+The	O
+cause	O
+of	O
+this	O
+disease	O
+in	O
+the	O
+majority	O
+of	O
+patients	O
+is	O
+unknown	O
+,	O
+even	O
+though	O
+some	O
+cases	O
+may	O
+be	O
+caused	O
+by	O
+smoke	O
+,	O
+other	O
+patients	O
+inhaled	B-PROC
+dust	O
+or	O
+drugs	O
+.	O
+
+Treatment	O
+with	O
+corticosteroids	B-CHED
+shows	O
+a	O
+rapid	O
+and	O
+dramatic	O
+positive	O
+response	O
+without	O
+recurrence	B-DISO
+.	O
+
+DPP4	B-PRGE
+specifically	O
+co	O
+-	O
+purified	O
+with	O
+the	O
+receptor	B-PRGE
+-	I-PRGE
+binding	I-PRGE
+S1	I-PRGE
+domain	I-PRGE
+of	O
+the	O
+hCoV	B-PRGE
+-	I-PRGE
+EMC	I-PRGE
+spike	I-PRGE
+protein	B-CHED
+from	O
+lysates	O
+of	O
+susceptible	O
+Huh	O
+-	O
+7	O
+cells	B-COMP
+.	O
+
+TITLE	O
+:	O
+Update	O
+:	O
+severe	O
+respiratory	O
+illness	O
+associated	O
+with	O
+a	O
+novel	B-SPEC
+coronavirus	I-SPEC
+--	O
+worldwide	O
+,	O
+2012	O
+-	O
+2013	O
+.	O
+
+This	O
+paper	O
+will	O
+give	O
+insight	O
+into	O
+the	O
+strengths	O
+and	O
+weaknesses	B-DISO
+of	O
+imaging	O
+modalities	O
+used	O
+in	O
+the	O
+management	O
+of	O
+patients	O
+with	O
+ARDS	B-DISO
+.	O
+
+Cerebral	B-DISO
+malaria	B-PATH
+and	O
+acute	O
+kidney	B-ANAT
+injury	O
+occurred	O
+earlier	O
+(	O
+median	O
+day	O
+1	O
+)	O
+than	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+(	O
+median	O
+day	O
+3	O
+).	O
+
+Patients	O
+who	O
+died	B-PROC
+succumbed	O
+to	O
+complications	O
+associated	O
+with	O
+a	O
+prolonged	O
+stay	O
+on	O
+ICU	O
+rather	O
+than	O
+malaria	B-PATH
+per	O
+se	O
+.	O
+
+In	O
+addition	O
+,	O
+we	O
+showed	O
+that	O
+,	O
+in	O
+cells	B-COMP
+transfected	O
+with	O
+plasmids	O
+that	O
+encoded	O
+the	O
+mutant	B-DISO
+(	O
+R106A	O
+)	O
+N	O
+protein	B-CHED
+and	O
+infected	O
+with	O
+virus	B-SPEC
+,	O
+the	O
+level	O
+of	O
+the	O
+matrix	B-PRGE
+protein	I-PRGE
+gene	I-PRGE
+was	O
+decreased	O
+by	O
+7	O
+-	O
+fold	O
+compared	O
+to	O
+cells	B-COMP
+that	O
+were	O
+transfected	O
+with	O
+the	O
+wild	O
+-	O
+type	O
+N	O
+protein	B-CHED
+.	O
+
+This	O
+finding	O
+suggests	O
+that	O
+R106	O
+,	O
+by	O
+enhancing	O
+binding	B-FUNC
+of	O
+the	O
+N	B-PRGE
+protein	I-PRGE
+to	O
+viral	O
+RNA	O
+plays	O
+a	O
+critical	O
+role	O
+in	O
+the	O
+viral	B-PROC
+replication	I-PROC
+.	O
+
+If	O
+these	O
+complications	O
+occur	O
+even	O
+with	O
+initial	O
+treatment	O
+with	O
+dantrolene	B-CHED
+,	O
+our	O
+experiences	O
+may	O
+be	O
+useful	O
+adjunctive	O
+treatments	O
+to	O
+consider	O
+.	O
+
+ABSTRACT	O
+:	O
+Natural	O
+disasters	O
+,	O
+infectious	B-DISO
+disease	I-DISO
+epidemics	O
+,	O
+terrorism	O
+,	O
+and	O
+major	O
+events	O
+like	O
+the	O
+nuclear	O
+incident	O
+at	O
+Fukushima	O
+all	O
+pose	O
+major	O
+potential	O
+challenges	O
+to	O
+public	O
+health	O
+and	O
+security	O
+.	O
+
+Events	O
+such	O
+as	O
+the	O
+anthrax	B-DISO
+letters	O
+of	O
+2001	O
+,	O
+Hurricanes	O
+Katrina	O
+,	O
+Irene	O
+,	O
+and	O
+Sandy	O
+,	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+(	O
+SARS	B-DISO
+)	O
+and	O
+West	B-DISO
+Nile	I-DISO
+virus	I-DISO
+outbreaks	O
+,	O
+and	O
+the	O
+2009	O
+H1N1	B-DISO
+influenza	I-DISO
+pandemic	O
+have	O
+demonstrated	O
+that	O
+public	O
+health	O
+,	O
+emergency	B-DISO
+management	O
+,	O
+and	O
+national	O
+security	O
+efforts	O
+are	O
+interconnected	O
+.	O
+
+All	O
+cases	O
+of	O
+falciparum	B-DISO
+malaria	I-DISO
+are	O
+potentially	O
+severe	O
+and	O
+life	O
+threatening	O
+,	O
+especially	O
+when	O
+managed	O
+inappropriately	O
+.	O
+
+Total	O
+29	O
+(	O
+61	O
+.	O
+70	O
+%)	O
+patients	O
+had	O
+jaundice	B-DISO
+of	O
+which	O
+20	O
+were	O
+with	O
+anemia	B-DISO
+.	O
+
+Total	O
+22	O
+(	O
+46	O
+.	O
+80	O
+%)	O
+had	O
+anemia	B-DISO
+of	O
+which	O
+20	O
+were	O
+with	O
+jaundice	B-DISO
+.	O
+
+One	O
+(	O
+2	O
+.	O
+12	O
+%)	O
+patient	O
+had	O
+four	O
+complications	O
+in	O
+the	O
+form	O
+of	O
+cerebral	B-DISO
+malaria	B-PATH
+with	O
+ARF	B-DISO
+with	O
+ARDS	B-DISO
+with	O
+thrombocytopenia	O
+with	O
+100	O
+%	O
+mortality	O
+.	O
+
+No	O
+plague	B-DISO
+cases	O
+occurred	O
+among	O
+family	B-SPEC
+and	O
+village	O
+contacts	O
+and	O
+health	O
+care	O
+workers	O
+.	O
+
+Principles	O
+of	O
+lung	B-ANAT
+-	O
+protective	O
+ventilation	O
+include	O
+:	O
+a	O
+)	O
+prevention	O
+of	O
+volutrauma	O
+(	O
+tidal	O
+volume	O
+4	O
+to	O
+8	O
+ml	O
+/	O
+kg	O
+predicted	O
+body	B-ANAT
+weight	O
+with	O
+plateau	O
+pressure	O
+<	O
+30	O
+cmH2O	O
+);	O
+b	O
+)	O
+prevention	O
+of	O
+atelectasis	B-DISO
+(	O
+positive	O
+end	B-PROC
+-	I-PROC
+expiratory	I-PROC
+pressure	O
+≥	O
+5	O
+cmH2O	O
+,	O
+as	O
+needed	O
+recruitment	B-DISO
+maneuvers	O
+);	O
+c	O
+)	O
+adequate	O
+ventilation	O
+(	O
+respiratory	O
+rate	O
+20	O
+to	O
+35	O
+breaths	O
+per	O
+minute	O
+);	O
+and	O
+d	O
+)	O
+prevention	O
+of	O
+hyperoxia	B-DISO
+(	O
+titrate	O
+inspired	B-PROC
+oxygen	B-CHED
+concentration	O
+to	O
+peripheral	B-PROC
+oxygen	I-PROC
+saturation	I-PROC
+(	O
+SpO2	O
+)	O
+levels	O
+of	O
+88	O
+to	O
+95	O
+%).	O
+
+Most	O
+patients	O
+tolerate	O
+lung	B-ANAT
+protective	O
+mechanical	O
+ventilation	O
+well	O
+without	O
+the	O
+need	O
+for	O
+excessive	O
+sedation	O
+.	O
+
+We	O
+prospectively	O
+followed	O
+patients	O
+with	O
+femoral	B-ANAT
+midshaft	O
+fracture	O
+,	O
+Injury	O
+Severity	O
+Score	O
+(	O
+ISS	B-DISO
+)	O
+>	O
+16	O
+points	O
+,	O
+or	O
+three	O
+fractures	O
+and	O
+Abbreviated	O
+Injury	O
+Scale	O
+(	O
+AIS	B-DISO
+)	O
+≥	O
+2	O
+points	O
+and	O
+another	O
+injury	O
+(	O
+AIS	B-DISO
+≥	O
+2	O
+points	O
+),	O
+and	O
+age	O
+18	O
+to	O
+65	O
+years	O
+.	O
+
+This	O
+paper	O
+reports	O
+the	O
+first	O
+case	O
+occurred	O
+in	O
+Mexico	O
+:	O
+a	O
+39	O
+-	O
+year	O
+-	O
+old	O
+woman	O
+with	O
+a	O
+history	O
+of	O
+diabetes	B-DISO
+mellitus	I-DISO
+type	I-DISO
+2	I-DISO
+and	O
+obesity	B-DISO
+grade	O
+II	O
+,	O
+which	O
+suffered	B-DISO
+atypical	O
+and	O
+aggressive	B-DISO
+pneumonia	B-DISO
+positive	O
+to	O
+coronavirus	B-SPEC
+.	O
+
+Its	O
+behavior	O
+in	O
+pregnancy	O
+,	O
+reported	O
+by	O
+Assistant	O
+General	O
+Direction	O
+of	O
+Epidemiology	O
+in	O
+Mexico	O
+,	O
+has	O
+placed	O
+this	O
+infection	B-DISO
+as	O
+a	O
+risk	O
+factor	O
+for	O
+women	O
+.	O
+
+The	O
+incidences	O
+of	O
+pancreatic	B-ANAT
+sepsis	B-DISO
+,	O
+multiple	B-DISO
+organ	I-DISO
+dysfunction	I-DISO
+syndrome	I-DISO
+and	O
+mortality	O
+were	O
+lower	O
+in	O
+the	O
+somatostatin	B-PRGE
+,	O
+somatostatin	B-PRGE
++	I-PRGE
+ulinastatin	I-PRGE
+,	O
+somatostatin	B-PRGE
++	I-PRGE
+S	I-PRGE
+miltiorrhiza	I-PRGE
+and	O
+somatostatin	B-PRGE
++	O
+ulinastatin	B-PRGE
++	I-PRGE
+S	I-PRGE
+miltiorrhiza	O
+subgroups	O
+compared	O
+with	O
+the	O
+basic	O
+treatment	O
+subgroup	O
+.	O
+
+FCoV	O
+RNA	O
+was	O
+detected	O
+in	O
+all	O
+4	O
+FIP	O
+cat	B-SPEC
+postmortem	O
+samples	O
+and	O
+in	O
+9	O
+of	O
+the	O
+16	O
+fecal	B-ANAT
+samples	O
+from	O
+contemporary	O
+-	O
+asymptomatic	O
+cats	B-SPEC
+.	O
+
+RESULTS	O
+:	O
+FCoV	O
+RNA	O
+was	O
+detected	O
+in	O
+all	O
+4	O
+FIP	B-DISO
+cat	B-SPEC
+postmortem	O
+samples	O
+and	O
+in	O
+9	O
+of	O
+the	O
+16	O
+fecal	B-ANAT
+samples	O
+from	O
+contemporary	O
+-	O
+asymptomatic	O
+cats	B-SPEC
+.	O
+
+ABSTRACT	O
+:	O
+Acute	O
+respiratory	O
+distress	O
+syndrome	O
+(	O
+ARDS	B-DISO
+)	O
+continues	O
+to	O
+be	O
+a	O
+major	O
+healthcare	O
+problem	O
+,	O
+affecting	O
+>	O
+190	O
+,	O
+000	O
+people	O
+in	O
+the	O
+USA	O
+annually	O
+,	O
+with	O
+a	O
+mortality	O
+of	O
+27	O
+-	O
+45	O
+%,	O
+depending	O
+on	O
+the	O
+severity	O
+of	O
+the	O
+illness	O
+and	O
+comorbidities	O
+.	O
+
+The	O
+primers	O
+were	O
+designed	O
+on	O
+the	O
+basis	O
+of	O
+highly	O
+conserved	O
+regions	O
+of	O
+several	O
+TGEV	B-SPEC
+sequences	O
+included	O
+in	O
+the	O
+analysis	O
+.	O
+
+TITLE	O
+:	O
+Identification	O
+of	O
+the	O
+first	O
+synthetic	O
+inhibitors	B-CHED
+of	O
+the	O
+type	B-PRGE
+II	I-PRGE
+transmembrane	B-COMP
+serine	B-CHED
+protease	I-PRGE
+TMPRSS2	I-PRGE
+suitable	O
+for	O
+inhibition	O
+of	O
+influenza	B-SPEC
+virus	B-PROC
+activation	I-PROC
+.	O
+
+The	O
+first	O
+series	O
+comprises	O
+substrate	O
+analogue	O
+inhibitors	O
+containing	O
+a	O
+4	O
+-	O
+amidinobenzylamide	O
+moiety	O
+at	O
+the	O
+P1	O
+position	O
+,	O
+whereby	O
+some	O
+of	O
+these	O
+analogues	O
+possess	B-DISO
+inhibition	B-PROC
+constants	O
+of	O
+approximately	O
+20	O
+nM	O
+.	O
+An	O
+improved	O
+potency	O
+was	O
+found	O
+for	O
+a	O
+second	O
+type	O
+derived	O
+from	O
+sulfonylated	O
+3	O
+-	O
+amindinophenylalanylamide	O
+derivatives	O
+.	O
+
+On	O
+the	O
+basis	O
+of	O
+the	O
+inhibitor	B-CHED
+studies	O
+,	O
+a	O
+series	O
+of	O
+new	O
+fluorogenic	O
+substrates	O
+containing	O
+a	O
+D	B-CHED
+-	I-CHED
+arginine	I-CHED
+residue	I-CHED
+at	O
+the	O
+P3	O
+position	O
+was	O
+synthesized	O
+,	O
+some	O
+of	O
+them	O
+were	O
+efficiently	O
+cleaved	B-ANAT
+by	O
+TMPRSS2	O
+.	O
+
+Patients	O
+were	O
+treated	O
+aggressively	O
+with	O
+a	O
+standard	O
+detoxification	B-PROC
+protocol	O
+consisting	O
+of	O
+gastric	B-ANAT
+lavage	O
+,	O
+active	O
+charcoal	O
+,	O
+charcoal	O
+hemoperfusion	O
+,	O
+and	O
+cyclophosphamide	B-CHED
+and	O
+steroid	B-CHED
+pulse	B-PROC
+therapies	O
+.	O
+
+In	O
+the	O
+end	O
+,	O
+2	O
+patients	O
+(	O
+33	O
+.	O
+3	O
+%)	O
+died	B-PROC
+from	O
+multiple	O
+-	O
+organ	B-DISO
+failure	I-DISO
+,	O
+despite	O
+intensive	O
+resuscitation	O
+.	O
+
+Evidently	O
+,	O
+a	O
+prompt	O
+diagnosis	O
+of	O
+paraquat	B-CHED
+poisoning	O
+and	O
+an	O
+immediate	O
+institution	O
+of	O
+a	O
+detoxification	B-PROC
+protocol	O
+is	O
+a	O
+prerequisite	O
+for	O
+a	O
+favorable	O
+outcome	O
+.	O
+
+TITLE	O
+:	O
+Carbon	B-CHED
+dioxide	I-CHED
+clearance	O
+in	O
+critical	O
+care	O
+.	O
+
+This	O
+review	O
+aims	O
+at	O
+defining	O
+the	O
+effects	O
+of	O
+hypercapnia	B-DISO
+and	O
+hypercapnic	B-DISO
+acidosis	I-DISO
+with	O
+a	O
+focus	O
+on	O
+the	O
+pros	O
+and	O
+cons	O
+of	O
+clearing	O
+carbon	B-CHED
+dioxide	I-CHED
+and	O
+the	O
+modalities	O
+that	O
+may	O
+enhance	O
+carbon	B-CHED
+dioxide	I-CHED
+clearance	O
+.	O
+
+Here	O
+we	O
+show	O
+that	O
+the	O
+type	B-PRGE
+II	I-PRGE
+transmembrane	I-PRGE
+serine	B-CHED
+proteases	I-PRGE
+TMPRSS2	B-PRGE
+and	O
+HAT	B-PRGE
+cleave	O
+the	O
+HCoV	B-PRGE
+-	I-PRGE
+229E	I-PRGE
+S	I-PRGE
+-	I-PRGE
+protein	B-CHED
+(	O
+229E	O
+-	O
+S	O
+)	O
+and	O
+augment	O
+229E	O
+-	O
+S	O
+-	O
+driven	O
+cell	B-PROC
+-	I-PROC
+cell	B-COMP
+fusion	I-PROC
+,	O
+suggesting	O
+that	O
+TMPRSS2	B-PRGE
+and	O
+HAT	B-PRGE
+can	O
+activate	O
+229E	O
+-	O
+S	O
+.	O
+Indeed	O
+,	O
+engineered	O
+expression	B-PROC
+of	O
+TMPRSS2	B-PRGE
+and	O
+HAT	B-PRGE
+rendered	O
+229E	O
+-	O
+S	O
+-	O
+driven	O
+virus	B-SPEC
+-	O
+cell	B-PROC
+fusion	I-PROC
+insensitive	O
+to	O
+an	O
+inhibitor	B-CHED
+of	O
+cathepsin	B-PRGE
+L	I-PRGE
+,	O
+a	O
+protease	O
+previously	O
+shown	O
+to	O
+facilitate	O
+HCoV	O
+-	O
+229E	O
+infection	B-DISO
+.	O
+
+In	O
+addition	O
+,	O
+evidence	O
+was	O
+obtained	O
+that	O
+activation	O
+by	O
+TMPRSS2	O
+rescues	O
+229E	O
+-	O
+S	O
+-	O
+dependent	O
+cell	B-COMP
+entry	O
+from	O
+inhibition	B-PROC
+by	O
+IFITM	O
+proteins	B-CHED
+.	O
+
+In	O
+sum	O
+,	O
+our	O
+results	O
+indicate	O
+that	O
+HCoV	B-SPEC
+-	I-SPEC
+229E	I-SPEC
+can	O
+employ	O
+redundant	O
+proteolytic	B-PROC
+pathways	B-PROC
+to	O
+ensure	O
+its	O
+activation	O
+in	O
+host	B-COMP
+cells	B-COMP
+.	O
+
+Two	O
+of	O
+the	O
+12	O
+critical	O
+residues	O
+identified	O
+to	O
+be	O
+essential	O
+for	O
+the	O
+N7	O
+-	O
+MTase	O
+were	O
+located	O
+at	O
+the	O
+N	O
+terminus	O
+of	O
+the	O
+core	O
+ExoN	B-PRGE
+domain	I-PRGE
+,	O
+reinforcing	O
+a	O
+role	O
+of	O
+the	O
+ExoN	B-PRGE
+domain	I-PRGE
+in	O
+the	O
+N7	B-PRGE
+-	I-PRGE
+MTase	I-PRGE
+activity	O
+of	O
+nsp14	O
+.	O
+
+These	O
+results	O
+provide	O
+insights	O
+into	O
+the	O
+structure	O
+and	O
+functional	O
+mechanisms	O
+of	O
+coronaviral	O
+nsp14	B-PRGE
+N7	I-PRGE
+-	I-PRGE
+MTase	I-PRGE
+.	O
+
+Coinfections	B-DISO
+were	O
+present	O
+in	O
+21	O
+samples	O
+.	O
+
+The	O
+most	O
+common	O
+discharge	B-ANAT
+diagnoses	O
+were	O
+""""	O
+URTI	B-DISO
+""""	O
+with	O
+or	O
+without	O
+LRTI	B-DISO
+/	O
+asthma	B-PATH
+(	O
+n	O
+=	O
+58	O
+).	O
+
+Coinfections	B-DISO
+were	O
+detected	O
+in	O
+21	O
+of	O
+the	O
+patients	O
+.	O
+
+Approximately	O
+40	O
+%	O
+(	O
+n	O
+=	O
+32	O
+)	O
+of	O
+the	O
+patients	O
+developed	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+(	O
+ARDS	B-DISO
+).	O
+
+TITLE	O
+:	O
+Design	O
+,	O
+synthesis	B-PROC
+and	O
+antiviral	B-CHED
+activity	O
+of	O
+2	O
+-(	O
+3	O
+-	O
+amino	O
+-	O
+4	O
+-	O
+piperazinylphenyl	O
+)	O
+chromone	B-CHED
+derivatives	O
+.	O
+
+ABSTRACT	O
+:	O
+Amiodarone	B-CHED
+pulmonary	B-DISO
+toxicity	I-DISO
+(	O
+APT	O
+)	O
+is	O
+the	O
+most	O
+serious	O
+side	B-DISO
+effect	I-DISO
+of	O
+amiodarone	B-CHED
+.	O
+
+The	O
+patient	O
+was	O
+weaned	B-PROC
+from	O
+mechanical	O
+ventilation	O
+and	O
+has	O
+done	O
+well	O
+without	O
+recurrence	B-DISO
+.	O
+
+The	O
+diagnosis	O
+of	O
+AAC	O
+remains	O
+challenging	O
+to	O
+make	O
+,	O
+since	O
+it	O
+generally	O
+occurs	O
+as	O
+a	O
+secondary	O
+event	O
+in	O
+acutely	O
+ill	B-DISO
+patients	O
+with	O
+another	O
+disease	O
+.	O
+
+Ultrasonography	O
+revealed	O
+gallbladder	B-ANAT
+with	O
+wall	O
+thickening	O
+in	O
+all	O
+patients	O
+,	O
+plus	O
+other	O
+(	O
+s	O
+)	O
+major	O
+criteria	O
+.	O
+
+During	O
+this	O
+process	O
+,	O
+gene	O
+recombinations	B-PROC
+often	O
+occur	O
+,	O
+resulting	O
+in	O
+novel	O
+subtype	O
+or	O
+coronavirus	B-SPEC
+emerge	O
+constantly	O
+.	O
+
+This	O
+minireview	O
+summarized	O
+major	O
+advances	O
+of	O
+recently	O
+identified	O
+coronaviruses	O
+,	O
+focusing	O
+on	O
+the	O
+genome	O
+structures	O
+and	O
+interspecies	O
+jumping	O
+mechanism	O
+of	O
+coronavirus	B-SPEC
+.	O
+
+ABSTRACT	O
+:	O
+Chronic	O
+Obstructive	O
+Pulmonary	O
+Disease	O
+(	O
+COPD	B-DISO
+)	O
+is	O
+often	O
+associated	O
+with	O
+comorbidities	O
+,	O
+especially	O
+cardiovascular	B-ANAT
+,	O
+that	O
+have	O
+a	O
+heavy	O
+burden	O
+in	O
+terms	O
+of	O
+hospitalization	O
+and	O
+mortality	O
+.	O
+
+For	O
+each	O
+patient	O
+we	O
+recorded	O
+anthropometric	O
+and	O
+anamnestic	O
+data	O
+,	O
+smoking	O
+habits	O
+,	O
+respiratory	B-PROC
+function	I-PROC
+,	O
+GOLD	B-CHED
+(	O
+Global	O
+initiative	O
+for	O
+chronic	B-DISO
+Obstructive	I-DISO
+Lung	I-DISO
+Disease	I-DISO
+)	O
+severity	O
+stage	O
+,	O
+Body	B-ANAT
+Mass	O
+Index	O
+(	O
+BMI	O
+),	O
+number	O
+of	O
+acute	O
+COPD	B-DISO
+exacerbations	O
+in	O
+previous	O
+years	O
+,	O
+presence	O
+and	O
+type	O
+of	O
+comorbidities	O
+,	O
+and	O
+the	O
+Charlson	O
+Comorbidity	O
+Index	O
+(	O
+CCI	O
+).	O
+
+There	O
+was	O
+a	O
+high	O
+prevalence	O
+of	O
+arterial	B-DISO
+hypertension	I-DISO
+(	O
+52	O
+.	O
+1	O
+%),	O
+metabolic	B-DISO
+syndrome	I-DISO
+(	O
+20	O
+.	O
+7	O
+%),	O
+cancers	B-DISO
+(	O
+13	O
+.	O
+6	O
+%)	O
+and	O
+diabetes	B-DISO
+(	O
+11	O
+.	O
+2	O
+%)	O
+in	O
+the	O
+whole	O
+study	O
+group	O
+,	O
+and	O
+of	O
+anxiety	O
+-	O
+depression	B-DISO
+syndrome	B-DISO
+in	O
+females	O
+(	O
+13	O
+%).	O
+
+Exacerbation	O
+frequency	O
+was	O
+positively	O
+correlated	O
+with	O
+dyspnea	B-DISO
+score	O
+and	O
+negatively	O
+with	O
+BMI	O
+.	O
+
+Use	O
+of	O
+combination	O
+of	O
+bronchodilators	O
+and	O
+inhaled	B-PROC
+corticosteroids	B-CHED
+was	O
+more	O
+frequent	O
+in	O
+younger	O
+patients	O
+with	O
+more	O
+severe	O
+airways	B-DISO
+obstruction	I-DISO
+and	O
+lower	O
+CCI	O
+.	O
+
+All	O
+interactions	O
+between	O
+TIM1	B-PRGE
+and	O
+pseudoviruses	O
+or	O
+VLPs	B-ANAT
+were	O
+PS	O
+-	O
+mediated	O
+,	O
+as	O
+demonstrated	O
+with	O
+liposome	O
+blocking	B-DISO
+and	O
+TIM1	B-PRGE
+mutagenesis	B-PROC
+experiments	O
+.	O
+
+Moreover	O
+,	O
+most	O
+epidemiological	O
+studies	O
+on	O
+ventilatory	O
+support	O
+were	O
+carried	O
+out	O
+before	O
+significant	O
+developments	O
+,	O
+such	O
+as	O
+lung	B-ANAT
+protective	O
+ventilation	O
+or	O
+broader	O
+application	O
+of	O
+non	O
+-	O
+invasive	O
+ventilation	O
+(	O
+NIV	O
+).	O
+
+ABSTRACT	O
+:	O
+Progress	O
+in	O
+intensive	O
+care	O
+(	O
+ICU	O
+)	O
+treatment	O
+of	O
+acute	O
+respiratory	O
+distress	O
+syndrome	O
+(	O
+ARDS	B-DISO
+)	O
+over	O
+the	O
+last	O
+20	O
+years	O
+includes	O
+the	O
+introduction	O
+of	O
+extracorporeal	O
+membrane	B-COMP
+oxygenation	B-PROC
+(	O
+ECMO	O
+)	O
+for	O
+CO2	B-CHED
+removal	O
+and	O
+the	O
+widespread	O
+use	O
+of	O
+evidence	O
+-	O
+based	O
+lung	B-ANAT
+-	O
+protective	O
+ventilatory	O
+strategies	O
+.	O
+
+TITLE	O
+:	O
+Mast	B-ANAT
+cells	I-ANAT
+in	O
+Canine	O
+parvovirus	B-DISO
+-	O
+2	O
+-	O
+associated	O
+enteritis	B-DISO
+with	O
+crypt	B-DISO
+abscess	I-DISO
+.	O
+
+In	O
+this	O
+study	O
+,	O
+investigation	O
+is	O
+made	O
+to	O
+determine	O
+if	O
+MCs	B-COMP
+are	O
+associated	O
+with	O
+Canine	O
+parvovirus	B-DISO
+-	O
+2	O
+(	O
+CPV	B-SPEC
+-	O
+2	O
+)-	O
+induced	O
+enteritis	B-DISO
+with	O
+crypt	B-DISO
+abscess	I-DISO
+(	O
+ECA	O
+).	O
+
+These	O
+included	O
+16	O
+dogs	B-SPEC
+exhibiting	O
+ECA	O
+positive	O
+for	O
+CPV	B-SPEC
+-	O
+2	O
+and	O
+negative	O
+for	O
+Canine	B-SPEC
+distemper	I-SPEC
+virus	I-SPEC
+and	O
+Canine	O
+coronavirus	B-SPEC
+by	O
+immunohistochemistry	O
+and	O
+fluorescent	O
+antibody	B-COMP
+test	O
+,	O
+12	O
+dogs	B-SPEC
+with	O
+inflammatory	B-DISO
+bowel	I-DISO
+disease	I-DISO
+(	O
+IBD	B-DISO
+),	O
+and	O
+6	O
+non	O
+-	O
+ECA	O
+/	O
+non	O
+-	O
+IBD	B-DISO
+(	O
+control	O
+)	O
+dogs	B-SPEC
+.	O
+
+The	O
+average	O
+total	O
+MCC	B-COMP
+per	O
+high	O
+-	O
+power	O
+field	O
+in	O
+ECA	O
+(	O
+40	O
+.	O
+8	O
+±	O
+2	O
+.	O
+2	O
+)	O
+and	O
+IBD	B-DISO
+(	O
+24	O
+.	O
+7	O
+±	O
+2	O
+.	O
+1	O
+)	O
+was	O
+significantly	O
+higher	O
+(	O
+P	O
+<	O
+.	O
+05	O
+)	O
+than	O
+in	O
+the	O
+control	O
+(	O
+3	O
+.	O
+4	O
+±	O
+0	O
+.	O
+6	O
+).	O
+
+In	O
+severe	O
+ARDS	B-DISO
+(	O
+PaO2	O
+/	O
+FIO2	O
+=	O
+P	O
+/	O
+F	O
+<	O
+100	O
+with	O
+positive	O
+end	B-PROC
+-	I-PROC
+expiratory	I-PROC
+pressure	O
+(	O
+PEEP	B-CHED
+)	O
+≥	O
+5	O
+cm	O
+H2O	B-CHED
+),	O
+current	O
+recommendations	O
+are	O
+to	O
+intubate	O
+the	O
+trachea	B-DISO
+of	O
+the	O
+patient	O
+and	O
+use	O
+mechanical	O
+ventilation	O
+,	O
+low	O
+tidal	O
+volume	O
+,	O
+high	O
+PEEP	B-CHED
+,	O
+prone	O
+positioning	O
+and	O
+possibly	O
+neuromuscular	B-DISO
+blockade	I-DISO
+in	O
+association	O
+with	O
+intravenous	O
+sedation	B-DISO
+.	O
+
+Firstly	O
+,	O
+spontaneous	O
+ventilation	O
+(	O
+SV	O
+)	O
+coupled	O
+with	O
+pressure	O
+support	O
+(	O
+PS	O
+)	O
+ventilation	O
+and	O
+high	O
+PEEP	B-CHED
+is	O
+possible	O
+from	O
+tracheal	O
+intubation	O
+onwards	O
+,	O
+with	O
+the	O
+possible	O
+exception	O
+of	O
+the	O
+short	O
+period	O
+following	O
+immediately	O
+tracheal	O
+intubation	O
+.	O
+
+The	O
+results	O
+show	O
+that	O
+the	O
+PEDV	B-PRGE
+N	I-PRGE
+protein	B-CHED
+localizes	O
+in	O
+the	O
+endoplasmic	B-COMP
+reticulum	I-COMP
+(	O
+ER	O
+),	O
+inhibits	O
+the	O
+IEC	O
+growth	B-PROC
+and	O
+prolongs	O
+S	B-PROC
+-	I-PROC
+phase	I-PROC
+cell	B-PATH
+cycle	I-PATH
+.	O
+
+These	O
+findings	O
+provide	O
+novel	O
+information	O
+on	O
+the	O
+function	O
+of	O
+the	O
+PEDV	B-PRGE
+N	I-PRGE
+protein	B-CHED
+and	O
+are	O
+likely	O
+to	O
+be	O
+very	O
+useful	O
+in	O
+understanding	O
+the	O
+molecular	O
+mechanisms	O
+responsible	O
+for	O
+PEDV	B-SPEC
+pathogenesis	B-DISO
+.	O
+
+We	O
+report	O
+two	O
+cases	O
+of	O
+young	O
+female	O
+patients	O
+afflicted	O
+by	O
+Lemierre	B-DISO
+syndrome	I-DISO
+with	O
+additional	O
+severe	O
+ARDS	B-DISO
+and	O
+present	O
+an	O
+overview	O
+of	O
+the	O
+current	O
+literature	O
+.	O
+
+In	O
+May	O
+2010	O
+,	O
+a	O
+malnourished	B-DISO
+young	O
+adult	O
+male	O
+mountain	O
+lion	B-SPEC
+(	O
+Puma	B-SPEC
+concolor	I-SPEC
+)	O
+from	O
+Kern	B-CHED
+County	O
+,	O
+California	B-SPEC
+,	O
+USA	O
+was	O
+euthanized	O
+because	O
+of	O
+concern	O
+for	O
+public	O
+safety	O
+,	O
+and	O
+a	O
+postmortem	O
+examination	O
+was	O
+performed	O
+.	O
+
+Congenital	B-DISO
+CMV	I-DISO
+infection	I-DISO
+should	O
+also	O
+be	O
+considered	O
+in	O
+newborns	O
+with	O
+severe	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+and	O
+refractory	O
+respiratory	B-DISO
+failure	I-DISO
+with	O
+progression	O
+to	O
+early	O
+chronic	B-DISO
+lung	I-DISO
+disease	I-DISO
+.	O
+
+The	O
+association	O
+between	O
+breast	B-ANAT
+milk	I-ANAT
+-	O
+transmitted	B-DISO
+CMV	B-SPEC
+and	O
+development	B-PROC
+of	O
+cystic	B-DISO
+lung	I-DISO
+disease	I-DISO
+and	O
+Wilson	B-DISO
+-	I-DISO
+Mikity	I-DISO
+syndrome	I-DISO
+has	O
+also	O
+been	O
+reported	O
+.	O
+
+Data	O
+analysis	O
+was	O
+performed	O
+by	O
+a	O
+multidisciplinary	O
+team	O
+using	O
+a	O
+grounded	O
+theory	O
+approach	O
+to	O
+generate	O
+themes	O
+inductively	O
+from	O
+respondents	O
+'	O
+expressed	B-PROC
+perspectives	O
+.	O
+
+TITLE	O
+:	O
+Unusual	O
+presentation	O
+of	O
+Guillain	O
+-	O
+Barré	O
+syndrome	B-DISO
+following	O
+traumatic	O
+bone	B-ANAT
+injuries	O
+:	O
+report	O
+of	O
+two	O
+cases	O
+.	O
+
+An	O
+oxygenator	O
+used	O
+in	O
+conjunction	O
+with	O
+a	O
+VAD	O
+may	O
+be	O
+a	O
+life	O
+-	O
+saving	O
+therapy	O
+,	O
+allowing	O
+adequate	O
+oxygenation	B-PROC
+and	O
+ventilation	O
+in	O
+severe	O
+respiratory	O
+and	O
+cardiac	B-DISO
+failure	I-DISO
+.	O
+
+ABSTRACT	O
+:	O
+A	O
+novel	O
+betacoronavirus	B-SPEC
+,	O
+human	B-SPEC
+coronavirus	I-SPEC
+(	O
+HCoV	O
+-	O
+EMC	B-COMP
+),	O
+has	O
+recently	O
+been	O
+detected	O
+in	O
+humans	B-SPEC
+with	O
+severe	O
+respiratory	B-DISO
+disease	I-DISO
+.	O
+
+Further	O
+characterization	O
+of	O
+HCoV	B-PRGE
+-	I-PRGE
+EMC	I-PRGE
+suggests	O
+that	O
+this	O
+virus	B-SPEC
+is	O
+different	O
+from	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+coronavirus	B-SPEC
+(	O
+SARS	B-DISO
+-	O
+CoV	O
+)	O
+because	O
+it	O
+is	O
+able	O
+to	O
+replicate	O
+in	O
+multiple	O
+mammalian	B-ANAT
+cell	B-COMP
+lines	O
+and	O
+it	O
+does	O
+not	O
+use	O
+angiotensin	B-PRGE
+-	I-PRGE
+converting	I-PRGE
+enzyme	I-PRGE
+2	I-PRGE
+as	O
+a	O
+receptor	O
+to	O
+achieve	O
+infection	B-DISO
+.	O
+
+In	O
+Guatemala	O
+(	O
+2011	O
+population	O
+14	O
+.	O
+7	O
+million	O
+persons	O
+),	O
+the	O
+annual	O
+number	O
+of	O
+hospitalized	O
+cases	O
+of	O
+influenza	B-DISO
+-	O
+associated	O
+pneumonia	B-DISO
+ranged	O
+from	O
+1	O
+,	O
+065	O
+-	O
+2	O
+,	O
+259	O
+(	O
+0	O
+.	O
+5	O
+-	O
+1	O
+.	O
+0	O
+per	O
+1	O
+,	O
+000	O
+persons	O
+)	O
+among	O
+children	O
+<	O
+5	O
+years	O
+old	O
+and	O
+779	O
+-	O
+2	O
+,	O
+252	O
+cases	O
+(	O
+0	O
+.	O
+1	O
+-	O
+0	O
+.	O
+2	O
+per	O
+1	O
+,	O
+000	O
+persons	O
+)	O
+for	O
+persons	O
+≥	O
+5	O
+years	O
+old	O
+,	O
+depending	O
+on	O
+year	O
+and	O
+base	O
+rate	O
+used	O
+.	O
+
+In	O
+both	O
+countries	O
+,	O
+the	O
+number	O
+of	O
+non	O
+-	O
+hospitalized	O
+influenza	B-DISO
+-	O
+associated	O
+cases	O
+was	O
+several	O
+-	O
+fold	O
+higher	O
+than	O
+the	O
+hospitalized	O
+cases	O
+.	O
+
+A	O
+novel	O
+reassortant	O
+avian	B-SPEC
+-	O
+origin	O
+influenza	B-PATH
+A	I-PATH
+(	O
+H7N9	B-PATH
+)	O
+virus	B-SPEC
+was	O
+isolated	O
+from	O
+respiratory	O
+specimens	O
+obtained	O
+from	O
+all	O
+three	O
+patients	O
+and	O
+was	O
+identified	O
+as	O
+H7N9	B-PATH
+.	O
+
+A	O
+T160A	O
+mutation	O
+was	O
+identified	O
+at	O
+the	O
+150	O
+-	O
+loop	O
+in	O
+the	O
+HA	B-PRGE
+gene	I-PRGE
+of	O
+all	O
+three	O
+viruses	B-SPEC
+.	O
+
+Importantly	O
+soluble	O
+fibrinogen	B-COMP
+in	O
+acute	O
+-	O
+phase	O
+concentrations	O
+(	O
+4	O
+-	O
+10	O
+mg	O
+mL	O
+(-	O
+1	O
+)	O
+)	O
+dose	O
+-	O
+dependently	O
+reduced	O
+neutrophil	B-ANAT
+firm	O
+adhesion	B-DISO
+to	O
+tumor	B-PRGE
+necrosis	I-PRGE
+factor	I-PRGE
+-	I-PRGE
+α	I-PRGE
+-	O
+activated	O
+endothelium	B-ANAT
+to	O
+40	O
+%	O
+under	O
+flow	O
+conditions	O
+.	O
+
+The	O
+histopathological	O
+findings	O
+in	O
+the	O
+affected	O
+lungs	B-ANAT
+were	O
+characterized	O
+by	O
+a	O
+granulomatous	B-DISO
+pneumonia	I-DISO
+.	O
+
+Exposure	O
+to	O
+other	O
+intercurrent	O
+factors	O
+,	O
+including	O
+adverse	O
+weather	O
+conditions	O
+and	O
+internal	O
+parasitism	B-PROC
+,	O
+may	O
+also	O
+have	O
+exacerbated	O
+the	O
+severity	O
+of	O
+disease	O
+.	O
+
+TITLE	O
+:	O
+Cross	B-PROC
+-	I-PROC
+reactive	I-PROC
+antibodies	B-COMP
+in	O
+convalescent	O
+SARS	B-DISO
+patients	O
+'	O
+sera	B-COMP
+against	O
+the	O
+emerging	O
+novel	O
+human	B-SPEC
+coronavirus	I-SPEC
+EMC	B-COMP
+(	O
+2012	O
+)	O
+by	O
+both	O
+immunofluorescent	O
+and	O
+neutralizing	O
+antibody	B-COMP
+tests	O
+.	O
+
+No	O
+blood	B-ANAT
+donor	B-CHED
+had	O
+antibody	B-COMP
+against	O
+either	O
+virus	B-SPEC
+.	O
+
+TITLE	O
+:	O
+Alcoholic	O
+lung	B-DISO
+disease	I-DISO
+.	O
+
+ABSTRACT	O
+:	O
+In	O
+addition	O
+to	O
+its	O
+well	O
+-	O
+known	O
+association	O
+with	O
+lung	B-ANAT
+infection	I-DISO
+(	O
+i	O
+.	O
+e	O
+.,	O
+pneumonia	O
+),	O
+alcohol	B-DISO
+abuse	I-DISO
+now	O
+is	O
+recognized	O
+as	O
+an	O
+independent	O
+factor	O
+that	O
+increases	O
+by	O
+three	O
+-	O
+to	O
+four	O
+-	O
+fold	O
+the	O
+incidence	O
+of	O
+the	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+,	O
+a	O
+severe	O
+form	O
+of	O
+acute	O
+lung	B-ANAT
+injury	O
+with	O
+a	O
+mortality	O
+rate	O
+of	O
+40	O
+to	O
+50	O
+percent	O
+.	O
+
+This	O
+translates	O
+to	O
+tens	O
+of	O
+thousands	O
+of	O
+excess	O
+deaths	B-PROC
+in	O
+the	O
+United	O
+States	O
+each	O
+year	O
+from	O
+alcohol	O
+-	O
+mediated	O
+lung	B-ANAT
+injury	O
+,	O
+which	O
+is	O
+comparable	O
+to	O
+scarring	B-DISO
+of	O
+the	O
+liver	B-ANAT
+(	O
+i	O
+.	O
+e	O
+.,	O
+cirrhosis	B-DISO
+)	O
+in	O
+terms	O
+of	O
+alcohol	O
+-	O
+related	O
+mortality	O
+.	O
+
+Functional	O
+signs	O
+were	O
+limited	O
+to	O
+respiratory	O
+dyspnea	B-DISO
+,	O
+it	O
+was	O
+associated	O
+to	O
+dysphagia	B-DISO
+in	O
+six	O
+cases	O
+,	O
+dry	O
+syndrome	B-DISO
+in	O
+five	O
+cases	O
+and	O
+Raynaud	B-DISO
+'	I-DISO
+s	I-DISO
+phenomenon	I-DISO
+in	O
+four	O
+cases	O
+.	O
+
+All	O
+patients	O
+were	O
+treated	O
+by	O
+steroids	B-CHED
+with	O
+improvement	O
+of	O
+dyspnea	B-DISO
+and	O
+stabilization	O
+of	O
+radiographs	O
+.	O
+
+TITLE	O
+:	O
+Avian	B-SPEC
+metapneumoviruses	B-SPEC
+expressing	O
+Infectious	B-DISO
+Bronchitis	B-DISO
+virus	B-SPEC
+genes	O
+are	O
+stable	O
+and	O
+induce	O
+protection	O
+.	O
+
+TITLE	O
+:	O
+Relationship	O
+between	O
+post	O
+-	O
+SARS	B-DISO
+osteonecrosis	B-DISO
+and	O
+PAI	B-PRGE
+-	I-PRGE
+1	I-PRGE
+4G	I-PRGE
+/	I-PRGE
+5G	I-PRGE
+gene	I-PRGE
+polymorphisms	O
+.	O
+
+Empty	O
+stomach	B-ANAT
+blood	B-ANAT
+samples	I-ANAT
+from	O
+cubital	O
+veins	B-ANAT
+were	O
+collected	O
+from	O
+both	O
+groups	O
+.	O
+
+In	O
+one	O
+cat	B-SPEC
+,	O
+two	O
+different	O
+lineages	O
+of	O
+FCoV	O
+,	O
+one	O
+enteric	O
+and	O
+one	O
+systemic	O
+,	O
+were	O
+found	O
+that	O
+segregated	O
+apart	O
+in	O
+the	O
+M	O
+gene	O
+tree	O
+.	O
+
+ARDS	B-DISO
+due	O
+to	O
+multiple	O
+etiologies	O
+was	O
+managed	O
+with	O
+ECMO	O
+in	O
+36	O
+adults	O
+.	O
+
+ECMO	O
+was	O
+successfully	O
+weaned	O
+in	O
+67	O
+%	O
+of	O
+patients	O
+,	O
+and	O
+60	O
+%	O
+survived	O
+to	O
+discharge	B-ANAT
+.	O
+
+ECMO	O
+provides	O
+support	O
+that	O
+prevents	O
+ventilator	O
+-	O
+induced	O
+lung	B-ANAT
+injury	O
+while	O
+the	O
+lungs	B-ANAT
+heal	B-PROC
+.	O
+
+The	O
+investigators	O
+present	O
+a	O
+series	O
+of	O
+36	O
+adults	O
+with	O
+refractory	O
+hypoxemic	O
+ARDS	B-DISO
+(	O
+ratio	O
+of	O
+partial	B-PROC
+pressure	I-PROC
+of	I-PROC
+oxygen	I-PROC
+to	O
+fraction	O
+of	O
+inspired	B-PROC
+oxygen	B-CHED
+<	O
+50	O
+)	O
+from	O
+17	O
+different	O
+facilities	O
+who	O
+,	O
+treated	O
+with	O
+ECMO	O
+at	O
+a	O
+single	O
+referral	O
+center	O
+,	O
+had	O
+a	O
+60	O
+%	O
+survival	O
+rate	O
+.	O
+
+This	O
+relatively	O
+young	O
+age	O
+is	O
+in	O
+sharp	O
+contrast	O
+to	O
+the	O
+ancient	O
+evolutionary	O
+history	O
+of	O
+their	O
+putative	O
+natural	O
+hosts	B-COMP
+,	O
+which	O
+began	O
+diversifying	O
+tens	O
+of	O
+millions	O
+of	O
+years	O
+ago	O
+.	O
+
+TITLE	O
+:	O
+Ultra	O
+-	O
+fast	B-FUNC
+separation	B-DISO
+of	O
+infectious	B-DISO
+disease	I-DISO
+-	O
+related	O
+small	O
+DNA	O
+molecules	O
+by	O
+single	O
+-	O
+and	O
+multi	O
+-	O
+channel	O
+microchip	O
+electrophoresis	O
+.	O
+
+As	O
+a	O
+model	O
+of	O
+infectious	B-DISO
+disease	I-DISO
+-	O
+related	O
+small	O
+DNA	O
+molecules	O
+,	O
+the	O
+spike	O
+glycoprotein	B-CHED
+(	O
+S	O
+)	O
+gene	O
+of	O
+the	O
+Feline	B-DISO
+infectious	I-DISO
+peritonitis	I-DISO
+(	O
+FIP	B-DISO
+)	O
+virus	B-SPEC
+was	O
+amplified	O
+using	O
+reverse	O
+transcript	O
+polymerase	O
+chain	O
+reaction	O
+.	O
+
+These	O
+two	O
+model	O
+solutions	O
+correspond	O
+to	O
+significantly	O
+different	O
+mechanical	O
+properties	O
+of	O
+the	O
+tissue	B-ANAT
+,	O
+and	O
+we	O
+discuss	O
+the	O
+implications	O
+of	O
+these	O
+different	O
+properties	O
+and	O
+the	O
+requirements	O
+for	O
+new	O
+experimental	O
+data	O
+to	O
+discriminate	O
+between	O
+the	O
+hypotheses	O
+.	O
+
+A	O
+tracheostomy	O
+tube	O
+was	O
+placed	O
+,	O
+and	O
+choanal	B-DISO
+atresia	I-DISO
+repair	B-PROC
+was	O
+eventually	O
+performed	O
+.	O
+
+In	O
+this	O
+study	O
+,	O
+a	O
+monoclonal	O
+antibody	B-COMP
+(	O
+MAb	O
+)	O
+designated	O
+7G7	O
+,	O
+against	O
+the	O
+TGEV	B-PRGE
+M	I-PRGE
+protein	B-CHED
+was	O
+generated	O
+by	O
+inoculating	O
+BALB	O
+/	O
+c	O
+mice	B-SPEC
+with	O
+TGEV	B-SPEC
+followed	O
+by	O
+hybridoma	B-ANAT
+technique	O
+.	O
+
+ABSTRACT	O
+:	O
+The	O
+variable	O
+regions	O
+of	O
+the	O
+heavy	O
+chain	O
+(	O
+VH	O
+)	O
+and	O
+light	O
+chain	O
+(	O
+VL	O
+)	O
+were	O
+amplified	O
+by	O
+RT	O
+-	O
+PCR	O
+from	O
+the	O
+hybridoma	B-ANAT
+6E6	O
+,	O
+which	O
+secretes	O
+the	O
+monoclonal	O
+antibody	B-COMP
+against	O
+PEDV	B-PRGE
+S	I-PRGE
+protein	B-CHED
+.	O
+
+The	O
+MAb	O
+1H4	O
+distinguished	O
+TGEV	B-SPEC
+from	O
+other	O
+control	O
+viruses	B-SPEC
+.	O
+
+CONCLUSIONS	O
+:	O
+Transmission	O
+tracking	O
+technique	O
+is	O
+practicable	O
+and	O
+efficient	O
+to	O
+trace	O
+the	O
+source	O
+of	O
+infection	B-DISO
+,	O
+analyze	O
+the	O
+transmission	O
+tracks	O
+,	O
+establish	O
+the	O
+isolation	O
+buffer	B-CHED
+area	O
+and	O
+explore	O
+the	O
+important	O
+geographic	O
+positions	O
+in	O
+epidemiological	O
+investigation	O
+.	O
+
+A	O
+majority	O
+of	O
+respondents	O
+reported	O
+almost	O
+always	O
+prescribing	O
+corticosteroids	B-CHED
+in	O
+the	O
+setting	O
+of	O
+significant	O
+bronchospasm	B-DISO
+in	O
+a	O
+mechanically	O
+ventilated	O
+patient	O
+(	O
+94	O
+%),	O
+recent	O
+corticosteroid	B-CHED
+use	O
+and	O
+low	O
+blood	B-PROC
+pressure	I-PROC
+(	O
+93	O
+%),	O
+and	O
+vasopressor	O
+-	O
+refractory	O
+septic	B-DISO
+shock	I-DISO
+(	O
+52	O
+%).	O
+
+TITLE	O
+:	O
+An	O
+experimental	O
+study	O
+of	O
+the	O
+survival	O
+of	O
+turkey	B-SPEC
+coronavirus	B-SPEC
+at	O
+room	O
+temperature	O
+and	O
++	O
+4	O
+°	O
+C	O
+.	O
+
+High	B-PRGE
+mobility	I-PRGE
+group	I-PRGE
+box	I-PRGE
+1	I-PRGE
+(	O
+HMGB1	B-PRGE
+),	O
+which	O
+was	O
+identified	O
+originally	O
+as	O
+a	O
+DNA	B-FUNC
+binding	I-FUNC
+protein	B-CHED
+,	O
+has	O
+been	O
+proposed	O
+as	O
+a	O
+mediator	O
+of	O
+acute	O
+lung	B-ANAT
+injury	O
+.	O
+
+In	O
+addition	O
+to	O
+its	O
+anti	O
+-	O
+coagulant	O
+activity	O
+,	O
+recombinant	B-PRGE
+thrombomodulin	I-PRGE
+(	O
+rTM	O
+)	O
+possesses	B-DISO
+an	O
+ability	O
+to	O
+suppress	O
+the	O
+inflammatory	B-DISO
+response	I-DISO
+through	O
+neutralizing	O
+HMGB1	B-PRGE
+.	O
+
+T	O
+(	O
+reg	O
+)	O
+cells	B-COMP
+were	O
+reduced	O
+significantly	O
+in	O
+the	O
+lungs	B-ANAT
+of	O
+ARDS	B-DISO
+mice	B-SPEC
+compared	O
+to	O
+those	O
+in	O
+mice	B-SPEC
+treated	O
+with	O
+LPS	B-DISO
+alone	O
+.	O
+
+These	O
+results	O
+suggest	O
+that	O
+HMGB1	B-PRGE
+is	O
+involved	O
+in	O
+the	O
+development	B-PROC
+of	O
+severe	O
+ARDS	B-DISO
+and	O
+rTM	O
+shows	O
+therapeutic	O
+effects	O
+through	O
+promoting	O
+the	O
+accumulation	O
+of	O
+T	O
+(	O
+reg	O
+)	O
+cells	B-COMP
+at	O
+the	O
+inflammatory	O
+sites	O
+.	O
+
+ABSTRACT	O
+:	O
+Feline	B-DISO
+infectious	I-DISO
+peritonitis	I-DISO
+(	O
+FIP	B-DISO
+)	O
+is	O
+a	O
+common	O
+,	O
+fatal	O
+,	O
+systemic	B-DISO
+disease	I-DISO
+of	O
+cats	B-SPEC
+.	O
+
+To	O
+date	O
+,	O
+the	O
+only	O
+treatment	O
+shown	O
+to	O
+increase	O
+survival	O
+rate	O
+in	O
+patients	O
+with	O
+ARDS	B-DISO
+is	O
+the	O
+use	O
+of	O
+supportive	O
+mechanical	O
+ventilation	O
+using	O
+low	O
+tidal	O
+volumes	O
+.	O
+
+Extracorporeal	O
+membrane	B-COMP
+oxygenation	B-PROC
+(	O
+ECMO	O
+)	O
+is	O
+a	O
+therapy	O
+that	O
+has	O
+been	O
+used	O
+in	O
+severe	O
+cases	O
+of	O
+ARDS	B-DISO
+when	O
+patients	O
+fail	O
+to	O
+improve	O
+with	O
+traditional	O
+management	O
+.	O
+
+The	O
+patient	O
+was	O
+treated	O
+according	O
+to	O
+the	O
+hospital	O
+protocol	O
+for	O
+the	O
+management	O
+of	O
+pneumonia	B-DISO
+and	O
+malnutrition	B-DISO
+.	O
+
+Difficulties	O
+in	O
+doing	O
+GWAS	O
+in	O
+cats	B-SPEC
+and	O
+interrogating	O
+complex	O
+genetic	O
+traits	O
+were	O
+discussed	O
+.	O
+
+These	O
+findings	O
+highlight	O
+relevant	O
+differences	O
+between	O
+these	O
+distantly	O
+related	O
+zoonotic	O
+CoVs	O
+in	O
+terms	O
+of	O
+their	O
+interaction	O
+with	O
+and	O
+evasion	O
+of	O
+the	O
+cellular	B-COMP
+innate	B-DISO
+immune	I-DISO
+response	I-DISO
+.	O
+
+Most	O
+often	O
+seen	O
+in	O
+females	O
+,	O
+it	O
+usually	O
+begins	O
+with	O
+a	O
+prodromal	O
+phase	O
+suggestive	O
+of	O
+an	O
+acute	O
+or	O
+subclinical	O
+upper	B-DISO
+respiratory	I-DISO
+tract	I-DISO
+infection	I-DISO
+that	O
+lasts	O
+for	O
+up	O
+to	O
+2	O
+weeks	O
+.	O
+
+ABSTRACT	O
+:	O
+We	O
+screened	O
+fecal	O
+specimens	O
+of	O
+4	O
+,	O
+758	O
+bats	B-SPEC
+from	O
+Ghana	O
+and	O
+272	O
+bats	B-SPEC
+from	O
+4	O
+European	O
+countries	O
+for	O
+betacoronaviruses	O
+.	O
+
+However	O
+,	O
+essential	O
+immune	O
+functions	O
+of	O
+FRCs	B-PROC
+,	O
+including	O
+homeostatic	B-PRGE
+chemokine	I-PRGE
+and	O
+interleukin	B-PRGE
+-	I-PRGE
+7	I-PRGE
+expression	B-PROC
+,	O
+were	O
+impaired	B-DISO
+.	O
+
+Structure	O
+analysis	O
+of	O
+new	O
+compounds	O
+(	O
+1	O
+-	O
+5	O
+)	O
+by	O
+NMR	O
+showed	O
+that	O
+they	O
+all	O
+contain	O
+a	O
+3	O
+,	O
+4	O
+-	O
+dihydro	O
+-	O
+2H	B-CHED
+-	I-CHED
+pyran	I-CHED
+moiety	O
+.	O
+
+Based	O
+on	O
+the	O
+208	O
+base	B-FUNC
+pair	I-FUNC
+(	O
+bp	O
+)	O
+sequence	O
+of	O
+novel	O
+HCoV	O
+reported	O
+by	O
+HPA	B-CHED
+of	O
+UK	O
+,	O
+we	O
+designed	O
+and	O
+obtained	O
+several	O
+pairs	O
+of	O
+primer	O
+(	O
+F	O
+-	O
+1	O
+,	O
+R	O
+-	O
+1	O
+;	O
+F	O
+-	O
+2	O
+,	O
+R	O
+-	O
+2	O
+)	O
+and	O
+Taqman	O
+probes	O
+(	O
+TZ1	O
+,	O
+TZ2	O
+)	O
+for	O
+detection	O
+of	O
+novel	O
+HCoV	O
+.	O
+Two	O
+of	O
+probes	O
+were	O
+modified	O
+with	O
+LNA	B-CHED
+(	O
+LNA	B-CHED
+-	O
+TZ1	O
+,	O
+LNA	B-CHED
+-	O
+TZ2	O
+).	O
+
+The	O
+upE	O
+or	O
+LNA	B-CHED
+-	O
+TZ1	O
+based	O
+real	O
+time	O
+RT	O
+-	O
+PCR	O
+assay	O
+was	O
+recommend	O
+for	O
+detection	O
+of	O
+novel	O
+HCoV	O
+.	O
+This	O
+study	O
+laid	O
+a	O
+foundation	O
+for	O
+improving	O
+the	O
+performance	O
+of	O
+novel	O
+HCoV	O
+detection	O
+.	O
+
+TITLE	O
+:	O
+[	O
+The	O
+detection	O
+and	O
+clinical	O
+feature	O
+of	O
+HcoV	B-SPEC
+-	I-SPEC
+nL63	I-SPEC
+in	O
+children	O
+with	O
+acute	B-DISO
+respiratory	B-ANAT
+tract	I-ANAT
+infection	I-DISO
+in	O
+Lanzhou	O
+city	O
+].	O
+
+From	O
+November	O
+2006	O
+to	O
+October	O
+2009	O
+,	O
+1169	O
+nasopharyngeal	B-ANAT
+aspirates	B-ANAT
+(	O
+NPA	B-CHED
+)	O
+were	O
+collected	O
+from	O
+children	O
+under	O
+14	O
+years	O
+old	O
+with	O
+ARTIs	O
+.	O
+
+Samples	O
+were	O
+screened	O
+for	O
+NL63	O
+using	O
+a	O
+reverse	B-PROC
+transcription	I-PROC
+-	O
+polymerase	O
+chain	O
+reaction	O
+(	O
+RT	O
+-	O
+PCR	O
+)	O
+and	O
+sequencing	O
+.	O
+
+25	O
+(	O
+25	O
+/	O
+35	O
+,	O
+71	O
+.	O
+43	O
+%)	O
+were	O
+co	O
+-	O
+infected	O
+with	O
+other	O
+respiratory	O
+viruses	B-SPEC
+,	O
+and	O
+human	O
+rhinovirus	O
+(	O
+HRV	O
+)	O
+were	O
+the	O
+most	O
+common	O
+additional	O
+respiratory	O
+virus	B-SPEC
+.	O
+
+Additionally	O
+,	O
+MHV	B-SPEC
+S	O
+assembly	O
+could	O
+also	O
+be	O
+rescued	O
+by	O
+the	O
+acidic	O
+carboxy	B-CHED
+-	O
+terminal	O
+domain	O
+of	O
+the	O
+nucleocapsid	B-COMP
+protein	B-CHED
+.	O
+
+TITLE	O
+:	O
+Risk	O
+factors	O
+for	O
+severe	O
+acute	O
+lower	O
+respiratory	B-DISO
+infections	I-DISO
+in	O
+children	O
+:	O
+a	O
+systematic	O
+review	O
+and	O
+meta	O
+-	O
+analysis	O
+.	O
+
+ABSTRACT	O
+:	O
+A	O
+novel	O
+human	B-SPEC
+coronavirus	I-SPEC
+(	O
+HCoV	O
+-	O
+EMC	B-COMP
+)	O
+was	O
+recently	O
+identified	O
+in	O
+the	O
+Middle	O
+East	O
+as	O
+the	O
+causative	O
+agent	O
+of	O
+a	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+(	O
+SARS	B-DISO
+)	O
+resembling	O
+the	O
+illness	O
+caused	O
+by	O
+SARS	B-DISO
+coronavirus	B-SPEC
+(	O
+SARS	B-DISO
+-	O
+CoV	O
+).	O
+
+Later	O
+in	O
+infection	B-DISO
+,	O
+HCoV	O
+-	O
+EMC	B-COMP
+induced	O
+a	O
+massive	O
+dysregulation	O
+of	O
+the	O
+host	B-COMP
+transcriptome	O
+,	O
+to	O
+a	O
+much	O
+greater	O
+extent	O
+than	O
+SARS	B-DISO
+-	O
+CoV	O
+.	O
+Both	O
+viruses	B-SPEC
+induced	O
+a	O
+similar	O
+activation	O
+of	O
+pattern	O
+recognition	O
+receptors	O
+and	O
+the	O
+interleukin	B-PRGE
+17	I-PRGE
+(	O
+IL	B-PROC
+-	I-PROC
+17	I-PROC
+)	O
+pathway	B-PROC
+,	O
+but	O
+HCoV	B-PRGE
+-	I-PRGE
+EMC	I-PRGE
+specifically	O
+down	O
+-	O
+regulated	O
+the	O
+expression	B-PROC
+of	O
+several	O
+genes	O
+within	O
+the	O
+antigen	B-PROC
+presentation	I-PROC
+pathway	I-PROC
+,	O
+including	O
+both	O
+type	O
+I	O
+and	O
+II	O
+major	B-PROC
+histocompatibility	I-PROC
+complex	I-PROC
+(	O
+MHC	B-PROC
+)	O
+genes	O
+.	O
+
+Overall	O
+,	O
+HCoV	O
+-	O
+EMC	B-COMP
+and	O
+SARS	B-DISO
+-	O
+CoV	O
+elicit	O
+distinct	O
+host	B-COMP
+gene	B-PROC
+expression	I-PROC
+responses	O
+,	O
+which	O
+might	O
+impact	O
+in	O
+vivo	O
+pathogenesis	B-DISO
+and	O
+could	O
+orient	O
+therapeutic	O
+strategies	O
+against	O
+that	O
+emergent	O
+virus	B-SPEC
+.	O
+
+Identification	O
+of	O
+a	O
+novel	B-SPEC
+coronavirus	I-SPEC
+causing	O
+fatal	O
+respiratory	B-DISO
+infection	I-DISO
+in	O
+humans	B-SPEC
+raises	O
+concerns	O
+about	O
+a	O
+possible	O
+widespread	O
+outbreak	O
+of	O
+severe	O
+respiratory	B-DISO
+infection	I-DISO
+similar	O
+to	O
+the	O
+one	O
+caused	O
+by	O
+SARS	B-DISO
+-	O
+CoV	O
+.	O
+Using	O
+a	O
+human	B-SPEC
+lung	B-ANAT
+epithelial	B-ANAT
+cell	I-ANAT
+line	O
+and	O
+global	O
+transcriptomic	O
+profiling	O
+,	O
+we	O
+identified	O
+differences	O
+in	O
+the	O
+host	B-PROC
+response	I-PROC
+between	O
+HCoV	B-PRGE
+-	I-PRGE
+EMC	I-PRGE
+and	I-PRGE
+SARS	B-DISO
+-	I-PRGE
+CoV	I-PRGE
+.	O
+This	O
+enables	O
+rapid	O
+assessment	O
+of	O
+viral	O
+properties	O
+and	O
+the	O
+ability	O
+to	O
+anticipate	O
+possible	O
+differences	O
+in	O
+human	B-SPEC
+clinical	O
+responses	O
+to	O
+HCoV	B-PRGE
+-	I-PRGE
+EMC	I-PRGE
+and	I-PRGE
+SARS	B-DISO
+-	I-PRGE
+CoV	I-PRGE
+.	O
+We	O
+used	O
+this	O
+information	O
+to	O
+predict	O
+potential	O
+effective	O
+drugs	O
+against	O
+HCoV	O
+-	O
+EMC	B-COMP
+,	O
+a	O
+method	O
+that	O
+could	O
+be	O
+more	O
+generally	O
+used	O
+to	O
+identify	O
+candidate	O
+therapeutics	O
+in	O
+future	O
+disease	O
+outbreaks	O
+.	O
+
+These	O
+data	O
+will	O
+help	O
+to	O
+generate	O
+hypotheses	O
+and	O
+make	O
+rapid	O
+advancements	O
+in	O
+characterizing	O
+this	O
+new	O
+virus	B-SPEC
+.	O
+
+The	O
+most	O
+common	O
+causes	O
+of	O
+ARDS	B-DISO
+are	O
+pneumonia	B-DISO
+and	O
+sepsis	B-DISO
+.	O
+
+The	O
+new	O
+definition	O
+of	O
+ARDS	B-DISO
+differentiates	O
+three	O
+levels	O
+of	O
+severity	O
+depending	O
+on	O
+the	O
+degree	O
+of	O
+hypoxaemia	O
+.	O
+
+The	O
+presence	O
+of	O
+a	O
+complete	O
+substrate	O
+-	O
+binding	B-FUNC
+pocket	O
+and	O
+oxyanion	O
+hole	O
+in	O
+both	O
+protomers	O
+suggests	O
+that	O
+they	O
+are	O
+both	O
+catalytically	O
+active	O
+,	O
+while	O
+the	O
+two	O
+domain	O
+IIIs	O
+show	O
+minor	O
+reorganization	O
+.	O
+
+ABSTRACT	O
+:	O
+The	O
+coronavirus	B-SPEC
+nucleocapsid	B-COMP
+(	O
+N	O
+)	O
+protein	B-CHED
+plays	O
+a	O
+multifunctional	O
+role	O
+in	O
+the	O
+virus	B-SPEC
+life	O
+cycle	O
+,	O
+from	O
+regulation	B-PROC
+of	O
+replication	O
+and	O
+transcription	B-PROC
+and	O
+genome	O
+packaging	O
+to	O
+modulation	O
+of	O
+host	O
+cell	B-COMP
+processes	I-COMP
+.	O
+
+Advances	O
+in	O
+epidemiology	O
+and	O
+virology	O
+have	O
+led	O
+to	O
+detection	O
+of	O
+other	O
+lapine	O
+viruses	B-SPEC
+that	O
+are	O
+now	O
+recognized	O
+as	O
+agents	O
+of	O
+emerging	B-DISO
+infectious	I-DISO
+diseases	I-DISO
+.	O
+
+A	O
+fourth	O
+highly	O
+pathogenic	O
+virus	B-SPEC
+designated	O
+leporid	B-SPEC
+herpesvirus	I-SPEC
+4	I-SPEC
+has	O
+been	O
+described	O
+in	O
+Canada	O
+and	O
+Alaska	O
+.	O
+
+TITLE	O
+:	O
+Extracorporeal	O
+membrane	B-COMP
+oxygenation	B-PROC
+and	O
+severe	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+secondary	O
+to	O
+Legionella	B-SPEC
+:	O
+10	O
+year	O
+experience	O
+.	O
+
+Furthermore	O
+,	O
+dieckol	B-CHED
+(	O
+8	O
+)	O
+exhibited	O
+a	O
+high	O
+association	O
+rate	O
+in	O
+the	O
+SPR	O
+sensorgram	O
+and	O
+formed	O
+extremely	O
+strong	O
+hydrogen	B-CHED
+bonds	O
+to	O
+the	O
+catalytic	O
+dyad	O
+(	O
+Cys145	O
+and	O
+His41	O
+)	O
+of	O
+the	O
+SARS	B-DISO
+-	I-PRGE
+CoV	I-PRGE
+3CL	I-PRGE
+(	O
+pro	B-PRGE
+).	O
+
+ABSTRACT	O
+:	O
+Equine	B-SPEC
+coronavirus	B-SPEC
+(	O
+ECoV	O
+)	O
+outbreaks	O
+have	O
+occurred	O
+three	O
+times	O
+at	O
+Obihiro	O
+Racecourse	O
+in	O
+Hokkaido	O
+,	O
+Japan	O
+.	O
+
+Several	O
+studies	O
+have	O
+investigated	O
+potential	O
+treatments	O
+for	O
+FIP	B-DISO
+.	O
+
+It	O
+was	O
+demonstrated	O
+that	O
+chloroquine	B-CHED
+has	O
+inhibitory	O
+effect	O
+against	O
+the	O
+replication	O
+of	O
+FIPV	O
+and	O
+anti	O
+-	O
+inflammatory	O
+effect	O
+in	O
+vitro	O
+.	O
+
+RESULTS	O
+:	O
+The	O
+indexes	O
+of	O
+pulmonary	B-PROC
+function	I-PROC
+were	O
+improved	O
+after	O
+treatment	O
+in	O
+both	O
+groups	O
+.	O
+
+TITLE	O
+:	O
+Emergence	O
+of	O
+avian	B-DISO
+influenza	B-PATH
+A	I-PATH
+(	O
+H7N9	O
+)	O
+virus	B-SPEC
+causing	O
+severe	O
+human	B-SPEC
+illness	O
+-	O
+China	O
+,	O
+February	O
+-	O
+April	O
+2013	O
+.	O
+
+ABSTRACT	O
+:	O
+On	O
+March	O
+29	O
+,	O
+2013	O
+,	O
+the	O
+Chinese	O
+Center	O
+for	O
+Disease	O
+Control	O
+and	O
+Prevention	O
+completed	O
+laboratory	O
+confirmation	O
+of	O
+three	O
+human	O
+infections	B-DISO
+with	O
+an	O
+avian	B-DISO
+influenza	B-PATH
+A	I-PATH
+(	O
+H7N9	O
+)	O
+virus	B-SPEC
+not	O
+previously	O
+reported	O
+in	O
+humans	B-SPEC
+.	O
+
+To	O
+gain	O
+a	O
+better	O
+understanding	O
+of	O
+nsp1	B-PRGE
+mode	O
+of	O
+action	O
+,	O
+we	O
+generated	O
+and	O
+analyzed	O
+38	O
+mutants	O
+of	O
+the	O
+SARS	B-PRGE
+-	I-PRGE
+CoV	I-PRGE
+nsp1	I-PRGE
+,	O
+targeting	B-PROC
+62	O
+solvent	B-CHED
+exposed	O
+residues	O
+out	O
+of	O
+the	O
+180	O
+amino	B-CHED
+acid	I-CHED
+protein	B-CHED
+.	O
+
+ABSTRACT	O
+:	O
+Dengue	O
+is	O
+a	O
+mosquito	B-SPEC
+-	O
+borne	O
+viral	B-DISO
+disease	I-DISO
+endemic	O
+in	O
+many	O
+countries	O
+in	O
+the	O
+tropics	O
+and	O
+sub	O
+-	O
+tropics	O
+.	O
+
+Seven	O
+patients	O
+presented	O
+with	O
+thrombocytopenia	O
+and	O
+hypoalbuminemia	O
+,	O
+five	O
+of	O
+which	O
+had	O
+hemoconcentration	O
+and	O
+increased	O
+ALT	B-FUNC
+and	O
+AST	B-PRGE
+indicative	O
+of	O
+liver	B-DISO
+damage	I-DISO
+.	O
+
+The	O
+uncommon	O
+presentations	O
+of	O
+dengue	B-DISO
+are	O
+likely	O
+a	O
+reflection	O
+of	O
+the	O
+changing	O
+demographics	O
+where	O
+adults	O
+are	O
+now	O
+more	O
+likely	O
+to	O
+contract	O
+dengue	B-DISO
+in	O
+dengue	B-DISO
+endemic	O
+regions	O
+.	O
+
+TITLE	O
+:	O
+Probe	O
+Reports	O
+from	O
+the	O
+NIH	O
+Molecular	O
+Libraries	O
+Program	O
+ABSTRACT	O
+:	O
+This	O
+report	O
+describes	O
+the	O
+high	O
+throughput	O
+screening	O
+(	O
+HTS	B-DISO
+)	O
+screening	O
+and	O
+optimization	O
+of	O
+a	O
+lead	O
+series	O
+of	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+(	O
+SARS	B-DISO
+)	O
+main	O
+proteinase	B-PROC
+3CLpro	O
+inhibitors	B-CHED
+leading	O
+to	O
+the	O
+identification	O
+of	O
+ML188	O
+,	O
+((	O
+
+In	O
+comparisons	O
+with	O
+the	O
+control	O
+subjects	O
+(	O
+n	O
+=	O
+18	O
+)	O
+and	O
+convalescent	O
+SARS	B-DISO
+patients	O
+without	O
+PTSD	B-DISO
+(	O
+n	O
+=	O
+26	O
+),	O
+the	O
+SARS	B-DISO
+-	O
+related	O
+PTSD	B-DISO
+group	O
+(	O
+n	O
+=	O
+18	O
+)	O
+had	O
+significantly	O
+lower	O
+N	O
+-	O
+acetylaspartate	O
+/	O
+creatine	B-CHED
+(	O
+NAA	B-CHED
+/	O
+Cr	O
+)	O
+in	O
+4	O
+regions	O
+of	O
+interest	O
+while	O
+the	O
+NAA	B-CHED
+/	O
+Cr	O
+of	O
+the	O
+convalescent	O
+SARS	B-DISO
+patients	O
+was	O
+significantly	O
+lower	O
+than	O
+controls	O
+in	O
+3	O
+regions	O
+of	O
+interest	O
+(	O
+ACG	O
+,	O
+PCG	O
+and	O
+LAPWM	O
+).	O
+
+RESULTS	O
+:	O
+In	O
+comparisons	O
+with	O
+the	O
+control	O
+subjects	O
+(	O
+n	O
+=	O
+18	O
+)	O
+and	O
+convalescent	O
+SARS	B-DISO
+patients	O
+without	O
+PTSD	B-DISO
+(	O
+n	O
+=	O
+26	O
+),	O
+the	O
+SARS	B-DISO
+-	O
+related	O
+PTSD	B-DISO
+group	O
+(	O
+n	O
+=	O
+18	O
+)	O
+had	O
+significantly	O
+lower	O
+N	O
+-	O
+acetylaspartate	O
+/	O
+creatine	B-CHED
+(	O
+NAA	B-CHED
+/	O
+Cr	O
+)	O
+in	O
+4	O
+regions	O
+of	O
+interest	O
+while	O
+the	O
+NAA	B-CHED
+/	O
+Cr	O
+of	O
+the	O
+convalescent	O
+SARS	B-DISO
+patients	O
+was	O
+significantly	O
+lower	O
+than	O
+controls	O
+in	O
+3	O
+regions	O
+of	O
+interest	O
+(	O
+ACG	O
+,	O
+PCG	O
+and	O
+LAPWM	O
+).	O
+
+The	O
+results	O
+indicate	O
+that	O
+there	O
+are	O
+two	O
+major	O
+groups	O
+of	O
+Chinese	O
+PEDVs	O
+,	O
+a	O
+Japanese	O
+PEDV	B-SPEC
+group	O
+and	O
+a	O
+Korean	O
+PEDV	B-SPEC
+group	O
+.	O
+
+The	O
+immunoreactivity	B-PROC
+between	O
+PEDV	B-SPEC
+particles	O
+or	O
+the	O
+bacterially	O
+expressed	B-PROC
+N	B-PRGE
+protein	I-PRGE
+and	O
+rabbit	B-SPEC
+anti	O
+-	O
+PEDV	B-SPEC
+serum	B-COMP
+was	O
+confirmed	O
+by	O
+immunofluorescence	O
+assays	O
+and	O
+Western	O
+blot	O
+.	O
+
+After	O
+four	O
+rounds	O
+of	O
+biopanning	O
+,	O
+10	O
+monoclonal	O
+phages	O
+with	O
+specific	O
+binding	B-PROC
+activity	I-PROC
+to	O
+the	O
+S1	B-PRGE
+-	I-PRGE
+RBD	I-PRGE
+protein	I-PRGE
+were	O
+obtained	O
+and	O
+subjected	O
+to	O
+binding	B-FUNC
+and	O
+diagnostic	O
+assays	O
+.	O
+
+ABSTRACT	O
+:	O
+In	O
+silico	O
+identification	O
+of	O
+T	B-PRGE
+-	I-PRGE
+cell	I-PRGE
+epitopes	I-PRGE
+is	O
+emerging	O
+as	O
+a	O
+new	O
+methodology	O
+for	O
+the	O
+study	O
+of	O
+epitope	B-CHED
+-	O
+based	O
+vaccines	O
+against	O
+viruses	B-SPEC
+and	O
+cancer	B-DISO
+.	O
+
+ABSTRACT	O
+:	O
+A	O
+56	O
+-	O
+year	O
+-	O
+old	O
+woman	O
+with	O
+a	O
+history	O
+of	O
+paraplegia	O
+and	O
+chronic	B-DISO
+pain	I-DISO
+due	O
+to	O
+neuromyelitis	B-DISO
+optica	I-DISO
+(	O
+Devic	B-DISO
+'	I-DISO
+s	I-DISO
+syndrome	I-DISO
+)	O
+was	O
+admitted	O
+to	O
+a	O
+spinal	B-ANAT
+cord	I-ANAT
+injury	O
+unit	O
+for	O
+management	O
+of	O
+a	O
+sacral	B-ANAT
+decubitus	B-DISO
+ulcer	I-DISO
+.	O
+
+We	O
+reason	O
+that	O
+the	O
+recalcitrant	O
+life	O
+-	O
+threatening	O
+hypokalemia	O
+was	O
+caused	O
+by	O
+several	O
+mechanisms	O
+including	O
+total	O
+body	B-ANAT
+potassium	B-DISO
+depletion	I-DISO
+(	O
+chronic	B-DISO
+respiratory	I-DISO
+acidosis	I-DISO
+),	O
+a	O
+shift	O
+of	O
+potassium	B-CHED
+from	O
+the	O
+extracellular	B-COMP
+to	O
+intracellular	B-COMP
+space	O
+(	O
+rapid	O
+correction	O
+of	O
+respiratory	B-DISO
+acidosis	I-DISO
+with	O
+mechanical	O
+ventilation	O
+),	O
+increased	O
+sodium	O
+delivery	O
+to	O
+the	O
+distal	O
+nephron	B-ANAT
+(	O
+normal	O
+saline	O
+resuscitation	O
+),	O
+hyperaldosteronism	B-DISO
+(	O
+secondary	O
+to	O
+hypotension	O
+plus	O
+administration	O
+of	O
+hydrocortisone	B-CHED
+)	O
+and	O
+hypomagnesemia	O
+.	O
+
+Serum	B-COMP
+potassium	B-CHED
+levels	O
+must	O
+be	O
+monitored	O
+closely	O
+in	O
+these	O
+patients	O
+,	O
+as	O
+failure	O
+to	O
+do	O
+so	O
+can	O
+lead	O
+to	O
+potentially	O
+lethal	O
+consequences	O
+.	O
+
+Multivariate	O
+analysis	O
+of	O
+the	O
+risk	O
+factors	O
+generated	O
+a	O
+new	O
+predictive	O
+model	O
+of	O
+mortality	O
+applicable	O
+within	O
+the	O
+first	O
+24h	O
+after	O
+ICU	O
+admission	O
+and	O
+comprising	O
+5	O
+main	O
+factors	O
+:	O
+age	O
+,	O
+CURB	B-DISO
+severity	O
+score	O
+3	O
+-	O
+4	O
+,	O
+septic	B-DISO
+shock	I-DISO
+,	O
+ARDS	B-DISO
+,	O
+and	O
+acute	B-DISO
+renal	I-DISO
+failure	I-DISO
+.	O
+
+TITLE	O
+:	O
+Another	O
+case	O
+of	O
+""""	O
+European	O
+hantavirus	B-DISO
+pulmonary	B-ANAT
+syndrome	I-DISO
+""""	O
+with	O
+severe	O
+lung	B-ANAT
+,	O
+prior	O
+to	O
+kidney	B-ANAT
+,	O
+involvement	O
+,	O
+and	O
+diagnosed	O
+by	O
+viral	O
+inclusions	O
+in	O
+lung	O
+macrophages	B-ANAT
+.	O
+
+TITLE	O
+:	O
+Clinical	O
+review	O
+:	O
+Acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+-	O
+clinical	O
+ventilator	O
+management	O
+and	O
+adjunct	O
+therapy	O
+.	O
+
+Adjunctive	O
+therapies	O
+discussed	O
+include	O
+pharmacologic	O
+techniques	O
+(	O
+for	O
+example	O
+,	O
+vasodilators	O
+,	O
+diuretics	O
+,	O
+neuromuscular	B-DISO
+blockade	I-DISO
+)	O
+and	O
+nonpharmacologic	O
+techniques	O
+(	O
+for	O
+example	O
+,	O
+prone	O
+position	O
+,	O
+alternative	O
+modes	O
+of	O
+ventilation	O
+).	O
+
+Current	O
+treatment	O
+of	O
+ALI	O
+/	O
+ARDS	B-DISO
+is	O
+primarily	O
+supportive	O
+,	O
+with	O
+lung	B-ANAT
+protective	O
+ventilation	O
+and	O
+fluid	O
+conserving	O
+strategies	O
+.	O
+
+TITLE	O
+:	O
+Prevalence	O
+and	O
+prognosis	O
+of	O
+cor	B-DISO
+pulmonale	I-DISO
+during	O
+protective	O
+ventilation	O
+for	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+.	O
+
+Two	O
+hundred	O
+and	O
+twenty	O
+-	O
+six	O
+consecutive	O
+patients	O
+with	O
+moderate	O
+to	O
+severe	O
+ARDS	B-DISO
+(	O
+Berlin	O
+definition	O
+)	O
+ventilated	O
+with	O
+plateau	O
+pressure	O
+limited	O
+at	O
+30	O
+cmH₂O	O
+(	O
+mean	O
+PEEP	B-CHED
+of	O
+8	O
+.	O
+8	O
+±	O
+3	O
+.	O
+6	O
+cmH₂O	O
+)	O
+underwent	O
+transesophageal	O
+echocardiography	O
+(	O
+TEE	O
+)	O
+within	O
+the	O
+first	O
+3	O
+days	O
+after	O
+the	O
+diagnosis	O
+of	O
+ARDS	B-DISO
+.	O
+
+Multivariate	O
+logistic	O
+regression	O
+identified	O
+infectious	B-DISO
+causes	O
+of	O
+lung	B-ANAT
+injury	O
+and	O
+higher	O
+driving	O
+pressures	O
+as	O
+independent	O
+factors	O
+associated	O
+with	O
+cor	B-DISO
+pulmonale	I-DISO
+.	O
+
+Cor	B-DISO
+pulmonale	I-DISO
+was	O
+associated	O
+with	O
+sepsis	B-DISO
+and	O
+higher	O
+values	O
+of	O
+driving	O
+pressure	O
+and	O
+was	O
+an	O
+independent	O
+risk	O
+factor	O
+for	O
+28	O
+-	O
+day	O
+mortality	O
+in	O
+our	O
+series	O
+.	O
+
+TITLE	O
+:	O
+Seroepidemiological	O
+Study	O
+on	O
+SARS	B-PRGE
+-	I-PRGE
+CoV	I-PRGE
+IgG	I-PRGE
+Antibodies	B-COMP
+of	O
+Different	O
+Populations	O
+from	O
+Several	O
+Areas	O
+.	O
+
+However	O
+,	O
+all	O
+specimens	O
+still	O
+were	O
+positive	O
+for	O
+SARS	B-PRGE
+-	I-PRGE
+CoV	I-PRGE
+IgG	I-PRGE
+in	O
+the	O
+48th	O
+month	O
+.	O
+
+Taken	O
+together	O
+,	O
+these	O
+results	O
+demonstrated	O
+that	O
+TGEV	B-SPEC
+infection	B-DISO
+promoted	O
+the	O
+activation	O
+of	O
+p38	B-PRGE
+MAPK	B-FUNC
+and	O
+p53	B-PRGE
+signalling	I-PRGE
+,	O
+and	O
+p53	B-PRGE
+signalling	B-PROC
+might	O
+play	O
+a	O
+dominant	O
+role	O
+in	O
+the	O
+regulation	B-PROC
+of	O
+cell	B-COMP
+apoptosis	B-PATH
+.	O
+
+He	O
+became	O
+ill	B-DISO
+36	O
+hours	O
+into	O
+the	O
+infusion	O
+with	O
+fever	B-PROC
+,	O
+respiratory	B-DISO
+failure	I-DISO
+,	O
+and	O
+circulatory	B-DISO
+collapse	I-DISO
+.	O
+
+He	O
+developed	O
+hyperferritinemia	O
+,	O
+cytopenias	B-DISO
+,	O
+hypofibrinogenemia	B-DISO
+,	O
+and	O
+a	O
+cytokine	O
+profile	O
+diagnostic	O
+for	O
+HLH	O
+.	O
+
+Patients	O
+treated	O
+with	O
+T	B-ANAT
+cell	I-ANAT
+-	O
+activating	O
+therapies	O
+,	O
+including	O
+blinatumomab	O
+,	O
+should	O
+be	O
+monitored	O
+for	O
+HLH	B-DISO
+,	O
+and	O
+cytokine	O
+-	O
+directed	O
+therapy	O
+may	O
+be	O
+considered	O
+in	O
+cases	O
+of	O
+life	O
+-	O
+threatening	O
+CRS	B-DISO
+.	O
+
+TITLE	O
+:	O
+Novel	O
+inhibitors	B-CHED
+of	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+coronavirus	B-SPEC
+entry	O
+that	O
+act	O
+by	O
+three	O
+distinct	O
+mechanisms	O
+.	O
+
+Studies	O
+on	O
+their	O
+mechanisms	O
+of	O
+action	O
+revealed	O
+that	O
+the	O
+compounds	O
+act	O
+by	O
+three	O
+distinct	O
+mechanisms	O
+:	O
+(	O
+i	O
+)	O
+SSAA09E2	O
+{	O
+N	O
+-[[	O
+4	O
+-(	O
+4	O
+-	O
+methylpiperazin	O
+-	O
+1	O
+-	O
+yl	O
+)	O
+phenyl	B-CHED
+]	O
+methyl	B-CHED
+]-	O
+1	B-CHED
+,	I-CHED
+2	I-CHED
+-	I-CHED
+oxazole	I-CHED
+-	O
+5	O
+-	O
+carboxamide	B-CHED
+}	O
+acts	O
+through	O
+a	O
+novel	O
+mechanism	B-PROC
+of	I-PROC
+action	I-PROC
+,	O
+by	O
+blocking	B-DISO
+early	O
+interactions	O
+of	O
+SARS	B-DISO
+-	O
+S	O
+with	O
+the	O
+receptor	O
+for	O
+SARS	B-PRGE
+-	I-PRGE
+CoV	I-PRGE
+,	O
+angiotensin	B-PRGE
+converting	I-PRGE
+enzyme	I-PRGE
+2	I-PRGE
+(	O
+ACE2	B-PRGE
+);	O
+(	O
+ii	O
+)	O
+SSAA09E1	O
+{[(	O
+Z	O
+)-	O
+1	O
+-	O
+thiophen	B-CHED
+-	O
+2	O
+-	O
+ylethylideneamino	O
+]	O
+thiourea	B-CHED
+}	O
+acts	O
+later	O
+,	O
+by	O
+blocking	B-DISO
+cathepsin	B-PRGE
+L	I-PRGE
+,	I-PRGE
+a	I-PRGE
+host	B-COMP
+protease	I-PRGE
+required	O
+for	O
+processing	O
+of	O
+SARS	B-DISO
+-	O
+S	O
+during	O
+viral	O
+entry	O
+;	O
+and	O
+(	O
+iii	O
+)	O
+SSAA09E3	O
+[	O
+N	O
+-(	O
+9	O
+,	O
+10	O
+-	O
+dioxo	O
+-	O
+9	O
+,	O
+10	O
+-	O
+dihydroanthracen	O
+-	O
+2	O
+-	O
+yl	O
+)	O
+benzamide	B-CHED
+]	O
+also	O
+acts	O
+later	O
+and	O
+does	O
+not	O
+affect	O
+interactions	O
+of	O
+SARS	B-PRGE
+-	I-PRGE
+S	I-PRGE
+with	O
+ACE2	B-PRGE
+or	O
+the	O
+enzymatic	O
+functions	O
+of	O
+cathepsin	B-PRGE
+L	I-PRGE
+but	O
+prevents	O
+fusion	O
+of	O
+the	O
+viral	B-COMP
+membrane	I-COMP
+with	O
+the	O
+host	B-COMP
+cellular	B-COMP
+membrane	I-COMP
+.	O
+
+Our	O
+work	O
+demonstrates	O
+that	O
+there	O
+are	O
+at	O
+least	O
+three	O
+independent	O
+strategies	O
+for	O
+blocking	B-DISO
+SARS	B-DISO
+-	O
+CoV	O
+entry	O
+,	O
+validates	O
+these	O
+mechanisms	O
+of	O
+inhibition	B-PROC
+,	O
+and	O
+introduces	O
+promising	O
+leads	O
+for	O
+the	O
+development	B-PROC
+of	O
+SARS	B-DISO
+therapeutics	O
+.	O
+
+However	O
+,	O
+under	O
+severe	O
+and	O
+persistent	O
+ER	O
+stress	O
+,	O
+prolonged	O
+UPR	O
+may	O
+activate	O
+unique	O
+pathways	B-PROC
+that	O
+lead	O
+to	O
+cell	B-PROC
+death	I-PROC
+.	O
+
+TITLE	O
+:	O
+Characterization	O
+of	O
+nephropathogenic	O
+infectious	B-DISO
+bronchitis	B-DISO
+virus	B-SPEC
+DMV	O
+/	O
+1639	O
+/	O
+11	O
+recovered	O
+from	O
+Delmarva	O
+broiler	O
+chickens	O
+in	O
+2011	O
+.	O
+
+Isolates	O
+of	O
+NIB	O
+virus	B-SPEC
+(	O
+NIBV	O
+)--	O
+DMV	O
+/	O
+1639	O
+/	O
+11	O
+,	O
+DMV	O
+/	O
+3432	O
+/	O
+11	O
+,	O
+and	O
+DMV	O
+/	O
+3902	O
+/	O
+11	O
+--	O
+were	O
+characterized	O
+by	O
+sequence	O
+analysis	O
+of	O
+the	O
+N	O
+-	O
+terminal	O
+subunit	O
+(	O
+S1	O
+)	O
+of	O
+the	O
+spike	O
+(	O
+S	O
+)	O
+gene	O
+.	O
+
+Although	O
+numerically	O
+fewer	O
+chickens	B-SPEC
+vaccinated	O
+with	O
+Mass	O
++	O
+Conn	O
+had	O
+interstitial	B-DISO
+nephritis	I-DISO
+compared	O
+with	O
+those	O
+vaccinated	O
+with	O
+Mass	O
++	O
+Ark	O
+,	O
+neither	O
+vaccine	O
+combination	O
+offered	O
+greater	O
+protection	O
+(	O
+P	O
+<	O
+0	O
+.	O
+05	O
+)	O
+than	O
+observed	O
+in	O
+unvaccinated	O
+chickens	B-SPEC
+challenged	O
+with	O
+DMV	O
+/	O
+1639	O
+/	O
+11	O
+.	O
+
+Patients	O
+died	B-PROC
+rather	O
+late	O
+when	O
+severe	O
+cholinergic	B-DISO
+crisis	I-DISO
+had	O
+mostly	O
+been	O
+overcome	O
+and	O
+death	B-PROC
+was	O
+therefore	O
+related	O
+to	O
+non	O
+-	O
+poison	B-CHED
+specific	O
+complications	O
+.	O
+
+ABSTRACT	O
+:	O
+Severe	O
+infections	O
+with	O
+influenza	B-SPEC
+virus	I-SPEC
+are	O
+characterized	O
+by	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+(	O
+ARDS	B-DISO
+),	O
+a	O
+life	O
+-	O
+threatening	O
+disorder	O
+in	O
+which	O
+the	O
+alveolocapillary	B-ANAT
+membrane	I-ANAT
+in	O
+the	O
+lung	B-ANAT
+becomes	O
+leaky	O
+.	O
+
+In	O
+this	O
+paper	O
+,	O
+we	O
+review	O
+evidence	O
+that	O
+lung	B-ANAT
+endothelial	B-ANAT
+activation	O
+and	O
+vascular	B-ANAT
+leak	O
+are	O
+a	O
+""""	O
+final	O
+common	O
+pathway	B-PROC
+""""	O
+in	O
+severe	O
+influenza	B-DISO
+,	O
+as	O
+has	O
+been	O
+reported	O
+in	O
+bacterial	B-DISO
+sepsis	I-DISO
+,	O
+and	O
+that	O
+enhancing	O
+endothelial	B-ANAT
+barrier	O
+function	O
+may	O
+improve	O
+the	O
+outcome	O
+of	O
+illness	O
+.	O
+
+We	O
+describe	O
+a	O
+number	O
+of	O
+experimental	O
+therapies	O
+that	O
+have	O
+shown	O
+promise	O
+in	O
+preventing	O
+or	O
+reversing	O
+increased	O
+vascular	O
+leak	O
+in	O
+animal	B-SPEC
+models	O
+of	O
+sepsis	B-DISO
+or	O
+influenza	B-DISO
+.	O
+
+At	O
+present	O
+time	O
+,	O
+at	O
+the	O
+age	O
+of	O
+7	O
+,	O
+he	O
+shows	O
+normal	B-PROC
+growth	I-PROC
+and	O
+cognitive	O
+development	B-PROC
+.	O
+
+In	O
+this	O
+multicenter	O
+,	O
+prospective	O
+,	O
+randomized	O
+,	O
+controlled	O
+trial	O
+,	O
+we	O
+randomly	O
+assigned	O
+466	O
+patients	O
+with	O
+severe	O
+ARDS	B-DISO
+to	O
+undergo	O
+prone	O
+-	O
+positioning	O
+sessions	O
+of	O
+at	O
+least	O
+16	O
+hours	O
+or	O
+to	O
+be	O
+left	O
+in	O
+the	O
+supine	O
+position	O
+.	O
+
+Severe	O
+ARDS	B-DISO
+was	O
+defined	O
+as	O
+a	O
+ratio	O
+of	O
+the	O
+partial	O
+pressure	O
+of	O
+arterial	B-ANAT
+oxygen	B-CHED
+to	O
+the	O
+fraction	O
+of	O
+inspired	B-PROC
+oxygen	B-CHED
+(	O
+FiO2	B-CHED
+)	O
+of	O
+less	O
+than	O
+150	O
+mm	O
+Hg	O
+,	O
+with	O
+an	O
+FiO2	B-CHED
+of	O
+at	O
+least	O
+0	O
+.	O
+6	O
+,	O
+a	O
+positive	O
+end	B-PROC
+-	I-PROC
+expiratory	I-PROC
+pressure	O
+of	O
+at	O
+least	O
+5	O
+cm	O
+of	O
+water	B-CHED
+,	O
+and	O
+a	O
+tidal	O
+volume	O
+close	O
+to	O
+6	O
+ml	O
+per	O
+kilogram	O
+of	O
+predicted	O
+body	B-ANAT
+weight	O
+.	O
+
+The	O
+incidence	O
+of	O
+complications	O
+did	O
+not	O
+differ	O
+significantly	O
+between	O
+the	O
+groups	O
+,	O
+except	O
+for	O
+the	O
+incidence	O
+of	O
+cardiac	B-ANAT
+arrests	O
+,	O
+which	O
+was	O
+higher	O
+in	O
+the	O
+supine	O
+group	O
+.	O
+
+Third	O
+,	O
+by	O
+measuring	O
+channel	O
+conductance	O
+in	O
+mixtures	O
+of	O
+neutral	O
+diphytanoyl	O
+phosphatidylcholine	O
+(	O
+DPhPC	O
+)	O
+lipids	B-CHED
+and	O
+negatively	O
+charged	O
+DPhPS	O
+lipids	B-CHED
+in	O
+low	O
+and	O
+high	O
+salt	B-CHED
+concentrations	O
+we	O
+conclude	O
+that	O
+the	O
+protein	B-CHED
+-	O
+lipid	B-CHED
+conformation	O
+in	O
+the	O
+channel	O
+is	O
+likely	O
+the	O
+same	O
+in	O
+charged	O
+and	O
+neutral	O
+lipids	B-CHED
+.	O
+
+Viruses	B-SPEC
+are	O
+one	O
+of	O
+the	O
+most	O
+common	O
+agents	O
+causing	O
+ARIs	O
+.	O
+
+Respiratory	B-SPEC
+syncytial	I-SPEC
+virus	I-SPEC
+(	O
+RSV	B-SPEC
+)	O
+was	O
+the	O
+most	O
+frequently	O
+detected	O
+pathogen	O
+(	O
+26	O
+.	O
+5	O
+%,	O
+36	O
+/	O
+136	O
+),	O
+followed	O
+by	O
+parainfluenza	B-DISO
+virus	B-SPEC
+(	O
+PIV	O
+)	O
+1	O
+-	O
+3	O
+(	O
+22	O
+.	O
+1	O
+%,	O
+30	O
+/	O
+136	O
+),	O
+human	B-SPEC
+rhinovirus	I-SPEC
+(	O
+HRV	O
+)	O
+(	O
+21	O
+.	O
+3	O
+%,	O
+29	O
+/	O
+136	O
+),	O
+human	B-SPEC
+coronavirus	I-SPEC
+(	O
+CoV	O
+)	O
+(	O
+10	O
+.	O
+3	O
+%,	O
+14	O
+/	O
+136	O
+)	O
+and	O
+human	B-SPEC
+adenovirus	B-DISO
+(	O
+HAdV	O
+)	O
+(	O
+9	O
+.	O
+6	O
+%,	O
+13	O
+/	O
+136	O
+).	O
+
+Our	O
+study	O
+suggests	O
+the	O
+protective	O
+role	O
+of	O
+the	O
+apoA	B-PRGE
+-	I-PRGE
+I	I-PRGE
+mimetic	I-PRGE
+peptide	I-PRGE
+L	I-PRGE
+-	I-PRGE
+4F	I-PRGE
+in	O
+ARDS	B-DISO
+and	O
+gram	O
+-	O
+negative	O
+endotoxemia	O
+and	O
+warrant	O
+further	O
+clinical	O
+evaluation	O
+.	O
+
+The	O
+sequestration	O
+of	O
+cerebral	B-ANAT
+vasculature	B-ANAT
+with	O
+parasitized	O
+red	B-ANAT
+blood	I-ANAT
+cells	I-ANAT
+is	O
+one	O
+of	O
+the	O
+proposed	O
+mechanisms	O
+for	O
+the	O
+development	B-PROC
+of	O
+cerebral	B-DISO
+malaria	B-PATH
+.	O
+
+Cerebral	B-DISO
+malaria	B-PATH
+should	O
+be	O
+suspected	O
+in	O
+any	O
+febrile	B-PROC
+patient	O
+from	O
+a	O
+malaria	B-PATH
+-	O
+endemic	O
+region	O
+with	O
+loss	O
+of	O
+consciousness	O
+.	O
+
+Concentrated	O
+ascites	O
+reinfusion	O
+therapy	O
+(	O
+CART	O
+)	O
+involves	O
+the	O
+filtration	O
+,	O
+concentration	O
+,	O
+and	O
+reinfusion	O
+of	O
+drained	O
+ascites	O
+,	O
+which	O
+contributes	O
+to	O
+reuse	O
+of	O
+autologous	O
+proteins	B-CHED
+.	O
+
+CART	B-PRGE
+has	O
+been	O
+reported	O
+as	O
+supportive	O
+therapy	O
+for	O
+patients	O
+with	O
+liver	B-DISO
+cirrhosis	I-DISO
+and	O
+cancer	B-DISO
+.	O
+
+CART	O
+after	O
+paracentesis	O
+reduces	O
+protein	B-CHED
+loss	O
+in	O
+ascites	O
+by	O
+reinfusion	O
+of	O
+autologous	O
+protein	B-CHED
+instead	O
+of	O
+exogenous	O
+albumin	B-PRGE
+preparations	O
+.	O
+
+This	O
+prospective	O
+cohort	O
+enrolled	O
+previously	O
+healthy	O
+term	O
+infants	O
+during	O
+inpatient	O
+or	O
+outpatient	O
+visits	O
+for	O
+acute	B-DISO
+URI	I-DISO
+or	O
+bronchiolitis	B-DISO
+during	O
+September	O
+to	O
+May	O
+2004	O
+to	O
+2008	O
+.	O
+
+ECMO	O
+should	O
+be	O
+reserved	O
+,	O
+therefore	O
+,	O
+for	O
+the	O
+most	O
+severely	O
+ill	B-DISO
+poisoned	O
+patients	O
+with	O
+a	O
+high	O
+risk	O
+of	O
+death	B-PROC
+.	O
+
+There	O
+are	O
+no	O
+randomised	O
+trials	O
+of	O
+ECMO	O
+in	O
+poisoned	O
+patients	O
+with	O
+refractory	B-DISO
+shock	I-DISO
+or	O
+who	O
+have	O
+ARDS	B-DISO
+caused	O
+by	O
+an	O
+intoxication	O
+.	O
+
+Using	O
+medical	O
+charts	O
+,	O
+we	O
+collected	O
+data	O
+on	O
+111	O
+patients	O
+with	O
+laboratory	O
+-	O
+confirmed	O
+avian	B-SPEC
+-	O
+origin	O
+influenza	B-PATH
+A	I-PATH
+(	O
+H7N9	O
+)	O
+infection	B-DISO
+through	O
+May	O
+10	O
+,	O
+2013	O
+.	O
+
+On	O
+admission	O
+,	O
+108	O
+patients	O
+(	O
+97	O
+.	O
+3	O
+%)	O
+had	O
+findings	O
+consistent	O
+with	O
+pneumonia	B-DISO
+.	O
+
+Bilateral	O
+ground	O
+-	O
+glass	O
+opacities	B-DISO
+and	O
+consolidation	O
+were	O
+the	O
+typical	O
+radiologic	O
+findings	O
+.	O
+
+The	O
+median	O
+times	O
+from	O
+the	O
+onset	O
+of	O
+illness	O
+and	O
+from	O
+the	O
+initiation	O
+of	O
+antiviral	B-CHED
+therapy	O
+to	O
+a	O
+negative	O
+viral	O
+test	O
+result	O
+on	O
+real	O
+-	O
+time	O
+reverse	O
+-	O
+transcriptase	B-PRGE
+-	I-PRGE
+polymerase	I-PRGE
+-	O
+chain	O
+-	O
+reaction	O
+assay	O
+were	O
+11	O
+days	O
+(	O
+interquartile	O
+range	O
+,	O
+9	O
+to	O
+16	O
+)	O
+and	O
+6	O
+days	O
+(	O
+interquartile	O
+range	O
+,	O
+4	O
+to	O
+7	O
+),	O
+respectively	O
+.	O
+
+RESULTS	O
+:	O
+Of	O
+the	O
+111	O
+patients	O
+we	O
+studied	O
+,	O
+76	O
+.	O
+6	O
+%	O
+were	O
+admitted	O
+to	O
+an	O
+intensive	O
+care	O
+unit	O
+(	O
+ICU	O
+),	O
+and	O
+27	O
+.	O
+0	O
+%	O
+died	B-PROC
+.	O
+
+Treatment	O
+with	O
+antiviral	B-CHED
+drugs	I-CHED
+was	O
+initiated	O
+in	O
+108	O
+patients	O
+(	O
+97	O
+.	O
+3	O
+%)	O
+at	O
+a	O
+median	O
+of	O
+7	O
+days	O
+after	O
+the	O
+onset	O
+of	O
+illness	O
+.	O
+
+TITLE	O
+:	O
+Cell	B-ANAT
+-	O
+type	O
+-	O
+specific	O
+activation	O
+of	O
+the	O
+oligoadenylate	B-PRGE
+synthetase	I-PRGE
+-	I-PRGE
+RNase	I-PRGE
+L	I-PRGE
+pathway	B-PROC
+by	O
+a	O
+murine	B-SPEC
+coronavirus	I-SPEC
+.	O
+
+The	O
+replication	O
+of	O
+wild	O
+-	O
+type	O
+MHV	B-SPEC
+strain	O
+A59	O
+(	O
+A59	O
+)	O
+and	O
+a	O
+mutant	B-DISO
+with	O
+an	O
+inactive	O
+phosphodiesterase	B-PROC
+(	O
+ns2	B-DISO
+-	O
+H126R	O
+)	O
+was	O
+assessed	O
+in	O
+primary	O
+hepatocytes	B-ANAT
+and	O
+primary	O
+central	B-ANAT
+nervous	I-ANAT
+system	I-ANAT
+(	O
+CNS	B-CHED
+)	O
+cell	B-COMP
+types	O
+-	O
+neurons	B-ANAT
+,	O
+astrocytes	B-ANAT
+,	O
+and	O
+oligodendrocytes	B-ANAT
+.	O
+
+To	O
+identify	O
+important	O
+M	O
+amino	B-CHED
+acid	I-CHED
+residues	O
+for	O
+VLP	B-COMP
+assembly	O
+,	O
+we	O
+coexpressed	O
+N	O
+with	O
+multiple	O
+M	O
+mutants	O
+containing	O
+substitution	O
+mutations	O
+at	O
+the	O
+amino	O
+-	O
+terminal	O
+ectodomain	O
+,	O
+carboxyl	O
+-	O
+terminal	O
+endodomain	O
+,	O
+or	O
+transmembrane	B-COMP
+segments	O
+.	O
+
+Results	O
+from	O
+cross	O
+-	O
+linking	O
+VLP	B-COMP
+analyses	O
+suggest	O
+that	O
+the	O
+cysteine	B-CHED
+residues	O
+63	O
+,	O
+85	O
+and	O
+158	O
+are	O
+not	O
+in	O
+close	O
+proximity	O
+to	O
+the	O
+M	O
+dimer	O
+interface	O
+.	O
+
+He	O
+is	O
+known	O
+across	O
+the	O
+globe	B-ANAT
+for	O
+his	O
+research	O
+and	O
+has	O
+been	O
+honored	O
+with	O
+a	O
+number	O
+of	O
+prestigious	O
+awards	O
+,	O
+including	O
+the	O
+EWR	O
+Steacie	O
+Prize	O
+,	O
+the	O
+Canadian	O
+Society	O
+of	O
+Microbiology	O
+Fisher	B-SPEC
+Scientific	O
+Award	O
+,	O
+a	O
+Medical	O
+Research	O
+Council	O
+scientist	O
+award	O
+,	O
+five	O
+Howard	O
+Hughes	O
+International	O
+Research	O
+Scholar	O
+Awards	O
+,	O
+a	O
+Canadian	O
+Institute	O
+of	O
+Health	O
+Research	O
+Distinguished	O
+Investigator	O
+award	O
+,	O
+British	O
+Columbia	O
+Biotech	O
+Innovation	O
+Award	O
+,	O
+the	O
+Michael	O
+Smith	O
+Health	O
+Research	O
+Prize	O
+,	O
+the	O
+Infectious	B-DISO
+Diseases	I-DISO
+Society	O
+of	O
+America	O
+Squibb	O
+award	O
+and	O
+the	O
+Jacob	O
+Biely	O
+Prize	O
+.	O
+
+ABSTRACT	O
+:	O
+We	O
+present	O
+three	O
+cases	O
+of	O
+pediatric	O
+patients	O
+with	O
+thrombocytopenia	O
+-	O
+associated	O
+multiple	B-DISO
+organ	I-DISO
+failure	I-DISO
+and	O
+the	O
+evidence	O
+for	O
+providing	O
+extracorporeal	O
+organ	B-ANAT
+support	O
+.	O
+
+In	O
+our	O
+previous	O
+work	O
+,	O
+the	O
+nonstructural	O
+protein	B-CHED
+(	O
+nsp	O
+)	O
+14	O
+of	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+coronavirus	B-SPEC
+(	O
+SARS	B-DISO
+-	O
+CoV	O
+)	O
+was	O
+identified	O
+as	O
+a	O
+cap	B-PRGE
+(	I-PRGE
+guanine	B-CHED
+-	I-PRGE
+N7	I-PRGE
+)-	I-PRGE
+methyltransferase	I-PRGE
+(	O
+N7	B-PRGE
+-	I-PRGE
+MTase	I-PRGE
+).	O
+
+In	O
+this	O
+study	O
+,	O
+we	O
+found	O
+that	O
+GTP	B-CHED
+,	O
+dGTP	B-CHED
+as	O
+well	O
+as	O
+cap	B-DISO
+analogs	O
+GpppG	O
+,	O
+GpppA	O
+and	O
+m7GpppG	O
+could	O
+be	O
+methylated	O
+by	O
+SARS	B-PRGE
+-	I-PRGE
+CoV	I-PRGE
+nsp14	I-PRGE
+.	O
+
+In	O
+contrast	O
+,	O
+the	O
+nsp14	O
+could	O
+not	O
+modify	O
+ATP	B-CHED
+,	O
+CTP	B-CHED
+,	O
+UTP	B-CHED
+,	O
+dATP	B-CHED
+,	O
+dCTP	B-CHED
+,	O
+dUTP	B-CHED
+or	O
+cap	B-DISO
+analog	O
+m7GpppA	O
+.	O
+Critical	O
+residues	O
+of	O
+nsp14	O
+essential	O
+for	O
+the	O
+methyltransferase	B-FUNC
+activity	I-FUNC
+on	O
+GTP	B-CHED
+were	O
+identified	O
+,	O
+which	O
+include	O
+F73	O
+,	O
+R84	O
+,	O
+W86	O
+,	O
+R310	O
+,	O
+D331	O
+,	O
+G333	O
+,	O
+P335	O
+,	O
+Y368	O
+,	O
+C414	O
+,	O
+and	O
+C416	O
+.	O
+
+Subsequent	O
+to	O
+the	O
+first	O
+report	O
+in	O
+France	O
+in	O
+2005	O
+,	O
+there	O
+have	O
+been	O
+17	O
+facial	B-ANAT
+allograft	O
+transplantations	O
+performed	O
+worldwide	O
+.	O
+
+This	O
+negative	O
+correlation	O
+was	O
+also	O
+observed	O
+for	O
+cortex	B-ANAT
+layers	B-ANAT
+IV	O
+-	O
+VI	O
+based	O
+on	O
+a	O
+new	O
+Transcriptomic	O
+Atlas	B-ANAT
+of	O
+the	O
+Mouse	B-SPEC
+Neocortical	O
+Layers	B-ANAT
+.	O
+
+TITLE	O
+:	O
+Laboratory	O
+surveillance	O
+of	O
+influenza	B-DISO
+-	I-DISO
+like	I-DISO
+illness	I-DISO
+in	O
+seven	O
+teaching	O
+hospitals	O
+,	O
+South	O
+Korea	O
+:	O
+2011	O
+-	O
+2012	O
+season	O
+.	O
+
+Influenza	B-SPEC
+A	I-SPEC
+virus	I-SPEC
+was	O
+the	O
+dominant	O
+agent	O
+(	O
+677	O
+,	O
+61	O
+.	O
+5	O
+%)	O
+in	O
+all	O
+age	O
+groups	O
+.	O
+
+The	O
+prevalence	O
+of	O
+human	B-SPEC
+metapneumovirus	I-SPEC
+was	O
+higher	O
+in	O
+patients	O
+more	O
+than	O
+50	O
+years	O
+old	O
+,	O
+while	O
+adenovirus	B-DISO
+was	O
+detected	O
+only	O
+in	O
+younger	O
+adults	O
+.	O
+
+CONCLUSIONS	O
+:	O
+This	O
+study	O
+is	O
+valuable	O
+as	O
+the	O
+first	O
+extensive	O
+laboratory	O
+surveillance	O
+of	O
+the	O
+epidemiology	O
+of	O
+respiratory	O
+viruses	B-SPEC
+in	O
+ILI	O
+patients	O
+through	O
+a	O
+teaching	O
+hospital	O
+-	O
+based	O
+influenza	B-DISO
+surveillance	O
+system	O
+in	O
+South	O
+Korea	O
+.	O
+
+MERS	O
+-	O
+CoV	O
+infection	B-DISO
+may	O
+cause	O
+a	O
+spectrum	O
+of	O
+clinical	O
+illness	O
+.	O
+
+ABSTRACT	O
+:	O
+A	O
+10	O
+-	O
+year	O
+-	O
+old	O
+domestic	O
+short	O
+hair	O
+cat	B-SPEC
+was	O
+referred	O
+for	O
+investigation	O
+of	O
+anorexia	B-DISO
+and	O
+polydipsia	B-DISO
+of	O
+3	O
+days	O
+'	O
+duration	O
+.	O
+
+Ultrasonographic	O
+evaluation	O
+of	O
+the	O
+abdomen	B-ANAT
+did	O
+not	O
+identify	O
+any	O
+abnormalities	O
+.	O
+
+Serum	B-COMP
+tests	O
+for	O
+feline	B-SPEC
+immunodeficiency	I-SPEC
+virus	I-SPEC
+(	O
+FIV	B-SPEC
+)	O
+and	O
+feline	B-SPEC
+leukaemia	B-DISO
+virus	B-SPEC
+(	O
+FeLV	O
+)	O
+were	O
+negative	O
+.	O
+
+Long	O
+bone	B-ANAT
+shaft	I-ANAT
+marrow	O
+was	O
+hyperplastic	B-DISO
+with	O
+a	O
+predominance	O
+of	O
+leukocyte	B-ANAT
+precursors	O
+and	O
+megakaryocytes	B-ANAT
+and	O
+splenic	B-ANAT
+red	I-ANAT
+pulp	I-ANAT
+showed	O
+mild	O
+extramedullary	B-DISO
+haemopoiesis	I-DISO
+.	O
+
+ABSTRACT	O
+:	O
+Non	O
+-	O
+invasive	O
+ventilation	O
+(	O
+NIV	O
+)	O
+is	O
+contraindicated	O
+or	O
+at	O
+least	O
+not	O
+recommended	O
+in	O
+patients	O
+with	O
+altered	O
+consciousness	O
+syndrome	B-DISO
+(	O
+ACS	B-FUNC
+)	O
+given	O
+to	O
+the	O
+poor	O
+compliance	O
+of	O
+confused	B-DISO
+/	O
+agitated	B-DISO
+patients	O
+,	O
+difficult	O
+management	O
+of	O
+accumulated	O
+secretion	B-PROC
+in	O
+depressed	O
+cough	B-DISO
+reflex	B-PROC
+,	O
+and	O
+risk	O
+of	O
+aspirative	O
+pneumonia	B-DISO
+in	O
+absence	O
+of	O
+airways	O
+protection	O
+.	O
+
+However	O
+,	O
+the	O
+possibility	O
+of	O
+avoiding	O
+ETI	B-CHED
+-	O
+related	O
+life	O
+-	O
+threatening	O
+complications	O
+by	O
+means	O
+of	O
+NIV	O
+,	O
+especially	O
+in	O
+fragile	O
+,	O
+older	O
+patients	O
+with	O
+multiple	O
+comorbidities	O
+,	O
+is	O
+an	O
+appealing	O
+option	O
+.	O
+
+The	O
+available	O
+published	O
+data	O
+dealing	O
+with	O
+the	O
+use	O
+of	O
+NIV	O
+in	O
+ACS	B-FUNC
+were	O
+obtained	O
+in	O
+patients	O
+with	O
+hypercapnic	B-DISO
+encephalopathy	I-DISO
+complicating	O
+severe	O
+exacerbations	O
+of	O
+COPD	B-DISO
+.	O
+
+Among	O
+purebreds	O
+,	O
+the	O
+positivities	O
+in	O
+the	O
+Norwegian	O
+forest	O
+cat	B-SPEC
+(	O
+92	O
+.	O
+3	O
+%)	O
+and	O
+Scottish	O
+fold	O
+(	O
+77	O
+.	O
+6	O
+%)	O
+were	O
+significantly	O
+higher	O
+than	O
+the	O
+average	O
+of	O
+purebreds	O
+(	O
+P	O
+=	O
+0	O
+.	O
+0274	O
+and	O
+0	O
+.	O
+0251	O
+,	O
+respectively	O
+).	O
+
+The	O
+positivity	O
+was	O
+significantly	O
+higher	O
+in	O
+males	O
+(	O
+51	O
+.	O
+5	O
+%)	O
+than	O
+in	O
+females	O
+(	O
+35	O
+.	O
+7	O
+%)	O
+(	O
+P	O
+<	O
+0	O
+.	O
+0001	O
+),	O
+whereas	O
+no	O
+gender	O
+difference	O
+has	O
+generally	O
+been	O
+noted	O
+in	O
+FCoV	O
+antibody	B-COMP
+prevalence	O
+,	O
+indicating	O
+that	O
+FIP	B-DISO
+more	O
+frequently	O
+develops	O
+in	O
+males	O
+among	O
+FCoV	O
+-	O
+infected	O
+cats	B-SPEC
+.	O
+
+Understanding	O
+of	O
+fundamental	O
+mechanisms	O
+involved	O
+in	O
+regulation	B-PROC
+of	O
+endothelial	B-ANAT
+permeability	O
+is	O
+essential	O
+for	O
+development	B-PROC
+of	O
+barrier	O
+protective	O
+therapeutic	O
+strategies	O
+.	O
+
+Therefore	O
+,	O
+understanding	O
+of	O
+basic	O
+barrier	O
+protective	O
+mechanisms	O
+in	O
+pulmonary	B-ANAT
+endothelium	B-ANAT
+is	O
+essential	O
+for	O
+selection	O
+of	O
+optimal	O
+treatment	O
+of	O
+pulmonary	B-DISO
+edema	I-DISO
+of	O
+different	O
+etiology	O
+.	O
+
+TITLE	O
+:	O
+Genetic	O
+characterization	O
+of	O
+Betacoronavirus	B-SPEC
+lineage	O
+C	O
+viruses	B-SPEC
+in	O
+bats	B-SPEC
+reveals	O
+marked	O
+sequence	O
+divergence	O
+in	O
+the	O
+spike	O
+protein	O
+of	O
+pipistrellus	B-PRGE
+bat	I-PRGE
+coronavirus	I-PRGE
+HKU5	I-PRGE
+in	O
+Japanese	O
+pipistrelle	O
+:	O
+implications	O
+for	O
+the	O
+origin	O
+of	O
+the	O
+novel	O
+Middle	O
+East	O
+respiratory	O
+syndrome	B-DISO
+coronavirus	B-SPEC
+.	O
+
+Although	O
+MERS	O
+-	O
+CoV	O
+may	O
+have	O
+diverged	O
+from	O
+potential	O
+lineage	O
+C	O
+betacoronaviruses	O
+in	O
+European	O
+bats	B-SPEC
+more	O
+recently	O
+,	O
+these	O
+bat	B-ENZY
+viruses	B-SPEC
+were	O
+unlikely	O
+to	O
+be	O
+the	O
+direct	O
+ancestor	O
+of	O
+MERS	O
+-	O
+CoV	O
+.	O
+Intensive	O
+surveillance	O
+for	O
+lineage	O
+C	O
+betaCoVs	O
+in	O
+Pipistrellus	B-SPEC
+and	O
+related	O
+bats	B-SPEC
+with	O
+diverse	O
+habitats	O
+and	O
+other	O
+animals	B-SPEC
+in	O
+the	O
+Middle	O
+East	O
+may	O
+fill	O
+the	O
+evolutionary	O
+gap	O
+.	O
+
+ABSTRACT	O
+:	O
+Feline	B-SPEC
+α1	B-PRGE
+-	I-PRGE
+acid	I-PRGE
+glycoprotein	I-PRGE
+(	O
+fAGP	O
+)	O
+modifies	O
+both	O
+its	O
+serum	B-COMP
+concentration	O
+and	O
+its	O
+glycan	B-CHED
+moiety	O
+during	O
+diseases	O
+.	O
+
+The	O
+flow	O
+cytometric	O
+method	O
+provided	O
+repeatable	O
+results	O
+for	O
+neutrophils	B-ANAT
+(	O
+coefficients	O
+of	O
+variations	O
+,	O
+CVs	B-DISO
+<	O
+15	O
+%)	O
+but	O
+not	O
+for	O
+monocytes	B-ANAT
+(	O
+CVs	B-DISO
+>	O
+20	O
+%)	O
+which	O
+had	O
+also	O
+a	O
+high	O
+individual	O
+variability	O
+.	O
+
+We	O
+report	O
+detailed	O
+clinical	O
+and	O
+virological	O
+data	O
+for	O
+two	O
+related	O
+cases	O
+of	O
+MERS	O
+-	O
+CoV	O
+disease	O
+,	O
+after	O
+nosocomial	O
+transmission	O
+of	O
+the	O
+virus	B-SPEC
+from	O
+one	O
+patient	O
+to	O
+another	O
+in	O
+a	O
+French	O
+hospital	O
+.	O
+
+Immunosuppression	B-PROC
+should	O
+also	O
+be	O
+taken	O
+into	O
+account	O
+as	O
+a	O
+risk	O
+factor	O
+.	O
+
+This	O
+report	O
+describes	O
+several	O
+events	O
+in	O
+which	O
+virus	B-SPEC
+isolation	O
+and	O
+identification	O
+by	O
+electron	O
+microscopy	O
+were	O
+critical	O
+to	O
+initial	O
+recognition	O
+of	O
+the	O
+etiologic	O
+agent	O
+,	O
+which	O
+was	O
+further	O
+analyzed	O
+by	O
+additional	O
+laboratory	O
+diagnostic	O
+assays	O
+.	O
+
+Lessons	O
+learned	B-PROC
+from	O
+the	O
+global	O
+SARS	B-DISO
+outbreak	O
+highlight	O
+the	O
+need	O
+to	O
+avoid	O
+complacency	O
+,	O
+strengthen	O
+efforts	O
+to	O
+improve	O
+global	O
+capacity	O
+to	O
+address	O
+the	O
+next	O
+pandemic	O
+using	O
+all	O
+available	O
+21st	O
+century	O
+tools	O
+,	O
+and	O
+support	O
+research	O
+to	O
+develop	O
+new	O
+treatment	O
+options	O
+,	O
+countermeasures	O
+,	O
+and	O
+insights	O
+while	O
+striving	O
+to	O
+address	O
+the	O
+global	O
+inequities	O
+that	O
+are	O
+the	O
+root	O
+cause	O
+of	O
+many	O
+of	O
+these	O
+challenges	O
+.	O
+
+Oxidants	B-CHED
+modify	O
+cellular	B-COMP
+proteins	B-CHED
+,	O
+lipids	B-CHED
+,	O
+carbohydrates	B-CHED
+,	O
+and	O
+DNA	O
+to	O
+cause	O
+their	O
+aberrant	O
+function	O
+.	O
+
+To	O
+counteract	O
+the	O
+oxidants	B-CHED
+an	O
+arsenal	O
+of	O
+antioxidants	B-CHED
+exists	O
+in	O
+the	O
+lung	B-ANAT
+to	O
+maintain	O
+the	O
+redox	B-PROC
+status	O
+,	O
+but	O
+when	O
+overwhelmed	O
+tissue	B-ANAT
+injury	O
+and	O
+exacerbation	O
+of	O
+inflammation	B-DISO
+occurs	O
+.	O
+
+It	O
+also	O
+exposed	O
+major	O
+weaknesses	B-DISO
+in	O
+several	O
+of	O
+these	O
+countries	O
+in	O
+coping	O
+with	O
+an	O
+outbreak	O
+of	O
+a	O
+newly	O
+emerged	O
+infectious	B-DISO
+disease	I-DISO
+.	O
+
+In	O
+the	O
+10	O
+years	O
+since	O
+the	O
+outbreak	O
+,	O
+in	O
+addition	O
+to	O
+the	O
+increase	O
+in	O
+knowledge	O
+of	O
+the	O
+biology	O
+and	O
+epidemiology	O
+of	O
+this	O
+disease	O
+,	O
+a	O
+major	O
+lesson	O
+learned	B-PROC
+is	O
+the	O
+value	O
+of	O
+having	O
+a	O
+national	O
+public	O
+health	O
+institute	O
+that	O
+is	O
+prepared	O
+to	O
+control	O
+disease	O
+outbreaks	O
+and	O
+designed	O
+to	O
+coordinate	O
+a	O
+national	O
+response	O
+and	O
+assist	O
+localities	O
+in	O
+their	O
+responses	O
+.	O
+
+The	O
+present	O
+study	O
+was	O
+to	O
+characterize	O
+the	O
+clinical	O
+outcomes	O
+of	O
+patients	O
+with	O
+severe	O
+acute	B-DISO
+pancreatitis	I-DISO
+complicated	O
+with	O
+GC	O
+.	O
+
+The	O
+indices	O
+analyzed	O
+included	O
+sepsis	B-DISO
+/	O
+septic	B-DISO
+shock	I-DISO
+,	O
+pancreatic	B-ANAT
+encephalopathy	B-DISO
+,	O
+acute	O
+respiratory	B-DISO
+distress	I-DISO
+syndrome	I-DISO
+,	I-DISO
+acute	I-DISO
+renal	B-ANAT
+failure	O
+,	O
+multiple	B-DISO
+organ	I-DISO
+dysfunction	I-DISO
+syndrome	I-DISO
+,	O
+and	O
+death	B-PROC
+.	O
+
+Seven	O
+hundred	O
+and	O
+thirty	O
+respiratory	B-ANAT
+samples	I-ANAT
+were	O
+tested	O
+by	O
+modified	O
+shell	B-ANAT
+vial	O
+culture	O
+method	O
+,	O
+RV16	O
+,	O
+and	O
+RV15	O
+.	O
+
+TITLE	O
+:	O
+Immunocytochemical	O
+demonstration	O
+of	O
+feline	B-DISO
+infectious	I-DISO
+peritonitis	I-DISO
+virus	B-SPEC
+within	O
+cerebrospinal	B-ANAT
+fluid	I-ANAT
+macrophages	B-ANAT
+.	O
+
+If	O
+this	O
+test	O
+proves	O
+highly	O
+specific	O
+,	O
+as	O
+for	O
+identification	O
+of	O
+feline	B-SPEC
+coronavirus	B-SPEC
+within	O
+tissue	B-ANAT
+or	O
+effusion	B-DISO
+macrophages	B-ANAT
+,	O
+it	O
+would	O
+be	O
+strongly	O
+supportive	O
+of	O
+an	O
+ante	O
+-	O
+mortem	O
+diagnosis	O
+of	O
+feline	B-DISO
+infectious	I-DISO
+peritonitis	I-DISO
+in	O
+cats	B-SPEC
+with	O
+central	B-ANAT
+nervous	I-ANAT
+system	I-ANAT
+involvement	O
+without	O
+the	O
+need	O
+for	O
+biopsy	O
+.	O
+
+ABSTRACT	O
+:	O
+The	O
+clinical	O
+presentation	O
+ofmyositis	O
+ranges	O
+from	O
+a	O
+painless	O
+muscle	O
+weakness	O
+to	O
+significant	O
+myalgia	B-DISO
+with	O
+muscle	B-DISO
+weakness	I-DISO
+and	O
+constitutional	O
+symptoms	O
+.	O
+
+Along	O
+with	O
+muscle	B-ANAT
+and	O
+skin	B-ANAT
+affection	O
+and	O
+constitutional	O
+symptoms	O
+,	O
+the	O
+disease	O
+can	O
+affect	O
+lungs	B-ANAT
+,	O
+joints	B-ANAT
+,	O
+heart	B-ANAT
+and	O
+gastrointestinal	B-ANAT
+system	I-ANAT
+.	O
+
+Severe	O
+forms	O
+of	O
+the	O
+disease	O
+with	O
+affection	O
+of	O
+the	O
+throat	B-ANAT
+and	O
+respiratory	B-ANAT
+muscles	I-ANAT
+can	O
+vitally	O
+endan	O
+-	O
+ger	B-COMP
+patients	O
+.	O
+
+Pathognomonic	O
+cutaneous	O
+manifestations	O
+of	O
+dermatomyositis	B-DISO
+are	O
+Gottron	O
+'	O
+s	O
+papules	O
+and	O
+heliotrope	O
+erythema	B-DISO
+.	O
+
+Treatment	O
+of	O
+polymyositis	B-DISO
+/	O
+dermatomyositis	B-DISO
+includes	O
+immunosuppressive	O
+/	O
+immunomodulatory	O
+therapy	O
+and	O
+supportive	O
+,	O
+symptomatic	O
+treatment	O
+.	O
+
+Immunosuppressants	O
+/	O
+immunomodulators	O
+are	O
+added	O
+in	O
+the	O
+therapy	O
+along	O
+with	O
+glucocorticoids	B-CHED
+for	O
+better	O
+control	O
+of	O
+the	O
+disease	O
+and	O
+to	O
+reduce	O
+the	O
+required	O
+dose	O
+of	O
+glucocorticoids	B-CHED
+(	O
+side	O
+effects	O
+of	O
+longterm	O
+high	O
+doses	O
+glucocorticoide	O
+use	O
+).	O
+
+Docking	B-PROC
+studies	O
+were	O
+performed	O
+to	O
+model	O
+the	O
+binding	B-FUNC
+interaction	O
+of	O
+the	O
+compound	O
+26m	O
+with	O
+the	O
+SARS	B-DISO
+-	I-PRGE
+CoV	I-PRGE
+3CL	I-PRGE
+protease	I-PRGE
+.	O
+
+TITLE	O
+:	O
+Management	O
+of	O
+autism	B-DISO
+in	O
+the	O
+adult	O
+intensive	O
+care	O
+unit	O
+.	O
+
+The	O
+use	O
+of	O
+dexmedetomidine	B-CHED
+to	O
+wean	B-PROC
+high	O
+-	O
+dose	O
+benzodiazepines	B-CHED
+and	O
+opiates	B-DISO
+also	O
+permitted	O
+successful	O
+liberation	O
+from	O
+mechanical	O
+ventilation	O
+.	O
+
+We	O
+confirmed	O
+the	O
+chylomicronemia	B-DISO
+syndrome	I-DISO
+with	O
+a	O
+triglyceride	B-CHED
+assay	O
+.	O
+
+A	O
+49	O
+-	O
+year	O
+-	O
+old	O
+man	B-CHED
+developed	O
+acute	O
+hypercapneic	O
+respiratory	B-DISO
+failure	I-DISO
+during	O
+an	O
+episode	O
+of	O
+community	O
+-	O
+acquired	O
+pneumonia	B-DISO
+.	O
+
+RESULTS	O
+:	O
+A	O
+49	O
+-	O
+year	O
+-	O
+old	O
+man	B-CHED
+developed	O
+acute	O
+hypercapneic	O
+respiratory	B-DISO
+failure	I-DISO
+during	O
+an	O
+episode	O
+of	O
+community	O
+-	O
+acquired	O
+pneumonia	B-DISO
+.	O
+
+Recombinant	O
+human	B-SPEC
+activated	B-PRGE
+protein	I-PRGE
+C	I-PRGE
+(	O
+APC	B-COMP
+)	O
+reportedly	O
+improves	O
+circulation	B-PROC
+and	O
+respiration	B-PROC
+in	O
+severe	B-DISO
+sepsis	I-DISO
+,	O
+but	O
+is	O
+contraindicated	O
+after	O
+head	B-ANAT
+injury	O
+because	O
+of	O
+increased	O
+risk	O
+of	O
+intracranial	B-DISO
+bleeding	I-DISO
+.	O
+
+The	O
+expressed	B-PROC
+products	O
+were	O
+purified	O
+by	O
+affinity	O
+chromatography	O
+then	O
+analyzed	O
+by	O
+SDS	B-DISO
+-	O
+PAGE	O
+and	O
+Western	O
+blotting	O
+.	O
+
+Recent	O
+data	O
+suggest	O
+that	O
+mild	O
+respiratory	O
+illness	O
+might	O
+be	O
+part	O
+of	O
+the	O
+clinical	O
+spectrum	O
+of	O
+MERS	O
+-	O
+CoV	O
+infection	B-DISO
+,	O
+and	O
+presentations	O
+might	O
+not	O
+initially	O
+include	O
+respiratory	B-DISO
+symptoms	I-DISO
+.	O
+
+Results	O
+of	O
+the	O
+present	O
+study	O
+suggest	O
+that	O
+infection	B-DISO
+-	O
+control	O
+practitioners	O
+should	O
+re	O
+-	O
+evaluate	O
+their	O
+strategy	O
+of	O
+screening	O
+patients	O
+at	O
+admission	O
+for	O
+contagious	O
+respiratory	O
+illness	O
+using	O
+symptom	B-DISO
+-	O
+and	O
+sign	O
+-	O
+based	O
+tests	O
+.	O
+
+TITLE	O
+:	O
+Porcine	B-SPEC
+hemagglutinating	O
+encephalomyelitis	B-DISO
+virus	B-SPEC
+induces	O
+apoptosis	B-PATH
+in	O
+a	O
+porcine	B-SPEC
+kidney	B-ANAT
+cell	I-ANAT
+line	O
+via	O
+caspase	O
+-	O
+dependent	O
+pathways	B-PROC
+.	O
+
+ABSTRACT	O
+:	O
+Porcine	B-SPEC
+hemagglutinating	O
+encephalomyelitis	B-DISO
+is	O
+an	O
+acute	O
+,	O
+highly	O
+contagious	B-DISO
+disease	I-DISO
+in	O
+piglets	O
+that	O
+is	O
+caused	O
+by	O
+the	O
+porcine	B-SPEC
+hemagglutinating	O
+encephalomyelitis	B-DISO
+virus	B-SPEC
+(	O
+PHEV	O
+).	O
+
+Apoptotic	O
+death	B-PROC
+of	O
+infected	O
+cells	B-COMP
+is	O
+detrimental	O
+to	O
+animals	B-SPEC
+because	O
+it	O
+causes	O
+cell	B-COMP
+and	O
+tissue	B-ANAT
+destruction	O
+.	O
+
+TITLE	O
+:	O
+[	O
+Current	O
+concepts	O
+and	O
+trends	O
+in	O
+management	O
+of	O
+ARDS	B-DISO
+:	O
+preface	O
+and	O
+comments	O
+].	O
+
+On	O
+the	O
+other	O
+hand	O
+,	O
+no	O
+pharmacological	O
+therapy	O
+has	O
+yet	O
+proved	O
+to	O
+be	O
+effective	O
+despite	O
+substantial	O
+effort	B-PROC
+devoted	O
+to	O
+development	B-PROC
+and	O
+research	O
+.	O
+
+Recently	O
+,	O
+a	O
+randomized	O
+trial	O
+and	O
+clinical	O
+experience	O
+in	O
+treating	O
+severe	O
+influenza	B-DISO
+have	O
+demonstrated	O
+favorable	O
+outcome	O
+of	O
+ECMO	O
+therapy	O
+in	O
+the	O
+management	O
+of	O
+severe	O
+ARDS	B-DISO
+.	O
+
+To	O
+determine	O
+the	O
+prevalence	O
+of	O
+9	O
+infectious	B-DISO
+agents	O
+in	O
+gastrointestinal	O
+(	O
+GI	O
+)-	O
+diseased	O
+and	O
+healthy	O
+foals	O
+with	O
+ages	O
+ranging	O
+from	O
+1	O
+to	O
+20	O
+weeks	O
+of	O
+age	O
+and	O
+to	O
+what	O
+degree	O
+coinfections	B-DISO
+are	O
+associated	O
+with	O
+clinical	O
+signs	O
+of	O
+GI	O
+disease	O
+.	O
+
+The	O
+overall	O
+prevalence	O
+for	O
+any	O
+infectious	B-DISO
+agent	O
+was	O
+63	O
+.	O
+2	O
+%	O
+in	O
+the	O
+GI	O
+-	O
+diseased	O
+group	O
+and	O
+43	O
+.	O
+2	O
+%	O
+in	O
+the	O
+healthy	O
+group	O
+.	O
+
+In	O
+the	O
+indirect	O
+immunofluorescence	O
+assay	O
+,	O
+proteins	B-CHED
+expression	B-PROC
+in	O
+DEV	O
+infected	O
+duck	B-SPEC
+embryo	B-ANAT
+fibroblasts	B-ANAT
+(	O
+DEFs	O
+)	O
+within	O
+24	O
+h	O
+post	O
+-	O
+infection	B-DISO
+(	O
+p	O
+.	O
+i	O
+.)	O
+was	O
+also	O
+effectively	O
+suppressed	O
+by	O
+resveratrol	B-CHED
+.	O
+
+ABSTRACT	O
+:	O
+Severe	O
+malaria	O
+due	O
+to	O
+P	B-SPEC
+.	I-SPEC
+vivax	I-SPEC
+infection	B-DISO
+is	O
+increasingly	O
+observed	O
+now	O
+a	O
+days	O
+.	O
+
+Organ	B-DISO
+failure	I-DISO
+in	O
+vivax	B-DISO
+malaria	I-DISO
+is	O
+caused	O
+by	O
+mechanisms	O
+of	O
+inflammation	B-DISO
+as	O
+well	O
+as	O
+sequestration	O
+.	O
+
+The	O
+complications	O
+seen	O
+in	O
+vivax	B-DISO
+malaria	I-DISO
+were	O
+:	O
+thrombocytopenia	O
+(	O
+68	O
+%),	O
+leukopenia	B-DISO
+(	O
+19	O
+%),	O
+ARDS	B-DISO
+(	O
+3	O
+%),	O
+high	O
+bilirubin	B-CHED
+(	O
+5	O
+%),	O
+acute	B-DISO
+renal	I-DISO
+failure	I-DISO
+(	O
+3	O
+.	O
+5	O
+%),	O
+anemia	B-DISO
+(	O
+3	O
+%),	O
+mucosal	B-ANAT
+bleeding	B-DISO
+(	O
+8	O
+%),	O
+cerebral	B-DISO
+malaria	B-PATH
+(	O
+3	O
+.	O
+5	O
+%),	O
+hypotension	O
+(	O
+5	O
+%),	O
+metabolic	B-DISO
+acidosis	I-DISO
+(	O
+4	O
+%)	O
+and	O
+death	B-PROC
+(	O
+1	O
+.	O
+77	O
+%).	O
+
+We	O
+hypothesize	O
+that	O
+HRR	B-PROC
+patients	O
+will	O
+have	O
+worse	O
+outcomes	O
+from	O
+crystalloid	B-COMP
+use	O
+.	O
+
+Ratios	O
+of	O
+fresh	B-ANAT
+frozen	I-ANAT
+plasma	I-ANAT
+-	O
+packed	O
+red	B-ANAT
+blood	I-ANAT
+cell	I-ANAT
+(	O
+PRBC	O
+)	O
+were	O
+calculated	O
+and	O
+divided	O
+in	O
+two	O
+groups	O
+:	O
+HRR	B-PROC
+(	O
+1	O
+-	O
+1	O
+:	O
+2	O
+)	O
+and	O
+low	O
+-	O
+ratio	O
+resuscitation	O
+(	O
+LRR	O
+<	O
+1	O
+:	O
+2	O
+).	O
+
+Major	O
+outcome	O
+of	O
+interest	O
+was	O
+to	O
+analyze	O
+the	O
+direct	O
+impact	O
+of	O
+24	O
+-	O
+hour	O
+crystalloid	B-COMP
+volume	O
+on	O
+HRR	B-PROC
+MTP	O
+patients	O
+who	O
+received	O
+10	O
+or	O
+more	O
+units	O
+of	O
+PRBC	O
+.	O
+
+Statistical	O
+analysis	O
+included	O
+analysis	O
+of	O
+variance	O
+,	O
+Fisher	B-SPEC
+'	O
+s	O
+exact	O
+,	O
+Kaplan	O
+-	O
+Meier	O
+(	O
+KM	O
+)	O
+survival	O
+curves	O
+,	O
+and	O
+multiple	O
+logistic	O
+regression	O
+.	O
+
+RESULTS	O
+:	O
+Total	O
+of	O
+five	O
+Level	O
+I	O
+trauma	O
+centers	O
+participated	O
+with	O
+451	O
+patients	O
+who	O
+received	O
+MTP	O
+with	O
+10	O
+or	O
+more	O
+units	O
+of	O
+PRBC	O
+(	O
+fresh	B-ANAT
+frozen	I-ANAT
+plasma	I-ANAT
+/	O
+PRBC	O
+ratios	O
+,	O
+n	O
+=	O
+365	O
+(	O
+80	O
+.	O
+9	O
+%)	O
+HRR	B-PROC
+vs	O
+.	O
+n	O
+=	O
+86	O
+(	O
+19	O
+.	O
+0	O
+%)	O
+LRR	O
+.	O
+
+Multivariate	O
+logistic	O
+regression	O
+models	O
+were	O
+developed	O
+controlling	O
+for	O
+age	O
+,	O
+sex	O
+,	O
+mechanisms	O
+of	O
+injury	O
+,	O
+arrival	O
+physiology	O
+,	O
+individual	O
+Abbreviated	O
+Injury	O
+Scale	O
+(	O
+AIS	O
+)	O
+scores	O
+,	O
+blood	B-ANAT
+transfusions	O
+,	O
+and	O
+crystalloid	B-COMP
+administration	O
+.	O
+
+Of	O
+the	O
+patients	O
+58	O
+.	O
+7	O
+%	O
+(	O
+731	O
+of	O
+1	O
+,	O
+245	O
+)	O
+met	B-CHED
+inclusion	O
+criteria	O
+.	O
+
+During	O
+early	O
+resuscitation	O
+(	O
+0	O
+-	O
+6	O
+h	O
+),	O
+logistic	O
+regression	O
+revealed	O
+age	O
+(	O
+odd	O
+ratio	O
+[	O
+OR	O
+],	O
+1	O
+.	O
+02	O
+;	O
+95	O
+%	O
+confidence	O
+interval	O
+[	O
+CI	O
+],	O
+1	O
+.	O
+00	O
+-	O
+1	O
+.	O
+04	O
+),	O
+chest	B-ANAT
+AIS	B-DISO
+score	O
+(	O
+OR	O
+,	O
+1	O
+.	O
+31	O
+;	O
+95	O
+%	O
+CI	O
+,	O
+1	O
+.	O
+10	O
+-	O
+1	O
+.	O
+57	O
+),	O
+and	O
+intravenously	O
+administered	O
+crystalloid	B-COMP
+fluids	B-ANAT
+given	O
+in	O
+500	O
+mL	O
+increments	O
+(	O
+OR	O
+,	O
+1	O
+.	O
+12	O
+;	O
+95	O
+%	O
+CI	O
+,	O
+1	O
+.	O
+01	O
+-	O
+1	O
+.	O
+25	O
+)	O
+as	O
+predictive	O
+of	O
+moderate	O
+or	O
+severe	O
+hypoxemia	O
+.	O
+
+Red	B-ANAT
+blood	I-ANAT
+cell	I-ANAT
+,	O
+plasma	B-ANAT
+,	O
+and	O
+platelet	B-ANAT
+transfusions	O
+(	O
+whether	O
+received	O
+during	O
+early	O
+or	O
+late	O
+resuscitation	O
+)	O
+failed	O
+to	O
+demonstrate	O
+an	O
+increased	O
+risk	O
+of	O
+developing	O
+moderate	O
+/	O
+severe	O
+hypoxemia	O
+.	O
+
+RESULTS	O
+:	O
+Between	O
+April	O
+1	O
+and	O
+May	O
+23	O
+,	O
+2013	O
+,	O
+a	O
+total	O
+of	O
+23	O
+cases	O
+of	O
+MERS	O
+-	O
+CoV	O
+infection	B-DISO
+were	O
+reported	O
+in	O
+the	O
+eastern	O
+province	O
+of	O
+Saudi	O
+Arabia	O
+.	O
+
+Viral	O
+loads	O
+were	O
+highest	O
+in	O
+samples	O
+from	O
+the	O
+lower	B-ANAT
+respiratory	I-ANAT
+tract	I-ANAT
+(	O
+up	O
+to	O
+1	O
+·	O
+2	O
+×	O
+10	O
+(	O
+6	O
+)	O
+copies	O
+per	O
+mL	O
+).	O
+
+The	O
+full	O
+virus	B-SPEC
+genome	O
+was	O
+combined	O
+with	O
+four	O
+other	O
+available	O
+full	O
+genome	O
+sequences	O
+in	O
+a	O
+maximum	O
+likelihood	O
+phylogeny	O
+,	O
+correlating	O
+branch	B-ANAT
+lengths	O
+with	O
+dates	O
+of	O
+isolation	O
+.	O
+
+TITLE	O
+:	O
+Community	O
+-	O
+acquired	O
+pneumonia	B-DISO
+in	O
+Chile	O
+:	O
+the	O
+clinical	O
+relevance	O
+in	O
+the	O
+detection	O
+of	O
+viruses	B-SPEC
+and	O
+atypical	O
+bacteria	O
+.	O
+
+TITLE	O
+:	O
+First	O
+cases	O
+of	O
+Middle	O
+East	O
+Respiratory	O
+Syndrome	B-DISO
+Coronavirus	B-SPEC
+(	O
+MERS	O
+-	O
+CoV	O
+)	O
+infections	B-DISO
+in	O
+France	O
+,	O
+investigations	O
+and	O
+implications	O
+for	O
+the	O
+prevention	O
+of	O
+human	O
+-	O
+to	O
+-	O
+human	B-SPEC
+transmission	O
+,	O
+France	O
+,	O
+May	O
+2013	O
+.	O
+
+Rigorous	O
+risk	O
+assessment	O
+is	O
+particularly	O
+challenging	O
+in	O
+a	O
+context	O
+where	O
+surveillance	O
+may	O
+be	O
+subject	O
+to	O
+under	O
+-	O
+ascertainment	O
+and	O
+a	O
+selection	O
+bias	B-SPEC
+towards	O
+more	O
+severe	O
+cases	O
+.	O
+
+We	O
+have	O
+utilized	O
+solution	O
+-	O
+state	O
+nuclear	O
+magnetic	O
+resonance	O
+spectroscopy	O
+to	O
+investigate	O
+DC	O
+-	O
+SIGNR	O
+binding	B-FUNC
+and	O
+herein	O
+report	O
+the	O
+first	O
+backbone	B-ANAT
+assignment	O
+of	O
+its	O
+active	O
+,	O
+calcium	B-CHED
+-	O
+bound	O
+carbohydrate	O
+recognition	O
+domain	O
+.	O
+
+This	O
+suggests	O
+that	O
+using	O
+the	O
+binding	B-FUNC
+mode	O
+of	O
+Man9GlcNAc	O
+,	O
+instead	O
+of	O
+those	O
+of	O
+small	O
+glycans	B-CHED
+,	O
+may	O
+provide	O
+a	O
+platform	O
+for	O
+the	O
+design	O
+of	O
+DC	O
+-	O
+SIGNR	O
+inhibitors	B-CHED
+selective	O
+for	O
+high	O
+mannose	B-CHED
+glycans	B-CHED
+(	O
+like	O
+those	O
+on	O
+HIV	B-DISO
+).	O
+
+ABSTRACT	O
+:	O
+Human	B-SPEC
+serum	B-ANAT
+albumin	I-PRGE
+(	O
+HSA	B-DISO
+)	O
+is	O
+the	O
+most	O
+abundant	O
+circulating	O
+protein	B-CHED
+and	O
+accounts	O
+for	O
+about	O
+70	O
+%	O
+of	O
+the	O
+plasma	B-ANAT
+colloid	B-ANAT
+osmotic	O
+pressure	O
+.	O
+
+HSA	B-DISO
+prescription	O
+should	O
+be	O
+not	O
+uncritically	O
+restricted	O
+.	O
+
+As	O
+a	O
+result	O
+,	O
+a	O
+more	O
+appropriate	O
+HSA	B-DISO
+use	O
+can	O
+be	O
+achieved	O
+maintaining	O
+the	O
+health	O
+care	O
+expenditure	O
+under	O
+control	O
+.	O
+
+Pediatric	O
+deaths	B-PROC
+in	O
+earthquakes	O
+are	O
+mainly	O
+due	O
+to	O
+cardiopulmonary	B-DISO
+arrest	I-DISO
+,	O
+severe	O
+craniocerebral	O
+injury	O
+,	O
+shock	O
+,	O
+crush	B-DISO
+syndrome	I-DISO
+,	O
+and	O
+multiple	B-DISO
+organ	I-DISO
+failure	I-DISO
+.	O
+
+ABSTRACT	O
+:	O
+Middle	O
+East	O
+respiratory	O
+syndrome	O
+coronavirus	B-SPEC
+(	O
+MERS	O
+-	O
+CoV	O
+),	O
+a	O
+novel	O
+human	B-SPEC
+coronavirus	I-SPEC
+that	O
+caused	O
+outbreaks	O
+of	O
+a	O
+SARS	B-DISO
+-	O
+like	O
+illness	O
+in	O
+the	O
+Middle	O
+East	O
+,	O
+is	O
+now	O
+considered	O
+a	O
+threat	O
+to	O
+global	O
+public	O
+health	O
+.	O
+
+TITLE	O
+:	O
+Middle	O
+East	O
+Respiratory	O
+Syndrome	B-DISO
+coronavirus	B-SPEC
+(	O
+MERS	O
+CoV	O
+):	O
+Update	O
+2013	O
+.	O
+
+TITLE	O
+:	O
+Genetic	O
+properties	O
+of	O
+endemic	O
+Chinese	O
+porcine	B-SPEC
+epidemic	B-DISO
+diarrhea	I-DISO
+virus	B-SPEC
+strains	O
+isolated	O
+since	O
+2010	O
+.	O
+
+ABSTRACT	O
+:	O
+Acute	O
+diarrhea	O
+outbreaks	O
+caused	O
+by	O
+porcine	B-SPEC
+epidemic	I-SPEC
+diarrhea	I-SPEC
+virus	I-SPEC
+(	O
+PEDV	B-SPEC
+)	O
+have	O
+been	O
+observed	O
+in	O
+various	O
+pig	B-SPEC
+-	O
+breeding	B-PROC
+provinces	O
+of	O
+China	O
+since	O
+December	O
+2010	O
+.	O
+
+During	O
+the	O
+period	O
+August	O
+13	O
+to	O
+September	O
+27	O
+,	O
+2010	O
+,	O
+case	O
+records	O
+of	O
+106	O
+patients	O
+with	O
+severe	O
+influenza	B-DISO
+like	I-DISO
+illness	I-DISO
+(	O
+ILI	O
+)	O
+and	O
+respiratory	B-DISO
+complications	I-DISO
+who	O
+underwent	O
+diagnostic	O
+testing	O
+by	O
+real	O
+-	O
+time	O
+polymerase	O
+chain	O
+reaction	O
+(	O
+RT	O
+-	O
+PCR	O
+)	O
+for	O
+confirmation	O
+of	O
+pH1N1	O
+-	O
+2009	O
+were	O
+retrospectively	O
+studied	O
+.	O
+
+ABSTRACT	O
+:	O
+Staphylococcus	B-SPEC
+toxic	B-DISO
+shock	I-DISO
+syndrome	I-DISO
+is	O
+a	O
+severe	O
+illness	O
+caused	O
+by	O
+infection	B-DISO
+with	O
+toxin	O
+producing	O
+Staphylococcus	B-SPEC
+aureus	I-SPEC
+and	O
+is	O
+associated	O
+with	O
+a	O
+poor	O
+outcome	O
+.	O
+
+We	O
+report	O
+a	O
+case	O
+of	O
+Staphylococcus	B-SPEC
+TSS	B-DISO
+presenting	O
+with	O
+cough	B-DISO
+and	O
+expectoration	B-ANAT
+along	O
+with	O
+multiple	O
+pneumatoceles	B-DISO
+visible	O
+on	O
+the	O
+chest	B-ANAT
+radiograph	O
+that	O
+progressed	O
+to	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+with	O
+eventual	O
+foci	O
+in	O
+brain	B-ANAT
+.	O
+
+TITLE	O
+:	O
+The	O
+clinical	O
+course	O
+of	O
+late	O
+diagnosed	O
+fatal	O
+cases	O
+of	O
+A	O
+(	O
+H1N1	O
+)	O
+influenza	B-DISO
+in	O
+Poland	O
+.	O
+
+A	O
+retrospective	O
+study	O
+of	O
+6	O
+fatal	O
+cases	O
+of	O
+pandemic	O
+influenza	B-DISO
+,	O
+aged	O
+23	O
+-	O
+41	O
+,	O
+including	O
+3	O
+women	O
+,	O
+hospitalised	O
+between	O
+November	O
+2009	O
+and	O
+February	O
+2011	O
+in	O
+different	O
+Polish	O
+medical	O
+centres	O
+.	O
+
+RESULTS	O
+:	O
+We	O
+present	O
+the	O
+clinical	O
+course	O
+of	O
+6	O
+late	O
+diagnosed	O
+cases	O
+of	O
+A	O
+(	O
+H1N1	O
+)	O
+influenza	B-DISO
+.	O
+
+Autopsies	O
+were	O
+performed	O
+in	O
+5	O
+cases	O
+and	O
+revealed	O
+haemorrhagic	B-DISO
+pneumonia	I-DISO
+in	O
+2	O
+patients	O
+.	O
+
+A	O
+previously	O
+published	O
+meta	B-SPEC
+-	O
+analysis	O
+of	O
+8	O
+comparative	O
+studies	O
+found	O
+no	O
+significant	O
+survival	O
+differences	O
+.	O
+
+Despite	O
+rapid	O
+parasite	O
+clearance	O
+times	O
+resulting	O
+from	O
+ET	O
+,	O
+there	O
+is	O
+no	O
+evidence	O
+for	O
+efficacy	O
+of	O
+ET	O
+as	O
+adjunctive	O
+therapy	O
+in	O
+severe	O
+malaria	B-PATH
+.	O
+
+We	O
+found	O
+87	O
+articles	O
+,	O
+mostly	O
+case	O
+reports	O
+or	O
+series	O
+,	O
+showing	O
+successful	O
+use	O
+of	O
+ET	O
+,	O
+likely	O
+reporting	O
+bias	B-SPEC
+.	O
+
+TITLE	O
+:	O
+Evolutionary	O
+dynamics	O
+of	O
+bovine	B-SPEC
+coronaviruses	O
+:	O
+natural	O
+selection	O
+pattern	O
+of	O
+the	O
+spike	O
+gene	O
+implies	O
+adaptive	O
+evolution	O
+of	O
+the	O
+strains	O
+.	O
+
+ABSTRACT	O
+:	O
+In	O
+previous	O
+work	O
+,	O
+we	O
+designed	O
+peptides	B-CHED
+that	O
+showed	O
+potent	O
+inhibition	B-PROC
+of	O
+Newcastle	B-SPEC
+disease	I-SPEC
+virus	I-SPEC
+(	O
+NDV	B-SPEC
+)	O
+and	O
+infectious	B-DISO
+bronchitis	B-DISO
+virus	B-SPEC
+(	O
+IBV	B-SPEC
+)	O
+infections	B-DISO
+in	O
+chicken	B-SPEC
+embryos	B-ANAT
+.	O
+
+Cytomegalovirus	O
+(	O
+CMV	B-SPEC
+)	O
+was	O
+detected	O
+in	O
+some	O
+RPTEC	O
+by	O
+cytology	O
+,	O
+an	O
+immunofluorescence	O
+assay	O
+,	O
+and	O
+PCR	O
+.	O
+
+Human	B-PRGE
+coronavirus	I-PRGE
+NL63	I-PRGE
+was	O
+isolated	O
+and	O
+identified	O
+by	O
+RT	O
+-	O
+PCR	O
+and	O
+sequencing	O
+,	O
+and	O
+its	O
+replication	O
+in	O
+a	O
+fresh	B-ANAT
+batch	O
+of	O
+RPTEC	O
+and	O
+another	O
+type	O
+of	O
+primary	O
+human	B-SPEC
+kidney	B-ANAT
+cells	B-COMP
+was	O
+confirmed	O
+.	O
+
+By	O
+molecular	O
+analysis	O
+of	O
+the	O
+whole	O
+genome	O
+,	O
+CaKV	O
+that	O
+appeared	O
+genetically	O
+closest	O
+to	O
+the	O
+murine	B-SPEC
+kobuvirus	B-SPEC
+(	O
+MuKV	O
+)	O
+and	O
+to	O
+the	O
+human	B-SPEC
+Aichi	B-SPEC
+virus	I-SPEC
+(	O
+AiV	O
+),	O
+may	O
+be	O
+classified	O
+in	O
+the	O
+Kobuvirus	B-SPEC
+genus	B-SPEC
+as	O
+new	O
+genotype	O
+(	O
+CaKV	B-PRGE
+type	I-PRGE
+1	I-PRGE
+)	O
+within	O
+the	O
+species	B-SPEC
+Aichivirus	O
+A	O
+.	O
+To	O
+date	O
+,	O
+there	O
+are	O
+no	O
+information	O
+on	O
+the	O
+epidemiology	O
+of	O
+these	O
+novel	O
+viruses	B-SPEC
+in	O
+other	O
+continents	O
+.	O
+
+ABSTRACT	O
+:	O
+Previous	O
+reports	O
+suggest	O
+that	O
+acute	O
+lung	O
+injury	O
+(	O
+ALI	O
+)/	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+(	O
+ARDS	B-DISO
+)	O
+is	O
+underdiagnosed	O
+in	O
+both	O
+adult	O
+and	O
+pediatric	O
+clinical	O
+practice	O
+.	O
+
+This	O
+retrospective	O
+study	O
+included	O
+intensive	O
+care	O
+unit	O
+(	O
+ICU	O
+)	O
+patients	O
+who	O
+died	B-PROC
+and	O
+underwent	O
+postmortem	O
+examination	O
+.	O
+
+However	O
+,	O
+those	O
+with	O
+a	O
+pulmonary	B-ANAT
+cause	O
+of	O
+ALI	O
+/	O
+ARDS	B-DISO
+were	O
+more	O
+likely	O
+to	O
+have	O
+a	O
+diagnosis	O
+recorded	O
+.	O
+
+Significant	O
+barriers	O
+remain	O
+to	O
+the	O
+recognition	O
+of	O
+ALI	O
+/	O
+ARDS	B-DISO
+and	O
+application	O
+of	O
+an	O
+evidence	O
+-	O
+based	O
+ventilator	O
+strategy	O
+.	O
+
+ABSTRACT	O
+:	O
+In	O
+2009	O
+pandemic	O
+caused	O
+by	O
+high	O
+-	O
+path	O
+fluenza	O
+A	O
+(	O
+H1N1	O
+),	O
+so	O
+called	O
+""""	O
+swine	O
+""""	O
+flu	B-DISO
+was	O
+registered	O
+in	O
+the	O
+world	O
+.	O
+
+Aphylaxis	O
+to	O
+this	O
+type	O
+of	O
+influenza	B-DISO
+lead	O
+to	O
+pandemic	O
+.	O
+
+It	O
+led	O
+to	O
+patient	O
+'	O
+s	O
+death	B-PROC
+.	O
+
+The	O
+BCoV	B-PRGE
+RT	I-PRGE
+-	I-PRGE
+RPA	I-PRGE
+was	O
+rapid	O
+(	O
+10	O
+-	O
+20	O
+min	O
+)	O
+and	O
+has	O
+an	O
+analytical	O
+sensitivity	O
+of	O
+19	O
+molecules	O
+.	O
+
+The	O
+BCoV	B-PRGE
+RT	I-PRGE
+-	I-PRGE
+RPA	I-PRGE
+constitutes	O
+a	O
+suitable	O
+accurate	O
+,	O
+sensitive	O
+and	O
+rapid	O
+alternative	O
+to	O
+the	O
+common	O
+measures	O
+used	O
+for	O
+BCoV	O
+diagnosis	O
+.	O
+
+Of	O
+the	O
+90	O
+homozygous	O
+sickle	B-ANAT
+cell	I-ANAT
+children	O
+with	O
+malaria	B-PATH
+,	O
+fever	B-PROC
+,	O
+pallor	B-DISO
+,	O
+and	O
+jaundice	B-DISO
+were	O
+the	O
+commonly	O
+-	O
+found	O
+symptoms	O
+.	O
+
+No	O
+death	B-PROC
+was	O
+observed	O
+in	O
+this	O
+series	O
+.	O
+
+No	O
+death	B-PROC
+was	O
+observed	O
+in	O
+this	O
+series	O
+.	O
+
+This	O
+prospective	O
+observational	O
+study	O
+was	O
+performed	O
+among	O
+children	O
+admitted	O
+with	O
+severe	O
+malaria	B-PATH
+at	O
+a	O
+tertiary	O
+care	O
+referral	O
+hospital	O
+of	O
+northern	O
+India	O
+from	O
+January	O
+2012	O
+to	O
+December	O
+2012	O
+.	O
+
+Children	O
+diagnosed	O
+with	O
+'	O
+severe	O
+malaria	B-PATH
+'	O
+(	O
+World	O
+Health	O
+Organization	O
+,	O
+2000	O
+),	O
+were	O
+started	O
+on	O
+intravenous	O
+artesunate	B-CHED
+followed	O
+by	O
+artemether	B-CHED
+-	O
+lumefantrine	B-CHED
+combination	O
+.	O
+
+The	O
+clinical	O
+presentation	O
+and	O
+outcome	O
+of	O
+severe	O
+vivax	B-DISO
+malaria	I-DISO
+was	O
+found	O
+to	O
+be	O
+similar	O
+to	O
+severe	O
+malaria	B-PATH
+caused	O
+by	O
+P	B-SPEC
+.	I-SPEC
+falciparum	I-SPEC
+and	O
+mixed	B-DISO
+infection	I-DISO
+,	O
+except	O
+for	O
+higher	O
+chances	O
+of	O
+severe	O
+anaemia	B-DISO
+among	O
+the	O
+children	O
+infected	O
+with	O
+P	B-SPEC
+.	I-SPEC
+falciparum	I-SPEC
+(	O
+P	O
+=	O
+0	O
+·	O
+04	O
+).	O
+
+Therefore	O
+,	O
+we	O
+repeated	O
+the	O
+Legionella	B-SPEC
+urinary	O
+antigen	B-CHED
+test	O
+,	O
+which	O
+was	O
+positive	O
+.	O
+
+On	O
+the	O
+basis	O
+of	O
+these	O
+results	O
+,	O
+sputum	B-ANAT
+polymerase	O
+chain	O
+reaction	O
+findings	O
+,	O
+and	O
+the	O
+four	O
+-	O
+fold	O
+elevation	O
+of	O
+paired	B-PRGE
+antibodies	I-PRGE
+,	O
+the	O
+patient	O
+was	O
+diagnosed	O
+as	O
+having	O
+Legionella	O
+pneumonia	O
+accompanied	O
+by	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+.	O
+
+We	O
+also	O
+administered	O
+a	O
+corticosteroid	B-CHED
+for	O
+severe	O
+pneumonia	B-DISO
+with	O
+the	O
+expectation	O
+of	O
+clinical	O
+improvement	O
+and	O
+to	O
+avoid	O
+intubation	O
+.	O
+
+TITLE	O
+:	O
+Severe	O
+respiratory	O
+syndromes	B-DISO
+:	O
+travel	O
+history	O
+matters	O
+.	O
+
+In	O
+2012	O
+,	O
+another	O
+outbreak	O
+of	O
+coronavirus	B-SPEC
+pneumonitis	B-DISO
+occurred	O
+in	O
+the	O
+Middle	O
+-	O
+East	O
+.	O
+
+In	O
+this	O
+study	O
+,	O
+we	O
+have	O
+tested	O
+the	O
+ethanolic	O
+extracts	O
+obtained	O
+by	O
+the	O
+Hypericum	B-SPEC
+hircinum	I-SPEC
+L	O
+.	O
+(	O
+Hypericaceae	B-SPEC
+)	O
+growing	O
+in	O
+Sardinia	O
+(	O
+Italy	O
+)	O
+on	O
+the	O
+HIV	B-SPEC
+-	I-SPEC
+1	I-SPEC
+RT	O
+-	O
+associated	O
+RNase	B-PRGE
+H	I-PRGE
+function	O
+and	O
+found	O
+that	O
+they	O
+have	O
+inhibitory	O
+effects	O
+.	O
+
+Betulinic	B-CHED
+acid	I-CHED
+and	O
+5	B-CHED
+,	I-CHED
+7	I-CHED
+,	I-CHED
+3	I-CHED
+',	I-CHED
+5	I-CHED
+'-	I-CHED
+tetrahydroxyflavanone	I-CHED
+7	O
+-	O
+O	O
+-	O
+glucoside	B-CHED
+were	O
+active	O
+on	O
+both	O
+RT	O
+-	O
+associated	O
+activities	O
+,	O
+and	O
+betulinic	B-CHED
+acid	I-CHED
+was	O
+also	O
+active	O
+on	O
+HIV	B-PRGE
+-	I-PRGE
+1	I-PRGE
+mutant	B-DISO
+RTs	B-DISO
+resistant	O
+to	O
+efavirenz	B-CHED
+.	O
+
+Overall	O
+,	O
+our	O
+results	O
+suggest	O
+that	O
+some	O
+of	O
+these	O
+compounds	O
+inhibit	O
+the	O
+HIV	B-SPEC
+-	I-SPEC
+1	I-SPEC
+RT	O
+binding	B-FUNC
+to	O
+an	O
+allosteric	O
+site	O
+previously	O
+described	O
+for	O
+other	O
+natural	O
+compounds	O
+and	O
+are	O
+potential	O
+leads	O
+for	O
+further	O
+drug	O
+development	B-PROC
+of	O
+a	O
+single	O
+molecules	O
+having	O
+dual	O
+inhibitory	O
+activity	O
+.	O
+
+However	O
+,	O
+a	O
+sometimes	O
+important	O
+improvement	O
+in	O
+oxygenation	B-PROC
+can	O
+occur	O
+shortly	O
+after	O
+starting	O
+administration	O
+.	O
+
+At	O
+present	O
+,	O
+albumin	B-PRGE
+treatment	O
+does	O
+not	O
+appear	O
+to	O
+be	O
+justified	O
+for	O
+limitation	O
+of	O
+pulmonary	B-DISO
+edema	I-DISO
+and	O
+respiratory	B-DISO
+morbidity	I-DISO
+.	O
+
+Aerosolized	O
+β2	O
+-	O
+agonists	B-CHED
+do	O
+not	O
+improve	O
+outcome	O
+in	O
+patients	O
+with	O
+ARDS	B-DISO
+and	O
+one	O
+study	O
+strongly	O
+suggests	O
+that	O
+intravenous	O
+salbutamol	B-CHED
+may	O
+worsen	O
+outcome	O
+in	O
+those	O
+patients	O
+.	O
+
+RESULTS	O
+:	O
+Of	O
+the	O
+27	O
+,	O
+276	O
+admissions	O
+,	O
+819	O
+(	O
+3	O
+%)	O
+eligible	O
+nonsurvivors	O
+were	O
+identified	O
+for	O
+the	O
+cause	O
+-	O
+of	O
+-	O
+death	B-PROC
+analyses	O
+.	O
+
+It	O
+can	O
+invade	O
+epithelial	B-ANAT
+cells	I-ANAT
+in	O
+the	O
+human	B-SPEC
+lower	B-ANAT
+respiratory	I-ANAT
+tract	I-ANAT
+and	O
+type	O
+II	O
+pneumonocytes	O
+in	O
+alveoli	B-ANAT
+,	O
+and	O
+replicated	O
+efficiently	O
+in	O
+ex	O
+vivo	O
+lung	B-ANAT
+and	O
+trachea	B-DISO
+explant	O
+culture	O
+and	O
+several	O
+mammalian	B-SPEC
+cell	B-COMP
+lines	O
+.	O
+
+In	O
+acute	O
+serum	B-COMP
+samples	O
+of	O
+H7N9	O
+-	O
+infected	O
+patients	O
+,	O
+increased	O
+levels	O
+of	O
+the	O
+chemokines	O
+and	O
+cytokines	O
+IP	B-PRGE
+-	I-PRGE
+10	I-PRGE
+,	O
+MIG	B-PRGE
+,	O
+MIP	B-PRGE
+-	I-PRGE
+1β	I-PRGE
+,	O
+MCP	B-PRGE
+-	I-PRGE
+1	I-PRGE
+,	O
+IL	B-FUNC
+-	I-FUNC
+6	I-FUNC
+,	O
+IL	B-FUNC
+-	I-FUNC
+8	I-FUNC
+and	O
+IFN	B-PRGE
+-	I-PRGE
+α	I-PRGE
+were	O
+detected	O
+.	O
+
+Using	O
+the	O
+H5N1	B-DISO
+influenza	I-DISO
+virus	O
+as	O
+a	O
+model	O
+,	O
+we	O
+first	O
+immunized	O
+rhesus	B-SPEC
+macaques	I-SPEC
+with	O
+recombinant	O
+adenoviruses	B-SPEC
+carrying	O
+a	O
+synthetic	O
+gene	O
+encoding	O
+hemagglutinin	O
+(	O
+HA	O
+).	O
+
+Following	O
+screening	O
+an	O
+antibody	O
+phage	O
+display	O
+library	O
+derived	O
+from	O
+the	O
+B	B-ANAT
+cells	I-ANAT
+of	O
+immunized	O
+monkeys	B-SPEC
+,	O
+we	O
+cloned	O
+selected	O
+macaque	B-PRGE
+immunoglobulin	B-PROC
+heavy	I-PRGE
+chain	I-PRGE
+and	O
+light	O
+chain	O
+variable	O
+regions	O
+into	O
+the	O
+human	B-PRGE
+IgG	I-PRGE
+constant	I-PRGE
+region	I-PRGE
+,	O
+which	O
+generated	O
+human	B-SPEC
+-	O
+macaque	B-SPEC
+chimeric	O
+mAbs	O
+exhibiting	O
+over	O
+97	O
+%	O
+homology	O
+to	O
+human	B-PRGE
+antibodies	B-COMP
+.	O
+
+In	O
+this	O
+study	O
+,	O
+three	O
+U	O
+.	O
+S	O
+.	O
+Food	O
+and	O
+Drug	O
+Administration	O
+-	O
+approved	O
+molecular	O
+multiplex	O
+platforms	O
+(	O
+Prodesse	O
+ProFLU	O
++/	O
+FAST	B-PRGE
++,	I-PRGE
+FilmArray	B-PRGE
+RP	I-PRGE
+,	I-PRGE
+and	I-PRGE
+Verigene	I-PRGE
+RV	I-PRGE
++)	I-PRGE
+were	O
+evaluated	O
+for	O
+influenza	B-SPEC
+virus	I-SPEC
+detection	O
+in	O
+171	O
+clinical	O
+samples	O
+collected	O
+during	O
+the	O
+Belgian	O
+2011	O
+-	O
+2012	O
+influenza	B-DISO
+season	O
+.	O
+
+An	O
+increase	O
+in	O
+macrophage	B-ANAT
+recruitment	B-DISO
+and	O
+activation	O
+in	O
+lung	B-ANAT
+tissues	I-ANAT
+infected	O
+with	O
+rTGEV	O
+-	O
+Δ7	O
+virus	B-SPEC
+was	O
+observed	O
+compared	O
+to	O
+cells	B-COMP
+infected	O
+with	O
+the	O
+parental	O
+virus	B-SPEC
+.	O
+
+In	O
+a	O
+porcine	B-SPEC
+animal	B-SPEC
+model	O
+,	O
+which	O
+is	O
+immunologically	O
+similar	O
+to	O
+humans	B-SPEC
+,	O
+we	O
+present	O
+a	O
+novel	O
+example	O
+of	O
+how	O
+viral	O
+proteins	B-CHED
+counteract	O
+host	B-COMP
+antiviral	B-CHED
+pathways	B-PROC
+to	O
+determine	O
+the	O
+infection	B-DISO
+outcome	O
+and	O
+pathogenesis	B-DISO
+.	O
+
+TITLE	O
+:	O
+Bilateral	O
+entry	O
+and	O
+release	B-PATH
+of	O
+Middle	O
+East	O
+respiratory	O
+syndrome	B-DISO
+coronavirus	B-SPEC
+induces	O
+profound	O
+apoptosis	O
+of	O
+human	B-SPEC
+bronchial	B-ANAT
+epithelial	B-ANAT
+cells	I-ANAT
+.	O
+
+ABSTRACT	O
+:	O
+The	O
+newly	O
+emerged	O
+Middle	O
+East	O
+respiratory	O
+syndrome	B-DISO
+coronavirus	B-SPEC
+(	O
+MERS	O
+-	O
+CoV	O
+)	O
+infects	O
+human	B-SPEC
+bronchial	B-ANAT
+epithelial	O
+Calu	O
+-	O
+3	O
+cells	B-COMP
+.	O
+
+Adalimumab	O
+is	O
+a	O
+recombinant	O
+human	O
+monoclonal	O
+antibody	B-COMP
+that	O
+blocks	O
+the	O
+effects	O
+of	O
+tumor	B-PRGE
+necrosis	I-PRGE
+factor	I-PRGE
+-	I-PRGE
+alpha	I-PRGE
+.	O
+
+He	O
+was	O
+successfully	O
+treated	O
+with	O
+mechanical	O
+ventilatory	O
+support	O
+and	O
+adjuvant	B-CHED
+therapy	O
+.	O
+
+Economic	O
+impacts	O
+of	O
+ILI	O
+(	O
+temperature	O
+≥	O
+37	O
+·	O
+8	O
+°	O
+C	O
+or	O
+parental	O
+report	O
+of	O
+fever	B-PROC
+,	O
+plus	O
+≥	O
+1	O
+respiratory	B-DISO
+symptoms	I-DISO
+)	O
+were	O
+collected	O
+at	O
+2	O
+and	O
+4	O
+weeks	O
+after	O
+ILI	O
+onset	O
+by	O
+telephone	O
+interview	O
+.	O
+
+In	O
+multivariate	O
+analyses	O
+,	O
+four	O
+variables	O
+were	O
+significantly	O
+associated	O
+with	O
+an	O
+increased	O
+number	O
+of	O
+healthcare	O
+visits	O
+per	O
+ILI	O
+:	O
+non	O
+-	O
+Caucasian	O
+child	O
+,	O
+living	O
+in	O
+a	O
+detached	O
+house	O
+,	O
+both	O
+parents	O
+in	O
+employed	O
+work	O
+and	O
+having	O
+an	O
+ILI	O
+with	O
+one	O
+or	O
+more	O
+viruses	B-SPEC
+identified	O
+.	O
+
+Healthcare	O
+visits	O
+were	O
+increased	O
+if	O
+the	O
+child	O
+was	O
+non	O
+-	O
+Caucasian	O
+,	O
+lived	O
+in	O
+a	O
+detached	O
+house	O
+,	O
+had	O
+working	O
+parents	O
+or	O
+had	O
+a	O
+virus	B-SPEC
+-	O
+positive	O
+ILI	O
+.	O
+
+TITLE	O
+:	O
+Obstetric	O
+infections	B-DISO
+.	O
+
+Group	O
+A	O
+streptococcal	B-DISO
+infection	I-DISO
+may	O
+produce	O
+necrotizing	B-DISO
+fasciitis	I-DISO
+and	O
+toxic	B-DISO
+shock	I-DISO
+.	O
+
+Malaria	B-PATH
+may	O
+be	O
+more	O
+severe	O
+in	O
+the	O
+pregnant	O
+woman	O
+,	O
+and	O
+carries	O
+significant	O
+risk	O
+to	O
+both	O
+mother	B-ANAT
+and	I-ANAT
+fetus	I-ANAT
+.	O
+
+Three	O
+phages	O
+expressing	O
+TGEV	B-PRGE
+-	I-PRGE
+M	I-PRGE
+-	I-PRGE
+binding	B-FUNC
+peptides	B-CHED
+were	O
+identified	O
+and	O
+characterized	O
+in	O
+more	O
+depth	O
+.	O
+
+A	O
+chemically	O
+synthesized	O
+,	O
+TGEV	B-SPEC
+-	O
+M7	O
+peptide	B-CHED
+(	O
+pepTGEV	O
+-	O
+M7	O
+;	O
+HALTPIKYIPPG	O
+)	O
+was	O
+evaluated	O
+for	O
+antiviral	B-CHED
+activity	O
+.	O
+
+Agence	O
+Nationale	O
+de	O
+la	O
+Recherche	O
+(	O
+Labex	O
+Integrative	O
+Biology	O
+of	O
+Emerging	B-DISO
+Infectious	I-DISO
+Diseases	I-DISO
+),	O
+and	O
+the	O
+European	O
+Community	O
+'	O
+s	O
+Seventh	O
+Framework	O
+Programme	O
+project	O
+PREDEMICS	O
+.	O
+
+TITLE	O
+:	O
+Mesenchymal	B-ANAT
+stem	I-ANAT
+cells	I-ANAT
+in	O
+acute	O
+lung	B-ANAT
+injury	O
+:	O
+are	O
+they	O
+ready	O
+for	O
+translational	B-PROC
+medicine	B-CHED
+?	O
+
+MSCs	B-FUNC
+could	O
+reduce	O
+the	O
+over	O
+-	O
+production	O
+of	O
+inflammatory	O
+mediators	O
+,	O
+leucocyte	B-ANAT
+infiltration	B-DISO
+,	O
+tissue	B-ANAT
+injury	O
+and	O
+pulmonary	B-DISO
+failure	I-DISO
+,	O
+and	O
+produce	O
+a	O
+number	O
+of	O
+benefit	O
+factors	O
+through	O
+interaction	O
+with	O
+other	O
+cells	B-COMP
+in	O
+the	O
+process	O
+of	O
+lung	B-ANAT
+tissue	I-ANAT
+repair	O
+.	O
+
+Our	O
+results	O
+show	O
+that	O
+MERS	O
+-	O
+CoV	O
+RBD	O
+consists	O
+of	O
+a	O
+core	O
+and	O
+a	O
+receptor	O
+-	O
+binding	B-FUNC
+subdomain	O
+.	O
+
+TITLE	O
+:	O
+Pathogenesis	B-PROC
+and	O
+transmission	O
+of	O
+avian	B-DISO
+influenza	B-PATH
+A	I-PATH
+(	O
+H7N9	O
+)	O
+virus	B-SPEC
+in	O
+ferrets	B-SPEC
+and	O
+mice	B-SPEC
+.	O
+
+Both	O
+H7N9	O
+viruses	B-SPEC
+replicated	O
+to	O
+higher	O
+titre	O
+in	O
+human	B-SPEC
+airway	B-ANAT
+epithelial	B-ANAT
+cells	I-ANAT
+and	O
+in	O
+the	O
+respiratory	O
+tract	O
+of	O
+ferrets	B-SPEC
+compared	O
+to	O
+a	O
+seasonal	O
+H3N2	B-CHED
+virus	B-SPEC
+.	O
+
+The	O
+lack	O
+of	O
+efficient	O
+respiratory	O
+droplet	O
+transmission	O
+was	O
+corroborated	O
+by	O
+low	O
+receptor	O
+-	O
+binding	B-FUNC
+specificity	O
+for	O
+human	B-PRGE
+-	I-PRGE
+like	I-PRGE
+α2	I-PRGE
+,	O
+6	O
+-	O
+linked	O
+sialosides	O
+.	O
+
+Several	O
+of	O
+the	O
+cases	O
+were	O
+likely	O
+a	O
+result	O
+of	O
+human	B-SPEC
+-	O
+to	O
+-	O
+human	B-SPEC
+transmission	O
+.	O
+
+The	O
+relationship	O
+between	O
+these	O
+categories	O
+and	O
+pulmonary	B-ANAT
+microvascular	B-PROC
+permeability	I-PROC
+as	O
+well	O
+as	O
+extravascular	O
+lung	B-ANAT
+water	B-CHED
+content	O
+,	O
+which	O
+is	O
+the	O
+hallmark	O
+of	O
+lung	B-ANAT
+pathophysiology	O
+,	O
+remains	O
+to	O
+be	O
+elucidated	O
+.	O
+
+Severity	O
+categories	O
+of	O
+ARDS	B-DISO
+described	O
+by	O
+the	O
+Berlin	O
+definition	O
+have	O
+good	O
+predictive	O
+validity	O
+and	O
+may	O
+be	O
+associated	O
+with	O
+increased	O
+extravascular	O
+lung	B-ANAT
+water	B-CHED
+and	O
+pulmonary	B-ANAT
+vascular	B-PROC
+permeability	I-PROC
+.	O
+
+Patients	O
+had	O
+PaO2	O
+/	O
+FiO2	O
+<	O
+100	O
+mm	O
+Hg	O
+at	O
+end	B-PROC
+-	I-PROC
+expiratory	I-PROC
+pressure	O
+≥	O
+10	O
+cm	O
+H2O	B-CHED
+.	O
+
+During	O
+HFO	O
+-	O
+TGI	O
+,	O
+systemic	O
+hemodynamics	B-PROC
+remained	O
+unchanged	O
+.	O
+
+The	O
+authors	O
+analyzed	O
+the	O
+pulmonary	B-ANAT
+distribution	O
+of	O
+radiolabeled	O
+microspheres	O
+in	O
+normal	O
+(	O
+n	O
+=	O
+6	O
+)	O
+and	O
+injured	O
+(	O
+n	O
+=	O
+12	O
+)	O
+anesthetized	O
+rat	B-SPEC
+lungs	B-ANAT
+using	O
+positron	B-CHED
+emission	B-ANAT
+tomography	O
+,	O
+computed	O
+tomography	O
+,	O
+and	O
+histological	O
+examination	O
+.	O
+
+The	O
+acid	O
+was	O
+instilled	O
+into	O
+the	O
+middle	O
+and	O
+basal	O
+regions	O
+of	O
+the	O
+lungs	B-ANAT
+.	O
+
+RESULTS	O
+:	O
+Injured	O
+regions	O
+demonstrate	O
+increased	O
+pulmonary	B-ANAT
+blood	B-PROC
+flow	I-PROC
+in	O
+association	O
+with	O
+reduced	O
+arterial	B-PROC
+pressure	I-PROC
+and	O
+the	O
+deterioration	O
+of	O
+arterial	B-ANAT
+oxygenation	B-PROC
+.	O
+
+ABSTRACT	O
+:	O
+Avian	O
+coronavirus	O
+(	O
+commonly	O
+known	O
+as	O
+Infectious	B-DISO
+bronchitis	B-DISO
+virus	B-SPEC
+[	O
+IBV	B-SPEC
+])	O
+is	O
+of	O
+major	O
+economic	O
+importance	O
+to	O
+commercial	O
+chicken	B-SPEC
+producers	O
+worldwide	O
+.	O
+
+Due	O
+to	O
+the	O
+existence	O
+of	O
+multiple	O
+serotypes	O
+and	O
+variants	O
+of	O
+the	O
+virus	B-SPEC
+that	O
+do	O
+not	O
+cross	O
+-	O
+protect	O
+,	O
+it	O
+is	O
+important	O
+to	O
+diagnose	O
+circulating	O
+serotypes	O
+and	O
+choose	O
+the	O
+right	O
+vaccine	O
+type	O
+for	O
+successful	O
+protection	O
+.	O
+
+Arterial	B-ANAT
+CO2	B-CHED
+partial	O
+pressure	O
+[	O
+54	O
+(	O
+45	O
+-	O
+74	O
+)	O
+vs	O
+.	O
+48	O
+(	O
+39	O
+-	O
+58	O
+)	O
+mmHg	O
+]	O
+remained	O
+unchanged	O
+.	O
+
+Previous	O
+studies	O
+have	O
+identified	O
+Ser190	O
+,	O
+Ser192	O
+,	O
+Thr378	O
+and	O
+Ser379	O
+as	O
+the	O
+phosphorylation	B-PROC
+sites	O
+for	O
+coronavirus	B-SPEC
+infectious	B-DISO
+bronchitis	B-DISO
+virus	B-SPEC
+(	O
+IBV	B-SPEC
+)	O
+N	O
+protein	B-CHED
+.	O
+
+This	O
+study	O
+reveals	O
+a	O
+cellular	B-COMP
+kinase	O
+responsible	O
+for	O
+phosphorylation	B-PROC
+of	O
+a	O
+coronavirus	B-SPEC
+N	B-PRGE
+protein	I-PRGE
+at	O
+two	O
+positions	O
+and	O
+the	O
+functional	O
+consequence	O
+of	O
+this	O
+modification	O
+on	O
+coronavirus	B-SPEC
+replication	O
+.	O
+
+Our	O
+results	O
+indicated	O
+that	O
+human	B-SPEC
+rhinovirus	I-SPEC
+/	O
+enterovirus	B-SPEC
+(	O
+HRV	O
+/	O
+EV	O
+)	O
+and	O
+coronavirus	B-SPEC
+(	O
+HCoV	O
+)	O
+were	O
+frequently	O
+detected	O
+in	O
+respiratory	B-ANAT
+samples	I-ANAT
+(	O
+48	O
+.	O
+81	O
+%	O
+and	O
+11	O
+.	O
+74	O
+%	O
+of	O
+infected	O
+samples	O
+,	O
+respectively	O
+),	O
+and	O
+the	O
+detection	O
+frequencies	O
+of	O
+these	O
+viruses	O
+were	O
+further	O
+increased	O
+in	O
+immunosuppressed	O
+patients	O
+.	O
+
+Outcomes	O
+were	O
+favourable	O
+after	O
+drug	B-DISO
+withdrawal	I-DISO
+,	O
+and	O
+symptomatic	O
+and	O
+topical	O
+steroid	B-CHED
+treatments	O
+.	O
+
+TITLE	O
+:	O
+Identification	O
+of	O
+cellular	B-COMP
+proteome	O
+using	O
+two	O
+-	O
+dimensional	O
+difference	O
+gel	O
+electrophoresis	O
+in	O
+ST	O
+cells	O
+infected	O
+with	O
+transmissible	O
+gastroenteritis	B-DISO
+coronavirus	B-SPEC
+.	O
+
+Information	O
+remains	O
+limited	O
+about	O
+the	O
+comparative	O
+protein	B-PROC
+expression	B-PROC
+of	O
+host	B-COMP
+cells	B-COMP
+in	O
+response	O
+to	O
+TGEV	B-SPEC
+infection	B-DISO
+.	O
+
+In	O
+this	O
+study	O
+,	O
+cellular	B-COMP
+protein	B-CHED
+response	O
+to	O
+TGEV	B-SPEC
+infection	B-DISO
+in	O
+swine	B-SPEC
+testes	B-ANAT
+(	O
+ST	O
+)	O
+cells	B-COMP
+was	O
+analyzed	O
+,	O
+using	O
+the	O
+proteomic	O
+method	O
+of	O
+two	O
+-	O
+dimensional	O
+difference	O
+gel	O
+electrophoresis	O
+(	O
+2D	O
+DIGE	O
+)	O
+coupled	O
+with	O
+MALDI	O
+-	O
+TOF	B-DISO
+-	O
+TOF	B-DISO
+/	O
+MS	O
+identification	O
+.	O
+
+All	O
+the	O
+protein	B-CHED
+spots	B-DISO
+were	O
+successfully	O
+identified	O
+.	O
+
+17	O
+altered	O
+cellular	B-COMP
+proteins	B-CHED
+that	O
+differentially	O
+expressed	B-PROC
+in	O
+TGEV	B-SPEC
+infection	B-DISO
+were	O
+identified	O
+.	O
+
+Taken	O
+together	O
+,	O
+these	O
+disease	O
+models	O
+highlight	O
+the	O
+plasticity	O
+of	O
+the	O
+respiratory	O
+control	O
+system	O
+in	O
+response	O
+to	O
+the	O
+development	B-PROC
+and	O
+progression	O
+of	O
+lung	B-DISO
+disease	I-DISO
+.	O
+
+Syndromic	O
+surveillance	O
+application	O
+for	O
+public	O
+health	O
+purposes	O
+has	O
+changed	O
+over	O
+time	O
+and	O
+reflects	O
+a	O
+dynamic	O
+evolution	B-PROC
+from	O
+the	O
+collection	O
+,	O
+interpretation	O
+of	O
+data	O
+with	O
+dissemination	O
+of	O
+data	O
+to	O
+those	O
+who	O
+need	O
+to	O
+act	O
+,	O
+to	O
+a	O
+more	O
+holistic	O
+approach	O
+that	O
+incorporates	O
+response	O
+as	O
+a	O
+core	O
+component	O
+of	O
+the	O
+surveillance	O
+system	O
+.	O
+
+TITLE	O
+:	O
+High	O
+-	O
+dose	O
+acetylsalicylic	B-CHED
+acid	I-CHED
+is	O
+superior	O
+to	O
+low	O
+-	O
+dose	O
+as	O
+well	O
+as	O
+to	O
+clopidogrel	B-CHED
+in	O
+preventing	O
+lipopolysaccharide	O
+-	O
+induced	O
+lung	B-ANAT
+injury	O
+in	O
+mice	B-SPEC
+.	O
+
+Also	O
+,	O
+the	O
+effect	O
+on	O
+lung	B-ANAT
+injury	O
+of	O
+inhibiting	O
+platelet	B-PROC
+activation	I-PROC
+by	O
+clopidogrel	B-CHED
+was	O
+investigated	O
+.	O
+
+ABSTRACT	O
+:	O
+Hemorrhage	O
+coupled	O
+with	O
+coagulopathy	B-DISO
+remains	O
+the	O
+leading	O
+cause	O
+of	O
+preventable	O
+in	O
+-	O
+hospital	O
+deaths	B-PROC
+among	O
+trauma	O
+patients	O
+.	O
+
+A	O
+ratio	O
+of	O
+1	O
+:	O
+1	O
+(	O
+RBC	B-ANAT
+:	O
+FP	O
+)	O
+was	O
+achieved	O
+in	O
+73	O
+%	O
+(	O
+27	O
+/	O
+37	O
+)	O
+in	O
+the	O
+fixed	B-ANAT
+-	O
+ratio	O
+group	O
+and	O
+22	O
+%	O
+(	O
+7	O
+/	O
+32	O
+)	O
+in	O
+the	O
+control	O
+group	O
+.	O
+
+Plasma	B-ANAT
+wastage	O
+was	O
+higher	O
+with	O
+the	O
+intervention	O
+protocol	O
+(	O
+22	O
+%	O
+[	O
+86	O
+/	O
+390	O
+]	O
+of	O
+FP	O
+units	O
+v	O
+.	O
+10	O
+%	O
+[	O
+30	O
+/	O
+289	O
+]	O
+in	O
+the	O
+control	O
+group	O
+).	O
+
+RESULTS	O
+:	O
+Overall	O
+,	O
+a	O
+transfusion	O
+ratio	O
+of	O
+1	O
+:	O
+1	O
+:	O
+1	O
+was	O
+achieved	O
+in	O
+57	O
+%	O
+(	O
+21	O
+/	O
+37	O
+)	O
+of	O
+patients	O
+in	O
+the	O
+fixed	B-ANAT
+-	O
+ratio	O
+group	O
+,	O
+as	O
+compared	O
+with	O
+6	O
+%	O
+(	O
+2	O
+/	O
+32	O
+)	O
+in	O
+the	O
+control	O
+group	O
+.	O
+
+No	O
+factor	O
+was	O
+independently	O
+associated	O
+with	O
+PFO	B-CHED
+,	O
+with	O
+only	O
+a	O
+trend	O
+for	O
+age	O
+(	O
+OR	O
+2	O
+.	O
+07	O
+;	O
+95	O
+%	O
+CI	O
+0	O
+.	O
+91	O
+-	O
+4	O
+.	O
+72	O
+;	O
+p	O
+=	O
+0	O
+.	O
+08	O
+).	O
+
+TEE	O
+screening	O
+allowed	O
+identification	O
+of	O
+ACP	B-DISO
+in	O
+one	O
+-	O
+fourth	O
+of	O
+patients	O
+submitted	O
+to	O
+protective	O
+ventilation	O
+for	O
+early	O
+moderate	O
+to	O
+severe	O
+ARDS	B-DISO
+.	O
+
+We	O
+report	O
+a	O
+case	O
+series	O
+of	O
+patients	O
+with	O
+severe	O
+Legionella	B-DISO
+pneumonia	I-DISO
+who	O
+developed	O
+the	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+(	O
+ARDS	B-DISO
+),	O
+failed	O
+to	O
+improve	O
+with	O
+mechanical	O
+ventilation	O
+alone	O
+and	O
+required	O
+extracorporeal	O
+life	O
+support	O
+(	O
+ECLS	O
+).	O
+
+Experiments	O
+performed	O
+in	O
+ex	O
+vivo	O
+spinal	B-ANAT
+cord	I-ANAT
+slice	O
+culture	O
+and	O
+in	O
+vitro	O
+neonatal	O
+microglial	B-ANAT
+culture	O
+confirmed	O
+direct	O
+microglial	B-ANAT
+infection	B-DISO
+.	O
+
+Recently	O
+,	O
+an	O
+FIP	B-DISO
+outbreak	O
+from	O
+an	O
+animal	B-SPEC
+shelter	O
+was	O
+confirmed	O
+in	O
+Taiwan	O
+.	O
+
+Two	O
+of	O
+the	O
+cats	B-SPEC
+that	O
+succumbed	O
+to	O
+FIP	B-DISO
+were	O
+found	O
+to	O
+harbor	O
+an	O
+identical	O
+nonsense	B-DISO
+mutation	I-DISO
+in	O
+the	O
+3c	O
+gene	O
+.	O
+
+Significantly	O
+reduced	O
+tracheal	O
+pathologic	O
+effects	O
+,	O
+measured	O
+according	O
+to	O
+ciliostasis	O
+and	O
+histology	O
+lesions	O
+,	O
+and	O
+reduced	O
+viral	O
+load	O
+were	O
+observed	O
+only	O
+in	O
+the	O
+full	O
+-	O
+dose	O
+vaccinated	O
+group	O
+at	O
+5	O
+days	O
+post	O
+-	O
+infection	B-DISO
+(	O
+dpi	O
+),	O
+while	O
+incomplete	O
+protection	O
+was	O
+observed	O
+for	O
+the	O
+subdose	O
+vaccinated	O
+groups	O
+.	O
+
+Lung	B-ANAT
+injury	O
+was	O
+established	O
+by	O
+intravenous	O
+infusion	O
+of	O
+oleic	B-CHED
+acid	I-CHED
+.	O
+
+Furthermore	O
+,	O
+plasma	B-PRGE
+stromal	B-ANAT
+cell	I-ANAT
+-	I-PRGE
+derived	I-PRGE
+factor	I-PRGE
+-	I-PRGE
+1	I-PRGE
+and	O
+vascular	B-PROC
+endothelial	B-ANAT
+growth	B-PROC
+factor	I-PROC
+concentrations	O
+were	O
+higher	O
+in	O
+acute	O
+lung	B-ANAT
+injury	O
+than	O
+in	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+at	O
+24	O
+hours	O
+.	O
+
+ABSTRACT	O
+:	O
+A	O
+25	O
+-	O
+kDa	O
+protein	B-CHED
+,	O
+with	O
+an	O
+N	B-CHED
+-	I-CHED
+terminal	I-CHED
+amino	I-CHED
+acid	I-CHED
+sequence	O
+homologous	O
+to	O
+that	O
+of	O
+xylanase	B-PROC
+inhibitor	B-CHED
+and	O
+designated	O
+as	O
+xylanase	B-PRGE
+inbibitor	I-PRGE
+-	I-PRGE
+like	I-PRGE
+protein	B-CHED
+(	O
+XILP	O
+)	O
+was	O
+purified	O
+from	O
+sorghum	B-SPEC
+seeds	O
+.	O
+
+The	O
+isolation	O
+protocol	O
+consisted	O
+of	O
+affinity	O
+chromatography	O
+,	O
+ion	B-PROC
+exchange	I-PROC
+chromatography	O
+,	O
+and	O
+gel	O
+filtration	O
+.	O
+
+XILP	O
+reduced	O
+the	O
+activity	O
+of	O
+HIV	B-SPEC
+-	I-SPEC
+1	I-SPEC
+reverse	B-PRGE
+transcriptase	I-PRGE
+with	O
+an	O
+IC50	O
+of	O
+11	O
+.	O
+1μM	O
+,	O
+but	O
+lacked	O
+inhibitory	O
+activity	O
+toward	O
+HIV	B-PRGE
+-	I-PRGE
+1	I-PRGE
+integrase	I-PRGE
+and	O
+SARS	B-PRGE
+coronavirus	B-SPEC
+proteinase	B-PROC
+.	O
+
+These	O
+viruses	B-SPEC
+include	O
+important	O
+human	B-SPEC
+and	O
+animal	B-SPEC
+pathogens	O
+,	O
+such	O
+as	O
+influenza	B-DISO
+,	O
+parainfluenza	B-DISO
+,	O
+mumps	B-DISO
+,	O
+corona	B-CHED
+,	O
+noro	O
+,	O
+rota	O
+,	O
+and	O
+DNA	O
+tumor	B-DISO
+viruses	B-SPEC
+.	O
+
+Variations	O
+in	O
+the	O
+receptor	O
+specificity	O
+are	O
+important	O
+determinants	O
+for	O
+host	B-COMP
+range	O
+,	O
+tissue	B-PROC
+tropism	B-PROC
+,	O
+pathogenicity	O
+,	O
+and	O
+transmissibility	O
+of	O
+these	O
+viruses	B-SPEC
+.	O
+
+Ages	O
+greater	O
+than	O
+55	O
+years	O
+,	O
+severity	O
+at	O
+admission	O
+(	O
+p	O
+<	O
+0	O
+.	O
+001	O
+),	O
+injured	O
+cranial	B-ANAT
+nerves	I-ANAT
+(	O
+p	O
+=	O
+0	O
+.	O
+008	O
+)	O
+and	O
+the	O
+needing	O
+of	O
+ventilator	O
+support	O
+(	O
+p	O
+=	O
+0	O
+.	O
+003	O
+)	O
+were	O
+associated	O
+with	O
+greater	O
+sequels	O
+at	O
+the	O
+discharge	B-ANAT
+and	O
+at	O
+the	O
+posterior	O
+reviews	O
+in	O
+the	O
+following	O
+months	O
+.	O
+
+There	O
+exists	O
+an	O
+endemic	O
+equilibrium	B-PROC
+which	O
+is	O
+locally	O
+asymptotically	O
+stable	O
+if	O
+the	O
+reproduction	B-PROC
+number	O
+is	O
+larger	O
+than	O
+unity	O
+.	O
+
+Oliguria	B-DISO
+and	O
+some	O
+degree	O
+of	O
+acute	B-DISO
+renal	I-DISO
+failure	I-DISO
+commonly	O
+develop	O
+in	O
+patients	O
+with	O
+moderate	O
+to	O
+severe	O
+OHSS	B-DISO
+and	O
+are	O
+usually	O
+due	O
+to	O
+prerenal	O
+causes	O
+.	O
+
+ABSTRACT	O
+:	O
+Coronaviruses	O
+have	O
+been	O
+thrust	O
+into	O
+the	O
+spotlight	O
+by	O
+the	O
+recurring	O
+novel	O
+human	O
+coronavirus	O
+infections	O
+following	O
+the	O
+2003	O
+SARS	B-DISO
+pandemic	O
+.	O
+
+In	O
+the	O
+years	O
+since	O
+the	O
+initial	O
+SARS	B-DISO
+outbreak	O
+,	O
+the	O
+arsenal	O
+to	O
+fight	O
+this	O
+virus	B-SPEC
+family	B-SPEC
+has	O
+been	O
+significantly	O
+increased	O
+by	O
+the	O
+rapid	O
+growth	B-PROC
+of	O
+coronavirus	B-SPEC
+research	O
+.	O
+
+A	O
+number	O
+of	O
+patented	O
+inhibitors	B-CHED
+with	O
+promising	O
+clinical	O
+potential	O
+have	O
+been	O
+developed	O
+via	O
+different	O
+methods	O
+of	O
+drug	O
+discovery	O
+,	O
+including	O
+virtual	O
+screening	O
+,	O
+natural	B-CHED
+product	I-CHED
+isolation	O
+and	O
+structure	O
+assisted	O
+rational	O
+drug	O
+design	O
+.	O
+
+ABSTRACT	O
+:	O
+Respiratory	B-DISO
+tract	I-DISO
+infections	I-DISO
+(	O
+RTIs	O
+)	O
+are	O
+a	O
+leading	O
+cause	O
+of	O
+mortality	O
+and	O
+morbidity	O
+.	O
+
+Artifical	O
+ventilatory	O
+support	O
+is	O
+commonly	O
+required	O
+and	O
+may	O
+exacerbate	O
+lung	B-ANAT
+injury	O
+.	O
+
+The	O
+primary	O
+objective	O
+of	O
+this	O
+review	O
+was	O
+to	O
+assess	O
+whether	O
+PLV	O
+reduced	O
+mortality	O
+(	O
+at	O
+28	O
+d	O
+,	O
+at	O
+discharge	B-ANAT
+from	O
+the	O
+intensive	O
+care	O
+unit	O
+(	O
+ICU	O
+),	O
+at	O
+discharge	B-ANAT
+from	O
+hospital	O
+and	O
+at	O
+one	O
+,	O
+two	O
+and	O
+five	O
+years	O
+)	O
+in	O
+adults	O
+with	O
+ALI	O
+or	O
+ARDS	B-DISO
+when	O
+compared	O
+with	O
+conventional	O
+ventilatory	O
+support	O
+.	O
+
+Clinical	O
+and	O
+laboratory	O
+research	O
+data	O
+generated	O
+in	O
+the	O
+past	O
+few	O
+months	O
+have	O
+provided	O
+new	O
+insights	O
+into	O
+the	O
+possible	O
+animal	B-SPEC
+reservoirs	O
+,	O
+transmissibility	O
+,	O
+and	O
+virulence	B-PROC
+of	O
+MERS	O
+-	O
+CoV	O
+,	O
+and	O
+the	O
+optimal	O
+laboratory	O
+diagnostic	O
+options	O
+and	O
+potential	O
+antiviral	B-CHED
+targets	O
+for	O
+MERS	O
+-	O
+CoV	O
+-	O
+associated	O
+infection	B-DISO
+.	O
+
+This	O
+method	O
+is	O
+general	O
+to	O
+any	O
+enveloped	O
+virus	B-SPEC
+-	O
+host	B-COMP
+cell	I-COMP
+pair	O
+,	O
+but	O
+demonstrated	O
+here	O
+for	O
+feline	B-SPEC
+coronavirus	B-SPEC
+(	O
+FCoV	O
+).	O
+
+The	O
+most	O
+commonly	O
+encountered	O
+viruses	B-SPEC
+,	O
+in	O
+order	B-SPEC
+of	O
+frequency	O
+,	O
+include	O
+influenza	B-DISO
+,	O
+respiratory	B-SPEC
+syncytial	I-SPEC
+virus	I-SPEC
+,	O
+parainfluenza	B-DISO
+and	O
+adenovirus	B-DISO
+.	O
+
+Current	O
+evidence	O
+suggests	O
+that	O
+the	O
+major	O
+mode	O
+of	O
+transmission	O
+of	O
+ARls	O
+is	O
+through	O
+large	O
+droplets	O
+,	O
+but	O
+transmission	O
+through	O
+contact	O
+(	O
+including	O
+hand	O
+contamination	O
+with	O
+subsequent	O
+self	O
+-	O
+inoculation	O
+)	O
+and	O
+infectious	B-DISO
+respiratory	O
+aerosols	O
+of	O
+various	O
+sizes	O
+and	O
+at	O
+short	O
+range	O
+(	O
+coined	O
+as	O
+""""	O
+opportunistic	O
+""""	O
+airborne	O
+transmission	O
+)	O
+may	O
+also	O
+occur	O
+for	O
+some	O
+pathogens	O
+.	O
+
+The	O
+potential	O
+acute	O
+risks	O
+to	O
+individual	O
+and	O
+population	O
+health	O
+include	O
+communicable	B-DISO
+diseases	I-DISO
+.	O
+
+To	O
+date	O
+,	O
+transmission	O
+studies	O
+have	O
+shown	O
+a	O
+low	O
+risk	O
+of	O
+onward	O
+human	B-SPEC
+transmission	O
+,	O
+with	O
+clinical	O
+presentation	O
+remaining	O
+severe	O
+for	O
+the	O
+majority	O
+.	O
+
+ABSTRACT	O
+:	O
+The	O
+emergence	O
+of	O
+a	O
+novel	O
+strain	O
+of	O
+coronavirus	B-SPEC
+in	O
+the	O
+Arabian	O
+Peninsula	O
+raised	O
+a	O
+global	O
+health	O
+concern	O
+in	O
+2012	O
+,	O
+partly	O
+because	O
+the	O
+majority	O
+of	O
+human	B-SPEC
+infections	B-DISO
+were	O
+fatal	O
+and	O
+partly	O
+due	O
+to	O
+its	O
+presumed	O
+animal	B-SPEC
+origin	O
+.	O
+
+An	O
+urgent	O
+meeting	O
+of	O
+scientific	O
+and	O
+public	O
+health	O
+experts	O
+was	O
+convened	O
+by	O
+WHO	O
+in	O
+January	O
+2013	O
+in	O
+view	O
+of	O
+the	O
+limited	O
+knowledge	O
+available	O
+on	O
+the	O
+epidemiological	O
+and	O
+natural	O
+history	O
+of	O
+infection	B-DISO
+with	O
+this	O
+novel	O
+virus	B-SPEC
+.	O
+
+Although	O
+a	O
+small	O
+subset	O
+of	O
+patients	O
+with	O
+co	O
+-	O
+inherited	O
+cystic	B-DISO
+fibrosis	I-DISO
+and	O
+other	B-DISO
+hemoglobinopathies	I-DISO
+have	O
+been	O
+reported	O
+,	O
+this	O
+patient	O
+developed	O
+early	O
+hematologic	O
+and	O
+pulmonary	B-DISO
+complications	I-DISO
+that	O
+were	O
+more	O
+severe	O
+than	O
+the	O
+previous	O
+cases	O
+.	O
+
+ABSTRACT	O
+:	O
+Middle	O
+East	O
+respiratory	O
+syndrome	B-DISO
+(	O
+MERS	O
+)	O
+is	O
+a	O
+new	O
+human	B-SPEC
+disease	O
+caused	O
+by	O
+a	O
+novel	B-SPEC
+coronavirus	I-SPEC
+(	O
+CoV	O
+).	O
+
+Major	O
+gaps	O
+in	O
+our	O
+knowledge	O
+of	O
+the	O
+epidemiology	O
+,	O
+community	O
+prevalence	O
+,	O
+and	O
+clinical	O
+spectrum	O
+of	O
+infection	B-DISO
+and	O
+disease	O
+need	O
+urgent	O
+definition	O
+.	O
+
+Human	B-PRGE
+coronavirus	I-PRGE
+HKU1	I-PRGE
+,	O
+first	O
+discovered	O
+in	O
+2005	O
+,	O
+has	O
+a	O
+worldwide	O
+prevalence	O
+and	O
+is	O
+associated	O
+with	O
+both	O
+upper	O
+and	O
+lower	B-ANAT
+respiratory	I-ANAT
+tract	I-ANAT
+disease	O
+in	O
+both	O
+children	O
+and	O
+adults	O
+.	O
+
+Type	O
+II	O
+alveolar	B-ANAT
+cells	B-COMP
+infected	O
+with	O
+HCoV	O
+-	O
+HKU1	O
+demonstrated	O
+formation	B-PROC
+of	O
+large	O
+syncytium	B-ANAT
+.	O
+
+These	O
+studies	O
+demonstrate	O
+that	O
+type	O
+II	O
+cells	B-COMP
+are	O
+a	O
+target	B-ANAT
+cell	I-ANAT
+for	O
+HCoV	O
+-	O
+HKU1	O
+infection	B-DISO
+in	O
+the	O
+lower	B-ANAT
+respiratory	I-ANAT
+tract	I-ANAT
+,	O
+that	O
+type	O
+II	O
+alveolar	B-ANAT
+cells	B-COMP
+are	O
+immune	O
+-	O
+competent	O
+in	O
+response	O
+to	O
+infection	B-DISO
+exhibiting	O
+a	O
+type	B-PRGE
+III	I-PRGE
+interferon	I-PRGE
+and	O
+proinflammatory	O
+chemokine	O
+response	O
+,	O
+and	O
+that	O
+cell	B-COMP
+to	O
+cell	B-COMP
+spread	O
+may	O
+be	O
+a	O
+major	O
+factor	O
+for	O
+spread	O
+of	O
+infection	B-DISO
+.	O
+
+A	O
+case	O
+series	O
+of	O
+four	O
+children	O
+with	O
+acute	O
+surgical	O
+presentation	O
+and	O
+prolonged	O
+unexplained	O
+postoperative	O
+sepsis	B-DISO
+,	O
+who	O
+were	O
+diagnosed	O
+with	O
+HLH	B-DISO
+.	O
+
+Eventually	O
+,	O
+HLH	B-DISO
+was	O
+diagnosed	O
+with	O
+bone	B-ANAT
+marrow	I-ANAT
+aspiration	B-DISO
+after	O
+an	O
+average	O
+of	O
+23	O
+days	O
+(	O
+range	O
+17	O
+-	O
+40	O
+),	O
+following	O
+the	O
+finding	O
+of	O
+significantly	O
+elevated	O
+ferritin	B-PRGE
+(	O
+up	O
+to	O
+293150	O
+ng	O
+/	O
+ml	O
+)	O
+and	O
+triglyceride	B-CHED
+levels	O
+.	O
+
+HLH	B-DISO
+can	O
+prove	O
+rapidly	O
+fatal	O
+without	O
+appropriate	O
+treatment	O
+.	O
+
+TITLE	O
+:	O
+Scoping	O
+review	O
+on	O
+search	O
+queries	O
+and	O
+social	O
+media	B-ANAT
+for	O
+disease	O
+surveillance	O
+:	O
+a	O
+chronology	O
+of	O
+innovation	O
+.	O
+
+ABSTRACT	O
+:	O
+The	O
+threat	O
+of	O
+a	O
+global	O
+pandemic	O
+posed	O
+by	O
+outbreaks	O
+of	O
+influenza	O
+H5N1	B-DISO
+(	O
+1997	O
+)	O
+and	O
+Severe	B-DISO
+Acute	I-DISO
+Respiratory	I-DISO
+Syndrome	I-DISO
+(	O
+SARS	B-DISO
+,	O
+2002	O
+),	O
+both	O
+diseases	O
+of	O
+zoonotic	O
+origin	O
+,	O
+provoked	O
+interest	O
+in	O
+improving	O
+early	O
+warning	O
+systems	O
+and	O
+reinforced	O
+the	O
+need	O
+for	O
+combining	O
+data	O
+from	O
+different	O
+sources	O
+.	O
+
+Most	O
+authors	O
+(	O
+24	O
+/	O
+32	O
+,	O
+75	O
+%)	O
+recommended	O
+that	O
+social	O
+media	B-ANAT
+programs	O
+should	O
+primarily	O
+be	O
+used	O
+to	O
+support	O
+existing	O
+surveillance	O
+programs	O
+.	O
+
+Further	O
+developments	O
+in	O
+digital	B-ANAT
+disease	O
+surveillance	O
+have	O
+the	O
+potential	O
+to	O
+improve	O
+sensitivity	O
+and	O
+specificity	O
+,	O
+passively	O
+through	O
+advances	O
+in	O
+machine	O
+learning	B-PROC
+and	O
+actively	O
+through	O
+engagement	O
+of	O
+users	O
+.	O
+
+Most	O
+authors	O
+(	O
+24	O
+/	O
+32	O
+,	O
+75	O
+%)	O
+recommended	O
+that	O
+social	O
+media	B-ANAT
+programs	O
+should	O
+primarily	O
+be	O
+used	O
+to	O
+support	O
+existing	O
+surveillance	O
+programs	O
+.	O
+
+TITLE	O
+:	O
+Sialic	B-CHED
+acid	I-CHED
+binding	I-FUNC
+properties	O
+of	O
+soluble	O
+coronavirus	B-SPEC
+spike	O
+(	O
+S1	O
+)	O
+proteins	B-CHED
+:	O
+differences	O
+between	O
+infectious	O
+bronchitis	B-DISO
+virus	B-SPEC
+and	O
+transmissible	O
+gastroenteritis	B-DISO
+virus	B-SPEC
+.	O
+
+ABSTRACT	O
+:	O
+The	O
+spike	O
+proteins	B-CHED
+of	O
+a	O
+number	O
+of	O
+coronaviruses	O
+are	O
+able	O
+to	O
+bind	B-FUNC
+to	O
+sialic	B-CHED
+acids	I-CHED
+present	O
+on	O
+the	O
+cell	B-COMP
+surface	I-COMP
+.	O
+
+ABSTRACT	O
+:	O
+A	O
+possible	O
+interference	O
+after	O
+Marek	B-DISO
+'	I-DISO
+s	I-DISO
+disease	I-DISO
+(	O
+MD	O
+)	O
+vaccination	O
+using	O
+an	O
+experimental	O
+bivalent	O
+vaccine	O
+,	O
+consisting	O
+of	O
+a	O
+redesigned	O
+CVI	B-PRGE
+-	I-PRGE
+988	I-PRGE
+/	I-PRGE
+Rispens	I-PRGE
+-	I-PRGE
+type	I-PRGE
+MDV	I-PRGE
+-	I-PRGE
+1	I-PRGE
+strain	O
+and	O
+herpesvirus	B-SPEC
+of	I-SPEC
+turkeys	I-SPEC
+,	O
+with	O
+vaccination	O
+against	O
+infectious	B-DISO
+bronchitis	B-DISO
+(	O
+IB	O
+)	O
+virus	B-SPEC
+(	O
+IBV	B-SPEC
+)	O
+or	O
+Newcastle	B-DISO
+disease	I-DISO
+(	O
+ND	O
+)	O
+virus	B-SPEC
+(	O
+NDV	B-SPEC
+)	O
+was	O
+examined	O
+.	O
+
+Thus	O
+,	O
+the	O
+vaccines	O
+can	O
+be	O
+administered	O
+concomitantly	O
+on	O
+chickens	B-SPEC
+'	O
+first	O
+day	O
+of	O
+life	O
+.	O
+
+ABSTRACT	O
+:	O
+In	O
+patients	O
+with	O
+highly	O
+contagious	O
+diseases	O
+that	O
+are	O
+spread	O
+by	O
+respiratory	O
+droplets	O
+or	O
+air	B-CHED
+-	O
+borne	O
+particles	O
+,	O
+the	O
+use	O
+of	O
+high	O
+-	O
+flow	O
+oxygen	B-CHED
+may	O
+carry	O
+a	O
+significant	O
+risk	O
+of	O
+nosocomial	O
+transmission	O
+.	O
+
+To	O
+date	O
+,	O
+no	O
+study	O
+has	O
+directly	O
+examined	O
+the	O
+epidemiology	O
+of	O
+ARDS	B-DISO
+in	O
+severe	B-DISO
+sepsis	I-DISO
+from	O
+the	O
+earliest	O
+presentation	O
+to	O
+the	O
+health	O
+care	O
+system	O
+,	O
+the	O
+emergency	B-DISO
+department	O
+(	O
+ED	O
+).	O
+
+Acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+was	O
+defined	O
+using	O
+the	O
+Berlin	O
+definition	O
+.	O
+
+The	O
+incidence	O
+of	O
+ARDS	B-DISO
+was	O
+6	O
+.	O
+2	O
+%	O
+(	O
+48	O
+/	O
+778	O
+patients	O
+)	O
+in	O
+the	O
+entire	O
+cohort	O
+.	O
+
+Acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+developed	O
+rapidly	O
+and	O
+was	O
+associated	O
+with	O
+significant	O
+mortality	O
+.	O
+
+The	O
+expression	B-PROC
+of	O
+CD107a	B-PRGE
+and	O
+NKG2D	B-PRGE
+,	O
+as	O
+well	O
+as	O
+the	O
+production	O
+of	O
+TNF	B-PRGE
+-	I-PRGE
+α	I-PRGE
+,	O
+IFN	B-PRGE
+-	I-PRGE
+γ	I-PRGE
+and	O
+IL	B-FUNC
+-	I-FUNC
+9	I-FUNC
+in	O
+hepatic	B-ANAT
+CD69	B-ANAT
++	I-ANAT
+NK	I-ANAT
+cells	I-ANAT
+was	O
+all	O
+significantly	O
+up	O
+-	O
+regulated	O
+during	O
+48	O
+-	O
+72	O
+h	O
+post	O
+-	O
+infection	B-DISO
+.	O
+
+Rather	O
+than	O
+being	O
+complacent	O
+about	O
+the	O
+results	O
+,	O
+we	O
+should	O
+envisage	O
+how	O
+to	O
+transform	O
+them	O
+into	O
+drug	O
+candidates	O
+that	O
+may	O
+be	O
+useful	O
+in	O
+combating	O
+SARS	B-DISO
+and	O
+related	O
+viral	B-DISO
+infections	I-DISO
+in	O
+the	O
+future	O
+.	O
+
+Previously	O
+,	O
+we	O
+demonstrated	O
+that	O
+this	O
+locus	O
+,	O
+which	O
+contains	O
+the	O
+gene	O
+for	O
+accessory	B-PRGE
+protein	I-PRGE
+3a	I-PRGE
+from	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+coronavirus	B-SPEC
+(	O
+SARS	B-DISO
+-	O
+CoV	O
+),	O
+encodes	O
+a	O
+protein	B-CHED
+that	O
+forms	O
+ion	B-FUNC
+channels	I-FUNC
+and	O
+regulates	O
+virus	B-SPEC
+release	B-PATH
+.	O
+
+Our	O
+findings	O
+revealed	O
+that	O
+the	O
+ORF4a	O
+proteins	B-CHED
+were	O
+expressed	B-PROC
+in	O
+infected	O
+cells	B-COMP
+and	O
+localized	O
+at	O
+the	O
+endoplasmic	B-COMP
+reticulum	I-COMP
+/	O
+Golgi	B-COMP
+intermediate	O
+compartment	B-ANAT
+(	O
+ERGIC	B-COMP
+).	O
+
+ABSTRACT	O
+:	O
+Laboratory	O
+capacity	O
+is	O
+needed	O
+in	O
+central	O
+Viet	O
+Nam	O
+to	O
+provide	O
+early	O
+warning	O
+to	O
+public	O
+health	O
+authorities	O
+of	O
+respiratory	O
+outbreaks	O
+of	O
+importance	O
+to	O
+human	B-SPEC
+health	O
+,	O
+for	O
+example	O
+the	O
+outbreak	O
+of	O
+influenza	B-PATH
+A	I-PATH
+(	O
+H1N1	O
+)	O
+pandemic	O
+in	O
+2009	O
+.	O
+
+Polymerase	O
+chain	O
+reaction	O
+(	O
+PCR	O
+)	O
+procedures	O
+established	O
+as	O
+part	O
+of	O
+a	O
+capacity	O
+-	O
+building	O
+process	O
+were	O
+used	O
+to	O
+conduct	B-PROC
+prospective	O
+respiratory	O
+surveillance	O
+in	O
+a	O
+region	O
+where	O
+few	O
+previous	O
+studies	O
+have	O
+been	O
+undertaken	O
+.	O
+
+Although	O
+aqueous	B-DISO
+humor	I-DISO
+contained	O
+predominantly	O
+neutrophils	B-ANAT
+in	O
+cats	B-SPEC
+with	O
+FIP	B-DISO
+and	O
+large	O
+reactive	O
+lymphocytes	B-ANAT
+and	O
+plasma	B-ANAT
+cells	I-ANAT
+appeared	O
+more	O
+frequent	O
+in	O
+cats	B-SPEC
+with	O
+idiopathic	O
+uveitis	B-DISO
+,	O
+neither	O
+clinical	O
+nor	O
+cytologic	O
+assessment	O
+of	O
+anterior	B-ANAT
+chamber	I-ANAT
+contents	O
+differed	O
+significantly	O
+between	O
+cats	B-SPEC
+with	O
+idiopathic	O
+or	O
+FIP	B-DISO
+-	O
+associated	O
+uveitis	B-DISO
+.	O
+
+However	O
+,	O
+cytologic	O
+cell	B-COMP
+grades	O
+and	O
+clinical	O
+grade	O
+of	O
+flare	B-DISO
+or	O
+cell	B-COMP
+numbers	O
+within	O
+the	O
+anterior	B-ANAT
+chamber	I-ANAT
+were	O
+not	O
+correlated	O
+.	O
+
+In	O
+this	O
+work	O
+,	O
+efficiently	O
+transfectable	O
+mouse	B-SPEC
+cell	B-ANAT
+lines	I-ANAT
+stably	O
+expressing	O
+the	O
+murine	B-SPEC
+SARS	B-DISO
+-	O
+CoV	O
+receptor	O
+angiotensin	B-PRGE
+converting	I-PRGE
+enzyme	I-PRGE
+2	I-PRGE
+(	O
+ACE2	B-PRGE
+)	O
+have	O
+been	O
+generated	O
+.	O
+
+These	O
+cell	B-ANAT
+lines	I-ANAT
+are	O
+valuable	O
+tools	O
+to	O
+perform	O
+in	O
+vitro	O
+studies	O
+in	O
+a	O
+mouse	B-SPEC
+cell	B-COMP
+system	O
+that	O
+reflects	O
+the	O
+species	B-SPEC
+used	O
+for	O
+in	O
+vivo	O
+studies	O
+of	O
+SARS	B-PRGE
+-	I-PRGE
+CoV	I-PRGE
+-	I-PRGE
+MA15	I-PRGE
+pathogenesis	B-DISO
+.	O
+
+TITLE	O
+:	O
+A	O
+family	B-SPEC
+cluster	O
+of	O
+Middle	O
+East	O
+Respiratory	O
+Syndrome	B-DISO
+Coronavirus	B-DISO
+infections	I-DISO
+related	O
+to	O
+a	O
+likely	O
+unrecognized	O
+asymptomatic	O
+or	O
+mild	O
+case	O
+.	O
+
+ABSTRACT	O
+:	O
+Ninety	O
+confirmed	O
+cases	O
+of	O
+Middle	O
+East	O
+Respiratory	O
+Syndrome	O
+Coronavirus	B-SPEC
+(	O
+MERS	O
+-	O
+CoV	O
+)	O
+have	O
+been	O
+reported	O
+to	O
+the	O
+World	O
+Health	O
+Organization	O
+.	O
+
+We	O
+report	O
+the	O
+details	O
+of	O
+a	O
+second	O
+family	B-SPEC
+cluster	O
+of	O
+MERS	O
+-	O
+CoV	O
+infections	B-DISO
+from	O
+Riyadh	O
+,	O
+Saudi	O
+Arabia	O
+.	O
+
+The	O
+values	O
+for	O
+positive	O
+end	B-PROC
+-	I-PROC
+expiratory	I-PROC
+pressure	O
+-	O
+induced	O
+recruitment	B-DISO
+,	O
+cyclic	O
+recruitment	B-DISO
+and	O
+derecruitment	O
+and	O
+strain	O
+were	O
+then	O
+calculated	O
+.	O
+
+This	O
+review	O
+explains	O
+the	O
+viral	O
+metagenomics	O
+strategy	O
+for	O
+virus	B-SPEC
+discovery	O
+and	O
+describes	O
+viruses	B-SPEC
+discovered	O
+in	O
+human	B-SPEC
+feces	B-ANAT
+in	O
+the	O
+past	O
+10	O
+years	O
+using	O
+this	O
+approach	O
+.	O
+
+A	O
+White	O
+man	B-CHED
+was	O
+found	O
+dead	B-PROC
+with	O
+signs	O
+of	O
+nausea	B-DISO
+and	I-DISO
+vomiting	I-DISO
+after	O
+repeatedly	O
+abusing	O
+bath	O
+salts	B-CHED
+during	O
+a	O
+weekend	O
+binge	B-DISO
+.	O
+
+Femoral	B-ANAT
+venous	B-ANAT
+blood	I-ANAT
+and	O
+urine	B-ANAT
+had	O
+MDPV	O
+concentrations	O
+of	O
+130	O
+ng	O
+/	O
+mL	O
+and	O
+3800	O
+ng	O
+/	O
+mL	O
+.	O
+The	O
+blood	B-ANAT
+and	O
+urine	B-ANAT
+MDPV	O
+concentrations	O
+are	O
+within	O
+the	O
+reported	O
+recreational	O
+concentration	O
+ranges	O
+(	O
+blood	B-ANAT
+24	O
+-	O
+241	O
+ng	O
+/	O
+mL	O
+and	O
+urine	B-ANAT
+34	O
+-	O
+3900	O
+ng	O
+/	O
+mL	O
+).	O
+
+ABSTRACT	O
+:	O
+Systems	O
+biology	O
+offers	O
+considerable	O
+promise	O
+in	O
+uncovering	O
+novel	O
+pathways	O
+by	O
+which	O
+viruses	B-SPEC
+and	O
+other	O
+microbial	O
+pathogens	O
+interact	O
+with	O
+host	B-COMP
+signaling	B-PROC
+and	O
+expression	B-PROC
+networks	O
+to	O
+mediate	O
+disease	O
+severity	O
+.	O
+
+We	O
+validated	O
+the	O
+importance	O
+of	O
+the	O
+urokinase	B-PRGE
+pathway	B-PROC
+for	O
+SARS	B-DISO
+-	O
+CoV	O
+disease	O
+severity	O
+using	O
+genetically	O
+defined	O
+knockout	O
+mice	B-SPEC
+,	O
+proteomic	O
+correlates	O
+of	O
+pathway	B-PROC
+activation	O
+,	O
+and	O
+pathological	O
+disease	O
+severity	O
+.	O
+
+Similar	O
+transcriptional	B-PROC
+signatures	O
+were	O
+noted	O
+in	O
+1918	O
+and	O
+2009	O
+H1N1	B-DISO
+influenza	I-DISO
+virus	O
+-	O
+infected	O
+mice	B-SPEC
+,	O
+suggesting	O
+a	O
+common	O
+,	O
+potentially	O
+treatable	O
+mechanism	O
+in	O
+development	B-PROC
+of	O
+virus	B-SPEC
+-	O
+induced	O
+ALI	O
+.	O
+
+Functional	O
+analyses	O
+of	O
+poly	O
+(	O
+A	O
+)	O
+tail	O
+length	O
+on	O
+specific	O
+viral	O
+RNA	O
+species	O
+,	O
+furthermore	O
+,	O
+revealed	O
+that	O
+translation	B-PROC
+,	O
+in	O
+vivo	O
+,	O
+of	O
+RNAs	O
+with	O
+the	O
+longer	O
+poly	O
+(	O
+A	O
+)	O
+tail	O
+was	O
+enhanced	O
+over	O
+those	O
+with	O
+the	O
+shorter	O
+poly	O
+(	O
+A	O
+).	O
+
+Despite	O
+continued	O
+improvements	O
+in	O
+the	O
+administration	O
+of	O
+noninvasive	O
+ventilation	O
+(	O
+NIV	O
+),	O
+refractory	O
+hypercapnia	B-DISO
+and	O
+hypercapnic	B-DISO
+acidosis	I-DISO
+continue	O
+to	O
+prevent	O
+its	O
+successful	O
+use	O
+in	O
+many	O
+patients	O
+.	O
+
+By	O
+HA	O
+-	O
+RBS	B-DISO
+direct	O
+sequencing	O
+of	O
+respiratory	O
+specimens	O
+,	O
+D222G	O
+and	O
+D222N	O
+viral	O
+variants	O
+were	O
+identified	O
+in	O
+a	O
+higher	O
+proportion	O
+in	O
+ICU	O
+patients	O
+(	O
+n	O
+=	O
+8	O
+/	O
+24	O
+,	O
+33	O
+·	O
+3	O
+%)	O
+than	O
+in	O
+patients	O
+with	O
+mild	O
+disease	O
+(	O
+n	O
+=	O
+2	O
+/	O
+34	O
+,	O
+6	O
+%)	O
+or	O
+in	O
+outpatients	O
+(	O
+n	O
+=	O
+0	O
+/	O
+44	O
+)	O
+(	O
+Fisher	B-SPEC
+'	O
+s	O
+exact	O
+test	O
+P	O
+<	O
+0	O
+·	O
+0001	O
+;	O
+OR	O
+38	O
+·	O
+5	O
+;	O
+CI	O
+95	O
+%	O
+4	O
+·	O
+494	O
+-	O
+329	O
+·	O
+9	O
+).	O
+
+D222G	O
+and	O
+D222N	O
+mutants	O
+were	O
+identified	O
+in	O
+upper	O
+and	O
+lower	O
+respiratory	B-ANAT
+samples	I-ANAT
+.	O
+
+The	O
+frequencies	O
+of	O
+detection	O
+of	O
+various	O
+viruses	B-SPEC
+among	O
+in	O
+-	O
+and	O
+outpatients	O
+were	O
+different	O
+.	O
+
+Simultaneous	O
+detection	O
+of	O
+two	O
+or	O
+more	O
+viruses	B-SPEC
+was	O
+found	O
+in	O
+377	O
+cases	O
+.	O
+
+Further	O
+studies	O
+are	O
+required	O
+to	O
+better	O
+understand	O
+the	O
+impact	O
+of	O
+coinfections	B-DISO
+in	O
+children	O
+with	O
+ARI	B-CHED
+.	O
+
+ABSTRACT	O
+:	O
+Mice	O
+that	O
+are	O
+transgenic	O
+(	O
+Tg	O
+)	O
+for	O
+T	B-PRGE
+cell	I-PRGE
+receptor	I-PRGE
+(	O
+TCR	B-COMP
+)	O
+expression	B-PROC
+are	O
+used	O
+extensively	O
+to	O
+analyze	O
+longitudinal	O
+T	B-ANAT
+cell	I-ANAT
+responses	O
+during	O
+effector	B-CHED
+and	O
+memory	B-PROC
+phases	O
+of	O
+the	O
+T	B-ANAT
+cell	I-ANAT
+response	O
+.	O
+
+We	O
+generated	O
+mice	B-SPEC
+that	O
+were	O
+transgenic	O
+for	O
+a	O
+TCR	B-COMP
+responding	O
+to	O
+a	O
+CD4	B-PRGE
+T	I-PRGE
+cell	I-PRGE
+epitope	B-CHED
+(	O
+epitope	B-CHED
+M133	O
+)	O
+that	O
+is	O
+immunodominant	O
+in	O
+mice	B-SPEC
+infected	O
+with	O
+a	O
+neurotropic	O
+coronavirus	B-SPEC
+,	O
+the	O
+JHM	O
+strain	O
+of	O
+mouse	B-DISO
+hepatitis	I-DISO
+virus	B-SPEC
+.	O
+
+The	O
+CD4	B-PRGE
+T	I-PRGE
+cell	O
+response	O
+to	O
+epitope	B-CHED
+M133	O
+is	O
+of	O
+particular	O
+interest	O
+because	O
+it	O
+may	O
+be	O
+pathogenic	O
+,	O
+protective	O
+or	O
+regulatory	O
+,	O
+depending	O
+upon	O
+the	O
+physiological	O
+setting	O
+.	O
+
+We	O
+applied	O
+an	O
+iterative	O
+process	O
+in	O
+which	O
+we	O
+identified	O
+a	O
+TCR	O
+-	O
+β	O
+chain	O
+expressed	B-PROC
+by	O
+all	O
+mice	B-SPEC
+that	O
+were	O
+examined	O
+('	O
+public	O
+sequence	O
+').	O
+
+This	O
+TCR	B-PRGE
+-	I-PRGE
+β	I-PRGE
+chain	I-PRGE
+was	O
+introduced	O
+into	O
+bone	B-ANAT
+marrow	I-ANAT
+cells	I-ANAT
+with	O
+a	O
+lentivirus	B-SPEC
+vector	O
+,	O
+generating	O
+TCR	B-PRGE
+-	I-PRGE
+β	I-PRGE
+retrogenic	O
+mice	B-SPEC
+.	O
+
+ABSTRACT	O
+:	O
+A	O
+new	O
+betacoronavirus	B-SPEC
+-	O
+Middle	O
+East	O
+respiratory	O
+syndrome	B-DISO
+coronavirus	B-SPEC
+(	O
+MERS	O
+-	O
+CoV	O
+)-	O
+has	O
+been	O
+identified	O
+in	O
+patients	O
+with	O
+severe	O
+acute	B-DISO
+respiratory	I-DISO
+infection	I-DISO
+.	O
+
+Although	O
+related	O
+viruses	B-SPEC
+infect	O
+bats	B-SPEC
+,	O
+molecular	O
+clock	O
+analyses	O
+have	O
+been	O
+unable	O
+to	O
+identify	O
+direct	O
+ancestors	O
+of	O
+MERS	O
+-	O
+CoV	O
+.	O
+Anecdotal	O
+exposure	O
+histories	O
+suggest	O
+that	O
+patients	O
+had	O
+been	O
+in	O
+contact	O
+with	O
+dromedary	B-SPEC
+camels	B-SPEC
+or	O
+goats	B-SPEC
+.	O
+
+MERS	O
+-	O
+CoV	O
+neutralising	O
+antibody	B-COMP
+titres	O
+varied	O
+between	O
+1	O
+/	O
+320	O
+and	O
+1	O
+/	O
+2560	O
+for	O
+the	O
+Omani	O
+camel	B-SPEC
+sera	B-COMP
+and	O
+between	O
+1	O
+/	O
+20	O
+and	O
+1	O
+/	O
+320	O
+for	O
+the	O
+Spanish	O
+camel	B-SPEC
+sera	B-COMP
+.	O
+
+There	O
+was	O
+no	O
+evidence	O
+for	O
+cross	O
+-	O
+neutralisation	O
+by	O
+bovine	B-SPEC
+coronavirus	B-SPEC
+antibodies	B-COMP
+.	O
+
+The	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+(	O
+SARS	B-DISO
+)	O
+epidemic	O
+and	O
+the	O
+2009	O
+H1N1	B-DISO
+influenza	I-DISO
+pandemic	O
+provided	O
+a	O
+better	O
+understanding	O
+of	O
+how	O
+viral	O
+pathogens	O
+mediate	O
+lung	B-ANAT
+injury	O
+.	O
+
+There	O
+is	O
+little	O
+evidence	O
+that	O
+corticosteroids	B-CHED
+are	O
+beneficial	O
+,	O
+and	O
+they	O
+might	O
+be	O
+harmful	O
+.	O
+
+We	O
+predicted	O
+a	O
+small	O
+set	O
+of	O
+regulatory	O
+factors	O
+with	O
+conserved	O
+behavior	O
+for	O
+consideration	O
+as	O
+important	O
+components	O
+of	O
+viral	B-DISO
+pathogenesis	I-DISO
+that	O
+might	O
+also	O
+serve	O
+as	O
+therapeutic	O
+targets	O
+for	O
+intervention	O
+.	O
+
+We	O
+have	O
+established	O
+a	O
+reverse	O
+genetics	O
+system	O
+for	O
+PEDV	B-SPEC
+based	O
+on	O
+targeted	B-PROC
+RNA	O
+recombination	B-PROC
+that	O
+allows	O
+the	O
+modification	O
+of	O
+the	O
+3	O
+'-	O
+end	O
+of	O
+the	O
+viral	B-COMP
+genome	I-COMP
+,	O
+which	O
+encodes	O
+the	O
+structural	O
+proteins	B-CHED
+and	O
+the	O
+ORF3	O
+protein	B-CHED
+.	O
+
+We	O
+demonstrated	O
+the	O
+expression	B-PROC
+of	O
+both	O
+GFP	O
+and	O
+Renilla	B-SPEC
+luciferase	B-ENZY
+as	O
+well	O
+as	O
+the	O
+application	O
+of	O
+these	O
+viruses	B-SPEC
+by	O
+establishing	O
+a	O
+convenient	O
+and	O
+rapid	O
+virus	B-PROC
+neutralization	I-PROC
+assay	O
+.	O
+
+ABSTRACT	O
+:	O
+Coronaviruses	O
+(	O
+CoV	O
+),	O
+like	O
+other	O
+positive	O
+-	O
+stranded	O
+RNA	O
+viruses	B-SPEC
+,	O
+redirect	O
+and	O
+rearrange	O
+host	O
+cell	B-COMP
+membranes	I-COMP
+for	O
+use	O
+as	O
+part	O
+of	O
+the	O
+viral	B-PROC
+genome	I-PROC
+replication	I-PROC
+and	O
+transcription	B-PROC
+machinery	O
+.	O
+
+Increased	O
+interferon	B-PRGE
+gamma	I-PRGE
+(	O
+IFN	B-PRGE
+-	I-PRGE
+γ	I-PRGE
+)	O
+expression	B-PROC
+was	O
+observed	O
+in	O
+the	O
+mucosal	B-ANAT
+immune	O
+compartment	B-ANAT
+,	O
+i	O
+.	O
+e	O
+.,	O
+HALT	O
+,	O
+after	O
+primary	O
+vaccination	O
+,	O
+but	O
+shifted	O
+to	O
+the	O
+systemic	O
+immune	O
+compartment	B-ANAT
+after	O
+boosting	O
+.	O
+
+TITLE	O
+:	O
+Emerging	O
+indications	O
+for	O
+extracorporeal	O
+membrane	B-COMP
+oxygenation	B-PROC
+in	O
+adults	O
+with	O
+respiratory	B-DISO
+failure	I-DISO
+.	O
+
+TITLE	O
+:	O
+Extracorporeal	O
+membrane	B-COMP
+oxygenation	B-PROC
+for	O
+severe	O
+respiratory	B-DISO
+failure	I-DISO
+in	O
+adult	O
+patients	O
+:	O
+a	O
+systematic	O
+review	O
+and	O
+meta	O
+-	O
+analysis	O
+of	O
+current	O
+evidence	O
+.	O
+
+Extracorporeal	O
+membrane	B-COMP
+oxygenation	B-PROC
+benefit	O
+on	O
+hospital	O
+mortality	O
+is	O
+unclear	O
+.	O
+
+TITLE	O
+:	O
+Molecular	O
+characterization	O
+and	O
+phylogenetic	O
+analysis	O
+of	O
+new	O
+variants	O
+of	O
+the	O
+porcine	B-SPEC
+epidemic	B-DISO
+diarrhea	I-DISO
+virus	I-SPEC
+in	O
+Gansu	O
+,	O
+China	O
+in	O
+2012	O
+.	O
+
+Our	O
+results	O
+suggest	O
+that	O
+these	O
+new	O
+PEDV	B-SPEC
+variant	O
+strains	O
+in	O
+Gansu	O
+Province	O
+might	O
+be	O
+from	O
+South	O
+Korean	O
+or	O
+South	O
+China	O
+,	O
+and	O
+the	O
+effectiveness	O
+of	O
+the	O
+CV777	O
+-	O
+based	O
+vaccine	O
+needs	O
+to	O
+be	O
+evaluated	O
+.	O
+
+We	O
+hypothesize	O
+that	O
+an	O
+excessive	O
+innate	O
+response	O
+contributes	O
+to	O
+the	O
+scale	O
+of	O
+the	O
+pathophysiologic	O
+effect	O
+in	O
+chickens	B-SPEC
+.	O
+
+TITLE	O
+:	O
+ACE2	B-PRGE
+-	O
+from	O
+the	O
+renin	B-PATH
+-	I-PATH
+angiotensin	B-CHED
+system	I-PATH
+to	O
+gut	B-ANAT
+microbiota	B-SPEC
+and	O
+malnutrition	B-DISO
+.	O
+
+ABSTRACT	O
+:	O
+The	O
+renin	B-ENZY
+-	I-ANAT
+angiotensin	B-CHED
+system	I-ANAT
+(	O
+RAS	B-PRGE
+)	O
+is	O
+a	O
+complex	O
+network	O
+that	O
+regulates	O
+blood	B-PROC
+pressure	I-PROC
+,	O
+electrolyte	O
+and	O
+fluid	O
+homeostasis	B-PROC
+,	O
+as	O
+well	O
+as	O
+the	O
+function	O
+of	O
+several	O
+organs	B-ANAT
+.	O
+
+In	O
+addition	O
+,	O
+ACE2	B-PRGE
+has	O
+functions	O
+independent	O
+of	O
+the	O
+RAS	B-PRGE
+:	O
+ACE2	B-PRGE
+is	O
+the	O
+receptor	O
+for	O
+the	O
+SARS	B-DISO
+coronavirus	B-SPEC
+and	O
+ACE2	B-PRGE
+is	O
+essential	O
+for	O
+expression	B-PROC
+of	O
+neutral	O
+amino	B-PRGE
+acid	I-PRGE
+transporters	I-PRGE
+in	O
+the	O
+gut	B-ANAT
+.	O
+
+Here	O
+we	O
+review	O
+and	O
+discuss	O
+the	O
+diverse	O
+functions	O
+of	O
+ACE2	B-PRGE
+and	O
+its	O
+relevance	O
+to	O
+human	B-SPEC
+pathologies	O
+.	O
+
+Histology	O
+revealed	O
+severe	O
+atrophy	B-DISO
+of	O
+villi	O
+in	O
+all	O
+segments	O
+of	O
+the	O
+small	B-ANAT
+intestines	I-ANAT
+with	O
+occasional	O
+villus	B-ANAT
+-	O
+epithelial	O
+syncytial	O
+cells	B-COMP
+,	O
+but	O
+testing	O
+for	O
+rotaviruses	B-SPEC
+and	O
+Transmissible	O
+gastroenteritis	B-DISO
+virus	B-SPEC
+(	O
+Alphacoronavirus	B-SPEC
+1	I-SPEC
+)	O
+were	O
+negative	O
+.	O
+
+The	O
+2013	O
+U	O
+.	O
+S	O
+.	O
+PEDV	B-SPEC
+had	O
+96	O
+.	O
+6	O
+-	O
+99	O
+.	O
+5	O
+%	O
+identity	O
+with	O
+all	O
+known	O
+PEDV	B-SPEC
+strains	O
+and	O
+the	O
+highest	O
+identity	O
+(>	O
+99	O
+.	O
+0	O
+%)	O
+to	O
+some	O
+of	O
+the	O
+2011	O
+-	O
+2012	O
+Chinese	O
+strains	O
+.	O
+
+Infection	O
+with	O
+the	O
+virus	B-SPEC
+has	O
+so	O
+far	O
+resulted	O
+in	O
+only	O
+91	O
+cases	O
+and	O
+46	O
+deaths	B-PROC
+(	O
+as	O
+of	O
+29	O
+July	O
+2013	O
+),	O
+but	O
+it	O
+is	O
+nonetheless	O
+setting	O
+off	O
+alarm	O
+bells	O
+among	O
+public	O
+health	O
+officials	O
+,	O
+including	O
+Margaret	O
+Chan	O
+,	O
+Director	O
+-	O
+General	O
+of	O
+the	O
+World	O
+Health	O
+Organization	O
+,	O
+who	O
+called	O
+MERS	O
+-	O
+CoV	O
+""""	O
+a	O
+threat	O
+to	O
+the	O
+entire	O
+world	O
+.	O
+
+TITLE	O
+:	O
+Coronaviruses	O
+lacking	O
+exoribonuclease	B-FUNC
+activity	I-FUNC
+are	O
+susceptible	O
+to	O
+lethal	O
+mutagenesis	B-PROC
+:	O
+evidence	O
+for	O
+proofreading	O
+and	O
+potential	O
+therapeutics	O
+.	O
+
+Additionally	O
+,	O
+the	O
+resistance	B-PROC
+of	O
+SARS	B-DISO
+-	O
+CoV	O
+to	O
+ribavirin	B-CHED
+(	O
+RBV	B-CHED
+)	O
+demonstrates	O
+the	O
+need	O
+to	O
+define	O
+new	O
+targets	O
+for	O
+inhibition	B-PROC
+of	O
+CoV	O
+replication	O
+.	O
+
+Finally	O
+,	O
+our	O
+results	O
+show	O
+the	O
+importance	O
+of	O
+ExoN	O
+as	O
+a	O
+target	O
+for	O
+inhibition	B-PROC
+,	O
+and	O
+suggest	O
+that	O
+small	O
+-	O
+molecule	O
+inhibitors	B-CHED
+of	O
+ExoN	O
+activity	O
+could	O
+be	O
+potential	O
+pan	B-COMP
+-	O
+CoV	O
+therapeutics	O
+in	O
+combination	O
+with	O
+RBV	B-CHED
+or	O
+RNA	O
+mutagens	B-CHED
+.	O
+
+The	O
+integrity	O
+of	O
+epithelial	O
+and	O
+endothelial	B-ANAT
+barriers	O
+in	O
+the	O
+lower	O
+airspaces	O
+of	O
+the	O
+lungs	B-ANAT
+has	O
+to	O
+be	O
+tightly	O
+regulated	O
+,	O
+in	O
+order	B-SPEC
+to	O
+prevent	O
+leakage	B-DISO
+and	O
+to	O
+assure	O
+efficient	O
+gas	B-ENZY
+exchange	O
+between	O
+the	O
+alveoli	B-ANAT
+and	O
+capillaries	B-ANAT
+.	O
+
+Toxin	O
+-	O
+induced	O
+endothelial	B-ANAT
+hyperpermeability	O
+can	O
+involve	O
+myosin	B-PRGE
+light	I-PRGE
+chain	I-PRGE
+phosphorylation	B-PROC
+and	O
+/	O
+or	O
+microtubule	B-COMP
+rearrangement	B-PROC
+.	O
+
+The	O
+enzyme	O
+arginase	B-PRGE
+,	O
+the	O
+activity	O
+of	O
+which	O
+can	O
+be	O
+regulated	O
+by	O
+the	O
+redox	B-PROC
+status	O
+of	O
+the	O
+cell	B-COMP
+,	O
+exists	O
+in	O
+two	O
+isoforms	B-PRGE
+-	I-PRGE
+arginase	I-PRGE
+1	I-PRGE
+(	O
+cytosolic	B-COMP
+)	O
+and	O
+arginase	B-PRGE
+2	I-PRGE
+(	O
+mitochondrial	B-COMP
+)	O
+-	O
+both	O
+of	O
+which	O
+can	O
+be	O
+expressed	B-PROC
+in	O
+lung	B-ANAT
+microvascular	O
+endothelial	B-ANAT
+cells	I-ANAT
+.	O
+
+Upon	O
+activation	O
+,	O
+arginase	B-PRGE
+competes	O
+with	O
+eNOS	B-PRGE
+for	O
+the	O
+substrate	O
+l	B-CHED
+-	I-CHED
+arginine	I-CHED
+,	O
+as	O
+such	O
+impairing	O
+eNOS	O
+-	O
+dependent	O
+NO	O
+generation	O
+and	O
+promoting	O
+reactive	B-CHED
+oxygen	I-CHED
+species	I-CHED
+generation	O
+by	O
+the	O
+enzyme	O
+.	O
+
+Clinical	O
+hallmarks	O
+of	O
+von	B-DISO
+Hippel	I-DISO
+-	I-DISO
+Lindau	I-DISO
+disease	I-DISO
+are	O
+the	O
+development	B-PROC
+of	O
+central	B-ANAT
+nervous	I-ANAT
+system	I-ANAT
+hemangioblastomas	B-DISO
+,	O
+renal	B-PATH
+cell	I-PATH
+carcinoma	I-PATH
+,	O
+pheochromocytoma	B-DISO
+,	O
+neuroendocrine	B-DISO
+tumors	I-DISO
+and	O
+endolymphatic	B-ANAT
+sac	I-ANAT
+tumors	B-DISO
+.	O
+
+No	O
+evidence	O
+of	O
+relationship	O
+between	O
+VHL	B-DISO
+disease	O
+and	O
+blood	B-DISO
+cancers	I-DISO
+has	O
+been	O
+demonstrated	O
+so	O
+far	O
+.	O
+
+Despite	O
+the	O
+fact	O
+that	O
+there	O
+is	O
+an	O
+increased	O
+risk	O
+of	O
+cancer	B-DISO
+development	B-PROC
+in	O
+hemodialyzed	O
+patients	O
+,	O
+cancer	B-DISO
+is	O
+a	O
+relatively	O
+rare	O
+cause	O
+of	O
+death	B-PROC
+in	O
+the	O
+dialysed	O
+population	O
+,	O
+and	O
+the	O
+most	O
+common	O
+malignancies	B-DISO
+are	O
+genitourinary	B-DISO
+cancers	I-DISO
+.	O
+
+Based	O
+on	O
+the	O
+duration	O
+and	O
+the	O
+highest	O
+level	O
+of	O
+IgY	O
+antibody	B-COMP
+against	O
+bovine	B-SPEC
+alimentary	B-ANAT
+tract	I-ANAT
+pathogens	O
+C	O
+vaccine	O
+was	O
+further	O
+used	O
+in	O
+next	O
+two	O
+trials	O
+for	O
+vaccination	O
+of	O
+1000	O
+hens	O
+each	O
+time	O
+.	O
+
+Spatial	O
+models	O
+tend	O
+to	O
+predict	O
+infection	B-DISO
+probability	O
+reasonably	O
+well	O
+when	O
+disease	O
+spread	O
+is	O
+propagated	O
+through	O
+contact	O
+networks	O
+in	O
+which	O
+contacts	O
+are	O
+only	O
+within	O
+a	O
+certain	O
+distance	O
+of	O
+each	O
+other	O
+.	O
+
+Identification	O
+and	O
+characterisation	O
+of	O
+the	O
+spike	O
+genes	O
+from	O
+TGEV	B-SPEC
+and	O
+PRCoV	O
+,	O
+detected	O
+in	O
+such	O
+outbreaks	O
+,	O
+were	O
+performed	O
+in	O
+Hungary	O
+.	O
+
+Novel	O
+viruses	B-SPEC
+from	O
+the	O
+families	O
+Picorna	O
+-,	O
+Papilloma	B-DISO
+-,	O
+and	O
+Anelloviridae	B-SPEC
+as	O
+well	O
+as	O
+known	O
+viruses	B-SPEC
+from	O
+the	O
+families	O
+Astro	O
+-,	O
+Corona	B-CHED
+-,	O
+Parvo	O
+-,	O
+and	O
+Hepeviridae	B-SPEC
+were	O
+identified	O
+in	O
+different	O
+ferret	B-SPEC
+cohorts	O
+.	O
+
+Firstly	O
+,	O
+coronaviruses	O
+,	O
+in	O
+addition	O
+to	O
+influenza	B-SPEC
+viruses	I-SPEC
+,	O
+can	O
+cause	O
+severe	O
+and	O
+rapidly	O
+spreading	O
+human	B-SPEC
+infections	B-DISO
+.	O
+
+Both	O
+viruses	B-SPEC
+also	O
+have	O
+close	O
+relationships	O
+with	O
+bat	B-ENZY
+coronaviruses	O
+.	O
+
+Studies	O
+based	O
+on	O
+laser	B-SPEC
+visualization	O
+technique	O
+with	O
+smoke	O
+particles	O
+as	O
+smokers	O
+in	O
+the	O
+human	B-SPEC
+patient	O
+simulator	O
+has	O
+shown	O
+that	O
+oxygen	B-CHED
+therapy	O
+via	O
+Hudson	O
+mask	O
+and	O
+nasal	B-ANAT
+cannula	B-SPEC
+could	O
+disperse	O
+exhaled	B-ANAT
+air	B-CHED
+of	O
+patients	O
+to	O
+0	O
+.	O
+4	O
+and	O
+1	O
+m	O
+respectively	O
+whereas	O
+jet	B-PRGE
+nebulizer	I-PRGE
+could	O
+disperse	O
+exhaled	B-PROC
+air	B-CHED
+>	O
+0	O
+.	O
+8	O
+m	O
+from	O
+the	O
+patient	O
+.	O
+
+Carefully	O
+designed	O
+clinical	O
+trials	O
+are	O
+required	O
+to	O
+determine	O
+the	O
+optimal	O
+timing	O
+and	O
+dosage	O
+of	O
+any	O
+antiviral	B-CHED
+agents	I-CHED
+,	O
+convalescent	O
+plasma	B-ANAT
+,	O
+and	O
+immuno	O
+-	O
+modulating	O
+agents	O
+in	O
+the	O
+treatment	O
+of	O
+the	O
+possibly	O
+immune	O
+-	O
+mediated	O
+lung	B-ANAT
+injury	O
+in	O
+SARS	B-DISO
+and	O
+newly	O
+emerged	O
+infection	B-DISO
+such	O
+as	O
+the	O
+Middle	O
+East	O
+Respiratory	O
+Syndrome	B-DISO
+.	O
+
+TITLE	O
+:	O
+Receptor	O
+-	O
+binding	B-FUNC
+domain	O
+as	O
+a	O
+target	O
+for	O
+developing	O
+SARS	B-DISO
+vaccines	O
+.	O
+
+Therefore	O
+,	O
+the	O
+development	B-PROC
+of	O
+effective	O
+and	O
+safe	O
+SARS	B-DISO
+vaccines	O
+is	O
+still	O
+needed	O
+.	O
+
+TITLE	O
+:	O
+Alarm	O
+bells	O
+over	O
+MERS	O
+coronavirus	B-SPEC
+.	O
+
+In	O
+this	O
+study	O
+,	O
+we	O
+produced	O
+a	O
+pseudovirus	O
+bearing	O
+the	O
+full	O
+-	O
+length	O
+spike	O
+(	O
+S	O
+)	O
+protein	B-CHED
+of	O
+MERS	O
+-	O
+CoV	O
+in	O
+the	O
+Env	B-PRGE
+-	O
+defective	O
+,	O
+luciferase	B-ENZY
+-	O
+expressing	O
+HIV	B-SPEC
+-	I-SPEC
+1	I-SPEC
+backbone	B-ANAT
+.	O
+
+Microglial	B-ANAT
+activation	O
+and	O
+phagocytosis	B-PROC
+are	O
+recognized	O
+to	O
+be	O
+critically	O
+important	O
+in	O
+the	O
+pathogenesis	B-DISO
+of	O
+demyelination	B-DISO
+.	O
+
+ABSTRACT	O
+:	O
+Mechanical	O
+circulatory	O
+support	O
+(	O
+MCS	B-COMP
+)	O
+is	O
+a	O
+rescue	O
+therapy	O
+for	O
+infants	O
+and	O
+children	O
+suffering	B-DISO
+from	O
+severe	O
+cardiorespiratory	B-DISO
+failure	I-DISO
+with	O
+specific	O
+system	O
+-	O
+related	O
+complications	O
+like	O
+bleeding	B-DISO
+,	O
+thromboembolism	B-DISO
+and	O
+device	O
+failure	O
+.	O
+
+Novel	O
+circuit	O
+components	O
+for	O
+temporary	O
+MCS	B-COMP
+with	O
+improved	O
+haemodynamic	O
+properties	O
+may	O
+improve	O
+patients	O
+'	O
+outcome	O
+and	O
+reduce	O
+system	O
+-	O
+related	O
+morbidities	O
+.	O
+
+We	O
+examined	O
+the	O
+association	O
+between	O
+receipt	O
+of	O
+a	O
+neuromuscular	O
+blocking	B-DISO
+agent	O
+and	O
+in	O
+-	O
+hospital	O
+mortality	O
+among	O
+mechanically	O
+ventilated	O
+patients	O
+with	O
+severe	B-DISO
+sepsis	I-DISO
+.	O
+
+Patients	O
+who	O
+received	O
+neuromuscular	O
+blocking	B-DISO
+agents	O
+were	O
+younger	O
+(	O
+mean	O
+age	O
+,	O
+62	O
+vs	O
+68	O
+),	O
+more	O
+likely	O
+to	O
+be	O
+treated	O
+with	O
+vasopressors	O
+(	O
+69	O
+%	O
+vs	O
+65	O
+%)	O
+and	O
+had	O
+a	O
+lower	O
+in	O
+-	O
+hospital	O
+mortality	O
+rate	O
+(	O
+31	O
+.	O
+9	O
+%	O
+vs	O
+38	O
+.	O
+3	O
+%,	O
+p	O
+<	O
+0	O
+.	O
+001	O
+).	O
+
+Among	O
+the	O
+patients	O
+with	O
+ARDS	B-DISO
+,	O
+extraalveolar	O
+air	B-CHED
+leak	O
+complications	O
+occurred	O
+in	O
+4	O
+cases	O
+.	O
+
+Five	O
+patients	O
+died	B-PROC
+,	O
+all	O
+of	O
+whom	O
+were	O
+severely	O
+immunocompromised	O
+.	O
+
+On	O
+follow	O
+-	O
+up	O
+,	O
+1	O
+patient	O
+had	O
+severe	O
+chronic	B-DISO
+respiratory	I-DISO
+failure	I-DISO
+related	O
+to	O
+lung	B-DISO
+fibrosis	I-DISO
+,	O
+and	O
+2	O
+patients	O
+had	O
+mild	O
+lower	B-ANAT
+limb	I-ANAT
+paraparesis	B-DISO
+along	O
+with	O
+bladder	B-DISO
+dysfunction	I-DISO
+,	O
+both	O
+of	O
+which	O
+were	O
+ascribable	O
+to	O
+measles	B-PATH
+-	O
+induced	O
+encephalitis	B-DISO
+and	O
+myelitis	B-DISO
+.	O
+
+ABSTRACT	O
+:	O
+Guillain	O
+-	O
+Barré	O
+syndrome	B-DISO
+(	O
+GBS	B-DISO
+)	O
+is	O
+the	O
+most	O
+common	O
+cause	O
+of	O
+acute	O
+flaccid	O
+paralysis	O
+in	O
+the	O
+developed	O
+world	O
+.	O
+
+Awareness	O
+of	O
+these	O
+complications	O
+,	O
+their	O
+detection	O
+and	O
+management	O
+,	O
+may	O
+help	O
+limit	O
+the	O
+morbidity	O
+of	O
+GBS	B-DISO
+.	O
+
+This	O
+article	O
+reviews	O
+the	O
+recent	O
+progress	O
+in	O
+research	O
+and	O
+treatment	O
+of	O
+inhalation	B-PROC
+injury	O
+,	O
+acute	O
+lung	B-ANAT
+injury	O
+,	O
+and	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+at	O
+home	O
+and	O
+abroad	O
+,	O
+focusing	O
+on	O
+the	O
+effect	O
+of	O
+mechanical	O
+ventilation	O
+models	O
+,	O
+including	O
+the	O
+non	O
+-	O
+invasive	O
+ventilation	O
+,	O
+lung	B-ANAT
+protective	O
+ventilation	O
+,	O
+liquid	O
+ventilation	O
+,	O
+high	O
+frequency	O
+ventilation	O
+,	O
+on	O
+respiratory	O
+support	O
+in	O
+early	O
+stage	O
+of	O
+inhalation	B-PROC
+injury	O
+.	O
+
+The	O
+aim	O
+of	O
+this	O
+case	O
+series	O
+was	O
+to	O
+describe	O
+the	O
+feasibility	O
+and	O
+pitfalls	O
+of	O
+combining	O
+positioning	O
+therapy	O
+and	O
+vvECMO	O
+in	O
+patients	O
+with	O
+severe	O
+ARDS	B-DISO
+.	O
+
+The	O
+lung	B-PROC
+compliance	I-PROC
+improved	O
+from	O
+20	O
+(	O
+17	O
+-	O
+28	O
+)	O
+to	O
+42	O
+(	O
+27	O
+-	O
+43	O
+)	O
+ml	O
+/	O
+cmH2O	O
+.	O
+
+TITLE	O
+:	O
+Middle	O
+East	O
+respiratory	O
+syndrome	B-DISO
+coronavirus	B-SPEC
+spike	O
+protein	B-CHED
+delivered	O
+by	O
+modified	O
+vaccinia	B-DISO
+virus	I-SPEC
+Ankara	O
+efficiently	O
+induces	O
+virus	O
+-	O
+neutralizing	O
+antibodies	B-COMP
+.	O
+
+The	O
+genetic	O
+stability	O
+and	O
+growth	B-PROC
+characteristics	O
+of	O
+MVA	B-CHED
+-	O
+MERS	O
+-	O
+S	O
+make	O
+it	O
+a	O
+suitable	O
+candidate	O
+vaccine	O
+for	O
+clinical	O
+testing	O
+.	O
+
+We	O
+collected	O
+lung	B-ANAT
+tissues	I-ANAT
+from	O
+fatal	O
+BPD	B-DISO
+cases	O
+and	O
+performed	O
+histology	O
+,	O
+immunohistochemistry	O
+,	O
+and	O
+high	O
+-	O
+precision	O
+three	O
+-	O
+dimensional	O
+reconstruction	O
+techniques	O
+.	O
+
+CONCLUSIONS	O
+:	O
+To	O
+our	O
+knowledge	O
+,	O
+this	O
+is	O
+the	O
+first	O
+case	O
+report	O
+of	O
+a	O
+clinical	O
+adverse	O
+reaction	O
+of	O
+AEP	B-PRGE
+from	O
+an	O
+atypical	B-CHED
+antipsychotic	I-CHED
+agent	I-CHED
+(	O
+risperidone	B-CHED
+).	O
+
+Among	O
+patients	O
+receiving	O
+mechanical	O
+ventilation	O
+,	O
+57	O
+%	O
+of	O
+the	O
+patients	O
+died	B-PROC
+;	O
+those	O
+having	O
+bronchial	B-ANAT
+epithelial	O
+lesions	O
+(	O
+22	O
+of	O
+56	O
+)	O
+required	O
+intubation	O
+earlier	O
+than	O
+others	O
+(	O
+1	O
+[	O
+1	O
+-	O
+4	O
+]	O
+vs	O
+4	O
+[	O
+1	O
+-	O
+6	O
+]	O
+d	O
+after	O
+hospital	O
+admission	O
+;	O
+p	O
+=	O
+0	O
+.	O
+027	O
+).	O
+
+However	O
+,	O
+in	O
+a	O
+multivariate	O
+analysis	O
+,	O
+CPV2	O
+was	O
+the	O
+only	O
+gastrointestinal	O
+pathogen	O
+associated	O
+with	O
+abnormal	O
+feces	B-ANAT
+.	O
+
+TITLE	O
+:	O
+Development	B-PROC
+of	O
+potent	O
+dipeptide	B-CHED
+-	O
+type	O
+SARS	B-DISO
+-	O
+CoV	O
+3CL	O
+protease	B-PROC
+inhibitors	I-PROC
+with	O
+novel	O
+P3	O
+scaffolds	O
+:	O
+design	O
+,	O
+synthesis	O
+,	O
+biological	O
+evaluation	O
+,	O
+and	O
+docking	B-PROC
+studies	O
+.	O
+
+TITLE	O
+:	O
+Adenovirus	B-SPEC
+respiratory	B-DISO
+infection	I-DISO
+in	O
+hospitalized	O
+children	O
+in	O
+Hong	O
+Kong	O
+:	O
+serotype	O
+-	O
+clinical	O
+syndrome	B-DISO
+association	O
+and	O
+risk	O
+factors	O
+for	O
+lower	B-DISO
+respiratory	I-DISO
+tract	I-DISO
+infection	I-DISO
+.	O
+
+ABSTRACT	O
+:	O
+Lower	B-DISO
+respiratory	I-DISO
+tract	I-DISO
+infections	I-DISO
+(	O
+LRTI	B-DISO
+)	O
+caused	O
+by	O
+adenovirus	B-DISO
+can	O
+be	O
+severe	O
+with	O
+resultant	O
+chronic	O
+pulmonary	B-ANAT
+sequelae	O
+.	O
+
+The	O
+clinical	O
+picture	O
+mimicked	O
+bacterial	B-DISO
+infection	I-DISO
+for	O
+its	O
+prolonged	O
+high	O
+fever	B-PROC
+and	O
+neutrophilic	B-PROC
+blood	B-ANAT
+picture	O
+.	O
+
+Children	O
+aged	O
+1	O
+to	O
+2	O
+years	O
+old	O
+were	O
+most	O
+at	O
+risk	O
+for	O
+adenovirus	B-DISO
+LRTI	B-DISO
+(	O
+adjusted	O
+p	O
+=	O
+0	O
+.	O
+0165	O
+).	O
+
+The	O
+majority	O
+of	O
+acute	B-DISO
+bronchiolitis	I-DISO
+(	O
+71	O
+.	O
+4	O
+%)	O
+were	O
+associated	O
+with	O
+serotype	O
+2	O
+infection	B-DISO
+,	O
+and	O
+this	O
+association	O
+was	O
+statistically	O
+significant	O
+(	O
+p	O
+<	O
+0	O
+.	O
+0001	O
+).	O
+
+Twenty	O
+-	O
+one	O
+amino	B-CHED
+acid	I-CHED
+differences	O
+were	O
+observed	O
+in	O
+the	O
+polyprotein	O
+1a	O
+/	O
+ab	O
+between	O
+the	O
+different	O
+passages	O
+.	O
+
+The	O
+mutation	O
+rate	O
+was	O
+calculated	O
+to	O
+be	O
+5	O
+.	O
+08	O
+-	O
+6	O
+.	O
+3	O
+×	O
+10	O
+(-	O
+6	O
+)	O
+nucleotides	O
+/	O
+site	O
+/	O
+passage	O
+in	O
+tissue	B-ANAT
+culture	O
+suggesting	O
+a	O
+relatively	O
+stable	O
+virus	B-SPEC
+.	O
+
+The	O
+degree	O
+of	O
+influence	O
+of	O
+vaccination	O
+on	O
+the	O
+incidence	O
+of	O
+influenza	B-DISO
+,	O
+the	O
+number	O
+and	O
+structure	O
+of	O
+complications	O
+as	O
+a	O
+result	O
+of	O
+vaccination	O
+and	O
+their	O
+impact	O
+on	O
+efficiency	O
+.	O
+
+ABSTRACT	O
+:	O
+Despite	O
+a	O
+significant	O
+amount	O
+of	O
+progress	O
+in	O
+the	O
+past	O
+decade	O
+,	O
+global	O
+infectious	O
+disease	O
+surveillance	O
+still	O
+often	O
+falters	O
+,	O
+as	O
+in	O
+the	O
+case	O
+of	O
+the	O
+emerging	O
+novel	B-SPEC
+coronavirus	I-SPEC
+that	O
+has	O
+killed	O
+at	O
+least	O
+17	O
+people	O
+in	O
+Saudi	O
+Arabia	O
+.	O
+
+It	O
+takes	O
+stock	O
+of	O
+problems	O
+in	O
+various	O
+countries	O
+'	O
+infectious	B-DISO
+disease	I-DISO
+surveillance	O
+systems	O
+and	O
+offers	O
+recommendations	O
+for	O
+how	O
+to	O
+improve	O
+surveillance	O
+and	O
+ensure	O
+more	O
+rapid	O
+reporting	O
+.	O
+
+Suggestions	O
+are	O
+also	O
+offered	O
+for	O
+ways	O
+to	O
+improve	O
+infectious	B-DISO
+disease	I-DISO
+surveillance	O
+strategies	O
+in	O
+resource	O
+-	O
+limited	O
+settings	O
+.	O
+
+ABSTRACT	O
+:	O
+Plasmodium	O
+vivax	O
+(	O
+p	B-SPEC
+.	I-SPEC
+vivax	I-SPEC
+)	O
+malaria	B-PATH
+was	O
+traditionally	O
+considered	O
+as	O
+benign	B-DISO
+tertian	I-DISO
+malaria	I-DISO
+,	O
+however	O
+,	O
+recent	O
+studies	O
+have	O
+pointed	O
+out	O
+that	O
+p	B-SPEC
+.	I-SPEC
+vivax	I-SPEC
+have	O
+potential	O
+to	O
+cause	O
+all	O
+severe	O
+complications	O
+previously	O
+attributed	O
+to	O
+p	B-SPEC
+.	I-SPEC
+falciparum	I-SPEC
+infection	B-DISO
+only	O
+.	O
+
+TITLE	O
+:	O
+Lung	B-ANAT
+ventilation	O
+strategies	O
+and	O
+regional	O
+lung	B-DISO
+inflammation	I-DISO
+.	O
+
+The	O
+group	O
+reports	O
+that	O
+a	O
+protective	O
+ventilation	O
+strategy	O
+may	O
+attenuate	O
+neutrophil	B-PROC
+activation	I-PROC
+in	O
+dependent	O
+lung	B-ANAT
+regions	O
+during	O
+early	O
+experimental	O
+ALI	O
+.	O
+
+These	O
+drug	O
+repurposing	O
+techniques	O
+have	O
+been	O
+successful	O
+in	O
+identifying	O
+new	O
+drug	O
+candidates	O
+for	O
+several	O
+types	O
+of	O
+cancers	B-DISO
+and	O
+were	O
+recently	O
+used	O
+to	O
+identify	O
+potential	O
+therapeutics	O
+against	O
+influenza	B-DISO
+,	O
+the	O
+newly	O
+discovered	O
+Middle	O
+Eastern	O
+Respiratory	O
+Syndrome	B-DISO
+coronavirus	B-SPEC
+and	O
+several	O
+parasitic	B-DISO
+diseases	I-DISO
+.	O
+
+TITLE	O
+:	O
+From	O
+SARS	B-DISO
+to	O
+MERS	O
+:	O
+10	O
+years	O
+of	O
+research	O
+on	O
+highly	O
+pathogenic	O
+human	B-SPEC
+coronaviruses	O
+.	O
+
+Taken	O
+together	O
+,	O
+these	O
+data	O
+suggest	O
+that	O
+treatment	O
+of	O
+MERS	O
+-	O
+CoV	O
+infected	O
+rhesus	B-SPEC
+macaques	I-SPEC
+with	O
+IFN	B-PRGE
+-	I-PRGE
+α2b	I-PRGE
+and	O
+ribavirin	B-CHED
+reduces	O
+virus	B-PROC
+replication	I-PROC
+,	O
+moderates	O
+the	O
+host	B-PROC
+response	I-PROC
+and	O
+improves	O
+clinical	O
+outcome	O
+.	O
+
+As	O
+their	O
+conditions	O
+became	O
+better	O
+,	O
+patients	O
+'	O
+EVLWI	O
+decreased	O
+to	O
+5	O
+.	O
+5	O
+±	O
+2	O
+.	O
+7	O
+ml	O
+/	O
+kg	O
+and	O
+7	O
+.	O
+0	O
+±	O
+3	O
+.	O
+0	O
+ml	O
+/	O
+kg	O
+,	O
+respectively	O
+at	O
+weaning	B-PROC
+.	O
+
+This	O
+virus	B-SPEC
+constitutes	O
+a	O
+vaccine	O
+candidate	O
+that	O
+may	O
+represent	O
+a	O
+balance	B-PROC
+between	O
+safety	O
+and	O
+efficacy	O
+for	O
+the	O
+induction	O
+of	O
+mucosal	B-PROC
+immunity	I-PROC
+,	O
+which	O
+is	O
+needed	O
+to	O
+prevent	O
+MERS	O
+-	O
+CoV	O
+infection	B-DISO
+.	O
+
+The	O
+timely	O
+identification	O
+of	O
+novel	O
+viruses	B-SPEC
+using	O
+NGS	O
+technologies	O
+is	O
+also	O
+important	O
+for	O
+us	O
+to	O
+control	O
+emerging	B-DISO
+infectious	I-DISO
+diseases	I-DISO
+caused	O
+by	O
+novel	O
+viruses	B-SPEC
+.	O
+
+By	O
+contrast	O
+,	O
+viral	O
+pseudotypes	O
+containing	O
+the	O
+surface	O
+protein	B-CHED
+GP	O
+of	O
+Marburg	B-SPEC
+virus	I-SPEC
+from	O
+the	O
+family	B-SPEC
+Filoviridae	I-SPEC
+infected	O
+all	O
+six	O
+cell	B-ANAT
+lines	I-ANAT
+though	O
+at	O
+different	O
+efficiency	O
+.	O
+
+These	O
+results	O
+indicate	O
+that	O
+bat	B-ENZY
+cells	B-COMP
+are	O
+more	O
+resistant	O
+to	O
+infection	B-DISO
+by	O
+coronaviruses	O
+than	O
+to	O
+infection	B-DISO
+by	O
+paramyxoviruses	O
+,	O
+filoviruses	O
+and	O
+influenza	B-SPEC
+viruses	I-SPEC
+.	O
+
+All	O
+specimens	O
+underwent	O
+testing	O
+with	O
+a	O
+wide	O
+panel	O
+of	O
+molecular	O
+assays	O
+targeting	B-PROC
+respiratory	O
+viruses	B-SPEC
+.	O
+
+In	O
+1991	O
+we	O
+published	O
+a	O
+report	O
+showing	O
+that	O
+,	O
+in	O
+ARDS	B-DISO
+patients	O
+,	O
+shifting	O
+from	O
+supine	O
+to	O
+prone	O
+position	O
+led	O
+immediately	O
+to	O
+the	O
+inversion	B-DISO
+of	O
+the	O
+inflation	O
+gradient	O
+and	O
+to	O
+a	O
+redistribution	O
+of	O
+densities	O
+from	O
+dorsal	O
+to	O
+ventral	O
+lung	B-ANAT
+regions	O
+.	O
+
+This	O
+led	O
+to	O
+a	O
+""""	O
+sponge	B-SPEC
+model	O
+""""	O
+as	O
+a	O
+wet	O
+sponge	B-SPEC
+,	O
+similar	O
+to	O
+a	O
+heavy	O
+edematous	B-DISO
+lung	B-ANAT
+,	O
+squeezes	O
+out	O
+the	O
+gas	B-ENZY
+in	O
+the	O
+most	O
+dependent	O
+regions	O
+,	O
+due	O
+to	O
+the	O
+weight	O
+-	O
+related	O
+increase	O
+of	O
+the	O
+compressive	O
+forces	O
+.	O
+
+Here	O
+we	O
+analyzed	O
+accessory	O
+proteins	B-CHED
+3	O
+,	O
+4a	O
+,	O
+4b	O
+,	O
+and	O
+5	O
+for	O
+their	O
+abilities	O
+to	O
+inhibit	O
+the	O
+type	B-PRGE
+I	I-PRGE
+interferon	I-PRGE
+response	O
+.	O
+
+In	O
+contrast	O
+,	O
+a	O
+single	O
+camostat	O
+treatment	O
+suppressed	O
+MERS	O
+-	O
+CoV	O
+entry	O
+into	O
+human	B-SPEC
+bronchial	B-ANAT
+submucosal	O
+gland	B-ANAT
+-	O
+derived	O
+Calu	O
+-	O
+3	O
+cells	B-COMP
+by	O
+10	O
+-	O
+fold	O
+and	O
+virus	B-SPEC
+growth	B-PROC
+by	O
+270	O
+-	O
+fold	O
+,	O
+although	O
+treatment	O
+with	O
+both	O
+camostat	O
+and	O
+(	O
+23	O
+,	O
+25	O
+)-	O
+trans	O
+-	O
+epoxysuccinyl	O
+-	O
+L	O
+-	O
+leucylamindo	O
+-	O
+3	O
+-	O
+methylbutane	O
+ethyl	B-CHED
+ester	B-CHED
+,	O
+a	O
+cathepsin	B-PRGE
+inhibitor	B-CHED
+,	O
+or	O
+treatment	O
+with	O
+leupeptin	O
+,	O
+an	O
+inhibitor	B-CHED
+of	O
+cysteine	B-CHED
+,	O
+serine	B-CHED
+,	O
+and	O
+threonine	B-CHED
+peptidases	O
+,	O
+was	O
+no	O
+more	O
+efficacious	O
+than	O
+treatment	O
+with	O
+camostat	O
+alone	O
+.	O
+
+These	O
+results	O
+suggest	O
+that	O
+a	O
+single	O
+treatment	O
+with	O
+camostat	O
+is	O
+sufficient	O
+to	O
+block	O
+MERS	O
+-	O
+CoV	O
+entry	O
+into	O
+a	O
+well	O
+-	O
+differentiated	B-PROC
+lung	B-ANAT
+-	O
+derived	O
+cell	B-ANAT
+line	I-ANAT
+.	O
+
+However	O
+,	O
+the	O
+intra	O
+-	O
+and	O
+intermolecular	O
+determinants	O
+of	O
+nsp5	B-PRGE
+activity	O
+and	O
+their	O
+conservation	O
+across	O
+divergent	O
+CoVs	O
+are	O
+unknown	O
+,	O
+in	O
+part	O
+due	O
+to	O
+challenges	O
+in	O
+cultivating	O
+many	O
+human	B-SPEC
+and	O
+zoonotic	O
+CoVs	O
+.	O
+
+To	O
+test	O
+for	O
+conservation	O
+of	O
+nsp5	B-PRGE
+structure	O
+-	O
+function	O
+determinants	O
+,	O
+we	O
+engineered	O
+chimeric	O
+betacoronavirus	B-SPEC
+murine	B-SPEC
+hepatitis	I-DISO
+virus	O
+(	O
+MHV	B-SPEC
+)	O
+genomes	O
+encoding	O
+nsp5	B-PRGE
+proteases	I-PRGE
+of	O
+human	B-SPEC
+and	O
+bat	B-ENZY
+alphacoronaviruses	O
+and	O
+betacoronaviruses	O
+.	O
+
+Exchange	O
+of	O
+nsp5	B-PRGE
+proteases	I-PRGE
+from	O
+HCoV	O
+-	O
+HKU1	O
+and	O
+HCoV	B-SPEC
+-	I-SPEC
+OC43	I-SPEC
+,	O
+which	O
+share	O
+the	O
+same	O
+genogroup	O
+,	O
+genogroup	O
+2a	O
+,	O
+with	O
+MHV	B-SPEC
+,	O
+allowed	O
+for	O
+immediate	O
+viral	O
+recovery	O
+with	O
+efficient	O
+replication	O
+albeit	O
+with	O
+impaired	B-DISO
+fitness	O
+in	O
+direct	O
+competition	O
+with	O
+wild	O
+-	O
+type	O
+MHV	B-SPEC
+.	O
+
+Median	O
+plasma	B-ANAT
+SP	O
+-	O
+D	O
+levels	O
+were	O
+significantly	O
+increased	O
+during	O
+episodes	O
+of	O
+microbial	O
+pneumonia	B-DISO
+,	O
+but	O
+not	O
+in	O
+the	O
+absence	O
+of	O
+pathologic	O
+respiratory	O
+findings	O
+,	O
+during	O
+microbial	B-DISO
+colonization	I-DISO
+,	O
+or	O
+during	O
+ACR	O
+up	O
+to	O
+grade	O
+A2	O
+-	O
+A3	O
+(	O
+P	O
+<	O
+0	O
+.	O
+05	O
+).	O
+
+By	O
+comparing	O
+our	O
+results	O
+with	O
+published	O
+expression	B-PROC
+profiling	O
+studies	O
+in	O
+animal	B-SPEC
+models	O
+of	O
+sepsis	B-DISO
+and	O
+lung	B-ANAT
+injury	O
+,	O
+we	O
+found	O
+aquaporin	B-PRGE
+-	I-PRGE
+1	I-PRGE
+to	O
+be	O
+differentially	O
+expressed	B-PROC
+across	O
+all	O
+studies	O
+.	O
+
+Aquaporin	B-PRGE
+-	I-PRGE
+1	I-PRGE
+is	O
+induced	O
+in	O
+leukocytes	B-ANAT
+of	O
+patients	O
+with	O
+ICU	O
+-	O
+acquired	O
+sepsis	B-DISO
+and	O
+exhibits	O
+higher	O
+expression	B-PROC
+in	O
+septic	B-DISO
+shock	I-DISO
+.	O
+
+The	O
+Beta	O
+-	O
+Agonist	B-CHED
+Lung	B-ANAT
+injury	O
+TrIal	O
+-	O
+2	O
+(	O
+BALTI	O
+-	O
+2	O
+)	O
+was	O
+initiated	O
+to	O
+evaluate	O
+the	O
+effects	O
+of	O
+this	O
+intervention	O
+on	O
+mortality	O
+in	O
+patients	O
+with	O
+ARDS	B-DISO
+.	O
+
+Intravenous	O
+infusion	O
+of	O
+salbutamol	B-CHED
+(	O
+15	O
+μg	O
+/	O
+kg	O
+IBW	O
+/	O
+hour	O
+)	O
+or	O
+placebo	O
+(	O
+0	O
+.	O
+9	O
+%	O
+saline	O
+)	O
+for	O
+up	O
+to	O
+7	O
+days	O
+.	O
+
+Recruitment	B-DISO
+was	O
+stopped	O
+after	O
+the	O
+second	O
+interim	O
+analysis	O
+because	O
+of	O
+safety	O
+concerns	O
+.	O
+
+Further	O
+trials	O
+of	O
+β	O
+-	O
+agonists	B-CHED
+in	O
+patients	O
+with	O
+ARDS	B-DISO
+are	O
+unlikely	O
+to	O
+be	O
+conducted	O
+.	O
+
+Salbutamol	B-CHED
+increased	O
+28	O
+-	O
+day	O
+mortality	O
+:	O
+55	O
+(	O
+34	O
+%)	O
+of	O
+161	O
+patients	O
+died	B-PROC
+in	O
+the	O
+salbutamol	B-CHED
+group	O
+compared	O
+with	O
+38	O
+(	O
+23	O
+%)	O
+of	O
+163	O
+in	O
+the	O
+placebo	O
+group	O
+(	O
+risk	O
+ratio	O
+1	O
+.	O
+47	O
+,	O
+95	O
+%	O
+confidence	O
+interval	O
+1	O
+.	O
+03	O
+to	O
+2	O
+.	O
+08	O
+).	O
+
+It	O
+was	O
+concluded	O
+that	O
+this	O
+assay	O
+can	O
+be	O
+used	O
+as	O
+a	O
+rapid	O
+tool	O
+for	O
+BCoV	O
+genotypes	O
+differentiation	B-PROC
+.	O
+
+His	O
+Model	O
+for	O
+End	O
+-	O
+Stage	O
+Liver	B-DISO
+Disease	I-DISO
+was	O
+25	O
+at	O
+that	O
+time	O
+.	O
+
+This	O
+study	O
+summarises	O
+a	O
+recent	O
+systematic	O
+review	O
+,	O
+which	O
+aimed	O
+to	O
+assess	O
+evidence	O
+that	O
+influenza	B-DISO
+or	O
+pneumococcal	O
+vaccination	O
+of	O
+HCWs	O
+provides	O
+indirect	O
+protection	O
+for	O
+those	O
+patients	O
+most	O
+at	O
+risk	O
+of	O
+severe	O
+or	O
+complicated	O
+acute	B-DISO
+respiratory	I-DISO
+infection	I-DISO
+.	O
+
+TITLE	O
+:	O
+Epidemiological	O
+and	O
+genetic	O
+characteristics	O
+associated	O
+with	O
+the	O
+severity	O
+of	O
+acute	B-DISO
+viral	I-DISO
+bronchiolitis	I-DISO
+by	O
+respiratory	B-SPEC
+syncytial	I-SPEC
+virus	I-SPEC
+.	O
+
+Polymorphisms	B-PROC
+of	O
+the	O
+TLRs	O
+,	O
+RANTES	B-PRGE
+,	O
+JUN	B-PRGE
+,	O
+IFNA5	B-PRGE
+,	O
+NOS2	B-PRGE
+,	O
+CX3CR1	B-PRGE
+,	O
+ILs	B-DISO
+,	O
+and	O
+VDR	B-PRGE
+genes	I-PRGE
+have	O
+been	O
+shown	O
+to	O
+be	O
+associated	O
+with	O
+more	O
+severe	O
+evolution	B-PROC
+of	O
+AVB	O
+by	O
+RSV	B-SPEC
+.	O
+
+TITLE	O
+:	O
+Thrombin	B-ENZY
+selectively	O
+engages	O
+LIM	B-PRGE
+kinase	I-PRGE
+1	I-PRGE
+and	O
+slingshot	B-PRGE
+-	I-PRGE
+1L	I-PRGE
+phosphatase	I-PRGE
+to	O
+regulate	O
+NF	O
+-	O
+κB	O
+activation	O
+and	O
+endothelial	O
+cell	O
+inflammation	B-DISO
+.	O
+
+Interestingly	O
+,	O
+LIMK1	B-PRGE
+or	O
+SSH	B-PRGE
+-	I-PRGE
+1L	I-PRGE
+depletion	O
+failed	O
+to	O
+inhibit	O
+TNF	B-PRGE
+-	I-PRGE
+α	I-PRGE
+-	O
+induced	O
+RelA	B-PRGE
+/	O
+p65	B-PRGE
+nuclear	B-PROC
+translocation	I-PROC
+and	O
+proinflammatory	O
+gene	B-PROC
+expression	I-PROC
+.	O
+
+To	O
+overcome	O
+this	O
+problem	O
+,	O
+we	O
+have	O
+developed	O
+a	O
+new	O
+duplex	O
+real	O
+-	O
+time	O
+PCR	O
+assay	O
+for	O
+the	O
+detection	O
+and	O
+differentiation	B-PROC
+of	O
+these	O
+two	O
+viruses	B-SPEC
+.	O
+
+Four	O
+-	O
+weeks	O
+-	O
+old	O
+SPF	B-PRGE
+chickens	I-PRGE
+were	O
+co	O
+-	O
+infected	O
+with	O
+both	O
+viruses	B-SPEC
+(	O
+NDV	B-SPEC
+-	O
+LaSota	O
+and	O
+AIV	B-PRGE
+-	I-PRGE
+H7N1	I-PRGE
+).	O
+
+However	O
+,	O
+no	O
+anti	B-PRGE
+-	I-PRGE
+S	I-PRGE
+IgM	I-PRGE
+was	O
+detected	O
+in	O
+healthy	O
+adults	O
+.	O
+
+However	O
+,	O
+we	O
+have	O
+previously	O
+shown	O
+that	O
+this	O
+domain	O
+of	O
+the	O
+embryo	B-ANAT
+-	O
+and	O
+cell	B-COMP
+culture	O
+adapted	O
+Beaudette	O
+strain	O
+,	O
+in	O
+contrast	O
+to	O
+that	O
+of	O
+the	O
+virulent	O
+M41	O
+strain	O
+,	O
+is	O
+not	O
+sufficient	O
+for	O
+binding	B-FUNC
+to	O
+chicken	B-SPEC
+trachea	B-DISO
+(	O
+Wickramasinghe	O
+et	O
+al	O
+.,	O
+2011	O
+).	O
+
+In	O
+contrast	O
+,	O
+Beaudette	O
+spike	O
+ectodomain	O
+had	O
+relatively	O
+weak	O
+ability	O
+to	O
+bind	B-FUNC
+to	O
+chicken	B-SPEC
+trachea	B-DISO
+,	O
+but	O
+displayed	O
+marked	O
+extended	O
+host	B-COMP
+range	O
+to	O
+mammalian	B-SPEC
+cells	B-COMP
+.	O
+
+In	O
+addition	O
+,	O
+we	O
+ablated	O
+expression	B-PROC
+of	O
+the	O
+accessory	O
+protein	B-CHED
+ORF5	O
+(	O
+rMERS	O
+•	O
+ORF5	O
+)	O
+and	O
+replaced	O
+it	O
+with	O
+tomato	B-SPEC
+red	B-PRGE
+fluorescent	I-PRGE
+protein	I-PRGE
+(	O
+rMERS	B-PRGE
+-	I-PRGE
+RFP	I-PRGE
+)	O
+or	O
+deleted	O
+the	O
+entire	O
+ORF3	O
+,	O
+4	O
+,	O
+and	O
+5	O
+accessory	O
+cluster	O
+(	O
+rMERS	O
+-	O
+ΔORF3	O
+-	O
+5	O
+).	O
+
+LOH	B-PROC
+is	O
+frequently	O
+associated	O
+with	O
+chronic	O
+conditions	O
+including	O
+cardiovascular	B-DISO
+diseases	I-DISO
+(	O
+CVD	B-DISO
+),	O
+obesity	B-DISO
+,	O
+osteoporosis	B-DISO
+,	O
+HIV	B-PATH
+infection	I-PATH
+,	O
+renal	B-DISO
+failure	I-DISO
+,	O
+and	O
+obstructive	B-DISO
+pulmonary	I-DISO
+diseases	I-DISO
+.	O
+
+In	O
+this	O
+paper	O
+,	O
+we	O
+critically	O
+reviewed	O
+the	O
+available	O
+evidence	O
+on	O
+LOH	B-PROC
+treatment	O
+focusing	O
+on	O
+possible	O
+risks	O
+and	O
+benefits	O
+.	O
+
+However	O
+,	O
+TRT	B-PRGE
+in	O
+healthy	O
+older	O
+men	O
+in	O
+near	O
+physiological	O
+doses	O
+does	O
+not	O
+appear	O
+to	O
+incur	O
+serious	O
+adverse	O
+events	O
+,	O
+although	O
+regular	O
+monitoring	O
+of	O
+prostate	O
+-	O
+specific	O
+antigen	B-CHED
+and	O
+hematocrit	O
+levels	O
+is	O
+required	O
+.	O
+
+TITLE	O
+:	O
+Factors	O
+associated	O
+with	O
+severe	O
+effects	O
+following	O
+acute	O
+glufosinate	B-CHED
+poisoning	O
+.	O
+
+They	O
+were	O
+divided	O
+into	O
+a	O
+group	O
+with	O
+respiratory	B-DISO
+arrest	I-DISO
+or	O
+convulsion	B-DISO
+during	O
+hospitalization	O
+(	O
+severe	O
+group	O
+)	O
+and	O
+a	O
+group	O
+without	O
+(	O
+non	O
+-	O
+severe	O
+group	O
+).	O
+
+Logistic	O
+regression	O
+analysis	O
+was	O
+performed	O
+with	O
+a	O
+backward	O
+elimination	B-PROC
+procedure	O
+.	O
+
+Deletion	O
+of	O
+the	O
+3c	B-PRGE
+gene	I-PRGE
+could	O
+therefore	O
+cause	O
+more	O
+efficient	O
+viral	B-PROC
+replication	I-PROC
+,	O
+which	O
+leads	O
+to	O
+a	O
+fatal	O
+infection	B-DISO
+.	O
+
+T	B-ANAT
+cell	I-ANAT
+epitope	B-CHED
+mapping	O
+strategies	O
+increasingly	O
+rely	O
+on	O
+algorithms	O
+that	O
+predict	O
+the	O
+binding	B-FUNC
+of	O
+peptides	B-CHED
+to	O
+MHC	B-PRGE
+molecules	I-PRGE
+.	O
+
+In	O
+this	O
+study	O
+,	O
+we	O
+evaluate	O
+the	O
+ability	O
+of	O
+NetMHCpan	O
+to	O
+predict	O
+antiviral	B-CHED
+CD8	B-PRGE
+(+)	O
+T	B-ANAT
+cell	I-ANAT
+epitopes	O
+that	O
+we	O
+identified	O
+with	O
+a	O
+traditional	O
+approach	O
+in	O
+patients	O
+of	O
+Asian	O
+ethnicity	O
+infected	O
+with	O
+Dengue	B-SPEC
+virus	I-SPEC
+,	O
+hepatitis	B-SPEC
+B	I-SPEC
+virus	I-SPEC
+,	O
+or	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+coronavirus	B-SPEC
+.	O
+
+Therefore	O
+,	O
+we	O
+aimed	O
+to	O
+investigate	O
+the	O
+expression	B-PROC
+of	O
+IL	B-FUNC
+-	I-FUNC
+33	I-FUNC
+in	O
+murine	B-SPEC
+fulminant	B-DISO
+hepatitis	I-DISO
+induced	O
+by	O
+a	O
+Toll	B-PRGE
+like	I-PRGE
+receptor	I-PRGE
+(	O
+TLR3	B-PRGE
+)	O
+viral	O
+mimetic	O
+,	O
+poly	O
+(	O
+I	O
+:	O
+C	O
+)	O
+or	O
+by	O
+pathogenic	O
+mouse	B-DISO
+hepatitis	I-DISO
+virus	B-SPEC
+(	O
+L2	O
+-	O
+MHV3	O
+).	O
+
+The	O
+CD1d	B-PRGE
+KO	I-PRGE
+(	O
+NKT	B-PRGE
+deficient	O
+)	O
+mice	B-SPEC
+showed	O
+hepatoprotection	O
+against	O
+poly	O
+(	O
+I	O
+:	O
+C	O
+)-	O
+induced	O
+hepatitis	B-DISO
+in	O
+association	O
+with	O
+increased	O
+number	O
+of	O
+IL	B-FUNC
+-	I-FUNC
+33	I-FUNC
+expressing	O
+hepatocytes	B-ANAT
+in	O
+CD1d	B-PRGE
+KO	I-PRGE
+mice	B-SPEC
+than	O
+WT	O
+controls	O
+.	O
+
+In	O
+conclusion	O
+,	O
+the	O
+alarmin	B-PRGE
+cytokine	I-PRGE
+IL	I-PRGE
+-	I-PRGE
+33	I-PRGE
+was	O
+over	O
+-	O
+expressed	B-PROC
+during	O
+fulminant	B-DISO
+hepatitis	I-DISO
+in	O
+mice	B-SPEC
+with	O
+LSEC	O
+,	O
+VEC	O
+and	O
+hepatocytes	B-ANAT
+as	O
+potential	O
+sources	O
+of	O
+IL	B-FUNC
+-	I-FUNC
+33	I-FUNC
+.	O
+
+There	O
+is	O
+little	O
+information	O
+regarding	O
+the	O
+host	B-COMP
+factors	O
+that	O
+correlate	O
+with	O
+and	O
+contribute	O
+to	O
+MHV	B-SPEC
+-	O
+induced	O
+demyelination	B-DISO
+.	O
+
+We	O
+found	O
+evidence	O
+that	O
+a	O
+Th1	O
+-	O
+biased	O
+cytokine	O
+/	O
+chemokine	O
+response	O
+and	O
+eicosanoid	B-CHED
+-	O
+derived	O
+inflammation	B-DISO
+accompany	O
+persistent	O
+MHV	B-SPEC
+infection	B-DISO
+and	O
+that	O
+antigen	B-PROC
+presentation	I-PROC
+is	O
+ongoing	O
+.	O
+
+TITLE	O
+:	O
+Middle	O
+East	O
+respiratory	O
+syndrome	B-DISO
+coronavirus	B-SPEC
+(	O
+MERS	O
+-	O
+CoV	O
+)	O
+causes	O
+transient	O
+lower	B-ANAT
+respiratory	I-ANAT
+tract	I-ANAT
+infection	I-DISO
+in	O
+rhesus	B-SPEC
+macaques	I-SPEC
+.	O
+
+This	O
+tropism	B-PROC
+of	O
+MERS	O
+-	O
+CoV	O
+for	O
+the	O
+lower	B-ANAT
+respiratory	I-ANAT
+tract	I-ANAT
+may	O
+explain	O
+the	O
+severity	O
+of	O
+the	O
+disease	O
+observed	O
+in	O
+humans	B-SPEC
+and	O
+the	O
+,	O
+up	O
+to	O
+now	O
+,	O
+limited	O
+human	B-SPEC
+-	O
+to	O
+-	O
+human	B-SPEC
+transmission	O
+.	O
+
+TITLE	O
+:	O
+Active	O
+replication	O
+of	O
+Middle	O
+East	O
+respiratory	O
+syndrome	B-DISO
+coronavirus	B-SPEC
+and	O
+aberrant	O
+induction	O
+of	O
+inflammatory	O
+cytokines	O
+and	O
+chemokines	O
+in	O
+human	O
+macrophages	B-ANAT
+:	O
+implications	O
+for	O
+pathogenesis	B-DISO
+.	O
+
+We	O
+conclusively	O
+showed	O
+that	O
+MERS	O
+-	O
+CoV	O
+can	O
+establish	O
+a	O
+productive	O
+infection	B-DISO
+in	O
+human	B-SPEC
+macrophages	B-ANAT
+.	O
+
+Astrovirus	O
+,	O
+rotavirus	B-SPEC
+,	O
+and	O
+reovirus	B-SPEC
+were	O
+detected	O
+alone	O
+or	O
+in	O
+various	O
+combinations	O
+in	O
+both	O
+LTS	O
+and	O
+non	O
+-	O
+LTS	O
+flocks	O
+.	O
+
+ABSTRACT	O
+:	O
+To	O
+investigate	O
+effects	O
+of	O
+low	O
+dietary	O
+vitamin	B-CHED
+A	I-CHED
+content	O
+on	O
+antibody	B-PROC
+responses	I-PROC
+in	O
+feedlot	O
+calves	O
+inoculated	O
+with	O
+an	O
+inactivated	O
+bovine	B-SPEC
+coronavirus	B-SPEC
+(	O
+BCoV	O
+)	O
+vaccine	O
+.	O
+
+Serum	B-COMP
+retinol	B-CHED
+concentrations	O
+were	O
+evaluated	O
+in	O
+blood	B-ANAT
+samples	I-ANAT
+obtained	O
+throughout	O
+the	O
+study	O
+.	O
+
+A	O
+low	O
+vitamin	B-CHED
+A	I-CHED
+diet	O
+compromised	O
+the	O
+serum	B-PRGE
+IgG1	B-COMP
+responses	O
+against	O
+inactivated	O
+BCoV	O
+vaccine	O
+,	O
+which	O
+suggested	O
+suppressed	O
+T	O
+-	O
+helper	O
+2	O
+-	O
+associated	O
+antibody	B-COMP
+(	O
+IgG1	B-COMP
+)	O
+responses	O
+.	O
+
+In	O
+July	O
+2013	O
+,	O
+the	O
+World	O
+Health	O
+Organization	O
+(	O
+WHO	O
+)	O
+International	O
+Health	O
+Regulations	O
+Emergency	B-DISO
+Committee	O
+determined	O
+that	O
+MERS	O
+-	O
+CoV	O
+did	O
+not	O
+meet	O
+criteria	O
+for	O
+a	O
+""""	O
+public	O
+health	O
+emergency	B-DISO
+of	O
+international	O
+concern	O
+","""	O
+but	O
+was	O
+nevertheless	O
+of	O
+""""	O
+serious	O
+and	O
+great	O
+concern	O
+"""."	O
+
+This	O
+report	O
+summarizes	O
+epidemiologic	O
+information	O
+and	O
+provides	O
+updates	O
+to	O
+CDC	O
+guidance	O
+about	O
+patient	O
+evaluation	O
+,	O
+case	O
+definitions	O
+,	O
+travel	O
+,	O
+and	O
+infection	B-DISO
+control	O
+as	O
+of	O
+September	O
+20	O
+,	O
+2013	O
+.	O
+
+The	O
+humanized	O
+anti	B-PRGE
+-	I-PRGE
+CD26	I-PRGE
+MAb	I-PRGE
+YS110	I-PRGE
+also	O
+significantly	O
+inhibited	O
+infection	B-DISO
+.	O
+
+These	O
+findings	O
+indicate	O
+that	O
+both	O
+2F9	O
+and	O
+YS110	O
+are	O
+potential	O
+therapeutic	O
+agents	O
+for	O
+MERS	O
+-	O
+CoV	O
+infection	B-DISO
+.	O
+
+TITLE	O
+:	O
+Structure	O
+of	O
+the	O
+fusion	O
+core	O
+and	O
+inhibition	B-PROC
+of	O
+fusion	O
+by	O
+a	O
+heptad	O
+repeat	O
+peptide	B-CHED
+derived	O
+from	O
+the	O
+S	O
+protein	O
+of	O
+Middle	O
+East	O
+respiratory	O
+syndrome	B-DISO
+coronavirus	B-SPEC
+.	O
+
+One	O
+of	O
+these	O
+trimers	O
+was	O
+successfully	O
+crystallized	O
+,	O
+and	O
+its	O
+structure	O
+was	O
+solved	O
+at	O
+a	O
+resolution	O
+of	O
+1	O
+.	O
+9	O
+Å	O
+.	O
+A	O
+canonical	O
+6	O
+-	O
+helix	O
+bundle	O
+,	O
+like	O
+those	O
+reported	O
+for	O
+other	O
+coronaviruses	O
+,	O
+was	O
+revealed	O
+,	O
+with	O
+three	O
+HR1	O
+helices	B-SPEC
+forming	O
+the	O
+central	O
+coiled	O
+-	O
+coil	O
+core	O
+and	O
+three	O
+HR2	O
+chains	O
+surrounding	O
+the	O
+core	O
+in	O
+the	O
+HR1	O
+side	O
+grooves	B-ANAT
+.	O
+
+The	O
+mortality	O
+was	O
+higher	O
+among	O
+patients	O
+who	O
+had	O
+an	O
+accompanying	O
+malignancy	B-DISO
+or	O
+immune	B-DISO
+deficiency	I-DISO
+(	O
+72	O
+.	O
+2	O
+%).	O
+
+Among	O
+the	O
+124	O
+influenza	B-DISO
+-	I-DISO
+like	I-DISO
+illness	I-DISO
+cases	O
+,	O
+~	O
+50	O
+%	O
+(	O
+58	O
+)	O
+were	O
+positive	O
+for	O
+influenza	B-SPEC
+A	I-SPEC
+virus	I-SPEC
+in	O
+WHO	O
+-	O
+CDC	O
+molecular	O
+assay	O
+,	O
+including	O
+subtyping	O
+.	O
+
+HA1	B-COMP
+region	O
+characterization	O
+showed	O
+an	O
+overall	O
+protein	B-CHED
+identity	O
+of	O
+98	O
+.	O
+5	O
+-	O
+99	O
+.	O
+4	O
+%.	O
+
+TITLE	O
+:	O
+A	O
+rare	O
+cause	O
+of	O
+dyspnea	B-DISO
+in	O
+emergency	B-DISO
+medicine	B-CHED
+:	O
+transfusion	B-DISO
+-	I-DISO
+related	I-DISO
+acute	I-DISO
+lung	I-DISO
+injury	I-DISO
+.	O
+
+She	O
+was	O
+managed	O
+as	O
+TRALI	B-DISO
+after	O
+diagnostic	O
+workup	O
+and	O
+transported	O
+to	O
+the	O
+intensive	O
+care	O
+unit	O
+.	O
+
+Blood	B-ANAT
+was	O
+analyzed	O
+for	O
+glucose	B-CHED
+and	O
+insulin	B-PRGE
+levels	O
+.	O
+
+Pneumonia	B-DISO
+in	O
+patients	O
+on	O
+the	O
+mechanical	O
+ventilation	O
+(	O
+L	O
+:	O
+21	O
+%,	O
+H	O
+:	O
+32	O
+%)	O
+and	O
+off	O
+mechanical	O
+ventilation	O
+(	O
+L	O
+:	O
+5	O
+%,	O
+H	O
+:	O
+15	O
+%),	O
+as	O
+well	O
+as	O
+ARDS	B-DISO
+were	O
+significantly	O
+higher	O
+in	O
+the	O
+high	O
+group	O
+(	O
+L	O
+:	O
+3	O
+%,	O
+H	O
+:	O
+19	O
+%),	O
+p	O
+<	O
+0	O
+.	O
+05	O
+,	O
+while	O
+atelectasis	B-DISO
+was	O
+not	O
+different	O
+.	O
+
+Upon	O
+enrollment	O
+and	O
+exit	O
+,	O
+calves	O
+were	O
+weighed	O
+,	O
+and	O
+blood	O
+,	O
+feces	B-ANAT
+,	O
+and	O
+liver	B-ANAT
+biopsies	O
+were	O
+collected	O
+for	O
+trace	O
+mineral	B-CHED
+analysis	O
+.	O
+
+Although	O
+statistically	O
+non	O
+-	O
+significant	O
+,	O
+there	O
+were	O
+clinically	O
+important	O
+findings	O
+identified	O
+for	O
+each	O
+of	O
+zinc	B-PRGE
+Met	B-CHED
+and	I-PRGE
+ZO	I-PRGE
+treatments	O
+.	O
+
+at	O
+enrollment	O
+and	O
+treated	O
+with	O
+zinc	B-CHED
+Met	B-CHED
+had	O
+higher	O
+odds	O
+of	O
+testing	O
+negative	O
+at	O
+exit	O
+compared	O
+to	O
+placebo	O
+calves	O
+(	O
+Odds	O
+Ratio	O
+(	O
+OR	O
+)=	O
+16	O
+.	O
+0	O
+).	O
+
+Among	O
+the	O
+eight	O
+cytokine	O
+genes	O
+,	O
+IL	O
+-	O
+1β	O
+,	O
+IL	B-FUNC
+-	I-FUNC
+6	I-FUNC
+and	O
+IL	B-FUNC
+-	I-FUNC
+8	I-FUNC
+induced	O
+by	O
+MERS	O
+-	O
+CoV	O
+were	O
+markedly	O
+higher	O
+than	O
+those	O
+induced	O
+by	O
+SARS	B-DISO
+-	O
+CoV	O
+at	O
+30	O
+h	O
+,	O
+whilst	O
+TNF	B-PRGE
+-	I-PRGE
+α	I-PRGE
+,	O
+IFN	B-PRGE
+-	I-PRGE
+β	I-PRGE
+and	O
+IP	B-PRGE
+-	I-PRGE
+10	I-PRGE
+induced	O
+by	O
+SARS	B-PRGE
+-	I-PRGE
+CoV	I-PRGE
+were	O
+markedly	O
+higher	O
+than	O
+those	O
+induced	O
+by	O
+MERS	O
+-	O
+CoV	O
+at	O
+24	O
+and	O
+30	O
+h	O
+in	O
+infected	O
+Calu	O
+-	O
+3	O
+cells	B-COMP
+.	O
+
+TITLE	O
+:	O
+Discovery	O
+of	O
+N	O
+-(	O
+benzo	O
+[	O
+1	O
+,	O
+2	O
+,	O
+3	O
+]	O
+triazol	O
+-	O
+1	O
+-	O
+yl	O
+)-	O
+N	O
+-(	O
+benzyl	B-CHED
+)	O
+acetamido	B-CHED
+)	O
+phenyl	B-CHED
+)	O
+carboxamides	B-CHED
+as	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+coronavirus	B-SPEC
+(	O
+SARS	B-DISO
+-	O
+CoV	O
+)	O
+3CLpro	O
+inhibitors	B-CHED
+:	O
+identification	O
+of	O
+ML300	O
+and	O
+noncovalent	O
+nanomolar	O
+inhibitors	B-CHED
+with	O
+an	O
+induced	O
+-	O
+fit	B-DISO
+binding	B-FUNC
+.	O
+
+ABSTRACT	O
+:	O
+Herein	O
+we	O
+report	O
+the	O
+discovery	O
+and	O
+SAR	B-CHED
+of	O
+a	O
+novel	O
+series	O
+of	O
+SARS	B-PRGE
+-	I-PRGE
+CoV	I-PRGE
+3CLpro	I-PRGE
+inhibitors	B-CHED
+identified	O
+through	O
+the	O
+NIH	O
+Molecular	O
+Libraries	O
+Probe	O
+Production	O
+Centers	O
+Network	O
+(	O
+MLPCN	O
+).	O
+
+ABSTRACT	O
+:	O
+A	O
+12	O
+-	O
+year	O
+-	O
+old	O
+,	O
+3	O
+.	O
+5	O
+-	O
+kg	O
+spayed	O
+female	O
+domestic	O
+shorthair	O
+cat	O
+had	O
+a	O
+tracheal	O
+mass	O
+identified	O
+as	O
+malignant	O
+B	B-DISO
+-	I-DISO
+cell	I-DISO
+lymphoma	I-DISO
+.	O
+
+Computed	O
+tomography	O
+imaging	O
+and	O
+arterial	B-ANAT
+blood	I-ANAT
+gas	O
+analysis	O
+supported	O
+a	O
+diagnosis	O
+of	O
+acute	O
+lung	B-ANAT
+injury	O
+.	O
+
+TITLE	O
+:	O
+Different	O
+mechanisms	O
+of	O
+inflammation	B-DISO
+induced	O
+in	O
+virus	B-SPEC
+and	O
+autoimmune	B-DISO
+-	O
+mediated	O
+models	O
+of	O
+multiple	B-DISO
+sclerosis	I-DISO
+in	O
+C57BL6	O
+mice	B-SPEC
+.	O
+
+Phylogenetic	O
+analysis	O
+revealed	O
+that	O
+the	O
+collected	O
+Fujian	O
+strains	O
+were	O
+very	O
+distant	O
+from	O
+the	O
+vaccine	O
+development	B-PROC
+strain	O
+CV777	O
+,	O
+which	O
+might	O
+be	O
+the	O
+reason	O
+why	O
+the	O
+vaccine	O
+was	O
+inefficient	O
+to	O
+control	O
+the	O
+disease	O
+.	O
+
+TITLE	O
+:	O
+Stability	O
+of	O
+Middle	O
+East	O
+respiratory	O
+syndrome	B-DISO
+coronavirus	B-SPEC
+(	O
+MERS	O
+-	O
+CoV	O
+)	O
+under	O
+different	O
+environmental	O
+conditions	O
+.	O
+
+Ninety	O
+-	O
+two	O
+of	O
+467	O
+patients	O
+who	O
+underwent	O
+ECMO	O
+between	O
+2005	O
+and	O
+2009	O
+had	O
+ARDS	B-DISO
+,	O
+and	O
+30	O
+consecutive	O
+adult	O
+patients	O
+of	O
+these	O
+92	O
+patients	O
+with	O
+severe	O
+ARDS	B-DISO
+and	O
+MODS	B-DISO
+were	O
+retrospectively	O
+analyzed	O
+in	O
+this	O
+study	O
+.	O
+
+All	O
+patients	O
+met	B-CHED
+the	O
+inclusion	O
+criteria	O
+of	O
+hemodynamic	B-DISO
+instability	I-DISO
+with	O
+high	O
+catecholamine	B-CHED
+infusion	O
+requirement	O
+and	O
+100	O
+%	O
+oxygen	B-CHED
+demand	O
+in	O
+ventilation	O
+and	O
+ECMO	O
+flow	O
+.	O
+
+TITLE	O
+:	O
+The	O
+evolution	B-PROC
+of	O
+codon	O
+usage	O
+in	O
+structural	O
+and	O
+non	O
+-	O
+structural	O
+viral	O
+genes	O
+:	O
+the	O
+case	O
+of	O
+Avian	B-SPEC
+coronavirus	I-SPEC
+and	O
+its	O
+natural	O
+host	B-COMP
+Gallus	B-SPEC
+gallus	I-SPEC
+.	O
+
+The	O
+spike	O
+gene	O
+showed	O
+only	O
+one	O
+100	O
+%	O
+conserved	O
+amino	B-CHED
+acid	I-CHED
+position	O
+coded	O
+by	O
+an	O
+A	B-SPEC
+.	I-SPEC
+coronavirus	I-SPEC
+preferred	O
+codon	O
+,	O
+a	O
+significantly	O
+low	O
+number	O
+when	O
+compared	O
+to	O
+the	O
+three	O
+other	O
+genes	O
+(	O
+p	O
+<	O
+0	O
+.	O
+0001	O
+).	O
+
+TITLE	O
+:	O
+Inhaled	B-PROC
+nitric	B-CHED
+oxide	I-CHED
+for	O
+the	O
+treatment	O
+of	O
+pulmonary	B-DISO
+arterial	B-ANAT
+hypertension	I-DISO
+.	O
+
+ABSTRACT	O
+:	O
+Following	O
+the	O
+recognition	O
+of	O
+nitric	O
+oxide	O
+(	O
+NO	O
+)	O
+as	O
+the	O
+""""	O
+endothelium	B-CHED
+-	I-CHED
+derived	I-CHED
+relaxing	I-CHED
+factor	I-CHED
+","""	O
+an	O
+explosion	O
+of	O
+laboratory	O
+and	O
+clinical	O
+research	O
+led	O
+to	O
+the	O
+development	B-PROC
+of	O
+inhaled	B-PROC
+NO	O
+as	O
+a	O
+potential	O
+therapy	O
+for	O
+patients	O
+with	O
+pulmonary	B-DISO
+arterial	B-ANAT
+hypertension	I-DISO
+(	O
+PAH	B-DISO
+).	O
+
+TITLE	O
+:	O
+Taking	O
+stock	O
+of	O
+the	O
+first	O
+133	O
+MERS	O
+coronavirus	B-SPEC
+cases	O
+globally	O
+--	O
+Is	O
+the	O
+epidemic	O
+changing	O
+?	O
+
+Men	B-PRGE
+have	O
+a	O
+higher	O
+CFR	O
+(	O
+52	O
+%)	O
+and	O
+are	O
+over	O
+-	O
+represented	O
+among	O
+cases	O
+.	O
+
+TITLE	O
+:	O
+Other	O
+viral	B-DISO
+pneumonias	I-DISO
+:	O
+coronavirus	B-SPEC
+,	O
+respiratory	B-SPEC
+syncytial	I-SPEC
+virus	I-SPEC
+,	O
+adenovirus	B-DISO
+,	O
+hantavirus	B-SPEC
+.	O
+
+TITLE	O
+:	O
+Broad	O
+-	O
+spectrum	O
+antivirals	B-CHED
+for	O
+the	O
+emerging	O
+Middle	O
+East	O
+respiratory	O
+syndrome	B-DISO
+coronavirus	B-SPEC
+.	O
+
+Only	O
+mycophenolic	B-CHED
+acid	I-CHED
+exhibited	O
+low	O
+EC50	O
+and	O
+high	O
+selectivity	O
+index	O
+.	O
+
+Additionally	O
+,	O
+ribavirin	B-CHED
+and	O
+interferons	O
+also	O
+exhibited	O
+in	O
+-	O
+vitro	O
+anti	O
+-	O
+MERS	O
+-	O
+CoV	O
+activity	O
+.	O
+
+The	O
+incidence	O
+,	O
+clinical	O
+presentation	O
+and	O
+outcome	O
+of	O
+symptomatic	O
+and	O
+asymptomatic	O
+VRTI	O
+in	O
+HSCT	O
+outpatient	O
+unit	O
+were	O
+prospectively	O
+evaluated	O
+during	O
+a	O
+single	O
+influenza	B-DISO
+season	O
+(	O
+January	O
+-	O
+March	O
+2011	O
+).	O
+
+After	O
+highly	O
+active	O
+antiretroviral	O
+treatment	O
+(	O
+HAART	O
+)	O
+was	O
+introduced	O
+at	O
+the	O
+age	O
+of	O
+35	O
+years	O
+old	O
+,	O
+serum	B-COMP
+level	O
+of	O
+human	B-DISO
+immunodeficiency	I-DISO
+virus	I-DISO
+(	O
+HIV	B-DISO
+)	O
+was	O
+not	O
+detected	O
+,	O
+but	O
+the	O
+number	O
+of	O
+CD4	B-PRGE
++	I-PRGE
+T	B-ANAT
+cells	I-ANAT
+was	O
+still	O
+less	O
+than	O
+200	O
+/	O
+μl	O
+.	O
+
+We	O
+speculated	O
+that	O
+VZV	B-SPEC
+vasculopathy	O
+caused	O
+by	O
+VZV	B-SPEC
+reactivation	O
+in	O
+CNS	B-CHED
+was	O
+involved	O
+in	O
+the	O
+pathomechanism	O
+of	O
+cerebral	B-DISO
+infarction	I-DISO
+rather	O
+than	O
+HIV	B-DISO
+vasculopathy	O
+in	O
+the	O
+case	O
+.	O
+
+Exacerbation	O
+of	O
+both	O
+COPD	B-DISO
+and	O
+asthma	B-PATH
+,	O
+which	O
+are	O
+basically	O
+defined	O
+and	O
+diagnosed	O
+by	O
+clinical	O
+symptoms	O
+,	O
+is	O
+associated	O
+with	O
+a	O
+rapid	O
+decline	O
+in	O
+lung	B-PROC
+function	I-PROC
+and	O
+increased	O
+mortality	O
+.	O
+
+Thus	O
+,	O
+whether	O
+MERS	O
+-	O
+CoV	O
+enters	O
+cells	B-COMP
+within	O
+endosomes	O
+or	O
+at	O
+the	O
+plasma	B-COMP
+membrane	I-COMP
+depends	O
+upon	O
+the	O
+host	O
+cell	B-COMP
+type	I-COMP
+and	O
+tissue	B-ANAT
+,	O
+and	O
+is	O
+determined	O
+by	O
+the	O
+location	O
+of	O
+host	B-COMP
+proteases	O
+that	O
+cleave	O
+the	O
+viral	B-PRGE
+spike	I-PRGE
+glycoprotein	I-PRGE
+and	O
+activate	O
+membrane	B-PROC
+fusion	I-PROC
+.	O
+
+TITLE	O
+:	O
+Viral	O
+etiology	O
+of	O
+influenza	B-DISO
+-	O
+like	O
+illnesses	O
+during	O
+the	O
+influenza	B-DISO
+season	O
+between	O
+December	O
+2011	O
+and	O
+April	O
+2012	O
+.	O
+
+Although	O
+AEP	O
+was	O
+self	O
+-	O
+limiting	O
+,	O
+consecutively	O
+experienced	O
+recurrent	O
+respiratory	B-DISO
+infections	I-DISO
+,	O
+severe	O
+atopic	B-DISO
+dermatitis	I-DISO
+,	O
+and	O
+vulnerability	O
+to	O
+viral	B-DISO
+infections	I-DISO
+,	O
+prompted	O
+us	O
+to	O
+evaluate	O
+the	O
+possibility	O
+of	O
+DOCK8	B-PRGE
+deficiency	O
+.	O
+
+Investigation	O
+of	O
+genomic	O
+DNA	O
+by	O
+multiplex	O
+ligation	O
+-	O
+dependent	O
+probe	O
+amplification	B-DISO
+(	O
+MLPA	O
+)	O
+revealed	O
+a	O
+heterozygous	O
+large	O
+deletion	O
+of	O
+77	O
+kb	O
+spanning	O
+from	O
+intron	O
+5	O
+to	O
+exon	O
+22	O
+.	O
+
+TITLE	O
+:	O
+Development	B-PROC
+of	O
+an	O
+infection	B-DISO
+screening	O
+system	O
+for	O
+entry	O
+inspection	O
+at	O
+airport	O
+quarantine	O
+stations	O
+using	O
+ear	O
+temperature	O
+,	O
+heart	B-ANAT
+and	O
+respiration	B-PROC
+rates	O
+.	O
+
+This	O
+work	O
+suggests	O
+that	O
+5E12	O
+would	O
+be	O
+a	O
+useful	O
+tool	O
+as	O
+a	O
+specific	O
+diagnostic	O
+reagent	B-CHED
+for	O
+detecting	O
+PEDV	B-PRGE
+S	I-PRGE
+protein	B-CHED
+.	O
+
+Children	O
+with	O
+multiple	O
+viral	O
+findings	O
+in	O
+their	O
+respiratory	O
+secretions	B-ANAT
+were	O
+older	O
+than	O
+those	O
+with	O
+a	O
+single	O
+detected	O
+virus	O
+.	O
+
+No	O
+differences	O
+were	O
+found	O
+regarding	O
+duration	O
+of	O
+hospitalisation	O
+,	O
+oxygen	B-CHED
+treatment	O
+or	O
+admittance	O
+to	O
+the	O
+intensive	O
+care	O
+unit	O
+.	O
+
+Faeces	B-ANAT
+were	O
+non	O
+-	O
+haemorrhagic	O
+.	O
+
+Macroscopically	O
+,	O
+the	O
+diarrhoeic	O
+piglets	O
+were	O
+characterized	O
+by	O
+filled	O
+stomachs	B-ANAT
+and	O
+flaccid	O
+intestines	B-ANAT
+without	O
+mucosal	B-ANAT
+changes	O
+.	O
+
+Based	O
+on	O
+the	O
+findings	O
+in	O
+the	O
+four	O
+herds	O
+the	O
+following	O
+case	O
+-	O
+definition	O
+of	O
+NNPDS	O
+was	O
+suggested	O
+:	O
+Non	O
+-	O
+haemorrhagic	B-DISO
+diarrhoea	I-DISO
+during	O
+the	O
+first	O
+week	O
+of	O
+life	O
+,	O
+without	O
+detection	O
+of	O
+known	O
+infectious	B-DISO
+pathogens	O
+,	O
+characterized	O
+by	O
+milk	O
+-	O
+filled	O
+stomachs	B-ANAT
+and	O
+flaccid	O
+intestines	B-ANAT
+at	O
+necropsy	O
+.	O
+
+Results	O
+revealed	O
+that	O
+the	O
+most	O
+important	O
+characteristics	O
+of	O
+health	O
+/	O
+medical	O
+institutions	O
+spokespersons	O
+are	O
+professional	O
+competence	O
+and	O
+good	O
+interaction	O
+with	O
+the	O
+media	B-ANAT
+.	O
+
+From	O
+2003	O
+to	O
+2009	O
+,	O
+we	O
+collected	O
+88	O
+faecal	B-ANAT
+samples	O
+from	O
+healthy	O
+cats	B-SPEC
+and	O
+11	O
+ascitic	B-ANAT
+fluids	I-ANAT
+from	O
+FIP	B-DISO
+cats	B-SPEC
+.	O
+
+Six	O
+divergent	O
+strains	O
+were	O
+identified	O
+with	O
+the	O
+N	B-PRGE
+gene	I-PRGE
+clustering	O
+with	O
+CCoV	O
+-	O
+I	O
+whereas	O
+the	O
+3	O
+'	O
+end	O
+of	O
+S	O
+was	O
+related	O
+to	O
+FCoV	O
+-	O
+I	O
+.	O
+Further	O
+analysis	O
+on	O
+those	O
+six	O
+samples	O
+was	O
+attempted	O
+by	O
+researching	O
+the	O
+presence	O
+of	O
+the	O
+ORF3	O
+gene	O
+,	O
+the	O
+latter	O
+being	O
+peculiar	O
+to	O
+CCoV	O
+-	O
+I	O
+to	O
+date	O
+.	O
+
+ABSTRACT	O
+:	O
+The	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+(	O
+SARS	B-DISO
+)	O
+pandemic	O
+revealed	O
+that	O
+zoonotic	O
+transmission	O
+of	O
+animal	B-SPEC
+coronaviruses	O
+(	O
+CoV	O
+)	O
+to	O
+humans	B-SPEC
+poses	O
+a	O
+significant	O
+threat	O
+to	O
+public	O
+health	O
+and	O
+warrants	O
+surveillance	O
+and	O
+the	O
+development	B-PROC
+of	O
+countermeasures	O
+.	O
+
+Nasopharyngeal	B-ANAT
+wash	O
+specimens	O
+were	O
+prospectively	O
+collected	O
+from	O
+60	O
+children	O
+with	O
+sickle	B-DISO
+cell	I-DISO
+disease	I-DISO
+and	O
+acute	O
+respiratory	O
+illness	O
+,	O
+over	O
+a	O
+1	O
+-	O
+year	O
+period	O
+.	O
+
+A	O
+respiratory	O
+virus	B-SPEC
+was	O
+detected	O
+in	O
+47	O
+(	O
+78	O
+%)	O
+patients	O
+.	O
+
+RESULTS	O
+:	O
+A	O
+respiratory	O
+virus	B-SPEC
+was	O
+detected	O
+in	O
+47	O
+(	O
+78	O
+%)	O
+patients	O
+.	O
+
+ABSTRACT	O
+:	O
+A	O
+class	O
+of	O
+tripeptidyl	O
+transition	B-DISO
+state	O
+inhibitors	B-CHED
+containing	O
+a	O
+P1	O
+glutamine	B-CHED
+surrogate	O
+,	O
+a	O
+P2	O
+leucine	B-CHED
+,	O
+and	O
+a	O
+P3	O
+arylalanines	O
+,	O
+was	O
+found	O
+to	O
+potently	O
+inhibit	O
+Norwalk	B-SPEC
+virus	I-SPEC
+replication	O
+in	O
+enzyme	O
+and	O
+cell	B-COMP
+based	O
+assays	O
+.	O
+
+An	O
+array	O
+of	O
+warheads	O
+,	O
+including	O
+aldehyde	B-CHED
+,	O
+α	O
+-	O
+ketoamide	O
+,	O
+bisulfite	B-CHED
+adduct	O
+,	O
+and	O
+α	O
+-	O
+hydroxyphosphonate	O
+transition	B-DISO
+state	O
+mimic	O
+,	O
+was	O
+also	O
+investigated	O
+.	O
+
+TITLE	O
+:	O
+The	O
+Rivalta	O
+'	O
+s	O
+test	O
+as	O
+a	O
+diagnostic	O
+variable	O
+in	O
+feline	B-SPEC
+effusions	B-DISO
+--	O
+evaluation	O
+of	O
+optimum	O
+reaction	O
+and	O
+storage	O
+conditions	O
+.	O
+
+ECMO	O
+support	O
+allowed	O
+adequate	O
+oxygenation	B-PROC
+and	O
+correction	O
+of	O
+hypercapnia	B-DISO
+under	O
+lung	B-ANAT
+protective	O
+ventilation	O
+,	O
+therefore	O
+reducing	O
+ventilator	O
+-	O
+induced	O
+lung	B-ANAT
+injury	O
+.	O
+
+TITLE	O
+:	O
+Sex	O
+and	O
+inflammation	B-DISO
+in	O
+respiratory	B-DISO
+diseases	I-DISO
+:	O
+a	O
+clinical	O
+viewpoint	O
+.	O
+
+Given	O
+that	O
+estrogens	B-CHED
+or	O
+androgens	B-CHED
+are	O
+known	O
+to	O
+modulate	O
+inflammation	B-DISO
+,	O
+their	O
+different	O
+levels	O
+in	O
+males	O
+and	O
+females	O
+cannot	O
+account	O
+for	O
+the	O
+sexual	B-PROC
+dimorphism	I-PROC
+observed	O
+in	O
+humans	B-SPEC
+and	O
+animals	B-SPEC
+from	O
+birth	B-PROC
+to	O
+death	B-PROC
+with	O
+regard	O
+to	O
+inflammation	B-DISO
+.	O
+
+Moreover	O
+,	O
+10	O
+%	O
+to	O
+15	O
+%	O
+of	O
+the	O
+genes	O
+from	O
+silenced	O
+X	B-COMP
+chromosome	I-COMP
+may	O
+escape	O
+inhibition	B-PROC
+.	O
+
+High	O
+IL	B-FUNC
+-	I-FUNC
+6	I-FUNC
+levels	O
+in	O
+males	O
+correlated	O
+with	O
+poorer	O
+prognosis	O
+and	O
+shorter	O
+longevity	O
+.	O
+
+In	O
+the	O
+cytoplasm	B-COMP
+of	O
+the	O
+infected	O
+cell	B-COMP
+,	O
+recognition	O
+of	O
+the	O
+presence	O
+of	O
+viral	O
+dsRNA	B-CHED
+as	O
+a	O
+signature	O
+of	O
+""""	O
+non	O
+-	O
+self	O
+""""	O
+nucleic	B-CHED
+acid	I-CHED
+is	O
+carried	O
+out	O
+by	O
+RIG	B-PRGE
+-	I-PRGE
+I	I-PRGE
+-	I-PRGE
+like	I-PRGE
+receptors	I-PRGE
+(	O
+RLRs	O
+),	O
+a	O
+set	O
+of	O
+dedicated	O
+helicases	B-PRGE
+whose	O
+activation	O
+leads	O
+to	O
+the	O
+production	O
+of	O
+type	B-PRGE
+I	I-PRGE
+interferon	I-PRGE
+α	I-PRGE
+/	O
+β	O
+(	O
+IFN	B-PRGE
+-	I-PRGE
+α	I-PRGE
+/	I-PRGE
+β	I-PRGE
+).	O
+
+To	O
+overcome	O
+the	O
+innate	O
+antiviral	B-PROC
+response	I-PROC
+,	O
+RNA	O
+viruses	B-SPEC
+encode	O
+suppressors	O
+of	O
+IFN	B-PRGE
+-	I-PRGE
+α	I-PRGE
+/	I-PRGE
+β	I-PRGE
+induction	O
+,	O
+which	O
+block	O
+RLRs	O
+recognition	O
+of	O
+dsRNA	B-CHED
+by	O
+means	O
+of	O
+different	O
+mechanisms	O
+that	O
+can	O
+be	O
+categorized	O
+into	O
+:	O
+(	O
+i	O
+)	O
+dsRNA	B-FUNC
+binding	I-FUNC
+and	O
+/	O
+or	O
+shielding	O
+"("""	O
+hide	B-ANAT
+"""),"	O
+(	O
+ii	O
+)	O
+dsRNA	B-CHED
+termini	O
+processing	O
+"("""	O
+mask	O
+""")"	O
+and	O
+(	O
+iii	O
+)	O
+direct	O
+interaction	O
+with	O
+components	O
+of	O
+the	O
+RLRs	O
+pathway	B-PROC
+"("""	O
+hit	O
+""")."	O
+
+Genetic	O
+and	O
+phylogenetic	O
+analyses	O
+of	O
+the	O
+three	O
+U	O
+.	O
+S	O
+.	O
+strains	O
+revealed	O
+a	O
+close	O
+relationship	O
+with	O
+Chinese	O
+PEDV	B-SPEC
+strains	O
+and	O
+their	O
+likely	O
+Chinese	O
+origin	O
+.	O
+
+The	O
+three	O
+emergent	O
+U	O
+.	O
+S	O
+.	O
+strains	O
+are	O
+most	O
+closely	O
+related	O
+to	O
+a	O
+strain	O
+isolated	O
+in	O
+2012	O
+from	O
+Anhui	O
+Province	O
+in	O
+China	O
+,	O
+which	O
+might	O
+be	O
+the	O
+result	O
+of	O
+multiple	O
+recombination	O
+events	O
+between	O
+different	O
+genetic	O
+lineages	O
+or	O
+sublineages	O
+of	O
+PEDV	B-SPEC
+.	O
+
+The	O
+data	O
+from	O
+this	O
+study	O
+have	O
+important	O
+implications	O
+for	O
+understanding	O
+the	O
+ongoing	O
+PEDV	B-SPEC
+outbreaks	O
+in	O
+the	O
+United	O
+States	O
+and	O
+will	O
+guide	O
+future	O
+efforts	O
+to	O
+develop	O
+effective	O
+preventive	O
+and	O
+control	O
+measures	O
+against	O
+PEDV	B-SPEC
+.	O
+
+Since	O
+its	O
+recognition	O
+in	O
+May	O
+2013	O
+,	O
+PEDV	B-SPEC
+has	O
+rapidly	O
+spread	O
+across	O
+the	O
+United	O
+States	O
+,	O
+resulting	O
+in	O
+high	O
+mortality	O
+in	O
+piglets	O
+in	O
+more	O
+than	O
+17	O
+States	O
+now	O
+.	O
+
+ABSTRACT	O
+:	O
+Despite	O
+environmental	O
+,	O
+social	O
+and	O
+ecological	O
+dependencies	O
+,	O
+emergence	O
+of	O
+zoonotic	O
+viruses	B-SPEC
+in	O
+human	B-SPEC
+populations	O
+is	O
+clearly	O
+also	O
+affected	O
+by	O
+genetic	O
+factors	O
+which	O
+determine	O
+cross	O
+-	O
+species	B-SPEC
+transmission	O
+potential	O
+.	O
+
+There	O
+were	O
+209	O
+samples	O
+(	O
+59	O
+.	O
+9	O
+%)	O
+of	O
+the	O
+349	O
+NPA	B-CHED
+specimens	O
+were	O
+positive	O
+for	O
+viruses	B-SPEC
+,	O
+which	O
+included	O
+117	O
+cases	O
+positive	O
+for	O
+human	B-SPEC
+rhinovirus	I-SPEC
+(	O
+HRV	O
+),	O
+60	O
+for	O
+respiratory	O
+syncytial	O
+virus	O
+(	O
+RSV	B-SPEC
+),	O
+20	O
+for	O
+influenza	B-SPEC
+virus	I-SPEC
+A	O
+(	O
+Inf	O
+A	O
+),	O
+10	O
+for	O
+adenovirus	B-DISO
+(	O
+ADV	O
+),	O
+6	O
+for	O
+parainfluenza	B-SPEC
+virus	I-SPEC
+type	I-SPEC
+3	I-SPEC
+(	O
+PIV	O
+-	O
+3	O
+),	O
+6	O
+for	O
+human	B-SPEC
+Boca	B-DISO
+virus	B-SPEC
+(	O
+HBoV	O
+),	O
+5	O
+for	O
+influenza	B-SPEC
+virus	I-SPEC
+C	O
+(	O
+Inf	O
+C	O
+),	O
+4	O
+for	O
+parainfluenza	B-SPEC
+virus	I-SPEC
+type	I-SPEC
+4	I-SPEC
+(	O
+PIV	O
+-	O
+4	O
+),	O
+4	O
+for	O
+human	B-SPEC
+coronavirus	I-SPEC
+-	O
+HKU1	O
+/	O
+OC43	O
+,	O
+3	O
+for	O
+influenza	B-SPEC
+virus	I-SPEC
+B	O
+(	O
+Inf	O
+B	O
+),	O
+3	O
+for	O
+WU	B-SPEC
+Polyomavirus	I-SPEC
+(	O
+WUPyV	O
+),	O
+2	O
+parainfluenza	B-SPEC
+virus	I-SPEC
+type	I-SPEC
+1	I-SPEC
+(	O
+PIV	O
+-	O
+1	O
+),	O
+2	O
+human	B-SPEC
+metapneumovirus	I-SPEC
+(	O
+HMPV	B-SPEC
+)	O
+and	O
+1	O
+human	B-SPEC
+coronavirus	I-SPEC
+-	O
+NL63	O
+/	O
+229E	O
+.	O
+
+The	O
+numbers	O
+of	O
+none	O
+serious	O
+cases	O
+in	O
+the	O
+virus	B-SPEC
+positive	O
+group	O
+were	O
+less	O
+than	O
+those	O
+in	O
+the	O
+virus	B-SPEC
+negative	O
+group	O
+while	O
+the	O
+numbers	O
+of	O
+extremely	O
+serious	O
+cases	O
+in	O
+the	O
+virus	B-SPEC
+positive	O
+group	O
+were	O
+higher	O
+than	O
+in	O
+the	O
+virus	B-SPEC
+negative	O
+group	O
+.	O
+
+Viral	O
+pathogen	O
+is	O
+a	O
+major	O
+cause	O
+of	O
+infectious	B-DISO
+disease	I-DISO
+in	O
+pediatric	O
+critical	B-DISO
+illnesses	I-DISO
+and	O
+virus	B-DISO
+infection	I-DISO
+may	O
+lead	O
+to	O
+severe	O
+illness	O
+.	O
+
+As	O
+RNA	O
+viruses	B-SPEC
+may	O
+coevolve	O
+with	O
+their	O
+hosts	B-COMP
+,	O
+we	O
+sought	O
+to	O
+investigate	O
+the	O
+closest	O
+sister	O
+taxon	O
+to	O
+bats	B-SPEC
+,	O
+the	O
+Eulipotyphla	O
+,	O
+and	O
+screened	O
+European	O
+hedgehogs	B-SPEC
+(	O
+Erinaceus	B-SPEC
+europaeus	I-SPEC
+)	O
+from	O
+Germany	O
+for	O
+CoV	O
+by	O
+nested	O
+reverse	B-PRGE
+transcriptase	I-PRGE
+PCR	O
+.	O
+
+A	O
+novel	O
+betacoronavirus	B-SPEC
+species	B-SPEC
+in	O
+a	O
+phylogenetic	O
+sister	O
+relationship	O
+to	O
+MERS	O
+-	O
+CoV	O
+and	O
+clade	B-PRGE
+c	I-PRGE
+bat	I-PRGE
+CoVs	I-PRGE
+was	O
+detected	O
+and	O
+characterized	O
+on	O
+the	O
+whole	O
+-	O
+genome	O
+level	O
+.	O
+
+Thirteen	O
+of	O
+27	O
+(	O
+48	O
+.	O
+2	O
+%)	O
+hedgehog	B-SPEC
+sera	B-COMP
+contained	O
+non	O
+-	O
+neutralizing	O
+antibodies	B-COMP
+against	O
+MERS	O
+-	O
+CoV	O
+.	O
+The	O
+animal	B-SPEC
+origins	O
+of	O
+this	O
+betacoronavirus	B-SPEC
+clade	O
+that	O
+includes	O
+MERS	O
+-	O
+CoV	O
+may	O
+thus	O
+include	O
+both	O
+bat	B-ENZY
+and	O
+nonbat	O
+hosts	B-COMP
+.	O
+
+TITLE	O
+:	O
+Hajj	O
+pilgrims	O
+knowledge	O
+about	O
+Middle	O
+East	O
+respiratory	O
+syndrome	B-DISO
+coronavirus	B-SPEC
+,	O
+August	O
+to	O
+September	O
+2013	O
+.	O
+
+Gasp	B-DISO
+latency	O
+and	O
+the	O
+time	O
+required	O
+for	O
+respiratory	O
+,	O
+HR	O
+,	O
+and	O
+MAP	O
+recovery	O
+following	O
+each	O
+episode	O
+were	O
+determined	O
+.	O
+
+ABSTRACT	O
+:	O
+Broncho	O
+-	O
+pulmonary	O
+dysplasia	B-DISO
+(	O
+BPD	B-DISO
+)	O
+is	O
+a	O
+chronic	O
+pulmonary	B-DISO
+disorder	I-DISO
+that	O
+follows	O
+premature	B-DISO
+birth	I-DISO
+.	O
+
+It	O
+is	O
+preceded	O
+by	O
+respiratory	B-DISO
+distress	I-DISO
+syndrome	I-DISO
+(	O
+RDS	O
+),	O
+characterized	O
+by	O
+acute	B-DISO
+respiratory	I-DISO
+failure	I-DISO
+due	O
+to	O
+deficiency	O
+of	O
+surfactant	B-CHED
+at	O
+birth	B-PROC
+.	O
+
+To	O
+build	O
+up	O
+new	O
+therapeutic	O
+strategies	O
+for	O
+BPD	B-DISO
+babies	O
+,	O
+it	O
+is	O
+necessary	O
+to	O
+understand	O
+the	O
+pathogenic	O
+mechanisms	O
+,	O
+which	O
+are	O
+complicated	O
+by	O
+environmental	O
+risk	O
+factors	O
+and	O
+genetic	O
+predisposition	O
+.	O
+
+The	O
+38	O
+identified	O
+risk	O
+factors	O
+for	O
+IAH	B-FUNC
+and	O
+24	O
+for	O
+ACS	B-FUNC
+could	O
+be	O
+clustered	O
+into	O
+three	O
+themes	O
+and	O
+eight	O
+subthemes	O
+.	O
+
+TITLE	O
+:	O
+Activity	O
+of	O
+and	O
+effect	O
+of	O
+subcutaneous	O
+treatment	O
+with	O
+the	O
+broad	O
+-	O
+spectrum	O
+antiviral	B-CHED
+lectin	B-PRGE
+griffithsin	I-PRGE
+in	O
+two	O
+laboratory	O
+rodent	B-SPEC
+models	O
+.	O
+
+Further	O
+,	O
+we	O
+showed	O
+that	O
+serum	B-COMP
+from	O
+GRFT	O
+-	O
+treated	O
+animals	B-SPEC
+retained	O
+antiviral	B-CHED
+activity	O
+against	O
+HIV	B-SPEC
+-	I-SPEC
+1	I-SPEC
+-	O
+enveloped	O
+pseudoviruses	O
+in	O
+a	O
+cell	B-COMP
+-	O
+based	O
+neutralization	O
+assay	O
+.	O
+
+ABSTRACT	O
+:	O
+Middle	O
+East	O
+respiratory	O
+syndrome	O
+coronavirus	B-SPEC
+MERS	O
+-	O
+CoV	O
+is	O
+a	O
+newly	O
+emerging	O
+respiratory	O
+virus	B-SPEC
+with	O
+a	O
+high	O
+case	O
+fatality	O
+rate	O
+among	O
+identified	O
+cases	O
+.	O
+
+For	O
+some	O
+emerging	O
+pathogens	O
+the	O
+bat	B-ENZY
+origin	O
+has	O
+been	O
+confirmed	O
+(	O
+such	O
+as	O
+lyssaviruses	B-SPEC
+,	O
+henipaviruses	B-SPEC
+,	O
+coronaviruses	O
+),	O
+for	O
+other	O
+it	O
+has	O
+been	O
+suggested	O
+(	O
+filoviruses	O
+).	O
+
+The	O
+RSV	B-SPEC
+and	O
+hMPV	B-SPEC
+epidemics	O
+of	O
+2009	O
+/	O
+2010	O
+erupted	O
+several	O
+weeks	O
+later	O
+than	O
+expected	O
+based	O
+on	O
+data	O
+collected	O
+in	O
+the	O
+PID	B-DISO
+-	O
+ARI	B-CHED
+-	O
+Network	O
+during	O
+the	O
+past	O
+10	O
+years	O
+,	O
+whereas	O
+in	O
+the	O
+2010	O
+/	O
+2011	O
+influenza	B-DISO
+season	O
+they	O
+occurred	O
+as	O
+expected	O
+.	O
+
+Overall	O
+presence	O
+of	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+appeared	O
+to	O
+have	O
+a	O
+limited	O
+impact	O
+on	O
+outcome	O
+.	O
+
+CONCLUSIONS	O
+:	O
+The	O
+prevalence	O
+of	O
+lung	B-ANAT
+injury	O
+is	O
+relatively	O
+low	O
+in	O
+acute	B-DISO
+liver	I-DISO
+failure	I-DISO
+,	O
+where	O
+21	O
+%	O
+fulfilled	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+criteria	O
+.	O
+
+PEDV	B-SPEC
+has	O
+a	O
+high	O
+detection	O
+rate	O
+in	O
+pig	B-SPEC
+herds	O
+in	O
+China	O
+.	O
+
+In	O
+June	O
+2012	O
+,	O
+the	O
+U	O
+.	O
+S	O
+.	O
+Food	O
+and	O
+Drug	O
+Administration	O
+authorized	O
+emergency	O
+use	O
+of	O
+the	O
+rRT	O
+-	O
+PCR	O
+assay	O
+panel	O
+as	O
+an	O
+in	O
+vitro	O
+diagnostic	O
+test	O
+for	O
+MERS	O
+-	O
+CoV	O
+.	O
+A	O
+kit	B-FUNC
+consisting	O
+of	O
+the	O
+three	O
+assay	O
+signatures	O
+and	O
+a	O
+positive	O
+control	O
+was	O
+assembled	O
+and	O
+distributed	O
+to	O
+public	O
+health	O
+laboratories	O
+in	O
+the	O
+United	O
+States	O
+and	O
+internationally	O
+to	O
+support	O
+MERS	O
+-	O
+CoV	O
+surveillance	O
+and	O
+public	O
+health	O
+responses	O
+.	O
+
+CD4	B-PRGE
+⁺	I-PRGE
+and	O
+CD8	B-PRGE
+⁺	I-PRGE
+T	B-ANAT
+cells	I-ANAT
+are	O
+essential	O
+to	O
+control	O
+infectious	B-DISO
+virus	B-SPEC
+but	O
+at	O
+the	O
+cost	O
+of	O
+tissue	B-ANAT
+damage	O
+.	O
+
+A	O
+panel	O
+that	O
+included	O
+11	O
+biomarkers	O
+of	O
+inflammation	B-DISO
+,	O
+fibroblast	B-PROC
+activation	I-PROC
+,	O
+proteolytic	B-PROC
+injury	O
+,	O
+endothelial	B-ANAT
+injury	O
+,	O
+and	O
+lung	B-ANAT
+epithelial	O
+injury	O
+was	O
+measured	O
+in	O
+plasma	B-ANAT
+from	O
+the	O
+morning	O
+of	O
+ICU	O
+day	O
+two	O
+.	O
+
+Using	O
+the	O
+five	O
+best	O
+-	O
+performing	O
+biomarkers	O
+(	O
+surfactant	B-CHED
+protein	B-PRGE
+-	I-PRGE
+D	I-PRGE
+(	O
+SP	B-PRGE
+-	I-PRGE
+D	I-PRGE
+),	O
+receptor	O
+for	O
+advanced	O
+glycation	O
+end	O
+-	O
+products	O
+(	O
+RAGE	O
+),	O
+interleukin	B-PRGE
+-	I-PRGE
+8	I-PRGE
+(	O
+IL	B-FUNC
+-	I-FUNC
+8	I-FUNC
+),	O
+club	B-PRGE
+cell	I-PRGE
+secretory	B-PROC
+protein	B-CHED
+(	O
+CC	O
+-	O
+16	O
+),	O
+and	O
+interleukin	B-PRGE
+-	I-PRGE
+6	I-PRGE
+(	O
+IL	B-FUNC
+-	I-FUNC
+6	I-FUNC
+))	O
+the	O
+area	O
+under	O
+the	O
+receiver	O
+operator	O
+characteristic	O
+curve	O
+(	O
+AUC	O
+)	O
+was	O
+0	O
+.	O
+75	O
+(	O
+95	O
+%	O
+CI	O
+:	O
+0	O
+.	O
+7	O
+to	O
+0	O
+.	O
+84	O
+)	O
+for	O
+the	O
+diagnosis	O
+of	O
+ARDS	B-DISO
+.	O
+
+TITLE	O
+:	O
+Brain	B-ANAT
+-	O
+type	O
+natriuretic	O
+peptide	B-CHED
+and	O
+right	O
+ventricular	B-PROC
+end	I-PROC
+-	I-PROC
+diastolic	I-PROC
+volume	I-PROC
+index	O
+measurements	O
+are	O
+imprecise	O
+estimates	O
+of	O
+circulating	O
+blood	O
+volume	O
+in	O
+critically	B-DISO
+ill	I-DISO
+subjects	O
+.	O
+
+Our	O
+study	O
+aimed	O
+to	O
+investigate	O
+retrospectively	O
+the	O
+presence	O
+of	O
+HCoVs	O
+in	O
+different	O
+populations	O
+of	O
+São	O
+Paulo	O
+presenting	O
+acute	O
+respiratory	B-DISO
+tract	I-DISO
+infections	I-DISO
+(	O
+ARIs	O
+)	O
+during	O
+the	O
+years	O
+of	O
+2001	O
+-	O
+2010	O
+.	O
+
+Perfusion	O
+computed	O
+tomography	O
+allows	O
+early	O
+diagnosis	O
+of	O
+pancreatic	B-DISO
+necrosis	B-PROC
+.	O
+
+Factors	O
+associated	O
+with	O
+greater	O
+fluid	O
+sequestration	O
+in	O
+AP	O
+are	O
+alcoholic	O
+etiology	O
+,	O
+an	O
+elevated	O
+hematocrit	O
+,	O
+and	O
+the	O
+presence	O
+of	O
+criteria	O
+of	O
+systemic	B-DISO
+inflammatory	I-DISO
+response	I-DISO
+syndrome	I-DISO
+;	O
+fluid	O
+sequestration	O
+is	O
+associated	O
+with	O
+a	O
+worse	O
+outcome	O
+.	O
+
+True	O
+pseudocysts	B-DISO
+(	O
+fluid	O
+collections	O
+without	O
+necrosis	B-PROC
+for	O
+more	O
+than	O
+4	O
+weeks	O
+)	O
+are	O
+a	O
+highly	O
+infrequent	O
+complication	B-DISO
+in	O
+AP	O
+.	O
+
+ABSTRACT	O
+:	O
+Pertussis	B-PATH
+is	O
+an	O
+illness	O
+that	O
+causes	O
+significant	O
+morbidity	O
+and	O
+mortality	O
+,	O
+especially	O
+in	O
+infants	O
+younger	O
+than	O
+3	O
+months	O
+old	O
+.	O
+
+Because	O
+bronchiolar	B-ANAT
+obstruction	B-DISO
+from	O
+inflammatory	O
+,	O
+mucous	B-ANAT
+,	O
+and	O
+airway	B-ANAT
+epithelial	O
+debris	O
+can	O
+be	O
+seen	O
+in	O
+severe	O
+pertussis	B-PATH
+,	O
+a	O
+regimen	O
+of	O
+repeated	O
+therapeutic	O
+bronchoscopy	O
+was	O
+initiated	O
+,	O
+and	O
+thick	O
+,	O
+inspissated	O
+secretions	B-ANAT
+were	O
+retrieved	O
+.	O
+
+In	O
+this	O
+study	O
+,	O
+we	O
+conducted	O
+global	O
+gene	B-PROC
+expression	I-PROC
+profiling	O
+of	O
+chicken	B-SPEC
+kidney	B-ANAT
+tissue	B-ANAT
+after	O
+nephropathogenic	O
+IBV	B-SPEC
+infection	B-DISO
+to	O
+better	O
+understand	O
+the	O
+interactions	O
+between	O
+host	B-COMP
+and	O
+virus	B-SPEC
+.	O
+
+IBV	B-SPEC
+infection	B-DISO
+contributed	O
+to	O
+differential	O
+expression	B-PROC
+of	O
+1777	O
+genes	O
+,	O
+of	O
+which	O
+876	O
+were	O
+up	O
+-	O
+regulated	O
+and	O
+901	O
+down	O
+-	O
+regulated	O
+in	O
+the	O
+kidney	B-ANAT
+compared	O
+to	O
+those	O
+of	O
+control	O
+chickens	B-SPEC
+and	O
+103	O
+associated	O
+with	O
+immune	O
+and	O
+inflammatory	B-DISO
+responses	I-DISO
+may	O
+play	O
+important	O
+roles	O
+in	O
+the	O
+host	B-PROC
+defense	B-PROC
+response	I-PROC
+during	O
+IBV	B-SPEC
+infection	B-DISO
+.	O
+
+Data	O
+from	O
+85	O
+consecutive	O
+ARDS	B-DISO
+patients	O
+equipped	O
+with	O
+ECMO	O
+by	O
+our	O
+mobile	O
+team	O
+and	O
+consequently	O
+admitted	O
+to	O
+our	O
+ICU	O
+were	O
+prospectively	O
+collected	O
+and	O
+analyzed	O
+.	O
+
+Age	O
+,	O
+SOFA	O
+score	O
+,	O
+and	O
+a	O
+diagnosis	O
+of	O
+influenza	B-DISO
+may	O
+be	O
+used	O
+to	O
+accurately	O
+evaluate	O
+the	O
+risk	O
+of	O
+death	B-PROC
+in	O
+ARDS	B-DISO
+patients	O
+considered	O
+for	O
+retrieval	O
+under	O
+ECMO	O
+from	O
+distant	O
+hospitals	O
+.	O
+
+Ophtalmoplegia	O
+,	O
+autonomic	B-DISO
+dysfunction	I-DISO
+and	O
+respiratory	B-DISO
+failure	I-DISO
+can	O
+be	O
+caused	O
+by	O
+botulism	O
+.	O
+
+TITLE	O
+:	O
+Prolonged	O
+duration	O
+ECMO	O
+for	O
+ARDS	B-DISO
+:	O
+futility	O
+,	O
+native	O
+lung	B-ANAT
+recovery	O
+,	O
+or	O
+transplantation	O
+?	O
+
+ABSTRACT	O
+:	O
+Extracorporeal	O
+membrane	O
+oxygenation	B-PROC
+(	O
+ECMO	O
+)	O
+is	O
+recommended	O
+as	O
+a	O
+treatment	O
+modality	O
+for	O
+severe	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+(	O
+PaO2	O
+/	O
+FiO2	O
+≤	O
+100	O
+mm	O
+Hg	O
+with	O
+positive	O
+end	B-PROC
+-	I-PROC
+expiratory	I-PROC
+pressure	O
+≥	O
+5	O
+cm	O
+H2O	B-CHED
+)	O
+as	O
+defined	O
+by	O
+the	O
+Berlin	O
+definition	O
+.	O
+
+At	O
+present	O
+,	O
+there	O
+are	O
+no	O
+established	O
+national	O
+criteria	O
+for	O
+when	O
+to	O
+consider	O
+futility	O
+or	O
+lung	B-ANAT
+transplantation	O
+in	O
+adult	O
+patients	O
+requiring	O
+ECMO	O
+for	O
+acute	B-DISO
+respiratory	I-DISO
+failure	I-DISO
+.	O
+
+The	O
+lung	O
+may	O
+have	O
+unexpected	O
+regenerative	O
+capacity	O
+with	O
+native	O
+lung	B-ANAT
+recovery	O
+after	O
+prolonged	O
+mechanical	O
+support	O
+,	O
+similar	O
+to	O
+acute	O
+kidney	B-ANAT
+injury	O
+and	O
+native	O
+renal	B-ANAT
+recovery	O
+.	O
+
+TITLE	O
+:	O
+Clinical	O
+features	O
+of	O
+patients	O
+with	O
+Guillain	O
+-	O
+Barré	O
+syndrome	B-DISO
+at	O
+seven	O
+hospitals	O
+on	O
+the	O
+East	O
+Coast	O
+of	O
+Australia	O
+.	O
+
+In	O
+contrast	O
+to	O
+other	O
+autoimmune	B-DISO
+diseases	I-DISO
+,	O
+males	O
+are	O
+more	O
+frequently	O
+affected	O
+.	O
+
+ABSTRACT	O
+:	O
+The	O
+2002	O
+-	O
+3	O
+pandemic	O
+caused	O
+by	O
+severe	O
+acute	O
+respiratory	O
+syndrome	O
+coronavirus	B-SPEC
+(	O
+SARS	B-DISO
+-	O
+CoV	O
+)	O
+was	O
+one	O
+of	O
+the	O
+most	O
+significant	O
+public	O
+health	O
+events	O
+in	O
+recent	O
+history	O
+.	O
+
+These	O
+results	O
+together	O
+suggest	O
+that	O
+the	O
+uORF	O
+represses	O
+ORF1	O
+translation	B-PROC
+yet	O
+plays	O
+a	O
+beneficial	O
+but	O
+nonessential	O
+role	O
+in	O
+coronavirus	B-SPEC
+replication	O
+in	O
+cell	B-COMP
+culture	O
+.	O
+
+TITLE	O
+:	O
+Architecture	O
+and	O
+biogenesis	B-PROC
+of	O
+plus	O
+-	O
+strand	O
+RNA	O
+virus	B-PROC
+replication	I-PROC
+factories	O
+.	O
+
+ABSTRACT	O
+:	O
+Plus	O
+-	O
+strand	O
+RNA	O
+virus	O
+replication	O
+occurs	O
+in	O
+tight	O
+association	O
+with	O
+cytoplasmic	B-COMP
+host	O
+cell	B-COMP
+membranes	I-COMP
+.	O
+
+Electron	O
+tomography	O
+studies	O
+conducted	O
+during	O
+the	O
+last	O
+couple	O
+of	O
+years	O
+revealed	O
+the	O
+three	O
+dimensional	O
+structure	O
+of	O
+numerous	O
+plus	O
+-	O
+strand	O
+RNA	O
+virus	B-PROC
+replication	I-PROC
+compartments	B-ANAT
+and	O
+highlight	O
+morphological	O
+analogies	O
+between	O
+different	O
+virus	B-SPEC
+families	O
+.	O
+
+Based	O
+on	O
+the	O
+morphology	O
+of	O
+virus	B-SPEC
+-	O
+induced	O
+membrane	B-COMP
+rearrangements	O
+,	O
+we	O
+propose	O
+two	O
+separate	O
+subclasses	O
+:	O
+the	O
+invaginated	B-DISO
+vesicle	B-COMP
+/	O
+spherule	O
+type	O
+and	O
+the	O
+double	O
+membrane	B-COMP
+vesicle	B-COMP
+type	O
+.	O
+
+New	O
+and	O
+emerging	O
+drugs	O
+address	O
+unique	O
+aspects	O
+of	O
+airway	B-ANAT
+inflammation	B-DISO
+and	O
+biology	O
+but	O
+at	O
+a	O
+significant	O
+financial	O
+cost	O
+.	O
+
+There	O
+have	O
+been	O
+case	O
+reports	O
+of	O
+complications	O
+like	O
+thrombocytopaenia	O
+,	O
+cerebral	B-DISO
+malaria	B-PATH
+,	O
+a	O
+disseminated	B-DISO
+intravascular	I-DISO
+coagulation	I-DISO
+,	O
+the	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+,	O
+hepatic	B-DISO
+dysfunction	I-DISO
+and	O
+renal	B-ANAT
+involvement	O
+.	O
+
+Besides	O
+hepatomegaly	B-DISO
+and	O
+splenomegaly	O
+which	O
+were	O
+the	O
+most	O
+common	O
+symptoms	O
+,	O
+which	O
+were	O
+seen	O
+in	O
+81	O
+.	O
+5	O
+%	O
+and	O
+72	O
+.	O
+2	O
+%	O
+children	O
+respectively	O
+,	O
+the	O
+various	O
+unusual	O
+manifestations	O
+seen	O
+were	O
+severe	O
+thrombocytopaenia	O
+(	O
+37	O
+%),	O
+jaundice	B-DISO
+with	O
+deranged	O
+LFT	O
+values	O
+(	O
+25	O
+.	O
+9	O
+%),	O
+abnormal	B-DISO
+bleeding	I-DISO
+(	O
+18	O
+.	O
+5	O
+%),	O
+impaired	B-DISO
+consciousness	I-DISO
+with	O
+a	O
+GCS	O
+of	O
+<	O
+9	O
+(	O
+18	O
+.	O
+5	O
+%),	O
+severe	O
+anaemia	B-DISO
+(	O
+14	O
+.	O
+8	O
+%),	O
+hypotension	O
+(	O
+11	O
+.	O
+1	O
+%),	O
+repeated	O
+convulsions	B-DISO
+(	O
+7	O
+.	O
+6	O
+%),	O
+pulmonary	B-DISO
+oedema	I-DISO
+/	O
+ARDS	B-DISO
+(	O
+5	O
+.	O
+6	O
+%)	O
+and	O
+ascites	O
+(	O
+5	O
+.	O
+6	O
+%).	O
+
+One	O
+of	O
+them	O
+was	O
+successfully	O
+treated	O
+with	O
+no	O
+incident	O
+of	O
+relapse	B-DISO
+within	O
+12	O
+-	O
+month	O
+medical	O
+follow	O
+-	O
+up	O
+.	O
+
+He	O
+succumbed	O
+to	O
+multiple	O
+complications	O
+including	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+and	O
+acute	B-DISO
+renal	I-DISO
+failure	I-DISO
+.	O
+
+TITLE	O
+:	O
+Aquaporin	B-FUNC
+-	I-PRGE
+4	I-PRGE
+antibodies	B-COMP
+,	O
+CNS	B-CHED
+acidosis	B-DISO
+and	O
+neuromyelitis	B-DISO
+optica	I-DISO
+:	O
+a	O
+potential	O
+link	O
+.	O
+
+In	O
+around	O
+80	O
+%	O
+of	O
+cases	O
+,	O
+NMO	B-CHED
+is	O
+caused	O
+by	O
+autoantibodies	O
+to	O
+astrocytic	B-ANAT
+aquaporin	B-PRGE
+-	I-PRGE
+4	I-PRGE
+(	O
+AQP4	B-PRGE
+),	O
+the	O
+most	O
+abundant	O
+water	B-CHED
+channel	O
+in	O
+the	O
+CNS	B-CHED
+.	O
+
+ABSTRACT	O
+:	O
+Should	O
+an	O
+emerging	B-DISO
+infectious	I-DISO
+disease	I-DISO
+outbreak	O
+or	O
+an	O
+environmental	O
+disaster	O
+occur	O
+,	O
+the	O
+collection	O
+of	O
+epidemiological	O
+data	O
+must	O
+start	O
+as	O
+soon	O
+as	O
+possible	O
+after	O
+the	O
+event	O
+'	O
+s	O
+onset	O
+.	O
+
+The	O
+catalogue	O
+of	O
+questions	O
+was	O
+initiated	O
+from	O
+a	O
+review	O
+of	O
+the	O
+KAP	O
+studies	O
+conducted	O
+during	O
+or	O
+after	O
+the	O
+2003	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+epidemic	O
+.	O
+
+This	O
+virus	B-SPEC
+,	O
+termed	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+-	O
+CoV	O
+was	O
+linked	O
+to	O
+a	O
+zoonotic	O
+origin	O
+from	O
+rhinolophid	O
+bats	B-SPEC
+in	O
+2005	O
+.	O
+
+We	O
+next	O
+discuss	O
+preliminary	O
+evidence	O
+for	O
+phylogenetic	O
+co	O
+-	O
+segregation	O
+of	O
+CoVs	O
+and	O
+bat	B-ENZY
+hosts	B-COMP
+encompassing	O
+the	O
+Betacoronavirus	B-SPEC
+clades	O
+b	O
+and	O
+d	O
+,	O
+with	O
+an	O
+emphasis	O
+on	O
+the	O
+sampling	O
+bias	B-SPEC
+that	O
+exists	O
+among	O
+bat	B-ENZY
+species	B-SPEC
+and	O
+other	O
+mammals	B-SPEC
+,	O
+then	O
+present	O
+examples	O
+of	O
+CoVs	O
+infecting	O
+different	O
+hosts	B-COMP
+on	O
+the	O
+one	O
+hand	O
+and	O
+viruses	B-SPEC
+apparently	O
+confined	O
+to	O
+host	B-COMP
+genera	O
+on	O
+the	O
+other	O
+.	O
+
+In	O
+this	O
+paper	O
+,	O
+our	O
+strategy	O
+of	O
+platform	O
+technology	O
+against	O
+various	O
+infectious	B-DISO
+diseases	I-DISO
+are	O
+introduced	O
+.	O
+
+ABSTRACT	O
+:	O
+The	O
+type	B-PRGE
+I	I-PRGE
+IFN	I-PRGE
+-	O
+mediated	O
+immune	B-PROC
+response	I-PROC
+is	O
+the	O
+first	O
+line	O
+of	O
+antiviral	B-CHED
+defence	O
+.	O
+
+Deletion	O
+of	O
+ORF7	O
+from	O
+FIPV	O
+strain	O
+79	O
+-	O
+1146	O
+(	O
+FIPV	O
+-	O
+Δ7	O
+)	O
+rendered	O
+the	O
+virus	B-SPEC
+more	O
+susceptible	O
+to	O
+IFN	B-PRGE
+-	I-PRGE
+α	I-PRGE
+treatment	O
+.	O
+
+TITLE	O
+:	O
+Over	O
+expression	B-PROC
+of	O
+a	O
+synthetic	O
+gene	O
+encoding	O
+interferon	B-PRGE
+lambda	I-PRGE
+using	O
+relative	O
+synonymous	O
+codon	O
+usage	O
+bias	O
+in	O
+Escherichia	B-SPEC
+coli	I-SPEC
+.	O
+
+The	O
+present	O
+study	O
+describes	O
+a	O
+computational	O
+approach	O
+known	O
+as	O
+relative	O
+synonymous	O
+codon	O
+usage	O
+(	O
+RSCU	O
+);	O
+used	O
+to	O
+enhance	O
+the	O
+expression	B-PROC
+of	O
+IFN	B-PRGE
+-	I-PRGE
+λ	I-PRGE
+protein	I-PRGE
+in	O
+a	O
+eukaryotic	O
+expression	B-PROC
+system	O
+.	O
+
+Higher	O
+concentrations	O
+of	O
+IPTG	B-CHED
+had	O
+no	O
+or	O
+negative	O
+effect	O
+on	O
+the	O
+expression	B-PROC
+of	O
+IFN	B-PRGE
+-	I-PRGE
+λ	I-PRGE
+.	O
+
+Patients	O
+were	O
+classified	O
+in	O
+mild	O
+,	O
+moderate	O
+and	O
+severe	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+.	O
+
+When	O
+patients	O
+were	O
+classified	O
+according	O
+to	O
+the	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+Berlin	O
+definition	O
+,	O
+the	O
+lung	B-ANAT
+open	O
+ventilation	O
+method	O
+was	O
+the	O
+only	O
+one	O
+which	O
+gave	O
+lower	O
+positive	O
+end	B-PROC
+-	I-PROC
+expiratory	I-PROC
+pressure	O
+levels	O
+in	O
+mild	O
+and	O
+moderate	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+compared	O
+with	O
+severe	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+(	O
+8	O
+±	O
+2	O
+and	O
+11	O
+±	O
+3	O
+cm	O
+H2O	B-CHED
+vs	O
+15	O
+±	O
+3	O
+cm	O
+H2O	B-CHED
+;	O
+p	O
+<	O
+0	O
+.	O
+05	O
+),	O
+whereas	O
+ExPress	O
+,	O
+stress	O
+index	O
+,	O
+and	O
+esophageal	B-PROC
+pressure	I-PROC
+methods	O
+gave	O
+similar	O
+positive	O
+end	B-PROC
+-	I-PROC
+expiratory	I-PROC
+pressure	O
+values	O
+in	O
+mild	O
+,	O
+moderate	O
+,	O
+and	O
+severe	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+.	O
+
+A	O
+39	O
+-	O
+year	O
+-	O
+old	O
+man	B-CHED
+presented	O
+to	O
+the	O
+emergency	B-DISO
+room	O
+with	O
+nausea	B-DISO
+,	O
+vomiting	B-DISO
+,	O
+and	O
+diarrhea	B-DISO
+9	O
+hours	O
+after	O
+ingestion	O
+of	O
+wild	B-SPEC
+garlic	I-SPEC
+.	O
+
+The	O
+development	B-PROC
+of	O
+a	O
+small	O
+-	O
+animal	B-SPEC
+model	O
+is	O
+critical	O
+for	O
+the	O
+understanding	O
+of	O
+this	O
+virus	B-SPEC
+and	O
+to	O
+aid	O
+in	O
+development	B-PROC
+of	O
+countermeasures	O
+against	O
+MERS	O
+-	O
+CoV	O
+.	O
+We	O
+found	O
+that	O
+BALB	O
+/	O
+c	O
+,	O
+129	O
+/	O
+SvEv	O
+and	O
+129	O
+/	O
+SvEv	O
+STAT1	B-PRGE
+knockout	O
+mice	B-SPEC
+are	O
+not	O
+permissive	O
+to	O
+MERS	O
+-	O
+CoV	O
+infection	B-DISO
+.	O
+
+TITLE	O
+:	O
+Isolation	O
+and	O
+characterization	O
+of	O
+porcine	B-SPEC
+epidemic	B-DISO
+diarrhea	I-DISO
+viruses	B-SPEC
+associated	O
+with	O
+the	O
+2013	O
+disease	O
+outbreak	O
+among	O
+swine	O
+in	O
+the	O
+United	O
+States	O
+.	O
+
+Here	O
+we	O
+describe	O
+two	O
+PEDV	B-SPEC
+isolates	O
+(	O
+ISU13	O
+-	O
+19338E	O
+and	O
+ISU13	O
+-	O
+22038	O
+)	O
+successfully	O
+obtained	O
+from	O
+the	O
+small	B-ANAT
+intestines	I-ANAT
+of	O
+piglets	O
+from	O
+sow	O
+farms	O
+in	O
+Indiana	O
+and	O
+Iowa	O
+,	O
+respectively	O
+.	O
+
+Further	O
+,	O
+infection	B-DISO
+with	O
+SARS	B-DISO
+-	O
+CoV	O
+-	O
+ΔE	O
+resulted	O
+in	O
+decreased	O
+activation	O
+of	O
+NF	O
+-	O
+κB	O
+compared	O
+to	O
+levels	O
+for	O
+the	O
+wild	O
+-	O
+type	O
+virus	B-SPEC
+.	O
+
+Contrasting	O
+the	O
+mild	O
+encephalitis	B-DISO
+and	O
+100	O
+%	O
+survival	O
+of	O
+MHV	B-SPEC
+-	O
+A59	O
+-	O
+infected	O
+wild	O
+-	O
+type	O
+(	O
+wt	O
+)	O
+mice	B-SPEC
+,	O
+nearly	O
+60	O
+%	O
+of	O
+infected	O
+Ifit2	O
+(-/-)	O
+mice	B-SPEC
+exhibited	O
+severe	O
+encephalitis	B-DISO
+and	O
+succumbed	O
+between	O
+6	O
+and	O
+8	O
+days	O
+postinfection	O
+.	O
+
+Massive	O
+blood	B-ANAT
+transfusion	O
+complicated	O
+6	O
+of	O
+every	O
+10	O
+,	O
+000	O
+deliveries	O
+with	O
+cases	O
+observed	O
+even	O
+in	O
+the	O
+smallest	O
+facilities	O
+.	O
+
+RESULTS	O
+:	O
+Massive	O
+blood	B-ANAT
+transfusion	O
+complicated	O
+6	O
+of	O
+every	O
+10	O
+,	O
+000	O
+deliveries	O
+with	O
+cases	O
+observed	O
+even	O
+in	O
+the	O
+smallest	O
+facilities	O
+.	O
+
+In	O
+the	O
+presence	O
+of	O
+known	O
+risk	O
+for	O
+receipt	O
+of	O
+massive	O
+blood	B-ANAT
+transfusion	O
+,	O
+women	O
+should	O
+be	O
+informed	O
+of	O
+this	O
+possibility	O
+,	O
+should	O
+deliver	O
+in	O
+a	O
+well	O
+-	O
+resourced	O
+facility	O
+if	O
+possible	O
+,	O
+and	O
+should	O
+receive	O
+appropriate	O
+blood	B-ANAT
+product	O
+preparation	O
+and	O
+venous	B-ANAT
+access	O
+in	O
+advance	O
+of	O
+delivery	O
+.	O
+
+Bioinformatic	O
+'	O
+s	O
+analysis	O
+,	O
+based	O
+on	O
+Felis	B-SPEC
+catus	I-SPEC
+2X	O
+annotated	O
+shotgun	O
+reference	O
+genome	O
+,	O
+using	O
+CLC	O
+bio	O
+Genome	O
+Workbench	O
+mapped	O
+both	O
+control	O
+and	O
+infected	O
+cell	B-COMP
+reads	O
+to	O
+18899	O
+genes	O
+out	O
+of	O
+19046	O
+annotated	O
+genes	O
+.	O
+
+Most	O
+genes	O
+were	O
+closely	O
+clustered	O
+together	O
+,	O
+suggesting	O
+a	O
+homogeneous	O
+expression	B-PROC
+.	O
+
+TITLE	O
+:	O
+Neurally	O
+adjusted	O
+ventilatory	O
+assist	O
+vs	O
+pressure	O
+support	O
+ventilation	O
+in	O
+infants	O
+recovering	O
+from	O
+severe	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+:	O
+nested	O
+study	O
+.	O
+
+Infants	O
+affected	O
+by	O
+severe	O
+ARDS	B-DISO
+requiring	O
+high	O
+-	O
+frequency	O
+ventilation	O
+and	O
+weaned	B-PROC
+with	O
+NAVA	O
+during	O
+2010	O
+were	O
+included	O
+.	O
+
+Similarly	O
+,	O
+Pao2	B-PRGE
+/	O
+Fio2	O
+ratio	O
+decreased	O
+less	O
+in	O
+NAVA	O
+than	O
+in	O
+PSV	O
+(	O
+P	O
+<	O
+.	O
+001	O
+).	O
+
+ABSTRACT	O
+:	O
+The	O
+influence	O
+of	O
+CD25	B-PRGE
+(+)	I-PRGE
+CD4	I-PRGE
+(+)	I-PRGE
+regulatory	B-ANAT
+T	I-ANAT
+cells	I-ANAT
+(	O
+Treg	O
+)	O
+on	O
+acute	O
+and	O
+chronic	O
+viral	B-DISO
+infection	I-DISO
+of	O
+the	O
+central	B-ANAT
+nervous	I-ANAT
+system	I-ANAT
+(	O
+CNS	B-CHED
+)	O
+was	O
+examined	O
+using	O
+a	O
+glial	B-ANAT
+tropic	O
+murine	B-SPEC
+coronavirus	I-SPEC
+.	O
+
+Treg	O
+in	O
+the	O
+CNS	B-CHED
+were	O
+highest	O
+during	O
+initial	O
+T	B-ANAT
+cell	I-ANAT
+mediated	O
+virus	B-SPEC
+control	O
+,	O
+decreased	O
+and	O
+then	O
+remained	O
+relatively	O
+stable	O
+during	O
+persistence	O
+.	O
+
+However	O
+,	O
+their	O
+absence	O
+during	O
+acute	B-DISO
+infection	I-DISO
+alters	O
+the	O
+ability	O
+of	O
+the	O
+host	B-COMP
+to	O
+limit	O
+tissue	B-ANAT
+damage	O
+.	O
+
+In	O
+this	O
+vein	B-ANAT
+,	O
+we	O
+propose	O
+the	O
+term	O
+""""	O
+critical	O
+asthma	B-PATH
+syndrome	B-DISO
+""""	O
+(	O
+CAS	B-DISO
+)	O
+to	O
+describe	O
+any	O
+child	O
+or	O
+adult	O
+who	O
+is	O
+at	O
+high	O
+risk	O
+for	O
+fatal	O
+asthma	B-PATH
+.	O
+
+CAS	B-DISO
+is	O
+not	O
+severe	B-DISO
+persistent	I-DISO
+asthma	B-PATH
+where	O
+control	O
+of	O
+symptoms	O
+and	O
+prevention	O
+of	O
+exacerbations	O
+are	O
+targets	O
+of	O
+chronic	B-DISO
+disease	I-DISO
+management	O
+in	O
+the	O
+outpatient	O
+setting	O
+.	O
+
+TITLE	O
+:	O
+Ventilatory	O
+strategies	O
+and	O
+supportive	O
+care	O
+in	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+.	O
+
+Patients	O
+usually	O
+receive	O
+high	O
+levels	O
+of	O
+supplemental	O
+oxygen	B-CHED
+to	O
+counteract	O
+the	O
+hypoxemia	O
+resulting	O
+from	O
+severe	O
+gas	B-ENZY
+exchange	O
+abnormalities	O
+.	O
+
+ABSTRACT	O
+:	O
+The	O
+value	O
+of	O
+adjunctive	O
+immunomodulatory	O
+therapies	O
+in	O
+treating	O
+severe	O
+influenza	O
+and	O
+other	O
+respiratory	O
+viral	B-DISO
+infections	I-DISO
+remains	O
+uncertain	O
+.	O
+
+In	O
+-	O
+ICU	O
+mortality	O
+rates	O
+were	O
+13	O
+%	O
+in	O
+non	O
+-	O
+ARDS	B-DISO
+,	O
+and	O
+,	O
+respectively	O
+,	O
+19	O
+%,	O
+32	O
+%	O
+and	O
+32	O
+%	O
+in	O
+mild	O
+,	O
+moderate	O
+and	O
+severe	O
+ARDS	B-DISO
+(	O
+P	O
+=	O
+0	O
+.	O
+22	O
+).	O
+
+With	O
+intubation	O
+rates	O
+below	O
+35	O
+%	O
+in	O
+non	O
+-	O
+ARDS	B-DISO
+and	O
+mild	O
+ARDS	B-DISO
+,	O
+NIV	O
+stands	O
+as	O
+the	O
+first	O
+-	O
+line	O
+approach	O
+;	O
+NIV	O
+may	O
+be	O
+attempted	O
+in	O
+ARDS	B-DISO
+patients	O
+with	O
+a	O
+PaO2	O
+/	O
+FiO2	O
+>	O
+150	O
+.	O
+
+For	O
+17	O
+/	O
+25	O
+samples	O
+,	O
+single	O
+infections	B-DISO
+were	O
+detected	O
+as	O
+follows	O
+:	O
+six	O
+CCoV	O
+-	O
+I	O
+,	O
+nine	B-PRGE
+CCoV	I-PRGE
+-	I-PRGE
+IIa	I-PRGE
+and	O
+two	O
+CCoV	B-PRGE
+-	I-PRGE
+IIb	I-PRGE
+.	O
+
+ABSTRACT	O
+:	O
+Two	O
+novel	O
+coronaviruses	O
+have	O
+emerged	O
+in	O
+humans	O
+in	O
+the	O
+twenty	O
+-	O
+first	O
+century	O
+:	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+coronavirus	B-SPEC
+(	O
+SARS	B-DISO
+-	O
+CoV	O
+)	O
+and	O
+Middle	O
+East	O
+respiratory	O
+syndrome	B-DISO
+coronavirus	B-SPEC
+(	O
+MERS	O
+-	O
+CoV	O
+),	O
+both	O
+of	O
+which	O
+cause	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+(	O
+ARDS	B-DISO
+)	O
+and	O
+are	O
+associated	O
+with	O
+high	O
+mortality	O
+rates	O
+.	O
+
+To	O
+date	O
+,	O
+114	O
+human	B-SPEC
+cases	O
+of	O
+MERS	O
+-	O
+CoV	O
+have	O
+been	O
+reported	O
+,	O
+with	O
+54	O
+fatalities	O
+.	O
+
+The	O
+lung	B-ANAT
+expression	B-PROC
+of	O
+adhesion	B-DISO
+molecules	O
+(	O
+intercellular	B-PRGE
+adhesion	I-PRGE
+molecule	I-PRGE
+1	I-PRGE
+,	O
+platelet	B-PRGE
+endothelial	B-ANAT
+cell	I-ANAT
+adhesion	I-PRGE
+molecule	I-PRGE
+1	I-PRGE
+,	O
+and	O
+vascular	B-PRGE
+cell	B-PROC
+adhesion	B-DISO
+molecule	I-PRGE
+[	O
+VCAM	O
+])	O
+was	O
+evaluated	O
+by	O
+immunohistochemistry	O
+.	O
+
+Thus	O
+,	O
+acute	O
+estradiol	B-CHED
+treatment	O
+could	O
+be	O
+considered	O
+as	O
+a	O
+potential	O
+therapeutic	O
+agent	O
+in	O
+ischemic	O
+events	O
+.	O
+
+This	O
+case	O
+raises	O
+an	O
+important	O
+issue	O
+of	O
+clinically	O
+considering	O
+involvement	O
+of	O
+the	O
+heart	B-ANAT
+in	O
+cases	O
+of	O
+disseminated	B-DISO
+blastomycosis	I-DISO
+.	O
+
+ABSTRACT	O
+:	O
+The	O
+type	B-PRGE
+II	I-PRGE
+transmembrane	I-PRGE
+serine	B-CHED
+proteases	I-PRGE
+TMPRSS2	B-PRGE
+and	O
+HAT	B-PRGE
+can	O
+cleave	O
+and	O
+activate	O
+the	O
+spike	O
+protein	B-CHED
+(	O
+S	O
+)	O
+of	O
+the	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+coronavirus	B-SPEC
+(	O
+SARS	B-DISO
+-	O
+CoV	O
+)	O
+for	O
+membrane	B-PROC
+fusion	I-PROC
+.	O
+
+However	O
+,	O
+no	O
+mechanistic	O
+insights	O
+into	O
+this	O
+process	O
+were	O
+obtained	O
+and	O
+the	O
+relevance	O
+of	O
+ACE2	O
+cleavage	B-PROC
+for	O
+SARS	B-PRGE
+-	I-PRGE
+CoV	I-PRGE
+S	I-PRGE
+protein	B-CHED
+(	O
+SARS	B-PRGE
+-	I-PRGE
+S	I-PRGE
+)	O
+activation	O
+has	O
+not	O
+been	O
+determined	O
+.	O
+
+Here	O
+,	O
+we	O
+show	O
+that	O
+arginine	B-CHED
+and	O
+lysine	B-CHED
+residues	O
+within	O
+ACE2	B-PRGE
+amino	B-CHED
+acids	I-CHED
+697	O
+to	O
+716	O
+are	O
+essential	O
+for	O
+cleavage	B-PROC
+by	O
+TMPRSS2	B-PRGE
+and	O
+HAT	B-PRGE
+and	O
+that	O
+ACE2	B-PRGE
+processing	O
+is	O
+required	O
+for	O
+augmentation	O
+of	O
+SARS	B-DISO
+-	O
+S	O
+-	O
+driven	O
+entry	O
+by	O
+these	O
+proteases	O
+.	O
+
+In	O
+contrast	O
+,	O
+ACE2	B-PRGE
+cleavage	B-PROC
+was	O
+dispensable	O
+for	O
+activation	O
+of	O
+the	O
+viral	O
+S	O
+protein	O
+.	O
+
+In	O
+this	O
+study	O
+,	O
+we	O
+discovered	O
+a	O
+novel	O
+gammacoronavirus	B-SPEC
+from	O
+fecal	B-ANAT
+samples	O
+from	O
+three	O
+Indo	B-SPEC
+-	I-SPEC
+Pacific	I-SPEC
+bottlenose	I-SPEC
+dolphins	I-SPEC
+(	O
+Tursiops	B-SPEC
+aduncus	I-SPEC
+),	O
+which	O
+we	O
+named	O
+bottlenose	O
+dolphin	O
+CoV	O
+(	O
+BdCoV	O
+)	O
+HKU22	O
+.	O
+
+ABSTRACT	O
+:	O
+Human	B-SPEC
+coronaviruses	O
+(	O
+HCoVs	O
+)	O
+are	O
+recognized	O
+respiratory	O
+pathogens	O
+with	O
+neuroinvasive	O
+and	O
+neurotropic	O
+properties	O
+in	O
+mice	B-SPEC
+and	O
+humans	B-SPEC
+.	O
+
+Herein	O
+,	O
+we	O
+show	O
+that	O
+glutamate	B-PROC
+recycling	I-PROC
+via	O
+the	O
+glial	B-PRGE
+transporter	I-PRGE
+1	I-PRGE
+protein	B-CHED
+transporter	I-PRGE
+and	O
+glutamine	B-PRGE
+synthetase	I-PRGE
+are	O
+central	O
+to	O
+the	O
+dysregulation	O
+of	O
+glutamate	B-PROC
+homeostasis	I-PROC
+and	O
+development	B-PROC
+of	O
+motor	O
+dysfunctions	O
+and	O
+paralytic	O
+disease	O
+in	O
+HCoV	O
+-	O
+OC43	O
+-	O
+infected	O
+mice	B-SPEC
+.	O
+
+Interestingly	O
+,	O
+memantine	B-CHED
+attenuated	O
+mortality	O
+rates	O
+and	O
+body	B-ANAT
+weight	O
+loss	O
+and	O
+reduced	O
+HCoV	B-SPEC
+-	I-SPEC
+OC43	I-SPEC
+replication	O
+in	O
+the	O
+central	B-ANAT
+nervous	I-ANAT
+system	I-ANAT
+in	O
+a	O
+dose	O
+-	O
+dependent	O
+manner	O
+.	O
+
+Mutations	O
+in	O
+the	O
+surface	O
+spike	O
+(	O
+S	O
+)	O
+protein	B-CHED
+of	O
+human	B-SPEC
+respiratory	O
+coronavirus	B-SPEC
+OC43	O
+appear	O
+after	O
+persistent	B-DISO
+infection	I-DISO
+of	O
+human	B-SPEC
+cells	B-COMP
+of	O
+the	O
+central	B-ANAT
+nervous	I-ANAT
+system	I-ANAT
+,	O
+a	O
+possible	O
+viral	O
+adaptation	B-PROC
+to	O
+this	O
+environment	O
+.	O
+
+In	O
+contrast	O
+,	O
+chronic	O
+MSE	O
+appearing	O
+a	O
+few	O
+days	O
+after	O
+CPR	B-ENZY
+is	O
+called	O
+Lance	O
+-	O
+Adams	O
+syndrome	B-DISO
+(	O
+LAS	O
+),	O
+which	O
+is	O
+characterized	O
+by	O
+preserved	O
+intellect	O
+and	O
+a	O
+favorable	O
+prognosis	O
+.	O
+
+Differential	O
+diagnosis	O
+was	O
+also	O
+challenging	O
+as	O
+LAS	O
+was	O
+developed	O
+8	O
+hours	O
+after	O
+the	O
+hypoxic	B-DISO
+event	O
+.	O
+
+TITLE	O
+:	O
+[	O
+Pharmacological	O
+treatment	O
+of	O
+hemorheological	O
+disorders	O
+in	O
+children	O
+with	O
+acute	O
+respiratory	B-DISO
+viral	B-PROC
+infection	I-PROC
+].	O
+
+The	O
+nuclear	B-PRGE
+enzyme	O
+poly	O
+(	O
+adenosine	B-CHED
+diphosphate	B-CHED
+-	O
+ribose	B-CHED
+)	O
+polymerase	O
+(	O
+PARP	B-PRGE
+)	O
+enhances	O
+the	O
+nuclear	O
+factor	O
+(	O
+NF	O
+)-	O
+κB	O
+-	O
+dependent	O
+transcription	B-PROC
+of	O
+inflammatory	O
+cytokines	O
+.	O
+
+This	O
+study	O
+was	O
+conducted	O
+to	O
+elucidate	O
+two	O
+questions	O
+:	O
+first	O
+,	O
+whether	O
+the	O
+activation	O
+of	O
+PARP	B-PRGE
+and	O
+NF	O
+-	O
+κB	O
+mediates	O
+the	O
+renal	B-ANAT
+inflammation	B-DISO
+secondary	O
+to	O
+the	O
+lipopolysaccharide	B-CHED
+(	O
+LPS	B-DISO
+)-	O
+induced	O
+acute	O
+lung	B-DISO
+inflammation	I-DISO
+;	O
+second	O
+,	O
+whether	O
+a	O
+PARP	B-PRGE
+inhibitor	B-CHED
+,	O
+3	B-CHED
+-	I-CHED
+aminobenzamide	I-CHED
+(	O
+3	O
+-	O
+AB	O
+),	O
+attenuates	O
+lung	B-ANAT
+and	O
+kidney	B-DISO
+inflammation	I-DISO
+by	O
+inhibiting	O
+NF	B-PRGE
+-	I-PRGE
+κB	I-PRGE
+-	I-PRGE
+dependent	I-PRGE
+proinflammatory	I-PRGE
+cytokines	I-PRGE
+.	O
+
+LPS	B-DISO
+induced	O
+metabolic	B-DISO
+acidosis	I-DISO
+,	O
+hypotension	O
+,	O
+hypoxemia	O
+,	O
+increased	O
+the	O
+lung	B-ANAT
+wet	O
+/	O
+dry	O
+ratio	O
+,	O
+increased	O
+the	O
+plasma	B-ANAT
+levels	O
+of	O
+creatinine	B-CHED
+and	O
+potassium	B-CHED
+,	O
+and	O
+increased	O
+the	O
+cytokine	O
+mRNA	B-CHED
+expressions	O
+in	O
+the	O
+lung	B-ANAT
+and	O
+kidney	B-ANAT
+.	O
+
+The	O
+PARP	B-PRGE
+inhibition	B-PROC
+attenuated	O
+lung	B-ANAT
+-	O
+kidney	B-ANAT
+crosstalk	B-PROC
+induced	O
+by	O
+intratracheal	O
+LPS	B-DISO
+instillation	O
+,	O
+partly	O
+via	O
+an	O
+inhibition	B-PROC
+of	O
+NF	B-PRGE
+-	I-PRGE
+κB	I-PRGE
+dependent	I-PRGE
+proinflammatory	I-PRGE
+cytokines	I-PRGE
+.	O
+
+TITLE	O
+:	O
+New	O
+and	O
+emerging	O
+pathogens	O
+in	O
+canine	O
+infectious	B-DISO
+respiratory	B-DISO
+disease	I-DISO
+.	O
+
+Etiology	O
+,	O
+clinical	O
+disease	O
+,	O
+pathogenesis	B-DISO
+,	O
+and	O
+epidemiology	O
+are	O
+described	O
+for	O
+each	O
+pathogen	O
+,	O
+with	O
+an	O
+emphasis	O
+on	O
+recent	O
+discoveries	O
+or	O
+novel	O
+findings	O
+.	O
+
+ABSTRACT	O
+:	O
+In	O
+2009	O
+,	O
+severe	O
+fever	B-PROC
+with	O
+thrombocytopenia	O
+syndrome	B-DISO
+virus	B-SPEC
+(	O
+SFTSV	O
+)	O
+was	O
+identified	O
+as	O
+a	O
+novel	O
+member	O
+of	O
+the	O
+genus	B-SPEC
+phlebovirus	I-SPEC
+in	O
+the	O
+Bunyaviridae	B-SPEC
+family	B-SPEC
+in	O
+China	O
+.	O
+
+Clinical	O
+and	O
+laboratory	O
+features	O
+of	O
+115	O
+hospitalized	O
+patients	O
+with	O
+SFTSV	O
+infection	B-DISO
+during	O
+the	O
+period	O
+from	O
+June	O
+2010	O
+to	O
+December	O
+2011	O
+in	O
+Northeast	O
+China	O
+were	O
+retrospectively	O
+reviewed	O
+.	O
+
+Due	O
+to	O
+infection	B-DISO
+with	O
+a	O
+novel	O
+bunyavirus	B-SPEC
+,	O
+the	O
+patients	O
+may	O
+sufferer	O
+multiple	O
+organ	B-ANAT
+dysfunction	O
+and	O
+die	O
+of	O
+multiple	B-DISO
+organ	I-DISO
+failure	I-DISO
+.	O
+
+ABSTRACT	O
+:	O
+The	O
+novel	O
+Middle	O
+East	O
+respiratory	O
+syndrome	O
+coronavirus	B-SPEC
+(	O
+MERS	O
+-	O
+CoV	O
+)	O
+had	O
+,	O
+as	O
+of	O
+Aug	O
+8	O
+,	O
+2013	O
+,	O
+caused	O
+111	O
+virologically	O
+confirmed	O
+or	O
+probable	O
+human	B-SPEC
+cases	O
+of	O
+infection	B-DISO
+worldwide	O
+.	O
+
+By	O
+showing	O
+that	O
+a	O
+slowly	O
+growing	O
+epidemic	O
+is	O
+underway	O
+either	O
+in	O
+human	B-SPEC
+beings	O
+or	O
+in	O
+an	O
+animal	B-SPEC
+reservoir	O
+,	O
+quantification	O
+of	O
+uncertainty	O
+in	O
+transmissibility	O
+estimates	O
+,	O
+and	O
+provision	O
+of	O
+the	O
+first	O
+estimates	O
+of	O
+the	O
+scale	O
+of	O
+the	O
+epidemic	O
+and	O
+extent	O
+of	O
+case	O
+detection	O
+biases	O
+,	O
+we	O
+provide	O
+valuable	O
+information	O
+for	O
+more	O
+informed	O
+risk	O
+assessment	O
+.	O
+
+Recently	O
+,	O
+a	O
+new	O
+coronavirus	B-SPEC
+,	O
+the	O
+Middle	O
+East	O
+Respiratory	O
+Syndrome	B-DISO
+Coronavirus	B-SPEC
+emerged	O
+,	O
+causing	O
+serious	O
+respiratory	O
+cases	O
+and	O
+death	B-PROC
+.	O
+
+The	O
+authors	O
+discuss	O
+a	O
+coronavirus	B-SPEC
+-	O
+associated	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+,	O
+which	O
+was	O
+detected	O
+in	O
+Hungary	O
+in	O
+2005	O
+and	O
+highlight	O
+its	O
+significance	O
+in	O
+2013	O
+.	O
+
+Based	O
+on	O
+the	O
+IgG	B-COMP
+antibody	I-COMP
+positivity	O
+of	O
+the	O
+serum	B-COMP
+samples	O
+,	O
+the	O
+patient	O
+was	O
+diagnosed	O
+as	O
+having	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+coronavirus	B-DISO
+infection	I-DISO
+in	O
+the	O
+past	O
+.	O
+
+TITLE	O
+:	O
+Alpha	O
+and	O
+lineage	O
+C	O
+betaCoV	O
+infections	B-DISO
+in	O
+Italian	O
+bats	B-SPEC
+.	O
+
+After	O
+controlling	O
+for	O
+institutional	O
+setting	O
+,	O
+reading	O
+the	O
+national	O
+preparedness	O
+plan	B-DISO
+was	O
+significantly	O
+associated	O
+with	O
+establishment	O
+of	O
+a	O
+BCP	O
+(	O
+OR	O
+5	O
+.	O
+86	O
+),	O
+and	O
+with	O
+knowledge	O
+of	O
+how	O
+to	O
+transfer	O
+a	O
+swab	O
+specimen	O
+to	O
+a	O
+local	O
+medical	O
+laboratory	O
+(	O
+OR	O
+5	O
+.	O
+60	O
+).	O
+
+After	O
+controlling	O
+for	O
+institutional	O
+setting	O
+,	O
+reading	O
+the	O
+national	O
+preparedness	O
+plan	B-DISO
+was	O
+significantly	O
+associated	O
+with	O
+establishment	O
+of	O
+a	O
+BCP	O
+(	O
+OR	O
+5	O
+.	O
+86	O
+),	O
+and	O
+with	O
+knowledge	O
+of	O
+how	O
+to	O
+transfer	O
+a	O
+swab	O
+specimen	O
+to	O
+a	O
+local	O
+medical	O
+laboratory	O
+(	O
+OR	O
+5	O
+.	O
+60	O
+).	O
+
+ABSTRACT	O
+:	O
+Middle	O
+East	O
+respiratory	O
+syndrome	B-DISO
+coronavirus	B-SPEC
+(	O
+MERS	O
+-	O
+CoV	O
+)	O
+emerged	O
+in	O
+2012	O
+,	O
+causing	O
+severe	O
+acute	B-DISO
+respiratory	I-DISO
+disease	I-DISO
+and	O
+pneumonia	B-DISO
+,	O
+with	O
+44	O
+%	O
+mortality	O
+among	O
+136	O
+cases	O
+to	O
+date	O
+.	O
+
+No	O
+complication	B-DISO
+related	O
+to	O
+PP	O
+was	O
+detected	O
+.	O
+
+ABSTRACT	O
+:	O
+This	O
+study	O
+describes	O
+the	O
+development	O
+of	O
+a	O
+spatio	O
+-	O
+temporal	O
+disease	O
+model	O
+based	O
+on	O
+the	O
+episodes	O
+of	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+(	O
+SARS	B-DISO
+)	O
+that	O
+took	O
+place	O
+in	O
+Hong	O
+Kong	O
+in	O
+2003	O
+.	O
+
+TITLE	O
+:	O
+Respiratory	O
+virus	B-SPEC
+detection	O
+:	O
+beyond	O
+influenza	B-DISO
+and	O
+RSV	B-SPEC
+into	O
+emerging	B-DISO
+infectious	I-DISO
+diseases	I-DISO
+.	O
+
+However	O
+,	O
+it	O
+is	O
+now	O
+becoming	O
+increasingly	O
+evident	O
+that	O
+the	O
+two	O
+-	O
+subunit	O
+HIV	B-SPEC
+-	I-SPEC
+1	I-SPEC
+RT	O
+is	O
+a	O
+highly	O
+versatile	O
+enzyme	O
+,	O
+undergoing	O
+major	O
+structural	O
+alterations	O
+in	O
+order	B-SPEC
+to	O
+interact	O
+with	O
+,	O
+position	O
+and	O
+ultimately	O
+hydrolyze	O
+the	O
+RNA	O
+component	O
+of	O
+an	O
+RNA	O
+/	O
+DNA	O
+hybrid	O
+.	O
+
+The	O
+CT	O
+appearance	O
+of	O
+the	O
+lesions	O
+corresponded	O
+to	O
+a	O
+spread	O
+of	O
+bilateral	O
+micro	O
+-	O
+connected	O
+pulmonary	B-ANAT
+nodules	B-DISO
+(	O
+a	O
+""""	O
+tree	O
+-	O
+in	O
+-	O
+bud	B-ANAT
+""""	O
+pattern	O
+)	O
+associated	O
+with	O
+obstructive	O
+ventilatory	O
+disorder	O
+.	O
+
+In	O
+this	O
+case	O
+,	O
+corticosteroids	B-CHED
+may	O
+be	O
+an	O
+effective	O
+adjunct	O
+by	O
+their	O
+action	O
+on	O
+the	O
+small	O
+airways	O
+.	O
+
+CONCLUSIONS	O
+:	O
+Mycoplasma	B-SPEC
+pneumoniae	I-SPEC
+may	O
+be	O
+responsible	O
+for	O
+severe	O
+respiratory	O
+illness	O
+in	O
+the	O
+form	O
+of	O
+bronchiolitis	B-DISO
+.	O
+
+The	O
+Proteus	B-SPEC
+syndrome	I-DISO
+is	O
+a	O
+very	O
+rare	O
+cause	O
+of	O
+pulmonary	O
+emphysema	O
+.	O
+
+The	O
+pathophysiology	O
+of	O
+emphysema	B-DISO
+in	O
+this	O
+syndrome	B-DISO
+is	O
+unknown	O
+.	O
+
+It	O
+can	O
+be	O
+hypothesized	O
+that	O
+the	O
+development	B-PROC
+of	O
+pulmonary	B-ANAT
+cysts	B-DISO
+leading	O
+to	O
+emphysema	B-DISO
+may	O
+share	O
+the	O
+same	O
+AKT1	B-PRGE
+activation	O
+pathway	B-PROC
+with	O
+lymphangioleiomyomatosis	B-DISO
+.	O
+
+For	O
+many	O
+years	O
+the	O
+traditional	O
+teaching	O
+has	O
+been	O
+that	O
+SCD	B-DISO
+is	O
+associated	O
+with	O
+the	O
+development	B-PROC
+of	O
+a	O
+restrictive	O
+lung	B-ANAT
+defect	O
+.	O
+
+TITLE	O
+:	O
+SARS	B-DISO
+-	I-PRGE
+CoV	I-PRGE
+ORF1b	I-PRGE
+-	O
+encoded	O
+nonstructural	O
+proteins	B-CHED
+12	O
+-	O
+16	O
+:	O
+replicative	O
+enzymes	O
+as	O
+antiviral	B-CHED
+targets	O
+.	O
+
+TITLE	O
+:	O
+Cell	B-ANAT
+-	O
+based	O
+antiviral	B-CHED
+screening	O
+against	O
+coronaviruses	O
+:	O
+developing	O
+virus	B-SPEC
+-	O
+specific	O
+and	O
+broad	O
+-	O
+spectrum	O
+inhibitors	O
+.	O
+
+In	O
+this	O
+article	O
+we	O
+review	O
+cell	B-COMP
+-	O
+based	O
+assays	O
+using	O
+infectious	B-DISO
+virus	B-SPEC
+(	O
+BSL	O
+-	O
+3	O
+)	O
+and	O
+surrogate	O
+assays	O
+(	O
+BSL	O
+-	O
+2	O
+)	O
+that	O
+can	O
+be	O
+implemented	O
+to	O
+accelerate	O
+antiviral	B-CHED
+development	B-PROC
+against	O
+MERS	O
+-	O
+CoV	O
+and	O
+future	O
+emergent	O
+coronaviruses	O
+.	O
+
+The	O
+median	O
+age	O
+of	O
+patients	O
+(	O
+n	O
+=	O
+161	O
+)	O
+was	O
+50	O
+years	O
+(	O
+range	O
+14	O
+months	O
+to	O
+94	O
+years	O
+),	O
+64	O
+.	O
+5	O
+%	O
+were	O
+male	O
+and	O
+63	O
+.	O
+4	O
+%	O
+experienced	O
+severe	O
+respiratory	B-DISO
+disease	I-DISO
+.	O
+
+RESULTS	O
+:	O
+The	O
+median	O
+age	O
+of	O
+patients	O
+(	O
+n	O
+=	O
+161	O
+)	O
+was	O
+50	O
+years	O
+(	O
+range	O
+14	O
+months	O
+to	O
+94	O
+years	O
+),	O
+64	O
+.	O
+5	O
+%	O
+were	O
+male	O
+and	O
+63	O
+.	O
+4	O
+%	O
+experienced	O
+severe	O
+respiratory	B-DISO
+disease	I-DISO
+.	O
+
+TITLE	O
+:	O
+Akt2	B-PRGE
+deficiency	O
+protects	O
+from	O
+acute	O
+lung	B-ANAT
+injury	O
+via	O
+alternative	O
+macrophage	B-PROC
+activation	I-PROC
+and	O
+miR	B-PRGE
+-	I-PRGE
+146a	I-PRGE
+induction	O
+in	O
+mice	B-SPEC
+.	O
+
+miR	B-PRGE
+-	I-PRGE
+146a	I-PRGE
+,	O
+an	O
+anti	O
+-	O
+inflammatory	O
+microRNA	O
+targeting	B-PROC
+TLR4	B-PRGE
+signaling	B-PROC
+,	O
+was	O
+induced	O
+during	O
+the	O
+late	O
+phase	O
+of	O
+lung	B-ANAT
+injury	O
+in	O
+WT	O
+mice	B-SPEC
+,	O
+whereas	O
+it	O
+was	O
+increased	O
+early	O
+in	O
+Akt2	B-PRGE
+(-/-)	O
+mice	B-SPEC
+.	O
+
+We	O
+detail	O
+outcomes	O
+of	O
+clinical	O
+examination	O
+,	O
+pulmonary	B-PROC
+function	I-PROC
+testing	O
+,	O
+quality	O
+of	O
+life	O
+assessment	O
+and	O
+radiographic	O
+appearance	O
+on	O
+CT	O
+Thorax	B-ANAT
+at	O
+follow	O
+-	O
+up	O
+at	O
+6	O
+months	O
+.	O
+
+Further	O
+clinical	O
+assessment	O
+and	O
+pulmonary	B-PROC
+function	I-PROC
+testing	O
+were	O
+performed	O
+at	O
+median	O
+19	O
+months	O
+(	O
+range	O
+18	O
+-	O
+21	O
+months	O
+)	O
+post	O
+-	O
+discharge	B-ANAT
+.	O
+
+At	O
+initial	O
+review	O
+all	O
+patients	O
+were	O
+found	O
+to	O
+have	O
+reduced	O
+gas	B-ENZY
+transfer	O
+(	O
+median	O
+predicted	O
+DLCO	O
+74	O
+%)	O
+with	O
+preservation	O
+of	O
+lung	B-PROC
+volumes	I-PROC
+and	O
+normal	O
+spirometrical	O
+values	O
+at	O
+6	O
+months	O
+(	O
+median	O
+FVC	B-PROC
+5	O
+.	O
+42L	O
+[	O
+101	O
+%	O
+predicted	O
+]	O
+and	O
+FEV14	O
+.	O
+5L	O
+[	O
+101	O
+.	O
+2	O
+%	O
+predicted	O
+]	O
+respectively	O
+),	O
+with	O
+improvements	O
+in	O
+gas	O
+transfer	O
+(	O
+median	O
+predicted	O
+DLCO	O
+83	O
+%)	O
+at	O
+subsequent	O
+testing	O
+.	O
+
+In	O
+the	O
+cloacal	B-ANAT
+swabs	O
+,	O
+TCoV	O
+was	O
+detected	O
+consistently	O
+at	O
+3	O
+,	O
+5	O
+,	O
+7	O
+,	O
+and	O
+12	O
+days	O
+postinoculation	O
+(	O
+DPI	O
+)	O
+with	O
+higher	O
+rates	O
+of	O
+detection	O
+after	O
+5	O
+DPI	O
+(>	O
+90	O
+%).	O
+
+TITLE	O
+:	O
+Cross	O
+-	O
+protective	O
+immune	B-PROC
+responses	I-PROC
+elicited	O
+by	O
+a	O
+Korean	O
+variant	O
+of	O
+infectious	B-DISO
+bronchitis	B-DISO
+virus	B-SPEC
+.	O
+
+IBVs	O
+continuously	O
+evolve	O
+by	O
+developing	O
+mutations	O
+in	O
+antigenic	O
+sites	O
+;	O
+therefore	O
+,	O
+an	O
+IBV	B-SPEC
+vaccine	O
+that	O
+provides	O
+broad	O
+cross	O
+-	O
+protection	O
+can	O
+be	O
+a	O
+highly	O
+relevant	O
+and	O
+practical	O
+method	O
+in	O
+IBV	B-SPEC
+control	O
+strategies	O
+.	O
+
+Although	O
+some	O
+IBV	B-SPEC
+vaccine	O
+strains	O
+are	O
+known	O
+to	O
+provide	O
+protection	O
+against	O
+multiple	O
+IBV	B-SPEC
+serotypes	O
+,	O
+in	O
+general	O
+commercially	O
+available	O
+IBV	B-SPEC
+vaccine	O
+strains	O
+provide	O
+protection	O
+against	O
+antigenically	O
+related	O
+viruses	B-SPEC
+but	O
+not	O
+distinct	O
+heterologous	O
+viruses	B-SPEC
+.	O
+
+Activation	O
+and	O
+recruitment	B-DISO
+of	O
+neutrophils	B-ANAT
+to	O
+the	O
+lung	B-ANAT
+is	O
+mostly	O
+attributable	O
+to	O
+local	O
+production	O
+of	O
+the	O
+chemokines	O
+.	O
+
+In	O
+this	O
+study	O
+,	O
+we	O
+sought	O
+to	O
+evaluate	O
+the	O
+extended	O
+temporal	O
+relationship	O
+between	O
+neutrophil	B-ANAT
+chemotactic	O
+factor	O
+expression	B-PROC
+and	O
+influx	O
+of	O
+neutrophils	B-ANAT
+into	O
+the	O
+lung	B-ANAT
+after	O
+intratracheal	O
+administration	O
+of	O
+either	O
+LPS	B-DISO
+or	O
+bleomycin	B-CHED
+.	O
+
+AVPdb	O
+contains	O
+detailed	O
+information	O
+of	O
+2683	O
+peptides	B-CHED
+,	O
+including	O
+624	O
+modified	O
+peptides	B-CHED
+experimentally	O
+tested	O
+for	O
+antiviral	B-CHED
+activity	O
+.	O
+
+TITLE	O
+:	O
+Tumor	B-DISO
+necrosis	I-DISO
+factor	I-FUNC
+α	I-PRGE
+(	O
+TNF	B-PRGE
+-	I-PRGE
+α	I-PRGE
+)	O
+receptor	O
+-	O
+I	O
+is	O
+required	O
+for	O
+TNF	B-PRGE
+-	I-PRGE
+α	I-PRGE
+-	O
+mediated	O
+fulminant	O
+virus	B-SPEC
+hepatitis	I-DISO
+caused	O
+by	O
+murine	O
+hepatitis	O
+virus	B-SPEC
+strain	O
+-	O
+3	O
+infection	B-DISO
+.	O
+
+Moreover	O
+,	O
+the	O
+infiltration	B-DISO
+of	O
+neutrophils	B-ANAT
+rather	O
+than	O
+Foxp3	O
+(+)	O
+regulatory	B-ANAT
+T	I-ANAT
+cells	I-ANAT
+,	O
+which	O
+produce	O
+proinflammatory	O
+factors	O
+and	O
+FGL2	B-PRGE
+directly	O
+,	O
+into	O
+the	O
+infected	O
+liver	B-ANAT
+and	I-ANAT
+spleen	I-ANAT
+tissues	B-ANAT
+was	O
+also	O
+decreased	O
+in	O
+TNFR1	B-PRGE
+(-/-)	O
+mice	B-SPEC
+.	O
+
+We	O
+reviewed	O
+available	O
+data	O
+from	O
+MERS	O
+-	O
+CoV	O
+case	O
+reports	O
+,	O
+and	O
+compared	O
+this	O
+with	O
+data	O
+on	O
+kinetics	O
+of	O
+shedding	O
+and	O
+immune	O
+response	O
+from	O
+published	O
+literature	O
+on	O
+other	O
+human	B-SPEC
+coronaviruses	O
+(	O
+hCoVs	O
+).	O
+
+Additionally	O
+,	O
+aptamers	O
+can	O
+potentially	O
+bind	B-FUNC
+any	O
+targets	O
+and	O
+any	O
+pathogen	O
+that	O
+is	O
+theoretically	O
+amenable	O
+to	O
+rapid	O
+targeting	B-PROC
+,	O
+making	O
+aptamers	O
+invaluable	O
+tools	O
+for	O
+treating	O
+a	O
+wide	O
+range	O
+of	O
+diseases	O
+.	O
+
+Overall	O
+,	O
+although	O
+high	O
+PEEP	B-CHED
+levels	O
+improve	O
+oxygenation	B-PROC
+and	O
+are	O
+safe	O
+,	O
+they	O
+do	O
+not	O
+result	O
+in	O
+a	O
+significant	O
+reduction	O
+of	O
+the	O
+mortality	O
+rates	O
+.	O
+
+Nevertheless	O
+,	O
+some	O
+metaanalyses	O
+have	O
+revealed	O
+2	O
+situations	O
+in	O
+which	O
+high	O
+PEEP	B-CHED
+may	O
+decrease	O
+mortality	O
+:	O
+When	O
+used	O
+in	O
+severe	O
+distress	O
+and	O
+when	O
+PEEP	B-CHED
+is	O
+set	O
+following	O
+the	O
+characteristics	O
+of	O
+lung	B-ANAT
+mechanics	O
+.	O
+
+Unfortunately	O
+,	O
+all	O
+of	O
+them	O
+have	O
+small	O
+sample	O
+sizes	O
+and	O
+have	O
+used	O
+different	O
+means	O
+to	O
+determine	O
+optimum	O
+PEEP	B-CHED
+.	O
+
+Based	O
+on	O
+the	O
+analysis	O
+of	O
+the	O
+partial	B-PRGE
+S	I-PRGE
+glycoprotein	I-PRGE
+genes	I-PRGE
+,	O
+the	O
+Thai	O
+PEDV	B-SPEC
+isolates	O
+were	O
+clustered	O
+into	O
+2	O
+groups	O
+related	O
+to	O
+Korean	O
+and	O
+Chinese	O
+field	O
+isolates	O
+.	O
+
+To	O
+investigate	O
+the	O
+epidemic	O
+characteristics	O
+of	O
+PEDV	B-SPEC
+,	O
+the	O
+complete	O
+ORF3	O
+genes	O
+of	O
+14	O
+PEDV	B-SPEC
+field	O
+strains	O
+from	O
+central	O
+China	O
+during	O
+2012	O
+to	O
+2013	O
+were	O
+cloned	O
+,	O
+sequenced	O
+and	O
+compared	O
+with	O
+reference	O
+strains	O
+.	O
+
+To	O
+determine	O
+the	O
+reason	O
+for	O
+recent	O
+vaccination	O
+failures	O
+,	O
+we	O
+also	O
+studied	O
+variations	O
+in	O
+antigenicity	O
+of	O
+field	O
+strains	O
+by	O
+analyzing	O
+the	O
+three	O
+neutralizing	O
+epitope	O
+regions	O
+in	O
+the	O
+S	B-PRGE
+gene	I-PRGE
+.	O
+
+TITLE	O
+:	O
+Effect	O
+of	O
+clarithromycin	B-CHED
+in	O
+patients	O
+with	O
+suspected	O
+Gram	O
+-	O
+negative	O
+sepsis	B-DISO
+:	O
+results	O
+of	O
+a	O
+randomized	O
+controlled	O
+trial	O
+.	O
+
+ABSTRACT	O
+:	O
+A	O
+previous	O
+randomized	O
+study	O
+showed	O
+that	O
+clarithromycin	O
+decreases	O
+the	O
+risk	O
+of	O
+death	B-PROC
+due	O
+to	O
+ventilator	B-DISO
+-	I-DISO
+associated	I-DISO
+pneumonia	I-DISO
+and	O
+shortens	O
+the	O
+time	O
+until	O
+infection	B-DISO
+resolution	O
+.	O
+
+Overall	O
+28	O
+day	O
+mortality	O
+was	O
+17	O
+.	O
+1	O
+%	O
+(	O
+51	O
+deaths	B-PROC
+)	O
+in	O
+the	O
+placebo	O
+arm	B-ANAT
+and	O
+18	O
+.	O
+5	O
+%	O
+(	O
+56	O
+deaths	B-PROC
+)	O
+in	O
+the	O
+clarithromycin	B-CHED
+arm	B-ANAT
+(	O
+P	O
+=	O
+0	O
+.	O
+671	O
+).	O
+
+Even	O
+with	O
+the	O
+development	B-PROC
+of	O
+new	O
+pharmaceuticals	B-CHED
+to	O
+treat	O
+tuberculosis	B-PATH
+,	O
+there	O
+is	O
+no	O
+indication	O
+that	O
+the	O
+disease	O
+will	O
+be	O
+eradicated	O
+.	O
+
+Phylogenetic	O
+classification	O
+showed	O
+that	O
+63	O
+E	B-SPEC
+.	I-SPEC
+coli	I-SPEC
+isolates	O
+belonged	O
+to	O
+groups	O
+B1	O
+(	O
+52	O
+.	O
+4	O
+%),	O
+A	O
+(	O
+25	O
+.	O
+4	O
+%)	O
+and	O
+B2	O
+(	O
+22	O
+.	O
+2	O
+%).	O
+
+The	O
+presence	O
+of	O
+R	B-SPEC
+.	I-SPEC
+equi	I-SPEC
+,	O
+Toxocara	B-SPEC
+sp	O
+,	O
+bovine	B-SPEC
+Coronavirus	B-SPEC
+and	O
+virulent	O
+E	B-SPEC
+.	I-SPEC
+coli	I-SPEC
+isolates	O
+in	O
+the	O
+environment	O
+of	O
+parks	O
+indicates	O
+that	O
+the	O
+sanitary	O
+conditions	O
+of	O
+the	O
+sand	O
+should	O
+be	O
+improved	O
+in	O
+order	B-SPEC
+to	O
+reduce	O
+the	O
+risks	O
+of	O
+fecal	B-ANAT
+transmission	O
+of	O
+pathogens	O
+of	O
+zoonotic	O
+potential	O
+to	O
+humans	B-SPEC
+in	O
+these	O
+places	O
+.	O
+
+TITLE	O
+:	O
+Mice	B-SPEC
+immunogenicity	O
+after	O
+vaccination	O
+by	O
+DNA	O
+vaccines	O
+containing	O
+individual	O
+genes	O
+of	O
+a	O
+new	O
+type	O
+of	O
+reovirus	O
+.	O
+
+The	O
+Surviving	O
+Sepsis	B-DISO
+Campaign	O
+(	O
+SSC	O
+)	O
+guidelines	O
+released	O
+in	O
+2012	O
+emphasize	O
+early	O
+recognition	O
+and	O
+treatment	O
+of	O
+sepsis	B-DISO
+,	O
+in	O
+an	O
+effort	B-PROC
+to	O
+reduce	O
+the	O
+burden	O
+of	O
+sepsis	B-DISO
+worldwide	O
+.	O
+
+Scoring	O
+systems	O
+have	O
+been	O
+developed	O
+in	O
+an	O
+effort	B-PROC
+to	O
+quantify	O
+the	O
+severity	O
+of	O
+lung	B-ANAT
+injury	O
+,	O
+with	O
+the	O
+most	O
+recent	O
+being	O
+the	O
+Berlin	O
+Definition	O
+.	O
+
+This	O
+system	O
+attempts	O
+to	O
+define	O
+acute	O
+lung	B-ANAT
+injury	O
+(	O
+ALI	O
+)	O
+and	O
+ARDS	B-DISO
+with	O
+more	O
+precision	O
+in	O
+terms	O
+of	O
+timing	O
+of	O
+disease	O
+onset	O
+,	O
+severity	O
+of	O
+disease	O
+,	O
+and	O
+chest	B-ANAT
+radiograph	O
+findings	O
+.	O
+
+Sepsis	B-DISO
+-	O
+related	O
+ARDS	B-DISO
+has	O
+a	O
+generally	O
+higher	O
+disease	O
+severity	O
+and	O
+poorer	O
+recovery	O
+period	O
+from	O
+lung	B-ANAT
+injury	O
+with	O
+an	O
+increased	O
+mortality	O
+rate	O
+.	O
+
+Prevention	O
+of	O
+ventilator	O
+-	O
+induced	O
+lung	B-ANAT
+injury	O
+(	O
+VILI	O
+)	O
+has	O
+been	O
+demonstrated	O
+to	O
+have	O
+a	O
+positive	O
+impact	O
+on	O
+outcomes	O
+in	O
+patients	O
+with	O
+ARDS	B-DISO
+.	O
+
+ABSTRACT	O
+:	O
+Since	O
+the	O
+2006	O
+Pandemic	O
+Influenza	B-DISO
+Preparedness	O
+and	O
+Response	O
+Plan	B-DISO
+according	O
+to	O
+the	O
+World	O
+Health	O
+Organization	O
+'	O
+s	O
+recommendation	O
+,	O
+the	O
+Republic	O
+of	O
+Korea	O
+has	O
+prepared	O
+and	O
+periodically	O
+evaluated	O
+the	O
+plan	B-DISO
+to	O
+respond	O
+to	O
+various	O
+public	O
+health	O
+crises	O
+including	O
+pandemic	O
+influenza	B-DISO
+.	O
+
+RESULTS	O
+:	O
+Of	O
+6069	O
+patients	O
+who	O
+underwent	O
+cardiac	B-ANAT
+surgery	O
+during	O
+the	O
+study	O
+period	O
+,	O
+37	O
+patients	O
+developed	O
+ARDS	B-DISO
+during	O
+the	O
+postoperative	O
+period	O
+.	O
+
+ABSTRACT	O
+:	O
+To	O
+gain	O
+comprehensive	O
+genetic	O
+information	O
+of	O
+circulating	O
+avian	B-SPEC
+coronavirus	I-SPEC
+infectious	B-DISO
+bronchitis	B-DISO
+virus	B-SPEC
+(	O
+IBV	B-SPEC
+)	O
+isolates	O
+in	O
+China	O
+,	O
+analysis	O
+of	O
+the	O
+phylogenetic	O
+tree	O
+,	O
+entropy	O
+of	O
+the	O
+amino	B-CHED
+acid	I-CHED
+sequences	O
+,	O
+and	O
+the	O
+positive	O
+selection	O
+as	O
+well	O
+as	O
+computational	O
+recombinations	B-PROC
+of	O
+S1	O
+,	O
+M	O
+and	O
+N	O
+genes	O
+of	O
+23	O
+IBV	B-SPEC
+isolates	O
+was	O
+conducted	O
+in	O
+the	O
+present	O
+study	O
+.	O
+
+The	O
+phylogenetic	O
+trees	O
+based	O
+on	O
+the	O
+S1	O
+,	O
+M	O
+and	O
+N	O
+genes	O
+exhibited	O
+considerably	O
+different	O
+topology	O
+and	O
+the	O
+CK	O
+/	O
+CH	O
+/	O
+LSC	B-PRGE
+/	O
+99I	O
+-	O
+type	O
+isolates	O
+were	O
+the	O
+predominant	O
+IBVs	O
+based	O
+on	O
+the	O
+phylogenetic	O
+analysis	O
+of	O
+S1	B-PRGE
+gene	I-PRGE
+.	O
+
+All	O
+patients	O
+were	O
+middle	O
+to	O
+old	O
+aged	O
+(	O
+mean	O
+age	O
+62	O
+years	O
+)	O
+and	O
+overweight	B-DISO
+(	O
+mean	O
+body	B-ANAT
+mass	O
+index	O
+31	O
+)	O
+patients	O
+.	O
+
+Time	O
+between	O
+onset	O
+of	O
+symptoms	O
+and	O
+onset	O
+of	O
+respiratory	B-DISO
+failure	I-DISO
+(	O
+days	O
+)	O
+were	O
+7	O
+-	O
+11	O
+days	O
+.	O
+
+Cross	O
+species	B-SPEC
+poultry	O
+-	O
+to	O
+-	O
+person	O
+transmission	O
+of	O
+this	O
+new	O
+reassortant	O
+avian	B-DISO
+influenza	I-DISO
+H7N9	O
+virus	B-SPEC
+can	O
+result	O
+in	O
+severe	O
+and	O
+fatal	O
+respiratory	B-DISO
+disease	I-DISO
+like	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+(	O
+ARDS	B-DISO
+)	O
+in	O
+humans	B-SPEC
+.	O
+
+TITLE	O
+:	O
+Dendritic	B-COMP
+cell	B-COMP
+-	O
+specific	O
+delivery	O
+of	O
+Flt3L	O
+by	O
+coronavirus	B-SPEC
+vectors	O
+secures	O
+induction	O
+of	O
+therapeutic	O
+antitumor	O
+immunity	O
+.	O
+
+Tracking	O
+of	O
+in	O
+vivo	O
+transduced	O
+DCs	B-DISO
+revealed	O
+that	O
+vectors	O
+encoding	O
+for	O
+Fms	B-DISO
+-	O
+like	O
+tyrosine	B-PRGE
+kinase	I-PRGE
+3	I-PRGE
+ligand	B-PROC
+(	O
+Flt3L	B-PRGE
+)	O
+exhibited	O
+a	O
+higher	O
+capacity	O
+to	O
+induce	O
+DC	O
+maturation	B-PROC
+compared	O
+to	O
+vectors	O
+delivering	O
+IL	B-FUNC
+-	I-FUNC
+2	I-FUNC
+or	O
+IL	B-FUNC
+-	I-FUNC
+15	I-FUNC
+.	O
+
+Peptides	B-CHED
+were	O
+selected	O
+using	O
+a	O
+plaque	B-DISO
+reduction	O
+assay	O
+to	O
+inhibit	O
+Feline	B-SPEC
+coronavirus	B-DISO
+infection	I-DISO
+.	O
+
+Our	O
+data	O
+suggest	O
+that	O
+the	O
+synthetic	O
+peptide	B-CHED
+FP5	O
+could	O
+serve	O
+as	O
+a	O
+valuable	O
+addition	O
+to	O
+the	O
+current	O
+FIP	B-DISO
+prevention	O
+methods	O
+.	O
+
+CONCLUSIONS	O
+:	O
+Our	O
+data	O
+suggest	O
+that	O
+the	O
+synthetic	O
+peptide	B-CHED
+FP5	O
+could	O
+serve	O
+as	O
+a	O
+valuable	O
+addition	O
+to	O
+the	O
+current	O
+FIP	B-DISO
+prevention	O
+methods	O
+.	O
+
+This	O
+result	O
+indicates	O
+that	O
+influenza	B-DISO
+vaccination	O
+strategy	O
+should	O
+be	O
+improved	O
+to	O
+meet	O
+the	O
+ambitious	O
+WHO	O
+coverage	O
+goals	O
+.	O
+
+These	O
+results	O
+indicated	O
+that	O
+these	O
+inhibitors	O
+could	O
+be	O
+potentially	O
+developed	O
+into	O
+anti	O
+-	O
+SARS	B-DISO
+drugs	O
+.	O
+
+TITLE	O
+:	O
+The	O
+structural	O
+and	O
+accessory	B-PRGE
+proteins	I-PRGE
+M	I-PRGE
+,	I-PRGE
+ORF	I-PRGE
+4a	I-PRGE
+,	I-PRGE
+ORF	I-PRGE
+4b	I-PRGE
+,	O
+and	O
+ORF	O
+5	O
+of	O
+Middle	O
+East	O
+respiratory	O
+syndrome	O
+coronavirus	B-SPEC
+(	O
+MERS	O
+-	O
+CoV	O
+)	O
+are	O
+potent	O
+interferon	B-PRGE
+antagonists	B-CHED
+.	O
+
+Further	O
+examination	O
+revealed	O
+that	O
+the	O
+ORF	B-PRGE
+4a	I-PRGE
+protein	I-PRGE
+of	O
+MERS	O
+-	O
+CoV	O
+has	O
+the	O
+most	O
+potential	O
+to	O
+counteract	O
+the	O
+antiviral	B-CHED
+effects	O
+of	O
+IFN	B-PRGE
+via	O
+the	O
+inhibition	B-PROC
+of	O
+both	O
+the	O
+interferon	B-PROC
+production	I-PROC
+(	O
+IFN	B-PRGE
+-	I-PRGE
+β	I-PRGE
+promoter	I-PRGE
+activity	O
+,	O
+IRF	B-PRGE
+-	I-PRGE
+3	I-PRGE
+/	I-PRGE
+7	I-PRGE
+and	O
+NF	O
+-	O
+κB	O
+activation	O
+)	O
+and	O
+ISRE	O
+promoter	O
+element	O
+signaling	B-PROC
+pathways	B-PROC
+.	O
+
+TITLE	O
+:	O
+Extracorporeal	O
+membrane	B-COMP
+oxygenation	B-PROC
+in	O
+adult	O
+patients	O
+with	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+.	O
+
+Of	O
+all	O
+the	O
+IFNs	O
+tested	O
+,	O
+IFN	B-PRGE
+-	I-PRGE
+β	I-PRGE
+showed	O
+the	O
+strongst	O
+inhibition	B-PROC
+of	O
+MERS	O
+-	O
+CoV	O
+in	O
+vitro	O
+,	O
+with	O
+an	O
+IC₅₀	O
+of	O
+1	O
+.	O
+37	O
+U	O
+ml	O
+(-	O
+1	O
+),	O
+41	O
+times	O
+lower	O
+than	O
+the	O
+previously	O
+reported	O
+IC₅₀	O
+(	O
+56	O
+.	O
+08	O
+U	O
+ml	O
+(-	O
+1	O
+))	O
+of	O
+IFN	O
+-	O
+α2b	O
+.	O
+
+IFN	B-PRGE
+-	I-PRGE
+β	I-PRGE
+inhibition	B-PROC
+was	O
+confirmed	O
+in	O
+the	O
+virus	B-SPEC
+yield	O
+reduction	O
+assay	O
+,	O
+with	O
+an	O
+IC90	O
+of	O
+38	O
+.	O
+8	O
+U	O
+ml	O
+(-	O
+1	O
+).	O
+
+In	O
+contrast	O
+,	O
+MPA	B-PRGE
+showed	O
+strong	O
+inhibition	B-PROC
+,	O
+with	O
+an	O
+IC₅₀	O
+of	O
+2	O
+.	O
+87	O
+µM	O
+.	O
+This	O
+drug	O
+has	O
+not	O
+been	O
+previously	O
+tested	O
+against	O
+MERS	O
+-	O
+CoV	O
+and	O
+may	O
+provide	O
+an	O
+alternative	O
+to	O
+ribavirin	B-CHED
+for	O
+treatment	O
+of	O
+MERS	O
+-	O
+CoV	O
+.	O
+In	O
+conclusion	O
+,	O
+IFN	B-PRGE
+-	I-PRGE
+β	I-PRGE
+,	O
+MPA	B-PRGE
+or	O
+a	O
+combination	O
+of	O
+the	O
+two	O
+may	O
+be	O
+beneficial	O
+in	O
+the	O
+treatment	O
+of	O
+MERS	O
+-	O
+CoV	O
+or	O
+as	O
+a	O
+post	O
+-	O
+exposure	O
+intervention	O
+in	O
+high	O
+-	O
+risk	O
+patients	O
+with	O
+known	O
+exposures	O
+to	O
+MERS	O
+-	O
+CoV	O
+.	O
+
+TITLE	O
+:	O
+Neutrophils	B-ANAT
+are	O
+needed	O
+for	O
+an	O
+effective	O
+immune	B-PROC
+response	I-PROC
+against	O
+pulmonary	B-ANAT
+rat	B-SPEC
+coronavirus	B-SPEC
+infection	I-DISO
+,	O
+but	O
+also	O
+contribute	O
+to	O
+pathology	O
+.	O
+
+This	O
+study	O
+evaluated	O
+the	O
+role	O
+of	O
+PMN	B-PROC
+during	O
+a	O
+non	O
+-	O
+fatal	O
+pulmonary	B-ANAT
+coronavirus	B-DISO
+infection	I-DISO
+in	O
+the	O
+natural	O
+host	B-COMP
+.	O
+
+Combined	O
+with	O
+in	O
+vitro	O
+experiments	O
+showing	O
+that	O
+PMN	B-PROC
+express	O
+cytokines	O
+and	O
+chemokines	O
+in	O
+response	O
+to	O
+RCoV	O
+-	O
+infected	O
+alveolar	B-ANAT
+epithelial	B-ANAT
+cells	I-ANAT
+,	O
+these	O
+findings	O
+support	O
+a	O
+role	O
+for	O
+PMN	B-PROC
+in	O
+eliciting	O
+an	O
+inflammatory	B-DISO
+response	I-DISO
+to	O
+RCoV	O
+infection	B-DISO
+.	O
+
+ABSTRACT	O
+:	O
+Pathogen	O
+-	O
+host	O
+interaction	O
+studies	O
+have	O
+demonstrated	O
+the	O
+importance	O
+of	O
+host	B-COMP
+factors	O
+in	O
+the	O
+pathogenesis	B-DISO
+of	O
+infectious	B-DISO
+disease	I-DISO
+.	O
+
+During	O
+10	O
+-	O
+fold	O
+cross	O
+validation	O
+on	O
+T1380	O
+using	O
+hybrid	O
+approach	O
+,	O
+we	O
+achieved	O
+a	O
+maximum	O
+Pearson	O
+Correlation	O
+Coefficient	O
+(	O
+PCC	B-DISO
+)	O
+of	O
+0	O
+.	O
+55	O
+between	O
+predicted	O
+and	O
+actual	O
+efficacy	O
+of	O
+viral	O
+siRNAs	O
+.	O
+
+SVM	O
+performed	O
+better	O
+than	O
+other	O
+machine	O
+learning	B-PROC
+techniques	O
+used	O
+like	O
+ANN	O
+,	O
+KNN	O
+and	O
+REP	B-FUNC
+Tree	O
+.	O
+
+ABSTRACT	O
+:	O
+Coronaviruses	O
+are	O
+a	O
+hot	O
+research	O
+topic	O
+because	O
+they	O
+can	O
+cause	O
+severe	O
+diseases	O
+in	O
+humans	B-SPEC
+and	O
+animals	B-SPEC
+.	O
+
+Unfortunately	O
+,	O
+the	O
+genetic	O
+basis	O
+of	O
+the	O
+host	B-COMP
+immune	B-PROC
+responses	I-PROC
+against	O
+IBV	B-SPEC
+is	O
+poorly	O
+understood	O
+.	O
+
+In	O
+addition	O
+,	O
+the	O
+major	O
+loci	O
+significantly	O
+associated	O
+with	O
+the	O
+antibody	B-COMP
+level	O
+against	O
+IBV	B-SPEC
+on	O
+GGA1	B-PRGE
+and	O
+GGA5	O
+could	O
+explain	O
+about	O
+12	O
+%	O
+and	O
+13	O
+%	O
+of	O
+the	O
+phenotypic	O
+variation	O
+,	O
+respectively	O
+.	O
+
+This	O
+study	O
+suggested	O
+that	O
+the	O
+chicken	B-SPEC
+genome	O
+has	O
+several	O
+important	O
+loci	O
+affecting	O
+the	O
+immune	B-PROC
+response	I-PROC
+against	O
+IBV	B-SPEC
+,	O
+and	O
+increases	O
+our	O
+knowledge	O
+of	O
+how	O
+to	O
+control	O
+outbreaks	O
+of	O
+infectious	B-DISO
+bronchitis	B-DISO
+.	O
+
+In	O
+the	O
+second	O
+case	O
+(	O
+an	O
+85	O
+-	O
+year	O
+-	O
+old	O
+man	B-CHED
+),	O
+abnormally	O
+high	O
+levels	O
+of	O
+anti	B-PRGE
+-	I-PRGE
+C	I-PRGE
+.	I-PRGE
+pneumoniae	I-PRGE
+IgM	I-PRGE
+were	O
+detected	O
+on	O
+admission	O
+.	O
+
+Neither	O
+of	O
+the	O
+patients	O
+displayed	O
+other	O
+pathogen	O
+-	O
+specific	O
+antigens	B-CHED
+or	O
+antibodies	B-COMP
+.	O
+
+Chlamydophila	B-DISO
+pneumonia	I-DISO
+is	O
+usually	O
+mild	O
+,	O
+although	O
+it	O
+can	O
+cause	O
+severe	O
+interstitial	B-DISO
+pneumonia	I-DISO
+and	O
+ARDS	B-DISO
+in	O
+reinfected	O
+patients	O
+and	O
+the	O
+elderly	O
+.	O
+
+New	O
+modes	O
+of	O
+assisted	O
+mechanical	O
+ventilation	O
+with	O
+improved	O
+patient	O
+ventilator	O
+interaction	O
+and	O
+enhanced	O
+variability	O
+of	O
+the	O
+respiratory	O
+pattern	O
+offer	O
+additional	O
+benefit	O
+on	O
+lung	B-PROC
+function	I-PROC
+and	O
+damage	O
+.	O
+
+PaO2	O
+/	O
+FiO2	O
+-	O
+ratio	O
+increased	O
+associated	O
+with	O
+the	O
+first	O
+and	O
+second	O
+PrP	B-CHED
+(	O
+p	O
+=	O
+0	O
+.	O
+002	O
+)	O
+and	O
+lasted	O
+after	O
+PrP	B-CHED
+in	O
+58	O
+%	O
+of	O
+these	O
+turning	O
+procedures	O
+"("""	O
+responders	O
+""")"	O
+without	O
+changes	O
+in	O
+ECMO	O
+blood	B-PROC
+flow	I-PROC
+,	O
+respiratory	O
+pressures	O
+,	O
+minute	O
+ventilation	O
+,	O
+portion	O
+of	O
+spontaneously	O
+triggered	O
+breathing	B-PROC
+,	O
+and	O
+compliance	O
+.	O
+
+Hemodynamics	B-PROC
+did	O
+not	O
+change	O
+with	O
+exception	O
+of	O
+increased	O
+mean	O
+pulmonary	B-ANAT
+arterial	B-PROC
+pressure	I-PROC
+during	O
+PrP	B-CHED
+and	O
+decrease	O
+after	O
+PrP	B-CHED
+(	O
+p	O
+<	O
+0	O
+.	O
+001	O
+),	O
+while	O
+norepinephrine	B-CHED
+dosage	O
+decreased	O
+(	O
+p	O
+=	O
+0	O
+.	O
+03	O
+)	O
+(	O
+MANOVA	O
+).	O
+
+68	O
+patients	O
+with	O
+severe	O
+inhomogeneous	O
+lung	B-ANAT
+injure	O
+(	O
+severe	O
+concomitant	O
+trauma	O
+,	O
+pneumonia	B-DISO
+,	O
+and	O
+pancreonecrosis	O
+)	O
+were	O
+involved	O
+in	O
+the	O
+study	O
+.	O
+
+Gas	B-PRGE
+status	O
+data	O
+improved	O
+both	O
+to	O
+gas	B-ENZY
+exchange	O
+efficacy	O
+in	O
+patients	O
+of	O
+basic	O
+group	O
+.	O
+
+Thus	O
+multilevel	O
+ventilation	O
+improves	O
+alveolar	O
+ventilation	O
+and	O
+arterial	B-ANAT
+oxygenation	B-PROC
+,	O
+decreases	O
+pulmonary	B-ANAT
+shunt	O
+and	O
+lung	B-ANAT
+injury	O
+and	O
+improves	O
+respiratory	O
+lung	B-ANAT
+functions	O
+.	O
+
+BV	O
+-	O
+Dual	O
+-	O
+S1	O
+elicited	O
+stronger	O
+humoral	O
+and	O
+cell	B-COMP
+-	O
+mediated	O
+immune	B-PROC
+responses	I-PROC
+,	O
+and	O
+showed	O
+greater	O
+capacity	O
+for	O
+induction	O
+of	O
+cytotoxic	B-ANAT
+T	I-ANAT
+lymphocyte	I-ANAT
+responses	O
+,	O
+compared	O
+with	O
+Ac	O
+-	O
+CMV	B-SPEC
+-	O
+S1	O
+in	O
+specific	O
+pathogen	O
+-	O
+free	O
+chickens	B-SPEC
+.	O
+
+ABSTRACT	O
+:	O
+Between	O
+June	O
+and	O
+September	O
+2013	O
+,	O
+sera	O
+from	O
+11	O
+dromedary	B-SPEC
+camels	B-SPEC
+,	O
+150	O
+goats	B-SPEC
+,	O
+126	O
+sheep	B-SPEC
+and	O
+91	O
+cows	B-SPEC
+were	O
+collected	O
+in	O
+Jordan	O
+,	O
+where	O
+the	O
+first	O
+human	B-SPEC
+Middle	O
+-	O
+East	O
+respiratory	O
+syndrome	B-DISO
+(	O
+MERS	O
+)	O
+cluster	O
+appeared	O
+in	O
+2012	O
+.	O
+
+All	O
+sera	B-COMP
+were	O
+tested	O
+for	O
+MERS	O
+-	O
+coronavirus	B-SPEC
+(	O
+MERS	O
+-	O
+CoV	O
+)	O
+specific	O
+antibodies	B-COMP
+by	O
+protein	B-CHED
+microarray	O
+with	O
+confirmation	O
+by	O
+virus	B-SPEC
+neutralisation	O
+.	O
+
+Although	O
+six	O
+sheep	B-SPEC
+sera	B-COMP
+reacted	O
+with	O
+MERS	B-PRGE
+-	I-PRGE
+CoV	I-PRGE
+antigen	I-PRGE
+,	I-PRGE
+neutralising	I-PRGE
+antibodies	B-COMP
+were	O
+not	O
+detected	O
+.	O
+
+TITLE	O
+:	O
+How	O
+the	O
+double	O
+spherules	O
+of	O
+infectious	B-DISO
+bronchitis	B-DISO
+virus	B-SPEC
+impact	O
+our	O
+understanding	O
+of	O
+RNA	O
+virus	B-SPEC
+replicative	O
+organelles	B-COMP
+.	O
+
+It	O
+is	O
+clear	O
+from	O
+these	O
+studies	O
+that	O
+whatever	O
+their	O
+purpose	O
+,	O
+organelle	B-COMP
+structure	I-COMP
+is	O
+dynamic	O
+(	O
+M	O
+.	O
+Ulasli	O
+,	O
+M	O
+.	O
+H	O
+.	O
+Verheije	O
+,	O
+C	O
+.	O
+A	O
+.	O
+de	O
+Haan	O
+,	O
+and	O
+F	O
+.	O
+Reggiori	O
+,	O
+Cell	B-COMP
+.	O
+
+Endpoints	O
+were	O
+duration	O
+of	O
+MV	O
+and	O
+LOS	O
+in	O
+the	O
+PICU	B-SPEC
+.	O
+
+It	O
+could	O
+be	O
+concluded	O
+that	O
+the	O
+enteric	O
+BCoV	O
+genealogy	O
+from	O
+newborn	O
+and	O
+adult	O
+cattle	B-SPEC
+is	O
+directly	O
+associated	O
+with	O
+geographic	O
+distribution	O
+patterns	O
+,	O
+when	O
+S	O
+and	O
+HE	O
+genes	O
+are	O
+taken	O
+into	O
+account	O
+.	O
+
+Pressure	B-DISO
+ulcers	I-DISO
+were	O
+assessed	O
+at	O
+the	O
+time	O
+of	O
+randomisation	O
+,	O
+7	O
+days	O
+later	O
+and	O
+on	O
+discharge	B-ANAT
+from	O
+the	O
+intensive	O
+care	O
+unit	O
+(	O
+ICU	O
+),	O
+using	O
+the	O
+four	O
+-	O
+stage	O
+Pressure	B-DISO
+Ulcers	I-DISO
+Advisory	O
+Panel	O
+system	O
+.	O
+
+TITLE	O
+:	O
+Middle	O
+East	O
+respiratory	O
+syndrome	B-DISO
+coronavirus	B-SPEC
+in	O
+dromedary	B-SPEC
+camels	B-SPEC
+:	O
+an	O
+outbreak	O
+investigation	O
+.	O
+
+We	O
+detected	O
+MERS	O
+-	O
+CoV	O
+in	O
+nose	B-ANAT
+swabs	O
+from	O
+three	O
+camels	B-SPEC
+by	O
+three	O
+independent	O
+RT	O
+-	O
+PCRs	O
+and	O
+sequencing	O
+.	O
+
+ABSTRACT	O
+:	O
+Development	B-PROC
+of	O
+vaccines	O
+for	O
+preventing	O
+a	O
+future	O
+pandemic	O
+of	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+(	O
+SARS	B-DISO
+)	O
+caused	O
+by	O
+SARS	B-DISO
+coronavirus	B-SPEC
+(	O
+SARS	B-DISO
+-	O
+CoV	O
+)	O
+and	O
+for	O
+biodefense	O
+preparedness	O
+is	O
+urgently	O
+needed	O
+.	O
+
+All	O
+constructs	O
+were	O
+expressed	O
+as	O
+recombinant	O
+proteins	B-CHED
+in	O
+yeast	B-SPEC
+.	O
+
+The	O
+purified	O
+recombinant	O
+proteins	B-CHED
+of	O
+these	O
+constructs	O
+were	O
+compared	O
+for	O
+their	O
+antigenicity	O
+,	O
+functionality	O
+and	O
+immunogenicity	O
+in	O
+mice	B-SPEC
+using	O
+alum	O
+as	O
+the	O
+adjuvant	B-CHED
+.	O
+
+We	O
+found	O
+that	O
+RBD219	O
+-	O
+N1	O
+exhibited	O
+high	O
+expression	B-PROC
+yield	O
+,	O
+and	O
+maintained	O
+its	O
+antigenicity	O
+and	O
+functionality	O
+.	O
+
+These	O
+trials	O
+suggested	O
+no	O
+benefit	O
+or	O
+even	O
+harm	O
+with	O
+HFOV	O
+in	O
+adults	O
+with	O
+early	O
+moderate	O
+-	O
+to	O
+-	O
+severe	O
+ARDS	B-DISO
+.	O
+
+ABSTRACT	O
+:	O
+Acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+(	O
+ARDS	B-DISO
+)	O
+is	O
+the	O
+most	O
+severe	O
+form	O
+of	O
+lung	B-ANAT
+injury	O
+,	O
+characterised	O
+by	O
+alveolar	B-DISO
+oedema	I-DISO
+and	O
+vascular	B-PROC
+permeability	I-PROC
+,	O
+in	O
+part	O
+due	O
+to	O
+disruption	O
+of	O
+the	O
+alveolar	B-ANAT
+capillary	B-ANAT
+membrane	B-COMP
+integrity	O
+.	O
+
+We	O
+performed	O
+a	O
+systematic	O
+review	O
+of	O
+studies	O
+reporting	O
+organ	B-ANAT
+-	O
+specific	O
+outcomes	O
+at	O
+28	O
+days	O
+or	O
+greater	O
+in	O
+survivors	O
+of	O
+severe	B-DISO
+sepsis	I-DISO
+.	O
+
+Future	O
+studies	O
+should	O
+attempt	O
+to	O
+characterize	O
+organ	B-ANAT
+dysfunction	O
+at	O
+greater	O
+than	O
+1	O
+month	O
+after	O
+an	O
+acute	O
+severe	B-DISO
+sepsis	I-DISO
+episode	O
+to	O
+determine	O
+the	O
+true	O
+prevalence	O
+long	O
+-	O
+term	O
+organ	B-ANAT
+dysfunction	O
+and	O
+treatments	O
+for	O
+prevention	O
+.	O
+
+RESULTS	O
+:	O
+We	O
+identified	O
+1	O
+,	O
+173	O
+articles	O
+and	O
+five	O
+met	B-CHED
+our	O
+inclusion	O
+criteria	O
+.	O
+
+For	O
+organ	B-DISO
+failure	I-DISO
+resolution	O
+the	O
+rates	O
+were	O
+highly	O
+variable	O
+.	O
+
+TITLE	O
+:	O
+Diagnostic	O
+and	O
+clinical	O
+observation	O
+on	O
+the	O
+infectious	B-DISO
+bronchitis	B-DISO
+virus	B-SPEC
+strain	O
+Q1	O
+in	O
+Italy	O
+.	O
+
+This	O
+IBV	B-SPEC
+variant	O
+was	O
+described	O
+for	O
+the	O
+first	O
+time	O
+in	O
+1998	O
+in	O
+China	O
+.	O
+
+Genomic	O
+studies	O
+revealed	O
+that	O
+two	O
+viral	O
+proteases	O
+,	O
+papain	B-PRGE
+-	I-PRGE
+like	I-PRGE
+protease	I-PRGE
+(	O
+PLpro	O
+)	O
+and	O
+3C	B-PRGE
+-	I-PRGE
+like	I-PRGE
+protease	I-PRGE
+(	O
+3CLpro	O
+),	O
+process	O
+the	O
+polyproteins	O
+encoded	O
+by	O
+the	O
+MERS	O
+-	O
+CoV	O
+genomic	O
+RNA	O
+.	O
+
+ABSTRACT	O
+:	O
+Influenza	O
+is	O
+a	O
+contagious	O
+respiratory	B-DISO
+disease	I-DISO
+caused	O
+by	O
+viruses	B-SPEC
+belonging	O
+to	O
+the	O
+family	B-SPEC
+Ortomyxoviridae	O
+.	O
+
+Among	O
+the	O
+influenza	B-SPEC
+viruses	I-SPEC
+type	O
+A	O
+,	O
+B	O
+and	O
+C	O
+,	O
+the	O
+A	O
+type	O
+virus	B-SPEC
+shows	O
+the	O
+most	O
+pathogenic	O
+potential	O
+.	O
+
+HE	O
+proteins	B-CHED
+mediate	O
+reversible	O
+binding	B-FUNC
+to	O
+sialic	B-PRGE
+acid	I-PRGE
+receptor	I-PRGE
+determinants	I-PRGE
+,	O
+very	O
+abundant	O
+glycan	B-CHED
+residues	O
+in	O
+the	O
+enteric	O
+and	O
+respiratory	B-ANAT
+tracts	I-ANAT
+.	O
+
+The	O
+phylogenetic	O
+analysis	O
+of	O
+HE	O
+coding	O
+sequences	O
+from	O
+porcine	B-SPEC
+torovirus	I-SPEC
+(	O
+PToV	O
+)	O
+field	O
+strains	O
+revealed	O
+the	O
+existence	O
+of	O
+two	O
+distinct	O
+HE	O
+lineages	O
+.	O
+
+The	O
+role	O
+of	O
+kidney	B-DISO
+infection	I-DISO
+in	O
+MERS	O
+is	O
+not	O
+understood	O
+.	O
+
+TITLE	O
+:	O
+Early	O
+fluid	O
+resuscitation	O
+with	O
+hydroxyethyl	O
+starch	B-CHED
+130	O
+/	O
+0	O
+.	O
+4	O
+(	O
+6	O
+%)	O
+in	O
+severe	O
+burn	O
+injury	O
+:	O
+a	O
+randomized	O
+,	O
+controlled	O
+,	O
+double	O
+-	O
+blind	O
+clinical	O
+trial	O
+.	O
+
+There	O
+are	O
+limited	O
+data	O
+on	O
+the	O
+efficacy	O
+of	O
+early	O
+fluid	O
+resuscitation	O
+with	O
+third	O
+-	O
+generation	O
+hydroxyethyl	O
+starch	B-CHED
+(	O
+HES	B-DISO
+130	O
+)	O
+in	O
+burn	O
+injury	O
+.	O
+
+ABSTRACT	O
+:	O
+A	O
+unique	O
+avian	B-SPEC
+-	O
+origin	O
+A	O
+/	O
+H7N9	O
+influenza	B-SPEC
+virus	I-SPEC
+has	O
+so	O
+far	O
+caused	O
+134	O
+cases	O
+with	O
+44	O
+deaths	B-PROC
+.	O
+
+Analysis	O
+of	O
+bronchoalveolar	O
+lavage	O
+samples	O
+showed	O
+up	O
+to	O
+1	O
+,	O
+000	O
+-	O
+fold	O
+greater	O
+cytokine	O
+/	O
+chemokine	O
+levels	O
+relative	O
+to	O
+plasma	B-ANAT
+.	O
+
+We	O
+performed	O
+an	O
+up	O
+-	O
+to	O
+-	O
+date	O
+meta	B-SPEC
+-	O
+analysis	O
+on	O
+this	O
+topic	O
+and	O
+elucidated	O
+the	O
+effect	O
+of	O
+prone	O
+positioning	O
+on	O
+overall	O
+mortality	O
+and	O
+associated	O
+complications	O
+.	O
+
+Ventilation	O
+in	O
+the	O
+prone	O
+position	O
+significantly	O
+reduced	O
+overall	O
+mortality	O
+in	O
+patients	O
+with	O
+severe	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+.	O
+
+An	O
+in	O
+vitro	O
+HNE	B-CHED
+inhibition	B-PROC
+assay	O
+was	O
+employed	O
+to	O
+screen	O
+a	O
+series	O
+of	O
+triterpenes	B-CHED
+.	O
+
+Of	O
+these	O
+pentacyclic	O
+triterpenes	B-CHED
+,	O
+ursolic	B-CHED
+acid	I-CHED
+exhibited	O
+the	O
+highest	O
+inhibitory	O
+potency	O
+(	O
+IC50	O
+=	O
+5	O
+.	O
+51	O
+µM	O
+).	O
+
+Here	O
+we	O
+show	O
+that	O
+a	O
+newly	O
+synthesized	O
+2	B-CHED
+-	I-CHED
+pyridone	I-CHED
+compound	O
+(	O
+FJU	O
+-	O
+C4	O
+)	O
+can	O
+suppress	O
+the	O
+expression	B-PROC
+of	O
+late	O
+inflammatory	O
+mediators	O
+such	O
+as	O
+iNOS	B-PRGE
+and	O
+COX	B-PRGE
+-	I-PRGE
+2	I-PRGE
+in	O
+murine	B-SPEC
+macrophages	B-ANAT
+.	O
+
+The	O
+chimeric	O
+VLPs	B-ANAT
+elicited	O
+significantly	O
+higher	O
+S1	O
+-	O
+specific	O
+antibody	B-PROC
+responses	I-PROC
+in	O
+intramuscularly	O
+immunized	O
+mice	B-SPEC
+and	O
+chickens	B-SPEC
+than	O
+inactivated	O
+IBV	B-SPEC
+viruses	B-SPEC
+.	O
+
+ABSTRACT	O
+:	O
+The	O
+novel	O
+pandemic	O
+influenza	B-PATH
+A	I-PATH
+(	O
+H1N1	O
+)	O
+caused	O
+an	O
+epidemic	O
+of	O
+critical	B-DISO
+illness	I-DISO
+,	O
+and	O
+some	O
+patients	O
+developed	O
+severe	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+(	O
+ARDS	B-DISO
+)	O
+or	O
+severe	O
+cardiopulmonary	B-DISO
+failure	I-DISO
+despite	O
+the	O
+use	O
+of	O
+conventional	O
+management	O
+.	O
+
+A	O
+normal	O
+left	B-PROC
+ventricular	I-PROC
+ejection	I-PROC
+fraction	O
+was	O
+documented	O
+on	O
+a	O
+2D	O
+echocardiography	O
+on	O
+day	O
+2	O
+.	O
+
+TITLE	O
+:	O
+Catastrophic	O
+antiphospholipid	B-DISO
+syndrome	I-DISO
+with	O
+severe	O
+acute	O
+thrombotic	B-DISO
+microangiopathy	I-DISO
+and	O
+hemorrhagic	O
+complications	O
+.	O
+
+The	O
+patient	O
+developed	O
+respiratory	B-DISO
+failure	I-DISO
+due	O
+to	O
+diffuse	O
+alveolar	B-ANAT
+hemorrhage	B-DISO
+.	O
+
+General	O
+linear	O
+models	O
+and	O
+bootstrapped	O
+Spearman	O
+correlations	O
+were	O
+used	O
+to	O
+examine	O
+changes	O
+in	O
+metabolic	B-PROC
+syndrome	I-DISO
+associated	O
+with	O
+training	O
+primary	O
+and	O
+secondary	O
+outcome	O
+variables	O
+.	O
+
+RESULTS	O
+:	O
+We	O
+observed	O
+a	O
+significant	O
+decrease	O
+in	O
+metabolic	B-DISO
+syndrome	I-DISO
+scores	O
+(	O
+P	O
+for	O
+trend	O
+=	O
+0	O
+.	O
+003	O
+)	O
+for	O
+AER	B-COMP
+(-	O
+0	O
+.	O
+59	O
+,	O
+95	O
+%	O
+CI	O
+=	O
+-	O
+1	O
+.	O
+00	O
+to	O
+-	O
+0	O
+.	O
+21	O
+)	O
+and	O
+AER	B-COMP
++	O
+RES	O
+(-	O
+0	O
+.	O
+79	O
+,	O
+95	O
+%	O
+CI	O
+=	O
+-	O
+1	O
+.	O
+40	O
+to	O
+-	O
+0	O
+.	O
+35	O
+),	O
+both	O
+being	O
+significant	O
+(	O
+P	O
+≤	O
+0	O
+.	O
+02	O
+)	O
+versus	O
+control	O
+(	O
+0	O
+.	O
+26	O
+,	O
+95	O
+%	O
+CI	O
+=	O
+-	O
+0	O
+.	O
+58	O
+to	O
+0	O
+.	O
+40	O
+)	O
+and	O
+RES	O
+(-	O
+0	O
+.	O
+13	O
+,	O
+95	O
+%	O
+CI	O
+=	O
+-	O
+1	O
+.	O
+00	O
+to	O
+0	O
+.	O
+24	O
+).	O
+
+This	O
+paper	O
+examined	O
+the	O
+current	O
+status	O
+of	O
+and	O
+developments	O
+in	O
+China	O
+'	O
+s	O
+response	O
+to	O
+emerging	B-DISO
+communicable	I-DISO
+diseases	I-DISO
+from	O
+the	O
+outbreak	O
+of	O
+SARS	B-DISO
+in	O
+2003	O
+to	O
+the	O
+outbreak	O
+of	O
+H7N9	O
+virus	B-DISO
+infection	I-DISO
+in	O
+2013	O
+.	O
+
+This	O
+mechanism	O
+for	O
+responding	O
+to	O
+emerging	B-DISO
+communicable	I-DISO
+diseases	I-DISO
+allowed	O
+China	O
+to	O
+successfully	O
+deal	O
+with	O
+outbreaks	O
+of	O
+the	O
+H5N1	O
+bird	B-DISO
+flu	I-DISO
+,	O
+H1N1	B-DISO
+flu	I-DISO
+,	O
+and	O
+H7N9	B-PRGE
+bird	I-PRGE
+flu	I-PRGE
+.	O
+
+A	O
+total	O
+of	O
+79	O
+(	O
+0	O
+.	O
+5	O
+%	O
+prevalence	O
+)	O
+specimens	O
+were	O
+positive	O
+for	O
+human	B-PRGE
+betacoronavirus	B-SPEC
+HKU1	I-PRGE
+RNA	I-PRGE
+.	O
+
+The	O
+purpose	O
+of	O
+this	O
+study	O
+was	O
+to	O
+evaluate	O
+whether	O
+serum	B-COMP
+levels	O
+of	O
+certain	O
+cytokines	O
+,	O
+measured	O
+immediately	O
+after	O
+initial	O
+injury	O
+,	O
+can	O
+be	O
+used	O
+as	O
+potential	O
+biomarkers	O
+for	O
+predicting	O
+the	O
+development	B-PROC
+and	O
+the	O
+degree	O
+of	O
+severity	O
+of	O
+the	O
+systemic	O
+inflammatory	B-DISO
+response	I-DISO
+(	O
+SIRS	B-DISO
+)	O
+in	O
+patients	O
+with	O
+moderate	O
+and	O
+severe	O
+trauma	O
+.	O
+
+Thirty	O
+cc	O
+of	O
+heparinized	O
+blood	B-ANAT
+were	O
+drawn	O
+from	O
+each	O
+individual	O
+within	O
+a	O
+few	O
+hours	O
+after	O
+the	O
+injury	O
+.	O
+
+High	O
+levels	O
+of	O
+pro	O
+-	O
+inflammatory	O
+cytokines	O
+IL	O
+-	O
+1β	O
+,-	O
+6	O
+,-	O
+8	O
+,-	O
+12	O
+,	O
+tumour	B-PRGE
+necrosis	I-PRGE
+factor	I-PRGE
+alpha	I-PRGE
+and	O
+interferon	B-PRGE
+gamma	I-PRGE
+were	O
+found	O
+in	O
+all	O
+injured	O
+patients	O
+compared	O
+to	O
+healthy	O
+controls	O
+.	O
+
+TITLE	O
+:	O
+Anaphylactic	B-DISO
+Shock	I-DISO
+:	O
+
+All	O
+patients	O
+were	O
+critically	B-DISO
+ill	I-DISO
+with	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+treated	O
+with	O
+adjunctive	O
+corticosteroids	B-CHED
+and	O
+were	O
+on	O
+mechanical	O
+ventilation	O
+at	O
+the	O
+time	O
+of	O
+initiation	O
+of	O
+therapy	O
+.	O
+
+RESULTS	O
+:	O
+All	O
+patients	O
+were	O
+critically	B-DISO
+ill	I-DISO
+with	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+treated	O
+with	O
+adjunctive	O
+corticosteroids	B-CHED
+and	O
+were	O
+on	O
+mechanical	O
+ventilation	O
+at	O
+the	O
+time	O
+of	O
+initiation	O
+of	O
+therapy	O
+.	O
+
+TITLE	O
+:	O
+Probabilistic	O
+differential	O
+diagnosis	O
+of	O
+Middle	O
+East	O
+respiratory	O
+syndrome	B-DISO
+(	O
+MERS	O
+)	O
+using	O
+the	O
+time	O
+from	O
+immigration	O
+to	O
+illness	O
+onset	O
+among	O
+imported	O
+cases	O
+.	O
+
+ABSTRACT	O
+:	O
+To	O
+evaluate	O
+the	O
+therapeutic	O
+efficacy	O
+of	O
+noninvasive	O
+positive	O
+pressure	O
+ventilation	O
+(	O
+NPPV	O
+)	O
+in	O
+the	O
+treatment	O
+of	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+(	O
+ARDS	B-DISO
+)	O
+following	O
+esophagectomy	O
+for	O
+esophageal	B-DISO
+cancer	I-DISO
+.	O
+
+IL	O
+-	O
+1β	O
+,	O
+IL	B-FUNC
+-	I-FUNC
+21	I-FUNC
+,	O
+and	O
+PTX3	B-PRGE
+concentrations	O
+were	O
+similar	O
+in	O
+the	O
+study	O
+groups	O
+.	O
+
+The	O
+only	O
+significant	O
+correlation	O
+between	O
+clinical	O
+periodontal	O
+parameters	O
+and	O
+salivary	O
+cytokines	O
+was	O
+found	O
+between	O
+clinical	O
+attachment	O
+level	O
+(	O
+CAL	O
+)	O
+and	O
+IL	B-FUNC
+-	I-FUNC
+21	I-FUNC
+(	O
+P	O
+=	O
+0	O
+.	O
+02	O
+).	O
+
+ABSTRACT	O
+:	O
+Whereas	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+(	O
+SARS	B-DISO
+)	O
+coronavirus	B-SPEC
+(	O
+SARS	B-DISO
+-	O
+CoV	O
+)	O
+is	O
+associated	O
+with	O
+severe	O
+disease	O
+,	O
+human	B-SPEC
+coronavirus	I-SPEC
+HKU1	I-SPEC
+(	O
+HCoV	O
+-	O
+HKU1	O
+)	O
+commonly	O
+circulates	O
+in	O
+the	O
+human	B-SPEC
+populations	O
+causing	O
+generally	O
+milder	O
+illness	O
+.	O
+
+A	O
+central	O
+region	O
+(	O
+amino	B-CHED
+acids	I-CHED
+201	O
+-	O
+400	O
+)	O
+of	O
+SARS	B-PRGE
+-	I-PRGE
+CoV	I-PRGE
+S1	I-PRGE
+was	O
+required	O
+for	O
+this	O
+activity	O
+.	O
+
+Prevalence	O
+of	O
+Co	O
+,	O
+Gi	O
+and	O
+Tr	O
+was	O
+higher	O
+in	O
+pedigree	O
+cats	B-SPEC
+compared	O
+to	O
+non	O
+-	O
+pedigree	O
+cats	B-SPEC
+(	O
+DSH	B-DISO
+)	O
+and	O
+prevalence	O
+decreased	O
+with	O
+increasing	O
+age	O
+for	O
+Co	O
+,	O
+Pa	O
+,	O
+Gi	O
+,	O
+Cr	O
+and	O
+Tr	O
+.	O
+
+The	O
+chest	B-ANAT
+X	O
+-	O
+ray	B-SPEC
+performed	O
+12hours	O
+later	O
+showed	O
+complete	O
+resolution	O
+of	O
+the	O
+atelectasis	B-DISO
+.	O
+
+Ventilation	O
+in	O
+prone	O
+position	O
+rescued	O
+this	O
+patient	O
+by	O
+maintaining	O
+oxygenation	B-PROC
+and	O
+sustaining	O
+improvement	O
+thereafter	O
+.	O
+
+Although	O
+all	O
+the	O
+extract	O
+treatments	O
+had	O
+an	O
+effect	O
+on	O
+IL	B-PROC
+-	I-PROC
+8	I-PROC
+secretion	B-ANAT
+,	O
+TRP	B-PRGE
+gene	B-PROC
+expression	I-PROC
+and	O
+virus	B-SPEC
+load	O
+after	O
+CoV	O
+infection	B-DISO
+,	O
+it	O
+was	O
+the	O
+Ah	O
+extract	O
+treatment	O
+that	O
+showed	O
+the	O
+biggest	O
+difference	O
+in	O
+virus	B-SPEC
+load	O
+.	O
+
+This	O
+study	O
+demonstrates	O
+that	O
+NPCs	O
+support	O
+replication	O
+following	O
+infection	B-DISO
+by	O
+the	O
+neurotropic	O
+JHM	O
+strain	O
+of	O
+mouse	B-DISO
+hepatitis	I-DISO
+virus	B-SPEC
+(	O
+JHMV	O
+).	O
+
+Importantly	O
+,	O
+cytokines	O
+secreted	B-PROC
+by	O
+CD4	B-PRGE
++	I-PRGE
+T	B-ANAT
+cells	I-ANAT
+inhibit	O
+JHMV	O
+replication	O
+in	O
+NPCs	O
+,	O
+and	O
+CD8	B-PRGE
++	I-PRGE
+T	B-ANAT
+cells	I-ANAT
+specifically	O
+target	O
+viral	O
+peptide	B-CHED
+-	O
+pulsed	O
+NPCs	O
+for	O
+lysis	B-DISO
+.	O
+
+Furthermore	O
+,	O
+treatment	O
+with	O
+IFN	B-PRGE
+-	I-PRGE
+γ	I-PRGE
+inhibits	O
+JHMV	O
+replication	O
+in	O
+a	O
+dose	O
+-	O
+dependent	O
+manner	O
+.	O
+
+It	O
+was	O
+also	O
+demonstrated	O
+that	O
+N	B-PRGE
+-	I-PRGE
+protein	I-PRGE
+binds	B-FUNC
+to	O
+nucleic	B-CHED
+acid	I-CHED
+at	O
+multiple	O
+sites	O
+with	O
+a	O
+coupled	O
+-	O
+allostery	O
+manner	O
+.	O
+
+ABSTRACT	O
+:	O
+Bovine	B-SPEC
+respiratory	I-SPEC
+syncytial	I-SPEC
+virus	I-SPEC
+(	O
+BRSV	B-SPEC
+)	O
+is	O
+one	O
+of	O
+the	O
+major	O
+pathogens	O
+involved	O
+in	O
+the	O
+bovine	B-SPEC
+respiratory	B-DISO
+disease	I-DISO
+(	O
+BRD	O
+)	O
+complex	O
+.	O
+
+When	O
+serology	O
+indicated	O
+that	O
+bovine	B-SPEC
+coronavirus	B-SPEC
+and	O
+/	O
+or	O
+bovine	B-SPEC
+parainfluenza	I-SPEC
+virus	I-SPEC
+3	I-SPEC
+were	O
+present	O
+,	O
+the	O
+number	O
+of	O
+BRSV	B-SPEC
+positive	O
+animals	B-SPEC
+in	O
+the	O
+herd	O
+was	O
+always	O
+higher	O
+,	O
+supporting	O
+the	O
+view	O
+of	O
+BRSV	B-SPEC
+as	O
+the	O
+main	O
+pathogen	O
+.	O
+
+The	O
+sequence	O
+variations	O
+between	O
+the	O
+two	O
+strains	O
+were	O
+in	O
+an	O
+antigenic	O
+important	O
+part	O
+of	O
+the	O
+G	B-PRGE
+protein	I-PRGE
+.	O
+
+TITLE	O
+:	O
+Emerging	O
+viral	B-DISO
+diseases	I-DISO
+of	O
+livestock	O
+in	O
+the	O
+developing	O
+world	O
+.	O
+
+TITLE	O
+:	O
+Choice	O
+of	O
+optimal	O
+time	O
+and	O
+type	O
+of	O
+orthopedic	O
+surgery	O
+in	O
+multiple	O
+injured	O
+patients	O
+with	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+(	O
+ARDS	B-DISO
+)	O
+depending	O
+on	O
+age	O
+:	O
+retrospective	O
+study	O
+.	O
+
+ARDS	B-DISO
+(	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+)	O
+is	O
+a	O
+part	O
+of	O
+MOFS	O
+.	O
+
+However	O
+,	O
+neither	O
+age	O
+nor	O
+severity	O
+of	O
+injury	O
+to	O
+the	O
+anatomical	O
+segments	O
+is	O
+a	O
+reliable	O
+criterion	O
+for	O
+assessing	O
+the	O
+severity	O
+of	O
+a	O
+patient	O
+'	O
+s	O
+condition	B-DISO
+.	O
+
+Feces	B-ANAT
+samples	O
+were	O
+tested	O
+for	O
+canine	B-SPEC
+distemper	I-SPEC
+virus	I-SPEC
+,	O
+canine	O
+coronavirus	B-SPEC
+,	O
+canine	O
+parvovirus	B-PRGE
+type	I-PRGE
+2	I-PRGE
+(	O
+CPV	B-SPEC
+-	O
+2	O
+),	O
+Clostridium	B-SPEC
+perfringens	I-SPEC
+alpha	I-PRGE
+toxin	I-PRGE
+(	O
+CPA	O
+),	O
+Cryptosporidium	B-SPEC
+spp	B-ENZY
+.,	O
+Giardia	B-PRGE
+spp	B-ENZY
+.,	I-PRGE
+and	I-PRGE
+Salmonella	B-DISO
+spp	B-ENZY
+.	O
+
+Cells	B-COMP
+and	O
+supernatants	O
+were	O
+harvested	O
+separately	O
+and	O
+virus	B-SPEC
+titers	O
+were	O
+quantified	O
+by	O
+plaque	B-DISO
+assay	O
+.	O
+
+TITLE	O
+:	O
+[	O
+Complicated	O
+form	O
+of	O
+A	O
+/	O
+HINI	O
+(	O
+2009	O
+)	O
+influenza	B-DISO
+in	O
+pregnant	O
+women	O
+].	O
+
+Control	O
+groups	O
+were	O
+comprised	O
+of	O
+100	O
+pregnant	O
+women	O
+with	O
+uncomplicated	O
+influenza	B-DISO
+and	O
+100	O
+ones	O
+who	O
+did	O
+not	O
+fall	O
+ill	B-DISO
+during	O
+flu	B-DISO
+pandemic	O
+.	O
+
+Most	O
+women	O
+developed	O
+pneumonia	B-DISO
+in	O
+the	O
+3d	O
+trimester	O
+Risk	O
+factors	O
+offlu	O
+complications	O
+included	O
+smoking	O
+,	O
+obesity	B-DISO
+,	O
+underlying	O
+respiratory	O
+and	O
+cardiovascular	B-ANAT
+diseases	O
+,	O
+sexually	B-DISO
+transmitted	I-DISO
+infections	I-DISO
+.	O
+
+Peritoneal	B-ANAT
+ventilation	O
+has	O
+long	O
+been	O
+desired	O
+for	O
+extrapulmonary	O
+oxygenation	B-PROC
+owing	O
+to	O
+easy	O
+access	O
+of	O
+the	O
+peritoneal	B-ANAT
+cavity	I-ANAT
+for	O
+catheterization	O
+and	O
+the	O
+relative	O
+safety	O
+compared	O
+to	O
+an	O
+extracorporeal	O
+circuit	O
+.	O
+
+Peritoneal	B-ANAT
+oxygenation	B-PROC
+with	O
+OMBs	O
+was	O
+therefore	O
+shown	O
+to	O
+be	O
+safe	O
+and	O
+effective	O
+,	O
+and	O
+the	O
+method	O
+requires	O
+less	O
+equipment	O
+and	O
+technical	O
+expertise	O
+than	O
+initiating	O
+and	O
+maintaining	O
+an	O
+extracorporeal	O
+circuit	O
+.	O
+
+The	O
+environmental	O
+origin	O
+of	O
+MERS	O
+-	O
+CoV	O
+is	O
+as	O
+yet	O
+unknown	O
+;	O
+however	O
+,	O
+its	O
+genome	O
+sequence	O
+is	O
+closely	O
+related	O
+to	O
+those	O
+of	O
+two	O
+bat	B-ENZY
+coronaviruses	O
+,	O
+named	O
+BtCoV	O
+-	O
+HKU4	O
+and	O
+BtCoV	O
+-	O
+HKU5	O
+,	O
+which	O
+were	O
+derived	O
+from	O
+Chinese	O
+bat	B-ENZY
+samples	O
+.	O
+
+A	O
+hallmark	O
+of	O
+highly	O
+pathogenic	O
+respiratory	O
+viruses	B-SPEC
+is	O
+their	O
+ability	O
+to	O
+evade	O
+the	O
+innate	B-DISO
+immune	I-DISO
+response	I-DISO
+of	O
+the	O
+host	B-COMP
+.	O
+
+MERS	O
+-	O
+CoV	O
+,	O
+similar	O
+to	O
+SARS	B-DISO
+-	O
+CoV	O
+,	O
+has	O
+been	O
+shown	O
+to	O
+inhibit	O
+type	B-PRGE
+I	I-PRGE
+IFN	I-PRGE
+induction	O
+in	O
+a	O
+variety	O
+of	O
+cell	B-COMP
+types	O
+in	O
+vitro	O
+.	O
+
+In	O
+this	O
+study	O
+,	O
+we	O
+have	O
+demonstrated	O
+that	O
+the	O
+ORF4b	B-PRGE
+-	I-PRGE
+encoded	I-PRGE
+accessory	I-PRGE
+protein	I-PRGE
+(	O
+p4b	O
+)	O
+of	O
+MERS	O
+-	O
+CoV	O
+,	O
+BtCoV	O
+-	O
+HKU4	O
+and	O
+BtCoV	O
+-	O
+HKU5	O
+may	O
+indeed	O
+facilitate	O
+innate	O
+immune	B-PROC
+evasion	I-PROC
+by	O
+inhibiting	O
+the	O
+type	B-PRGE
+I	I-PRGE
+IFN	I-PRGE
+and	O
+NF	O
+-	O
+κB	O
+signalling	B-PROC
+pathways	B-PROC
+.	O
+
+ABSTRACT	O
+:	O
+Acute	B-DISO
+respiratory	I-DISO
+failure	I-DISO
+(	O
+ARF	B-DISO
+)	O
+is	O
+the	O
+main	O
+reason	O
+for	O
+intensive	O
+care	O
+unit	O
+(	O
+ICU	O
+)	O
+admissions	O
+in	O
+patients	O
+with	O
+hematologic	B-DISO
+malignancies	I-DISO
+(	O
+HMs	B-DISO
+).	O
+
+TITLE	O
+:	O
+Successful	O
+treatment	O
+of	O
+cardiogenic	B-DISO
+shock	I-DISO
+with	O
+an	O
+intraaortic	O
+balloon	O
+pump	O
+following	O
+aluminium	B-CHED
+phosphide	I-CHED
+poisoning	O
+.	O
+
+We	O
+report	O
+on	O
+the	O
+use	O
+of	O
+an	O
+intra	O
+-	O
+aortic	B-ANAT
+balloon	O
+pump	O
+(	O
+IABP	O
+)	O
+in	O
+a	O
+24	O
+-	O
+year	O
+-	O
+old	O
+woman	O
+brought	O
+to	O
+our	O
+hospital	O
+after	O
+an	O
+intentional	O
+ingestion	O
+of	O
+a	O
+tablet	O
+of	O
+AlP	B-CHED
+(	O
+3	O
+g	O
+),	O
+which	O
+caused	O
+refractory	O
+AlP	B-CHED
+-	O
+induced	O
+cardiogenic	B-DISO
+shock	I-DISO
+and	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+(	O
+ARDS	B-DISO
+).	O
+
+IABP	O
+was	O
+successfully	O
+used	O
+and	O
+may	O
+improve	O
+future	O
+prognoses	O
+for	O
+severely	O
+poisoned	O
+AlP	O
+patients	O
+with	O
+refractory	O
+cardiogenic	B-DISO
+shock	I-DISO
+.	O
+
+Multivariate	O
+logistic	O
+regression	O
+analysis	O
+showed	O
+that	O
+the	O
+underlying	O
+disease	O
+scores	O
+[	O
+odds	O
+ratio	O
+(	O
+OR	O
+)=	O
+1	O
+.	O
+874	O
+,	O
+95	O
+%	O
+confidence	O
+interval	O
+(	O
+95	O
+%	O
+CI	O
+)	O
+1	O
+.	O
+138	O
+-	O
+3	O
+.	O
+084	O
+,	O
+P	O
+=	O
+0	O
+.	O
+014	O
+],	O
+whether	O
+patients	O
+occurrence	O
+of	O
+severe	B-DISO
+sepsis	I-DISO
+/	O
+septic	B-DISO
+shock	I-DISO
+(	O
+OR	O
+=	O
+0	O
+.	O
+167	O
+,	O
+95	O
+%	O
+CI	O
+0	O
+.	O
+064	O
+-	O
+0	O
+.	O
+435	O
+,	O
+P	O
+=	O
+0	O
+.	O
+000	O
+)	O
+and	O
+SOFA	O
+scores	O
+(	O
+OR	O
+=	O
+1	O
+.	O
+498	O
+,	O
+95	O
+%	O
+CI	O
+1	O
+.	O
+283	O
+-	O
+1	O
+.	O
+750	O
+,	O
+P	O
+=	O
+0	O
+.	O
+000	O
+)	O
+were	O
+independent	O
+factors	O
+for	O
+predicting	O
+28	O
+-	O
+day	O
+mortality	O
+.	O
+
+AUC	O
+for	O
+PCT	B-DISO
+was	O
+0	O
+.	O
+636	O
+(	O
+0	O
+.	O
+548	O
+-	O
+0	O
+.	O
+724	O
+),	O
+P	O
+=	O
+0	O
+.	O
+004	O
+.	O
+
+ABSTRACT	O
+:	O
+We	O
+detected	O
+ferret	O
+coronaviruses	O
+in	O
+44	O
+(	O
+55	O
+.	O
+7	O
+%)	O
+of	O
+79	O
+pet	O
+ferrets	B-SPEC
+tested	O
+in	O
+Japan	O
+and	O
+classified	O
+the	O
+viruses	B-SPEC
+into	O
+2	O
+genotypes	O
+on	O
+the	O
+basis	O
+of	O
+genotype	O
+-	O
+specific	O
+PCR	O
+.	O
+
+In	O
+contrast	O
+,	O
+in	O
+cl	O
+-	O
+2	O
+infection	B-DISO
+,	O
+10	O
+-	O
+20	O
+%	O
+of	O
+the	O
+infected	O
+mice	B-SPEC
+exhibited	O
+apoptosis	B-PATH
+in	O
+the	O
+hippocampus	B-SPEC
+,	O
+which	O
+was	O
+primarily	O
+observed	O
+in	O
+the	O
+CA1	B-ANAT
+subregion	O
+.	O
+
+The	O
+protein	B-CHED
+and	O
+the	O
+lipid	B-CHED
+charges	O
+configure	O
+a	O
+polarized	O
+interface	O
+that	O
+yields	O
+local	O
+ionic	O
+concentrations	O
+and	O
+electric	O
+potentials	O
+that	O
+are	O
+very	O
+different	O
+from	O
+those	O
+of	O
+the	O
+bulk	O
+electrolyte	O
+.	O
+
+ABSTRACT	O
+:	O
+The	O
+outbreak	O
+of	O
+Middle	O
+East	O
+respiratory	O
+syndrome	B-DISO
+coronavirus	B-SPEC
+(	O
+MERS	O
+-	O
+CoV	O
+)	O
+infections	B-DISO
+and	O
+diseases	O
+represents	O
+a	O
+potential	O
+threat	O
+for	O
+worldwide	O
+spread	O
+and	O
+requires	O
+development	B-PROC
+of	O
+effective	O
+therapeutic	O
+strategies	O
+.	O
+
+In	O
+this	O
+study	O
+,	O
+we	O
+revealed	O
+a	O
+novel	O
+positive	O
+function	O
+of	O
+an	O
+exchange	O
+protein	B-CHED
+directly	O
+activated	O
+by	O
+cyclic	B-PRGE
+AMP	I-PRGE
+1	I-PRGE
+(	O
+cAMP	B-PRGE
+-	I-PRGE
+1	I-PRGE
+;	O
+Epac	B-PRGE
+-	I-PRGE
+1	I-PRGE
+)	O
+on	O
+MERS	O
+-	O
+CoV	O
+replication	O
+.	O
+
+ABSTRACT	O
+:	O
+Replicative	O
+capacity	O
+of	O
+Middle	O
+East	O
+respiratory	O
+syndrome	O
+coronavirus	B-SPEC
+(	O
+MERS	O
+-	O
+CoV	O
+)	O
+was	O
+assessed	O
+in	O
+cell	B-ANAT
+lines	I-ANAT
+derived	O
+from	O
+livestock	O
+and	O
+peridomestic	O
+small	O
+mammals	B-SPEC
+on	O
+the	O
+Arabian	O
+Peninsula	O
+.	O
+
+Prevention	O
+against	O
+type	O
+II	O
+FIPV	O
+79	O
+-	O
+1146	O
+strain	O
+-	O
+induced	O
+FIP	B-DISO
+was	O
+slightly	O
+better	O
+in	O
+specific	O
+pathogen	O
+-	O
+free	O
+cats	B-SPEC
+treated	O
+with	O
+NP7	O
+and	O
+NP8	O
+with	O
+fCpG	O
+-	O
+ODNs	O
+.	O
+
+However	O
+,	O
+immune	B-DISO
+tolerance	I-DISO
+was	O
+suggested	O
+to	O
+be	O
+induced	O
+by	O
+the	O
+high	O
+dose	O
+and	O
+frequency	O
+of	O
+NP7	O
+and	O
+NP8	O
+with	O
+fCpG	O
+-	O
+ODNs	O
+.	O
+
+However	O
+,	O
+immune	B-DISO
+tolerance	I-DISO
+was	O
+suggested	O
+to	O
+be	O
+induced	O
+by	O
+the	O
+high	O
+dose	O
+and	O
+frequency	O
+of	O
+NP7	O
+and	O
+NP8	O
+with	O
+fCpG	O
+-	O
+ODNs	O
+.	O
+
+The	O
+National	O
+Trauma	O
+Data	O
+Bank	O
+was	O
+used	O
+for	O
+a	O
+retrospective	O
+analysis	O
+of	O
+the	O
+injury	O
+patterns	O
+,	O
+management	O
+,	O
+and	O
+clinical	O
+outcomes	O
+associated	O
+with	O
+flail	B-DISO
+chest	I-DISO
+injuries	O
+.	O
+
+Patients	O
+with	O
+a	O
+flail	B-DISO
+chest	I-DISO
+injury	O
+admitted	O
+from	O
+2007	O
+to	O
+2009	O
+were	O
+included	O
+in	O
+the	O
+analysis	O
+.	O
+
+RESULTS	O
+:	O
+Flail	B-DISO
+chest	I-DISO
+injury	O
+was	O
+identified	O
+in	O
+3	O
+,	O
+467	O
+patients	O
+;	O
+the	O
+mean	O
+age	O
+was	O
+52	O
+.	O
+5	O
+years	O
+,	O
+and	O
+77	O
+%	O
+of	O
+the	O
+patients	O
+were	O
+male	O
+.	O
+
+Kaempferol	B-CHED
+derivatives	O
+with	O
+rhamnose	B-CHED
+residue	O
+also	O
+seem	O
+to	O
+be	O
+quite	O
+effective	O
+.	O
+
+Early	O
+diagnosis	O
+and	O
+surgical	O
+intervention	O
+of	O
+the	O
+compartment	B-DISO
+syndrome	I-DISO
+can	O
+lead	O
+to	O
+full	O
+recovery	O
+while	O
+any	O
+delay	O
+in	O
+management	O
+can	O
+be	O
+devastating	O
+and	O
+can	O
+lead	O
+to	O
+permanent	O
+disability	O
+.	O
+
+The	O
+presence	O
+of	O
+peripheral	B-ANAT
+nervous	I-ANAT
+system	I-ANAT
+injuries	O
+may	O
+portend	O
+a	O
+poor	O
+prognosis	O
+and	O
+can	O
+also	O
+lead	O
+to	O
+long	O
+term	O
+disability	O
+.	O
+
+TITLE	O
+:	O
+Reverse	B-PROC
+transcription	I-PROC
+recombinase	O
+polymerase	O
+amplification	B-DISO
+assay	O
+for	O
+the	O
+detection	O
+of	O
+middle	O
+East	O
+respiratory	O
+syndrome	O
+coronavirus	B-SPEC
+.	O
+
+A	O
+rapid	O
+point	O
+-	O
+of	O
+-	O
+care	O
+test	O
+is	O
+needed	O
+to	O
+allow	O
+more	O
+widespread	O
+mobile	O
+detection	O
+of	O
+the	O
+virus	B-SPEC
+directly	O
+from	O
+patient	O
+material	O
+.	O
+
+We	O
+present	O
+a	O
+case	O
+of	O
+G	B-PRGE
+-	I-PRGE
+CSF	I-PRGE
+-	O
+producing	O
+lung	B-DISO
+cancer	B-SPEC
+with	O
+marked	O
+leukocytosis	B-DISO
+,	O
+which	O
+rapidly	O
+led	O
+to	O
+severe	O
+ARDS	B-DISO
+after	O
+the	O
+patient	O
+developed	O
+pneumonia	B-DISO
+.	O
+
+We	O
+report	O
+MERS	O
+-	O
+CoV	O
+data	O
+from	O
+5065	O
+Kingdom	B-SPEC
+of	O
+Saudi	O
+Arabia	O
+individuals	O
+who	O
+were	O
+screened	O
+for	O
+MERS	O
+-	O
+CoV	O
+over	O
+a	O
+12	O
+-	O
+month	O
+period	O
+.	O
+
+ABSTRACT	O
+:	O
+Feline	B-SPEC
+viral	B-DISO
+diseases	I-DISO
+are	O
+common	O
+and	O
+cats	O
+can	O
+be	O
+presented	O
+with	O
+a	O
+variety	O
+of	O
+clinical	O
+manifestations	O
+.	O
+
+International	O
+consensus	O
+defines	O
+AMS	B-DISO
+as	O
+a	O
+constellation	O
+of	O
+subjective	O
+,	O
+non	O
+-	O
+specific	O
+symptoms	O
+.	O
+
+Hence	O
+,	O
+these	O
+symptoms	O
+may	O
+not	O
+belong	O
+together	O
+as	O
+a	O
+single	O
+syndrome	B-DISO
+.	O
+
+Sleep	B-DISO
+disturbance	I-DISO
+correlates	O
+poorly	O
+with	O
+other	O
+symptoms	O
+of	O
+AMS	B-DISO
+(	O
+Mean	O
+Spearman	O
+correlation	O
+0	O
+.	O
+25	O
+).	O
+
+TITLE	O
+:	O
+Design	O
+,	O
+synthesis	B-PROC
+,	O
+antiviral	B-CHED
+activity	O
+,	O
+and	O
+structure	O
+-	O
+activity	O
+relationships	O
+(	O
+SARs	B-DISO
+)	O
+of	O
+two	O
+types	O
+of	O
+structurally	O
+novel	O
+phenanthroindo	O
+/	O
+quinolizidine	O
+analogues	O
+.	O
+
+Her	O
+colloid	B-ANAT
+osmotic	O
+pressure	O
+was	O
+4	O
+.	O
+6mmHg	O
+.	O
+
+Following	O
+a	O
+bolus	O
+dose	O
+of	O
+prednisolone	B-CHED
+(	O
+500mg	O
+),	O
+fluid	O
+resuscitation	O
+was	O
+initiated	O
+.	O
+
+During	O
+volume	O
+loading	O
+,	O
+anasarca	B-DISO
+and	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+rapidly	O
+developed	O
+.	O
+
+A	O
+laboratory	O
+analysis	O
+of	O
+her	O
+complement	O
+system	O
+suggested	O
+the	O
+presence	O
+of	O
+C1	B-DISO
+inhibitor	I-DISO
+deficiency	I-DISO
+as	O
+the	O
+cause	O
+for	O
+systemic	B-ANAT
+capillary	I-ANAT
+leakage	B-DISO
+.	O
+
+TITLE	O
+:	O
+Validation	O
+of	O
+respiratory	O
+inductive	O
+plethysmography	O
+(	O
+LifeShirt	O
+)	O
+in	O
+obesity	B-DISO
+hypoventilation	I-DISO
+syndrome	I-DISO
+.	O
+
+Among	O
+13	O
+OHS	B-DISO
+participants	O
+(	O
+162	O
+paired	O
+measures	O
+),	O
+RIPLS	O
+-	O
+spirometer	O
+agreement	O
+was	O
+unacceptable	O
+for	O
+VT	O
+:	O
+mean	O
+difference	O
+(	O
+MD	O
+)	O
+3	O
+mL	O
+(	O
+1	O
+%);	O
+limits	O
+of	O
+agreement	O
+(	O
+LOA	B-SPEC
+)	O
+-	O
+216	O
+to	O
+220	O
+mL	O
+(±	O
+36	O
+%);	O
+V	O
+˙	O
+E	O
+MD	O
+0	O
+.	O
+1	O
+L	O
+min	O
+(-	O
+1	O
+)	O
+(	O
+2	O
+%);	O
+LOA	B-SPEC
+-	O
+4	O
+.	O
+1	O
+to	O
+4	O
+.	O
+3	O
+L	O
+min	O
+(-	O
+1	O
+)	O
+(±	O
+36	O
+%);	O
+and	O
+fB	O
+:	O
+MD	O
+0	O
+.	O
+2	O
+br	O
+min	O
+(-	O
+1	O
+)	O
+(	O
+2	O
+%);	O
+LOA	B-SPEC
+-	O
+4	O
+.	O
+6	O
+to	O
+5	O
+.	O
+0	O
+br	O
+min	O
+(-	O
+1	O
+)	O
+(±	O
+27	O
+%).	O
+
+Reanalysis	O
+of	O
+all	O
+available	O
+epidemiological	O
+data	O
+resulted	O
+in	O
+a	O
+total	O
+of	O
+5327	O
+probable	O
+cases	O
+of	O
+SARS	B-DISO
+,	O
+of	O
+whom	O
+343	O
+died	B-PROC
+.	O
+
+Analysis	O
+of	O
+the	O
+impact	O
+of	O
+interventions	O
+demonstrated	O
+that	O
+strong	O
+political	O
+commitment	O
+and	O
+a	O
+centrally	O
+coordinated	O
+response	O
+was	O
+the	O
+most	O
+important	O
+factor	O
+to	O
+control	O
+SARS	O
+in	O
+mainland	O
+China	O
+,	O
+whereas	O
+the	O
+most	O
+stringent	O
+control	O
+measures	O
+were	O
+all	O
+initiated	O
+when	O
+the	O
+epidemic	O
+was	O
+already	O
+dying	B-PROC
+down	O
+.	O
+
+TITLE	O
+:	O
+Structure	O
+-	O
+based	O
+discovery	O
+of	O
+Middle	O
+East	O
+respiratory	O
+syndrome	B-DISO
+coronavirus	B-SPEC
+fusion	O
+inhibitor	B-CHED
+.	O
+
+Here	O
+we	O
+characterize	O
+the	O
+six	O
+-	O
+helix	O
+bundle	O
+fusion	O
+core	O
+structure	O
+of	O
+MERS	B-PRGE
+-	I-PRGE
+CoV	I-PRGE
+spike	I-PRGE
+protein	I-PRGE
+S2	I-PRGE
+subunit	I-PRGE
+by	O
+X	O
+-	O
+ray	B-SPEC
+crystallography	O
+and	O
+biophysical	O
+analysis	O
+.	O
+
+Pathological	O
+specimens	O
+(	O
+11	O
+/	O
+17	O
+)	O
+showed	O
+a	O
+bronchiolocentric	O
+,	O
+temporally	O
+homogenous	O
+,	O
+acute	O
+lung	B-ANAT
+injury	O
+pattern	O
+with	O
+sparing	O
+of	O
+the	O
+subpleural	O
+and	O
+peripheral	O
+alveolar	B-ANAT
+areas	O
+.	O
+
+Data	O
+on	O
+critically	B-DISO
+ill	I-DISO
+patients	O
+with	O
+MERS	O
+-	O
+CoV	O
+infection	B-DISO
+are	O
+limited	O
+.	O
+
+MERS	O
+-	O
+CoV	O
+causes	O
+severe	O
+acute	O
+hypoxemic	O
+respiratory	B-DISO
+failure	I-DISO
+and	O
+considerable	O
+extrapulmonary	O
+organ	B-ANAT
+dysfunction	O
+and	O
+is	O
+associated	O
+with	O
+high	O
+mortality	O
+.	O
+
+The	O
+health	O
+care	O
+-	O
+associated	O
+cluster	O
+suggests	O
+that	O
+human	B-SPEC
+-	O
+to	O
+-	O
+human	B-SPEC
+transmission	O
+does	O
+occur	O
+with	O
+unprotected	O
+exposure	O
+.	O
+
+This	O
+is	O
+the	O
+first	O
+occurrence	O
+of	O
+stillbirth	B-DISO
+during	O
+an	O
+infection	B-DISO
+with	O
+MERS	O
+-	O
+CoV	O
+and	O
+may	O
+have	O
+bearing	O
+upon	O
+the	O
+surveillance	O
+and	O
+management	O
+of	O
+pregnant	O
+women	O
+in	O
+settings	O
+of	O
+unexplained	O
+respiratory	O
+illness	O
+potentially	O
+due	O
+to	O
+MERS	O
+-	O
+CoV	O
+.	O
+Future	O
+prospective	O
+investigations	O
+of	O
+MERS	O
+-	O
+CoV	O
+should	O
+ascertain	O
+pregnancy	O
+status	O
+and	O
+obtain	O
+further	O
+pregnancy	O
+-	O
+related	O
+data	O
+,	O
+including	O
+biological	O
+specimens	O
+for	O
+confirmatory	O
+testing	O
+.	O
+
+However	O
+,	O
+new	O
+threats	O
+such	O
+as	O
+Middle	O
+East	O
+respiratory	O
+syndrome	B-DISO
+coronavirus	B-SPEC
+(	O
+MERS	O
+-	O
+CoV	O
+)	O
+and	O
+influenza	B-PATH
+A	I-PATH
+(	O
+H7N9	O
+)	O
+present	O
+continued	O
+challenges	O
+,	O
+reinforcing	O
+the	O
+need	O
+to	O
+improve	O
+the	O
+global	O
+capacity	O
+to	O
+prevent	O
+,	O
+detect	O
+,	O
+and	O
+respond	O
+to	O
+public	O
+health	O
+threats	O
+.	O
+
+During	O
+March	O
+-	O
+September	O
+2013	O
+,	O
+CDC	O
+and	O
+the	O
+Vietnamese	O
+Ministry	O
+of	O
+Health	O
+(	O
+MoH	O
+)	O
+collaborated	O
+on	O
+a	O
+GHS	O
+demonstration	O
+project	O
+to	O
+improve	O
+public	O
+health	O
+emergency	B-DISO
+detection	O
+and	O
+response	O
+capacity	O
+.	O
+
+Lessons	O
+learned	B-PROC
+included	O
+awareness	O
+that	O
+integrated	O
+functions	O
+within	O
+the	O
+health	O
+system	O
+for	O
+GHS	O
+require	O
+careful	O
+planning	O
+,	O
+stakeholder	O
+buy	O
+-	O
+in	O
+,	O
+and	O
+intradepartmental	O
+and	O
+interdepartmental	O
+coordination	B-PROC
+and	O
+communication	O
+.	O
+
+ABSTRACT	O
+:	O
+The	O
+sudden	O
+emergence	O
+of	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+coronavirus	B-SPEC
+(	O
+SARS	B-DISO
+-	O
+CoV	O
+)	O
+in	O
+2002	O
+and	O
+,	O
+more	O
+recently	O
+,	O
+Middle	O
+Eastern	O
+respiratory	O
+syndrome	B-DISO
+CoV	O
+(	O
+MERS	O
+-	O
+CoV	O
+)	O
+underscores	O
+the	O
+importance	O
+of	O
+understanding	O
+critical	O
+aspects	O
+of	O
+CoV	O
+infection	B-DISO
+and	O
+pathogenesis	B-DISO
+.	O
+
+However	O
+,	O
+the	O
+absence	O
+of	O
+either	O
+MDA5	B-PRGE
+or	O
+IFIT1	B-PRGE
+,	O
+IFN	B-PRGE
+-	I-PRGE
+responsive	I-PRGE
+genes	I-PRGE
+that	O
+recognize	O
+unmethylated	O
+2	O
+'-	O
+O	O
+RNA	O
+,	O
+resulted	O
+in	O
+restored	O
+replication	O
+and	O
+virulence	B-PROC
+of	O
+the	O
+dNSP16	O
+mutant	B-DISO
+virus	B-SPEC
+.	O
+
+Preventing	O
+recognition	O
+by	O
+the	O
+host	B-COMP
+immune	B-PROC
+response	I-PROC
+represents	O
+a	O
+critical	O
+aspect	O
+necessary	O
+for	O
+successful	O
+viral	B-DISO
+infection	I-DISO
+.	O
+
+Several	O
+viruses	B-SPEC
+,	O
+including	O
+SARS	B-PRGE
+-	I-PRGE
+CoV	I-PRGE
+,	O
+utilize	O
+virally	O
+encoded	O
+2	O
+'-	O
+O	O
+-	O
+MTases	O
+to	O
+camouflage	O
+and	O
+obscure	O
+their	O
+viral	O
+RNA	O
+from	O
+host	B-COMP
+cell	I-COMP
+sensing	O
+machinery	O
+,	O
+thus	O
+preventing	O
+recognition	O
+and	O
+activation	O
+of	O
+cell	B-COMP
+intrinsic	O
+defense	O
+pathways	B-PROC
+.	O
+
+ABSTRACT	O
+:	O
+Few	O
+studies	O
+have	O
+prospectively	O
+assessed	O
+viral	O
+etiologies	O
+of	O
+acute	B-DISO
+respiratory	I-DISO
+infections	I-DISO
+in	O
+community	O
+-	O
+based	O
+elderly	O
+individuals	O
+.	O
+
+TITLE	O
+:	O
+Persistent	O
+pulmonary	B-DISO
+arterial	B-ANAT
+hypertension	I-DISO
+in	O
+the	O
+newborn	O
+(	O
+PPHN	O
+):	O
+a	O
+frequent	O
+manifestation	O
+of	O
+TMEM70	O
+defective	O
+patients	O
+.	O
+
+Six	O
+were	O
+homozygous	O
+for	O
+the	O
+c	O
+.	O
+317	O
+-	O
+2A	O
+>	O
+G	O
+mutation	O
+,	O
+2	O
+were	O
+compound	O
+heterozygous	O
+for	B-PRGE
+mutations	I-PRGE
+c	I-PRGE
+.	I-PRGE
+317	I-PRGE
+-	I-PRGE
+2A	I-PRGE
+>	O
+G	O
+and	O
+c	O
+.	O
+628A	O
+>	O
+C	O
+and	O
+1	O
+was	O
+homozygous	O
+for	O
+the	O
+novel	O
+c	O
+.	O
+701A	O
+>	O
+C	O
+mutation	O
+.	O
+
+Pulmonary	B-DISO
+hypertension	I-DISO
+has	O
+rarely	O
+been	O
+reported	O
+in	O
+mitochondrial	B-DISO
+disorders	I-DISO
+and	O
+,	O
+so	O
+far	O
+,	O
+it	O
+has	O
+been	O
+described	O
+in	O
+association	O
+with	O
+TMEM70	B-PRGE
+deficiency	O
+only	O
+in	O
+one	O
+patient	O
+.	O
+
+TITLE	O
+:	O
+Synthesis	B-PROC
+and	O
+biological	O
+evaluation	O
+of	O
+2	O
+-	O
+oxonicotinonitriles	O
+and	O
+2	O
+-	O
+oxonicotinonitrile	O
+based	O
+nucleoside	B-CHED
+analogues	I-CHED
+.	O
+
+ABSTRACT	O
+:	O
+Drug	B-PROC
+resistance	I-PROC
+and	O
+emergence	O
+of	O
+new	O
+pathogens	O
+highlight	O
+the	O
+need	O
+for	O
+developing	O
+new	O
+therapeutic	O
+agents	O
+.	O
+
+The	O
+findings	O
+obtained	O
+with	O
+flavivirus	B-SPEC
+should	O
+be	O
+applicable	O
+to	O
+other	O
+RNA	O
+viruses	B-SPEC
+.	O
+
+In	O
+this	O
+study	O
+we	O
+aimed	O
+to	O
+investigate	O
+the	O
+effect	O
+of	O
+intravenous	O
+infusion	O
+of	O
+PFC	O
+emulsion	O
+on	O
+lipopolysaccharide	B-CHED
+(	O
+LPS	B-DISO
+)	O
+induced	O
+ALI	O
+in	O
+rats	B-SPEC
+and	O
+elucidate	O
+its	O
+mechanism	B-PROC
+of	I-PROC
+action	I-PROC
+.	O
+
+Forty	O
+two	O
+Wistar	B-SPEC
+rats	I-SPEC
+were	O
+randomly	O
+divided	O
+into	O
+three	O
+groups	O
+:	O
+6	O
+rats	B-SPEC
+were	O
+treated	O
+with	O
+saline	O
+solution	O
+by	O
+intratracheal	O
+instillation	O
+(	O
+control	O
+group	O
+),	O
+18	O
+rats	B-SPEC
+were	O
+treated	O
+with	O
+LPS	B-DISO
+by	O
+intratracheal	O
+instillation	O
+(	O
+LPS	B-DISO
+group	O
+)	O
+and	O
+the	O
+other	O
+18	O
+rats	B-SPEC
+received	O
+PFC	O
+through	O
+femoral	O
+vein	O
+prior	O
+to	O
+LPS	B-DISO
+instillation	O
+(	O
+LPS	O
++	O
+PFC	O
+group	O
+).	O
+
+The	O
+rats	B-SPEC
+in	O
+the	O
+control	O
+group	O
+were	O
+sacrificed	O
+6	O
+hours	O
+later	O
+after	O
+saline	O
+instillation	O
+.	O
+
+Our	O
+results	O
+indicate	O
+that	O
+intravenous	O
+infusion	O
+of	O
+PFC	O
+inhibits	O
+the	O
+infiltration	B-DISO
+of	O
+PMNs	O
+into	O
+lung	B-ANAT
+tissue	I-ANAT
+,	O
+which	O
+has	O
+been	O
+shown	O
+as	O
+the	O
+core	O
+pathogenesis	B-DISO
+of	O
+ALI	O
+/	O
+ARDS	B-DISO
+.	O
+
+TITLE	O
+:	O
+Clinical	O
+Manifestations	O
+,	O
+Treatment	O
+,	O
+and	O
+Outcome	O
+of	O
+Hospitalized	O
+Patients	O
+with	O
+Plasmodium	B-SPEC
+vivax	I-SPEC
+Malaria	B-PATH
+in	O
+Two	O
+Indian	O
+States	O
+:	O
+A	O
+Retrospective	O
+Study	O
+.	O
+
+Compared	O
+to	O
+acute	B-DISO
+pain	I-DISO
+,	O
+there	O
+is	O
+limited	O
+evidence	O
+in	O
+the	O
+literature	O
+on	O
+prolonged	O
+pain	O
+in	O
+infants	O
+.	O
+
+Results	O
+of	O
+this	O
+study	O
+showed	O
+that	O
+nursing	B-PROC
+documentation	O
+related	O
+to	O
+pain	O
+assessment	O
+is	O
+not	O
+systematic	O
+.	O
+
+CONCLUSIONS	O
+:	O
+This	O
+study	O
+highlighted	O
+the	O
+difficulty	O
+in	O
+managing	O
+pain	O
+in	O
+neonates	O
+who	O
+are	O
+exposed	O
+to	O
+numerous	O
+painful	B-DISO
+procedures	O
+.	O
+
+ABSTRACT	O
+:	O
+Mesenchymal	O
+stem	B-ANAT
+/	O
+stromal	B-ANAT
+cells	I-ANAT
+(	O
+MSCs	B-FUNC
+)	O
+offer	O
+considerable	O
+promise	O
+as	O
+a	O
+novel	O
+therapeutic	O
+strategy	O
+for	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+(	O
+ARDS	B-DISO
+).	O
+
+MSCs	B-FUNC
+have	O
+been	O
+demonstrated	O
+to	O
+decrease	O
+injury	O
+and	O
+/	O
+or	O
+restore	O
+function	O
+in	O
+other	O
+organs	B-ANAT
+,	O
+including	O
+the	O
+kidney	B-ANAT
+,	O
+liver	B-ANAT
+and	O
+heart	B-ANAT
+.	O
+
+The	O
+ultimate	O
+success	O
+of	O
+MSCs	B-FUNC
+as	O
+a	O
+therapy	O
+for	O
+patients	O
+with	O
+ARDS	B-DISO
+will	O
+likely	O
+be	O
+dependent	O
+on	O
+a	O
+greater	O
+knowledge	O
+of	O
+their	O
+mechanisms	O
+of	O
+action	O
+and	O
+the	O
+determination	O
+of	O
+the	O
+optimal	O
+strategies	O
+for	O
+their	O
+use	O
+in	O
+the	O
+clinical	O
+setting	O
+.	O
+
+Between	O
+March	O
+and	O
+July	O
+2003	O
+,	O
+a	O
+total	O
+of	O
+539	O
+patients	O
+with	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+(	O
+SARS	B-DISO
+)	O
+were	O
+treated	O
+with	O
+five	O
+different	O
+types	O
+of	O
+steroid	B-CHED
+.	O
+
+CONCLUSIONS	O
+:	O
+We	O
+found	O
+that	O
+some	O
+common	O
+respiratory	O
+viruses	B-SPEC
+,	O
+such	O
+as	O
+adenoviruses	B-SPEC
+,	O
+enteroviruses	B-SPEC
+,	O
+rhinoviruses	B-SPEC
+,	O
+and	O
+coronaviruses	O
+,	O
+were	O
+associated	O
+with	O
+KD	O
+cases	O
+.	O
+
+TITLE	O
+:	O
+Clinical	O
+epidemiology	O
+of	O
+bocavirus	B-SPEC
+,	O
+rhinovirus	B-SPEC
+,	O
+two	O
+polyomaviruses	B-SPEC
+and	O
+four	O
+coronaviruses	O
+in	O
+HIV	O
+-	O
+infected	O
+and	O
+HIV	B-DISO
+-	O
+uninfected	O
+South	O
+African	O
+children	O
+.	O
+
+Combined	O
+with	O
+previously	O
+-	O
+tested	O
+viruses	B-SPEC
+,	O
+respiratory	O
+viruses	B-SPEC
+were	O
+identified	O
+in	O
+60	O
+.	O
+9	O
+%	O
+of	O
+HIV	B-DISO
+-	O
+infected	O
+and	O
+78	O
+.	O
+3	O
+%	O
+of	O
+HIV	B-DISO
+-	O
+uninfected	O
+children	O
+.	O
+
+Among	O
+the	O
+265	O
+patients	O
+included	O
+,	O
+150	O
+(	O
+56	O
+.	O
+6	O
+%)	O
+reported	O
+at	O
+least	O
+one	O
+respiratory	B-DISO
+symptom	I-DISO
+of	O
+which	O
+13	O
+(	O
+8	O
+.	O
+7	O
+%)	O
+had	O
+positive	O
+swabs	O
+for	O
+at	O
+least	O
+one	O
+respiratory	O
+virus	B-SPEC
+,	O
+and	O
+115	O
+patients	O
+reported	O
+any	O
+respiratory	B-DISO
+symptom	I-DISO
+of	O
+which	O
+10	O
+(	O
+8	O
+.	O
+7	O
+%)	O
+had	O
+positive	O
+swabs	O
+for	O
+respiratory	O
+virus	B-SPEC
+.	O
+
+These	O
+viruses	B-SPEC
+depend	O
+on	O
+cathepsin	B-PRGE
+L	I-PRGE
+for	O
+entry	O
+into	O
+their	O
+target	B-ANAT
+cells	I-ANAT
+.	O
+
+The	O
+small	O
+molecule	O
+can	O
+be	O
+further	O
+optimized	O
+and	O
+developed	O
+into	O
+a	O
+potent	O
+broad	O
+-	O
+spectrum	O
+antiviral	B-CHED
+drug	I-CHED
+.	O
+
+Besides	O
+these	O
+structural	O
+roles	O
+,	O
+N	B-PRGE
+protein	I-PRGE
+associates	O
+with	O
+a	O
+component	O
+of	O
+the	O
+replicase	B-PRGE
+-	I-PRGE
+transcriptase	I-PRGE
+complex	O
+,	O
+nonstructural	O
+protein	B-CHED
+3	O
+,	O
+at	O
+a	O
+critical	O
+early	O
+stage	O
+of	O
+infection	B-DISO
+.	O
+
+Mapping	O
+of	O
+revertants	O
+of	O
+the	O
+resulting	O
+chimeric	O
+viruses	B-SPEC
+provided	O
+evidence	O
+for	O
+extensive	O
+intramolecular	O
+interactions	O
+between	O
+the	O
+two	O
+RNA	O
+-	O
+binding	B-FUNC
+domains	O
+.	O
+
+These	O
+results	O
+more	O
+clearly	O
+delineate	O
+the	O
+functions	O
+of	O
+N	B-PRGE
+protein	I-PRGE
+and	O
+establish	O
+a	O
+basis	O
+for	O
+further	O
+exploration	O
+of	O
+the	O
+mechanism	O
+of	O
+genomic	O
+RNA	O
+packaging	O
+.	O
+
+TITLE	O
+:	O
+MERS	B-PRGE
+-	I-PRGE
+CoV	I-PRGE
+papain	I-PRGE
+-	I-PRGE
+like	I-PRGE
+protease	I-PRGE
+has	O
+deISGylating	O
+and	O
+deubiquitinating	B-PROC
+activities	O
+.	O
+
+This	O
+initial	O
+down	B-PROC
+-	I-PROC
+regulation	I-PROC
+followed	O
+by	O
+the	O
+induction	O
+of	O
+innate	B-DISO
+immune	I-DISO
+response	I-DISO
+to	O
+IBV	B-SPEC
+infection	B-DISO
+appears	O
+to	O
+be	O
+inadequate	O
+for	O
+the	O
+control	O
+of	O
+IBV	B-SPEC
+genome	O
+accumulation	O
+and	O
+consequent	O
+histopathological	O
+changes	O
+in	O
+these	O
+tissues	B-ANAT
+.	O
+
+TITLE	O
+:	O
+Extracorporeal	O
+life	O
+support	O
+for	O
+adults	O
+with	O
+severe	O
+acute	B-DISO
+respiratory	I-DISO
+failure	I-DISO
+.	O
+
+TITLE	O
+:	O
+Influenza	B-DISO
+A	I-PATH
+(	O
+H1N1	B-PATH
+)	O
+vs	O
+non	O
+-	O
+H1N1	B-PATH
+ARDS	B-DISO
+:	O
+analysis	O
+of	O
+clinical	O
+course	O
+.	O
+
+Clinical	O
+course	O
+of	O
+H1N1	O
+-	O
+ARDS	B-DISO
+is	O
+substantially	O
+different	O
+from	O
+non	O
+-	O
+H1N1	O
+-	O
+ARDS	B-DISO
+.	O
+
+Only	O
+Sepsis	B-DISO
+-	O
+Related	O
+Organ	B-DISO
+Failure	I-DISO
+Assessment	O
+score	O
+could	O
+be	O
+identified	O
+as	O
+an	O
+independent	O
+predictor	O
+of	O
+extracorporeal	O
+lung	B-ANAT
+support	O
+.	O
+
+HCPS	O
+starts	O
+as	O
+a	O
+dengue	B-DISO
+-	O
+like	O
+acute	O
+febrile	B-DISO
+illness	I-DISO
+but	O
+after	O
+about	O
+3	O
+days	O
+progresses	O
+to	O
+respiratory	B-DISO
+failure	I-DISO
+and	O
+cardiogenic	B-DISO
+shock	I-DISO
+,	O
+leading	O
+to	O
+a	O
+high	O
+fatality	O
+rate	O
+that	O
+reaches	O
+50	O
+%	O
+for	O
+patients	O
+infected	O
+with	O
+ARQV	O
+.	O
+
+TITLE	O
+:	O
+Isolation	O
+of	O
+bovine	B-SPEC
+coronavirus	B-SPEC
+(	O
+bcoV	O
+)	O
+in	O
+vero	O
+cell	B-ANAT
+line	I-ANAT
+and	O
+its	O
+confirmation	O
+by	O
+direct	O
+FAT	B-PRGE
+and	O
+RT	O
+-	O
+PCR	O
+.	O
+
+Studies	O
+regarding	O
+epidemiology	O
+,	O
+virus	B-SPEC
+isolation	O
+and	O
+molecular	O
+detection	O
+from	O
+India	O
+are	O
+very	O
+few	O
+.	O
+
+Subsequently	O
+BCoV	O
+got	O
+adapted	O
+to	O
+the	O
+vero	O
+cell	B-ANAT
+line	I-ANAT
+upto	O
+three	O
+passages	O
+,	O
+which	O
+was	O
+confirmed	O
+both	O
+at	O
+genomic	O
+and	O
+antigenic	O
+levels	O
+by	O
+dFAT	O
+and	O
+RT	O
+-	O
+PCR	O
+testing	O
+.	O
+
+ABSTRACT	O
+:	O
+The	O
+outbreak	O
+of	O
+the	O
+SARS	B-DISO
+coronavirus	B-SPEC
+in	O
+2002	O
+/	O
+2003	O
+and	O
+the	O
+recent	O
+disease	O
+cases	O
+with	O
+a	O
+new	O
+human	B-SPEC
+coronavirus	I-SPEC
+(	O
+originally	O
+designated	O
+EMC	B-PRGE
+-	I-PRGE
+CoV	I-PRGE
+,	O
+recently	O
+renamed	O
+MERS	O
+-	O
+CoV	O
+)	O
+have	O
+put	O
+the	O
+focus	O
+onto	O
+the	O
+virus	B-SPEC
+family	B-SPEC
+Coronaviridae	I-SPEC
+.	O
+
+Bats	B-SPEC
+are	O
+considered	O
+to	O
+serve	O
+as	O
+a	O
+natural	O
+reservoir	O
+for	O
+coronaviruses	O
+infecting	O
+mammals	B-SPEC
+.	O
+
+Structural	O
+and	O
+enzymatic	O
+studies	O
+revealed	O
+that	O
+SARS	B-PRGE
+-	I-PRGE
+CoV	I-PRGE
+PLpro	I-PRGE
+can	O
+act	O
+as	O
+both	O
+a	O
+protease	O
+to	O
+cleave	O
+peptide	B-CHED
+bonds	O
+and	O
+also	O
+as	O
+a	O
+deubiquitinating	B-PROC
+(	O
+DUB	O
+)	O
+enzyme	O
+to	O
+cleave	O
+the	O
+isopeptide	O
+bonds	O
+found	O
+in	O
+polyubiquitin	B-PRGE
+chains	I-PRGE
+.	O
+
+Importantly	O
+,	O
+mutations	O
+that	O
+alter	O
+DUB	B-PRGE
+activity	O
+but	O
+not	O
+viral	B-PRGE
+protease	I-PRGE
+activity	O
+have	O
+been	O
+identified	O
+and	O
+arteriviruses	B-SPEC
+expressing	O
+DUB	B-PRGE
+mutants	I-PRGE
+stimulated	O
+higher	O
+levels	O
+of	O
+acute	O
+inflammatory	O
+cytokines	O
+after	O
+infection	B-DISO
+.	O
+
+Here	O
+,	O
+we	O
+review	O
+studies	O
+describing	O
+the	O
+PLPs	O
+'	O
+enzymatic	B-PROC
+activity	I-PROC
+and	O
+their	O
+role	O
+in	O
+virus	B-DISO
+pathogenesis	B-PROC
+.	O
+
+The	O
+development	B-PROC
+of	O
+postoperative	O
+pulmonary	B-DISO
+complications	I-DISO
+is	O
+related	O
+to	O
+various	O
+perioperative	O
+factors	O
+.	O
+
+The	O
+application	O
+of	O
+protective	O
+invasive	O
+ventilation	O
+,	O
+with	O
+low	O
+tidal	O
+volumes	O
+,	O
+has	O
+been	O
+found	O
+to	O
+reduce	O
+lung	O
+injury	O
+and	O
+mortality	O
+in	O
+patients	O
+with	O
+lung	B-ANAT
+injury	O
+or	O
+healthy	O
+lungs	B-ANAT
+.	O
+
+TITLE	O
+:	O
+Use	O
+of	O
+recombinant	O
+nucleocapsid	B-COMP
+proteins	B-CHED
+for	O
+serological	O
+diagnosis	O
+of	O
+feline	B-SPEC
+coronavirus	B-SPEC
+infection	I-DISO
+by	O
+three	O
+immunochromatographic	O
+tests	O
+.	O
+
+Recombinant	B-PRGE
+FCoV	I-PRGE
+nucleocapsid	I-PRGE
+protein	B-CHED
+(	O
+rNP	B-COMP
+)	O
+was	O
+used	O
+as	O
+a	O
+conjugate	O
+or	O
+test	O
+line	O
+in	O
+all	O
+3	O
+ICA	B-CHED
+kits	O
+(	O
+CJIgG	O
+/	O
+TNP	B-PRGE
+,	O
+CJNP	O
+/	O
+TNP	B-PRGE
+,	O
+and	O
+CJNP	B-PRGE
+/	I-PRGE
+TPA	I-PRGE
+).	O
+
+ABSTRACT	O
+:	O
+Monocytes	B-ANAT
+infected	O
+with	O
+feline	B-DISO
+infectious	I-DISO
+peritonitis	I-DISO
+virus	B-SPEC
+,	O
+a	O
+coronavirus	B-SPEC
+,	O
+express	O
+viral	O
+proteins	B-CHED
+in	O
+their	O
+plasma	B-COMP
+membranes	I-COMP
+.	O
+
+In	O
+this	O
+study	O
+,	O
+site	B-PROC
+-	I-PROC
+directed	I-PROC
+mutagenesis	I-PROC
+and	O
+thermal	O
+stability	O
+experiments	O
+on	O
+electrostatic	O
+,	O
+hydrophobic	O
+,	O
+and	O
+polar	O
+residues	O
+to	O
+dissect	O
+their	O
+roles	O
+in	O
+stabilizing	O
+the	O
+S2	O
+postfusion	O
+conformation	O
+was	O
+performed	O
+.	O
+
+TITLE	O
+:	O
+[	O
+Anti	O
+-	O
+virus	B-SPEC
+research	O
+of	O
+triterpenoids	B-CHED
+in	O
+licorice	B-SPEC
+].	O
+
+It	O
+is	O
+a	O
+traditional	O
+Chinese	O
+herbal	O
+medicine	B-CHED
+.	O
+
+This	O
+review	O
+provided	O
+a	O
+summary	O
+of	O
+the	O
+recent	O
+anti	O
+-	O
+virus	B-SPEC
+research	O
+progress	O
+on	O
+several	O
+triterpenoids	B-CHED
+in	O
+licorice	B-SPEC
+,	O
+such	O
+as	O
+glycyrrhizic	B-CHED
+acid	I-CHED
+,	O
+glycyrrhizin	B-CHED
+,	O
+glycyrrhetinic	B-CHED
+acid	I-CHED
+and	O
+its	O
+derivatives	O
+.	O
+
+In	O
+this	O
+study	O
+,	O
+we	O
+characterized	O
+MERS	B-PRGE
+-	I-PRGE
+CoV	I-PRGE
+4a	I-PRGE
+protein	I-PRGE
+as	O
+a	O
+novel	O
+immunosuppressive	O
+factor	O
+that	O
+antagonizes	O
+type	B-PROC
+I	I-PROC
+interferon	I-PROC
+production	I-PROC
+.	O
+
+RNA	B-FUNC
+binding	I-FUNC
+of	O
+MERS	B-PRGE
+-	I-PRGE
+CoV	I-PRGE
+4a	I-PRGE
+protein	I-PRGE
+was	O
+required	O
+for	O
+IFN	B-PRGE
+antagonism	O
+,	O
+a	O
+property	O
+shared	O
+by	O
+4a	O
+protein	B-CHED
+of	O
+bat	B-ENZY
+coronavirus	I-SPEC
+HKU5	I-SPEC
+but	O
+not	O
+by	O
+the	O
+counterpart	O
+in	O
+bat	O
+coronavirus	O
+HKU4	O
+.	O
+
+TITLE	O
+:	O
+Inhibitory	O
+effect	O
+of	O
+silver	B-CHED
+nanomaterials	O
+on	O
+transmissible	O
+virus	B-SPEC
+-	O
+induced	O
+host	B-COMP
+cell	I-COMP
+infections	B-DISO
+.	O
+
+ABSTRACT	O
+:	O
+Coronaviruses	O
+belong	O
+to	O
+the	O
+family	B-SPEC
+Coronaviridae	I-SPEC
+,	O
+which	O
+primarily	O
+cause	O
+infection	B-DISO
+of	O
+the	O
+upper	O
+respiratory	O
+and	O
+gastrointestinal	B-ANAT
+tract	I-ANAT
+of	O
+hosts	B-COMP
+.	O
+
+We	O
+also	O
+identified	O
+peptides	B-CHED
+that	O
+strongly	O
+induce	O
+Th1	B-PRGE
+activity	O
+from	O
+those	O
+derived	O
+from	O
+the	O
+structural	O
+proteins	B-CHED
+(	O
+S	O
+,	O
+M	O
+,	O
+and	O
+N	O
+proteins	B-CHED
+)	O
+of	O
+FIPV	O
+based	O
+on	O
+this	O
+and	O
+previous	O
+studies	O
+(	O
+Satoh	O
+et	O
+al	O
+.	O
+[	O
+19	O
+]).	O
+
+TITLE	O
+:	O
+IgG	B-PRGE
+Fc	I-PRGE
+N	I-PRGE
+-	O
+glycosylation	B-PROC
+in	O
+Guillain	O
+-	O
+Barré	O
+syndrome	B-DISO
+treated	O
+with	O
+immunoglobulins	O
+.	O
+
+The	O
+working	O
+mechanism	O
+of	O
+IVIg	O
+in	O
+autoimmune	B-DISO
+diseases	I-DISO
+has	O
+not	O
+been	O
+elucidated	O
+,	O
+but	O
+previous	O
+studies	O
+indicate	O
+that	O
+some	O
+anti	O
+-	O
+inflammatory	O
+effects	O
+may	O
+be	O
+mediated	O
+by	O
+the	O
+N	O
+-	O
+glycosylation	B-PROC
+of	O
+the	O
+Fc	B-PRGE
+-	I-PRGE
+portion	I-PRGE
+of	I-PRGE
+IgG	I-PRGE
+.	O
+GBS	B-DISO
+is	O
+a	O
+model	O
+disease	O
+to	O
+investigate	O
+these	O
+effects	O
+because	O
+GBS	B-DISO
+is	O
+an	O
+acute	O
+and	O
+monophasic	O
+disorder	O
+usually	O
+affecting	O
+healthy	O
+persons	O
+,	O
+which	O
+is	O
+treated	O
+with	O
+a	O
+standard	O
+course	O
+of	O
+IVIg	O
+,	O
+although	O
+the	O
+clinical	O
+response	O
+is	O
+highly	O
+variable	O
+.	O
+
+Treatment	O
+-	O
+naive	O
+GBS	B-DISO
+patients	O
+compared	O
+with	O
+age	O
+-	O
+and	O
+sex	O
+-	O
+matched	O
+controls	O
+had	O
+lower	O
+levels	O
+of	O
+galactosylation	O
+of	O
+IgG1	B-COMP
+and	O
+IgG2	B-COMP
+.	O
+
+The	O
+observation	O
+of	O
+phylogenetically	O
+related	O
+MERS	O
+-	O
+CoV	O
+in	O
+geographically	O
+diverse	O
+locations	O
+must	O
+be	O
+taken	O
+into	O
+account	O
+in	O
+efforts	O
+to	O
+identify	O
+the	O
+animal	B-SPEC
+source	O
+and	O
+transmission	O
+of	O
+the	O
+virus	B-SPEC
+.	O
+
+BAL	B-ENZY
+supernatants	O
+and	O
+sera	B-COMP
+were	O
+used	O
+to	O
+assess	O
+cytokines	O
+and	O
+chemokines	O
+secretion	O
+by	O
+enzyme	O
+-	O
+linked	O
+immunosorbent	O
+assay	O
+.	O
+
+The	O
+first	O
+patient	O
+died	B-PROC
+rapidly	O
+after	O
+3	O
+weeks	O
+in	O
+the	O
+intensive	O
+care	O
+unit	O
+,	O
+the	O
+second	O
+patient	O
+still	O
+recovers	O
+from	O
+infection	B-DISO
+.	O
+
+TITLE	O
+:	O
+Acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+in	O
+wartime	O
+military	O
+burns	O
+:	O
+application	O
+of	O
+the	O
+Berlin	O
+criteria	O
+.	O
+
+ABSTRACT	O
+:	O
+Acute	O
+respiratory	O
+distress	O
+syndrome	O
+(	O
+ARDS	B-DISO
+)	O
+prevalence	O
+and	O
+related	O
+outcomes	O
+in	O
+burned	O
+military	O
+casualties	O
+from	O
+Iraq	O
+and	O
+Afghanistan	O
+have	O
+not	O
+been	O
+described	O
+previously	O
+.	O
+
+Size	O
+of	O
+burn	O
+was	O
+associated	O
+with	O
+moderate	O
+or	O
+severe	O
+ARDS	B-DISO
+by	O
+univariate	O
+analysis	O
+but	O
+was	O
+not	O
+an	O
+independent	O
+predictor	O
+of	O
+ARDS	B-DISO
+by	O
+multivariate	O
+logistic	O
+regression	O
+(	O
+p	O
+>	O
+0	O
+.	O
+05	O
+).	O
+
+In	O
+this	O
+cohort	O
+of	O
+military	O
+casualties	O
+with	O
+thermal	O
+injuries	O
+,	O
+nearly	O
+a	O
+third	O
+required	O
+mechanical	O
+ventilation	O
+;	O
+of	O
+those	O
+,	O
+nearly	O
+one	O
+third	O
+developed	O
+ARDS	B-DISO
+,	O
+and	O
+nearly	O
+one	O
+third	O
+of	O
+patients	O
+with	O
+ARDS	B-DISO
+did	O
+not	O
+survive	O
+.	O
+
+Moderate	O
+and	O
+severe	O
+ARDS	B-DISO
+increased	O
+the	O
+odds	O
+of	O
+death	B-PROC
+by	O
+more	O
+than	O
+fourfold	O
+and	O
+ninefold	O
+,	O
+respectively	O
+.	O
+
+Prevalence	O
+of	O
+ARDS	B-DISO
+in	O
+this	O
+cohort	O
+was	O
+32	O
+.	O
+6	O
+%,	O
+with	O
+a	O
+crude	O
+overall	O
+mortality	O
+of	O
+16	O
+.	O
+5	O
+%.	O
+
+ABSTRACT	O
+:	O
+Enveloped	O
+viruses	B-SPEC
+carry	O
+highly	O
+specialized	O
+glycoproteins	B-CHED
+that	O
+catalyze	O
+membrane	B-PROC
+fusion	I-PROC
+under	O
+strict	O
+spatial	O
+and	O
+temporal	O
+control	O
+.	O
+
+We	O
+constructed	O
+chimeric	O
+DPP4	B-PRGE
+receptors	I-PRGE
+that	O
+have	O
+the	O
+virus	B-SPEC
+-	O
+binding	B-FUNC
+domains	O
+of	O
+indigenous	O
+Middle	O
+Eastern	O
+animals	B-SPEC
+and	O
+assessed	O
+the	O
+activities	O
+of	O
+these	O
+receptors	O
+in	O
+supporting	O
+S	B-PRGE
+protein	I-PRGE
+binding	O
+and	O
+virus	B-SPEC
+entry	O
+.	O
+
+Infection	B-DISO
+susceptibility	O
+correlated	O
+with	O
+affinities	O
+of	O
+the	O
+receptors	O
+for	O
+viral	O
+spike	O
+proteins	B-CHED
+.	O
+
+ABSTRACT	O
+:	O
+From	O
+September	O
+2012	O
+to	O
+July	O
+2013	O
+,	O
+81	O
+laboratory	O
+-	O
+confirmed	O
+cases	O
+of	O
+infection	B-DISO
+with	O
+Middle	O
+East	O
+respiratory	O
+syndrome	B-DISO
+coronavirus	B-SPEC
+(	O
+MERS	O
+-	O
+CoV	O
+),	O
+including	O
+45	O
+deaths	B-PROC
+(	O
+a	O
+case	O
+fatality	O
+ratio	O
+of	O
+55	O
+%)	O
+have	O
+been	O
+reported	O
+from	O
+eight	O
+countries	O
+.	O
+
+TITLE	O
+:	O
+Identification	O
+of	O
+Mycoplasma	B-SPEC
+suis	I-SPEC
+antigens	B-CHED
+and	O
+development	B-PROC
+of	O
+a	O
+multiplex	O
+microbead	O
+immunoassay	O
+.	O
+
+Selected	O
+antigens	B-CHED
+were	O
+used	O
+to	O
+develop	O
+a	O
+MIA	O
+.	O
+
+Assay	O
+specificity	O
+was	O
+tested	O
+using	O
+sera	B-COMP
+from	O
+pigs	B-SPEC
+seropositive	O
+for	O
+other	O
+pathogens	O
+(	O
+2	O
+different	O
+pigs	B-SPEC
+seropositive	O
+for	O
+each	O
+pathogen	O
+).	O
+
+Samples	O
+from	O
+51	O
+field	O
+pigs	B-SPEC
+and	O
+2	O
+pigs	B-SPEC
+during	O
+the	O
+course	O
+of	O
+acute	O
+(	O
+pig	B-SPEC
+1	O
+)	O
+and	O
+chronic	O
+(	O
+pig	B-SPEC
+2	O
+)	O
+infections	B-DISO
+were	O
+tested	O
+using	O
+MIA	O
+,	O
+indirect	O
+hemagglutination	O
+assay	O
+(	O
+IHA	O
+),	O
+and	O
+quantitative	O
+polymerase	O
+chain	O
+reaction	O
+(	O
+qPCR	O
+).	O
+
+Fecal	B-ANAT
+transplantation	O
+seems	O
+so	O
+far	O
+to	O
+be	O
+the	O
+most	O
+effective	O
+treatment	O
+of	O
+recurrent	O
+C	O
+.	O
+dificile	O
+.	O
+
+25	O
+-	O
+OHD	O
+levels	O
+did	O
+not	O
+differ	O
+between	O
+cases	O
+with	O
+ALI	O
+/	O
+ARDS	B-DISO
+and	O
+controls	O
+in	O
+either	O
+the	O
+sepsis	B-DISO
+or	O
+trauma	O
+cohorts	O
+.	O
+
+Using	O
+a	O
+conditional	O
+logistic	O
+regression	O
+model	O
+,	O
+sepsis	B-DISO
+patients	O
+during	O
+the	O
+winter	O
+season	O
+with	O
+higher	O
+25	O
+-	O
+OHD	B-DISO
+levels	O
+were	O
+more	O
+likely	O
+to	O
+develop	O
+acute	O
+lung	B-ANAT
+injury	O
+(	O
+odds	O
+ratio	O
+1	O
+.	O
+68	O
+,	O
+95	O
+%	O
+confidence	O
+interval	O
+of	O
+1	O
+.	O
+05	O
+to	O
+2	O
+.	O
+69	O
+,	O
+P	O
+=	O
+0	O
+.	O
+03	O
+).	O
+
+Serum	B-COMP
+25	O
+-	O
+OHD	B-DISO
+measured	O
+early	O
+after	O
+admission	O
+to	O
+intensive	O
+care	O
+is	O
+not	O
+associated	O
+with	O
+the	O
+development	B-PROC
+of	O
+acute	O
+lung	B-ANAT
+injury	O
+,	O
+hospital	O
+or	O
+one	O
+-	O
+year	O
+mortality	O
+in	O
+critically	B-DISO
+ill	I-DISO
+patients	O
+with	O
+sepsis	B-DISO
+although	O
+lower	O
+25	O
+-	O
+OHD	B-DISO
+levels	O
+were	O
+associated	O
+with	O
+higher	O
+one	O
+-	O
+year	O
+mortality	O
+in	O
+patients	O
+with	O
+severe	O
+trauma	O
+.	O
+
+Higher	O
+one	O
+-	O
+year	O
+mortality	O
+after	O
+trauma	O
+was	O
+associated	O
+with	O
+lower	O
+25	O
+-	O
+OHD	B-DISO
+levels	O
+(	O
+HR	O
+0	O
+.	O
+50	O
+,	O
+CI	O
+0	O
+.	O
+35	O
+,	O
+0	O
+.	O
+72	O
+P	O
+=	O
+0	O
+.	O
+001	O
+).	O
+
+immunization	O
+pathways	B-PROC
+.	O
+
+Symptoms	O
+usually	O
+resolve	O
+spontaneously	O
+during	O
+the	O
+following	O
+weeks	O
+,	O
+but	O
+frequent	O
+relapse	B-DISO
+can	O
+occur	O
+and	O
+in	O
+some	O
+cases	O
+swelling	B-DISO
+may	O
+lead	O
+to	O
+compartment	B-DISO
+syndrome	I-DISO
+.	O
+
+TITLE	O
+:	O
+The	O
+discovery	O
+of	O
+asunaprevir	O
+(	O
+BMS	O
+-	O
+650032	O
+),	O
+an	O
+orally	B-ANAT
+efficacious	O
+NS3	B-PRGE
+protease	B-CHED
+inhibitor	I-CHED
+for	O
+the	O
+treatment	O
+of	O
+hepatitis	O
+C	O
+virus	B-DISO
+infection	I-DISO
+.	O
+
+To	O
+compare	O
+viral	O
+qPCR	O
+findings	O
+from	O
+children	O
+with	O
+ARI	B-CHED
+versus	O
+asymptomatic	O
+control	O
+subjects	O
+.	O
+
+Bocavirus	B-SPEC
+was	O
+associated	O
+with	O
+ARI	B-CHED
+even	O
+after	O
+adjustment	O
+for	O
+coinfections	B-DISO
+with	O
+other	O
+viruses	B-SPEC
+and	O
+was	O
+associated	O
+with	O
+severe	O
+disease	O
+.	O
+
+TITLE	O
+:	O
+Assessing	O
+the	O
+quality	O
+of	O
+studies	O
+supporting	O
+genetic	O
+susceptibility	O
+and	O
+outcomes	O
+of	O
+ARDS	B-DISO
+.	O
+
+However	O
+,	O
+little	O
+is	O
+known	O
+about	O
+the	O
+genes	O
+that	O
+are	O
+responsible	O
+for	O
+patient	O
+susceptibility	O
+and	O
+outcome	O
+of	O
+ARDS	B-DISO
+.	O
+
+Methodological	O
+flaws	O
+are	O
+still	O
+abundant	O
+among	O
+genetic	O
+association	O
+studies	O
+with	O
+ARDS	B-DISO
+and	O
+here	O
+,	O
+we	O
+aimed	O
+to	O
+highlight	O
+the	O
+quality	O
+criteria	O
+where	O
+the	O
+standards	O
+have	O
+not	O
+been	O
+reached	O
+,	O
+to	O
+expose	O
+the	O
+associated	O
+genes	O
+to	O
+facilitate	O
+replication	O
+attempts	O
+,	O
+and	O
+to	O
+provide	O
+quick	O
+-	O
+reference	O
+guidance	O
+for	O
+future	O
+studies	O
+.	O
+
+Studies	O
+were	O
+considered	O
+if	O
+a	O
+statistically	O
+significant	O
+association	O
+was	O
+declared	O
+with	O
+either	O
+susceptibility	O
+or	O
+outcomes	O
+of	O
+all	O
+-	O
+cause	O
+ARDS	B-DISO
+.	O
+
+and	O
+Eimeria	B-SPEC
+spp	B-ENZY
+.	O
+
+The	O
+mean	O
+age	O
+was	O
+46	O
+.	O
+5	O
+days	O
+and	O
+the	O
+odds	O
+of	O
+being	O
+infected	O
+with	O
+Giardia	B-DISO
+spp	B-ENZY
+.	O
+
+and	O
+Eimeria	B-SPEC
+spp	B-ENZY
+.	O
+could	O
+be	O
+detected	O
+in	O
+646	O
+/	O
+1564	O
+samples	O
+(	O
+41	O
+.	O
+3	O
+%)	O
+and	O
+208	O
+/	O
+1564	O
+samples	O
+(	O
+13	O
+.	O
+3	O
+%),	O
+respectively	O
+,	O
+with	O
+a	O
+mean	O
+age	O
+of	O
+11	O
+.	O
+3	O
+and	O
+55	O
+.	O
+0	O
+days	O
+,	O
+respectively	O
+.	O
+
+Finally	O
+,	O
+the	O
+less	O
+lipophilic	O
+bis	B-FUNC
+(	O
+amide	B-CHED
+)	O
+3e	O
+and	O
+methoxypyridine	O
+5c	O
+exhibit	O
+significantly	O
+improved	O
+metabolic	B-PROC
+stability	O
+and	O
+are	O
+viable	O
+candidates	O
+for	O
+advancing	O
+to	O
+in	O
+vivo	O
+studies	O
+.	O
+
+Thus	O
+,	O
+key	O
+events	O
+in	O
+the	O
+pathogenesis	B-DISO
+of	O
+FIP	B-DISO
+are	O
+systemic	B-DISO
+infection	I-DISO
+with	O
+FIPV	O
+,	O
+effective	O
+and	O
+sustainable	O
+viral	B-PROC
+replication	I-PROC
+in	O
+monocytes	B-ANAT
+,	O
+and	O
+activation	O
+of	O
+infected	O
+monocytes	B-ANAT
+.	O
+
+IMPORTANCE	O
+This	O
+study	O
+was	O
+undertaken	O
+to	O
+determine	O
+the	O
+historical	O
+and	O
+current	O
+prevalence	O
+of	O
+Middle	O
+East	O
+respiratory	O
+syndrome	B-DISO
+(	O
+MERS	B-DISO
+)	O
+coronavirus	B-DISO
+infection	I-DISO
+in	O
+dromedary	B-SPEC
+camels	B-SPEC
+and	O
+other	O
+livestock	O
+in	O
+the	O
+Kingdom	B-SPEC
+of	O
+Saudi	O
+Arabia	O
+,	O
+where	O
+the	O
+index	O
+case	O
+and	O
+the	O
+majority	O
+of	O
+cases	O
+of	O
+MERS	B-DISO
+have	O
+been	O
+reported	O
+.	O
+
+Twelve	O
+(	O
+63	O
+.	O
+15	O
+%)	O
+patients	O
+could	O
+not	O
+be	O
+weaned	B-PROC
+off	O
+and	O
+died	B-PROC
+while	O
+still	O
+on	O
+extracorporeal	O
+membrane	B-COMP
+oxygenator	O
+support	O
+.	O
+
+Our	O
+institutional	O
+experience	O
+of	O
+extracorporeal	O
+membrane	B-COMP
+oxygenator	O
+support	O
+for	O
+cardiac	B-ANAT
+indications	O
+in	O
+adult	O
+patients	O
+indicates	O
+poor	O
+survival	O
+.	O
+
+TITLE	O
+:	O
+Outcome	O
+of	O
+acute	O
+East	O
+African	B-PATH
+trypanosomiasis	I-PATH
+in	O
+a	O
+Polish	O
+traveller	O
+treated	O
+with	O
+pentamidine	B-CHED
+.	O
+
+We	O
+present	O
+the	O
+first	O
+and	O
+an	O
+unusual	O
+case	O
+of	O
+East	O
+African	B-PATH
+trypanosomiasis	I-PATH
+imported	O
+to	O
+Poland	O
+by	O
+a	O
+patient	O
+returning	O
+from	O
+a	O
+tourist	O
+trip	O
+to	O
+Uganda	O
+and	O
+Rwanda	O
+,	O
+which	O
+was	O
+successfully	O
+treated	O
+with	O
+pentamidine	B-CHED
+.	O
+
+T	B-SPEC
+.	I-SPEC
+brucei	I-SPEC
+rhodesiense	I-SPEC
+subspecies	O
+was	O
+finally	O
+identified	O
+on	O
+the	O
+basis	O
+of	O
+the	O
+characteristic	O
+serum	B-PRGE
+resistance	B-PROC
+-	I-PRGE
+associated	I-PRGE
+gene	I-PRGE
+using	O
+a	O
+polymerase	O
+chain	O
+reaction	O
+,	O
+and	O
+a	O
+seroconversion	O
+of	O
+specific	O
+immunoglobulin	B-PRGE
+M	I-PRGE
+and	O
+G	O
+antibodies	B-COMP
+in	O
+the	O
+peripheral	B-ANAT
+blood	I-ANAT
+by	O
+enzyme	O
+-	O
+linked	O
+immunosorbent	O
+assay	O
+.	O
+
+Sleeping	B-DISO
+sickness	I-DISO
+should	O
+always	O
+be	O
+considered	O
+in	O
+the	O
+differential	O
+diagnosis	O
+of	O
+fever	B-PROC
+in	O
+people	O
+returning	O
+from	O
+safari	O
+trips	O
+to	O
+the	O
+national	O
+parks	O
+or	O
+nature	O
+reserves	O
+of	O
+sub	O
+-	O
+Saharan	O
+Africa	O
+.	O
+
+Tonsillar	B-ANAT
+tissue	I-ANAT
+from	O
+patients	O
+with	O
+OSA	B-DISO
+and	O
+RI	O
+was	O
+subjected	O
+to	O
+multiplex	O
+quantitative	O
+real	O
+time	O
+reverse	B-PROC
+transcription	I-PROC
+PCR	O
+(	O
+mqRTPCR	O
+),	O
+analyzed	O
+for	O
+the	O
+presence	O
+of	O
+common	O
+respiratory	O
+viruses	B-SPEC
+'	O
+genetic	O
+material	O
+.	O
+
+Respiratory	O
+viruses	B-SPEC
+nucleic	B-CHED
+acids	I-CHED
+(	O
+24	O
+detections	O
+)	O
+were	O
+observed	O
+in	O
+17	O
+(	O
+50	O
+%)	O
+OSA	B-DISO
+samples	O
+.	O
+
+We	O
+retrospectively	O
+analyzed	O
+data	O
+from	O
+critically	B-DISO
+ill	I-DISO
+-	O
+patients	O
+with	O
+moderate	O
+and	O
+severe	O
+ARDS	B-DISO
+who	O
+received	O
+HFPV	O
+.	O
+
+A	O
+total	O
+of	O
+42	O
+patients	O
+(	O
+20	O
+with	O
+pneumonia	B-DISO
+-	O
+related	O
+ARDS	B-DISO
+and	O
+22	O
+non	O
+-	O
+septic	O
+ARDS	B-DISO
+cases	O
+)	O
+were	O
+evaluable	B-DISO
+.	O
+
+Baseline	O
+demographic	O
+characteristics	O
+,	O
+severity	O
+of	O
+illness	O
+,	O
+lung	B-ANAT
+injury	O
+score	O
+;	O
+pH	O
+and	O
+respiratory	O
+variables	O
+were	O
+comparable	O
+between	O
+pneumonia	B-DISO
+and	O
+non	O
+-	O
+sepsis	B-DISO
+-	O
+related	O
+ARDS	B-DISO
+.	O
+
+Oxygenation	B-PROC
+improved	O
+more	O
+in	O
+non	O
+-	O
+septic	O
+than	O
+in	O
+pneumonia	B-DISO
+-	O
+related	O
+ARDS	B-DISO
+.	O
+
+ABSTRACT	O
+:	O
+Human	O
+infections	B-DISO
+caused	O
+by	O
+avian	B-SPEC
+influenza	I-SPEC
+virus	I-SPEC
+A	O
+(	O
+H7N9	O
+)	O
+re	O
+-	O
+emerged	O
+in	O
+late	O
+2013	O
+.	O
+
+The	O
+influenza	B-PATH
+A	I-PATH
+/	O
+Hong	O
+Kong	O
+/	O
+470129	O
+/	O
+2013	O
+virus	B-SPEC
+strain	O
+was	O
+detected	O
+in	O
+a	O
+patient	O
+with	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+,	O
+deranged	O
+liver	B-PROC
+function	I-PROC
+and	O
+coagulation	B-PROC
+profile	O
+,	O
+cytopenia	B-DISO
+,	O
+and	O
+rhabdomyolysis	B-DISO
+.	O
+
+The	O
+patient	O
+required	O
+salvage	O
+by	O
+extracorporeal	O
+membrane	B-COMP
+oxygenation	B-PROC
+.	O
+
+The	O
+unique	O
+mutation	O
+PA	O
+L336M	O
+may	O
+enhance	O
+viral	B-PROC
+replication	I-PROC
+and	O
+therefore	O
+disease	O
+severity	O
+.	O
+
+Lower	B-DISO
+respiratory	I-DISO
+tract	I-DISO
+infection	I-DISO
+occurred	O
+in	O
+33	O
+%	O
+of	O
+children	O
+with	O
+HCoV	B-SPEC
+-	I-SPEC
+OC43	I-SPEC
+and	O
+25	O
+%	O
+of	O
+children	O
+with	O
+HCoV	B-SPEC
+-	I-SPEC
+NL63	I-SPEC
+.	O
+
+Overall	O
+,	O
+a	O
+substantial	O
+burden	O
+of	O
+disease	O
+associated	O
+with	O
+both	O
+HCoV	B-SPEC
+-	I-SPEC
+OC43	I-SPEC
+and	O
+HCoV	B-SPEC
+-	I-SPEC
+NL63	I-SPEC
+was	O
+observed	O
+for	O
+hospitalized	O
+children	O
+<	O
+5	O
+years	O
+of	O
+age	O
+.	O
+
+ABSTRACT	O
+:	O
+Since	O
+late	O
+2010	O
+,	O
+the	O
+outbreak	O
+of	O
+porcine	B-SPEC
+epidemic	B-DISO
+diarrhea	I-DISO
+(	O
+PED	O
+)	O
+in	O
+China	O
+has	O
+resulted	O
+in	O
+the	O
+deaths	B-PROC
+of	O
+millions	O
+of	O
+suckling	O
+piglets	O
+.	O
+
+Examples	O
+are	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+coronavirus	B-SPEC
+(	O
+SARS	B-DISO
+-	O
+CoV	O
+)	O
+and	O
+novel	O
+variants	O
+of	O
+influenza	B-SPEC
+A	I-SPEC
+virus	I-SPEC
+,	O
+such	O
+as	O
+H5N1	B-DISO
+and	O
+pandemic	O
+H1N1	O
+.	O
+
+Reporting	O
+rates	O
+of	O
+syncope	B-DISO
+or	O
+loss	O
+of	O
+consciousness	O
+and	O
+seizures	B-DISO
+with	O
+qHPV	O
+vaccine	O
+were	O
+17	O
+and	O
+3	O
+.	O
+2	O
+per	O
+100	O
+,	O
+000	O
+doses	O
+administered	O
+,	O
+respectively	O
+,	O
+and	O
+15	O
+and	O
+1	O
+.	O
+6	O
+for	O
+syncope	B-DISO
+or	O
+loss	O
+of	O
+consciousness	O
+and	O
+syncopal	O
+seizures	B-DISO
+occurred	O
+on	O
+the	O
+day	O
+of	O
+vaccination	O
+.	O
+
+The	O
+reporting	O
+rates	O
+of	O
+syncope	B-DISO
+or	O
+loss	O
+of	O
+consciousness	O
+and	O
+seizures	B-DISO
+were	O
+6	O
+.	O
+4	O
+and	O
+0	O
+.	O
+4	O
+,	O
+for	O
+the	O
+other	O
+vaccines	O
+.	O
+
+Four	O
+hundred	O
+thirty	O
+-	O
+seven	O
+respiratory	B-ANAT
+samples	I-ANAT
+were	O
+tested	O
+by	O
+modified	O
+shell	B-ANAT
+vial	O
+culture	O
+method	O
+,	O
+RV	O
+15	O
+ACE	B-ENZY
+,	O
+and	O
+AdvanSure	O
+.	O
+
+Sensitivities	O
+of	O
+culture	O
+,	O
+RV15	O
+,	O
+and	O
+AdvanSure	O
+for	O
+each	O
+virus	O
+tested	O
+were	O
+as	O
+follows	O
+:	O
+91	O
+/	O
+100	O
+/	O
+96	O
+%	O
+for	O
+influenza	B-PATH
+A	I-PATH
+,	O
+60	O
+/	O
+0	O
+/	O
+100	O
+%	O
+for	O
+influenza	B-DISO
+B	O
+,	O
+63	O
+/	O
+95	O
+/	O
+97	O
+%	O
+for	O
+RSV	B-SPEC
+,	O
+69	O
+/	O
+81	O
+/	O
+89	O
+%	O
+for	O
+adenovirus	B-DISO
+,	O
+and	O
+87	O
+/	O
+93	O
+/	O
+93	O
+%	O
+for	O
+parainfluenza	B-DISO
+virus	B-SPEC
+.	O
+
+For	O
+viruses	B-SPEC
+not	O
+covered	O
+by	O
+culture	O
+,	O
+sensitivities	O
+of	O
+RV15	O
+and	O
+AdvanSure	O
+were	O
+as	O
+follows	O
+:	O
+77	O
+/	O
+88	O
+%	O
+for	O
+rhinovirus	B-SPEC
+,	O
+100	O
+/	O
+100	O
+%	O
+for	O
+coronavirus	B-SPEC
+OC43	O
+,	O
+40	O
+/	O
+100	O
+%	O
+for	O
+coronavirus	B-SPEC
+229E	O
+/	O
+NL63	O
+,	O
+13	O
+/	O
+100	O
+%	O
+for	O
+metapneumovirus	B-SPEC
+,	O
+and	O
+44	O
+/	O
+100	O
+%	O
+for	O
+bocavirus	B-SPEC
+.	O
+
+TITLE	O
+:	O
+The	O
+potential	O
+efficacy	O
+of	O
+noninvasive	O
+ventilation	O
+with	O
+administration	O
+of	O
+a	O
+neutrophil	B-ANAT
+elastase	I-ENZY
+inhibitor	I-CHED
+for	O
+acute	O
+respiratory	O
+distress	O
+syndrome	O
+.	O
+
+ARDS	B-DISO
+-	O
+patients	O
+were	O
+treated	O
+with	O
+NIV	O
+and	O
+a	O
+neutrophil	B-CHED
+elastase	I-CHED
+inhibitor	I-CHED
+.	O
+
+The	O
+aim	O
+of	O
+this	O
+study	O
+was	O
+to	O
+evaluate	O
+if	O
+the	O
+exposure	O
+to	O
+Avian	B-SPEC
+metapneumovirus	I-SPEC
+(	O
+aMPV	O
+)	O
+and	O
+/	O
+or	O
+to	O
+Turkey	B-DISO
+hemorrhagic	I-DISO
+enteritis	I-DISO
+virus	B-SPEC
+(	O
+THEV	B-SPEC
+)	O
+was	O
+significant	O
+for	O
+the	O
+induction	O
+of	O
+episodes	O
+of	O
+colibacillosis	B-DISO
+in	O
+aMPV	O
+and	O
+THEV	B-SPEC
+vaccinated	O
+turkeys	B-SPEC
+.	O
+
+Field	O
+subtype	O
+B	O
+aMPVs	O
+were	O
+detected	O
+in	O
+all	O
+flocks	O
+at	O
+different	O
+ages	O
+of	O
+life	O
+always	O
+associated	O
+with	O
+respiratory	O
+signs	O
+and	O
+increase	O
+of	O
+colibacillosis	B-DISO
+-	O
+associated	O
+mortality	O
+.	O
+
+TITLE	O
+:	O
+The	O
+emergence	O
+of	O
+the	O
+Middle	O
+East	O
+respiratory	O
+syndrome	B-DISO
+coronavirus	B-SPEC
+.	O
+
+While	O
+parent	O
+virus	B-SPEC
+FIPV	O
+DF	O
+-	O
+2	O
+developed	O
+feline	B-DISO
+infectious	I-DISO
+peritonitis	I-DISO
+in	O
+all	O
+the	O
+infected	O
+cats	B-SPEC
+,	O
+its	O
+recombinant	O
+virus	B-SPEC
+PBFIPV	O
+-	O
+DF	O
+-	O
+2	O
+,	O
+differing	O
+only	O
+in	O
+seven	O
+nucleotides	B-CHED
+,	O
+proved	O
+to	O
+be	O
+surprisingly	O
+low	O
+virulent	O
+,	O
+although	O
+caused	O
+an	O
+acute	O
+febrile	B-PROC
+episode	O
+similarly	O
+to	O
+the	O
+original	O
+FIPV	O
+DF	O
+-	O
+2	O
+.	O
+
+ABSTRACT	O
+:	O
+Community	O
+-	O
+acquired	O
+pneumonia	O
+(	O
+CAP	B-DISO
+)	O
+is	O
+a	O
+common	O
+cause	O
+of	O
+sepsis	B-DISO
+.	O
+
+TITLE	O
+:	O
+Prolonged	O
+venovenous	O
+extracorporeal	O
+membrane	B-COMP
+oxygenation	B-PROC
+without	O
+anticoagulation	B-PROC
+:	O
+a	O
+case	O
+of	O
+Goodpasture	B-DISO
+syndrome	I-DISO
+-	O
+related	O
+pulmonary	B-DISO
+haemorrhage	I-DISO
+.	O
+
+ABSTRACT	O
+:	O
+Comparing	O
+sequences	O
+of	O
+archived	O
+viruses	O
+collected	O
+over	O
+many	O
+years	O
+to	O
+the	O
+present	O
+allows	O
+the	O
+study	O
+of	O
+viral	O
+evolution	B-PROC
+and	O
+contributes	O
+to	O
+the	O
+design	O
+of	O
+new	O
+vaccines	O
+.	O
+
+Use	O
+of	O
+these	O
+sequencing	O
+technologies	O
+would	O
+be	O
+advantageous	O
+in	O
+examining	O
+viral	O
+evolution	B-PROC
+.	O
+
+This	O
+conferred	O
+sequence	O
+independence	O
+by	O
+random	O
+priming	O
+both	O
+first	O
+and	O
+second	O
+strand	O
+cDNA	O
+synthesis	B-PROC
+.	O
+
+We	O
+want	O
+to	O
+present	O
+a	O
+newborn	O
+case	O
+of	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+caused	O
+by	O
+near	O
+drowning	O
+.	O
+
+Antibiotics	B-CHED
+were	O
+given	O
+to	O
+prevent	O
+infection	B-DISO
+.	O
+
+Four	O
+hours	O
+later	O
+,	O
+poractant	O
+alfa	O
+(	O
+Curosurf	O
+)	O
+administered	O
+repeatedly	O
+at	O
+the	O
+same	O
+dosage	O
+because	O
+of	O
+hypoxemia	O
+(	O
+PaO2	O
+/	O
+FIO2	O
+ratio	O
+,	O
+124	O
+;	O
+SaO2	B-PROC
+,	O
+88	O
+%).	O
+
+TITLE	O
+:	O
+Use	O
+of	O
+respiratory	O
+and	O
+facial	B-ANAT
+protection	O
+.	O
+
+Three	O
+groups	O
+of	O
+patients	O
+were	O
+identified	O
+:	O
+those	O
+with	O
+neither	O
+ARF	B-DISO
+nor	O
+SS	O
+(	O
+Group	O
+A	O
+),	O
+those	O
+with	O
+only	O
+ARF	B-DISO
+(	O
+Group	B-DISO
+B	I-DISO
+)	O
+and	O
+those	O
+with	O
+both	O
+ARF	B-DISO
+and	O
+SS	O
+(	O
+Group	O
+C	O
+)	O
+on	O
+admission	O
+.	O
+
+The	O
+contemporary	O
+occurrence	O
+of	O
+ARF	B-DISO
+and	O
+SS	O
+was	O
+associated	O
+with	O
+age	O
+(	O
+p	O
+=	O
+0	O
+.	O
+002	O
+),	O
+residency	O
+in	O
+nursing	B-PROC
+home	O
+(	O
+p	O
+=	O
+0	O
+.	O
+007	O
+),	O
+COPD	B-DISO
+(	O
+p	O
+<	O
+0	O
+.	O
+001	O
+),	O
+multilobar	O
+involvement	O
+(	O
+p	O
+<	O
+0	O
+.	O
+001	O
+)	O
+and	O
+renal	B-DISO
+disease	I-DISO
+(	O
+p	O
+<	O
+0	O
+.	O
+001	O
+).	O
+
+4	O
+.	O
+2	O
+%	O
+of	O
+patients	O
+in	O
+Group	O
+A	O
+died	B-PROC
+,	O
+9	O
+.	O
+3	O
+%	O
+in	O
+Group	B-DISO
+B	I-DISO
+and	O
+26	O
+%	O
+in	O
+Group	O
+C	O
+,	O
+p	O
+<	O
+0	O
+.	O
+001	O
+.	O
+
+After	O
+adjustment	O
+,	O
+the	O
+presence	O
+of	O
+only	O
+ARF	B-DISO
+had	O
+an	O
+OR	O
+for	O
+in	O
+-	O
+hospital	O
+mortality	O
+of	O
+1	O
+.	O
+85	O
+(	O
+p	O
+=	O
+0	O
+.	O
+011	O
+)	O
+and	O
+the	O
+presence	O
+of	O
+both	O
+ARF	B-DISO
+and	O
+SS	O
+had	O
+an	O
+OR	O
+of	O
+6	O
+.	O
+32	O
+(	O
+p	O
+<	O
+0	O
+.	O
+001	O
+).	O
+
+A	O
+quantitative	O
+RT	O
+-	O
+LAMP	O
+of	O
+FHMNV	O
+with	O
+a	O
+high	O
+correlation	O
+coefficient	O
+(	O
+r	O
+(	O
+2	O
+)=	O
+0	O
+.	O
+9926	O
+)	O
+was	O
+also	O
+developed	O
+and	O
+the	O
+result	O
+of	O
+quantitation	O
+of	O
+viral	O
+copies	O
+in	O
+tissue	B-ANAT
+samples	O
+of	O
+infected	O
+fish	B-SPEC
+showed	O
+that	O
+the	O
+viral	O
+loads	O
+of	O
+the	O
+infected	O
+fish	B-SPEC
+tissue	B-ANAT
+samples	O
+reached	O
+up	O
+to	O
+4	O
+.	O
+7	O
+×	O
+10	O
+(	O
+10	O
+)	O
+copies	O
+per	O
+mg	O
+.	O
+
+TITLE	O
+:	O
+The	O
+host	B-PRGE
+protease	I-PRGE
+TMPRSS2	I-PRGE
+plays	O
+a	O
+major	O
+role	O
+in	O
+in	O
+vivo	O
+replication	O
+of	O
+emerging	O
+H7N9	O
+and	O
+seasonal	O
+influenza	O
+viruses	O
+.	O
+
+In	O
+TMPRSS2	O
+KO	O
+mice	B-SPEC
+infected	O
+with	O
+LP	O
+IAVs	O
+,	O
+cleavage	B-PROC
+of	O
+HA	O
+was	O
+severely	O
+impaired	B-DISO
+,	O
+and	O
+consequently	O
+,	O
+the	O
+majority	O
+of	O
+LP	O
+IAV	O
+progeny	O
+particles	O
+failed	O
+to	O
+gain	O
+infectivity	O
+,	O
+while	O
+the	O
+viruses	O
+were	O
+fully	O
+activated	O
+proteolytically	O
+in	O
+TMPRSS2	O
++/+	O
+wild	O
+-	O
+type	O
+(	O
+WT	O
+)	O
+mice	B-SPEC
+.	O
+
+TITLE	O
+:	O
+Autopsy	O
+findings	O
+in	O
+fatal	O
+dengue	B-DISO
+haemorrhagic	I-DISO
+fever	I-DISO
+-	O
+06	O
+Cases	O
+.	O
+
+The	O
+patient	O
+,	O
+a	O
+68	O
+-	O
+year	O
+-	O
+old	O
+woman	O
+with	O
+a	O
+4	O
+-	O
+years	O
+history	O
+of	O
+Parkinson	B-PATH
+'	I-PATH
+s	I-PATH
+disease	I-PATH
+,	O
+presented	O
+with	O
+hyperthermia	B-PROC
+and	O
+severe	O
+muscular	B-ANAT
+rigidity	I-DISO
+.	O
+
+Stridor	B-DISO
+was	O
+auscultated	O
+but	O
+breathing	B-PROC
+was	O
+not	O
+labored	O
+.	O
+
+During	O
+surgery	O
+anesthesia	B-DISO
+was	O
+maintained	O
+with	O
+sevoflurane	B-CHED
+,	O
+remifentanil	B-CHED
+and	O
+rocuronium	B-CHED
+.	O
+
+Four	O
+main	O
+mechanisms	O
+leading	O
+to	O
+VALI	O
+are	O
+:	O
+1	O
+)	O
+increased	O
+stress	O
+and	O
+strain	O
+,	O
+induced	O
+by	O
+high	O
+tidal	O
+volume	O
+(	O
+VT	O
+);	O
+2	O
+)	O
+increased	O
+shear	O
+stress	O
+,	O
+i	O
+.	O
+e	O
+.	O
+opening	O
+and	O
+closing	O
+,	O
+of	O
+previously	O
+atelectatic	O
+alveolar	B-ANAT
+units	O
+;	O
+3	O
+)	O
+distribution	O
+of	O
+perfusion	O
+and	O
+4	O
+)	O
+biotrauma	O
+.	O
+
+In	O
+severe	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+patients	O
+,	O
+low	O
+VT	O
+,	O
+higher	O
+levels	O
+of	O
+positive	O
+end	O
+expiratory	B-PROC
+pressure	O
+,	O
+long	O
+duration	O
+prone	O
+position	O
+and	O
+neuromuscular	B-DISO
+blockade	I-DISO
+within	O
+the	O
+first	O
+48	O
+hours	O
+are	O
+associated	O
+to	O
+a	O
+better	O
+outcome	O
+.	O
+
+TITLE	O
+:	O
+Imported	O
+falciparum	B-DISO
+malaria	I-DISO
+among	O
+adults	O
+requiring	O
+intensive	O
+care	O
+:	O
+analysis	O
+of	O
+the	O
+literature	O
+.	O
+
+ABSTRACT	O
+:	O
+As	O
+a	O
+continuation	O
+of	O
+our	O
+efforts	O
+to	O
+discover	O
+and	O
+develop	O
+back	O
+-	O
+up	O
+analogs	O
+of	O
+DAPYs	O
+,	O
+novel	O
+substituted	O
+nitropyridine	O
+derivatives	O
+were	O
+designed	O
+via	O
+a	O
+structure	O
+-	O
+based	O
+core	O
+refining	O
+approach	O
+,	O
+synthesized	O
+and	O
+evaluated	O
+for	O
+their	O
+in	O
+vitro	O
+HIV	B-SPEC
+-	I-SPEC
+1	I-SPEC
+activity	O
+in	O
+MT	O
+-	O
+4	O
+cells	B-COMP
+.	O
+
+Most	O
+notably	O
+,	O
+the	O
+compound	O
+7b	O
+was	O
+identified	O
+as	O
+the	O
+most	O
+promising	O
+candidate	O
+in	O
+inhibiting	O
+HIV	B-SPEC
+-	I-SPEC
+1	I-SPEC
+replication	O
+with	O
+an	O
+EC50	O
+value	O
+of	O
+0	O
+.	O
+056	O
+μM	O
+and	O
+a	O
+selective	O
+index	O
+(	O
+SI	O
+)	O
+of	O
+1251	O
+,	O
+which	O
+were	O
+much	O
+better	O
+than	O
+those	O
+of	O
+NVP	B-CHED
+(	O
+EC₅₀	O
+=	O
+0	O
+.	O
+23	O
+μM	O
+)	O
+and	O
+DLV	O
+(	O
+EC₅₀	O
+=	O
+0	O
+.	O
+51	O
+μM	O
+).	O
+
+Here	O
+,	O
+we	O
+show	O
+that	O
+a	O
+chimeric	B-PRGE
+S	I-PRGE
+protein	I-PRGE
+,	O
+containing	O
+the	O
+six	O
+C	O
+-	O
+terminal	O
+amino	B-CHED
+acids	I-CHED
+of	O
+the	O
+glycoprotein	B-CHED
+G	O
+of	O
+vesicular	B-SPEC
+stomatitis	I-SPEC
+virus	I-SPEC
+(	O
+VSV	O
+)	O
+is	O
+no	O
+longer	O
+retained	O
+intracellularly	O
+,	O
+despite	O
+the	O
+presence	O
+of	O
+the	O
+tyrosine	B-CHED
+tetrapeptide	B-CHED
+motif	O
+.	O
+
+Analysis	O
+of	O
+mutant	O
+proteins	B-CHED
+generated	O
+by	O
+site	B-PROC
+-	I-PROC
+directed	I-PROC
+mutagenesis	I-PROC
+revealed	O
+that	O
+a	O
+single	O
+amino	B-CHED
+acid	I-CHED
+exchange	O
+(	O
+1445K	O
+/	O
+M	O
+,	O
+position	O
+:	O
++	O
+2	O
+downstream	O
+of	O
+the	O
+tyrosine	B-CHED
+-	O
+based	O
+motif	O
+)	O
+was	O
+responsible	O
+for	O
+the	O
+altered	O
+sorting	B-PROC
+behavior	O
+.	O
+
+Inhibition	B-PROC
+of	O
+C5a	B-PRGE
+/	O
+C5aR	B-PRGE
+interactions	O
+is	O
+expected	O
+to	O
+be	O
+beneficial	O
+in	O
+the	O
+clinical	O
+treatment	O
+of	O
+FH	O
+patients	O
+.	O
+
+Of	O
+etiotropic	O
+treatment	O
+of	O
+influenza	B-DISO
+and	O
+other	O
+ARVI	O
+include	O
+a	O
+wide	O
+spectrum	O
+of	O
+antiviral	B-CHED
+drugs	I-CHED
+,	O
+among	O
+which	O
+are	O
+the	O
+drugs	O
+with	O
+a	O
+restricted	O
+spectrum	O
+,	O
+basically	O
+used	O
+in	O
+influenza	B-DISO
+,	O
+and	O
+a	O
+general	O
+spectrum	O
+used	O
+in	O
+influenza	B-DISO
+and	O
+other	O
+ARVI	O
+as	O
+a	O
+prophylactic	O
+or	O
+therapeutic	O
+intention	O
+.	O
+
+The	O
+expressed	B-PROC
+protein	B-CHED
+,	O
+used	O
+in	O
+ELISA	O
+,	O
+effectively	O
+detected	O
+chicken	B-PRGE
+anti	I-PRGE
+-	I-PRGE
+IBV	B-SPEC
+antibodies	B-COMP
+with	O
+high	O
+specificity	O
+.	O
+
+ABSTRACT	O
+:	O
+Coronaviruses	O
+cause	O
+respiratory	B-DISO
+disease	I-DISO
+in	O
+humans	B-SPEC
+that	O
+can	O
+range	O
+from	O
+mild	O
+to	O
+severe	O
+.	O
+
+TITLE	O
+:	O
+Enhanced	O
+innate	O
+antiviral	B-CHED
+gene	B-PROC
+expression	I-PROC
+,	O
+IFN	B-PRGE
+-	I-PRGE
+α	I-PRGE
+,	O
+and	O
+cytolytic	O
+responses	O
+are	O
+predictive	O
+of	O
+mucosal	B-ANAT
+immune	O
+recovery	O
+during	O
+simian	B-SPEC
+immunodeficiency	I-SPEC
+virus	B-DISO
+infection	I-DISO
+.	O
+
+Although	O
+an	O
+abundance	O
+of	O
+memory	B-PROC
+CD4	B-PRGE
+(+)	O
+T	B-ANAT
+cells	I-ANAT
+at	O
+mucosal	B-ANAT
+sites	O
+render	O
+them	O
+highly	O
+susceptible	O
+to	O
+HIV	B-PATH
+infection	I-PATH
+,	O
+the	O
+gut	B-ANAT
+and	O
+not	O
+the	O
+lung	B-ANAT
+experiences	O
+severe	O
+and	O
+sustained	O
+CD4	B-PRGE
+(+)	O
+T	B-ANAT
+cell	I-ANAT
+depletion	O
+and	O
+tissue	B-ANAT
+disruption	O
+.	O
+
+Pyrrolidine	B-CHED
+dithiocarbamate	O
+,	O
+a	O
+STAT	B-PRGE
+/	O
+NF	O
+-	O
+κB	O
+inhibitor	B-CHED
+and	O
+free	O
+radical	B-CHED
+scavenger	I-CHED
+,	O
+was	O
+administered	O
+systemically	O
+to	O
+a	O
+subset	O
+of	O
+mice	B-SPEC
+to	O
+determine	O
+whether	O
+this	O
+altered	O
+the	O
+muscle	B-PROC
+contraction	B-DISO
+response	O
+.	O
+
+ABSTRACT	O
+:	O
+Infectious	B-DISO
+bronchitis	B-DISO
+coronavirus	B-SPEC
+(	O
+IBV	B-SPEC
+),	O
+Newcastle	B-SPEC
+disease	I-SPEC
+virus	I-SPEC
+(	O
+NDV	B-SPEC
+),	O
+and	O
+avian	B-SPEC
+influenza	I-SPEC
+virus	I-SPEC
+(	O
+AIV	O
+)	O
+H9	O
+subtype	O
+are	O
+major	O
+pathogens	O
+of	O
+chickens	B-SPEC
+causing	O
+serious	O
+respiratory	B-DISO
+tract	I-DISO
+disease	I-DISO
+and	O
+heavy	O
+economic	O
+losses	O
+.	O
+
+Gene	B-PROC
+expression	I-PROC
+of	O
+IL	O
+-	O
+1β	O
+and	O
+IL	O
+-	O
+6receptors	O
+in	O
+the	O
+tubular	O
+gland	B-ANAT
+cells	B-COMP
+of	O
+the	O
+isthmus	O
+and	O
+uterus	B-ANAT
+was	O
+analyzed	O
+by	O
+reverse	B-PRGE
+transcriptase	I-PRGE
+polymerase	I-PRGE
+chain	O
+reaction	O
+.	O
+
+The	O
+expression	B-PROC
+of	O
+IL	B-PRGE
+-	I-PRGE
+6	I-PRGE
+receptor	I-PRGE
+,	O
+but	O
+not	O
+IL	B-PRGE
+-	I-PRGE
+1β	I-PRGE
+receptor	I-PRGE
+,	O
+was	O
+identified	O
+in	O
+the	O
+tubular	O
+gland	B-ANAT
+cells	B-COMP
+in	O
+the	O
+isthmus	O
+and	O
+uterus	B-ANAT
+.	O
+
+The	O
+patient	O
+also	O
+received	O
+pralidoxime	B-CHED
+.	O
+
+ABSTRACT	O
+:	O
+Abstract	O
+Acute	O
+lung	O
+injury	O
+(	O
+ALI	O
+)	O
+and	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+(	O
+ARDS	B-DISO
+)	O
+are	O
+severe	O
+syndromes	B-DISO
+resulting	O
+from	O
+the	O
+diffuse	O
+damage	O
+of	O
+the	O
+pulmonary	B-ANAT
+parenchyma	B-ANAT
+.	O
+
+Although	O
+animal	B-SPEC
+models	O
+of	O
+ALI	O
+/	O
+ARDS	B-DISO
+have	O
+pointed	O
+out	O
+a	O
+variety	O
+of	O
+new	O
+ideas	O
+for	O
+study	O
+,	O
+there	O
+are	O
+still	O
+limited	O
+data	O
+regarding	O
+the	O
+initiating	O
+factors	O
+,	O
+the	O
+critical	O
+steps	O
+in	O
+the	O
+progression	O
+of	O
+the	O
+disease	O
+,	O
+and	O
+the	O
+central	O
+mechanisms	O
+dictating	O
+its	O
+resolution	O
+or	O
+progression	O
+to	O
+lung	B-ANAT
+scarring	B-DISO
+.	O
+
+We	O
+developed	O
+an	O
+inferential	O
+transmission	O
+model	O
+capable	O
+of	O
+distinguishing	O
+the	O
+signal	O
+of	O
+human	B-SPEC
+-	O
+to	O
+-	O
+human	B-SPEC
+transmission	O
+from	O
+the	O
+background	O
+noise	O
+of	O
+direct	O
+spillover	O
+transmission	O
+(	O
+e	O
+.	O
+g	O
+.	O
+from	O
+markets	O
+or	O
+farms	O
+).	O
+
+Applying	O
+our	O
+method	O
+to	O
+data	O
+from	O
+the	O
+three	O
+largest	O
+outbreaks	O
+of	O
+influenza	B-PATH
+A	I-PATH
+/	O
+H7N9	O
+outbreak	O
+in	O
+China	O
+in	O
+2013	O
+,	O
+we	O
+found	O
+evidence	O
+that	O
+human	B-SPEC
+-	O
+to	O
+-	O
+human	B-SPEC
+transmission	O
+accounted	O
+for	O
+13	O
+%	O
+(	O
+95	O
+%	O
+credible	O
+interval	O
+1	O
+%-	O
+32	O
+%)	O
+of	O
+cases	O
+overall	O
+.	O
+
+In	O
+addition	O
+,	O
+for	O
+almost	O
+three	O
+decades	O
+now	O
+,	O
+the	O
+scientific	O
+literature	O
+has	O
+also	O
+demonstrated	O
+that	O
+HCoV	O
+are	O
+neuroinvasive	O
+and	O
+neurotropic	O
+and	O
+could	O
+induce	O
+an	O
+overactivation	O
+of	O
+the	O
+immune	B-ANAT
+system	I-ANAT
+,	O
+in	O
+part	O
+by	O
+participating	O
+in	O
+the	O
+activation	O
+of	O
+autoreactive	O
+immune	O
+cells	B-COMP
+that	O
+could	O
+be	O
+associated	O
+with	O
+autoimmunity	B-DISO
+in	O
+susceptible	O
+individuals	O
+.	O
+
+Given	O
+all	O
+these	O
+properties	O
+,	O
+it	O
+has	O
+been	O
+suggested	O
+that	O
+these	O
+recognized	O
+human	B-SPEC
+respiratory	O
+pathogens	O
+could	O
+be	O
+associated	O
+with	O
+the	O
+triggering	O
+or	O
+the	O
+exacerbation	O
+of	O
+neurological	O
+diseases	O
+for	O
+which	O
+the	O
+etiology	O
+remains	O
+unknown	O
+or	O
+poorly	O
+understood	O
+.	O
+
+Meanwhile	O
+,	O
+we	O
+showed	O
+that	O
+PLpro	O
+-	O
+TM	O
+physically	O
+interacts	O
+with	O
+TRAF3	B-PRGE
+,	O
+TBK1	B-ENZY
+,	O
+IKKε	O
+,	O
+STING	O
+,	O
+and	O
+IRF3	B-PRGE
+,	O
+the	O
+key	O
+components	O
+that	O
+assemble	O
+the	O
+STING	O
+-	O
+TRAF3	B-PRGE
+-	O
+TBK1	B-FUNC
+complex	O
+for	O
+activation	O
+of	O
+IFN	B-PRGE
+expression	B-PROC
+.	O
+
+We	O
+demonstrate	O
+that	O
+the	O
+fusion	O
+of	O
+green	B-PRGE
+fluorescent	I-PRGE
+protein	I-PRGE
+and	O
+firefly	B-ENZY
+luciferase	I-ENZY
+with	O
+either	O
+nonstructural	O
+protein	B-CHED
+2	O
+or	O
+3	O
+is	O
+tolerated	O
+and	O
+that	O
+these	O
+reporter	O
+-	O
+replicase	B-PRGE
+fusions	O
+can	O
+be	O
+used	O
+to	O
+quantitate	O
+replication	O
+complex	O
+formation	B-PROC
+and	O
+virus	B-PROC
+replication	I-PROC
+.	O
+
+TITLE	O
+:	O
+Severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+vs	O
+.	O
+the	O
+Middle	O
+East	O
+respiratory	O
+syndrome	B-DISO
+.	O
+
+More	O
+studies	O
+are	O
+needed	O
+to	O
+understand	O
+MERS	O
+-	O
+CoV	O
+in	O
+order	B-SPEC
+to	O
+guide	O
+public	O
+health	O
+infection	B-DISO
+control	O
+measures	O
+and	O
+treatment	O
+.	O
+
+The	O
+primary	O
+aim	O
+of	O
+this	O
+study	O
+was	O
+to	O
+investigate	O
+the	O
+role	O
+of	O
+E	B-SPEC
+.	I-SPEC
+coli	I-SPEC
+,	O
+Enterococcus	B-SPEC
+spp	B-ENZY
+.,	O
+C	B-SPEC
+.	I-SPEC
+perfringens	I-SPEC
+and	O
+C	B-SPEC
+.	I-SPEC
+difficile	I-SPEC
+in	O
+the	O
+pathogenesis	B-DISO
+of	O
+neonatal	O
+porcine	B-SPEC
+diarrhea	B-DISO
+with	O
+no	O
+established	O
+casual	O
+agents	O
+.	O
+
+Fluorescence	O
+in	O
+situ	O
+hybridization	B-PROC
+with	O
+oligonucleotide	B-CHED
+probes	O
+was	O
+applied	O
+on	O
+the	O
+fixed	B-ANAT
+intestinal	B-ANAT
+tissue	B-ANAT
+samples	O
+from	O
+51	O
+diarrheic	O
+and	O
+50	O
+non	O
+-	O
+diarrheic	O
+piglets	O
+collected	O
+from	O
+four	O
+Danish	O
+farms	O
+during	O
+outbreaks	O
+of	O
+neonatal	B-DISO
+diarrhea	I-DISO
+not	O
+caused	O
+by	O
+well	O
+-	O
+known	O
+enteric	O
+pathogens	O
+.	O
+
+However	O
+,	O
+Enterococcus	B-SPEC
+spp	B-ENZY
+.	O
+was	O
+primarily	O
+detected	O
+in	O
+the	O
+diarrheic	O
+piglets	O
+.	O
+
+These	O
+bacteria	B-SPEC
+were	O
+identified	O
+as	O
+E	B-SPEC
+.	I-SPEC
+coli	I-SPEC
+and	O
+Enterococcus	B-SPEC
+spp	B-ENZY
+.	O
+
+A	O
+triple	O
+antibiotic	B-CHED
+therapy	O
+with	O
+ceftriaxone	B-CHED
+,	O
+amikacin	B-CHED
+,	O
+and	O
+josamycin	O
+was	O
+started	O
+.	O
+
+The	O
+appropriate	O
+antibiotic	B-CHED
+therapy	O
+associated	O
+with	O
+corticosteroids	B-CHED
+and	O
+immunoglobulins	O
+led	O
+to	O
+clinical	O
+improvement	O
+and	O
+the	O
+patient	O
+progressed	O
+toward	O
+complete	O
+recovery	O
+.	O
+
+Early	O
+treatment	O
+with	O
+neuraminidase	B-PROC
+inhibitors	I-PROC
+improved	O
+survival	O
+,	O
+but	O
+the	O
+efficacy	O
+of	O
+antivirals	B-CHED
+was	O
+hampered	O
+by	O
+resistant	O
+mutants	O
+.	O
+
+The	O
+emergence	O
+of	O
+A	O
+(	O
+H7N9	O
+)	O
+virus	B-SPEC
+represents	O
+a	O
+significant	O
+health	O
+threat	O
+.	O
+
+Likewise	O
+,	O
+advanced	O
+age	O
+correlated	O
+with	O
+more	O
+adverse	O
+disease	O
+outcomes	O
+following	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+coronavirus	B-SPEC
+(	O
+SARS	B-DISO
+-	O
+CoV	O
+)	O
+infection	B-DISO
+in	O
+humans	B-SPEC
+.	O
+
+Furthermore	O
+,	O
+PKR	B-PRGE
+deficiency	O
+selectively	O
+reduced	O
+IL	B-PROC
+-	I-PROC
+10	I-PROC
+production	I-PROC
+in	O
+CD4	B-PRGE
+,	O
+but	O
+not	O
+CD8	B-PRGE
+T	I-PRGE
+cells	O
+,	O
+without	O
+affecting	O
+CNS	B-CHED
+pathology	B-DISO
+.	O
+
+TITLE	O
+:	O
+How	O
+change	O
+of	O
+public	O
+transportation	O
+usage	O
+reveals	O
+fear	O
+of	O
+the	O
+SARS	B-DISO
+virus	B-SPEC
+in	O
+a	O
+city	O
+.	O
+
+Instead	O
+,	O
+delayed	O
+MHV	B-SPEC
+-	O
+3	O
+replication	O
+coincided	O
+with	O
+high	O
+levels	O
+of	O
+cellular	B-COMP
+ISGylation	O
+.	O
+
+Activation	O
+of	O
+the	O
+pathway	B-PROC
+is	O
+very	O
+good	O
+at	O
+suppressing	O
+viral	O
+production	O
+,	O
+but	O
+over	O
+time	O
+the	O
+virus	B-SPEC
+overwhelms	O
+the	O
+host	B-PROC
+response	I-PROC
+and	O
+the	O
+effects	O
+of	O
+the	O
+ISG15	B-PRGE
+pathway	B-PROC
+.	O
+
+Real	O
+-	O
+time	O
+polymerase	O
+chain	O
+reaction	O
+(	O
+PCR	O
+)	O
+was	O
+used	O
+to	O
+detect	O
+hMPV	B-SPEC
+infection	B-DISO
+.	O
+
+RESULTS	O
+:	O
+The	O
+prevalence	O
+of	O
+hMPV	B-SPEC
+for	O
+all	O
+age	O
+groups	O
+was	O
+6	O
+.	O
+3	O
+%.	O
+
+TITLE	O
+:	O
+New	O
+alphacoronavirus	B-SPEC
+in	O
+Mystacina	B-SPEC
+tuberculata	I-SPEC
+bats	B-SPEC
+,	O
+New	O
+Zealand	O
+.	O
+
+The	O
+viruses	B-SPEC
+were	O
+dried	B-ANAT
+on	O
+stainless	O
+steel	O
+discs	O
+in	O
+20	O
+-	O
+or	O
+40	O
+-	O
+μL	O
+aliquots	O
+and	O
+exposed	O
+to	O
+HPV	O
+produced	O
+by	O
+a	O
+Clarus	O
+L	O
+generator	O
+(	O
+Bioquell	O
+,	O
+Horsham	O
+,	O
+PA	O
+,	O
+USA	O
+)	O
+in	O
+a	O
+0	O
+.	O
+2	O
+-	O
+m	O
+(	O
+3	O
+)	O
+environmental	O
+chamber	B-ANAT
+.	O
+
+Nucleic	B-CHED
+acids	I-CHED
+collected	O
+using	O
+FTA	O
+Cards	O
+without	O
+the	O
+need	O
+for	O
+a	O
+cold	B-DISO
+-	O
+chain	O
+or	O
+special	O
+liquid	O
+media	B-ANAT
+handling	O
+provided	O
+realtime	O
+PCR	O
+results	O
+consistent	O
+(	O
+96	O
+.	O
+8	O
+%	O
+agreement	O
+,	O
+kappa	B-PRGE
+0	I-PRGE
+.	O
+923	O
+[	O
+95	O
+%	O
+CI	O
+=	O
+0	O
+.	O
+89	O
+-	O
+0	O
+.	O
+96	O
+])	O
+with	O
+the	O
+same	O
+specimens	O
+collected	O
+using	O
+traditional	O
+viral	O
+transport	B-PROC
+media	B-ANAT
+and	O
+shipped	O
+on	O
+ice	O
+using	O
+the	O
+U	O
+.	O
+S	O
+.	O
+Department	O
+of	O
+Transportation	O
+mandated	O
+liquid	O
+handling	O
+requirements	O
+.	O
+
+Deceased	B-PROC
+donors	O
+with	O
+previous	O
+hepatitis	B-DISO
+C	I-DISO
+infection	I-DISO
+may	O
+represent	O
+a	O
+safe	O
+resource	O
+to	O
+expand	O
+the	O
+donor	B-CHED
+pool	O
+.	O
+
+Therefore	O
+,	O
+we	O
+performed	O
+time	O
+course	O
+experiments	O
+in	O
+which	O
+Vero	B-ANAT
+cells	I-ANAT
+were	O
+C	O
+.	O
+pecorum	O
+/	O
+PEDV	B-SPEC
+infected	O
+in	O
+the	O
+presence	O
+of	O
+cycloheximide	B-CHED
+(	O
+CHX	O
+),	O
+which	O
+inhibits	O
+viral	O
+but	O
+not	O
+chlamydial	O
+protein	B-PROC
+synthesis	I-PROC
+.	O
+
+These	O
+data	O
+demonstrate	O
+that	O
+PEDV	B-SPEC
+co	B-DISO
+-	I-DISO
+infection	I-DISO
+-	O
+induced	O
+chlamydial	O
+persistence	O
+/	O
+stress	O
+is	O
+reversible	O
+and	O
+suggest	O
+that	O
+this	O
+induction	O
+(	O
+i	O
+)	O
+does	O
+not	O
+require	O
+viral	B-PROC
+replication	I-PROC
+in	O
+host	B-COMP
+cells	B-COMP
+;	O
+and	O
+(	O
+ii	O
+)	O
+does	O
+not	O
+require	O
+de	O
+novo	O
+host	B-COMP
+or	O
+viral	B-PROC
+protein	I-PROC
+synthesis	I-PROC
+.	O
+
+Reovirus	B-SPEC
+pathogenicity	O
+has	O
+been	O
+associated	O
+with	O
+virus	B-SPEC
+-	O
+induced	O
+apoptosis	B-PATH
+in	O
+cultured	B-ANAT
+cells	I-ANAT
+and	O
+in	O
+vivo	O
+.	O
+
+We	O
+also	O
+investigated	O
+BYD1	O
+caused	O
+systemic	O
+complications	O
+in	O
+suckling	O
+mice	B-SPEC
+.	O
+
+Collectively	O
+,	O
+our	O
+data	O
+suggest	O
+that	O
+BYD1	O
+μ1	O
+-	O
+and	O
+σ1	O
+-	O
+induced	O
+apoptosis	B-PATH
+is	O
+involved	O
+in	O
+the	O
+multi	O
+-	O
+organ	B-ANAT
+lesions	O
+in	O
+a	O
+suckling	O
+mouse	B-SPEC
+BYD1	O
+infection	B-DISO
+model	O
+.	O
+
+TITLE	O
+:	O
+Role	O
+of	O
+alveolar	B-ANAT
+macrophages	I-ANAT
+in	O
+the	O
+inflammatory	B-DISO
+response	I-DISO
+after	O
+trauma	O
+.	O
+
+Moreover	O
+,	O
+patients	O
+with	O
+low	O
+OCT	O
+results	O
+at	O
+T24	O
+exhibited	O
+more	O
+severe	O
+respiratory	B-DISO
+failure	I-DISO
+(	O
+P	O
+<	O
+0	O
+.	O
+01	O
+).	O
+
+We	O
+excluded	O
+trials	O
+of	O
+newborns	O
+and	O
+children	O
+;	O
+and	O
+those	O
+on	O
+short	O
+-	O
+term	O
+interventions	O
+,	O
+ARDS	B-DISO
+prevention	O
+,	O
+or	O
+post	O
+-	O
+traumatic	B-DISO
+lung	I-DISO
+injury	O
+.	O
+
+We	O
+also	O
+reviewed	O
+all	O
+meta	B-SPEC
+-	O
+analyses	O
+of	O
+RCTs	O
+in	O
+this	O
+field	O
+that	O
+addressed	O
+mortality	O
+.	O
+
+There	O
+is	O
+limited	O
+supportive	O
+evidence	O
+that	O
+specific	O
+interventions	O
+can	O
+decrease	O
+mortality	O
+in	O
+ARDS	B-DISO
+.	O
+
+ABSTRACT	O
+:	O
+Coronavirus	O
+envelope	B-COMP
+(	O
+CoV	O
+E	O
+)	O
+proteins	B-CHED
+are	O
+∼	O
+100	O
+-	O
+residue	O
+polypeptides	B-CHED
+with	O
+at	O
+least	O
+one	O
+channel	O
+-	O
+forming	O
+α	O
+-	O
+helical	O
+transmembrane	B-COMP
+(	O
+TM	O
+)	O
+domain	O
+.	O
+
+TITLE	O
+:	O
+Mounier	B-DISO
+-	I-DISO
+Kuhn	I-DISO
+syndrome	I-DISO
+masquerading	O
+pulmonary	B-DISO
+thromboembolism	I-DISO
+in	O
+an	O
+elderly	O
+male	O
+.	O
+
+It	O
+results	O
+in	O
+recurrent	O
+lower	B-DISO
+respiratory	I-DISO
+tract	I-DISO
+infections	I-DISO
+and	O
+bronchiectasis	B-DISO
+.	O
+
+In	O
+severe	O
+cases	O
+,	O
+patients	O
+may	O
+present	O
+with	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+requiring	O
+hospital	O
+admission	O
+and	O
+ventilatory	O
+support	O
+.	O
+
+Clinical	O
+examination	O
+and	O
+chest	B-ANAT
+radiography	O
+may	O
+be	O
+misleading	O
+in	O
+these	O
+patients	O
+as	O
+tracheobronchomegaly	B-DISO
+is	O
+easily	O
+overlooked	O
+on	O
+radiographs	O
+.	O
+
+TITLE	O
+:	O
+Human	B-SPEC
+adult	O
+bone	B-ANAT
+marrow	I-ANAT
+-	O
+derived	O
+stem	B-ANAT
+cells	I-ANAT
+decrease	O
+severity	O
+of	O
+lipopolysaccharide	B-CHED
+-	O
+induced	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+in	O
+sheep	B-SPEC
+.	O
+
+In	O
+order	B-SPEC
+to	O
+improve	O
+preparedness	O
+and	O
+responsiveness	O
+during	O
+future	O
+outbreaks	O
+of	O
+novel	O
+CoVs	O
+,	O
+information	O
+and	O
+problems	O
+regarding	O
+serological	O
+diagnosis	O
+that	O
+occurred	O
+during	O
+the	O
+SARS	B-DISO
+-	O
+CoV	O
+should	O
+be	O
+acknowledged	O
+.	O
+
+In	O
+this	O
+review	O
+we	O
+summarize	O
+the	O
+performance	O
+of	O
+different	O
+serological	O
+assays	O
+as	O
+well	O
+as	O
+the	O
+applicability	O
+of	O
+the	O
+two	O
+main	O
+applied	O
+antigens	B-CHED
+(	O
+spike	O
+and	O
+nucleocapsid	B-COMP
+protein	B-CHED
+)	O
+used	O
+during	O
+the	O
+SARS	B-DISO
+-	O
+CoV	O
+outbreak	O
+.	O
+
+We	O
+highlight	O
+challenges	O
+and	O
+potential	O
+pitfalls	O
+that	O
+occur	O
+when	O
+dealing	O
+with	O
+a	O
+novel	O
+emerging	O
+coronavirus	B-SPEC
+like	O
+MERS	O
+-	O
+CoV	O
+.	O
+In	O
+addition	O
+we	O
+describe	O
+problems	O
+that	O
+might	O
+occur	O
+when	O
+animal	B-SPEC
+sera	B-COMP
+are	O
+tested	O
+in	O
+serological	O
+assays	O
+for	O
+the	O
+identification	O
+of	O
+putative	O
+reservoirs	O
+.	O
+
+Cloacal	B-ANAT
+swabs	O
+were	O
+collected	O
+from	O
+20	O
+chickens	B-SPEC
+in	O
+each	O
+flock	O
+approximately	O
+every	O
+6	O
+weeks	O
+.	O
+
+Oral	B-ANAT
+challenge	O
+infection	B-DISO
+with	O
+TGEV	B-SPEC
+was	O
+performed	O
+when	O
+the	O
+pigs	B-SPEC
+had	O
+been	O
+fed	O
+for	O
+1	O
+week	O
+with	O
+the	O
+respective	O
+diet	O
+.	O
+
+Excepting	O
+state	B-DISO
+anxiety	I-DISO
+,	O
+other	O
+affective	O
+measures	O
+including	O
+""""	O
+anticipated	O
+worry	O
+""","	O
+""""	O
+experienced	O
+worry	O
+""""	O
+and	O
+""""	O
+current	O
+worry	O
+""""	O
+specific	O
+to	O
+A	O
+/	O
+H1N1	O
+risk	O
+were	O
+consistently	O
+and	O
+strongly	O
+associated	O
+with	O
+adoption	O
+of	O
+protective	O
+behaviors	B-PROC
+across	O
+different	O
+survey	O
+periods	B-PROC
+.	O
+
+Perceived	O
+A	O
+/	O
+H1N1	O
+severity	O
+relative	O
+to	O
+SARS	B-DISO
+had	O
+stronger	O
+associations	O
+with	O
+adoption	O
+of	O
+protective	O
+behaviors	B-PROC
+in	O
+the	O
+late	O
+epidemic	O
+periods	B-PROC
+than	O
+in	O
+the	O
+early	O
+epidemic	O
+periods	B-PROC
+.	O
+
+TITLE	O
+:	O
+Synthesis	B-PROC
+and	O
+anti	O
+-	O
+HIV	B-DISO
+activity	O
+of	O
+4	O
+-(	O
+naphthalen	B-CHED
+-	I-CHED
+1	I-CHED
+-	I-CHED
+yl	I-CHED
+)-	O
+1	O
+,	O
+2	O
+,	O
+5	O
+-	O
+thiadiazol	O
+-	O
+3	O
+-	O
+hydroxyl	B-CHED
+derivatives	O
+.	O
+
+ABSTRACT	O
+:	O
+A	O
+series	O
+of	O
+4	O
+-(	O
+naphthalen	O
+-	O
+1	O
+-	O
+yl	O
+)-	O
+1	O
+,	O
+2	O
+,	O
+5	O
+-	O
+thiadiazol	O
+-	O
+3	O
+-	O
+hydroxyl	B-CHED
+derivatives	O
+(	O
+Ia	O
+-	O
+Im	O
+and	O
+IIa	B-PRGE
+-	I-PRGE
+IIe	I-PRGE
+)	O
+designed	O
+as	O
+novel	O
+HIV	B-SPEC
+-	I-SPEC
+1	I-SPEC
+non	B-PROC
+-	I-PROC
+nucleoside	I-PROC
+reverse	B-CHED
+transcriptase	I-CHED
+inhibitors	I-CHED
+(	O
+NNRTIs	O
+)	O
+was	O
+synthesized	O
+via	O
+an	O
+expeditious	O
+route	O
+and	O
+evaluated	O
+for	O
+their	O
+anti	O
+-	O
+HIV	B-DISO
+activities	O
+in	O
+MT	O
+-	O
+4	O
+cell	B-COMP
+cultures	O
+.	O
+
+Broilers	O
+were	O
+more	O
+susceptible	O
+to	O
+infection	B-DISO
+than	O
+SPF	B-PRGE
+chickens	I-PRGE
+,	O
+and	O
+seroconversion	O
+was	O
+detected	O
+in	O
+all	O
+of	O
+the	O
+chicks	O
+.	O
+
+TITLE	O
+:	O
+Triggering	O
+unfolded	O
+protein	B-CHED
+response	O
+by	O
+2	B-CHED
+-	I-CHED
+Deoxy	I-CHED
+-	I-CHED
+D	I-CHED
+-	I-CHED
+glucose	I-CHED
+inhibits	O
+porcine	B-SPEC
+epidemic	B-DISO
+diarrhea	I-DISO
+virus	I-SPEC
+propagation	O
+.	O
+
+In	O
+the	O
+present	O
+studies	O
+,	O
+we	O
+first	O
+evaluated	O
+if	O
+porcine	B-SPEC
+epidemic	I-SPEC
+diarrhea	I-SPEC
+virus	I-SPEC
+(	O
+PEDV	B-SPEC
+)	O
+infection	B-DISO
+activated	O
+the	O
+UPR	O
+pathways	B-PROC
+.	O
+
+Western	O
+blot	O
+and	O
+real	O
+-	O
+time	O
+PCR	O
+identified	O
+the	O
+differences	O
+of	O
+UPR	O
+genes	O
+in	O
+response	O
+to	O
+PEDV	B-SPEC
+infection	B-DISO
+.	O
+
+The	O
+results	O
+suggested	O
+that	O
+PEDV	B-SPEC
+infection	B-DISO
+induced	I-DISO
+UPR	O
+in	O
+Vero	B-ANAT
+cells	I-ANAT
+.	O
+
+All	O
+these	O
+results	O
+support	O
+the	O
+therapeutic	O
+potential	O
+of	O
+using	O
+2	O
+-	O
+DG	O
+or	O
+glucose	B-CHED
+/	O
+mannose	B-CHED
+analogs	O
+to	O
+induce	O
+the	O
+UPR	O
+to	O
+block	O
+virus	B-PROC
+replication	I-PROC
+.	O
+
+Fifty	O
+percentage	O
+of	O
+subjects	O
+reported	O
+allergy	B-DISO
+,	O
+59	O
+%	O
+had	O
+≥	O
+1	O
+nasopharyngeal	B-ANAT
+viruses	B-SPEC
+,	O
+and	O
+24	O
+%	O
+had	O
+≥	O
+1	O
+intratonsillar	O
+viruses	B-SPEC
+.	O
+
+These	O
+two	O
+clusters	B-CHED
+became	O
+more	O
+distinctive	O
+in	O
+the	O
+presence	O
+of	O
+viral	B-DISO
+infection	I-DISO
+or	O
+allergy	B-DISO
+.	O
+
+A	O
+negative	O
+correlation	O
+between	O
+antiviral	B-CHED
+cytokines	O
+and	O
+IL	B-FUNC
+-	I-FUNC
+10	I-FUNC
+,	O
+IL	B-PROC
+-	I-PROC
+17	I-PROC
+,	O
+IL	O
+-	O
+37	O
+,	O
+FOXP3	B-PRGE
+,	O
+and	O
+RORC2	O
+was	O
+observed	O
+only	O
+in	O
+the	O
+presence	O
+of	O
+viruses	B-SPEC
+,	O
+and	O
+interestingly	O
+,	O
+IL	B-FUNC
+-	I-FUNC
+13	I-FUNC
+strongly	O
+correlated	O
+with	O
+antiviral	B-CHED
+cytokines	O
+.	O
+
+TITLE	O
+:	O
+Comparison	O
+of	O
+the	O
+Berlin	O
+definition	O
+with	O
+the	O
+American	O
+European	O
+consensus	O
+definition	O
+for	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+in	O
+burn	O
+patients	O
+.	O
+
+Smoke	O
+inhalation	B-PROC
+,	O
+pneumonia	B-DISO
+and	O
+inflammation	B-DISO
+process	I-DISO
+are	O
+the	O
+major	O
+causes	O
+of	O
+ARDS	B-DISO
+in	O
+burn	O
+patients	O
+.	O
+
+This	O
+definition	O
+may	O
+facilitate	O
+prompt	O
+recognition	O
+of	O
+ARDS	B-DISO
+in	O
+burn	O
+patients	O
+,	O
+and	O
+promote	O
+protective	O
+ventilation	O
+strategy	O
+to	O
+a	O
+larger	O
+number	O
+of	O
+patients	O
+.	O
+
+ABSTRACT	O
+:	O
+A	O
+toddler	O
+presented	O
+with	O
+poor	O
+appetite	O
+,	O
+weight	O
+loss	O
+and	O
+frequent	O
+respiratory	B-DISO
+tract	I-DISO
+infections	I-DISO
+for	O
+the	O
+past	O
+6	O
+months	O
+,	O
+fever	B-PROC
+and	O
+increasing	O
+paleness	B-DISO
+for	O
+the	O
+past	O
+2	O
+months	O
+and	O
+bilateral	O
+pedal	B-DISO
+oedema	I-DISO
+for	O
+the	O
+past	O
+1	O
+month	O
+.	O
+
+The	O
+mechanisms	O
+how	O
+viral	O
+agents	O
+affect	O
+the	O
+pathogenesis	B-DISO
+as	O
+well	O
+as	O
+the	O
+inflammatory	O
+and	O
+immune	B-PROC
+response	I-PROC
+of	O
+CF	O
+are	O
+discussed	O
+.	O
+
+TITLE	O
+:	O
+Emergence	O
+of	O
+a	O
+new	O
+genotype	O
+of	O
+avian	B-DISO
+infectious	I-DISO
+bronchitis	I-DISO
+virus	B-SPEC
+in	O
+Brazil	O
+.	O
+
+This	O
+research	O
+analyzed	O
+IBV	B-SPEC
+positive	O
+poultry	O
+flocks	O
+from	O
+different	O
+rearing	O
+regions	O
+to	O
+verify	O
+the	O
+S1	B-PRGE
+gene	I-PRGE
+variability	O
+and	O
+geographic	O
+distribution	O
+of	O
+variant	O
+IBV	B-SPEC
+strains	O
+in	O
+recent	O
+years	O
+(	O
+2010	O
+and	O
+2011	O
+).	O
+
+They	O
+also	O
+elucidated	O
+factors	O
+contributing	O
+to	O
+the	O
+persistence	O
+of	O
+Ark	B-PRGE
+vaccine	O
+in	O
+the	O
+field	O
+.	O
+
+TITLE	O
+:	O
+[	O
+Juvenile	B-DISO
+myelomonocytic	I-DISO
+leukemias	I-DISO
+].	O
+
+The	O
+only	O
+curative	O
+treatment	O
+is	O
+bone	B-ANAT
+marrow	I-ANAT
+transplantation	O
+but	O
+approximately	O
+35	O
+%	O
+of	O
+patients	O
+relapse	B-DISO
+.	O
+
+JMML	B-DISO
+clinical	O
+course	O
+is	O
+highly	O
+heterogeneous	O
+and	O
+unpredictable	O
+.	O
+
+Several	O
+research	O
+directions	O
+are	O
+currently	O
+being	O
+explored	O
+to	O
+improve	O
+prognosis	O
+prediction	O
+and	O
+provide	O
+more	O
+effective	O
+targeted	B-PROC
+treatments	O
+.	O
+
+In	O
+this	O
+study	O
+,	O
+we	O
+looked	O
+at	O
+thousands	O
+of	O
+infected	O
+cells	B-COMP
+and	O
+identified	O
+two	O
+coronavirus	B-SPEC
+mutants	O
+that	O
+made	O
+half	O
+as	O
+many	O
+organelles	B-COMP
+as	O
+normal	O
+and	O
+two	O
+others	O
+that	O
+made	O
+typical	O
+numbers	O
+but	O
+smaller	O
+organelles	B-COMP
+.	O
+
+None	O
+of	O
+these	O
+viruses	B-SPEC
+was	O
+found	O
+to	O
+be	O
+significantly	O
+less	O
+fit	B-DISO
+than	O
+wild	O
+-	O
+type	O
+,	O
+and	O
+two	O
+were	O
+actually	O
+fitter	O
+in	O
+tests	O
+in	O
+two	O
+kinds	O
+of	O
+cells	B-COMP
+.	O
+
+As	O
+determined	O
+by	O
+commercial	O
+multi	O
+-	O
+PCR	O
+kit	B-FUNC
+and	O
+conventional	O
+PCR	O
+(	O
+for	O
+HBoV	O
+and	O
+WUPyV	O
+),	O
+the	O
+diagnostic	O
+sensitivity	O
+of	O
+the	O
+Respiratory	O
+Panel	O
+for	O
+each	O
+viral	O
+targets	O
+ranged	O
+from	O
+50	O
+.	O
+0	O
+%	O
+to	O
+100	O
+.	O
+0	O
+%,	O
+the	O
+diagnostic	O
+specificity	O
+was	O
+96	O
+.	O
+2	O
+%-	O
+100	O
+.	O
+0	O
+%,	O
+and	O
+accordance	O
+rate	O
+was	O
+93	O
+.	O
+2	O
+%	O
+-	O
+100	O
+.	O
+0	O
+%,	O
+the	O
+kappa	O
+correlation	O
+of	O
+eight	O
+viral	O
+targets	O
+was	O
+>	O
+0	O
+.	O
+75	O
+.	O
+
+Two	O
+liquid	O
+chip	O
+assay	O
+panels	O
+,	O
+developed	O
+based	O
+on	O
+xMAP	O
+technology	O
+,	O
+can	O
+detect	O
+5	O
+types	O
+/	O
+subtypes	O
+of	O
+influenza	B-SPEC
+viruses	I-SPEC
+and	O
+14	O
+respiratory	O
+viruses	B-SPEC
+simultaneously	O
+in	O
+one	O
+reaction	O
+in	O
+6	O
+hours	O
+.	O
+
+They	O
+are	O
+potentially	O
+rapid	O
+,	O
+sensitive	O
+,	O
+specific	O
+,	O
+and	O
+high	O
+throughput	O
+diagnostic	O
+tools	O
+for	O
+major	O
+viral	O
+pathogens	O
+associated	O
+with	O
+respiratory	B-DISO
+tract	I-DISO
+infection	I-DISO
+.	O
+
+RESULTS	O
+:	O
+The	O
+Influenza	B-DISO
+Panel	O
+returned	O
+the	O
+analytical	O
+sensitivity	O
+of	O
+4	O
+-	O
+10	O
+copies	O
+vRNA	O
+/	O
+microL	O
+of	O
+sample	O
+for	O
+seasonal	O
+H1N1	O
+,	O
+H3N2	B-CHED
+,	O
+pandemic	O
+H1N1	O
+,	O
+and	O
+B	O
+,	O
+and	O
+200	O
+copies	O
+vRNA	O
+/	O
+microL	O
+of	O
+sample	O
+for	O
+H5	O
+.	O
+
+He	O
+was	O
+placed	O
+on	O
+extracorporeal	O
+membrane	B-COMP
+oxygenation	B-PROC
+to	O
+stabilise	O
+his	O
+condition	B-DISO
+.	O
+
+In	O
+addition	O
+to	O
+the	O
+different	O
+regional	O
+camel	B-SPEC
+festivals	O
+in	O
+neighboring	O
+countries	O
+,	O
+Hafr	O
+Al	O
+-	O
+Batin	O
+has	O
+the	O
+biggest	O
+camel	B-SPEC
+market	O
+in	O
+the	O
+entire	O
+Kingdom	B-SPEC
+and	O
+hosts	B-COMP
+an	O
+annual	O
+camel	B-SPEC
+festival	O
+.	O
+
+On	O
+the	O
+other	O
+hand	O
+,	O
+localized	O
+and	O
+encapsulated	O
+infections	B-DISO
+(	O
+e	O
+.	O
+g	O
+.,	O
+abscess	B-DISO
+,	O
+endocarditis	B-DISO
+and	O
+early	O
+stages	O
+of	O
+infections	B-DISO
+)	O
+can	O
+be	O
+associated	O
+with	O
+lowered	O
+PCT	B-DISO
+values	O
+.	O
+
+ABSTRACT	O
+:	O
+In	O
+2003	O
+,	O
+China	O
+'	O
+s	O
+handling	O
+of	O
+the	O
+early	O
+stages	O
+of	O
+the	O
+epidemic	O
+of	O
+severe	O
+acute	O
+respiratory	O
+syndrome	O
+(	O
+SARS	B-DISO
+)	O
+was	O
+heavily	O
+criticized	O
+and	O
+generally	O
+considered	O
+to	O
+be	O
+suboptimal	O
+.	O
+
+TITLE	O
+:	O
+Acute	O
+respiratory	O
+viral	B-DISO
+infections	I-DISO
+in	O
+pediatric	B-DISO
+cancer	I-DISO
+patients	O
+undergoing	O
+chemotherapy	O
+.	O
+
+Respiratory	O
+viruses	B-SPEC
+were	O
+detected	O
+in	O
+50	O
+samples	O
+:	O
+rhinoviruses	B-SPEC
+(	O
+23	O
+.	O
+1	O
+%),	O
+respiratory	B-SPEC
+syncytial	I-SPEC
+virus	I-SPEC
+AB	O
+(	O
+8	O
+.	O
+7	O
+%),	O
+and	O
+coronavirus	B-SPEC
+(	O
+6	O
+.	O
+8	O
+%).	O
+
+Fever	B-PROC
+in	O
+neutropenic	O
+patients	O
+was	O
+observed	O
+in	O
+13	O
+%,	O
+of	O
+which	O
+four	O
+(	O
+30	O
+.	O
+7	O
+)	O
+were	O
+positive	O
+for	O
+viruses	B-SPEC
+.	O
+
+ABSTRACT	O
+:	O
+Poxviruses	B-SPEC
+are	O
+important	O
+pathogens	O
+of	O
+man	B-CHED
+and	O
+numerous	O
+domestic	O
+and	O
+wild	O
+animal	O
+species	B-SPEC
+.	O
+
+Here	O
+,	O
+we	O
+review	O
+the	O
+natural	O
+history	O
+of	O
+poxviruses	B-SPEC
+in	O
+bats	B-SPEC
+and	O
+highlight	O
+the	O
+relationship	O
+of	O
+the	O
+viruses	B-SPEC
+to	O
+each	O
+other	O
+and	O
+their	O
+context	O
+in	O
+the	O
+Poxviridae	B-SPEC
+family	B-SPEC
+.	O
+
+The	O
+mean	O
+CT	O
+score	O
+of	O
+the	O
+affected	O
+lung	B-ANAT
+parenchyma	I-ANAT
+at	O
+discharge	B-ANAT
+was	O
+30	O
+%	O
+lower	O
+than	O
+the	O
+initial	O
+CT	O
+examination	O
+(	O
+P	O
+<	O
+0	O
+.	O
+05	O
+).	O
+
+TITLE	O
+:	O
+Pulmonary	B-ANAT
+retention	B-PROC
+of	O
+primed	O
+neutrophils	B-ANAT
+:	O
+a	O
+novel	O
+protective	O
+host	B-PROC
+response	I-PROC
+,	O
+which	O
+is	O
+impaired	B-DISO
+in	O
+the	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+.	O
+
+We	O
+demonstrated	O
+minimal	O
+delay	O
+and	O
+retention	B-PROC
+of	O
+unprimed	O
+neutrophils	B-ANAT
+transiting	O
+the	O
+healthy	O
+human	B-SPEC
+pulmonary	B-ANAT
+vasculature	I-ANAT
+,	O
+but	O
+marked	O
+retention	B-PROC
+of	O
+primed	O
+neutrophils	B-ANAT
+;	O
+these	O
+latter	O
+cells	B-COMP
+then	O
+'	O
+deprime	O
+'	O
+and	O
+are	O
+re	O
+-	O
+released	O
+into	O
+the	O
+systemic	O
+circulation	B-PROC
+.	O
+
+Further	O
+,	O
+we	O
+show	O
+that	O
+this	O
+physiological	O
+depriming	O
+mechanism	O
+may	O
+fail	O
+in	O
+patients	O
+with	O
+ARDS	B-DISO
+,	O
+resulting	O
+in	O
+increased	O
+numbers	O
+of	O
+primed	O
+neutrophils	B-ANAT
+within	O
+the	O
+systemic	O
+circulation	B-PROC
+.	O
+
+Not	O
+only	O
+did	O
+B2	O
+-	O
+derived	O
+peripheral	O
+monocytes	B-ANAT
+differentiate	O
+into	O
+macrophages	B-ANAT
+more	O
+readily	O
+than	O
+the	O
+B19	O
+monocytes	B-ANAT
+,	O
+but	O
+as	O
+determined	O
+by	O
+NO	O
+production	O
+,	O
+macrophages	B-ANAT
+from	O
+B2	O
+and	O
+B2	O
+on	O
+B19	O
+genetic	O
+background	O
+chicks	O
+were	O
+also	O
+significantly	O
+more	O
+responsive	O
+to	O
+either	O
+stimulant	O
+.	O
+
+TITLE	O
+:	O
+Prevention	O
+and	O
+treatment	O
+of	O
+viral	O
+respiratory	B-DISO
+infections	I-DISO
+by	O
+traditional	O
+Chinese	O
+herbs	O
+.	O
+
+Many	O
+commercial	O
+herbal	O
+medicines	O
+containing	O
+one	O
+or	O
+more	O
+compounds	O
+have	O
+been	O
+successfully	O
+applied	O
+to	O
+prevent	O
+and	O
+treat	O
+viral	B-DISO
+infections	I-DISO
+of	O
+respiratory	B-ANAT
+tract	I-ANAT
+clinically	O
+.	O
+
+Prospectively	O
+collected	O
+data	O
+of	O
+879	O
+patients	O
+undergoing	O
+elective	O
+hepatic	B-ANAT
+resection	O
+were	O
+analyzed	O
+.	O
+
+Adjusted	O
+for	O
+age	O
+,	O
+independent	O
+predictors	O
+of	O
+OS	O
+were	O
+comorbidities	O
+(	O
+HR	O
+=	O
+1	O
+.	O
+51	O
+;	O
+p	O
+=	O
+0	O
+.	O
+001	O
+),	O
+major	O
+hepatectomy	O
+(	O
+HR	O
+=	O
+1	O
+.	O
+33	O
+;	O
+p	O
+=	O
+0	O
+.	O
+025	O
+),	O
+increased	O
+EBL	O
+(	O
+HR	O
+=	O
+1	O
+.	O
+32	O
+;	O
+p	O
+=	O
+0	O
+.	O
+031	O
+),	O
+and	O
+postoperative	B-DISO
+complications	I-DISO
+(	O
+HR	O
+=	O
+1	O
+.	O
+64	O
+;	O
+p	O
+<	O
+0	O
+.	O
+001	O
+).	O
+
+The	O
+patient	O
+was	O
+hospitalized	O
+due	O
+to	O
+an	O
+acute	O
+confusional	B-DISO
+state	I-DISO
+,	O
+severe	O
+respiratory	B-DISO
+distress	I-DISO
+and	O
+hemolytic	B-DISO
+anemia	I-DISO
+.	O
+
+One	O
+day	O
+prior	O
+to	O
+hospitalization	O
+,	O
+she	O
+was	O
+involved	O
+in	O
+a	O
+minor	O
+motor	O
+vehicle	O
+accident	O
+,	O
+yet	O
+she	O
+and	O
+her	O
+family	B-SPEC
+denied	O
+any	O
+injuries	O
+due	O
+to	O
+the	O
+accident	O
+and	O
+the	O
+patient	O
+did	O
+not	O
+complain	O
+of	O
+pain	O
+.	O
+
+A	O
+mean	O
+of	O
+5	O
+.	O
+5	O
+different	O
+viruses	B-SPEC
+were	O
+shed	O
+in	O
+diarrhoeic	O
+piglets	O
+,	O
+and	O
+one	O
+piglet	O
+was	O
+in	O
+fact	O
+co	O
+-	O
+infected	O
+with	O
+11	O
+different	O
+viruses	O
+.	O
+
+Here	O
+,	O
+we	O
+have	O
+developed	O
+a	O
+neutralizing	O
+monoclonal	O
+antibody	B-COMP
+(	O
+MAb	O
+),	O
+designated	O
+Mersmab1	O
+,	O
+which	O
+potently	O
+blocks	O
+MERS	O
+-	O
+CoV	O
+entry	O
+into	O
+human	B-SPEC
+cells	B-COMP
+.	O
+
+Here	O
+,	O
+we	O
+have	O
+produced	O
+a	O
+neutralizing	O
+monoclonal	O
+antibody	B-COMP
+with	O
+the	O
+capacity	O
+to	O
+effectively	O
+block	O
+MERS	O
+-	O
+CoV	O
+entry	O
+into	O
+permissive	O
+human	B-SPEC
+cells	B-COMP
+.	O
+
+If	O
+humanized	O
+,	O
+this	O
+antibody	B-COMP
+may	O
+be	O
+used	O
+as	O
+a	O
+prophylactic	O
+and	O
+therapeutic	O
+agent	O
+against	O
+MERS	O
+-	O
+CoV	O
+infections	B-DISO
+.	O
+
+Phylogenetic	O
+analysis	O
+based	O
+on	O
+a	O
+conserved	O
+region	O
+of	O
+the	O
+RNA	B-PRGE
+-	I-PRGE
+dependent	I-PRGE
+RNA	I-PRGE
+polymerase	I-PRGE
+gene	I-PRGE
+revealed	O
+that	O
+alphacoronaviruses	O
+had	O
+diversities	O
+with	O
+some	O
+obvious	O
+differences	O
+from	O
+those	O
+reported	O
+previously	O
+.	O
+
+Further	O
+analysis	O
+showed	O
+that	O
+alpha	O
+-	O
+and	O
+betacoronaviruses	O
+have	O
+different	O
+circulation	B-PROC
+and	O
+transmission	O
+dynamics	O
+in	O
+bat	B-ENZY
+populations	O
+.	O
+
+ABSTRACT	O
+:	O
+Mycoplasma	B-DISO
+pneumoniae	I-SPEC
+(	O
+MP	O
+)	O
+is	O
+a	O
+common	O
+childhood	O
+pathogen	O
+associated	O
+with	O
+atypical	B-DISO
+pneumonia	I-DISO
+(	O
+AP	O
+).	O
+
+In	O
+2003	O
+,	O
+World	O
+Health	O
+Organization	O
+(	O
+WHO	O
+)	O
+coined	O
+the	O
+word	O
+SARS	B-DISO
+(	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+)	O
+in	O
+patients	O
+with	O
+severe	O
+acute	O
+respiratory	B-DISO
+symptoms	I-DISO
+(	O
+sars	B-DISO
+)	O
+for	O
+an	O
+outbreak	O
+of	O
+AP	O
+in	O
+Hong	O
+Kong	O
+due	O
+to	O
+a	O
+novel	B-SPEC
+coronavirus	I-SPEC
+.	O
+
+Streptococcus	B-SPEC
+pneumoniae	I-SPEC
+was	O
+not	O
+isolated	O
+in	O
+this	O
+girl	O
+with	O
+'	O
+typical	O
+'	O
+pneumonia	B-DISO
+by	O
+symptomatology	O
+and	O
+chest	B-ANAT
+radiography	O
+,	O
+but	O
+tracheal	B-ANAT
+aspirate	I-ANAT
+identified	O
+MP	O
+instead	O
+.	O
+
+Experimental	O
+and	O
+clinical	O
+studies	O
+have	O
+suggested	O
+that	O
+the	O
+pathogenesis	B-DISO
+of	O
+lung	B-ANAT
+injuries	O
+in	O
+MP	O
+infection	B-DISO
+is	O
+associated	O
+with	O
+a	O
+cell	B-DISO
+-	I-DISO
+mediated	I-DISO
+immune	I-DISO
+reaction	I-DISO
+,	O
+and	O
+high	O
+responsiveness	O
+to	O
+corticosteroid	B-CHED
+therapy	O
+has	O
+been	O
+reported	O
+especially	O
+for	O
+severe	O
+disease	O
+.	O
+
+The	O
+case	O
+patients	O
+were	O
+more	O
+likely	O
+to	O
+be	O
+overweight	B-DISO
+than	O
+the	O
+control	O
+group	O
+(	O
+mean	O
+body	B-ANAT
+mass	O
+index	O
+,	O
+32	O
+vs	O
+27	O
+.	O
+8	O
+;	O
+P	O
+=	O
+.	O
+035	O
+),	O
+to	O
+have	O
+diabetes	B-DISO
+mellitus	I-DISO
+(	O
+87	O
+%	O
+vs	O
+47	O
+%;	O
+odds	O
+ratio	O
+[	O
+OR	O
+],	O
+7	O
+.	O
+24	O
+;	O
+P	O
+=	O
+.	O
+015	O
+),	O
+and	O
+to	O
+have	O
+end	B-DISO
+-	I-DISO
+stage	I-DISO
+renal	I-DISO
+disease	I-DISO
+(	O
+33	O
+%	O
+vs	O
+7	O
+%;	O
+OR	O
+,	O
+7	O
+;	O
+P	O
+=	O
+.	O
+012	O
+).	O
+
+MERS	O
+-	O
+CoV	O
+patients	O
+were	O
+more	O
+likely	O
+to	O
+have	O
+a	O
+normal	O
+white	B-ANAT
+blood	I-ANAT
+cell	I-ANAT
+count	O
+than	O
+the	O
+control	O
+group	O
+(	O
+82	O
+%	O
+vs	O
+52	O
+%;	O
+OR	O
+,	O
+4	O
+.	O
+33	O
+;	O
+P	O
+=	O
+.	O
+029	O
+).	O
+
+We	O
+determined	O
+that	O
+the	O
+initial	O
+appropriate	O
+antibiotics	B-CHED
+use	O
+was	O
+an	O
+independent	O
+clinical	O
+factor	O
+and	O
+day	B-PRGE
+1	I-PRGE
+high	I-PRGE
+-	I-PRGE
+mobility	I-PRGE
+group	I-PRGE
+protein	I-PRGE
+B1	I-PRGE
+(	O
+HMGB1	B-PRGE
+)	O
+concentration	O
+was	O
+an	O
+independent	O
+biomarker	B-CHED
+for	O
+ICU	O
+mortality	O
+.	O
+
+Intravenous	O
+peramivir	O
+,	O
+veno	O
+-	O
+venous	B-ANAT
+extracorporeal	O
+membrane	B-COMP
+oxygenation	B-PROC
+(	O
+VV	O
+-	O
+ECMO	O
+)	O
+and	O
+continuous	O
+veno	O
+-	O
+venous	B-ANAT
+hemofiltration	O
+were	O
+given	O
+on	O
+the	O
+same	O
+day	O
+of	O
+lab	O
+diagnosis	O
+because	O
+of	O
+severe	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+and	O
+acute	B-DISO
+renal	I-DISO
+failure	I-DISO
+.	O
+
+TITLE	O
+:	O
+Performance	O
+and	O
+clinical	O
+validation	O
+of	O
+the	O
+RealStar	O
+MERS	O
+-	O
+CoV	O
+Kit	B-FUNC
+for	O
+detection	O
+of	O
+Middle	O
+East	O
+respiratory	O
+syndrome	O
+coronavirus	B-SPEC
+RNA	O
+.	O
+
+In	O
+-	O
+house	O
+molecular	O
+diagnostic	O
+methods	O
+for	O
+this	O
+virus	B-SPEC
+termed	O
+Middle	O
+East	O
+respiratory	O
+syndrome	B-DISO
+coronavirus	B-SPEC
+(	O
+MERS	O
+-	O
+CoV	O
+)	O
+allowed	O
+sensitive	O
+MERS	O
+-	O
+CoV	O
+RNA	O
+detection	O
+in	O
+patient	O
+samples	O
+.	O
+
+An	O
+internal	O
+amplification	B-DISO
+control	O
+was	O
+included	O
+into	O
+the	O
+RT	O
+-	O
+PCR	O
+assays	O
+targeting	B-PROC
+the	O
+genomic	O
+region	O
+upstream	B-PRGE
+of	I-PRGE
+the	I-PRGE
+Envelope	I-PRGE
+gene	I-PRGE
+(	O
+upE	O
+)	O
+and	O
+within	O
+open	O
+reading	O
+frame	O
+(	O
+ORF	O
+)	O
+1A	O
+.	O
+
+A	O
+total	O
+of	O
+55	O
+patients	O
+hospitalized	O
+with	O
+CAP	B-DISO
+were	O
+enrolled	O
+into	O
+the	O
+prospective	O
+study	O
+between	O
+February	O
+2010	O
+and	O
+December	O
+2010	O
+.	O
+
+There	O
+was	O
+no	O
+significant	O
+difference	O
+in	O
+terms	O
+of	O
+mean	O
+age	O
+,	O
+immune	B-PROC
+status	I-PROC
+,	O
+leukocyte	B-ANAT
+count	O
+,	O
+C	B-PRGE
+-	I-PRGE
+reactive	I-PRGE
+protein	I-PRGE
+(	O
+CRP	B-PRGE
+)	O
+values	O
+,	O
+hospitalization	O
+duration	O
+and	O
+CURB	B-DISO
+-	O
+65	O
+score	O
+between	O
+bacterial	O
+and	O
+mixed	O
+viral	O
+-	O
+bacterial	O
+detections	O
+.	O
+
+Concomitance	O
+of	O
+bacterial	O
+and	O
+viral	O
+agents	O
+is	O
+frequent	O
+and	O
+resemble	O
+with	O
+bacterial	B-DISO
+infections	I-DISO
+alone	O
+.	O
+
+CONCLUSIONS	O
+:	O
+Concomitance	O
+of	O
+bacterial	O
+and	O
+viral	O
+agents	O
+is	O
+frequent	O
+and	O
+resemble	O
+with	O
+bacterial	B-DISO
+infections	I-DISO
+alone	O
+.	O
+
+Newly	O
+emerging	O
+and	O
+re	O
+-	O
+emerging	O
+infections	B-DISO
+of	O
+the	O
+respiratory	B-ANAT
+tract	I-ANAT
+,	O
+especially	O
+influenza	B-DISO
+,	O
+SARS	B-DISO
+,	O
+and	O
+hantavirus	B-SPEC
+post	O
+considerable	O
+medical	O
+problems	O
+.	O
+
+It	O
+provides	O
+the	O
+compelling	O
+evidence	O
+that	O
+illuminates	O
+cytokine	B-DISO
+storm	I-DISO
+in	O
+influenza	B-DISO
+pathogenesis	B-DISO
+and	O
+the	O
+clear	O
+findings	O
+that	O
+cytokine	B-DISO
+storm	I-DISO
+is	O
+chemically	O
+tractable	O
+by	O
+therapy	O
+directed	O
+toward	O
+sphingosine	B-PRGE
+-	I-PRGE
+1	I-PRGE
+-	I-PRGE
+phosphate	I-PRGE
+receptor	I-PRGE
+(	O
+S1PR	O
+)	O
+modulation	O
+,	O
+specifically	O
+S1P1R	O
+agonist	B-CHED
+therapy	O
+.	O
+
+The	O
+mechanism	O
+(	O
+s	O
+)	O
+of	O
+how	O
+S1P1R	O
+signaling	B-PROC
+works	O
+and	O
+the	O
+pathways	O
+involved	O
+are	O
+subjects	O
+of	O
+this	O
+review	O
+.	O
+
+Mechanical	O
+stretch	O
+-	O
+augmented	O
+acute	O
+lung	B-ANAT
+injury	O
+was	O
+also	O
+attenuated	O
+through	O
+pharmacological	O
+inhibition	B-PROC
+of	O
+NF	O
+-	O
+κB	O
+activity	O
+by	O
+SN50	O
+and	O
+NRF	B-PRGE
+expression	B-PROC
+by	O
+NRF	O
+short	O
+interfering	O
+RNA	O
+.	O
+
+Understanding	O
+the	O
+protective	O
+effects	O
+of	O
+neutrophil	B-CHED
+elastase	I-CHED
+inhibitor	I-CHED
+associated	O
+with	O
+the	O
+reduction	O
+of	O
+MIP	B-DISO
+-	O
+2	O
+allow	O
+clarification	O
+of	O
+the	O
+pathophysiological	O
+mechanisms	O
+regulating	O
+severe	O
+lung	B-DISO
+inflammation	I-DISO
+and	O
+development	B-PROC
+of	O
+possible	O
+therapeutic	O
+strategies	O
+involved	O
+in	O
+acute	O
+lung	B-ANAT
+injury	O
+.	O
+
+TITLE	O
+:	O
+Transnational	O
+quarantine	O
+rhetorics	O
+:	O
+public	O
+mobilization	O
+in	O
+SARS	B-DISO
+and	O
+in	O
+H1N1	B-DISO
+flu	I-DISO
+.	O
+
+SimPlot	O
+analysis	O
+of	O
+the	O
+7	O
+.	O
+2	O
+-	O
+kb	O
+3	O
+'	O
+end	O
+of	O
+the	O
+N1	O
+/	O
+08	O
+genome	O
+with	O
+the	O
+same	O
+region	O
+for	O
+other	O
+Australian	O
+reference	O
+strains	O
+identified	O
+the	O
+sites	O
+of	O
+recombination	B-PROC
+as	O
+immediately	O
+upstream	O
+and	O
+downstream	O
+of	O
+the	O
+S1	B-PRGE
+gene	I-PRGE
+.	O
+
+A	O
+pathogenicity	O
+study	O
+in	O
+2	O
+-	O
+week	O
+-	O
+old	O
+chickens	B-SPEC
+found	O
+that	O
+N1	O
+/	O
+08	O
+had	O
+similar	O
+pathogenicity	O
+for	O
+chicken	B-SPEC
+respiratory	O
+tissues	B-ANAT
+to	O
+that	O
+reported	O
+for	O
+subgroup	O
+2	O
+strains	O
+rather	O
+than	O
+subgroup	O
+3	O
+strains	O
+.	O
+
+In	O
+a	O
+previous	O
+study	O
+,	O
+the	O
+endogenous	O
+peptide	B-CHED
+adrenomedullin	O
+(	O
+AM	O
+)	O
+protected	O
+murine	B-SPEC
+lungs	B-ANAT
+from	O
+VILI	O
+.	O
+
+We	O
+hypothesized	O
+that	O
+mechanical	O
+ventilation	O
+(	O
+MV	O
+)	O
+contributes	O
+to	O
+lung	B-ANAT
+injury	O
+and	O
+sepsis	B-DISO
+in	O
+pneumonia	B-DISO
+,	O
+and	O
+that	O
+AM	O
+may	O
+reduce	O
+lung	B-ANAT
+injury	O
+and	O
+multiple	B-DISO
+organ	I-DISO
+failure	I-DISO
+in	O
+ventilated	O
+mice	B-SPEC
+with	O
+pneumococcal	B-DISO
+pneumonia	I-DISO
+.	O
+
+MV	O
+dramatically	O
+increased	O
+lung	B-ANAT
+and	O
+blood	B-ANAT
+cytokines	O
+but	O
+not	O
+lung	B-ANAT
+leukocyte	B-ANAT
+counts	O
+in	O
+pneumonia	B-DISO
+.	O
+
+Interestingly	O
+,	O
+compound	O
+4e	O
+could	O
+inhibit	O
+not	O
+only	O
+HBsAg	O
+and	O
+HBeAg	O
+secretions	B-ANAT
+but	O
+also	O
+HBV	B-DISO
+DNA	B-PATH
+replication	I-PATH
+with	O
+SI	O
+values	O
+of	O
+20	O
+.	O
+3	O
+,	O
+125	O
+.	O
+0	O
+and	O
+104	O
+.	O
+9	O
+.	O
+
+Adjunctive	O
+therapies	O
+in	O
+ARDS	B-DISO
+include	O
+a	O
+conservative	O
+fluid	O
+management	O
+strategy	O
+,	O
+as	O
+well	O
+as	O
+neuromuscular	B-DISO
+blockade	I-DISO
+and	O
+prone	O
+positioning	O
+in	O
+moderate	O
+-	O
+to	O
+-	O
+severe	O
+disease	O
+.	O
+
+Results	O
+:	O
+In	O
+the	O
+control	O
+group	O
+,	O
+the	O
+human	B-SPEC
+coronavirus	I-SPEC
+and	O
+human	B-SPEC
+rhinovirus	I-SPEC
+were	O
+diagnosed	O
+in	O
+one	O
+of	O
+the	O
+patients	O
+and	O
+the	O
+human	B-SPEC
+respiratory	I-SPEC
+syncytial	I-SPEC
+virus	I-SPEC
+in	O
+another	O
+.	O
+
+Conclusion	O
+:	O
+The	O
+results	O
+did	O
+not	O
+demonstrate	O
+a	O
+statistically	O
+significant	O
+relationship	O
+between	O
+nasal	O
+polyposis	O
+and	O
+respiratory	O
+viruses	B-SPEC
+.	O
+
+The	O
+spike	O
+glycoproteins	B-CHED
+of	O
+coronaviruses	O
+reside	O
+on	O
+the	O
+surface	O
+of	O
+the	O
+virion	B-COMP
+and	O
+are	O
+responsible	O
+for	O
+virus	B-SPEC
+entry	O
+.	O
+
+None	O
+of	O
+these	O
+strategies	O
+has	O
+progressed	O
+to	O
+an	O
+approved	O
+human	B-SPEC
+coronavirus	I-SPEC
+vaccine	O
+in	O
+the	O
+ten	O
+years	O
+since	O
+SARS	B-DISO
+-	O
+CoV	O
+emerged	O
+.	O
+
+Here	O
+we	O
+describe	O
+a	O
+novel	O
+method	O
+for	O
+generating	O
+MERS	O
+-	O
+CoV	O
+and	O
+SARS	B-PRGE
+-	I-PRGE
+CoV	I-PRGE
+full	O
+-	O
+length	O
+spike	O
+nanoparticles	B-CHED
+,	O
+which	O
+in	O
+combination	O
+with	O
+adjuvants	B-CHED
+are	O
+able	O
+to	O
+produce	O
+high	O
+titer	O
+antibodies	B-COMP
+in	O
+mice	B-SPEC
+.	O
+
+Thus	O
+,	O
+most	O
+coronaviruses	O
+exit	O
+through	O
+the	O
+apical	O
+surface	O
+,	O
+several	O
+through	O
+the	O
+basolateral	O
+one	O
+,	O
+although	O
+the	O
+Middle	O
+East	O
+respiratory	O
+syndrome	B-DISO
+coronavirus	B-SPEC
+appears	O
+to	O
+use	O
+both	O
+sides	O
+.	O
+
+ABSTRACT	O
+:	O
+A	O
+strain	O
+of	O
+transmissible	O
+gastroenteritis	O
+virus	B-SPEC
+(	O
+TGEV	B-SPEC
+),	O
+SHXB	O
+,	O
+was	O
+isolated	O
+in	O
+Shanghai	O
+,	O
+China	O
+.	O
+
+ABSTRACT	O
+:	O
+In	O
+2011	O
+,	O
+autochthonous	O
+Plasmodium	O
+vivax	O
+malaria	B-PATH
+emerged	O
+in	O
+a	O
+focal	O
+geographical	O
+area	O
+in	O
+Greece	O
+after	O
+importation	O
+by	O
+immigrants	O
+from	O
+the	O
+Indian	O
+subcontinent	O
+.	O
+
+Understanding	O
+the	O
+molecular	O
+and	O
+cellular	B-COMP
+mechanisms	O
+governing	O
+muted	O
+cellular	B-COMP
+and	O
+humoral	O
+responses	O
+that	O
+occur	O
+post	O
+-	O
+injury	O
+resulting	O
+in	O
+impaired	B-DISO
+host	B-PROC
+defense	I-PROC
+following	O
+infection	B-DISO
+is	O
+critical	O
+for	O
+improving	O
+the	O
+overall	O
+quality	O
+of	O
+life	O
+of	O
+individuals	O
+with	O
+SCI	O
+.	O
+
+Data	O
+from	O
+two	O
+American	O
+College	O
+of	O
+Surgeons	O
+-	O
+verified	O
+Level	O
+1	O
+trauma	O
+centers	O
+,	O
+which	O
+maintain	O
+detailed	O
+records	O
+of	O
+patients	O
+with	O
+acute	O
+hypoxemic	O
+respiratory	B-DISO
+failure	I-DISO
+(	O
+AHRF	O
+),	O
+were	O
+evaluated	O
+retrospectively	O
+.	O
+
+ECLS	O
+patients	O
+received	O
+more	O
+blood	B-ANAT
+transfusions	O
+and	O
+had	O
+more	O
+bleeding	B-DISO
+complications	O
+,	O
+while	O
+the	O
+CONV	O
+patients	O
+had	O
+more	O
+pulmonary	B-DISO
+complications	I-DISO
+.	O
+
+We	O
+hypothesize	O
+that	O
+flight	B-PROC
+,	O
+a	O
+factor	O
+common	O
+to	O
+all	O
+bats	B-SPEC
+but	O
+to	O
+no	O
+other	O
+mammals	B-SPEC
+,	O
+provides	O
+an	O
+intensive	O
+selective	O
+force	O
+for	O
+coexistence	O
+with	O
+viral	O
+parasites	O
+through	O
+a	O
+daily	O
+cycle	O
+that	O
+elevates	O
+metabolism	B-PROC
+and	O
+body	B-ANAT
+temperature	O
+analogous	O
+to	O
+the	O
+febrile	B-PROC
+response	O
+in	O
+other	O
+mammals	B-SPEC
+.	O
+
+ABSTRACT	O
+:	O
+A	O
+series	O
+of	O
+7	O
+-	O
+methoxycryptopleurine	O
+derivatives	O
+2	O
+-	O
+23	O
+were	O
+prepared	O
+and	O
+evaluated	O
+for	O
+their	O
+antiviral	O
+activity	O
+against	O
+tobacco	B-SPEC
+mosaic	I-SPEC
+virus	I-SPEC
+(	O
+TMV	B-SPEC
+)	O
+for	O
+the	O
+first	O
+time	O
+.	O
+
+However	O
+,	O
+the	O
+study	O
+showed	O
+that	O
+diarrhoea	B-DISO
+restricted	O
+to	O
+the	O
+day	O
+of	O
+birth	B-PROC
+did	O
+not	O
+affect	O
+ADG	O
+and	O
+suggested	O
+this	O
+phenomenon	O
+to	O
+be	O
+unrelated	O
+to	O
+the	O
+syndrome	B-DISO
+.	O
+
+In	O
+addition	O
+,	O
+these	O
+animals	B-SPEC
+can	O
+act	O
+as	O
+disease	O
+reservoirs	O
+for	O
+wild	O
+animal	B-SPEC
+populations	O
+by	O
+occasional	O
+contact	O
+.	O
+
+Porcine	B-SPEC
+hemagglutinating	O
+encephalomyelitis	B-DISO
+virus	B-SPEC
+(	O
+PHEV	O
+)	O
+was	O
+detected	O
+in	O
+suckling	O
+and	O
+weaning	B-PROC
+pigs	B-SPEC
+by	O
+RT	O
+-	O
+PCR	O
+assays	O
+.	O
+
+These	O
+results	O
+may	O
+provide	O
+some	O
+insights	O
+into	O
+the	O
+genotype	O
+of	O
+the	O
+etiological	O
+agent	O
+responsible	O
+for	O
+the	O
+porcine	B-SPEC
+hemagglutinating	O
+encephalomyelitis	B-DISO
+outbreak	O
+and	O
+could	O
+also	O
+provide	O
+a	O
+comparative	O
+view	O
+of	O
+the	O
+genomics	O
+of	O
+the	O
+five	O
+structural	O
+proteins	B-CHED
+of	O
+PHEV	O
+.	O
+
+IBV	B-SPEC
+heterotypic	O
+protection	O
+was	O
+assessed	O
+using	O
+a	O
+prime	O
+-	O
+boost	O
+approach	O
+with	O
+a	O
+commercially	O
+available	O
+attenuated	O
+IBV	B-SPEC
+Massachusetts	O
+(	O
+Mass	O
+)-	O
+type	O
+vaccine	O
+.	O
+
+A	O
+significant	O
+difference	O
+(	O
+P	O
+<	O
+0	O
+.	O
+05	O
+)	O
+was	O
+determined	O
+between	O
+these	O
+groups	O
+regarding	O
+incidence	O
+of	O
+detection	O
+of	O
+challenge	O
+IBV	B-SPEC
+RNA	O
+in	O
+the	O
+trachea	B-DISO
+;	O
+viral	O
+RNA	O
+was	O
+detected	O
+in	O
+50	O
+%	O
+of	O
+rLS	B-PRGE
+/	I-PRGE
+IBV	B-SPEC
+.	I-PRGE
+S2	I-PRGE
++	I-PRGE
+Mass	I-PRGE
+-	I-PRGE
+vaccinated	I-PRGE
+chickens	B-SPEC
+while	I-PRGE
+chickens	B-SPEC
+vaccinated	O
+with	O
+Mass	O
++	O
+Mass	O
+and	O
+unvaccinated	O
+challenged	O
+controls	O
+showed	O
+84	O
+and	O
+90	O
+%	O
+incidence	O
+of	O
+IBV	B-SPEC
+RNA	O
+detection	O
+in	O
+the	O
+trachea	B-DISO
+,	O
+respectively	O
+.	O
+
+The	O
+higher	O
+vaccine	O
+virus	B-SPEC
+heterogeneity	O
+observed	O
+in	O
+chickens	B-SPEC
+vaccinated	O
+with	O
+vaccine	O
+B	O
+compared	O
+with	O
+those	O
+vaccinated	O
+with	O
+vaccine	O
+A	O
+may	O
+be	O
+responsible	O
+for	O
+these	O
+differences	O
+.	O
+
+To	O
+evaluate	O
+the	O
+role	O
+of	O
+HCoV	O
+infection	B-DISO
+in	O
+patients	O
+with	O
+Kawasaki	B-DISO
+disease	I-DISO
+,	O
+immunofluorescence	O
+assays	O
+and	O
+virus	B-SPEC
+neutralizing	O
+tests	O
+were	O
+performed	O
+.	O
+
+Immunofluorescence	O
+assays	O
+detected	O
+no	O
+difference	O
+in	O
+HCoV	B-SPEC
+-	I-SPEC
+NL63	I-SPEC
+antibody	B-COMP
+positivity	O
+between	O
+the	O
+patients	O
+with	O
+Kawasaki	B-DISO
+disease	I-DISO
+and	O
+controls	O
+,	O
+whereas	O
+the	O
+rate	O
+of	O
+HCoV	B-SPEC
+-	I-SPEC
+229E	I-SPEC
+antibody	B-COMP
+positivity	O
+was	O
+higher	O
+in	O
+the	O
+patients	O
+with	O
+Kawasaki	B-DISO
+disease	I-DISO
+than	O
+that	O
+in	O
+controls	O
+.	O
+
+TITLE	O
+:	O
+The	O
+YXXΦ	O
+motif	O
+within	O
+the	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+coronavirus	B-SPEC
+(	O
+SARS	B-DISO
+-	O
+CoV	O
+)	O
+3a	O
+protein	B-CHED
+is	O
+crucial	O
+for	O
+its	O
+intracellular	B-PROC
+transport	B-PROC
+.	O
+
+ABSTRACT	O
+:	O
+Six	O
+coronaviruses	O
+,	O
+including	O
+the	O
+recently	O
+identified	O
+Middle	O
+East	O
+respiratory	O
+syndrome	O
+coronavirus	B-SPEC
+,	O
+are	O
+known	O
+to	O
+target	O
+the	O
+human	B-SPEC
+respiratory	B-ANAT
+tract	I-ANAT
+causing	O
+mild	O
+to	O
+severe	O
+disease	O
+.	O
+
+Their	O
+interaction	O
+with	O
+receptors	O
+expressed	B-PROC
+on	O
+cells	B-COMP
+located	O
+in	O
+the	O
+respiratory	B-ANAT
+tract	I-ANAT
+is	O
+an	O
+essential	O
+first	O
+step	O
+in	O
+the	O
+infection	B-DISO
+.	O
+
+We	O
+report	O
+the	O
+clinical	O
+presentation	O
+and	O
+outcome	O
+of	O
+MERS	O
+-	O
+CoV	O
+infection	B-DISO
+in	O
+11	O
+pediatric	O
+patients	O
+.	O
+
+Whether	O
+E	O
+can	O
+release	B-PATH
+from	O
+cells	B-COMP
+or	O
+E	O
+/	O
+N	O
+interaction	O
+exists	O
+so	O
+as	O
+to	O
+contribute	O
+to	O
+enhanced	O
+VLP	B-COMP
+production	O
+is	O
+unknown	O
+.	O
+
+ABSTRACT	O
+:	O
+Recent	O
+evidence	O
+suggests	O
+that	O
+a	O
+mutation	O
+in	O
+the	O
+spike	O
+protein	B-CHED
+gene	O
+of	O
+feline	B-SPEC
+coronavirus	B-SPEC
+(	O
+FCoV	O
+),	O
+which	O
+results	O
+in	O
+an	O
+amino	B-CHED
+acid	I-CHED
+change	O
+from	O
+methionine	B-CHED
+to	O
+leucine	B-CHED
+at	O
+position	O
+1058	O
+,	O
+may	O
+be	O
+associated	O
+with	O
+feline	B-DISO
+infectious	I-DISO
+peritonitis	I-DISO
+(	O
+FIP	B-DISO
+).	O
+
+At	O
+admission	O
+,	O
+the	O
+patients	O
+in	O
+the	O
+failure	O
+group	O
+had	O
+significantly	O
+higher	O
+respiratory	O
+rate	O
+values	O
+(	O
+36	O
+.	O
+9	O
+±	O
+7	O
+.	O
+8	O
+vs	O
+30	O
+.	O
+5	O
+±	O
+3	O
+.	O
+3	O
+breaths	O
+/	O
+min	O
+;	O
+P	O
+=.	O
+036	O
+),	O
+plasma	B-ANAT
+N	O
+-	O
+terminal	O
+fragment	O
+of	O
+the	O
+prohormone	B-CHED
+of	O
+B	B-PRGE
+-	I-PRGE
+type	I-PRGE
+natriuretic	I-PRGE
+peptide	I-PRGE
+(	O
+NT	O
+-	O
+proBNP	O
+)	O
+levels	O
+(	O
+4528	O
+.	O
+8	O
+±	O
+4012	O
+.	O
+8	O
+vs	O
+634	O
+.	O
+6	O
+±	O
+808	O
+.	O
+0	O
+pg	O
+/	O
+mL	O
+;	O
+P	O
+=.	O
+023	O
+)	O
+and	O
+serum	B-PRGE
+C	I-PRGE
+-	I-PRGE
+reactive	I-PRGE
+protein	B-CHED
+values	O
+(	O
+72	O
+.	O
+0	O
+±	O
+50	O
+.	O
+0	O
+vs	O
+20	O
+.	O
+7	O
+±	O
+24	O
+.	O
+0	O
+μg	O
+/	O
+mL	O
+;	O
+P	O
+=.	O
+0289	O
+)	O
+with	O
+respect	O
+to	O
+those	O
+in	O
+the	O
+success	O
+group	O
+.	O
+
+Noninvasive	O
+ventilation	O
+failure	O
+was	O
+correlated	O
+to	O
+the	O
+plasma	B-PRGE
+NT	I-PRGE
+-	I-PRGE
+proBNP	I-PRGE
+levels	O
+at	O
+RICU	O
+admission	O
+(	O
+P	O
+=.	O
+0326	O
+)	O
+with	O
+an	O
+odds	O
+ratio	O
+of	O
+12	O
+.	O
+2	O
+(	O
+95	O
+%	O
+CI	O
+,	O
+1	O
+.	O
+2	O
+to	O
+infinity	O
+)	O
+in	O
+the	O
+patients	O
+with	O
+abnormally	O
+high	O
+values	O
+(>	O
+900	O
+pg	O
+/	O
+mL	O
+).	O
+
+Lung	B-ANAT
+-	O
+protective	O
+ventilation	O
+with	O
+high	O
+positive	O
+end	B-PROC
+-	I-PROC
+expiratory	I-PROC
+pressure	O
+and	O
+low	O
+tidal	O
+volume	O
+and	O
+early	O
+prone	O
+positioning	O
+in	O
+severe	O
+cases	O
+improve	O
+survival	O
+rate	O
+.	O
+
+ABSTRACT	O
+:	O
+Guided	O
+by	O
+crystal	O
+structures	O
+of	O
+HIV	B-SPEC
+-	I-SPEC
+1	I-SPEC
+RT	O
+/	O
+DAPY	O
+complex	O
+and	O
+molecular	O
+modeling	O
+studies	O
+,	O
+a	O
+series	O
+of	O
+novel	O
+DAPY	O
+derivatives	O
+were	O
+rationally	O
+designed	O
+,	O
+synthesized	O
+and	O
+evaluated	O
+for	O
+their	O
+anti	O
+-	O
+HIV	B-DISO
+activities	O
+.	O
+
+Preliminary	O
+structure	O
+-	O
+activity	O
+relationships	O
+(	O
+SARs	B-DISO
+)	O
+and	O
+molecular	O
+modeling	O
+of	O
+these	O
+new	O
+analogues	O
+were	O
+also	O
+discussed	O
+in	O
+detail	O
+.	O
+
+TITLE	O
+:	O
+Th2	O
+-	O
+type	O
+inflammation	B-DISO
+under	O
+conditions	O
+of	O
+pre	O
+-	O
+existing	O
+chronic	B-DISO
+disease	I-DISO
+is	O
+associated	O
+with	O
+liver	B-ANAT
+damage	I-DISO
+in	O
+patients	O
+with	O
+avian	B-DISO
+influenza	I-DISO
+H7N9	O
+virus	B-SPEC
+.	O
+
+ABSTRACT	O
+:	O
+Most	O
+patients	O
+infected	O
+with	O
+avian	B-SPEC
+H7N9	O
+influenza	B-SPEC
+virus	I-SPEC
+develop	O
+severe	O
+disease	O
+,	O
+including	O
+respiratory	B-DISO
+failure	I-DISO
+,	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+(	O
+ARDS	B-DISO
+),	O
+and	O
+multi	B-DISO
+-	I-DISO
+organ	I-DISO
+failure	I-DISO
+.	O
+
+However	O
+,	O
+their	O
+fatal	B-DISO
+outcomes	I-DISO
+and	O
+critically	O
+severe	O
+illness	O
+were	O
+significantly	O
+associated	O
+with	O
+high	O
+serum	B-COMP
+levels	O
+of	O
+tumor	B-FUNC
+necrosis	I-FUNC
+factor	I-FUNC
+(	O
+TNF	O
+)-	O
+α	O
+.	O
+
+MERS	O
+-	O
+CoV	O
+was	O
+related	O
+to	O
+the	O
+2C	O
+betacoronavirus	B-SPEC
+clade	O
+and	O
+is	O
+closely	O
+related	O
+to	O
+Tylonycteris	B-PRGE
+bat	I-PRGE
+coronavirus	I-PRGE
+HKU4	I-PRGE
+and	O
+Pipistrellus	B-PRGE
+bat	I-PRGE
+coronavirus	I-PRGE
+HKU5	I-PRGE
+.	O
+
+Recently	O
+,	O
+there	O
+were	O
+reports	O
+supposed	O
+to	O
+be	O
+cases	O
+of	O
+human	B-SPEC
+to	O
+human	B-SPEC
+infection	B-DISO
+.	O
+
+In	O
+the	O
+same	O
+period	O
+,	O
+seven	O
+PEDV	B-SPEC
+strains	O
+were	O
+also	O
+isolated	O
+in	O
+Guangdong	O
+by	O
+other	O
+laboratories	O
+.	O
+
+To	O
+our	O
+knowledge	O
+,	O
+these	O
+results	O
+provide	O
+the	O
+first	O
+report	O
+on	O
+human	B-SPEC
+nAbs	O
+against	O
+MERS	O
+-	O
+CoV	O
+that	O
+may	O
+contribute	O
+to	O
+MERS	O
+-	O
+CoV	O
+clearance	O
+and	O
+evolution	B-PROC
+.	O
+
+Despite	O
+establishing	O
+a	O
+systemic	B-DISO
+infection	I-DISO
+,	O
+SNV	O
+differentially	O
+activated	O
+host	B-COMP
+responses	O
+exclusively	O
+in	O
+the	O
+pulmonary	B-ANAT
+endothelium	B-ANAT
+,	O
+potentially	O
+the	O
+mechanism	O
+leading	O
+to	O
+acute	O
+severe	O
+respiratory	B-DISO
+distress	I-DISO
+.	O
+
+MERS	O
+-	O
+4	O
+and	O
+MERS	O
+-	O
+27	O
+inhibited	O
+infection	B-DISO
+of	O
+both	O
+pseudotyped	O
+and	O
+live	O
+MERS	O
+-	O
+CoV	O
+with	O
+IC50	O
+(	O
+half	O
+-	O
+maximal	O
+inhibitory	O
+concentration	O
+)	O
+at	O
+nanomolar	O
+concentrations	O
+.	O
+
+Consensus	O
+dromedary	B-SPEC
+MERS	O
+-	O
+CoV	O
+genome	O
+sequences	O
+were	O
+the	O
+same	O
+with	O
+either	O
+template	O
+source	O
+and	O
+identical	O
+to	O
+published	O
+human	B-PRGE
+MERS	I-PRGE
+-	I-PRGE
+CoV	I-PRGE
+sequences	I-PRGE
+.	O
+
+In	O
+conclusion	O
+,	O
+E	B-PRGE
+protein	I-PRGE
+IC	O
+activity	O
+represents	O
+a	O
+new	O
+determinant	O
+for	O
+SARS	B-DISO
+-	O
+CoV	O
+virulence	B-PROC
+.	O
+
+ABSTRACT	O
+:	O
+The	O
+recently	O
+discovered	O
+Middle	O
+East	O
+respiratory	O
+syndrome	B-DISO
+coronavirus	B-SPEC
+(	O
+MERS	O
+-	O
+CoV	O
+)	O
+continues	O
+to	O
+infect	O
+humans	B-SPEC
+,	O
+with	O
+high	O
+mortality	O
+.	O
+
+The	O
+exceptionally	O
+high	O
+neutralization	O
+activity	O
+of	O
+these	O
+antibodies	B-COMP
+and	O
+especially	O
+m336	O
+suggests	O
+that	O
+they	O
+have	O
+great	O
+potential	O
+for	O
+prophylaxis	O
+and	O
+therapy	O
+of	O
+MERS	O
+-	O
+CoV	O
+infection	B-DISO
+in	O
+humans	B-SPEC
+and	O
+as	O
+a	O
+tool	O
+for	O
+development	B-PROC
+of	O
+vaccine	O
+immunogens	O
+.	O
+
+It	O
+therefore	O
+may	O
+have	O
+great	O
+potential	O
+as	O
+a	O
+candidate	O
+therapeutic	O
+and	O
+as	O
+a	O
+reagent	B-CHED
+to	O
+facilitate	O
+the	O
+development	B-PROC
+of	O
+vaccines	O
+against	O
+MERS	O
+-	O
+CoV	O
+.	O
+
+The	O
+positive	O
+rate	O
+was	O
+53	O
+%	O
+(	O
+81	O
+/	O
+154	O
+)	O
+for	O
+nasopharyngeal	B-ANAT
+swabs	O
+and	O
+68	O
+%	O
+(	O
+105	O
+/	O
+154	O
+)	O
+for	O
+sputum	B-ANAT
+(	O
+P	O
+<	O
+0	O
+.	O
+001	O
+).	O
+
+To	O
+address	O
+this	O
+deficiency	O
+,	O
+high	O
+-	O
+throughput	O
+real	O
+time	O
+RT	O
+-	O
+PCR	O
+TaqMan	O
+assays	O
+were	O
+developed	O
+to	O
+measure	O
+the	O
+expression	B-PROC
+of	O
+fifteen	O
+immune	O
+mediators	O
+associated	O
+with	O
+the	O
+innate	O
+and	O
+adaptive	B-PROC
+immune	I-PROC
+responses	I-PROC
+(	O
+IFNα	O
+,	O
+IFNβ	O
+,	O
+IFNγ	O
+,	O
+IL1α	O
+,	O
+IL1β	O
+,	O
+IL2	B-PRGE
+,	O
+IL4	B-PRGE
+,	O
+IL6	B-PRGE
+,	O
+IL8	B-PRGE
+,	O
+IL10	B-PRGE
+,	O
+IL12p40	B-PRGE
+,	O
+IL17	B-PRGE
+,	O
+Granzyme	B-PRGE
+A	I-PRGE
+,	O
+MCP1	B-PRGE
+,	O
+TNFα	O
+),	O
+as	O
+well	O
+as	O
+four	O
+endogenous	O
+housekeeping	O
+genes	O
+(	O
+ATF4	B-PRGE
+,	O
+HPRT	B-FUNC
+,	O
+GAPDH	B-PRGE
+,	O
+L32	B-PRGE
+).	O
+
+TITLE	O
+:	O
+Epidemiology	O
+of	O
+acute	B-DISO
+respiratory	I-DISO
+infections	I-DISO
+in	O
+children	O
+in	O
+Guangzhou	O
+:	O
+a	O
+three	O
+-	O
+year	O
+study	O
+.	O
+
+Structural	O
+overlays	O
+were	O
+performed	O
+with	O
+HIV	B-SPEC
+-	I-SPEC
+1	I-SPEC
+and	O
+PFV	B-CHED
+RNase	B-PRGE
+H	I-PRGE
+to	O
+propose	O
+the	O
+RDS1643	O
+binding	B-FUNC
+site	O
+in	O
+HIV	B-SPEC
+-	I-SPEC
+1	I-SPEC
+RNase	B-PRGE
+H	I-PRGE
+.	O
+Our	O
+results	O
+suggest	O
+that	O
+this	O
+approach	O
+can	O
+be	O
+used	O
+to	O
+establish	O
+PFV	B-CHED
+RNase	B-PRGE
+H	I-PRGE
+as	O
+a	O
+model	O
+system	O
+for	O
+HIV	B-SPEC
+-	I-SPEC
+1	I-SPEC
+RNase	B-PRGE
+H	I-PRGE
+in	O
+order	B-SPEC
+to	O
+identify	O
+putative	O
+inhibitor	B-CHED
+binding	B-FUNC
+sites	O
+in	O
+HIV	B-SPEC
+-	I-SPEC
+1	I-SPEC
+RNase	B-PRGE
+H	I-PRGE
+.	O
+
+TITLE	O
+:	O
+T	O
+-	O
+tube	O
+drainage	B-ANAT
+and	O
+intercostals	B-ANAT
+muscle	I-ANAT
+flap	B-ANAT
+reinforcement	O
+for	O
+the	O
+management	O
+of	O
+intrathoracic	O
+esophago	O
+-	O
+gastric	O
+anastomotic	B-DISO
+leakage	I-DISO
+with	O
+pyothorax	B-DISO
+:	O
+a	O
+case	O
+report	O
+.	O
+
+ABSTRACT	O
+:	O
+Isolation	O
+of	O
+porcine	B-SPEC
+epidemic	B-DISO
+diarrhea	I-DISO
+coronavirus	B-SPEC
+(	O
+PEDV	B-SPEC
+)	O
+from	O
+clinical	O
+material	O
+in	O
+cell	B-COMP
+culture	O
+requires	O
+supplementation	O
+of	O
+trypsin	B-PRGE
+.	O
+
+This	O
+may	O
+relate	O
+to	O
+the	O
+confinement	O
+of	O
+PEDV	B-SPEC
+natural	O
+infection	B-DISO
+to	O
+the	O
+protease	O
+-	O
+rich	O
+small	B-ANAT
+intestine	I-ANAT
+of	O
+pigs	B-SPEC
+.	O
+
+Here	O
+,	O
+we	O
+provide	O
+new	O
+insight	O
+into	O
+the	O
+protease	O
+-	O
+dependent	O
+cell	B-COMP
+entry	O
+of	O
+PEDV	B-SPEC
+.	O
+
+TITLE	O
+:	O
+[	O
+Clinical	O
+study	O
+of	O
+early	O
+use	O
+of	O
+neuromuscular	O
+blocking	B-DISO
+agents	O
+in	O
+patients	O
+with	O
+severe	B-DISO
+sepsis	I-DISO
+and	O
+acute	O
+respiratory	O
+distress	O
+syndrome	O
+].	O
+
+ABSTRACT	O
+:	O
+To	O
+observe	O
+the	O
+clinical	O
+effects	O
+of	O
+early	O
+use	O
+of	O
+neuromuscular	O
+blocking	B-DISO
+agents	O
+(	O
+NMBA	O
+)	O
+in	O
+patients	O
+with	O
+severe	B-DISO
+sepsis	I-DISO
+and	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+(	O
+ARDS	B-DISO
+).	O
+
+96	O
+patients	O
+with	O
+severe	B-DISO
+sepsis	I-DISO
+and	O
+ARDS	B-DISO
+admitted	O
+from	O
+July	O
+2012	O
+to	O
+September	O
+2013	O
+to	O
+intensive	O
+care	O
+unit	O
+(	O
+ICU	O
+)	O
+of	O
+Liuzhou	O
+People	O
+'	O
+s	O
+Hospital	O
+in	O
+Guangxi	O
+Zhuang	O
+Autonomous	O
+Region	O
+were	O
+enrolled	O
+and	O
+divided	O
+into	O
+severe	O
+ARDS	B-DISO
+group	O
+(	O
+n	O
+=	O
+48	O
+)	O
+and	O
+moderate	O
+ARDS	B-DISO
+group	O
+(	O
+n	O
+=	O
+48	O
+)	O
+according	O
+to	O
+the	O
+Berlin	O
+definition	O
+of	O
+ARDS	B-DISO
+.	O
+
+In	O
+moderate	O
+or	O
+severe	O
+ARDS	B-DISO
+group	O
+,	O
+there	O
+were	O
+no	O
+statistically	O
+significant	O
+difference	O
+in	O
+APACHEII	O
+score	O
+,	O
+SOFA	O
+score	O
+,	O
+PaO2	O
+/	O
+FiO2	O
+,	O
+ScvO2	O
+,	O
+Lac	B-PRGE
+and	O
+CRP	B-PRGE
+before	O
+treatment	O
+between	O
+two	O
+groups	O
+.	O
+
+The	O
+oxygenation	B-PROC
+index	O
+(	O
+OI	O
+),	O
+peak	O
+inspiratory	B-PROC
+pressure	O
+(	O
+PIP	B-CHED
+),	O
+plat	O
+pressure	O
+(	O
+Pplat	O
+)	O
+and	O
+central	O
+venous	B-PROC
+pressure	I-PROC
+(	O
+CVP	B-PROC
+)	O
+were	O
+markedly	O
+elevated	O
+(	O
+OI	O
+:	O
+324	O
+.	O
+7	O
+±	O
+117	O
+.	O
+2	O
+mmHg	O
+vs	O
+.	O
+173	O
+.	O
+4	O
+±	O
+95	O
+.	O
+8	O
+mmHg	O
+,	O
+t	O
+=	O
+5	O
+.	O
+913	O
+,	O
+P	O
+=	O
+0	O
+.	O
+000	O
+;	O
+PIP	B-CHED
+:	O
+34	O
+.	O
+7	O
+±	O
+9	O
+.	O
+1	O
+cmH2O	O
+vs	O
+.	O
+26	O
+.	O
+1	O
+±	O
+7	O
+.	O
+9	O
+cmH2O	O
+,	O
+t	O
+=	O
+4	O
+.	O
+222	O
+,	O
+P	O
+=	O
+0	O
+.	O
+000	O
+;	O
+Pplat	O
+:	O
+30	O
+.	O
+5	O
+±	O
+8	O
+.	O
+4	O
+cmH2O	O
+vs	O
+.	O
+22	O
+.	O
+2	O
+±	O
+7	O
+.	O
+1	O
+cmH2O	O
+,	O
+t	O
+=	O
+4	O
+.	O
+465	O
+,	O
+P	O
+=	O
+0	O
+.	O
+000	O
+;	O
+CVP	B-PROC
+:	O
+12	O
+.	O
+1	O
+±	O
+3	O
+.	O
+5	O
+mmHg	O
+vs	O
+.	O
+8	O
+.	O
+8	O
+±	O
+2	O
+.	O
+2	O
+mmHg	O
+,	O
+t	O
+=	O
+4	O
+.	O
+723	O
+,	O
+P	O
+=	O
+0	O
+.	O
+000	O
+)	O
+when	O
+PEEP	B-CHED
+was	O
+increased	O
+from	O
+(	O
+6	O
+.	O
+4	O
+±	O
+1	O
+.	O
+0	O
+)	O
+cmH2O	O
+to	O
+(	O
+14	O
+.	O
+5	O
+±	O
+2	O
+.	O
+0	O
+)	O
+cmH2O	O
+(	O
+1	O
+cmH2O	O
+=	O
+0	O
+.	O
+098	O
+kPa	O
+).	O
+
+18	O
+patients	O
+with	O
+BHI	O
+<	O
+0	O
+.	O
+1	O
+at	O
+baseline	O
+demonstrated	O
+that	O
+cerebral	B-ANAT
+vasomotor	O
+reactivity	O
+was	O
+poor	O
+.	O
+
+BHI	O
+was	O
+slightly	O
+decreased	O
+with	O
+increase	O
+in	O
+PEEP	B-CHED
+(	O
+0	O
+.	O
+78	O
+±	O
+0	O
+.	O
+16	O
+vs	O
+.	O
+0	O
+.	O
+86	O
+±	O
+0	O
+.	O
+19	O
+,	O
+t	O
+=	O
+1	O
+.	O
+905	O
+,	O
+P	O
+=	O
+0	O
+.	O
+061	O
+).	O
+
+(	O
+2	O
+)	O
+The	O
+areas	O
+under	O
+the	O
+ROC	O
+curve	O
+of	O
+0	O
+h	O
+blood	B-ANAT
+lactate	B-CHED
+,	O
+6	O
+h	O
+lactate	B-CHED
+clearance	O
+rate	O
+and	O
+APACHE	O
+II	O
+score	O
+for	O
+predicting	O
+death	B-PROC
+were	O
+0	O
+.	O
+699	O
+±	O
+0	O
+.	O
+083	O
+(	O
+95	O
+%	O
+CI	O
+:	O
+0	O
+.	O
+567	O
+∼	O
+0	O
+.	O
+892	O
+,	O
+P	O
+<	O
+0	O
+.	O
+05	O
+)	O
+,	O
+0	O
+.	O
+871	O
+±	O
+0	O
+.	O
+119	O
+(	O
+95	O
+%	O
+CI	O
+:	O
+0	O
+.	O
+724	O
+∼	O
+0	O
+.	O
+980	O
+,	O
+P	O
+<	O
+0	O
+.	O
+05	O
+)	O
+and	O
+0	O
+.	O
+836	O
+±	O
+0	O
+.	O
+063	O
+(	O
+95	O
+%	O
+CI	O
+:	O
+0	O
+.	O
+713	O
+∼	O
+0	O
+.	O
+958	O
+,	O
+P	O
+<	O
+0	O
+.	O
+05	O
+)	O
+.	O
+
+In	O
+multivariable	O
+analysis	O
+,	O
+death	B-PROC
+was	O
+independently	O
+associated	O
+only	O
+with	O
+length	O
+of	O
+ICU	O
+admission	O
+[	O
+odds	O
+ratio	O
+(	O
+OR	O
+)	O
+95	O
+%	O
+confidence	O
+intervals	O
+(	O
+95	O
+%	O
+CI	O
+)	O
+1	O
+.	O
+36	O
+(	O
+1	O
+.	O
+14	O
+-	O
+1	O
+.	O
+61	O
+)].	O
+
+TITLE	O
+:	O
+Plasmodium	B-SPEC
+falciparum	I-SPEC
+Malaria	B-PATH
+Complicated	O
+by	O
+Symmetrical	O
+Peripheral	B-DISO
+Gangrene	I-DISO
+,	O
+Bowel	B-DISO
+Ischemia	I-DISO
+,	O
+Repeated	O
+Candidemia	O
+,	O
+and	O
+Bacteraemia	B-DISO
+.	O
+
+Predictors	O
+of	O
+pneumothorax	B-DISO
+varied	O
+between	O
+GA	O
+groups	O
+.	O
+
+ABSTRACT	O
+:	O
+This	O
+communication	O
+describes	O
+the	O
+coinfection	B-DISO
+with	O
+feline	B-SPEC
+panleukopenia	I-SPEC
+virus	I-SPEC
+(	O
+FPV	B-SPEC
+),	O
+feline	B-SPEC
+herpesvirus	I-SPEC
+1	I-SPEC
+(	O
+FeHV	O
+-	O
+1	O
+),	O
+feline	B-SPEC
+calicivirus	I-SPEC
+(	O
+FCV	B-CHED
+)	O
+and	O
+feline	B-SPEC
+coronavirus	B-SPEC
+(	O
+FCoV	O
+)	O
+in	O
+a	O
+1	O
+year	O
+‑	O
+old	O
+domestic	B-SPEC
+cat	I-SPEC
+living	O
+in	O
+a	O
+feline	B-SPEC
+shelter	O
+.	O
+
+ABSTRACT	O
+:	O
+Twenty	O
+-	O
+two	O
+flocks	O
+of	O
+turkeys	O
+affected	O
+by	O
+enteric	O
+problems	O
+,	O
+with	O
+ages	O
+between	O
+10	O
+and	O
+104	O
+days	O
+and	O
+located	O
+in	O
+the	O
+Southern	O
+region	O
+of	O
+Brazil	O
+,	O
+were	O
+surveyed	O
+for	O
+turkey	B-SPEC
+by	O
+PCR	O
+for	O
+turkey	B-SPEC
+astrovirus	I-SPEC
+type	O
+2	O
+(	O
+TAstV	O
+-	O
+2	O
+),	O
+turkey	B-SPEC
+coronavirus	B-SPEC
+(	O
+TCoV	O
+),	O
+hemorrhagic	B-DISO
+enteritis	I-DISO
+virus	B-SPEC
+(	O
+HEV	B-SPEC
+),	O
+rotavirus	B-SPEC
+,	O
+reovirus	B-SPEC
+,	O
+Salmonella	B-DISO
+spp	B-ENZY
+.,	O
+and	O
+Lawsonia	B-SPEC
+intracellularis	I-SPEC
+(	O
+Li	B-SPEC
+)	O
+infections	B-DISO
+.	O
+
+Six	O
+were	O
+positive	O
+for	O
+Salmonella	B-PRGE
+spp	B-ENZY
+.	O
+
+ABSTRACT	O
+:	O
+We	O
+report	O
+a	O
+case	O
+of	O
+a	O
+49	O
+-	O
+year	O
+-	O
+old	O
+Japanese	O
+man	B-CHED
+,	O
+who	O
+was	O
+admitted	O
+to	O
+our	O
+hospital	O
+because	O
+of	O
+severe	O
+dyspnea	B-DISO
+.	O
+
+It	O
+was	O
+assumed	O
+that	O
+severely	O
+low	O
+serum	B-COMP
+folate	B-CHED
+might	O
+be	O
+related	O
+to	O
+his	O
+malnutrition	B-DISO
+,	O
+probably	O
+caused	O
+by	O
+habitual	O
+alcohol	O
+consumption	O
+.	O
+
+ABSTRACT	O
+:	O
+The	O
+complete	O
+genome	O
+sequence	O
+of	O
+a	O
+porcine	O
+epidemic	O
+diarrhea	O
+virus	O
+variant	O
+,	O
+strain	O
+SHQP	O
+/	O
+YM	O
+/	O
+2013	O
+,	O
+from	O
+China	O
+was	O
+determined	O
+and	O
+compared	O
+with	O
+those	O
+of	O
+other	O
+porcine	B-SPEC
+epidemic	B-DISO
+diarrhea	I-DISO
+viruses	B-SPEC
+.	O
+
+The	O
+full	O
+-	O
+length	O
+genome	O
+was	O
+28	O
+,	O
+038	O
+nucleotides	B-CHED
+(	O
+nt	O
+)	O
+in	O
+length	O
+without	O
+the	O
+poly	O
+(	O
+A	O
+)	O
+tail	O
+,	O
+and	O
+it	O
+was	O
+similar	O
+to	O
+that	O
+of	O
+other	O
+reported	O
+PEDV	B-SPEC
+strains	O
+,	O
+with	O
+the	O
+characteristic	O
+gene	O
+order	B-SPEC
+5	O
+'-	O
+replicase	B-PRGE
+(	O
+1a	O
+/	O
+1b	O
+)	O
+-	O
+S	O
+-	O
+ORF3	O
+-	O
+E	O
+-	O
+M	O
+-	O
+N	O
+-	O
+3	O
+'.	O
+
+Nucleotide	B-CHED
+sequence	O
+analysis	O
+based	O
+on	O
+individual	O
+virus	B-SPEC
+genes	O
+indicated	O
+a	O
+close	O
+relationship	O
+between	O
+the	O
+S	O
+gene	O
+of	O
+SHQP	O
+/	O
+YM	O
+/	O
+2013	O
+and	O
+those	O
+of	O
+the	O
+four	O
+Korean	O
+field	O
+strains	O
+from	O
+2008	O
+-	O
+2009	O
+.	O
+
+In	O
+the	O
+NIV	O
+success	O
+group	O
+(	O
+n	O
+=	O
+63	O
+),	O
+33	O
+patients	O
+(	O
+53	O
+%)	O
+experienced	O
+a	O
+delayed	O
+response	O
+to	O
+NIV	O
+(	O
+with	O
+persistent	O
+hypercapnic	B-DISO
+acidosis	I-DISO
+during	O
+the	O
+first	O
+6	O
+hours	O
+).	O
+
+We	O
+aimed	O
+to	O
+determine	O
+the	O
+frequency	O
+of	O
+a	O
+broad	O
+panel	O
+of	O
+respiratory	O
+viruses	B-SPEC
+including	O
+human	B-SPEC
+bocavirus	I-SPEC
+(	O
+HBoV	O
+)	O
+and	O
+to	O
+assess	O
+the	O
+clinical	O
+characteristics	O
+of	O
+acute	B-DISO
+bronchiolitis	I-DISO
+in	O
+a	O
+group	O
+of	O
+children	O
+under	O
+24	O
+months	O
+of	O
+age	O
+.	O
+
+Including	O
+the	O
+co	B-DISO
+-	I-DISO
+infections	I-DISO
+,	O
+the	O
+most	O
+commonly	O
+detected	O
+virus	B-SPEC
+was	O
+RV	O
+(	O
+n	O
+=	O
+10	O
+;	O
+30	O
+.	O
+3	O
+%),	O
+followed	O
+by	O
+influenza	B-PATH
+A	I-PATH
+[	O
+H1N1	O
+]	O
+(	O
+n	O
+=	O
+6	O
+;	O
+18	O
+.	O
+1	O
+%),	O
+AdV	O
+(	O
+n	O
+=	O
+6	O
+;	O
+18	O
+.	O
+1	O
+%),	O
+RSV	B-SPEC
+(	O
+n	O
+=	O
+4	O
+;	O
+12	O
+.	O
+1	O
+%)	O
+and	O
+PIV	O
+(	O
+n	O
+=	O
+3	O
+;	O
+9	O
+%),	O
+however	O
+HBoV	O
+and	O
+hMPV	B-SPEC
+were	O
+not	O
+detected	O
+in	O
+the	O
+control	O
+group	O
+.	O
+
+It	O
+was	O
+concluded	O
+that	O
+viral	O
+etiology	O
+should	O
+be	O
+investigated	O
+in	O
+selected	O
+cases	O
+to	O
+prevent	O
+unnecessary	O
+antibiotic	B-CHED
+treatment	O
+and	O
+to	O
+initiate	O
+appropriate	O
+antiviral	B-CHED
+therapy	O
+when	O
+necessary	O
+.	O
+
+TITLE	O
+:	O
+Respiratory	O
+viruses	B-SPEC
+in	O
+exacerbations	O
+of	O
+non	O
+-	O
+cystic	B-DISO
+fibrosis	I-DISO
+bronchiectasis	B-DISO
+in	O
+children	O
+.	O
+
+ABSTRACT	O
+:	O
+Respiratory	O
+viral	O
+infections	O
+precipitate	O
+exacerbations	O
+of	O
+chronic	O
+respiratory	B-DISO
+diseases	I-DISO
+such	O
+as	O
+asthma	B-PATH
+and	O
+chronic	B-DISO
+obstructive	I-DISO
+pulmonary	I-DISO
+disease	I-DISO
+though	O
+similar	O
+data	O
+in	O
+non	O
+-	O
+cystic	B-DISO
+fibrosis	I-DISO
+(	O
+CF	O
+)	O
+bronchiectasis	B-DISO
+are	O
+missing	O
+.	O
+
+Time	O
+-	O
+sequenced	O
+cohort	O
+studies	O
+are	O
+needed	O
+to	O
+determine	O
+the	O
+role	O
+of	O
+viral	O
+-	O
+bacterial	O
+interactions	O
+in	O
+exacerbations	O
+of	O
+bronchiectasis	B-DISO
+.	O
+
+To	O
+stabilize	O
+the	O
+segment	O
+of	O
+paradoxical	O
+chest	B-ANAT
+wall	I-ANAT
+movement	B-PROC
+we	O
+performed	O
+the	O
+Nuss	O
+operation	O
+on	O
+a	O
+patient	O
+with	O
+multiple	B-DISO
+myeloma	I-DISO
+who	O
+sustained	O
+blunt	O
+thoracic	B-DISO
+trauma	O
+.	O
+
+The	O
+involvement	O
+of	O
+the	O
+spine	B-COMP
+is	O
+common	O
+,	O
+with	O
+clinical	O
+features	O
+ranging	O
+from	O
+simple	O
+changes	O
+in	O
+spinal	O
+morphology	O
+"("""	O
+fish	B-SPEC
+-	O
+mouth	B-ANAT
+""""	O
+appearance	O
+)	O
+up	O
+to	O
+vertebral	B-ANAT
+bodies	O
+fractures	O
+with	O
+kyphotic	O
+deformity	B-DISO
+.	O
+
+We	O
+report	O
+here	O
+a	O
+case	O
+of	O
+a	O
+young	O
+man	B-CHED
+affected	O
+by	O
+multiple	O
+pathological	O
+symptomatic	O
+vertebral	B-ANAT
+fractures	O
+at	O
+the	O
+thoraco	O
+-	O
+lumbar	B-ANAT
+junction	O
+,	O
+secondary	O
+to	O
+a	O
+well	O
+controlled	O
+but	O
+severe	O
+form	O
+of	O
+sickle	B-DISO
+cell	I-DISO
+disease	I-DISO
+.	O
+
+TITLE	O
+:	O
+Hospital	O
+-	O
+associated	O
+outbreak	O
+of	O
+Middle	O
+East	O
+respiratory	O
+syndrome	B-DISO
+coronavirus	B-SPEC
+:	O
+a	O
+serologic	O
+,	O
+epidemiologic	O
+,	O
+and	O
+clinical	O
+description	O
+.	O
+
+Novel	O
+serologic	O
+tests	O
+allowed	O
+for	O
+the	O
+detection	O
+of	O
+otherwise	O
+unrecognized	O
+cases	O
+of	O
+MERS	O
+-	O
+CoV	O
+infection	B-DISO
+among	O
+contacts	O
+in	O
+a	O
+Jordanian	O
+hospital	O
+-	O
+associated	O
+respiratory	O
+illness	O
+outbreak	O
+in	O
+April	O
+2012	O
+,	O
+resulting	O
+in	O
+a	O
+total	O
+of	O
+9	O
+test	O
+-	O
+positive	O
+cases	O
+.	O
+
+We	O
+infected	O
+importin	O
+-	O
+α7	O
+gene	O
+-	O
+deficient	O
+(	O
+α7	O
+(-/-))	O
+mice	B-SPEC
+with	O
+a	O
+recombinant	O
+H1N1	B-DISO
+influenza	I-DISO
+virus	O
+and	O
+compared	O
+the	O
+in	O
+vivo	O
+viral	O
+kinetics	O
+with	O
+those	O
+in	O
+wild	O
+-	O
+type	O
+(	O
+WT	O
+)	O
+mice	B-SPEC
+.	O
+
+In	O
+summary	O
+,	O
+these	O
+data	O
+show	O
+that	O
+a	O
+cellular	B-COMP
+factor	O
+,	O
+importin	O
+-	O
+α7	O
+,	O
+is	O
+required	O
+for	O
+enhanced	O
+virus	B-PROC
+replication	I-PROC
+in	O
+the	O
+alveolar	B-ANAT
+epithelium	I-ANAT
+,	O
+resulting	O
+in	O
+elevated	O
+cytokine	O
+and	O
+chemokine	O
+levels	O
+,	O
+extensive	O
+mononuclear	O
+infiltration	B-DISO
+,	O
+and	O
+thus	O
+,	O
+severe	O
+pneumonia	B-DISO
+and	O
+enhanced	O
+virulence	B-PROC
+in	O
+mice	B-SPEC
+.	O
+
+SIRS	B-DISO
+was	O
+considered	O
+positive	O
+if	O
+patients	O
+had	O
+two	O
+or	O
+more	O
+of	O
+the	O
+following	O
+:	O
+temperature	O
+of	O
+>	O
+38ºC	O
+or	O
+<	O
+36ºC	O
+;	O
+heart	B-ANAT
+rate	O
+>	O
+90	O
+beats	O
+/	O
+min	O
+;	O
+respiratory	O
+rate	O
+>	O
+20	O
+/	O
+min	O
+or	O
+PaCO2	O
+<	O
+32	O
+mmHg	O
+or	O
+the	O
+use	O
+of	O
+mechanical	O
+ventilation	O
+;	O
+WBC	B-ANAT
+>	O
+12000	O
+/	O
+mm	O
+(	O
+3	O
+)	O
+or	O
+<	O
+4000	O
+/	O
+mm	O
+(	O
+3	O
+)	O
+or	O
+more	O
+than	O
+10	O
+%	O
+immature	O
+neutrophil	B-ANAT
+count	O
+.	O
+
+ABSTRACT	O
+:	O
+Toxic	O
+epidermal	O
+necrolysis	O
+syndrome	B-DISO
+(	O
+TEN	O
+)	O
+is	O
+a	O
+rare	O
+severe	O
+cutaneous	O
+adverse	O
+drug	O
+reaction	O
+that	O
+involves	O
+skin	B-ANAT
+and	O
+mucous	B-ANAT
+membranes	I-ANAT
+.	O
+
+Especially	O
+,	O
+for	O
+inactivation	B-DISO
+effect	O
+and	O
+curative	O
+effect	O
+,	O
+compounds	O
+4a	O
+,	O
+6a	O
+,	O
+7a	O
+,	O
+11a	O
+,	O
+14a	O
+,	O
+and	O
+14b	O
+showed	O
+higher	O
+activity	O
+at	O
+both	O
+concentrations	O
+(	O
+500	O
+μg	O
+mL	O
+(-	O
+1	O
+)	O
+and	O
+100	O
+μg	O
+mL	O
+(-	O
+1	O
+))	O
+than	O
+commercial	O
+Ningnanmycin	O
+.	O
+
+Respiratory	B-ANAT
+tract	I-ANAT
+samples	O
+from	O
+cases	O
+of	O
+MERS	O
+-	O
+CoV	O
+infection	B-DISO
+confirmed	O
+by	O
+polymerase	O
+chain	O
+reaction	O
+(	O
+PCR	O
+)	O
+were	O
+investigated	O
+to	O
+determine	O
+the	O
+MERS	O
+-	O
+CoV	O
+load	O
+and	O
+fraction	O
+of	O
+the	O
+MERS	O
+-	O
+CoV	O
+genome	O
+.	O
+
+The	O
+genome	O
+yield	O
+from	O
+tracheal	O
+aspirates	B-ANAT
+and	O
+bronchoalveolar	O
+lavage	O
+samples	O
+were	O
+similar	O
+(	O
+P	O
+=	O
+.	O
+1174	O
+).	O
+
+The	O
+genome	O
+yield	O
+from	O
+tracheal	O
+aspirates	B-ANAT
+and	O
+bronchoalveolar	O
+lavage	O
+samples	O
+were	O
+similar	O
+(	O
+P	O
+=	O
+.	O
+1174	O
+).	O
+
+After	O
+a	O
+half	O
+century	O
+,	O
+FIP	B-DISO
+remains	O
+one	O
+of	O
+the	O
+last	O
+important	O
+infections	B-DISO
+of	O
+cats	B-SPEC
+for	O
+which	O
+we	O
+have	O
+no	O
+single	O
+diagnostic	O
+test	O
+,	O
+no	O
+vaccine	O
+and	O
+no	O
+definitive	O
+explanations	O
+for	O
+how	O
+virus	B-SPEC
+and	O
+host	B-COMP
+interact	O
+to	O
+cause	O
+disease	O
+.	O
+
+Although	O
+much	O
+has	O
+been	O
+learned	B-PROC
+about	O
+FIP	B-DISO
+in	O
+the	O
+last	O
+5	O
+years	O
+,	O
+the	O
+ultimate	O
+answers	O
+remain	O
+for	O
+yet	O
+more	O
+studies	O
+.	O
+
+Moreover	O
+,	O
+these	O
+compounds	O
+also	O
+inhibit	O
+the	O
+replication	O
+of	O
+SARS	B-DISO
+coronavirus	B-SPEC
+and	O
+human	B-SPEC
+coronavirus	I-SPEC
+229E	I-SPEC
+.	O
+
+ABSTRACT	O
+:	O
+Outbreaks	O
+of	O
+emerging	O
+infections	B-DISO
+present	O
+health	O
+professionals	O
+with	O
+the	O
+unique	O
+challenge	O
+of	O
+trying	O
+to	O
+select	O
+appropriate	O
+pharmacologic	O
+treatments	O
+in	O
+the	O
+clinic	O
+with	O
+little	O
+time	O
+available	O
+for	O
+drug	O
+testing	O
+and	O
+development	B-PROC
+.	O
+
+Selection	O
+of	O
+compounds	O
+for	O
+inclusion	O
+in	O
+the	O
+library	O
+was	O
+dependent	O
+on	O
+current	O
+or	O
+previous	O
+FDA	O
+approval	O
+or	O
+advanced	O
+clinical	O
+development	B-PROC
+.	O
+
+ABSTRACT	O
+:	O
+Coronaviruses	O
+comprise	O
+a	O
+large	O
+group	O
+of	O
+emergent	O
+human	O
+and	O
+animal	B-SPEC
+pathogens	O
+,	O
+including	O
+the	O
+highly	O
+pathogenic	O
+SARS	B-DISO
+-	O
+CoV	O
+and	O
+MERS	O
+-	O
+CoV	O
+strains	O
+that	O
+cause	O
+significant	O
+morbidity	O
+and	O
+mortality	O
+in	O
+infected	O
+individuals	O
+,	O
+especially	O
+the	O
+elderly	O
+.	O
+
+Using	O
+SARS	B-PRGE
+-	I-PRGE
+CoV	I-PRGE
+as	O
+a	O
+model	O
+,	O
+dynamic	O
+transcriptional	B-PROC
+network	I-PROC
+changes	O
+and	O
+disease	O
+-	O
+associated	O
+phenotypes	O
+have	O
+been	O
+identified	O
+in	O
+different	O
+genetic	O
+backgrounds	O
+,	O
+leading	O
+to	O
+the	O
+promise	O
+of	O
+population	O
+-	O
+wide	O
+discovery	O
+of	O
+the	O
+underpinnings	O
+of	O
+Coronavirus	B-SPEC
+pathogenesis	B-DISO
+.	O
+
+However	O
+,	O
+the	O
+cellular	B-COMP
+dynamics	O
+that	O
+underlie	O
+transplanted	B-ANAT
+NPC	B-COMP
+-	O
+mediated	O
+remyelination	B-PROC
+have	O
+not	O
+been	O
+described	O
+.	O
+
+A	O
+strong	O
+neutralizing	O
+antibody	B-PROC
+response	I-PROC
+generated	O
+against	O
+the	O
+spike	B-PRGE
+(	I-PRGE
+S	I-PRGE
+)	I-PRGE
+glycoprotein	I-PRGE
+of	O
+SARS	B-PRGE
+-	I-PRGE
+CoV	I-PRGE
+is	O
+completely	O
+protective	O
+in	O
+the	O
+susceptible	O
+host	B-COMP
+.	O
+
+Interestingly	O
+,	O
+the	O
+acute	O
+phase	O
+of	O
+SARS	B-DISO
+in	O
+humans	B-SPEC
+is	O
+associated	O
+with	O
+a	O
+severe	O
+reduction	O
+in	O
+the	O
+number	O
+of	O
+T	B-ANAT
+cells	I-ANAT
+in	O
+the	O
+blood	B-ANAT
+.	O
+
+While	O
+successful	O
+respiratory	O
+viruses	B-SPEC
+overcome	O
+individual	O
+ISG	O
+effectors	O
+,	O
+analysis	O
+of	O
+the	O
+global	O
+ISG	O
+response	O
+and	O
+subsequent	O
+viral	O
+antagonism	O
+has	O
+yet	O
+to	O
+be	O
+examined	O
+.	O
+
+In	O
+addition	O
+,	O
+the	O
+data	O
+revealed	O
+that	O
+highly	O
+virulent	O
+HPAI	B-FUNC
+virus	B-SPEC
+and	O
+MERS	O
+-	O
+CoV	O
+induce	O
+repressive	O
+histone	O
+modifications	O
+,	O
+which	O
+downregulate	O
+expression	B-PROC
+of	O
+ISG	O
+subsets	O
+.	O
+
+Notably	O
+,	O
+influenza	B-PRGE
+A	I-PRGE
+virus	I-PRGE
+NS1	B-DISO
+appears	O
+to	O
+play	O
+a	O
+central	O
+role	O
+in	O
+this	O
+histone	B-PRGE
+-	O
+mediated	O
+downregulation	B-PROC
+in	O
+highly	O
+pathogenic	O
+influenza	B-DISO
+strains	O
+.	O
+
+These	O
+findings	O
+were	O
+subsequently	O
+confirmed	O
+and	O
+explored	O
+,	O
+revealing	O
+both	O
+a	O
+common	O
+pathway	B-PROC
+of	O
+antagonism	O
+via	O
+type	O
+I	O
+interferon	B-PRGE
+(	O
+IFN	B-PRGE
+)	O
+delay	O
+as	O
+well	O
+as	O
+a	O
+novel	O
+avenue	O
+for	O
+control	O
+by	O
+altered	O
+histone	B-PROC
+modification	I-PROC
+.	O
+
+Tailoring	O
+tidal	O
+volume	O
+on	O
+residual	B-PROC
+functional	I-PROC
+capacity	I-PROC
+,	O
+however	O
+,	O
+is	O
+preferable	O
+.	O
+
+In	O
+case	O
+of	O
+unchanged	O
+conditions	O
+or	O
+increased	O
+ARDS	B-DISO
+severity	O
+a	O
+referral	O
+center	O
+should	O
+be	O
+contacted	O
+.	O
+
+The	O
+injury	O
+severity	O
+score	O
+was	O
+51	O
+for	O
+his	O
+pattern	O
+of	O
+injuries	O
+(	O
+hemopneumothorax	B-DISO
+left	O
+,	O
+sternum	B-ANAT
+fracture	O
+,	O
+pneumothorax	B-DISO
+right	O
+,	O
+pneumomediastinum	B-DISO
+,	O
+intracerebral	O
+bleeding	B-DISO
+,	O
+scalping	B-ANAT
+injury	O
+occipital	B-ANAT
+,	O
+fracture	O
+of	O
+the	O
+ninth	B-ANAT
+thoracic	I-ANAT
+vertebral	I-ANAT
+body	I-ANAT
+,	O
+and	O
+complete	O
+paraplegia	B-DISO
+).	O
+
+ABSTRACT	O
+:	O
+Severe	B-SPEC
+acute	I-SPEC
+respiratory	I-SPEC
+syndrome	I-SPEC
+-	I-SPEC
+related	I-SPEC
+coronavirus	I-SPEC
+(	O
+SARS	B-DISO
+-	O
+CoV	O
+)	O
+is	O
+an	O
+emerging	O
+pathogen	O
+that	O
+causes	O
+severe	O
+respiratory	O
+illness	O
+.	O
+
+Interestingly	O
+,	O
+mutations	O
+in	O
+the	O
+non	O
+-	O
+nucleoside	B-CHED
+RT	O
+inhibitor	B-CHED
+binding	B-FUNC
+pocket	O
+strongly	O
+affected	O
+RNase	O
+H	O
+inhibition	B-PROC
+by	O
+the	O
+propenone	O
+derivatives	O
+without	O
+decreasing	O
+their	O
+capacity	O
+to	O
+inhibit	O
+DP	O
+activity	O
+,	O
+which	O
+suggests	O
+long	O
+-	O
+range	O
+RT	O
+structural	O
+effects	O
+.	O
+
+Furthermore	O
+,	O
+using	O
+the	O
+aforementioned	O
+techniques	O
+along	O
+with	O
+Northern	O
+blot	O
+assay	O
+,	O
+we	O
+specifically	O
+defined	O
+the	O
+cis	B-DISO
+-	O
+acting	O
+RNA	O
+elements	O
+within	O
+the	O
+3	O
+'-	O
+terminal	O
+55	O
+nucleotides	B-CHED
+(	O
+nts	B-ANAT
+)	O
+which	O
+function	O
+in	O
+the	O
+synthesis	B-PROC
+of	O
+(-)-	O
+or	O
+(+)-	O
+strand	O
+BCoV	O
+DI	O
+RNA	O
+.	O
+
+The	O
+major	O
+findings	O
+are	O
+as	O
+follows	O
+:	O
+(	O
+i	O
+)	O
+nts	B-ANAT
+from	O
+-	O
+5	O
+to	O
+-	O
+39	O
+within	O
+the	O
+3	O
+'-	O
+terminal	O
+55	O
+nts	B-ANAT
+are	O
+the	O
+cis	B-DISO
+-	O
+acting	O
+elements	O
+responsible	O
+for	O
+(-)-	O
+strand	O
+BCoV	O
+DI	O
+RNA	B-PROC
+synthesis	I-PROC
+,	O
+(	O
+ii	O
+)	O
+nts	B-ANAT
+from	O
+-	O
+3	O
+to	O
+-	O
+34	O
+within	O
+the	O
+3	O
+'-	O
+terminal	O
+55	O
+nts	B-ANAT
+are	O
+cis	B-DISO
+-	O
+acting	O
+elements	O
+required	O
+for	O
+(+)-	O
+strand	O
+BCoV	O
+DI	O
+RNA	B-PROC
+synthesis	I-PROC
+,	O
+and	O
+(	O
+iii	O
+)	O
+the	O
+nucleotide	B-CHED
+species	B-SPEC
+at	O
+the	O
+3	O
+'-	O
+most	O
+position	O
+(-	O
+1	O
+)	O
+is	O
+important	O
+,	O
+but	O
+not	O
+critical	O
+,	O
+for	O
+both	O
+(-)-	O
+and	O
+(+)-	O
+strand	O
+BCoV	O
+DI	O
+RNA	B-PROC
+synthesis	I-PROC
+.	O
+
+These	O
+results	O
+demonstrate	O
+that	O
+the	O
+3	O
+'-	O
+terminal	O
+55	O
+nts	B-ANAT
+in	O
+BCoV	B-PRGE
+DI	I-PRGE
+RNA	I-PRGE
+harbor	O
+cis	B-DISO
+-	O
+acting	O
+RNA	O
+elements	O
+required	O
+for	O
+both	O
+(-)-	O
+and	O
+(+)-	O
+strand	O
+DI	O
+RNA	B-PROC
+synthesis	I-PROC
+and	O
+extend	O
+our	O
+knowledge	O
+on	O
+the	O
+mechanisms	O
+of	O
+coronavirus	B-SPEC
+replication	O
+.	O
+
+We	O
+applied	O
+latent	O
+class	B-SPEC
+modelling	O
+to	O
+identify	O
+subphenotypes	O
+using	O
+clinical	O
+and	O
+biological	O
+data	O
+.	O
+
+In	O
+both	O
+cohorts	O
+,	O
+we	O
+identified	O
+a	O
+hyperinflammatory	O
+subphenotype	O
+(	O
+phenotype	O
+2	O
+)	O
+that	O
+was	O
+characterised	O
+by	O
+higher	O
+plasma	B-ANAT
+concentrations	O
+of	O
+inflammatory	O
+biomarkers	O
+,	O
+a	O
+higher	O
+prevalence	O
+of	O
+vasopressor	O
+use	O
+,	O
+lower	O
+serum	B-COMP
+bicarbonate	B-CHED
+concentrations	O
+,	O
+and	O
+a	O
+higher	O
+prevalence	O
+of	O
+sepsis	B-DISO
+than	O
+phenotype	O
+1	O
+.	O
+
+Mutagenesis	B-PROC
+of	O
+residues	O
+within	O
+this	O
+ridge	O
+region	O
+revealed	O
+that	O
+these	O
+mutants	O
+retain	O
+viral	O
+protease	B-PROC
+activity	I-PROC
+and	O
+the	O
+ability	O
+to	O
+catalyze	O
+hydrolysis	O
+of	O
+mono	B-DISO
+-	O
+ubiquitin	B-PROC
+.	O
+
+This	O
+identification	O
+of	O
+key	O
+and	O
+unique	O
+sites	O
+in	O
+PLpro	O
+required	O
+for	O
+recognition	O
+and	O
+processing	O
+of	O
+diubiquitin	B-PRGE
+and	O
+ISG15	B-PRGE
+versus	O
+mono	B-PRGE
+-	I-PRGE
+ubiquitin	B-PROC
+and	O
+protease	B-PROC
+activity	I-PROC
+provides	O
+new	O
+insight	O
+into	O
+ubiquitin	B-PROC
+-	O
+chain	O
+and	O
+ISG15	O
+recognition	O
+and	O
+highlights	O
+a	O
+role	O
+for	O
+PLpro	B-PRGE
+DUB	I-PRGE
+and	O
+deISGylase	O
+activity	O
+in	O
+antagonism	O
+of	O
+the	O
+innate	B-DISO
+immune	I-DISO
+response	I-DISO
+.	O
+
+With	O
+this	O
+in	O
+mind	O
+,	O
+there	O
+is	O
+a	O
+need	O
+to	O
+incorporate	O
+better	O
+and	O
+more	O
+suitable	O
+adjuvants	B-CHED
+in	O
+the	O
+vaccines	O
+to	O
+elicit	O
+the	O
+elevated	O
+immune	B-PROC
+response	I-PROC
+in	O
+the	O
+host	B-COMP
+.	O
+
+TITLE	O
+:	O
+Human	B-SPEC
+infection	B-DISO
+with	O
+MERS	O
+coronavirus	B-SPEC
+after	O
+exposure	O
+to	O
+infected	O
+camels	B-SPEC
+,	O
+Saudi	O
+Arabia	O
+,	O
+2013	O
+.	O
+
+Analysis	O
+of	O
+the	O
+whole	O
+human	B-SPEC
+-	O
+derived	O
+virus	B-SPEC
+and	O
+15	O
+%	O
+of	O
+the	O
+camel	B-SPEC
+-	O
+derived	O
+virus	B-SPEC
+sequence	O
+yielded	O
+nucleotide	B-CHED
+polymorphism	B-PROC
+signatures	O
+suggestive	O
+of	O
+cross	O
+-	O
+species	B-SPEC
+transmission	O
+.	O
+
+Camels	B-SPEC
+may	O
+act	O
+as	O
+a	O
+direct	O
+source	O
+of	O
+human	B-SPEC
+MERS	O
+-	O
+CoV	O
+infection	B-DISO
+.	O
+
+TITLE	O
+:	O
+Salvage	O
+of	O
+severe	O
+ischemic	O
+lower	B-ANAT
+limb	I-ANAT
+having	O
+peak	O
+creatine	B-CHED
+phosphokinase	O
+level	O
+exceeding	O
+200	O
+,	O
+000	O
+IU	O
+/	O
+L	O
+treated	O
+by	O
+continuous	O
+hemodiafiltration	O
+.	O
+
+ABSTRACT	O
+:	O
+We	O
+performed	O
+revascularization	O
+by	O
+an	O
+anti	O
+-	O
+anatomical	O
+bypass	O
+in	O
+a	O
+40	O
+-	O
+year	O
+-	O
+old	O
+man	O
+with	O
+extended	O
+ischemia	B-DISO
+of	O
+both	O
+legs	B-ANAT
+beyond	O
+12	O
+hr	O
+after	O
+onset	O
+because	O
+of	O
+traumatic	O
+aortic	B-DISO
+dissection	I-DISO
+.	O
+
+TITLE	O
+:	O
+Fever	B-PROC
+screening	O
+of	O
+seasonal	O
+influenza	B-DISO
+patients	O
+using	O
+a	O
+cost	O
+-	O
+effective	O
+thermopile	O
+array	O
+with	O
+small	O
+pixels	O
+for	O
+close	O
+-	O
+range	O
+thermometry	O
+.	O
+
+Retinal	B-DISO
+degeneration	I-DISO
+resistant	O
+CD	O
+-	O
+1	O
+mice	B-SPEC
+do	O
+not	O
+develop	O
+either	O
+the	O
+late	O
+phase	O
+or	O
+autoimmune	B-DISO
+reactivity	O
+.	O
+
+Two	O
+clones	O
+were	O
+identified	O
+,	O
+villin	B-PRGE
+-	I-PRGE
+2	I-PRGE
+protein	I-PRGE
+and	O
+α	B-PRGE
+-	I-PRGE
+fodrin	I-PRGE
+protein	I-PRGE
+.	O
+
+TITLE	O
+:	O
+Group	B-DISO
+B	I-DISO
+betacoronavirus	B-SPEC
+in	O
+rhinolophid	O
+bats	B-SPEC
+,	O
+Japan	O
+.	O
+
+We	O
+then	O
+used	O
+reverse	O
+-	O
+transcription	B-PROC
+PCR	O
+to	O
+look	O
+for	O
+the	O
+coronavirus	B-SPEC
+RNA	O
+-	O
+dependent	O
+RNA	B-PRGE
+polymerase	I-PRGE
+gene	I-PRGE
+in	O
+fecal	B-ANAT
+samples	O
+collected	O
+from	O
+27	O
+little	B-SPEC
+Japanese	I-SPEC
+horseshoe	I-SPEC
+bats	I-SPEC
+and	O
+found	O
+eight	O
+were	O
+provisionally	O
+positive	O
+.	O
+
+We	O
+found	O
+that	O
+these	O
+six	O
+samples	O
+were	O
+positive	O
+in	O
+coronavirus	B-DISO
+infection	I-DISO
+,	O
+and	O
+they	O
+belonged	O
+to	O
+the	O
+group	B-DISO
+B	I-DISO
+Betacornavirus	O
+by	O
+phylogenetic	O
+analysis	O
+.	O
+
+We	O
+postulate	O
+that	O
+the	O
+higher	O
+-	O
+order	B-SPEC
+structure	O
+promotes	O
+(+)-	O
+strand	O
+synthesis	B-PROC
+.	O
+
+We	O
+suggest	O
+that	O
+these	O
+results	O
+have	O
+implications	O
+for	O
+viral	B-PROC
+genome	I-PROC
+replication	I-PROC
+and	O
+explain	O
+,	O
+in	O
+part	O
+,	O
+why	O
+coronavirus	B-SPEC
+sgmRNAs	O
+fail	O
+to	O
+replicate	O
+.	O
+
+ABSTRACT	O
+:	O
+Porcine	B-SPEC
+epidemic	I-SPEC
+diarrhea	I-SPEC
+virus	I-SPEC
+(	O
+PEDV	B-SPEC
+),	O
+a	O
+porcine	B-SPEC
+enteropathogenic	O
+coronavirus	B-SPEC
+,	O
+causes	O
+lethal	O
+watery	B-DISO
+diarrhea	I-DISO
+in	O
+piglets	O
+and	O
+results	O
+in	O
+large	O
+economic	O
+losses	O
+in	O
+many	O
+Asian	O
+and	O
+European	O
+countries	O
+.	O
+
+Previous	O
+studies	O
+have	O
+shown	O
+that	O
+PEDV	B-SPEC
+infection	B-DISO
+inhibits	O
+the	O
+synthesis	B-PROC
+of	O
+type	O
+I	O
+interferon	B-PRGE
+(	O
+IFN	B-PRGE
+),	O
+and	O
+viral	B-PRGE
+papain	I-PRGE
+-	I-PRGE
+like	I-PRGE
+protease	I-PRGE
+2	I-PRGE
+has	O
+been	O
+identified	O
+as	O
+an	O
+IFN	B-PRGE
+antagonist	B-PROC
+.	O
+
+Here	O
+we	O
+screened	O
+a	O
+collection	O
+of	O
+16671	O
+diverse	O
+compounds	O
+for	O
+anti	B-PRGE
+-	I-PRGE
+human	I-PRGE
+coronavirus	I-PRGE
+229E	I-PRGE
+activity	O
+and	O
+identified	O
+an	O
+inhibitor	B-CHED
+,	O
+designated	O
+K22	O
+,	O
+that	O
+specifically	O
+targets	O
+membrane	B-COMP
+-	O
+bound	O
+coronaviral	O
+RNA	B-PROC
+synthesis	I-PROC
+.	O
+
+ABSTRACT	O
+:	O
+To	O
+initiate	O
+infections	B-DISO
+,	O
+many	O
+coronaviruses	O
+use	O
+sialic	B-CHED
+acids	I-CHED
+,	O
+either	O
+as	O
+receptor	O
+determinants	O
+or	O
+as	O
+attachment	O
+factors	O
+helping	O
+the	O
+virus	B-SPEC
+find	O
+its	O
+receptor	O
+underneath	O
+the	O
+heavily	O
+glycosylated	O
+mucus	B-COMP
+layer	I-COMP
+.	O
+
+Among	O
+patients	O
+with	O
+normal	O
+daytime	O
+SpO2	O
+,	O
+35	O
+%	O
+had	O
+nocturnal	O
+and	O
+42	O
+%	O
+postexercise	O
+hypoxia	B-DISO
+.	O
+
+Median	O
+percentage	O
+of	O
+the	O
+predicted	O
+distance	O
+covered	O
+during	O
+a	O
+6	O
+-	O
+minute	O
+walk	O
+test	O
+was	O
+86	O
+%	O
+[	O
+46	O
+-	O
+120	O
+];	O
+the	O
+distance	O
+was	O
+negatively	O
+associated	O
+with	O
+LDH	B-PRGE
+(	O
+P	O
+=	O
+0	O
+.	O
+044	O
+)	O
+and	O
+with	O
+a	O
+past	O
+history	O
+of	O
+acute	B-DISO
+chest	I-DISO
+syndrome	I-DISO
+(	O
+P	O
+=	O
+0	O
+.	O
+009	O
+).	O
+
+She	O
+developed	O
+obstructive	B-DISO
+uropathy	I-DISO
+and	O
+bilateral	B-DISO
+hydronephrosis	I-DISO
+from	O
+mucosal	B-ANAT
+debris	O
+and	O
+sludge	B-ANAT
+.	O
+
+However	O
+,	O
+acute	B-DISO
+renal	I-DISO
+failure	I-DISO
+secondary	O
+to	O
+ureteral	B-DISO
+obstruction	I-DISO
+and	O
+perforation	O
+has	O
+never	O
+been	O
+described	O
+.	O
+
+However	O
+,	O
+in	O
+the	O
+1980s	O
+several	O
+investigators	O
+provided	O
+novel	O
+evidence	O
+that	O
+the	O
+primary	O
+mechanism	O
+for	O
+removal	O
+of	O
+alveolar	B-DISO
+edema	I-DISO
+fluid	O
+depended	O
+on	O
+active	B-PROC
+ion	I-PROC
+transport	I-PROC
+across	O
+the	O
+alveolar	B-ANAT
+epithelium	I-ANAT
+.	O
+
+Compounds	O
+(	O
+1	O
+-	O
+6	O
+)	O
+displayed	O
+significant	O
+inhibitory	O
+activity	O
+with	O
+IC50	O
+values	O
+in	O
+the	O
+range	O
+15	O
+.	O
+8	O
+-	O
+70	O
+.	O
+1	O
+µM	O
+.	O
+The	O
+new	O
+cinnamic	O
+amide	B-CHED
+6	O
+was	O
+found	O
+to	O
+be	O
+most	O
+potent	O
+inhibitor	B-CHED
+with	O
+an	O
+IC50	O
+of	O
+15	O
+.	O
+8	O
+µM	O
+.	O
+In	O
+kinetic	O
+studies	O
+,	O
+all	O
+inhibitors	O
+exhibited	O
+mixed	O
+type	O
+inhibition	B-PROC
+.	O
+
+Multiple	O
+sequence	O
+alignment	O
+(	O
+MSA	B-DISO
+)	O
+approach	O
+was	O
+employed	O
+among	O
+spike	O
+(	O
+S	O
+),	O
+membrane	B-COMP
+(	O
+M	O
+),	O
+enveloped	O
+(	O
+E	O
+)	O
+and	O
+nucleocapsid	B-COMP
+(	O
+N	O
+)	O
+protein	B-CHED
+and	O
+replicase	B-PRGE
+polyprotein	O
+1ab	O
+to	O
+identify	O
+which	O
+one	O
+is	O
+highly	O
+conserve	O
+in	O
+all	O
+coronaviruses	O
+strains	O
+.	O
+
+We	O
+found	O
+that	O
+conserved	O
+region	O
+is	O
+present	O
+only	O
+in	O
+the	O
+RNA	O
+directed	O
+RNA	B-PRGE
+polymerase	I-PRGE
+protein	B-CHED
+.	O
+
+Overexpression	B-PROC
+of	O
+activin	B-PRGE
+A	I-PRGE
+in	O
+the	O
+lung	B-ANAT
+causes	O
+similar	O
+histopathological	O
+changes	O
+as	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+(	O
+ARDS	B-DISO
+).	O
+
+Interleukin	B-PRGE
+6	I-PRGE
+(	O
+IL	B-FUNC
+-	I-FUNC
+6	I-FUNC
+),	O
+which	O
+in	O
+experimental	O
+studies	O
+increases	O
+after	O
+activin	B-PROC
+A	O
+release	B-PATH
+,	O
+is	O
+known	O
+to	O
+be	O
+related	O
+to	O
+the	O
+severity	O
+of	O
+H1N1	O
+infection	B-DISO
+.	O
+
+We	O
+have	O
+used	O
+primary	O
+human	B-SPEC
+immune	O
+cells	B-COMP
+to	O
+evaluate	O
+their	O
+susceptibility	O
+to	O
+infection	B-DISO
+by	O
+SARS	B-DISO
+-	O
+CoV	O
+in	O
+the	O
+presence	O
+of	O
+anti	O
+-	O
+Spike	O
+antibodies	B-COMP
+.	O
+
+Fluorescence	O
+microscopy	O
+and	O
+real	O
+-	O
+time	O
+quantitative	O
+reverse	B-PRGE
+transcriptase	I-PRGE
+polymerase	O
+chain	O
+reaction	O
+(	O
+RT	O
+-	O
+PCR	O
+)	O
+were	O
+utilized	O
+to	O
+assess	O
+occurrence	O
+and	O
+consequences	O
+of	O
+infection	B-DISO
+.	O
+
+We	O
+show	O
+here	O
+that	O
+anti	O
+-	O
+Spike	O
+immune	O
+serum	B-COMP
+increased	O
+infection	B-DISO
+of	O
+human	B-SPEC
+monocyte	B-ANAT
+-	I-ANAT
+derived	I-ANAT
+macrophages	I-ANAT
+by	O
+replication	O
+-	O
+competent	O
+SARS	B-DISO
+-	O
+CoV	O
+as	O
+well	O
+as	O
+Spike	O
+-	O
+pseudotyped	O
+lentiviral	O
+particles	O
+(	O
+SARS	B-DISO
+-	O
+CoVpp	O
+).	O
+
+Among	O
+these	O
+SNP	O
+,	O
+the	O
+fFING	O
++	O
+428	O
+T	O
+allele	O
+was	O
+shown	O
+to	O
+be	O
+a	O
+FIP	B-DISO
+-	O
+resistant	O
+allele	O
+(	O
+p	O
+=	O
+0	O
+.	O
+03	O
+),	O
+and	O
+the	O
+heterozygous	O
+genotypes	O
+01C	O
+/	O
+T	O
+and	O
++	O
+408C	O
+/	O
+T	O
+were	O
+found	O
+to	O
+be	O
+FIP	O
+-	O
+susceptible	O
+factors	O
+(	O
+p	O
+=	O
+0	O
+.	O
+004	O
+).	O
+
+Publications	O
+describing	O
+randomized	O
+controlled	O
+trials	O
+(	O
+RCTs	O
+)	O
+in	O
+which	O
+investigators	O
+have	O
+compared	O
+prone	O
+and	O
+supine	O
+ventilation	O
+were	O
+retrieved	O
+by	O
+searching	O
+the	O
+following	O
+electronic	O
+databases	O
+:	O
+PubMed	O
+/	O
+MEDLINE	O
+,	O
+the	O
+Cochrane	O
+Library	O
+,	O
+the	O
+Web	B-DISO
+of	O
+Science	O
+and	O
+Elsevier	O
+Science	O
+(	O
+inception	O
+to	O
+May	O
+2013	O
+).	O
+
+PP	O
+was	O
+shown	O
+to	O
+reduce	O
+both	O
+60	O
+-	O
+day	O
+mortality	O
+(	O
+n	O
+=	O
+518	O
+,	O
+RR	O
+=	O
+0	O
+.	O
+82	O
+,	O
+95	O
+%	O
+CI	O
+=	O
+0	O
+.	O
+68	O
+to	O
+0	O
+.	O
+99	O
+;	O
+P	O
+=	O
+0	O
+.	O
+04	O
+)	O
+and	O
+90	O
+-	O
+day	O
+mortality	O
+(	O
+n	O
+=	O
+516	O
+,	O
+RR	O
+=	O
+0	O
+.	O
+57	O
+,	O
+95	O
+%	O
+CI	O
+=	O
+0	O
+.	O
+43	O
+to	O
+0	O
+.	O
+75	O
+;	O
+P	O
+<	O
+0	O
+.	O
+0001	O
+)	O
+in	O
+ARDS	B-DISO
+patients	O
+ventilated	O
+with	O
+PEEP	B-CHED
+≥	O
+10	O
+cmH2O	O
+.	O
+
+ABSTRACT	O
+:	O
+Acute	O
+respiratory	O
+distress	O
+syndrome	O
+(	O
+ARDS	B-DISO
+)	O
+in	O
+humans	B-SPEC
+is	O
+caused	O
+by	O
+an	O
+unchecked	O
+proinflammatory	O
+response	O
+that	O
+results	O
+in	O
+diffuse	O
+and	O
+severe	O
+lung	B-ANAT
+injury	O
+,	O
+and	O
+it	O
+is	O
+associated	O
+with	O
+a	O
+mortality	O
+rate	O
+of	O
+35	O
+to	O
+45	O
+%.	O
+
+Mesenchymal	O
+stromal	B-ANAT
+cells	I-ANAT
+(	O
+MSCs	B-FUNC
+;	O
+'	O
+adult	O
+stem	B-ANAT
+cells	I-ANAT
+')	O
+could	O
+represent	O
+a	O
+promising	O
+new	O
+therapy	O
+for	O
+this	O
+syndrome	B-DISO
+,	O
+since	O
+preclinical	O
+evidence	O
+suggests	O
+that	O
+MSCs	B-FUNC
+may	O
+ameliorate	O
+lung	B-ANAT
+injury	O
+.	O
+
+The	O
+primary	O
+outcome	O
+will	O
+be	O
+death	B-PROC
+.	O
+
+Secondary	O
+outcomes	O
+will	O
+include	O
+the	O
+four	O
+key	O
+features	O
+of	O
+preclinical	O
+acute	O
+lung	O
+injury	O
+as	O
+defined	O
+by	O
+the	O
+American	O
+Thoracic	B-DISO
+Society	O
+consensus	O
+conference	O
+(	O
+histologic	O
+evidence	O
+of	O
+lung	B-ANAT
+injury	O
+,	O
+altered	O
+alveolar	B-ANAT
+capillary	B-ANAT
+barrier	O
+,	O
+lung	B-ANAT
+inflammatory	B-DISO
+response	I-DISO
+,	O
+and	O
+physiological	O
+dysfunction	O
+)	O
+and	O
+pathogen	O
+clearance	O
+for	O
+acute	O
+lung	B-ANAT
+injury	O
+models	O
+that	O
+are	O
+caused	O
+by	O
+infection	B-DISO
+.	O
+
+Our	O
+results	O
+will	O
+help	O
+translational	B-PROC
+scientists	O
+and	O
+clinical	O
+trialists	O
+to	O
+determine	O
+whether	O
+sufficient	O
+evidence	O
+exists	O
+to	O
+perform	O
+a	O
+human	B-SPEC
+clinical	O
+trial	O
+.	O
+
+TITLE	O
+:	O
+Severe	O
+flucloxacillin	B-CHED
+-	O
+induced	O
+acute	B-DISO
+generalized	I-DISO
+exanthematous	I-DISO
+pustulosis	I-DISO
+(	O
+AGEP	B-DISO
+),	O
+with	O
+toxic	B-DISO
+epidermal	B-ANAT
+necrolysis	I-DISO
+(	O
+TEN	B-DISO
+)-	O
+like	O
+features	O
+:	O
+does	O
+overlap	O
+between	O
+AGEP	B-DISO
+and	O
+TEN	B-DISO
+exist	O
+?	O
+
+Thus	O
+,	O
+the	O
+inflammatory	B-DISO
+response	I-DISO
+of	O
+Fut9	B-PRGE
+(-/-)	O
+mice	B-SPEC
+was	O
+examined	O
+using	O
+the	O
+highly	O
+neurovirulent	O
+mouse	B-DISO
+hepatitis	I-DISO
+virus	B-SPEC
+(	O
+MHV	B-SPEC
+)	O
+JHMV	O
+srr7	O
+strain	O
+.	O
+
+Furthermore	O
+,	O
+Fut9	B-PRGE
+(-/-)	O
+mice	B-SPEC
+were	O
+refractory	O
+to	O
+the	O
+in	O
+vivo	O
+inoculation	O
+of	O
+endotoxin	O
+(	O
+LPS	B-DISO
+)	O
+compared	O
+with	O
+wild	O
+-	O
+type	O
+mice	B-SPEC
+.	O
+
+These	O
+same	O
+peptides	B-CHED
+had	O
+no	O
+inhibitory	O
+effects	O
+on	O
+infection	B-DISO
+of	O
+Vero	B-ANAT
+cells	I-ANAT
+by	O
+porcine	B-SPEC
+epidemic	I-SPEC
+diarrhea	I-SPEC
+virus	I-SPEC
+(	O
+PEDV	B-SPEC
+).	O
+
+Immunofluoresence	O
+assays	O
+indicated	O
+that	O
+inhibition	B-PROC
+of	O
+PEDV	B-SPEC
+infection	B-DISO
+by	O
+peptide	B-CHED
+H	O
+was	O
+independent	O
+of	O
+pAPN	O
+.	O
+
+ABSTRACT	O
+:	O
+IL	B-FUNC
+-	I-FUNC
+27	I-FUNC
+is	O
+a	O
+pleiotropic	O
+member	O
+of	O
+the	O
+IL	B-FUNC
+-	I-FUNC
+6	I-FUNC
+and	O
+IL	B-PRGE
+-	I-PRGE
+12	I-PRGE
+cytokine	I-PRGE
+family	B-SPEC
+composed	O
+of	O
+the	O
+IL	B-PRGE
+-	I-PRGE
+27p28	I-PRGE
+and	O
+the	O
+EBV	O
+-	O
+induced	O
+gene	O
+3	O
+.	O
+
+Rather	O
+,	O
+it	O
+limits	O
+CNS	B-CHED
+inflammation	B-DISO
+and	O
+impairs	O
+control	O
+of	O
+CNS	B-CHED
+virus	B-PROC
+replication	I-PROC
+via	O
+induction	O
+of	O
+IL	B-FUNC
+-	I-FUNC
+10	I-FUNC
+in	O
+virus	B-SPEC
+-	O
+specific	O
+CD4	B-PRGE
++	I-PRGE
+T	B-ANAT
+cells	I-ANAT
+.	O
+
+We	O
+hypothesised	O
+that	O
+clinical	O
+grade	O
+hMSCs	O
+would	O
+reduce	O
+the	O
+severity	O
+of	O
+acute	O
+lung	B-ANAT
+injury	O
+(	O
+ALI	O
+)	O
+and	O
+would	O
+be	O
+safe	O
+in	O
+a	O
+sheep	B-SPEC
+model	O
+of	O
+ARDS	B-DISO
+.	O
+
+Human	B-SPEC
+MSCs	B-FUNC
+were	O
+well	O
+tolerated	O
+and	O
+improved	O
+oxygenation	B-PROC
+and	O
+decreased	O
+pulmonary	B-DISO
+oedema	I-DISO
+in	O
+a	O
+sheep	B-SPEC
+model	O
+of	O
+severe	O
+ARDS	B-DISO
+.	O
+
+It	O
+is	O
+currently	O
+considered	O
+to	O
+be	O
+one	O
+of	O
+the	O
+leading	O
+causes	O
+of	O
+severe	O
+posttransfusion	O
+morbidity	O
+and	O
+acute	O
+mortality	O
+in	O
+countries	O
+with	O
+a	O
+high	O
+development	B-PROC
+index	O
+.	O
+
+Infectious	B-DISO
+bronchitis	B-DISO
+virus	B-SPEC
+was	O
+detected	O
+by	O
+reverse	O
+-	O
+transcription	B-PROC
+,	O
+real	O
+-	O
+time	O
+PCR	O
+of	O
+the	O
+5	O
+'	O
+untranslated	O
+region	O
+.	O
+
+There	O
+were	O
+similar	O
+frequencies	O
+of	O
+IBV	B-SPEC
+-	O
+positive	O
+flocks	O
+in	O
+farms	O
+from	O
+different	O
+regions	O
+of	O
+the	O
+country	O
+,	O
+most	O
+often	O
+in	O
+broilers	O
+(	O
+average	O
+54	O
+%)	O
+compared	O
+with	O
+breeders	O
+(	O
+average	O
+30	O
+.	O
+8	O
+%).	O
+
+ABSTRACT	O
+:	O
+We	O
+describe	O
+the	O
+isolation	O
+and	O
+sequencing	O
+of	O
+Middle	O
+East	O
+respiratory	O
+syndrome	O
+coronavirus	B-SPEC
+(	O
+MERS	O
+-	O
+CoV	O
+)	O
+obtained	O
+from	O
+a	O
+dromedary	B-SPEC
+camel	B-SPEC
+and	O
+from	O
+a	O
+patient	O
+who	O
+died	B-PROC
+of	O
+laboratory	O
+-	O
+confirmed	O
+MERS	O
+-	O
+CoV	O
+infection	B-DISO
+after	O
+close	O
+contact	O
+with	O
+camels	B-SPEC
+that	O
+had	O
+rhinorrhea	B-DISO
+.	O
+
+TITLE	O
+:	O
+US	O
+-	O
+like	O
+strain	O
+of	O
+porcine	B-SPEC
+epidemic	I-SPEC
+diarrhea	I-SPEC
+virus	I-SPEC
+outbreaks	O
+in	O
+Taiwan	O
+,	O
+2013	O
+-	O
+2014	O
+.	O
+
+Furthermore	O
+,	O
+transplantation	O
+of	O
+differentiated	B-PROC
+RAE	O
+-	O
+1	O
+(-)	O
+allogeneic	O
+NPCs	O
+into	O
+JHMV	O
+-	O
+infected	O
+BALB	O
+/	O
+c	O
+mice	B-SPEC
+resulted	O
+in	O
+enhanced	O
+survival	O
+,	O
+highlighting	O
+a	O
+role	O
+for	O
+the	O
+NKG2D	B-PRGE
+/	O
+RAE	B-PRGE
+-	I-PRGE
+1	I-PRGE
+signaling	B-PROC
+axis	B-SPEC
+in	O
+allograft	B-PATH
+rejection	I-PATH
+.	O
+
+Viral	B-DISO
+infection	I-DISO
+of	O
+cultured	B-ANAT
+cells	I-ANAT
+increased	O
+RAE	B-PRGE
+-	I-PRGE
+1	I-PRGE
+expression	B-PROC
+,	O
+resulting	O
+in	O
+enhanced	O
+NK	B-ANAT
+cell	I-ANAT
+-	O
+mediated	O
+killing	O
+through	O
+NKG2D	B-PRGE
+recognition	O
+.	O
+
+TITLE	O
+:	O
+Structural	O
+and	O
+functional	O
+characterization	O
+of	O
+MERS	B-PRGE
+coronavirus	I-PRGE
+papain	B-ENZY
+-	I-PRGE
+like	I-PRGE
+protease	I-PRGE
+.	O
+
+TITLE	O
+:	O
+Acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+in	O
+patients	O
+with	O
+malignancies	B-DISO
+.	O
+
+ABSTRACT	O
+:	O
+Little	O
+attention	O
+has	O
+been	O
+given	O
+to	O
+ARDS	O
+in	O
+cancer	B-DISO
+patients	O
+,	O
+despite	O
+their	O
+high	O
+risk	O
+for	O
+pulmonary	B-DISO
+complications	I-DISO
+.	O
+
+In	O
+cancer	B-DISO
+patients	O
+,	O
+90	O
+%	O
+of	O
+ARDS	B-DISO
+cases	O
+are	O
+infection	B-DISO
+-	O
+related	O
+,	O
+including	O
+one	O
+-	O
+third	O
+due	O
+to	O
+invasive	O
+fungal	B-DISO
+infections	I-DISO
+.	O
+
+RESULTS	O
+:	O
+Of	O
+1	O
+,	O
+004	O
+included	O
+patients	O
+(	O
+86	O
+%	O
+with	O
+hematological	B-DISO
+malignancies	I-DISO
+and	O
+14	O
+%	O
+with	O
+solid	B-DISO
+tumors	I-DISO
+),	O
+444	O
+(	O
+44	O
+.	O
+2	O
+%)	O
+had	O
+neutropenia	O
+.	O
+
+Risk	O
+factors	O
+for	O
+higher	O
+mortality	O
+were	O
+allogeneic	O
+bone	B-ANAT
+-	O
+marrow	O
+transplantation	O
+,	O
+modified	O
+SOFA	O
+,	O
+NIV	O
+failure	O
+,	O
+severe	O
+ARDS	B-DISO
+,	O
+and	O
+invasive	O
+fungal	B-DISO
+infection	I-DISO
+.	O
+
+Recently	O
+,	O
+the	O
+MERS	O
+-	O
+CoV	O
+receptor	O
+dipeptidyl	B-PRGE
+peptidase	I-PRGE
+4	I-PRGE
+(	O
+DPP4	B-PRGE
+)	O
+was	O
+identified	O
+and	O
+the	O
+specific	O
+interaction	O
+of	O
+the	O
+receptor	O
+-	O
+binding	B-FUNC
+domain	O
+(	O
+RBD	O
+)	O
+of	O
+MERS	B-PRGE
+-	I-PRGE
+CoV	I-PRGE
+spike	I-PRGE
+protein	I-PRGE
+and	O
+DPP4	B-PRGE
+was	O
+determined	O
+by	O
+crystallography	O
+.	O
+
+Modeling	O
+of	O
+the	O
+DPP4	B-PRGE
+and	O
+MERS	O
+-	O
+CoV	O
+RBD	O
+interaction	O
+predicted	O
+the	O
+ability	O
+of	O
+MERS	O
+-	O
+CoV	O
+to	O
+bind	B-FUNC
+the	O
+DPP4s	O
+of	O
+camel	B-SPEC
+,	O
+goat	B-SPEC
+,	O
+cow	B-SPEC
+,	O
+and	O
+sheep	B-SPEC
+.	O
+
+The	O
+inability	O
+of	O
+MERS	O
+-	O
+CoV	O
+to	O
+infect	O
+commonly	O
+used	O
+animal	B-SPEC
+models	O
+,	O
+such	O
+as	O
+hamster	B-SPEC
+,	O
+mice	B-SPEC
+,	O
+and	O
+ferrets	B-SPEC
+,	O
+indicates	O
+the	O
+presence	O
+of	O
+a	O
+species	B-SPEC
+barrier	O
+.	O
+
+ABSTRACT	O
+:	O
+Strongyloides	B-SPEC
+stercoralis	I-SPEC
+hyperinfection	O
+syndrome	B-DISO
+is	O
+a	O
+rare	O
+,	O
+yet	O
+highly	O
+fatal	O
+disorder	O
+.	O
+
+Some	O
+in	O
+vitro	O
+studies	O
+have	O
+indicated	O
+immunological	O
+aspects	O
+of	O
+GAPDH	B-PRGE
+function	O
+,	O
+although	O
+there	O
+is	O
+no	O
+definite	O
+study	O
+discussing	O
+the	O
+advantage	O
+of	O
+GAPDH	B-PRGE
+as	O
+a	O
+therapeutic	O
+target	O
+.	O
+
+In	O
+lung	B-ANAT
+tissue	I-ANAT
+,	O
+LPS	B-DISO
+-	O
+induced	O
+acute	O
+injury	O
+and	O
+neutrophil	B-ANAT
+accumulation	O
+were	O
+strongly	O
+inhibited	O
+by	O
+GAPDH	B-PRGE
+pre	O
+-	O
+injection	O
+.	O
+
+These	O
+data	O
+suggest	O
+the	O
+therapeutic	O
+potential	O
+of	O
+GAPDH	B-PRGE
+for	O
+sepsis	B-DISO
+-	O
+related	O
+ALI	O
+/	O
+ARDS	B-DISO
+.	O
+
+ABSTRACT	O
+:	O
+A	O
+triangular	O
+framework	O
+with	O
+a	O
+terpyridine	O
+and	O
+shielded	O
+phenanthroline	B-CHED
+at	O
+its	O
+termini	O
+constitutes	O
+an	O
+open	O
+/	O
+close	O
+nanoswitch	O
+that	O
+is	O
+toggled	O
+by	O
+chemical	O
+inputs	O
+.	O
+
+TITLE	O
+:	O
+Middle	O
+East	O
+respiratory	O
+syndrome	B-DISO
+coronavirus	B-SPEC
+(	O
+MERS	O
+-	O
+CoV	O
+)	O
+infections	B-DISO
+in	O
+two	O
+returning	O
+travellers	O
+in	O
+the	O
+Netherlands	O
+,	O
+May	O
+2014	O
+.	O
+
+ABSTRACT	O
+:	O
+Two	O
+patients	O
+,	O
+returning	O
+to	O
+the	O
+Netherlands	O
+from	O
+pilgrimage	O
+in	O
+Medina	O
+and	O
+Mecca	O
+,	O
+Kingdom	B-SPEC
+of	O
+Saudi	O
+Arabia	O
+,	O
+were	O
+diagnosed	O
+with	O
+Middle	O
+East	O
+respiratory	O
+syndrome	B-DISO
+coronavirus	B-SPEC
+(	O
+MERS	O
+-	O
+CoV	O
+)	O
+infection	B-DISO
+in	O
+May	O
+2014	O
+.	O
+
+Recently	O
+,	O
+the	O
+occurrence	O
+of	O
+Guillain	O
+-	O
+Barré	O
+Syndrome	B-DISO
+after	O
+major	O
+and	O
+minor	O
+surgical	O
+operations	O
+has	O
+been	O
+increasingly	O
+debated	O
+.	O
+
+Laboratory	O
+tests	O
+revealed	O
+hyponatremia	O
+linked	O
+to	O
+syndrome	B-DISO
+of	I-DISO
+inappropriate	I-DISO
+antidiuretic	I-DISO
+hormone	I-DISO
+secretion	I-DISO
+,	O
+the	O
+patient	O
+'	O
+s	O
+fluids	B-ANAT
+were	O
+restricted	O
+,	O
+and	O
+furosemide	B-CHED
+and	O
+3	O
+%	O
+NaCl	B-CHED
+treatment	O
+was	O
+initiated	O
+.	O
+
+Cerebrospinal	B-ANAT
+fluid	I-ANAT
+examination	O
+showed	O
+320	O
+mg	O
+/	O
+dL	O
+protein	B-CHED
+,	O
+and	O
+acute	O
+motor	O
+-	O
+sensorial	O
+axonal	B-DISO
+neuropathy	I-DISO
+was	O
+identified	O
+by	O
+electromyelography	O
+.	O
+
+ABSTRACT	O
+:	O
+An	O
+essential	O
+function	O
+of	O
+innate	O
+immunity	O
+is	O
+to	O
+distinguish	O
+self	O
+from	O
+non	O
+-	O
+self	O
+and	O
+receptors	O
+have	O
+evolved	O
+to	O
+specifically	O
+recognize	O
+viral	B-ANAT
+components	I-ANAT
+and	O
+initiate	O
+the	O
+expression	B-PROC
+of	O
+antiviral	B-CHED
+proteins	B-CHED
+to	O
+restrict	O
+viral	B-PROC
+replication	I-PROC
+.	O
+
+TITLE	O
+:	O
+[	O
+New	O
+viruses	B-SPEC
+:	O
+myth	O
+,	O
+fantasy	O
+or	O
+reality	O
+?].	O
+
+The	O
+MHV	B-SPEC
+spike	O
+protein	B-CHED
+(	O
+S	O
+)	O
+is	O
+a	O
+major	O
+virulence	B-PROC
+determinant	O
+which	O
+in	O
+addition	O
+to	O
+binding	B-FUNC
+to	O
+cellular	B-COMP
+receptors	O
+to	O
+mediate	O
+cell	B-COMP
+entry	O
+and	O
+facilitate	O
+virus	B-SPEC
+spread	O
+to	O
+adjacent	O
+cells	B-COMP
+by	O
+cell	B-PROC
+-	I-PROC
+cell	B-COMP
+fusion	I-PROC
+,	O
+also	O
+is	O
+a	O
+molecular	O
+mimic	O
+of	O
+the	O
+FcγRII	B-PRGE
+receptor	I-PRGE
+.	O
+
+Mutation	O
+of	O
+the	O
+cysteine	O
+in	O
+position	O
+547	O
+to	O
+alanine	B-CHED
+and	O
+alanine	B-CHED
+replacements	O
+at	O
+residues	O
+581	O
+-	O
+586	O
+was	O
+lethal	O
+.	O
+
+TITLE	O
+:	O
+Epidemiology	O
+and	O
+microbiological	O
+investigations	O
+of	O
+community	O
+-	O
+acquired	O
+pneumonia	B-DISO
+in	O
+children	O
+admitted	O
+at	O
+the	O
+emergency	O
+department	O
+of	O
+a	O
+university	O
+hospital	O
+.	O
+
+Mean	O
+age	O
+was	O
+higher	O
+in	O
+the	O
+case	O
+of	O
+documented	O
+bacterial	B-DISO
+infection	I-DISO
+(	O
+P	O
+<	O
+0	O
+.	O
+05	O
+).	O
+
+Pulmonary	B-DISO
+complication	I-DISO
+related	O
+with	O
+IPEX	B-DISO
+has	O
+not	O
+been	O
+elucidated	O
+exactly	O
+.	O
+
+Here	O
+,	O
+we	O
+report	O
+4	O
+IPEX	B-DISO
+patients	O
+,	O
+3	O
+of	O
+which	O
+died	B-PROC
+from	O
+severe	O
+pulmonary	B-DISO
+disease	I-DISO
+.	O
+
+The	O
+FOXP3	B-PRGE
+gene	I-PRGE
+was	O
+sequenced	O
+and	O
+RNA	O
+analysis	O
+was	O
+performed	O
+.	O
+
+ABSTRACT	O
+:	O
+Previous	O
+trials	O
+of	O
+higher	O
+positive	O
+end	B-PROC
+-	I-PROC
+expiratory	I-PROC
+pressure	O
+(	O
+PEEP	B-CHED
+)	O
+for	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+(	O
+ARDS	B-DISO
+)	O
+failed	O
+to	O
+demonstrate	O
+mortality	O
+benefit	O
+,	O
+possibly	O
+because	O
+of	O
+differences	O
+in	O
+lung	B-ANAT
+recruitability	O
+among	O
+patients	O
+with	O
+ARDS	B-DISO
+.	O
+
+Changes	O
+in	O
+compliance	O
+and	O
+dead	B-PROC
+space	O
+were	O
+not	O
+associated	O
+with	O
+mortality	O
+.	O
+
+TITLE	O
+:	O
+Annotation	B-PRGE
+of	I-PRGE
+long	I-PRGE
+non	I-PRGE
+-	I-PRGE
+coding	I-PRGE
+RNAs	I-PRGE
+expressed	B-PROC
+in	O
+collaborative	O
+cross	O
+founder	B-DISO
+mice	B-SPEC
+in	O
+response	O
+to	O
+respiratory	O
+virus	O
+infection	O
+reveals	O
+a	O
+new	O
+class	B-SPEC
+of	O
+interferon	B-PRGE
+-	O
+stimulated	O
+transcripts	O
+.	O
+
+Sixteen	O
+patients	O
+(	O
+88	O
+.	O
+9	O
+%)	O
+were	O
+discharged	O
+and	O
+another	O
+2	O
+(	O
+11	O
+.	O
+1	O
+%)	O
+remained	O
+comatose	B-DISO
+in	O
+hospital	O
+.	O
+
+TITLE	O
+:	O
+Membrane	B-ANAT
+rearrangements	O
+mediated	O
+by	O
+coronavirus	B-SPEC
+nonstructural	O
+proteins	B-CHED
+3	O
+and	O
+4	O
+.	O
+
+These	O
+structures	O
+,	O
+which	O
+were	O
+able	O
+to	O
+recruit	O
+other	O
+nsps	O
+,	O
+were	O
+only	O
+detected	O
+when	O
+nsp3	B-PRGE
+and	O
+nsp4	B-PRGE
+were	O
+derived	O
+from	O
+the	O
+same	O
+coronavirus	B-SPEC
+species	B-SPEC
+.	O
+
+We	O
+propose	O
+,	O
+based	O
+on	O
+the	O
+analysis	O
+of	O
+a	O
+large	O
+number	O
+of	O
+nsp3	B-PRGE
+and	O
+nsp4	B-PRGE
+mutants	I-PRGE
+,	O
+that	O
+interaction	O
+between	O
+the	O
+large	O
+luminal	B-CHED
+loops	O
+of	O
+these	O
+proteins	B-CHED
+drives	O
+the	O
+formation	B-PROC
+of	O
+membrane	B-COMP
+rearrangements	O
+,	O
+onto	O
+which	O
+the	O
+coronavirus	O
+replication	O
+-	O
+transcription	B-PROC
+complexes	O
+assemble	O
+in	O
+infected	O
+cells	B-COMP
+.	O
+
+Reasons	O
+for	O
+differences	O
+in	O
+the	O
+tissue	B-PROC
+tropism	B-PROC
+and	O
+pathogenicity	O
+between	O
+IBV	B-SPEC
+strains	O
+,	O
+e	O
+.	O
+g	O
+.	O
+a	O
+predilection	O
+for	O
+the	O
+kidneys	B-ANAT
+or	O
+the	O
+oviduct	B-ANAT
+are	O
+still	O
+an	O
+open	O
+question	O
+.	O
+
+As	O
+most	O
+IBV	O
+strains	O
+do	O
+not	O
+infect	O
+permanent	O
+cell	B-ANAT
+lines	I-ANAT
+and	O
+show	O
+infection	B-DISO
+only	O
+in	O
+primary	O
+chicken	B-ANAT
+cells	B-COMP
+of	O
+the	O
+target	O
+organs	B-ANAT
+,	O
+we	O
+developed	O
+a	O
+culture	O
+system	O
+for	O
+chicken	B-SPEC
+oviduct	B-ANAT
+explants	O
+.	O
+
+Two	O
+patients	O
+were	O
+alive	O
+,	O
+with	O
+a	O
+good	O
+immunovirological	O
+profile	O
+and	O
+they	O
+went	O
+back	B-ANAT
+to	O
+their	O
+previous	O
+quality	O
+of	O
+life	O
+.	O
+
+The	O
+seroprevalence	O
+of	O
+FeLV	O
+and	O
+FIV	B-SPEC
+were	O
+8	O
+%	O
+and	O
+8	O
+%,	O
+respectively	O
+.	O
+
+Case	O
+responders	O
+should	O
+be	O
+prepared	O
+for	O
+mass	O
+treatment	O
+of	O
+infectious	B-DISO
+diseases	I-DISO
+and	O
+should	O
+implement	O
+protocols	O
+to	O
+prevent	O
+transmission	O
+of	O
+feline	B-SPEC
+or	O
+zoonotic	O
+infections	B-DISO
+during	O
+the	O
+emergency	B-DISO
+response	O
+and	O
+when	O
+transferring	O
+the	O
+rescued	O
+cats	B-SPEC
+to	O
+other	O
+shelters	O
+or	O
+to	O
+adopters	O
+.	O
+
+ABSTRACT	O
+:	O
+The	O
+influenza	O
+H1N1	O
+epidemics	O
+in	O
+2009	O
+led	O
+a	O
+substantial	O
+number	O
+of	O
+people	O
+to	O
+develop	O
+severe	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+and	O
+refractory	O
+hypoxemia	O
+.	O
+
+We	O
+included	O
+RCTs	O
+of	O
+pharmacologic	O
+therapies	O
+compared	O
+with	O
+placebo	O
+or	O
+no	O
+therapy	O
+for	O
+adult	O
+patients	O
+with	O
+ARDS	B-DISO
+,	O
+using	O
+authors	O
+'	O
+definitions	O
+,	O
+which	O
+reported	O
+on	O
+mortality	O
+(≤	O
+3	O
+months	O
+after	O
+randomization	O
+).	O
+
+Meta	B-SPEC
+-	O
+analysis	O
+of	O
+older	O
+trials	O
+of	O
+prostaglandin	B-CHED
+E1	I-CHED
+also	O
+showed	O
+no	O
+effect	O
+.	O
+
+Moreover	O
+,	O
+a	O
+time	O
+course	O
+study	O
+showed	O
+that	O
+SOCS3	B-PRGE
+level	O
+was	O
+increased	O
+remarkably	O
+in	O
+the	O
+liver	B-ANAT
+of	O
+BALB	O
+/	O
+cJ	O
+mice	B-SPEC
+at	O
+72	O
+h	O
+post	O
+-	O
+infection	B-DISO
+.	O
+
+TITLE	O
+:	O
+Prevalence	O
+of	O
+Pneumocystis	B-SPEC
+jirovecii	I-SPEC
+pneumonia	B-DISO
+(	O
+2010	O
+-	O
+2013	O
+):	O
+the	O
+first	O
+Croatian	O
+report	O
+.	O
+
+Here	O
+,	O
+we	O
+report	O
+the	O
+characterization	O
+of	O
+a	O
+novel	O
+herpesvirus	B-SPEC
+isolated	O
+from	O
+an	O
+Indonesian	O
+pteropodid	O
+bat	B-ENZY
+.	O
+
+Genome	O
+sequence	O
+analysis	O
+suggested	O
+that	O
+the	O
+virus	B-SPEC
+is	O
+a	O
+member	O
+of	O
+the	O
+genus	B-SPEC
+Simplexvirus	I-SPEC
+within	O
+the	O
+subfamily	B-SPEC
+Alphaherpesvirinae	I-SPEC
+,	O
+which	O
+also	O
+includes	O
+common	O
+human	B-SPEC
+viruses	B-SPEC
+,	O
+such	O
+as	O
+herpes	B-SPEC
+simplex	I-SPEC
+virus	I-SPEC
+1	I-SPEC
+and	O
+herpes	B-SPEC
+simplex	I-SPEC
+virus	I-SPEC
+2	I-SPEC
+.	O
+
+However	O
+,	O
+a	O
+large	O
+-	O
+scale	O
+study	O
+on	O
+the	O
+prevalence	O
+of	O
+viral	B-DISO
+infections	I-DISO
+across	O
+multiple	O
+provinces	O
+and	O
+seasons	O
+has	O
+not	O
+been	O
+previously	O
+reported	O
+from	O
+China	O
+.	O
+
+Influenza	B-SPEC
+viruses	I-SPEC
+were	O
+the	O
+main	O
+cause	O
+of	O
+the	O
+ALRIs	O
+in	O
+adults	O
+and	O
+elderly	O
+.	O
+
+ABSTRACT	O
+:	O
+To	O
+present	O
+the	O
+3	O
+-	O
+year	O
+experience	O
+of	O
+using	O
+venovenous	O
+extracorporeal	O
+membrane	B-COMP
+oxygenation	B-PROC
+for	O
+patients	O
+with	O
+severe	O
+respiratory	B-DISO
+failure	I-DISO
+in	O
+a	O
+single	O
+centre	O
+in	O
+Hong	O
+Kong	O
+.	O
+
+RESULTS	O
+:	O
+Overall	O
+,	O
+31	O
+patients	O
+(	O
+mean	O
+age	O
+,	O
+42	O
+.	O
+2	O
+years	O
+,	O
+standard	O
+deviation	O
+,	O
+14	O
+.	O
+1	O
+years	O
+;	O
+21	O
+males	O
+)	O
+received	O
+venovenous	O
+extracorporeal	O
+membrane	B-COMP
+oxygenation	B-PROC
+for	O
+the	O
+treatment	O
+of	O
+severe	O
+respiratory	B-DISO
+failure	I-DISO
+.	O
+
+We	O
+describe	O
+the	O
+use	O
+of	O
+lung	B-ANAT
+ultrasound	O
+imaging	O
+and	O
+findings	O
+in	O
+two	O
+cases	O
+of	O
+severe	O
+respiratory	B-DISO
+failure	I-DISO
+from	O
+avian	B-DISO
+influenza	B-PATH
+A	I-PATH
+(	O
+H7N9	O
+)	O
+infection	B-DISO
+.	O
+
+Lung	B-ANAT
+ultrasound	O
+imaging	O
+may	O
+assist	O
+in	O
+the	O
+efficient	O
+allocation	O
+of	O
+intensive	O
+care	O
+for	O
+patients	O
+with	O
+respiratory	B-DISO
+failure	I-DISO
+from	O
+viral	O
+pulmonary	B-DISO
+infections	I-DISO
+,	O
+especially	O
+in	O
+resource	O
+scarce	O
+settings	O
+or	O
+situations	O
+such	O
+as	O
+future	O
+respiratory	O
+virus	B-SPEC
+outbreaks	O
+or	O
+pandemics	O
+.	O
+
+RESULTS	O
+:	O
+IN	O
+BOTH	B-PRGE
+PATIENTS	I-PRGE
+,	I-PRGE
+CHARACTERISTIC	I-PRGE
+LUNG	I-PRGE
+ULTRASOUND	I-PRGE
+FINDINGS	I-PRGE
+HAVE	I-PRGE
+BEEN	I-PRGE
+OBSERVED	I-PRGE
+AS	I-PRGE
+PREVIOUSLY	I-PRGE
+DESCRIBED	I-PRGE
+IN	I-PRGE
+VIRAL	I-PRGE
+PULMONARY	B-DISO
+INFECTIONS	I-DISO
+:	O
+subpleural	O
+consolidations	O
+associated	O
+or	O
+not	O
+with	O
+local	O
+pleural	B-DISO
+effusion	I-DISO
+.	O
+
+ABSTRACT	O
+:	O
+Programmed	O
+-	O
+1	O
+ribosomal	O
+frameshifting	O
+(-	O
+1PRF	O
+)	O
+is	O
+an	O
+mRNA	B-CHED
+recoding	O
+event	O
+utilized	O
+by	O
+cells	B-COMP
+to	O
+enhance	O
+the	O
+information	O
+content	O
+of	O
+the	O
+genome	O
+and	O
+to	O
+regulate	O
+gene	B-PROC
+expression	I-PROC
+.	O
+
+The	O
+mechanism	O
+of	O
+-	O
+1PRF	O
+and	O
+its	O
+timing	O
+during	O
+translation	B-PROC
+elongation	I-PROC
+are	O
+unclear	O
+.	O
+
+Frameshifting	O
+occurs	O
+at	O
+a	O
+late	O
+stage	O
+of	O
+translocation	B-DISO
+when	O
+the	O
+two	O
+tRNAs	O
+are	O
+bound	O
+to	O
+adjacent	O
+slippery	O
+sequence	O
+codons	O
+of	O
+the	O
+mRNA	B-CHED
+.	O
+
+The	O
+downstream	O
+pseudoknot	O
+in	O
+the	O
+mRNA	B-CHED
+impairs	O
+the	O
+closing	O
+movement	B-PROC
+of	O
+the	O
+30S	B-PRGE
+subunit	I-PRGE
+head	B-ANAT
+,	O
+the	O
+dissociation	B-DISO
+of	O
+EF	B-PRGE
+-	I-PRGE
+G	I-PRGE
+,	O
+and	O
+the	O
+release	B-PATH
+of	O
+tRNA	B-FUNC
+from	O
+the	O
+ribosome	B-COMP
+.	O
+
+TITLE	O
+:	O
+Clinical	O
+and	O
+epidemiological	O
+analysis	O
+of	O
+the	O
+first	O
+case	O
+of	O
+human	B-SPEC
+infection	B-DISO
+with	O
+avian	B-SPEC
+influenza	B-PATH
+A	I-PATH
+(	O
+H7N9	O
+)	O
+virus	B-SPEC
+in	O
+Shenzhen	O
+,	O
+China	O
+.	O
+
+One	O
+of	O
+the	O
+epimers	O
+,	O
+4	O
+-[(	O
+1S	O
+,	O
+3R	O
+,	O
+4R	O
+,	O
+7R	O
+)-	O
+7	O
+-	O
+hydroxy	B-CHED
+-	O
+1	O
+-(	O
+hydroxymethyl	B-CHED
+)-	O
+2	O
+,	O
+5	O
+-	O
+dioxabicyclo	O
+[	O
+2	O
+.	O
+2	O
+.	O
+1	O
+]	O
+heptan	B-CHED
+-	O
+3	O
+-	O
+yl	O
+]-	O
+3	O
+-	O
+oxo	B-CHED
+-	O
+3	O
+,	O
+4	O
+-	O
+dihydropyrazine	O
+-	O
+2	O
+-	O
+carboxamide	B-CHED
+8a	O
+,	O
+with	O
+high	O
+antiviral	B-CHED
+activities	O
+(	O
+IC50	O
+=	O
+7	O
+.	O
+41	O
+,	O
+5	O
+.	O
+63	O
+μm	O
+for	O
+H3N2	B-CHED
+and	O
+H1N1	O
+,	O
+respectively	O
+)	O
+and	O
+remarkable	O
+low	O
+cytotoxicity	B-DISO
+(	O
+TC50	O
+>	O
+200	O
+μm	O
+),	O
+has	O
+great	O
+potential	O
+for	O
+further	O
+development	B-PROC
+as	O
+a	O
+novel	O
+anti	O
+-	O
+influenza	B-PATH
+A	I-PATH
+agent	O
+.	O
+
+The	O
+complete	O
+genome	O
+sequences	O
+of	O
+the	O
+strains	O
+were	O
+identical	O
+or	O
+almost	O
+identical	O
+(	O
+one	O
+synonymous	O
+single	O
+-	O
+nucleotide	B-CHED
+polymorphism	B-PROC
+(	O
+SNP	O
+)	O
+in	O
+the	O
+ORF1a	O
+/	O
+1b	O
+genomic	O
+sequence	O
+).	O
+
+Interestingly	O
+,	O
+comparative	O
+genome	O
+analysis	O
+of	O
+recent	O
+Korean	O
+PEDV	B-SPEC
+isolates	O
+and	O
+other	O
+strains	O
+revealed	O
+that	O
+the	O
+complete	O
+genome	O
+sequences	O
+of	O
+recent	O
+Korean	O
+strains	O
+were	O
+almost	O
+identical	O
+(	O
+99	O
+.	O
+9	O
+%)	O
+to	O
+those	O
+of	O
+the	O
+US	O
+PEDV	B-SPEC
+strains	O
+isolated	O
+in	O
+2013	O
+.	O
+
+Other	O
+stages	O
+including	O
+reverse	B-PROC
+transcription	I-PROC
+initiation	O
+in	O
+retroviruses	B-SPEC
+,	O
+nuclear	B-PROC
+export	I-PROC
+and	O
+viral	B-PROC
+packaging	I-PROC
+are	O
+specifically	O
+dependent	O
+on	O
+the	O
+proper	O
+3	O
+-	O
+dimensional	O
+folding	O
+of	O
+multiple	O
+RNA	O
+domains	O
+to	O
+recruit	O
+necessary	O
+viral	O
+and	O
+host	B-COMP
+factors	O
+required	O
+for	O
+activity	O
+.	O
+
+Preliminary	O
+data	O
+suggest	O
+that	O
+feral	O
+Australian	O
+dromedaries	B-SPEC
+may	O
+be	O
+free	O
+of	O
+MERS	O
+-	O
+CoV	O
+but	O
+larger	O
+confirmatory	O
+studies	O
+are	O
+needed	O
+.	O
+
+ABSTRACT	O
+:	O
+Antibodies	B-COMP
+to	O
+Middle	O
+East	O
+respiratory	O
+syndrome	B-DISO
+coronavirus	B-SPEC
+(	O
+MERS	O
+-	O
+CoV	O
+)	O
+were	O
+detected	O
+in	O
+serum	B-COMP
+and	O
+milk	O
+collected	O
+according	O
+to	O
+local	O
+customs	O
+from	O
+33	O
+camels	B-SPEC
+in	O
+Qatar	O
+,	O
+April	O
+2014	O
+.	O
+
+Analyses	O
+of	O
+flight	B-PROC
+passenger	O
+data	O
+from	O
+ME	O
+countries	O
+indicate	O
+areas	O
+at	O
+high	O
+risk	O
+of	O
+importation	O
+.	O
+
+Additionally	O
+,	O
+regional	O
+ventilation	O
+was	O
+monitored	O
+by	O
+EIT	O
+for	O
+the	O
+evaluation	O
+of	O
+ventilation	O
+in	O
+real	O
+-	O
+time	O
+at	O
+bedside	O
+with	O
+one	O
+prominent	O
+case	O
+of	O
+pneumothorax	B-DISO
+.	O
+
+In	O
+48	O
+cases	O
+(	O
+7	O
+.	O
+0	O
+%	O
+of	O
+the	O
+686	O
+enrolled	O
+patients	O
+;	O
+12	O
+.	O
+6	O
+%	O
+of	O
+the	O
+381	O
+in	O
+whom	O
+a	O
+virus	B-SPEC
+was	O
+detected	O
+)	O
+the	O
+presence	O
+of	O
+a	O
+coronavirus	B-SPEC
+demonstrated	O
+.	O
+
+Acute	B-DISO
+respiratory	I-DISO
+infections	I-DISO
+caused	O
+by	O
+coronavirus	B-SPEC
+mainly	O
+affect	O
+middle	O
+-	O
+aged	O
+male	O
+smokers	O
+,	O
+who	O
+are	O
+often	O
+affected	O
+by	O
+previous	O
+diseases	O
+.	O
+
+The	O
+most	O
+common	O
+clinical	O
+picture	O
+has	O
+been	O
+nonspecific	O
+influenza	B-DISO
+symptoms	O
+.	O
+
+ABSTRACT	O
+:	O
+In	O
+Ohio	O
+,	O
+United	O
+States	O
+,	O
+in	O
+early	O
+2014	O
+,	O
+a	O
+deltacoronavirus	O
+was	O
+detected	O
+in	O
+feces	O
+and	O
+intestine	B-ANAT
+samples	O
+from	O
+pigs	B-SPEC
+with	O
+diarrheal	B-DISO
+disease	I-DISO
+.	O
+
+All	O
+tests	O
+worked	O
+with	O
+effusions	B-DISO
+,	O
+even	O
+when	O
+only	O
+blood	B-ANAT
+products	O
+were	O
+stipulated	O
+in	O
+the	O
+instruction	O
+manual	O
+.	O
+
+For	O
+FCoV	O
+screening	O
+,	O
+speed	O
+and	O
+sensitivity	O
+are	O
+important	O
+,	O
+and	O
+for	O
+FCoV	O
+elimination	B-PROC
+antibody	B-COMP
+titre	O
+is	O
+essential	O
+.	O
+
+While	O
+MERS	O
+-	O
+CoV	O
+is	O
+not	O
+yet	O
+as	O
+contagious	O
+as	O
+seasonal	O
+influenza	B-DISO
+or	O
+the	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+(	O
+SARS	B-DISO
+)	O
+that	O
+started	O
+in	O
+China	O
+and	O
+then	O
+swept	O
+around	O
+the	O
+globe	B-ANAT
+in	O
+2003	O
+,	O
+it	O
+is	O
+more	O
+deadly	O
+.	O
+
+The	O
+World	O
+Health	O
+Organization	O
+reports	O
+that	O
+roughly	O
+one	O
+-	O
+quarter	O
+of	O
+514	O
+people	O
+who	O
+have	O
+tested	O
+positive	O
+for	O
+the	O
+virus	B-SPEC
+have	O
+died	B-PROC
+.	O
+
+This	O
+study	O
+investigated	O
+the	O
+prevalence	O
+of	O
+human	B-SPEC
+coronavirus	I-SPEC
+(	O
+HCoV	O
+)	O
+and	O
+characterized	O
+the	O
+molecular	O
+viral	O
+genetics	O
+.	O
+
+TITLE	O
+:	O
+Etiology	O
+of	O
+severe	O
+community	O
+-	O
+acquired	O
+pneumonia	B-DISO
+during	O
+the	O
+2013	O
+Hajj	O
+-	O
+part	O
+of	O
+the	O
+MERS	O
+-	O
+CoV	O
+surveillance	O
+program	O
+.	O
+
+Haemophilus	B-SPEC
+influenzae	I-SPEC
+and	O
+Streptococcus	B-SPEC
+pneumoniae	I-SPEC
+were	O
+the	O
+predominant	O
+bacteria	B-SPEC
+,	O
+detected	O
+in	O
+57	O
+.	O
+7	O
+%	O
+and	O
+53	O
+.	O
+8	O
+%,	O
+respectively	O
+,	O
+of	O
+the	O
+positive	O
+samples	O
+,	O
+followed	O
+by	O
+Moraxella	B-SPEC
+catarrhalis	I-SPEC
+(	O
+36	O
+.	O
+4	O
+%).	O
+
+We	O
+pause	O
+ventilation	O
+for	O
+20	O
+min	O
+and	O
+determine	O
+T	O
+at	O
+the	O
+meniscus	B-SPEC
+that	O
+is	O
+present	O
+at	O
+the	O
+flooded	O
+alveolar	B-ANAT
+mouth	B-ANAT
+.	O
+
+TITLE	O
+:	O
+Gene	O
+-	O
+expression	B-PROC
+patterns	O
+in	O
+the	O
+cerebral	B-ANAT
+cortex	I-ANAT
+of	O
+mice	B-SPEC
+infected	O
+with	O
+porcine	B-SPEC
+haemagglutinating	O
+encephalomyelitis	O
+virus	B-SPEC
+detected	O
+using	O
+microarray	O
+.	O
+
+TITLE	O
+:	O
+EF1A	B-PRGE
+interacting	O
+with	O
+nucleocapsid	B-PRGE
+protein	B-CHED
+of	O
+transmissible	O
+gastroenteritis	B-DISO
+coronavirus	B-SPEC
+and	O
+plays	O
+a	O
+role	O
+in	O
+virus	O
+replication	O
+.	O
+
+In	O
+vitro	O
+and	O
+in	O
+virus	B-SPEC
+-	O
+infected	O
+cells	B-COMP
+interaction	O
+was	O
+then	O
+confirmed	O
+by	O
+co	O
+-	O
+precipitation	B-PROC
+.	O
+
+The	O
+present	O
+study	O
+thus	O
+provides	O
+a	O
+protein	B-CHED
+-	O
+related	O
+information	O
+that	O
+should	O
+be	O
+useful	O
+for	O
+underlying	O
+mechanism	O
+of	O
+coronavirus	B-SPEC
+replication	O
+.	O
+
+We	O
+present	O
+a	O
+case	O
+of	O
+babesiosis	B-DISO
+presenting	O
+with	O
+ARDS	B-DISO
+.	O
+
+In	O
+this	O
+framework	O
+,	O
+we	O
+will	O
+review	O
+the	O
+recent	O
+findings	O
+on	O
+fluid	O
+strategy	O
+and	O
+edema	B-DISO
+clearance	O
+in	O
+ARDS	B-DISO
+.	O
+
+A	O
+possible	O
+drawback	O
+associated	O
+with	O
+conservative	O
+strategy	O
+is	O
+the	O
+impaired	B-DISO
+cognitive	O
+function	O
+.	O
+
+Beta	B-PRGE
+-	I-PRGE
+2	I-PRGE
+agonist	B-CHED
+therapy	O
+does	O
+not	O
+accelerate	O
+edema	B-DISO
+clearance	O
+and	O
+is	O
+potentially	O
+dangerous	O
+.	O
+
+TITLE	O
+:	O
+Techniques	O
+used	O
+for	O
+the	O
+discovery	O
+of	O
+therapeutic	O
+compounds	O
+:	O
+The	O
+case	O
+of	O
+SARS	B-DISO
+.	O
+
+Sixty	O
+-	O
+one	O
+dogs	B-SPEC
+with	O
+CIRD	O
+and	O
+90	O
+clinically	O
+healthy	O
+dogs	B-SPEC
+from	O
+Southern	O
+Germany	O
+were	O
+prospectively	O
+enrolled	O
+in	O
+this	O
+study	O
+.	O
+
+ABSTRACT	O
+:	O
+Acute	B-DISO
+respiratory	I-DISO
+failure	I-DISO
+with	O
+diffuse	O
+pulmonary	B-ANAT
+opacities	B-DISO
+is	O
+an	O
+unusual	O
+manifestation	O
+following	O
+influenza	B-DISO
+vaccination	O
+.	O
+
+No	O
+disease	O
+recurrence	B-DISO
+was	O
+observed	O
+at	O
+the	O
+6	O
+-	O
+month	O
+follow	O
+-	O
+up	O
+.	O
+
+A	O
+tidal	O
+volume	O
+of	O
+6	O
+ml	O
+/	O
+kg	O
+or	O
+less	O
+was	O
+targeted	B-PROC
+by	O
+76	O
+%	O
+of	O
+respondents	O
+,	O
+and	O
+58	O
+%	O
+targeted	B-PROC
+a	O
+positive	O
+end	B-PROC
+-	I-PROC
+expiratory	I-PROC
+pressure	O
+of	O
+6	O
+-	O
+10	O
+cm	O
+H2O	B-CHED
+while	O
+ventilating	O
+patients	O
+on	O
+VV	O
+-	O
+ECMO	O
+.	O
+
+Although	O
+ventilation	O
+practices	O
+in	O
+patients	O
+supported	O
+by	O
+VV	O
+-	O
+ECMO	O
+vary	O
+across	O
+ELSO	O
+centers	O
+internationally	O
+,	O
+the	O
+majority	O
+of	O
+centers	O
+used	O
+a	O
+strategy	O
+that	O
+targeted	B-PROC
+lung	B-ANAT
+-	O
+protective	O
+thresholds	O
+and	O
+prioritized	O
+weaning	B-PROC
+VV	O
+-	O
+ECMO	O
+over	O
+mechanical	O
+ventilation	O
+.	O
+
+TITLE	O
+:	O
+Infection	B-DISO
+in	O
+severe	O
+asthma	B-PATH
+exacerbations	O
+and	O
+critical	O
+asthma	B-PATH
+syndrome	B-DISO
+.	O
+
+Samples	O
+with	O
+infection	B-DISO
+of	O
+other	O
+respiratory	O
+viruses	B-SPEC
+preserved	O
+in	O
+our	O
+lab	O
+were	O
+used	O
+to	O
+evaluate	O
+specificity	O
+of	O
+this	O
+assay	O
+.	O
+
+No	O
+cross	B-PROC
+reaction	I-PROC
+was	O
+observed	O
+with	O
+other	O
+respiratory	O
+viruses	B-SPEC
+.	O
+
+The	O
+inflammasome	O
+has	O
+evolved	O
+for	O
+this	O
+purpose	O
+and	O
+is	O
+an	O
+important	O
+surveillance	O
+system	O
+that	O
+,	O
+when	O
+triggered	O
+,	O
+fights	O
+infection	B-DISO
+and	O
+eliminates	O
+pathogens	O
+.	O
+
+Here	O
+we	O
+show	O
+that	O
+mouse	B-SPEC
+AKAP7	B-PRGE
+rapidly	O
+degrades	O
+2	O
+-	O
+5A	O
+with	O
+kinetics	O
+similar	O
+to	O
+that	O
+of	O
+murine	B-SPEC
+coronavirus	I-SPEC
+(	O
+mouse	B-DISO
+hepatitis	I-DISO
+virus	B-SPEC
+[	O
+MHV	B-SPEC
+])	O
+strain	O
+A59	B-PRGE
+ns2	I-PRGE
+and	O
+human	B-PRGE
+rotavirus	B-SPEC
+strain	I-PRGE
+WA	I-PRGE
+VP3	I-PRGE
+proteins	B-CHED
+.	O
+
+ns2	B-DISO
+confers	O
+virulence	B-PROC
+by	O
+cleaving	O
+2	O
+',	O
+5	O
+'-	O
+oligoadenylate	O
+(	O
+2	O
+-	O
+5A	O
+)	O
+activators	O
+of	O
+RNase	B-PRGE
+L	I-PRGE
+in	O
+macrophages	B-ANAT
+.	O
+
+INO	B-PRGE
+was	O
+given	O
+for	O
+ARDS	B-DISO
+,	O
+but	O
+coincidentally	O
+it	O
+also	O
+improved	O
+the	O
+raised	B-DISO
+intracranial	I-DISO
+pressure	I-DISO
+(	O
+ICP	B-DISO
+)	O
+and	O
+patient	O
+'	O
+s	O
+neurological	O
+outcome	O
+.	O
+
+The	O
+case	O
+report	O
+will	O
+be	O
+followed	O
+by	O
+literature	O
+review	O
+on	O
+the	O
+role	O
+of	O
+INO	B-PRGE
+in	O
+raised	O
+ICP	B-DISO
+.	O
+
+TITLE	O
+:	O
+Coronavirus	B-SPEC
+infection	I-DISO
+,	O
+ER	O
+stress	O
+,	O
+apoptosis	B-PATH
+and	O
+innate	B-PROC
+immunity	I-PROC
+.	O
+
+Activation	O
+of	O
+the	O
+three	O
+branches	O
+of	O
+UPR	O
+modulates	O
+a	O
+wide	O
+variety	O
+of	O
+signaling	B-PROC
+pathways	B-PROC
+,	O
+such	O
+as	O
+mitogen	B-PRGE
+-	I-PRGE
+activated	I-PRGE
+protein	B-CHED
+(	I-PRGE
+MAP	I-PRGE
+)	I-PRGE
+kinase	I-PRGE
+activation	O
+,	O
+autophagy	B-PROC
+,	O
+apoptosis	B-PATH
+,	O
+and	O
+innate	B-DISO
+immune	I-DISO
+response	I-DISO
+.	O
+
+In	O
+addition	O
+,	O
+some	O
+novel	O
+unique	O
+clusters	B-CHED
+(	O
+UNT	B-CHED
+)	O
+of	O
+HCoV	B-SPEC
+-	I-SPEC
+OC43	I-SPEC
+were	O
+found	O
+in	O
+the	O
+S	O
+-	O
+and	O
+N	O
+-	O
+based	O
+phylogenetic	O
+trees	O
+.	O
+
+TITLE	O
+:	O
+Crystal	B-ANAT
+structure	O
+of	O
+the	O
+papain	B-PRGE
+-	I-PRGE
+like	I-PRGE
+protease	I-PRGE
+of	O
+MERS	O
+coronavirus	B-SPEC
+reveals	O
+unusual	O
+,	O
+potentially	O
+druggable	O
+active	O
+-	O
+site	O
+features	O
+.	O
+
+To	O
+address	O
+this	O
+,	O
+we	O
+investigated	O
+the	O
+effects	O
+of	O
+different	O
+repetitive	O
+peptides	B-CHED
+expressed	B-PROC
+by	O
+L	B-SPEC
+.	I-SPEC
+casei	I-SPEC
+,	O
+specifically	O
+the	O
+MDP	B-PRGE
+and	O
+tuftsin	B-PRGE
+fusion	I-PRGE
+protein	I-PRGE
+(	O
+MT	O
+)	O
+repeated	O
+20	O
+and	O
+40	O
+times	O
+(	O
+20MT	O
+and	O
+40MT	O
+),	O
+in	O
+mice	B-SPEC
+also	O
+expressing	O
+the	O
+D	O
+antigenic	O
+site	O
+of	O
+the	O
+spike	O
+(	O
+S	O
+)	O
+protein	B-CHED
+of	O
+transmissible	O
+gastroenteritis	B-DISO
+virus	B-SPEC
+(	O
+TGEV	B-SPEC
+)	O
+on	O
+intestinal	B-ANAT
+and	O
+systemic	O
+immune	B-PROC
+responses	I-PROC
+and	O
+confirmed	O
+the	O
+immunoregulation	B-PROC
+of	O
+these	O
+peptides	B-CHED
+.	O
+
+The	O
+structural	O
+information	O
+on	O
+these	O
+proteins	B-CHED
+is	O
+also	O
+limited	O
+,	O
+with	O
+only	O
+two	O
+(	O
+p7a	O
+and	O
+p9b	O
+)	O
+having	O
+their	O
+structures	O
+determined	O
+by	O
+X	O
+-	O
+ray	B-SPEC
+crystallography	O
+.	O
+
+TITLE	O
+:	O
+From	O
+SARS	B-DISO
+in	O
+2003	O
+to	O
+H1N1	O
+in	O
+2009	O
+:	O
+lessons	O
+learned	B-PROC
+from	O
+Taiwan	O
+in	O
+preparation	O
+for	O
+the	O
+next	O
+pandemic	O
+.	O
+
+TITLE	O
+:	O
+Risk	O
+factors	O
+for	O
+febrile	B-DISO
+neutropenia	I-DISO
+in	O
+patients	O
+receiving	O
+docetaxel	B-CHED
+chemotherapy	O
+for	O
+castration	O
+-	O
+resistant	O
+prostate	O
+cancer	B-SPEC
+.	O
+
+ABSTRACT	O
+:	O
+Docetaxel	B-CHED
+is	O
+a	O
+standard	O
+therapy	O
+for	O
+patients	O
+with	O
+castration	O
+-	O
+resistant	O
+prostate	B-PATH
+cancer	B-SPEC
+(	O
+CRPC	O
+).	O
+
+However	O
+,	O
+docetaxel	B-CHED
+-	O
+associated	O
+adverse	O
+events	O
+(	O
+AEs	O
+)	O
+such	O
+as	O
+febrile	B-DISO
+neutropenia	I-DISO
+(	O
+FN	O
+)	O
+can	O
+impair	O
+quality	O
+of	O
+life	O
+and	O
+may	O
+become	O
+life	O
+-	O
+threatening	O
+.	O
+
+A	O
+62	O
+-	O
+year	O
+-	O
+old	O
+Caucasian	O
+female	O
+was	O
+admitted	O
+with	O
+septic	B-DISO
+shock	I-DISO
+,	O
+acute	O
+respiratory	B-DISO
+distress	I-DISO
+syndrome	I-DISO
+,	I-DISO
+acute	I-DISO
+renal	B-DISO
+failure	I-DISO
+,	O
+metabolic	B-DISO
+acidosis	I-DISO
+and	O
+disseminated	B-DISO
+intravascular	I-DISO
+coagulation	I-DISO
+after	O
+suffering	B-DISO
+two	O
+small	O
+bites	O
+from	O
+her	O
+dog	B-SPEC
+.	O
+
+ABSTRACT	O
+:	O
+Sixty	O
+-	O
+two	O
+strains	O
+of	O
+avian	O
+infectious	O
+bronchitis	O
+virus	B-SPEC
+(	O
+IBV	B-SPEC
+)	O
+were	O
+isolated	O
+from	O
+diseased	O
+chickens	B-SPEC
+at	O
+different	O
+farms	O
+in	O
+southern	O
+China	O
+during	O
+2011	O
+-	O
+2012	O
+,	O
+and	O
+66	O
+.	O
+1	O
+%	O
+of	O
+the	O
+isolated	O
+strains	O
+were	O
+associated	O
+with	O
+typical	O
+nephritis	B-DISO
+.	O
+
+This	O
+report	O
+highlights	O
+the	O
+benefits	O
+of	O
+combining	O
+MAT	B-FUNC
+and	O
+PCR	O
+methods	O
+in	O
+early	O
+diagnosis	O
+of	O
+leptospirosis	B-DISO
+.	O
+
+Chest	B-ANAT
+X	O
+-	O
+ray	B-SPEC
+analysis	O
+was	O
+suggestive	O
+of	O
+non	O
+-	O
+cardiac	B-ANAT
+pulmonary	B-ANAT
+edema	I-DISO
+in	O
+view	O
+of	O
+bilateral	O
+fluffy	O
+opacity	B-DISO
+without	O
+cardiomegaly	O
+.	O
+
+ABSTRACT	O
+:	O
+In	O
+the	O
+present	O
+study	O
+,	O
+we	O
+aimed	O
+to	O
+determine	O
+whether	O
+mice	B-SPEC
+with	O
+coronavirus	B-SPEC
+-	O
+induced	O
+encephalomyelitis	B-DISO
+(	O
+CIE	B-DISO
+)	O
+develop	O
+neurogenic	O
+bladder	B-DISO
+dysfunction	I-DISO
+that	O
+is	O
+comparable	O
+with	O
+the	O
+neurogenic	O
+detrusor	B-ANAT
+overactivity	O
+observed	O
+in	O
+patients	O
+with	O
+multiple	B-DISO
+sclerosis	I-DISO
+.	O
+
+One	O
+week	O
+after	O
+inoculation	O
+with	O
+the	O
+A59	O
+strain	O
+of	O
+mouse	B-DISO
+hepatitis	I-DISO
+virus	B-SPEC
+,	O
+mice	B-SPEC
+became	O
+increasingly	O
+sensitive	O
+to	O
+von	O
+Frey	O
+filament	B-ANAT
+testing	O
+with	O
+responses	O
+enhanced	O
+by	O
+45	O
+%	O
+(	O
+n	O
+=	O
+8	O
+,	O
+P	O
+≤	O
+0	O
+.	O
+05	O
+vs	O
+.	O
+baseline	O
+at	O
+4	O
+g	O
+);	O
+however	O
+,	O
+this	O
+initial	O
+increase	O
+in	O
+sensitivity	O
+was	O
+followed	O
+by	O
+gradual	O
+and	O
+significant	O
+diminution	O
+of	O
+abdominal	B-ANAT
+sensitivity	O
+to	O
+mechanical	O
+stimulation	O
+by	O
+4	O
+wk	O
+postinoculation	O
+.	O
+
+In	O
+this	O
+study	O
+,	O
+a	O
+codon	O
+-	O
+optimized	O
+PEDV	B-PRGE
+S1	I-PRGE
+gene	I-PRGE
+containing	O
+amino	B-CHED
+acid	I-CHED
+residues	O
+25	O
+-	O
+738	O
+was	O
+synthesized	O
+based	O
+on	O
+a	O
+multiple	O
+alignment	O
+of	O
+the	O
+S	O
+amino	B-CHED
+acid	I-CHED
+sequences	O
+of	O
+PEDV	B-SPEC
+field	O
+isolates	O
+and	O
+used	O
+to	O
+establish	O
+a	O
+stable	O
+porcine	O
+cell	B-ANAT
+line	I-ANAT
+constitutively	O
+expressing	O
+the	O
+PEDV	B-PRGE
+S1	I-PRGE
+protein	B-CHED
+.	O
+
+We	O
+then	O
+tested	O
+the	O
+ability	O
+of	O
+vaccination	O
+with	O
+the	O
+recombinant	B-PRGE
+S1	I-PRGE
+protein	I-PRGE
+to	O
+protect	O
+piglets	O
+against	O
+PEDV	B-SPEC
+.	O
+
+Furthermore	O
+,	O
+direct	O
+inhibition	O
+of	O
+AIF	O
+strongly	O
+impaired	B-DISO
+PEDV	B-SPEC
+infection	B-DISO
+and	O
+virus	B-SPEC
+-	O
+induced	O
+apoptosis	B-PATH
+.	O
+
+Alteration	O
+of	O
+cytokines	O
+profiles	O
+through	O
+manipulation	O
+of	O
+the	O
+innate	O
+immune	B-ANAT
+system	I-ANAT
+by	O
+innate	O
+immune	O
+stimulants	O
+may	O
+be	O
+helpful	O
+in	O
+inhibiting	O
+virus	B-PROC
+replication	I-PROC
+in	O
+otherwise	O
+permissive	O
+cells	B-COMP
+.	O
+
+The	O
+aim	O
+of	O
+present	O
+studies	O
+was	O
+to	O
+characterize	O
+innate	B-DISO
+immune	I-DISO
+responses	I-DISO
+capable	O
+of	O
+inhibiting	O
+infectious	B-DISO
+bronchitis	B-DISO
+virus	B-SPEC
+(	O
+IBV	B-SPEC
+)	O
+replication	O
+in	O
+chicken	B-SPEC
+lungs	B-ANAT
+after	O
+in	O
+ovo	B-SPEC
+administration	O
+of	O
+CpG	B-PRGE
+ODN	I-PRGE
+.	O
+
+Our	O
+data	O
+showed	O
+significant	O
+differential	O
+up	B-PROC
+-	I-PROC
+regulation	I-PROC
+of	O
+IFN	B-PRGE
+-	I-PRGE
+γ	I-PRGE
+,	O
+IL	B-FUNC
+-	I-FUNC
+8	I-FUNC
+(	O
+CXCLi2	O
+)	O
+and	O
+MIP	B-PRGE
+-	I-PRGE
+1β	I-PRGE
+genes	I-PRGE
+and	O
+suppression	B-DISO
+of	O
+IL	B-PRGE
+-	I-PRGE
+6	I-PRGE
+gene	B-PROC
+expression	I-PROC
+being	O
+associated	O
+with	O
+inhibition	B-PROC
+of	O
+IBV	B-SPEC
+replication	O
+in	O
+lungs	B-ANAT
+tissue	I-ANAT
+retrieved	O
+from	O
+embryos	B-ANAT
+pre	O
+-	O
+treated	O
+with	O
+CpG	B-PRGE
+ODN	I-PRGE
+.	O
+
+It	O
+is	O
+expected	O
+that	O
+understanding	O
+of	O
+the	O
+innate	O
+immune	B-PROC
+modulation	I-PROC
+of	O
+target	O
+tissues	B-ANAT
+by	O
+the	O
+virus	B-SPEC
+and	O
+innate	O
+immune	O
+stimulants	O
+will	O
+be	O
+helpful	O
+in	O
+identification	O
+of	O
+valuable	O
+targets	O
+for	O
+development	B-PROC
+of	O
+novel	O
+,	O
+safe	O
+,	O
+effective	O
+and	O
+economical	O
+control	O
+strategies	O
+against	O
+IBV	B-SPEC
+infection	B-DISO
+in	O
+chickens	B-SPEC
+.	O
+
+In	O
+clinical	O
+practice	O
+,	O
+great	O
+efforts	O
+should	O
+be	O
+dedicated	O
+to	O
+improving	O
+the	O
+diagnosis	O
+of	O
+severe	O
+respiratory	B-DISO
+disease	I-DISO
+;	O
+the	O
+introduction	O
+of	O
+innovative	O
+molecular	O
+technologies	O
+,	O
+as	O
+VIDISCA	O
+-	O
+454	O
+,	O
+will	O
+certainly	O
+help	O
+in	O
+reducing	O
+such	O
+""""	O
+diagnostic	O
+gap	O
+.	O
+
+Nasal	O
+mucosa	O
+as	O
+site	O
+of	O
+vaccine	O
+administration	O
+can	O
+stimulate	O
+respiratory	O
+mucosal	B-PROC
+immunity	I-PROC
+by	O
+interacting	O
+with	O
+the	O
+nasopharyngeal	B-ANAT
+-	O
+associated	O
+lymphoid	B-ANAT
+tissues	I-ANAT
+(	O
+NALT	O
+).	O
+
+Some	O
+imidazo	O
+[	O
+4	O
+,	O
+5	O
+-	O
+b	O
+]	O
+pyridines	O
+emerged	O
+as	O
+new	O
+derivatives	O
+endowed	O
+with	O
+antiviral	B-CHED
+activity	O
+against	O
+Vaccinia	B-SPEC
+Virus	I-SPEC
+(	O
+VV	O
+)	O
+at	O
+concentrations	O
+ranging	O
+from	O
+2	O
+to	O
+16	O
+μM	O
+.	O
+In	O
+particular	O
+,	O
+compound	O
+2b	O
+demonstrate	O
+to	O
+be	O
+about	O
+10	O
+times	O
+more	O
+potent	O
+than	O
+Cidofovir	B-CHED
+,	O
+used	O
+as	O
+reference	O
+drug	O
+.	O
+
+Similarly	O
+,	O
+the	O
+imidazo	O
+[	O
+4	O
+,	O
+5	O
+-	O
+c	O
+]	O
+pyridines	B-CHED
+and	O
+N	O
+-	O
+benzylidenequinolinamines	O
+derivatives	O
+resulted	O
+active	O
+against	O
+Bovine	B-DISO
+Viral	I-DISO
+Diarrhoea	I-DISO
+virus	B-SPEC
+(	O
+BVDV	B-SPEC
+),	O
+at	O
+concentrations	O
+ranging	O
+from	O
+1	O
+.	O
+2	O
+to	O
+28	O
+μM	O
+.	O
+Above	O
+all	O
+compounds	O
+1	O
+,	O
+3a	O
+and	O
+3f	O
+showed	O
+an	O
+EC50	O
+of	O
+the	O
+same	O
+order	B-SPEC
+of	O
+magnitude	O
+of	O
+the	O
+reference	O
+drug	O
+,	O
+the	O
+2	O
+'-	O
+C	O
+-	O
+methyl	B-CHED
+-	O
+guanosine	B-CHED
+.	O
+
+ABSTRACT	O
+:	O
+Bivalve	B-SPEC
+shellfish	O
+are	O
+at	O
+constant	O
+risk	O
+of	O
+being	O
+exposed	O
+to	O
+pathogens	O
+as	O
+a	O
+consequence	O
+of	O
+contamination	O
+of	O
+the	O
+shellfish	O
+beds	O
+with	O
+human	O
+or	O
+animal	B-SPEC
+waste	O
+originating	O
+from	O
+sewage	O
+treatment	O
+plants	B-SPEC
+or	O
+slurry	O
+fertilized	O
+fields	O
+.	O
+
+Other	O
+zoonotic	O
+pathogens	O
+such	O
+as	O
+hepatitis	B-SPEC
+E	I-SPEC
+virus	I-SPEC
+(	O
+HEV	B-SPEC
+),	O
+rotavirus	B-SPEC
+(	O
+RV	O
+)	O
+and	O
+Salmonella	B-DISO
+from	O
+livestock	O
+may	O
+also	O
+be	O
+transmitted	B-DISO
+to	O
+shellfish	O
+via	O
+this	O
+route	O
+.	O
+
+Respiratory	O
+viruses	B-SPEC
+were	O
+investigated	O
+from	O
+nasopharyngeal	B-ANAT
+swabs	O
+of	O
+76	O
+patients	O
+diagnosed	O
+with	O
+atypical	B-DISO
+pneumonia	I-DISO
+and	O
+64	O
+healthy	O
+controls	O
+using	O
+the	O
+CLART	O
+Pneumovir	O
+(	O
+Genomica	O
+,	O
+Spain	O
+)	O
+kit	B-FUNC
+and	O
+from	O
+10	O
+mL	O
+blood	B-ANAT
+samples	I-ANAT
+of	O
+the	O
+same	O
+subjects	O
+.	O
+
+Parainfluenza	B-SPEC
+Virus	I-SPEC
+type	I-SPEC
+3	I-SPEC
+and	O
+M	B-SPEC
+.	I-SPEC
+pneumoniae	I-SPEC
+were	O
+found	O
+alone	O
+or	O
+together	O
+as	O
+the	O
+most	O
+common	O
+microorganisms	O
+while	O
+no	O
+cases	O
+of	O
+human	B-SPEC
+bocavirus	I-SPEC
+,	O
+adenovirus	B-DISO
+,	O
+rhinovirus	B-SPEC
+,	O
+or	O
+coronavirus	B-SPEC
+were	O
+detected	O
+.	O
+
+TITLE	O
+:	O
+Development	B-PROC
+and	O
+evaluation	O
+of	O
+a	O
+duplex	O
+real	O
+-	O
+time	O
+RT	O
+-	O
+PCR	O
+for	O
+detection	O
+and	O
+differentiation	B-PROC
+of	O
+virulent	O
+and	O
+variant	O
+strains	O
+of	O
+porcine	O
+epidemic	B-DISO
+diarrhea	I-DISO
+viruses	B-SPEC
+from	O
+the	O
+United	O
+States	O
+.	O
+
+A	O
+new	O
+variant	O
+strain	O
+of	O
+PEDV	B-SPEC
+emerged	O
+in	O
+the	O
+US	O
+in	O
+the	O
+late	O
+December	O
+,	O
+2013	O
+.	O
+
+The	O
+infection	B-DISO
+is	O
+self	O
+-	O
+limited	O
+in	O
+60	O
+%	O
+of	O
+cases	O
+.	O
+
+Manifestations	O
+of	O
+chronic	B-DISO
+disease	I-DISO
+include	O
+residual	O
+nodules	B-DISO
+,	O
+chronic	O
+cavities	B-DISO
+,	O
+persistent	O
+pneumonia	B-DISO
+with	O
+or	O
+without	O
+adenopathy	O
+,	O
+pleural	B-DISO
+effusion	I-DISO
+,	O
+and	O
+regressive	O
+changes	O
+.	O
+
+ABSTRACT	O
+:	O
+The	O
+Severe	B-DISO
+Acute	I-DISO
+Respiratory	I-DISO
+Syndrome	I-DISO
+Coronavirus	B-SPEC
+(	O
+SARS	B-DISO
+-	O
+CoV	O
+)	O
+is	O
+the	O
+etiological	O
+agent	O
+for	O
+the	O
+infectious	B-DISO
+disease	I-DISO
+,	O
+SARS	B-DISO
+,	O
+which	O
+first	O
+emerged	O
+10	O
+years	O
+ago	O
+.	O
+
+Patients	O
+with	O
+RSV	B-PRGE
+B	I-PRGE
+,	O
+hRV	O
+,	O
+or	O
+AdV	O
+tended	O
+to	O
+be	O
+younger	O
+,	O
+and	O
+those	O
+infected	O
+with	O
+RSV	B-SPEC
+A	O
+and	O
+hMPV	B-SPEC
+were	O
+likely	O
+to	O
+be	O
+older	O
+.	O
+
+The	O
+lack	O
+of	O
+assays	O
+to	O
+easily	O
+detect	O
+the	O
+different	O
+steps	O
+of	O
+entry	O
+severely	O
+hampers	O
+the	O
+analysis	O
+of	O
+this	O
+key	O
+process	O
+in	O
+virus	B-DISO
+infection	I-DISO
+.	O
+
+Here	O
+we	O
+describe	O
+novel	O
+,	O
+highly	O
+adaptable	O
+viral	O
+entry	O
+assays	O
+making	O
+use	O
+of	O
+minimal	O
+complementation	O
+of	O
+the	O
+E	B-PRGE
+.	I-PRGE
+coli	I-PRGE
+β	I-PRGE
+-	I-PRGE
+galactosidase	I-PRGE
+in	O
+mammalian	B-SPEC
+cells	B-COMP
+.	O
+
+Serum	O
+albumin	B-PRGE
+(	O
+OR	O
+,	O
+0	O
+.	O
+52	O
+;	O
+95	O
+%	O
+CI	O
+,	O
+0	O
+.	O
+31	O
+-	O
+0	O
+.	O
+87	O
+)	O
+and	O
+Acute	O
+Physiology	O
+and	O
+Chronic	O
+Health	O
+Evaluation	O
+II	O
+score	O
+(	O
+OR	O
+,	O
+1	O
+.	O
+08	O
+;	O
+95	O
+%	O
+CI	O
+,	O
+1	O
+.	O
+04	O
+-	O
+1	O
+.	O
+13	O
+)	O
+on	O
+admission	O
+were	O
+the	O
+most	O
+informative	O
+covariates	O
+for	O
+the	O
+development	B-PROC
+of	O
+ARDS	B-DISO
+in	O
+the	O
+regression	O
+model	O
+.	O
+
+We	O
+conducted	O
+a	O
+systematic	O
+review	O
+and	O
+exploratory	O
+meta	B-SPEC
+-	O
+analysis	O
+to	O
+assess	O
+the	O
+overall	O
+evidence	O
+.	O
+
+We	O
+determined	O
+the	O
+full	O
+genome	O
+sequence	O
+of	O
+a	O
+CoV	O
+directly	O
+from	O
+fecal	B-ANAT
+material	O
+obtained	O
+from	O
+a	O
+South	O
+African	O
+Neoromicia	B-SPEC
+capensis	I-SPEC
+bat	B-ENZY
+(	O
+NeoCoV	O
+).	O
+
+NeoCoV	O
+shared	O
+essential	O
+details	O
+of	O
+genome	O
+architecture	O
+with	O
+MERS	O
+-	O
+CoV	O
+.	O
+Eighty	O
+-	O
+five	O
+percent	O
+of	O
+the	O
+NeoCoV	O
+genome	O
+was	O
+identical	O
+to	O
+MERS	O
+-	O
+CoV	O
+at	O
+the	O
+nucleotide	B-CHED
+level	O
+.	O
+
+The	O
+bat	B-ENZY
+virus	B-SPEC
+roots	O
+the	O
+phylogenetic	O
+tree	O
+of	O
+MERS	O
+-	O
+CoV	O
+,	O
+providing	O
+evidence	O
+for	O
+an	O
+evolution	B-PROC
+of	O
+MERS	O
+-	O
+CoV	O
+in	O
+camels	B-SPEC
+that	O
+preceded	O
+that	O
+in	O
+humans	B-SPEC
+.	O
+
+The	O
+revised	O
+tree	O
+suggests	O
+that	O
+humans	B-SPEC
+are	O
+infected	O
+by	O
+camels	B-SPEC
+rather	O
+than	O
+vice	O
+versa	O
+.	O
+
+Currently	O
+,	O
+there	O
+are	O
+no	O
+specific	O
+drugs	O
+for	O
+prevention	O
+or	O
+treatment	O
+for	O
+MERS	O
+-	O
+CoV	O
+and	O
+vaccine	O
+development	B-PROC
+is	O
+in	O
+the	O
+early	O
+stages	O
+.	O
+
+Like	O
+SARS	B-PRGE
+-	I-PRGE
+CoV	I-PRGE
+,	O
+MERS	O
+-	O
+CoV	O
+threatens	O
+global	O
+health	O
+security	O
+.	O
+
+ABSTRACT	O
+:	O
+Acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+(	O
+ARDS	B-DISO
+)	O
+continues	O
+to	O
+have	O
+significant	O
+mortality	O
+and	O
+morbidity	O
+.	O
+
+The	O
+only	O
+intervention	O
+proven	O
+to	O
+reduce	O
+mortality	O
+is	O
+the	O
+use	O
+of	O
+lung	B-ANAT
+-	O
+protective	O
+mechanical	O
+ventilation	O
+strategies	O
+,	O
+although	O
+such	O
+a	O
+strategy	O
+may	O
+lead	O
+to	O
+problematic	O
+hypercapnia	B-DISO
+.	O
+
+Organ	B-DISO
+failure	I-DISO
+-	O
+free	O
+days	O
+or	O
+ICU	O
+stay	O
+have	O
+not	O
+been	O
+shown	O
+to	O
+decrease	O
+with	O
+ECCOvR	O
+.	O
+Carbon	B-CHED
+dioxide	I-CHED
+removal	O
+was	O
+widely	O
+demonstrated	O
+as	O
+feasible	O
+,	O
+facilitating	O
+the	O
+use	O
+of	O
+lower	O
+tidal	O
+volume	O
+ventilation	O
+.	O
+
+TITLE	O
+:	O
+Regulation	B-PROC
+of	O
+coronaviral	O
+poly	O
+(	O
+A	O
+)	O
+tail	O
+length	O
+during	O
+infection	B-DISO
+is	O
+not	O
+coronavirus	B-SPEC
+species	B-SPEC
+-	O
+or	O
+host	O
+cell	O
+-	O
+specific	O
+.	O
+
+Here	O
+,	O
+we	O
+examined	O
+whether	O
+the	O
+regulation	B-PROC
+of	O
+viral	O
+poly	O
+(	O
+A	O
+)	O
+tail	O
+length	O
+is	O
+cell	B-COMP
+-	O
+type	O
+independent	O
+and	O
+whether	O
+it	O
+is	O
+a	O
+common	O
+feature	O
+of	O
+coronaviruses	O
+to	O
+assess	O
+the	O
+significance	O
+of	O
+the	O
+regulation	B-PROC
+.	O
+
+Modified	O
+Vaccinia	B-SPEC
+Virus	I-SPEC
+Ankara	O
+(	O
+MVA	B-CHED
+)	O
+is	O
+a	O
+replication	O
+-	O
+deficient	O
+viral	O
+vector	O
+that	O
+holds	O
+great	O
+promise	O
+as	O
+a	O
+vaccine	O
+platform	O
+.	O
+
+TITLE	O
+:	O
+Does	O
+form	O
+meet	O
+function	O
+in	O
+the	O
+coronavirus	B-SPEC
+replicative	O
+organelle	B-COMP
+?	O
+
+Two	O
+or	O
+more	O
+viruses	B-SPEC
+were	O
+detected	O
+in	O
+39	O
+.	O
+4	O
+per	O
+cent	O
+of	O
+positive	O
+submissions	O
+,	O
+with	O
+BoCV	O
+and	O
+BRSV	B-SPEC
+most	O
+commonly	O
+present	O
+as	O
+one	O
+of	O
+the	O
+two	O
+partners	O
+in	O
+detection	O
+.	O
+
+TITLE	O
+:	O
+From	O
+SARS	B-DISO
+to	O
+MERS	O
+:	O
+crystallographic	O
+studies	O
+on	O
+coronaviral	O
+proteases	O
+enable	O
+antiviral	B-CHED
+drug	I-CHED
+design	O
+.	O
+
+The	O
+role	O
+of	O
+X	O
+-	O
+ray	B-SPEC
+crystallography	O
+in	O
+structure	O
+-	O
+assisted	O
+drug	O
+discovery	O
+against	O
+these	O
+targets	O
+is	O
+discussed	O
+.	O
+
+The	O
+paper	O
+closes	O
+with	O
+a	O
+brief	O
+discussion	O
+of	O
+structure	O
+-	O
+based	O
+discovery	O
+of	O
+antivirals	B-CHED
+in	O
+an	O
+academic	O
+setting	O
+.	O
+
+The	O
+observed	O
+epidemiology	O
+is	O
+different	O
+to	O
+SARS	B-DISO
+,	O
+which	O
+showed	O
+a	O
+classic	O
+epidemic	O
+curve	O
+and	O
+was	O
+over	O
+in	O
+eight	O
+months	O
+.	O
+
+There	O
+were	O
+statistically	O
+significant	O
+differences	O
+between	O
+groups	O
+in	O
+the	O
+quantities	O
+of	O
+FFP	O
+,	O
+FFP	O
+:	O
+PRBC	O
+,	O
+platelets	O
+,	O
+and	O
+crystalloids	O
+administered	O
+,	O
+as	O
+well	O
+as	O
+the	O
+initial	O
+diastolic	O
+blood	B-PROC
+pressure	I-PROC
+.	O
+
+TITLE	O
+:	O
+Effects	O
+of	O
+therapeutic	O
+approach	O
+on	O
+the	O
+neonatal	O
+evolution	B-PROC
+of	O
+very	O
+low	O
+birth	B-PROC
+weight	O
+infants	O
+with	O
+patent	O
+ductus	O
+arteriosus	O
+.	O
+
+Newborns	O
+who	O
+died	B-PROC
+or	O
+were	O
+transferred	O
+until	O
+the	O
+third	O
+day	O
+of	O
+life	O
+,	O
+and	O
+those	O
+with	O
+presence	O
+of	O
+congenital	B-DISO
+malformation	I-DISO
+or	O
+infection	B-DISO
+were	O
+excluded	O
+.	O
+
+Apgar	O
+score	O
+<	O
+4	O
+,	O
+male	O
+gender	O
+,	O
+Score	O
+for	O
+Neonatal	O
+Acute	O
+Physiology	O
+Perinatal	O
+Extension	O
+(	O
+SNAPPE	O
+II	O
+),	O
+respiratory	B-DISO
+distress	I-DISO
+syndrome	I-DISO
+(	O
+RDS	O
+),	O
+late	O
+sepsis	B-DISO
+(	O
+LS	O
+),	O
+mechanical	O
+ventilation	O
+(	O
+MV	O
+),	O
+surfactant	B-CHED
+(<	O
+2	O
+h	O
+of	O
+life	O
+),	O
+and	O
+time	O
+of	O
+MV	O
+.	O
+
+Theoretical	O
+advantages	O
+of	O
+ECLS	O
+for	O
+respiratory	B-DISO
+failure	I-DISO
+include	O
+the	O
+ability	O
+to	O
+rest	B-FUNC
+the	O
+lungs	B-ANAT
+by	O
+avoiding	O
+injurious	O
+mechanical	O
+ventilator	O
+settings	O
+and	O
+the	O
+potential	O
+to	O
+facilitate	O
+early	O
+mobilization	O
+,	O
+which	O
+may	O
+be	O
+advantageous	O
+for	O
+bridging	O
+to	O
+recovery	O
+or	O
+to	O
+lung	B-ANAT
+transplantation	O
+.	O
+
+The	O
+identification	O
+of	O
+both	O
+the	O
+intermediate	O
+host	B-COMP
+and	O
+the	O
+exact	O
+route	O
+of	O
+transmission	O
+of	O
+MERS	O
+-	O
+CoV	O
+is	O
+crucial	O
+for	O
+the	O
+subsequent	O
+prevention	O
+of	O
+the	O
+introduction	O
+of	O
+the	O
+virus	B-SPEC
+into	O
+the	O
+human	B-SPEC
+population	O
+.	O
+
+Sedation	B-DISO
+depth	O
+was	O
+evaluated	O
+after	O
+48	O
+hours	O
+of	O
+MV	O
+.	O
+
+In	O
+a	O
+multivariate	O
+analysis	O
+,	O
+age	O
+(	O
+Odds	O
+Ratio	O
+(	O
+OR	O
+)	O
+1	O
+.	O
+02	O
+;	O
+95	O
+%	O
+confidence	O
+interval	O
+(	O
+CI	O
+)	O
+1	O
+.	O
+00	O
+to	O
+1	O
+.	O
+03	O
+),	O
+Charlson	O
+Comorbidity	O
+Index	O
+>	O
+2	O
+(	O
+OR	O
+2	O
+.	O
+06	O
+;	O
+95	O
+%	O
+CI	O
+,	O
+1	O
+.	O
+44	O
+to	O
+2	O
+.	O
+94	O
+),	O
+Simplified	O
+Acute	O
+Physiology	O
+Score	O
+3	O
+(	O
+SAPS	O
+3	O
+)	O
+score	O
+(	O
+OR	O
+1	O
+.	O
+02	O
+;	O
+CI	O
+95	O
+%,	O
+1	O
+.	O
+00	O
+to	O
+1	O
+.	O
+04	O
+),	O
+severe	O
+ARDS	B-DISO
+(	O
+OR	O
+1	O
+.	O
+44	O
+;	O
+CI	O
+95	O
+%,	O
+1	O
+.	O
+09	O
+to	O
+1	O
+.	O
+91	O
+)	O
+and	O
+deep	O
+sedation	B-DISO
+(	O
+OR	O
+2	O
+.	O
+36	O
+;	O
+CI	O
+95	O
+%,	O
+1	O
+.	O
+31	O
+to	O
+4	O
+.	O
+25	O
+)	O
+were	O
+independently	O
+associated	O
+with	O
+increased	O
+hospital	O
+mortality	O
+.	O
+
+The	O
+maximal	O
+superimposed	O
+pressure	O
+was	O
+12	O
+±	O
+3	O
+,	O
+12	O
+±	O
+2	O
+,	O
+and	O
+13	O
+±	O
+1	O
+cm	O
+H2O	B-CHED
+in	O
+mild	O
+,	O
+moderate	O
+,	O
+and	O
+severe	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+,	O
+respectively	O
+,	O
+(	O
+P	O
+=	O
+0	O
+.	O
+0533	O
+)	O
+with	O
+a	O
+corresponding	O
+CT	O
+-	O
+derived	O
+PEEP	B-CHED
+of	O
+16	O
+±	O
+5	O
+,	O
+16	O
+±	O
+5	O
+,	O
+and	O
+18	O
+±	O
+5	O
+cm	O
+H2O	B-CHED
+(	O
+P	O
+=	O
+0	O
+.	O
+48	O
+).	O
+
+ABSTRACT	O
+:	O
+Middle	O
+East	O
+respiratory	O
+syndrome	B-DISO
+coronavirus	B-SPEC
+(	O
+MERS	O
+-	O
+CoV	O
+)	O
+is	O
+a	O
+novel	O
+betacoronavirus	B-SPEC
+that	O
+has	O
+been	O
+circulating	O
+in	O
+the	O
+Arabian	O
+Peninsula	O
+since	O
+2012	O
+and	O
+causing	O
+severe	O
+respiratory	B-DISO
+infections	I-DISO
+in	O
+humans	B-SPEC
+.	O
+
+These	O
+data	O
+indicate	O
+that	O
+the	O
+virus	O
+was	O
+circulating	O
+in	O
+this	O
+farm	O
+concurrently	O
+with	O
+its	O
+detection	O
+in	O
+the	O
+camel	B-SPEC
+and	O
+in	O
+the	O
+patient	O
+,	O
+which	O
+warrants	O
+further	O
+investigations	O
+for	O
+the	O
+possible	O
+airborne	O
+transmission	O
+of	O
+MERS	O
+-	O
+CoV	O
+.	O
+Importance	O
+:	O
+This	O
+work	O
+clearly	O
+highlights	O
+the	O
+importance	O
+of	O
+continuous	O
+surveillance	O
+and	O
+infection	B-DISO
+control	O
+measures	O
+to	O
+control	O
+the	O
+global	O
+public	O
+threat	O
+of	O
+MERS	O
+-	O
+CoV	O
+.	O
+While	O
+current	O
+MERS	O
+-	O
+CoV	O
+transmission	O
+appears	O
+to	O
+be	O
+limited	O
+,	O
+we	O
+advise	O
+minimal	O
+contact	O
+with	O
+camels	B-SPEC
+,	O
+especially	O
+for	O
+immunocompromised	O
+individuals	O
+,	O
+and	O
+the	O
+use	O
+of	O
+appropriate	O
+health	O
+,	O
+safety	O
+,	O
+and	O
+infection	B-DISO
+prevention	O
+and	O
+control	O
+measures	O
+when	O
+dealing	O
+with	O
+infected	O
+patients	O
+.	O
+
+TITLE	O
+:	O
+S1	O
+of	O
+distinct	O
+IBV	B-SPEC
+population	O
+expressed	B-PROC
+from	O
+recombinant	O
+adenovirus	B-DISO
+confers	O
+protection	O
+against	O
+challenge	O
+.	O
+
+The	O
+highest	O
+immunoglobulin	B-PRGE
+A	I-PRGE
+(	O
+IgA	B-PRGE
+)	O
+spot	B-SPEC
+-	O
+forming	O
+cell	B-COMP
+(	O
+SFC	B-COMP
+)	O
+response	O
+was	O
+observed	O
+in	O
+the	O
+Harderian	O
+glands	B-ANAT
+(	O
+HG	O
+)	O
+and	O
+to	O
+a	O
+lesser	O
+extent	O
+in	O
+the	O
+spleen	B-ANAT
+and	O
+conjunctiva	B-ANAT
+-	O
+associated	O
+lymphoid	B-ANAT
+tissues	I-ANAT
+,	O
+while	O
+a	O
+limited	O
+IgG	B-PRGE
+SFC	I-PRGE
+response	O
+was	O
+observed	O
+in	O
+either	O
+the	O
+mucosal	B-ANAT
+or	O
+systemic	O
+immune	O
+compartment	B-ANAT
+.	O
+
+Furthermore	O
+,	O
+IgA	B-PRGE
+IBV	B-SPEC
+-	O
+specific	O
+antibody	B-COMP
+levels	O
+significantly	O
+increased	O
+over	O
+controls	O
+3	O
+days	O
+earlier	O
+in	O
+tears	B-ANAT
+and	O
+4	O
+days	O
+earlier	O
+in	O
+plasma	B-ANAT
+than	O
+did	O
+IgG	B-PRGE
+antibodies	I-PRGE
+.	O
+
+Thus	O
+,	O
+lower	O
+mucosal	B-ANAT
+IgA	B-COMP
+antibody	I-COMP
+levels	O
+are	O
+observed	O
+upon	O
+secondary	O
+exposure	O
+to	O
+IBV	B-SPEC
+,	O
+which	O
+may	O
+contribute	O
+to	O
+vulnerability	O
+of	O
+host	B-COMP
+epithelial	B-ANAT
+cells	I-ANAT
+to	O
+infection	B-DISO
+by	O
+IBV	B-SPEC
+and	O
+persistence	O
+of	O
+the	O
+Ark	B-PRGE
+serotype	I-PRGE
+.	O
+
+ABSTRACT	O
+:	O
+Periodic	O
+monitoring	O
+of	O
+poultry	O
+flocks	O
+in	O
+the	O
+United	O
+States	O
+via	O
+molecular	O
+diagnostic	O
+methods	O
+has	O
+revealed	O
+a	O
+number	O
+of	O
+potential	O
+enteric	O
+viral	O
+pathogens	O
+in	O
+continuous	O
+circulation	O
+in	O
+turkeys	B-SPEC
+and	O
+chickens	B-SPEC
+.	O
+
+A	O
+subset	O
+of	O
+sputum	B-ANAT
+samples	O
+positive	O
+for	O
+10	O
+common	O
+viruses	B-SPEC
+by	O
+a	O
+uniplex	O
+RT	O
+-	O
+PCR	O
+was	O
+selected	O
+.	O
+
+TITLE	O
+:	O
+Virus	B-SPEC
+-	O
+specific	O
+memory	B-PROC
+CD8	B-PRGE
+T	I-PRGE
+cells	O
+provide	O
+substantial	O
+protection	O
+from	O
+lethal	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+coronavirus	B-DISO
+infection	I-DISO
+.	O
+
+Several	O
+studies	O
+have	O
+demonstrated	O
+the	O
+role	O
+of	O
+neutralizing	O
+antibodies	B-COMP
+induced	O
+by	O
+the	O
+spike	O
+(	O
+S	O
+)	O
+glycoprotein	B-CHED
+in	O
+protecting	O
+susceptible	O
+hosts	B-COMP
+from	O
+lethal	O
+infection	B-DISO
+.	O
+
+The	O
+spike	O
+protein	B-CHED
+of	O
+MERS	O
+-	O
+CoV	O
+(	O
+MERS	O
+-	O
+S	O
+)	O
+facilitates	O
+viral	O
+entry	B-PROC
+into	I-PROC
+host	I-PROC
+cells	B-COMP
+,	O
+which	O
+depends	O
+on	O
+activation	O
+of	O
+MERS	O
+-	O
+S	O
+by	O
+cellular	B-COMP
+proteases	O
+.	O
+
+ABSTRACT	O
+:	O
+Infiltration	O
+and	O
+runoff	O
+from	O
+manured	O
+agricultural	O
+fields	O
+can	O
+result	O
+in	O
+livestock	O
+pathogens	O
+reaching	B-PROC
+groundwater	O
+and	O
+surface	O
+waters	O
+.	O
+
+Twenty	O
+liters	O
+of	O
+dechlorinated	O
+tap	O
+water	B-CHED
+(	O
+pH	O
+7	O
+)	O
+were	O
+seeded	O
+with	O
+the	O
+test	O
+organisms	O
+,	O
+and	O
+then	O
+passed	O
+through	O
+a	O
+glass	O
+wool	O
+filter	O
+using	O
+a	O
+peristaltic	O
+pump	O
+(	O
+flow	O
+rate	O
+=	O
+1	O
+liter	O
+min	O
+(-	O
+1	O
+)).	O
+
+Glass	O
+wool	O
+filtration	O
+is	O
+a	O
+cost	O
+-	O
+effective	O
+method	O
+for	O
+concentrating	O
+several	O
+waterborne	O
+pathogens	O
+of	O
+bovine	B-SPEC
+origin	O
+simultaneously	O
+,	O
+although	O
+recovery	O
+may	O
+be	O
+low	O
+for	O
+some	O
+specific	O
+taxa	O
+such	O
+as	O
+bovine	B-SPEC
+viral	I-SPEC
+diarrhea	I-SPEC
+virus	I-SPEC
+1	I-SPEC
+.	O
+
+Results	O
+from	O
+the	O
+simulation	O
+analysis	O
+discovered	O
+that	O
+the	O
+relative	O
+errors	O
+and	O
+the	O
+standard	O
+deviations	O
+of	O
+the	O
+Chen	B-SPEC
+[	O
+7	O
+,	O
+8	O
+]	O
+(	O
+method	O
+3	O
+),	O
+Chen	B-SPEC
+[	O
+9	O
+]	O
+(	O
+method	O
+4	O
+)	O
+were	O
+minor	O
+with	O
+high	O
+accuracy	O
+.	O
+
+Circulation	B-PROC
+of	O
+the	O
+virus	B-SPEC
+among	O
+dromedaries	B-SPEC
+across	O
+broad	O
+areas	O
+of	O
+Africa	O
+may	O
+indicate	O
+that	O
+this	O
+disease	O
+is	O
+currently	O
+underdiagnosed	O
+in	O
+humans	B-SPEC
+outside	O
+the	O
+Arabian	O
+Peninsula	O
+.	O
+
+ABSTRACT	O
+:	O
+Both	O
+porcine	B-DISO
+reproductive	B-PROC
+and	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+and	O
+swine	B-DISO
+influenza	I-DISO
+are	O
+acute	O
+,	O
+highly	O
+contagious	O
+swine	B-SPEC
+diseases	O
+.	O
+
+The	O
+HA	O
+and	O
+M1	O
+proteins	B-CHED
+from	O
+the	O
+H3N2	B-CHED
+influenza	B-SPEC
+virus	I-SPEC
+and	O
+the	O
+PRRSV	B-PRGE
+GP5	I-PRGE
+protein	B-CHED
+fused	O
+to	O
+the	O
+cytoplasmic	B-COMP
+and	O
+transmembrane	B-COMP
+domains	O
+of	O
+the	O
+NA	B-PRGE
+protein	I-PRGE
+were	O
+both	O
+incorporated	O
+into	O
+the	O
+chimeric	O
+VLPs	B-ANAT
+.	O
+
+Taken	O
+together	O
+,	O
+the	O
+results	O
+suggested	O
+that	O
+the	O
+chimeric	O
+VLP	B-COMP
+vaccine	O
+represents	O
+a	O
+potential	O
+strategy	O
+for	O
+the	O
+development	B-PROC
+of	O
+a	O
+safe	O
+and	O
+effective	O
+vaccine	O
+to	O
+control	O
+PRRSV	B-SPEC
+and	O
+H3N2	B-CHED
+influenza	B-SPEC
+virus	I-SPEC
+.	O
+
+Detection	O
+rates	O
+vary	O
+between	O
+the	O
+two	O
+sites	O
+for	O
+different	O
+viruses	B-SPEC
+.	O
+
+When	O
+conservative	O
+oxygenation	B-PROC
+methods	O
+fail	O
+,	O
+a	O
+lifesaving	O
+measure	O
+is	O
+the	O
+introduction	O
+of	O
+extracorporeal	O
+membrane	B-COMP
+oxygenation	B-PROC
+(	O
+ECMO	O
+).	O
+
+These	O
+cases	O
+were	O
+mostly	O
+conjoined	O
+to	O
+the	O
+implantation	B-PROC
+phase	O
+or	O
+the	O
+early	O
+postoperative	O
+phase	O
+and	O
+vary	O
+between	O
+right	B-ANAT
+heart	I-ANAT
+perforation	O
+to	O
+migration	B-PROC
+of	O
+the	O
+cannula	B-SPEC
+.	O
+
+This	O
+review	O
+focuses	O
+on	O
+complications	O
+allied	O
+to	O
+commercially	O
+available	O
+dual	O
+-	O
+lumen	B-ANAT
+,	O
+single	O
+,	O
+venovenous	O
+cannula	B-SPEC
+implantation	B-PROC
+,	O
+pointing	O
+out	O
+the	O
+critical	O
+segments	O
+of	O
+the	O
+implantation	B-PROC
+process	O
+and	O
+analyzing	O
+the	O
+structure	O
+of	O
+the	O
+device	O
+.	O
+
+Antibody	B-COMP
+-	O
+dependent	O
+enhancement	O
+(	O
+ADE	B-CHED
+)	O
+is	O
+a	O
+mechanism	O
+through	O
+which	O
+dengue	B-SPEC
+viruses	I-SPEC
+,	O
+feline	B-SPEC
+coronaviruses	O
+,	O
+and	O
+HIV	B-DISO
+viruses	B-SPEC
+take	O
+advantage	O
+of	O
+anti	O
+-	O
+viral	O
+humoral	B-PROC
+immune	I-PROC
+responses	I-PROC
+to	O
+infect	O
+host	B-COMP
+target	B-ANAT
+cells	I-ANAT
+.	O
+
+We	O
+found	O
+that	O
+higher	O
+concentrations	O
+of	O
+anti	O
+-	O
+sera	B-COMP
+against	O
+SARS	B-PRGE
+-	I-PRGE
+CoV	I-PRGE
+neutralized	O
+SARS	B-DISO
+-	I-DISO
+CoV	I-DISO
+infection	I-DISO
+,	O
+while	O
+highly	O
+diluted	O
+anti	B-PRGE
+-	I-PRGE
+sera	I-PRGE
+significantly	O
+increased	O
+SARS	B-DISO
+-	I-DISO
+CoV	I-DISO
+infection	I-DISO
+and	O
+induced	O
+higher	O
+levels	O
+of	O
+apoptosis	B-PATH
+.	O
+
+Describe	O
+the	O
+kinetics	O
+and	O
+pattern	O
+of	O
+viral	O
+excretion	B-PROC
+in	O
+two	O
+infected	O
+patients	O
+.	O
+
+TITLE	O
+:	O
+Coronavirus	B-SPEC
+Nsp10	O
+,	O
+a	O
+critical	O
+co	O
+-	O
+factor	O
+for	O
+activation	O
+of	O
+multiple	O
+replicative	O
+enzymes	O
+.	O
+
+Using	O
+alanine	B-CHED
+-	O
+scanning	O
+mutagenesis	B-PROC
+,	O
+in	O
+cellulo	O
+bioluminescence	B-PROC
+resonance	O
+energy	B-PROC
+transfer	I-PROC
+experiments	O
+,	O
+and	O
+in	O
+vitro	O
+pulldown	O
+assays	O
+,	O
+we	O
+have	O
+now	O
+identified	O
+the	O
+key	O
+residues	O
+on	O
+the	O
+nsp10	O
+surface	O
+that	O
+interact	O
+with	O
+nsp14	O
+.	O
+
+ABSTRACT	O
+:	O
+Hemolytic	O
+-	O
+uremic	O
+syndrome	O
+(	O
+HUS	O
+)	O
+is	O
+a	O
+leading	O
+cause	O
+of	O
+acute	B-DISO
+renal	I-DISO
+failure	I-DISO
+in	O
+infants	O
+and	O
+young	O
+children	O
+.	O
+
+Early	O
+start	O
+of	O
+plasmapheresis	O
+and	O
+meticulous	O
+supportive	O
+treatment	O
+in	O
+the	O
+intensive	O
+care	O
+unit	O
+,	O
+including	O
+renal	B-ANAT
+placement	O
+therapy	O
+,	O
+may	O
+be	O
+the	O
+therapy	O
+of	O
+choice	O
+in	O
+severe	O
+cases	O
+of	O
+HUS	O
+presented	O
+by	O
+MOF	B-DISO
+.	O
+
+TITLE	O
+:	O
+Antibodies	B-COMP
+against	O
+MERS	O
+coronavirus	B-SPEC
+in	O
+dromedary	B-SPEC
+camels	B-SPEC
+,	O
+Kenya	O
+,	O
+1992	O
+-	O
+2013	O
+.	O
+
+ABSTRACT	O
+:	O
+We	O
+obtained	O
+the	O
+full	O
+genome	O
+of	O
+Middle	O
+East	O
+respiratory	O
+syndrome	O
+coronavirus	B-SPEC
+(	O
+MERS	O
+-	O
+CoV	O
+)	O
+from	O
+a	O
+camel	B-SPEC
+in	O
+Qatar	O
+.	O
+
+TITLE	O
+:	O
+Placement	O
+of	O
+a	O
+caudal	B-ANAT
+vena	B-ANAT
+cava	I-ANAT
+stent	O
+for	O
+treatment	O
+of	O
+Budd	O
+-	O
+Chiari	O
+-	O
+like	O
+syndrome	B-DISO
+in	O
+a	O
+4	O
+-	O
+month	O
+-	O
+old	O
+Ragdoll	O
+cat	O
+.	O
+
+The	O
+cat	B-SPEC
+was	O
+anesthetized	O
+,	O
+and	O
+the	O
+subhepatic	O
+portion	O
+of	O
+the	O
+caudal	B-ANAT
+vena	B-ANAT
+cava	I-ANAT
+was	O
+identified	O
+and	O
+accessed	O
+via	O
+median	O
+celiotomy	O
+and	O
+direct	O
+venipuncture	O
+.	O
+
+To	O
+the	O
+authors	O
+'	O
+knowledge	O
+,	O
+this	O
+is	O
+the	O
+first	O
+report	O
+of	O
+successful	O
+treatment	O
+of	O
+a	O
+congenital	O
+caudal	B-ANAT
+vena	B-ANAT
+cava	I-ANAT
+obstruction	B-DISO
+by	O
+means	O
+of	O
+stent	O
+placement	O
+in	O
+a	O
+juvenile	O
+cat	B-SPEC
+.	O
+
+Active	O
+,	O
+prospective	O
+,	O
+continuous	O
+,	O
+hospital	O
+-	O
+based	O
+SARI	O
+surveillance	O
+is	O
+useful	O
+in	O
+supporting	O
+pandemic	O
+preparedness	O
+for	O
+emerging	O
+influenza	B-PATH
+A	I-PATH
+(	O
+H7N9	O
+)	O
+virus	B-SPEC
+infections	B-DISO
+and	O
+seasonal	O
+influenza	B-DISO
+prevention	O
+and	O
+control	O
+.	O
+
+TITLE	O
+:	O
+Faecal	B-ANAT
+virome	O
+of	O
+cats	B-SPEC
+in	O
+an	O
+animal	B-SPEC
+shelter	O
+.	O
+
+ABSTRACT	O
+:	O
+We	O
+describe	O
+the	O
+metagenomics	O
+-	O
+derived	O
+feline	B-SPEC
+enteric	O
+virome	O
+in	O
+the	O
+faeces	B-ANAT
+of	O
+25	O
+cats	B-SPEC
+from	O
+a	O
+single	O
+shelter	O
+in	O
+California	B-SPEC
+.	O
+
+Our	O
+study	O
+shows	O
+that	O
+IAPV	O
+is	O
+established	O
+as	O
+a	O
+persistent	B-DISO
+infection	I-DISO
+in	O
+honey	B-SPEC
+bee	I-SPEC
+populations	O
+,	O
+likely	O
+enabled	O
+by	O
+both	O
+horizontal	O
+and	O
+vertical	B-DISO
+transmission	I-DISO
+pathways	B-PROC
+.	O
+
+The	O
+phenotypic	O
+differences	O
+in	O
+pathology	B-DISO
+among	O
+different	O
+strains	O
+of	O
+IAPV	O
+found	O
+globally	O
+may	O
+be	O
+due	O
+to	O
+high	O
+levels	O
+of	O
+standing	B-PROC
+genetic	O
+variation	O
+.	O
+
+The	O
+evidence	O
+that	O
+silencing	O
+an	O
+IAPV	O
+-	O
+encoded	O
+putative	O
+suppressor	O
+of	O
+RNAi	B-PROC
+reduces	O
+IAPV	O
+replication	O
+suggests	O
+a	O
+functional	O
+assignment	O
+for	O
+a	O
+particular	O
+genomic	O
+region	O
+of	O
+IAPV	O
+and	O
+closely	O
+related	O
+viruses	B-SPEC
+from	O
+the	O
+Family	B-SPEC
+Dicistroviridae	I-SPEC
+,	O
+and	O
+indicates	O
+a	O
+novel	O
+therapeutic	O
+strategy	O
+for	O
+limiting	O
+multiple	O
+honey	B-SPEC
+bee	I-SPEC
+viruses	B-SPEC
+simultaneously	O
+and	O
+reducing	O
+colony	O
+losses	O
+due	O
+to	O
+viral	B-DISO
+diseases	I-DISO
+.	O
+
+Microscopic	O
+examination	O
+provided	O
+the	O
+definitive	O
+diagnosis	O
+of	O
+cause	O
+of	O
+death	B-PROC
+.	O
+
+A	O
+live	O
+attenuated	O
+duck	B-SPEC
+enteritis	I-SPEC
+virus	I-SPEC
+(	O
+DEV	O
+;	O
+a	O
+herpesvirus	B-SPEC
+)	O
+vaccine	O
+has	O
+been	O
+used	O
+routinely	O
+to	O
+control	O
+lethal	O
+DEV	O
+in	O
+ducks	B-SPEC
+since	O
+the	O
+1960s	O
+.	O
+
+After	O
+two	O
+doses	O
+of	O
+recombinant	O
+virus	B-SPEC
+,	O
+rDEV	O
+-	O
+PrM	O
+/	O
+TE	O
+completely	O
+protected	O
+ducks	B-SPEC
+from	O
+DTMUV	O
+challenge	O
+,	O
+whereas	O
+rDEV	O
+-	O
+TE	O
+only	O
+conferred	O
+partial	O
+protection	O
+.	O
+
+TITLE	O
+:	O
+Nucleic	B-ANAT
+acid	I-CHED
+-	O
+based	O
+differential	O
+diagnostic	O
+assays	O
+for	O
+feline	B-SPEC
+coronavirus	B-SPEC
+.	O
+
+Nearly	O
+a	O
+decade	O
+following	O
+the	O
+SARS	B-DISO
+epidemic	O
+,	O
+a	O
+new	O
+coronavirus	B-SPEC
+causing	O
+severe	O
+viral	B-DISO
+pneumonia	I-DISO
+has	O
+emerged	O
+,	O
+i	O
+.	O
+e	O
+.,	O
+middle	O
+east	O
+respiratory	O
+syndrome	B-DISO
+(	O
+MERS	O
+).	O
+
+As	O
+the	O
+rates	O
+of	O
+MS	O
+are	O
+increasing	O
+,	O
+particularly	O
+among	O
+women	O
+,	O
+environmental	O
+factors	O
+such	O
+as	O
+viral	B-DISO
+infections	I-DISO
+are	O
+coming	O
+to	O
+the	O
+foreground	O
+as	O
+potential	O
+agents	O
+in	O
+triggering	O
+disease	O
+in	O
+genetically	O
+susceptible	O
+individuals	O
+.	O
+
+This	O
+review	O
+highlights	O
+pathological	O
+aspects	O
+related	O
+to	O
+two	O
+pre	O
+-	O
+clinical	O
+viral	O
+models	O
+for	O
+MS	O
+;	O
+data	O
+are	O
+consistent	O
+between	O
+these	O
+two	O
+models	O
+as	O
+experimental	O
+infection	B-DISO
+of	O
+susceptible	O
+mice	B-SPEC
+can	O
+induce	O
+axonal	O
+degeneration	B-DISO
+associated	O
+with	O
+demyelination	B-DISO
+.	O
+
+TITLE	O
+:	O
+An	O
+evaluation	O
+of	O
+contaminated	O
+complete	O
+feed	O
+as	O
+a	O
+vehicle	O
+for	O
+porcine	B-SPEC
+epidemic	I-SPEC
+diarrhea	I-SPEC
+virus	B-PROC
+infection	I-PROC
+of	O
+naïve	O
+pigs	B-SPEC
+following	O
+consumption	O
+via	O
+natural	O
+feeding	B-PROC
+behavior	I-PROC
+:	O
+proof	O
+of	O
+concept	O
+.	O
+
+ABSTRACT	O
+:	O
+Since	O
+its	O
+initial	O
+detection	O
+in	O
+May	O
+2013	O
+,	O
+porcine	B-SPEC
+epidemic	I-SPEC
+diarrhea	I-SPEC
+virus	I-SPEC
+(	O
+PEDV	B-SPEC
+)	O
+has	O
+spread	O
+rapidly	O
+throughout	O
+the	O
+US	O
+swine	B-SPEC
+industry	O
+.	O
+
+For	O
+the	O
+purpose	O
+of	O
+a	O
+Positive	O
+control	O
+,	O
+piglets	O
+were	O
+allowed	O
+to	O
+ingest	O
+feed	O
+spiked	O
+with	O
+stock	O
+PEDV	B-SPEC
+(	O
+Ct	O
+=	O
+18	O
+.	O
+23	O
+)	O
+while	O
+the	O
+negative	O
+control	O
+group	O
+received	O
+PEDV	B-SPEC
+-	O
+free	O
+feed	O
+.	O
+
+These	O
+data	O
+provide	O
+proof	O
+of	O
+concept	O
+that	O
+contaminated	O
+complete	O
+feed	O
+can	O
+serve	O
+as	O
+a	O
+vehicle	O
+for	O
+PEDV	B-SPEC
+infection	B-DISO
+of	O
+naïve	O
+pigs	B-SPEC
+using	O
+natural	O
+feeding	B-PROC
+behavior	I-PROC
+.	O
+
+Clinical	O
+signs	O
+of	O
+PEDV	B-SPEC
+infection	B-DISO
+(	O
+vomiting	B-DISO
+and	O
+diarrhea	B-DISO
+)	O
+and	O
+viral	B-DISO
+shedding	I-DISO
+were	O
+observed	O
+in	O
+both	O
+the	O
+Positive	O
+control	O
+and	O
+Treatment	O
+group	O
+'	O
+post	O
+-	O
+consumption	O
+with	O
+virus	B-SPEC
+and	O
+microscopic	O
+lesions	O
+detected	O
+in	O
+intestinal	B-ANAT
+samples	O
+No	O
+evidence	O
+of	O
+infection	B-DISO
+was	O
+observed	O
+in	O
+the	O
+Negative	O
+controls	O
+.	O
+
+Hypoxemia	O
+during	O
+or	O
+immediately	O
+after	O
+the	O
+BAL	B-ENZY
+was	O
+the	O
+most	O
+common	O
+complication	B-DISO
+.	O
+
+TITLE	O
+:	O
+Identification	O
+of	O
+highly	O
+conserved	O
+residues	O
+involved	O
+in	O
+inhibition	B-PROC
+of	O
+HIV	B-SPEC
+-	I-SPEC
+1	I-SPEC
+RNase	B-PRGE
+H	I-PRGE
+function	O
+by	O
+Diketo	O
+acid	O
+derivatives	O
+.	O
+
+To	O
+investigate	O
+the	O
+DKA	O
+binding	B-FUNC
+site	O
+of	O
+RNase	B-PRGE
+H	I-PRGE
+and	O
+the	O
+mechanism	B-PROC
+of	I-PROC
+action	I-PROC
+,	O
+six	O
+couples	O
+of	O
+ester	B-CHED
+and	O
+acid	O
+DKAs	O
+,	O
+derived	O
+from	O
+6	O
+-[	O
+1	O
+-(	O
+4	O
+-	O
+fluorophenyl	O
+)	O
+methyl	B-CHED
+-	O
+1H	B-CHED
+-	I-CHED
+pyrrol	I-CHED
+-	I-CHED
+2	I-CHED
+-	I-CHED
+yl	I-CHED
+)]-	O
+2	O
+,	O
+4	O
+-	O
+dioxo	O
+-	O
+5	O
+-	O
+hexenoic	B-CHED
+acid	I-CHED
+ethyl	B-CHED
+ester	B-CHED
+(	O
+RDS1643	O
+),	O
+were	O
+synthesized	O
+and	O
+tested	O
+on	O
+both	O
+RNase	B-PRGE
+H	I-PRGE
+and	O
+IN	O
+functions	O
+.	O
+
+The	O
+ester	B-CHED
+derivative	O
+RDS1759	O
+selectively	O
+inhibited	O
+RNase	B-FUNC
+H	I-FUNC
+activity	I-FUNC
+and	O
+viral	B-PROC
+replication	I-PROC
+in	O
+the	O
+low	O
+micromolar	O
+range	O
+,	O
+making	O
+contacts	O
+with	O
+residues	O
+Q475	O
+,	O
+N474	O
+,	O
+and	O
+Y501	O
+.	O
+
+The	O
+modification	O
+or	O
+deletion	O
+of	O
+different	O
+motifs	O
+within	O
+E	B-PRGE
+protein	I-PRGE
+,	O
+including	O
+the	O
+transmembrane	B-COMP
+domain	O
+that	O
+harbors	O
+an	O
+ion	B-FUNC
+channel	I-FUNC
+activity	I-FUNC
+,	O
+small	O
+sequences	O
+within	O
+the	O
+middle	O
+region	O
+of	O
+the	O
+carboxy	B-CHED
+-	O
+terminus	O
+of	O
+E	B-PRGE
+protein	I-PRGE
+,	O
+and	O
+its	O
+most	O
+carboxy	B-CHED
+-	O
+terminal	O
+end	O
+,	O
+which	O
+contains	O
+a	O
+PDZ	O
+domain	O
+-	O
+binding	B-FUNC
+motif	O
+(	O
+PBM	O
+),	O
+is	O
+sufficient	O
+to	O
+attenuate	O
+the	O
+virus	B-SPEC
+.	O
+
+These	O
+data	O
+indicate	O
+that	O
+despite	O
+its	O
+small	O
+size	O
+,	O
+E	B-PRGE
+protein	I-PRGE
+drastically	O
+influences	O
+the	O
+replication	O
+of	O
+CoVs	O
+and	O
+their	O
+pathogenicity	O
+.	O
+
+MHV	B-SPEC
+-	O
+induced	O
+macropinocytosis	B-PROC
+requires	O
+fusogenic	O
+spike	O
+protein	B-CHED
+on	O
+the	O
+cell	B-COMP
+surface	I-COMP
+and	O
+is	O
+dependent	O
+on	O
+epidermal	B-PRGE
+growth	B-PROC
+factor	I-PRGE
+receptor	B-PROC
+activation	I-PROC
+.	O
+
+Macropinocytosis	B-PROC
+is	O
+induced	O
+by	O
+many	O
+pathogens	O
+to	O
+enter	O
+host	B-COMP
+cells	B-COMP
+,	O
+but	O
+other	O
+functions	O
+for	O
+macropinocytosis	B-PROC
+in	O
+virus	B-PROC
+replication	I-PROC
+are	O
+unknown	O
+.	O
+
+The	O
+negative	O
+results	O
+contrast	O
+with	O
+the	O
+high	O
+prevalence	O
+of	O
+coronaviruses	O
+detected	O
+in	O
+fecal	B-ANAT
+pellets	O
+from	O
+live	O
+-	O
+captured	O
+bats	B-SPEC
+in	O
+some	O
+European	O
+countries	O
+.	O
+
+We	O
+report	O
+a	O
+rare	O
+case	O
+of	O
+19	O
+-	O
+year	O
+-	O
+old	O
+young	O
+male	O
+patient	O
+with	O
+complaint	O
+of	O
+severe	O
+ill	B-DISO
+-	O
+defined	O
+type	O
+of	O
+pain	O
+in	O
+both	O
+jaws	B-ANAT
+associated	O
+with	O
+plaques	B-DISO
+and	O
+papules	O
+on	O
+extensor	B-ANAT
+surfaces	O
+of	O
+upper	O
+and	O
+lower	B-ANAT
+extremities	I-ANAT
+with	O
+bodyache	O
+and	O
+myalgia	B-DISO
+.	O
+
+ABSTRACT	O
+:	O
+Host	O
+genetic	O
+factors	O
+are	O
+thought	O
+to	O
+modulated	O
+the	O
+severity	O
+of	O
+disease	O
+caused	O
+by	O
+infection	B-DISO
+with	O
+the	O
+2009	O
+H1N1	O
+pandemic	O
+influenza	B-SPEC
+virus	I-SPEC
+(	O
+H1N1pdm09	O
+).	O
+
+We	O
+recruited	O
+29	O
+H1N1pdm09	O
+infected	O
+subjects	O
+from	O
+Southern	O
+Europe	O
+(	O
+mostly	O
+Italians	O
+)	O
+with	O
+a	O
+wide	O
+clinical	O
+spectrum	O
+of	O
+disease	O
+symptoms	O
+;	O
+the	O
+sample	O
+included	O
+7	O
+subjects	O
+who	O
+developed	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+requiring	O
+extracorporeal	O
+membrane	B-COMP
+oxygenation	B-PROC
+.	O
+
+Protease	B-PROC
+inhibitors	I-PROC
+blocking	B-DISO
+the	O
+replication	O
+of	O
+coronavirus	B-SPEC
+(	O
+CoV	O
+),	O
+including	O
+the	O
+causative	O
+agents	O
+of	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+(	O
+SARS	B-DISO
+)	O
+and	O
+Middle	O
+East	O
+respiratory	O
+syndrome	B-DISO
+(	O
+MERS	O
+),	O
+provide	O
+a	O
+promising	O
+foundation	O
+for	O
+the	O
+development	B-PROC
+of	O
+anticoronaviral	O
+therapeutics	O
+.	O
+
+Using	O
+reverse	O
+genetics	O
+to	O
+generate	O
+isogenic	O
+viruses	B-SPEC
+with	O
+mutant	B-DISO
+3CLpros	O
+,	O
+we	O
+found	O
+that	O
+viruses	B-SPEC
+encoding	O
+double	O
+-	O
+mutant	B-DISO
+3CLpros	O
+are	O
+fully	O
+resistant	O
+to	O
+the	O
+inhibitor	B-CHED
+and	O
+exhibit	O
+a	O
+significant	O
+delay	O
+in	O
+proteolytic	B-PROC
+processing	I-PROC
+of	O
+the	O
+viral	B-PRGE
+replicase	I-PRGE
+polyprotein	I-PRGE
+.	O
+
+Biochemical	O
+analysis	O
+verified	O
+double	O
+-	O
+mutant	B-DISO
+3CLpro	O
+enzyme	O
+as	O
+impaired	B-DISO
+for	O
+protease	B-PROC
+activity	I-PROC
+and	O
+exhibiting	O
+reduced	O
+sensitivity	O
+to	O
+the	O
+inhibitor	B-CHED
+and	O
+revealed	O
+a	O
+delayed	O
+kinetics	O
+of	O
+inhibitor	B-CHED
+hydrolysis	O
+and	O
+activity	O
+restoration	O
+.	O
+
+Furthermore	O
+,	O
+the	O
+inhibitor	B-CHED
+-	O
+resistant	O
+virus	B-SPEC
+was	O
+shown	O
+to	O
+be	O
+highly	O
+attenuated	O
+in	O
+mice	B-SPEC
+.	O
+
+We	O
+used	O
+this	O
+system	O
+to	O
+demonstrate	O
+the	O
+in	O
+vivo	O
+efficacy	O
+of	O
+an	O
+inhibitor	B-CHED
+of	O
+the	O
+papain	B-PRGE
+-	I-PRGE
+like	I-PRGE
+protease	I-PRGE
+of	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+coronavirus	B-SPEC
+.	O
+
+He	O
+was	O
+treated	O
+with	O
+antibiotics	B-CHED
+,	O
+intravenous	O
+immunoglobulin	B-PROC
+,	O
+and	O
+oxygen	B-CHED
+by	O
+nasal	B-ANAT
+cannula	B-SPEC
+.	O
+
+US	O
+clinicians	O
+must	O
+be	O
+vigilant	O
+for	O
+MERS	O
+-	O
+CoV	O
+in	O
+patients	O
+with	O
+febrile	B-PROC
+and	O
+/	O
+or	O
+respiratory	O
+illness	O
+with	O
+recent	O
+travel	O
+to	O
+the	O
+Arabian	O
+Peninsula	O
+,	O
+especially	O
+among	O
+healthcare	O
+workers	O
+.	O
+
+M133	O
+Tregs	O
+inhibited	O
+the	O
+proliferation	B-DISO
+but	O
+not	O
+initial	O
+activation	O
+of	O
+M133	O
+Tconv	O
+in	O
+draining	O
+lymph	B-ANAT
+nodes	I-ANAT
+(	O
+DLN	O
+).	O
+
+Thus	O
+,	O
+virus	B-SPEC
+-	O
+specific	O
+Tregs	O
+inhibited	O
+pathogenic	O
+CD4	B-PRGE
+T	I-PRGE
+cell	O
+responses	O
+during	O
+priming	O
+and	O
+effector	B-CHED
+stages	O
+,	O
+particularly	O
+those	O
+recognizing	O
+cognate	O
+antigen	B-CHED
+,	O
+and	O
+decreased	O
+mortality	O
+and	O
+morbidity	O
+without	O
+affecting	O
+virus	B-SPEC
+clearance	O
+.	O
+
+Therefore	O
+,	O
+it	O
+is	O
+urgently	O
+necessary	O
+to	O
+develop	O
+as	O
+many	O
+specific	O
+genetic	O
+diagnostic	O
+methods	O
+as	O
+possible	O
+to	O
+allow	O
+stable	O
+diagnosis	O
+of	O
+MERS	O
+-	O
+CoV	O
+infections	B-DISO
+.	O
+
+Reverse	B-PROC
+transcription	I-PROC
+-	O
+loop	O
+-	O
+mediated	O
+isothermal	O
+amplification	B-DISO
+(	O
+RT	O
+-	O
+LAMP	O
+)	O
+is	O
+a	O
+genetic	O
+diagnostic	O
+method	O
+used	O
+widely	O
+for	O
+the	O
+detection	O
+of	O
+viral	O
+pathogens	O
+,	O
+which	O
+requires	O
+only	O
+a	O
+single	O
+temperature	O
+for	O
+amplification	B-DISO
+,	O
+and	O
+can	O
+be	O
+completed	O
+in	O
+less	O
+than	O
+1	O
+h	O
+.	O
+This	O
+study	O
+developed	O
+a	O
+novel	O
+RT	O
+-	O
+LAMP	O
+assay	O
+for	O
+detecting	O
+MERS	O
+-	O
+CoV	O
+using	O
+primer	O
+sets	O
+targeting	O
+a	O
+conserved	B-PRGE
+nucleocapsid	I-PRGE
+protein	B-CHED
+region	O
+.	O
+
+We	O
+did	O
+a	O
+prospective	O
+,	O
+matched	O
+,	O
+case	O
+-	O
+control	O
+study	O
+in	O
+Niger	B-SPEC
+between	O
+Aug	O
+1	O
+,	O
+2001	O
+,	O
+and	O
+Oct	B-PRGE
+31	I-PRGE
+,	O
+2006	O
+,	O
+in	O
+children	O
+younger	O
+than	O
+12	O
+years	O
+to	O
+assess	O
+risk	O
+factors	O
+for	O
+acute	O
+noma	B-DISO
+.	O
+
+After	O
+inclusion	O
+of	O
+microbiological	O
+data	O
+,	O
+a	O
+reduced	O
+proportion	O
+of	O
+Fusobacterium	B-SPEC
+(	O
+4	O
+·	O
+63	O
+,	O
+1	O
+·	O
+61	O
+-	O
+13	O
+·	O
+35	O
+),	O
+Capnocytophaga	B-SPEC
+(	O
+3	O
+·	O
+69	O
+,	O
+1	O
+·	O
+48	O
+-	O
+9	O
+·	O
+17	O
+),	O
+Neisseria	B-SPEC
+(	O
+3	O
+·	O
+24	O
+,	O
+1	O
+·	O
+10	O
+-	O
+9	O
+·	O
+55	O
+),	O
+and	O
+Spirochaeta	B-SPEC
+in	O
+the	O
+mouth	B-ANAT
+(	O
+7	O
+·	O
+77	O
+,	O
+2	O
+·	O
+12	O
+-	O
+28	O
+·	O
+42	O
+),	O
+and	O
+an	O
+increased	O
+proportion	O
+of	O
+Prevotella	B-SPEC
+(	O
+2	O
+·	O
+53	O
+,	O
+1	O
+·	O
+07	O
+-	O
+5	O
+·	O
+98	O
+),	O
+were	O
+associated	O
+with	O
+noma	B-DISO
+.	O
+
+ABSTRACT	O
+:	O
+The	O
+coronavirus	B-SPEC
+nucleocapsid	B-ANAT
+(	O
+N	O
+)	O
+is	O
+a	O
+structural	O
+protein	B-CHED
+that	O
+forms	O
+complexes	O
+with	O
+genomic	O
+RNA	O
+,	O
+interacts	O
+with	O
+the	O
+viral	B-COMP
+membrane	I-COMP
+protein	B-CHED
+during	O
+virion	B-PROC
+assembly	I-PROC
+and	O
+plays	O
+a	O
+critical	O
+role	O
+in	O
+enhancing	O
+the	O
+efficiency	O
+of	O
+virus	B-SPEC
+transcription	B-PROC
+and	O
+assembly	O
+.	O
+
+ABSTRACT	O
+:	O
+Tracheal	B-ANAT
+mucosa	I-ANAT
+is	O
+the	O
+primary	O
+site	O
+of	O
+replication	O
+of	O
+avian	B-DISO
+infectious	I-DISO
+bronchitis	I-DISO
+virus	B-SPEC
+(	O
+IBV	B-SPEC
+),	O
+which	O
+leads	O
+to	O
+both	O
+morphologic	O
+and	O
+immune	O
+modulatory	O
+changes	O
+in	O
+this	O
+organ	B-ANAT
+.	O
+
+The	O
+severity	O
+of	O
+clinical	O
+manifestations	O
+is	O
+directly	O
+related	O
+to	O
+the	O
+degree	O
+of	O
+CD18	B-PRGE
+deficiency	O
+.	O
+
+However	O
+,	O
+the	O
+risk	O
+of	O
+P	B-SPEC
+.	I-SPEC
+vivax	I-SPEC
+resulting	O
+in	O
+complicated	B-DISO
+malaria	I-DISO
+and	O
+mortality	O
+is	O
+not	O
+as	O
+firmly	O
+established	O
+as	O
+it	O
+is	O
+with	O
+Plasmodium	B-SPEC
+falciparum	I-SPEC
+.	O
+
+Severe	O
+malaria	B-PATH
+was	O
+defined	O
+as	O
+per	O
+the	O
+World	O
+Health	O
+Organization	O
+'	O
+s	O
+guidelines	O
+.	O
+
+Nevertheless	O
+,	O
+its	O
+high	O
+recombination	B-PROC
+rate	O
+may	O
+result	O
+in	O
+the	O
+loss	O
+of	O
+the	O
+full	O
+-	O
+length	O
+foreign	O
+gene	O
+,	O
+limiting	O
+their	O
+use	O
+as	O
+vectors	O
+.	O
+
+Further	O
+improvement	O
+of	O
+TGEV	B-SPEC
+-	O
+derived	O
+vectors	O
+will	O
+require	O
+the	O
+engineering	O
+of	O
+vectors	O
+with	O
+decreased	O
+recombination	B-PROC
+rate	O
+.	O
+
+Advances	O
+in	O
+medical	O
+and	O
+ventilatory	O
+management	O
+of	O
+severe	O
+lung	B-ANAT
+injury	O
+and	O
+ARDS	B-DISO
+have	O
+improved	O
+outcomes	O
+in	O
+some	O
+patients	O
+,	O
+but	O
+these	O
+advances	O
+fail	O
+to	O
+consistently	O
+""""	O
+rescue	O
+""""	O
+a	O
+significant	O
+proportion	O
+of	O
+those	O
+affected	O
+.	O
+
+ABSTRACT	O
+:	O
+Extracorporeal	O
+membrane	B-ANAT
+oxygenation	B-PROC
+(	O
+ECMO	O
+)	O
+and	O
+extracorporeal	O
+CO	O
+(	O
+2	O
+)	O
+removal	O
+(	O
+ECCO	O
+(	O
+2	O
+)	O
+R	O
+)	O
+techniques	O
+have	O
+increasingly	O
+been	O
+applied	O
+in	O
+patients	O
+with	O
+severe	O
+acute	O
+lung	B-ANAT
+injury	O
+refractory	O
+to	O
+conventional	O
+mechanical	O
+ventilatory	O
+support	O
+.	O
+
+The	O
+objectives	O
+of	O
+this	O
+article	O
+are	O
+to	O
+review	O
+current	O
+concepts	O
+of	O
+extracorporeal	O
+life	O
+support	O
+techniques	O
+(	O
+ECMO	O
+and	O
+ECCO	O
+(	O
+2	O
+)	O
+R	O
+systems	O
+)	O
+and	O
+provide	O
+the	O
+rationale	O
+for	O
+their	O
+application	O
+in	O
+patients	O
+with	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+,	O
+chronic	B-DISO
+obstruction	I-DISO
+pulmonary	B-DISO
+disease	I-DISO
+,	O
+and	O
+as	O
+adjunctive	O
+therapy	O
+for	O
+bridging	O
+patients	O
+to	O
+lung	B-ANAT
+transplantation	O
+.	O
+
+TITLE	O
+:	O
+Emergent	O
+severe	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+caused	O
+by	O
+adenovirus	B-DISO
+type	O
+55	O
+in	O
+immunocompetent	O
+adults	O
+in	O
+2013	O
+:	O
+a	O
+prospective	O
+observational	O
+study	O
+.	O
+
+We	O
+conducted	O
+a	O
+prospective	O
+,	O
+single	O
+-	O
+center	O
+observational	O
+study	O
+of	O
+pneumonia	B-DISO
+with	O
+ARDS	B-DISO
+in	O
+immunocompetent	O
+adults	O
+admitted	O
+to	O
+our	O
+respiratory	O
+ICU	O
+.	O
+
+The	O
+results	O
+for	O
+a	O
+total	O
+of	O
+five	O
+consecutive	O
+patients	O
+with	O
+severe	O
+ARDS	B-DISO
+with	O
+confirmed	O
+HAdV	O
+-	O
+55	O
+infection	B-DISO
+were	O
+included	O
+.	O
+
+The	O
+mean	O
+time	O
+from	O
+onset	O
+to	O
+dyspnea	B-DISO
+was	O
+5	O
+days	O
+.	O
+
+Thus	O
+,	O
+palmitoylation	B-PROC
+of	O
+the	O
+S	B-PRGE
+protein	I-PRGE
+of	O
+Alphacoronaviruses	O
+is	O
+dispensable	O
+for	O
+S	O
+-	O
+M	O
+interaction	O
+,	O
+but	O
+required	O
+for	O
+the	O
+generation	O
+of	O
+progeny	O
+virions	B-COMP
+.	O
+
+Believed	O
+to	O
+have	O
+originated	O
+from	O
+bats	B-SPEC
+,	O
+MERS	O
+-	O
+CoV	O
+is	O
+genetically	O
+related	O
+to	O
+bat	B-ENZY
+coronaviruses	O
+HKU4	O
+and	O
+HKU5	O
+.	O
+
+To	O
+understand	O
+how	O
+bat	B-ENZY
+coronaviruses	O
+transmit	O
+to	O
+humans	B-SPEC
+,	O
+we	O
+investigated	O
+the	O
+receptor	O
+usage	O
+and	O
+cell	B-COMP
+entry	O
+activity	O
+of	O
+the	O
+virus	B-SPEC
+-	O
+surface	O
+spike	O
+proteins	B-CHED
+of	O
+HKU4	O
+and	O
+HKU5	O
+.	O
+
+Second	O
+,	O
+in	O
+the	O
+absence	O
+of	O
+exogenous	O
+proteases	O
+,	O
+both	O
+MERS	O
+-	O
+CoV	O
+and	O
+HKU4	O
+spikes	O
+mediate	O
+pseudovirus	O
+entry	O
+into	O
+bat	B-ENZY
+cells	B-COMP
+,	O
+whereas	O
+only	O
+MERS	O
+-	O
+CoV	O
+spike	O
+,	O
+but	O
+not	O
+HKU4	O
+spike	O
+,	O
+mediates	O
+pseudovirus	O
+entry	O
+into	O
+human	O
+cells	B-COMP
+.	O
+
+These	O
+results	O
+establish	O
+DPP4	B-PRGE
+as	O
+a	O
+functional	O
+receptor	O
+for	O
+HKU4	O
+and	O
+host	B-PRGE
+cellular	B-COMP
+proteases	I-PRGE
+as	O
+a	O
+host	B-COMP
+range	O
+determinant	O
+for	O
+HKU4	O
+.	O
+
+They	O
+also	O
+suggest	O
+that	O
+DPP4	B-PRGE
+-	O
+recognizing	O
+bat	B-ENZY
+coronaviruses	O
+threaten	O
+human	B-SPEC
+health	O
+because	O
+of	O
+their	O
+spikes	O
+'	O
+capability	O
+to	O
+adapt	O
+to	O
+human	B-SPEC
+cells	B-COMP
+for	O
+cross	O
+-	O
+species	B-SPEC
+transmissions	O
+.	O
+
+The	O
+aim	O
+of	O
+the	O
+present	O
+study	O
+was	O
+to	O
+characterize	O
+a	O
+murine	O
+model	O
+of	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+(	O
+ARDS	B-DISO
+)	O
+abiding	O
+by	O
+the	O
+Berlin	O
+definition	O
+of	O
+human	B-DISO
+ARDS	I-DISO
+and	O
+guidelines	O
+for	O
+animal	B-SPEC
+models	O
+of	O
+ARDS	B-DISO
+.	O
+
+Patients	O
+with	O
+fibrosis	B-DISO
+on	O
+CT	O
+had	O
+lower	O
+response	O
+to	O
+steroids	B-CHED
+(	O
+OR	O
+,	O
+0	O
+.	O
+03	O
+;	O
+(	O
+0	O
+.	O
+005	O
+-	O
+0	O
+.	O
+21	O
+)).	O
+
+Mortality	O
+is	O
+high	O
+in	O
+ILD	B-PRGE
+-	I-PRGE
+associated	I-PRGE
+ARF	I-PRGE
+.	O
+
+Here	O
+,	O
+we	O
+expressed	B-PROC
+and	O
+purified	O
+the	O
+cytoplasmic	B-ANAT
+domain	I-ANAT
+of	O
+the	O
+3a	O
+protein	B-CHED
+,	O
+called	O
+Cyto3a	O
+,	O
+as	O
+a	O
+recombinant	O
+His	O
+-	O
+tagged	O
+protein	B-CHED
+in	O
+the	O
+E	B-SPEC
+.	I-SPEC
+coli	I-SPEC
+.	O
+
+ABSTRACT	O
+:	O
+Porcine	O
+epidemic	O
+diarrhea	O
+virus	O
+(	O
+PEDV	B-SPEC
+)	O
+is	O
+a	O
+causative	O
+agent	O
+of	O
+porcine	B-SPEC
+epidemic	B-DISO
+diarrhea	I-DISO
+;	O
+consequently	O
+,	O
+the	O
+small	B-ANAT
+intestine	I-ANAT
+was	O
+believed	O
+to	O
+be	O
+its	O
+only	O
+target	O
+organ	B-ANAT
+.	O
+
+In	O
+this	O
+study	O
+,	O
+we	O
+found	O
+that	O
+PEDV	B-SPEC
+infected	O
+not	O
+only	O
+the	O
+small	B-ANAT
+intestines	I-ANAT
+,	O
+but	O
+also	O
+the	O
+respiratory	B-ANAT
+tract	I-ANAT
+.	O
+
+The	O
+rapid	O
+spread	O
+of	O
+PEDV	B-SPEC
+has	O
+raised	O
+concerns	O
+about	O
+the	O
+role	O
+of	O
+feed	O
+and	O
+particularly	O
+pork	O
+-	O
+by	O
+-	O
+product	O
+components	O
+such	O
+as	O
+spray	O
+-	O
+dried	B-ANAT
+porcine	B-SPEC
+plasma	B-ANAT
+(	O
+SDPP	O
+)	O
+in	O
+PEDV	B-SPEC
+transmission	O
+.	O
+
+Another	O
+group	O
+,	O
+EGG	B-ANAT
+-	O
+PEDV	B-SPEC
+,	O
+was	O
+orally	B-ANAT
+administered	O
+a	O
+commercial	O
+egg	B-ANAT
+-	O
+derived	O
+liquid	O
+PEDV	B-SPEC
+globulin	O
+product	O
+from	O
+dpi	B-PRGE
+-	I-PRGE
+4	I-PRGE
+through	O
+6	O
+.	O
+
+TITLE	O
+:	O
+Use	O
+of	O
+heliox	O
+delivered	O
+via	O
+high	O
+-	O
+flow	O
+nasal	B-ANAT
+cannula	B-SPEC
+to	O
+treat	O
+an	O
+infant	O
+with	O
+coronavirus	B-SPEC
+-	O
+related	O
+respiratory	O
+infection	O
+and	O
+severe	O
+acute	O
+air	B-CHED
+-	O
+flow	O
+obstruction	B-DISO
+.	O
+
+In	O
+infants	O
+,	O
+coronavirus	B-DISO
+infection	I-DISO
+can	O
+cause	O
+bronchitis	B-DISO
+,	O
+bronchiolitis	B-DISO
+,	O
+and	O
+pneumonia	B-DISO
+in	O
+variable	O
+combinations	O
+and	O
+can	O
+produce	O
+enough	O
+air	O
+-	O
+flow	O
+obstruction	B-DISO
+to	O
+cause	O
+respiratory	B-DISO
+failure	I-DISO
+.	O
+
+This	O
+review	O
+will	O
+summarize	O
+the	O
+research	O
+progress	O
+in	O
+the	O
+functions	O
+of	O
+coronavirus	B-SPEC
+accessory	O
+genes	O
+.	O
+
+Interestingly	O
+,	O
+administration	O
+of	O
+a	O
+p38	B-FUNC
+MAPK	B-FUNC
+inhibitor	B-CHED
+led	O
+to	O
+an	O
+increase	O
+in	O
+mice	B-SPEC
+survival	O
+after	O
+infection	B-DISO
+with	O
+SARS	B-DISO
+-	O
+CoV	O
+,	O
+confirming	O
+the	O
+relevance	O
+of	O
+this	O
+pathway	B-PROC
+in	O
+SARS	B-DISO
+-	O
+CoV	O
+virulence	B-PROC
+.	O
+
+Here	O
+,	O
+we	O
+analyzed	O
+TTSPs	O
+,	O
+reported	O
+to	O
+be	O
+expressed	B-PROC
+in	O
+the	O
+respiratory	B-ANAT
+system	I-ANAT
+,	O
+for	O
+the	O
+ability	O
+to	O
+activate	O
+influenza	B-SPEC
+viruses	I-SPEC
+and	O
+coronaviruses	O
+.	O
+
+A	O
+relatively	O
+simple	O
+serotyping	O
+method	O
+to	O
+distinguish	O
+between	O
+two	O
+types	O
+of	O
+FCoV	O
+infection	B-DISO
+was	O
+developed	O
+.	O
+
+CONCLUSIONS	O
+:	O
+A	O
+relatively	O
+simple	O
+serotyping	O
+method	O
+to	O
+distinguish	O
+between	O
+two	O
+types	O
+of	O
+FCoV	O
+infection	B-DISO
+was	O
+developed	O
+.	O
+
+TITLE	O
+:	O
+[	O
+Effect	O
+of	O
+unilateral	O
+lung	B-ANAT
+recruitment	B-DISO
+maneuver	O
+on	O
+hemodynamics	B-PROC
+and	O
+dead	B-PROC
+space	O
+ratio	O
+in	O
+pigs	B-SPEC
+with	O
+unilateral	O
+acute	O
+respiratory	O
+distress	O
+syndrome	O
+].	O
+
+(	O
+2	O
+)	O
+VD	O
+/	O
+VT	O
+changes	O
+:	O
+with	O
+an	O
+increase	O
+in	O
+RM	O
+pressure	O
+,	O
+the	O
+oxygenation	B-PROC
+index	O
+(	O
+PaO₂	B-PRGE
+/	O
+FiO₂	O
+)	O
+in	O
+control	O
+group	O
+showed	O
+a	O
+tendency	O
+of	O
+gradual	O
+decrease	O
+,	O
+and	O
+the	O
+level	O
+at	O
+60	O
+cmH₂O	O
+was	O
+significantly	O
+lower	O
+than	O
+that	O
+at	O
+20	O
+cmH₂O	O
+and	O
+40	O
+cmH₂O	O
+(	O
+126	O
+.	O
+40	O
+±	O
+37	O
+.	O
+55	O
+mmHg	O
+vs	O
+.	O
+187	O
+.	O
+40	O
+±	O
+21	O
+.	O
+66	O
+mmHg	O
+,	O
+175	O
+.	O
+20	O
+±	O
+23	O
+.	O
+00	O
+mmHg	O
+,	O
+both	O
+P	O
+<	O
+0	O
+.	O
+01	O
+).	O
+
+Host	B-COMP
+factors	O
+influencing	O
+viral	B-PROC
+replication	I-PROC
+are	O
+poorly	O
+understood	O
+in	O
+bats	B-SPEC
+and	O
+are	O
+likely	O
+to	O
+include	O
+both	O
+pre	O
+-	O
+and	O
+post	O
+-	O
+transcriptional	B-PROC
+regulatory	O
+mechanisms	O
+.	O
+
+Within	O
+one	O
+cat	B-SPEC
+,	O
+viral	O
+sequences	O
+from	O
+different	O
+organs	B-ANAT
+were	O
+similar	O
+or	O
+identical	O
+,	O
+whereas	O
+greater	O
+discrepancies	O
+were	O
+found	O
+comparing	O
+sequences	O
+from	O
+various	O
+cats	B-SPEC
+.	O
+
+TITLE	O
+:	O
+Mass	O
+gathering	O
+medicine	B-CHED
+:	O
+2014	O
+Hajj	O
+and	O
+Umra	O
+preparation	O
+as	O
+a	O
+leading	O
+example	O
+.	O
+
+Before	O
+widespread	O
+diffusion	O
+of	O
+ECMO	O
+,	O
+new	O
+trials	O
+should	O
+test	O
+the	O
+efficacy	O
+of	O
+early	O
+initiation	O
+or	O
+CO2	B-CHED
+removal	O
+in	O
+addition	O
+to	O
+,	O
+or	O
+even	O
+as	O
+an	O
+alternative	O
+to	O
+mechanical	O
+ventilation	O
+for	O
+severe	O
+ARDS	B-DISO
+.	O
+
+ABSTRACT	O
+:	O
+An	O
+indirect	O
+porcine	O
+epidemic	O
+diarrhea	O
+virus	O
+(	O
+PEDV	B-SPEC
+)	O
+anti	B-PRGE
+-	I-PRGE
+immunoglobulin	I-PRGE
+(	O
+Ig	O
+)	O
+G	O
+ELISA	O
+based	O
+on	O
+the	O
+S1	O
+portion	O
+of	O
+the	O
+spike	O
+protein	B-CHED
+was	O
+validated	O
+and	O
+compared	O
+with	O
+an	O
+indirect	O
+immunofluorescence	O
+assay	O
+.	O
+
+ABSTRACT	O
+:	O
+Cysteine	B-CHED
+-	O
+containing	O
+peptides	B-CHED
+represent	O
+an	O
+important	O
+class	B-SPEC
+of	O
+T	B-PRGE
+cell	I-PRGE
+epitopes	I-PRGE
+,	O
+yet	O
+their	O
+prevalence	O
+remains	O
+underestimated	O
+.	O
+
+The	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+(	O
+SARS	B-DISO
+)-	O
+CoV	O
+was	O
+identified	O
+as	O
+the	O
+etiologic	O
+agent	O
+of	O
+the	O
+2002	O
+-	O
+2003	O
+international	O
+SARS	B-DISO
+outbreak	O
+.	O
+
+Finally	O
+,	O
+transient	O
+ORF	O
+-	O
+9b	O
+expression	B-PROC
+led	O
+to	O
+a	O
+strong	O
+induction	O
+of	O
+autophagy	B-PROC
+in	O
+cells	B-COMP
+.	O
+
+Sepsis	B-DISO
+and	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+involve	O
+the	O
+release	B-PATH
+of	O
+inflammatory	O
+mediators	O
+to	O
+the	O
+systemic	O
+circulation	B-PROC
+,	O
+propagating	O
+the	O
+cellular	B-COMP
+and	O
+molecular	O
+response	O
+and	O
+affecting	O
+distal	O
+organs	B-ANAT
+,	O
+including	O
+the	O
+brain	B-ANAT
+.	O
+
+Conditioned	O
+medium	O
+collected	O
+from	O
+an	O
+in	O
+vitro	O
+lipopolysaccharide	B-CHED
+-	O
+induced	O
+airway	B-ANAT
+epithelial	B-ANAT
+cell	I-ANAT
+injury	O
+model	O
+using	O
+human	B-SPEC
+A549	O
+alveolar	B-ANAT
+cells	B-COMP
+was	O
+subsequently	O
+added	O
+at	O
+increasing	O
+concentrations	O
+(	O
+no	O
+conditioned	O
+,	O
+2	O
+%,	O
+5	O
+%,	O
+10	O
+%,	O
+15	O
+%,	O
+25	O
+%,	O
+and	O
+50	O
+%)	O
+to	O
+a	O
+rat	B-SPEC
+mixed	O
+brain	B-ANAT
+cell	I-ANAT
+culture	O
+containing	O
+both	O
+astrocytes	B-ANAT
+and	O
+neurons	O
+.	O
+
+ABSTRACT	O
+:	O
+This	O
+study	O
+investigated	O
+the	O
+effects	O
+of	O
+a	O
+pragmatic	O
+lifestyle	O
+intervention	O
+in	O
+obese	B-DISO
+adults	O
+with	O
+continuous	O
+positive	O
+airway	B-ANAT
+pressure	O
+-	O
+treated	O
+obstructive	B-DISO
+sleep	I-DISO
+apnoea	I-DISO
+hypopnoea	B-DISO
+syndrome	I-DISO
+(	O
+OSAHS	B-DISO
+).	O
+
+At	O
+end	O
+-	O
+point	O
+,	O
+the	O
+intervention	O
+group	O
+exhibited	O
+small	O
+reductions	O
+in	O
+body	B-ANAT
+mass	O
+(-	O
+1	O
+.	O
+8	O
+[-	O
+3	O
+.	O
+0	O
+,	O
+-	O
+0	O
+.	O
+5	O
+]	O
+kg	O
+;	O
+P	O
+=	O
+0	O
+.	O
+007	O
+)	O
+and	O
+body	O
+fat	O
+percentage	O
+(-	O
+1	O
+[-	O
+2	O
+,	O
+0	O
+]%;	O
+P	O
+=	O
+0	O
+.	O
+044	O
+)	O
+and	O
+moderate	O
+improvements	O
+in	O
+C	O
+-	O
+reactive	O
+protein	B-CHED
+(-	O
+1	O
+.	O
+3	O
+[-	O
+2	O
+.	O
+4	O
+,	O
+-	O
+0	O
+.	O
+2	O
+]	O
+mg	O
+·	O
+L	O
+(-	O
+1	O
+);	O
+P	O
+=	O
+0	O
+.	O
+028	O
+)	O
+and	O
+exercise	O
+capacity	O
+(	O
+95	O
+[	O
+50	O
+,	O
+139	O
+]	O
+m	O
+;	O
+P	O
+<	O
+0	O
+.	O
+001	O
+).	O
+
+We	O
+discuss	O
+specific	O
+applications	O
+of	O
+the	O
+framework	O
+to	O
+the	O
+2003	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+(	O
+SARS	B-DISO
+)	O
+outbreak	O
+in	O
+Singapore	O
+and	O
+the	O
+2001	O
+foot	B-ANAT
+-	I-DISO
+and	I-DISO
+-	I-DISO
+mouth	B-ANAT
+disease	I-DISO
+virus	I-SPEC
+(	O
+FMDV	B-SPEC
+)	O
+outbreak	O
+in	O
+Great	O
+Britain	O
+.	O
+
+Infiltration	B-DISO
+of	O
+inflammatory	O
+virus	B-SPEC
+-	O
+specific	O
+T	B-ANAT
+cells	I-ANAT
+(	O
+tetramer	O
+staining	O
+)	O
+into	O
+the	O
+CNS	O
+of	O
+FTY720	B-CHED
+-	O
+treated	O
+mice	B-SPEC
+was	O
+determined	O
+using	O
+flow	O
+cytometry	O
+.	O
+
+These	O
+results	O
+correlated	O
+with	O
+impaired	B-DISO
+ability	O
+to	O
+control	O
+viral	B-PROC
+replication	I-PROC
+(	O
+P	O
+<	O
+0	O
+.	O
+05	O
+)	O
+within	O
+the	O
+CNS	B-CHED
+at	O
+days	O
+7	O
+and	O
+14	O
+post	O
+-	O
+infection	B-DISO
+,	O
+which	O
+was	O
+associated	O
+with	O
+diminished	O
+accumulation	O
+of	O
+virus	B-SPEC
+-	O
+specific	O
+CD4	B-PRGE
++	I-PRGE
+and	O
+CD8	B-PRGE
++	I-PRGE
+T	B-ANAT
+cells	I-ANAT
+(	O
+P	O
+<	O
+0	O
+.	O
+05	O
+)	O
+into	O
+the	O
+CNS	B-CHED
+.	O
+
+FTY720	B-CHED
+treatment	O
+reduces	O
+the	O
+severity	O
+of	O
+neuroinflammatory	O
+-	O
+mediated	O
+demyelination	B-DISO
+by	O
+restricting	O
+the	O
+access	O
+of	O
+disease	O
+-	O
+causing	O
+lymphocytes	B-ANAT
+into	O
+the	O
+CNS	B-CHED
+but	O
+is	O
+not	O
+associated	O
+with	O
+viral	O
+recrudescence	O
+in	O
+this	O
+model	O
+.	O
+
+RESULTS	O
+:	O
+Administration	O
+of	O
+FTY720	B-CHED
+to	O
+JHMV	O
+-	O
+infected	O
+mice	B-SPEC
+resulted	O
+in	O
+increased	O
+clinical	O
+disease	O
+severity	O
+and	O
+mortality	O
+.	O
+
+ECoV	O
+was	O
+also	O
+detected	O
+in	O
+nasal	B-ANAT
+swabs	O
+from	O
+all	O
+horses	B-SPEC
+,	O
+suggesting	O
+that	O
+respiratory	O
+transmission	O
+of	O
+ECoV	O
+may	O
+occur	O
+.	O
+
+White	B-ANAT
+blood	I-ANAT
+cell	I-ANAT
+counts	O
+and	O
+serum	B-COMP
+amyloid	B-DISO
+A	O
+concentrations	O
+changed	O
+relative	O
+to	O
+the	O
+clinical	O
+condition	B-DISO
+of	O
+the	O
+inoculated	O
+horses	B-SPEC
+;	O
+these	O
+may	O
+be	O
+useful	O
+markers	O
+for	O
+monitoring	O
+the	O
+clinical	O
+status	O
+of	O
+horses	B-SPEC
+infected	O
+with	O
+ECoV	O
+.	O
+This	O
+is	O
+the	O
+first	O
+report	O
+of	O
+induction	O
+of	O
+clinical	O
+signs	O
+of	O
+ECoV	O
+infection	B-DISO
+in	O
+horses	B-SPEC
+by	O
+experimental	O
+inoculation	O
+.	O
+
+TITLE	O
+:	O
+Catalytic	O
+function	O
+and	O
+substrate	O
+specificity	O
+of	O
+the	O
+papain	B-PRGE
+-	I-PRGE
+like	I-PRGE
+protease	I-PRGE
+domain	I-PRGE
+of	O
+nsp3	B-PRGE
+from	O
+the	O
+Middle	O
+East	O
+respiratory	O
+syndrome	O
+coronavirus	B-SPEC
+.	O
+
+ABSTRACT	O
+:	O
+The	O
+papain	B-PRGE
+-	I-PRGE
+like	I-PRGE
+protease	I-PRGE
+(	O
+PLpro	O
+)	O
+domain	O
+from	O
+the	O
+deadly	O
+Middle	O
+East	O
+respiratory	O
+syndrome	B-DISO
+coronavirus	B-SPEC
+(	O
+MERS	O
+-	O
+CoV	O
+)	O
+was	O
+overexpressed	O
+and	O
+purified	O
+.	O
+
+MERS	O
+-	O
+CoV	O
+PLpro	O
+constructs	O
+with	O
+and	O
+without	O
+the	O
+putative	O
+ubiquitin	B-PRGE
+-	I-PRGE
+like	I-PRGE
+(	O
+UBL	B-PRGE
+)	O
+domain	O
+at	O
+the	O
+N	O
+terminus	O
+were	O
+found	O
+to	O
+possess	B-DISO
+protease	O
+,	O
+deubiquitinating	B-PROC
+,	O
+deISGylating	O
+,	O
+and	O
+interferon	B-PRGE
+antagonism	O
+activities	O
+in	O
+transfected	O
+HEK293T	O
+cells	B-COMP
+.	O
+
+Unlocking	O
+the	O
+secrets	O
+of	O
+how	O
+coronavirus	B-SPEC
+(	O
+CoV	O
+)	O
+papain	B-PRGE
+-	I-PRGE
+like	I-PRGE
+proteases	I-PRGE
+(	O
+PLpros	O
+)	O
+perform	O
+their	O
+multifunctional	O
+roles	O
+during	O
+viral	B-PROC
+replication	I-PROC
+entails	O
+a	O
+complete	O
+mechanistic	O
+understanding	O
+of	O
+their	O
+substrate	O
+recognition	O
+and	O
+enzymatic	O
+activities	O
+.	O
+
+We	O
+show	O
+that	O
+the	O
+PLpro	O
+domains	O
+from	O
+the	O
+MERS	O
+and	O
+SARS	B-DISO
+coronaviruses	O
+can	O
+recognize	O
+and	O
+process	O
+the	O
+same	O
+substrates	O
+,	O
+but	O
+with	O
+different	O
+catalytic	O
+efficiencies	O
+.	O
+
+The	O
+results	O
+from	O
+this	O
+study	O
+provide	O
+valuable	O
+information	O
+for	O
+understanding	O
+how	O
+MERS	O
+-	O
+CoV	O
+PLpro	O
+-	O
+mediated	O
+antagonism	O
+of	O
+the	O
+host	B-COMP
+innate	B-DISO
+immune	I-DISO
+response	I-DISO
+is	O
+orchestrated	O
+,	O
+as	O
+well	O
+as	O
+insight	O
+into	O
+the	O
+design	O
+of	O
+inhibitors	B-CHED
+against	O
+MERS	O
+-	O
+CoV	O
+PLpro	O
+.	O
+
+ABSTRACT	O
+:	O
+The	O
+unfolded	O
+-	O
+protein	B-CHED
+response	O
+(	O
+UPR	O
+)	O
+is	O
+a	O
+signal	B-PROC
+transduction	I-PROC
+cascade	O
+triggered	O
+by	O
+perturbation	O
+of	O
+the	O
+homeostasis	B-PROC
+of	O
+the	O
+endoplasmic	B-COMP
+reticulum	I-COMP
+(	O
+ER	O
+).	O
+
+UPR	O
+resolves	O
+ER	O
+stress	O
+by	O
+activating	O
+a	O
+cascade	O
+of	O
+cellular	B-COMP
+responses	O
+,	O
+including	O
+the	O
+induction	O
+of	O
+molecular	O
+chaperones	O
+,	O
+translational	B-PROC
+attenuation	I-PROC
+,	O
+ER	O
+-	O
+associated	O
+degradation	O
+,	O
+and	O
+other	O
+mechanisms	O
+.	O
+
+Moreover	O
+,	O
+IRE1α	O
+antagonized	O
+IBV	B-SPEC
+-	O
+induced	O
+apoptosis	B-PATH
+by	O
+modulating	O
+the	O
+phosphorylation	B-PROC
+status	O
+of	O
+the	O
+proapoptotic	O
+c	B-PRGE
+-	I-PRGE
+Jun	I-PRGE
+N	I-PRGE
+-	I-PRGE
+terminal	I-PRGE
+kinase	I-PRGE
+(	O
+JNK	B-FUNC
+)	O
+and	O
+the	O
+prosurvival	B-PRGE
+RAC	I-PRGE
+-	I-PRGE
+alpha	I-PRGE
+serine	I-PRGE
+/	I-PRGE
+threonine	B-CHED
+-	I-PRGE
+protein	B-ENZY
+kinase	I-ENZY
+(	O
+Akt	B-PRGE
+).	O
+
+Molecular	O
+characterization	O
+of	O
+the	O
+interactions	O
+between	O
+coronaviruses	O
+and	O
+host	B-COMP
+cells	B-COMP
+is	O
+pivotal	O
+to	O
+understanding	O
+the	O
+pathogenicity	O
+and	O
+species	B-SPEC
+specificity	O
+of	O
+coronavirus	B-DISO
+infection	I-DISO
+.	O
+
+This	O
+study	O
+demonstrates	O
+that	O
+UPR	O
+activation	O
+constitutes	O
+a	O
+major	O
+aspect	O
+of	O
+coronavirus	B-SPEC
+-	O
+host	B-COMP
+interactions	O
+.	O
+
+Inclusion	O
+criteria	O
+were	O
+age	O
+≥	O
+18	O
+years	O
+and	O
+the	O
+presence	O
+of	O
+criteria	O
+for	O
+severe	O
+ARF	B-DISO
+justifying	O
+ICU	O
+admission	O
+.	O
+
+No	O
+significant	O
+difference	O
+was	O
+found	O
+between	O
+the	O
+two	O
+groups	O
+in	O
+the	O
+demographics	O
+including	O
+the	O
+median	O
+patient	O
+age	O
+,	O
+sex	O
+ratio	O
+,	O
+initial	O
+Acute	O
+Physiology	O
+and	O
+Chronic	O
+Health	O
+Evaluation	O
+II	O
+scores	O
+,	O
+initial	O
+pulmonary	B-PROC
+function	I-PROC
+and	O
+the	O
+sources	O
+of	O
+ARDS	B-DISO
+.	O
+
+In	O
+contrast	O
+,	O
+in	O
+samples	O
+obtained	O
+from	O
+faeces	B-ANAT
+of	O
+healthy	O
+cats	B-SPEC
+,	O
+the	O
+ORF3c	O
+was	O
+never	O
+affected	O
+by	O
+such	O
+mutations	O
+.	O
+
+Our	O
+findings	O
+suggest	O
+that	O
+mutations	O
+of	O
+3c	O
+and	O
+spike	O
+protein	B-CHED
+genes	O
+correlate	O
+with	O
+the	O
+occurrence	O
+of	O
+FIP	B-DISO
+.	O
+
+The	O
+study	O
+included	O
+inpatients	O
+3	O
+months	O
+or	O
+older	O
+with	O
+an	O
+acute	O
+respiratory	B-ANAT
+tract	I-ANAT
+illness	O
+,	O
+most	O
+admitted	O
+through	O
+the	O
+emergency	B-DISO
+department	O
+.	O
+
+The	O
+increase	O
+in	O
+disease	O
+severity	O
+in	O
+dogs	B-SPEC
+and	O
+the	O
+emergence	O
+of	O
+novel	O
+CCoVs	O
+can	O
+be	O
+attributed	O
+to	O
+the	O
+high	O
+level	O
+of	O
+recombination	B-PROC
+within	O
+the	O
+spike	O
+gene	O
+that	O
+can	O
+occur	O
+during	O
+infection	B-DISO
+by	O
+more	O
+than	O
+one	O
+CCoV	O
+type	O
+in	O
+the	O
+same	O
+host	B-COMP
+.	O
+
+TITLE	O
+:	O
+Effect	O
+of	O
+small	O
+interfering	O
+RNAs	O
+on	O
+in	O
+vitro	O
+replication	O
+and	O
+gene	B-PROC
+expression	I-PROC
+of	O
+feline	B-SPEC
+coronavirus	B-SPEC
+.	O
+
+Automated	O
+alerts	O
+may	O
+be	O
+useful	O
+for	O
+identifying	O
+patients	O
+with	O
+severe	O
+ARDS	B-DISO
+who	O
+may	O
+be	O
+ECMO	O
+candidates	O
+.	O
+
+TITLE	O
+:	O
+Lung	B-ANAT
+postmortem	O
+autopsy	O
+revealing	O
+extramedullary	O
+involvement	O
+in	O
+multiple	B-DISO
+myeloma	I-DISO
+causing	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+.	O
+
+ABSTRACT	O
+:	O
+This	O
+study	O
+reports	O
+the	O
+complete	O
+genome	O
+sequence	O
+of	O
+an	O
+infectious	O
+bronchitis	B-DISO
+virus	B-SPEC
+(	O
+CK	O
+/	O
+CH	O
+/	O
+SD	O
+/	O
+121220	O
+,	O
+KJ128295	O
+)	O
+isolated	O
+in	O
+2012	O
+from	O
+Shandong	O
+Province	O
+in	O
+northern	O
+China	O
+.	O
+
+ABSTRACT	O
+:	O
+After	O
+surgery	O
+,	O
+hypoxemia	O
+and	O
+/	O
+or	O
+acute	B-DISO
+respiratory	I-DISO
+failure	I-DISO
+(	O
+ARF	B-DISO
+)	O
+mainly	O
+develop	O
+following	O
+abdominal	B-ANAT
+and	O
+/	O
+or	O
+thoracic	B-DISO
+surgery	O
+.	O
+
+Maintenance	O
+of	O
+adequate	O
+oxygenation	B-PROC
+in	O
+the	O
+postoperative	O
+period	O
+is	O
+of	O
+major	O
+importance	O
+,	O
+especially	O
+when	O
+pulmonary	B-DISO
+complications	I-DISO
+such	O
+as	O
+ARF	B-DISO
+occur	O
+.	O
+
+Although	O
+invasive	O
+endotracheal	O
+mechanical	O
+ventilation	O
+has	O
+remained	O
+the	O
+cornerstone	O
+of	O
+ventilatory	O
+strategy	O
+for	O
+many	O
+years	O
+for	O
+severe	O
+acute	B-DISO
+respiratory	I-DISO
+failure	I-DISO
+,	O
+several	O
+studies	O
+have	O
+shown	O
+that	O
+mortality	O
+associated	O
+with	O
+pulmonary	B-DISO
+disease	I-DISO
+is	O
+largely	O
+related	O
+to	O
+complications	O
+of	O
+postoperative	O
+reintubation	O
+and	O
+mechanical	O
+ventilation	O
+.	O
+
+Rationale	O
+for	O
+postoperative	O
+NIV	O
+use	O
+is	O
+the	O
+same	O
+as	O
+the	O
+post	O
+-	O
+extubation	O
+NIV	O
+use	O
+plus	O
+the	O
+specificities	O
+due	O
+to	O
+the	O
+respiratory	O
+modifications	O
+induced	O
+by	O
+the	O
+surgery	O
+and	O
+anesthesia	B-DISO
+.	O
+
+A	O
+total	O
+of	O
+310	O
+chicken	B-SPEC
+sera	B-COMP
+samples	O
+were	O
+tested	O
+using	O
+the	O
+commercial	O
+IDEXX	O
+kit	B-FUNC
+along	O
+with	O
+the	O
+assay	O
+developed	O
+.	O
+
+ABSTRACT	O
+:	O
+Viral	B-DISO
+infection	I-DISO
+converts	O
+the	O
+normal	O
+constitution	O
+of	O
+a	O
+cell	B-COMP
+to	O
+optimise	O
+viral	O
+entry	O
+,	O
+replication	O
+,	O
+and	O
+virion	B-COMP
+production	O
+.	O
+
+In	O
+our	O
+work	O
+,	O
+the	O
+results	O
+showed	O
+that	O
+IPEC	O
+-	O
+J2	O
+cells	B-COMP
+were	O
+susceptible	O
+to	O
+TGEV	B-SPEC
+and	O
+PEDV	B-SPEC
+infection	B-DISO
+.	O
+
+Finally	O
+,	O
+the	O
+PEDV	B-SPEC
+and	O
+TGEV	B-SPEC
+infection	B-DISO
+affected	O
+the	O
+MAPK	B-FUNC
+pathway	B-PROC
+,	O
+and	O
+inhibition	B-PROC
+of	O
+MAPK	B-FUNC
+pathway	B-PROC
+regulated	O
+the	O
+changes	O
+of	O
+tight	B-COMP
+junctions	I-COMP
+and	O
+microfilaments	B-COMP
+of	O
+cells	B-COMP
+.	O
+
+RSV	B-SPEC
+was	O
+a	O
+most	O
+common	O
+viral	O
+etiology	O
+in	O
+the	O
+hospitalized	O
+young	O
+children	O
+less	O
+than	O
+5	O
+years	O
+of	O
+age	O
+with	O
+pneumonia	B-DISO
+.	O
+
+We	O
+aimed	O
+to	O
+compare	O
+MERS	O
+-	O
+CoV	O
+isolates	O
+from	O
+dromedaries	B-SPEC
+in	O
+Saudi	O
+Arabia	O
+and	O
+Egypt	O
+with	O
+a	O
+prototype	O
+human	B-SPEC
+MERS	O
+-	O
+CoV	O
+to	O
+assess	O
+virus	B-PROC
+replication	I-PROC
+competence	O
+and	O
+cell	B-COMP
+tropism	B-PROC
+in	O
+ex	O
+-	O
+vivo	O
+cultures	O
+of	O
+human	B-SPEC
+bronchus	B-ANAT
+and	I-ANAT
+lung	I-ANAT
+.	O
+
+King	O
+Faisal	O
+University	O
+,	O
+Egyptian	O
+National	O
+Research	O
+Centre	O
+,	O
+Hong	O
+Kong	O
+Food	O
+and	O
+Health	O
+Bureau	O
+,	O
+National	O
+Institute	O
+of	O
+Allergy	B-DISO
+and	O
+Infectious	B-DISO
+Diseases	I-DISO
+,	O
+and	O
+European	O
+Community	O
+Seventh	O
+Framework	O
+Program	O
+.	O
+
+Prompted	O
+by	O
+the	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+(	O
+SARS	B-DISO
+)	O
+outbreak	O
+in	O
+2003	O
+,	O
+China	O
+has	O
+prioritised	O
+the	O
+control	O
+of	O
+cross	O
+-	O
+border	B-ANAT
+transmission	O
+of	O
+infectious	B-DISO
+diseases	I-DISO
+and	O
+other	O
+health	O
+-	O
+related	O
+risks	O
+.	O
+
+Forty	O
+-	O
+seven	O
+CAP	B-DISO
+patients	O
+were	O
+infected	O
+by	O
+a	O
+single	O
+virus	B-SPEC
+(	O
+24	O
+influenza	B-SPEC
+A	I-SPEC
+virus	I-SPEC
+,	O
+5	O
+influenza	B-DISO
+B	O
+,	O
+10	O
+parainfluenza	B-SPEC
+virus	I-SPEC
+type	I-SPEC
+3	I-SPEC
+[	O
+PIV	O
+-	O
+3	O
+],	O
+2	O
+PIV	O
+-	O
+1	O
+,	O
+2	O
+adenovirus	B-DISO
+,	O
+2	O
+human	B-SPEC
+rhinovirus	I-SPEC
+and	O
+2	O
+coronavirus	B-SPEC
+OC43	O
+),	O
+five	O
+cases	O
+by	O
+two	O
+or	O
+three	O
+viruses	B-SPEC
+co	B-DISO
+-	I-DISO
+infection	I-DISO
+.	O
+
+On	O
+multivariate	O
+analysis	O
+,	O
+myalgia	B-DISO
+was	O
+included	O
+in	O
+the	O
+model	O
+for	O
+pneumonia	B-DISO
+associated	O
+with	O
+influenza	B-PATH
+infection	B-DISO
+.	O
+
+ABSTRACT	O
+:	O
+The	O
+Middle	O
+East	O
+respiratory	O
+syndrome	O
+coronavirus	B-SPEC
+(	O
+MERS	O
+-	O
+CoV	O
+)	O
+was	O
+first	O
+described	O
+in	O
+2012	O
+and	O
+,	O
+subsequently	O
+,	O
+many	O
+cases	O
+were	O
+reported	O
+with	O
+a	O
+lower	O
+case	O
+fatality	O
+rate	O
+than	O
+initial	O
+cases	O
+.	O
+
+So	O
+far	O
+,	O
+circulating	O
+virus	B-SPEC
+strains	O
+remain	O
+similar	O
+under	O
+continuous	O
+monitoring	O
+,	O
+with	O
+no	O
+genetic	O
+changes	O
+.	O
+
+TITLE	O
+:	O
+The	O
+impact	O
+of	O
+cardiac	B-ANAT
+dysfunction	O
+on	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+and	O
+mortality	O
+in	O
+mechanically	O
+ventilated	O
+patients	O
+with	O
+severe	O
+sepsis	O
+and	O
+septic	B-DISO
+shock	I-DISO
+:	O
+an	O
+observational	O
+study	O
+.	O
+
+Treatment	O
+is	O
+only	O
+supportive	O
+,	O
+therefore	O
+elucidating	O
+modifiable	O
+factors	O
+that	O
+could	O
+prevent	O
+ARDS	B-DISO
+could	O
+have	O
+a	O
+profound	O
+impact	O
+on	O
+outcome	O
+.	O
+
+In	O
+this	O
+retrospective	O
+observational	O
+cohort	O
+study	O
+of	O
+mechanically	O
+ventilated	O
+patients	O
+with	O
+severe	B-DISO
+sepsis	I-DISO
+and	O
+septic	B-DISO
+shock	I-DISO
+,	O
+122	O
+patients	O
+were	O
+assessed	O
+for	O
+the	O
+impact	O
+of	O
+sepsis	B-DISO
+-	O
+associated	O
+cardiac	B-ANAT
+dysfunction	O
+on	O
+incidence	O
+of	O
+ARDS	B-DISO
+(	O
+primary	O
+outcome	O
+)	O
+and	O
+mortality	O
+.	O
+
+Nevertheless	O
+,	O
+impaired	B-DISO
+virus	B-SPEC
+control	O
+in	O
+the	O
+absence	O
+of	O
+CD4	B-PRGE
+T	I-PRGE
+cells	O
+was	O
+associated	O
+with	O
+gradually	O
+diminished	O
+CNS	B-PRGE
+CD8	I-PRGE
+T	B-ANAT
+-	I-ANAT
+cell	I-ANAT
+interferon	I-PRGE
+-	I-PRGE
+γ	I-PRGE
+production	O
+.	O
+
+Transfer	O
+of	O
+memory	B-PROC
+CD8	B-PRGE
+T	I-PRGE
+cells	O
+to	O
+reduce	O
+viral	O
+load	O
+in	O
+CD4	B-PRGE
+-	O
+depleted	O
+mice	B-SPEC
+reverted	O
+the	O
+recipient	O
+CNS	B-CHED
+CD8	B-PRGE
+T	I-PRGE
+-	O
+cell	O
+phenotype	O
+to	O
+that	O
+in	O
+wild	O
+-	O
+type	O
+control	O
+mice	B-SPEC
+.	O
+
+Conducted	O
+research	O
+showed	O
+that	O
+heparan	B-CHED
+sulfate	I-CHED
+proteoglycans	B-CHED
+function	O
+as	O
+adhesion	B-DISO
+molecules	O
+,	O
+increasing	O
+the	O
+virus	B-SPEC
+density	O
+on	O
+cell	B-COMP
+surface	I-COMP
+and	O
+possibly	O
+facilitating	O
+the	O
+interaction	O
+between	O
+HCoV	B-SPEC
+-	I-SPEC
+NL63	I-SPEC
+and	O
+its	O
+receptor	O
+.	O
+
+Despite	O
+severe	O
+epidemic	O
+outbreaks	O
+on	O
+several	O
+occasions	O
+and	O
+lack	O
+of	O
+antiviral	B-CHED
+drug	I-CHED
+,	O
+not	O
+much	O
+progress	O
+has	O
+been	O
+made	O
+with	O
+regard	O
+to	O
+an	O
+epitope	B-CHED
+-	O
+based	O
+vaccine	O
+designed	O
+for	O
+HCoV	O
+.	O
+In	O
+this	O
+study	O
+,	O
+a	O
+computational	O
+approach	O
+was	O
+adopted	O
+to	O
+identify	O
+a	O
+multiepitope	O
+vaccine	O
+candidate	O
+against	O
+this	O
+virus	B-SPEC
+that	O
+could	O
+be	O
+suitable	O
+to	O
+trigger	O
+a	O
+significant	O
+immune	B-PROC
+response	I-PROC
+.	O
+
+Both	O
+T	B-ANAT
+cell	I-ANAT
+immunity	B-PROC
+and	O
+B	B-ANAT
+cell	I-ANAT
+immunity	B-PROC
+were	O
+checked	O
+for	O
+the	O
+peptides	B-CHED
+to	O
+ensure	O
+that	O
+they	O
+had	O
+the	O
+capacity	O
+to	O
+induce	O
+both	O
+humoral	O
+and	O
+cell	B-PROC
+-	I-PROC
+mediated	I-PROC
+immunity	I-PROC
+.	O
+
+TITLE	O
+:	O
+The	O
+pattern	O
+of	O
+Middle	O
+East	O
+respiratory	O
+syndrome	B-DISO
+coronavirus	B-SPEC
+in	O
+Saudi	O
+Arabia	O
+:	O
+a	O
+descriptive	O
+epidemiological	O
+analysis	O
+of	O
+data	O
+from	O
+the	O
+Saudi	O
+Ministry	O
+of	O
+Health	O
+.	O
+
+ABSTRACT	O
+:	O
+This	O
+study	O
+describes	O
+the	O
+epidemiology	O
+of	O
+Middle	O
+East	O
+respiratory	O
+syndrome	O
+coronavirus	B-SPEC
+(	O
+MERS	O
+-	O
+CoV	O
+)	O
+in	O
+Saudi	O
+Arabia	O
+.	O
+
+The	O
+highest	O
+number	O
+of	O
+cases	O
+and	O
+deaths	B-PROC
+occurred	O
+between	O
+April	O
+and	O
+May	O
+2014	O
+.	O
+
+In	O
+this	O
+study	O
+,	O
+a	O
+change	O
+in	O
+ventilator	O
+management	O
+was	O
+associated	O
+with	O
+an	O
+anesthesia	B-DISO
+machine	O
+exchange	O
+.	O
+
+The	O
+smaller	O
+Vt	O
+and	O
+lower	O
+PIP	B-CHED
+noted	O
+in	O
+the	O
+post	O
+group	O
+may	O
+imply	O
+a	O
+lower	O
+risk	O
+of	O
+volutrauma	O
+and	O
+barotrauma	O
+,	O
+which	O
+may	O
+be	O
+significant	O
+in	O
+at	O
+-	O
+risk	O
+populations	O
+.	O
+
+New	O
+anesthesia	B-DISO
+machines	O
+were	O
+associated	O
+with	O
+a	O
+non	O
+-	O
+statistically	O
+significant	O
+reduction	O
+in	O
+postoperative	O
+ARDS	B-DISO
+.	O
+
+ABSTRACT	O
+:	O
+Several	O
+new	O
+viral	O
+respiratory	B-ANAT
+tract	I-ANAT
+infectious	B-DISO
+diseases	I-DISO
+with	O
+epidemic	O
+potential	O
+that	O
+threaten	O
+global	O
+health	O
+security	O
+have	O
+emerged	O
+in	O
+the	O
+past	O
+15	O
+years	O
+.	O
+
+TITLE	O
+:	O
+Emerging	O
+novel	O
+and	O
+antimicrobial	B-CHED
+-	O
+resistant	O
+respiratory	B-DISO
+tract	I-DISO
+infections	I-DISO
+:	O
+new	O
+drug	O
+development	B-PROC
+and	O
+therapeutic	O
+options	O
+.	O
+
+She	O
+had	O
+a	O
+medical	O
+history	O
+of	O
+osteosarcoma	B-DISO
+of	O
+the	O
+leg	B-ANAT
+and	O
+hyperthyroidism	B-DISO
+.	O
+
+On	O
+arrival	O
+,	O
+her	O
+vital	O
+signs	O
+indicated	O
+septic	O
+shock	O
+,	O
+with	O
+a	O
+white	B-ANAT
+blood	I-ANAT
+cell	I-ANAT
+count	O
+of	O
+3	O
+.	O
+5	O
+×	O
+10	O
+(	O
+3	O
+)/	O
+μl	O
+.	O
+
+Because	O
+the	O
+patient	O
+'	O
+s	O
+PaO2	O
+/	O
+FiO2	O
+remained	O
+less	O
+than	O
+60	O
+mmHg	O
+and	O
+her	O
+blood	B-PROC
+pressure	I-PROC
+was	O
+unstable	O
+despite	O
+aggressive	B-DISO
+conventional	O
+management	O
+,	O
+venoarterial	O
+ECMO	O
+was	O
+administered	O
+approximately	O
+11	O
+h	O
+after	O
+her	O
+arrival	O
+.	O
+
+This	O
+patient	O
+'	O
+s	O
+successful	O
+outcome	O
+might	O
+be	O
+attributable	O
+to	O
+early	O
+establishment	O
+of	O
+ECMO	O
+to	O
+prevent	O
+ventilation	O
+-	O
+induced	O
+lung	B-ANAT
+injury	O
+.	O
+
+Like	O
+every	O
+other	O
+interventional	O
+procedure	O
+,	O
+celiac	B-ANAT
+plexus	I-ANAT
+block	O
+has	O
+its	O
+own	O
+potential	O
+complications	O
+and	O
+hazards	O
+among	O
+them	O
+pneumothorax	B-DISO
+and	O
+ARDS	B-DISO
+are	O
+very	O
+rare	O
+.	O
+
+TITLE	O
+:	O
+Immunogenicity	O
+of	O
+an	O
+adenoviral	B-SPEC
+-	O
+based	O
+Middle	O
+East	O
+Respiratory	O
+Syndrome	B-DISO
+coronavirus	B-SPEC
+vaccine	O
+in	O
+BALB	O
+/	O
+c	O
+mice	O
+.	O
+
+MERS	O
+-	O
+CoV	O
+has	O
+infected	O
+dromedary	B-SPEC
+camel	B-SPEC
+populations	O
+in	O
+the	O
+Middle	O
+East	O
+at	O
+high	O
+rates	O
+,	O
+representing	O
+an	O
+immediate	O
+source	O
+of	O
+human	B-SPEC
+infection	B-DISO
+.	O
+
+ABSTRACT	O
+:	O
+Vaccines	O
+have	O
+been	O
+invaluable	O
+for	O
+global	O
+health	O
+,	O
+saving	O
+lives	O
+and	O
+reducing	O
+healthcare	O
+costs	O
+,	O
+while	O
+also	O
+raising	O
+the	O
+quality	O
+of	O
+human	B-SPEC
+life	O
+.	O
+
+The	O
+full	O
+-	O
+length	O
+genomes	O
+of	O
+CK	O
+/	O
+CH	O
+/	O
+LDL	B-CHED
+/	O
+97I	O
+P5	O
+and	O
+P115	B-PRGE
+were	O
+amplified	O
+and	O
+sequenced	O
+.	O
+
+Changes	O
+were	O
+observed	O
+in	O
+nsp4	B-PRGE
+,	O
+nsp9	O
+,	O
+nsp11	O
+/	O
+12	O
+,	O
+nsp14	O
+,	O
+nsp15	O
+,	O
+nsp16	O
+,	O
+and	O
+ORF3a	O
+,	O
+but	O
+these	O
+did	O
+not	O
+result	O
+in	O
+amino	B-PROC
+acid	I-PROC
+substitutions	I-PROC
+or	O
+did	O
+not	O
+show	O
+functional	O
+variations	O
+.	O
+
+TITLE	O
+:	O
+Evidence	O
+for	O
+substrate	O
+binding	B-FUNC
+-	O
+induced	O
+zwitterion	B-CHED
+formation	B-PROC
+in	O
+the	O
+catalytic	O
+Cys	B-CHED
+-	O
+His	O
+dyad	O
+of	O
+the	O
+SARS	O
+-	O
+CoV	O
+main	O
+protease	O
+.	O
+
+The	O
+SARS	B-PRGE
+-	I-PRGE
+CoV	I-PRGE
+M	I-PRGE
+(	O
+pro	B-PRGE
+)	O
+and	O
+related	O
+CoV	O
+proteases	O
+have	O
+several	O
+distinct	O
+features	O
+,	O
+such	O
+as	O
+an	O
+uncharged	O
+Cys	B-CHED
+-	O
+His	O
+catalytic	O
+dyad	O
+embedded	O
+in	O
+a	O
+chymotrypsin	B-PRGE
+-	I-PRGE
+like	I-PRGE
+protease	I-PRGE
+fold	O
+,	O
+that	O
+clearly	O
+separate	O
+these	O
+enzymes	O
+from	O
+archetypical	O
+cysteine	B-CHED
+proteases	O
+.	O
+
+Our	O
+simulations	O
+,	O
+comprising	O
+the	O
+free	O
+enzyme	O
+as	O
+well	O
+as	O
+substrate	O
+-	O
+enzyme	O
+and	O
+inhibitor	B-CHED
+-	O
+enzyme	O
+complexes	O
+,	O
+lead	O
+us	O
+to	O
+predict	O
+that	O
+zwitterion	O
+formation	B-PROC
+is	O
+fostered	O
+by	O
+substrate	O
+binding	B-FUNC
+but	O
+not	O
+inhibitor	B-CHED
+binding	B-FUNC
+.	O
+
+These	O
+findings	O
+suggest	O
+ways	O
+to	O
+achieve	O
+improved	O
+inhibitors	B-CHED
+.	O
+
+TITLE	O
+:	O
+One	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+coronavirus	B-SPEC
+protein	B-COMP
+complex	I-COMP
+integrates	O
+processive	O
+RNA	B-PRGE
+polymerase	I-PRGE
+and	O
+exonuclease	O
+activities	O
+.	O
+
+POCKITTM	O
+Nucleic	B-CHED
+Acid	I-CHED
+Analyzer	O
+is	O
+a	O
+field	O
+-	O
+deployable	O
+device	O
+capable	O
+of	O
+generating	O
+automatically	O
+interpreted	O
+insulated	O
+isothermal	O
+polymerase	O
+chain	O
+reaction	O
+(	O
+iiPCR	O
+)	O
+results	O
+from	O
+extracted	O
+nucleic	B-CHED
+acid	I-CHED
+within	O
+one	O
+hour	O
+.	O
+
+In	O
+this	O
+study	O
+,	O
+reverse	B-PROC
+transcription	I-PROC
+iiPCR	O
+(	O
+RT	O
+-	O
+iiPCR	O
+)	O
+was	O
+developed	O
+to	O
+facilitate	O
+point	O
+-	O
+of	O
+-	O
+need	O
+diagnosis	O
+of	O
+CDV	B-CHED
+infection	B-DISO
+.	O
+
+Analytical	O
+sensitivity	O
+(	O
+limit	O
+of	O
+detection	O
+95	O
+%)	O
+of	O
+the	O
+established	O
+CDV	B-CHED
+RT	O
+-	O
+iiPCR	O
+was	O
+about	O
+11	O
+copies	O
+of	O
+in	O
+vitro	O
+transcribed	O
+RNA	O
+per	O
+reaction	O
+.	O
+
+However	O
+,	O
+the	O
+key	O
+factors	O
+mediating	O
+complement	B-PROC
+activation	I-PROC
+in	O
+FH	O
+remain	O
+elusive	O
+.	O
+
+Liver	B-ANAT
+tissues	I-ANAT
+were	O
+isolated	O
+from	O
+FH	O
+patients	O
+infected	O
+by	O
+hepatitis	B-SPEC
+B	I-SPEC
+virus	I-SPEC
+(	O
+HBV	B-DISO
+)	O
+and	O
+from	O
+mice	B-SPEC
+infected	O
+with	O
+murine	B-DISO
+hepatitis	I-DISO
+virus	B-SPEC
+strain	O
+3	O
+(	O
+MHV	B-SPEC
+-	O
+3	O
+).	O
+
+Similar	O
+observations	O
+were	O
+made	O
+in	O
+the	O
+murine	B-SPEC
+FH	O
+models	O
+.	O
+
+Administration	O
+of	O
+antagonists	B-CHED
+against	O
+C5aR	B-PRGE
+or	O
+TNF	B-PRGE
+-	I-PRGE
+α	I-PRGE
+ameliorated	O
+MHV	B-SPEC
+-	O
+3	O
+-	O
+induced	O
+FH	O
+.	O
+
+ABSTRACT	O
+:	O
+Critical	B-DISO
+illness	I-DISO
+polyneuropathy	I-DISO
+and	O
+critical	B-DISO
+illness	I-DISO
+myopathy	I-DISO
+are	O
+frequent	O
+complications	O
+of	O
+severe	O
+illness	O
+that	O
+involve	O
+sensorimotor	O
+axons	B-COMP
+and	O
+skeletal	B-ANAT
+muscles	I-ANAT
+,	O
+respectively	O
+.	O
+
+Critical	B-DISO
+illness	I-DISO
+polyneuropathy	I-DISO
+/	O
+myopathy	B-DISO
+in	O
+isolation	O
+or	O
+combination	O
+increases	O
+intensive	O
+care	O
+unit	O
+morbidity	O
+via	O
+the	O
+inability	O
+or	O
+difficulty	O
+in	O
+weaning	B-PROC
+these	O
+patients	O
+off	O
+mechanical	O
+ventilation	O
+.	O
+
+TITLE	O
+:	O
+Recurrent	O
+Spontaneous	B-DISO
+Pneumothorax	I-DISO
+during	O
+the	O
+Recovery	O
+Phase	O
+of	O
+ARDS	B-DISO
+Due	O
+to	O
+H1N1	O
+Infection	B-DISO
+.	O
+
+Mechanical	O
+ventilation	O
+with	O
+high	O
+PEEP	B-CHED
+improved	O
+patient	O
+'	O
+s	O
+gas	B-ENZY
+exchange	O
+parameters	O
+within	O
+3	O
+weeks	O
+.	O
+
+After	O
+successful	O
+drainage	B-ANAT
+therapy	O
+,	O
+the	O
+patient	O
+was	O
+discharged	O
+.	O
+
+In	O
+this	O
+case	O
+,	O
+early	O
+administration	O
+of	O
+acyclovir	B-CHED
+and	O
+a	O
+high	O
+-	O
+dose	O
+of	O
+immunoglobulin	B-PROC
+,	O
+combined	O
+with	O
+mechanical	O
+respiratory	O
+support	O
+,	O
+proved	O
+adequate	O
+for	O
+treatment	O
+of	O
+this	O
+severe	O
+illness	O
+.	O
+
+HKU4	O
+-	O
+RBD	O
+,	O
+however	O
+,	O
+is	O
+less	O
+adapted	O
+to	O
+hCD26	O
+than	O
+MERS	O
+-	O
+RBD	O
+,	O
+explaining	O
+its	O
+lower	O
+affinity	O
+for	O
+receptor	B-FUNC
+binding	I-FUNC
+.	O
+
+We	O
+then	O
+provide	O
+an	O
+in	O
+-	O
+depth	O
+literature	O
+review	O
+to	O
+summarise	O
+the	O
+known	O
+mechanisms	O
+by	O
+which	O
+RNA	O
+viruses	B-SPEC
+of	O
+the	O
+families	O
+Flaviviridae	B-SPEC
+and	O
+Coronaviridae	B-SPEC
+evade	O
+sensing	O
+through	O
+STING	O
+.	O
+
+ABSTRACT	O
+:	O
+Data	O
+regarding	O
+the	O
+treatment	O
+efficacy	O
+of	O
+integrative	O
+treatment	O
+of	O
+Traditional	O
+Chinese	O
+Medicine	B-CHED
+(	O
+TCM	O
+)	O
+and	O
+Western	O
+Medicine	B-CHED
+(	O
+WM	O
+)	O
+in	O
+treating	O
+patients	O
+with	O
+(	O
+SARS	B-DISO
+)	O
+are	O
+conflicting	O
+.	O
+
+Compared	O
+with	O
+patients	O
+receiving	O
+WM	O
+treatment	O
+alone	O
+,	O
+patients	O
+receiving	O
+integrative	O
+treatment	O
+were	O
+more	O
+likely	O
+to	O
+have	O
+complete	O
+or	O
+partial	O
+resolution	O
+of	O
+pulmonary	B-DISO
+infiltrate	I-DISO
+(	O
+RD	O
+=	O
+0	O
+.	O
+18	O
+,	O
+95	O
+%	O
+CI	O
+;	O
+0	O
+.	O
+07	O
+to	O
+0	O
+.	O
+30	O
+),	O
+lower	O
+average	O
+daily	O
+dosage	O
+(	O
+mg	O
+)	O
+of	O
+corticosteroid	B-CHED
+(	O
+WMD	O
+=-	O
+60	O
+.	O
+27	O
+,	O
+95	O
+%	O
+CI	O
+;	O
+-	O
+70	O
+.	O
+58	O
+to	O
+-	O
+49	O
+.	O
+96	O
+),	O
+higher	O
+CD4	B-PRGE
++	I-PRGE
+counts	O
+(	O
+cells	B-COMP
+/	O
+uL	O
+)	O
+(	O
+WMD	O
+=	O
+167	O
+.	O
+96	O
+,	O
+95	O
+%	O
+CI	O
+;	O
+109	O
+.	O
+68	O
+to	O
+226	O
+.	O
+24	O
+),	O
+and	O
+shorter	O
+time	O
+to	O
+defervescence	O
+(	O
+days	O
+)	O
+(	O
+WMD	O
+=	O
+-	O
+1	O
+.	O
+06	O
+,	O
+95	O
+%	O
+CI	O
+;-	O
+1	O
+.	O
+60	O
+to	O
+-	O
+0	O
+.	O
+53	O
+).	O
+
+TITLE	O
+:	O
+Expression	B-PROC
+patterns	O
+of	O
+plasma	B-PRGE
+von	I-PRGE
+Willebrand	I-PRGE
+factor	I-PRGE
+and	O
+serum	B-COMP
+interleukin	B-PRGE
+-	I-PRGE
+8	I-PRGE
+in	O
+patients	O
+with	O
+early	O
+-	O
+stage	O
+severe	O
+pulmonary	O
+contusion	O
+.	O
+
+Interleukin	B-PRGE
+-	I-PRGE
+8	I-PRGE
+(	O
+IL	B-FUNC
+-	I-FUNC
+8	I-FUNC
+),	O
+as	O
+a	O
+proinflammatory	O
+mediator	O
+causing	O
+recruitment	B-DISO
+of	O
+inflammatory	B-ANAT
+cells	I-ANAT
+,	O
+induces	O
+an	O
+increase	O
+in	O
+oxidant	B-CHED
+stress	O
+mediators	O
+and	O
+makes	O
+it	O
+as	O
+a	O
+key	O
+parameter	O
+for	O
+localized	O
+inflammation	B-DISO
+.	O
+
+This	O
+study	O
+was	O
+to	O
+investigate	O
+the	O
+expression	B-PROC
+of	O
+plasma	B-PRGE
+vWF	I-PRGE
+and	O
+IL	B-FUNC
+-	I-FUNC
+8	I-FUNC
+and	O
+their	O
+association	O
+with	O
+the	O
+severity	O
+and	O
+outcomes	O
+of	O
+severe	O
+pulmonary	B-ANAT
+contusion	O
+.	O
+
+The	O
+concentrations	O
+of	O
+plasma	B-ANAT
+vWF	B-PRGE
+and	O
+serum	B-PRGE
+IL	B-FUNC
+-	I-FUNC
+8	I-FUNC
+were	O
+significantly	O
+increased	O
+in	O
+all	O
+severe	O
+pulmonary	B-ANAT
+contusion	O
+patients	O
+at	O
+all	O
+time	O
+points	O
+in	O
+comparison	O
+with	O
+the	O
+control	O
+group	O
+.	O
+
+The	O
+concentrations	O
+of	O
+plasma	B-ANAT
+vWF	B-PRGE
+in	O
+patients	O
+with	O
+ARDS	B-DISO
+increased	O
+during	O
+the	O
+whole	O
+study	O
+period	O
+,	O
+but	O
+vWF	B-PRGE
+in	O
+patients	O
+with	O
+non	O
+-	O
+ARDS	B-DISO
+increased	O
+gradually	O
+until	O
+day	O
+5	O
+and	O
+then	O
+decreased	O
+at	O
+day	O
+7	O
+.	O
+
+CONCLUSIONS	O
+:	O
+The	O
+elevated	O
+levels	O
+of	O
+plasma	B-PRGE
+vWF	I-PRGE
+and	O
+serum	B-PRGE
+IL	B-FUNC
+-	I-FUNC
+8	I-FUNC
+in	O
+severe	O
+pulmonary	B-ANAT
+contusion	O
+patients	O
+reflect	O
+the	O
+severity	O
+of	O
+pulmonary	B-ANAT
+injury	O
+and	O
+patients	O
+outcomes	O
+,	O
+suggesting	O
+that	O
+the	O
+plasma	B-ANAT
+vWF	B-PRGE
+and	O
+serum	B-PRGE
+IL	B-FUNC
+-	I-FUNC
+8	I-FUNC
+are	O
+sensitive	O
+markers	O
+for	O
+clinical	O
+evaluation	O
+of	O
+the	O
+severity	O
+of	O
+pulmonary	B-ANAT
+injury	O
+and	O
+predication	O
+of	O
+patient	O
+prognosis	O
+.	O
+
+The	O
+oxygen	B-CHED
+exchange	O
+levels	O
+of	O
+the	O
+two	O
+groups	O
+were	O
+examined	O
+based	O
+on	O
+the	O
+arterial	B-ANAT
+blood	I-ANAT
+gas	O
+analysis	O
+at	O
+different	O
+times	O
+(	O
+0	O
+,	O
+24	O
+,	O
+72	O
+hours	O
+and	O
+7	O
+days	O
+of	O
+treatment	O
+)	O
+in	O
+the	O
+two	O
+groups	O
+.	O
+
+The	O
+APACHE	O
+II	O
+score	O
+in	O
+the	O
+two	O
+groups	O
+reduced	O
+gradually	O
+after	O
+7	O
+-	O
+day	O
+treatment	O
+,	O
+and	O
+the	O
+APACHE	O
+II	O
+score	O
+on	O
+the	O
+7th	O
+day	O
+in	O
+group	B-DISO
+B	I-DISO
+was	O
+significantly	O
+lower	O
+than	O
+that	O
+in	O
+group	O
+A	O
+(	O
+8	O
+.	O
+2	O
+±	O
+3	O
+.	O
+8	O
+vs	O
+.	O
+17	O
+.	O
+2	O
+±	O
+6	O
+.	O
+8	O
+,	O
+P	O
+<	O
+0	O
+.	O
+01	O
+).	O
+
+RESULTS	O
+:	O
+The	O
+levels	O
+of	O
+CcvO2	O
+,	O
+CaO2	B-CHED
+on	O
+day	O
+7	O
+in	O
+group	O
+A	O
+were	O
+significantly	O
+lower	O
+than	O
+those	O
+in	O
+group	B-DISO
+B	I-DISO
+(	O
+CcvO2	O
+:	O
+0	O
+.	O
+60	O
+±	O
+0	O
+.	O
+24	O
+vs	O
+.	O
+0	O
+.	O
+72	O
+±	O
+0	O
+.	O
+28	O
+,	O
+P	O
+<	O
+0	O
+.	O
+05	O
+;	O
+CaO2	B-CHED
+:	O
+0	O
+.	O
+84	O
+±	O
+0	O
+.	O
+43	O
+vs	O
+.	O
+0	O
+.	O
+94	O
+±	O
+0	O
+.	O
+46	O
+,	O
+P	O
+<	O
+0	O
+.	O
+05	O
+).	O
+
+The	O
+APACHE	O
+II	O
+score	O
+in	O
+the	O
+two	O
+groups	O
+reduced	O
+gradually	O
+after	O
+7	O
+-	O
+day	O
+treatment	O
+,	O
+and	O
+the	O
+APACHE	O
+II	O
+score	O
+on	O
+the	O
+7th	O
+day	O
+in	O
+group	B-DISO
+B	I-DISO
+was	O
+significantly	O
+lower	O
+than	O
+that	O
+in	O
+group	O
+A	O
+(	O
+8	O
+.	O
+2	O
+±	O
+3	O
+.	O
+8	O
+vs	O
+.	O
+17	O
+.	O
+2	O
+±	O
+6	O
+.	O
+8	O
+,	O
+P	O
+<	O
+0	O
+.	O
+01	O
+).	O
+
+Among	O
+chronically	B-DISO
+ill	I-DISO
+patients	O
+,	O
+the	O
+use	O
+of	O
+complementary	O
+and	O
+alternative	O
+medicine	B-CHED
+(	O
+CAM	B-DISO
+)	O
+is	O
+reported	O
+to	O
+be	O
+widespread	O
+.	O
+
+However	O
+,	O
+extremely	O
+little	O
+is	O
+known	O
+about	O
+the	O
+use	O
+of	O
+CAM	B-DISO
+by	O
+SARS	B-DISO
+survivors	O
+in	O
+the	O
+post	O
+-	O
+SARS	B-DISO
+period	O
+and	O
+even	O
+less	O
+is	O
+known	O
+about	O
+how	O
+the	O
+use	O
+of	O
+CAM	B-DISO
+is	O
+related	O
+to	O
+the	O
+unpleasant	O
+social	O
+and	O
+medical	O
+-	O
+treatment	O
+experiences	O
+of	O
+SARS	B-DISO
+survivors	O
+,	O
+their	O
+eagerness	O
+to	O
+re	O
+-	O
+establish	O
+social	O
+networks	O
+,	O
+and	O
+their	O
+awareness	O
+to	O
+prepare	O
+for	O
+future	O
+epidemics	O
+.	O
+
+The	O
+participants	O
+practised	O
+tai	B-PRGE
+chi	I-PRGE
+not	O
+only	O
+because	O
+they	O
+sought	O
+to	O
+improve	O
+their	O
+health	O
+but	O
+also	O
+because	O
+it	O
+provided	O
+a	O
+crucial	O
+social	O
+function	O
+and	O
+meaning	O
+to	O
+them	O
+.	O
+
+TITLE	O
+:	O
+The	O
+genotyping	O
+of	O
+infectious	B-DISO
+bronchitis	B-DISO
+virus	B-SPEC
+in	O
+Taiwan	O
+by	O
+a	O
+multiplex	O
+amplification	B-DISO
+refractory	O
+mutation	O
+system	O
+reverse	O
+transcription	O
+polymerase	O
+chain	O
+reaction	O
+.	O
+
+Following	O
+sequence	O
+alignment	O
+of	O
+IBV	B-SPEC
+strains	O
+,	O
+a	O
+combination	O
+of	O
+selective	O
+primer	O
+sets	O
+was	O
+designed	O
+to	O
+individually	O
+amplify	O
+the	O
+IBV	B-SPEC
+wild	O
+-	O
+type	O
+and	O
+vaccine	O
+strains	O
+using	O
+a	O
+multiplex	O
+amplification	B-DISO
+refractory	O
+mutation	O
+system	O
+reverse	B-PROC
+transcription	I-PROC
+polymerase	O
+chain	O
+reaction	O
+(	O
+ARMS	B-DISO
+RT	O
+-	O
+PCR	O
+)	O
+approach	O
+.	O
+
+This	O
+system	O
+was	O
+shown	O
+to	O
+discriminate	O
+the	O
+IBV	B-SPEC
+wild	O
+-	O
+type	O
+and	O
+vaccine	O
+strains	O
+.	O
+
+TITLE	O
+:	O
+Combined	O
+use	O
+of	O
+non	O
+-	O
+biological	O
+artificial	O
+liver	B-ANAT
+treatments	O
+for	O
+patients	O
+with	O
+acute	B-DISO
+liver	B-ANAT
+failure	I-DISO
+complicated	O
+by	O
+multiple	O
+organ	O
+dysfunction	O
+syndrome	O
+.	O
+
+Heart	B-ANAT
+rate	O
+(	O
+HR	O
+)	O
+before	O
+and	O
+after	O
+treatment	O
+,	O
+mean	O
+arterial	B-ANAT
+pressure	I-PROC
+(	O
+MAP	O
+),	O
+respiratory	O
+index	O
+(	O
+PaO2	O
+/	O
+FiO2	O
+),	O
+hepatic	O
+function	O
+,	O
+platelet	B-ANAT
+count	O
+,	O
+and	O
+blood	B-PROC
+coagulation	I-PROC
+were	O
+determined	O
+.	O
+
+Significant	O
+improvement	O
+was	O
+observed	O
+in	O
+HR	O
+,	O
+MAP	O
+,	O
+PaO2	O
+/	O
+FiO2	O
+,	O
+total	O
+bilirubin	B-CHED
+(	O
+TBIL	O
+)	O
+and	O
+alanine	B-PRGE
+aminotransferase	I-PRGE
+(	O
+ALT	B-FUNC
+)	O
+levels	O
+after	O
+treatment	O
+(	O
+P	O
+<	O
+0	O
+.	O
+05	O
+).	O
+
+ABSTRACT	O
+:	O
+Apoptosis	B-PATH
+of	O
+alveolar	B-ANAT
+macrophages	I-ANAT
+(	O
+AMs	B-DISO
+)	O
+plays	O
+a	O
+pathogenic	O
+role	O
+in	O
+acute	O
+lung	B-ANAT
+injury	O
+(	O
+ALI	O
+)	O
+and	O
+its	O
+severe	O
+type	O
+,	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+(	O
+ARDS	B-DISO
+).	O
+
+In	O
+this	O
+study	O
+,	O
+we	O
+used	O
+a	O
+large	O
+panel	O
+of	O
+human	B-SPEC
+nAbs	O
+against	O
+an	O
+epitope	B-CHED
+that	O
+overlaps	O
+the	O
+interface	O
+between	O
+the	O
+RBD	O
+and	O
+its	O
+receptor	O
+,	O
+angiotensin	B-PRGE
+-	I-PRGE
+converting	I-PRGE
+enzyme	I-PRGE
+2	I-PRGE
+(	O
+ACE2	B-PRGE
+),	O
+to	O
+assess	O
+their	O
+cross	O
+-	O
+neutralization	O
+activities	O
+against	O
+a	O
+panel	O
+of	O
+human	B-SPEC
+and	O
+zoonotic	O
+SARS	B-DISO
+-	O
+CoVs	O
+and	O
+neutralization	O
+escape	O
+mutants	O
+.	O
+
+We	O
+also	O
+investigated	O
+the	O
+neutralization	O
+escape	O
+profiles	O
+of	O
+these	O
+nAbs	O
+and	O
+evaluated	O
+their	O
+effects	O
+on	O
+receptor	B-FUNC
+binding	I-FUNC
+and	O
+virus	O
+fitness	O
+in	O
+vitro	O
+and	O
+in	O
+mice	B-SPEC
+.	O
+
+We	O
+found	O
+that	O
+some	O
+nAbs	O
+had	O
+great	O
+potency	O
+and	O
+breadth	O
+in	O
+neutralizing	O
+multiple	O
+viral	O
+strains	O
+,	O
+including	O
+neutralization	O
+escape	O
+viruses	B-SPEC
+derived	O
+from	O
+other	O
+nAbs	O
+;	O
+however	O
+,	O
+no	O
+single	O
+nAb	O
+or	O
+combination	O
+of	O
+two	O
+blocked	O
+neutralization	O
+escape	O
+.	O
+
+Interestingly	O
+,	O
+in	O
+mice	B-SPEC
+the	O
+neutralization	O
+escape	O
+mutant	B-DISO
+viruses	B-SPEC
+showed	O
+either	O
+attenuation	O
+(	O
+Urbani	O
+background	O
+)	O
+or	O
+increased	O
+virulence	B-PROC
+(	O
+GD03	O
+background	O
+)	O
+consistent	O
+with	O
+the	O
+different	O
+binding	B-FUNC
+affinities	O
+between	O
+their	O
+RBDs	O
+and	O
+the	O
+mouse	B-SPEC
+ACE2	B-PRGE
+.	O
+
+Our	O
+results	O
+suggest	O
+that	O
+targeting	B-PROC
+conserved	O
+regions	O
+with	O
+less	O
+plasticity	O
+and	O
+more	O
+structural	O
+constraint	O
+rather	O
+than	O
+the	O
+SARS	B-DISO
+-	O
+CoV	O
+RBD	O
+-	O
+like	O
+region	O
+(	O
+s	O
+)	O
+should	O
+have	O
+broader	O
+utility	O
+for	O
+antibody	B-COMP
+-	O
+based	O
+immunotherapy	O
+.	O
+
+TITLE	O
+:	O
+Determinants	O
+of	O
+mortality	O
+,	O
+intensive	O
+care	O
+requirement	O
+and	O
+prolonged	O
+hospitalization	O
+in	O
+malaria	B-DISO
+-	O
+a	O
+tertiary	O
+care	O
+hospital	O
+based	O
+cohort	O
+study	O
+from	O
+South	O
+-	O
+Western	O
+India	O
+.	O
+
+A	O
+tertiary	O
+care	O
+hospital	O
+based	O
+retrospective	O
+study	O
+was	O
+conducted	O
+from	O
+the	O
+year	O
+2007	O
+to	O
+2011	O
+among	O
+microscopically	O
+proven	O
+adult	O
+malaria	B-PATH
+patients	O
+.	O
+
+More	O
+than	O
+three	O
+days	O
+of	O
+history	O
+of	O
+fever	B-PROC
+,	O
+cerebral	B-DISO
+malaria	B-PATH
+,	O
+PE	O
+/	O
+ARDS	B-DISO
+,	O
+renal	B-DISO
+failure	I-DISO
+,	O
+metabolic	B-DISO
+acidosis	I-DISO
+,	O
+hyperparasitaemia	O
+,	O
+leucocytosis	B-DISO
+and	O
+severe	O
+thrombocytopaenia	O
+were	O
+independently	O
+associated	O
+factors	O
+with	O
+intensive	O
+care	O
+requirement	O
+.	O
+
+RESULTS	O
+:	O
+Of	O
+a	O
+total	O
+of	O
+922	O
+malaria	B-PATH
+cases	O
+studied	O
+,	O
+more	O
+than	O
+seven	O
+days	O
+of	O
+hospitalization	O
+was	O
+the	O
+most	O
+frequent	O
+outcome	O
+(	O
+21	O
+.	O
+8	O
+%	O
+(	O
+201	O
+),	O
+95	O
+%	O
+CI	O
+=	O
+19	O
+.	O
+1	O
+-	O
+24	O
+.	O
+5	O
+%)	O
+followed	O
+by	O
+intensive	O
+care	O
+requirement	O
+(	O
+8	O
+.	O
+6	O
+%	O
+(	O
+79	O
+),	O
+95	O
+%	O
+CI	O
+=	O
+6	O
+.	O
+8	O
+-	O
+10	O
+.	O
+4	O
+%)	O
+and	O
+in	O
+-	O
+hospital	O
+mortality	O
+(	O
+1	O
+.	O
+2	O
+%	O
+(	O
+11	O
+),	O
+95	O
+%	O
+CI	O
+=	O
+0	O
+.	O
+5	O
+-	O
+1	O
+.	O
+9	O
+%).	O
+
+ABSTRACT	O
+:	O
+To	O
+conduct	B-PROC
+a	O
+country	O
+-	O
+wide	O
+prevalence	O
+study	O
+of	O
+bovine	B-SPEC
+group	B-SPEC
+A	I-SPEC
+rotavirus	I-SPEC
+,	O
+coronavirus	B-SPEC
+,	O
+Cryptosporidium	B-SPEC
+parvum	I-SPEC
+,	O
+Salmonella	B-PRGE
+spp	B-ENZY
+.	O
+and	O
+enterotoxigenic	O
+K99	O
+(+)	O
+Escherichia	B-SPEC
+coli	I-SPEC
+(	O
+K99	O
+)	O
+in	O
+calves	O
+on	O
+New	O
+Zealand	O
+dairy	O
+farms	O
+.	O
+
+The	O
+standardised	O
+farm	O
+prevalences	O
+of	O
+bovine	B-SPEC
+group	B-SPEC
+A	I-SPEC
+rotavirus	I-SPEC
+,	O
+bovine	B-SPEC
+coronavirus	B-SPEC
+and	O
+C	B-SPEC
+.	I-SPEC
+parvum	I-SPEC
+were	O
+46	O
+,	O
+14	O
+and	O
+18	O
+%,	O
+respectively	O
+,	O
+in	O
+calves	O
+that	O
+were	O
+1	O
+-	O
+5	O
+days	O
+-	O
+old	O
+,	O
+and	O
+57	O
+,	O
+31	O
+and	O
+52	O
+%,	O
+respectively	O
+,	O
+in	O
+calves	O
+that	O
+were	O
+9	O
+-	O
+21	O
+days	O
+-	O
+old	O
+.	O
+
+This	O
+study	O
+provides	O
+epidemiological	O
+estimates	O
+of	O
+the	O
+prevalence	O
+of	O
+calves	O
+'	O
+enteropathogens	O
+in	O
+New	O
+Zealand	O
+,	O
+which	O
+could	O
+be	O
+used	O
+for	O
+infection	B-DISO
+risk	O
+assessment	O
+or	O
+estimation	O
+of	O
+the	O
+environmental	O
+loads	O
+of	O
+pathogens	O
+shed	O
+in	O
+cattle	B-SPEC
+faeces	B-ANAT
+.	O
+
+Using	O
+the	O
+Gravy	O
+,	O
+Aroma	B-CHED
+,	O
+and	O
+CAI	O
+values	O
+,	O
+a	O
+role	O
+of	O
+natural	O
+selection	O
+in	O
+the	O
+PEDV	B-SPEC
+codon	O
+usage	O
+pattern	O
+was	O
+also	O
+identified	O
+.	O
+
+Neutral	O
+analysis	O
+indicated	O
+that	O
+natural	O
+selection	O
+pressure	O
+plays	O
+a	O
+more	O
+important	O
+role	O
+than	O
+mutational	O
+bias	B-SPEC
+in	O
+codon	O
+usage	O
+bias	B-SPEC
+.	O
+
+TITLE	O
+:	O
+Searching	O
+for	O
+an	O
+ideal	O
+vaccine	O
+candidate	O
+among	O
+different	O
+MERS	B-PRGE
+coronavirus	B-SPEC
+receptor	I-PRGE
+-	I-PRGE
+binding	B-FUNC
+fragments	I-PRGE
+--	O
+the	O
+importance	O
+of	O
+immunofocusing	O
+in	O
+subunit	O
+vaccine	O
+design	O
+.	O
+
+ABSTRACT	O
+:	O
+Non	O
+-	O
+pharmaceutical	O
+interventions	O
+(	O
+NPIs	O
+)	O
+are	O
+an	O
+important	O
+public	O
+health	O
+tool	O
+for	O
+responding	O
+to	O
+infectious	B-DISO
+disease	I-DISO
+outbreaks	O
+,	O
+including	O
+pandemics	O
+.	O
+
+This	O
+study	O
+draws	O
+on	O
+survey	O
+data	O
+from	O
+four	O
+regions	O
+--	O
+Hong	O
+Kong	O
+,	O
+Singapore	O
+,	O
+Taiwan	O
+,	O
+and	O
+the	O
+United	O
+States	O
+--	O
+collected	O
+following	O
+the	O
+Severe	B-DISO
+Acute	I-DISO
+Respiratory	I-DISO
+Syndrome	I-DISO
+(	O
+SARS	B-DISO
+)	O
+outbreak	O
+of	O
+2002	O
+-	O
+03	O
+,	O
+and	O
+employs	O
+regression	O
+techniques	O
+to	O
+estimate	O
+predictors	O
+of	O
+NPI	O
+support	O
+.	O
+
+Although	O
+dromedary	B-SPEC
+camels	B-SPEC
+appear	O
+to	O
+be	O
+the	O
+most	O
+important	O
+source	O
+in	O
+primary	O
+cases	O
+,	O
+nosocomial	O
+transmission	O
+has	O
+proved	O
+to	O
+be	O
+a	O
+major	O
+cause	O
+of	O
+secondary	B-DISO
+infections	I-DISO
+.	O
+
+TITLE	O
+:	O
+The	O
+role	O
+of	O
+myeloid	B-PROC
+cell	I-PROC
+activation	I-PROC
+and	O
+arginine	B-PROC
+metabolism	I-PROC
+in	O
+the	O
+pathogenesis	B-DISO
+of	O
+virus	B-SPEC
+-	O
+induced	O
+diseases	O
+.	O
+
+NO	O
+has	O
+direct	O
+antiviral	B-CHED
+properties	O
+against	O
+some	O
+viruses	B-SPEC
+,	O
+whereas	O
+during	O
+other	O
+virus	B-SPEC
+infections	B-DISO
+NO	O
+can	O
+mediate	O
+immunopathology	B-DISO
+and	O
+/	O
+or	O
+inhibit	O
+the	O
+antiviral	B-CHED
+immune	B-PROC
+response	I-PROC
+to	O
+promote	O
+chronic	B-DISO
+infection	I-DISO
+.	O
+
+RAGE	O
+and	O
+cytokeratin	O
+18	O
+isoforms	O
+correlated	O
+significantly	O
+but	O
+to	O
+a	O
+low	O
+extent	O
+with	O
+interleukin	B-PRGE
+6	I-PRGE
+,	O
+while	O
+the	O
+isoforms	O
+of	O
+both	O
+parameters	O
+correlated	O
+to	O
+a	O
+high	O
+extent	O
+with	O
+one	O
+another	O
+.	O
+
+TITLE	O
+:	O
+Incidence	O
+rate	O
+of	O
+community	O
+-	O
+acquired	O
+sepsis	B-DISO
+among	O
+hospitalized	O
+acute	O
+medical	O
+patients	O
+-	O
+a	O
+population	O
+-	O
+based	O
+survey	O
+.	O
+
+Through	O
+the	O
+review	O
+and	O
+analysis	O
+of	O
+the	O
+available	O
+disease	O
+models	O
+,	O
+investigators	O
+can	O
+employ	O
+the	O
+most	O
+appropriate	O
+available	O
+model	O
+to	O
+study	O
+various	O
+aspects	O
+of	O
+CoV	O
+pathogenesis	O
+and	O
+evaluate	O
+possible	O
+antiviral	B-CHED
+treatments	O
+that	O
+may	O
+potentially	O
+be	O
+successful	O
+in	O
+future	O
+treatment	O
+and	O
+prevention	O
+of	O
+severe	O
+CoV	O
+respiratory	B-DISO
+infections	I-DISO
+.	O
+
+TITLE	O
+:	O
+Detection	O
+of	O
+Influenza	B-DISO
+and	O
+Other	O
+Respiratory	O
+Viruses	B-SPEC
+Carried	O
+Out	O
+in	O
+the	O
+Influenza	B-DISO
+Project	O
+-	O
+Monitoring	O
+Vaccine	O
+Effectiveness	O
+(	O
+I	O
+-	O
+MOVE	O
+).	O
+
+TITLE	O
+:	O
+An	O
+evaluation	O
+of	O
+a	O
+liquid	O
+antimicrobial	B-CHED
+(	O
+Sal	B-CHED
+CURB	O
+®)	O
+for	O
+reducing	O
+the	O
+risk	O
+of	O
+porcine	B-SPEC
+epidemic	B-DISO
+diarrhea	I-DISO
+virus	B-DISO
+infection	I-DISO
+of	O
+naïve	O
+pigs	B-SPEC
+during	O
+consumption	O
+of	O
+contaminated	O
+feed	O
+.	O
+
+To	O
+test	O
+its	O
+effect	O
+against	O
+PEDV	B-SPEC
+,	O
+Sal	B-CHED
+CURB	O
+®-	O
+treated	O
+feed	O
+was	O
+spiked	O
+with	O
+a	O
+stock	O
+isolate	O
+of	O
+PEDV	B-SPEC
+(	O
+Ct	O
+=	O
+25	O
+.	O
+22	O
+),	O
+which	O
+PEDV	B-SPEC
+-	O
+naïve	O
+piglets	O
+were	O
+allowed	O
+to	O
+ingest	O
+via	O
+natural	O
+feeding	B-PROC
+behavior	I-PROC
+(	O
+ad	O
+libitum	O
+)	O
+for	O
+a	O
+14	O
+-	O
+day	O
+period	O
+.	O
+
+TITLE	O
+:	O
+Overlapping	O
+and	O
+distinct	O
+molecular	O
+determinants	O
+dictating	O
+the	O
+antiviral	B-CHED
+activities	O
+of	O
+TRIM56	B-PRGE
+against	O
+flaviviruses	O
+and	O
+coronavirus	B-SPEC
+.	O
+
+Moreover	O
+,	O
+by	O
+engineering	O
+cell	B-COMP
+lines	I-ANAT
+conditionally	O
+expressing	O
+various	O
+TRIM56	B-PRGE
+mutants	I-PRGE
+,	O
+we	O
+demonstrated	O
+that	O
+TRIM56	B-PRGE
+'	O
+s	O
+antiflavivirus	O
+effects	O
+required	O
+both	O
+the	O
+E3	B-PRGE
+ligase	I-PRGE
+activity	O
+that	O
+lies	O
+in	O
+the	O
+N	O
+-	O
+terminal	O
+RING	O
+domain	O
+and	O
+the	O
+integrity	O
+of	O
+its	O
+C	O
+-	O
+terminal	O
+portion	O
+,	O
+while	O
+the	O
+restriction	O
+of	O
+HCoV	B-SPEC
+-	I-SPEC
+OC43	I-SPEC
+relied	O
+upon	O
+the	O
+TRIM56	B-PRGE
+E3	I-PRGE
+ligase	I-PRGE
+activity	O
+alone	O
+.	O
+
+Herein	O
+,	O
+we	O
+demonstrate	O
+that	O
+TRIM56	B-PRGE
+restricts	O
+two	O
+medically	O
+important	O
+flaviviruses	B-SPEC
+,	O
+yellow	B-SPEC
+fever	I-SPEC
+virus	I-SPEC
+(	O
+YFV	B-SPEC
+)	O
+and	O
+dengue	B-SPEC
+virus	I-SPEC
+serotype	O
+2	O
+(	O
+DENV2	O
+),	O
+and	O
+a	O
+human	B-SPEC
+coronavirus	I-SPEC
+,	O
+HCoV	B-SPEC
+-	I-SPEC
+OC43	I-SPEC
+,	O
+but	O
+not	O
+encephalomyocarditis	B-SPEC
+virus	I-SPEC
+,	O
+a	O
+picornavirus	B-SPEC
+.	O
+
+TITLE	O
+:	O
+Genotypic	O
+characterization	O
+of	O
+canine	O
+coronaviruses	O
+associated	O
+with	O
+fatal	O
+canine	O
+neonatal	O
+enteritis	B-DISO
+in	O
+the	O
+United	O
+States	O
+.	O
+
+Comparative	O
+sequence	O
+analyses	O
+of	O
+viral	O
+RNA	O
+extracted	O
+from	O
+intestinal	B-ANAT
+tissues	B-ANAT
+revealed	O
+CCoV	O
+-	O
+II	O
+genotype	O
+in	O
+9	O
+out	O
+of	O
+11	O
+puppies	O
+.	O
+
+Infection	B-DISO
+with	O
+CCoV	O
+alone	O
+was	O
+found	O
+in	O
+five	O
+puppies	O
+,	O
+of	O
+which	O
+two	O
+also	O
+had	O
+small	B-ANAT
+intestinal	I-ANAT
+intussusception	O
+.	O
+
+Similar	O
+differences	O
+were	O
+not	O
+observed	O
+in	O
+A549	O
+cells	B-COMP
+,	O
+suggesting	O
+that	O
+cellular	B-COMP
+context	O
+and	O
+/	O
+or	O
+IFITM	O
+expression	B-PROC
+levels	O
+can	O
+impact	O
+inhibition	B-PROC
+efficiency	O
+.	O
+
+TITLE	O
+:	O
+Diagnostic	O
+value	O
+of	O
+surfactant	B-CHED
+protein	B-CHED
+-	O
+a	O
+in	O
+severe	O
+acute	B-DISO
+pancreatitis	I-DISO
+-	O
+induced	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+.	O
+
+The	O
+best	O
+cut	O
+-	O
+off	O
+value	O
+for	O
+the	O
+serum	B-COMP
+SP	B-PRGE
+-	I-PRGE
+A	I-PRGE
+level	O
+for	O
+the	O
+diagnosis	O
+of	O
+SAP	B-PRGE
+-	O
+induced	O
+ARDS	B-DISO
+was	O
+150	O
+ug	O
+/	O
+ml	O
+and	O
+the	O
+area	O
+under	O
+the	O
+ROC	O
+curve	O
+of	O
+SP	O
+-	O
+A	O
+was	O
+0	O
+.	O
+88	O
+.	O
+
+RESULTS	O
+:	O
+Serum	B-COMP
+SP	B-PRGE
+-	I-PRGE
+A	I-PRGE
+levels	O
+in	O
+Baseline	O
+,	O
+SO	O
+group	O
+,	O
+SAP	B-PRGE
+group	O
+,	O
+ARDS	B-DISO
+group	O
+,	O
+and	O
+non	O
+-	O
+ARDS	B-DISO
+group	O
+were	O
+43	O
+.	O
+15	O
+±	O
+14	O
+.	O
+29	O
+,	O
+51	O
+.	O
+91	O
+±	O
+16	O
+.	O
+99	O
+,	O
+193	O
+.	O
+4	O
+±	O
+35	O
+.	O
+37	O
+,	O
+198	O
+.	O
+0	O
++	O
+29	O
+.	O
+73	O
+,	O
+and	O
+185	O
+.	O
+7	O
+±	O
+43	O
+.	O
+21	O
+ug	O
+/	O
+ml	O
+,	O
+respectively	O
+.	O
+
+Uniaxial	O
+stretch	O
+(	O
+10	O
+-	O
+30	O
+%	O
+in	O
+strain	O
+)	O
+was	O
+applied	O
+to	O
+fibroblasts	B-ANAT
+cultured	O
+in	O
+a	O
+silicone	B-CHED
+chamber	B-ANAT
+coated	O
+with	O
+type	B-PRGE
+I	I-PRGE
+collagen	I-PRGE
+using	O
+a	O
+stretching	O
+apparatus	B-ANAT
+.	O
+
+In	O
+spite	O
+of	O
+several	O
+outbreaks	O
+in	O
+the	O
+very	O
+recent	O
+years	O
+,	O
+no	O
+vaccine	O
+against	O
+this	O
+deadly	O
+virus	B-SPEC
+is	O
+developed	O
+yet	O
+.	O
+
+The	O
+immune	O
+parameters	O
+of	O
+this	O
+region	O
+were	O
+determined	O
+using	O
+different	O
+in	O
+silico	O
+tools	O
+and	O
+Immune	O
+Epitope	B-CHED
+Database	O
+(	O
+IEDB	O
+).	O
+
+The	O
+state	O
+of	O
+the	O
+art	O
+of	O
+extracorporeal	O
+lung	B-ANAT
+support	O
+is	O
+presented	O
+with	O
+an	O
+overview	O
+of	O
+the	O
+different	O
+systems	O
+,	O
+the	O
+indications	O
+,	O
+efficiency	O
+and	O
+potential	O
+side	O
+effects	O
+.	O
+
+Due	O
+to	O
+potentially	O
+severe	O
+complications	O
+the	O
+use	O
+should	O
+be	O
+restricted	O
+to	O
+specialized	O
+centers	O
+with	O
+experience	O
+in	O
+the	O
+treatment	O
+of	O
+severe	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+(	O
+ARDS	B-DISO
+).	O
+
+RESULTS	O
+:	O
+The	O
+VV	O
+-	O
+ECMO	O
+systems	O
+may	O
+be	O
+indicated	O
+in	O
+severe	O
+,	O
+refractory	O
+and	O
+predominantly	O
+hypoxemic	O
+lung	B-ANAT
+failure	O
+(	O
+pAO2	O
+/	O
+FIO2	O
+<	O
+80	O
+mmHg	O
+).	O
+
+All	O
+patients	O
+achieved	O
+neutrophil	B-ANAT
+engraftment	B-PROC
+by	O
+a	O
+median	O
+of	O
+day	O
+18	O
+(	O
+range	O
+:	O
+day	O
+11	O
+-	O
+61	O
+).	O
+
+The	O
+incidences	O
+of	O
+II	O
+-	O
+IV	O
+or	O
+III	O
+-	O
+IV	O
+acute	B-DISO
+GVHD	I-DISO
+were	O
+nine	O
+(	O
+81	O
+.	O
+8	O
+%)	O
+or	O
+seven	O
+patients	O
+(	O
+63	O
+.	O
+6	O
+%),	O
+respectively	O
+.	O
+
+Chronic	B-DISO
+GVHD	I-DISO
+was	O
+observed	O
+in	O
+five	O
+(	O
+55	O
+.	O
+6	O
+%)	O
+out	O
+of	O
+nine	O
+evaluable	B-DISO
+patients	O
+.	O
+
+Stimulation	O
+of	O
+epithelial	B-FUNC
+sodium	I-FUNC
+channel	I-FUNC
+(	O
+ENaC	O
+)	O
+promotes	O
+Na	O
+(+)	O
+transport	B-PROC
+,	O
+a	O
+rate	O
+-	O
+limiting	O
+step	O
+for	O
+pulmonary	B-DISO
+edema	I-DISO
+reabsorption	O
+.	O
+
+However	O
+,	O
+the	O
+contribution	O
+of	O
+these	O
+cofactors	B-CHED
+to	O
+immunity	B-PROC
+and	O
+disease	O
+incidence	O
+has	O
+not	O
+been	O
+determined	O
+.	O
+
+The	O
+cats	B-SPEC
+were	O
+housed	O
+under	O
+optimized	O
+conditions	O
+of	O
+nutrition	O
+,	O
+husbandry	O
+,	O
+and	O
+quarantine	O
+to	O
+eliminate	O
+most	O
+of	O
+the	O
+cofactors	B-CHED
+implicated	O
+in	O
+FIPV	O
+infection	B-DISO
+outcome	O
+and	O
+were	O
+uniformly	O
+challenge	O
+exposed	O
+to	O
+the	O
+same	O
+field	O
+strain	O
+of	O
+serotype	O
+1	O
+FIPV	O
+.	O
+
+Exposure	O
+to	O
+non	O
+-	O
+FIP	B-DISO
+-	O
+inducing	O
+feline	B-SPEC
+coronaviruses	O
+prior	O
+to	O
+challenge	O
+with	O
+virulent	O
+FIPV	O
+did	O
+not	O
+significantly	O
+affect	O
+FIP	B-DISO
+incidence	O
+but	O
+did	O
+accelerate	O
+the	O
+disease	O
+course	O
+in	O
+some	O
+cats	B-SPEC
+.	O
+
+Multidimensional	O
+scaling	O
+(	O
+MDS	B-DISO
+)	O
+segregated	O
+the	O
+107	O
+cats	B-SPEC
+into	O
+three	O
+distinct	O
+families	O
+based	O
+primarily	O
+on	O
+a	O
+common	O
+sire	O
+(	O
+s	O
+),	O
+and	O
+resistant	O
+and	O
+susceptible	O
+cats	B-SPEC
+were	O
+equally	O
+distributed	O
+within	O
+each	O
+family	B-SPEC
+.	O
+
+TITLE	O
+:	O
+Efficacy	O
+of	O
+continuous	O
+renal	B-ANAT
+replacement	O
+therapy	O
+in	O
+the	O
+treatment	O
+of	O
+severe	O
+acute	B-DISO
+pancreatitis	I-DISO
+associated	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+.	O
+
+Arterial	B-ANAT
+oxygen	B-PROC
+tension	B-DISO
+(	O
+PaO2	O
+),	O
+oxygenation	B-PROC
+index	O
+(	O
+OI	O
+)	O
+as	O
+well	O
+as	O
+dynamic	O
+pulmonary	B-ANAT
+compliance	O
+were	O
+all	O
+elevated	O
+significantly	O
+,	O
+whereas	O
+peak	O
+inspiratory	B-PROC
+pressure	O
+significantly	O
+decreased	O
+at	O
+6h	O
+,	O
+12h	O
+and	O
+24h	O
+after	O
+CRRT	O
+respectively	O
+;	O
+serum	B-COMP
+cytokine	O
+level	O
+and	O
+CRP	B-PRGE
+significantly	O
+decreased	O
+(	O
+p	O
+<	O
+0	O
+.	O
+05	O
+).	O
+
+In	O
+the	O
+present	O
+study	O
+,	O
+we	O
+demonstrated	O
+that	O
+the	O
+C	O
+-	O
+terminus	O
+of	O
+M	B-PRGE
+-	I-PRGE
+protein	I-PRGE
+interacts	O
+with	O
+the	O
+PH	O
+(	O
+pleckstrin	B-PRGE
+homology	O
+)	O
+domain	O
+of	O
+PDK1	B-FUNC
+.	O
+
+TITLE	O
+:	O
+Evidence	O
+of	O
+recombinant	O
+strains	O
+of	O
+porcine	B-SPEC
+epidemic	I-SPEC
+diarrhea	I-SPEC
+virus	I-SPEC
+,	O
+United	O
+States	O
+,	O
+2013	O
+.	O
+
+TITLE	O
+:	O
+[	O
+Complete	O
+genomic	O
+analysis	O
+of	O
+a	O
+novel	O
+infectious	B-DISO
+bronchitis	B-DISO
+virus	B-SPEC
+isolate	O
+].	O
+
+The	O
+complete	O
+genome	O
+of	O
+CK	O
+/	O
+CH	O
+/	O
+SD09	O
+/	O
+005	O
+consisted	O
+of	O
+27691	O
+nucleotides	B-CHED
+(	O
+nt	O
+),	O
+excluding	O
+the	O
+5	O
+'	O
+cap	B-DISO
+and	O
+3	O
+'	O
+poly	O
+A	O
+tail	O
+.	O
+
+When	O
+compared	O
+with	O
+all	O
+reference	O
+strains	O
+except	O
+GX	O
+-	O
+NN09032	O
+,	O
+CK	O
+/	O
+CH	O
+/	O
+SD09	O
+/	O
+005	O
+showed	O
+the	O
+highest	O
+similarity	O
+to	O
+ck	O
+/	O
+CH	O
+/	O
+LDL	O
+/	O
+091022	O
+and	O
+SDIB821	O
+/	O
+2012	O
+(	O
+QX	O
+-	O
+like	O
+)	O
+in	O
+the	O
+replicase	B-PRGE
+gene	I-PRGE
+(	O
+Gene	B-PRGE
+1	I-PRGE
+)	O
+and	O
+3	O
+'	O
+UTR	O
+,	O
+with	O
+a	O
+sequence	O
+identity	O
+rate	O
+of	O
+97	O
+%	O
+and	O
+98	O
+%,	O
+respectively	O
+.	O
+
+However	O
+,	O
+CK	O
+/	O
+CH	O
+/	O
+SD09	O
+/	O
+005	O
+exhibited	O
+lower	O
+levels	O
+of	O
+similarity	O
+with	O
+ck	O
+/	O
+CH	O
+/	O
+LDL	B-CHED
+/	O
+091022	O
+and	O
+SDIB821	O
+/	O
+2012	O
+in	O
+S	O
+-	O
+3a	O
+-	O
+3b	O
+-	O
+3c	O
+/	O
+E	O
+-	O
+M	O
+-	O
+5a	O
+-	O
+5b	O
+-	O
+N	O
+with	O
+a	O
+sequence	O
+identity	O
+of	O
+72	O
+%	O
+-	O
+90	O
+%.	O
+
+ABSTRACT	O
+:	O
+This	O
+study	O
+aimed	O
+to	O
+understand	O
+the	O
+dynamic	O
+distribution	O
+of	O
+infectious	B-DISO
+bronchitis	B-DISO
+virus	B-SPEC
+(	O
+IBV	B-SPEC
+)	O
+Jin	O
+-	O
+13	O
+strain	O
+in	O
+SPF	B-PRGE
+chickens	I-PRGE
+.	O
+
+Samples	O
+of	O
+heart	B-ANAT
+,	O
+liver	B-ANAT
+,	O
+spleen	B-ANAT
+,	O
+lung	B-ANAT
+,	O
+trachea	B-DISO
+,	O
+kidney	B-ANAT
+and	O
+duodenum	B-ANAT
+were	O
+collected	O
+and	O
+the	O
+N	B-PRGE
+gene	I-PRGE
+was	O
+detected	O
+by	O
+Sybr	B-CHED
+Green	I-CHED
+I	I-CHED
+real	O
+-	O
+time	O
+quantitative	O
+RT	O
+-	O
+PCR	O
+assays	O
+.	O
+
+All	O
+specimens	O
+were	O
+examined	O
+by	O
+multiplex	O
+RT	O
+-	O
+PCR	O
+for	O
+the	O
+following	O
+15	O
+respiratory	B-ANAT
+tract	I-ANAT
+viruses	B-SPEC
+:	O
+adenovirus	B-DISO
+(	O
+ADV	O
+),	O
+human	B-SPEC
+rhinovirus	I-SPEC
+(	O
+HRV	O
+),	O
+human	B-SPEC
+parainfluenza	B-DISO
+virus	B-SPEC
+(	O
+PIV	O
+types	O
+1	O
+-	O
+4	O
+),	O
+influenza	B-SPEC
+virus	I-SPEC
+A	O
+(	O
+FluA	O
+),	O
+influenza	B-SPEC
+virus	I-SPEC
+B	O
+(	O
+FluB	O
+),	O
+human	B-SPEC
+enterovirus	B-SPEC
+(	O
+HEV	B-SPEC
+),	O
+respiratory	B-SPEC
+syncytial	I-SPEC
+virus	I-SPEC
+(	O
+RSV	B-SPEC
+-	O
+A	O
+and	O
+-	O
+B	O
+),	O
+human	B-SPEC
+metapneumovirus	I-SPEC
+(	O
+HMPV	B-SPEC
+),	O
+human	B-SPEC
+coronavirus	I-SPEC
+(	O
+HCoV	B-SPEC
+-	I-SPEC
+229E	I-SPEC
+/	O
+NL63	O
+and	O
+-	O
+OC43	O
+/	O
+HKU1	O
+),	O
+and	O
+human	B-SPEC
+bocavirus	I-SPEC
+(	O
+HBoV	O
+).	O
+
+Among	O
+the	O
+483	O
+cases	O
+of	O
+ILI	O
+,	O
+214	O
+(	O
+44	O
+.	O
+31	O
+%)	O
+were	O
+positive	O
+for	O
+viruses	B-SPEC
+,	O
+including	O
+ADV	O
+(	O
+8	O
+.	O
+7	O
+%),	O
+HEV	O
+(	O
+8	O
+.	O
+7	O
+%),	O
+RSV	B-PRGE
+-	I-PRGE
+A	I-PRGE
+(	O
+8	O
+.	O
+07	O
+%),	O
+HRV	O
+(	O
+7	O
+.	O
+45	O
+%),	O
+FluA	O
+(	O
+5	O
+.	O
+38	O
+%),	O
+HCoV	B-SPEC
+-	I-SPEC
+OC43	I-SPEC
+/	O
+HKU1	O
+(	O
+2	O
+.	O
+9	O
+%),	O
+PIV	O
+-	O
+3	O
+(	O
+2	O
+.	O
+9	O
+%),	O
+HMPV	B-SPEC
+(	O
+1	O
+.	O
+86	O
+%),	O
+PIV	O
+-	O
+1	O
+(	O
+1	O
+.	O
+24	O
+%),	O
+HCoV	B-SPEC
+-	I-SPEC
+229E	I-SPEC
+/	O
+NL63	O
+(	O
+1	O
+.	O
+04	O
+%),	O
+PIV	O
+-	O
+2	O
+(	O
+1	O
+.	O
+04	O
+%),	O
+HBoV	O
+(	O
+0	O
+.	O
+83	O
+%),	O
+and	O
+FluB	O
+(	O
+0	O
+.	O
+41	O
+%).	O
+
+Recent	O
+disease	O
+outbreaks	O
+such	O
+as	O
+Nipah	B-SPEC
+virus	I-SPEC
+,	O
+SARS	B-DISO
+,	O
+avian	B-DISO
+influenza	I-DISO
+H5N1	B-DISO
+,	O
+bluetongue	B-DISO
+serotype	O
+8	O
+and	O
+Schmallenberg	O
+virus	B-SPEC
+have	O
+led	O
+to	O
+realising	O
+that	O
+we	O
+need	O
+to	O
+explicitly	O
+take	O
+into	O
+account	O
+the	O
+underlying	O
+complex	O
+interactions	O
+between	O
+environmental	O
+,	O
+epidemiological	O
+and	O
+social	O
+factors	O
+which	O
+are	O
+often	O
+also	O
+spatially	O
+and	O
+temporally	O
+heterogeneous	O
+as	O
+well	O
+as	O
+interconnected	O
+across	O
+affected	O
+regions	O
+and	O
+beyond	O
+.	O
+
+ALI	O
+is	O
+characterized	O
+by	O
+marked	O
+acute	O
+inflammation	B-DISO
+with	O
+elevated	O
+alveolar	B-ANAT
+cytokine	O
+levels	O
+.	O
+
+LPS	B-DISO
+-	O
+induced	O
+acute	O
+lung	B-DISO
+inflammation	I-DISO
+was	O
+significantly	O
+exacerbated	O
+in	O
+Spred	O
+-	O
+2	O
+(-/-)	O
+mice	B-SPEC
+compared	O
+with	O
+WT	O
+mice	B-SPEC
+,	O
+as	O
+indicated	O
+by	O
+the	O
+numbers	O
+of	O
+infiltrating	B-DISO
+leukocytes	B-ANAT
+,	O
+levels	O
+of	O
+alveolar	B-PRGE
+TNF	I-PRGE
+-	I-PRGE
+α	I-PRGE
+,	O
+CXCL2	B-PRGE
+and	O
+CCL2	B-PRGE
+in	O
+a	O
+later	O
+phase	O
+,	O
+and	O
+lung	B-ANAT
+pathology	B-DISO
+.	O
+
+Mini	O
+-	O
+genome	O
+replication	O
+studies	O
+and	O
+virus	B-SPEC
+reassortment	O
+experiments	O
+demonstrated	O
+that	O
+bat	B-ENZY
+-	O
+influenza	B-DISO
+has	O
+very	O
+limited	O
+genetic	O
+and	O
+protein	B-CHED
+compatibility	O
+with	O
+Type	O
+A	O
+or	O
+Type	O
+B	O
+influenza	B-SPEC
+viruses	I-SPEC
+,	O
+yet	O
+it	O
+readily	O
+reassorts	O
+with	O
+another	O
+divergent	O
+bat	B-ENZY
+-	O
+influenza	B-SPEC
+virus	I-SPEC
+,	O
+suggesting	O
+that	O
+the	O
+bat	B-ENZY
+-	O
+influenza	B-DISO
+lineage	O
+may	O
+represent	O
+a	O
+new	O
+Genus	B-SPEC
+/	O
+Species	B-SPEC
+within	O
+the	O
+Orthomyxoviridae	B-SPEC
+family	B-SPEC
+.	O
+
+Collectively	O
+,	O
+our	O
+data	O
+indicate	O
+that	O
+the	O
+bat	B-ENZY
+-	O
+influenza	B-SPEC
+viruses	I-SPEC
+recently	O
+identified	O
+are	O
+authentic	O
+viruses	B-SPEC
+that	O
+pose	O
+little	O
+,	O
+if	O
+any	O
+,	O
+pandemic	O
+threat	O
+to	O
+humans	B-SPEC
+;	O
+however	O
+,	O
+they	O
+provide	O
+new	O
+insights	O
+into	O
+the	O
+evolution	B-PROC
+and	O
+basic	O
+biology	O
+of	O
+influenza	B-SPEC
+viruses	I-SPEC
+.	O
+
+ABSTRACT	O
+:	O
+The	O
+recent	O
+emergence	O
+of	O
+Middle	O
+East	O
+Respiratory	O
+Syndrome	O
+Coronavirus	B-SPEC
+(	O
+MERS	O
+-	O
+CoV	O
+),	O
+nearly	O
+a	O
+decade	O
+after	O
+the	O
+Severe	B-DISO
+Acute	I-DISO
+Respiratory	I-DISO
+Syndrome	I-DISO
+(	O
+SARS	B-DISO
+)	O
+CoV	O
+,	O
+highlights	O
+the	O
+importance	O
+of	O
+understanding	O
+and	O
+developing	O
+therapeutic	O
+treatment	O
+for	O
+current	O
+and	O
+emergent	O
+CoVs	O
+.	O
+
+Importantly	O
+,	O
+the	O
+work	O
+also	O
+identifies	O
+a	O
+number	O
+of	O
+approaches	O
+to	O
+exploit	O
+this	O
+understanding	O
+for	O
+therapeutic	O
+treatment	O
+and	O
+the	O
+data	O
+clearly	O
+illustrate	O
+the	O
+importance	O
+of	O
+NSP16	B-PRGE
+2	I-PRGE
+'	I-PRGE
+O	I-PRGE
+-	I-PRGE
+MTase	I-PRGE
+activity	O
+for	O
+CoV	O
+infection	B-DISO
+and	O
+pathogenesis	B-DISO
+.	O
+
+In	O
+patients	O
+with	O
+severe	O
+MERS	O
+-	O
+CoV	O
+infection	B-DISO
+,	O
+ribavirin	B-CHED
+and	O
+interferon	B-PRGE
+alfa	I-PRGE
+-	I-PRGE
+2a	I-PRGE
+therapy	O
+is	O
+associated	O
+with	O
+significantly	O
+improved	O
+survival	O
+at	O
+14	O
+days	O
+,	O
+but	O
+not	O
+at	O
+28	O
+days	O
+.	O
+
+TITLE	O
+:	O
+Pathogenesis	B-PROC
+of	O
+porcine	B-SPEC
+epidemic	I-SPEC
+diarrhea	I-SPEC
+virus	I-SPEC
+isolate	O
+(	O
+US	O
+/	O
+Iowa	O
+/	O
+18984	O
+/	O
+2013	O
+)	O
+in	O
+3	O
+-	O
+week	O
+-	O
+old	O
+weaned	B-PROC
+pigs	B-SPEC
+.	O
+
+Diarrhea	B-DISO
+was	O
+observed	O
+in	O
+challenged	O
+pigs	B-SPEC
+beginning	O
+for	O
+some	O
+on	O
+dpi	O
+2	O
+,	O
+affecting	O
+a	O
+majority	O
+of	O
+pigs	B-SPEC
+by	O
+dpi	O
+6	O
+and	O
+subsiding	O
+by	O
+dpi	O
+10	O
+.	O
+
+Average	O
+daily	O
+gain	O
+was	O
+significantly	O
+lower	O
+(	O
+P	O
+<	O
+0	O
+.	O
+001	O
+)	O
+for	O
+one	O
+week	O
+post	O
+-	O
+infection	B-DISO
+in	O
+challenged	O
+pigs	B-SPEC
+.	O
+
+ABSTRACT	O
+:	O
+Porcine	O
+epidemic	O
+diarrhea	O
+virus	O
+(	O
+PEDV	B-SPEC
+),	O
+which	O
+emerged	O
+in	O
+the	O
+United	O
+States	O
+in	O
+2013	O
+,	O
+has	O
+spread	O
+throughout	O
+North	O
+America	O
+.	O
+
+TITLE	O
+:	O
+The	O
+spray	O
+-	O
+drying	O
+process	O
+is	O
+sufficient	O
+to	O
+inactivate	O
+infectious	B-DISO
+porcine	B-SPEC
+epidemic	B-DISO
+diarrhea	I-DISO
+virus	I-SPEC
+in	O
+plasma	O
+.	O
+
+In	O
+contrast	O
+,	O
+PEDV	B-PRGE
+RNA	I-PRGE
+in	O
+feces	B-ANAT
+was	O
+not	O
+detected	O
+in	O
+any	O
+of	O
+the	O
+pigs	B-SPEC
+in	O
+the	O
+other	O
+groups	O
+including	O
+the	O
+SD	O
+-	O
+PEDV	B-SPEC
+-	O
+CONTROL	O
+group	O
+and	O
+none	O
+of	O
+the	O
+pigs	B-SPEC
+had	O
+seroconverted	O
+by	O
+termination	O
+of	O
+the	O
+project	O
+at	O
+dpi	O
+28	O
+.	O
+
+Additionally	O
+,	O
+plasma	B-ANAT
+collected	O
+from	O
+PEDV	B-SPEC
+infected	O
+pigs	B-SPEC
+at	O
+peak	O
+disease	O
+did	O
+not	O
+contain	O
+infectious	B-DISO
+PEDV	B-SPEC
+.	O
+
+Moreover	O
+,	O
+>	O
+140	O
+,	O
+000	O
+deaths	B-PROC
+occur	O
+annually	O
+as	O
+a	O
+result	O
+of	O
+chronic	O
+lung	B-DISO
+diseases	I-DISO
+,	O
+some	O
+of	O
+which	O
+may	O
+be	O
+complicated	O
+by	O
+an	O
+infectious	B-DISO
+process	I-DISO
+.	O
+
+Herein	O
+,	O
+we	O
+present	O
+host	B-COMP
+and	O
+viral	O
+factors	O
+that	O
+participate	O
+in	O
+the	O
+regulation	B-PROC
+of	O
+the	O
+possible	O
+pathogenic	O
+processes	O
+associated	O
+with	O
+CNS	B-DISO
+infection	I-DISO
+by	O
+human	B-SPEC
+coronaviruses	O
+and	O
+we	O
+try	O
+to	O
+decipher	O
+the	O
+intricate	O
+interplay	O
+between	O
+virus	B-SPEC
+and	O
+host	B-COMP
+target	B-ANAT
+cells	I-ANAT
+in	O
+order	B-SPEC
+to	O
+characterize	O
+their	O
+role	O
+in	O
+the	O
+virus	B-SPEC
+life	O
+cycle	O
+as	O
+well	O
+as	O
+in	O
+the	O
+capacity	O
+of	O
+the	O
+cell	B-COMP
+to	O
+respond	O
+to	O
+viral	O
+invasion	B-DISO
+.	O
+
+ABSTRACT	O
+:	O
+Asthma	B-PATH
+is	O
+the	O
+most	O
+common	O
+chronic	B-DISO
+disease	I-DISO
+in	O
+childhood	O
+.	O
+
+Viruses	B-SPEC
+were	O
+detected	O
+in	O
+23	O
+.	O
+8	O
+%	O
+of	O
+them	O
+(	O
+30	O
+/	O
+126	O
+).	O
+
+We	O
+report	O
+here	O
+a	O
+carbohydrate	B-CHED
+microarray	O
+analysis	O
+of	O
+a	O
+number	O
+of	O
+tumor	B-DISO
+-	O
+associated	O
+carbohydrates	B-CHED
+for	O
+their	O
+serum	B-COMP
+antibody	B-COMP
+reactivities	O
+and	O
+potential	O
+immunogenicity	O
+in	O
+humans	B-SPEC
+.	O
+
+ABSTRACT	O
+:	O
+Optimal	O
+ventilator	O
+management	O
+for	O
+patients	O
+with	O
+acute	O
+respiratory	O
+distress	O
+syndrome	O
+(	O
+ARDS	B-DISO
+)	O
+remains	O
+uncertain	O
+.	O
+
+Although	O
+MERS	O
+-	O
+CoV	O
+remained	O
+detectable	O
+in	O
+the	O
+respiratory	B-ANAT
+tract	I-ANAT
+secretions	B-ANAT
+of	O
+the	O
+patient	O
+until	O
+the	O
+fourth	O
+week	O
+of	O
+illness	O
+,	O
+viraemia	B-DISO
+was	O
+last	O
+detected	O
+2	O
+days	O
+after	O
+initiation	O
+of	O
+triple	O
+combination	O
+therapy	O
+with	O
+pegylated	O
+interferon	B-PRGE
+,	O
+ribavirin	B-CHED
+and	O
+lopinavir	O
+/	O
+ritonavir	B-CHED
+,	O
+administered	O
+from	O
+Day	O
+13	O
+of	O
+illness	O
+.	O
+
+The	O
+coronavirus	B-SPEC
+spike	O
+(	O
+S	O
+)	O
+protein	B-CHED
+is	O
+the	O
+main	O
+determinant	O
+of	O
+viral	O
+entry	O
+,	O
+and	O
+although	O
+it	O
+was	O
+previously	O
+shown	O
+that	O
+MERS	O
+-	O
+CoV	O
+S	O
+can	O
+be	O
+activated	O
+by	O
+various	O
+proteases	O
+,	O
+the	O
+details	O
+of	O
+the	O
+mechanisms	O
+of	O
+proteolytic	B-PROC
+activation	O
+of	O
+fusion	O
+are	O
+still	O
+incompletely	O
+characterized	O
+.	O
+
+Inhibition	B-PROC
+of	O
+furin	B-PROC
+activity	I-PROC
+was	O
+shown	O
+to	O
+decrease	O
+MERS	O
+-	O
+CoV	O
+S	O
+-	O
+mediated	O
+entry	O
+,	O
+as	O
+well	O
+as	O
+infection	B-DISO
+by	O
+the	O
+virus	B-SPEC
+.	O
+
+ABSTRACT	O
+:	O
+In	O
+September	O
+2012	O
+a	O
+novel	O
+coronavirus	O
+(	O
+CoV	O
+)	O
+caused	O
+severe	O
+respiratory	B-DISO
+tract	I-DISO
+infections	I-DISO
+in	O
+patients	O
+from	O
+The	O
+Arabian	O
+Peninsula	O
+.	O
+
+This	O
+value	O
+of	O
+the	O
+serial	O
+interval	O
+for	O
+pertussis	B-PATH
+is	O
+,	O
+to	O
+the	O
+best	O
+of	O
+our	O
+knowledge	O
+,	O
+the	O
+first	O
+that	O
+is	O
+based	O
+on	O
+observations	O
+.	O
+
+ABSTRACT	O
+:	O
+Characterization	O
+of	O
+canine	O
+coronavirus	O
+(	O
+CCoV	O
+)	O
+strains	O
+currently	O
+in	O
+circulation	B-PROC
+is	O
+essential	O
+for	O
+understanding	O
+viral	O
+evolution	B-PROC
+.	O
+
+TITLE	O
+:	O
+The	O
+economic	O
+effect	O
+of	O
+extracorporeal	O
+membrane	B-COMP
+oxygenation	B-PROC
+to	O
+support	O
+adults	O
+with	O
+severe	O
+respiratory	B-DISO
+failure	I-DISO
+in	O
+Brazil	O
+:	O
+a	O
+hypothetical	O
+analysis	O
+.	O
+
+ABSTRACT	O
+:	O
+Coronaviruses	O
+contain	O
+a	O
+positive	O
+-	O
+sense	B-PROC
+single	O
+-	O
+stranded	O
+genomic	O
+(	O
+g	O
+)	O
+RNA	O
+,	O
+which	O
+encodes	O
+nonstructural	O
+proteins	B-CHED
+.	O
+
+Appropriate	O
+readthrough	O
+of	O
+body	B-ANAT
+TRSs	O
+is	O
+required	O
+to	O
+produce	O
+longer	O
+sgmRNAs	O
+and	O
+full	O
+-	O
+length	O
+gRNA	O
+.	O
+
+We	O
+find	O
+that	O
+phosphorylation	B-PROC
+of	O
+the	O
+viral	B-COMP
+nucleocapsid	I-COMP
+(	O
+N	O
+)	O
+by	O
+host	B-COMP
+glycogen	B-PRGE
+synthase	I-PRGE
+kinase	I-PRGE
+-	I-PRGE
+3	I-PRGE
+(	O
+GSK	B-PRGE
+-	I-PRGE
+3	I-PRGE
+)	O
+is	O
+required	O
+for	O
+template	O
+switching	O
+.	O
+
+Here	O
+,	O
+we	O
+report	O
+ECMO	O
+as	O
+a	O
+bridge	O
+for	O
+right	B-ANAT
+main	I-ANAT
+bronchus	I-ANAT
+reconstruction	O
+and	O
+recovery	O
+of	O
+traumatic	B-DISO
+wet	I-DISO
+lung	I-DISO
+in	O
+a	O
+31	O
+-	O
+year	O
+-	O
+old	O
+male	O
+multi	O
+-	O
+trauma	O
+patient	O
+with	O
+right	O
+main	O
+bronchial	B-ANAT
+disruption	O
+,	O
+bilateral	O
+pulmonary	B-ANAT
+contusion	O
+,	O
+cerebral	B-ANAT
+contusion	O
+and	O
+long	B-ANAT
+bone	I-ANAT
+fracture	O
+.	O
+
+TITLE	O
+:	O
+Porcine	B-SPEC
+epidemic	I-SPEC
+diarrhea	I-SPEC
+virus	B-DISO
+infection	I-DISO
+:	O
+inhibition	B-PROC
+by	O
+polysaccharide	B-CHED
+from	O
+Ginkgo	B-SPEC
+biloba	I-SPEC
+exocarp	O
+and	O
+mode	O
+of	O
+its	O
+action	O
+.	O
+
+Polysaccharide	B-CHED
+also	O
+showed	O
+effective	O
+inhibitory	O
+effects	O
+when	O
+added	O
+at	O
+the	O
+viral	O
+attachment	O
+and	O
+entry	O
+steps	O
+.	O
+
+Moreover	O
+,	O
+polysaccharide	B-CHED
+effectively	O
+inactivated	O
+PEDV	B-SPEC
+infection	B-DISO
+in	O
+time	O
+-,	O
+dose	O
+-	O
+and	O
+temperature	O
+-	O
+dependent	O
+manners	O
+.	O
+
+Overall	O
+,	O
+this	O
+research	O
+revealed	O
+that	O
+polysaccharide	O
+could	O
+inhibit	O
+PEDV	B-SPEC
+infection	B-DISO
+,	O
+and	O
+that	O
+polysaccharide	B-CHED
+may	O
+be	O
+involved	O
+in	O
+PEDV	B-SPEC
+-	O
+Vero	B-ANAT
+cell	I-ANAT
+interactions	O
+,	O
+as	O
+the	O
+virus	B-SPEC
+attachment	O
+and	O
+entry	O
+to	O
+the	O
+Vero	B-ANAT
+cells	I-ANAT
+was	O
+hindered	O
+by	O
+the	O
+polysaccharide	B-CHED
+.	O
+
+Refractory	O
+seizures	B-DISO
+,	O
+GCS	O
+<	O
+8	O
+,	O
+bradycardia	B-DISO
+,	O
+shock	O
+and	O
+severe	O
+anaemia	B-DISO
+were	O
+independent	O
+predictors	O
+for	O
+mortality	O
+in	O
+children	O
+of	O
+AFE	O
+.	O
+
+The	O
+development	B-PROC
+of	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+is	O
+associated	O
+with	O
+increased	O
+mortality	O
+and	O
+higher	O
+prevalence	O
+of	O
+complications	O
+,	O
+representing	O
+the	O
+actual	O
+challenge	O
+in	O
+the	O
+management	O
+of	O
+children	O
+with	O
+severe	O
+acute	B-DISO
+viral	I-DISO
+bronchiolitis	I-DISO
+.	O
+
+Anemia	B-DISO
+was	O
+observed	O
+in	O
+78	O
+%	O
+of	O
+the	O
+sample	O
+.	O
+
+Fever	B-PROC
+(	O
+43	O
+,	O
+61	O
+.	O
+4	O
+%),	O
+dyspnea	B-DISO
+(	O
+42	O
+,	O
+60	O
+%),	O
+and	O
+cough	B-DISO
+(	O
+38	O
+,	O
+54	O
+.	O
+3	O
+%)	O
+were	O
+the	O
+most	O
+common	O
+symptoms	O
+.	O
+
+The	O
+majority	O
+developed	O
+pneumonia	B-DISO
+(	O
+63	O
+,	O
+90	O
+%)	O
+and	O
+required	O
+intensive	O
+care	O
+(	O
+49	O
+,	O
+70	O
+%).	O
+
+MERS	O
+-	O
+CoV	O
+can	O
+cause	O
+severe	O
+infection	B-DISO
+requiring	O
+intensive	O
+care	O
+and	O
+has	O
+a	O
+high	O
+mortality	O
+.	O
+
+TITLE	O
+:	O
+Coronavirus	B-SPEC
+-	O
+induced	O
+ER	B-PROC
+stress	I-PROC
+response	I-PROC
+and	O
+its	O
+involvement	O
+in	O
+regulation	B-PROC
+of	O
+coronavirus	B-SPEC
+-	O
+host	B-COMP
+interactions	O
+.	O
+
+We	O
+analyzed	O
+the	O
+impact	O
+of	O
+this	O
+negative	O
+fluid	B-PROC
+balance	I-PROC
+strategy	O
+upon	O
+pulmonary	B-ANAT
+,	O
+hemodynamic	B-PROC
+,	O
+and	O
+renal	B-PROC
+function	I-PROC
+.	O
+
+Three	O
+out	O
+of	O
+four	O
+hypoxic	B-DISO
+patients	O
+with	O
+elevated	O
+EVLWI	O
+tolerated	O
+the	O
+NFB	O
+protocol	O
+.	O
+
+Noninvasive	O
+mechanical	O
+ventilation	O
+is	O
+an	O
+alternative	O
+treatment	O
+for	O
+patients	O
+with	O
+COPD	B-DISO
+exacerbations	O
+.	O
+
+The	O
+objective	O
+of	O
+the	O
+literature	O
+reviews	O
+was	O
+to	O
+verify	O
+noninvasive	O
+mechanical	O
+ventilation	O
+benefits	O
+and	O
+complications	O
+in	O
+acute	O
+exacerbations	O
+of	O
+chronic	B-DISO
+obstructive	I-DISO
+pulmonary	I-DISO
+disease	I-DISO
+in	O
+patients	O
+.	O
+
+Instead	O
+,	O
+UV	O
+-	O
+inactivated	O
+SHXB	O
+(	O
+UV	O
+-	O
+SHXB	O
+)	O
+had	O
+the	O
+opposite	O
+effects	O
+in	O
+immature	O
+Mo	O
+-	O
+DCs	B-DISO
+.	O
+
+Genetic	B-PROC
+polymorphisms	I-PROC
+are	O
+gene	O
+variations	O
+in	O
+at	O
+least	O
+1	O
+%	O
+population	O
+.	O
+
+These	O
+gene	O
+variations	O
+may	O
+influence	O
+the	O
+inflammatory	O
+response	O
+mediators	O
+'	O
+expression	B-PROC
+,	O
+directly	O
+affecting	O
+the	O
+susceptibility	O
+to	O
+acute	O
+lung	B-ANAT
+injury	O
+,	O
+the	O
+intensity	O
+of	O
+lung	B-ANAT
+parenchyma	I-ANAT
+inflammation	B-DISO
+,	O
+the	O
+development	B-PROC
+clinical	O
+course	O
+and	O
+outcome	O
+.	O
+
+TITLE	O
+:	O
+Evaluation	O
+of	O
+indirect	O
+immunofluorescence	O
+antibody	B-COMP
+test	O
+and	O
+enzyme	O
+-	O
+linked	O
+immunosorbent	O
+assay	O
+for	O
+the	O
+diagnosis	O
+of	O
+infection	O
+by	O
+Leishmania	O
+infantum	O
+in	O
+clinically	O
+normal	O
+and	O
+sick	O
+cats	B-SPEC
+.	O
+
+Overall	O
+,	O
+the	O
+conservation	O
+pattern	O
+identified	O
+for	O
+5	O
+'	O
+and	O
+3	O
+'-	O
+terminal	O
+RNA	O
+structural	O
+elements	O
+in	O
+the	O
+genomes	O
+of	O
+alpha	O
+-	O
+and	O
+betacoronaviruses	O
+is	O
+in	O
+agreement	O
+with	O
+the	O
+widely	O
+used	O
+replicase	B-PRGE
+polyprotein	O
+-	O
+based	O
+classification	O
+of	O
+the	O
+Coronavirinae	B-SPEC
+,	O
+suggesting	O
+co	O
+-	O
+evolution	B-PROC
+of	O
+the	O
+coronavirus	B-SPEC
+replication	O
+machinery	O
+with	O
+cognate	O
+cis	B-DISO
+-	O
+acting	O
+RNA	O
+elements	O
+.	O
+
+To	O
+investigate	O
+if	O
+this	O
+change	O
+was	O
+sustained	O
+,	O
+nasal	B-ANAT
+and	O
+hand	O
+carriage	O
+rates	O
+were	O
+compared	O
+between	O
+the	O
+earlier	O
+studies	O
+and	O
+a	O
+further	O
+sampling	O
+in	O
+2011	O
+.	O
+
+In	O
+2011	O
+,	O
+nasal	B-ANAT
+carriage	O
+was	O
+similar	O
+to	O
+2003	O
+(	O
+22	O
+·	O
+9	O
+%),	O
+while	O
+hand	O
+contamination	O
+dropped	O
+further	O
+to	O
+3	O
+·	O
+7	O
+%	O
+(	O
+P	O
+<	O
+0	O
+·	O
+001	O
+).	O
+
+The	O
+majority	O
+of	O
+respondents	O
+set	O
+permissive	O
+blood	B-PROC
+gas	B-ENZY
+targets	O
+(	O
+hypoxia	B-DISO
+(	O
+92	O
+%),	O
+hypercapnia	B-DISO
+(	O
+58	O
+%)	O
+and	O
+pH	O
+(	O
+90	O
+%)).	O
+
+Diffuse	O
+interstitial	B-ANAT
+alveolar	B-ANAT
+infiltrates	B-DISO
+were	O
+seen	O
+in	O
+the	O
+chest	B-ANAT
+X	O
+-	O
+Ray	B-SPEC
+.	O
+
+He	O
+developed	O
+multiple	O
+organ	B-ANAT
+dysfunction	O
+syndromes	B-DISO
+(	O
+pulmonary	B-ANAT
+,	O
+renal	B-ANAT
+,	O
+coagulation	B-PROC
+,	O
+cardiovascular	B-ANAT
+and	O
+metabolic	B-PROC
+).	O
+
+The	O
+most	O
+important	O
+laboratory	O
+findings	O
+were	O
+thrombocytopenia	O
+,	O
+elevated	O
+hematocrit	O
+and	O
+hemoglobin	O
+concentrations	O
+,	O
+elevated	O
+liver	B-ANAT
+enzymes	O
+,	O
+elevated	O
+lactate	B-PRGE
+dehydrogenase	I-PRGE
+and	O
+a	O
+positive	O
+sorology	O
+for	O
+Hantavirus	B-SPEC
+(	O
+ELISA	O
+IgM	B-PRGE
+positive	O
+).	O
+
+An	O
+early	O
+and	O
+adequate	O
+resuscitation	O
+with	O
+goal	O
+-	O
+directed	O
+therapy	O
+enabled	O
+the	O
+reversion	O
+of	O
+the	O
+multiple	B-DISO
+organ	I-DISO
+failure	I-DISO
+syndromes	B-DISO
+and	O
+a	O
+favorable	O
+outcome	O
+,	O
+despite	O
+the	O
+severity	O
+of	O
+the	O
+disease	O
+.	O
+
+ABSTRACT	O
+:	O
+Corticosteroids	B-CHED
+were	O
+introduced	O
+in	O
+the	O
+treatment	O
+of	O
+severe	O
+infection	O
+as	O
+early	O
+as	O
+in	O
+the	O
+nineteen	O
+forties	O
+.	O
+
+When	O
+the	O
+results	O
+of	O
+the	O
+ACTH	B-PRGE
+test	O
+are	O
+available	O
+,	O
+treatment	O
+should	O
+be	O
+continued	O
+for	O
+7	O
+days	O
+in	O
+the	O
+non	O
+responders	O
+to	O
+ACTH	B-PRGE
+and	O
+withdraw	O
+in	O
+the	O
+responders	O
+.	O
+
+Whether	O
+responders	O
+to	O
+ACTH	B-PRGE
+with	O
+high	O
+baseline	O
+cortisol	B-CHED
+levels	O
+(>	O
+34	O
+µg	O
+/	O
+dL	O
+)	O
+have	O
+tissue	B-ANAT
+resistance	B-PROC
+to	O
+cortisol	B-CHED
+and	O
+also	O
+should	O
+receive	O
+exogenous	O
+hormones	B-CHED
+remains	O
+to	O
+be	O
+evaluated	O
+in	O
+clinical	O
+trials	O
+.	O
+
+Although	O
+the	O
+mortality	O
+rate	O
+from	O
+sepsis	B-DISO
+in	O
+children	O
+has	O
+steadily	O
+decreased	O
+in	O
+the	O
+last	O
+decades	O
+,	O
+the	O
+mortality	O
+rate	O
+in	O
+newborns	O
+remains	O
+high	O
+(	O
+20	O
+%	O
+to	O
+40	O
+%)	O
+despite	O
+the	O
+development	B-PROC
+in	O
+intensive	O
+care	O
+.	O
+
+The	O
+administration	O
+of	O
+the	O
+drug	O
+was	O
+successful	O
+and	O
+the	O
+patient	O
+recovered	O
+from	O
+the	O
+organ	B-ANAT
+dysfunction	O
+without	O
+bleeding	B-DISO
+.	O
+
+The	O
+data	O
+were	O
+collected	O
+by	O
+face	B-DISO
+-	O
+to	O
+-	O
+face	B-DISO
+interviews	O
+in	O
+the	O
+period	O
+of	O
+October	O
+2005	O
+to	O
+March	O
+2006	O
+.	O
+
+Thirty	O
+one	O
+(	O
+44	O
+.	O
+3	O
+%)	O
+of	O
+the	O
+interviewed	O
+finds	O
+the	O
+ideal	O
+PEEP	B-CHED
+through	O
+the	O
+best	O
+SpO2	O
+with	O
+minor	O
+FiO2	O
+.	O
+
+A	O
+15	O
+-	O
+year	O
+-	O
+old	O
+man	B-CHED
+with	O
+human	B-DISO
+immunodeficiency	I-DISO
+virus	I-DISO
+(	O
+HIV	B-DISO
+)	O
+infection	B-DISO
+and	O
+a	O
+29	O
+-	O
+year	O
+-	O
+old	O
+immunocompetent	O
+female	O
+were	O
+admitted	O
+in	O
+the	O
+ICU	O
+with	O
+primary	O
+varicella	B-DISO
+infection	I-DISO
+and	O
+pneumonia	B-DISO
+.	O
+
+A	O
+bronchial	B-ANAT
+sample	O
+of	O
+sputum	B-ANAT
+showed	O
+Strongyloides	B-SPEC
+stercoralis	I-SPEC
+worms	B-DISO
+.	O
+
+The	O
+severity	O
+form	O
+of	O
+the	O
+disease	O
+is	O
+caused	O
+,	O
+mainly	O
+by	O
+P	O
+.	O
+falciparum	O
+and	O
+may	O
+occur	O
+together	O
+with	O
+cerebral	B-ANAT
+,	O
+kidney	B-ANAT
+,	O
+pulmonary	B-ANAT
+,	O
+hematologic	O
+,	O
+circulatory	B-PROC
+and	O
+hepatic	B-ANAT
+complications	O
+.	O
+
+During	O
+his	O
+stay	O
+at	O
+the	O
+hospital	O
+,	O
+P	O
+.	O
+Falciparum	B-DISO
+Malaria	I-DISO
+was	O
+diagnosed	O
+through	O
+the	O
+thick	O
+drop	O
+test	O
+.	O
+
+After	O
+being	O
+discharged	O
+from	O
+the	O
+hospital	O
+,	O
+the	O
+patient	O
+did	O
+not	O
+present	O
+any	O
+cerebral	B-ANAT
+,	O
+pulmonary	B-ANAT
+or	O
+kidney	B-ANAT
+sequel	O
+.	O
+
+ABSTRACT	O
+:	O
+This	O
+prospective	O
+longitudinal	O
+study	O
+investigated	O
+the	O
+epidemiology	O
+of	O
+enteric	O
+disease	O
+associated	O
+with	O
+infections	B-DISO
+in	O
+calves	O
+aging	B-PROC
+up	O
+to	O
+70	O
+days	O
+.	O
+
+A	O
+total	O
+of	O
+850	O
+fecal	B-ANAT
+samples	O
+were	O
+collected	O
+from	O
+67	O
+calves	O
+.	O
+
+Virulence	B-PROC
+factors	O
+of	O
+Escherichia	B-SPEC
+coli	I-SPEC
+were	O
+identified	O
+in	O
+103	O
+strains	O
+:	O
+eae	O
+(	O
+7	O
+),	O
+K99	B-PRGE
+/	I-PRGE
+STa	I-PRGE
+(	I-PRGE
+7	I-PRGE
+),	I-PRGE
+Stx1	I-PRGE
+(	I-PRGE
+7	I-PRGE
+),	I-PRGE
+Stx1	B-PRGE
+/	I-PRGE
+eae	I-PRGE
+(	I-PRGE
+36	I-PRGE
+),	I-PRGE
+Stx1	B-PRGE
+/	O
+Stx2	B-PRGE
+/	O
+eae	O
+(	O
+2	O
+),	O
+Stx2	B-PRGE
+(	O
+43	O
+),	O
+and	O
+Stx2	B-PRGE
+/	I-PRGE
+eae	I-PRGE
+(	I-PRGE
+1	I-PRGE
+).	I-PRGE
+
+Rotavirus	B-SPEC
+was	O
+detected	O
+in	O
+49	O
+(	O
+5	O
+.	O
+76	O
+%)	O
+fecal	B-ANAT
+samples	O
+collected	O
+from	O
+33	O
+calves	O
+(	O
+49	O
+.	O
+2	O
+%).	O
+
+TITLE	O
+:	O
+Evolutionary	O
+and	O
+bioinformatic	O
+analysis	O
+of	O
+the	O
+spike	O
+glycoprotein	B-CHED
+gene	O
+of	O
+H120	O
+vaccine	O
+strain	O
+protectotype	O
+of	O
+infectious	O
+bronchitis	B-DISO
+virus	B-SPEC
+from	O
+India	O
+.	O
+
+Nucleotide	B-CHED
+and	O
+amino	B-CHED
+acid	I-CHED
+sequence	O
+comparisons	O
+have	O
+shown	O
+that	O
+the	O
+reported	O
+spike	O
+gene	O
+from	O
+Indian	O
+isolates	O
+have	O
+71	O
+.	O
+8	O
+%-	O
+99	O
+%	O
+and	O
+71	O
+.	O
+4	O
+%-	O
+96	O
+.	O
+9	O
+%	O
+genetic	O
+similarity	O
+with	O
+the	O
+sequenced	O
+H120	O
+strain	O
+.	O
+
+Based	O
+on	O
+nucleotide	B-CHED
+and	O
+amino	B-CHED
+acid	I-CHED
+relatedness	O
+studies	O
+of	O
+the	O
+vaccine	O
+strain	O
+with	O
+reported	O
+IBV	B-SPEC
+sequences	O
+from	O
+India	O
+,	O
+it	O
+is	O
+shown	O
+that	O
+the	O
+current	O
+vaccine	O
+strain	O
+is	O
+efficient	O
+in	O
+controlling	O
+the	O
+IBV	B-SPEC
+infection	B-DISO
+.	O
+
+ABSTRACT	O
+:	O
+Acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+(	O
+ARDS	B-DISO
+)	O
+is	O
+an	O
+uncommon	O
+condition	B-DISO
+in	O
+pregnant	O
+patients	O
+.	O
+
+CONCLUSIONS	O
+:	O
+Serious	O
+community	O
+-	O
+based	O
+infectious	B-DISO
+diseases	I-DISO
+are	O
+a	O
+personal	O
+concern	O
+for	O
+GPs	B-DISO
+and	O
+FPs	B-FUNC
+,	O
+and	O
+have	O
+considerable	O
+effects	O
+on	O
+their	O
+clinical	O
+practice	O
+.	O
+
+Nasopharyngeal	B-ANAT
+aspirates	B-ANAT
+were	O
+obtained	O
+from	O
+162	O
+individuals	O
+between	O
+August	O
+2007	O
+-	O
+August	O
+2009	O
+.	O
+
+Mechanically	O
+ventilated	O
+ICU	O
+patients	O
+were	O
+screened	O
+for	O
+severe	O
+hypoxemic	O
+respiratory	B-DISO
+failure	I-DISO
+(	O
+Murray	O
+lung	B-ANAT
+injury	O
+score	O
+of	O
+≥	O
+3	O
+).	O
+
+Survival	O
+to	O
+hospital	O
+discharge	B-ANAT
+was	O
+the	O
+dependent	O
+variable	O
+.	O
+
+Severe	O
+hyperammonemia	B-DISO
+(	O
+677	O
+μmol	O
+/	O
+L	O
+,	O
+reference	O
+range	O
+≤	O
+60	O
+μmol	O
+/	O
+L	O
+)	O
+was	O
+identified	O
+in	O
+one	O
+animal	B-SPEC
+with	O
+signs	O
+of	O
+encephalopathic	O
+disease	O
+that	O
+subsequently	O
+died	B-PROC
+.	O
+
+Viruses	B-SPEC
+from	O
+Riyadh	O
+and	O
+Jeddah	O
+were	O
+isolated	O
+and	O
+studied	O
+in	O
+cell	B-COMP
+culture	O
+.	O
+
+Here	O
+,	O
+we	O
+report	O
+the	O
+case	O
+of	O
+a	O
+child	O
+(	O
+German	O
+,	O
+male	O
+)	O
+with	O
+H1N1	O
+-	O
+associated	O
+fulminate	B-CHED
+respiratory	O
+and	O
+secondary	O
+hemodynamic	B-PROC
+deterioration	O
+who	O
+was	O
+rescued	O
+by	O
+initial	O
+emergent	O
+ECMO	O
+established	O
+through	O
+a	O
+dialysis	B-SPEC
+catheter	O
+and	O
+subsequent	O
+switch	O
+to	O
+central	O
+cannulation	O
+following	O
+median	O
+sternotomy	O
+.	O
+
+Exposure	O
+to	O
+MERS	O
+-	O
+CoV	O
+via	O
+direct	O
+contact	O
+with	O
+animals	B-SPEC
+or	O
+dairy	O
+products	O
+seems	O
+unlikely	O
+for	O
+the	O
+two	O
+Dutch	O
+cases	O
+.	O
+
+More	O
+comprehensive	O
+research	O
+into	O
+sources	O
+of	O
+infection	B-DISO
+in	O
+the	O
+Arabian	O
+Peninsula	O
+is	O
+needed	O
+to	O
+strengthen	O
+and	O
+specify	O
+the	O
+prevention	O
+of	O
+MERS	O
+-	O
+CoV	O
+infections	B-DISO
+.	O
+
+RESULTS	O
+:	O
+Twelve	O
+non	O
+-	O
+cases	O
+drank	O
+unpasteurized	O
+camel	B-SPEC
+milk	O
+and	O
+had	O
+contact	O
+with	O
+camels	B-SPEC
+.	O
+
+In	O
+parallel	O
+,	O
+DNA	O
+aptamers	O
+that	O
+form	O
+G4s	O
+have	O
+been	O
+described	O
+as	O
+inhibitors	B-CHED
+and	O
+diagnostic	O
+tools	O
+to	O
+detect	O
+viruses	B-SPEC
+[	O
+e	O
+.	O
+g	O
+.,	O
+hepatitis	B-SPEC
+A	I-SPEC
+virus	I-SPEC
+(	O
+HAV	B-DISO
+),	O
+EBV	O
+,	O
+cauliflower	B-SPEC
+mosaic	I-SPEC
+virus	I-SPEC
+(	O
+CaMV	B-SPEC
+),	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+virus	B-SPEC
+(	O
+SARS	B-DISO
+),	O
+simian	B-SPEC
+virus	I-SPEC
+40	I-SPEC
+(	O
+SV40	B-SPEC
+)].	O
+
+TITLE	O
+:	O
+Proteome	O
+profile	O
+of	O
+swine	B-SPEC
+testicular	O
+cells	B-COMP
+infected	O
+with	O
+porcine	B-SPEC
+transmissible	I-DISO
+gastroenteritis	I-DISO
+coronavirus	O
+.	O
+
+ABSTRACT	O
+:	O
+The	O
+interactions	O
+occurring	O
+between	O
+a	O
+virus	B-SPEC
+and	O
+a	O
+host	B-COMP
+cell	I-COMP
+during	O
+a	O
+viral	B-DISO
+infection	I-DISO
+are	O
+complex	O
+.	O
+
+A	O
+proteomic	O
+approach	O
+using	O
+isobaric	O
+tags	O
+for	O
+relative	O
+and	O
+absolute	O
+quantitation	O
+(	O
+iTRAQ	O
+)-	O
+coupled	O
+two	O
+-	O
+dimensional	O
+liquid	O
+chromatography	O
+-	O
+tandem	O
+mass	O
+spectrometry	O
+identification	O
+was	O
+conducted	O
+on	O
+the	O
+TGEV	B-SPEC
+-	O
+infected	O
+ST	O
+cells	B-COMP
+.	O
+
+To	O
+our	O
+knowledge	O
+,	O
+this	O
+study	O
+is	O
+the	O
+first	O
+time	O
+the	O
+response	O
+profile	O
+of	O
+ST	O
+host	B-COMP
+cells	B-COMP
+following	O
+TGEV	B-SPEC
+infection	B-DISO
+has	O
+been	O
+analyzed	O
+using	O
+iTRAQ	O
+technology	O
+,	O
+and	O
+our	O
+description	O
+of	O
+the	O
+late	O
+proteomic	O
+changes	O
+that	O
+are	O
+occurring	O
+after	O
+the	O
+time	O
+of	O
+vigorous	O
+viral	O
+production	O
+are	O
+novel	O
+.	O
+
+TITLE	O
+:	O
+Swift	B-SPEC
+recovery	O
+of	O
+severe	O
+acute	O
+hypoxemic	O
+respiratory	B-DISO
+failure	I-DISO
+under	O
+non	O
+-	O
+invasive	O
+ventilation	O
+.	O
+
+High	O
+eosinophilia	B-DISO
+is	O
+connected	O
+with	O
+production	O
+of	O
+cytotoxic	O
+eosinophilic	O
+proteins	B-CHED
+which	O
+can	O
+cause	O
+eosinophilic	O
+vasculitis	B-DISO
+or	O
+eosinophilic	B-DISO
+myocarditis	I-DISO
+.	O
+
+ABSTRACT	O
+:	O
+Because	O
+of	O
+technological	O
+advancements	O
+and	O
+encouraging	O
+experiences	O
+during	O
+the	O
+2009	O
+influenza	B-PATH
+A	I-PATH
+(	O
+H1N1	O
+)	O
+epidemic	O
+,	O
+many	O
+critical	O
+care	O
+clinicians	O
+consider	O
+extracorporeal	O
+membrane	B-COMP
+oxygenation	B-PROC
+(	O
+ECMO	O
+)	O
+a	O
+reasonable	O
+strategy	O
+for	O
+managing	O
+patients	O
+with	O
+refractory	O
+hypoxemia	O
+when	O
+standardized	O
+therapies	O
+have	O
+failed	O
+.	O
+
+Nasal	O
+and	O
+throat	B-ANAT
+swab	I-ANAT
+specimens	O
+were	O
+obtained	O
+from	O
+129	O
+pilgrims	O
+in	O
+2013	O
+before	O
+they	O
+departed	O
+from	O
+France	O
+and	O
+before	O
+they	O
+left	O
+Saudi	O
+Arabia	O
+,	O
+and	O
+tested	O
+by	O
+PCR	O
+for	O
+respiratory	O
+viruses	B-SPEC
+and	O
+bacteria	B-SPEC
+.	O
+
+TITLE	O
+:	O
+Characterization	O
+of	O
+cellular	B-COMP
+and	O
+humoral	B-PROC
+immune	I-PROC
+responses	I-PROC
+after	O
+IBV	B-SPEC
+infection	B-DISO
+in	O
+chicken	B-SPEC
+lines	O
+differing	O
+in	O
+MBL	O
+serum	O
+concentration	O
+.	O
+
+The	O
+number	O
+of	O
+TCRγδ	O
++	O
+CD8α	O
++	O
+cells	O
+in	O
+the	O
+blood	B-ANAT
+of	O
+noninfected	O
+chickens	B-SPEC
+increased	O
+from	O
+week	O
+0	O
+to	O
+3	O
+p	O
+.	O
+i	O
+.	O
+
+In	O
+particular	O
+,	O
+the	O
+WHO	O
+has	O
+been	O
+severely	O
+compromised	O
+by	O
+post	O
+-	O
+2003	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+(	O
+SARS	B-DISO
+)	O
+staffing	O
+,	O
+budget	O
+cuts	O
+,	O
+a	O
+weakened	O
+IHR	O
+treaty	O
+,	O
+and	O
+no	O
+unambiguous	O
+legal	O
+mandate	O
+.	O
+
+ABSTRACT	O
+:	O
+Hantavirus	B-SPEC
+Pulmonary	B-ANAT
+Syndrome	I-DISO
+(	O
+HPS	B-DISO
+)	O
+is	O
+a	O
+disease	O
+of	O
+viral	O
+etiology	O
+that	O
+affects	O
+humans	B-SPEC
+causing	O
+severe	O
+acute	O
+respiratory	B-DISO
+symptoms	I-DISO
+.	O
+
+These	O
+reactions	O
+are	O
+the	O
+first	O
+steps	O
+of	O
+N	O
+-	O
+linked	O
+glycan	B-CHED
+processing	O
+and	O
+are	O
+essential	O
+for	O
+proper	O
+folding	O
+and	O
+function	O
+of	O
+many	O
+glycoproteins	B-CHED
+.	O
+
+RecV	O
+and	O
+inspiratory	B-PROC
+capacity	O
+(	O
+IC	O
+)	O
+were	O
+determined	O
+in	O
+12	O
+LH	O
+and	O
+in	O
+25	O
+ARDS	B-DISO
+patients	O
+during	O
+incremental	O
+PEEP	B-CHED
+(	O
+steps	O
+of	O
+2	O
+cmH2	B-DISO
+O	O
+).	O
+
+Maximum	O
+plateau	O
+pressure	O
+was	O
+reached	O
+with	O
+fewer	O
+PEEP	B-CHED
+steps	O
+in	O
+ARDS	B-DISO
+compared	O
+with	O
+LH	O
+patients	O
+(	O
+11	O
+vs	O
+.	O
+14	O
+,	O
+P	O
+<	O
+0	O
+.	O
+01	O
+).	O
+
+In	O
+contrast	O
+,	O
+current	O
+transfusion	O
+guidelines	O
+for	O
+critically	B-DISO
+ill	I-DISO
+patients	O
+support	O
+restrictive	O
+transfusion	O
+practice	O
+.	O
+
+We	O
+retrospectively	O
+analyzed	O
+18	O
+patients	O
+receiving	O
+vvECMO	O
+due	O
+to	O
+severe	O
+ARDS	B-DISO
+.	O
+
+Mean	O
+lactate	B-CHED
+clearance	O
+from	O
+the	O
+first	O
+to	O
+the	O
+third	O
+day	O
+was	O
+45	O
+.	O
+4	O
+±	O
+28	O
+.	O
+3	O
+%,	O
+with	O
+no	O
+significant	O
+difference	O
+between	O
+survivors	O
+and	O
+nonsurvivors	O
+(	O
+P	O
+=	O
+0	O
+.	O
+19	O
+).	O
+
+In	O
+our	O
+cohort	O
+of	O
+patients	O
+treated	O
+with	O
+ECMO	O
+due	O
+to	O
+severe	O
+ARDS	B-DISO
+,	O
+the	O
+application	O
+of	O
+a	O
+restrictive	O
+transfusion	O
+protocol	O
+did	O
+not	O
+result	O
+in	O
+an	O
+increased	O
+mortality	O
+.	O
+
+The	O
+carbon	B-CHED
+dioxide	I-CHED
+,	O
+which	O
+is	O
+highly	O
+soluble	O
+in	O
+perflubron	B-CHED
+,	O
+was	O
+used	O
+to	O
+relax	O
+airway	B-ANAT
+smooth	B-ANAT
+muscle	I-ANAT
+.	O
+
+ABSTRACT	O
+:	O
+Surveillance	O
+of	O
+Middle	O
+East	O
+respiratory	O
+syndrome	B-DISO
+coronavirus	B-SPEC
+(	O
+MERS	O
+-	O
+CoV	O
+)	O
+was	O
+conducted	O
+to	O
+explore	O
+the	O
+possible	O
+introduction	O
+and	O
+circulation	B-PROC
+of	O
+this	O
+novel	O
+virus	B-SPEC
+in	O
+Catalonia	O
+,	O
+northeastern	O
+Spain	O
+.	O
+
+These	O
+differentially	O
+expressed	B-PROC
+proteins	B-CHED
+were	O
+involved	O
+in	O
+the	O
+cell	B-PATH
+cycle	I-PATH
+,	O
+cellular	B-PROC
+growth	B-PROC
+and	O
+proliferation	B-DISO
+,	O
+the	O
+innate	B-DISO
+immune	I-DISO
+response	I-DISO
+,	O
+etc	O
+.	O
+
+The	O
+lungs	B-ANAT
+of	O
+the	O
+3	O
+dogs	B-SPEC
+submitted	O
+for	O
+necropsy	O
+were	O
+diffusely	O
+and	O
+severely	O
+reddened	O
+due	O
+to	O
+hyperemia	B-DISO
+and	O
+hemorrhage	B-DISO
+.	O
+
+Affymetrix	O
+Microarray	O
+analysis	O
+for	O
+mRNA	B-PROC
+expression	B-PROC
+data	O
+reveals	O
+expression	B-PROC
+of	O
+inflammatory	O
+mediators	O
+that	O
+are	O
+known	O
+to	O
+be	O
+released	O
+by	O
+activated	O
+microglia	B-ANAT
+.	O
+
+Real	O
+-	O
+time	O
+guidance	O
+of	O
+lung	B-ANAT
+recruitment	B-DISO
+under	O
+bedside	O
+lung	B-ANAT
+ultrasound	O
+(	O
+US	O
+)	O
+assessment	O
+in	O
+adults	O
+has	O
+shown	O
+to	O
+be	O
+an	O
+effective	O
+procedure	O
+for	O
+performing	O
+RM	O
+that	O
+avoids	O
+ionizing	O
+radiation	O
+overexposure	O
+.	O
+
+White	B-ANAT
+cell	I-ANAT
+counts	O
+were	O
+normal	O
+or	O
+decreased	O
+.	O
+
+Recent	O
+advances	O
+in	O
+the	O
+fields	O
+of	O
+virology	O
+and	O
+pathology	B-DISO
+have	O
+been	O
+fundamental	O
+in	O
+improving	O
+our	O
+understanding	O
+of	O
+viral	B-DISO
+pathogenesis	I-DISO
+,	O
+in	O
+providing	O
+improved	O
+vaccination	O
+strategies	O
+and	O
+in	O
+developing	O
+newer	O
+,	O
+more	O
+effective	O
+treatments	O
+for	O
+patients	O
+worldwide	O
+.	O
+
+TITLE	O
+:	O
+Effects	O
+of	O
+ultraprotective	O
+ventilation	O
+,	O
+extracorporeal	O
+carbon	B-CHED
+dioxide	I-CHED
+removal	O
+,	O
+and	O
+spontaneous	O
+breathing	O
+on	O
+lung	B-ANAT
+morphofunction	O
+and	O
+inflammation	B-DISO
+in	O
+experimental	O
+severe	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+.	O
+
+Animals	B-SPEC
+(	O
+n	O
+=	O
+7	O
+per	O
+group	O
+)	O
+were	O
+randomly	O
+assigned	O
+to	O
+6	O
+h	O
+of	O
+MV	O
+(	O
+airway	B-ANAT
+pressure	O
+release	B-PATH
+ventilation	O
+)	O
+with	O
+:	O
+(	O
+1	O
+)	O
+conventional	O
+P	O
+-	O
+MV	O
+with	O
+VT	O
+≈	O
+6	O
+ml	O
+/	O
+kg	O
+(	O
+P	O
+-	O
+MVcontr	O
+);	O
+(	O
+2	O
+)	O
+UP	O
+-	O
+MV	O
+with	O
+VT	O
+≈	O
+3	O
+ml	O
+/	O
+kg	O
+(	O
+UP	O
+-	O
+MVcontr	O
+);	O
+(	O
+3	O
+)	O
+UP	O
+-	O
+MV	O
+with	O
+VT	O
+≈	O
+3	O
+ml	O
+/	O
+kg	O
+and	O
+SB	O
+(	O
+UP	O
+-	O
+MVspont	O
+);	O
+and	O
+(	O
+4	O
+)	O
+UP	O
+-	O
+MV	O
+with	O
+VT	O
+≈	O
+3	O
+ml	O
+/	O
+kg	O
+and	O
+pressure	O
+supported	O
+SB	O
+(	O
+UP	O
+-	O
+MVPS	O
+).	O
+
+Pneumonia	B-DISO
+accounted	O
+for	O
+82	O
+%	O
+of	O
+ARDS	B-DISO
+causes	O
+.	O
+
+RESULTS	O
+:	O
+Of	O
+607	O
+subjects	O
+admitted	O
+,	O
+560	O
+required	O
+ventilatory	O
+or	O
+oxygen	B-CHED
+support	O
+,	O
+among	O
+whom	O
+180	O
+received	O
+noninvasive	O
+ventilatory	O
+support	O
+.	O
+
+TITLE	O
+:	O
+Multiple	O
+bilateral	O
+branch	B-ANAT
+retinal	B-DISO
+artery	I-DISO
+occlusions	I-DISO
+in	O
+a	O
+patient	O
+with	O
+sickle	B-DISO
+cell	I-DISO
+disease	I-DISO
+with	O
+vancomycin	O
+red	B-DISO
+man	I-DISO
+syndrome	I-DISO
+.	O
+
+ABSTRACT	O
+:	O
+To	O
+report	O
+a	O
+case	O
+of	O
+multiple	O
+bilateral	O
+branch	B-ANAT
+retinal	B-DISO
+artery	I-DISO
+occlusions	I-DISO
+associated	O
+with	O
+vancomycin	B-CHED
+infusion	O
+in	O
+an	O
+African	O
+American	O
+patient	O
+in	O
+acute	O
+sickle	O
+crisis	O
+.	O
+
+CONCLUSIONS	O
+:	O
+Retinal	B-DISO
+artery	I-DISO
+occlusion	B-PROC
+is	O
+a	O
+rare	O
+but	O
+potentially	O
+devastating	O
+complication	B-DISO
+of	O
+sickle	B-DISO
+cell	I-DISO
+disease	I-DISO
+.	O
+
+Nevertheless	O
+,	O
+MHV	O
+was	O
+shown	O
+to	O
+be	O
+less	O
+sensitive	O
+to	O
+perturbation	O
+of	O
+endosomal	O
+pH	O
+than	O
+vesicular	B-SPEC
+stomatitis	I-SPEC
+virus	I-SPEC
+and	O
+influenza	B-SPEC
+A	I-SPEC
+virus	I-SPEC
+,	O
+which	O
+fuse	O
+in	O
+early	O
+and	O
+late	O
+endosomes	O
+,	O
+respectively	O
+.	O
+
+Fusion	O
+of	O
+MHV	B-SPEC
+was	O
+severely	O
+inhibited	O
+by	O
+a	O
+pan	B-PRGE
+-	I-PRGE
+lysosomal	B-ANAT
+protease	B-CHED
+inhibitor	I-CHED
+,	O
+while	O
+trafficking	B-PROC
+of	O
+MHV	B-SPEC
+to	O
+lysosomes	B-COMP
+and	O
+processing	O
+by	O
+lysosomal	B-PRGE
+proteases	I-PRGE
+was	O
+no	O
+longer	O
+required	O
+when	O
+a	O
+furin	B-ENZY
+cleavage	B-PROC
+site	O
+was	O
+introduced	O
+in	O
+the	O
+S	B-PRGE
+protein	I-PRGE
+immediately	O
+upstream	O
+of	O
+the	O
+fusion	O
+peptide	B-CHED
+.	O
+
+They	O
+had	O
+an	O
+infusion	O
+of	O
+methyl	B-CHED
+-	O
+D9	O
+-	O
+choline	B-CHED
+chloride	I-CHED
+and	O
+small	O
+volume	O
+bronchoalveolar	B-ANAT
+lavage	I-ANAT
+fluid	I-ANAT
+(	O
+BALF	O
+)	O
+was	O
+obtained	O
+at	O
+0	O
+,	O
+6	O
+,	O
+12	O
+,	O
+24	O
+,	O
+48	O
+,	O
+72	O
+and	O
+96	O
+hours	O
+.	O
+
+Controls	O
+were	O
+healthy	O
+volunteers	O
+,	O
+who	O
+had	O
+BALF	O
+at	O
+24	O
+and	O
+48	O
+hours	O
+after	O
+methyl	O
+-	O
+D9	O
+-	O
+choline	B-CHED
+infusion	O
+.	O
+
+BALF	O
+of	O
+patients	O
+with	O
+ARDS	B-DISO
+consisted	O
+of	O
+diminished	O
+total	O
+PC	O
+and	O
+fractional	O
+PC16	O
+:	O
+0	O
+/	O
+16	O
+:	O
+0	O
+concentrations	O
+compared	O
+to	O
+healthy	O
+controls	O
+.	O
+
+The	O
+enrichment	O
+of	O
+methyl	B-CHED
+-	O
+D9	O
+-	O
+choline	B-CHED
+into	O
+surfactant	B-CHED
+total	O
+PC	O
+is	O
+nearly	O
+doubled	O
+in	O
+patients	O
+,	O
+with	O
+considerable	O
+variation	O
+between	O
+individuals	O
+.	O
+
+Of	O
+the	O
+gammacoronaviruses	O
+that	O
+mainly	O
+infect	O
+birds	B-SPEC
+,	O
+little	O
+is	O
+known	O
+about	O
+the	O
+activation	O
+of	O
+the	O
+host	B-COMP
+immune	B-PROC
+response	I-PROC
+.	O
+
+Genetically	O
+diverse	O
+CoVs	O
+have	O
+been	O
+reported	O
+from	O
+wild	O
+aquatic	O
+birds	B-SPEC
+that	O
+may	O
+represent	O
+a	O
+potential	O
+reservoir	O
+for	O
+avian	B-SPEC
+CoVs	O
+as	O
+well	O
+as	O
+hosts	B-COMP
+for	O
+mutations	O
+and	O
+recombination	B-PROC
+events	O
+leading	O
+to	O
+new	O
+serotypes	O
+or	O
+genera	O
+.	O
+
+Lipid	B-COMP
+rafts	I-COMP
+,	O
+enriched	O
+in	O
+sphingolipids	B-CHED
+,	O
+cholesterol	B-CHED
+and	O
+associated	O
+proteins	B-CHED
+,	O
+are	O
+special	O
+plasma	B-COMP
+membrane	I-COMP
+microdomains	O
+involved	O
+in	O
+several	O
+processes	O
+in	O
+viral	B-DISO
+infections	I-DISO
+.	O
+
+Possible	O
+mechanisms	O
+of	O
+death	B-PROC
+include	O
+respiratory	B-DISO
+depression	I-DISO
+,	O
+central	B-DISO
+nervous	I-DISO
+system	I-DISO
+depression	I-DISO
+,	O
+and	O
+serotonin	B-DISO
+syndrome	I-DISO
+.	O
+
+TITLE	O
+:	O
+The	O
+amino	B-CHED
+acids	I-CHED
+736	O
+-	O
+761	O
+of	O
+the	O
+MERS	B-PRGE
+-	I-PRGE
+CoV	I-PRGE
+spike	I-PRGE
+protein	I-PRGE
+induce	O
+neutralizing	O
+antibodies	B-COMP
+:	O
+implications	O
+for	O
+the	O
+development	O
+of	O
+vaccines	O
+and	O
+antiviral	B-CHED
+agents	I-CHED
+.	O
+
+Therapy	O
+included	O
+broad	O
+-	O
+spectrum	O
+antibiotics	B-CHED
+,	O
+surgery	O
+of	O
+the	O
+primary	O
+infectious	B-DISO
+lesion	O
+,	O
+and	O
+postoperative	O
+anticoagulation	B-PROC
+.	O
+
+Seven	O
+patients	O
+were	O
+intubated	O
+,	O
+and	O
+two	O
+developed	O
+severe	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+.	O
+
+RESULTS	O
+:	O
+The	O
+primary	B-DISO
+infection	I-DISO
+sites	O
+were	O
+found	O
+in	O
+the	O
+middle	B-ANAT
+ear	I-ANAT
+(	O
+11	O
+),	O
+oropharynx	B-ANAT
+(	O
+8	O
+),	O
+sinus	B-DISO
+(	O
+3	O
+),	O
+and	O
+oral	B-ANAT
+cavity	I-ANAT
+(	O
+1	O
+).	O
+
+All	O
+23	O
+patients	O
+survived	O
+the	O
+disseminated	O
+infection	B-DISO
+without	O
+consecutive	O
+systemic	O
+morbidity	O
+.	O
+
+CONCLUSIONS	O
+:	O
+In	O
+the	O
+pre	O
+-	O
+antibiotic	B-CHED
+time	O
+,	O
+septic	O
+internal	B-ANAT
+jugular	I-ANAT
+vein	I-ANAT
+thrombophlebitis	B-DISO
+was	O
+a	O
+highly	O
+fatal	O
+condition	B-DISO
+with	O
+a	O
+mortality	O
+rate	O
+of	O
+90	O
+%.	O
+
+TITLE	O
+:	O
+Angiotensin	B-CHED
+-	I-PRGE
+converting	I-PRGE
+enzyme	I-PRGE
+2	I-PRGE
+(	O
+ACE2	B-PRGE
+)	O
+mediates	O
+influenza	B-DISO
+H7N9	O
+virus	B-SPEC
+-	O
+induced	O
+acute	O
+lung	B-ANAT
+injury	O
+.	O
+
+The	O
+healthy	O
+subjects	O
+harbored	O
+primarily	O
+Streptococcus	B-SPEC
+,	O
+whereas	O
+the	O
+patients	O
+showed	O
+an	O
+enrichment	O
+of	O
+Haemophilus	B-SPEC
+or	O
+Moraxella	B-SPEC
+.	O
+
+The	O
+oropharyngeal	B-ANAT
+types	O
+were	O
+not	O
+associated	O
+with	O
+the	O
+type	O
+of	O
+viruses	B-SPEC
+,	O
+but	O
+were	O
+rather	O
+linked	O
+to	O
+the	O
+age	O
+of	O
+the	O
+subjects	O
+.	O
+
+TITLE	O
+:	O
+Dead	B-PROC
+space	O
+:	O
+the	O
+physiology	O
+of	O
+wasted	B-DISO
+ventilation	O
+.	O
+
+Sows	O
+were	O
+vaccinated	O
+intramuscularly	O
+twice	O
+at	O
+four	O
+and	O
+two	O
+weeks	O
+prior	O
+to	O
+farrowing	B-PROC
+with	O
+2ml	O
+/	O
+head	B-ANAT
+vaccine	O
+dose	O
+.	O
+
+Among	O
+recombinant	O
+spike	O
+S1	O
+,	O
+S2	O
+,	O
+S3	O
+,	O
+and	O
+nucleocapsid	B-PRGE
+N	I-PRGE
+protein	B-CHED
+of	O
+PEDV	B-SPEC
+,	O
+S3	B-PRGE
+protein	I-PRGE
+presented	O
+the	O
+highest	O
+antibody	B-COMP
+level	O
+in	O
+the	O
+K	O
+/	O
+K	O
+group	O
+.	O
+
+CONCLUSIONS	O
+:	O
+Killed	O
+PEDV	B-SPEC
+SM98	O
+vaccine	O
+induced	O
+higher	O
+antibody	B-COMP
+levels	O
+.	O
+
+Respiratory	O
+syncytial	O
+virus	O
+was	O
+isolated	O
+in	O
+33	O
+patients	O
+,	O
+human	B-SPEC
+rhinovirus	I-SPEC
+(	O
+hRV	O
+)	O
+in	O
+22	O
+,	O
+adenovirus	B-DISO
+(	O
+AdV	O
+)	O
+in	O
+19	O
+,	O
+human	B-SPEC
+metapneumovirus	I-SPEC
+in	O
+13	O
+,	O
+influenza	B-SPEC
+virus	I-SPEC
+in	O
+10	O
+,	O
+parainfluenza	B-DISO
+virus	B-SPEC
+in	O
+7	O
+,	O
+human	B-SPEC
+corona	B-CHED
+virus	B-SPEC
+(	O
+hCoV	O
+)	O
+in	O
+4	O
+,	O
+and	O
+human	B-SPEC
+bocavirus	I-SPEC
+in	O
+one	O
+.	O
+
+Respiratory	B-SPEC
+syncytial	I-SPEC
+virus	I-SPEC
+was	O
+isolated	O
+in	O
+33	O
+patients	O
+,	O
+human	B-SPEC
+rhinovirus	I-SPEC
+(	O
+hRV	O
+)	O
+in	O
+22	O
+,	O
+adenovirus	B-DISO
+(	O
+AdV	O
+)	O
+in	O
+19	O
+,	O
+human	B-SPEC
+metapneumovirus	I-SPEC
+in	O
+13	O
+,	O
+influenza	B-SPEC
+virus	I-SPEC
+in	O
+10	O
+,	O
+parainfluenza	B-DISO
+virus	B-SPEC
+in	O
+7	O
+,	O
+human	B-SPEC
+corona	B-CHED
+virus	B-SPEC
+(	O
+hCoV	O
+)	O
+in	O
+4	O
+,	O
+and	O
+human	B-SPEC
+bocavirus	I-SPEC
+in	O
+one	O
+.	O
+
+Current	O
+data	O
+on	O
+approved	O
+and	O
+novel	O
+treatments	O
+for	O
+non	O
+-	O
+influenza	B-DISO
+respiratory	O
+viruses	B-SPEC
+such	O
+as	O
+MERS	O
+-	O
+CoV	O
+,	O
+respiratory	B-SPEC
+syncytial	I-SPEC
+virus	I-SPEC
+(	O
+RSV	B-SPEC
+)	O
+and	O
+rhinoviruses	B-SPEC
+and	O
+the	O
+challenges	O
+of	O
+treating	O
+immunocompromised	O
+patients	O
+with	O
+respiratory	B-DISO
+infections	I-DISO
+was	O
+highlighted	O
+.	O
+
+There	O
+were	O
+343	O
+critical	O
+patients	O
+included	O
+in	O
+this	O
+prospective	O
+multicenter	O
+cohort	O
+study	O
+,	O
+of	O
+which	O
+163	O
+patients	O
+who	O
+developed	O
+ARDS	O
+were	O
+considered	O
+as	O
+ARDS	B-DISO
+group	O
+(	O
+2	O
+case	O
+lost	B-CHED
+to	O
+follow	O
+-	O
+up	O
+,	O
+and	O
+49	O
+died	B-PROC
+)	O
+and	O
+180	O
+patients	O
+who	O
+did	O
+not	O
+developed	O
+ARDS	B-DISO
+regarded	O
+as	O
+severe	O
+control	O
+group	O
+(	O
+1	O
+case	O
+lost	B-CHED
+to	O
+follow	O
+-	O
+up	O
+,	O
+and	O
+34	O
+died	B-PROC
+).	O
+
+Three	O
+patients	O
+died	B-PROC
+in	O
+control	O
+group	O
+,	O
+which	O
+was	O
+directly	O
+associated	O
+with	O
+lung	B-ANAT
+injury	O
+deterioration	O
+.	O
+
+The	O
+independent	O
+risk	O
+factors	O
+of	O
+ARDS	B-DISO
+were	O
+analyzed	O
+by	O
+univariate	O
+and	O
+multivariable	O
+logistic	O
+regression	O
+.	O
+
+To	O
+identify	O
+cell	B-COMP
+-	O
+specific	O
+ATF3	B-PRGE
+-	O
+dependent	O
+mechanisms	O
+of	O
+susceptibility	O
+to	O
+ALI	O
+/	O
+VILI	O
+,	O
+we	O
+generated	O
+ATF3	B-PRGE
+chimera	B-DISO
+by	O
+adoptive	O
+bone	B-ANAT
+marrow	I-ANAT
+(	O
+BM	O
+)	O
+transfer	O
+and	O
+randomized	O
+to	O
+inhaled	B-PROC
+saline	O
+or	O
+lipopolysacharide	O
+(	O
+LPS	B-DISO
+)	O
+in	O
+the	O
+presence	O
+of	O
+mechanical	O
+ventilation	O
+(	O
+MV	O
+).	O
+
+In	O
+contrast	O
+,	O
+absence	O
+of	O
+ATF3	B-PRGE
+in	O
+parenchymal	O
+cells	B-COMP
+resulted	O
+in	O
+loss	O
+of	O
+alveolar	B-ANAT
+-	O
+capillary	B-ANAT
+membrane	B-COMP
+integrity	O
+and	O
+increased	O
+exudative	O
+edema	B-DISO
+.	O
+
+ABSTRACT	O
+:	O
+The	O
+development	B-PROC
+of	O
+an	O
+effective	O
+vaccine	O
+is	O
+critical	O
+for	O
+prevention	O
+of	O
+a	O
+Middle	O
+East	O
+respiratory	O
+syndrome	B-DISO
+coronavirus	B-SPEC
+(	O
+MERS	O
+-	O
+CoV	O
+)	O
+pandemic	O
+.	O
+
+On	O
+the	O
+basis	O
+of	O
+a	O
+distinct	O
+reservoir	O
+and	O
+ecological	O
+niche	O
+,	O
+sequence	O
+analyses	O
+,	O
+and	O
+expression	B-PROC
+of	O
+flagella	B-ANAT
+,	O
+we	O
+designate	O
+these	O
+isolates	O
+as	O
+a	O
+novel	O
+Bartonella	B-SPEC
+sp	O
+.	O
+named	O
+Bartonella	B-SPEC
+dromedarii	O
+sp	O
+.	O
+nov	O
+.	O
+Further	O
+studies	O
+are	O
+required	O
+to	O
+explore	O
+its	O
+zoonotic	O
+potential	O
+.	O
+
+TITLE	O
+:	O
+Acquisition	O
+of	O
+new	O
+protein	B-CHED
+domains	O
+by	O
+coronaviruses	O
+:	O
+analysis	O
+of	O
+overlapping	O
+genes	O
+coding	O
+for	O
+proteins	O
+N	O
+and	O
+9b	O
+in	O
+SARS	B-DISO
+coronavirus	B-SPEC
+.	O
+
+TITLE	O
+:	O
+Respiratory	O
+Precautions	O
+for	O
+Protection	O
+from	O
+Bioaerosols	O
+or	O
+Infectious	B-DISO
+Agents	O
+:	O
+A	O
+Review	O
+of	O
+the	O
+Clinical	O
+Effectiveness	O
+and	O
+Guidelines	O
+ABSTRACT	O
+:	O
+
+Healthcare	O
+workers	O
+(	O
+HCWs	O
+)	O
+are	O
+vulnerable	O
+to	O
+exposure	O
+to	O
+these	O
+agents	O
+given	O
+the	O
+nature	O
+of	O
+their	O
+jobs	O
+,	O
+and	O
+as	O
+a	O
+result	O
+,	O
+risk	O
+both	O
+becoming	O
+infected	O
+,	O
+and	O
+spreading	O
+the	O
+infectious	B-DISO
+agents	O
+to	O
+other	O
+patients	O
+.	O
+
+The	O
+study	O
+cohort	O
+of	O
+119	O
+adults	O
+with	O
+bronchiectasis	B-DISO
+was	O
+followed	O
+up	O
+prospectively	O
+for	O
+12	O
+months	O
+.	O
+
+The	O
+most	O
+common	O
+viruses	B-SPEC
+found	O
+in	O
+patients	O
+experiencing	O
+exacerbations	O
+were	O
+coronavirus	B-SPEC
+(	O
+19	O
+of	O
+65	O
+,	O
+39	O
+.	O
+2	O
+%),	O
+rhinovirus	B-SPEC
+(	O
+16	O
+of	O
+65	O
+,	O
+24	O
+.	O
+6	O
+%),	O
+and	O
+influenza	B-PATH
+A	I-PATH
+/	O
+B	O
+viruses	B-SPEC
+(	O
+16	O
+of	O
+65	O
+,	O
+24	O
+.	O
+6	O
+%).	O
+
+However	O
+,	O
+despite	O
+the	O
+advanced	O
+diagnostic	O
+methods	O
+currently	O
+in	O
+use	O
+,	O
+in	O
+20	O
+to	O
+50	O
+%	O
+of	O
+respiratory	B-ANAT
+samples	I-ANAT
+a	O
+specific	O
+pathogen	O
+cannot	O
+be	O
+detected	O
+.	O
+
+TITLE	O
+:	O
+Comparison	O
+of	O
+serum	B-COMP
+neutralization	O
+and	O
+enzyme	O
+-	O
+linked	O
+immunosorbent	O
+assay	O
+on	O
+sera	B-COMP
+from	O
+porcine	B-SPEC
+epidemic	I-SPEC
+diarrhea	I-SPEC
+virus	I-SPEC
+vaccinated	O
+pigs	B-SPEC
+.	O
+
+For	O
+prokaryotic	O
+expression	B-PROC
+of	O
+partial	O
+fragments	O
+of	O
+spike	O
+protein	B-CHED
+the	O
+size	O
+and	O
+location	O
+of	O
+S1	O
+,	O
+S2	O
+,	O
+and	O
+S3	O
+,	O
+and	O
+full	B-PRGE
+nucleocapsid	I-PRGE
+protein	B-CHED
+,	O
+polymerase	O
+chain	O
+reaction	O
+was	O
+performed	O
+using	O
+specific	O
+primers	O
+.	O
+
+TITLE	O
+:	O
+Acute	B-DISO
+respiratory	I-DISO
+failure	I-DISO
+onset	O
+in	O
+a	O
+patient	O
+with	O
+Guillain	O
+-	O
+Barré	O
+syndrome	B-DISO
+after	O
+Legionella	B-SPEC
+-	O
+associated	O
+pneumonia	O
+:	O
+a	O
+case	O
+report	O
+.	O
+
+Few	O
+weeks	O
+after	O
+,	O
+dysphagia	B-DISO
+occurred	O
+and	O
+electrophysiologic	O
+tests	O
+showed	O
+progressive	O
+axonal	O
+involvement	O
+with	O
+spread	O
+of	O
+demyelination	B-DISO
+to	O
+the	O
+cranial	B-ANAT
+nerves	I-ANAT
+.	O
+
+An	O
+analysis	O
+of	O
+virus	B-SPEC
+discovery	O
+indicates	O
+that	O
+the	O
+small	O
+number	O
+of	O
+novel	O
+viruses	B-SPEC
+discovered	O
+annually	O
+is	O
+an	O
+artifact	O
+of	O
+inadequate	O
+surveillance	O
+in	O
+tropical	O
+and	O
+subtropical	O
+countries	O
+,	O
+where	O
+even	O
+established	O
+endemic	O
+pathogens	O
+are	O
+often	O
+misdiagnosed	O
+.	O
+
+Many	O
+of	O
+the	O
+emerging	O
+viruses	B-SPEC
+of	O
+the	O
+future	O
+are	O
+already	O
+infecting	O
+humans	B-SPEC
+but	O
+remain	O
+to	O
+be	O
+uncovered	O
+by	O
+a	O
+strategy	O
+of	O
+disease	O
+surveillance	O
+in	O
+selected	O
+populations	O
+.	O
+
+In	O
+a	O
+univariate	O
+analysis	O
+median	O
+platelet	B-ANAT
+(	O
+PLT	O
+)	O
+count	O
+at	O
+ICU	O
+admission	O
+(	O
+162	O
+vs	O
+.	O
+97	O
+×	O
+10	O
+/	O
+L	O
+;	O
+p	O
+=	O
+0	O
+.	O
+046	O
+)	O
+and	O
+pre	O
+-	O
+day	O
+1	O
+(	O
+118	O
+.	O
+5	O
+vs	O
+.	O
+62	O
+.	O
+5	O
+×	O
+10	O
+/	O
+L	O
+;	O
+p	O
+=	O
+0	O
+.	O
+046	O
+)	O
+was	O
+higher	O
+in	O
+the	O
+ECMO	O
+-	O
+weaned	B-PROC
+group	O
+than	O
+those	O
+in	O
+the	O
+weaning	O
+failure	O
+group	O
+.	O
+
+Using	O
+a	O
+PLT	O
+level	O
+of	O
+70	O
+×	O
+10	O
+/	O
+L	O
+,	O
+the	O
+odds	O
+ratio	O
+for	O
+successful	O
+ECMO	O
+weaning	B-PROC
+was	O
+11	O
+.	O
+0	O
+(	O
+95	O
+%	O
+confidence	O
+interval	O
+[	O
+CI	O
+]	O
+1	O
+.	O
+34	O
+-	O
+87	O
+.	O
+16	O
+;	O
+p	O
+=	O
+0	O
+.	O
+023	O
+)	O
+in	O
+the	O
+multivariate	O
+analysis	O
+.	O
+
+Upon	O
+admission	O
+,	O
+we	O
+immediately	O
+initiated	O
+artificial	O
+organ	B-ANAT
+support	O
+systems	O
+,	O
+including	O
+ventilator	O
+,	O
+continuous	O
+renal	B-ANAT
+replacement	O
+therapy	O
+,	O
+and	O
+cardiovascular	B-CHED
+drug	I-CHED
+infusion	O
+for	O
+septic	O
+multiple	B-DISO
+organ	I-DISO
+failure	I-DISO
+and	O
+source	O
+control	O
+.	O
+
+The	O
+case	O
+developed	O
+abdominal	B-DISO
+compartment	I-DISO
+syndrome	I-DISO
+,	O
+for	O
+which	O
+we	O
+performed	O
+a	O
+bedside	O
+decompressive	O
+laparotomy	O
+in	O
+the	O
+ICU	O
+.	O
+
+We	O
+hypothesized	O
+that	O
+recipients	O
+of	O
+lungs	B-ANAT
+from	O
+heavy	O
+drinkers	O
+would	O
+be	O
+more	O
+susceptible	O
+to	O
+lung	B-ANAT
+injury	O
+following	O
+transplantation	O
+.	O
+
+In	O
+this	O
+retrospective	O
+cohort	O
+study	O
+,	O
+donor	B-CHED
+histories	O
+and	O
+transplant	B-ANAT
+outcomes	O
+were	O
+reviewed	O
+in	O
+192	O
+consecutive	O
+lung	B-ANAT
+transplant	B-ANAT
+recipients	O
+.	O
+
+Donors	O
+were	O
+classified	O
+as	O
+No	O
+Alcohol	O
+Use	O
+,	O
+Moderate	O
+Alcohol	O
+Use	O
+,	O
+or	O
+Heavy	B-DISO
+Alcohol	I-DISO
+Use	I-DISO
+based	O
+on	O
+documented	O
+donor	B-CHED
+histories	O
+.	O
+
+RESULTS	O
+:	O
+Freedom	O
+from	O
+mechanical	O
+ventilation	O
+took	O
+longer	O
+in	O
+the	O
+lung	B-ANAT
+transplant	B-ANAT
+recipients	O
+whose	O
+donors	O
+had	O
+Heavy	B-DISO
+Alcohol	I-DISO
+Use	I-DISO
+,	O
+compared	O
+with	O
+those	O
+whose	O
+donors	O
+had	O
+No	O
+Alcohol	O
+Use	O
+or	O
+Moderate	O
+Alcohol	O
+Use	O
+(	O
+p	O
+=	O
+0	O
+.	O
+01	O
+).	O
+
+TITLE	O
+:	O
+Non	O
+-	O
+invasive	O
+assessment	O
+of	O
+lung	B-ANAT
+elastance	O
+in	O
+patients	O
+with	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+.	O
+
+ELLB	O
+was	O
+assessed	O
+for	O
+each	O
+step	O
+as	O
+the	O
+ratio	O
+between	O
+the	O
+change	O
+in	O
+PEEP	B-CHED
+and	O
+the	O
+induced	O
+end	B-PROC
+-	I-PROC
+expiratory	I-PROC
+lung	B-PROC
+volume	I-PROC
+change	O
+measured	O
+by	O
+direct	O
+spirometry	O
+.	O
+
+There	O
+were	O
+no	O
+linear	O
+correlation	O
+between	O
+ELLB	O
+/	O
+ERS	B-DISO
+and	O
+ELPeso	O
+/	O
+ERS	B-DISO
+during	O
+the	O
+increase	O
+and	O
+the	O
+decrease	O
+of	O
+PEEP	B-CHED
+(	O
+R²	O
+=	O
+0	O
+.	O
+00	O
+;	O
+R²	O
+=	O
+0	O
+.	O
+00	O
+,	O
+respectively	O
+).	O
+
+An	O
+immunocompetent	O
+54	O
+-	O
+year	O
+-	O
+old	O
+woman	O
+was	O
+exposed	O
+to	O
+plant	B-SPEC
+mulch	O
+during	O
+gardening	O
+and	O
+subsequently	O
+developed	O
+pulmonary	B-DISO
+failure	I-DISO
+that	O
+progressed	O
+to	O
+sepsis	B-DISO
+with	O
+multiorgan	B-DISO
+failure	I-DISO
+.	O
+
+Previous	O
+work	O
+showed	O
+that	O
+mouse	B-DISO
+hepatitis	I-DISO
+virus	B-SPEC
+strain	O
+A59	O
+(	O
+MHV	B-SPEC
+-	O
+A59	O
+)	O
+with	O
+a	O
+mutated	O
+catalytic	O
+site	O
+(	O
+N1348A	O
+)	O
+replicated	O
+similarly	O
+to	O
+wild	O
+-	O
+type	O
+virus	B-SPEC
+but	O
+was	O
+unable	O
+to	O
+cause	O
+acute	B-DISO
+hepatitis	I-DISO
+in	O
+mice	B-SPEC
+.	O
+
+ABSTRACT	O
+:	O
+Receptor	O
+recognition	O
+by	O
+viruses	B-SPEC
+is	O
+the	O
+first	O
+and	O
+essential	O
+step	O
+of	O
+viral	B-DISO
+infections	I-DISO
+of	O
+host	B-COMP
+cells	B-COMP
+.	O
+
+Coronaviruses	O
+recognize	O
+a	O
+variety	O
+of	O
+host	B-COMP
+receptors	O
+,	O
+infect	O
+many	O
+hosts	B-COMP
+,	O
+and	O
+are	O
+health	O
+threats	O
+to	O
+humans	B-SPEC
+and	O
+animals	B-SPEC
+.	O
+
+The	O
+receptor	B-PRGE
+-	I-PRGE
+binding	I-PRGE
+S1	I-PRGE
+subunit	I-PRGE
+of	I-PRGE
+coronavirus	B-SPEC
+spike	I-PRGE
+proteins	B-CHED
+contains	O
+two	O
+distinctive	O
+domains	O
+,	O
+the	O
+N	O
+-	O
+terminal	O
+domain	O
+(	O
+S1	O
+-	O
+NTD	O
+)	O
+and	O
+the	O
+C	O
+-	O
+terminal	O
+domain	O
+(	O
+S1	B-PRGE
+-	I-PRGE
+CTD	I-PRGE
+),	O
+both	O
+of	O
+which	O
+can	O
+function	O
+as	O
+receptor	O
+-	O
+binding	B-FUNC
+domains	O
+(	O
+RBDs	O
+).	O
+
+TITLE	O
+:	O
+[	O
+Effects	O
+of	O
+lung	B-ANAT
+protective	O
+ventilation	O
+strategy	O
+combined	O
+with	O
+lung	B-ANAT
+recruitment	B-DISO
+maneuver	O
+on	O
+patients	O
+with	O
+severe	O
+burn	O
+complicated	O
+with	O
+acute	O
+respiratory	O
+distress	O
+syndrome	O
+].	O
+
+Lung	B-ANAT
+protective	O
+ventilation	O
+strategy	O
+combining	O
+lung	B-ANAT
+recruitment	B-DISO
+maneuver	O
+can	O
+significantly	O
+improve	O
+the	O
+oxygenation	B-PROC
+in	O
+patients	O
+with	O
+severe	O
+burn	O
+complicated	O
+with	O
+ARDS	B-DISO
+and	O
+may	O
+therefore	O
+improve	O
+the	O
+prognosis	O
+.	O
+
+(	O
+3	O
+)	O
+The	O
+patients	O
+received	O
+mechanical	O
+ventilation	O
+at	O
+2	O
+to	O
+72	O
+h	O
+after	O
+burn	O
+,	O
+lasting	O
+for	O
+14	O
+-	O
+32	O
+(	O
+21	O
+±	O
+13	O
+)	O
+d	O
+.	O
+At	O
+post	O
+injury	O
+day	O
+3	O
+-	O
+14	O
+(	O
+7	O
+±	O
+5	O
+)	O
+d	O
+,	O
+lung	B-ANAT
+recruitment	B-DISO
+maneuver	O
+was	O
+applied	O
+for	O
+2	O
+-	O
+5	O
+(	O
+3	O
+.	O
+0	O
+±	O
+2	O
+.	O
+0	O
+)	O
+d	O
+.	O
+All	O
+15	O
+patients	O
+recovered	O
+without	O
+other	O
+complications	O
+.	O
+
+We	O
+enrolled	O
+614	O
+children	O
+aged	O
+2	O
+to	O
+59	O
+months	O
+with	O
+acute	O
+respiratory	B-DISO
+symptoms	I-DISO
+presenting	O
+at	O
+the	O
+emergency	B-DISO
+paediatric	O
+unit	O
+of	O
+Mulago	O
+hospital	O
+.	O
+
+Children	O
+with	O
+'	B-PATH
+asthma	I-PATH
+syndrome	B-DISO
+'	O
+had	O
+a	O
+significantly	O
+shorter	O
+hospital	O
+stay	O
+compared	O
+to	O
+those	O
+with	O
+pneumonia	B-DISO
+(	O
+p	O
+<	O
+0	O
+.	O
+001	O
+).	O
+
+Factors	O
+independently	O
+associated	O
+with	O
+prolonged	O
+hospitalization	O
+among	O
+children	O
+with	O
+asthma	B-PATH
+syndrome	B-DISO
+included	O
+age	O
+less	O
+than	O
+12	O
+months	O
+(	O
+RR	O
+=	O
+1	O
+.	O
+2	O
+,	O
+95	O
+%	O
+CI	O
+1	O
+.	O
+0	O
+-	O
+1	O
+.	O
+4	O
+),	O
+hypoxemia	O
+(	O
+RR	O
+=	O
+1	O
+.	O
+4	O
+,	O
+95	O
+%	O
+CI	O
+1	O
+.	O
+2	O
+-	O
+1	O
+.	O
+7	O
+),	O
+and	O
+severe	B-DISO
+malnutrition	I-DISO
+(	O
+RR	O
+=	O
+1	O
+.	O
+5	O
+95	O
+%	O
+CI	O
+1	O
+.	O
+3	O
+-	O
+1	O
+.	O
+8	O
+).	O
+
+Studies	O
+have	O
+revealed	O
+both	O
+functional	O
+conservation	O
+and	O
+mechanistic	O
+divergence	O
+among	O
+the	O
+nsp1	B-PRGE
+of	O
+different	O
+mammalian	B-SPEC
+CoVs	O
+in	O
+perturbing	O
+host	B-COMP
+gene	B-PROC
+expression	I-PROC
+and	O
+antiviral	B-CHED
+responses	O
+.	O
+
+TITLE	O
+:	O
+How	O
+and	O
+why	O
+overcome	O
+the	O
+impediments	O
+to	O
+resolution	O
+:	O
+lessons	O
+from	O
+rhinolophid	O
+and	O
+hipposiderid	O
+bats	B-SPEC
+.	O
+
+It	O
+has	O
+been	O
+shown	O
+that	O
+host	B-COMP
+phylogeny	O
+is	O
+the	O
+primary	O
+factor	O
+that	O
+determines	O
+a	O
+virus	B-SPEC
+'	O
+s	O
+persistence	O
+,	O
+replicative	O
+ability	O
+,	O
+and	O
+can	O
+act	O
+as	O
+a	O
+predictor	O
+of	O
+new	O
+emerging	O
+disease	O
+.	O
+
+29	O
+patients	O
+(	O
+69	O
+%)	O
+were	O
+transported	O
+with	O
+extracorporeal	O
+membrane	B-COMP
+oxygenation	B-PROC
+support	O
+,	O
+while	O
+13	O
+patients	O
+(	O
+31	O
+%)	O
+were	O
+transported	O
+with	O
+conventional	O
+ventilation	O
+.	O
+
+TITLE	O
+:	O
+Anaphylaxis	B-DISO
+:	O
+Unique	O
+aspects	O
+of	O
+clinical	O
+diagnosis	O
+and	O
+management	O
+in	O
+infants	O
+(	O
+birth	B-PROC
+to	O
+age	O
+2	O
+years	O
+).	O
+
+ABSTRACT	O
+:	O
+In	O
+this	O
+rostrum	O
+we	O
+aim	O
+to	O
+increase	O
+awareness	O
+of	O
+anaphylaxis	O
+in	O
+infancy	O
+in	O
+order	B-SPEC
+to	O
+improve	O
+clinical	O
+diagnosis	O
+,	O
+management	O
+,	O
+and	O
+prevention	O
+of	O
+recurrences	B-DISO
+.	O
+
+Anaphylaxis	B-DISO
+is	O
+increasingly	O
+reported	O
+in	O
+this	O
+age	O
+group	O
+.	O
+
+Epinephrine	B-CHED
+(	O
+adrenaline	B-CHED
+)	O
+treatment	O
+is	O
+underused	O
+in	O
+health	O
+care	O
+and	O
+community	O
+settings	O
+.	O
+
+During	O
+7	O
+days	O
+of	O
+ECMO	O
+use	O
+,	O
+organ	B-ANAT
+dysfunction	O
+scores	O
+were	O
+significantly	O
+lower	O
+for	O
+survivors	O
+than	O
+nonsurvivors	O
+.	O
+
+Severe	O
+ARDS	B-DISO
+patients	O
+who	O
+are	O
+younger	O
+,	O
+have	O
+shorter	O
+duration	O
+of	O
+mechanical	O
+ventilation	O
+,	O
+and	O
+lower	O
+organ	B-ANAT
+dysfunction	O
+scores	O
+before	O
+ECMO	O
+initiation	O
+have	O
+more	O
+favorable	O
+survival	O
+outcome	O
+.	O
+
+The	O
+scores	O
+for	O
+protein	B-CHED
+were	O
+significantly	O
+higher	O
+in	O
+cases	O
+with	O
+longer	O
+survival	O
+after	O
+burn	O
+(	O
+p	O
+<	O
+0	O
+.	O
+03	O
+).	O
+
+Histological	O
+findings	O
+associated	O
+with	O
+diffuse	B-DISO
+alveolar	I-DISO
+damage	I-DISO
+(	O
+DAD	O
+),	O
+which	O
+is	O
+the	O
+pathological	O
+correlate	O
+of	O
+the	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+(	O
+ARDS	B-DISO
+),	O
+were	O
+seen	O
+in	O
+approximately	O
+42	O
+%	O
+of	O
+autopsies	O
+studied	O
+.	O
+
+RESULTS	O
+:	O
+Type	O
+II	O
+epithelial	B-PROC
+cell	I-PROC
+proliferation	B-DISO
+was	O
+significantly	O
+more	O
+common	O
+in	O
+cases	O
+with	O
+a	O
+longer	O
+time	O
+between	O
+burn	O
+and	O
+admission	O
+(	O
+p	O
+<	O
+0	O
+.	O
+02	O
+).	O
+
+The	O
+emergence	O
+of	O
+deadly	O
+human	B-SPEC
+coronaviruses	O
+,	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+coronavirus	B-SPEC
+(	O
+SARS	B-DISO
+-	O
+CoV	O
+),	O
+and	O
+Middle	O
+East	O
+respiratory	O
+syndrome	B-DISO
+coronavirus	B-SPEC
+(	O
+MERS	O
+-	O
+CoV	O
+)	O
+have	O
+bolstered	O
+research	O
+in	O
+these	O
+viral	O
+and	O
+often	O
+zoonotic	O
+pathogens	O
+.	O
+
+The	O
+aim	O
+of	O
+this	O
+article	O
+was	O
+to	O
+review	O
+the	O
+role	O
+of	O
+noninvasive	O
+ventilation	O
+(	O
+NIV	O
+)	O
+in	O
+acute	O
+pulmonary	O
+infectious	B-DISO
+diseases	I-DISO
+,	O
+such	O
+as	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+(	O
+SARS	B-DISO
+),	O
+H1N1	O
+and	O
+tuberculosis	B-PATH
+,	O
+and	O
+to	O
+assess	O
+the	O
+risk	O
+of	O
+disease	B-DISO
+transmission	I-DISO
+with	O
+the	O
+use	O
+of	O
+NIV	O
+from	O
+patients	O
+to	O
+healthcare	O
+workers	O
+.	O
+
+This	O
+strong	O
+indication	O
+of	O
+vaccine	O
+association	O
+led	O
+to	O
+the	O
+withdrawal	B-DISO
+of	O
+live	O
+793B	O
+vaccine	O
+use	O
+on	O
+all	O
+of	O
+the	O
+farms	O
+of	O
+the	O
+study	O
+.	O
+
+The	O
+control	O
+of	O
+IBV	B-SPEC
+in	O
+the	O
+field	O
+is	O
+hampered	O
+by	O
+the	O
+many	O
+different	O
+strains	O
+circulating	O
+worldwide	O
+and	O
+the	O
+limited	O
+protection	O
+across	O
+strains	O
+due	O
+to	O
+serotype	O
+diversity	O
+.	O
+
+TITLE	O
+:	O
+A	O
+structural	O
+view	O
+of	O
+coronavirus	B-SPEC
+-	O
+receptor	B-PROC
+interactions	I-PROC
+.	O
+
+ABSTRACT	O
+:	O
+In	O
+the	O
+coronavirus	B-SPEC
+(	O
+CoV	B-SPEC
+),	O
+the	O
+envelope	O
+spike	O
+(	O
+S	O
+)	O
+glycoprotein	B-CHED
+is	O
+responsible	O
+for	O
+CoV	B-SPEC
+cell	B-COMP
+entry	O
+and	O
+host	B-COMP
+-	O
+to	O
+-	O
+host	B-COMP
+transmission	O
+.	O
+
+CoV	O
+responsible	O
+for	O
+recent	O
+outbreaks	O
+have	O
+extraordinary	O
+potential	O
+for	O
+cross	O
+-	O
+species	B-SPEC
+transmission	O
+;	O
+their	O
+RBD	O
+bear	B-SPEC
+large	O
+platforms	O
+specialized	O
+in	O
+recognition	O
+of	O
+receptors	O
+from	O
+different	O
+species	B-SPEC
+,	O
+which	O
+facilitates	O
+host	B-COMP
+-	O
+to	O
+-	O
+host	B-COMP
+circulation	B-PROC
+and	O
+adaptation	B-PROC
+to	O
+man	B-CHED
+.	O
+
+Real	O
+-	O
+time	O
+RT	O
+-	O
+PCR	O
+revealed	O
+a	O
+unique	O
+course	O
+of	O
+infection	B-DISO
+for	O
+the	O
+SCID	B-DISO
+group	O
+.	O
+
+Therefore	O
+,	O
+amino	B-PROC
+acid	I-PROC
+substitutions	I-PROC
+that	O
+appear	O
+during	O
+acute	B-DISO
+infection	I-DISO
+are	O
+likely	O
+the	O
+result	O
+of	O
+the	O
+adaptation	B-PROC
+of	O
+the	O
+virus	B-SPEC
+to	O
+replication	O
+in	O
+pigs	B-SPEC
+and	O
+not	O
+immune	O
+selection	O
+.	O
+
+However	O
+,	O
+anti	O
+-	O
+coronavirus	B-SPEC
+drugs	O
+currently	O
+are	O
+not	O
+available	O
+.	O
+
+In	O
+an	O
+effort	B-PROC
+to	O
+assist	O
+rapid	O
+development	B-PROC
+of	O
+anti	O
+-	O
+coronavirus	B-SPEC
+drugs	O
+,	O
+here	O
+we	O
+screened	O
+the	O
+NIH	O
+Clinical	O
+Collection	O
+in	O
+cell	B-COMP
+culture	O
+using	O
+a	O
+luciferase	B-ENZY
+reporter	O
+-	O
+expressing	O
+recombinant	O
+murine	B-SPEC
+coronavirus	I-SPEC
+.	O
+
+Since	O
+the	O
+NIH	O
+Clinical	O
+Collection	O
+consists	O
+of	O
+compounds	O
+that	O
+have	O
+already	O
+been	O
+through	O
+clinical	O
+trials	O
+,	O
+these	O
+small	O
+molecule	O
+inhibitors	B-CHED
+have	O
+a	O
+great	O
+potential	O
+for	O
+rapid	O
+development	B-PROC
+as	O
+anti	O
+-	O
+coronavirus	B-SPEC
+drugs	O
+.	O
+
+Etiology	O
+of	O
+EA	O
+COPD	B-DISO
+are	O
+mainly	O
+infectious	B-DISO
+,	O
+viral	O
+(	O
+rhinovirus	B-SPEC
+,	O
+influenzae	O
+or	O
+parainfluenzae	O
+virus	B-SPEC
+,	O
+coronavirus	B-SPEC
+,	O
+adenovirus	B-DISO
+and	O
+respiratory	B-SPEC
+syncytial	I-SPEC
+virus	I-SPEC
+)	O
+or	O
+bacterial	O
+(	O
+Haemophilus	B-SPEC
+influenzae	I-SPEC
+,	O
+Streptococcus	B-SPEC
+pneumoniae	I-SPEC
+,	O
+or	O
+Moraxella	B-SPEC
+catarrhalis	I-SPEC
+).	O
+
+AE	O
+COPD	O
+treatments	O
+consist	O
+on	O
+increase	O
+in	O
+bronchodilators	O
+,	O
+chest	B-ANAT
+physiotherapy	O
+,	O
+and	O
+antibiotics	B-CHED
+if	O
+sputum	B-ANAT
+is	O
+frankly	O
+purulent	O
+.	O
+
+During	O
+hospitalization	O
+,	O
+oxygen	B-CHED
+supplementation	O
+and	O
+thromboprophylaxis	O
+could	O
+be	O
+prescribed	O
+.	O
+
+The	O
+catalytic	O
+Cys	B-CHED
+of	O
+PLP1α	O
+is	O
+unusual	O
+in	O
+being	O
+adjacent	O
+to	O
+an	O
+Ala	B-CHED
+instead	O
+of	O
+a	O
+Typ	B-PRGE
+.	O
+
+All	O
+eight	O
+of	O
+the	O
+minor	O
+structural	O
+proteins	B-CHED
+were	O
+found	O
+to	O
+be	O
+required	O
+for	O
+production	O
+of	O
+infectious	B-DISO
+extracellular	B-COMP
+virus	B-SPEC
+.	O
+
+ABSTRACT	O
+:	O
+The	O
+recent	O
+Middle	O
+East	O
+respiratory	O
+syndrome	B-DISO
+coronavirus	B-SPEC
+(	O
+MERS	O
+-	O
+CoV	O
+)	O
+outbreak	O
+poses	O
+a	O
+serious	O
+threat	O
+to	O
+public	O
+health	O
+.	O
+
+Here	O
+,	O
+we	O
+summarize	O
+recent	O
+advances	O
+in	O
+identifying	O
+human	B-SPEC
+neutralizing	O
+monoclonal	B-PRGE
+antibodies	I-PRGE
+(	O
+mAbs	O
+)	O
+against	O
+MERS	O
+-	O
+CoV	O
+,	O
+describe	O
+their	O
+mechanisms	O
+of	O
+action	O
+,	O
+and	O
+analyze	O
+their	O
+potential	O
+for	O
+treatment	O
+of	O
+MERS	O
+-	O
+CoV	O
+infections	B-DISO
+.	O
+
+Because	O
+of	O
+threatening	O
+respiratory	B-DISO
+failure	I-DISO
+,	O
+tracheal	O
+intubation	O
+was	O
+performed	O
+immediately	O
+after	O
+ICU	O
+admission	O
+.	O
+
+A	O
+first	O
+attempt	O
+of	O
+extubation	O
+was	O
+performed	O
+on	O
+day	O
+5	O
+,	O
+but	O
+re	O
+-	O
+intubation	O
+was	O
+required	O
+because	O
+of	O
+laryngeal	B-DISO
+edema	I-DISO
+.	O
+
+For	O
+example	O
+,	O
+screening	O
+of	O
+Mallards	B-SPEC
+for	O
+influenza	B-PATH
+A	I-PATH
+viruses	B-SPEC
+(	O
+IAV	O
+)	O
+have	O
+repeatedly	O
+revealed	O
+high	O
+prevalence	O
+and	O
+large	O
+subtype	O
+diversity	O
+in	O
+the	O
+Northern	O
+Hemisphere	O
+.	O
+
+Disease	O
+dynamics	O
+are	O
+the	O
+result	O
+of	O
+an	O
+interplay	O
+between	O
+parasites	O
+,	O
+host	B-COMP
+immune	B-PROC
+responses	I-PROC
+,	O
+and	O
+resources	O
+;	O
+and	O
+is	O
+imperative	O
+that	O
+we	O
+begin	O
+to	O
+include	O
+all	O
+factors	O
+to	O
+better	O
+understand	O
+infectious	B-DISO
+disease	I-DISO
+risk	O
+.	O
+
+TITLE	O
+:	O
+Discovery	O
+,	O
+diversity	O
+and	O
+evolution	B-PROC
+of	O
+novel	O
+coronaviruses	O
+sampled	O
+from	O
+rodents	B-SPEC
+in	O
+China	O
+.	O
+
+In	O
+contrast	O
+,	O
+LRNV	O
+harbored	O
+by	O
+Rattus	B-SPEC
+norvegicus	I-SPEC
+formed	O
+a	O
+distinct	O
+lineage	O
+within	O
+the	O
+genus	B-SPEC
+Alphacoronavirus	B-SPEC
+in	O
+the	O
+3CL	O
+(	O
+pro	B-CHED
+),	O
+RdRp	B-FUNC
+,	O
+and	O
+Hel	B-PRGE
+gene	I-PRGE
+trees	O
+,	O
+but	O
+formed	O
+a	O
+more	O
+divergent	O
+lineage	O
+in	O
+the	O
+N	O
+and	O
+S	O
+gene	O
+trees	O
+,	O
+indicative	O
+of	O
+a	O
+recombinant	O
+origin	O
+.	O
+
+One	O
+hundred	O
+four	O
+weekly	O
+self	O
+-	O
+collected	O
+nasal	B-ANAT
+swabs	O
+were	O
+obtained	O
+,	O
+with	O
+a	O
+median	O
+of	O
+4	O
+samples	O
+per	O
+patient	O
+(	O
+range	O
+1	O
+-	O
+17	O
+).	O
+
+To	O
+assess	O
+the	O
+role	O
+of	O
+HCoVs	O
+in	O
+acute	B-DISO
+gastroenteritis	I-DISO
+(	O
+AGE	O
+)	O
+in	O
+children	O
+.	O
+
+HCoVs	O
+were	O
+detected	O
+simultaneously	O
+in	O
+stool	B-ANAT
+and	O
+nasal	B-ANAT
+swab	O
+samples	O
+in	O
+17	O
+children	O
+,	O
+in	O
+nasal	B-ANAT
+swabs	O
+alone	O
+in	O
+33	O
+children	O
+,	O
+and	O
+in	O
+the	O
+stools	B-ANAT
+alone	O
+in	O
+two	O
+children	O
+.	O
+
+HCoVs	O
+can	O
+be	O
+detected	O
+in	O
+the	O
+stools	B-ANAT
+of	O
+children	O
+with	O
+AGE	O
+,	O
+but	O
+usually	O
+together	O
+with	O
+well	O
+-	O
+known	O
+gastroenteritis	B-DISO
+viruses	B-SPEC
+,	O
+and	O
+concomitantly	O
+in	O
+the	O
+respiratory	B-ANAT
+tract	I-ANAT
+.	O
+
+HCoVs	O
+were	O
+present	O
+in	O
+the	O
+stools	B-ANAT
+of	O
+eight	O
+(	O
+4	O
+.	O
+7	O
+%)	O
+of	O
+the	O
+172	O
+children	O
+with	O
+AGE	O
+;	O
+in	O
+six	O
+of	O
+these	O
+cases	O
+,	O
+the	O
+nasal	B-ANAT
+swab	O
+sample	O
+was	O
+also	O
+positive	O
+for	O
+the	O
+respective	O
+HCoV	O
+.	O
+Additionally	O
+,	O
+in	O
+six	O
+of	O
+the	O
+eight	O
+cases	O
+,	O
+the	O
+stool	B-ANAT
+sample	I-ANAT
+contained	O
+either	O
+rotavirus	B-SPEC
+or	O
+calicivirus	O
+.	O
+
+These	O
+results	O
+suggest	O
+that	O
+these	O
+direct	O
+acting	O
+antiviral	B-CHED
+compounds	O
+,	O
+or	O
+their	O
+derivatives	O
+,	O
+warrant	O
+further	O
+investigation	O
+for	O
+clinical	O
+use	O
+in	O
+cats	B-SPEC
+with	O
+FIP	B-DISO
+.	O
+
+As	O
+of	O
+May	O
+9	O
+,	O
+2014	O
+,	O
+536	O
+laboratory	O
+-	O
+confirmed	O
+cases	O
+and	O
+145	O
+deaths	B-PROC
+have	O
+been	O
+reported	O
+globally	O
+.	O
+
+Currently	O
+,	O
+health	O
+care	O
+-	O
+associated	O
+outbreaks	O
+are	O
+playing	O
+a	O
+pivotal	O
+role	O
+in	O
+the	O
+evolution	B-PROC
+of	O
+the	O
+MERS	O
+-	O
+CoV	O
+epidemic	O
+in	O
+countries	O
+in	O
+the	O
+Arabian	O
+Peninsula	O
+.	O
+
+ABSTRACT	O
+:	O
+Respiratory	B-DISO
+tract	I-DISO
+infections	I-DISO
+(	O
+RTIs	O
+)	O
+are	O
+common	O
+during	O
+the	O
+Hajj	O
+season	O
+and	O
+are	O
+caused	O
+by	O
+a	O
+variety	O
+of	O
+organisms	O
+,	O
+which	O
+can	O
+be	O
+transmitted	B-DISO
+via	O
+the	O
+air	B-CHED
+or	O
+contaminated	O
+surfaces	O
+.	O
+
+Active	O
+air	B-CHED
+sampling	O
+was	O
+conducted	O
+using	O
+air	B-CHED
+biosamplers	O
+,	O
+and	O
+swabs	O
+were	O
+used	O
+to	O
+sample	O
+frequently	O
+touched	O
+surfaces	O
+.	O
+
+Of	O
+the	O
+58	O
+environmental	B-SPEC
+samples	I-SPEC
+,	O
+8	O
+were	O
+positive	O
+for	O
+at	O
+least	O
+1	O
+pathogen	O
+.	O
+
+The	O
+handles	O
+of	O
+1	O
+chair	O
+were	O
+cocontaminated	O
+with	O
+coronavirus	B-SPEC
+OC43	O
+/	O
+HKU1	O
+and	O
+H	O
+influenzae	O
+.	O
+
+Respiratory	O
+pathogens	O
+were	O
+detected	O
+in	O
+the	O
+air	B-CHED
+and	O
+on	O
+surfaces	O
+in	O
+the	O
+KAAI	O
+Airport	O
+in	O
+Pilgrims	O
+City	O
+.	O
+
+RESULTS	O
+:	O
+Of	O
+the	O
+58	O
+environmental	B-SPEC
+samples	I-SPEC
+,	O
+8	O
+were	O
+positive	O
+for	O
+at	O
+least	O
+1	O
+pathogen	O
+.	O
+
+In	O
+summary	O
+,	O
+PEDV	B-SPEC
+was	O
+not	O
+infectious	B-DISO
+on	O
+cell	B-COMP
+culture	O
+within	O
+7	O
+days	O
+when	O
+stored	O
+at	O
+room	O
+temperature	O
+and	O
+within	O
+21	O
+days	O
+when	O
+stored	O
+at	O
+refrigerated	O
+temperature	O
+.	O
+
+TITLE	O
+:	O
+Genomics	O
+and	O
+proteomics	O
+of	O
+mycobacteriophage	O
+patience	O
+,	O
+an	O
+accidental	O
+tourist	O
+in	O
+the	O
+Mycobacterium	B-SPEC
+neighborhood	O
+.	O
+
+We	O
+describe	O
+here	O
+mycobacteriophage	O
+Patience	O
+,	O
+a	O
+newly	O
+isolated	O
+phage	O
+recovered	O
+using	O
+Mycobacterium	B-SPEC
+smegmatis	I-SPEC
+mc	O
+(	O
+2	O
+)	O
+155	O
+as	O
+a	O
+host	B-COMP
+.	O
+
+The	O
+viral	B-COMP
+genome	I-COMP
+has	O
+an	O
+abundance	O
+of	O
+codons	O
+that	O
+are	O
+rare	O
+in	O
+the	O
+host	B-COMP
+and	O
+are	O
+decoded	O
+by	O
+wobble	O
+tRNA	B-FUNC
+pairing	O
+,	O
+although	O
+the	O
+phage	O
+grows	O
+well	O
+and	O
+expression	B-PROC
+of	O
+most	O
+of	O
+the	O
+genes	O
+is	O
+detected	O
+by	O
+mass	O
+spectrometry	O
+.	O
+
+The	O
+time	O
+for	O
+the	O
+incubation	O
+steps	O
+for	O
+a	O
+single	O
+assay	O
+was	O
+reduced	O
+by	O
+more	O
+than	O
+50	O
+%,	O
+without	O
+affecting	O
+assay	O
+performance	O
+,	O
+since	O
+intermediate	O
+wash	O
+steps	O
+became	O
+redundant	O
+in	O
+the	O
+continuously	O
+perfused	O
+bead	O
+trapping	O
+capillary	B-ANAT
+.	O
+
+TITLE	O
+:	O
+Intravenous	O
+fish	B-SPEC
+oil	O
+in	O
+adult	O
+intensive	O
+care	O
+unit	O
+patients	O
+.	O
+
+While	O
+significant	O
+beneficial	O
+effects	O
+on	O
+infection	B-DISO
+rates	O
+and	O
+the	O
+lengths	O
+of	O
+ICU	O
+and	O
+hospital	O
+stays	O
+have	O
+concordantly	O
+been	O
+identified	O
+in	O
+three	O
+recent	O
+meta	B-SPEC
+-	O
+analyses	O
+on	O
+non	O
+-	O
+ICU	O
+surgical	O
+patients	O
+,	O
+the	O
+level	O
+of	O
+evidence	O
+is	O
+not	O
+so	O
+clear	O
+for	O
+critically	B-DISO
+ill	I-DISO
+patients	O
+.	O
+
+Thus	O
+,	O
+obvious	O
+positive	O
+secondary	O
+outcome	O
+effects	O
+with	O
+intravenous	O
+fish	B-SPEC
+oil	O
+have	O
+not	O
+yet	O
+been	O
+shown	O
+to	O
+transfer	O
+to	O
+lower	O
+mortality	O
+in	O
+critically	B-DISO
+ill	I-DISO
+patients	O
+.	O
+
+However	O
+,	O
+it	O
+is	O
+not	O
+known	O
+whether	O
+DMV	O
+morphology	O
+or	O
+another	O
+function	O
+of	O
+nsp4	B-PRGE
+glycosylation	B-PROC
+is	O
+responsible	O
+for	O
+effects	O
+on	O
+virus	B-PROC
+replication	I-PROC
+.	O
+
+Residues	O
+in	O
+nsp4	B-PRGE
+distinct	O
+from	O
+glycosylation	B-PROC
+sites	O
+,	O
+particularly	O
+in	O
+the	O
+endoplasmic	B-COMP
+reticulum	I-COMP
+(	O
+ER	O
+)	O
+luminal	B-CHED
+loop	O
+1	O
+,	O
+independently	O
+disrupted	O
+both	O
+the	O
+number	O
+and	O
+morphology	O
+of	O
+DMVs	O
+and	O
+exacerbated	O
+DMV	O
+changes	O
+associated	O
+with	O
+loss	O
+of	O
+glycosylation	B-PROC
+.	O
+
+The	O
+results	O
+also	O
+suggest	O
+that	O
+nsp4	B-PRGE
+glycosylation	B-PROC
+serves	O
+roles	O
+in	O
+replication	O
+in	O
+addition	O
+to	O
+the	O
+organization	O
+and	O
+stability	O
+of	O
+MHV	B-SPEC
+-	O
+induced	O
+double	O
+-	O
+membrane	B-COMP
+vesicles	B-COMP
+.	O
+
+Three	O
+viral	O
+nonstructural	O
+proteins	B-CHED
+(	O
+nsps	O
+),	O
+nsp3	B-PRGE
+,	O
+nsp4	B-PRGE
+,	O
+and	O
+nsp6	O
+,	O
+are	O
+known	O
+to	O
+be	O
+required	O
+for	O
+DMV	O
+formation	B-PROC
+.	O
+
+TITLE	O
+:	O
+Pan	B-ANAT
+-	I-PRGE
+human	B-SPEC
+coronavirus	I-SPEC
+and	I-PRGE
+human	B-SPEC
+bocavirus	I-SPEC
+SYBR	I-PRGE
+Green	O
+and	O
+TaqMan	O
+PCR	O
+assays	O
+;	O
+use	O
+in	O
+studying	O
+influenza	B-DISO
+A	I-PATH
+viruses	B-SPEC
+co	B-DISO
+-	I-DISO
+infection	I-DISO
+and	O
+risk	O
+of	O
+hospitalization	O
+.	O
+
+This	O
+study	O
+investigated	O
+the	O
+association	O
+between	O
+influenza	B-PATH
+A	I-PATH
+viruses	B-SPEC
+co	B-DISO
+-	I-DISO
+infection	I-DISO
+with	O
+hBoV	O
+and	O
+hCoV	O
+and	O
+severity	O
+and	O
+the	O
+sensitivity	O
+of	O
+a	O
+real	O
+-	O
+time	O
+polymerase	O
+chain	O
+reaction	O
+(	O
+RT	O
+-	O
+PCR	O
+)	O
+assay	O
+for	O
+identification	O
+of	O
+15	O
+coronaviruses	O
+.	O
+
+A	O
+previously	O
+published	O
+PCR	O
+targeting	B-PROC
+the	O
+NS1	B-PRGE
+Gene	I-PRGE
+of	O
+all	O
+known	O
+human	B-SPEC
+bocavirus	I-SPEC
+strains	O
+was	O
+also	O
+utilized	O
+.	O
+
+Association	O
+between	O
+co	B-DISO
+-	I-DISO
+infection	I-DISO
+and	O
+disease	O
+outcome	O
+was	O
+assessed	O
+using	O
+logistic	O
+regression	O
+.	O
+
+A	O
+higher	O
+proportion	O
+(	O
+61	O
+.	O
+5	O
+%;	O
+8	O
+/	O
+13	O
+)	O
+of	O
+SeasFluA	O
+/	O
+hBoV	O
+co	B-DISO
+-	I-DISO
+infections	I-DISO
+were	O
+identified	O
+in	O
+patients	O
+that	O
+were	O
+admitted	O
+either	O
+to	O
+a	O
+general	O
+ward	O
+or	O
+the	O
+intensive	O
+care	O
+unit	O
+compared	O
+to	O
+44	O
+.	O
+3	O
+%	O
+(	O
+66	O
+/	O
+149	O
+)	O
+of	O
+single	O
+SeasFlu	O
+A	O
+virus	B-SPEC
+infections	B-DISO
+(	O
+OR	O
+2	O
+.	O
+5	O
+95	O
+%	O
+CI	O
+0	O
+.	O
+67	O
+-	O
+9	O
+.	O
+34	O
+,	O
+p	O
+=	O
+0	O
+.	O
+17	O
+).	O
+
+Exposure	O
+to	O
+poultry	O
+and	O
+fomites	O
+are	O
+considered	O
+the	O
+likely	O
+sources	O
+of	O
+infection	B-DISO
+for	O
+H7N9	O
+,	O
+H5N1	B-DISO
+,	O
+and	O
+H10N8	O
+,	O
+with	O
+limited	O
+human	B-SPEC
+-	O
+to	O
+-	O
+human	B-SPEC
+transmission	O
+in	O
+close	O
+contacts	O
+.	O
+
+The	O
+S2	O
+subunit	O
+of	O
+the	O
+S	B-PRGE
+glycoprotein	I-PRGE
+of	O
+SARS	B-PRGE
+-	I-PRGE
+CoV	I-PRGE
+carries	O
+out	O
+fusion	O
+between	O
+the	O
+virus	B-SPEC
+and	O
+the	O
+host	B-COMP
+cells	B-COMP
+.	O
+
+To	O
+decrease	O
+diarrhoea	B-DISO
+problems	O
+among	O
+neonatal	O
+calves	O
+,	O
+a	O
+standard	O
+protocol	O
+was	O
+tested	O
+on	O
+13	O
+herds	O
+(	O
+treatment	O
+group	O
+)	O
+where	O
+both	O
+C	B-SPEC
+.	I-SPEC
+parvum	I-SPEC
+and	O
+either	O
+E	B-SPEC
+.	I-SPEC
+coli	I-SPEC
+or	O
+rota	O
+-	O
+or	O
+coronavirus	B-SPEC
+were	O
+identified	O
+as	O
+being	O
+involved	O
+,	O
+the	O
+other	O
+11	O
+herds	O
+served	O
+as	O
+control	O
+group	O
+.	O
+
+The	O
+protocol	O
+consisted	O
+of	O
+2	O
+points	O
+of	O
+action	O
+:	O
+preventive	O
+vaccination	O
+of	O
+dams	O
+against	O
+E	B-SPEC
+.	I-SPEC
+coli	I-SPEC
+,	O
+rota	O
+-	O
+and	O
+coronavirus	B-SPEC
+,	O
+and	O
+preventive	O
+administration	O
+of	O
+halofuginone	O
+lactate	O
+to	O
+newborn	O
+calves	O
+.	O
+
+Non	O
+-	O
+significant	O
+results	O
+were	O
+obtained	O
+for	O
+the	O
+effect	O
+of	O
+the	O
+protocol	O
+on	O
+duration	O
+of	O
+diarrhoea	B-DISO
+and	O
+the	O
+effect	O
+of	O
+the	O
+colostral	O
+IgG	B-PRGE
+quantity	O
+on	O
+the	O
+risk	O
+of	O
+diarrhoea	B-DISO
+.	O
+
+TITLE	O
+:	O
+[	O
+Pulse	B-PROC
+indicator	B-CHED
+continuous	O
+cardiac	B-ANAT
+output	O
+measurement	O
+-	O
+guided	O
+treatment	O
+aids	O
+two	O
+pediatric	O
+patients	O
+with	O
+severe	O
+acute	O
+pancreatitis	O
+complicated	O
+with	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+].	O
+
+After	O
+a	O
+1	O
+-	O
+week	O
+dosage	O
+of	O
+chemotherapeutic	O
+drugs	O
+(	O
+pegaspargase	O
+and	O
+mitoxantrone	O
+),	O
+he	O
+suffered	B-DISO
+SAP	B-PRGE
+combined	O
+with	O
+ARDS	B-DISO
+.	O
+
+Two	O
+hours	O
+later	O
+,	O
+GEDVI	O
+significantly	O
+increased	O
+to	O
+600	O
+ml	O
+/	O
+m²	O
+and	O
+ELVWI	O
+significantly	O
+increased	O
+to	O
+10	O
+ml	O
+/	O
+kg	O
+,	O
+the	O
+oxygenation	B-PROC
+index	O
+declined	O
+to	O
+155	O
+mmHg	O
+,	O
+the	O
+bedside	O
+chest	B-ANAT
+X	O
+-	O
+ray	B-SPEC
+showed	O
+a	O
+significant	O
+decrease	O
+of	O
+permeability	O
+(	O
+right	B-ANAT
+lung	I-ANAT
+)	O
+and	O
+PEEP	B-CHED
+was	O
+adjusted	O
+to	O
+5	O
+cmH₂O	O
+(	O
+1	O
+cmH₂O	O
+=	O
+0	O
+.	O
+098	O
+kPa	O
+),	O
+indicating	O
+circulating	O
+overload	O
+.	O
+
+According	O
+to	O
+the	O
+initial	O
+data	O
+of	O
+PiCCO	O
+,	O
+EVLWI	O
+was	O
+9	O
+ml	O
+/	O
+kg	O
+,	O
+GEDVI	O
+was	O
+519	O
+ml	O
+/	O
+m²	O
+,	O
+the	O
+oxygenation	B-PROC
+index	O
+was	O
+298	O
+mmHg	O
+,	O
+the	O
+bedside	O
+chest	B-ANAT
+X	O
+-	O
+ray	B-SPEC
+showed	O
+decreased	O
+permeability	O
+and	O
+PEEP	B-CHED
+was	O
+adjusted	O
+to	O
+5	O
+cmH₂O	O
+,	O
+suggesting	O
+the	O
+existence	O
+of	O
+ARDS	B-DISO
+.	O
+
+To	O
+guide	O
+fluid	O
+management	O
+,	O
+the	O
+cardiac	B-ANAT
+index	O
+(	O
+CI	O
+)	O
+was	O
+measured	O
+to	O
+assess	O
+cardiac	B-PROC
+function	I-PROC
+,	O
+the	O
+global	O
+end	O
+-	O
+diastolic	O
+volume	O
+index	O
+(	O
+GEDVI	O
+)	O
+was	O
+used	O
+to	O
+evaluate	O
+cardiac	B-ANAT
+preload	O
+,	O
+and	O
+the	O
+extravascular	O
+lung	B-ANAT
+water	B-CHED
+index	O
+(	O
+EVLWI	O
+)	O
+was	O
+used	O
+to	O
+evaluate	O
+the	O
+pulmonary	B-DISO
+edema	I-DISO
+.	O
+
+The	O
+primary	O
+endpoint	O
+was	O
+the	O
+rate	O
+of	O
+DAD	O
+according	O
+to	O
+the	O
+ARDS	B-DISO
+stage	O
+in	O
+the	O
+patients	O
+with	O
+nonresolving	O
+ARDS	B-DISO
+who	O
+had	O
+OLB	O
+.	O
+
+On	O
+this	O
+basis	O
+,	O
+the	O
+systematic	O
+use	O
+of	O
+steroids	B-CHED
+in	O
+nonresolving	O
+ARDS	B-DISO
+is	O
+not	O
+recommended	O
+.	O
+
+ABSTRACT	O
+:	O
+P34	B-PRGE
+is	O
+an	O
+antimicrobial	B-CHED
+peptide	B-CHED
+produced	O
+by	O
+a	O
+Bacillus	B-SPEC
+sp	I-SPEC
+.	O
+strain	O
+isolated	O
+from	O
+the	O
+intestinal	B-ANAT
+contents	I-ANAT
+of	O
+a	O
+fish	B-SPEC
+in	O
+the	O
+Brazilian	O
+Amazon	B-SPEC
+basin	O
+with	O
+reported	O
+antibacterial	O
+activity	O
+.	O
+
+The	O
+results	O
+showed	O
+that	O
+the	O
+peptide	B-CHED
+P34	O
+exhibited	O
+antiviral	B-CHED
+activity	O
+against	O
+EAV	B-SPEC
+and	O
+FHV	O
+-	O
+1	O
+.	O
+
+This	O
+finding	O
+prompted	O
+us	O
+to	O
+identify	O
+other	O
+potential	O
+mechanisms	O
+of	O
+inhibition	B-PROC
+of	O
+PLpro	O
+on	O
+IFN	B-PRGE
+induction	O
+.	O
+
+We	O
+have	O
+used	O
+plasmids	O
+expressing	O
+PLpro	O
+and	O
+IRF3	B-PRGE
+including	O
+an	O
+IRF3	B-PRGE
+mutant	I-PRGE
+that	O
+is	O
+constitutively	O
+active	O
+,	O
+called	O
+IRF3	B-PRGE
+(	O
+5D	O
+).	O
+
+Watery	O
+fecal	B-ANAT
+stools	B-ANAT
+were	O
+significantly	O
+correlated	O
+with	O
+C	O
+.	O
+parvum	O
+(	O
+p	O
+<	O
+0	O
+.	O
+05	O
+).	O
+
+The	O
+set	O
+included	O
+the	O
+type	O
+I	O
+FCoV	O
+strain	O
+Black	O
+,	O
+a	O
+type	O
+I	O
+FCoV	O
+strain	O
+Black	O
+with	O
+restored	O
+accessory	O
+gene	B-PRGE
+7b	I-PRGE
+,	O
+two	O
+chimeric	O
+type	O
+I	O
+/	O
+type	O
+II	O
+FCoVs	O
+and	O
+the	O
+highly	O
+pathogenic	O
+type	O
+II	O
+FCoV	O
+strain	O
+79	O
+-	O
+1146	O
+.	O
+
+One	O
+key	O
+area	O
+of	O
+research	O
+in	O
+the	O
+positive	O
+sense	B-PROC
+RNA	O
+virus	B-SPEC
+field	O
+,	O
+due	O
+to	O
+its	O
+central	O
+role	O
+in	O
+virus	B-PROC
+replication	I-PROC
+,	O
+is	O
+the	O
+induction	O
+of	O
+cellular	B-COMP
+membrane	I-COMP
+rearrangements	O
+by	O
+this	O
+class	B-SPEC
+of	O
+viruses	B-SPEC
+for	O
+the	O
+assembly	O
+of	O
+virus	B-PROC
+replication	I-PROC
+complexes	O
+.	O
+
+ABSTRACT	O
+:	O
+Interactions	O
+between	O
+live	O
+Newcastle	B-SPEC
+disease	I-SPEC
+virus	I-SPEC
+(	O
+NDV	B-SPEC
+),	O
+avian	B-SPEC
+metapneumovirus	I-SPEC
+(	O
+aMPV	O
+)	O
+and	O
+infectious	B-DISO
+bronchitis	B-DISO
+virus	B-SPEC
+(	O
+IBV	B-SPEC
+)	O
+vaccines	O
+following	O
+simultaneous	O
+vaccination	O
+of	O
+day	O
+old	O
+specific	O
+pathogen	O
+free	O
+(	O
+SPF	O
+)	O
+chicks	O
+were	O
+evaluated	O
+.	O
+
+aMPV	O
+vaccine	O
+when	O
+given	O
+with	O
+other	O
+live	O
+vaccines	O
+suppressed	O
+levels	O
+of	O
+aMPV	O
+enzyme	O
+-	O
+linked	O
+immunosorbent	O
+assay	O
+(	O
+ELISA	O
+)	O
+antibodies	B-COMP
+.	O
+
+Three	O
+respiratory	O
+clinical	O
+samples	O
+were	O
+tested	O
+on	O
+well	O
+-	O
+differentiated	B-PROC
+pseudostratified	O
+tracheobronchial	O
+human	B-SPEC
+airway	B-ANAT
+epithelial	O
+(	O
+HAE	O
+)	O
+cultures	O
+grown	O
+at	O
+an	O
+air	B-CHED
+-	O
+liquid	O
+interface	O
+,	O
+which	O
+resemble	O
+the	O
+airway	B-ANAT
+epithelium	B-ANAT
+.	O
+
+We	O
+present	O
+here	O
+a	O
+new	O
+method	O
+for	O
+virus	B-SPEC
+discovery	O
+that	O
+requires	O
+a	O
+virus	B-SPEC
+culture	O
+on	O
+primary	O
+cells	B-COMP
+and	O
+an	O
+antibody	B-COMP
+detection	O
+.	O
+
+CONCLUSIONS	O
+:	O
+We	O
+present	O
+here	O
+a	O
+new	O
+method	O
+for	O
+virus	B-SPEC
+discovery	O
+that	O
+requires	O
+a	O
+virus	B-SPEC
+culture	O
+on	O
+primary	O
+cells	B-COMP
+and	O
+an	O
+antibody	B-COMP
+detection	O
+.	O
+
+Samples	O
+from	O
+mumps	B-SPEC
+virus	I-SPEC
+-	O
+negative	O
+patients	O
+presenting	O
+unilateral	O
+or	O
+bilateral	B-DISO
+parotitis	I-DISO
+or	O
+other	O
+salivary	B-ANAT
+gland	I-ANAT
+swelling	B-DISO
+were	O
+tested	O
+for	O
+Epstein	B-SPEC
+-	I-SPEC
+Barr	I-SPEC
+virus	I-SPEC
+(	O
+EBV	O
+)	O
+by	O
+real	O
+-	O
+time	O
+PCR	O
+and	O
+for	O
+respiratory	O
+viruses	B-SPEC
+by	O
+two	O
+multiplex	O
+-	O
+PCR	O
+-	O
+based	O
+assays	O
+to	O
+detect	O
+parainfluenza	B-DISO
+virus	B-SPEC
+(	O
+PIV	O
+)	O
+1	O
+-	O
+4	O
+,	O
+influenza	B-SPEC
+virus	I-SPEC
+(	O
+InV	O
+)	O
+A	O
+,	O
+B	O
+and	O
+C	O
+,	O
+respiratory	B-SPEC
+syncytial	I-SPEC
+virus	I-SPEC
+(	O
+RSV	B-SPEC
+),	O
+enterovirus	B-SPEC
+,	O
+coronavirus	B-SPEC
+229E	O
+,	O
+coronavirus	B-SPEC
+OC43	O
+,	O
+and	O
+rhinovirus	B-SPEC
+.	O
+
+Oral	B-ANAT
+samples	O
+were	O
+collected	O
+on	O
+the	O
+first	O
+day	O
+of	O
+glandular	B-ANAT
+swelling	B-DISO
+in	O
+53	O
+patients	O
+(	O
+52	O
+.	O
+5	O
+%),	O
+and	O
+on	O
+the	O
+first	O
+two	O
+days	O
+in	O
+74	O
+patients	O
+(	O
+73	O
+.	O
+3	O
+%).	O
+
+Owing	O
+to	O
+problems	O
+such	O
+as	O
+long	O
+periods	B-PROC
+of	O
+virus	B-DISO
+shedding	I-DISO
+,	O
+existing	O
+vaccines	O
+cannot	O
+provide	O
+complete	O
+protection	O
+from	O
+PEDV	B-SPEC
+infection	B-DISO
+.	O
+
+Interestingly	O
+,	O
+a	O
+functional	O
+mutant	B-DISO
+(	O
+N60K	O
+)	O
+of	O
+nsp9	O
+was	O
+identified	O
+to	O
+compensate	O
+for	O
+a	O
+6	O
+nt	O
+insertion	B-PROC
+mutation	I-PROC
+of	O
+the	O
+3	O
+'-	O
+untranslated	O
+region	O
+(	O
+UTR	O
+),	O
+which	O
+is	O
+critical	O
+for	O
+viral	O
+RNA	B-PROC
+synthesis	I-PROC
+.	O
+
+TITLE	O
+:	O
+Antiviral	B-CHED
+potential	O
+of	O
+ERK	B-FUNC
+/	O
+MAPK	B-FUNC
+and	O
+PI3K	B-FUNC
+/	O
+AKT	B-PRGE
+/	O
+mTOR	B-PRGE
+signaling	B-PROC
+modulation	O
+for	O
+Middle	O
+East	O
+respiratory	O
+syndrome	O
+coronavirus	B-DISO
+infection	I-DISO
+as	O
+identified	O
+by	O
+temporal	O
+kinome	O
+analysis	O
+.	O
+
+The	O
+overrepresentation	O
+of	O
+specific	O
+intermediates	O
+within	O
+these	O
+pathways	B-PROC
+determined	O
+by	O
+pathway	B-PROC
+and	O
+functional	O
+network	O
+analysis	O
+of	O
+our	O
+kinome	O
+data	O
+correlated	O
+with	O
+similar	O
+patterns	O
+of	O
+phosphorylation	B-PROC
+determined	O
+through	O
+Western	O
+blot	O
+array	O
+analysis	O
+.	O
+
+In	O
+addition	O
+,	O
+analysis	O
+of	O
+the	O
+effects	O
+of	O
+specific	O
+kinase	B-PROC
+inhibitors	I-PROC
+on	O
+MERS	O
+-	O
+CoV	O
+infection	B-DISO
+in	O
+tissue	B-ANAT
+culture	O
+models	O
+confirmed	O
+these	O
+cellular	B-COMP
+response	O
+observations	O
+.	O
+
+Six	O
+required	O
+salvage	O
+extracorporeal	O
+membrane	B-COMP
+oxygenation	B-PROC
+with	O
+one	O
+survivor	O
+.	O
+
+ECMO	O
+was	O
+weaned	B-PROC
+at	O
+a	O
+mean	O
+duration	O
+of	O
+188	O
+(	O
+range	O
+,	O
+43	O
+-	O
+672	O
+)	O
+h	O
+in	O
+all	O
+patients	O
+.	O
+
+Aiming	O
+to	O
+reduce	O
+transfusion	O
+requirements	O
+,	O
+we	O
+implemented	O
+a	O
+blood	B-ANAT
+conservation	O
+protocol	O
+in	O
+adults	O
+with	O
+severe	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+(	O
+ARDS	B-DISO
+)	O
+receiving	O
+ECMO	O
+.	O
+
+The	O
+physiologic	O
+effects	O
+of	O
+hypercapnia	B-DISO
+are	O
+increasingly	O
+well	O
+understood	O
+,	O
+and	O
+important	O
+recent	O
+insights	O
+have	O
+emerged	O
+regarding	O
+the	O
+cellular	B-COMP
+and	O
+molecular	O
+mechanisms	O
+of	O
+action	O
+of	O
+hypercapnia	B-DISO
+and	O
+acidosis	B-DISO
+.	O
+
+Patients	O
+transported	O
+via	O
+EMS	O
+were	O
+older	O
+(	O
+P	O
+<	O
+0	O
+.	O
+01	O
+),	O
+had	O
+fewer	O
+lactates	O
+>	O
+4	O
+(	O
+P	O
+<	O
+0	O
+.	O
+02	O
+),	O
+a	O
+more	O
+altered	B-DISO
+mental	I-DISO
+status	I-DISO
+(	O
+P	O
+<	O
+0	O
+.	O
+01	O
+),	O
+and	O
+higher	O
+respiratory	O
+rates	O
+(	O
+P	O
+<	O
+0	O
+.	O
+05	O
+)	O
+than	O
+did	O
+walk	O
+-	O
+in	O
+patients	O
+.	O
+
+In	O
+a	O
+logistic	O
+model	O
+,	O
+mortality	O
+was	O
+associated	O
+with	O
+increasing	O
+age	O
+(	O
+adjusted	O
+odds	O
+ratio	O
+1	O
+.	O
+3	O
+;	O
+95	O
+%	O
+confidence	O
+interval	O
+[	O
+CI	O
+]	O
+1	O
+.	O
+2	O
+-	O
+1	O
+.	O
+4	O
+),	O
+higher	O
+first	O
+-	O
+measured	O
+ED	O
+lactates	O
+(	O
+1	O
+.	O
+2	O
+;	O
+95	O
+%	O
+CI	O
+1	O
+.	O
+1	O
+-	O
+1	O
+.	O
+2	O
+),	O
+and	O
+increased	O
+initial	O
+SOFA	O
+score	O
+(	O
+adjusted	O
+odds	O
+ratio	O
+1	O
+.	O
+2	O
+;	O
+95	O
+%	O
+CI	O
+1	O
+.	O
+1	O
+-	O
+1	O
+.	O
+3	O
+)	O
+but	O
+not	O
+EMS	O
+arrival	O
+or	O
+prehospital	O
+fluids	B-ANAT
+.	O
+
+Here	O
+,	O
+we	O
+provide	O
+evidence	O
+that	O
+PLP2	B-PRGE
+,	O
+a	O
+catalytic	O
+domain	O
+of	O
+the	O
+nonstructural	O
+protein	B-CHED
+3	O
+of	O
+human	B-PRGE
+coronavirus	I-PRGE
+NL63	I-PRGE
+(	O
+HCoV	B-SPEC
+-	I-SPEC
+NL63	I-SPEC
+),	O
+deubiquitinates	O
+and	O
+stabilizes	O
+the	O
+cellular	B-COMP
+oncoprotein	O
+MDM2	B-PRGE
+and	O
+induces	O
+the	O
+proteasomal	O
+degradation	O
+of	O
+p53	B-PRGE
+.	O
+
+ABSTRACT	O
+:	O
+Ultraviolet	O
+(	O
+UV	O
+)	O
+reactors	O
+used	O
+for	O
+disinfecting	O
+water	B-CHED
+and	O
+wastewater	O
+must	O
+be	O
+validated	O
+and	O
+monitored	O
+over	O
+time	O
+.	O
+
+A	O
+tunable	O
+laser	B-SPEC
+from	O
+the	O
+National	O
+Institute	O
+of	O
+Standards	O
+and	O
+Technology	O
+was	O
+used	O
+to	O
+isolate	O
+single	O
+UV	O
+wavelengths	O
+at	O
+10	O
+nm	O
+intervals	O
+between	O
+210	O
+and	O
+290	O
+nm	O
+.	O
+
+Of	O
+the	O
+coliphage	O
+,	O
+MS2	O
+exhibited	O
+the	O
+highest	O
+relative	O
+sensitivity	O
+below	O
+240	O
+nm	O
+,	O
+relative	O
+to	O
+its	O
+sensitivity	O
+at	O
+254	O
+nm	O
+,	O
+followed	O
+by	O
+Q	B-PRGE
+Beta	I-PRGE
+,	O
+T1UV	O
+,	O
+T7m	O
+and	O
+T7	O
+coliphage	O
+.	O
+
+ABSTRACT	O
+:	O
+To	O
+characterize	O
+the	O
+2013	O
+-	O
+2014	O
+epidemic	O
+season	O
+from	O
+the	O
+results	O
+of	O
+detection	O
+of	O
+influenza	O
+infection	B-DISO
+in	O
+patients	O
+;	O
+to	O
+provide	O
+the	O
+molecular	O
+genetic	O
+characteristics	O
+of	O
+the	O
+strains	O
+isolated	O
+from	O
+deceased	B-PROC
+patients	O
+.	O
+
+However	O
+,	O
+studies	O
+are	O
+required	O
+to	O
+assess	O
+the	O
+knowledge	O
+and	O
+attitude	O
+of	O
+HCWs	O
+at	O
+national	O
+level	O
+so	O
+that	O
+effective	O
+interventions	O
+could	O
+be	O
+designed	O
+as	O
+surveillance	O
+and	O
+infection	B-DISO
+control	O
+measures	O
+are	O
+critical	O
+to	O
+global	O
+public	O
+health	O
+.	O
+
+This	O
+study	O
+aimed	O
+at	O
+evaluating	O
+cytokine	O
+-	O
+associated	O
+single	O
+nucleotide	B-CHED
+polymorphisms	B-PROC
+(	O
+SNPs	B-PROC
+),	O
+i	O
+.	O
+e	O
+.,	O
+tumor	B-PRGE
+necrosis	I-PRGE
+factor	I-PRGE
+alpha	I-PRGE
+(	O
+TNF	B-PRGE
+-	I-PRGE
+α	I-PRGE
+),	O
+receptor	O
+-	O
+associated	O
+SNPs	B-PROC
+,	O
+i	O
+.	O
+e	O
+.,	O
+C	B-PRGE
+-	I-PRGE
+type	I-PRGE
+lectin	I-PRGE
+DC	I-PRGE
+-	O
+SIGN	O
+(	O
+CD209	B-PRGE
+),	O
+and	O
+the	O
+five	O
+FIP	B-DISO
+-	O
+associated	O
+SNPs	B-PROC
+identified	O
+from	O
+Birman	O
+cats	B-SPEC
+of	O
+USA	O
+and	O
+Denmark	O
+origins	O
+and	O
+their	O
+associations	O
+with	O
+the	O
+outcome	O
+of	O
+FCoV	O
+infection	B-DISO
+in	O
+71	O
+FIP	B-DISO
+cats	B-SPEC
+and	O
+93	O
+FCoV	O
+infected	O
+non	O
+-	O
+FIP	B-DISO
+cats	B-SPEC
+in	O
+a	O
+genetically	O
+more	O
+diverse	O
+cat	B-SPEC
+populations	O
+.	O
+
+The	O
+level	O
+of	O
+positive	O
+end	B-PROC
+-	I-PROC
+expiratory	I-PROC
+pressure	O
+applied	O
+may	O
+greatly	O
+affect	O
+PaO2	O
+/	O
+FIO2	O
+,	O
+thereby	O
+masking	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+severity	O
+,	O
+which	O
+should	O
+reflect	O
+the	O
+underlying	O
+lung	B-ANAT
+injury	O
+(	O
+lung	B-DISO
+edema	I-DISO
+and	O
+recruitability	O
+).	O
+
+The	O
+potentially	O
+recruitable	O
+lung	B-ANAT
+was	O
+the	O
+only	O
+CT	O
+-	O
+derived	O
+variable	O
+independently	O
+associated	O
+with	O
+ICU	O
+mortality	O
+(	O
+p	O
+=	O
+0	O
+.	O
+007	O
+).	O
+
+ABSTRACT	O
+:	O
+Background	O
+:	O
+Bat	O
+-	O
+borne	O
+viruses	B-SPEC
+pose	O
+a	O
+potential	O
+risk	O
+to	O
+human	B-SPEC
+health	O
+and	O
+are	O
+the	O
+focus	O
+of	O
+increasing	O
+scientific	O
+interest	O
+.	O
+
+Fecal	B-ANAT
+samples	O
+were	O
+collected	O
+from	O
+bats	B-SPEC
+across	O
+Hungary	O
+.	O
+
+We	O
+performed	O
+group	O
+-	O
+specific	O
+RT	O
+-	O
+PCR	O
+screening	O
+for	O
+astro	O
+-,	O
+calici	O
+-,	O
+corona	B-CHED
+-,	O
+lyssa	B-DISO
+-,	O
+othoreo	O
+-,	O
+paramyxo	O
+-,	O
+and	O
+rotaviruses	B-SPEC
+.	O
+
+The	O
+Hungarian	O
+BtCalV	O
+did	O
+not	O
+cluster	O
+with	O
+any	O
+of	O
+the	O
+calcivirus	O
+genera	O
+identified	O
+in	O
+the	O
+family	B-SPEC
+so	O
+far	O
+.	O
+
+TITLE	O
+:	O
+A	O
+retrospective	O
+study	O
+of	O
+the	O
+clinical	O
+benefit	O
+from	O
+acetylsalicylic	B-CHED
+acid	I-CHED
+desensitization	B-PROC
+in	O
+patients	O
+with	O
+nasal	O
+polyposis	O
+and	O
+asthma	B-PATH
+.	O
+
+ABSTRACT	O
+:	O
+Aspirin	B-CHED
+-	O
+exacerbated	O
+respiratory	B-DISO
+disease	I-DISO
+(	O
+AERD	O
+),	O
+also	O
+known	O
+as	O
+Samter	O
+'	O
+s	O
+triad	B-COMP
+,	O
+is	O
+a	O
+clinical	O
+syndrome	B-DISO
+which	O
+consists	O
+of	O
+aspirin	B-CHED
+(	O
+ASA	B-CHED
+)	O
+intolerance	B-PROC
+,	O
+chronic	B-DISO
+rhinosinusitis	I-DISO
+with	O
+nasal	B-DISO
+polyposis	I-DISO
+,	O
+and	O
+intrinsic	O
+bronchial	B-DISO
+asthma	B-PATH
+(	O
+Press	O
+Med	O
+119	O
+:	O
+48	O
+-	O
+51	O
+,	O
+1922	O
+).	O
+
+Further	O
+,	O
+it	O
+allows	O
+patients	O
+to	O
+tolerate	O
+additional	O
+ASA	B-CHED
+and	O
+other	O
+non	O
+-	O
+steroidal	O
+anti	O
+-	O
+inflammatories	O
+(	O
+NSAIDs	B-CHED
+)	O
+when	O
+needed	O
+for	O
+supplemental	O
+analgesia	B-DISO
+or	O
+for	O
+cardio	O
+-	O
+protection	O
+.	O
+
+This	O
+is	O
+of	O
+particular	O
+benefit	O
+in	O
+those	O
+who	O
+require	O
+these	O
+medications	O
+for	O
+improved	O
+quality	O
+of	O
+life	O
+,	O
+and	O
+for	O
+reduced	O
+morbidity	O
+and	O
+mortality	O
+,	O
+such	O
+as	O
+those	O
+with	O
+cardiovascular	B-DISO
+disease	I-DISO
+or	O
+chronic	B-DISO
+pain	I-DISO
+.	O
+
+The	O
+best	O
+way	O
+to	O
+ensure	O
+mechanical	O
+ventilation	O
+in	O
+ARDS	B-DISO
+patients	O
+is	O
+still	O
+debated	O
+,	O
+recent	O
+data	O
+arguing	O
+for	O
+a	O
+muscle	B-ANAT
+paralysis	O
+and	O
+a	O
+controlled	O
+ventilation	O
+whereas	O
+other	O
+elements	O
+being	O
+in	O
+favor	O
+of	O
+a	O
+preserved	O
+spontaneous	O
+breathing	B-PROC
+.	O
+
+However	O
+,	O
+federal	O
+guidelines	O
+for	O
+licensing	O
+IBV	B-SPEC
+vaccines	O
+indicate	O
+that	O
+challenge	O
+-	O
+virus	B-SPEC
+detection	O
+following	O
+vaccination	O
+is	O
+to	O
+be	O
+conducted	O
+in	O
+embryonated	O
+eggs	O
+.	O
+
+The	O
+nine	O
+residues	O
+at	O
+the	O
+interface	O
+between	O
+the	O
+virus	B-SPEC
+spikes	O
+and	O
+the	O
+lancets	O
+4	O
+and	O
+5	O
+of	O
+host	B-COMP
+DPP4	B-PRGE
+can	O
+be	O
+used	O
+as	O
+a	O
+predictive	O
+tool	O
+for	O
+the	O
+host	O
+tropism	B-PROC
+and	O
+virus	B-SPEC
+affinity	O
+to	O
+host	B-PRGE
+cell	I-PRGE
+receptors	I-PRGE
+.	O
+
+While	O
+all	O
+vaccines	O
+protected	O
+against	O
+lethal	O
+infection	B-DISO
+,	O
+addition	O
+of	O
+adjuvant	B-CHED
+significantly	O
+increased	O
+serum	O
+neutralizing	O
+-	O
+antibody	B-COMP
+titers	O
+and	O
+reduced	O
+lung	B-ANAT
+virus	B-SPEC
+titers	O
+on	O
+day	O
+3	O
+postchallenge	O
+.	O
+
+Protection	O
+against	O
+eosinophilic	O
+immunopathology	B-DISO
+by	O
+vaccines	O
+containing	O
+delta	O
+inulin	B-CHED
+adjuvants	B-CHED
+correlated	O
+better	O
+with	O
+enhanced	O
+T	B-PRGE
+-	I-PRGE
+cell	I-PRGE
+gamma	I-PRGE
+interferon	I-PRGE
+(	O
+IFN	B-PRGE
+-	I-PRGE
+γ	I-PRGE
+)	O
+recall	O
+responses	O
+rather	O
+than	O
+reduced	O
+interleukin	B-PRGE
+-	I-PRGE
+4	I-PRGE
+(	O
+IL	B-FUNC
+-	I-FUNC
+4	I-FUNC
+)	O
+responses	O
+,	O
+suggesting	O
+that	O
+immunopathology	B-DISO
+predominantly	O
+reflects	O
+an	O
+inadequate	O
+vaccine	O
+-	O
+induced	O
+Th1	O
+response	O
+.	O
+
+We	O
+report	O
+the	O
+first	O
+case	O
+of	O
+a	O
+patient	O
+with	O
+HAE	O
+who	O
+experienced	O
+an	O
+abdominal	O
+attack	O
+precipitated	O
+by	O
+a	O
+retroperitoneal	B-ANAT
+bleed	B-DISO
+while	O
+being	O
+converted	O
+from	O
+warfarin	B-CHED
+to	O
+heparin	B-CHED
+in	O
+preparation	O
+for	O
+surgery	O
+.	O
+
+Through	O
+randomized	O
+trials	O
+,	O
+short	O
+-	O
+term	O
+use	O
+of	O
+neuromuscular	B-DISO
+blockade	I-DISO
+at	O
+initial	O
+stage	O
+of	O
+mechanical	O
+ventilation	O
+,	O
+prone	O
+ventilation	O
+in	O
+severe	O
+ARDS	B-DISO
+,	O
+and	O
+extracorporeal	O
+membrane	B-COMP
+oxygenation	B-PROC
+in	O
+ARDS	B-DISO
+with	O
+influenza	B-DISO
+pneumonia	I-DISO
+showed	O
+beneficial	O
+efficacy	O
+.	O
+
+We	O
+found	O
+evidence	O
+of	O
+moderately	O
+high	O
+quality	O
+to	O
+support	O
+a	O
+strong	O
+recommendation	O
+for	O
+pressure	O
+limitation	O
+and	O
+small	O
+tidal	O
+volumes	O
+in	O
+patients	O
+with	O
+ARDS	B-DISO
+.	O
+
+Preclinical	O
+studies	O
+support	O
+the	O
+efficacy	O
+of	O
+mesenchymal	O
+stem	B-ANAT
+(	O
+stromal	O
+)	O
+cells	B-COMP
+(	O
+MSCs	B-FUNC
+)	O
+in	O
+the	O
+treatment	O
+of	O
+lung	B-ANAT
+injury	O
+.	O
+
+Patients	O
+were	O
+enrolled	O
+in	O
+the	O
+intensive	O
+care	O
+units	O
+at	O
+University	O
+of	O
+California	B-SPEC
+,	O
+San	O
+Francisco	O
+,	O
+CA	O
+,	O
+USA	O
+,	O
+Stanford	O
+University	O
+,	O
+Stanford	O
+,	O
+CA	O
+,	O
+USA	O
+,	O
+and	O
+Massachusetts	O
+General	O
+Hospital	O
+,	O
+Boston	O
+,	O
+MA	O
+,	O
+USA	O
+,	O
+between	O
+July	O
+8	O
+,	O
+2013	O
+,	O
+and	O
+Jan	O
+13	O
+,	O
+2014	O
+.	O
+
+The	O
+first	O
+three	O
+patients	O
+were	O
+treated	O
+with	O
+low	O
+dose	O
+MSCs	B-FUNC
+(	O
+1	O
+million	O
+cells	B-COMP
+/	O
+kg	O
+predicted	O
+bodyweight	O
+[	O
+PBW	O
+]),	O
+the	O
+next	O
+three	O
+patients	O
+received	O
+intermediate	O
+dose	O
+MSCs	B-FUNC
+(	O
+5	O
+million	O
+cells	B-COMP
+/	O
+kg	O
+PBW	O
+),	O
+and	O
+the	O
+final	O
+three	O
+patients	O
+received	O
+high	O
+dose	O
+MSCs	B-FUNC
+(	O
+10	O
+million	O
+cells	B-COMP
+/	O
+kg	O
+PBW	O
+).	O
+
+TITLE	O
+:	O
+Levels	O
+of	O
+feline	B-DISO
+infectious	I-DISO
+peritonitis	I-DISO
+virus	B-SPEC
+in	O
+blood	B-ANAT
+,	O
+effusions	B-DISO
+,	O
+and	O
+various	O
+tissues	B-ANAT
+and	O
+the	O
+role	O
+of	O
+lymphopenia	O
+in	O
+disease	O
+outcome	O
+following	O
+experimental	O
+infection	B-DISO
+.	O
+
+Furthermore	O
+,	O
+the	O
+function	O
+of	O
+vimentin	B-COMP
+cytoskeleton	B-COMP
+in	O
+ST	O
+cells	B-COMP
+during	O
+TGEV	B-SPEC
+infection	B-DISO
+was	O
+examined	O
+.	O
+
+TITLE	O
+:	O
+Cytokine	O
+systems	O
+approach	O
+demonstrates	O
+differences	O
+in	O
+innate	O
+and	O
+pro	B-CHED
+-	O
+inflammatory	O
+host	B-COMP
+responses	O
+between	O
+genetically	O
+distinct	O
+MERS	O
+-	O
+CoV	O
+isolates	O
+.	O
+
+Using	O
+topological	O
+techniques	O
+,	O
+including	O
+persistence	O
+homology	O
+and	O
+filtered	O
+clustering	O
+,	O
+we	O
+performed	O
+a	O
+comparative	O
+transcriptional	B-PROC
+analysis	O
+of	O
+human	O
+Calu	O
+-	O
+3	O
+cell	B-COMP
+host	B-COMP
+responses	O
+to	O
+the	O
+different	O
+MERS	O
+-	O
+CoV	O
+strains	O
+,	O
+with	O
+MERS	B-PRGE
+-	I-PRGE
+CoV	I-PRGE
+Eng	I-PRGE
+1	I-PRGE
+inducing	O
+early	O
+kinetic	O
+changes	O
+,	O
+between	O
+3	O
+and	O
+12	O
+hours	O
+post	O
+infection	B-DISO
+,	O
+compared	O
+to	O
+MERS	O
+-	O
+CoV	O
+SA	O
+1	O
+.	O
+
+Combining	O
+statistical	O
+analysis	O
+of	O
+infection	B-DISO
+and	O
+cytokine	O
+-	O
+stimulated	O
+Calu	B-PRGE
+-	I-PRGE
+3	I-PRGE
+transcriptomics	I-PRGE
+,	O
+we	O
+identified	O
+differential	O
+innate	O
+responses	O
+,	O
+including	O
+up	B-PROC
+-	I-PROC
+regulation	I-PROC
+of	O
+extracellular	B-COMP
+remodeling	O
+genes	O
+following	O
+MERS	B-PRGE
+-	I-PRGE
+CoV	I-PRGE
+Eng	I-PRGE
+1	I-PRGE
+infection	B-DISO
+and	O
+differential	O
+pro	B-CHED
+-	O
+inflammatory	B-DISO
+responses	I-DISO
+.	O
+
+Through	O
+our	O
+genomics	O
+-	O
+based	O
+approach	O
+,	O
+we	O
+found	O
+topological	O
+differences	O
+in	O
+the	O
+kinetics	O
+and	O
+magnitude	O
+of	O
+the	O
+host	B-PROC
+response	I-PROC
+to	O
+MERS	O
+-	O
+CoV	O
+SA	O
+1	O
+and	O
+MERS	B-PRGE
+-	I-PRGE
+CoV	I-PRGE
+Eng	I-PRGE
+1	I-PRGE
+,	O
+with	O
+differential	O
+expression	B-PROC
+of	O
+innate	O
+immune	O
+and	O
+pro	B-CHED
+-	O
+inflammatory	O
+responsive	O
+genes	O
+as	O
+a	O
+result	O
+of	O
+IFN	B-PRGE
+,	O
+TNF	B-PRGE
+and	O
+IL	O
+-	O
+1α	O
+signaling	B-PROC
+.	O
+
+RESULTS	O
+:	O
+Using	O
+topological	O
+techniques	O
+,	O
+including	O
+persistence	O
+homology	O
+and	O
+filtered	O
+clustering	O
+,	O
+we	O
+performed	O
+a	O
+comparative	O
+transcriptional	B-PROC
+analysis	O
+of	O
+human	B-SPEC
+Calu	O
+-	O
+3	O
+cell	B-COMP
+host	B-COMP
+responses	O
+to	O
+the	O
+different	O
+MERS	O
+-	O
+CoV	O
+strains	O
+,	O
+with	O
+MERS	B-PRGE
+-	I-PRGE
+CoV	I-PRGE
+Eng	I-PRGE
+1	I-PRGE
+inducing	O
+early	O
+kinetic	O
+changes	O
+,	O
+between	O
+3	O
+and	O
+12	O
+hours	O
+post	O
+infection	B-DISO
+,	O
+compared	O
+to	O
+MERS	O
+-	O
+CoV	O
+SA	O
+1	O
+.	O
+
+Combining	O
+statistical	O
+analysis	O
+of	O
+infection	B-DISO
+and	O
+cytokine	O
+-	O
+stimulated	O
+Calu	B-PRGE
+-	I-PRGE
+3	I-PRGE
+transcriptomics	I-PRGE
+,	O
+we	O
+identified	O
+differential	O
+innate	O
+responses	O
+,	O
+including	O
+up	B-PROC
+-	I-PROC
+regulation	I-PROC
+of	O
+extracellular	B-COMP
+remodeling	O
+genes	O
+following	O
+MERS	B-PRGE
+-	I-PRGE
+CoV	I-PRGE
+Eng	I-PRGE
+1	I-PRGE
+infection	B-DISO
+and	O
+differential	O
+pro	B-CHED
+-	O
+inflammatory	B-DISO
+responses	I-DISO
+.	O
+
+Patients	O
+with	O
+evidence	O
+of	O
+acute	B-DISO
+coronary	I-DISO
+syndrome	I-DISO
+were	O
+excluded	O
+.	O
+
+Patients	O
+with	O
+increased	O
+cTnI	B-PRGE
+levels	O
+showed	O
+higher	O
+in	O
+-	O
+ICU	O
+mortality	O
+(	O
+38	O
+.	O
+6	O
+%	O
+vs	O
+21	O
+.	O
+9	O
+%,	O
+P	O
+=	O
+.	O
+028	O
+).	O
+
+They	O
+died	B-PROC
+of	O
+massive	B-DISO
+hemorrhage	I-DISO
+and	O
+meningoencephalitis	B-DISO
+,	O
+and	O
+domestic	O
+children	O
+were	O
+diagnosed	O
+and	O
+treated	O
+within	O
+two	O
+to	O
+4	O
+weeks	O
+after	O
+onset	O
+,	O
+5	O
+cases	O
+were	O
+cured	O
+,	O
+one	O
+case	O
+died	B-PROC
+of	O
+severe	O
+pneumonia	B-DISO
+.	O
+
+A	O
+serious	O
+complication	B-DISO
+consisted	O
+of	O
+one	O
+or	O
+more	O
+of	O
+the	O
+following	O
+occurrences	O
+:	O
+acute	O
+lung	B-ANAT
+injury	O
+/	O
+adult	O
+respiratory	B-DISO
+distress	I-DISO
+syndrome	I-DISO
+,	I-DISO
+acute	I-DISO
+kidney	B-ANAT
+injury	O
+,	O
+cardiac	B-DISO
+arrest	I-DISO
+with	O
+cardiopulmonary	B-ANAT
+resuscitation	O
+,	O
+decubitus	B-DISO
+ulcer	I-DISO
+,	O
+deep	B-DISO
+vein	I-DISO
+thrombosis	I-DISO
+,	O
+enterocutaneous	B-DISO
+fistula	I-DISO
+,	O
+extremity	B-ANAT
+compartment	B-DISO
+syndrome	I-DISO
+,	O
+mortality	O
+,	O
+myocardial	B-DISO
+infarction	I-DISO
+,	O
+pneumonia	B-DISO
+,	O
+pulmonary	B-DISO
+embolism	I-DISO
+,	O
+severe	B-DISO
+sepsis	I-DISO
+,	O
+stroke	B-DISO
+/	O
+cerebral	B-DISO
+vascular	B-ANAT
+accident	I-DISO
+,	O
+unplanned	O
+intubation	O
+,	O
+or	O
+unplanned	O
+return	O
+to	O
+operating	O
+room	O
+.	O
+
+In	O
+May	O
+2011	O
+,	O
+the	O
+MOH	O
+replaced	O
+paper	O
+-	O
+based	O
+collection	O
+with	O
+an	O
+electronic	O
+data	O
+collection	O
+system	O
+using	O
+Field	O
+Adapted	O
+Survey	O
+Toolkit	O
+(	O
+FAST	B-FUNC
+)	O
+on	O
+HTC	O
+Touch	B-PROC
+Pro2	O
+smartphones	O
+at	O
+four	O
+sentinel	O
+sites	O
+.	O
+
+Incidence	O
+of	O
+GBS	B-DISO
+was	O
+greater	O
+in	O
+winter	O
+than	O
+summer	O
+,	O
+but	O
+this	O
+was	O
+not	O
+evident	O
+in	O
+all	O
+geographical	O
+regions	O
+.	O
+
+MxA	B-PRGE
+is	O
+an	O
+informative	O
+general	O
+marker	O
+for	O
+the	O
+most	O
+common	O
+acute	O
+virus	B-SPEC
+infections	B-DISO
+.	O
+
+TITLE	O
+:	O
+Successful	O
+recovery	O
+of	O
+MERS	O
+CoV	O
+pneumonia	B-DISO
+in	O
+a	O
+patient	O
+with	O
+acquired	B-DISO
+immunodeficiency	I-DISO
+syndrome	I-DISO
+:	O
+a	O
+case	O
+report	O
+.	O
+
+ABSTRACT	O
+:	O
+Middle	O
+East	O
+Respiratory	O
+Syndrome	B-DISO
+Coronavirus	B-SPEC
+(	O
+MERS	O
+CoV	O
+)	O
+may	O
+cause	O
+severe	O
+pneumonia	B-DISO
+with	O
+significant	O
+morbidity	O
+and	O
+mortality	O
+,	O
+particularly	O
+in	O
+patients	O
+with	O
+multiple	O
+comorbid	O
+condition	B-DISO
+.	O
+
+ABSTRACT	O
+:	O
+Middle	O
+East	O
+respiratory	O
+syndrome	B-DISO
+coronavirus	B-SPEC
+(	O
+MERS	O
+-	O
+CoV	O
+)	O
+is	O
+a	O
+new	O
+highly	O
+pathogenic	O
+human	B-SPEC
+coronaviruses	O
+that	O
+emerged	O
+in	O
+Jeddah	O
+and	O
+Saudi	O
+Arabia	O
+and	O
+has	O
+quickly	O
+spread	O
+to	O
+other	O
+countries	O
+in	O
+Middle	O
+East	O
+,	O
+Europe	O
+and	O
+North	O
+Africa	O
+since	O
+2012	O
+.	O
+
+Their	O
+inhibition	B-PROC
+mechanisms	O
+and	O
+mutually	O
+binding	B-FUNC
+synergistic	O
+effect	O
+were	O
+also	O
+investigated	O
+.	O
+
+It	O
+is	O
+possible	O
+that	O
+the	O
+recent	O
+intensification	O
+of	O
+camel	B-SPEC
+herding	O
+in	O
+the	O
+Arabian	O
+Peninsula	O
+has	O
+increased	O
+the	O
+virus	B-SPEC
+'	O
+reproductive	B-PROC
+number	O
+and	O
+attack	O
+rate	O
+in	O
+camel	B-SPEC
+herds	O
+while	O
+the	O
+'	O
+urbanization	O
+'	O
+of	O
+camel	B-SPEC
+herding	O
+increased	O
+the	O
+frequency	O
+of	O
+zoonotic	O
+'	O
+spillover	O
+'	O
+infections	B-DISO
+from	O
+camels	B-SPEC
+to	O
+humans	B-SPEC
+.	O
+
+The	O
+oxygenation	B-PROC
+response	O
+to	O
+recruitment	B-DISO
+maneuvers	O
+was	O
+associated	O
+with	O
+better	O
+outcome	O
+in	O
+patients	O
+with	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+from	O
+influenza	B-PATH
+A	I-PATH
+(	O
+H1N1	O
+).	O
+
+TITLE	O
+:	O
+Coronavirus	B-SPEC
+MHV	B-SPEC
+-	O
+A59	O
+infects	O
+the	O
+lung	B-ANAT
+and	O
+causes	O
+severe	O
+pneumonia	B-DISO
+in	O
+C57BL	O
+/	O
+6	O
+mice	B-SPEC
+.	O
+
+These	O
+results	O
+suggest	O
+that	O
+intranasal	O
+infection	B-DISO
+of	O
+MHV	B-SPEC
+-	O
+A59	O
+would	O
+serve	O
+as	O
+a	O
+surrogate	O
+mouse	B-SPEC
+model	O
+of	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+by	O
+SARS	B-DISO
+-	O
+CoV	O
+and	O
+MERS	O
+-	O
+CoV	O
+infections	B-DISO
+.	O
+
+In	O
+this	O
+study	O
+,	O
+we	O
+investigated	O
+the	O
+role	O
+of	O
+NLRP3	B-PRGE
+inflammasomes	I-PRGE
+in	O
+mice	B-SPEC
+with	O
+HALI	O
+.	O
+
+We	O
+hypothesized	O
+that	O
+INO	B-PRGE
+may	O
+act	O
+not	O
+only	O
+by	O
+vasodilation	B-DISO
+in	O
+ventilated	O
+lung	B-ANAT
+regions	O
+,	O
+but	O
+also	O
+by	O
+causing	O
+vasoconstriction	B-DISO
+via	O
+endothelin	O
+(	O
+ET	B-PRGE
+-	I-PRGE
+1	I-PRGE
+)	O
+in	O
+atelectatic	O
+,	O
+nonventilated	O
+lung	B-ANAT
+regions	O
+.	O
+
+We	O
+conclude	O
+that	O
+INO	O
+in	O
+short	O
+-	O
+term	O
+experiments	O
+,	O
+in	O
+addition	O
+to	O
+causing	O
+selective	O
+pulmonary	B-ANAT
+vasodilation	B-DISO
+in	O
+ventilated	O
+lung	B-ANAT
+regions	O
+,	O
+increases	O
+the	O
+ET	B-PRGE
+-	I-PRGE
+A	I-PRGE
+/	O
+ET	B-PRGE
+-	I-PRGE
+B	I-PRGE
+mRNA	I-PRGE
+expression	B-PROC
+ratio	O
+in	O
+lung	B-ANAT
+tissue	I-ANAT
+.	O
+
+Such	O
+vasoconstriction	B-DISO
+may	O
+be	O
+an	O
+important	O
+additional	O
+factor	O
+explaining	O
+the	O
+effect	O
+of	O
+INO	O
+.	O
+
+TITLE	O
+:	O
+Acute	O
+cerebellar	B-DISO
+dysfunction	I-DISO
+with	O
+neuromuscular	B-DISO
+manifestations	I-DISO
+after	O
+scorpionism	O
+presumably	O
+caused	O
+by	O
+Tityus	O
+obscurus	O
+in	O
+Santarém	O
+,	O
+Pará	O
+/	O
+Brazil	O
+.	O
+
+ABSTRACT	O
+:	O
+Porcine	B-SPEC
+coronavirus	B-DISO
+infections	I-DISO
+have	O
+known	O
+as	O
+they	O
+are	O
+specific	O
+to	O
+pigs	B-SPEC
+with	O
+predominantly	O
+enteric	O
+or	O
+respiratory	B-DISO
+diseases	I-DISO
+.	O
+
+No	O
+laboratory	O
+animal	B-SPEC
+model	O
+is	O
+yet	O
+been	O
+developed	O
+in	O
+porcine	B-SPEC
+coronaviruses	O
+study	O
+.	O
+
+After	O
+screen	O
+on	O
+pubs	O
+from	O
+the	O
+microinjected	O
+mice	B-SPEC
+,	O
+we	O
+confirmed	O
+two	O
+transgenic	O
+lines	O
+expressing	O
+porcine	B-SPEC
+APN	O
+in	O
+various	O
+organs	B-ANAT
+.	O
+
+In	O
+addition	O
+,	O
+the	O
+Chinese	O
+holiday	O
+effect	O
+led	O
+to	O
+irregular	O
+spread	O
+of	O
+SARS	B-DISO
+,	O
+but	O
+the	O
+panic	O
+effect	O
+was	O
+more	O
+apparent	O
+in	O
+the	O
+middle	O
+and	O
+late	O
+stages	O
+of	O
+the	O
+epidemic	O
+.	O
+
+ABSTRACT	O
+:	O
+Ebola	B-SPEC
+virus	I-SPEC
+(	O
+EBOV	O
+)	O
+causes	O
+hemorrhagic	B-DISO
+fevers	I-DISO
+with	O
+high	O
+mortality	O
+rates	O
+.	O
+
+For	O
+EBOV	O
+,	O
+the	O
+long	O
+lag	O
+is	O
+not	O
+due	O
+to	O
+the	O
+large	O
+size	O
+or	O
+unusual	O
+shape	O
+of	O
+EBOV	O
+filaments	O
+,	O
+the	O
+need	O
+to	O
+prime	O
+EBOV	O
+GP	O
+to	O
+the	O
+19	O
+-	O
+kDa	O
+receptor	O
+-	O
+binding	B-FUNC
+species	B-SPEC
+,	O
+or	O
+a	O
+need	O
+for	O
+unusually	O
+low	O
+endosomal	O
+pH	O
+.	O
+In	O
+contrast	O
+,	O
+since	O
+we	O
+observed	O
+that	O
+EBOV	O
+entry	O
+occurs	O
+upon	O
+arrival	O
+in	O
+Niemann	B-PRGE
+-	I-PRGE
+Pick	I-PRGE
+C1	I-PRGE
+(	O
+NPC1	B-DISO
+)-	O
+positive	O
+endolysosomes	O
+(	O
+LE	O
+/	O
+Lys	B-CHED
+),	O
+we	O
+propose	O
+that	O
+trafficking	B-PROC
+to	O
+LE	O
+/	O
+Lys	B-CHED
+is	O
+a	O
+key	O
+rate	O
+-	O
+defining	O
+step	O
+.	O
+
+Our	O
+findings	O
+suggest	O
+that	O
+both	O
+EBOV	O
+and	O
+SARS	B-DISO
+traffic	O
+deep	O
+into	O
+the	O
+endocytic	O
+pathway	B-PROC
+for	O
+entry	O
+and	O
+that	O
+they	O
+do	O
+so	O
+to	O
+access	O
+higher	O
+cathepsin	B-PRGE
+activity	O
+.	O
+
+Its	O
+N	O
+-	O
+terminal	O
+domain	O
+(	O
+NTD	O
+)	O
+demonstrated	O
+higher	O
+sequence	O
+identity	O
+to	O
+the	O
+bovine	B-SPEC
+coronavirus	B-SPEC
+(	O
+BCoV	B-SPEC
+)	O
+NTD	O
+than	O
+to	O
+the	O
+mouse	B-DISO
+hepatitis	I-DISO
+virus	B-SPEC
+(	O
+MHV	B-SPEC
+)	O
+NTD	O
+,	O
+with	O
+3	O
+of	O
+4	O
+critical	O
+sugar	O
+-	O
+binding	B-FUNC
+residues	O
+in	O
+BCoV	B-SPEC
+and	O
+2	O
+of	O
+14	O
+contact	O
+residues	O
+at	O
+the	O
+MHV	B-SPEC
+NTD	O
+/	O
+murine	B-SPEC
+CEACAM1a	O
+interface	O
+being	O
+conserved	O
+.	O
+
+TITLE	O
+:	O
+The	O
+SARS	B-PRGE
+-	I-PRGE
+coronavirus	B-SPEC
+papain	B-ENZY
+-	I-PRGE
+like	I-PRGE
+protease	I-PRGE
+:	O
+structure	O
+,	O
+function	O
+and	O
+inhibition	B-PROC
+by	O
+designed	O
+antiviral	B-CHED
+compounds	O
+.	O
+
+Among	O
+nine	O
+survivors	O
+,	O
+one	O
+survivor	O
+was	O
+lost	B-CHED
+to	O
+follow	O
+-	O
+up	O
+.	O
+
+ABSTRACT	O
+:	O
+To	O
+describe	O
+the	O
+epidemiologic	O
+and	O
+clinical	O
+characteristics	O
+of	O
+critically	O
+ill	O
+pregnant	O
+and	O
+postpartum	O
+women	O
+with	O
+influenza	B-PATH
+infection	B-DISO
+reported	O
+in	O
+the	O
+2013	O
+-	O
+2014	O
+season	O
+.	O
+
+Seven	O
+patients	O
+who	O
+tested	O
+positive	O
+by	O
+polymerase	O
+chain	O
+reaction	O
+also	O
+had	O
+rapid	O
+influenza	B-DISO
+diagnostic	O
+testing	O
+performed	O
+;	O
+only	O
+one	O
+(	O
+14	O
+%)	O
+had	O
+a	O
+positive	O
+rapid	O
+influenza	B-DISO
+diagnostic	O
+test	O
+results	O
+.	O
+
+TITLE	O
+:	O
+Inhibitory	O
+effects	O
+of	O
+lithium	B-CHED
+chloride	I-CHED
+on	O
+replication	O
+of	O
+type	O
+II	O
+porcine	B-DISO
+reproductive	B-PROC
+and	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+virus	I-SPEC
+in	O
+vitro	O
+.	O
+
+The	O
+expression	B-PROC
+of	O
+viral	O
+mRNA	B-CHED
+and	O
+protein	B-CHED
+was	O
+measured	O
+by	O
+real	O
+-	O
+time	O
+PCR	O
+and	O
+indirect	O
+immunofluorescence	O
+assay	O
+,	O
+respectively	O
+.	O
+
+TITLE	O
+:	O
+Mechanical	O
+ventilation	O
+management	O
+during	O
+extracorporeal	O
+membrane	B-COMP
+oxygenation	B-PROC
+for	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+:	O
+a	O
+retrospective	O
+international	O
+multicenter	O
+study	O
+.	O
+
+Protective	O
+mechanical	O
+ventilation	O
+strategies	O
+were	O
+routinely	O
+used	O
+in	O
+high	O
+-	O
+volume	O
+extracorporeal	O
+membrane	B-COMP
+oxygenation	B-PROC
+centers	O
+.	O
+
+Immunohistochemistry	O
+of	O
+lymph	B-ANAT
+node	I-ANAT
+biopsies	O
+confirmed	O
+feline	B-DISO
+infectious	I-DISO
+peritonitis	I-DISO
+.	O
+
+In	O
+this	O
+essay	O
+we	O
+will	O
+firstly	O
+review	O
+the	O
+basics	O
+of	O
+ARDS	B-DISO
+and	O
+ECLA	O
+.	O
+
+ABSTRACT	O
+:	O
+The	O
+mortality	O
+rate	O
+among	O
+patients	O
+suffering	B-DISO
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+(	O
+ARDS	B-DISO
+)	O
+remains	O
+high	O
+despite	O
+implementation	O
+at	O
+clinical	O
+centers	O
+of	O
+the	O
+lung	B-ANAT
+protective	O
+ventilatory	O
+strategies	O
+recommended	O
+by	O
+the	O
+International	O
+Guidelines	O
+for	O
+Management	O
+of	O
+Severe	B-DISO
+Sepsis	I-DISO
+and	O
+Septic	B-DISO
+Shock	I-DISO
+,	O
+2012	O
+.	O
+
+ABSTRACT	O
+:	O
+The	O
+outbreak	O
+of	O
+infectious	O
+diseases	O
+such	O
+as	O
+influenza	B-DISO
+,	O
+dengue	B-DISO
+fever	I-DISO
+,	O
+and	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+(	O
+SARS	B-DISO
+)	O
+are	O
+threatening	O
+the	O
+global	O
+health	O
+.	O
+
+Patient	O
+groups	O
+differed	O
+significantly	O
+at	O
+72	O
+hours	O
+postpartum	O
+for	O
+Plt	B-PRGE
+and	O
+LDH	B-PRGE
+values	O
+and	O
+at	O
+24	O
+and	O
+48	O
+hours	O
+for	O
+bilirubin	B-CHED
+.	O
+
+Patients	O
+who	O
+progressed	O
+had	O
+acute	O
+kidney	O
+injury	O
+and	O
+other	O
+severe	O
+maternal	O
+morbidity	O
+,	O
+including	O
+one	O
+case	O
+of	O
+maternal	B-PROC
+death	I-PROC
+.	O
+
+Tryptophan	B-PROC
+catabolism	B-PROC
+is	O
+an	O
+endogenous	O
+mechanism	O
+that	O
+restricts	O
+excessive	O
+immune	B-PROC
+responses	I-PROC
+,	O
+thereby	O
+preventing	O
+immunopathology	B-DISO
+.	O
+
+Moreover	O
+,	O
+infected	O
+mice	B-SPEC
+treated	O
+with	O
+MT	O
+did	O
+express	O
+anti	B-PRGE
+-	I-PRGE
+FAH	I-PRGE
+autoAb	I-PRGE
+and	O
+high	O
+levels	O
+of	O
+serum	B-PRGE
+HMGB1	I-PRGE
+.	O
+
+However	O
+,	O
+the	O
+most	O
+recent	O
+experimental	O
+study	O
+,	O
+using	O
+naturally	O
+infected	O
+influenza	B-DISO
+volunteers	O
+as	O
+the	O
+source	O
+,	O
+showed	O
+negative	O
+results	O
+from	O
+all	O
+the	O
+manikins	O
+that	O
+were	O
+exposed	O
+.	O
+
+TITLE	O
+:	O
+Bovine	B-SPEC
+respiratory	I-SPEC
+syncytial	I-SPEC
+virus	I-SPEC
+and	O
+bovine	B-SPEC
+coronavirus	B-SPEC
+in	O
+Swedish	O
+organic	O
+and	O
+conventional	O
+dairy	O
+herds	O
+.	O
+
+RESULTS	O
+:	O
+The	O
+prevalence	O
+of	O
+positive	O
+herds	O
+ranged	O
+from	O
+73	O
+.	O
+4	O
+%	O
+to	O
+82	O
+.	O
+3	O
+%	O
+for	O
+BRSV	B-SPEC
+and	O
+from	O
+76	O
+.	O
+8	O
+%	O
+to	O
+85	O
+.	O
+3	O
+%	O
+for	O
+BoCV	O
+among	O
+OM	O
+and	O
+CM	O
+herds	O
+,	O
+over	O
+the	O
+three	O
+sampling	O
+occasions	O
+.	O
+
+To	O
+identify	O
+genes	O
+associated	O
+with	O
+antibody	B-COMP
+levels	O
+against	O
+ND	O
+and	O
+IB	O
+,	O
+a	O
+genome	O
+-	O
+wide	O
+association	O
+study	O
+was	O
+performed	O
+using	O
+specific	O
+-	O
+locus	O
+amplified	O
+fragment	O
+sequencing	O
+(	O
+SLAF	O
+-	O
+seq	O
+)	O
+technology	O
+in	O
+Jinghai	O
+yellow	O
+chickens	B-SPEC
+.	O
+
+Of	O
+these	O
+,	O
+rsZ2494661	O
+and	O
+rsZ2494710	O
+reached	O
+the	O
+5	O
+%	O
+Bonferroni	O
+genome	O
+-	O
+wide	O
+significance	O
+level	O
+(	O
+5	O
+.	O
+5E	O
+-	O
+07	O
+)	O
+and	O
+they	O
+were	O
+both	O
+134	O
+.	O
+7	O
+kb	O
+downstream	O
+of	O
+the	O
+SETBP1	B-PRGE
+gene	I-PRGE
+.	O
+
+The	O
+remaining	O
+four	O
+SNPs	O
+had	O
+'	O
+suggestive	O
+'	O
+genome	O
+-	O
+wide	O
+significance	O
+levels	O
+(	O
+1	O
+.	O
+1E	O
+-	O
+05	O
+)	O
+and	O
+they	O
+were	O
+within	O
+or	O
+near	O
+the	O
+Plexin	B-PRGE
+B1	I-PRGE
+,	O
+LRRN1	B-PRGE
+and	O
+PDGFC	B-PRGE
+genes	I-PRGE
+.	O
+
+One	O
+-	O
+way	O
+cross	O
+-	O
+reactions	O
+were	O
+observed	O
+by	O
+CCIF	O
+between	O
+TGEV	O
+Miller	O
+hyperimmune	O
+pig	B-SPEC
+antisera	O
+and	O
+all	O
+PEDV	B-SPEC
+strains	O
+.	O
+
+Antigenic	O
+and	O
+biologic	O
+variations	O
+between	O
+the	O
+prototype	O
+and	O
+current	O
+PEDV	B-SPEC
+strains	O
+could	O
+explain	O
+,	O
+at	O
+least	O
+partially	O
+,	O
+the	O
+recurrence	B-DISO
+of	O
+PEDV	B-SPEC
+epidemics	O
+.	O
+
+By	O
+further	O
+mapping	O
+,	O
+we	O
+found	O
+that	O
+polymorphisms	B-PROC
+in	O
+JHM	O
+.	O
+WU	O
+structural	O
+protein	B-CHED
+M	O
+and	O
+nonstructural	O
+replicase	B-PRGE
+proteins	I-PRGE
+nsp1	B-PRGE
+and	O
+nsp13	O
+are	O
+essential	O
+for	O
+liver	B-ANAT
+pathogenesis	B-DISO
+.	O
+
+The	O
+Betacoronavirus	B-SPEC
+genus	B-SPEC
+includes	O
+human	B-SPEC
+pathogens	O
+,	O
+some	O
+of	O
+which	O
+cause	O
+severe	O
+respiratory	B-DISO
+disease	I-DISO
+.	O
+
+We	O
+found	O
+that	O
+very	O
+small	O
+changes	O
+in	O
+coronavirus	B-SPEC
+proteins	B-CHED
+can	O
+profoundly	O
+affect	O
+tropism	B-PROC
+and	O
+virulence	B-PROC
+.	O
+
+Understanding	O
+virulence	B-PROC
+determinants	O
+will	O
+aid	O
+in	O
+the	O
+design	O
+of	O
+vaccines	O
+and	O
+antiviral	B-CHED
+strategies	O
+.	O
+
+Animal	B-SPEC
+models	O
+are	O
+needed	O
+for	O
+studying	O
+pathogenesis	B-DISO
+and	O
+for	O
+development	B-PROC
+of	O
+preventive	O
+and	O
+therapeutic	O
+agents	O
+against	O
+MERS	O
+-	O
+CoV	O
+infection	B-DISO
+.	O
+
+We	O
+have	O
+developed	O
+this	O
+transgenic	O
+mouse	B-SPEC
+model	O
+as	O
+indicated	O
+in	O
+this	O
+study	O
+.	O
+
+We	O
+show	O
+that	O
+transgenic	B-SPEC
+mice	I-SPEC
+globally	O
+expressing	O
+hCD26	O
+/	O
+DPP4	B-PRGE
+were	O
+fully	O
+permissive	O
+to	O
+MERS	O
+-	O
+CoV	O
+infection	B-DISO
+,	O
+resulting	O
+in	O
+relentless	O
+weight	O
+loss	O
+and	O
+death	B-PROC
+within	O
+days	O
+postinfection	O
+.	O
+
+High	O
+infectious	O
+virus	B-SPEC
+titers	O
+were	O
+recovered	O
+primarily	O
+from	O
+the	O
+lungs	B-ANAT
+and	O
+brains	B-ANAT
+of	O
+mice	B-SPEC
+at	O
+2	O
+and	O
+4	O
+days	O
+postinfection	O
+,	O
+respectively	O
+,	O
+whereas	O
+viral	O
+RNAs	O
+were	O
+also	O
+detected	O
+in	O
+the	O
+heart	B-ANAT
+,	O
+spleen	B-ANAT
+,	O
+and	O
+intestine	B-ANAT
+,	O
+indicating	O
+a	O
+disseminating	O
+viral	B-DISO
+infection	I-DISO
+.	O
+
+Mice	B-SPEC
+are	O
+the	O
+most	O
+desirable	O
+small	O
+-	O
+animal	B-SPEC
+species	B-SPEC
+for	O
+this	O
+purpose	O
+because	O
+of	O
+availability	O
+and	O
+the	O
+existence	O
+of	O
+a	O
+thorough	O
+knowledge	O
+base	O
+,	O
+particularly	O
+of	O
+genetics	O
+and	O
+immunology	O
+.	O
+
+So	O
+,	O
+initial	O
+studies	O
+were	O
+done	O
+with	O
+nonhuman	O
+primates	B-SPEC
+,	O
+expensive	O
+models	O
+of	O
+limited	O
+availability	O
+.	O
+
+ABSTRACT	O
+:	O
+Chronic	B-DISO
+rhinosinusitis	I-DISO
+(	O
+CRS	B-DISO
+)	O
+is	O
+a	O
+common	O
+illness	O
+,	O
+yet	O
+little	O
+is	O
+known	O
+about	O
+its	O
+pathogenesis	B-DISO
+,	O
+including	O
+the	O
+role	O
+played	O
+by	O
+respiratory	O
+viruses	B-SPEC
+.	O
+
+A	O
+transversal	O
+prospective	O
+study	O
+was	O
+conducted	O
+to	O
+analyze	O
+the	O
+seasonality	O
+of	O
+CRS	B-DISO
+using	O
+real	O
+-	O
+time	O
+polymerase	O
+chain	O
+reaction	O
+to	O
+detect	O
+respiratory	O
+virus	B-SPEC
+genomes	O
+in	O
+secretions	B-ANAT
+and	O
+tissue	B-ANAT
+samples	O
+from	O
+patients	O
+with	O
+CRS	B-DISO
+with	O
+and	O
+without	O
+nasal	B-DISO
+polyps	I-DISO
+.	O
+
+Characteristic	O
+histopathological	O
+findings	O
+of	O
+AEP	O
+consist	O
+of	O
+alveolar	B-DISO
+edema	I-DISO
+with	O
+infiltration	B-DISO
+of	O
+eosinophils	B-ANAT
+and	O
+lymphocytes	B-ANAT
+and	O
+edema	B-DISO
+of	O
+perivascular	O
+area	O
+and	O
+interlobular	O
+septa	O
+.	O
+
+The	O
+alveolar	B-ANAT
+spaces	O
+showed	O
+fibrinous	O
+exudates	B-ANAT
+.	O
+
+Because	O
+AEP	O
+does	O
+not	O
+exhibit	O
+lung	B-DISO
+fibrosis	I-DISO
+histopathologically	O
+,	O
+it	O
+should	O
+not	O
+to	O
+be	O
+included	O
+in	O
+DAD	O
+which	O
+is	O
+associated	O
+with	O
+lung	B-DISO
+fibrosis	I-DISO
+.	O
+
+The	O
+expression	B-PROC
+of	O
+the	O
+genes	O
+of	O
+toll	B-PRGE
+-	I-PRGE
+like	I-PRGE
+receptor	I-PRGE
+7	I-PRGE
+(	O
+TLR7	B-PRGE
+),	O
+natural	B-PRGE
+killer	I-PRGE
+cell	I-PRGE
+receptor	I-PRGE
+(	O
+BNK	B-PRGE
+),	O
+cytotoxic	O
+substances	O
+(	O
+granzyme	O
+,	O
+perforin	B-PRGE
+),	O
+and	O
+cytokines	O
+(	O
+CXCL12	B-PRGE
+,	O
+CX3CL1	B-PRGE
+,	O
+and	O
+IFNγ	O
+)	O
+were	O
+examined	O
+by	O
+real	O
+-	O
+time	O
+polymerase	O
+chain	O
+reaction	O
+analysis	O
+.	O
+
+We	O
+previously	O
+reported	O
+the	O
+successful	O
+in	O
+vitro	O
+inhibition	B-PROC
+of	O
+FIPV	O
+replication	O
+by	O
+synthetic	O
+siRNA	O
+mediated	O
+RNA	B-PROC
+interference	I-PROC
+(	O
+RNAi	B-PROC
+)	O
+in	O
+an	O
+immortalised	O
+cell	B-ANAT
+line	I-ANAT
+(	O
+McDonagh	O
+et	O
+al	O
+.,	O
+2011	O
+).	O
+
+The	O
+Cell	B-COMP
+'	O
+s	O
+First	O
+Line	O
+of	O
+Antiviral	B-CHED
+Defense	O
+.	O
+
+ABSTRACT	O
+:	O
+Animal	B-SPEC
+cells	B-COMP
+use	O
+a	O
+wide	O
+variety	O
+of	O
+mechanisms	O
+to	O
+slow	O
+or	O
+prevent	O
+replication	O
+of	O
+viruses	O
+.	O
+
+At	O
+least	O
+three	O
+human	B-PRGE
+IFITM	I-PRGE
+proteins	B-CHED
+-	I-PRGE
+IFITM1	I-PRGE
+,	O
+IFITM2	B-PRGE
+,	O
+and	O
+IFITM3	B-PRGE
+-	O
+have	O
+antiviral	B-CHED
+activities	O
+.	O
+
+The	O
+disease	O
+presents	O
+as	O
+severe	O
+respiratory	B-DISO
+infection	I-DISO
+often	O
+with	O
+shock	O
+,	O
+acute	O
+kidney	B-ANAT
+injury	O
+,	O
+and	O
+coagulopathy	B-DISO
+.	O
+
+These	O
+are	O
+so	O
+far	O
+the	O
+first	O
+reported	O
+cases	O
+of	O
+neurologic	O
+injury	O
+associated	O
+with	O
+MERS	O
+-	O
+CoV	O
+infection	B-DISO
+.	O
+
+The	O
+findings	O
+indicated	O
+that	O
+durable	O
+lactogenic	O
+immunity	B-PROC
+was	O
+present	O
+in	O
+sows	O
+previously	O
+exposed	O
+to	O
+a	O
+mild	O
+strain	O
+of	O
+PEDv	B-SPEC
+and	O
+this	O
+immunity	B-PROC
+induced	O
+cross	O
+-	O
+protection	O
+to	O
+representative	O
+virulent	O
+PEDv	B-SPEC
+.	O
+
+ABSTRACT	O
+:	O
+Porcine	B-SPEC
+epidemic	I-SPEC
+diarrhea	I-SPEC
+virus	I-SPEC
+(	O
+PEDV	B-SPEC
+)	O
+causes	O
+an	O
+acute	O
+,	O
+highly	O
+contagious	O
+,	O
+and	O
+devastating	O
+viral	O
+enteric	O
+disease	O
+with	O
+a	O
+high	O
+mortality	O
+rate	O
+in	O
+suckling	O
+pigs	B-SPEC
+.	O
+
+We	O
+formulate	O
+and	O
+analyze	O
+a	O
+simple	O
+compartmental	O
+model	O
+with	O
+heterogeneous	O
+mixing	O
+to	O
+describe	O
+nosocomial	O
+transmission	O
+and	O
+determine	O
+the	O
+reproduction	B-PROC
+number	O
+and	O
+final	O
+size	O
+relation	O
+.	O
+
+TITLE	O
+:	O
+High	O
+secretion	B-PROC
+of	O
+interferons	O
+by	O
+human	B-SPEC
+plasmacytoid	B-ANAT
+dendritic	I-ANAT
+cells	B-COMP
+upon	O
+recognition	O
+of	O
+Middle	O
+East	O
+respiratory	O
+syndrome	O
+coronavirus	B-SPEC
+.	O
+
+Furthermore	O
+,	O
+active	O
+transcription	B-PROC
+of	O
+MERS	O
+-	O
+CoV	O
+N	O
+RNA	O
+and	O
+subsequent	O
+N	O
+protein	B-PROC
+expression	B-PROC
+were	O
+evident	O
+in	O
+infected	O
+pDCs	O
+,	O
+indicating	O
+abortive	O
+infection	B-DISO
+.	O
+
+Understanding	O
+the	O
+pathogenesis	B-DISO
+of	O
+this	O
+highly	O
+pathogenic	O
+CoV	O
+is	O
+crucial	O
+for	O
+developing	O
+successful	O
+treatment	O
+strategies	O
+.	O
+
+To	O
+identify	O
+E	O
+protein	B-CHED
+regions	O
+and	O
+host	B-COMP
+responses	O
+that	O
+contribute	O
+to	O
+rSARS	O
+-	O
+CoV	O
+-	O
+MA15	O
+-	O
+ΔE	O
+attenuation	O
+,	O
+several	O
+mutants	O
+(	O
+rSARS	O
+-	O
+CoV	O
+-	O
+MA15	O
+-	O
+E	O
+*)	O
+containing	O
+point	B-PROC
+mutations	I-PROC
+or	O
+deletions	O
+in	O
+the	O
+amino	O
+-	O
+terminal	O
+or	O
+the	O
+carboxy	B-CHED
+-	O
+terminal	O
+regions	O
+of	O
+the	O
+E	B-PRGE
+protein	I-PRGE
+were	O
+generated	O
+.	O
+
+Amino	B-PROC
+acid	I-PROC
+substitutions	I-PROC
+in	O
+the	O
+amino	O
+terminus	O
+,	O
+or	O
+deletion	O
+of	O
+regions	O
+in	O
+the	O
+internal	O
+carboxy	B-CHED
+-	O
+terminal	O
+region	O
+of	O
+E	B-PRGE
+protein	I-PRGE
+,	O
+led	O
+to	O
+virus	B-SPEC
+attenuation	O
+.	O
+
+TITLE	O
+:	O
+A	O
+Computational	O
+Approach	O
+for	O
+Predicting	O
+Role	O
+of	O
+Human	B-PRGE
+MicroRNAs	I-PRGE
+in	O
+MERS	O
+-	O
+CoV	O
+Genome	O
+.	O
+
+We	O
+are	O
+investigating	O
+potential	O
+antiviral	B-CHED
+therapeutics	O
+against	O
+MERS	O
+-	O
+CoV	O
+by	O
+using	O
+host	B-COMP
+microRNAs	O
+(	O
+miRNAs	O
+)	O
+which	O
+may	O
+downregulate	O
+viral	O
+gene	B-PROC
+expression	I-PROC
+to	O
+quell	O
+viral	B-PROC
+replication	I-PROC
+.	O
+
+The	O
+etiology	O
+of	O
+this	O
+disease	O
+is	O
+complex	O
+and	O
+the	O
+presumed	O
+triggering	O
+factors	O
+can	O
+be	O
+divided	O
+into	O
+infectious	B-DISO
+and	O
+non	O
+-	O
+infectious	B-DISO
+agents	O
+.	O
+
+The	O
+present	O
+report	O
+describes	O
+a	O
+case	O
+of	O
+Porcine	B-PRGE
+Circovirus	I-PRGE
+type	I-PRGE
+2	I-PRGE
+(	O
+PCV2	O
+),	O
+infection	B-DISO
+associated	O
+with	O
+lesions	O
+of	O
+PNES	O
+at	O
+the	O
+weaning	B-PROC
+stage	O
+of	O
+a	O
+farrow	O
+-	O
+to	O
+-	O
+finish	O
+pig	B-SPEC
+farm	O
+.	O
+
+Metaphylaxis	O
+of	O
+this	O
+case	O
+included	O
+intramuscular	O
+injection	O
+of	O
+florfenicol	O
+for	O
+the	O
+treatment	O
+and	O
+control	O
+of	O
+skin	B-ANAT
+lesions	O
+and	O
+respiratory	O
+signs	O
+.	O
+
+In	O
+conclusion	O
+,	O
+sub	O
+-	O
+acute	O
+PCV2	O
+infection	B-DISO
+could	O
+be	O
+included	O
+in	O
+triggering	O
+factors	O
+PNES	O
+in	O
+weaners	O
+.	O
+
+The	O
+mass	O
+vaccination	O
+against	O
+PCV2	O
+of	O
+infected	O
+piglets	O
+might	O
+be	O
+effective	O
+in	O
+reduction	O
+of	O
+clinical	O
+signs	O
+and	O
+losses	O
+of	O
+PNES	O
+in	O
+cases	O
+of	O
+PCV2	O
+infection	B-DISO
+associated	O
+with	O
+PNES	O
+.	O
+
+ABSTRACT	O
+:	O
+The	O
+design	O
+and	O
+evaluation	O
+of	O
+a	O
+novel	O
+decahydroisoquinolin	O
+scaffold	O
+as	O
+an	O
+inhibitor	B-CHED
+for	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+(	O
+SARS	B-DISO
+)	O
+chymotrypsin	B-PRGE
+-	I-PRGE
+like	I-PRGE
+protease	I-PRGE
+(	O
+3CL	O
+(	O
+pro	B-CHED
+))	O
+are	O
+described	O
+.	O
+
+Biophysical	O
+and	O
+transgenic	O
+mouse	B-SPEC
+models	O
+have	O
+provided	O
+insight	O
+into	O
+the	O
+mechanisms	O
+underlying	O
+surfactant	B-CHED
+protein	B-CHED
+and	O
+alveolar	B-ANAT
+homeostasis	B-PROC
+.	O
+
+ABSTRACT	O
+:	O
+In	O
+response	O
+to	O
+the	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+(	O
+SARS	B-DISO
+)	O
+pandemic	O
+of	O
+2003	O
+and	O
+the	O
+influenza	B-DISO
+pandemic	O
+of	O
+2009	O
+,	O
+many	O
+countries	O
+instituted	O
+border	B-ANAT
+measures	O
+as	O
+a	O
+means	O
+of	O
+stopping	O
+or	O
+slowing	O
+the	O
+spread	O
+of	O
+disease	O
+.	O
+
+The	O
+results	O
+suggest	O
+that	O
+the	O
+assay	O
+developed	O
+here	O
+is	O
+a	O
+useful	O
+tool	O
+for	O
+the	O
+rapid	O
+diagnosis	O
+and	O
+epidemiological	O
+surveillance	O
+of	O
+MERS	O
+-	O
+CoV	O
+infection	B-DISO
+in	O
+dromedary	B-SPEC
+camels	B-SPEC
+.	O
+
+An	O
+outbreak	O
+of	O
+a	O
+severe	O
+respiratory	B-DISO
+disease	I-DISO
+--	O
+fibrinous	O
+pleuropneumonia	B-DISO
+syndrome	B-DISO
+,	O
+most	O
+likely	O
+caused	O
+by	O
+Mycoplasma	B-SPEC
+ovipneumoniae	I-SPEC
+--	O
+led	O
+to	O
+a	O
+marked	O
+population	O
+decline	O
+.	O
+
+Population	O
+-	O
+level	O
+changes	O
+were	O
+analyzed	O
+before	O
+and	O
+during	O
+the	O
+course	O
+of	O
+the	O
+outbreak	O
+in	O
+selected	O
+blood	B-ANAT
+parameters	O
+(	O
+white	B-ANAT
+blood	I-ANAT
+cells	I-ANAT
+[	O
+WBC	B-ANAT
+],	O
+blood	B-ANAT
+urea	B-CHED
+nitrogen	B-CHED
+[	O
+BUN	O
+],	O
+and	O
+creatinine	B-CHED
+).	O
+
+ABSTRACT	O
+:	O
+CDC	O
+continues	O
+to	O
+work	O
+with	O
+the	O
+World	O
+Health	O
+Organization	O
+(	O
+WHO	O
+)	O
+and	O
+other	O
+partners	O
+to	O
+closely	O
+monitor	O
+Middle	O
+East	O
+respiratory	O
+syndrome	B-DISO
+coronavirus	B-SPEC
+(	O
+MERS	O
+-	O
+CoV	O
+)	O
+infections	B-DISO
+globally	O
+and	O
+to	O
+better	O
+understand	O
+the	O
+risks	O
+to	O
+public	O
+health	O
+.	O
+
+In	O
+the	O
+absence	O
+of	O
+adjuvant	O
+,	O
+S377	O
+-	O
+588	O
+-	O
+Fc	O
+alone	O
+induced	O
+readily	O
+detectable	O
+neutralizing	O
+antibody	B-COMP
+and	O
+T	B-ANAT
+-	I-ANAT
+cell	I-ANAT
+responses	O
+in	O
+immunized	O
+mice	B-SPEC
+.	O
+
+Phylogenetic	O
+analysis	O
+suggested	O
+that	O
+these	O
+bat	B-ENZY
+CoVs	O
+are	O
+related	O
+to	O
+members	O
+of	O
+the	O
+genus	B-SPEC
+Betacoronavirus	B-SPEC
+.	O
+
+Blood	B-ANAT
+product	O
+ratios	O
+of	O
+1	O
+:	O
+1	O
+:	O
+1	O
+(	O
+338	O
+patients	O
+)	O
+vs	O
+1	O
+:	O
+1	O
+:	O
+2	O
+(	O
+342	O
+patients	O
+)	O
+during	O
+active	O
+resuscitation	O
+in	O
+addition	O
+to	O
+all	O
+local	O
+standard	O
+-	O
+of	O
+-	O
+care	O
+interventions	O
+(	O
+uncontrolled	O
+).	O
+
+Exsanguination	B-DISO
+,	O
+which	O
+was	O
+the	O
+predominant	O
+cause	O
+of	O
+death	B-PROC
+within	O
+the	O
+first	O
+24	O
+hours	O
+,	O
+was	O
+significantly	O
+decreased	O
+in	O
+the	O
+1	O
+:	O
+1	O
+:	O
+1	O
+group	O
+(	O
+9	O
+.	O
+2	O
+%	O
+vs	O
+14	O
+.	O
+6	O
+%	O
+in	O
+1	O
+:	O
+1	O
+:	O
+2	O
+group	O
+;	O
+difference	O
+,	O
+-	O
+5	O
+.	O
+4	O
+%	O
+[	O
+95	O
+%	O
+CI	O
+,	O
+-	O
+10	O
+.	O
+4	O
+%	O
+to	O
+-	O
+0	O
+.	O
+5	O
+%];	O
+P	O
+=	O
+.	O
+03	O
+).	O
+
+Among	O
+patients	O
+with	O
+severe	O
+trauma	O
+and	O
+major	O
+bleeding	B-DISO
+,	O
+early	O
+administration	O
+of	O
+plasma	B-ANAT
+,	O
+platelets	B-ANAT
+,	O
+and	O
+red	B-ANAT
+blood	I-ANAT
+cells	I-ANAT
+in	O
+a	O
+1	O
+:	O
+1	O
+:	O
+1	O
+ratio	O
+compared	O
+with	O
+a	O
+1	O
+:	O
+1	O
+:	O
+2	O
+ratio	O
+did	O
+not	O
+result	O
+in	O
+significant	O
+differences	O
+in	O
+mortality	O
+at	O
+24	O
+hours	O
+or	O
+at	O
+30	O
+days	O
+.	O
+
+Despite	O
+the	O
+1	O
+:	O
+1	O
+:	O
+1	O
+group	O
+receiving	O
+more	O
+plasma	B-ANAT
+(	O
+median	O
+of	O
+7	O
+U	O
+vs	O
+5	O
+U	O
+,	O
+P	O
+<	O
+.	O
+001	O
+)	O
+and	O
+platelets	B-ANAT
+(	O
+12	O
+U	O
+vs	O
+6	O
+U	O
+,	O
+P	O
+<	O
+.	O
+001	O
+)	O
+and	O
+similar	O
+amounts	O
+of	O
+red	B-ANAT
+blood	I-ANAT
+cells	I-ANAT
+(	O
+9	O
+U	O
+)	O
+over	O
+the	O
+first	O
+24	O
+hours	O
+,	O
+no	O
+differences	O
+between	O
+the	O
+2	O
+groups	O
+were	O
+found	O
+for	O
+the	O
+23	O
+prespecified	O
+complications	O
+,	O
+including	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+,	O
+multiple	B-DISO
+organ	I-DISO
+failure	I-DISO
+,	O
+venous	B-DISO
+thromboembolism	I-DISO
+,	O
+sepsis	B-DISO
+,	O
+and	O
+transfusion	O
+-	O
+related	O
+complications	O
+.	O
+
+For	O
+analysing	O
+coronavirus	B-SPEC
+diversity	O
+in	O
+a	O
+bat	B-ENZY
+species	B-SPEC
+-	O
+rich	O
+country	O
+,	O
+a	O
+total	O
+of	O
+421	O
+anal	B-ANAT
+swabs	O
+/	O
+faecal	B-ANAT
+samples	O
+from	O
+Costa	B-ANAT
+Rican	O
+bats	B-SPEC
+were	O
+screened	O
+for	O
+CoV	B-PRGE
+RNA	I-PRGE
+-	I-PRGE
+dependent	I-PRGE
+RNA	I-PRGE
+polymerase	I-PRGE
+(	O
+RdRp	B-FUNC
+)	O
+gene	O
+sequences	O
+by	O
+a	O
+pancoronavirus	O
+PCR	O
+.	O
+
+These	O
+results	O
+provide	O
+insight	O
+into	O
+DPP4	B-PRGE
+species	B-SPEC
+-	O
+specific	O
+differences	O
+impacting	O
+MERS	O
+-	O
+CoV	O
+host	B-COMP
+range	O
+and	O
+may	O
+inform	O
+MERS	O
+-	O
+CoV	O
+mouse	B-SPEC
+model	O
+development	B-PROC
+.	O
+
+As	O
+controls	O
+,	O
+the	O
+vesicular	B-SPEC
+stomatitis	I-SPEC
+virus	I-SPEC
+(	O
+VSV	O
+)	O
+and	O
+influenza	B-SPEC
+A	I-SPEC
+virus	I-SPEC
+(	O
+IAV	O
+)	O
+were	O
+included	O
+.	O
+
+Consistently	O
+,	O
+nanomolar	O
+concentrations	O
+of	O
+the	O
+cardiotonic	O
+steroids	B-CHED
+ouabain	B-CHED
+and	O
+bufalin	B-CHED
+,	O
+which	O
+are	O
+known	O
+not	O
+to	O
+affect	O
+the	O
+transport	B-PROC
+function	O
+of	O
+Na	O
+(+),	O
+K	B-PRGE
+(+)-	I-PRGE
+ATPase	I-PRGE
+,	O
+inhibited	O
+infection	B-DISO
+of	O
+cells	B-COMP
+with	O
+MHV	B-SPEC
+,	O
+FIPV	O
+,	O
+Middle	O
+East	O
+respiratory	O
+syndrome	O
+(	O
+MERS	O
+)-	O
+CoV	O
+,	O
+and	O
+VSV	O
+,	O
+but	O
+not	O
+IAV	O
+,	O
+when	O
+the	O
+compounds	O
+were	O
+present	O
+during	O
+virus	B-SPEC
+inoculation	O
+.	O
+
+TITLE	O
+:	O
+Severe	O
+Falciparum	B-DISO
+Malaria	I-DISO
+-	O
+Difference	O
+in	O
+Mortality	O
+among	O
+Male	O
+and	O
+Nonpregnant	O
+Females	O
+.	O
+
+In	O
+this	O
+paper	O
+,	O
+a	O
+rapid	O
+ultraperformance	O
+liquid	O
+chromatography	O
+coupled	O
+with	O
+diode	O
+-	O
+array	O
+detector	O
+and	O
+quadrupole	O
+time	O
+-	O
+of	O
+-	O
+flight	B-PROC
+mass	O
+spectrometry	O
+(	O
+UPLC	O
+-	O
+DAD	O
+-	O
+QTOF	O
+-	O
+MS	O
+)	O
+method	O
+was	O
+established	O
+for	O
+qualitative	O
+and	O
+quantitative	O
+analysis	O
+of	O
+the	O
+major	O
+constituents	O
+of	O
+LQC	O
+.	O
+
+Comparisons	O
+across	O
+the	O
+three	O
+the	O
+Berlin	O
+categories	O
+showed	O
+significant	O
+differences	O
+in	O
+the	O
+number	O
+of	O
+ventilator	O
+-	O
+free	O
+days	O
+(	O
+21	O
+,	O
+20	O
+,	O
+and	O
+5	O
+d	O
+,	O
+p	O
+=	O
+0	O
+.	O
+001	O
+)	O
+and	O
+mortality	O
+for	O
+severe	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+(	O
+41	O
+%)	O
+in	O
+comparison	O
+with	O
+mild	O
+(	O
+0	O
+)	O
+and	O
+moderate	O
+(	O
+15	O
+%)	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+(	O
+p	O
+=	O
+0	O
+.	O
+02	O
+).	O
+
+No	O
+differences	O
+in	O
+PICU	B-SPEC
+or	O
+hospital	O
+stay	O
+were	O
+observed	O
+across	O
+the	O
+groups	O
+.	O
+
+U	O
+ranges	O
+among	O
+virus	B-SPEC
+isolates	O
+from	O
+30	O
+.	O
+7	O
+%	O
+to	O
+40	O
+.	O
+3	O
+%,	O
+and	O
+C	O
+makes	O
+the	O
+opposite	O
+movement	B-PROC
+from	O
+20	O
+.	O
+0	O
+%	O
+to	O
+12	O
+.	O
+9	O
+%,	O
+respectively	O
+.	O
+
+The	O
+relevance	O
+for	O
+evolution	B-PROC
+of	O
+the	O
+novel	O
+human	B-SPEC
+pathogens	O
+MERS	O
+and	O
+SARS	B-DISO
+is	O
+discussed	O
+.	O
+
+MERS	O
+-	O
+CoV	O
+has	O
+a	O
+broader	O
+tropism	B-PROC
+than	O
+SARS	B-DISO
+-	O
+CoV	O
+,	O
+rapidly	O
+triggers	O
+cellular	B-COMP
+damage	O
+,	O
+employs	O
+a	O
+different	O
+receptor	O
+and	O
+induces	O
+a	O
+delayed	O
+proinflammatory	O
+response	O
+in	O
+cells	B-COMP
+.	O
+
+High	O
+frequency	O
+oscillatory	O
+ventilation	O
+is	O
+an	O
+alternative	O
+form	O
+of	O
+mechanical	O
+ventilation	O
+with	O
+some	O
+attractive	O
+features	O
+in	O
+respect	O
+to	O
+attempting	O
+to	O
+improve	O
+gas	B-ENZY
+exchange	O
+limiting	O
+ventilator	O
+induced	O
+lung	B-ANAT
+injury	O
+.	O
+
+The	O
+aim	O
+of	O
+this	O
+study	O
+was	O
+to	O
+ascertain	O
+whether	O
+plasma	B-ANAT
+levels	O
+of	O
+sRAGE	O
+were	O
+elevated	O
+in	O
+ARDS	B-DISO
+patients	O
+compared	O
+with	O
+appropriate	O
+controls	O
+.	O
+
+Significant	O
+correlations	O
+were	O
+found	O
+between	O
+plasma	B-ANAT
+sRAGE	O
+levels	O
+and	O
+PaO2	O
+:	O
+FiO2	O
+ratio	O
+(	O
+P	O
+<	O
+0	O
+.	O
+05	O
+,	O
+r	O
+=	O
+0	O
+.	O
+36	O
+).	O
+
+Our	O
+results	O
+demonstrate	O
+that	O
+elevated	O
+levels	O
+of	O
+plasma	B-ANAT
+sRAGE	O
+may	O
+provide	O
+a	O
+useful	O
+marker	O
+for	O
+ventilated	O
+ARDS	B-DISO
+patients	O
+.	O
+
+ABSTRACT	O
+:	O
+ORF3	O
+is	O
+a	O
+supplemental	O
+open	O
+reading	O
+frame	O
+coding	O
+for	O
+an	O
+accessory	O
+glycoprotein	B-CHED
+gp3	O
+of	O
+unknown	O
+function	O
+,	O
+only	O
+present	O
+in	O
+genotype	O
+I	O
+canine	O
+strain	O
+(	O
+CCoV	O
+-	O
+I	O
+)	O
+and	O
+some	O
+atypical	O
+feline	B-SPEC
+FCoV	O
+strains	O
+.	O
+
+All	O
+proteins	B-CHED
+oligomerise	O
+through	O
+covalent	B-PROC
+bonds	O
+,	O
+are	O
+N	O
+-	O
+glycosylated	O
+and	O
+are	O
+maintained	O
+in	O
+the	O
+ER	O
+in	O
+non	O
+-	O
+infected	O
+but	O
+also	O
+in	O
+CCoV	O
+-	O
+II	O
+infected	O
+cells	B-COMP
+,	O
+without	O
+any	O
+specific	O
+retention	B-PROC
+signal	O
+.	O
+
+However	O
+,	O
+it	O
+is	O
+currently	O
+unclear	O
+which	O
+protease	O
+(	O
+s	O
+)	O
+facilitate	O
+viral	O
+spread	O
+in	O
+the	O
+infected	O
+host	B-COMP
+.	O
+
+K11777	O
+inhibition	B-PROC
+of	O
+SARS	B-DISO
+-	O
+CoV	O
+and	O
+Ebola	B-SPEC
+virus	I-SPEC
+entry	O
+was	O
+observed	O
+in	O
+the	O
+sub	O
+-	O
+nanomolar	O
+range	O
+.	O
+
+TITLE	O
+:	O
+Genotyping	O
+coronaviruses	O
+associated	O
+with	O
+feline	B-DISO
+infectious	I-DISO
+peritonitis	I-DISO
+.	O
+
+In	O
+this	O
+study	O
+,	O
+two	O
+amino	O
+acid	O
+differences	O
+fully	O
+discriminated	O
+the	O
+two	O
+classes	O
+of	O
+genomes	O
+:	O
+these	O
+were	O
+both	O
+located	O
+in	O
+the	O
+S2	O
+domain	O
+of	O
+the	O
+virus	B-SPEC
+surface	O
+glycoprotein	B-CHED
+gene	O
+.	O
+
+These	O
+events	O
+involve	O
+structural	O
+rearrangements	O
+,	O
+including	O
+heteromerization	O
+between	O
+two	O
+heptad	O
+repeats	O
+(	O
+HR1	O
+and	O
+HR2	O
+)	O
+to	O
+form	O
+a	O
+trimer	O
+of	O
+dimers	O
+as	O
+a	O
+six	O
+-	O
+helix	O
+bundle	O
+(	O
+6	O
+-	O
+HB	O
+),	O
+a	O
+quaternary	O
+protein	B-CHED
+structure	O
+that	O
+brings	O
+two	O
+distant	O
+clusters	B-CHED
+of	O
+hydrophobic	O
+sequences	O
+into	O
+the	O
+proximity	O
+of	O
+each	O
+other	O
+,	O
+the	O
+internal	O
+fusion	O
+peptide	B-CHED
+(	O
+IFP	O
+)	O
+preceding	O
+HR1	O
+,	O
+and	O
+the	O
+highly	O
+conserved	O
+tryptophan	B-CHED
+(	O
+Trp	B-ENZY
+)-	O
+rich	O
+membrane	B-COMP
+proximal	O
+external	O
+region	O
+(	O
+MPER	O
+)	O
+following	O
+HR2	O
+.	O
+
+Here	O
+,	O
+we	O
+show	O
+that	O
+MPER	B-PRGE
+can	O
+undergo	O
+self	O
+-	O
+oligomerization	O
+and	O
+heteromerization	O
+with	O
+IFP	O
+,	O
+events	O
+that	O
+are	O
+Trp	B-ENZY
+-	O
+dependent	O
+.	O
+
+In	O
+comparison	O
+,	O
+little	O
+high	O
+-	O
+order	B-SPEC
+oligomer	O
+was	O
+formed	O
+between	O
+M	O
+-	O
+wt	O
+and	O
+fusion	O
+peptide	B-CHED
+.	O
+
+Overall	O
+,	O
+our	O
+results	O
+show	O
+that	O
+Trp	B-ENZY
+residues	O
+of	O
+MPER	O
+play	O
+a	O
+key	O
+role	O
+in	O
+maintaining	O
+the	O
+structure	O
+and	O
+functions	O
+of	O
+MPER	O
+,	O
+allowing	O
+it	O
+to	O
+interact	O
+with	O
+IFP	O
+to	O
+form	O
+a	O
+MPER	O
+-	O
+IFP	O
+heteromer	O
+,	O
+a	O
+putative	O
+quaternary	O
+structure	O
+extending	O
+from	O
+the	O
+6	O
+-	O
+HB	O
+,	O
+and	O
+function	O
+in	O
+membrane	B-PROC
+fusion	I-PROC
+.	O
+
+Finally	O
+,	O
+we	O
+showed	O
+that	O
+a	O
+MPER	O
+peptide	B-CHED
+could	O
+serve	O
+as	O
+an	O
+inhibitor	B-CHED
+in	O
+the	O
+entry	O
+process	O
+.	O
+
+TITLE	O
+:	O
+Effects	O
+of	O
+different	O
+tidal	O
+volume	O
+ventilation	O
+on	O
+paraquat	B-CHED
+-	O
+induced	O
+acute	O
+lung	B-ANAT
+injury	O
+in	O
+piglets	O
+.	O
+
+The	O
+piglets	O
+showed	O
+ALI	O
+/	O
+ARDS	B-DISO
+in	O
+4	O
+.	O
+5	O
+±	O
+0	O
+.	O
+8	O
+hours	O
+after	O
+PQ	O
+intraperitoneal	O
+injection	O
+.	O
+
+PIP	B-CHED
+and	O
+plateau	O
+pressure	O
+(	O
+Pplat	O
+)	O
+in	O
+the	O
+small	O
+VT	O
+group	O
+decreased	O
+gradually	O
+and	O
+in	O
+the	O
+middle	O
+and	O
+large	O
+VT	O
+group	O
+they	O
+increased	O
+after	O
+ventilation	O
+.	O
+
+RESULTS	O
+:	O
+The	O
+piglets	O
+showed	O
+ALI	O
+/	O
+ARDS	B-DISO
+in	O
+4	O
+.	O
+5	O
+±	O
+0	O
+.	O
+8	O
+hours	O
+after	O
+PQ	O
+intraperitoneal	O
+injection	O
+.	O
+
+TITLE	O
+:	O
+Preemptive	O
+enteral	O
+nutrition	B-PROC
+enriched	O
+with	O
+eicosapentaenoic	B-CHED
+acid	I-CHED
+,	O
+gamma	B-CHED
+-	I-CHED
+linolenic	I-CHED
+acid	I-CHED
+and	O
+antioxidants	B-CHED
+in	O
+severe	O
+multiple	O
+trauma	O
+:	O
+a	O
+prospective	O
+,	O
+randomized	O
+,	O
+double	O
+-	O
+blind	B-DISO
+study	O
+.	O
+
+The	O
+development	B-PROC
+of	O
+infectious	B-DISO
+complications	O
+and	O
+fatty	B-CHED
+acid	I-CHED
+red	B-ANAT
+blood	I-ANAT
+cell	I-ANAT
+membrane	O
+composition	O
+were	O
+also	O
+assessed	O
+.	O
+
+Additional	O
+studies	O
+need	O
+to	O
+be	O
+performed	O
+in	O
+which	O
+the	O
+amount	O
+of	O
+supplementation	O
+is	O
+targeted	B-PROC
+to	O
+a	O
+potentially	O
+measurable	O
+endpoint	O
+,	O
+e	O
+.	O
+g	O
+.	O
+the	O
+O	O
+-	O
+3I	O
+.	O
+
+HRV	O
+was	O
+co	O
+-	O
+detected	O
+with	O
+bocavirus	B-SPEC
+,	O
+human	B-SPEC
+coronavirus	I-SPEC
+,	O
+and	O
+respiratory	B-SPEC
+syncytial	I-SPEC
+virus	I-SPEC
+in	O
+21	O
+(	O
+24	O
+.	O
+7	O
+%),	O
+17	O
+(	O
+20	O
+.	O
+0	O
+%),	O
+and	O
+14	O
+(	O
+16	O
+.	O
+5	O
+%),	O
+respectively	O
+.	O
+
+We	O
+tested	O
+170	O
+(	O
+57	O
+.	O
+6	O
+%)	O
+of	O
+the	O
+295	O
+HRV	O
+-	O
+positive	O
+samples	O
+:	O
+117	O
+HRV	O
+strains	O
+were	O
+typed	O
+by	O
+using	O
+the	O
+VP4	B-PRGE
+/	O
+VP2	B-PRGE
+method	O
+and	O
+53	O
+by	O
+using	O
+5	O
+'	O
+UTR	O
+method	O
+.	O
+
+ABSTRACT	O
+:	O
+Infectious	B-DISO
+complications	O
+,	O
+particularly	O
+in	O
+the	O
+respiratory	O
+tract	O
+of	O
+critically	B-DISO
+ill	I-DISO
+patients	O
+,	O
+are	O
+related	O
+to	O
+increased	O
+mortality	O
+.	O
+
+We	O
+summarize	O
+the	O
+major	O
+clinical	O
+studies	O
+on	O
+respiratory	B-DISO
+infections	I-DISO
+in	O
+critically	B-DISO
+ill	I-DISO
+patients	O
+published	O
+in	O
+2013	O
+.	O
+
+TITLE	O
+:	O
+Enteric	O
+viruses	B-SPEC
+in	O
+turkey	B-SPEC
+enteritis	B-DISO
+.	O
+
+Enteric	O
+diseases	O
+such	O
+as	O
+poult	O
+enteritis	B-DISO
+complex	O
+(	O
+PEC	O
+)	O
+in	O
+turkeys	B-SPEC
+do	O
+not	O
+allow	O
+their	O
+production	O
+potential	O
+to	O
+be	O
+achieved	O
+to	O
+its	O
+maximum	O
+.	O
+
+A	O
+number	O
+of	O
+viruses	B-SPEC
+,	O
+bacteria	B-SPEC
+,	O
+and	O
+protozoa	O
+have	O
+been	O
+implicated	O
+but	O
+the	O
+primary	O
+etiology	O
+has	O
+not	O
+been	O
+definitively	O
+established	O
+.	O
+
+With	O
+the	O
+advent	O
+of	O
+rapid	O
+molecular	O
+diagnostic	O
+methods	O
+and	O
+next	O
+generation	O
+nucleic	B-CHED
+acid	I-CHED
+sequencing	O
+,	O
+researchers	O
+have	O
+made	O
+long	O
+strides	O
+in	O
+identification	O
+and	O
+characterization	O
+of	O
+viruses	B-SPEC
+associated	O
+with	O
+PEC	O
+.	O
+
+This	O
+is	O
+the	O
+first	O
+report	O
+of	O
+FIP	B-DISO
+in	O
+an	O
+African	O
+lion	B-SPEC
+and	O
+the	O
+first	O
+report	O
+of	O
+ocular	B-PROC
+FIP	B-DISO
+in	O
+a	O
+non	O
+-	O
+domestic	O
+felid	B-SPEC
+.	O
+
+PEDV	B-SPEC
+entry	O
+into	O
+polarized	O
+cells	B-COMP
+and	O
+pAPN	O
+grown	O
+on	O
+membrane	B-COMP
+inserts	O
+occurs	O
+via	O
+apical	B-ANAT
+membrane	I-ANAT
+.	O
+
+These	O
+results	O
+imply	O
+the	O
+possibility	O
+that	O
+PEDV	B-SPEC
+infection	B-DISO
+may	O
+proceed	O
+by	O
+lateral	O
+spread	O
+of	O
+virus	B-SPEC
+in	O
+intestinal	B-ANAT
+epithelial	B-ANAT
+cells	I-ANAT
+.	O
+
+In	O
+this	O
+study	O
+,	O
+nine	O
+alkylated	O
+chalcones	B-CHED
+(	O
+1	O
+-	O
+9	O
+)	O
+and	O
+four	O
+coumarins	B-CHED
+(	O
+10	O
+-	O
+13	O
+)	O
+were	O
+isolated	O
+from	O
+Angelica	B-SPEC
+keiskei	I-SPEC
+,	O
+and	O
+the	O
+inhibitory	O
+activities	O
+of	O
+these	O
+constituents	O
+against	O
+SARS	B-DISO
+-	O
+CoV	O
+proteases	O
+(	O
+3CL	O
+(	O
+pro	B-CHED
+)	O
+and	O
+PL	O
+(	O
+pro	B-CHED
+))	O
+were	O
+determined	O
+(	O
+cell	B-COMP
+-	O
+free	O
+/	O
+based	O
+).	O
+
+R0	O
+was	O
+estimated	O
+using	O
+the	O
+incidence	O
+decay	O
+with	O
+exponential	O
+adjustment	O
+"("""	O
+IDEA	B-SPEC
+""")"	O
+method	O
+,	O
+while	O
+period	O
+-	O
+specific	O
+case	O
+fatality	O
+rates	O
+that	O
+incorporated	O
+non	O
+-	O
+attributed	O
+death	B-PROC
+data	O
+were	O
+estimated	O
+using	O
+Monte	O
+Carlo	O
+simulation	O
+.	O
+
+IDEA	B-SPEC
+model	O
+fits	B-DISO
+suggested	O
+a	O
+higher	O
+R0	O
+in	O
+Jeddah	O
+(	O
+3	O
+.	O
+5	O
+-	O
+6	O
+.	O
+7	O
+)	O
+than	O
+in	O
+Riyadh	O
+(	O
+2	O
+.	O
+0	O
+-	O
+2	O
+.	O
+8	O
+);	O
+control	O
+parameters	O
+suggested	O
+more	O
+rapid	O
+reduction	O
+in	O
+transmission	O
+in	O
+the	O
+former	O
+city	O
+than	O
+the	O
+latter	O
+.	O
+
+TITLE	O
+:	O
+Respiratory	B-DISO
+infections	I-DISO
+:	O
+respiratory	B-DISO
+infections	I-DISO
+in	O
+immigrants	O
+to	O
+the	O
+United	O
+States	O
+.	O
+
+Medical	O
+-	O
+surgical	O
+,	O
+trauma	O
+,	O
+cardiac	B-ANAT
+,	O
+and	O
+neurologic	O
+ICUs	O
+of	O
+five	O
+U	O
+.	O
+S	O
+.	O
+academic	O
+medical	O
+centers	O
+located	O
+in	O
+California	B-SPEC
+,	O
+Pennsylvania	O
+,	O
+Washington	O
+,	O
+North	O
+Carolina	O
+,	O
+and	O
+Massachusetts	O
+.	O
+
+Two	O
+hundred	O
+seventy	O
+-	O
+five	O
+patients	O
+with	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+at	O
+high	O
+risk	O
+of	O
+death	B-PROC
+or	O
+severe	O
+functional	O
+impairment	B-DISO
+,	O
+their	O
+546	O
+surrogate	O
+decision	O
+makers	O
+,	O
+and	O
+their	O
+150	O
+physicians	O
+.	O
+
+The	O
+estimated	O
+FCoV	O
+and	O
+FIV	B-SPEC
+seroprevalence	O
+(	O
+95	O
+%	O
+confidence	O
+intervals	O
+)	O
+were	O
+37	O
+%	O
+(	O
+30	O
+-	O
+45	O
+%)	O
+and	O
+11	O
+%	O
+(	O
+6	O
+-	O
+16	O
+%),	O
+respectively	O
+and	O
+FeLV	O
+prevalence	O
+was	O
+1	O
+%	O
+(	O
+0	O
+-	O
+3	O
+%).	O
+
+FCoV	O
+seropositivity	O
+was	O
+also	O
+associated	O
+with	O
+a	O
+high	O
+white	B-ANAT
+blood	I-ANAT
+cell	I-ANAT
+count	O
+,	O
+high	O
+plasma	B-PRGE
+globulin	I-PRGE
+,	O
+low	O
+plasma	B-ANAT
+albumin	B-PRGE
+and	O
+low	O
+blood	B-ANAT
+urea	B-CHED
+nitrogen	B-CHED
+.	O
+
+A	O
+total	O
+146	O
+(	O
+22	O
+.	O
+4	O
+%)	O
+of	O
+the	O
+symptomatic	O
+returnees	O
+tested	O
+positive	O
+for	O
+at	O
+least	O
+one	O
+respiratory	O
+virus	B-SPEC
+compared	O
+with	O
+33	O
+(	O
+17	O
+.	O
+6	O
+%)	O
+of	O
+the	O
+asymptomatic	O
+pilgrims	O
+who	O
+had	O
+at	O
+least	O
+one	O
+detectable	O
+virus	B-SPEC
+in	O
+their	O
+sample	O
+.	O
+
+Many	O
+current	O
+studies	O
+have	O
+reported	O
+possible	O
+application	O
+of	O
+aptamers	O
+as	O
+a	O
+treatment	O
+or	O
+diagnostic	O
+tool	O
+in	O
+viral	B-DISO
+infections	I-DISO
+,	O
+e	O
+.	O
+g	O
+.,	O
+HIV	B-DISO
+(	O
+Human	B-DISO
+Immunodeficiency	I-DISO
+Virus	I-DISO
+),	O
+HBV	B-DISO
+(	O
+Hepatitis	B-SPEC
+B	I-SPEC
+Virus	I-SPEC
+),	O
+HCV	B-SPEC
+(	O
+Hepatitis	B-SPEC
+C	I-SPEC
+Virus	I-SPEC
+),	O
+SARS	B-DISO
+(	O
+Severe	O
+Acute	O
+Respiratory	O
+Syndrome	O
+),	O
+H5N1	B-DISO
+avian	B-DISO
+influenza	I-DISO
+and	O
+recently	O
+spread	O
+Ebola	O
+.	O
+
+ABSTRACT	O
+:	O
+Although	O
+bilateral	O
+paramedian	O
+thalamic	O
+infarctions	B-DISO
+occur	O
+more	O
+frequently	O
+in	O
+adults	O
+than	O
+in	O
+children	O
+,	O
+they	O
+are	O
+rare	O
+entities	O
+at	O
+any	O
+age	O
+.	O
+
+The	O
+second	O
+child	O
+developed	O
+headache	B-DISO
+,	O
+somnolence	O
+,	O
+agitation	B-DISO
+,	O
+and	O
+speech	B-DISO
+dysfunction	I-DISO
+following	O
+an	O
+upper	B-DISO
+respiratory	I-DISO
+tract	I-DISO
+infection	I-DISO
+.	O
+
+Bilateral	O
+thalamic	B-ANAT
+lesions	O
+were	O
+documented	O
+on	O
+magnetic	O
+resonance	O
+imaging	O
+of	O
+both	O
+children	O
+.	O
+
+Bilateral	O
+infarctions	B-DISO
+of	O
+the	O
+paramedian	O
+thalamus	B-ANAT
+may	O
+result	O
+in	O
+severe	O
+illness	O
+and	O
+impairment	B-DISO
+.	O
+
+Thus	O
+,	O
+the	O
+serious	O
+PED	O
+epidemics	O
+in	O
+China	O
+and	O
+South	O
+Korea	O
+in	O
+recent	O
+years	O
+were	O
+caused	O
+by	O
+the	O
+complex	O
+subgroups	O
+of	O
+PEDV	B-SPEC
+.	O
+
+TITLE	O
+:	O
+Broad	O
+-	O
+spectrum	O
+inhibitors	B-CHED
+against	O
+3C	B-PRGE
+-	I-PRGE
+like	I-PRGE
+proteases	I-PRGE
+of	O
+feline	B-SPEC
+coronaviruses	O
+and	O
+feline	B-SPEC
+caliciviruses	O
+.	O
+
+Furthermore	O
+,	O
+the	O
+in	O
+vivo	O
+efficacy	O
+of	O
+3CLpro	O
+inhibitors	B-CHED
+was	O
+evaluated	O
+using	O
+a	O
+mouse	B-SPEC
+model	O
+of	O
+coronavirus	B-DISO
+infection	I-DISO
+.	O
+
+However	O
+,	O
+no	O
+studies	O
+have	O
+previously	O
+reported	O
+a	O
+structural	O
+platform	O
+for	O
+the	O
+design	O
+of	O
+antiviral	B-CHED
+drugs	I-CHED
+with	O
+activities	O
+against	O
+these	O
+viruses	B-SPEC
+or	O
+on	O
+the	O
+efficacy	O
+of	O
+3CLpro	O
+inhibitors	B-CHED
+against	O
+coronavirus	B-DISO
+infection	I-DISO
+in	O
+experimental	O
+animals	B-SPEC
+.	O
+
+However	O
+,	O
+the	O
+thermal	O
+stability	O
+of	O
+the	O
+Ubl	B-PRGE
+mutant	I-PRGE
+PLP2	I-PRGE
+was	O
+significantly	O
+reduced	O
+at	O
+30	O
+°	O
+C	O
+,	O
+thereby	O
+reducing	O
+the	O
+total	O
+enzymatic	B-PROC
+activity	I-PROC
+.	O
+
+Furthermore	O
+,	O
+we	O
+show	O
+that	O
+a	O
+CoV	O
+encoding	O
+the	O
+mutant	B-PRGE
+Ubl	I-PRGE
+domain	I-PRGE
+is	O
+unable	O
+to	O
+replicate	O
+at	O
+high	B-PROC
+temperature	I-PROC
+or	O
+cause	O
+lethal	O
+disease	O
+in	O
+mice	B-SPEC
+.	O
+
+Our	O
+results	O
+identify	O
+the	O
+coronavirus	B-SPEC
+Ubl	B-PRGE
+domain	O
+as	O
+a	O
+novel	O
+modulator	O
+of	O
+viral	O
+protease	O
+stability	O
+and	O
+reveal	O
+manipulating	O
+the	O
+Ubl	B-PRGE
+domain	I-PRGE
+as	O
+a	O
+new	O
+approach	O
+for	O
+attenuating	O
+coronavirus	B-SPEC
+replication	O
+and	O
+pathogenesis	B-DISO
+.	O
+
+The	O
+clinical	O
+symptoms	O
+of	O
+SP	O
+,	O
+its	O
+incidence	O
+,	O
+relationship	O
+between	O
+SP	O
+and	O
+sepsis	B-DISO
+are	O
+considered	O
+along	O
+with	O
+predictors	O
+of	O
+adverse	O
+outcome	O
+.	O
+
+TITLE	O
+:	O
+Do	O
+not	O
+drown	O
+the	O
+patient	O
+:	O
+appropriate	O
+fluid	O
+management	O
+in	O
+critical	B-DISO
+illness	I-DISO
+.	O
+
+ABSTRACT	O
+:	O
+Administering	O
+intravenous	O
+fluids	O
+to	O
+support	O
+the	O
+circulation	B-PROC
+in	O
+critically	B-DISO
+ill	I-DISO
+patients	O
+has	O
+been	O
+a	O
+mainstay	O
+of	O
+emergency	B-DISO
+medicine	B-CHED
+and	O
+critical	O
+care	O
+for	O
+decades	O
+,	O
+especially	O
+(	O
+but	O
+not	O
+exclusively	O
+)	O
+in	O
+patients	O
+with	O
+distributive	O
+or	O
+hypovolemic	B-DISO
+shock	I-DISO
+.	O
+
+Furthermore	O
+,	O
+2	O
+recently	O
+published	O
+large	O
+multicenter	O
+trials	O
+(	O
+ARISE	O
+and	O
+ProCESS	O
+)	O
+have	O
+discredited	O
+the	O
+""""	O
+early	O
+goal	O
+-	O
+directed	O
+therapy	O
+""""	O
+approach	O
+,	O
+which	O
+used	O
+prespecified	O
+targets	O
+of	O
+central	O
+venous	O
+pressure	O
+and	O
+venous	B-ANAT
+saturation	O
+to	O
+guide	O
+fluid	O
+and	O
+vasopressor	O
+administration	O
+.	O
+
+ABSTRACT	O
+:	O
+Human	B-PRGE
+coronavirus	I-PRGE
+(	O
+HCoV	O
+)	O
+NL63	O
+was	O
+first	O
+described	O
+in	O
+2004	O
+and	O
+is	O
+associated	O
+with	O
+respiratory	O
+tract	O
+disease	O
+of	O
+varying	O
+severity	O
+.	O
+
+The	O
+aim	O
+of	O
+the	O
+present	O
+study	O
+was	O
+to	O
+characterize	O
+the	O
+HCoV	B-PRGE
+-	I-PRGE
+NL63	I-PRGE
+nucleocapsid	B-COMP
+protein	B-CHED
+.	O
+
+We	O
+did	O
+not	O
+identify	O
+Middle	O
+East	O
+respiratory	O
+coronavirus	B-SPEC
+carriage	O
+.	O
+
+The	O
+genome	O
+of	O
+coronaviruses	O
+encodes	O
+a	O
+hydrophobic	O
+transmembrane	B-COMP
+protein	B-CHED
+,	O
+the	O
+envelope	B-PRGE
+(	I-PRGE
+E	I-PRGE
+)	I-PRGE
+protein	B-CHED
+.	O
+
+No	O
+difference	O
+was	O
+observed	O
+,	O
+suggesting	O
+that	O
+a	O
+viroporin	O
+other	O
+than	O
+the	O
+E	O
+protein	B-CHED
+influences	O
+the	O
+differences	O
+in	O
+the	O
+actions	O
+of	O
+HMA	O
+and	O
+DIDS	B-CHED
+on	O
+FIPV	O
+serotypes	O
+I	O
+and	O
+II	O
+.	O
+
+ABSTRACT	O
+:	O
+Although	O
+much	O
+recent	O
+focus	O
+has	O
+been	O
+on	O
+the	O
+recognition	O
+of	O
+Ebola	O
+virus	O
+disease	O
+among	O
+travelers	O
+from	O
+West	O
+Africa	O
+,	O
+cases	O
+of	O
+Middle	O
+East	O
+respiratory	O
+syndrome	B-DISO
+coronavirus	B-SPEC
+(	O
+MERS	O
+-	O
+CoV	O
+),	O
+including	O
+travel	O
+-	O
+associated	O
+cases	O
+,	O
+continue	O
+to	O
+be	O
+reported	O
+.	O
+
+ABSTRACT	O
+:	O
+Infectious	B-DISO
+agents	O
+associated	O
+with	O
+community	O
+-	O
+acquired	O
+pneumonia	B-DISO
+(	O
+CAP	B-DISO
+)	O
+are	O
+under	O
+-	O
+studied	O
+.	O
+
+Proportion	O
+of	O
+rhinovirus	B-SPEC
+was	O
+higher	O
+in	O
+patients	O
+with	O
+excluded	O
+CAP	B-DISO
+compared	O
+with	O
+other	O
+diagnostic	O
+categories	O
+(	O
+p	O
+=	O
+0	O
+.	O
+01	O
+).	O
+
+Their	O
+imputability	O
+and	O
+impact	O
+in	O
+early	O
+management	O
+of	O
+CAP	B-DISO
+deserve	O
+further	O
+studies	O
+.	O
+
+TITLE	O
+:	O
+Arbekacin	B-CHED
+treatment	O
+of	O
+a	O
+patient	O
+infected	O
+with	O
+a	O
+Pseudomonas	B-SPEC
+putida	I-SPEC
+producing	O
+a	O
+metallo	B-PRGE
+-	I-PRGE
+beta	B-ENZY
+-	I-ENZY
+lactamase	I-ENZY
+.	O
+
+ABSTRACT	O
+:	O
+Treatment	O
+of	O
+infections	B-DISO
+caused	O
+by	O
+multidrug	O
+-	O
+resistant	O
+Pseudomonas	B-SPEC
+species	B-SPEC
+is	O
+difficult	O
+because	O
+few	O
+antibiotics	B-CHED
+active	O
+against	O
+such	O
+organisms	O
+are	O
+available	O
+.	O
+
+However	O
+,	O
+no	O
+clinical	O
+report	O
+on	O
+arbekacin	B-CHED
+treatment	O
+of	O
+a	O
+human	B-SPEC
+infection	B-DISO
+with	O
+a	O
+multidrug	O
+-	O
+resistant	O
+Pseudomonas	B-SPEC
+has	O
+appeared	O
+to	O
+date	O
+.	O
+
+The	O
+patient	O
+was	O
+subjected	O
+to	O
+induced	B-DISO
+hypothermia	I-DISO
+.	O
+
+The	O
+causative	O
+organism	O
+was	O
+a	O
+strain	O
+of	O
+Pseudomonas	B-SPEC
+putida	I-SPEC
+that	O
+produced	O
+a	O
+metallo	B-PRGE
+-	I-PRGE
+beta	I-PRGE
+-	I-PRGE
+lactamase	I-PRGE
+.	O
+
+Strains	O
+of	O
+P	B-SPEC
+.	I-SPEC
+putida	I-SPEC
+producing	O
+metallo	B-PRGE
+-	I-PRGE
+beta	I-PRGE
+-	I-PRGE
+lactamases	I-PRGE
+have	O
+become	O
+more	O
+widespread	O
+in	O
+recent	O
+years	O
+.	O
+
+Colistin	B-CHED
+is	O
+traditionally	O
+the	O
+drug	O
+of	O
+last	O
+resort	O
+to	O
+treat	O
+infections	B-DISO
+with	O
+multidrug	O
+-	O
+resistant	O
+Pseudomonas	B-SPEC
+.	O
+
+However	O
+,	O
+colistin	B-CHED
+use	O
+is	O
+associated	O
+with	O
+a	O
+very	O
+high	O
+frequency	O
+of	O
+adverse	B-DISO
+effects	I-DISO
+,	O
+and	O
+the	O
+costs	O
+of	O
+such	O
+therapy	O
+are	O
+not	O
+covered	O
+by	O
+the	O
+Japanese	O
+health	O
+insurance	O
+system	O
+.	O
+
+ABSTRACT	O
+:	O
+In	O
+patients	O
+with	O
+severe	B-DISO
+sepsis	I-DISO
+,	O
+depression	B-DISO
+of	O
+cardiac	B-ANAT
+performance	O
+is	O
+common	O
+and	O
+is	O
+often	O
+associated	O
+with	O
+left	O
+ventricular	B-ANAT
+(	O
+LV	O
+)	O
+dilatation	B-DISO
+to	O
+maintain	O
+stroke	B-DISO
+volume	O
+.	O
+
+Among	O
+patients	O
+with	O
+SIMD	O
+,	O
+GEDI	O
+was	O
+higher	O
+in	O
+patients	O
+with	O
+SVV	B-SPEC
+>	O
+13	O
+%	O
+than	O
+in	O
+patients	O
+with	O
+SVV	B-SPEC
+≤	O
+13	O
+%	O
+on	O
+the	O
+day	O
+of	O
+enrollment	O
+(	O
+872	O
+[	O
+785	O
+-	O
+996	O
+]	O
+mL	O
+/	O
+m	O
+(	O
+2	O
+)	O
+vs	O
+.	O
+640	O
+[	O
+597	O
+-	O
+696	O
+]	O
+mL	O
+/	O
+m	O
+(	O
+2	O
+);	O
+p	O
+<	O
+0	O
+.	O
+001	O
+);	O
+this	O
+finding	O
+differed	O
+from	O
+the	O
+generally	O
+recognized	O
+relationship	O
+between	O
+GEDI	O
+and	O
+SVV	B-SPEC
+.	O
+
+Case	O
+2	O
+:	O
+a	O
+78	O
+-	O
+year	O
+-	O
+old	O
+woman	O
+with	O
+CKD	O
+on	O
+hemodialysis	O
+(	O
+HD	O
+)	O
+was	O
+admitted	O
+to	O
+the	O
+ICU	O
+after	O
+cardiovascular	B-ANAT
+surgery	O
+.	O
+
+PSP	B-DISO
+in	O
+kidney	B-DISO
+dysfunction	I-DISO
+patients	O
+will	O
+be	O
+high	O
+despite	O
+non	O
+-	O
+infectious	B-DISO
+conditions	O
+.	O
+
+We	O
+identified	O
+atoms	B-CHED
+with	O
+common	O
+distributed	O
+spatial	O
+occupancy	O
+in	O
+PDB	B-DISO
+structures	O
+of	O
+N10	B-PRGE
+protein	I-PRGE
+,	O
+N11	B-PRGE
+protein	I-PRGE
+,	O
+an	O
+influenza	B-PATH
+A	B-PRGE
+neuraminidase	I-PRGE
+,	O
+an	O
+influenza	B-PRGE
+B	I-PRGE
+neuraminidase	B-ENZY
+,	O
+and	O
+a	O
+bacterial	B-PRGE
+neuraminidase	I-PRGE
+.	O
+
+Spatially	O
+invariant	O
+residues	O
+in	O
+the	O
+N6	O
+and	O
+influenza	B-DISO
+B	B-PRGE
+neuraminidase	I-PRGE
+active	O
+sites	O
+were	O
+found	O
+in	O
+previously	O
+unidentified	O
+spatially	O
+equivalent	O
+sites	O
+in	O
+the	O
+N10	O
+and	O
+N11	O
+proteins	B-CHED
+.	O
+
+We	O
+found	O
+the	O
+corresponding	O
+secondary	O
+and	O
+tertiary	O
+structures	O
+of	O
+the	O
+aligned	O
+proteins	B-CHED
+to	O
+be	O
+largely	O
+identical	O
+despite	O
+significant	O
+sequence	O
+divergence	O
+.	O
+
+Very	O
+little	O
+is	O
+currently	O
+known	O
+about	O
+the	O
+available	O
+proteases	O
+in	O
+bats	B-SPEC
+.	O
+
+To	O
+assess	O
+the	O
+association	O
+between	O
+BRD	O
+and	O
+antibody	B-COMP
+titers	O
+,	O
+38	O
+calves	O
+<	O
+3	O
+months	O
+old	O
+that	O
+were	O
+treated	O
+for	O
+BRD	O
+were	O
+matched	O
+with	O
+38	O
+untreated	O
+calves	O
+.	O
+
+To	O
+investigate	O
+the	O
+effect	O
+of	O
+vaccination	O
+on	O
+antibody	B-COMP
+titers	O
+,	O
+24	O
+calves	O
+were	O
+randomly	O
+assigned	O
+to	O
+be	O
+vaccinated	O
+against	O
+bovine	B-SPEC
+respiratory	I-SPEC
+syncytial	I-SPEC
+virus	I-SPEC
+(	O
+BRSV	B-SPEC
+),	O
+bovine	B-PRGE
+viral	I-PRGE
+diarrhea	I-PRGE
+virus	I-PRGE
+types	I-PRGE
+1	I-PRGE
+and	I-PRGE
+2	I-PRGE
+,	O
+bovine	B-PRGE
+herpesvirus	I-PRGE
+type	I-PRGE
+1	I-PRGE
+(	O
+BHV1	O
+),	O
+and	O
+parainfluenza	B-SPEC
+virus	I-SPEC
+type	I-SPEC
+3	I-SPEC
+at	O
+2	O
+weeks	O
+of	O
+age	O
+(	O
+n	O
+=	O
+6	O
+),	O
+5	O
+weeks	O
+of	O
+age	O
+(	O
+6	O
+),	O
+and	O
+both	O
+2	O
+and	O
+5	O
+weeks	O
+of	O
+age	O
+(	O
+6	O
+)	O
+or	O
+were	O
+assigned	O
+to	O
+be	O
+unvaccinated	O
+controls	O
+(	O
+6	O
+).	O
+
+Calves	O
+with	O
+high	O
+initial	O
+antibody	B-COMP
+titers	O
+against	O
+BRSV	B-SPEC
+and	O
+BHV1	O
+had	O
+lower	O
+odds	O
+of	O
+BRD	O
+than	O
+did	O
+calves	O
+with	O
+low	O
+initial	O
+antibody	B-COMP
+titers	O
+against	O
+those	O
+2	O
+pathogens	O
+.	O
+
+Clinical	O
+BRD	O
+and	O
+the	O
+serologic	O
+response	O
+of	O
+dairy	O
+calves	O
+were	O
+associated	O
+with	O
+initial	O
+antibody	B-COMP
+titers	O
+against	O
+BRSV	B-SPEC
+and	O
+BHV1	O
+.	O
+
+RESULTS	O
+:	O
+Calves	O
+with	O
+initial	O
+antibody	B-COMP
+titers	O
+against	O
+BRSV	B-SPEC
+<	O
+1	O
+:	O
+64	O
+that	O
+were	O
+treated	O
+for	O
+BRD	O
+had	O
+a	O
+slower	O
+rate	O
+of	O
+anti	O
+-	O
+BRSV	B-SPEC
+antibody	B-COMP
+decay	B-DISO
+than	O
+did	O
+similar	O
+calves	O
+that	O
+were	O
+not	O
+treated	O
+for	O
+BRD	O
+.	O
+
+ABSTRACT	O
+:	O
+Guinea	O
+fowl	O
+coronavirus	B-SPEC
+(	O
+GfCoV	O
+),	O
+a	O
+recently	O
+characterized	O
+avian	B-SPEC
+coronavirus	I-SPEC
+,	O
+was	O
+identified	O
+from	O
+outbreaks	O
+of	O
+fulminating	O
+disease	O
+(	O
+peracute	O
+enteritis	B-DISO
+)	O
+in	O
+guinea	B-SPEC
+fowl	I-SPEC
+in	O
+France	O
+.	O
+
+Of	O
+the	O
+64	O
+patients	O
+who	O
+had	O
+been	O
+reported	O
+as	O
+asymptomatic	O
+,	O
+33	O
+(	O
+52	O
+%)	O
+were	O
+interviewed	O
+,	O
+and	O
+26	O
+of	O
+these	O
+33	O
+(	O
+79	O
+%)	O
+reported	O
+at	O
+least	O
+one	O
+symptom	B-DISO
+that	O
+was	O
+consistent	O
+with	O
+a	O
+viral	O
+respiratory	O
+illness	O
+.	O
+
+While	O
+the	O
+second	O
+patient	O
+presented	O
+with	O
+respiratory	B-ANAT
+tract	I-ANAT
+symptoms	O
+,	O
+remained	O
+stable	O
+and	O
+had	O
+an	O
+excellent	O
+clinical	O
+recovery	O
+despite	O
+recent	O
+reception	B-PROC
+of	O
+thymoglobulin	O
+induction	O
+.	O
+
+This	O
+is	O
+a	O
+rare	O
+report	O
+of	O
+MERS	O
+CoV	O
+infection	B-DISO
+in	O
+renal	B-ANAT
+transplant	B-ANAT
+recipients	O
+.	O
+
+TITLE	O
+:	O
+Coronaviruses	O
+:	O
+an	O
+overview	O
+of	O
+their	O
+replication	O
+and	O
+pathogenesis	B-DISO
+.	O
+
+TITLE	O
+:	O
+Serological	O
+diagnosis	O
+of	O
+feline	B-SPEC
+coronavirus	B-DISO
+infection	I-DISO
+by	O
+immunochromatographic	O
+test	O
+.	O
+
+ABSTRACT	O
+:	O
+The	O
+immunochromatographic	O
+assay	O
+(	O
+ICA	O
+)	O
+is	O
+a	O
+simple	O
+antibody	B-COMP
+-	O
+antigen	B-CHED
+detection	O
+method	O
+,	O
+the	O
+results	O
+of	O
+which	O
+can	O
+be	O
+rapidly	O
+obtained	O
+at	O
+a	O
+low	O
+cost	O
+.	O
+
+The	O
+Protein	B-PRGE
+A	I-PRGE
+and	O
+affinity	O
+-	O
+purified	O
+cat	B-PRGE
+anti	I-PRGE
+-	I-PRGE
+FCoV	I-PRGE
+IgG	I-PRGE
+are	O
+blotted	O
+on	O
+the	O
+test	O
+line	O
+and	O
+the	O
+control	O
+line	O
+,	O
+respectively	O
+,	O
+of	O
+the	O
+nitrocellulose	B-CHED
+membrane	B-COMP
+.	O
+
+This	O
+predisposition	O
+is	O
+primarily	O
+due	O
+to	O
+high	O
+error	O
+rate	O
+,	O
+and	O
+limited	O
+proofreading	O
+capability	O
+of	O
+the	O
+viral	B-PRGE
+polymerase	I-PRGE
+and	O
+by	O
+recombination	B-PROC
+.	O
+
+The	O
+embryonated	O
+egg	B-ANAT
+also	O
+has	O
+been	O
+shown	O
+to	O
+be	O
+suitable	O
+for	O
+isolation	O
+and	O
+propagation	O
+of	O
+pheasant	O
+coronavirus	B-SPEC
+,	O
+a	O
+proposed	O
+member	O
+of	O
+the	O
+Gammacoronavirus	B-SPEC
+genus	B-SPEC
+.	O
+
+In	O
+this	O
+chapter	O
+we	O
+outline	O
+the	O
+methods	O
+by	O
+which	O
+we	O
+establish	O
+fully	O
+differentiated	B-PROC
+airway	B-ANAT
+epithelium	B-ANAT
+and	O
+its	O
+use	O
+for	O
+human	B-SPEC
+coronavirus	I-SPEC
+propagation	O
+.	O
+
+Recent	O
+studies	O
+on	O
+the	O
+proteome	O
+of	O
+coronavirus	B-SPEC
+virions	B-COMP
+have	O
+shown	O
+that	O
+in	O
+addition	O
+to	O
+the	O
+structural	O
+proteins	B-CHED
+,	O
+accessory	O
+and	O
+non	O
+-	O
+structural	O
+virus	B-SPEC
+proteins	B-CHED
+and	O
+a	O
+wide	O
+variety	O
+of	O
+host	B-COMP
+cell	I-COMP
+proteins	B-CHED
+associate	O
+with	O
+virus	B-COMP
+particles	I-COMP
+.	O
+
+This	O
+diversity	O
+of	O
+genotypes	O
+provides	O
+a	O
+mechanism	O
+in	O
+which	O
+a	O
+virus	B-SPEC
+population	O
+can	O
+evolve	O
+and	O
+adapt	O
+to	O
+a	O
+changing	O
+environment	O
+.	O
+
+Here	O
+we	O
+describe	O
+the	O
+engineering	O
+of	O
+CoV	O
+full	O
+-	O
+length	O
+cDNA	O
+clones	O
+as	O
+bacterial	O
+artificial	O
+chromosomes	B-COMP
+(	O
+BACs	O
+),	O
+using	O
+the	O
+Middle	O
+East	O
+respiratory	O
+syndrome	B-DISO
+CoV	O
+(	O
+MERS	O
+-	O
+CoV	O
+)	O
+as	O
+a	O
+model	O
+.	O
+
+TITLE	O
+:	O
+Identification	O
+of	O
+protein	B-CHED
+receptors	O
+for	O
+coronaviruses	O
+by	O
+mass	O
+spectrometry	O
+.	O
+
+This	O
+receptor	O
+binds	B-FUNC
+feline	B-SPEC
+coronavirus	B-SPEC
+(	O
+FECV	B-SPEC
+1683	O
+).	O
+
+In	O
+the	O
+field	O
+of	O
+virology	O
+,	O
+it	O
+has	O
+proven	O
+instrumental	O
+to	O
+identify	O
+virus	B-SPEC
+-	O
+host	B-COMP
+interactions	O
+that	O
+are	O
+involved	O
+in	O
+viral	O
+embezzlement	O
+of	O
+cellular	B-COMP
+functions	O
+and	O
+inhibition	B-PROC
+of	O
+immune	O
+mechanisms	O
+.	O
+
+ABSTRACT	O
+:	O
+Feline	B-SPEC
+infectious	I-DISO
+peritonitis	I-DISO
+(	O
+FIP	O
+)	O
+is	O
+a	O
+lethal	O
+systemic	B-DISO
+disease	I-DISO
+caused	O
+by	O
+FIP	B-DISO
+virus	B-SPEC
+(	O
+FIPV	O
+).	O
+
+TITLE	O
+:	O
+Studying	O
+the	O
+dynamics	O
+of	O
+coronavirus	B-SPEC
+replicative	O
+structures	O
+.	O
+
+The	O
+environment	O
+inside	O
+a	O
+TEM	B-COMP
+is	O
+not	O
+favorable	O
+for	O
+biological	O
+material	O
+(	O
+high	O
+vacuum	O
+and	O
+high	O
+energy	O
+electrons	O
+).	O
+
+Also	O
+biological	O
+samples	O
+have	O
+little	O
+or	O
+no	O
+intrinsic	O
+electron	O
+contrast	O
+,	O
+and	O
+rarely	O
+do	O
+they	O
+naturally	O
+exist	O
+in	O
+very	O
+thin	O
+sheets	O
+,	O
+as	O
+is	O
+required	O
+for	O
+optimum	O
+resolution	O
+in	O
+the	O
+TEM	B-COMP
+.	O
+
+TITLE	O
+:	O
+Use	O
+of	O
+extracorporeal	O
+membrane	B-COMP
+oxygenation	B-PROC
+in	O
+severe	O
+traumatic	B-DISO
+lung	I-DISO
+injury	O
+with	O
+respiratory	B-DISO
+failure	I-DISO
+.	O
+
+Severe	O
+lung	B-ANAT
+injury	O
+with	O
+respiratory	B-DISO
+failure	I-DISO
+is	O
+often	O
+encountered	O
+in	O
+trauma	O
+patients	O
+.	O
+
+The	O
+purified	O
+whole	B-PRGE
+viral	I-PRGE
+antigen	I-PRGE
+of	O
+Sczy3	O
+strain	O
+was	O
+used	O
+to	O
+immunize	O
+BALB	O
+/	O
+c	O
+mice	B-SPEC
+to	O
+produce	O
+hybridoma	B-ANAT
+-	O
+secreting	B-PROC
+anti	O
+-	O
+IBV	B-SPEC
+MAbs	O
+.	O
+
+Then	O
+,	O
+female	O
+BALB	O
+/	O
+c	O
+mice	B-SPEC
+were	O
+immunized	O
+with	O
+the	O
+purified	O
+recombinant	B-PRGE
+N	I-PRGE
+protein	I-PRGE
+and	O
+one	O
+strain	O
+of	O
+hybridoma	B-ANAT
+cells	B-COMP
+named	O
+2B8	O
+secreting	B-PROC
+anti	O
+-	O
+N	O
+protein	B-CHED
+monoclonal	B-PRGE
+antibodies	I-PRGE
+(	O
+MAb	O
+)	O
+was	O
+obtained	O
+by	O
+hybridoma	B-ANAT
+technique	O
+.	O
+
+This	O
+work	O
+indicated	O
+that	O
+the	O
+MAb	O
+would	O
+be	O
+a	O
+valuable	O
+tool	O
+as	O
+a	O
+specific	O
+diagnostic	O
+reagent	B-CHED
+for	O
+PEDV	B-SPEC
+epidemiological	O
+surveys	O
+and	O
+diagnosis	O
+in	O
+the	O
+future	O
+.	O
+
+Patients	O
+with	O
+severe	O
+hypoxemia	O
+and	O
+cardiopulmonary	B-DISO
+failure	I-DISO
+(	O
+n	O
+=	O
+139	O
+)	O
+at	O
+referring	O
+hospitals	O
+in	O
+whom	O
+conventional	O
+therapy	O
+was	O
+unsuccessful	O
+were	O
+treated	O
+with	O
+iNO	B-PRGE
+in	O
+the	O
+intensive	O
+care	O
+units	O
+in	O
+anticipation	O
+of	O
+transfer	O
+to	O
+a	O
+tertiary	O
+center	O
+.	O
+
+Treatment	O
+wih	O
+iNO	O
+was	O
+initiated	O
+by	O
+the	O
+critical	O
+care	O
+transport	B-PROC
+team	O
+in	O
+114	O
+patients	O
+and	O
+continued	O
+in	O
+25	O
+patients	O
+.	O
+
+Arterial	B-ANAT
+blood	I-ANAT
+gas	O
+analysis	O
+was	O
+done	O
+before	O
+and	O
+after	O
+iNO	O
+treatment	O
+.	O
+
+Patients	O
+treated	O
+with	O
+iNO	O
+had	O
+significant	O
+improvement	O
+in	O
+oxygenation	B-PROC
+:	O
+mean	O
+(	O
+SD	O
+)	O
+for	O
+PaO2	O
+increased	O
+from	O
+60	O
+.	O
+7	O
+(	O
+20	O
+.	O
+2	O
+)	O
+to	O
+72	O
+.	O
+3	O
+(	O
+40	O
+.	O
+6	O
+)	O
+mm	O
+Hg	O
+(	O
+P	O
+=.	O
+008	O
+),	O
+and	O
+mean	O
+(	O
+SD	O
+)	O
+for	O
+ratio	O
+of	O
+PaO2	O
+to	O
+fraction	O
+of	O
+inspired	O
+oxygen	B-CHED
+(	O
+P	O
+:	O
+F	O
+)	O
+increased	O
+from	O
+62	O
+.	O
+4	O
+(	O
+26	O
+.	O
+1	O
+)	O
+to	O
+73	O
+.	O
+1	O
+(	O
+42	O
+.	O
+6	O
+)	O
+(	O
+P	O
+=	O
+.	O
+03	O
+).	O
+
+These	O
+results	O
+suggested	O
+that	O
+either	O
+the	O
+introduction	O
+of	O
+a	O
+disubstituted	O
+amide	B-CHED
+structure	O
+at	O
+the	O
+17	O
+-	O
+COOH	O
+of	O
+ursolic	B-CHED
+acid	I-CHED
+or	O
+alteration	O
+of	O
+the	O
+C	O
+-	O
+3	O
+configuration	O
+of	O
+ursolic	B-CHED
+acid	I-CHED
+from	O
+3β	O
+-	O
+to	O
+3α	O
+-	O
+forms	O
+was	O
+helpful	O
+to	O
+significantly	O
+improve	O
+the	O
+selective	O
+index	O
+while	O
+keeping	O
+their	O
+antiviral	B-CHED
+activities	O
+.	O
+
+In	O
+particular	O
+,	O
+the	O
+nature	O
+of	O
+the	O
+aromatic	O
+group	O
+in	O
+the	O
+position	O
+4	O
+of	O
+the	O
+thiazole	B-CHED
+ring	O
+plays	O
+a	O
+key	O
+role	O
+in	O
+the	O
+modulation	O
+of	O
+the	O
+activity	O
+towards	O
+the	O
+two	O
+RT	O
+-	O
+associated	O
+functions	O
+.	O
+
+In	O
+the	O
+asymptomatic	B-DISO
+condition	I-DISO
+,	O
+human	B-SPEC
+parechovirus	I-SPEC
+,	O
+adenovirus	B-DISO
+,	O
+enterovirus	B-SPEC
+,	O
+rhinovirus	B-SPEC
+,	O
+coronavirus	B-SPEC
+229E	O
+and	O
+HKU1	O
+were	O
+observed	O
+in	O
+45	O
+episodes	O
+.	O
+
+To	O
+develop	O
+a	O
+simple	O
+,	O
+reliable	O
+MERS	O
+-	O
+CoV	O
+variant	O
+typing	O
+assay	O
+to	O
+facilitate	O
+monitoring	O
+of	O
+MERS	O
+-	O
+CoV	O
+diversity	O
+in	O
+animals	B-SPEC
+and	O
+humans	B-SPEC
+.	O
+
+VHL	B-DISO
+,	O
+one	O
+of	O
+these	O
+proteins	B-CHED
+,	O
+was	O
+proven	O
+to	O
+interact	O
+with	O
+nsp16	O
+both	O
+in	O
+vitro	O
+and	O
+in	O
+vivo	O
+.	O
+
+Our	O
+results	O
+have	O
+revealed	O
+the	O
+role	O
+of	O
+cellular	B-COMP
+VHL	B-DISO
+in	O
+the	O
+regulation	O
+of	O
+SARS	B-DISO
+-	O
+CoV	O
+replication	O
+.	O
+
+The	O
+authors	O
+estimated	O
+the	O
+economic	O
+costs	O
+of	O
+inadequate	O
+breastfeeding	B-PROC
+as	O
+follows	O
+:	O
+the	O
+sum	O
+of	O
+direct	O
+health	O
+care	O
+costs	O
+for	O
+diseases	O
+whose	O
+risk	O
+increases	O
+when	O
+infants	O
+are	O
+non	O
+-	O
+exclusively	O
+breastfed	O
+<	O
+6	O
+mo	O
+or	O
+are	O
+not	O
+breastfed	O
+from	O
+ages	O
+6	O
+to	O
+<	O
+11	O
+mo	O
+,	O
+lost	B-CHED
+future	O
+earnings	O
+due	O
+to	O
+premature	O
+infant	O
+death	B-PROC
+,	O
+and	O
+the	O
+costs	O
+of	O
+purchasing	O
+infant	O
+formula	O
+.	O
+
+This	O
+study	O
+provides	O
+costs	O
+of	O
+inadequate	O
+breastfeeding	B-PROC
+that	O
+had	O
+not	O
+been	O
+quantified	O
+in	O
+Mexico	O
+.	O
+
+Although	O
+less	O
+common	O
+,	O
+patients	O
+presenting	O
+with	O
+non	O
+-	O
+falciparum	O
+even	O
+in	O
+the	O
+United	O
+States	O
+can	O
+develop	O
+severe	O
+illness	O
+,	O
+and	O
+severe	O
+illness	O
+in	O
+patients	O
+having	O
+malaria	B-PATH
+of	O
+any	O
+species	B-SPEC
+threatens	O
+life	O
+.	O
+
+An	O
+automated	O
+multiplex	O
+PCR	O
+device	O
+,	O
+the	O
+FilmArray	O
+-	O
+Respiratory	O
+Panel	O
+(	O
+FilmArray	O
+-	O
+RP	O
+),	O
+can	O
+detect	O
+17	O
+viral	O
+and	O
+3	O
+bacterial	O
+pathogens	O
+in	O
+a	O
+closed	O
+system	O
+that	O
+requires	O
+only	O
+5	O
+min	O
+of	O
+hands	B-ANAT
+-	O
+on	O
+time	O
+and	O
+1h	O
+of	O
+instrumentation	O
+time	O
+.	O
+
+TITLE	O
+:	O
+Veno	O
+-	O
+veno	O
+-	O
+arterial	B-ANAT
+extracorporeal	O
+membrane	B-COMP
+oxygenation	B-PROC
+for	O
+respiratory	B-DISO
+failure	I-DISO
+with	O
+severe	O
+haemodynamic	O
+impairment	O
+:	O
+technique	O
+and	O
+early	O
+outcomes	O
+.	O
+
+ABSTRACT	O
+:	O
+Patients	O
+with	O
+respiratory	B-DISO
+failure	I-DISO
+may	O
+benefit	O
+from	O
+veno	O
+-	O
+venous	B-ANAT
+and	O
+veno	O
+-	O
+arterial	B-ANAT
+extracorporeal	O
+membrane	B-COMP
+oxygenation	B-PROC
+(	O
+ECMO	O
+)	O
+support	O
+.	O
+
+Here	O
+,	O
+we	O
+retrospectively	O
+analysed	O
+the	O
+characteristics	O
+and	O
+outcomes	O
+of	O
+patients	O
+commenced	O
+on	O
+either	O
+veno	O
+-	O
+venous	B-ANAT
+or	O
+veno	O
+-	O
+arterial	B-ANAT
+ECMO	O
+due	O
+to	O
+respiratory	B-DISO
+failure	I-DISO
+,	O
+and	O
+then	O
+switched	O
+to	O
+v	O
+-	O
+v	O
+-	O
+a	O
+ECMO	O
+.	O
+
+ECMO	O
+-	O
+related	O
+complications	O
+were	O
+bleeding	B-DISO
+(	O
+n	O
+=	O
+3	O
+)	O
+and	O
+leg	B-DISO
+ischaemia	I-DISO
+(	O
+n	O
+=	O
+2	O
+).	O
+
+However	O
+,	O
+hypercapnic	B-DISO
+acidosis	I-DISO
+resulting	O
+from	O
+ventilation	O
+at	O
+lower	O
+tidal	O
+volume	O
+enhances	O
+pulmonary	B-DISO
+hypertension	I-DISO
+and	O
+might	O
+induce	O
+right	O
+ventricular	B-ANAT
+(	O
+RV	O
+)	O
+failure	O
+.	O
+
+We	O
+investigated	O
+if	O
+extracorporeal	O
+veno	O
+-	O
+venous	B-ANAT
+CO2	B-CHED
+removal	O
+therapy	O
+could	O
+have	O
+beneficial	O
+effects	O
+on	O
+pulmonary	B-PROC
+circulation	B-PROC
+and	O
+RV	O
+function	O
+.	O
+
+A	O
+micromanometer	O
+-	O
+tipped	O
+catheter	O
+was	O
+inserted	O
+into	O
+the	O
+main	O
+pulmonary	B-ANAT
+artery	I-ANAT
+and	O
+an	O
+admittance	O
+micromanometer	O
+-	O
+tipped	O
+catheter	O
+was	O
+inserted	O
+into	O
+the	O
+right	B-ANAT
+ventricle	I-ANAT
+.	O
+
+Protective	O
+ventilation	O
+was	O
+then	O
+achieved	O
+,	O
+and	O
+the	O
+pigs	O
+were	O
+connected	O
+to	O
+a	O
+pump	O
+-	O
+driven	O
+extracorporeal	O
+membrane	B-COMP
+oxygenator	O
+(	O
+PALP	O
+,	O
+Maquet	O
+,	O
+Germany	O
+)	O
+in	O
+order	B-SPEC
+to	O
+achieve	O
+CO2	B-CHED
+removal	O
+.	O
+
+Systolic	O
+pulmonary	B-ANAT
+artery	I-ANAT
+pressure	O
+significantly	O
+increased	O
+from	O
+29	O
+.	O
+6	O
+±	O
+1	O
+.	O
+8	O
+to	O
+43	O
+.	O
+9	O
+±	O
+2	O
+.	O
+0	O
+mmHg	O
+(	O
+P	O
+<	O
+0	O
+.	O
+001	O
+).	O
+
+The	O
+primary	O
+structure	O
+-	O
+activity	O
+relationships	O
+(	O
+SARs	B-DISO
+)	O
+suggested	O
+that	O
+the	O
+conjugated	O
+derivatives	O
+of	O
+p	O
+-	O
+HAP	O
+glycoside	B-CHED
+and	O
+substituted	O
+cinnamic	B-CHED
+acids	I-CHED
+(	O
+2a	O
+-	O
+2i	O
+)	O
+obviously	O
+enhanced	O
+the	O
+activity	O
+against	O
+HBV	B-DISO
+DNA	B-PATH
+replication	I-PATH
+with	O
+IC50	O
+values	O
+ranged	O
+from	O
+5	O
+.	O
+8	O
+to	O
+74	O
+.	O
+4	O
+μM	O
+.	O
+
+Although	O
+there	O
+was	O
+no	O
+abnormal	O
+finding	O
+in	O
+the	O
+testes	B-ANAT
+,	O
+serum	B-COMP
+testicular	B-DISO
+tumor	I-DISO
+markers	O
+showed	O
+marked	O
+elevation	O
+.	O
+
+ABSTRACT	O
+:	O
+Porcine	O
+deltacoronavirus	O
+(	O
+PDCoV	O
+)	O
+is	O
+a	O
+novel	B-SPEC
+coronavirus	I-SPEC
+that	O
+causes	O
+diarrhea	B-DISO
+in	O
+nursing	B-PROC
+piglets	O
+.	O
+
+We	O
+also	O
+isolated	O
+PDCoV	O
+[	O
+OH	O
+-	O
+FD22	O
+(	O
+DC44	B-PRGE
+)	O
+strain	O
+]	O
+in	O
+LLC	B-COMP
+-	O
+PK	O
+cells	B-COMP
+from	O
+intestinal	B-ANAT
+contents	I-ANAT
+of	O
+PDCoV	O
+OH	O
+-	O
+FD22	O
+strain	O
+-	O
+inoculated	O
+gnotobiotic	O
+(	O
+Gn	O
+)	O
+pigs	B-SPEC
+.	O
+
+The	O
+full	O
+-	O
+length	O
+S	O
+and	O
+N	O
+genes	O
+were	O
+sequenced	O
+to	O
+study	O
+PDCoV	O
+genetic	O
+changes	O
+after	O
+passage	O
+in	O
+Gn	O
+pigs	O
+and	O
+cell	B-COMP
+culture	O
+(	O
+passage	O
+11	O
+[	O
+P11	O
+]	O
+and	O
+P20	O
+).	O
+
+Genetically	O
+,	O
+the	O
+S	O
+and	O
+N	O
+genes	O
+of	O
+the	O
+PDCoV	O
+isolates	O
+were	O
+relatively	O
+stable	O
+during	O
+the	O
+first	O
+20	O
+passages	O
+in	O
+cell	B-COMP
+culture	O
+,	O
+with	O
+only	O
+5	O
+nucleotide	B-CHED
+changes	O
+,	O
+each	O
+corresponding	O
+to	O
+an	O
+amino	B-CHED
+acid	I-CHED
+change	O
+.	O
+
+Altogether	O
+,	O
+34	O
+/	O
+112	O
+ASS	B-SPEC
+patients	O
+had	O
+received	O
+Rtx	O
+;	O
+24	O
+/	O
+34	O
+had	O
+severe	O
+ILD	O
+and	O
+>	O
+12	O
+months	O
+follow	O
+-	O
+up	O
+post	O
+-	O
+Rtx	O
+(	O
+median	O
+52	O
+months	O
+).	O
+
+The	O
+mortality	O
+rate	O
+in	O
+the	O
+Rtx	O
+-	O
+treated	O
+group	O
+was	O
+comparable	O
+to	O
+that	O
+of	O
+the	O
+remaining	O
+ASS	B-SPEC
+cohort	O
+(	O
+25	O
+/	O
+78	O
+deceased	B-PROC
+;	O
+32	O
+%).	O
+
+The	O
+study	O
+indicates	O
+that	O
+Rtx	O
+could	O
+be	O
+a	O
+treatment	O
+option	O
+for	O
+selected	O
+ASS	B-SPEC
+patients	O
+,	O
+but	O
+infections	B-DISO
+should	O
+be	O
+given	O
+attention	O
+.	O
+
+ABSTRACT	O
+:	O
+The	O
+study	O
+aimed	O
+to	O
+evaluate	O
+cell	O
+surface	O
+mobilisation	O
+of	O
+CD107a	B-PRGE
+as	O
+a	O
+general	O
+activation	O
+marker	O
+on	O
+chicken	B-SPEC
+cytotoxic	B-ANAT
+T	I-ANAT
+cells	I-ANAT
+(	O
+CTL	B-ANAT
+).	O
+
+In	O
+chickens	B-SPEC
+experimentally	O
+infected	O
+with	O
+IBV	B-SPEC
+,	O
+higher	O
+frequencies	O
+of	O
+CTL	B-ANAT
+isolated	O
+from	O
+respiratory	O
+tissues	B-ANAT
+were	O
+positive	O
+for	O
+CD107a	B-PRGE
+on	O
+the	O
+cell	B-COMP
+surface	I-COMP
+compared	O
+to	O
+those	O
+from	O
+uninfected	O
+control	O
+chickens	B-SPEC
+indicating	O
+in	O
+vivo	O
+activation	O
+.	O
+
+CONCLUSIONS	O
+:	O
+Recovery	O
+was	O
+longer	O
+with	O
+acute	O
+gastrointestinal	B-DISO
+infection	I-DISO
+and	O
+acute	O
+motor	O
+axonal	B-DISO
+neuropathy	I-DISO
+.	O
+
+A	O
+25	O
+year	O
+old	O
+male	O
+with	O
+no	O
+significant	O
+past	O
+medical	O
+history	O
+had	O
+been	O
+admitted	O
+to	O
+a	O
+local	O
+hospital	O
+due	O
+to	O
+dyspnea	B-DISO
+and	O
+fever	B-PROC
+.	O
+
+The	O
+diagnosis	O
+of	O
+ARDS	B-DISO
+,	O
+HIV	B-PATH
+infection	I-PATH
+and	O
+MDR	B-FUNC
+bacterial	O
+and	O
+fungal	O
+VAP	O
+was	O
+made	O
+.	O
+
+Airway	B-ANAT
+pressure	O
+release	B-PATH
+ventilation	O
+may	O
+be	O
+an	O
+important	O
+option	O
+as	O
+a	O
+ventilatory	O
+mode	O
+for	O
+management	O
+of	O
+maternal	O
+respiratory	B-DISO
+failure	I-DISO
+during	O
+pregnancy	O
+.	O
+
+The	O
+established	O
+ELISA	O
+was	O
+also	O
+examined	O
+with	O
+serum	B-COMP
+samples	O
+obtained	O
+from	O
+turkeys	B-SPEC
+experimentally	O
+infected	O
+with	O
+TCoV	O
+.	O
+Those	O
+serum	B-COMP
+samples	O
+were	O
+collected	O
+at	O
+various	O
+time	O
+intervals	O
+from	O
+1	O
+to	O
+63	O
+days	O
+post	O
+-	O
+infection	B-DISO
+.	O
+
+Additionally	O
+,	O
+the	O
+poorly	O
+aerated	O
+tissue	B-ANAT
+presented	O
+the	O
+largest	O
+uptake	O
+concentration	O
+after	O
+27	O
+hours	O
+.	O
+
+Protective	O
+Acute	B-DISO
+Respiratory	I-DISO
+Distress	I-DISO
+Syndrome	I-DISO
+Network	O
+strategy	O
+did	O
+not	O
+attenuate	O
+global	O
+pulmonary	B-DISO
+inflammation	I-DISO
+during	O
+the	O
+first	O
+27	O
+hours	O
+after	O
+severe	O
+lung	B-ANAT
+insult	O
+.	O
+
+ABSTRACT	O
+:	O
+A	O
+novel	O
+porcine	O
+deltacoronavirus	O
+(	O
+PdCV	O
+)	O
+was	O
+first	O
+discovered	O
+in	O
+Ohio	O
+and	O
+Indiana	O
+in	O
+February	O
+2014	O
+,	O
+rapidly	O
+spread	O
+to	O
+other	O
+states	O
+in	O
+the	O
+United	O
+States	O
+and	O
+Canada	O
+,	O
+and	O
+caused	O
+significant	O
+economic	O
+loss	O
+in	O
+the	O
+swine	B-SPEC
+industry	O
+.	O
+
+Here	O
+,	O
+we	O
+characterized	O
+U	O
+.	O
+S	O
+.	O
+PdCV	O
+isolates	O
+and	O
+determined	O
+their	O
+virulence	B-PROC
+in	O
+gnotobiotic	O
+and	O
+conventional	O
+piglets	O
+.	O
+
+Within	O
+1	O
+to	O
+3	O
+days	O
+postinfection	O
+,	O
+profuse	O
+watery	B-DISO
+diarrhea	I-DISO
+,	O
+vomiting	B-DISO
+,	O
+and	O
+dehydration	B-DISO
+were	O
+observed	O
+.	O
+
+High	O
+levels	O
+of	O
+viral	O
+RNA	O
+(	O
+8	O
+to	O
+11	O
+log	O
+RNA	O
+copies	O
+/	O
+g	O
+)	O
+were	O
+detected	O
+in	O
+intestinal	B-ANAT
+tissues	B-ANAT
+/	O
+luminal	B-CHED
+contents	O
+and	O
+feces	B-ANAT
+of	O
+infected	O
+piglets	O
+,	O
+whereas	O
+moderate	O
+RNA	O
+levels	O
+(	O
+2	O
+to	O
+5	O
+log	O
+RNA	O
+copies	O
+/	O
+g	O
+)	O
+were	O
+detected	O
+in	O
+blood	B-ANAT
+,	O
+lung	B-ANAT
+,	O
+liver	B-ANAT
+,	O
+and	O
+kidney	B-ANAT
+,	O
+indicating	O
+multisystemic	O
+dissemination	O
+of	O
+the	O
+virus	B-SPEC
+.	O
+
+Examples	O
+of	O
+porcine	B-SPEC
+CoVs	O
+include	O
+porcine	B-DISO
+transmissible	I-DISO
+gastroenteritis	I-DISO
+coronavirus	B-SPEC
+(	O
+TGEV	B-SPEC
+),	O
+porcine	B-SPEC
+epidemic	I-SPEC
+diarrhea	I-SPEC
+virus	I-SPEC
+(	O
+PEDV	B-SPEC
+),	O
+and	O
+porcine	B-SPEC
+respiratory	O
+coronavirus	B-SPEC
+(	O
+PRCV	O
+).	O
+
+In	O
+February	O
+2014	O
+,	O
+another	O
+porcine	B-SPEC
+CoV	O
+,	O
+porcine	B-SPEC
+deltacoronavirus	O
+(	O
+PdCV	O
+),	O
+emerged	O
+in	O
+Ohio	O
+and	O
+Indiana	O
+and	O
+subsequently	O
+spread	O
+rapidly	O
+across	O
+the	O
+United	O
+States	O
+and	O
+Canada	O
+,	O
+causing	O
+significant	O
+economic	O
+losses	O
+.	O
+
+This	O
+RNA	O
+motif	O
+presented	O
+high	O
+homology	O
+with	O
+the	O
+GAIT	O
+element	O
+,	O
+involved	O
+in	O
+the	O
+modulation	O
+of	O
+the	O
+inflammatory	B-DISO
+response	I-DISO
+.	O
+
+These	O
+novel	O
+findings	O
+may	O
+be	O
+of	O
+relevance	O
+for	O
+other	O
+coronaviruses	O
+and	O
+could	O
+serve	O
+as	O
+the	O
+basis	O
+for	O
+the	O
+development	B-PROC
+of	O
+novel	O
+antiviral	B-CHED
+strategies	O
+.	O
+
+Her	O
+liver	B-PROC
+function	I-PROC
+,	O
+clinical	O
+signs	B-DISO
+and	I-DISO
+symptoms	I-DISO
+improved	O
+significantly	O
+.	O
+
+Following	O
+convection	O
+enhanced	O
+delivery	O
+(	O
+CED	B-DISO
+),	O
+conventional	O
+gene	O
+vectors	O
+are	O
+confined	O
+to	O
+the	O
+injection	O
+site	O
+,	O
+presumably	O
+by	O
+adhesive	O
+interactions	O
+with	O
+the	O
+brain	B-ANAT
+ECM	B-COMP
+and	O
+do	O
+not	O
+provide	O
+gene	B-PROC
+expression	I-PROC
+beyond	O
+the	O
+point	O
+of	O
+administration	O
+.	O
+
+Norovirus	B-PRGE
+3C	I-PRGE
+-	I-PRGE
+like	I-PRGE
+protease	I-PRGE
+is	O
+essential	O
+for	O
+viral	B-PROC
+replication	I-PROC
+,	O
+consequently	O
+,	O
+inhibition	B-PROC
+of	O
+this	O
+enzyme	O
+is	O
+a	O
+fruitful	O
+avenue	O
+of	O
+investigation	O
+that	O
+may	O
+lead	O
+to	O
+the	O
+emergence	O
+of	O
+antinorovirus	O
+therapeutics	O
+.	O
+
+We	O
+also	O
+demonstrate	O
+herein	O
+in	O
+vivo	O
+efficacy	O
+of	O
+an	O
+inhibitor	B-CHED
+using	O
+the	O
+murine	B-SPEC
+model	O
+of	O
+norovirus	B-SPEC
+infection	B-DISO
+.	O
+
+TITLE	O
+:	O
+Systemic	O
+and	O
+mucosal	B-PROC
+immunity	I-PROC
+in	O
+mice	B-SPEC
+elicited	O
+by	O
+a	O
+single	O
+immunization	O
+with	O
+human	B-SPEC
+adenovirus	B-SPEC
+type	O
+5	O
+or	O
+41	O
+vector	O
+-	O
+based	O
+vaccines	O
+carrying	O
+the	O
+spike	O
+protein	B-CHED
+of	O
+Middle	O
+East	O
+respiratory	O
+syndrome	B-DISO
+coronavirus	B-SPEC
+.	O
+
+ABSTRACT	O
+:	O
+An	O
+ideal	O
+vaccine	O
+against	O
+mucosal	B-ANAT
+pathogens	O
+such	O
+as	O
+Middle	O
+East	O
+respiratory	O
+syndrome	B-DISO
+coronavirus	B-SPEC
+(	O
+MERS	O
+-	O
+CoV	O
+)	O
+should	O
+confer	O
+sustained	O
+,	O
+protective	O
+immunity	B-PROC
+at	O
+both	O
+systemic	O
+and	O
+mucosal	B-ANAT
+levels	O
+.	O
+
+Here	O
+,	O
+we	O
+evaluated	O
+the	O
+in	O
+vivo	O
+systemic	O
+and	O
+mucosal	B-ANAT
+antigen	B-CHED
+-	O
+specific	O
+immune	B-PROC
+responses	I-PROC
+induced	O
+by	O
+a	O
+single	O
+intramuscular	O
+or	O
+intragastric	O
+administration	O
+of	O
+recombinant	O
+adenoviral	B-SPEC
+type	O
+5	O
+(	O
+Ad5	B-DISO
+)	O
+or	O
+type	O
+41	O
+(	O
+Ad41	O
+)	O
+-	O
+based	O
+vaccines	O
+expressing	O
+the	O
+MERS	O
+-	O
+CoV	O
+spike	O
+(	O
+S	O
+)	O
+protein	B-CHED
+.	O
+
+Despite	O
+being	O
+admitted	O
+rapidly	O
+to	O
+hospital	O
+,	O
+his	O
+heart	B-DISO
+rate	I-DISO
+decreased	I-DISO
+associated	O
+with	O
+respiratory	B-DISO
+distress	I-DISO
+.	O
+
+It	O
+was	O
+found	O
+that	O
+the	O
+compartments	B-ANAT
+and	O
+ducts	B-ANAT
+were	O
+not	O
+airtight	O
+.	O
+
+Unfortunately	O
+,	O
+a	O
+seafarer	O
+on	O
+board	O
+a	O
+bulk	O
+carrier	O
+died	B-PROC
+in	O
+2008	O
+because	O
+of	O
+acute	O
+phosphine	B-CHED
+poisoning	O
+.	O
+
+Sporadic	O
+human	B-SPEC
+cases	O
+of	O
+avian	B-PRGE
+A	I-PRGE
+(	I-PRGE
+H5N6	I-PRGE
+),	I-PRGE
+A	I-PRGE
+(	I-PRGE
+H10N8	I-PRGE
+)	I-PRGE
+and	I-PRGE
+A	I-PRGE
+(	O
+H6N1	O
+)	O
+have	O
+also	O
+emerged	O
+.	O
+
+ABSTRACT	O
+:	O
+The	O
+impact	O
+of	O
+porcine	O
+epidemic	O
+diarrhea	O
+virus	O
+(	O
+PEDv	B-SPEC
+)	O
+infection	B-DISO
+on	O
+the	O
+US	O
+pork	O
+industry	O
+has	O
+mainly	O
+been	O
+attributed	O
+to	O
+the	O
+mortality	O
+that	O
+it	O
+causes	O
+in	O
+suckling	O
+piglets	O
+,	O
+and	O
+,	O
+consequently	O
+,	O
+much	O
+effort	B-PROC
+has	O
+been	O
+invested	O
+in	O
+the	O
+quantification	O
+of	O
+its	O
+effect	O
+in	O
+sow	O
+farms	O
+.	O
+
+These	O
+findings	O
+help	O
+to	O
+quantify	O
+the	O
+impact	O
+of	O
+PEDv	B-SPEC
+infection	B-DISO
+in	O
+the	O
+US	O
+and	O
+,	O
+ultimately	O
+,	O
+contribute	O
+to	O
+efforts	O
+to	O
+quantify	O
+the	O
+cost	O
+-	O
+effectiveness	O
+of	O
+disease	O
+prevention	O
+and	O
+control	O
+measures	O
+.	O
+
+Thus	O
+,	O
+the	O
+incidence	O
+of	O
+unpredictive	O
+cardiopulmonary	B-DISO
+arrest	I-DISO
+is	O
+high	O
+.	O
+
+Recently	O
+,	O
+a	O
+SAP	O
+patient	O
+in	O
+our	O
+intensive	O
+care	O
+unit	O
+had	O
+sudden	B-DISO
+cardiac	I-DISO
+arrest	I-DISO
+.	O
+
+Usually	O
+,	O
+we	O
+would	O
+stop	O
+existing	O
+CRRT	O
+when	O
+cardiac	B-DISO
+arrest	I-DISO
+occurred	O
+.	O
+
+ABSTRACT	O
+:	O
+Hepatitis	B-SPEC
+E	I-SPEC
+virus	I-SPEC
+(	O
+HEV	B-SPEC
+)	O
+is	O
+the	O
+most	O
+common	O
+cause	O
+of	O
+acute	O
+viral	O
+hepatitis	O
+worldwide	O
+.	O
+
+Fortunately	O
+,	O
+major	O
+strides	O
+have	O
+been	O
+made	O
+recently	O
+in	O
+the	O
+management	O
+of	O
+chronic	B-DISO
+hepatitis	I-DISO
+E	I-DISO
+patients	O
+.	O
+
+ABSTRACT	O
+:	O
+The	O
+acute	O
+lung	B-ANAT
+injury	O
+(	O
+ALI	O
+)	O
+model	O
+is	O
+characterised	O
+by	O
+a	O
+severe	O
+acute	B-DISO
+inflammatory	I-DISO
+response	I-DISO
+in	O
+the	O
+lungs	B-ANAT
+that	O
+represents	O
+the	O
+pathogenesis	B-DISO
+of	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+(	O
+ARDS	B-DISO
+).	O
+
+Eucalyptol	B-CHED
+attenuated	O
+inflammation	B-DISO
+-	O
+associated	O
+increases	O
+in	O
+cell	B-COMP
+numbers	O
+,	O
+matrix	B-PRGE
+metalloproteinase	I-PRGE
+-	I-PRGE
+9	I-PRGE
+(	O
+MMP	B-PRGE
+-	I-PRGE
+9	I-PRGE
+)	O
+expression	B-PROC
+,	O
+production	O
+of	O
+cytokines	O
+(	O
+tumour	B-DISO
+necrosis	I-DISO
+factor	O
+-	O
+α	O
+and	O
+interleukin	B-PRGE
+-	I-PRGE
+6	I-PRGE
+)	O
+and	O
+nitric	B-CHED
+oxide	I-CHED
+,	O
+and	O
+nuclear	B-PRGE
+factor	I-PRGE
+-	I-PRGE
+kappa	I-PRGE
+B	I-PRGE
+(	O
+NF	O
+-	O
+κB	O
+)	O
+and	O
+phosphorylated	O
+extracellular	B-PRGE
+signal	I-PRGE
+-	I-PRGE
+regulated	I-PRGE
+kinase	I-PRGE
+protein	B-CHED
+levels	O
+induced	O
+by	O
+LPS	B-DISO
+in	O
+bronchoalveolar	B-ANAT
+lavage	I-ANAT
+fluid	I-ANAT
+from	O
+ALI	O
+mice	B-SPEC
+.	O
+
+Collectively	O
+,	O
+these	O
+results	O
+indicate	O
+that	O
+eucalyptol	B-CHED
+acts	O
+through	O
+a	O
+mechanism	O
+involving	O
+decreased	O
+MMP	B-PRGE
+-	I-PRGE
+9	I-PRGE
+expression	B-PROC
+and	O
+an	O
+extracellular	B-ENZY
+signal	I-ENZY
+-	I-ENZY
+regulated	I-ENZY
+kinase	I-ENZY
+-	O
+dependent	O
+NF	O
+-	O
+κB	O
+pathway	B-PROC
+to	O
+exert	B-PROC
+anti	O
+-	O
+inflammatory	O
+actions	O
+in	O
+acute	O
+lung	B-DISO
+inflammation	I-DISO
+.	O
+
+Google	O
+Trends	O
+was	O
+used	O
+to	O
+investigate	O
+how	O
+the	O
+volume	O
+of	O
+interest	O
+in	O
+various	O
+infection	B-DISO
+control	O
+topics	O
+had	O
+changed	O
+over	O
+time	O
+.	O
+
+Unlike	O
+2G12	O
+,	O
+which	O
+is	O
+strictly	O
+specific	O
+for	O
+the	O
+high	O
+-	O
+density	O
+Man9GlcNAc2Asn	O
+(	O
+Man9	B-PRGE
+)-	O
+clusters	B-CHED
+,	O
+GNA	B-CHED
+recognizes	O
+a	O
+number	O
+of	O
+N	B-CHED
+-	I-CHED
+glycan	I-CHED
+cryptic	O
+sugar	O
+moieties	O
+.	O
+
+Virulence	B-PROC
+--	O
+the	O
+harm	O
+a	O
+pathogen	O
+does	O
+to	O
+its	O
+host	B-COMP
+-	O
+can	O
+be	O
+extremely	O
+high	O
+following	O
+a	O
+host	B-COMP
+shift	O
+(	O
+for	O
+example	O
+Ebola	O
+,	O
+HIV	B-DISO
+,	O
+and	O
+SARs	B-DISO
+),	O
+while	O
+other	O
+host	B-COMP
+shifts	O
+may	O
+go	O
+undetected	O
+as	O
+they	O
+cause	O
+few	O
+symptoms	O
+in	O
+the	O
+new	O
+host	B-COMP
+.	O
+
+Recent	O
+data	O
+indicate	O
+that	O
+vaccinating	O
+children	O
+also	O
+protects	O
+adults	O
+against	O
+CAP	B-DISO
+by	O
+generating	O
+significant	O
+herd	B-PROC
+immunity	I-PROC
+,	O
+and	O
+that	O
+the	O
+conjugated	O
+pneumococcal	O
+vaccine	O
+in	O
+adults	O
+may	O
+offer	O
+some	O
+efficacy	O
+in	O
+preventing	O
+CAP	B-DISO
+caused	O
+by	O
+vaccine	O
+serotypes	O
+.	O
+
+However	O
+,	O
+new	O
+evidence	O
+shows	O
+that	O
+(	O
+at	O
+least	O
+in	O
+Europe	O
+)	O
+pneumonia	B-DISO
+caused	O
+by	O
+MDRO	O
+remains	O
+uncommon	O
+even	O
+in	O
+HCAP	O
+category	O
+patients	O
+.	O
+
+TITLE	O
+:	O
+The	O
+caspase	B-PRGE
+inhibitor	I-PRGE
+zVAD	I-PRGE
+increases	O
+lung	B-DISO
+inflammation	I-DISO
+in	O
+pneumovirus	B-DISO
+infection	I-DISO
+in	O
+mice	B-SPEC
+.	O
+
+The	O
+aim	O
+of	O
+this	O
+study	O
+was	O
+to	O
+determine	O
+the	O
+effect	O
+of	O
+the	O
+broad	O
+caspase	B-PRGE
+inhibitor	B-CHED
+Z	B-PRGE
+-	I-PRGE
+VAD	I-PRGE
+(	I-PRGE
+OMe	I-PRGE
+)-	I-PRGE
+FMK	I-PRGE
+(	O
+zVAD	O
+)	O
+on	O
+inflammation	B-DISO
+and	O
+lung	B-ANAT
+injury	O
+in	O
+a	O
+mouse	B-SPEC
+pneumovirus	B-SPEC
+model	O
+for	O
+severe	O
+RSV	B-SPEC
+disease	O
+.	O
+
+TITLE	O
+:	O
+Analysis	O
+of	O
+protein	B-PROC
+expression	B-PROC
+changes	O
+of	O
+the	O
+Vero	O
+E6	O
+cells	B-COMP
+infected	O
+with	O
+classic	O
+PEDV	B-SPEC
+strain	O
+CV777	O
+by	O
+using	O
+quantitative	O
+proteomic	O
+technique	O
+.	O
+
+The	O
+identification	O
+of	O
+proteins	B-CHED
+associated	O
+with	O
+PEDV	B-SPEC
+infection	B-DISO
+might	O
+provide	O
+insight	O
+into	O
+PEDV	B-SPEC
+pathogenesis	B-DISO
+and	O
+facilitate	O
+the	O
+development	B-PROC
+of	O
+novel	O
+antiviral	B-CHED
+strategies	O
+.	O
+
+Among	O
+the	O
+disease	O
+-	O
+related	O
+functions	O
+,	O
+certain	O
+anti	O
+-	O
+viral	O
+pathways	B-PROC
+and	O
+proteins	B-CHED
+,	O
+such	O
+as	O
+the	O
+RIG	B-PRGE
+-	I-PRGE
+I	I-PRGE
+-	I-PRGE
+like	I-PRGE
+receptor	I-PRGE
+,	O
+Rap1	B-PRGE
+,	O
+autophagy	B-PROC
+,	O
+mitogen	B-PRGE
+-	I-PRGE
+activated	I-PRGE
+protein	B-CHED
+kinase	I-PRGE
+,	O
+PI3K	B-FUNC
+-	O
+Akt	B-PRGE
+and	O
+Jak	B-PROC
+-	O
+STAT	B-PRGE
+signaling	B-PROC
+pathways	B-PROC
+,	O
+and	O
+integrin	B-PRGE
+β2	I-PRGE
+/	O
+β3	O
+and	O
+cystatin	B-PRGE
+-	I-PRGE
+C	I-PRGE
+proteins	I-PRGE
+,	O
+represented	O
+potential	O
+factors	O
+in	O
+PEDV	B-SPEC
+infection	B-DISO
+.	O
+
+This	O
+syndrome	B-DISO
+has	O
+raised	O
+global	O
+public	O
+health	O
+concerns	O
+about	O
+the	O
+dissemination	O
+of	O
+an	O
+emerging	B-DISO
+infectious	I-DISO
+disease	I-DISO
+and	O
+highlights	O
+the	O
+need	O
+for	O
+a	O
+coordinated	O
+global	O
+response	O
+to	O
+contain	O
+such	O
+a	O
+disease	O
+threat	O
+.	O
+
+A	O
+newer	O
+form	O
+of	O
+ventilation	O
+called	O
+high	O
+frequency	O
+oscillatory	O
+ventilation	O
+has	O
+been	O
+shown	O
+in	O
+experimental	O
+studies	O
+to	O
+result	O
+in	O
+less	O
+lung	B-ANAT
+injury	O
+.	O
+
+Pulmonary	B-ANAT
+air	B-CHED
+leaks	O
+,	O
+defined	O
+as	O
+gross	O
+air	B-CHED
+leaks	O
+or	O
+pulmonary	B-DISO
+interstitial	B-ANAT
+emphysema	I-DISO
+,	O
+occurred	O
+more	O
+frequently	O
+in	O
+the	O
+HFOV	O
+group	O
+,	O
+whereas	O
+the	O
+risk	O
+of	O
+severe	O
+retinopathy	B-DISO
+of	I-DISO
+prematurity	I-DISO
+was	O
+significantly	O
+reduced	O
+.	O
+
+TITLE	O
+:	O
+Self	O
+-	O
+assembly	O
+of	O
+a	O
+nine	O
+-	O
+residue	O
+amyloid	B-DISO
+-	O
+forming	O
+peptide	B-CHED
+fragment	O
+of	O
+SARS	B-DISO
+corona	B-CHED
+virus	B-SPEC
+E	I-PRGE
+-	I-PRGE
+protein	B-CHED
+:	O
+mechanism	O
+of	O
+self	O
+aggregation	O
+and	O
+amyloid	B-DISO
+-	O
+inhibition	B-PROC
+of	O
+hIAPP	O
+.	O
+
+TITLE	O
+:	O
+Next	O
+generation	O
+sequencing	O
+technologies	O
+:	O
+tool	O
+to	O
+study	O
+avian	B-SPEC
+virus	B-SPEC
+diversity	O
+.	O
+
+Taken	O
+together	O
+,	O
+the	O
+accumulated	O
+genetic	O
+variations	O
+of	O
+the	O
+current	O
+field	O
+PEDV	B-SPEC
+strains	O
+might	O
+have	O
+led	O
+to	O
+antigenic	O
+changes	O
+of	O
+the	O
+viruses	B-SPEC
+,	O
+which	O
+might	O
+confer	O
+the	O
+less	O
+effectiveness	O
+or	O
+failure	O
+of	O
+the	O
+CV777	O
+-	O
+based	O
+vaccines	O
+currently	O
+being	O
+widely	O
+used	O
+in	O
+Jiangxi	O
+,	O
+China	O
+.	O
+
+The	O
+combined	O
+incidence	O
+of	O
+viral	O
+coinfections	B-DISO
+with	O
+other	O
+pathogens	O
+was	O
+12	O
+.	O
+4	O
+%	O
+(	O
+95	O
+%	O
+CI	O
+=	O
+9	O
+.	O
+7	O
+-	O
+15	O
+.	O
+0	O
+).	O
+
+TITLE	O
+:	O
+Effects	O
+of	O
+a	O
+recruitment	B-DISO
+maneuver	O
+on	O
+plasma	B-ANAT
+levels	O
+of	O
+soluble	O
+RAGE	O
+in	O
+patients	O
+with	O
+diffuse	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+:	O
+a	O
+prospective	O
+randomized	O
+crossover	O
+study	O
+.	O
+
+Protective	O
+ventilation	O
+was	O
+applied	O
+,	O
+and	O
+RM	O
+consisted	O
+of	O
+the	O
+application	O
+of	O
+40	O
+cmH2O	O
+airway	B-ANAT
+pressure	O
+for	O
+40	O
+s	O
+.	O
+Arterial	B-ANAT
+blood	I-ANAT
+was	O
+sampled	O
+for	O
+gas	O
+analyses	O
+and	O
+sRAGE	O
+measurements	O
+,	O
+5	O
+min	O
+pre	O
+-	O
+RM	O
+(	O
+or	O
+40	O
+-	O
+s	O
+-	O
+long	O
+sham	O
+period	O
+),	O
+5	O
+,	O
+30	O
+min	O
+,	O
+1	O
+,	O
+4	O
+,	O
+and	O
+6	O
+h	O
+after	O
+the	O
+RM	O
+(	O
+or	O
+40	O
+-	O
+s	O
+-	O
+long	O
+sham	O
+period	O
+).	O
+
+Mean	O
+PaO2	O
+/	O
+FiO2	O
+,	O
+tidal	O
+volume	O
+,	O
+PEEP	B-CHED
+,	O
+and	O
+plateau	O
+pressure	O
+were	O
+125	O
+mmHg	O
+,	O
+6	O
+.	O
+8	O
+ml	O
+/	O
+kg	O
+(	O
+ideal	O
+body	B-ANAT
+weight	O
+),	O
+and	O
+13	O
+and	O
+26	O
+cmH2O	O
+,	O
+respectively	O
+.	O
+
+Median	O
+baseline	O
+plasma	B-ANAT
+sRAGE	O
+levels	O
+were	O
+3	O
+,	O
+232	O
+pg	O
+/	O
+ml	O
+.	O
+
+RESULTS	O
+:	O
+Mean	O
+PaO2	O
+/	O
+FiO2	O
+,	O
+tidal	O
+volume	O
+,	O
+PEEP	B-CHED
+,	O
+and	O
+plateau	O
+pressure	O
+were	O
+125	O
+mmHg	O
+,	O
+6	O
+.	O
+8	O
+ml	O
+/	O
+kg	O
+(	O
+ideal	O
+body	B-ANAT
+weight	O
+),	O
+and	O
+13	O
+and	O
+26	O
+cmH2O	O
+,	O
+respectively	O
+.	O
+
+The	O
+idea	B-SPEC
+of	O
+Saudi	O
+CDC	O
+is	O
+attractive	O
+and	O
+even	O
+""""	O
+sexy	O
+""""	O
+
+This	O
+article	O
+proposes	O
+three	O
+initial	O
+,	O
+but	O
+essential	O
+,	O
+steps	O
+for	O
+such	O
+revitalization	O
+to	O
+take	O
+place	O
+:	O
+political	O
+will	O
+and	O
+support	O
+,	O
+integration	O
+of	O
+PHC	B-PRGE
+and	O
+PH	O
+,	O
+and	O
+on	O
+-	O
+job	O
+professional	O
+programs	O
+for	O
+the	O
+workforce	O
+.	O
+
+TITLE	O
+:	O
+A	O
+novel	O
+dromedary	B-SPEC
+camel	B-SPEC
+enterovirus	B-SPEC
+in	O
+the	O
+family	B-SPEC
+Picornaviridae	I-SPEC
+from	O
+dromedaries	B-SPEC
+in	O
+the	O
+Middle	O
+East	O
+.	O
+
+Whilst	O
+picornaviruses	B-SPEC
+are	O
+known	O
+to	O
+infect	O
+various	O
+animals	B-SPEC
+,	O
+their	O
+existence	O
+in	O
+dromedaries	B-SPEC
+was	O
+unknown	O
+.	O
+
+In	O
+the	O
+current	O
+study	O
+,	O
+we	O
+exploited	O
+atypical	O
+expression	B-PROC
+schemes	O
+to	O
+uncouple	O
+PLP1	B-PRGE
+from	O
+the	O
+processing	O
+of	O
+nsp1	B-PRGE
+and	O
+nsp2	B-PRGE
+in	O
+order	O
+to	O
+investigate	O
+the	O
+requirements	O
+of	O
+nsp3	B-PRGE
+domains	I-PRGE
+for	O
+viral	O
+RNA	B-PROC
+synthesis	I-PROC
+.	O
+
+In	O
+the	O
+second	O
+strategy	O
+,	O
+a	O
+picornavirus	B-SPEC
+autoprocessing	O
+element	O
+was	O
+used	O
+to	O
+separate	O
+a	O
+truncated	O
+nsp1	B-PRGE
+from	O
+nsp3	B-PRGE
+.	O
+
+ABSTRACT	O
+:	O
+To	O
+verify	O
+whether	O
+porcine	O
+deltacoronavirus	O
+infection	B-DISO
+induces	O
+disease	O
+,	O
+we	O
+inoculated	O
+gnotobiotic	O
+pigs	B-SPEC
+with	O
+2	O
+virus	B-SPEC
+strains	O
+(	O
+OH	O
+-	O
+FD22	O
+and	O
+OH	O
+-	O
+FD100	O
+)	O
+identified	O
+by	O
+2	O
+specific	O
+reverse	B-PROC
+transcription	I-PROC
+PCRs	O
+.	O
+
+ABSTRACT	O
+:	O
+Developing	O
+countries	O
+are	O
+at	O
+risk	O
+of	O
+importing	O
+Middle	O
+East	O
+Respiratory	O
+Syndrome	O
+Corona	B-CHED
+Virus	B-SPEC
+(	O
+MERS	O
+CoV	O
+)	O
+from	O
+the	O
+Middle	O
+East	O
+.	O
+
+In	O
+the	O
+current	O
+hot	B-DISO
+spots	I-DISO
+for	O
+MERS	O
+CoV	O
+a	O
+sizeable	O
+portion	O
+of	O
+the	O
+population	O
+is	O
+from	O
+other	O
+countries	O
+,	O
+but	O
+many	O
+of	O
+these	O
+countries	O
+have	O
+yet	O
+to	O
+detect	O
+any	O
+importation	O
+of	O
+MERS	O
+CoV	O
+.	O
+To	O
+assess	O
+the	O
+disease	B-DISO
+transmission	I-DISO
+in	O
+these	O
+countries	O
+,	O
+supplemental	O
+surveillance	O
+strategies	O
+are	O
+urgently	O
+needed	O
+beyond	O
+the	O
+currently	O
+recommended	O
+measures	O
+.	O
+
+Furthermore	O
+,	O
+TLR2	B-PRGE
+was	O
+involved	O
+in	O
+PEDV	B-SPEC
+N	O
+-	O
+induced	O
+NF	O
+-	O
+κB	O
+activation	O
+in	O
+IECs	O
+.	O
+
+ABSTRACT	O
+:	O
+Influenza	B-DISO
+H7N9	O
+and	O
+H1N1pdm	O
+can	O
+cause	O
+severe	O
+human	B-SPEC
+infections	B-DISO
+.	O
+
+After	O
+adjusting	O
+age	O
+and	O
+gender	O
+,	O
+no	O
+significant	O
+differences	O
+in	O
+chronic	O
+medical	O
+conditions	O
+or	O
+treatment	O
+were	O
+found	O
+between	O
+severely	O
+ill	B-DISO
+patients	O
+with	O
+H7N9	O
+and	O
+H1N1pdm	O
+.	O
+
+RESULTS	O
+:	O
+After	O
+adjusting	O
+age	O
+and	O
+gender	O
+,	O
+no	O
+significant	O
+differences	O
+in	O
+chronic	O
+medical	O
+conditions	O
+or	O
+treatment	O
+were	O
+found	O
+between	O
+severely	O
+ill	B-DISO
+patients	O
+with	O
+H7N9	O
+and	O
+H1N1pdm	O
+.	O
+
+An	O
+infectious	O
+aerosol	O
+is	O
+a	O
+collection	O
+of	O
+pathogen	O
+-	O
+laden	O
+particles	O
+in	O
+air	B-CHED
+.	O
+
+TITLE	O
+:	O
+Pathogenicity	O
+and	O
+pathogenesis	B-DISO
+of	O
+a	O
+United	O
+States	O
+porcine	B-SPEC
+deltacoronavirus	O
+cell	B-COMP
+culture	O
+isolate	O
+in	O
+5	O
+-	O
+day	O
+-	O
+old	O
+neonatal	O
+piglets	O
+.	O
+
+The	O
+pathogenicity	O
+and	O
+pathogenesis	B-DISO
+of	O
+PDCoV	O
+was	O
+investigated	O
+following	O
+orogastric	O
+inoculation	O
+of	O
+5	O
+-	O
+day	O
+-	O
+old	O
+piglets	O
+with	O
+a	O
+plaque	B-DISO
+-	O
+purified	O
+PDCoV	O
+cell	B-COMP
+culture	O
+isolate	O
+(	O
+3	O
+×	O
+10	O
+(	O
+4	O
+)	O
+TCID50	O
+per	O
+pig	B-SPEC
+).	O
+
+This	O
+review	O
+summarizes	O
+recent	O
+gains	O
+in	O
+our	O
+knowledge	O
+of	O
+how	O
+cytoplasmic	B-COMP
+RNA	O
+viruses	B-SPEC
+use	O
+these	O
+co	O
+-	O
+opted	O
+host	B-COMP
+nuclear	O
+factors	O
+in	O
+new	O
+functional	O
+roles	O
+supporting	O
+virus	B-SPEC
+translation	B-PROC
+and	O
+virus	B-SPEC
+RNA	B-PROC
+replication	I-PROC
+and	O
+common	O
+themes	O
+employed	O
+between	O
+different	O
+virus	O
+groups	O
+.	O
+
+Our	O
+model	O
+of	O
+risk	O
+stratification	O
+outperformed	O
+the	O
+stratification	O
+using	O
+baseline	O
+PaO₂	B-PRGE
+/	O
+FiO₂	O
+and	O
+non	O
+-	O
+standardised	O
+PaO₂	B-PRGE
+/	O
+FiO₂	O
+at	O
+24	O
+h	O
+,	O
+when	O
+analysed	O
+by	O
+the	O
+predictive	O
+receiver	O
+operating	O
+characteristic	O
+(	O
+ROC	O
+)	O
+curve	O
+:	O
+area	O
+under	O
+the	O
+ROC	O
+curve	O
+for	O
+stratification	O
+at	O
+baseline	O
+was	O
+0	O
+.	O
+583	O
+(	O
+95	O
+%	O
+CI	O
+0	O
+.	O
+525	O
+to	O
+0	O
+.	O
+636	O
+),	O
+0	O
+.	O
+605	O
+(	O
+95	O
+%	O
+CI	O
+0	O
+.	O
+552	O
+to	O
+0	O
+.	O
+658	O
+)	O
+at	O
+24	O
+h	O
+without	O
+SVS	O
+and	O
+0	O
+.	O
+693	O
+(	O
+95	O
+%	O
+CI	O
+0	O
+.	O
+645	O
+to	O
+0	O
+.	O
+742	O
+)	O
+at	O
+24	O
+h	O
+under	O
+SVS	O
+(	O
+p	O
+<	O
+0	O
+.	O
+000001	O
+).	O
+
+We	O
+genotyped	O
+the	O
+CCL2	B-PRGE
+G	I-PRGE
+-	I-PRGE
+2518A	I-PRGE
+and	O
+MBL	O
+codon	O
+54	O
+variant	O
+(	O
+A	O
+/	O
+B	O
+)	O
+in	O
+4	O
+case	O
+-	O
+control	O
+populations	O
+of	O
+Chinese	O
+descent	O
+,	O
+totally	O
+consisting	O
+of	O
+932	O
+patients	O
+with	O
+SARS	B-DISO
+and	O
+982	O
+control	O
+subjects	O
+.	O
+
+RESULTS	O
+:	O
+Both	O
+the	O
+high	O
+-	O
+CCL2	B-PRGE
+-	O
+producing	O
+GG	O
+genotype	O
+and	O
+the	O
+low	O
+-	O
+MBL	O
+-	O
+producing	O
+B	B-PRGE
+allele	I-PRGE
+were	O
+consistently	O
+associated	O
+with	O
+increased	O
+risks	O
+of	O
+SARS	B-DISO
+-	I-DISO
+CoV	I-DISO
+infection	I-DISO
+in	O
+all	O
+4	O
+case	O
+-	O
+control	O
+populations	O
+(	O
+joint	B-ANAT
+P	O
+=	O
+1	O
+.	O
+6	O
+×	O
+10	O
+(-	O
+4	O
+)	O
+and	O
+4	O
+.	O
+9	O
+×	O
+10	O
+(-	O
+8	O
+),	O
+for	O
+CCL2	B-PRGE
+and	O
+MBL	B-PRGE
+respectively	O
+),	O
+with	O
+no	O
+interaction	O
+between	O
+polymorphisms	B-PROC
+could	O
+be	O
+detected	O
+.	O
+
+The	O
+patient	O
+sustained	O
+anterior	O
+subluxation	O
+at	O
+cervical	B-ANAT
+spine	I-ANAT
+levels	O
+C5	O
+-	O
+C6	O
+and	O
+severe	O
+spinal	B-ANAT
+canal	I-ANAT
+compromise	O
+with	O
+cord	B-DISO
+compression	I-DISO
+and	O
+edema	B-DISO
+from	O
+C5	O
+to	O
+C7	O
+,	O
+resulting	O
+in	O
+quadriplegia	B-DISO
+.	O
+
+The	O
+patient	O
+developed	O
+aspiration	B-DISO
+pneumonia	I-DISO
+for	O
+which	O
+he	O
+was	O
+given	O
+vancomycin	B-CHED
+and	O
+piperacillin	B-CHED
+-	O
+tazobactam	O
+.	O
+
+The	O
+multi	B-PRGE
+-	I-PRGE
+epitope	I-PRGE
+antigen	B-CHED
+SE	I-PRGE
+protein	B-CHED
+was	O
+designed	O
+by	O
+arranging	O
+three	O
+S	O
+gene	O
+fragments	O
+(	O
+166	O
+-	O
+247	O
+aa	O
+,	O
+S1	B-PRGE
+gene	I-PRGE
+;	O
+501	O
+-	O
+515	O
+aa	O
+,	O
+S1	B-PRGE
+gene	I-PRGE
+;	O
+8	O
+-	O
+30	O
+aa	O
+,	O
+S2	B-PRGE
+gene	I-PRGE
+)	O
+in	O
+tandem	O
+.	O
+
+It	O
+was	O
+identified	O
+to	O
+be	O
+approximately	O
+32	O
+kDa	O
+as	O
+a	O
+His	O
+-	O
+tagged	O
+fusion	O
+protein	B-CHED
+and	O
+can	O
+bind	B-FUNC
+IBV	B-SPEC
+positive	O
+serum	B-COMP
+by	O
+western	O
+blot	O
+analysis	O
+.	O
+
+ABSTRACT	O
+:	O
+Objective	O
+Fibre	B-ANAT
+-	O
+optic	B-ANAT
+bronchoscopy	O
+with	O
+bronchoalveolar	O
+lavage	O
+(	O
+FOB	O
+-	O
+BAL	B-ENZY
+)	O
+is	O
+an	O
+important	O
+tool	O
+for	O
+diagnosing	O
+and	O
+selecting	O
+treatment	O
+for	O
+acutely	O
+hypoxaemic	O
+patients	O
+with	O
+diffuse	O
+lung	B-ANAT
+infiltrates	B-DISO
+.	O
+
+However	O
+,	O
+FOB	B-PRGE
+-	I-PRGE
+BAL	I-PRGE
+carries	O
+a	O
+risk	O
+of	O
+significant	O
+hypoxaemia	O
+and	O
+subsequent	O
+tracheal	O
+intubation	O
+during	O
+and	O
+after	O
+the	O
+procedure	O
+.	O
+
+Data	O
+regarding	O
+the	O
+recovered	O
+volume	O
+of	O
+BAL	B-ENZY
+fluid	O
+,	O
+incidence	O
+of	O
+tracheal	O
+intubation	O
+within	O
+eight	O
+hours	O
+after	O
+the	O
+completion	O
+of	O
+FOB	B-PRGE
+-	I-PRGE
+BAL	I-PRGE
+,	O
+respiratory	O
+and	O
+haemodynamic	O
+parameters	O
+and	O
+treatment	O
+modifications	O
+were	O
+collected	O
+for	O
+the	O
+evaluation	O
+.	O
+
+Host	B-COMP
+cell	I-COMP
+components	O
+prime	O
+these	O
+viral	O
+surface	O
+glycoproteins	B-CHED
+to	O
+catalyze	O
+membrane	B-PROC
+fusion	I-PROC
+at	O
+specific	O
+times	O
+and	O
+places	O
+during	O
+virus	B-SPEC
+cell	B-COMP
+entry	O
+.	O
+
+This	O
+research	O
+focuses	O
+on	O
+coronavirus	B-SPEC
+and	O
+influenza	B-SPEC
+A	I-SPEC
+virus	I-SPEC
+cell	B-COMP
+entry	O
+and	O
+identifies	O
+TEMs	O
+as	O
+sites	O
+of	O
+viral	O
+proteolysis	B-PROC
+,	O
+thereby	O
+defining	O
+subcellular	O
+locations	O
+of	O
+virus	B-SPEC
+priming	O
+with	O
+greater	O
+precision	O
+.	O
+
+TITLE	O
+:	O
+Porcine	B-SPEC
+epidemic	I-SPEC
+diarrhea	I-SPEC
+virus	B-DISO
+infection	I-DISO
+:	O
+Etiology	O
+,	O
+epidemiology	O
+,	O
+pathogenesis	B-DISO
+and	O
+immunoprophylaxis	O
+.	O
+
+PEDV	B-SPEC
+infections	B-DISO
+cause	O
+acute	O
+,	O
+severe	O
+atrophic	B-DISO
+enteritis	B-DISO
+accompanied	O
+by	O
+viremia	B-DISO
+that	O
+leads	O
+to	O
+profound	O
+diarrhea	B-DISO
+and	I-DISO
+vomiting	I-DISO
+,	O
+followed	O
+by	O
+extensive	O
+dehydration	B-DISO
+,	O
+which	O
+is	O
+the	O
+major	O
+cause	O
+of	O
+death	B-PROC
+in	O
+nursing	B-PROC
+piglets	O
+.	O
+
+The	O
+risk	O
+of	O
+skidding	O
+and	O
+epidemiological	O
+complications	O
+conditionally	O
+designated	O
+as	O
+high	O
+,	O
+moderate	O
+and	O
+minimal	O
+risk	O
+importation	O
+of	O
+measles	B-SPEC
+virus	I-SPEC
+-	O
+Rate	O
+was	O
+considered	O
+as	O
+high	O
+.	O
+
+The	O
+E	O
+and	O
+3b	O
+protein	B-CHED
+products	O
+play	O
+key	O
+roles	O
+in	O
+coronavirus	B-SPEC
+virulence	B-PROC
+,	O
+and	O
+RNA	B-PROC
+folding	I-PROC
+demonstrated	O
+that	O
+the	O
+mutations	O
+in	O
+the	O
+5	O
+'	O
+UTR	O
+did	O
+not	O
+alter	O
+the	O
+predicted	O
+secondary	O
+structure	O
+.	O
+
+Template	O
+-	O
+based	O
+protein	B-CHED
+structure	O
+modelling	O
+produced	O
+the	O
+first	O
+theoretical	O
+model	O
+of	O
+the	O
+IBV	B-SPEC
+spike	O
+monomer	O
+.	O
+
+TITLE	O
+:	O
+Serotype	O
+shift	O
+of	O
+a	O
+793	O
+/	O
+B	O
+genotype	O
+infectious	B-DISO
+bronchitis	B-DISO
+coronavirus	B-SPEC
+by	O
+natural	O
+recombination	B-PROC
+.	O
+
+Whereas	O
+,	O
+vaccination	O
+of	O
+specific	O
+pathogen	O
+-	O
+free	O
+chickens	B-SPEC
+with	O
+the	O
+4	O
+/	O
+91	O
+vaccine	O
+provided	O
+better	O
+protection	O
+against	O
+challenge	O
+with	O
+ck	O
+/	O
+CH	O
+/	O
+LHLJ	O
+/	O
+140906	O
+than	O
+did	O
+vaccination	O
+with	O
+the	O
+H120	O
+strain	O
+according	O
+to	O
+the	O
+result	O
+of	O
+virus	B-SPEC
+re	O
+-	O
+isolation	O
+.	O
+
+At	O
+PIDs	O
+1	O
+-	O
+5	O
+,	O
+PEDV	B-SPEC
+-	O
+infected	O
+pigs	B-SPEC
+exhibited	O
+mildly	O
+to	O
+extensively	O
+disorganized	O
+,	O
+irregular	O
+distribution	O
+and	O
+reduced	O
+expression	B-PROC
+of	O
+ZO	B-PRGE
+-	I-PRGE
+1	I-PRGE
+or	O
+E	B-PRGE
+-	I-PRGE
+Cadherin	I-PRGE
+in	O
+villous	O
+,	O
+but	O
+not	O
+crypt	B-ANAT
+epithelial	B-ANAT
+cells	I-ANAT
+of	O
+the	O
+jejunum	B-ANAT
+and	O
+ileum	B-ANAT
+,	O
+but	O
+not	O
+in	O
+the	O
+large	B-ANAT
+intestine	I-ANAT
+,	O
+when	O
+compared	O
+to	O
+the	O
+negative	O
+controls	O
+.	O
+
+Our	O
+results	O
+suggest	O
+a	O
+possible	O
+involvement	O
+of	O
+structurally	O
+impaired	B-DISO
+TJ	O
+and	O
+AJ	O
+in	O
+the	O
+pathogenesis	B-DISO
+of	O
+PEDV	B-SPEC
+,	O
+potentially	O
+leading	O
+to	O
+secondary	O
+bacterial	B-DISO
+infections	I-DISO
+.	O
+
+ABSTRACT	O
+:	O
+The	O
+management	O
+of	O
+respiratory	O
+virus	B-SPEC
+infections	B-DISO
+prior	O
+to	O
+hematopoietic	B-ANAT
+cell	I-ANAT
+transplant	B-ANAT
+(	O
+HCT	O
+)	O
+is	O
+difficult	O
+.	O
+
+Of	O
+458	O
+patients	O
+,	O
+116	O
+(	O
+25	O
+%)	O
+had	O
+respiratory	O
+viruses	B-SPEC
+detected	O
+pre	O
+-	O
+HCT	O
+.	O
+
+TITLE	O
+:	O
+An	O
+isolated	O
+outbreak	O
+of	O
+influenza	B-PATH
+A	I-PATH
+H1N1	O
+in	O
+a	O
+haematological	O
+department	O
+during	O
+post	O
+-	O
+pandemic	O
+period	O
+.	O
+
+Here	O
+we	O
+report	O
+the	O
+fulminant	O
+course	O
+of	O
+influenza	B-DISO
+AH1N1	O
+infection	B-DISO
+in	O
+the	O
+postpandemic	O
+period	O
+in	O
+a	O
+group	O
+of	O
+patients	O
+in	O
+a	O
+single	O
+hematology	O
+department	O
+.	O
+
+RESULTS	O
+:	O
+Fourteen	O
+patients	O
+with	O
+hematological	B-DISO
+disorders	I-DISO
+unexpectedly	O
+developed	O
+acute	B-DISO
+respiratory	I-DISO
+failure	I-DISO
+ARDS	B-DISO
+(	O
+Acute	B-DISO
+Respiratory	I-DISO
+Distress	I-DISO
+Syndrome	I-DISO
+).	O
+
+Three	O
+doses	O
+of	O
+simvastatin	B-CHED
+(	O
+20	O
+mg	O
+/	O
+kg	O
+)	O
+or	O
+saline	O
+were	O
+injected	O
+intraperitoneally	O
+on	O
+days	O
+-	O
+2	O
+,	O
+-	O
+1	O
+and	O
+0	O
+of	O
+the	O
+experiment	O
+.	O
+
+Ventilation	O
+with	O
+high	O
+tidal	O
+volume	O
+(	O
+HVt	O
+)	O
+resulted	O
+in	O
+significantly	O
+increased	O
+lung	B-ANAT
+elastance	O
+by	O
+3	O
+-	O
+fold	O
+and	O
+decreased	B-DISO
+lung	I-DISO
+compliance	I-DISO
+by	O
+45	O
+%	O
+compared	O
+to	O
+low	O
+tidal	O
+volume	O
+(	O
+LVt	O
+)	O
+but	O
+simvastatin	B-CHED
+abrogated	O
+lung	B-ANAT
+mechanical	O
+alterations	O
+of	O
+HVt	O
+.	O
+
+High	O
+-	O
+dose	O
+simvastatin	B-CHED
+prevents	O
+experimental	O
+hyperinflation	B-DISO
+lung	I-DISO
+injury	O
+by	O
+angioprotective	O
+and	O
+anti	O
+-	O
+inflammatory	O
+effects	O
+.	O
+
+Wet	O
+mount	O
+microscopy	O
+from	O
+respiratory	B-ANAT
+samples	I-ANAT
+showed	O
+broad	O
+-	O
+based	O
+yeast	B-SPEC
+consistent	O
+with	O
+B	B-SPEC
+.	I-SPEC
+dermatitidis	I-SPEC
+.	O
+
+In	O
+addition	O
+to	O
+early	O
+appropriate	O
+antimicrobial	B-CHED
+therapy	O
+,	O
+transfer	O
+to	O
+an	O
+institution	O
+experienced	O
+with	O
+ECMO	O
+should	O
+be	O
+considered	O
+when	O
+caring	O
+for	O
+patients	O
+from	O
+endemic	O
+areas	O
+with	O
+rapidly	O
+progressive	O
+respiratory	B-DISO
+failure	I-DISO
+.	O
+
+ABSTRACT	O
+:	O
+Sepsis	B-DISO
+is	O
+a	O
+common	O
+disease	O
+seen	O
+in	O
+critically	O
+ill	O
+patients	O
+.	O
+
+ABSTRACT	O
+:	O
+The	O
+envelopes	O
+of	O
+coronaviruses	O
+(	O
+CoVs	O
+)	O
+contain	O
+primarily	O
+three	O
+proteins	O
+;	O
+the	O
+two	O
+major	O
+glycoproteins	B-CHED
+spike	O
+(	O
+S	O
+)	O
+and	O
+membrane	B-COMP
+(	O
+M	O
+),	O
+and	O
+envelope	B-COMP
+(	O
+E	O
+),	O
+a	O
+non	O
+-	O
+glycosylated	O
+protein	B-CHED
+.	O
+
+Unlike	O
+other	O
+enveloped	O
+viruses	B-SPEC
+,	O
+CoVs	O
+bud	B-ANAT
+and	O
+assemble	O
+at	O
+the	O
+endoplasmic	B-COMP
+reticulum	I-COMP
+(	O
+ER	O
+)-	O
+Golgi	B-COMP
+intermediate	O
+compartment	B-ANAT
+(	O
+ERGIC	B-COMP
+).	O
+
+TITLE	O
+:	O
+Mutations	O
+in	O
+coronavirus	B-SPEC
+nonstructural	O
+protein	B-CHED
+10	O
+decrease	O
+virus	B-PROC
+replication	I-PROC
+fidelity	O
+.	O
+
+R80A	O
+/	O
+E82A	O
+-	O
+ExoN	O
+(+)	O
+reached	O
+a	O
+peak	O
+titer	O
+similar	O
+to	O
+and	O
+demonstrated	O
+RNA	B-PROC
+synthesis	I-PROC
+kinetics	O
+comparable	O
+to	O
+those	O
+seen	O
+with	O
+WT	O
+-	O
+ExoN	O
+(+).	O
+
+Proteins	B-CHED
+,	O
+such	O
+as	O
+HIV	B-SPEC
+-	I-SPEC
+1	I-SPEC
+trans	O
+-	O
+activator	O
+of	O
+transcription	B-PROC
+(	O
+TAT	B-ENZY
+)	O
+and	O
+Antennapedia	B-PRGE
+homeodomain	I-PRGE
+protein	I-PRGE
+,	O
+are	O
+capable	O
+of	O
+crossing	O
+cellular	B-COMP
+membranes	B-ANAT
+.	O
+
+Being	O
+able	O
+to	O
+incorporate	O
+the	O
+key	O
+features	O
+of	O
+these	O
+proteins	B-CHED
+that	O
+enable	O
+cell	B-COMP
+entry	O
+into	O
+simpler	O
+scaffolds	O
+opens	O
+up	O
+a	O
+wide	O
+range	O
+of	O
+opportunities	O
+for	O
+the	O
+development	B-PROC
+of	O
+new	O
+delivery	O
+reagents	B-CHED
+with	O
+improved	O
+performance	O
+.	O
+
+These	O
+scaffolds	O
+deviate	O
+from	O
+the	O
+normal	O
+peptide	B-CHED
+backbone	B-ANAT
+,	O
+allowing	O
+for	O
+simpler	O
+,	O
+synthetic	O
+procedures	O
+to	O
+make	O
+carriers	O
+and	O
+tune	O
+chemical	O
+compositions	O
+for	O
+application	O
+specific	O
+needs	O
+.	O
+
+Successful	O
+design	O
+of	O
+polymeric	O
+protein	B-CHED
+mimics	O
+would	O
+allow	O
+researchers	O
+to	O
+further	O
+understand	O
+the	O
+key	O
+features	O
+in	O
+proteins	B-CHED
+and	O
+peptides	B-CHED
+necessary	O
+for	O
+efficient	O
+delivery	O
+and	O
+to	O
+design	O
+the	O
+next	O
+generation	O
+of	O
+more	O
+efficient	O
+delivery	O
+reagents	B-CHED
+.	O
+
+ABSTRACT	O
+:	O
+Transpulmonary	O
+bubble	O
+transit	O
+(	O
+TPBT	O
+)	O
+detected	O
+with	O
+contrast	O
+echocardiography	O
+is	O
+reported	O
+as	O
+a	O
+sign	O
+of	O
+intrapulmonary	O
+shunt	O
+during	O
+cirrhosis	B-DISO
+or	O
+exercise	O
+in	O
+healthy	O
+humans	B-SPEC
+.	O
+
+Patients	O
+with	O
+moderate	O
+-	O
+to	O
+-	O
+large	O
+TPBT	O
+had	O
+higher	O
+values	O
+of	O
+cardiac	B-ANAT
+index	O
+and	O
+heart	B-ANAT
+rate	O
+as	O
+compared	O
+to	O
+those	O
+without	O
+TPBT	O
+.	O
+
+Moderate	O
+-	O
+to	O
+-	O
+large	O
+TPBT	O
+was	O
+detected	O
+with	O
+contrast	O
+echocardiography	O
+in	O
+26	O
+%	O
+of	O
+patients	O
+with	O
+ARDS	B-DISO
+.	O
+
+Postoperatively	O
+,	O
+pneumonia	B-DISO
+,	I-DISO
+ventilator	I-DISO
+-	I-DISO
+associated	I-DISO
+pneumonia	B-DISO
+,	O
+renal	B-ANAT
+replacement	O
+therapy	O
+,	O
+hemotherapy	O
+,	O
+and	O
+cardiac	B-DISO
+arrhythmia	I-DISO
+were	O
+associated	O
+with	O
+the	O
+appearance	O
+of	O
+some	O
+degree	O
+of	O
+transient	O
+dysfunction	O
+of	O
+gas	B-ENZY
+exchange	O
+,	O
+which	O
+was	O
+a	O
+risk	O
+factor	O
+for	O
+reintubation	O
+,	O
+pneumonia	B-DISO
+,	I-DISO
+ventilator	I-DISO
+-	I-DISO
+associated	I-DISO
+pneumonia	B-DISO
+,	O
+and	O
+renal	B-ANAT
+replacement	O
+therapy	O
+in	O
+the	O
+postoperative	O
+period	O
+of	O
+cardiac	B-ANAT
+surgery	O
+and	O
+cardiac	B-ANAT
+procedures	O
+.	O
+
+TITLE	O
+:	O
+Characterizing	O
+the	O
+transmission	O
+potential	O
+of	O
+zoonotic	O
+infections	B-DISO
+from	O
+minor	O
+outbreaks	O
+.	O
+
+ABSTRACT	O
+:	O
+The	O
+transmission	O
+potential	O
+of	O
+a	O
+novel	O
+infection	O
+depends	O
+on	O
+both	O
+the	O
+inherent	O
+transmissibility	O
+of	O
+a	O
+pathogen	O
+,	O
+and	O
+the	O
+level	O
+of	O
+susceptibility	O
+in	O
+the	O
+host	B-COMP
+population	O
+.	O
+
+Extracorporeal	O
+membrane	B-COMP
+oxygenation	B-PROC
+may	O
+be	O
+a	O
+useful	O
+tool	O
+in	O
+non	O
+-	O
+operative	O
+management	O
+of	O
+tracheal	O
+injury	O
+in	O
+the	O
+setting	O
+of	O
+severe	O
+respiratory	B-DISO
+failure	I-DISO
+and	O
+need	O
+for	O
+prolonged	O
+intubation	O
+.	O
+
+The	O
+venovenous	O
+extracorporeal	O
+membrane	B-COMP
+oxygenation	B-PROC
+and	O
+ventilator	O
+management	O
+were	O
+essential	O
+for	O
+this	O
+patient	O
+'	O
+s	O
+recovery	O
+.	O
+
+TITLE	O
+:	O
+Characteristics	O
+and	O
+Outcomes	O
+of	O
+Middle	O
+East	O
+Respiratory	O
+Syndrome	B-DISO
+Coronavirus	B-SPEC
+Patients	O
+Admitted	O
+to	O
+an	O
+Intensive	O
+Care	O
+Unit	O
+in	O
+Jeddah	O
+,	O
+Saudi	O
+Arabia	O
+.	O
+
+RESULTS	O
+:	O
+Eight	O
+patients	O
+were	O
+admitted	O
+to	O
+the	O
+ICU	O
+with	O
+MERS	O
+-	O
+CoV	O
+infection	B-DISO
+.	O
+
+European	O
+Union	O
+,	O
+German	O
+Centre	O
+for	O
+Infection	B-DISO
+Research	O
+,	O
+Federal	O
+Ministry	O
+of	O
+Education	O
+and	O
+Research	O
+,	O
+German	O
+Research	O
+Council	O
+,	O
+and	O
+Ministry	O
+of	O
+Health	O
+of	O
+Saudi	O
+Arabia	O
+.	O
+
+Along	O
+with	O
+progress	O
+in	O
+MERS	O
+animal	B-SPEC
+model	O
+development	B-PROC
+,	O
+these	O
+obstacles	O
+can	O
+be	O
+circumvented	O
+or	O
+at	O
+least	O
+mitigated	O
+.	O
+
+We	O
+observed	O
+delay	O
+in	O
+diagnostic	O
+and	O
+therapeutic	O
+procedures	O
+in	O
+patients	O
+with	O
+clinical	O
+signs	O
+for	O
+the	O
+presence	O
+of	O
+severe	O
+respiratory	B-DISO
+disorders	I-DISO
+.	O
+
+IgM	B-COMP
+antibody	B-PROC
+was	O
+positive	O
+in	O
+all	O
+the	O
+17	O
+cases	O
+,	O
+which	O
+included	O
+9	O
+male	O
+cases	O
+,	O
+8	O
+female	O
+cases	O
+,	O
+and	O
+their	O
+age	O
+was	O
+from	O
+2	O
+months	O
+to	O
+10	O
+years	O
+.	O
+
+All	O
+the	O
+17	O
+patients	O
+received	O
+mechanical	O
+ventilation	O
+because	O
+of	O
+severe	O
+respiratory	B-DISO
+distress	I-DISO
+within	O
+1	O
+week	O
+of	O
+onset	O
+,	O
+of	O
+which	O
+14	O
+cases	O
+were	O
+complicated	O
+with	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+(	O
+acute	O
+ARDS	B-DISO
+),	O
+6	O
+cases	O
+of	O
+tension	B-DISO
+pneumothorax	I-DISO
+,	O
+3	O
+cases	O
+were	O
+complicated	O
+with	O
+bronchitis	B-DISO
+,	O
+laryngeal	B-DISO
+obstruction	I-DISO
+III	O
+degrees	O
+,	O
+and	O
+totally	O
+7	O
+cases	O
+died	B-PROC
+.	O
+
+Fourteen	O
+cases	O
+failed	O
+to	O
+inoculate	O
+measles	B-PATH
+vaccine	O
+.	O
+
+The	O
+aim	O
+of	O
+this	O
+study	O
+was	O
+to	O
+determine	O
+the	O
+plasma	B-ANAT
+level	O
+of	O
+soluble	O
+receptors	O
+for	O
+advanced	O
+glycation	O
+end	O
+-	O
+products	O
+(	O
+sRAGE	O
+)	O
+and	O
+aquaporin	B-PRGE
+5	I-PRGE
+(	O
+AQP5	B-PRGE
+)	O
+in	O
+preterm	O
+infants	O
+with	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+(	O
+RDS	O
+).	O
+
+All	O
+34	O
+Scrub	B-DISO
+typhus	I-DISO
+patients	O
+without	O
+ARDS	B-DISO
+recovered	O
+completely	O
+.	O
+
+Scrub	B-DISO
+typhus	I-DISO
+is	O
+an	O
+important	O
+differential	O
+diagnosis	O
+in	O
+a	O
+patients	O
+having	O
+fever	B-PROC
+with	O
+thrombocytopenia	O
+.	O
+
+Among	O
+24	O
+Scrub	B-DISO
+typhus	I-DISO
+patients	O
+with	O
+ARDS	B-DISO
+,	O
+22	O
+patients	O
+recovered	O
+,	O
+and	O
+2	O
+patients	O
+died	B-PROC
+.	O
+
+TITLE	O
+:	O
+Respiratory	O
+paralysis	O
+in	O
+a	O
+child	O
+:	O
+The	O
+severe	O
+axonal	O
+variant	O
+of	O
+childhood	O
+Guillain	O
+-	O
+Barré	O
+syndrome	B-DISO
+.	O
+
+Diagnosis	O
+relies	O
+solely	O
+on	O
+accurate	O
+neurophysiologic	O
+testing	O
+and	O
+is	O
+important	O
+because	O
+the	O
+available	O
+treatment	O
+options	O
+for	O
+GBS	B-DISO
+are	O
+frequently	O
+ineffective	O
+in	O
+these	O
+variants	O
+.	O
+
+ABSTRACT	O
+:	O
+GATA	O
+-	O
+2	O
+transcription	O
+factor	O
+deficiency	O
+has	O
+recently	O
+been	O
+described	O
+in	O
+patients	O
+with	O
+a	O
+propensity	O
+towards	O
+myeloid	B-DISO
+malignancy	I-DISO
+associated	O
+with	O
+other	O
+highly	O
+variable	O
+phenotypic	O
+features	O
+:	O
+chronic	O
+leukocytopenias	B-DISO
+(	O
+dendritic	B-ANAT
+cell	B-COMP
+-,	O
+monocyto	O
+-,	O
+granulocyto	O
+-,	O
+lymphocytopenia	B-DISO
+),	O
+increased	O
+susceptibility	O
+to	O
+infections	B-DISO
+,	O
+lymphatic	B-ANAT
+vasculature	B-ANAT
+abnormalities	O
+,	O
+and	O
+sensorineural	B-DISO
+deafness	I-DISO
+.	O
+
+At	O
+the	O
+time	O
+of	O
+the	O
+initial	O
+presentation	O
+to	O
+the	O
+hospital	O
+,	O
+serological	O
+signs	O
+of	O
+acute	B-DISO
+infection	I-DISO
+with	O
+Epstein	B-SPEC
+-	I-SPEC
+Barr	I-SPEC
+virus	I-SPEC
+(	O
+EBV	B-SPEC
+)	O
+were	O
+present	O
+;	O
+EBV	B-DISO
+viremia	I-DISO
+with	O
+atypical	O
+serological	O
+response	O
+persisted	O
+during	O
+two	O
+-	O
+year	O
+follow	O
+up	O
+.	O
+
+Diagnosis	O
+was	O
+confirmed	O
+by	O
+detection	O
+of	O
+the	O
+previously	O
+published	O
+heterozygous	O
+mutation	B-PRGE
+in	I-PRGE
+GATA2	I-PRGE
+(	O
+c	O
+.	O
+1081	O
+C	O
+>	O
+T	O
+,	O
+p	O
+.	O
+
+The	O
+brother	O
+had	O
+no	O
+clinically	O
+relevant	O
+ailments	O
+despite	O
+leukocyte	B-ANAT
+changes	O
+similar	O
+to	O
+the	O
+index	O
+patient	O
+.	O
+
+While	O
+assays	O
+detecting	O
+nucleic	B-CHED
+acids	I-CHED
+were	O
+implemented	O
+quickly	O
+,	O
+assays	O
+to	O
+detect	O
+anti	O
+-	O
+PDCoV	O
+antibodies	B-COMP
+have	O
+not	O
+been	O
+available	O
+.	O
+
+In	O
+addition	O
+,	O
+anti	B-PRGE
+-	I-PRGE
+PDCoV	I-PRGE
+IgG	I-PRGE
+antibodies	I-PRGE
+were	O
+detected	O
+in	O
+archived	O
+samples	O
+collected	O
+in	O
+2010	O
+,	O
+perhaps	O
+indicating	O
+an	O
+earlier	O
+undetected	O
+introduction	O
+into	O
+the	O
+U	O
+.	O
+S	O
+.	O
+pig	B-SPEC
+population	O
+.	O
+
+Overall	O
+,	O
+the	O
+obtained	O
+data	O
+suggest	O
+that	O
+PDCoV	O
+seroprevalence	O
+in	O
+U	O
+.	O
+S	O
+.	O
+pigs	B-SPEC
+is	O
+lower	O
+compared	O
+to	O
+PEDV	B-SPEC
+and	O
+PDCoV	O
+may	O
+have	O
+been	O
+introduced	O
+to	O
+the	O
+U	O
+.	O
+S	O
+.	O
+prior	O
+to	O
+PEDV	B-SPEC
+.	O
+
+The	O
+aim	O
+of	O
+this	O
+review	O
+was	O
+to	O
+present	O
+the	O
+clinical	O
+evidence	O
+supporting	O
+the	O
+use	O
+of	O
+RMs	O
+in	O
+patients	O
+with	O
+ARDS	B-DISO
+and	O
+during	O
+general	B-PROC
+anesthesia	I-PROC
+and	O
+as	O
+well	O
+their	O
+potential	O
+biological	O
+effects	O
+in	O
+experimental	O
+models	O
+of	O
+acute	O
+lung	B-ANAT
+injury	O
+.	O
+
+Lung	B-ANAT
+injury	O
+was	O
+mild	O
+in	O
+mice	B-SPEC
+with	O
+isolated	O
+HS	O
+or	O
+OA	O
+injection	O
+.	O
+
+RESULTS	O
+:	O
+The	O
+posttraumatic	O
+lung	B-ANAT
+injury	O
+group	O
+demonstrated	O
+significantly	O
+higher	O
+IL	B-FUNC
+-	I-FUNC
+6	I-FUNC
+levels	O
+when	O
+compared	O
+with	O
+HS	O
+group	O
+(	O
+744	O
+.	O
+8	O
+±	O
+104	O
+versus	O
+297	O
+.	O
+7	O
+±	O
+134	O
+pg	O
+/	O
+mL	O
+;	O
+P	O
+=	O
+0	O
+.	O
+004	O
+).	O
+
+Thirty	O
+seven	O
+alphacoronaviruses	O
+,	O
+nine	O
+lineage	O
+D	O
+betacoronaviruses	O
+,	O
+and	O
+one	O
+lineage	O
+B	O
+betacoronavirus	B-SPEC
+(	O
+SARS	B-DISO
+-	O
+CoV	O
+related	O
+)	O
+were	O
+identified	O
+.	O
+
+Despite	O
+elevated	O
+systolic	O
+pulmonary	B-ANAT
+artery	I-ANAT
+pressure	O
+(	O
+sPAP	O
+),	O
+patients	O
+with	O
+isolated	O
+PFO	B-CHED
+had	O
+a	O
+normal	O
+RV	O
+systolic	O
+function	O
+.	O
+
+RESULTS	O
+:	O
+ACP	B-DISO
+was	O
+present	O
+in	O
+36	O
+patients	O
+,	O
+PFO	B-CHED
+in	O
+21	O
+patients	O
+,	O
+both	O
+PFO	B-CHED
+and	O
+ACP	B-DISO
+in	O
+8	O
+patients	O
+and	O
+the	O
+130	O
+remaining	O
+patients	O
+had	O
+neither	O
+PFO	B-CHED
+nor	O
+ACP	B-DISO
+.	O
+
+TITLE	O
+:	O
+Development	B-PROC
+of	O
+a	O
+nanoparticle	B-CHED
+-	O
+assisted	O
+PCR	O
+assay	O
+for	O
+detection	O
+of	O
+porcine	B-SPEC
+epidemic	B-DISO
+diarrhea	I-DISO
+virus	I-SPEC
+.	O
+
+This	O
+is	O
+the	O
+first	O
+report	O
+to	O
+demonstrate	O
+the	O
+application	O
+of	O
+a	O
+nanoPCR	O
+assay	O
+for	O
+the	O
+detection	O
+of	O
+PEDV	B-SPEC
+.	O
+
+The	O
+aim	O
+of	O
+this	O
+study	O
+was	O
+to	O
+investigate	O
+the	O
+Th17	O
+/	O
+Treg	O
+pattern	O
+and	O
+its	O
+impact	O
+on	O
+disease	O
+severity	O
+and	O
+outcomes	O
+in	O
+patients	O
+with	O
+ARDS	B-DISO
+.	O
+
+ABSTRACT	O
+:	O
+While	O
+it	O
+is	O
+known	O
+that	O
+acute	O
+respiratory	O
+illness	O
+(	O
+ARI	B-CHED
+)	O
+is	O
+caused	O
+by	O
+an	O
+array	O
+of	O
+viruses	B-SPEC
+,	O
+less	O
+is	O
+known	O
+about	O
+co	O
+-	O
+detections	O
+and	O
+the	O
+resultant	O
+comparative	O
+symptoms	O
+and	O
+illness	O
+burden	O
+.	O
+
+Among	O
+outpatients	O
+with	O
+ARI	B-CHED
+,	O
+69	O
+%	O
+of	O
+visits	O
+were	O
+associated	O
+with	O
+a	O
+viral	O
+etiology	O
+.	O
+
+Co	O
+-	O
+detections	O
+of	O
+specific	O
+clusters	B-CHED
+of	O
+viruses	B-SPEC
+were	O
+observed	O
+in	O
+9	O
+%	O
+of	O
+ARI	B-CHED
+cases	O
+particularly	O
+in	O
+children	O
+,	O
+were	O
+less	O
+frequent	O
+in	O
+households	O
+without	O
+children	O
+,	O
+and	O
+were	O
+less	O
+symptomatic	O
+(	O
+e	O
+.	O
+g	O
+.,	O
+lower	O
+fever	B-PROC
+)	O
+than	O
+single	O
+infections	B-DISO
+.	O
+
+ABSTRACT	O
+:	O
+We	O
+studied	O
+the	O
+value	O
+of	O
+routine	O
+biochemical	O
+variables	O
+albumin	B-PRGE
+,	O
+C	B-PRGE
+-	I-PRGE
+reactive	I-PRGE
+protein	I-PRGE
+(	O
+CRP	B-PRGE
+)	O
+and	O
+lactate	B-PRGE
+dehydrogenase	I-PRGE
+(	O
+LDH	B-PRGE
+)	O
+to	O
+improve	O
+prediction	O
+and	O
+monitoring	O
+of	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+(	O
+ARDS	B-DISO
+)	O
+severity	O
+in	O
+the	O
+intensive	O
+care	O
+unit	O
+.	O
+
+Low	O
+baseline	O
+albumin	B-PRGE
+levels	O
+were	O
+moderately	O
+associated	O
+with	O
+maximum	O
+Berlin	O
+and	O
+LIS	B-FUNC
+categories	O
+within	O
+7	O
+days	O
+;	O
+an	O
+elevated	O
+CRP	B-PRGE
+level	O
+was	O
+moderately	O
+associated	O
+with	O
+maximum	O
+Berlin	O
+categories	O
+only	O
+.	O
+
+LDH	B-PRGE
+levels	O
+predicted	O
+28	O
+-	O
+day	O
+mortality	O
+.	O
+
+Certain	O
+Malagasy	O
+bats	B-SPEC
+can	O
+be	O
+frequently	O
+found	O
+in	O
+close	O
+contact	O
+with	O
+humans	B-SPEC
+and	O
+frugivorous	O
+bats	B-SPEC
+feed	O
+in	O
+the	O
+same	O
+trees	O
+where	O
+people	O
+collect	O
+and	O
+consume	O
+fruits	O
+and	O
+are	O
+hunted	O
+and	O
+consumed	O
+as	O
+bush	O
+meat	O
+.	O
+
+Frugivorous	O
+bats	B-SPEC
+belonging	O
+to	O
+three	O
+species	B-SPEC
+were	O
+captured	O
+in	O
+four	O
+different	O
+regions	O
+of	O
+Madagascar	O
+.	O
+
+We	O
+analyzed	O
+fecal	B-ANAT
+and	O
+throat	B-ANAT
+swabs	O
+to	O
+detect	O
+the	O
+presence	O
+of	O
+virus	B-SPEC
+through	O
+amplification	B-DISO
+of	O
+the	O
+RNA	B-PRGE
+-	I-PRGE
+dependent	I-PRGE
+RNA	I-PRGE
+polymerase	I-PRGE
+(	O
+RdRp	B-FUNC
+)	O
+gene	O
+,	O
+which	O
+is	O
+highly	O
+conserved	O
+in	O
+all	O
+known	O
+coronaviruses	O
+.	O
+
+Our	O
+findings	O
+suggest	O
+that	O
+CoVs	O
+circulate	O
+in	O
+frugivorous	O
+bats	B-SPEC
+of	O
+Madagascar	O
+,	O
+demonstrating	O
+the	O
+needs	O
+to	O
+evaluate	O
+spillover	O
+risk	O
+to	O
+human	B-SPEC
+populations	O
+especially	O
+for	O
+individuals	O
+that	O
+hunt	O
+and	O
+consume	O
+infected	O
+bats	B-SPEC
+.	O
+
+RESULTS	O
+:	O
+From	O
+351	O
+frugivorous	O
+bats	B-SPEC
+,	O
+we	O
+detected	O
+14	O
+coronaviruses	O
+from	O
+two	O
+endemic	O
+bats	B-SPEC
+species	B-SPEC
+,	O
+of	O
+which	O
+13	O
+viruses	B-SPEC
+were	O
+identified	O
+from	O
+Pteropus	B-SPEC
+rufus	I-SPEC
+and	O
+one	O
+from	O
+Eidolon	B-SPEC
+dupreanum	O
+,	O
+giving	O
+an	O
+overall	O
+prevalence	O
+of	O
+4	O
+.	O
+5	O
+%.	O
+
+ABSTRACT	O
+:	O
+Feline	B-DISO
+infectious	I-DISO
+peritonitis	I-DISO
+is	O
+a	O
+fatal	O
+disease	O
+of	O
+cats	B-SPEC
+caused	O
+by	O
+infection	B-DISO
+with	O
+feline	B-SPEC
+coronavirus	B-SPEC
+(	O
+FCoV	O
+).	O
+
+RESULTS	O
+:	O
+To	O
+develop	O
+an	O
+RT	O
+-	O
+PCR	O
+method	O
+for	O
+detection	O
+and	O
+genotyping	O
+of	O
+FCoV	O
+,	O
+we	O
+performed	O
+comparative	O
+genome	O
+analysis	O
+using	O
+WGSs	O
+of	O
+32	O
+FCoV	O
+,	O
+7	O
+CCoV	O
+and	O
+5	O
+TGEV	B-SPEC
+strains	O
+obtained	O
+from	O
+NCBI	O
+.	O
+
+As	O
+the	O
+PCR	O
+target	O
+,	O
+we	O
+focused	O
+on	O
+the	O
+nsp14	O
+coding	O
+region	O
+,	O
+which	O
+is	O
+highly	O
+conserved	O
+and	O
+phylogenetically	O
+informative	O
+,	O
+and	O
+developed	O
+a	O
+PCR	O
+method	O
+targeting	B-PROC
+nsp14	O
+partial	O
+sequences	O
+.	O
+
+PCV2	O
+and	O
+HEV	B-SPEC
+are	O
+both	O
+highly	O
+prevalent	O
+in	O
+pig	B-SPEC
+farms	O
+in	O
+China	O
+.	O
+
+Immunohistochemical	O
+staining	O
+showed	O
+HEV	B-SPEC
+-	O
+and	O
+PCV2	B-PRGE
+-	I-PRGE
+antigen	I-PRGE
+-	O
+positive	O
+signals	O
+in	O
+the	O
+livers	B-ANAT
+,	O
+kidneys	B-ANAT
+,	O
+lungs	B-ANAT
+,	O
+lymph	B-ANAT
+nodes	I-ANAT
+,	O
+and	O
+intestine	B-ANAT
+.	O
+
+Currently	O
+,	O
+there	O
+is	O
+no	O
+effective	O
+pharmacological	O
+treatment	O
+for	O
+acute	O
+lung	B-ANAT
+injury	O
+.	O
+
+These	O
+results	O
+suggest	O
+that	O
+the	O
+novel	O
+curcumin	B-CHED
+analog	O
+c26	O
+has	O
+remarkable	O
+protective	O
+effects	O
+on	O
+LPS	B-DISO
+-	O
+induced	O
+ALI	O
+in	O
+rat	B-SPEC
+.	O
+
+Sixty	O
+-	O
+nine	O
+patients	O
+were	O
+identified	O
+(	O
+80	O
+%	O
+male	O
+;	O
+age	O
+,	O
+35	O
+y	O
+[	O
+range	O
+,	O
+24	O
+-	O
+49	O
+];	O
+ISS	B-DISO
+27	O
+[	O
+9	O
+-	O
+59	O
+]).	O
+
+Patients	O
+with	O
+head	B-ANAT
+injuries	O
+had	O
+a	O
+lower	O
+incidence	O
+of	O
+hypoxemia	O
+from	O
+pneumonia	B-DISO
+.	O
+
+A	O
+therapeutic	O
+drug	O
+that	O
+is	O
+effective	O
+against	O
+FIP	B-DISO
+has	O
+not	O
+yet	O
+been	O
+developed	O
+.	O
+
+In	O
+the	O
+present	O
+study	O
+,	O
+we	O
+synthesized	O
+30	O
+overlapping	O
+peptides	B-CHED
+based	O
+on	O
+the	O
+amino	B-CHED
+acid	I-CHED
+sequence	O
+of	O
+the	O
+S1	B-PRGE
+domain	I-PRGE
+of	O
+the	O
+type	O
+I	O
+FIPV	O
+strain	O
+KU	O
+-	O
+2	O
+S	O
+protein	B-CHED
+,	O
+and	O
+investigated	O
+their	O
+inhibitory	O
+effects	O
+on	O
+FIPV	O
+infection	B-DISO
+.	O
+
+The	O
+efficiency	O
+of	O
+type	O
+I	O
+FIPV	O
+infection	B-DISO
+was	O
+increased	O
+by	O
+diluting	O
+the	O
+virus	B-SPEC
+with	O
+medium	O
+containing	O
+a	O
+polycation	B-CHED
+.	O
+
+The	O
+mortality	O
+rate	O
+in	O
+patients	O
+with	O
+renal	B-DISO
+failure	I-DISO
+(	O
+14	O
+),	O
+including	O
+8	O
+on	O
+haemodialysis	O
+,	O
+was	O
+100	O
+%.	O
+
+ABSTRACT	O
+:	O
+This	O
+study	O
+was	O
+conducted	O
+to	O
+investigate	O
+the	O
+impacts	O
+of	O
+deoxynivalenol	O
+(	O
+DON	O
+)	O
+feeding	O
+either	O
+alone	O
+or	O
+in	O
+combination	O
+with	O
+a	O
+microbial	O
+feed	O
+additive	O
+(	O
+MFA	O
+)	O
+on	O
+the	O
+immune	B-PROC
+response	I-PROC
+to	O
+a	O
+viral	O
+vaccine	O
+and	O
+serum	B-COMP
+clinical	O
+chemical	O
+parameters	O
+.	O
+
+The	O
+development	B-PROC
+of	O
+a	O
+novel	O
+vaccine	O
+based	O
+on	O
+the	O
+Taiwan	O
+or	O
+the	O
+global	O
+non	O
+-	O
+S	O
+INDEL	B-PROC
+strains	O
+may	O
+be	O
+contributive	O
+to	O
+the	O
+control	O
+of	O
+the	O
+current	O
+global	O
+porcine	B-SPEC
+epidemic	B-DISO
+diarrhoea	I-DISO
+outbreaks	O
+.	O
+
+This	O
+is	O
+the	O
+first	O
+reported	O
+case	O
+of	O
+acquired	O
+factor	B-DISO
+V	I-DISO
+deficiency	I-DISO
+in	O
+a	O
+patient	O
+receiving	O
+extracorporeal	O
+membrane	B-COMP
+oxygenation	B-PROC
+for	O
+Legionella	B-DISO
+pneumonia	I-DISO
+.	O
+
+ABSTRACT	O
+:	O
+The	O
+Middle	O
+Eastern	O
+Respiratory	O
+Syndrome	O
+Coronavirus	B-SPEC
+is	O
+a	O
+serious	O
+and	O
+emerging	O
+issue	O
+in	O
+Saudi	O
+Arabia	O
+and	O
+the	O
+world	O
+.	O
+
+Approval	O
+was	O
+sought	O
+and	O
+received	O
+by	O
+the	O
+Ethics	O
+Committee	O
+for	O
+the	O
+College	O
+of	O
+Nursing	B-PROC
+.	O
+
+Nursing	B-PROC
+colleges	O
+must	O
+respond	O
+thoroughly	O
+to	O
+protect	O
+students	O
+and	O
+staff	O
+and	O
+prevent	O
+spread	O
+of	O
+disease	O
+into	O
+the	O
+university	O
+community	O
+in	O
+the	O
+midst	O
+of	O
+an	O
+epidemic	O
+.	O
+
+Through	O
+yeast	B-SPEC
+two	O
+-	O
+hybrid	O
+screening	O
+,	O
+we	O
+identified	O
+eight	B-PRGE
+potential	I-PRGE
+cellular	I-PRGE
+P6	I-PRGE
+-	I-PRGE
+interacting	I-PRGE
+proteins	B-CHED
+from	O
+a	O
+human	B-SPEC
+spleen	B-ANAT
+cDNA	O
+library	O
+.	O
+
+This	O
+study	O
+revealed	O
+a	O
+new	O
+mechanism	O
+of	O
+SARS	B-PRGE
+-	I-PRGE
+CoV	I-PRGE
+P6	I-PRGE
+in	O
+limiting	O
+the	O
+IFN	B-PRGE
+signaling	B-PROC
+to	O
+promote	O
+SARS	B-DISO
+-	O
+CoV	O
+survival	O
+in	O
+host	O
+cells	B-COMP
+.	O
+
+To	O
+test	O
+this	O
+hypothesis	O
+the	O
+IBV	B-SPEC
+-	O
+specific	B-PROC
+immune	I-PROC
+response	I-PROC
+and	O
+immune	O
+protection	O
+were	O
+measured	O
+in	O
+chicks	O
+vaccinated	O
+at	O
+different	O
+ages	O
+.	O
+
+In	O
+addition	O
+,	O
+IgG	B-PRGE
+antibodies	I-PRGE
+from	O
+the	O
+1	O
+-	O
+day	O
+-	O
+old	O
+group	O
+had	O
+lower	O
+avidity	O
+indices	O
+than	O
+day	O
+28	O
+vaccinated	O
+birds	O
+.	O
+
+TITLE	O
+:	O
+Acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+associated	O
+with	O
+tumor	B-DISO
+lysis	I-DISO
+syndrome	I-DISO
+in	O
+a	O
+child	O
+with	O
+acute	B-DISO
+lymphoblastic	I-DISO
+leukemia	I-DISO
+.	O
+
+The	O
+presence	O
+of	O
+coronavirus	B-SPEC
+in	O
+the	O
+left	B-ANAT
+eye	I-ANAT
+was	O
+confirmed	O
+by	O
+positive	O
+immunohistochemistry	O
+.	O
+
+Systemic	O
+coronavirus	B-SPEC
+disease	O
+in	O
+ferrets	B-SPEC
+closely	O
+resembles	O
+feline	B-DISO
+infectious	I-DISO
+peritonitis	I-DISO
+(	O
+FIP	B-DISO
+)	O
+in	O
+domestic	B-SPEC
+cats	I-SPEC
+,	O
+which	O
+can	O
+manifest	O
+with	O
+anterior	B-DISO
+uveitis	I-DISO
+,	O
+chorioretinitis	B-DISO
+,	O
+optic	B-DISO
+neuritis	I-DISO
+,	O
+and	O
+retinal	B-DISO
+detachment	I-DISO
+.	O
+
+ABSTRACT	O
+:	O
+Rapid	O
+and	O
+reliable	O
+laboratory	O
+diagnosis	O
+of	O
+persons	O
+suspected	O
+of	O
+Middle	O
+East	O
+respiratory	O
+syndrome	B-DISO
+coronavirus	B-SPEC
+(	O
+MERS	O
+-	O
+CoV	O
+)	O
+infection	B-DISO
+is	O
+important	O
+for	O
+timely	O
+implementation	O
+of	O
+infection	B-DISO
+control	O
+practices	O
+and	O
+disease	O
+management	O
+.	O
+
+In	O
+addition	O
+,	O
+monitoring	O
+molecular	O
+changes	O
+in	O
+the	O
+virus	B-SPEC
+can	O
+help	O
+elucidate	O
+chains	O
+of	O
+transmission	O
+and	O
+identify	O
+mutations	O
+that	O
+might	O
+influence	O
+virus	B-SPEC
+transmission	O
+efficiency	O
+.	O
+
+Therefore	O
+,	O
+this	O
+study	O
+assesses	O
+the	O
+association	O
+between	O
+maturation	B-PROC
+and	O
+aging	B-PROC
+and	O
+pulmonary	B-ANAT
+responses	O
+to	O
+injury	O
+in	O
+animal	B-SPEC
+models	O
+of	O
+lung	B-ANAT
+injury	O
+.	O
+
+Increasing	O
+age	O
+seems	O
+to	O
+be	O
+correlated	O
+with	O
+exaggerated	O
+pulmonary	B-ANAT
+responses	O
+to	O
+injury	O
+,	O
+ultimately	O
+leading	O
+to	O
+more	O
+severe	O
+lung	B-ANAT
+injury	O
+.	O
+
+In	O
+addition	O
+,	O
+results	O
+indicate	O
+the	O
+existence	O
+of	O
+age	O
+-	O
+dependent	O
+changes	O
+in	O
+key	O
+components	O
+of	O
+the	O
+intracellular	B-COMP
+signaling	B-PROC
+pathways	B-PROC
+involved	O
+in	O
+the	O
+inflammatory	B-DISO
+response	I-DISO
+.	O
+
+TITLE	O
+:	O
+Comparison	O
+of	O
+Coagulation	B-PROC
+Parameters	O
+,	O
+Anticoagulation	B-PROC
+,	O
+and	O
+Need	O
+for	O
+Transfusion	O
+in	O
+Patients	O
+on	O
+Interventional	O
+Lung	O
+Assist	O
+or	O
+Veno	O
+-	O
+Venous	B-ANAT
+Extracorporeal	O
+Membrane	B-COMP
+Oxygenation	B-PROC
+.	O
+
+ABSTRACT	O
+:	O
+Cost	O
+-	O
+effective	O
+interventions	O
+are	O
+needed	O
+to	O
+control	O
+the	O
+transmission	O
+of	O
+viral	O
+respiratory	B-DISO
+tract	I-DISO
+infections	I-DISO
+(	O
+RTIs	O
+)	O
+in	O
+mass	O
+gatherings	O
+.	O
+
+The	O
+Acute	O
+Physiology	O
+and	O
+Chronic	O
+Health	O
+Evaluation	O
+(	O
+APACHE	O
+)	O
+II	O
+,	O
+APACHE	O
+III	O
+,	O
+Multiple	O
+Organ	B-ANAT
+Dysfunction	O
+Score	O
+(	O
+MODS	B-DISO
+),	O
+Simplified	O
+Acute	O
+Physiology	O
+Score	O
+II	O
+(	O
+SAPS	O
+II	O
+),	O
+and	O
+Sepsis	B-DISO
+-	O
+related	O
+Organ	B-DISO
+Failure	I-DISO
+Assessment	O
+(	O
+SOFA	O
+)	O
+scores	O
+were	O
+calculated	O
+for	O
+patients	O
+.	O
+
+The	O
+value	O
+of	O
+exacerbation	O
+frequency	O
+for	O
+predicting	O
+the	O
+outcome	O
+of	O
+COPD	B-DISO
+was	O
+excellent	O
+(	O
+AUC	O
+:	O
+0	O
+.	O
+892	O
+),	O
+with	O
+a	O
+sensitivity	O
+of	O
+0	O
+.	O
+851	O
+and	O
+a	O
+specificity	O
+of	O
+0	O
+.	O
+797	O
+.	O
+
+ABSTRACT	O
+:	O
+Prone	O
+positioning	O
+for	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+(	O
+ARDS	B-DISO
+)	O
+has	O
+no	O
+impact	O
+on	O
+mortality	O
+despite	O
+significant	O
+improvements	O
+in	O
+oxygenation	B-PROC
+.	O
+
+However	O
+,	O
+further	O
+additional	O
+randomized	O
+controlled	O
+design	O
+to	O
+study	O
+are	O
+required	O
+for	O
+confirm	O
+benefit	O
+of	O
+prone	O
+position	O
+in	O
+ARDS	B-DISO
+.	O
+
+Prone	O
+positioning	O
+was	O
+not	O
+associated	O
+with	O
+an	O
+increased	O
+incidence	O
+of	O
+cardiac	B-DISO
+events	I-DISO
+(	O
+RR	O
+1	O
+.	O
+01	O
+,	O
+95	O
+%	O
+CI	O
+,	O
+0	O
+.	O
+87	O
+-	O
+1	O
+.	O
+17	O
+)	O
+or	O
+ventilator	B-DISO
+associated	I-DISO
+pneumonia	I-DISO
+(	O
+RR	O
+0	O
+.	O
+88	O
+,	O
+95	O
+%	O
+CI	O
+,	O
+0	O
+.	O
+71	O
+-	O
+1	O
+.	O
+09	O
+),	O
+but	O
+it	O
+was	O
+associated	O
+with	O
+an	O
+increased	O
+incidence	O
+of	O
+pressure	B-DISO
+sores	I-DISO
+(	O
+RR	O
+1	O
+.	O
+23	O
+,	O
+95	O
+%	O
+CI	O
+,	O
+1	O
+.	O
+07	O
+-	O
+1	O
+.	O
+41	O
+)	O
+and	O
+endotracheal	O
+dislocation	O
+(	O
+RR	O
+1	O
+.	O
+33	O
+,	O
+95	O
+%	O
+CI	O
+,	O
+1	O
+.	O
+02	O
+-	O
+1	O
+.	O
+74	O
+).	O
+
+Nursing	B-PROC
+research	O
+has	O
+increased	O
+understanding	O
+of	O
+the	O
+implications	O
+of	O
+infectious	B-DISO
+diseases	I-DISO
+in	O
+hospitals	O
+.	O
+
+Brain	B-ANAT
+magnetic	O
+resonant	O
+imaging	O
+(	O
+MRI	O
+)	O
+revealed	O
+a	O
+strikingly	O
+selective	O
+white	B-ANAT
+matter	I-ANAT
+injury	O
+early	O
+in	O
+the	O
+course	O
+of	O
+the	O
+disease	O
+.	O
+
+TITLE	O
+:	O
+A	O
+small	O
+region	O
+of	O
+porcine	B-PRGE
+hemagglutinating	I-PRGE
+encephalomyelitis	B-DISO
+virus	B-SPEC
+spike	I-PRGE
+protein	B-CHED
+interacts	O
+with	O
+the	O
+neural	O
+cell	O
+adhesion	O
+molecule	O
+.	O
+
+This	O
+fragment	O
+may	O
+be	O
+the	O
+receptor	O
+-	O
+binding	B-FUNC
+domain	O
+that	O
+mediates	O
+PHEV	O
+binding	B-FUNC
+to	O
+NCAM	O
+.	O
+
+The	O
+aim	O
+of	O
+this	O
+study	O
+was	O
+to	O
+investigate	O
+the	O
+prevalence	O
+of	O
+human	B-SPEC
+coronavirus	I-SPEC
+(	O
+HCoV	O
+)-	O
+NL63	O
+,	O
+human	B-SPEC
+metapneumovirus	I-SPEC
+(	O
+hMPV	B-SPEC
+),	O
+human	B-SPEC
+bocavirus	I-SPEC
+(	O
+Boca	B-DISO
+),	O
+human	B-SPEC
+polyomavirus	B-SPEC
+KI	O
+(	O
+KIV	O
+)	O
+and	O
+human	B-SPEC
+polyomavirus	B-SPEC
+WU	O
+(	O
+WUV	O
+)	O
+in	O
+respiratory	B-DISO
+tract	I-DISO
+infections	I-DISO
+(	O
+RTI	B-DISO
+)	O
+in	O
+Kuwait	O
+.	O
+
+TITLE	O
+:	O
+Human	B-SPEC
+Coronavirus	I-SPEC
+HKU1	I-SPEC
+Spike	I-PRGE
+Protein	B-CHED
+Uses	O
+O	B-CHED
+-	I-CHED
+Acetylated	I-CHED
+Sialic	I-CHED
+Acid	I-CHED
+as	O
+an	O
+Attachment	O
+Receptor	O
+Determinant	O
+and	O
+Employs	O
+Hemagglutinin	O
+-	O
+Esterase	O
+Protein	B-CHED
+as	O
+a	O
+Receptor	O
+-	O
+Destroying	O
+Enzyme	O
+.	O
+
+We	O
+established	O
+a	O
+miniaturized	O
+luciferase	B-ENZY
+gene	O
+reporter	O
+assay	O
+in	O
+A549	O
+cells	B-COMP
+that	O
+measures	O
+IFN	B-PRGE
+-	I-PRGE
+β	I-PRGE
+induction	O
+by	O
+viral	O
+dsRNA	B-CHED
+and	O
+is	O
+dose	O
+-	O
+dependently	O
+inhibited	O
+by	O
+VP35	O
+expression	B-PROC
+.	O
+
+When	O
+compared	O
+to	O
+influenza	B-PRGE
+A	I-PRGE
+virus	I-PRGE
+NS1	B-DISO
+protein	B-CHED
+,	O
+EBOV	O
+VP35	O
+showed	O
+improved	O
+inhibition	B-PROC
+of	O
+viral	O
+dsRNA	B-CHED
+-	O
+based	O
+IFN	B-PRGE
+-	I-PRGE
+β	I-PRGE
+induction	O
+.	O
+
+A	O
+high	O
+quality	O
+homology	O
+model	O
+of	O
+the	O
+OC43	O
+3CL	O
+(	O
+pro	B-PRGE
+)	O
+was	O
+successfully	O
+generated	O
+in	O
+an	O
+active	O
+conformation	O
+.	O
+
+CONCLUSIONS	O
+:	O
+The	O
+lead	O
+compound	O
+16R	O
+may	O
+represent	O
+a	O
+broad	O
+-	O
+spectrum	O
+inhibitor	B-CHED
+of	O
+the	O
+3CL	O
+(	O
+pro	B-CHED
+)	O
+of	O
+OC43	O
+and	O
+potentially	O
+other	O
+coronaviruses	O
+.	O
+
+For	O
+pathology	B-DISO
+and	O
+immunofluorescence	O
+staining	O
+for	O
+Ki67	O
+(	O
+marker	O
+for	O
+crypt	B-ANAT
+proliferation	B-DISO
+)	O
+and	O
+LGR5	B-PRGE
+(	O
+marker	O
+for	O
+crypt	B-ANAT
+stem	B-ANAT
+cell	I-ANAT
+),	O
+3	O
+-	O
+4	O
+pigs	B-SPEC
+were	O
+euthanized	O
+at	O
+postinoculation	O
+days	O
+(	O
+PIDs	O
+)	O
+1	O
+,	O
+3	O
+and	O
+5	O
+.	O
+
+In	O
+contrast	O
+,	O
+weaned	B-PROC
+pigs	B-SPEC
+did	O
+not	O
+show	O
+evidence	O
+of	O
+PEDV	B-SPEC
+infection	B-DISO
+at	O
+PID	B-DISO
+1	O
+.	O
+
+Pigs	B-SPEC
+exhibited	O
+high	O
+fecal	B-ANAT
+shedding	O
+titers	O
+at	O
+PIDs	O
+2	O
+-	O
+5	O
+and	O
+mild	O
+to	O
+severe	O
+atrophic	B-DISO
+enteritis	B-DISO
+at	O
+PIDs	O
+3	O
+-	O
+5	O
+,	O
+indicating	O
+a	O
+longer	O
+incubation	O
+for	O
+PEDV	B-SPEC
+infection	B-DISO
+.	O
+
+ABSTRACT	O
+:	O
+Clinical	O
+disease	O
+associated	O
+with	O
+porcine	B-SPEC
+epidemic	I-SPEC
+diarrhea	I-SPEC
+virus	I-SPEC
+(	O
+PEDV	B-SPEC
+)	O
+infection	B-DISO
+in	O
+naïve	O
+pigs	B-SPEC
+is	O
+well	O
+chronicled	O
+;	O
+however	O
+,	O
+information	O
+on	O
+endemic	O
+PEDV	B-SPEC
+infection	B-DISO
+is	O
+limited	O
+.	O
+
+All	O
+PG	O
+/	O
+C	O
+pigs	B-SPEC
+were	O
+PEDV	B-SPEC
+PCR	O
+-	O
+negative	O
+post	O
+-	O
+challenge	O
+.	O
+
+After	O
+virus	B-SPEC
+inoculation	O
+,	O
+neither	O
+clinical	O
+signs	O
+nor	O
+evident	O
+gross	O
+lesions	O
+were	O
+observed	O
+.	O
+
+ABSTRACT	O
+:	O
+This	O
+study	O
+was	O
+conducted	O
+to	O
+evaluate	O
+the	O
+effects	O
+of	O
+open	O
+endotracheal	O
+suctioning	O
+on	O
+gas	B-ENZY
+exchange	O
+and	O
+respiratory	B-PROC
+mechanics	I-PROC
+in	O
+ARF	B-DISO
+patients	O
+under	O
+the	O
+modes	O
+of	O
+PCV	B-CHED
+or	O
+VCV	O
+.	O
+
+Furthermore	O
+,	O
+the	O
+initial	O
+respiratory	B-ANAT
+system	I-ANAT
+compliance	O
+(	O
+C	O
+rs	O
+)	O
+decreased	O
+by	O
+29	O
+.	O
+6	O
+%	O
+and	O
+28	O
+.	O
+5	O
+%	O
+at	O
+1	O
+min	O
+and	O
+10	O
+min	O
+,	O
+respectively	O
+.	O
+
+Summarily	O
+,	O
+endotracheal	O
+suctioning	O
+may	O
+impair	O
+gas	O
+exchange	O
+and	O
+decrease	O
+lung	B-PROC
+compliance	I-PROC
+in	O
+ARF	B-DISO
+patients	O
+receiving	O
+mechanical	O
+ventilation	O
+under	O
+both	O
+PCV	B-CHED
+and	O
+VCV	O
+modes	O
+,	O
+but	O
+endotracheal	O
+suctioning	O
+effects	O
+on	O
+gas	B-ENZY
+exchange	O
+were	O
+more	O
+severe	O
+and	O
+longer	O
+-	O
+lasting	O
+under	O
+PCV	B-CHED
+mode	O
+than	O
+VCV	O
+.	O
+
+Recent	O
+advances	O
+in	O
+recombinant	O
+DNA	O
+technology	O
+have	O
+resulted	O
+in	O
+experimental	O
+IB	O
+vaccines	O
+that	O
+show	O
+promise	O
+in	O
+antibody	B-FUNC
+and	O
+T	B-ANAT
+-	I-ANAT
+cells	I-ANAT
+responses	O
+,	O
+comparable	O
+to	O
+live	O
+attenuated	O
+vaccines	O
+.	O
+
+One	O
+group	O
+of	O
+C57BL	O
+/	O
+6J	O
+mice	B-SPEC
+received	O
+LPS	B-DISO
+via	O
+intratracheal	O
+injection	O
+(	O
+n	O
+=	O
+6	O
+),	O
+and	O
+another	O
+received	O
+sterile	B-DISO
+water	B-CHED
+(	O
+n	O
+=	O
+7	O
+).	O
+
+In	O
+concordance	O
+with	O
+the	O
+16s	B-CHED
+-	O
+tag	B-DISO
+data	O
+,	O
+Stenotrohomonas	O
+maltophilia	O
+(	O
+Xanthomonadaceae	B-SPEC
+)	O
+and	O
+Ochrobactrum	B-SPEC
+anthropi	I-SPEC
+(	O
+Brucellaceae	B-SPEC
+)	O
+were	O
+isolated	O
+from	O
+lungs	B-ANAT
+of	O
+mice	B-SPEC
+from	O
+both	O
+groups	O
+.	O
+
+ABSTRACT	O
+:	O
+Although	O
+bacteria	O
+are	O
+the	O
+main	O
+pathogens	O
+involved	O
+in	O
+community	O
+-	O
+acquired	O
+pneumonia	B-DISO
+,	O
+a	O
+significant	O
+number	O
+of	O
+community	O
+-	O
+acquired	O
+pneumonia	B-DISO
+are	O
+caused	O
+by	O
+viruses	B-SPEC
+,	O
+either	O
+directly	O
+or	O
+as	O
+part	O
+of	O
+a	O
+co	B-DISO
+-	I-DISO
+infection	I-DISO
+.	O
+
+Neuraminidase	B-PROC
+inhibitors	I-PROC
+for	O
+viral	B-DISO
+pneumonia	I-DISO
+have	O
+been	O
+shown	O
+to	O
+reduce	O
+transmission	O
+in	O
+cases	O
+of	O
+exposure	O
+and	O
+to	O
+improve	O
+the	O
+clinical	O
+progress	O
+of	O
+patients	O
+in	O
+intensive	O
+care	O
+;	O
+their	O
+use	O
+in	O
+common	O
+infections	B-DISO
+is	O
+not	O
+recommended	O
+.	O
+
+ABSTRACT	O
+:	O
+High	O
+frequency	O
+oscillatory	O
+ventilation	O
+(	O
+HFOV	O
+)	O
+is	O
+theoretically	O
+ideal	O
+for	O
+lung	O
+protective	O
+strategy	O
+ventilation	O
+(	O
+LPSV	O
+)	O
+in	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+(	O
+ARDS	B-DISO
+).	O
+
+The	O
+presence	O
+of	O
+hemodynamic	B-DISO
+instability	I-DISO
+was	O
+not	O
+different	O
+in	O
+both	O
+groups	O
+.	O
+
+RESULTS	O
+:	O
+Between	O
+June	O
+2010	O
+and	O
+February	O
+2014	O
+,	O
+49	O
+patients	O
+with	O
+moderate	O
+to	O
+severe	O
+ARDS	B-DISO
+were	O
+included	O
+.	O
+
+TITLE	O
+:	O
+International	O
+Health	O
+Regulations	O
+(	O
+2005	O
+)	O
+facilitate	O
+communication	O
+for	O
+in	O
+-	O
+flight	B-PROC
+contacts	O
+of	O
+a	O
+Middle	O
+East	O
+respiratory	O
+syndrome	O
+case	O
+,	O
+Hong	O
+Kong	O
+Special	O
+Administrative	O
+Region	O
+,	O
+2014	O
+.	O
+
+As	O
+an	O
+alternative	O
+,	O
+fluid	O
+resuscitation	O
+with	O
+hypertonic	O
+saline	O
+((	O
+HS	O
+)	O
+NaCl	B-CHED
+7	O
+.	O
+5	O
+%)	O
+has	O
+been	O
+described	O
+as	O
+a	O
+promising	O
+therapeutical	O
+agent	O
+in	O
+sepsis	B-DISO
+-	O
+induced	O
+ARDS	B-DISO
+by	O
+the	O
+diminished	O
+amount	O
+of	O
+fluid	O
+necessary	O
+.	O
+
+As	O
+molecular	O
+testing	O
+can	O
+be	O
+limited	O
+by	O
+a	O
+short	O
+time	O
+window	O
+in	O
+which	O
+the	O
+virus	B-SPEC
+is	O
+present	O
+,	O
+serological	O
+testing	O
+provides	O
+information	O
+about	O
+past	O
+infections	B-DISO
+and	O
+virus	B-SPEC
+spread	O
+in	O
+populations	O
+after	O
+the	O
+virus	B-SPEC
+has	O
+been	O
+cleared	O
+.	O
+
+This	O
+study	O
+aimed	O
+at	O
+screening	O
+available	O
+sera	B-COMP
+from	O
+100	O
+free	O
+-	O
+ranging	O
+,	O
+frugivorous	O
+bats	B-SPEC
+(	O
+Eidolon	B-SPEC
+helvum	I-SPEC
+)	O
+sampled	O
+in	O
+2009	O
+/	O
+10	O
+in	O
+Ghana	O
+,	O
+for	O
+the	O
+presence	O
+of	O
+antibodies	B-COMP
+against	O
+the	O
+complete	O
+panel	O
+of	O
+influenza	B-DISO
+A	I-PATH
+haemagglutinin	O
+(	O
+HA	O
+)	O
+types	O
+ranging	O
+from	O
+H1	O
+to	O
+H18	O
+by	O
+means	O
+of	O
+a	O
+protein	B-CHED
+microarray	O
+platform	O
+.	O
+
+This	O
+technique	O
+enables	O
+simultaneous	O
+serological	O
+testing	O
+against	O
+multiple	O
+recombinant	O
+HA	O
+-	O
+types	O
+in	O
+5	O
+μl	O
+of	O
+serum	B-COMP
+.	O
+
+TITLE	O
+:	O
+Case	O
+Report	O
+Serious	O
+pulmonary	B-DISO
+infection	I-DISO
+in	O
+a	O
+splenectomized	O
+patient	O
+with	O
+adult	O
+type	B-DISO
+1	I-DISO
+Gaucher	I-DISO
+disease	I-DISO
+.	O
+
+Surprisingly	O
+,	O
+on	O
+the	O
+first	O
+postoperative	O
+day	O
+,	O
+the	O
+patient	O
+developed	O
+a	O
+lung	B-DISO
+infection	I-DISO
+.	O
+
+Herein	O
+,	O
+we	O
+report	O
+a	O
+case	O
+in	O
+which	O
+computed	O
+tomography	O
+(	O
+CT	O
+)-	O
+guided	O
+percutaneous	O
+lung	B-ANAT
+biopsy	O
+was	O
+used	O
+to	O
+diagnose	O
+EP	O
+without	O
+alveolar	B-ANAT
+eosinophilia	B-DISO
+or	O
+peripheral	O
+eosinophilia	B-DISO
+.	O
+
+CT	O
+-	O
+guided	O
+percutaneous	O
+lung	B-ANAT
+biopsy	O
+may	O
+represent	O
+a	O
+new	O
+tool	O
+for	O
+the	O
+diagnosis	O
+of	O
+EP	O
+in	O
+patients	O
+without	O
+typical	O
+alveolar	B-ANAT
+eosinophilia	B-DISO
+or	O
+peripheral	O
+eosinophilia	B-DISO
+.	O
+
+TITLE	O
+:	O
+Coronavirus	B-SPEC
+Infections	I-DISO
+in	O
+Pediatric	O
+Outpatients	O
+with	O
+Febrile	B-PROC
+Respiratory	B-DISO
+Tract	I-DISO
+Infections	I-DISO
+in	O
+Hiroshima	O
+,	O
+Japan	O
+,	O
+over	O
+a	O
+3	O
+-	O
+Year	O
+Period	O
+.	O
+
+Overheated	O
+polytetrafluoroethylene	B-CHED
+can	O
+generate	O
+toxic	O
+fumes	O
+,	O
+inducing	O
+acute	B-DISO
+pulmonary	I-DISO
+edema	I-DISO
+in	O
+some	O
+cases	O
+.	O
+
+A	O
+literature	O
+review	O
+was	O
+performed	O
+to	O
+survey	O
+all	O
+reported	O
+cases	O
+of	O
+polytetrafluoroethylene	B-CHED
+fume	O
+-	O
+induced	O
+pulmonary	B-DISO
+edema	I-DISO
+.	O
+
+Our	O
+search	O
+revealed	O
+that	O
+(	O
+1	O
+)	O
+systemic	B-DISO
+inflammatory	I-DISO
+response	I-DISO
+syndrome	I-DISO
+was	O
+frequently	O
+accompanied	O
+by	O
+pulmonary	B-DISO
+edema	I-DISO
+,	O
+and	O
+(	O
+2	O
+)	O
+common	O
+computed	O
+tomography	O
+findings	O
+were	O
+bilateral	O
+ground	O
+-	O
+glass	O
+opacities	B-DISO
+,	O
+patchy	O
+consolidation	O
+and	O
+peripheral	O
+area	O
+sparing	O
+.	O
+
+In	O
+this	O
+study	O
+,	O
+we	O
+have	O
+developed	O
+a	O
+new	O
+real	O
+-	O
+time	O
+RT	O
+-	O
+LAMP	O
+method	O
+,	O
+which	O
+is	O
+rapid	O
+,	O
+sensitive	O
+and	O
+efficient	O
+to	O
+detect	O
+PEDV	B-SPEC
+.	O
+This	O
+method	O
+holds	O
+great	O
+promises	O
+not	O
+only	O
+in	O
+laboratory	O
+detection	O
+and	O
+discrimination	O
+of	O
+PEDV	B-SPEC
+but	O
+also	O
+in	O
+large	O
+scale	O
+field	O
+and	O
+clinical	O
+studies	O
+.	O
+
+By	O
+substitution	O
+of	O
+a	O
+single	O
+amino	B-CHED
+acid	I-CHED
+in	O
+the	O
+S	B-PRGE
+protein	I-PRGE
+,	O
+we	O
+created	O
+a	O
+recombinant	O
+PEDV	B-SPEC
+with	O
+an	O
+artificial	O
+furin	B-PRGE
+protease	O
+cleavage	B-PROC
+site	O
+N	O
+terminal	O
+of	O
+the	O
+putative	O
+fusion	O
+peptide	B-CHED
+(	O
+PEDV	B-SPEC
+-	O
+SFCS	O
+).	O
+
+PEDV	B-SPEC
+-	O
+SFCS	O
+exhibited	O
+trypsin	B-PRGE
+-	O
+independent	O
+cell	B-PROC
+-	I-PROC
+cell	B-COMP
+fusion	I-PROC
+and	O
+was	O
+able	O
+to	O
+replicate	O
+in	O
+culture	O
+cells	B-COMP
+independently	O
+of	O
+trypsin	B-PRGE
+,	O
+though	O
+to	O
+low	O
+titer	O
+.	O
+
+Using	O
+next	O
+-	O
+generation	O
+transcriptome	O
+sequencing	O
+(	O
+mRNA	B-CHED
+-	O
+seq	O
+),	O
+we	O
+profiled	O
+the	O
+transcriptional	B-PROC
+response	O
+of	O
+Pteropus	B-SPEC
+vampyrus	I-SPEC
+bat	B-ENZY
+kidney	B-ANAT
+(	O
+PVK	B-CHED
+)	O
+cells	B-COMP
+to	O
+Newcastle	B-SPEC
+disease	I-SPEC
+virus	I-SPEC
+(	O
+NDV	B-SPEC
+),	O
+an	O
+avian	B-SPEC
+paramyxovirus	I-SPEC
+known	O
+to	O
+elicit	O
+a	O
+strong	O
+innate	B-DISO
+immune	I-DISO
+response	I-DISO
+in	O
+mammalian	B-SPEC
+cells	B-COMP
+.	O
+
+In	O
+contrast	O
+to	O
+NDV	B-SPEC
+infection	B-DISO
+,	O
+HeV	B-SPEC
+and	O
+NiV	O
+infection	B-DISO
+of	O
+PVK	B-CHED
+cells	B-COMP
+failed	O
+to	O
+induce	O
+these	O
+innate	B-DISO
+immune	I-DISO
+response	I-DISO
+genes	O
+.	O
+
+ABSTRACT	O
+:	O
+Arteriviruses	B-SPEC
+are	O
+a	O
+family	B-SPEC
+of	O
+positive	O
+-	O
+stranded	O
+RNA	O
+viruses	B-SPEC
+that	O
+includes	O
+the	O
+prototypic	O
+equine	B-SPEC
+arteritis	I-SPEC
+virus	I-SPEC
+(	O
+EAV	B-SPEC
+)	O
+and	O
+porcine	B-SPEC
+reproductive	I-SPEC
+and	I-SPEC
+respiratory	I-SPEC
+syndrome	I-SPEC
+virus	I-SPEC
+(	O
+PRRSV	B-SPEC
+).	O
+
+All	O
+horses	B-SPEC
+were	O
+subsequently	O
+challenged	O
+with	O
+the	O
+virulent	O
+KY84	O
+strain	O
+of	O
+EAV	B-SPEC
+.	O
+
+In	O
+addition	O
+,	O
+the	O
+DUB	O
+-	O
+negative	O
+virus	B-SPEC
+provided	O
+a	O
+similar	O
+degree	O
+of	O
+protection	O
+against	O
+clinical	O
+disease	O
+as	O
+its	O
+DUB	O
+-	O
+positive	O
+parental	O
+counterpart	O
+.	O
+
+Human	B-SPEC
+pathogens	O
+in	O
+the	O
+Orthomyxoviridae	B-SPEC
+and	O
+Coronaviridae	B-SPEC
+families	O
+,	O
+especially	O
+pandemic	O
+H1N1	O
+and	O
+avian	B-SPEC
+H5N1	B-DISO
+influenza	I-DISO
+A	O
+viruses	B-SPEC
+and	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+coronavirus	B-SPEC
+(	O
+SARS	B-DISO
+-	O
+CoV	O
+),	O
+were	O
+investigated	O
+.	O
+
+We	O
+retrospectively	O
+reviewed	O
+all	O
+ARDS	B-DISO
+patients	O
+who	O
+met	B-CHED
+the	O
+Berlin	O
+definition	O
+and	O
+underwent	O
+open	O
+lung	B-ANAT
+biopsy	O
+from	O
+January	O
+1999	O
+to	O
+January	O
+2014	O
+in	O
+a	O
+referred	O
+medical	O
+center	O
+.	O
+
+Decontamination	O
+was	O
+done	O
+with	O
+high	O
+-	O
+density	O
+water	B-CHED
+and	O
+glycerol	B-CHED
+.	O
+
+Early	O
+complications	O
+in	O
+form	O
+of	O
+metabolic	B-DISO
+acidosis	I-DISO
+and	O
+acute	B-DISO
+renal	I-DISO
+failure	I-DISO
+required	O
+hemodialysis	O
+.	O
+
+The	O
+patient	O
+survived	O
+after	O
+multiple	B-DISO
+organ	I-DISO
+failures	I-DISO
+and	O
+widespread	O
+burns	O
+despite	O
+the	O
+fact	O
+that	O
+it	O
+has	O
+been	O
+observed	O
+that	O
+outcome	O
+of	O
+phenol	B-CHED
+burns	O
+with	O
+>	O
+60	O
+(	O
+2	O
+)	O
+inches	O
+of	O
+skin	B-ANAT
+affected	O
+or	O
+two	O
+or	O
+more	O
+organs	B-ANAT
+failure	O
+involving	O
+renal	B-ANAT
+system	O
+is	O
+nearly	O
+fatal	O
+.	O
+
+Among	O
+the	O
+351	O
+(	O
+47	O
+.	O
+8	O
+%)	O
+patients	O
+diagnosed	O
+with	O
+viral	O
+infections	B-DISO
+,	I-DISO
+viral	I-DISO
+mixed	O
+detection	O
+was	O
+identified	O
+in	O
+49	O
+patients	O
+(	O
+14	O
+%),	O
+with	O
+human	B-SPEC
+rhinovirus	I-SPEC
+(	O
+HRV	O
+)	O
+being	O
+the	O
+most	O
+common	O
+virus	B-SPEC
+associated	O
+with	O
+viral	O
+mixed	O
+detection	O
+(	O
+7	O
+.	O
+1	O
+%),	O
+followed	O
+by	O
+adenovirus	B-DISO
+(	O
+AdV	O
+)	O
+(	O
+4	O
+%)	O
+and	O
+human	B-PRGE
+coronavirus	I-PRGE
+-	I-PRGE
+OC43	I-PRGE
+(	O
+HCoV	B-SPEC
+-	I-SPEC
+OC43	I-SPEC
+)	O
+(	O
+3	O
+.	O
+7	O
+%).	O
+
+There	O
+were	O
+statistical	O
+significance	O
+differences	O
+between	O
+mixed	O
+and	O
+single	O
+detection	O
+in	O
+patients	O
+diagnosed	O
+with	O
+bronchiolitis	B-DISO
+(	O
+P	O
+=	O
+0	O
+.	O
+002	O
+)	O
+and	O
+pneumonia	B-DISO
+(	O
+P	O
+=	O
+0	O
+.	O
+019	O
+).	O
+
+When	O
+purified	O
+histones	O
+were	O
+delivered	O
+to	O
+lung	B-ANAT
+via	O
+the	O
+airways	O
+,	O
+intense	O
+inflammatory	O
+injury	O
+ensued	O
+and	O
+type	O
+II	O
+cells	O
+developed	O
+large	O
+blebs	B-DISO
+indicating	O
+cellular	B-COMP
+damage	O
+and	O
+apoptosis	B-PATH
+.	O
+
+However	O
+,	O
+these	O
+in	O
+vitro	O
+conditions	O
+vary	O
+quite	O
+drastically	O
+from	O
+the	O
+tissues	B-ANAT
+that	O
+are	O
+commonly	O
+infected	O
+in	O
+vivo	O
+.	O
+
+Over	O
+the	O
+years	O
+,	O
+a	O
+number	O
+of	O
+systems	O
+have	O
+been	O
+developed	O
+that	O
+allow	O
+the	O
+establishment	O
+of	O
+three	O
+-	O
+dimensional	O
+(	O
+3D	O
+)	O
+tissue	B-ANAT
+structures	O
+that	O
+have	O
+properties	O
+similar	O
+to	O
+their	O
+in	O
+vivo	O
+3D	O
+counterparts	O
+.	O
+
+We	O
+present	O
+a	O
+systematic	O
+review	O
+of	O
+the	O
+literature	O
+along	O
+with	O
+evidence	O
+-	O
+and	O
+consensus	O
+-	O
+based	O
+recommendations	O
+on	O
+the	O
+use	O
+of	O
+extracorporeal	O
+treatment	O
+in	O
+salicylate	B-CHED
+poisoning	O
+.	O
+
+RESULTS	O
+:	O
+Eighty	O
+-	O
+four	O
+articles	O
+met	B-CHED
+inclusion	O
+criteria	O
+,	O
+including	O
+1	O
+controlled	O
+clinical	O
+trial	O
+,	O
+3	O
+animal	B-SPEC
+studies	O
+,	O
+and	O
+80	O
+case	O
+reports	O
+or	O
+case	O
+series	O
+,	O
+yielding	O
+an	O
+overall	O
+very	O
+low	O
+quality	O
+of	O
+evidence	O
+for	O
+all	O
+recommendations	O
+.	O
+
+ABSTRACT	O
+:	O
+In	O
+patients	O
+presenting	O
+with	O
+severe	O
+dyspnea	O
+,	O
+several	O
+diagnostic	O
+challenges	O
+arise	O
+in	O
+distinguishing	O
+the	O
+diagnosis	O
+of	O
+pneumothorax	B-DISO
+versus	O
+several	O
+other	O
+pulmonary	B-ANAT
+etiologies	O
+like	O
+bullous	B-DISO
+lung	I-DISO
+disease	I-DISO
+,	O
+pneumonia	O
+,	O
+interstitial	B-DISO
+lung	B-ANAT
+disease	I-DISO
+,	O
+and	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+.	O
+
+Delayed	O
+social	O
+separation	B-DISO
+of	O
+calves	O
+might	O
+reduce	O
+human	B-SPEC
+infection	B-DISO
+risk	O
+.	O
+
+TITLE	O
+:	O
+A	O
+novel	O
+pathogenic	O
+Mammalian	B-SPEC
+orthoreovirus	I-SPEC
+from	O
+diarrheic	O
+pigs	B-SPEC
+and	O
+Swine	B-SPEC
+blood	B-ANAT
+meal	O
+in	O
+the	O
+United	O
+States	O
+.	O
+
+Biological	O
+characterization	O
+of	O
+two	O
+representative	O
+isolates	O
+revealed	O
+trypsin	B-PRGE
+resistance	B-PROC
+and	O
+thermostability	O
+at	O
+90	O
+°	O
+C	O
+.	O
+
+Genetic	O
+and	O
+phylogenetic	O
+analyses	O
+of	O
+two	O
+MRV3	O
+isolates	O
+revealed	O
+that	O
+they	O
+are	O
+identical	O
+but	O
+differed	O
+significantly	O
+from	O
+nonpathogenic	O
+mammalian	B-SPEC
+orthoreoviruses	B-SPEC
+circulating	O
+in	O
+the	O
+United	O
+States	O
+.	O
+
+TITLE	O
+:	O
+Adenovirus	B-SPEC
+pneumonia	B-DISO
+complicated	O
+with	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+:	O
+a	O
+case	O
+report	O
+.	O
+
+Chest	B-ANAT
+x	O
+-	O
+rays	B-SPEC
+showed	O
+progressively	O
+increasing	O
+infiltrations	O
+and	O
+pleural	B-DISO
+effusions	I-DISO
+in	O
+both	O
+lung	B-ANAT
+fields	O
+within	O
+11	O
+days	O
+.	O
+
+Adenovirus	B-DISO
+pneumonia	B-DISO
+in	O
+children	O
+can	O
+manifest	O
+with	O
+severe	O
+pulmonary	B-ANAT
+morbidity	O
+and	O
+respiratory	B-DISO
+failure	I-DISO
+.	O
+
+Typical	O
+for	O
+these	O
+diseases	O
+is	O
+a	O
+natural	O
+circulation	O
+between	O
+reservoir	O
+animals	B-SPEC
+in	O
+remote	O
+areas	O
+.	O
+
+Humans	B-SPEC
+may	O
+also	O
+become	O
+infected	O
+with	O
+viruses	B-SPEC
+through	O
+aerosol	O
+by	O
+intruding	O
+into	O
+bat	B-ENZY
+roosting	O
+caves	O
+or	O
+via	O
+direct	O
+contact	O
+with	O
+bats	B-SPEC
+,	O
+such	O
+as	O
+catching	B-DISO
+bats	B-SPEC
+or	O
+been	O
+bitten	O
+by	O
+bats	B-SPEC
+.	O
+
+Similarly	O
+,	O
+CBH	O
+response	O
+and	O
+antibody	B-COMP
+titers	O
+against	O
+Newcastle	O
+and	O
+infectious	B-DISO
+bronchitis	B-DISO
+disease	O
+viruses	B-SPEC
+were	O
+markedly	O
+(	O
+P	O
+<	O
+0	O
+.	O
+05	O
+)	O
+greater	O
+in	O
+chicks	O
+fed	O
+on	O
+diets	O
+supplemented	O
+with	O
+20	O
+to	O
+80	O
+mg	O
+/	O
+kg	O
+of	O
+genistein	B-CHED
+.	O
+
+Dietary	O
+inclusion	O
+of	O
+genistein	B-CHED
+increased	O
+(	O
+P	O
+<	O
+0	O
+.	O
+05	O
+)	O
+lymphocytes	B-ANAT
+and	O
+subsequently	O
+reduced	O
+(	O
+P	O
+<	O
+0	O
+.	O
+01	O
+)	O
+heterophil	B-ANAT
+to	O
+lymphocyte	B-ANAT
+ratio	O
+.	O
+
+In	O
+this	O
+study	O
+,	O
+we	O
+analyzed	O
+the	O
+role	O
+of	O
+complement	O
+-	O
+derived	O
+anaphylatoxins	O
+in	O
+the	O
+pathogenesis	B-DISO
+of	O
+experimental	O
+acute	O
+lung	B-ANAT
+injury	O
+/	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+(	O
+ALI	O
+/	O
+ARDS	B-DISO
+)	O
+in	O
+C57BL	O
+/	O
+6J	O
+mice	B-SPEC
+.	O
+
+Poorly	O
+controlled	O
+thoracotomy	O
+pain	O
+in	O
+the	O
+acute	O
+phase	O
+may	O
+also	O
+lead	O
+to	O
+the	O
+development	B-PROC
+of	O
+a	O
+chronic	B-DISO
+pain	I-DISO
+syndrome	I-DISO
+.	O
+
+Due	O
+to	O
+hypotension	O
+and	O
+fluid	O
+losses	O
+following	O
+surgery	O
+,	O
+he	O
+was	O
+maintained	O
+on	O
+intravenous	O
+sedato	O
+-	O
+analgesia	B-DISO
+during	O
+postoperative	O
+mechanical	O
+ventilation	O
+.	O
+
+The	O
+usefulness	O
+of	O
+this	O
+block	O
+has	O
+been	O
+discussed	O
+in	O
+the	O
+management	O
+of	O
+pain	O
+of	O
+rib	B-CHED
+fractures	O
+and	O
+breast	B-ANAT
+surgeries	O
+.	O
+
+Here	O
+,	O
+we	O
+describe	O
+the	O
+successful	O
+management	O
+of	O
+thoracotomy	O
+pain	O
+using	O
+the	O
+serratus	B-ANAT
+anterior	I-ANAT
+plane	O
+block	O
+.	O
+
+ABSTRACT	O
+:	O
+Respiratory	B-SPEC
+Syncytial	I-SPEC
+Virus	I-SPEC
+(	O
+RSV	B-SPEC
+)	O
+is	O
+one	O
+of	O
+the	O
+main	O
+causes	O
+of	O
+respiratory	B-DISO
+infections	I-DISO
+during	O
+the	O
+first	O
+year	O
+of	O
+life	O
+.	O
+
+Hospitalization	O
+for	O
+bronchiolitis	B-DISO
+(	O
+ICD	B-DISO
+-	O
+9	O
+code	O
+466	O
+.	O
+1	O
+)	O
+during	O
+the	O
+first	O
+year	O
+of	O
+life	O
+was	O
+assessed	O
+through	O
+phone	O
+interview	O
+at	O
+the	O
+end	O
+of	O
+the	O
+RSV	B-SPEC
+season	O
+(	O
+November	O
+-	O
+March	O
+)	O
+and	O
+at	O
+the	O
+completion	O
+of	O
+the	O
+first	O
+year	O
+of	O
+life	O
+.	O
+
+A	O
+new	O
+cluster	O
+E	O
+was	O
+invariably	O
+detected	O
+from	O
+nsp12	O
+,	O
+S	O
+,	O
+and	O
+N	O
+data	O
+while	O
+the	O
+analysis	O
+of	O
+nsp12	O
+and	O
+N	O
+genes	O
+revealed	O
+the	O
+existence	O
+of	O
+new	O
+F	O
+and	O
+G	O
+clusters	B-CHED
+respectively	O
+.	O
+
+When	O
+compared	O
+with	O
+conventional	O
+antibody	B-COMP
+-	O
+based	O
+ELISA	O
+,	O
+phage	O
+-	O
+mediated	O
+ELISA	O
+was	O
+more	O
+sensitive	O
+;	O
+however	O
+,	O
+it	O
+did	O
+not	O
+perform	O
+better	O
+than	O
+semi	O
+-	O
+quantitative	O
+RT	O
+-	O
+PCR	O
+,	O
+though	O
+phage	O
+-	O
+mediated	O
+ELISA	O
+was	O
+quicker	O
+and	O
+easier	O
+to	O
+set	O
+up	O
+.	O
+
+Previously	O
+,	O
+it	O
+was	O
+shown	O
+that	O
+MyD88	B-PRGE
+,	O
+an	O
+adaptor	O
+protein	B-CHED
+necessary	O
+for	O
+signaling	B-PROC
+by	O
+multiple	O
+TLRs	O
+,	O
+is	O
+a	O
+required	O
+component	O
+of	O
+the	O
+innate	B-DISO
+immune	I-DISO
+response	I-DISO
+to	O
+mouse	B-SPEC
+-	O
+adapted	O
+SARS	B-DISO
+-	I-DISO
+CoV	I-DISO
+infection	I-DISO
+in	O
+vivo	O
+.	O
+
+Our	O
+findings	O
+indicate	O
+that	O
+a	O
+balanced	O
+immune	B-PROC
+response	I-PROC
+operating	O
+through	O
+both	O
+TRIF	B-PRGE
+-	O
+driven	O
+and	O
+MyD88	B-PRGE
+-	O
+driven	O
+pathways	B-PROC
+likely	O
+provides	O
+the	O
+most	O
+effective	O
+host	B-COMP
+cell	I-COMP
+intrinsic	O
+antiviral	B-CHED
+defense	O
+responses	O
+to	O
+severe	O
+SARS	B-DISO
+-	O
+CoV	O
+disease	O
+,	O
+while	O
+removal	O
+of	O
+either	O
+branch	B-ANAT
+of	I-ANAT
+TLR	O
+signaling	B-PROC
+causes	O
+lethal	O
+SARS	B-PRGE
+-	I-PRGE
+CoV	I-PRGE
+disease	O
+in	O
+our	O
+mouse	B-SPEC
+model	O
+.	O
+
+On	O
+a	O
+repeat	O
+head	B-ANAT
+imaging	O
+,	O
+vasogenic	O
+edema	B-DISO
+(	O
+P	O
+=	O
+0	O
+.	O
+023	O
+)	O
+and	O
+subcortical	B-ANAT
+white	B-ANAT
+matter	I-ANAT
+lesions	O
+(	O
+P	O
+=	O
+0	O
+.	O
+011	O
+)	O
+were	O
+significantly	O
+higher	O
+in	O
+patients	O
+with	O
+SE	O
+than	O
+those	O
+without	O
+SE	O
+,	O
+while	O
+hematoma	B-DISO
+growth	B-PROC
+(	O
+P	O
+=	O
+0	O
+.	O
+000	O
+),	O
+infarction	B-DISO
+progress	O
+(	O
+P	O
+=	O
+0	O
+.	O
+003	O
+),	O
+and	O
+recurrent	O
+subarachnoid	B-DISO
+hemorrhage	I-DISO
+(	O
+SAH	B-CHED
+)	O
+(	O
+P	O
+=	O
+0	O
+.	O
+011	O
+)	O
+were	O
+significantly	O
+lower	O
+in	O
+patients	O
+with	O
+SE	O
+than	O
+those	O
+without	O
+SE	O
+.	O
+
+The	O
+30	O
+-	O
+day	O
+mortality	O
+in	O
+stroke	B-DISO
+patients	O
+with	O
+SE	O
+was	O
+higher	O
+than	O
+those	O
+without	O
+SE	O
+(	O
+76	O
+.	O
+1	O
+%	O
+vs	O
+.	O
+45	O
+.	O
+8	O
+%,	O
+P	O
+=	O
+0	O
+.	O
+003	O
+).	O
+
+High	O
+fever	B-PROC
+and	O
+severe	O
+SIRS	B-DISO
+are	O
+two	O
+early	O
+predictors	O
+of	O
+stroke	B-DISO
+patients	O
+with	O
+SE	O
+,	O
+and	O
+survival	O
+rates	O
+were	O
+worse	O
+in	O
+stroke	B-DISO
+patients	O
+with	O
+SE	O
+than	O
+those	O
+without	O
+SE	O
+.	O
+
+The	O
+30	O
+-	O
+day	O
+mortality	O
+in	O
+stroke	B-DISO
+patients	O
+with	O
+SE	O
+was	O
+higher	O
+than	O
+those	O
+without	O
+SE	O
+(	O
+76	O
+.	O
+1	O
+%	O
+vs	O
+.	O
+45	O
+.	O
+8	O
+%,	O
+P	O
+=	O
+0	O
+.	O
+003	O
+).	O
+
+Rhinoviruses	B-SPEC
+and	O
+PI	O
+viruses	B-SPEC
+were	O
+determined	O
+throughout	O
+the	O
+epidemic	O
+season	O
+,	O
+bocavirus	B-SPEC
+and	O
+adenoviruses	B-SPEC
+--	O
+during	O
+the	O
+autumn	O
+-	O
+winter	O
+period	O
+,	O
+RS	O
+-	O
+virus	B-SPEC
+and	O
+MPV	B-SPEC
+--	O
+during	O
+winter	O
+-	O
+spring	O
+.	O
+
+RS	O
+-	O
+virus	B-DISO
+infection	I-DISO
+at	O
+the	O
+debut	O
+of	O
+CAP	B-DISO
+in	O
+children	O
+younger	O
+than	O
+3	O
+years	O
+in	O
+55	O
+.	O
+5	O
+%	O
+of	O
+cases	O
+is	O
+associated	O
+with	O
+the	O
+development	B-PROC
+of	O
+broncho	O
+-	O
+obstructive	O
+syndrome	B-DISO
+.	O
+
+The	O
+fraction	O
+of	O
+viruses	B-SPEC
+in	O
+etiologic	O
+structure	O
+ofARI	O
+in	O
+children	O
+varies	O
+depending	O
+on	O
+immune	O
+layer	B-ANAT
+,	O
+season	O
+and	O
+age	O
+of	O
+children	O
+.	O
+
+This	O
+MERS	O
+-	O
+CoV	O
+infection	B-DISO
+model	O
+demonstrates	O
+the	O
+safety	O
+and	O
+efficacy	O
+of	O
+the	O
+candidate	O
+vaccine	O
+.	O
+
+We	O
+compared	O
+two	O
+age	O
+-	O
+and	O
+sex	O
+-	O
+matched	O
+groups	O
+of	O
+29	O
+patients	O
+,	O
+with	O
+and	O
+without	O
+respiratory	B-DISO
+dysfunction	I-DISO
+.	O
+
+Patients	O
+with	O
+sepsis	B-DISO
+-	O
+induced	O
+ARDS	B-DISO
+showed	O
+significantly	O
+higher	O
+median	O
+levels	O
+of	O
+TF	O
+compared	O
+with	O
+patients	O
+without	O
+ARDS	B-DISO
+(	O
+1425	O
+.	O
+5	O
+(	O
+1019	O
+.	O
+9	O
+to	O
+2595	O
+.	O
+2	O
+)	O
+pg	O
+/	O
+ml	O
+vs	O
+916	O
+.	O
+2	O
+(	O
+724	O
+.	O
+1	O
+to	O
+1618	O
+.	O
+2	O
+)	O
+pg	O
+/	O
+ml	O
+,	O
+P	O
+<	O
+0	O
+.	O
+001	O
+),	O
+and	O
+compared	O
+with	O
+sepsis	B-DISO
+patients	O
+(	O
+943	O
+.	O
+5	O
+(	O
+786	O
+.	O
+4	O
+to	O
+992	O
+.	O
+4	O
+)	O
+pg	O
+/	O
+ml	O
+,	O
+P	O
+<	O
+0	O
+.	O
+001	O
+)	O
+on	O
+the	O
+day	O
+of	O
+admission	O
+.	O
+
+The	O
+AUC	O
+of	O
+TF	O
+for	O
+predicting	O
+30	O
+-	O
+day	O
+mortality	O
+in	O
+severe	B-DISO
+sepsis	I-DISO
+patients	O
+was	O
+0	O
+.	O
+718	O
+(	O
+95	O
+%	O
+CI	O
+0	O
+.	O
+641	O
+-	O
+0	O
+.	O
+794	O
+).	O
+
+However	O
+,	O
+there	O
+was	O
+no	O
+significant	O
+difference	O
+in	O
+the	O
+plasma	B-ANAT
+TFPI	O
+values	O
+among	O
+the	O
+healthy	O
+control	O
+,	O
+sepsis	B-DISO
+and	O
+severe	B-DISO
+sepsis	I-DISO
+groups	O
+(	O
+P	O
+>	O
+0	O
+.	O
+05	O
+).	O
+
+RESULTS	O
+:	O
+Patients	O
+with	O
+sepsis	B-DISO
+-	O
+induced	O
+ARDS	B-DISO
+showed	O
+significantly	O
+higher	O
+median	O
+levels	O
+of	O
+TF	O
+compared	O
+with	O
+patients	O
+without	O
+ARDS	B-DISO
+(	O
+1425	O
+.	O
+5	O
+(	O
+1019	O
+.	O
+9	O
+to	O
+2595	O
+.	O
+2	O
+)	O
+pg	O
+/	O
+ml	O
+vs	O
+916	O
+.	O
+2	O
+(	O
+724	O
+.	O
+1	O
+to	O
+1618	O
+.	O
+2	O
+)	O
+pg	O
+/	O
+ml	O
+,	O
+P	O
+<	O
+0	O
+.	O
+001	O
+),	O
+and	O
+compared	O
+with	O
+sepsis	B-DISO
+patients	O
+(	O
+943	O
+.	O
+5	O
+(	O
+786	O
+.	O
+4	O
+to	O
+992	O
+.	O
+4	O
+)	O
+pg	O
+/	O
+ml	O
+,	O
+P	O
+<	O
+0	O
+.	O
+001	O
+)	O
+on	O
+the	O
+day	O
+of	O
+admission	O
+.	O
+
+ABSTRACT	O
+:	O
+The	O
+novel	O
+avian	B-SPEC
+origin	O
+influenza	B-PATH
+A	I-PATH
+(	O
+H7N9	O
+)	O
+virus	B-SPEC
+has	O
+caused	O
+severe	O
+diseases	O
+in	O
+humans	B-SPEC
+in	O
+eastern	O
+China	O
+since	O
+the	O
+spring	O
+of	O
+2013	O
+.	O
+
+Statins	O
+are	O
+expected	O
+to	O
+attenuate	O
+inflammation	B-DISO
+in	O
+the	O
+lungs	B-ANAT
+of	O
+patients	O
+with	O
+ARDS	B-DISO
+due	O
+to	O
+their	O
+anti	O
+-	O
+inflammatory	O
+effects	O
+.	O
+
+ABSTRACT	O
+:	O
+The	O
+most	O
+severe	O
+complication	B-DISO
+of	O
+influenza	B-DISO
+is	O
+viral	B-DISO
+pneumonia	I-DISO
+,	O
+which	O
+can	O
+lead	O
+to	O
+the	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+.	O
+
+Recently	O
+,	O
+TGF	O
+-	O
+α	O
+/	O
+EGFR	B-FUNC
+signaling	B-PROC
+has	O
+also	O
+been	O
+shown	O
+to	O
+regulate	O
+innate	B-DISO
+immune	I-DISO
+responses	I-DISO
+in	O
+bronchial	B-ANAT
+epithelial	B-ANAT
+cells	I-ANAT
+.	O
+
+TITLE	O
+:	O
+Noninvasive	O
+support	O
+and	O
+ventilation	O
+for	O
+pediatric	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+:	O
+proceedings	O
+from	O
+the	O
+Pediatric	O
+Acute	O
+Lung	O
+Injury	O
+Consensus	O
+Conference	O
+.	O
+
+Electronic	O
+searches	O
+were	O
+made	O
+in	O
+PubMed	O
+,	O
+EMBASE	O
+,	O
+Web	B-DISO
+of	O
+Science	O
+,	O
+Cochrane	O
+Library	O
+,	O
+and	O
+Scopus	B-SPEC
+with	O
+the	O
+following	O
+specific	O
+keywords	O
+:	O
+noninvasive	O
+ventilation	O
+,	O
+noninvasive	O
+positive	O
+pressure	O
+ventilation	O
+,	O
+continuous	O
+positive	O
+airway	B-ANAT
+pressure	O
+,	O
+and	O
+high	O
+-	O
+flow	O
+nasal	O
+cannula	B-SPEC
+.	O
+
+Randomized	O
+and	O
+nonrandomized	O
+controlled	O
+trials	O
+,	O
+controlled	O
+before	O
+-	O
+and	O
+-	O
+after	O
+studies	O
+,	O
+concurrent	O
+cohort	O
+studies	O
+,	O
+interrupted	O
+time	O
+series	O
+studies	O
+,	O
+historically	O
+controlled	O
+studies	O
+,	O
+cohort	O
+studies	O
+,	O
+cross	O
+-	O
+sectional	O
+studies	O
+,	O
+and	O
+uncontrolled	O
+longitudinal	O
+studies	O
+were	O
+included	O
+for	O
+data	O
+synthesis	B-PROC
+.	O
+
+An	O
+oronasal	O
+interface	O
+provides	O
+superior	O
+support	O
+,	O
+but	O
+close	O
+monitoring	O
+of	O
+children	O
+is	O
+required	O
+due	O
+to	O
+the	O
+risk	O
+of	O
+progressive	O
+respiratory	B-DISO
+failure	I-DISO
+and	O
+the	O
+potential	O
+need	O
+for	O
+intubation	O
+.	O
+
+The	O
+use	O
+of	O
+high	O
+-	O
+flow	O
+nasal	B-ANAT
+cannula	B-SPEC
+is	O
+a	O
+promising	O
+treatment	O
+for	O
+respiratory	B-DISO
+disease	I-DISO
+;	O
+however	O
+,	O
+at	O
+this	O
+time	O
+,	O
+the	O
+efficacy	O
+of	O
+high	O
+-	O
+flow	O
+nasal	B-ANAT
+cannula	B-SPEC
+compared	O
+with	O
+noninvasive	O
+positive	O
+pressure	O
+ventilation	O
+is	O
+unknown	O
+.	O
+
+These	O
+recommendations	O
+are	O
+intended	O
+to	O
+initiate	O
+discussion	O
+regarding	O
+optimal	O
+mechanical	O
+ventilation	O
+management	O
+for	O
+children	O
+with	O
+pediatric	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+and	O
+identify	O
+areas	O
+of	O
+controversy	O
+requiring	O
+further	O
+investigation	O
+.	O
+
+Recommendations	O
+developed	O
+and	O
+the	O
+supporting	O
+literature	O
+were	O
+distributed	O
+to	O
+all	O
+panel	O
+members	O
+without	O
+a	O
+conflict	O
+of	O
+interest	O
+and	O
+were	O
+scored	O
+by	O
+using	O
+the	O
+Research	O
+ANd	O
+Development	B-PROC
+/	O
+University	O
+of	O
+California	B-SPEC
+,	O
+Los	O
+Angeles	O
+Appropriateness	O
+method	O
+.	O
+
+Future	O
+studies	O
+are	O
+definitely	O
+warranted	O
+to	O
+establish	O
+the	O
+role	O
+,	O
+if	O
+any	O
+,	O
+of	O
+these	O
+ancillary	O
+treatment	O
+modalities	O
+in	O
+pediatric	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+.	O
+
+The	O
+attachment	O
+pattern	O
+of	O
+the	O
+hemagglutinin	B-PRGE
+protein	I-PRGE
+was	O
+in	O
+line	O
+with	O
+the	O
+reported	O
+tropism	B-PROC
+of	O
+influenza	B-SPEC
+virus	I-SPEC
+H5N1	B-DISO
+,	O
+confirming	O
+the	O
+validity	O
+of	O
+TMAs	O
+in	O
+profiling	O
+the	O
+initial	O
+virus	B-PROC
+-	I-PROC
+host	B-COMP
+interaction	I-PROC
+.	O
+
+Avian	B-DISO
+Infectious	I-DISO
+Bronchitis	I-DISO
+(	O
+IB	O
+),	O
+caused	O
+by	O
+Corona	B-CHED
+virus	B-SPEC
+,	O
+is	O
+OIE	O
+-	O
+listed	O
+disease	O
+and	O
+characterized	O
+by	O
+respiratory	O
+,	O
+renal	B-ANAT
+and	O
+urogenital	B-ANAT
+involvements	O
+,	O
+causing	O
+high	O
+mortality	O
+.	O
+
+Economic	O
+losses	O
+are	O
+encountered	O
+due	O
+to	O
+loss	O
+of	O
+productive	O
+performance	O
+of	O
+both	O
+egg	B-ANAT
+and	O
+meat	O
+-	O
+type	O
+chickens	B-SPEC
+.	O
+
+Several	O
+conventional	O
+and	O
+molecular	O
+diagnostic	O
+methods	O
+have	O
+been	O
+described	O
+for	O
+the	O
+diagnosis	O
+of	O
+IB	O
+in	O
+chickens	B-SPEC
+.	O
+'	O
+
+TITLE	O
+:	O
+Clonidine	B-CHED
+withdrawal	B-DISO
+induced	O
+sympathetic	O
+surge	O
+.	O
+
+ABSTRACT	O
+:	O
+A	O
+30	O
+-	O
+year	O
+-	O
+old	O
+man	B-CHED
+with	O
+a	O
+history	O
+of	O
+epilepsy	O
+and	O
+substance	O
+misuse	O
+presented	O
+to	O
+the	O
+hospital	O
+with	O
+status	B-DISO
+epilepticus	I-DISO
+.	O
+
+Phylogenetically	O
+,	O
+HCoV	O
+-	O
+EMC	B-COMP
+is	O
+clustered	O
+with	O
+Ty	O
+-	O
+BatCoV	O
+HKU4	O
+/	O
+Pi	O
+-	O
+BatCoV	O
+HKU5	O
+with	O
+high	O
+bootstrap	O
+supports	O
+,	O
+indicating	O
+that	O
+HCoV	O
+-	O
+EMC	B-COMP
+is	O
+a	O
+group	O
+C	O
+betaCoV	O
+.	O
+The	O
+major	O
+difference	O
+between	O
+HCoV	B-PRGE
+-	I-PRGE
+EMC	I-PRGE
+and	O
+Ty	O
+-	O
+BatCoV	O
+HKU4	O
+/	O
+Pi	O
+-	O
+BatCoV	O
+HKU5	O
+is	O
+in	O
+the	O
+region	O
+between	O
+S	O
+and	O
+E	O
+,	O
+where	O
+HCoV	B-PRGE
+-	I-PRGE
+EMC	I-PRGE
+possesses	B-DISO
+five	O
+ORFs	O
+(	O
+NS3a	O
+-	O
+NS3e	O
+)	O
+instead	O
+of	O
+four	O
+,	O
+with	O
+low	O
+(	O
+31	O
+%-	O
+62	O
+%)	O
+amino	B-CHED
+acid	I-CHED
+identities	O
+to	O
+Ty	O
+-	O
+BatCoV	O
+HKU4	O
+/	O
+Pi	O
+-	O
+BatCoV	O
+HKU5	O
+.	O
+
+Pathway	B-PROC
+analysis	O
+grouped	O
+subsets	O
+of	O
+these	O
+factors	O
+in	O
+specific	O
+cellular	B-COMP
+processes	O
+,	O
+including	O
+the	O
+innate	B-DISO
+immune	I-DISO
+response	I-DISO
+and	O
+the	O
+metabolism	B-PROC
+of	O
+complex	O
+lipids	B-CHED
+,	O
+which	O
+appear	O
+to	O
+play	O
+a	O
+role	O
+in	O
+SARS	B-DISO
+-	I-DISO
+CoV	I-DISO
+infection	I-DISO
+.	O
+
+Our	O
+screen	O
+identified	O
+a	O
+variety	O
+of	O
+hits	O
+and	O
+will	O
+form	O
+the	O
+basis	O
+for	O
+more	O
+detailed	O
+follow	O
+-	O
+up	O
+studies	O
+that	O
+should	O
+contribute	O
+to	O
+a	O
+better	O
+understanding	O
+of	O
+SARS	B-DISO
+-	O
+CoV	O
+replication	O
+and	O
+coronavirus	B-SPEC
+-	O
+host	B-COMP
+interactions	O
+in	O
+general	O
+.	O
+
+Previous	O
+studies	O
+showed	O
+that	O
+the	O
+2	O
+'-	O
+O	O
+-	O
+MTase	O
+activity	O
+of	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+coronavirus	B-SPEC
+(	O
+SARS	B-DISO
+-	O
+CoV	O
+)	O
+nonstructural	B-PRGE
+protein	I-PRGE
+16	I-PRGE
+(	O
+nsp16	O
+)	O
+needs	O
+to	O
+be	O
+activated	O
+by	O
+nsp10	O
+,	O
+whereas	O
+nsp16	O
+of	O
+feline	B-SPEC
+coronavirus	B-SPEC
+(	O
+FCoV	O
+)	O
+alone	O
+possesses	B-DISO
+2	O
+'-	O
+O	B-PRGE
+-	I-PRGE
+MTase	I-PRGE
+activity	O
+(	O
+E	O
+.	O
+Decroly	O
+et	O
+al	O
+.,	O
+J	O
+Virol	O
+82	O
+:	O
+8071	O
+-	O
+8084	O
+,	O
+2008	O
+,	O
+http	O
+://	O
+dx	O
+.	O
+doi	O
+.	O
+org	O
+/	O
+10	O
+.	O
+1128	O
+/	O
+JVI	O
+.	O
+00407	O
+-	O
+08	O
+;	O
+M	O
+.	O
+Bouvet	O
+et	O
+al	O
+.,	O
+PLoS	O
+Pathog	O
+6	O
+:	O
+e1000863	O
+,	O
+2010	O
+,	O
+http	O
+://	O
+dx	O
+.	O
+doi	O
+.	O
+org	O
+/	O
+10	O
+.	O
+1371	O
+/	O
+journal	O
+.	O
+ppat	B-ENZY
+.	O
+1000863	O
+;	O
+E	O
+.	O
+Decroly	O
+et	O
+al	O
+.,	O
+PLoS	O
+Pathog	O
+7	O
+:	O
+e1002059	O
+,	O
+2011	O
+,	O
+http	O
+://	O
+dx	O
+.	O
+doi	O
+.	O
+org	O
+/	O
+10	O
+.	O
+1371	O
+/	O
+journal	O
+.	O
+ppat	O
+.	O
+1002059	O
+;	O
+Y	O
+.	O
+Chen	B-SPEC
+et	O
+al	O
+.,	O
+PLoS	O
+Pathog	O
+7	O
+:	O
+e1002294	O
+,	O
+2011	O
+,	O
+http	O
+://	O
+dx	O
+.	O
+doi	O
+.	O
+org	O
+/	O
+10	O
+.	O
+1371	O
+/	O
+journal	O
+.	O
+ppat	B-ENZY
+.	O
+1002294	O
+)	O
+.	O
+
+Coronaviruses	O
+are	O
+important	O
+pathogens	O
+of	O
+animals	B-SPEC
+and	O
+human	B-SPEC
+with	O
+high	O
+zoonotic	O
+potential	O
+.	O
+
+Our	O
+current	O
+results	O
+demonstrate	O
+that	O
+stimulation	O
+of	O
+nsp16	B-PRGE
+2	I-PRGE
+'-	I-PRGE
+O	I-PRGE
+-	I-PRGE
+MTase	I-PRGE
+activity	O
+by	O
+nsp10	O
+is	O
+a	O
+common	O
+mechanism	O
+for	O
+coronaviruses	O
+,	O
+and	O
+nsp10	O
+is	O
+functionally	O
+interchangeable	O
+in	O
+the	O
+stimulation	O
+of	O
+nsp16	O
+among	O
+different	O
+coronaviruses	O
+,	O
+which	O
+underlies	O
+the	O
+rationale	O
+for	O
+developing	O
+inhibitory	O
+peptides	B-CHED
+.	O
+
+In	O
+our	O
+in	O
+-	O
+depth	O
+bioinformatics	O
+analysis	O
+of	O
+nsp12	O
+,	O
+the	O
+protein	B-CHED
+was	O
+confirmed	O
+to	O
+be	O
+family	B-SPEC
+specific	O
+whilst	O
+having	O
+diverged	O
+much	O
+further	O
+than	O
+other	O
+nidovirus	B-SPEC
+ORF1b	O
+-	O
+encoded	O
+proteins	B-CHED
+,	O
+including	O
+those	O
+of	O
+the	O
+family	B-SPEC
+Coronaviridae	I-SPEC
+.	O
+
+ABSTRACT	O
+:	O
+Porcine	O
+aminopeptidase	B-ENZY
+N	I-ENZY
+(	O
+pAPN	O
+)	O
+is	O
+a	O
+functional	O
+receptor	O
+for	O
+porcine	B-SPEC
+epidemic	I-SPEC
+diarrhoea	I-SPEC
+virus	I-SPEC
+(	O
+PEDV	B-SPEC
+).	O
+
+TITLE	O
+:	O
+Design	O
+,	O
+synthesis	B-PROC
+and	O
+evaluation	O
+of	O
+a	O
+series	O
+of	O
+acyclic	O
+fleximer	O
+nucleoside	B-CHED
+analogues	I-CHED
+with	O
+anti	O
+-	O
+coronavirus	O
+activity	O
+.	O
+
+The	O
+virus	B-SPEC
+was	O
+first	O
+isolated	O
+from	O
+a	O
+patient	O
+who	O
+died	B-PROC
+from	O
+a	O
+severe	O
+respiratory	O
+illness	O
+in	O
+June	O
+,	O
+2012	O
+,	O
+in	O
+Jeddah	O
+,	O
+Saudi	O
+Arabia	O
+.	O
+
+Clinical	O
+features	O
+of	O
+MERS	O
+range	O
+from	O
+asymptomatic	O
+or	O
+mild	O
+disease	O
+to	O
+acute	O
+respiratory	O
+distress	O
+syndrome	O
+and	O
+multiorgan	B-DISO
+failure	I-DISO
+resulting	O
+in	O
+death	B-PROC
+,	O
+especially	O
+in	O
+individuals	O
+with	O
+underlying	O
+comorbidities	O
+.	O
+
+ABSTRACT	O
+:	O
+Perioperative	O
+complications	O
+commonly	O
+include	O
+oxygenation	B-PROC
+and	O
+ventilation	O
+abnormalities	O
+.	O
+
+Ventilation	O
+impairment	B-DISO
+may	O
+be	O
+due	O
+to	O
+either	O
+neurologic	O
+compromise	O
+such	O
+as	O
+cervical	B-ANAT
+intervertebral	B-DISO
+disk	I-DISO
+disease	I-DISO
+or	O
+severe	O
+parenchymal	O
+disease	O
+,	O
+while	O
+oxygenation	B-PROC
+failure	O
+may	O
+result	O
+from	O
+either	O
+the	O
+underlying	O
+disease	O
+or	O
+severe	O
+complications	O
+such	O
+as	O
+aspiration	B-DISO
+pneumonia	I-DISO
+,	O
+volume	B-DISO
+overload	I-DISO
+,	O
+pulmonary	B-DISO
+thromboembolism	I-DISO
+,	O
+or	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+.	O
+
+Methicillin	B-DISO
+-	I-DISO
+resistant	I-DISO
+Staphylococcus	B-SPEC
+aureus	I-SPEC
+(	O
+MRSA	B-DISO
+),	O
+Moraxella	B-SPEC
+catarrhalis	I-SPEC
+,	O
+and	O
+coronavirus	B-SPEC
+were	O
+the	O
+most	O
+frequently	O
+detected	O
+potentially	O
+infectious	B-DISO
+agents	O
+.	O
+
+Of	O
+the	O
+100	O
+HCPs	O
+tested	O
+during	O
+the	O
+summer	O
+,	O
+37	O
+tested	O
+positive	O
+for	O
+at	O
+least	O
+1	O
+bacterium	B-SPEC
+,	O
+and	O
+4	O
+tested	O
+positive	O
+for	O
+a	O
+viral	O
+agent	O
+.	O
+
+Although	O
+asymptomatic	O
+HCPs	O
+certainly	O
+harbor	O
+a	O
+number	O
+of	O
+different	O
+potentially	O
+infectious	B-DISO
+agents	O
+,	O
+future	O
+studies	O
+are	O
+needed	O
+to	O
+determine	O
+whether	O
+colonized	O
+pathogens	O
+are	O
+transmitted	B-DISO
+or	O
+initiate	O
+infection	B-DISO
+in	O
+at	O
+-	O
+risk	O
+patient	O
+populations	O
+.	O
+
+ABSTRACT	O
+:	O
+Despite	O
+decades	O
+of	O
+research	O
+,	O
+acute	O
+respiratory	O
+distress	O
+syndrome	O
+(	O
+ARDS	B-DISO
+)	O
+remains	O
+an	O
+important	O
+clinical	O
+challenge	O
+due	O
+to	O
+an	O
+incomplete	O
+understanding	O
+of	O
+the	O
+pathophysiological	O
+mechanisms	O
+.	O
+
+Many	O
+substitutions	O
+,	O
+insertions	O
+,	O
+deletions	O
+,	O
+and	O
+some	O
+frameshifts	O
+and	O
+recombination	B-PROC
+events	O
+have	O
+occurred	O
+in	O
+the	O
+genome	O
+of	O
+the	O
+DdCoV	O
+,	O
+as	O
+compared	B-PRGE
+with	I-PRGE
+the	I-PRGE
+coronavirus	I-PRGE
+dominant	I-PRGE
+in	I-PRGE
+chickens	B-SPEC
+(	O
+CdCoV	O
+).	O
+
+TITLE	O
+:	O
+Ligand	B-CHED
+-	O
+induced	O
+Dimerization	O
+of	O
+Middle	O
+East	O
+Respiratory	O
+Syndrome	B-DISO
+(	O
+MERS	O
+)	O
+Coronavirus	B-SPEC
+nsp5	B-PRGE
+Protease	I-PRGE
+(	O
+3CLpro	O
+):	O
+IMPLICATIONS	O
+FOR	O
+nsp5	B-PRGE
+REGULATION	B-PROC
+AND	O
+THE	O
+DEVELOPMENT	B-PROC
+OF	O
+ANTIVIRALS	B-CHED
+.	O
+
+TITLE	O
+:	O
+China	O
+upgrades	O
+surveillance	O
+and	O
+control	O
+measures	O
+of	O
+Middle	O
+East	O
+respiratory	O
+syndrome	B-DISO
+(	O
+MERS	O
+).	O
+
+Although	O
+the	O
+Chinese	O
+government	O
+issued	O
+the	O
+MERS	O
+Prevention	O
+and	O
+Control	O
+Plan	B-DISO
+in	O
+2013	O
+,	O
+a	O
+novel	O
+edition	O
+was	O
+released	O
+on	O
+June	O
+5	O
+,	O
+2015	O
+to	O
+better	O
+cope	O
+with	O
+the	O
+current	O
+epidemic	O
+situation	O
+.	O
+
+Protein	O
+histochemistry	O
+showed	O
+that	O
+the	O
+tissue	B-ANAT
+binding	B-FUNC
+specificity	O
+of	O
+S1	O
+proteins	B-CHED
+of	O
+turkey	B-SPEC
+,	O
+quail	O
+,	O
+and	O
+guineafowl	B-SPEC
+CoVs	O
+was	O
+limited	O
+to	O
+intestinal	B-ANAT
+tissues	B-ANAT
+of	O
+each	O
+particular	O
+host	B-COMP
+,	O
+in	O
+accordance	O
+with	O
+the	O
+reported	O
+pathogenicity	O
+of	O
+these	O
+viruses	B-SPEC
+in	O
+vivo	O
+.	O
+
+In	O
+conclusion	O
+,	O
+our	O
+data	O
+demonstrate	O
+not	O
+only	O
+that	O
+enteric	O
+gammacoronaviruses	O
+recognize	O
+a	O
+novel	O
+glycan	B-PRGE
+receptor	I-PRGE
+but	O
+also	O
+that	O
+enterotropism	O
+may	O
+be	O
+correlated	O
+with	O
+the	O
+high	O
+specificity	O
+of	O
+spike	O
+proteins	B-CHED
+for	O
+such	O
+glycans	B-CHED
+expressed	B-PROC
+in	O
+the	O
+intestines	B-ANAT
+of	O
+the	O
+avian	B-SPEC
+host	B-COMP
+.	O
+
+In	O
+turkey	B-SPEC
+,	O
+guineafowl	B-SPEC
+,	O
+and	O
+quail	O
+,	O
+coronaviruses	O
+have	O
+been	O
+reported	O
+to	O
+be	O
+the	O
+major	O
+causative	O
+agent	O
+of	O
+enteric	O
+diseases	O
+.	O
+
+Specifically	O
+,	O
+turkey	B-SPEC
+coronavirus	B-SPEC
+outbreaks	O
+have	O
+been	O
+reported	O
+in	O
+North	O
+America	O
+,	O
+Europe	O
+,	O
+and	O
+Australia	O
+for	O
+several	O
+decades	O
+.	O
+
+Recently	O
+,	O
+a	O
+gammacoronavirus	B-SPEC
+was	O
+isolated	O
+from	O
+guineafowl	B-SPEC
+with	O
+fulminating	O
+disease	O
+.	O
+
+TITLE	O
+:	O
+Identification	O
+and	O
+pathogenicity	O
+of	O
+a	O
+variant	O
+porcine	B-SPEC
+epidemic	I-SPEC
+diarrhea	I-SPEC
+virus	I-SPEC
+field	O
+strain	O
+with	O
+reduced	O
+virulence	O
+.	O
+
+This	O
+virus	B-SPEC
+gradually	O
+became	O
+the	O
+main	O
+subtype	O
+of	O
+PEDV	B-SPEC
+worldwide	O
+.	O
+
+The	O
+S	B-PRGE
+gene	I-PRGE
+of	O
+FL2013	O
+has	O
+a	O
+7	O
+-	O
+aa	O
+deletion	O
+(	O
+FEKVHVQ	O
+)	O
+in	O
+the	O
+C	O
+-	O
+terminus	O
+comparison	O
+with	O
+the	O
+other	O
+G2	O
+PEDV	O
+sequences	O
+.	O
+
+TITLE	O
+:	O
+Effects	O
+of	O
+porcine	B-SPEC
+epidemic	I-SPEC
+diarrhea	I-SPEC
+virus	I-SPEC
+on	O
+porcine	B-SPEC
+monocyte	B-ANAT
+-	O
+derived	O
+dendritic	B-ANAT
+cells	B-COMP
+and	O
+intestinal	B-ANAT
+dendritic	B-ANAT
+cells	B-COMP
+.	O
+
+ABSTRACT	O
+:	O
+Infection	B-DISO
+with	O
+porcine	B-SPEC
+epidemic	I-SPEC
+diarrhea	I-SPEC
+virus	I-SPEC
+(	O
+PEDV	B-SPEC
+)	O
+causes	O
+damage	O
+to	O
+intestinal	B-ANAT
+epithelial	B-ANAT
+cells	I-ANAT
+and	O
+results	O
+in	O
+acute	B-DISO
+diarrhea	I-DISO
+and	O
+dehydration	B-DISO
+with	O
+high	O
+mortality	O
+rates	O
+in	O
+swine	B-SPEC
+.	O
+
+Dendritic	B-ANAT
+cells	B-COMP
+(	O
+DCs	B-DISO
+)	O
+are	O
+highly	O
+effective	O
+antigen	B-ANAT
+-	I-ANAT
+presenting	I-ANAT
+cells	B-COMP
+widely	O
+distributed	O
+beneath	O
+the	O
+intestinal	B-ANAT
+epithelium	I-ANAT
+,	O
+thus	O
+making	O
+them	O
+an	O
+early	O
+target	O
+for	O
+virus	B-SPEC
+contact	O
+.	O
+
+Consistent	O
+with	O
+these	O
+results	O
+,	O
+after	O
+48	O
+h	O
+of	O
+CV777	O
+infection	B-DISO
+,	O
+there	O
+is	O
+enhancement	O
+in	O
+the	O
+ability	O
+of	O
+porcine	B-SPEC
+intestinal	B-ANAT
+DCs	B-DISO
+to	O
+sample	O
+the	O
+antigen	B-CHED
+and	O
+activate	O
+T	B-PROC
+-	I-PROC
+cell	I-PROC
+proliferation	B-DISO
+in	O
+vivo	O
+.	O
+
+In	O
+this	O
+study	O
+,	O
+the	O
+presence	O
+of	O
+gastroenteritis	O
+viruses	B-SPEC
+(	O
+rotavirus	B-SPEC
+A	I-SPEC
+,	O
+porcine	B-SPEC
+circovirus	I-SPEC
+,	O
+adenovirus	B-DISO
+,	O
+and	O
+porcine	B-SPEC
+bocavirus	B-SPEC
+)	O
+was	O
+investigated	O
+in	O
+a	O
+selection	O
+of	O
+archived	O
+faecal	B-ANAT
+samples	O
+from	O
+asymptomatic	O
+piglets	O
+from	O
+a	O
+commercial	O
+farm	O
+in	O
+Ireland	O
+.	O
+
+ABSTRACT	O
+:	O
+Extracorporeal	O
+lung	B-ANAT
+support	O
+is	O
+currently	O
+used	O
+in	O
+the	O
+treatment	O
+of	O
+patients	O
+with	O
+severe	O
+respiratory	B-DISO
+failure	I-DISO
+until	O
+organ	B-ANAT
+recovery	O
+and	O
+as	O
+a	O
+bridge	O
+to	O
+further	O
+therapeutic	O
+modalities	O
+.	O
+
+A	O
+total	O
+of	O
+262	O
+consecutive	O
+adult	O
+patients	O
+with	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+have	O
+been	O
+treated	O
+with	O
+extracorporeal	O
+membrane	B-COMP
+oxygenation	B-PROC
+between	O
+January	O
+2007	O
+and	O
+May	O
+2012	O
+.	O
+
+TITLE	O
+:	O
+Anthrax	B-SPEC
+lethal	B-ENZY
+toxin	I-ENZY
+-	O
+induced	O
+lung	B-ANAT
+injury	O
+and	O
+treatment	O
+by	O
+activating	O
+MK2	B-PRGE
+.	O
+
+Since	O
+vascular	B-ANAT
+leak	O
+can	O
+also	O
+be	O
+observed	O
+consistently	O
+in	O
+rats	B-SPEC
+injected	O
+intravenously	O
+with	O
+LeTx	O
+,	O
+the	O
+latter	O
+might	O
+present	O
+a	O
+simple	O
+physiologically	O
+relevant	O
+animal	B-SPEC
+model	O
+of	O
+acute	O
+lung	B-ANAT
+injury	O
+(	O
+ALI	O
+).	O
+
+TITLE	O
+:	O
+Therapeutic	O
+Effects	O
+of	O
+Human	B-SPEC
+Mesenchymal	B-ANAT
+Stem	I-ANAT
+Cell	I-ANAT
+-	O
+derived	O
+Microvesicles	O
+in	O
+Severe	O
+Pneumonia	B-DISO
+in	O
+Mice	O
+.	O
+
+We	O
+investigated	O
+the	O
+effects	O
+of	O
+human	B-SPEC
+MSC	O
+MVs	O
+on	O
+lung	B-DISO
+inflammation	I-DISO
+,	O
+protein	B-CHED
+permeability	O
+,	O
+bacterial	O
+clearance	O
+,	O
+and	O
+survival	O
+after	O
+severe	O
+bacterial	B-DISO
+pneumonia	I-DISO
+.	O
+
+We	O
+tested	O
+the	O
+effects	O
+of	O
+MVs	O
+derived	O
+from	O
+human	B-SPEC
+MSCs	B-FUNC
+on	O
+Escherichia	B-DISO
+coli	I-DISO
+pneumonia	I-DISO
+in	O
+mice	B-SPEC
+.	O
+
+MVs	O
+enhanced	O
+monocyte	B-ANAT
+phagocytosis	B-PROC
+of	O
+bacteria	B-SPEC
+while	O
+decreasing	O
+inflammatory	O
+cytokine	B-PROC
+secretion	I-PROC
+and	O
+increased	O
+intracellular	B-COMP
+ATP	B-CHED
+levels	O
+in	O
+injured	O
+alveolar	B-ANAT
+epithelial	O
+type	O
+2	O
+cells	B-COMP
+.	O
+
+Prestimulation	O
+of	O
+MSCs	B-FUNC
+with	O
+a	O
+toll	O
+-	O
+like	O
+receptor	O
+3	O
+agonist	B-CHED
+further	O
+enhanced	O
+the	O
+therapeutic	O
+effects	O
+of	O
+the	O
+released	O
+MVs	O
+.	O
+
+Among	O
+these	O
+patients	O
+,	O
+CoV	O
+was	O
+detected	O
+in	O
+9	O
+.	O
+7	O
+%	O
+of	O
+unique	O
+infection	B-DISO
+episodes	O
+,	O
+with	O
+only	O
+rhinovirus	B-SPEC
+/	O
+enterovirus	B-SPEC
+(	O
+RhV	O
+/	O
+EnV	B-PRGE
+)	O
+infection	B-DISO
+being	O
+more	O
+common	O
+.	O
+
+RESULTS	O
+:	O
+CoV	O
+was	O
+identified	O
+in	O
+2	O
+.	O
+6	O
+%	O
+(	O
+n	O
+=	O
+43	O
+)	O
+of	O
+all	O
+samples	O
+analyzed	O
+(	O
+n	O
+=	O
+1661	O
+)	O
+and	O
+in	O
+6	O
+.	O
+8	O
+%	O
+of	O
+all	O
+samples	O
+testing	O
+positive	O
+for	O
+a	O
+respiratory	O
+virus	B-SPEC
+(	O
+n	O
+=	O
+631	O
+).	O
+
+However	O
+,	O
+the	O
+molecular	O
+mechanisms	O
+underlying	O
+ET	B-PRGE
+-	I-PRGE
+1	I-PRGE
+-	O
+mediated	O
+expression	B-PROC
+of	O
+VCAM	B-PRGE
+-	I-PRGE
+1	I-PRGE
+on	O
+human	B-SPEC
+tracheal	O
+smooth	B-COMP
+muscle	I-COMP
+cells	I-COMP
+(	O
+HTSMCs	O
+)	O
+were	O
+largely	O
+unknown	O
+.	O
+
+We	O
+evaluated	O
+the	O
+capability	O
+of	O
+disinfectants	B-CHED
+to	O
+both	O
+inactivate	O
+PEDV	B-SPEC
+and	O
+sufficiently	O
+damage	O
+viral	O
+RNA	O
+beyond	O
+RT	O
+-	O
+PCR	O
+detection	O
+.	O
+
+However	O
+,	O
+no	O
+disinfectants	B-CHED
+eliminated	O
+RT	O
+-	O
+PCR	O
+detection	O
+of	O
+PEDV	B-SPEC
+across	O
+all	O
+replicates	O
+;	O
+although	O
+,	O
+0	O
+.	O
+52	O
+%,	O
+1	O
+.	O
+03	O
+%	O
+and	O
+2	O
+.	O
+06	O
+%	O
+solutions	O
+of	O
+sodium	O
+hypochlorite	O
+and	O
+0	O
+.	O
+5	O
+%	O
+oxidizing	B-CHED
+agent	I-CHED
+did	O
+intermittently	O
+produce	O
+RT	O
+-	O
+PCR	O
+negatives	O
+.	O
+
+Ultimately	O
+,	O
+viable	O
+PEDV	B-SPEC
+was	O
+not	O
+detected	O
+following	O
+application	O
+of	O
+each	O
+of	O
+the	O
+tested	O
+disinfectants	B-CHED
+,	O
+however	O
+in	O
+most	O
+cases	O
+RT	O
+-	O
+PCR	O
+detection	O
+of	O
+viral	O
+RNA	O
+remained	O
+.	O
+
+We	O
+performed	O
+a	O
+case	O
+-	O
+control	O
+study	O
+of	O
+321	O
+patients	O
+fulfilling	O
+international	O
+criteria	O
+for	O
+severe	B-DISO
+sepsis	I-DISO
+and	O
+ARDS	B-DISO
+who	O
+were	O
+admitted	O
+to	O
+a	O
+Spanish	O
+network	O
+of	O
+post	O
+-	O
+surgical	O
+and	O
+critical	O
+care	O
+units	O
+,	O
+as	O
+well	O
+as	O
+871	O
+population	O
+-	O
+based	O
+controls	O
+.	O
+
+A	O
+better	O
+understanding	O
+of	O
+the	O
+role	O
+of	O
+virus	B-SPEC
+infections	B-DISO
+in	O
+this	O
+condition	B-DISO
+is	O
+needed	O
+to	O
+improve	O
+clinical	O
+management	O
+and	O
+preventive	O
+measures	O
+.	O
+
+Nasopharyngeal	B-ANAT
+aspirates	B-ANAT
+were	O
+obtained	O
+and	O
+analysed	O
+by	O
+real	O
+-	O
+time	O
+PCR	O
+for	O
+15	O
+viruses	B-SPEC
+.	O
+
+There	O
+was	O
+no	O
+association	O
+with	O
+parainfluenza	B-DISO
+virus	B-SPEC
+,	O
+human	B-SPEC
+enterovirus	B-SPEC
+or	O
+rhinovirus	B-SPEC
+and	O
+coronavirus	B-SPEC
+and	O
+bocavirus	B-SPEC
+were	O
+negatively	O
+associated	O
+with	O
+CAP	B-DISO
+.	O
+
+There	O
+was	O
+no	O
+association	O
+with	O
+parainfluenza	B-DISO
+virus	B-SPEC
+,	O
+human	B-SPEC
+enterovirus	B-SPEC
+or	O
+rhinovirus	B-SPEC
+and	O
+coronavirus	B-SPEC
+and	O
+bocavirus	B-SPEC
+were	O
+negatively	O
+associated	O
+with	O
+CAP	B-DISO
+.	O
+
+The	O
+aim	O
+of	O
+this	O
+study	O
+was	O
+to	O
+determine	O
+the	O
+seasonal	O
+distribution	O
+of	O
+agent	O
+viruses	B-SPEC
+in	O
+childhood	O
+respiratory	B-DISO
+infections	I-DISO
+in	O
+our	O
+region	O
+.	O
+
+Parainfluenza	B-DISO
+virus	I-SPEC
+type	I-SPEC
+4	I-SPEC
+,	O
+human	O
+metapneumovirus	O
+,	O
+rhinovirus	B-SPEC
+,	O
+coronavirus	B-SPEC
+,	O
+human	B-SPEC
+bocavirus	I-SPEC
+were	O
+investigated	O
+using	O
+multiplex	O
+PCR	O
+test	O
+.	O
+
+Parainfluenza	B-DISO
+and	O
+respiratory	B-SPEC
+syncytial	I-SPEC
+virus	I-SPEC
+were	O
+found	O
+most	O
+frequently	O
+in	O
+December	O
+-	O
+february	O
+(	O
+58	O
+%	O
+and	O
+59	O
+%,	O
+respectively	O
+,	O
+influenza	B-SPEC
+viruses	I-SPEC
+were	O
+found	O
+most	O
+frequently	O
+in	O
+November	O
+-	O
+december	O
+(	O
+72	O
+%)	O
+and	O
+adenoviruses	B-SPEC
+were	O
+found	O
+most	O
+frequently	O
+in	O
+may	O
+-	O
+september	O
+(	O
+56	O
+%).	O
+
+Although	O
+only	O
+supportive	O
+therapies	O
+are	O
+administered	O
+generally	O
+in	O
+viral	O
+infections	B-DISO
+,	I-DISO
+viral	I-DISO
+investigations	O
+are	O
+important	O
+in	O
+terms	O
+of	O
+determining	O
+the	O
+measures	O
+to	O
+be	O
+taken	O
+by	O
+determining	O
+the	O
+causes	O
+as	O
+well	O
+as	O
+in	O
+terms	O
+of	O
+establishing	O
+a	O
+general	O
+database	O
+.	O
+
+Multivariable	O
+analysis	O
+showed	O
+that	O
+the	O
+duration	O
+of	O
+pre	O
+-	O
+ECMO	O
+ventilation	O
+was	O
+a	O
+significant	O
+independent	O
+predictor	O
+of	O
+death	B-PROC
+(	O
+odds	O
+ratio	O
+[	O
+OR	O
+],	O
+2	O
+.	O
+25	O
+;	O
+95	O
+%	O
+confidence	O
+interval	O
+[	O
+CI	O
+],	O
+1	O
+.	O
+29	O
+to	O
+3	O
+.	O
+90	O
+;	O
+p	O
+=	O
+0	O
+.	O
+004	O
+),	O
+whereas	O
+the	O
+concomitant	O
+use	O
+of	O
+continuous	O
+venovenous	O
+hemodialysis	O
+(	O
+CVVHD	O
+)	O
+was	O
+associated	O
+with	O
+improved	O
+survival	O
+(	O
+OR	O
+,	O
+0	O
+.	O
+55	O
+;	O
+95	O
+%	O
+CI	O
+,	O
+0	O
+.	O
+31	O
+to	O
+0	O
+.	O
+97	O
+;	O
+p	O
+=	O
+0	O
+.	O
+038	O
+).	O
+
+Increased	O
+viscosity	O
+and	O
+cell	B-PROC
+adhesion	B-DISO
+result	O
+in	O
+vasoocclusion	O
+.	O
+
+Thus	O
+,	O
+two	O
+β	O
+-	O
+CoVs	O
+in	O
+group	O
+A	O
+,	O
+HKU1	O
+and	O
+murine	B-SPEC
+CoV	O
+,	O
+have	O
+evolved	O
+to	O
+use	O
+different	O
+regions	O
+of	O
+their	O
+spike	O
+glycoproteins	B-CHED
+to	O
+recognize	O
+their	O
+respective	O
+receptor	O
+proteins	B-CHED
+.	O
+
+TITLE	O
+:	O
+The	O
+Nucleocapsid	B-PRGE
+Protein	B-CHED
+of	O
+Coronaviruses	O
+Acts	O
+as	O
+a	O
+Viral	O
+Suppressor	O
+of	O
+RNA	B-PROC
+Silencing	I-PROC
+in	O
+Mammalian	B-SPEC
+Cells	B-COMP
+.	O
+
+Respiratory	O
+secretions	B-ANAT
+were	O
+tested	O
+for	O
+nucleic	B-CHED
+acids	I-CHED
+of	O
+a	O
+panel	O
+of	O
+respiratory	O
+viruses	B-SPEC
+.	O
+
+An	O
+increase	O
+in	O
+antibody	B-COMP
+titer	O
+was	O
+assessed	O
+for	O
+4	O
+coronavirus	B-SPEC
+strains	O
+.	O
+
+Coronavirus	B-SPEC
+-	O
+associated	O
+illnesses	O
+(	O
+percent	O
+of	O
+illnesses	O
+,	O
+group	O
+1	O
+vs	O
+group	O
+2	O
+)	O
+were	O
+characterized	O
+by	O
+myalgias	B-DISO
+(	O
+21	O
+%	O
+vs	O
+68	O
+%,	O
+P	O
+<	O
+.	O
+01	O
+),	O
+chills	B-DISO
+(	O
+50	O
+%	O
+vs	O
+52	O
+%),	O
+dyspnea	B-DISO
+(	O
+71	O
+%	O
+vs	O
+24	O
+%,	O
+P	O
+<	O
+.	O
+01	O
+),	O
+headache	B-DISO
+(	O
+64	O
+%	O
+vs	O
+72	O
+%),	O
+malaise	B-DISO
+(	O
+64	O
+%	O
+vs	O
+84	O
+%),	O
+cough	B-DISO
+(	O
+86	O
+%	O
+vs	O
+68	O
+%),	O
+sputum	B-PROC
+production	I-PROC
+(	O
+86	O
+%	O
+vs	O
+60	O
+%),	O
+sore	B-DISO
+throat	I-DISO
+(	O
+64	O
+%	O
+vs	O
+80	O
+%),	O
+and	O
+nasal	B-DISO
+congestion	I-DISO
+(	O
+93	O
+%	O
+vs	O
+96	O
+%).	O
+
+To	O
+assess	O
+the	O
+relationship	O
+between	O
+the	O
+severity	O
+of	O
+acute	O
+-	O
+HCA	O
+or	O
+IAI	O
+and	O
+the	O
+development	B-PROC
+of	O
+RDS	O
+in	O
+preterm	O
+newborns	O
+due	O
+to	O
+preterm	B-DISO
+labor	I-DISO
+and	O
+intact	O
+membranes	B-ANAT
+(	O
+PTL	O
+)	O
+or	O
+preterm	B-DISO
+premature	I-DISO
+rupture	I-DISO
+of	I-DISO
+membranes	I-DISO
+(	O
+preterm	O
+-	O
+PROM	O
+)	O
+without	O
+fetal	B-DISO
+growth	B-PROC
+restriction	I-DISO
+(	O
+FGR	O
+).	O
+
+Amniotic	B-ANAT
+fluid	I-ANAT
+MMP	B-CHED
+-	O
+8	O
+was	O
+measured	O
+in	O
+196	O
+patients	O
+delivered	O
+within	O
+7	O
+days	O
+of	O
+amniocentesis	O
+.	O
+
+Mild	O
+to	O
+moderate	O
+,	O
+but	O
+not	O
+minimal	O
+or	O
+severe	O
+,	O
+acute	O
+-	O
+HCA	O
+(	O
+minimal	O
+,	O
+24	O
+%;	O
+mild	O
+,	O
+13	O
+%;	O
+moderate	O
+,	O
+19	O
+%;	O
+severe	O
+,	O
+41	O
+%;	O
+preterm	O
+-	O
+reference	O
+group	O
+,	O
+26	O
+%)	O
+or	O
+IAI	O
+(	O
+minimal	O
+,	O
+24	O
+%;	O
+mild	O
+,	O
+11	O
+%;	O
+moderate	O
+,	O
+17	O
+%;	O
+severe	O
+,	O
+25	O
+%;	O
+preterm	O
+reference	O
+group	O
+,	O
+23	O
+%)	O
+was	O
+associated	O
+with	O
+a	O
+significant	O
+decrease	O
+in	O
+RDS	O
+as	O
+compared	O
+with	O
+the	O
+preterm	O
+reference	O
+group	O
+(	O
+each	O
+for	O
+p	O
+<	O
+0	O
+.	O
+05	O
+after	O
+the	O
+adjustment	O
+of	O
+gestational	O
+age	O
+at	O
+delivery	O
+,	O
+antenatal	O
+corticosteroid	B-CHED
+use	O
+,	O
+newborn	O
+gender	O
+,	O
+cesarean	O
+delivery	O
+and	O
+preterm	O
+-	O
+PROM	O
+as	O
+a	O
+cause	O
+of	O
+preterm	B-DISO
+birth	I-DISO
+).	O
+
+ABSTRACT	O
+:	O
+Severe	O
+acute	O
+lung	B-ANAT
+injury	O
+(	O
+ALI	O
+)	O
+often	O
+develops	O
+into	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+(	O
+ARDS	B-DISO
+).	O
+
+We	O
+used	O
+a	O
+specific	O
+inhibitor	B-CHED
+PD98059	O
+to	O
+antagonize	O
+phosphorylation	B-PROC
+of	O
+p42	B-PRGE
+/	O
+p44	B-PRGE
+MAPK	B-FUNC
+,	O
+or	O
+used	O
+a	O
+specific	O
+inhibitor	B-CHED
+SN203580	O
+to	O
+antagonize	O
+phosphorylation	B-PROC
+of	O
+p38	B-PRGE
+MAPK	B-FUNC
+,	O
+or	O
+used	O
+a	O
+specific	O
+inhibitor	B-CHED
+SIS3	O
+to	O
+antagonize	O
+phosphorylation	B-PROC
+of	O
+SMAD3	B-PRGE
+.	O
+
+PDGF	B-FUNC
+activated	O
+p38	B-FUNC
+MAPK	B-FUNC
+and	O
+p42	B-PRGE
+/	O
+p44	B-PRGE
+MAPK	B-FUNC
+,	O
+but	O
+not	O
+SMAD3	B-PRGE
+in	O
+HLF	O
+cells	B-COMP
+.	O
+
+To	O
+our	O
+knowledge	O
+,	O
+this	O
+is	O
+the	O
+first	O
+report	O
+of	O
+severe	O
+respiratory	B-DISO
+failure	I-DISO
+after	O
+type	O
+B	O
+influenza	B-PATH
+infection	B-DISO
+.	O
+
+TITLE	O
+:	O
+Neutralization	O
+Analysis	O
+of	O
+a	O
+Chicken	B-SPEC
+Single	O
+-	O
+Chain	O
+Variable	O
+Fragment	O
+Derived	O
+from	O
+an	O
+Immune	O
+Antibody	B-FUNC
+Library	O
+Against	O
+Infectious	B-DISO
+Bronchitis	B-DISO
+Virus	B-SPEC
+.	O
+
+ABSTRACT	O
+:	O
+Avian	B-DISO
+infectious	I-DISO
+bronchitis	I-DISO
+virus	B-SPEC
+(	O
+IBV	B-SPEC
+),	O
+which	O
+is	O
+prevalent	O
+in	O
+many	O
+countries	O
+causing	O
+severe	O
+economic	O
+loss	O
+to	O
+the	O
+poultry	O
+industry	O
+,	O
+causes	O
+infectious	B-DISO
+bronchitis	B-DISO
+(	O
+IB	O
+)	O
+in	O
+birds	B-SPEC
+.	O
+
+In	O
+this	O
+study	O
+,	O
+six	O
+anti	B-PRGE
+-	I-PRGE
+IBV	I-PRGE
+chicken	B-SPEC
+scFvs	I-PRGE
+,	O
+ZL	O
+.	O
+10	O
+,	O
+ZL	O
+.	O
+64	O
+,	O
+ZL	O
+.	O
+78	O
+,	O
+ZL	O
+.	O
+80	O
+,	O
+ZL	O
+.	O
+138	O
+,	O
+and	O
+ZL	O
+.	O
+256	O
+,	O
+were	O
+obtained	O
+by	O
+screening	O
+random	O
+clones	O
+from	O
+an	O
+immune	O
+antibody	B-COMP
+library	O
+.	O
+
+ABSTRACT	O
+:	O
+A	O
+severe	O
+porcine	B-SPEC
+epidemic	B-DISO
+diarrhea	I-DISO
+(	O
+PED	O
+)	O
+epizootic	O
+has	O
+been	O
+affecting	O
+pigs	B-SPEC
+of	O
+all	O
+ages	O
+that	O
+are	O
+characterized	O
+by	O
+high	O
+mortality	O
+among	O
+suckling	O
+piglets	O
+in	O
+China	O
+since	O
+late	O
+2010	O
+,	O
+causing	O
+significant	O
+economic	O
+losses	O
+.	O
+
+Obtaining	O
+a	O
+current	O
+-	O
+circulating	O
+PEDV	B-SPEC
+variant	O
+isolate	O
+that	O
+can	O
+grow	O
+efficiently	O
+in	O
+cell	B-COMP
+culture	O
+is	O
+prerequisite	O
+for	O
+the	O
+development	B-PROC
+of	O
+efficient	O
+vaccines	O
+.	O
+
+The	O
+growth	B-PROC
+curve	O
+of	O
+Vero	B-ANAT
+cell	I-ANAT
+-	O
+adapted	O
+HN1303	O
+in	O
+cell	B-COMP
+culture	O
+was	O
+determined	O
+,	O
+and	O
+dynamics	O
+of	O
+virus	O
+production	O
+was	O
+confirmed	O
+by	O
+immunoperoxidase	O
+monolayer	O
+assay	O
+(	O
+IPMA	O
+).	O
+
+TITLE	O
+:	O
+Risks	O
+to	O
+healthcare	O
+workers	O
+with	O
+emerging	O
+diseases	O
+:	O
+lessons	O
+from	O
+MERS	O
+-	O
+CoV	O
+,	O
+Ebola	O
+,	O
+SARS	B-DISO
+,	O
+and	O
+avian	B-SPEC
+flu	I-DISO
+.	O
+
+To	O
+date	O
+,	O
+there	O
+are	O
+no	O
+reports	O
+of	O
+avian	B-DISO
+influenza	I-DISO
+transmission	O
+to	O
+HCPs	O
+from	O
+affected	O
+cases	O
+.	O
+
+Among	O
+them	O
+,	O
+seven	O
+positive	O
+selection	O
+sites	O
+were	O
+chronologically	O
+traced	O
+in	O
+the	O
+temporal	O
+evolution	B-PROC
+routes	O
+of	O
+genotype	O
+D	O
+,	O
+and	O
+six	O
+were	O
+located	O
+around	O
+the	O
+critical	O
+sugar	B-PROC
+binding	I-PROC
+region	O
+in	O
+the	O
+N	O
+-	O
+terminal	O
+domain	O
+(	O
+NTD	O
+)	O
+of	O
+S	O
+protein	O
+,	O
+an	O
+important	O
+sugar	B-PROC
+binding	I-PROC
+domain	O
+of	O
+CoV	O
+.	O
+These	O
+findings	O
+suggest	O
+that	O
+the	O
+genetic	B-PROC
+drift	I-PROC
+of	O
+the	O
+S	B-PRGE
+gene	I-PRGE
+may	O
+play	O
+an	O
+important	O
+role	O
+in	O
+genotype	O
+persistence	O
+in	O
+human	B-SPEC
+populations	O
+,	O
+providing	O
+insights	O
+into	O
+the	O
+mechanisms	O
+of	O
+HCoV	B-SPEC
+-	I-SPEC
+OC43	I-SPEC
+adaptive	O
+evolution	B-PROC
+.	O
+
+TITLE	O
+:	O
+Plasma	B-ANAT
+suPAR	O
+as	O
+a	O
+prognostic	O
+biological	B-CHED
+marker	I-CHED
+for	O
+ICU	O
+mortality	O
+in	O
+ARDS	B-DISO
+patients	O
+.	O
+
+TITLE	O
+:	O
+Immunoprophylactic	O
+effect	O
+of	O
+chicken	B-PRGE
+egg	B-ANAT
+yolk	B-COMP
+antibody	B-COMP
+(	O
+IgY	O
+)	O
+against	O
+a	O
+recombinant	B-PRGE
+S1	I-PRGE
+domain	I-PRGE
+of	O
+the	O
+porcine	O
+epidemic	O
+diarrhea	O
+virus	O
+spike	O
+protein	B-CHED
+in	O
+piglets	O
+.	O
+
+p38	B-FUNC
+mitogen	B-PRGE
+-	I-PRGE
+activated	I-PRGE
+protein	B-CHED
+kinase	I-PRGE
+is	O
+central	O
+to	O
+the	O
+regulation	B-PROC
+of	O
+multiple	O
+inflammatory	O
+mediators	O
+implicated	O
+in	O
+acute	O
+organ	B-ANAT
+dysfunction	O
+and	O
+is	O
+the	O
+target	O
+for	O
+a	O
+novel	O
+class	B-SPEC
+of	O
+cytokine	O
+-	O
+suppressive	O
+anti	B-CHED
+-	I-CHED
+inflammatory	I-CHED
+drugs	I-CHED
+.	O
+
+Data	O
+suggest	O
+the	O
+overcrowding	O
+,	O
+late	O
+recognition	O
+of	O
+MERS	O
+-	O
+CoV	O
+cases	O
+,	O
+and	O
+inadequate	O
+infection	B-DISO
+control	O
+practices	O
+contribute	O
+significantly	O
+to	O
+the	O
+transmission	O
+.	O
+
+ABSTRACT	O
+:	O
+Acute	B-DISO
+Respiratory	I-DISO
+Infections	I-DISO
+(	O
+ARIs	O
+)	O
+are	O
+responsible	O
+for	O
+considerable	O
+morbidity	O
+and	O
+mortality	O
+worldwide	O
+.	O
+
+Documentation	O
+of	O
+respiratory	O
+specimens	O
+can	O
+help	O
+for	O
+an	O
+appropriate	O
+clinical	O
+management	O
+with	O
+a	O
+significant	O
+effect	O
+on	O
+the	O
+disease	O
+progress	O
+in	O
+patient	O
+,	O
+the	O
+antimicrobial	B-CHED
+therapy	O
+used	O
+and	O
+the	O
+risk	O
+of	O
+secondary	O
+spread	O
+of	O
+infection	B-DISO
+.	O
+
+The	O
+infection	B-DISO
+is	O
+acquired	O
+by	O
+coming	O
+into	O
+contact	O
+with	O
+infected	O
+animals	B-SPEC
+,	O
+animal	B-SPEC
+products	O
+,	O
+or	O
+with	O
+patients	O
+who	O
+have	O
+the	O
+syndrome	B-DISO
+.	O
+
+Within	O
+the	O
+endocytic	O
+compartment	B-ANAT
+,	O
+reovirus	B-SPEC
+undergoes	O
+stepwise	O
+disassembly	O
+,	O
+which	O
+is	O
+followed	O
+by	O
+release	B-PATH
+of	O
+the	O
+transcriptionally	O
+active	O
+viral	B-ANAT
+core	I-ANAT
+into	O
+the	O
+cytoplasm	B-COMP
+.	O
+
+In	O
+contrast	O
+,	O
+treatment	O
+of	O
+cells	B-COMP
+with	O
+methiothepin	B-CHED
+mesylate	O
+,	O
+a	O
+serotonin	B-CHED
+antagonist	B-PROC
+,	O
+enhanced	O
+infection	B-DISO
+by	O
+reovirus	B-SPEC
+.	O
+
+TITLE	O
+:	O
+Imported	O
+case	O
+of	O
+MERS	O
+-	O
+CoV	O
+infection	B-DISO
+identified	O
+in	O
+China	O
+,	O
+May	O
+2015	O
+:	O
+detection	O
+and	O
+lesson	O
+learned	B-PROC
+.	O
+
+HRV	O
+was	O
+the	O
+most	O
+commonly	O
+detected	O
+virus	B-SPEC
+(	O
+30	O
+%),	O
+in	O
+which	O
+70	O
+%	O
+were	O
+diagnosed	O
+as	O
+either	O
+pneumonia	B-DISO
+or	O
+bronchiolitis	B-DISO
+.	O
+
+To	O
+date	O
+,	O
+the	O
+cellular	B-COMP
+factors	O
+involved	O
+in	O
+PEDV	B-SPEC
+replication	O
+have	O
+not	O
+been	O
+well	O
+defined	O
+.	O
+
+These	O
+findings	O
+indicate	O
+that	O
+the	O
+ERK	B-FUNC
+signaling	B-PROC
+pathway	I-PROC
+plays	O
+an	O
+important	O
+role	O
+in	O
+the	O
+PEDV	B-SPEC
+life	O
+cycle	O
+and	O
+beneficially	O
+contributes	O
+to	O
+viral	B-DISO
+infection	I-DISO
+.	O
+
+Most	O
+patients	O
+presented	O
+with	O
+non	O
+-	O
+specific	O
+clinical	O
+symptoms	O
+(	O
+nuchal	B-DISO
+rigidity	I-DISO
+and	O
+ataxia	B-DISO
+)	O
+and	O
+showed	O
+a	O
+rapidly	O
+progressive	B-DISO
+disease	I-DISO
+course	O
+(	O
+71	O
+%).	O
+
+One	O
+patient	O
+died	B-PROC
+and	O
+only	O
+two	O
+patients	O
+recovered	O
+completely	O
+.	O
+
+ABSTRACT	O
+:	O
+Viral	B-DISO
+pathogenesis	I-DISO
+studies	O
+in	O
+mice	O
+have	O
+relied	O
+on	O
+markers	O
+of	O
+severe	O
+systemic	B-DISO
+disease	I-DISO
+,	O
+rather	O
+than	O
+clinically	O
+relevant	O
+measures	O
+,	O
+to	O
+evaluate	O
+respiratory	B-DISO
+virus	I-DISO
+infection	I-DISO
+;	O
+thus	O
+confounding	O
+connections	O
+to	O
+human	B-SPEC
+disease	O
+.	O
+
+Immune	B-PROC
+responses	I-PROC
+and	O
+protection	O
+efficacy	O
+of	O
+the	O
+vaccination	O
+vector	O
+were	O
+assessed	O
+in	O
+both	O
+mice	B-SPEC
+and	O
+pig	B-SPEC
+models	O
+.	O
+
+The	O
+cytokine	O
+assays	O
+were	O
+employed	O
+and	O
+the	O
+results	O
+indicated	O
+that	O
+both	O
+the	O
+Th1	O
+-	O
+type	O
+and	O
+Th2	O
+-	O
+type	O
+cytokine	O
+levels	O
+raised	O
+after	O
+vaccination	O
+with	O
+rSPV	O
+-	O
+SA	O
+in	O
+mice	B-SPEC
+models	O
+.	O
+
+When	O
+screening	O
+for	O
+causes	O
+of	O
+death	B-PROC
+in	O
+the	O
+first	O
+year	O
+after	O
+HSCT	O
+in	O
+the	O
+844	O
+patients	O
+,	O
+we	O
+found	O
+that	O
+RVI	O
+as	O
+a	O
+cause	O
+of	O
+death	B-PROC
+was	O
+only	O
+evident	O
+in	O
+the	O
+first	O
+100	O
+days	O
+after	O
+HSCT	O
+.	O
+
+These	O
+results	O
+contribute	O
+to	O
+our	O
+understanding	O
+of	O
+honey	B-SPEC
+bee	I-SPEC
+colony	O
+losses	O
+in	O
+temperate	O
+regions	O
+.	O
+
+ABSTRACT	O
+:	O
+Traditional	O
+approaches	O
+to	O
+antimicrobial	B-CHED
+drug	I-CHED
+development	B-PROC
+are	O
+poorly	O
+suited	O
+to	O
+combatting	O
+the	O
+emergence	O
+of	O
+novel	O
+pathogens	O
+.	O
+
+Here	O
+we	O
+demonstrate	O
+the	O
+use	O
+of	O
+the	O
+VelocImmune	O
+technology	O
+(	O
+a	O
+mouse	B-SPEC
+that	O
+expresses	O
+human	B-PRGE
+antibody	B-COMP
+-	I-PRGE
+variable	I-PRGE
+heavy	I-PRGE
+chains	I-PRGE
+and	O
+κ	O
+light	O
+chains	O
+)	O
+alongside	O
+the	O
+VelociGene	O
+technology	O
+(	O
+which	O
+allows	O
+for	O
+rapid	O
+engineering	O
+of	O
+the	O
+mouse	B-SPEC
+genome	O
+)	O
+to	O
+quickly	O
+develop	O
+and	O
+evaluate	O
+antibodies	B-COMP
+against	O
+an	O
+emerging	O
+viral	B-DISO
+disease	I-DISO
+.	O
+
+The	O
+main	O
+reason	O
+of	O
+apneic	B-DISO
+test	O
+difficulties	O
+was	O
+severe	O
+gas	B-ENZY
+exchange	O
+disturbances	O
+secondary	O
+to	O
+ARDS	B-DISO
+.	O
+
+A	O
+common	O
+cause	O
+of	O
+death	B-PROC
+in	O
+adults	O
+is	O
+acute	B-DISO
+chest	I-DISO
+syndrome	I-DISO
+(	O
+AChS	B-DISO
+)	O
+with	O
+resulting	O
+hypoxemic	O
+respiratory	B-DISO
+failure	I-DISO
+.	O
+
+ABSTRACT	O
+:	O
+Noninvasive	O
+positive	O
+-	O
+pressure	O
+ventilation	O
+(	O
+NPPV	O
+)	O
+in	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+(	O
+ARDS	B-DISO
+)	O
+is	O
+controversial	O
+.	O
+
+In	O
+this	O
+retrospective	O
+,	O
+single	O
+-	O
+center	O
+cohort	O
+study	O
+,	O
+demographic	O
+data	O
+,	O
+clinical	O
+and	O
+biochemical	O
+parameters	O
+of	O
+AP	O
+and	O
+developed	O
+ARDS	B-DISO
+on	O
+admission	O
+as	O
+well	O
+as	O
+before	O
+and	O
+after	O
+use	O
+of	O
+NPPV	O
+,	O
+and	O
+clinical	O
+outcomes	O
+were	O
+retrieved	O
+from	O
+the	O
+medical	O
+record	O
+database	O
+.	O
+
+We	O
+found	O
+substantial	O
+potential	O
+for	O
+superspreading	O
+;	O
+even	O
+though	O
+it	O
+is	O
+likely	O
+that	O
+R0	O
+<	O
+1	O
+overall	O
+,	O
+our	O
+analysis	O
+indicates	O
+that	O
+cluster	O
+sizes	O
+of	O
+over	O
+150	O
+cases	O
+are	O
+not	O
+unexpected	O
+forMERS	O
+-	O
+CoV	O
+infection	B-DISO
+.	O
+
+Accelerated	O
+virus	B-SPEC
+control	O
+in	O
+mice	B-SPEC
+lacking	O
+the	O
+anti	B-PRGE
+-	I-PRGE
+inflammatory	I-PRGE
+cytokine	I-PRGE
+IL	I-PRGE
+-	I-PRGE
+10	I-PRGE
+was	O
+associated	O
+with	O
+limited	O
+initial	O
+demyelination	B-DISO
+,	O
+but	O
+low	O
+viral	O
+mRNA	B-CHED
+persistence	O
+similar	O
+to	O
+WT	O
+mice	B-SPEC
+and	O
+declining	O
+antiviral	B-CHED
+cellular	B-PROC
+immunity	I-PROC
+.	O
+
+The	O
+formation	B-PROC
+of	O
+discrete	O
+foci	O
+of	O
+demyelination	B-DISO
+in	O
+IL	B-FUNC
+-	I-FUNC
+10	I-FUNC
+sufficient	O
+mice	B-SPEC
+correlated	O
+with	O
+IL	B-PRGE
+-	I-PRGE
+10	I-PRGE
+receptor	B-PROC
+expression	I-PROC
+exclusively	O
+on	O
+astrocytes	B-ANAT
+in	O
+areas	O
+of	O
+demyelination	B-DISO
+suggesting	O
+a	O
+critical	O
+role	O
+for	O
+IL	B-FUNC
+-	I-FUNC
+10	I-FUNC
+signaling	B-PROC
+to	O
+astrocytes	B-ANAT
+in	O
+limiting	O
+expansion	O
+of	O
+initial	O
+areas	O
+of	O
+white	B-ANAT
+matter	I-ANAT
+damage	O
+.	O
+
+These	O
+early	O
+and	O
+late	O
+phases	O
+are	O
+based	O
+on	O
+the	O
+timing	O
+in	O
+relationship	O
+to	O
+lung	B-ANAT
+injury	O
+and	O
+the	O
+underlying	O
+mechanisms	O
+.	O
+
+TITLE	O
+:	O
+Emergence	O
+of	O
+porcine	B-SPEC
+epidemic	I-SPEC
+diarrhea	I-SPEC
+virus	I-SPEC
+in	O
+southern	O
+Germany	O
+.	O
+
+Epidemic	O
+outbreaks	O
+of	O
+diarrhea	B-DISO
+affecting	O
+pigs	B-SPEC
+of	O
+all	O
+age	O
+groups	O
+were	O
+reported	O
+in	O
+three	O
+farms	O
+,	O
+one	O
+fattening	O
+farm	O
+and	O
+two	O
+piglet	O
+producing	O
+farms	O
+,	O
+in	O
+South	O
+-	O
+Western	O
+Germany	O
+between	O
+May	O
+and	O
+November	O
+2014	O
+.	O
+
+This	O
+strain	O
+with	O
+insertions	O
+and	O
+deletions	O
+in	O
+the	O
+S	B-PRGE
+-	I-PRGE
+gene	I-PRGE
+(	O
+so	O
+called	O
+INDEL	B-PROC
+strains	O
+)	O
+was	O
+reported	O
+to	O
+show	O
+lower	O
+virulence	B-PROC
+.	O
+
+ABSTRACT	O
+:	O
+Coronaviruses	O
+(	O
+CoVs	O
+)	O
+assemble	O
+by	O
+budding	B-PATH
+into	O
+the	O
+lumen	B-ANAT
+of	O
+the	O
+early	O
+Golgi	B-COMP
+complex	I-COMP
+prior	O
+to	O
+exocytosis	B-PROC
+.	O
+
+The	O
+small	B-PRGE
+CoV	I-PRGE
+envelope	I-PRGE
+(	O
+E	O
+)	O
+protein	B-CHED
+plays	O
+roles	O
+in	O
+assembly	O
+,	O
+virion	B-COMP
+release	B-PATH
+,	O
+and	O
+pathogenesis	B-DISO
+.	O
+
+A	O
+high	O
+-	O
+order	B-SPEC
+oligomer	O
+of	O
+IBV	B-SPEC
+E	O
+is	O
+required	O
+for	O
+the	O
+production	O
+of	O
+virus	B-ANAT
+-	I-ANAT
+like	I-ANAT
+particles	I-ANAT
+(	O
+VLPs	B-ANAT
+),	O
+implicating	O
+this	O
+form	O
+of	O
+the	O
+protein	B-CHED
+in	O
+virion	B-PROC
+assembly	I-PROC
+.	O
+
+TITLE	O
+:	O
+[	O
+Mechanisms	O
+of	O
+viral	O
+emergence	O
+and	O
+interspecies	O
+transmission	O
+:	O
+the	O
+exemple	O
+of	O
+simian	O
+foamy	B-SPEC
+viruses	I-SPEC
+in	O
+Central	O
+Africa	O
+].	O
+
+In	O
+this	O
+review	O
+,	O
+after	O
+an	O
+introduction	O
+on	O
+emerging	O
+viruses	B-SPEC
+,	O
+we	O
+will	O
+briefly	O
+present	O
+the	O
+results	O
+of	O
+a	O
+large	O
+epidemiological	O
+study	O
+performed	O
+in	O
+groups	O
+of	O
+Bantus	O
+and	O
+Pygmies	O
+living	O
+in	O
+villages	O
+and	O
+settlements	O
+located	O
+in	O
+the	O
+rain	O
+forest	O
+of	O
+the	O
+South	O
+region	O
+of	O
+Cameroon	O
+.	O
+
+From	O
+August	O
+2009	O
+to	O
+July	O
+2013	O
+,	O
+206	O
+patients	O
+with	O
+Yangming	O
+Fushi	O
+syndrome	B-DISO
+combined	O
+with	O
+ALI	O
+/	O
+ARDS	B-DISO
+were	O
+enrolled	O
+in	O
+the	O
+intensive	O
+care	O
+units	O
+(	O
+ICUs	O
+)	O
+of	O
+the	O
+following	O
+five	O
+hospitals	O
+:	O
+Tianjin	O
+Nankai	O
+Hospital	O
+,	O
+Dongzhimen	O
+Hospital	O
+Affiliated	O
+to	O
+Beijing	O
+Traditional	O
+Chinese	O
+Medicine	B-CHED
+University	O
+,	O
+General	O
+Hospital	O
+of	O
+Tianjin	O
+Medical	O
+University	O
+,	O
+the	O
+First	O
+Affiliated	O
+Hospital	O
+of	O
+Dalian	O
+Medical	O
+University	O
+,	O
+and	O
+Wuxi	O
+Third	O
+People	O
+'	O
+s	O
+Hospital	O
+in	O
+Jiangsu	O
+Province	O
+.	O
+
+Logistic	O
+regression	O
+analysis	O
+was	O
+used	O
+to	O
+look	O
+for	O
+the	O
+independent	O
+risk	O
+factors	O
+of	O
+death	B-PROC
+of	O
+patients	O
+.	O
+
+were	O
+all	O
+obviously	O
+higher	O
+in	O
+the	O
+death	B-PROC
+group	O
+than	O
+those	O
+in	O
+the	O
+survival	O
+group	O
+.	O
+
+RESULTS	O
+:	O
+There	O
+were	O
+124	O
+cases	O
+with	O
+severe	O
+acute	B-DISO
+pancreatitis	I-DISO
+(	O
+SAP	O
+),	O
+which	O
+was	O
+the	O
+most	O
+common	O
+disease	O
+with	O
+manifestation	O
+of	O
+Yangming	O
+Fushi	O
+syndrome	B-DISO
+combined	O
+with	O
+ALI	O
+/	O
+ARDS	B-DISO
+,	O
+accounting	O
+for	O
+60	O
+.	O
+19	O
+%	O
+of	O
+all	O
+the	O
+patients	O
+.	O
+
+312	O
+patients	O
+with	O
+sepsis	B-DISO
+admitted	O
+to	O
+Department	O
+of	O
+Emergency	B-DISO
+of	O
+China	O
+Medical	O
+University	O
+Affiliated	O
+First	O
+Hospital	O
+were	O
+retrospectively	O
+analyzed	O
+,	O
+and	O
+they	O
+were	O
+divided	O
+into	O
+two	O
+groups	O
+according	O
+to	O
+development	B-PROC
+of	O
+ARDS	B-DISO
+,	O
+which	O
+was	O
+defined	O
+according	O
+to	O
+the	O
+Berlin	O
+new	O
+definition	O
+.	O
+
+Univariate	O
+analysis	O
+showed	O
+that	O
+age	O
+(	O
+t	O
+=-	O
+2	O
+.	O
+134	O
+,	O
+P	O
+=	O
+0	O
+.	O
+035	O
+),	O
+oxygenation	B-PROC
+index	O
+(	O
+t	O
+=-	O
+4	O
+.	O
+245	O
+,	O
+P	O
+=	O
+0	O
+.	O
+001	O
+),	O
+arterial	B-ANAT
+lactate	B-CHED
+(	O
+Lac	B-PRGE
+,	O
+t	O
+=	O
+6	O
+.	O
+245	O
+,	O
+P	O
+<	O
+0	O
+.	O
+001	O
+),	O
+drugs	O
+for	O
+vascular	B-DISO
+diseases	I-DISO
+(	O
+χ2	O
+=	O
+4	O
+.	O
+261	O
+,	O
+P	O
+=	O
+0	O
+.	O
+026	O
+),	O
+shock	O
+(	O
+χ2	O
+=	O
+4	O
+.	O
+386	O
+,	O
+P	O
+=	O
+0	O
+.	O
+021	O
+),	O
+MEDS	B-DISO
+(	O
+t	O
+=	O
+4	O
+.	O
+021	O
+,	O
+P	O
+=	O
+0	O
+.	O
+045	O
+),	O
+LIPS	B-ANAT
+(	O
+t	O
+=	O
+5	O
+.	O
+569	O
+,	O
+P	O
+<	O
+0	O
+.	O
+001	O
+),	O
+lung	B-ANAT
+infections	B-DISO
+(	O
+χ2	O
+=	O
+4	O
+.	O
+289	O
+,	O
+P	O
+=	O
+0	O
+.	O
+025	O
+),	O
+and	O
+mechanical	O
+ventilation	O
+(	O
+χ2	O
+=	O
+6	O
+.	O
+245	O
+,	O
+P	O
+=	O
+0	O
+.	O
+001	O
+)	O
+were	O
+related	O
+to	O
+ARDS	B-DISO
+.	O
+
+Bedside	O
+LUS	O
+,	O
+which	O
+is	O
+simple	O
+and	O
+easily	O
+available	O
+,	O
+could	O
+evaluate	O
+the	O
+changes	O
+in	O
+pulmonary	B-PROC
+ventilation	I-PROC
+area	O
+of	O
+ARDS	B-DISO
+,	O
+and	O
+its	O
+degree	O
+of	O
+severity	O
+,	O
+and	O
+prognosis	O
+including	O
+prediction	O
+of	O
+mortality	O
+of	O
+the	O
+patients	O
+.	O
+
+ABSTRACT	O
+:	O
+Middle	O
+East	O
+respiratory	O
+syndrome	B-DISO
+(	O
+MERS	O
+)	O
+coronavirus	B-SPEC
+(	O
+Co	O
+-	O
+V	O
+)	O
+contains	O
+a	O
+single	O
+spike	O
+(	O
+S	O
+)	O
+protein	B-CHED
+,	O
+which	O
+binds	B-FUNC
+to	O
+a	O
+receptor	O
+molecule	O
+,	O
+dipeptidyl	B-PRGE
+peptidase	I-PRGE
+4	I-PRGE
+(	O
+DPP4	B-PRGE
+;	O
+also	O
+known	O
+as	O
+CD26	B-PRGE
+),	O
+and	O
+serves	O
+as	O
+a	O
+neutralizing	O
+antigen	B-CHED
+.	O
+
+We	O
+also	O
+examined	O
+associations	O
+between	O
+new	O
+-	O
+onset	O
+AF	O
+and	O
+markers	O
+of	O
+inflammation	B-DISO
+(	O
+interleukin	B-PRGE
+6	I-PRGE
+and	O
+interleukin	B-PRGE
+8	I-PRGE
+),	O
+myocardial	O
+injury	O
+(	O
+troponin	B-PRGE
+I	I-PRGE
+),	O
+autonomic	B-ANAT
+activation	O
+(	O
+epinephrine	B-CHED
+),	O
+and	O
+atrial	B-ANAT
+stretch	O
+(	O
+central	O
+venous	B-PROC
+pressure	I-PROC
+)	O
+as	O
+well	O
+as	O
+other	O
+clinical	O
+characteristics	O
+.	O
+
+We	O
+did	O
+not	O
+identify	O
+associations	O
+between	O
+new	O
+-	O
+onset	O
+AF	O
+and	O
+baseline	O
+central	O
+venous	B-PROC
+pressure	I-PROC
+,	O
+plasma	B-ANAT
+levels	O
+of	O
+troponin	B-PRGE
+I	I-PRGE
+,	O
+epinephrine	B-CHED
+,	O
+interleukin	B-PRGE
+6	I-PRGE
+,	O
+or	O
+interleukin	B-PRGE
+8	I-PRGE
+.	O
+
+The	O
+result	O
+suggested	O
+that	O
+compared	O
+with	O
+the	O
+P110	O
+strain	O
+,	O
+the	O
+P3	O
+strain	O
+induced	O
+a	O
+more	O
+pronounced	O
+host	B-COMP
+innate	B-DISO
+immune	I-DISO
+response	I-DISO
+.	O
+
+Furthermore	O
+,	O
+we	O
+observed	O
+that	O
+recombinant	O
+AvBDs	O
+(	O
+including	O
+2	O
+,	O
+6	O
+,	O
+and	O
+12	O
+)	O
+demonstrated	O
+obvious	O
+anti	O
+-	O
+viral	O
+activity	O
+against	O
+IBV	B-SPEC
+in	O
+vitro	O
+.	O
+
+Our	O
+findings	O
+contribute	O
+to	O
+the	O
+proposal	O
+that	O
+IBV	B-SPEC
+infection	B-DISO
+induces	O
+an	O
+increase	O
+in	O
+the	O
+messenger	B-CHED
+RNA	I-CHED
+(	O
+mRNA	B-CHED
+)	O
+expression	B-PROC
+of	O
+some	O
+AvBDs	O
+and	O
+TLRs	O
+,	O
+which	O
+suggests	O
+that	O
+AvBDs	O
+may	O
+play	O
+significant	O
+roles	O
+in	O
+the	O
+resistance	B-PROC
+of	O
+chickens	B-SPEC
+to	O
+IBV	B-SPEC
+replication	O
+.	O
+
+Since	O
+the	O
+first	O
+identification	O
+of	O
+Middle	O
+Eastern	O
+Respiratory	O
+Syndrome	O
+coronavirus	B-SPEC
+(	O
+MERS	O
+-	O
+CoV	O
+)	O
+in	O
+2012	O
+the	O
+virus	B-SPEC
+has	O
+infected	O
+1289	O
+humans	B-SPEC
+with	O
+approximately	O
+40	O
+%	O
+mortalities	O
+.	O
+
+Human	B-SPEC
+-	O
+to	O
+-	O
+human	B-SPEC
+transmission	O
+though	O
+was	O
+observed	O
+on	O
+several	O
+occasions	O
+in	O
+past	O
+,	O
+it	O
+is	O
+documented	O
+as	O
+non	O
+-	O
+sustainable	O
+event	O
+.	O
+
+TITLE	O
+:	O
+Human	B-SPEC
+infection	B-DISO
+with	O
+a	O
+novel	O
+,	O
+highly	O
+pathogenic	O
+avian	B-DISO
+influenza	B-PATH
+A	I-PATH
+(	O
+H5N6	O
+)	O
+virus	B-SPEC
+:	O
+Virological	O
+and	O
+clinical	O
+findings	O
+.	O
+
+The	O
+patient	O
+,	O
+who	O
+presented	O
+with	O
+fever	B-PROC
+,	O
+severe	O
+pneumonia	B-DISO
+,	O
+leucopenia	B-DISO
+,	O
+and	O
+lymphopenia	B-DISO
+,	O
+developed	O
+septic	B-DISO
+shock	I-DISO
+and	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+(	O
+ARDS	B-DISO
+),	O
+and	O
+died	B-PROC
+on	O
+day	O
+10	O
+after	O
+illness	O
+onset	O
+.	O
+
+A	O
+novel	O
+reassortant	O
+avian	B-SPEC
+-	O
+origin	O
+influenza	B-PATH
+A	I-PATH
+(	O
+H5N6	O
+)	O
+virus	B-SPEC
+was	O
+isolated	O
+from	O
+the	O
+throat	B-ANAT
+swab	I-ANAT
+or	O
+trachea	B-DISO
+aspirate	B-ANAT
+of	O
+the	O
+patient	O
+.	O
+
+The	O
+cleavage	B-PROC
+site	O
+of	O
+the	O
+HA	B-PRGE
+gene	I-PRGE
+contained	O
+multiple	O
+basic	O
+amino	B-CHED
+acids	I-CHED
+,	O
+indicating	O
+that	O
+the	O
+novel	O
+H5N6	O
+virus	B-SPEC
+was	O
+highly	O
+pathogenic	O
+in	O
+chicken	B-SPEC
+.	O
+
+The	O
+possibility	O
+of	O
+NPE	O
+should	O
+be	O
+considered	O
+in	O
+relatively	O
+young	O
+patients	O
+with	O
+higher	O
+glucose	B-CHED
+and	O
+lower	O
+blood	B-ANAT
+pH	O
+value	O
+.	O
+
+RESULTS	O
+:	O
+Although	O
+the	O
+mean	O
+arterial	B-PROC
+pressure	I-PROC
+was	O
+similar	O
+between	O
+these	O
+two	O
+groups	O
+,	O
+the	O
+median	O
+pH	O
+and	O
+the	O
+bicarbonate	B-CHED
+ion	I-CHED
+(	O
+HCO	O
+(	O
+3	O
+)(-))	O
+were	O
+significantly	O
+lower	O
+in	O
+the	O
+NPE	O
+group	O
+than	O
+in	O
+the	O
+non	O
+-	O
+NPE	O
+group	O
+(	O
+pH	O
+:	O
+7	O
+.	O
+32	O
+vs	O
+.	O
+7	O
+.	O
+39	O
+,	O
+P	O
+=	O
+0	O
+.	O
+002	O
+;	O
+HCO	O
+(	O
+3	O
+)(-),	O
+20	O
+.	O
+6	O
+mmol	O
+/	O
+L	O
+vs	O
+.	O
+22	O
+.	O
+7	O
+mmol	O
+/	O
+L	O
+,	O
+P	O
+=	O
+0	O
+.	O
+01	O
+).	O
+
+Moreover	O
+,	O
+alanine	B-CHED
+replacement	O
+of	O
+charged	O
+amino	B-CHED
+-	I-CHED
+acid	I-CHED
+residues	I-CHED
+of	O
+the	O
+SUD	B-PRGE
+-	I-PRGE
+M	I-PRGE
+domain	I-PRGE
+,	O
+which	O
+are	O
+likely	O
+involved	O
+in	O
+G	O
+-	O
+quadruplex	O
+-	O
+binding	B-FUNC
+,	O
+caused	O
+abrogation	O
+of	O
+RTC	O
+activity	O
+.	O
+
+We	O
+used	O
+a	O
+previously	O
+developed	O
+methodology	O
+to	O
+determine	O
+severe	O
+influenza	B-DISO
+burden	O
+in	O
+South	O
+Africa	O
+.	O
+
+We	O
+applied	O
+rates	O
+of	O
+hospitalized	O
+and	O
+non	O
+-	O
+hospitalized	O
+influenza	B-DISO
+-	O
+associated	O
+SARI	O
+to	O
+census	O
+data	O
+to	O
+calculate	O
+the	O
+national	O
+number	O
+of	O
+cases	O
+.	O
+
+In	O
+2010	O
+,	O
+there	O
+were	O
+an	O
+estimated	O
+21	O
+,	O
+555	O
+total	O
+severe	O
+influenza	B-DISO
+cases	O
+in	O
+HIV	B-DISO
+-	O
+uninfected	O
+individuals	O
+and	O
+13	O
+,	O
+876	O
+in	O
+HIV	B-DISO
+-	O
+infected	O
+individuals	O
+.	O
+
+TITLE	O
+:	O
+Cytomegalovirus	B-SPEC
+pneumonia	I-DISO
+as	O
+the	O
+first	O
+manifestation	O
+of	O
+severe	B-DISO
+combined	I-DISO
+immunodeficiency	I-DISO
+.	O
+
+Severe	B-DISO
+combined	I-DISO
+immunodeficiency	I-DISO
+is	O
+a	O
+pediatric	O
+emergency	B-DISO
+condition	B-DISO
+and	O
+given	O
+the	O
+significant	O
+impact	O
+of	O
+pulmonary	B-ANAT
+CMV	B-DISO
+infection	I-DISO
+in	O
+SCID	B-DISO
+children	O
+,	O
+establishing	O
+an	O
+accurate	O
+etiological	O
+diagnosis	O
+is	O
+of	O
+essential	O
+importance	O
+in	O
+instituting	O
+the	O
+specific	O
+treatment	O
+and	O
+improving	O
+the	O
+outcome	O
+.	O
+
+Polymorphisms	B-PROC
+at	O
+OAS1	B-PRGE
+have	O
+been	O
+shown	O
+to	O
+correlate	O
+with	O
+differential	O
+susceptibility	O
+to	O
+several	O
+infections	B-DISO
+of	O
+great	O
+public	O
+health	O
+significance	O
+,	O
+including	O
+hepatitis	B-SPEC
+C	I-SPEC
+virus	I-SPEC
+,	O
+SARS	B-DISO
+coronavirus	B-SPEC
+,	O
+and	O
+West	B-DISO
+Nile	I-DISO
+virus	I-DISO
+.	O
+
+Here	O
+,	O
+we	O
+used	O
+51	O
+respiratory	B-ANAT
+samples	I-ANAT
+from	O
+32	O
+patients	O
+with	O
+confirmed	O
+MERS	O
+-	O
+CoV	O
+infection	B-DISO
+for	O
+virus	B-SPEC
+isolation	O
+in	O
+Vero	O
+B4	O
+and	O
+Caco	O
+-	O
+2	O
+cells	B-COMP
+.	O
+
+We	O
+found	O
+Caco	O
+-	O
+2	O
+cells	B-COMP
+to	O
+significantly	O
+enhance	O
+isolation	O
+success	O
+over	O
+routinely	O
+used	O
+Vero	B-ANAT
+cells	I-ANAT
+.	O
+
+TITLE	O
+:	O
+Transmissible	O
+gastroenteritis	B-DISO
+virus	B-SPEC
+(	O
+TGEV	B-SPEC
+)	O
+infection	B-DISO
+alters	O
+the	O
+expression	B-PROC
+of	O
+cellular	B-COMP
+microRNA	O
+species	O
+that	O
+affect	O
+transcription	B-PROC
+of	O
+TGEV	B-SPEC
+gene	O
+7	O
+.	O
+
+TGEV	B-SPEC
+infection	B-DISO
+has	O
+emerged	O
+as	O
+a	O
+major	O
+cause	O
+of	O
+severe	O
+gastroenteritis	B-DISO
+and	O
+leads	O
+to	O
+alterations	O
+of	O
+many	O
+cellular	B-COMP
+processes	O
+.	O
+
+In	O
+conclusion	O
+,	O
+differentially	O
+expressed	B-PROC
+miR	O
+-	O
+4331	O
+that	O
+is	O
+caused	O
+by	O
+TGEV	B-SPEC
+infection	B-DISO
+can	O
+suppress	O
+transcription	B-PROC
+of	O
+TGEV	B-PRGE
+gene	I-PRGE
+7	I-PRGE
+via	O
+targeting	B-PROC
+cellular	B-COMP
+CDCA7	B-PRGE
+.	O
+
+Porcine	B-SPEC
+epidemic	B-DISO
+diarrhoea	I-DISO
+with	O
+non	O
+-	O
+lethal	O
+effects	O
+in	O
+piglets	O
+was	O
+identified	O
+in	O
+Tottori	O
+prefecture	O
+in	O
+October	O
+2014	O
+.	O
+
+The	O
+results	O
+of	O
+this	O
+study	O
+demonstrated	O
+that	O
+Virus	O
+Counter	B-CHED
+is	O
+a	O
+simple	O
+and	O
+reliable	O
+method	O
+to	O
+quantify	O
+the	O
+viral	B-COMP
+particles	I-COMP
+of	O
+PEDV	B-SPEC
+.	O
+
+Sedation	B-DISO
+was	O
+performed	O
+only	O
+intermittently	O
+in	O
+72	O
+(	O
+60	O
+%)	O
+patients	O
+,	O
+was	O
+switched	O
+to	O
+continuously	O
+in	O
+37	O
+(	O
+31	O
+%)	O
+and	O
+was	O
+applied	O
+only	O
+continuously	O
+in	O
+11	O
+(	O
+9	O
+%).	O
+
+In	O
+non	O
+-	O
+DNI	O
+patients	O
+(	O
+n	O
+=	O
+39	O
+),	O
+no	O
+patient	O
+required	O
+intubation	O
+due	O
+to	O
+agitation	B-DISO
+with	O
+continuous	O
+sedation	B-DISO
+,	O
+and	O
+in	O
+DNI	O
+patients	O
+(	O
+n	O
+=	O
+81	O
+),	O
+96	O
+%	O
+of	O
+patients	O
+could	O
+continue	O
+NIV	O
+treatment	O
+.	O
+
+According	O
+to	O
+RASS	O
+scores	O
+,	O
+sedation	B-DISO
+during	O
+NIV	O
+in	O
+proficient	O
+hospitals	O
+may	O
+be	O
+favorably	O
+used	O
+to	O
+potentially	O
+avoid	O
+NIV	O
+failure	O
+in	O
+agitated	B-DISO
+patients	O
+,	O
+even	O
+in	O
+those	O
+having	O
+diseases	O
+with	O
+poor	O
+evidence	O
+of	O
+the	O
+usefulness	O
+of	O
+NIV	O
+.	O
+
+Serious	O
+maternal	O
+complications	O
+were	O
+defined	O
+as	O
+:	O
+hemorrhage	B-DISO
+(	O
+blood	B-ANAT
+loss	I-DISO
+≥	O
+1500	O
+mL	O
+,	O
+blood	O
+transfusion	O
+,	O
+or	O
+hysterectomy	O
+for	O
+hemorrhage	B-DISO
+),	O
+infection	B-DISO
+(	O
+endometritis	B-DISO
+,	O
+wound	B-DISO
+dehiscence	I-DISO
+,	O
+or	O
+wound	B-DISO
+infection	I-DISO
+requiring	O
+antibiotics	B-CHED
+,	O
+reopening	O
+,	O
+or	O
+unexpected	O
+procedure	O
+),	O
+intensive	O
+care	O
+unit	O
+admission	O
+,	O
+or	O
+death	B-PROC
+.	O
+
+The	O
+risk	O
+of	O
+maternal	O
+complications	O
+after	O
+early	O
+preterm	B-DISO
+delivery	I-DISO
+is	O
+substantial	O
+,	O
+particularly	O
+in	O
+women	O
+who	O
+undergo	O
+cesarean	O
+delivery	O
+.	O
+
+There	O
+was	O
+no	O
+significant	O
+difference	O
+in	O
+complication	B-DISO
+rates	O
+between	O
+CCD	B-DISO
+and	O
+LTCD	O
+(	O
+aRR	O
+,	O
+1	O
+.	O
+37	O
+;	O
+95	O
+%	O
+CI	O
+,	O
+0	O
+.	O
+95	O
+-	O
+1	O
+.	O
+97	O
+)	O
+or	O
+between	O
+CCD	B-DISO
+and	O
+LVCD	O
+(	O
+aRR	O
+,	O
+1	O
+.	O
+56	O
+;	O
+95	O
+%	O
+CI	O
+,	O
+0	O
+.	O
+48	O
+-	O
+5	O
+.	O
+07	O
+).	O
+
+CONCLUSIONS	O
+:	O
+The	O
+risk	O
+of	O
+maternal	O
+complications	O
+after	O
+early	O
+preterm	B-DISO
+delivery	I-DISO
+is	O
+substantial	O
+,	O
+particularly	O
+in	O
+women	O
+who	O
+undergo	O
+cesarean	O
+delivery	O
+.	O
+
+ABSTRACT	O
+:	O
+Only	O
+a	O
+few	O
+pneumotropic	O
+types	O
+of	O
+the	O
+human	B-SPEC
+adenoviruses	B-SPEC
+(	O
+e	O
+.	O
+g	O
+.	O
+type	O
+B14p1	O
+)	O
+cause	O
+severe	O
+lower	B-DISO
+respiratory	I-DISO
+tract	I-DISO
+infections	I-DISO
+like	O
+pneumonia	B-DISO
+and	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+(	O
+ARDS	B-DISO
+)	O
+even	O
+in	O
+immunocompetent	O
+patients	O
+.	O
+
+The	O
+efficient	O
+""""	O
+apical	O
+to	O
+apical	O
+""""	O
+replication	O
+cycle	O
+of	O
+HAdV	O
+-	O
+B14p1	O
+can	O
+promote	O
+endobronchial	O
+dissemination	O
+of	O
+the	O
+infection	B-DISO
+from	O
+the	O
+upper	O
+to	O
+the	O
+lower	B-ANAT
+respiratory	I-ANAT
+tract	I-ANAT
+.	O
+
+Recent	O
+developments	O
+include	O
+experimental	O
+and	O
+clinical	O
+evidence	O
+that	O
+a	O
+stepwise	O
+extended	O
+recruitment	B-DISO
+maneuver	O
+may	O
+cause	O
+an	O
+improvement	O
+in	O
+aerated	O
+lung	B-PROC
+volume	I-PROC
+and	O
+decrease	O
+the	O
+biological	O
+impact	O
+seen	O
+with	O
+the	O
+traditionally	O
+used	O
+sustained	O
+inflation	O
+,	O
+with	O
+less	O
+adverse	B-DISO
+effects	I-DISO
+.	O
+
+In	O
+patients	O
+with	O
+severe	O
+ARDS	B-DISO
+,	O
+applicating	O
+2	O
+-	O
+4	O
+hours	O
+validity	O
+of	O
+prone	O
+position	O
+ventilation	O
+significantly	O
+improves	O
+the	O
+pulmonary	B-PROC
+ventilation	I-PROC
+,	O
+more	O
+than	O
+4	O
+h	O
+PPV	B-CHED
+do	O
+not	O
+better	O
+for	O
+patients	O
+probably	O
+.	O
+
+RESULTS	O
+:	O
+The	O
+aeration	O
+score	O
+of	O
+the	O
+lung	B-ANAT
+at	O
+T1	O
+,	O
+T2	O
+,	O
+T3	O
+,	O
+T4	O
+was	O
+significantly	O
+reduced	O
+than	O
+T0	O
+all	O
+,	O
+the	O
+ventilation	O
+situation	O
+of	O
+mainly	O
+areas	O
+was	O
+improved	O
+after	O
+2	O
+h	O
+PPV	B-CHED
+(	O
+P	O
+<	O
+0	O
+.	O
+05	O
+),	O
+4	O
+h	O
+later	O
+it	O
+was	O
+not	O
+distinguished	O
+(	O
+P	O
+>	O
+0	O
+.	O
+05	O
+);	O
+the	O
+value	O
+of	O
+PaO	B-PRGE
+(	I-PRGE
+2	I-PRGE
+),	I-PRGE
+PaO	B-PROC
+(	I-PRGE
+2	I-PRGE
+)/	I-PRGE
+FiO	I-PRGE
+(	I-PRGE
+2	I-PRGE
+)	I-PRGE
+was	O
+greater	O
+at	O
+T1	O
+,	O
+T2	O
+,	O
+T3	O
+,	O
+T4	O
+than	O
+T0	O
+(	O
+P	O
+<	O
+0	O
+.	O
+05	O
+),	O
+the	O
+value	O
+of	O
+the	O
+oxygen	B-CHED
+fraction	O
+was	O
+significant	O
+increased	O
+at	O
+T2	O
+than	O
+T1	O
+(	O
+t	O
+=	O
+2	O
+.	O
+840	O
+,	O
+P	O
+<	O
+0	O
+.	O
+05	O
+);	O
+the	O
+number	O
+of	O
+patients	O
+with	O
+oxygen	B-CHED
+fractions	O
+>	O
+300	O
+mmHg	O
+after	O
+5	O
+days	O
+PPV	B-CHED
+was	O
+65	O
+(	O
+83	O
+.	O
+3	O
+%);	O
+there	O
+were	O
+30	O
+(	O
+38	O
+.	O
+5	O
+%)	O
+patients	O
+free	O
+of	O
+mechanical	O
+ventilation	O
+after	O
+7	O
+days	O
+;	O
+the	O
+28	O
+-	O
+day	O
+mortality	O
+was	O
+7	O
+(	O
+8	O
+.	O
+97	O
+%).	O
+
+And	O
+the	O
+values	O
+of	O
+EVLWI	O
+and	O
+PVPI	O
+of	O
+three	O
+groups	O
+from	O
+Day	O
+1	O
+-	O
+4	O
+were	O
+monitored	O
+by	O
+pulse	B-PROC
+indicator	B-CHED
+continuous	O
+cardiac	B-ANAT
+output	O
+(	O
+PiCCO	O
+).	O
+
+TITLE	O
+:	O
+[	O
+Clinical	O
+efficacy	O
+and	O
+safety	O
+of	O
+ulinastatin	B-PRGE
+plus	O
+octreotide	B-CHED
+for	O
+patients	O
+with	O
+severe	O
+acute	B-DISO
+pancreatitis	I-DISO
+].	O
+
+And	O
+the	O
+incidences	O
+of	O
+such	O
+complications	O
+as	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+(	O
+ARDS	B-DISO
+),	O
+acute	B-DISO
+renal	I-DISO
+failure	I-DISO
+and	O
+shock	O
+of	O
+observation	O
+group	O
+(	O
+10	O
+.	O
+0	O
+%,	O
+5	O
+.	O
+0	O
+%,	O
+13	O
+.	O
+3	O
+%)	O
+were	O
+significantly	O
+lower	O
+than	O
+those	O
+of	O
+control	O
+group	O
+(	O
+36	O
+.	O
+7	O
+%,	O
+21	O
+.	O
+7	O
+%,	O
+33	O
+.	O
+3	O
+%)	O
+(	O
+P	O
+<	O
+0	O
+.	O
+05	O
+).	O
+
+Several	O
+demographic	O
+and	O
+laboratory	O
+parameters	O
+as	O
+well	O
+as	O
+composite	O
+critical	B-DISO
+illness	I-DISO
+scoring	O
+systems	O
+are	O
+reliable	O
+early	O
+predictors	O
+of	O
+mortality	O
+in	O
+sepsis	B-DISO
+.	O
+
+Sequence	O
+analysis	O
+showed	O
+the	O
+circulation	B-PROC
+of	O
+at	O
+least	O
+five	O
+different	O
+virus	B-SPEC
+strains	O
+at	O
+these	O
+premises	O
+,	O
+suggesting	O
+that	O
+this	O
+location	O
+is	O
+a	O
+driver	O
+of	O
+MERS	O
+-	O
+CoV	O
+circulation	B-PROC
+and	O
+a	O
+high	O
+-	O
+risk	O
+area	O
+for	O
+human	B-SPEC
+exposure	O
+.	O
+
+ABSTRACT	O
+:	O
+The	O
+emergence	O
+of	O
+Severe	B-DISO
+Acute	I-DISO
+Respiratory	I-DISO
+Syndrome	I-DISO
+coronavirus	B-SPEC
+(	O
+SARS	B-DISO
+-	O
+CoV	O
+)	O
+and	O
+Middle	O
+East	O
+Respiratory	O
+Syndrome	B-DISO
+coronavirus	B-SPEC
+(	O
+MERS	O
+-	O
+CoV	O
+),	O
+two	O
+strains	O
+of	O
+animal	B-SPEC
+coronaviruses	O
+that	O
+crossed	O
+the	O
+species	B-SPEC
+barrier	O
+to	O
+infect	O
+and	O
+cause	O
+severe	O
+respiratory	B-DISO
+infections	I-DISO
+in	O
+humans	B-SPEC
+within	O
+the	O
+last	O
+12	O
+years	O
+,	O
+have	O
+taught	O
+us	O
+that	O
+coronaviruses	O
+represent	O
+a	O
+global	O
+threat	O
+that	O
+does	O
+not	O
+recognize	O
+international	O
+borders	O
+.	O
+
+In	O
+this	O
+review	O
+,	O
+we	O
+present	O
+factors	O
+to	O
+consider	O
+in	O
+establishing	O
+an	O
+animal	B-SPEC
+model	O
+for	O
+the	O
+study	O
+of	O
+novel	O
+coronaviruses	O
+and	O
+compare	O
+the	O
+different	O
+animal	B-SPEC
+models	O
+that	O
+have	O
+been	O
+employed	O
+to	O
+study	O
+SARS	B-DISO
+-	O
+CoV	O
+and	O
+MERS	O
+-	O
+CoV	O
+.	O
+
+The	O
+objectives	O
+of	O
+this	O
+study	O
+were	O
+to	O
+review	O
+signalment	O
+,	O
+clinical	O
+signs	O
+and	O
+laboratory	O
+features	O
+in	O
+a	O
+large	O
+number	O
+of	O
+naturally	O
+occurring	O
+cases	O
+of	O
+feline	O
+infectious	O
+peritonitis	O
+(	O
+FIP	B-DISO
+),	O
+and	O
+to	O
+evaluate	O
+potential	O
+changes	O
+in	O
+diagnostic	O
+criteria	O
+for	O
+FIP	B-DISO
+and	O
+compare	O
+findings	O
+in	O
+cats	B-SPEC
+with	O
+and	O
+without	O
+effusion	B-DISO
+.	O
+
+Male	O
+sex	O
+and	O
+young	O
+age	O
+were	O
+significantly	O
+correlated	O
+with	O
+FIP	B-DISO
+.	O
+
+No	O
+breed	B-PROC
+predisposition	O
+was	O
+observed	O
+and	O
+the	O
+majority	O
+of	O
+cats	B-SPEC
+presented	O
+were	O
+domestic	O
+shorthair	O
+and	O
+mixed	O
+breed	B-PROC
+.	O
+
+Band	B-ANAT
+neutrophilia	O
+was	O
+documented	O
+in	O
+44	O
+.	O
+3	O
+%	O
+(	O
+81	O
+/	O
+183	O
+),	O
+of	O
+which	O
+35	O
+.	O
+8	O
+%	O
+did	O
+not	O
+have	O
+mature	O
+neutrophilia	O
+.	O
+
+Lymphopenia	B-DISO
+,	O
+observed	O
+significantly	O
+more	O
+often	O
+with	O
+effusion	B-DISO
+,	O
+was	O
+documented	O
+in	O
+only	O
+26	O
+.	O
+8	O
+%	O
+of	O
+cats	B-SPEC
+without	O
+effusion	B-DISO
+.	O
+
+The	O
+low	O
+prevalence	O
+of	O
+lymphopenia	B-DISO
+in	O
+cats	B-SPEC
+without	O
+effusion	B-DISO
+suggests	O
+that	O
+this	O
+is	O
+not	O
+a	O
+useful	O
+parameter	O
+in	O
+non	O
+-	O
+effusive	O
+FIP	B-DISO
+.	O
+
+Globulins	O
+and	O
+A	O
+:	O
+G	O
+ratio	O
+were	O
+of	O
+higher	O
+diagnostic	O
+value	O
+than	O
+hyperproteinaemia	B-DISO
+.	O
+
+TITLE	O
+:	O
+Rapid	O
+and	O
+sensitive	O
+detection	O
+of	O
+Feline	B-SPEC
+immunodeficiency	I-SPEC
+virus	I-SPEC
+using	O
+an	O
+insulated	O
+isothermal	O
+PCR	O
+-	O
+based	O
+assay	O
+with	O
+a	O
+point	O
+-	O
+of	O
+-	O
+need	O
+PCR	O
+detection	O
+platform	O
+.	O
+
+The	O
+established	O
+reaction	O
+did	O
+not	O
+amplify	O
+any	O
+nontargeted	O
+feline	B-SPEC
+pathogens	O
+,	O
+including	O
+Felid	B-SPEC
+herpesvirus	I-SPEC
+1	I-SPEC
+,	O
+feline	B-SPEC
+coronavirus	B-SPEC
+,	O
+Feline	B-SPEC
+calicivirus	I-SPEC
+,	O
+Feline	B-SPEC
+leukemia	I-SPEC
+virus	I-SPEC
+,	O
+Mycoplasma	B-SPEC
+haemofelis	I-SPEC
+,	O
+and	O
+Chlamydophila	B-SPEC
+felis	I-SPEC
+.	O
+
+ABSTRACT	O
+:	O
+Sixty	O
+-	O
+seven	O
+-	O
+year	O
+-	O
+old	O
+patient	O
+,	O
+diagnosed	O
+with	O
+multiple	B-DISO
+myeloma	I-DISO
+who	O
+had	O
+received	O
+autologous	O
+stem	B-ANAT
+cell	I-ANAT
+transplantation	O
+,	O
+following	O
+bortezomib	B-CHED
+,	O
+dexamethasone	B-CHED
+and	O
+thalidomide	B-CHED
+conventional	O
+regimen	O
+,	O
+achieving	O
+complete	O
+response	O
+,	O
+developed	O
+rash	B-DISO
+,	O
+diarrhea	B-DISO
+,	O
+and	O
+severe	O
+respiratory	B-DISO
+failure	I-DISO
+,	O
+80	O
+days	O
+after	O
+the	O
+transplantation	O
+procedure	O
+.	O
+
+We	O
+present	O
+the	O
+case	O
+of	O
+a	O
+40	O
+-	O
+year	O
+-	O
+old	O
+SLE	B-DISO
+female	O
+with	O
+fulminant	O
+pneumonia	B-DISO
+after	O
+remission	B-DISO
+of	O
+nephritis	B-DISO
+treated	O
+with	O
+rituximab	O
+,	O
+who	O
+developed	O
+severe	O
+pulmonary	B-DISO
+mucormycosis	I-DISO
+that	O
+led	O
+to	O
+her	O
+rapid	O
+death	B-PROC
+from	O
+acute	B-DISO
+respiratory	I-DISO
+failure	I-DISO
+and	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+.	O
+
+TITLE	O
+:	O
+Targeting	B-PROC
+zoonotic	O
+viruses	B-SPEC
+:	O
+Structure	O
+-	O
+based	O
+inhibition	B-PROC
+of	O
+the	O
+3C	B-PRGE
+-	I-PRGE
+like	I-PRGE
+protease	I-PRGE
+from	O
+bat	B-ENZY
+coronavirus	I-SPEC
+HKU4	I-SPEC
+--	O
+The	O
+likely	O
+reservoir	O
+host	O
+to	O
+the	O
+human	B-SPEC
+coronavirus	I-SPEC
+that	O
+causes	O
+Middle	O
+East	O
+Respiratory	O
+Syndrome	B-DISO
+(	O
+MERS	O
+).	O
+
+Sequence	O
+alignment	O
+of	O
+HKU4	B-PRGE
+-	I-PRGE
+CoV	I-PRGE
+3CL	I-PRGE
+(	I-PRGE
+pro	I-PRGE
+),	I-PRGE
+and	O
+two	O
+other	O
+lineage	B-PRGE
+C	I-PRGE
+Betacoronaviruses	I-PRGE
+3CL	I-PRGE
+(	I-PRGE
+pro	I-PRGE
+)'	I-PRGE
+s	I-PRGE
+,	O
+HKU5	O
+-	O
+CoV	O
+and	O
+MERS	B-PRGE
+-	I-PRGE
+CoV	I-PRGE
+3CL	I-PRGE
+(	I-PRGE
+pro	I-PRGE
+),	I-PRGE
+show	O
+that	O
+the	O
+active	O
+site	O
+residues	O
+of	O
+HKU4	B-PRGE
+-	I-PRGE
+CoV	I-PRGE
+3CL	I-PRGE
+(	I-PRGE
+pro	I-PRGE
+)	I-PRGE
+that	O
+participate	O
+in	O
+inhibitor	B-CHED
+binding	B-FUNC
+are	O
+conserved	O
+in	O
+HKU5	O
+-	O
+CoV	O
+and	O
+MERS	O
+-	O
+CoV	O
+3CL	O
+(	O
+pro	B-PRGE
+).	O
+
+Recently	O
+,	O
+the	O
+NIH	O
+NHLBI	O
+Panel	O
+redefined	O
+sepsis	B-DISO
+as	O
+'	O
+severe	O
+endothelial	B-DISO
+dysfunction	I-DISO
+syndrome	B-DISO
+in	O
+response	O
+to	O
+intravascular	O
+and	O
+extravascular	O
+infections	B-DISO
+causing	O
+reversible	O
+or	O
+irreversible	O
+injury	O
+to	O
+the	O
+microcirculation	B-PROC
+responsible	O
+for	O
+multiple	B-DISO
+organ	I-DISO
+failure	I-DISO
+'.	O
+
+Microvascular	O
+endothelial	B-ANAT
+injury	O
+underlies	O
+sepsis	B-DISO
+-	I-DISO
+associated	I-DISO
+hypotension	I-DISO
+,	O
+edema	B-DISO
+,	O
+disseminated	B-DISO
+intravascular	I-DISO
+coagulation	I-DISO
+,	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+and	O
+acute	O
+kidney	B-ANAT
+injury	O
+.	O
+
+TITLE	O
+:	O
+Molecular	O
+investigation	O
+of	O
+a	O
+full	O
+-	O
+length	O
+genome	O
+of	O
+a	O
+Q1	O
+-	O
+like	O
+IBV	B-SPEC
+strain	O
+isolated	O
+in	O
+Italy	O
+in	O
+2013	O
+.	O
+
+ABSTRACT	O
+:	O
+Since	O
+1996	O
+a	O
+new	O
+Infectious	O
+Bronchitis	B-DISO
+virus	B-SPEC
+(	O
+IBV	B-SPEC
+)	O
+genotype	O
+,	O
+referred	O
+to	O
+as	O
+Q1	O
+,	O
+circulated	O
+in	O
+China	O
+and	O
+was	O
+reported	O
+for	O
+the	O
+first	O
+time	O
+in	O
+Italy	O
+in	O
+2011	O
+,	O
+associated	O
+with	O
+an	O
+increase	O
+of	O
+mortality	O
+,	O
+kidney	B-ANAT
+lesions	O
+and	O
+proventriculitis	O
+.	O
+
+During	O
+northern	O
+Italian	O
+outbreak	O
+of	O
+respiratory	B-DISO
+disease	I-DISO
+in	O
+a	O
+broiler	O
+flock	O
+in	O
+2013	O
+,	O
+an	O
+IBV	B-SPEC
+strain	O
+was	O
+detected	O
+by	O
+RT	O
+-	O
+PCR	O
+and	O
+characterized	O
+as	O
+Q1	O
+-	O
+like	O
+based	O
+on	O
+partial	O
+S1	O
+sequence	O
+.	O
+
+TITLE	O
+:	O
+The	O
+effect	O
+of	O
+risk	O
+-	O
+taking	O
+behaviour	B-PROC
+in	O
+epidemic	O
+models	O
+.	O
+
+In	O
+this	O
+review	O
+,	O
+we	O
+discuss	O
+the	O
+current	O
+state	O
+of	O
+knowledge	O
+of	O
+animal	B-SPEC
+models	O
+of	O
+MERS	O
+-	O
+CoV	O
+infection	B-DISO
+.	O
+
+Dromedary	B-SPEC
+camels	B-SPEC
+,	O
+considered	O
+to	O
+be	O
+the	O
+reservoir	O
+for	O
+MERS	O
+-	O
+CoV	O
+,	O
+develop	O
+a	O
+mild	O
+upper	O
+respiratory	O
+tract	O
+infection	O
+with	O
+abundant	O
+viral	B-DISO
+shedding	I-DISO
+.	O
+
+Transgenic	O
+hDPP4	O
+mice	B-SPEC
+develop	O
+severe	O
+and	O
+lethal	O
+respiratory	B-DISO
+disease	I-DISO
+upon	O
+inoculation	O
+with	O
+MERS	O
+-	O
+CoV	O
+.	O
+These	O
+hDPP4	O
+transgenic	B-SPEC
+mice	I-SPEC
+are	O
+potentially	O
+the	O
+ideal	O
+first	O
+line	O
+animal	B-SPEC
+model	O
+for	O
+efficacy	O
+testing	O
+of	O
+therapeutic	O
+and	O
+prophylactic	O
+countermeasures	O
+.	O
+
+According	O
+to	O
+Tile	O
+classification	O
+of	O
+pelvic	B-ANAT
+fractures	O
+,	O
+16	O
+cases	O
+were	O
+type	O
+B	O
+and	O
+12	O
+cases	O
+were	O
+type	O
+C	O
+.	O
+Injury	O
+severity	O
+score	O
+(	O
+ISS	B-DISO
+)	O
+averaged	O
+32	O
+.	O
+0	O
+±	O
+3	O
+.	O
+4	O
+.	O
+
+And	O
+limbs	B-ANAT
+fracture	O
+was	O
+temporary	O
+dealing	O
+with	O
+bone	B-ANAT
+traction	O
+or	O
+plaster	O
+external	O
+fixation	O
+,	O
+etc	O
+.	O
+
+Damage	O
+control	O
+resuscitation	O
+(	O
+DCR	O
+)	O
+integrates	O
+the	O
+main	O
+links	O
+such	O
+as	O
+damage	O
+control	O
+operation	O
+and	O
+allowable	O
+low	O
+blood	B-PROC
+pressure	I-PROC
+(	O
+or	O
+limited	O
+liquid	O
+resuscitation	O
+)	O
+and	O
+hemostatic	B-PROC
+control	O
+resuscitation	O
+,	O
+was	O
+early	O
+effective	O
+treatment	O
+measures	O
+for	O
+the	O
+patients	O
+with	O
+severe	O
+multiple	O
+trauma	O
+in	O
+the	O
+pelvic	B-ANAT
+fractures	O
+.	O
+
+RESULTS	O
+:	O
+Five	O
+cases	O
+were	O
+died	B-PROC
+after	O
+4	O
+to	O
+15	O
+hours	O
+into	O
+hospital	O
+(	O
+3	O
+cases	O
+died	B-PROC
+for	O
+severe	O
+trauma	O
+-	O
+hemorrhagic	B-DISO
+shock	I-DISO
+and	O
+2	O
+cases	O
+for	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+).	O
+
+The	O
+success	O
+rat	B-SPEC
+of	O
+recovery	O
+was	O
+82	O
+.	O
+2	O
+%	O
+(	O
+23	O
+/	O
+28	O
+).	O
+
+TITLE	O
+:	O
+Occupational	O
+Exposure	O
+to	O
+Dromedaries	B-SPEC
+and	O
+Risk	O
+for	O
+MERS	O
+-	O
+CoV	O
+Infection	B-DISO
+,	O
+Qatar	O
+,	O
+2013	O
+-	O
+2014	O
+.	O
+
+ABSTRACT	O
+:	O
+We	O
+determined	O
+the	O
+presence	O
+of	O
+neutralizing	O
+antibodies	O
+to	O
+Middle	O
+East	O
+respiratory	O
+syndrome	B-DISO
+coronavirus	B-SPEC
+in	O
+persons	O
+in	O
+Qatar	O
+with	O
+and	O
+without	O
+dromedary	B-SPEC
+contact	O
+.	O
+
+Findings	O
+also	O
+showed	O
+evidence	O
+for	O
+substantial	O
+underestimation	O
+of	O
+the	O
+infection	B-DISO
+in	O
+populations	O
+at	O
+risk	O
+in	O
+Qatar	O
+.	O
+
+TITLE	O
+:	O
+Treatment	O
+With	O
+Lopinavir	O
+/	O
+Ritonavir	B-CHED
+or	O
+Interferon	B-PRGE
+-	I-PRGE
+β1b	I-PRGE
+Improves	O
+Outcome	O
+of	O
+MERS	O
+-	O
+CoV	O
+Infection	B-DISO
+in	O
+a	O
+Nonhuman	O
+Primate	O
+Model	O
+of	O
+Common	B-SPEC
+Marmoset	I-SPEC
+.	O
+
+Respiratory	B-PROC
+mechanics	I-PROC
+,	O
+blood	B-PROC
+gases	I-PROC
+,	O
+hemodynamics	B-PROC
+,	O
+and	O
+whole	O
+-	O
+lung	B-ANAT
+CT	O
+were	O
+recorded	O
+at	O
+the	O
+two	O
+PEEP	B-CHED
+levels	O
+.	O
+
+There	O
+was	O
+no	O
+significant	O
+difference	O
+between	O
+collapsed	B-DISO
+lung	I-DISO
+volume	O
+(	O
+P	O
+=	O
+0	O
+.	O
+07	O
+)	O
+and	O
+hyperinflation	B-DISO
+lung	I-DISO
+volume	O
+(	O
+P	O
+=	O
+0	O
+.	O
+76	O
+)	O
+in	O
+the	O
+two	O
+groups	O
+.	O
+
+Stress	O
+index	O
+can	O
+be	O
+used	O
+to	O
+titrate	O
+PEEP	B-CHED
+in	O
+the	O
+prone	O
+position	O
+in	O
+a	O
+surfactant	B-CHED
+-	O
+depleted	O
+lung	B-ANAT
+injury	O
+model	O
+.	O
+
+To	O
+determine	O
+the	O
+relevance	O
+of	O
+TNF	B-PRGE
+-	I-PRGE
+α	I-PRGE
+in	O
+disrupting	O
+bronchial	B-ANAT
+endothelial	B-ANAT
+cell	I-ANAT
+function	O
+,	O
+we	O
+stimulated	O
+human	B-SPEC
+THP	B-CHED
+-	O
+1	O
+macrophages	B-ANAT
+with	O
+lipopolysaccharide	B-CHED
+(	O
+LPS	B-DISO
+)	O
+and	O
+used	O
+the	O
+resulting	O
+cytokine	O
+-	O
+supplemented	O
+media	B-ANAT
+to	O
+disrupt	O
+normal	O
+endothelial	B-ANAT
+cell	I-ANAT
+functions	O
+.	O
+
+Our	O
+findings	O
+highlight	O
+the	O
+importance	O
+of	O
+IFN	B-PRGE
+-	I-PRGE
+β	I-PRGE
+production	O
+by	O
+infected	O
+BMECs	O
+in	O
+preserving	O
+BBB	B-CHED
+function	O
+and	O
+preventing	O
+access	O
+of	O
+blood	B-ANAT
+-	O
+borne	O
+infectious	B-DISO
+viruses	B-SPEC
+to	O
+the	O
+brain	B-ANAT
+.	O
+
+BBB	B-CHED
+invasion	B-DISO
+by	O
+CoVs	O
+correlates	O
+with	O
+virus	B-SPEC
+-	O
+induced	O
+disruption	O
+of	O
+tight	B-COMP
+junctions	I-COMP
+on	O
+BMECs	O
+,	O
+leading	O
+to	O
+BBB	B-CHED
+dysfunction	O
+and	O
+enhanced	O
+permeability	O
+.	O
+
+Using	O
+immunohistochemistry	O
+to	O
+examine	O
+changes	O
+in	O
+the	O
+number	O
+of	O
+CD4	B-PRGE
+(+)	O
+and	O
+CD8	B-PRGE
+(+)	O
+cells	B-COMP
+in	O
+the	O
+trachea	B-DISO
+,	O
+it	O
+was	O
+found	O
+that	O
+overall	O
+patterns	O
+of	O
+CD8	O
+(+)	O
+cells	B-COMP
+were	O
+dominant	O
+compared	O
+to	O
+those	O
+of	O
+CD4	B-PRGE
+(+)	O
+cells	B-COMP
+in	O
+the	O
+two	O
+vaccinated	O
+groups	O
+.	O
+
+All	O
+groups	O
+were	O
+challenged	O
+oculonasally	O
+with	O
+a	O
+virulent	O
+Q1	O
+strain	O
+at	O
+28	O
+doa	B-SPEC
+,	O
+and	O
+their	O
+protection	O
+was	O
+assessed	O
+.	O
+
+ABSTRACT	O
+:	O
+Middle	O
+East	O
+respiratory	O
+syndrome	B-DISO
+(	O
+MERS	O
+)	O
+is	O
+associated	O
+with	O
+a	O
+mortality	O
+rate	O
+of	O
+>	O
+35	O
+%.	O
+
+Here	O
+,	O
+we	O
+further	O
+investigated	O
+the	O
+interplay	O
+between	O
+human	B-SPEC
+primary	O
+T	B-ANAT
+cells	I-ANAT
+and	O
+MERS	O
+-	O
+CoV	O
+in	O
+disease	O
+pathogenesis	B-DISO
+.	O
+
+ABSTRACT	O
+:	O
+Necrotizing	O
+tracheobronchitis	O
+due	O
+to	O
+Aspergillus	B-PRGE
+spp	B-ENZY
+is	O
+a	O
+rare	O
+form	O
+of	O
+invasive	B-DISO
+aspergillosis	I-DISO
+.	O
+
+SARs	B-DISO
+analysis	O
+indicated	O
+that	O
+quinoxalin	O
+-	O
+2	O
+(	O
+1H	O
+)-	O
+one	O
+containing	O
+a	O
+4	O
+-	O
+aryl	O
+-	O
+substituted	O
+thiazol	O
+-	O
+2	O
+-	O
+amine	B-CHED
+moiety	O
+was	O
+optimal	O
+for	O
+antiviral	B-CHED
+activity	O
+.	O
+
+Introducing	O
+a	O
+hydrogen	B-CHED
+-	O
+bond	O
+acceptor	B-CHED
+(	O
+such	O
+as	O
+ester	B-CHED
+or	O
+amide	B-CHED
+group	I-CHED
+)	O
+at	O
+the	O
+C	O
+-	O
+3	O
+position	O
+of	O
+quinoxalin	O
+-	O
+2	O
+(	O
+1H	O
+)-	O
+one	O
+was	O
+beneficial	O
+for	O
+the	O
+antiviral	B-CHED
+potency	O
+,	O
+and	O
+especially	O
+,	O
+N	O
+,	O
+N	O
+-	O
+disubstituted	O
+amide	O
+was	O
+far	O
+superior	O
+to	O
+N	O
+-	O
+monosubstituted	O
+amide	B-CHED
+.	O
+
+Incorporation	O
+of	O
+more	O
+than	O
+one	O
+halogen	B-CHED
+(	O
+fluorine	B-CHED
+or	O
+chlorine	B-CHED
+atom	I-CHED
+)	O
+or	O
+a	O
+strong	O
+electron	O
+-	O
+withdrawing	O
+group	O
+on	O
+the	O
+benzene	B-CHED
+ring	I-CHED
+of	O
+the	O
+thiazole	B-CHED
+-	O
+phenyl	B-CHED
+moiety	O
+might	O
+reduce	O
+electron	O
+atmosphere	O
+density	O
+further	O
+and	O
+resulted	O
+in	O
+a	O
+dramatical	O
+loss	O
+of	O
+activity	O
+.	O
+
+These	O
+coronaviruses	O
+contain	O
+a	O
+surface	O
+-	O
+located	O
+spike	O
+(	O
+S	O
+)	O
+protein	B-CHED
+that	O
+initiates	O
+infection	B-DISO
+by	O
+mediating	O
+receptor	O
+-	O
+recognition	O
+and	O
+membrane	B-PROC
+fusion	I-PROC
+and	O
+is	O
+therefore	O
+a	O
+key	O
+factor	O
+in	O
+host	B-COMP
+specificity	O
+.	O
+
+Shorter	O
+target	O
+,	O
+better	O
+stability	O
+and	O
+higher	O
+sensitivity	O
+mean	O
+such	O
+an	O
+assay	O
+would	O
+be	O
+valid	O
+for	O
+feline	B-SPEC
+identification	O
+even	O
+in	O
+degraded	O
+specimens	O
+.	O
+
+The	O
+evaluation	O
+confirmed	O
+that	O
+RT	O
+-	O
+PCRs	O
+targeting	B-PROC
+the	O
+ORF1b	O
+are	O
+less	O
+sensitive	O
+,	O
+and	O
+therefore	O
+not	O
+advised	O
+for	O
+primary	O
+diagnostics	O
+.	O
+
+It	O
+is	O
+the	O
+wide	O
+application	O
+of	O
+this	O
+technology	O
+that	O
+makes	O
+breakthrough	O
+in	O
+SDB	O
+treatment	O
+,	O
+and	O
+has	O
+given	O
+rise	O
+to	O
+a	O
+new	O
+interdisciplinary	O
+area	O
+sleep	B-PROC
+medicine	B-CHED
+.	O
+
+TITLE	O
+:	O
+Middle	O
+East	O
+respiratory	O
+syndrome	B-DISO
+coronavirus	B-SPEC
+(	O
+MERS	O
+-	O
+CoV	O
+):	O
+A	O
+cluster	O
+analysis	O
+with	O
+implications	O
+for	O
+global	O
+management	O
+of	O
+suspected	O
+cases	O
+.	O
+
+Fourteen	O
+cases	O
+appeared	O
+to	O
+be	O
+linked	O
+to	O
+one	O
+cluster	O
+involving	O
+healthcare	O
+workers	O
+(	O
+HCWs	O
+),	O
+family	B-SPEC
+and	O
+patient	O
+contacts	O
+.	O
+
+TITLE	O
+:	O
+Assessing	O
+the	O
+risk	O
+of	O
+observing	O
+multiple	O
+generations	O
+of	O
+Middle	O
+East	O
+respiratory	O
+syndrome	B-DISO
+(	O
+MERS	O
+)	O
+cases	O
+given	O
+an	O
+imported	O
+case	O
+.	O
+
+TITLE	O
+:	O
+Quantitative	O
+Proteomics	O
+Identifies	O
+Serum	B-PRGE
+Response	I-PRGE
+Factor	I-PRGE
+Binding	B-FUNC
+Protein	B-PRGE
+1	I-PRGE
+as	O
+a	O
+Host	B-COMP
+Factor	O
+for	O
+Hepatitis	O
+C	O
+Virus	O
+Entry	O
+.	O
+
+We	O
+have	O
+developed	O
+a	O
+quantitative	O
+proteomics	O
+protocol	O
+to	O
+identify	O
+HCV	B-SPEC
+-	O
+triggered	O
+CD81	B-PRGE
+interactions	O
+and	O
+found	O
+26	O
+dynamic	O
+binding	B-FUNC
+partners	O
+.	O
+
+These	O
+results	O
+demonstrate	O
+the	O
+use	O
+of	O
+quantitative	O
+proteomics	O
+to	O
+elucidate	O
+pathogen	O
+entry	O
+and	O
+underscore	O
+the	O
+importance	O
+of	O
+host	O
+protein	B-CHED
+-	O
+protein	B-CHED
+interactions	O
+during	O
+HCV	B-SPEC
+invasion	B-DISO
+.	O
+
+The	O
+gut	B-ANAT
+microbiota	B-SPEC
+may	O
+play	O
+a	O
+critical	O
+role	O
+in	O
+the	O
+gut	B-ANAT
+health	O
+of	O
+the	O
+host	B-COMP
+.	O
+
+Most	O
+commensal	O
+bacteria	B-SPEC
+(	O
+i	O
+.	O
+e	O
+.	O
+Psychrobacter	B-SPEC
+,	O
+Prevotella	B-SPEC
+,	O
+and	O
+Faecalibacterium	B-SPEC
+)	O
+in	O
+the	O
+healthy	O
+gastrointestinal	B-ANAT
+tract	I-ANAT
+were	O
+decreased	O
+due	O
+to	O
+dysbiosis	O
+induced	O
+by	O
+PEDV	B-SPEC
+infection	B-DISO
+.	O
+
+ABSTRACT	O
+:	O
+Prone	O
+position	O
+is	O
+used	O
+to	O
+recruit	O
+collapsed	O
+dependent	O
+lung	B-ANAT
+regions	O
+during	O
+severe	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+,	O
+improving	O
+lung	B-ANAT
+elastance	O
+and	O
+lung	B-ANAT
+gas	B-ENZY
+content	O
+.	O
+
+Ten	O
+healthy	O
+pigs	B-SPEC
+under	O
+general	O
+anaesthesia	B-DISO
+and	O
+paralysis	O
+underwent	O
+a	O
+pressure	O
+-	O
+volume	O
+curve	O
+of	O
+the	O
+respiratory	B-ANAT
+system	I-ANAT
+,	O
+chest	B-ANAT
+wall	I-ANAT
+and	O
+lung	B-ANAT
+in	O
+supine	O
+and	O
+prone	O
+positions	O
+;	O
+the	O
+respective	O
+elastances	O
+were	O
+measured	O
+.	O
+
+In	O
+healthy	O
+pigs	B-SPEC
+,	O
+prone	O
+position	O
+ameliorates	O
+lung	B-ANAT
+mechanical	O
+properties	O
+and	O
+increases	O
+functional	B-PROC
+residual	I-PROC
+capacity	I-PROC
+independently	O
+from	O
+lung	B-ANAT
+recruitment	B-DISO
+,	O
+through	O
+a	O
+redistribution	O
+of	O
+lung	B-ANAT
+aeration	O
+.	O
+
+ABSTRACT	O
+:	O
+In	O
+May	O
+2015	O
+,	O
+South	O
+Korea	O
+reported	O
+its	O
+first	O
+case	O
+of	O
+Middle	O
+East	O
+respiratory	O
+syndrome	B-DISO
+coronavirus	B-SPEC
+(	O
+MERS	O
+-	O
+CoV	O
+)	O
+infection	B-DISO
+in	O
+a	O
+68	O
+-	O
+year	O
+-	O
+old	O
+man	B-CHED
+with	O
+a	O
+history	O
+of	O
+travel	O
+in	O
+the	O
+Middle	O
+East	O
+.	O
+
+In	O
+the	O
+presence	O
+of	O
+secondary	B-DISO
+infections	I-DISO
+,	O
+an	O
+understanding	O
+of	O
+the	O
+transmission	O
+dynamics	O
+of	O
+the	O
+virus	B-SPEC
+is	O
+crucial	O
+.	O
+
+Healthcare	O
+switching	O
+has	O
+probably	O
+accounted	O
+for	O
+the	O
+emergence	O
+of	O
+multiple	O
+generations	O
+of	O
+secondary	B-DISO
+infection	I-DISO
+.	O
+
+The	O
+fact	O
+that	O
+it	O
+took	O
+only	O
+4	O
+mo	O
+from	O
+the	O
+initial	O
+screening	O
+of	O
+B	B-ANAT
+cells	I-ANAT
+derived	O
+from	O
+a	O
+convalescent	O
+patient	O
+for	O
+the	O
+development	B-PROC
+of	O
+a	O
+stable	O
+chinese	B-SPEC
+hamster	I-SPEC
+ovary	B-ANAT
+(	O
+CHO	B-FUNC
+)	O
+cell	B-ANAT
+line	I-ANAT
+producing	O
+neutralizing	O
+antibodies	B-COMP
+at	O
+more	O
+than	O
+5	O
+g	O
+/	O
+L	O
+provides	O
+an	O
+example	O
+of	O
+a	O
+rapid	O
+pathway	B-PROC
+toward	O
+the	O
+generation	O
+of	O
+effective	O
+antiviral	B-CHED
+therapies	O
+against	O
+emerging	O
+viruses	B-SPEC
+.	O
+
+Dose	O
+reduction	O
+is	O
+recommended	O
+for	O
+patients	O
+with	O
+moderate	O
+or	O
+worse	O
+renal	B-DISO
+impairment	I-DISO
+.	O
+
+Efforts	O
+focused	O
+solely	O
+on	O
+the	O
+receptor	O
+-	O
+binding	B-FUNC
+domain	O
+(	O
+RBD	O
+)	O
+of	O
+the	O
+viral	B-PRGE
+Spike	I-PRGE
+(	I-PRGE
+S	I-PRGE
+)	I-PRGE
+glycoprotein	I-PRGE
+may	O
+not	O
+optimize	O
+neutralizing	O
+antibody	B-COMP
+(	O
+NAb	O
+)	O
+responses	O
+.	O
+
+Patients	O
+with	O
+sepsis	B-DISO
+-	O
+related	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+have	O
+higher	O
+mortality	O
+.	O
+
+At	O
+6	O
+h	O
+after	O
+saline	O
+or	O
+LPS	B-DISO
+,	O
+animals	B-SPEC
+were	O
+sacrificed	O
+,	O
+and	O
+lungs	B-ANAT
+were	O
+obtained	O
+for	O
+analyzing	O
+superoxide	B-CHED
+production	O
+,	O
+water	B-CHED
+accumulation	O
+,	O
+histologic	O
+assessment	O
+,	O
+and	O
+protein	B-CHED
+expressions	O
+of	O
+Wnt3a	B-PRGE
+and	O
+Wnt5a	B-PRGE
+signaling	B-PROC
+pathway	I-PROC
+.	O
+
+The	O
+lung	B-ANAT
+from	O
+rats	B-SPEC
+with	O
+endotoxic	B-DISO
+shock	I-DISO
+exhibited	O
+significant	O
+decreases	O
+in	O
+the	O
+levels	O
+of	O
+Wnt3a	B-PRGE
+,	O
+Fzd1	B-PRGE
+,	O
+Dsh1	B-DISO
+,	O
+phosphorylated	O
+GSK	B-PRGE
+-	I-PRGE
+3β	I-PRGE
+at	O
+Ser9	O
+,	O
+and	O
+β	B-PRGE
+-	I-PRGE
+catenin	I-PRGE
+.	O
+
+While	O
+the	O
+CCoV	O
+-	O
+II	O
+genome	O
+has	O
+been	O
+completely	O
+sequenced	O
+,	O
+to	O
+date	O
+there	O
+are	O
+no	O
+complete	O
+genomic	O
+sequence	O
+data	O
+available	O
+publicly	O
+for	O
+CCoV	O
+-	O
+I	O
+.	O
+Thus	O
+,	O
+the	O
+aim	O
+of	O
+the	O
+present	O
+study	O
+was	O
+to	O
+analyze	O
+the	O
+full	O
+-	O
+length	O
+genome	O
+of	O
+a	O
+CCoV	O
+-	O
+I	O
+prototype	O
+strain	O
+that	O
+had	O
+been	O
+recovered	O
+from	O
+a	O
+dog	B-SPEC
+with	O
+diarrhea	B-DISO
+in	O
+Italy	O
+.	O
+
+However	O
+,	O
+two	O
+distinct	O
+features	O
+were	O
+observed	O
+in	O
+the	O
+CCoV	O
+-	O
+I	O
+genome	O
+:	O
+(	O
+i	O
+)	O
+the	O
+presence	O
+of	O
+an	O
+additional	O
+ORF	O
+between	O
+the	O
+spike	O
+(	O
+S	O
+)	O
+protein	B-CHED
+gene	O
+and	O
+ORF3a	O
+;	O
+(	O
+ii	O
+)	O
+the	O
+diversity	O
+of	O
+the	O
+S	B-PRGE
+protein	I-PRGE
+,	O
+which	O
+is	O
+more	O
+closely	O
+related	O
+to	O
+that	O
+of	O
+feline	B-SPEC
+coronavirus	B-SPEC
+type	O
+I	O
+and	O
+presents	O
+a	O
+furin	B-PRGE
+cleavage	B-PROC
+site	O
+.	O
+
+Genetic	O
+studies	O
+on	O
+MERS	O
+-	O
+CoV	O
+have	O
+shown	O
+that	O
+ORF1ab	O
+encodes	O
+replicase	B-PRGE
+polyproteins	I-PRGE
+and	O
+play	O
+a	O
+foremost	O
+role	O
+in	O
+viral	B-DISO
+infection	I-DISO
+.	O
+
+In	O
+the	O
+current	O
+study	O
+,	O
+four	O
+effective	O
+miRNA	O
+and	O
+five	O
+siRNA	O
+molecules	O
+for	O
+silencing	O
+of	O
+nine	O
+different	O
+strains	O
+of	O
+MERS	O
+-	O
+CoV	O
+were	O
+rationally	O
+designed	O
+and	O
+corroborated	O
+using	O
+computational	O
+methods	O
+,	O
+which	O
+might	O
+lead	O
+to	O
+knockdown	O
+the	O
+activity	O
+of	O
+virus	B-SPEC
+.	O
+
+ABSTRACT	O
+:	O
+Polyvalent	O
+infectious	B-DISO
+bronchitis	B-DISO
+virus	B-SPEC
+vaccination	O
+is	O
+common	O
+worldwide	O
+.	O
+
+Even	O
+when	O
+Mass	O
+and	O
+Ark	O
+vaccines	O
+were	O
+inoculated	O
+into	O
+separate	O
+eyes	B-ANAT
+,	O
+Mass	O
+vaccine	O
+virus	B-SPEC
+was	O
+able	O
+to	O
+outcompete	O
+Ark	O
+vaccine	O
+virus	B-SPEC
+.	O
+
+Furthermore	O
+,	O
+Ark	B-PRGE
+vaccine	I-PRGE
+virus	I-PRGE
+RNA	I-PRGE
+was	O
+not	O
+detectable	O
+until	O
+10	O
+DPV	O
+in	O
+most	O
+tear	B-ANAT
+samples	O
+from	O
+chickens	B-SPEC
+vaccinated	O
+with	O
+both	O
+Ark	O
+and	O
+Mass	O
+vaccines	O
+at	O
+varying	O
+Ark	B-PRGE
+vaccine	O
+doses	O
+,	O
+while	O
+high	O
+concentrations	O
+of	O
+Mass	O
+virus	B-SPEC
+RNA	O
+were	O
+detectable	O
+at	O
+3	O
+-	O
+7	O
+DPV	O
+.	O
+
+The	O
+different	O
+replication	O
+dynamics	O
+of	O
+Ark	O
+and	O
+Mass	O
+viruses	B-SPEC
+in	O
+chickens	B-SPEC
+vaccinated	O
+with	O
+combined	O
+vaccines	O
+did	O
+not	O
+result	O
+in	O
+reduced	O
+protection	O
+against	O
+Ark	B-PRGE
+challenge	O
+at	O
+21	O
+DPV	O
+.	O
+
+The	O
+source	O
+of	O
+the	O
+virus	B-SPEC
+has	O
+focused	O
+on	O
+bats	B-SPEC
+and	O
+dromedary	B-SPEC
+camels	B-SPEC
+but	O
+the	O
+exact	O
+mode	O
+of	O
+disease	B-DISO
+transmission	I-DISO
+continues	O
+to	O
+be	O
+debated	O
+.	O
+
+Translated	O
+amino	B-CHED
+acid	I-CHED
+alterations	O
+were	O
+minimal	O
+but	O
+still	O
+may	O
+have	O
+played	O
+an	O
+important	O
+role	O
+in	O
+the	O
+persistence	O
+of	O
+this	O
+virus	B-SPEC
+despite	O
+the	O
+use	O
+of	O
+live	O
+793B	O
+vaccines	O
+.	O
+
+MEDLINE	O
+,	O
+EMBASE	O
+,	O
+and	O
+PubMed	O
+Central	O
+(	O
+1972	O
+to	O
+June	O
+1	O
+,	O
+2015	O
+)	O
+were	O
+queried	O
+with	O
+the	O
+following	O
+search	O
+term	O
+combinations	O
+:	O
+""""	O
+Oral	B-ANAT
+""""	O
+AND	O
+""""	O
+ribavirin	B-CHED
+""""	O
+AND	O
+"("""	O
+respiratory	B-SPEC
+syncytial	I-SPEC
+virus	I-SPEC
+""""	O
+OR	O
+""""	O
+metapneumovirus	B-SPEC
+""""	O
+OR	O
+""""	O
+parainfluenza	B-DISO
+""""	O
+OR	O
+""""	O
+coronavirus	B-SPEC
+""""	O
+OR	O
+""""	O
+rhinovirus	B-SPEC
+""""	O
+OR	O
+""""	O
+enterovirus	B-SPEC
+""""	O
+OR	O
+""""	O
+adenovirus	B-DISO
+""")."	O
+
+All	O
+studies	O
+except	O
+for	O
+2	O
+Middle	O
+East	O
+respiratory	O
+syndrome	B-DISO
+coronavirus	B-SPEC
+(	O
+MERS	O
+-	O
+CoV	O
+)	O
+studies	O
+were	O
+in	O
+immunocompromised	O
+patients	O
+(	O
+9	O
+malignancy	B-DISO
+/	O
+stem	O
+cell	B-ANAT
+transplant	I-ANAT
+,	O
+4	O
+lung	B-ANAT
+transplant	B-ANAT
+).	O
+
+Some	O
+serological	O
+assays	O
+for	O
+PEDV	B-SPEC
+have	O
+been	O
+previously	O
+described	O
+,	O
+but	O
+few	O
+were	O
+readily	O
+available	O
+in	O
+the	O
+U	O
+.	O
+S	O
+.	O
+Several	O
+U	O
+.	O
+S	O
+.	O
+laboratories	O
+quickly	O
+developed	O
+indirect	O
+fluorescent	O
+antibody	B-COMP
+(	O
+IFA	O
+)	O
+assays	O
+for	O
+the	O
+detection	O
+of	O
+antibodies	B-COMP
+to	O
+PEDV	B-SPEC
+in	O
+swine	B-SPEC
+serum	B-COMP
+,	O
+indicating	O
+prior	O
+exposure	O
+.	O
+
+A	O
+recombinant	O
+North	O
+American	O
+nucleoprotein	O
+(	O
+NP	O
+)	O
+based	O
+iELISA	O
+was	O
+developed	O
+and	O
+validated	O
+along	O
+with	O
+a	O
+bELISA	O
+using	O
+newly	O
+developed	O
+PEDV	B-SPEC
+-	O
+NP	O
+specific	O
+biotinylated	O
+monoclonal	B-PRGE
+antibodies	I-PRGE
+(	O
+mAbs	O
+)	O
+and	O
+an	O
+FMIA	O
+using	O
+magnetic	O
+beads	O
+coupled	O
+with	O
+expressed	B-PROC
+NA	O
+PEDV	B-SPEC
+-	O
+NP	O
+.	O
+
+CONCLUSIONS	O
+:	O
+Well	O
+-	O
+validated	O
+iELISA	O
+,	O
+bELISA	O
+and	O
+FMIA	O
+assays	O
+for	O
+the	O
+detection	O
+of	O
+PEDV	B-SPEC
+antibodies	B-COMP
+were	O
+developed	O
+and	O
+showed	O
+good	O
+correlation	O
+with	O
+IFA	O
+and	O
+each	O
+other	O
+.	O
+
+ABSTRACT	O
+:	O
+Acute	O
+respiratory	O
+distress	O
+syndrome	O
+(	O
+ARDS	B-DISO
+)	O
+is	O
+the	O
+most	O
+severe	O
+form	O
+of	O
+respiratory	B-DISO
+failure	I-DISO
+.	O
+
+However	O
+,	O
+the	O
+pathogenesis	B-DISO
+of	O
+pediatric	O
+ARDS	B-DISO
+is	O
+complex	O
+,	O
+and	O
+therefore	O
+,	O
+it	O
+can	O
+be	O
+expected	O
+that	O
+many	O
+genes	O
+might	O
+contribute	O
+.	O
+
+Operative	O
+techniques	O
+in	O
+liver	B-ANAT
+trauma	O
+are	O
+some	O
+of	O
+the	O
+most	O
+challenging	O
+.	O
+
+They	O
+include	O
+the	O
+broad	O
+and	O
+complex	O
+area	O
+,	O
+from	O
+damage	O
+control	O
+to	O
+liver	B-ANAT
+resection	O
+.	O
+
+Non	O
+-	O
+survivors	O
+have	O
+significant	O
+hypotension	O
+on	O
+arrival	O
+and	O
+lower	O
+Glasgow	O
+Coma	B-DISO
+Scale	O
+(	O
+GCS	O
+)	O
+on	O
+admission	O
+(	O
+p	O
+=	O
+0	O
+.	O
+000	O
+;	O
+p	O
+=	O
+0	O
+.	O
+0001	O
+).	O
+
+There	O
+was	O
+significant	O
+difference	O
+in	O
+the	O
+amount	O
+of	O
+red	B-ANAT
+blood	I-ANAT
+cells	I-ANAT
+(	O
+RBC	B-ANAT
+)	O
+transfusion	O
+in	O
+the	O
+first	O
+24	O
+h	O
+between	O
+survivors	O
+and	O
+non	O
+-	O
+survivors	O
+(	O
+p	O
+=	O
+0	O
+.	O
+001	O
+).	O
+
+TITLE	O
+:	O
+Assessment	O
+of	O
+the	O
+awareness	O
+level	O
+of	O
+dental	O
+students	O
+toward	O
+Middle	O
+East	O
+Respiratory	O
+Syndrome	B-DISO
+-	O
+coronavirus	O
+.	O
+
+TITLE	O
+:	O
+Phylogenetic	O
+analysis	O
+of	O
+avian	B-DISO
+infectious	I-DISO
+bronchitis	B-PRGE
+virus	I-PRGE
+S1	I-PRGE
+glycoprotein	B-CHED
+regions	O
+reveals	O
+emergence	O
+of	O
+a	O
+new	O
+genotype	O
+in	O
+Moroccan	O
+broiler	O
+chicken	O
+flocks	O
+.	O
+
+Only	O
+a	O
+few	O
+amino	O
+-	O
+acid	O
+changes	O
+in	O
+the	O
+S1	O
+subunit	O
+of	O
+wild	O
+-	O
+type	O
+IBVS	O
+proteins	B-CHED
+may	O
+result	O
+in	O
+mutants	O
+unaffected	O
+by	O
+current	O
+vaccines	O
+.	O
+
+An	O
+immunoadhesin	O
+targeting	B-PROC
+the	O
+MERS	O
+coronavirus	B-SPEC
+is	O
+in	O
+an	O
+early	O
+stage	O
+of	O
+development	B-PROC
+.	O
+
+The	O
+crystals	B-ANAT
+were	O
+monoclinic	O
+and	O
+belonged	O
+to	O
+space	O
+group	O
+P21	O
+,	O
+with	O
+unit	O
+-	O
+cell	B-COMP
+parameters	O
+a	O
+=	O
+35	O
+.	O
+60	O
+,	O
+b	O
+=	O
+109	O
+.	O
+64	O
+,	O
+c	O
+=	O
+91	O
+.	O
+99	O
+Å	O
+,	O
+β	O
+=	O
+101	O
+.	O
+22	O
+°.	O
+
+ABSTRACT	O
+:	O
+China	O
+successfully	O
+achieved	O
+universal	O
+health	O
+insurance	O
+coverage	O
+in	O
+2011	O
+,	O
+representing	O
+the	O
+largest	O
+expansion	O
+of	O
+insurance	O
+coverage	O
+in	O
+human	B-SPEC
+history	O
+.	O
+
+We	O
+developed	O
+and	O
+validated	O
+an	O
+indirect	O
+enzyme	O
+-	O
+linked	O
+immunosorbent	O
+assay	O
+(	O
+ELISA	O
+)	O
+based	O
+on	O
+the	O
+recombinant	O
+membrane	B-COMP
+(	O
+M	O
+)	O
+protein	B-CHED
+of	O
+PEDV	B-SPEC
+.	O
+
+He	O
+had	O
+no	O
+chills	B-DISO
+,	O
+cough	B-DISO
+,	O
+expectoration	B-ANAT
+,	O
+short	B-DISO
+of	I-DISO
+breath	I-DISO
+,	O
+abdominal	B-DISO
+pain	I-DISO
+,	O
+diarrhea	B-DISO
+,	O
+frequent	O
+micturition	B-PROC
+,	O
+or	O
+urgency	O
+or	O
+pain	O
+of	O
+urination	B-PROC
+,	O
+and	O
+no	O
+sore	B-DISO
+throat	I-DISO
+.	O
+
+(	O
+2	O
+)	O
+Auxiliary	O
+examination	O
+:	O
+3	O
+copies	O
+of	O
+throat	B-ANAT
+swab	I-ANAT
+specimens	O
+for	O
+virus	B-SPEC
+nucleic	B-CHED
+acid	I-CHED
+detection	O
+were	O
+performed	O
+by	O
+the	O
+Disease	O
+Prevention	O
+Control	O
+Center	O
+of	O
+China	O
+(	O
+China	O
+CDC	O
+),	O
+and	O
+they	O
+were	O
+positive	O
+on	O
+May	O
+29th	O
+,	O
+2015	O
+,	O
+and	O
+also	O
+for	O
+serum	B-COMP
+,	O
+sputum	B-ANAT
+and	O
+stool	B-ANAT
+.	O
+
+Ribavirin	B-CHED
+2	O
+.	O
+0	O
+g	O
+was	O
+given	O
+as	O
+the	O
+first	O
+dose	O
+,	O
+and	O
+was	O
+switched	O
+to	O
+600	O
+mg	O
+every	O
+8	O
+h	O
+(	O
+q8h	O
+),	O
+and	O
+it	O
+was	O
+reduced	O
+to	O
+600	O
+mg	O
+q12h	O
+after	O
+10	O
+days	O
+,	O
+and	O
+extenuated	O
+since	O
+the	O
+13th	O
+day	O
+.	O
+
+Interferon	B-PRGE
+was	O
+given	O
+once	O
+a	O
+week	O
+,	O
+but	O
+only	O
+one	O
+dose	O
+was	O
+used	O
+.	O
+
+Mild	O
+shortness	B-DISO
+of	I-DISO
+breath	I-DISO
+and	O
+diarrhea	B-DISO
+after	O
+exertion	B-PROC
+were	O
+noticed	O
+.	O
+
+He	O
+had	O
+no	O
+chest	B-DISO
+pain	I-DISO
+,	O
+difficulty	O
+in	O
+breathing	B-PROC
+or	O
+other	O
+symptoms	O
+.	O
+
+There	O
+was	O
+dullness	O
+on	O
+percussion	O
+in	O
+both	O
+sides	O
+of	O
+chest	B-ANAT
+,	O
+and	O
+it	O
+disappeared	O
+gradually	O
+.	O
+
+Fine	O
+moist	B-DISO
+rales	I-DISO
+were	O
+detectable	O
+in	O
+scapular	O
+area	O
+and	O
+interscapular	O
+area	O
+on	O
+the	O
+5th	O
+day	O
+,	O
+and	O
+they	O
+disappeared	O
+after	O
+3	O
+days	O
+.	O
+
+Breath	B-ANAT
+sounds	O
+on	O
+both	O
+sides	O
+was	O
+weak	O
+,	O
+and	O
+it	O
+became	O
+more	O
+obvious	O
+in	O
+the	O
+right	B-ANAT
+lung	I-ANAT
+after	O
+5	O
+days	O
+,	O
+and	O
+returned	O
+to	O
+normal	O
+after	O
+18	O
+days	O
+.	O
+
+The	O
+viral	O
+nucleic	B-CHED
+acid	I-CHED
+test	O
+as	O
+performed	O
+by	O
+the	O
+Center	O
+for	O
+Disease	O
+Control	O
+of	O
+Guangdong	O
+(	O
+CDC	O
+,	O
+Guangdong	O
+)	O
+showed	O
+that	O
+the	O
+pharyngeal	B-ANAT
+swab	O
+cultured	O
+turned	O
+negative	O
+on	O
+the	O
+3rd	O
+day	O
+,	O
+that	O
+of	O
+serum	B-COMP
+specimens	O
+turned	O
+negative	O
+on	O
+the	O
+8th	O
+day	O
+,	O
+that	O
+of	O
+stool	B-ANAT
+specimen	I-ANAT
+after	O
+2	O
+weeks	O
+,	O
+and	O
+it	O
+was	O
+persistently	O
+positive	O
+for	O
+sputum	B-ANAT
+culture	O
+until	O
+5	O
+days	O
+before	O
+discharge	B-ANAT
+.	O
+
+The	O
+oxygenation	B-PROC
+index	O
+gradually	O
+increased	O
+,	O
+and	O
+it	O
+was	O
+over	O
+300	O
+mmHg	O
+(	O
+1	O
+mmHg	O
+=	O
+0	O
+.	O
+133	O
+kPa	O
+)	O
+after	O
+15	O
+days	O
+.	O
+
+RESULTS	O
+:	O
+(	O
+1	O
+)	O
+A	O
+43	O
+years	O
+old	O
+male	O
+of	O
+South	O
+Korean	O
+nationality	O
+was	O
+admitted	O
+with	O
+the	O
+complaint	O
+of	O
+back	B-DISO
+ache	I-DISO
+for	O
+7	O
+days	O
+and	O
+fever	B-PROC
+2	O
+days	O
+with	O
+the	O
+following	O
+characteristics	O
+:	O
+back	B-DISO
+ache	I-DISO
+7	O
+days	O
+ago	O
+,	O
+without	O
+fever	B-PROC
+or	O
+cough	B-DISO
+or	O
+expectoration	B-ANAT
+.	O
+
+Adult	O
+animals	B-SPEC
+in	O
+many	O
+countries	O
+in	O
+the	O
+Middle	O
+East	O
+as	O
+well	O
+as	O
+in	O
+North	O
+and	O
+East	O
+Africa	O
+showed	O
+high	O
+(>	O
+90	O
+%)	O
+seroprevalence	O
+to	O
+the	O
+virus	B-SPEC
+.	O
+
+Adjunctive	O
+corticosteroids	B-CHED
+were	O
+associated	O
+with	O
+possible	O
+reductions	O
+in	O
+all	O
+-	O
+cause	O
+mortality	O
+(	O
+12	O
+trials	O
+;	O
+1974	O
+patients	O
+;	O
+risk	O
+ratio	O
+[	O
+RR	O
+],	O
+0	O
+.	O
+67	O
+[	O
+95	O
+%	O
+CI	O
+,	O
+0	O
+.	O
+45	O
+to	O
+1	O
+.	O
+01	O
+];	O
+risk	O
+difference	O
+[	O
+RD	O
+],	O
+2	O
+.	O
+8	O
+%;	O
+moderate	O
+certainty	O
+),	O
+need	O
+for	O
+mechanical	O
+ventilation	O
+(	O
+5	O
+trials	O
+;	O
+1060	O
+patients	O
+;	O
+RR	O
+,	O
+0	O
+.	O
+45	O
+[	O
+CI	O
+,	O
+0	O
+.	O
+26	O
+to	O
+0	O
+.	O
+79	O
+];	O
+RD	O
+,	O
+5	O
+.	O
+0	O
+%;	O
+moderate	O
+certainty	O
+),	O
+and	O
+the	O
+acute	O
+respiratory	O
+distress	O
+syndrome	O
+(	O
+4	O
+trials	O
+;	O
+945	O
+patients	O
+;	O
+RR	O
+,	O
+0	O
+.	O
+24	O
+[	O
+CI	O
+,	O
+0	O
+.	O
+10	O
+to	O
+0	O
+.	O
+56	O
+];	O
+RD	O
+,	O
+6	O
+.	O
+2	O
+%;	O
+moderate	O
+certainty	O
+).	O
+
+The	O
+indicators	O
+of	O
+pulmonary	B-ANAT
+vascular	B-PROC
+permeability	I-PROC
+,	O
+pulmonary	B-PROC
+circulation	B-PROC
+,	I-PROC
+blood	I-PROC
+gases	O
+,	O
+and	O
+hemodynamics	B-PROC
+as	O
+well	O
+as	O
+APACHE	O
+II	O
+and	O
+ALI	O
+scores	O
+were	O
+detected	O
+on	O
+days	O
+1	O
+,	O
+3	O
+,	O
+and	O
+7	O
+.	O
+
+TITLE	O
+:	O
+Retinal	B-ANAT
+Hemorrhages	I-DISO
+in	O
+Severe	O
+Non	O
+-	O
+cerebral	B-ANAT
+Plasmodium	B-DISO
+vivax	I-DISO
+Malaria	B-PATH
+in	O
+an	O
+Adult	O
+.	O
+
+We	O
+describe	O
+26	O
+GPA	O
+patients	O
+with	O
+≥	O
+1	O
+tracheal	O
+(	O
+mainly	O
+subglottic	B-ANAT
+,	O
+SGS	B-DISO
+)	O
+and	O
+/	O
+or	O
+bronchial	B-DISO
+stenosis	B-SPEC
+(	O
+ses	O
+)	O
+(	O
+BS	O
+(	O
+s	O
+)).	O
+Sixteen	O
+patients	O
+had	O
+solitary	O
+SGS	B-DISO
+and	O
+10	O
+had	O
+≥	O
+1	O
+BS	O
+(	O
+s	O
+).	O
+
+However	O
+,	O
+cyclophosphamide	B-CHED
+seemed	O
+to	O
+effectively	O
+treat	O
+BSs	B-DISO
+,	O
+but	O
+not	O
+SGS	B-DISO
+,	O
+and	O
+rituximab	O
+may	O
+be	O
+of	O
+interest	O
+for	O
+SGS	B-DISO
+management	O
+.	O
+
+There	O
+were	O
+no	O
+detrimental	O
+effects	O
+in	O
+terms	O
+of	O
+lung	B-ANAT
+mechanics	O
+,	O
+auto	B-DISO
+-	I-DISO
+PEEP	I-DISO
+generation	O
+,	O
+hemodynamics	B-PROC
+,	O
+or	O
+gas	B-ENZY
+exchange	O
+.	O
+
+This	O
+strategy	O
+also	O
+allowed	O
+decreasing	O
+airway	B-ANAT
+pressures	O
+while	O
+maintaining	O
+stable	O
+PaCO2	O
+levels	O
+.	O
+
+CONCLUSIONS	O
+:	O
+Despite	O
+limited	O
+evidence	O
+and	O
+relatively	O
+few	O
+randomized	O
+trials	O
+in	O
+children	O
+,	O
+ECMO	O
+remains	O
+the	O
+safety	O
+net	O
+for	O
+patients	O
+with	O
+severe	O
+respiratory	B-DISO
+failure	I-DISO
+.	O
+
+TITLE	O
+:	O
+Detection	O
+and	O
+molecular	O
+characterisation	O
+of	O
+bovine	B-SPEC
+corona	B-CHED
+and	O
+toroviruses	B-SPEC
+from	O
+Croatian	O
+cattle	B-SPEC
+.	O
+
+ABSTRACT	O
+:	O
+Despite	O
+the	O
+identification	O
+of	O
+horseshoe	B-SPEC
+bats	I-SPEC
+as	O
+the	O
+reservoir	O
+of	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+(	O
+SARS	B-DISO
+)-	O
+related	O
+coronaviruses	O
+(	O
+SARSr	O
+-	O
+CoVs	O
+),	O
+the	O
+origin	O
+of	O
+SARS	B-PRGE
+-	I-PRGE
+CoV	I-PRGE
+ORF8	I-PRGE
+,	O
+which	O
+contains	O
+the	O
+29	O
+-	O
+nucleotide	B-CHED
+signature	O
+deletion	O
+among	O
+human	B-SPEC
+strains	O
+,	O
+remains	O
+obscure	O
+.	O
+
+The	O
+genomes	O
+of	O
+two	O
+betacoronaviruses	O
+,	O
+SARSr	O
+-	O
+Rf	O
+-	O
+BatCoV	O
+YNLF_31C	O
+and	O
+YNLF_34C	O
+,	O
+from	O
+greater	O
+horseshoe	O
+bats	O
+(	O
+Rhinolophus	B-SPEC
+ferrumequinum	I-SPEC
+),	O
+possessed	B-DISO
+93	O
+%	O
+nucleotide	B-CHED
+identities	O
+to	O
+human	B-SPEC
+/	O
+civet	B-SPEC
+SARSr	O
+-	O
+CoV	O
+genomes	O
+.	O
+
+In	O
+particular	O
+,	O
+SARSr	O
+-	O
+Rs	O
+-	O
+BatCoVs	O
+from	O
+Chinese	O
+horseshoe	B-SPEC
+bats	I-SPEC
+(	O
+Rhinolophus	B-SPEC
+sinicus	I-SPEC
+)	O
+exhibited	O
+<	O
+40	O
+%	O
+amino	B-CHED
+acid	I-CHED
+identities	O
+to	O
+human	B-SPEC
+/	O
+civet	B-SPEC
+SARS	B-DISO
+-	O
+CoV	O
+in	O
+the	O
+ORF8	O
+protein	B-CHED
+.	O
+
+Nasal	B-ANAT
+/	O
+throat	B-ANAT
+swabs	O
+from	O
+acute	O
+illnesses	O
+were	O
+collected	O
+and	O
+tested	O
+by	O
+influenza	B-DISO
+RT	O
+-	O
+PCR	O
+(	O
+all	O
+four	O
+classes	O
+).	O
+
+RESULTS	O
+:	O
+A	O
+multi	O
+-	O
+fragment	O
+antigen	B-CHED
+,	O
+termed	O
+BE	O
+,	O
+which	O
+was	O
+composed	O
+of	O
+eight	O
+antigenic	O
+fragments	O
+selected	O
+from	O
+the	O
+three	O
+major	O
+proteins	B-CHED
+(	O
+S	O
+,	O
+M	O
+,	O
+and	O
+N	O
+)	O
+of	O
+IBV	B-SPEC
+,	O
+was	O
+expressed	B-PROC
+in	O
+Escherichia	B-SPEC
+coli	I-SPEC
+.	O
+
+TITLE	O
+:	O
+Complete	O
+Genome	O
+Sequence	O
+of	O
+Middle	O
+East	O
+Respiratory	O
+Syndrome	B-DISO
+Coronavirus	B-SPEC
+KOR	O
+/	O
+KNIH	O
+/	O
+002_05_2015	O
+,	O
+Isolated	O
+in	O
+South	O
+Korea	O
+.	O
+
+ABSTRACT	O
+:	O
+The	O
+full	O
+genome	O
+sequence	O
+of	O
+a	O
+Middle	O
+East	O
+respiratory	O
+syndrome	O
+coronavirus	B-SPEC
+(	O
+MERS	O
+-	O
+CoV	O
+)	O
+was	O
+identified	O
+from	O
+cultured	O
+and	O
+isolated	O
+in	O
+Vero	B-ANAT
+cells	I-ANAT
+.	O
+
+ABSTRACT	O
+:	O
+Light	O
+fullerenes	B-CHED
+attract	O
+significant	O
+interest	O
+in	O
+pharmacy	O
+and	O
+medicine	O
+as	O
+drug	O
+vectors	O
+and	O
+antioxidants	B-CHED
+and	O
+to	O
+block	O
+AIDS	B-SPEC
+virus	I-SPEC
+enzyme	O
+.	O
+
+We	O
+report	O
+a	O
+28	O
+-	O
+year	O
+-	O
+old	O
+pregnant	O
+woman	O
+(	O
+26	O
+weeks	O
+gestation	B-PROC
+)	O
+with	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+in	O
+whom	O
+ECMO	O
+support	O
+was	O
+necessary	O
+for	O
+survival	O
+,	O
+and	O
+she	O
+was	O
+transported	O
+to	O
+another	O
+facility	O
+1	O
+,	O
+155	O
+km	O
+away	O
+with	O
+the	O
+aid	O
+of	O
+the	O
+portable	O
+ECMO	O
+system	O
+.	O
+
+The	O
+unusually	O
+short	O
+helical	O
+hairpin	O
+structure	O
+of	O
+the	O
+protein	B-CHED
+might	O
+explain	O
+its	O
+ability	O
+to	O
+deform	O
+bilayers	O
+and	O
+is	O
+reminiscent	O
+of	O
+other	O
+peptides	B-CHED
+with	O
+membrane	B-COMP
+disrupting	O
+functionalities	O
+.	O
+
+ABSTRACT	O
+:	O
+In	O
+2012	O
+Middle	O
+-	O
+East	O
+respiratory	O
+syndrome	O
+coronavirus	B-SPEC
+(	O
+MERS	O
+-	O
+CoV	O
+)	O
+was	O
+evolved	O
+in	O
+the	O
+Arabian	O
+Peninsula	O
+.	O
+
+For	O
+eight	O
+patients	O
+,	O
+the	O
+identity	O
+of	O
+the	O
+rhinoviruses	B-SPEC
+,	O
+including	O
+4	O
+cases	O
+of	O
+HRV	O
+-	O
+C	O
+,	O
+3	O
+cases	O
+of	O
+HRV	O
+-	O
+A	O
+,	O
+and	O
+a	O
+single	O
+case	O
+of	O
+HRV	O
+-	O
+B	O
+,	O
+was	O
+corroborated	O
+using	O
+partial	O
+sequencing	O
+of	O
+the	O
+5	O
+non	O
+-	O
+coding	O
+regions	O
+and	O
+phylogenetic	O
+analysis	O
+.	O
+
+TITLE	O
+:	O
+Flexibility	O
+as	O
+a	O
+Strategy	O
+in	O
+Nucleoside	B-CHED
+Antiviral	B-CHED
+Drug	I-CHED
+Design	O
+.	O
+
+This	O
+concept	O
+,	O
+however	O
+,	O
+went	O
+against	O
+years	O
+of	O
+enzyme	O
+-	O
+substrate	O
+binding	B-FUNC
+theory	O
+.	O
+
+ABSTRACT	O
+:	O
+The	O
+lack	O
+of	O
+optimal	O
+porcine	B-SPEC
+cell	B-ANAT
+lines	I-ANAT
+has	O
+severely	O
+impeded	O
+the	O
+study	O
+and	O
+progress	O
+in	O
+elucidation	O
+of	O
+porcine	B-SPEC
+epidemic	I-SPEC
+diarrhea	I-SPEC
+virus	I-SPEC
+(	O
+PEDV	B-SPEC
+)	O
+pathogenesis	B-DISO
+.	O
+
+Limited	O
+reports	O
+showed	O
+that	O
+PEDV	B-SPEC
+could	O
+inhibit	O
+type	B-PROC
+I	I-PROC
+interferon	I-PROC
+production	I-PROC
+.	O
+
+As	O
+the	O
+key	O
+IFN	B-PRGE
+-	I-PRGE
+β	I-PRGE
+transcription	I-PRGE
+factors	I-PRGE
+,	O
+we	O
+found	O
+that	O
+dsRNA	B-CHED
+-	O
+induced	O
+activation	O
+of	O
+IFN	B-PRGE
+regulatory	I-PRGE
+factor	I-PRGE
+3	I-PRGE
+(	O
+IRF	B-PRGE
+-	I-PRGE
+3	I-PRGE
+)	O
+was	O
+inhibited	O
+after	O
+PEDV	B-SPEC
+infection	B-DISO
+,	O
+but	O
+not	O
+nuclear	B-PRGE
+factor	I-PRGE
+-	I-PRGE
+kappaB	I-PRGE
+(	O
+NF	O
+-	O
+κB	O
+).	O
+
+In	O
+the	O
+upstream	O
+of	O
+IRF	B-PRGE
+-	I-PRGE
+3	I-PRGE
+,	O
+TANK	B-PRGE
+-	I-PRGE
+binding	I-PRGE
+kinase	I-PRGE
+1	I-PRGE
+(	O
+TBK1	B-FUNC
+)-	O
+or	O
+inhibitor	B-CHED
+of	O
+κB	B-PRGE
+kinase	I-PRGE
+-	I-PRGE
+ε	I-PRGE
+(	O
+IKKε	O
+)-	O
+mediated	O
+IFN	B-PRGE
+-	I-PRGE
+β	I-PRGE
+production	O
+was	O
+not	O
+blocked	O
+by	O
+PEDV	B-SPEC
+,	O
+while	O
+RIG	B-PRGE
+-	I-PRGE
+I	I-PRGE
+-	O
+and	O
+its	O
+adapter	O
+molecule	O
+IFN	B-PRGE
+-	I-PRGE
+β	I-PRGE
+promoter	I-PRGE
+stimulator	I-PRGE
+1	I-PRGE
+(	O
+IPS	B-PRGE
+-	I-PRGE
+1	I-PRGE
+)-	O
+mediated	O
+IFN	B-PRGE
+-	I-PRGE
+β	I-PRGE
+production	O
+were	O
+completely	O
+inhibited	O
+after	O
+PEDV	B-SPEC
+infection	B-DISO
+.	O
+
+TITLE	O
+:	O
+In	O
+Vivo	O
+Effects	O
+of	O
+Mesenchymal	O
+Stromal	B-ANAT
+Cells	I-ANAT
+in	O
+Two	O
+Patients	O
+With	O
+Severe	O
+Acute	B-DISO
+Respiratory	I-DISO
+Distress	I-DISO
+Syndrome	I-DISO
+.	O
+
+Notable	O
+members	O
+include	O
+West	B-DISO
+Nile	I-DISO
+virus	I-DISO
+,	O
+Dengue	B-SPEC
+virus	I-SPEC
+,	O
+Chikungunya	B-DISO
+,	O
+Severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+(	O
+SARS	B-DISO
+)	O
+Coronavirus	B-SPEC
+and	O
+enteroviruses	B-SPEC
+of	O
+the	O
+Picornaviridae	B-SPEC
+family	B-SPEC
+.	O
+
+TITLE	O
+:	O
+Concentration	O
+,	O
+Size	O
+Distribution	O
+,	O
+and	O
+Infectivity	O
+of	O
+Airborne	O
+Particles	O
+Carrying	O
+Swine	B-SPEC
+Viruses	B-SPEC
+.	O
+
+Air	O
+samples	O
+collected	O
+for	O
+the	O
+first	O
+9	O
+,	O
+20	O
+and	O
+the	O
+last	O
+3	O
+days	O
+of	O
+the	O
+study	O
+were	O
+analyzed	O
+for	O
+IAV	O
+,	O
+PRRSV	B-SPEC
+and	O
+PEDV	B-SPEC
+,	O
+respectively	O
+,	O
+using	O
+quantitative	O
+reverse	B-PROC
+transcription	I-PROC
+polymerase	O
+chain	O
+reaction	O
+(	O
+RT	O
+-	O
+PCR	O
+)	O
+and	O
+quantified	O
+as	O
+geometric	O
+mean	O
+copies	O
+/	O
+m	O
+(	O
+3	O
+)	O
+within	O
+each	O
+size	O
+range	O
+.	O
+
+ABSTRACT	O
+:	O
+Naloxone	O
+is	O
+commonly	O
+administered	O
+in	O
+emergency	B-DISO
+department	O
+(	O
+ED	O
+)	O
+to	O
+reverse	O
+opioid	B-DISO
+intoxication	I-DISO
+.	O
+
+Several	O
+naloxone	B-CHED
+dose	O
+recommendations	O
+exist	O
+for	O
+acute	O
+management	O
+of	O
+opioid	B-DISO
+intoxication	I-DISO
+based	O
+on	O
+limited	O
+published	O
+clinical	O
+data	O
+.	O
+
+Fifteen	O
+ED	O
+patients	O
+with	O
+moderate	O
+to	O
+severe	O
+opioid	O
+-	O
+induced	O
+ventilatory	B-DISO
+depression	I-DISO
+(	O
+median	O
+RR	O
+,	O
+6	O
+breaths	O
+/	O
+min	O
+)	O
+who	O
+were	O
+managed	O
+using	O
+low	O
+-	O
+dose	O
+naloxone	O
+strategy	O
+were	O
+identified	O
+.	O
+
+ED	O
+patients	O
+with	O
+moderate	O
+to	O
+severe	O
+opioid	O
+-	O
+induced	O
+ventilatory	B-DISO
+depression	I-DISO
+can	O
+be	O
+reversed	O
+using	O
+0	O
+.	O
+04	O
+mg	O
+IV	O
+naloxone	B-CHED
+with	O
+appropriate	O
+dose	O
+titration	O
+.	O
+
+RESULTS	O
+:	O
+Fifteen	O
+ED	O
+patients	O
+with	O
+moderate	O
+to	O
+severe	O
+opioid	O
+-	O
+induced	O
+ventilatory	B-DISO
+depression	I-DISO
+(	O
+median	O
+RR	O
+,	O
+6	O
+breaths	O
+/	O
+min	O
+)	O
+who	O
+were	O
+managed	O
+using	O
+low	O
+-	O
+dose	O
+naloxone	B-CHED
+strategy	O
+were	O
+identified	O
+.	O
+
+The	O
+recent	O
+increase	O
+in	O
+cases	O
+of	O
+MERS	O
+in	O
+the	O
+Middle	O
+East	O
+coupled	O
+with	O
+the	O
+lack	O
+of	O
+approved	O
+antiviral	B-CHED
+therapies	O
+or	O
+vaccines	O
+to	O
+treat	O
+or	O
+prevent	O
+this	O
+infection	B-DISO
+are	O
+causes	O
+for	O
+concern	O
+.	O
+
+Upon	O
+MERS	O
+viral	O
+challenge	O
+,	O
+all	O
+of	O
+the	O
+monkeys	B-SPEC
+in	O
+the	O
+control	O
+-	O
+vaccinated	O
+group	O
+developed	O
+characteristic	O
+disease	O
+,	O
+including	O
+pneumonia	B-DISO
+.	O
+
+TITLE	O
+:	O
+Challenges	O
+and	O
+Strategies	O
+of	O
+Laboratory	O
+Diagnosis	O
+for	O
+Newly	O
+Emerging	O
+Influenza	B-SPEC
+Viruses	I-SPEC
+in	O
+Taiwan	O
+:	O
+A	O
+Decade	O
+after	O
+SARS	O
+.	O
+
+The	O
+capacity	O
+of	O
+influenza	B-PATH
+A	I-PATH
+to	O
+cross	O
+species	B-SPEC
+barriers	O
+presents	O
+a	O
+potential	O
+threat	O
+to	O
+human	B-SPEC
+health	O
+.	O
+
+Given	O
+the	O
+mutations	O
+of	O
+avian	B-DISO
+flu	I-DISO
+viruses	B-SPEC
+such	O
+as	O
+H7N9	O
+,	O
+H6N1	O
+,	O
+and	O
+H10N8	O
+,	O
+all	O
+countries	O
+,	O
+including	O
+Taiwan	O
+,	O
+must	O
+equip	O
+themselves	O
+to	O
+face	B-DISO
+a	O
+possible	O
+epidemic	O
+or	O
+pandemic	O
+.	O
+
+During	O
+2013	O
+-	O
+2014	O
+,	O
+the	O
+department	O
+investigated	O
+54	O
+travelers	O
+for	O
+MERS	O
+-	O
+CoV	O
+;	O
+none	O
+tested	O
+positive	O
+,	O
+but	O
+32	O
+(	O
+62	O
+%)	O
+of	O
+52	O
+travelers	O
+with	O
+suspected	O
+MERS	O
+-	O
+CoV	O
+had	O
+other	O
+respiratory	O
+viruses	B-SPEC
+.	O
+
+ABSTRACT	O
+:	O
+Notification	O
+of	O
+2	O
+imported	O
+cases	O
+of	O
+infection	O
+with	O
+Middle	O
+East	O
+respiratory	O
+syndrome	B-DISO
+coronavirus	B-SPEC
+in	O
+the	O
+Netherlands	O
+triggered	O
+comprehensive	O
+monitoring	O
+of	O
+contacts	O
+.	O
+
+Observed	O
+low	O
+rates	O
+of	O
+virus	B-SPEC
+transmission	O
+and	O
+the	O
+psychological	B-DISO
+effect	O
+of	O
+contact	O
+monitoring	O
+indicate	O
+that	O
+thoughtful	O
+assessment	O
+of	O
+close	O
+contacts	O
+is	O
+prudent	O
+and	O
+must	O
+be	O
+guided	O
+by	O
+clinical	O
+and	O
+epidemiologic	O
+risk	O
+factors	O
+.	O
+
+Amino	B-CHED
+acid	I-CHED
+changes	O
+occurred	O
+at	O
+four	O
+positions	O
+in	O
+the	O
+spike	O
+(	O
+S	O
+)	O
+gene	O
+and	O
+,	O
+at	O
+two	O
+positions	O
+in	O
+the	O
+S	B-PRGE
+gene	I-PRGE
+,	O
+large	O
+shifts	O
+in	O
+frequencies	O
+of	O
+aa	O
+encoding	O
+were	O
+observed	O
+.	O
+
+Synonymous	O
+nucleotide	B-CHED
+changes	O
+and	O
+changes	O
+in	O
+noncoding	O
+regions	O
+of	O
+the	O
+genome	O
+were	O
+observed	O
+at	O
+eight	O
+genome	O
+positions	O
+.	O
+
+From	O
+an	O
+applied	O
+perspective	O
+,	O
+the	O
+fact	O
+that	O
+CEK	B-PRGE
+adaptation	B-PROC
+of	O
+embryo	B-ANAT
+-	O
+attenuated	O
+Ark	O
+vaccines	O
+reduces	O
+population	O
+heterogeneity	O
+,	O
+and	O
+that	O
+changes	O
+do	O
+not	O
+revert	O
+after	O
+one	O
+replication	O
+cycle	O
+in	O
+ECE	O
+or	O
+in	O
+chickens	B-SPEC
+,	O
+provides	O
+an	O
+opportunity	O
+to	O
+improve	O
+commercial	O
+ArkDPI	O
+-	O
+derived	O
+vaccines	O
+.	O
+
+To	O
+identify	O
+antigen	B-CHED
+epitopes	O
+with	O
+specificity	O
+for	O
+PEDV	B-SPEC
+,	O
+a	O
+monoclonal	O
+antibody	B-COMP
+(	O
+MAb	O
+-	O
+5E12	O
+)	O
+against	O
+the	O
+immunodominant	O
+region	O
+of	O
+the	O
+PEDV	B-PRGE
+Spike	I-PRGE
+protein	B-CHED
+(	O
+S1	O
+)	O
+was	O
+used	O
+as	O
+the	O
+target	O
+for	O
+biopanning	O
+a	O
+12	O
+-	O
+mer	O
+phage	O
+display	O
+,	O
+random	O
+peptide	B-CHED
+library	O
+.	O
+
+Using	O
+this	O
+method	O
+,	O
+a	O
+new	O
+technique	O
+to	O
+simultaneously	O
+detect	O
+6	O
+kinds	O
+of	O
+febrile	B-PROC
+respiratory	O
+viruses	B-SPEC
+in	O
+a	O
+protein	B-CHED
+chip	O
+was	O
+developed	O
+.	O
+
+TITLE	O
+:	O
+The	O
+role	O
+of	O
+inhaled	B-PROC
+prostacyclin	B-CHED
+in	O
+treating	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+.	O
+
+TITLE	O
+:	O
+Balloon	O
+-	O
+Occluded	B-DISO
+Retrograde	O
+Transvenous	O
+Obliteration	O
+for	O
+the	O
+Treatment	O
+of	O
+Gastric	B-DISO
+Varices	I-DISO
+:	O
+Polidocanol	B-CHED
+Foam	O
+Versus	O
+Liquid	O
+Ethanolamine	B-CHED
+Oleate	B-CHED
+.	O
+
+The	O
+variance	O
+in	O
+laboratory	O
+data	O
+values	O
+associated	O
+with	O
+hemolysis	B-DISO
+was	O
+significantly	O
+greater	O
+with	O
+ethanolamine	B-CHED
+oleate	B-CHED
+.	O
+
+No	O
+postprocedural	O
+rebleeding	O
+from	O
+the	O
+gastric	B-DISO
+varices	I-DISO
+was	O
+observed	O
+during	O
+a	O
+median	O
+follow	O
+-	O
+up	O
+time	O
+of	O
+39	O
+.	O
+5	O
+months	O
+after	O
+procedures	O
+with	O
+ethanolamine	B-CHED
+oleate	B-CHED
+and	O
+34	O
+months	O
+after	O
+procedures	O
+with	O
+polidocanol	B-CHED
+foam	O
+.	O
+
+ABSTRACT	O
+:	O
+The	O
+recent	O
+emergence	O
+of	O
+Middle	O
+East	O
+respiratory	O
+syndrome	O
+coronavirus	B-SPEC
+from	O
+the	O
+Middle	O
+East	O
+and	O
+its	O
+discovery	O
+from	O
+dromedary	B-SPEC
+camels	B-SPEC
+has	O
+boosted	O
+interest	O
+in	O
+the	O
+search	O
+for	O
+novel	O
+viruses	B-SPEC
+in	O
+dromedaries	B-SPEC
+.	O
+
+Although	O
+DcAstV	O
+was	O
+most	O
+closely	O
+related	O
+to	O
+a	O
+recently	O
+characterized	O
+porcine	B-SPEC
+AstV	O
+2	O
+,	O
+their	O
+capsid	B-ANAT
+proteins	B-CHED
+only	O
+shared	O
+60	O
+-	O
+66	O
+%	O
+amino	B-CHED
+acid	I-CHED
+identity	O
+,	O
+with	O
+a	O
+mean	O
+amino	B-CHED
+acid	I-CHED
+genetic	O
+distance	O
+of	O
+0	O
+.	O
+372	O
+.	O
+
+This	O
+lack	O
+was	O
+rectified	O
+by	O
+a	O
+2011	O
+workshop	O
+report	O
+by	O
+the	O
+American	O
+Thoracic	B-DISO
+Society	O
+,	O
+which	O
+defined	O
+the	O
+main	O
+features	O
+proposed	O
+to	O
+delineate	O
+the	O
+presence	O
+of	O
+ARDS	B-DISO
+in	O
+laboratory	O
+animals	B-SPEC
+.	O
+
+TITLE	O
+:	O
+X	O
+-	O
+ray	B-SPEC
+Structural	O
+and	O
+Functional	O
+Studies	O
+of	O
+the	O
+Three	O
+Tandemly	O
+Linked	O
+Domains	O
+of	O
+Non	O
+-	O
+structural	O
+Protein	O
+3	O
+(	O
+nsp3	B-PRGE
+)	O
+from	O
+Murine	B-DISO
+Hepatitis	I-DISO
+Virus	B-SPEC
+Reveal	O
+Conserved	O
+Functions	O
+.	O
+
+We	O
+report	O
+here	O
+the	O
+x	O
+-	O
+ray	B-SPEC
+structure	O
+of	O
+three	O
+tandemly	O
+linked	O
+domains	O
+of	O
+MHV	B-PRGE
+nsp3	I-PRGE
+,	O
+including	O
+the	O
+papain	B-PRGE
+-	I-PRGE
+like	I-PRGE
+protease	I-PRGE
+2	I-PRGE
+(	O
+PLP2	B-PRGE
+)	O
+catalytic	O
+domain	O
+,	O
+the	O
+ubiquitin	B-PRGE
+-	I-PRGE
+like	I-PRGE
+domain	I-PRGE
+2	I-PRGE
+(	O
+Ubl2	B-PRGE
+),	O
+and	O
+a	O
+third	O
+domain	O
+that	O
+we	O
+call	O
+the	O
+DPUP	O
+(	O
+domain	O
+preceding	O
+Ubl2	O
+and	O
+PLP2	B-PRGE
+)	O
+domain	O
+.	O
+
+DPUP	O
+has	O
+close	O
+structural	O
+similarity	O
+to	O
+the	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+coronavirus	B-SPEC
+unique	O
+domain	O
+C	O
+(	O
+SUD	O
+-	O
+C	O
+),	O
+suggesting	O
+that	O
+this	O
+domain	O
+may	O
+not	O
+be	O
+unique	O
+to	O
+the	O
+severe	O
+acute	O
+respiratory	O
+syndrome	O
+coronavirus	B-SPEC
+.	O
+
+These	O
+studies	O
+extend	O
+substantially	O
+our	O
+structural	O
+knowledge	O
+of	O
+MHV	B-PRGE
+nsp3	I-PRGE
+,	O
+providing	O
+a	O
+platform	O
+for	O
+further	O
+investigation	O
+of	O
+the	O
+role	O
+of	O
+nsp3	B-PRGE
+domains	I-PRGE
+in	O
+MHV	B-SPEC
+viral	B-PROC
+replication	I-PROC
+.	O
+
+TITLE	O
+:	O
+Construction	O
+of	O
+an	O
+oral	B-ANAT
+vaccine	O
+for	O
+transmissible	O
+gastroenteritis	B-DISO
+virus	B-SPEC
+based	O
+on	O
+the	O
+TGEV	B-SPEC
+N	I-PRGE
+gene	I-PRGE
+expressed	O
+in	O
+an	O
+attenuated	O
+Salmonella	B-DISO
+typhimurium	O
+vector	O
+.	O
+
+To	O
+evaluate	O
+the	O
+safety	O
+and	O
+stability	O
+of	O
+the	O
+developed	O
+vaccine	O
+,	O
+different	O
+dosages	O
+(	O
+5	O
+×	O
+10	O
+(	O
+8	O
+),	O
+1	O
+×	O
+10	O
+(	O
+9	O
+),	O
+and	O
+2	O
+×	O
+10	O
+(	O
+9	O
+)	O
+CFU	O
+/	O
+mice	B-SPEC
+)	O
+of	O
+SL7207	O
+(	O
+pVAX	O
+-	O
+N	O
+)	O
+were	O
+inoculated	O
+to	O
+6	O
+-	O
+week	O
+-	O
+old	O
+mice	B-SPEC
+.	O
+
+They	O
+commonly	O
+use	O
+polymerase	O
+chain	O
+reaction	O
+(	O
+PCR	O
+)	O
+and	O
+reverse	B-PROC
+transcription	I-PROC
+PCR	O
+.	O
+
+Here	O
+we	O
+offer	O
+a	O
+multiplexed	O
+assay	O
+for	O
+a	O
+panel	O
+of	O
+respiratory	O
+viruses	B-SPEC
+that	O
+mitigates	O
+these	O
+problems	O
+by	O
+combining	O
+several	O
+nucleic	B-CHED
+acid	I-CHED
+analogs	O
+from	O
+the	O
+emerging	O
+field	O
+of	O
+synthetic	O
+biology	O
+:	O
+(	O
+i	O
+)	O
+self	O
+-	O
+avoiding	O
+molecular	B-PROC
+recognition	I-PROC
+systems	O
+(	O
+SAMRSs	O
+),	O
+which	O
+facilitate	O
+multiplexing	O
+,	O
+and	O
+(	O
+ii	O
+)	O
+artificially	O
+expanded	O
+genetic	O
+information	O
+systems	O
+(	O
+AEGISs	O
+),	O
+which	O
+enable	O
+low	O
+-	O
+noise	O
+PCR	O
+.	O
+
+TITLE	O
+:	O
+Role	O
+of	O
+Extracorporeal	O
+Membrane	B-COMP
+Oxygenation	B-PROC
+in	O
+Aluminum	B-CHED
+Phosphide	I-CHED
+Poisoning	O
+-	O
+Induced	O
+Reversible	O
+Myocardial	O
+Dysfunction	O
+:	O
+A	O
+Novel	O
+Therapeutic	O
+Modality	O
+.	O
+
+At	O
+9	O
+months	O
+of	O
+follow	O
+-	O
+up	O
+,	O
+all	O
+five	O
+surviving	O
+patients	O
+were	O
+doing	O
+well	O
+,	O
+with	O
+the	O
+near	O
+normalization	O
+of	O
+ventricular	B-PROC
+function	I-PROC
+.	O
+
+TITLE	O
+:	O
+Surveillance	O
+operation	O
+for	O
+the	O
+141st	O
+confirmed	O
+case	O
+of	O
+Middle	O
+East	O
+Respiratory	O
+Syndrome	B-DISO
+coronavirus	B-SPEC
+in	O
+response	O
+to	O
+the	O
+patient	O
+'	O
+s	O
+prior	O
+travel	O
+to	O
+Jeju	O
+Island	O
+.	O
+
+Although	O
+the	O
+visiting	O
+period	O
+might	O
+be	O
+interpreted	O
+as	O
+the	O
+incubation	O
+period	O
+of	O
+MERS	O
+,	O
+the	O
+province	O
+decided	O
+to	O
+conduct	B-PROC
+active	O
+surveillance	O
+to	O
+prevent	O
+a	O
+worst	O
+-	O
+case	O
+scenario	O
+.	O
+
+ABSTRACT	O
+:	O
+A	O
+domestic	O
+ferret	O
+from	O
+Lima	B-SPEC
+,	O
+Peru	O
+,	O
+died	B-PROC
+after	O
+ten	O
+days	O
+of	O
+non	O
+-	O
+specific	O
+clinical	O
+signs	O
+.	O
+
+The	O
+results	O
+suggest	O
+an	O
+activation	O
+of	O
+a	O
+highly	O
+complex	O
+transcriptional	B-PROC
+program	O
+in	O
+response	O
+to	O
+chest	B-ANAT
+trauma	O
+.	O
+
+TITLE	O
+:	O
+Novel	O
+Uses	O
+of	O
+Extracorporeal	O
+Membrane	B-COMP
+Oxygenation	B-PROC
+in	O
+Adults	O
+.	O
+
+There	O
+is	O
+hope	O
+for	O
+the	O
+development	B-PROC
+of	O
+destination	O
+device	O
+therapy	O
+,	O
+which	O
+could	O
+have	O
+significant	O
+implications	O
+for	O
+acute	O
+and	O
+chronic	O
+management	O
+of	O
+severe	O
+respiratory	O
+and	O
+cardiac	B-DISO
+disease	I-DISO
+.	O
+
+Cross	O
+-	O
+reactivity	O
+assays	O
+demonstrated	O
+that	O
+iELISA	O
+was	O
+PEDV	B-SPEC
+-	O
+specific	O
+.	O
+
+Using	O
+genome	O
+-	O
+wide	O
+small	O
+interfering	O
+RNA	O
+(	O
+siRNA	O
+)	O
+screening	O
+,	O
+we	O
+identified	O
+83	O
+novel	O
+genes	O
+supporting	O
+infectious	B-DISO
+bronchitis	B-DISO
+virus	B-SPEC
+(	O
+IBV	B-SPEC
+)	O
+replication	O
+in	O
+human	B-SPEC
+cells	B-COMP
+.	O
+
+Loss	O
+of	O
+VCP	O
+inhibits	O
+a	O
+previously	O
+uncharacterized	O
+degradation	O
+of	O
+the	O
+nucleocapsid	B-PRGE
+N	I-PRGE
+protein	B-CHED
+.	O
+
+Coronaviruses	O
+are	O
+RNA	O
+viruses	B-SPEC
+representing	O
+a	O
+real	O
+threat	O
+for	O
+public	O
+health	O
+,	O
+as	O
+evidenced	O
+by	O
+SARS	B-DISO
+and	O
+the	O
+emerging	O
+MERS	O
+.	O
+
+ABSTRACT	O
+:	O
+The	O
+newly	O
+emerged	O
+Middle	O
+East	O
+respiratory	O
+syndrome	B-DISO
+coronavirus	B-SPEC
+(	O
+MERS	O
+-	O
+CoV	O
+)	O
+and	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+CoV	O
+(	O
+SARS	B-DISO
+-	O
+CoV	O
+)	O
+represent	O
+highly	O
+pathogenic	O
+human	B-SPEC
+CoVs	O
+that	O
+share	O
+a	O
+property	O
+to	O
+inhibit	O
+host	B-COMP
+gene	B-PROC
+expression	I-PROC
+at	O
+the	O
+posttranscriptional	O
+level	O
+.	O
+
+The	O
+present	O
+study	O
+represents	O
+a	O
+meaningful	O
+step	O
+toward	O
+a	O
+better	O
+understanding	O
+of	O
+the	O
+factors	O
+and	O
+molecular	O
+mechanisms	O
+governing	O
+the	O
+virulence	B-PROC
+and	O
+pathogenesis	B-DISO
+of	O
+MERS	O
+-	O
+CoV	O
+.	O
+
+The	O
+benefits	O
+in	O
+ARDS	B-DISO
+outcomes	O
+caused	O
+by	O
+these	O
+interventions	O
+have	O
+been	O
+confirmed	O
+by	O
+several	O
+prospective	O
+randomized	O
+controlled	O
+trials	O
+(	O
+RCTs	O
+)	O
+and	O
+are	O
+attributed	O
+to	O
+reduction	O
+in	O
+volutrauma	O
+.	O
+
+A	O
+42	O
+-	O
+year	O
+-	O
+old	O
+male	O
+Turkish	O
+citizen	O
+who	O
+worked	O
+as	O
+an	O
+employee	O
+in	O
+Jeddah	O
+,	O
+Kingdom	B-SPEC
+of	O
+Saudi	O
+Arabia	O
+,	O
+admitted	O
+to	O
+hospital	O
+with	O
+the	O
+complaints	O
+of	O
+fever	O
+and	O
+malaise	B-DISO
+on	O
+25	O
+-	O
+26	O
+September	O
+2014	O
+.	O
+
+Since	O
+his	O
+symptoms	O
+went	O
+on	O
+and	O
+got	O
+worse	O
+,	O
+he	O
+returned	O
+to	O
+Turkey	B-SPEC
+,	O
+and	O
+hospitalized	O
+in	O
+a	O
+hospital	O
+'	O
+s	O
+intensive	O
+care	O
+unit	O
+in	O
+Hatay	O
+on	O
+6th	O
+of	O
+October	O
+with	O
+the	O
+symptoms	O
+of	O
+fever	B-PROC
+,	O
+malaise	B-DISO
+,	O
+sweating	O
+,	O
+cough	B-DISO
+and	O
+respiratory	B-DISO
+distress	I-DISO
+.	O
+
+N	B-PRGE
+gene	I-PRGE
+was	O
+chosen	O
+as	O
+it	O
+comprised	O
+a	O
+two	O
+aminoacid	O
+deletion	O
+in	O
+the	O
+corresponding	O
+published	O
+sequence	O
+from	O
+the	O
+patient	O
+treated	O
+in	O
+London	O
+,	O
+United	O
+Kingdom	B-SPEC
+.	O
+
+Notably	O
+,	O
+the	O
+recent	O
+human	B-SPEC
+-	O
+to	O
+-	O
+human	B-SPEC
+'	O
+superspreading	O
+'	O
+of	O
+MERS	O
+-	O
+CoV	O
+in	O
+hospitals	O
+in	O
+South	O
+Korea	O
+has	O
+raised	O
+a	O
+major	O
+global	O
+health	O
+concern	O
+.	O
+
+The	O
+novel	O
+mAbs	O
+and	O
+the	O
+epitopes	O
+identified	O
+will	O
+be	O
+useful	O
+for	O
+developing	O
+diagnostic	O
+assays	O
+for	O
+IBV	B-SPEC
+infections	B-DISO
+.	O
+
+TITLE	O
+:	O
+A	O
+Multicenter	O
+Retrospective	O
+Review	O
+of	O
+Prone	O
+Position	O
+Ventilation	O
+(	O
+PPV	B-CHED
+)	O
+in	O
+Treatment	O
+of	O
+Severe	O
+Human	O
+H7N9	O
+Avian	B-DISO
+Flu	I-DISO
+.	O
+
+After	O
+treatment	O
+with	O
+35	O
+PPV	B-CHED
+sessions	O
+,	O
+the	O
+oxygenation	B-PROC
+index	O
+(	O
+OI	O
+)	O
+values	O
+of	O
+the	O
+six	O
+patients	O
+when	O
+measured	O
+post	O
+-	O
+PPV	B-CHED
+and	O
+post	O
+-	O
+supine	O
+position	O
+ventilation	O
+(	O
+SPV	O
+)	O
+were	O
+significantly	O
+higher	O
+than	O
+those	O
+measured	O
+pre	O
+-	O
+PPV	B-CHED
+(	O
+P	O
+<	O
+0	O
+.	O
+05	O
+).	O
+The	O
+six	O
+patients	O
+showed	O
+no	O
+significant	O
+differences	O
+in	O
+their	O
+values	O
+for	O
+respiratory	O
+rate	O
+(	O
+RR	O
+),	O
+peak	O
+inspiratory	B-PROC
+pressure	O
+(	O
+PIP	B-CHED
+),	O
+tidal	O
+volume	O
+(	O
+TV	O
+)	O
+or	O
+arterial	B-ANAT
+partial	O
+pressure	O
+of	O
+carbon	B-CHED
+dioxide	I-CHED
+(	O
+PaCO2	O
+)	O
+when	O
+compared	O
+pre	O
+-	O
+PPV	B-CHED
+,	O
+post	O
+-	O
+PPV	B-CHED
+,	O
+and	O
+post	O
+-	O
+SPV	O
+.	O
+
+CONCLUSIONS	O
+:	O
+PPV	B-CHED
+provided	O
+improved	O
+oxygenation	B-PROC
+that	O
+was	O
+sustained	O
+after	O
+returning	O
+to	O
+a	O
+supine	O
+position	O
+,	O
+and	O
+resulted	O
+in	O
+decreased	O
+carbon	B-DISO
+dioxide	I-DISO
+retention	B-PROC
+.	O
+
+Thirty	O
+-	O
+day	O
+mortality	O
+,	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+,	O
+and	O
+acute	O
+renal	B-ANAT
+injury	O
+were	O
+similar	O
+in	O
+the	O
+restrictive	O
+and	O
+liberal	O
+transfusion	O
+groups	O
+in	O
+both	O
+age	O
+groups	O
+.	O
+
+However	O
+,	O
+in	O
+the	O
+older	O
+patients	O
+,	O
+cardiogenic	B-DISO
+shock	I-DISO
+was	O
+more	O
+frequent	O
+in	O
+patients	O
+in	O
+the	O
+restrictive	O
+transfusion	O
+group	O
+(	O
+12	O
+.	O
+8	O
+%	O
+vs	O
+5	O
+.	O
+2	O
+%,	O
+P	O
+=	O
+.	O
+031	O
+).	O
+
+ABSTRACT	O
+:	O
+A	O
+male	O
+domestic	B-SPEC
+ferret	I-SPEC
+(	O
+Mustela	B-SPEC
+putorius	I-SPEC
+furo	I-SPEC
+),	O
+which	O
+was	O
+purchased	O
+from	O
+outside	O
+of	O
+Japan	O
+at	O
+13	O
+weeks	O
+of	O
+age	O
+,	O
+was	O
+euthanized	O
+at	O
+18	O
+months	O
+of	O
+age	O
+because	O
+of	O
+poor	O
+health	O
+.	O
+
+The	O
+deposition	O
+of	O
+immune	O
+complexes	O
+may	O
+have	O
+been	O
+associated	O
+with	O
+FCoV	O
+infection	B-DISO
+.	O
+
+Akkermansia	B-SPEC
+belonging	O
+to	O
+Verrucomicrobia	B-SPEC
+was	O
+higher	O
+in	O
+VC	O
+piglets	O
+than	O
+in	O
+VD	O
+piglets	O
+.	O
+
+ABSTRACT	O
+:	O
+Severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+coronavirus	B-SPEC
+(	O
+SARS	B-DISO
+-	O
+CoV	O
+)	O
+proteins	B-CHED
+including	O
+ORF6	B-PRGE
+inhibit	O
+Type	O
+I	O
+interferon	B-PRGE
+(	O
+IFN	B-PRGE
+)	O
+signaling	B-PROC
+.	O
+
+TITLE	O
+:	O
+Crystallization	O
+and	O
+preliminary	O
+X	O
+-	O
+ray	B-SPEC
+crystallographic	O
+analysis	O
+of	O
+a	O
+nonstructural	O
+protein	B-CHED
+15	O
+mutant	O
+from	O
+Human	B-SPEC
+coronavirus	I-SPEC
+229E	I-SPEC
+.	O
+
+ABSTRACT	O
+:	O
+We	O
+present	O
+findings	O
+describing	O
+the	O
+epidemiology	O
+of	O
+non	O
+-	O
+severe	O
+acute	O
+respiratory	O
+syndrome	O
+human	B-SPEC
+coronavirus	I-SPEC
+-	O
+associated	O
+influenza	B-DISO
+-	I-DISO
+like	I-DISO
+illness	I-DISO
+from	O
+a	O
+population	O
+-	O
+based	O
+active	O
+follow	O
+-	O
+up	O
+study	O
+in	O
+four	O
+different	O
+regions	O
+of	O
+Peru	O
+.	O
+
+However	O
+,	O
+at	O
+present	O
+specific	O
+preventive	O
+or	O
+curative	O
+strategies	O
+for	O
+the	O
+treatment	O
+of	O
+lung	B-ANAT
+failure	O
+in	O
+pneumonia	B-DISO
+in	O
+addition	O
+to	O
+antibiotics	B-CHED
+are	O
+still	O
+missing	O
+.	O
+
+The	O
+aim	O
+of	O
+this	O
+mini	O
+-	O
+review	O
+is	O
+to	O
+give	O
+a	O
+short	O
+overview	O
+of	O
+some	O
+,	O
+but	O
+not	O
+all	O
+,	O
+adjuvant	B-CHED
+therapeutic	O
+strategies	O
+for	O
+pneumonia	B-DISO
+and	O
+its	O
+most	O
+important	O
+complications	O
+,	O
+sepsis	B-DISO
+and	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+,	O
+and	O
+briefly	O
+discuss	O
+future	O
+perspectives	O
+.	O
+
+Pulse	B-PROC
+oximetric	O
+oxygen	B-CHED
+saturation	O
+(	O
+SpO2	O
+),	O
+partial	B-PROC
+pressure	I-PROC
+of	I-PROC
+oxygen	I-PROC
+(	O
+PaO2	O
+),	O
+fraction	O
+of	O
+inspired	B-PROC
+oxygen	B-CHED
+(	O
+FiO2	O
+),	O
+provider	O
+diagnoses	O
+,	O
+and	O
+chest	B-ANAT
+radiograph	O
+closest	O
+to	O
+time	O
+of	O
+ultrasound	O
+were	O
+recorded	O
+or	O
+interpreted	O
+.	O
+
+For	O
+pulmonary	B-ANAT
+ultrasound	O
+assessments	O
+interpreted	O
+by	O
+the	O
+study	O
+physician	O
+,	O
+the	O
+sensitivity	O
+and	O
+specificity	O
+of	O
+ultrasound	O
+interstitial	B-ANAT
+syndrome	B-DISO
+bilaterally	O
+and	O
+involving	O
+at	O
+least	O
+three	O
+lung	B-ANAT
+fields	O
+were	O
+80	O
+%	O
+(	O
+95	O
+%	O
+CI	O
+63	O
+-	O
+92	O
+)	O
+and	O
+62	O
+%	O
+(	O
+95	O
+%	O
+CI	O
+49	O
+-	O
+74	O
+)	O
+for	O
+radiographic	O
+criteria	O
+for	O
+ARDS	B-DISO
+.	O
+
+Combining	O
+SpO2	O
+/	O
+FiO2	O
+with	O
+ultrasound	O
+to	O
+determine	O
+oxygenation	B-PROC
+and	O
+radiographic	O
+criteria	O
+for	O
+ARDS	B-DISO
+,	O
+the	O
+sensitivity	O
+was	O
+83	O
+%	O
+(	O
+95	O
+%	O
+CI	O
+52	O
+-	O
+98	O
+)	O
+and	O
+specificity	O
+was	O
+62	O
+%	O
+(	O
+95	O
+%	O
+CI	O
+38	O
+-	O
+82	O
+).	O
+
+ABSTRACT	O
+:	O
+Porcine	O
+epidemic	O
+diarrhea	O
+virus	O
+(	O
+PEDV	B-SPEC
+)	O
+is	O
+a	O
+member	O
+of	O
+the	O
+coronaviridae	B-SPEC
+family	B-SPEC
+,	O
+which	O
+can	O
+cause	O
+acute	O
+and	O
+highly	O
+contagious	O
+enteric	O
+disease	O
+of	O
+swine	B-SPEC
+characterized	O
+by	O
+severe	O
+entero	O
+-	O
+pathogenic	O
+diarrhea	B-DISO
+in	O
+piglets	O
+.	O
+
+Our	O
+results	O
+suggest	O
+that	O
+RNAi	B-PROC
+might	O
+be	O
+a	O
+promising	O
+new	O
+strategy	O
+against	O
+PEDV	B-SPEC
+infection	B-DISO
+.	O
+
+However	O
+,	O
+in	O
+spite	O
+of	O
+the	O
+importance	O
+of	O
+bats	B-SPEC
+for	O
+terrestrial	O
+biotic	O
+communities	O
+and	O
+ecosystem	O
+ecology	O
+,	O
+the	O
+diversity	O
+in	O
+their	O
+biology	O
+and	O
+lifestyles	O
+remain	O
+poorly	O
+known	O
+and	O
+underappreciated	O
+.	O
+
+Finally	O
+,	O
+a	O
+more	O
+fundamental	O
+research	O
+about	O
+immune	O
+mechanisms	O
+developed	O
+in	O
+viral	B-DISO
+infections	I-DISO
+is	O
+essential	O
+to	O
+reveal	O
+the	O
+reasons	O
+why	O
+Chiroptera	B-SPEC
+are	O
+so	O
+efficient	O
+reservoir	O
+hosts	B-COMP
+.	O
+
+TITLE	O
+:	O
+Detection	O
+of	O
+12	O
+respiratory	O
+viruses	B-SPEC
+by	O
+duplex	O
+real	O
+time	O
+PCR	O
+assays	O
+in	O
+respiratory	B-ANAT
+samples	I-ANAT
+.	O
+
+TITLE	O
+:	O
+Transmission	O
+characteristics	O
+of	O
+MERS	O
+and	O
+SARS	B-DISO
+in	O
+the	O
+healthcare	O
+setting	O
+:	O
+a	O
+comparative	O
+study	O
+.	O
+
+Exposure	O
+patterns	O
+differed	O
+slightly	O
+by	O
+disease	O
+generation	O
+,	O
+however	O
+,	O
+especially	O
+for	O
+SARS	B-DISO
+.	O
+
+After	O
+the	O
+initial	O
+5	O
+days	O
+of	O
+diagnostics	O
+at	O
+the	O
+pulmonary	B-ANAT
+ward	O
+,	O
+the	O
+patient	O
+required	O
+a	O
+further	O
+97	O
+days	O
+of	O
+hospital	O
+treatment	O
+and	O
+spent	O
+63	O
+days	O
+at	O
+the	O
+Intensive	O
+Care	O
+Unit	O
+.	O
+
+He	O
+underwent	O
+immediate	O
+systemic	O
+management	O
+,	O
+but	O
+methicillin	B-DISO
+-	I-DISO
+resistant	I-DISO
+Staphylococcus	B-SPEC
+aureus	I-SPEC
+(	O
+MRSA	B-DISO
+)	O
+pneumonia	B-DISO
+and	O
+enteritis	B-DISO
+were	O
+uncontrolled	O
+,	O
+resulting	O
+in	O
+death	B-PROC
+on	O
+day	O
+43	O
+.	O
+
+Intriguingly	O
+,	O
+exogenous	O
+ns12	O
+.	O
+9	O
+and	O
+heterologous	O
+viroporins	O
+with	O
+ion	B-FUNC
+channel	I-FUNC
+activity	I-FUNC
+could	O
+compensate	O
+for	O
+the	O
+production	O
+of	O
+HCoV	O
+-	O
+OC43	O
+-	O
+Δns12	O
+.	O
+9	O
+,	O
+indicating	O
+that	O
+the	O
+ion	B-FUNC
+channel	I-FUNC
+activity	I-FUNC
+of	O
+ns12	O
+.	O
+9	O
+plays	O
+a	O
+significant	O
+role	O
+in	O
+the	O
+production	O
+of	O
+infectious	B-DISO
+virions	B-COMP
+.	O
+
+Moreover	O
+,	O
+reduced	O
+viral	B-PROC
+replication	I-PROC
+,	O
+inflammatory	B-DISO
+response	I-DISO
+,	O
+and	O
+virulence	B-PROC
+in	O
+HCoV	B-SPEC
+-	I-SPEC
+OC43	I-SPEC
+-	O
+Δns12	O
+.	O
+9	O
+-	O
+infected	O
+mice	B-SPEC
+were	O
+observed	O
+compared	O
+to	O
+the	O
+levels	O
+for	O
+HCoV	B-SPEC
+-	I-SPEC
+OC43	I-SPEC
+-	O
+WT	O
+-	O
+infected	O
+mice	B-SPEC
+.	O
+
+Furthermore	O
+,	O
+mice	B-SPEC
+infected	O
+with	O
+HCoV	B-SPEC
+-	I-SPEC
+OC43	I-SPEC
+-	O
+Δns12	O
+.	O
+9	O
+exhibited	O
+reduced	O
+inflammation	B-DISO
+and	O
+virulence	B-PROC
+accompanied	O
+by	O
+a	O
+lower	O
+titer	O
+in	O
+the	O
+brain	B-ANAT
+than	O
+that	O
+of	O
+wild	O
+-	O
+type	O
+-	O
+infected	O
+mice	B-SPEC
+,	O
+suggesting	O
+the	O
+ns12	O
+.	O
+9	O
+viroporin	O
+influences	O
+virus	B-DISO
+pathogenesis	B-PROC
+.	O
+
+The	O
+use	O
+of	O
+enteral	O
+diets	O
+enriched	O
+with	O
+eicosapentaenoic	B-CHED
+acid	I-CHED
+(	O
+EPA	B-CHED
+)	O
+and	O
+gamma	B-CHED
+-	I-CHED
+linolenic	I-CHED
+acid	I-CHED
+(	O
+GLA	B-CHED
+)	O
+has	O
+reported	O
+promising	O
+results	O
+,	O
+showing	O
+an	O
+improvement	O
+in	O
+respiratory	O
+variables	O
+and	O
+haemodynamics	O
+.	O
+
+ABSTRACT	O
+:	O
+ABO	O
+blood	O
+types	O
+are	O
+determined	O
+by	O
+antigen	B-CHED
+modifications	O
+on	O
+glycoproteins	B-CHED
+and	O
+glycolipids	B-CHED
+and	O
+associated	O
+with	O
+altered	O
+plasma	B-ANAT
+levels	O
+of	O
+inflammatory	O
+and	O
+endothelial	B-ANAT
+injury	O
+markers	O
+implicated	O
+in	O
+AKI	O
+pathogenesis	B-DISO
+.	O
+
+MERS	O
+-	O
+CoV	O
+is	O
+able	O
+to	O
+infect	O
+a	O
+range	O
+of	O
+cell	B-COMP
+types	O
+,	O
+but	O
+replicates	O
+to	O
+high	O
+titers	O
+in	O
+Vero	O
+E6	O
+cells	B-COMP
+.	O
+
+ABSTRACT	O
+:	O
+An	O
+outbreak	O
+of	O
+porcine	B-SPEC
+epidemic	I-SPEC
+diarrhea	I-SPEC
+virus	I-SPEC
+(	O
+PEDV	B-SPEC
+)	O
+in	O
+the	O
+South	O
+of	O
+Portugal	O
+in	O
+January	O
+2015	O
+and	O
+the	O
+spread	O
+of	O
+PEDV	B-SPEC
+northwards	O
+in	O
+the	O
+territory	O
+are	O
+described	O
+.	O
+
+The	O
+presence	O
+of	O
+CPV	B-SPEC
+-	O
+2	O
+in	O
+the	O
+samples	O
+was	O
+determined	O
+by	O
+PCR	O
+amplification	B-DISO
+of	O
+the	O
+VP2	B-PRGE
+gene	I-PRGE
+(	O
+568	O
+bp	O
+)	O
+of	O
+CPV	B-SPEC
+-	O
+2	O
+.	O
+
+Coinfections	B-DISO
+with	O
+canine	O
+coronavirus	B-SPEC
+,	O
+canine	O
+kobuvirus	B-SPEC
+,	O
+and	O
+canine	O
+bocavirus	B-SPEC
+were	O
+identified	O
+.	O
+
+Travel	O
+to	O
+locations	O
+experiencing	O
+outbreaks	O
+such	O
+as	O
+Ebola	B-DISO
+virus	I-DISO
+disease	I-DISO
+,	O
+Middle	O
+East	O
+respiratory	O
+syndrome	B-DISO
+,	O
+avian	B-DISO
+influenza	I-DISO
+,	O
+and	O
+chikungunya	B-DISO
+call	O
+for	O
+specific	O
+alerts	O
+on	O
+preventive	O
+strategies	O
+.	O
+
+Genetic	B-PROC
+recombination	I-PROC
+events	O
+between	O
+group	O
+3	O
+and	O
+group	O
+5	O
+of	O
+clade	O
+B	O
+may	O
+have	O
+implications	O
+for	O
+the	O
+transmissibility	O
+of	O
+the	O
+virus	B-SPEC
+.	O
+
+TITLE	O
+:	O
+The	O
+detection	O
+and	O
+genetic	O
+characterization	O
+based	O
+on	O
+the	O
+S1	B-PRGE
+gene	I-PRGE
+region	O
+of	O
+BCoVs	O
+from	O
+respiratory	O
+and	O
+enteric	O
+infections	O
+in	O
+Turkey	B-SPEC
+.	O
+
+A	O
+total	O
+of	O
+18	O
+test	O
+samples	O
+(	O
+16	O
+feces	B-ANAT
+and	O
+2	O
+nasal	B-ANAT
+swap	O
+samples	O
+)	O
+were	O
+detected	O
+positive	O
+by	O
+ELISA	O
+and	O
+/	O
+or	O
+RT	O
+-	O
+PCR	O
+targeting	B-PROC
+the	O
+BCoV	B-PRGE
+N	I-PRGE
+gene	I-PRGE
+.	O
+
+Since	O
+then	O
+,	O
+more	O
+than	O
+1	O
+,	O
+000	O
+cases	O
+of	O
+MERS	O
+-	O
+CoV	O
+infection	B-DISO
+have	O
+been	O
+confirmed	O
+;	O
+infection	B-DISO
+is	O
+typically	O
+associated	O
+with	O
+considerable	O
+morbidity	O
+and	O
+,	O
+in	O
+approximately	O
+30	O
+%	O
+of	O
+cases	O
+,	O
+mortality	O
+.	O
+
+The	O
+integration	B-PROC
+of	O
+antigen	B-CHED
+-	O
+coding	O
+genes	O
+into	O
+recombinant	O
+MV	O
+resulting	O
+in	O
+coexpression	O
+of	O
+MV	O
+and	O
+foreign	O
+antigens	B-CHED
+can	O
+efficiently	O
+be	O
+achieved	O
+.	O
+
+Using	O
+during	O
+ventilatory	O
+support	O
+of	O
+patients	O
+with	O
+initial	O
+symptoms	O
+of	O
+the	O
+syndrome	B-DISO
+of	O
+acute	O
+lung	B-ANAT
+damage	O
+and	O
+reduced	O
+lung	B-PROC
+function	I-PROC
+restrictive	O
+positive	O
+end	O
+-	O
+expiratory	O
+pressure	O
+of	O
+6	O
+-	O
+10	O
+cm	O
+of	O
+water	B-CHED
+column	B-ANAT
+when	O
+the	O
+conventional	O
+(	O
+1	O
+:	O
+2	O
+;	O
+1	O
+:	O
+2	O
+.	O
+5	O
+at	O
+p	O
+≤	O
+0	O
+.	O
+05	O
+)	O
+and	O
+invert	O
+(	O
+2	O
+:	O
+1	O
+at	O
+p	O
+≤	O
+0	O
+,	O
+1	O
+)	O
+ratio	O
+inhale	B-PROC
+/	O
+exhale	O
+,	O
+relatively	O
+low	O
+tidal	O
+volume	O
+(	O
+6	O
+-	O
+8	O
+ml	O
+/	O
+kg	O
+)	O
+allows	O
+increase	O
+the	O
+compliance	O
+of	O
+the	O
+lung	B-ANAT
+tissue	I-ANAT
+to	O
+11	O
+-	O
+29	O
+%.	O
+
+Increased	O
+expiratory	B-PROC
+time	O
+constant	O
+has	O
+a	O
+direct	O
+correlation	O
+with	O
+the	O
+value	O
+of	O
+airway	B-PROC
+resistance	I-PROC
+was	O
+due	O
+not	O
+only	O
+to	O
+the	O
+maintenance	O
+of	O
+optimal	O
+parameters	O
+for	O
+MVV	O
+(	O
+mechanical	O
+voluntary	O
+ventilation	O
+),	O
+but	O
+regular	O
+lavage	O
+of	O
+the	O
+tracheobronchial	B-ANAT
+tree	I-ANAT
+,	O
+which	O
+allows	O
+to	O
+maintain	O
+patency	O
+of	O
+the	O
+lower	B-ANAT
+respiratory	I-ANAT
+tract	I-ANAT
+.	O
+
+Previously	O
+reported	O
+cases	O
+of	O
+severe	O
+Burkholderia	B-SPEC
+cepacia	I-SPEC
+complex	I-SPEC
+lung	B-DISO
+infection	I-DISO
+in	O
+immunocompetent	O
+hosts	B-COMP
+include	O
+pneumonia	B-DISO
+,	O
+bronchiectasis	B-DISO
+,	O
+pyopneumothorax	B-DISO
+,	O
+and	O
+cavitary	O
+lesions	O
+.	O
+
+We	O
+present	O
+a	O
+case	O
+of	O
+a	O
+64	O
+-	O
+year	O
+-	O
+old	O
+man	B-CHED
+with	O
+Streptococcus	B-SPEC
+pneumoniae	I-SPEC
+community	O
+-	O
+acquired	O
+pneumonia	B-DISO
+whose	O
+hospital	O
+course	O
+was	O
+complicated	O
+by	O
+developing	O
+cavitary	O
+lung	B-ANAT
+lesions	O
+,	O
+bacteremia	B-DISO
+,	O
+and	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+.	O
+
+TITLE	O
+:	O
+Thoracic	B-ANAT
+Trauma	O
+Severity	O
+score	O
+on	O
+admission	O
+allows	O
+to	O
+determine	O
+the	O
+risk	O
+of	O
+delayed	O
+ARDS	B-DISO
+in	O
+trauma	O
+patients	O
+with	O
+pulmonary	O
+contusion	O
+.	O
+
+The	O
+global	O
+ability	O
+of	O
+the	O
+TTS	O
+score	O
+to	O
+predict	O
+ARDS	B-DISO
+was	O
+studied	O
+by	O
+ROC	O
+curves	O
+with	O
+a	O
+threshold	O
+analysis	O
+using	O
+a	O
+grey	O
+zone	O
+approach	O
+.	O
+
+The	O
+area	O
+under	O
+the	O
+ROC	O
+curves	O
+for	O
+the	O
+TTS	O
+score	O
+in	O
+predicting	O
+ARDS	B-DISO
+was	O
+0	O
+.	O
+82	O
+(	O
+95	O
+%	O
+CI	O
+0	O
+.	O
+78	O
+-	O
+0	O
+.	O
+86	O
+)	O
+in	O
+the	O
+overall	O
+population	O
+.	O
+
+An	O
+extreme	O
+TTS	O
+score	O
+on	O
+admission	O
+accurately	O
+predicts	O
+the	O
+occurrence	O
+of	O
+delayed	O
+ARDS	B-DISO
+in	O
+blunt	O
+thoracic	B-DISO
+trauma	O
+patients	O
+affected	O
+by	O
+pulmonary	B-ANAT
+contusion	O
+.	O
+
+RESULTS	O
+:	O
+Of	O
+329	O
+patients	O
+studied	O
+(	O
+75	O
+%	O
+men	O
+,	O
+mean	O
+age	O
+36	O
+.	O
+9	O
+years	O
+[	O
+SD	O
+17	O
+.	O
+8	O
+years	O
+],	O
+mean	O
+Injury	O
+Severity	O
+Score	O
+21	O
+.	O
+7	O
+[	O
+SD	O
+16	O
+.	O
+0	O
+]),	O
+82	O
+(	O
+25	O
+%)	O
+presented	O
+with	O
+ARDS	B-DISO
+(	O
+mean	O
+lowest	O
+PaO2	O
+/	O
+FiO2	O
+ratio	O
+of	O
+131	O
+[	O
+SD	O
+34	O
+]).	O
+
+A	O
+TTS	O
+score	O
+of	O
+13	O
+-	O
+25	O
+was	O
+found	O
+to	O
+be	O
+independent	O
+risk	O
+factors	O
+of	O
+ARDS	B-DISO
+(	O
+OR	O
+25	O
+.	O
+8	O
+[	O
+95	O
+%	O
+CI	O
+6	O
+.	O
+7	O
+-	O
+99	O
+.	O
+6	O
+]	O
+P	O
+<	O
+0	O
+.	O
+001	O
+).	O
+
+When	O
+divided	O
+according	O
+to	O
+outcome	O
+,	O
+the	O
+BNP	B-PRGE
+level	O
+in	O
+the	O
+death	B-PROC
+group	O
+(	O
+267	O
+.	O
+07	O
+±	O
+45	O
+.	O
+06	O
+pg	O
+/	O
+ml	O
+)	O
+was	O
+significantly	O
+higher	O
+than	O
+in	O
+the	O
+survival	O
+group	O
+(	O
+128	O
+.	O
+99	O
+±	O
+45	O
+.	O
+42	O
+pg	O
+/	O
+ml	O
+).	O
+
+Overall	O
+,	O
+docking	B-PROC
+and	O
+biochemical	O
+results	O
+suggest	O
+that	O
+kuwanon	O
+-	O
+L	O
+binds	B-FUNC
+to	O
+an	O
+allosteric	O
+binding	B-FUNC
+pocket	O
+and	O
+can	O
+be	O
+considered	O
+an	O
+attractive	O
+lead	O
+for	O
+the	O
+development	B-PROC
+of	O
+new	O
+allosteric	O
+IN	O
+antiviral	B-CHED
+agents	I-CHED
+.	O
+
+Porcine	B-SPEC
+epidemic	B-DISO
+diarrhea	I-DISO
+is	O
+now	O
+worldwide	O
+distributed	O
+and	O
+causing	O
+huge	O
+economic	O
+losses	O
+to	O
+swine	B-SPEC
+industry	O
+.	O
+
+ABSTRACT	O
+:	O
+Five	O
+Ib	O
+-	O
+type	O
+cyclopeptide	O
+alkaloids	O
+,	O
+jubanines	O
+F	O
+-	O
+J	O
+(	O
+1	O
+-	O
+5	O
+),	O
+and	O
+three	O
+known	O
+compounds	O
+,	O
+nummularine	O
+B	O
+(	O
+6	O
+),	O
+daechuine	O
+-	O
+S3	O
+(	O
+7	O
+),	O
+and	O
+mucronine	O
+K	O
+(	O
+8	O
+)	O
+were	O
+isolated	O
+from	O
+the	O
+roots	O
+of	O
+Ziziphus	B-SPEC
+jujuba	I-SPEC
+.	O
+
+This	O
+is	O
+a	O
+retrospective	O
+observational	O
+cohort	O
+study	O
+of	O
+adult	O
+severe	B-DISO
+sepsis	I-DISO
+and	O
+septic	B-DISO
+shock	I-DISO
+patients	O
+with	O
+elevated	O
+lactate	B-CHED
+presenting	O
+to	O
+a	O
+large	O
+academic	O
+ED	O
+.	O
+
+Emergency	B-DISO
+department	O
+mechanical	O
+ventilation	O
+was	O
+independently	O
+associated	O
+with	O
+development	B-PROC
+of	O
+ARDS	B-DISO
+(	O
+aOR	B-FUNC
+,	O
+3	O
+.	O
+5	O
+;	O
+1	O
+.	O
+8	O
+-	O
+7	O
+.	O
+0	O
+).	O
+
+In	O
+the	O
+a	O
+priori	O
+subgroup	O
+of	O
+patients	O
+mechanically	O
+ventilated	O
+in	O
+the	O
+ED	O
+(	O
+n	O
+=	O
+97	O
+),	O
+those	O
+who	O
+developed	O
+ARDS	B-DISO
+received	O
+higher	O
+tidal	O
+volumes	O
+compared	O
+to	O
+patients	O
+who	O
+did	O
+not	O
+develop	O
+ARDS	B-DISO
+(	O
+8	O
+.	O
+7	O
+mL	O
+/	O
+kg	O
+predicted	O
+body	B-ANAT
+weight	O
+[	O
+interquartile	O
+range	O
+,	O
+7	O
+.	O
+6	O
+-	O
+9	O
+.	O
+5	O
+]	O
+vs	O
+7	O
+.	O
+6	O
+[	O
+interquartile	O
+range	O
+,	O
+6	O
+.	O
+8	O
+-	O
+9	O
+.	O
+0	O
+];	O
+P	O
+<.	O
+01	O
+).	O
+
+ABSTRACT	O
+:	O
+Here	O
+we	O
+designed	O
+and	O
+tested	O
+two	O
+highly	O
+specific	O
+quantitative	O
+TaqMan	O
+(®)-	O
+MGB	O
+-	O
+based	O
+reverse	B-PRGE
+transcriptase	I-PRGE
+quantitative	O
+polymerase	O
+chain	O
+reaction	O
+(	O
+RT	O
+-	O
+qPCR	O
+)	O
+assays	O
+for	O
+Middle	O
+East	O
+Respiratory	O
+Syndrome	B-DISO
+(	O
+MERS	O
+).	O
+
+CONCLUSIONS	O
+:	O
+SAR	B-PRGE
+for	O
+laboratory	O
+-	O
+confirmed	O
+influenza	B-DISO
+in	O
+South	O
+Africa	O
+was	O
+higher	O
+than	O
+previously	O
+reported	O
+SARs	B-DISO
+.	O
+
+TITLE	O
+:	O
+Middle	O
+East	O
+respiratory	O
+syndrome	B-DISO
+:	O
+SARS	B-DISO
+redux	O
+?	O
+
+ABSTRACT	O
+:	O
+Middle	O
+East	O
+respiratory	O
+syndrome	B-DISO
+(	O
+MERS	B-DISO
+)	O
+is	O
+caused	O
+by	O
+the	O
+Middle	O
+East	O
+respiratory	O
+syndrome	B-DISO
+coronavirus	B-SPEC
+(	O
+MERS	B-DISO
+-	O
+CoV	O
+).	O
+
+Although	O
+predominantly	O
+affecting	O
+countries	O
+across	O
+the	O
+Arabian	O
+Peninsula	O
+,	O
+the	O
+infection	B-DISO
+has	O
+been	O
+exported	O
+by	O
+travelers	O
+to	O
+countries	O
+around	O
+the	O
+world	O
+,	O
+including	O
+the	O
+United	O
+States	O
+.	O
+
+Regarding	O
+longer	O
+time	O
+periods	B-PROC
+,	O
+influenza	B-DISO
+epidemics	O
+occasionally	O
+occur	O
+very	O
+early	O
+in	O
+the	O
+season	O
+,	O
+as	O
+during	O
+the	O
+2009	O
+pandemic	O
+.	O
+
+Whether	O
+early	O
+occurrence	O
+of	O
+influenza	B-DISO
+epidemics	O
+impacts	O
+outbreaks	O
+of	O
+other	O
+common	O
+seasonal	O
+viruses	B-SPEC
+is	O
+not	O
+clear	O
+.	O
+
+Between	O
+2003	O
+and	O
+2012	O
+,	O
+influenza	B-DISO
+B	O
+,	O
+RSV	B-SPEC
+,	O
+and	O
+coronavirus	B-SPEC
+showed	O
+shifts	O
+in	O
+their	O
+occurrence	O
+when	O
+influenza	B-PATH
+A	I-PATH
+epidemics	O
+occurred	O
+earlier	O
+than	O
+usual	O
+(	O
+before	O
+week	O
+1	O
+).	O
+
+Occurrence	O
+of	O
+rhinovirus	B-SPEC
+,	O
+norovirus	B-SPEC
+,	O
+rotavirus	B-SPEC
+,	O
+and	O
+enterovirus	B-SPEC
+did	O
+not	O
+change	O
+.	O
+
+The	O
+potent	O
+antiviral	B-CHED
+activity	O
+of	O
+both	O
+GO	O
+and	O
+rGO	O
+can	O
+be	O
+attributed	O
+to	O
+the	O
+unique	O
+single	O
+-	O
+layer	B-ANAT
+structure	O
+and	O
+negative	O
+charge	O
+.	O
+
+First	O
+,	O
+GO	O
+exhibited	O
+potent	O
+antiviral	B-CHED
+activity	O
+when	O
+conjugated	O
+with	O
+PVP	B-CHED
+,	O
+a	O
+nonionic	O
+polymer	B-CHED
+,	O
+but	O
+not	O
+when	O
+conjugated	O
+with	O
+PDDA	B-CHED
+,	O
+a	O
+cationic	O
+polymer	B-CHED
+.	O
+
+However	O
+,	O
+infectious	B-DISO
+diseases	I-DISO
+still	O
+remain	O
+a	O
+major	O
+population	O
+health	O
+issue	O
+and	O
+this	O
+may	O
+be	O
+exacerbated	O
+by	O
+rapid	O
+urbanization	O
+and	O
+unprecedented	O
+impacts	O
+of	O
+climate	O
+change	O
+.	O
+
+TITLE	O
+:	O
+Synthesis	B-PROC
+and	O
+antiviral	B-CHED
+activity	O
+of	O
+maleopimaric	O
+and	O
+quinopimaric	O
+acids	O
+'	O
+derivatives	O
+.	O
+
+ABSTRACT	O
+:	O
+We	O
+report	O
+a	O
+unique	O
+clinical	O
+case	O
+about	O
+an	O
+18	O
+-	O
+year	O
+-	O
+old	O
+woman	O
+,	O
+immediately	O
+post	O
+-	O
+partum	O
+after	O
+an	O
+urgent	O
+C	O
+-	O
+section	O
+,	O
+who	O
+survived	O
+severe	B-DISO
+sepsis	I-DISO
+,	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+(	O
+ARDS	B-DISO
+)	O
+and	O
+disseminated	B-DISO
+intravascular	I-DISO
+coagulation	I-DISO
+(	O
+DIC	B-DISO
+)	O
+and	O
+was	O
+successfully	O
+treated	O
+with	O
+11	O
+different	O
+antibiotics	B-CHED
+,	O
+massive	O
+blood	B-ANAT
+transfusions	O
+and	O
+repetitive	O
+surgeries	O
+and	O
+was	O
+on	O
+extracorporeal	O
+membrane	B-COMP
+oxygenation	B-PROC
+(	O
+ECMO	O
+)	O
+support	O
+for	O
+22	O
+days	O
+.	O
+
+Clinical	O
+and	O
+laboratory	O
+characteristics	O
+of	O
+viral	O
+lower	B-DISO
+respiratory	I-DISO
+tract	I-DISO
+infections	I-DISO
+significantly	O
+differ	O
+.	O
+
+With	O
+the	O
+advance	O
+of	O
+viral	O
+detection	O
+methods	O
+and	O
+increase	O
+of	O
+knowledge	O
+it	O
+becomes	O
+possible	O
+to	O
+characterize	O
+different	O
+respiratory	O
+viral	B-DISO
+infections	I-DISO
+and	O
+to	O
+improve	O
+the	O
+differential	O
+diagnosis	O
+.	O
+
+RESULTS	O
+:	O
+Pneumonia	B-DISO
+was	O
+present	O
+in	O
+71	O
+.	O
+4	O
+%	O
+of	O
+all	O
+coronavirus	B-DISO
+infections	I-DISO
+,	O
+35	O
+.	O
+1	O
+%	O
+of	O
+all	O
+respiratory	B-DISO
+syncytial	I-DISO
+virus	I-DISO
+infections	I-DISO
+,	O
+and	O
+13	O
+.	O
+0	O
+%	O
+of	O
+all	O
+rhinovirus	B-SPEC
+infections	B-DISO
+.	O
+
+In	O
+adenovirus	B-DISO
+infections	I-DISO
+mean	O
+C	O
+-	O
+reactive	O
+protein	B-CHED
+value	O
+was	O
+72	O
+.	O
+4	O
+mg	O
+/	O
+L	O
+and	O
+white	B-ANAT
+blood	I-ANAT
+cell	I-ANAT
+count	O
+19	O
+.	O
+000	O
+/	O
+µl	O
+,	O
+both	O
+significantly	O
+higher	O
+than	O
+in	O
+other	O
+viruses	B-SPEC
+(	O
+p	O
+<	O
+0	O
+.	O
+01	O
+).	O
+
+The	O
+result	O
+was	O
+further	O
+applied	O
+to	O
+identify	O
+the	O
+origin	O
+of	O
+PEDV	B-SPEC
+that	O
+caused	O
+the	O
+2014	O
+epidemic	O
+in	O
+Taiwan	O
+.	O
+
+Furthermore	O
+,	O
+the	O
+proportion	O
+of	O
+nodes	B-ANAT
+with	O
+high	O
+posterior	O
+support	O
+(	O
+posterior	O
+probability	O
+>	O
+0	O
+.	O
+8	O
+)	O
+was	O
+similar	O
+between	O
+nsp3	B-PRGE
+and	O
+S	O
+genes	O
+.	O
+
+ABSTRACT	O
+:	O
+Severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+(	O
+SARS	B-DISO
+)	O
+emerged	O
+in	O
+November	O
+2002	O
+as	O
+a	O
+case	O
+of	O
+atypical	B-DISO
+pneumonia	I-DISO
+in	O
+China	O
+,	O
+and	O
+the	O
+causative	O
+agent	O
+of	O
+SARS	B-DISO
+was	O
+identified	O
+to	O
+be	O
+a	O
+novel	B-SPEC
+coronavirus	I-SPEC
+,	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+coronavirus	B-SPEC
+(	O
+SARS	B-DISO
+-	O
+CoV	O
+).	O
+
+TITLE	O
+:	O
+Evidence	O
+for	O
+an	O
+Ancestral	O
+Association	O
+of	O
+Human	B-PRGE
+Coronavirus	I-PRGE
+229E	I-PRGE
+with	O
+Bats	B-SPEC
+.	O
+
+Only	O
+hipposiderid	O
+bats	B-SPEC
+tested	O
+positive	O
+.	O
+
+HCoV	B-SPEC
+-	I-SPEC
+229E	I-SPEC
+and	O
+the	O
+alpaca	B-SPEC
+virus	B-SPEC
+showed	O
+a	O
+major	O
+deletion	O
+in	O
+the	O
+spike	O
+S1	O
+region	O
+compared	O
+to	O
+all	O
+bat	B-ENZY
+viruses	B-SPEC
+.	O
+
+Analyses	O
+of	O
+four	O
+full	O
+genomes	O
+from	O
+229E	O
+-	O
+related	O
+bat	B-ENZY
+CoVs	O
+revealed	O
+an	O
+eighth	O
+open	O
+reading	O
+frame	O
+(	O
+ORF8	O
+)	O
+located	O
+at	O
+the	O
+genomic	O
+3	O
+'	O
+end	O
+.	O
+
+ABSTRACT	O
+:	O
+The	O
+cellular	O
+protease	O
+TMPRSS2	B-PRGE
+cleaves	O
+and	O
+activates	O
+the	O
+influenza	B-SPEC
+virus	I-SPEC
+hemagglutinin	O
+(	O
+HA	O
+)	O
+and	O
+TMPRSS2	B-PRGE
+expression	B-PROC
+is	O
+essential	O
+for	O
+viral	O
+spread	O
+and	O
+pathogenesis	B-DISO
+in	O
+mice	B-SPEC
+.	O
+
+However	O
+,	O
+previous	O
+studies	O
+on	O
+viral	B-PROC
+activation	I-PROC
+by	O
+TMPRSS2	O
+focused	O
+on	O
+a	O
+492	O
+amino	B-CHED
+acids	I-CHED
+comprising	O
+form	O
+of	O
+the	O
+protein	B-CHED
+(	O
+isoform	O
+2	O
+)	O
+while	O
+other	O
+TMPRSS2	O
+isoforms	O
+,	O
+generated	O
+upon	O
+alternative	B-PROC
+splicing	I-PROC
+of	O
+the	O
+tmprss2	B-PRGE
+mRNA	I-PRGE
+,	O
+have	O
+not	O
+been	O
+characterized	O
+.	O
+
+Blood	B-ANAT
+samples	I-ANAT
+were	O
+also	O
+taken	O
+from	O
+their	O
+dams	O
+during	O
+the	O
+first	O
+sampling	O
+.	O
+
+As	O
+a	O
+result	O
+,	O
+there	O
+is	O
+a	O
+need	O
+to	O
+develop	O
+technologies	O
+that	O
+can	O
+meet	O
+the	O
+heavy	O
+demand	O
+of	O
+an	O
+all	O
+-	O
+embedded	O
+,	O
+inexpensive	O
+,	O
+specific	O
+and	O
+fast	B-FUNC
+biosensing	O
+for	O
+the	O
+detection	O
+and	O
+screening	O
+of	O
+pathogens	O
+in	O
+active	O
+or	O
+latent	O
+forms	O
+to	O
+offer	O
+quick	O
+diagnosis	O
+and	O
+early	O
+treatments	O
+in	O
+order	O
+to	O
+avoid	O
+disease	O
+aggravation	O
+and	O
+unnecessary	O
+late	O
+treatment	O
+costs	O
+.	O
+
+In	O
+early	O
+ARDS	B-DISO
+,	O
+most	O
+of	O
+the	O
+ΔEELV	O
+occurs	O
+within	O
+the	O
+first	O
+minute	O
+,	O
+and	O
+change	O
+is	O
+completed	O
+within	O
+2	O
+minutes	O
+,	O
+following	O
+an	O
+increase	O
+or	O
+decrease	O
+in	O
+PEEP	B-CHED
+.	O
+
+This	O
+study	O
+is	O
+focused	O
+on	O
+apoptosis	B-PATH
+and	O
+transcriptional	B-PROC
+profiling	O
+of	O
+FIPV	O
+-	O
+infected	O
+cells	B-COMP
+following	O
+in	O
+vitro	O
+infection	B-DISO
+of	O
+CRFK	O
+cells	B-COMP
+with	O
+FIPV	O
+79	O
+-	O
+1146	O
+WSU	O
+.	O
+
+An	O
+aggregate	O
+of	O
+4546	O
+genes	O
+(	O
+2229	O
+down	O
+-	O
+regulated	O
+and	O
+2317	O
+up	O
+-	O
+regulated	O
+)	O
+from	O
+17	O
+cellular	B-COMP
+process	I-COMP
+,	O
+11	O
+molecular	O
+functions	O
+and	O
+130	O
+possible	O
+biological	O
+pathways	B-PROC
+were	O
+affected	O
+by	O
+FIPV	O
+.	O
+
+Moreover	O
+,	O
+we	O
+observed	O
+that	O
+the	O
+compound	O
+did	O
+not	O
+show	O
+cytotoxicity	B-DISO
+up	O
+to	O
+80	O
+µMconcentration	O
+.	O
+
+TITLE	O
+:	O
+Crescentic	B-DISO
+glomerulonephritis	I-DISO
+in	O
+a	O
+child	O
+with	O
+Heiner	O
+syndrome	B-DISO
+.	O
+
+Using	O
+the	O
+spike	O
+receptor	O
+-	O
+binding	B-FUNC
+domain	O
+of	O
+MERS	O
+-	O
+CoV	O
+(	O
+MERS	O
+-	O
+RBD	O
+)	O
+to	O
+immunize	O
+mice	B-SPEC
+,	O
+we	O
+identified	O
+two	O
+neutralizing	O
+monoclonal	O
+antibodies	B-COMP
+(	O
+mAbs	O
+)	O
+4C2	O
+and	O
+2E6	O
+.	O
+
+2E6	O
+also	O
+blocks	O
+receptor	B-FUNC
+binding	I-FUNC
+,	O
+and	O
+competes	O
+with	O
+4C2	O
+for	O
+binding	B-FUNC
+to	O
+MERS	O
+-	O
+RBD	O
+.	O
+
+Common	O
+pathogens	O
+such	O
+as	O
+calicivirus	O
+and	O
+Influenza	O
+virus	O
+as	O
+well	O
+as	O
+blood	B-ANAT
+-	O
+borne	O
+pathogens	O
+such	O
+as	O
+human	B-DISO
+immunodeficiency	I-DISO
+virus	I-DISO
+,	O
+hepatitis	B-DISO
+B	I-DISO
+and	O
+C	O
+virus	B-SPEC
+,	O
+gastro	B-ANAT
+-	O
+intestinal	B-DISO
+infections	I-DISO
+such	O
+as	O
+Campylobacter	B-SPEC
+and	O
+Salmonella	B-DISO
+and	O
+vector	O
+-	O
+borne	O
+pathogens	O
+such	O
+as	O
+Borrelia	B-DISO
+were	O
+all	O
+in	O
+the	O
+highest	O
+priority	O
+group	O
+.	O
+
+In	O
+addition	O
+to	O
+this	O
+,	O
+we	O
+found	O
+that	O
+independently	O
+of	O
+its	O
+accessory	O
+proteins	B-CHED
+,	O
+IBV	B-SPEC
+inhibits	O
+IFN	B-PRGE
+-	O
+mediated	O
+phosphorylation	B-PROC
+and	O
+translocation	B-DISO
+of	O
+STAT1	B-PRGE
+.	O
+
+In	O
+summary	O
+,	O
+we	O
+show	O
+that	O
+IBV	B-SPEC
+uses	O
+multiple	O
+strategies	O
+to	O
+counteract	O
+the	O
+IFN	B-PRGE
+response	O
+.	O
+
+During	O
+the	O
+most	O
+recent	O
+evolution	B-PROC
+of	O
+MERS	O
+-	O
+CoV	O
+,	O
+adaptive	O
+mutations	O
+in	O
+the	O
+HR1	O
+(	O
+Q	O
+/	O
+R	O
+/	O
+H1020	O
+)	O
+arose	O
+in	O
+camels	B-SPEC
+or	O
+in	O
+a	O
+previous	O
+host	B-COMP
+and	O
+spread	O
+to	O
+humans	B-SPEC
+.	O
+
+New	O
+ventilatory	O
+approaches	O
+are	O
+needed	O
+to	O
+safely	O
+treat	O
+patients	O
+with	O
+ARDS	B-DISO
+,	O
+and	O
+recent	O
+studies	O
+have	O
+suggested	O
+the	O
+potential	O
+utility	O
+of	O
+open	O
+-	O
+lung	B-ANAT
+strategies	O
+.	O
+
+This	O
+review	O
+is	O
+focused	O
+on	O
+the	O
+theoretical	O
+and	O
+practical	O
+aspects	O
+of	O
+APRV	O
+and	O
+HFOV	O
+,	O
+provides	O
+an	O
+overview	O
+of	O
+the	O
+current	O
+evidence	O
+,	O
+and	O
+addresses	O
+their	O
+possible	O
+use	O
+in	O
+the	O
+treatment	O
+of	O
+ARDS	B-DISO
+.	O
+
+The	O
+SPR	O
+biosensor	O
+was	O
+developed	O
+by	O
+immobilizing	O
+nine	O
+respiratory	O
+virus	B-SPEC
+-	O
+specific	O
+oligonucleotides	B-CHED
+in	O
+an	O
+SPR	O
+chip	O
+.	O
+
+However	O
+,	O
+due	O
+to	O
+the	O
+complex	O
+etiology	O
+of	O
+RTIs	O
+,	O
+the	O
+clinical	O
+diagnosis	O
+,	O
+treatment	O
+,	O
+and	O
+prevention	O
+of	O
+these	O
+infections	B-DISO
+remain	O
+challenging	O
+,	O
+especially	O
+in	O
+developing	O
+countries	O
+.	O
+
+Of	O
+the	O
+18	O
+pathogens	O
+analyzed	O
+,	O
+four	O
+were	O
+detected	O
+with	O
+a	O
+positive	O
+detection	O
+rate	O
+(	O
+PDR	B-DISO
+)	O
+>	O
+5	O
+%:	O
+influenza	B-SPEC
+A	I-SPEC
+virus	I-SPEC
+(	O
+IAV	O
+)	O
+>	O
+respiratory	B-SPEC
+syncytial	I-SPEC
+virus	I-SPEC
+(	O
+RSV	B-SPEC
+)	O
+>	O
+Mycoplasma	B-SPEC
+pneumoniae	I-SPEC
+(	O
+MP	O
+)	O
+>	O
+human	B-SPEC
+coronavirus	I-SPEC
+(	O
+HCoV	O
+).	O
+
+Although	O
+clinically	O
+distinguishing	O
+specific	O
+pathogens	O
+responsible	O
+for	O
+RTIs	O
+is	O
+difficult	O
+,	O
+the	O
+epidemiological	O
+and	O
+clinical	O
+characteristics	O
+of	O
+the	O
+various	O
+RTI	B-DISO
+-	O
+causing	O
+agents	O
+could	O
+provide	O
+clues	O
+for	O
+clinicians	O
+,	O
+thereby	O
+informing	O
+decisions	O
+regarding	O
+prevention	O
+and	O
+medication	O
+and	O
+guiding	O
+appropriate	O
+public	O
+health	O
+strategies	O
+.	O
+
+ABSTRACT	O
+:	O
+Middle	O
+East	O
+Respiratory	O
+Syndrome	B-DISO
+Coronavirus	B-SPEC
+(	O
+MERS	O
+-	O
+CoV	O
+)	O
+is	O
+an	O
+emerging	B-DISO
+infectious	I-DISO
+disease	I-DISO
+that	O
+can	O
+present	O
+with	O
+flu	B-DISO
+-	I-DISO
+like	I-DISO
+symptoms	I-DISO
+.	O
+
+ABSTRACT	O
+:	O
+The	O
+infectious	B-DISO
+dose	O
+of	O
+a	O
+virus	B-SPEC
+pool	O
+of	O
+original	O
+US	O
+PEDV	B-SPEC
+strain	O
+PC22A	O
+was	O
+determined	O
+in	O
+4	O
+-	O
+day	O
+-	O
+old	O
+,	O
+cesarean	O
+-	O
+derived	O
+,	O
+colostrum	B-ANAT
+-	O
+deprived	O
+(	O
+CDCD	O
+)	O
+piglets	O
+.	O
+
+The	O
+median	O
+pig	B-SPEC
+diarrhea	B-DISO
+dose	O
+(	O
+PDD50	O
+)	O
+of	O
+the	O
+virus	B-SPEC
+pool	O
+was	O
+determined	O
+as	O
+7	O
+.	O
+35	O
+log10	O
+PDD50	O
+/	O
+mL	O
+,	O
+similar	O
+to	O
+the	O
+cell	B-COMP
+culture	O
+infectious	B-DISO
+titer	O
+,	O
+7	O
+.	O
+75	O
+log10	O
+plaque	B-DISO
+-	O
+forming	O
+units	O
+(	O
+PFU	B-CHED
+)/	O
+mL	O
+.	O
+100	O
+PDD50	O
+caused	O
+watery	B-DISO
+diarrhea	I-DISO
+in	O
+all	O
+conventional	O
+suckling	O
+piglets	O
+(	O
+n	O
+=	O
+12	O
+)	O
+derived	O
+from	O
+a	O
+PEDV	B-SPEC
+-	O
+naive	O
+sow	O
+,	O
+whereas	O
+1000	O
+and	O
+10	O
+000	O
+PDD50	O
+did	O
+not	O
+cause	O
+diarrhea	B-DISO
+in	O
+piglets	O
+derived	O
+from	O
+two	O
+PEDV	B-SPEC
+-	O
+field	O
+exposed	O
+-	O
+recovered	O
+sows	O
+.	O
+
+This	O
+information	O
+is	O
+important	O
+for	O
+future	O
+PEDV	B-SPEC
+challenge	O
+studies	O
+and	O
+validation	O
+of	O
+PEDV	B-SPEC
+vaccines	O
+.	O
+
+TITLE	O
+:	O
+Leg	B-ANAT
+for	O
+life	O
+?	O
+
+A	O
+pregnant	O
+woman	O
+was	O
+admitted	O
+with	O
+respiratory	B-DISO
+failure	I-DISO
+due	O
+to	O
+H1N1	B-DISO
+influenza	I-DISO
+.	O
+
+24h	O
+later	O
+VA	O
+-	O
+ECMO	O
+was	O
+reinstalled	O
+with	O
+surgical	O
+denudation	O
+of	O
+femoral	B-ANAT
+vessels	I-ANAT
+in	O
+another	O
+department	O
+.	O
+
+The	O
+wound	O
+underwent	O
+negative	O
+pressure	O
+therapy	O
+for	O
+10	O
+days	O
+and	O
+was	O
+skin	B-ANAT
+grafted	O
+.	O
+
+In	O
+the	O
+present	O
+study	O
+we	O
+aimed	O
+at	O
+assessing	O
+NDV	B-SPEC
+and	O
+IBV	B-SPEC
+prevalences	O
+in	O
+Ivory	O
+-	O
+Coast	O
+by	O
+molecular	O
+screening	O
+of	O
+>	O
+22	O
+,	O
+000	O
+avian	B-SPEC
+swabs	O
+by	O
+nested	O
+PCR	O
+and	O
+by	O
+serology	O
+testing	O
+of	O
+close	O
+to	O
+2000	O
+avian	B-SPEC
+sera	B-COMP
+from	O
+2010	O
+through	O
+2012	O
+.	O
+
+A	O
+number	O
+of	O
+vaccine	O
+candidates	O
+have	O
+been	O
+developed	O
+on	O
+the	O
+basis	O
+of	O
+viral	O
+vectors	O
+,	O
+recombinant	O
+proteins	B-CHED
+,	O
+DNAs	O
+,	O
+nanoparticles	B-CHED
+,	O
+and	O
+recombinant	O
+MERS	O
+-	O
+CoV	O
+,	O
+and	O
+some	O
+of	O
+them	O
+have	O
+shown	O
+efficacy	O
+in	O
+laboratory	O
+animals	B-SPEC
+.	O
+
+TITLE	O
+:	O
+Real	O
+-	O
+time	O
+characterization	O
+of	O
+risks	O
+of	O
+death	B-PROC
+associated	O
+with	O
+the	O
+Middle	O
+East	O
+respiratory	O
+syndrome	B-DISO
+(	O
+MERS	O
+)	O
+in	O
+the	O
+Republic	O
+of	O
+Korea	O
+,	O
+2015	O
+.	O
+
+ABSTRACT	O
+:	O
+An	O
+outbreak	O
+of	O
+the	O
+Middle	O
+East	O
+respiratory	O
+syndrome	B-DISO
+(	O
+MERS	O
+),	O
+comprising	O
+185	O
+cases	O
+linked	O
+to	O
+healthcare	O
+facilities	O
+,	O
+occurred	O
+in	O
+the	O
+Republic	O
+of	O
+Korea	O
+from	O
+May	O
+to	O
+July	O
+2015	O
+.	O
+
+While	O
+accounting	O
+for	O
+the	O
+time	O
+delay	O
+from	O
+illness	O
+onset	O
+to	O
+death	B-PROC
+,	O
+risk	O
+factors	O
+for	O
+death	B-PROC
+were	O
+identified	O
+using	O
+a	O
+linear	O
+predictor	O
+tied	O
+to	O
+a	O
+logit	O
+model	O
+.	O
+
+Because	O
+MERS	O
+outbreaks	O
+are	O
+greatly	O
+amplified	O
+in	O
+the	O
+healthcare	O
+setting	O
+,	O
+enhanced	O
+infection	B-DISO
+control	O
+practices	O
+in	O
+medical	O
+facilities	O
+should	O
+strive	O
+to	O
+shield	O
+risk	O
+groups	O
+from	O
+MERS	O
+exposure	O
+.	O
+
+Seasonal	O
+occurrence	O
+in	O
+GBS	B-DISO
+is	O
+prominent	O
+in	O
+winter	O
+484	O
+(	O
+41	O
+.	O
+50	O
+%)	O
+and	O
+mechanically	O
+ventilated	O
+were	O
+449	O
+(	O
+38	O
+.	O
+50	O
+%)	O
+patients	O
+.	O
+
+48	O
+(	O
+4	O
+.	O
+11	O
+%)	O
+deaths	B-PROC
+were	O
+attributed	O
+to	O
+GBS	B-DISO
+.	O
+
+However	O
+,	O
+no	O
+antigen	B-CHED
+detection	O
+assay	O
+for	O
+commercial	O
+use	O
+is	O
+available	O
+for	O
+diagnosis	O
+.	O
+
+One	O
+such	O
+sensor	O
+,	O
+MDA5	B-PRGE
+,	O
+detects	O
+viral	O
+RNA	O
+and	O
+triggers	O
+induction	O
+of	O
+type	B-PRGE
+I	I-PRGE
+interferons	I-PRGE
+,	O
+chemical	O
+messengers	O
+that	O
+induce	O
+inflammation	B-DISO
+and	O
+help	O
+regulate	O
+the	O
+immune	B-PROC
+responses	I-PROC
+.	O
+
+In	O
+the	O
+networks	O
+,	O
+we	O
+found	O
+5	O
+significant	O
+proteins	B-CHED
+including	O
+FAN	B-PRGE
+,	O
+CPSF2	B-PRGE
+,	O
+AGO1	B-PRGE
+,	O
+AGO2	B-PRGE
+and	O
+PAX5	B-PRGE
+.	O
+
+This	O
+have	O
+enabled	O
+the	O
+development	B-PROC
+of	O
+specific	O
+devices	O
+for	O
+the	O
+extracorporeal	O
+removal	O
+of	O
+CO2	B-CHED
+.	O
+
+These	O
+devices	O
+have	O
+a	O
+simpler	O
+configuration	O
+than	O
+extracorporeal	O
+membrane	B-COMP
+oxygenation	B-PROC
+devices	O
+and	O
+uses	O
+lower	O
+blood	B-PROC
+flows	I-PROC
+which	O
+could	O
+reduce	O
+the	O
+potential	O
+complications	O
+.	O
+
+Infection	B-DISO
+with	O
+this	O
+virus	B-SPEC
+often	O
+caused	O
+severe	O
+pneumonia	B-DISO
+and	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+resulting	O
+in	O
+a	O
+case	O
+fatality	O
+rate	O
+>	O
+35	O
+%.	O
+
+The	O
+mice	B-SPEC
+and	O
+ferrets	B-SPEC
+were	O
+then	O
+challenged	O
+with	O
+H7N9	O
+A	O
+/	O
+Anhui	O
+/	O
+1	O
+/	O
+2013	O
+influenza	B-DISO
+virus	I-SPEC
+.	O
+
+The	O
+PEDV	B-SPEC
+infected	O
+suckling	O
+pigs	B-SPEC
+showed	O
+severe	O
+diarrhea	B-DISO
+and	I-DISO
+vomiting	I-DISO
+at	O
+PID	B-DISO
+1	O
+,	O
+whereas	O
+the	O
+PEDV	B-SPEC
+infected	O
+weaned	B-PROC
+pigs	B-SPEC
+showed	O
+milder	O
+clinical	O
+signs	O
+starting	O
+at	O
+PID	B-DISO
+3	O
+.	O
+
+There	O
+was	O
+no	O
+mortality	O
+in	O
+either	O
+infected	O
+suckling	O
+or	O
+infected	O
+weaned	B-PROC
+pigs	B-SPEC
+.	O
+
+Strikingly	O
+,	O
+PEDV	B-SPEC
+infected	O
+suckling	O
+pigs	B-SPEC
+had	O
+significantly	O
+lower	O
+NK	B-ANAT
+cell	I-ANAT
+frequencies	O
+,	O
+undetectable	O
+NK	B-ANAT
+cell	I-ANAT
+activity	O
+and	O
+lower	O
+IFNγ	O
+producing	O
+NK	B-ANAT
+cells	I-ANAT
+in	O
+blood	B-ANAT
+and	O
+ileum	B-ANAT
+compared	O
+to	O
+PEDV	B-SPEC
+infected	O
+weaned	B-PROC
+pigs	B-SPEC
+.	O
+
+The	O
+S	B-PROC
+-	I-PROC
+phase	I-PROC
+arrest	O
+is	O
+associated	O
+with	O
+a	O
+decrease	O
+in	O
+level	O
+of	O
+cyclin	B-PRGE
+A	I-PRGE
+.	O
+Furthermore	O
+,	O
+our	O
+results	O
+revealed	O
+that	O
+the	O
+M	B-PRGE
+protein	I-PRGE
+of	O
+PEDV	B-SPEC
+does	O
+not	O
+induce	O
+endoplasmic	B-COMP
+reticulum	I-COMP
+(	O
+ER	O
+)	O
+stress	O
+and	O
+does	O
+not	O
+activate	O
+NF	O
+-	O
+κB	O
+which	O
+is	O
+responsible	O
+for	O
+IL	O
+-	O
+8	O
+and	O
+Bcl	B-PRGE
+-	I-PRGE
+2	I-PRGE
+expression	B-PROC
+.	O
+
+FTY720	B-CHED
+treatment	O
+of	O
+cultured	O
+NPCs	O
+resulted	O
+in	O
+increased	O
+mitogen	B-PRGE
+-	I-PRGE
+activated	I-PRGE
+protein	B-CHED
+kinase	I-PRGE
+phosphorylation	B-PROC
+and	O
+migration	B-PROC
+after	O
+exposure	O
+to	O
+the	O
+chemokine	O
+CXCL12	O
+.	O
+
+In	O
+21	O
+-	O
+day	O
+-	O
+old	O
+pigs	B-SPEC
+,	O
+10ml	O
+of	O
+inoculum	O
+with	O
+titers	O
+560	O
+-	O
+5	O
+.	O
+6	O
+TCID50	O
+/	O
+ml	O
+(	O
+Ct	O
+24	O
+.	O
+2	O
+-	O
+31	O
+.	O
+4	O
+)	O
+resulted	O
+in	O
+100	O
+%	O
+infection	B-DISO
+in	O
+each	O
+group	O
+while	O
+10ml	O
+of	O
+inoculum	O
+with	O
+titers	O
+0	O
+.	O
+56	O
+-	O
+0	O
+.	O
+0056	O
+TCID50	O
+/	O
+ml	O
+(	O
+Ct	O
+values	O
+35	O
+.	O
+3	O
+->	O
+45	O
+)	O
+did	O
+not	O
+establish	O
+infection	B-DISO
+in	O
+any	O
+pigs	B-SPEC
+under	O
+study	O
+conditions	O
+as	O
+determined	O
+by	O
+clinical	O
+signs	O
+,	O
+PCR	O
+,	O
+histopathology	O
+,	O
+immunohistochemistry	O
+,	O
+and	O
+antibody	B-PROC
+response	I-PROC
+.	O
+
+TITLE	O
+:	O
+Aetiological	O
+role	O
+of	O
+common	O
+respiratory	O
+viruses	B-SPEC
+in	O
+acute	O
+lower	O
+respiratory	B-DISO
+infections	I-DISO
+in	O
+children	O
+under	O
+five	O
+years	O
+:	O
+A	O
+systematic	O
+review	O
+and	O
+meta	O
+-	O
+analysis	O
+.	O
+
+ABSTRACT	O
+:	O
+Characterized	O
+animal	B-SPEC
+models	O
+are	O
+needed	O
+for	O
+studying	O
+the	O
+pathogenesis	B-DISO
+of	O
+and	O
+evaluating	O
+medical	O
+countermeasures	O
+for	O
+persisting	O
+Middle	O
+East	O
+respiratory	O
+syndrome	B-DISO
+-	O
+coronavirus	B-SPEC
+(	O
+MERS	O
+-	O
+CoV	O
+)	O
+infections	B-DISO
+.	O
+
+We	O
+further	O
+characterized	O
+this	O
+model	O
+by	O
+determining	O
+both	O
+the	O
+ID50	O
+and	O
+the	O
+LD50	O
+of	O
+MERS	O
+-	O
+CoV	O
+in	O
+order	B-SPEC
+to	O
+establish	O
+both	O
+an	O
+infection	B-DISO
+model	O
+and	O
+a	O
+lethal	O
+model	O
+for	O
+MERS	O
+and	O
+followed	O
+this	O
+by	O
+investigating	O
+the	O
+antibody	B-PROC
+responses	I-PROC
+and	O
+immunity	B-PROC
+of	O
+the	O
+mice	B-SPEC
+that	O
+survived	O
+MERS	O
+-	O
+CoV	O
+infection	B-DISO
+.	O
+
+Similarly	O
+,	O
+significant	O
+age	O
+by	O
+HIV	O
+interactions	O
+were	O
+found	O
+indicating	O
+stronger	O
+associations	O
+between	O
+older	O
+age	O
+and	O
+decreased	O
+FA	O
+in	O
+the	O
+posterior	O
+limbs	B-ANAT
+of	O
+the	O
+internal	B-ANAT
+capsules	I-ANAT
+,	O
+cerebral	B-ANAT
+peduncles	I-ANAT
+,	O
+and	O
+anterior	O
+corona	B-ANAT
+radiata	I-ANAT
+in	O
+HIV	O
++	O
+vs	O
+.	O
+HIV	B-DISO
+-	O
+participants	O
+.	O
+
+This	O
+review	O
+covers	O
+4	O
+topics	O
+:	O
+(	O
+1	O
+)	O
+ophthalmic	B-CHED
+SJS	B-DISO
+,	O
+(	O
+2	O
+)	O
+human	B-PRGE
+leukocyte	B-ANAT
+antigen	B-CHED
+(	O
+HLA	B-PRGE
+)	O
+analysis	O
+,	O
+(	O
+3	O
+)	O
+genome	O
+-	O
+wide	O
+association	O
+studies	O
+,	O
+and	O
+(	O
+4	O
+)	O
+other	O
+pathogenic	O
+factors	O
+.	O
+
+Integrating	O
+phenotypic	O
+and	O
+genetic	O
+data	O
+narrowed	O
+this	O
+region	O
+to	O
+a	O
+single	O
+gene	O
+,	O
+Trim55	B-PRGE
+,	O
+an	O
+E3	B-PRGE
+ubiquitin	I-PRGE
+ligase	I-PRGE
+with	O
+a	O
+role	O
+in	O
+muscle	B-PROC
+fiber	I-PROC
+maintenance	I-PROC
+.	O
+
+These	O
+data	O
+establish	O
+the	O
+Collaborative	O
+Cross	O
+platform	O
+as	O
+a	O
+powerful	O
+genetic	O
+resource	O
+for	O
+uncovering	O
+genetic	O
+contributions	O
+of	O
+complex	O
+traits	O
+in	O
+microbial	B-DISO
+disease	I-DISO
+severity	O
+,	O
+inflammation	B-DISO
+and	O
+virus	B-PROC
+replication	I-PROC
+in	O
+models	O
+of	O
+outbred	O
+populations	O
+.	O
+
+ABSTRACT	O
+:	O
+Infectious	B-DISO
+Bronchitis	B-DISO
+is	O
+a	O
+highly	O
+contagious	O
+respiratory	B-DISO
+disease	I-DISO
+which	O
+causes	O
+tracheal	O
+lesions	O
+and	O
+also	O
+affects	O
+the	O
+reproductive	B-PROC
+tract	O
+and	O
+is	O
+responsible	O
+for	O
+large	O
+economic	O
+losses	O
+to	O
+the	O
+poultry	O
+industry	O
+every	O
+year	O
+.	O
+
+The	O
+virus	B-SPEC
+is	O
+difficult	O
+to	O
+control	O
+by	O
+vaccination	O
+,	O
+so	O
+new	O
+methods	O
+to	O
+curb	B-DISO
+the	O
+impact	O
+of	O
+the	O
+disease	O
+need	O
+to	O
+be	O
+sought	O
+.	O
+
+ABSTRACT	O
+:	O
+The	O
+Middle	O
+East	O
+Respiratory	O
+Coronavirus	O
+(	O
+MERS	O
+-	O
+CoV	O
+)	O
+was	O
+first	O
+isolated	O
+from	O
+a	O
+patient	O
+who	O
+died	B-PROC
+with	O
+severe	O
+pneumonia	B-DISO
+in	O
+June	O
+2012	O
+.	O
+
+A	O
+significant	O
+proportion	O
+of	O
+patients	O
+present	O
+with	O
+non	O
+-	O
+respiratory	B-DISO
+symptoms	I-DISO
+such	O
+as	O
+headache	B-DISO
+,	O
+myalgia	B-DISO
+,	O
+vomiting	B-DISO
+and	O
+diarrhoea	B-DISO
+.	O
+
+Evidence	O
+from	O
+multiple	O
+sources	O
+implicates	O
+dromedary	B-SPEC
+camels	B-SPEC
+as	O
+natural	O
+hosts	B-COMP
+of	O
+MERS	O
+-	O
+CoV	O
+.	O
+Camel	B-SPEC
+to	O
+human	B-SPEC
+transmission	O
+has	O
+been	O
+demonstrated	O
+,	O
+but	O
+the	O
+exact	O
+mechanism	O
+of	O
+infection	B-DISO
+remains	O
+uncertain	O
+.	O
+
+Patients	O
+with	O
+HAdV	O
+infections	B-DISO
+and	O
+hospitalized	O
+in	O
+a	O
+medical	O
+center	O
+between	O
+2009	O
+and	O
+2013	O
+were	O
+divided	O
+into	O
+severe	O
+or	O
+nonsevere	O
+HAdV	O
+infections	B-DISO
+based	O
+on	O
+whether	O
+or	O
+not	O
+they	O
+received	O
+intensive	O
+care	O
+.	O
+
+HAdV	O
+pneumonia	B-DISO
+was	O
+identified	O
+for	O
+comparison	O
+.	O
+
+This	O
+case	O
+highlights	O
+the	O
+importance	O
+of	O
+a	O
+high	O
+index	O
+of	O
+suspicion	O
+for	O
+superimposed	O
+fungal	B-DISO
+infections	I-DISO
+in	O
+patients	O
+who	O
+are	O
+critically	B-DISO
+ill	I-DISO
+and	O
+immunocompromised	O
+.	O
+
+IBV	B-SPEC
+virus	B-ANAT
+-	I-ANAT
+like	I-ANAT
+particles	I-ANAT
+(	O
+VLPs	B-ANAT
+)	O
+were	O
+generated	O
+through	O
+the	O
+co	B-DISO
+-	I-DISO
+infection	I-DISO
+with	O
+three	O
+recombinant	O
+baculoviruses	O
+separately	O
+encoding	O
+M	O
+,	O
+E	O
+or	O
+the	O
+recombinant	O
+S	O
+genes	O
+.	O
+
+This	O
+work	O
+provides	O
+basic	O
+information	O
+for	O
+the	O
+mechanism	O
+of	O
+IBV	O
+VLP	B-COMP
+formation	B-PROC
+and	O
+develops	O
+a	O
+platform	O
+for	O
+further	O
+designing	O
+IBV	B-SPEC
+VLP	B-COMP
+-	O
+based	O
+vaccines	O
+against	O
+IBV	B-SPEC
+or	O
+other	O
+viruses	B-SPEC
+.	O
+
+The	O
+addition	O
+of	O
+prone	O
+positioning	O
+therapy	O
+used	O
+concurrently	O
+with	O
+ECMO	O
+can	O
+further	O
+aid	O
+in	O
+optimizing	O
+alveolar	B-ANAT
+recruitment	B-DISO
+and	O
+reducing	O
+ventilator	O
+-	O
+induced	O
+lung	B-ANAT
+injury	O
+,	O
+ultimately	O
+resulting	O
+in	O
+fewer	O
+ICU	O
+admission	O
+days	O
+and	O
+improved	O
+overall	O
+survival	O
+.	O
+
+Chest	B-ANAT
+tube	O
+dislodgment	O
+and	O
+airway	B-ANAT
+dislodgment	O
+did	O
+not	O
+occur	O
+in	O
+any	O
+of	O
+the	O
+studies	O
+included	O
+.	O
+
+The	O
+authors	O
+who	O
+reported	O
+adverse	B-DISO
+effects	I-DISO
+stated	O
+that	O
+the	O
+episodes	O
+were	O
+quickly	O
+and	O
+successfully	O
+reversible	O
+.	O
+
+RESULTS	O
+:	O
+Seven	O
+studies	O
+fit	B-DISO
+the	O
+study	O
+inclusion	O
+criteria	O
+(	O
+1	O
+prospective	O
+cohort	O
+study	O
+,	O
+3	O
+retrospective	O
+cohort	O
+studies	O
+,	O
+and	O
+3	O
+case	O
+series	O
+).	O
+
+ABSTRACT	O
+:	O
+It	O
+is	O
+often	O
+difficult	O
+for	O
+a	O
+physician	O
+to	O
+distinguish	O
+between	O
+viral	O
+and	O
+bacterial	O
+causes	O
+of	O
+respiratory	O
+infections	O
+and	O
+this	O
+may	O
+result	O
+in	O
+overuse	O
+of	O
+antibiotics	B-CHED
+.	O
+
+Randomized	O
+172	O
+influenza	B-DISO
+-	O
+negative	O
+respiratory	O
+specimens	O
+of	O
+all	O
+age	O
+groups	O
+of	O
+hospitalized	O
+patients	O
+were	O
+collected	O
+.	O
+
+The	O
+2015	O
+MERS	O
+-	O
+CoV	O
+,	O
+2003	O
+SARS	O
+-	O
+CoV	O
+,	O
+and	O
+to	O
+a	O
+lesser	O
+extent	O
+2014	O
+-	O
+15	O
+Ebola	B-SPEC
+virus	I-SPEC
+outbreaks	O
+were	O
+driven	O
+by	O
+super	O
+-	O
+spreaders	O
+.	O
+
+Full	O
+genome	O
+sequence	O
+was	O
+obtained	O
+from	O
+sputum	B-ANAT
+specimens	O
+of	O
+the	O
+index	O
+patient	O
+.	O
+
+Thorough	O
+reprocessing	O
+of	O
+endoscopes	O
+using	O
+high	O
+-	O
+level	O
+disinfection	O
+and	O
+sterilization	O
+methods	O
+may	O
+be	O
+essential	O
+for	O
+reducing	O
+the	O
+risk	O
+of	O
+infection	B-DISO
+.	O
+
+Feline	B-SPEC
+coronavirus	B-SPEC
+RNA	O
+was	O
+detected	O
+using	O
+a	O
+reverse	B-PRGE
+transcriptase	I-PRGE
+quantitative	O
+polymerase	O
+chain	O
+reaction	O
+assay	O
+(	O
+qRT	O
+-	O
+PCR	O
+),	O
+and	O
+positive	O
+samples	O
+underwent	O
+pyrosequencing	O
+of	O
+position	O
+1058	O
+with	O
+or	O
+without	O
+Sanger	O
+sequencing	O
+of	O
+position	O
+1060	O
+in	O
+the	O
+FCoV	B-PRGE
+spike	I-PRGE
+protein	I-PRGE
+.	O
+
+Results	O
+Seventeen	O
+(	O
+85	O
+%)	O
+of	O
+the	O
+effusion	B-ANAT
+samples	O
+from	O
+20	O
+cats	B-SPEC
+with	O
+FIP	B-DISO
+were	O
+positive	O
+for	O
+FCoV	B-PRGE
+RNA	I-PRGE
+,	O
+whereas	O
+none	O
+of	O
+the	O
+23	O
+cats	B-SPEC
+with	O
+other	O
+diseases	O
+were	O
+positive	O
+.	O
+
+Pyrosequencing	O
+of	O
+the	O
+17	O
+FCoV	O
+-	O
+positive	O
+samples	O
+showed	O
+that	O
+11	O
+(	O
+65	O
+%)	O
+of	O
+the	O
+cats	B-SPEC
+had	O
+leucine	B-CHED
+and	O
+two	O
+(	O
+12	O
+%)	O
+had	O
+methionine	B-CHED
+at	O
+position	O
+1058	O
+.	O
+
+Twenty	O
+Bordetella	B-SPEC
+avium	I-SPEC
+colonies	O
+were	O
+recovered	O
+from	O
+one	O
+of	O
+five	O
+fully	O
+protected	O
+birds	B-SPEC
+,	O
+and	O
+only	O
+five	O
+colonies	O
+were	O
+isolated	O
+from	O
+two	O
+of	O
+five	O
+partially	O
+protected	O
+birds	B-SPEC
+without	O
+ciliostasis	O
+,	O
+whereas	O
+in	O
+birds	B-SPEC
+with	O
+ciliostasis	O
+,	O
+numerous	O
+colonies	O
+were	O
+isolated	O
+.	O
+
+Thus	O
+,	O
+it	O
+appears	O
+that	O
+examining	O
+both	O
+criteria	O
+would	O
+be	O
+important	O
+when	O
+evaluating	O
+IBV	B-SPEC
+vaccine	O
+efficacy	O
+.	O
+
+TITLE	O
+:	O
+Epidemiology	O
+of	O
+Avian	B-DISO
+Infectious	I-DISO
+Bronchitis	I-DISO
+Virus	B-SPEC
+Genotypes	O
+in	O
+Iran	O
+(	O
+2010	O
+-	O
+2014	O
+).	O
+
+Thus	O
+,	O
+different	O
+substituents	O
+were	O
+introduced	O
+on	O
+N	O
+atom	B-CHED
+at	O
+position	O
+1	O
+or	O
+the	O
+O	O
+atom	B-CHED
+at	O
+position	O
+2	O
+of	O
+the	O
+leads	O
+;	O
+contextually	O
+,	O
+several	O
+groups	O
+were	O
+inserted	O
+on	O
+the	O
+nitrogen	B-CHED
+atom	I-CHED
+at	O
+position	O
+7	O
+of	O
+diaminoquinoline	O
+intermediates	O
+.	O
+
+Particularly	O
+,	O
+compounds	O
+4	O
+,	O
+11b	O
+,	O
+11c	O
+,	O
+13c	O
+,	O
+15a	O
+,	O
+18	O
+and	O
+21	O
+resulted	O
+active	O
+against	O
+BVDV	B-SPEC
+at	O
+concentrations	O
+ranging	O
+from	O
+1	O
+.	O
+3	O
+to	O
+5	O
+μM	O
+.	O
+Compound	O
+21	O
+was	O
+also	O
+evaluated	O
+for	O
+its	O
+activity	O
+on	O
+the	O
+BVDV	B-SPEC
+RdRp	B-FUNC
+.	O
+
+Molecular	O
+simulation	O
+results	O
+provided	O
+a	O
+molecular	O
+rationale	O
+for	O
+the	O
+anti	O
+-	O
+BVDV	B-SPEC
+activity	O
+of	O
+these	O
+compounds	O
+.	O
+
+These	O
+DN	O
+T	B-ANAT
+cells	I-ANAT
+were	O
+predominantly	O
+consisted	O
+of	O
+a	O
+TCRαβ	O
+(+)	O
+subset	O
+expressing	O
+high	O
+levels	O
+of	O
+CD44	B-PRGE
+and	O
+did	O
+not	O
+produce	O
+cytokine	B-PRGE
+except	I-PRGE
+IL	I-PRGE
+-	I-PRGE
+2	I-PRGE
+.	O
+
+Following	O
+MHV	B-SPEC
+-	O
+3	O
+infection	B-DISO
+,	O
+membrane	B-COMP
+mfgl2	O
+expression	B-PROC
+and	O
+functional	O
+procoagulant	O
+activity	O
+increased	O
+remarkably	O
+in	O
+the	O
+DN	O
+T	B-ANAT
+cells	I-ANAT
+.	O
+
+Introduction	O
+of	O
+a	O
+recombinant	O
+adenovirus	B-DISO
+which	O
+encoded	O
+a	O
+microRNA	O
+specifically	O
+targeting	B-PROC
+mfgl2	B-PRGE
+gene	I-PRGE
+(	O
+Ad	O
+-	O
+mfgl2	O
+-	O
+miRNA	O
+)	O
+in	O
+vivo	O
+significantly	O
+inhibited	O
+the	O
+hepatic	B-ANAT
+expression	B-PROC
+of	O
+mfgl2	O
+and	O
+improved	O
+survival	O
+in	O
+mice	B-SPEC
+.	O
+
+However	O
+,	O
+isolates	O
+ck	O
+/	O
+CH	O
+/	O
+LDL	O
+/	O
+110931	O
+and	O
+ck	O
+/	O
+CH	O
+/	O
+LHB	B-PRGE
+/	O
+130573	O
+were	O
+serotypically	O
+different	O
+from	O
+their	O
+parental	O
+viruses	B-SPEC
+and	O
+from	O
+other	O
+serotypes	O
+in	O
+this	O
+study	O
+.	O
+
+Reflecting	O
+the	O
+latest	O
+evidence	O
+for	O
+antiviral	B-CHED
+drugs	I-CHED
+in	O
+the	O
+treatment	O
+of	O
+MERS	O
+-	O
+CoV	O
+infection	B-DISO
+and	O
+the	O
+experiences	O
+of	O
+treating	O
+MERS	O
+patients	O
+in	O
+Republic	O
+of	O
+Korea	O
+,	O
+these	O
+guidelines	O
+focus	O
+on	O
+antiviral	B-CHED
+drugs	I-CHED
+to	O
+achieve	O
+effective	O
+treatment	O
+of	O
+MERS	O
+-	O
+CoV	O
+infections	B-DISO
+.	O
+
+We	O
+report	O
+the	O
+case	O
+of	O
+5	O
+-	O
+month	O
+-	O
+old	O
+infant	O
+who	O
+presented	O
+a	O
+normal	O
+development	B-PROC
+until	O
+the	O
+age	O
+of	O
+4	O
+months	O
+when	O
+a	O
+respiratory	B-DISO
+infection	I-DISO
+caused	O
+an	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+with	O
+a	O
+fatal	O
+outcome	O
+.	O
+
+Animals	B-SPEC
+immunized	O
+with	O
+a	O
+vaccine	O
+candidate	O
+were	O
+uniformly	O
+protected	O
+from	O
+lethal	O
+infection	B-DISO
+.	O
+
+These	O
+new	O
+mouse	B-SPEC
+models	O
+of	O
+MERS	O
+-	O
+CoV	O
+should	O
+be	O
+useful	O
+for	O
+investigation	O
+of	O
+early	O
+disease	O
+mechanisms	O
+and	O
+therapeutic	O
+interventions	O
+.	O
+
+ABSTRACT	O
+:	O
+The	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+(	O
+SARS	B-DISO
+)	O
+coronavirus	B-SPEC
+(	O
+CoV	O
+)	O
+identified	O
+in	O
+2003	O
+has	O
+infected	O
+∼	O
+8000	O
+people	O
+worldwide	O
+,	O
+killing	O
+nearly	O
+10	O
+%	O
+of	O
+them	O
+.	O
+
+More	O
+data	O
+are	O
+needed	O
+to	O
+determine	O
+whether	O
+modulation	O
+of	O
+virus	B-SPEC
+load	O
+by	O
+therapeutic	O
+agents	O
+affects	O
+clinical	O
+outcomes	O
+.	O
+
+Surface	O
+protection	O
+and	O
+disinfection	O
+against	O
+microorganisms	O
+,	O
+including	O
+viruses	B-SPEC
+,	O
+is	O
+performed	O
+by	O
+sanitization	O
+of	O
+the	O
+skin	B-ANAT
+surface	I-ANAT
+through	O
+hand	O
+washing	O
+with	O
+soap	O
+and	O
+water	B-CHED
+,	O
+surface	O
+disinfectants	B-CHED
+,	O
+and	O
+hand	O
+sanitizers	O
+,	O
+particularly	O
+alcohol	O
+-	O
+based	O
+hand	O
+sanitizers	O
+.	O
+
+There	O
+is	O
+a	O
+need	O
+for	O
+a	O
+novel	O
+approach	O
+to	O
+protect	O
+humans	B-SPEC
+and	O
+livestock	O
+from	O
+infections	B-DISO
+of	O
+pathogenic	O
+viruses	B-SPEC
+that	O
+is	O
+broadly	O
+effective	O
+,	O
+long	O
+-	O
+lasting	O
+(	O
+persistent	O
+),	O
+non	O
+-	O
+toxic	O
+,	O
+and	O
+environment	O
+-	O
+friendly	O
+.	O
+
+TITLE	O
+:	O
+Low	O
+-	O
+Level	O
+Expression	B-PROC
+of	O
+the	O
+E1B	B-PRGE
+20	I-PRGE
+-	I-PRGE
+Kilodalton	I-PRGE
+Protein	I-PRGE
+by	O
+Adenovirus	B-DISO
+14p1	O
+Enhances	O
+Viral	O
+Immunopathogenesis	O
+.	O
+
+A	O
+small	O
+-	O
+animal	B-SPEC
+model	O
+of	O
+Ad14	B-DISO
+-	O
+induced	O
+lung	B-DISO
+infection	I-DISO
+was	O
+used	O
+to	O
+test	O
+the	O
+translational	B-PROC
+relevance	O
+of	O
+these	O
+in	O
+vitro	O
+observations	O
+.	O
+
+Three	O
+reviewers	O
+independently	O
+assessed	O
+all	O
+patients	O
+enrolled	O
+in	O
+the	O
+study	O
+for	O
+acute	O
+lung	B-ANAT
+injury	O
+/	O
+ARDS	B-DISO
+using	O
+the	O
+Berlin	O
+and	O
+the	O
+American	O
+-	O
+European	O
+Consensus	O
+Conference	O
+(	O
+AECC	O
+)	O
+definitions	O
+.	O
+
+ARDS	B-DISO
+by	O
+either	O
+definition	O
+was	O
+associated	O
+with	O
+increased	O
+mortality	O
+(	O
+p	O
+=	O
+0	O
+.	O
+04	O
+)	O
+but	O
+not	O
+with	O
+differences	O
+in	O
+functional	O
+outcome	O
+as	O
+measured	O
+by	O
+the	O
+GOS	O
+score	O
+at	O
+6	O
+months	O
+.	O
+
+Severe	O
+TBI	O
+is	O
+associated	O
+with	O
+an	O
+incidence	O
+of	O
+ARDS	B-DISO
+ranging	O
+from	O
+20	O
+%	O
+to	O
+25	O
+%.	O
+
+The	O
+combination	O
+of	O
+ribavirin	B-CHED
+and	O
+interferon	B-PRGE
+-	I-PRGE
+α	I-PRGE
+has	O
+been	O
+the	O
+most	O
+widely	O
+used	O
+therapy	O
+for	O
+this	O
+infection	B-DISO
+.	O
+
+Low	O
+tidal	O
+volume	O
+,	O
+pressure	O
+limitation	O
+and	O
+prone	O
+positioning	O
+in	O
+severe	O
+ARDS	B-DISO
+patients	O
+appear	O
+to	O
+be	O
+of	O
+some	O
+benefit	O
+.	O
+
+Over	O
+40	O
+years	O
+of	O
+clinical	O
+trials	O
+have	O
+consistently	O
+reported	O
+improved	O
+oxygenation	B-PROC
+in	O
+approximately	O
+70	O
+%	O
+of	O
+subjects	O
+with	O
+ARDS	B-DISO
+.	O
+
+Maximal	O
+oxygenation	B-PROC
+improvement	O
+occurs	O
+over	O
+a	O
+wide	O
+time	O
+frame	O
+ranging	O
+from	O
+several	O
+hours	O
+to	O
+several	O
+days	O
+.	O
+
+Meta	B-SPEC
+-	O
+analyses	O
+of	O
+randomized	O
+controlled	O
+trials	O
+suggest	O
+that	O
+PP	O
+provides	O
+a	O
+survival	O
+advantage	O
+only	O
+in	O
+patients	O
+with	O
+relatively	O
+severe	O
+ARDS	B-DISO
+(	O
+PaO2	O
+/	O
+FIO2	O
+<	O
+150	O
+mm	O
+Hg	O
+).	O
+
+Moreover	O
+,	O
+survival	O
+is	O
+enhanced	O
+when	O
+patients	O
+are	O
+managed	O
+with	O
+a	O
+smaller	O
+tidal	O
+volume	O
+(≤	O
+8	O
+mL	O
+/	O
+kg	O
+),	O
+higher	O
+PEEP	B-CHED
+(	O
+10	O
+-	O
+13	O
+cm	O
+H2O	B-CHED
+),	O
+and	O
+longer	O
+duration	O
+of	O
+PP	O
+sessions	O
+(>	O
+10	O
+-	O
+12	O
+h	O
+/	O
+session	O
+).	O
+
+ABSTRACT	O
+:	O
+Most	O
+cases	O
+of	O
+Middle	O
+East	O
+Respiratory	O
+Syndrome	B-DISO
+(	O
+MERS	O
+)	O
+infection	B-DISO
+in	O
+Korea	O
+(	O
+outbreak	O
+:	O
+May	O
+11	O
+-	O
+July	O
+4	O
+,	O
+2015	O
+)	O
+occurred	O
+in	O
+hospital	O
+settings	O
+,	O
+with	O
+uncertain	O
+transmission	O
+modes	O
+in	O
+some	O
+cases	O
+.	O
+
+A	O
+29	O
+-	O
+year	O
+-	O
+old	O
+man	B-CHED
+living	O
+in	O
+Pyeongtaek	O
+presented	O
+on	O
+June	O
+16	O
+with	O
+a	O
+febrile	B-PROC
+sensation	B-PROC
+,	O
+chills	B-DISO
+,	O
+and	O
+myalgia	B-DISO
+.	O
+
+An	O
+epidemiological	O
+investigation	O
+of	O
+all	O
+possible	O
+infection	B-DISO
+routes	O
+indicated	O
+two	O
+likely	O
+modes	O
+of	O
+transmission	O
+:	O
+exposure	O
+to	O
+MERS	O
+in	O
+Pyeongtaek	O
+St	O
+.	O
+Mary	O
+'	O
+s	O
+Hospital	O
+during	O
+a	O
+visit	O
+to	O
+his	O
+hospitalized	O
+father	O
+(	O
+May	O
+18	O
+-	O
+29	O
+),	O
+and	O
+infection	B-DISO
+through	O
+frequent	O
+contact	O
+with	O
+his	O
+father	O
+between	O
+the	O
+latter	O
+'	O
+s	O
+referral	O
+to	O
+Pyeongtaek	O
+Good	O
+Samaritan	O
+Bagae	O
+Hospital	O
+for	O
+treatment	O
+without	O
+confirmatory	O
+diagnosis	O
+until	O
+his	O
+death	O
+(	O
+May	O
+29	O
+-	O
+June	O
+6	O
+).	O
+
+ABSTRACT	O
+:	O
+The	O
+recent	O
+outbreak	O
+of	O
+Middle	O
+East	O
+Respiratory	O
+Syndrome	B-DISO
+(	O
+MERS	O
+)	O
+coronavirus	B-DISO
+infection	I-DISO
+in	O
+Korea	O
+resulted	O
+in	O
+large	O
+socioeconomic	O
+losses	O
+.	O
+
+This	O
+provoked	O
+the	O
+Korean	O
+government	O
+and	O
+the	O
+general	O
+public	O
+to	O
+recognize	O
+the	O
+importance	O
+of	O
+having	O
+a	O
+well	O
+-	O
+established	O
+system	O
+against	O
+infectious	B-DISO
+diseases	I-DISO
+.	O
+
+We	O
+suggest	O
+that	O
+governmental	O
+authorities	O
+in	O
+Korea	O
+enforce	O
+preventive	O
+policies	O
+,	O
+foster	O
+the	O
+development	B-PROC
+of	O
+highly	O
+qualified	O
+personnel	O
+,	O
+and	O
+increase	O
+investment	O
+in	O
+the	O
+public	O
+health	O
+domain	O
+of	O
+infectious	B-DISO
+disease	I-DISO
+prevention	O
+.	O
+
+The	O
+aim	O
+of	O
+the	O
+study	O
+was	O
+to	O
+determine	O
+the	O
+size	O
+and	O
+location	O
+of	O
+homogeneous	O
+inflamed	O
+/	O
+noninflamed	O
+and	O
+inhomogeneous	O
+inflamed	O
+/	O
+noninflamed	O
+lung	B-ANAT
+compartments	B-ANAT
+and	O
+their	O
+association	O
+with	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+(	O
+ARDS	B-DISO
+)	O
+severity	O
+.	O
+
+The	O
+inhomogeneous	O
+compartment	B-ANAT
+with	O
+high	O
+[(	O
+18	O
+)	O
+F	O
+]	O
+FDG	O
+uptake	O
+was	O
+preferentially	O
+located	O
+in	O
+the	O
+dependent	O
+lung	B-ANAT
+(	O
+21	O
+±	O
+10	O
+%	O
+versus	O
+12	O
+±	O
+10	O
+%,	O
+p	O
+<	O
+0	O
+.	O
+0001	O
+),	O
+mostly	O
+at	O
+the	O
+open	O
+/	O
+closed	O
+interfaces	O
+and	O
+related	O
+to	O
+recruitability	O
+(	O
+r	O
+(	O
+2	O
+)=	O
+0	O
+.	O
+53	O
+,	O
+p	O
+<	O
+0	O
+.	O
+001	O
+).	O
+The	O
+homogeneous	O
+lung	B-ANAT
+compartment	B-ANAT
+with	O
+normal	O
+inflation	O
+and	O
+[(	O
+18	O
+)	O
+F	O
+]	O
+FDG	O
+uptake	O
+decreases	O
+with	O
+ARDS	B-DISO
+severity	O
+,	O
+while	O
+the	O
+inhomogeneous	O
+poorly	O
+/	O
+not	O
+inflated	O
+compartment	B-ANAT
+increases	O
+.	O
+
+In	O
+addition	O
+,	O
+we	O
+introduced	O
+the	O
+smoothing	O
+spline	O
+clustering	O
+(	O
+SSC	O
+)	O
+method	O
+to	O
+estimate	O
+the	O
+highly	O
+variable	O
+sites	O
+for	O
+some	O
+sub	O
+-	O
+clusters	B-CHED
+.	O
+
+MRSA	B-DISO
+most	O
+closely	O
+resembled	O
+a	O
+Type	O
+I	O
+pathogen	O
+.	O
+
+A	O
+diffuse	O
+comet	B-SPEC
+tail	O
+sign	O
+or	O
+a	O
+consolidation	O
+score	O
+≤	O
+6	O
+and	O
+a	O
+lung	B-ANAT
+ultrasound	O
+score	O
+<	O
+25	O
+were	O
+observed	O
+in	O
+four	O
+patients	O
+.	O
+
+The	O
+occurrence	O
+of	O
+ACS	B-FUNC
+12	O
+-	O
+48	O
+months	O
+(	O
+P	O
+=	O
+0	O
+.	O
+019	O
+)	O
+after	O
+the	O
+loss	O
+was	O
+positively	O
+correlated	O
+with	O
+SCI	O
+-	O
+CG	O
+scores	O
+.	O
+
+Its	O
+course	O
+is	O
+usually	O
+mild	O
+and	O
+tends	O
+to	O
+limit	O
+itself	O
+,	O
+but	O
+in	O
+severe	O
+cases	O
+it	O
+can	O
+cause	O
+death	B-PROC
+.	O
+
+Owing	O
+to	O
+severe	O
+respiratory	B-DISO
+failure	I-DISO
+the	O
+patients	O
+were	O
+admitted	O
+to	O
+Respiratory	O
+Intermediate	O
+Care	O
+.	O
+
+Non	O
+-	O
+survivors	O
+had	O
+a	O
+significantly	O
+higher	O
+AAST	O
+grade	O
+(	O
+p	O
+=	O
+0	O
+.	O
+0001	O
+),	O
+higher	B-PRGE
+aspartate	I-PRGE
+aminotransferase	I-PRGE
+level	O
+(	O
+p	O
+=	O
+0	O
+.	O
+01	O
+),	O
+lower	O
+hemoglobin	B-PRGE
+level	O
+(	O
+p	O
+=	O
+0	O
+.	O
+0001	O
+),	O
+associated	O
+brain	B-ANAT
+injury	O
+(	O
+p	O
+=	O
+0	O
+.	O
+0001	O
+),	O
+perioperative	O
+complications	O
+(	O
+p	O
+=	O
+0	O
+.	O
+001	O
+)	O
+and	O
+higher	O
+transfusion	O
+score	O
+(	O
+p	O
+=	O
+0	O
+.	O
+0001	O
+).	O
+
+Patients	O
+with	O
+high	O
+-	O
+grade	O
+liver	B-ANAT
+trauma	O
+who	O
+present	O
+with	O
+hemorrhagic	B-DISO
+shock	I-DISO
+and	O
+associated	O
+severe	O
+injury	O
+should	O
+be	O
+managed	O
+operatively	O
+.	O
+
+ABSTRACT	O
+:	O
+Fat	B-DISO
+embolism	I-DISO
+syndrome	I-DISO
+(	O
+FES	O
+)	O
+is	O
+a	O
+clinical	O
+manifestation	O
+that	O
+consists	O
+of	O
+multiple	O
+organ	B-ANAT
+dysfunction	O
+due	O
+to	O
+fat	B-DISO
+emboli	I-DISO
+.	O
+
+Forty	O
+-	O
+eight	O
+(	O
+58	O
+%)	O
+patients	O
+had	O
+virus	B-SPEC
+-	O
+positive	O
+samples	O
+,	O
+with	O
+49	O
+virus	B-SPEC
+positives	O
+detected	O
+by	O
+either	O
+swab	O
+(	O
+one	O
+patient	O
+had	O
+a	O
+dual	O
+viral	O
+co	B-DISO
+-	I-DISO
+infection	I-DISO
+).	O
+
+We	O
+provide	O
+the	O
+first	O
+large	O
+-	O
+scale	O
+epidemiological	O
+analysis	O
+of	O
+ARDS	B-DISO
+incidence	O
+and	O
+outcomes	O
+in	O
+Asia	O
+.	O
+
+TITLE	O
+:	O
+Comparative	O
+Genomic	O
+Analysis	O
+of	O
+Classical	O
+and	O
+Variant	O
+Virulent	O
+Parental	O
+/	O
+Attenuated	O
+Strains	O
+of	O
+Porcine	B-SPEC
+Epidemic	I-SPEC
+Diarrhea	I-SPEC
+Virus	I-SPEC
+.	O
+
+In	O
+addition	O
+,	O
+to	O
+increase	O
+vaccine	O
+biosafety	O
+,	O
+we	O
+introduced	O
+additional	O
+attenuating	O
+mutations	O
+into	O
+the	O
+nsp1	B-PRGE
+protein	I-PRGE
+.	O
+
+TITLE	O
+:	O
+Clinical	O
+report	O
+of	O
+serious	O
+complications	O
+associated	O
+with	O
+measles	B-DISO
+pneumonia	I-DISO
+in	O
+children	O
+hospitalized	O
+at	O
+Shengjing	O
+hospital	O
+,	O
+China	O
+.	O
+
+The	O
+clinical	O
+characteristics	O
+of	O
+complications	O
+such	O
+as	O
+hypoxemia	O
+,	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+(	O
+ARDS	B-DISO
+),	O
+sepsis	B-DISO
+,	O
+pneumothorax	B-DISO
+,	O
+multiple	B-DISO
+organ	I-DISO
+dysfunction	I-DISO
+syndrome	I-DISO
+(	O
+MODS	B-DISO
+),	O
+and	O
+intracranial	B-ANAT
+infection	B-DISO
+were	O
+retrospectively	O
+analyzed	O
+;	O
+in	O
+addition	O
+,	O
+the	O
+death	B-PROC
+cases	O
+were	O
+summarized	O
+and	O
+analyzed	O
+.	O
+
+Children	O
+with	O
+measles	B-DISO
+pneumonia	I-DISO
+may	O
+experience	O
+multiple	O
+serious	O
+complications	O
+,	O
+among	O
+which	O
+ARDS	B-DISO
+and	O
+pneumothorax	B-DISO
+are	O
+particularly	O
+serious	O
+.	O
+
+ABSTRACT	O
+:	O
+Because	O
+of	O
+limitations	O
+of	O
+the	O
+esophageal	O
+balloon	O
+technique	O
+,	O
+the	O
+value	O
+of	O
+using	O
+esophageal	B-PROC
+pressure	I-PROC
+(	O
+Pes	B-ANAT
+)-	O
+guided	O
+end	B-PROC
+-	I-PROC
+expiratory	I-PROC
+transpulmonary	O
+pressure	O
+(	O
+PL	O
+-	O
+exp	O
+)	O
+to	O
+maintain	O
+lung	B-ANAT
+recruitment	B-DISO
+in	O
+adult	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+is	O
+controversial	O
+.	O
+
+This	O
+study	O
+aimed	O
+to	O
+investigate	O
+whether	O
+tailoring	O
+PL	O
+-	O
+exp	O
+to	O
+greater	O
+than	O
+0	O
+was	O
+enough	O
+to	O
+maintain	O
+lung	B-ANAT
+recruitment	B-DISO
+.	O
+
+Open	O
+-	O
+lung	B-ANAT
+PEEP	B-CHED
+(	O
+OL	O
+-	O
+PEEP	B-CHED
+)	O
+was	O
+determined	O
+by	O
+computed	O
+tomography	O
+,	O
+while	O
+Pes	B-ANAT
+-	O
+guided	O
+PEEP	B-CHED
+(	O
+Pes	B-ANAT
+-	O
+PEEP	B-CHED
+)	O
+was	O
+to	O
+maintain	O
+PL	O
+-	O
+exp	O
+greater	O
+than	O
+0	O
+.	O
+
+Compared	O
+with	O
+OL	O
+-	O
+PEEP	B-CHED
+,	O
+the	O
+nonaerated	O
+lung	B-ANAT
+region	O
+was	O
+significantly	O
+increased	O
+at	O
+Pes	B-ANAT
+-	O
+PEEP	B-CHED
+.	O
+
+Superimposed	O
+pressure	O
+(	O
+SP	O
+)	O
+of	O
+the	O
+lung	B-ANAT
+tissue	I-ANAT
+between	O
+the	O
+esophageal	O
+plane	O
+and	O
+the	O
+dorsal	O
+level	O
+was	O
+higher	O
+at	O
+Pes	B-ANAT
+-	O
+PEEP	B-CHED
+than	O
+at	O
+OL	O
+-	O
+PEEP	B-CHED
+,	O
+whereas	O
+PL	B-PRGE
+-	I-PRGE
+exp	I-PRGE
+at	O
+the	O
+dorsal	O
+level	O
+was	O
+lower	O
+at	O
+Pes	B-ANAT
+-	O
+PEEP	B-CHED
+than	O
+at	O
+OL	O
+-	O
+PEEP	B-CHED
+(-	O
+1	O
+.	O
+5	O
+[	O
+0	O
+.	O
+7	O
+]	O
+cm	O
+H2O	B-CHED
+vs	O
+.	O
+2	O
+.	O
+5	O
+[	O
+1	O
+.	O
+5	O
+]	O
+cm	O
+H2O	B-CHED
+,	O
+p	O
+<	O
+0	O
+.	O
+001	O
+).	O
+
+CONCLUSIONS	O
+:	O
+In	O
+this	O
+surfactant	B-CHED
+-	O
+depleted	O
+model	O
+,	O
+maintaining	O
+PL	O
+-	O
+exp	O
+just	O
+greater	O
+than	O
+0	O
+using	O
+Pes	B-ANAT
+was	O
+unable	O
+to	O
+maintain	O
+lung	B-ANAT
+recruitment	B-DISO
+;	O
+this	O
+was	O
+partly	O
+caused	O
+by	O
+a	O
+lack	O
+of	O
+compensation	B-PROC
+for	O
+the	O
+increased	O
+SP	O
+between	O
+the	O
+esophageal	O
+plane	O
+and	O
+the	O
+dorsal	O
+level	O
+.	O
+
+TITLE	O
+:	O
+Extracorporeal	O
+decarboxylation	O
+in	O
+patients	O
+with	O
+severe	O
+traumatic	O
+brain	B-ANAT
+injury	O
+and	O
+ARDS	B-DISO
+enables	O
+effective	O
+control	O
+of	O
+intracranial	O
+pressure	O
+.	O
+
+Pumpless	O
+extracorporeal	O
+lung	B-ANAT
+assist	O
+(	O
+pECLA	O
+)	O
+devices	O
+(	O
+iLA	B-PRGE
+Membrane	I-PRGE
+Ventilator	I-PRGE
+;	O
+Novalung	O
+,	O
+Heilbronn	O
+,	O
+Germany	O
+)	O
+can	O
+improve	O
+decarboxylation	O
+without	O
+aggravation	O
+associated	O
+with	O
+invasive	O
+ventilation	O
+.	O
+
+To	O
+evaluate	O
+effects	O
+on	O
+ICP	B-DISO
+,	O
+the	O
+volume	O
+of	O
+daily	O
+cerebrospinal	B-ANAT
+fluid	I-ANAT
+(	O
+CSF	B-ANAT
+)	O
+drainage	B-ANAT
+needed	O
+to	O
+maintain	O
+the	O
+set	O
+ICP	B-DISO
+threshold	O
+was	O
+compared	O
+pre	O
+-	O
+and	O
+postimplant	O
+.	O
+
+The	O
+volume	O
+of	O
+daily	O
+CSF	B-ANAT
+drainage	B-ANAT
+needed	O
+to	O
+maintain	O
+ICP	B-DISO
+at	O
+20	O
+mmHg	O
+decreased	O
+significantly	O
+from	O
+141	O
+.	O
+5	O
+±	O
+103	O
+.	O
+5	O
+ml	O
+to	O
+62	O
+.	O
+2	O
+±	O
+68	O
+.	O
+1	O
+ml	O
+(	O
+p	O
+=	O
+0	O
+.	O
+037	O
+).	O
+
+RESULTS	O
+:	O
+The	O
+ΔP	O
+values	O
+after	O
+pECLA	O
+implantation	B-PROC
+decreased	O
+from	O
+a	O
+mean	O
+17	O
+.	O
+1	O
+±	O
+0	O
+.	O
+7	O
+cm	O
+/	O
+H2O	B-CHED
+to	O
+11	O
+.	O
+9	O
+±	O
+0	O
+.	O
+5	O
+cm	O
+/	O
+H2O	B-CHED
+(	O
+p	O
+=	O
+0	O
+.	O
+011	O
+).	O
+
+TITLE	O
+:	O
+Mortality	O
+Predictors	O
+in	O
+Acute	B-DISO
+Respiratory	I-DISO
+Distress	I-DISO
+Syndrome	I-DISO
+Renal	B-ANAT
+Transplant	B-ANAT
+Recipients	O
+With	O
+ESKAPE	O
+/	O
+rESKAPE	O
+Pneumonia	O
+.	O
+
+Mortality	O
+in	O
+ARDS	B-DISO
+renal	B-ANAT
+recipients	O
+with	O
+ESKAPE	O
+/	O
+rESKAPE	O
+pneumonia	B-DISO
+was	O
+associated	O
+with	O
+the	O
+severity	O
+of	O
+ARDS	B-DISO
+,	O
+elevated	O
+serum	B-COMP
+creatinine	B-CHED
+level	O
+,	O
+or	O
+depressed	O
+febrile	B-PROC
+response	O
+at	O
+ARDS	B-DISO
+onset	O
+.	O
+
+The	O
+independent	O
+determinants	O
+of	O
+mortality	O
+were	O
+associated	O
+with	O
+ARDS	B-DISO
+renal	B-ANAT
+recipients	O
+with	O
+rESKAPE	O
+pneumonia	B-DISO
+were	O
+serum	B-COMP
+creatinine	B-CHED
+level	O
+>	O
+1	O
+.	O
+5	O
+mg	O
+/	O
+dL	O
+(	O
+OR	O
+13	O
+.	O
+7	O
+,	O
+95	O
+%	O
+CI	O
+1	O
+.	O
+3	O
+-	O
+142	O
+.	O
+1	O
+,	O
+P	O
+=	O
+.	O
+028	O
+)	O
+and	O
+body	B-ANAT
+temperature	O
+less	O
+than	O
+38	O
+°	O
+C	O
+(	O
+OR	O
+5	O
+.	O
+5	O
+(	O
+95	O
+%	O
+CI	O
+1	O
+.	O
+1	O
+-	O
+26	O
+.	O
+6	O
+)	O
+at	O
+ARDS	B-DISO
+onset	O
+,	O
+P	O
+=	O
+.	O
+035	O
+).	O
+
+Traditional	O
+models	O
+for	O
+controlling	O
+the	O
+spread	O
+of	O
+the	O
+vector	O
+are	O
+futile	O
+given	O
+the	O
+rapid	O
+pace	O
+at	O
+which	O
+bats	B-SPEC
+'	O
+habitats	O
+are	O
+eroded	O
+.	O
+
+Eight	O
+patients	O
+developed	O
+LRTI	B-DISO
+,	O
+four	O
+of	O
+whom	O
+had	O
+severe	O
+pneumonia	B-DISO
+or	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+;	O
+these	O
+four	O
+patients	O
+died	B-PROC
+despite	O
+receiving	O
+intensive	O
+care	O
+.	O
+
+TITLE	O
+:	O
+Synthesis	B-PROC
+and	O
+Antiviral	B-CHED
+Evaluation	O
+of	O
+Some	O
+C	O
+(	O
+3	O
+)-	O
+Symmetrical	O
+Trialkoxy	O
+-	O
+Substituted	O
+1	B-CHED
+,	I-CHED
+3	I-CHED
+,	I-CHED
+5	I-CHED
+-	I-CHED
+Triazines	I-CHED
+and	O
+Their	O
+Molecular	O
+Geometry	O
+.	O
+
+ABSTRACT	O
+:	O
+As	O
+one	O
+of	O
+our	O
+projects	O
+,	O
+we	O
+here	O
+report	O
+some	O
+new	O
+molecular	O
+modifications	O
+of	O
+2	B-CHED
+,	I-CHED
+4	I-CHED
+,	I-CHED
+6	I-CHED
+-	I-CHED
+trichloro	I-CHED
+-	I-CHED
+1	I-CHED
+,	I-CHED
+3	I-CHED
+,	I-CHED
+5	I-CHED
+-	I-CHED
+triazine	I-CHED
+(	O
+TCTAZ	O
+:	O
+1	O
+)	O
+to	O
+symmetrical	O
+2	O
+,	O
+4	O
+,	O
+6	O
+-	O
+trialkoxy	O
+-	O
+or	O
+2	O
+,	O
+4	O
+,	O
+6	O
+-	O
+triaryloxy	O
+-	O
+substituted	O
+1	B-CHED
+,	I-CHED
+3	I-CHED
+,	I-CHED
+5	I-CHED
+-	I-CHED
+triazine	I-CHED
+(	O
+TAZ	B-CHED
+)	O
+molecules	O
+,	O
+as	O
+well	O
+as	O
+the	O
+results	O
+of	O
+anti	B-PRGE
+-	I-PRGE
+herpes	I-PRGE
+simplex	I-PRGE
+virus	I-PRGE
+type	I-PRGE
+1	I-PRGE
+(	O
+anti	O
+-	O
+HSV	B-SPEC
+-	I-SPEC
+1	I-SPEC
+)	O
+activity	O
+evaluation	O
+of	O
+synthesized	O
+2	O
+,	O
+4	O
+,	O
+6	O
+-	O
+trisubstituted	O
+TAZ	B-CHED
+derivatives	O
+.	O
+
+In	O
+this	O
+paper	O
+,	O
+we	O
+also	O
+report	O
+the	O
+results	O
+of	O
+the	O
+preparation	O
+of	O
+newly	O
+targeted	B-PROC
+TAZ	O
+derivatives	O
+and	O
+the	O
+structure	O
+-	O
+activity	O
+relationships	O
+(	O
+SARs	B-DISO
+)	O
+of	O
+these	O
+trialkoxy	O
+-	O
+substituted	O
+TAZ	O
+derivatives	O
+and	O
+related	O
+compounds	O
+.	O
+
+Subset	O
+analyses	O
+identified	O
+CCL2	B-PRGE
+as	O
+an	O
+additional	O
+risk	O
+factor	O
+for	O
+tuberculosis	B-PATH
+(	O
+rs1024611	O
+;	O
+OR	O
+=	O
+0	O
+.	O
+79	O
+[	O
+0	O
+.	O
+72	O
+-	O
+0	O
+.	O
+88	O
+]).	O
+
+Similar	O
+behavior	O
+was	O
+observed	O
+in	O
+tracer	B-CHED
+gas	B-ENZY
+,	O
+particle	O
+experiments	O
+,	O
+and	O
+flight	B-PROC
+infection	B-DISO
+data	O
+for	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+.	O
+
+NIRFI	O
+signals	O
+were	O
+correlated	O
+with	O
+inflammatory	O
+cellular	B-COMP
+and	O
+biochemical	O
+markers	O
+of	O
+lungs	B-ANAT
+.	O
+
+RT	O
+-	O
+PCR	O
+studies	O
+showed	O
+an	O
+elevated	O
+lung	B-ANAT
+expression	B-PROC
+of	O
+alphavbeta5	B-PRGE
+integrin	I-PRGE
+receptors	I-PRGE
+,	O
+12	O
+h	O
+post	O
+-	O
+IL	B-PRGE
+-	I-PRGE
+1beta	I-PRGE
+instillation	O
+.	O
+
+We	O
+categorized	O
+81	O
+eligible	O
+patients	O
+into	O
+bacterial	B-DISO
+infection	I-DISO
+,	O
+viral	B-DISO
+infection	I-DISO
+,	O
+coinfection	B-DISO
+,	O
+and	O
+non	O
+-	O
+infectious	B-DISO
+groups	O
+.	O
+
+CAT	B-PRGE
+score	O
+was	O
+positively	O
+correlated	O
+with	O
+LOS	O
+.	O
+
+The	O
+metabolic	B-DISO
+acidosis	I-DISO
+associated	O
+with	O
+severe	O
+hypokalemia	O
+definitely	O
+contributed	O
+to	O
+the	O
+complex	O
+arrhythmias	B-DISO
+.	O
+
+The	O
+overall	O
+ICU	O
+mortality	O
+rate	O
+was	O
+not	O
+significantly	O
+different	O
+in	O
+mild	O
+,	O
+moderate	O
+and	O
+severe	O
+ARDS	B-DISO
+(	O
+50	O
+%,	O
+50	O
+%	O
+and	O
+56	O
+%,	O
+p	O
+=	O
+0	O
+.	O
+25	O
+).	O
+
+A	O
+multiple	O
+logistic	O
+regression	O
+analysis	O
+indicated	O
+that	O
+age	O
+,	O
+sequential	O
+organ	B-ANAT
+function	O
+assessment	O
+score	O
+and	O
+community	O
+-	O
+acquired	O
+ARDS	B-DISO
+were	O
+independently	O
+associated	O
+with	O
+hospital	O
+mortality	O
+.	O
+
+The	O
+number	O
+of	O
+ICU	O
+-	O
+free	O
+days	O
+was	O
+significantly	O
+higher	O
+in	O
+community	O
+-	O
+acquired	O
+ARDS	B-DISO
+than	O
+in	O
+hospital	O
+-	O
+acquired	O
+and	O
+ICU	O
+-	O
+acquired	O
+ARDS	B-DISO
+(	O
+8	O
+±	O
+10	O
+,	O
+4	O
+±	O
+8	O
+,	O
+and	O
+3	O
+±	O
+6	O
+days	O
+,	O
+p	O
+=	O
+0	O
+.	O
+001	O
+).	O
+
+RESULTS	O
+:	O
+Of	O
+the	O
+3002	O
+patients	O
+screened	O
+,	O
+296	O
+patients	O
+had	O
+a	O
+diagnosis	O
+of	O
+ARDS	B-DISO
+,	O
+including	O
+70	O
+(	O
+23	O
+.	O
+7	O
+%)	O
+with	O
+community	O
+-	O
+acquired	O
+ARDS	B-DISO
+,	O
+83	O
+(	O
+28	O
+%)	O
+with	O
+hospital	O
+-	O
+acquired	O
+ARDS	B-DISO
+,	O
+and	O
+143	O
+(	O
+48	O
+.	O
+3	O
+%)	O
+with	O
+ICU	O
+-	O
+acquired	O
+ARDS	B-DISO
+.	O
+
+Previous	O
+studies	O
+have	O
+shown	O
+that	O
+PEDV	B-PRGE
+ORF3	I-PRGE
+encodes	O
+an	O
+ion	O
+channel	O
+protein	B-CHED
+.	O
+
+In	O
+this	O
+study	O
+,	O
+we	O
+developed	O
+a	O
+Vero	O
+cell	B-ANAT
+line	I-ANAT
+that	O
+stably	O
+expresses	O
+PEDV	B-PRGE
+ORF3	I-PRGE
+gene	I-PRGE
+.	O
+
+The	O
+index	O
+case	O
+was	O
+a	O
+35	O
+-	O
+yr	O
+-	O
+old	O
+man	B-CHED
+who	O
+had	O
+vigorous	O
+coughing	B-DISO
+while	O
+staying	O
+at	O
+the	O
+ER	O
+for	O
+58	O
+hr	O
+.	O
+
+Similarly	O
+,	O
+neurogenic	B-DISO
+shock	I-DISO
+is	O
+a	O
+known	O
+complication	B-DISO
+of	O
+spinal	B-ANAT
+cord	I-ANAT
+injury	O
+reported	O
+incidence	O
+is	O
+more	O
+than	O
+20	O
+%	O
+in	O
+isolated	O
+upper	O
+cervical	B-ANAT
+spinal	O
+injury	O
+.	O
+
+We	O
+report	O
+a	O
+case	O
+of	O
+high	O
+spinal	O
+AVM	O
+rupture	O
+presenting	O
+as	O
+SM	O
+,	O
+NPE	O
+,	O
+and	O
+neurogenic	B-DISO
+shock	I-DISO
+.	O
+
+CONCLUSIONS	O
+:	O
+There	O
+were	O
+many	O
+important	O
+additions	O
+to	O
+the	O
+critical	O
+care	O
+pharmacotherapy	O
+literature	O
+in	O
+2014	O
+,	O
+including	O
+a	O
+joint	B-ANAT
+guideline	O
+for	O
+the	O
+management	O
+of	O
+AF	O
+and	O
+reports	O
+of	O
+clinical	O
+trials	O
+.	O
+
+ABSTRACT	O
+:	O
+Infectious	B-DISO
+diseases	I-DISO
+are	O
+still	O
+among	O
+the	O
+leading	O
+causes	O
+of	O
+death	O
+worldwide	O
+due	O
+to	O
+their	O
+persistence	O
+,	O
+emergence	O
+,	O
+and	O
+reemergence	O
+.	O
+
+TITLE	O
+:	O
+Structure	O
+-	O
+based	O
+virtual	O
+screening	O
+and	O
+experimental	O
+validation	O
+of	O
+the	O
+discovery	O
+of	O
+inhibitors	B-CHED
+targeted	O
+towards	O
+the	O
+human	B-PRGE
+coronavirus	I-PRGE
+nucleocapsid	B-COMP
+protein	B-CHED
+.	O
+
+ABSTRACT	O
+:	O
+Nucleocapsid	B-PRGE
+protein	B-CHED
+(	O
+NP	O
+),	O
+an	O
+essential	O
+RNA	O
+-	O
+binding	B-FUNC
+viral	O
+protein	B-CHED
+in	O
+human	B-SPEC
+coronavirus	I-SPEC
+(	O
+CoV	O
+)-	O
+infected	O
+cells	B-COMP
+,	O
+is	O
+required	O
+for	O
+the	O
+replication	O
+and	O
+transcription	B-PROC
+of	O
+viral	O
+RNA	O
+.	O
+
+Fluorescence	O
+titration	O
+and	O
+X	O
+-	O
+ray	B-SPEC
+crystallography	O
+studies	O
+indicated	O
+that	O
+H3	O
+antagonizes	O
+the	O
+binding	B-FUNC
+between	O
+HCoV	B-SPEC
+-	I-SPEC
+OC43	I-SPEC
+NP	O
+and	O
+RNA	O
+by	O
+interacting	O
+with	O
+the	O
+N	O
+-	O
+terminal	O
+domain	O
+of	O
+the	O
+NP	O
+.	O
+
+The	O
+positive	O
+detection	O
+rate	O
+of	O
+single	O
+MMPs	O
+-	O
+and	O
+duplex	O
+MMPs	O
+-	O
+based	O
+duplex	O
+UNDP	O
+-	O
+PCR	O
+was	O
+identical	O
+,	O
+with	O
+29	O
+.	O
+6	O
+%	O
+for	O
+PCV2	O
+,	O
+9	O
+.	O
+3	O
+%	O
+for	O
+TGEV	B-SPEC
+and	O
+3	O
+.	O
+7	O
+%	O
+for	O
+PCV2	O
+and	O
+TGEV	B-SPEC
+mixed	B-DISO
+infection	I-DISO
+.	O
+
+Using	O
+a	O
+molecular	O
+cDNA	O
+infectious	B-DISO
+clone	O
+to	O
+generate	O
+a	O
+corresponding	O
+recombinant	O
+virus	B-SPEC
+,	O
+we	O
+show	O
+for	O
+the	O
+first	O
+time	O
+that	O
+such	O
+point	B-PROC
+mutation	I-PROC
+in	O
+the	O
+HCoV	B-PRGE
+-	I-PRGE
+OC43	I-PRGE
+S	I-PRGE
+glycoprotein	B-CHED
+creates	O
+a	O
+functional	O
+cleavage	B-PROC
+site	O
+between	O
+the	O
+S1	O
+and	O
+S2	O
+portions	O
+of	O
+the	O
+S	B-PRGE
+protein	I-PRGE
+.	O
+
+While	O
+the	O
+corresponding	O
+recombinant	O
+virus	B-SPEC
+retained	O
+its	O
+neuroinvasive	O
+properties	O
+,	O
+this	O
+mutation	O
+led	O
+to	O
+decreased	O
+neurovirulence	O
+while	O
+potentially	O
+modifying	O
+the	O
+mode	O
+of	O
+virus	B-SPEC
+spread	O
+,	O
+likely	O
+leading	O
+to	O
+a	O
+limited	O
+dissemination	O
+within	O
+the	O
+CNS	B-CHED
+.	O
+
+They	O
+are	O
+characterized	O
+by	O
+a	O
+pseudocyclic	O
+backbone	B-ANAT
+with	O
+two	O
+to	O
+four	O
+prolines	O
+and	O
+three	O
+disulfides	B-CHED
+arranged	O
+in	O
+a	O
+knotted	O
+motif	O
+.	O
+
+However	O
+,	O
+a	O
+strategic	O
+early	O
+therapeutic	O
+approach	O
+on	O
+ICU	O
+admission	O
+might	O
+try	O
+to	O
+prevent	O
+the	O
+progress	O
+of	O
+the	O
+acute	O
+disease	O
+towards	O
+chronic	O
+critical	B-DISO
+illness	I-DISO
+.	O
+
+ABSTRACT	O
+:	O
+The	O
+emergence	O
+of	O
+severe	O
+acute	O
+respiratory	O
+syndrome	O
+coronavirus	B-SPEC
+(	O
+SARS	B-DISO
+-	O
+CoV	O
+)	O
+and	O
+Middle	O
+East	O
+respiratory	O
+syndrome	B-DISO
+(	O
+MERS	O
+)-	O
+CoV	O
+underscores	O
+the	O
+threat	O
+of	O
+cross	O
+-	O
+species	B-SPEC
+transmission	O
+events	O
+leading	O
+to	O
+outbreaks	O
+in	O
+humans	B-SPEC
+.	O
+
+Evaluation	O
+of	O
+available	O
+SARS	B-DISO
+-	O
+based	O
+immune	O
+-	O
+therapeutic	O
+and	O
+prophylactic	O
+modalities	O
+revealed	O
+poor	O
+efficacy	O
+;	O
+both	O
+monoclonal	O
+antibody	B-COMP
+and	O
+vaccine	O
+approaches	O
+failed	O
+to	O
+neutralize	O
+and	O
+protect	O
+from	O
+infection	B-DISO
+with	O
+CoVs	O
+using	O
+the	O
+novel	O
+spike	O
+protein	B-CHED
+.	O
+
+Our	O
+work	O
+suggests	O
+a	O
+potential	O
+risk	O
+of	O
+SARS	B-DISO
+-	O
+CoV	O
+re	O
+-	O
+emergence	O
+from	O
+viruses	B-SPEC
+currently	O
+circulating	O
+in	O
+bat	B-ENZY
+populations	O
+.	O
+
+The	O
+recent	O
+outbreak	O
+of	O
+MERS	O
+coronavirus	B-SPEC
+(	O
+MERS	O
+-	O
+CoV	O
+)	O
+infection	B-DISO
+has	O
+led	O
+to	O
+1	O
+338	O
+laboratory	O
+-	O
+confirmed	O
+cases	O
+in	O
+26	O
+countries	O
+worldwide	O
+as	O
+reported	O
+till	O
+19	O
+June	O
+,	O
+2015	O
+.	O
+
+Enveloped	O
+viruses	B-SPEC
+are	O
+often	O
+susceptible	O
+to	O
+environmental	O
+stresses	O
+,	O
+but	O
+the	O
+human	B-SPEC
+coronaviruses	O
+responsible	O
+for	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+(	O
+SARS	B-DISO
+)	O
+and	O
+Middle	O
+East	O
+respiratory	O
+syndrome	B-DISO
+(	O
+MERS	O
+)	O
+have	O
+recently	O
+caused	O
+increasing	O
+concern	O
+of	O
+contact	O
+transmission	O
+during	O
+outbreaks	O
+.	O
+
+However	O
+,	O
+rapid	O
+inactivation	B-DISO
+,	O
+irreversible	O
+destruction	O
+of	O
+viral	O
+RNA	O
+,	O
+and	O
+massive	O
+structural	O
+damage	O
+were	O
+observed	O
+in	O
+coronavirus	B-SPEC
+exposed	O
+to	O
+copper	B-CHED
+and	O
+copper	B-CHED
+alloy	O
+surfaces	O
+.	O
+
+Pulmonary	B-DISO
+embolism	I-DISO
+,	O
+pneumothorax	B-DISO
+and	O
+deep	B-DISO
+venous	B-ANAT
+thrombosis	I-DISO
+were	O
+identified	O
+based	O
+on	O
+imaging	O
+results	O
+.	O
+
+ABSTRACT	O
+:	O
+Flexible	O
+bronchoscopy	O
+is	O
+essential	O
+for	O
+appropriate	O
+care	O
+during	O
+mechanical	O
+ventilation	O
+,	O
+but	O
+can	O
+significantly	O
+affect	O
+mechanical	O
+ventilation	O
+of	O
+the	O
+lungs	B-ANAT
+,	O
+particularly	O
+for	O
+patients	O
+with	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+.	O
+
+Immediately	O
+following	O
+the	O
+insertion	O
+of	O
+the	O
+bronchoscope	O
+into	O
+the	O
+tracheal	O
+tube	O
+,	O
+either	O
+minute	O
+ventilation	O
+decreased	O
+significantly	O
+,	O
+or	O
+positive	O
+end	B-PROC
+-	I-PROC
+expiratory	I-PROC
+pressure	O
+increased	O
+substantially	O
+,	O
+according	O
+to	O
+the	O
+setting	O
+of	O
+the	O
+inspiratory	B-PROC
+pressure	O
+limit	O
+.	O
+
+The	O
+increase	O
+in	O
+end	B-PROC
+-	I-PROC
+expiratory	I-PROC
+pressure	O
+led	O
+to	O
+an	O
+equivalent	O
+increase	O
+in	O
+the	O
+plateau	O
+pressure	O
+,	O
+and	O
+lung	B-ANAT
+-	O
+protective	O
+ventilation	O
+was	O
+significantly	O
+altered	O
+during	O
+the	O
+procedure	O
+.	O
+
+One	O
+hundred	O
+and	O
+twenty	O
+cats	B-SPEC
+met	B-CHED
+the	O
+inclusion	O
+criteria	O
+.	O
+
+Neoplasia	B-DISO
+was	O
+diagnosed	O
+in	O
+six	O
+cats	B-SPEC
+(	O
+5	O
+.	O
+0	O
+%).	O
+
+Because	O
+of	O
+the	O
+high	O
+prevalence	O
+of	O
+FIP	B-DISO
+,	O
+young	O
+cats	B-SPEC
+with	O
+uveitis	B-DISO
+should	O
+be	O
+evaluated	O
+for	O
+hyperglobulinemia	O
+and	O
+FCoV	O
+serology	O
+should	O
+be	O
+performed	O
+as	O
+minimal	O
+diagnostics	O
+.	O
+
+The	O
+data	O
+demonstrate	O
+the	O
+presence	O
+of	O
+APC	B-COMP
+capable	O
+of	O
+activating	O
+SR	O
+T	B-ANAT
+cells	I-ANAT
+in	O
+both	O
+draining	O
+lymph	B-ANAT
+nodes	I-ANAT
+and	O
+the	O
+CNS	B-CHED
+temporally	O
+correlating	O
+with	O
+overt	O
+demyelination	B-DISO
+.	O
+
+We	O
+applied	O
+no	O
+language	O
+constraints	O
+,	O
+and	O
+we	O
+reran	O
+the	O
+searches	O
+in	O
+CENTRAL	O
+,	O
+MEDLINE	O
+,	O
+EMBASE	O
+,	O
+CINAHL	O
+and	O
+LILACS	B-SPEC
+in	O
+June	O
+2015	O
+.	O
+
+Reporting	O
+of	O
+arrhythmias	B-DISO
+was	O
+reduced	O
+with	O
+PP	O
+,	O
+with	O
+an	O
+RR	O
+of	O
+0	O
+.	O
+64	O
+(	O
+95	O
+%	O
+CI	O
+0	O
+.	O
+47	O
+to	O
+0	O
+.	O
+87	O
+).	O
+
+ABSTRACT	O
+:	O
+Infectious	O
+disease	O
+outbreaks	O
+and	O
+epidemics	O
+such	O
+as	O
+those	O
+due	O
+to	O
+SARS	B-DISO
+,	O
+influenza	B-DISO
+,	O
+measles	B-PATH
+,	O
+tuberculosis	B-PATH
+,	O
+and	O
+Middle	O
+East	O
+respiratory	O
+syndrome	B-DISO
+coronavirus	B-SPEC
+have	O
+raised	O
+concern	O
+about	O
+the	O
+airborne	O
+transmission	O
+of	O
+pathogens	O
+in	O
+indoor	O
+environments	O
+.	O
+
+Blood	B-ANAT
+viral	O
+RNA	O
+does	O
+not	O
+seem	O
+to	O
+be	O
+infectious	B-DISO
+.	O
+
+Six	O
+oleic	B-CHED
+acid	I-CHED
+-	O
+injured	O
+pigs	B-SPEC
+were	O
+ventilated	O
+at	O
+positive	O
+end	B-PROC
+-	I-PROC
+expiratory	I-PROC
+pressure	O
+(	O
+PEEP	B-CHED
+)	O
+0	O
+and	O
+10	O
+cm	O
+H2O	B-CHED
+before	O
+and	O
+after	O
+a	O
+recruitment	B-DISO
+maneuver	O
+(	O
+PEEP	B-CHED
+=	O
+20	O
+cm	O
+H2O	B-CHED
+).	O
+
+In	O
+addition	O
+,	O
+six	O
+patients	O
+with	O
+moderate	O
+-	O
+to	O
+-	O
+severe	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+were	O
+ventilated	O
+with	O
+three	O
+strategies	O
+(	O
+peak	O
+inspiratory	B-PROC
+pressure	O
+/	O
+PEEP	B-CHED
+:	O
+20	O
+/	O
+8	O
+,	O
+32	O
+/	O
+8	O
+,	O
+and	O
+32	O
+/	O
+20	O
+cm	O
+H2O	B-CHED
+).	O
+
+In	O
+the	O
+animal	B-SPEC
+model	O
+,	O
+recruitment	B-DISO
+caused	O
+a	O
+significant	O
+decrease	O
+in	O
+dynamic	O
+strain	O
+(	O
+from	O
+[	O
+mean	O
+±	O
+SD	O
+]	O
+0	O
+.	O
+4	O
+±	O
+0	O
+.	O
+12	O
+to	O
+0	O
+.	O
+25	O
+±	O
+0	O
+.	O
+07	O
+,	O
+P	O
+<	O
+0	O
+.	O
+01	O
+),	O
+while	O
+increasing	O
+the	O
+static	O
+component	O
+.	O
+
+A	O
+79	O
+-	O
+year	O
+-	O
+old	O
+women	O
+was	O
+hospitalized	O
+complaining	O
+of	O
+right	O
+eyelid	B-DISO
+swelling	I-DISO
+,	O
+severe	O
+hyperemia	B-DISO
+and	O
+purulent	O
+conjunctival	B-DISO
+discharge	I-DISO
+in	O
+the	O
+right	B-ANAT
+eye	I-ANAT
+.	O
+
+Because	O
+diffusion	O
+-	O
+weighted	O
+magnetic	O
+resonance	O
+imaging	O
+(	O
+MRI	O
+)	O
+findings	O
+demonstrated	O
+right	O
+optic	B-DISO
+neuritis	I-DISO
+and	O
+ventriculitis	B-DISO
+,	O
+enucleation	B-PROC
+of	O
+her	O
+right	B-ANAT
+eye	I-ANAT
+was	O
+performed	O
+based	O
+on	O
+the	O
+diagnosis	O
+of	O
+pyogenic	O
+ventriculitis	O
+via	O
+the	O
+optic	B-ANAT
+nerve	I-ANAT
+.	O
+
+CONCLUSIONS	O
+:	O
+Severe	O
+bacterial	B-DISO
+endophthalmitis	I-DISO
+may	O
+cause	O
+intracranial	B-ANAT
+infection	B-DISO
+via	O
+the	O
+optic	B-ANAT
+nerve	I-ANAT
+.	O
+
+In	O
+this	O
+article	O
+,	O
+we	O
+review	O
+the	O
+evidence	O
+supporting	O
+a	O
+bat	B-ENZY
+/	O
+camel	B-SPEC
+origin	O
+of	O
+human	B-SPEC
+MERS	O
+-	O
+CoV	O
+infection	B-DISO
+and	O
+current	O
+knowledge	O
+on	O
+the	O
+modes	O
+of	O
+camel	B-SPEC
+-	O
+to	O
+-	O
+human	B-SPEC
+transmission	O
+of	O
+MERS	O
+-	O
+CoV	O
+.	O
+
+TITLE	O
+:	O
+Structural	O
+basis	O
+for	O
+the	O
+development	B-PROC
+of	O
+SARS	B-PRGE
+3CL	I-PRGE
+protease	B-PROC
+inhibitors	I-PROC
+from	O
+a	O
+peptide	B-CHED
+mimic	O
+to	O
+an	O
+aza	O
+-	O
+decaline	O
+scaffold	O
+.	O
+
+In	O
+this	O
+report	O
+,	O
+we	O
+reveal	O
+two	O
+crystal	B-ANAT
+structures	O
+of	O
+SARS	B-PRGE
+3CL	I-PRGE
+(	I-PRGE
+pro	B-CHED
+)	I-PRGE
+complexed	O
+with	O
+two	O
+new	O
+inhibitors	B-CHED
+based	O
+on	O
+our	O
+previous	O
+work	O
+.	O
+
+Thus	O
+,	O
+starting	O
+from	O
+a	O
+substrate	O
+mimic	O
+inhibitor	B-CHED
+,	O
+a	O
+design	O
+for	O
+a	O
+central	O
+scaffold	O
+for	O
+a	O
+low	O
+molecular	O
+weight	O
+inhibitor	B-CHED
+was	O
+evaluated	O
+to	O
+develop	O
+a	O
+further	O
+potent	O
+inhibitor	B-CHED
+.	O
+
+[(	O
+18	O
+)	O
+F	O
+]-	O
+FDG	O
+uptake	O
+is	O
+increased	O
+in	O
+activated	O
+immune	O
+cells	B-COMP
+in	O
+response	B-PROC
+to	I-PROC
+virus	I-PROC
+entry	O
+and	O
+can	O
+be	O
+localized	O
+by	O
+PET	O
+imaging	O
+.	O
+
+TITLE	O
+:	O
+Intra	B-DISO
+-	I-DISO
+abdominal	I-DISO
+hypertension	I-DISO
+complicating	O
+pancreatitis	B-DISO
+-	O
+induced	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+in	O
+three	O
+patients	O
+on	O
+extracorporeal	O
+membrane	B-COMP
+oxygenation	B-PROC
+.	O
+
+No	O
+surgical	O
+interventions	O
+were	O
+taken	O
+to	O
+relieve	O
+abdominal	B-DISO
+compartment	I-DISO
+syndrome	I-DISO
+.	O
+
+Monitoring	O
+intraabdominal	O
+pressure	O
+is	O
+a	O
+valuable	O
+adjunct	O
+to	O
+decision	O
+making	O
+while	O
+caring	O
+for	O
+these	O
+high	O
+-	O
+risk	O
+critically	B-DISO
+ill	I-DISO
+patients	O
+.	O
+
+33	O
+out	O
+of	O
+81	O
+interactions	O
+were	O
+identified	O
+by	O
+BiFC	O
+,	O
+much	O
+more	O
+than	O
+that	O
+identified	O
+by	O
+the	O
+yeast	B-SPEC
+two	O
+-	O
+hybrid	O
+(	O
+Y2H	O
+)	O
+system	O
+.	O
+
+We	O
+have	O
+developed	O
+a	O
+method	O
+for	O
+rapid	O
+de	O
+novo	O
+assembly	O
+of	O
+the	O
+novel	O
+influenza	B-PATH
+A	I-PATH
+H7N9	O
+virus	B-SPEC
+genome	O
+directly	O
+from	O
+the	O
+tracheal	B-ANAT
+aspirate	I-ANAT
+of	O
+a	O
+patient	O
+using	O
+semiconductor	O
+sequencer	O
+without	O
+culture	O
+and	O
+prior	O
+sequence	O
+information	O
+.	O
+
+TITLE	O
+:	O
+Glial	B-ANAT
+response	O
+in	O
+the	O
+central	B-ANAT
+nervous	I-ANAT
+system	I-ANAT
+of	O
+cats	B-SPEC
+with	O
+feline	B-DISO
+infectious	I-DISO
+peritonitis	I-DISO
+.	O
+
+A	O
+microglial	B-ANAT
+response	O
+was	O
+present	O
+only	O
+in	O
+severe	O
+lesions	O
+,	O
+and	O
+RCA	B-PRGE
+-	I-PRGE
+I	I-PRGE
+expression	B-PROC
+was	O
+detected	O
+primarily	O
+in	O
+gitter	O
+cells	B-COMP
+and	O
+resting	B-ANAT
+microglia	B-ANAT
+.	O
+
+RESULTS	O
+:	O
+An	O
+important	O
+astrocytic	B-ANAT
+response	O
+in	O
+many	O
+areas	O
+of	O
+the	O
+CNS	B-CHED
+of	O
+all	O
+cats	B-SPEC
+,	O
+including	O
+the	O
+periventricular	O
+areas	O
+of	O
+lateral	B-ANAT
+ventricles	I-ANAT
+and	O
+fourth	B-ANAT
+ventricle	I-ANAT
+,	O
+the	O
+molecular	B-ANAT
+layer	I-ANAT
+of	I-ANAT
+the	I-ANAT
+cerebellum	I-ANAT
+and	O
+cerebral	B-ANAT
+cortex	I-ANAT
+,	O
+was	O
+visualized	O
+.	O
+
+TITLE	O
+:	O
+Kinetics	O
+of	O
+Serologic	O
+Responses	O
+to	O
+MERS	O
+Coronavirus	B-DISO
+Infection	I-DISO
+in	O
+Humans	B-SPEC
+,	O
+South	O
+Korea	O
+.	O
+
+Delayed	O
+antibody	B-PROC
+responses	I-PROC
+with	O
+the	O
+neutralization	O
+test	O
+were	O
+associated	O
+with	O
+more	O
+severe	O
+disease	O
+.	O
+
+Full	O
+genome	O
+sequencing	O
+showed	O
+the	O
+virus	B-SPEC
+to	O
+be	O
+closely	O
+related	O
+to	O
+strains	O
+reported	O
+from	O
+North	O
+America	O
+,	O
+showing	O
+a	O
+sequence	O
+identity	O
+of	O
+up	O
+to	O
+99	O
+.	O
+8	O
+%.	O
+
+Concurrent	O
+hepatobiliary	B-ANAT
+dysfunction	O
+/	O
+disseminated	B-DISO
+intravascular	I-DISO
+coagulation	I-DISO
+was	O
+noted	O
+in	O
+43	O
+patients	O
+(	O
+5	O
+.	O
+6	O
+%	O
+of	O
+total	O
+;	O
+18	O
+-	O
+75	O
+years	O
+old	O
+;	O
+47	O
+%	O
+women	O
+).	O
+
+ABSTRACT	O
+:	O
+Recently	O
+several	O
+infectious	O
+agents	O
+with	O
+a	O
+zoonotic	O
+potential	O
+have	O
+been	O
+detected	O
+in	O
+different	O
+bat	B-ENZY
+species	B-SPEC
+.	O
+
+In	O
+initial	O
+studies	O
+,	O
+the	O
+tetrahydroisoquinoline	O
+compounds	O
+demonstrate	O
+sub	O
+-	O
+nanomolar	O
+activity	O
+in	O
+a	O
+HIV	B-SPEC
+-	I-SPEC
+1	I-SPEC
+pseudotype	O
+viral	B-DISO
+infection	I-DISO
+assay	O
+used	O
+as	O
+the	O
+initial	O
+screen	O
+for	O
+inhibitory	O
+activity	O
+.	O
+
+The	O
+region	O
+of	O
+sequence	O
+containing	O
+the	O
+S	O
+gene	O
+was	O
+unique	O
+in	O
+grouping	O
+all	O
+turkey	B-SPEC
+and	O
+guinea	B-SPEC
+fowl	I-SPEC
+coronaviruses	O
+together	O
+,	O
+separating	O
+them	O
+from	O
+IBVs	O
+.	O
+
+Here	O
+,	O
+we	O
+investigated	O
+the	O
+dissemination	O
+of	O
+PEDV	B-SPEC
+infection	B-DISO
+in	O
+two	O
+areas	O
+located	O
+in	O
+the	O
+regions	O
+with	O
+the	O
+highest	O
+swine	B-SPEC
+density	O
+in	O
+the	O
+country	O
+(	O
+Southeast	O
+and	O
+Midwest	O
+)	O
+including	O
+more	O
+than	O
+2400	O
+farms	O
+.	O
+
+The	O
+protocol	O
+outlined	O
+here	O
+represents	O
+a	O
+rapid	O
+and	O
+reliable	O
+method	O
+for	O
+the	O
+generation	O
+of	O
+high	O
+-	O
+titre	O
+pseudotype	O
+viral	B-COMP
+particles	I-COMP
+with	O
+the	O
+MERS	B-PRGE
+-	I-PRGE
+CoV	I-PRGE
+spike	I-PRGE
+protein	B-CHED
+on	O
+a	O
+lentiviral	O
+core	O
+,	O
+and	O
+is	O
+adapted	O
+from	O
+previously	O
+published	O
+protocols	O
+.	O
+
+This	O
+protocol	O
+has	O
+a	O
+number	O
+of	O
+advantages	O
+including	O
+:•	O
+Use	O
+of	O
+readily	O
+available	O
+reagents	B-CHED
+.•	O
+Consistent	O
+,	O
+high	O
+virus	B-SPEC
+titres	O
+.•	O
+Rapid	O
+generation	O
+of	O
+novel	O
+glycoproteins	B-CHED
+for	O
+research	O
+into	O
+strain	O
+variation	O
+.	O
+
+Logistic	O
+regression	O
+analysis	O
+was	O
+used	O
+to	O
+identify	O
+factors	O
+associated	O
+with	O
+PED	O
+infection	B-DISO
+.	O
+
+PED	O
+in	O
+locally	O
+-	O
+exposed	O
+farms	O
+was	O
+associated	O
+(	O
+P	O
+<	O
+0	O
+.	O
+05	O
+)	O
+with	O
+increased	O
+farm	O
+size	O
+(	O
+in	O
+100	O
+pig	B-SPEC
+increments	O
+),	O
+shorter	O
+distances	O
+to	O
+the	O
+closest	O
+PED	O
+-	O
+positive	O
+farm	O
+(	O
+less	O
+than1	O
+,	O
+001m	O
+),	O
+and	O
+a	O
+disinfectant	B-CHED
+contact	O
+time	O
+of	O
+less	O
+than	O
+20min	O
+.	O
+
+In	O
+this	O
+study	O
+,	O
+3	O
+-	O
+4	O
+day	O
+-	O
+old	O
+conventional	O
+suckling	O
+piglets	O
+were	O
+inoculated	O
+with	O
+S	O
+-	O
+INDEL	B-PROC
+PEDV	B-SPEC
+Iowa106	O
+(	O
+4	O
+pig	B-SPEC
+litters	O
+)	O
+to	O
+study	O
+its	O
+virulence	B-PROC
+.	O
+
+All	O
+S	O
+-	O
+INDEL	B-PROC
+Iowa106	O
+-	O
+and	O
+the	O
+original	O
+US	O
+PC21A	O
+-	O
+inoculated	O
+piglets	O
+developed	O
+diarrhea	B-DISO
+.	O
+
+Two	O
+of	O
+four	O
+S	O
+-	O
+INDEL	B-PROC
+Iowa106	O
+-	O
+infected	O
+sows	O
+and	O
+the	O
+original	O
+PC21A	O
+-	O
+infected	O
+sow	O
+showed	O
+anorexia	B-DISO
+and	O
+watery	B-DISO
+diarrhea	I-DISO
+for	O
+1	O
+-	O
+4	O
+days	O
+.	O
+
+In	O
+addition	O
+,	O
+almost	O
+half	O
+of	O
+the	O
+population	O
+remains	O
+unaware	O
+that	O
+bats	B-SPEC
+and	O
+camels	B-SPEC
+are	O
+the	O
+most	O
+likely	O
+sources	O
+of	O
+the	O
+virus	B-SPEC
+.	O
+
+TITLE	O
+:	O
+Influenza	B-DISO
+virus	I-SPEC
+emitted	O
+by	O
+naturally	O
+-	O
+infected	O
+hosts	B-COMP
+in	O
+a	O
+healthcare	O
+setting	O
+.	O
+
+This	O
+pilot	O
+study	O
+highlights	O
+the	O
+feasibility	O
+and	O
+importance	O
+of	O
+conducting	B-PROC
+a	O
+larger	O
+-	O
+scale	O
+study	O
+to	O
+identify	O
+determinants	O
+of	O
+exposure	O
+and	O
+transmission	O
+from	O
+patient	O
+to	O
+HCW	O
+.	O
+
+This	O
+suggests	O
+that	O
+there	O
+may	O
+clinically	O
+meaningful	O
+differences	O
+between	O
+patients	O
+with	O
+less	O
+and	O
+more	O
+severe	O
+INH	O
+,	O
+and	O
+that	O
+further	O
+refinement	O
+of	O
+the	O
+grades	O
+0	O
+to	O
+4	O
+AIS	B-DISO
+INH	O
+severity	O
+should	O
+be	O
+subjected	O
+to	O
+additional	O
+investigation	O
+.	O
+
+TITLE	O
+:	O
+Controversies	O
+in	O
+the	O
+Management	O
+of	O
+Severe	O
+ARDS	B-DISO
+:	O
+
+PEEP	B-CHED
+titration	O
+using	O
+transpulmonary	O
+pressure	O
+estimations	O
+assisted	O
+by	O
+esophageal	O
+manometry	O
+has	O
+been	O
+shown	O
+to	O
+result	O
+in	O
+a	O
+substantial	O
+improvement	O
+in	O
+oxygenation	B-PROC
+.	O
+
+Extracorporeal	O
+membrane	B-COMP
+oxygenation	B-PROC
+(	O
+ECMO	O
+)	O
+has	O
+been	O
+used	O
+increasingly	O
+since	O
+the	O
+mid	O
+-	O
+2000s	O
+in	O
+part	O
+due	O
+to	O
+the	O
+H1N1	O
+epidemic	O
+.	O
+
+TITLE	O
+:	O
+Epidemiology	O
+of	O
+11	O
+respiratory	O
+RNA	O
+viruses	B-SPEC
+in	O
+a	O
+cohort	O
+of	O
+hospitalized	O
+children	O
+in	O
+Riyadh	O
+,	O
+Saudi	O
+Arabia	O
+.	O
+
+The	O
+children	O
+all	O
+fit	B-DISO
+the	O
+defined	O
+clinical	O
+criteria	O
+for	O
+febrile	B-DISO
+infection	I-DISO
+-	O
+related	O
+epilepsy	B-DISO
+syndrome	B-DISO
+;	O
+all	O
+had	O
+a	O
+history	O
+of	O
+normal	O
+psychomotor	B-PROC
+development	I-PROC
+who	O
+presented	O
+with	O
+acute	O
+-	O
+onset	O
+catastrophic	O
+partial	O
+status	B-DISO
+epilepticus	I-DISO
+associated	O
+with	O
+a	O
+febrile	B-DISO
+illness	I-DISO
+or	O
+unspecific	O
+infectious	B-DISO
+process	I-DISO
+.	O
+
+Ketogenic	B-PROC
+diet	O
+was	O
+initiated	O
+in	O
+four	O
+of	O
+seven	O
+patients	O
+with	O
+limited	O
+response	O
+.	O
+
+Febrile	B-DISO
+infection	I-DISO
+-	O
+related	O
+epilepsy	B-DISO
+syndrome	B-DISO
+is	O
+a	O
+devastating	O
+epilepsy	B-DISO
+syndrome	B-DISO
+of	O
+childhood	O
+without	O
+a	O
+diagnostic	O
+biologic	O
+marker	O
+.	O
+
+TITLE	O
+:	O
+Transmission	O
+of	O
+SARS	B-DISO
+and	O
+MERS	O
+coronaviruses	O
+and	O
+influenza	B-SPEC
+virus	I-SPEC
+in	O
+healthcare	O
+settings	O
+:	O
+the	O
+possible	O
+role	O
+of	O
+dry	O
+surface	O
+contamination	O
+.	O
+
+Infection	B-DISO
+prevention	O
+and	O
+control	O
+implications	O
+include	O
+the	O
+need	O
+for	O
+hand	O
+hygiene	O
+and	O
+personal	O
+protective	O
+equipment	O
+to	O
+minimize	O
+self	O
+-	O
+contamination	O
+and	O
+to	O
+protect	O
+against	O
+inoculation	O
+of	O
+mucosal	B-ANAT
+surfaces	O
+and	O
+the	O
+respiratory	B-ANAT
+tract	I-ANAT
+,	O
+and	O
+enhanced	O
+surface	O
+cleaning	O
+and	O
+disinfection	O
+in	O
+healthcare	O
+settings	O
+.	O
+
+TITLE	O
+:	O
+Dipeptidyl	B-PRGE
+Peptidase	I-PRGE
+4	I-PRGE
+Distribution	O
+in	O
+the	O
+Human	B-SPEC
+Respiratory	B-ANAT
+Tract	I-ANAT
+:	O
+Implications	O
+for	O
+the	O
+Middle	O
+East	O
+Respiratory	O
+Syndrome	O
+.	O
+
+DPP4	B-PRGE
+was	O
+also	O
+found	O
+in	O
+a	O
+subset	O
+of	O
+mononuclear	B-ANAT
+leukocytes	I-ANAT
+and	O
+in	O
+serous	O
+cells	B-COMP
+of	O
+submucosal	O
+glands	B-ANAT
+.	O
+
+We	O
+speculate	O
+that	O
+the	O
+preferential	O
+spatial	O
+localization	B-PROC
+of	O
+DPP4	B-PRGE
+in	O
+alveolar	B-ANAT
+regions	O
+may	O
+explain	O
+why	O
+MERS	O
+is	O
+characterized	O
+by	O
+lower	B-ANAT
+respiratory	I-ANAT
+tract	I-ANAT
+disease	O
+.	O
+
+Preventing	O
+ARDS	O
+as	O
+a	O
+severe	O
+complication	B-DISO
+in	O
+the	O
+cardiovascular	B-ANAT
+surgery	O
+setting	O
+may	O
+help	O
+to	O
+reduce	O
+morbidity	O
+and	O
+mortality	O
+.	O
+
+Especially	O
+,	O
+use	O
+of	O
+low	O
+tidal	O
+volumes	O
+,	O
+avoiding	O
+of	O
+fluid	B-DISO
+overload	I-DISO
+and	O
+restrictive	O
+blood	B-ANAT
+transfusion	O
+regimes	O
+may	O
+help	O
+to	O
+prevent	O
+ARDS	B-DISO
+.	O
+
+Assessments	O
+of	O
+viral	O
+protein	B-CHED
+and	O
+RNA	O
+levels	O
+in	O
+infected	O
+cells	B-COMP
+showed	O
+that	O
+both	O
+viruses	B-SPEC
+were	O
+impaired	B-DISO
+in	O
+their	O
+ability	O
+to	O
+replicate	O
+in	O
+these	O
+cells	B-COMP
+.	O
+
+CONCLUSIONS	O
+:	O
+A	O
+serious	O
+alveolar	B-ANAT
+hemorrhage	B-DISO
+in	O
+a	O
+young	O
+patient	O
+should	O
+raise	O
+suspicion	O
+of	O
+silicone	O
+embolism	B-DISO
+syndrome	B-DISO
+,	O
+especially	O
+if	O
+there	O
+are	O
+cutaneous	O
+lesions	O
+compatible	O
+with	O
+injections	O
+.	O
+
+TITLE	O
+:	O
+Sensitivity	O
+of	O
+porcine	B-SPEC
+epidemic	I-SPEC
+diarrhea	I-SPEC
+virus	I-SPEC
+(	O
+PEDV	B-SPEC
+)	O
+to	O
+pH	O
+and	O
+heat	O
+treatment	O
+in	O
+the	O
+presence	O
+or	O
+absence	O
+of	O
+porcine	O
+plasma	B-ANAT
+.	O
+
+TITLE	O
+:	O
+Retrospective	O
+testing	O
+and	O
+case	O
+series	O
+study	O
+of	O
+porcine	B-SPEC
+delta	O
+coronavirus	B-SPEC
+in	O
+U	O
+.	O
+S	O
+.	O
+swine	B-SPEC
+herds	O
+.	O
+
+The	O
+average	O
+number	O
+of	O
+animals	B-SPEC
+on	O
+each	O
+operation	O
+exhibiting	O
+clinical	O
+signs	O
+(	O
+morbidity	O
+)	O
+and	O
+the	O
+average	O
+number	O
+of	O
+case	O
+fatalities	O
+was	O
+greatest	O
+for	O
+suckling	O
+and	O
+weaned	B-PROC
+pigs	B-SPEC
+.	O
+
+The	O
+number	O
+of	O
+confirmed	O
+influenza	B-DISO
+cases	O
+varied	O
+from	O
+1	O
+,	O
+210	O
+in	O
+2009	O
+/	O
+10	O
+to	O
+321	O
+in	O
+2011	O
+/	O
+12	O
+.	O
+
+ABSTRACT	O
+:	O
+Influenza	B-DISO
+A	I-PATH
+and	O
+B	O
+,	O
+and	O
+many	O
+unrelated	O
+viruses	B-SPEC
+including	O
+rhinovirus	B-SPEC
+,	O
+RSV	B-SPEC
+,	O
+adenovirus	B-DISO
+,	O
+metapneumovirus	B-SPEC
+and	O
+coronavirus	B-SPEC
+share	O
+the	O
+same	O
+seasonality	O
+,	O
+since	O
+these	O
+viral	O
+acute	O
+respiratory	B-DISO
+tract	I-DISO
+infections	I-DISO
+(	O
+vARIs	O
+)	O
+are	O
+much	O
+more	O
+common	O
+in	O
+winter	O
+than	O
+summer	O
+.	O
+
+ABSTRACT	O
+:	O
+Despite	O
+advances	O
+in	O
+management	O
+over	O
+the	O
+last	O
+several	O
+decades	O
+,	O
+sepsis	O
+and	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+(	O
+ARDS	B-DISO
+)	O
+still	O
+remain	O
+major	O
+clinical	O
+challenges	O
+and	O
+the	O
+leading	O
+causes	O
+of	O
+death	B-PROC
+for	O
+patients	O
+in	O
+intensive	O
+care	O
+units	O
+(	O
+ICUs	O
+)	O
+due	O
+to	O
+insufficient	O
+understanding	O
+of	O
+the	O
+pathophysiological	O
+mechanisms	O
+of	O
+these	O
+diseases	O
+.	O
+
+TITLE	O
+:	O
+Genomic	O
+and	O
+evolutionary	O
+inferences	O
+between	O
+American	O
+and	O
+global	O
+strains	O
+of	O
+porcine	B-SPEC
+epidemic	B-DISO
+diarrhea	I-DISO
+virus	I-SPEC
+.	O
+
+We	O
+determined	O
+the	O
+complete	O
+genomes	O
+of	O
+93	O
+PEDV	B-SPEC
+field	O
+samples	O
+from	O
+US	O
+swine	B-SPEC
+and	O
+analyzed	O
+the	O
+data	O
+in	O
+conjunction	O
+with	O
+complete	O
+genome	O
+sequences	O
+available	O
+from	O
+GenBank	O
+(	O
+n	O
+=	O
+126	O
+)	O
+to	O
+determine	O
+the	O
+most	O
+variable	O
+genomic	O
+areas	O
+.	O
+
+These	O
+finding	O
+suggest	O
+that	O
+significant	O
+genetic	O
+events	O
+outside	O
+of	O
+the	O
+spike	O
+region	O
+have	O
+contributed	O
+to	O
+the	O
+evolution	B-PROC
+of	O
+PEDV	B-SPEC
+.	O
+
+This	O
+study	O
+investigated	O
+the	O
+incidence	O
+and	O
+cause	O
+of	O
+pulmonary	B-DISO
+edema	I-DISO
+in	O
+patients	O
+with	O
+SAH	B-CHED
+by	O
+using	O
+hemodynamic	B-PROC
+monitoring	O
+with	O
+PiCCO	O
+-	O
+plus	O
+pulse	B-PROC
+contour	O
+analysis	O
+.	O
+
+In	O
+the	O
+early	O
+phase	O
+(	O
+Days	O
+1	O
+-	O
+5	O
+after	O
+SAH	B-CHED
+),	O
+the	O
+daily	O
+water	B-PROC
+balance	B-CHED
+of	O
+the	O
+PE	O
+group	O
+was	O
+slightly	O
+positive	O
+.	O
+
+Despite	O
+improving	O
+respiratory	B-PROC
+function	I-PROC
+,	O
+the	O
+patient	O
+died	B-PROC
+of	O
+multisystem	B-DISO
+organ	I-DISO
+failure	I-DISO
+on	O
+day	O
+38	O
+of	O
+ECMO	O
+treatment	O
+.	O
+
+Patients	O
+with	O
+ARDS	B-DISO
+should	O
+be	O
+managed	O
+with	O
+low	O
+tidal	O
+volume	O
+ventilation	O
+.	O
+
+Dembo	O
+-	O
+PCR	O
+simultaneously	O
+detects	O
+a	O
+total	O
+of	O
+19	O
+diarrhea	B-DISO
+-	O
+causing	O
+pathogens	O
+,	O
+including	O
+viruses	B-SPEC
+,	O
+bacteria	B-SPEC
+and	O
+protozoa	O
+.	O
+
+A	O
+total	O
+of	O
+8	O
+fecal	B-ANAT
+samples	O
+,	O
+collected	O
+from	O
+6	O
+diarrheic	O
+cattle	B-SPEC
+,	O
+1	O
+diarrheic	O
+calf	B-ANAT
+and	O
+1	O
+healthy	O
+cow	B-SPEC
+,	O
+were	O
+tested	O
+using	O
+Dembo	O
+-	O
+PCR	O
+to	O
+validate	O
+the	O
+assay	O
+'	O
+s	O
+clinical	O
+performance	O
+.	O
+
+The	O
+results	O
+obtained	O
+from	O
+the	O
+pairwise	O
+comparison	O
+and	O
+nucleotide	O
+similarity	O
+showed	O
+that	O
+the	O
+recombination	B-PROC
+breakpoint	O
+was	O
+located	O
+in	O
+the	O
+nsp14	B-PRGE
+gene	I-PRGE
+at	O
+nucleotides	B-CHED
+17055	O
+-	O
+17083	O
+.	O
+
+Our	O
+results	O
+also	O
+indicate	O
+that	O
+the	O
+replicase	B-PRGE
+gene	I-PRGE
+of	O
+IBV	B-SPEC
+isolate	O
+ck	O
+/	O
+CH	O
+/	O
+LGX	O
+/	O
+130530	O
+is	O
+associated	O
+with	O
+viral	O
+pathogenicity	O
+.	O
+
+However	O
+,	O
+pretreatment	O
+of	O
+mice	B-SPEC
+with	O
+imatinib	B-CHED
+increased	O
+lung	B-PRGE
+catalase	B-FUNC
+activity	I-FUNC
+and	O
+decreased	O
+intravenous	O
+LPS	B-DISO
+-	O
+induced	O
+lung	B-ANAT
+oxidant	B-CHED
+injury	O
+as	O
+measured	O
+by	O
+γ	O
+-	O
+H2AX	B-PRGE
+,	O
+a	O
+marker	O
+of	O
+oxidant	B-CHED
+-	O
+induced	O
+DNA	B-DISO
+damage	I-DISO
+,	O
+lung	B-ANAT
+apoptosis	B-PATH
+,	O
+and	O
+pulmonary	B-DISO
+edema	I-DISO
+.	O
+
+Spleen	B-ANAT
+lymphocytes	B-ANAT
+were	O
+collected	O
+from	O
+specific	O
+-	O
+pathogen	O
+free	O
+(	O
+SPF	O
+)	O
+chicken	B-SPEC
+that	O
+had	O
+been	O
+immunized	O
+with	O
+the	O
+S1	B-PRGE
+protein	I-PRGE
+expression	B-PROC
+plasmid	O
+,	O
+pV	O
+-	O
+S1	O
+,	O
+and	O
+were	O
+stimulated	O
+by	O
+the	O
+synthesized	O
+peptides	B-CHED
+.	O
+
+Four	O
+epitopes	O
+(	O
+P8SRIQTATDP	O
+,	O
+P9SRNATGSQP	O
+,	O
+P18GAYAVVNV	O
+,	O
+and	O
+P19SRIQTATQP	O
+)	O
+were	O
+identified	O
+to	O
+stimulate	O
+CD8	B-PRGE
+(+)	O
+T	B-PROC
+cell	I-PROC
+proliferation	B-DISO
+and	O
+IFN	B-PRGE
+-	I-PRGE
+γ	I-PRGE
+secretion	B-PROC
+,	O
+indicating	O
+their	O
+efficacy	O
+as	O
+CTL	B-ANAT
+epitopes	O
+in	O
+chicken	B-SPEC
+.	O
+
+This	O
+study	O
+provides	O
+a	O
+new	O
+method	O
+to	O
+screen	O
+virus	B-SPEC
+CTL	B-ANAT
+epitopes	O
+in	O
+chicken	B-SPEC
+and	O
+to	O
+develop	O
+poly	O
+-	O
+CTL	B-ANAT
+-	O
+epitope	B-CHED
+DNA	O
+vaccines	O
+.	O
+
+In	O
+this	O
+study	O
+,	O
+biochemical	O
+alterations	O
+of	O
+the	O
+lipid	B-CHED
+composition	O
+of	O
+the	O
+lungs	B-ANAT
+were	O
+investigated	O
+as	O
+possible	O
+contributing	O
+factors	O
+to	O
+the	O
+severity	O
+of	O
+murine	B-SPEC
+MA	O
+-	O
+ALI	O
+/	O
+ARDS	B-DISO
+.	O
+
+Chickens	B-SPEC
+primed	O
+or	O
+primed	O
+and	O
+boosted	O
+with	O
+a	O
+Massachusetts	O
+(	O
+Mass	O
+)-	O
+type	O
+attenuated	O
+vaccine	O
+were	O
+subsequently	O
+challenged	O
+with	O
+either	O
+IBV	B-SPEC
+Arkansas	O
+(	O
+Ark	O
+)	O
+or	O
+GA13	O
+-	O
+type	O
+virulent	O
+strains	O
+.	O
+
+This	O
+makes	O
+it	O
+increasingly	O
+difficult	O
+to	O
+prevent	O
+and	O
+control	O
+IBV	B-SPEC
+infections	B-DISO
+,	O
+despite	O
+routine	O
+vaccination	O
+.	O
+
+In	O
+addition	O
+to	O
+commercial	O
+poultry	O
+,	O
+backyard	O
+poultry	O
+and	O
+free	O
+-	O
+ranging	O
+birds	B-SPEC
+may	O
+serve	O
+as	O
+a	O
+'	O
+hub	O
+'	O
+for	O
+ACoV	O
+transmission	O
+within	O
+a	O
+particular	O
+area	O
+.	O
+
+These	O
+birds	B-SPEC
+may	O
+be	O
+capable	O
+of	O
+spreading	O
+viruses	B-SPEC
+,	O
+either	O
+to	O
+areas	O
+of	O
+close	O
+proximity	O
+,	O
+or	O
+to	O
+remote	O
+places	O
+via	O
+migration	B-PROC
+and	O
+trade	O
+.	O
+
+Previous	O
+studies	O
+have	O
+shown	O
+that	O
+MERS	O
+-	O
+CoV	O
+ORF4b	O
+antagonizes	O
+the	O
+early	O
+antiviral	B-PRGE
+alpha	I-PRGE
+/	I-PRGE
+beta	I-PRGE
+interferon	I-PRGE
+(	O
+IFN	B-PRGE
+-	I-PRGE
+α	I-PRGE
+/	I-PRGE
+β	I-PRGE
+)	O
+response	O
+,	O
+which	O
+may	O
+significantly	O
+contribute	O
+to	O
+MERS	O
+-	O
+CoV	O
+pathogenesis	B-DISO
+;	O
+however	O
+,	O
+the	O
+underlying	O
+mechanism	O
+is	O
+poorly	O
+understood	O
+.	O
+
+Further	O
+analysis	O
+showed	O
+that	O
+ORF4b	O
+could	O
+also	O
+inhibit	O
+IRF3	B-PRGE
+and	O
+IRF7	B-PRGE
+-	O
+induced	O
+production	O
+of	O
+IFN	B-PRGE
+-	I-PRGE
+β	I-PRGE
+,	O
+whereas	O
+deletion	O
+of	O
+the	O
+nuclear	O
+localization	B-PROC
+signal	O
+of	O
+ORF4b	O
+abrogated	O
+its	O
+ability	O
+to	O
+inhibit	O
+IRF3	B-PRGE
+and	O
+IRF7	B-PRGE
+-	O
+induced	O
+production	O
+of	O
+IFN	B-PRGE
+-	I-PRGE
+β	I-PRGE
+,	O
+but	O
+not	O
+IFN	B-PRGE
+-	I-PRGE
+β	I-PRGE
+production	O
+induced	O
+by	O
+RIG	B-PRGE
+-	I-PRGE
+I	I-PRGE
+,	O
+MDA5	B-PRGE
+,	O
+MAVS	B-PRGE
+,	O
+IKKε	O
+,	O
+and	O
+TBK	O
+-	O
+1	O
+,	O
+suggesting	O
+that	O
+ORF4b	O
+could	O
+inhibit	O
+the	O
+induction	O
+of	O
+IFN	B-PRGE
+-	I-PRGE
+β	I-PRGE
+in	O
+both	O
+the	O
+cytoplasm	B-COMP
+and	O
+nucleus	B-COMP
+.	O
+
+MERS	O
+-	O
+CoV	O
+ORF4b	O
+antagonizes	O
+the	O
+early	O
+antiviral	B-PROC
+response	I-PROC
+,	O
+which	O
+may	O
+contribute	O
+to	O
+MERS	O
+-	O
+CoV	O
+pathogenesis	B-DISO
+.	O
+
+Here	O
+,	O
+we	O
+report	O
+the	O
+identification	O
+of	O
+the	O
+interferon	B-PRGE
+(	O
+IFN	B-PRGE
+)	O
+antagonism	O
+mechanism	O
+of	O
+MERS	O
+-	O
+CoV	O
+ORF4b	O
+.	O
+
+ABSTRACT	O
+:	O
+Plant	B-SPEC
+molecular	O
+farming	O
+(	O
+PMF	O
+),	O
+defined	O
+as	O
+the	O
+practice	O
+of	O
+using	O
+plants	O
+to	O
+produce	O
+human	B-SPEC
+therapeutic	O
+proteins	B-CHED
+,	O
+has	O
+received	O
+worldwide	O
+interest	O
+.	O
+
+ABSTRACT	O
+:	O
+Bats	B-SPEC
+are	O
+a	O
+reservoir	O
+for	O
+a	O
+diverse	O
+range	O
+of	O
+viruses	B-SPEC
+,	O
+including	O
+coronaviruses	O
+(	O
+CoVs	O
+).	O
+
+Based	O
+on	O
+the	O
+analysis	O
+of	O
+a	O
+fragment	O
+of	O
+the	O
+RNA	B-PRGE
+-	I-PRGE
+dependent	I-PRGE
+RNA	I-PRGE
+polymerase	I-PRGE
+(	O
+RdRp	B-FUNC
+)	O
+gene	O
+,	O
+phylogenetic	O
+analyses	O
+show	O
+that	O
+alpha	O
+-	O
+CoVs	O
+sequences	O
+detected	O
+in	O
+French	O
+bats	B-SPEC
+are	O
+closely	O
+related	O
+to	O
+other	O
+European	O
+bat	B-ENZY
+alpha	O
+-	O
+CoVs	O
+.	O
+
+Phylogeographic	O
+analyses	O
+of	O
+RdRp	B-FUNC
+sequences	O
+show	O
+that	O
+several	O
+CoVs	O
+strains	O
+circulate	O
+in	O
+European	O
+bats	B-SPEC
+:	O
+(	O
+i	O
+)	O
+old	O
+strains	O
+detected	O
+that	O
+have	O
+probably	O
+diverged	O
+a	O
+long	O
+time	O
+ago	O
+and	O
+are	O
+detected	O
+in	O
+different	O
+bat	B-ENZY
+subspecies	O
+;	O
+(	O
+ii	O
+)	O
+strains	O
+detected	O
+in	O
+Myotis	O
+and	O
+Pipistrellus	B-SPEC
+bat	B-ENZY
+species	B-SPEC
+that	O
+have	O
+more	O
+recently	O
+diverged	O
+.	O
+
+Fifteen	O
+articles	O
+conformed	O
+to	O
+the	O
+inclusion	O
+and	O
+exclusion	O
+criteria	O
+for	O
+further	O
+meta	B-SPEC
+-	O
+analysis	O
+on	O
+the	O
+basis	O
+of	O
+a	O
+wide	O
+range	O
+of	O
+publications	O
+searched	O
+from	O
+databases	O
+involving	O
+PubMed	O
+,	O
+EMBASE	O
+,	O
+Web	O
+of	O
+Science	O
+,	O
+Medline	O
+,	O
+ISI	O
+.	O
+
+ABSTRACT	O
+:	O
+The	O
+role	O
+of	O
+viruses	O
+in	O
+chronic	B-DISO
+rhinosinusitis	I-DISO
+(	O
+CRS	B-DISO
+)	O
+is	O
+poorly	O
+understood	O
+.	O
+
+In	O
+part	O
+,	O
+this	O
+is	O
+secondary	O
+to	O
+difficulty	O
+in	O
+isolating	O
+viruses	B-SPEC
+.	O
+
+Although	O
+traditional	O
+detection	O
+methods	O
+for	O
+respiratory	O
+viruses	B-SPEC
+have	O
+had	O
+little	O
+clinical	O
+utility	O
+,	O
+modern	O
+viral	O
+screening	O
+techniques	O
+that	O
+use	O
+molecular	O
+sequencing	O
+are	O
+now	O
+both	O
+rapid	O
+and	O
+feasible	O
+,	O
+which	O
+makes	O
+analysis	O
+of	O
+the	O
+paranasal	B-ANAT
+sinus	I-ANAT
+microbiome	O
+more	O
+accessible	O
+.	O
+
+In	O
+this	O
+study	O
+,	O
+respiratory	O
+viruses	B-SPEC
+were	O
+more	O
+commonly	O
+isolated	O
+from	O
+patients	O
+with	O
+CRS	B-DISO
+compared	O
+with	O
+healthy	O
+controls	O
+.	O
+
+Moreover	O
+,	O
+viral	B-DISO
+infection	I-DISO
+may	O
+play	O
+a	O
+greater	O
+role	O
+in	O
+symptom	B-DISO
+exacerbation	O
+in	O
+CRSsNP	O
+than	O
+in	O
+CRSwNP	O
+.	O
+
+TITLE	O
+:	O
+Structural	O
+Factors	O
+of	O
+the	O
+Middle	O
+East	O
+Respiratory	O
+Syndrome	B-DISO
+Coronavirus	B-SPEC
+Outbreak	O
+as	O
+a	O
+Public	O
+Health	O
+Crisis	O
+in	O
+Korea	O
+and	O
+Future	O
+Response	O
+Strategies	O
+.	O
+
+ABSTRACT	O
+:	O
+The	O
+recent	O
+Middle	O
+East	O
+respiratory	O
+syndrome	O
+coronavirus	B-SPEC
+(	O
+MERS	O
+-	O
+CoV	O
+)	O
+outbreak	O
+has	O
+originated	O
+from	O
+a	O
+failure	O
+in	O
+the	O
+national	O
+quarantine	O
+system	O
+in	O
+the	O
+Republic	O
+of	O
+Korea	O
+as	O
+most	O
+basic	O
+role	O
+of	O
+protecting	O
+the	O
+safety	O
+and	O
+lives	O
+of	O
+its	O
+citizens	O
+.	O
+
+ABSTRACT	O
+:	O
+Since	O
+the	O
+Middle	O
+East	O
+respiratory	O
+syndrome	O
+(	O
+MERS	B-DISO
+)	O
+outbreak	O
+in	O
+the	O
+Republic	O
+of	O
+Korea	O
+(	O
+hereafter	O
+Korea	O
+)	O
+began	O
+on	O
+May	O
+11	O
+,	O
+2015	O
+,	O
+a	O
+total	O
+of	O
+186	O
+persons	O
+have	O
+been	O
+infected	O
+by	O
+the	O
+MERS	B-DISO
+coronavirus	B-SPEC
+,	O
+38	O
+of	O
+whom	O
+have	O
+died	B-PROC
+.	O
+
+In	O
+addition	O
+,	O
+pork	O
+consumers	O
+who	O
+experienced	O
+reduced	O
+-	O
+supply	O
+-	O
+induced	O
+pork	O
+-	O
+price	O
+increases	O
+were	O
+likely	O
+harmed	O
+directly	O
+by	O
+higher	O
+prices	O
+paid	O
+for	O
+pork	O
+and	O
+indirectly	O
+as	O
+prices	O
+of	O
+competing	O
+meats	O
+were	O
+also	O
+likely	O
+strengthened	O
+by	O
+PEDV	B-SPEC
+.	O
+
+Further	O
+,	O
+the	O
+B	B-ANAT
+-	I-ANAT
+cell	I-ANAT
+,	O
+helper	B-ANAT
+T	I-ANAT
+-	I-ANAT
+cell	I-ANAT
+and	O
+cytotoxic	B-ANAT
+T	I-ANAT
+lymphocyte	I-ANAT
+(	O
+CTL	B-ANAT
+)	O
+epitopes	O
+were	O
+screened	O
+and	O
+mapped	O
+to	O
+the	O
+N	B-PRGE
+protein	I-PRGE
+.	O
+
+ABSTRACT	O
+:	O
+Noninvasive	O
+ventilation	O
+(	O
+NIV	O
+)	O
+is	O
+used	O
+as	O
+an	O
+initial	O
+ventilatory	O
+support	O
+in	O
+acute	O
+respiratory	O
+distress	O
+syndrome	O
+(	O
+ARDS	B-DISO
+),	O
+but	O
+its	O
+utility	O
+is	O
+unclear	O
+,	O
+and	O
+persistence	O
+in	O
+those	O
+who	O
+do	O
+not	O
+improve	O
+may	O
+delay	O
+intubation	O
+and	O
+lead	O
+to	O
+adverse	O
+outcomes	O
+.	O
+
+This	O
+is	O
+a	O
+difficult	O
+task	O
+since	O
+there	O
+is	O
+a	O
+marked	O
+variability	O
+regarding	O
+the	O
+methodology	O
+of	O
+the	O
+few	O
+,	O
+large	O
+epidemiological	O
+,	O
+and	O
+observational	O
+studies	O
+on	O
+ARDS	B-DISO
+.	O
+
+On	O
+the	O
+basis	O
+of	O
+current	O
+evidence	O
+,	O
+it	O
+seems	O
+that	O
+the	O
+incidence	O
+and	O
+overall	O
+hospital	O
+mortality	O
+of	O
+ARDS	B-DISO
+has	O
+not	O
+changed	O
+substantially	O
+in	O
+the	O
+last	O
+decade	O
+.	O
+
+Current	O
+hospital	O
+mortality	O
+of	O
+combined	O
+moderate	O
+and	O
+severe	O
+ARDS	B-DISO
+reported	O
+in	O
+observational	O
+studies	O
+is	O
+greater	O
+than	O
+40	O
+%.	O
+
+During	O
+the	O
+first	O
+5	O
+days	O
+of	O
+extracorporeal	O
+membrane	B-COMP
+oxygenation	B-PROC
+therapy	O
+,	O
+prothrombin	B-PRGE
+fragment	I-PRGE
+1	I-PRGE
+.	I-PRGE
+2	I-PRGE
+(	O
+F1	B-PRGE
+.	I-PRGE
+2	I-PRGE
+)	I-PRGE
+(	I-PRGE
+1	I-PRGE
+.	I-PRGE
+36	I-PRGE
+-	I-PRGE
+2	I-PRGE
+.	I-PRGE
+4	I-PRGE
+µM	I-PRGE
+),	O
+thrombin	B-PRGE
+-	O
+antithrombin	B-PRGE
+complex	O
+(	O
+14	O
+.	O
+5	O
+-	O
+50	O
+µg	O
+/	O
+L	O
+),	O
+and	O
+D	O
+-	O
+dimers	O
+(	O
+6	O
+.	O
+00	O
+-	O
+27	O
+.	O
+0	O
+mg	O
+/	O
+L	O
+)	O
+increased	O
+,	O
+whereas	O
+fibrinogen	B-COMP
+values	O
+dropped	O
+from	O
+5	O
+.	O
+8	O
+to	O
+4	O
+.	O
+1	O
+g	O
+/	O
+L	O
+.	O
+The	O
+three	O
+different	O
+extracorporeal	O
+membrane	B-COMP
+oxygenation	B-PROC
+systems	O
+did	O
+not	O
+show	O
+any	O
+differences	O
+with	O
+regard	O
+to	O
+hemostasis	B-PROC
+,	O
+anticoagulation	B-PROC
+,	O
+hemolysis	B-DISO
+,	O
+and	O
+inflammatory	O
+parameters	O
+within	O
+the	O
+first	O
+5	O
+days	O
+of	O
+extracorporeal	O
+membrane	B-COMP
+oxygenation	B-PROC
+therapy	O
+.	O
+
+Over	O
+time	O
+,	O
+miniaturized	O
+veno	O
+-	O
+venous	B-ANAT
+extracorporeal	O
+membrane	B-COMP
+oxygenation	B-PROC
+therapy	O
+increasingly	O
+activates	O
+coagulation	B-PROC
+.	O
+
+It	O
+remains	O
+unknown	O
+,	O
+however	O
+,	O
+how	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+coronavirus	B-SPEC
+(	O
+SARS	B-DISO
+-	O
+CoV	O
+)	O
+evades	O
+respiratory	O
+innate	B-PROC
+immunity	I-PROC
+to	O
+establish	O
+a	O
+systemic	B-DISO
+infection	I-DISO
+.	O
+
+This	O
+study	O
+provides	O
+a	O
+comprehensive	O
+overview	O
+of	O
+the	O
+spatiotemporal	O
+interactions	O
+of	O
+SARS	B-DISO
+-	O
+CoV	O
+,	O
+monocytes	B-ANAT
+/	O
+macrophages	B-ANAT
+,	O
+and	O
+the	O
+DC	O
+network	O
+in	O
+mucosal	B-ANAT
+tissues	I-ANAT
+and	O
+highlights	O
+the	O
+fact	O
+that	O
+,	O
+while	O
+these	O
+innate	O
+cells	B-COMP
+contribute	O
+to	O
+viral	O
+clearance	O
+,	O
+they	O
+probably	O
+also	O
+serve	O
+as	O
+shelters	O
+and	O
+vehicles	O
+to	O
+provide	O
+a	O
+mechanism	O
+for	O
+the	O
+virus	B-SPEC
+to	O
+escape	O
+host	B-COMP
+mucosal	B-ANAT
+innate	B-PROC
+immunity	I-PROC
+and	O
+disseminate	O
+systemically	O
+.	O
+
+ACP	B-DISO
+was	O
+found	O
+in	O
+164	O
+of	O
+the	O
+752	O
+patients	O
+(	O
+prevalence	O
+of	O
+22	O
+%;	O
+95	O
+%	O
+confidence	O
+interval	O
+19	O
+-	O
+25	O
+%).	O
+
+Hospital	O
+mortality	O
+did	O
+not	O
+differ	O
+between	O
+patients	O
+with	O
+or	O
+without	O
+ACP	B-DISO
+,	O
+but	O
+it	O
+was	O
+significantly	O
+higher	O
+in	O
+patients	O
+with	O
+severe	O
+ACP	B-DISO
+than	O
+in	O
+the	O
+other	O
+patients	O
+[	O
+31	O
+/	O
+54	O
+(	O
+57	O
+%)	O
+vs	O
+.	O
+291	O
+/	O
+698	O
+(	O
+42	O
+%);	O
+p	O
+=	O
+0	O
+.	O
+03	O
+].	O
+
+We	O
+report	O
+a	O
+22	O
+%	O
+prevalence	O
+of	O
+ACP	B-DISO
+and	O
+a	O
+poor	O
+outcome	O
+of	O
+severe	O
+ACP	B-DISO
+.	O
+
+TITLE	O
+:	O
+Pathogenicity	O
+and	O
+tissue	B-PROC
+tropism	B-PROC
+of	O
+infectious	B-DISO
+bronchitis	B-DISO
+virus	B-SPEC
+is	O
+associated	O
+with	O
+elevated	O
+apoptosis	B-PROC
+and	O
+innate	B-DISO
+immune	I-DISO
+responses	I-DISO
+.	O
+
+Feline	B-DISO
+infectious	I-DISO
+peritonitis	I-DISO
+virus	B-SPEC
+(	O
+FIPV	O
+)	O
+belongs	O
+to	O
+the	O
+genus	B-SPEC
+Alphacoronavirus	B-SPEC
+,	O
+resulting	O
+in	O
+a	O
+lethal	O
+systemic	B-DISO
+granulomatous	I-DISO
+disease	I-DISO
+called	O
+feline	B-DISO
+infectious	I-DISO
+peritonitis	I-DISO
+(	O
+FIP	B-DISO
+),	O
+which	O
+is	O
+one	O
+of	O
+the	O
+most	O
+important	O
+fatal	O
+infectious	B-DISO
+diseases	I-DISO
+of	O
+cats	B-SPEC
+worldwide	O
+.	O
+
+Here	O
+,	O
+we	O
+report	O
+the	O
+crystal	B-ANAT
+structure	O
+of	O
+FIPV	O
+M	O
+(	O
+pro	B-CHED
+)	O
+in	O
+complex	O
+with	O
+dual	O
+inhibitors	B-CHED
+,	O
+a	O
+zinc	B-CHED
+ion	I-CHED
+and	O
+a	O
+Michael	O
+acceptor	B-CHED
+.	O
+
+Coronaviruses	O
+(	O
+CoVs	O
+)	O
+have	O
+the	O
+largest	O
+genome	O
+size	O
+among	O
+all	O
+RNA	O
+viruses	B-SPEC
+.	O
+
+CoV	O
+infection	B-DISO
+causes	O
+various	O
+diseases	O
+in	O
+humans	B-SPEC
+and	O
+animals	B-SPEC
+,	O
+including	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+(	O
+SARS	B-DISO
+)	O
+and	O
+Middle	O
+East	O
+respiratory	O
+syndrome	B-DISO
+(	O
+MERS	O
+).	O
+
+ABSTRACT	O
+:	O
+Accidental	O
+inhalation	B-PROC
+of	O
+powder	O
+is	O
+a	O
+potential	O
+problem	O
+for	O
+infants	O
+.	O
+
+TITLE	O
+:	O
+Critical	O
+Assessment	O
+of	O
+the	O
+Important	O
+Residues	O
+Involved	O
+in	O
+the	O
+Dimerization	O
+and	O
+Catalysis	O
+of	O
+MERS	O
+Coronavirus	B-SPEC
+Main	O
+Protease	O
+.	O
+
+Studies	O
+to	O
+understand	O
+the	O
+virus	B-SPEC
+are	O
+necessary	O
+and	O
+urgent	O
+.	O
+
+One	O
+mutation	O
+,	O
+M298R	O
+,	O
+resulted	O
+in	O
+a	O
+stable	O
+dimer	O
+with	O
+a	O
+higher	O
+level	O
+of	O
+proteolytic	B-PROC
+activity	O
+than	O
+the	O
+wild	O
+-	O
+type	O
+enzyme	O
+.	O
+
+TITLE	O
+:	O
+Plasma	B-ANAT
+angiopoietin	B-PRGE
+-	I-PRGE
+2	I-PRGE
+outperforms	O
+other	O
+markers	O
+of	O
+endothelial	B-ANAT
+injury	O
+in	O
+prognosticating	O
+pediatric	O
+ARDS	O
+mortality	O
+.	O
+
+ABSTRACT	O
+:	O
+Porcine	B-SPEC
+respiratory	B-DISO
+disease	I-DISO
+complex	I-PRGE
+(	O
+PRDC	B-PRGE
+)	O
+is	O
+one	O
+of	O
+the	O
+most	O
+important	O
+health	O
+concerns	O
+for	O
+pig	B-SPEC
+producers	O
+and	O
+can	O
+involve	O
+multiple	O
+viral	O
+and	O
+bacterial	O
+pathogens	O
+.	O
+
+We	O
+evaluated	O
+three	O
+different	O
+strategies	O
+for	O
+managing	O
+the	O
+trade	O
+-	O
+off	O
+between	O
+increasing	O
+respiratory	O
+rate	O
+and	O
+reducing	O
+tidal	O
+volume	O
+while	O
+attempting	O
+to	O
+maintain	O
+the	O
+partial	O
+pressure	O
+of	O
+carbon	B-CHED
+dioxide	I-CHED
+in	O
+arterial	B-ANAT
+blood	I-ANAT
+(	O
+PaCO2	O
+)	O
+constant	O
+on	O
+a	O
+computational	O
+simulator	O
+configured	O
+with	O
+ARDS	O
+patient	O
+datasets	O
+.	O
+
+TITLE	O
+:	O
+Impact	O
+of	O
+overlap	B-DISO
+syndrome	I-DISO
+on	O
+severity	O
+of	O
+acute	O
+exacerbation	O
+of	O
+chronic	B-DISO
+obstructive	I-DISO
+pulmonary	B-ANAT
+disease	I-DISO
+.	O
+
+CONCLUSIONS	O
+:	O
+Overlap	B-DISO
+syndromes	I-DISO
+are	O
+more	O
+likely	O
+have	O
+respiratory	B-DISO
+failure	I-DISO
+compared	O
+to	O
+only	O
+COPD	B-DISO
+during	O
+AECOPD	O
+.	O
+
+Acute	O
+upper	O
+airway	O
+obstruction	O
+by	O
+food	O
+led	O
+to	O
+transient	O
+cardiac	B-DISO
+arrest	I-DISO
+,	O
+and	O
+negative	O
+pressure	O
+pulmonary	B-DISO
+hemorrhage	I-DISO
+(	O
+NPPH	O
+)	O
+occurred	O
+1	O
+hour	O
+after	O
+the	O
+foreign	O
+body	B-ANAT
+obstruction	B-DISO
+.	O
+
+ABSTRACT	O
+:	O
+Cerebral	O
+edema	O
+(	O
+CE	O
+)	O
+and	O
+non	O
+cardiogenic	B-DISO
+pulmonary	I-DISO
+edema	I-DISO
+(	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+,	O
+ARDS	B-DISO
+)	O
+are	O
+life	O
+-	O
+threatening	O
+complications	O
+of	O
+diabetic	B-DISO
+ketoacidosis	I-DISO
+(	O
+DKA	O
+).	O
+
+In	O
+contrast	O
+to	O
+CE	O
+complicating	O
+DKA	O
+,	O
+which	O
+is	O
+primarily	O
+reported	O
+in	O
+pediatric	O
+patients	O
+,	O
+ARDS	B-DISO
+is	O
+rarely	O
+described	O
+in	O
+this	O
+age	O
+group	O
+.	O
+
+ABSTRACT	O
+:	O
+Porcine	O
+epidemic	O
+diarrhea	O
+virus	O
+(	O
+PEDV	B-SPEC
+)	O
+is	O
+an	O
+economically	O
+devastating	O
+enteric	O
+disease	O
+in	O
+the	O
+swine	B-SPEC
+industry	O
+.	O
+
+In	O
+conclusion	O
+,	O
+in	O
+sows	O
+infected	O
+with	O
+PEDV	B-SPEC
+the	O
+presence	O
+of	O
+effector	B-CHED
+/	O
+memory	B-ANAT
+B	I-ANAT
+cell	B-COMP
+response	O
+and	O
+strong	O
+virus	B-PROC
+neutralization	I-PROC
+titers	O
+in	O
+plasma	B-ANAT
+up	O
+to	O
+6	O
+months	O
+post	O
+-	O
+infection	B-DISO
+,	O
+suggests	O
+their	O
+potential	O
+to	O
+protect	O
+sows	O
+from	O
+reinfection	O
+and	O
+provide	O
+maternal	O
+immunity	B-PROC
+to	O
+neonates	O
+,	O
+but	O
+challenge	O
+studies	O
+are	O
+required	O
+to	O
+confirm	O
+such	O
+responses	O
+.	O
+
+As	O
+part	O
+of	O
+prerelease	O
+health	O
+protocols	O
+,	O
+samples	O
+were	O
+obtained	O
+from	O
+29	O
+parrots	B-SPEC
+on	O
+three	O
+different	O
+occasions	O
+while	O
+in	O
+captivity	O
+and	O
+once	O
+after	O
+their	O
+release	B-PATH
+.	O
+
+Patients	O
+meeting	O
+the	O
+American	O
+-	O
+European	O
+Consensus	O
+Conference	O
+definition	O
+for	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+were	O
+considered	O
+for	O
+the	O
+study	O
+.	O
+
+At	O
+12	O
+-	O
+36	O
+hours	O
+after	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+onset	O
+,	O
+patients	O
+were	O
+assessed	O
+under	O
+standardized	O
+ventilator	O
+settings	O
+(	O
+FIO2	O
+≥	O
+0	O
+.	O
+5	O
+,	O
+positive	O
+end	B-PROC
+-	I-PROC
+expiratory	I-PROC
+pressure	O
+≥	O
+10	O
+cm	O
+H2O	B-CHED
+).	O
+
+Mortality	O
+at	O
+day	O
+-	O
+60	O
+(	O
+29	O
+%	O
+open	O
+lung	B-ANAT
+approach	O
+vs	O
+.	O
+33	O
+%	O
+Acute	B-DISO
+Respiratory	I-DISO
+Distress	I-DISO
+Syndrome	I-DISO
+Network	O
+protocol	O
+,	O
+p	O
+=	O
+0	O
+.	O
+18	O
+,	O
+log	O
+rank	O
+test	O
+),	O
+ICU	O
+mortality	O
+(	O
+25	O
+%	O
+open	O
+lung	B-ANAT
+approach	O
+vs	O
+.	O
+30	O
+%	O
+Acute	B-DISO
+Respiratory	I-DISO
+Distress	I-DISO
+Syndrome	I-DISO
+network	O
+protocol	O
+,	O
+p	O
+=	O
+0	O
+.	O
+53	O
+Fisher	B-SPEC
+'	O
+s	O
+exact	O
+test	O
+),	O
+and	O
+ventilator	O
+-	O
+free	O
+days	O
+(	O
+8	O
+[	O
+0	O
+-	O
+20	O
+]	O
+open	O
+lung	B-ANAT
+approach	O
+vs	O
+.	O
+7	O
+[	O
+0	O
+-	O
+20	O
+]	O
+d	O
+Acute	B-DISO
+Respiratory	I-DISO
+Distress	I-DISO
+Syndrome	I-DISO
+network	O
+protocol	O
+,	O
+p	O
+=	O
+0	O
+.	O
+53	O
+Wilcoxon	O
+rank	O
+test	O
+)	O
+were	O
+not	O
+significantly	O
+different	O
+.	O
+
+In	O
+patients	O
+with	O
+established	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+,	O
+open	O
+lung	B-ANAT
+approach	O
+improved	O
+oxygenation	B-PROC
+and	O
+driving	O
+pressure	O
+,	O
+without	O
+detrimental	O
+effects	O
+on	O
+mortality	O
+,	O
+ventilator	O
+-	O
+free	O
+days	O
+,	O
+or	O
+barotrauma	O
+.	O
+
+Paricalcitol	B-CHED
+treatment	O
+partially	O
+inhibited	O
+these	O
+pathological	O
+changes	O
+in	O
+WT	O
+mice	B-SPEC
+by	O
+maintaining	O
+the	O
+mRNA	B-CHED
+and	O
+protein	B-PROC
+expression	B-PROC
+levels	O
+of	O
+occludin	B-PRGE
+(	O
+P	O
+<	O
+0	O
+.	O
+01	O
+)	O
+and	O
+ZO	O
+‑	O
+1	O
+(	O
+P	O
+<	O
+0	O
+.	O
+05	O
+).	O
+
+A	O
+lack	O
+of	O
+VDRs	O
+in	O
+the	O
+pulmonary	B-ANAT
+epithelial	O
+barrier	O
+appeared	O
+to	O
+compromise	O
+its	O
+defense	O
+,	O
+leading	O
+to	O
+more	O
+severe	O
+LPS	O
+‑	O
+induced	O
+lung	B-ANAT
+injury	O
+.	O
+
+Furthermore	O
+,	O
+vitamin	B-CHED
+D	I-CHED
+treatment	O
+alleviated	O
+LPS	O
+‑	O
+induced	O
+lung	B-ANAT
+injury	O
+and	O
+preserved	O
+alveolar	B-ANAT
+barrier	O
+function	O
+.	O
+
+TITLE	O
+:	O
+Middle	O
+East	O
+respiratory	O
+syndrome	B-DISO
+coronavirus	B-SPEC
+(	O
+MERS	O
+-	O
+CoV	O
+)	O
+in	O
+dromedary	B-SPEC
+camels	B-SPEC
+in	O
+Nigeria	O
+,	O
+2015	O
+.	O
+
+MERS	O
+-	O
+CoV	O
+RNA	O
+was	O
+detected	O
+in	O
+14	O
+(	O
+11	O
+%)	O
+of	O
+132	O
+nasal	B-ANAT
+swabs	O
+and	O
+antibody	B-COMP
+in	O
+126	O
+(	O
+96	O
+%)	O
+of	O
+131	O
+serum	B-COMP
+samples	O
+.	O
+
+Our	O
+studies	O
+demonstrated	O
+that	O
+MHV	B-SPEC
+infection	B-DISO
+downregulated	O
+Cx43	O
+expression	B-PROC
+at	O
+protein	B-CHED
+and	O
+mRNA	B-CHED
+levels	O
+in	O
+vitro	O
+in	O
+primary	O
+astrocytes	B-ANAT
+obtained	O
+from	O
+neonatal	O
+mouse	O
+brains	B-ANAT
+.	O
+
+We	O
+found	O
+that	O
+MHV	B-SPEC
+infection	B-DISO
+leads	O
+to	O
+the	O
+downregulation	B-PROC
+of	O
+Cx43	B-PRGE
+in	O
+vivo	O
+in	O
+the	O
+CNS	B-CHED
+.	O
+
+Here	O
+we	O
+describe	O
+the	O
+clinical	O
+signs	O
+,	O
+pathologic	O
+findings	O
+,	O
+and	O
+diagnosis	O
+by	O
+immunohistochemistry	O
+using	O
+an	O
+FIPV3	O
+-	O
+70	O
+monoclonal	O
+antibody	B-COMP
+of	O
+systemic	O
+coronaviral	O
+disease	O
+in	O
+5	O
+ferrets	B-SPEC
+,	O
+2	O
+of	O
+which	O
+were	O
+strictly	O
+laboratory	O
+-	O
+housed	O
+;	O
+the	O
+remaining	O
+3	O
+were	O
+referred	O
+from	O
+veterinary	O
+private	O
+practices	O
+.	O
+
+TITLE	O
+:	O
+Co	O
+-	O
+circulation	B-PROC
+of	O
+three	O
+camel	B-SPEC
+coronavirus	B-SPEC
+species	B-SPEC
+and	O
+recombination	B-PROC
+of	O
+MERS	O
+-	O
+CoVs	O
+in	O
+Saudi	O
+Arabia	O
+.	O
+
+Camels	B-SPEC
+therefore	O
+serve	O
+as	O
+an	O
+important	O
+reservoir	O
+for	O
+the	O
+maintenance	O
+and	O
+diversification	O
+of	O
+the	O
+MERS	O
+-	O
+CoVs	O
+and	O
+are	O
+the	O
+source	O
+of	O
+human	B-SPEC
+infections	B-DISO
+with	O
+this	O
+virus	B-SPEC
+.	O
+
+ABSTRACT	O
+:	O
+Middle	O
+East	O
+respiratory	O
+syndrome	B-DISO
+coronavirus	B-SPEC
+(	O
+MERS	O
+-	O
+CoV	O
+)	O
+infections	B-DISO
+have	O
+led	O
+to	O
+an	O
+ongoing	O
+outbreak	O
+in	O
+humans	B-SPEC
+,	O
+which	O
+was	O
+fueled	O
+by	O
+multiple	O
+zoonotic	O
+MERS	O
+-	O
+CoV	O
+introductions	O
+from	O
+dromedary	B-SPEC
+camels	B-SPEC
+.	O
+
+Here	O
+we	O
+show	O
+that	O
+a	O
+modified	O
+vaccinia	B-SPEC
+virus	I-SPEC
+Ankara	O
+(	O
+MVA	B-CHED
+)	O
+vaccine	O
+expressing	O
+the	O
+MERS	B-PRGE
+-	I-PRGE
+CoV	I-PRGE
+spike	I-PRGE
+protein	I-PRGE
+confers	O
+mucosal	B-PROC
+immunity	I-PROC
+in	O
+dromedary	B-SPEC
+camels	B-SPEC
+.	O
+
+During	O
+the	O
+late	O
+clinical	O
+phase	O
+of	O
+MERS	O
+,	O
+viable	O
+virus	B-SPEC
+could	O
+be	O
+isolated	O
+in	O
+3	O
+of	O
+the	O
+4	O
+enrolled	O
+patients	O
+on	O
+day	O
+18	O
+to	O
+day	O
+25	O
+after	O
+symptom	B-DISO
+onset	O
+.	O
+
+Using	O
+a	O
+state	O
+-	O
+of	O
+-	O
+the	O
+-	O
+art	O
+biodegradable	O
+polymer	B-CHED
+,	O
+poly	O
+(	O
+β	O
+-	O
+amino	O
+ester	B-CHED
+),	O
+colloidally	O
+stable	O
+sub	O
+-	O
+100	O
+nm	O
+DNA	O
+nanoparticles	B-CHED
+are	O
+engineered	O
+with	O
+a	O
+nonadhesive	O
+polyethylene	B-CHED
+glycol	I-CHED
+corona	B-CHED
+that	O
+are	O
+able	O
+to	O
+avoid	O
+the	O
+adhesive	O
+and	O
+steric	O
+hindrances	O
+imposed	O
+by	O
+the	O
+extracellular	B-COMP
+matrix	I-COMP
+.	O
+
+These	O
+nanoparticles	B-CHED
+provide	O
+a	O
+biodegradable	O
+DNA	O
+nanoparticle	B-CHED
+platform	O
+enabling	O
+uniform	O
+transgene	O
+expression	B-PROC
+patterns	O
+in	O
+vivo	O
+and	O
+hold	O
+promise	O
+for	O
+the	O
+treatment	O
+of	O
+neurological	O
+diseases	O
+.	O
+
+We	O
+compare	O
+the	O
+environmental	O
+breadth	O
+of	O
+conditions	O
+under	O
+which	O
+cases	O
+have	O
+reported	O
+camel	B-SPEC
+contacts	O
+with	O
+that	O
+of	O
+the	O
+broader	O
+population	O
+of	O
+all	O
+cases	O
+,	O
+to	O
+assess	O
+whether	O
+camel	B-SPEC
+-	O
+associated	O
+cases	O
+occur	O
+under	O
+a	O
+more	O
+restricted	O
+set	O
+of	O
+environmental	O
+circumstances	O
+.	O
+
+Use	O
+of	O
+either	O
+proning	O
+or	O
+high	O
+-	O
+PEEP	B-CHED
+likely	O
+improves	O
+survival	O
+in	O
+moderate	O
+-	O
+severe	O
+ARDS	B-DISO
+;	O
+the	O
+role	O
+for	O
+both	O
+concomitantly	O
+remains	O
+unknown	O
+.	O
+
+MERS	O
+-	O
+CoV	O
+can	O
+also	O
+effectively	O
+infect	O
+human	B-SPEC
+primary	O
+T	B-ANAT
+cells	I-ANAT
+and	O
+induce	O
+massive	O
+apoptosis	B-PATH
+in	O
+these	O
+cells	B-COMP
+.	O
+
+ABSTRACT	O
+:	O
+The	O
+cellular	B-COMP
+actin	B-PRGE
+cytoskeleton	I-ANAT
+presents	O
+a	O
+barrier	O
+that	O
+must	O
+be	O
+overcome	O
+by	O
+many	O
+viruses	O
+,	O
+and	O
+it	O
+has	O
+become	O
+increasingly	O
+apparent	O
+many	O
+viral	O
+species	B-SPEC
+have	O
+developed	O
+a	O
+diverse	O
+repertoire	O
+of	O
+mechanisms	O
+to	O
+hijack	O
+cellular	B-COMP
+actin	B-PRGE
+-	O
+regulating	O
+signalling	B-PROC
+pathways	B-PROC
+as	O
+part	O
+of	O
+their	O
+cell	B-COMP
+entry	O
+processes	O
+.	O
+
+TITLE	O
+:	O
+Multiorgan	O
+WU	B-SPEC
+Polyomavirus	I-SPEC
+Infection	O
+in	O
+Bone	B-ANAT
+Marrow	I-ANAT
+Transplant	B-ANAT
+Recipient	O
+.	O
+
+Although	O
+the	O
+role	O
+of	O
+WUPyV	O
+as	O
+a	O
+human	B-SPEC
+pathogen	O
+remains	O
+unclear	O
+,	O
+these	O
+results	O
+clearly	O
+demonstrate	O
+evidence	O
+for	O
+infection	B-DISO
+of	O
+respiratory	B-ANAT
+tract	I-ANAT
+tissues	B-ANAT
+in	O
+this	O
+patient	O
+.	O
+
+Questionnaires	O
+were	O
+mailed	O
+to	O
+38	O
+emergency	B-DISO
+facilities	O
+that	O
+agreed	O
+to	O
+participate	O
+in	O
+the	O
+study	O
+.	O
+
+The	O
+ingestion	O
+of	O
+products	O
+containing	O
+glyphosate	B-CHED
+isopropylamine	B-CHED
+or	O
+ammonium	B-CHED
+salts	I-CHED
+,	O
+and	O
+polyoxyethyleneamine	O
+(	O
+POEA	B-CHED
+)	O
+as	O
+a	O
+surfactant	B-CHED
+,	O
+can	O
+cause	O
+severe	O
+organ	B-ANAT
+injury	O
+.	O
+
+During	O
+September	O
+2014	O
+-	O
+January	O
+2015	O
+,	O
+an	O
+outbreak	O
+of	O
+38	O
+cases	O
+of	O
+MERS	O
+was	O
+reported	O
+from	O
+4	O
+healthcare	O
+facilities	O
+in	O
+Taif	O
+,	O
+Saudi	O
+Arabia	O
+;	O
+21	O
+of	O
+the	O
+38	O
+case	O
+-	O
+patients	O
+died	B-PROC
+.	O
+
+Further	O
+investigation	O
+is	O
+needed	O
+to	O
+better	O
+understand	O
+animal	O
+-	O
+to	O
+-	O
+human	B-SPEC
+transmission	O
+of	O
+MERS	O
+-	O
+CoV	O
+.	O
+
+The	O
+outbreak	O
+of	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+(	O
+SARS	B-DISO
+)	O
+in	O
+2003	O
+and	O
+Middle	O
+East	O
+respiratory	O
+syndrome	B-DISO
+(	O
+MERS	O
+)	O
+less	O
+than	O
+10	O
+years	O
+later	O
+demonstrates	O
+the	O
+potential	O
+of	O
+coronaviruses	O
+to	O
+cross	O
+species	B-SPEC
+boundaries	O
+and	O
+further	O
+highlights	O
+the	O
+importance	O
+of	O
+identifying	O
+novel	O
+lead	B-CHED
+compounds	I-CHED
+with	O
+broad	O
+spectrum	O
+activity	O
+.	O
+
+TITLE	O
+:	O
+Glucose	B-CHED
+-	I-ENZY
+6	I-ENZY
+-	I-ENZY
+Phosphate	B-CHED
+Dehydrogenase	I-ENZY
+Enhances	O
+Antiviral	B-PROC
+Response	I-PROC
+through	O
+Downregulation	B-PROC
+of	O
+NADPH	B-CHED
+Sensor	I-PRGE
+HSCARG	I-PRGE
+and	O
+Upregulation	B-PROC
+of	O
+NF	O
+-	O
+κB	O
+Signaling	B-PROC
+.	O
+
+ABSTRACT	O
+:	O
+Glucose	B-PRGE
+-	I-PRGE
+6	I-PRGE
+-	I-PRGE
+phosphate	B-CHED
+dehydrogenase	I-PRGE
+(	O
+G6PD	B-PRGE
+)-	O
+deficient	O
+cells	B-COMP
+are	O
+highly	O
+susceptible	O
+to	O
+viral	B-DISO
+infection	I-DISO
+.	O
+
+Molecular	O
+analysis	O
+revealed	O
+that	O
+the	O
+promoter	O
+activities	O
+of	O
+TNF	B-PRGE
+-	I-PRGE
+α	I-PRGE
+and	O
+MX1	B-PRGE
+were	O
+downregulated	O
+in	O
+G6PD	B-ENZY
+-	O
+knockdown	O
+cells	B-COMP
+,	O
+and	O
+that	O
+the	O
+IκB	O
+degradation	O
+and	O
+DNA	B-FUNC
+binding	I-FUNC
+activity	O
+of	O
+NF	O
+-	O
+κB	O
+were	O
+decreased	O
+.	O
+
+TITLE	O
+:	O
+MERS	O
+coronavirus	B-SPEC
+:	O
+diagnostics	O
+,	O
+epidemiology	O
+and	O
+transmission	O
+.	O
+
+Precisely	O
+how	O
+virus	B-SPEC
+transmits	O
+to	O
+humans	B-SPEC
+remains	O
+unknown	O
+but	O
+close	O
+and	O
+lengthy	O
+exposure	O
+appears	O
+to	O
+be	O
+a	O
+requirement	O
+.	O
+
+The	O
+KSA	O
+is	O
+the	O
+focal	O
+point	O
+of	O
+MERS	O
+,	O
+with	O
+the	O
+majority	O
+of	O
+human	B-SPEC
+cases	O
+.	O
+
+When	O
+the	O
+xiamycins	O
+were	O
+tested	O
+for	O
+inhibitory	O
+activity	O
+on	O
+porcine	B-SPEC
+epidemic	I-SPEC
+diarrhea	I-SPEC
+virus	I-SPEC
+(	O
+PEDV	B-SPEC
+),	O
+xiamycin	O
+D	O
+(	O
+2	O
+)	O
+showed	O
+the	O
+strongest	O
+inhibitory	O
+effect	O
+on	O
+PEDV	B-SPEC
+replication	O
+(	O
+EC50	O
+=	O
+0	O
+.	O
+93	O
+μM	O
+)	O
+with	O
+low	O
+cytotoxicity	B-DISO
+(	O
+CC50	O
+=	O
+56	O
+.	O
+03	O
+μM	O
+),	O
+thus	O
+displaying	O
+a	O
+high	O
+selective	O
+index	O
+(	O
+60	O
+.	O
+31	O
+).	O
+
+In	O
+this	O
+study	O
+,	O
+we	O
+developed	O
+a	O
+transgenic	O
+mouse	B-SPEC
+model	O
+globally	O
+expressing	O
+codon	O
+-	O
+optimized	O
+human	B-PRGE
+dipeptidyl	I-PRGE
+peptidase	I-PRGE
+4	I-PRGE
+(	O
+hDPP4	O
+),	O
+the	O
+receptor	O
+for	O
+MERS	O
+-	O
+CoV	O
+.	O
+After	O
+intranasal	O
+inoculation	O
+with	O
+MERS	O
+-	O
+CoV	O
+,	O
+the	O
+mice	B-SPEC
+rapidly	O
+developed	O
+severe	O
+pneumonia	B-DISO
+and	O
+multi	O
+-	O
+organ	B-ANAT
+damage	O
+,	O
+with	O
+viral	B-PROC
+replication	I-PROC
+being	O
+detected	O
+in	O
+the	O
+lungs	B-ANAT
+on	O
+day	O
+5	O
+and	O
+in	O
+the	O
+lungs	B-ANAT
+,	O
+kidneys	B-ANAT
+and	O
+brains	B-ANAT
+on	O
+day	O
+9	O
+post	O
+-	O
+infection	B-DISO
+.	O
+
+Taken	O
+together	O
+,	O
+this	O
+study	O
+characterizes	O
+the	O
+tropism	B-PROC
+of	O
+MERS	O
+-	O
+CoV	O
+upon	O
+infection	B-DISO
+.	O
+
+Importantly	O
+,	O
+this	O
+hDPP4	O
+-	O
+expressing	O
+transgenic	O
+mouse	B-SPEC
+model	O
+will	O
+be	O
+applicable	O
+for	O
+studying	O
+the	O
+pathogenesis	B-DISO
+of	O
+MERS	O
+-	O
+CoV	O
+infection	B-DISO
+and	O
+investigating	O
+the	O
+efficacy	O
+of	O
+vaccines	O
+and	O
+antiviral	B-CHED
+agents	I-CHED
+designed	O
+to	O
+combat	B-CHED
+MERS	O
+-	O
+CoV	O
+infection	B-DISO
+.	O
+
+All	O
+subjects	O
+received	O
+lung	B-ANAT
+-	O
+protective	O
+ventilation	O
+and	O
+1	O
+mg	O
+/	O
+kg	O
+/	O
+d	O
+methylprednisolone	B-CHED
+infusion	O
+for	O
+ARDS	B-DISO
+.	O
+
+The	O
+ante	O
+-	O
+mortem	O
+diagnosis	O
+of	O
+FIP	B-DISO
+in	O
+clinical	O
+cases	O
+is	O
+still	O
+challenging	O
+.	O
+
+Further	O
+studies	O
+are	O
+necessary	O
+to	O
+evaluate	O
+the	O
+usefulness	O
+of	O
+the	O
+sequencing	O
+step	O
+including	O
+FCoV	O
+-	O
+RNA	O
+-	O
+positive	O
+cats	B-SPEC
+with	O
+and	O
+without	O
+FIP	B-DISO
+.	O
+
+RESULTS	O
+:	O
+Among	O
+the	O
+received	O
+data	O
+sets	O
+,	O
+three	O
+employed	O
+an	O
+in	O
+-	O
+house	O
+-	O
+developed	O
+real	O
+-	O
+time	O
+reverse	O
+-	O
+transcription	B-PROC
+polymerase	O
+chain	O
+reaction	O
+(	O
+rRT	O
+-	O
+PCR	O
+)	O
+assay	O
+and	O
+the	O
+others	O
+applied	O
+various	O
+commercial	O
+rRT	O
+-	O
+PCR	O
+kits	O
+.	O
+
+The	O
+pulmonary	B-PROC
+functions	I-PROC
+of	O
+SARS	B-DISO
+patents	O
+largely	O
+returned	O
+to	O
+normal	O
+after	O
+10	O
+years	O
+of	O
+convalescence	O
+,	O
+and	O
+the	O
+lung	B-PROC
+function	I-PROC
+damage	O
+was	O
+characterized	O
+by	O
+diffusing	O
+and	O
+restrictive	O
+ventilatory	O
+dysfunctions	O
+.	O
+
+Twenty	O
+-	O
+five	O
+percent	O
+of	O
+patients	O
+were	O
+treated	O
+with	O
+neuromuscular	O
+blockade	O
+,	O
+10	O
+.	O
+1	O
+%	O
+received	O
+inhaled	B-PROC
+pulmonary	B-ANAT
+vasodilators	O
+,	O
+and	O
+extracorporeal	O
+membrane	B-COMP
+oxygenation	B-PROC
+was	O
+initiated	O
+in	O
+2	O
+.	O
+6	O
+%.	O
+
+We	O
+found	O
+that	O
+IL	B-PROC
+-	I-PROC
+17	I-PROC
+level	O
+was	O
+elevated	O
+in	O
+bronchoalveolar	O
+lavage	O
+(	O
+BAL	B-ENZY
+)	O
+fluid	O
+of	O
+ALI	O
+mice	B-SPEC
+.	O
+
+Management	O
+of	O
+IL	B-PROC
+-	I-PROC
+17	I-PROC
+could	O
+modulate	O
+LPS	B-DISO
+-	O
+induced	O
+pulmonary	B-DISO
+inflammation	I-DISO
+,	O
+as	O
+reflected	O
+by	O
+the	O
+total	O
+cell	B-COMP
+and	O
+neutrophil	B-ANAT
+counts	O
+,	O
+proinflammatory	O
+cytokines	O
+,	O
+as	O
+well	O
+as	O
+chemokines	O
+in	O
+BAL	B-ENZY
+fluid	O
+.	O
+
+Most	O
+of	O
+the	O
+specimens	O
+were	O
+sputum	B-ANAT
+(	O
+73	O
+.	O
+5	O
+%).	O
+
+We	O
+conducted	O
+histologic	O
+analysis	O
+and	O
+immunofluorescence	O
+(	O
+IF	O
+)	O
+staining	O
+for	O
+the	O
+detection	O
+of	O
+PDCoV	O
+antigens	B-CHED
+,	O
+and	O
+TUNEL	O
+assay	O
+in	O
+singly	O
+or	O
+serially	O
+cut	O
+tissue	B-ANAT
+sections	O
+from	O
+the	O
+small	O
+and	O
+large	O
+intestines	B-ANAT
+of	O
+four	O
+,	O
+11	O
+-	O
+to	O
+14	O
+-	O
+day	O
+-	O
+old	O
+gnotobiotic	O
+pigs	B-SPEC
+,	O
+inoculated	O
+orally	B-ANAT
+with	O
+8	O
+.	O
+8	O
+-	O
+11	O
+.	O
+0log10	O
+genomic	O
+equivalents	O
+(	O
+GE	O
+)	O
+of	O
+US	O
+PDCoV	O
+strains	O
+OH	O
+-	O
+FD22	O
+or	O
+OH	O
+-	O
+FD100	O
+(	O
+n	O
+=	O
+3	O
+),	O
+or	O
+mock	O
+(	O
+n	O
+=	O
+1	O
+).	O
+
+Of	O
+the	O
+scenarios	O
+,	O
+flexible	O
+intermediate	O
+bulk	O
+containers	O
+"("""	O
+feed	O
+totes	O
+""")"	O
+used	O
+to	O
+transport	B-PROC
+bulk	O
+feed	O
+serving	O
+as	O
+fomites	O
+for	O
+movement	B-PROC
+of	O
+PED	O
+virus	B-SPEC
+provided	O
+the	O
+simplest	O
+explanation	O
+for	O
+the	O
+accumulated	O
+findings	O
+of	O
+the	O
+investigation	O
+.	O
+
+WD	O
+has	O
+not	O
+been	O
+described	O
+in	O
+beef	O
+cattle	B-SPEC
+herds	O
+of	O
+tropical	O
+countries	O
+.	O
+
+Other	O
+enteric	O
+microorganisms	O
+occasionally	O
+identified	O
+in	O
+adult	O
+cattle	O
+and	O
+evaluated	O
+in	O
+this	O
+study	O
+such	O
+as	O
+bovine	B-SPEC
+groups	O
+A	O
+,	O
+B	O
+,	O
+and	O
+C	O
+rotavirus	B-SPEC
+,	O
+bovine	B-SPEC
+viral	I-SPEC
+diarrhea	I-SPEC
+virus	I-SPEC
+,	O
+bovine	B-SPEC
+torovirus	I-SPEC
+,	O
+aichivirus	O
+B	O
+,	O
+and	O
+Eimeria	B-SPEC
+sp	O
+.	O
+were	O
+not	O
+identified	O
+in	O
+the	O
+fecal	B-ANAT
+samples	O
+.	O
+
+Old	O
+age	O
+was	O
+associated	O
+with	O
+a	O
+higher	O
+occurrence	O
+of	O
+AKI	B-PRGE
+in	O
+the	O
+univariate	O
+analysis	O
+(	O
+HR	O
+[	O
+95	O
+%	O
+CI	O
+]:	O
+1	O
+.	O
+069	O
+[	O
+1	O
+.	O
+013	O
+-	O
+1	O
+.	O
+128	O
+],	O
+P	O
+=	O
+0	O
+.	O
+016	O
+)	O
+and	O
+remained	O
+a	O
+significant	O
+predictor	O
+of	O
+the	O
+occurrence	O
+of	O
+AKI	O
+after	O
+adjustment	O
+for	O
+comorbidities	O
+and	O
+the	O
+application	O
+of	O
+a	O
+mechanical	O
+ventilator	O
+.	O
+
+Diabetes	B-DISO
+,	O
+AKI	O
+,	O
+and	O
+the	O
+application	O
+of	O
+a	O
+continuous	O
+renal	B-ANAT
+replacement	O
+therapy	O
+(	O
+CRRT	O
+)	O
+were	O
+risk	O
+factors	O
+for	O
+mortality	O
+in	O
+the	O
+univariate	O
+analysis	O
+(	O
+HR	O
+[	O
+95	O
+%	O
+CI	O
+]:	O
+diabetes	B-DISO
+;	O
+10	O
+.	O
+133	O
+[	O
+1	O
+.	O
+692	O
+-	O
+60	O
+.	O
+697	O
+],	O
+AKI	O
+;	O
+12	O
+.	O
+744	O
+[	O
+1	O
+.	O
+418	O
+-	O
+114	O
+.	O
+565	O
+],	O
+CRRT	O
+;	O
+10	O
+.	O
+254	O
+[	O
+1	O
+.	O
+626	O
+-	O
+64	O
+.	O
+666	O
+],	O
+respectively	O
+).	O
+
+Here	O
+,	O
+we	O
+report	O
+renal	B-ANAT
+complications	O
+and	O
+their	O
+prognosis	O
+in	O
+30	O
+Korean	O
+patients	O
+with	O
+MERS	O
+-	O
+CoV	O
+.	O
+
+Our	O
+estimate	O
+of	O
+R	O
+0	O
+for	O
+the	O
+South	O
+Korea	O
+MERS	O
+-	O
+CoV	O
+nosocomial	O
+outbreak	O
+further	O
+highlights	O
+the	O
+importance	O
+and	O
+the	O
+risk	O
+involved	O
+in	O
+cluster	O
+infections	B-DISO
+and	O
+superspreading	O
+events	O
+in	O
+crowded	O
+settings	O
+such	O
+as	O
+hospitals	O
+.	O
+
+Although	O
+TLS	O
+has	O
+been	O
+reported	O
+in	O
+disseminated	O
+ARMS	B-DISO
+,	O
+this	O
+singular	B-CHED
+case	O
+of	O
+life	O
+-	O
+threatening	O
+respiratory	O
+deterioration	O
+developing	O
+after	O
+initiation	O
+of	O
+chemotherapy	O
+presented	O
+unique	O
+therapeutic	O
+dilemmas	O
+.	O
+
+While	O
+the	O
+disease	O
+was	O
+seldom	O
+reported	O
+in	O
+Europe	O
+within	O
+the	O
+last	O
+few	O
+decades	O
+,	O
+a	O
+few	O
+recent	O
+reports	O
+re	O
+-	O
+emergence	O
+of	O
+PED	B-PRGE
+in	O
+German	O
+pig	B-SPEC
+farms	O
+.	O
+
+The	O
+hitherto	O
+isolated	O
+German	O
+strain	O
+seems	O
+to	O
+be	O
+closely	O
+related	O
+to	O
+a	O
+low	O
+pathogenic	O
+PEDV	B-SPEC
+variant	O
+from	O
+the	O
+USA	O
+.	O
+
+Gastrointestinal	B-DISO
+symptoms	I-DISO
+among	O
+fattening	O
+pigs	B-SPEC
+were	O
+generally	O
+mild	O
+,	O
+quickly	O
+resolving	O
+and	O
+did	O
+not	O
+lead	O
+to	O
+death	B-PROC
+.	O
+
+CONCLUSIONS	O
+:	O
+This	O
+is	O
+the	O
+first	O
+report	O
+demonstrating	O
+the	O
+presence	O
+of	O
+PEDV	B-SPEC
+in	O
+Austria	O
+.	O
+
+The	O
+viruses	B-SPEC
+strains	O
+isolated	O
+from	O
+the	O
+cases	O
+in	O
+Korea	O
+and	O
+the	O
+imported	O
+case	O
+in	O
+China	O
+show	O
+no	O
+significant	O
+variation	O
+compared	O
+with	O
+the	O
+strains	O
+isolated	O
+in	O
+the	O
+Middle	O
+East	O
+.	O
+
+These	O
+pipelines	O
+were	O
+implemented	O
+and	O
+detected	O
+parvovirus	B-DISO
+sequence	O
+in	O
+the	O
+sample	O
+that	O
+the	O
+ECBC	O
+iterative	O
+analysis	O
+previously	O
+failed	O
+to	O
+identify	O
+.	O
+
+After	O
+that	O
+,	O
+interactions	O
+between	O
+GM	O
+changes	O
+and	O
+white	B-ANAT
+matter	I-ANAT
+alterations	O
+were	O
+investigated	O
+by	O
+using	O
+a	O
+correlation	O
+analysis	O
+.	O
+
+The	O
+HIV	B-DISO
+-	O
+infected	O
+patients	O
+displayed	O
+decreased	O
+GM	O
+volume	O
+,	O
+mainly	O
+located	O
+in	O
+the	O
+bilateral	O
+frontal	O
+cortices	O
+,	O
+bilateral	O
+anterior	B-ANAT
+cingulate	I-ANAT
+cortex	I-ANAT
+,	O
+and	O
+left	O
+supplementary	O
+motor	B-ANAT
+area	I-ANAT
+(	O
+P	O
+<	O
+0	O
+.	O
+05	O
+,	O
+false	O
+discovery	O
+rate	O
+-	O
+corrected	O
+).	O
+
+We	O
+obtained	O
+blood	B-ANAT
+,	O
+urine	B-ANAT
+,	O
+and	O
+exhaled	B-PROC
+breath	B-ANAT
+condensate	O
+samples	O
+.	O
+
+Nine	O
+(	O
+31	O
+.	O
+0	O
+%)	O
+also	O
+reported	O
+asthma	B-PATH
+-	O
+like	O
+symptoms	O
+on	O
+questionnaire	O
+.	O
+
+Hydroxyurea	B-CHED
+therapy	O
+might	O
+lessen	O
+the	O
+severity	O
+of	O
+AHR	B-PRGE
+in	O
+affected	O
+individuals	O
+.	O
+
+Among	O
+MCT	B-ENZY
+positive	O
+subjects	O
+,	O
+those	O
+on	O
+hydroxyurea	B-CHED
+had	O
+significantly	O
+less	O
+severe	O
+AHR	O
+as	O
+quantified	O
+by	O
+PC20	O
+(	O
+P	O
+=	O
+0	O
+.	O
+014	O
+).	O
+
+ABSTRACT	O
+:	O
+We	O
+report	O
+the	O
+isolation	O
+and	O
+characterization	O
+of	O
+a	O
+novel	O
+bat	B-ENZY
+coronavirus	B-SPEC
+which	O
+is	O
+much	O
+closer	O
+to	O
+the	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+coronavirus	B-SPEC
+(	O
+SARS	B-DISO
+-	O
+CoV	O
+)	O
+in	O
+genomic	O
+sequence	O
+than	O
+others	O
+previously	O
+reported	O
+,	O
+particularly	O
+in	O
+its	O
+S	O
+gene	O
+.	O
+
+Thus	O
+,	O
+monitoring	O
+of	O
+bovine	B-SPEC
+coronavirus	B-SPEC
+in	O
+Ireland	O
+is	O
+important	O
+as	O
+the	O
+current	O
+isolates	O
+in	O
+circulation	B-PROC
+in	O
+the	O
+south	O
+of	O
+Ireland	O
+may	O
+be	O
+diverging	O
+from	O
+the	O
+available	O
+vaccine	O
+strain	O
+,	O
+which	O
+may	O
+have	O
+implications	O
+regarding	O
+future	O
+BCoV	O
+vaccine	O
+efficacy	O
+.	O
+
+ABSTRACT	O
+:	O
+Postobstructive	O
+pulmonary	O
+edema	O
+(	O
+POPE	B-CHED
+),	O
+sudden	O
+pulmonary	B-DISO
+edema	I-DISO
+after	O
+upper	B-DISO
+airway	I-DISO
+obstruction	I-DISO
+,	O
+is	O
+an	O
+important	O
+disease	O
+entity	O
+for	O
+pediatric	O
+emergency	B-DISO
+physicians	O
+to	O
+recognize	O
+and	O
+initiate	O
+prompt	O
+treatment	O
+.	O
+
+Type	O
+1	O
+POPE	B-CHED
+occurs	O
+after	O
+a	O
+sudden	O
+,	O
+severe	O
+upper	B-DISO
+airway	I-DISO
+obstruction	I-DISO
+,	O
+whereas	O
+type	B-PRGE
+2	I-PRGE
+POPE	I-PRGE
+develops	O
+after	O
+acute	O
+relief	O
+of	O
+chronic	O
+airway	B-ANAT
+obstructive	O
+.	O
+
+Type	O
+2	O
+POPE	B-CHED
+should	O
+be	O
+considered	O
+in	O
+a	O
+patient	O
+presenting	O
+with	O
+respiratory	O
+distress	O
+and	O
+a	O
+history	O
+of	O
+sleep	B-DISO
+apnea	I-DISO
+.	O
+
+TITLE	O
+:	O
+Lipid	B-CHED
+-	O
+Mediated	O
+Targeting	B-PROC
+with	O
+Membrane	B-COMP
+-	O
+Wrapped	O
+Nanoparticles	B-CHED
+in	O
+the	O
+Presence	O
+of	O
+Corona	B-CHED
+Formation	B-PROC
+.	O
+
+ABSTRACT	O
+:	O
+Membrane	B-COMP
+-	O
+wrapped	O
+nanoparticles	B-CHED
+represent	O
+a	O
+versatile	O
+platform	O
+for	O
+utilizing	O
+specific	O
+lipid	B-CHED
+-	O
+receptor	B-PROC
+interactions	I-PROC
+,	O
+such	O
+as	O
+siallyllactose	O
+-	O
+mediated	O
+binding	B-FUNC
+of	O
+the	O
+ganglioside	B-PRGE
+GM3	I-PRGE
+to	O
+Siglec1	B-PRGE
+(	O
+CD169	B-PRGE
+),	O
+for	O
+targeting	B-PROC
+purposes	O
+.	O
+
+We	O
+characterize	O
+nonspecific	O
+protein	B-CHED
+adsorption	O
+(	O
+corona	B-CHED
+formation	B-PROC
+)	O
+to	O
+membrane	B-COMP
+-	O
+wrapped	O
+nanoparticles	B-CHED
+with	O
+core	O
+diameters	O
+of	O
+approximately	O
+35	O
+and	O
+80	O
+nm	O
+and	O
+its	O
+effect	O
+on	O
+the	O
+GM3	B-CHED
+-	O
+mediated	O
+targeting	B-PROC
+efficacy	O
+as	O
+a	O
+function	O
+of	O
+surface	O
+charge	O
+through	O
+combined	O
+in	O
+vitro	O
+and	O
+in	O
+vivo	O
+studies	O
+.	O
+
+ABSTRACT	O
+:	O
+Middle	O
+East	O
+respiratory	O
+syndrome	O
+coronavirus	B-SPEC
+(	O
+MERS	O
+-	O
+CoV	O
+)	O
+was	O
+first	O
+identified	O
+in	O
+a	O
+human	B-SPEC
+with	O
+severe	O
+pneumonia	B-DISO
+in	O
+2012	O
+.	O
+
+Pulmonary	B-ANAT
+expression	B-PROC
+of	O
+the	O
+MERS	B-PRGE
+-	I-PRGE
+CoV	I-PRGE
+receptor	I-PRGE
+,	O
+dipeptidyl	B-PRGE
+peptidase	I-PRGE
+4	I-PRGE
+,	O
+was	O
+similar	O
+in	O
+marmosets	B-SPEC
+and	O
+macaques	B-SPEC
+.	O
+
+Together	O
+,	O
+the	O
+rhesus	B-SPEC
+macaque	I-SPEC
+and	O
+common	B-SPEC
+marmoset	I-SPEC
+models	O
+of	O
+MERS	O
+-	O
+CoV	O
+span	O
+the	O
+wide	O
+range	O
+of	O
+disease	O
+severity	O
+reported	O
+in	O
+MERS	O
+-	O
+CoV	O
+-	O
+infected	O
+humans	B-SPEC
+,	O
+which	O
+will	O
+aid	O
+in	O
+investigating	O
+MERS	O
+-	O
+CoV	O
+disease	O
+pathogenesis	B-DISO
+.	O
+
+ABSTRACT	O
+:	O
+This	O
+commentary	O
+highlights	O
+the	O
+article	O
+by	O
+Ng	O
+et	O
+al	O
+,	O
+emphasizing	O
+the	O
+need	O
+for	O
+autopsies	O
+to	O
+better	O
+model	O
+infectious	B-DISO
+diseases	I-DISO
+such	O
+as	O
+Middle	O
+East	O
+respiratory	O
+syndrome	B-DISO
+.	O
+
+The	O
+common	O
+causes	O
+for	O
+poor	O
+outcome	O
+were	O
+multiorgan	B-DISO
+failure	I-DISO
+,	O
+encephalopathy	B-DISO
+and	O
+refractory	B-DISO
+shock	I-DISO
+.	O
+
+The	O
+atypical	O
+manifestations	O
+of	O
+dengue	B-DISO
+fever	I-DISO
+are	O
+no	O
+more	O
+a	O
+rare	O
+entity	O
+.	O
+
+Clinicians	O
+should	O
+have	O
+a	O
+high	O
+index	O
+of	O
+suspicion	O
+and	O
+vigilance	O
+for	O
+atypical	O
+manifestations	O
+of	O
+dengue	B-DISO
+fever	I-DISO
+as	O
+lack	O
+of	O
+timely	O
+detection	O
+and	O
+management	O
+could	O
+be	O
+fatal	O
+.	O
+
+Impaired	B-DISO
+consciousness	I-DISO
+was	O
+the	O
+most	O
+ominous	O
+atypical	O
+manifestation	O
+of	O
+severe	O
+dengue	B-DISO
+infection	B-DISO
+.	O
+
+The	O
+common	O
+causes	O
+for	O
+poor	O
+outcome	O
+were	O
+multiorgan	B-DISO
+failure	I-DISO
+,	O
+encephalopathy	B-DISO
+and	O
+refractory	B-DISO
+shock	I-DISO
+.	O
+
+TITLE	O
+:	O
+Anti	O
+-	O
+inflammatory	O
+effects	O
+of	O
+indirubin	O
+derivatives	O
+on	O
+influenza	B-SPEC
+A	I-SPEC
+virus	I-SPEC
+-	O
+infected	O
+human	B-SPEC
+pulmonary	B-ANAT
+microvascular	O
+endothelial	B-ANAT
+cells	I-ANAT
+.	O
+
+H9N2	O
+infection	O
+rapidly	O
+triggered	O
+the	O
+activation	O
+of	O
+innate	B-PROC
+immunity	I-PROC
+through	O
+phosphorylation	B-PROC
+of	O
+signaling	B-CHED
+molecules	I-CHED
+including	O
+mitogen	B-PRGE
+-	I-PRGE
+activated	I-PRGE
+protein	B-CHED
+kinases	I-PRGE
+(	O
+MAPKs	O
+)	O
+and	O
+signal	B-PRGE
+transducer	I-PRGE
+and	I-PRGE
+activator	I-PRGE
+of	I-PRGE
+transcription	I-PRGE
+(	O
+STAT	O
+)	O
+proteins	B-CHED
+.	O
+
+To	O
+study	O
+the	O
+genetic	O
+factors	O
+that	O
+regulate	O
+pathogenesis	B-DISO
+and	O
+transmission	O
+,	O
+we	O
+developed	O
+a	O
+molecular	O
+clone	O
+of	O
+PEDV	B-SPEC
+strain	O
+PC22A	O
+.	O
+
+However	O
+,	O
+the	O
+diarrheic	O
+scores	O
+in	O
+icPEDV	O
+-	O
+ΔORF3	O
+-	O
+RFP	B-CHED
+-	O
+infected	O
+pigs	B-SPEC
+were	O
+lower	O
+than	O
+those	O
+in	O
+wild	O
+-	O
+type	O
+-	O
+virus	B-SPEC
+-	O
+or	O
+icPEDV	O
+-	O
+infected	O
+pigs	B-SPEC
+,	O
+and	O
+the	O
+virus	B-SPEC
+formed	O
+smaller	O
+plaques	B-DISO
+than	O
+those	O
+of	O
+PC22A	O
+.	O
+
+We	O
+reported	O
+previously	O
+that	O
+myeloid	B-ANAT
+cells	I-ANAT
+express	O
+significantly	O
+higher	O
+basal	O
+levels	O
+of	O
+OAS	B-DISO
+transcripts	O
+than	O
+nonmyeloid	O
+cells	B-COMP
+.	O
+
+However	O
+,	O
+ns2	B-DISO
+(	O
+H126R	O
+)	O
+failed	O
+to	O
+induce	O
+RNase	B-PRGE
+L	I-PRGE
+activation	O
+in	O
+BMM	O
+treated	O
+with	O
+IFNAR1	B-PRGE
+-	I-PRGE
+blocking	I-PRGE
+antibody	B-COMP
+,	O
+as	O
+well	O
+as	O
+in	O
+Ifnar1	O
+(-/-)	O
+BMM	O
+,	O
+both	O
+expressing	O
+low	O
+basal	O
+levels	O
+of	O
+Oas	B-DISO
+genes	O
+.	O
+
+Thus	O
+,	O
+activation	O
+of	O
+RNase	B-PRGE
+L	I-PRGE
+does	O
+not	O
+require	O
+virus	B-SPEC
+-	O
+induced	O
+IFN	B-PRGE
+but	O
+rather	O
+correlates	O
+with	O
+adequate	O
+levels	O
+of	O
+basal	O
+Oas	B-PRGE
+gene	B-PROC
+expression	I-PROC
+,	O
+maintained	O
+by	O
+basal	O
+IFN	B-PRGE
+signaling	B-PROC
+.	O
+
+Comparison	O
+of	O
+macro	O
+domains	O
+from	O
+MERS	O
+-	O
+CoV	O
+and	O
+other	O
+human	B-SPEC
+CoVs	O
+revealed	O
+structural	O
+differences	O
+in	O
+the	O
+α1	O
+helix	O
+alters	O
+how	O
+the	O
+conserved	O
+Asp	B-CHED
+-	O
+20	O
+interacts	O
+with	O
+ADP	B-CHED
+-	O
+ribose	B-CHED
+and	O
+may	O
+explain	O
+the	O
+efficient	O
+binding	B-FUNC
+of	O
+the	O
+MERS	O
+-	O
+CoV	O
+macro	O
+domain	O
+to	O
+ADP	O
+-	O
+ribose	B-CHED
+.	O
+
+ABSTRACT	O
+:	O
+This	O
+study	O
+investigated	O
+the	O
+association	O
+between	O
+presence	O
+of	O
+respiratory	O
+pathogens	O
+and	O
+development	B-PROC
+of	O
+Canine	O
+Infectious	B-DISO
+Respiratory	B-DISO
+Disease	I-DISO
+Complex	O
+(	O
+CIRDC	O
+)	O
+in	O
+dogs	B-SPEC
+in	O
+5	O
+Canadian	O
+small	O
+animal	B-SPEC
+clinics	O
+.	O
+
+TITLE	O
+:	O
+Clinical	O
+Implications	O
+of	O
+5	O
+Cases	O
+of	O
+Middle	O
+East	O
+Respiratory	O
+Syndrome	B-DISO
+Coronavirus	B-DISO
+Infection	I-DISO
+in	O
+a	O
+South	O
+Korean	O
+Outbreak	O
+.	O
+
+A	O
+shorter	O
+incubation	O
+period	O
+was	O
+associated	O
+with	O
+more	O
+severe	O
+disease	O
+and	O
+greater	O
+risk	O
+of	O
+mortality	O
+,	O
+and	O
+the	O
+severity	O
+of	O
+fever	B-PROC
+predicted	O
+the	O
+prognosis	O
+of	O
+MERS	O
+-	O
+CoV	O
+infection	B-DISO
+-	O
+related	O
+pneumonia	B-DISO
+.	O
+
+In	O
+our	O
+study	O
+,	O
+the	O
+clinical	O
+,	O
+laboratory	O
+and	O
+histopathological	O
+findings	O
+confirmed	O
+sepsis	B-DISO
+and	O
+the	O
+damage	O
+of	O
+the	O
+alveolar	B-ANAT
+-	O
+capillary	B-ANAT
+membrane	B-COMP
+in	O
+a	O
+dose	O
+-	O
+dependent	O
+manner	O
+.	O
+
+TITLE	O
+:	O
+Heterologous	O
+live	O
+infectious	B-DISO
+bronchitis	B-DISO
+virus	B-SPEC
+vaccination	O
+in	O
+day	O
+-	O
+old	O
+commercial	O
+broiler	O
+chicks	O
+:	O
+clinical	O
+signs	O
+,	O
+ciliary	O
+health	O
+,	O
+immune	O
+responses	O
+and	O
+protection	O
+against	O
+variant	O
+infectious	B-DISO
+bronchitis	B-DISO
+viruses	B-SPEC
+.	O
+
+Significantly	O
+higher	O
+levels	O
+of	O
+CD4	B-PRGE
++	I-PRGE
+and	O
+CD8	B-PRGE
++	I-PRGE
+expression	B-PROC
+were	O
+observed	O
+in	O
+the	O
+Mass2	O
++	O
+793B2	O
+-	O
+vaccinated	O
+group	O
+compared	O
+to	O
+the	O
+other	O
+groups	O
+(	O
+subscripts	O
+indicate	O
+different	O
+manufacturers	O
+).	O
+
+ABSTRACT	O
+:	O
+Porcine	O
+epidemic	O
+diarrhea	O
+virus	O
+(	O
+PEDV	B-SPEC
+)	O
+has	O
+caused	O
+devastating	O
+impact	O
+on	O
+pig	B-SPEC
+-	O
+rearing	O
+industry	O
+in	O
+China	O
+and	O
+current	O
+vaccine	O
+is	O
+not	O
+effective	O
+against	O
+the	O
+circulating	O
+PEDV	B-SPEC
+variants	O
+.	O
+
+TITLE	O
+:	O
+Abdominal	B-ANAT
+Muscle	I-ANAT
+Activity	O
+during	O
+Mechanical	O
+Ventilation	O
+Increases	O
+Lung	B-ANAT
+Injury	O
+in	O
+Severe	O
+Acute	B-DISO
+Respiratory	I-DISO
+Distress	I-DISO
+Syndrome	I-DISO
+.	O
+
+ABSTRACT	O
+:	O
+It	O
+has	O
+proved	O
+that	O
+muscle	B-ANAT
+paralysis	O
+was	O
+more	O
+protective	O
+for	O
+injured	O
+lung	B-ANAT
+in	O
+severe	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+(	O
+ARDS	B-DISO
+),	O
+but	O
+the	O
+precise	O
+mechanism	O
+is	O
+not	O
+clear	O
+.	O
+
+Respiratory	O
+variables	O
+,	O
+end	O
+-	O
+expiratory	O
+volume	O
+(	O
+EELV	O
+)	O
+and	O
+gas	B-ENZY
+exchange	O
+were	O
+assessed	O
+during	O
+mechanical	O
+ventilation	O
+.	O
+
+CONCLUSIONS	O
+:	O
+Abdominal	B-ANAT
+muscle	I-ANAT
+activity	O
+during	O
+mechanically	O
+ventilation	O
+is	O
+one	O
+of	O
+the	O
+injurious	O
+factors	O
+in	O
+severe	O
+ARDS	B-DISO
+,	O
+so	O
+abdominal	B-ANAT
+muscle	I-ANAT
+paralysis	O
+might	O
+be	O
+an	O
+effective	O
+strategy	O
+to	O
+minimize	O
+ventilator	O
+-	O
+induce	O
+lung	B-ANAT
+injury	O
+.	O
+
+Mortality	O
+associated	O
+risk	O
+factors	O
+,	O
+the	O
+use	O
+of	O
+rescue	O
+therapies	O
+and	O
+Berlin	O
+'	O
+s	O
+stratification	O
+for	O
+moderate	O
+and	O
+severe	O
+ARDS	B-DISO
+patients	O
+were	O
+considered	O
+.	O
+
+Co	B-DISO
+-	I-DISO
+infection	I-DISO
+caused	O
+significantly	O
+higher	O
+rates	O
+of	O
+breathing	B-DISO
+difficulties	I-DISO
+,	O
+cough	B-DISO
+,	O
+and	O
+sore	B-DISO
+throat	I-DISO
+than	O
+those	O
+of	O
+single	O
+infection	B-DISO
+with	O
+HCoV	B-SPEC
+-	I-SPEC
+NL63	I-SPEC
+and	O
+influenza	B-PATH
+A	I-PATH
+/	O
+H1N1	O
+.	O
+
+This	O
+study	O
+involved	O
+participants	O
+and	O
+data	O
+from	O
+an	O
+existing	O
+program	O
+called	O
+the	O
+Swine	B-SPEC
+Health	O
+Monitoring	O
+Project	O
+.	O
+
+These	O
+data	O
+,	O
+in	O
+conjunction	O
+with	O
+diagnostic	O
+reports	O
+,	O
+were	O
+used	O
+to	O
+estimate	O
+the	O
+time	O
+required	O
+for	O
+the	O
+herd	O
+to	O
+produce	O
+PEDV	B-SPEC
+PCR	O
+negative	O
+pigs	B-SPEC
+and	O
+the	O
+production	O
+loss	O
+.	O
+
+The	O
+pathophysiological	O
+causes	O
+are	O
+:	O
+the	O
+change	O
+in	O
+the	O
+pressure	O
+gradients	O
+in	O
+the	O
+pulmonary	B-ANAT
+capillaries	B-ANAT
+,	O
+the	O
+impaired	B-DISO
+membrane	B-PROC
+permeability	I-PROC
+of	O
+the	O
+alveolocapillary	O
+in	O
+the	O
+lungs	B-ANAT
+,	O
+and	O
+impaired	B-DISO
+lymphatic	B-ANAT
+drainage	B-ANAT
+.	O
+
+Acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+(	O
+ARDS	B-DISO
+)	O
+is	O
+the	O
+most	O
+common	O
+cause	O
+of	O
+respiratory	B-DISO
+failure	I-DISO
+.	O
+
+Despite	O
+the	O
+publication	O
+of	O
+the	O
+ARDSNet	O
+study	O
+and	O
+adoption	O
+of	O
+lung	B-ANAT
+protective	O
+ventilation	O
+,	O
+the	O
+mortality	O
+for	O
+acute	B-DISO
+respiratory	I-DISO
+failure	I-DISO
+due	O
+to	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+has	O
+continued	O
+to	O
+remain	O
+high	O
+.	O
+
+This	O
+technology	O
+has	O
+evolved	O
+over	O
+the	O
+past	O
+couple	O
+of	O
+decades	O
+and	O
+has	O
+been	O
+noted	O
+to	O
+be	O
+safe	O
+and	O
+successful	O
+,	O
+especially	O
+during	O
+the	O
+worldwide	O
+H1N1	B-DISO
+influenza	I-DISO
+pandemic	O
+with	O
+good	O
+survival	O
+rates	O
+.	O
+
+Critically	B-DISO
+ill	I-DISO
+children	O
+aged	O
+from	O
+2	O
+months	O
+to	O
+18	O
+years	O
+were	O
+included	O
+.	O
+
+Of	O
+380	O
+children	O
+,	O
+53	O
+children	O
+(	O
+14	O
+%)	O
+had	O
+AKI	O
+(	O
+met	B-CHED
+any	O
+of	O
+the	O
+RIFLE	O
+criteria	O
+).	O
+
+Significant	O
+risk	O
+factors	O
+for	O
+AKI	B-PRGE
+following	O
+multivariate	O
+analysis	O
+were	O
+:	O
+age	O
+1	O
+-	O
+5	O
+,	O
+PRISM	O
+score	O
+(>	O
+10	O
+)	O
+at	O
+admission	O
+,	O
+shock	O
+,	O
+infection	B-DISO
+,	O
+thrombocytopenia	O
+,	O
+hypo	O
+-	O
+albuminaemia	O
+and	O
+multi	O
+-	O
+organ	B-ANAT
+dysfunction	O
+.	O
+
+The	O
+presence	O
+of	O
+pathogens	O
+in	O
+piglets	O
+alone	O
+does	O
+not	O
+determine	O
+the	O
+occurrence	O
+of	O
+diarrhea	B-DISO
+episodes	O
+.	O
+
+ABSTRACT	O
+:	O
+Herein	O
+,	O
+we	O
+disclose	O
+a	O
+general	O
+and	O
+flexible	O
+access	O
+to	O
+spirocyclopropyl	O
+oxindoles	O
+by	O
+a	O
+domino	O
+Michael	O
+/	O
+intramolecular	O
+nucleophilic	O
+substitution	O
+pathway	B-PROC
+with	O
+variously	O
+substituted	O
+vinyl	B-CHED
+selenones	O
+and	O
+enolizable	O
+oxindoles	O
+in	O
+aqueous	O
+sodium	B-CHED
+hydroxide	I-CHED
+solution	O
+.	O
+
+Rapid	O
+and	O
+strong	O
+stiffening	O
+of	O
+primary	O
+neutrophils	B-ANAT
+and	O
+monocytes	B-ANAT
+was	O
+induced	O
+within	O
+30	O
+minutes	O
+(	O
+mean	O
+ET	O
+>	O
+50	O
+seconds	O
+)	O
+by	O
+sera	B-COMP
+from	O
+the	O
+ARDS	B-DISO
+group	O
+compared	O
+with	O
+both	O
+the	O
+healthy	O
+subjects	O
+and	O
+the	O
+ACPE	O
+groups	O
+(	O
+mean	O
+ET	O
+<	O
+1	O
+second	O
+)	O
+(	O
+p	O
+<	O
+0	O
+.	O
+05	O
+).	O
+
+The	O
+inhibition	B-PROC
+of	O
+leukocyte	B-ANAT
+stiffening	O
+with	O
+blocking	B-DISO
+antibodies	B-COMP
+might	O
+inspire	O
+future	O
+therapeutic	O
+strategies	O
+.	O
+
+(	O
+5	O
+)	O
+There	O
+were	O
+16	O
+hospitalized	O
+cases	O
+with	O
+single	O
+infection	B-DISO
+of	O
+HCoVs	O
+in	O
+this	O
+study	O
+,	O
+of	O
+which	O
+12	O
+cases	O
+were	O
+diagnosed	O
+as	O
+bronchopneumonia	B-DISO
+,	O
+3	O
+cases	O
+developed	O
+acute	O
+laryngeal	B-DISO
+obstruction	I-DISO
+,	O
+2	O
+cases	O
+had	O
+acute	O
+bronchial	B-DISO
+asthma	B-PATH
+attack	O
+.	O
+
+(	O
+6	O
+)	O
+There	O
+were	O
+no	O
+significant	O
+differences	O
+in	O
+the	O
+incidence	O
+of	O
+clinical	O
+manifestations	O
+(	O
+including	O
+cough	B-DISO
+,	O
+gasping	B-DISO
+,	O
+dyspnea	B-DISO
+,	O
+fever	B-PROC
+and	O
+abnormality	O
+on	O
+chest	B-ANAT
+X	O
+-	O
+ray	B-SPEC
+),	O
+complications	O
+(	O
+including	O
+respiratory	B-DISO
+failure	I-DISO
+,	O
+myocardial	O
+damage	O
+,	O
+and	O
+acute	O
+bronchial	B-DISO
+asthma	B-PATH
+attack	O
+)	O
+and	O
+mechanical	O
+ventilation	O
+between	O
+hospitalized	O
+ALRTI	O
+patients	O
+with	O
+single	O
+HCoV	O
+infection	B-DISO
+and	O
+193	O
+patients	O
+with	O
+single	O
+RSV	B-DISO
+infection	I-DISO
+in	O
+the	O
+same	O
+period	O
+.	O
+
+The	O
+clinical	O
+presentation	O
+of	O
+the	O
+children	O
+infected	O
+with	O
+the	O
+pandemic	O
+(	O
+H1N1	O
+)	O
+2009	O
+influenza	B-SPEC
+virus	I-SPEC
+did	O
+not	O
+differ	O
+significantly	O
+from	O
+that	O
+of	O
+children	O
+infected	O
+with	O
+seasonal	O
+influenza	B-DISO
+.	O
+
+The	O
+CCoV	O
+prevalence	O
+in	O
+diarrheic	O
+dogs	B-SPEC
+differed	O
+significantly	O
+with	O
+immunization	O
+status	O
+,	O
+regions	O
+,	O
+seasons	O
+,	O
+and	O
+ages	O
+.	O
+
+The	O
+26	B-PRGE
+CCoV	I-PRGE
+-	I-PRGE
+IIa	I-PRGE
+strains	O
+showed	O
+genetic	O
+diversity	O
+when	O
+compared	O
+with	O
+reference	O
+strains	O
+from	O
+China	O
+and	O
+other	O
+countries	O
+.	O
+
+TITLE	O
+:	O
+Impact	O
+of	O
+Mated	B-PROC
+Female	O
+Nonproductive	O
+Days	O
+in	O
+Breeding	B-PROC
+Herd	O
+after	O
+Porcine	B-SPEC
+Epidemic	B-DISO
+Diarrhea	I-DISO
+Virus	I-SPEC
+Outbreak	O
+.	O
+
+Impacts	O
+of	O
+the	O
+PEDV	B-SPEC
+infection	B-DISO
+on	O
+the	O
+reproductive	B-PROC
+performance	O
+were	O
+more	O
+severe	O
+in	O
+pregnant	O
+gilts	O
+than	O
+in	O
+sows	O
+.	O
+
+TITLE	O
+:	O
+Development	B-PROC
+of	O
+a	O
+Neutralizing	O
+Monoclonal	O
+Antibody	B-COMP
+Against	O
+Porcine	B-SPEC
+Epidemic	I-SPEC
+Diarrhea	I-SPEC
+Virus	I-SPEC
+S1	O
+Protein	O
+.	O
+
+The	O
+two	O
+monoclonal	O
+antibodies	B-COMP
+specifically	O
+reacted	O
+with	O
+PEDV	B-PRGE
+rS1	I-PRGE
+protein	B-CHED
+,	O
+as	O
+proven	O
+by	O
+Western	O
+blot	O
+and	O
+indirect	O
+immunofluorescence	O
+assay	O
+.	O
+
+ABSTRACT	O
+:	O
+The	O
+functional	O
+role	O
+of	O
+the	O
+ELR	B-PRGE
+(+)	I-PRGE
+chemokine	I-PRGE
+CXCL1	I-PRGE
+in	O
+host	B-PROC
+defense	I-PROC
+and	O
+disease	O
+following	O
+infection	B-DISO
+of	O
+the	O
+CNS	B-CHED
+with	O
+the	O
+neurotropic	O
+JHM	O
+strain	O
+of	O
+mouse	B-DISO
+hepatitis	I-DISO
+virus	B-SPEC
+(	O
+JHMV	O
+)	O
+was	O
+examined	O
+.	O
+
+A	O
+further	O
+study	O
+showed	O
+that	O
+the	O
+CBP	B-PRGE
+degradation	O
+by	O
+nsp1	B-PRGE
+was	O
+proteasome	B-PATH
+-	O
+dependent	O
+.	O
+
+TITLE	O
+:	O
+Deciphering	O
+MERS	O
+-	O
+CoV	O
+Evolution	B-PROC
+in	O
+Dromedary	B-SPEC
+Camels	B-SPEC
+.	O
+
+A	O
+recent	O
+study	O
+provides	O
+new	O
+insights	O
+into	O
+the	O
+evolution	B-PROC
+and	O
+transmission	O
+of	O
+MERS	O
+-	O
+CoV	O
+in	O
+dromedary	B-SPEC
+camels	B-SPEC
+.	O
+
+TITLE	O
+:	O
+Hajj	O
+-	O
+associated	O
+viral	O
+respiratory	B-DISO
+infections	I-DISO
+:	O
+A	O
+systematic	O
+review	O
+.	O
+
+Severe	B-DISO
+Acute	I-DISO
+Respiratory	I-DISO
+Syndrome	I-DISO
+coronavirus	B-SPEC
+and	O
+Middle	O
+East	O
+Respiratory	O
+Syndrome	B-DISO
+coronavirus	B-SPEC
+(	O
+MERS	O
+)	O
+were	O
+never	O
+isolated	O
+in	O
+Hajj	O
+pilgrims	O
+.	O
+
+The	O
+viruses	B-SPEC
+most	O
+commonly	O
+isolated	O
+from	O
+symptomatic	O
+patients	O
+during	O
+the	O
+Hajj	O
+by	O
+PCR	O
+were	O
+rhinovirus	B-SPEC
+(	O
+5	O
+.	O
+9	O
+-	O
+48	O
+.	O
+8	O
+%	O
+prevalence	O
+),	O
+followed	O
+by	O
+influenza	B-SPEC
+virus	I-SPEC
+(	O
+4	O
+.	O
+5	O
+-	O
+13	O
+.	O
+9	O
+%)	O
+and	O
+non	O
+-	O
+MERS	O
+coronaviruses	O
+(	O
+2	O
+.	O
+7	O
+-	O
+13	O
+.	O
+2	O
+%)	O
+with	O
+most	O
+infections	B-DISO
+due	O
+to	O
+coronavirus	B-SPEC
+229E	O
+;	O
+other	O
+viruses	B-SPEC
+were	O
+less	O
+frequently	O
+isolated	O
+.	O
+
+ABSTRACT	O
+:	O
+Respiratory	O
+viruses	O
+spread	O
+in	O
+humans	B-SPEC
+across	O
+wide	O
+geographical	O
+areas	O
+in	O
+short	O
+periods	B-PROC
+of	O
+time	O
+,	O
+resulting	O
+in	O
+high	O
+levels	O
+of	O
+morbidity	O
+and	O
+mortality	O
+.	O
+
+There	O
+is	O
+no	O
+recent	O
+evidence	O
+of	O
+sea	O
+transport	B-PROC
+accelerating	O
+influenza	B-DISO
+or	O
+coronavirus	B-SPEC
+spread	O
+to	O
+new	O
+areas	O
+.	O
+
+Lentiviral	O
+and	O
+rhabdoviral	O
+pseudotypes	O
+are	O
+excellent	O
+tools	O
+for	O
+studying	O
+enveloped	O
+viruses	B-SPEC
+and	O
+have	O
+contributed	O
+to	O
+many	O
+recent	O
+advances	O
+in	O
+areas	O
+such	O
+as	O
+receptor	O
+usage	O
+,	O
+viral	O
+entry	O
+and	O
+serology	O
+.	O
+
+They	O
+also	O
+allow	O
+the	O
+initial	O
+characterization	O
+of	O
+aspects	O
+of	O
+infection	B-DISO
+such	O
+as	O
+cellular	B-PROC
+tropism	B-PROC
+for	O
+difficult	O
+to	O
+culture	O
+viruses	B-SPEC
+.	O
+
+Simultaneously	O
+,	O
+P	O
+(	O
+tcCO2	O
+)	O
+was	O
+measured	O
+using	O
+a	O
+digital	B-ANAT
+monitor	O
+.	O
+
+TITLE	O
+:	O
+A	O
+molecular	O
+arms	B-DISO
+race	O
+between	O
+host	B-COMP
+innate	O
+antiviral	B-PROC
+response	I-PROC
+and	O
+emerging	O
+human	B-SPEC
+coronaviruses	O
+.	O
+
+On	O
+the	O
+other	O
+hand	O
+,	O
+the	O
+counter	B-CHED
+-	O
+measures	O
+evolved	O
+by	O
+SARS	B-DISO
+and	O
+MERS	O
+coronaviruses	O
+to	O
+circumvent	O
+host	B-PROC
+defense	I-PROC
+are	O
+also	O
+dissected	O
+.	O
+
+The	O
+present	O
+guideline	O
+has	O
+been	O
+drafted	O
+on	O
+the	O
+basis	O
+of	O
+the	O
+experiences	O
+of	O
+infection	B-DISO
+control	O
+in	O
+the	O
+South	O
+Korean	O
+hospitals	O
+involved	O
+in	O
+the	O
+recent	O
+MERS	O
+outbreak	O
+and	O
+on	O
+domestic	O
+and	O
+international	O
+infection	B-DISO
+prevention	O
+and	O
+control	O
+guidelines	O
+.	O
+
+To	O
+ensure	O
+efficient	O
+MERS	O
+-	O
+CoV	O
+infection	B-DISO
+prevention	O
+and	O
+control	O
+,	O
+care	O
+should	O
+be	O
+taken	O
+to	O
+provide	O
+comprehensive	O
+infection	O
+control	O
+measures	O
+including	O
+contact	O
+control	O
+,	O
+hand	O
+hygiene	O
+,	O
+personal	O
+protective	O
+equipment	O
+,	O
+disinfection	O
+,	O
+and	O
+environmental	O
+cleaning	O
+.	O
+
+ABSTRACT	O
+:	O
+Mucolipidosis	B-DISO
+(	O
+ML	O
+)	O
+II	O
+alpha	O
+/	O
+beta	O
+is	O
+an	O
+autosomal	B-COMP
+recessive	O
+disease	O
+caused	O
+by	O
+reduced	O
+enzyme	B-FUNC
+activity	I-FUNC
+of	O
+N	B-CHED
+-	I-CHED
+acetylglucosamine	I-CHED
+-	O
+1	O
+-	O
+phosphotransferase	O
+.	O
+
+ABSTRACT	O
+:	O
+Middle	O
+East	O
+respiratory	O
+syndrome	O
+coronavirus	B-SPEC
+(	O
+MERS	O
+-	O
+CoV	O
+)	O
+is	O
+an	O
+emerging	O
+human	B-SPEC
+pathogen	O
+related	O
+to	O
+SARS	B-DISO
+virus	B-SPEC
+.	O
+
+In	O
+vitro	O
+studies	O
+indicate	O
+this	O
+virus	B-SPEC
+may	O
+have	O
+a	O
+broad	O
+host	B-COMP
+range	O
+suggesting	O
+an	O
+increased	O
+pandemic	O
+potential	O
+.	O
+
+Genetic	O
+and	O
+epidemiological	O
+evidence	O
+indicate	O
+camels	B-SPEC
+serve	O
+as	O
+a	O
+reservoir	O
+for	O
+MERS	O
+virus	B-SPEC
+but	O
+the	O
+mechanism	O
+of	O
+cross	O
+species	B-SPEC
+transmission	O
+is	O
+unclear	O
+and	O
+many	O
+questions	O
+remain	O
+regarding	O
+the	O
+susceptibility	O
+of	O
+humans	B-SPEC
+to	O
+infection	B-DISO
+.	O
+
+Deep	O
+sequencing	O
+data	O
+was	O
+obtained	O
+from	O
+the	O
+nasal	B-ANAT
+samples	O
+of	O
+three	O
+camels	B-SPEC
+that	O
+had	O
+been	O
+experimentally	O
+infected	O
+with	O
+a	O
+human	B-SPEC
+MERS	O
+-	O
+CoV	O
+isolate	O
+.	O
+
+In	O
+this	O
+context	O
+,	O
+this	O
+present	O
+review	O
+summarizes	O
+a	O
+large	O
+body	B-ANAT
+of	O
+evidence	O
+implicating	O
+miRNAs	O
+and	O
+their	O
+target	O
+molecules	O
+in	O
+ALI	O
+/	O
+ARDS	B-DISO
+originating	O
+largely	O
+from	O
+studies	O
+using	O
+animal	B-SPEC
+and	O
+cell	B-COMP
+culture	O
+model	O
+systems	O
+of	O
+ALI	O
+/	O
+ARDS	B-DISO
+.	O
+
+We	O
+have	O
+also	O
+focused	O
+on	O
+the	O
+involvement	O
+of	O
+miRNAs	O
+in	O
+macrophage	B-ANAT
+polarization	O
+,	O
+which	O
+play	O
+a	O
+critical	O
+role	O
+in	O
+regulating	O
+the	O
+pathogenesis	O
+of	O
+ALI	O
+/	O
+ARDS	B-DISO
+.	O
+
+Here	O
+,	O
+we	O
+performed	O
+a	O
+comprehensive	O
+review	O
+of	O
+published	O
+literature	O
+and	O
+summarized	O
+the	O
+epidemiology	O
+of	O
+the	O
+virus	B-SPEC
+.	O
+
+In	O
+addition	O
+,	O
+we	O
+summarized	O
+the	O
+virological	O
+aspects	O
+of	O
+the	O
+infection	B-DISO
+and	O
+reviewed	O
+the	O
+animal	B-SPEC
+models	O
+used	O
+as	O
+well	O
+as	O
+vaccination	O
+and	O
+antiviral	B-CHED
+tested	O
+against	O
+it	O
+.	O
+
+While	O
+position	O
+720	O
+is	O
+variable	O
+in	O
+camel	B-SPEC
+-	O
+derived	O
+viruses	B-SPEC
+,	O
+suggesting	O
+that	O
+the	O
+selective	O
+event	O
+does	O
+not	O
+represent	O
+a	O
+specific	O
+adaptation	B-PROC
+to	O
+humans	B-SPEC
+,	O
+the	O
+R911C	O
+substitution	O
+was	O
+observed	O
+only	O
+in	O
+human	B-SPEC
+-	O
+derived	O
+MERS	O
+-	O
+CoV	O
+isolates	O
+,	O
+including	O
+the	O
+viral	O
+strain	O
+responsible	O
+for	O
+the	O
+recent	O
+South	O
+Korean	O
+outbreak	O
+.	O
+
+We	O
+investigated	O
+the	O
+evolution	B-PROC
+of	O
+ORF1a	B-PRGE
+and	I-PRGE
+ORF1b	I-PRGE
+in	O
+lineage	O
+C	O
+betaCoVs	O
+and	O
+in	O
+87	O
+sequenced	O
+MERS	O
+-	O
+CoV	O
+isolates	O
+.	O
+
+Several	O
+selected	O
+sites	O
+were	O
+found	O
+to	O
+be	O
+located	O
+in	O
+functionally	O
+relevant	O
+protein	B-CHED
+regions	O
+,	O
+and	O
+some	O
+of	O
+them	O
+corresponded	O
+to	O
+functional	O
+mutations	O
+in	O
+other	O
+coronaviruses	O
+.	O
+
+S	O
+-	O
+MB	O
+DATK	O
+is	O
+an	O
+active	O
+mimic	O
+of	O
+native	O
+SP	O
+-	O
+B	O
+.	O
+Synthetic	O
+surfactants	B-CHED
+containing	O
+S	O
+-	O
+MB	O
+DATK	O
+(	O
+or	O
+related	O
+peptides	B-CHED
+)	O
+combined	O
+with	O
+lipids	B-CHED
+appear	O
+to	O
+have	O
+significant	O
+future	O
+potential	O
+for	O
+treating	O
+clinical	O
+states	O
+of	O
+surfactant	B-CHED
+deficiency	O
+or	O
+dysfunction	O
+,	O
+such	O
+as	O
+neonatal	O
+and	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndromes	B-DISO
+.	O
+
+However	O
+,	O
+despite	O
+diminished	O
+germinal	B-ANAT
+center	I-ANAT
+B	B-ANAT
+cells	I-ANAT
+and	O
+follicular	B-ANAT
+helper	B-ANAT
+T	I-ANAT
+cells	I-ANAT
+in	O
+draining	O
+lymph	B-ANAT
+nodes	I-ANAT
+,	O
+ASC	O
+in	O
+bone	B-ANAT
+marrow	I-ANAT
+and	O
+antiviral	B-CHED
+serum	B-COMP
+antibody	B-COMP
+were	O
+intact	O
+in	O
+the	O
+absence	O
+of	O
+CXCL13	B-PRGE
+.	O
+
+ABSTRACT	O
+:	O
+To	O
+compare	O
+the	O
+discrepancy	O
+between	O
+the	O
+new	O
+(	O
+2012	O
+)	O
+and	O
+the	O
+old	O
+(	O
+1992	O
+)	O
+Atlanta	B-SPEC
+classification	O
+criteria	O
+for	O
+defining	O
+severity	O
+,	O
+organ	B-DISO
+failure	I-DISO
+and	O
+local	O
+complications	O
+in	O
+patients	O
+with	O
+acute	B-DISO
+pancreatitis	I-DISO
+(	O
+AP	O
+).	O
+
+Multi	O
+-	O
+factor	O
+scoring	O
+system	O
+and	O
+single	O
+serum	B-COMP
+marker	O
+were	O
+recorded	O
+and	O
+calculated	O
+using	O
+the	O
+acute	B-DISO
+pancreatitis	I-DISO
+database	O
+.	O
+
+ABSTRACT	O
+:	O
+Radiologic	O
+findings	O
+of	O
+Middle	O
+East	O
+respiratory	O
+syndrome	O
+(	O
+MERS	O
+),	O
+a	O
+novel	B-SPEC
+coronavirus	I-SPEC
+infection	O
+,	O
+have	O
+been	O
+rarely	O
+reported	O
+.	O
+
+We	O
+report	O
+a	O
+30	O
+-	O
+year	O
+-	O
+old	O
+male	O
+presented	O
+with	O
+fever	B-PROC
+,	O
+abdominal	B-DISO
+pain	I-DISO
+,	O
+and	O
+diarrhea	B-DISO
+,	O
+who	O
+was	O
+diagnosed	O
+with	O
+MERS	O
+.	O
+
+The	O
+compound	O
+was	O
+also	O
+an	O
+inhibitor	B-CHED
+of	O
+the	O
+RNase	B-FUNC
+H	I-FUNC
+activity	I-FUNC
+of	O
+wild	B-PRGE
+-	I-PRGE
+type	I-PRGE
+HIV	I-PRGE
+-	I-PRGE
+1	I-PRGE
+group	I-PRGE
+O	I-PRGE
+RT	I-PRGE
+,	O
+although	O
+we	O
+observed	O
+a	O
+6	O
+.	O
+5	O
+-	O
+fold	O
+increase	O
+in	O
+the	O
+IC50	O
+in	O
+comparison	O
+with	O
+the	O
+prototypic	O
+HIV	B-SPEC
+-	I-SPEC
+1	I-SPEC
+group	O
+M	O
+subtype	O
+B	O
+enzyme	O
+.	O
+
+There	O
+are	O
+four	O
+major	O
+epitope	B-CHED
+regions	O
+in	O
+the	O
+spike	O
+glycoprotein	B-CHED
+:	O
+a	O
+CO	O
+-	O
+26K	O
+equivalent	O
+(	O
+COE	O
+)	O
+domain	O
+,	O
+SS2	B-PRGE
+and	O
+SS6	O
+epitopes	O
+,	O
+and	O
+an	O
+epitope	B-CHED
+region	O
+recognized	O
+by	O
+the	O
+2C10	O
+monoclonal	O
+antibody	B-COMP
+.	O
+
+Phylogenetic	O
+analysis	O
+of	O
+the	O
+complete	O
+spike	O
+gene	O
+sequences	O
+from	O
+the	O
+seven	O
+strains	O
+revealed	O
+that	O
+they	O
+clustered	O
+within	O
+the	O
+G2	O
+group	O
+but	O
+were	O
+distantly	O
+related	O
+to	O
+the	O
+North	O
+American	O
+and	O
+INDELs	O
+clusters	B-CHED
+.	O
+
+In	O
+addition	O
+,	O
+antibody	B-COMP
+neutralization	O
+assay	O
+and	O
+shRNA	O
+knockdown	O
+experiments	O
+indicated	O
+a	O
+vital	O
+role	O
+of	O
+vimentin	B-COMP
+in	O
+cell	B-COMP
+binding	B-FUNC
+and	O
+uptake	O
+of	O
+SARS	B-PRGE
+-	I-PRGE
+CoV	I-PRGE
+VLPs	B-ANAT
+and	O
+the	O
+viral	O
+spike	O
+protein	B-CHED
+.	O
+
+RESULTS	O
+:	O
+A	O
+host	B-COMP
+intracellular	I-COMP
+filamentous	O
+cytoskeletal	B-COMP
+protein	B-CHED
+vimentin	B-COMP
+was	O
+identified	O
+by	O
+immunoprecipitation	O
+and	O
+LC	O
+-	O
+MS	O
+/	O
+MS	O
+analysis	O
+following	O
+chemical	O
+cross	O
+-	O
+linking	O
+on	O
+Vero	O
+E6	O
+cells	B-COMP
+that	O
+were	O
+pre	O
+-	O
+incubated	O
+with	O
+the	O
+SARS	B-PRGE
+-	I-PRGE
+CoV	I-PRGE
+spike	I-PRGE
+protein	B-CHED
+.	O
+
+The	O
+DIA	B-CHED
+showed	O
+9	O
+.	O
+41	O
+%	O
+higher	O
+sensitivity	O
+and	O
+15	O
+.	O
+5	O
+%	O
+higher	O
+specificity	O
+than	O
+the	O
+clinical	O
+sign	O
+determination	O
+method	O
+.	O
+
+None	O
+of	O
+the	O
+patients	O
+with	O
+moderately	O
+severe	O
+AP	O
+died	B-PROC
+during	O
+their	O
+intensive	O
+care	O
+unit	O
+stay	O
+vs	O
+.	O
+29	O
+.	O
+5	O
+%	O
+with	O
+severe	O
+AP	O
+(	O
+p	O
+=	O
+0	O
+.	O
+049	O
+).	O
+
+By	O
+the	O
+single	O
+factor	O
+analysis	O
+,	O
+the	O
+following	O
+lab	O
+data	O
+in	O
+the	O
+death	B-PROC
+group	O
+were	O
+found	O
+significantly	O
+lower	O
+than	O
+those	O
+in	O
+the	O
+survival	O
+group	O
+:	O
+S	O
+-	O
+ChE	O
+levels	O
+(	O
+kU	O
+/	O
+L	O
+:	O
+2	O
+.	O
+748	O
+±	O
+0	O
+.	O
+826	O
+vs	O
+.	O
+4	O
+.	O
+489	O
+±	O
+1	O
+.	O
+360	O
+,	O
+t	O
+'	O
+=	O
+7	O
+.	O
+274	O
+,	O
+P	O
+=	O
+0	O
+.	O
+000	O
+),	O
+arterial	B-ANAT
+partial	B-PROC
+pressure	I-PROC
+of	I-PROC
+oxygen	I-PROC
+[	O
+PaO2	O
+(	O
+mmHg	O
+,	O
+1	O
+mmHg	O
+=	O
+0	O
+.	O
+133	O
+kPa	O
+):	O
+52	O
+.	O
+55	O
+±	O
+18	O
+.	O
+29	O
+vs	O
+.	O
+60	O
+.	O
+83	O
+±	O
+16	O
+.	O
+65	O
+,	O
+t	O
+=	O
+2	O
+.	O
+196	O
+,	O
+P	O
+=	O
+0	O
+.	O
+031	O
+],	O
+oxygenation	B-PROC
+index	O
+(	O
+mmHg	O
+:	O
+114	O
+.	O
+20	O
+±	O
+48	O
+.	O
+01	O
+vs	O
+.	O
+167	O
+.	O
+10	O
+±	O
+69	O
+.	O
+68	O
+,	O
+t	O
+'	O
+=	O
+4	O
+.	O
+229	O
+,	O
+P	O
+=	O
+0	O
+.	O
+000	O
+),	O
+and	O
+carbon	B-CHED
+dioxide	I-CHED
+combining	O
+power	O
+[	O
+CO2	B-CHED
+-	O
+CP	O
+(	O
+mmol	O
+/	O
+L	O
+):	O
+22	O
+.	O
+85	O
+±	O
+5	O
+.	O
+44	O
+vs	O
+.	O
+26	O
+.	O
+00	O
+±	O
+7	O
+.	O
+63	O
+,	O
+t	O
+'	O
+=	O
+2	O
+.	O
+225	O
+,	O
+P	O
+=	O
+0	O
+.	O
+029	O
+].	O
+
+The	O
+sensitivity	O
+,	O
+specificity	O
+,	O
+positive	O
+predictive	O
+value	O
+and	O
+negative	O
+predictive	O
+value	O
+in	O
+predicting	O
+death	B-PROC
+risk	O
+in	O
+patients	O
+with	O
+severe	O
+pneumonia	B-DISO
+were	O
+(	O
+80	O
+.	O
+0	O
+%,	O
+78	O
+.	O
+0	O
+%,	O
+76	O
+.	O
+19	O
+%	O
+and	O
+81	O
+.	O
+82	O
+%),	O
+(	O
+95	O
+.	O
+0	O
+%,	O
+70	O
+.	O
+0	O
+%,	O
+73	O
+.	O
+08	O
+%	O
+and	O
+94	O
+.	O
+12	O
+%)	O
+and	O
+(	O
+70	O
+.	O
+0	O
+%,	O
+91	O
+.	O
+0	O
+%,	O
+87	O
+.	O
+50	O
+%,	O
+77	O
+.	O
+78	O
+%),	O
+respectively	O
+.	O
+
+TITLE	O
+:	O
+Can	O
+lung	B-ANAT
+ultrasonography	O
+predict	O
+prone	O
+positioning	O
+response	O
+in	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+patients	O
+?	O
+
+The	O
+latter	O
+was	O
+assessed	O
+for	O
+at	O
+least	O
+12	O
+hours	O
+6	O
+different	O
+ultrasonography	O
+windows	O
+were	O
+performed	O
+on	O
+each	O
+hemithorax	B-ANAT
+before	O
+prone	O
+(	O
+H0	O
+,	O
+H2	O
+,	O
+H12	O
+before	O
+return	O
+to	O
+supine	O
+and	O
+at	O
+H14	B-ANAT
+(	O
+2	O
+hours	O
+after	O
+return	O
+to	O
+supine	O
+).	O
+
+RESULTS	O
+:	O
+Association	O
+of	O
+each	O
+lung	B-ANAT
+region	O
+aspect	O
+to	O
+PP	O
+oxygenation	B-PROC
+response	O
+was	O
+compared	O
+between	O
+the	O
+2	O
+groups	O
+.	O
+
+At	O
+12	O
+months	O
+following	O
+hematopoietic	B-ANAT
+stem	I-ANAT
+cell	I-ANAT
+transplantation	O
+,	O
+89	O
+patients	O
+(	O
+66	O
+.	O
+9	O
+%)	O
+who	O
+developed	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+had	O
+died	B-PROC
+.	O
+
+BLAST	B-ANAT
+search	O
+for	O
+motifs	O
+M1	O
+-	O
+M6	O
+revealed	O
+that	O
+M3	O
+-	O
+M5	O
+were	O
+almost	O
+identical	O
+to	O
+the	O
+strain	O
+ZMDZY	O
+identified	O
+in	O
+2011	O
+in	O
+China	O
+,	O
+while	O
+M1	O
+and	O
+M2	O
+were	O
+similar	O
+to	O
+other	O
+Chinese	O
+strains	O
+isolated	O
+in	O
+2011	O
+-	O
+2012	O
+.	O
+
+TITLE	O
+:	O
+A	O
+new	O
+perspective	O
+on	O
+C	B-PRGE
+-	I-PRGE
+reactive	I-PRGE
+protein	I-PRGE
+in	O
+H7N9	O
+infections	B-DISO
+.	O
+
+RESULTS	O
+:	O
+Compared	O
+with	O
+H1N1	O
+virus	B-SPEC
+,	O
+it	O
+was	O
+found	O
+that	O
+H7N9	O
+virus	B-SPEC
+induced	O
+higher	O
+expression	B-PROC
+of	O
+CRP	B-PRGE
+,	O
+leading	O
+to	O
+cytokine	O
+storms	O
+.	O
+
+And	O
+likewise	O
+,	O
+mild	O
+,	O
+moderate	O
+,	O
+severe	O
+ARDS	B-DISO
+patients	O
+had	O
+1	O
+,	O
+6	O
+,	O
+9	O
+cases	O
+of	O
+death	B-PROC
+,	O
+respectively	O
+.	O
+
+Besides	O
+,	O
+OI	O
+was	O
+a	O
+predictive	O
+protection	O
+factor	O
+of	O
+ARDS	B-DISO
+,	O
+whereas	O
+lactic	B-CHED
+acid	I-CHED
+,	O
+EVLWI	O
+and	O
+PVPI	O
+were	O
+risk	O
+factors	O
+.	O
+
+EVLWI	O
+,	O
+PVPI	O
+were	O
+positively	O
+correlated	O
+with	O
+the	O
+severity	O
+of	O
+ARDS	B-DISO
+illness	O
+;	O
+EVLWI	O
+can	O
+be	O
+used	O
+as	O
+an	O
+independent	O
+risk	O
+factor	O
+for	O
+forecasting	O
+ARDS	B-DISO
+death	B-PROC
+,	O
+jointing	B-ANAT
+EVLWI	O
+with	O
+PVPI	O
+could	O
+improve	O
+the	O
+accuracy	O
+of	O
+ARDS	B-DISO
+death	B-PROC
+forecasting	O
+.	O
+
+CONCLUSIONS	O
+:	O
+EVLWI	O
+,	O
+PVPI	O
+were	O
+positively	O
+correlated	O
+with	O
+the	O
+severity	O
+of	O
+ARDS	B-DISO
+illness	O
+;	O
+EVLWI	O
+can	O
+be	O
+used	O
+as	O
+an	O
+independent	O
+risk	O
+factor	O
+for	O
+forecasting	O
+ARDS	B-DISO
+death	B-PROC
+,	O
+jointing	B-ANAT
+EVLWI	O
+with	O
+PVPI	O
+could	O
+improve	O
+the	O
+accuracy	O
+of	O
+ARDS	B-DISO
+death	B-PROC
+forecasting	O
+.	O
+
+Respiratory	B-PROC
+mechanics	I-PROC
+and	O
+gas	B-ENZY
+-	O
+exchange	O
+were	O
+measured	O
+.	O
+
+There	O
+were	O
+not	O
+corrletions	O
+between	O
+IAP	B-PRGE
+and	O
+end	B-PRGE
+-	I-PRGE
+expiratory	I-PRGE
+Ptp	B-DISO
+(	O
+Ptp	B-PRGE
+-	I-PRGE
+e	I-PRGE
+)	O
+and	O
+end	B-PRGE
+-	I-PRGE
+inspiratory	I-PRGE
+Ptp	B-DISO
+(	O
+Ptp	B-PRGE
+-	I-PRGE
+i	I-PRGE
+)	O
+(	O
+P	O
+>	O
+0	O
+.	O
+05	O
+).	O
+
+Compared	O
+with	O
+baseline	O
+,	O
+lung	B-PROC
+compliance	I-PROC
+(	O
+CL	O
+)	O
+(	O
+48	O
+.	O
+1	O
+±	O
+10	O
+.	O
+3	O
+)	O
+cmH2O	O
+vs	O
+(	O
+25	O
+.	O
+7	O
+±	O
+6	O
+.	O
+4	O
+)	O
+cmH2O	O
+and	O
+oxygenation	B-PROC
+index	O
+(	O
+PaO2	O
+/	O
+FiO2	O
+)	O
+(	O
+235	O
+±	O
+48	O
+)	O
+mmHg	O
+vs	O
+(	O
+160	O
+±	O
+35	O
+)	O
+mmHg	O
+improved	O
+obviously	O
+(	O
+P	O
+<	O
+0	O
+.	O
+05	O
+),	O
+dead	B-PROC
+space	O
+fraction	O
+(	O
+VD	O
+/	O
+VT	O
+)	O
+(	O
+0	O
+.	O
+48	O
+±	O
+0	O
+.	O
+07	O
+)	O
+vs	O
+(	O
+0	O
+.	O
+59	O
+±	O
+0	O
+.	O
+06	O
+)	O
+decreased	O
+(	O
+P	O
+<	O
+0	O
+.	O
+05	O
+),	O
+but	O
+Ccw	O
+and	O
+respiratory	O
+compliance	O
+(	O
+Cr	O
+)	O
+didn	O
+'	O
+t	O
+improve	O
+(	O
+P	O
+>	O
+0	O
+.	O
+05	O
+).	O
+
+RESULTS	O
+:	O
+Plat	O
+pressure	O
+(	O
+Pplat	O
+)	O
+increased	O
+and	O
+the	O
+compliance	O
+of	O
+chest	B-ANAT
+wall	I-ANAT
+(	O
+Ccw	O
+)	O
+decreased	O
+when	O
+intraabdominal	B-ANAT
+pressure	O
+(	O
+IAP	O
+)	O
+increased	O
+.	O
+
+RESULTS	O
+:	O
+A	O
+total	O
+of	O
+135	O
+intubated	O
+trauma	O
+patients	O
+with	O
+pulmonary	B-ANAT
+contusions	O
+were	O
+identified	O
+over	O
+the	O
+study	O
+period	O
+.	O
+
+CONCLUSIONS	O
+:	O
+Amongst	O
+intubated	O
+blunt	O
+trauma	O
+patients	O
+with	O
+confirmed	O
+pulmonary	B-ANAT
+contusions	O
+diagnosis	O
+,	O
+an	O
+initial	O
+chest	B-ANAT
+radiograph	O
+that	O
+reveals	O
+immediate	O
+pulmonary	B-ANAT
+contusion	O
+is	O
+associated	O
+with	O
+higher	O
+mortality	O
+and	O
+ARDS	B-DISO
+compared	O
+with	O
+the	O
+absence	O
+of	O
+such	O
+findings	O
+.	O
+
+The	O
+analysis	O
+of	O
+risk	O
+factors	O
+of	O
+associative	O
+pathology	B-DISO
+development	B-PROC
+,	O
+roentgenographic	O
+study	O
+,	O
+investigation	O
+of	O
+the	O
+function	O
+of	O
+external	O
+respiration	B-PROC
+(	O
+FER	B-CHED
+)	O
+(	O
+peak	O
+flowmetry	O
+,	O
+spirometry	O
+),	O
+intracavitary	O
+pH	O
+-	O
+metry	O
+,	O
+esophagofibrogastroduodenoscopy	O
+(	O
+EFGDS	O
+)	O
+and	O
+ultrasonic	O
+investigation	O
+(	O
+USI	O
+)	O
+of	O
+the	O
+organs	B-ANAT
+of	O
+the	O
+gastro	B-ANAT
+-	O
+intestinal	B-ANAT
+tract	I-ANAT
+(	O
+GIT	O
+)	O
+were	O
+carried	O
+out	O
+.	O
+
+In	O
+a	O
+severe	O
+course	O
+of	O
+bronchial	B-DISO
+asthma	B-PATH
+GERD	B-DISO
+was	O
+detected	O
+3	O
+,	O
+4	O
+times	O
+more	O
+frequently	O
+in	O
+the	O
+boys	O
+,	O
+while	O
+in	O
+a	O
+lengthy	O
+course	O
+of	O
+pneumonia	B-DISO
+with	O
+BOS	B-DISO
+--	O
+1	O
+,	O
+9	O
+times	O
+more	O
+frequently	O
+in	O
+the	O
+girls	O
+.	O
+
+The	O
+designed	O
+individual	O
+anti	O
+-	O
+reflux	B-DISO
+programs	O
+in	O
+complex	O
+therapy	O
+of	O
+respiratory	O
+organs	B-ANAT
+'	O
+diseases	O
+with	O
+BOS	B-DISO
+associated	O
+with	O
+GERD	B-DISO
+reduce	O
+the	O
+frequency	O
+of	O
+exacerbations	O
+and	O
+hospitalizations	O
+of	O
+patients	O
+with	O
+BA	O
+,	O
+improve	O
+their	O
+life	O
+quality	O
+.	O
+
+ABSTRACT	O
+:	O
+Avoiding	O
+pain	O
+,	O
+agitation	B-DISO
+and	O
+delirium	B-DISO
+as	O
+well	O
+as	O
+avoiding	O
+unnecessary	O
+deep	O
+sedation	B-DISO
+is	O
+a	O
+powerful	O
+yet	O
+challenging	O
+strategy	O
+in	O
+critical	O
+care	O
+medicine	B-CHED
+.	O
+
+While	O
+completely	O
+disabling	O
+spontaneous	O
+ventilation	O
+with	O
+or	O
+without	O
+neuromuscular	B-DISO
+blockade	I-DISO
+is	O
+not	O
+a	O
+standard	O
+strategy	O
+in	O
+ARDS	B-DISO
+,	O
+it	O
+might	O
+be	O
+temporarily	O
+required	O
+in	O
+patients	O
+with	O
+severe	O
+ARDS	B-DISO
+,	O
+who	O
+have	O
+substantial	O
+dyssynchrony	O
+or	O
+persistent	O
+hypoxaemia	O
+.	O
+
+Since	O
+pain	O
+,	O
+agitation	B-DISO
+and	O
+delirium	B-DISO
+compromise	O
+respiratory	B-PROC
+function	I-PROC
+they	O
+should	O
+also	O
+be	O
+regarded	O
+during	O
+noninvasive	O
+ventilation	O
+and	O
+during	O
+ventilator	O
+weaning	O
+.	O
+
+Comparing	O
+uninfected	O
+L10H	O
+and	O
+L10L	O
+birds	B-SPEC
+,	O
+we	O
+identified	O
+1698	O
+and	O
+1424	O
+differentially	O
+expressed	B-PROC
+(	O
+DE	O
+)	O
+genes	O
+at	O
+weeks	O
+1	O
+and	O
+3	O
+,	O
+respectively	O
+.	O
+
+The	O
+observed	O
+transcriptome	O
+differences	O
+between	O
+the	O
+two	O
+lines	O
+indicate	O
+that	O
+selection	O
+for	O
+MBL	O
+had	O
+influenced	O
+innate	O
+as	O
+well	O
+as	O
+adaptive	O
+immunity	B-PROC
+.	O
+
+RESULTS	O
+:	O
+Comparing	O
+uninfected	O
+L10H	O
+and	O
+L10L	O
+birds	B-SPEC
+,	O
+we	O
+identified	O
+1698	O
+and	O
+1424	O
+differentially	O
+expressed	B-PROC
+(	O
+DE	O
+)	O
+genes	O
+at	O
+weeks	O
+1	O
+and	O
+3	O
+,	O
+respectively	O
+.	O
+
+In	O
+the	O
+ICU	O
+,	O
+patients	O
+with	O
+sepsis	B-DISO
+,	O
+ARDS	B-DISO
+,	O
+community	O
+-	O
+acquired	O
+pneumonia	B-DISO
+,	O
+exacerbation	O
+of	O
+chronic	B-DISO
+obstructive	I-DISO
+pulmonary	I-DISO
+disease	I-DISO
+,	O
+severe	O
+asthma	B-PATH
+,	O
+or	O
+trauma	O
+may	O
+receive	O
+corticosteroids	B-CHED
+.	O
+
+ABSTRACT	O
+:	O
+Despite	O
+the	O
+crucial	O
+role	O
+of	O
+domestic	O
+dogs	O
+as	O
+reservoirs	O
+for	O
+zoonosis	B-DISO
+and	O
+some	O
+of	O
+the	O
+most	O
+threatening	O
+diseases	O
+for	O
+wild	O
+carnivores	B-SPEC
+such	O
+as	O
+distemper	B-DISO
+and	O
+parvovirosis	O
+,	O
+little	O
+is	O
+known	O
+about	O
+the	O
+epidemiological	O
+features	O
+and	O
+the	O
+risk	O
+factors	O
+involved	O
+in	O
+pathogen	O
+exposure	O
+of	O
+dogs	B-SPEC
+that	O
+live	O
+in	O
+human	B-SPEC
+/	O
+wildlife	O
+interfaces	O
+and	O
+actually	O
+contacts	O
+wildlife	O
+.	O
+
+Remarkably	O
+,	O
+factors	O
+linked	O
+to	O
+free	O
+-	O
+ranging	O
+behaviour	B-PROC
+of	O
+dogs	B-SPEC
+were	O
+associated	O
+with	O
+the	O
+exposure	O
+for	O
+all	O
+pathogens	O
+detected	O
+.	O
+
+Remarkably	O
+,	O
+in	O
+the	O
+other	O
+cat	B-SPEC
+neither	O
+clinical	O
+signs	O
+nor	O
+acute	O
+shedding	O
+were	O
+seen	O
+,	O
+but	O
+virus	O
+was	O
+detected	O
+in	O
+blood	B-ANAT
+cells	I-ANAT
+from	O
+3	O
+dpi	O
+,	O
+and	O
+shedding	O
+of	O
+non	O
+-	O
+enterotropic	O
+,	O
+mutated	O
+viruses	B-SPEC
+suddenly	O
+occurred	O
+from	O
+14	O
+dpi	O
+onwards	O
+.	O
+
+Two	O
+groups	O
+of	O
+NHPs	O
+were	O
+treated	O
+with	O
+either	O
+a	O
+human	B-PRGE
+anti	I-PRGE
+-	I-PRGE
+MERS	I-PRGE
+monoclonal	O
+antibody	B-COMP
+3B11	O
+-	O
+N	O
+or	O
+E410	O
+-	O
+N	O
+,	O
+an	O
+anti	O
+-	O
+HIV	B-DISO
+antibody	B-COMP
+.	O
+
+MERS	O
+-	O
+CoV	O
+Jordan	O
+-	O
+n3	O
+/	O
+2012	O
+infection	B-DISO
+resulted	O
+in	O
+quantifiable	O
+changes	O
+by	O
+computed	O
+tomography	O
+,	O
+but	O
+limited	O
+other	O
+clinical	O
+signs	O
+of	O
+disease	O
+.	O
+
+Evolution	B-PROC
+analysis	O
+showed	O
+that	O
+the	O
+Kenyan	O
+HCoV	B-SPEC
+-	I-SPEC
+OC43	I-SPEC
+and	O
+HCoV	B-SPEC
+-	I-SPEC
+NL63	I-SPEC
+isolates	O
+were	O
+under	O
+purifying	O
+selection	O
+.	O
+
+By	O
+means	O
+of	O
+histological	O
+examination	O
+and	O
+biochemical	O
+assays	O
+,	O
+the	O
+severity	O
+of	O
+lung	B-ANAT
+injury	O
+was	O
+assessed	O
+in	O
+the	O
+aspects	O
+of	O
+tissue	B-ANAT
+damages	O
+,	O
+myeloperoxidase	B-FUNC
+activity	I-FUNC
+,	O
+and	O
+levels	O
+of	O
+pro	B-CHED
+-	O
+inflammatory	O
+cytokines	O
+.	O
+
+This	O
+study	O
+is	O
+the	O
+first	O
+to	O
+report	O
+the	O
+oral	B-ANAT
+administration	O
+of	O
+dihydro	O
+-	O
+resveratrol	B-CHED
+ameliorated	O
+acute	B-DISO
+pancreatitis	I-DISO
+-	O
+associated	O
+lung	B-ANAT
+injury	O
+via	O
+an	O
+inhibitory	O
+modulation	O
+of	O
+pro	B-CHED
+-	O
+inflammatory	B-DISO
+response	I-DISO
+,	O
+which	O
+was	O
+associated	O
+with	O
+a	O
+suppression	B-DISO
+of	O
+the	O
+NF	O
+-	O
+κB	O
+signaling	B-PROC
+pathway	I-PROC
+.	O
+
+TITLE	O
+:	O
+Small	O
+interfering	O
+RNA	B-PROC
+expression	I-PROC
+inhibits	O
+avian	B-DISO
+infectious	I-DISO
+bronchitis	I-DISO
+virus	B-PROC
+replication	I-PROC
+and	O
+inflammatory	B-PROC
+response	I-PROC
+.	O
+
+Inflammatory	B-DISO
+responses	I-DISO
+and	O
+oxidative	B-PATH
+damage	I-PATH
+were	O
+significantly	O
+decreased	O
+,	O
+yielding	O
+minimal	O
+tissue	B-ANAT
+injury	O
+.	O
+
+RESULTS	O
+:	O
+Monocytes	B-ANAT
+producing	O
+siRNA	O
+efficiently	O
+inhibit	O
+IBV	B-SPEC
+replication	O
+.	O
+
+However	O
+,	O
+clinical	O
+features	O
+of	O
+MERS	O
+range	O
+from	O
+mild	O
+disease	O
+to	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+and	O
+multiorgan	B-DISO
+failure	I-DISO
+resulting	O
+in	O
+death	B-PROC
+,	O
+especially	O
+in	O
+individuals	O
+with	O
+underlying	O
+comorbidities	O
+.	O
+
+To	O
+date	O
+,	O
+about	O
+one	O
+in	O
+three	O
+people	O
+died	B-PROC
+as	O
+a	O
+result	O
+of	O
+MERS	O
+.	O
+
+ABSTRACT	O
+:	O
+Cigarette	O
+smoke	O
+exposure	O
+is	O
+associated	O
+with	O
+an	O
+increased	O
+risk	O
+of	O
+the	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+(	O
+ARDS	B-DISO
+);	O
+however	O
+,	O
+the	O
+mechanisms	O
+underlying	O
+this	O
+relationship	O
+remain	O
+largely	O
+unknown	O
+.	O
+
+Smokers	O
+had	O
+exaggerated	O
+inflammation	B-DISO
+compared	O
+with	O
+non	O
+-	O
+smokers	O
+,	O
+with	O
+increased	O
+BAL	B-ENZY
+interleukin	I-PRGE
+-	I-PRGE
+1β	I-PRGE
+(	O
+p	O
+=	O
+0	O
+.	O
+002	O
+),	O
+neutrophils	O
+(	O
+p	O
+=	O
+0	O
+.	O
+02	O
+),	O
+plasma	B-ANAT
+interleukin	B-PRGE
+-	I-PRGE
+8	I-PRGE
+(	O
+p	O
+=	O
+0	O
+.	O
+003	O
+),	O
+and	O
+plasma	B-PRGE
+matrix	I-PRGE
+metalloproteinase	I-PRGE
+-	I-PRGE
+8	I-PRGE
+(	O
+p	O
+=	O
+0	O
+.	O
+006	O
+).	O
+
+ABSTRACT	O
+:	O
+During	O
+the	O
+2015	O
+outbreak	O
+of	O
+Middle	O
+East	O
+respiratory	O
+syndrome	O
+coronavirus	B-SPEC
+(	O
+MERS	O
+-	O
+CoV	O
+)	O
+in	O
+Korea	O
+,	O
+186	O
+persons	O
+were	O
+infected	O
+,	O
+resulting	O
+in	O
+38	O
+fatalities	O
+.	O
+
+The	O
+objective	O
+of	O
+this	O
+study	O
+was	O
+to	O
+compare	O
+the	O
+pathogenicity	O
+differences	O
+of	O
+the	O
+US	O
+PEDV	B-SPEC
+prototype	O
+and	O
+S	O
+-	O
+INDEL	B-PROC
+-	O
+variant	O
+strains	O
+in	O
+conventional	O
+neonatal	O
+piglets	O
+under	O
+experimental	O
+infections	B-DISO
+.	O
+
+All	O
+three	O
+PEDV	B-SPEC
+prototype	O
+isolates	O
+tested	O
+in	O
+this	O
+study	O
+,	O
+regardless	O
+of	O
+their	O
+phylogenetic	O
+clades	O
+,	O
+had	O
+similar	O
+pathogenicity	O
+and	O
+caused	O
+severe	O
+enteric	O
+disease	O
+in	O
+5	O
+-	O
+day	O
+-	O
+old	O
+pigs	O
+as	O
+evidenced	O
+by	O
+clinical	O
+signs	O
+,	O
+faecal	B-ANAT
+virus	B-DISO
+shedding	I-DISO
+,	O
+and	O
+gross	O
+and	O
+histopathological	O
+lesions	O
+.	O
+
+ABSTRACT	O
+:	O
+The	O
+Middle	O
+East	O
+respiratory	O
+syndrome	O
+coronavirus	B-SPEC
+(	O
+MERS	O
+-	O
+CoV	O
+)	O
+outbreak	O
+in	O
+South	O
+Korea	O
+in	O
+2015	O
+has	O
+drawn	O
+public	O
+attention	O
+regarding	O
+the	O
+legal	O
+regulation	B-PROC
+of	O
+infectious	B-DISO
+disease	I-DISO
+control	O
+in	O
+Korea	O
+.	O
+
+During	O
+the	O
+outbreak	O
+of	O
+Middle	O
+East	O
+respiratory	O
+syndrome	B-DISO
+coronavirus	B-SPEC
+(	O
+MERS	O
+-	O
+CoV	O
+)	O
+in	O
+the	O
+Republic	O
+of	O
+Korea	O
+in	O
+2015	O
+,	O
+serious	O
+challenges	O
+emerged	O
+regarding	O
+important	O
+ethical	O
+issues	O
+,	O
+such	O
+as	O
+transparency	O
+and	O
+the	O
+protection	O
+of	O
+privacy	O
+.	O
+
+The	O
+MERS	O
+-	O
+CoV	O
+epidemic	O
+in	O
+Korea	O
+created	O
+significant	O
+public	O
+support	O
+for	O
+more	O
+aggressive	B-DISO
+early	O
+interventions	O
+in	O
+future	O
+outbreaks	O
+.	O
+
+Influenza	B-DISO
+vaccination	O
+should	O
+be	O
+a	O
+priority	O
+for	O
+all	O
+Hajj	O
+pilgrims	O
+,	O
+as	O
+recommended	O
+by	O
+experts	O
+.	O
+
+Although	O
+there	O
+is	O
+no	O
+consensus	O
+about	O
+the	O
+veno	O
+-	O
+veno	O
+-	O
+arterial	B-ANAT
+mode	O
+of	O
+extracorporeal	O
+membrane	B-COMP
+oxygenation	B-PROC
+,	O
+this	O
+combined	O
+mode	O
+can	O
+be	O
+helpful	O
+in	O
+patients	O
+with	O
+acute	O
+refractory	O
+respiratory	O
+and	O
+cardiac	B-DISO
+failure	I-DISO
+,	O
+as	O
+shown	O
+in	O
+the	O
+present	O
+case	O
+.	O
+
+However	O
+,	O
+for	O
+decades	O
+the	O
+RNA	B-PROC
+capping	I-PROC
+mechanisms	O
+of	O
+coronaviruses	O
+remained	O
+unknown	O
+.	O
+
+Since	O
+2003	O
+,	O
+the	O
+outbreak	O
+of	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+coronavirus	B-SPEC
+has	O
+drawn	O
+increased	O
+attention	O
+and	O
+stimulated	O
+numerous	O
+studies	O
+on	O
+the	O
+molecular	O
+virology	O
+of	O
+coronaviruses	O
+.	O
+
+ABSTRACT	O
+:	O
+Middle	O
+East	O
+Respiratory	O
+Syndrome	B-DISO
+coronavirus	B-SPEC
+(	O
+MERS	O
+-	O
+CoV	O
+)	O
+emerged	O
+in	O
+2012	O
+has	O
+since	O
+resulted	O
+in	O
+sporadic	O
+cases	O
+,	O
+intra	O
+-	O
+familial	O
+transmission	O
+and	O
+major	O
+outbreaks	O
+in	O
+healthcare	O
+settings	O
+.	O
+
+The	O
+clinical	O
+picture	O
+of	O
+MERS	O
+-	O
+CoV	O
+includes	O
+asymptomatic	B-DISO
+infections	I-DISO
+,	O
+mild	O
+or	O
+moderately	O
+symptomatic	O
+cases	O
+and	O
+fatal	O
+disease	O
+.	O
+
+This	O
+neuroprotective	O
+effect	O
+of	O
+BDNF	O
+is	O
+also	O
+observed	O
+in	O
+vivo	O
+in	O
+a	O
+viral	O
+vector	O
+-	O
+based	O
+knockdown	O
+mouse	B-SPEC
+cerebellar	B-ANAT
+model	O
+.	O
+
+The	O
+model	O
+was	O
+designed	O
+to	O
+capture	O
+a	O
+)	O
+any	O
+signal	O
+of	O
+the	O
+serial	O
+interval	O
+distribution	O
+in	O
+the	O
+initial	O
+stochastic	O
+phase	O
+b	O
+)	O
+the	O
+growth	B-PROC
+rate	O
+of	O
+the	O
+exponential	O
+phase	O
+and	O
+c	O
+)	O
+the	O
+unique	O
+combination	O
+of	O
+R0	O
+and	O
+Tg	O
+that	O
+generates	O
+a	O
+specific	O
+shape	O
+of	O
+peak	O
+incidence	O
+when	O
+the	O
+susceptible	O
+portion	O
+of	O
+a	O
+small	O
+population	O
+is	O
+depleted	O
+.	O
+
+Repeated	O
+application	O
+of	O
+these	O
+methods	O
+to	O
+small	O
+scale	O
+outbreaks	O
+at	O
+the	O
+start	O
+of	O
+an	O
+epidemic	O
+would	O
+permit	B-SPEC
+accurate	O
+estimates	O
+of	O
+key	O
+parameters	O
+.	O
+
+Commercially	O
+available	O
+systems	O
+are	O
+manually	O
+controlled	O
+,	O
+although	O
+an	O
+automatically	O
+controlled	O
+ECLA	O
+could	O
+allow	O
+individualized	O
+and	O
+continuous	O
+adaption	B-PROC
+to	O
+clinical	O
+requirements	O
+.	O
+
+Proof	O
+of	O
+concept	O
+could	O
+be	O
+demonstrated	O
+for	O
+this	O
+novel	O
+automatically	O
+controlled	O
+veno	O
+-	O
+venous	B-ANAT
+ECLA	O
+circuit	O
+.	O
+
+This	O
+anti	B-PRGE
+-	I-PRGE
+fTNF	I-PRGE
+-	I-PRGE
+alpha	I-PRGE
+mAb	I-PRGE
+2	I-PRGE
+-	I-PRGE
+4	I-PRGE
+was	O
+confirmed	O
+to	O
+inhibit	O
+the	O
+following	O
+fTNF	B-PRGE
+-	I-PRGE
+alpha	I-PRGE
+-	O
+induced	O
+conditions	O
+in	O
+vitro	O
+.	O
+
+ABSTRACT	O
+:	O
+We	O
+analyzed	O
+a	O
+multi	O
+-	O
+drug	O
+resistant	O
+(	O
+MR	O
+)	O
+HIV	B-SPEC
+-	I-SPEC
+1	I-SPEC
+reverse	B-PRGE
+transcriptase	I-PRGE
+(	O
+RT	O
+),	O
+subcloned	O
+from	O
+a	O
+patient	O
+-	O
+derived	O
+subtype	O
+CRF02_AG	O
+,	O
+harboring	O
+45	O
+amino	B-CHED
+acid	I-CHED
+exchanges	O
+,	O
+amongst	O
+them	O
+four	O
+thymidine	B-CHED
+analog	O
+mutations	O
+(	O
+TAMs	O
+)	O
+relevant	O
+for	O
+high	O
+-	O
+level	O
+AZT	B-CHED
+(	O
+azidothymidine	B-CHED
+)	O
+resistance	B-PROC
+by	O
+AZTMP	O
+excision	O
+(	O
+M41L	O
+,	O
+D67N	O
+,	O
+T215Y	O
+,	O
+K219E	O
+)	O
+as	O
+well	O
+as	O
+four	O
+substitutions	O
+of	O
+the	O
+AZTTP	O
+discrimination	O
+pathway	B-PROC
+(	O
+A62V	O
+,	O
+V75I	O
+,	O
+F116Y	O
+and	O
+Q151M	O
+).	O
+
+TITLE	O
+:	O
+Serial	O
+measurements	O
+of	O
+troponin	B-PRGE
+and	O
+echocardiography	O
+in	O
+patients	O
+with	O
+moderate	O
+-	O
+to	O
+-	O
+severe	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+.	O
+
+TITLE	O
+:	O
+Outcome	O
+of	O
+Severe	O
+Dengue	B-DISO
+Viral	B-DISO
+Infection	I-DISO
+-	O
+caused	O
+Acute	B-DISO
+Liver	I-DISO
+Failure	I-DISO
+in	O
+Thai	O
+Children	O
+.	O
+
+Lactate	B-PRGE
+dehydrogenase	I-PRGE
+levels	O
+had	O
+positive	O
+correlations	O
+with	O
+AST	B-ENZY
+(	O
+r	O
+=	O
+0	O
+.	O
+95	O
+)	O
+and	O
+ALT	B-FUNC
+(	O
+r	O
+=	O
+0	O
+.	O
+87	O
+)	O
+(	O
+all	O
+p	O
+<	O
+0	O
+.	O
+01	O
+).	O
+
+The	O
+median	O
+(	O
+interquartile	O
+range	O
+)	O
+days	O
+before	O
+the	O
+AST	B-PRGE
+and	O
+ALT	B-FUNC
+levels	O
+returned	O
+to	O
+lower	O
+than	O
+200	O
+U	O
+/	O
+L	O
+after	O
+the	O
+ALF	O
+were	O
+10	O
+.	O
+5	O
+(	O
+8	O
+.	O
+8	O
+,	O
+12	O
+.	O
+8	O
+)	O
+and	O
+10	O
+.	O
+5	O
+(	O
+7	O
+.	O
+8	O
+,	O
+14	O
+.	O
+0	O
+)	O
+days	O
+,	O
+respectively	O
+.	O
+
+TITLE	O
+:	O
+Evaluation	O
+of	O
+antiviral	B-CHED
+activities	O
+of	O
+Houttuynia	B-SPEC
+cordata	I-SPEC
+Thunb	O
+.	O
+
+Cinanserin	O
+hydrochloride	B-CHED
+was	O
+also	O
+tested	O
+against	O
+MHV	B-SPEC
+.	O
+
+However	O
+,	O
+the	O
+synergistic	O
+efficacy	O
+of	O
+the	O
+flavonoid	B-CHED
+combination	O
+was	O
+still	O
+less	O
+than	O
+that	O
+of	O
+the	O
+EA	O
+fraction	O
+.	O
+
+Currently	O
+,	O
+different	O
+cell	B-COMP
+culture	O
+systems	O
+are	O
+available	O
+to	O
+recapitulate	O
+the	O
+human	B-SPEC
+airways	O
+,	O
+including	O
+the	O
+Air	B-PRGE
+-	I-PRGE
+Liquid	I-PRGE
+Interface	I-PRGE
+(	O
+ALI	O
+)	O
+human	B-SPEC
+airway	B-ANAT
+epithelium	B-ANAT
+(	O
+HAE	O
+)	O
+model	O
+.	O
+
+These	O
+organotypic	O
+human	B-SPEC
+airway	B-ANAT
+cultures	O
+represent	O
+a	O
+universal	O
+platform	O
+to	O
+study	O
+respiratory	O
+virus	B-PROC
+-	I-PROC
+host	B-COMP
+interaction	I-PROC
+by	O
+offering	O
+more	O
+detailed	O
+insights	O
+compared	O
+to	O
+cell	B-ANAT
+lines	I-ANAT
+.	O
+
+Additionally	O
+,	O
+the	O
+epidemic	O
+potential	O
+of	O
+this	O
+virus	B-SPEC
+family	B-SPEC
+highlights	O
+the	O
+need	O
+for	O
+both	O
+vaccines	O
+and	O
+antivirals	B-CHED
+.	O
+
+The	O
+interaction	O
+between	O
+VNPs	O
+derived	O
+from	O
+Tobacco	B-SPEC
+mosaic	I-SPEC
+virus	I-SPEC
+(	O
+TMV	B-SPEC
+)	O
+and	O
+plasma	B-ANAT
+proteins	B-CHED
+is	O
+investigated	O
+,	O
+and	O
+it	O
+is	O
+found	O
+that	O
+the	O
+VNP	B-PRGE
+protein	I-PRGE
+corona	B-CHED
+is	O
+significantly	O
+less	O
+abundant	O
+compared	O
+to	O
+the	O
+corona	B-CHED
+of	O
+synthetic	O
+particles	O
+.	O
+
+ABSTRACT	O
+:	O
+Feline	O
+coronaviruses	O
+(	O
+FCoVs	O
+)	O
+encode	O
+five	O
+accessory	O
+proteins	B-CHED
+termed	O
+3a	O
+,	O
+3b	O
+,	O
+3c	O
+,	O
+7a	O
+and	O
+7b	O
+of	O
+unknown	O
+function	O
+.	O
+
+Based	O
+on	O
+successful	O
+application	O
+of	O
+PEG	O
+-	O
+IFN	B-PRGE
+against	O
+the	O
+related	O
+SARS	B-DISO
+coronavirus	B-SPEC
+in	O
+animal	B-SPEC
+experiments	O
+,	O
+a	O
+single	O
+injection	O
+of	O
+180	O
+μg	O
+PEG	B-PRGE
+-	I-PRGE
+IFN	I-PRGE
+-	I-PRGE
+α2b	I-PRGE
+was	O
+applied	O
+.	O
+
+The	O
+accessibility	O
+of	O
+the	O
+highly	O
+conserved	O
+fusion	O
+peptide	B-CHED
+at	O
+the	O
+periphery	O
+of	O
+the	O
+trimer	O
+indicates	O
+potential	O
+vaccinology	O
+strategies	O
+to	O
+elicit	O
+broadly	O
+neutralizing	O
+antibodies	O
+against	O
+coronaviruses	O
+.	O
+
+The	O
+haemodynamic	O
+consequences	O
+of	O
+positive	O
+pressure	O
+ventilation	O
+depend	O
+on	O
+the	O
+underlying	O
+chronic	O
+cardiopulmonary	B-ANAT
+pathologies	O
+leading	O
+to	O
+the	O
+acute	B-DISO
+respiratory	I-DISO
+failure	I-DISO
+that	O
+was	O
+the	O
+indication	O
+for	O
+ventilation	O
+.	O
+
+In	O
+this	O
+review	O
+,	O
+we	O
+will	O
+focus	O
+on	O
+severe	O
+COPD	B-DISO
+exacerbation	I-DISO
+,	O
+acute	B-DISO
+left	I-DISO
+heart	I-DISO
+failure	I-DISO
+and	O
+weaning	B-PROC
+from	O
+ventilation	O
+.	O
+
+TITLE	O
+:	O
+Classification	O
+of	O
+Extrapulmonary	O
+Manifestations	O
+Due	O
+to	O
+Mycoplasma	B-SPEC
+pneumoniae	I-SPEC
+Infection	B-DISO
+on	O
+the	O
+Basis	O
+of	O
+Possible	O
+Pathogenesis	O
+.	O
+
+Concomitant	O
+use	O
+of	O
+immunomodulators	O
+,	O
+such	O
+as	O
+corticosteroids	B-CHED
+or	O
+immunoglobulins	O
+with	O
+antibiotics	B-CHED
+effective	O
+against	O
+M	B-SPEC
+.	I-SPEC
+pneumoniae	I-SPEC
+,	O
+can	O
+be	O
+considered	O
+as	O
+treatment	O
+modalities	O
+for	O
+most	O
+severe	O
+cases	O
+,	O
+such	O
+as	O
+encephalitis	B-DISO
+.	O
+
+Further	O
+studies	O
+would	O
+be	O
+necessary	O
+to	O
+construct	O
+a	O
+comprehensive	O
+therapeutic	O
+strategy	O
+,	O
+covering	O
+microbiology	O
+(	O
+antibiotics	B-CHED
+),	O
+immunology	O
+(	O
+immunomodulators	O
+),	O
+and	O
+hematology	O
+(	O
+anticoagulants	B-CHED
+).	O
+
+ABSTRACT	O
+:	O
+Most	O
+of	O
+the	O
+intracellular	B-COMP
+pattern	O
+recognition	O
+receptors	O
+(	O
+PRRs	B-DISO
+)	O
+reside	O
+in	O
+either	O
+the	O
+endolysosome	B-COMP
+or	O
+the	O
+cytoplasm	B-COMP
+to	O
+sense	B-PROC
+pathogen	O
+-	O
+derived	O
+RNAs	O
+,	O
+DNAs	O
+,	O
+or	O
+synthetic	O
+analogs	O
+of	O
+double	O
+-	O
+stranded	O
+RNA	O
+(	O
+dsRNA	B-CHED
+),	O
+such	O
+as	O
+poly	O
+(	O
+I	O
+:	O
+C	O
+).	O
+
+M	B-PRGE
+protein	I-PRGE
+rather	O
+than	O
+M	O
+mRNA	O
+is	O
+responsible	O
+for	O
+M	O
+-	O
+mediated	O
+IFN	B-PRGE
+-	I-PRGE
+β	I-PRGE
+induction	O
+that	O
+is	O
+preferentially	O
+associated	O
+with	O
+the	O
+activation	O
+of	O
+the	O
+Toll	B-PRGE
+-	I-PRGE
+like	I-PRGE
+receptor	I-PRGE
+(	O
+TLR	O
+)	O
+adaptor	O
+proteins	B-CHED
+MyD88	B-PRGE
+,	O
+TIRAP	B-PRGE
+,	O
+and	O
+TICAM2	B-PRGE
+but	O
+not	O
+the	O
+RIG	B-PRGE
+-	I-PRGE
+I	I-PRGE
+signaling	B-PROC
+cascade	I-PROC
+.	O
+
+The	O
+antagonist	B-PROC
+of	O
+both	O
+TLR2	B-PRGE
+and	O
+TLR4	B-PRGE
+did	O
+not	O
+impede	O
+M	O
+-	O
+mediated	O
+IFN	B-PRGE
+-	I-PRGE
+β	I-PRGE
+induction	O
+,	O
+indicating	O
+that	O
+the	O
+driving	O
+force	O
+for	O
+the	O
+activation	O
+of	O
+IFN	B-PRGE
+-	I-PRGE
+β	I-PRGE
+production	O
+was	O
+generated	O
+from	O
+inside	O
+the	O
+cells	B-COMP
+.	O
+
+Overall	O
+,	O
+our	O
+study	O
+indicates	O
+for	O
+the	O
+first	O
+time	O
+that	O
+a	O
+pathogen	O
+-	O
+derived	O
+protein	B-CHED
+is	O
+able	O
+to	O
+function	O
+as	O
+a	O
+cytosolic	B-COMP
+PAMP	O
+to	O
+stimulate	O
+type	B-PROC
+I	I-PROC
+interferon	I-PROC
+production	I-PROC
+by	O
+activating	O
+a	O
+noncanonical	O
+TLR	O
+signaling	B-PROC
+cascade	I-PROC
+in	O
+a	O
+TRAF3	B-PRGE
+-	O
+independent	O
+manner	O
+.	O
+
+Viral	O
+protein	B-CHED
+can	O
+serve	O
+as	O
+a	O
+pathogen	O
+-	O
+associated	O
+molecular	O
+pattern	O
+(	O
+PAMP	O
+)	O
+that	O
+is	O
+usually	O
+recognized	O
+by	O
+certain	O
+pathogen	O
+recognition	O
+receptors	O
+(	O
+PRRs	B-DISO
+)	O
+on	O
+the	O
+cell	B-COMP
+surface	I-COMP
+,	O
+such	O
+as	O
+Toll	B-PRGE
+-	I-PRGE
+like	I-PRGE
+receptor	I-PRGE
+2	I-PRGE
+(	O
+TLR2	B-PRGE
+)	O
+and	O
+TLR4	B-PRGE
+.	O
+
+After	O
+admission	O
+,	O
+HIV	B-PATH
+infection	I-PATH
+was	O
+eventually	O
+confirmed	O
+by	O
+plasma	B-ANAT
+HIV	B-DISO
+RNA	O
+testing	O
+.	O
+
+CONCLUSIONS	O
+:	O
+This	O
+case	O
+underscores	O
+the	O
+importance	O
+of	O
+plasma	B-ANAT
+RNA	O
+test	O
+in	O
+conjunction	O
+with	O
+HIV	B-DISO
+antibody	B-COMP
+test	O
+for	O
+some	O
+rare	O
+patients	O
+with	O
+HIV	B-PATH
+infection	I-PATH
+who	O
+present	O
+with	O
+severe	O
+immunodeficiency	B-DISO
+and	O
+opportunistic	B-DISO
+infections	I-DISO
+or	O
+malignancy	B-DISO
+.	O
+
+TITLE	O
+:	O
+Treatment	O
+strategies	O
+for	O
+Middle	O
+East	O
+respiratory	O
+syndrome	B-DISO
+coronavirus	B-SPEC
+.	O
+
+ABSTRACT	O
+:	O
+Middle	O
+East	O
+respiratory	O
+syndrome	O
+coronavirus	B-SPEC
+(	O
+MERS	O
+-	O
+CoV	O
+),	O
+an	O
+emerging	B-DISO
+infectious	I-DISO
+disease	I-DISO
+of	O
+growing	O
+global	O
+importance	O
+,	O
+has	O
+caused	O
+severe	O
+acute	B-DISO
+respiratory	I-DISO
+disease	I-DISO
+in	O
+more	O
+than	O
+1600	O
+people	O
+,	O
+resulting	O
+in	O
+almost	O
+600	O
+deaths	B-PROC
+.	O
+
+TITLE	O
+:	O
+Dysregulated	O
+Type	O
+I	O
+Interferon	O
+and	O
+Inflammatory	O
+Monocyte	B-ANAT
+-	O
+Macrophage	B-ANAT
+Responses	O
+Cause	O
+Lethal	O
+Pneumonia	B-DISO
+in	O
+SARS	B-DISO
+-	O
+CoV	O
+-	O
+Infected	O
+Mice	B-SPEC
+.	O
+
+ABSTRACT	O
+:	O
+Highly	O
+pathogenic	O
+human	B-SPEC
+respiratory	O
+coronaviruses	O
+cause	O
+acute	O
+lethal	O
+disease	O
+characterized	O
+by	O
+exuberant	O
+inflammatory	B-DISO
+responses	I-DISO
+and	O
+lung	B-ANAT
+damage	O
+.	O
+
+Of	O
+102	O
+cases	O
+of	O
+severe	O
+CAP	B-DISO
+,	O
+samples	O
+were	O
+obtained	O
+in	O
+91	O
+cases	O
+and	O
+48	O
+(	O
+52	O
+.	O
+7	O
+%)	O
+were	O
+positive	O
+for	O
+respiratory	O
+viruses	O
+.	O
+
+The	O
+most	O
+common	O
+viruses	B-SPEC
+were	O
+RSV	B-SPEC
+(	O
+n	O
+=	O
+22	O
+;	O
+45	O
+.	O
+8	O
+%),	O
+rhinovirus	B-SPEC
+(	O
+n	O
+=	O
+11	O
+;	O
+22	O
+.	O
+9	O
+%)	O
+and	O
+adenovirus	B-DISO
+(	O
+n	O
+=	O
+9	O
+;	O
+18	O
+.	O
+7	O
+%).	O
+
+All	O
+patients	O
+required	O
+oxygen	B-CHED
+therapy	O
+and	O
+17	O
+(	O
+35	O
+.	O
+4	O
+%)	O
+required	O
+mechanical	O
+ventilation	O
+.	O
+
+ABSTRACT	O
+:	O
+In	O
+humans	B-SPEC
+,	O
+infections	B-DISO
+with	O
+the	O
+human	O
+coronavirus	O
+(	O
+HCoV	B-SPEC
+)	O
+strains	O
+HCoV	B-SPEC
+-	I-SPEC
+229E	I-SPEC
+,	O
+HCoV	B-SPEC
+-	I-SPEC
+OC43	I-SPEC
+,	O
+HCoV	B-SPEC
+-	I-SPEC
+NL63	I-SPEC
+and	O
+HCoV	B-SPEC
+-	O
+HKU1	O
+usually	O
+result	O
+in	O
+mild	O
+,	O
+self	O
+-	O
+limiting	O
+upper	B-DISO
+respiratory	I-DISO
+tract	I-DISO
+infections	I-DISO
+,	O
+such	O
+as	O
+the	O
+common	B-DISO
+cold	I-DISO
+.	O
+
+This	O
+paper	O
+provides	O
+an	O
+overview	O
+of	O
+facts	O
+and	O
+emergency	O
+situations	O
+which	O
+can	O
+be	O
+encountered	O
+in	O
+the	O
+care	O
+of	O
+patients	O
+with	O
+autoimmune	B-DISO
+systemic	O
+diseases	O
+and	O
+vasculitides	B-DISO
+.	O
+
+ABSTRACT	O
+:	O
+Middle	O
+East	O
+respiratory	O
+syndrome	O
+coronavirus	B-SPEC
+(	O
+MERS	O
+-	O
+CoV	O
+)	O
+was	O
+initially	O
+isolated	O
+from	O
+a	O
+Saudi	O
+Arabian	O
+man	B-CHED
+with	O
+fatal	O
+pneumonia	B-DISO
+.	O
+
+This	O
+review	O
+provides	O
+an	O
+overview	O
+of	O
+the	O
+current	O
+state	O
+of	O
+knowledge	O
+on	O
+human	O
+MERS	O
+-	O
+CoV	O
+infections	B-DISO
+,	O
+the	O
+probable	O
+origin	O
+of	O
+MERS	O
+-	O
+CoV	O
+,	O
+and	O
+the	O
+available	O
+animal	B-SPEC
+models	O
+of	O
+MERS	O
+-	O
+CoV	O
+infection	B-DISO
+.	O
+
+HCV	B-SPEC
+was	O
+cultivated	O
+in	O
+the	O
+presence	O
+of	O
+increasing	O
+Galanthus	B-SPEC
+nivalis	I-SPEC
+agglutinin	O
+(	O
+GNA	B-CHED
+),	O
+Cyanovirin	O
+-	O
+N	O
+,	O
+Concanavalin	O
+-	O
+A	O
+or	O
+Griffithsin	O
+concentrations	O
+,	O
+during	O
+more	O
+than	O
+eight	O
+weeks	O
+.	O
+
+ABSTRACT	O
+:	O
+The	O
+International	O
+Society	O
+for	O
+Influenza	B-DISO
+and	O
+other	O
+Respiratory	O
+Virus	B-DISO
+Diseases	I-DISO
+(	O
+isirv	O
+)	O
+held	O
+its	O
+4th	O
+Antiviral	B-CHED
+Group	O
+Conference	O
+at	O
+the	O
+University	O
+of	O
+Texas	O
+on	O
+2	O
+-	O
+4	O
+June	O
+,	O
+2015	O
+.	O
+
+Of	O
+the	O
+657	O
+patients	O
+aged	O
+≥	O
+40	O
+years	O
+,	O
+377	O
+(	O
+57	O
+.	O
+3	O
+%)	O
+died	B-PROC
+.	O
+
+These	O
+data	O
+suggest	O
+that	O
+Sp6	O
+can	O
+induce	O
+the	O
+activated	O
+avian	B-SPEC
+lymphocytes	B-ANAT
+in	O
+vitro	O
+to	O
+produce	O
+CTL	B-ANAT
+,	O
+which	O
+is	O
+the	O
+CTL	B-ANAT
+epitope	B-CHED
+in	O
+IBV	B-SPEC
+S1	O
+.	O
+
+ABSTRACT	O
+:	O
+Severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+(	O
+SARS	B-DISO
+)	O
+is	O
+caused	O
+by	O
+a	O
+newly	O
+emerged	O
+coronavirus	B-SPEC
+that	O
+infected	O
+more	O
+than	O
+8000	O
+individuals	O
+and	O
+resulted	O
+in	O
+more	O
+than	O
+800	O
+(	O
+10	O
+-	O
+15	O
+%)	O
+fatalities	O
+in	O
+2003	O
+.	O
+
+TITLE	O
+:	O
+[	O
+Corynebacterium	B-SPEC
+ulcerans	I-SPEC
+pulmonary	B-DISO
+infection	I-DISO
+].	O
+
+TITLE	O
+:	O
+Conformational	O
+Flexibility	O
+of	O
+a	O
+Short	O
+Loop	O
+near	O
+the	O
+Active	O
+Site	O
+of	O
+the	O
+SARS	B-PRGE
+-	I-PRGE
+3CLpro	I-PRGE
+is	O
+Essential	O
+to	O
+Maintain	O
+Catalytic	O
+Activity	O
+.	O
+
+ABSTRACT	O
+:	O
+The	O
+SARS	B-PRGE
+3C	I-PRGE
+-	I-PRGE
+like	I-PRGE
+proteinase	B-PROC
+(	O
+SARS	B-PRGE
+-	I-PRGE
+3CLpro	I-PRGE
+),	O
+which	O
+is	O
+the	O
+main	O
+proteinase	B-PROC
+of	O
+the	O
+SARS	B-DISO
+coronavirus	B-SPEC
+,	O
+is	O
+essential	O
+to	O
+the	O
+virus	B-SPEC
+life	O
+cycle	O
+.	O
+
+There	O
+are	O
+no	O
+typical	O
+clinical	O
+features	O
+of	O
+malaria	B-PATH
+;	O
+even	O
+fever	B-PROC
+is	O
+not	O
+invariably	O
+present	O
+.	O
+
+Management	O
+of	O
+malaria	B-PATH
+depends	O
+on	O
+awareness	O
+of	O
+the	O
+diagnosis	O
+and	O
+on	O
+performing	O
+the	O
+correct	O
+diagnostic	O
+tests	O
+:	O
+the	O
+diagnosis	O
+cannot	O
+be	O
+excluded	O
+until	O
+more	O
+than	O
+one	O
+blood	B-ANAT
+specimen	I-ANAT
+has	O
+been	O
+examined	O
+.	O
+
+Other	O
+travel	O
+related	O
+infections	B-DISO
+,	O
+especially	O
+viral	O
+haemorrhagic	O
+fevers	B-PROC
+,	O
+should	O
+also	O
+be	O
+considered	O
+.	O
+
+Uncomplicated	O
+P	B-SPEC
+.	I-SPEC
+falciparum	I-SPEC
+malaria	O
+should	O
+be	O
+treated	O
+with	O
+an	O
+artemisinin	B-CHED
+combination	O
+therapy	O
+(	O
+Grade	O
+1A	O
+).	O
+
+Quinine	B-CHED
+or	O
+atovaquone	B-CHED
+-	O
+proguanil	B-CHED
+(	O
+Malarone	O
+(®))	O
+can	O
+be	O
+used	O
+if	O
+an	O
+ACT	O
+is	O
+not	O
+available	O
+.	O
+
+They	O
+may	O
+require	O
+haemodynamic	O
+support	O
+and	O
+management	O
+of	O
+:	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+,	O
+disseminated	B-DISO
+intravascular	I-DISO
+coagulation	I-DISO
+,	O
+acute	O
+kidney	B-ANAT
+injury	O
+,	O
+seizures	B-DISO
+,	O
+and	O
+severe	O
+intercurrent	O
+infections	B-DISO
+including	O
+Gram	B-DISO
+-	I-DISO
+negative	I-DISO
+bacteraemia	I-DISO
+/	O
+septicaemia	B-DISO
+.	O
+
+Children	O
+with	O
+uncomplicated	O
+malaria	B-PATH
+should	O
+be	O
+treated	O
+with	O
+an	O
+ACT	O
+(	O
+artemether	B-CHED
+-	O
+lumefantrine	B-CHED
+or	O
+dihydroartemisinin	B-CHED
+-	O
+piperaquine	O
+)	O
+as	O
+first	O
+line	O
+treatment	O
+(	O
+Grade	O
+1A	O
+).	O
+
+Organ	B-DISO
+failure	I-DISO
+occurred	O
+in	O
+74	O
+.	O
+7	O
+%	O
+of	O
+patients	O
+in	O
+the	O
+ICU	O
+,	O
+mostly	O
+respiratory	O
+(	O
+53	O
+.	O
+8	O
+%),	O
+cardiovascular	B-ANAT
+(	O
+44	O
+.	O
+5	O
+%),	O
+and	O
+renal	B-ANAT
+(	O
+44	O
+.	O
+6	O
+%).	O
+
+RESULTS	O
+:	O
+Among	O
+the	O
+5550	O
+patients	O
+admitted	O
+during	O
+the	O
+study	O
+periods	B-PROC
+,	O
+663	O
+(	O
+11	O
+.	O
+9	O
+%)	O
+had	O
+SARI	O
+.	O
+
+ABSTRACT	O
+:	O
+Atypical	B-DISO
+hemolytic	I-DISO
+uremic	I-DISO
+syndrome	I-DISO
+(	O
+aHUS	O
+)	O
+is	O
+caused	O
+by	O
+alternative	B-PROC
+complement	I-PROC
+pathway	I-PROC
+dysregulation	O
+,	O
+leading	O
+to	O
+systemic	O
+thrombotic	B-DISO
+microangiopathy	I-DISO
+(	O
+TMA	B-CHED
+)	O
+and	O
+severe	O
+end	O
+-	O
+organ	B-ANAT
+damage	O
+.	O
+
+However	O
+,	O
+the	O
+incidence	O
+and	O
+associated	O
+causes	O
+of	O
+ARDS	B-DISO
+in	O
+isolated	O
+TBI	O
+have	O
+not	O
+been	O
+well	O
+studied	O
+.	O
+
+In	O
+unadjusted	O
+logistic	O
+regression	O
+analyses	O
+,	O
+the	O
+odds	O
+of	O
+developing	O
+ARDS	B-DISO
+were	O
+significantly	O
+associated	O
+with	O
+head	B-ANAT
+AIS	B-DISO
+score	O
+(	O
+odds	O
+ratio	O
+[	O
+OR	O
+],	O
+1	O
+.	O
+8	O
+;	O
+p	O
+=	O
+0	O
+.	O
+018	O
+),	O
+male	O
+sex	O
+(	O
+OR	O
+,	O
+2	O
+.	O
+9	O
+;	O
+p	O
+=	O
+0	O
+.	O
+012	O
+),	O
+and	O
+early	O
+transfusion	O
+of	O
+platelets	B-ANAT
+(	O
+OR	O
+,	O
+2	O
+.	O
+8	O
+;	O
+p	O
+=	O
+0	O
+.	O
+003	O
+).	O
+
+Early	O
+transfusion	O
+of	O
+platelets	B-ANAT
+after	O
+severe	O
+TBI	O
+may	O
+be	O
+a	O
+modifiable	O
+risk	O
+factor	O
+for	O
+ARDS	B-DISO
+,	O
+and	O
+these	O
+findings	O
+invite	O
+further	O
+investigation	O
+into	O
+causal	O
+mechanisms	O
+driving	O
+this	O
+observed	O
+association	O
+.	O
+
+CONCLUSIONS	O
+:	O
+In	O
+the	O
+era	B-CHED
+of	O
+balanced	O
+hemostatic	B-PROC
+resuscitation	O
+practices	O
+,	O
+severity	O
+of	O
+head	B-ANAT
+injury	O
+,	O
+male	O
+sex	O
+,	O
+early	O
+crystalloids	O
+,	O
+and	O
+early	O
+transfusion	O
+of	O
+platelets	B-ANAT
+are	O
+associated	O
+with	O
+a	O
+higher	O
+risk	O
+of	O
+ARDS	B-DISO
+after	O
+severe	O
+isolated	O
+TBI	O
+.	O
+
+Early	O
+transfusion	O
+of	O
+platelets	B-ANAT
+after	O
+severe	O
+TBI	O
+may	O
+be	O
+a	O
+modifiable	O
+risk	O
+factor	O
+for	O
+ARDS	B-DISO
+,	O
+and	O
+these	O
+findings	O
+invite	O
+further	O
+investigation	O
+into	O
+causal	O
+mechanisms	O
+driving	O
+this	O
+observed	O
+association	O
+.	O
+
+The	O
+virus	B-SPEC
+exists	O
+in	O
+a	O
+wide	O
+variety	O
+of	O
+genetically	O
+distinct	O
+viral	O
+types	O
+,	O
+and	O
+both	O
+phylogenetic	O
+analysis	O
+and	O
+measures	O
+of	O
+pairwise	O
+similarity	O
+among	O
+nucleotide	B-CHED
+or	O
+amino	B-CHED
+acid	I-CHED
+sequences	O
+have	O
+been	O
+used	O
+to	O
+classify	O
+IBV	B-SPEC
+strains	O
+.	O
+
+By	O
+using	O
+complete	O
+nucleotide	B-CHED
+sequences	O
+of	O
+the	O
+S1	O
+gene	O
+we	O
+determined	O
+the	O
+phylogenetic	O
+structure	O
+of	O
+IBV	B-SPEC
+,	O
+which	O
+in	O
+turn	O
+allowed	O
+us	O
+to	O
+define	O
+6	O
+genotypes	O
+that	O
+together	O
+comprise	O
+32	O
+distinct	O
+viral	O
+lineages	O
+and	O
+a	O
+number	O
+of	O
+inter	O
+-	O
+lineage	O
+recombinants	O
+.	O
+
+ABSTRACT	O
+:	O
+Ligands	O
+of	O
+the	O
+endothelial	O
+-	O
+enriched	O
+tunica	B-PRGE
+interna	I-PRGE
+endothelial	B-ANAT
+cell	I-ANAT
+kinase	I-PRGE
+2	I-PRGE
+(	O
+Tie2	B-PRGE
+)	O
+are	O
+markedly	O
+imbalanced	O
+in	O
+severe	O
+infections	B-DISO
+associated	O
+with	O
+vascular	B-ANAT
+leakage	B-DISO
+,	O
+yet	O
+regulation	B-PROC
+of	O
+the	O
+receptor	O
+itself	O
+has	O
+been	O
+understudied	O
+in	O
+this	O
+context	O
+.	O
+
+Here	O
+,	O
+we	O
+show	O
+that	O
+TIE2	B-PRGE
+gene	I-PRGE
+expression	O
+may	O
+constitute	O
+a	O
+novel	O
+vascular	B-ANAT
+barrier	O
+control	O
+mechanism	O
+in	O
+diverse	O
+infections	B-DISO
+.	O
+
+It	O
+was	O
+observed	O
+that	O
+the	O
+distribution	O
+of	O
+respiratory	B-ANAT
+tract	I-ANAT
+viruses	B-SPEC
+showed	O
+variance	O
+by	O
+age	O
+groups	O
+.	O
+
+Influenza	B-SPEC
+viruses	I-SPEC
+were	O
+detected	O
+in	O
+55	O
+.	O
+9	O
+%	O
+of	O
+118	O
+patients	O
+who	O
+were	O
+found	O
+to	O
+be	O
+compatible	O
+with	O
+the	O
+definition	O
+of	O
+""""	O
+influenza	B-DISO
+-	I-DISO
+like	I-DISO
+illness	I-DISO
+""""	O
+specified	O
+in	O
+the	O
+Center	O
+for	O
+Disease	O
+Control	O
+and	O
+Prevention	O
+guidelines	O
+and	O
+other	O
+viral	O
+agenst	O
+were	O
+detected	O
+in	O
+44	O
+%.	O
+
+ABSTRACT	O
+:	O
+Infectious	O
+bronchitis	B-DISO
+virus	B-SPEC
+(	O
+IBV	B-SPEC
+)	O
+is	O
+one	O
+of	O
+the	O
+most	O
+critical	O
+pathogens	O
+in	O
+the	O
+poultry	O
+industry	O
+,	O
+causing	O
+serious	O
+economic	O
+losses	O
+in	O
+all	O
+countries	O
+including	O
+Iraq	O
+.	O
+
+IBV	B-SPEC
+has	O
+many	O
+genotypes	O
+that	O
+do	O
+not	O
+confer	O
+any	O
+cross	O
+-	O
+protection	O
+.	O
+
+One	O
+Chinese	O
+-	O
+like	O
+recombinant	O
+virus	B-SPEC
+(	O
+DY12	B-PRGE
+-	I-PRGE
+2	I-PRGE
+-	I-PRGE
+like	I-PRGE
+)	O
+that	O
+had	O
+not	O
+been	O
+reported	O
+in	O
+the	O
+Middle	O
+East	O
+was	O
+detected	O
+.	O
+
+ABSTRACT	O
+:	O
+Acute	O
+lung	O
+injury	O
+(	O
+ALI	O
+)	O
+and	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+(	O
+ARDS	B-DISO
+)	O
+are	O
+clinically	O
+severe	O
+respiratory	B-DISO
+disorders	I-DISO
+,	O
+and	O
+there	O
+are	O
+currently	O
+no	O
+Food	O
+and	O
+Drug	O
+Administration	O
+-	O
+approved	O
+drug	O
+therapies	O
+.	O
+
+Emerging	O
+studies	O
+suggest	O
+that	O
+the	O
+NLRP3	B-PRGE
+inflammasome	I-PRGE
+plays	O
+a	O
+critical	O
+role	O
+during	O
+ALI	O
+.	O
+
+Lack	O
+of	O
+DPP4	B-PRGE
+expression	B-PROC
+may	O
+be	O
+the	O
+primary	O
+cause	O
+of	O
+limited	O
+MERS	O
+-	O
+CoV	O
+replication	O
+in	O
+the	O
+human	B-SPEC
+upper	B-ANAT
+respiratory	I-ANAT
+tract	I-ANAT
+and	O
+hence	O
+restrict	O
+transmission	O
+.	O
+
+Our	O
+results	O
+show	O
+that	O
+the	O
+carboxy	B-CHED
+-	O
+terminal	O
+domain	O
+of	O
+N	B-PRGE
+protein	I-PRGE
+,	O
+N3	O
+,	O
+is	O
+necessary	O
+and	O
+sufficient	O
+for	O
+interaction	O
+with	O
+M	O
+protein	O
+.	O
+
+However	O
+,	O
+despite	O
+some	O
+previous	O
+genetic	O
+and	O
+biochemical	O
+evidence	O
+that	O
+mapped	O
+interactions	O
+with	O
+N	O
+to	O
+the	O
+carboxy	B-CHED
+terminus	O
+of	O
+M	O
+,	O
+it	O
+was	O
+not	O
+possible	O
+to	O
+define	O
+a	O
+short	O
+linear	O
+region	O
+of	O
+M	B-PRGE
+protein	I-PRGE
+sufficient	O
+for	O
+assembly	O
+with	O
+N	O
+.	O
+Thus	O
+,	O
+interactions	O
+with	O
+N	B-PRGE
+protein	I-PRGE
+likely	O
+involve	O
+multiple	O
+linearly	O
+discontiguous	O
+regions	O
+of	O
+the	O
+M	O
+endodomain	O
+.	O
+
+The	O
+SARS	B-DISO
+-	O
+CoV	O
+M	O
+chimera	B-DISO
+exhibited	O
+a	O
+conditional	O
+growth	B-PROC
+defect	O
+that	O
+was	O
+partially	O
+suppressed	O
+by	O
+mutations	O
+in	O
+the	O
+envelope	B-PRGE
+(	I-PRGE
+E	I-PRGE
+)	I-PRGE
+protein	B-CHED
+.	O
+
+ABSTRACT	O
+:	O
+Accumulating	O
+data	O
+suggest	O
+that	O
+tripartite	O
+-	O
+motif	O
+-	O
+containing	O
+(	O
+TRIM	B-PRGE
+)	O
+proteins	B-CHED
+participate	O
+in	O
+host	B-COMP
+responses	O
+to	O
+viral	B-DISO
+infections	I-DISO
+,	O
+either	O
+by	O
+acting	O
+as	O
+direct	O
+antiviral	B-CHED
+restriction	O
+factors	O
+or	O
+through	O
+regulating	O
+innate	O
+immune	O
+signaling	B-PROC
+of	O
+the	O
+host	B-COMP
+.	O
+
+Interestingly	O
+,	O
+the	O
+anti	O
+-	O
+influenza	B-SPEC
+virus	I-SPEC
+activity	O
+was	O
+independent	O
+of	O
+the	O
+E3	O
+ligase	O
+activity	O
+,	O
+B	O
+-	O
+box	O
+,	O
+or	O
+coiled	O
+-	O
+coil	O
+domain	O
+.	O
+
+ABSTRACT	O
+:	O
+We	O
+analyzed	O
+data	O
+for	O
+170	O
+patients	O
+in	O
+South	O
+Korea	O
+who	O
+had	O
+laboratory	O
+-	O
+confirmed	O
+infection	O
+with	O
+Middle	O
+East	O
+respiratory	O
+syndrome	B-DISO
+coronavirus	B-SPEC
+.	O
+
+Beginning	O
+3	O
+hours	O
+after	O
+completion	O
+of	O
+the	O
+infusion	O
+,	O
+he	O
+developed	O
+progressive	O
+tachycardia	O
+,	O
+fever	B-PROC
+,	O
+hypotension	O
+requiring	O
+vasopressor	O
+infusion	O
+,	O
+and	O
+increasing	O
+oxygen	B-CHED
+requirements	O
+.	O
+
+Laboratory	O
+studies	O
+revealed	O
+leukopenia	B-DISO
+,	O
+thrombocytopenia	O
+,	O
+elevated	O
+C	B-PRGE
+-	I-PRGE
+reactive	I-PRGE
+protein	I-PRGE
+,	O
+abnormal	O
+coagulation	B-PROC
+profile	O
+,	O
+metabolic	B-DISO
+acidosis	I-DISO
+,	O
+and	O
+negative	O
+cultures	O
+.	O
+
+TITLE	O
+:	O
+Structural	O
+characterization	O
+of	O
+the	O
+N	O
+-	O
+terminal	O
+part	O
+of	O
+the	O
+MERS	O
+-	O
+CoV	O
+nucleocapsid	B-COMP
+by	O
+X	O
+-	O
+ray	B-SPEC
+diffraction	O
+and	O
+small	O
+-	O
+angle	O
+X	O
+-	O
+ray	O
+scattering	O
+.	O
+
+This	O
+model	O
+presents	O
+the	O
+N	O
+-	O
+terminal	O
+region	O
+of	O
+the	O
+MERS	O
+-	O
+CoV	O
+as	O
+a	O
+monomer	O
+that	O
+displays	O
+structural	O
+features	O
+in	O
+common	O
+with	O
+other	O
+coronavirus	B-SPEC
+NTDs	O
+.	O
+
+TITLE	O
+:	O
+[	O
+Pulmonary	B-ANAT
+complications	I-DISO
+of	O
+malaria	B-PATH
+:	O
+An	O
+update	O
+].	O
+
+ABSTRACT	O
+:	O
+Malaria	B-PATH
+is	O
+the	O
+most	O
+important	O
+parasitic	B-DISO
+disease	I-DISO
+worldwide	O
+,	O
+being	O
+a	O
+public	O
+health	O
+challenge	O
+in	O
+more	O
+than	O
+90	O
+countries	O
+.	O
+
+Virus	B-DISO
+shedding	I-DISO
+was	O
+detected	O
+in	O
+the	O
+respiratory	O
+and	O
+intestinal	B-ANAT
+tract	I-ANAT
+for	O
+up	O
+to	O
+9	O
+days	O
+.	O
+
+MERS	O
+-	O
+CoV	O
+replicated	O
+transiently	O
+in	O
+the	O
+respiratory	O
+and	O
+,	O
+to	O
+a	O
+lesser	O
+extent	O
+,	O
+the	O
+intestinal	O
+tracts	B-ANAT
+and	O
+internal	O
+organs	B-ANAT
+;	O
+with	O
+limited	O
+histopathological	O
+changes	O
+observed	O
+only	O
+in	O
+the	O
+lungs	B-ANAT
+.	O
+
+Although	O
+feline	B-DISO
+infectious	I-DISO
+peritonitis	I-DISO
+(	O
+FIP	B-DISO
+)	O
+is	O
+a	O
+very	O
+common	O
+disease	O
+,	O
+the	O
+ante	O
+-	O
+mortem	O
+diagnosis	O
+of	O
+this	O
+disease	B-DISO
+still	I-DISO
+remains	O
+a	O
+challenge	O
+.	O
+
+Conclusions	O
+and	O
+relevance	O
+Once	O
+the	O
+clinical	O
+disease	O
+of	O
+FIP	B-DISO
+develops	O
+in	O
+a	O
+cat	B-SPEC
+,	O
+it	O
+always	O
+leads	O
+to	O
+death	B-PROC
+,	O
+and	O
+most	O
+of	O
+the	O
+cats	B-SPEC
+are	O
+euthanased	O
+within	O
+a	O
+few	O
+days	O
+or	O
+weeks	O
+.	O
+
+These	O
+data	O
+indicate	O
+that	O
+the	O
+Le	O
+(	O
+x	O
+)	O
+structure	O
+could	O
+play	O
+a	O
+role	O
+in	O
+syncytial	B-ANAT
+formation	I-ANAT
+and	O
+cell	B-COMP
+-	O
+to	O
+-	O
+cell	B-COMP
+infection	B-DISO
+during	O
+the	O
+late	O
+phase	O
+of	O
+infection	B-DISO
+.	O
+
+TITLE	O
+:	O
+[	O
+Hypercapnic	B-DISO
+respiratory	I-DISO
+failure	I-DISO
+.	O
+
+In	O
+hypercapnic	B-DISO
+respiratory	I-DISO
+failure	I-DISO
+with	O
+a	O
+pH	O
+<	O
+7	O
+.	O
+35	O
+non	O
+-	O
+invasive	O
+ventilation	O
+(	O
+NIV	O
+)	O
+is	O
+primarily	O
+indicated	O
+unless	O
+there	O
+are	O
+contraindications	O
+.	O
+
+In	O
+patients	O
+with	O
+severe	O
+respiratory	B-DISO
+acidosis	I-DISO
+NIV	O
+requires	O
+a	O
+skilled	O
+and	O
+experienced	O
+team	O
+and	O
+close	O
+monitoring	O
+in	O
+order	B-SPEC
+to	O
+perceive	O
+a	O
+failure	O
+of	O
+NIV	O
+.	O
+
+In	O
+acute	O
+exacerbation	O
+of	O
+COPD	B-DISO
+ventilator	O
+settings	O
+need	O
+a	O
+long	O
+expiration	B-PROC
+and	O
+short	O
+inspiration	B-PROC
+time	O
+to	O
+avoid	O
+further	O
+hyperinflation	B-DISO
+and	O
+an	O
+increase	O
+in	O
+intrinsic	O
+positive	O
+end	B-PROC
+-	I-PROC
+expiratory	I-PROC
+pressure	O
+(	O
+PEEP	B-CHED
+).	O
+
+The	O
+Large	O
+Observational	O
+Study	O
+to	O
+Understand	O
+the	O
+Global	O
+Impact	O
+of	O
+Severe	O
+Acute	B-DISO
+Respiratory	I-DISO
+Failure	I-DISO
+(	O
+LUNG	B-ANAT
+SAFE	O
+)	O
+was	O
+an	O
+international	O
+,	O
+multicenter	O
+,	O
+prospective	O
+cohort	O
+study	O
+of	O
+patients	O
+undergoing	O
+invasive	O
+or	O
+noninvasive	O
+ventilation	O
+,	O
+conducted	O
+during	O
+4	O
+consecutive	O
+weeks	O
+in	O
+the	O
+winter	O
+of	O
+2014	O
+in	O
+a	O
+convenience	O
+sample	O
+of	O
+459	O
+ICUs	O
+from	O
+50	O
+countries	O
+across	O
+5	O
+continents	O
+.	O
+
+Secondary	O
+outcomes	O
+included	O
+assessment	O
+of	O
+clinician	O
+recognition	O
+of	O
+ARDS	B-DISO
+,	O
+the	O
+application	O
+of	O
+ventilatory	O
+management	O
+,	O
+the	O
+use	O
+of	O
+adjunctive	O
+interventions	O
+in	O
+routine	O
+clinical	O
+practice	O
+,	O
+and	O
+clinical	O
+outcomes	O
+from	O
+ARDS	B-DISO
+.	O
+
+Of	O
+these	O
+,	O
+2377	O
+patients	O
+developed	O
+ARDS	B-DISO
+in	O
+the	O
+first	O
+48	O
+hours	O
+and	O
+whose	O
+respiratory	B-DISO
+failure	I-DISO
+was	O
+managed	O
+with	O
+invasive	O
+mechanical	O
+ventilation	O
+.	O
+
+Plateau	O
+pressure	O
+was	O
+measured	O
+in	O
+40	O
+.	O
+1	O
+%	O
+(	O
+95	O
+%	O
+CI	O
+,	O
+38	O
+.	O
+2	O
+-	O
+42	O
+.	O
+1	O
+),	O
+whereas	O
+82	O
+.	O
+6	O
+%	O
+(	O
+95	O
+%	O
+CI	O
+,	O
+81	O
+.	O
+0	O
+%-	O
+84	O
+.	O
+1	O
+%)	O
+received	O
+a	O
+positive	O
+end	O
+-	O
+expository	O
+pressure	O
+(	O
+PEEP	B-CHED
+)	O
+of	O
+less	O
+than	O
+12	O
+cm	O
+H2O	B-CHED
+.	O
+
+This	O
+syndrome	B-DISO
+appeared	O
+to	O
+be	O
+underrecognized	O
+and	O
+undertreated	O
+and	O
+associated	O
+with	O
+a	O
+high	O
+mortality	O
+rate	O
+.	O
+
+These	O
+findings	O
+indicate	O
+the	O
+potential	O
+for	O
+improvement	O
+in	O
+the	O
+management	O
+of	O
+patients	O
+with	O
+ARDS	B-DISO
+.	O
+
+No	O
+vaccines	O
+are	O
+currently	O
+licensed	O
+for	O
+SARS	B-DISO
+-	O
+CoV	O
+and	O
+important	O
+efforts	O
+have	O
+been	O
+performed	O
+during	O
+the	O
+first	O
+outbreak	O
+to	O
+develop	O
+diagnostic	O
+tools	O
+.	O
+
+The	O
+availability	O
+of	O
+recombinant	B-PRGE
+N	I-PRGE
+and	I-PRGE
+M	I-PRGE
+proteins	I-PRGE
+from	O
+plants	B-SPEC
+opens	O
+the	O
+way	O
+to	O
+further	O
+evaluation	O
+of	O
+their	O
+potential	O
+utility	O
+for	O
+the	O
+development	B-PROC
+of	O
+diagnostic	O
+and	O
+protection	O
+/	O
+therapy	O
+tools	O
+to	O
+be	O
+quickly	O
+manufactured	O
+,	O
+at	O
+low	O
+cost	O
+and	O
+with	O
+minimal	O
+risk	O
+,	O
+to	O
+face	B-DISO
+potential	O
+new	O
+highly	O
+infectious	B-DISO
+SARS	B-DISO
+-	O
+CoV	O
+outbreaks	O
+.	O
+
+We	O
+retrospectively	O
+analyzed	O
+the	O
+clinical	O
+reports	O
+of	O
+10	O
+patients	O
+who	O
+underwent	O
+awake	O
+ECMO	O
+due	O
+to	O
+postoperative	O
+ARDS	B-DISO
+between	O
+August	O
+2012	O
+and	O
+May	O
+2015	O
+.	O
+
+Two	O
+cases	O
+failed	O
+awake	O
+ECMO	O
+and	O
+died	B-PROC
+due	O
+to	O
+disease	O
+aggravation	O
+.	O
+
+Additionally	O
+,	O
+it	O
+is	O
+possible	O
+for	O
+patients	O
+to	O
+breathe	O
+spontaneously	O
+,	O
+which	O
+might	O
+prevents	O
+respiratory	B-ANAT
+muscle	I-ANAT
+dystrophy	B-DISO
+.	O
+
+We	O
+weaned	B-PROC
+that	O
+patient	O
+from	O
+ECMO	O
+2	O
+days	O
+later	O
+.	O
+
+For	O
+example	O
+in	O
+acute	O
+lung	B-ANAT
+injury	O
+(	O
+ALI	O
+)	O
+and	O
+its	O
+most	O
+severe	O
+form	O
+,	O
+the	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+(	O
+ARDS	B-DISO
+),	O
+lung	B-ANAT
+microvessel	B-ANAT
+endothelia	O
+lose	O
+their	O
+junctional	O
+integrity	O
+resulting	O
+in	O
+leakiness	O
+of	O
+the	O
+endothelial	B-ANAT
+barrier	O
+and	O
+accumulation	O
+of	O
+protein	B-CHED
+rich	O
+edema	B-DISO
+.	O
+
+Most	O
+people	O
+who	O
+arrive	O
+in	O
+Sweden	O
+with	O
+suspicious	O
+symptoms	O
+will	O
+likely	O
+have	O
+other	O
+diseases	O
+than	O
+Ebola	O
+/	O
+MERS	O
+,	O
+for	O
+example	O
+malaria	B-PATH
+or	O
+pneumococci	O
+,	O
+but	O
+we	O
+still	O
+need	O
+to	O
+take	O
+care	O
+of	O
+these	O
+patients	O
+and	O
+be	O
+able	O
+to	O
+provide	O
+optimal	O
+treatment	O
+of	O
+electrolyte	O
+disturbances	O
+,	O
+kidney	B-DISO
+failure	I-DISO
+,	O
+bleedings	O
+etc	O
+.	O
+
+Herein	O
+we	O
+review	O
+such	O
+animal	B-SPEC
+models	O
+,	O
+which	O
+are	O
+mostly	O
+limited	O
+to	O
+rodent	B-SPEC
+models	O
+of	O
+burn	O
+-	O
+induced	O
+,	O
+inflammatory	O
+,	O
+and	O
+neuropathic	B-DISO
+pain	I-DISO
+.	O
+
+TITLE	O
+:	O
+Identification	O
+and	O
+Comparison	O
+of	O
+Receptor	B-FUNC
+Binding	I-FUNC
+Characteristics	O
+of	O
+the	O
+Spike	B-PRGE
+Protein	I-PRGE
+of	O
+Two	O
+Porcine	O
+Epidemic	O
+Diarrhea	O
+Virus	O
+Strains	O
+.	O
+
+The	O
+spike	O
+(	O
+S	O
+)	O
+protein	B-CHED
+mediates	O
+PEDV	B-SPEC
+entry	B-PROC
+into	I-PROC
+host	I-PROC
+cells	B-COMP
+.	O
+
+The	O
+C	O
+-	O
+terminal	O
+domain	O
+(	O
+CTD	O
+)	O
+of	O
+the	O
+S1	B-PRGE
+domain	I-PRGE
+is	O
+bound	O
+to	O
+pAPN	O
+.	O
+
+The	O
+prototype	O
+strain	O
+demonstrated	O
+similar	O
+receptor	O
+-	O
+binding	B-PROC
+activity	I-PROC
+compared	O
+with	O
+the	O
+variant	O
+field	O
+isolate	O
+.	O
+
+Our	O
+results	O
+indicated	O
+that	O
+S	O
+proteins	B-CHED
+from	O
+different	O
+coronaviruses	O
+displayed	O
+varied	O
+abilities	O
+to	O
+mediate	O
+pseudotyped	O
+virus	B-DISO
+infection	I-DISO
+.	O
+
+TITLE	O
+:	O
+Identifying	O
+determinants	O
+of	O
+heterogeneous	O
+transmission	O
+dynamics	O
+of	O
+the	O
+Middle	O
+East	O
+respiratory	O
+syndrome	B-DISO
+(	O
+MERS	O
+)	O
+outbreak	O
+in	O
+the	O
+Republic	O
+of	O
+Korea	O
+,	O
+2015	O
+:	O
+a	O
+retrospective	O
+epidemiological	O
+analysis	O
+.	O
+
+ABSTRACT	O
+:	O
+To	O
+investigate	O
+the	O
+heterogeneous	O
+transmission	O
+patterns	O
+of	O
+Middle	O
+East	O
+respiratory	O
+syndrome	B-DISO
+(	O
+MERS	O
+)	O
+in	O
+the	O
+Republic	O
+of	O
+Korea	O
+,	O
+with	O
+a	O
+particular	O
+focus	O
+on	O
+epidemiological	O
+characteristics	O
+of	O
+superspreaders	O
+.	O
+
+TITLE	O
+:	O
+The	O
+Effects	O
+of	O
+Prone	O
+Position	O
+Ventilation	O
+on	O
+Experimental	O
+Mild	O
+Acute	O
+Lung	B-ANAT
+Injury	O
+Induced	O
+by	O
+Intraperitoneal	O
+Lipopolysaccharide	O
+Injection	O
+in	O
+Rats	B-SPEC
+.	O
+
+ABSTRACT	O
+:	O
+The	O
+benefits	O
+of	O
+prone	O
+position	O
+ventilation	O
+are	O
+well	O
+demonstrated	O
+in	O
+the	O
+severe	O
+forms	O
+of	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+,	O
+but	O
+not	O
+in	O
+the	O
+milder	O
+forms	O
+.	O
+
+TITLE	O
+:	O
+A	O
+Dimerization	O
+-	O
+Dependent	O
+Mechanism	O
+Drives	O
+the	O
+Endoribonuclease	O
+Function	O
+of	O
+Porcine	B-DISO
+Reproductive	B-PROC
+and	I-DISO
+Respiratory	I-DISO
+Syndrome	I-DISO
+Virus	I-SPEC
+nsp11	O
+.	O
+
+Here	O
+,	O
+we	O
+report	O
+the	O
+first	O
+crystal	B-ANAT
+structure	O
+of	O
+the	O
+arterivirus	B-PRGE
+nsp11	I-PRGE
+protein	B-CHED
+from	O
+PRRSV	B-SPEC
+,	O
+which	O
+exhibits	O
+a	O
+unique	O
+structure	O
+and	O
+assembles	O
+into	O
+an	O
+asymmetric	O
+dimer	O
+whose	O
+structure	O
+is	O
+completely	O
+different	O
+from	O
+the	O
+hexameric	O
+structure	O
+of	O
+coronavirus	B-SPEC
+nsp15	O
+.	O
+
+Mutagenesis	B-PROC
+and	O
+structural	O
+analysis	O
+revealed	O
+NendoU	O
+active	O
+site	O
+residues	O
+,	O
+which	O
+are	O
+conserved	O
+throughout	O
+the	O
+order	B-SPEC
+Nidovirales	I-SPEC
+(	O
+families	O
+Arteriviridae	B-SPEC
+and	O
+Coronaviridae	B-SPEC
+)	O
+and	O
+the	O
+major	O
+determinants	O
+of	O
+dimerization	O
+(	O
+Ser74	O
+and	O
+Phe76	O
+)	O
+in	O
+Arteriviridae	B-SPEC
+Importantly	O
+,	O
+these	O
+findings	O
+may	O
+provide	O
+a	O
+new	O
+structural	O
+basis	O
+for	O
+antiviral	B-CHED
+drug	I-CHED
+development	B-PROC
+.	O
+
+The	O
+dose	O
+of	O
+methylprednisolone	B-CHED
+was	O
+tapered	O
+to	O
+0	O
+.	O
+25	O
+mg	O
+/(	O
+kg	O
+·	O
+d	O
+)	O
+after	O
+4	O
+weeks	O
+and	O
+was	O
+adjusted	O
+according	O
+to	O
+the	O
+occurrence	O
+and	O
+severity	O
+of	O
+chronic	B-DISO
+graft	I-DISO
+-	I-DISO
+versus	I-DISO
+-	I-DISO
+host	B-COMP
+disease	I-DISO
+(	O
+cGVHD	B-DISO
+).	O
+
+TITLE	O
+:	O
+[	O
+Ventilatory	O
+strategy	O
+for	O
+ARDS	B-DISO
+].	O
+
+TITLE	O
+:	O
+Korean	O
+Society	O
+for	O
+Laboratory	O
+Medicine	B-CHED
+Practice	O
+Guidelines	O
+for	O
+the	O
+Molecular	O
+Diagnosis	O
+of	O
+Middle	O
+East	O
+Respiratory	O
+Syndrome	O
+During	O
+an	O
+Outbreak	O
+in	O
+Korea	O
+in	O
+2015	O
+.	O
+
+On	O
+June	O
+3	O
+,	O
+2015	O
+,	O
+the	O
+Korean	O
+Society	O
+for	O
+Laboratory	O
+Medicine	B-CHED
+(	O
+KSLM	O
+)	O
+launched	O
+a	O
+MERS	O
+-	O
+CoV	O
+Laboratory	O
+Response	O
+Task	O
+Force	O
+(	O
+LR	O
+-	O
+TF	O
+)	O
+to	O
+facilitate	O
+clinical	O
+laboratories	O
+to	O
+set	O
+up	O
+the	O
+diagnosis	O
+of	O
+MERS	O
+-	O
+CoV	O
+infection	B-DISO
+.	O
+
+The	O
+guidelines	O
+described	O
+here	O
+are	O
+an	O
+updated	O
+version	O
+that	O
+includes	O
+case	O
+definition	O
+,	O
+indications	O
+for	O
+testing	O
+,	O
+specimen	O
+type	O
+and	O
+protocols	O
+for	O
+specimen	O
+collection	O
+,	O
+specimen	O
+packing	O
+and	O
+transport	O
+,	O
+specimen	O
+handling	O
+and	O
+nucleic	B-CHED
+acid	I-CHED
+extraction	O
+,	O
+molecular	O
+detection	O
+of	O
+MERS	O
+-	O
+CoV	O
+,	O
+interpretation	O
+of	O
+results	O
+and	O
+reporting	O
+,	O
+and	O
+laboratory	O
+safety	O
+.	O
+
+The	O
+mean	O
+C	O
+(	O
+T	O
+)	O
+value	O
+for	O
+each	O
+concentration	O
+was	O
+different	O
+depending	O
+on	O
+which	O
+commercial	O
+kit	B-FUNC
+was	O
+used	O
+for	O
+the	O
+assay	O
+.	O
+
+RESULTS	O
+:	O
+The	O
+first	O
+EQA	O
+phase	O
+results	O
+for	O
+46	O
+participants	O
+showed	O
+a	O
+linear	O
+relationship	O
+between	O
+the	O
+threshold	O
+cycle	O
+(	O
+C	O
+(	O
+T	O
+))	O
+values	O
+of	O
+RNA	O
+materials	O
+and	O
+the	O
+logarithmic	O
+concentrations	O
+for	O
+both	O
+upE	O
+and	O
+ORF1a	B-PRGE
+gene	I-PRGE
+targets	I-PRGE
+(	O
+R²	O
+=	O
+0	O
+.	O
+73	O
+and	O
+0	O
+.	O
+75	O
+,	O
+respectively	O
+).	O
+
+Both	O
+HCoV	B-SPEC
+-	I-SPEC
+OC43	I-SPEC
+and	O
+HCoV	O
+-	O
+HKU1	O
+were	O
+co	O
+-	O
+circulating	O
+throughout	O
+the	O
+year	O
+,	O
+with	O
+the	O
+lowest	O
+detection	O
+rates	O
+reported	O
+in	O
+the	O
+October	O
+-	O
+January	O
+period	O
+.	O
+
+Phylogenetic	O
+analysis	O
+revealed	O
+that	O
+27	O
+.	O
+3	O
+%	O
+of	O
+the	O
+HCoV	O
+-	O
+HKU1	O
+strains	O
+belong	O
+to	O
+genotype	O
+A	O
+while	O
+72	O
+.	O
+7	O
+%	O
+belongs	O
+to	O
+genotype	O
+B	O
+.	O
+The	O
+tree	O
+root	B-ANAT
+of	O
+HCoV	O
+-	O
+HKU1	O
+was	O
+similar	O
+to	O
+that	O
+of	O
+HCoV	B-SPEC
+-	I-SPEC
+OC43	I-SPEC
+,	O
+with	O
+the	O
+tMRCA	O
+of	O
+genotypes	O
+A	O
+and	O
+B	O
+estimated	O
+around	O
+the	O
+1990s	O
+and	O
+2000s	O
+,	O
+respectively	O
+.	O
+
+As	O
+a	O
+result	O
+,	O
+Lys	B-CHED
+113	O
+,	O
+Arg	B-CHED
+125	O
+,	O
+Tyr	B-CHED
+127	O
+,	O
+Glu	B-CHED
+173	O
+,	O
+Tyr	B-CHED
+190	O
+residues	O
+that	O
+play	O
+an	O
+important	O
+role	O
+in	O
+virus	B-PROC
+replication	I-PROC
+were	O
+determined	O
+.	O
+
+PANTHER	O
+TOOL	O
+and	O
+DAVID	O
+platform	O
+were	O
+used	O
+for	O
+the	O
+analysis	O
+of	O
+GO	O
+and	O
+Pathway	B-PROC
+.	O
+
+RESULTS	O
+:	O
+One	O
+set	O
+of	O
+MERS	O
+-	O
+CoV	O
+related	O
+microarray	O
+data	O
+and	O
+27	O
+target	O
+genes	O
+of	O
+ribavirin	B-CHED
+and	O
+interferon	B-PRGE
+-	I-PRGE
+α	I-PRGE
+were	O
+acquired	O
+from	O
+the	O
+online	O
+databases	O
+.	O
+
+TITLE	O
+:	O
+Age	O
+-	O
+related	O
+presence	O
+of	O
+selected	O
+viral	O
+and	O
+bacterial	O
+pathogens	O
+in	O
+paraffin	O
+-	O
+embedded	O
+lung	B-ANAT
+samples	O
+of	O
+dogs	O
+with	O
+pneumonia	B-DISO
+.	O
+
+The	O
+correct	O
+detection	O
+of	O
+CDV	O
+had	O
+been	O
+achieved	O
+in	O
+ten	O
+out	O
+of	O
+eleven	O
+positive	O
+cases	O
+(	O
+90	O
+.	O
+9	O
+%)	O
+upon	O
+initial	O
+investigation	O
+,	O
+but	O
+the	O
+presence	O
+of	O
+bacterial	O
+pathogens	O
+,	O
+like	O
+B	B-SPEC
+.	I-SPEC
+bronchiseptica	I-SPEC
+(	O
+10	O
+cases	O
+)	O
+and	O
+P	B-SPEC
+.	I-SPEC
+multocida	I-SPEC
+(	O
+17	O
+cases	O
+)	O
+had	O
+been	O
+missed	O
+in	O
+all	O
+but	O
+one	O
+case	O
+.	O
+
+Ribosome	B-COMP
+profiling	O
+is	O
+a	O
+technique	O
+which	O
+exploits	O
+the	O
+capacity	O
+of	O
+the	O
+translating	O
+ribosome	B-COMP
+to	O
+protect	O
+around	O
+30	O
+nucleotides	B-CHED
+of	O
+mRNA	B-CHED
+from	O
+ribonuclease	O
+digestion	B-PROC
+.	O
+
+Ribosome	B-COMP
+-	O
+protected	O
+mRNA	B-CHED
+fragments	O
+are	O
+purified	O
+,	O
+subjected	O
+to	O
+deep	O
+sequencing	O
+and	O
+mapped	O
+back	B-ANAT
+to	O
+the	O
+transcriptome	O
+to	O
+give	O
+a	O
+global	O
+""""	O
+snap	B-FUNC
+-	O
+shot	O
+""""	O
+of	O
+translation	B-PROC
+.	O
+
+TITLE	O
+:	O
+Acute	B-DISO
+Respiratory	I-DISO
+Distress	I-DISO
+Syndrome	I-DISO
+.	O
+
+Other	O
+methods	O
+that	O
+include	O
+prone	O
+positioning	O
+for	O
+ventilation	O
+have	O
+also	O
+shown	O
+improvements	O
+in	O
+oxygenation	B-PROC
+.	O
+
+Endothelial	B-ANAT
+activation	O
+biomarkers	O
+(	O
+soluble	O
+vascular	O
+cell	B-PROC
+adhesion	B-DISO
+molecule	O
+-	O
+1	O
+[	O
+sVCAM	O
+-	O
+1	O
+],	O
+soluble	O
+endothelial	B-PRGE
+selectin	B-PROC
+[	O
+sESEL	O
+],	O
+angiopoietin	B-PRGE
+-	I-PRGE
+1	I-PRGE
+[	O
+Ang	B-PRGE
+-	I-PRGE
+1	I-PRGE
+]	O
+and	O
+angiopoietin	B-PRGE
+-	I-PRGE
+2	I-PRGE
+[	O
+Ang	B-PRGE
+-	I-PRGE
+2	I-PRGE
+])	O
+were	O
+measured	O
+in	O
+bronchoalveolar	B-ANAT
+lavage	I-ANAT
+fluid	I-ANAT
+.	O
+
+Patients	O
+with	O
+ARDS	B-DISO
+had	O
+significantly	O
+higher	O
+median	O
+sVCAM	O
+-	O
+1	O
+concentrations	O
+in	O
+the	O
+bronchoalveolar	B-ANAT
+lavage	I-ANAT
+fluid	I-ANAT
+compared	O
+with	O
+healthy	O
+volunteers	O
+(	O
+985	O
+vs	O
+119	O
+pg	O
+/	O
+mL	O
+,	O
+p	O
+=	O
+0	O
+.	O
+03	O
+).	O
+
+Additionally	O
+,	O
+there	O
+was	O
+a	O
+trend	O
+toward	O
+greater	O
+bronchoalveolar	B-ANAT
+lavage	I-ANAT
+fluid	I-ANAT
+sVCAM	O
+-	O
+1	O
+concentrations	O
+among	O
+patients	O
+with	O
+moderate	O
+/	O
+severe	O
+compared	O
+to	O
+mild	O
+ARDS	B-DISO
+(	O
+1395	O
+vs	O
+209	O
+pg	O
+/	O
+mL	O
+,	O
+p	O
+=	O
+0	O
+.	O
+06	O
+).	O
+
+TITLE	O
+:	O
+Carotid	B-ANAT
+body	I-ANAT
+chemoreceptors	B-ANAT
+,	O
+sympathetic	O
+neural	O
+activation	O
+,	O
+and	O
+cardiometabolic	O
+disease	O
+.	O
+
+The	O
+classical	O
+construct	O
+considers	O
+the	O
+CB	O
+as	O
+the	O
+main	O
+peripheral	O
+oxygen	B-CHED
+sensor	O
+,	O
+triggering	O
+reflex	B-PROC
+physiological	O
+responses	O
+to	O
+acute	O
+hypoxemia	O
+and	O
+facilitating	O
+the	O
+ventilatory	O
+acclimation	B-PROC
+to	O
+chronic	O
+hypoxemia	O
+at	O
+high	O
+altitude	O
+.	O
+
+TITLE	O
+:	O
+Coexistence	O
+of	O
+multiple	O
+coronaviruses	O
+in	O
+several	O
+bat	B-ENZY
+colonies	O
+in	O
+an	O
+abandoned	O
+mineshaft	O
+.	O
+
+Chest	B-ANAT
+radiography	O
+revealed	O
+in	O
+the	O
+lower	O
+lung	B-ANAT
+fields	O
+accentuated	O
+bronchovascular	O
+lung	B-ANAT
+markings	O
+and	O
+multiple	O
+small	O
+patchy	O
+opacities	B-DISO
+.	O
+
+Laboratory	O
+tests	O
+were	O
+negative	O
+for	O
+viruses	B-SPEC
+known	O
+to	O
+cause	O
+myocarditis	B-DISO
+.	O
+
+Using	O
+a	O
+retrospective	O
+cohort	O
+,	O
+a	O
+simple	O
+prediction	O
+score	O
+was	O
+developed	O
+to	O
+improve	O
+early	O
+identification	O
+of	O
+ARDS	B-DISO
+patients	O
+who	O
+were	O
+likely	O
+to	O
+progress	O
+to	O
+severe	O
+ARDS	B-DISO
+within	O
+7	O
+days	O
+.	O
+
+ABSTRACT	O
+:	O
+The	O
+optimal	O
+treatment	O
+for	O
+respiratory	B-SPEC
+syncytial	I-SPEC
+virus	I-SPEC
+(	O
+RSV	B-SPEC
+)	O
+infection	B-DISO
+in	O
+adult	O
+immunocompromised	O
+patients	O
+is	O
+unknown	O
+.	O
+
+We	O
+assessed	O
+the	O
+management	O
+of	O
+RSV	B-SPEC
+and	O
+other	O
+non	O
+-	O
+influenza	B-DISO
+respiratory	O
+viruses	B-SPEC
+in	O
+Midwestern	O
+transplant	B-ANAT
+centers	O
+.	O
+
+TITLE	O
+:	O
+Preparedness	O
+for	O
+ebolavirus	B-SPEC
+disease	O
+outbreak	O
+in	O
+Japan	O
+:	O
+Necessity	O
+of	O
+Biosafety	O
+level	O
+-	O
+4	O
+facility	O
+.	O
+
+The	O
+evidence	O
+indicates	O
+that	O
+infectious	B-DISO
+BSL	O
+-	O
+4	O
+pathogens	O
+such	O
+as	O
+Ebola	O
+and	O
+Marburg	B-SPEC
+viruses	I-SPEC
+cannot	O
+be	O
+manipulated	O
+in	O
+Japan	O
+,	O
+making	O
+it	O
+impossible	O
+to	O
+study	O
+the	O
+BSL	O
+-	O
+4	O
+pathogens	O
+using	O
+the	O
+infectious	B-DISO
+viruses	B-SPEC
+.	O
+
+Because	O
+these	O
+emerging	O
+virus	B-SPEC
+infections	B-DISO
+are	O
+caused	O
+by	O
+the	O
+zoonotic	O
+pathogens	O
+,	O
+the	O
+eradiation	O
+and	O
+the	O
+elimination	B-PROC
+of	O
+these	O
+infectious	B-DISO
+diseases	I-DISO
+are	O
+impossible	O
+.	O
+
+The	O
+origin	O
+-	O
+based	O
+and	O
+destination	O
+-	O
+based	O
+spatial	O
+dependence	B-DISO
+positively	O
+affected	O
+migrant	O
+flows	O
+(	O
+i	O
+.	O
+e	O
+.,	O
+due	O
+to	O
+those	O
+seeking	O
+jobs	O
+)	O
+from	O
+the	O
+neighbours	O
+of	O
+origin	O
+and	O
+destination	O
+locations	O
+.	O
+
+ABSTRACT	O
+:	O
+The	O
+Middle	O
+East	O
+respiratory	O
+syndrome	O
+coronavirus	B-SPEC
+(	O
+MERS	O
+-	O
+CoV	O
+)	O
+is	O
+a	O
+novel	O
+enzootic	O
+betacoronavirus	B-SPEC
+that	O
+was	O
+first	O
+described	O
+in	O
+September	O
+2012	O
+.	O
+
+MERS	O
+-	O
+CoV	O
+RNA	O
+and	O
+viable	O
+virus	B-SPEC
+have	O
+been	O
+isolated	O
+from	O
+dromedary	B-SPEC
+camels	B-SPEC
+,	O
+including	O
+some	O
+with	O
+respiratory	B-DISO
+symptoms	I-DISO
+.	O
+
+Furthermore	O
+,	O
+near	O
+-	O
+identical	O
+strains	O
+of	O
+MERS	O
+-	O
+CoV	O
+have	O
+been	O
+isolated	O
+from	O
+epidemiologically	O
+linked	O
+humans	B-SPEC
+and	O
+camels	B-SPEC
+,	O
+confirming	O
+inter	O
+-	O
+transmission	O
+,	O
+most	O
+probably	O
+from	O
+camels	B-SPEC
+to	O
+humans	B-SPEC
+.	O
+
+Amongst	O
+the	O
+important	O
+measures	O
+to	O
+control	O
+MERS	O
+-	O
+CoV	O
+spread	O
+are	O
+strict	O
+regulation	B-PROC
+of	O
+camel	B-SPEC
+movement	B-PROC
+,	O
+regular	O
+herd	O
+screening	O
+and	O
+isolation	O
+of	O
+infected	O
+camels	B-SPEC
+,	O
+use	O
+of	O
+personal	O
+protective	O
+equipment	O
+by	O
+camel	B-SPEC
+handlers	O
+and	O
+enforcing	O
+rules	O
+banning	O
+all	O
+consumption	O
+of	O
+unpasteurized	O
+camel	B-SPEC
+milk	O
+and	O
+urine	B-ANAT
+.	O
+
+Here	O
+,	O
+we	O
+analyzed	O
+the	O
+phylogenetic	O
+,	O
+temporal	O
+distribution	O
+,	O
+population	O
+history	O
+,	O
+and	O
+clinical	O
+manifestations	O
+among	O
+patients	O
+infected	O
+with	O
+HCoV	B-SPEC
+-	I-SPEC
+NL63	I-SPEC
+and	O
+HCoV	B-SPEC
+-	I-SPEC
+229E	I-SPEC
+.	O
+
+A	O
+peak	O
+in	O
+the	O
+number	O
+of	O
+HCoV	B-SPEC
+-	I-SPEC
+NL63	I-SPEC
+infections	B-DISO
+was	O
+recorded	O
+between	O
+June	O
+and	O
+October	O
+2012	O
+.	O
+
+The	O
+study	O
+described	O
+the	O
+seasonality	O
+,	O
+molecular	O
+diversity	O
+,	O
+and	O
+evolutionary	O
+dynamics	O
+of	O
+human	B-SPEC
+alphacoronavirus	B-SPEC
+infections	B-DISO
+in	O
+a	O
+tropical	O
+region	O
+.	O
+
+In	O
+conclusion	O
+,	O
+the	O
+severity	O
+of	O
+MERS	O
+-	O
+HCP	B-DISO
+and	O
+SARS	B-DISO
+-	O
+HCP	B-DISO
+was	O
+lower	O
+than	O
+that	O
+of	O
+MERS	O
+-	O
+non	O
+-	O
+HCP	B-DISO
+and	O
+SARS	B-DISO
+-	O
+non	O
+-	O
+HCP	B-DISO
+due	O
+to	O
+younger	O
+age	O
+and	O
+early	O
+confirmation	O
+in	O
+HCP	B-DISO
+groups	O
+.	O
+
+In	O
+particular	O
+,	O
+our	O
+study	O
+shows	O
+that	O
+(	O
+i	O
+)	O
+human	B-SPEC
+coronavirus	I-SPEC
+infections	O
+are	O
+more	O
+common	O
+during	O
+influenza	B-DISO
+seasons	O
+and	O
+in	O
+co	B-DISO
+-	I-DISO
+infections	I-DISO
+than	O
+previously	O
+recognized	O
+,	O
+(	O
+ii	O
+)	O
+factors	O
+associated	O
+with	O
+co	B-DISO
+-	I-DISO
+infection	I-DISO
+differ	O
+from	O
+those	O
+associated	O
+with	O
+viral	B-DISO
+infection	I-DISO
+overall	O
+,	O
+(	O
+iii	O
+)	O
+virus	B-SPEC
+prevalence	O
+has	O
+increased	O
+over	O
+time	O
+especially	O
+in	O
+infants	O
+aged	O
+<	O
+1	O
+year	O
+,	O
+and	O
+(	O
+iv	O
+)	O
+viral	B-DISO
+infection	I-DISO
+risk	O
+is	O
+greater	O
+in	O
+the	O
+post	O
+-	O
+2009	O
+pandemic	O
+era	B-CHED
+,	O
+likely	O
+reflecting	O
+a	O
+widespread	O
+change	O
+in	O
+the	O
+viral	O
+population	O
+that	O
+warrants	O
+further	O
+investigation	O
+.	O
+
+Here	O
+,	O
+we	O
+isolated	O
+13	O
+new	O
+viral	O
+genomes	O
+and	O
+found	O
+that	O
+12	O
+of	O
+them	O
+possess	B-DISO
+a	O
+point	B-PROC
+mutation	I-PROC
+in	O
+the	O
+receptor	O
+-	O
+binding	B-FUNC
+domain	O
+of	O
+viral	B-PRGE
+spike	I-PRGE
+protein	I-PRGE
+,	O
+resulting	O
+in	O
+reduced	O
+affinity	O
+to	O
+the	O
+human	B-PRGE
+cognate	I-PRGE
+receptor	I-PRGE
+,	O
+CD26	B-PRGE
+,	O
+compared	O
+to	O
+the	O
+wild	O
+-	O
+type	O
+virus	B-SPEC
+.	O
+
+These	O
+unexpected	O
+findings	O
+suggest	O
+that	O
+MERS	O
+-	O
+CoV	O
+adaptation	B-PROC
+in	O
+humans	B-SPEC
+may	O
+be	O
+driven	O
+by	O
+host	B-COMP
+immunological	O
+pressure	O
+.	O
+
+Cofilin	B-PRGE
+is	O
+involved	O
+in	O
+F	B-COMP
+-	I-COMP
+actin	I-COMP
+reorganization	O
+and	O
+TGEV	B-SPEC
+entry	O
+.	O
+
+EGFR	B-FUNC
+is	O
+also	O
+the	O
+upstream	O
+activator	O
+of	O
+mitogen	B-CHED
+-	I-ENZY
+activated	I-ENZY
+protein	I-ENZY
+kinase	I-ENZY
+(	O
+MAPK	B-FUNC
+)	O
+signaling	B-PROC
+pathways	B-PROC
+that	O
+is	O
+involved	O
+in	O
+F	B-COMP
+-	I-COMP
+actin	I-COMP
+reorganization	O
+.	O
+
+In	O
+conlusion	O
+,	O
+these	O
+results	O
+provide	O
+valuable	O
+data	O
+of	O
+the	O
+mechanisms	O
+which	O
+are	O
+responsible	O
+for	O
+the	O
+TGEV	B-SPEC
+pathogenesis	B-DISO
+and	O
+may	O
+lead	O
+to	O
+the	O
+development	B-PROC
+of	O
+new	O
+methods	O
+about	O
+controlling	O
+TGEV	B-SPEC
+.	O
+
+TITLE	O
+:	O
+Pre	O
+-	O
+fusion	O
+structure	O
+of	O
+a	O
+human	B-PRGE
+coronavirus	I-PRGE
+spike	I-PRGE
+protein	B-CHED
+.	O
+
+Here	O
+we	O
+present	O
+the	O
+4	O
+.	O
+0	O
+Å	O
+resolution	O
+structure	O
+of	O
+the	O
+trimeric	O
+HKU1	B-PRGE
+S	I-PRGE
+protein	I-PRGE
+determined	O
+using	O
+single	O
+-	O
+particle	O
+cryo	O
+-	O
+electron	O
+microscopy	O
+.	O
+
+These	O
+studies	O
+should	O
+also	O
+serve	O
+as	O
+a	O
+foundation	O
+for	O
+the	O
+structure	O
+-	O
+based	O
+design	O
+of	O
+betacoronavirus	B-SPEC
+vaccine	O
+immunogens	O
+.	O
+
+ABSTRACT	O
+:	O
+Since	O
+there	O
+is	O
+no	O
+available	O
+serological	O
+methods	O
+to	O
+detect	O
+antibodies	O
+to	O
+ferret	B-SPEC
+coronavirus	B-SPEC
+(	O
+FRCoV	O
+),	O
+an	O
+enzyme	O
+-	O
+linked	O
+immunosorbent	O
+assay	O
+(	O
+ELISA	O
+)	O
+using	O
+recombinant	O
+partial	O
+nucleocapsid	B-COMP
+(	O
+N	O
+)	O
+proteins	B-CHED
+of	O
+the	O
+ferret	B-SPEC
+coronavirus	B-SPEC
+(	O
+FRCoV	O
+)	O
+Yamaguchi	O
+-	O
+1	O
+strain	O
+was	O
+developed	O
+to	O
+establish	O
+a	O
+serological	O
+method	O
+for	O
+detection	O
+of	O
+FRCoV	O
+infection	B-DISO
+.	O
+
+180	O
+-	O
+374	O
+of	O
+the	O
+N	B-PRGE
+protein	I-PRGE
+.	O
+
+Surprisingly	O
+,	O
+89	O
+%	O
+ferrets	B-SPEC
+in	O
+Japan	O
+had	O
+been	O
+infected	O
+with	O
+FRCoV	O
+.	O
+These	O
+results	O
+indicated	O
+that	O
+our	O
+established	O
+ELISA	O
+using	O
+a	O
+.	O
+a	O
+.	O
+
+1	O
+-	O
+179	O
+of	O
+the	O
+N	O
+protein	B-CHED
+is	O
+useful	O
+for	O
+detection	O
+of	O
+antibody	O
+to	O
+FRCoV	O
+for	O
+diagnosis	O
+and	O
+seroepidemiology	O
+of	O
+FRCoV	O
+infection	B-DISO
+.	O
+
+Although	O
+the	O
+patient	O
+was	O
+in	O
+respiratory	B-DISO
+failure	I-DISO
+,	O
+necessitated	O
+mechanical	O
+ventilation	O
+,	O
+and	O
+intensive	O
+care	O
+(	O
+ICU	O
+)	O
+admission	O
+,	O
+a	O
+healthy	O
+infant	O
+was	O
+delivered	O
+.	O
+
+In	O
+this	O
+study	O
+we	O
+screened	O
+764	O
+samples	O
+from	O
+22	O
+avian	B-SPEC
+species	B-SPEC
+of	O
+the	O
+orders	O
+Anseriformes	B-SPEC
+and	O
+Charadriiformes	B-SPEC
+in	O
+Sweden	O
+collected	O
+in	O
+2006	O
+/	O
+2007	O
+for	O
+CoV	O
+,	O
+with	O
+an	O
+overall	O
+CoV	O
+prevalence	O
+of	O
+18	O
+.	O
+7	O
+%,	O
+which	O
+is	O
+higher	O
+than	O
+many	O
+other	O
+wild	O
+bird	B-SPEC
+surveys	O
+.	O
+
+Sequences	O
+from	O
+two	O
+of	O
+the	O
+Greater	O
+Scaup	O
+CoV	O
+fell	O
+into	O
+an	O
+infrequently	O
+detected	O
+lineage	O
+,	O
+shared	O
+only	O
+with	O
+a	O
+Tufted	B-SPEC
+Duck	I-SPEC
+(	O
+Aythya	B-SPEC
+fuligula	I-SPEC
+)	O
+CoV	O
+.	O
+Coronavirus	B-SPEC
+sequences	O
+from	O
+Mallards	O
+in	O
+this	O
+study	O
+were	O
+highly	O
+similar	O
+to	O
+CoV	O
+sequences	O
+from	O
+the	O
+sample	O
+species	B-SPEC
+and	O
+location	O
+in	O
+2011	O
+,	O
+suggesting	O
+long	O
+-	O
+term	O
+maintenance	O
+in	O
+this	O
+population	O
+.	O
+
+This	O
+study	O
+lays	O
+the	O
+basis	O
+for	O
+the	O
+rational	O
+design	O
+of	O
+more	O
+potent	O
+inhibitors	B-CHED
+of	O
+RT	O
+dimerization	O
+.	O
+
+Movement	B-PROC
+of	O
+animals	B-SPEC
+among	O
+farms	O
+is	O
+hypothesised	O
+to	O
+have	O
+played	O
+a	O
+role	O
+in	O
+the	O
+spread	O
+of	O
+PED	O
+among	O
+farms	O
+.	O
+
+Here	O
+we	O
+present	O
+the	O
+crystal	B-ANAT
+structure	O
+of	O
+HCoV	B-SPEC
+-	I-SPEC
+NL63	I-SPEC
+M	O
+(	O
+pro	B-PRGE
+)	O
+in	O
+complex	O
+with	O
+a	O
+Michael	O
+acceptor	B-CHED
+inhibitor	B-CHED
+N3	O
+.	O
+
+42	O
+patients	O
+were	O
+diagnosed	O
+with	O
+Guillain	O
+-	O
+Barré	O
+syndrome	B-DISO
+during	O
+the	O
+study	O
+period	O
+.	O
+
+Labex	O
+Integrative	O
+Biology	O
+of	O
+Emerging	B-DISO
+Infectious	I-DISO
+Diseases	I-DISO
+,	O
+EU	O
+7th	O
+framework	O
+program	O
+PREDEMICS	O
+.	O
+
+The	O
+severe	O
+,	O
+generalised	O
+manifestation	O
+of	O
+Guillain	O
+-	O
+Barré	O
+syndrome	B-DISO
+with	O
+respiratory	B-DISO
+failure	I-DISO
+affects	O
+20	O
+-	O
+30	O
+%	O
+of	O
+cases	O
+.	O
+
+Treatment	O
+with	O
+intravenous	O
+immunoglobulin	B-PROC
+or	O
+plasma	B-ANAT
+exchange	O
+is	O
+the	O
+optimal	O
+management	O
+approach	O
+,	O
+alongside	O
+supportive	O
+care	O
+.	O
+
+ABSTRACT	O
+:	O
+Monocytes	B-ANAT
+and	O
+macrophages	B-ANAT
+are	O
+key	O
+components	O
+of	O
+the	O
+innate	O
+immune	O
+system	O
+yet	O
+
+Notably	O
+,	O
+given	O
+that	O
+teicoplanin	O
+has	O
+routinely	O
+been	O
+used	O
+in	O
+the	O
+clinic	O
+with	O
+low	O
+toxicity	O
+,	O
+our	O
+work	O
+provides	O
+a	O
+promising	O
+prospect	O
+for	O
+the	O
+prophylaxis	O
+and	O
+treatment	O
+of	O
+Ebola	O
+,	O
+MERS	O
+,	O
+and	O
+SARS	B-DISO
+virus	B-DISO
+infection	I-DISO
+.	O
+
+The	O
+virus	B-SPEC
+is	O
+believed	O
+to	O
+have	O
+originated	O
+from	O
+bats	B-SPEC
+and	O
+transmitted	B-DISO
+to	O
+human	B-SPEC
+through	O
+intermediate	O
+animals	B-SPEC
+such	O
+as	O
+civet	B-SPEC
+cats	I-SPEC
+.	O
+
+In	O
+this	O
+study	O
+,	O
+the	O
+screening	O
+for	O
+the	O
+presence	O
+of	O
+SARS	B-DISO
+-	O
+specific	O
+T	B-ANAT
+cells	I-ANAT
+in	O
+a	O
+cohort	O
+of	O
+three	O
+SARS	B-DISO
+-	O
+recovered	O
+individuals	O
+at	O
+9	O
+and	O
+11	O
+years	O
+post	O
+-	O
+infection	B-DISO
+was	O
+carried	O
+out	O
+,	O
+and	O
+all	O
+memory	B-PROC
+T	B-ANAT
+cell	I-ANAT
+responses	O
+detected	O
+target	O
+the	O
+SARS	B-PRGE
+-	I-PRGE
+CoV	I-PRGE
+structural	I-PRGE
+proteins	B-CHED
+.	O
+
+Two	O
+CD8	B-PRGE
+(+)	O
+T	B-ANAT
+cell	I-ANAT
+responses	O
+targeting	B-PROC
+the	O
+SARS	B-DISO
+-	O
+CoV	O
+membrane	B-COMP
+(	O
+M	O
+)	O
+and	O
+nucleocapsid	B-COMP
+(	O
+N	O
+)	O
+proteins	B-CHED
+were	O
+characterized	O
+by	O
+determining	O
+their	O
+HLA	B-PRGE
+restriction	O
+and	O
+minimal	O
+T	B-ANAT
+cell	B-COMP
+epitope	B-CHED
+regions	O
+.	O
+
+Early	O
+prone	O
+combined	O
+with	O
+ACPC	O
+-	O
+IRV	B-PROC
+in	O
+H1N1	O
+patients	O
+having	O
+severe	O
+ARDS	B-DISO
+can	O
+be	O
+used	O
+as	O
+a	O
+rescue	O
+therapy	O
+and	O
+it	O
+should	O
+be	O
+confirmed	O
+by	O
+large	O
+observational	O
+studies	O
+.	O
+
+TITLE	O
+:	O
+Characterization	O
+and	O
+analysis	O
+of	O
+an	O
+infectious	B-DISO
+bronchitis	B-DISO
+virus	B-SPEC
+strain	O
+isolated	O
+from	O
+southern	O
+China	O
+in	O
+2013	O
+.	O
+
+Their	O
+effectiveness	O
+depends	O
+on	O
+whether	O
+there	O
+is	O
+a	O
+good	O
+antigenic	O
+match	O
+between	O
+circulating	O
+viruses	B-SPEC
+and	O
+vaccine	O
+strains	O
+.	O
+
+In	O
+Poland	O
+,	O
+the	O
+2014	O
+/	O
+2015	O
+influenza	B-DISO
+epidemic	I-DISO
+started	O
+in	O
+week	O
+5	O
+(	O
+January	O
+/	O
+February	O
+)	O
+of	O
+2015	O
+and	O
+continued	O
+until	O
+week	O
+17	O
+(	O
+April	O
+)	O
+of	O
+2015	O
+.	O
+
+Among	O
+the	O
+2416	O
+tested	O
+specimens	O
+,	O
+22	O
+.	O
+6	O
+%	O
+of	O
+influenza	B-DISO
+cases	O
+were	O
+positive	O
+for	O
+A	O
+/	O
+H3N2	B-CHED
+/,	O
+while	O
+A	O
+/	O
+H1N1	O
+/	O
+pdm09	O
+constituted	O
+14	O
+.	O
+6	O
+%	O
+cases	O
+.	O
+
+Other	O
+detected	O
+causes	O
+of	O
+influenza	B-DISO
+-	I-DISO
+like	I-DISO
+illness	I-DISO
+consisted	O
+of	O
+respiratory	B-SPEC
+syncytial	I-SPEC
+virus	I-SPEC
+(	O
+RSV	B-SPEC
+),	O
+being	O
+predominant	O
+,	O
+and	O
+,	O
+sporadically	O
+,	O
+human	B-SPEC
+coronavirus	I-SPEC
+,	O
+parainfluenza	B-DISO
+1	O
+-	O
+3	O
+,	O
+rhinovirus	B-SPEC
+,	O
+and	O
+adenovirus	B-DISO
+.	O
+
+TITLE	O
+:	O
+Glycan	B-CHED
+Engagement	O
+by	O
+Viruses	B-SPEC
+:	O
+Receptor	O
+Switches	O
+and	O
+Specificity	O
+.	O
+
+Severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+coronavirus	B-SPEC
+(	O
+SARS	B-DISO
+-	O
+CoV	O
+)	O
+emerged	O
+in	O
+2003	O
+in	O
+Southeast	O
+Asia	O
+and	O
+rapidly	O
+spread	O
+around	O
+the	O
+world	O
+before	O
+it	O
+was	O
+controlled	O
+by	O
+public	O
+health	O
+intervention	O
+strategies	O
+.	O
+
+Coronaviruses	O
+encode	O
+proofreading	O
+machinery	O
+,	O
+unique	O
+in	O
+the	O
+RNA	O
+virus	B-SPEC
+world	O
+,	O
+to	O
+ensure	O
+the	O
+maintenance	O
+of	O
+their	O
+large	O
+genome	O
+size	O
+.	O
+
+However	O
+,	O
+not	O
+all	O
+infected	O
+patients	O
+present	O
+with	O
+fever	B-PROC
+.	O
+
+Compared	O
+to	O
+normothermic	O
+patients	O
+,	O
+the	O
+adjusted	O
+hazard	O
+ratio	O
+of	O
+30	O
+-	O
+day	O
+mortality	O
+among	O
+hypothermic	O
+patients	O
+was	O
+1	O
+.	O
+62	O
+(	O
+95	O
+%	O
+CI	O
+1	O
+.	O
+06	O
+-	O
+2	O
+.	O
+49	O
+)	O
+and	O
+0	O
+.	O
+74	O
+(	O
+95	O
+%	O
+CI	O
+0	O
+.	O
+58	O
+-	O
+0	O
+.	O
+94	O
+)	O
+among	O
+patients	O
+with	O
+fever	B-PROC
+.	O
+
+ABSTRACT	O
+:	O
+MERS	O
+-	O
+CoV	O
+is	O
+a	O
+newly	O
+emerged	O
+human	O
+coronavirus	O
+reported	O
+closely	O
+related	O
+with	O
+HKU4	O
+and	O
+HKU5	B-PRGE
+Bat	I-PRGE
+coronaviruses	O
+.	O
+
+We	O
+report	O
+a	O
+case	O
+of	O
+GBS	B-DISO
+in	O
+a	O
+5	O
+-	O
+month	O
+-	O
+old	O
+girl	O
+.	O
+
+GBS	B-DISO
+should	O
+be	O
+considered	O
+as	O
+a	O
+differential	O
+diagnosis	O
+in	O
+acute	O
+onset	O
+respiratory	B-DISO
+failure	I-DISO
+with	O
+neuromuscular	B-DISO
+weakness	I-DISO
+in	O
+infants	O
+.	O
+
+The	O
+most	O
+common	O
+clinical	O
+diagnosis	O
+was	O
+respiratory	B-DISO
+tract	I-DISO
+infections	I-DISO
+(	O
+169	O
+[	O
+91	O
+.	O
+5	O
+%]),	O
+followed	O
+by	O
+diarrheal	B-DISO
+diseases	I-DISO
+(	O
+13	O
+[	O
+7	O
+%]),	O
+and	O
+there	O
+was	O
+one	O
+case	O
+of	O
+MERS	O
+-	O
+CoV	O
+.	O
+Patients	O
+spent	O
+a	O
+median	O
+of	O
+5	O
+(	O
+3	O
+-	O
+7	O
+)	O
+days	O
+as	O
+hospital	O
+inpatients	O
+and	O
+overall	O
+mortality	O
+was	O
+1	O
+.	O
+1	O
+%.	O
+
+ABSTRACT	O
+:	O
+A	O
+previous	O
+study	O
+demonstrated	O
+the	O
+existence	O
+of	O
+a	O
+natural	O
+resistance	B-PROC
+to	O
+feline	B-DISO
+infectious	I-DISO
+peritonitis	I-DISO
+virus	B-SPEC
+(	O
+FIPV	O
+)	O
+among	O
+36	O
+%	O
+of	O
+randomly	O
+bred	O
+laboratory	O
+cats	B-SPEC
+.	O
+
+The	O
+subsequent	O
+effects	O
+of	O
+inbreeding	B-PROC
+were	O
+measured	O
+using	O
+42	O
+genome	O
+-	O
+wide	O
+STR	B-ENZY
+markers	O
+.	O
+
+The	O
+continuing	O
+threat	O
+posed	O
+by	O
+pandemic	O
+influenza	B-DISO
+as	O
+well	O
+as	O
+the	O
+emergence	O
+of	O
+novel	O
+respiratory	O
+viruses	B-SPEC
+also	O
+capable	O
+of	O
+producing	O
+severe	O
+acute	O
+lung	B-ANAT
+injury	O
+such	O
+as	O
+SARS	B-PRGE
+-	I-PRGE
+CoV	I-PRGE
+,	O
+MERS	O
+-	O
+CoV	O
+,	O
+and	O
+enterovirus	B-SPEC
+D68	O
+,	O
+highlights	O
+the	O
+need	O
+for	O
+an	O
+understanding	O
+of	O
+the	O
+immune	O
+mechanisms	O
+that	O
+contribute	O
+to	O
+virus	B-SPEC
+elimination	B-PROC
+and	O
+immune	O
+-	O
+mediated	O
+injury	O
+.	O
+
+ABSTRACT	O
+:	O
+Severe	O
+community	O
+-	O
+acquired	O
+pneumonia	O
+(	O
+CAP	B-DISO
+)	O
+caused	O
+by	O
+human	B-SPEC
+adenovirus	B-DISO
+(	O
+HAdV	B-DISO
+),	O
+especially	O
+HAdV	B-DISO
+type	O
+55	O
+(	O
+HAdV	B-DISO
+-	O
+55	O
+)	O
+in	O
+immunocompetent	O
+adults	O
+has	O
+raised	O
+increasing	O
+concerns	O
+.	O
+
+The	O
+rapid	O
+development	B-PROC
+of	O
+bilateral	O
+consolidations	O
+within	O
+10	O
+days	O
+after	O
+illness	O
+onset	O
+were	O
+the	O
+most	O
+common	O
+radiographic	O
+finding	O
+,	O
+usually	O
+accompanied	O
+by	O
+adjacent	O
+ground	O
+glass	O
+opacities	B-DISO
+and	O
+pleural	B-DISO
+effusions	I-DISO
+.	O
+
+Amongst	O
+these	O
+,	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+(	O
+ARDS	B-DISO
+)	O
+is	O
+a	O
+particularly	O
+rare	O
+complication	B-DISO
+.	O
+
+The	O
+few	O
+cases	O
+reported	O
+describe	O
+the	O
+onset	O
+of	O
+ARDS	B-DISO
+after	O
+initiation	O
+of	O
+anti	O
+-	O
+malarial	O
+therapy	O
+as	O
+a	O
+post	O
+inflammatory	B-DISO
+response	I-DISO
+.	O
+
+TITLE	O
+:	O
+Detection	O
+and	O
+Phylogenetic	O
+Analysis	O
+of	O
+Porcine	B-SPEC
+Deltacoronavirus	O
+in	O
+Korean	O
+Swine	B-SPEC
+Farms	O
+,	O
+2015	O
+.	O
+
+Batch	O
+1	O
+(	O
+segment	O
+1	O
+)	O
+simulated	O
+transport	B-PROC
+of	O
+contaminated	O
+ingredients	O
+from	O
+manufacturing	O
+plants	B-SPEC
+in	O
+Beijing	O
+(	O
+day	O
+1	O
+post	O
+-	O
+contamination	O
+(	O
+PC	O
+)).	O
+
+In	O
+contrast	O
+,	O
+viable	O
+PEDV	B-SPEC
+was	O
+not	O
+detected	O
+in	O
+any	O
+samples	O
+treated	O
+with	O
+LA	O
+or	O
+MCFA	B-CHED
+.	O
+
+ABSTRACT	O
+:	O
+Bovine	B-SPEC
+coronaviruses	O
+(	O
+BCoVs	O
+)	O
+are	O
+widespread	O
+around	O
+the	O
+world	O
+and	O
+cause	O
+enteric	O
+or	O
+respiratory	B-DISO
+infections	I-DISO
+among	O
+cattle	B-SPEC
+.	O
+
+Sub	B-PRGE
+-	I-PRGE
+cluster	I-PRGE
+C2	I-PRGE
+includes	O
+BCoVs	O
+from	O
+Europe	O
+.	O
+
+The	O
+numerous	O
+recombination	B-PROC
+detected	O
+between	O
+HCoV	B-SPEC
+-	I-SPEC
+OC43	I-SPEC
+were	O
+much	O
+less	O
+frequent	O
+for	O
+BCoV	O
+.	O
+The	O
+analysis	O
+points	O
+thus	O
+to	O
+the	O
+influence	O
+of	O
+different	O
+evolutive	O
+constraints	O
+in	O
+these	O
+two	O
+close	O
+groups	O
+.	O
+
+In	O
+this	O
+observational	O
+study	O
+,	O
+use	O
+of	O
+early	O
+ECMO	O
+compared	O
+to	O
+conventional	O
+mechanical	O
+ventilation	O
+alone	O
+in	O
+patients	O
+who	O
+had	O
+severe	O
+hypoxemic	O
+respiratory	B-DISO
+failure	I-DISO
+was	O
+associated	O
+with	O
+a	O
+lower	O
+risk	O
+of	O
+mortality	O
+and	O
+a	O
+longer	O
+length	O
+of	O
+stay	O
+.	O
+
+TITLE	O
+:	O
+Disseminated	B-DISO
+tuberculosis	I-DISO
+with	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+lacking	O
+granuloma	B-DISO
+formation	I-PROC
+in	O
+the	O
+lung	O
+.	O
+
+An	O
+immunosuppressive	O
+condition	B-DISO
+might	O
+inhibit	O
+air	B-CHED
+-	O
+space	O
+pneumonia	B-DISO
+to	O
+become	O
+granulomatous	B-DISO
+inflammation	I-DISO
+as	O
+an	O
+initial	O
+stage	O
+of	O
+pulmonary	B-DISO
+tuberculosis	B-PATH
+.	O
+
+ABSTRACT	O
+:	O
+Avian	B-SPEC
+influenza	B-SPEC
+viruses	I-SPEC
+(	O
+AIVs	O
+)	O
+circulate	O
+naturally	O
+in	O
+wild	O
+aquatic	O
+birds	B-SPEC
+,	O
+infect	O
+domestic	O
+poultry	O
+,	O
+and	O
+are	O
+capable	O
+of	O
+causing	O
+sporadic	O
+bird	B-SPEC
+-	O
+to	O
+-	O
+human	B-SPEC
+transmissions	O
+.	O
+
+Both	O
+H5N1	B-DISO
+and	O
+H7N9	O
+cause	O
+severe	O
+influenza	B-DISO
+disease	O
+in	O
+humans	B-SPEC
+,	O
+manifested	O
+by	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+,	O
+multi	B-DISO
+-	I-DISO
+organ	I-DISO
+failure	I-DISO
+,	O
+and	O
+high	O
+mortality	O
+rates	O
+of	O
+60	O
+%	O
+and	O
+35	O
+%,	O
+respectively	O
+.	O
+
+ABSTRACT	O
+:	O
+Acute	O
+Respiratory	O
+Distress	O
+Syndrome	O
+(	O
+ARDS	B-DISO
+)	O
+is	O
+a	O
+severe	O
+lung	B-ANAT
+inflammatory	B-DISO
+disorder	I-DISO
+with	O
+a	O
+30	O
+-	O
+50	O
+%	O
+mortality	O
+.	O
+
+On	O
+the	O
+cellular	B-COMP
+level	O
+there	O
+is	O
+pulmonary	O
+capillary	B-ANAT
+endothelial	I-ANAT
+cell	I-ANAT
+permeability	O
+and	O
+fluid	O
+leakage	B-DISO
+into	O
+the	O
+pulmonary	B-ANAT
+parenchyma	B-ANAT
+,	O
+followed	O
+by	O
+neutrophils	B-ANAT
+,	O
+cytokines	O
+and	O
+an	O
+acute	B-DISO
+inflammatory	I-DISO
+response	I-DISO
+.	O
+
+TITLE	O
+:	O
+Prevalence	O
+of	O
+avian	B-SPEC
+respiratory	O
+viruses	B-SPEC
+in	O
+broiler	O
+flocks	O
+in	O
+Egypt	O
+.	O
+
+TITLE	O
+:	O
+Construction	O
+of	O
+a	O
+bivalent	O
+DNA	O
+vaccine	O
+co	O
+-	O
+expressing	O
+S	O
+genes	O
+of	O
+transmissible	O
+gastroenteritis	B-DISO
+virus	B-SPEC
+and	O
+porcine	B-SPEC
+epidemic	I-SPEC
+diarrhea	I-SPEC
+virus	I-SPEC
+delivered	O
+by	O
+attenuated	O
+Salmonella	B-DISO
+typhimurium	O
+.	O
+
+In	O
+particular	O
+,	O
+the	O
+levels	O
+of	O
+IFN	B-PRGE
+-	I-PRGE
+γ	I-PRGE
+and	O
+IL	B-FUNC
+-	I-FUNC
+4	I-FUNC
+were	O
+higher	O
+than	O
+those	O
+induced	O
+by	O
+the	O
+single	O
+-	O
+gene	O
+vaccine	O
+SL7207	O
+(	O
+pVAXD	B-PRGE
+-	I-PRGE
+PS1	I-PRGE
+)	O
+(	O
+p	O
+<	O
+0	O
+.	O
+05	O
+).	O
+
+To	O
+identify	O
+and	O
+describe	O
+epidemiologic	O
+and	O
+clinical	O
+characteristics	O
+of	O
+persons	O
+with	O
+healthcare	O
+-	O
+associated	O
+infection	B-DISO
+,	O
+we	O
+reviewed	O
+laboratory	O
+-	O
+confirmed	O
+MERS	O
+-	O
+CoV	O
+cases	O
+reported	O
+to	O
+the	O
+Health	O
+Authority	O
+of	O
+Abu	B-CHED
+Dhabi	O
+during	O
+January	O
+1	O
+,	O
+2013	O
+-	O
+May	O
+9	O
+,	O
+2014	O
+.	O
+
+The	O
+recent	O
+outbreak	O
+of	O
+a	O
+novel	O
+corona	B-CHED
+virus	B-SPEC
+(	O
+MERS	O
+-	O
+CoV	O
+)	O
+highlighted	O
+the	O
+importance	O
+of	O
+PH	O
+services	O
+and	O
+the	O
+need	O
+for	O
+a	O
+competent	O
+PH	O
+workforce	O
+.	O
+
+The	O
+incidence	O
+of	O
+ARDS	B-DISO
+within	O
+5	O
+days	O
+of	O
+admission	O
+was	O
+45	O
+%.	O
+
+Taken	O
+together	O
+,	O
+this	O
+review	O
+provides	O
+valuable	O
+guidelines	O
+toward	O
+the	O
+development	B-PROC
+of	O
+an	O
+effective	O
+and	O
+safe	O
+MERS	O
+vaccine	O
+.	O
+
+ABSTRACT	O
+:	O
+The	O
+objective	O
+of	O
+the	O
+Scandinavian	O
+Society	O
+of	O
+Anaesthesiology	O
+and	O
+Intensive	O
+Care	O
+Medicine	B-CHED
+(	O
+SSAI	O
+)	O
+task	O
+force	O
+on	O
+fluid	O
+and	O
+drug	O
+therapy	O
+in	O
+adults	O
+with	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+(	O
+ARDS	B-DISO
+)	O
+was	O
+to	O
+provide	O
+clinically	O
+relevant	O
+,	O
+evidence	O
+-	O
+based	O
+treatment	O
+recommendations	O
+according	O
+to	O
+standards	O
+for	O
+trustworthy	O
+guidelines	O
+.	O
+
+A	O
+total	O
+of	O
+seven	O
+ARDS	B-DISO
+interventions	O
+were	O
+assessed	O
+.	O
+
+Current	O
+management	O
+of	O
+AMR	O
+-	O
+RTI	B-DISO
+patients	O
+focuses	O
+on	O
+pathogen	O
+-	O
+directed	O
+antimicrobial	B-CHED
+treatment	O
+.	O
+
+Two	O
+other	O
+novel	O
+HDT	O
+candidates	O
+,	O
+DAS181	O
+and	O
+resveratrol	B-CHED
+show	O
+antiinfluenza	O
+effects	O
+.	O
+
+Novel	O
+kinase	B-PROC
+inhibitors	I-PROC
+SB203580	O
+(	O
+MAPK	B-PRGE
+-	I-PRGE
+2	I-PRGE
+antagonist	B-PROC
+)	O
+and	O
+LY294002	B-CHED
+(	O
+phosphoinositide	B-CHED
+-	O
+3	O
+kinases	O
+antagonist	B-PROC
+)	O
+exhibit	O
+promising	O
+anti	O
+-	O
+MERS	O
+-	O
+CoV	O
+activity	O
+.	O
+
+In	O
+this	O
+context	O
+,	O
+owing	O
+to	O
+its	O
+essential	O
+role	O
+in	O
+HIV	B-DISO
+genome	O
+replication	O
+,	O
+the	O
+reverse	B-ENZY
+transcriptase	I-ENZY
+associated	O
+ribonuclease	O
+H	O
+(	O
+RNase	O
+H	O
+)	O
+has	O
+proven	O
+to	O
+be	O
+an	O
+appealing	O
+target	O
+.	O
+
+Mechanistic	O
+studies	O
+suggested	O
+selective	O
+inhibition	B-PROC
+of	O
+the	O
+RNase	O
+H	O
+through	O
+binding	B-FUNC
+to	O
+an	O
+innovative	O
+allosteric	O
+site	O
+,	O
+which	O
+could	O
+be	O
+further	O
+exploited	O
+to	O
+enrich	O
+this	O
+class	B-SPEC
+of	O
+inhibitors	B-CHED
+.	O
+
+The	O
+animals	B-SPEC
+were	O
+tested	O
+for	O
+the	O
+prevalence	O
+and	O
+expression	B-PROC
+of	O
+porcine	B-SPEC
+endogenous	O
+retroviruses	B-SPEC
+(	O
+PERVs	O
+)	O
+and	O
+the	O
+presence	O
+of	O
+some	O
+selected	O
+microorganisms	O
+,	O
+among	O
+them	O
+HEV	B-SPEC
+,	O
+PCMV	O
+,	O
+and	O
+porcine	B-SPEC
+lymphotropic	O
+herpesviruses	B-SPEC
+(	O
+PLHVs	O
+)	O
+using	O
+highly	O
+sensitive	O
+and	O
+specific	O
+PCR	O
+and	O
+RT	O
+-	O
+PCR	O
+methods	O
+.	O
+
+The	O
+animals	B-SPEC
+were	O
+free	O
+of	O
+eight	O
+other	O
+microorganisms	O
+tested	O
+,	O
+but	O
+some	O
+were	O
+seropositive	O
+for	O
+porcine	B-SPEC
+circovirus	I-SPEC
+2	I-SPEC
+(	O
+PCV2	O
+),	O
+porcine	B-SPEC
+reproductive	I-SPEC
+and	I-SPEC
+respiratory	I-SPEC
+syndrome	I-SPEC
+virus	I-SPEC
+(	O
+PRRSV	B-SPEC
+),	O
+and	O
+porcine	B-SPEC
+epidemic	I-SPEC
+diarrhea	I-SPEC
+virus	I-SPEC
+(	O
+PEDV	B-SPEC
+).	O
+
+CONCLUSIONS	O
+:	O
+Based	O
+on	O
+medical	O
+examinations	O
+by	O
+veterinarians	O
+,	O
+the	O
+AaMP	B-PRGE
+are	O
+in	O
+a	O
+good	O
+health	O
+status	O
+and	O
+seem	O
+to	O
+harbor	O
+only	O
+few	O
+microorganisms	O
+.	O
+
+Intense	O
+research	O
+has	O
+shown	O
+that	O
+macro	O
+domains	O
+bind	B-FUNC
+ADP	B-CHED
+-	O
+ribose	B-CHED
+and	O
+other	O
+derivatives	O
+,	O
+but	O
+it	O
+still	O
+remains	O
+intangible	O
+about	O
+their	O
+exact	O
+function	O
+.	O
+
+Five	O
+compounds	O
+exhibited	O
+moderate	O
+to	O
+excellent	O
+potencies	O
+inhibiting	O
+wild	O
+-	O
+type	O
+(	O
+wt	O
+)	O
+HIV	B-SPEC
+-	I-SPEC
+1	I-SPEC
+replication	O
+with	O
+EC50	O
+values	O
+ranging	O
+from	O
+31	O
+.	O
+36	O
+μM	O
+to	O
+0	O
+.	O
+11	O
+μM	O
+.	O
+Among	O
+them	O
+,	O
+compound	O
+15b	O
+was	O
+identified	O
+as	O
+the	O
+most	O
+potent	O
+inhibitor	B-CHED
+with	O
+EC50	O
+values	O
+of	O
+0	O
+.	O
+11	O
+μM	O
+and	O
+2	O
+.	O
+18	O
+μM	O
+against	O
+wt	O
+and	O
+K103N	O
+/	O
+Y181C	O
+double	O
+mutant	B-DISO
+HIV	B-SPEC
+-	I-SPEC
+1	I-SPEC
+strain	O
+(	O
+RES056	O
+),	O
+respectively	O
+.	O
+
+Aggressive	B-DISO
+diagnostic	O
+efforts	O
+showed	O
+sero	O
+-	O
+positivity	O
+for	O
+Legionella	B-SPEC
+IgM	B-PRGE
+.	O
+The	O
+patient	O
+recovered	O
+following	O
+antibiotic	B-CHED
+therapy	O
+and	O
+cesarean	O
+delivery	O
+.	O
+
+In	O
+severe	O
+cases	O
+that	O
+are	O
+refractory	O
+to	O
+antimicrobial	B-CHED
+treatment	O
+,	O
+cesarean	O
+delivery	O
+may	O
+help	O
+resolve	O
+compromised	O
+maternal	O
+respiratory	O
+status	O
+.	O
+
+ABSTRACT	O
+:	O
+The	O
+proteasome	O
+inhibitor	O
+bortezomib	B-CHED
+is	O
+indicated	O
+for	O
+use	O
+in	O
+the	O
+treatment	O
+of	O
+multiple	B-DISO
+myeloma	I-DISO
+(	O
+MM	O
+)	O
+patients	O
+.	O
+
+The	O
+most	O
+common	O
+side	O
+effects	O
+are	O
+neurological	O
+and	O
+gastrointestinal	O
+,	O
+while	O
+severe	O
+pulmonary	B-DISO
+complications	I-DISO
+are	O
+rarely	O
+described	O
+.	O
+
+Subsequent	O
+to	O
+the	O
+administration	O
+of	O
+chemotherapy	O
+,	O
+the	O
+patient	O
+developed	O
+an	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+.	O
+
+A	O
+diagnosis	O
+of	O
+bortezomib	B-CHED
+-	O
+induced	O
+severe	O
+pulmonary	B-DISO
+complications	I-DISO
+was	O
+formed	O
+.	O
+
+Systemic	O
+corticosteroid	B-CHED
+therapy	O
+led	O
+to	O
+a	O
+rapid	O
+improvement	O
+in	O
+clinical	O
+conditions	O
+and	O
+radiological	O
+findings	O
+.	O
+
+Additionally	O
+,	O
+a	O
+relatively	O
+low	O
+dose	O
+rather	O
+than	O
+a	O
+high	O
+dose	O
+of	O
+corticosteroids	B-CHED
+could	O
+obtain	O
+a	O
+better	O
+outcome	O
+.	O
+
+The	O
+overarching	O
+goal	O
+of	O
+this	O
+article	O
+is	O
+to	O
+provide	O
+radiologists	O
+with	O
+the	O
+most	O
+up	O
+-	O
+to	O
+-	O
+date	O
+information	O
+regarding	O
+the	O
+underlying	O
+epidemiology	O
+,	O
+pathophysiology	O
+,	O
+clinical	O
+features	O
+,	O
+and	O
+imaging	O
+findings	O
+related	O
+to	O
+Middle	O
+East	O
+respiratory	O
+syndrome	O
+coronavirus	B-SPEC
+(	O
+MERS	O
+-	O
+CoV	O
+),	O
+a	O
+potentially	O
+deadly	O
+new	O
+infection	B-DISO
+.	O
+
+In	O
+this	O
+issue	O
+of	O
+the	O
+JCI	O
+,	O
+Peteranderl	O
+and	O
+colleagues	O
+define	O
+a	O
+paracrine	B-PROC
+communication	I-PROC
+between	O
+macrophages	B-ANAT
+and	O
+type	O
+II	O
+alveolar	B-ANAT
+epithelial	B-ANAT
+cells	I-ANAT
+during	O
+influenza	B-PATH
+infection	B-DISO
+where	O
+IFNα	O
+induces	O
+macrophage	B-ANAT
+secretion	B-PROC
+of	O
+TRAIL	B-PRGE
+that	O
+causes	O
+endocytosis	B-PATH
+of	O
+Na	B-PRGE
+,	I-PRGE
+K	I-PRGE
+-	I-PRGE
+ATPase	I-PRGE
+by	O
+the	O
+alveolar	B-ANAT
+epithelium	I-ANAT
+.	O
+
+Inhibition	B-PROC
+of	O
+the	O
+TRAIL	B-PATH
+signaling	B-PROC
+pathway	I-PROC
+has	O
+been	O
+shown	O
+to	O
+improve	O
+lung	B-ANAT
+injury	O
+after	O
+influenza	B-PATH
+infection	B-DISO
+,	O
+and	O
+future	O
+studies	O
+will	O
+be	O
+needed	O
+to	O
+determine	O
+if	O
+blocking	B-DISO
+this	O
+pathway	B-PROC
+is	O
+a	O
+viable	O
+option	O
+in	O
+the	O
+treatment	O
+of	O
+ARDS	B-DISO
+.	O
+
+At	O
+higher	O
+levels	O
+of	O
+extracorporeal	O
+carbon	B-CHED
+dioxide	I-CHED
+extraction	O
+,	O
+pressure	O
+generated	O
+in	O
+the	O
+first	O
+100	O
+ms	O
+of	O
+inspiration	B-PROC
+against	O
+an	O
+occluded	B-DISO
+airway	B-ANAT
+decreased	O
+from	O
+2	O
+.	O
+8	O
+±	O
+2	O
+.	O
+7	O
+cm	O
+H2O	B-CHED
+(	O
+PSV	O
+,	O
+GF0	O
+%)	O
+and	O
+3	O
+.	O
+0	O
+±	O
+2	O
+.	O
+1	O
+cm	O
+H2O	B-CHED
+(	O
+NAVA	O
+,	O
+GF0	O
+%)	O
+to	O
+0	O
+.	O
+9	O
+±	O
+0	O
+.	O
+5	O
+cm	O
+H2O	B-CHED
+(	O
+PSV	O
+,	O
+GF100	O
+%)	O
+and	O
+1	O
+.	O
+0	O
+±	O
+0	O
+.	O
+8	O
+cm	O
+H2O	B-CHED
+(	O
+NAVA	O
+,	O
+GF100	O
+%;	O
+P	O
+<	O
+0	O
+.	O
+001	O
+)	O
+and	O
+patients	O
+'	O
+inspiratory	B-PROC
+muscle	B-ANAT
+pressure	O
+passed	O
+from	O
+8	O
+.	O
+5	O
+±	O
+6	O
+.	O
+3	O
+and	O
+6	O
+.	O
+5	O
+±	O
+5	O
+.	O
+5	O
+cm	O
+H2O	B-CHED
+to	O
+4	O
+.	O
+5	O
+±	O
+3	O
+.	O
+1	O
+and	O
+4	O
+.	O
+2	O
+±	O
+3	O
+.	O
+7	O
+cm	O
+H2O	B-CHED
+(	O
+P	O
+<	O
+0	O
+.	O
+001	O
+).	O
+
+TITLE	O
+:	O
+Perioperative	O
+kinetics	O
+of	O
+endocan	O
+in	O
+patients	O
+undergoing	O
+cardiac	B-ANAT
+surgery	O
+with	O
+and	O
+without	O
+cardiopulmonary	B-ANAT
+bypass	O
+.	O
+
+Following	O
+administration	O
+of	O
+protamine	O
+,	O
+endocan	O
+concentrations	O
+steadily	O
+increased	O
+in	O
+all	O
+patients	O
+,	O
+reaching	B-PROC
+a	O
+steady	O
+state	O
+between	O
+2	O
+and	O
+6h	O
+.	O
+
+Serum	B-ANAT
+Amyloid	B-DISO
+P	O
+Contained	O
+in	O
+Alveolar	B-ANAT
+Fluid	O
+From	O
+Patients	O
+With	O
+Acute	B-DISO
+Respiratory	I-DISO
+Distress	I-DISO
+Syndrome	I-DISO
+Mediates	O
+the	O
+Inhibition	B-PROC
+of	I-PROC
+Monocyte	I-PROC
+Differentiation	I-PROC
+into	O
+Fibrocyte	B-ANAT
+.	O
+
+Plasma	B-ANAT
+and	O
+broncho	O
+-	O
+alveolar	B-ANAT
+lavage	I-ANAT
+fluid	I-ANAT
+serum	B-COMP
+amyloid	B-DISO
+P	O
+contents	O
+were	O
+determined	O
+by	O
+western	O
+blot	O
+and	O
+enzyme	O
+-	O
+linked	O
+immunosorbent	O
+assay	O
+.	O
+
+Serum	B-COMP
+amyloid	B-DISO
+P	O
+concentration	O
+was	O
+decreased	O
+in	O
+plasma	B-ANAT
+and	O
+dramatically	O
+increased	O
+in	O
+broncho	O
+-	O
+alveolar	B-ANAT
+lavage	I-ANAT
+fluid	I-ANAT
+during	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+.	O
+
+Serum	B-COMP
+amyloid	B-DISO
+P	O
+depletion	O
+decreased	O
+the	O
+inhibitory	O
+effect	O
+of	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+broncho	O
+-	O
+alveolar	B-ANAT
+lavage	I-ANAT
+fluid	I-ANAT
+by	O
+60	O
+%,	O
+whereas	O
+serum	B-COMP
+amyloid	B-DISO
+P	O
+replenishment	O
+of	O
+serum	B-COMP
+amyloid	B-DISO
+P	O
+-	O
+depleted	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+broncho	O
+-	O
+alveolar	B-ANAT
+lavage	I-ANAT
+fluid	I-ANAT
+restored	O
+their	O
+full	O
+inhibitory	O
+effect	O
+.	O
+
+To	O
+reduce	O
+the	O
+incidence	O
+of	O
+pulmonary	B-DISO
+aspiration	I-DISO
+,	O
+rapid	O
+sequence	O
+induction	O
+and	O
+intubation	O
+and	O
+awake	O
+tracheal	O
+intubation	O
+are	O
+commonly	O
+chosen	O
+anesthetic	O
+techniques	O
+for	O
+the	O
+management	O
+of	O
+patients	O
+at	O
+risk	O
+of	O
+aspiration	B-DISO
+of	O
+gastric	B-ANAT
+or	O
+esophageal	B-ANAT
+contents	I-ANAT
+.	O
+
+The	O
+aim	O
+of	O
+this	O
+study	O
+was	O
+to	O
+evaluate	O
+the	O
+safety	O
+and	O
+feasibility	O
+of	O
+prone	O
+positioning	O
+for	O
+patients	O
+with	O
+severe	O
+ARDS	B-DISO
+during	O
+ECMO	O
+therapy	O
+.	O
+
+Causes	O
+for	O
+ARDS	B-DISO
+were	O
+pneumonia	B-DISO
+(	O
+n	O
+=	O
+20	O
+)	O
+and	O
+aspiration	B-DISO
+(	O
+n	O
+=	O
+2	O
+)	O
+and	O
+four	O
+patients	O
+had	O
+different	O
+rare	O
+causes	O
+of	O
+ARDS	B-DISO
+.	O
+
+ABSTRACT	O
+:	O
+Avian	B-SPEC
+infectious	I-DISO
+bronchitis	I-DISO
+is	O
+a	O
+highly	O
+contagious	B-DISO
+disease	I-DISO
+caused	O
+by	O
+infectious	B-DISO
+bronchitis	B-DISO
+virus	B-SPEC
+(	O
+IBV	B-SPEC
+)	O
+that	O
+affects	O
+poultry	O
+production	O
+worldwide	O
+.	O
+
+The	O
+combined	O
+risks	O
+of	O
+wildlife	O
+trade	O
+in	O
+Lao	O
+PDR	B-DISO
+to	O
+human	B-SPEC
+health	O
+and	O
+biodiversity	O
+highlight	O
+the	O
+need	O
+for	O
+a	O
+multi	O
+-	O
+sector	O
+approach	O
+to	O
+effectively	O
+protect	O
+public	O
+health	O
+,	O
+economic	O
+interests	O
+and	O
+biodiversity	O
+.	O
+
+ABSTRACT	O
+:	O
+Severe	O
+acute	O
+pancreatitis	O
+(	O
+SAP	O
+)	O
+can	O
+often	O
+be	O
+complicated	O
+by	O
+acute	O
+lung	B-ANAT
+injury	O
+(	O
+ALI	O
+)	O
+and	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+(	O
+ARDS	B-DISO
+),	O
+leading	O
+to	O
+increased	O
+mortality	O
+.	O
+
+Furthermore	O
+,	O
+MODS	B-DISO
+and	O
+APACHE	O
+II	O
+scores	O
+decreased	O
+to	O
+a	O
+greater	O
+extent	O
+in	O
+the	O
+study	O
+group	O
+,	O
+paralleled	O
+by	O
+a	O
+lower	O
+occurrence	O
+of	O
+MPDS	O
+and	O
+ARDS	B-DISO
+.	O
+
+Furthermore	O
+,	O
+MODS	B-DISO
+and	O
+APACHE	O
+II	O
+scores	O
+decreased	O
+to	O
+a	O
+greater	O
+extent	O
+in	O
+the	O
+study	O
+group	O
+,	O
+paralleled	O
+by	O
+a	O
+lower	O
+occurrence	O
+of	O
+MPDS	O
+and	O
+ARDS	B-DISO
+.	O
+
+TITLE	O
+:	O
+FATAL	O
+GASTRIC	B-DISO
+DILATION	I-DISO
+IN	O
+TWO	O
+ADULT	O
+BLACK	B-SPEC
+-	I-SPEC
+FOOTED	I-SPEC
+FERRETS	I-SPEC
+(	O
+MUSTELA	B-SPEC
+NIGRIPES	I-SPEC
+).	O
+
+TITLE	O
+:	O
+A	O
+clinical	O
+perspective	O
+of	O
+sepsis	B-DISO
+-	O
+associated	O
+delirium	B-DISO
+.	O
+
+The	O
+duration	O
+of	O
+delirium	B-DISO
+in	O
+intensive	O
+care	O
+patients	O
+is	O
+associated	O
+with	O
+long	O
+-	O
+term	O
+functional	O
+disability	O
+and	O
+cognitive	B-DISO
+impairment	I-DISO
+,	O
+although	O
+this	O
+syndrome	B-DISO
+usually	O
+reverses	O
+after	O
+the	O
+successful	O
+treatment	O
+of	O
+sepsis	B-DISO
+.	O
+
+ABSTRACT	O
+:	O
+Stray	O
+cats	O
+in	O
+the	O
+city	O
+of	O
+Milan	O
+,	O
+Italy	O
+,	O
+were	O
+tested	O
+for	O
+Leishmania	B-SPEC
+infantum	I-SPEC
+and	O
+other	O
+selected	O
+infections	B-DISO
+.	O
+
+Twenty	O
+-	O
+seven	O
+cats	B-SPEC
+(	O
+30	O
+.	O
+0	O
+%)	O
+were	O
+seroreactive	O
+by	O
+indirect	O
+fluorescent	O
+antibody	B-COMP
+test	O
+(	O
+IFAT	O
+),	O
+with	O
+an	O
+antibody	B-COMP
+titer	O
+of	O
+1	O
+:	O
+40	O
+for	O
+16	O
+(	O
+17	O
+.	O
+7	O
+%)	O
+cats	B-SPEC
+and	O
+1	O
+:	O
+80	O
+(	O
+cut	O
+-	O
+off	O
+for	O
+feline	B-SPEC
+L	B-DISO
+.	I-DISO
+infantum	I-DISO
+infection	B-DISO
+)	O
+for	O
+11	O
+(	O
+12	O
+.	O
+2	O
+%)	O
+cats	B-SPEC
+.	O
+
+The	O
+frequency	O
+of	O
+seroreactivity	O
+to	O
+L	B-DISO
+.	I-DISO
+infantum	I-DISO
+was	O
+significantly	O
+higher	O
+in	O
+FCoV	O
+-	O
+seropositive	O
+cats	B-SPEC
+(	O
+OR	O
+=	O
+4	O
+.	O
+4	O
+,	O
+P	O
+=	O
+0	O
+.	O
+04	O
+).	O
+
+TITLE	O
+:	O
+Middle	O
+East	O
+respiratory	O
+syndrome	B-DISO
+:	O
+A	O
+new	O
+global	O
+threat	O
+.	O
+
+Human	B-SPEC
+-	O
+to	O
+-	O
+human	B-SPEC
+transmission	O
+is	O
+reported	O
+in	O
+the	O
+community	O
+with	O
+droplet	O
+and	O
+contact	O
+spread	O
+being	O
+the	O
+possible	O
+modes	O
+.	O
+
+TITLE	O
+:	O
+Two	O
+-	O
+way	O
+antigenic	O
+cross	O
+-	O
+reactivity	O
+between	O
+porcine	B-SPEC
+epidemic	I-SPEC
+diarrhea	I-SPEC
+virus	I-SPEC
+and	O
+porcine	B-SPEC
+deltacoronavirus	O
+.	O
+
+As	O
+a	O
+practical	O
+matter	O
+,	O
+prevention	O
+of	O
+these	O
+two	O
+very	O
+similar	O
+diseases	O
+of	O
+swine	B-SPEC
+will	O
+require	O
+the	O
+development	B-PROC
+of	O
+separate	O
+virus	B-SPEC
+-	O
+specific	O
+vaccine	O
+products	O
+.	O
+
+Malarial	O
+hepatopathy	B-DISO
+was	O
+associated	O
+with	O
+a	O
+higher	O
+incidence	O
+of	O
+cerebral	B-DISO
+malaria	B-PATH
+,	O
+shock	O
+,	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+(	O
+ARDS	B-DISO
+)	O
+and	O
+acute	O
+kidney	B-ANAT
+injury	O
+in	O
+both	O
+overall	O
+(	O
+p	O
+<	O
+0	O
+.	O
+05	O
+each	O
+)	O
+and	O
+falciparum	B-DISO
+malaria	I-DISO
+(	O
+p	O
+<	O
+0	O
+.	O
+05	O
+each	O
+)	O
+and	O
+hyponatremia	O
+and	O
+disseminated	B-DISO
+intravascular	I-DISO
+coagulation	I-DISO
+only	O
+in	O
+overall	O
+malaria	B-PATH
+(	O
+p	O
+<	O
+0	O
+.	O
+05	O
+).	O
+
+Malarial	O
+hepatopathy	B-DISO
+is	O
+likely	O
+to	O
+occur	O
+in	O
+presence	O
+of	O
+other	O
+malarial	O
+complications	O
+.	O
+
+It	O
+is	O
+an	O
+epiphenomenon	O
+in	O
+severe	O
+malaria	B-PATH
+and	O
+indicative	O
+of	O
+severe	O
+disease	O
+.	O
+
+TITLE	O
+:	O
+A	O
+phase	O
+trial	O
+of	O
+the	O
+oral	B-ANAT
+Lactobacillus	B-SPEC
+casei	I-SPEC
+vaccine	O
+polarizes	O
+Th2	B-ANAT
+cell	I-ANAT
+immunity	B-PROC
+against	O
+transmissible	O
+gastroenteritis	O
+coronavirus	B-DISO
+infection	I-DISO
+.	O
+
+Immunization	O
+with	O
+recombinant	O
+Lactobacillus	B-SPEC
+is	O
+crucial	O
+for	O
+investigations	O
+of	O
+the	O
+effect	O
+of	O
+immunization	O
+,	O
+such	O
+as	O
+the	O
+first	O
+immunization	O
+time	O
+and	O
+dose	O
+.	O
+
+TITLE	O
+:	O
+Fat	O
+(	O
+al	O
+)	O
+attraction	O
+:	O
+Picornaviruses	B-SPEC
+Usurp	O
+Lipid	B-CHED
+Transfer	O
+at	O
+Membrane	B-COMP
+Contact	O
+Sites	O
+to	O
+Create	O
+Replication	O
+Organelles	O
+.	O
+
+The	O
+goal	O
+of	O
+this	O
+study	O
+was	O
+to	O
+describe	O
+the	O
+clinical	O
+and	O
+physiological	B-PROC
+effects	I-PROC
+of	O
+APRV	O
+in	O
+patients	O
+with	O
+established	O
+ARDS	B-DISO
+.	O
+
+This	O
+retrospective	O
+observational	O
+study	O
+was	O
+performed	O
+in	O
+a	O
+23	O
+-	O
+bed	B-DISO
+adult	O
+intensive	O
+care	O
+unit	O
+in	O
+a	O
+tertiary	O
+extracorporeal	O
+membrane	B-COMP
+oxygenation	B-PROC
+(	O
+ECMO	O
+)	O
+referral	O
+centre	O
+.	O
+
+Our	O
+primary	O
+outcome	O
+was	O
+the	O
+correlation	O
+between	O
+the	O
+end	O
+tidal	O
+CO2	B-CHED
+(	O
+EtCO2	O
+)	O
+and	O
+the	O
+clinical	O
+decision	O
+of	O
+hospital	O
+admission	O
+and	O
+discharge	B-ANAT
+.	O
+
+Wang	O
+clinical	O
+respiratory	O
+severity	O
+score	O
+was	O
+found	O
+,	O
+by	O
+using	O
+multivariate	O
+models	O
+,	O
+to	O
+predict	O
+nasogastric	B-ANAT
+tube	O
+need	O
+,	O
+oxygen	B-CHED
+desaturation	O
+days	O
+,	O
+and	O
+length	O
+of	O
+hospitalization	O
+.	O
+
+CONCLUSIONS	O
+:	O
+Capnometry	O
+readings	O
+upon	O
+arrival	O
+to	O
+the	O
+ED	O
+did	O
+not	O
+predict	O
+hospital	O
+admission	O
+or	O
+hospital	O
+discharge	B-ANAT
+eligibility	O
+.	O
+
+However	O
+,	O
+the	O
+expression	B-PROC
+level	O
+of	O
+cytoplasmic	B-PRGE
+MERS	I-PRGE
+-	I-PRGE
+CoV	I-PRGE
+NS4b	I-PRGE
+protein	B-CHED
+is	O
+sufficient	O
+to	O
+prevent	O
+activation	O
+of	O
+RNase	B-PRGE
+L	I-PRGE
+.	O
+Finally	O
+,	O
+this	O
+is	O
+the	O
+first	O
+report	O
+of	O
+an	O
+RNase	B-PRGE
+L	I-PRGE
+antagonist	B-PROC
+expressed	B-PROC
+by	O
+a	O
+human	B-SPEC
+or	O
+bat	B-ENZY
+coronavirus	B-SPEC
+and	O
+provides	O
+a	O
+specific	O
+mechanism	O
+by	O
+which	O
+this	O
+occurs	O
+.	O
+
+Antiviral	B-CHED
+treatment	O
+was	O
+associated	O
+with	O
+a	O
+rapid	O
+improvement	O
+in	O
+fever	B-PROC
+,	O
+ascites	O
+,	O
+lymphopenia	B-DISO
+and	O
+gross	O
+signs	O
+of	O
+illness	O
+and	O
+cats	B-SPEC
+returned	O
+to	O
+normal	O
+health	O
+within	O
+20	O
+days	O
+or	O
+less	O
+of	O
+treatment	O
+.	O
+
+Transmissible	O
+gastroenteritis	B-DISO
+virus	B-SPEC
+(	O
+TGEV	B-SPEC
+)	O
+is	O
+a	O
+porcine	B-SPEC
+enteropathogenic	O
+coronavirus	B-SPEC
+which	O
+induces	O
+malabsorption	B-DISO
+and	O
+lethal	O
+watery	B-DISO
+diarrhea	I-DISO
+in	O
+suckling	O
+piglets	O
+.	O
+
+The	O
+proportion	O
+of	O
+ALI	O
+was	O
+significantly	O
+higher	O
+in	O
+pulmonary	B-DISO
+sepsis	B-SPEC
+;	O
+further	O
+,	O
+a	O
+complication	B-DISO
+of	O
+ALI	O
+was	O
+associated	O
+with	O
+higher	O
+mortality	O
+in	O
+sepsis	B-DISO
+from	O
+pulmonary	B-ANAT
+and	O
+other	O
+sources	O
+,	O
+but	O
+not	O
+in	O
+abdominal	B-DISO
+sepsis	B-SPEC
+.	O
+
+The	O
+antiviral	B-PROC
+response	I-PROC
+of	O
+autophagy	B-PROC
+was	O
+confirmed	O
+by	O
+using	O
+siRNA	O
+to	O
+reduce	O
+the	O
+expression	B-PROC
+of	O
+gene	B-PRGE
+p300	I-PRGE
+,	O
+which	O
+otherwise	O
+inhibits	O
+autophagy	B-PROC
+.	O
+
+TITLE	O
+:	O
+Mapping	O
+the	O
+Specific	O
+Amino	B-CHED
+Acid	I-CHED
+Residues	O
+That	O
+Make	O
+Hamster	B-SPEC
+DPP4	B-PRGE
+Functional	O
+as	O
+a	O
+Receptor	O
+for	O
+Middle	O
+East	O
+Respiratory	O
+Syndrome	O
+Coronavirus	B-SPEC
+.	O
+
+The	O
+novel	O
+emerging	O
+coronavirus	B-SPEC
+MERS	O
+-	O
+CoV	O
+has	O
+infected	O
+>	O
+1	O
+,	O
+600	O
+people	O
+worldwide	O
+,	O
+and	O
+the	O
+case	O
+fatality	O
+rate	O
+is	O
+∼	O
+36	O
+%.	O
+
+In	O
+this	O
+study	O
+,	O
+we	O
+show	O
+that	O
+by	O
+changing	O
+4	O
+amino	B-CHED
+acids	I-CHED
+in	O
+hamster	B-SPEC
+DPP4	B-PRGE
+,	O
+this	O
+protein	B-CHED
+functions	O
+as	O
+a	O
+receptor	O
+for	O
+MERS	O
+-	O
+CoV	O
+.	O
+This	O
+work	O
+is	O
+vital	O
+in	O
+the	O
+development	B-PROC
+of	O
+new	O
+small	O
+-	O
+animal	B-SPEC
+models	O
+,	O
+which	O
+will	O
+broaden	O
+our	O
+understanding	O
+of	O
+MERS	O
+-	O
+CoV	O
+and	O
+be	O
+instrumental	O
+in	O
+the	O
+development	O
+of	O
+countermeasures	O
+.	O
+
+Thus	O
+,	O
+the	O
+FPs	B-FUNC
+of	O
+3	O
+different	O
+lineages	O
+of	O
+β	O
+-	O
+CoVs	O
+are	O
+conserved	O
+in	O
+location	O
+within	O
+the	O
+S	O
+glycoproteins	B-CHED
+and	O
+in	O
+their	O
+functions	O
+,	O
+although	O
+their	O
+amino	B-CHED
+acid	I-CHED
+sequences	O
+have	O
+diverged	O
+significantly	O
+during	O
+CoV	O
+evolution	B-PROC
+.	O
+
+K480	O
+likely	O
+enhances	O
+the	O
+nucleophilicity	O
+of	O
+the	O
+Cys	B-CHED
+.	O
+
+This	O
+study	O
+reports	O
+the	O
+preliminary	O
+findings	O
+of	O
+the	O
+first	O
+known	O
+human	B-SPEC
+case	O
+of	O
+H5N6	O
+in	O
+Yunnan	O
+province	O
+.	O
+
+These	O
+findings	O
+suggest	O
+that	O
+the	O
+expanding	O
+and	O
+enhancing	O
+of	O
+surveillance	O
+in	O
+both	O
+avian	B-SPEC
+and	O
+humans	B-SPEC
+are	O
+necessary	O
+to	O
+monitor	O
+the	O
+evolution	O
+of	O
+H5	O
+influenza	B-SPEC
+virus	I-SPEC
+and	O
+to	O
+facilitate	O
+early	O
+detection	O
+of	O
+suspected	O
+cases	O
+.	O
+
+TITLE	O
+:	O
+Outbreak	O
+of	O
+diarrhea	B-DISO
+among	O
+preweaning	O
+alpacas	B-SPEC
+(	O
+Vicugna	B-SPEC
+pacos	I-SPEC
+)	O
+in	O
+the	O
+southern	O
+Peruvian	O
+highland	O
+.	O
+
+The	O
+findings	O
+from	O
+this	O
+study	O
+warrant	O
+the	O
+provision	O
+of	O
+subsidies	O
+for	O
+future	O
+assessment	O
+of	O
+the	O
+potential	O
+economic	O
+impact	O
+of	O
+these	O
+infections	B-DISO
+on	O
+the	O
+productivity	O
+of	O
+the	O
+Peruvian	O
+alpaca	B-SPEC
+industry	O
+.	O
+
+Patients	O
+who	O
+were	O
+treated	O
+with	O
+ECMO	O
+for	O
+severe	O
+ARDS	B-DISO
+had	O
+an	O
+improved	O
+mortality	O
+compared	O
+with	O
+historical	O
+controls	O
+.	O
+
+ECMO	O
+should	O
+be	O
+considered	O
+at	O
+the	O
+early	O
+onset	O
+of	O
+severe	O
+ARDS	B-DISO
+to	O
+improve	O
+survival	O
+.	O
+
+Timing	O
+from	O
+the	O
+onset	O
+of	O
+severe	O
+ARDS	B-DISO
+to	O
+ECMO	O
+intervention	O
+occurred	O
+at	O
+a	O
+mean	O
+1	O
+.	O
+9	O
+±	O
+1	O
+.	O
+4	O
+days	O
+.	O
+
+ECMO	O
+should	O
+be	O
+considered	O
+at	O
+the	O
+early	O
+onset	O
+of	O
+severe	O
+ARDS	B-DISO
+to	O
+improve	O
+survival	O
+.	O
+
+His	O
+respiratory	O
+sounds	O
+were	O
+clear	O
+and	O
+chest	B-ANAT
+radiography	O
+did	O
+not	O
+show	O
+any	O
+abnormal	O
+shadows	O
+,	O
+but	O
+his	O
+arterial	B-ANAT
+blood	I-ANAT
+gas	O
+examination	O
+showed	O
+type	O
+II	O
+respiratory	B-DISO
+failure	I-DISO
+.	O
+
+With	O
+an	O
+early	O
+diagnosis	O
+and	O
+minimum	O
+immunotherapy	O
+,	O
+we	O
+report	O
+herein	O
+on	O
+a	O
+case	O
+of	O
+IAV	O
+(	O
+H3N2	B-CHED
+)-	O
+related	O
+HLH	B-DISO
+which	O
+was	O
+treated	O
+successfully	O
+.	O
+
+Respiratory	O
+clinical	O
+signs	O
+and	O
+gross	O
+lesions	O
+consisting	O
+of	O
+tracheal	O
+caseous	O
+exudate	B-ANAT
+and	O
+plugs	O
+,	O
+and	O
+swollen	O
+kidneys	B-ANAT
+(	O
+with	O
+or	O
+without	O
+)	O
+urate	B-CHED
+deposits	O
+were	O
+observed	O
+in	O
+SPF	O
+and	O
+broiler	O
+chicks	O
+.	O
+
+TITLE	O
+:	O
+Age	O
+,	O
+PaO2	O
+/	O
+FIO2	O
+,	O
+and	O
+Plateau	O
+Pressure	O
+Score	O
+:	O
+A	O
+Proposal	O
+for	O
+a	O
+Simple	O
+Outcome	O
+Score	O
+in	O
+Patients	O
+With	O
+the	O
+Acute	B-DISO
+Respiratory	I-DISO
+Distress	I-DISO
+Syndrome	I-DISO
+.	O
+
+Six	O
+-	O
+hundred	O
+patients	O
+meeting	O
+Berlin	O
+criteria	O
+for	O
+moderate	O
+and	O
+severe	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+enrolled	O
+in	O
+two	O
+independent	O
+cohorts	O
+treated	O
+with	O
+lung	B-ANAT
+-	O
+protective	O
+ventilation	O
+.	O
+
+We	O
+found	O
+that	O
+a	O
+9	O
+-	O
+point	O
+score	O
+based	O
+on	O
+patient	O
+'	O
+s	O
+age	O
+,	O
+PaO2	O
+/	O
+FIO2	O
+ratio	O
+,	O
+and	O
+plateau	O
+pressure	O
+at	O
+24	O
+hours	O
+after	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+diagnosis	O
+was	O
+associated	O
+with	O
+death	B-PROC
+.	O
+
+The	O
+N	O
+-	O
+terminal	O
+subunit	O
+of	O
+spike	O
+protein	B-CHED
+(	O
+S1	O
+)	O
+is	O
+responsible	O
+for	O
+virus	B-SPEC
+binding	B-FUNC
+to	O
+the	O
+cellular	B-COMP
+receptor	O
+and	O
+contains	O
+a	O
+number	O
+of	O
+neutralizing	O
+antibody	B-COMP
+epitopes	O
+.	O
+
+A	O
+pregnant	O
+sow	O
+was	O
+intramuscularly	O
+immunized	O
+three	O
+times	O
+with	O
+adjuvanted	O
+recombinant	O
+protein	B-CHED
+prior	O
+to	O
+farrowing	B-PROC
+.	O
+
+Administration	O
+of	O
+the	O
+subunit	O
+vaccine	O
+in	O
+a	O
+sow	O
+resulted	O
+in	O
+induction	O
+of	O
+S1	B-PRGE
+-	I-PRGE
+specific	I-PRGE
+IgG	I-PRGE
+and	O
+IgA	B-PRGE
+that	O
+were	O
+passively	O
+transferred	O
+to	O
+the	O
+suckling	O
+piglets	O
+.	O
+
+TITLE	O
+:	O
+Crisis	O
+prevention	O
+and	O
+management	O
+by	O
+infection	B-DISO
+control	O
+nurses	O
+during	O
+the	O
+Middle	O
+East	O
+respiratory	O
+coronavirus	O
+outbreak	O
+in	O
+Korea	O
+.	O
+
+TITLE	O
+:	O
+Soluble	O
+form	O
+of	O
+the	O
+receptor	O
+for	O
+advanced	O
+glycation	O
+end	O
+-	O
+products	O
+attenuates	O
+inflammatory	O
+pathogenesis	B-PROC
+in	O
+a	O
+rat	B-SPEC
+model	O
+of	O
+lipopolysaccharide	B-CHED
+-	O
+induced	O
+lung	B-ANAT
+injury	O
+.	O
+
+TITLE	O
+:	O
+The	O
+standard	O
+of	O
+care	O
+of	O
+patients	O
+with	O
+ARDS	B-DISO
+:	O
+ventilatory	O
+settings	O
+and	O
+rescue	O
+therapies	O
+for	O
+refractory	O
+hypoxemia	O
+.	O
+
+For	O
+mechanical	O
+ventilation	O
+specific	O
+settings	O
+are	O
+recommended	O
+:	O
+limitation	O
+of	O
+tidal	O
+volume	O
+(	O
+6	O
+ml	O
+/	O
+kg	O
+predicted	O
+body	B-ANAT
+weight	O
+),	O
+adequate	O
+high	O
+PEEP	B-CHED
+(>	O
+12	O
+cmH2O	O
+),	O
+a	O
+recruitment	B-DISO
+manoeuvre	O
+in	O
+special	O
+situations	O
+,	O
+and	O
+a	O
+'	O
+balanced	O
+'	O
+respiratory	O
+rate	O
+(	O
+20	O
+-	O
+30	O
+/	O
+min	O
+).	O
+
+TITLE	O
+:	O
+Fatal	O
+transfusion	O
+-	O
+transmitted	B-DISO
+infection	B-DISO
+due	O
+to	O
+Citrobacter	B-SPEC
+koseri	I-SPEC
+.	O
+
+She	O
+had	O
+previously	O
+given	O
+blood	B-ANAT
+.	O
+
+The	O
+quality	O
+of	O
+life	O
+(	O
+QOL	O
+)	O
+of	O
+the	O
+patients	O
+in	O
+most	O
+dimension	O
+were	O
+impaired	B-DISO
+and	O
+(	O
+58	O
+%)	O
+of	O
+patients	O
+had	O
+unfavourable	O
+QOL	O
+.	O
+
+One	O
+large	O
+multicentre	O
+RCT	O
+was	O
+terminated	O
+early	O
+because	O
+of	O
+increased	O
+mortality	O
+in	O
+participants	O
+randomized	O
+to	O
+HFO	O
+compared	O
+to	O
+mechanical	O
+ventilation	O
+with	O
+low	O
+tidal	O
+volume	O
+and	O
+high	O
+positive	O
+end	O
+expiratory	B-PROC
+pressure	O
+,	O
+with	O
+HFO	O
+reserved	O
+only	O
+as	O
+a	O
+rescue	O
+therapy	O
+.	O
+
+ABSTRACT	O
+:	O
+At	O
+least	O
+two	O
+genetically	O
+different	O
+porcine	B-SPEC
+epidemic	I-SPEC
+diarrhea	I-SPEC
+virus	I-SPEC
+(	O
+PEDV	B-SPEC
+)	O
+strains	O
+have	O
+been	O
+identified	O
+in	O
+the	O
+United	O
+States	O
+(	O
+U	O
+.	O
+S	O
+.	O
+PEDV	B-SPEC
+prototype	O
+and	O
+S	O
+-	O
+INDEL	B-PROC
+-	O
+variant	O
+strains	O
+).	O
+
+Three	O
+groups	O
+of	O
+PEDV	B-SPEC
+-	O
+negative	O
+,	O
+3	O
+-	O
+week	O
+-	O
+old	O
+pigs	B-SPEC
+(	O
+five	O
+pigs	B-SPEC
+per	O
+group	O
+)	O
+were	O
+inoculated	O
+orally	B-ANAT
+with	O
+a	O
+U	O
+.	O
+S	O
+.	O
+PEDV	B-SPEC
+prototype	O
+isolate	O
+(	O
+previously	O
+isolated	O
+in	O
+our	O
+lab	O
+),	O
+an	O
+S	O
+-	O
+INDEL	B-PROC
+-	O
+variant	O
+isolate	O
+or	O
+virus	B-SPEC
+-	O
+negative	O
+culture	O
+medium	O
+.	O
+
+Antibodies	B-COMP
+against	O
+the	O
+two	O
+PEDV	B-SPEC
+strains	O
+could	O
+be	O
+detected	O
+by	O
+all	O
+three	O
+ELISAs	O
+although	O
+detection	O
+rates	O
+varied	O
+to	O
+some	O
+degree	O
+.	O
+
+Antibodies	B-COMP
+against	O
+the	O
+two	O
+PEDV	B-SPEC
+strains	O
+could	O
+be	O
+detected	O
+by	O
+all	O
+three	O
+ELISAs	O
+although	O
+detection	O
+rates	O
+varied	O
+to	O
+some	O
+degree	O
+.	O
+
+The	O
+records	O
+of	O
+730	O
+consecutive	O
+patients	O
+with	O
+ARDS	B-DISO
+were	O
+queried	O
+for	O
+respiratory	O
+ECMO	O
+eligibility	O
+and	O
+ECMO	O
+contraindications	O
+.	O
+
+RESULTS	O
+:	O
+Of	O
+the	O
+730	O
+patients	O
+with	O
+ARDS	B-DISO
+,	O
+168	O
+(	O
+23	O
+.	O
+0	O
+%)	O
+met	B-CHED
+ECMO	O
+inclusion	O
+criteria	O
+and	O
+515	O
+(	O
+70	O
+.	O
+5	O
+%)	O
+never	O
+met	B-CHED
+ECMO	O
+eligibility	O
+due	O
+to	O
+inadequately	O
+severe	O
+disease	O
+.	O
+
+TITLE	O
+:	O
+Single	O
+-	O
+Site	O
+Low	O
+-	O
+Flow	O
+Veno	O
+-	O
+Venous	B-ANAT
+Extracorporeal	O
+Lung	B-ANAT
+Support	O
+Does	O
+Not	O
+Influence	O
+Hemodynamic	B-PROC
+Monitoring	O
+by	O
+Transpulmonary	O
+Thermodilution	O
+.	O
+
+In	O
+the	O
+present	O
+work	O
+,	O
+the	O
+influence	O
+of	O
+single	O
+-	O
+site	O
+low	O
+-	O
+flow	O
+veno	O
+-	O
+venous	B-ANAT
+ECLS	O
+(	O
+LFVV	O
+-	O
+ECLS	O
+)	O
+on	O
+hemodynamic	B-PROC
+monitoring	O
+by	O
+transpulmonary	O
+thermodilution	O
+(	O
+TPTD	O
+)	O
+was	O
+prospectively	O
+investigated	O
+.	O
+
+For	O
+single	O
+-	O
+site	O
+LFVV	O
+-	O
+ECLS	O
+,	O
+a	O
+22	O
+Fr	O
+twin	O
+-	O
+port	O
+double	O
+-	O
+lumen	B-ANAT
+cannula	B-SPEC
+was	O
+inserted	O
+percutaneously	O
+into	O
+the	O
+right	O
+jugular	B-ANAT
+vein	I-ANAT
+.	O
+
+Hemodynamic	B-PROC
+monitoring	O
+was	O
+performed	O
+using	O
+the	O
+Pulse	B-PROC
+index	O
+Continuous	O
+Cardiac	B-ANAT
+Output	O
+system	O
+.	O
+
+TITLE	O
+:	O
+Coronavirus	B-SPEC
+Infection	I-DISO
+and	O
+Diversity	O
+in	O
+Bats	B-SPEC
+in	O
+the	O
+Australasian	O
+Region	O
+.	O
+
+Sequence	O
+analysis	O
+of	O
+the	O
+spike	O
+protein	B-CHED
+(	O
+S	O
+)	O
+genes	O
+showed	O
+that	O
+each	O
+specimen	O
+had	O
+unique	O
+characteristics	O
+,	O
+and	O
+that	O
+the	O
+PEDV1	O
+/	O
+S	O
+/	O
+4	O
+strain	O
+could	O
+be	O
+differentiated	B-PROC
+from	O
+the	O
+others	O
+via	O
+a	O
+unique	O
+mutation	O
+of	O
+the	O
+S	B-PRGE
+gene	I-PRGE
+.	O
+
+TITLE	O
+:	O
+A	O
+Case	O
+Report	O
+of	O
+a	O
+Middle	O
+East	O
+Respiratory	O
+Syndrome	B-DISO
+Survivor	O
+with	O
+Kidney	B-ANAT
+Biopsy	O
+Results	O
+.	O
+
+The	O
+isotope	O
+dilution	O
+mass	O
+spectrometry	O
+traceable	O
+serum	B-COMP
+creatinine	B-CHED
+level	O
+increased	O
+to	O
+3	O
+.	O
+0	O
+mg	O
+/	O
+dL	O
+.	O
+We	O
+performed	O
+a	O
+kidney	B-ANAT
+biopsy	O
+8	O
+weeks	O
+after	O
+the	O
+onset	O
+of	O
+symptoms	O
+.	O
+
+ABSTRACT	O
+:	O
+Prone	O
+position	O
+ventilation	O
+(	O
+PPV	B-CHED
+)	O
+improves	O
+mortality	O
+in	O
+severe	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+(	O
+ARDS	B-DISO
+),	O
+but	O
+outcomes	O
+following	O
+its	O
+use	O
+in	O
+lung	B-ANAT
+transplant	B-ANAT
+recipients	O
+are	O
+not	O
+known	O
+.	O
+
+He	O
+was	O
+managed	O
+with	O
+PPV	B-CHED
+for	O
+22	O
+days	O
+and	O
+had	O
+a	O
+prolonged	O
+ICU	O
+stay	O
+complicated	O
+by	O
+hypoxic	B-DISO
+ischemic	B-DISO
+optic	I-DISO
+neuropathy	I-DISO
+leading	O
+to	O
+blindness	B-DISO
+.	O
+
+In	O
+most	O
+situations	O
+of	O
+RV	O
+overload	O
+induced	O
+by	O
+inspiration	B-PROC
+,	O
+significant	O
+pulse	B-PROC
+pressure	I-PROC
+variations	O
+are	O
+observed	O
+,	O
+either	O
+called	O
+'	O
+pulsus	O
+paradoxus	O
+'	O
+in	O
+spontaneously	O
+breathing	B-PROC
+patients	O
+or	O
+'	O
+reverse	O
+pulsus	O
+paradoxus	O
+'	O
+in	O
+mechanically	O
+ventilated	O
+patients	O
+.	O
+
+Pulse	B-PROC
+pressure	I-PROC
+variations	O
+,	O
+central	O
+venous	B-PROC
+pressure	I-PROC
+and	O
+especially	O
+echocardiography	O
+may	O
+monitor	O
+RV	O
+function	O
+in	O
+abnormal	O
+clinical	O
+situations	O
+.	O
+
+Weaning	B-PROC
+using	O
+NAVA	O
+restored	O
+the	O
+regular	O
+respiration	B-PROC
+and	O
+stable	O
+and	O
+normal	O
+acid	B-PROC
+-	I-PROC
+base	I-PROC
+balance	I-PROC
+.	O
+
+TITLE	O
+:	O
+The	O
+Ratio	O
+of	O
+Partial	O
+Pressure	O
+Arterial	B-ANAT
+Oxygen	B-CHED
+and	O
+Fraction	O
+of	O
+Inspired	B-PROC
+Oxygen	B-CHED
+1	O
+Day	O
+After	O
+Acute	B-DISO
+Respiratory	I-DISO
+Distress	I-DISO
+Syndrome	I-DISO
+Onset	O
+Can	O
+Predict	O
+the	O
+Outcomes	O
+of	O
+Involving	O
+Patients	O
+.	O
+
+We	O
+aimed	O
+to	O
+determine	O
+the	O
+predictive	O
+validity	O
+of	O
+the	O
+stabilized	O
+ratio	O
+of	O
+partial	O
+pressure	O
+arterial	B-ANAT
+oxygen	B-CHED
+and	O
+fraction	O
+of	O
+inspired	B-PROC
+oxygen	B-CHED
+(	O
+PaO2	O
+/	O
+FiO2	O
+ratio	O
+)	O
+following	O
+standard	O
+ventilator	O
+setting	O
+in	O
+the	O
+prognosis	O
+of	O
+patients	O
+with	O
+ARDS	B-DISO
+.	O
+This	O
+prospective	O
+observational	O
+study	O
+was	O
+conducted	O
+in	O
+a	O
+single	O
+tertiary	O
+medical	O
+center	O
+in	O
+Taiwan	O
+and	O
+compared	O
+the	O
+stabilized	O
+PaO2	O
+/	O
+FiO2	O
+ratio	O
+(	O
+Day	O
+1	O
+)	O
+following	O
+standard	O
+ventilator	O
+settings	O
+and	O
+the	O
+PaO2	O
+/	O
+FiO2	O
+ratio	O
+on	O
+the	O
+day	O
+patients	O
+met	B-CHED
+ARDS	B-DISO
+Berlin	O
+criteria	O
+(	O
+Day	O
+0	O
+).	O
+
+Positive	O
+BAC	O
+group	O
+required	O
+significantly	O
+less	O
+packed	O
+red	B-ANAT
+blood	I-ANAT
+cells	I-ANAT
+and	O
+fresh	B-ANAT
+frozen	I-ANAT
+plasma	I-ANAT
+(	O
+P	O
+<	O
+0	O
+.	O
+05	O
+).	O
+
+However	O
+,	O
+lowered	O
+systemic	B-PRGE
+IL	I-PRGE
+-	I-PRGE
+6	I-PRGE
+levels	O
+and	O
+leukocyte	B-ANAT
+counts	O
+in	O
+the	O
+BAC	O
+group	O
+were	O
+also	O
+detected	O
+after	O
+matching	O
+,	O
+indicating	O
+that	O
+this	O
+effect	O
+is	O
+ISS	B-DISO
+-	O
+independent	O
+.	O
+
+This	O
+study	O
+shows	O
+that	O
+positive	O
+BAC	O
+in	O
+TBI	O
+patients	O
+is	O
+associated	O
+with	O
+lower	O
+systemic	O
+IL	B-FUNC
+-	I-FUNC
+6	I-FUNC
+levels	O
+and	O
+leukocyte	B-ANAT
+numbers	O
+,	O
+indicating	O
+that	O
+positive	O
+BAC	O
+may	O
+have	O
+immunosuppressive	O
+effects	O
+in	O
+this	O
+cohort	O
+of	O
+patients	O
+compared	O
+with	O
+TBI	O
+patients	O
+who	O
+were	O
+not	O
+alcohol	O
+intoxicated	O
+.	O
+
+However	O
+,	O
+lowered	O
+systemic	B-PRGE
+IL	I-PRGE
+-	I-PRGE
+6	I-PRGE
+levels	O
+and	O
+leukocyte	B-ANAT
+counts	O
+in	O
+the	O
+BAC	O
+group	O
+were	O
+also	O
+detected	O
+after	O
+matching	O
+,	O
+indicating	O
+that	O
+this	O
+effect	O
+is	O
+ISS	B-DISO
+-	O
+independent	O
+.	O
+
+TITLE	O
+:	O
+[	O
+Phylogenetic	O
+variability	O
+of	O
+human	B-SPEC
+metapneumovirus	I-SPEC
+strains	O
+circulating	O
+in	O
+Turkey	B-SPEC
+during	O
+two	O
+consecutive	O
+epidemic	O
+seasons	O
+].	O
+
+Nucleotide	B-CHED
+diversity	O
+was	O
+higher	O
+than	O
+aminoacid	O
+diversity	O
+between	O
+and	O
+within	O
+lineages	O
+found	O
+in	O
+this	O
+study	O
+.	O
+
+The	O
+lesions	O
+observed	O
+were	O
+milder	O
+,	O
+compared	O
+to	O
+the	O
+US	O
+classical	O
+strain	O
+of	O
+PEDV	B-SPEC
+.	O
+
+Our	O
+study	O
+,	O
+for	O
+the	O
+first	O
+time	O
+,	O
+reports	O
+the	O
+histological	O
+lesions	O
+caused	O
+by	O
+the	O
+variant	O
+PEDV	B-SPEC
+OH851	O
+strain	O
+from	O
+a	O
+field	O
+case	O
+.	O
+
+In	O
+addition	O
+,	O
+genomic	O
+characterization	O
+demonstrated	O
+that	O
+US	O
+variant	O
+PEDV	B-SPEC
+is	O
+more	O
+closely	O
+related	O
+to	O
+European	O
+-	O
+like	O
+strains	O
+in	O
+the	O
+first	O
+1170	O
+nt	O
+of	O
+the	O
+5	O
+'	O
+spike	O
+gene	O
+but	O
+to	O
+US	O
+classical	O
+PEDV	B-SPEC
+strains	O
+in	O
+the	O
+remaining	O
+genome	O
+,	O
+suggesting	O
+that	O
+the	O
+variant	O
+PEDV	B-SPEC
+strain	O
+may	O
+derive	O
+from	O
+a	O
+recombinant	O
+event	O
+between	O
+the	O
+US	O
+classical	O
+and	O
+European	O
+-	O
+like	O
+PEDV	B-SPEC
+strains	O
+.	O
+
+ABSTRACT	O
+:	O
+Recent	O
+outbreaks	O
+of	O
+porcine	B-SPEC
+epidemic	I-SPEC
+diarrhea	I-SPEC
+virus	I-SPEC
+(	O
+PEDV	B-SPEC
+)	O
+and	O
+porcine	B-SPEC
+deltacoronavirus	O
+(	O
+PDCoV	O
+)	O
+in	O
+multiple	O
+countries	O
+have	O
+caused	O
+significant	O
+economic	O
+losses	O
+and	O
+remain	O
+a	O
+serious	O
+challenge	O
+to	O
+the	O
+swine	B-SPEC
+industry	O
+.	O
+
+In	O
+the	O
+present	O
+study	O
+,	O
+a	O
+singleplex	O
+PEDV	B-SPEC
+RT	O
+-	O
+iiPCR	O
+,	O
+a	O
+singleplex	O
+PDCoV	O
+RT	O
+-	O
+iiPCR	O
+,	O
+and	O
+a	O
+duplex	O
+PEDV	B-SPEC
+/	O
+PDCoV	O
+real	O
+-	O
+time	O
+RT	O
+-	O
+PCR	O
+(	O
+rRT	O
+-	O
+PCR	O
+)	O
+commercial	O
+reagents	B-CHED
+targeting	B-PROC
+the	O
+M	B-PRGE
+gene	I-PRGE
+were	O
+compared	O
+to	O
+an	O
+N	O
+gene	O
+-	O
+based	O
+PEDV	B-SPEC
+rRT	O
+-	O
+PCR	O
+and	O
+an	O
+M	O
+gene	O
+-	O
+based	O
+PDCoV	O
+rRT	O
+-	O
+PCR	O
+that	O
+were	O
+previously	O
+published	O
+and	O
+used	O
+as	O
+reference	O
+PCRs	O
+.	O
+
+Compared	O
+to	O
+the	O
+reference	O
+PEDV	B-SPEC
+rRT	O
+-	O
+PCR	O
+,	O
+the	O
+sensitivity	O
+,	O
+specificity	O
+and	O
+accuracy	O
+of	O
+the	O
+PEDV	B-SPEC
+RT	O
+-	O
+iiPCR	O
+were	O
+97	O
+.	O
+73	O
+%,	O
+98	O
+.	O
+78	O
+%,	O
+and	O
+98	O
+.	O
+24	O
+%,	O
+respectively	O
+,	O
+and	O
+those	O
+of	O
+the	O
+duplex	O
+PEDV	B-SPEC
+/	O
+PDCoV	O
+rRT	O
+-	O
+PCR	O
+were	O
+98	O
+.	O
+86	O
+%,	O
+96	O
+.	O
+34	O
+%,	O
+and	O
+97	O
+.	O
+65	O
+%,	O
+respectively	O
+.	O
+
+Immunological	O
+TRALI	B-DISO
+was	O
+tested	O
+in	O
+mice	B-SPEC
+exhibiting	O
+severe	O
+thrombocytopenia	O
+or	O
+platelet	B-DISO
+dysfunction	I-DISO
+.	O
+
+Results	O
+TRALI	B-DISO
+was	O
+tested	O
+in	O
+the	O
+context	O
+of	O
+severe	O
+thrombocytopenia	O
+provoked	O
+by	O
+the	O
+administration	O
+of	O
+diphtheria	O
+toxin	O
+(	O
+DT	O
+)	O
+in	O
+transgenic	O
+iDTR	O
+mice	B-SPEC
+selectively	O
+expressing	O
+DT	B-PRGE
+receptor	I-PRGE
+in	O
+megakaryocytes	B-ANAT
+.	O
+
+TITLE	O
+:	O
+The	O
+effect	O
+of	O
+porcine	B-SPEC
+reproductive	I-SPEC
+and	I-SPEC
+respiratory	I-SPEC
+syndrome	I-SPEC
+virus	I-SPEC
+and	O
+porcine	B-SPEC
+epidemic	B-DISO
+diarrhea	I-DISO
+virus	I-SPEC
+challenge	O
+on	O
+growing	O
+pigs	B-SPEC
+I	O
+:	O
+Growth	B-PROC
+performance	O
+and	O
+digestibility	O
+.	O
+
+During	O
+the	O
+test	O
+period	O
+,	O
+PRRS	B-DISO
+reduced	O
+ADG	O
+and	O
+ADFI	O
+by	O
+30	O
+and	O
+26	O
+%,	O
+respectively	O
+(	O
+<	O
+0	O
+.	O
+05	O
+),	O
+compared	O
+with	O
+control	O
+pigs	B-SPEC
+,	O
+whereas	O
+PRP	B-CHED
+decreased	O
+ADG	O
+,	O
+ADFI	O
+,	O
+and	O
+G	O
+:	O
+F	O
+by	O
+45	O
+,	O
+30	O
+,	O
+and	O
+23	O
+%,	O
+respectively	O
+(	O
+<	O
+0	O
+.	O
+05	O
+).	O
+
+Altogether	O
+,	O
+PRRS	B-DISO
+reduced	O
+growth	B-PROC
+but	O
+did	O
+not	O
+alter	O
+digestibility	O
+.	O
+
+Treatments	O
+3	O
+and	O
+4	O
+were	O
+inoculated	O
+with	O
+PED	O
+virus	B-SPEC
+on	O
+14	O
+d	O
+after	O
+inoculation	O
+(	O
+dpi	O
+)	O
+and	O
+all	O
+pigs	B-SPEC
+were	O
+euthanized	O
+7	O
+d	O
+later	O
+(	O
+21	O
+dpi	O
+).	O
+
+Ex	O
+vivo	O
+transepithelial	O
+electrical	O
+resistance	B-PROC
+(	O
+TER	B-COMP
+)	O
+did	O
+not	O
+differ	O
+between	O
+CON	O
+and	O
+PRRS	B-DISO
+pigs	B-SPEC
+(	O
+P	O
+<	O
+0	O
+.	O
+05	O
+)	O
+but	O
+was	O
+reduced	O
+by	O
+40	O
+%	O
+in	O
+PED	O
+alone	O
+(	O
+<	O
+0	O
+.	O
+01	O
+).	O
+
+Interestingly	O
+,	O
+TER	B-COMP
+was	O
+increased	O
+(	O
+<	O
+0	O
+.	O
+01	O
+)	O
+in	O
+the	O
+PRP	B-CHED
+pigs	B-SPEC
+.	O
+
+Active	B-PROC
+transport	I-PROC
+of	O
+glucose	B-CHED
+was	O
+increased	O
+in	O
+PRRS	B-DISO
+pigs	B-SPEC
+over	O
+CON	O
+pigs	B-SPEC
+(	O
+<	O
+0	O
+.	O
+01	O
+),	O
+whereas	O
+PED	O
+had	O
+pigs	B-SPEC
+increased	O
+(	O
+<	O
+0	O
+.	O
+01	O
+)	O
+active	O
+glutamine	B-PROC
+transport	B-PROC
+over	O
+the	O
+CON	O
+pigs	B-SPEC
+.	O
+
+Altogether	O
+,	O
+PED	O
+but	O
+not	O
+PRRS	B-DISO
+challenges	O
+alter	O
+intestinal	B-ANAT
+morphology	O
+and	O
+integrity	O
+in	O
+growing	O
+pigs	B-SPEC
+.	O
+
+TITLE	O
+:	O
+Interdisciplinary	O
+Peripartum	O
+Management	O
+of	O
+Acute	B-DISO
+Respiratory	I-DISO
+Distress	I-DISO
+Syndrome	I-DISO
+with	O
+Extracorporeal	O
+Membrane	O
+Oxygenation	B-PROC
+-	O
+a	O
+Case	O
+Report	O
+and	O
+Literature	O
+Review	O
+.	O
+
+One	O
+of	O
+the	O
+indications	O
+is	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+(	O
+ARDS	B-DISO
+)	O
+for	O
+which	O
+,	O
+in	O
+some	O
+severe	O
+cases	O
+,	O
+ECMO	O
+represents	O
+the	O
+only	O
+possibility	O
+to	O
+save	O
+lives	O
+.	O
+
+Several	O
+decades	O
+of	O
+advances	O
+in	O
+acute	O
+management	O
+and	O
+treatment	O
+,	O
+as	O
+well	O
+as	O
+better	O
+understanding	O
+of	O
+approaches	O
+to	O
+ventilation	O
+,	O
+oxygenation	O
+,	O
+and	O
+surfactant	B-CHED
+regulation	B-PROC
+have	O
+contributed	O
+to	O
+improvements	O
+in	O
+patient	O
+recovery	O
+.	O
+
+ABSTRACT	O
+:	O
+Dromedaries	B-SPEC
+in	O
+Africa	O
+and	O
+elsewhere	O
+carry	O
+the	O
+Middle	O
+East	O
+respiratory	O
+syndrome	O
+coronavirus	B-SPEC
+(	O
+MERS	O
+-	O
+CoV	O
+).	O
+
+Co	O
+-	O
+expression	B-PROC
+of	O
+the	O
+third	O
+EAV	B-SPEC
+transmembrane	B-COMP
+protein	B-CHED
+(	O
+nsp5	B-PRGE
+),	O
+expressed	B-PROC
+as	O
+part	O
+of	O
+a	O
+self	O
+-	O
+cleaving	O
+polypeptide	B-CHED
+that	O
+mimics	O
+viral	O
+polyprotein	O
+processing	O
+in	O
+infected	O
+cells	B-COMP
+,	O
+led	O
+to	O
+the	O
+formation	B-PROC
+of	O
+DMVs	O
+whose	O
+size	O
+was	O
+more	O
+homogenous	O
+and	O
+closer	O
+to	O
+what	O
+is	O
+observed	O
+upon	O
+EAV	B-SPEC
+infection	B-DISO
+,	O
+suggesting	O
+a	O
+regulatory	O
+role	O
+for	O
+nsp5	B-PRGE
+in	O
+modulating	O
+membrane	B-COMP
+curvature	O
+and	O
+DMV	O
+formation	B-PROC
+.	O
+
+TITLE	O
+:	O
+Transport	B-PROC
+of	O
+Mechanically	O
+Ventilated	O
+Patients	O
+in	O
+the	O
+Prone	O
+Position	O
+.	O
+
+All	O
+patients	O
+were	O
+mechanically	O
+ventilated	O
+for	O
+respiratory	B-DISO
+failure	I-DISO
+and	O
+transported	O
+by	O
+specialized	O
+nonphysician	O
+critical	O
+care	O
+teams	O
+.	O
+
+Utilizing	O
+direct	O
+medical	O
+oversight	O
+and	O
+real	O
+-	O
+time	O
+technical	O
+support	O
+from	O
+the	O
+clinical	O
+department	O
+,	O
+each	O
+patient	O
+underwent	O
+a	O
+thorough	O
+bedside	O
+evaluation	O
+,	O
+transport	B-PROC
+ventilator	O
+trial	O
+,	O
+and	O
+transfer	O
+to	O
+a	O
+transport	B-PROC
+stretcher	O
+either	O
+with	O
+the	O
+endotracheal	O
+tube	O
+secured	O
+by	O
+an	O
+anesthesia	B-DISO
+pillow	O
+or	O
+overhanging	O
+the	O
+stretcher	O
+.	O
+
+Their	O
+mean	O
+age	O
+was	O
+47	O
+.	O
+7	O
+±	O
+61	O
+.	O
+2	O
+(	O
+m	O
+)	O
+and	O
+body	B-ANAT
+weight	O
+was	O
+25	O
+.	O
+3	O
+±	O
+27	O
+.	O
+1	O
+(	O
+kg	O
+).	O
+
+Hemodynamic	B-PROC
+and	O
+serious	O
+complications	O
+were	O
+not	O
+significantly	O
+affected	O
+after	O
+LVRM	O
+.	O
+
+Moreover	O
+,	O
+no	O
+serious	O
+complication	B-DISO
+was	O
+noted	O
+.	O
+
+ABSTRACT	O
+:	O
+Consideration	O
+of	O
+lung	O
+transplantation	O
+in	O
+patients	O
+with	O
+systemic	B-DISO
+sclerosis	I-DISO
+(	O
+SSc	O
+)	O
+remains	O
+guarded	O
+,	O
+often	O
+due	O
+to	O
+the	O
+concern	O
+for	O
+esophageal	B-DISO
+dysfunction	I-DISO
+and	O
+the	O
+associated	O
+potential	O
+for	O
+allograft	O
+injury	O
+and	O
+suboptimal	O
+post	O
+-	O
+lung	B-ANAT
+transplantation	O
+outcomes	O
+.	O
+
+We	O
+retrospectively	O
+reviewed	O
+all	O
+lung	B-PRGE
+transplants	B-ANAT
+at	O
+our	O
+center	O
+from	O
+January	O
+1	O
+,	O
+2000	O
+through	O
+August	O
+31	O
+,	O
+2012	O
+(	O
+n	O
+=	O
+562	O
+),	O
+comparing	O
+the	O
+SSc	O
+group	O
+(	O
+n	O
+=	O
+35	O
+)	O
+to	O
+the	O
+following	O
+lung	B-ANAT
+transplant	B-ANAT
+diagnostic	O
+subsets	O
+:	O
+all	O
+non	O
+-	O
+SSc	O
+(	O
+n	O
+=	O
+527	O
+),	O
+non	O
+-	O
+SSc	O
+diffuse	O
+fibrotic	O
+lung	B-DISO
+disease	I-DISO
+(	O
+n	O
+=	O
+264	O
+),	O
+and	O
+a	O
+non	O
+-	O
+SSc	O
+matched	O
+group	O
+(	O
+n	O
+=	O
+109	O
+).	O
+
+ABSTRACT	O
+:	O
+The	O
+digestive	B-ANAT
+tract	I-ANAT
+is	O
+the	O
+entry	O
+site	O
+for	O
+transmissible	O
+gastroenteritis	B-DISO
+virus	B-SPEC
+(	O
+TGEV	B-SPEC
+).	O
+
+We	O
+examined	O
+whether	O
+RA	O
+assist	O
+parenteral	O
+vaccination	O
+of	O
+pigs	B-SPEC
+could	O
+improve	O
+mucosal	B-PROC
+immunity	I-PROC
+.	O
+
+Porcine	B-SPEC
+T	B-ANAT
+-	I-ANAT
+cells	I-ANAT
+expressed	B-PROC
+β7	B-PRGE
+integrin	I-PRGE
+and	O
+CCR9	B-PRGE
+receptors	I-PRGE
+and	O
+migrated	O
+to	O
+CCL25	B-PRGE
+by	O
+a	O
+mechanism	O
+that	O
+was	O
+dependent	O
+of	O
+activation	O
+by	O
+RA	O
+-	O
+pretreated	O
+DCs	B-DISO
+,	O
+rather	O
+than	O
+direct	O
+activation	O
+by	O
+RA	O
+.	O
+
+The	O
+aim	O
+of	O
+this	O
+study	O
+was	O
+to	O
+determine	O
+the	O
+frequency	O
+of	O
+respiratory	B-SPEC
+syncytial	I-SPEC
+virus	I-SPEC
+(	O
+RSV	B-SPEC
+)	O
+and	O
+of	O
+7	O
+other	O
+viruses	B-SPEC
+in	O
+children	O
+for	O
+LRTI	B-DISO
+in	O
+4	O
+capitals	O
+from	O
+this	O
+region	O
+,	O
+and	O
+investigate	O
+their	O
+association	O
+with	O
+several	O
+risk	O
+factors	O
+,	O
+including	O
+meteorological	O
+data	O
+.	O
+
+From	O
+April	O
+2012	O
+to	O
+March	O
+2013	O
+,	O
+507	O
+children	O
+,	O
+aged	O
+up	O
+to	O
+24	O
+months	O
+and	O
+hospitalized	O
+with	O
+LRTI	B-DISO
+in	O
+one	O
+of	O
+the	O
+participating	O
+centers	O
+at	O
+Aracajú	O
+,	O
+Salvador	O
+,	O
+Recife	O
+,	O
+and	O
+Maceió	O
+,	O
+had	O
+a	O
+sample	O
+of	O
+nasopharyngeal	B-ANAT
+aspirate	I-ANAT
+collected	O
+and	O
+analyzed	O
+for	O
+the	O
+following	O
+viruses	B-SPEC
+by	O
+reverse	O
+-	O
+transcription	B-PROC
+polymerase	O
+chain	O
+reaction	O
+followed	O
+by	O
+hybridization	O
+on	O
+low	O
+-	O
+density	O
+microarrays	O
+:	O
+RSV	B-SPEC
+,	O
+influenza	B-DISO
+,	O
+parainfluenza	B-DISO
+,	O
+adenovirus	B-DISO
+,	O
+rhinovirus	B-SPEC
+,	O
+metapneumovirus	B-SPEC
+,	O
+bocavirus	B-SPEC
+,	O
+and	O
+coronavirus	B-SPEC
+.	O
+
+Some	O
+of	O
+these	O
+findings	O
+differ	O
+from	O
+those	O
+reported	O
+for	O
+other	O
+regions	O
+in	O
+Brazil	O
+and	O
+may	O
+be	O
+used	O
+to	O
+guide	O
+policies	O
+that	O
+address	O
+LRTI	B-DISO
+.	O
+
+In	O
+addition	O
+to	O
+fundamental	O
+pathophysiology	O
+of	O
+lung	B-ANAT
+injury	O
+,	O
+the	O
+article	O
+also	O
+focuses	O
+on	O
+established	O
+and	O
+modern	O
+treatment	O
+strategies	O
+.	O
+
+In	O
+summary	O
+,	O
+CCoV	O
+and	O
+CRCoV	O
+rNPs	O
+were	O
+successfully	O
+expressed	B-PROC
+in	O
+E	B-SPEC
+.	I-SPEC
+coli	I-SPEC
+and	O
+showed	O
+antigenic	O
+cross	O
+-	O
+reactivity	O
+with	O
+antisera	O
+raised	O
+against	O
+human	B-SPEC
+coronaviruses	O
+.	O
+
+ABSTRACT	O
+:	O
+Large	O
+-	O
+scale	O
+influenza	O
+outbreaks	O
+over	O
+the	O
+last	O
+decade	O
+,	O
+such	O
+as	O
+SARS	B-DISO
+and	O
+H1N1	O
+,	O
+have	O
+brought	O
+to	O
+global	O
+attention	O
+the	O
+importance	O
+of	O
+emergency	B-DISO
+risk	O
+communication	O
+and	O
+prompted	O
+the	O
+international	O
+community	O
+to	O
+develop	O
+communication	O
+responses	O
+.	O
+
+ABSTRACT	O
+:	O
+In	O
+modern	O
+intensive	O
+care	O
+medicine	O
+,	O
+lungs	B-ANAT
+and	O
+kidneys	B-ANAT
+frequently	O
+are	O
+involved	O
+in	O
+the	O
+context	O
+of	O
+multiorgan	B-DISO
+failure	I-DISO
+.	O
+
+The	O
+results	O
+from	O
+the	O
+first	O
+experimental	O
+and	O
+clinical	O
+applications	O
+are	O
+encouraging	O
+:	O
+it	O
+is	O
+expected	O
+that	O
+a	O
+system	O
+including	O
+continuous	O
+renal	B-ANAT
+replacement	O
+therapy	O
+and	O
+ECCO2R	O
+will	O
+develop	O
+from	O
+the	O
+current	O
+pioneering	O
+attempts	O
+into	O
+a	O
+feasible	O
+multiple	O
+-	O
+organ	B-ANAT
+support	O
+platform	O
+to	O
+become	O
+commonly	O
+used	O
+as	O
+a	O
+routine	O
+tool	O
+in	O
+intensive	O
+care	O
+units	O
+.	O
+
+MERS	O
+coronavirus	B-SPEC
+transmission	O
+probably	O
+was	O
+multifocal	O
+,	O
+occurring	O
+in	O
+multiple	O
+hospital	O
+settings	O
+.	O
+
+The	O
+reverse	B-PROC
+transcription	I-PROC
+CPA	O
+system	O
+was	O
+further	O
+optimized	O
+for	O
+detecting	O
+PEDV	B-SPEC
+RNA	O
+in	O
+clinical	O
+specimens	O
+.	O
+
+Thus	O
+,	O
+our	O
+findings	O
+call	O
+for	O
+epidemiologic	O
+investigation	O
+of	O
+the	O
+possible	O
+scenarios	O
+for	O
+contact	O
+and	O
+airborne	O
+transmission	O
+,	O
+and	O
+raise	O
+concern	O
+regarding	O
+the	O
+adequacy	O
+of	O
+current	O
+infection	B-DISO
+control	O
+procedures	O
+.	O
+
+We	O
+also	O
+included	O
+studies	O
+that	O
+compared	O
+the	O
+effect	O
+of	O
+various	O
+ways	O
+of	O
+donning	O
+or	O
+removing	O
+PPE	B-PRGE
+,	O
+and	O
+the	O
+effects	O
+of	O
+various	O
+types	O
+of	O
+training	O
+in	O
+PPE	B-CHED
+use	O
+on	O
+the	O
+same	O
+outcomes	O
+.	O
+
+Different	O
+types	O
+of	O
+PPE	B-CHED
+versus	O
+each	O
+otherIn	O
+simulation	O
+studies	O
+,	O
+contamination	O
+rates	O
+varied	O
+from	O
+25	O
+%	O
+to	O
+100	O
+%	O
+of	O
+participants	O
+for	O
+all	O
+types	O
+of	O
+PPE	B-CHED
+.	O
+
+One	O
+retrospective	O
+cohort	O
+study	O
+assessed	O
+the	O
+effect	O
+of	O
+active	O
+training	O
+-	O
+defined	O
+as	O
+face	B-DISO
+-	O
+to	O
+-	O
+face	B-DISO
+instruction	O
+-	O
+versus	O
+passive	O
+training	O
+-	O
+defined	O
+as	O
+folders	O
+or	O
+videos	O
+-	O
+on	O
+noncompliance	O
+with	O
+PPE	B-CHED
+use	O
+and	O
+on	O
+noncompliance	O
+with	O
+doffing	O
+guidance	O
+.	O
+
+However	O
+,	O
+the	O
+data	O
+all	O
+come	O
+from	O
+single	O
+studies	O
+with	O
+high	O
+risk	O
+of	O
+bias	B-SPEC
+and	O
+we	O
+are	O
+uncertain	O
+about	O
+the	O
+estimates	O
+of	O
+effects	O
+.	O
+
+M	O
+proteins	B-CHED
+from	O
+MERS	O
+-	O
+CoV	O
+and	O
+SARS	B-DISO
+-	O
+CoV	O
+have	O
+three	O
+highly	O
+similar	O
+conserved	O
+N	O
+-	O
+terminal	O
+transmembrane	B-COMP
+domains	O
+and	O
+a	O
+C	O
+-	O
+terminal	O
+region	O
+.	O
+
+ABSTRACT	O
+:	O
+The	O
+incidence	O
+of	O
+severe	O
+respiratory	O
+complications	O
+in	O
+patients	O
+with	O
+pelvis	B-ANAT
+fractures	O
+needing	O
+intensive	O
+care	O
+have	O
+not	O
+previously	O
+been	O
+studied	O
+.	O
+
+The	O
+patients	O
+who	O
+developed	O
+AHF	O
+/	O
+ARDS	B-DISO
+had	O
+a	O
+higher	O
+incidence	O
+of	O
+lung	B-ANAT
+contusion	O
+(	O
+P	O
+=	O
+0	O
+.	O
+04	O
+)	O
+and	O
+the	O
+surgical	O
+stabilization	O
+was	O
+performed	O
+earlier	O
+(	O
+5	O
+versus	O
+10	O
+days	O
+)	O
+in	O
+these	O
+patients	O
+(	O
+P	O
+=	O
+0	O
+.	O
+03	O
+).	O
+
+The	O
+patients	O
+who	O
+developed	O
+AHF	O
+/	O
+ARDS	B-DISO
+had	O
+a	O
+higher	O
+incidence	O
+of	O
+lung	B-ANAT
+contusion	O
+(	O
+P	O
+=	O
+0	O
+.	O
+04	O
+)	O
+and	O
+the	O
+surgical	O
+stabilization	O
+was	O
+performed	O
+earlier	O
+(	O
+5	O
+versus	O
+10	O
+days	O
+)	O
+in	O
+these	O
+patients	O
+(	O
+P	O
+=	O
+0	O
+.	O
+03	O
+).	O
+
+TITLE	O
+:	O
+Disease	O
+-	O
+specific	O
+dynamic	O
+biomarkers	O
+selected	O
+by	O
+integrating	O
+inflammatory	O
+mediators	O
+with	O
+clinical	O
+informatics	O
+in	O
+ARDS	B-DISO
+patients	O
+with	O
+severe	O
+pneumonia	B-DISO
+.	O
+
+ABSTRACT	O
+:	O
+Acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+(	O
+ARDS	B-DISO
+)	O
+is	O
+a	O
+heterogeneous	O
+syndrome	B-DISO
+that	O
+occurs	O
+as	O
+a	O
+result	O
+of	O
+various	O
+risk	O
+factors	O
+,	O
+including	O
+either	O
+direct	O
+or	O
+indirect	O
+lung	B-ANAT
+injury	O
+,	O
+and	O
+systemic	O
+inflammation	B-DISO
+triggered	O
+also	O
+by	O
+severe	O
+pneumonia	B-DISO
+(	O
+SP	O
+).	O
+
+Cellular	B-PRGE
+kinases	I-PRGE
+phosphorylate	O
+BCX4430	O
+to	O
+a	O
+triphosphate	B-CHED
+that	O
+mimics	O
+ATP	B-CHED
+;	O
+viral	B-PRGE
+RNA	I-PRGE
+polymerases	I-PRGE
+incorporate	O
+the	O
+drug	O
+'	O
+s	O
+monophosphate	O
+nucleotide	B-CHED
+into	O
+the	O
+growing	O
+RNA	O
+chain	O
+,	O
+causing	O
+premature	O
+chain	O
+termination	O
+.	O
+
+Future	O
+research	O
+should	O
+include	O
+in	O
+vitro	O
+mechanism	O
+studies	O
+,	O
+animal	B-SPEC
+models	O
+of	O
+MERS	O
+-	O
+CoV	O
+infection	B-DISO
+,	O
+clinical	O
+trials	O
+,	O
+including	O
+dose	O
+-	O
+ranging	O
+trials	O
+,	O
+and	O
+evaluation	O
+of	O
+combination	O
+therapy	O
+with	O
+other	O
+potential	O
+MERS	O
+-	O
+CoV	O
+antivirals	B-CHED
+.	O
+
+Methods	O
+Prospectively	O
+,	O
+CSF	B-ANAT
+samples	O
+of	O
+41	O
+cats	B-SPEC
+were	O
+investigated	O
+,	O
+including	O
+cats	B-SPEC
+with	O
+histopathologically	O
+confirmed	O
+FIP	B-DISO
+and	O
+neurological	O
+signs	O
+(	O
+n	O
+=	O
+10	O
+),	O
+cats	B-SPEC
+with	O
+confirmed	O
+FIP	B-DISO
+without	O
+CNS	B-CHED
+involvement	O
+(	O
+n	O
+=	O
+11	O
+),	O
+cats	B-SPEC
+with	O
+neurological	O
+signs	O
+but	O
+another	O
+confirmed	O
+CNS	B-DISO
+disease	I-DISO
+(	O
+n	O
+=	O
+17	O
+),	O
+and	O
+cats	B-SPEC
+without	O
+neurological	O
+signs	O
+and	O
+a	O
+disease	O
+other	O
+than	O
+FIP	B-DISO
+(	O
+n	O
+=	O
+3	O
+).	O
+
+ABSTRACT	O
+:	O
+The	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+(	O
+ARDS	B-DISO
+)	O
+is	O
+characterized	O
+by	O
+arterial	B-ANAT
+hypoxemia	O
+accompanied	O
+by	O
+severe	O
+inflammation	B-DISO
+and	O
+alterations	O
+to	O
+the	O
+pulmonary	B-ANAT
+surfactant	B-CHED
+system	O
+.	O
+
+Mmp3	B-PRGE
+(-/-)	O
+mice	B-SPEC
+maintained	O
+higher	O
+arterial	B-ANAT
+oxygenation	B-PROC
+compared	O
+with	O
+WT	O
+mice	B-SPEC
+at	O
+the	O
+completion	O
+of	O
+ventilation	O
+.	O
+
+These	O
+findings	O
+further	O
+support	O
+a	O
+role	O
+of	O
+Mmp3	B-PRGE
+as	O
+an	O
+attractive	O
+therapeutic	O
+target	O
+for	O
+drug	O
+development	B-PROC
+in	O
+the	O
+setting	O
+of	O
+ARDS	B-DISO
+.	O
+
+Cases	O
+were	O
+identified	O
+using	O
+the	O
+World	O
+Health	O
+Organization	O
+'	O
+s	O
+Integrated	O
+Management	O
+of	O
+Childhood	O
+Illnesses	O
+'	O
+definition	O
+of	O
+severe	O
+pneumonia	B-DISO
+.	O
+
+TITLE	O
+:	O
+Use	O
+of	O
+a	O
+dual	O
+lumen	B-ANAT
+cannula	B-SPEC
+for	O
+venovenous	O
+extra	O
+corporeal	O
+membrane	B-COMP
+oxygenation	B-PROC
+in	O
+a	O
+patient	O
+with	O
+acute	O
+respiratory	O
+distress	O
+syndrome	O
+and	O
+a	O
+previously	O
+inserted	O
+inferior	B-ANAT
+vena	I-ANAT
+cava	I-ANAT
+filter	O
+:	O
+a	O
+case	O
+report	O
+.	O
+
+A	O
+decreased	O
+expression	B-PROC
+pattern	O
+of	O
+induced	O
+COX	B-PRGE
+-	I-PRGE
+2	I-PRGE
+and	O
+reduced	O
+production	O
+of	O
+downstream	O
+PGE2	B-CHED
+occurred	O
+upon	O
+TNF	B-PRGE
+-	I-PRGE
+α	I-PRGE
+stimulation	O
+in	O
+G6PD	B-PRGE
+-	O
+kd	O
+A549	O
+cells	B-COMP
+compared	O
+with	O
+scramble	O
+control	O
+A549	O
+cells	B-COMP
+.	O
+
+Because	O
+prone	O
+positioning	O
+does	O
+not	O
+produce	O
+a	O
+significant	O
+increase	O
+in	O
+intra	O
+-	O
+abdominal	B-ANAT
+pressure	O
+,	O
+it	O
+does	O
+not	O
+exert	B-PROC
+deleterious	O
+effects	O
+on	O
+the	O
+microcirculation	B-PROC
+of	O
+intra	O
+-	O
+abdominal	B-ANAT
+organs	I-ANAT
+.	O
+
+LCA60	O
+antibody	B-COMP
+was	O
+generated	O
+using	O
+the	O
+Cellclone	O
+Technology	O
+from	O
+the	O
+immortalized	O
+B	B-ANAT
+cells	I-ANAT
+of	O
+a	O
+human	B-SPEC
+donor	B-CHED
+recovering	O
+from	O
+MERS	O
+.	O
+
+Currently	O
+,	O
+the	O
+LCA60	O
+antibody	B-COMP
+is	O
+being	O
+considered	O
+for	O
+clinical	O
+development	B-PROC
+,	O
+which	O
+includes	O
+prophylaxis	O
+in	O
+individuals	O
+at	O
+risk	O
+and	O
+a	O
+treatment	O
+for	O
+severe	O
+MERS	O
+-	O
+CoV	O
+infections	O
+.	O
+
+A	O
+PEDV	B-SPEC
+strain	O
+,	O
+YC2014	O
+,	O
+was	O
+isolated	O
+from	O
+intestinal	B-ANAT
+samples	O
+of	O
+suckling	O
+piglets	O
+with	O
+acute	B-DISO
+diarrhea	I-DISO
+in	O
+2014	O
+.	O
+
+The	O
+S	O
+gene	O
+sequence	O
+of	O
+YC2014	O
+shared	O
+only	O
+93	O
+.	O
+9	O
+%	O
+~	O
+94	O
+.	O
+4	O
+%	O
+identities	O
+with	O
+classical	O
+CV777	O
+,	O
+DR13	O
+and	O
+JS2008	O
+strains	O
+,	O
+with	O
+15	O
+nucleotide	B-CHED
+insertion	O
+in	O
+three	O
+sites	O
+and	O
+three	O
+nucleotide	B-CHED
+deletion	O
+in	O
+one	O
+site	O
+.	O
+
+The	O
+YC2014	O
+PEDV	B-SPEC
+strain	O
+could	O
+provide	O
+piglets	O
+against	O
+homologous	O
+challenge	O
+.	O
+
+TITLE	O
+:	O
+Guidelines	O
+for	O
+the	O
+Laboratory	O
+Diagnosis	O
+of	O
+Middle	O
+East	O
+Respiratory	O
+Syndrome	B-DISO
+Coronavirus	B-SPEC
+in	O
+Korea	O
+.	O
+
+Silver	B-CHED
+nanoparticles	B-CHED
+have	O
+demonstrated	O
+strong	O
+antiviral	B-CHED
+activity	O
+,	O
+and	O
+graphene	B-CHED
+is	O
+a	O
+potential	O
+antimicrobial	B-CHED
+material	O
+due	O
+to	O
+its	O
+large	O
+surface	O
+area	O
+,	O
+high	O
+carrier	O
+mobility	O
+,	O
+and	O
+biocompatibility	B-PROC
+.	O
+
+The	O
+SYBR	B-CHED
+green	I-CHED
+I	I-CHED
+real	O
+-	O
+time	O
+RT	O
+-	O
+PCR	O
+test	O
+described	O
+herein	O
+can	O
+be	O
+used	O
+to	O
+rapidly	O
+distinguish	O
+IBV	O
+from	O
+other	O
+respiratory	O
+pathogens	O
+,	O
+which	O
+is	O
+important	O
+for	O
+diagnosis	O
+and	O
+control	O
+of	O
+infectious	B-DISO
+bronchitis	B-DISO
+outbreaks	O
+in	O
+Morocco	O
+.	O
+
+G	O
+-	O
+N	O
+lesions	O
+exhibited	O
+a	O
+necrotic	B-PROC
+center	O
+surrounded	O
+by	O
+abundant	O
+macrophages	B-ANAT
+,	O
+some	O
+T	B-ANAT
+-	I-ANAT
+lymphocytes	I-ANAT
+,	O
+plasma	B-ANAT
+cells	I-ANAT
+,	O
+and	O
+a	O
+few	O
+B	B-ANAT
+-	I-ANAT
+lymphocytes	I-ANAT
+.	O
+
+TITLE	O
+:	O
+Serological	O
+Study	O
+of	O
+An	O
+Imported	O
+Case	O
+of	O
+Middle	O
+East	O
+Respiratory	O
+Syndrome	B-DISO
+and	O
+His	O
+Close	O
+Contacts	O
+in	O
+China	O
+,	O
+2015	O
+.	O
+
+This	O
+study	O
+investigated	O
+the	O
+influence	O
+of	O
+acute	O
+hypovolemia	O
+on	O
+the	O
+respiratory	B-ANAT
+system	I-ANAT
+.	O
+
+We	O
+performed	O
+a	O
+secondary	O
+analysis	O
+of	O
+a	O
+previous	O
+study	O
+including	O
+8	O
+pigs	B-SPEC
+with	O
+ARDS	B-DISO
+-	O
+like	O
+syndrome	B-DISO
+induced	O
+by	O
+lung	B-ANAT
+lavage	O
+and	O
+surfactant	B-CHED
+depletion	O
+method	O
+(	O
+ARDS	B-DISO
+group	O
+)	O
+and	O
+10	O
+mechanically	O
+ventilated	O
+pigs	B-SPEC
+with	O
+no	O
+intervention	O
+(	O
+CTRL	O
+group	O
+).	O
+
+In	O
+the	O
+ARDS	B-DISO
+group	O
+,	O
+after	O
+hemorrhage	B-DISO
+,	O
+shunt	O
+decreased	O
+(-	O
+28	O
++/-	O
+
+Furthermore	O
+,	O
+the	O
+present	O
+model	O
+does	O
+not	O
+consider	O
+the	O
+impact	O
+of	O
+blood	B-DISO
+loss	I-DISO
+induced	O
+decrease	O
+of	O
+DO2	O
+on	O
+other	O
+vital	O
+organs	B-ANAT
+function	O
+.	O
+
+It	O
+is	O
+associated	O
+with	O
+severe	O
+morbidity	O
+and	O
+mortality	O
+,	O
+and	O
+is	O
+not	O
+treatable	O
+with	O
+the	O
+currently	O
+available	O
+antiviral	B-CHED
+therapies	O
+.	O
+
+Dexmedetomidine	B-CHED
+(	O
+DEX	O
+)	O
+is	O
+a	O
+sedative	B-CHED
+that	O
+produces	O
+minimal	O
+respiratory	B-DISO
+depression	I-DISO
+with	O
+opioid	O
+-	O
+sparing	O
+effects	O
+.	O
+
+The	O
+primary	O
+outcome	O
+measure	O
+was	O
+the	O
+mean	O
+time	O
+in	O
+target	O
+RASS	O
+(	O
+0	O
+=	O
+alert	O
+and	O
+calm	O
+to	O
+-	O
+2	O
+=	O
+light	O
+sedation	B-DISO
+).	O
+
+Dexmedetomidine	B-CHED
+was	O
+found	O
+to	O
+be	O
+associated	O
+with	O
+significantly	O
+more	O
+hypotension	O
+.	O
+
+TITLE	O
+:	O
+[	O
+The	O
+clinical	O
+analysis	O
+of	O
+extracorporeal	O
+membrane	B-COMP
+oxygenation	B-PROC
+for	O
+adult	O
+severe	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+].	O
+
+Mean	O
+time	O
+of	O
+mechanical	O
+ventilation	O
+before	O
+ECMO	O
+therapy	O
+was	O
+(	O
+71	O
+±	O
+25	O
+)	O
+h	O
+.	O
+The	O
+main	O
+factors	O
+(	O
+the	O
+lowest	O
+PaO2	O
+/	O
+FiO2	O
+and	O
+pH	O
+,	O
+the	O
+highest	O
+PEEP	B-CHED
+,	O
+PaCO2	O
+and	O
+serum	B-COMP
+lactate	B-CHED
+level	O
+,	O
+the	O
+grade	O
+of	O
+APACHEⅡ	O
+,	O
+Murray	O
+and	O
+SOFA	O
+)	O
+between	O
+the	O
+ECMO	O
+group	O
+and	O
+the	O
+control	O
+group	O
+were	O
+not	O
+significantly	O
+different	O
+(	O
+all	O
+P	O
+>	O
+0	O
+.	O
+05	O
+).	O
+
+Our	O
+experience	O
+suggests	O
+that	O
+VV	O
+-	O
+ECMO	O
+may	O
+be	O
+an	O
+effective	O
+life	O
+support	O
+treatment	O
+for	O
+severe	O
+ARDS	B-DISO
+and	O
+should	O
+be	O
+used	O
+as	O
+early	O
+as	O
+possible	O
+when	O
+the	O
+ECMO	O
+criteria	O
+are	O
+met	B-CHED
+.	O
+
+None	O
+of	O
+them	O
+had	O
+a	O
+laboratory	O
+-	O
+confirmed	O
+MERS	O
+-	O
+CoV	O
+infection	B-DISO
+.	O
+
+More	O
+than	O
+100	O
+diferent	O
+viruses	B-SPEC
+are	O
+associated	O
+with	O
+these	O
+mammals	B-SPEC
+,	O
+particularly	O
+Rhabdoviridae	B-SPEC
+(	O
+Lyssavirus	B-SPEC
+like	O
+rabies	B-SPEC
+virus	I-SPEC
+),	O
+Paramyxoviridae	B-SPEC
+(	O
+like	O
+Nipah	O
+and	O
+Hendra	O
+viruses	B-SPEC
+),	O
+Filoviridae	B-SPEC
+(	O
+Ebola	O
+and	O
+Marburg	B-SPEC
+viruses	I-SPEC
+)	O
+and	O
+Coronavirida	O
+(	O
+viruses	B-SPEC
+causing	O
+SARS	B-DISO
+and	O
+MERS	O
+).	O
+
+For	O
+those	O
+viruses	B-SPEC
+,	O
+bats	B-SPEC
+are	O
+efficient	O
+reservoirs	O
+and	O
+disseminators	O
+.	O
+
+Besides	O
+mature	O
+ERfibs	O
+,	O
+immature	O
+Erfibs	O
+without	O
+associations	O
+with	O
+other	O
+extracellular	B-PRGE
+matrix	I-PRGE
+components	I-PRGE
+like	I-PRGE
+laminin	I-PRGE
+and	O
+collagen	B-COMP
+appeared	O
+after	O
+infection	B-DISO
+,	O
+suggesting	O
+that	O
+the	O
+CNS	B-CHED
+creates	O
+a	O
+unique	O
+conduit	O
+system	O
+for	O
+immune	O
+communication	O
+triggered	O
+by	O
+viral	O
+invasion	B-DISO
+.	O
+
+ABSTRACT	O
+:	O
+Acute	O
+lung	B-ANAT
+injury	O
+(	O
+ALI	O
+)	O
+and	O
+the	O
+more	O
+severe	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+(	O
+ARDS	B-DISO
+)	O
+are	O
+common	O
+and	O
+complex	O
+inflammatory	O
+lung	B-DISO
+diseases	I-DISO
+.	O
+
+Certain	O
+types	O
+of	O
+miRNAs	O
+are	O
+abnormally	O
+expressed	B-PROC
+in	O
+response	O
+to	O
+lung	B-ANAT
+injury	O
+.	O
+
+The	O
+results	O
+of	O
+this	O
+study	O
+showed	O
+that	O
+E	B-SPEC
+.	I-SPEC
+coli	I-SPEC
+can	O
+be	O
+used	O
+as	O
+an	O
+appropriate	O
+host	B-COMP
+to	O
+produce	O
+the	O
+recombinant	B-PRGE
+VP8	I-PRGE
+-	I-PRGE
+S2	I-PRGE
+protein	I-PRGE
+.	O
+
+This	O
+protein	B-CHED
+was	O
+expressed	B-PROC
+by	O
+induction	O
+of	O
+IPTG	B-CHED
+at	O
+concentration	O
+of	O
+1mM	O
+and	O
+it	O
+was	O
+confirmed	O
+by	O
+Ni	O
+-	O
+NTA	B-CHED
+column	B-ANAT
+,	O
+dot	O
+-	O
+blotting	O
+analysis	O
+and	O
+SDS	B-DISO
+-	O
+PAGE	O
+electrophoresis	O
+.	O
+
+CONCLUSIONS	O
+:	O
+The	O
+results	O
+of	O
+this	O
+study	O
+showed	O
+that	O
+E	B-SPEC
+.	I-SPEC
+coli	I-SPEC
+can	O
+be	O
+used	O
+as	O
+an	O
+appropriate	O
+host	B-COMP
+to	O
+produce	O
+the	O
+recombinant	B-PRGE
+VP8	I-PRGE
+-	I-PRGE
+S2	I-PRGE
+protein	I-PRGE
+.	O
+
+The	O
+respiratory	B-DISO
+failure	I-DISO
+was	O
+suspected	O
+to	O
+be	O
+caused	O
+by	O
+Pneumocystis	B-SPEC
+carinii	I-SPEC
+and	O
+cotrimoxazol	O
+therapy	O
+,	O
+oxygen	B-CHED
+therapy	O
+and	O
+anti	O
+-	O
+retroviral	B-SPEC
+therapy	O
+were	O
+established	O
+.	O
+
+The	O
+genetic	O
+information	O
+for	O
+these	O
+novel	O
+alphacoronaviruses	O
+will	O
+improve	O
+our	O
+understanding	O
+of	O
+the	O
+evolution	B-PROC
+and	O
+genetic	O
+diversity	O
+of	O
+coronaviruses	O
+,	O
+with	O
+potentially	O
+important	O
+implications	O
+for	O
+the	O
+transmission	O
+of	O
+human	B-SPEC
+diseases	O
+.	O
+
+To	O
+conduct	B-PROC
+a	O
+nationwide	O
+survey	O
+of	O
+critical	O
+care	O
+physicians	O
+in	O
+the	O
+United	O
+States	O
+regarding	O
+accepted	O
+definitions	O
+and	O
+management	O
+strategies	O
+for	O
+severe	O
+and	O
+refractory	O
+hypoxemia	O
+.	O
+
+Here	O
+,	O
+we	O
+present	O
+the	O
+crystal	B-ANAT
+structures	O
+of	O
+PEDV	B-PRGE
+3CL	I-PRGE
+(	I-PRGE
+pro	B-CHED
+)	I-PRGE
+and	O
+a	O
+molecular	O
+complex	O
+between	O
+an	O
+inactive	O
+PEDV	B-PRGE
+3CL	I-PRGE
+(	I-PRGE
+pro	B-CHED
+)	I-PRGE
+variant	I-PRGE
+C144A	I-PRGE
+bound	O
+to	O
+a	O
+peptide	B-CHED
+substrate	O
+.	O
+
+TITLE	O
+:	O
+Inverted	O
+stress	O
+-	O
+induced	O
+cardiomyopathy	B-DISO
+as	O
+a	O
+unusual	O
+variant	O
+of	O
+acute	B-DISO
+heart	I-DISO
+failure	I-DISO
+after	O
+cesarean	O
+delivery	O
+-	O
+a	O
+case	O
+report	O
+.	O
+
+Due	O
+to	O
+low	O
+blood	B-PROC
+pressure	I-PROC
+she	O
+demanded	O
+the	O
+administration	O
+of	O
+inotropic	O
+agents	O
+.	O
+
+Further	O
+research	O
+surrounding	O
+sedative	B-CHED
+requirements	O
+,	O
+clearance	O
+,	O
+and	O
+patient	O
+response	O
+during	O
+ECMO	O
+is	O
+required	O
+.	O
+
+CONCLUSIONS	O
+:	O
+Although	O
+the	O
+application	O
+of	O
+ECMO	O
+during	O
+severe	O
+ARDS	B-DISO
+resulted	O
+in	O
+a	O
+period	O
+of	O
+maximum	O
+sedation	B-DISO
+exposure	O
+that	O
+was	O
+both	O
+greater	O
+and	O
+took	O
+longer	O
+to	O
+reach	B-PROC
+,	O
+factors	O
+other	O
+than	O
+ECMO	O
+,	O
+particularly	O
+high	O
+-	O
+dose	O
+opioid	O
+administration	O
+,	O
+appeared	O
+more	O
+likely	O
+to	O
+account	O
+for	O
+this	O
+maximum	O
+sedation	B-DISO
+use	O
+.	O
+
+The	O
+effect	O
+of	O
+HFNC	O
+applied	O
+in	O
+the	O
+first	O
+imported	O
+MERS	O
+patient	O
+with	O
+complication	B-DISO
+of	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+(	O
+ARDS	B-DISO
+)	O
+to	O
+China	O
+was	O
+observed	O
+.	O
+
+Oxygen	B-CHED
+treatment	O
+was	O
+stopped	O
+on	O
+the	O
+23rd	O
+day	O
+,	O
+and	O
+SpO2	O
+was	O
+maintained	O
+at	O
+0	O
+.	O
+98	O
+-	O
+1	O
+.	O
+00	O
+.	O
+
+Each	O
+observed	O
+indicator	B-CHED
+was	O
+analyzed	O
+by	O
+univariate	O
+analysis	O
+,	O
+and	O
+factors	O
+leading	O
+to	O
+death	B-PROC
+were	O
+further	O
+analyzed	O
+by	O
+logistic	O
+regression	O
+.	O
+
+RESULTS	O
+:	O
+Compared	O
+with	O
+the	O
+survival	O
+group	O
+,	O
+the	O
+age	O
+in	O
+non	O
+-	O
+survival	O
+group	O
+was	O
+older	O
+(	O
+years	O
+old	O
+:	O
+51	O
+.	O
+50	O
+±	O
+18	O
+.	O
+31	O
+vs	O
+.	O
+45	O
+.	O
+54	O
+±	O
+14	O
+.	O
+70	O
+,	O
+t	O
+=	O
+-	O
+2	O
+.	O
+456	O
+,	O
+P	O
+=	O
+0	O
+.	O
+016	O
+);	O
+SCr	O
+was	O
+increased	O
+(	O
+µmol	O
+/	O
+L	O
+:	O
+94	O
+.	O
+18	O
+±	O
+65	O
+.	O
+51	O
+vs	O
+.	O
+72	O
+.	O
+42	O
+±	O
+28	O
+.	O
+22	O
+,	O
+t	O
+=	O
+-	O
+2	O
+.	O
+611	O
+,	O
+P	O
+=	O
+0	O
+.	O
+011	O
+);	O
+APACHE	O
+II	O
+score	O
+(	O
+24	O
+.	O
+30	O
+±	O
+6	O
+.	O
+23	O
+vs	O
+.	O
+16	O
+.	O
+38	O
+±	O
+6	O
+.	O
+19	O
+,	O
+t	O
+=	O
+-	O
+9	O
+.	O
+353	O
+,	O
+P	O
+<	O
+0	O
+.	O
+001	O
+)	O
+and	O
+SOFA	O
+score	O
+were	O
+higher	O
+(	O
+7	O
+.	O
+84	O
+±	O
+3	O
+.	O
+68	O
+vs	O
+.	O
+4	O
+.	O
+43	O
+±	O
+2	O
+.	O
+75	O
+,	O
+t	O
+=	O
+-	O
+7	O
+.	O
+049	O
+,	O
+P	O
+<	O
+0	O
+.	O
+001	O
+);	O
+and	O
+the	O
+incidence	O
+of	O
+emergency	B-DISO
+intubation	O
+[	O
+79	O
+.	O
+7	O
+%	O
+(	O
+51	O
+/	O
+64	O
+)	O
+vs	O
+.	O
+42	O
+.	O
+7	O
+%	O
+(	O
+141	O
+/	O
+330	O
+),	O
+χ²	O
+=	O
+29	O
+.	O
+309	O
+,	O
+P	O
+<	O
+0	O
+.	O
+001	O
+]	O
+and	O
+sepsis	B-DISO
+was	O
+also	O
+higher	O
+[	O
+48	O
+.	O
+4	O
+%	O
+(	O
+31	O
+/	O
+64	O
+)	O
+vs	O
+.	O
+30	O
+.	O
+3	O
+%	O
+(	O
+100	O
+/	O
+330	O
+),	O
+χ²	O
+=	O
+18	O
+.	O
+512	O
+,	O
+P	O
+<	O
+0	O
+.	O
+001	O
+],	O
+but	O
+PLT	O
+count	O
+(	O
+X	O
+10⁹	O
+/	O
+L	O
+:	O
+112	O
+.	O
+75	O
+±	O
+59	O
+.	O
+85	O
+vs	O
+.	O
+144	O
+.	O
+12	O
+±	O
+68	O
+.	O
+28	O
+,	O
+t	O
+=	O
+3	O
+.	O
+428	O
+,	O
+P	O
+=	O
+0	O
+.	O
+001	O
+)	O
+and	O
+GCS	O
+score	O
+(	O
+6	O
+.	O
+44	O
+±	O
+4	O
+.	O
+20	O
+vs	O
+.	O
+11	O
+.	O
+02	O
+±	O
+3	O
+.	O
+93	O
+,	O
+t	O
+=	O
+8	O
+.	O
+449	O
+,	O
+P	O
+<	O
+0	O
+.	O
+001	O
+)	O
+were	O
+significantly	O
+lower	O
+.	O
+
+The	O
+patients	O
+of	O
+the	O
+late	O
+group	O
+were	O
+subdivided	O
+into	O
+6	O
+-	O
+hour	O
+and	O
+24	O
+-	O
+hour	O
+reaching	B-PROC
+standard	O
+groups	O
+and	O
+non	O
+-	O
+reaching	B-PROC
+standard	O
+group	O
+according	O
+to	O
+the	O
+time	O
+of	O
+reaching	O
+standard	O
+of	O
+EGDT	O
+.	O
+
+In	O
+the	O
+late	O
+group	O
+,	O
+it	O
+was	O
+shown	O
+by	O
+single	O
+factor	O
+analysis	O
+that	O
+the	O
+age	O
+,	O
+the	O
+case	O
+history	O
+of	O
+chronic	B-DISO
+disease	I-DISO
+,	O
+infection	B-DISO
+sites	I-DISO
+,	O
+WBC	B-ANAT
+,	O
+pH	O
+value	O
+,	O
+Lac	B-PRGE
+,	O
+and	O
+ScvO₂	O
+before	O
+treatment	O
+,	O
+6	O
+-	O
+hour	O
+urine	B-ANAT
+output	O
+after	O
+treatment	O
+,	O
+the	O
+number	O
+of	O
+organ	B-ANAT
+with	O
+failure	O
+,	O
+the	O
+use	O
+of	O
+antibiotics	B-CHED
+within	O
+1	O
+hour	O
+,	O
+and	O
+incidence	O
+of	O
+AKI	O
+or	O
+ALI	O
+/	O
+ARDS	B-DISO
+within	O
+24	O
+hours	O
+were	O
+risk	O
+factors	O
+of	O
+28	O
+-	O
+day	O
+death	B-PROC
+(	O
+P	O
+<	O
+0	O
+.	O
+05	O
+or	O
+P	O
+<	O
+0	O
+.	O
+01	O
+).	O
+
+The	O
+Lac	B-CHED
+in	O
+6	O
+-	O
+hour	O
+EGDT	O
+group	O
+was	O
+lowered	O
+more	O
+significantly	O
+as	O
+compared	O
+with	O
+that	O
+in	O
+24	O
+-	O
+hour	O
+EGDT	O
+group	O
+(	O
+mmol	O
+/	O
+L	O
+:	O
+1	O
+.	O
+64	O
+±	O
+0	O
+.	O
+40	O
+vs	O
+.	O
+3	O
+.	O
+01	O
+±	O
+1	O
+.	O
+13	O
+,	O
+P	O
+<	O
+0	O
+.	O
+01	O
+),	O
+while	O
+MAP	O
+and	O
+ScvO2	O
+were	O
+increased	O
+significantly	O
+[	O
+MAP	O
+(	O
+mmHg	O
+):	O
+81	O
+.	O
+82	O
+±	O
+18	O
+.	O
+01	O
+vs	O
+.	O
+69	O
+.	O
+01	O
+±	O
+9	O
+.	O
+63	O
+;	O
+ScvO₂	O
+:	O
+0	O
+.	O
+718	O
+±	O
+0	O
+.	O
+034	O
+vs	O
+.	O
+0	O
+.	O
+658	O
+±	O
+0	O
+.	O
+036	O
+,	O
+P	O
+<	O
+0	O
+.	O
+05	O
+and	O
+P	O
+<	O
+0	O
+.	O
+01	O
+].	O
+
+TITLE	O
+:	O
+Reverse	B-PROC
+transcription	I-PROC
+-	O
+PCR	O
+assays	O
+for	O
+the	O
+differentiation	B-PROC
+of	O
+various	O
+US	O
+porcine	B-SPEC
+epidemic	B-DISO
+diarrhea	I-DISO
+virus	I-SPEC
+strains	O
+.	O
+
+ABSTRACT	O
+:	O
+Concurrently	O
+,	O
+several	O
+porcine	B-SPEC
+epidemic	I-SPEC
+diarrhea	I-SPEC
+virus	I-SPEC
+(	O
+PEDV	B-SPEC
+)	O
+variants	O
+are	O
+circulating	O
+in	O
+US	O
+swine	B-SPEC
+farms	O
+,	O
+including	O
+the	O
+original	O
+US	O
+and	O
+the	O
+spike	O
+insertion	O
+-	O
+deletion	O
+(	O
+S	O
+-	O
+INDEL	B-PROC
+)	O
+strains	O
+.	O
+
+The	O
+presence	O
+of	O
+human	B-SPEC
+herpes	B-SPEC
+simplex	I-SPEC
+virus	I-SPEC
+1	I-SPEC
+,	O
+human	B-SPEC
+cytomegalovirus	I-SPEC
+and	O
+Epstein	B-SPEC
+-	I-SPEC
+Barr	I-SPEC
+virus	I-SPEC
+in	O
+respiratory	B-ANAT
+samples	I-ANAT
+of	O
+critically	B-DISO
+ill	I-DISO
+patients	O
+is	O
+increasingly	O
+reported	O
+even	O
+without	O
+canonical	O
+immunosuppression	B-PROC
+.	O
+
+This	O
+study	O
+aims	O
+to	O
+characterize	O
+mechanically	O
+ventilated	O
+patients	O
+in	O
+the	O
+emergency	B-DISO
+department	O
+(	O
+ED	O
+),	O
+describe	O
+the	O
+initial	O
+ED	O
+ventilator	O
+settings	O
+,	O
+and	O
+assess	O
+for	O
+associations	O
+between	O
+lung	B-ANAT
+protective	O
+ventilation	O
+strategies	O
+in	O
+the	O
+ED	O
+and	O
+outcomes	O
+.	O
+
+This	O
+was	O
+a	O
+multicenter	O
+,	O
+prospective	O
+,	O
+observational	O
+study	O
+of	O
+mechanical	O
+ventilation	O
+at	O
+3	O
+academic	O
+EDs	B-DISO
+.	O
+
+The	O
+review	O
+includes	O
+verotoxin	O
+-	O
+producing	O
+Escherichia	B-SPEC
+coli	I-SPEC
+O104	O
+:	O
+H4	O
+infections	B-DISO
+,	O
+MERS	O
+-	O
+CoV	O
+infections	B-DISO
+,	O
+Ebola	B-DISO
+virus	I-DISO
+disease	I-DISO
+,	O
+malaria	B-PATH
+,	O
+dengue	B-DISO
+fever	I-DISO
+,	O
+West	B-DISO
+Nile	I-DISO
+fever	I-DISO
+,	O
+chikungunya	B-DISO
+and	O
+cholera	B-DISO
+.	O
+
+MERS	O
+-	O
+CoV	O
+can	O
+infect	O
+multiple	O
+host	B-COMP
+species	B-SPEC
+and	O
+cause	O
+severe	O
+diseases	O
+in	O
+human	B-SPEC
+.	O
+
+TITLE	O
+:	O
+Trigger	O
+factor	O
+assisted	O
+soluble	O
+expression	B-PROC
+of	O
+recombinant	B-PRGE
+spike	I-PRGE
+protein	I-PRGE
+of	O
+porcine	B-SPEC
+epidemic	B-DISO
+diarrhea	I-DISO
+virus	I-SPEC
+in	O
+Escherichia	B-SPEC
+coli	I-SPEC
+.	O
+
+Detection	O
+was	O
+enhanced	O
+more	O
+than	O
+10	O
+-	O
+fold	O
+when	O
+coupled	O
+to	O
+plaque	B-DISO
+assays	O
+and	O
+qRT	O
+-	O
+PCR	O
+.	O
+
+ABSTRACT	O
+:	O
+The	O
+cytoplasmic	B-COMP
+tails	B-ANAT
+of	O
+some	O
+coronavirus	B-SPEC
+(	O
+CoV	B-SPEC
+)	O
+spike	O
+(	O
+S	O
+)	O
+proteins	B-CHED
+contain	O
+an	O
+endoplasmic	B-COMP
+reticulum	I-COMP
+retrieval	O
+signal	O
+(	O
+ERRS	O
+)	O
+that	O
+can	O
+retrieve	O
+S	O
+proteins	B-CHED
+from	O
+the	O
+Golgi	B-COMP
+to	O
+the	O
+endoplasmic	B-COMP
+reticulum	I-COMP
+(	O
+ER	O
+);	O
+this	O
+process	O
+is	O
+thought	O
+to	O
+accumulate	O
+S	O
+proteins	B-CHED
+at	O
+the	O
+CoV	B-SPEC
+budding	B-PATH
+site	O
+,	O
+the	O
+ER	B-COMP
+-	I-COMP
+Golgi	I-COMP
+intermediate	I-COMP
+compartment	I-COMP
+(	O
+ERGIC	B-COMP
+),	O
+and	O
+to	O
+facilitate	O
+S	B-PRGE
+protein	I-PRGE
+incorporation	O
+into	O
+virions	B-COMP
+.	O
+
+These	O
+results	O
+suggest	O
+that	O
+the	O
+ERRS	O
+of	O
+SARS	B-DISO
+-	O
+CoV	O
+contributes	O
+to	O
+intracellular	B-COMP
+S	B-PRGE
+protein	I-PRGE
+accumulation	O
+specifically	O
+in	O
+the	O
+post	O
+-	O
+medial	B-ANAT
+Golgi	I-ANAT
+compartment	B-ANAT
+and	O
+to	O
+S	B-PRGE
+protein	I-PRGE
+incorporation	O
+into	O
+VLPs	B-ANAT
+.	O
+
+However	O
+,	O
+I	O
+argue	O
+that	O
+people	O
+wear	O
+a	O
+facemask	O
+not	O
+merely	O
+for	O
+infection	B-DISO
+prevention	O
+,	O
+and	O
+various	O
+sociocultural	O
+reasons	O
+have	O
+been	O
+motivating	O
+people	O
+to	O
+wear	O
+(	O
+and	O
+not	O
+wear	O
+)	O
+a	O
+facemask	O
+.	O
+
+These	O
+cases	O
+were	O
+secondary	O
+to	O
+community	O
+-	O
+acquired	O
+cases	O
+,	O
+which	O
+may	O
+also	O
+cause	O
+family	B-SPEC
+outbreaks	O
+.	O
+
+TITLE	O
+:	O
+Profound	O
+opiate	O
+toxicity	O
+in	O
+gastroparesis	B-DISO
+following	O
+therapeutic	O
+dose	O
+.	O
+
+It	O
+is	O
+associated	O
+with	O
+a	O
+number	O
+of	O
+conditions	O
+including	O
+diabetes	B-DISO
+,	O
+Parkinson	B-PATH
+'	I-PATH
+s	I-PATH
+disease	I-PATH
+,	O
+multiple	B-DISO
+sclerosis	I-DISO
+,	O
+previous	O
+abdominal	B-ANAT
+surgeries	O
+and	O
+connective	B-DISO
+tissue	I-DISO
+disorders	I-DISO
+,	O
+including	O
+scleroderma	B-DISO
+and	O
+Ehlers	B-DISO
+-	I-DISO
+Danlos	I-DISO
+syndrome	I-DISO
+.	O
+
+We	O
+report	O
+a	O
+case	O
+of	O
+a	O
+20	O
+-	O
+year	O
+-	O
+old	O
+woman	O
+with	O
+Ehlers	B-DISO
+-	I-DISO
+Danlos	I-DISO
+syndrome	I-DISO
+who	O
+developed	O
+respiratory	B-DISO
+depression	I-DISO
+after	O
+being	O
+administered	O
+a	O
+therapeutic	O
+dose	O
+of	O
+morphine	B-CHED
+.	O
+
+The	O
+patient	O
+required	O
+further	O
+support	O
+from	O
+intensive	O
+care	O
+until	O
+she	O
+recovered	O
+,	O
+and	O
+eventually	O
+underwent	O
+a	O
+gastric	B-ANAT
+pacing	O
+procedure	O
+for	O
+symptomatic	O
+relief	O
+.	O
+
+Here	O
+,	O
+we	O
+extensively	O
+review	O
+what	O
+is	O
+currently	O
+known	O
+about	O
+ZIKV	O
+,	O
+from	O
+molecular	O
+biology	O
+,	O
+transmission	O
+routes	O
+,	O
+ecology	O
+,	O
+and	O
+epidemiology	O
+,	O
+to	O
+clinical	O
+manifestations	O
+,	O
+pathogenesis	B-DISO
+,	O
+diagnosis	O
+,	O
+prophylaxis	O
+,	O
+and	O
+public	O
+health	O
+.	O
+
+Following	O
+mouse	O
+immunization	O
+and	O
+hybridoma	B-ANAT
+generation	O
+,	O
+we	O
+selected	O
+seven	O
+hybridoma	B-ANAT
+clones	O
+that	O
+produced	O
+mAbs	O
+with	O
+exclusive	O
+reactivity	O
+against	O
+MERS	O
+-	O
+CoV	O
+NP	O
+.	O
+
+After	O
+subcloning	O
+,	O
+one	O
+strain	O
+of	O
+hybridoma	B-ANAT
+cells	B-COMP
+named	O
+1B2	O
+secreting	B-PROC
+porcine	B-SPEC
+BST	O
+-	O
+2	O
+protein	B-CHED
+monoclonal	B-PRGE
+antibody	I-PRGE
+(	O
+MAb	O
+)	O
+was	O
+obtained	O
+.	O
+
+Bootstrap	O
+studies	O
+indicated	O
+that	O
+almost	O
+500	O
+patients	O
+would	O
+be	O
+needed	O
+to	O
+confirm	O
+a	O
+significant	O
+reduction	O
+in	O
+mortality	O
+from	O
+corticosteroids	B-CHED
+(	O
+type	O
+I	O
+error	O
+=	O
+0	O
+.	O
+05	O
+,	O
+power	O
+=	O
+80	O
+%).	O
+Blastomycosis	B-DISO
+is	O
+an	O
+uncommon	O
+,	O
+albeit	O
+important	O
+,	O
+cause	O
+of	O
+ARDS	B-DISO
+in	O
+this	O
+geographic	O
+area	O
+.	O
+
+All	O
+RVA	O
+isolates	O
+were	O
+confirmed	O
+by	O
+LSI	O
+VetMAX	O
+™	O
+Triplex	O
+Ruminant	B-SPEC
+Rotavirus	B-SPEC
+&	O
+Coronavirus	B-SPEC
+Real	O
+-	O
+Time	O
+PCR	O
+kit	B-FUNC
+.	O
+
+The	O
+first	O
+sign	O
+of	O
+CPE	O
+detected	O
+consisted	O
+of	O
+increased	O
+cell	B-COMP
+granularity	O
+,	O
+obscure	O
+cell	B-COMP
+boundaries	O
+,	O
+cell	B-COMP
+rounding	O
+,	O
+and	O
+eventual	O
+degeneration	B-DISO
+and	O
+detachment	B-DISO
+of	O
+cells	B-COMP
+.	O
+
+Our	O
+study	O
+constitutes	O
+a	O
+crucial	O
+and	O
+a	O
+necessary	O
+step	O
+allowing	O
+preventive	O
+and	O
+veterinary	O
+medicine	B-CHED
+to	O
+support	O
+RVA	O
+disease	O
+controls	O
+in	O
+the	O
+country	O
+.	O
+
+This	O
+review	O
+aims	O
+to	O
+provide	O
+a	O
+general	O
+overview	O
+on	O
+IB	O
+disease	O
+distribution	O
+in	O
+African	O
+countries	O
+and	O
+an	O
+update	O
+on	O
+the	O
+available	O
+studies	O
+of	O
+IBV	B-SPEC
+variants	O
+in	O
+each	O
+country	O
+.	O
+
+ABSTRACT	O
+:	O
+The	O
+immune	O
+responses	O
+in	O
+control	O
+dogs	B-SPEC
+[	O
+1	O
+to	O
+4	O
+years	O
+of	O
+age	O
+,	O
+body	B-ANAT
+condition	B-DISO
+score	O
+(	O
+BCS	O
+):	O
+4	O
+to	O
+5	O
+out	O
+of	O
+9	O
+]	O
+were	O
+compared	O
+to	O
+those	O
+of	O
+aging	B-PROC
+dogs	B-SPEC
+(	O
+based	O
+on	O
+breed	B-PROC
+and	O
+body	B-ANAT
+size	O
+)	O
+either	O
+categorized	O
+as	O
+lean	O
+(	O
+BCS	O
+:	O
+4	O
+to	O
+5	O
+out	O
+of	O
+9	O
+)	O
+or	O
+obese	B-DISO
+(	O
+BCS	O
+:	O
+8	O
+to	O
+9	O
+out	O
+of	O
+9	O
+).	O
+
+Molecular	O
+simulation	O
+study	O
+and	O
+surface	O
+plasmon	O
+resonance	O
+analysis	O
+confirmed	O
+that	O
+compound	O
+8	O
+stabilized	O
+HA2	O
+subunit	O
+of	O
+hemagglutinin	O
+(	O
+HA	O
+)	O
+by	O
+binding	B-FUNC
+with	O
+amino	B-CHED
+acid	I-CHED
+residues	O
+LYS	B-CHED
+-	O
+26	O
+,	O
+ASN	B-CHED
+-	O
+53	O
+,	O
+ASN	B-CHED
+-	O
+27	O
+and	O
+ASN	B-CHED
+-	O
+50	O
+,	O
+therefore	O
+may	O
+prevent	O
+HA	O
+from	O
+conformational	O
+rearranging	O
+,	O
+which	O
+is	O
+a	O
+critical	O
+step	O
+for	O
+viral	O
+entry	O
+.	O
+
+Diagnosis	O
+was	O
+confirmed	O
+in	O
+all	O
+patients	O
+using	O
+real	O
+-	O
+time	O
+reverse	B-PROC
+transcription	I-PROC
+polymerase	O
+chain	O
+reaction	O
+on	O
+respiratory	B-ANAT
+samples	I-ANAT
+.	O
+
+Twenty	O
+-	O
+three	O
+(	O
+74	O
+.	O
+2	O
+%)	O
+patients	O
+died	B-PROC
+in	O
+the	O
+ICU	O
+.	O
+
+In	O
+this	O
+study	O
+,	O
+we	O
+utilized	O
+viral	O
+metagenomic	O
+sequencing	O
+to	O
+explore	O
+the	O
+virome	O
+of	O
+nasal	B-ANAT
+swab	O
+samples	O
+obtained	O
+from	O
+feedlot	O
+cattle	B-SPEC
+with	O
+acute	O
+BRD	O
+and	O
+asymptomatic	O
+pen	O
+-	O
+mates	B-SPEC
+at	O
+six	O
+and	O
+four	O
+feedlots	O
+in	O
+Mexico	O
+and	O
+the	O
+USA	O
+,	O
+respectively	O
+,	O
+in	O
+April	O
+-	O
+October	O
+2015	O
+.	O
+
+Twenty	O
+-	O
+one	O
+viruses	B-SPEC
+were	O
+detected	O
+,	O
+with	O
+bovine	B-SPEC
+rhinitis	B-DISO
+A	O
+(	O
+52	O
+.	O
+7	O
+%)	O
+and	O
+B	O
+(	O
+23	O
+.	O
+7	O
+%)	O
+virus	B-SPEC
+,	O
+and	O
+bovine	B-SPEC
+coronavirus	B-SPEC
+(	O
+24	O
+.	O
+7	O
+%)	O
+being	O
+the	O
+most	O
+commonly	O
+identified	O
+.	O
+
+In	O
+contrast	O
+,	O
+all	O
+the	O
+pigs	B-SPEC
+in	O
+the	O
+other	O
+two	O
+groups	O
+showed	O
+evidence	O
+of	O
+infection	B-DISO
+.	O
+
+PEDV	B-SPEC
+RNA	O
+excretion	B-PROC
+occurred	O
+for	O
+at	O
+least	O
+2	O
+weeks	O
+.	O
+
+The	O
+aim	O
+of	O
+the	O
+current	O
+study	O
+was	O
+to	O
+assess	O
+any	O
+effect	O
+of	O
+wild	O
+and	O
+vaccine	O
+Australian	O
+infectious	B-DISO
+bronchitis	B-DISO
+virus	B-SPEC
+(	O
+IBV	B-SPEC
+)	O
+strains	O
+on	O
+shell	B-ANAT
+colour	O
+in	O
+brown	O
+-	O
+shelled	O
+eggs	O
+.	O
+
+The	O
+mean	O
+PP	O
+IX	O
+/	O
+g	O
+of	O
+shell	B-ANAT
+with	O
+and	O
+without	O
+cuticle	O
+was	O
+significantly	O
+higher	O
+on	O
+day	O
+1	O
+p	O
+.	O
+i	O
+.	O
+
+Western	O
+blot	O
+analysis	O
+with	O
+anti	O
+-	O
+Lys48	O
+and	O
+anti	B-PRGE
+-	I-PRGE
+Lys63	I-PRGE
+ubiquitin	B-PROC
+antibodies	I-PRGE
+indicated	O
+the	O
+SARS	B-DISO
+-	O
+CoV	O
+PLPro	O
+removed	O
+Lys63	B-PRGE
+-	I-PRGE
+linked	I-PRGE
+ubiquitin	I-PRGE
+chains	I-PRGE
+of	O
+TRAF3	B-PRGE
+and	O
+TRAF6	B-PRGE
+,	O
+but	O
+not	O
+Lys48	B-PRGE
+-	I-PRGE
+linked	I-PRGE
+ubiquitin	I-PRGE
+chains	I-PRGE
+in	O
+un	O
+-	O
+treated	O
+and	O
+treated	O
+cells	B-COMP
+.	O
+
+Northern	O
+blot	O
+analysis	O
+revealed	O
+at	O
+least	O
+seven	O
+distinct	O
+RNA	O
+species	B-SPEC
+,	O
+corresponding	O
+to	O
+predicted	O
+subgenomic	O
+mRNAs	O
+and	O
+confirming	O
+the	O
+core	O
+sequence	O
+of	O
+transcription	B-PROC
+regulatory	O
+sequence	O
+motifs	O
+as	O
+5	O
+'-	O
+UCUAAAC	O
+-	O
+3	O
+'	O
+as	O
+we	O
+predicted	O
+previously	O
+.	O
+
+Antibodies	B-COMP
+against	O
+DcCoV	O
+UAE	O
+-	O
+HKU23	O
+were	O
+detected	O
+in	O
+58	O
+(	O
+98	O
+.	O
+3	O
+%)	O
+and	O
+59	O
+(	O
+100	O
+%)	O
+of	O
+the	O
+59	O
+dromedary	B-SPEC
+sera	B-COMP
+by	O
+immunofluorescence	O
+and	O
+neutralization	O
+antibody	B-COMP
+tests	O
+,	O
+respectively	O
+.	O
+
+SILA	O
+is	O
+a	O
+relatively	O
+common	O
+complication	B-DISO
+of	O
+salbutamol	B-CHED
+therapy	O
+in	O
+moderate	O
+/	O
+severe	O
+asthma	B-PATH
+exacerbations	O
+.	O
+
+TITLE	O
+:	O
+Patient	O
+characteristics	O
+infected	O
+with	O
+Middle	O
+East	O
+respiratory	O
+syndrome	B-DISO
+coronavirus	B-DISO
+infection	I-DISO
+in	O
+a	O
+tertiary	O
+hospital	O
+.	O
+
+ABSTRACT	O
+:	O
+In	O
+April	O
+2014	O
+,	O
+a	O
+surge	O
+in	O
+cases	O
+of	O
+Middle	O
+East	O
+respiratory	O
+syndrome	O
+coronavirus	B-SPEC
+(	O
+MERS	O
+-	O
+CoV	O
+)	O
+infection	B-DISO
+was	O
+seen	O
+in	O
+Jeddah	O
+,	O
+Saudi	O
+Arabia	O
+.	O
+
+During	O
+infection	B-DISO
+of	O
+target	B-ANAT
+cell	I-ANAT
+,	O
+MERS	B-PRGE
+-	I-PRGE
+CoV	I-PRGE
+S	I-PRGE
+protein	I-PRGE
+S1	I-PRGE
+subunit	I-PRGE
+binds	B-FUNC
+to	O
+the	O
+cellular	B-PRGE
+receptor	I-PRGE
+(	O
+DPP4	B-PRGE
+),	O
+and	O
+its	O
+S2	O
+subunit	O
+HR1	O
+and	O
+HR2	O
+regions	O
+intact	O
+with	O
+each	O
+other	O
+to	O
+form	O
+a	O
+stable	O
+six	O
+-	O
+helix	O
+bundle	O
+to	O
+mediate	O
+the	O
+fusion	O
+between	O
+virus	B-SPEC
+and	O
+target	O
+cell	B-COMP
+membranes	I-COMP
+.	O
+
+The	O
+potential	O
+drugs	O
+against	O
+MERS	O
+-	O
+CoV	O
+mainly	O
+consist	O
+of	O
+monoclonal	O
+antibodies	B-COMP
+,	O
+peptides	B-CHED
+and	O
+small	O
+molecular	O
+agents	O
+.	O
+
+TITLE	O
+:	O
+End	B-PROC
+-	I-PROC
+Expiratory	I-PROC
+Lung	B-PROC
+Volume	I-PROC
+in	O
+Patients	O
+with	O
+Acute	B-DISO
+Respiratory	I-DISO
+Distress	I-DISO
+Syndrome	I-DISO
+:	O
+A	O
+Time	O
+Course	O
+Analysis	O
+.	O
+
+ABSTRACT	O
+:	O
+Lung	O
+injury	O
+can	O
+be	O
+caused	O
+by	O
+ventilation	O
+and	O
+non	O
+-	O
+physiological	O
+lung	B-ANAT
+stress	O
+(	O
+transpulmonary	O
+pressure	O
+)	O
+and	O
+strain	O
+[	O
+inflated	O
+volume	O
+over	O
+functional	B-PROC
+residual	I-PROC
+capacity	I-PROC
+ratio	O
+(	O
+FRC	B-PROC
+)].	O
+
+EELV	O
+did	O
+not	O
+change	O
+significantly	O
+for	O
+up	O
+to	O
+7	O
+days	O
+in	O
+patients	O
+with	O
+ARDS	B-DISO
+.	O
+
+Bedside	O
+measurement	O
+of	O
+EELV	O
+may	O
+be	O
+a	O
+novel	O
+approach	O
+to	O
+individualise	O
+lung	B-ANAT
+-	O
+protective	O
+ventilation	O
+on	O
+the	O
+basis	O
+of	O
+calculation	O
+of	O
+dynamic	O
+strain	O
+as	O
+the	O
+ratio	O
+of	O
+VT	O
+to	O
+EELV	O
+.	O
+
+None	O
+of	O
+them	O
+had	O
+a	O
+history	O
+of	O
+travel	O
+,	O
+contact	O
+with	O
+animals	B-SPEC
+,	O
+or	O
+consumption	O
+of	O
+camel	B-SPEC
+milk	O
+products	O
+,	O
+however	O
+,	O
+all	O
+of	O
+the	O
+patients	O
+had	O
+contact	O
+with	O
+a	O
+person	O
+who	O
+had	O
+been	O
+in	O
+Saudi	O
+-	O
+Arabia	O
+and	O
+experienced	O
+respiratory	B-DISO
+infection	I-DISO
+.	O
+
+The	O
+rapid	O
+control	O
+of	O
+an	O
+outbreak	O
+is	O
+important	O
+for	O
+reducing	O
+the	O
+financial	O
+losses	O
+arising	O
+from	O
+PED	O
+infections	B-DISO
+.	O
+
+Bats	B-SPEC
+harbor	O
+genetically	O
+diverse	O
+SARS	B-DISO
+-	O
+like	O
+coronaviruses	O
+(	O
+SL	O
+-	O
+CoVs	O
+),	O
+and	O
+some	O
+of	O
+them	O
+have	O
+the	O
+potential	O
+for	O
+interspecies	O
+transmission	O
+.	O
+
+In	O
+this	O
+study	O
+,	O
+we	O
+show	O
+that	O
+a	O
+ronivirus	O
+,	O
+gill	B-SPEC
+-	I-SPEC
+associated	I-SPEC
+virus	I-SPEC
+(	O
+GAV	O
+),	O
+encodes	O
+the	O
+2	B-PRGE
+'-	I-PRGE
+O	I-PRGE
+-	I-PRGE
+MTase	I-PRGE
+activity	O
+,	O
+although	O
+we	O
+could	O
+not	O
+detect	O
+2	B-PRGE
+'-	I-PRGE
+O	I-PRGE
+-	I-PRGE
+MTase	I-PRGE
+activity	O
+for	O
+the	O
+homologous	O
+protein	B-CHED
+of	O
+a	O
+torovirus	B-SPEC
+,	O
+equine	B-SPEC
+torovirus	I-SPEC
+,	O
+which	O
+is	O
+more	O
+closely	O
+related	O
+to	O
+coronaviruses	O
+.	O
+
+TITLE	O
+:	O
+The	O
+Role	O
+of	O
+Human	B-SPEC
+Coronaviruses	O
+in	O
+Children	O
+Hospitalized	O
+for	O
+Acute	B-DISO
+Bronchiolitis	I-DISO
+,	O
+Acute	B-DISO
+Gastroenteritis	I-DISO
+,	O
+and	O
+Febrile	B-DISO
+Seizures	I-DISO
+:	O
+A	O
+2	O
+-	O
+Year	O
+Prospective	O
+Study	O
+.	O
+
+It	O
+seems	O
+that	O
+an	O
+etiological	O
+role	O
+of	O
+HCoVs	O
+is	O
+most	O
+likely	O
+in	O
+children	O
+with	O
+FS	O
+,	O
+considering	O
+that	O
+they	O
+had	O
+a	O
+higher	O
+proportion	O
+of	O
+positive	O
+HCoVs	O
+results	O
+than	O
+patients	O
+with	O
+AB	O
+and	O
+those	O
+with	O
+AGE	O
+,	O
+and	O
+had	O
+the	O
+highest	O
+viral	O
+load	O
+;	O
+however	O
+,	O
+the	O
+co	O
+-	O
+detection	O
+of	O
+other	O
+viruses	B-SPEC
+was	O
+52	O
+.	O
+6	O
+%.	O
+
+According	O
+to	O
+the	O
+number	O
+of	O
+organ	B-ANAT
+failures	O
+,	O
+ACLF	O
+is	O
+graded	O
+into	O
+three	O
+stages	O
+:	O
+ACLF	O
+-	O
+1	O
+=	O
+single	O
+renal	B-DISO
+failure	I-DISO
+or	O
+single	O
+nonrenal	O
+organ	B-DISO
+failure	I-DISO
+if	O
+associated	O
+with	O
+renal	B-ANAT
+dysfunction	O
+and	O
+/	O
+or	O
+cerebral	B-ANAT
+dysfunction	I-DISO
+;	O
+ACLF	O
+-	O
+2	O
+=	O
+two	O
+organ	O
+failures	O
+;	O
+and	O
+ACLF	O
+-	O
+3	O
+=	O
+three	O
+to	O
+six	O
+organ	B-ANAT
+failures	O
+,	O
+with	O
+increasing	O
+28	O
+-	O
+day	O
+mortality	O
+rate	O
+(	O
+from	O
+23	O
+%-	O
+74	O
+%).	O
+
+TITLE	O
+:	O
+SARS	B-PRGE
+coronavirus	B-SPEC
+papain	B-PRGE
+-	I-PRGE
+like	I-PRGE
+protease	I-PRGE
+induces	O
+Egr	B-PRGE
+-	I-PRGE
+1	I-PRGE
+-	O
+dependent	O
+up	B-PROC
+-	I-PROC
+regulation	I-PROC
+of	O
+TGF	O
+-	O
+β1	O
+via	O
+ROS	B-CHED
+/	O
+p38	B-FUNC
+MAPK	B-FUNC
+/	O
+STAT3	B-PRGE
+pathway	B-PROC
+.	O
+
+Analysis	O
+of	O
+the	O
+PEDV	B-PRGE
+3CL	I-PRGE
+(	I-PRGE
+pro	B-CHED
+)	I-PRGE
+structure	O
+and	O
+comparison	O
+to	O
+other	O
+coronaviral	O
+3CL	O
+(	O
+pro	B-CHED
+)'	O
+s	O
+from	O
+the	O
+same	O
+alpha	O
+-	O
+coronavirus	B-SPEC
+phylogeny	O
+shows	O
+that	O
+the	O
+overall	O
+structures	O
+and	O
+active	O
+site	O
+architectures	O
+across	O
+3CL	O
+(	O
+pro	B-CHED
+)'	O
+s	O
+are	O
+conserved	O
+,	O
+with	O
+the	O
+exception	O
+of	O
+a	O
+loop	O
+that	O
+comprises	O
+the	O
+protease	O
+S2	O
+pocket	O
+.	O
+
+Structural	O
+comparison	O
+reveals	O
+that	O
+the	O
+majority	O
+of	O
+residues	O
+involved	O
+in	O
+(	O
+R	O
+)-	O
+16	O
+binding	B-FUNC
+to	O
+SARS	B-PRGE
+-	I-PRGE
+3CL	I-PRGE
+(	O
+pro	B-PRGE
+)	O
+are	O
+conserved	O
+in	O
+PEDV	B-SPEC
+-	O
+3CL	O
+(	O
+pro	B-CHED
+);	O
+however	O
+,	O
+the	O
+sequence	O
+variation	O
+and	O
+positional	O
+difference	O
+in	O
+the	O
+loop	O
+forming	O
+the	O
+S2	O
+pocket	O
+may	O
+account	O
+for	O
+large	O
+observed	O
+difference	O
+in	O
+IC50	O
+values	O
+.	O
+
+TITLE	O
+:	O
+Some	O
+serum	B-COMP
+acute	O
+phase	O
+proteins	B-CHED
+and	O
+immunoglobulins	O
+concentrations	O
+in	O
+calves	O
+with	O
+rotavirus	B-SPEC
+,	O
+coronavirus	O
+,	O
+E	B-SPEC
+.	I-SPEC
+coli	I-SPEC
+F5	O
+and	O
+Eimeria	B-SPEC
+species	B-SPEC
+.	O
+
+SAA	O
+and	O
+Hp	O
+levels	O
+of	O
+the	O
+group	B-DISO
+B	I-DISO
+and	O
+group	O
+P	O
+were	O
+significantly	O
+higher	O
+than	O
+the	O
+group	O
+V	O
+(	O
+P	O
+<	O
+0	O
+.	O
+05	O
+).	O
+
+The	O
+mechanisms	O
+by	O
+which	O
+four	O
+typical	O
+anti	O
+-	O
+inflammatory	O
+ingredients	O
+from	O
+QF	O
+,	O
+arctigenin	O
+(	O
+ATG	O
+),	O
+cholic	B-CHED
+acid	I-CHED
+(	O
+CLA	B-CHED
+),	O
+chlorogenic	B-CHED
+acid	I-CHED
+(	O
+CGA	O
+)	O
+and	O
+sinapic	B-CHED
+acid	I-CHED
+(	O
+SPA	O
+),	O
+regulate	O
+anti	O
+-	O
+inflammatory	O
+signaling	B-PROC
+pathways	B-PROC
+and	O
+related	O
+targets	O
+were	O
+investigated	O
+using	O
+molecular	O
+biology	O
+and	O
+molecular	O
+docking	B-PROC
+techniques	O
+.	O
+
+TITLE	O
+:	O
+[	O
+Plasmodium	B-SPEC
+falciparum	I-SPEC
+malaria	B-PATH
+:	O
+evaluation	O
+of	O
+three	O
+imported	O
+cases	O
+].	O
+
+Parasitological	O
+examination	O
+of	O
+the	O
+Giemsa	O
+-	O
+stained	O
+peripheral	B-ANAT
+blood	I-ANAT
+smear	O
+of	O
+these	O
+two	O
+patients	O
+demonstrated	O
+ring	O
+forms	O
+compatible	O
+with	O
+P	B-DISO
+.	I-DISO
+falciparum	I-DISO
+.	O
+
+In	O
+conclusion	O
+,	O
+the	O
+present	O
+study	O
+provided	O
+a	O
+novel	O
+treatment	O
+strategy	O
+for	O
+ARDS	B-DISO
+by	O
+modulating	O
+the	O
+balance	B-PROC
+of	O
+Treg	O
+/	O
+Th17	O
+and	O
+the	O
+subsequent	O
+immune	B-PROC
+response	I-PROC
+via	O
+cAMP	B-PROC
+signaling	I-PROC
+,	O
+which	O
+requires	O
+pre	O
+-	O
+clinical	O
+and	O
+clinical	O
+validation	O
+.	O
+
+There	O
+are	O
+five	O
+scoping	O
+reviews	O
+,	O
+a	O
+commentary	O
+,	O
+a	O
+letter	O
+to	O
+the	O
+editor	O
+,	O
+an	O
+opinion	O
+piece	O
+and	O
+an	O
+editorial	O
+pertaining	O
+to	O
+the	O
+theme	O
+""""	O
+Elimination	B-PROC
+of	O
+tropical	B-DISO
+disease	I-DISO
+through	O
+surveillance	O
+and	O
+response	O
+"""."	O
+
+The	O
+present	O
+study	O
+reports	O
+the	O
+development	B-PROC
+and	O
+validation	O
+of	O
+specific	O
+RT	O
+-	O
+qPCR	O
+assays	O
+for	O
+the	O
+detection	O
+of	O
+two	O
+major	O
+IBV	B-SPEC
+genotypes	O
+:	O
+South	O
+America	O
+I	O
+(	O
+SAI	O
+)	O
+and	O
+Asia	O
+/	O
+South	O
+America	O
+II	O
+(	O
+A	O
+/	O
+SAII	O
+).	O
+
+Finally	O
+,	O
+we	O
+demonstrate	O
+that	O
+this	O
+preference	O
+for	O
+C	O
+-	O
+terminal	O
+proline	O
+residues	O
+was	O
+observed	O
+in	O
+Hendra	B-SPEC
+virus	I-SPEC
+-	O
+derived	O
+peptides	B-CHED
+presented	O
+by	O
+Ptal	B-ENZY
+-	O
+N	O
+*	O
+01	O
+:	O
+01	O
+on	O
+the	O
+surface	O
+of	O
+infected	O
+cells	B-COMP
+.	O
+
+Six	O
+-	O
+day	O
+-	O
+old	O
+piglets	O
+born	O
+to	O
+vaccinated	O
+or	O
+unvaccinated	O
+sows	O
+were	O
+challenged	O
+with	O
+the	O
+homogeneous	O
+KNU	O
+-	O
+141112	O
+virus	B-SPEC
+.	O
+
+TITLE	O
+:	O
+Mortality	O
+predictors	O
+in	O
+recipients	O
+developing	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+due	O
+to	O
+pneumonia	B-DISO
+after	O
+kidney	B-ANAT
+transplantation	O
+.	O
+
+The	O
+most	O
+common	O
+ARDS	B-DISO
+was	O
+diagnosed	O
+within	O
+6	O
+months	O
+after	O
+transplantation	O
+(	O
+76	O
+/	O
+94	O
+;	O
+80	O
+.	O
+9	O
+%).	O
+
+There	O
+were	O
+39	O
+deaths	B-PROC
+in	O
+these	O
+recipients	O
+(	O
+39	O
+/	O
+94	O
+;	O
+41	O
+.	O
+5	O
+%).	O
+
+Infection	B-DISO
+-	O
+related	O
+mortality	O
+in	O
+kidney	B-ANAT
+transplant	I-ANAT
+patients	O
+with	O
+ARDS	B-DISO
+was	O
+associated	O
+with	O
+high	O
+serum	B-COMP
+creatinine	B-CHED
+level	O
+and	O
+severe	O
+ARDS	B-DISO
+.	O
+
+How	O
+the	O
+switch	B-PRGE
+in	I-PRGE
+esterase	I-PRGE
+substrate	O
+specificity	O
+was	O
+realized	O
+remained	O
+unresolved	O
+,	O
+however	O
+.	O
+
+After	O
+excluding	O
+88	O
+patients	O
+(	O
+40	O
+with	O
+AE	O
+-	O
+COPD	B-DISO
+and	O
+48	O
+with	O
+CP	O
+-	O
+COPD	B-DISO
+)	O
+who	O
+did	O
+not	O
+undergo	O
+a	O
+multiplex	O
+RT	O
+-	O
+PCR	O
+test	O
+for	O
+respiratory	O
+viruses	B-SPEC
+,	O
+the	O
+demographic	O
+characteristics	O
+,	O
+identified	O
+viruses	B-SPEC
+,	O
+and	O
+clinical	O
+outcomes	O
+of	O
+the	O
+AE	O
+-	O
+COPD	B-DISO
+and	O
+CP	O
+-	O
+COPD	B-DISO
+groups	O
+were	O
+compared	O
+.	O
+
+The	O
+most	O
+common	O
+virus	B-SPEC
+was	O
+influenza	B-SPEC
+virus	I-SPEC
+in	O
+the	O
+AE	O
+-	O
+COPD	B-DISO
+group	O
+(	O
+33	O
+.	O
+7	O
+%)	O
+versus	O
+human	B-SPEC
+coronavirus	I-SPEC
+(	O
+24	O
+.	O
+1	O
+%)	O
+in	O
+the	O
+CP	O
+-	O
+COPD	B-DISO
+group	O
+.	O
+
+Here	O
+we	O
+discuss	O
+the	O
+properties	O
+of	O
+current	O
+PEDV	B-SPEC
+diagnostic	O
+assays	O
+and	O
+prospects	O
+for	O
+improving	O
+diagnostic	O
+strategies	O
+in	O
+the	O
+future	O
+.	O
+
+TITLE	O
+:	O
+Relationship	O
+between	O
+different	O
+enteric	O
+viral	B-DISO
+infections	I-DISO
+and	O
+the	O
+occurrence	O
+of	O
+diarrhea	B-DISO
+in	O
+broiler	O
+flocks	O
+in	O
+Jordan	O
+.	O
+
+Patients	O
+with	O
+diabetes	B-DISO
+mellitus	I-DISO
+(	O
+to	O
+minimize	O
+the	O
+overlap	O
+between	O
+acute	B-DISO
+stress	I-DISO
+hyperglycaemia	B-DISO
+and	O
+diabetic	O
+hyperglycaemia	B-DISO
+)	O
+were	O
+excluded	O
+.	O
+
+About	O
+34	O
+(	O
+40	O
+%)	O
+of	O
+patients	O
+were	O
+admitted	O
+with	O
+hyperglycaemia	B-DISO
+(	O
+RBS	B-DISO
+≥	O
+200	O
+mg	O
+/	O
+dl	O
+)	O
+over	O
+the	O
+study	O
+period	O
+.	O
+
+It	O
+can	O
+be	O
+a	O
+predictive	O
+factor	O
+for	O
+mortality	O
+rate	O
+,	O
+ICU	O
+stay	O
+,	O
+GCS	O
+arrival	O
+,	O
+VAP	O
+&	O
+RDS	O
+,	O
+hospital	O
+stay	O
+and	O
+ISS	B-DISO
+.	O
+
+CONCLUSIONS	O
+:	O
+Hyperglycaemia	B-DISO
+after	O
+severe	O
+TBI	O
+(	O
+RBS	B-DISO
+≥	O
+200	O
+)	O
+is	O
+associated	O
+with	O
+poor	O
+outcome	O
+.	O
+
+TITLE	O
+:	O
+Middle	O
+East	O
+Respiratory	O
+Syndrome	B-DISO
+Coronavirus	B-SPEC
+Transmission	O
+in	O
+Extended	O
+Family	B-SPEC
+,	O
+Saudi	O
+Arabia	O
+,	O
+2014	O
+.	O
+
+ABSTRACT	O
+:	O
+Preclinical	O
+development	O
+of	O
+and	O
+research	O
+on	O
+potential	O
+Middle	O
+East	O
+respiratory	O
+syndrome	B-DISO
+coronavirus	B-SPEC
+(	O
+MERS	O
+-	O
+CoV	O
+)	O
+medical	O
+countermeasures	O
+remain	O
+preliminary	O
+;	O
+advancements	O
+are	O
+needed	O
+before	O
+most	O
+countermeasures	O
+are	O
+ready	O
+to	O
+be	O
+tested	O
+in	O
+human	B-SPEC
+clinical	O
+trials	O
+.	O
+
+TITLE	O
+:	O
+Receptor	O
+Interacting	O
+Protein	B-CHED
+3	O
+-	O
+Mediated	O
+Necroptosis	B-DISO
+Promotes	O
+Lipopolysaccharide	B-CHED
+-	O
+Induced	O
+Inflammation	B-DISO
+and	O
+Acute	B-DISO
+Respiratory	I-DISO
+Distress	I-DISO
+Syndrome	I-DISO
+in	O
+Mice	B-SPEC
+.	O
+
+ABSTRACT	O
+:	O
+Necrosis	B-PROC
+amplifies	O
+inflammation	B-DISO
+and	O
+plays	O
+important	O
+roles	O
+in	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+(	O
+ARDS	B-DISO
+).	O
+
+Necroptosis	B-DISO
+is	O
+a	O
+newly	O
+identified	O
+programmed	O
+necrosis	B-PROC
+that	O
+is	O
+mediated	O
+by	O
+receptor	B-PRGE
+interacting	I-PRGE
+protein	I-PRGE
+3	I-PRGE
+(	O
+RIP3	B-PRGE
+).	O
+
+Results	O
+showed	O
+that	O
+in	O
+high	O
+dose	O
+LPS	B-DISO
+(	O
+30mg	O
+/	O
+kg	O
+and	O
+40mg	O
+/	O
+kg	O
+)	O
+-	O
+induced	O
+severe	O
+ARDS	B-DISO
+,	O
+RIP3	B-PRGE
+protein	I-PRGE
+was	O
+increased	O
+significantly	O
+,	O
+accompanied	O
+by	O
+increases	O
+of	O
+p	O
+-	O
+RIP3	B-PRGE
+and	O
+MLKL	B-PRGE
+,	O
+while	O
+in	O
+low	O
+dose	O
+LPS	B-DISO
+(	O
+10mg	O
+/	O
+kg	O
+and	O
+20mg	O
+/	O
+kg	O
+)	O
+-	O
+induced	O
+mild	O
+ARDS	B-DISO
+,	O
+apoptosis	B-PATH
+was	O
+remarkably	O
+increased	O
+.	O
+
+It	O
+is	O
+concluded	O
+that	O
+RIP3	B-PRGE
+-	O
+mediated	O
+necroptosis	B-DISO
+is	O
+a	O
+major	O
+mechanism	O
+of	O
+enhanced	O
+inflammation	B-DISO
+and	O
+lung	B-ANAT
+tissue	I-ANAT
+injury	O
+in	O
+high	O
+dose	O
+LPS	B-DISO
+-	O
+induced	O
+severe	O
+ARDS	B-DISO
+in	O
+mice	B-SPEC
+.	O
+
+Three	O
+patients	O
+infected	O
+with	O
+HCoV	O
+(	O
+9	O
+%)	O
+died	B-PROC
+from	O
+respiratory	B-DISO
+infection	I-DISO
+.	O
+
+Detected	O
+antibody	B-COMP
+prevalence	O
+was	O
+90	O
+%	O
+for	O
+CAV	B-SPEC
+,	O
+28	O
+%	O
+for	O
+CCV	B-DISO
+,	O
+12	O
+%	O
+for	O
+CDV	B-CHED
+,	O
+93	O
+%	O
+for	O
+CHV	O
+,	O
+0	O
+%	O
+for	O
+CPI	B-DISO
+,	O
+20	O
+%	O
+for	O
+CPV	B-SPEC
+,	O
+0	O
+%	O
+for	O
+N	B-SPEC
+.	I-SPEC
+caninum	I-SPEC
+,	O
+and	O
+86	O
+%	O
+for	O
+T	B-SPEC
+.	I-SPEC
+gondii	I-SPEC
+.	O
+
+The	O
+following	O
+day	O
+,	O
+the	O
+patient	O
+developed	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+(	O
+ARDS	B-DISO
+)	O
+and	O
+was	O
+put	O
+on	O
+a	O
+respirator	O
+.	O
+
+Japanese	B-DISO
+spotted	I-DISO
+fever	I-DISO
+is	O
+noted	O
+to	O
+occur	O
+in	O
+any	O
+place	O
+other	O
+than	O
+Kobe	O
+City	O
+.	O
+
+ABSTRACT	O
+:	O
+γ	O
+-	O
+Hydroxybutyrate	O
+(	O
+GHB	B-CHED
+)	O
+is	O
+a	O
+common	O
+drug	O
+of	O
+abuse	B-DISO
+and	O
+poses	O
+important	O
+health	O
+risks	O
+to	O
+users	O
+in	O
+the	O
+form	O
+of	O
+respiratory	O
+,	O
+cardiovascular	B-ANAT
+,	O
+mental	O
+,	O
+or	O
+traumatic	O
+adverse	O
+events	O
+.	O
+
+After	O
+acute	O
+treatment	O
+has	O
+passed	O
+,	O
+withdrawal	B-DISO
+could	O
+be	O
+severe	O
+in	O
+chronic	O
+abusers	O
+that	O
+could	O
+harm	O
+the	O
+patient	O
+directly	O
+or	O
+drive	O
+them	O
+back	O
+into	O
+reuse	O
+.	O
+
+TITLE	O
+:	O
+A	O
+Case	O
+of	O
+Acute	O
+Motor	O
+Axonal	B-DISO
+Neuropathy	I-DISO
+Mimicking	O
+Brain	B-DISO
+Death	B-PROC
+and	O
+Review	O
+of	O
+the	O
+Literature	O
+.	O
+
+ABSTRACT	O
+:	O
+We	O
+describe	O
+a	O
+case	O
+report	O
+of	O
+fulminant	O
+Guillain	O
+-	O
+Barré	O
+syndrome	O
+(	O
+GBS	B-DISO
+)	O
+mimicking	O
+brain	B-DISO
+death	B-PROC
+.	O
+
+A	O
+previously	O
+healthy	O
+60	O
+-	O
+year	O
+-	O
+old	O
+male	O
+was	O
+admitted	O
+to	O
+the	O
+neurointensive	O
+care	O
+unit	O
+after	O
+developing	O
+rapidly	O
+progressive	O
+weakness	B-DISO
+and	O
+respiratory	B-DISO
+failure	I-DISO
+.	O
+
+Transcranial	O
+Doppler	O
+(	O
+TCD	B-DISO
+)	O
+ultrasound	O
+showed	O
+appropriate	O
+blood	B-PROC
+flow	I-PROC
+to	O
+the	O
+brain	B-ANAT
+.	O
+
+Determinants	O
+revealed	O
+for	O
+polyUb	O
+(	O
+Lys48	O
+)	O
+specificity	O
+should	O
+prove	O
+useful	O
+in	O
+understanding	O
+PLpro	O
+deubiquitinating	O
+activities	O
+in	O
+coronavirus	B-DISO
+infections	I-DISO
+.	O
+
+Additionally	O
+,	O
+it	O
+might	O
+improve	O
+the	O
+delivery	O
+of	O
+aerosolised	O
+bronchodilators	O
+in	O
+obstructive	B-DISO
+lung	I-DISO
+disease	I-DISO
+in	O
+general	O
+.	O
+
+TITLE	O
+:	O
+Pulmonary	B-ANAT
+Vascular	B-ANAT
+Dysfunction	O
+and	O
+Cor	B-DISO
+Pulmonale	I-DISO
+During	O
+Acute	B-DISO
+Respiratory	I-DISO
+Distress	I-DISO
+Syndrome	I-DISO
+in	O
+Sicklers	O
+.	O
+
+These	O
+results	O
+suggest	O
+a	O
+predominant	O
+role	O
+for	O
+PVD	B-DISO
+in	O
+the	O
+pathogenesis	B-DISO
+of	O
+severe	O
+forms	O
+of	O
+ACS	B-FUNC
+.	O
+
+TITLE	O
+:	O
+Extracorporeal	O
+circuit	O
+for	O
+Panton	O
+-	O
+Valentine	O
+leukocidin	O
+-	O
+producing	O
+Staphylococcus	B-SPEC
+aureus	I-SPEC
+necrotizing	B-DISO
+pneumonia	I-DISO
+.	O
+
+PVL	O
+-	O
+SA	O
+pneumonia	B-DISO
+is	O
+characterized	O
+by	O
+extensive	O
+parenchymal	O
+injuries	O
+,	O
+including	O
+necrotic	B-PROC
+and	O
+hemorrhagic	O
+complications	O
+.	O
+
+These	O
+viruses	B-SPEC
+infect	O
+epithelial	B-ANAT
+cells	I-ANAT
+of	O
+the	O
+small	B-ANAT
+intestine	I-ANAT
+and	O
+cause	O
+watery	B-DISO
+diarrhea	I-DISO
+,	O
+dehydration	B-DISO
+,	O
+and	O
+a	O
+high	O
+mortality	O
+in	O
+neonatal	O
+piglets	O
+.	O
+
+Type	O
+I	O
+interferons	O
+(	O
+IFN	B-PRGE
+-	I-PRGE
+α	I-PRGE
+/	I-PRGE
+β	I-PRGE
+)	O
+are	O
+major	O
+antiviral	B-CHED
+cytokines	O
+forming	O
+host	B-COMP
+innate	B-PROC
+immunity	I-PROC
+,	O
+and	O
+in	O
+turn	O
+,	O
+these	O
+enteric	O
+coronaviruses	O
+have	O
+evolved	O
+to	O
+modulate	O
+the	O
+host	B-COMP
+innate	O
+immune	O
+signaling	B-PROC
+during	O
+infection	B-DISO
+.	O
+
+ABSTRACT	O
+:	O
+Emergence	O
+of	O
+the	O
+porcine	O
+epidemic	O
+diarrhea	O
+virus	O
+(	O
+PEDV	B-SPEC
+)	O
+as	O
+a	O
+global	O
+threat	O
+to	O
+the	O
+swine	B-SPEC
+industry	O
+underlies	O
+the	O
+urgent	O
+need	O
+for	O
+deeper	O
+understanding	O
+of	O
+this	O
+virus	B-SPEC
+.	O
+
+A	O
+major	O
+reason	O
+is	O
+the	O
+lack	O
+of	O
+genetic	O
+tools	O
+for	O
+studying	O
+PEDV	B-SPEC
+.	O
+
+Our	O
+results	O
+showed	O
+that	O
+PEDV	B-SPEC
+activates	O
+p38	B-FUNC
+MAPK	B-FUNC
+and	O
+JNK1	B-PRGE
+/	O
+2	O
+up	O
+to	O
+24h	O
+post	O
+-	O
+infection	B-DISO
+,	O
+whereas	O
+,	O
+thereafter	O
+their	O
+phosphorylation	B-PROC
+levels	O
+recede	O
+to	O
+baseline	O
+levels	O
+or	O
+even	O
+fall	O
+below	O
+them	O
+.	O
+
+However	O
+,	O
+independent	O
+treatments	O
+with	O
+either	O
+SAPK	B-FUNC
+inhibitor	B-CHED
+did	O
+not	O
+inhibit	O
+PEDV	B-SPEC
+-	O
+induced	O
+apoptotic	B-PROC
+cell	I-PROC
+death	I-PROC
+mediated	O
+by	O
+activation	O
+of	O
+mitochondrial	B-PRGE
+apoptosis	B-PATH
+-	I-PRGE
+inducing	I-PRGE
+factor	I-PRGE
+(	O
+AIF	B-PRGE
+)	O
+suggesting	O
+that	O
+SAPKs	O
+are	O
+irrelevant	O
+to	O
+the	O
+apoptosis	B-PROC
+pathway	B-PROC
+during	O
+PEDV	B-SPEC
+infection	B-DISO
+.	O
+
+We	O
+developed	O
+an	O
+enzyme	O
+-	O
+linked	O
+immunosorbent	O
+assay	O
+(	O
+ELISA	O
+)	O
+targeting	B-PROC
+antibodies	B-COMP
+to	O
+the	O
+spike	O
+(	O
+S	O
+)	O
+protein	B-CHED
+of	O
+EqCoV	O
+and	O
+validated	O
+its	O
+use	O
+,	O
+using	O
+acute	O
+and	O
+convalescent	O
+sera	B-COMP
+from	O
+83	O
+adult	O
+horses	B-SPEC
+involved	O
+in	O
+6	O
+outbreaks	O
+.	O
+
+The	O
+EqCoV	B-PRGE
+S	I-PRGE
+protein	I-PRGE
+-	O
+based	O
+ELISA	O
+was	O
+able	O
+to	O
+reliably	O
+detect	O
+antibodies	B-COMP
+to	O
+EqCoV	O
+in	O
+naturally	O
+infected	O
+horses	B-SPEC
+.	O
+
+The	O
+findings	O
+of	O
+this	O
+study	O
+suggest	O
+that	O
+during	O
+the	O
+Middle	O
+East	O
+respiratory	O
+syndrome	O
+-	O
+coronavirus	B-SPEC
+outbreak	O
+,	O
+emergency	B-DISO
+nurses	O
+experienced	O
+ethical	O
+problems	O
+tied	O
+to	O
+a	O
+mind	O
+-	O
+set	O
+of	O
+avoiding	O
+patients	O
+.	O
+
+Three	O
+factors	O
+were	O
+found	O
+to	O
+influence	O
+emergency	B-DISO
+nurses	O
+'	O
+ethical	O
+problems	O
+(	O
+in	O
+order	B-SPEC
+of	O
+influence	O
+):	O
+cognition	B-PROC
+of	O
+social	O
+stigmatization	O
+,	O
+level	O
+of	O
+agreement	O
+with	O
+infection	B-DISO
+control	O
+measures	O
+,	O
+and	O
+perceived	O
+risk	O
+.	O
+
+CONCLUSIONS	O
+:	O
+Through	O
+this	O
+study	O
+,	O
+we	O
+obtained	O
+information	O
+on	O
+emergency	B-DISO
+nurses	O
+'	O
+ethical	O
+problems	O
+during	O
+the	O
+Middle	O
+East	O
+respiratory	O
+syndrome	B-DISO
+-	O
+coronavirus	B-SPEC
+outbreak	O
+and	O
+identified	O
+the	O
+factors	O
+that	O
+influence	O
+them	O
+.	O
+
+In	O
+contrast	O
+to	O
+ORF1ab	O
+and	O
+structural	O
+proteins	B-CHED
+,	O
+the	O
+putative	O
+proteins	B-CHED
+encoded	O
+by	O
+ORF3	O
+,	O
+ORF4a	O
+,	O
+ORF4b	O
+,	O
+ORF5	O
+and	O
+ORF8b	O
+in	O
+the	O
+MERS	O
+-	O
+CoV	O
+genome	O
+do	O
+not	O
+share	O
+homology	O
+with	O
+any	O
+known	O
+host	B-COMP
+or	O
+virus	B-SPEC
+protein	B-CHED
+,	O
+other	O
+than	O
+those	O
+of	O
+its	O
+closely	O
+related	O
+lineage	O
+C	O
+ßCoVs	O
+.	O
+
+TITLE	O
+:	O
+Corrigendum	O
+to	O
+""""	O
+Middle	O
+East	O
+Respiratory	O
+Syndrome	B-DISO
+Coronavirus	B-SPEC
+Outbreak	O
+in	O
+the	O
+Republic	O
+of	O
+Korea	O
+,	O
+2015	O
+""""	O
+[	O
+Volume	O
+6	O
+,	O
+Issue	O
+4	O
+,	O
+August	O
+2015	O
+,	O
+269	O
+-	O
+278	O
+].	O
+
+We	O
+aimed	O
+to	O
+assess	O
+the	O
+effectiveness	O
+of	O
+infection	B-DISO
+control	O
+measures	O
+among	O
+healthcare	O
+workers	O
+(	O
+HCWs	O
+)	O
+who	O
+were	O
+exposed	O
+to	O
+a	O
+MERS	O
+patient	O
+and	O
+/	O
+or	O
+his	O
+body	B-ANAT
+fluids	I-ANAT
+in	O
+our	O
+institute	O
+.	O
+
+The	O
+median	O
+(	O
+IQR	O
+)	O
+cumulative	O
+duration	O
+of	O
+work	O
+of	O
+HCWs	O
+with	O
+the	O
+patient	O
+'	O
+s	O
+blood	B-ANAT
+or	O
+body	B-ANAT
+fluids	I-ANAT
+in	O
+laboratory	O
+was	O
+67	O
+.	O
+5	O
+(	O
+43	O
+.	O
+7	O
+-	O
+117	O
+.	O
+5	O
+)	O
+minutes	O
+.	O
+
+These	O
+data	O
+suggest	O
+multiple	O
+PEDV	B-SPEC
+invasions	O
+from	O
+abroad	O
+to	O
+Japan	O
+.	O
+
+In	O
+addition	O
+,	O
+one	O
+of	O
+the	O
+strains	O
+acquired	O
+an	O
+additional	O
+mutation	O
+in	O
+another	O
+neutralizing	O
+epitope	B-CHED
+that	O
+is	O
+highly	O
+conserved	O
+among	O
+PEDVs	O
+,	O
+including	O
+the	O
+classical	O
+and	O
+recent	O
+isolates	O
+.	O
+
+The	O
+primary	O
+goal	O
+of	O
+this	O
+study	O
+was	O
+to	O
+develop	O
+methods	O
+to	O
+reduce	O
+the	O
+lead	O
+time	O
+for	O
+serological	O
+assay	O
+development	B-PROC
+.	O
+
+The	O
+computationally	O
+designed	O
+enzyme	O
+-	O
+linked	O
+immunosorbent	O
+assay	O
+(	O
+ELISA	O
+)	O
+was	O
+validated	O
+using	O
+169	O
+field	O
+sera	B-COMP
+,	O
+whose	O
+statuses	O
+were	O
+determined	O
+by	O
+a	O
+PEDV	B-SPEC
+-	O
+specific	O
+immunofluorescence	O
+assay	O
+.	O
+
+Comparison	O
+of	O
+the	O
+computationally	O
+designed	O
+ELISA	O
+to	O
+a	O
+conventionally	O
+developed	O
+ELISA	O
+,	O
+using	O
+bacterially	O
+expressed	B-PROC
+N	B-PRGE
+protein	I-PRGE
+,	O
+and	O
+to	O
+the	O
+immunofluorescence	O
+assay	O
+showed	O
+a	O
+high	O
+degree	O
+of	O
+agreement	O
+among	O
+the	O
+three	O
+tests	O
+(	O
+mean	O
+kappa	O
+statistic	O
+,	O
+0	O
+.	O
+842	O
+).	O
+
+To	O
+investigate	O
+the	O
+pathogenicity	O
+of	O
+this	O
+variant	O
+,	O
+TTR	B-PRGE
+-	I-PRGE
+2	I-PRGE
+/	O
+JPN	O
+/	O
+2014	O
+,	O
+we	O
+performed	O
+experimental	O
+infection	B-DISO
+using	O
+colostrum	B-ANAT
+-	O
+deprived	O
+piglets	O
+and	O
+compared	O
+the	O
+results	O
+with	O
+those	O
+from	O
+the	O
+North	O
+American	O
+type	O
+PEDV	B-SPEC
+,	O
+OKN	O
+-	O
+1	O
+/	O
+JPN	O
+/	O
+2013	O
+.	O
+
+Moreover	O
+,	O
+there	O
+were	O
+differences	O
+in	O
+virus	B-SPEC
+distribution	O
+and	O
+lesions	O
+on	O
+the	O
+intestines	B-ANAT
+between	O
+the	O
+two	O
+PEDV	B-SPEC
+-	O
+inoculated	O
+groups	O
+.	O
+
+Recently	O
+,	O
+dengue	B-DISO
+fever	I-DISO
+,	O
+Alkhumra	O
+hemorrhagic	B-DISO
+fever	I-DISO
+,	O
+and	O
+Rift	B-DISO
+Valley	I-DISO
+fever	I-DISO
+have	O
+emerged	O
+but	O
+no	O
+case	O
+of	O
+MERS	O
+-	O
+coronavirus	B-SPEC
+,	O
+appeared	O
+in	O
+Saudi	O
+Arabia	O
+in	O
+2012	O
+,	O
+have	O
+yet	O
+been	O
+observed	O
+during	O
+the	O
+2012	O
+-	O
+2014	O
+Hajj	O
+.	O
+
+In	O
+this	O
+study	O
+,	O
+our	O
+results	O
+show	O
+that	O
+the	O
+expression	B-PROC
+of	O
+Mo	O
+-	O
+DCs	B-DISO
+surface	O
+markers	O
+such	O
+as	O
+SWC3a	B-PRGE
+(+)	I-PRGE
+CD1a	I-PRGE
+(+),	I-PRGE
+SWC3a	B-PRGE
+(+)	I-PRGE
+CD80	I-PRGE
+/	I-PRGE
+86	I-PRGE
+(+)	I-PRGE
+and	O
+SWC3a	B-PRGE
+(+)	I-PRGE
+SLA	I-PRGE
+-	I-PRGE
+II	I-PRGE
+-	I-PRGE
+DR	I-PRGE
+(+)	O
+is	O
+increased	O
+after	O
+incubation	O
+with	O
+UV	O
+-	O
+PEDV	B-SPEC
+for	O
+24h	O
+.	O
+
+We	O
+conclude	O
+that	O
+UV	O
+-	O
+PEDV	B-SPEC
+may	O
+be	O
+a	O
+useful	O
+and	O
+safe	O
+vaccine	O
+to	O
+trigger	O
+adaptive	O
+immunity	B-PROC
+.	O
+
+ABSTRACT	O
+:	O
+Middle	O
+East	O
+Respiratory	O
+Syndrome	O
+Coronavirus	B-SPEC
+(	O
+MERS	O
+-	O
+CoV	O
+)	O
+was	O
+first	O
+discovered	O
+in	O
+September	O
+2012	O
+in	O
+Saudi	O
+Arabia	O
+.	O
+
+Data	O
+from	O
+both	O
+syndromes	B-DISO
+show	O
+year	O
+-	O
+round	O
+influenza	B-DISO
+transmission	O
+but	O
+with	O
+increased	O
+caseloads	O
+associated	O
+with	O
+the	O
+rainy	O
+seasons	O
+.	O
+
+ABSTRACT	O
+:	O
+Developing	O
+a	O
+radiofrequency	O
+(	O
+RF	O
+)	O
+coil	O
+system	O
+that	O
+produces	O
+a	O
+uniform	O
+B1	O
+(+)	O
+field	O
+(	O
+circularly	O
+polarized	O
+component	O
+of	O
+the	O
+transverse	O
+magnetic	O
+field	O
+responsible	O
+for	O
+excitation	O
+)	O
+and	O
+low	O
+specific	O
+absorption	O
+rate	O
+(	O
+SAR	B-CHED
+)	O
+is	O
+critical	O
+for	O
+high	O
+performance	O
+ultrahigh	O
+field	O
+human	B-SPEC
+imaging	O
+.	O
+
+In	O
+the	O
+present	O
+survey	O
+,	O
+in	O
+order	B-SPEC
+to	O
+search	O
+for	O
+markers	O
+that	O
+can	O
+differentiate	O
+FECV	B-SPEC
+and	O
+FIPV	O
+,	O
+several	O
+clones	O
+of	O
+the	O
+3a	O
+-	O
+c	O
+,	O
+E	O
+,	O
+and	O
+M	O
+genes	O
+were	O
+sequenced	O
+from	O
+samples	O
+obtained	O
+from	O
+cats	B-SPEC
+with	O
+or	O
+without	O
+FIP	B-DISO
+.	O
+
+Using	O
+NIV	O
+is	O
+discussed	O
+in	O
+mild	O
+-	O
+to	O
+-	O
+moderate	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+(	O
+ARDS	B-DISO
+)	O
+patients	O
+(	O
+PaO2	O
+/	O
+FiO2	O
+>	O
+150	O
+).	O
+
+Pressure	O
+support	O
+or	O
+inspiratory	B-PROC
+positive	O
+airway	B-ANAT
+pressure	O
+(	O
+IPAP	O
+),	O
+external	O
+positive	O
+end	O
+expiratory	B-PROC
+pressure	O
+(	O
+PEEP	B-CHED
+)	O
+or	O
+expiratory	B-PROC
+positive	O
+airway	B-ANAT
+pressure	O
+(	O
+EPAP	O
+)	O
+levels	O
+were	O
+titrated	O
+to	O
+achieve	O
+an	O
+expiratory	B-PROC
+tidal	O
+volume	O
+of	O
+8	O
+to	O
+10	O
+ml	O
+/	O
+kg	O
+according	O
+to	O
+ideal	O
+body	B-ANAT
+weight	O
+,	O
+SpO2	O
+>	O
+90	O
+%	O
+and	O
+respiratory	O
+rate	O
+below	O
+25	O
+/	O
+min	O
+.	O
+
+Through	O
+sitedirected	O
+mutagenesis	B-PROC
+,	O
+we	O
+demonstrate	O
+that	O
+conserved	O
+Asp165	O
+and	O
+non	O
+-	O
+conserved	O
+Asp164	O
+are	O
+important	O
+for	O
+the	O
+catalytic	O
+activities	O
+of	O
+MERS	O
+-	O
+CoV	O
+PL	O
+(	O
+pro	O
+).	O
+
+In	O
+our	O
+study	O
+,	O
+the	O
+overall	O
+hospital	O
+survival	O
+was	O
+46	O
+%	O
+and	O
+successful	O
+weaning	B-PROC
+rate	O
+was	O
+58	O
+%.	O
+
+Previously	O
+,	O
+we	O
+proposed	O
+the	O
+cationically	O
+modified	O
+chitosan	B-CHED
+,	O
+N	O
+-(	O
+2	O
+-	O
+hydroxypropyl	O
+)-	O
+3	O
+-	O
+trimethylammonium	B-CHED
+chitosan	B-CHED
+chloride	B-CHED
+(	O
+HTCC	B-CHED
+),	O
+and	O
+its	O
+hydrophobically	O
+-	O
+modified	O
+derivative	O
+(	O
+HM	O
+-	O
+HTCC	B-CHED
+)	O
+as	O
+potent	O
+inhibitors	B-CHED
+of	O
+the	O
+coronavirus	B-SPEC
+HCoV	B-SPEC
+-	I-SPEC
+NL63	I-SPEC
+.	O
+
+Virus	B-SPEC
+encoding	O
+a	O
+G332A	O
+substitution	O
+in	O
+nsp14	O
+displayed	O
+delayed	O
+replication	O
+kinetics	O
+and	O
+decreased	O
+peak	O
+titers	O
+relative	O
+to	O
+wild	O
+-	O
+type	O
+(	O
+WT	O
+)	O
+MHV	B-SPEC
+.	O
+
+These	O
+parameters	O
+can	O
+be	O
+used	O
+as	O
+surrogate	O
+noninvasive	O
+RV	O
+hemodynamic	B-PROC
+measurements	O
+to	O
+be	O
+manipulated	O
+to	O
+improve	O
+mortality	O
+in	O
+patients	O
+with	O
+ARDS	B-DISO
+and	O
+contributory	O
+RV	O
+dysfunction	O
+.	O
+
+Though	O
+not	O
+confirmed	O
+yet	O
+,	O
+multiple	O
+surveillance	O
+and	O
+phylogenetic	O
+studies	O
+suggest	O
+a	O
+bat	B-ENZY
+origin	O
+.	O
+
+TITLE	O
+:	O
+Extensive	O
+coronavirus	B-SPEC
+-	O
+induced	O
+membrane	B-COMP
+rearrangements	O
+are	O
+not	O
+a	O
+determinant	O
+of	O
+pathogenicity	O
+.	O
+
+In	O
+summary	O
+,	O
+in	O
+moderate	O
+-	O
+to	O
+-	O
+severe	O
+ARDS	B-DISO
+or	O
+in	O
+the	O
+presence	O
+of	O
+other	O
+organ	B-DISO
+failure	I-DISO
+,	O
+noninvasive	O
+ventilatory	O
+support	O
+presents	O
+a	O
+high	O
+risk	O
+of	O
+failure	O
+:	O
+in	O
+those	O
+cases	O
+the	O
+risk	O
+/	O
+benefit	O
+of	O
+delayed	O
+mechanical	O
+ventilation	O
+should	O
+be	O
+evaluated	O
+carefully	O
+.	O
+
+In	O
+patients	O
+with	O
+acute	O
+respiratory	O
+,	O
+circulatory	B-PROC
+or	O
+neurologic	O
+distress	O
+,	O
+several	O
+surgical	O
+procedures	O
+must	O
+be	O
+performed	O
+without	O
+delay	O
+by	O
+whichever	O
+surgeon	O
+is	O
+on	O
+call	O
+.	O
+
+Our	O
+goal	O
+is	O
+to	O
+describe	O
+these	O
+salvage	O
+procedures	O
+including	O
+invasive	O
+approaches	O
+to	O
+the	O
+upper	B-ANAT
+respiratory	I-ANAT
+tract	I-ANAT
+,	O
+decompressive	O
+thoracostomy	O
+,	O
+hemostatic	B-PROC
+or	O
+resuscitative	O
+thoracotomy	O
+,	O
+hemostatic	B-PROC
+laparotomy	O
+,	O
+preperitoneal	O
+pelvic	B-ANAT
+packing	O
+,	O
+external	O
+pelvic	B-ANAT
+fixation	O
+by	O
+a	O
+pelvi	O
+-	O
+clamp	O
+,	O
+decompressive	O
+craniotomy	O
+.	O
+
+Therefore	O
+,	O
+development	B-PROC
+of	O
+effective	O
+vaccines	O
+against	O
+PEDV	B-SPEC
+variant	O
+strains	O
+is	O
+urgently	O
+needed	O
+.	O
+
+Therefore	O
+,	O
+the	O
+NTD	O
+of	O
+S1	B-PRGE
+domain	I-PRGE
+could	O
+be	O
+an	O
+attractive	O
+target	O
+for	O
+the	O
+development	B-PROC
+of	O
+subunit	O
+vaccines	O
+.	O
+
+S25	O
+-	O
+229	O
+IBs	B-DISO
+were	O
+solubilized	O
+in	O
+20	O
+mM	O
+sodium	B-CHED
+acetate	I-CHED
+(	O
+pH	O
+4	O
+.	O
+5	O
+)	O
+buffer	O
+containing	O
+8	O
+M	O
+urea	B-CHED
+and	O
+1	O
+mM	O
+dithiothreitol	B-CHED
+with	O
+95	O
+%	O
+yield	O
+.	O
+
+PEDV	B-SPEC
+was	O
+first	O
+identified	O
+in	O
+the	O
+1980s	O
+in	O
+China	O
+,	O
+and	O
+since	O
+then	O
+,	O
+it	O
+has	O
+become	O
+one	O
+of	O
+the	O
+most	O
+common	O
+viral	O
+causes	O
+of	O
+diarrhea	B-DISO
+.	O
+
+This	O
+review	O
+presents	O
+a	O
+comprehensive	O
+description	O
+of	O
+PEDV	B-SPEC
+history	O
+,	O
+prevalence	O
+,	O
+molecular	O
+features	O
+,	O
+and	O
+prevention	O
+and	O
+control	O
+strategies	O
+in	O
+China	O
+.	O
+
+ABSTRACT	O
+:	O
+MERS	O
+coronavirus	B-SPEC
+cases	O
+notified	O
+in	O
+the	O
+Middle	O
+East	O
+region	O
+since	O
+the	O
+identification	O
+of	O
+the	O
+virus	B-SPEC
+in	O
+2012	O
+have	O
+displayed	O
+variations	O
+in	O
+time	O
+and	O
+across	O
+geography	O
+.	O
+
+ABSTRACT	O
+:	O
+Middle	O
+East	O
+respiratory	O
+syndrome	O
+coronavirus	B-SPEC
+(	O
+MERS	O
+-	O
+CoV	O
+)	O
+is	O
+a	O
+virus	B-SPEC
+that	O
+causes	O
+severe	O
+viral	B-DISO
+pneumonia	I-DISO
+in	O
+humans	B-SPEC
+,	O
+known	O
+to	O
+have	O
+a	O
+high	O
+mortality	O
+rate	O
+and	O
+a	O
+similarity	O
+in	O
+clinical	O
+symptoms	O
+with	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+coronavirus	B-SPEC
+.	O
+
+Scopus	B-SPEC
+database	O
+was	O
+searched	O
+on	O
+March	O
+4	O
+,	O
+2016	O
+for	O
+MERS	O
+-	O
+CoV	O
+publications	O
+published	O
+between	O
+2012	O
+and	O
+2015	O
+.	O
+
+Inactivated	O
+MERS	O
+-	O
+CoV	O
+vaccine	O
+appears	O
+to	O
+carry	O
+a	O
+hypersensitive	O
+-	O
+type	O
+lung	B-ANAT
+pathology	B-DISO
+risk	O
+from	O
+MERS	O
+-	O
+CoV	O
+infection	B-DISO
+that	O
+is	O
+similar	O
+to	O
+that	O
+found	O
+with	O
+inactivated	O
+SARS	B-DISO
+-	O
+CoV	O
+vaccines	O
+from	O
+SARS	B-DISO
+-	I-DISO
+CoV	I-DISO
+infection	I-DISO
+.	O
+
+ABSTRACT	O
+:	O
+Porcine	B-SPEC
+deltacoronavirus	O
+(	O
+PDCoV	O
+)	O
+was	O
+first	O
+reported	O
+in	O
+Hong	O
+Kong	O
+,	O
+China	O
+in	O
+2012	O
+and	O
+reported	O
+in	O
+United	O
+States	O
+swine	B-SPEC
+in	O
+February	O
+2014	O
+.	O
+
+This	O
+review	O
+discusses	O
+PDCoV	O
+infection	B-DISO
+dynamics	O
+and	O
+appropriate	O
+sample	O
+collection	O
+for	O
+diagnostic	O
+testing	O
+,	O
+the	O
+commonly	O
+used	O
+virological	O
+and	O
+serological	O
+methods	O
+for	O
+PDCoV	O
+diagnosis	O
+,	O
+prevalence	O
+and	O
+genetic	O
+evolution	B-PROC
+of	O
+PDCoVs	O
+.	O
+
+ABSTRACT	O
+:	O
+Helicopter	O
+emergency	B-DISO
+medical	O
+services	O
+(	O
+HEMS	O
+)	O
+extend	O
+the	O
+reach	B-PROC
+of	O
+a	O
+tertiary	O
+care	O
+center	O
+significantly	O
+.	O
+
+Our	O
+study	O
+was	O
+performed	O
+to	O
+clarify	O
+the	O
+role	O
+of	O
+HEMS	O
+in	O
+severe	B-DISO
+sepsis	I-DISO
+and	O
+septic	B-DISO
+shock	I-DISO
+.	O
+
+The	O
+patients	O
+transported	O
+by	O
+HEMS	O
+had	O
+a	O
+significantly	O
+faster	O
+median	O
+transport	O
+time	O
+(	O
+1	O
+.	O
+3	O
+versus	O
+1	O
+.	O
+7	O
+h	O
+,	O
+p	O
+<	O
+0	O
+.	O
+01	O
+),	O
+faster	O
+time	O
+to	O
+meeting	O
+criteria	O
+for	O
+severe	B-DISO
+sepsis	I-DISO
+or	O
+septic	B-DISO
+shock	I-DISO
+(	O
+1	O
+.	O
+2	O
+versus	O
+2	O
+.	O
+9	O
+h	O
+,	O
+p	O
+<	O
+0	O
+.	O
+01	O
+),	O
+a	O
+higher	O
+SOFA	O
+score	O
+(	O
+9	O
+versus	O
+7	O
+,	O
+p	O
+<	O
+0	O
+.	O
+01	O
+),	O
+higher	O
+incidence	O
+of	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+(	O
+38	O
+versus	O
+18	O
+%,	O
+p	O
+=	O
+0	O
+.	O
+013	O
+),	O
+higher	O
+need	O
+for	O
+invasive	O
+mechanical	O
+ventilation	O
+(	O
+60	O
+versus	O
+41	O
+%	O
+p	O
+=	O
+0	O
+.	O
+014	O
+),	O
+higher	O
+ICU	O
+mortality	O
+(	O
+13	O
+.	O
+3	O
+versus	O
+4	O
+.	O
+1	O
+%,	O
+p	O
+=	O
+0	O
+.	O
+024	O
+),	O
+and	O
+an	O
+increased	O
+hospital	O
+mortality	O
+(	O
+17	O
+versus	O
+30	O
+%,	O
+p	O
+=	O
+0	O
+.	O
+04	O
+)	O
+when	O
+compared	O
+to	O
+those	O
+transported	O
+by	O
+ground	O
+.	O
+
+ABSTRACT	O
+:	O
+Venovenous	O
+extracorporeal	O
+membrane	O
+oxygenation	B-PROC
+(	O
+VV	O
+-	O
+ECMO	O
+)	O
+is	O
+a	O
+therapeutic	O
+option	O
+in	O
+the	O
+management	O
+of	O
+the	O
+most	O
+severe	O
+forms	O
+of	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+.	O
+
+Finally	O
+,	O
+for	O
+each	O
+modification	O
+of	O
+oxygenation	B-PROC
+parameters	O
+,	O
+specific	O
+measures	O
+are	O
+proposed	O
+to	O
+restore	O
+an	O
+adequate	O
+oxygenation	B-PROC
+by	O
+extracorporeal	O
+membrane	B-COMP
+oxygenation	B-PROC
+.	O
+
+RESULTS	O
+:	O
+We	O
+propose	O
+a	O
+stepwise	O
+approach	O
+that	O
+could	O
+guide	O
+specific	O
+intervention	O
+to	O
+improve	O
+oxygenation	B-PROC
+during	O
+VV	O
+-	O
+ECMO	O
+.	O
+
+Knowledge	O
+,	O
+preventive	O
+behaviours	O
+and	O
+risk	O
+perception	O
+related	O
+to	O
+Middle	O
+East	O
+respiratory	O
+syndrome	O
+were	O
+measured	O
+using	O
+scales	B-ANAT
+developed	O
+through	O
+a	O
+preliminary	O
+survey	O
+and	O
+validity	O
+testing	O
+.	O
+
+Enhancing	O
+Middle	O
+East	O
+respiratory	O
+syndrome	B-DISO
+-	O
+related	O
+knowledge	O
+by	O
+considering	O
+cooperation	O
+between	O
+hospitals	O
+and	O
+universities	O
+will	O
+sharpen	O
+nursing	B-PROC
+students	O
+'	O
+risk	O
+perception	O
+of	O
+the	O
+disease	O
+and	O
+effectively	O
+increase	O
+their	O
+preventive	O
+behaviours	O
+.	O
+
+Enhancing	O
+Middle	O
+East	O
+respiratory	O
+syndrome	B-DISO
+-	O
+related	O
+knowledge	O
+by	O
+considering	O
+cooperation	O
+between	O
+hospitals	O
+and	O
+universities	O
+will	O
+sharpen	O
+nursing	B-PROC
+students	O
+'	O
+risk	O
+perception	O
+of	O
+the	O
+disease	O
+and	O
+effectively	O
+increase	O
+their	O
+preventive	O
+behaviours	O
+.	O
+
+She	O
+recovered	O
+,	O
+and	O
+delivered	O
+a	O
+healthy	O
+baby	O
+by	O
+emergency	B-DISO
+cesarean	O
+section	O
+(	O
+C	O
+-	O
+sec	B-CHED
+).	O
+
+Nevertheless	O
+,	O
+BufCoV	O
+HKU26	O
+possessed	B-DISO
+distinct	O
+accessory	O
+proteins	B-CHED
+between	O
+spike	O
+and	O
+envelope	B-COMP
+compared	O
+to	O
+BCoV	O
+.	O
+Sugar	O
+-	O
+binding	B-FUNC
+residues	O
+in	O
+the	O
+N	O
+-	O
+terminal	O
+domain	O
+of	O
+S	B-PRGE
+protein	I-PRGE
+in	O
+BCoV	O
+are	O
+conserved	O
+in	O
+BufCoV	O
+HKU26	O
+.	O
+
+At	O
+least	O
+629	O
+known	O
+negative	O
+serum	B-COMP
+samples	O
+and	O
+311	O
+known	O
+positive	O
+samples	O
+were	O
+evaluated	O
+for	O
+each	O
+assay	O
+.	O
+
+The	O
+standard	O
+McMaster	O
+flotation	O
+technique	O
+was	O
+used	O
+to	O
+detect	O
+eggs	O
+and	O
+oocysts	O
+in	O
+feces	B-ANAT
+.	O
+
+That	O
+Confers	O
+Resistance	O
+to	O
+Multiple	O
+Mutagens	B-CHED
+.	O
+
+We	O
+sought	O
+to	O
+determine	O
+whether	O
+homology	O
+modeling	O
+could	O
+identify	O
+putative	O
+determinants	O
+of	O
+nucleotide	B-CHED
+selectivity	O
+and	O
+fidelity	O
+in	O
+CoV	O
+RdRps	O
+.	O
+
+Fidelity	O
+-	O
+altering	O
+mutations	O
+previously	O
+identified	O
+in	O
+coxsackie	O
+virus	O
+B3	O
+(	O
+CVB3	O
+)	O
+were	O
+mapped	O
+onto	O
+the	O
+nsp12	O
+-	O
+RdRp	B-FUNC
+model	O
+structure	O
+and	O
+then	O
+engineered	O
+into	O
+the	O
+MHV	B-SPEC
+genome	O
+with	O
+[	O
+nsp14	O
+-	O
+ExoN	O
+(+)]	O
+or	O
+without	O
+[	O
+nsp14	O
+-	O
+ExoN	O
+(-)]	O
+ExoN	O
+activity	O
+.	O
+
+Using	O
+this	O
+method	O
+,	O
+we	O
+identified	O
+two	O
+mutations	O
+conferring	O
+resistance	B-PROC
+to	O
+the	O
+mutagen	B-CHED
+5	B-CHED
+-	I-CHED
+fluorouracil	I-CHED
+(	O
+5	B-CHED
+-	I-CHED
+FU	I-CHED
+):	O
+nsp12	O
+-	O
+M611F	O
+and	O
+nsp12	O
+-	O
+V553I	O
+.	O
+
+The	O
+results	O
+also	O
+indicate	O
+that	O
+,	O
+with	O
+regard	O
+to	O
+nucleotide	B-CHED
+selectivity	O
+,	O
+nsp14	O
+-	O
+ExoN	O
+is	O
+epistatic	O
+to	O
+nsp12	O
+-	O
+RdRp	B-FUNC
+,	O
+consistent	O
+with	O
+its	O
+proposed	O
+role	O
+in	O
+a	O
+multiprotein	O
+replicase	B-PRGE
+-	O
+proofreading	O
+complex	O
+.	O
+
+Coronaviruses	O
+(	O
+CoVs	O
+)	O
+are	O
+the	O
+only	O
+known	O
+RNA	O
+viruses	B-SPEC
+to	O
+encode	O
+a	O
+proofreading	O
+exonuclease	O
+(	O
+nsp14	O
+-	O
+ExoN	O
+),	O
+as	O
+well	O
+as	O
+other	O
+replicase	B-PRGE
+proteins	I-PRGE
+involved	O
+in	O
+regulation	B-PROC
+of	O
+fidelity	O
+.	O
+
+As	O
+such	O
+,	O
+our	O
+study	O
+is	O
+a	O
+significant	O
+step	O
+forward	O
+in	O
+the	O
+understanding	O
+of	O
+coronavirus	B-SPEC
+biology	O
+and	O
+closes	O
+a	O
+gap	O
+in	O
+the	O
+understanding	O
+of	O
+some	O
+IBV	B-SPEC
+virulence	B-PROC
+strategies	O
+.	O
+
+This	O
+process	O
+is	O
+referred	O
+to	O
+as	O
+host	B-COMP
+shutoff	O
+.	O
+
+Phylogenetic	O
+analysis	O
+showed	O
+that	O
+FRCoV	O
+-	O
+NL	O
+-	O
+2010	O
+is	O
+most	O
+closely	O
+related	O
+to	O
+mink	B-SPEC
+CoV	O
+,	O
+forming	O
+a	O
+separate	O
+clade	O
+of	O
+mustelid	B-SPEC
+alphacoronavirus	B-SPEC
+that	O
+split	O
+off	O
+early	O
+from	O
+other	O
+alphacoronaviruses	O
+.	O
+
+Based	O
+on	O
+sequence	O
+homology	O
+of	O
+the	O
+complete	O
+genome	O
+,	O
+we	O
+propose	O
+that	O
+these	O
+mustelid	B-SPEC
+coronaviruses	O
+may	O
+be	O
+assigned	O
+to	O
+a	O
+new	O
+species	B-SPEC
+.	O
+
+TITLE	O
+:	O
+Airway	B-ANAT
+Memory	B-PROC
+CD4	I-PRGE
+(+)	O
+T	B-ANAT
+Cells	I-ANAT
+Mediate	O
+Protective	O
+Immunity	B-PROC
+against	O
+Emerging	O
+Respiratory	O
+Coronaviruses	O
+.	O
+
+Airway	B-ANAT
+memory	B-PROC
+CD4	B-PRGE
+(+)	O
+T	O
+cells	O
+differed	O
+phenotypically	O
+and	O
+functionally	O
+from	O
+lung	B-ANAT
+-	O
+derived	O
+cells	B-COMP
+and	O
+were	O
+crucial	O
+for	O
+protection	O
+against	O
+both	O
+CoVs	O
+in	O
+mice	B-SPEC
+.	O
+
+On	O
+Site	O
+One	O
+,	O
+PEDV	B-SPEC
+was	O
+detected	O
+by	O
+rRT	O
+-	O
+PCR	O
+at	O
+6	O
+days	O
+post	O
+exposure	O
+(	O
+DPE	B-CHED
+)	O
+in	O
+all	O
+sample	O
+types	O
+.	O
+
+The	O
+last	O
+rRT	O
+-	O
+PCR	O
+positives	O
+were	O
+detected	O
+in	O
+rectal	O
+swabs	O
+and	O
+oral	B-ANAT
+fluids	B-ANAT
+on	O
+69	O
+DPE	B-CHED
+.	O
+
+Analysis	O
+of	O
+the	O
+PEDV	B-PRGE
+oral	B-ANAT
+fluid	I-PRGE
+IgA	I-PRGE
+WV	I-PRGE
+ELISA	I-PRGE
+found	O
+that	O
+a	O
+cutoff	O
+of	O
+S	O
+/	O
+P	O
+≥	O
+0	O
+.	O
+80	O
+provided	O
+a	O
+diagnostic	O
+sensitivity	O
+of	O
+1	O
+.	O
+00	O
+(	O
+95	O
+%	O
+CI	O
+:	O
+0	O
+.	O
+92	O
+,	O
+1	O
+.	O
+00	O
+)	O
+and	O
+a	O
+diagnostic	O
+specificity	O
+of	O
+1	O
+.	O
+00	O
+(	O
+95	O
+%	O
+CI	O
+:	O
+0	O
+.	O
+99	O
+,	O
+1	O
+.	O
+00	O
+).	O
+
+This	O
+study	O
+showed	O
+that	O
+oral	B-ANAT
+fluid	O
+-	O
+based	O
+testing	O
+could	O
+provide	O
+an	O
+easy	O
+and	O
+""""	O
+animal	B-SPEC
+-	O
+friendly	O
+""""	O
+approach	O
+to	O
+sample	O
+collection	O
+for	O
+nucleic	B-CHED
+acid	I-CHED
+and	O
+/	O
+or	O
+antibody	B-COMP
+-	O
+based	O
+surveillance	O
+of	O
+PEDV	B-SPEC
+in	O
+swine	B-SPEC
+populations	O
+.	O
+
+The	O
+highest	O
+NA	O
+was	O
+observed	O
+in	O
+colostrum	O
+on	O
+day	O
+1	O
+,	O
+and	O
+decreased	O
+rapidly	O
+in	O
+milk	O
+at	O
+day	O
+3	O
+,	O
+then	O
+gradually	O
+declined	O
+from	O
+day	O
+3	O
+to	O
+day	O
+19	O
+post	O
+-	O
+farrowing	B-PROC
+.	O
+
+Nonetheless	O
+,	O
+antigen	B-CHED
+-	O
+specific	O
+lymphocytes	B-ANAT
+are	O
+ultimately	O
+able	O
+to	O
+accumulate	O
+within	O
+the	O
+CNS	B-CHED
+and	O
+contribute	O
+to	O
+defense	O
+by	O
+reducing	O
+or	O
+eliminating	O
+the	O
+invading	O
+viral	O
+pathogen	O
+.	O
+
+In	O
+addition	O
+,	O
+the	O
+evolution	B-PROC
+of	O
+PEDV	B-SPEC
+results	O
+in	O
+variants	O
+with	O
+distinct	O
+genetic	O
+features	O
+and	O
+virulence	B-PROC
+differences	O
+;	O
+thus	O
+PEDV	B-SPEC
+can	O
+serve	O
+as	O
+a	O
+model	O
+to	O
+explore	O
+the	O
+molecular	O
+mechanisms	O
+of	O
+coronavirus	B-SPEC
+evolution	B-PROC
+and	O
+pathogenesis	B-DISO
+.	O
+
+This	O
+information	O
+and	O
+review	O
+of	O
+researches	O
+will	O
+aid	O
+in	O
+the	O
+development	B-PROC
+of	O
+strategies	O
+for	O
+control	O
+and	O
+prevention	O
+of	O
+PED	O
+.	O
+
+ABSTRACT	O
+:	O
+To	O
+evaluate	O
+the	O
+mechanism	O
+by	O
+which	O
+a	O
+large	O
+outbreak	O
+of	O
+porcine	B-SPEC
+epidemic	B-DISO
+diarrhea	I-DISO
+(	O
+PED	B-DISO
+)	O
+occurred	O
+in	O
+Japan	O
+,	O
+where	O
+the	O
+majority	O
+of	O
+sows	O
+are	O
+vaccinated	O
+,	O
+we	O
+isolated	O
+two	O
+new	O
+strains	O
+of	O
+PED	B-DISO
+virus	B-SPEC
+(	O
+PEDV	B-SPEC
+)	O
+from	O
+the	O
+intestines	B-ANAT
+of	O
+piglets	O
+and	O
+found	O
+that	O
+they	O
+showed	O
+greater	O
+similarity	O
+to	O
+US	O
+isolates	O
+(	O
+group	O
+II	O
+PEDV	B-SPEC
+)	O
+than	O
+to	O
+the	O
+Japanese	O
+vaccine	O
+strain	O
+(	O
+group	O
+I	O
+PEDV	B-SPEC
+).	O
+
+Of	O
+the	O
+74	O
+piglets	O
+samples	O
+among	O
+the	O
+203	O
+fecal	B-ANAT
+samples	O
+,	O
+65	O
+(	O
+87	O
+.	O
+8	O
+%)	O
+were	O
+positive	O
+for	O
+PKV	O
+.	O
+
+Herein	O
+we	O
+describe	O
+the	O
+case	O
+of	O
+a	O
+previously	O
+healthy	O
+16	O
+-	O
+year	O
+-	O
+old	O
+male	O
+without	O
+history	O
+of	O
+travel	O
+,	O
+diagnosed	O
+with	O
+typhoid	B-DISO
+fever	I-DISO
+complicated	O
+by	O
+septic	B-DISO
+shock	I-DISO
+and	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+treated	O
+with	O
+high	O
+-	O
+dose	O
+dexamethasone	B-CHED
+.	O
+
+This	O
+case	O
+details	O
+severe	O
+complications	O
+of	O
+typhoid	B-DISO
+fever	I-DISO
+that	O
+are	O
+uncommonly	O
+seen	O
+in	O
+developed	O
+countries	O
+,	O
+and	O
+the	O
+successful	O
+response	O
+to	O
+high	O
+-	O
+dose	O
+dexamethasone	B-CHED
+as	O
+adjunct	O
+therapy	O
+.	O
+
+TITLE	O
+:	O
+[	O
+Sequencing	O
+and	O
+Serologic	O
+Identification	O
+of	O
+S1	O
+Genes	O
+of	O
+Infectious	B-DISO
+Bronchitis	B-DISO
+Viruses	B-SPEC
+Isolated	O
+during	O
+2012	O
+-	O
+2013	O
+in	O
+Guangxi	O
+Province	O
+,	O
+China	O
+].	O
+
+The	O
+S1	B-PRGE
+gene	I-PRGE
+of	O
+15	O
+IBV	B-SPEC
+field	O
+isolates	O
+during	O
+2012	O
+-	O
+2013	O
+underwent	O
+analyses	O
+in	O
+terms	O
+of	O
+the	O
+similarity	O
+of	O
+amino	O
+-	O
+acid	O
+sequences	O
+,	O
+creation	O
+of	O
+phylogenetic	O
+trees	O
+,	O
+recombination	B-PROC
+,	O
+and	O
+serologic	O
+identification	O
+.	O
+
+These	O
+results	O
+suggested	O
+that	O
+not	O
+only	O
+the	O
+genotype	O
+,	O
+but	O
+also	O
+the	O
+serotype	O
+of	O
+IBV	B-SPEC
+field	O
+isolates	O
+in	O
+Guangxi	O
+Province	O
+had	O
+distinct	O
+variations	O
+,	O
+and	O
+that	O
+increasing	O
+numbers	O
+of	O
+genotypes	O
+and	O
+serotypes	O
+are	O
+in	O
+circulation	B-PROC
+.	O
+
+ABSTRACT	O
+:	O
+Middle	O
+East	O
+respiratory	O
+syndrome	B-DISO
+coronavirus	B-SPEC
+(	O
+MERS	O
+-	O
+CoV	O
+)	O
+was	O
+identified	O
+as	O
+a	O
+novel	O
+human	B-SPEC
+coronavirus	I-SPEC
+and	O
+posed	O
+great	O
+threat	O
+to	O
+public	O
+health	O
+world	O
+wide	O
+,	O
+which	O
+calls	O
+for	O
+the	O
+development	B-PROC
+of	O
+effective	O
+and	O
+safe	O
+vaccine	O
+urgently	O
+.	O
+
+Our	O
+study	O
+identified	O
+a	O
+promising	O
+peptide	O
+vaccine	O
+candidate	O
+against	O
+MERS	O
+-	O
+CoV	O
+and	O
+provided	O
+an	O
+experimental	O
+support	O
+for	O
+bioinformatics	O
+-	O
+based	O
+design	O
+of	O
+peptide	B-CHED
+vaccine	O
+.	O
+
+General	O
+depression	B-DISO
+and	O
+cough	B-DISO
+were	O
+the	O
+signs	O
+that	O
+correlated	O
+best	O
+with	O
+shedding	O
+of	O
+BCoV	B-PRGE
+RNA	I-PRGE
+,	O
+while	O
+peak	O
+respiratory	O
+rate	O
+and	O
+peak	O
+rectal	O
+temperature	O
+appeared	O
+more	O
+than	O
+a	O
+week	O
+later	O
+than	O
+the	O
+peak	O
+shedding	O
+.	O
+
+Prolonged	O
+shedding	O
+of	O
+BCoV	B-PRGE
+RNA	I-PRGE
+can	O
+occur	O
+,	O
+but	O
+detection	O
+of	O
+viral	O
+RNA	O
+does	O
+not	O
+necessarily	O
+indicate	O
+a	O
+transmission	O
+potential	O
+.	O
+
+Fundamental	O
+questions	O
+about	O
+circulating	O
+viruses	B-SPEC
+and	O
+transmission	O
+routes	O
+remain	O
+.	O
+
+TITLE	O
+:	O
+Angiotensin	B-CHED
+-	I-PRGE
+converting	I-PRGE
+enzyme	I-PRGE
+2	I-PRGE
+prevents	O
+lipopolysaccharide	B-CHED
+-	O
+induced	O
+rat	B-SPEC
+acute	O
+lung	B-ANAT
+injury	O
+via	O
+suppressing	O
+the	O
+ERK1	O
+/	O
+2	O
+and	O
+NF	O
+-	O
+κB	O
+signaling	B-PROC
+pathways	B-PROC
+.	O
+
+ACE2	B-PRGE
+has	O
+been	O
+shown	O
+to	O
+protect	O
+against	O
+lung	B-ANAT
+injury	O
+.	O
+
+LPS	B-DISO
+-	O
+induced	O
+lung	B-ANAT
+injury	O
+and	O
+inflammatory	B-DISO
+response	I-DISO
+were	O
+significantly	O
+prevented	O
+by	O
+ACE2	B-PRGE
+overexpression	B-PROC
+and	O
+deteriorated	O
+by	O
+Ace2	B-PRGE
+shRNA	I-PRGE
+.	O
+
+Importantly	O
+,	O
+the	O
+blockade	O
+of	O
+ACE2	B-PRGE
+on	O
+LPS	B-DISO
+-	O
+induced	O
+phosphorylation	B-PROC
+of	O
+ERK1	B-PRGE
+/	I-PRGE
+2	I-PRGE
+,	O
+p38	B-FUNC
+and	O
+p50	B-PRGE
+/	O
+p65	B-PRGE
+was	O
+also	O
+abolished	O
+by	O
+A779	O
+.	O
+
+A	O
+retrospective	O
+study	O
+was	O
+conducted	O
+of	O
+all	O
+confirmed	O
+MERS	O
+-	O
+CoV	O
+infections	B-DISO
+from	O
+March	O
+2014	O
+to	O
+May	O
+2014	O
+at	O
+two	O
+tertiary	O
+care	O
+hospitals	O
+in	O
+Al	O
+-	O
+Madinah	O
+region	O
+(	O
+Saudi	O
+Arabia	O
+).	O
+
+The	O
+death	B-PROC
+rate	O
+was	O
+higher	O
+for	O
+men	O
+(	O
+52	O
+%)	O
+than	O
+for	O
+women	O
+(	O
+23	O
+%).	O
+
+TITLE	O
+:	O
+A	O
+Bibliometric	O
+Analysis	O
+of	O
+PubMed	O
+Literature	O
+on	O
+Middle	O
+East	O
+Respiratory	O
+Syndrome	B-DISO
+.	O
+
+TITLE	O
+:	O
+Recommendations	O
+for	O
+a	O
+Standardized	O
+Avian	B-SPEC
+Coronavirus	I-SPEC
+(	O
+AvCoV	O
+)	O
+Nomenclature	O
+:	O
+Outcome	O
+from	O
+Discussions	O
+Within	O
+the	O
+Framework	O
+of	O
+the	O
+European	O
+Union	O
+COST	O
+Action	O
+FA1207	O
+:	O
+""""	O
+Towards	O
+Control	O
+of	O
+Avian	O
+Coronaviruses	O
+:	O
+Strategies	O
+for	O
+Vaccination	O
+,	O
+Diagnosis	O
+and	O
+Surveillance	O
+"""."	O
+
+ABSTRACT	O
+:	O
+Viruses	B-SPEC
+within	O
+the	O
+Coronaviridae	B-SPEC
+family	B-SPEC
+show	O
+variations	O
+within	O
+their	O
+genome	O
+sequences	O
+,	O
+especially	O
+within	O
+the	O
+major	O
+structural	O
+protein	B-CHED
+,	O
+the	O
+Spike	B-PRGE
+(	I-PRGE
+S	I-PRGE
+)	I-PRGE
+glycoprotein	I-PRGE
+gene	I-PRGE
+.	O
+
+Moreover	O
+,	O
+the	O
+typical	O
+Ark	O
+vaccine	O
+subpopulations	O
+emerging	O
+in	O
+chickens	B-SPEC
+vaccinated	O
+with	O
+commercial	O
+Ark	O
+vaccines	O
+were	O
+not	O
+detected	O
+in	O
+chickens	B-SPEC
+vaccinated	O
+with	O
+the	O
+CEK	O
+-	O
+adapted	O
+virus	B-SPEC
+.	O
+
+In	O
+this	O
+study	O
+,	O
+chickens	B-SPEC
+vaccinated	O
+with	O
+a	O
+low	O
+dose	O
+(	O
+1	O
+.	O
+6	O
+×	O
+10	O
+(	O
+3	O
+)	O
+EID50	O
+/	O
+bird	B-SPEC
+,	O
+where	O
+EID50	O
+is	O
+50	O
+%	O
+embryo	B-ANAT
+infectious	B-DISO
+dose	O
+)	O
+of	O
+CEK	B-PRGE
+-	O
+adapted	O
+Ark	O
+vaccine	O
+at	O
+5	O
+days	O
+of	O
+age	O
+showed	O
+a	O
+significant	O
+reduction	O
+of	O
+IBV	B-SPEC
+RNA	O
+in	O
+lachrymal	O
+fluids	B-ANAT
+and	O
+decreased	O
+incidence	O
+of	O
+IBV	B-SPEC
+RNA	O
+detection	O
+in	O
+tracheal	O
+swabs	O
+5	O
+days	O
+after	O
+challenge	O
+compared	O
+to	O
+unvaccinated	O
+challenged	O
+chickens	B-SPEC
+.	O
+
+All	O
+vaccinated	O
+chicken	B-SPEC
+groups	O
+showed	O
+a	O
+significant	O
+reduction	O
+of	O
+respiratory	O
+signs	O
+and	O
+viral	O
+load	O
+5	O
+days	O
+after	O
+Ark	O
+virulent	O
+challenge	O
+compared	O
+to	O
+unvaccinated	O
+challenged	O
+controls	O
+.	O
+
+No	O
+viral	O
+subpopulations	O
+different	O
+from	O
+the	O
+challenge	O
+virus	B-SPEC
+were	O
+detected	O
+in	O
+chickens	B-SPEC
+vaccinated	O
+with	O
+CEK	B-PRGE
+-	I-PRGE
+Ark	I-PRGE
+after	O
+challenge	O
+.	O
+
+Compared	O
+with	O
+M41	O
+and	O
+Ark	B-PRGE
+,	O
+Cal	B-PRGE
+99	I-PRGE
+and	O
+CA1737	O
+showed	O
+intermediate	O
+variability	O
+.	O
+
+ABSTRACT	O
+:	O
+Runting	O
+stunting	O
+syndrome	O
+(	O
+RSS	B-DISO
+)	O
+is	O
+a	O
+disease	O
+condition	B-DISO
+that	O
+affects	O
+broilers	O
+and	O
+causes	O
+impaired	B-DISO
+growth	B-PROC
+and	O
+poor	O
+feed	O
+conversion	O
+because	O
+of	O
+enteritis	B-DISO
+characterized	O
+by	O
+pale	B-DISO
+and	O
+distended	O
+small	B-ANAT
+intestines	I-ANAT
+with	O
+watery	O
+contents	O
+.	O
+
+Histopathology	O
+of	O
+the	O
+intestines	B-ANAT
+revealed	O
+increased	O
+cellularity	O
+of	O
+the	O
+lamina	B-ANAT
+propria	I-ANAT
+,	O
+blunting	O
+of	O
+villi	O
+,	O
+and	O
+cystic	O
+changes	O
+in	O
+the	O
+crypts	O
+.	O
+
+There	O
+were	O
+no	O
+lesions	O
+in	O
+the	O
+respiratory	B-ANAT
+system	I-ANAT
+,	O
+and	O
+no	O
+IBV	B-PRGE
+antigen	B-CHED
+was	O
+detected	O
+in	O
+trachea	B-DISO
+,	O
+lung	B-ANAT
+,	O
+air	B-ANAT
+sac	B-COMP
+,	O
+conjunctiva	B-ANAT
+,	O
+and	O
+cecal	B-ANAT
+tonsils	B-ANAT
+.	O
+
+A	O
+coronavirus	B-SPEC
+was	O
+isolated	O
+from	O
+the	O
+intestine	B-ANAT
+of	O
+chicken	B-SPEC
+embryos	B-ANAT
+but	O
+not	O
+from	O
+the	O
+allantoic	O
+sac	B-COMP
+inoculated	O
+with	O
+the	O
+intestinal	B-ANAT
+contents	I-ANAT
+of	O
+the	O
+broiler	O
+chicks	O
+.	O
+
+Nucleic	B-CHED
+acid	I-CHED
+sequence	O
+identities	O
+to	O
+other	O
+IBV	B-SPEC
+genotypes	O
+were	O
+lower	O
+.	O
+
+Nasopharyngeal	B-ANAT
+aspirates	B-ANAT
+were	O
+collected	O
+during	O
+87	O
+episodes	O
+of	O
+febrile	B-DISO
+neutropenia	I-DISO
+in	O
+children	O
+age	O
+0	O
+-	O
+18	O
+years	O
+,	O
+being	O
+treated	O
+at	O
+a	O
+children	O
+'	O
+s	O
+oncology	O
+unit	O
+between	O
+January	O
+2013	O
+and	O
+June	O
+2014	O
+.	O
+
+Real	O
+-	O
+time	O
+polymerase	O
+chain	O
+reaction	O
+was	O
+used	O
+to	O
+determine	O
+the	O
+presence	O
+of	O
+16	O
+respiratory	O
+viruses	B-SPEC
+.	O
+
+The	O
+same	O
+virus	B-SPEC
+was	O
+detected	O
+at	O
+follow	O
+-	O
+up	O
+in	O
+one	O
+coronavirus	B-SPEC
+and	O
+six	O
+rhinovirus	B-SPEC
+episodes	O
+.	O
+
+Genotyping	O
+revealed	O
+a	O
+different	O
+rhinovirus	B-SPEC
+species	B-SPEC
+in	O
+two	O
+of	O
+the	O
+six	O
+rhinovirus	B-SPEC
+infections	B-DISO
+.	O
+
+TITLE	O
+:	O
+Single	O
+-	O
+dose	O
+treatment	O
+with	O
+a	O
+humanized	O
+neutralizing	O
+antibody	B-COMP
+affords	O
+full	O
+protection	O
+of	O
+a	O
+human	B-SPEC
+transgenic	O
+mouse	B-SPEC
+model	O
+from	O
+lethal	O
+Middle	O
+East	O
+respiratory	O
+syndrome	B-DISO
+(	O
+MERS	O
+)-	O
+coronavirus	B-DISO
+infection	I-DISO
+.	O
+
+hMS	B-DISO
+-	O
+1	O
+significantly	O
+blocked	O
+MERS	O
+-	O
+CoV	O
+RBD	O
+binding	B-FUNC
+to	O
+its	O
+viral	O
+receptor	O
+,	O
+human	B-PRGE
+dipeptidyl	I-PRGE
+peptidase	I-PRGE
+4	I-PRGE
+(	O
+hDPP4	O
+),	O
+potently	O
+neutralized	O
+infection	B-DISO
+by	O
+a	O
+prototype	O
+MERS	O
+-	O
+CoV	O
+,	O
+and	O
+effectively	O
+cross	O
+-	O
+neutralized	O
+evolved	O
+MERS	O
+-	O
+CoV	O
+isolates	O
+through	O
+recognizing	O
+highly	O
+conserved	O
+RBD	O
+epitopes	O
+.	O
+
+Key	O
+events	O
+contributing	O
+to	O
+the	O
+development	B-PROC
+of	O
+ALI	O
+/	O
+ARDS	B-DISO
+are	O
+:	O
+increased	O
+oxidative	O
+and	O
+proteotoxic	O
+stresses	O
+,	O
+unresolved	O
+inflammation	B-DISO
+,	O
+and	O
+compromised	O
+alveolar	B-ANAT
+-	O
+capillary	B-ANAT
+barrier	O
+function	O
+.	O
+
+TITLE	O
+:	O
+Biological	O
+Activities	O
+of	O
+Aerial	O
+Parts	O
+Extracts	O
+of	O
+Euphorbia	B-SPEC
+characias	I-SPEC
+.	O
+
+Ethanolic	O
+extracts	O
+from	O
+leaves	O
+and	O
+flowers	O
+displayed	O
+the	O
+highest	O
+inhibitory	O
+activity	O
+against	O
+acetylcholinesterase	B-PRGE
+and	O
+butyrylcholinesterase	B-PRGE
+,	O
+showing	O
+potential	O
+properties	O
+against	O
+Alzheimer	B-PATH
+'	I-PATH
+s	I-PATH
+disease	I-PATH
+.	O
+
+We	O
+propose	O
+a	O
+simple	O
+sampling	O
+strategy	O
+to	O
+enrich	O
+in	O
+especially	O
+dangerous	O
+pathogens	O
+with	O
+a	O
+low	O
+background	O
+for	O
+molecular	O
+diagnostics	O
+by	O
+targeting	B-PROC
+blood	B-ANAT
+-	O
+borne	O
+pathogens	O
+in	O
+the	O
+healthiest	O
+age	O
+groups	O
+.	O
+
+TITLE	O
+:	O
+Cellular	B-ANAT
+entry	O
+of	O
+the	O
+porcine	B-SPEC
+epidemic	I-SPEC
+diarrhea	I-SPEC
+virus	I-SPEC
+.	O
+
+The	O
+virus	B-SPEC
+replicates	O
+extensively	O
+and	O
+almost	O
+exclusively	O
+in	O
+the	O
+epithelial	B-ANAT
+cells	I-ANAT
+of	O
+the	O
+small	B-ANAT
+intestine	I-ANAT
+resulting	O
+in	O
+villus	B-ANAT
+atrophy	B-DISO
+,	O
+malabsorption	B-DISO
+and	O
+severe	B-DISO
+diarrhea	I-DISO
+.	O
+
+Here	O
+we	O
+review	O
+the	O
+current	O
+data	O
+on	O
+PEDV	O
+entry	O
+into	O
+its	O
+host	B-COMP
+cell	I-COMP
+,	O
+including	O
+therein	O
+our	O
+new	O
+observations	O
+regarding	O
+the	O
+functional	O
+role	O
+of	O
+the	O
+sialic	B-FUNC
+acid	I-FUNC
+binding	B-PROC
+activity	I-PROC
+of	O
+the	O
+S	B-PRGE
+protein	I-PRGE
+in	O
+virus	B-DISO
+infection	I-DISO
+.	O
+
+Consecutive	O
+VD	O
+/	O
+VT	O
+measurements	O
+were	O
+obtained	O
+based	O
+upon	O
+a	O
+prediction	O
+equation	O
+validated	O
+by	O
+Frankenfield	O
+et	O
+al	O
+for	O
+dead	B-PROC
+-	O
+space	O
+ventilation	O
+fraction	O
+:	O
+VD	O
+/	O
+VT	O
+=	O
+0	O
+.	O
+320	O
++	O
+0	O
+.	O
+0106	O
+(	O
+PaCO₂	O
+-	O
+ETCO₂	O
+)⁺	O
+0	O
+.	O
+003	O
+(	O
+RR	O
+)⁺	O
+0	O
+.	O
+0015	O
+(	O
+age	O
+)	O
+in	O
+adult	O
+patients	O
+who	O
+had	O
+infection	B-DISO
+-	O
+related	O
+severe	O
+pneumonia	B-DISO
+and	O
+were	O
+confirmed	O
+as	O
+having	O
+ARDS	B-DISO
+.	O
+
+TITLE	O
+:	O
+Taking	O
+forward	O
+a	O
+'	O
+One	O
+Health	O
+'	O
+approach	O
+for	O
+turning	O
+the	O
+tide	O
+against	O
+the	O
+Middle	O
+East	O
+respiratory	O
+syndrome	B-DISO
+coronavirus	B-SPEC
+and	O
+other	O
+zoonotic	O
+pathogens	O
+with	O
+epidemic	O
+potential	O
+.	O
+
+The	O
+One	O
+Health	O
+concept	O
+focuses	O
+on	O
+the	O
+relationship	O
+and	O
+interconnectedness	O
+between	O
+Humans	O
+,	O
+Animals	B-SPEC
+and	O
+the	O
+Environment	O
+,	O
+and	O
+recognizes	O
+that	O
+the	O
+health	O
+and	O
+wellbeing	O
+of	O
+humans	B-SPEC
+is	O
+intimately	O
+connected	O
+to	O
+the	O
+health	O
+of	O
+animals	B-SPEC
+and	O
+their	O
+environment	O
+(	O
+and	O
+vice	O
+versa	O
+).	O
+
+ABSTRACT	O
+:	O
+Prone	O
+position	O
+(	O
+PP	O
+)	O
+improves	O
+oxygenation	B-PROC
+and	O
+outcome	O
+of	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+(	O
+ARDS	B-DISO
+)	O
+patients	O
+with	O
+a	O
+PaO2	O
+/	O
+FiO2	O
+ratio	O
+<	O
+150	O
+mmHg	O
+.	O
+
+The	O
+patients	O
+with	O
+focal	O
+and	O
+non	O
+-	O
+focal	O
+ARDS	B-DISO
+showed	O
+no	O
+difference	O
+in	O
+global	O
+reaeration	O
+score	O
+.	O
+
+Oxygenation	B-PROC
+response	O
+was	O
+not	O
+associated	O
+with	O
+aeration	O
+changes	O
+.	O
+
+This	O
+supports	O
+the	O
+hypothesis	O
+that	O
+camel	B-SPEC
+imports	O
+from	O
+Africa	O
+are	O
+not	O
+of	O
+significance	O
+for	O
+circulation	O
+of	O
+the	O
+virus	B-SPEC
+in	O
+camel	B-SPEC
+populations	O
+of	O
+the	O
+Arabian	O
+Peninsula	O
+.	O
+
+Our	O
+goal	O
+was	O
+to	O
+assess	O
+new	O
+predictors	O
+of	O
+inadequate	O
+linezolid	B-CHED
+concentrations	O
+often	O
+observed	O
+in	O
+critically	B-DISO
+ill	I-DISO
+patients	O
+.	O
+
+These	O
+infections	B-DISO
+have	O
+little	O
+commercial	O
+potential	O
+and	O
+are	O
+not	O
+a	O
+high	O
+priority	O
+for	O
+the	O
+pharmaceutical	B-CHED
+industry	O
+.	O
+
+It	O
+is	O
+important	O
+to	O
+identify	O
+high	O
+risk	O
+patients	O
+and	O
+haemodialysis	O
+with	O
+reduced	O
+dialysis	B-SPEC
+efficacy	O
+and	O
+gradual	O
+urea	B-CHED
+reduction	O
+is	O
+recommended	O
+.	O
+
+RESULTS	O
+:	O
+The	O
+leading	O
+maternal	O
+complications	O
+associated	O
+with	O
+HELLP	B-DISO
+syndrome	I-DISO
+were	O
+the	O
+following	O
+:	O
+severe	B-DISO
+preeclampsia	I-DISO
+,	O
+eclampsia	B-DISO
+,	O
+placental	B-DISO
+abruption	I-DISO
+,	O
+acute	B-DISO
+pulmonary	I-DISO
+edema	I-DISO
+,	O
+acute	B-DISO
+kidney	I-DISO
+failure	I-DISO
+,	O
+disseminated	B-DISO
+intravascular	I-DISO
+coagulation	I-DISO
+syndrome	B-DISO
+,	O
+and	O
+immediate	O
+maternal	B-PROC
+death	I-PROC
+.	O
+
+The	O
+present	O
+study	O
+reports	O
+on	O
+the	O
+emergence	O
+and	O
+spread	O
+of	O
+recombinant	O
+clusters	B-CHED
+detected	O
+in	O
+Italy	O
+and	O
+Spain	O
+between	O
+2012	O
+and	O
+2014	O
+.	O
+
+Based	O
+on	O
+the	O
+partial	O
+S1	O
+sequencing	O
+,	O
+27	O
+IBV	B-SPEC
+strains	O
+originating	O
+from	O
+Spain	O
+and	O
+nine	O
+from	O
+Italy	O
+were	O
+initially	O
+classified	O
+as	O
+being	O
+closely	O
+related	O
+to	O
+the	O
+Guandong	O
+/	O
+Xindadi	O
+(	O
+XDN	O
+)	O
+genotype	O
+.	O
+
+Our	O
+data	O
+support	O
+the	O
+hypothesis	O
+of	O
+two	O
+different	O
+scenarios	O
+:	O
+firstly	O
+,	O
+in	O
+Spain	O
+,	O
+the	O
+large	O
+and	O
+homogeneous	O
+clade	O
+probably	O
+originated	O
+from	O
+a	O
+single	O
+offspring	O
+of	O
+the	O
+recombinant	O
+founder	B-DISO
+,	O
+which	O
+became	O
+dominant	O
+and	O
+spread	O
+throughout	O
+the	O
+country	O
+.	O
+
+Emergency	B-DISO
+department	O
+(	O
+ED	O
+)	O
+personnel	O
+must	O
+be	O
+prepared	O
+to	O
+address	O
+concerns	O
+from	O
+patients	O
+presenting	O
+with	O
+symptoms	O
+consistent	O
+with	O
+acute	O
+Zika	B-SPEC
+virus	I-SPEC
+infection	O
+,	O
+especially	O
+those	O
+who	O
+are	O
+pregnant	O
+or	O
+planning	O
+travel	O
+to	O
+Zika	O
+-	O
+endemic	O
+regions	O
+,	O
+as	O
+well	O
+as	O
+those	O
+women	O
+planning	O
+to	O
+become	O
+pregnant	O
+and	O
+their	O
+partners	O
+.	O
+
+If	O
+after	O
+a	O
+rapid	O
+evaluation	O
+,	O
+Zika	O
+or	O
+other	B-DISO
+arthropod	I-DISO
+-	I-DISO
+borne	I-DISO
+diseases	I-DISO
+are	O
+the	O
+only	O
+concern	O
+,	O
+isolation	O
+(	O
+contact	O
+,	O
+droplet	O
+,	O
+airborne	O
+)	O
+is	O
+unnecessary	O
+.	O
+
+There	O
+was	O
+a	O
+significant	O
+improvement	O
+in	O
+partial	O
+oxygen	B-CHED
+pressure	O
+/	O
+fraction	O
+of	O
+inspired	B-PROC
+oxygen	B-CHED
+(	O
+PaO2	O
+/	O
+FiO2	O
+)	O
+24	O
+hours	O
+after	O
+CRRT	O
+onset	O
+compared	O
+with	O
+baseline	O
+(	O
+median	O
+change	O
+=	O
+51	O
+.	O
+5	O
+;	O
+range	O
+=	O
+-	O
+19	O
+to	O
+450	O
+.	O
+5	O
+;	O
+P	O
+<	O
+.	O
+001	O
+)	O
+as	O
+well	O
+as	O
+decreases	O
+in	O
+FiO2	O
+,	O
+peak	O
+inspiratory	B-PROC
+pressure	O
+,	O
+positive	O
+end	B-PROC
+-	I-PROC
+expiratory	I-PROC
+pressure	O
+,	O
+and	O
+mean	O
+airway	B-ANAT
+pressure	O
+(	O
+P	O
+<	O
+.	O
+05	O
+).	O
+
+TITLE	O
+:	O
+Survival	O
+Predictors	O
+for	O
+Severe	O
+ARDS	B-DISO
+Patients	O
+Treated	O
+with	O
+Extracorporeal	O
+Membrane	B-COMP
+Oxygenation	B-PROC
+:	O
+A	O
+Retrospective	O
+Study	O
+in	O
+China	O
+.	O
+
+ABSTRACT	O
+:	O
+Extracorporeal	O
+membrane	B-COMP
+oxygenation	B-PROC
+(	O
+ECMO	O
+)	O
+is	O
+increasingly	O
+being	O
+applied	O
+as	O
+life	O
+support	O
+for	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+(	O
+ARDS	B-DISO
+)	O
+patients	O
+.	O
+
+Of	O
+the	O
+identified	O
+pre	O
+-	O
+ECMO	O
+factors	O
+,	O
+advanced	O
+age	O
+,	O
+a	O
+long	O
+duration	O
+of	O
+ventilation	O
+before	O
+ECMO	O
+,	O
+a	O
+higher	O
+Acute	O
+Physiology	O
+and	O
+Chronic	O
+Health	O
+Evaluation	O
+II	O
+(	O
+APACHE	O
+II	O
+)	O
+score	O
+,	O
+underlying	O
+lung	B-DISO
+disease	I-DISO
+,	O
+and	O
+pulmonary	B-ANAT
+barotrauma	O
+prior	O
+to	O
+ECMO	O
+were	O
+associated	O
+with	O
+unsuccessful	O
+weaning	B-PROC
+from	O
+ECMO	O
+.	O
+
+ABSTRACT	O
+:	O
+Status	B-DISO
+asthmaticus	I-DISO
+can	O
+develop	O
+into	O
+a	O
+life	O
+-	O
+threatening	O
+disorder	O
+that	O
+requires	O
+mechanical	O
+ventilation	O
+.	O
+
+Despite	O
+rescue	O
+therapies	O
+such	O
+as	O
+pressure	O
+control	O
+ventilation	O
+with	O
+high	O
+inspiratory	B-PROC
+pressures	O
+,	O
+inhaled	B-PROC
+beta2	B-PRGE
+agonists	B-CHED
+and	O
+antimuscarinic	O
+drugs	O
+,	O
+intravenous	O
+salbutamol	B-CHED
+,	O
+methylprednisolone	B-CHED
+and	O
+magnesium	B-CHED
+sulfate	I-CHED
+,	O
+her	O
+condition	B-DISO
+gradually	O
+deteriorated	O
+.	O
+
+At	O
+the	O
+end	O
+of	O
+incubation	O
+,	O
+the	O
+virus	B-SPEC
+titers	O
+were	O
+determined	O
+by	O
+inoculation	O
+of	O
+Vero	O
+-	O
+81	O
+cells	B-COMP
+and	O
+the	O
+virus	B-SPEC
+inactivation	B-DISO
+kinetics	O
+were	O
+modeled	O
+using	O
+the	O
+Weibull	O
+distribution	O
+model	O
+.	O
+
+On	O
+the	O
+view	O
+of	O
+the	O
+interest	O
+on	O
+and	O
+importance	O
+of	O
+CoVs	O
+in	O
+bats	B-SPEC
+the	O
+occurrence	O
+and	O
+molecular	O
+characterization	O
+of	O
+CoV	O
+were	O
+conducted	O
+in	O
+bats	B-SPEC
+from	O
+Brazil	O
+.	O
+
+Of	O
+the	O
+recent	O
+emerged	O
+G2a	O
+viruses	B-SPEC
+,	O
+J3142	O
+strains	O
+showed	O
+potential	O
+recombination	B-PROC
+breakpoint	O
+(	O
+376	O
+-	O
+2	O
+,	O
+143nt	O
+)	O
+of	O
+S1	B-PRGE
+gene	I-PRGE
+between	O
+KNU1303_Korea	O
+strain_G2a	O
+(	O
+KJ451046	O
+)	O
+and	O
+45RWVCF0712_Thailand	O
+strain_G2b	O
+(	O
+KF724935	O
+).	O
+
+Using	O
+the	O
+SCHOOL	O
+approach	O
+and	O
+the	O
+SARS	B-DISO
+-	I-PRGE
+CoV	I-PRGE
+fusion	I-PRGE
+peptide	B-CHED
+sequence	I-PRGE
+,	O
+we	O
+rationally	O
+designed	O
+a	O
+novel	O
+immunomodulatory	O
+peptide	O
+that	O
+targets	O
+TCR	B-COMP
+.	O
+
+We	O
+present	O
+a	O
+case	O
+of	O
+a	O
+community	O
+-	O
+acquired	O
+Serratia	B-SPEC
+marcescens	I-SPEC
+bacteremia	B-DISO
+leading	O
+to	O
+Respiratory	B-DISO
+Distress	I-DISO
+Syndrome	I-DISO
+in	O
+a	O
+previously	O
+healthy	O
+51	O
+-	O
+year	O
+-	O
+old	O
+man	B-CHED
+without	O
+identifiable	O
+risk	O
+factors	O
+.	O
+
+ABSTRACT	O
+:	O
+The	O
+Middle	O
+East	O
+respiratory	O
+syndrome	B-DISO
+coronavirus	B-SPEC
+(	O
+MERS	O
+-	O
+CoV	O
+)	O
+is	O
+associated	O
+with	O
+life	O
+-	O
+threatening	O
+severe	O
+illnesses	O
+and	O
+a	O
+mortality	O
+rate	O
+of	O
+approximately	O
+35	O
+%,	O
+particularly	O
+in	O
+patients	O
+with	O
+underlying	O
+comorbidities	O
+.	O
+
+In	O
+conclusion	O
+,	O
+protection	O
+against	O
+MERS	O
+-	O
+CoV	O
+and	O
+other	O
+respiratory	B-DISO
+infections	I-DISO
+can	O
+be	O
+improved	O
+if	O
+public	O
+health	O
+vaccination	O
+strategies	O
+are	O
+tailored	O
+to	O
+target	O
+persons	O
+with	O
+chronic	B-DISO
+disorders	I-DISO
+.	O
+
+The	O
+two	O
+PEDV	B-SPEC
+isolates	O
+,	O
+CBR1	B-PRGE
+/	I-PRGE
+2014	I-PRGE
+and	O
+EAS1	O
+/	O
+2014	O
+,	O
+were	O
+28	O
+,	O
+039	O
+and	O
+28	O
+,	O
+033	O
+nucleotides	B-CHED
+in	O
+length	O
+and	O
+showed	O
+96	O
+.	O
+2	O
+%	O
+and	O
+93	O
+.	O
+6	O
+%	O
+similarities	O
+at	O
+nucleotide	B-CHED
+and	O
+amino	B-CHED
+acid	I-CHED
+levels	O
+respectively	O
+.	O
+
+Compared	O
+to	O
+EAS1	O
+/	O
+2014	O
+,	O
+CBR1	B-PRGE
+/	O
+2014	O
+has	O
+2	O
+insertions	O
+of	O
+4	O
+((	O
+56	O
+)	O
+GENQ	O
+(	O
+59	O
+))	O
+and	O
+1	O
+((	O
+140	O
+)	O
+N	O
+)	O
+amino	B-CHED
+acid	I-CHED
+positions	O
+56	O
+-	O
+59	O
+and	O
+140	O
+,	O
+and	O
+2	O
+deletions	O
+of	O
+2	O
+((	O
+160	O
+)	O
+DG	O
+(	O
+161	O
+))	O
+and	O
+1	O
+((	O
+1199	O
+)	O
+Y	O
+)	O
+amino	O
+acid	O
+positions	O
+160	O
+-	O
+161	O
+and	O
+1199	O
+.	O
+
+TITLE	O
+:	O
+Transduction	B-PROC
+of	O
+hematopoietic	B-ANAT
+stem	I-ANAT
+cells	I-ANAT
+to	O
+stimulate	O
+RNA	B-PROC
+interference	I-PROC
+against	O
+feline	B-SPEC
+infectious	I-DISO
+peritonitis	I-DISO
+.	O
+
+TITLE	O
+:	O
+Acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+in	O
+adenovirus	B-DISO
+type	O
+4	O
+pneumonia	B-DISO
+:	O
+A	O
+case	O
+report	O
+.	O
+
+In	O
+this	O
+report	O
+,	O
+we	O
+describe	O
+the	O
+case	O
+of	O
+a	O
+36	O
+years	O
+-	O
+old	O
+woman	O
+admitted	O
+to	O
+our	O
+intensive	O
+care	O
+unit	O
+(	O
+ICU	O
+)	O
+with	O
+severe	O
+respiratory	B-DISO
+distress	I-DISO
+syndrome	I-DISO
+caused	O
+by	O
+adenovirus	B-DISO
+pneumonia	B-DISO
+,	O
+that	O
+required	O
+invasive	O
+respiratory	O
+support	O
+(	O
+mechanical	O
+ventilation	O
+and	O
+extracorporeal	O
+membrane	B-COMP
+oxygenation	B-PROC
+).	O
+
+Among	O
+the	O
+40	O
+farms	O
+,	O
+6	O
+camel	B-SPEC
+farms	O
+were	O
+positive	O
+for	O
+MERS	O
+-	O
+CoV	O
+;	O
+the	O
+virus	B-SPEC
+was	O
+not	O
+detected	O
+in	O
+the	O
+single	O
+sheep	O
+farm	O
+.	O
+
+The	O
+aim	O
+of	O
+this	O
+study	O
+was	O
+to	O
+confirm	O
+and	O
+identify	O
+porcine	B-SPEC
+epidemic	I-SPEC
+diarrhea	I-SPEC
+virus	I-SPEC
+(	O
+PEDV	B-SPEC
+)	O
+in	O
+samples	O
+from	O
+piglets	O
+with	O
+suggestive	O
+clinical	O
+signs	O
+using	O
+virological	O
+,	O
+histological	O
+,	O
+and	O
+molecular	O
+techniques	O
+.	O
+
+Incidence	O
+of	O
+stroke	B-DISO
+,	O
+deep	O
+sternal	O
+infection	B-DISO
+and	O
+mortality	O
+was	O
+similar	O
+in	O
+both	O
+groups	O
+.	O
+
+It	O
+has	O
+lower	O
+overall	O
+morbidity	O
+than	O
+conventional	O
+CABG	O
+Its	O
+main	O
+limitations	O
+are	O
+hemodynamic	B-DISO
+instability	I-DISO
+and	O
+inability	O
+to	O
+find	O
+a	O
+deeply	O
+embedded	O
+target	B-ANAT
+vessel	I-ANAT
+.	O
+
+Elevated	O
+OX	O
+-	O
+K	O
+titers	O
+suggestive	O
+of	O
+scrub	B-DISO
+typhus	I-DISO
+were	O
+seen	O
+in	O
+80	O
+%	O
+(	O
+147	O
+/	O
+184	O
+).	O
+
+TITLE	O
+:	O
+Analytical	O
+and	O
+Clinical	O
+Validation	O
+of	O
+Six	O
+Commercial	O
+Middle	O
+East	O
+Respiratory	O
+Syndrome	B-DISO
+Coronavirus	B-SPEC
+RNA	O
+Detection	O
+Kits	O
+Based	O
+on	O
+Real	O
+-	O
+Time	O
+Reverse	O
+-	O
+Transcription	B-PROC
+PCR	O
+.	O
+
+No	O
+cross	O
+-	O
+reactivity	O
+with	O
+other	O
+respiratory	O
+viruses	B-SPEC
+was	O
+found	O
+.	O
+
+Compared	O
+with	O
+the	O
+control	O
+,	O
+which	O
+were	O
+prepared	O
+by	O
+adding	O
+a	O
+one	O
+-	O
+tenth	O
+volume	O
+of	O
+1	O
+:	O
+1	O
+,	O
+000	O
+diluted	O
+viral	O
+culture	O
+to	O
+PBS	B-DISO
+solution	O
+,	O
+the	O
+ranges	O
+of	O
+Ct	O
+values	O
+obtained	O
+by	O
+the	O
+PBS	B-DISO
+and	O
+NALC	O
+methods	O
+differed	O
+significantly	O
+from	O
+the	O
+mean	O
+control	O
+Ct	O
+of	O
+33	O
+.	O
+2	O
+(	O
+both	O
+P	O
+<	O
+0	O
+.	O
+0001	O
+).	O
+
+To	O
+better	O
+understand	O
+the	O
+antigenicity	O
+and	O
+pathogenesis	B-DISO
+of	O
+this	O
+genotype	O
+,	O
+the	O
+characteristics	O
+of	O
+the	O
+ck	O
+/	O
+CH	O
+/	O
+LDL	B-CHED
+/	O
+140520	O
+strain	O
+were	O
+compared	O
+to	O
+those	O
+of	O
+four	O
+commercial	O
+IB	O
+vaccine	O
+strains	O
+that	O
+are	O
+used	O
+commonly	O
+in	O
+China	O
+,	O
+as	O
+well	O
+as	O
+four	O
+attenuated	O
+viruses	B-SPEC
+that	O
+represent	O
+two	O
+types	O
+of	O
+IBV	B-SPEC
+strains	O
+,	O
+which	O
+are	O
+believed	O
+to	O
+have	O
+originated	O
+in	O
+China	O
+and	O
+are	O
+the	O
+predominant	O
+IBV	B-SPEC
+types	O
+circulating	O
+in	O
+chicken	B-SPEC
+flocks	O
+in	O
+China	O
+and	O
+many	O
+other	O
+parts	O
+of	O
+the	O
+world	O
+.	O
+
+TITLE	O
+:	O
+Pressure	O
+-	O
+controlled	O
+inverse	O
+ratio	O
+ventilation	O
+as	O
+a	O
+rescue	O
+therapy	O
+for	O
+severe	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+.	O
+
+The	O
+mean	O
+duration	O
+of	O
+IRV	B-PROC
+was	O
+10	O
+.	O
+5	O
+days	O
+,	O
+and	O
+all	O
+survivors	O
+were	O
+weaned	B-PROC
+from	O
+mechanical	O
+ventilation	O
+and	O
+discharged	O
+.	O
+
+Univariate	O
+analysis	O
+showed	O
+that	O
+the	O
+duration	O
+of	O
+IRV	B-PROC
+was	O
+associated	O
+with	O
+the	O
+90	O
+-	O
+day	O
+mortality	O
+rate	O
+.	O
+
+Pressure	O
+-	O
+controlled	O
+IRV	B-PROC
+provided	O
+acceptable	O
+gas	B-ENZY
+exchange	O
+without	O
+apparent	O
+complications	O
+and	O
+served	O
+as	O
+a	O
+successful	O
+bridge	O
+to	O
+conventional	O
+treatment	O
+when	O
+used	O
+as	O
+a	O
+rescue	O
+therapy	O
+for	O
+moderate	O
+to	O
+severe	O
+ARDS	B-DISO
+.	O
+
+Nineteen	O
+thousand	O
+nine	O
+hundred	O
+seven	O
+dogs	B-SPEC
+from	O
+pet	O
+hospitals	O
+in	O
+the	O
+cities	O
+of	O
+Luoyang	O
+,	O
+Anyang	O
+,	O
+Jiaozuo	O
+,	O
+Sanmenxia	O
+,	O
+Xinxiang	O
+,	O
+Zhengzhou	O
+in	O
+Henan	O
+province	O
+between	O
+2009	O
+and	O
+2014	O
+were	O
+investigated	O
+.	O
+
+CPV	B-SPEC
+2c	O
+was	O
+not	O
+observed	O
+in	O
+this	O
+study	O
+.	O
+
+TITLE	O
+:	O
+Safe	O
+and	O
+Sensitive	O
+Antiviral	B-CHED
+Screening	O
+Platform	O
+Based	O
+on	O
+Recombinant	B-PRGE
+Human	I-PRGE
+Coronavirus	I-PRGE
+OC43	I-PRGE
+Expressing	O
+the	O
+Luciferase	O
+Reporter	O
+Gene	O
+.	O
+
+Here	O
+,	O
+we	O
+developed	O
+four	O
+infectious	B-DISO
+recombinant	O
+HCoVs	O
+-	O
+OC43	O
+(	O
+rHCoVs	O
+-	O
+OC43	O
+)	O
+which	O
+express	O
+the	O
+Renilla	B-SPEC
+luciferase	B-ENZY
+(	O
+Rluc	O
+)	O
+reporter	O
+gene	O
+.	O
+
+Among	O
+these	O
+four	O
+rHCoVs	O
+-	O
+OC43	O
+,	O
+rOC43	O
+-	O
+ns2DelRluc	O
+(	O
+generated	O
+by	O
+replacing	O
+ns2	B-DISO
+with	O
+the	O
+Rluc	B-PRGE
+gene	I-PRGE
+)	O
+showed	O
+robust	O
+luciferase	B-PROC
+activity	I-PROC
+with	O
+only	O
+a	O
+slight	O
+impact	O
+on	O
+its	O
+growth	B-PROC
+characteristics	O
+.	O
+
+Therefore	O
+,	O
+rOC43	O
+-	O
+ns2DelRluc	O
+represents	O
+a	O
+promising	O
+safe	O
+and	O
+sensitive	O
+platform	O
+for	O
+high	O
+-	O
+throughput	O
+antiviral	B-CHED
+screening	O
+and	O
+quantitative	O
+analysis	O
+of	O
+viral	B-PROC
+replication	I-PROC
+.	O
+
+The	O
+initial	O
+medical	O
+treatment	O
+for	O
+ALI	O
+/	O
+ARDS	B-DISO
+is	O
+inhibition	B-PROC
+of	O
+NET	O
+formation	B-PROC
+and	O
+intravasated	O
+platelet	B-PROC
+aggregation	I-PROC
+to	O
+prevent	O
+endothelial	B-ANAT
+cell	I-ANAT
+damage	O
+(	O
+Phase	O
+1	O
+).	O
+
+Furthermore	O
+,	O
+the	O
+implementation	O
+of	O
+quality	O
+indicators	O
+for	O
+the	O
+early	O
+management	O
+of	O
+severe	B-DISO
+sepsis	I-DISO
+and	O
+septic	B-DISO
+shock	I-DISO
+is	O
+strongly	O
+associated	O
+with	O
+a	O
+reduced	O
+mortality	O
+.	O
+
+The	O
+hypothesis	O
+of	O
+rickettsiosis	B-DISO
+was	O
+made	O
+on	O
+the	O
+basis	O
+of	O
+a	O
+comprehensive	O
+medical	O
+history	O
+and	O
+was	O
+confirmed	O
+by	O
+serological	O
+tests	O
+.	O
+
+Oxygenation	B-PROC
+index	O
+was	O
+increased	O
+,	O
+airway	B-ANAT
+peak	O
+pressure	O
+(	O
+Ppeak	O
+)	O
+was	O
+reduced	O
+,	O
+the	O
+lung	B-ANAT
+dynamic	O
+compliance	O
+improved	O
+,	O
+extravascular	O
+lung	B-ANAT
+water	B-CHED
+was	O
+relieved	O
+,	O
+functional	B-PROC
+residual	I-PROC
+capacity	I-PROC
+increased	O
+and	O
+Murray	O
+score	O
+was	O
+improved	O
+.	O
+
+In	O
+patients	O
+suffering	B-DISO
+from	O
+moderate	O
+to	O
+severe	O
+ARDS	B-DISO
+,	O
+application	O
+of	O
+APRV	O
+improved	O
+lung	B-PROC
+function	I-PROC
+and	O
+hemodynamics	B-PROC
+.	O
+
+It	O
+also	O
+reduced	O
+the	O
+need	O
+for	O
+sedatives	B-CHED
+and	O
+the	O
+duration	O
+of	O
+mechanical	O
+ventilation	O
+as	O
+well	O
+as	O
+days	O
+in	O
+ICU	O
+.	O
+
+TNF	B-PRGE
+-	I-PRGE
+α	I-PRGE
+and	O
+IL	B-FUNC
+-	I-FUNC
+10	I-FUNC
+concentrations	O
+in	O
+the	O
+alveolar	B-ANAT
+lavage	O
+,	O
+probability	O
+of	O
+survival	O
+and	O
+days	O
+without	O
+organ	B-DISO
+failure	I-DISO
+were	O
+similar	O
+in	O
+both	O
+groups	O
+.	O
+
+TITLE	O
+:	O
+Porcine	B-SPEC
+Epidemic	I-SPEC
+Diarrhea	I-SPEC
+Virus	B-DISO
+Infection	I-DISO
+Inhibits	O
+Interferon	B-PATH
+Signaling	I-PATH
+by	O
+Targeted	B-PROC
+Degradation	O
+of	O
+STAT1	O
+.	O
+
+Furthermore	O
+,	O
+we	O
+report	O
+that	O
+PEDV	B-SPEC
+-	O
+induced	O
+STAT1	B-PRGE
+degradation	O
+inhibits	O
+IFN	B-PRGE
+-	I-PRGE
+α	I-PRGE
+signal	B-PROC
+transduction	I-PROC
+pathways	I-PROC
+.	O
+
+The	O
+molecular	O
+mechanism	O
+is	O
+the	O
+degradation	O
+of	O
+STAT1	B-PRGE
+by	O
+PEDV	B-SPEC
+infection	B-DISO
+in	O
+a	O
+proteasome	B-PATH
+-	O
+dependent	O
+manner	O
+.	O
+
+ATRA	O
+was	O
+re	O
+-	O
+started	O
+on	O
+day	O
+29	O
+at	O
+half	O
+the	O
+original	O
+dose	O
+because	O
+of	O
+residual	O
+APL	B-DISO
+blasts	B-ANAT
+.	O
+
+ABSTRACT	O
+:	O
+Fire	O
+-	O
+eater	O
+'	O
+s	O
+pneumonia	O
+is	O
+an	O
+exogenous	O
+chemical	B-DISO
+pneumonitis	I-DISO
+after	O
+accidental	O
+aspiration	B-DISO
+of	O
+hydrocarbon	B-CHED
+fluids	B-ANAT
+during	O
+the	O
+act	O
+of	O
+fire	O
+-	O
+eating	B-PROC
+.	O
+
+ABSTRACT	O
+:	O
+Severe	O
+acidosis	B-DISO
+can	O
+cause	O
+noninvasive	O
+ventilation	O
+(	O
+NIV	O
+)	O
+failure	O
+in	O
+chronic	B-DISO
+obstructive	I-DISO
+pulmonary	I-DISO
+disease	I-DISO
+(	O
+COPD	B-DISO
+)	O
+patients	O
+with	O
+acute	O
+hypercapnic	B-DISO
+respiratory	I-DISO
+failure	I-DISO
+(	O
+AHRF	O
+).	O
+
+Four	O
+groups	O
+have	O
+been	O
+differentiated	B-PROC
+:	O
+(	O
+1	O
+)	O
+absence	O
+or	O
+(	O
+2	O
+)	O
+presence	O
+of	O
+systemic	B-DISO
+inflammatory	I-DISO
+response	I-DISO
+syndrome	I-DISO
+,	O
+(	O
+3	O
+)	O
+SS	O
+or	O
+(	O
+4	O
+)	O
+SSh	O
+;	O
+and	O
+2	O
+groups	O
+,	O
+among	O
+the	O
+patients	O
+admitted	O
+for	O
+acute	B-DISO
+respiratory	I-DISO
+failure	I-DISO
+:	O
+absence	O
+or	O
+presence	O
+of	O
+sCAP	B-PRGE
+.	O
+
+TITLE	O
+:	O
+High	O
+frequency	O
+oscillatory	O
+ventilation	O
+in	O
+leptospirosis	B-DISO
+pulmonary	B-DISO
+hemorrhage	I-DISO
+syndrome	B-DISO
+:	O
+A	O
+case	O
+series	O
+study	O
+.	O
+
+Two	O
+did	O
+not	O
+receive	O
+pressure	B-DISO
+ulcer	I-DISO
+preventive	O
+measures	O
+and	O
+subsequently	O
+developed	O
+multiple	O
+necrotic	B-PROC
+facial	B-ANAT
+pressure	B-DISO
+ulcers	I-DISO
+related	O
+to	O
+prone	O
+positioning	O
+for	O
+treatment	O
+of	O
+ARDS	B-DISO
+.	O
+
+The	O
+other	O
+2	O
+patients	O
+were	O
+managed	O
+on	O
+a	O
+thin	O
+silicone	B-CHED
+foam	O
+dressing	O
+;	O
+neither	O
+of	O
+these	O
+patients	O
+developed	O
+facial	B-ANAT
+pressure	B-DISO
+ulcers	I-DISO
+during	O
+pronation	B-PROC
+therapy	O
+.	O
+
+The	O
+study	O
+reveals	O
+that	O
+during	O
+the	O
+acute	O
+stage	O
+of	O
+infection	B-DISO
+,	O
+both	O
+strains	O
+induce	O
+inflammatory	O
+innate	B-DISO
+immune	I-DISO
+response	I-DISO
+genes	O
+,	O
+whereas	O
+upregulation	B-PROC
+of	O
+several	O
+immunoglobulin	B-PRGE
+genes	I-PRGE
+during	O
+chronic	O
+stage	O
+infection	B-DISO
+is	O
+unique	O
+to	O
+infection	O
+with	O
+the	O
+demyelinating	O
+strain	O
+.	O
+
+TITLE	O
+:	O
+[	O
+The	O
+Isolation	O
+and	O
+Identification	O
+of	O
+Infectious	B-DISO
+Bronchitis	B-DISO
+Virus	B-SPEC
+PTFY	O
+Strain	O
+in	O
+Muscovy	B-SPEC
+Ducks	I-SPEC
+].	O
+
+The	O
+swelling	B-DISO
+and	O
+congestive	O
+ovary	B-ANAT
+was	O
+visible	O
+after	O
+autopsy	O
+.	O
+
+The	O
+virus	B-SPEC
+was	O
+isolated	O
+and	O
+identified	O
+by	O
+the	O
+methods	O
+of	O
+virus	B-SPEC
+culture	O
+in	O
+chicken	B-SPEC
+embryo	B-ANAT
+,	O
+physical	O
+and	O
+chemical	O
+properties	O
+test	O
+,	O
+hemagglutinin	O
+test	O
+,	O
+NDV	B-SPEC
+(	O
+Newcastle	O
+diseases	O
+Virus	B-SPEC
+)	O
+interference	O
+test	O
+,	O
+electron	O
+microscope	O
+observation	O
+,	O
+pathogenicity	O
+test	O
+and	O
+the	O
+gene	O
+sequence	O
+analysis	O
+.	O
+
+The	O
+strain	O
+was	O
+identified	O
+as	O
+IBV	B-SPEC
+isolate	O
+and	O
+this	O
+study	O
+confirmed	O
+the	O
+pathogenicity	O
+of	O
+IBV	B-SPEC
+to	O
+Muscovy	B-SPEC
+ducks	I-SPEC
+.	O
+
+ABSTRACT	O
+:	O
+The	O
+deltacoronavirus	O
+is	O
+a	O
+new	O
+member	O
+of	O
+the	O
+subfamily	O
+Coronaviridae	B-SPEC
+of	O
+the	O
+family	B-SPEC
+Coronaviridae	I-SPEC
+.	O
+
+With	O
+this	O
+information	O
+,	O
+and	O
+using	O
+reverse	O
+genetics	O
+systems	O
+,	O
+it	O
+is	O
+possible	O
+to	O
+design	O
+viruses	B-SPEC
+with	O
+modifications	O
+in	O
+the	O
+viral	O
+proteins	O
+acting	O
+as	O
+virulence	B-PROC
+factors	O
+,	O
+which	O
+may	O
+lead	O
+to	O
+attenuated	O
+viruses	B-SPEC
+and	O
+,	O
+therefore	O
+,	O
+vaccine	O
+candidates	O
+.	O
+
+Veno	O
+-	O
+venous	B-ANAT
+ECMO	O
+was	O
+started	O
+at	O
+the	O
+end	O
+of	O
+lung	B-ANAT
+injury	O
+induction	O
+with	O
+a	O
+flow	O
+>	O
+60	O
+ml	O
+/	O
+kg	O
+/	O
+min	O
+resulting	O
+in	O
+rapid	O
+reversal	O
+of	O
+hypoxemia	O
+and	O
+pulmonary	B-DISO
+hypertension	I-DISO
+.	O
+
+They	O
+must	O
+not	O
+be	O
+discharged	O
+from	O
+the	O
+hospital	O
+early	O
+and	O
+must	O
+be	O
+followed	O
+for	O
+at	O
+least	O
+48	O
+hours	O
+even	O
+if	O
+they	O
+don	O
+'	O
+t	O
+have	O
+respiratory	B-DISO
+symptoms	I-DISO
+.	O
+
+It	O
+should	O
+be	O
+kept	O
+in	O
+mind	O
+that	O
+severe	O
+pulmonary	O
+complications	O
+can	O
+develop	O
+in	O
+patients	O
+with	O
+chemical	B-DISO
+pneumonia	I-DISO
+.	O
+
+ABSTRACT	O
+:	O
+Infectious	B-DISO
+bronchitis	B-DISO
+virus	B-SPEC
+(	O
+IBV	B-SPEC
+)	O
+is	O
+a	O
+coronavirus	B-SPEC
+which	O
+affects	O
+chickens	B-SPEC
+of	O
+all	O
+ages	O
+.	O
+
+ABSTRACT	O
+:	O
+In	O
+2015	O
+,	O
+a	O
+large	O
+outbreak	O
+of	O
+Middle	O
+East	O
+respiratory	O
+syndrome	O
+coronavirus	B-SPEC
+(	O
+MERS	O
+-	O
+CoV	O
+)	O
+infection	B-DISO
+occurred	O
+following	O
+a	O
+single	O
+patient	O
+exposure	O
+in	O
+an	O
+emergency	B-DISO
+room	O
+at	O
+the	O
+Samsung	O
+Medical	O
+Center	O
+,	O
+a	O
+tertiary	O
+-	O
+care	O
+hospital	O
+in	O
+Seoul	O
+,	O
+South	O
+Korea	O
+.	O
+
+We	O
+analysed	O
+attack	O
+rates	O
+,	O
+incubation	O
+periods	B-PROC
+of	O
+the	O
+virus	B-SPEC
+,	O
+and	O
+risk	O
+factors	O
+for	O
+transmission	O
+.	O
+
+The	O
+attack	O
+rate	O
+was	O
+highest	O
+in	O
+group	O
+A	O
+(	O
+20	O
+%	O
+[	O
+23	O
+/	O
+117	O
+]	O
+vs	O
+5	O
+%	O
+[	O
+3	O
+/	O
+58	O
+]	O
+in	O
+group	B-DISO
+B	I-DISO
+vs	O
+1	O
+%	O
+[	O
+4	O
+/	O
+500	O
+]	O
+in	O
+group	O
+C	O
+;	O
+p	O
+<	O
+0	O
+·	O
+0001	O
+),	O
+and	O
+was	O
+2	O
+%	O
+(	O
+5	O
+/	O
+218	O
+)	O
+in	O
+health	O
+-	O
+care	O
+workers	O
+.	O
+
+Protocolized	O
+approaches	O
+for	O
+the	O
+evaluation	O
+of	O
+patients	O
+with	O
+acute	B-DISO
+respiratory	I-DISO
+failure	I-DISO
+or	O
+distress	O
+are	O
+discussed	O
+.	O
+
+The	O
+professional	O
+focus	O
+of	O
+the	O
+majority	O
+of	O
+respondents	O
+was	O
+critical	O
+care	O
+(	O
+106	O
+/	O
+249	O
+(	O
+43	O
+%)),	O
+pediatrics	O
+(	O
+59	O
+/	O
+249	O
+,	O
+(	O
+24	O
+%))	O
+or	O
+internal	O
+medicine	B-CHED
+(	O
+52	O
+/	O
+249	O
+(	O
+21	O
+%))	O
+but	O
+none	O
+was	O
+blood	B-ANAT
+banking	O
+.	O
+
+Mean	O
+expiratory	B-PROC
+positive	O
+airway	B-ANAT
+pressure	O
+(	O
+EPAP	O
+)	O
+was	O
+5	O
+.	O
+8	O
+cm	O
+H2O	B-CHED
+(	O
+range	O
+4	O
+to	O
+8	O
+cm	O
+H2O	B-CHED
+).	O
+
+ABSTRACT	O
+:	O
+Influenza	B-PATH
+A	I-PATH
+(	O
+H5N1	B-DISO
+)	O
+virus	B-SPEC
+infects	O
+a	O
+variety	O
+of	O
+animals	B-SPEC
+,	O
+birds	B-SPEC
+and	O
+humans	B-SPEC
+.	O
+
+Mesenchymal	O
+stromal	O
+/	O
+stem	B-ANAT
+cells	I-ANAT
+(	O
+MSCs	B-FUNC
+)	O
+are	O
+adult	O
+multi	O
+-	O
+progenitor	B-ANAT
+cells	I-ANAT
+that	O
+can	O
+modulate	O
+the	O
+immune	B-PROC
+response	I-PROC
+and	O
+enhance	O
+repair	B-PROC
+of	O
+damaged	O
+tissue	B-ANAT
+and	O
+thus	O
+may	O
+provide	O
+a	O
+therapeutic	O
+option	O
+for	O
+ARDS	B-DISO
+.	O
+
+MSCs	B-FUNC
+appear	O
+to	O
+exert	B-PROC
+their	O
+effects	O
+via	O
+multiple	O
+mechanisms	O
+-	O
+some	O
+are	O
+cell	B-PROC
+interaction	I-PROC
+dependent	O
+whereas	O
+others	O
+are	O
+paracrine	B-PROC
+dependent	O
+resulting	O
+from	O
+both	O
+soluble	O
+secreted	B-PROC
+products	O
+and	O
+microvesicles	O
+/	O
+exosomes	O
+derived	O
+from	O
+the	O
+cells	O
+.	O
+
+ECMO	O
+transport	O
+may	O
+be	O
+an	O
+effective	O
+method	O
+of	O
+transferring	O
+patients	O
+with	O
+severe	O
+ARDS	B-DISO
+.	O
+
+Six	O
+days	O
+later	O
+,	O
+further	O
+deterioration	O
+of	O
+gas	B-ENZY
+exchange	O
+prompted	O
+the	O
+decision	O
+to	O
+intubate	O
+.	O
+
+However	O
+,	O
+he	O
+experienced	O
+progressive	O
+deterioration	O
+of	O
+arterial	B-ANAT
+oxygenation	B-PROC
+despite	O
+conventional	O
+ventilatory	O
+support	O
+.	O
+
+TITLE	O
+:	O
+Performance	O
+of	O
+Multiple	O
+Risk	O
+Assessment	O
+Tools	O
+to	O
+Predict	O
+Mortality	O
+for	O
+Adult	B-DISO
+Respiratory	I-DISO
+Distress	I-DISO
+Syndrome	I-DISO
+with	O
+Extracorporeal	O
+Membrane	B-COMP
+Oxygenation	B-PROC
+Therapy	O
+:	O
+An	O
+External	O
+Validation	O
+Study	O
+Based	O
+on	O
+Chinese	O
+Single	O
+-	O
+center	O
+Data	O
+.	O
+
+B1648	O
+was	O
+productively	O
+replicating	O
+in	O
+KUL01	O
+(+)	O
+monocytic	B-ANAT
+cells	B-COMP
+in	O
+contrast	O
+with	O
+M41	B-PRGE
+.	O
+
+Retrospective	O
+analysis	O
+of	O
+disease	O
+spectrum	O
+,	O
+EN	O
+approach	O
+,	O
+preparation	O
+,	O
+speed	O
+and	O
+time	O
+as	O
+well	O
+as	O
+adverse	O
+reactions	O
+and	O
+outcomes	O
+in	O
+47	O
+pediatric	O
+patients	O
+with	O
+gastrointestinal	B-DISO
+disease	I-DISO
+underwent	O
+EN	O
+therapy	O
+during	O
+July	O
+2014	O
+to	O
+March	O
+2015	O
+.	O
+
+Twenty	O
+-	O
+one	O
+cases	O
+suffered	B-DISO
+from	O
+different	O
+degrees	O
+of	O
+adverse	O
+reactions	O
+,	O
+including	O
+vomiting	B-DISO
+in	O
+7	O
+cases	O
+,	O
+abdominal	B-DISO
+pain	I-DISO
+and	O
+bloating	B-DISO
+in	O
+3	O
+,	O
+diarrhea	B-DISO
+in	O
+12	O
+,	O
+secondary	O
+respiratory	B-DISO
+infections	I-DISO
+in	O
+5	O
+.	O
+
+The	O
+nutrition	B-PROC
+indicators	O
+before	O
+and	O
+after	O
+EN	O
+therapy	O
+were	O
+compared	O
+by	O
+paired	O
+t	O
+-	O
+test	O
+.	O
+
+The	O
+objective	O
+of	O
+the	O
+CONSISE	O
+ROSES	B-SPEC
+-	O
+I	O
+statement	O
+was	O
+to	O
+improve	O
+the	O
+quality	O
+and	O
+transparency	O
+of	O
+reporting	O
+of	O
+influenza	B-DISO
+seroepidemiologic	O
+studies	O
+and	O
+facilitate	O
+the	O
+assessment	O
+of	O
+the	O
+validity	O
+and	O
+generalizability	O
+of	O
+published	O
+results	O
+.	O
+
+ABSTRACT	O
+:	O
+This	O
+paper	O
+combines	O
+two	O
+advances	O
+to	O
+detect	O
+MERS	O
+-	O
+CoV	O
+,	O
+the	O
+causative	O
+agent	O
+of	O
+Middle	O
+East	O
+Respiratory	O
+Syndrome	B-DISO
+,	O
+that	O
+have	O
+emerged	O
+over	O
+the	O
+past	O
+few	O
+years	O
+from	O
+the	O
+new	O
+field	O
+of	O
+""""	O
+synthetic	O
+biology	O
+"""."	O
+
+Both	O
+are	O
+based	O
+on	O
+an	O
+older	O
+concept	O
+,	O
+where	O
+molecular	O
+beacons	O
+are	O
+used	O
+as	O
+the	O
+downstream	O
+detection	O
+of	O
+viral	O
+RNA	O
+in	O
+biological	O
+mixtures	O
+followed	O
+by	O
+reverse	B-PROC
+transcription	I-PROC
+PCR	O
+amplification	B-DISO
+.	O
+
+Combining	O
+these	O
+technologies	O
+in	O
+primers	O
+with	O
+components	O
+of	O
+a	O
+self	O
+-	O
+avoiding	O
+molecular	B-PROC
+recognition	I-PROC
+system	O
+(	O
+SAMRS	O
+),	O
+we	O
+detect	O
+50	O
+copies	O
+of	O
+MERS	B-PRGE
+-	I-PRGE
+CoV	I-PRGE
+RNA	I-PRGE
+in	O
+a	O
+multiplexed	O
+respiratory	O
+virus	B-SPEC
+panel	O
+by	O
+generating	O
+fluorescence	O
+signal	O
+visible	O
+to	O
+human	B-SPEC
+eye	B-ANAT
+and	O
+/	O
+or	O
+camera	B-SPEC
+.	O
+
+Lectins	O
+are	O
+attractive	O
+anti	O
+-	O
+coronavirus	B-SPEC
+candidates	O
+because	O
+of	O
+the	O
+highly	O
+glycosylated	O
+nature	O
+of	O
+the	O
+spike	O
+protein	B-CHED
+.	O
+
+Due	O
+to	O
+its	O
+wide	O
+expression	B-PROC
+profile	O
+,	O
+TRPV4	B-PRGE
+is	O
+implicated	O
+in	O
+multiple	O
+pathophysiological	O
+states	O
+.	O
+
+There	O
+were	O
+no	O
+statistically	O
+significant	O
+differences	O
+in	O
+surgical	O
+situation	O
+,	O
+length	O
+of	O
+ICU	O
+stay	O
+,	O
+and	O
+occurrence	O
+of	O
+major	O
+complications	O
+including	O
+infection	B-DISO
+,	O
+ARDS	B-DISO
+,	O
+and	O
+MODS	B-DISO
+/	O
+MOF	B-DISO
+in	O
+patients	O
+among	O
+these	O
+three	O
+years	O
+(	O
+with	O
+χ	O
+(	O
+2	O
+)	O
+values	O
+from	O
+0	O
+.	O
+48	O
+to	O
+2	O
+.	O
+43	O
+,	O
+W	O
+=	O
+2	O
+.	O
+100	O
+,	O
+P	O
+values	O
+above	O
+0	O
+.	O
+05	O
+).	O
+
+A	O
+confirmed	O
+case	O
+was	O
+defined	O
+as	O
+positive	O
+reverse	B-PROC
+transcription	I-PROC
+polymerase	O
+chain	O
+reaction	O
+test	O
+for	O
+MERS	O
+-	O
+CoV	O
+.	O
+RESULTS	O
+Of	O
+the	O
+130	O
+suspected	O
+cases	O
+,	O
+81	O
+(	O
+62	O
+%)	O
+were	O
+confirmed	O
+and	O
+49	O
+(	O
+38	O
+%)	O
+were	O
+probable	O
+.	O
+
+ABSTRACT	O
+:	O
+The	O
+Ebola	O
+virus	O
+disease	O
+outbreak	O
+in	O
+West	O
+Africa	O
+and	O
+the	O
+Middle	O
+East	O
+Respiratory	O
+Syndrome	B-DISO
+outbreak	O
+in	O
+the	O
+Republic	O
+of	O
+Korea	O
+have	O
+given	O
+huge	O
+impacts	O
+in	O
+different	O
+aspects	O
+.	O
+
+ABSTRACT	O
+:	O
+The	O
+emergence	O
+of	O
+the	O
+Middle	O
+East	O
+Respiratory	O
+Syndrome	O
+(	O
+MERS	O
+)	O
+in	O
+Saudi	O
+Arabia	O
+has	O
+intensified	O
+focus	O
+on	O
+Acute	B-DISO
+Respiratory	I-DISO
+Infections	I-DISO
+[	O
+ARIs	O
+].	O
+
+Children	O
+(	O
+aged	O
+≤	O
+13	O
+)	O
+presenting	O
+with	O
+ARI	B-CHED
+between	O
+January	O
+2012	O
+and	O
+December	O
+2013	O
+tested	O
+for	O
+15	O
+RVs	O
+using	O
+the	O
+Seeplex	O
+
+ABSTRACT	O
+:	O
+Stiff	B-DISO
+-	I-DISO
+person	I-DISO
+syndrome	I-DISO
+(	O
+SPS	B-DISO
+)	O
+is	O
+a	O
+rare	B-DISO
+disorder	I-DISO
+characterized	O
+by	O
+progressive	O
+muscle	B-DISO
+stiffness	I-DISO
+,	O
+rigidity	B-DISO
+,	O
+and	O
+spasms	B-DISO
+involving	O
+the	O
+axial	O
+muscles	B-ANAT
+.	O
+
+Thus	O
+,	O
+the	O
+onset	O
+of	O
+apnea	B-DISO
+during	O
+SPS	B-DISO
+should	O
+be	O
+considered	O
+a	O
+criterion	O
+of	O
+high	O
+severity	O
+and	O
+should	O
+lead	O
+to	O
+intensive	O
+care	O
+unit	O
+(	O
+ICU	O
+)	O
+admission	O
+for	O
+continuous	O
+monitoring	O
+.	O
+
+In	O
+patients	O
+with	O
+severe	O
+disease	O
+who	O
+are	O
+unresponsive	O
+to	O
+symptomatic	O
+treatment	O
+with	O
+benzodiazepines	O
+and	O
+baclofen	B-CHED
+,	O
+or	O
+in	O
+patients	O
+with	O
+life	O
+-	O
+threatening	O
+complications	O
+,	O
+early	O
+immunotherapy	O
+by	O
+intravenous	O
+immunoglobulins	O
+should	O
+be	O
+considered	O
+.	O
+
+CONCLUSIONS	O
+:	O
+Onset	O
+of	O
+apneas	B-DISO
+during	O
+SPS	B-DISO
+should	O
+be	O
+considered	O
+as	O
+a	O
+signal	O
+of	O
+possible	O
+progression	O
+toward	O
+acute	B-DISO
+respiratory	I-DISO
+failure	I-DISO
+and	O
+sudden	B-DISO
+death	I-DISO
+,	O
+and	O
+should	O
+lead	O
+to	O
+ICU	O
+admission	O
+for	O
+continuous	O
+monitoring	O
+.	O
+
+Little	O
+is	O
+known	O
+about	O
+the	O
+role	O
+of	O
+extracorporeal	O
+membrane	B-COMP
+oxygenation	B-PROC
+for	O
+management	O
+in	O
+this	O
+setting	O
+.	O
+
+Those	O
+who	O
+were	O
+aware	O
+of	O
+MERS	O
+-	O
+CoV	O
+were	O
+more	O
+likely	O
+to	O
+receive	O
+recommended	O
+vaccines	O
+[	O
+odds	O
+ratio	O
+(	O
+OR	O
+)	O
+3	O
+.	O
+1	O
+,	O
+95	O
+%	O
+confidence	O
+interval	O
+(	O
+CI	O
+):	O
+1	O
+.	O
+5	O
+-	O
+5	O
+.	O
+9	O
+,	O
+P	O
+<	O
+0	O
+.	O
+01	O
+],	O
+but	O
+there	O
+was	O
+no	O
+significant	O
+difference	O
+in	O
+avoiding	O
+camels	B-SPEC
+or	O
+their	O
+raw	O
+products	O
+during	O
+Hajj	O
+between	O
+those	O
+who	O
+were	O
+aware	O
+of	O
+MERS	O
+-	O
+CoV	O
+and	O
+those	O
+who	O
+were	O
+not	O
+(	O
+OR	O
+1	O
+.	O
+2	O
+,	O
+95	O
+%	O
+CI	O
+:	O
+0	O
+.	O
+3	O
+-	O
+5	O
+.	O
+2	O
+,	O
+P	O
+=	O
+0	O
+.	O
+7	O
+).	O
+
+A	O
+total	O
+of	O
+300	O
+day	O
+-	O
+old	O
+pullet	O
+chicks	O
+were	O
+randomly	O
+assigned	O
+to	O
+3	O
+dietary	O
+treatments	O
+including	O
+:	O
+a	O
+basal	O
+diet	O
+(	O
+Control	O
+),	O
+and	O
+diets	O
+containing	O
+YDC	O
+,	O
+and	O
+SNB	O
+(	O
+Lactobacillus	B-SPEC
+acidophilus	I-SPEC
+,	O
+L	B-SPEC
+.	I-SPEC
+casei	I-SPEC
+,	O
+Streptococcus	B-SPEC
+faecium	I-SPEC
+,	O
+and	O
+Bacillus	B-SPEC
+subtilis	I-SPEC
+,	O
+and	O
+YDC	O
+).	O
+
+Finally	O
+,	O
+in	O
+experiment	O
+3	O
+,	O
+on	O
+d	O
+21	O
+and	O
+28	O
+posthatch	O
+,	O
+10	O
+birds	B-SPEC
+per	O
+treatment	O
+were	O
+immunized	O
+intramuscularly	O
+with	O
+both	O
+sheep	B-SPEC
+red	B-ANAT
+blood	I-ANAT
+cells	I-ANAT
+(	O
+SRBC	B-COMP
+)	O
+and	O
+bovine	B-PRGE
+serum	B-COMP
+albumin	I-PRGE
+(	O
+BSA	B-PRGE
+),	O
+and	O
+11	O
+after	O
+immunization	O
+serum	B-COMP
+samples	O
+were	O
+analyzed	O
+by	O
+hemagglutination	B-PROC
+assay	O
+for	O
+antibody	B-PROC
+response	I-PROC
+to	O
+SRBC	B-COMP
+,	O
+and	O
+by	O
+ELISA	O
+for	O
+serum	B-PRGE
+IgM	I-PRGE
+and	O
+IgG	B-PRGE
+response	O
+to	O
+BSA	B-PRGE
+.	O
+
+TITLE	O
+:	O
+Korean	O
+Asthma	B-PATH
+Guideline	O
+2014	O
+:	O
+Summary	O
+of	O
+Major	O
+Updates	O
+to	O
+the	O
+Korean	O
+Asthma	B-PATH
+Guideline	O
+2014	O
+.	O
+
+This	O
+guideline	O
+focuses	O
+on	O
+adult	O
+patients	O
+with	O
+asthma	B-PATH
+and	O
+aims	O
+to	O
+deliver	O
+up	O
+to	O
+date	O
+scientific	O
+evidence	O
+and	O
+recommendations	O
+to	O
+general	O
+physicians	O
+for	O
+the	O
+management	O
+of	O
+asthma	B-PATH
+.	O
+
+TITLE	O
+:	O
+A	O
+Curious	O
+Case	O
+of	O
+Acute	B-DISO
+Respiratory	I-DISO
+Failure	I-DISO
+:	O
+
+Although	O
+it	O
+is	O
+usually	O
+associated	O
+with	O
+elevated	O
+creatine	B-CHED
+phosphokinase	O
+level	O
+,	O
+some	O
+patients	O
+may	O
+have	O
+amyopathic	B-DISO
+dermatomyositis	I-DISO
+(	O
+ADM	O
+)	O
+like	O
+presentation	O
+with	O
+predominant	O
+skin	B-ANAT
+involvement	O
+.	O
+
+ABSTRACT	O
+:	O
+On	O
+May	O
+20th	O
+2015	O
+,	O
+a	O
+68	O
+year	O
+old	O
+man	O
+was	O
+the	O
+first	O
+to	O
+be	O
+diagnosed	O
+with	O
+Middle	O
+East	O
+Respiratory	O
+Syndrome	B-DISO
+-	O
+Corona	B-CHED
+Virus	B-SPEC
+(	O
+MERS	O
+-	O
+CoV	O
+)	O
+in	O
+Korea	O
+.	O
+
+TITLE	O
+:	O
+Institutional	O
+Preparedness	O
+to	O
+Prevent	O
+Future	O
+Middle	O
+East	O
+Respiratory	O
+Syndrome	B-DISO
+Coronavirus	B-SPEC
+-	O
+Like	O
+Outbreaks	O
+in	O
+Republic	O
+of	O
+Korea	O
+.	O
+
+Thereafter	O
+,	O
+186	O
+Korean	O
+people	O
+were	O
+infected	O
+with	O
+the	O
+MERS	O
+-	O
+CoV	O
+in	O
+a	O
+short	O
+time	O
+through	O
+human	B-SPEC
+-	O
+to	O
+-	O
+human	B-SPEC
+transmission	O
+.	O
+
+Nevertheless	O
+,	O
+with	O
+the	O
+same	O
+infecting	O
+virus	B-SPEC
+strain	O
+,	O
+Korea	O
+experienced	O
+the	O
+largest	O
+MERS	O
+-	O
+CoV	O
+outbreak	O
+outside	O
+the	O
+Arabian	O
+Peninsula	O
+,	O
+primarily	O
+due	O
+to	O
+the	O
+different	O
+characteristics	O
+of	O
+population	O
+density	O
+and	O
+the	O
+healthcare	O
+system	O
+.	O
+
+TITLE	O
+:	O
+Outbreaks	O
+of	O
+Middle	O
+East	O
+Respiratory	O
+Syndrome	B-DISO
+in	O
+Two	O
+Hospitals	O
+Initiated	O
+by	O
+a	O
+Single	O
+Patient	O
+in	O
+Daejeon	O
+,	O
+South	O
+Korea	O
+.	O
+
+In	O
+Hospital	O
+B	O
+,	O
+the	O
+median	O
+incubation	O
+period	O
+was	O
+shorter	O
+(	O
+4	O
+.	O
+6	O
+days	O
+vs	O
+.	O
+10	O
+.	O
+8	O
+days	O
+),	O
+the	O
+median	O
+time	O
+to	O
+pneumonia	B-DISO
+development	B-PROC
+was	O
+faster	O
+(	O
+3	O
+days	O
+vs	O
+.	O
+6	O
+days	O
+)	O
+and	O
+mortality	O
+was	O
+higher	O
+(	O
+70	O
+%	O
+vs	O
+.	O
+30	O
+.	O
+8	O
+%)	O
+than	O
+in	O
+Hospital	O
+A	O
+.	O
+MERS	O
+-	O
+CoV	O
+isolates	O
+from	O
+11	O
+cases	O
+formed	O
+a	O
+single	O
+monophyletic	O
+clade	O
+,	O
+with	O
+the	O
+closest	O
+similarity	O
+to	O
+strains	O
+from	O
+Riyadh	O
+.	O
+
+RESULTS	O
+:	O
+In	O
+Daejeon	O
+,	O
+a	O
+MERS	O
+patient	O
+(	O
+the	O
+index	O
+case	O
+)	O
+was	O
+hospitalized	O
+at	O
+Hospital	O
+A	O
+in	O
+the	O
+first	O
+week	O
+of	O
+illness	O
+and	O
+was	O
+transferred	O
+to	O
+Hospital	O
+B	O
+because	O
+of	O
+pneumonia	B-DISO
+progression	O
+in	O
+the	O
+second	O
+week	O
+of	O
+illness	O
+,	O
+where	O
+he	O
+received	O
+a	O
+bronchoscopic	O
+examination	O
+and	O
+nebulizer	O
+therapy	O
+.	O
+
+The	O
+generational	O
+reproduction	B-PROC
+number	O
+(	O
+Rg	O
+)	O
+and	O
+case	O
+reproduction	B-PROC
+number	O
+(	O
+R	O
+(	O
+c	O
+)	O
+)	O
+were	O
+estimated	O
+over	O
+time	O
+.	O
+
+Older	O
+age	O
+,	O
+presence	O
+of	O
+coexisting	O
+medical	O
+conditions	O
+including	O
+diabetes	B-DISO
+or	O
+chronic	B-DISO
+lung	I-DISO
+disease	I-DISO
+,	O
+presence	O
+of	O
+dyspnea	B-DISO
+,	O
+hypotension	O
+,	O
+and	O
+leukocytosis	B-DISO
+at	O
+admission	O
+,	O
+and	O
+the	O
+use	O
+of	O
+mechanical	O
+ventilation	O
+were	O
+revealed	O
+to	O
+be	O
+independent	O
+predictors	O
+of	O
+death	B-PROC
+.	O
+
+TITLE	O
+:	O
+Combination	O
+of	O
+ECMO	O
+and	O
+cytokine	O
+adsorption	O
+therapy	O
+for	O
+severe	B-DISO
+sepsis	I-DISO
+with	O
+cardiogenic	B-DISO
+shock	I-DISO
+and	O
+ARDS	O
+due	O
+to	O
+Panton	O
+-	O
+Valentine	O
+leukocidin	O
+-	O
+positive	O
+Staphylococcus	B-DISO
+aureus	I-DISO
+pneumonia	I-DISO
+and	O
+H1N1	O
+.	O
+
+We	O
+describe	O
+the	O
+case	O
+of	O
+a	O
+33	O
+-	O
+year	O
+-	O
+old	O
+patient	O
+who	O
+developed	O
+acute	O
+cardiovascular	B-DISO
+collapse	I-DISO
+and	O
+ARDS	B-DISO
+secondary	O
+to	O
+superinfection	B-DISO
+of	O
+Panton	O
+-	O
+Valentine	O
+leukocidin	O
+-	O
+positive	O
+Staphylococcus	B-SPEC
+aureus	I-SPEC
+and	O
+H1N1	O
+pneumonia	B-DISO
+who	O
+underwent	O
+successful	O
+combination	O
+therapy	O
+for	O
+severe	B-DISO
+sepsis	I-DISO
+-	O
+related	O
+cardiomyopathy	B-DISO
+and	O
+respiratory	B-DISO
+failure	I-DISO
+using	O
+extracorporeal	O
+membrane	B-COMP
+oxygenation	B-PROC
+and	O
+cytokine	O
+adsorption	O
+therapy	O
+.	O
+
+TITLE	O
+:	O
+Role	O
+of	O
+Complement	O
+C5	O
+in	O
+Experimental	O
+Blunt	O
+Chest	B-ANAT
+Trauma	O
+-	O
+Induced	O
+Septic	O
+Acute	O
+Lung	B-ANAT
+Injury	O
+(	O
+ALI	O
+).	O
+
+RESULTS	O
+:	O
+In	O
+lung	B-ANAT
+tissue	I-ANAT
+interleukin	B-PRGE
+(	O
+IL	O
+)-	O
+6	O
+,	O
+monocyte	B-PRGE
+chemo	I-PRGE
+attractant	B-PROC
+protein	B-CHED
+-	I-PRGE
+1	I-PRGE
+(	O
+MCP	B-PRGE
+-	I-PRGE
+1	I-PRGE
+)	O
+and	O
+granulocyte	B-PRGE
+-	I-PRGE
+colony	I-PRGE
+stimulating	I-PRGE
+factor	I-PRGE
+(	O
+G	B-PRGE
+-	I-PRGE
+CSF	I-PRGE
+)	O
+was	O
+elevated	O
+in	O
+both	O
+C5	O
+-/-	O
+mice	B-SPEC
+and	O
+wildtype	O
+littermates	O
+(	O
+wt	O
+),	O
+whereas	O
+caspase	B-PRGE
+-	I-PRGE
+3	I-PRGE
+was	O
+reduced	O
+in	O
+lungs	B-ANAT
+after	O
+DH	O
+in	O
+C5	O
+-/-	O
+mice	B-SPEC
+.	O
+
+A	O
+combination	O
+of	O
+rodent	B-SPEC
+and	O
+nonhuman	O
+primate	B-SPEC
+models	O
+should	O
+be	O
+considered	O
+in	O
+evaluating	O
+and	O
+developing	O
+preventive	O
+and	O
+therapeutic	O
+vaccine	O
+candidates	O
+.	O
+
+Older	O
+patients	O
+(	O
+OR	O
+1	O
+.	O
+06	O
+(	O
+1	O
+.	O
+00	O
+to	O
+1	O
+.	O
+13	O
+),	O
+P	O
+=	O
+0	O
+.	O
+045	O
+)	O
+and	O
+those	O
+with	O
+mid	O
+-	O
+oesophageal	O
+tumours	B-DISO
+(	O
+OR	O
+7	O
+.	O
+48	O
+(	O
+1	O
+.	O
+62	O
+-	O
+34	O
+.	O
+5	O
+),	O
+P	O
+=	O
+0	O
+.	O
+010	O
+)	O
+had	O
+a	O
+higher	O
+risk	O
+for	O
+ARDS	B-DISO
+.	O
+
+Early	O
+and	O
+late	O
+ARDS	B-DISO
+after	O
+oesophagectomy	O
+increases	O
+intensive	O
+care	O
+and	O
+hospital	O
+length	O
+of	O
+stay	O
+.	O
+
+Given	O
+the	O
+high	O
+incidence	O
+of	O
+ARDS	B-DISO
+,	O
+cohorts	O
+of	O
+patients	O
+undergoing	O
+oesophagectomy	O
+may	O
+be	O
+useful	O
+as	O
+models	O
+for	O
+studies	O
+investigating	O
+ARDS	B-DISO
+prevention	O
+and	O
+treatment	O
+.	O
+
+Older	O
+patients	O
+(	O
+OR	O
+1	O
+.	O
+06	O
+(	O
+1	O
+.	O
+00	O
+to	O
+1	O
+.	O
+13	O
+),	O
+P	O
+=	O
+0	O
+.	O
+045	O
+)	O
+and	O
+those	O
+with	O
+mid	O
+-	O
+oesophageal	O
+tumours	B-DISO
+(	O
+OR	O
+7	O
+.	O
+48	O
+(	O
+1	O
+.	O
+62	O
+-	O
+34	O
+.	O
+5	O
+),	O
+P	O
+=	O
+0	O
+.	O
+010	O
+)	O
+had	O
+a	O
+higher	O
+risk	O
+for	O
+ARDS	B-DISO
+.	O
+
+The	O
+macro	O
+domain	O
+is	O
+an	O
+ancient	O
+and	O
+highly	O
+evolutionarily	O
+conserved	O
+protein	B-CHED
+domain	O
+widely	O
+distributed	O
+throughout	O
+all	O
+kingdoms	O
+of	O
+life	O
+,	O
+including	O
+viruses	B-SPEC
+.	O
+
+Three	O
+viral	O
+families	O
+,	O
+Coronaviridae	B-SPEC
+,	O
+Togaviridae	B-SPEC
+,	O
+and	O
+Hepeviridae	B-SPEC
+,	O
+possess	B-DISO
+macro	O
+domains	O
+embedded	O
+in	O
+their	O
+polyproteins	O
+.	O
+
+In	O
+the	O
+case	O
+of	O
+hepatitis	B-SPEC
+E	I-SPEC
+virus	I-SPEC
+,	O
+the	O
+adjacent	O
+viral	O
+helicase	B-PRGE
+domain	I-PRGE
+dramatically	O
+increases	O
+the	O
+binding	B-FUNC
+of	O
+the	O
+macro	O
+domain	O
+to	O
+PAR	B-PRGE
+and	O
+simulates	O
+the	O
+demodification	O
+activity	O
+.	O
+
+TITLE	O
+:	O
+Predicting	O
+the	O
+international	O
+spread	O
+of	O
+Middle	O
+East	O
+respiratory	O
+syndrome	B-DISO
+(	O
+MERS	O
+).	O
+
+Although	O
+model	O
+fit	B-DISO
+measured	O
+by	O
+Akaike	O
+Information	O
+Criterion	O
+(	O
+AIC	B-DISO
+)	O
+was	O
+improved	O
+by	O
+including	O
+country	O
+-	O
+specific	O
+religion	O
+(	O
+i	O
+.	O
+e	O
+.	O
+Muslim	O
+majority	O
+country	O
+),	O
+the	O
+predictive	O
+performance	O
+as	O
+measured	O
+by	O
+AUC	O
+was	O
+not	O
+improved	O
+after	O
+accounting	O
+for	O
+this	O
+covariate	O
+.	O
+
+Eligible	O
+patients	O
+will	O
+be	O
+randomly	O
+allocated	O
+to	O
+two	O
+arms	B-DISO
+:	O
+(	O
+i	O
+)	O
+conventional	O
+treatment	O
+without	O
+dexamethasone	B-CHED
+,	O
+(	O
+ii	O
+)	O
+conventional	O
+treatment	O
+plus	O
+dexamethasone	B-CHED
+.	O
+
+However	O
+,	O
+the	O
+patient	O
+developed	O
+severe	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+(	O
+ARDS	B-DISO
+)	O
+on	O
+the	O
+2nd	O
+day	O
+,	O
+and	O
+as	O
+a	O
+result	O
+,	O
+she	O
+underwent	O
+extracorporeal	O
+membrane	B-COMP
+oxygenation	B-PROC
+(	O
+ECMO	O
+).	O
+
+She	O
+was	O
+weaned	B-PROC
+from	O
+ECMO	O
+on	O
+the	O
+10th	O
+day	O
+,	O
+as	O
+her	O
+respiratory	O
+status	O
+gradually	O
+improved	O
+.	O
+
+Compared	O
+with	O
+nonobese	O
+women	O
+,	O
+super	O
+obese	B-DISO
+women	O
+had	O
+twofold	O
+odds	O
+of	O
+acute	O
+(	O
+5	O
+vs	O
+.	O
+10	O
+%;	O
+adjusted	O
+odds	O
+ratio	O
+[	O
+aOR	B-FUNC
+]:	O
+1	O
+.	O
+81	O
+,	O
+95	O
+%	O
+confidence	O
+interval	O
+[	O
+CI	O
+]:	O
+1	O
+.	O
+59	O
+-	O
+2	O
+.	O
+73	O
+)	O
+and	O
+severe	O
+(	O
+3	O
+vs	O
+.	O
+6	O
+%;	O
+aOR	B-FUNC
+:	O
+2	O
+.	O
+08	O
+;	O
+95	O
+%	O
+CI	O
+:	O
+1	O
+.	O
+59	O
+-	O
+2	O
+.	O
+73	O
+)	O
+neonatal	O
+morbidity	O
+.	O
+
+TITLE	O
+:	O
+Detection	O
+of	O
+RSV	B-SPEC
+Antibodies	B-COMP
+in	O
+Human	B-SPEC
+Plasma	B-ANAT
+by	O
+Enzyme	O
+Immunoassays	O
+.	O
+
+ABSTRACT	O
+:	O
+Enzyme	O
+immunoassays	O
+(	O
+EIAs	O
+)	O
+to	O
+detect	O
+and	O
+quantify	O
+antibodies	O
+against	O
+respiratory	B-SPEC
+syncytial	I-SPEC
+virus	I-SPEC
+(	O
+RSV	B-SPEC
+)	O
+and	O
+RSV	B-PRGE
+proteins	B-CHED
+in	O
+human	B-SPEC
+plasma	B-ANAT
+or	O
+sera	B-COMP
+are	O
+described	O
+.	O
+
+All	O
+three	O
+EIAs	O
+have	O
+been	O
+evaluated	O
+for	O
+detecting	O
+and	O
+quantifying	O
+the	O
+respective	O
+antibodies	B-COMP
+in	O
+human	B-SPEC
+sera	B-COMP
+or	O
+plasma	B-ANAT
+.	O
+
+Abelson	O
+Kinase	B-PROC
+Inhibitors	I-PROC
+Are	O
+Potent	O
+Inhibitors	B-CHED
+of	O
+Severe	B-DISO
+Acute	I-DISO
+Respiratory	I-DISO
+Syndrome	I-DISO
+Coronavirus	B-SPEC
+and	O
+Middle	O
+East	O
+Respiratory	O
+Syndrome	B-DISO
+Coronavirus	B-SPEC
+Fusion	O
+.	O
+
+Both	O
+SARS	B-PRGE
+-	I-PRGE
+CoV	I-PRGE
+and	O
+MERS	O
+-	O
+CoV	O
+are	O
+zoonotic	O
+infections	B-DISO
+,	O
+with	O
+bats	B-SPEC
+as	O
+the	O
+primary	O
+source	O
+.	O
+
+The	O
+emergence	O
+of	O
+SARS	B-PRGE
+-	I-PRGE
+CoV	I-PRGE
+and	O
+MERS	O
+-	O
+CoV	O
+provides	O
+evidence	O
+that	O
+coronaviruses	O
+are	O
+currently	O
+spreading	O
+from	O
+zoonotic	O
+sources	O
+and	O
+can	O
+be	O
+highly	O
+pathogenic	O
+,	O
+causing	O
+serious	O
+morbidity	O
+and	O
+mortality	O
+in	O
+humans	B-SPEC
+.	O
+
+ABSTRACT	O
+:	O
+A	O
+new	O
+family	O
+of	O
+IFNs	O
+called	O
+type	B-PRGE
+III	I-PRGE
+IFN	I-PRGE
+or	O
+IFN	B-PRGE
+-	I-PRGE
+λ	I-PRGE
+has	O
+been	O
+described	O
+,	O
+and	O
+shown	O
+to	O
+induce	O
+antiviral	B-CHED
+activity	O
+against	O
+several	O
+viruses	B-SPEC
+in	O
+the	O
+cell	B-COMP
+culture	O
+.	O
+
+This	O
+inhibitory	O
+effect	O
+of	O
+poIFN	O
+-	O
+λ3	O
+on	O
+PEDV	B-SPEC
+was	O
+observed	O
+under	O
+three	O
+different	O
+treatment	O
+conditions	O
+.	O
+
+For	O
+inclusion	O
+,	O
+the	O
+patients	O
+had	O
+to	O
+fulfill	O
+Yamaguchi	O
+or	O
+Fautrel	O
+classification	O
+criteria	O
+,	O
+show	O
+respiratory	B-DISO
+symptoms	I-DISO
+,	O
+and	O
+have	O
+imaging	O
+evidence	O
+of	O
+pulmonary	B-DISO
+involvement	I-DISO
+,	O
+and	O
+data	O
+allowing	O
+exclusion	O
+of	O
+infectious	B-DISO
+,	O
+cardiogenic	O
+,	O
+toxic	O
+,	O
+or	O
+iatrogenic	O
+cause	O
+of	O
+PLI	O
+should	O
+be	O
+available	O
+.	O
+
+Among	O
+these	O
+30	O
+AOSD	O
++	O
+PLI	O
+cases	O
+,	O
+12	O
+presented	O
+an	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+(	O
+ARDS	B-DISO
+)	O
+and	O
+the	O
+remaining	O
+18	O
+another	O
+PLI	O
+.	O
+
+In	O
+this	O
+report	O
+,	O
+we	O
+identified	O
+and	O
+characterized	O
+previously	O
+unknown	O
+and	O
+diverse	O
+genetic	O
+clusters	B-CHED
+of	O
+bat	B-ENZY
+coronaviruses	O
+in	O
+the	O
+Atlantic	O
+Forest	O
+Biome	O
+,	O
+Brazil	O
+.	O
+
+Serum	B-COMP
+was	O
+collected	O
+4	O
+to	O
+6	O
+weeks	O
+after	O
+the	O
+last	O
+contact	O
+with	O
+a	O
+confirmed	O
+MERS	O
+patient	O
+.	O
+
+In	O
+addition	O
+,	O
+a	O
+partial	O
+co	O
+-	O
+localization	B-PROC
+of	O
+TGEV	B-SPEC
+spike	O
+proteins	B-CHED
+with	O
+authentic	O
+host	B-COMP
+cell	I-COMP
+β	O
+-	O
+tubulin	B-PRGE
+was	O
+observed	O
+.	O
+
+Furthermore	O
+,	O
+drug	O
+-	O
+induced	O
+microtubule	B-PROC
+depolymerization	I-PROC
+led	O
+to	O
+changes	O
+in	O
+spike	O
+protein	B-PROC
+distribution	I-PROC
+,	O
+a	O
+reduction	O
+in	O
+the	O
+release	B-PATH
+of	O
+infectious	B-DISO
+virus	B-COMP
+particles	I-COMP
+and	O
+less	O
+amount	O
+of	O
+spike	O
+protein	B-CHED
+incorporated	O
+into	O
+virions	B-COMP
+.	O
+
+HPIV	O
+pneumonia	B-DISO
+in	O
+recipients	O
+of	O
+hematopoietic	B-PRGE
+stem	I-PRGE
+cell	I-PRGE
+transplant	B-ANAT
+(	O
+HSCT	O
+)	O
+is	O
+associated	O
+with	O
+50	O
+%	O
+acute	O
+mortality	O
+and	O
+75	O
+%	O
+mortality	O
+at	O
+6	O
+months	O
+.	O
+
+TITLE	O
+:	O
+Update	O
+on	O
+Human	B-SPEC
+Rhinovirus	I-SPEC
+and	O
+Coronavirus	B-DISO
+Infections	I-DISO
+.	O
+
+The	O
+role	O
+these	O
+viruses	B-SPEC
+play	O
+in	O
+patients	O
+with	O
+chronic	B-DISO
+lung	I-DISO
+disease	I-DISO
+such	O
+as	O
+asthma	B-PATH
+makes	O
+the	O
+search	O
+for	O
+antiviral	B-CHED
+agents	I-CHED
+of	O
+increased	O
+importance	O
+.	O
+
+The	O
+high	O
+mortality	O
+rates	O
+in	O
+family	B-SPEC
+-	O
+based	O
+and	O
+hospital	O
+-	O
+based	O
+outbreaks	O
+were	O
+reported	O
+among	O
+patients	O
+with	O
+comorbidities	O
+such	O
+as	O
+diabetes	B-DISO
+and	O
+renal	B-DISO
+failure	I-DISO
+.	O
+
+Key	O
+areas	O
+of	O
+interest	O
+are	O
+surveillance	O
+programs	O
+,	O
+political	O
+limitations	O
+on	O
+our	O
+ability	O
+to	O
+respond	O
+quickly	O
+enough	O
+to	O
+emerging	O
+threats	O
+,	O
+media	B-ANAT
+management	O
+,	O
+public	O
+information	O
+dissemination	O
+,	O
+infection	O
+control	O
+,	O
+prophylaxis	O
+,	O
+and	O
+individual	O
+patient	O
+management	O
+.	O
+
+TITLE	O
+:	O
+Antivirals	B-CHED
+for	O
+Respiratory	O
+Viral	B-DISO
+Infections	I-DISO
+:	O
+Problems	O
+and	O
+Prospects	O
+.	O
+
+Direct	O
+bilirubin	B-CHED
+and	O
+the	O
+arterial	B-ANAT
+oxygen	B-PROC
+tension	B-DISO
+/	O
+fraction	O
+of	O
+inspired	B-PROC
+oxygen	B-CHED
+ratio	O
+were	O
+significantly	O
+higher	O
+in	O
+the	O
+SLED	O
+group	O
+.	O
+
+The	O
+chimeric	O
+VP8	O
+-	O
+S2	O
+gene	O
+was	O
+cloned	O
+and	O
+sub	O
+-	O
+cloned	O
+into	O
+pGH	B-CHED
+and	O
+pET32a	O
+(+)	O
+vectors	O
+.	O
+
+Specific	O
+IgY	O
+against	O
+the	O
+recombinant	O
+VP8	O
+-	O
+S2	O
+could	O
+be	O
+recommended	O
+as	O
+a	O
+candidate	O
+for	O
+passive	O
+immunization	O
+against	O
+bovine	B-SPEC
+rotavirus	B-SPEC
+and	O
+bovine	B-SPEC
+coronavirus	B-SPEC
+.	O
+
+Using	O
+mouse	B-DISO
+hepatitis	I-DISO
+virus	B-SPEC
+(	O
+MHV	B-SPEC
+)	O
+infections	B-DISO
+as	O
+animal	B-SPEC
+models	O
+of	O
+viral	B-DISO
+hepatitis	I-DISO
+,	O
+we	O
+report	O
+for	O
+the	O
+first	O
+time	O
+that	O
+in	O
+vitro	O
+and	O
+in	O
+vivo	O
+infection	B-DISO
+of	O
+LSECs	O
+by	O
+the	O
+pathogenic	O
+MHV3	O
+serotype	O
+leads	O
+to	O
+a	O
+reversion	O
+of	O
+their	O
+intrinsic	O
+anti	O
+-	O
+inflammatory	O
+phenotype	O
+toward	O
+a	O
+proinflammatory	O
+profile	O
+as	O
+well	O
+to	O
+as	O
+disorders	O
+in	O
+vascular	B-ANAT
+factors	O
+,	O
+correlating	O
+with	O
+the	O
+severity	O
+of	O
+hepatitis	B-DISO
+.	O
+
+These	O
+results	O
+highlight	O
+a	O
+new	O
+virus	B-SPEC
+-	O
+promoted	O
+mechanism	O
+of	O
+exacerbation	O
+of	O
+liver	B-ANAT
+inflammatory	B-DISO
+response	I-DISO
+during	O
+acute	B-DISO
+hepatitis	I-DISO
+.	O
+
+In	O
+the	O
+current	O
+study	O
+,	O
+using	O
+the	O
+virus	B-SPEC
+overlay	O
+protein	B-FUNC
+binding	I-FUNC
+assay	O
+(	O
+VOPBA	O
+),	O
+we	O
+identified	O
+carcinoembryonic	O
+antigen	B-CHED
+-	O
+related	O
+cell	B-PROC
+adhesion	B-DISO
+molecule	O
+5	O
+(	O
+CEACAM5	B-PRGE
+)	O
+as	O
+a	O
+novel	O
+cell	B-FUNC
+surface	I-FUNC
+binding	I-FUNC
+target	O
+of	O
+MERS	O
+-	O
+CoV	O
+.	O
+CEACAM5	O
+coimmunoprecipitated	O
+with	O
+the	O
+spike	O
+protein	B-CHED
+of	O
+MERS	O
+-	O
+CoV	O
+in	O
+both	O
+overexpressed	O
+and	O
+endogenous	O
+settings	O
+.	O
+
+TITLE	O
+:	O
+Prevalence	O
+of	O
+Sleep	B-DISO
+-	I-DISO
+Disordered	I-DISO
+Breathing	B-PROC
+and	O
+Patient	O
+Characteristics	O
+in	O
+a	O
+Coronary	B-ANAT
+Artery	I-ANAT
+Disease	I-DISO
+Cohort	O
+Undergoing	O
+Cardiovascular	O
+Rehabilitation	O
+.	O
+
+SDB	O
+severity	O
+did	O
+not	O
+vary	O
+significantly	O
+in	O
+patients	O
+with	O
+stable	O
+CAD	B-DISO
+or	O
+on	O
+the	O
+basis	O
+of	O
+left	B-PROC
+ventricular	I-PROC
+ejection	I-PROC
+fraction	O
+.	O
+
+Multivariate	O
+logistic	O
+regression	O
+identified	O
+age	O
+,	O
+sex	O
+,	O
+body	B-ANAT
+mass	O
+index	O
+,	O
+and	O
+CABG	O
+as	O
+independent	O
+risk	O
+factors	O
+for	O
+severe	O
+SDB	O
+.	O
+
+CONCLUSIONS	O
+:	O
+SDB	O
+is	O
+a	O
+highly	O
+prevalent	O
+comorbidity	O
+in	O
+patients	O
+with	O
+CAD	B-DISO
+,	O
+particularly	O
+those	O
+who	O
+have	O
+undergone	O
+CABG	O
+.	O
+
+Nine	O
+possible	O
+recombination	B-PROC
+events	O
+were	O
+identified	O
+between	O
+the	O
+29	O
+identifed	O
+S1	O
+genes	O
+and	O
+the	O
+3	O
+S1	O
+reference	O
+genes	O
+from	O
+early	O
+Chinese	O
+PEDV	B-SPEC
+strains	O
+.	O
+
+The	O
+factors	O
+that	O
+regulate	O
+neutrophil	B-ANAT
+infiltration	B-DISO
+into	O
+the	O
+inflamed	O
+lung	B-ANAT
+and	O
+our	O
+understanding	O
+of	O
+the	O
+pathomechanisms	O
+in	O
+ARDS	B-DISO
+remain	O
+incomplete	O
+.	O
+
+BAL	B-ENZY
+fluid	O
+from	O
+patients	O
+with	O
+ARDS	B-DISO
+was	O
+highly	O
+chemotactic	O
+for	O
+human	B-SPEC
+neutrophils	B-ANAT
+and	O
+neutralising	O
+either	O
+CCL2	B-PRGE
+or	O
+CCL7	B-PRGE
+attenuated	O
+the	O
+neutrophil	B-DISO
+chemotactic	I-DISO
+response	I-DISO
+.	O
+
+This	O
+study	O
+highlights	O
+important	O
+inflammatory	O
+chemokines	O
+involved	O
+in	O
+regulating	O
+neutrophil	B-DISO
+migration	I-DISO
+,	O
+which	O
+may	O
+have	O
+potential	O
+value	O
+as	O
+therapeutic	O
+targets	O
+for	O
+the	O
+treatment	O
+of	O
+ARDS	B-DISO
+.	O
+
+RESULTS	O
+:	O
+CCL2	B-PRGE
+and	O
+CCL7	B-PRGE
+were	O
+significantly	O
+elevated	O
+in	O
+BAL	B-ENZY
+fluid	O
+recovered	O
+from	O
+LPS	B-DISO
+-	O
+challenged	O
+volunteers	O
+and	O
+patients	O
+with	O
+ARDS	B-DISO
+.	O
+
+TITLE	O
+:	O
+Occurrence	O
+and	O
+sequence	O
+analysis	O
+of	O
+porcine	B-SPEC
+deltacoronaviruses	O
+in	O
+southern	O
+China	O
+.	O
+
+TITLE	O
+:	O
+Immunogenicity	O
+and	O
+protective	O
+efficacy	O
+of	O
+recombinant	O
+fusion	O
+proteins	B-CHED
+containing	O
+spike	O
+protein	B-CHED
+of	O
+infectious	B-DISO
+bronchitis	B-DISO
+virus	B-SPEC
+and	O
+hemagglutinin	O
+of	O
+H3N2	B-CHED
+influenza	B-SPEC
+virus	I-SPEC
+in	O
+chickens	B-SPEC
+.	O
+
+However	O
+,	O
+there	O
+is	O
+a	O
+paucity	O
+of	O
+data	O
+regarding	O
+long	O
+-	O
+term	O
+CT	O
+findings	O
+in	O
+survivors	O
+after	O
+SARS	B-DISO
+.	O
+
+PICU	B-SPEC
+patients	O
+.	O
+
+Compared	O
+with	O
+children	O
+with	O
+other	O
+enteroviruses	B-SPEC
+and	O
+rhinoviruses	B-SPEC
+,	O
+children	O
+with	O
+enterovirus	B-SPEC
+D68	O
+were	O
+more	O
+likely	O
+to	O
+have	O
+a	O
+history	O
+of	O
+asthma	B-PATH
+(	O
+64	O
+%	O
+vs	O
+45	O
+%)	O
+or	O
+multiple	O
+prior	O
+wheezing	B-DISO
+episodes	O
+(	O
+54	O
+%	O
+vs	O
+34	O
+%;	O
+p	O
+<	O
+0	O
+.	O
+01	O
+for	O
+both	O
+).	O
+
+ABSTRACT	O
+:	O
+BACKGROUND	O
+Unexplained	O
+renal	B-DISO
+insufficiency	I-DISO
+combined	O
+with	O
+hepatic	B-DISO
+failure	I-DISO
+is	O
+a	O
+common	O
+problem	O
+encountered	O
+by	O
+clinicians	O
+.	O
+
+His	O
+symptoms	O
+started	O
+with	O
+dark	B-DISO
+urine	I-DISO
+,	O
+severe	O
+cramps	B-DISO
+in	O
+the	O
+thighs	B-ANAT
+,	O
+and	O
+chills	B-DISO
+.	O
+
+Positive	O
+physical	O
+examination	O
+findings	O
+included	O
+mild	O
+tachycardia	O
+and	O
+hypotension	O
+,	O
+scleral	B-DISO
+icterus	I-DISO
+,	O
+and	O
+tenderness	B-DISO
+over	O
+abdomen	B-ANAT
+,	O
+costovertebral	O
+angles	O
+,	O
+and	O
+thighs	B-ANAT
+.	O
+
+The	O
+patient	O
+'	O
+s	O
+condition	B-DISO
+drastically	O
+improved	O
+after	O
+initiation	O
+of	O
+doxycycline	B-CHED
+.	O
+
+On	O
+subsequent	O
+days	O
+,	O
+the	O
+patient	O
+'	O
+s	O
+Leptospira	B-SPEC
+antibody	B-COMP
+results	O
+were	O
+available	O
+,	O
+showing	O
+titers	O
+of	O
+more	O
+than	O
+1	O
+:	O
+3200	O
+.	O
+
+The	O
+MERS	O
+outbreak	O
+was	O
+sparked	O
+by	O
+an	O
+exported	O
+case	O
+from	O
+the	O
+Middle	O
+East	O
+,	O
+which	O
+remains	O
+a	O
+concern	O
+as	O
+the	O
+reservoir	O
+of	O
+infection	B-DISO
+(	O
+thought	O
+to	O
+be	O
+camels	B-SPEC
+)	O
+continues	O
+to	O
+exist	O
+in	O
+the	O
+Middle	O
+East	O
+,	O
+and	O
+sporadic	O
+cases	O
+in	O
+the	O
+community	O
+and	O
+outbreaks	O
+in	O
+health	O
+-	O
+care	O
+settings	O
+continue	O
+to	O
+occur	O
+there	O
+.	O
+
+This	O
+risk	O
+assessment	O
+highlights	O
+the	O
+need	O
+for	O
+Singapore	O
+to	O
+stay	O
+vigilant	O
+and	O
+to	O
+continue	O
+enhancing	O
+core	O
+public	O
+health	O
+capacities	O
+to	O
+detect	O
+and	O
+respond	O
+to	O
+MERS	O
+coronavirus	B-SPEC
+.	O
+
+SM	B-PRGE
+synthase	I-PRGE
+(	O
+SMS	B-DISO
+)	O
+is	O
+a	O
+key	O
+enzyme	O
+in	O
+the	O
+synthesis	B-PROC
+of	O
+SM	O
+,	O
+however	O
+,	O
+the	O
+effect	O
+of	O
+SMS	B-DISO
+on	O
+the	O
+inflammatory	O
+pathway	B-PROC
+involving	O
+nuclear	B-PRGE
+factor	I-PRGE
+(	O
+NF	O
+)‑	O
+κB	O
+induced	O
+by	O
+LPS	B-DISO
+remains	O
+to	O
+be	O
+elucidated	O
+.	O
+
+Under	O
+the	O
+premise	O
+of	O
+the	O
+establishment	O
+of	O
+an	O
+ALI	O
+mouse	B-SPEC
+model	O
+induced	O
+by	O
+LPS	O
+,	O
+the	O
+present	O
+study	O
+established	O
+a	O
+control	O
+group	O
+,	O
+LPS	B-DISO
+group	O
+and	O
+pyrrolidine	B-CHED
+dithiocarbamate	O
+(	O
+PDTC	O
+;	O
+an	O
+NF	O
+‑	O
+κB	O
+pathway	B-PROC
+inhibitor	B-CHED
+)	O
+group	O
+.	O
+
+Hematoxylin	B-CHED
+‑	I-CHED
+eosin	I-CHED
+staining	O
+,	O
+reverse	B-PROC
+transcription	O
+‑	O
+quantitative	O
+polymerase	O
+chain	O
+reaction	O
+analysis	O
+,	O
+western	O
+blot	O
+analysis	O
+and	O
+thin	O
+layer	B-ANAT
+chromatography	O
+were	O
+used	O
+to	O
+investigate	O
+the	O
+mechanism	O
+of	O
+SMS	B-DISO
+in	O
+ALI	O
+.	O
+
+These	O
+findings	O
+suggested	O
+that	O
+the	O
+degree	O
+of	O
+lung	B-ANAT
+injury	O
+was	O
+reduced	O
+during	O
+the	O
+acute	O
+inflammatory	B-DISO
+reaction	I-DISO
+when	O
+NF	O
+‑	O
+κB	O
+was	O
+inhibited	O
+,	O
+and	O
+that	O
+the	O
+expression	B-PROC
+of	O
+SMS2	B-FUNC
+may	O
+affect	O
+the	O
+induction	O
+of	O
+the	O
+NF	O
+‑	O
+κB	O
+pathway	B-PROC
+by	O
+LPS	B-DISO
+through	O
+CD14	B-PRGE
+.	O
+
+TITLE	O
+:	O
+Association	O
+Between	O
+Train	O
+-	O
+of	O
+-	O
+Four	O
+Values	O
+and	O
+Gas	B-ENZY
+Exchange	O
+Indices	O
+in	O
+Moderate	O
+to	O
+Severe	O
+Acute	B-DISO
+Respiratory	I-DISO
+Distress	I-DISO
+Syndrome	I-DISO
+.	O
+
+TITLE	O
+:	O
+Eosinophilic	B-DISO
+Lung	I-DISO
+Diseases	O
+.	O
+
+Within	O
+the	O
+55	O
+South	O
+China	O
+PEDV	B-SPEC
+field	O
+strains	O
+,	O
+the	O
+deduced	O
+amino	B-CHED
+acid	I-CHED
+sequence	O
+identities	O
+ranged	O
+from	O
+93	O
+.	O
+8	O
+%	O
+to	O
+99	O
+.	O
+9	O
+%	O
+and	O
+ranged	O
+from	O
+90	O
+.	O
+7	O
+%	O
+to	O
+99	O
+.	O
+5	O
+%	O
+when	O
+compared	O
+with	O
+the	O
+foreign	O
+reference	O
+strains	O
+in	O
+GenBank	O
+.	O
+
+The	O
+available	O
+vaccines	O
+against	O
+IBV	B-SPEC
+cannot	O
+cover	O
+new	O
+variants	O
+.	O
+
+Each	O
+cowcalf	O
+-	O
+pair	O
+was	O
+visited	O
+three	O
+times	O
+within	O
+the	O
+first	O
+6	O
+weeks	O
+of	O
+life	O
+to	O
+collect	O
+data	O
+of	O
+the	O
+farm	O
+and	O
+animals	B-SPEC
+,	O
+as	O
+well	O
+as	O
+blood	B-ANAT
+,	O
+faecal	B-ANAT
+,	O
+colostral	O
+and	O
+milk	O
+samples	O
+.	O
+
+Cryptosporidium	O
+oocysts	O
+were	O
+diagnosed	O
+with	O
+the	O
+modified	O
+Ziehl	O
+-	O
+Neelsen	O
+staining	O
+,	O
+other	O
+protozoa	O
+with	O
+the	O
+SAFC	O
+method	O
+and	O
+Eimeria	B-SPEC
+oocysts	O
+and	O
+helminth	O
+eggs	O
+were	O
+diagnosed	O
+with	O
+the	O
+combined	O
+sedimentation	O
+/	O
+floatation	O
+test	O
+.	O
+
+Calves	O
+housed	O
+in	O
+open	O
+sheds	O
+showed	O
+significantly	O
+more	O
+often	O
+diarrhea	B-DISO
+,	O
+i	O
+.	O
+e	O
+.	O
+they	O
+shed	O
+more	O
+Cryptosporidium	B-SPEC
+oocysts	O
+during	O
+the	O
+first	O
+4	O
+days	O
+and	O
+7	O
+to	O
+20	O
+days	O
+post	O
+natum	O
+,	O
+respectively	O
+.	O
+
+In	O
+general	O
+,	O
+the	O
+nucleotide	O
+bias	B-SPEC
+was	O
+the	O
+major	O
+determinant	O
+of	O
+the	O
+virus	B-SPEC
+-	O
+specific	O
+codon	O
+usages	O
+,	O
+thus	O
+limiting	O
+a	O
+role	O
+for	O
+codon	O
+selection	O
+and	O
+translational	B-PROC
+control	O
+.	O
+
+TITLE	O
+:	O
+p53	B-PRGE
+down	O
+-	O
+regulates	O
+SARS	B-DISO
+coronavirus	B-SPEC
+replication	O
+and	O
+is	O
+targeted	B-PROC
+by	O
+the	O
+SARS	B-DISO
+-	O
+unique	O
+domain	O
+and	O
+PLpro	O
+via	O
+E3	O
+ubiquitin	O
+ligase	O
+RCHY1	O
+.	O
+
+We	O
+show	O
+that	O
+p53	B-PRGE
+inhibits	O
+replication	O
+of	O
+infectious	B-DISO
+SARS	B-PRGE
+-	I-PRGE
+CoV	I-PRGE
+as	O
+well	O
+as	O
+of	O
+replicons	O
+and	O
+human	B-SPEC
+coronavirus	I-SPEC
+NL63	I-SPEC
+.	O
+
+TITLE	O
+:	O
+The	O
+Acute	B-DISO
+Respiratory	I-DISO
+Distress	I-DISO
+Syndrome	I-DISO
+(	O
+ARDS	B-DISO
+)	O
+in	O
+mechanically	O
+ventilated	O
+burn	O
+patients	O
+:	O
+An	O
+analysis	O
+of	O
+risk	O
+factors	O
+,	O
+clinical	O
+features	O
+,	O
+and	O
+outcomes	O
+using	O
+the	O
+Berlin	O
+ARDS	O
+definition	O
+.	O
+
+This	O
+study	O
+'	O
+s	O
+purpose	O
+was	O
+to	O
+use	O
+the	O
+Berlin	O
+definition	O
+to	O
+determine	O
+the	O
+incidence	O
+of	O
+ARDS	B-DISO
+,	O
+and	O
+its	O
+associated	O
+respiratory	B-DISO
+morbidity	I-DISO
+,	O
+and	O
+mortality	O
+among	O
+civilian	O
+burn	O
+patients	O
+.	O
+
+The	O
+%	O
+FT	O
+burn	O
+predicted	O
+the	O
+development	B-PROC
+of	O
+moderate	O
+to	O
+severe	O
+ARDS	B-DISO
+[	O
+OR	O
+1	O
+.	O
+034	O
+,	O
+95	O
+%	O
+CI	O
+(	O
+1	O
+.	O
+013	O
+-	O
+1	O
+.	O
+055	O
+),	O
+p	O
+=	O
+0	O
+.	O
+001	O
+].	O
+
+ARDS	B-DISO
+developed	O
+in	O
+the	O
+1st	O
+week	O
+after	O
+burn	O
+in	O
+86	O
+%	O
+of	O
+cases	O
+.	O
+
+Increasing	O
+severity	O
+of	O
+ARDS	B-DISO
+based	O
+upon	O
+the	O
+Berlin	O
+definition	O
+was	O
+associated	O
+with	O
+a	O
+significantly	O
+greater	O
+duration	O
+of	O
+mechanical	O
+ventilation	O
+and	O
+a	O
+trend	O
+toward	O
+higher	O
+mortality	O
+.	O
+
+However	O
+,	O
+its	O
+general	O
+application	O
+has	O
+been	O
+hampered	O
+by	O
+difficulty	O
+in	O
+identifying	O
+a	O
+specific	O
+ligand	B-PROC
+-	O
+responsive	O
+pseudoknot	O
+that	O
+also	O
+functions	O
+as	O
+a	O
+ligand	B-PROC
+-	O
+dependent	O
+-	O
+1	O
+PRF	O
+stimulator	O
+.	O
+
+TITLE	O
+:	O
+A	O
+dynamic	O
+compartmental	O
+model	O
+for	O
+the	O
+Middle	O
+East	O
+respiratory	O
+syndrome	B-DISO
+outbreak	O
+in	O
+the	O
+Republic	O
+of	O
+Korea	O
+:	O
+A	O
+retrospective	O
+analysis	O
+on	O
+control	O
+interventions	O
+and	O
+superspreading	O
+events	O
+.	O
+
+Our	O
+model	O
+was	O
+able	O
+to	O
+provide	O
+a	O
+good	O
+fit	B-DISO
+to	O
+the	O
+trajectory	O
+of	O
+the	O
+outbreak	O
+and	O
+was	O
+useful	O
+to	O
+analyze	O
+the	O
+role	O
+of	O
+hypothetical	O
+control	O
+scenarios	O
+.	O
+
+ABSTRACT	O
+:	O
+Acute	B-DISO
+respiratory	I-DISO
+failure	I-DISO
+(	O
+ARF	B-DISO
+)	O
+is	O
+a	O
+leading	O
+indication	O
+for	O
+performing	O
+critical	O
+care	O
+ultrasonography	O
+(	O
+CCUS	O
+)	O
+which	O
+,	O
+in	O
+these	O
+patients	O
+,	O
+combines	O
+critical	O
+care	O
+echocardiography	O
+(	O
+CCE	O
+)	O
+and	O
+chest	B-ANAT
+ultrasonography	O
+.	O
+
+Some	O
+classical	O
+CIRD	O
+agents	O
+,	O
+such	O
+as	O
+canine	O
+adenoviruses	B-SPEC
+,	O
+canine	B-SPEC
+distemper	I-SPEC
+virus	I-SPEC
+and	O
+canid	B-SPEC
+herpesvirus	I-SPEC
+1	I-SPEC
+,	O
+were	O
+not	O
+detected	O
+at	O
+all	O
+,	O
+as	O
+were	O
+not	O
+other	O
+emerging	O
+respiratory	O
+viruses	B-SPEC
+(	O
+canine	O
+influenza	B-SPEC
+virus	I-SPEC
+,	O
+canine	O
+hepacivirus	B-SPEC
+)	O
+and	O
+bacteria	B-SPEC
+(	O
+Streptococcus	O
+equi	O
+subsp	O
+.	O
+
+Human	B-SPEC
+-	O
+and	O
+dromedary	B-SPEC
+-	O
+derived	O
+viruses	B-SPEC
+are	O
+each	O
+monophyletic	O
+,	O
+suggesting	O
+ecological	O
+isolation	O
+.	O
+
+However	O
+,	O
+inefficient	O
+replication	O
+in	O
+several	O
+mucosa	B-ANAT
+-	O
+derived	O
+cell	B-ANAT
+lines	I-ANAT
+and	O
+airway	B-ANAT
+epithelial	O
+cultures	O
+suggested	O
+lack	O
+of	O
+adaptation	B-PROC
+to	O
+the	O
+human	B-SPEC
+host	B-COMP
+.	O
+
+Antibodies	B-COMP
+in	O
+human	B-SPEC
+sera	B-COMP
+neutralized	O
+dromedary	B-SPEC
+-	O
+derived	O
+viruses	B-SPEC
+,	O
+suggesting	O
+population	O
+immunity	B-PROC
+against	O
+dromedary	B-SPEC
+viruses	B-SPEC
+.	O
+
+ABSTRACT	O
+:	O
+In	O
+pathological	O
+situations	O
+such	O
+as	O
+ischemia	B-DISO
+-	O
+reperfusion	O
+and	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+,	O
+reactive	B-CHED
+oxygen	I-CHED
+species	I-CHED
+(	O
+ROS	B-CHED
+)	O
+are	O
+produced	O
+by	O
+different	O
+systems	O
+which	O
+are	O
+involved	O
+in	O
+endothelial	B-ANAT
+cells	I-ANAT
+injury	O
+,	O
+ultimately	O
+leading	O
+to	O
+severe	O
+organ	B-ANAT
+dysfunctions	O
+.	O
+
+The	O
+biphasic	O
+effect	O
+was	O
+not	O
+seen	O
+with	O
+ERK1	B-PRGE
+/	I-PRGE
+2	I-PRGE
+where	O
+a	O
+decrease	O
+in	O
+phosphorylation	B-PROC
+only	O
+was	O
+observed	O
+.	O
+
+A	O
+new	O
+potential	O
+recombination	B-PROC
+hotspot	O
+[	O
+ATTTT	O
+(	O
+T	O
+/	O
+A	O
+)]	O
+was	O
+identified	O
+,	O
+implying	O
+that	O
+recombination	B-PROC
+events	O
+may	O
+become	O
+more	O
+and	O
+more	O
+common	O
+.	O
+
+Six	O
+of	O
+the	O
+seven	O
+field	O
+isolates	O
+(	O
+all	O
+except	O
+for	O
+cK	O
+/	O
+CH	O
+/	O
+SCYB	B-PRGE
+/	O
+140913	O
+)	O
+cross	O
+-	O
+reacted	O
+well	O
+with	O
+anti	O
+-	O
+sera	B-COMP
+against	O
+other	O
+field	O
+strains	O
+.	O
+
+Impact	O
+on	O
+Intensive	O
+Care	O
+Unit	O
+-	O
+Acquired	O
+Weakness	B-DISO
+.	O
+
+ABSTRACT	O
+:	O
+Systemic	O
+inflammation	O
+and	O
+duration	O
+of	O
+immobilization	O
+are	O
+strong	O
+independent	O
+risk	O
+factors	O
+for	O
+the	O
+development	B-PROC
+of	O
+intensive	O
+care	O
+unit	O
+-	O
+acquired	O
+weakness	B-DISO
+(	O
+ICUAW	O
+).	O
+
+TITLE	O
+:	O
+Feasibility	O
+of	O
+Using	O
+Convalescent	O
+Plasma	B-ANAT
+Immunotherapy	O
+for	O
+MERS	O
+-	O
+CoV	O
+Infection	B-DISO
+,	O
+Saudi	O
+Arabia	O
+.	O
+
+ABSTRACT	O
+:	O
+Confirmation	O
+of	O
+an	O
+imported	O
+case	O
+of	O
+infection	O
+with	O
+Middle	O
+East	O
+respiratory	O
+syndrome	B-DISO
+coronavirus	B-SPEC
+in	O
+China	O
+triggered	O
+intensive	O
+contact	O
+tracing	O
+and	O
+mandatory	O
+monitoring	O
+.	O
+
+Contact	O
+monitoring	O
+detected	O
+no	O
+secondary	B-DISO
+transmission	I-DISO
+of	O
+infection	B-DISO
+in	O
+China	O
+.	O
+
+ABSTRACT	O
+:	O
+One	O
+of	O
+the	O
+most	O
+characteristic	O
+pathological	O
+changes	O
+in	O
+cats	B-SPEC
+that	O
+have	O
+succumbed	O
+to	O
+feline	B-DISO
+infectious	I-DISO
+peritonitis	I-DISO
+(	O
+FIP	B-DISO
+)	O
+is	O
+a	O
+multifocal	O
+granulomatous	O
+phlebitis	B-DISO
+.	O
+
+Immunofluorescence	O
+analysis	O
+revealed	O
+that	O
+the	O
+endothelial	O
+expression	B-PROC
+of	O
+P	B-PRGE
+-	I-PRGE
+selectin	I-PRGE
+,	O
+E	B-PRGE
+-	I-PRGE
+selectin	I-PRGE
+,	O
+intercellular	B-PRGE
+adhesion	I-PRGE
+molecule	I-PRGE
+1	I-PRGE
+(	O
+ICAM	B-PRGE
+-	I-PRGE
+1	I-PRGE
+)	O
+and	O
+vascular	B-PRGE
+cell	B-PROC
+adhesion	B-DISO
+molecule	I-PRGE
+1	I-PRGE
+(	O
+VCAM	B-PRGE
+-	I-PRGE
+1	I-PRGE
+)	O
+was	O
+elevated	O
+in	O
+veins	B-ANAT
+close	O
+to	O
+granulomatous	O
+infiltrates	B-DISO
+in	O
+the	O
+renal	B-ANAT
+cortex	I-ANAT
+of	O
+FIP	B-DISO
+patients	O
+compared	O
+to	O
+non	O
+-	O
+infiltrated	B-DISO
+regions	O
+and	O
+specimens	O
+from	O
+healthy	O
+cats	B-SPEC
+.	O
+
+Next	O
+,	O
+we	O
+showed	O
+that	O
+feline	B-SPEC
+venous	B-ANAT
+ECs	O
+become	O
+activated	O
+when	O
+exposed	O
+to	O
+supernatant	O
+from	O
+feline	B-DISO
+infectious	I-DISO
+peritonitis	I-DISO
+virus	B-SPEC
+(	O
+FIPV	O
+)-	O
+infected	O
+monocytes	B-ANAT
+,	O
+as	O
+indicated	O
+by	O
+increased	O
+adhesion	B-DISO
+molecule	O
+expression	B-PROC
+.	O
+
+Taken	O
+together	O
+,	O
+our	O
+results	O
+strongly	O
+indicate	O
+that	O
+FIPV	O
+activates	O
+ECs	O
+to	O
+increase	O
+monocyte	B-ANAT
+adhesion	B-DISO
+by	O
+an	O
+indirect	O
+route	O
+,	O
+in	O
+which	O
+proinflammatory	O
+factors	O
+released	O
+from	O
+virus	B-SPEC
+-	O
+infected	O
+monocytes	B-ANAT
+act	O
+as	O
+key	O
+intermediates	O
+.	O
+
+Similarly	O
+,	O
+patients	O
+with	O
+mild	O
+frailty	O
+(	O
+OR	O
+1	O
+.	O
+88	O
+;	O
+95	O
+%	O
+CI	O
+1	O
+.	O
+33	O
+-	O
+2	O
+.	O
+66	O
+),	O
+moderate	O
+frailty	O
+(	O
+OR	O
+3	O
+.	O
+83	O
+;	O
+95	O
+%	O
+CI	O
+2	O
+.	O
+71	O
+-	O
+5	O
+.	O
+41	O
+),	O
+and	O
+severe	O
+frailty	O
+(	O
+OR	O
+6	O
+.	O
+97	O
+;	O
+95	O
+%	O
+CI	O
+4	O
+.	O
+98	O
+-	O
+9	O
+.	O
+74	O
+)	O
+had	O
+significantly	O
+increased	O
+odds	O
+of	O
+developing	O
+a	O
+major	O
+in	O
+-	O
+hospital	O
+complication	B-DISO
+(	O
+all	O
+P	O
+<	O
+0	O
+.	O
+001	O
+).	O
+
+Twenty	O
+-	O
+two	O
+percent	O
+met	B-CHED
+the	O
+primary	O
+outcome	O
+,	O
+21	O
+%	O
+died	B-PROC
+,	O
+and	O
+57	O
+%	O
+developed	O
+kidney	B-ANAT
+injury	O
+.	O
+
+Fluid	O
+volume	O
+was	O
+not	O
+associated	O
+with	O
+intubation	O
+in	O
+patients	O
+with	O
+a	O
+low	O
+syndecan	B-PRGE
+-	I-PRGE
+1	I-PRGE
+level	O
+but	O
+was	O
+associated	O
+with	O
+intubation	O
+in	O
+those	O
+with	O
+high	O
+syndecan	O
+-	O
+1	O
+levels	O
+.	O
+
+In	O
+order	B-SPEC
+to	O
+understand	O
+if	O
+these	O
+animals	B-SPEC
+could	O
+be	O
+infected	O
+,	O
+we	O
+challenged	O
+young	O
+goats	B-SPEC
+and	O
+horses	B-SPEC
+and	O
+adult	O
+sheep	B-SPEC
+with	O
+MERS	O
+-	O
+CoV	O
+by	O
+intranasal	O
+inoculation	O
+.	O
+
+During	O
+the	O
+four	O
+weeks	O
+following	O
+inoculation	O
+,	O
+neutralizing	O
+antibodies	B-COMP
+were	O
+detected	O
+in	O
+the	O
+young	O
+goats	B-SPEC
+,	O
+but	O
+not	O
+in	O
+sheep	B-SPEC
+or	O
+horses	B-SPEC
+.	O
+
+TMPRSS2	O
+,	O
+which	O
+is	O
+localized	O
+to	O
+the	O
+plasma	B-COMP
+membrane	I-COMP
+,	O
+is	O
+a	O
+serine	B-PRGE
+protease	I-PRGE
+responsible	O
+for	O
+the	O
+proteolysis	B-PROC
+of	O
+S	O
+in	O
+the	O
+post	O
+-	O
+receptor	O
+-	O
+binding	B-FUNC
+stage	O
+.	O
+
+Herein	O
+,	O
+a	O
+facile	O
+approach	O
+to	O
+formulate	O
+synthetic	O
+virus	B-ANAT
+-	I-ANAT
+like	I-ANAT
+particles	I-ANAT
+(	O
+sVLPs	O
+)	O
+is	O
+demonstrated	O
+by	O
+exploiting	O
+the	O
+phenomenon	O
+of	O
+protein	B-CHED
+corona	B-CHED
+formation	B-PROC
+induced	O
+by	O
+the	O
+high	O
+-	O
+energy	O
+surfaces	O
+of	O
+synthetic	O
+nanoparticles	B-CHED
+.	O
+
+As	O
+compared	O
+to	O
+inoculation	O
+with	O
+free	O
+proteins	B-CHED
+,	O
+vaccination	O
+with	O
+the	O
+sVLPs	O
+showed	O
+enhanced	O
+lymphatic	B-PRGE
+antigen	B-CHED
+delivery	I-PRGE
+,	I-PRGE
+stronger	I-PRGE
+antibody	B-COMP
+titers	O
+,	O
+increased	O
+splenic	B-ANAT
+T	B-ANAT
+-	I-ANAT
+cell	I-ANAT
+response	O
+,	O
+and	O
+reduced	O
+infection	B-DISO
+-	O
+associated	B-DISO
+symptoms	I-DISO
+in	O
+an	O
+avian	B-SPEC
+model	O
+of	O
+coronavirus	B-DISO
+infection	I-DISO
+.	O
+
+Comparison	O
+to	O
+a	O
+commercial	O
+whole	O
+inactivated	O
+virus	B-SPEC
+vaccine	O
+also	O
+showed	O
+evidence	O
+of	O
+superior	O
+antiviral	B-CHED
+protection	O
+by	O
+the	O
+sVLPs	O
+.	O
+
+The	O
+study	O
+demonstrates	O
+a	O
+simple	O
+yet	O
+robust	O
+method	O
+in	O
+bridging	O
+viral	O
+antigens	B-CHED
+with	O
+synthetic	O
+nanoparticles	B-CHED
+for	O
+improved	O
+vaccine	O
+application	O
+;	O
+it	O
+has	O
+practical	O
+implications	O
+in	O
+the	O
+management	O
+of	O
+human	B-SPEC
+viral	B-DISO
+infections	I-DISO
+as	O
+well	O
+as	O
+in	O
+animal	B-SPEC
+agriculture	O
+.	O
+
+Methods	O
+Agarose	B-CHED
+gel	O
+electrophoresis	O
+(	O
+AGE	O
+)	O
+and	O
+capillary	B-ANAT
+zone	O
+electrophoresis	O
+(	O
+CZE	O
+)	O
+from	O
+cats	B-SPEC
+with	O
+FIP	B-DISO
+and	O
+healthy	O
+cats	B-SPEC
+recorded	O
+in	O
+the	O
+periods	B-PROC
+2004	O
+-	O
+2009	O
+and	O
+2013	O
+-	O
+2014	O
+were	O
+retrospectively	O
+analysed	O
+.	O
+
+TITLE	O
+:	O
+TGEV	B-SPEC
+infection	B-DISO
+up	O
+-	O
+regulates	O
+FcRn	O
+expression	B-PROC
+via	O
+activation	O
+of	O
+NF	O
+-	O
+κB	O
+signaling	B-PROC
+.	O
+
+How	O
+porcine	B-PRGE
+FcRn	I-PRGE
+(	O
+pFcRn	O
+)	O
+expression	B-PROC
+is	O
+regulated	O
+by	O
+pathogenic	O
+infection	B-DISO
+remains	O
+unknown	O
+.	O
+
+In	O
+addition	O
+,	O
+the	O
+NF	O
+-	O
+κB	O
+signaling	B-PROC
+pathway	I-PROC
+was	O
+activated	O
+in	O
+IPEC	O
+-	O
+J2	O
+cells	B-COMP
+by	O
+TGEV	B-SPEC
+infection	B-DISO
+.	O
+
+Transient	O
+transfection	B-PROC
+of	O
+pFcRn	O
+promoter	O
+luciferase	B-ENZY
+report	O
+plasmids	O
+with	O
+overexpression	B-PROC
+of	O
+NF	O
+-	O
+κB	O
+p65	O
+transcription	O
+factor	O
+enhanced	O
+the	O
+activation	O
+of	O
+the	O
+luciferase	B-ENZY
+report	O
+plasmids	O
+.	O
+
+Together	O
+,	O
+the	O
+data	O
+provide	O
+the	O
+first	O
+evidence	O
+that	O
+TGEV	B-SPEC
+infection	B-DISO
+up	O
+-	O
+regulates	O
+pFcRn	O
+expression	B-PROC
+via	O
+activation	O
+of	O
+NF	O
+-	O
+κB	O
+signaling	B-PROC
+.	O
+
+How	O
+viruses	B-SPEC
+coordinate	O
+the	O
+intracellular	B-COMP
+trafficking	B-PROC
+of	O
+both	O
+RNA	O
+and	O
+protein	B-CHED
+components	O
+to	O
+the	O
+assembly	O
+sites	O
+of	O
+infectious	B-DISO
+particles	O
+at	O
+the	O
+cell	B-COMP
+surface	I-COMP
+remains	O
+a	O
+long	O
+-	O
+standing	B-PROC
+question	O
+.	O
+
+ABSTRACT	O
+:	O
+Mouse	B-DISO
+hepatitis	I-DISO
+virus	B-SPEC
+strain	O
+A59	O
+infection	B-DISO
+of	O
+mice	B-SPEC
+is	O
+a	O
+useful	O
+tool	O
+for	O
+studying	O
+virus	B-PROC
+-	I-PROC
+host	B-COMP
+interaction	I-PROC
+during	O
+hepatitis	B-DISO
+development	B-PROC
+.	O
+
+These	O
+results	O
+demonstrate	O
+the	O
+suitability	O
+of	O
+ORFV121	O
+gene	O
+locus	O
+as	O
+an	O
+insertion	O
+site	O
+for	O
+heterologous	O
+gene	B-PROC
+expression	I-PROC
+and	O
+delivery	O
+by	O
+ORFV	O
+-	O
+based	O
+viral	O
+vectors	O
+.	O
+
+Additionally	O
+,	O
+the	O
+results	O
+provide	O
+evidence	O
+of	O
+the	O
+potential	O
+of	O
+ORFV	O
+as	O
+a	O
+vaccine	O
+delivery	O
+vector	O
+for	O
+enteric	O
+viral	B-DISO
+diseases	I-DISO
+of	O
+swine	B-SPEC
+.	O
+
+ABSTRACT	O
+:	O
+Porcine	B-SPEC
+epidemic	I-SPEC
+diarrhea	I-SPEC
+virus	I-SPEC
+(	O
+PEDV	B-SPEC
+)	O
+has	O
+recently	O
+caused	O
+high	O
+mortality	O
+in	O
+suckling	O
+piglets	O
+with	O
+subsequent	O
+large	O
+economic	O
+losses	O
+to	O
+the	O
+swine	B-SPEC
+industry	O
+.	O
+
+The	O
+risk	O
+of	O
+secondary	B-DISO
+transmission	I-DISO
+following	O
+importation	O
+increased	O
+with	O
+the	O
+time	O
+to	O
+case	O
+isolation	O
+or	O
+death	B-PROC
+(	O
+OR	O
+=	O
+1	O
+.	O
+7	O
+p	O
+=	O
+0	O
+.	O
+04	O
+)	O
+and	O
+more	O
+precisely	O
+with	O
+the	O
+duration	O
+of	O
+hospitalization	O
+(	O
+OR	O
+=	O
+1	O
+.	O
+7	O
+,	O
+p	O
+=	O
+0	O
+.	O
+02	O
+).	O
+
+TITLE	O
+:	O
+Influenza	B-DISO
+-	I-DISO
+like	I-DISO
+illness	I-DISO
+outbreaks	O
+in	O
+nursing	B-PROC
+homes	O
+in	O
+Corsica	O
+,	O
+France	O
+,	O
+2014	O
+-	O
+2015	O
+:	O
+epidemiological	O
+and	O
+molecular	O
+characterization	O
+.	O
+
+Of	O
+the	O
+22	O
+residents	O
+with	O
+a	O
+nasopharyngeal	B-ANAT
+sample	O
+,	O
+13	O
+(	O
+59	O
+%)	O
+were	O
+positive	O
+for	O
+at	O
+least	O
+one	O
+of	O
+the	O
+11	O
+pathogens	O
+analysed	O
+.	O
+
+Of	O
+patients	O
+with	O
+a	O
+confirmed	O
+influenza	B-PATH
+A	I-PATH
+(	O
+H3N2	B-CHED
+),	O
+10	O
+(	O
+91	O
+%)	O
+were	O
+vaccinated	O
+against	O
+influenza	B-DISO
+during	O
+the	O
+2014	O
+-	O
+2015	O
+season	O
+.	O
+
+Two	O
+influenza	B-DISO
+outbreaks	O
+were	O
+reported	O
+in	O
+two	O
+NHs	B-DISO
+,	O
+caused	O
+by	O
+influenza	B-PATH
+A	I-PATH
+(	O
+H3N2	B-CHED
+)	O
+strains	O
+belonging	O
+to	O
+cluster	B-PRGE
+3C	I-PRGE
+.	I-PRGE
+3	I-PRGE
+and	I-PRGE
+3C	I-PRGE
+.	I-PRGE
+2a	I-PRGE
+.	O
+
+Critical	O
+to	O
+this	O
+discovery	O
+process	O
+was	O
+the	O
+employment	O
+of	O
+an	O
+ex	O
+vivo	O
+cardiovascular	B-ANAT
+(	O
+CV	B-ANAT
+)	O
+model	O
+which	O
+served	O
+to	O
+identify	O
+compounds	O
+that	O
+,	O
+like	O
+2	O
+,	O
+were	O
+free	O
+of	O
+the	O
+CV	B-ANAT
+liabilities	O
+that	O
+resulted	O
+in	O
+the	O
+discontinuation	O
+of	O
+BMS	O
+-	O
+605339	O
+(	O
+1	O
+)	O
+from	O
+clinical	O
+trials	O
+.	O
+
+TITLE	O
+:	O
+Full	O
+-	O
+length	O
+genome	O
+sequencing	O
+analysis	O
+of	O
+avian	B-DISO
+infectious	I-DISO
+bronchitis	I-DISO
+virus	B-SPEC
+isolate	O
+associated	O
+with	O
+nephropathogenic	O
+infection	O
+.	O
+
+In	O
+this	O
+study	O
+,	O
+a	O
+new	O
+highly	O
+virulent	O
+nephropathogenic	O
+IBV	B-SPEC
+strain	O
+named	O
+CK	O
+/	O
+CH	O
+/	O
+XDC	O
+-	O
+2	O
+/	O
+2013	O
+was	O
+identified	O
+from	O
+a	O
+vaccinated	O
+flock	O
+with	O
+clinical	O
+signs	O
+of	O
+IB	O
+in	O
+the	O
+Jiangsu	O
+province	O
+of	O
+China	O
+.	O
+
+The	O
+full	O
+-	O
+length	O
+genome	O
+sequence	O
+of	O
+the	O
+isolate	O
+was	O
+27	O
+,	O
+714	O
+nucleotides	B-CHED
+long	O
+,	O
+and	O
+the	O
+genome	O
+was	O
+organized	O
+similarly	O
+to	O
+classical	O
+IBV	B-SPEC
+strains	O
+.	O
+
+The	O
+spike	O
+glycoprotein	B-CHED
+(	O
+S	O
+)	O
+gene	O
+had	O
+the	O
+greatest	O
+similarity	O
+to	O
+the	O
+nephropathogenic	O
+BJ	O
+strain	O
+and	O
+showed	O
+an	O
+8	O
+amino	B-CHED
+acid	I-CHED
+insertion	O
+(	O
+YSNGNSDV	O
+)	O
+at	O
+73	O
+to	O
+80	O
+sites	O
+and	O
+3	O
+amino	O
+acid	O
+deletion	O
+at	O
+sites	O
+126	O
+to	O
+128	O
+compared	O
+to	O
+the	O
+IBV	B-SPEC
+vaccine	O
+strains	O
+.	O
+
+A	O
+recombination	B-PROC
+analysis	O
+of	O
+the	O
+S	B-PRGE
+gene	I-PRGE
+showed	O
+that	O
+the	O
+new	O
+isolate	O
+evolved	O
+from	O
+the	O
+IBV	B-SPEC
+BJ	O
+strain	O
+and	O
+the	O
+KM91	O
+vaccine	O
+strain	O
+.	O
+
+ABSTRACT	O
+:	O
+Mortality	O
+rates	O
+for	O
+severe	O
+community	O
+-	O
+acquired	O
+pneumonia	O
+(	O
+CAP	B-DISO
+)	O
+range	O
+from	O
+17	O
+to	O
+48	O
+%	O
+in	O
+published	O
+studies	O
+.	O
+
+Although	O
+MERS	O
+-	O
+CoV	O
+generally	O
+causes	O
+subclinical	O
+or	O
+mild	O
+disease	O
+,	O
+infection	B-DISO
+can	O
+result	O
+in	O
+serious	O
+outcomes	O
+,	O
+including	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+and	O
+multi	B-DISO
+-	I-DISO
+organ	I-DISO
+failure	I-DISO
+in	O
+patients	O
+with	O
+comorbidities	O
+.	O
+
+ABSTRACT	O
+:	O
+High	O
+-	O
+frequency	O
+oscillatory	O
+ventilation	O
+(	O
+HFOV	O
+)	O
+has	O
+not	O
+been	O
+shown	O
+to	O
+be	O
+beneficial	O
+in	O
+the	O
+management	O
+of	O
+moderate	O
+-	O
+to	O
+-	O
+severe	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+(	O
+ARDS	B-DISO
+).	O
+
+HFOV	O
+with	O
+high	O
+level	O
+of	O
+mPaw	O
+increases	O
+transpulmonary	O
+pressures	O
+without	O
+improvement	O
+in	O
+oxygenation	B-PROC
+.	O
+
+ABSTRACT	O
+:	O
+Porcine	O
+deltacoronavirus	O
+(	O
+PDCoV	O
+)	O
+is	O
+a	O
+newly	O
+identified	O
+virus	B-SPEC
+that	O
+has	O
+been	O
+detected	O
+in	O
+swine	B-SPEC
+herds	O
+of	O
+North	O
+America	O
+associated	O
+with	O
+enteric	O
+disease	O
+.	O
+
+ABSTRACT	O
+:	O
+Myalgic	B-DISO
+encephalomyelitis	I-DISO
+chronic	B-DISO
+fatigue	I-DISO
+syndrome	I-DISO
+(	O
+ME	O
+/	O
+CFS	B-DISO
+)	O
+is	O
+a	O
+common	O
+debilitating	O
+disorder	O
+associated	O
+with	O
+an	O
+intense	O
+fatigue	B-DISO
+,	O
+a	O
+reduced	O
+physical	O
+activity	O
+,	O
+and	O
+an	O
+impaired	B-DISO
+quality	O
+of	O
+life	O
+.	O
+
+Intravenous	O
+(	O
+IV	O
+)	O
+high	O
+-	O
+dose	O
+steroid	B-CHED
+therapy	O
+(	O
+methylprednisolone	B-CHED
+:	O
+1	O
+g	O
+/	O
+day	O
+×	O
+3	O
+days	O
+),	O
+followed	O
+by	O
+oral	B-ANAT
+prednisolone	B-CHED
+(	O
+PSL	O
+)	O
+(	O
+40	O
+mg	O
+/	O
+day	O
+),	O
+and	O
+IV	B-PRGE
+immunoglobulin	I-PRGE
+(	O
+IVIg	O
+,	O
+0	O
+.	O
+4	O
+g	O
+/	O
+kg	O
+/	O
+day	O
+×	O
+5	O
+days	O
+)	O
+administrations	O
+resulted	O
+in	O
+the	O
+amelioration	O
+of	O
+these	O
+symptoms	O
+.	O
+
+Lactobacillus	B-SPEC
+plantarum	I-SPEC
+-	O
+Biocenol	O
+(	O
+TM	O
+)	O
+LP96	O
+(	O
+CCM	B-DISO
+7512	O
+),	O
+Lactobacillus	B-SPEC
+fermentum	I-SPEC
+-	O
+Biocenol	O
+(	O
+TM	O
+)	O
+LF99	O
+(	O
+CCM	B-DISO
+7514	O
+)	O
+and	O
+flaxseed	B-SPEC
+(	O
+rich	O
+in	O
+n	O
+-	O
+3	O
+polyunsaturated	B-CHED
+fatty	I-CHED
+acids	I-CHED
+)	O
+were	O
+administered	O
+to	O
+36	O
+conventional	O
+piglets	O
+from	O
+a	O
+problematic	O
+breed	B-PROC
+with	O
+confirmed	O
+presence	O
+of	O
+enterotoxigenic	O
+Escherichia	B-SPEC
+coli	I-SPEC
+and	O
+Coronavirus	B-SPEC
+.	O
+
+©	O
+2015	O
+Japanese	O
+Society	O
+of	O
+Animal	B-SPEC
+Science	O
+.	O
+
+Current	O
+treatment	O
+options	O
+for	O
+MERS	O
+can	O
+be	O
+categorized	O
+as	O
+:	O
+immunotherapy	O
+with	O
+virus	B-SPEC
+-	O
+specific	O
+antibodies	B-COMP
+in	O
+convalescent	O
+plasma	B-ANAT
+;	O
+polyclonal	O
+and	O
+monoclonal	O
+antibodies	B-COMP
+produced	O
+in	O
+vitro	O
+or	O
+in	O
+genetically	O
+modified	O
+animals	B-SPEC
+;	O
+and	O
+antiviral	B-CHED
+agents	I-CHED
+.	O
+
+The	O
+odds	O
+ratio	O
+for	O
+maternal	O
+mortality	O
+in	O
+patients	O
+ventilated	O
+early	O
+was	O
+0	O
+.	O
+39	O
+as	O
+against	O
+5	O
+in	O
+those	O
+with	O
+ARDS	B-DISO
+.	O
+
+ABSTRACT	O
+:	O
+On	O
+the	O
+basis	O
+of	O
+partial	O
+sequencing	O
+of	O
+the	O
+infectious	B-DISO
+bronchitis	B-DISO
+virus	B-SPEC
+(	O
+IBV	B-SPEC
+)	O
+S1	O
+gene	O
+,	O
+this	O
+study	O
+investigated	O
+the	O
+molecular	O
+diversity	O
+of	O
+the	O
+virus	B-SPEC
+in	O
+two	O
+life	O
+periods	B-PROC
+of	O
+a	O
+batch	O
+of	O
+breeding	B-PROC
+hens	O
+at	O
+the	O
+field	O
+level	O
+.	O
+
+In	O
+this	O
+phase	O
+,	O
+the	O
+Ma5	O
+vaccine	O
+strain	O
+was	O
+detected	O
+in	O
+the	O
+kidneys	B-ANAT
+,	O
+small	B-ANAT
+intestine	I-ANAT
+,	O
+and	O
+oviduct	B-ANAT
+of	O
+the	O
+hens	O
+.	O
+
+However	O
+,	O
+a	O
+previously	O
+unidentified	O
+IBV	O
+variant	O
+was	O
+found	O
+in	O
+the	O
+cecal	B-ANAT
+tonsils	B-ANAT
+.	O
+
+TITLE	O
+:	O
+Effect	O
+of	O
+setting	O
+high	O
+APRV	O
+guided	O
+by	O
+expiratory	B-PROC
+inflection	O
+point	O
+of	O
+pressure	O
+-	O
+volume	O
+curve	O
+on	O
+oxygen	O
+delivery	O
+in	O
+canine	O
+models	O
+of	O
+severe	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+.	O
+
+Our	O
+study	O
+aim	O
+was	O
+to	O
+investigate	O
+the	O
+molecular	O
+epidemiology	O
+of	O
+human	B-SPEC
+CoV	O
+strains	O
+circulating	O
+in	O
+Arkansas	O
+,	O
+their	O
+genetic	O
+variability	O
+and	O
+their	O
+association	O
+with	O
+reported	O
+influenza	B-DISO
+-	I-DISO
+like	I-DISO
+symptoms	I-DISO
+.	O
+
+At	O
+the	O
+age	O
+of	O
+6	O
+wk	O
+,	O
+in	O
+total	O
+,	O
+180	O
+cockerels	O
+were	O
+assigned	O
+to	O
+12	O
+treatment	O
+groups	O
+,	O
+3	O
+(	O
+rearing	O
+system	O
+)	O
+×	O
+4	O
+(	O
+Aseel	O
+chicken	B-SPEC
+variety	O
+)	O
+factorial	O
+arrangement	O
+in	O
+7	O
+randomized	O
+complete	O
+blocks	O
+,	O
+replicated	O
+3	O
+times	O
+with	O
+5	O
+birds	B-SPEC
+in	O
+each	O
+replicate	O
+(	O
+45	O
+birds	B-SPEC
+of	O
+each	O
+variety	O
+;	O
+60	O
+birds	B-SPEC
+in	O
+each	O
+rearing	O
+system	O
+;	O
+36	O
+total	O
+replicates	O
+).	O
+
+After	O
+laboratory	O
+analysis	O
+,	O
+the	O
+recorded	O
+data	O
+for	O
+blood	B-ANAT
+biochemical	O
+profile	O
+and	O
+immune	B-PROC
+response	I-PROC
+were	O
+analyzed	O
+by	O
+using	O
+2	O
+-	O
+way	O
+ANOVA	O
+under	O
+factorial	O
+arrangement	O
+.	O
+
+Peshawari	O
+birds	B-SPEC
+indicated	O
+higher	O
+(	O
+P	O
+<	O
+0	O
+.	O
+05	O
+)	O
+concentration	O
+of	O
+glucose	B-CHED
+,	O
+total	O
+protein	B-CHED
+,	O
+albumin	B-PRGE
+,	O
+uric	B-CHED
+acid	I-CHED
+,	O
+creatinine	B-CHED
+,	O
+and	O
+titers	O
+to	O
+NDV	B-SPEC
+and	O
+IBV	B-SPEC
+.	O
+
+Cholesterol	B-CHED
+level	O
+was	O
+found	O
+to	O
+be	O
+greater	O
+(	O
+P	O
+<	O
+0	O
+.	O
+05	O
+)	O
+in	O
+birds	B-SPEC
+of	O
+LK	O
+and	O
+SN	O
+.	O
+
+The	O
+results	O
+highlight	O
+that	O
+CF	O
+rearing	O
+system	O
+expediently	O
+affects	O
+glucose	B-CHED
+and	O
+total	O
+protein	B-CHED
+levels	O
+in	O
+birds	B-SPEC
+;	O
+SI	O
+and	O
+FR	O
+confer	O
+maximum	O
+antibody	B-COMP
+titers	O
+to	O
+NDV	B-SPEC
+and	O
+IBV	B-SPEC
+.	O
+
+Pre	O
+-	O
+ECMO	O
+PF	O
+ratio	O
+,	O
+neuromuscular	B-DISO
+blockade	I-DISO
+,	O
+and	O
+prone	O
+position	O
+,	O
+as	O
+well	O
+as	O
+ventilatory	O
+variables	O
+did	O
+not	O
+differ	O
+between	O
+groups	O
+.	O
+
+ABSTRACT	O
+:	O
+The	O
+Middle	O
+East	O
+respiratory	O
+syndrome	O
+coronavirus	B-SPEC
+(	O
+MERS	O
+-	O
+CoV	O
+)	O
+was	O
+exported	O
+to	O
+Korea	O
+in	O
+2015	O
+,	O
+resulting	O
+in	O
+a	O
+threat	O
+to	O
+neighboring	O
+nations	O
+.	O
+
+We	O
+collected	O
+the	O
+number	O
+of	O
+daily	O
+laboratory	O
+-	O
+confirmed	O
+MERS	O
+cases	O
+and	O
+quarantined	O
+cases	O
+from	O
+May	O
+11	O
+,	O
+2015	O
+to	O
+June	O
+26	O
+,	O
+2015	O
+using	O
+the	O
+Korean	O
+government	O
+MERS	O
+portal	B-ANAT
+.	O
+
+(	O
+3	O
+)	O
+The	O
+rates	O
+of	O
+abnormal	O
+pancreatic	B-ANAT
+ultrasound	O
+in	O
+control	O
+group	O
+,	O
+mildly	O
+elevated	O
+group	O
+and	O
+highly	O
+elevated	O
+group	O
+were	O
+0	O
+.	O
+90	O
+%(	O
+4	O
+/	O
+443	O
+),	O
+14	O
+.	O
+06	O
+%(	O
+9	O
+/	O
+64	O
+),	O
+20	O
+.	O
+83	O
+%(	O
+5	O
+/	O
+24	O
+)(	O
+χ	O
+(	O
+2	O
+)=	O
+52	O
+.	O
+925	O
+,	O
+P	O
+=	O
+0	O
+.	O
+000	O
+).	O
+
+The	O
+risk	O
+factors	O
+of	O
+elevated	O
+amylase	B-PRGE
+or	O
+lipase	B-PRGE
+were	O
+age	O
+,	O
+convulsions	B-DISO
+,	O
+consciousness	O
+,	O
+BE	O
+,	O
+PCT	B-DISO
+,	O
+calcium	B-CHED
+,	O
+mechanical	O
+ventilation	O
+,	O
+severe	B-DISO
+sepsis	I-DISO
+and	O
+MODS	B-DISO
+(	O
+OR	O
+=	O
+1	O
+.	O
+155	O
+,	O
+1	O
+.	O
+491	O
+,	O
+2	O
+.	O
+237	O
+,	O
+0	O
+.	O
+949	O
+,	O
+0	O
+.	O
+604	O
+,	O
+1	O
+.	O
+008	O
+,	O
+0	O
+.	O
+660	O
+,	O
+1	O
+.	O
+907	O
+,	O
+0	O
+.	O
+836	O
+,	O
+P	O
+all	O
+<	O
+0	O
+.	O
+05	O
+).	O
+
+The	O
+occurrence	O
+rate	O
+of	O
+hyperamylasemia	B-DISO
+or	O
+high	O
+lipase	B-PRGE
+levels	O
+in	O
+critically	B-DISO
+ill	I-DISO
+children	O
+were	O
+lower	O
+than	O
+adults	O
+,	O
+elevated	O
+pancreatic	B-ANAT
+enzymes	O
+was	O
+accompanied	O
+by	O
+the	O
+progression	O
+of	O
+critical	B-DISO
+illness	I-DISO
+,	O
+pancreatic	B-ANAT
+enzymes	O
+elevated	O
+probably	O
+due	O
+to	O
+pancreatic	B-ANAT
+damage	O
+,	O
+which	O
+positively	O
+correlated	O
+with	O
+severity	O
+of	O
+the	O
+disease	O
+and	O
+the	O
+prognosis	O
+.	O
+
+ABSTRACT	O
+:	O
+Here	O
+,	O
+we	O
+present	O
+a	O
+case	O
+of	O
+a	O
+tracheal	B-DISO
+fistula	I-DISO
+due	O
+to	O
+an	O
+anastomotic	O
+insufficiency	O
+following	O
+abdominothoracic	O
+esophageal	O
+resection	O
+.	O
+
+TITLE	O
+:	O
+Analysis	O
+of	O
+Spatiotemporal	O
+Characteristics	O
+of	O
+Pandemic	O
+SARS	B-DISO
+Spread	O
+in	O
+Mainland	O
+China	O
+.	O
+
+To	O
+determine	O
+the	O
+effect	O
+of	O
+Vt	O
+size	O
+,	O
+and	O
+of	O
+the	O
+ventilator	O
+mode	O
+used	O
+for	O
+its	O
+delivery	O
+(	O
+volume	O
+vs	O
+.	O
+pressure	O
+control	O
+),	O
+on	O
+the	O
+magnitude	O
+of	O
+patient	O
+-	O
+ventilator	O
+dyssynchrony	O
+in	O
+patients	O
+with	O
+or	O
+at	O
+risk	O
+for	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+.	O
+
+TITLE	O
+:	O
+Orally	B-ANAT
+Administrated	O
+Whole	O
+Yeast	B-SPEC
+Vaccine	O
+Against	O
+Porcine	B-SPEC
+Epidemic	I-SPEC
+Diarrhea	I-SPEC
+Virus	I-SPEC
+
+The	O
+pathological	O
+damage	O
+to	O
+the	O
+cystic	O
+oviducts	B-ANAT
+were	O
+observed	O
+throughout	O
+the	O
+surveillance	O
+period	O
+.	O
+
+ABSTRACT	O
+:	O
+To	O
+investigate	O
+the	O
+predictive	O
+values	O
+of	O
+different	O
+critical	O
+scoring	O
+systems	O
+for	O
+mortality	O
+in	O
+patients	O
+with	O
+severe	O
+acute	B-DISO
+respiratory	I-DISO
+failure	I-DISO
+(	O
+ARF	B-DISO
+)	O
+supported	O
+by	O
+venovenous	O
+extracorporeal	O
+membrane	B-COMP
+oxygenation	B-PROC
+(	O
+VV	O
+-	O
+ECMO	O
+).	O
+
+Acute	O
+Physiology	O
+and	O
+Chronic	O
+Health	O
+Evaluation	O
+(	O
+APACHE	O
+)	O
+Ⅱ	O
+,	O
+Ⅲ	O
+,	O
+Ⅳ	O
+,	O
+Simplified	O
+Acute	O
+Physiology	O
+Score	O
+Ⅱ	O
+(	O
+SAPS	O
+)	O
+Ⅱ	O
+,	O
+Sequential	O
+Organ	B-DISO
+Failure	I-DISO
+Assessment	O
+(	O
+SOFA	O
+),	O
+ECMO	O
+net	O
+,	O
+PRedicting	O
+dEath	B-PROC
+for	O
+SEvere	O
+ARDS	B-DISO
+on	O
+VVECMO	O
+(	O
+PRESERVE	O
+),	O
+and	O
+Respiratory	O
+ECMO	O
+Survival	O
+Prediction	O
+(	O
+RESP	O
+)	O
+scores	O
+were	O
+collected	O
+within	O
+6	O
+hours	O
+before	O
+VV	O
+-	O
+ECMO	O
+support	O
+.	O
+
+(	O
+4	O
+)	O
+Multiple	O
+logistic	O
+regression	O
+analysis	O
+showed	O
+that	O
+PEEP	B-CHED
+(	O
+OR	O
+=	O
+1	O
+.	O
+555	O
+,	O
+95	O
+%	O
+CI	O
+:	O
+1	O
+.	O
+097	O
+-	O
+2	O
+.	O
+204	O
+,	O
+P	O
+<	O
+0	O
+.	O
+05	O
+),	O
+APACHE	O
+Ⅳ	O
+score	O
+(	O
+OR	O
+=	O
+1	O
+.	O
+152	O
+,	O
+95	O
+%	O
+CI	O
+:	O
+1	O
+.	O
+021	O
+-	O
+1	O
+.	O
+301	O
+,	O
+P	O
+<	O
+0	O
+.	O
+05	O
+),	O
+and	O
+PRESERVE	O
+score	O
+(	O
+OR	O
+=	O
+4	O
+.	O
+984	O
+,	O
+95	O
+%	O
+CI	O
+:	O
+1	O
+.	O
+531	O
+-	O
+16	O
+.	O
+227	O
+,	O
+P	O
+<	O
+0	O
+.	O
+05	O
+)	O
+were	O
+independent	O
+risk	O
+factors	O
+associated	O
+with	O
+mortality	O
+of	O
+patients	O
+supported	O
+by	O
+VV	O
+-	O
+ECMO	O
+.	O
+
+India	O
+,	O
+Pakistan	O
+and	O
+Bangladesh	O
+are	O
+the	O
+highest	O
+risk	O
+countries	O
+which	O
+have	O
+yet	O
+to	O
+report	O
+a	O
+case	O
+,	O
+and	O
+should	O
+be	O
+prepared	O
+for	O
+the	O
+possibility	O
+of	O
+(	O
+pilgrims	O
+and	O
+general	O
+)	O
+travellers	O
+returning	O
+infected	O
+with	O
+MERS	O
+-	O
+CoV	O
+.	O
+In	O
+addition	O
+,	O
+the	O
+UK	O
+,	O
+Egypt	O
+,	O
+Turkey	B-SPEC
+and	O
+the	O
+USA	O
+are	O
+at	O
+risk	O
+of	O
+more	O
+cases	O
+.	O
+
+The	O
+highly	O
+lethal	O
+Middle	O
+Eastern	O
+respiratory	O
+syndrome	B-DISO
+coronavirus	B-SPEC
+(	O
+MERS	O
+-	O
+CoV	O
+)	O
+remains	O
+in	O
+the	O
+WHO	O
+list	O
+of	O
+top	O
+emerging	O
+diseases	O
+likely	O
+to	O
+cause	O
+major	O
+epidemics	O
+.	O
+
+ABSTRACT	O
+:	O
+Infectious	B-DISO
+bronchitis	B-DISO
+virus	B-SPEC
+(	O
+IBV	B-SPEC
+)	O
+continues	O
+to	O
+circulate	O
+worldwide	O
+,	O
+with	O
+a	O
+significant	O
+impact	O
+on	O
+the	O
+poultry	O
+industry	O
+and	O
+affecting	O
+both	O
+vaccinated	O
+and	O
+unvaccinated	O
+flocks	O
+.	O
+
+The	O
+deduced	O
+amino	B-CHED
+acid	I-CHED
+sequence	O
+of	O
+HVRs	O
+of	O
+the	O
+variant	O
+subgroups	O
+indicated	O
+different	O
+genetic	O
+features	O
+in	O
+comparison	O
+to	O
+the	O
+classic	O
+vaccine	O
+group	O
+(	O
+H120	O
+lineage	O
+).	O
+
+Hence	O
+,	O
+continuous	O
+follow	O
+-	O
+up	O
+of	O
+the	O
+current	O
+vaccine	O
+strategy	O
+is	O
+highly	O
+recommended	O
+for	O
+better	O
+control	O
+and	O
+prevention	O
+of	O
+infectious	B-DISO
+bronchitis	B-DISO
+virus	B-SPEC
+in	O
+the	O
+poultry	O
+sector	O
+in	O
+Egypt	O
+.	O
+
+ABSTRACT	O
+:	O
+MicroRNAs	O
+(	O
+miRNAs	O
+)	O
+are	O
+noncoding	O
+RNAs	O
+that	O
+modulate	O
+cellular	B-COMP
+gene	B-PROC
+expression	I-PROC
+,	O
+primarily	O
+at	O
+the	O
+post	O
+-	O
+transcriptional	B-PROC
+level	O
+.	O
+
+These	O
+findings	O
+support	O
+a	O
+novel	O
+role	O
+for	O
+miR	O
+-	O
+155	O
+in	O
+host	B-PROC
+defense	I-PROC
+in	O
+a	O
+model	O
+of	O
+viral	O
+-	O
+induced	O
+encephalomyelitis	B-DISO
+.	O
+
+Further	O
+,	O
+miR	O
+-	O
+155	O
+can	O
+play	O
+either	O
+a	O
+host	B-COMP
+-	O
+protective	O
+or	O
+host	B-COMP
+-	O
+damaging	O
+role	O
+during	O
+neuroinflammation	O
+depending	O
+on	O
+the	O
+disease	O
+trigger	O
+.	O
+
+TITLE	O
+:	O
+Risks	O
+of	O
+Death	B-PROC
+and	O
+Severe	O
+Disease	O
+in	O
+Patients	O
+With	O
+Middle	O
+East	O
+Respiratory	O
+Syndrome	B-DISO
+Coronavirus	B-SPEC
+,	O
+2012	O
+-	O
+2015	O
+.	O
+
+In	O
+total	O
+,	O
+87	O
+.	O
+54	O
+%	O
+acknowledged	O
+that	O
+they	O
+routinely	O
+used	O
+alcohol	O
+-	O
+based	O
+hand	O
+rub	O
+,	O
+87	O
+.	O
+4	O
+%	O
+had	O
+sufficiently	O
+decontaminated	O
+hands	B-ANAT
+even	O
+under	O
+high	O
+work	O
+pressure	O
+,	O
+and	O
+78	O
+.	O
+6	O
+%	O
+addressed	O
+that	O
+this	O
+practice	O
+was	O
+not	O
+affected	O
+by	O
+less	O
+compliant	O
+colleagues	O
+.	O
+
+In	O
+addition	O
+,	O
+AvCoV	O
+-	O
+IBV	B-SPEC
+RNA	O
+was	O
+detected	O
+in	O
+the	O
+tracheas	B-ANAT
+27	O
+/	O
+30	O
+(	O
+90	O
+%),	O
+lungs	B-ANAT
+31	O
+/	O
+49	O
+(	O
+62	O
+.	O
+2	O
+%),	O
+caecal	O
+tonsils	B-ANAT
+7	O
+/	O
+22	O
+(	O
+31	O
+.	O
+8	O
+%),	O
+and	O
+kidneys	B-ANAT
+4	O
+/	O
+49	O
+(	O
+8	O
+.	O
+1	O
+%)	O
+of	O
+broiler	O
+flocks	O
+examined	O
+.	O
+
+In	O
+conclusion	O
+,	O
+genetically	O
+different	O
+AvCoV	O
+-	O
+IBV	B-SPEC
+strains	O
+,	O
+including	O
+vaccine	O
+-	O
+like	O
+strains	O
+,	O
+based	O
+on	O
+their	O
+partial	O
+S1	O
+sequence	O
+,	O
+are	O
+circulating	O
+in	O
+broiler	O
+and	O
+layer	B-ANAT
+chicken	B-SPEC
+flocks	O
+in	O
+Turkey	B-SPEC
+and	O
+the	O
+Israeli	O
+variant	O
+-	O
+2	O
+strain	O
+is	O
+undergoing	O
+evolution	B-PROC
+.	O
+
+After	O
+surveillance	O
+carried	O
+out	O
+in	O
+2009	O
+and	O
+2010	O
+,	O
+some	O
+farmers	O
+started	O
+vaccinating	O
+quail	O
+with	O
+the	O
+Massachusetts	O
+avian	B-DISO
+infectious	I-DISO
+bronchitis	I-DISO
+virus	B-SPEC
+serotype	O
+.	O
+
+TITLE	O
+:	O
+Sevoflurane	B-CHED
+for	O
+Sedation	B-DISO
+in	O
+Acute	B-DISO
+Respiratory	I-DISO
+Distress	I-DISO
+Syndrome	I-DISO
+.	O
+
+Asplenic	O
+patients	O
+may	O
+be	O
+at	O
+additional	O
+increased	O
+risk	O
+of	O
+intravascular	B-DISO
+haemolysis	I-DISO
+.	O
+
+A	O
+61	O
+years	O
+old	O
+asplenic	O
+man	B-CHED
+was	O
+admitted	O
+to	O
+a	O
+tertiary	O
+referral	O
+hospital	O
+in	O
+Sabah	O
+,	O
+Malaysia	O
+,	O
+with	O
+severe	O
+knowlesi	O
+malaria	B-PATH
+characterized	O
+by	O
+hyperparasitaemia	O
+(	O
+7	O
+.	O
+9	O
+%),	O
+jaundice	B-DISO
+,	O
+respiratory	B-DISO
+distress	I-DISO
+,	O
+metabolic	B-PROC
+acidosis	I-DISO
+,	O
+and	O
+acute	O
+kidney	O
+injury	O
+.	O
+
+An	O
+asplenic	O
+patient	O
+with	O
+hyperparasitaemic	O
+severe	O
+knowlesi	O
+malaria	B-PATH
+developed	O
+haemoglobinuria	B-DISO
+after	O
+treatment	O
+with	O
+intravenous	O
+artesunate	B-CHED
+.	O
+
+Although	O
+in	O
+this	O
+case	O
+the	O
+patient	O
+made	O
+a	O
+rapid	O
+recovery	O
+,	O
+knowlesi	O
+malaria	B-PATH
+patients	O
+with	O
+this	O
+unusual	O
+complication	B-DISO
+should	O
+be	O
+closely	O
+monitored	O
+for	O
+potential	O
+deterioration	O
+.	O
+
+To	O
+date	O
+,	O
+there	O
+are	O
+no	O
+approved	O
+treatments	O
+for	O
+patients	O
+infected	O
+with	O
+MERS	O
+coronavirus	B-SPEC
+(	O
+MERS	O
+-	O
+CoV	O
+),	O
+a	O
+virus	B-SPEC
+that	O
+continues	O
+to	O
+infect	O
+new	O
+patients	O
+and	O
+that	O
+has	O
+now	O
+spread	O
+from	O
+the	O
+Middle	O
+East	O
+to	O
+Asia	O
+.	O
+
+This	O
+report	O
+demonstrates	O
+the	O
+first	O
+isolation	O
+of	O
+Tioman	B-SPEC
+virus	I-SPEC
+from	O
+a	O
+region	O
+where	O
+Nipah	B-SPEC
+virus	I-SPEC
+activity	O
+has	O
+been	O
+noticed	O
+in	O
+the	O
+past	O
+and	O
+recent	O
+years	O
+.	O
+
+ABSTRACT	O
+:	O
+During	O
+a	O
+severe	O
+outbreak	O
+of	O
+diarrhoea	O
+and	O
+vomiting	O
+in	O
+a	O
+pig	B-SPEC
+herd	O
+in	O
+Central	O
+Eastern	O
+Europe	O
+,	O
+faecal	B-ANAT
+samples	O
+were	O
+tested	O
+positive	O
+for	O
+porcine	B-SPEC
+epidemic	I-SPEC
+diarrhoea	I-SPEC
+virus	I-SPEC
+(	O
+PEDV	B-SPEC
+)	O
+and	O
+negative	O
+for	O
+transmissible	O
+gastroenteritis	B-DISO
+virus	B-SPEC
+(	O
+TGEV	B-SPEC
+)	O
+using	O
+a	O
+commercial	O
+RT	O
+-	O
+qPCR	O
+assay	O
+that	O
+can	O
+detect	O
+both	O
+of	O
+these	O
+coronaviruses	O
+.	O
+
+TITLE	O
+:	O
+Experimental	O
+infection	B-DISO
+of	O
+gnotobiotic	O
+pigs	B-SPEC
+with	O
+the	O
+cell	B-COMP
+-	O
+culture	O
+-	O
+adapted	O
+porcine	B-SPEC
+deltacoronavirus	O
+strain	O
+OH	O
+-	O
+FD22	O
+.	O
+
+The	O
+observed	O
+vertical	B-DISO
+transmission	I-DISO
+rate	O
+ranged	O
+between	O
+27	O
+.	O
+7	O
+%	O
+and	O
+48	O
+.	O
+29	O
+%.	O
+
+The	O
+case	O
+fatality	O
+rate	O
+(	O
+CFR	O
+)	O
+at	O
+the	O
+only	O
+center	O
+that	O
+reported	O
+deaths	B-PROC
+was	O
+5	O
+.	O
+3	O
+%.	O
+
+RESULTS	O
+:	O
+The	O
+observed	O
+vertical	B-DISO
+transmission	I-DISO
+rate	O
+ranged	O
+between	O
+27	O
+.	O
+7	O
+%	O
+and	O
+48	O
+.	O
+29	O
+%.	O
+
+TITLE	O
+:	O
+Polymorphisms	B-PROC
+in	O
+the	O
+S1	B-PRGE
+spike	I-PRGE
+glycoprotein	I-PRGE
+of	O
+Arkansas	O
+-	O
+type	O
+infectious	B-DISO
+bronchitis	B-DISO
+virus	B-SPEC
+(	O
+IBV	B-SPEC
+)	O
+show	O
+differential	O
+binding	O
+to	O
+host	B-COMP
+tissues	B-ANAT
+and	O
+altered	O
+antigenicity	O
+.	O
+
+Using	O
+recombinant	O
+ArkDPI	O
+S1	O
+proteins	B-CHED
+,	O
+we	O
+conducted	O
+binding	B-FUNC
+assays	O
+on	O
+chicken	B-SPEC
+tracheas	B-ANAT
+and	O
+embryonic	B-ANAT
+chorioallantoic	B-ANAT
+membrane	I-ANAT
+(	O
+CAM	B-DISO
+).	O
+
+The	O
+most	O
+common	O
+complications	O
+were	O
+liver	B-DISO
+dysfunction	I-DISO
+,	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+,	O
+encephalopathy	B-DISO
+,	O
+pleural	B-DISO
+effusion	I-DISO
+,	O
+ascites	O
+,	O
+myocarditis	B-DISO
+,	O
+myositis	B-DISO
+,	O
+acute	O
+kidney	B-ANAT
+injury	O
+,	O
+and	O
+disseminated	O
+intravascular	O
+coagulopathy	B-DISO
+.	O
+
+The	O
+common	O
+causes	O
+for	O
+poor	O
+outcome	O
+were	O
+multiorgan	B-DISO
+failure	I-DISO
+,	O
+encephalopathy	B-DISO
+,	O
+and	O
+fluid	O
+refractory	B-DISO
+shock	I-DISO
+.	O
+
+This	O
+case	O
+report	O
+describes	O
+a	O
+rare	O
+central	O
+venous	B-ANAT
+catheter	O
+tip	O
+malposition	O
+in	O
+the	O
+right	B-ANAT
+internal	I-ANAT
+mammary	I-ANAT
+artery	I-ANAT
+.	O
+
+However	O
+,	O
+central	O
+venous	B-ANAT
+waveforms	O
+detected	O
+by	O
+the	O
+catheter	O
+using	O
+a	O
+pressure	O
+lot	O
+transducer	O
+were	O
+later	O
+found	O
+to	O
+be	O
+absent	O
+.	O
+
+Further	O
+imaging	O
+studies	O
+,	O
+including	O
+plain	O
+radiography	O
+,	O
+computed	O
+tomography	O
+,	O
+and	O
+angiography	O
+,	O
+confirmed	O
+central	O
+venous	B-ANAT
+catheter	O
+malposition	O
+in	O
+the	O
+internal	B-ANAT
+mammary	I-ANAT
+artery	I-ANAT
+.	O
+
+All	O
+chickens	B-SPEC
+tested	O
+for	O
+avian	B-DISO
+influenza	I-DISO
+and	O
+Newcastle	B-DISO
+disease	I-DISO
+viruses	B-SPEC
+using	O
+real	O
+time	O
+reverse	B-PROC
+transcription	I-PROC
+polymerase	O
+chain	O
+reaction	O
+were	O
+negative	O
+.	O
+
+To	O
+account	O
+for	O
+error	O
+within	O
+the	O
+experiments	O
+,	O
+the	O
+levels	O
+of	O
+target	O
+gene	B-PROC
+transcription	I-PROC
+are	O
+normalized	O
+to	O
+that	O
+of	O
+suitable	O
+reference	O
+genes	O
+.	O
+
+Despite	O
+publication	O
+of	O
+the	O
+MIQE	O
+(	O
+Minimum	O
+Information	O
+for	O
+Publication	O
+of	O
+Quantitative	O
+Real	O
+-	O
+Time	O
+PCR	O
+Experiments	O
+)	O
+guidelines	O
+in	O
+2009	O
+,	O
+single	O
+un	O
+-	O
+tested	O
+reference	O
+genes	O
+are	O
+often	O
+used	O
+for	O
+normalization	O
+of	O
+qPCR	O
+assays	O
+in	O
+avian	B-SPEC
+research	O
+studies	O
+.	O
+
+Our	O
+medical	O
+center	O
+did	O
+not	O
+previously	O
+have	O
+a	O
+ground	O
+CCT	B-DISO
+service	O
+,	O
+and	O
+therefore	O
+,	O
+in	O
+these	O
+cases	O
+,	O
+a	O
+physician	O
+and	O
+/	O
+or	O
+a	O
+respiratory	O
+therapist	O
+was	O
+sent	O
+with	O
+the	O
+paramedic	O
+team	O
+.	O
+
+In	O
+all	O
+4	O
+cases	O
+,	O
+the	O
+ground	O
+transport	B-PROC
+team	O
+enhanced	O
+the	O
+intensive	O
+care	O
+provided	O
+to	O
+these	O
+patients	O
+prior	O
+to	O
+arrival	O
+at	O
+the	O
+tertiary	O
+care	O
+center	O
+.	O
+
+In	O
+2	O
+of	O
+the	O
+cases	O
+,	O
+although	O
+limited	O
+by	O
+the	O
+profound	O
+hypoxemia	O
+,	O
+the	O
+team	O
+decreased	O
+the	O
+pressures	O
+and	O
+tidal	O
+volumes	O
+in	O
+an	O
+effort	B-PROC
+to	O
+approach	O
+evidence	O
+-	O
+based	O
+ventilator	O
+goals	O
+.	O
+
+ABSTRACT	O
+:	O
+Coronavirus	O
+causes	O
+respiratory	B-DISO
+infections	I-DISO
+in	O
+humans	B-SPEC
+.	O
+
+There	O
+were	O
+19	O
+(	O
+0	O
+.	O
+32	O
+%)	O
+HCoV	O
+-	O
+HKU1	O
+,	O
+19	O
+(	O
+0	O
+.	O
+32	O
+%)	O
+HCoV	B-SPEC
+-	I-SPEC
+NL63	I-SPEC
+,	O
+5	O
+(	O
+0	O
+.	O
+09	O
+%)	O
+HCoV	B-SPEC
+-	I-SPEC
+229E	I-SPEC
+,	O
+and	O
+3	O
+(	O
+0	O
+.	O
+05	O
+%)	O
+HCoV	B-SPEC
+-	I-SPEC
+OC43	I-SPEC
+.	O
+
+We	O
+present	O
+a	O
+case	O
+of	O
+acute	B-DISO
+chest	I-DISO
+pain	I-DISO
+in	O
+a	O
+58	O
+-	O
+year	O
+-	O
+old	O
+male	O
+with	O
+severe	O
+asthma	B-PATH
+,	O
+which	O
+regressed	O
+after	O
+sublingual	B-ANAT
+administration	O
+of	O
+nitroglycerine	B-CHED
+.	O
+
+A	O
+year	O
+and	O
+a	O
+half	O
+later	O
+,	O
+there	O
+is	O
+still	O
+reduced	O
+strength	O
+and	O
+sensory	B-DISO
+loss	I-DISO
+.	O
+
+This	O
+peptide	B-CHED
+exhibited	O
+a	O
+high	O
+level	O
+of	O
+serological	O
+reactivity	O
+(	O
+64	O
+%),	O
+which	O
+resulted	O
+from	O
+the	O
+additive	O
+responses	O
+of	O
+two	O
+tandem	O
+epitopes	O
+(	O
+S597	O
+-	O
+603	O
+and	O
+S604	O
+-	O
+625	O
+)	O
+and	O
+a	O
+long	O
+-	O
+term	O
+human	O
+B	O
+-	O
+cell	B-ANAT
+memory	B-PROC
+response	O
+with	O
+antisera	O
+from	O
+convalescent	O
+SARS	B-DISO
+patients	O
+.	O
+
+ABSTRACT	O
+:	O
+Canine	O
+infectious	B-DISO
+respiratory	B-DISO
+disease	I-DISO
+complex	O
+(	O
+CIRDC	O
+)	O
+viruses	B-SPEC
+have	O
+been	O
+detected	O
+in	O
+dogs	B-SPEC
+with	O
+respiratory	O
+illness	O
+.	O
+
+The	O
+two	O
+multiplex	O
+PCR	O
+assays	O
+were	O
+then	O
+validated	O
+on	O
+102	O
+respiratory	B-ANAT
+samples	I-ANAT
+collected	O
+from	O
+51	O
+dogs	B-SPEC
+with	O
+respiratory	O
+illness	O
+by	O
+sensitivity	O
+and	O
+specificity	O
+determination	O
+in	O
+comparison	O
+to	O
+conventional	O
+simplex	B-ANAT
+PCR	O
+and	O
+a	O
+rapid	O
+three	O
+-	O
+antigen	B-CHED
+test	O
+kit	B-FUNC
+.	O
+
+Compared	O
+to	O
+the	O
+three	O
+-	O
+antigen	B-CHED
+test	O
+kit	B-FUNC
+,	O
+the	O
+multiplex	O
+PCR	O
+assays	O
+yielded	O
+100	O
+%	O
+sensitivity	O
+and	O
+more	O
+than	O
+83	O
+%	O
+specificity	O
+for	O
+detection	O
+of	O
+CAdV	O
+-	O
+2	O
+and	O
+CDV	B-CHED
+,	O
+but	O
+not	O
+for	O
+CIV	B-SPEC
+.	O
+
+The	O
+literature	O
+on	O
+the	O
+association	O
+between	O
+plasma	B-ANAT
+inflammatory	O
+cytokines	O
+and	O
+ARDS	B-DISO
+in	O
+patients	O
+with	O
+TBI	O
+is	O
+sparse	O
+.	O
+
+The	O
+study	O
+was	O
+a	O
+secondary	O
+analysis	O
+of	O
+the	O
+safety	O
+of	O
+a	O
+randomized	O
+trial	O
+of	O
+erythropoietin	B-PROC
+and	O
+transfusion	O
+threshold	O
+in	O
+patients	O
+with	O
+severe	O
+TBI	O
+.	O
+
+All	O
+subjects	O
+received	O
+chimeric	B-PRGE
+antigen	I-PRGE
+receptor	I-PRGE
+-	O
+modified	O
+T	B-ANAT
+cell	I-ANAT
+therapy	O
+.	O
+
+Fourteen	O
+(	O
+36	O
+%)	O
+developed	O
+cardiovascular	B-ANAT
+dysfunction	O
+treated	O
+with	O
+vasoactive	O
+infusions	O
+a	O
+median	O
+of	O
+5	O
+days	O
+after	O
+T	B-ANAT
+cell	I-ANAT
+therapy	O
+.	O
+
+TITLE	O
+:	O
+External	O
+validation	O
+of	O
+the	O
+APPS	O
+,	O
+a	O
+new	O
+and	O
+simple	O
+outcome	O
+prediction	O
+score	O
+in	O
+patients	O
+with	O
+the	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+.	O
+
+After	O
+thorough	O
+temporal	O
+external	O
+validation	O
+of	O
+the	O
+APPS	O
+,	O
+we	O
+tested	O
+the	O
+spatial	O
+external	O
+validity	O
+in	O
+a	O
+cohort	O
+of	O
+ARDS	B-DISO
+patients	O
+recruited	O
+during	O
+3	O
+years	O
+in	O
+two	O
+hospitals	O
+in	O
+the	O
+Netherlands	O
+.	O
+
+Currently	O
+,	O
+few	O
+bat	B-ENZY
+cell	B-ANAT
+lines	I-ANAT
+have	O
+been	O
+developed	O
+and	O
+only	O
+Tb1	B-PRGE
+-	I-PRGE
+Lu	I-PRGE
+,	O
+derived	O
+from	O
+Tadarida	B-SPEC
+brasiliensis	I-SPEC
+is	O
+commercially	O
+available	O
+.	O
+
+Subclones	O
+of	O
+this	O
+cell	B-ANAT
+line	I-ANAT
+expressed	B-PROC
+both	O
+epithelial	O
+and	O
+fibroblast	B-ANAT
+markers	O
+to	O
+varying	O
+extents	O
+.	O
+
+TITLE	O
+:	O
+Building	O
+predictive	O
+models	O
+for	O
+MERS	O
+-	O
+CoV	O
+infections	B-DISO
+using	O
+data	O
+mining	O
+techniques	O
+.	O
+
+The	O
+infection	B-DISO
+with	O
+MERS	O
+-	O
+CoV	O
+can	O
+lead	O
+to	O
+fatal	O
+complications	O
+,	O
+however	O
+little	O
+information	O
+is	O
+known	O
+about	O
+this	O
+novel	O
+virus	B-SPEC
+.	O
+
+ABSTRACT	O
+:	O
+Legionnaires	O
+'	O
+disease	O
+is	O
+a	O
+bacterial	B-DISO
+disease	I-DISO
+of	O
+the	O
+respiratory	B-ANAT
+system	I-ANAT
+caused	O
+by	O
+a	O
+gram	O
+-	O
+negative	O
+germ	O
+whose	O
+clinical	O
+manifestation	O
+can	O
+be	O
+benign	O
+limiting	O
+to	O
+flu	B-DISO
+-	O
+like	O
+syndrome	B-DISO
+or	O
+can	O
+be	O
+more	O
+severe	O
+being	O
+characterized	O
+by	O
+pneumonia	B-DISO
+which	O
+may	O
+be	O
+complicated	O
+by	O
+multisystem	O
+disease	O
+that	O
+can	O
+lead	O
+to	O
+death	B-PROC
+.	O
+
+The	O
+PEI	O
+financial	O
+support	O
+allows	O
+to	O
+maintain	O
+the	O
+majority	O
+of	O
+the	O
+14	O
+(	O
+DRC	O
+)	O
+and	O
+12	O
+(	O
+RCI	O
+)	O
+staff	O
+involved	O
+in	O
+the	O
+polio	B-DISO
+laboratory	O
+as	O
+full	O
+or	O
+in	O
+part	O
+time	O
+members	O
+.	O
+
+It	O
+has	O
+established	O
+strong	O
+Polio	B-DISO
+Laboratory	O
+network	O
+that	O
+contributed	O
+to	O
+the	O
+strengthening	O
+of	O
+capacities	O
+and	O
+its	O
+expansion	O
+to	O
+surveillance	O
+of	O
+other	O
+viral	O
+priority	O
+diseases	O
+such	O
+as	O
+measles	B-PATH
+,	O
+yellow	B-DISO
+fever	I-DISO
+,	O
+Influenza	B-DISO
+,	O
+MERS	O
+-	O
+CoV	O
+and	O
+Ebola	O
+.	O
+
+We	O
+emphasize	O
+the	O
+diagnosis	O
+of	O
+ZIKV	O
+infection	B-DISO
+,	O
+including	O
+maternal	O
+clinical	O
+manifestations	O
+,	O
+maternal	O
+and	O
+fetal	B-ANAT
+laboratory	O
+confirmation	O
+,	O
+and	O
+possible	O
+autopsy	O
+if	O
+need	O
+.	O
+
+The	O
+chance	O
+of	O
+catch	B-DISO
+-	O
+up	O
+growth	B-PROC
+may	O
+decrease	O
+the	O
+number	O
+of	O
+pervious	O
+""""	O
+diagnosed	O
+""""	O
+microcephaly	B-DISO
+.	O
+
+The	O
+pathogenesis	B-DISO
+of	O
+neuro	O
+-	O
+psychiatric	B-DISO
+disorders	I-DISO
+in	O
+NCGS	O
+is	O
+unclear	O
+.	O
+
+The	O
+effect	O
+of	O
+diet	O
+and	O
+nutrition	B-PROC
+on	O
+autistic	B-DISO
+spectrum	O
+disorders	O
+has	O
+been	O
+investigated	O
+in	O
+the	O
+last	O
+two	O
+decades	O
+,	O
+particularly	O
+focusing	O
+on	O
+the	O
+symptoms	O
+of	O
+hyperactivity	O
+and	O
+attention	O
+.	O
+
+Abnormalities	O
+of	O
+host	B-COMP
+-	O
+microbiota	B-SPEC
+interactions	O
+or	O
+of	O
+gut	B-ANAT
+-	O
+microbiota	B-SPEC
+composition	O
+have	O
+been	O
+associated	O
+with	O
+central	B-DISO
+nervous	I-DISO
+system	I-DISO
+disorders	I-DISO
+,	O
+such	O
+as	O
+autism	B-DISO
+,	O
+anxiety	O
+,	O
+depression	B-DISO
+and	O
+the	O
+integrity	O
+of	O
+intestinal	B-ANAT
+microbiota	B-SPEC
+may	O
+be	O
+considered	O
+a	O
+potential	O
+therapeutic	O
+goal	O
+to	O
+treat	O
+these	O
+conditions	O
+.	O
+
+The	O
+2	O
+other	O
+animals	B-SPEC
+were	O
+treated	O
+with	O
+THAM	B-CHED
+but	O
+without	O
+hemofiltration	O
+.	O
+
+Control	O
+-	O
+group	O
+had	O
+an	O
+uneven	O
+evolution	B-PROC
+until	O
+the	O
+end	O
+of	O
+the	O
+experiment	O
+.	O
+
+To	O
+describe	O
+different	O
+manifestations	O
+of	O
+pulmonary	B-DISO
+TB	I-DISO
+in	O
+patients	O
+in	O
+the	O
+ICU	O
+.	O
+
+We	O
+set	O
+up	O
+a	O
+retrospective	O
+study	O
+using	O
+nasal	B-ANAT
+swabs	O
+collected	O
+by	O
+sentinel	O
+GPs	B-DISO
+from	O
+ILI	O
+patients	O
+in	O
+2011	O
+and	O
+2012	O
+.	O
+
+Patients	O
+were	O
+categorized	O
+as	O
+receiving	O
+dexmedetomidine	B-CHED
+as	O
+a	O
+primary	O
+sedative	B-CHED
+,	O
+secondary	O
+sedative	B-CHED
+,	O
+periextubation	O
+agent	O
+,	O
+or	O
+never	O
+prescribed	O
+.	O
+
+Of	O
+1	O
+,	O
+224	O
+usual	O
+care	O
+patients	O
+,	O
+596	O
+(	O
+49	O
+%)	O
+received	O
+dexmedetomidine	B-CHED
+.	O
+
+Investigation	O
+of	O
+the	O
+temporal	O
+dynamics	O
+of	O
+B	B-PROC
+cell	I-PROC
+activation	I-PROC
+in	O
+draining	O
+cervical	B-ANAT
+lymph	I-ANAT
+nodes	I-ANAT
+(	O
+CLN	B-CHED
+)	O
+and	O
+the	O
+CNS	B-CHED
+revealed	O
+that	O
+peak	O
+CNS	B-CHED
+infiltration	B-DISO
+of	O
+early	O
+activated	O
+,	O
+unswitched	O
+IgD	B-PRGE
+
+Our	O
+findings	O
+suggest	O
+that	O
+the	O
+risk	O
+of	O
+pathogen	O
+spillover	O
+from	O
+Desmodus	B-SPEC
+rotundus	I-SPEC
+,	O
+including	O
+between	O
+domestic	O
+animal	B-SPEC
+species	B-SPEC
+,	O
+is	O
+possible	O
+and	O
+warrants	O
+further	O
+investigation	O
+to	O
+characterize	O
+this	O
+microbial	O
+diversity	O
+and	O
+expand	O
+our	O
+understanding	O
+of	O
+foraging	O
+ecology	O
+in	O
+their	O
+populations	O
+.	O
+
+We	O
+also	O
+found	O
+that	O
+receptors	O
+for	O
+the	O
+proinflammatory	O
+cytokine	O
+tumor	B-PRGE
+necrosis	I-PRGE
+factor	I-PRGE
+alpha	I-PRGE
+(	O
+TNFα	O
+)	O
+promote	O
+pathogenesis	B-DISO
+,	O
+presumably	O
+through	O
+excessive	O
+inflammation	B-DISO
+.	O
+
+The	O
+results	O
+presented	O
+here	O
+suggest	O
+the	O
+role	O
+of	O
+Kepi	O
+in	O
+the	O
+host	B-PROC
+response	I-PROC
+to	O
+SARS	B-PRGE
+-	I-PRGE
+CoV	I-PRGE
+,	O
+as	O
+well	O
+as	O
+inflammatory	O
+activity	O
+driving	O
+pathogenesis	B-DISO
+through	O
+TNFα	O
+signaling	B-PROC
+in	O
+SARS	B-DISO
+-	O
+CoV	O
+infections	B-DISO
+.	O
+
+TITLE	O
+:	O
+Fatality	O
+risks	O
+for	O
+nosocomial	O
+outbreaks	O
+of	O
+Middle	O
+East	O
+respiratory	O
+syndrome	B-DISO
+coronavirus	B-SPEC
+in	O
+the	O
+Middle	O
+East	O
+and	O
+South	O
+Korea	O
+.	O
+
+Specific	O
+pathogen	O
+-	O
+free	O
+chickens	B-SPEC
+were	O
+vaccinated	O
+with	O
+pV	B-PRGE
+-	I-PRGE
+S1B	I-PRGE
++	I-PRGE
+S1T	I-PRGE
+and	O
+control	O
+plasmids	O
+twice	O
+to	O
+elicit	O
+strong	O
+humoral	O
+and	O
+cellular	B-PROC
+immune	I-PROC
+response	I-PROC
+,	O
+as	O
+indicated	O
+by	O
+viral	O
+neutralization	O
+titers	O
+and	O
+results	O
+of	O
+CD8	B-PRGE
+
+We	O
+collected	O
+data	O
+on	O
+the	O
+prevalence	O
+and	O
+diversity	O
+of	O
+viral	O
+and	O
+parasitic	O
+pathogens	O
+in	O
+a	O
+small	O
+lion	B-SPEC
+population	O
+in	O
+eastern	O
+Botswana	O
+.	O
+
+This	O
+is	O
+particularly	O
+important	O
+as	O
+there	O
+is	O
+an	O
+initiative	O
+to	O
+incorporate	O
+this	O
+population	O
+into	O
+a	O
+larger	O
+metapopulation	O
+of	O
+lions	B-SPEC
+from	O
+adjacent	O
+South	O
+Africa	O
+and	O
+Zimbabwe	O
+.	O
+
+TITLE	O
+:	O
+Effect	O
+of	O
+different	O
+vaccination	O
+strategies	O
+on	O
+IBV	B-SPEC
+QX	O
+population	O
+dynamics	O
+and	O
+clinical	O
+outbreaks	O
+.	O
+
+Both	O
+AST	B-PRGE
+,	O
+and	O
+ALT	B-FUNC
+values	O
+were	O
+significantly	O
+higher	O
+in	O
+MERS	O
+-	O
+CoV	O
+infected	O
+group	O
+(	O
+AST	B-ENZY
+median	O
+42	O
+vs	O
+36	O
+,	O
+P	O
+:	O
+0	O
+.	O
+03	O
+,	O
+and	O
+ALT	B-FUNC
+median	O
+33	O
+vs	O
+28	O
+,	O
+P	O
+:	O
+0	O
+.	O
+003	O
+).	O
+
+TITLE	O
+:	O
+The	O
+evidence	O
+of	O
+porcine	B-SPEC
+hemagglutinating	O
+encephalomyelitis	B-DISO
+virus	B-SPEC
+induced	O
+nonsuppurative	O
+encephalitis	B-DISO
+as	O
+the	O
+cause	O
+of	O
+death	B-PROC
+in	O
+piglets	O
+.	O
+
+These	O
+findings	O
+suggested	O
+that	O
+the	O
+virus	B-SPEC
+had	O
+a	O
+strong	O
+tropism	B-PROC
+for	O
+CNS	B-CHED
+,	O
+in	O
+this	O
+way	O
+,	O
+inducing	O
+nonsuppurative	O
+encephalitis	B-DISO
+as	O
+the	O
+cause	O
+of	O
+death	B-PROC
+in	O
+piglets	O
+.	O
+
+At	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+onset	O
+,	O
+there	O
+was	O
+minimal	O
+difference	O
+in	O
+mortality	O
+between	O
+mild	O
+or	O
+moderate	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+by	O
+both	O
+Berlin	O
+(	O
+32	O
+.	O
+4	O
+%	O
+vs	O
+25	O
+.	O
+0	O
+%,	O
+respectively	O
+)	O
+and	O
+Pediatric	O
+Acute	O
+Lung	B-ANAT
+Injury	O
+Consensus	O
+Conference	O
+(	O
+16	O
+.	O
+7	O
+%	O
+vs	O
+18	O
+.	O
+6	O
+%,	O
+respectively	O
+)	O
+criteria	O
+,	O
+but	O
+higher	O
+mortality	O
+for	O
+severe	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+(	O
+Berlin	O
+,	O
+43	O
+.	O
+6	O
+%;	O
+Pediatric	O
+Acute	O
+Lung	B-ANAT
+Injury	O
+Consensus	O
+Conference	O
+,	O
+37	O
+.	O
+0	O
+%).	O
+
+TITLE	O
+:	O
+A	O
+Bat	B-SPEC
+-	O
+Derived	O
+Putative	O
+Cross	O
+-	O
+Family	B-SPEC
+Recombinant	O
+Coronavirus	B-SPEC
+with	O
+a	O
+Reovirus	B-SPEC
+Gene	O
+.	O
+
+ABSTRACT	O
+:	O
+The	O
+emergence	O
+of	O
+severe	O
+acute	O
+respiratory	O
+syndrome	O
+coronavirus	B-SPEC
+(	O
+SARS	B-DISO
+-	O
+CoV	O
+)	O
+in	O
+2002	O
+and	O
+Middle	O
+East	O
+respiratory	O
+syndrome	B-DISO
+coronavirus	B-SPEC
+(	O
+MERS	O
+-	O
+CoV	O
+)	O
+in	O
+2012	O
+has	O
+generated	O
+enormous	O
+interest	O
+in	O
+the	O
+biodiversity	O
+,	O
+genomics	O
+and	O
+cross	O
+-	O
+species	B-SPEC
+transmission	O
+potential	O
+of	O
+coronaviruses	O
+,	O
+especially	O
+those	O
+from	O
+bats	B-SPEC
+,	O
+the	O
+second	O
+most	O
+speciose	O
+order	B-SPEC
+of	O
+mammals	B-SPEC
+.	O
+
+TITLE	O
+:	O
+Lavage	O
+-	O
+induced	O
+Surfactant	B-CHED
+Depletion	O
+in	O
+Pigs	B-SPEC
+As	O
+a	O
+Model	O
+of	O
+the	O
+Acute	B-DISO
+Respiratory	I-DISO
+Distress	I-DISO
+Syndrome	I-DISO
+(	O
+ARDS	B-DISO
+).	O
+
+Severe	O
+lung	B-ANAT
+injury	O
+with	O
+a	O
+reproducible	O
+deterioration	O
+of	O
+pulmonary	B-PROC
+gas	B-ENZY
+exchange	I-PROC
+and	O
+hemodynamics	B-PROC
+can	O
+be	O
+induced	O
+in	O
+anesthetized	O
+pigs	B-SPEC
+using	O
+repeated	O
+lung	B-ANAT
+lavages	O
+with	O
+warmed	O
+0	O
+.	O
+9	O
+%	O
+saline	O
+(	O
+50	O
+ml	O
+/	O
+kg	O
+body	B-ANAT
+weight	O
+).	O
+
+RNA	O
+was	O
+extracted	O
+and	O
+tested	O
+by	O
+reverse	B-PROC
+transcription	I-PROC
+polymerase	O
+chain	O
+reaction	O
+(	O
+RT	O
+-	O
+PCR	O
+)	O
+for	O
+the	O
+presence	O
+of	O
+rotavirus	B-SPEC
+,	O
+norovirus	B-SPEC
+,	O
+astrovirus	O
+,	O
+torovirus	B-SPEC
+,	O
+coronavirus	B-SPEC
+and	O
+bovine	B-SPEC
+viral	I-SPEC
+diarrhea	I-SPEC
+virus	I-SPEC
+.	O
+
+Overall	O
+,	O
+76	O
+%	O
+(	O
+19	O
+/	O
+25	O
+)	O
+of	O
+samples	O
+tested	O
+positive	O
+for	O
+one	O
+or	O
+more	O
+viruses	B-SPEC
+.	O
+
+About	O
+37	O
+%	O
+(	O
+7	O
+/	O
+19	O
+)	O
+of	O
+positive	O
+samples	O
+had	O
+two	O
+different	O
+viruses	B-SPEC
+.	O
+
+TITLE	O
+:	O
+Compartment	B-ANAT
+Syndrome	I-DISO
+as	O
+a	O
+Result	O
+of	O
+Systemic	B-DISO
+Capillary	I-DISO
+Leak	I-DISO
+Syndrome	I-DISO
+.	O
+
+Ongoing	O
+hemodynamic	B-PROC
+(	O
+Norepinephrine	B-CHED
+and	O
+Milrinone	B-CHED
+infusion	O
+)	O
+and	O
+respiratory	O
+(	O
+ventilator	O
+)	O
+support	O
+in	O
+the	O
+ICU	O
+was	O
+provided	O
+until	O
+resolution	O
+of	O
+intravascular	O
+fluid	O
+extravasation	B-DISO
+.	O
+
+Patients	O
+present	O
+with	O
+significant	O
+hypotension	O
+,	O
+hemoconcentration	O
+,	O
+hypovolemia	O
+,	O
+and	O
+oliguria	B-DISO
+.	O
+
+Severe	B-DISO
+edema	I-DISO
+results	O
+from	O
+leakage	B-DISO
+of	O
+fluid	O
+and	O
+proteins	B-CHED
+into	O
+tissue	B-ANAT
+.	O
+
+TITLE	O
+:	O
+Characterization	O
+of	O
+Two	O
+Monoclonal	O
+Antibodies	B-COMP
+That	O
+Recognize	O
+Linker	O
+Region	O
+and	O
+Carboxyl	O
+Terminal	O
+Domain	O
+of	O
+Coronavirus	O
+Nucleocapsid	B-COMP
+Protein	B-CHED
+.	O
+
+Overall	O
+,	O
+the	O
+rate	O
+of	O
+fever	B-PROC
+in	O
+confirmed	O
+viral	O
+respiratory	B-DISO
+infections	I-DISO
+in	O
+adult	O
+HCWs	O
+was	O
+23	O
+·	O
+4	O
+%	O
+(	O
+37	O
+/	O
+158	O
+).	O
+
+More	O
+than	O
+75	O
+%	O
+of	O
+adults	O
+with	O
+a	O
+viral	B-DISO
+respiratory	I-DISO
+infection	I-DISO
+do	O
+not	O
+have	O
+fever	B-PROC
+,	O
+which	O
+is	O
+an	O
+important	O
+finding	O
+for	O
+clinical	O
+triage	O
+of	O
+adult	O
+patients	O
+with	O
+respiratory	B-DISO
+infections	I-DISO
+.	O
+
+The	O
+accepted	O
+definition	O
+of	O
+'	B-DISO
+influenza	I-DISO
+-	I-DISO
+like	I-DISO
+illness	I-DISO
+'	O
+includes	O
+fever	B-PROC
+and	O
+may	O
+be	O
+insensitive	O
+for	O
+surveillance	O
+when	O
+high	O
+case	O
+-	O
+finding	O
+is	O
+required	O
+.	O
+
+The	O
+morphogenesis	B-PROC
+and	O
+proliferative	B-DISO
+rule	O
+of	O
+TGEV	B-SPEC
+in	O
+porcine	B-SPEC
+IECs	O
+were	O
+investigated	O
+using	O
+transmission	O
+electron	O
+microscopy	O
+,	O
+indirect	O
+immunofluorescence	O
+assays	O
+and	O
+real	O
+-	O
+time	O
+fluorescence	O
+quantitative	O
+PCR	O
+.	O
+
+Observations	O
+under	O
+the	O
+TEM	B-COMP
+indicated	O
+that	O
+the	O
+enveloped	O
+viral	B-COMP
+particles	I-COMP
+were	O
+roughly	O
+spherical	O
+,	O
+with	O
+diameters	O
+of	O
+between	O
+80	O
+and	O
+120nm	O
+.	O
+
+The	O
+results	O
+also	O
+showed	O
+that	O
+from	O
+0	O
+to	O
+12h	O
+after	O
+TGEV	B-SPEC
+infection	B-DISO
+of	O
+porcine	B-SPEC
+IECs	O
+,	O
+the	O
+intracellular	O
+viral	O
+RNA	O
+content	O
+did	O
+not	O
+change	O
+significantly	O
+.	O
+
+This	O
+study	O
+provided	O
+a	O
+theoretical	O
+foundation	O
+for	O
+further	O
+study	O
+on	O
+the	O
+infection	B-DISO
+characteristics	O
+of	O
+TGEV	B-SPEC
+in	O
+target	B-ANAT
+cells	I-ANAT
+.	O
+
+ABSTRACT	O
+:	O
+Alveolar	B-ANAT
+epithelial	O
+regeneration	B-PROC
+is	O
+essential	O
+for	O
+resolution	O
+of	O
+the	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+(	O
+ARDS	B-DISO
+).	O
+
+To	O
+determine	O
+whether	O
+neutrophils	B-ANAT
+influence	O
+alveolar	B-ANAT
+epithelial	O
+repair	B-PROC
+in	O
+vivo	O
+,	O
+we	O
+developed	O
+a	O
+unilateral	O
+acid	O
+injury	O
+model	O
+that	O
+creates	O
+a	O
+severe	O
+yet	O
+survivable	O
+injury	O
+with	O
+features	O
+similar	O
+to	O
+ARDS	B-DISO
+.	O
+
+The	O
+syndrome	B-DISO
+is	O
+often	O
+associated	O
+with	O
+an	O
+infection	B-DISO
+with	O
+
+Bat	B-ENZY
+coronavirus	B-SPEC
+(	O
+BatCoV	O
+)	O
+HKU9	O
+is	O
+an	O
+important	O
+betacoronavirus	B-SPEC
+(	O
+betaCoV	O
+)	O
+that	O
+is	O
+phylogenetically	O
+affiliated	O
+with	O
+the	O
+same	O
+genus	B-SPEC
+as	O
+MERS	O
+-	O
+CoV	O
+.	O
+The	O
+bat	B-ENZY
+surveillance	O
+data	O
+indicated	O
+that	O
+BatCoV	O
+HKU9	O
+has	O
+been	O
+widely	O
+spreading	O
+and	O
+circulating	O
+in	O
+bats	B-SPEC
+.	O
+
+Via	O
+comparison	O
+of	O
+the	O
+available	O
+RBD	O
+structures	O
+,	O
+we	O
+further	O
+proposed	O
+a	O
+homologous	O
+intersubdomain	O
+binding	B-FUNC
+mode	O
+in	O
+betaCoV	O
+RBDs	O
+that	O
+anchors	O
+the	O
+external	O
+subdomain	O
+to	O
+the	O
+core	O
+subdomain	O
+.	O
+
+The	O
+viruses	B-SPEC
+most	O
+strongly	O
+associated	O
+with	O
+febrile	B-DISO
+seizures	I-DISO
+were	O
+influenza	B-DISO
+,	O
+respiratory	B-SPEC
+syncytial	I-SPEC
+virus	I-SPEC
+,	O
+parainfluenza	B-DISO
+,	O
+human	B-SPEC
+coronavirus	I-SPEC
+,	O
+and	O
+rotavirus	B-SPEC
+.	O
+
+ABSTRACT	O
+:	O
+We	O
+determined	O
+tissue	B-ANAT
+localization	B-PROC
+,	O
+shedding	O
+patterns	O
+,	O
+virus	B-SPEC
+carriage	O
+,	O
+antibody	B-PROC
+response	I-PROC
+,	O
+and	O
+aerosol	O
+transmission	O
+of	O
+Porcine	B-SPEC
+epidemic	I-SPEC
+diarrhea	I-SPEC
+virus	I-SPEC
+(	O
+PEDV	B-SPEC
+)	O
+following	O
+inoculation	O
+of	O
+4	O
+-	O
+week	O
+-	O
+old	O
+feeder	O
+pigs	B-SPEC
+.	O
+
+Thirty	O
+-	O
+three	O
+pigs	B-SPEC
+were	O
+randomly	O
+assigned	O
+to	O
+1	O
+of	O
+3	O
+groups	O
+for	O
+the	O
+42	O
+-	O
+day	O
+study	O
+:	O
+inoculated	O
+(	O
+group	O
+A	O
+;	O
+n	O
+=	O
+23	O
+),	O
+contact	O
+transmission	O
+(	O
+group	B-DISO
+B	I-DISO
+;	O
+n	O
+=	O
+5	O
+),	O
+and	O
+aerosol	O
+transmission	O
+(	O
+group	O
+C	O
+;	O
+n	O
+=	O
+5	O
+).	O
+
+Emesis	B-DISO
+was	O
+the	O
+first	O
+clinical	O
+sign	O
+noted	O
+at	O
+3	O
+days	O
+postinoculation	O
+(	O
+dpi	O
+)	O
+followed	O
+by	O
+mild	O
+to	O
+moderate	O
+diarrhea	B-DISO
+lasting	O
+5	O
+more	O
+days	O
+.	O
+
+The	O
+aim	O
+of	O
+the	O
+present	O
+study	O
+was	O
+to	O
+highlight	O
+the	O
+clinical	O
+features	O
+of	O
+scrub	B-DISO
+typhus	I-DISO
+-	O
+associated	O
+HLH	B-DISO
+in	O
+children	O
+.	O
+
+TITLE	O
+:	O
+Awareness	O
+of	O
+droplet	O
+and	O
+airborne	O
+isolation	O
+precautions	O
+among	O
+dental	O
+health	O
+professionals	O
+during	O
+the	O
+outbreak	O
+of	O
+corona	B-DISO
+virus	B-PROC
+infection	I-PROC
+in	O
+Riyadh	O
+city	O
+,	O
+Saudi	O
+Arabia	O
+.	O
+
+A	O
+cross	O
+-	O
+sectional	O
+survey	O
+was	O
+conducted	O
+among	O
+406	O
+dental	O
+health	O
+professionals	O
+(	O
+DHPs	B-ENZY
+)	O
+working	O
+in	O
+selected	O
+dental	O
+facilities	O
+in	O
+Riyadh	O
+city	O
+,	O
+Saudi	O
+Arabia	O
+during	O
+the	O
+outbreak	O
+of	O
+MERS	O
+(	O
+April	O
+-	O
+June	O
+2013	O
+).	O
+
+TITLE	O
+:	O
+The	O
+Emulsified	O
+PFC	O
+Oxycyte	O
+ABSTRACT	O
+:	O
+Perfluorocarbons	O
+(	O
+PFCs	O
+)	O
+can	O
+transport	B-PROC
+50	O
+times	O
+more	O
+oxygen	B-CHED
+than	O
+human	B-SPEC
+plasma	B-ANAT
+.	O
+
+TITLE	O
+:	O
+Epidemiology	O
+,	O
+clinical	O
+characteristics	O
+,	O
+laboratory	O
+findings	O
+and	O
+severity	O
+of	O
+respiratory	B-SPEC
+syncytial	I-SPEC
+virus	I-SPEC
+acute	O
+lower	B-DISO
+respiratory	I-DISO
+infection	I-DISO
+in	O
+Malaysian	O
+children	O
+,	O
+2008	O
+-	O
+2013	O
+.	O
+
+Infants	O
+less	O
+than	O
+6	O
+months	O
+old	O
+with	O
+RSV	B-PRGE
+ALRI	I-PRGE
+tend	O
+to	O
+be	O
+afebrile	O
+at	O
+presentation	O
+.	O
+
+As	O
+the	O
+mechanistic	O
+pathway	B-PROC
+for	O
+this	O
+ability	O
+is	O
+not	O
+fully	O
+known	O
+,	O
+we	O
+extended	O
+previous	O
+studies	O
+on	O
+influenza	B-SPEC
+virus	I-SPEC
+tropism	B-PROC
+in	O
+cultured	O
+human	B-SPEC
+pulmonary	B-ANAT
+endothelial	B-ANAT
+cells	I-ANAT
+.	O
+
+We	O
+found	O
+that	O
+a	O
+subset	O
+of	O
+avian	B-DISO
+influenza	B-SPEC
+viruses	I-SPEC
+,	O
+including	O
+potentially	O
+pandemic	O
+H5N1	B-DISO
+,	O
+H7N9	O
+,	O
+and	O
+H9N2	O
+viruses	B-SPEC
+,	O
+could	O
+infect	O
+human	B-SPEC
+pulmonary	B-ANAT
+endothelial	B-ANAT
+cells	I-ANAT
+(	O
+HULEC	O
+)	O
+with	O
+high	O
+efficiency	O
+compared	O
+to	O
+human	B-PRGE
+H1N1	I-PRGE
+or	O
+H3N2	B-CHED
+viruses	B-SPEC
+.	O
+
+Epitope	B-PROC
+spreading	I-PROC
+,	O
+molecular	B-PROC
+mimicry	I-PROC
+,	O
+cryptic	O
+antigen	B-CHED
+,	O
+and	O
+bystander	O
+activation	O
+have	O
+been	O
+implicated	O
+as	O
+mechanisms	O
+responsible	O
+for	O
+activating	O
+self	O
+-	O
+reactive	O
+(	O
+SR	O
+)	O
+immune	O
+cells	B-COMP
+,	O
+ultimately	O
+leading	O
+to	O
+organ	B-ANAT
+-	O
+specific	O
+autoimmune	B-DISO
+disease	I-DISO
+.	O
+
+Serum	B-COMP
+cytokine	O
+and	O
+chemokine	O
+levels	O
+in	O
+serial	O
+serum	B-COMP
+samples	O
+were	O
+measured	O
+using	O
+enzyme	O
+-	O
+linked	O
+immunosorbent	O
+assay	O
+.	O
+
+Here	O
+,	O
+we	O
+review	O
+our	O
+current	O
+understanding	O
+of	O
+coronavirus	B-SPEC
+cis	B-DISO
+-	O
+acting	O
+RNA	O
+elements	O
+,	O
+focusing	O
+on	O
+elements	O
+required	O
+for	O
+genome	O
+replication	O
+and	O
+packaging	O
+.	O
+
+Recent	O
+bioinformatic	O
+,	O
+biochemical	O
+,	O
+and	O
+genetic	O
+studies	O
+suggest	O
+a	O
+previously	O
+unknown	O
+level	O
+of	O
+conservation	O
+of	O
+cis	B-DISO
+-	O
+acting	O
+RNA	O
+structures	O
+among	O
+different	O
+coronavirus	B-SPEC
+genera	O
+and	O
+,	O
+in	O
+some	O
+cases	O
+,	O
+even	O
+beyond	O
+genus	B-SPEC
+boundaries	O
+.	O
+
+TITLE	O
+:	O
+Feline	B-SPEC
+Coronaviruses	O
+:	O
+Pathogenesis	B-DISO
+of	O
+Feline	B-DISO
+Infectious	I-DISO
+Peritonitis	I-DISO
+.	O
+
+The	O
+two	O
+coronaviruses	O
+are	O
+thought	O
+to	O
+encode	O
+an	O
+unusually	O
+large	O
+number	O
+of	O
+factors	O
+that	O
+allow	O
+them	O
+to	O
+thrive	O
+and	O
+replicate	O
+in	O
+the	O
+presence	O
+of	O
+efficient	O
+host	B-PROC
+defense	I-PROC
+mechanisms	O
+,	O
+especially	O
+the	O
+antiviral	B-CHED
+interferon	B-PRGE
+system	O
+.	O
+
+TITLE	O
+:	O
+Coronavirus	B-SPEC
+Spike	O
+Protein	B-CHED
+and	O
+Tropism	B-PROC
+Changes	O
+.	O
+
+The	O
+seasonality	O
+of	O
+influenza	B-DISO
+in	O
+ILI	O
+cases	O
+was	O
+November	O
+-	O
+February	O
+,	O
+and	O
+that	O
+in	O
+SARI	O
+cases	O
+was	O
+November	O
+-	O
+March	O
+,	O
+peaking	O
+in	O
+January	O
+.	O
+
+TITLE	O
+:	O
+Middle	O
+East	O
+respiratory	O
+syndrome	B-DISO
+coronavirus	B-SPEC
+:	O
+current	O
+knowledge	O
+and	O
+future	O
+considerations	O
+.	O
+
+Elevated	O
+C	B-PRGE
+-	I-PRGE
+creative	I-PRGE
+protein	I-PRGE
+,	O
+aspartate	B-PRGE
+aminotransferase	I-PRGE
+,	O
+creatine	B-PRGE
+kinase	I-PRGE
+,	O
+and	O
+lymphocytopenia	B-DISO
+predicted	O
+a	O
+higher	O
+risk	O
+of	O
+developing	O
+ARDS	B-DISO
+.	O
+
+The	O
+study	O
+aims	O
+were	O
+to	O
+determine	O
+the	O
+seroprevalence	O
+at	O
+herd	O
+level	O
+,	O
+to	O
+evaluate	O
+risk	O
+factors	O
+for	O
+BRSV	B-SPEC
+and	O
+BCoV	O
+seropositivity	O
+,	O
+and	O
+to	O
+assess	O
+how	O
+these	O
+factors	O
+were	O
+associated	O
+with	O
+the	O
+spatial	O
+distribution	O
+of	O
+positive	O
+herds	O
+.	O
+
+Purchase	O
+of	O
+livestock	O
+was	O
+an	O
+additional	O
+risk	O
+factor	O
+for	O
+BCoV	O
+seropositivity	O
+,	O
+included	O
+in	O
+the	O
+model	O
+as	O
+in	O
+-	O
+degree	O
+,	O
+which	O
+was	O
+defined	O
+as	O
+the	O
+number	O
+of	O
+incoming	O
+movements	B-PROC
+from	O
+individual	O
+herds	O
+,	O
+through	O
+animal	B-SPEC
+purchase	O
+,	O
+over	O
+a	O
+period	O
+of	O
+five	O
+years	O
+.	O
+
+TITLE	O
+:	O
+Spontaneous	B-DISO
+Bacterial	I-DISO
+Peritonitis	I-DISO
+and	O
+Anasarca	B-DISO
+in	O
+a	O
+Female	O
+Patient	O
+with	O
+Ovarian	B-ANAT
+Hyperstimulation	I-DISO
+Syndrome	I-DISO
+Complicated	O
+by	O
+Respiratory	O
+and	O
+Kidney	O
+Failure	O
+.	O
+
+She	O
+presented	O
+to	O
+the	O
+emergency	B-DISO
+department	O
+with	O
+abdominal	B-ANAT
+and	O
+chest	B-DISO
+pain	I-DISO
+,	O
+loose	B-DISO
+stool	I-DISO
+,	O
+vomiting	B-DISO
+,	O
+shortness	B-DISO
+of	I-DISO
+breath	I-DISO
+and	O
+decreasing	O
+urine	B-ANAT
+output	O
+.	O
+
+Ascites	O
+was	O
+further	O
+complicated	O
+by	O
+spontaneous	B-DISO
+bacterial	I-DISO
+peritonitis	I-DISO
+(	O
+SBP	O
+),	O
+which	O
+had	O
+already	O
+been	O
+reported	O
+before	O
+.	O
+
+This	O
+critically	B-DISO
+ill	I-DISO
+patient	O
+was	O
+treated	O
+in	O
+a	O
+special	O
+care	O
+unit	O
+,	O
+and	O
+she	O
+fully	O
+recovered	O
+with	O
+supportive	O
+measures	O
+.	O
+
+TITLE	O
+:	O
+First	O
+epidemiological	O
+study	O
+of	O
+sars	B-DISO
+.	O
+
+Among	O
+the	O
+COPD	O
+exacerbations	O
+,	O
+viral	B-DISO
+infection	I-DISO
+was	O
+detected	O
+in	O
+78	O
+episodes	O
+(	O
+28	O
+.	O
+1	O
+%)	O
+from	O
+67	O
+subjects	O
+.	O
+
+In	O
+multivariate	O
+regression	O
+analysis	O
+adjusting	O
+for	O
+sex	O
+,	O
+age	O
+,	O
+BMI	O
+,	O
+lung	B-PROC
+function	I-PROC
+and	O
+history	O
+of	O
+exacerbations	O
+,	O
+female	O
+subjects	O
+were	O
+found	O
+to	O
+be	O
+significantly	O
+associated	O
+with	O
+viral	B-DISO
+infections	I-DISO
+in	O
+COPD	B-DISO
+exacerbations	O
+(	O
+Odds	O
+ratio	O
+2	O
+.	O
+58	O
+,	O
+95	O
+%	O
+CI	O
+1	O
+.	O
+25	O
+-	O
+5	O
+.	O
+31	O
+,	O
+P	O
+=	O
+0	O
+.	O
+010	O
+).	O
+
+Without	O
+a	O
+travel	O
+history	O
+,	O
+few	O
+clinical	O
+and	O
+radiological	O
+features	O
+can	O
+reliably	O
+differentiate	O
+MERS	O
+from	O
+SARS	B-DISO
+.	O
+
+ABSTRACT	O
+:	O
+Viruses	B-SPEC
+rapidly	O
+evolve	O
+and	O
+can	O
+emerge	O
+in	O
+unpredictable	O
+ways	O
+.	O
+
+Viruses	B-SPEC
+that	O
+are	O
+known	O
+foodborne	O
+threats	O
+include	O
+hepatitis	B-SPEC
+E	I-SPEC
+virus	I-SPEC
+,	O
+tick	B-SPEC
+-	I-SPEC
+borne	I-SPEC
+encephalitis	I-SPEC
+virus	I-SPEC
+,	O
+enteroviruses	B-SPEC
+,	O
+adenovirus	B-DISO
+,	O
+and	O
+astroviruses	O
+,	O
+among	O
+others	O
+.	O
+
+Viruses	B-SPEC
+may	O
+potentially	O
+evolve	O
+and	O
+emerge	O
+as	O
+a	O
+result	O
+of	O
+modern	O
+agricultural	O
+practices	O
+which	O
+can	O
+concentrate	O
+livestock	O
+and	O
+bring	O
+them	O
+into	O
+contact	O
+with	O
+wild	O
+animals	B-SPEC
+.	O
+
+ABSTRACT	O
+:	O
+Porcine	O
+epidemic	B-DISO
+diarrhea	I-DISO
+coronavirus	B-SPEC
+(	O
+PEDV	B-SPEC
+)	O
+is	O
+currently	O
+devastating	O
+the	O
+United	O
+States	O
+pork	O
+industry	O
+by	O
+causing	O
+an	O
+80	O
+-	O
+100	O
+%	O
+fatality	O
+rate	O
+in	O
+infected	O
+piglets	O
+.	O
+
+Here	O
+we	O
+systematically	O
+investigated	O
+the	O
+roles	O
+of	O
+different	O
+proteases	O
+in	O
+PEDV	B-SPEC
+entry	O
+using	O
+pseudovirus	O
+entry	O
+,	O
+biochemical	O
+,	O
+and	O
+live	O
+virus	B-DISO
+infection	I-DISO
+assays	O
+.	O
+
+Extracellular	B-PRGE
+trypsin	B-ENZY
+activates	O
+PEDV	B-SPEC
+entry	O
+when	O
+lysosomal	B-PRGE
+cysteine	B-CHED
+proteases	I-PRGE
+are	O
+inhibited	O
+.	O
+
+ABSTRACT	O
+:	O
+Human	B-SPEC
+coronavirus	I-SPEC
+229E	I-SPEC
+(	O
+HCoV	B-SPEC
+-	I-SPEC
+229E	I-SPEC
+),	O
+a	O
+causative	O
+agent	O
+of	O
+the	O
+common	B-DISO
+cold	I-DISO
+,	O
+enters	O
+host	B-COMP
+cells	B-COMP
+via	O
+two	O
+distinct	O
+pathways	B-PROC
+:	O
+one	O
+is	O
+mediated	O
+by	O
+cell	B-COMP
+surface	I-COMP
+proteases	O
+,	O
+particularly	O
+transmembrane	B-PRGE
+protease	I-PRGE
+serine	B-CHED
+2	I-PRGE
+(	O
+TMPRSS2	B-PRGE
+),	O
+and	O
+the	O
+other	O
+by	O
+endosomal	B-PRGE
+cathepsin	I-PRGE
+L	I-PRGE
+.	O
+Thus	O
+,	O
+specific	O
+inhibitors	B-CHED
+of	O
+these	O
+proteases	O
+block	O
+virus	B-DISO
+infection	I-DISO
+.	O
+
+Here	O
+,	O
+we	O
+examined	O
+the	O
+mechanism	O
+of	O
+cell	B-COMP
+entry	O
+used	O
+by	O
+a	O
+pseudotyped	O
+virus	B-SPEC
+bearing	O
+the	O
+HCoV	B-SPEC
+-	I-SPEC
+229E	I-SPEC
+spike	O
+(	O
+S	O
+)	O
+protein	B-CHED
+in	O
+the	O
+presence	O
+or	O
+absence	O
+of	O
+protease	B-PROC
+inhibitors	I-PROC
+.	O
+
+Two	O
+amino	B-PROC
+acid	I-PROC
+substitutions	I-PROC
+(	O
+R642M	O
+and	O
+N714K	O
+)	O
+in	O
+the	O
+S	B-PRGE
+protein	I-PRGE
+of	O
+HCoV	B-SPEC
+-	I-SPEC
+229E	I-SPEC
+clinical	O
+isolates	O
+altered	O
+their	O
+sensitivity	O
+to	O
+a	O
+cathepsin	O
+L	O
+inhibitor	O
+,	O
+suggesting	O
+that	O
+these	O
+amino	B-CHED
+acids	I-CHED
+were	O
+responsible	O
+for	O
+cathepsin	B-PRGE
+L	I-PRGE
+use	I-PRGE
+.	O
+
+Here	O
+,	O
+we	O
+found	O
+that	O
+clinical	O
+isolates	O
+of	O
+HCoV	B-SPEC
+-	I-SPEC
+229E	I-SPEC
+preferentially	O
+utilize	O
+the	O
+cell	B-COMP
+surface	I-COMP
+protease	O
+TMPRSS2	O
+rather	O
+than	O
+endosomal	B-PRGE
+cathepsin	I-PRGE
+L	I-PRGE
+.	O
+The	O
+endosome	B-COMP
+is	O
+a	O
+main	O
+site	O
+of	O
+Toll	B-PRGE
+-	I-PRGE
+like	I-PRGE
+receptor	I-PRGE
+recognition	O
+,	O
+which	O
+then	O
+triggers	O
+an	O
+innate	B-DISO
+immune	I-DISO
+response	I-DISO
+;	O
+therefore	O
+,	O
+HCoV	B-SPEC
+-	I-SPEC
+229E	I-SPEC
+presumably	O
+evolved	O
+to	O
+bypass	O
+the	O
+endosome	B-COMP
+by	O
+entering	O
+the	O
+cell	B-COMP
+via	O
+TMPRSS2	O
+.	O
+
+Thus	O
+,	O
+the	O
+virus	B-SPEC
+uses	O
+a	O
+simple	O
+mechanism	O
+to	O
+evade	O
+the	O
+host	B-COMP
+innate	O
+immune	B-ANAT
+system	I-ANAT
+.	O
+
+Data	O
+regarding	O
+AP	O
+etiology	O
+,	O
+severity	O
+,	O
+and	O
+development	B-PROC
+of	O
+organ	B-DISO
+failure	I-DISO
+were	O
+registered	O
+.	O
+
+The	O
+common	O
+causes	O
+of	O
+diarrhea	B-DISO
+are	O
+infections	B-DISO
+with	O
+viruses	B-SPEC
+and	O
+bacteria	B-SPEC
+,	O
+diarrhea	B-DISO
+due	O
+to	O
+a	O
+systemic	B-DISO
+infection	I-DISO
+other	O
+than	O
+gastrointestinal	O
+,	O
+diarrhea	B-DISO
+associated	O
+with	O
+antibiotic	B-CHED
+administration	O
+,	O
+and	O
+feeding	O
+related	O
+diarrhea	B-DISO
+.	O
+
+TITLE	O
+:	O
+Detection	O
+of	O
+nidoviruses	B-SPEC
+in	O
+live	O
+pythons	B-SPEC
+and	O
+boas	B-SPEC
+.	O
+
+ABSTRACT	O
+:	O
+Nidoviruses	B-SPEC
+have	O
+recently	O
+been	O
+described	O
+as	O
+a	O
+putative	O
+cause	O
+of	O
+severe	O
+respiratory	O
+disease	O
+in	O
+pythons	B-SPEC
+in	O
+the	O
+USA	O
+and	O
+Europe	O
+.	O
+
+They	O
+were	O
+most	O
+commonly	O
+detected	O
+in	O
+ball	B-SPEC
+pythons	I-SPEC
+(	O
+Python	B-SPEC
+[	O
+P	O
+.]	O
+regius	O
+)	O
+and	O
+Indian	O
+rock	O
+pythons	B-SPEC
+(	O
+P	B-SPEC
+.	I-SPEC
+molurus	I-SPEC
+),	O
+but	O
+were	O
+also	O
+detected	O
+for	O
+the	O
+first	O
+time	O
+in	O
+other	O
+python	B-SPEC
+species	B-SPEC
+,	O
+including	O
+Morelia	B-SPEC
+spp	B-ENZY
+.	O
+
+RESULTS	O
+:	O
+Nidoviruses	B-SPEC
+were	O
+detected	O
+in	O
+27	O
+.	O
+4	O
+%	O
+of	O
+the	O
+pythons	B-SPEC
+and	O
+2	O
+.	O
+4	O
+%	O
+of	O
+the	O
+boas	B-SPEC
+tested	O
+.	O
+
+Oral	B-ANAT
+swabs	O
+were	O
+most	O
+commonly	O
+tested	O
+positive	O
+.	O
+
+This	O
+paper	O
+reports	O
+the	O
+first	O
+complete	O
+genome	O
+sequence	O
+of	O
+a	O
+Brazil	O
+type	O
+of	O
+this	O
+virus	B-SPEC
+(	O
+27	O
+,	O
+615	O
+nucleotides	B-CHED
+[	O
+nt	O
+])	O
+isolated	O
+from	O
+the	O
+kidneys	B-ANAT
+of	O
+a	O
+chicken	B-SPEC
+.	O
+
+Based	O
+on	O
+DNA	O
+sequences	O
+for	O
+the	O
+gene	O
+encoding	O
+the	O
+S	B-PRGE
+protein	I-PRGE
+,	O
+the	O
+avian	B-SPEC
+coronaviruses	O
+detected	O
+in	O
+the	O
+quail	O
+and	O
+pheasant	O
+are	O
+related	O
+to	O
+the	O
+IBV	B-SPEC
+793B	O
+and	O
+Massachusetts	O
+types	O
+,	O
+respectively	O
+.	O
+
+ABSTRACT	O
+:	O
+Authors	O
+of	O
+recent	O
+meta	O
+-	O
+analyses	O
+have	O
+reported	O
+that	O
+prolonged	O
+glucocorticoid	B-CHED
+treatment	O
+is	O
+associated	O
+with	O
+significant	O
+improvements	O
+in	O
+patients	O
+with	O
+severe	O
+pneumonia	B-DISO
+or	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+(	O
+ARDS	B-DISO
+)	O
+of	O
+multifactorial	O
+etiology	O
+.	O
+
+In	O
+this	O
+double	O
+-	O
+blind	B-DISO
+,	O
+single	O
+-	O
+center	O
+(	O
+Siriraj	O
+Hospital	O
+,	O
+Bangkok	O
+),	O
+randomized	O
+,	O
+placebo	O
+-	O
+controlled	O
+trial	O
+,	O
+we	O
+recruited	O
+adult	O
+patients	O
+with	O
+severe	B-DISO
+sepsis	I-DISO
+within	O
+12	O
+h	O
+of	O
+their	O
+meeting	O
+ARDS	B-DISO
+criteria	O
+.	O
+
+Hyperglycemia	B-DISO
+had	O
+no	O
+impact	O
+on	O
+outcome	O
+.	O
+
+The	O
+purpose	O
+of	O
+this	O
+review	O
+is	O
+to	O
+discuss	O
+the	O
+function	O
+of	O
+proteins	B-CHED
+responsible	O
+for	O
+formation	B-PROC
+of	O
+the	O
+coronavirus	B-SPEC
+replicative	O
+organelle	B-COMP
+.	O
+
+ABSTRACT	O
+:	O
+Resistance	B-PROC
+to	O
+respiratory	O
+pathogens	O
+,	O
+including	O
+coronavirus	B-SPEC
+-	O
+induced	B-DISO
+infection	I-DISO
+and	O
+clinical	O
+illness	O
+in	O
+chickens	B-SPEC
+has	O
+been	O
+correlated	O
+with	O
+the	O
+B	B-PRGE
+(	I-PRGE
+MHC	I-PRGE
+)	I-PRGE
+complex	I-PRGE
+and	O
+differential	O
+ex	O
+vivo	O
+macrophage	B-ANAT
+responses	O
+.	O
+
+These	O
+results	O
+suggest	O
+that	O
+MERS	O
+-	O
+CoV	O
+RBD	O
+in	O
+its	O
+trimeric	O
+form	O
+maintains	O
+native	O
+conformation	O
+and	O
+induces	O
+protective	O
+neutralizing	O
+antibodies	B-COMP
+,	O
+making	O
+it	O
+a	O
+candidate	O
+for	O
+further	O
+therapeutic	O
+development	B-PROC
+.	O
+
+TITLE	O
+:	O
+Discovery	O
+of	O
+novel	O
+piperidine	B-CHED
+-	O
+substituted	O
+indolylarylsulfones	O
+as	O
+potent	O
+HIV	B-DISO
+NNRTIs	O
+via	O
+structure	O
+-	O
+guided	O
+scaffold	O
+morphing	O
+and	O
+fragment	O
+rearrangement	O
+.	O
+
+For	O
+lower	B-DISO
+respiratory	I-DISO
+tract	I-DISO
+infections	I-DISO
+blood	B-ANAT
+culture	O
+,	O
+serum	B-COMP
+procalcitonin	O
+,	O
+serum	B-PRGE
+antibodies	B-COMP
+to	O
+Mycoplasma	B-DISO
+and	O
+Chlamydia	B-SPEC
+and	O
+urinary	O
+Streptococcus	B-PRGE
+pneumoniae	I-PRGE
+antigen	B-CHED
+were	O
+also	O
+assayed	O
+.	O
+
+Of	O
+these	O
+,	O
+samples	O
+were	O
+processed	O
+in	O
+395	O
+episodes	O
+(	O
+upper	B-DISO
+respiratory	I-DISO
+tract	I-DISO
+infection	I-DISO
+:	O
+377	O
+;	O
+lower	B-DISO
+respiratory	I-DISO
+tract	I-DISO
+infection	I-DISO
+:	O
+18	O
+).	O
+
+In	O
+lower	B-DISO
+respiratory	I-DISO
+tract	I-DISO
+infections	B-PROC
+,	I-PROC
+viral	I-PROC
+infections	O
+were	O
+detected	O
+in	O
+12	O
+(	O
+66	O
+.	O
+7	O
+%)	O
+episodes	O
+,	O
+bacterial	B-DISO
+infections	I-DISO
+in	O
+17	O
+(	O
+94	O
+.	O
+4	O
+%)	O
+episodes	O
+and	O
+mixed	O
+bacterial	O
+-	O
+viral	B-DISO
+infections	I-DISO
+in	O
+8	O
+(	O
+44	O
+.	O
+4	O
+%)	O
+episodes	O
+.	O
+
+RESULTS	O
+:	O
+A	O
+total	O
+of	O
+503	O
+ARI	B-CHED
+episodes	O
+were	O
+documented	O
+in	O
+310	O
+infants	O
+for	O
+an	O
+incidence	O
+rate	O
+of	O
+1	O
+.	O
+8	O
+episodes	O
+per	O
+infant	O
+per	O
+year	O
+.	O
+
+There	O
+was	O
+no	O
+significant	O
+difference	O
+in	O
+symptom	B-DISO
+duration	O
+with	O
+virus	B-SPEC
+types	O
+.	O
+
+ABSTRACT	O
+:	O
+To	O
+improve	O
+the	O
+outcome	O
+of	O
+the	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+(	O
+ARDS	B-DISO
+),	O
+one	O
+needs	O
+to	O
+identify	O
+potentially	O
+modifiable	O
+factors	O
+associated	O
+with	O
+mortality	O
+.	O
+
+Non	O
+-	O
+modifiable	O
+factors	O
+associated	O
+with	O
+worsened	O
+outcome	O
+from	O
+ARDS	B-DISO
+included	O
+older	O
+age	O
+,	O
+active	O
+neoplasm	B-DISO
+,	I-DISO
+hematologic	I-DISO
+neoplasm	B-DISO
+,	O
+and	O
+chronic	B-DISO
+liver	I-DISO
+failure	I-DISO
+.	O
+
+Moreover	O
+the	O
+divergent	O
+sanitary	O
+situations	O
+and	O
+exposures	O
+to	O
+animals	B-SPEC
+among	O
+populations	O
+in	O
+the	O
+Arabian	O
+Peninsula	O
+,	O
+where	O
+human	B-SPEC
+primary	O
+cases	O
+appear	O
+to	O
+dominate	O
+,	O
+vs	O
+.	O
+other	O
+regions	O
+in	O
+the	O
+Middle	O
+East	O
+and	O
+Africa	O
+,	O
+with	O
+no	O
+reported	O
+human	B-SPEC
+clinical	O
+cases	O
+and	O
+where	O
+the	O
+virus	B-SPEC
+has	O
+been	O
+detected	O
+only	O
+in	O
+dromedaries	B-SPEC
+,	O
+represents	O
+huge	O
+scientific	O
+and	O
+health	O
+challenges	O
+.	O
+
+Here	O
+,	O
+we	O
+have	O
+used	O
+expert	O
+-	O
+opinion	O
+elicitation	O
+in	O
+order	B-SPEC
+to	O
+obtain	O
+ideas	O
+on	O
+relative	O
+importance	O
+of	O
+MERS	O
+-	O
+CoV	O
+risk	O
+factors	O
+and	O
+estimates	O
+of	O
+transmission	O
+risks	O
+from	O
+various	O
+types	O
+of	O
+contact	O
+between	O
+humans	O
+and	O
+dromedaries	B-SPEC
+.	O
+
+Fourteen	O
+experts	O
+with	O
+diverse	O
+and	O
+extensive	O
+experience	O
+in	O
+MERS	O
+-	O
+CoV	O
+relevant	O
+fields	O
+were	O
+enrolled	O
+and	O
+completed	O
+an	O
+online	O
+questionnaire	O
+that	O
+examined	O
+pathways	B-PROC
+based	O
+on	O
+several	O
+scenarios	O
+,	O
+e	O
+.	O
+g	O
+.,	O
+camels	B-SPEC
+-	O
+camels	B-SPEC
+,	O
+camels	B-SPEC
+-	O
+human	B-SPEC
+,	O
+bats	B-SPEC
+/	O
+other	O
+species	B-SPEC
+to	O
+camels	B-SPEC
+/	O
+humans	B-SPEC
+,	O
+and	O
+the	O
+role	O
+of	O
+diverse	O
+biological	O
+substances	O
+(	O
+milk	O
+,	O
+urine	B-ANAT
+,	O
+etc	O
+.)	O
+and	O
+potential	O
+fomites	O
+.	O
+
+Common	O
+radiological	O
+pulmonary	B-ANAT
+abnormalities	O
+included	O
+pleural	B-DISO
+effusion	I-DISO
+(	O
+14	O
+.	O
+6	O
+%),	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+(	O
+14	O
+%),	O
+airspace	O
+opacity	B-DISO
+(	O
+10	O
+.	O
+5	O
+%),	O
+reticulonodular	O
+opacities	B-DISO
+(	O
+10	O
+.	O
+3	O
+%),	O
+peribronchial	O
+thickening	O
+(	O
+5	O
+.	O
+8	O
+%),	O
+and	O
+pulmonary	B-DISO
+edema	I-DISO
+(	O
+2	O
+%).	O
+
+TITLE	O
+:	O
+Serosurvey	O
+for	O
+Selected	O
+Viral	O
+Pathogens	O
+among	O
+Sympatric	O
+Species	B-SPEC
+of	O
+the	O
+African	O
+Large	O
+Predator	O
+Guild	O
+in	O
+Northern	O
+Botswana	O
+.	O
+
+ABSTRACT	O
+:	O
+Despite	O
+the	O
+availability	O
+of	O
+effective	O
+antiretroviral	O
+therapies	O
+,	O
+drugs	O
+for	O
+HIV	B-SPEC
+-	I-SPEC
+1	I-SPEC
+treatment	O
+with	O
+new	O
+mode	O
+of	O
+action	O
+are	O
+still	O
+needed	O
+.	O
+
+An	O
+innovative	O
+approach	O
+is	O
+aimed	O
+to	O
+identify	O
+dual	O
+HIV	B-SPEC
+-	I-SPEC
+1	I-SPEC
+inhibitors	B-CHED
+,	O
+small	O
+molecules	O
+that	O
+can	O
+inhibit	O
+two	O
+viral	O
+functions	O
+at	O
+the	O
+same	O
+time	O
+.	O
+
+Rhubarb	B-SPEC
+,	O
+originated	O
+from	O
+Rheum	B-SPEC
+palmatum	I-SPEC
+L	O
+.	O
+and	O
+Rheum	B-SPEC
+officinale	I-SPEC
+Baill	O
+.,	O
+is	O
+one	O
+of	O
+the	O
+earliest	O
+and	O
+most	O
+commonly	O
+used	O
+medicinal	O
+plants	B-SPEC
+in	O
+Traditional	O
+Chinese	O
+Medicine	B-CHED
+(	O
+TCM	O
+)	O
+practice	O
+.	O
+
+Active	O
+compounds	O
+were	O
+then	O
+assayed	O
+for	O
+their	O
+effects	O
+on	O
+HIV	O
+-	O
+1	O
+mutated	O
+RTs	B-DISO
+,	O
+integrase	B-PRGE
+(	O
+IN	O
+)	O
+and	O
+viral	B-PROC
+replication	I-PROC
+.	O
+
+CONCLUSIONS	O
+:	O
+Sennoside	O
+A	O
+is	O
+a	O
+new	O
+scaffold	O
+for	O
+the	O
+development	B-PROC
+of	O
+HIV	B-SPEC
+-	I-SPEC
+1	I-SPEC
+dual	O
+RT	O
+inhibitors	B-CHED
+.	O
+
+The	O
+objective	O
+of	O
+this	O
+study	O
+is	O
+to	O
+investigate	O
+the	O
+potential	O
+role	O
+of	O
+Nur77	B-PRGE
+and	O
+its	O
+underlying	O
+mechanism	O
+in	O
+the	O
+regulation	B-PROC
+of	O
+endothelin	B-PRGE
+-	I-PRGE
+1	I-PRGE
+(	O
+ET	B-PRGE
+-	I-PRGE
+1	I-PRGE
+)	O
+expression	B-PROC
+in	O
+lipopolysaccharide	B-CHED
+(	O
+LPS	B-DISO
+)-	O
+induced	O
+A549	O
+cells	B-COMP
+and	O
+an	O
+ARDS	B-DISO
+rat	B-SPEC
+model	O
+.	O
+
+Pharmacological	O
+activation	O
+of	O
+Nur77	O
+by	O
+cytosporone	O
+B	O
+(	O
+CsnB	B-PRGE
+)	O
+inhibited	O
+ET	B-PRGE
+-	I-PRGE
+1	I-PRGE
+expression	B-PROC
+in	O
+ARDS	B-DISO
+rats	B-SPEC
+,	O
+decreased	O
+LPS	B-DISO
+-	O
+induced	O
+phosphorylation	B-PROC
+of	O
+NF	O
+-	O
+κB	O
+and	O
+p38	B-FUNC
+MAPK	B-FUNC
+,	O
+and	O
+relieved	O
+lung	B-ANAT
+,	O
+liver	B-ANAT
+,	O
+and	O
+kidney	B-ANAT
+injury	O
+.	O
+
+TITLE	O
+:	O
+Isatin	B-CHED
+thiazoline	O
+hybrids	O
+as	O
+dual	O
+inhibitors	B-CHED
+of	O
+HIV	B-SPEC
+-	I-SPEC
+1	I-SPEC
+reverse	B-PRGE
+transcriptase	I-PRGE
+.	O
+
+ABSTRACT	O
+:	O
+A	O
+series	O
+of	O
+3	O
+-	O
+3	O
+-{	O
+2	O
+-[	O
+2	O
+-	O
+3	O
+-	O
+methyl	O
+-	O
+4	O
+-	O
+phenyl	B-CHED
+-	O
+2	O
+,	O
+3	O
+-	O
+dihydro	O
+-	O
+1	O
+,	O
+3	O
+-	O
+thiazol	O
+-	O
+2	O
+-	O
+ylidene	O
+]	O
+hydrazin	B-CHED
+-	O
+1	O
+-	O
+ylidene	O
+-	O
+2	O
+,	O
+3	O
+-	O
+dihydro	O
+-	O
+1H	O
+-	O
+indol	B-CHED
+-	I-CHED
+2	I-CHED
+-	I-CHED
+one	I-CHED
+derivatives	O
+has	O
+been	O
+designed	O
+and	O
+synthesized	O
+to	O
+study	O
+their	O
+activity	O
+on	O
+both	O
+HIV	B-SPEC
+-	I-SPEC
+1	I-SPEC
+(	O
+Human	B-PRGE
+Immunodeficiency	I-PRGE
+Virus	I-PRGE
+type	I-PRGE
+1	I-PRGE
+)	O
+RT	O
+(	O
+Reverse	B-PRGE
+Transcriptase	I-PRGE
+)	O
+associated	O
+functions	O
+.	O
+
+ABSTRACT	O
+:	O
+Hemolytic	B-DISO
+uremic	I-DISO
+syndrome	I-DISO
+(	O
+HUS	O
+)	O
+is	O
+a	O
+thrombotic	B-DISO
+microangiopathy	I-DISO
+defined	O
+by	O
+thrombocytopenia	O
+,	O
+non	O
+-	O
+immune	O
+microangiopathic	B-DISO
+hemolytic	I-DISO
+anemia	I-DISO
+and	O
+acute	B-DISO
+renal	I-DISO
+failure	I-DISO
+.	O
+
+The	O
+atypical	O
+HUS	O
+,	O
+in	O
+contrast	O
+to	O
+STEC	O
+-	O
+HUS	O
+which	O
+tends	O
+to	O
+occur	O
+as	O
+a	O
+single	O
+event	O
+,	O
+is	O
+a	O
+chronic	O
+condition	B-DISO
+and	O
+involves	O
+a	O
+poorer	O
+prognosis	O
+.	O
+
+This	O
+drug	O
+has	O
+shown	O
+an	O
+improvement	O
+in	O
+platelet	B-ANAT
+count	O
+,	O
+cessation	O
+of	O
+hemolysis	B-DISO
+,	O
+improvement	O
+of	O
+renal	B-PROC
+function	I-PROC
+within	O
+a	O
+few	O
+days	O
+after	O
+the	O
+treatment	O
+.	O
+
+ABSTRACT	O
+:	O
+Since	O
+2010	O
+,	O
+outbreaks	O
+of	O
+variant	O
+porcine	B-SPEC
+epidemic	I-SPEC
+diarrhea	I-SPEC
+virus	I-SPEC
+(	O
+PEDV	B-SPEC
+)	O
+have	O
+swept	O
+across	O
+the	O
+world	O
+causing	O
+substantial	O
+economic	O
+losses	O
+.	O
+
+In	O
+vivo	O
+experiments	O
+demonstrated	O
+that	O
+the	O
+rescued	O
+virus	B-SPEC
+displayed	O
+similar	O
+pathogenicity	O
+to	O
+the	O
+parental	O
+isolate	O
+,	O
+causing	O
+high	O
+mortality	O
+rates	O
+in	O
+suckling	O
+pigs	O
+.	O
+
+This	O
+study	O
+provided	O
+a	O
+strong	O
+basis	O
+for	O
+the	O
+development	B-PROC
+of	O
+live	O
+attenuated	O
+vaccines	O
+and	O
+for	O
+research	O
+into	O
+the	O
+pathogenic	O
+mechanisms	O
+of	O
+this	O
+virus	B-SPEC
+.	O
+
+ABSTRACT	O
+:	O
+Amiodarone	B-CHED
+is	O
+often	O
+used	O
+in	O
+the	O
+suppression	B-DISO
+of	O
+tachyarrhythmias	O
+.	O
+
+Post	O
+-	O
+operatively	O
+,	O
+the	O
+patient	O
+was	O
+admitted	O
+to	O
+the	O
+ICU	O
+for	O
+ventilator	O
+management	O
+and	O
+continued	O
+to	O
+receive	O
+his	O
+home	O
+dose	O
+of	O
+amiodarone	B-CHED
+400	O
+mg	O
+orally	B-ANAT
+twice	O
+daily	O
+,	O
+which	O
+he	O
+had	O
+been	O
+taking	O
+for	O
+the	O
+past	O
+3	O
+months	O
+.	O
+
+PI4KIIIα	O
+is	O
+one	O
+of	O
+four	O
+mammalian	B-SPEC
+phosphatidylinositol	B-PRGE
+-	I-PRGE
+4	I-PRGE
+kinases	I-PRGE
+and	O
+has	O
+recently	O
+drawn	O
+significant	O
+attention	O
+as	O
+an	O
+emerging	O
+target	O
+for	O
+hepatitis	B-SPEC
+C	I-SPEC
+virus	I-SPEC
+(	O
+HCV	B-SPEC
+)	O
+treatment	O
+.	O
+
+RESULTS	O
+:	O
+A	O
+total	O
+of	O
+159	O
+patients	O
+with	O
+ARDS	B-DISO
+were	O
+evaluated	O
+,	O
+but	O
+just	O
+70	O
+patients	O
+were	O
+included	O
+.	O
+
+Eight	O
+HCWs	O
+had	O
+MERS	O
+requiring	O
+ICU	O
+admission	O
+(	O
+median	O
+stay	O
+=	O
+28	O
+days	O
+):	O
+Seven	O
+developed	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+,	O
+four	O
+were	O
+treated	O
+with	O
+prone	O
+positioning	O
+,	O
+four	O
+needed	O
+continuous	O
+renal	B-ANAT
+replacement	O
+therapy	O
+and	O
+one	O
+had	O
+extracorporeal	O
+membrane	B-COMP
+oxygenation	B-PROC
+.	O
+
+Although	O
+most	O
+ICU	O
+staff	O
+expressed	B-PROC
+concerns	O
+about	O
+acquiring	O
+MERS	O
+,	O
+all	O
+reported	O
+to	O
+work	O
+normally	O
+.	O
+
+Most	O
+patients	O
+had	O
+multiorgan	B-DISO
+failure	I-DISO
+.	O
+
+We	O
+performed	O
+a	O
+systematic	O
+review	O
+of	O
+the	O
+available	O
+literature	O
+to	O
+investigate	O
+the	O
+safety	O
+and	O
+efficacy	O
+of	O
+vv	O
+-	O
+ECMO	O
+in	O
+posttraumatic	O
+ARDS	B-DISO
+,	O
+focusing	O
+on	O
+the	O
+use	O
+of	O
+different	O
+anticoagulation	B-PROC
+strategies	O
+and	O
+risk	O
+of	O
+bleeding	B-DISO
+on	O
+patients	O
+with	O
+multiple	O
+injuries	O
+.	O
+
+Eleven	O
+patients	O
+developed	O
+complications	O
+during	O
+treatment	O
+with	O
+ECMO	O
+with	O
+three	O
+cases	O
+of	O
+major	O
+bleeding	B-DISO
+.	O
+
+In	O
+all	O
+documented	O
+cases	O
+of	O
+bleeding	B-DISO
+a	O
+bolus	O
+and	O
+infusion	O
+of	O
+heparin	B-CHED
+was	O
+administered	O
+,	O
+aiming	O
+for	O
+an	O
+activated	O
+clotting	B-PROC
+time	O
+(	O
+ACT	O
+)	O
+target	O
+longer	O
+than	O
+150	O
+seconds	O
+.	O
+
+A	O
+heparin	B-CHED
+bolus	O
+was	O
+given	O
+in	O
+16	O
+cases	O
+.	O
+
+All	O
+had	O
+MERS	O
+-	O
+CoV	O
+infection	B-DISO
+ruled	O
+out	O
+by	O
+RT	O
+-	O
+PCR	O
+or	O
+clinical	O
+assessment	O
+.	O
+
+Of	O
+these	O
+,	O
+62	O
+(	O
+27	O
+%)	O
+tested	O
+positive	O
+for	O
+seasonal	O
+influenza	B-DISO
+.	O
+
+TITLE	O
+:	O
+Clinical	O
+predictors	O
+of	O
+early	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+in	O
+trauma	O
+patients	O
+.	O
+
+MERS	O
+-	O
+CoV	O
+p4a	O
+is	O
+a	O
+dsRNA	B-FUNC
+binding	I-FUNC
+protein	B-CHED
+.	O
+
+Mutation	O
+of	O
+the	O
+dsRNA	B-FUNC
+binding	I-FUNC
+motif	O
+in	O
+p4a	O
+disrupted	O
+its	O
+PKR	B-PRGE
+antagonistic	O
+activity	O
+.	O
+
+This	O
+virus	B-SPEC
+also	O
+suppressed	O
+the	O
+dsRNA	B-CHED
+-	O
+independent	O
+stress	B-PATH
+response	I-PATH
+pathway	B-PROC
+.	O
+
+TITLE	O
+:	O
+Disinfection	O
+of	O
+aircraft	O
+:	O
+Appropriate	O
+disinfectants	B-CHED
+and	O
+standard	O
+operating	O
+procedures	O
+for	O
+highly	O
+infectious	O
+diseases	O
+.	O
+
+ABSTRACT	O
+:	O
+For	O
+infectious	B-DISO
+diseases	I-DISO
+caused	O
+by	O
+highly	O
+pathogenic	O
+agents	O
+(	O
+e	O
+.	O
+g	O
+.,	O
+Ebola	O
+/	O
+Lassa	B-DISO
+fever	I-DISO
+virus	B-SPEC
+,	O
+SARS	B-DISO
+-/	O
+MERS	O
+-	O
+CoV	O
+,	O
+pandemic	O
+influenza	B-SPEC
+virus	I-SPEC
+)	O
+which	O
+have	O
+the	O
+potential	O
+to	O
+spread	O
+over	O
+several	O
+continents	O
+within	O
+only	O
+a	O
+few	O
+days	O
+,	O
+international	O
+Health	O
+Protection	O
+Authorities	O
+have	O
+taken	O
+appropriate	O
+measures	O
+to	O
+limit	O
+the	O
+consequences	O
+of	O
+a	O
+possible	O
+spread	O
+.	O
+
+Camel	B-SPEC
+vaccines	O
+can	O
+be	O
+developed	O
+in	O
+a	O
+faster	O
+time	O
+with	O
+fewer	O
+regulations	O
+and	O
+lower	O
+costs	O
+and	O
+could	O
+clear	O
+this	O
+virus	B-SPEC
+from	O
+the	O
+Arabian	O
+Peninsula	O
+if	O
+accompanied	O
+by	O
+efficient	O
+public	O
+health	O
+measures	O
+.	O
+
+We	O
+performed	O
+a	O
+prospective	O
+study	O
+of	O
+acute	B-DISO
+bronchitis	I-DISO
+at	O
+31	O
+hospitals	O
+and	O
+clinics	O
+in	O
+Korea	O
+from	O
+July	O
+2011	O
+to	O
+June	O
+2012	O
+.	O
+
+Sputum	B-ANAT
+specimens	O
+were	O
+collected	O
+for	O
+polymerase	O
+chain	O
+reaction	O
+(	O
+PCR	O
+)	O
+and	O
+culture	O
+of	O
+microorganisms	O
+.	O
+
+Bacteria	B-SPEC
+-	O
+only	O
+,	O
+virus	B-SPEC
+-	O
+only	O
+,	O
+and	O
+mixed	B-DISO
+infections	I-DISO
+(	O
+bacteria	B-SPEC
+plus	O
+virus	B-SPEC
+)	O
+accounted	O
+for	O
+36	O
+.	O
+7	O
+%	O
+(	O
+98	O
+/	O
+291	O
+),	O
+17	O
+.	O
+2	O
+%	O
+(	O
+50	O
+/	O
+291	O
+),	O
+and	O
+18	O
+.	O
+9	O
+%	O
+(	O
+55	O
+/	O
+291	O
+)	O
+of	O
+infections	B-DISO
+,	O
+respectively	O
+.	O
+
+RESULTS	O
+:	O
+Of	O
+the	O
+811	O
+enrolled	O
+patients	O
+,	O
+291	O
+had	O
+acceptable	O
+sputum	B-ANAT
+specimens	O
+that	O
+were	O
+included	O
+for	O
+analysis	O
+of	O
+the	O
+etiologic	O
+distribution	O
+.	O
+
+ABSTRACT	O
+:	O
+Middle	O
+East	O
+respiratory	O
+syndrome	B-DISO
+coronavirus	B-SPEC
+(	O
+MERS	O
+-	O
+CoV	O
+)	O
+infects	O
+humans	B-SPEC
+from	O
+zoonotic	O
+sources	O
+and	O
+causes	O
+severe	O
+pulmonary	B-DISO
+disease	I-DISO
+.	O
+
+Fusion	O
+occurs	O
+only	O
+after	O
+S	O
+proteins	B-CHED
+are	O
+cleaved	B-ANAT
+sequentially	O
+,	O
+first	O
+during	O
+their	O
+secretion	B-PROC
+through	O
+the	O
+exocytic	O
+organelles	B-COMP
+of	O
+virus	B-SPEC
+-	O
+producing	O
+cells	B-COMP
+,	O
+and	O
+second	O
+after	O
+virus	B-SPEC
+binding	B-FUNC
+to	O
+target	O
+-	O
+cell	B-COMP
+receptors	O
+.	O
+
+Without	O
+the	O
+first	O
+cleavages	O
+,	O
+S	O
+proteins	O
+resisted	O
+cell	B-COMP
+receptor	O
+-	O
+induced	O
+conformational	O
+changes	O
+,	O
+which	O
+restricted	O
+the	O
+second	O
+,	O
+fusion	O
+-	O
+activating	O
+cleavages	O
+.	O
+
+TITLE	O
+:	O
+Antiviral	B-CHED
+Compounds	O
+Against	O
+Nucleocapsid	B-COMP
+Protein	B-CHED
+of	O
+Porcine	B-SPEC
+Epidemic	I-SPEC
+Diarrhea	I-SPEC
+Virus	I-SPEC
+.	O
+
+The	O
+aim	O
+of	O
+this	O
+research	O
+was	O
+to	O
+screen	O
+and	O
+characterize	O
+the	O
+compounds	O
+that	O
+could	O
+inhibit	O
+the	O
+activity	O
+of	O
+PEDV	B-PRGE
+N	I-PRGE
+protein	B-CHED
+.	O
+
+The	O
+gene	O
+encoding	O
+PEDV	B-PRGE
+N	I-PRGE
+protein	B-CHED
+obtained	O
+from	O
+PEDV	B-SPEC
+Thai	O
+isolate	O
+was	O
+cloned	O
+and	O
+expressed	B-PROC
+in	O
+E	B-SPEC
+.	I-SPEC
+coli	I-SPEC
+.	O
+
+Compound	O
+14	O
+also	O
+showed	O
+reasonable	O
+PK	O
+exposures	O
+in	O
+preclinical	O
+species	B-SPEC
+(	O
+rat	B-SPEC
+and	O
+dog	B-SPEC
+).	O
+
+Two	O
+infectious	B-DISO
+bronchitis	B-DISO
+viruses	B-SPEC
+(	O
+IBV	B-SPEC
+)	O
+were	O
+isolated	O
+from	O
+chickens	B-SPEC
+with	O
+respiratory	B-DISO
+disease	I-DISO
+in	O
+Sudan	O
+.	O
+
+Whole	O
+genome	O
+analysis	O
+of	O
+IBV	B-SPEC
+/	O
+Ck	O
+/	O
+Sudan	O
+/	O
+AR251	O
+-	O
+15	O
+/	O
+2014	O
+isolate	O
+by	O
+next	O
+generation	O
+sequencing	O
+revealed	O
+a	O
+genome	O
+size	O
+of	O
+27	O
+,	O
+646	O
+nucleotides	B-CHED
+harbouring	O
+13	O
+open	O
+reading	O
+frames	O
+:	O
+5	O
+'-	O
+1a	O
+-	O
+1b	O
+-	O
+S	O
+-	O
+3a	O
+-	O
+3b	O
+-	O
+E	O
+-	O
+M	O
+-	O
+4b	O
+-	O
+4c	O
+-	O
+5a	O
+-	O
+5b	O
+-	O
+N	O
+-	O
+6b	O
+-	O
+3	O
+'.	O
+
+ABSTRACT	O
+:	O
+Endoribonuclease	B-PRGE
+(	I-PRGE
+NendoU	I-PRGE
+)	I-PRGE
+is	O
+unique	O
+and	O
+conserved	O
+as	O
+a	O
+major	O
+genetic	B-PROC
+marker	I-PROC
+in	O
+nidoviruses	B-SPEC
+that	O
+infect	O
+vertebrate	B-SPEC
+hosts	B-COMP
+.	O
+
+Several	O
+strategies	O
+focusing	O
+on	O
+the	O
+binding	B-FUNC
+grooves	B-ANAT
+of	O
+the	O
+NHR	O
+trimer	O
+have	O
+been	O
+adopted	O
+to	O
+increase	O
+the	O
+antiviral	B-CHED
+activity	O
+of	O
+the	O
+CHR	B-DISO
+peptides	B-CHED
+.	O
+
+Here	O
+,	O
+we	O
+developed	O
+a	O
+novel	O
+and	O
+simple	O
+strategy	O
+to	O
+improve	O
+the	O
+existing	O
+peptide	B-CHED
+-	O
+based	O
+HIV	B-CHED
+fusion	I-CHED
+inhibitors	I-CHED
+.	O
+
+This	O
+new	O
+approach	O
+of	O
+identifying	O
+a	O
+potential	O
+binding	B-FUNC
+pocket	O
+outside	O
+the	O
+traditional	O
+target	O
+and	O
+creating	O
+an	O
+artificial	O
+tail	O
+anchor	O
+can	O
+be	O
+widely	O
+applied	O
+to	O
+design	O
+novel	O
+fusion	O
+inhibitors	B-CHED
+against	O
+other	O
+class	B-SPEC
+I	O
+enveloped	O
+viruses	B-SPEC
+,	O
+such	O
+as	O
+Middle	O
+East	O
+respiratory	O
+syndrome	B-DISO
+coronavirus	B-SPEC
+(	O
+MERS	O
+-	O
+CoV	O
+).	O
+
+The	O
+OC43	O
+strain	O
+(	O
+HCoV	B-SPEC
+-	I-SPEC
+OC43	I-SPEC
+)	O
+was	O
+reported	O
+to	O
+induce	O
+neuronal	B-PROC
+cell	I-PROC
+death	I-PROC
+,	O
+which	O
+may	O
+participate	O
+in	O
+neuropathogenesis	B-DISO
+.	O
+
+These	O
+RBD	O
+mutants	O
+with	O
+diminished	O
+DPP4	B-PRGE
+binding	B-FUNC
+also	O
+led	O
+to	O
+virus	B-SPEC
+attenuation	O
+,	O
+suggesting	O
+that	O
+immunoevasion	O
+after	O
+RBD	O
+immunization	O
+is	O
+accompanied	O
+by	O
+loss	O
+of	O
+viral	O
+fitness	O
+.	O
+
+These	O
+RBD	O
+-	O
+based	O
+vaccine	O
+candidates	O
+maintained	O
+good	O
+functionality	O
+,	O
+antigenicity	O
+,	O
+and	O
+immunogenicity	O
+,	O
+and	O
+they	O
+induced	O
+strong	O
+cross	O
+-	O
+neutralizing	O
+antibodies	B-COMP
+against	O
+infection	B-DISO
+by	O
+divergent	O
+pseudotyped	O
+and	O
+live	O
+MERS	O
+-	O
+CoV	O
+strains	O
+,	O
+as	O
+well	O
+as	O
+antibody	B-COMP
+escape	O
+MERS	O
+-	O
+CoV	O
+mutants	O
+.	O
+
+TITLE	O
+:	O
+A	O
+Novel	O
+Porcine	B-SPEC
+Circovirus	I-SPEC
+Distantly	O
+Related	O
+to	O
+Known	O
+Circoviruses	O
+Is	O
+Associated	O
+with	O
+Porcine	B-SPEC
+Dermatitis	B-DISO
+and	O
+Nephropathy	B-DISO
+Syndrome	B-DISO
+and	O
+Reproductive	B-PROC
+Failure	O
+.	O
+
+Despite	O
+being	O
+effectively	O
+controlled	O
+by	O
+commercial	O
+vaccines	O
+,	O
+PCV2	O
+remains	O
+one	O
+of	O
+the	O
+most	O
+economically	O
+significant	O
+viruses	B-SPEC
+of	O
+swine	B-SPEC
+.	O
+
+The	O
+apparent	O
+prevalence	O
+of	O
+Babesia	B-SPEC
+sp	O
+.	O
+and	O
+Borrelia	B-DISO
+sp	O
+.	O
+in	O
+blood	B-ANAT
+smears	O
+was	O
+consistent	O
+with	O
+previous	O
+studies	O
+.	O
+
+Babesia	B-SPEC
+-	O
+infected	O
+individuals	O
+had	O
+a	O
+regenerative	O
+response	O
+of	O
+the	O
+erythrocytic	B-ANAT
+lineage	O
+,	O
+an	O
+active	O
+inflammatory	B-DISO
+response	I-DISO
+and	O
+hepatic	B-PROC
+function	I-PROC
+impairment	B-DISO
+.	O
+
+TITLE	O
+:	O
+Lung	B-ANAT
+remodeling	O
+associated	O
+with	O
+recovery	O
+from	O
+acute	O
+lung	B-ANAT
+injury	O
+.	O
+
+ABSTRACT	O
+:	O
+Acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+(	O
+ARDS	B-DISO
+)	O
+is	O
+a	O
+disease	O
+with	O
+a	O
+variety	O
+of	O
+causes	O
+and	O
+is	O
+defined	O
+by	O
+severe	O
+hypoxemia	O
+.	O
+
+We	O
+found	O
+that	O
+regions	O
+of	O
+intrinsic	O
+disorder	O
+are	O
+rarely	O
+conserved	O
+among	O
+different	O
+coronavirus	B-SPEC
+protein	B-CHED
+families	O
+,	O
+with	O
+the	O
+primary	O
+exception	O
+of	O
+the	O
+nucleocapsid	B-COMP
+.	O
+
+The	O
+identified	O
+sequence	O
+motif	O
+is	O
+found	O
+within	O
+the	O
+nonstructural	O
+protein	B-CHED
+(	O
+NSP	O
+)	O
+12	O
+and	O
+constitutes	O
+an	O
+antiviral	B-CHED
+target	O
+potentially	O
+effective	O
+against	O
+the	O
+present	O
+day	O
+and	O
+future	O
+coronaviruses	O
+.	O
+
+ABSTRACT	O
+:	O
+Fibroblastic	O
+reticular	O
+cells	O
+(	O
+FRCs	B-PROC
+)	O
+of	O
+secondary	B-ANAT
+lymphoid	I-ANAT
+organs	I-ANAT
+form	O
+distinct	O
+niches	O
+for	O
+interaction	O
+with	O
+hematopoietic	O
+cells	B-COMP
+.	O
+
+Moreover	O
+,	O
+FRC	B-PROC
+-	O
+specific	O
+ablation	O
+of	O
+the	O
+innate	O
+immunological	O
+sensing	O
+adaptor	O
+MyD88	B-PRGE
+unleashed	I-PRGE
+IL	I-PRGE
+-	I-PRGE
+15	I-PRGE
+production	O
+by	O
+FRCs	B-PROC
+during	O
+infection	B-DISO
+with	O
+an	O
+enteropathogenic	O
+virus	B-SPEC
+,	O
+which	O
+led	O
+to	O
+hyperactivation	O
+of	O
+group	O
+1	O
+ILCs	O
+and	O
+substantially	O
+altered	O
+the	O
+differentiation	B-PROC
+of	O
+helper	B-ANAT
+T	I-ANAT
+cells	I-ANAT
+.	O
+
+Accelerated	O
+clearance	O
+of	O
+virus	B-SPEC
+by	O
+group	O
+1	O
+ILCs	O
+precipitated	O
+severe	O
+intestinal	B-ANAT
+inflammatory	B-DISO
+disease	I-DISO
+with	O
+commensal	O
+dysbiosis	O
+,	O
+loss	O
+of	O
+intestinal	B-ANAT
+barrier	O
+function	O
+and	O
+diminished	O
+resistance	B-PROC
+to	O
+colonization	O
+.	O
+
+In	O
+a	O
+retrospective	O
+and	O
+observational	O
+study	O
+,	O
+48	O
+children	O
+with	O
+severe	O
+PARDS	O
+between	O
+January	O
+2009	O
+and	O
+July	O
+2015	O
+were	O
+divided	O
+into	O
+two	O
+groups	O
+:	O
+26	O
+in	O
+HFOV	O
+group	O
+and	O
+22	O
+in	O
+CMV	B-SPEC
+group	O
+.	O
+
+The	O
+arterial	O
+partial	B-PROC
+pressure	I-PROC
+of	I-PROC
+oxygen	I-PROC
+(	O
+PaO	B-PROC
+HFOV	O
+as	O
+an	O
+efficient	O
+alternative	O
+therapy	O
+could	O
+significantly	O
+improve	O
+hypoxemia	O
+and	O
+promote	O
+CO	O
+RESULTS	O
+:	O
+The	O
+arterial	B-ANAT
+partial	B-PROC
+pressure	I-PROC
+of	I-PROC
+oxygen	I-PROC
+(	O
+PaO	B-PROC
+CONCLUSIONS	O
+:	O
+HFOV	O
+as	O
+an	O
+efficient	O
+alternative	O
+therapy	O
+could	O
+significantly	O
+improve	O
+hypoxemia	O
+and	O
+promote	O
+CO	O
+
+RNA	O
+fragments	O
+indicating	O
+the	O
+presence	O
+of	O
+coronavirus	B-SPEC
+,	O
+vesivirus	B-SPEC
+,	O
+and	O
+morbillivirus	B-SPEC
+were	O
+not	O
+detected	O
+.	O
+
+The	O
+mean	O
+log	O
+reductions	O
+in	O
+the	O
+viral	O
+titers	O
+were	O
+≥	O
+4	O
+.	O
+07	O
+and	O
+≥	O
+4	O
+.	O
+42	O
+for	O
+the	O
+pooled	O
+and	O
+individual	O
+donor	B-CHED
+plasma	B-ANAT
+,	O
+respectively	O
+.	O
+
+Sepsis	B-DISO
+was	O
+induced	O
+by	O
+a	O
+caecal	O
+ligation	O
+and	O
+puncture	O
+model	O
+in	O
+pigs	B-SPEC
+.	O
+
+Here	O
+,	O
+we	O
+characterized	O
+an	O
+intriguing	O
+phenomenon	O
+in	O
+which	O
+the	O
+nucleocapsids	O
+of	O
+some	O
+PEDV	B-SPEC
+strains	O
+are	O
+proteolytically	O
+processed	O
+by	O
+the	O
+virally	O
+encoded	O
+main	O
+protease	O
+.	O
+
+Our	O
+results	O
+demonstrated	O
+that	O
+vaccinated	O
+mice	B-SPEC
+were	O
+fully	O
+protected	O
+from	O
+the	O
+MERS	O
+-	O
+CoV	O
+challenge	O
+,	O
+as	O
+indicated	O
+by	O
+the	O
+significantly	O
+lower	O
+MERS	O
+-	O
+CoV	O
+titers	O
+and	O
+MERS	O
+-	O
+CoV	O
+and	O
+mRNA	B-CHED
+levels	O
+in	O
+challenged	O
+mice	B-SPEC
+than	O
+those	O
+in	O
+unvaccinated	O
+controls	O
+.	O
+
+Rabies	B-SPEC
+virus	I-SPEC
+-	O
+based	O
+vectors	O
+have	O
+been	O
+proven	O
+to	O
+be	O
+efficient	O
+dual	O
+vaccines	O
+against	O
+rabies	B-DISO
+and	O
+emergent	O
+infectious	B-DISO
+diseases	I-DISO
+such	O
+as	O
+Ebola	B-SPEC
+virus	I-SPEC
+.	O
+
+ABSTRACT	O
+:	O
+Glucocorticoid	B-CHED
+-	O
+induced	O
+leucine	B-CHED
+zipper	O
+(	O
+GILZ	O
+)	O
+is	O
+a	O
+potent	O
+anti	O
+-	O
+inflammatory	O
+protein	B-CHED
+involved	O
+in	O
+neutrophil	B-PROC
+apoptosis	B-PATH
+and	O
+the	O
+resolution	O
+of	O
+inflammation	B-DISO
+.	O
+
+Long	O
+oligonucleotides	O
+that	O
+showed	O
+an	O
+evident	O
+directional	O
+change	O
+observed	O
+in	O
+common	O
+for	O
+the	O
+three	O
+subtypes	O
+corresponded	O
+to	O
+some	O
+of	O
+influenza	B-PATH
+A	I-PATH
+siRNAs	O
+,	O
+whose	O
+activities	O
+have	O
+been	O
+experimentally	O
+proven	O
+.	O
+
+TITLE	O
+:	O
+A	O
+Comparative	O
+Study	O
+of	O
+Clinical	O
+Presentation	O
+and	O
+Risk	O
+Factors	O
+for	O
+Adverse	O
+Outcome	O
+in	O
+Patients	O
+Hospitalised	O
+with	O
+Acute	B-DISO
+Respiratory	I-DISO
+Disease	I-DISO
+Due	O
+to	O
+MERS	O
+Coronavirus	B-SPEC
+or	O
+Other	O
+Causes	O
+.	O
+
+ABSTRACT	O
+:	O
+Middle	O
+East	O
+Respiratory	O
+syndrome	B-DISO
+(	O
+MERS	O
+)	O
+first	O
+emerged	O
+in	O
+Saudi	O
+Arabia	O
+in	O
+2012	O
+and	O
+remains	O
+a	O
+global	O
+health	O
+concern	O
+.	O
+
+Variables	O
+associated	O
+with	O
+adverse	O
+outcome	O
+were	O
+older	O
+age	O
+and	O
+diabetes	B-DISO
+as	O
+a	O
+co	O
+-	O
+morbid	O
+illness	O
+.	O
+
+ABSTRACT	O
+:	O
+Health	O
+care	O
+-	O
+acquired	O
+viral	O
+respiratory	B-DISO
+infections	I-DISO
+are	O
+common	O
+and	O
+cause	O
+increased	O
+patient	O
+morbidity	O
+and	O
+mortality	O
+.	O
+
+Respiratory	B-SPEC
+syncytial	I-SPEC
+virus	I-SPEC
+and	O
+influenza	B-SPEC
+virus	I-SPEC
+are	O
+frequently	O
+transmitted	B-DISO
+in	O
+the	O
+hospital	O
+setting	O
+.	O
+
+Acidified	O
+milk	O
+replacer	O
+was	O
+prepared	O
+to	O
+a	O
+target	O
+pH	O
+between	O
+4	O
+.	O
+0	O
+and	O
+4	O
+.	O
+5	O
+using	O
+formic	B-CHED
+acid	I-CHED
+.	O
+
+Calves	O
+were	O
+weaned	B-PROC
+off	O
+milk	O
+replacer	O
+at	O
+approximately	O
+6wk	O
+of	O
+age	O
+.	O
+
+Fecal	O
+consistency	O
+scores	O
+were	O
+assigned	O
+each	O
+week	O
+from	O
+birth	B-PROC
+until	O
+weaning	B-PROC
+.	O
+
+Two	O
+independent	O
+reviewers	O
+assessed	O
+each	O
+paper	O
+for	O
+methodological	O
+validity	O
+prior	O
+to	O
+inclusion	O
+in	O
+the	O
+review	O
+using	O
+standardised	O
+critical	O
+appraisal	O
+instruments	O
+from	O
+the	O
+Joanna	B-SPEC
+Briggs	O
+Institute	O
+.	O
+
+Findings	O
+indicated	O
+that	O
+although	O
+health	O
+care	O
+workers	O
+perceived	O
+personal	O
+and	O
+familial	O
+health	O
+risks	O
+and	O
+stigmatization	O
+from	O
+their	O
+exposure	O
+to	O
+emerging	O
+acute	O
+respiratory	O
+infectious	B-DISO
+diseases	I-DISO
+,	O
+the	O
+majority	O
+were	O
+accepting	O
+of	O
+these	O
+risks	O
+.	O
+
+We	O
+did	O
+not	O
+consider	O
+observational	O
+studies	O
+that	O
+focused	O
+only	O
+on	O
+the	O
+presence	O
+of	O
+visitors	O
+during	O
+specific	O
+procedures	O
+,	O
+resuscitation	O
+,	O
+or	O
+childbirth	B-PROC
+.	O
+
+Information	O
+was	O
+extracted	O
+from	O
+each	O
+paper	O
+independently	O
+by	O
+two	O
+reviewers	O
+using	O
+the	O
+standardized	O
+data	O
+extraction	O
+tool	O
+developed	O
+by	O
+the	O
+Joanna	B-SPEC
+Briggs	O
+Institute	O
+.	O
+
+The	O
+MPLEx	O
+method	O
+is	O
+a	O
+simple	O
+,	O
+fast	B-FUNC
+,	O
+and	O
+robust	O
+protocol	O
+that	O
+can	O
+be	O
+applied	O
+for	O
+integrative	O
+multi	O
+-	O
+omic	O
+measurements	O
+from	O
+diverse	O
+sample	O
+types	O
+(	O
+e	O
+.	O
+g	O
+.,	O
+environmental	O
+,	O
+
+The	O
+study	O
+enrolled	O
+40	O
+patients	O
+,	O
+20	O
+of	O
+whom	O
+had	O
+H1N1	O
+-	O
+induced	O
+ARDS	B-DISO
+.	O
+
+A	O
+longitudinal	O
+profile	O
+of	O
+the	O
+infection	B-DISO
+showed	O
+that	O
+seroconversion	O
+detected	O
+by	O
+ELISAs	O
+based	O
+on	O
+the	O
+recombinant	O
+extracellular	B-COMP
+domain	O
+,	O
+S	B-PRGE
+,	I-PRGE
+S1	I-PRGE
+and	I-PRGE
+receptor	I-PRGE
+-	I-PRGE
+binding	I-PRGE
+domain	I-PRGE
+(	O
+RBD	O
+)	O
+antigens	B-CHED
+occurred	O
+as	O
+early	O
+as	O
+neutralizing	O
+antibodies	B-COMP
+were	O
+detected	O
+by	O
+the	O
+ppNT	O
+and	O
+earlier	O
+than	O
+antibodies	B-COMP
+were	O
+detected	O
+by	O
+the	O
+inactivated	O
+MERS	O
+-	O
+CoV	O
+and	O
+N	O
+-	O
+terminal	O
+domain	O
+(	O
+NTD	O
+)	O
+ELISAs	O
+.	O
+
+We	O
+observed	O
+that	O
+the	O
+delivery	O
+of	O
+exogenous	O
+materials	O
+,	O
+including	O
+lipopolysaccharide	B-CHED
+(	O
+LPS	B-DISO
+),	O
+Poly	O
+IC	O
+and	O
+silica	B-CHED
+nanoparticles	B-CHED
+,	O
+by	O
+microinjection	O
+triggered	O
+significant	O
+time	O
+-	O
+and	O
+dose	O
+-	O
+dependent	O
+neutrophil	O
+recruitment	B-DISO
+into	O
+the	O
+swim	O
+bladder	B-ANAT
+.	O
+
+Neutrophils	B-ANAT
+infiltrated	B-DISO
+the	O
+LPS	B-DISO
+-	O
+injected	O
+swim	O
+bladder	B-ANAT
+through	O
+the	O
+blood	B-ANAT
+capillaries	I-ANAT
+around	O
+the	O
+pneumatic	O
+duct	B-ANAT
+or	O
+a	O
+site	O
+near	O
+the	O
+pronephric	B-ANAT
+duct	I-ANAT
+.	O
+
+We	O
+included	O
+234	O
+patients	O
+:	O
+146	O
+(	O
+62	O
+.	O
+4	O
+%)	O
+influenza	B-PATH
+A	I-PATH
+(	O
+H1N1	O
+)	O
+and	O
+88	O
+(	O
+37	O
+.	O
+6	O
+%)	O
+A	O
+(	O
+H3N2	B-CHED
+).	O
+
+Blood	B-ANAT
+and	O
+bronchial	B-ANAT
+alveolar	I-ANAT
+lavage	I-ANAT
+fluid	I-ANAT
+(	O
+BAL	B-ENZY
+)	O
+from	O
+humans	B-SPEC
+(	O
+n	O
+=	O
+10	O
+-	O
+13	O
+)	O
+with	O
+ARDS	B-DISO
+and	O
+controls	O
+(	O
+n	O
+=	O
+5	O
+-	O
+10	O
+)	O
+as	O
+well	O
+as	O
+a	O
+murine	B-SPEC
+model	O
+of	O
+ARDS	B-DISO
+(	O
+n	O
+=	O
+5	O
+-	O
+6	O
+)	O
+with	O
+controls	O
+(	O
+n	O
+=	O
+6	O
+-	O
+7	O
+)	O
+were	O
+studied	O
+.	O
+
+Similar	O
+results	O
+are	O
+seen	O
+in	O
+the	O
+serum	B-COMP
+(	O
+9396	O
+.	O
+1	O
+pg	O
+/	O
+mL	O
+(	O
+SD	O
+1546	O
+.	O
+0	O
+)	O
+vs	O
+.	O
+3464	O
+.	O
+5	O
+pg	O
+/	O
+mL	O
+(	O
+SD	O
+2511	O
+.	O
+8	O
+),	O
+p	O
+=	O
+0	O
+.	O
+001	O
+)	O
+and	O
+BAL	B-ENZY
+fluid	O
+(	O
+2891	O
+.	O
+7	O
+pg	O
+/	O
+mL	O
+(	O
+SD	O
+868	O
+.	O
+1	O
+)	O
+vs	O
+.	O
+1385	O
+.	O
+9	O
+pg	O
+/	O
+mL	O
+(	O
+SD	O
+927	O
+.	O
+8	O
+),	O
+p	O
+=	O
+0	O
+.	O
+012	O
+)	O
+of	O
+mice	B-SPEC
+.	O
+
+BAL	B-ENZY
+fluid	O
+from	O
+mice	B-SPEC
+with	O
+ARDS	B-DISO
+dampens	O
+the	O
+TNF	B-PRGE
+-	I-PRGE
+α	I-PRGE
+production	O
+compared	O
+to	O
+cells	B-ANAT
+cultured	I-ANAT
+with	O
+BAL	B-ENZY
+lacking	O
+sPD	B-PRGE
+-	I-PRGE
+1	I-PRGE
+(	O
+2	O
+.	O
+7	O
+pg	O
+/	O
+mL	O
+(	O
+SD	O
+3	O
+.	O
+8	O
+)	O
+vs	O
+.	O
+52	O
+.	O
+38	O
+pg	O
+/	O
+mL	O
+(	O
+SD	O
+25	O
+.	O
+1	O
+),	O
+p	O
+=	O
+0	O
+.	O
+002	O
+).	O
+
+Front	O
+-	O
+loading	O
+gilts	O
+in	O
+combination	O
+with	O
+herd	O
+closure	O
+is	O
+more	O
+cost	O
+-	O
+effective	O
+than	O
+back	B-ANAT
+-	O
+loading	O
+.	O
+
+Despite	O
+the	O
+extra	O
+spending	O
+on	O
+intensive	O
+biosecurity	O
+protocols	O
+,	O
+the	O
+overall	O
+loss	O
+reductions	O
+achieved	O
+by	O
+the	O
+intensive	O
+biosecurity	O
+effort	B-PROC
+can	O
+be	O
+significant	O
+.	O
+
+For	O
+instance	O
+,	O
+we	O
+observed	O
+that	O
+all	O
+four	O
+residues	O
+(	O
+38	O
+,	O
+43	O
+,	O
+63	O
+,	O
+and	O
+68	O
+)	O
+that	O
+have	O
+been	O
+shown	O
+to	O
+be	O
+critical	O
+for	O
+binding	B-FUNC
+to	O
+host	B-COMP
+tissues	B-ANAT
+,	O
+were	O
+found	O
+at	O
+the	O
+surface	O
+of	O
+the	O
+predicted	O
+structure	O
+of	O
+Massachusetts	O
+(	O
+Mass	O
+)	O
+S1	O
+spike	O
+.	O
+
+ABSTRACT	O
+:	O
+Despite	O
+advances	O
+in	O
+mechanical	O
+ventilation	O
+,	O
+severe	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+(	O
+ARDS	B-DISO
+)	O
+is	O
+associated	O
+with	O
+high	O
+morbidity	O
+and	O
+mortality	O
+rates	O
+ranging	O
+from	O
+26	O
+%	O
+to	O
+58	O
+%.	O
+
+This	O
+review	O
+defines	O
+severe	O
+ARDS	B-DISO
+;	O
+describes	O
+the	O
+ECMO	O
+circuit	O
+;	O
+and	O
+discusses	O
+recent	O
+research	O
+,	O
+optimal	O
+use	O
+of	O
+the	O
+ECMO	O
+circuit	O
+,	O
+limitations	O
+of	O
+therapy	O
+including	O
+potential	O
+complications	O
+,	O
+economic	O
+impact	O
+,	O
+and	O
+logistical	O
+factors	O
+;	O
+and	O
+discusses	O
+future	O
+research	O
+considerations	O
+.	O
+
+TITLE	O
+:	O
+[	O
+Dermatomyositis	B-DISO
+associated	O
+with	O
+anti	B-PRGE
+-	I-PRGE
+MDA5	I-PRGE
+antibodies	I-PRGE
+and	O
+pneumocystis	B-DISO
+pneumonia	I-DISO
+:	O
+Two	O
+lethal	O
+cases	O
+].	O
+
+TITLE	O
+:	O
+Alisporivir	O
+inhibits	O
+MERS	O
+-	O
+and	O
+SARS	B-DISO
+-	O
+coronavirus	B-SPEC
+replication	O
+in	O
+cell	B-COMP
+culture	O
+,	O
+but	O
+not	O
+SARS	B-DISO
+-	O
+coronavirus	B-SPEC
+infection	I-DISO
+in	O
+a	O
+mouse	B-SPEC
+model	O
+.	O
+
+ABSTRACT	O
+:	O
+Currently	O
+,	O
+there	O
+is	O
+no	O
+registered	O
+treatment	O
+for	O
+infections	B-DISO
+with	O
+emerging	O
+zoonotic	O
+coronaviruses	O
+like	O
+SARS	B-DISO
+-	O
+and	O
+MERS	O
+-	O
+coronavirus	B-SPEC
+.	O
+
+Ribavirin	B-CHED
+was	O
+found	O
+to	O
+further	O
+potentiate	O
+the	O
+antiviral	B-CHED
+effect	O
+of	O
+alisporivir	O
+in	O
+these	O
+cell	B-COMP
+culture	O
+-	O
+based	O
+infection	B-DISO
+models	O
+,	O
+but	O
+this	O
+combination	O
+treatment	O
+was	O
+unable	O
+to	O
+improve	O
+the	O
+outcome	O
+of	O
+SARS	B-DISO
+-	I-DISO
+CoV	I-DISO
+infection	I-DISO
+in	O
+a	O
+mouse	B-SPEC
+model	O
+.	O
+
+In	O
+this	O
+case	O
+,	O
+discontinuation	O
+of	O
+eptifibatide	B-CHED
+and	O
+transfusion	O
+of	O
+apheresis	O
+platelets	B-DISO
+increased	I-DISO
+the	O
+platelet	B-ANAT
+count	O
+(	O
+137	O
+K	O
+/	O
+uL	O
+)	O
+the	O
+following	O
+day	O
+,	O
+and	O
+the	O
+patient	O
+subsequently	O
+underwent	O
+successful	O
+coronary	B-ANAT
+artery	I-ANAT
+surgery	O
+using	O
+cardiopulmonary	B-ANAT
+bypass	O
+.	O
+
+The	O
+link	O
+between	O
+steroid	B-CHED
+treatment	O
+and	O
+the	O
+risk	O
+of	O
+osteonecrosis	B-DISO
+in	O
+SARS	B-DISO
+patients	O
+remains	O
+unknown	O
+.	O
+
+The	O
+present	O
+meta	B-SPEC
+-	O
+analysis	O
+aimed	O
+to	O
+examine	O
+the	O
+dose	O
+-	O
+response	O
+association	O
+between	O
+steroid	B-CHED
+therapy	O
+and	O
+osteonecrosis	B-DISO
+incidence	O
+in	O
+SARS	B-DISO
+patients	O
+.	O
+
+TITLE	O
+:	O
+Celastrol	B-CHED
+inhibits	O
+dengue	B-SPEC
+virus	B-PROC
+replication	I-PROC
+via	O
+up	O
+-	O
+regulating	O
+type	B-PRGE
+I	I-PRGE
+interferon	I-PRGE
+and	O
+downstream	O
+interferon	O
+-	O
+stimulated	O
+responses	O
+.	O
+
+Celastrol	B-CHED
+is	O
+a	O
+quinone	B-CHED
+methide	O
+triterpene	B-CHED
+and	O
+the	O
+most	O
+abundant	O
+bioactive	O
+constituent	O
+isolated	O
+from	O
+the	O
+root	B-ANAT
+extracts	O
+of	O
+T	O
+.	O
+wilfordii	O
+.	O
+
+The	O
+precise	O
+anti	O
+-	O
+DENV	O
+replication	O
+mechanism	O
+of	O
+celastrol	B-CHED
+was	O
+clarified	O
+using	O
+specific	O
+RNA	B-PROC
+silencing	I-PROC
+and	O
+specific	O
+inhibitor	B-CHED
+.	O
+
+Demographic	O
+,	O
+hemodynamic	B-PROC
+,	O
+physiologic	O
+,	O
+and	O
+ventilator	O
+data	O
+at	O
+the	O
+time	O
+of	O
+the	O
+paired	O
+PEEP	B-CHED
+and	O
+ICP	B-DISO
+observations	O
+were	O
+recorded	O
+.	O
+
+Demographic	O
+,	O
+hemodynamic	B-PROC
+,	O
+physiologic	O
+,	O
+and	O
+ventilator	O
+data	O
+at	O
+the	O
+time	O
+of	O
+the	O
+paired	O
+PEEP	B-CHED
+and	O
+ICP	B-DISO
+observations	O
+were	O
+recorded	O
+.	O
+
+There	O
+are	O
+concerns	O
+that	O
+the	O
+use	O
+of	O
+positive	O
+end	B-PROC
+-	I-PROC
+expiratory	I-PROC
+pressure	O
+(	O
+PEEP	B-CHED
+)	O
+in	O
+patients	O
+with	O
+brain	B-ANAT
+injury	O
+may	O
+potentially	O
+elevate	O
+intracranial	B-PROC
+pressure	I-PROC
+(	O
+ICP	B-DISO
+).	O
+
+In	O
+the	O
+present	O
+study	O
+,	O
+we	O
+investigate	O
+the	O
+different	O
+effects	O
+of	O
+PEEP	B-CHED
+on	O
+the	O
+pleural	O
+pressure	O
+and	O
+ICP	B-DISO
+in	O
+different	O
+respiratory	B-PROC
+mechanics	I-PROC
+.	O
+
+Patients	O
+will	O
+be	O
+sedated	O
+and	O
+paralysed	O
+;	O
+airway	O
+pressure	O
+and	O
+oesophageal	B-PROC
+pressure	I-PROC
+will	O
+be	O
+measured	O
+during	O
+end	O
+-	O
+inspiratory	B-PROC
+occlusion	B-DISO
+and	O
+end	B-PROC
+-	I-PROC
+expiratory	I-PROC
+occlusion	B-DISO
+.	O
+
+Elastance	O
+of	O
+the	O
+chest	B-ANAT
+wall	I-ANAT
+,	O
+the	O
+lungs	B-ANAT
+and	O
+the	O
+respiratory	B-ANAT
+system	I-ANAT
+will	O
+be	O
+calculated	O
+at	O
+PEEP	B-CHED
+levels	O
+of	O
+5	O
+,	O
+10	O
+and	O
+15	O
+cm	O
+H	O
+The	O
+study	O
+protocol	O
+and	O
+consent	O
+forms	O
+were	O
+approved	O
+by	O
+the	O
+Institutional	O
+Review	O
+Board	O
+of	O
+Fujian	O
+Provincial	O
+Hospital	O
+.	O
+
+ABSTRACT	O
+:	O
+A	O
+47	O
+-	O
+year	O
+-	O
+old	O
+man	O
+was	O
+admitted	O
+to	O
+the	O
+intensive	O
+care	O
+unit	O
+a	O
+few	O
+hours	O
+after	O
+presenting	O
+to	O
+emergency	B-DISO
+department	O
+with	O
+acute	O
+diplopia	B-DISO
+and	O
+dysphonia	O
+.	O
+
+Statistically	O
+significant	O
+differences	O
+in	O
+the	O
+detection	O
+of	O
+influenza	B-SPEC
+virus	I-SPEC
+A	O
+(	O
+P	O
+=	O
+0	O
+.	O
+000	O
+),	O
+the	O
+total	O
+detection	O
+of	O
+parainfluenza	B-DISO
+viruses	B-SPEC
+(	O
+P	O
+=	O
+0	O
+.	O
+008	O
+)	O
+and	O
+coinfection	B-DISO
+(	O
+P	O
+=	O
+0	O
+.	O
+004	O
+)	O
+were	O
+observed	O
+between	O
+the	O
+patient	O
+and	O
+control	O
+groups	O
+.	O
+
+A	O
+total	O
+of	O
+40	O
+consecutive	O
+patients	O
+with	O
+severe	O
+biventricular	B-DISO
+heart	I-DISO
+failure	I-DISO
+underwent	O
+Berlin	O
+Heart	B-ANAT
+Excor	O
+implantation	B-PROC
+with	O
+(	O
+CS	O
+status	O
+,	O
+n	O
+=	O
+20	O
+,	O
+50	O
+%)	O
+or	O
+without	O
+(	O
+control	O
+,	O
+n	O
+=	O
+20	O
+,	O
+50	O
+%)	O
+the	O
+need	O
+for	O
+preoperative	O
+ECLS	O
+as	O
+a	O
+bridge	O
+to	O
+long	O
+-	O
+term	O
+device	O
+from	O
+March	O
+2007	O
+to	O
+May	O
+2015	O
+at	O
+our	O
+institution	O
+.	O
+
+Demographics	O
+and	O
+preoperative	O
+baseline	O
+characteristics	O
+as	O
+well	O
+as	O
+early	O
+and	O
+long	O
+-	O
+term	O
+outcomes	O
+including	O
+mortality	O
+and	O
+complication	B-DISO
+rates	O
+were	O
+retrospectively	O
+compared	O
+between	O
+the	O
+two	O
+groups	O
+.	O
+
+ECLS	O
+in	O
+critical	O
+CS	O
+as	O
+a	O
+bridge	O
+to	O
+implantation	B-PROC
+of	O
+the	O
+Berlin	O
+Heart	B-ANAT
+Excor	O
+ventricular	B-ANAT
+assist	O
+device	O
+is	O
+safe	O
+and	O
+is	O
+associated	O
+with	O
+improvement	O
+in	O
+end	O
+-	O
+organ	B-ANAT
+function	O
+leading	O
+to	O
+similar	O
+excellent	O
+early	O
+and	O
+long	O
+-	O
+term	O
+survival	O
+and	O
+incidences	O
+of	O
+major	O
+complications	O
+as	O
+in	O
+patients	O
+without	O
+the	O
+need	O
+for	O
+preoperative	O
+ECLS	O
+support	O
+.	O
+
+TITLE	O
+:	O
+A	O
+comprehensive	O
+microbiological	O
+safety	O
+approach	O
+for	O
+agarose	B-CHED
+encapsulated	O
+porcine	B-SPEC
+islets	O
+intended	O
+for	O
+clinical	O
+trials	O
+.	O
+
+Porcine	B-SPEC
+respiratory	O
+coronavirus	B-SPEC
+was	O
+found	O
+to	O
+be	O
+present	O
+in	O
+the	O
+herd	O
+,	O
+as	O
+expected	O
+for	O
+domestic	O
+swine	B-SPEC
+.	O
+
+Isolated	O
+peripheral	B-ANAT
+blood	I-ANAT
+mononuclear	I-ANAT
+cells	I-ANAT
+from	O
+all	O
+time	O
+points	O
+were	O
+negative	O
+for	O
+PCV	B-CHED
+(	O
+Type	O
+2	O
+),	O
+PLHV	O
+,	O
+PRRSV	B-SPEC
+,	O
+PCMV	O
+,	O
+and	O
+PERV	O
+-	O
+A	O
+,	O
+PERV	O
+-	O
+B	O
+,	O
+and	O
+PERV	O
+-	O
+C	O
+by	O
+PCR	O
+analysis	O
+in	O
+all	O
+six	O
+recipient	O
+animals	B-SPEC
+.	O
+
+Isolated	O
+peripheral	B-ANAT
+blood	I-ANAT
+mononuclear	I-ANAT
+cells	I-ANAT
+from	O
+all	O
+time	O
+points	O
+were	O
+negative	O
+for	O
+PCV	B-CHED
+(	O
+Type	O
+2	O
+),	O
+PLHV	O
+,	O
+PRRSV	B-SPEC
+,	O
+PCMV	O
+,	O
+and	O
+PERV	O
+-	O
+A	O
+,	O
+PERV	O
+-	O
+B	O
+,	O
+and	O
+PERV	O
+-	O
+C	O
+by	O
+PCR	O
+analysis	O
+in	O
+all	O
+six	O
+recipient	O
+animals	B-SPEC
+.	O
+
+The	O
+problem	O
+of	O
+finding	O
+a	O
+potent	O
+drug	O
+against	O
+HCoV	O
+strains	O
+lies	O
+in	O
+the	O
+inability	O
+of	O
+finding	O
+a	O
+drug	O
+that	O
+stops	O
+the	O
+viral	B-PROC
+replication	I-PROC
+through	O
+inhibiting	O
+its	O
+important	O
+proteins	B-CHED
+.	O
+
+Therefore	O
+,	O
+scientists	O
+reverted	O
+towards	O
+the	O
+investigation	O
+of	O
+different	O
+drugs	O
+that	O
+can	O
+more	O
+specifically	O
+target	O
+proteins	B-CHED
+.	O
+
+In	O
+this	O
+study	O
+,	O
+four	O
+anti	O
+-	O
+HCV	B-SPEC
+drugs	O
+(	O
+one	O
+approved	O
+by	O
+FDA	O
+and	O
+others	O
+under	O
+clinical	O
+trials	O
+)	O
+are	O
+tested	O
+against	O
+HCoV	O
+polymerases	O
+.	O
+
+MK	O
+-	O
+0608	O
+showed	O
+a	O
+performance	O
+that	O
+is	O
+comparable	O
+to	O
+Ribavirin	B-CHED
+.	O
+
+ABSTRACT	O
+:	O
+Biosynthesis	O
+of	O
+nanoparticles	B-CHED
+inside	O
+S	B-SPEC
+.	I-SPEC
+aureus	I-SPEC
+cells	B-COMP
+has	O
+enhanced	O
+the	O
+sensitivity	O
+of	O
+immunoassays	O
+based	O
+on	O
+the	O
+S	B-SPEC
+.	I-SPEC
+aureus	I-SPEC
+nanoparticles	B-CHED
+.	O
+
+In	O
+this	O
+study	O
+,	O
+a	O
+simple	O
+way	O
+to	O
+conjugate	O
+antigens	B-CHED
+to	O
+the	O
+S	B-SPEC
+.	I-SPEC
+aureus	I-SPEC
+nanobioparticles	O
+was	O
+developed	O
+by	O
+utilizing	O
+a	O
+cell	B-COMP
+wall	I-COMP
+binding	B-FUNC
+domain	O
+(	O
+CBD	O
+)	O
+from	O
+a	O
+bacteriophage	B-SPEC
+lysin	B-PRGE
+PlyV12	I-PRGE
+.	O
+
+As	O
+far	O
+as	O
+we	O
+know	O
+,	O
+this	O
+is	O
+the	O
+first	O
+time	O
+to	O
+realize	O
+the	O
+detection	O
+of	O
+viral	O
+antibodies	O
+based	O
+on	O
+S	B-SPEC
+.	I-SPEC
+aureus	I-SPEC
+nanoparticles	B-CHED
+.	O
+
+The	O
+results	O
+do	O
+not	O
+differ	O
+much	O
+in	O
+immunocompetent	O
+patients	O
+supported	O
+by	O
+extracorporeal	O
+membrane	B-COMP
+oxygenation	B-PROC
+(	O
+ECMO	O
+).	O
+
+First	O
+,	O
+the	O
+time	O
+interval	O
+between	O
+mechanical	O
+ventilator	O
+support	O
+and	O
+ECMO	O
+implantation	B-PROC
+was	O
+shorter	O
+.	O
+
+ABSTRACT	O
+:	O
+to	O
+analyze	O
+the	O
+circulation	O
+of	O
+respiratory	O
+viruses	B-SPEC
+in	O
+people	O
+living	O
+in	O
+the	O
+metropolitan	O
+area	O
+of	O
+Belo	O
+Horizonte	O
+,	O
+Brazil	O
+,	O
+and	O
+hospitalized	O
+in	O
+Belo	O
+Horizonte	O
+from	O
+2011	O
+to	O
+2013	O
+.	O
+
+this	O
+is	O
+a	O
+descriptive	O
+study	O
+of	O
+5	O
+,	O
+158	O
+patients	O
+with	O
+Severe	B-DISO
+Acute	I-DISO
+Respiratory	I-DISO
+Syndrome	I-DISO
+;	O
+a	O
+comparison	O
+was	O
+made	O
+between	O
+the	O
+characteristics	O
+of	O
+confirmed	O
+cases	O
+and	O
+those	O
+of	O
+discarded	O
+cases	O
+or	O
+cases	O
+without	O
+swab	O
+samples	O
+.	O
+
+monitoring	O
+respiratory	O
+viruses	B-SPEC
+contributes	O
+to	O
+knowledge	O
+about	O
+periods	B-PROC
+of	O
+virus	B-SPEC
+circulation	B-PROC
+and	O
+the	O
+adoption	O
+of	O
+specific	O
+control	O
+measures	O
+.	O
+
+CONCLUSIONS	O
+:	O
+monitoring	O
+respiratory	O
+viruses	B-SPEC
+contributes	O
+to	O
+knowledge	O
+about	O
+periods	B-PROC
+of	O
+virus	B-SPEC
+circulation	B-PROC
+and	O
+the	O
+adoption	O
+of	O
+specific	O
+control	O
+measures	O
+.	O
+
+Levels	O
+of	O
+serum	B-PRGE
+amylase	I-PRGE
+and	O
+lipase	B-PRGE
+were	O
+elevated	O
+to	O
+663	O
+U	O
+/	O
+L	O
+and	O
+3	O
+,	O
+232	O
+U	O
+/	O
+L	O
+.	O
+Contrast	O
+-	O
+enhanced	O
+abdominal	B-ANAT
+CT	O
+showed	O
+pancreatic	B-ANAT
+swelling	B-DISO
+,	O
+peri	O
+-	O
+pancreatic	B-ANAT
+fat	O
+infiltration	B-DISO
+and	O
+fluid	O
+collection	O
+.	O
+
+TITLE	O
+:	O
+Increased	O
+frequency	O
+of	O
+porcine	B-SPEC
+epidemic	I-SPEC
+diarrhea	I-SPEC
+virus	B-DISO
+shedding	I-DISO
+and	O
+lesions	O
+in	O
+suckling	O
+pigs	B-SPEC
+compared	O
+to	O
+nursery	O
+pigs	O
+and	O
+protective	O
+immunity	B-PROC
+in	O
+nursery	O
+pigs	B-SPEC
+after	O
+homologous	O
+re	O
+-	O
+challenge	O
+.	O
+
+Pigs	B-SPEC
+were	O
+randomly	O
+assigned	O
+into	O
+group	O
+1	O
+(	O
+n	O
+=	O
+40	O
+,	O
+no	O
+PEDV	B-SPEC
+exposure	O
+),	O
+group	O
+2	O
+(	O
+n	O
+=	O
+43	O
+,	O
+PEDV	B-SPEC
+inoculation	O
+at	O
+10	O
+days	O
+of	O
+age	O
+)	O
+and	O
+group	O
+3	O
+(	O
+n	O
+=	O
+48	O
+,	O
+PEDV	B-SPEC
+inoculation	O
+at	O
+8	O
+weeks	O
+of	O
+age	O
+).	O
+
+In	O
+homologous	O
+challenged	O
+pigs	B-SPEC
+,	O
+no	O
+clinical	O
+signs	O
+or	O
+lesions	O
+were	O
+found	O
+,	O
+and	O
+PEDV	B-SPEC
+fecal	B-ANAT
+shedding	O
+was	O
+restricted	O
+to	O
+less	O
+than	O
+10	O
+%	O
+of	O
+the	O
+pigs	B-SPEC
+indicating	O
+the	O
+existence	O
+of	O
+homologous	O
+protection	O
+44	O
+days	O
+after	O
+initial	O
+PEDV	B-SPEC
+exposure	O
+.	O
+
+Coinfection	B-DISO
+was	O
+detected	O
+in	O
+43	O
+.	O
+8	O
+%	O
+of	O
+children	O
+with	O
+HCoV	O
+.	O
+Interestingly	O
+,	O
+one	O
+patient	O
+had	O
+both	O
+HCoV	B-SPEC
+-	I-SPEC
+OC43	I-SPEC
+and	O
+HCoV	B-SPEC
+-	I-SPEC
+NL63	I-SPEC
+.	O
+
+However	O
+,	O
+compared	O
+with	O
+that	O
+of	O
+RSV	B-DISO
+infection	I-DISO
+,	O
+the	O
+disease	O
+course	O
+HCoV	O
+was	O
+short	O
+.	O
+
+These	O
+epitopes	O
+should	O
+be	O
+eliminated	O
+in	O
+vaccine	O
+design	O
+,	O
+but	O
+there	O
+is	O
+no	O
+reliable	O
+method	O
+for	O
+evaluating	O
+an	O
+epitope	B-CHED
+'	O
+s	O
+capacity	O
+to	O
+elicit	O
+neutralizing	O
+immune	B-PROC
+responses	I-PROC
+.	O
+
+His	O
+symptoms	O
+at	O
+presentation	O
+included	O
+epigastric	B-ANAT
+abdominal	B-DISO
+pain	I-DISO
+,	O
+haematemesis	B-DISO
+and	O
+generalised	O
+weakness	B-DISO
+.	O
+
+He	O
+died	B-PROC
+within	O
+24	O
+hours	O
+of	O
+presentation	O
+from	O
+a	O
+combination	O
+of	O
+systemic	B-DISO
+inflammatory	I-DISO
+response	I-DISO
+syndrome	I-DISO
+,	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+and	O
+disseminated	B-DISO
+intravascular	I-DISO
+coagulation	B-PROC
+.	O
+
+Indeed	O
+,	O
+OSAS	B-DISO
+prevalence	O
+increases	O
+in	O
+post	O
+-	O
+menopausal	B-PROC
+women	O
+.	O
+
+In	O
+rodents	B-SPEC
+,	O
+exposure	O
+to	O
+CIH	O
+-	O
+related	O
+redox	B-PROC
+stress	O
+causes	O
+upper	O
+airway	O
+muscle	B-DISO
+weakness	I-DISO
+and	O
+fatigue	B-DISO
+,	O
+associated	O
+with	O
+mitochondrial	B-COMP
+dysfunction	O
+.	O
+
+Archived	O
+influenza	B-DISO
+-	O
+negative	O
+respiratory	O
+swabs	O
+were	O
+retested	O
+using	O
+multiplex	O
+RT	O
+-	O
+PCR	O
+to	O
+detect	O
+16	O
+respiratory	O
+virus	B-SPEC
+targets	O
+.	O
+
+ABSTRACT	O
+:	O
+Human	O
+coronaviruses	O
+HCoV	B-SPEC
+-	I-SPEC
+OC43	I-SPEC
+,	O
+HCoV	B-SPEC
+-	I-SPEC
+229E	I-SPEC
+,	O
+HCoV	B-SPEC
+-	I-SPEC
+NL63	I-SPEC
+and	O
+HCoV	O
+-	O
+HKU1	O
+are	O
+common	O
+respiratory	O
+viruses	B-SPEC
+associated	O
+with	O
+acute	B-DISO
+respiratory	I-DISO
+infection	I-DISO
+.	O
+
+TITLE	O
+:	O
+IL	B-FUNC
+-	I-FUNC
+17	I-FUNC
+protein	B-CHED
+levels	O
+in	O
+both	O
+induced	B-ANAT
+sputum	I-ANAT
+and	O
+plasma	B-ANAT
+are	O
+increased	O
+in	O
+stable	O
+but	O
+not	O
+acute	B-DISO
+asthma	I-DISO
+individuals	O
+with	O
+obesity	B-DISO
+.	O
+
+IL	B-PROC
+-	I-PROC
+17	I-PROC
+is	O
+associated	O
+with	O
+neutrophilic	B-PROC
+inflammation	B-DISO
+,	O
+steroid	B-CHED
+resistance	B-PROC
+and	O
+severe	O
+asthma	B-PATH
+,	O
+but	O
+its	O
+importance	O
+in	O
+the	O
+association	O
+between	O
+asthma	B-PATH
+and	O
+obesity	B-DISO
+is	O
+unknown	O
+.	O
+
+Significant	O
+increase	O
+in	O
+plasma	B-PRGE
+IL	B-PROC
+-	I-PROC
+17	I-PROC
+levels	O
+was	O
+also	O
+noted	O
+and	O
+associated	O
+with	O
+elevated	O
+depressive	B-DISO
+symptoms	I-DISO
+in	O
+obesity	B-DISO
+.	O
+
+In	O
+acute	B-DISO
+asthma	I-DISO
+,	O
+IL	B-PROC
+-	I-PROC
+17	I-PROC
+expression	B-PROC
+,	O
+like	O
+most	O
+other	O
+clinical	O
+measures	O
+,	O
+was	O
+similar	O
+among	O
+lean	O
+,	O
+overweight	B-DISO
+and	O
+obese	B-DISO
+groups	O
+,	O
+but	O
+was	O
+higher	O
+in	O
+acute	O
+versus	O
+stable	O
+asthma	B-PATH
+subjects	O
+,	O
+with	O
+sputum	B-PRGE
+IL	B-PROC
+-	I-PROC
+17	I-PROC
+correlating	O
+positively	O
+with	O
+sputum	B-ANAT
+neutrophils	B-ANAT
+and	O
+negatively	O
+with	O
+FEV	B-SPEC
+
+ESR	O
+showed	O
+that	O
+both	O
+FPs	O
+increase	O
+lipid	B-CHED
+packing	O
+and	O
+head	B-ANAT
+group	O
+ordering	O
+as	O
+well	O
+as	O
+reduce	O
+the	O
+intramembrane	O
+water	B-CHED
+content	O
+for	O
+anionic	O
+membranes	B-ANAT
+.	O
+
+Therefore	O
+,	O
+bending	B-DISO
+moment	O
+in	O
+the	O
+bilayer	O
+could	O
+be	O
+generated	O
+,	O
+promoting	O
+negative	O
+curvature	O
+.	O
+
+The	O
+significance	O
+of	O
+the	O
+ordering	O
+effect	O
+,	O
+membrane	B-COMP
+dehydration	B-DISO
+,	O
+changes	O
+in	O
+the	O
+curvature	O
+properties	O
+and	O
+the	O
+possible	O
+role	O
+of	O
+negatively	O
+charged	O
+phospholipids	B-CHED
+in	O
+helping	O
+to	O
+overcome	O
+the	O
+high	O
+kinetic	O
+barrier	O
+involved	O
+in	O
+the	O
+different	O
+stages	O
+of	O
+the	O
+SARS	B-DISO
+-	O
+CoV	O
+-	O
+mediated	O
+membrane	B-PROC
+fusion	I-PROC
+are	O
+discussed	O
+.	O
+
+ABSTRACT	O
+:	O
+Middle	O
+East	O
+respiratory	O
+syndrome	O
+coronavirus	B-SPEC
+(	O
+MERS	O
+-	O
+CoV	O
+)	O
+is	O
+a	O
+novel	O
+virus	B-SPEC
+that	O
+emerged	O
+in	O
+2012	O
+,	O
+causing	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+(	O
+ARDS	B-DISO
+),	O
+severe	O
+pneumonia	B-DISO
+-	O
+like	O
+symptoms	O
+and	O
+multi	B-DISO
+-	I-DISO
+organ	I-DISO
+failure	I-DISO
+,	O
+with	O
+a	O
+case	O
+fatality	O
+rate	O
+of	O
+∼	O
+36	O
+%.	O
+
+Serial	O
+MERS	O
+-	O
+CoV	O
+passage	O
+in	O
+these	O
+engineered	O
+mice	B-SPEC
+was	O
+then	O
+used	O
+to	O
+generate	O
+a	O
+mouse	B-SPEC
+-	O
+adapted	O
+virus	B-SPEC
+that	O
+replicated	O
+efficiently	O
+within	O
+the	O
+lungs	B-ANAT
+and	O
+evoked	O
+symptoms	O
+indicative	O
+of	O
+severe	O
+ARDS	B-DISO
+,	O
+including	O
+decreased	O
+survival	O
+,	O
+extreme	O
+weight	O
+loss	O
+,	O
+decreased	O
+pulmonary	B-PROC
+function	I-PROC
+,	O
+pulmonary	B-DISO
+haemorrhage	I-DISO
+and	O
+pathological	O
+signs	O
+indicative	O
+of	O
+end	O
+-	O
+stage	O
+lung	B-DISO
+disease	I-DISO
+.	O
+
+It	O
+couples	O
+a	O
+one	O
+-	O
+step	O
+isothermal	O
+RNA	O
+amplification	B-DISO
+method	O
+and	O
+a	O
+bio	O
+-	O
+optical	O
+sensor	O
+for	O
+simultaneous	O
+viral	O
+RNA	O
+amplification	B-DISO
+/	O
+detection	O
+in	O
+a	O
+label	O
+-	O
+free	O
+and	O
+real	O
+-	O
+time	O
+manner	O
+.	O
+
+The	O
+iROAD	O
+assay	O
+offers	O
+a	O
+one	O
+-	O
+step	O
+viral	O
+RNA	O
+amplification	B-DISO
+/	O
+detection	O
+example	O
+to	O
+rapid	O
+analysis	O
+(<	O
+20min	O
+).	O
+
+The	O
+detection	O
+limit	O
+of	O
+iROAD	O
+assay	O
+was	O
+found	O
+to	O
+be	O
+10	O
+-	O
+times	O
+more	O
+sensitive	O
+than	O
+that	O
+of	O
+real	O
+-	O
+time	O
+reverse	B-PROC
+transcription	I-PROC
+-	O
+PCR	O
+method	O
+.	O
+
+TITLE	O
+:	O
+Non	B-DISO
+-	I-DISO
+cardiogenic	I-DISO
+pulmonary	I-DISO
+edema	I-DISO
+,	O
+rhabdomyolysis	B-DISO
+and	O
+myocardial	O
+injury	O
+following	O
+heroin	B-CHED
+inhalation	B-PROC
+:	O
+a	O
+case	O
+report	O
+.	O
+
+Heroin	B-CHED
+inhalation	B-PROC
+may	O
+cause	O
+severe	O
+complications	O
+,	O
+such	O
+as	O
+non	B-DISO
+-	I-DISO
+cardiogenic	I-DISO
+pulmonary	I-DISO
+edema	I-DISO
+,	O
+rhabdomyolysis	B-DISO
+or	O
+myocardial	O
+injury	O
+.	O
+
+Although	O
+the	O
+outcome	O
+might	O
+vary	O
+with	O
+different	O
+rescue	O
+procedures	O
+,	O
+most	O
+of	O
+them	O
+will	O
+improve	O
+oxygenation	B-PROC
+.	O
+
+Early	O
+involvement	O
+of	O
+an	O
+ARDS	B-DISO
+or	O
+extracorporeal	O
+membrane	B-COMP
+oxygenation	B-PROC
+center	O
+should	O
+be	O
+considered	O
+to	O
+ensure	O
+optimal	O
+care	O
+.	O
+
+PubMed	O
+and	O
+Web	B-DISO
+of	O
+Science	O
+databases	O
+were	O
+searched	O
+for	O
+clinical	O
+and	O
+epidemiological	O
+studies	O
+on	O
+confirmed	O
+cases	O
+of	O
+MERS	O
+.	O
+
+Subsequently	O
+,	O
+potential	O
+associations	O
+between	O
+MERS	O
+-	O
+associated	O
+death	B-PROC
+and	O
+age	O
+,	O
+sex	O
+,	O
+underlying	O
+medical	O
+conditions	O
+and	O
+study	O
+design	O
+were	O
+explored	O
+.	O
+
+Both	O
+NS	O
+and	O
+tracheal	O
+washes	O
+(	O
+TW	O
+)	O
+were	O
+collected	O
+monthly	O
+on	O
+52	O
+Standardbred	O
+racehorses	B-SPEC
+at	O
+training	O
+,	O
+over	O
+27	O
+consecutive	O
+months	O
+(	O
+581	O
+samples	O
+).	O
+
+ABSTRACT	O
+:	O
+Genome	O
+sequence	O
+analysis	O
+of	O
+Middle	O
+East	O
+respiratory	O
+syndrome	B-DISO
+coronavirus	B-SPEC
+(	O
+MERS	O
+-	O
+CoV	O
+)	O
+variants	O
+from	O
+patient	O
+specimens	O
+has	O
+revealed	O
+the	O
+evolutionary	O
+dynamics	O
+and	O
+mechanisms	O
+of	O
+pathogenesis	B-DISO
+of	O
+the	O
+virus	B-SPEC
+.	O
+
+The	O
+heterogeneity	O
+could	O
+be	O
+transmitted	O
+in	O
+a	O
+close	O
+association	O
+with	O
+variation	O
+in	O
+the	O
+consensus	O
+sequences	O
+,	O
+suggesting	O
+the	O
+occurrence	O
+of	O
+multiple	O
+MERS	O
+-	O
+CoV	O
+infections	B-DISO
+.	O
+
+Analysis	O
+of	O
+intrapatient	O
+heterogeneity	O
+revealed	O
+a	O
+relationship	O
+between	O
+D510G	O
+and	O
+I529T	O
+mutations	O
+in	O
+the	O
+receptor	O
+-	O
+binding	B-FUNC
+domain	O
+(	O
+RBD	O
+)	O
+of	O
+the	O
+viral	B-PRGE
+spike	I-PRGE
+glycoprotein	I-PRGE
+.	O
+
+These	O
+results	O
+prove	O
+the	O
+susceptibility	O
+of	O
+llamas	O
+and	O
+pigs	B-SPEC
+to	O
+MERS	O
+-	O
+CoV	O
+infection	B-DISO
+.	O
+
+ABSTRACT	O
+:	O
+Despite	O
+regular	O
+co	O
+-	O
+vaccination	O
+of	O
+two	O
+different	O
+strains	O
+of	O
+live	O
+infectious	B-DISO
+bronchitis	B-DISO
+vaccine	O
+viruses	B-SPEC
+,	O
+little	O
+is	O
+known	O
+about	O
+possible	O
+mutations	O
+in	O
+these	O
+viruses	B-SPEC
+following	O
+vaccination	O
+.	O
+
+Results	O
+indicate	O
+that	O
+viral	O
+titres	O
+reduced	O
+over	O
+the	O
+duration	O
+of	O
+the	O
+study	O
+;	O
+conversely	O
+,	O
+the	O
+amount	O
+of	O
+detected	O
+infectious	B-DISO
+bronchitis	B-DISO
+virus	B-SPEC
+genome	O
+increased	O
+.	O
+
+TITLE	O
+:	O
+Feline	B-SPEC
+coronavirus	B-SPEC
+replication	O
+is	O
+affected	O
+by	O
+both	O
+cyclophilin	B-PRGE
+A	I-PRGE
+and	O
+cyclophilin	B-PRGE
+B	I-PRGE
+.	O
+ABSTRACT	O
+:	O
+Feline	O
+coronavirus	B-SPEC
+(	O
+FCoV	O
+)	O
+causes	O
+the	O
+fatal	O
+disease	O
+feline	B-DISO
+infectious	I-DISO
+peritonitis	I-DISO
+,	O
+which	O
+is	O
+currently	O
+incurable	O
+by	O
+drug	O
+treatment	O
+,	O
+and	O
+no	O
+effective	O
+vaccines	O
+are	O
+available	O
+.	O
+
+ABSTRACT	O
+:	O
+Recent	O
+advances	O
+in	O
+the	O
+technology	O
+of	O
+extracorporeal	O
+respiratory	O
+assist	O
+systems	O
+have	O
+led	O
+to	O
+a	O
+renewed	O
+interest	O
+in	O
+extracorporeal	O
+carbon	B-CHED
+dioxide	I-CHED
+removal	O
+(	O
+ECCOR	O
+).	O
+
+TITLE	O
+:	O
+Inhaled	B-PROC
+nitric	B-CHED
+oxide	I-CHED
+and	O
+the	O
+risk	O
+of	O
+renal	B-ANAT
+dysfunction	O
+in	O
+patients	O
+with	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+:	O
+a	O
+propensity	O
+-	O
+matched	O
+cohort	O
+study	O
+.	O
+
+It	O
+has	O
+been	O
+demonstrated	O
+that	O
+the	O
+conformation	O
+of	O
+MHC	B-PRGE
+class	B-SPEC
+I	I-PRGE
+(	O
+MHC	B-PROC
+I	O
+)	O
+molecules	O
+can	O
+be	O
+adjusted	O
+by	O
+the	O
+presented	O
+peptide	B-CHED
+,	O
+which	O
+impacts	O
+T	B-PROC
+cell	I-PROC
+activation	I-PROC
+.	O
+
+ABSTRACT	O
+:	O
+Adenovirus	B-DISO
+infections	I-DISO
+are	O
+associated	O
+with	O
+respiratory	O
+(	O
+especially	O
+upper	O
+respiratory	O
+)	O
+infection	B-DISO
+and	O
+gastrointestinal	B-DISO
+disease	I-DISO
+and	O
+occur	O
+primarily	O
+in	O
+infants	O
+and	O
+children	O
+.	O
+
+Although	O
+rare	O
+in	O
+adults	O
+,	O
+severe	O
+lower	O
+respiratory	O
+adenovirus	B-DISO
+infections	I-DISO
+including	O
+pneumonia	B-DISO
+are	O
+reported	O
+in	O
+specific	O
+populations	O
+,	O
+such	O
+as	O
+military	O
+recruits	O
+and	O
+immunocompromised	O
+patients	O
+.	O
+
+Of	O
+these	O
+55	O
+plants	B-SPEC
+,	O
+only	O
+six	O
+plants	B-SPEC
+have	O
+been	O
+studied	O
+in	O
+vitro	O
+against	O
+viral	O
+pathogens	O
+causing	O
+bronchitis	O
+.	O
+
+We	O
+invite	O
+the	O
+attention	O
+of	O
+researchers	O
+for	O
+detailed	O
+ethnopharmacological	O
+and	O
+phytochemical	O
+studies	O
+on	O
+unexplored	O
+plants	B-SPEC
+used	O
+to	O
+treat	O
+bronchitis	B-DISO
+for	O
+the	O
+development	B-PROC
+of	O
+novel	O
+antiviral	B-CHED
+drugs	I-CHED
+.	O
+
+We	O
+use	O
+the	O
+difference	O
+in	O
+difference	O
+approach	O
+and	O
+also	O
+conduct	B-PROC
+a	O
+falsification	B-DISO
+check	O
+and	O
+robustness	O
+check	O
+.	O
+
+The	O
+results	O
+suggest	O
+that	O
+older	O
+workers	O
+faced	O
+a	O
+higher	O
+possibility	O
+of	O
+unemployment	O
+after	O
+the	O
+Middle	O
+East	O
+Respiratory	O
+Syndrome	B-DISO
+outbreak	O
+.	O
+
+The	O
+vulnerability	O
+in	O
+the	O
+young	O
+group	O
+partially	O
+increased	O
+compared	O
+to	O
+the	O
+30s	O
+and	O
+40s	O
+age	O
+groups	O
+due	O
+to	O
+their	O
+relative	O
+vulnerability	O
+in	O
+the	O
+labor	B-PROC
+market	O
+despite	O
+being	O
+healthy	O
+.	O
+
+RESULTS	O
+:	O
+The	O
+results	O
+suggest	O
+that	O
+older	O
+workers	O
+faced	O
+a	O
+higher	O
+possibility	O
+of	O
+unemployment	O
+after	O
+the	O
+Middle	O
+East	O
+Respiratory	O
+Syndrome	B-DISO
+outbreak	O
+.	O
+
+ABSTRACT	O
+:	O
+Legionella	B-SPEC
+pneumophila	I-SPEC
+,	O
+a	O
+major	O
+cause	O
+of	O
+Legionnaires	B-DISO
+'	I-DISO
+disease	I-DISO
+,	O
+accounts	O
+for	O
+2	O
+-	O
+15	O
+%	O
+of	O
+all	O
+community	O
+-	O
+acquired	O
+pneumonia	B-DISO
+requiring	O
+hospitalization	O
+and	O
+up	O
+to	O
+30	O
+%	O
+of	O
+community	O
+-	O
+acquired	O
+pneumonia	B-DISO
+requiring	O
+intensive	O
+care	O
+unit	O
+admission	O
+.	O
+
+A	O
+retrospective	O
+multicenter	O
+observational	O
+study	O
+was	O
+conducted	O
+with	O
+all	O
+patients	O
+with	O
+confirmed	O
+Legionnaires	B-DISO
+'	I-DISO
+disease	I-DISO
+in	O
+the	O
+Niagara	O
+Region	O
+of	O
+the	O
+Province	O
+of	O
+Ontario	O
+,	O
+Canada	O
+,	O
+from	O
+June	O
+to	O
+December	O
+2013	O
+.	O
+
+Legionnaires	B-DISO
+'	I-DISO
+disease	I-DISO
+should	O
+be	O
+considered	O
+during	O
+the	O
+late	O
+spring	O
+and	O
+summer	O
+months	O
+in	O
+patients	O
+with	O
+a	O
+history	O
+of	O
+tobacco	B-SPEC
+use	O
+and	O
+various	O
+comorbidities	O
+.	O
+
+RESULTS	O
+:	O
+From	O
+June	O
+to	O
+December	O
+2013	O
+,	O
+there	O
+were	O
+14	O
+hospitalized	O
+cases	O
+of	O
+Legionnaires	B-DISO
+'	I-DISO
+disease	I-DISO
+in	O
+the	O
+Niagara	O
+Region	O
+.	O
+
+Guillain	O
+-	O
+Barré	O
+syndrome	B-DISO
+can	O
+also	O
+be	O
+complicated	O
+by	O
+dysautonomia	O
+necessitating	O
+specific	O
+therapies	O
+.	O
+
+Comorbidities	O
+are	O
+closely	O
+associated	O
+with	O
+HRV	O
+infections	B-DISO
+.	O
+
+ABSTRACT	O
+:	O
+In	O
+this	O
+paper	O
+design	O
+and	O
+synthesis	B-PROC
+of	O
+a	O
+scaffold	O
+comprising	O
+primaquine	B-CHED
+(	O
+PQ	O
+)	O
+motif	O
+and	O
+cinnamic	B-CHED
+acid	I-CHED
+derivatives	O
+(	O
+CADs	O
+)	O
+bound	O
+directly	O
+(	O
+compounds	O
+
+TITLE	O
+:	O
+Comparative	O
+Proteome	O
+Analysis	O
+of	O
+Porcine	B-SPEC
+Jejunum	B-ANAT
+Tissues	B-ANAT
+in	O
+Response	O
+to	O
+a	O
+Virulent	O
+Strain	O
+of	O
+Porcine	O
+Epidemic	O
+Diarrhea	O
+Virus	O
+and	O
+Its	O
+Attenuated	O
+Strain	O
+.	O
+
+ABSTRACT	O
+:	O
+Porcine	B-SPEC
+epidemic	I-SPEC
+diarrhea	I-SPEC
+virus	I-SPEC
+(	O
+PEDV	B-SPEC
+),	O
+a	O
+predominant	O
+cause	O
+of	O
+acute	O
+enteric	O
+infection	B-DISO
+,	O
+leads	O
+to	O
+severe	O
+dehydrating	O
+diarrhea	B-DISO
+and	O
+mortality	O
+in	O
+piglets	O
+all	O
+over	O
+the	O
+world	O
+.	O
+
+All	O
+of	O
+these	O
+involved	O
+interferon	B-PRGE
+-	O
+stimulated	O
+genes	O
+(	O
+ISGs	O
+)	O
+which	O
+were	O
+up	O
+-	O
+regulated	O
+in	O
+jejunums	B-ANAT
+by	O
+both	O
+of	O
+the	O
+PEDV	B-SPEC
+-	O
+infected	O
+groups	O
+.	O
+
+Nucleotide	B-CHED
+deletions	O
+were	O
+seen	O
+only	O
+in	O
+the	O
+group	O
+given	O
+the	O
+combination	O
+of	O
+Mass	O
+and	O
+Ark	O
+.	O
+Of	O
+the	O
+16	O
+sequenced	O
+samples	O
+in	O
+this	O
+group	O
+,	O
+13	O
+contained	O
+the	O
+same	O
+AAT	B-FUNC
+deletion	O
+at	O
+position	O
+1033	O
+1035	O
+in	O
+the	O
+Ark	B-PRGE
+strains	O
+.	O
+
+Findings	O
+presented	O
+in	O
+this	O
+study	O
+demonstrate	O
+alteration	O
+in	O
+the	O
+S1	O
+nucleotide	B-CHED
+sequence	O
+following	O
+co	O
+-	O
+administration	O
+of	O
+live	O
+IBV	B-SPEC
+vaccines	O
+.	O
+
+ABSTRACT	O
+:	O
+Airborne	O
+pathogens	O
+-	O
+either	O
+transmitted	O
+via	O
+aerosol	O
+or	O
+droplets	O
+-	O
+include	O
+a	O
+wide	O
+variety	O
+of	O
+highly	O
+infectious	B-DISO
+and	O
+dangerous	O
+microbes	O
+such	O
+as	O
+variola	B-SPEC
+virus	I-SPEC
+,	O
+measles	B-SPEC
+virus	I-SPEC
+,	O
+influenza	B-PATH
+A	I-PATH
+viruses	B-SPEC
+,	O
+Mycobacterium	B-SPEC
+tuberculosis	I-SPEC
+,	O
+Streptococcus	B-SPEC
+pneumoniae	I-SPEC
+,	O
+and	O
+Bordetella	B-SPEC
+pertussis	I-SPEC
+.	O
+
+TITLE	O
+:	O
+Outcomes	O
+and	O
+survival	O
+prediction	O
+models	O
+for	O
+severe	O
+adult	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+treated	O
+with	O
+extracorporeal	O
+membrane	O
+oxygenation	B-PROC
+.	O
+
+Higher	O
+age	O
+,	O
+immunocompromised	O
+status	O
+,	O
+associated	O
+extra	O
+-	O
+pulmonary	O
+organ	B-ANAT
+dysfunction	O
+,	O
+low	O
+respiratory	O
+compliance	O
+and	O
+non	O
+-	O
+influenzae	O
+diagnosis	O
+seem	O
+to	O
+be	O
+the	O
+main	O
+determinants	O
+of	O
+poorer	O
+outcome	O
+.	O
+
+Severe	O
+vector	O
+-	O
+mediated	O
+diseases	O
+may	O
+be	O
+complicated	O
+by	O
+ARDS	B-DISO
+or	O
+myocarditis	B-DISO
+,	O
+which	O
+are	O
+both	O
+associated	O
+with	O
+a	O
+high	O
+mortality	O
+rate	O
+.	O
+
+We	O
+conclude	O
+that	O
+ECMO	O
+treatment	O
+can	O
+be	O
+beneficial	O
+in	O
+patients	O
+with	O
+severe	O
+dengue	B-DISO
+,	O
+malaria	B-PATH
+,	O
+and	O
+acute	O
+Chagas	B-DISO
+disease	I-DISO
+,	O
+if	O
+complicated	O
+by	O
+pulmonary	B-ANAT
+or	O
+cardiac	B-DISO
+complications	I-DISO
+.	O
+
+Here	O
+we	O
+have	O
+investigated	O
+the	O
+effect	O
+of	O
+type	O
+I	O
+interferon	B-PRGE
+(	O
+IFN	B-PRGE
+)	O
+treatment	O
+on	O
+the	O
+formation	B-PROC
+of	O
+arterivirus	B-SPEC
+-	O
+induced	O
+membrane	B-COMP
+structures	O
+.	O
+
+ABSTRACT	O
+:	O
+Malaria	B-PATH
+remains	O
+one	O
+of	O
+the	O
+greatest	O
+burdens	O
+to	O
+global	O
+health	O
+,	O
+causing	O
+nearly	O
+500	O
+,	O
+000	O
+deaths	B-PROC
+in	O
+2014	O
+.	O
+
+We	O
+have	O
+previously	O
+shown	O
+that	O
+a	O
+proportion	O
+of	O
+DBA	B-DISO
+/	O
+2	O
+mice	B-SPEC
+infected	O
+with	O
+Plasmodium	B-SPEC
+berghei	I-SPEC
+ANKA	O
+(	O
+PbA	B-CHED
+)	O
+develop	O
+ALI	O
+/	O
+ARDS	B-DISO
+and	O
+that	O
+these	O
+mice	B-SPEC
+recapitulate	O
+various	O
+aspects	O
+of	O
+the	O
+human	B-SPEC
+syndrome	B-DISO
+,	O
+such	O
+as	O
+pulmonary	B-DISO
+edema	I-DISO
+,	O
+hemorrhaging	O
+,	O
+pleural	B-DISO
+effusion	I-DISO
+and	O
+hypoxemia	O
+.	O
+
+The	O
+depletion	O
+of	O
+neutrophils	B-ANAT
+,	O
+treatment	O
+with	O
+AMD3100	O
+(	O
+a	O
+CXCR4	B-FUNC
+antagonist	B-PROC
+),	O
+Pulmozyme	O
+(	O
+human	B-PRGE
+recombinant	I-PRGE
+DNase	B-ENZY
+)	O
+or	O
+Sivelestat	O
+(	O
+inhibitor	B-CHED
+of	O
+neutrophil	B-PRGE
+elastase	I-PRGE
+)	O
+decreased	O
+the	O
+development	B-PROC
+of	O
+malaria	B-PATH
+-	O
+associated	O
+ALI	O
+/	O
+ARDS	B-DISO
+and	O
+significantly	O
+increased	O
+mouse	B-SPEC
+survival	O
+.	O
+
+SPF	B-PRGE
+chickens	I-PRGE
+were	O
+intranasally	O
+inoculated	O
+with	O
+104	O
+EID50	O
+/	O
+0	O
+.	O
+1	O
+ml	O
+of	O
+the	O
+virus	B-SPEC
+.	O
+
+Clinical	O
+signs	O
+,	O
+gross	O
+pathology	B-DISO
+,	O
+and	O
+histological	O
+changes	O
+were	O
+recorded	O
+.	O
+
+TITLE	O
+:	O
+Community	O
+-	O
+Acquired	O
+Pneumonia	B-DISO
+in	O
+Adults	O
+:	O
+Diagnosis	O
+and	O
+Management	O
+.	O
+
+Patients	O
+with	O
+risk	O
+factors	O
+for	O
+methicillin	B-DISO
+-	I-DISO
+resistant	I-DISO
+Staphylococcus	B-SPEC
+aureus	I-SPEC
+should	O
+be	O
+given	O
+vancomycin	B-CHED
+or	O
+linezolid	B-CHED
+,	O
+or	O
+ceftaroline	B-CHED
+in	O
+resistant	O
+cases	O
+.	O
+
+Three	O
+(	O
+18	O
+%)	O
+of	O
+the	O
+patients	O
+had	O
+non	O
+-	O
+ischemic	O
+LGE	O
+in	O
+the	O
+basal	O
+inferolateral	O
+wall	O
+and	O
+21	O
+%	O
+demonstrated	O
+elevated	O
+global	O
+ECV	O
+values	O
+suggestive	O
+of	O
+interstitial	B-ANAT
+myocardial	B-DISO
+fibrosis	I-DISO
+.	O
+
+The	O
+observed	O
+structural	O
+abnormalities	O
+seem	O
+to	O
+result	O
+from	O
+an	O
+interplay	O
+between	O
+the	O
+storage	B-DISO
+disease	I-DISO
+and	O
+other	O
+comorbidities	O
+and	O
+they	O
+did	O
+not	O
+affect	O
+short	O
+-	O
+term	O
+to	O
+mid	O
+-	O
+term	O
+prognosis	O
+in	O
+adult	O
+Pompe	O
+patients	O
+.	O
+
+ABSTRACT	O
+:	O
+Porcine	B-SPEC
+epidemic	I-SPEC
+diarrhea	I-SPEC
+virus	I-SPEC
+(	O
+PEDV	B-SPEC
+)	O
+has	O
+caused	O
+economic	O
+losses	O
+in	O
+the	O
+Americas	O
+,	O
+Asia	O
+and	O
+Europe	O
+in	O
+recent	O
+years	O
+.	O
+
+Although	O
+the	O
+epidemic	O
+was	O
+unprecedented	O
+,	O
+the	O
+world	O
+had	O
+previously	O
+experienced	O
+several	O
+acute	O
+public	O
+health	O
+emergencies	O
+requiring	O
+global	O
+coordination	B-PROC
+.	O
+
+However	O
+no	O
+such	O
+work	O
+was	O
+conducted	O
+in	O
+Cambodia	O
+or	O
+Lao	O
+PDR	B-DISO
+.	O
+
+They	O
+were	O
+tested	O
+for	O
+the	O
+presence	O
+of	O
+coronavirus	B-SPEC
+by	O
+consensus	O
+reverse	B-PROC
+transcription	I-PROC
+-	O
+PCR	O
+assay	O
+.	O
+
+The	O
+βCoVs	O
+group	O
+is	O
+known	O
+to	O
+include	O
+some	O
+coronaviruses	O
+highly	O
+pathogenic	O
+to	O
+human	B-SPEC
+,	O
+such	O
+as	O
+SARS	B-DISO
+-	O
+CoV	O
+and	O
+MERS	O
+-	O
+CoV	O
+.	O
+All	O
+coronavirus	B-SPEC
+sequences	O
+generated	O
+from	O
+frugivorous	O
+bats	B-SPEC
+(	O
+family	B-SPEC
+Pteropodidae	I-SPEC
+)	O
+(	O
+n	O
+=	O
+55	O
+)	O
+clustered	O
+with	O
+other	O
+bat	B-ENZY
+βCoVs	O
+of	O
+lineage	O
+D	O
+,	O
+whereas	O
+one	O
+coronavirus	B-SPEC
+from	O
+Pipistrellus	B-SPEC
+coromandra	I-SPEC
+fell	O
+in	O
+the	O
+lineage	O
+C	O
+of	O
+βCoVs	O
+which	O
+also	O
+includes	O
+the	O
+MERS	O
+-	O
+CoV	O
+.	O
+αCoVs	O
+were	O
+all	O
+detected	O
+in	O
+various	O
+genera	O
+of	O
+insectivorous	O
+bats	B-SPEC
+and	O
+clustered	O
+with	O
+diverse	O
+bat	B-ENZY
+αCoV	O
+sequences	O
+previously	O
+published	O
+.	O
+
+Three	O
+new	O
+bat	B-ENZY
+genera	O
+and	O
+species	B-SPEC
+were	O
+newly	O
+identified	O
+as	O
+host	B-COMP
+of	O
+coronaviruses	O
+,	O
+namely	O
+Macroglossus	B-SPEC
+sp	O
+.,	O
+Megaerops	B-SPEC
+niphanae	I-SPEC
+and	O
+Myotis	B-SPEC
+horsfieldii	I-SPEC
+.	O
+
+ABSTRACT	O
+:	O
+The	O
+increasing	O
+reports	O
+of	O
+Middle	O
+East	O
+Respiratory	O
+Syndrome	B-DISO
+(	O
+MERS	B-DISO
+)	O
+caused	O
+by	O
+MERS	B-DISO
+coronavirus	B-SPEC
+(	O
+MERS	B-DISO
+-	O
+CoV	O
+)	O
+from	O
+many	O
+countries	O
+emphasize	O
+its	O
+importance	O
+for	O
+international	O
+travel	O
+.	O
+
+However	O
+detection	O
+of	O
+flu	B-DISO
+emphasises	O
+preventive	O
+strategies	O
+like	O
+vaccination	O
+.	O
+
+During	O
+the	O
+past	O
+decade	O
+,	O
+models	O
+have	O
+been	O
+used	O
+to	O
+predict	O
+the	O
+likelihood	O
+and	O
+magnitude	O
+of	O
+infectious	B-DISO
+disease	I-DISO
+outbreaks	O
+,	O
+inform	O
+emergency	B-DISO
+response	O
+activities	O
+in	O
+real	O
+time	O
+(	O
+1	O
+),	O
+and	O
+develop	O
+plans	O
+and	O
+preparedness	O
+strategies	O
+for	O
+future	O
+events	O
+,	O
+the	O
+latter	O
+of	O
+which	O
+proved	O
+invaluable	O
+during	O
+outbreaks	O
+such	O
+as	O
+severe	O
+acute	O
+respiratory	O
+syndrome	O
+and	O
+pandemic	O
+influenza	B-DISO
+(	O
+2	O
+-	O
+6	O
+).	O
+
+ABSTRACT	O
+:	O
+Recent	O
+studies	O
+have	O
+shown	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+(	O
+ARDS	B-DISO
+)	O
+to	O
+be	O
+underdiagnosed	O
+and	O
+inadequately	O
+treated	O
+,	O
+as	O
+evidenced	O
+by	O
+underutilization	O
+of	O
+low	O
+-	O
+tidal	O
+volume	O
+ventilation	O
+.	O
+
+Furthermore	O
+,	O
+we	O
+will	O
+highlight	O
+the	O
+role	O
+of	O
+global	O
+investigations	O
+of	O
+host	B-COMP
+kinases	O
+,	O
+the	O
+kinome	O
+,	O
+for	O
+investigating	O
+emerging	O
+and	O
+re	O
+-	O
+emerging	O
+viral	O
+pathogens	O
+from	O
+the	O
+context	O
+of	O
+characterizing	O
+cellular	O
+responses	O
+and	O
+identifying	O
+novel	O
+therapeutic	O
+targets	O
+.	O
+
+However	O
+,	O
+the	O
+lack	O
+of	O
+professional	O
+immune	O
+cells	B-COMP
+such	O
+as	O
+dendritic	B-ANAT
+cells	B-COMP
+(	O
+DC	O
+)	O
+and	O
+macrophages	B-ANAT
+has	O
+greatly	O
+limited	O
+the	O
+significance	O
+of	O
+current	O
+investigations	O
+.	O
+
+Cells	B-COMP
+with	O
+the	O
+phenotype	O
+,	O
+morphology	O
+and	O
+functional	O
+features	O
+of	O
+monocyte	B-ANAT
+-	O
+derived	O
+DC	O
+,	O
+bona	O
+fide	O
+DC	O
+or	O
+macrophages	B-ANAT
+were	O
+obtained	O
+in	O
+GM	B-PRGE
+-	I-PRGE
+CSF	I-PRGE
+/	O
+IL4	B-PRGE
+,	O
+FLT3L	B-PRGE
+or	O
+CSF	B-FUNC
+-	I-FUNC
+1	I-FUNC
+cultures	O
+,	O
+respectively	O
+.	O
+
+This	O
+review	O
+details	O
+which	O
+viruses	B-SPEC
+are	O
+likely	O
+to	O
+caused	O
+further	O
+outbreaks	O
+and	O
+looks	O
+at	O
+the	O
+strategies	O
+and	O
+tools	O
+available	O
+to	O
+UK	O
+medical	O
+professionals	O
+to	O
+mitigate	O
+the	O
+threat	O
+posed	O
+.	O
+
+ABSTRACT	O
+:	O
+The	O
+Middle	O
+East	O
+Respiratory	O
+Syndrome	O
+Coronavirus	B-SPEC
+(	O
+MERS	O
+-	O
+CoV	O
+)	O
+is	O
+an	O
+important	O
+emerging	O
+respiratory	O
+pathogen	O
+.	O
+
+The	O
+results	O
+from	O
+individual	O
+animals	B-SPEC
+,	O
+especially	O
+when	O
+the	O
+infection	B-DISO
+has	O
+occurred	O
+within	O
+an	O
+experimental	O
+situation	O
+,	O
+show	O
+more	O
+variation	O
+.	O
+
+The	O
+S1	B-PRGE
+glycoprotein	I-PRGE
+gene	O
+of	O
+N1	O
+/	O
+88	O
+,	O
+a	O
+subgroup	O
+2	O
+strain	O
+,	O
+shares	O
+a	O
+high	O
+nucleotide	B-CHED
+identity	O
+with	O
+the	O
+sequence	O
+of	O
+the	O
+S1	B-PRGE
+gene	I-PRGE
+of	O
+the	O
+recent	O
+isolate	O
+N1	O
+/	O
+08	O
+.	O
+
+Group	O
+2	O
+-	O
+8	O
+serum	B-COMP
+antibody	B-COMP
+-	O
+positive	O
+sows	O
+and	O
+their	O
+91	O
+piglets	O
+.	O
+
+Specifically	O
+,	O
+Group	O
+1	O
+piglets	O
+shed	O
+more	O
+virus	B-SPEC
+on	O
+DPIs	O
+1	O
+to	O
+5	O
+,	O
+were	O
+hypothermic	O
+at	O
+all	O
+sampling	O
+points	O
+except	O
+DPIs	O
+9	O
+,	O
+11	O
+,	O
+and	O
+12	O
+,	O
+gained	O
+weight	O
+more	O
+slowly	O
+,	O
+and	O
+exhibited	O
+lower	O
+survivability	O
+than	O
+Group	O
+2	O
+piglets	O
+.	O
+
+The	O
+spreaders	O
+with	O
+≥	O
+4	O
+transmissions	O
+exhibited	O
+higher	O
+values	O
+for	O
+pre	O
+-	O
+isolation	O
+contacts	O
+(	O
+777	O
+vs	O
+.	O
+78	O
+),	O
+pre	O
+-	O
+isolation	O
+emergency	B-DISO
+room	O
+visits	O
+(	O
+100	O
+%	O
+vs	O
+.	O
+35	O
+.	O
+3	O
+%),	O
+and	O
+doctor	O
+-	O
+shopping	O
+(	O
+100	O
+%	O
+vs	O
+.	O
+47	O
+.	O
+1	O
+%),	O
+compared	O
+to	O
+other	O
+spreaders	O
+.	O
+
+ABSTRACT	O
+:	O
+ADP	B-CHED
+-	O
+ribosylation	O
+is	O
+a	O
+common	O
+posttranslational	B-PROC
+modification	I-PROC
+that	O
+may	O
+have	O
+antiviral	B-CHED
+properties	O
+and	O
+impact	O
+innate	B-PROC
+immunity	I-PROC
+.	O
+
+We	O
+identified	O
+several	O
+macrodomain	O
+mutations	O
+that	O
+greatly	O
+reduced	O
+nsp3	B-PRGE
+'	O
+s	O
+de	O
+-	O
+ADP	B-CHED
+-	O
+ribosylation	O
+activity	O
+in	O
+vitro	O
+Next	O
+,	O
+we	O
+created	O
+recombinant	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+coronavirus	B-SPEC
+(	O
+SARS	B-DISO
+-	O
+CoV	O
+)	O
+strains	O
+with	O
+these	O
+mutations	O
+.	O
+
+Further	O
+,	O
+macrodomain	O
+mutant	B-DISO
+virus	B-SPEC
+elicited	O
+an	O
+early	O
+,	O
+enhanced	O
+interferon	B-PRGE
+(	O
+IFN	B-PRGE
+),	O
+interferon	B-PRGE
+-	O
+stimulated	O
+gene	O
+(	O
+ISG	O
+),	O
+and	O
+proinflammatory	O
+cytokine	O
+response	O
+in	O
+mice	B-SPEC
+and	O
+in	O
+a	O
+human	B-SPEC
+bronchial	B-ANAT
+epithelial	I-ANAT
+cell	I-ANAT
+line	O
+.	O
+
+The	O
+macrodomain	O
+is	O
+a	O
+ubiquitous	O
+structural	O
+domain	O
+that	O
+removes	O
+ADP	B-CHED
+-	O
+ribose	B-CHED
+from	O
+proteins	B-CHED
+,	O
+reversing	O
+the	O
+activity	O
+of	O
+ADP	B-PRGE
+-	I-PRGE
+ribosyltransferases	I-PRGE
+.	O
+
+TITLE	O
+:	O
+Activation	B-PROC
+of	I-PROC
+Coagulation	I-PROC
+and	O
+Fibrinolysis	B-PROC
+in	O
+Acute	B-DISO
+Respiratory	I-DISO
+Distress	I-DISO
+Syndrome	I-DISO
+:	O
+A	O
+Prospective	O
+Pilot	O
+Study	O
+.	O
+
+We	O
+hypothesized	O
+that	O
+ARDS	B-DISO
+development	B-PROC
+might	O
+be	O
+associated	O
+with	O
+changes	O
+in	O
+plasma	B-ANAT
+coagulation	B-PROC
+and	O
+fibrinolysis	B-PROC
+.	O
+
+Inclusion	O
+criteria	O
+were	O
+patients	O
+with	O
+PaO	B-PROC
+Of	O
+24	O
+patients	O
+at	O
+risk	O
+,	O
+6	O
+developed	O
+mild	O
+ARDS	B-DISO
+and	O
+4	O
+of	O
+each	O
+moderate	O
+or	O
+severe	O
+ARDS	B-DISO
+,	O
+respectively	O
+,	O
+3	O
+±	O
+2	O
+(	O
+mean	O
+±	O
+SD	O
+)	O
+days	O
+after	O
+inclusion	O
+.	O
+
+Median	O
+plasma	B-ANAT
+concentrations	O
+of	O
+TF	O
+and	O
+PAI	B-PRGE
+-	I-PRGE
+1	I-PRGE
+were	O
+significantly	O
+higher	O
+at	O
+This	O
+pilot	O
+study	O
+showed	O
+that	O
+increased	O
+plasma	B-ANAT
+concentrations	O
+of	O
+TF	O
+and	O
+PAI	B-PRGE
+-	I-PRGE
+1	I-PRGE
+might	O
+support	O
+ARDS	B-DISO
+diagnoses	O
+in	O
+mechanically	O
+ventilated	O
+patients	O
+after	O
+7	O
+days	O
+in	O
+ICU	O
+.	O
+
+TITLE	O
+:	O
+The	O
+Middle	O
+East	O
+Respiratory	O
+Syndrome	B-DISO
+Coronavirus	B-SPEC
+-	O
+A	O
+Continuing	O
+Risk	O
+to	O
+Global	O
+Health	O
+Security	O
+.	O
+
+ABSTRACT	O
+:	O
+Two	O
+new	O
+zoonotic	O
+coronaviruses	O
+causing	O
+disease	O
+in	O
+humans	O
+(	O
+Zumla	O
+et	O
+al	O
+.	O
+2015a	O
+;	O
+Hui	O
+and	O
+Zumla	O
+2015	O
+;	O
+Peiris	O
+et	O
+al	O
+.	O
+2003	O
+;	O
+Yu	B-SPEC
+et	O
+al	O
+.	O
+2014	O
+)	O
+have	O
+been	O
+the	O
+focus	O
+of	O
+international	O
+attention	O
+for	O
+the	O
+past	O
+14	O
+years	O
+due	O
+to	O
+their	O
+epidemic	O
+potential	O
+;	O
+(	O
+1	O
+)	O
+The	O
+Severe	B-DISO
+Acute	I-DISO
+Respiratory	I-DISO
+Syndrome	I-DISO
+coronavirus	B-SPEC
+(	O
+SARS	B-DISO
+-	O
+CoV	O
+)	O
+(	O
+Peiris	O
+et	O
+al	O
+.	O
+2003	O
+)	O
+first	O
+discovered	O
+in	O
+China	O
+in	O
+2001	O
+caused	O
+a	O
+major	O
+global	O
+epidemic	O
+of	O
+the	O
+Severe	B-DISO
+Acute	I-DISO
+Respiratory	I-DISO
+Syndrome	I-DISO
+(	O
+SARS	B-DISO
+).	O
+
+TITLE	O
+:	O
+[	O
+Clinical	O
+efficacy	O
+of	O
+different	O
+doses	O
+of	O
+gamma	B-PRGE
+globulin	I-PRGE
+combined	O
+with	O
+glucocorticoid	B-CHED
+in	O
+treatment	O
+of	O
+moderate	O
+/	O
+severe	O
+acute	O
+Guillain	O
+-	O
+Barré	O
+syndrome	O
+in	O
+children	O
+:	O
+a	O
+comparative	O
+analysis	O
+].	O
+
+ABSTRACT	O
+:	O
+Malaria	O
+is	O
+a	O
+serious	O
+disease	O
+,	O
+caused	O
+by	O
+the	O
+parasite	O
+of	O
+the	O
+genus	B-SPEC
+
+ABSTRACT	O
+:	O
+Drug	O
+-	O
+induced	O
+lung	B-ANAT
+injury	O
+(	O
+DLI	O
+)	O
+can	O
+result	O
+from	O
+a	O
+vast	O
+number	O
+of	O
+agents	O
+,	O
+and	O
+sometimes	O
+presents	O
+findings	O
+similar	O
+to	O
+those	O
+of	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+(	O
+ARDS	B-DISO
+).	O
+
+We	O
+hypothesized	O
+that	O
+endothelial	B-ANAT
+injuries	O
+are	O
+an	O
+important	O
+aspect	O
+of	O
+pathogenesis	B-DISO
+in	O
+severe	O
+DLI	O
+.	O
+
+Of	O
+the	O
+2580	O
+patients	O
+who	O
+underwent	O
+a	O
+bronchoalveolar	O
+lavage	O
+(	O
+BAL	B-ENZY
+)	O
+procedure	O
+at	O
+Tosei	O
+General	O
+Hospital	O
+between	O
+May	O
+2007	O
+and	O
+February	O
+2015	O
+,	O
+we	O
+retrospectively	O
+analysed	O
+the	O
+data	O
+of	O
+68	O
+DLI	O
+patients	O
+.	O
+
+At	O
+the	O
+time	O
+of	O
+diagnosis	O
+,	O
+39	O
+patients	O
+(	O
+57	O
+%)	O
+had	O
+respiratory	O
+failure	O
+(	O
+partial	B-PROC
+pressure	I-PROC
+of	I-PROC
+oxygen	I-PROC
+/	O
+inspiratory	B-PROC
+oxygen	B-CHED
+fraction	O
+ratio	O
+,	O
+PaO	B-PROC
+Soluble	O
+TM	O
+in	O
+BALF	O
+is	O
+an	O
+independent	O
+predictor	O
+of	O
+severe	O
+DLI	O
+.	O
+
+These	O
+findings	O
+underscore	O
+the	O
+importance	O
+of	O
+pulmonary	B-ANAT
+endothelial	B-ANAT
+injuries	O
+in	O
+the	O
+pathogenesis	B-DISO
+of	O
+severe	O
+DLI	O
+.	O
+
+RESULTS	O
+:	O
+At	O
+the	O
+time	O
+of	O
+diagnosis	O
+,	O
+39	O
+patients	O
+(	O
+57	O
+%)	O
+had	O
+respiratory	B-DISO
+failure	I-DISO
+(	O
+partial	B-PROC
+pressure	I-PROC
+of	I-PROC
+oxygen	I-PROC
+/	O
+inspiratory	B-PROC
+oxygen	B-CHED
+fraction	O
+ratio	O
+,	O
+PaO	B-PROC
+CONCLUSIONS	O
+:	O
+Soluble	O
+TM	O
+in	O
+BALF	O
+is	O
+an	O
+independent	O
+predictor	O
+of	O
+severe	O
+DLI	O
+.	O
+
+TITLE	O
+:	O
+Hepatitis	B-DISO
+E	I-DISO
+Virus	B-DISO
+Infection	I-DISO
+after	O
+Platelet	B-ANAT
+Transfusion	O
+in	O
+an	O
+Immunocompetent	O
+Trauma	O
+Patient	O
+.	O
+
+Genotyping	O
+confirmed	O
+HEV	B-SPEC
+in	O
+a	O
+transfused	O
+platelet	B-ANAT
+pool	O
+and	O
+the	O
+donor	B-CHED
+.	O
+
+Previously	O
+we	O
+have	O
+demonstrated	O
+that	O
+PDCoV	O
+infection	B-DISO
+suppresses	O
+the	O
+production	O
+of	O
+interferon	B-PRGE
+-	I-PRGE
+beta	I-PRGE
+(	O
+IFN	B-PRGE
+-	I-PRGE
+β	I-PRGE
+),	O
+while	O
+the	O
+detailed	O
+mechanisms	O
+are	O
+poorly	O
+understood	O
+.	O
+
+Patient	O
+-	O
+related	O
+clinical	O
+risk	O
+factors	O
+were	O
+defined	O
+as	O
+coronary	B-ANAT
+atherosclerotic	B-DISO
+heart	B-ANAT
+disease	I-DISO
+,	O
+cerebral	O
+infarction	O
+,	O
+diabetes	B-DISO
+mellitus	I-DISO
+,	O
+cirrhosis	B-DISO
+,	O
+chronic	B-DISO
+kidney	I-DISO
+disease	I-DISO
+,	O
+arrhythmia	B-DISO
+,	O
+asthma	B-PATH
+,	O
+chronic	B-DISO
+obstructive	I-DISO
+pulmonary	I-DISO
+disease	I-DISO
+,	O
+hypertension	B-DISO
+,	O
+and	O
+previous	O
+interventional	O
+pulmonology	O
+treatment	O
+.	O
+
+Third	O
+,	O
+invest	O
+in	O
+investigator	O
+-	O
+led	O
+clinical	O
+research	O
+networks	O
+that	O
+are	O
+primed	O
+and	O
+incentivised	O
+to	O
+respond	O
+to	O
+outbreak	O
+infections	B-DISO
+,	O
+and	O
+which	O
+can	O
+call	O
+on	O
+the	O
+support	O
+and	O
+resources	O
+of	O
+a	O
+central	O
+centre	O
+of	O
+excellence	O
+.	O
+
+We	O
+confirmed	O
+that	O
+residues	O
+18	O
+-	O
+133	O
+(	O
+designated	O
+NEP	B-PRGE
+-	I-PRGE
+D4	I-PRGE
+)	O
+and	O
+residues	O
+252	O
+-	O
+262	O
+(	O
+designated	O
+NEP	B-PRGE
+-	I-PRGE
+D6	I-PRGE
+)	O
+were	O
+the	O
+epitopes	O
+targeted	B-PROC
+by	O
+MAbs	O
+PN	O
+-	O
+D4	O
+and	O
+PN	O
+-	O
+D6	O
+,	O
+respectively	O
+.	O
+
+All	O
+these	O
+results	O
+suggest	O
+that	O
+these	O
+two	O
+novel	O
+epitopes	O
+and	O
+their	O
+cognate	O
+MAbs	O
+could	O
+serve	O
+as	O
+the	O
+basis	O
+for	O
+the	O
+development	B-PROC
+of	O
+precise	O
+diagnostic	O
+assays	O
+for	O
+PEDV	B-SPEC
+.	O
+
+Thus	O
+,	O
+new	O
+compounds	O
+with	O
+original	O
+modes	O
+of	O
+action	O
+are	O
+continuously	O
+required	O
+,	O
+and	O
+natural	B-CHED
+products	I-CHED
+have	O
+ever	O
+been	O
+a	O
+very	O
+interesting	O
+class	B-SPEC
+of	O
+pharmacologically	O
+active	O
+molecules	O
+.	O
+
+ABSTRACT	O
+:	O
+Acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+(	O
+ARDS	B-DISO
+)	O
+is	O
+defined	O
+as	O
+a	O
+syndrome	B-DISO
+of	O
+acute	O
+onset	O
+,	O
+with	O
+bilateral	O
+opacities	B-DISO
+on	O
+chest	B-ANAT
+imaging	O
+and	O
+respiratory	B-DISO
+failure	I-DISO
+not	O
+caused	O
+by	O
+cardiac	B-DISO
+failure	I-DISO
+,	O
+leading	O
+to	O
+mild	O
+,	O
+moderate	O
+,	O
+or	O
+severe	O
+oxygenation	B-PROC
+impairment	B-DISO
+.	O
+
+The	O
+syndrome	B-DISO
+is	O
+most	O
+commonly	O
+a	O
+manifestation	O
+of	O
+sepsis	B-DISO
+-	O
+induced	O
+organ	B-ANAT
+dysfunction	O
+,	O
+characterized	O
+by	O
+disruption	O
+of	O
+endothelial	B-ANAT
+barrier	O
+integrity	O
+and	O
+diffuse	O
+lung	B-ANAT
+damage	O
+.	O
+
+TITLE	O
+:	O
+[	O
+Risk	O
+factors	O
+for	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+following	O
+surgeries	O
+for	O
+pediatric	O
+critical	O
+and	O
+complex	O
+congenital	O
+heart	O
+disease	O
+].	O
+
+ABSTRACT	O
+:	O
+To	O
+explore	O
+the	O
+risk	O
+factors	O
+for	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+(	O
+ARDS	B-DISO
+)	O
+in	O
+children	O
+receiving	O
+surgeries	O
+for	O
+critical	O
+and	O
+complex	O
+congenital	B-DISO
+heart	I-DISO
+disease	I-DISO
+(	O
+CCHD	O
+).	O
+
+Univariate	O
+analyses	O
+and	O
+logistic	O
+regression	O
+were	O
+used	O
+to	O
+analyze	O
+the	O
+risk	O
+factors	O
+contributing	O
+to	O
+the	O
+occurrence	O
+of	O
+ARDS	B-DISO
+following	O
+the	O
+surgeries	O
+.	O
+
+The	O
+risk	O
+factors	O
+of	O
+ARDS	B-DISO
+identified	O
+in	O
+these	O
+children	O
+can	O
+predict	O
+the	O
+occurrence	O
+of	O
+ARDS	B-DISO
+following	O
+the	O
+surgeries	O
+and	O
+timely	O
+interventions	O
+can	O
+improve	O
+the	O
+success	O
+rate	O
+in	O
+treatment	O
+of	O
+postoperative	O
+ARDS	B-DISO
+in	O
+children	O
+with	O
+CCHD	O
+.	O
+
+Logistic	O
+regression	O
+analyses	O
+showed	O
+that	O
+intraoperative	O
+ACC	B-DISO
+time	O
+,	O
+CPB	O
+time	O
+,	O
+the	O
+maximum	O
+increasing	O
+rate	O
+of	O
+lactic	B-CHED
+acid	I-CHED
+within	O
+24	O
+h	O
+after	O
+operation	O
+,	O
+serum	B-COMP
+procalcitonin	O
+24	O
+h	O
+after	O
+operation	O
+and	O
+intraoperative	O
+blood	B-DISO
+loss	I-DISO
+were	O
+independent	O
+risk	O
+factors	O
+for	O
+postoperative	O
+ARDS	B-DISO
+.	O
+
+TITLE	O
+:	O
+Use	O
+of	O
+Aptamers	O
+as	O
+Diagnostics	O
+Tools	O
+and	O
+Antiviral	B-CHED
+Agents	I-CHED
+for	O
+Human	B-SPEC
+Viruses	B-SPEC
+.	O
+
+Our	O
+data	O
+support	O
+a	O
+polyphyletic	O
+origin	O
+of	O
+MERS	O
+-	O
+CoV	O
+in	O
+dromedaries	B-SPEC
+and	O
+the	O
+co	O
+-	O
+circulation	B-PROC
+of	O
+diverse	O
+MERS	O
+-	O
+CoVs	O
+including	O
+recombinant	O
+strains	O
+in	O
+the	O
+UAE	O
+.	O
+
+The	O
+use	O
+of	O
+cultured	O
+ex	O
+vivo	O
+infected	O
+human	B-SPEC
+lung	B-ANAT
+tissue	I-ANAT
+may	O
+overcome	O
+some	O
+of	O
+these	O
+limitations	O
+and	O
+complement	O
+traditional	O
+models	O
+.	O
+
+While	O
+the	O
+amplitude	O
+of	O
+tidal	O
+volume	O
+appears	O
+set	O
+<	O
+6	O
+mL	O
+kg	O
+⁻	O
+¹	O
+,	O
+the	O
+level	O
+of	O
+positive	O
+end	B-PROC
+-	I-PROC
+expiratory	I-PROC
+pressure	O
+(	O
+PEEP	B-CHED
+)	O
+remains	O
+controversial	O
+.	O
+
+Therefore	O
+,	O
+in	O
+early	O
+severe	O
+diffuse	O
+ARDS	B-DISO
+,	O
+this	O
+review	O
+argues	O
+for	O
+a	O
+combination	O
+of	O
+a	O
+high	O
+PEEP	B-CHED
+(	O
+preferably	O
+titrated	O
+on	O
+transpulmonary	O
+pressure	O
+)	O
+with	O
+spontaneous	O
+ventilation	O
++	O
+pressure	O
+support	O
+(	O
+or	O
+newer	O
+modes	O
+of	O
+ventilation	O
+).	O
+
+However	O
+,	O
+conditionalities	O
+are	O
+stringent	O
+:	O
+upfront	O
+circulatory	B-PROC
+optimization	O
+,	O
+upright	O
+positioning	O
+,	O
+lowered	O
+VO₂	O
+,	O
+lowered	O
+acidotic	O
+and	O
+hypercapnic	B-DISO
+drives	O
+,	O
+sedation	B-DISO
+without	O
+ventilatory	B-DISO
+depression	I-DISO
+and	O
+without	O
+lowered	O
+muscular	B-ANAT
+tone	O
+.	O
+
+TITLE	O
+:	O
+Stochastic	O
+modelling	O
+of	O
+infectious	B-DISO
+diseases	I-DISO
+for	O
+heterogeneous	O
+populations	O
+.	O
+
+ABSTRACT	O
+:	O
+Infectious	B-DISO
+diseases	I-DISO
+such	O
+as	O
+SARS	B-DISO
+and	O
+H1N1	O
+can	O
+significantly	O
+impact	O
+people	O
+'	O
+s	O
+lives	O
+and	O
+cause	O
+severe	O
+social	O
+and	O
+economic	O
+damages	O
+.	O
+
+ABSTRACT	O
+:	O
+Porcine	O
+deltacoronavirus	O
+(	O
+PDCoV	O
+)	O
+was	O
+identified	O
+in	O
+intestinal	B-ANAT
+samples	O
+collected	O
+from	O
+piglets	O
+with	O
+diarrhea	B-DISO
+in	O
+Thailand	O
+in	O
+2015	O
+.	O
+
+TITLE	O
+:	O
+A	O
+novel	O
+experimental	O
+model	O
+of	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+in	O
+pig	B-SPEC
+.	O
+
+Single	O
+cycle	O
+included	O
+two	O
+subsequent	O
+lavages	O
+followed	O
+by	O
+detergent	B-CHED
+suction	O
+.	O
+
+In	O
+remaining	O
+two	O
+animals	B-SPEC
+an	O
+unmanageable	O
+hypotension	O
+developed	O
+.	O
+
+However	O
+,	O
+the	O
+association	O
+between	O
+OSA	B-DISO
+and	O
+the	O
+exacerbation	O
+of	O
+severe	O
+asthma	B-PATH
+remains	O
+unclear	O
+.	O
+
+The	O
+frequency	O
+of	O
+severe	O
+asthma	B-PATH
+exacerbations	O
+was	O
+significantly	O
+higher	O
+among	O
+the	O
+asthma	B-PATH
+patients	O
+with	O
+OSA	B-DISO
+compared	O
+with	O
+those	O
+who	O
+did	O
+not	O
+have	O
+OSA	B-DISO
+(	O
+p	O
+<	O
+0	O
+.	O
+001	O
+).	O
+
+This	O
+phenomenon	O
+could	O
+be	O
+extended	O
+to	O
+other	O
+betacoronaviruses	O
+utilizing	O
+CTD1	O
+of	O
+the	O
+S1	O
+subunit	O
+for	O
+receptor	B-FUNC
+binding	I-FUNC
+,	O
+which	O
+provides	O
+new	O
+insights	O
+into	O
+the	O
+intermediate	O
+states	O
+of	O
+coronavirus	B-SPEC
+pre	O
+-	O
+fusion	O
+spike	O
+trimer	O
+during	O
+infection	B-DISO
+.	O
+
+ABSTRACT	O
+:	O
+Prevalence	O
+of	O
+Middle	O
+East	O
+respiratory	O
+syndrome	O
+coronavirus	B-SPEC
+(	O
+MERS	O
+-	O
+CoV	O
+)	O
+was	O
+determined	O
+in	O
+45	O
+dromedary	B-SPEC
+camels	B-SPEC
+from	O
+two	O
+geographically	O
+separated	O
+herds	O
+in	O
+Jordan	O
+.	O
+
+TITLE	O
+:	O
+Complete	O
+genome	O
+sequence	O
+analysis	O
+of	O
+chicken	B-SPEC
+astrovirus	I-SPEC
+isolate	O
+from	O
+India	O
+.	O
+
+ABSTRACT	O
+:	O
+Chicken	B-SPEC
+astroviruses	O
+have	O
+been	O
+known	O
+to	O
+cause	O
+severe	O
+disease	O
+in	O
+chickens	B-SPEC
+leading	O
+to	O
+increased	O
+mortality	O
+and	O
+""""	O
+white	O
+chicks	O
+""""	O
+condition	B-DISO
+.	O
+
+The	O
+epitope	B-CHED
+analysis	O
+by	O
+SVMTriP	O
+identified	O
+two	O
+unique	O
+epitopes	O
+in	O
+our	O
+isolate	O
+,	O
+seven	O
+shared	O
+epitopes	O
+among	O
+Indian	O
+isolates	O
+and	O
+two	O
+shared	O
+epitopes	O
+among	O
+all	O
+isolates	O
+except	O
+Poland	O
+isolate	O
+which	O
+carried	O
+all	O
+distinct	O
+epitopes	O
+.	O
+
+NMBA	O
+infusion	O
+was	O
+associated	O
+with	O
+an	O
+improvement	O
+in	O
+oxygenation	B-PROC
+in	O
+both	O
+moderate	O
+and	O
+severe	O
+ARDS	B-DISO
+,	O
+accompanied	O
+by	O
+a	O
+decrease	O
+in	O
+both	O
+plateau	O
+pressure	O
+and	O
+total	O
+positive	O
+end	B-PROC
+-	I-PROC
+expiratory	I-PROC
+pressure	O
+.	O
+
+We	O
+also	O
+describe	O
+how	O
+these	O
+particles	O
+are	O
+used	O
+to	O
+infect	O
+susceptible	O
+cells	B-COMP
+and	O
+to	O
+perform	O
+a	O
+quantitative	O
+infectivity	O
+readout	O
+by	O
+a	O
+luciferase	B-ENZY
+assay	O
+.	O
+
+The	O
+median	O
+PaO	B-PROC
+Evaluation	O
+of	O
+oxygenation	B-PROC
+with	O
+PEEP	B-CHED
+may	O
+provide	O
+useful	O
+information	O
+for	O
+predicting	O
+short	O
+-	O
+term	O
+mortality	O
+in	O
+patients	O
+with	O
+AE	O
+-	O
+IPF	O
+.	O
+
+Our	O
+hypothesis	O
+was	O
+that	O
+this	O
+method	O
+is	O
+reasonable	O
+if	O
+tissue	B-ANAT
+hypoxia	B-DISO
+is	O
+avoided	O
+.	O
+
+TITLE	O
+:	O
+Late	O
+-	O
+onset	O
+moderate	O
+to	O
+severe	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+is	O
+associated	O
+with	O
+shorter	O
+survival	O
+and	O
+higher	O
+mortality	O
+:	O
+a	O
+two	O
+-	O
+stage	O
+association	O
+study	O
+.	O
+
+RESULTS	O
+:	O
+Late	O
+-	O
+onset	O
+ARDS	B-DISO
+,	O
+defined	O
+as	O
+onset	O
+over	O
+48	O
+h	O
+after	O
+intensive	O
+care	O
+unit	O
+(	O
+ICU	O
+)	O
+admission	O
+(	O
+N	O
+=	O
+273	O
+,	O
+31	O
+%),	O
+was	O
+associated	O
+with	O
+shorter	O
+28	O
+-	O
+day	O
+survival	O
+time	O
+:	O
+HR	O
+=	O
+2	O
+.	O
+24	O
+,	O
+95	O
+%	O
+CI	O
+1	O
+.	O
+48	O
+-	O
+3	O
+.	O
+39	O
+,	O
+P	O
+=	O
+1	O
+.	O
+24	O
+×	O
+10	O
+
+We	O
+will	O
+underline	O
+how	O
+a	O
+holistic	O
+framework	O
+of	O
+respiratory	O
+and	O
+hemodynamic	B-PROC
+support	O
+should	O
+be	O
+provided	O
+to	O
+patients	O
+with	O
+ARDS	B-DISO
+,	O
+aiming	O
+to	O
+ensure	O
+adequate	O
+gas	B-ENZY
+exchange	O
+by	O
+promoting	O
+lung	B-ANAT
+recruitment	B-DISO
+while	O
+minimizing	O
+the	O
+risk	O
+of	O
+ventilator	O
+-	O
+induced	O
+lung	O
+injury	O
+.	O
+
+A	O
+total	O
+of	O
+1004	O
+met	B-CHED
+the	O
+Berlin	O
+definition	O
+of	O
+ARDS	B-DISO
+.	O
+
+As	O
+a	O
+result	O
+,	O
+genetic	O
+resources	O
+of	O
+camelids	O
+must	O
+continue	O
+to	O
+be	O
+maintained	O
+as	O
+living	O
+collections	O
+of	O
+animals	B-SPEC
+.	O
+
+The	O
+results	O
+suggest	O
+potential	O
+linkages	O
+among	O
+viral	O
+strategies	O
+for	O
+the	O
+regulation	B-PROC
+of	O
+cell	B-PROC
+survival	I-PROC
+activities	O
+,	O
+possibly	O
+through	O
+an	O
+interaction	O
+of	O
+N	B-PRGE
+protein	I-PRGE
+with	O
+NPM1	B-PRGE
+which	O
+prevents	O
+its	O
+proteolytic	B-PROC
+cleavage	B-PROC
+and	O
+enhances	O
+cell	B-PROC
+survival	I-PROC
+,	O
+thus	O
+ultimately	O
+promoting	O
+the	O
+replication	O
+of	O
+PEDV	B-SPEC
+.	O
+
+The	O
+majority	O
+of	O
+respondents	O
+(	O
+70	O
+.	O
+4	O
+%)	O
+felt	O
+at	O
+risk	O
+of	O
+contracting	O
+a	O
+MERS	O
+-	O
+CoV	O
+infection	B-DISO
+at	O
+work	O
+,	O
+69	O
+.	O
+1	O
+%	O
+felt	O
+threatened	O
+if	O
+a	O
+colleague	O
+contracted	O
+MERS	O
+-	O
+CoV	O
+,	O
+60	O
+.	O
+9	O
+%	O
+felt	O
+obliged	O
+to	O
+care	O
+for	O
+patients	O
+infected	O
+with	O
+MERS	O
+-	O
+CoV	O
+and	O
+87	O
+.	O
+8	O
+%	O
+did	O
+not	O
+feel	O
+safe	O
+at	O
+work	O
+using	O
+standard	O
+precautions	O
+.	O
+
+Concurrent	O
+infections	B-DISO
+of	O
+dengue	B-DISO
+and	O
+malaria	B-PATH
+are	O
+rare	O
+due	O
+to	O
+the	O
+different	O
+habitats	O
+of	O
+its	O
+vectors	O
+and	O
+activities	O
+of	O
+different	O
+carrier	O
+mosquitoes	B-SPEC
+.	O
+
+Plasmodium	B-SPEC
+knowlesi	I-SPEC
+is	O
+also	O
+a	O
+common	O
+cause	O
+of	O
+malaria	B-PATH
+in	O
+Malaysia	O
+with	O
+one	O
+of	O
+the	O
+highest	O
+rates	O
+of	O
+mortality	O
+.	O
+
+Despite	O
+aggressive	B-DISO
+supportive	O
+treatment	O
+in	O
+the	O
+intensive	O
+care	O
+unit	O
+(	O
+ICU	O
+),	O
+the	O
+patient	O
+had	O
+unresolved	O
+acidosis	B-DISO
+as	O
+well	O
+as	O
+multi	B-DISO
+-	I-DISO
+organ	I-DISO
+failure	I-DISO
+involving	O
+respiratory	O
+,	O
+renal	B-ANAT
+,	O
+liver	B-ANAT
+,	O
+and	O
+haematological	O
+systems	O
+.	O
+
+Signature	O
+amino	B-PROC
+acid	I-PROC
+substitutions	I-PROC
+and	O
+a	O
+glycine	B-CHED
+residue	I-CHED
+insertion	O
+at	O
+the	O
+N	O
+-	O
+terminal	O
+domain	O
+of	O
+the	O
+S1	O
+subunit	O
+of	O
+the	O
+spike	O
+gene	O
+,	O
+among	O
+others	O
+,	O
+exhibited	O
+further	O
+distinction	O
+in	O
+a	O
+recombination	O
+pattern	O
+,	O
+to	O
+which	O
+these	O
+clusters	B-CHED
+were	O
+classified	O
+as	O
+genotypes	O
+F	O
+and	O
+G	O
+.	O
+The	O
+phylogeographic	O
+mapping	O
+of	O
+the	O
+global	O
+spike	O
+gene	O
+indicated	O
+that	O
+the	O
+genetically	O
+similar	O
+HCoV	B-SPEC
+-	I-SPEC
+OC43	I-SPEC
+genotypes	O
+F	O
+and	O
+G	O
+strains	O
+were	O
+potentially	O
+circulating	O
+in	O
+China	O
+,	O
+Japan	O
+,	O
+Thailand	O
+and	O
+Europe	O
+as	O
+early	O
+as	O
+the	O
+late	O
+2000s	O
+.	O
+
+TITLE	O
+:	O
+Systematic	O
+,	O
+active	O
+surveillance	O
+for	O
+Middle	O
+East	O
+respiratory	O
+syndrome	B-DISO
+coronavirus	B-SPEC
+in	O
+camels	B-SPEC
+in	O
+Egypt	O
+.	O
+
+ABSTRACT	O
+:	O
+Middle	O
+East	O
+respiratory	O
+syndrome	O
+coronavirus	B-SPEC
+(	O
+MERS	O
+-	O
+CoV	O
+)	O
+causes	O
+severe	O
+human	B-SPEC
+infections	B-DISO
+and	O
+dromedary	B-SPEC
+camels	B-SPEC
+are	O
+considered	O
+an	O
+intermediary	O
+host	B-COMP
+.	O
+
+Findings	O
+related	O
+to	O
+waning	O
+antibodies	B-COMP
+and	O
+re	O
+-	O
+infection	B-DISO
+have	O
+implications	O
+for	O
+camel	B-SPEC
+vaccine	O
+development	B-PROC
+,	O
+disease	O
+management	O
+and	O
+zoonotic	O
+threat	O
+.	O
+
+TITLE	O
+:	O
+Military	O
+-	O
+civilian	O
+cooperative	O
+emergency	B-DISO
+response	O
+to	O
+infectious	B-DISO
+disease	I-DISO
+prevention	O
+and	O
+control	O
+in	O
+China	O
+.	O
+
+ABSTRACT	O
+:	O
+In	O
+recent	O
+years	O
+,	O
+the	O
+incidence	O
+of	O
+severe	O
+infectious	O
+diseases	O
+has	O
+increased	O
+,	O
+and	O
+the	O
+number	O
+of	O
+emerging	B-DISO
+infectious	I-DISO
+diseases	I-DISO
+continues	O
+to	O
+increase	O
+.	O
+
+The	O
+Chinese	O
+government	O
+and	O
+military	O
+forces	O
+have	O
+paid	O
+a	O
+great	O
+deal	O
+of	O
+attention	O
+to	O
+infectious	B-DISO
+disease	I-DISO
+prevention	O
+and	O
+control	O
+,	O
+and	O
+using	O
+military	O
+-	O
+civilian	O
+cooperation	O
+,	O
+they	O
+have	O
+successfully	O
+prevented	O
+numerous	O
+severe	O
+epidemic	O
+situations	O
+,	O
+such	O
+as	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+(	O
+SARS	B-DISO
+),	O
+influenza	B-PATH
+A	I-PATH
+(	O
+H1N1	O
+),	O
+avian	B-DISO
+influenza	I-DISO
+H5N1	B-DISO
+and	O
+H7N9	O
+,	O
+and	O
+Ebola	B-DISO
+hemorrhagic	I-DISO
+fever	I-DISO
+,	O
+while	O
+actively	O
+maintained	O
+public	O
+health	O
+,	O
+economic	O
+development	B-PROC
+,	O
+and	O
+national	O
+construction	O
+.	O
+
+TITLE	O
+:	O
+Social	O
+Big	O
+Data	O
+Analysis	O
+of	O
+Information	O
+Spread	O
+and	O
+Perceived	O
+Infection	B-DISO
+Risk	O
+During	O
+the	O
+2015	O
+Middle	O
+East	O
+Respiratory	O
+Syndrome	O
+Outbreak	O
+in	O
+South	O
+Korea	O
+.	O
+
+Underlying	O
+cardiovascular	B-DISO
+diseases	I-DISO
+,	O
+such	O
+as	O
+chronic	B-DISO
+heart	I-DISO
+failure	I-DISO
+,	O
+arteriosclerosis	B-DISO
+and	O
+dysrhythmia	B-DISO
+can	O
+either	O
+deteriorate	O
+due	O
+to	O
+infections	B-DISO
+or	O
+be	O
+newly	O
+manifested	O
+as	O
+a	O
+result	O
+of	O
+pneumonia	B-DISO
+.	O
+
+ABSTRACT	O
+:	O
+The	O
+United	O
+States	O
+swine	B-SPEC
+industry	O
+was	O
+first	O
+confronted	O
+with	O
+porcine	B-SPEC
+epidemic	I-SPEC
+diarrhea	I-SPEC
+virus	I-SPEC
+(	O
+PEDV	B-SPEC
+)	O
+in	O
+2013	O
+.	O
+
+Most	O
+IBV	B-SPEC
+strains	O
+have	O
+the	O
+typical	O
+genomic	O
+organization	O
+of	O
+other	O
+gamacoronaviruses	O
+,	O
+however	O
+,	O
+two	O
+strains	O
+lacked	O
+3a	O
+and	O
+5b	O
+genes	O
+as	O
+a	O
+result	O
+of	O
+a	O
+nucleotide	B-CHED
+change	O
+within	O
+the	O
+start	O
+codon	O
+in	O
+the	O
+3a	O
+or	O
+5b	O
+genes	O
+.	O
+
+Most	O
+of	O
+these	O
+viruses	B-SPEC
+disappeared	O
+(	O
+before	O
+mid	O
+-	O
+2005	O
+)	O
+because	O
+they	O
+were	O
+not	O
+""""	O
+fit	B-DISO
+""""	O
+to	O
+adaptation	B-PROC
+in	O
+chickens	B-SPEC
+.	O
+
+TITLE	O
+:	O
+Widespread	O
+Virus	B-PROC
+Replication	I-PROC
+in	O
+Alveoli	B-ANAT
+Drives	O
+Acute	B-DISO
+Respiratory	I-DISO
+Distress	I-DISO
+Syndrome	I-DISO
+in	O
+Aerosolized	O
+H5N1	O
+Influenza	O
+Infection	O
+of	O
+Macaques	B-SPEC
+.	O
+
+This	O
+new	O
+nonhuman	O
+primate	B-SPEC
+model	O
+will	O
+advance	O
+vaccine	O
+and	O
+therapeutic	O
+approaches	O
+to	O
+prevent	O
+and	O
+treat	O
+human	B-SPEC
+disease	O
+caused	O
+by	O
+highly	O
+pathogenic	O
+avian	B-DISO
+influenza	B-SPEC
+viruses	I-SPEC
+.	O
+
+To	O
+study	O
+this	O
+disease	O
+process	O
+in	O
+experimental	O
+animals	B-SPEC
+,	O
+mice	B-SPEC
+are	O
+infected	O
+,	O
+most	O
+commonly	O
+,	O
+with	O
+neurotropic	O
+strains	O
+of	O
+mouse	B-DISO
+hepatitis	I-DISO
+virus	B-SPEC
+,	O
+a	O
+coronavirus	B-SPEC
+or	O
+Theiler	O
+'	O
+s	O
+murine	B-DISO
+encephalomyelitis	I-DISO
+,	O
+a	O
+picornavirus	B-SPEC
+.	O
+
+Areas	O
+covered	O
+:	O
+The	O
+purpose	O
+of	O
+this	O
+review	O
+is	O
+to	O
+provide	O
+an	O
+overview	O
+of	O
+the	O
+main	O
+antiviral	B-CHED
+agents	I-CHED
+used	O
+for	O
+the	O
+treatment	O
+of	O
+respiratory	O
+viral	B-DISO
+infections	I-DISO
+in	O
+immunocompromised	O
+patients	O
+and	O
+review	O
+of	O
+the	O
+new	O
+agents	O
+in	O
+the	O
+pipeline	O
+.	O
+
+ABSTRACT	O
+:	O
+Middle	O
+East	O
+respiratory	O
+syndrome	O
+coronavirus	B-SPEC
+was	O
+first	O
+described	O
+in	O
+2012	O
+.	O
+
+Charting	O
+the	O
+decline	O
+in	O
+PaO2	O
+/	O
+FiO2	O
+ratio	O
+in	O
+a	O
+mechanically	O
+ventilated	O
+pig	B-SPEC
+confirmed	O
+that	O
+ricin	B-FUNC
+-	O
+induced	O
+respiratory	O
+damage	O
+complies	O
+with	O
+the	O
+accepted	O
+diagnostic	O
+criteria	O
+for	O
+ARDS	B-DISO
+.	O
+
+We	O
+selected	O
+16	O
+bovine	B-SPEC
+respiratory	O
+pathogens	O
+(	O
+bovine	B-SPEC
+viral	I-SPEC
+diarrhea	I-SPEC
+virus	I-SPEC
+,	O
+bovine	B-SPEC
+coronavirus	B-SPEC
+,	O
+bovine	B-SPEC
+parainfluenza	I-SPEC
+virus	I-SPEC
+3	I-SPEC
+,	O
+bovine	B-SPEC
+respiratory	I-SPEC
+syncytial	I-SPEC
+virus	I-SPEC
+,	O
+influenza	B-SPEC
+D	I-SPEC
+virus	I-SPEC
+,	O
+bovine	B-SPEC
+rhinitis	B-DISO
+A	O
+virus	B-SPEC
+,	O
+bovine	B-SPEC
+rhinitis	I-SPEC
+B	I-SPEC
+virus	I-SPEC
+,	O
+bovine	B-SPEC
+herpesvirus	I-SPEC
+1	I-SPEC
+,	O
+bovine	B-SPEC
+adenovirus	B-DISO
+3	O
+,	O
+bovine	B-SPEC
+adenovirus	B-DISO
+7	O
+,	O
+Mannheimia	B-SPEC
+haemolytica	I-SPEC
+,	O
+Pasteurella	B-SPEC
+multocida	I-SPEC
+,	O
+Histophilus	B-SPEC
+somni	I-SPEC
+,	O
+Trueperella	B-SPEC
+pyogenes	O
+,	O
+Mycoplasma	B-SPEC
+bovis	I-SPEC
+and	O
+Ureaplasma	B-SPEC
+diversum	I-SPEC
+)	O
+as	O
+detection	O
+targets	O
+and	O
+designed	O
+novel	O
+specific	O
+primer	O
+-	O
+probe	O
+sets	O
+for	O
+nine	O
+of	O
+them	O
+.	O
+
+ABSTRACT	O
+:	O
+A	O
+pandemic	O
+of	O
+obesity	O
+is	O
+sweeping	O
+all	O
+across	O
+the	O
+globe	B-ANAT
+and	O
+the	O
+Middle	O
+East	O
+region	O
+also	O
+does	O
+not	O
+remain	O
+untouched	O
+by	O
+this	O
+prevailing	O
+pandemic	O
+.	O
+
+We	O
+will	O
+also	O
+suggest	O
+to	O
+control	O
+this	O
+epidemic	O
+of	O
+obesity	B-DISO
+and	O
+OSA	B-DISO
+so	O
+that	O
+the	O
+corrective	O
+measure	O
+could	O
+be	O
+taken	O
+at	O
+health	O
+ministry	O
+level	O
+to	O
+help	O
+people	O
+of	O
+this	O
+region	O
+to	O
+fight	O
+against	O
+obesity	B-DISO
+and	O
+related	O
+disorders	O
+,	O
+primarily	O
+OSA	B-DISO
+.	O
+
+The	O
+electrostatic	O
+interaction	O
+between	O
+TMV	B-SPEC
+-	O
+wt	O
+and	O
+TMV	B-SPEC
+-	O
+lys	B-CHED
+nanoparticles	B-CHED
+became	O
+the	O
+driving	O
+force	O
+in	O
+the	O
+highly	O
+controlled	O
+buildup	O
+of	O
+the	O
+multilayer	O
+TMV	B-SPEC
+constructs	O
+.	O
+
+We	O
+conducted	O
+two	O
+web	B-DISO
+-	O
+based	O
+,	O
+cross	O
+-	O
+sectional	O
+surveys	O
+of	O
+ICU	O
+organizational	O
+practices	O
+in	O
+Pennsylvania	O
+acute	O
+care	O
+hospitals	O
+,	O
+in	O
+2005	O
+(	O
+chief	O
+nursing	B-PROC
+officer	O
+respondents	O
+)	O
+and	O
+2014	O
+(	O
+ICU	O
+nurse	O
+manager	O
+respondents	O
+).	O
+
+Of	O
+223	O
+eligible	O
+respondents	O
+,	O
+nurse	O
+managers	O
+from	O
+136	O
+(	O
+61	O
+%)	O
+medical	O
+,	O
+surgical	O
+,	O
+mixed	O
+medical	O
+-	O
+surgical	O
+,	O
+cardiac	B-ANAT
+,	O
+and	O
+specialty	O
+ICUs	O
+in	O
+98	O
+hospitals	O
+completed	O
+the	O
+2014	O
+survey	O
+,	O
+compared	O
+with	O
+124	O
+of	O
+164	O
+(	O
+76	O
+%)	O
+chief	O
+nursing	B-PROC
+officers	O
+in	O
+the	O
+2005	O
+survey	O
+.	O
+
+In	O
+a	O
+multivariate	O
+analysis	O
+,	O
+the	O
+only	O
+variables	O
+that	O
+were	O
+correlated	O
+with	O
+longer	O
+hospital	O
+stay	O
+were	O
+the	O
+use	O
+of	O
+oxygen	B-CHED
+and	O
+nebulizer	O
+therapy	O
+,	O
+irrespective	O
+of	O
+the	O
+viral	O
+pathogen	O
+.	O
+
+Children	O
+with	O
+RT	O
+-	O
+PCR	O
+positive	O
+test	O
+results	O
+had	O
+a	O
+significant	O
+higher	O
+disease	O
+severity	O
+,	O
+fever	B-PROC
+,	O
+length	O
+of	O
+hospital	O
+stay	O
+,	O
+days	O
+of	O
+extra	O
+oxygen	B-CHED
+supply	O
+,	O
+and	O
+days	O
+of	O
+antibiotic	B-CHED
+treatment	O
+than	O
+children	O
+with	O
+a	O
+negative	O
+RT	O
+-	O
+PCR	O
+test	O
+result	O
+.	O
+
+Disease	O
+(	O
+severity	O
+),	O
+management	O
+and	O
+outcome	O
+in	O
+pediatric	O
+ARI	B-CHED
+are	O
+not	O
+associated	O
+with	O
+a	O
+specific	O
+virus	B-SPEC
+.	O
+
+The	O
+X	O
+-	O
+ray	B-SPEC
+structure	O
+of	O
+MERS	B-PRGE
+PLpro	I-PRGE
+-∆	I-PRGE
+Ubl2	I-PRGE
+was	O
+determined	O
+to	O
+1	O
+.	O
+9	O
+Å	O
+and	O
+compared	O
+to	O
+PLpro	O
+containing	O
+the	O
+N	O
+-	O
+terminal	O
+Ubl2	B-PRGE
+domain	O
+.	O
+
+However	O
+,	O
+it	O
+may	O
+cause	O
+severe	O
+lower	B-DISO
+respiratory	I-DISO
+tract	I-DISO
+infection	I-DISO
+,	O
+and	O
+the	O
+clinical	O
+course	O
+may	O
+be	O
+severe	O
+in	O
+immunocompromised	O
+patients	O
+.	O
+
+We	O
+present	O
+a	O
+fatal	O
+lower	B-ANAT
+respiratory	I-ANAT
+tract	I-ANAT
+disease	O
+associated	O
+with	O
+HCoV	B-SPEC
+-	I-SPEC
+NL63	I-SPEC
+in	O
+a	O
+7	O
+-	O
+month	O
+-	O
+old	O
+malnourished	B-DISO
+infant	O
+.	O
+
+Our	O
+results	O
+indicated	O
+that	O
+lipid	B-COMP
+rafts	I-COMP
+serve	O
+as	O
+attachment	O
+factors	O
+during	O
+the	O
+early	O
+stages	O
+of	O
+IBV	B-SPEC
+infection	B-DISO
+,	O
+especially	O
+during	O
+the	O
+attachment	O
+stage	O
+.	O
+
+TITLE	O
+:	O
+Vaccination	O
+against	O
+infectious	B-DISO
+bronchitis	B-DISO
+virus	B-SPEC
+:	O
+A	O
+continuous	O
+challenge	O
+.	O
+
+Novel	O
+vaccine	O
+technology	O
+development	B-PROC
+has	O
+been	O
+slow	O
+,	O
+and	O
+is	O
+hindered	O
+by	O
+the	O
+constraints	O
+of	O
+large	O
+-	O
+scale	O
+poultry	O
+production	O
+.	O
+
+Further	O
+complicating	O
+the	O
+situation	O
+is	O
+the	O
+lack	O
+of	O
+knowledge	O
+of	O
+IBV	B-SPEC
+protein	B-CHED
+and	O
+host	B-COMP
+cell	I-COMP
+interactions	O
+,	O
+making	O
+targeted	B-PROC
+vaccine	O
+intervention	O
+strategies	O
+near	O
+impossible	O
+.	O
+
+Healthy	O
+adults	O
+(	O
+18	O
+-	O
+45	O
+years	O
+of	O
+age	O
+)	O
+were	O
+randomized	O
+into	O
+ARMS	B-DISO
+-	O
+I	O
+or	O
+placebo	O
+group	O
+(	O
+50	O
+subjects	O
+each	O
+).	O
+
+Secondary	O
+objectives	O
+were	O
+to	O
+evaluate	O
+safety	O
+,	O
+tolerability	O
+,	O
+rate	O
+of	O
+virus	O
+detection	O
+,	O
+acceptability	O
+and	O
+adherence	O
+;	O
+effect	O
+on	O
+URI	O
+-	O
+associated	O
+absenteeism	O
+and	O
+medical	O
+visits	O
+;	O
+and	O
+effect	O
+of	O
+prior	O
+influenza	B-DISO
+vaccination	O
+on	O
+study	O
+outcomes	O
+.	O
+
+Prior	O
+influenza	B-DISO
+vaccination	O
+had	O
+no	O
+effect	O
+on	O
+study	O
+outcome	O
+.	O
+
+ABSTRACT	O
+:	O
+A	O
+series	O
+of	O
+potent	O
+and	O
+novel	O
+acylsulfonamide	O
+-	O
+bearing	O
+triazines	O
+were	O
+synthesized	O
+and	O
+the	O
+structure	O
+-	O
+activity	O
+relationships	O
+(	O
+SARs	B-DISO
+)	O
+as	O
+HCV	B-SPEC
+entry	O
+inhibitors	B-CHED
+were	O
+evaluated	O
+.	O
+
+This	O
+acylsulfonamide	O
+series	O
+was	O
+derived	O
+from	O
+an	O
+early	O
+lead	O
+,	O
+4	O
+-(	O
+4	O
+-(	O
+1	O
+-(	O
+4	O
+-	O
+chlorophenyl	O
+)	O
+cyclopropylamino	O
+)-	O
+6	O
+-(	O
+2	O
+,	O
+2	O
+,	O
+2	O
+-	O
+trifluoroethoxy	O
+)-	O
+1	O
+,	O
+3	O
+,	O
+5	O
+-	O
+triazin	B-CHED
+-	O
+2	O
+-	O
+ylamino	O
+)	O
+benzoic	B-CHED
+acid	I-CHED
+wherein	O
+the	O
+carboxylic	B-CHED
+acid	I-CHED
+was	O
+replaced	O
+with	O
+an	O
+acylsulfonamide	O
+moiety	O
+.	O
+
+Propofol	B-CHED
+exposure	O
+was	O
+significantly	O
+higher	O
+in	O
+patients	O
+with	O
+ICUAW	O
+compared	O
+to	O
+controls	O
+(	O
+63	O
+.	O
+5	O
+%	O
+vs	O
+.	O
+33	O
+.	O
+8	O
+%,	O
+p	O
+<	O
+0	O
+.	O
+001	O
+).	O
+
+The	O
+overall	O
+pipeline	O
+of	O
+inactivation	B-DISO
+and	O
+subsequent	O
+proteomic	O
+,	O
+metabolomic	O
+,	O
+and	O
+lipidomic	O
+analyses	O
+was	O
+evaluated	O
+using	O
+a	O
+human	B-SPEC
+epithelial	O
+lung	B-ANAT
+cell	B-ANAT
+line	I-ANAT
+infected	O
+with	O
+wild	O
+-	O
+type	O
+and	O
+mutant	B-DISO
+influenza	B-DISO
+H7N9	O
+viruses	B-SPEC
+,	O
+thereby	O
+demonstrating	O
+that	O
+MPLEx	O
+yields	O
+biomaterial	O
+of	O
+sufficient	O
+quality	O
+for	O
+subsequent	O
+multi	O
+-	O
+omics	O
+analyses	O
+.	O
+
+The	O
+levels	O
+of	O
+stress	O
+,	O
+reliability	O
+/	O
+practice	O
+of	O
+preventive	O
+behaviors	B-PROC
+,	O
+hand	O
+washing	O
+practice	O
+and	O
+policy	O
+credibility	O
+during	O
+the	O
+outbreak	O
+period	O
+were	O
+analyzed	O
+for	O
+each	O
+cluster	O
+.	O
+
+TITLE	O
+:	O
+Effect	O
+of	O
+the	O
+Protein	B-CHED
+Corona	B-CHED
+on	O
+Antibody	B-COMP
+-	O
+Antigen	B-FUNC
+Binding	I-FUNC
+in	O
+Nanoparticle	B-CHED
+Sandwich	O
+Immunoassays	O
+.	O
+
+Treatment	O
+was	O
+started	O
+once	O
+the	O
+diagnosis	O
+of	O
+disseminated	O
+adenovirus	B-DISO
+infection	I-DISO
+was	O
+made	O
+;	O
+however	O
+,	O
+at	O
+that	O
+time	O
+patient	O
+was	O
+suffering	B-DISO
+from	O
+refractory	O
+hypoxaemia	O
+,	O
+respiratory	B-DISO
+acidosis	I-DISO
+,	O
+right	B-DISO
+heart	I-DISO
+failure	I-DISO
+and	O
+septic	B-DISO
+shock	I-DISO
+.	O
+
+RESULTS	O
+:	O
+VEGF	B-PRGE
+was	O
+not	O
+associated	O
+with	O
+ISS	B-DISO
+(	O
+p	O
+>	O
+0	O
+.	O
+05	O
+);	O
+sVEGFR1	O
+was	O
+positively	O
+associated	O
+with	O
+ISS	B-DISO
+(	O
+r	O
+=	O
+0	O
+.	O
+459	O
+,	O
+p	O
+<	O
+0	O
+.	O
+0001	O
+);	O
+however	O
+,	O
+sVEGFR2	O
+was	O
+negatively	O
+associated	O
+with	O
+ISS	B-DISO
+(	O
+r	O
+=	O
+0	O
+.	O
+510	O
+,	O
+p	O
+<	O
+0	O
+.	O
+0001	O
+).	O
+
+TITLE	O
+:	O
+Rhodoccocus	O
+Equi	O
+Pneumonia	B-DISO
+and	O
+Paradoxical	O
+Immune	B-DISO
+Reconstitution	I-DISO
+Inflammatory	I-DISO
+Syndrome	I-DISO
+in	O
+a	O
+Patient	O
+with	O
+Acquired	O
+Immune	O
+Deficiency	O
+Syndrome	O
+(	O
+AIDS	O
+).	O
+
+To	O
+evaluate	O
+the	O
+ability	O
+of	O
+electrical	B-PROC
+impedance	I-PROC
+tomography	O
+(	O
+EIT	O
+)	O
+to	O
+monitor	O
+a	O
+PEEP	B-CHED
+trial	O
+and	O
+to	O
+derive	O
+from	O
+EIT	O
+the	O
+best	O
+compromise	O
+PEEP	B-CHED
+in	O
+this	O
+setting	O
+.	O
+
+RESULTS	O
+:	O
+Anti	B-PRGE
+-	I-PRGE
+CoV	I-PRGE
+IgM	I-PRGE
+antibodies	I-PRGE
+were	O
+detected	O
+in	O
+22	O
+/	O
+183	O
+(	O
+12	O
+.	O
+02	O
+%)	O
+and	O
+26	O
+/	O
+236	O
+(	O
+11	O
+.	O
+02	O
+%)	O
+patients	O
+with	O
+acute	O
+encephalitis	B-DISO
+-	O
+like	O
+syndrome	B-DISO
+and	O
+respiratory	B-DISO
+tract	I-DISO
+infection	I-DISO
+,	O
+respectively	O
+.	O
+
+TITLE	O
+:	O
+Clinical	O
+validation	O
+of	O
+3	O
+commercial	O
+real	O
+-	O
+time	O
+reverse	B-ENZY
+transcriptase	I-ENZY
+polymerase	O
+chain	O
+reaction	O
+assays	O
+for	O
+the	O
+detection	O
+of	O
+Middle	O
+East	O
+respiratory	O
+syndrome	O
+coronavirus	B-SPEC
+from	O
+upper	B-ANAT
+respiratory	I-ANAT
+tract	I-ANAT
+specimens	O
+.	O
+
+Results	O
+showed	O
+i	O
+)	O
+the	O
+TIB	B-PRGE
+MolBiol	I-PRGE
+®	I-PRGE
+LightMix	I-PRGE
+UpE	I-PRGE
+and	I-PRGE
+Orf1a	I-PRGE
+assays	I-PRGE
+(	O
+TIB	O
+MolBiol	O
+,	O
+Berlin	O
+,	O
+Germany	O
+)	O
+to	O
+be	O
+the	O
+most	O
+sensitive	O
+,	O
+followed	O
+by	O
+ii	O
+)	O
+the	O
+Anyplex	O
+™	O
+Seegene	O
+MERS	O
+-	O
+CoV	O
+assay	O
+(	O
+Seegene	O
+,	O
+Seoul	O
+,	O
+Korea	O
+),	O
+and	O
+finally	O
+iii	O
+)	O
+the	O
+PrimerDesign	O
+™	O
+Genesig	O
+®	O
+HCoV_2012	O
+assay	O
+(	O
+PrimerDesign	O
+,	O
+England	O
+,	O
+United	O
+Kingdom	B-SPEC
+).	O
+
+TITLE	O
+:	O
+Severe	O
+hypercapnia	B-DISO
+and	O
+outcome	O
+of	O
+mechanically	O
+ventilated	O
+patients	O
+with	O
+moderate	O
+or	O
+severe	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+.	O
+
+We	O
+performed	O
+a	O
+secondary	O
+analysis	O
+of	O
+three	O
+prospective	O
+non	O
+-	O
+interventional	O
+cohort	O
+studies	O
+focusing	O
+on	O
+ARDS	B-DISO
+patients	O
+from	O
+927	O
+intensive	O
+care	O
+units	O
+(	O
+ICUs	O
+)	O
+in	O
+40	O
+countries	O
+.	O
+
+Although	O
+IPEC	O
+-	O
+J2	O
+cells	B-COMP
+responded	O
+to	O
+both	O
+IFN	B-PRGE
+-	I-PRGE
+alpha	I-PRGE
+and	O
+lambda	O
+,	O
+transcriptional	B-PROC
+profiling	O
+of	O
+ISGs	O
+(	O
+specifically	O
+ISG15	B-PRGE
+,	O
+OASL	B-PRGE
+,	O
+MxA	B-PRGE
+,	O
+and	O
+IFITMs	O
+)	O
+differed	O
+when	O
+induced	O
+by	O
+either	O
+IFN	B-PRGE
+-	I-PRGE
+alpha	I-PRGE
+or	O
+rpIFN	O
+-	O
+L	O
+.	O
+Therefore	O
+,	O
+our	O
+data	O
+provide	O
+the	O
+experimental	O
+evidence	O
+that	O
+porcine	B-PRGE
+IFN	I-PRGE
+-	I-PRGE
+L	I-PRGE
+suppresses	O
+PEDV	B-SPEC
+infection	B-DISO
+of	O
+IPEC	O
+-	O
+J2	O
+cells	B-COMP
+,	O
+which	O
+may	O
+offer	O
+a	O
+promising	O
+therapeutic	O
+for	O
+combating	O
+PED	O
+in	O
+piglets	O
+.	O
+
+ABSTRACT	O
+:	O
+The	O
+emergence	O
+of	O
+new	O
+infectious	O
+bronchitis	B-DISO
+virus	B-SPEC
+(	O
+IBV	B-SPEC
+)	O
+variants	O
+is	O
+often	O
+disastrous	O
+in	O
+the	O
+poultry	O
+industry	O
+.	O
+
+Recombination	B-PROC
+analysis	O
+revealed	O
+that	O
+three	O
+recombination	B-PROC
+events	O
+could	O
+be	O
+found	O
+in	O
+the	O
+genome	O
+of	O
+CK	O
+/	O
+CH	O
+/	O
+2010	O
+/	O
+JT	O
+-	O
+1	O
+at	O
+positions	O
+24709	O
+-	O
+365	O
+,	O
+17160	O
+-	O
+19811	O
+and	O
+21136	O
+-	O
+21770	O
+.	O
+
+All	O
+of	O
+these	O
+data	O
+demonstrated	O
+that	O
+CK	O
+/	O
+CH	O
+/	O
+2010	O
+/	O
+JT	O
+-	O
+1	O
+is	O
+a	O
+new	O
+recombinant	O
+genotype	O
+IBV	O
+with	O
+high	O
+virulence	B-PROC
+.	O
+
+Our	O
+findings	O
+suggest	O
+that	O
+the	O
+surveillance	O
+of	O
+new	O
+genotype	O
+strains	O
+of	O
+IBV	B-SPEC
+is	O
+very	O
+important	O
+for	O
+developing	O
+more	O
+effective	O
+anti	O
+-	O
+IBV	B-SPEC
+strategies	O
+.	O
+
+All	O
+polyphenols	B-CHED
+were	O
+more	O
+potent	O
+against	O
+papain	B-PRGE
+-	I-PRGE
+like	I-PRGE
+protease	I-PRGE
+(	O
+PL	O
+
+Phylogenetic	O
+analysis	O
+of	O
+the	O
+six	O
+FmoPV	O
+-	O
+positive	O
+cats	B-SPEC
+showed	O
+that	O
+the	O
+strains	O
+were	O
+grouped	O
+into	O
+cluster	O
+D	O
+and	O
+had	O
+high	O
+similarity	O
+(	O
+98	O
+.	O
+5	O
+-	O
+100	O
+%)	O
+with	O
+strains	O
+from	O
+Japan	O
+and	O
+Germany	O
+.	O
+
+The	O
+genotypes	O
+found	O
+in	O
+this	O
+study	O
+were	O
+similar	O
+to	O
+previously	O
+reported	O
+strains	O
+,	O
+indicating	O
+that	O
+circulating	O
+morbilliviruses	B-SPEC
+in	O
+Turkey	B-SPEC
+are	O
+conserved	O
+.	O
+
+We	O
+reviewed	O
+the	O
+postmortem	O
+cases	O
+of	O
+cecal	B-ANAT
+infarction	B-DISO
+in	O
+dairy	O
+calves	O
+≤	O
+30	O
+d	O
+of	O
+age	O
+that	O
+had	O
+been	O
+submitted	O
+over	O
+the	O
+course	O
+of	O
+5	O
+y	O
+to	O
+the	O
+Tulare	O
+branch	B-ANAT
+of	I-ANAT
+the	O
+California	B-SPEC
+Animal	B-SPEC
+Health	O
+and	O
+Food	O
+Safety	O
+Laboratory	O
+System	O
+.	O
+
+Cecal	B-ANAT
+infarction	B-DISO
+cases	O
+were	O
+then	O
+compared	O
+to	O
+controls	O
+using	O
+a	O
+retrospective	O
+matched	O
+case	O
+-	O
+control	O
+study	O
+design	O
+.	O
+
+TITLE	O
+:	O
+Middle	O
+east	O
+respiratory	O
+syndrome	B-DISO
+corona	B-CHED
+virus	B-SPEC
+spike	O
+glycoprotein	B-CHED
+suppresses	O
+macrophage	B-ANAT
+responses	O
+via	O
+DPP4	O
+-	O
+mediated	O
+induction	O
+of	O
+IRAK	B-PRGE
+-	I-PRGE
+M	I-PRGE
+and	O
+PPARγ	O
+.	O
+
+TITLE	O
+:	O
+One	O
+-	O
+Pot	B-DISO
+Reverse	O
+Transcriptional	B-PROC
+Loop	O
+-	O
+Mediated	O
+Isothermal	O
+Amplification	B-DISO
+(	O
+RT	O
+-	O
+LAMP	O
+)	O
+for	O
+Detecting	O
+MERS	O
+-	O
+CoV	O
+.	O
+ABSTRACT	O
+:	O
+Due	O
+to	O
+the	O
+limitation	O
+of	O
+rapid	O
+development	O
+of	O
+specific	O
+antiviral	B-CHED
+drug	I-CHED
+or	O
+vaccine	O
+for	O
+novel	O
+emerging	O
+viruses	B-SPEC
+,	O
+an	O
+accurate	O
+and	O
+rapid	O
+diagnosis	O
+is	O
+a	O
+key	O
+to	O
+manage	O
+the	O
+virus	B-SPEC
+spread	O
+.	O
+
+The	O
+most	O
+commonly	O
+detected	O
+pathogens	O
+were	O
+rhinovirus	B-SPEC
+/	O
+enterovirus	B-SPEC
+and	O
+respiratory	B-SPEC
+syncytial	I-SPEC
+virus	I-SPEC
+,	O
+and	O
+these	O
+were	O
+the	O
+only	O
+pathogens	O
+determined	O
+to	O
+play	O
+a	O
+significant	O
+role	O
+in	O
+cause	O
+of	O
+death	B-PROC
+.	O
+
+MERS	O
+-	O
+CoV	O
+vaccine	O
+forms	O
+and	O
+delivery	O
+systems	O
+,	O
+together	O
+with	O
+comparable	O
+development	O
+strategies	O
+against	O
+SARS	B-PRGE
+-	I-PRGE
+CoV	I-PRGE
+are	O
+additionally	O
+addressed	O
+.	O
+
+Expert	O
+opinion	O
+:	O
+Vaccines	O
+must	O
+be	O
+combined	O
+with	O
+delivery	O
+systems	O
+,	O
+administration	O
+routes	O
+,	O
+and	O
+adjuvants	B-CHED
+to	O
+maximize	O
+T	B-ANAT
+-	I-ANAT
+cell	I-ANAT
+responses	O
+as	O
+well	O
+as	O
+neutralizing	O
+antibody	B-PROC
+production	I-PROC
+.	O
+
+High	O
+immune	B-PROC
+responses	I-PROC
+require	O
+further	O
+study	O
+in	O
+animal	B-SPEC
+models	O
+,	O
+such	O
+as	O
+human	B-SPEC
+receptor	O
+-	O
+expressing	O
+mice	B-SPEC
+,	O
+non	O
+-	O
+human	B-SPEC
+primates	B-SPEC
+,	O
+and	O
+camels	B-SPEC
+.	O
+
+TITLE	O
+:	O
+Dynamic	O
+driving	O
+pressure	O
+associated	O
+mortality	O
+in	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+with	O
+extracorporeal	O
+membrane	O
+oxygenation	B-PROC
+.	O
+
+After	O
+ECMO	O
+initiation	O
+,	O
+tidal	O
+volume	O
+,	O
+peak	O
+inspiratory	B-PROC
+pressure	O
+and	O
+dynamic	O
+driving	O
+pressure	O
+were	O
+decreased	O
+,	O
+while	O
+positive	O
+end	B-PROC
+-	I-PROC
+expiratory	I-PROC
+pressure	O
+levels	O
+were	O
+relative	O
+maintained	O
+.	O
+
+For	O
+severe	O
+ARDS	B-DISO
+patients	O
+receiving	O
+ECMO	O
+,	O
+immunocompromised	O
+status	O
+,	O
+APACHE	O
+II	O
+score	O
+and	O
+the	O
+duration	O
+of	O
+ARDS	B-DISO
+before	O
+ECMO	O
+initiation	O
+were	O
+significantly	O
+associated	O
+with	O
+ICU	O
+survival	O
+.	O
+
+RESULTS	O
+:	O
+A	O
+total	O
+of	O
+158	O
+severe	O
+ARDS	B-DISO
+patients	O
+received	O
+ECMO	O
+were	O
+finally	O
+analyzed	O
+.	O
+
+ABSTRACT	O
+:	O
+Nasal	B-ANAT
+continuous	O
+positive	O
+airway	B-ANAT
+pressure	O
+(	O
+nCPAP	O
+)	O
+is	O
+currently	O
+the	O
+gold	B-CHED
+standard	O
+for	O
+respiratory	O
+support	O
+for	O
+moderate	O
+to	O
+severe	O
+acute	B-DISO
+viral	I-DISO
+bronchiolitis	I-DISO
+(	O
+AVB	O
+).	O
+
+Although	O
+oxygen	B-CHED
+delivery	O
+via	O
+high	O
+flow	O
+nasal	B-ANAT
+cannula	B-SPEC
+(	O
+HFNC	O
+)	O
+is	O
+increasingly	O
+used	O
+,	O
+evidence	O
+of	O
+its	O
+efficacy	O
+and	O
+safety	O
+is	O
+lacking	O
+in	O
+infants	O
+.	O
+
+To	O
+examine	O
+this	O
+question	O
+,	O
+we	O
+used	O
+4	O
+cell	B-COMP
+types	O
+:	O
+human	B-SPEC
+immature	O
+dendritic	B-ANAT
+cells	B-COMP
+and	O
+NIH3T3	O
+cells	B-COMP
+expressing	O
+either	O
+wild	O
+-	O
+type	O
+DC	O
+-	O
+SIGN	O
+or	O
+2	O
+internalization	O
+-	O
+deficient	O
+DC	O
+-	O
+SIGN	O
+mutants	O
+,	O
+in	O
+which	O
+either	O
+the	O
+3	O
+cytoplasmic	B-COMP
+internalization	O
+motifs	O
+are	O
+silenced	O
+by	O
+alanine	B-CHED
+substitutions	O
+or	O
+the	O
+cytoplasmic	B-ANAT
+region	I-ANAT
+is	O
+truncated	O
+.	O
+
+Moreover	O
+,	O
+all	O
+3	O
+DC	O
+-	O
+SIGN	O
+molecules	O
+on	O
+NIH3T3	O
+cells	B-COMP
+supported	O
+cell	B-COMP
+infection	B-DISO
+.	O
+
+TITLE	O
+:	O
+Impact	O
+of	O
+thrombosis	B-DISO
+on	O
+pulmonary	B-ANAT
+endothelial	B-ANAT
+injury	O
+and	O
+repair	B-PROC
+following	O
+sepsis	B-DISO
+.	O
+
+These	O
+patients	O
+were	O
+hospitalized	O
+with	O
+acute	O
+febrile	B-PROC
+respiratory	O
+illness	O
+,	O
+initially	O
+managed	O
+as	O
+potential	O
+MERS	O
+-	O
+CoV	O
+infections	B-DISO
+,	O
+but	O
+were	O
+eventually	O
+diagnosed	O
+with	O
+influenza	B-DISO
+.	O
+
+We	O
+highlight	O
+the	O
+significant	O
+role	O
+that	O
+respiratory	O
+viruses	B-SPEC
+play	O
+in	O
+CF	O
+lung	B-DISO
+disease	I-DISO
+and	O
+argue	O
+that	O
+these	O
+pathogens	O
+represent	O
+an	O
+under	O
+-	O
+exploited	O
+target	O
+in	O
+the	O
+battle	O
+to	O
+control	O
+patients	O
+'	O
+symptoms	O
+and	O
+disease	B-DISO
+progression	I-DISO
+.	O
+
+This	O
+virus	B-SPEC
+was	O
+first	O
+isolated	O
+from	O
+a	O
+patient	O
+who	O
+died	B-PROC
+from	O
+severe	O
+respiratory	O
+illness	O
+in	O
+June	O
+2012	O
+in	O
+Jeddah	O
+,	O
+Kingdom	B-SPEC
+of	O
+Saudi	O
+Arabia	O
+.	O
+
+-	O
+The	O
+Impact	O
+Infectious	B-DISO
+Disease	I-DISO
+has	O
+on	O
+the	O
+Health	O
+of	O
+Paramedics	O
+:	O
+A	O
+Scoping	O
+Review	O
+.	O
+
+Contraction	B-DISO
+of	O
+infectious	B-DISO
+diseases	I-DISO
+is	O
+generally	O
+low	O
+;	O
+exceptions	O
+to	O
+this	O
+are	O
+MRSA	B-DISO
+colonization	O
+,	O
+influenza	B-DISO
+,	O
+and	O
+SARS	B-DISO
+.	O
+
+While	O
+the	O
+enzymatic	B-PROC
+activity	I-PROC
+and	O
+crystal	B-ANAT
+structure	O
+of	O
+nsp15	O
+are	O
+well	O
+defined	O
+,	O
+its	O
+role	O
+in	O
+replication	O
+remains	O
+elusive	O
+.	O
+
+Finally	O
+,	O
+we	O
+found	O
+that	O
+nsp15	O
+interacted	O
+with	O
+RTC	O
+-	O
+associated	O
+proteins	B-CHED
+nsp8	O
+and	O
+nsp12	O
+during	O
+infection	B-DISO
+,	O
+and	O
+this	O
+interaction	O
+was	O
+RNA	O
+independent	O
+.	O
+
+We	O
+set	O
+out	O
+to	O
+determine	O
+the	O
+contribution	O
+of	O
+viruses	B-SPEC
+in	O
+the	O
+causation	O
+of	O
+hospitalized	O
+patients	O
+with	O
+AECOPD	O
+.	O
+
+Our	O
+data	O
+calls	O
+for	O
+prompt	O
+investigation	O
+during	O
+an	O
+exacerbation	O
+for	O
+viruses	B-SPEC
+to	O
+obviate	O
+inappropriate	O
+antibiotic	B-CHED
+use	O
+and	O
+institute	O
+antiviral	B-CHED
+therapy	O
+in	O
+viral	B-DISO
+disease	I-DISO
+amenable	O
+to	O
+antiviral	B-CHED
+therapy	O
+.	O
+
+These	O
+two	O
+diagnoses	O
+should	O
+be	O
+promptly	O
+investigated	O
+and	O
+systematically	O
+treated	O
+in	O
+lung	O
+transplant	B-ANAT
+recipients	O
+.	O
+
+TITLE	O
+:	O
+Neurovirulent	B-PRGE
+Murine	I-PRGE
+Coronavirus	I-PRGE
+JHM	I-PRGE
+.	I-PRGE
+SD	I-PRGE
+Uses	I-PRGE
+Cellular	B-COMP
+Zinc	B-CHED
+Metalloproteases	I-PRGE
+for	O
+Virus	B-SPEC
+Entry	O
+and	O
+Cell	O
+-	O
+Cell	B-COMP
+Fusion	O
+.	O
+
+ABSTRACT	O
+:	O
+The	O
+coronavirus	B-SPEC
+(	O
+CoV	O
+)	O
+S	O
+protein	B-CHED
+requires	O
+cleavage	B-PROC
+by	O
+host	B-COMP
+cell	I-COMP
+proteases	O
+to	O
+mediate	O
+virus	B-SPEC
+-	O
+cell	B-COMP
+and	O
+cell	B-PROC
+-	I-PROC
+cell	B-COMP
+fusion	I-PROC
+.	O
+
+Suppression	B-DISO
+of	O
+virus	B-SPEC
+by	O
+metalloprotease	B-PRGE
+inhibition	B-PROC
+varied	O
+among	O
+tested	O
+cell	B-ANAT
+lines	I-ANAT
+and	O
+MHV	B-SPEC
+S	O
+proteins	B-CHED
+,	O
+suggesting	O
+a	O
+role	O
+for	O
+metalloprotease	B-PRGE
+use	O
+in	O
+strain	O
+-	O
+dependent	O
+tropism	B-PROC
+.	O
+
+We	O
+conclude	O
+that	O
+zinc	B-PRGE
+metalloproteases	I-PRGE
+must	O
+be	O
+considered	O
+potential	O
+contributors	O
+to	O
+coronavirus	B-SPEC
+fusion	O
+.	O
+
+Cases	O
+were	O
+analysed	O
+for	O
+general	O
+characteristics	O
+,	O
+exposure	O
+source	O
+,	O
+timeline	O
+and	O
+infection	B-DISO
+generation	O
+.	O
+
+Compounds	O
+2	O
+,	O
+12	O
+,	O
+and	O
+17	O
+were	O
+selected	O
+and	O
+investigated	O
+for	O
+their	O
+inhibition	B-PROC
+of	O
+proteins	B-CHED
+required	O
+for	O
+PEDV	B-SPEC
+replication	O
+.	O
+
+While	O
+prior	O
+meta	B-SPEC
+-	O
+analyses	O
+suggested	O
+benefit	O
+for	O
+HFOV	O
+,	O
+updated	O
+systematic	O
+reviews	O
+published	O
+this	O
+year	O
+,	O
+which	O
+include	O
+two	O
+large	O
+recent	O
+clinical	O
+trials	O
+,	O
+now	O
+show	O
+no	O
+statistically	O
+significant	O
+impact	O
+of	O
+HFOV	O
+on	O
+mortality	O
+in	O
+adults	O
+with	O
+ARDS	B-DISO
+.	O
+
+It	O
+is	O
+possible	O
+that	O
+HFOV	O
+would	O
+be	O
+safer	O
+and	O
+more	O
+effective	O
+with	O
+a	O
+more	O
+individualized	O
+approach	O
+to	O
+setting	O
+mean	O
+airway	B-ANAT
+pressure	O
+(	O
+mPaw	O
+).	O
+
+TITLE	O
+:	O
+Early	O
+endonuclease	O
+-	O
+mediated	O
+evasion	O
+of	O
+RNA	O
+sensing	O
+ensures	O
+efficient	O
+coronavirus	B-SPEC
+replication	O
+.	O
+
+The	O
+advent	O
+of	O
+new	O
+diagnostic	O
+technologies	O
+,	O
+particularly	O
+multiplex	O
+reverse	B-PROC
+transcription	I-PROC
+polymerase	O
+chain	O
+reaction	O
+,	O
+have	O
+increased	O
+the	O
+recognition	O
+of	O
+viral	O
+respiratory	B-DISO
+infections	I-DISO
+in	O
+critically	B-DISO
+ill	I-DISO
+adults	O
+.	O
+
+The	O
+transmission	O
+route	O
+and	O
+the	O
+possibility	O
+of	O
+other	O
+intermediary	O
+animal	B-SPEC
+sources	O
+remain	O
+uncertain	O
+among	O
+many	O
+sporadic	O
+primary	O
+cases	O
+.	O
+
+Clinical	O
+trial	O
+options	O
+for	O
+MERS	O
+-	O
+CoV	O
+infection	B-DISO
+include	O
+monotherapy	O
+and	O
+combination	O
+therapy	O
+.	O
+
+Acute	O
+Physiology	O
+and	O
+Chronic	O
+Health	O
+Evaluation	O
+(	O
+APACHE	O
+)	O
+scores	O
+and	O
+several	O
+plasma	B-ANAT
+biological	O
+markers	O
+have	O
+been	O
+identified	O
+to	O
+predict	O
+the	O
+death	B-PROC
+or	O
+treatment	O
+outcome	O
+of	O
+sepsis	B-DISO
+induced	O
+ALI	O
+.	O
+
+The	O
+relative	O
+plasma	B-ANAT
+miR	O
+-	O
+155	O
+and	O
+miR	O
+-	O
+146a	O
+concentrations	O
+were	O
+significantly	O
+increased	O
+in	O
+severe	B-DISO
+sepsis	I-DISO
+and	O
+sepsis	B-DISO
+-	O
+induced	O
+cases	O
+of	O
+ALI	O
+,	O
+compared	O
+with	O
+control	O
+subjects	O
+.	O
+
+Primary	O
+duodenal	B-DISO
+ulcers	I-DISO
+are	O
+rare	O
+in	O
+children	O
+but	O
+stress	O
+induced	O
+ulceration	B-DISO
+in	O
+stomach	B-ANAT
+occurs	O
+more	O
+often	O
+in	O
+neonatal	O
+period	O
+due	O
+to	O
+birth	B-DISO
+asphyxia	I-DISO
+,	O
+prolonged	B-DISO
+labour	I-DISO
+,	O
+cesarean	O
+deliveries	O
+,	O
+instrumentations	O
+,	O
+respiratory	B-DISO
+distress	I-DISO
+syndrome	I-DISO
+and	O
+sepsis	B-DISO
+.	O
+
+We	O
+report	O
+a	O
+case	O
+of	O
+a	O
+neonate	O
+with	O
+stress	O
+induced	O
+gastric	B-DISO
+bleeding	I-DISO
+following	O
+birth	B-DISO
+asphyxia	I-DISO
+who	O
+presented	O
+with	O
+massive	B-DISO
+gastrointestinal	I-DISO
+bleed	I-DISO
+manifesting	O
+as	O
+hematemesis	B-DISO
+and	O
+massive	O
+rectal	B-DISO
+bleeding	I-DISO
+.	O
+
+ABSTRACT	O
+:	O
+Postpneumonectomy	O
+acute	O
+respiratory	O
+distress	O
+syndrome	O
+(	O
+ppARDS	O
+)	O
+is	O
+a	O
+life	O
+-	O
+threatening	O
+condition	B-DISO
+with	O
+a	O
+disastrous	O
+prognosis	O
+.	O
+
+In	O
+all	O
+nidoviruses	B-SPEC
+,	O
+the	O
+C	O
+-	O
+terminal	O
+RdRp	B-FUNC
+domain	O
+is	O
+linked	O
+to	O
+a	O
+conserved	O
+N	O
+-	O
+terminal	O
+domain	O
+,	O
+which	O
+has	O
+been	O
+coined	O
+NiRAN	O
+(	O
+nidovirus	B-SPEC
+RdRp	B-FUNC
+-	O
+associated	O
+nucleotidyl	B-PRGE
+transferase	I-PRGE
+).	O
+
+Understanding	O
+RdRp	B-FUNC
+behaviour	B-PROC
+and	O
+interactions	O
+during	O
+RNA	B-PROC
+synthesis	I-PROC
+and	O
+subsequent	O
+processing	O
+will	O
+be	O
+key	O
+to	O
+rationalising	O
+the	O
+evolutionary	O
+success	O
+of	O
+nidoviruses	B-SPEC
+and	O
+the	O
+development	B-PROC
+of	O
+antiviral	B-CHED
+strategies	O
+.	O
+
+In	O
+our	O
+studies	O
+,	O
+we	O
+found	O
+that	O
+glycyrrhizin	B-CHED
+,	O
+the	O
+major	O
+component	O
+of	O
+licorice	B-SPEC
+root	B-ANAT
+extracts	O
+,	O
+could	O
+moderately	O
+inhibit	O
+PEDV	B-SPEC
+infection	B-DISO
+in	O
+Vero	B-ANAT
+cells	I-ANAT
+,	O
+when	O
+analyzed	O
+by	O
+western	O
+blot	O
+,	O
+qRT	O
+-	O
+PCR	O
+and	O
+a	O
+plaque	B-DISO
+formation	B-PROC
+assay	O
+.	O
+
+Pen	O
+feed	O
+intake	O
+and	O
+BW	O
+were	O
+recorded	O
+on	O
+dpi	B-PRGE
+2	I-PRGE
+,	O
+5	O
+,	O
+7	O
+,	O
+and	O
+weekly	O
+thereafter	O
+until	O
+dpi	O
+42	O
+.	O
+
+Control	O
+pigs	B-SPEC
+remained	O
+negative	O
+for	O
+PEDV	B-SPEC
+and	O
+PDCoV	O
+throughout	O
+the	O
+experiment	O
+.	O
+
+This	O
+study	O
+provides	O
+further	O
+insight	O
+into	O
+the	O
+longitudinal	O
+impact	O
+swine	B-SPEC
+enteric	O
+coronaviruses	O
+have	O
+on	O
+growing	O
+pigs	B-SPEC
+.	O
+
+ABSTRACT	O
+:	O
+Immunodeficiency	B-DISO
+is	O
+both	O
+a	O
+preexisting	O
+condition	B-DISO
+and	O
+a	O
+risk	O
+factor	O
+for	O
+mortality	O
+in	O
+pediatric	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+.	O
+
+Univariable	O
+logistic	O
+regression	O
+evaluated	O
+the	O
+association	O
+between	O
+pediatric	O
+acute	O
+respiratory	O
+distress	O
+syndrome	O
+and	O
+PICU	B-SPEC
+mortality	O
+.	O
+
+Nonsurvivors	O
+were	O
+more	O
+likely	O
+to	O
+have	O
+multiple	O
+consecutive	O
+days	O
+at	O
+moderate	O
+and	O
+severe	O
+pediatric	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+(	O
+p	O
+<	O
+0	O
+.	O
+001	O
+).	O
+
+Length	O
+of	O
+invasive	O
+mechanical	O
+ventilation	O
+,	O
+length	O
+of	O
+PICU	B-SPEC
+stay	O
+,	O
+and	O
+mortality	O
+increased	O
+as	O
+the	O
+severity	O
+of	O
+pediatric	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+worsened	O
+.	O
+
+During	O
+simulations	O
+,	O
+25	O
+of	O
+27	O
+(	O
+92	O
+.	O
+5	O
+%)	O
+students	O
+had	O
+one	O
+or	O
+more	O
+lapses	O
+in	O
+technique	O
+and	O
+12	O
+(	O
+44	O
+%)	O
+contaminated	O
+their	O
+skin	B-ANAT
+with	O
+fluorescent	O
+lotion	O
+.	O
+
+For	O
+100	O
+residents	O
+,	O
+fellows	O
+and	O
+attending	O
+physicians	O
+representing	O
+67	O
+different	O
+medical	O
+schools	O
+,	O
+only	O
+53	O
+%	O
+reported	O
+receiving	O
+training	O
+in	O
+use	O
+of	O
+PPE	B-CHED
+and	O
+only	O
+39	O
+%	O
+selected	O
+correct	O
+donning	O
+and	O
+doffing	O
+sequence	O
+.	O
+
+The	O
+patient	O
+developed	O
+a	O
+severe	O
+acute	O
+distress	B-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+which	O
+was	O
+successfully	O
+supported	O
+by	O
+extracorporeal	O
+membrane	B-COMP
+oxygenation	B-PROC
+and	O
+treated	O
+with	O
+antiviral	B-CHED
+therapy	O
+.	O
+
+The	O
+survival	O
+rate	O
+of	O
+the	O
+ECMO	O
+-	O
+transport	B-PROC
+group	O
+was	O
+comparable	O
+to	O
+the	O
+conventional	O
+transport	B-PROC
+or	O
+the	O
+non	O
+-	O
+transport	B-PROC
+group	O
+(	O
+both	O
+p	O
+=	O
+1	O
+.	O
+000	O
+).	O
+
+A	O
+cross	O
+-	O
+sectional	O
+survey	O
+was	O
+conducted	O
+using	O
+the	O
+Gulf	O
+Indicators	O
+(	O
+GI	O
+)	O
+smartphone	O
+app	B-CHED
+among	O
+people	O
+in	O
+the	O
+six	O
+GCC	O
+countries	O
+,	O
+namely	O
+Saudi	O
+Arabia	O
+,	O
+Kuwait	O
+,	O
+the	O
+United	O
+Arab	O
+Emirates	O
+,	O
+Qatar	O
+,	O
+Bahrain	O
+,	O
+and	O
+Oman	O
+.	O
+
+ABSTRACT	O
+:	O
+The	O
+WHO	O
+Consensus	O
+Document	O
+on	O
+the	O
+epidemiology	O
+of	O
+the	O
+SARS	B-DISO
+epidemic	O
+in	O
+2003	O
+,	O
+included	O
+a	O
+report	O
+on	O
+a	O
+concentrated	O
+outbreak	O
+in	O
+one	O
+Hong	O
+Kong	O
+housing	O
+block	O
+which	O
+was	O
+considered	O
+a	O
+'	O
+super	O
+-	O
+spreading	O
+event	O
+'.	O
+
+A	O
+sanitary	O
+plumbing	O
+system	O
+was	O
+built	O
+,	O
+representing	O
+two	O
+floors	O
+of	O
+a	O
+building	O
+,	O
+with	O
+simulated	O
+toilet	O
+flushes	B-DISO
+on	O
+the	O
+lower	O
+floor	O
+and	O
+a	O
+sterile	B-DISO
+chamber	B-ANAT
+with	O
+extractor	O
+fan	O
+on	O
+the	O
+floor	O
+above	O
+.	O
+
+Empty	O
+U	O
+-	O
+traps	B-DISO
+allowed	O
+aerosolised	O
+pathogens	O
+to	O
+enter	O
+the	O
+chamber	B-ANAT
+,	O
+encouraging	O
+cross	O
+-	O
+transmission	O
+.	O
+
+The	O
+aim	O
+of	O
+this	O
+study	O
+was	O
+to	O
+determine	O
+if	O
+the	O
+lung	B-ANAT
+inflammatory	B-DISO
+response	I-DISO
+to	O
+
+ABSTRACT	O
+:	O
+The	O
+objective	O
+of	O
+this	O
+retrospective	O
+cohort	O
+study	O
+was	O
+to	O
+assess	O
+the	O
+impact	O
+of	O
+implementation	O
+of	O
+different	O
+levels	O
+of	O
+infection	B-DISO
+prevention	O
+and	O
+control	O
+(	O
+IPC	B-CHED
+)	O
+measures	O
+during	O
+an	O
+outbreak	O
+of	O
+Middle	O
+East	O
+respiratory	O
+syndrome	B-DISO
+(	O
+MERS	O
+)	O
+in	O
+a	O
+large	O
+tertiary	O
+hospital	O
+in	O
+Saudi	O
+Arabia	O
+.	O
+
+Rapid	O
+response	O
+teams	O
+conducted	O
+repeated	O
+assessments	O
+of	O
+IPC	B-CHED
+and	O
+monitored	O
+implementation	O
+of	O
+corrective	O
+measures	O
+using	O
+a	O
+detailed	O
+structured	O
+checklist	O
+.	O
+
+The	O
+SAR	B-CHED
+/	O
+10	O
+,	O
+000	O
+dropped	O
+from	O
+75	O
+(	O
+95	O
+%	O
+confidence	O
+interval	O
+[	O
+CI	O
+],	O
+55	O
+-	O
+99	O
+)	O
+in	O
+phase	O
+I	O
+to	O
+29	O
+(	O
+95	O
+%	O
+CI	O
+,	O
+17	O
+-	O
+46	O
+)	O
+and	O
+3	O
+(	O
+95	O
+%	O
+CI	O
+,	O
+0	O
+-	O
+17	O
+)	O
+in	O
+phases	O
+II	O
+and	O
+III	O
+,	O
+respectively	O
+.	O
+
+ABSTRACT	O
+:	O
+Middle	O
+East	O
+Respiratory	O
+Syndrome	O
+(	O
+MERS	O
+)	O
+is	O
+a	O
+zoonotic	O
+viral	B-DISO
+disease	I-DISO
+that	O
+can	O
+be	O
+transmitted	B-DISO
+from	O
+dromedaries	B-SPEC
+to	O
+human	B-SPEC
+beings	O
+.	O
+
+Although	O
+MERS	O
+has	O
+been	O
+associated	O
+with	O
+30	O
+%	O
+case	O
+fatality	O
+in	O
+human	B-SPEC
+beings	O
+,	O
+MERS	O
+coronavirus	B-SPEC
+(	O
+MERS	O
+-	O
+CoV	O
+)	O
+infection	B-DISO
+in	O
+dromedaries	B-SPEC
+is	O
+usually	O
+asymptomatic	O
+.	O
+
+No	O
+MERS	O
+-	O
+CoV	O
+or	O
+antibodies	B-COMP
+against	O
+the	O
+virus	B-SPEC
+have	O
+been	O
+detected	O
+in	O
+camelids	O
+other	O
+than	O
+dromedaries	B-SPEC
+.	O
+
+A	O
+total	O
+of	O
+504	O
+/	O
+5247	O
+horses	B-SPEC
+(	O
+9	O
+.	O
+6	O
+%)	O
+horses	B-SPEC
+tested	O
+seropositive	O
+.	O
+
+Survival	O
+to	O
+discharge	B-ANAT
+was	O
+58	O
+%	O
+for	O
+VV	O
+ECMO	O
+in	O
+contrast	O
+to	O
+43	O
+%	O
+for	O
+VA	O
+ECMO	O
+(	O
+p	O
+=	O
+0	O
+.	O
+002	O
+).	O
+
+ABSTRACT	O
+:	O
+Coronaviruses	O
+(	O
+CoVs	O
+)	O
+are	O
+large	O
+ribonucleic	B-CHED
+acid	I-CHED
+(	O
+RNA	O
+)	O
+viruses	B-SPEC
+causing	O
+primarily	O
+respiratory	B-DISO
+disease	I-DISO
+in	O
+humans	B-SPEC
+.	O
+
+With	O
+increasing	O
+numbers	O
+of	O
+infections	B-DISO
+and	O
+deaths	B-PROC
+from	O
+MERS	O
+-	O
+CoV	O
+,	O
+development	B-PROC
+of	O
+a	O
+rapid	O
+and	O
+reliable	O
+kit	B-FUNC
+was	O
+crucial	O
+to	O
+prevent	O
+further	O
+spread	O
+of	O
+MERS	O
+-	O
+CoV	O
+.	O
+In	O
+this	O
+study	O
+,	O
+we	O
+present	O
+two	O
+real	O
+-	O
+time	O
+reverse	O
+-	O
+transcription	B-PROC
+polymerase	O
+chain	O
+reaction	O
+(	O
+rRT	O
+-	O
+PCR	O
+)	O
+assays	O
+for	O
+in	O
+-	O
+house	O
+rapid	O
+and	O
+sensitive	O
+diagnostic	O
+testing	O
+of	O
+MERS	O
+-	O
+CoV	O
+,	O
+detecting	O
+the	O
+regions	O
+upstream	O
+of	O
+the	O
+envelope	B-COMP
+gene	O
+(	O
+upE	O
+)	O
+and	O
+open	O
+reading	O
+frame	O
+(	O
+ORF	O
+)	O
+1b	O
+,	O
+respectively	O
+,	O
+for	O
+initial	O
+screening	O
+and	O
+final	O
+confirmation	O
+of	O
+MERS	O
+-	O
+CoV	O
+infection	B-DISO
+,	O
+as	O
+recommended	O
+by	O
+the	O
+world	O
+health	O
+organization	O
+(	O
+WHO	O
+).	O
+
+ABSTRACT	O
+:	O
+Human	O
+coronaviruses	O
+(	O
+HCoV	O
+)	O
+are	O
+RNA	O
+viruses	B-SPEC
+that	O
+cause	O
+respiratory	B-DISO
+tract	I-DISO
+infections	I-DISO
+with	O
+viral	B-PROC
+replication	I-PROC
+of	O
+limited	O
+duration	O
+.	O
+
+The	O
+rate	O
+of	O
+nonsynonymous	O
+mutations	O
+was	O
+higher	O
+in	O
+the	O
+HCoV	B-SPEC
+-	I-SPEC
+OC43	I-SPEC
+isolates	O
+than	O
+in	O
+hepatitis	B-PATH
+C	I-PATH
+(	O
+HCV	B-SPEC
+)	O
+virus	B-SPEC
+genotype	O
+1a	O
+isolates	O
+analyzed	O
+for	O
+comparison	O
+in	O
+this	O
+study	O
+.	O
+
+Acute	B-DISO
+necrotizing	I-DISO
+pancreatitis	I-DISO
+commonly	O
+presents	O
+as	O
+pancreatic	B-DISO
+abscess	I-DISO
+occasionally	O
+with	O
+systemic	O
+complications	O
+.	O
+
+A	O
+computerized	O
+tomography	O
+(	O
+CT	O
+)	O
+scan	O
+confirmed	O
+necrotizing	B-DISO
+pancreatitis	I-DISO
+with	O
+multiple	B-DISO
+abscesses	I-DISO
+spreading	O
+bilaterally	O
+in	O
+the	O
+pelvic	B-ANAT
+cavity	I-ANAT
+.	O
+
+TITLE	O
+:	O
+Mental	O
+health	O
+status	O
+of	O
+people	O
+isolated	O
+due	O
+to	O
+Middle	O
+East	O
+Respiratory	O
+Syndrome	B-DISO
+.	O
+
+Risk	O
+factors	O
+for	O
+experiencing	O
+anxiety	O
+symptoms	O
+and	O
+anger	O
+at	O
+four	O
+to	O
+six	O
+months	O
+after	O
+release	B-PATH
+included	O
+symptoms	O
+related	O
+to	O
+MERS	O
+during	O
+isolation	O
+,	O
+inadequate	O
+supplies	O
+(	O
+food	O
+,	O
+clothes	O
+,	O
+accommodation	O
+),	O
+social	O
+networking	O
+activities	O
+(	O
+email	O
+,	O
+text	O
+,	O
+Internet	O
+),	O
+history	O
+of	O
+psychiatric	O
+illnesses	O
+,	O
+and	O
+financial	O
+loss	O
+.	O
+
+In	O
+the	O
+second	O
+experiment	O
+,	O
+another	O
+two	O
+groups	O
+were	O
+established	O
+by	O
+transfusion	O
+with	O
+either	O
+mtDNA	B-COMP
+(	O
+mtDNA	B-COMP
+group	O
+)	O
+or	O
+phosphate	B-CHED
+-	O
+buffered	O
+saline	O
+(	O
+phosphate	B-CHED
+-	O
+buffered	O
+saline	O
+group	O
+).	O
+
+ABSTRACT	O
+:	O
+Avian	B-DISO
+infectious	I-DISO
+bronchitis	I-DISO
+virus	B-SPEC
+(	O
+IBV	B-SPEC
+)	O
+primarily	O
+replicates	O
+in	O
+epithelial	B-ANAT
+cells	I-ANAT
+of	O
+the	O
+upper	B-ANAT
+respiratory	I-ANAT
+tract	I-ANAT
+of	O
+chickens	B-SPEC
+,	O
+inducing	O
+both	O
+morphological	O
+and	O
+immune	O
+modulatory	O
+changes	O
+.	O
+
+This	O
+study	O
+compared	O
+the	O
+expression	B-PROC
+profile	O
+of	O
+genes	O
+related	O
+to	O
+immune	B-PROC
+responses	I-PROC
+in	O
+tracheal	O
+samples	O
+after	O
+challenge	O
+with	O
+two	O
+Brazilian	O
+field	O
+isolates	O
+(	O
+A	O
+and	O
+B	O
+)	O
+of	O
+IBV	B-SPEC
+from	O
+the	O
+same	O
+genotype	O
+,	O
+associating	O
+these	O
+responses	O
+with	O
+viral	B-PROC
+replication	I-PROC
+and	O
+with	O
+pathological	O
+changes	O
+in	O
+trachea	B-DISO
+and	O
+kidney	B-ANAT
+.	O
+
+We	O
+detected	O
+a	O
+suppressive	O
+effect	O
+on	O
+the	O
+early	O
+activation	O
+of	O
+TLR7	B-PRGE
+pathway	B-PROC
+,	O
+followed	O
+by	O
+lower	O
+expression	B-PROC
+levels	O
+of	O
+inflammatory	O
+related	O
+genes	O
+induced	O
+by	O
+challenge	O
+with	O
+the	O
+IBV	B-SPEC
+B	O
+isolate	O
+when	O
+compared	O
+to	O
+the	O
+challenge	O
+with	O
+to	O
+the	O
+IBV	O
+A	O
+isolate	O
+.	O
+
+TITLE	O
+:	O
+Doxycycline	B-CHED
+Induces	O
+Mitophagy	B-PROC
+and	O
+Suppresses	O
+Production	O
+of	O
+Interferon	B-PRGE
+-	I-PRGE
+β	I-PRGE
+in	O
+IPEC	O
+-	O
+J2	O
+Cells	B-COMP
+.	O
+
+ABSTRACT	O
+:	O
+The	O
+delta	O
+total	O
+nucleated	O
+cells	B-COMP
+(	O
+ΔTNC	O
+)	O
+measurement	O
+with	O
+the	O
+Sysmex	O
+XT	O
+-	O
+2000iV	O
+(	O
+Sysmex	O
+Europe	O
+,	O
+Norderstedt	O
+,	O
+Germany	O
+)	O
+has	O
+high	O
+diagnostic	O
+accuracy	O
+on	O
+effusions	B-DISO
+in	O
+feline	B-DISO
+infectious	I-DISO
+peritonitis	I-DISO
+(	O
+FIP	B-DISO
+)	O
+cases	O
+,	O
+but	O
+the	O
+test	O
+can	O
+be	O
+performed	O
+only	O
+on	O
+fresh	B-ANAT
+samples	O
+.	O
+
+The	O
+influence	O
+of	O
+the	O
+protein	B-CHED
+content	O
+,	O
+number	O
+of	O
+added	O
+cells	B-COMP
+,	O
+and	O
+magnitude	O
+of	O
+dilution	O
+were	O
+also	O
+investigated	O
+.	O
+
+ABSTRACT	O
+:	O
+Inborn	O
+errors	O
+of	O
+cobalamin	O
+(	O
+Cbl	B-PRGE
+)	O
+metabolism	B-PROC
+form	O
+a	O
+large	O
+group	O
+of	O
+rare	B-DISO
+diseases	I-DISO
+.	O
+
+One	O
+of	O
+these	O
+,	O
+Cbl	B-PRGE
+deficiency	I-PRGE
+type	I-PRGE
+C	I-PRGE
+(	O
+CblC	B-PRGE
+),	O
+is	O
+a	O
+well	O
+-	O
+known	O
+cause	O
+of	O
+thrombotic	B-DISO
+microangiopathy	I-DISO
+(	O
+TMA	B-CHED
+),	O
+especially	O
+in	O
+infants	O
+.	O
+
+However	O
+,	O
+there	O
+has	O
+only	O
+been	O
+a	O
+single	O
+published	O
+case	O
+of	O
+TMA	B-CHED
+associated	O
+to	O
+Cbl	B-PRGE
+deficiency	I-PRGE
+type	I-PRGE
+G	I-PRGE
+(	O
+CblG	B-PRGE
+),	O
+also	O
+known	O
+as	O
+methionine	B-DISO
+synthase	I-DISO
+deficiency	I-DISO
+(	O
+MSD	B-DISO
+).	O
+
+Further	O
+examination	O
+revealed	O
+signs	O
+of	O
+TMA	B-CHED
+,	O
+and	O
+the	O
+patient	O
+progressed	O
+to	O
+acute	B-DISO
+renal	I-DISO
+failure	I-DISO
+(	O
+ARF	B-DISO
+).	O
+
+We	O
+sought	O
+to	O
+determine	O
+the	O
+frequency	O
+,	O
+timing	O
+,	O
+and	O
+risk	O
+factors	O
+for	O
+extrapulmonary	O
+organ	B-ANAT
+dysfunction	O
+and	O
+the	O
+independent	O
+association	O
+of	O
+multiple	B-DISO
+organ	I-DISO
+dysfunction	I-DISO
+syndrome	I-DISO
+with	O
+outcomes	O
+in	O
+pediatric	O
+acute	B-DISO
+respiratory	I-DISO
+failure	I-DISO
+.	O
+
+Secondary	O
+observational	O
+analysis	O
+of	O
+the	O
+Randomized	O
+Evaluation	O
+of	O
+Sedation	B-DISO
+Titration	O
+for	O
+Respiratory	B-DISO
+Failure	I-DISO
+cluster	O
+-	O
+randomized	O
+prospective	O
+clinical	O
+trial	O
+conducted	O
+between	O
+2009	O
+and	O
+2013	O
+.	O
+
+The	O
+molecular	O
+mechanisms	O
+regulating	O
+emerging	O
+coronavirus	B-SPEC
+pathogenesis	B-DISO
+are	O
+complex	O
+and	O
+include	O
+virus	B-SPEC
+-	O
+host	B-COMP
+interactions	O
+associated	O
+with	O
+entry	O
+,	O
+replication	O
+,	O
+egress	O
+and	O
+innate	O
+immune	O
+control	O
+.	O
+
+Epigenetic	O
+modifications	O
+,	O
+such	O
+as	O
+histone	B-PATH
+modifications	I-PATH
+,	O
+DNA	B-PROC
+methylation	I-PROC
+,	O
+chromatin	B-PROC
+remodeling	I-PROC
+,	O
+and	O
+non	O
+-	O
+coding	O
+RNAs	O
+,	O
+function	O
+as	O
+important	O
+regulators	O
+that	O
+remodel	O
+host	B-COMP
+chromatin	B-COMP
+,	O
+altering	O
+host	B-COMP
+expression	B-PROC
+patterns	O
+and	O
+networks	O
+in	O
+a	O
+highly	O
+flexible	O
+manner	O
+.	O
+
+TITLE	O
+:	O
+Jumping	O
+species	B-SPEC
+-	O
+a	O
+mechanism	O
+for	O
+coronavirus	B-SPEC
+persistence	O
+and	O
+survival	O
+.	O
+
+For	O
+coronaviruses	O
+(	O
+CoVs	O
+),	O
+broad	O
+diversity	O
+exists	O
+within	O
+bat	B-ENZY
+populations	O
+and	O
+uniquely	O
+positions	O
+them	O
+to	O
+seed	O
+future	O
+emergence	O
+events	O
+.	O
+
+ABSTRACT	O
+:	O
+To	O
+evaluate	O
+the	O
+development	B-PROC
+of	O
+an	O
+extracorporeal	O
+membrane	B-COMP
+oxygenation	B-PROC
+(	O
+ECMO	O
+)	O
+program	O
+for	O
+the	O
+treatment	O
+of	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+(	O
+ARDS	B-DISO
+)	O
+in	O
+adults	O
+.	O
+
+In	O
+Saudi	O
+Arabia	O
+recent	O
+significant	O
+hospital	O
+outbreaks	O
+,	O
+including	O
+Middle	O
+East	O
+Respiratory	O
+Syndrome	B-DISO
+Coronavirus	B-SPEC
+(	O
+MERS	O
+-	O
+CoV	O
+),	O
+have	O
+resulted	O
+from	O
+lack	O
+of	O
+,	O
+or	O
+breakdown	B-DISO
+in	O
+,	O
+infection	B-DISO
+prevention	O
+and	O
+control	O
+procedures	O
+.	O
+
+TITLE	O
+:	O
+""""	O
+Your	O
+Health	O
+Essential	O
+for	O
+Your	O
+Hajj	O
+""":"	O
+Muslim	O
+pilgrims	O
+'	O
+knowledge	O
+,	O
+attitudes	O
+and	O
+practices	O
+regarding	O
+Middle	O
+East	O
+respiratory	O
+syndrome	B-DISO
+coronavirus	B-SPEC
+(	O
+MERS	O
+-	O
+CoV	O
+)	O
+during	O
+Hajj	O
+season	O
+.	O
+
+TITLE	O
+:	O
+Vaccine	O
+development	B-PROC
+for	O
+emerging	O
+virulent	O
+infectious	B-DISO
+diseases	I-DISO
+.	O
+
+TITLE	O
+:	O
+SARS	B-DISO
+-	O
+CoV	O
+-	O
+Encoded	O
+Small	B-PRGE
+RNAs	I-PRGE
+Contribute	O
+to	O
+Infection	B-DISO
+-	O
+Associated	O
+Lung	B-ANAT
+Pathology	B-DISO
+.	O
+
+TITLE	O
+:	O
+Serologic	O
+Evidence	O
+for	O
+MERS	O
+-	O
+CoV	O
+Infection	B-DISO
+in	O
+Dromedary	B-SPEC
+Camels	B-SPEC
+,	O
+Punjab	O
+,	O
+Pakistan	O
+,	O
+2012	O
+-	O
+2015	O
+.	O
+
+This	O
+study	O
+is	O
+the	O
+first	O
+to	O
+report	O
+the	O
+development	B-PROC
+of	O
+an	O
+nsp	O
+-	O
+based	O
+ELISA	O
+to	O
+detect	O
+an	O
+antibody	B-COMP
+to	O
+IBV	B-SPEC
+.	O
+
+When	O
+support	O
+with	O
+mechanical	O
+ventilation	O
+failed	O
+,	O
+extracorporeal	O
+membrane	B-COMP
+oxygenation	B-PROC
+(	O
+ECMO	O
+)	O
+was	O
+initiated	O
+.	O
+
+ECMO	O
+and	O
+mechanical	O
+ventilation	O
+were	O
+discontinued	O
+by	O
+day	O
+-	O
+7	O
+and	O
+the	O
+patient	O
+recovered	O
+with	O
+no	O
+long	O
+-	O
+term	O
+ARDS	B-DISO
+sequelae	O
+.	O
+
+TITLE	O
+:	O
+Heat	B-PROC
+shock	I-PROC
+protein	B-CHED
+70	O
+in	O
+lung	B-ANAT
+and	O
+kidney	B-ANAT
+of	O
+specific	O
+-	O
+pathogen	O
+-	O
+free	O
+chickens	B-SPEC
+is	O
+a	O
+receptor	O
+-	O
+associated	O
+protein	O
+that	O
+interacts	O
+with	O
+the	O
+binding	B-FUNC
+domain	O
+of	O
+the	O
+spike	O
+protein	B-CHED
+of	O
+infectious	B-DISO
+bronchitis	B-DISO
+virus	B-SPEC
+.	O
+
+In	O
+this	O
+study	O
+,	O
+we	O
+identified	O
+this	O
+binding	B-FUNC
+domain	O
+in	O
+a	O
+different	O
+strain	O
+,	O
+as	O
+well	O
+as	O
+the	O
+cellular	B-COMP
+proteins	B-CHED
+that	O
+interact	O
+with	O
+it	O
+.	O
+
+A	O
+total	O
+of	O
+12	O
+healthy	O
+male	O
+pigs	B-SPEC
+,	O
+weighing	O
+12	O
+±	O
+1	O
+.	O
+8	O
+kg	O
+,	O
+were	O
+randomly	O
+and	O
+equally	O
+assigned	O
+to	O
+the	O
+control	O
+and	O
+experimental	O
+groups	O
+.	O
+
+The	O
+nuclear	B-PRGE
+factor	I-PRGE
+κB	I-PRGE
+p65	I-PRGE
+protein	I-PRGE
+content	O
+of	O
+the	O
+heart	B-ANAT
+,	O
+lung	B-ANAT
+,	O
+and	O
+kidney	B-ANAT
+tissues	B-ANAT
+was	O
+also	O
+detected	O
+using	O
+western	O
+blot	O
+.	O
+
+ABSTRACT	O
+:	O
+In	O
+2012	O
+,	O
+a	O
+Dog	B-SPEC
+circovirus	B-SPEC
+(	O
+DogCV	O
+)	O
+was	O
+discovered	O
+in	O
+the	O
+USA	O
+,	O
+which	O
+was	O
+followed	O
+by	O
+further	O
+descriptions	O
+of	O
+the	O
+virus	B-SPEC
+in	O
+the	O
+USA	O
+,	O
+Italy	O
+and	O
+Germany	O
+.	O
+
+The	O
+present	O
+study	O
+is	O
+the	O
+first	O
+to	O
+examine	O
+the	O
+prevalence	O
+of	O
+DogCV	O
+in	O
+faeces	B-ANAT
+of	O
+dogs	B-SPEC
+from	O
+Germany	O
+and	O
+other	O
+European	O
+countries	O
+.	O
+
+TITLE	O
+:	O
+Comparative	O
+pathology	B-DISO
+of	O
+rhesus	B-SPEC
+macaque	I-SPEC
+and	O
+common	B-SPEC
+marmoset	I-SPEC
+animal	B-SPEC
+models	O
+with	O
+Middle	O
+East	O
+respiratory	O
+syndrome	O
+coronavirus	B-SPEC
+.	O
+
+Although	O
+Thai	O
+PEDV	B-SPEC
+have	O
+been	O
+evolved	O
+into	O
+6	O
+subgroups	O
+(	O
+TH1	B-PRGE
+-	I-PRGE
+6	I-PRGE
+),	O
+Subgroup	O
+TH1	O
+strains	O
+with	O
+the	O
+unique	O
+9	O
+nucleotides	O
+(	O
+CAA	B-PRGE
+GGG	B-CHED
+AAT	B-FUNC
+)	O
+insertion	O
+between	O
+688th	O
+-	O
+689th	O
+position	O
+of	O
+spike	O
+(	O
+changing	O
+amino	B-CHED
+acid	I-CHED
+from	O
+N	O
+to	O
+TREY	O
+)	O
+insertion	O
+has	O
+become	O
+the	O
+dominant	O
+subgroup	O
+since	O
+2014	O
+.	O
+
+TITLE	O
+:	O
+Prone	O
+positioning	O
+in	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+after	O
+abdominal	B-ANAT
+surgery	O
+:	O
+a	O
+multicenter	O
+retrospective	O
+study	O
+:	O
+SAPRONADONF	O
+(	O
+Study	O
+of	O
+Ards	O
+and	O
+PRONe	O
+position	O
+After	O
+abDOmiNal	B-ANAT
+surgery	O
+in	O
+France	O
+).	O
+
+Our	O
+aim	O
+was	O
+to	O
+investigate	O
+the	O
+prevalence	O
+of	O
+surgical	O
+complications	O
+between	O
+patients	O
+with	O
+and	O
+without	O
+prone	O
+position	O
+after	O
+abdominal	B-ANAT
+surgery	O
+.	O
+
+This	O
+study	O
+was	O
+a	O
+multicenter	O
+retrospective	O
+cohort	O
+of	O
+patients	O
+with	O
+ARDS	B-DISO
+in	O
+a	O
+context	O
+of	O
+recent	O
+abdominal	B-ANAT
+surgery	O
+.	O
+
+Primary	O
+outcome	O
+was	O
+the	O
+number	O
+of	O
+patients	O
+who	O
+had	O
+at	O
+least	O
+one	O
+surgical	O
+complication	B-DISO
+that	O
+could	O
+be	O
+induced	O
+or	O
+worsened	O
+by	O
+prone	O
+position	O
+.	O
+
+Secondary	O
+outcomes	O
+included	O
+effects	O
+of	O
+prone	O
+position	O
+on	O
+oxygenation	B-PROC
+.	O
+
+ABSTRACT	O
+:	O
+Administration	O
+of	O
+naloxone	O
+is	O
+a	O
+common	O
+treatment	O
+for	O
+opioid	O
+-	O
+dependent	O
+patients	O
+who	O
+present	O
+with	O
+respiratory	B-DISO
+depression	I-DISO
+.	O
+
+We	O
+present	O
+a	O
+20	O
+-	O
+year	O
+-	O
+old	O
+morphine	B-CHED
+-	O
+addicted	O
+man	B-CHED
+who	O
+presented	O
+with	O
+methadone	B-CHED
+-	O
+induced	O
+respiratory	B-DISO
+depression	I-DISO
+and	O
+responded	O
+safely	O
+and	O
+effectively	O
+to	O
+intravenous	O
+administration	O
+of	O
+buprenorphine	B-CHED
+.	O
+
+Buprenorphine	B-CHED
+may	O
+be	O
+a	O
+useful	O
+alternative	O
+opioid	O
+reversal	O
+agent	O
+for	O
+opioid	O
+-	O
+dependent	O
+patients	O
+.	O
+
+ABSTRACT	O
+:	O
+The	O
+Middle	O
+East	O
+respiratory	O
+syndrome	O
+coronavirus	B-SPEC
+(	O
+MERS	O
+-	O
+CoV	O
+)	O
+was	O
+first	O
+discovered	O
+in	O
+late	O
+2012	O
+and	O
+has	O
+gone	O
+on	O
+to	O
+cause	O
+over	O
+1800	O
+infections	B-DISO
+and	O
+650	O
+deaths	B-PROC
+.	O
+
+In	O
+this	O
+study	O
+,	O
+we	O
+demonstrate	O
+protection	O
+induced	O
+by	O
+vaccination	O
+with	O
+a	O
+recombinant	O
+MERS	O
+-	O
+CoV	O
+S	O
+nanoparticle	B-CHED
+vaccine	O
+and	O
+Matrix	O
+-	O
+M1	O
+adjuvant	B-CHED
+combination	O
+in	O
+mice	B-SPEC
+.	O
+
+TITLE	O
+:	O
+Comparison	O
+of	O
+Influenza	B-DISO
+Epidemiological	O
+and	O
+Virological	O
+Characteristics	O
+between	O
+Outpatients	O
+and	O
+Inpatients	O
+in	O
+Zhejiang	O
+Province	O
+,	O
+China	O
+,	O
+March	O
+2011	O
+-	O
+June	O
+2015	O
+.	O
+
+Our	O
+study	O
+use	O
+the	O
+surveillance	O
+data	O
+collected	O
+from	O
+16	O
+sentinel	O
+hospitals	O
+across	O
+Zhejiang	O
+Province	O
+during	O
+March	O
+2011	O
+through	O
+June	O
+2015	O
+,	O
+including	O
+the	O
+demographic	O
+information	O
+and	O
+respiratory	O
+specimens	O
+from	O
+influenza	B-DISO
+-	I-DISO
+like	I-DISO
+illness	I-DISO
+(	O
+ILI	O
+)	O
+patients	O
+and	O
+severe	O
+acute	O
+respiratory	O
+illness	O
+(	O
+SARI	O
+)	O
+patients	O
+.	O
+
+Acute	B-DISO
+hemorrhagic	I-DISO
+edema	I-DISO
+of	I-DISO
+infancy	I-DISO
+(	O
+AHEI	O
+)	O
+is	O
+a	O
+benign	O
+type	O
+of	O
+small	O
+-	O
+vessel	B-ANAT
+leukocytoclastic	B-DISO
+vasculitis	I-DISO
+that	O
+presents	O
+with	O
+progressive	O
+purpura	B-DISO
+and	O
+has	O
+an	O
+excellent	O
+prognosis	O
+.	O
+
+In	O
+this	O
+study	O
+,	O
+we	O
+filtered	O
+the	O
+significantly	O
+expressed	B-PROC
+genes	O
+in	O
+mouse	B-SPEC
+pneumonia	B-DISO
+using	O
+mRNA	B-CHED
+microarray	O
+analysis	O
+.	O
+
+Future	O
+directions	O
+in	O
+the	O
+diagnosis	O
+of	O
+MERS	O
+and	O
+other	O
+emerging	B-DISO
+infectious	I-DISO
+disease	I-DISO
+investigations	O
+are	O
+also	O
+highlighted	O
+.	O
+
+ABSTRACT	O
+:	O
+High	O
+-	O
+frequency	O
+oscillatory	O
+ventilation	O
+(	O
+HFOV	O
+)	O
+is	O
+theoretically	O
+beneficial	O
+for	O
+lung	B-ANAT
+protection	O
+,	O
+but	O
+the	O
+results	O
+of	O
+clinical	O
+trials	O
+are	O
+inconsistent	O
+,	O
+with	O
+study	O
+-	O
+level	O
+meta	B-SPEC
+-	O
+analyses	O
+suggesting	O
+no	O
+significant	O
+effect	O
+on	O
+mortality	O
+.	O
+
+ABSTRACT	O
+:	O
+In	O
+pediatric	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+,	O
+lung	B-ANAT
+injury	O
+is	O
+mediated	O
+by	O
+immune	O
+activation	O
+and	O
+severe	O
+inflammation	B-DISO
+.	O
+
+Detailed	O
+analysis	O
+showed	O
+that	O
+nsp5	B-PRGE
+cleaved	B-ANAT
+signal	B-PRGE
+transducer	I-PRGE
+and	I-PRGE
+activator	I-PRGE
+of	I-PRGE
+transcription	I-PRGE
+2	I-PRGE
+(	O
+STAT2	B-PRGE
+)	O
+but	O
+not	O
+Janus	B-PRGE
+kinase	I-PRGE
+1	I-PRGE
+(	O
+JAK1	B-PRGE
+),	O
+tyrosine	B-PRGE
+kinase	I-PRGE
+2	I-PRGE
+(	O
+TYK2	B-PRGE
+),	O
+STAT1	B-PRGE
+,	O
+and	O
+interferon	B-PRGE
+regulatory	I-PRGE
+factor	I-PRGE
+9	I-PRGE
+(	O
+IRF9	B-PRGE
+),	O
+key	O
+molecules	O
+of	O
+the	O
+JAK	B-PROC
+-	O
+STAT	B-PRGE
+pathway	B-PROC
+.	O
+
+This	O
+flexibility	O
+was	O
+evident	O
+in	O
+either	O
+the	O
+free	O
+form	O
+or	O
+when	O
+bound	O
+with	O
+ubiquitin	B-PROC
+.	O
+
+We	O
+derived	O
+our	O
+model	O
+using	O
+individual	O
+data	O
+from	O
+478	O
+acute	O
+respiratory	O
+distress	O
+syndrome	O
+patients	O
+and	O
+assessed	O
+its	O
+replicability	O
+in	O
+a	O
+separate	O
+cohort	O
+of	O
+300	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+patients	O
+.	O
+
+The	O
+body	B-ANAT
+mass	O
+index	O
+exceeded	O
+30	O
+kg	O
+/	O
+m2	O
+in	O
+227	O
+(	O
+4	O
+.	O
+3	O
+%)	O
+patients	O
+.	O
+
+TITLE	O
+:	O
+Sagittal	B-ANAT
+-	O
+lung	B-ANAT
+CT	O
+measurements	O
+in	O
+the	O
+evaluation	O
+of	O
+asthma	B-PATH
+-	O
+COPD	B-DISO
+overlap	B-DISO
+syndrome	I-DISO
+:	O
+a	O
+distinctive	O
+phenotype	O
+from	O
+COPD	O
+alone	O
+.	O
+
+ABSTRACT	O
+:	O
+This	O
+study	O
+aimed	O
+at	O
+investigating	O
+the	O
+capability	O
+of	O
+sagittal	B-ANAT
+-	O
+lung	B-ANAT
+computed	O
+tomography	O
+(	O
+CT	O
+)	O
+measurements	O
+in	O
+differentiating	O
+chronic	B-DISO
+obstructive	I-DISO
+pulmonary	I-DISO
+disease	I-DISO
+(	O
+COPD	B-DISO
+)	O
+and	O
+asthma	B-PATH
+-	O
+COPD	B-DISO
+overlap	B-DISO
+syndrome	I-DISO
+(	O
+ACOS	O
+).	O
+
+ABSTRACT	O
+:	O
+The	O
+potential	O
+for	O
+infection	O
+by	O
+coronaviruses	O
+(	O
+CoVs	O
+)	O
+has	O
+become	O
+a	O
+serious	O
+concern	O
+with	O
+the	O
+recent	O
+emergence	O
+of	O
+Middle	O
+East	O
+respiratory	O
+syndrome	B-DISO
+and	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+(	O
+SARS	B-DISO
+)	O
+in	O
+the	O
+human	B-SPEC
+population	O
+.	O
+
+N	B-CHED
+-	I-CHED
+Acetylcysteine	I-CHED
+(	O
+NAC	B-COMP
+)	O
+has	O
+been	O
+shown	O
+to	O
+reduce	O
+endotoxin	O
+-	O
+induced	O
+intestinal	B-ANAT
+dysfunction	O
+.	O
+
+To	O
+assess	O
+the	O
+clinical	O
+relevance	O
+of	O
+the	O
+relation	O
+between	O
+viral	O
+load	O
+,	O
+determined	O
+by	O
+cycle	O
+threshold	O
+(	O
+CT	O
+)	O
+value	O
+of	O
+real	O
+-	O
+time	O
+reverse	B-PROC
+transcription	I-PROC
+-	O
+polymerase	O
+chain	O
+reaction	O
+assays	O
+and	O
+disease	O
+severity	O
+in	O
+children	O
+with	O
+single	O
+-	O
+and	O
+multiple	O
+viral	O
+ARI	B-CHED
+.	O
+
+TITLE	O
+:	O
+Peritonsillar	B-DISO
+abscess	I-DISO
+:	O
+clinical	O
+aspects	O
+of	O
+microbiology	O
+,	O
+risk	O
+factors	O
+,	O
+and	O
+the	O
+association	O
+with	O
+parapharyngeal	O
+abscess	O
+.	O
+
+Furthermore	O
+,	O
+smoking	O
+may	O
+be	O
+associated	O
+with	O
+increased	O
+risk	O
+of	O
+peritonsillar	B-DISO
+abscess	I-DISO
+(	O
+PTA	B-DISO
+)	O
+development	B-PROC
+,	O
+although	O
+the	O
+magnitude	O
+of	O
+the	O
+association	O
+has	O
+not	O
+been	O
+estimated	O
+.	O
+
+There	O
+are	O
+three	O
+accepted	O
+methods	O
+of	O
+surgical	O
+intervension	O
+:	O
+needle	O
+aspiration	B-DISO
+,	O
+incision	B-ANAT
+and	O
+drainage	B-ANAT
+(	O
+ID	O
+),	O
+and	O
+acute	O
+tonsillectomy	O
+(	O
+á	O
+chaud	O
+).	O
+
+Culturing	O
+of	O
+PTA	B-DISO
+pus	B-CHED
+aspirates	B-ANAT
+often	O
+yields	O
+a	O
+polymicrobial	O
+mixture	B-CHED
+of	O
+aerobes	O
+and	O
+anaerobes	O
+.	O
+
+The	O
+trend	O
+towards	O
+de	O
+-	O
+escalated	O
+surgical	O
+intervention	O
+and	O
+increasing	O
+reliance	O
+on	O
+antibiotic	B-CHED
+treatment	O
+,	O
+require	O
+studies	O
+defining	O
+the	O
+significant	O
+pathogens	O
+in	O
+PTA	B-DISO
+in	O
+order	B-SPEC
+to	O
+determine	O
+optimal	O
+antibiotic	B-CHED
+regimens	O
+.	O
+
+We	O
+found	O
+increasing	O
+levels	O
+(	O
+at	O
+least	O
+two	O
+-	O
+fold	O
+)	O
+of	O
+anti	O
+-	O
+FN	O
+antibodies	B-COMP
+in	O
+eight	O
+of	O
+11	O
+FN	O
+-	O
+positive	O
+(	O
+in	O
+the	O
+tonsillar	B-ANAT
+cultures	O
+)	O
+PTA	B-DISO
+patients	O
+,	O
+which	O
+was	O
+significantly	O
+more	O
+frequent	O
+compared	O
+to	O
+none	O
+of	O
+four	O
+FN	O
+-	O
+negative	O
+PTA	B-DISO
+patients	O
+and	O
+nine	O
+of	O
+47	O
+electively	O
+tonsillectomized	O
+controls	O
+(	O
+P	O
+=	O
+0	O
+.	O
+026	O
+and	O
+P	O
+<	O
+0	O
+.	O
+001	O
+,	O
+respectively	O
+).	O
+
+However	O
+,	O
+bacteremia	B-DISO
+during	O
+elective	O
+tonsillectomy	O
+was	O
+at	O
+least	O
+as	O
+prevalent	O
+as	O
+bacteremia	B-DISO
+during	O
+quinsy	B-DISO
+tonsillectomy	O
+,	O
+which	O
+challenges	O
+the	O
+distinction	O
+made	O
+by	O
+the	O
+European	O
+Society	O
+of	O
+Cardiology	O
+between	O
+quinsy	B-DISO
+and	O
+elective	O
+tonsillectomy	O
+,	O
+namely	O
+that	O
+antibiotic	B-CHED
+prophylaxis	O
+is	O
+only	O
+recommended	O
+to	O
+patients	O
+undergoing	O
+procedures	O
+to	O
+treat	O
+an	O
+established	O
+infection	B-DISO
+(	O
+i	O
+.	O
+e	O
+.	O
+PTA	B-DISO
+).	O
+
+The	O
+development	B-PROC
+of	O
+anti	O
+-	O
+FN	O
+antibodies	B-COMP
+in	O
+FN	O
+-	O
+positive	O
+PTA	B-DISO
+patients	O
+.	O
+
+The	O
+survival	O
+time	O
+from	O
+the	O
+start	O
+of	O
+PI	O
+treatment	O
+in	O
+cats	B-SPEC
+diagnosed	O
+with	O
+dry	B-DISO
+FIP	I-DISO
+showed	O
+that	O
+of	O
+the	O
+60	O
+cats	B-SPEC
+with	O
+dry	B-DISO
+FIP	I-DISO
+treated	O
+with	O
+PI	O
+,	O
+8	O
+survived	O
+over	O
+200	O
+days	O
+,	O
+and	O
+4	O
+of	O
+60	O
+survived	O
+over	O
+300	O
+days	O
+.	O
+
+A	O
+literature	O
+search	O
+identified	O
+59	O
+cats	B-SPEC
+with	O
+non	O
+-	O
+effusive	O
+or	O
+dry	B-DISO
+FIP	I-DISO
+;	O
+no	O
+cat	O
+with	O
+only	O
+dry	B-DISO
+FIP	I-DISO
+lived	O
+longer	O
+than	O
+200	O
+days	O
+.	O
+
+The	O
+role	O
+of	O
+rhinovirus	B-SPEC
+has	O
+become	O
+predominant	O
+with	O
+respect	O
+to	O
+respiratory	B-SPEC
+syncytial	I-SPEC
+virus	I-SPEC
+.	O
+
+In	O
+addition	O
+,	O
+PDVAC	O
+has	O
+also	O
+supported	O
+vaccine	O
+development	B-PROC
+efforts	O
+against	O
+important	O
+emerging	O
+pathogens	O
+,	O
+including	O
+Middle	O
+Eastern	O
+Coronavirus	B-SPEC
+(	O
+MERS	O
+CoV	O
+)	O
+and	O
+Zika	B-SPEC
+virus	I-SPEC
+.	O
+
+TITLE	O
+:	O
+Middle	O
+East	O
+respiratory	O
+syndrome	B-DISO
+coronavirus	B-SPEC
+:	O
+review	O
+of	O
+the	O
+current	O
+situation	O
+in	O
+the	O
+world	O
+.	O
+
+The	O
+epidemiology	O
+of	O
+the	O
+infection	B-DISO
+is	O
+compatible	O
+with	O
+multiple	O
+introductions	O
+of	O
+the	O
+virus	B-SPEC
+into	O
+humans	B-SPEC
+from	O
+an	O
+animal	B-SPEC
+reservoir	O
+,	O
+probably	O
+dromedary	B-SPEC
+camels	B-SPEC
+.	O
+
+TITLE	O
+:	O
+Isolation	O
+and	O
+molecular	O
+characterisation	O
+of	O
+Halicephalobus	B-SPEC
+gingivalis	I-SPEC
+in	O
+the	O
+brain	B-ANAT
+of	O
+a	O
+horse	B-SPEC
+in	O
+Piedmont	O
+,	O
+Italy	O
+.	O
+
+At	O
+post	O
+-	O
+mortem	O
+examination	O
+no	O
+skin	B-ANAT
+lesions	O
+were	O
+observed	O
+,	O
+all	O
+organs	B-ANAT
+appeared	O
+normal	O
+on	O
+gross	O
+evaluation	O
+and	O
+only	O
+head	B-ANAT
+and	O
+blood	B-ANAT
+samples	I-ANAT
+were	O
+further	O
+investigated	O
+.	O
+
+WN	O
+surveillance	O
+can	O
+help	O
+to	O
+deepen	O
+our	O
+knowledge	O
+of	O
+horse	B-SPEC
+neurological	B-DISO
+disorders	I-DISO
+investigating	O
+their	O
+causes	O
+and	O
+incidence	O
+.	O
+
+Overexpression	B-PROC
+of	O
+occludin	B-PRGE
+in	O
+target	B-ANAT
+cells	I-ANAT
+makes	O
+them	O
+more	O
+susceptible	O
+to	O
+PEDV	B-SPEC
+infection	B-DISO
+,	O
+whereas	O
+ablation	O
+of	O
+occludin	B-PRGE
+expression	B-PROC
+by	O
+use	O
+of	O
+small	O
+interfering	O
+RNA	O
+(	O
+siRNA	O
+)	O
+in	O
+target	B-ANAT
+cells	I-ANAT
+significantly	O
+reduces	O
+their	O
+susceptibility	O
+to	O
+virus	B-DISO
+infection	I-DISO
+.	O
+
+To	O
+better	O
+understand	O
+the	O
+molecular	O
+epidemiology	O
+and	O
+genetic	O
+diversity	O
+of	O
+PEDV	B-SPEC
+field	O
+isolates	O
+,	O
+in	O
+this	O
+study	O
+,	O
+we	O
+characterised	O
+the	O
+complete	O
+genome	O
+sequence	O
+of	O
+a	O
+novel	O
+PEDV	B-SPEC
+variant	O
+JSCZ1601	O
+from	O
+a	O
+outbreak	O
+in	O
+China	O
+in	O
+2016	O
+.	O
+
+ABSTRACT	O
+:	O
+Middle	O
+East	O
+respiratory	O
+syndrome	B-DISO
+(	O
+MERS	O
+)	O
+continues	O
+to	O
+raise	O
+worldwide	O
+concerns	O
+due	O
+to	O
+its	O
+pandemic	O
+potential	O
+.	O
+
+CASE	O
+REPORT	O
+A	O
+76	O
+-	O
+year	O
+-	O
+old	O
+male	O
+presented	O
+with	O
+acute	O
+onset	O
+of	O
+diaphoresis	B-DISO
+and	O
+altered	B-DISO
+mental	I-DISO
+status	I-DISO
+.	O
+
+ABSTRACT	O
+:	O
+Open	O
+lung	B-ANAT
+strategy	O
+during	O
+ARDS	B-DISO
+aims	O
+to	O
+decrease	O
+the	O
+ventilator	O
+-	O
+induced	O
+lung	B-ANAT
+injury	O
+by	O
+minimizing	O
+the	O
+atelectrauma	O
+and	O
+stress	O
+/	O
+strain	O
+maldistribution	O
+.	O
+
+Human	B-SPEC
+rhinovirus	I-SPEC
+,	O
+respiratory	B-SPEC
+syncytial	I-SPEC
+virus	I-SPEC
+,	O
+influenza	B-SPEC
+virus	I-SPEC
+and	O
+coronavirus	B-SPEC
+have	O
+been	O
+considered	O
+as	O
+the	O
+most	O
+important	O
+respiratory	O
+pathogens	O
+and	O
+relatively	O
+little	O
+attention	O
+has	O
+been	O
+paid	O
+to	O
+the	O
+role	O
+of	O
+parainfluenza	B-DISO
+viruses	B-SPEC
+(	O
+hPIVs	O
+).	O
+
+Alternative	O
+ventilator	O
+strategies	O
+include	O
+high	O
+-	O
+frequency	O
+ventilation	O
+and	O
+airway	B-ANAT
+pressure	O
+release	B-PATH
+ventilation	O
+.	O
+
+Based	O
+on	O
+the	O
+severity	O
+of	O
+clinical	O
+signs	O
+,	O
+histopathological	O
+lesions	O
+and	O
+the	O
+distribution	O
+of	O
+PEDV	B-SPEC
+antigens	B-CHED
+in	O
+the	O
+gut	B-ANAT
+,	O
+the	O
+virulence	B-PROC
+of	O
+P100	B-PRGE
+and	O
+above	O
+,	O
+but	O
+not	O
+P95C13	O
+(	O
+CCL81	O
+),	O
+was	O
+markedly	O
+reduced	O
+in	O
+4	O
+-	O
+day	O
+-	O
+old	O
+,	O
+caesarian	O
+-	O
+derived	O
+,	O
+colostrum	B-ANAT
+-	O
+deprived	O
+piglets	O
+.	O
+
+Sequence	O
+analysis	O
+revealed	O
+that	O
+the	O
+virulent	O
+viruses	B-SPEC
+[	O
+P3	O
+and	O
+P95C13	O
+(	O
+CCL81	O
+)]	O
+had	O
+one	O
+,	O
+one	O
+,	O
+sixteen	O
+(	O
+including	O
+an	O
+early	O
+termination	O
+of	O
+nine	O
+amino	B-CHED
+acids	I-CHED
+)	O
+and	O
+two	O
+amino	B-CHED
+acid	I-CHED
+differences	O
+in	O
+non	O
+-	O
+structure	B-PRGE
+protein	I-PRGE
+1	I-PRGE
+(	O
+nsp1	B-PRGE
+),	O
+nsp4	B-PRGE
+,	O
+spike	O
+and	O
+membrane	B-COMP
+proteins	B-CHED
+,	O
+respectively	O
+,	O
+from	O
+the	O
+fully	O
+attenuated	O
+P160	O
+.	O
+
+Two	O
+strains	O
+,	O
+RVA	O
+/	O
+Cow	B-SPEC
+-	O
+wt	O
+/	O
+TUR	O
+/	O
+Amasya	O
+-	O
+1	O
+/	O
+2015	O
+/	O
+G8P	O
+[	O
+5	O
+]	O
+and	O
+RVA	O
+/	O
+Cow	B-SPEC
+-	O
+wt	O
+/	O
+TUR	B-PRGE
+/	O
+Amasya	O
+-	O
+2	O
+/	O
+2015	O
+/	O
+G8P	O
+[	O
+5	O
+]	O
+were	O
+genotyped	O
+as	O
+G8	O
+-	O
+P	O
+[	O
+5	O
+]-	O
+I2	O
+-	O
+R2	O
+-	O
+C2	O
+-	O
+M2	O
+-	O
+A3	O
+-	O
+N2	O
+-	O
+T6	O
+-	O
+E2	O
+-	O
+H3	O
+and	O
+showed	O
+>	O
+99	O
+%	O
+nucleotide	B-CHED
+sequence	O
+identity	O
+among	O
+themselves	O
+.	O
+
+ABSTRACT	O
+:	O
+Observational	O
+research	O
+focused	O
+upon	O
+emerging	B-DISO
+infectious	I-DISO
+diseases	I-DISO
+such	O
+as	O
+Ebola	B-SPEC
+virus	I-SPEC
+,	O
+Middle	O
+East	O
+respiratory	O
+syndrome	B-DISO
+,	O
+and	O
+Zika	B-SPEC
+virus	I-SPEC
+has	O
+been	O
+challenging	O
+to	O
+quickly	O
+initiate	O
+.	O
+
+However	O
+,	O
+some	O
+pathogens	O
+,	O
+including	O
+viruses	B-SPEC
+,	O
+have	O
+evolved	O
+unique	O
+trick	O
+to	O
+escape	O
+or	O
+exploit	O
+autophagy	B-PROC
+.	O
+
+CQ	O
+treatment	O
+enhanced	O
+the	O
+LC3	O
+lipidation	O
+in	O
+PHEV	O
+-	O
+infected	O
+Neuro	O
+-	O
+2a	O
+cells	B-COMP
+but	O
+lowered	O
+PHEV	O
+replication	O
+.	O
+
+These	O
+results	O
+show	O
+that	O
+PHEV	O
+infection	B-DISO
+induces	O
+atypical	O
+autophagy	B-PROC
+and	O
+causes	O
+the	O
+appearance	O
+of	O
+autophagosomes	O
+but	O
+blocks	O
+the	O
+fusion	O
+with	O
+lysosomes	B-COMP
+,	O
+which	O
+is	O
+necessary	O
+for	O
+the	O
+replication	O
+of	O
+PHEV	O
+in	O
+nerve	B-ANAT
+cells	I-ANAT
+.	O
+
+TITLE	O
+:	O
+Agreement	O
+Among	O
+4	O
+Sampling	O
+Methods	O
+to	O
+Identify	O
+Respiratory	O
+Pathogens	O
+in	O
+Dairy	O
+Calves	O
+with	O
+Acute	O
+Bovine	B-SPEC
+Respiratory	B-DISO
+Disease	I-DISO
+.	O
+
+Agreement	O
+among	O
+TTW	O
+and	O
+NS	O
+,	O
+TTW	O
+and	O
+NPS	O
+,	O
+and	O
+TTW	O
+and	O
+BAL	B-ENZY
+,	O
+was	O
+very	O
+good	O
+for	O
+identification	O
+of	O
+P	B-SPEC
+.	I-SPEC
+multocida	I-SPEC
+,	O
+M	B-SPEC
+.	I-SPEC
+haemolytica	I-SPEC
+,	O
+and	O
+M	B-SPEC
+.	I-SPEC
+bovis	I-SPEC
+.	O
+
+Receiver	O
+operating	O
+characteristic	O
+analysis	O
+showed	O
+that	O
+an	O
+ISI	O
+of	O
+≥	O
+8	O
+predicted	O
+pneumonia	B-DISO
+with	O
+a	O
+positive	O
+predictive	O
+value	O
+of	O
+>	O
+80	O
+%	O
+for	O
+RVI	O
+caused	O
+by	O
+RSV	B-SPEC
+,	O
+influenza	B-DISO
+,	O
+adenovirus	B-DISO
+,	O
+and	O
+parainfluenza	B-DISO
+,	O
+while	O
+it	O
+was	O
+not	O
+predictive	O
+for	O
+coronavirus	B-SPEC
+and	O
+rhinovirus	B-SPEC
+.	O
+
+RESULTS	O
+:	O
+RVI	O
+occurred	O
+year	O
+-	O
+round	O
+in	O
+our	O
+tropical	O
+transplant	B-ANAT
+center	O
+,	O
+with	O
+peaks	O
+in	O
+the	O
+middle	O
+and	O
+end	O
+of	O
+the	O
+year	O
+.	O
+
+ABSTRACT	O
+:	O
+Influenza	B-SPEC
+virus	I-SPEC
+is	O
+still	O
+a	O
+huge	O
+threat	O
+to	O
+the	O
+world	O
+-	O
+wide	O
+public	O
+health	O
+.	O
+
+We	O
+analysed	O
+the	O
+TGEV	B-PRGE
+ORF3	I-PRGE
+gene	I-PRGE
+using	O
+nested	O
+polymerase	O
+chain	O
+reaction	O
+and	O
+identified	O
+an	O
+ORF3a	O
+deletion	O
+in	O
+three	O
+field	O
+strains	O
+of	O
+TGEV	B-SPEC
+collected	O
+from	O
+piglets	O
+in	O
+China	O
+in	O
+2015	O
+.	O
+
+We	O
+observed	O
+that	O
+the	O
+level	O
+of	O
+infection	B-DISO
+and	O
+replication	O
+with	O
+spray	O
+vaccination	O
+matches	O
+with	O
+that	O
+of	O
+eye	B-ANAT
+drop	O
+vaccination	O
+when	O
+chicks	O
+received	O
+100	O
+times	O
+the	O
+standard	O
+dose	O
+for	O
+the	O
+commercial	O
+ArkDPI	O
+vaccine	O
+.	O
+
+Thus	O
+,	O
+the	O
+minimum	O
+infectious	B-DISO
+dose	O
+for	O
+the	O
+ArkDPI	O
+vaccine	O
+using	O
+a	O
+hatchery	O
+spray	O
+cabinet	O
+appears	O
+to	O
+be	O
+dependent	O
+on	O
+the	O
+amount	O
+of	O
+this	O
+minor	O
+subpopulation	O
+reaching	B-PROC
+the	O
+chicks	O
+.	O
+
+When	O
+tested	O
+in	O
+the	O
+2	O
+-	O
+day	O
+-	O
+old	O
+pig	B-SPEC
+model	O
+,	O
+rBJ2011C	O
+caused	O
+severe	B-DISO
+diarrhea	I-DISO
+of	O
+piglets	O
+with	O
+extensive	O
+damages	O
+to	O
+the	O
+intestinal	O
+epithelium	O
+,	O
+leading	O
+to	O
+100	O
+%	O
+fatality	O
+within	O
+48	O
+hours	O
+.	O
+
+TITLE	O
+:	O
+Nanomedicine	O
+for	O
+the	O
+Treatment	O
+of	O
+Acute	B-DISO
+Respiratory	I-DISO
+Distress	I-DISO
+Syndrome	I-DISO
+.	O
+
+The	O
+2016	O
+ATS	B-DISO
+Bear	B-SPEC
+Cage	O
+Award	O
+-	O
+winning	O
+Proposal	O
+.	O
+
+A	O
+look	O
+back	B-ANAT
+at	O
+virus	B-SPEC
+detection	O
+results	O
+in	O
+NPWs	O
+from	O
+the	O
+same	O
+83	O
+individuals	O
+at	O
+the	O
+time	O
+of	O
+tonsillectomy	O
+revealed	O
+that	O
+73	O
+.	O
+5	O
+%	O
+(	O
+61	O
+/	O
+83	O
+)	O
+were	O
+positive	O
+for	O
+one	O
+or	O
+more	O
+viruses	B-SPEC
+.	O
+
+Rhinovirus	B-SPEC
+(	O
+RV	O
+)	O
+was	O
+the	O
+agent	O
+most	O
+frequently	O
+detected	O
+,	O
+in	O
+38	O
+of	O
+83	O
+subjects	O
+(	O
+45	O
+.	O
+8	O
+%),	O
+followed	O
+by	O
+enterovirus	B-SPEC
+in	O
+7	O
+(	O
+8	O
+.	O
+4	O
+%),	O
+human	B-SPEC
+metapneumovirus	I-SPEC
+in	O
+6	O
+(	O
+7	O
+.	O
+2	O
+%),	O
+human	B-SPEC
+respiratory	I-SPEC
+syncytial	I-SPEC
+virus	I-SPEC
+in	O
+3	O
+(	O
+3	O
+.	O
+6	O
+%)	O
+and	O
+human	B-SPEC
+coronavirus	I-SPEC
+in	O
+1	O
+(	O
+1	O
+.	O
+2	O
+%).	O
+
+Remarkably	O
+,	O
+there	O
+was	O
+no	O
+detection	O
+of	O
+adenovirus	B-DISO
+(	O
+HAdV	O
+)	O
+or	O
+human	B-PRGE
+bocavirus	I-PRGE
+(	O
+HBoV	O
+)	O
+in	O
+asymptomatic	O
+individuals	O
+in	O
+follow	O
+-	O
+up	O
+of	O
+adenotonsillectomy	O
+.	O
+
+TITLE	O
+:	O
+The	O
+papain	B-PRGE
+-	I-PRGE
+like	I-PRGE
+protease	I-PRGE
+of	O
+avian	B-DISO
+infectious	I-DISO
+bronchitis	I-DISO
+virus	B-SPEC
+has	O
+deubiquitinating	B-PROC
+activity	O
+.	O
+
+In	O
+this	O
+study	O
+,	O
+we	O
+found	O
+that	O
+IBV	B-SPEC
+exhibits	O
+strong	O
+global	O
+DUB	O
+activity	O
+with	O
+significant	O
+reductions	O
+of	O
+the	O
+levels	O
+of	O
+ubiquitin	B-PROC
+(	O
+Ub	O
+)-,	O
+K48	O
+-,	O
+and	O
+K63	O
+-	O
+conjugated	B-CHED
+proteins	I-CHED
+.	O
+
+TITLE	O
+:	O
+Extracellular	B-ANAT
+matrix	I-ANAT
+in	O
+the	O
+CNS	B-CHED
+induced	O
+by	O
+neuropathogenic	O
+viral	B-DISO
+infection	I-DISO
+.	O
+
+ABSTRACT	O
+:	O
+During	O
+the	O
+early	O
+phase	O
+of	O
+infection	O
+with	O
+an	O
+extremely	O
+neurovirulent	O
+murine	B-SPEC
+coronavirus	I-SPEC
+,	O
+cl	B-PRGE
+-	I-PRGE
+2	I-PRGE
+,	O
+the	O
+ER	B-PRGE
+-	I-PRGE
+TR7	I-PRGE
+antigen	I-PRGE
+(	O
+ERag	O
+)-	O
+positive	O
+fibers	O
+(	O
+ERfibs	O
+)	O
+associated	O
+with	O
+laminin	B-PRGE
+and	O
+collagen	B-PRGE
+III	I-PRGE
+show	O
+a	O
+rapid	O
+increase	O
+in	O
+expression	B-PROC
+levels	O
+in	O
+the	O
+meninges	B-ANAT
+,	O
+followed	O
+by	O
+an	O
+appearance	O
+of	O
+the	O
+antigens	B-CHED
+in	O
+the	O
+ventricle	B-ANAT
+and	O
+brain	B-ANAT
+parenchyma	B-ANAT
+.	O
+
+Then	O
+,	O
+cl	O
+-	O
+2	O
+invades	O
+the	O
+ventricle	B-ANAT
+and	O
+ventricular	B-ANAT
+wall	I-ANAT
+along	O
+the	O
+newly	O
+assembled	O
+ERfibs	O
+after	O
+infection	B-DISO
+,	O
+using	O
+them	O
+as	O
+a	O
+pathway	B-PROC
+from	O
+the	O
+meninges	B-ANAT
+,	O
+the	O
+initial	O
+site	O
+of	O
+infection	B-DISO
+.	O
+
+In	O
+the	O
+brain	B-ANAT
+parenchyma	B-ANAT
+,	O
+astrocytes	B-ANAT
+were	O
+found	O
+to	O
+produce	O
+the	O
+main	O
+components	O
+of	O
+mature	O
+ERfibs	O
+,	O
+such	O
+as	O
+collagen	B-ANAT
+,	O
+laminin	B-PRGE
+and	O
+ERag	O
+,	O
+which	O
+have	O
+been	O
+identified	O
+in	O
+the	O
+lymphoid	B-ANAT
+organs	I-ANAT
+.	O
+
+In	O
+addition	O
+,	O
+the	O
+brain	B-ANAT
+parenchymal	O
+cells	B-COMP
+that	O
+produce	O
+interferon	B-PRGE
+β	I-PRGE
+after	O
+infection	B-DISO
+in	O
+spite	O
+of	O
+their	O
+residence	O
+away	O
+from	O
+the	O
+sites	O
+of	O
+viral	O
+invasion	B-DISO
+were	O
+surrounded	O
+by	O
+ERfibs	O
+,	O
+which	O
+were	O
+closely	O
+associated	O
+with	O
+astrocytic	B-ANAT
+fibers	O
+.	O
+
+Pigs	B-SPEC
+do	O
+not	O
+recapitulate	O
+human	B-SPEC
+MERS	O
+-	O
+CoV	O
+and	O
+are	O
+unlikely	O
+to	O
+constitute	O
+a	O
+reservoir	O
+in	O
+nature	O
+.	O
+
+Between	O
+December	O
+1	O
+,	O
+2012	O
+,	O
+and	O
+May	O
+31	O
+,	O
+2015	O
+,	O
+this	O
+observational	O
+study	O
+recruited	O
+patients	O
+admitted	O
+to	O
+our	O
+tertiary	O
+medical	O
+center	O
+who	O
+met	B-CHED
+the	O
+Berlin	O
+criteria	O
+for	O
+ARDS	B-DISO
+and	O
+who	O
+had	O
+their	O
+NT	O
+-	O
+proBNP	O
+measured	O
+.	O
+
+ABSTRACT	O
+:	O
+Interleukin	B-PRGE
+-	I-PRGE
+22	I-PRGE
+(	O
+IL	B-FUNC
+-	I-FUNC
+22	I-FUNC
+),	O
+a	O
+member	O
+of	O
+the	O
+IL	B-PRGE
+-	I-PRGE
+10	I-PRGE
+superfamily	B-SPEC
+,	O
+plays	O
+essential	O
+roles	O
+in	O
+fighting	O
+against	O
+mucosal	B-ANAT
+microbial	O
+infection	B-DISO
+and	O
+maintaining	O
+mucosal	B-ANAT
+barrier	O
+integrity	O
+within	O
+the	O
+intestine	B-ANAT
+.	O
+
+The	O
+significant	O
+antiviral	B-CHED
+activity	O
+of	O
+IL	B-FUNC
+-	I-FUNC
+22	I-FUNC
+to	O
+curtail	O
+multiple	O
+enteric	O
+diarrhea	B-DISO
+viruses	B-SPEC
+in	O
+vitro	O
+suggests	O
+that	O
+pIL	B-PRGE
+-	I-PRGE
+22	I-PRGE
+could	O
+be	O
+a	O
+novel	O
+therapeutic	O
+against	O
+devastating	O
+viral	B-DISO
+diarrhea	I-DISO
+in	O
+piglets	O
+.	O
+
+Here	O
+we	O
+have	O
+collected	O
+samples	O
+from	O
+Mallards	B-SPEC
+(	O
+Anas	B-SPEC
+platyrhynchos	I-SPEC
+)	O
+residing	O
+in	O
+a	O
+pond	O
+in	O
+central	O
+Uppsala	O
+,	O
+Sweden	O
+,	O
+from	O
+January	O
+2013	O
+to	O
+January	O
+2014	O
+.	O
+
+We	O
+also	O
+demonstrate	O
+that	O
+AstroV	O
+might	O
+be	O
+a	O
+larger	O
+burden	O
+to	O
+urban	O
+ducks	B-SPEC
+than	O
+IAV	O
+,	O
+and	O
+should	O
+be	O
+better	O
+assessed	O
+to	O
+demonstrate	O
+the	O
+degree	O
+to	O
+which	O
+wild	O
+birds	B-SPEC
+contribute	O
+to	O
+the	O
+epidemiology	O
+of	O
+these	O
+viruses	B-SPEC
+.	O
+
+Mortality	O
+rates	O
+were	O
+compared	O
+among	O
+HCT	O
+recipients	O
+with	O
+LRTD	O
+caused	O
+by	O
+HCoV	O
+,	O
+respiratory	B-SPEC
+syncytial	I-SPEC
+virus	I-SPEC
+(	O
+RSV	B-SPEC
+),	O
+influenza	B-SPEC
+virus	I-SPEC
+,	O
+or	O
+parainfluenza	B-DISO
+virus	B-SPEC
+(	O
+PIV	O
+)	O
+by	O
+multivariable	O
+Cox	O
+regression	O
+analysis	O
+.	O
+
+Among	O
+23	O
+available	O
+BAL	B-ENZY
+samples	O
+,	O
+48	O
+%	O
+were	O
+strain	O
+OC43	O
+,	O
+22	O
+%	O
+were	O
+NL63	O
+,	O
+17	O
+%	O
+were	O
+229E	O
+,	O
+and	O
+13	O
+%	O
+were	O
+HKU1	O
+.	O
+
+Patients	O
+with	O
+Legionella	B-DISO
+pneumonia	I-DISO
+were	O
+slightly	O
+older	O
+than	O
+patients	O
+with	O
+acute	B-DISO
+respiratory	I-DISO
+failure	I-DISO
+of	O
+other	O
+etiologies	O
+(	O
+51	O
+[	O
+48	O
+-	O
+56	O
+]	O
+vs	O
+45	O
+[	O
+35	O
+-	O
+54	O
+]),	O
+but	O
+with	O
+no	O
+significant	O
+differences	O
+in	O
+acute	B-DISO
+respiratory	I-DISO
+failure	I-DISO
+severity	O
+between	O
+groups	O
+:	O
+Pao	B-PROC
+In	O
+Legionella	B-DISO
+pneumonia	I-DISO
+complicated	O
+by	O
+refractory	O
+respiratory	B-DISO
+failure	I-DISO
+,	O
+ECMO	O
+support	O
+allowed	O
+patient	O
+stabilization	O
+under	O
+lung	B-ANAT
+protective	O
+ventilation	O
+and	O
+high	O
+survival	O
+rates	O
+.	O
+
+TITLE	O
+:	O
+Structural	O
+Characterization	O
+of	O
+Human	B-PRGE
+Coronavirus	I-PRGE
+NL63	I-PRGE
+N	I-PRGE
+Protein	B-CHED
+.	O
+
+It	O
+is	O
+estimated	O
+that	O
+1	O
+to	O
+10	O
+%	O
+of	O
+the	O
+population	O
+suffers	B-DISO
+annually	O
+from	O
+cold	B-DISO
+-	O
+like	O
+symptoms	O
+related	O
+to	O
+infection	B-DISO
+with	O
+human	B-SPEC
+coronavirus	I-SPEC
+NL63	I-SPEC
+(	O
+HCoV	B-SPEC
+-	I-SPEC
+NL63	I-SPEC
+),	O
+an	O
+alphacoronavirus	B-SPEC
+.	O
+
+The	O
+nucleocapsid	B-COMP
+(	O
+N	O
+)	O
+protein	B-CHED
+,	O
+the	O
+major	O
+structural	O
+component	O
+of	O
+the	O
+capsid	B-ANAT
+,	O
+facilitates	O
+RNA	O
+packing	O
+,	O
+links	O
+the	O
+capsid	B-ANAT
+to	O
+the	O
+envelope	B-COMP
+,	O
+and	O
+is	O
+also	O
+involved	O
+in	O
+multiple	O
+other	O
+processes	O
+,	O
+including	O
+viral	B-PROC
+replication	I-PROC
+and	O
+evasion	O
+of	O
+the	O
+immune	B-ANAT
+system	I-ANAT
+.	O
+
+Overall	O
+,	O
+this	O
+study	O
+expands	O
+our	O
+understanding	O
+of	O
+the	O
+initial	O
+steps	O
+of	O
+N	O
+protein	B-CHED
+-	O
+nucleic	B-CHED
+acid	I-CHED
+interaction	O
+and	O
+may	O
+facilitate	O
+future	O
+efforts	O
+to	O
+control	O
+the	O
+associated	O
+infections	B-DISO
+.	O
+
+It	O
+is	O
+ingested	O
+as	O
+an	O
+oral	B-ANAT
+prodrug	B-CHED
+that	O
+is	O
+rapidly	O
+metabolized	B-PROC
+by	O
+carboxylesterase	B-PRGE
+1	I-PRGE
+(	O
+CES1	B-PRGE
+)	O
+to	O
+its	O
+active	O
+form	O
+,	O
+oseltamivir	B-CHED
+carboxylate	B-CHED
+.	O
+
+An	O
+open	O
+-	O
+label	B-CHED
+,	O
+two	O
+-	O
+period	O
+,	O
+one	O
+-	O
+sequence	O
+,	O
+multiple	O
+-	O
+dose	O
+study	O
+was	O
+conducted	O
+in	O
+19	O
+healthy	O
+male	O
+volunteers	O
+.	O
+
+Oseltamivir	B-CHED
+(	O
+75	O
+mg	O
+)	O
+was	O
+orally	B-ANAT
+administered	O
+on	O
+Day	O
+1	O
+and	O
+Day	O
+8	O
+,	O
+and	O
+dexamethasone	B-CHED
+(	O
+1	O
+.	O
+5	O
+mg	O
+)	O
+was	O
+administered	O
+once	O
+daily	O
+from	O
+Day	O
+3	O
+to	O
+Day	O
+8	O
+.	O
+
+The	O
+geometric	O
+mean	O
+ratio	O
+(	O
+90	O
+%	O
+confidence	O
+interval	O
+)	O
+of	O
+the	O
+metabolic	B-PROC
+ratio	O
+(	O
+oseltamivir	B-CHED
+carboxylate	B-CHED
+AUC	O
+Coadministration	O
+of	O
+dexamethasone	B-CHED
+with	O
+oseltamivir	B-CHED
+slightly	O
+decreased	O
+systemic	O
+exposure	O
+to	O
+oseltamivir	B-CHED
+and	O
+oseltamivir	B-CHED
+carboxylate	B-CHED
+in	O
+healthy	O
+volunteers	O
+.	O
+
+However	O
+,	O
+coadministration	O
+of	O
+oseltamivir	B-CHED
+and	O
+dexamethasone	B-CHED
+did	O
+not	O
+appear	O
+to	O
+have	O
+a	O
+clinically	O
+relevant	O
+effect	O
+on	O
+the	O
+PK	O
+of	O
+oseltamivir	B-CHED
+;	O
+based	O
+on	O
+these	O
+results	O
+,	O
+dexamethasone	B-CHED
+can	O
+be	O
+coadministered	O
+with	O
+oseltamivir	B-CHED
+.	O
+
+RESULTS	O
+:	O
+Area	O
+under	O
+the	O
+plasma	B-ANAT
+concentration	O
+-	O
+time	O
+curve	O
+(	O
+AUC	O
+)	O
+of	O
+oseltamivir	B-CHED
+and	O
+oseltamivir	B-CHED
+carboxylate	B-CHED
+decreased	O
+after	O
+dexamethasone	B-CHED
+treatment	O
+for	O
+6	O
+days	O
+.	O
+
+Different	O
+vaccine	O
+candidates	O
+have	O
+been	O
+investigated	O
+but	O
+serious	O
+safety	O
+concerns	O
+remain	O
+over	O
+protein	B-CHED
+or	O
+full	O
+-	O
+length	O
+spike	O
+(	O
+S	O
+)	O
+protein	B-CHED
+-	O
+based	O
+vaccines	O
+.	O
+
+Importantly	O
+,	O
+both	O
+constructs	O
+induced	O
+cross	O
+-	O
+neutralizing	O
+Abs	O
+against	O
+multiple	O
+strains	O
+of	O
+human	B-SPEC
+and	O
+camel	B-SPEC
+origins	O
+.	O
+
+Oral	B-ANAT
+swabs	O
+were	O
+the	O
+second	O
+most	O
+frequently	O
+positive	O
+(	O
+35	O
+.	O
+7	O
+%),	O
+followed	O
+by	O
+rectal	O
+swabs	O
+(	O
+28	O
+.	O
+5	O
+%).	O
+
+In	O
+addition	O
+,	O
+the	O
+highest	O
+viral	O
+load	O
+,	O
+expressed	B-PROC
+as	O
+a	O
+cycle	O
+threshold	O
+(	O
+Ct	O
+)	O
+value	O
+of	O
+11	O
+.	O
+27	O
+,	O
+was	O
+obtained	O
+from	O
+a	O
+nasal	B-ANAT
+swab	O
+.	O
+
+All	O
+tested	O
+samples	O
+from	O
+domestic	O
+animals	O
+and	O
+bats	B-SPEC
+were	O
+negative	O
+for	O
+MERS	O
+-	O
+CoV	O
+antibodies	B-COMP
+except	O
+one	O
+sheep	B-SPEC
+sample	O
+which	O
+showed	O
+a	O
+1	O
+:	O
+640	O
+titre	O
+.	O
+
+The	O
+presence	O
+of	O
+neutralising	O
+antibodies	B-COMP
+in	O
+one	O
+sheep	B-SPEC
+apparently	O
+in	O
+contact	O
+with	O
+seropositive	O
+camels	B-SPEC
+calls	O
+for	O
+further	O
+studies	O
+on	O
+domestic	O
+animals	B-SPEC
+in	O
+contact	O
+with	O
+camels	B-SPEC
+.	O
+
+To	O
+survey	O
+the	O
+baseline	O
+status	O
+of	O
+the	O
+emerging	O
+and	O
+endemic	O
+zoonoses	B-DISO
+programmes	O
+of	O
+the	O
+Latin	O
+American	O
+and	O
+the	O
+Caribbean	O
+(	O
+LAC	B-CHED
+)	O
+countries	O
+,	O
+the	O
+Pan	B-COMP
+American	O
+Health	O
+Organization	O
+(	O
+PAHO	O
+)	O
+conducted	O
+a	O
+survey	O
+of	O
+priority	O
+emerging	O
+and	O
+endemic	O
+zoonoses	B-DISO
+,	O
+countries	O
+´	O
+prioritization	O
+criteria	O
+and	O
+methodologies	O
+,	O
+and	O
+suggestions	O
+to	O
+strengthen	O
+countries	O
+capacities	O
+and	O
+regional	O
+approaches	O
+to	O
+zoonoses	B-DISO
+control	O
+.	O
+
+For	O
+all	O
+zoonoses	B-DISO
+,	O
+the	O
+majority	O
+of	O
+respondents	O
+(	O
+69	O
+%)	O
+ranked	O
+their	O
+relationship	O
+with	O
+the	O
+other	O
+Ministry	O
+as	O
+productive	O
+or	O
+very	O
+productive	O
+,	O
+and	O
+31	O
+%	O
+minimally	O
+productive	O
+.	O
+
+ABSTRACT	O
+:	O
+The	O
+inflammatory	O
+chemokine	O
+,	O
+interferon	B-FUNC
+-	I-FUNC
+gamma	I-FUNC
+inducible	O
+protein	B-CHED
+of	O
+10kDa	O
+(	O
+IP	O
+-	O
+10	O
+),	O
+is	O
+a	O
+biomarker	B-CHED
+associated	O
+with	O
+several	O
+conditions	O
+.	O
+
+Healthy	O
+adults	O
+ages	O
+30	O
+-	O
+69	O
+were	O
+followed	O
+for	O
+a	O
+single	O
+season	O
+for	O
+ARI	B-CHED
+incidence	O
+and	O
+severity	O
+.	O
+
+When	O
+a	O
+participant	O
+reported	O
+ARI	B-CHED
+symptoms	O
+,	O
+nasal	B-ANAT
+swab	O
+and	O
+lavage	O
+for	O
+PCR	O
+-	O
+based	O
+viral	O
+identification	O
+and	O
+blood	B-ANAT
+samples	I-ANAT
+were	O
+collected	O
+within	O
+the	O
+first	O
+72h	O
+of	O
+ARI	B-CHED
+symptoms	O
+.	O
+
+RESULTS	O
+:	O
+Serum	B-COMP
+IP	O
+-	O
+10	O
+concentrations	O
+from	O
+225	O
+ARI	B-CHED
+episodes	O
+correlated	O
+with	O
+ARI	B-CHED
+global	O
+severity	O
+(	O
+rho	O
+0	O
+.	O
+28	O
+[	O
+95	O
+%	O
+CI	O
+:	O
+0	O
+.	O
+15	O
+-	O
+0	O
+.	O
+39	O
+];	O
+p	O
+<	O
+0	O
+.	O
+001	O
+).	O
+
+ABSTRACT	O
+:	O
+In	O
+Egypt	O
+,	O
+currently	O
+two	O
+geographically	O
+restricted	O
+genotypes	O
+of	O
+the	O
+infectious	B-DISO
+bronchitis	B-DISO
+coronavirus	B-SPEC
+(	O
+IBV	B-SPEC
+)	O
+are	O
+circulating	O
+with	O
+detrimental	O
+effects	O
+for	O
+poultry	O
+industry	O
+.	O
+
+ABSTRACT	O
+:	O
+We	O
+describe	O
+a	O
+case	O
+of	O
+severe	O
+refractory	O
+hypoxemia	O
+requiring	O
+prolonged	O
+extra	O
+corporeal	O
+membrane	O
+oxygenation	B-PROC
+(	O
+ECMO	O
+)	O
+support	O
+in	O
+a	O
+case	O
+of	O
+postpartum	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+(	O
+ARDS	B-DISO
+).	O
+
+TITLE	O
+:	O
+Retrospective	O
+investigation	O
+and	O
+evolutionary	O
+analysis	O
+of	O
+a	O
+novel	O
+porcine	B-SPEC
+deltacoronavirus	O
+strain	O
+detected	O
+in	O
+Thailand	O
+from	O
+2008	O
+to	O
+2015	O
+.	O
+
+We	O
+performed	O
+a	O
+retrospective	O
+investigation	O
+of	O
+the	O
+presence	O
+of	O
+PDCoV	O
+in	O
+intestinal	B-ANAT
+samples	O
+collected	O
+from	O
+piglets	O
+with	O
+diarrhea	B-DISO
+in	O
+Thailand	O
+from	O
+2008	O
+to	O
+2015	O
+using	O
+RT	O
+-	O
+PCR	O
+.	O
+
+Vaccination	O
+of	O
+specific	O
+pathogen	O
+-	O
+free	O
+chickens	B-SPEC
+with	O
+the	O
+rLaSota	O
+-	O
+S1	O
+strain	O
+induced	O
+NDV	B-SPEC
+hemagglutination	B-PROC
+inhibition	B-PROC
+antibodies	B-COMP
+,	O
+and	O
+it	O
+protected	O
+chickens	B-SPEC
+from	O
+challenge	O
+with	O
+virulent	O
+NDV	B-SPEC
+.	O
+
+Better	O
+protection	O
+efficiency	O
+was	O
+observed	O
+after	O
+a	O
+booster	O
+vaccination	O
+,	O
+which	O
+resulted	O
+in	O
+higher	O
+antibody	O
+titers	O
+,	O
+significantly	O
+fewer	O
+disease	O
+symptoms	O
+,	O
+and	O
+reduced	O
+virus	B-PROC
+replication	I-PROC
+and	O
+shedding	O
+.	O
+
+Early	O
+evidence	O
+suggests	O
+that	O
+therapeutic	O
+hypothermia	O
+(	O
+TH	O
+)	O
+could	O
+be	O
+a	O
+viable	O
+treatment	O
+for	O
+acute	B-DISO
+respiratory	I-DISO
+failure	I-DISO
+.	O
+
+Phylogenetic	O
+analysis	O
+of	O
+S	B-PRGE
+gene	I-PRGE
+and	O
+N	B-PRGE
+gene	I-PRGE
+revealed	O
+that	O
+11	O
+of	O
+13	O
+PDCoV	O
+strains	O
+belonged	O
+to	O
+Chinese	O
+lineage	O
+.	O
+
+TITLE	O
+:	O
+Patterns	O
+of	O
+Human	B-SPEC
+Respiratory	O
+Viruses	B-SPEC
+and	O
+Lack	O
+of	O
+MERS	O
+-	O
+Coronavirus	B-SPEC
+in	O
+Patients	O
+with	O
+Acute	O
+Upper	B-ANAT
+Respiratory	I-ANAT
+Tract	I-ANAT
+Infections	I-DISO
+in	O
+Southwestern	O
+Province	O
+of	O
+Saudi	O
+Arabia	O
+.	O
+
+Moreover	O
+,	O
+coinfection	O
+was	O
+not	O
+uncommon	O
+in	O
+this	O
+study	O
+,	O
+in	O
+which	O
+17	O
+.	O
+3	O
+%	O
+of	O
+the	O
+infected	O
+patients	O
+had	O
+dual	O
+infections	B-DISO
+due	O
+to	O
+several	O
+combinations	O
+of	O
+viruses	B-SPEC
+.	O
+
+Our	O
+study	O
+confirms	O
+that	O
+MERS	O
+-	O
+CoV	O
+is	O
+not	O
+common	O
+in	O
+the	O
+southwestern	O
+region	O
+of	O
+Saudi	O
+Arabia	O
+and	O
+shows	O
+high	O
+diversity	O
+and	O
+prevalence	O
+of	O
+other	O
+common	O
+respiratory	O
+viruses	B-SPEC
+.	O
+
+We	O
+examine	O
+the	O
+relationship	O
+between	O
+epidemic	O
+containment	O
+and	O
+the	O
+disease	O
+dynamics	O
+of	O
+symptoms	O
+and	O
+infectiousness	O
+for	O
+seven	O
+case	O
+-	O
+study	O
+diseases	O
+with	O
+diverse	O
+natural	O
+histories	O
+,	O
+including	O
+Ebola	O
+,	O
+influenza	B-DISO
+A	I-PATH
+,	O
+and	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+(	O
+SARS	B-DISO
+).	O
+
+Compared	O
+to	O
+treatment	O
+with	O
+the	O
+prototypical	O
+inflammatory	O
+cytokine	B-PRGE
+interleukin	I-PRGE
+(	I-PRGE
+IL	I-PRGE
+)-	I-PRGE
+1	I-PRGE
+,	O
+HCoV	B-SPEC
+-	I-SPEC
+229E	I-SPEC
+replication	O
+was	O
+found	O
+to	O
+attenuate	O
+the	O
+inducible	O
+activity	O
+of	O
+the	O
+transcription	B-PRGE
+factor	I-PRGE
+(	O
+TF	O
+)	O
+NF	O
+-	O
+κB	O
+and	O
+to	O
+restrict	O
+the	O
+nuclear	O
+concentration	O
+of	O
+NF	O
+-	O
+κB	O
+subunits	O
+by	O
+(	O
+i	O
+)	O
+an	O
+unusual	O
+mechanism	O
+involving	O
+partial	O
+degradation	O
+of	O
+IKKβ	O
+,	O
+NEMO	B-PRGE
+and	O
+IκBα	O
+and	O
+(	O
+ii	O
+)	O
+upregulation	B-PROC
+of	O
+TNFAIP3	B-PRGE
+(	O
+A20	B-PRGE
+),	O
+although	O
+constitutive	O
+IKK	O
+activity	O
+and	O
+basal	O
+TNFAIP3	B-PRGE
+expression	B-PROC
+levels	O
+were	O
+shown	O
+to	O
+be	O
+required	O
+for	O
+efficient	O
+virus	B-PROC
+replication	I-PROC
+.	O
+
+Second	O
+,	O
+we	O
+characterized	O
+actively	O
+transcribed	O
+genomic	O
+regions	O
+and	O
+enhancers	O
+in	O
+HCoV	B-SPEC
+-	I-SPEC
+229E	I-SPEC
+-	O
+infected	O
+cells	B-COMP
+and	O
+systematically	O
+correlated	O
+the	O
+genome	O
+-	O
+wide	O
+gene	B-PROC
+expression	I-PROC
+changes	O
+with	O
+the	O
+recruitment	B-DISO
+of	O
+Ser5	B-PRGE
+-	O
+phosphorylated	O
+RNA	B-PRGE
+polymerase	I-PRGE
+II	I-PRGE
+and	O
+prototypical	O
+histone	B-PATH
+modifications	I-PATH
+(	O
+H3K9ac	O
+,	O
+H3K36ac	O
+,	O
+H4K5ac	O
+,	O
+H3K27ac	O
+,	O
+H3K4me1	O
+).	O
+
+Furthermore	O
+,	O
+both	O
+HCoV	B-PRGE
+-	I-PRGE
+229E	I-PRGE
+replication	I-PRGE
+and	I-PRGE
+IL	B-FUNC
+-	I-FUNC
+1	I-FUNC
+were	O
+shown	O
+to	O
+upregulate	O
+a	O
+small	O
+set	O
+of	O
+genes	O
+encoding	O
+immunomodulatory	O
+factors	O
+that	O
+bind	B-FUNC
+p65	B-PRGE
+at	O
+promoters	O
+and	O
+require	O
+IKKβ	O
+activity	O
+and	O
+p65	B-PRGE
+for	O
+expression	B-PROC
+.	O
+
+TITLE	O
+:	O
+Porcine	B-SPEC
+epidemic	I-SPEC
+diarrhea	I-SPEC
+virus	I-SPEC
+virus	B-ANAT
+-	I-ANAT
+like	I-ANAT
+particles	I-ANAT
+produced	O
+in	O
+insect	B-SPEC
+cells	B-COMP
+induce	O
+specific	O
+immune	O
+responses	O
+in	O
+mice	B-SPEC
+.	O
+
+ABSTRACT	O
+:	O
+Psychiatric	O
+morbidity	O
+after	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+(	O
+ARDS	B-DISO
+)	O
+is	O
+common	O
+,	O
+and	O
+our	O
+current	O
+ability	O
+to	O
+predict	O
+psychiatric	B-DISO
+symptoms	I-DISO
+based	O
+on	O
+patient	O
+-	O
+and	O
+illness	O
+-	O
+specific	O
+factors	O
+is	O
+limited	O
+.	O
+
+We	O
+assessed	O
+symptoms	O
+of	O
+anxiety	O
+,	O
+depression	B-DISO
+,	O
+and	O
+posttraumatic	B-DISO
+stress	I-DISO
+disorder	I-DISO
+(	O
+PTSD	B-DISO
+)	O
+in	O
+long	O
+-	O
+term	O
+survivors	O
+of	O
+ARDS	B-DISO
+,	O
+as	O
+well	O
+as	O
+the	O
+associated	O
+changes	O
+in	O
+cortisol	B-CHED
+levels	O
+.	O
+
+VILI	O
+is	O
+characterized	O
+by	O
+damage	O
+to	O
+the	O
+epithelial	O
+barrier	O
+with	O
+subsequent	O
+pulmonary	B-DISO
+edema	I-DISO
+and	O
+profound	O
+hypoxia	B-DISO
+.	O
+
+Available	O
+lung	B-ANAT
+-	O
+protective	O
+ventilator	O
+strategies	O
+offer	O
+only	O
+a	O
+modest	O
+benefit	O
+in	O
+preventing	O
+VILI	O
+because	O
+they	O
+cannot	O
+impede	O
+alveolar	B-ANAT
+overdistension	O
+and	O
+concomitant	O
+epithelial	O
+barrier	O
+dysfunction	O
+in	O
+the	O
+inflamed	O
+lung	B-ANAT
+regions	O
+.	O
+
+All	O
+3	O
+viruses	B-SPEC
+were	O
+detectable	O
+in	O
+association	O
+with	O
+aerosolized	O
+particles	O
+.	O
+
+Proportions	O
+of	O
+positive	O
+sampling	O
+events	O
+were	O
+69	O
+%	O
+for	O
+PEDV	O
+,	O
+61	O
+%	O
+for	O
+HPAIV	O
+,	O
+and	O
+8	O
+%	O
+for	O
+PRRSV	B-SPEC
+.	O
+
+ABSTRACT	O
+:	O
+Porcine	B-SPEC
+epidemic	I-SPEC
+diarrhea	I-SPEC
+virus	I-SPEC
+(	O
+PEDV	B-SPEC
+)	O
+is	O
+an	O
+emerging	O
+pathogenic	O
+coronavirus	B-SPEC
+that	O
+causes	O
+a	O
+significant	O
+economic	O
+burden	O
+to	O
+the	O
+swine	B-SPEC
+industry	O
+.	O
+
+TITLE	O
+:	O
+Development	B-PROC
+of	O
+Allograft	O
+Cancer	B-DISO
+after	O
+Lung	B-ANAT
+Transplantation	O
+:	O
+A	O
+Case	O
+Report	O
+.	O
+
+Usage	O
+of	O
+extended	O
+criteria	O
+donors	O
+seems	O
+a	O
+successful	O
+strategy	O
+to	O
+overcome	O
+shortage	O
+of	O
+donor	B-CHED
+lungs	B-ANAT
+by	O
+the	O
+increasing	O
+number	O
+of	O
+lung	B-ANAT
+transplant	B-ANAT
+candidates	O
+.	O
+
+Subsequent	O
+treatment	O
+with	O
+acid	B-CHED
+anhydrides	I-CHED
+such	O
+as	O
+cis	B-DISO
+-	O
+aconitic	O
+anhydride	O
+(	O
+CA	O
+)	O
+and	O
+succinic	B-CHED
+anhydride	I-CHED
+(	O
+SA	O
+)	O
+converted	O
+amines	B-CHED
+of	O
+lysine	B-CHED
+residues	O
+in	O
+TAT	B-ENZY
+peptide	B-CHED
+to	O
+β	O
+-	O
+carboxylic	O
+amides	B-CHED
+,	O
+introducing	O
+carboxylic	O
+groups	O
+that	O
+undergo	O
+pH	O
+-	O
+dependent	O
+protonation	O
+and	O
+deprotonation	O
+.	O
+
+32	O
+/	O
+237	O
+(	O
+13	O
+.	O
+5	O
+%)	O
+patients	O
+died	B-PROC
+.	O
+
+A	O
+sole	B-ANAT
+bacterial	O
+or	O
+viral	O
+pathogen	O
+was	O
+identified	O
+in	O
+48	O
+/	O
+237	O
+(	O
+20	O
+.	O
+1	O
+%)	O
+and	O
+41	O
+/	O
+237	O
+(	O
+17	O
+.	O
+9	O
+%)	O
+patients	O
+,	O
+respectively	O
+.	O
+
+The	O
+VCL	B-PRGE
+-	I-PRGE
+D841H	I-PRGE
+variant	O
+was	O
+engineered	O
+and	O
+either	O
+coexpressed	O
+with	O
+cardiac	B-PRGE
+sodium	I-PRGE
+channel	I-PRGE
+(	O
+SCN5A	B-PRGE
+)	O
+in	O
+HEK293	O
+cells	B-COMP
+or	O
+overexpressed	O
+in	O
+human	B-SPEC
+induced	O
+pluripotent	O
+stem	B-ANAT
+-	O
+cell	B-COMP
+-	O
+derived	O
+cardiomyocytes	B-ANAT
+to	O
+examine	O
+its	O
+effects	O
+on	O
+sodium	O
+channel	O
+function	O
+using	O
+the	O
+whole	O
+-	O
+cell	B-COMP
+patch	O
+-	O
+clamp	O
+method	O
+.	O
+
+ABSTRACT	O
+:	O
+Pathogenic	O
+human	O
+coronaviruses	O
+(	O
+CoVs	O
+),	O
+such	O
+as	O
+the	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+(	O
+SARS	B-DISO
+)-	O
+CoV	O
+and	O
+the	O
+Middle	O
+East	O
+respiratory	O
+syndrome	B-DISO
+-	O
+CoV	O
+,	O
+cause	O
+acute	O
+respiratory	O
+illness	O
+.	O
+
+The	O
+chronic	O
+toxicity	O
+derived	O
+from	O
+the	O
+current	O
+anti	O
+-	O
+retroviral	B-SPEC
+therapy	O
+limits	O
+the	O
+prolonged	O
+use	O
+of	O
+several	O
+antiretroviral	O
+agents	O
+,	O
+continuously	O
+requiring	O
+the	O
+discovery	O
+of	O
+new	O
+antiviral	B-CHED
+agents	I-CHED
+with	O
+innovative	O
+strategies	O
+of	O
+action	O
+.	O
+
+HIV	B-SPEC
+-	I-SPEC
+1	I-SPEC
+IN	O
+and	O
+Reverse	B-PRGE
+Transcriptase	I-PRGE
+-	O
+associated	O
+Ribonuclease	B-PRGE
+H	I-PRGE
+(	O
+RNase	B-PRGE
+H	I-PRGE
+)	O
+active	O
+sites	O
+show	O
+structural	O
+homologies	O
+,	O
+with	O
+the	O
+presence	O
+of	O
+two	O
+Mg	O
+(	O
+II	O
+)	O
+cofactors	B-CHED
+,	O
+hence	O
+it	O
+seems	O
+possible	O
+to	O
+inhibit	O
+both	O
+enzymes	O
+by	O
+means	O
+of	O
+chelating	O
+ligands	O
+with	O
+analogous	O
+structural	O
+features	O
+.	O
+
+During	O
+the	O
+pandemic	O
+,	O
+different	O
+sanitary	O
+responses	O
+were	O
+documented	O
+between	O
+Europe	O
+and	O
+North	O
+America	O
+in	O
+terms	O
+of	O
+vaccination	O
+and	O
+compliance	O
+with	O
+infection	B-DISO
+prevention	O
+and	O
+control	O
+measures	O
+.	O
+
+Those	O
+suspected	O
+as	O
+a	O
+source	O
+of	O
+viral	B-PROC
+transmission	I-PROC
+were	O
+categorized	O
+into	O
+the	O
+spreader	O
+groups	O
+(	O
+super	O
+-	O
+spreader	O
+[	O
+n	O
+=	O
+5	O
+]	O
+and	O
+usual	O
+-	O
+spreader	O
+[	O
+n	O
+=	O
+10	O
+])	O
+and	O
+compared	O
+to	O
+the	O
+non	O
+-	O
+spreader	O
+group	O
+(	O
+n	O
+=	O
+171	O
+).	O
+
+ABSTRACT	O
+:	O
+Advances	O
+in	O
+diagnostic	O
+techniques	O
+have	O
+led	O
+to	O
+better	O
+distinction	O
+between	O
+types	O
+of	O
+vasculitis	O
+,	O
+potentially	O
+affecting	O
+the	O
+utility	O
+of	O
+the	O
+1990	O
+ACR	O
+classification	O
+criteria	O
+for	O
+vasculitis	B-DISO
+.	O
+
+Data	O
+from	O
+1095	O
+patients	O
+with	O
+primary	B-DISO
+systemic	I-DISO
+vasculitis	I-DISO
+and	O
+415	O
+with	O
+comparator	O
+conditions	O
+were	O
+available	O
+.	O
+
+Of	O
+cases	O
+identified	O
+by	O
+their	O
+respective	O
+criteria	O
+,	O
+16	O
+.	O
+9	O
+%	O
+also	O
+met	B-CHED
+criteria	O
+for	O
+other	O
+vasculitides	B-DISO
+.	O
+
+Five	O
+individuals	O
+died	B-PROC
+during	O
+hospitalization	O
+.	O
+
+1	O
+results	O
+,	O
+a	O
+second	O
+experiment	O
+was	O
+developed	O
+to	O
+determine	O
+the	O
+impact	O
+of	O
+lower	O
+processing	O
+temperatures	O
+on	O
+PEDV	B-SPEC
+quantity	O
+and	O
+infectivity	O
+.	O
+
+2	O
+,	O
+PEDV	B-SPEC
+-	O
+inoculated	O
+feed	O
+was	O
+pelleted	O
+at	O
+1	O
+of	O
+5	O
+conditioning	O
+temperatures	O
+(	O
+37	O
+.	O
+8	O
+,	O
+46	O
+.	O
+1	O
+,	O
+54	O
+.	O
+4	O
+,	O
+62	O
+.	O
+8	O
+,	O
+and	O
+71	O
+.	O
+1	O
+°	O
+C	O
+)	O
+for	O
+30	O
+s	O
+.	O
+The	O
+5	O
+increasing	O
+processing	O
+temperatures	O
+led	O
+to	O
+feed	O
+with	O
+respective	O
+mean	O
+Ct	O
+values	O
+of	O
+32	O
+.	O
+5	O
+,	O
+34	O
+.	O
+6	O
+,	O
+37	O
+.	O
+0	O
+,	O
+36	O
+.	O
+5	O
+,	O
+and	O
+36	O
+.	O
+7	O
+,	O
+respectively	O
+.	O
+
+Sentinel	O
+pigs	B-SPEC
+in	O
+the	O
+low	O
+biosecurity	O
+group	O
+(	O
+LB	O
+)	O
+became	O
+PEDV	B-SPEC
+positive	O
+after	O
+the	O
+first	O
+movement	B-PROC
+of	O
+study	O
+personnel	O
+from	O
+the	O
+INF	B-PRGE
+group	I-PRGE
+.	O
+
+The	O
+viral	O
+spike	O
+(	O
+S	O
+)	O
+glycoprotein	B-CHED
+,	O
+responsible	O
+for	O
+receptor	B-FUNC
+binding	I-FUNC
+and	O
+cell	B-COMP
+entry	O
+,	O
+is	O
+the	O
+major	O
+target	O
+for	O
+neutralizing	O
+antibodies	B-COMP
+.	O
+
+However	O
+,	O
+knowledge	O
+of	O
+antibody	B-COMP
+epitopes	O
+,	O
+their	O
+nature	O
+and	O
+location	O
+in	O
+the	O
+spike	O
+structure	O
+,	O
+and	O
+the	O
+mechanisms	O
+by	O
+which	O
+the	O
+antibodies	B-COMP
+interfere	O
+with	O
+infection	B-DISO
+is	O
+scarce	O
+.	O
+
+By	O
+expression	B-PROC
+of	O
+different	O
+S1	O
+protein	O
+fragments	O
+,	O
+six	O
+antibody	B-COMP
+epitope	B-CHED
+classes	O
+distributed	O
+over	O
+the	O
+five	O
+structural	O
+domains	O
+of	O
+the	O
+S1	B-PRGE
+subunit	I-PRGE
+were	O
+identified	O
+.	O
+
+Our	O
+observations	O
+picture	O
+the	O
+antibody	B-COMP
+epitope	B-CHED
+landscape	O
+of	O
+the	O
+PEDV	B-PRGE
+S1	I-PRGE
+subunit	I-PRGE
+and	O
+reveal	O
+that	O
+its	O
+cell	B-COMP
+attachment	I-COMP
+domains	O
+are	O
+key	O
+targets	O
+of	O
+neutralizing	O
+antibodies	B-COMP
+.	O
+
+After	O
+binding	B-FUNC
+to	O
+their	O
+respective	O
+IFN	B-PRGE
+receptors	I-PRGE
+and	O
+activation	O
+of	O
+the	O
+cellular	B-COMP
+JAK	B-PROC
+/	O
+signal	O
+transducer	O
+and	O
+activator	O
+of	O
+transcription	B-PROC
+signaling	B-PROC
+cascade	I-PROC
+,	O
+they	O
+stimulate	O
+the	O
+transcription	B-PROC
+of	O
+a	O
+plethora	O
+of	O
+IFN	B-PRGE
+-	O
+stimulated	O
+genes	O
+(	O
+ISGs	O
+)	O
+in	O
+infected	O
+as	O
+well	O
+as	O
+bystander	O
+cells	B-COMP
+such	O
+as	O
+the	O
+non	O
+-	O
+infected	O
+epithelium	B-ANAT
+and	O
+cells	B-COMP
+of	O
+the	O
+immune	B-ANAT
+system	I-ANAT
+.	O
+
+Emerging	B-DISO
+infectious	I-DISO
+diseases	I-DISO
+are	O
+defined	O
+as	O
+those	O
+whose	O
+incidence	O
+in	O
+humans	B-SPEC
+has	O
+increased	O
+in	O
+the	O
+past	O
+two	O
+decades	O
+or	O
+threaten	O
+to	O
+increase	O
+in	O
+the	O
+near	O
+future	O
+.	O
+
+All	O
+newly	O
+-	O
+identified	O
+betacoronaviruses	O
+were	O
+SARS	B-DISO
+-	O
+related	O
+Rhinolophus	B-SPEC
+bat	B-ENZY
+coronaviruses	O
+(	O
+SARSr	O
+-	O
+Rh	O
+-	O
+BatCoV	O
+).	O
+
+Inter	O
+-	O
+species	B-SPEC
+transmission	O
+among	O
+bats	B-SPEC
+from	O
+the	O
+same	O
+genus	B-SPEC
+was	O
+also	O
+commonplace	O
+in	O
+both	O
+the	O
+alphacoronaviruses	O
+and	O
+betacoronaviruses	O
+.	O
+
+Therefore	O
+,	O
+providing	O
+accurate	O
+information	O
+and	O
+data	O
+to	O
+the	O
+public	O
+,	O
+establishing	O
+trust	O
+,	O
+and	O
+facilitating	O
+the	O
+development	B-PROC
+of	O
+an	O
+attitude	O
+will	O
+all	O
+be	O
+important	O
+in	O
+future	O
+crises	O
+.	O
+
+ABSTRACT	O
+:	O
+There	O
+are	O
+two	O
+biotypes	O
+of	O
+feline	B-SPEC
+coronavirus	B-SPEC
+(	O
+FCoV	O
+):	O
+the	O
+self	O
+-	O
+limiting	O
+feline	B-SPEC
+enteric	B-SPEC
+coronavirus	I-SPEC
+(	O
+FECV	B-SPEC
+)	O
+and	O
+the	O
+feline	B-DISO
+infectious	I-DISO
+peritonitis	I-DISO
+virus	B-SPEC
+(	O
+FIPV	O
+),	O
+which	O
+causes	O
+feline	B-DISO
+infectious	I-DISO
+peritonitis	I-DISO
+(	O
+FIP	B-DISO
+),	O
+a	O
+fatal	O
+disease	O
+associated	O
+with	O
+cats	B-SPEC
+living	O
+in	O
+multi	O
+-	O
+cat	B-SPEC
+environments	O
+.	O
+
+As	O
+expected	O
+,	O
+the	O
+secretion	B-PROC
+of	O
+IL1β	O
+,	O
+IL6	B-PRGE
+and	O
+TNFα	O
+was	O
+readily	O
+detected	O
+in	O
+the	O
+supernatant	O
+of	O
+peritoneal	B-ANAT
+effusions	I-ANAT
+of	O
+the	O
+FCoV	O
+-	O
+positive	O
+cats	B-SPEC
+.	O
+
+In	O
+this	O
+study	O
+,	O
+our	O
+findings	O
+were	O
+the	O
+first	O
+to	O
+demonstrate	O
+that	O
+LiCl	B-CHED
+inhibition	B-PROC
+of	O
+the	O
+FMDV	B-SPEC
+replication	O
+.	O
+
+In	O
+this	O
+article	O
+,	O
+we	O
+summarize	O
+pulmonary	B-ANAT
+fibrotic	O
+changes	O
+observed	O
+after	O
+a	O
+SARS	B-DISO
+-	I-DISO
+CoV	I-DISO
+infection	I-DISO
+,	O
+discuss	O
+the	O
+extent	O
+to	O
+which	O
+other	O
+respiratory	O
+viruses	B-SPEC
+induce	O
+fibrosis	O
+,	O
+describe	O
+available	O
+animal	B-SPEC
+models	O
+to	O
+study	O
+the	O
+development	B-PROC
+of	O
+SARS	B-DISO
+-	O
+CoV	O
+induced	O
+fibrosis	B-DISO
+and	O
+review	O
+evidence	O
+that	O
+pulmonary	B-DISO
+fibrosis	I-DISO
+is	O
+caused	O
+by	O
+a	O
+hyperactive	O
+host	B-PROC
+response	I-PROC
+to	O
+lung	B-ANAT
+injury	O
+mediated	O
+by	O
+epidermal	B-PRGE
+growth	B-PROC
+factor	I-PRGE
+receptor	I-PRGE
+(	O
+EGFR	B-FUNC
+)	O
+signaling	B-PROC
+.	O
+
+We	O
+screened	O
+for	O
+both	O
+DNA	O
+and	O
+RNA	O
+viruses	B-SPEC
+;	O
+specifically	O
+,	O
+astroviruses	O
+(	O
+AstVs	O
+),	O
+adenoviruses	B-SPEC
+(	O
+ADVs	O
+),	O
+caliciviruses	O
+(	O
+CalVs	O
+),	O
+coronaviruses	O
+(	O
+CoVs	O
+),	O
+flaviviruses	B-SPEC
+,	O
+filoviruses	O
+,	O
+paramyxoviruses	O
+(	O
+PMVs	O
+),	O
+polyomaviruses	B-SPEC
+(	O
+PYVs	O
+)	O
+and	O
+rotaviruses	B-SPEC
+.	O
+
+We	O
+used	O
+family	B-SPEC
+-	O
+specific	O
+primers	O
+,	O
+amplicon	O
+sequencing	O
+and	O
+further	O
+characterization	O
+by	O
+phylogenetic	O
+analysis	O
+.	O
+
+PNA	B-CHED
+probes	O
+are	O
+an	O
+attractive	O
+alternative	O
+to	O
+DNA	O
+and	O
+RNA	O
+probes	O
+because	O
+they	O
+are	O
+chemically	O
+and	O
+biologically	O
+stable	O
+,	O
+easily	O
+synthesized	O
+,	O
+and	O
+hybridize	O
+efficiently	O
+with	O
+the	O
+complementary	O
+DNA	O
+strands	O
+.	O
+
+ABSTRACT	O
+:	O
+Infections	B-DISO
+of	O
+the	O
+respiratory	B-ANAT
+tract	I-ANAT
+can	O
+be	O
+caused	O
+by	O
+a	O
+diversity	O
+of	O
+pathogens	O
+,	O
+both	O
+viral	O
+and	O
+bacterial	O
+.	O
+
+Doubling	O
+the	O
+concentration	O
+of	O
+the	O
+additives	O
+reduced	O
+the	O
+delta	O
+value	O
+to	O
+≤	O
+0	O
+.	O
+28	O
+days	O
+(	O
+Commercial	O
+feed	O
+additives	O
+(	O
+acidifiers	O
+and	O
+salt	B-CHED
+)	O
+may	O
+be	O
+utilized	O
+as	O
+a	O
+strategy	O
+to	O
+decrease	O
+risk	O
+of	O
+PDCoV	O
+in	O
+feed	O
+,	O
+specially	O
+,	O
+commercial	O
+feed	O
+acidifiers	O
+at	O
+double	O
+the	O
+recommended	O
+concentrations	O
+reduced	O
+PDCoV	O
+survival	O
+in	O
+complete	O
+feed	O
+during	O
+storage	B-PROC
+at	O
+room	O
+temperature	O
+.	O
+
+Hypoxemia	O
+is	O
+mainly	O
+due	O
+to	O
+intrapulmonary	O
+shunt	O
+,	O
+whereas	O
+increased	O
+alveolar	B-ANAT
+dead	B-PROC
+space	O
+explains	O
+the	O
+alteration	O
+of	O
+CO	O
+
+ABSTRACT	O
+:	O
+Prior	O
+studies	O
+suggest	O
+hypothermia	O
+may	O
+be	O
+beneficial	O
+in	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+,	O
+but	O
+cooling	O
+causes	O
+shivering	O
+and	O
+increases	O
+metabolism	B-PROC
+.	O
+
+Retrospective	O
+review	O
+of	O
+58	O
+patients	O
+with	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+based	O
+on	O
+Berlin	O
+criteria	O
+and	O
+PaO2	O
+/	O
+FIO2	O
+less	O
+than	O
+150	O
+who	O
+received	O
+neuromuscular	B-DISO
+blockade	I-DISO
+.	O
+
+TITLE	O
+:	O
+Investigating	O
+hyperventilation	B-DISO
+syndrome	I-DISO
+in	O
+patients	O
+suffering	B-DISO
+from	O
+empty	O
+nose	B-ANAT
+syndrome	B-DISO
+.	O
+
+HVS	B-FUNC
+was	O
+defined	O
+by	O
+a	O
+delayed	O
+return	O
+of	O
+the	O
+end	O
+-	O
+tidal	O
+partial	O
+pressure	O
+of	O
+carbon	B-CHED
+dioxide	I-CHED
+in	O
+the	O
+expired	O
+gas	B-ENZY
+to	O
+baseline	O
+during	O
+HVPT	O
+.	O
+
+HVS	B-FUNC
+was	O
+diagnosed	O
+in	O
+17	O
+of	O
+these	O
+patients	O
+(	O
+77	O
+.	O
+3	O
+%).	O
+
+ABSTRACT	O
+:	O
+In	O
+May	O
+of	O
+2013	O
+,	O
+porcine	B-SPEC
+epidemic	I-SPEC
+diarrhea	I-SPEC
+virus	I-SPEC
+(	O
+PEDV	B-SPEC
+)	O
+was	O
+detected	O
+in	O
+swine	B-SPEC
+for	O
+the	O
+first	O
+time	O
+in	O
+North	O
+America	O
+.	O
+
+Three	O
+-	O
+week	O
+-	O
+old	O
+barrows	O
+were	O
+inoculated	O
+intragastrically	O
+with	O
+5	O
+mL	O
+of	O
+PEDV	B-SPEC
+-	O
+negative	O
+feces	B-ANAT
+for	O
+the	O
+negative	O
+control	O
+,	O
+5	O
+mL	O
+of	O
+untreated	O
+PEDV	B-SPEC
+-	O
+positive	O
+feces	B-ANAT
+for	O
+the	O
+positive	O
+control	O
+,	O
+and	O
+5	O
+mL	O
+or	O
+10	O
+mL	O
+of	O
+PEDV	B-SPEC
+-	O
+positive	O
+feces	B-ANAT
+that	O
+was	O
+subjected	O
+to	O
+treatment	O
+with	O
+a	O
+1	O
+:	O
+16	O
+or	O
+1	O
+:	O
+32	O
+concentrations	O
+of	O
+accelerated	O
+hydrogen	B-CHED
+peroxide	I-CHED
+disinfectant	B-CHED
+for	O
+a	O
+contact	O
+time	O
+of	O
+30	O
+min	O
+at	O
+20	O
+°	O
+C	O
+.	O
+
+TITLE	O
+:	O
+Three	O
+Hypothetical	O
+Inflammation	B-DISO
+Pathobiology	O
+Phenotypes	O
+and	O
+Pediatric	O
+Sepsis	B-DISO
+-	O
+Induced	O
+Multiple	B-DISO
+Organ	I-DISO
+Failure	I-DISO
+Outcome	O
+.	O
+
+Prospective	O
+cohort	O
+study	O
+comparing	O
+children	O
+with	O
+severe	B-DISO
+sepsis	I-DISO
+and	O
+any	O
+of	O
+three	O
+phenotypes	O
+:	O
+1	O
+)	O
+immunoparalysis	O
+-	O
+associated	O
+multiple	B-DISO
+organ	I-DISO
+failure	I-DISO
+(	O
+whole	B-ANAT
+blood	I-ANAT
+ex	O
+vivo	O
+tumor	B-FUNC
+necrosis	I-FUNC
+factor	I-FUNC
+response	B-PROC
+to	I-PROC
+endotoxin	I-PROC
+<	O
+200	O
+pg	O
+/	O
+mL	O
+),	O
+2	O
+)	O
+thrombocytopenia	O
+-	O
+associated	O
+multiple	B-DISO
+organ	I-DISO
+failure	I-DISO
+(	O
+new	O
+onset	O
+thrombocytopenia	O
+with	O
+acute	O
+kidney	B-ANAT
+injury	O
+and	O
+a	O
+disintegrin	O
+and	O
+metalloproteinase	B-PRGE
+with	O
+a	O
+thrombospondin	O
+type	O
+1	O
+motif	O
+,	O
+member	O
+13	O
+activity	O
+<	O
+57	O
+%),	O
+and	O
+/	O
+or	O
+3	O
+)	O
+sequential	O
+multiple	B-DISO
+organ	I-DISO
+failure	I-DISO
+with	O
+hepatobiliary	B-ANAT
+dysfunction	O
+(	O
+respiratory	B-DISO
+distress	I-DISO
+followed	O
+by	O
+liver	B-DISO
+dysfunction	I-DISO
+with	O
+soluble	O
+Fas	B-PRGE
+ligand	B-PROC
+>	O
+200	O
+pg	O
+/	O
+mL	O
+),	O
+to	O
+those	O
+without	O
+any	O
+of	O
+these	O
+phenotypes	O
+.	O
+
+Extracorporeal	O
+membrane	B-COMP
+oxygenation	B-PROC
+may	O
+serve	O
+as	O
+rescue	O
+therapy	O
+in	O
+refractory	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+but	O
+has	O
+not	O
+been	O
+assessed	O
+in	O
+allogeneic	O
+hematopoietic	B-ANAT
+stem	I-ANAT
+cell	I-ANAT
+transplantation	O
+recipients	O
+.	O
+
+These	O
+viruses	B-SPEC
+were	O
+detected	O
+in	O
+both	O
+healthy	O
+and	O
+diseased	O
+birds	B-SPEC
+.	O
+
+ABSTRACT	O
+:	O
+The	O
+model	O
+of	O
+infectious	B-DISO
+disease	I-DISO
+prevention	O
+and	O
+control	O
+changed	O
+significantly	O
+in	O
+China	O
+after	O
+the	O
+outbreak	O
+in	O
+2003	O
+of	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+(	O
+SARS	B-DISO
+),	O
+but	O
+trends	O
+and	O
+epidemiological	O
+features	O
+of	O
+infectious	B-DISO
+diseases	I-DISO
+are	O
+rarely	O
+studied	O
+.	O
+
+In	O
+this	O
+study	O
+,	O
+we	O
+aimed	O
+to	O
+assess	O
+specific	O
+incidence	O
+and	O
+mortality	O
+trends	O
+of	O
+45	O
+notifiable	O
+infectious	B-DISO
+diseases	I-DISO
+from	O
+2004	O
+to	O
+2013	O
+in	O
+China	O
+and	O
+to	O
+investigate	O
+the	O
+overall	O
+effectiveness	O
+of	O
+current	O
+prevention	O
+and	O
+control	O
+strategies	O
+.	O
+
+We	O
+estimated	O
+the	O
+annual	O
+percentage	O
+change	O
+in	O
+incidence	O
+of	O
+each	O
+infectious	B-DISO
+disease	I-DISO
+using	O
+joinpoint	O
+regression	O
+.	O
+
+The	O
+infectious	B-DISO
+diseases	I-DISO
+with	O
+the	O
+highest	O
+yearly	O
+incidence	O
+were	O
+hand	B-DISO
+,	I-DISO
+foot	I-DISO
+,	I-DISO
+and	I-DISO
+mouth	B-ANAT
+disease	I-DISO
+(	O
+114	O
+·	O
+48	O
+per	O
+100	O
+000	O
+),	O
+hepatitis	B-DISO
+B	I-DISO
+(	O
+81	O
+·	O
+57	O
+per	O
+100	O
+000	O
+),	O
+and	O
+tuberculosis	B-PATH
+(	O
+80	O
+·	O
+33	O
+per	O
+100	O
+000	O
+).	O
+
+Comprehensive	O
+analysis	O
+of	O
+ubiquitin	B-PROC
+-	O
+conjugated	B-CHED
+proteins	I-CHED
+using	O
+immunoprecipitation	O
+and	O
+nanoLC	O
+-	O
+MS	O
+/	O
+MS	O
+indicated	O
+that	O
+SARS	B-PRGE
+-	I-PRGE
+CoV	I-PRGE
+PLpro	I-PRGE
+caused	O
+the	O
+change	O
+in	O
+the	O
+ubiquitination	B-PROC
+profile	O
+of	O
+Rho	O
+GTPase	O
+family	O
+proteins	B-CHED
+,	O
+in	O
+which	O
+linked	O
+with	O
+the	O
+increase	O
+of	O
+Rho	B-PRGE
+-	I-PRGE
+like	I-PRGE
+GTPase	I-PRGE
+family	I-PRGE
+proteins	B-CHED
+.	O
+
+Though	O
+still	O
+in	O
+its	O
+infancy	O
+,	O
+airway	B-ANAT
+protease	O
+inhibition	B-PROC
+represents	O
+an	O
+attractive	O
+host	B-COMP
+-	O
+cell	B-COMP
+targeting	B-PROC
+approach	O
+to	O
+combat	B-CHED
+respiratory	O
+viruses	B-SPEC
+such	O
+as	O
+influenza	B-DISO
+.	O
+
+ABSTRACT	O
+:	O
+Extracorporeal	O
+membrane	O
+oxygenation	B-PROC
+is	O
+used	O
+as	O
+a	O
+last	O
+resort	O
+during	O
+neonatal	O
+and	O
+pediatric	O
+resuscitation	O
+in	O
+case	O
+of	O
+refractory	O
+circulatory	B-PROC
+or	O
+respiratory	B-DISO
+failure	I-DISO
+under	O
+maximum	O
+conventional	O
+therapies	O
+.	O
+
+Neurological	O
+impairment	B-DISO
+can	O
+occur	O
+during	O
+ECMO	O
+(	O
+cranial	B-ANAT
+hemorrhage	B-DISO
+,	O
+seizure	B-DISO
+or	O
+stroke	B-DISO
+).	O
+
+Various	O
+studies	O
+have	O
+investigated	O
+bat	B-ENZY
+viruses	B-SPEC
+in	O
+tropical	O
+regions	O
+,	O
+but	O
+to	O
+date	O
+there	O
+are	O
+no	O
+data	O
+regarding	O
+viruses	B-SPEC
+with	O
+zoonotic	O
+potential	O
+that	O
+circulate	O
+in	O
+bat	B-ENZY
+and	O
+rat	B-SPEC
+populations	O
+in	O
+Viet	O
+Nam	O
+.	O
+
+Faecal	B-ANAT
+and	O
+urine	B-ANAT
+samples	O
+were	O
+screened	O
+for	O
+the	O
+presence	O
+of	O
+RNA	O
+from	O
+paramyxoviruses	O
+,	O
+coronaviruses	O
+and	O
+filoviruses	O
+.	O
+
+The	O
+main	O
+organizing	O
+principles	O
+of	O
+the	O
+CDCMN	O
+are	O
+centralized	O
+isolation	O
+of	O
+patients	O
+with	O
+severe	O
+highly	O
+infectious	B-DISO
+diseases	I-DISO
+and	O
+centralization	O
+of	O
+medical	O
+resources	O
+,	O
+as	O
+well	O
+as	O
+a	O
+network	O
+of	O
+designated	O
+regional	O
+hospitals	O
+like	O
+those	O
+in	O
+other	O
+countries	O
+.	O
+
+Many	O
+communication	O
+strategies	O
+,	O
+ranging	O
+from	O
+traditional	O
+media	B-ANAT
+to	O
+social	O
+and	O
+new	O
+media	B-ANAT
+,	O
+have	O
+been	O
+implemented	O
+to	O
+improve	O
+transparency	O
+in	O
+public	O
+communication	O
+and	O
+promote	O
+civic	O
+engagement	O
+.	O
+
+Furthermore	O
+,	O
+the	O
+potential	O
+emergence	O
+of	O
+highly	O
+pathogenic	O
+strains	O
+of	O
+influenza	B-SPEC
+virus	I-SPEC
+poses	O
+a	O
+significant	O
+public	O
+health	O
+threat	O
+.	O
+
+Thus	O
+,	O
+the	O
+development	B-PROC
+of	O
+vaccines	O
+capable	O
+of	O
+eliciting	O
+long	O
+-	O
+lasting	O
+protective	O
+immunity	B-PROC
+to	O
+those	O
+pathogens	O
+is	O
+a	O
+major	O
+public	O
+health	O
+priority	O
+.	O
+
+TITLE	O
+:	O
+The	O
+effect	O
+of	O
+diatomaceous	O
+earth	O
+in	O
+live	O
+,	O
+attenuated	O
+infectious	B-DISO
+bronchitis	B-DISO
+vaccine	O
+,	O
+immune	B-PROC
+responses	I-PROC
+,	O
+and	O
+protection	O
+against	O
+challenge	O
+.	O
+
+Massive	O
+application	O
+and	O
+generation	O
+of	O
+a	O
+protective	O
+local	O
+mucosal	B-ANAT
+and	O
+humoral	B-PROC
+immunity	I-PROC
+with	O
+no	O
+adverse	B-DISO
+effects	I-DISO
+is	O
+the	O
+main	O
+goal	O
+for	O
+this	O
+strategy	O
+.	O
+
+Correspondence	O
+analysis	O
+reveals	O
+the	O
+presence	O
+of	O
+3	O
+genetic	O
+clusters	B-CHED
+based	O
+on	O
+codon	O
+usage	O
+in	O
+PLpro	O
+and	O
+3CLpro	O
+.	O
+
+The	O
+results	O
+suggested	O
+a	O
+close	O
+association	O
+between	O
+C	B-PRGE
+-	I-PRGE
+C	I-PRGE
+motif	I-PRGE
+chemokine	I-PRGE
+ligand	I-PRGE
+2	I-PRGE
+(	O
+CCL2	B-PRGE
+)	O
+expressions	O
+and	O
+ALI	O
+induced	O
+by	O
+a	O
+lethal	O
+H7N9	O
+virus	B-SPEC
+strain	O
+(	O
+A	O
+/	O
+Hebei	O
+/	O
+01	O
+/	O
+2013	O
+).	O
+
+More	O
+importantly	O
+,	O
+CCL2	B-PRGE
+deficiency	O
+ameliorated	O
+H7N9	O
+-	O
+induced	O
+ALI	O
+in	O
+mice	B-SPEC
+as	O
+determined	O
+by	O
+weight	O
+loss	O
+,	O
+survival	O
+rate	O
+,	O
+the	O
+wet	O
+:	O
+dry	O
+ratio	O
+of	O
+the	O
+lung	O
+,	O
+and	O
+pathology	B-DISO
+.	O
+
+In	O
+other	O
+experiments	O
+,	O
+right	O
+ventricular	B-ANAT
+systolic	O
+pressure	O
+was	O
+recorded	O
+during	O
+hypoxic	O
+challenges	O
+in	O
+uninjured	O
+WT	O
+mice	B-SPEC
+pretreated	O
+with	O
+rHuIL	O
+-	O
+6	O
+or	O
+rHuIL	O
+-	O
+6	O
++	O
+non	O
+-	O
+selective	O
+nitric	O
+oxide	O
+synthase	O
+inhibitor	O
+L	O
+-	O
+NAME	B-SPEC
+or	O
+vehicle	O
+.	O
+
+This	O
+is	O
+a	O
+syndrome	B-DISO
+that	O
+in	O
+some	O
+ways	O
+mimics	O
+severe	B-DISO
+sepsis	I-DISO
+with	O
+associated	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+,	O
+possibly	O
+requiring	O
+a	O
+ventilator	O
+and	O
+vasopressor	O
+support	O
+.	O
+
+The	O
+objectives	O
+of	O
+this	O
+study	O
+were	O
+to	O
+determine	O
+the	O
+prevalence	O
+of	O
+feline	B-SPEC
+coronavirus	B-SPEC
+(	O
+FCoV	O
+)	O
+viremia	B-DISO
+,	O
+and	O
+its	O
+replication	O
+in	O
+peripheral	B-ANAT
+blood	I-ANAT
+using	O
+quantitative	O
+RT	B-PRGE
+-	I-PRGE
+PCR	I-PRGE
+(	O
+qRT	O
+-	O
+PCR	O
+)	O
+methodology	O
+in	O
+a	O
+population	O
+of	O
+205	O
+healthy	O
+shelter	O
+cats	B-SPEC
+in	O
+Southern	O
+California	B-SPEC
+,	O
+as	O
+well	O
+as	O
+to	O
+assess	O
+any	O
+possible	O
+connection	O
+to	O
+longitudinal	O
+development	B-PROC
+of	O
+feline	B-DISO
+infectious	I-DISO
+peritonitis	I-DISO
+(	O
+FIP	B-DISO
+).	O
+
+From	O
+50	O
+of	O
+these	O
+cats	B-SPEC
+,	O
+fecal	B-ANAT
+samples	O
+were	O
+also	O
+examined	O
+.	O
+
+More	O
+data	O
+are	O
+needed	O
+on	O
+RVIs	O
+in	O
+the	O
+solid	O
+organ	B-ANAT
+transplant	I-ANAT
+population	O
+,	O
+particularly	O
+regarding	O
+their	O
+effect	O
+on	O
+rejection	O
+and	O
+graft	B-DISO
+dysfunction	I-DISO
+.	O
+
+A	O
+constellation	O
+of	O
+physical	O
+and	O
+psychological	B-DISO
+problems	O
+can	O
+develop	O
+or	O
+persist	O
+for	O
+up	O
+to	O
+5	O
+years	O
+in	O
+patients	O
+with	O
+ARDS	B-DISO
+.	O
+
+Cell	B-COMP
+-	O
+free	O
+supernatants	O
+(	O
+CFS	B-DISO
+)	O
+and	O
+live	O
+LAB	O
+were	O
+evaluated	O
+for	O
+antiviral	B-CHED
+activities	O
+by	O
+co	O
+-	O
+incubation	O
+on	O
+Vero	B-ANAT
+cells	I-ANAT
+and	O
+challenged	O
+with	O
+a	O
+pandemic	O
+strain	O
+of	O
+PEDV	B-SPEC
+isolated	O
+from	O
+pigs	B-SPEC
+in	O
+Thailand	O
+.	O
+
+plantarum	O
+showed	O
+the	O
+antiviral	B-CHED
+effect	O
+against	O
+PEDV	B-SPEC
+;	O
+however	O
+,	O
+the	O
+same	O
+antiviral	B-CHED
+effect	O
+could	O
+not	O
+be	O
+observed	O
+in	O
+Ent	B-ANAT
+.	O
+
+Two	O
+groups	O
+of	O
+4	O
+animals	B-SPEC
+each	O
+received	O
+a	O
+2	O
+-	O
+hour	O
+infusion	O
+of	O
+LPS	B-DISO
+through	O
+the	O
+external	B-ANAT
+jugular	I-ANAT
+vein	I-ANAT
+.	O
+
+Serial	O
+measurements	O
+of	O
+blood	B-PROC
+gases	I-PROC
+were	O
+performed	O
+every	O
+30	O
+minutes	O
+until	O
+the	O
+partial	B-PROC
+pressure	I-PROC
+of	I-PROC
+oxygen	I-PROC
+/	O
+fraction	O
+of	O
+inspired	B-PROC
+oxygen	B-CHED
+ratio	O
+dropped	O
+below	O
+150	O
+on	O
+two	O
+consecutive	O
+readings	O
+.	O
+
+Therefore	O
+,	O
+the	O
+activity	O
+of	O
+PLPs	O
+from	O
+SARS	B-PRGE
+-	I-PRGE
+CoV	I-PRGE
+,	O
+MERS	O
+-	O
+CoV	O
+,	O
+and	O
+mouse	B-DISO
+hepatitis	I-DISO
+virus	O
+was	O
+evaluated	O
+against	O
+seven	O
+ISG15s	O
+originating	O
+from	O
+an	O
+assortment	O
+of	O
+animal	B-SPEC
+species	B-SPEC
+susceptible	O
+,	O
+and	O
+not	O
+,	O
+to	O
+certain	O
+coronavirus	B-DISO
+infections	I-DISO
+.	O
+
+The	O
+first	O
+X	O
+-	O
+ray	B-SPEC
+structure	O
+of	O
+the	O
+full	B-PRGE
+-	I-PRGE
+length	I-PRGE
+mISG15	I-PRGE
+protein	I-PRGE
+is	O
+also	O
+reported	O
+and	O
+highlights	O
+a	O
+unique	O
+,	O
+twisted	O
+hinge	O
+region	O
+of	O
+ISG15	B-PRGE
+that	O
+is	O
+not	O
+conserved	O
+in	O
+hISG15	O
+,	O
+suggesting	O
+a	O
+potential	O
+role	O
+in	O
+differential	O
+recognition	O
+.	O
+
+Taken	O
+together	O
+,	O
+this	O
+new	O
+information	O
+provides	O
+a	O
+structural	O
+and	O
+biochemical	O
+understanding	O
+of	O
+the	O
+distinct	O
+specificities	O
+among	O
+coronavirus	B-SPEC
+PLPs	O
+observed	O
+and	O
+addresses	O
+a	O
+critical	O
+gap	O
+of	O
+how	O
+PLPs	O
+can	O
+interact	O
+with	O
+ISG15s	O
+from	O
+a	O
+wide	O
+variety	O
+of	O
+species	B-SPEC
+.	O
+
+ABSTRACT	O
+:	O
+Clinical	B-DISO
+findings	I-DISO
+,	O
+mortality	O
+,	O
+and	O
+morbidity	O
+rates	O
+differ	O
+among	O
+influenza	B-DISO
+subspecies	O
+.	O
+
+Two	O
+patients	O
+with	O
+chronic	B-DISO
+diseases	I-DISO
+and	O
+H1N1	O
+infection	B-DISO
+died	B-PROC
+secondary	O
+to	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+.	O
+
+ABSTRACT	O
+:	O
+GATA2	B-PRGE
+mutations	O
+have	O
+been	O
+identified	O
+in	O
+various	O
+diseases	O
+,	O
+such	O
+as	O
+MonoMAC	O
+syndrome	B-DISO
+,	O
+Emberger	B-DISO
+syndrome	I-DISO
+,	O
+familial	O
+myelodysplastic	B-DISO
+syndrome	I-DISO
+,	O
+acute	B-DISO
+myeloid	I-DISO
+leukaemia	I-DISO
+and	O
+dendritic	B-ANAT
+cell	B-COMP
+,	O
+monocyte	B-ANAT
+,	O
+B	B-ANAT
+-	I-ANAT
+cell	I-ANAT
+and	O
+natural	O
+killer	O
+-	O
+cell	B-COMP
+deficiency	O
+.	O
+
+ABSTRACT	O
+:	O
+Plastic	B-DISO
+bronchitis	I-DISO
+is	O
+used	O
+to	O
+designate	O
+endobronchial	O
+plugs	O
+of	O
+rubber	B-CHED
+-	O
+like	O
+consistency	O
+that	O
+form	O
+into	O
+bronchial	B-ANAT
+trees	O
+.	O
+
+We	O
+report	O
+the	O
+first	O
+sickle	B-ANAT
+cell	I-ANAT
+adult	O
+case	O
+of	O
+plastic	B-DISO
+bronchitis	I-DISO
+during	O
+acute	B-DISO
+chest	I-DISO
+syndrome	I-DISO
+.	O
+
+Patients	O
+with	O
+MERS	O
+-	O
+CoV	O
+infection	B-DISO
+showed	O
+variable	O
+hematologic	O
+parameters	O
+over	O
+time	O
+.	O
+
+We	O
+determined	O
+the	O
+role	O
+of	O
+the	O
+antifibrinolytic	O
+protein	B-PRGE
+plasminogen	I-PRGE
+activator	I-PRGE
+inhibitor	B-CHED
+-	I-PRGE
+1	I-PRGE
+(	O
+PAI	B-PRGE
+-	I-PRGE
+1	I-PRGE
+)	O
+in	O
+alcohol	O
+enhancement	O
+of	O
+experimental	O
+endotoxin	O
+-	O
+induced	O
+ALI	O
+.	O
+
+Wild	O
+-	O
+type	O
+,	O
+PAI	B-PRGE
+-	I-PRGE
+1	I-PRGE
+
+The	O
+distribution	O
+of	O
+DPP4	B-PRGE
+in	O
+the	O
+respiratory	B-ANAT
+tract	I-ANAT
+tissues	B-ANAT
+of	O
+humans	B-SPEC
+and	O
+camels	B-SPEC
+reflects	O
+MERS	O
+-	O
+CoV	O
+tropism	B-PROC
+.	O
+
+The	O
+pathogenesis	B-DISO
+of	O
+TGEV	B-SPEC
+is	O
+strongly	O
+associated	O
+with	O
+inflammation	B-DISO
+.	O
+
+Phosphorylation	B-PROC
+of	O
+NF	B-PRGE
+-	I-PRGE
+κB	I-PRGE
+subunit	I-PRGE
+p65	I-PRGE
+and	O
+proinflammatory	O
+cytokine	B-PROC
+production	I-PROC
+were	O
+greatly	O
+decreased	O
+after	O
+knockdown	O
+of	O
+retinoic	B-CHED
+acid	I-CHED
+-	O
+inducible	O
+gene	B-PRGE
+I	I-PRGE
+(	O
+RIG	O
+-	O
+I	O
+)-	O
+like	O
+receptors	O
+(	O
+RLRs	O
+)	O
+or	O
+its	O
+adaptors	O
+MAVS	O
+and	O
+STING	O
+,	O
+while	O
+only	O
+slight	O
+reduction	O
+was	O
+observed	O
+in	O
+cells	B-COMP
+following	O
+silencing	O
+of	O
+Toll	B-PRGE
+-	I-PRGE
+like	I-PRGE
+receptor	I-PRGE
+adaptors	O
+,	O
+MyD88	B-PRGE
+and	O
+TRIF	B-PRGE
+.	O
+
+Furthermore	O
+,	O
+TGEV	B-SPEC
+infection	B-DISO
+significantly	O
+upregulated	O
+mRNA	B-PROC
+expression	B-PROC
+of	O
+RIG	B-PRGE
+-	I-PRGE
+I	I-PRGE
+and	O
+MDA5	B-PRGE
+.	O
+
+Other	O
+ARDS	B-DISO
+cohorts	O
+revealed	O
+a	O
+high	O
+heterogeneity	O
+in	O
+reported	O
+concomitant	O
+diseases	O
+,	O
+but	O
+sepsis	B-DISO
+and	O
+pneumonia	B-DISO
+were	O
+most	O
+frequently	O
+reported	O
+.	O
+
+ABSTRACT	O
+:	O
+Ventilator	B-DISO
+-	I-DISO
+associated	I-DISO
+pneumonia	I-DISO
+(	O
+VAP	O
+)	O
+due	O
+to	O
+Pseudomonas	B-SPEC
+aeruginosa	I-SPEC
+has	O
+a	O
+high	O
+mortality	O
+and	O
+recurrence	B-DISO
+rate	O
+,	O
+especially	O
+in	O
+patients	O
+with	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+(	O
+ARDS	B-DISO
+).	O
+
+The	O
+TIS	O
+group	O
+had	O
+significantly	O
+lower	O
+recurrence	B-DISO
+of	O
+P	O
+.	O
+aeruginosa	O
+VAP	O
+(	O
+22	O
+.	O
+7	O
+%	O
+vs	O
+.	O
+52	O
+.	O
+4	O
+%,	O
+P	O
+=	O
+0	O
+.	O
+04	O
+)	O
+and	O
+ICU	O
+mortality	O
+(	O
+22	O
+.	O
+7	O
+%	O
+vs	O
+.	O
+63	O
+.	O
+6	O
+%,	O
+P	O
+<	O
+0	O
+.	O
+01	O
+)	O
+than	O
+the	O
+control	O
+group	O
+.	O
+
+Bacterial	O
+concentration	O
+in	O
+tracheal	B-ANAT
+aspirate	I-ANAT
+(	O
+mean	O
+log	O
+10	O
+cfu	O
+/	O
+mL	O
+±	O
+SD	O
+on	O
+days	O
+2	O
+-	O
+5	O
+:	O
+1	O
+.	O
+2	O
+±	O
+1	O
+.	O
+3	O
+vs	O
+.	O
+5	O
+.	O
+0	O
+±	O
+2	O
+.	O
+3	O
+,	O
+P	O
+<	O
+0	O
+.	O
+01	O
+)	O
+decreased	O
+more	O
+rapidly	O
+and	O
+markedly	O
+in	O
+the	O
+TIS	O
+group	O
+compared	O
+with	O
+the	O
+control	O
+group	O
+.	O
+
+The	O
+phenylisoserine	O
+backbone	B-ANAT
+was	O
+found	O
+by	O
+simulation	O
+on	O
+GOLD	B-CHED
+software	O
+and	O
+the	O
+structure	O
+activity	O
+relationship	O
+study	O
+of	O
+phenylisoserine	O
+derivatives	O
+gave	O
+SK80	O
+with	O
+an	O
+IC	O
+
+For	O
+all	O
+patients	O
+with	O
+ARDS	B-DISO
+,	O
+the	O
+recommendation	O
+is	O
+strong	O
+for	O
+mechanical	O
+ventilation	O
+using	O
+lower	O
+tidal	O
+volumes	O
+(	O
+4	O
+-	O
+8	O
+ml	O
+/	O
+kg	O
+predicted	O
+body	B-ANAT
+weight	O
+)	O
+and	O
+lower	O
+inspiratory	B-PROC
+pressures	O
+(	O
+plateau	O
+pressure	O
+<	O
+30	O
+cm	O
+H	O
+The	O
+panel	O
+formulated	O
+and	O
+provided	O
+the	O
+rationale	O
+for	O
+recommendations	O
+on	O
+selected	O
+ventilatory	O
+interventions	O
+for	O
+adult	O
+patients	O
+with	O
+ARDS	B-DISO
+.	O
+
+Compared	O
+with	O
+healthy	O
+control	O
+group	O
+,	O
+both	O
+CRP	B-PRGE
+and	O
+PCT	B-DISO
+in	O
+serum	B-COMP
+of	O
+ARDS	B-DISO
+group	O
+were	O
+higher	O
+[	O
+CRP	B-PRGE
+(	O
+mg	O
+/	O
+L	O
+):	O
+146	O
+.	O
+32	O
+(	O
+111	O
+.	O
+31	O
+,	O
+168	O
+.	O
+49	O
+)	O
+vs	O
+.	O
+6	O
+.	O
+08	O
+(	O
+4	O
+.	O
+47	O
+,	O
+7	O
+.	O
+89	O
+),	O
+PCT	B-DISO
+(	O
+μg	O
+/	O
+L	O
+):	O
+3	O
+.	O
+46	O
+(	O
+1	O
+.	O
+98	O
+,	O
+5	O
+.	O
+56	O
+)	O
+vs	O
+.	O
+0	O
+.	O
+02	O
+(	O
+0	O
+.	O
+01	O
+,	O
+0	O
+.	O
+04	O
+),	O
+both	O
+P	O
+<	O
+0	O
+.	O
+01	O
+],	O
+and	O
+the	O
+two	O
+showed	O
+sustained	O
+upward	O
+trends	O
+with	O
+the	O
+ARDS	B-DISO
+course	O
+of	O
+disease	O
+.	O
+
+Using	O
+a	O
+PCT	B-DISO
+cut	O
+-	O
+off	O
+value	O
+of	O
+>	O
+4	O
+.	O
+35	O
+μg	O
+/	O
+L	O
+for	O
+predicting	O
+28	O
+-	O
+day	O
+mortality	O
+,	O
+the	O
+sensitivity	O
+and	O
+specificity	O
+was	O
+92	O
+.	O
+2	O
+%	O
+and	O
+63	O
+.	O
+2	O
+%,	O
+respectively	O
+,	O
+and	O
+the	O
+positive	O
+and	O
+negative	O
+likelihood	O
+ratios	O
+were	O
+2	O
+.	O
+50	O
+and	O
+0	O
+.	O
+12	O
+respectively	O
+.	O
+
+ABSTRACT	O
+:	O
+Acute	B-DISO
+respiratory	I-DISO
+failure	I-DISO
+(	O
+ARF	B-DISO
+)	O
+is	O
+one	O
+primary	O
+cause	O
+of	O
+intensive	O
+care	O
+unit	O
+(	O
+ICU	O
+)	O
+admittance	O
+,	O
+which	O
+is	O
+usually	O
+treated	O
+with	O
+intubation	O
+and	O
+mechanical	O
+ventilation	O
+in	O
+order	B-SPEC
+to	O
+maintain	O
+a	O
+necessary	O
+ventilation	O
+and	O
+oxygenation	B-PROC
+function	O
+.	O
+
+By	O
+reviewing	O
+the	O
+mechanism	O
+of	O
+stem	B-ANAT
+cell	I-ANAT
+therapy	O
+for	O
+ALI	O
+,	O
+therapeutic	O
+potential	O
+of	O
+hUCMSCs	O
+in	O
+the	O
+treatment	O
+of	O
+severe	O
+burns	O
+with	O
+ALI	O
+and	O
+a	O
+new	O
+approach	O
+for	O
+clinical	O
+treatment	O
+was	O
+provided	O
+.	O
+
+TITLE	O
+:	O
+Inhibition	B-PROC
+of	O
+epidermal	B-PRGE
+growth	B-PROC
+factor	I-PRGE
+receptor	I-PRGE
+attenuates	O
+LPS	B-DISO
+-	O
+induced	O
+inflammation	B-DISO
+and	O
+acute	O
+lung	O
+injury	O
+in	O
+rats	B-SPEC
+.	O
+
+Inhibition	B-PROC
+of	O
+epidermal	B-PRGE
+growth	B-PROC
+factor	I-PRGE
+receptor	I-PRGE
+(	O
+EGFR	B-FUNC
+)	O
+has	O
+been	O
+found	O
+to	O
+be	O
+able	O
+to	O
+reduce	O
+inflammatory	B-DISO
+response	I-DISO
+.	O
+
+Mechanistically	O
+,	O
+LPS	B-DISO
+induced	O
+EGFR	B-FUNC
+activation	O
+via	O
+TLR4	B-PRGE
+and	O
+c	B-PRGE
+-	I-PRGE
+Src	I-PRGE
+signaling	B-PROC
+.	O
+
+Of	O
+those	O
+,	O
+fifteen	O
+cases	O
+had	O
+pulmonary	B-ANAT
+manifestations	O
+,	O
+eight	O
+had	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+(	O
+ARDS	B-DISO
+)	O
+(	O
+53	O
+%),	O
+seven	O
+had	O
+enteric	O
+bacterial	B-DISO
+pneumonia	I-DISO
+(	O
+46	O
+%)	O
+and	O
+five	O
+had	O
+pulmonary	B-DISO
+hemorrhage	I-DISO
+(	O
+33	O
+%).	O
+
+This	O
+CT	O
+finding	O
+suggests	O
+alveolar	B-ANAT
+hemorrhage	B-DISO
+could	O
+be	O
+used	O
+as	O
+a	O
+potential	O
+marker	O
+indicating	O
+the	O
+transition	B-DISO
+from	O
+latent	O
+to	O
+symptomatic	O
+state	O
+.	O
+
+TITLE	O
+:	O
+Pathogenic	O
+human	B-SPEC
+coronavirus	I-SPEC
+infections	O
+:	O
+causes	O
+and	O
+consequences	O
+of	O
+cytokine	B-DISO
+storm	I-DISO
+and	O
+immunopathology	B-DISO
+.	O
+
+Severe	O
+pneumonia	B-DISO
+caused	O
+by	O
+pathogenic	O
+hCoVs	O
+is	O
+often	O
+associated	O
+with	O
+rapid	O
+virus	B-PROC
+replication	I-PROC
+,	O
+massive	O
+inflammatory	B-DISO
+cell	I-DISO
+infiltration	I-DISO
+and	O
+elevated	O
+pro	B-CHED
+-	O
+inflammatory	O
+cytokine	O
+/	O
+chemokine	O
+responses	O
+resulting	O
+in	O
+acute	O
+lung	B-ANAT
+injury	O
+(	O
+ALI	O
+),	O
+and	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+(	O
+ARDS	B-DISO
+).	O
+
+Here	O
+we	O
+review	O
+the	O
+current	O
+understanding	O
+of	O
+how	O
+a	O
+dysregulated	O
+immune	O
+response	O
+may	O
+cause	O
+lung	B-ANAT
+immunopathology	B-DISO
+leading	O
+to	O
+deleterious	O
+clinical	O
+manifestations	O
+after	O
+pathogenic	O
+hCoV	O
+infections	B-DISO
+.	O
+
+The	O
+use	O
+of	O
+venovenous	O
+ECMO	O
+(	O
+VV	O
+-	O
+ECMO	O
+)	O
+is	O
+increasing	O
+in	O
+the	O
+most	O
+severe	O
+forms	O
+of	O
+acute	O
+lung	B-ANAT
+injury	O
+.	O
+
+Phylogenetic	O
+network	O
+analysis	O
+of	O
+Ark	B-PRGE
+isolates	O
+showed	O
+two	O
+predominant	O
+groups	O
+linked	O
+by	O
+2	O
+mutations	O
+,	O
+consistent	O
+with	O
+subpopulations	O
+found	O
+in	O
+commercial	O
+vaccines	O
+for	O
+this	O
+IBV	B-SPEC
+type	O
+.	O
+
+Selection	O
+pressure	O
+analysis	O
+showed	O
+that	O
+the	O
+DMV	O
+/	O
+1639	O
+and	O
+Mass	O
+-	O
+type	O
+strains	O
+were	O
+evolving	O
+under	O
+negative	O
+selection	O
+,	O
+whereas	O
+the	O
+Ark	O
+type	O
+viruses	B-SPEC
+had	O
+evolved	O
+under	O
+positive	O
+selection	O
+.	O
+
+TITLE	O
+:	O
+Human	B-SPEC
+Neutralizing	O
+Monoclonal	O
+Antibody	B-COMP
+Inhibition	B-PROC
+of	O
+Middle	O
+East	O
+Respiratory	O
+Syndrome	B-DISO
+Coronavirus	B-SPEC
+Replication	O
+in	O
+the	O
+Common	B-SPEC
+Marmoset	I-SPEC
+.	O
+
+ABSTRACT	O
+:	O
+Middle	O
+East	O
+respiratory	O
+syndrome	B-DISO
+coronavirus	B-SPEC
+(	O
+MERS	O
+-	O
+CoV	O
+)	O
+infection	B-DISO
+in	O
+humans	B-SPEC
+is	O
+highly	O
+lethal	O
+,	O
+with	O
+a	O
+fatality	O
+rate	O
+of	O
+35	O
+%.	O
+
+To	O
+our	O
+knowledge	O
+,	O
+this	O
+study	O
+is	O
+the	O
+first	O
+to	O
+report	O
+a	O
+human	B-SPEC
+neutralizing	O
+monoclonal	O
+antibody	B-COMP
+that	O
+completely	O
+inhibits	O
+MERS	O
+-	O
+CoV	O
+replication	O
+in	O
+common	B-SPEC
+marmosets	I-SPEC
+.	O
+
+The	O
+present	O
+study	O
+was	O
+done	O
+in	O
+a	O
+tertiary	O
+care	O
+children	O
+'	O
+s	O
+hospital	O
+for	O
+rapid	O
+identification	O
+of	O
+viruses	B-SPEC
+causing	O
+SARI	O
+among	O
+children	O
+less	O
+than	O
+or	O
+equal	O
+to	O
+five	O
+years	O
+of	O
+age	O
+using	O
+multiplex	O
+real	O
+-	O
+time	O
+reverse	B-PROC
+transcription	I-PROC
+polymerase	O
+chain	O
+reaction	O
+(	O
+RT	O
+-	O
+PCR	O
+)	O
+kit	B-FUNC
+.	O
+
+A	O
+total	O
+of	O
+155	O
+throat	B-ANAT
+swabs	O
+were	O
+collected	O
+from	O
+equal	O
+number	O
+of	O
+children	O
+suspected	O
+to	O
+have	O
+SARI	O
+and	O
+processed	O
+for	O
+extraction	O
+of	O
+nucleic	B-CHED
+acids	I-CHED
+using	O
+automated	O
+extraction	O
+system	O
+.	O
+
+HMPV	B-SPEC
+was	O
+the	O
+most	O
+predominant	O
+virus	B-SPEC
+.	O
+
+The	O
+healthcare	O
+-	O
+associated	O
+transmission	O
+of	O
+Middle	O
+East	O
+respiratory	O
+syndrome	B-DISO
+coronavirus	B-SPEC
+(	O
+MERS	O
+-	O
+CoV	O
+)	O
+has	O
+been	O
+attributed	O
+to	O
+overcrowding	O
+,	O
+delayed	O
+diagnosis	O
+,	O
+and	O
+the	O
+breakdown	B-DISO
+of	O
+infection	B-DISO
+control	O
+systems	O
+.	O
+
+Strict	O
+infection	B-DISO
+control	O
+precautions	O
+and	O
+a	O
+well	O
+-	O
+prepared	O
+hospital	O
+system	O
+may	O
+have	O
+contributed	O
+to	O
+no	O
+nosocomial	O
+transmission	O
+occurring	O
+during	O
+the	O
+treatment	O
+of	O
+MERS	O
+-	O
+CoV	O
+infections	B-DISO
+imported	O
+to	O
+Thailand	O
+.	O
+
+Continuous	O
+vigilance	O
+and	O
+strengthening	O
+of	O
+infection	B-DISO
+control	O
+systems	O
+will	O
+shape	O
+the	O
+capacity	O
+to	O
+prevent	O
+and	O
+control	O
+MERS	O
+-	O
+CoV	O
+or	O
+new	O
+emerging	O
+disease	B-DISO
+transmission	I-DISO
+.	O
+
+In	O
+the	O
+present	O
+study	O
+,	O
+we	O
+found	O
+that	O
+miR	O
+-	O
+19	O
+inhibited	O
+the	O
+expression	B-PROC
+of	O
+p47phox	B-PRGE
+in	O
+macrophages	B-ANAT
+,	O
+resulting	O
+in	O
+the	O
+alleviation	O
+of	O
+the	O
+lipopolysaccharides	B-CHED
+(	O
+LPS	B-DISO
+)-	O
+induced	O
+inflammatory	B-DISO
+response	I-DISO
+.	O
+
+TITLE	O
+:	O
+Epidemiology	O
+and	O
+Clinical	O
+Features	O
+of	O
+Human	B-SPEC
+Coronaviruses	O
+in	O
+the	O
+Pediatric	O
+Population	O
+.	O
+
+In	O
+hospitalized	O
+children	O
+,	O
+young	O
+age	O
+and	O
+CCCs	B-CHED
+,	O
+but	O
+not	O
+HCoV	O
+type	O
+,	O
+were	O
+associated	O
+with	O
+increased	O
+severity	O
+of	O
+illness	O
+.	O
+
+HTCC	O
+-	O
+NS	O
+/	O
+MS	O
+were	O
+studied	O
+as	O
+the	O
+adsorbents	O
+of	O
+human	B-PRGE
+coronavirus	I-PRGE
+NL63	I-PRGE
+(	O
+HCoV	B-SPEC
+-	I-SPEC
+NL63	I-SPEC
+),	O
+mouse	B-DISO
+hepatitis	I-DISO
+virus	B-SPEC
+(	O
+MHV	B-SPEC
+),	O
+and	O
+human	B-PRGE
+coronavirus	I-PRGE
+HCoV	B-SPEC
+-	I-SPEC
+OC43	I-SPEC
+particles	O
+in	O
+aqueous	O
+virus	B-SPEC
+suspensions	O
+.	O
+
+TITLE	O
+:	O
+Obesity	B-DISO
+and	O
+perioperative	O
+noninvasive	O
+ventilation	O
+in	O
+bariatric	O
+surgery	O
+.	O
+
+Certain	O
+comorbidities	O
+associated	O
+with	O
+obesity	B-DISO
+(	O
+e	O
+.	O
+g	O
+.,	O
+metabolic	B-PROC
+syndrome	B-DISO
+,	I-DISO
+obstructive	I-DISO
+sleep	I-DISO
+apnea	I-DISO
+,	O
+pulmonary	B-DISO
+disease	I-DISO
+)	O
+further	O
+increase	O
+the	O
+risk	O
+of	O
+perioperative	O
+complications	O
+.	O
+
+Taken	O
+together	O
+,	O
+our	O
+findings	O
+demonstrate	O
+that	O
+coronavirus	B-SPEC
+nsp15	O
+is	O
+critical	O
+for	O
+evasion	O
+of	O
+host	B-COMP
+dsRNA	B-CHED
+sensors	O
+in	O
+macrophages	B-ANAT
+and	O
+reveal	O
+that	O
+modulating	O
+nsp15	O
+stability	O
+and	O
+activity	O
+is	O
+a	O
+strategy	O
+for	O
+generating	O
+live	O
+-	O
+attenuated	O
+vaccines	O
+.	O
+
+Respiratory	B-DISO
+failure	I-DISO
+developed	O
+,	O
+requiring	O
+intubation	O
+and	O
+mechanical	O
+ventilation	O
+.	O
+
+Changes	O
+on	O
+diffusion	O
+-	O
+weighted	O
+MRI	O
+of	O
+the	O
+brain	B-ANAT
+showed	O
+the	O
+characteristic	O
+heart	B-ANAT
+-	O
+shaped	O
+BMP	B-CHED
+infarction	B-DISO
+,	O
+indicating	O
+occlusion	B-DISO
+of	O
+a	O
+unilateral	O
+ASA	B-CHED
+.	O
+
+TITLE	O
+:	O
+Assessment	O
+of	O
+1	O
+-	O
+year	O
+Outcomes	O
+in	O
+Survivors	O
+of	O
+Severe	O
+Acute	B-DISO
+Respiratory	I-DISO
+Distress	I-DISO
+Syndrome	I-DISO
+Receiving	O
+Extracorporeal	O
+Membrane	O
+Oxygenation	B-PROC
+or	O
+Mechanical	O
+Ventilation	O
+:	O
+A	O
+Prospective	O
+Observational	O
+Study	O
+.	O
+
+ABSTRACT	O
+:	O
+Little	O
+is	O
+known	O
+about	O
+the	O
+long	O
+-	O
+term	O
+outcomes	O
+of	O
+severe	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+(	O
+ARDS	B-DISO
+)	O
+patients	O
+requiring	O
+extracorporeal	O
+membrane	B-COMP
+oxygenation	B-PROC
+(	O
+ECMO	O
+).	O
+
+ECMO	O
+and	O
+non	O
+-	O
+ECMO	O
+survivors	O
+showed	O
+similar	O
+pulmonary	B-PROC
+function	I-PROC
+,	O
+morphological	O
+abnormalities	O
+,	O
+resting	B-ANAT
+arterial	B-ANAT
+blood	I-ANAT
+gas	O
+values	O
+,	O
+and	O
+6	O
+-	O
+min	O
+walking	O
+distance	O
+.	O
+
+One	O
+-	O
+year	O
+posthospital	O
+discharge	B-ANAT
+,	O
+severe	O
+ARDS	B-DISO
+survivors	O
+receiving	O
+ECMO	O
+or	O
+MV	O
+demonstrated	O
+comparable	O
+outcomes	O
+.	O
+
+RESULTS	O
+:	O
+ARDS	B-DISO
+patients	O
+receiving	O
+ECMO	O
+had	O
+a	O
+significantly	O
+higher	O
+Acute	O
+Physiology	O
+and	O
+Chronic	O
+Health	O
+Evaluation	O
+II	O
+score	O
+(	O
+30	O
+.	O
+3	O
+±	O
+6	O
+.	O
+7	O
+vs	O
+.	O
+26	O
+.	O
+5	O
+±	O
+7	O
+.	O
+3	O
+,	O
+P	O
+=	O
+0	O
+.	O
+036	O
+),	O
+lung	B-ANAT
+injury	O
+score	O
+(	O
+3	O
+.	O
+3	O
+±	O
+0	O
+.	O
+4	O
+vs	O
+.	O
+2	O
+.	O
+8	O
+±	O
+0	O
+.	O
+5	O
+,	O
+P	O
+=	O
+0	O
+.	O
+000	O
+),	O
+Sequential	O
+Organ	B-DISO
+Failure	I-DISO
+Assessment	O
+score	O
+(	O
+10	O
+.	O
+8	O
+±	O
+3	O
+.	O
+5	O
+vs	O
+.	O
+7	O
+.	O
+9	O
+±	O
+3	O
+.	O
+1	O
+,	O
+P	O
+=	O
+0	O
+.	O
+000	O
+),	O
+lower	O
+PaO2	O
+/	O
+FiO2ratio	O
+([	O
+mmHg	O
+,	O
+1	O
+mmHg	O
+=	O
+0	O
+.	O
+133	O
+kPa	O
+],	O
+68	O
+.	O
+3	O
+±	O
+16	O
+.	O
+1	O
+vs	O
+.	O
+84	O
+.	O
+8	O
+±	O
+16	O
+.	O
+5	O
+,	O
+P	O
+=	O
+0	O
+.	O
+000	O
+),	O
+and	O
+increased	O
+extrapulmonary	O
+organ	B-DISO
+failure	I-DISO
+(	O
+2	O
+[	O
+1	O
+,	O
+3	O
+]	O
+vs	O
+.	O
+1	O
+[	O
+1	O
+,	O
+1	O
+],	O
+P	O
+=	O
+0	O
+.	O
+025	O
+)	O
+compared	O
+with	O
+patients	O
+not	O
+receiving	O
+ECMO	O
+.	O
+
+Extensive	O
+hemodynamics	B-PROC
+,	O
+oxygen	B-CHED
+dynamics	O
+,	O
+and	O
+lung	B-PROC
+function	I-PROC
+were	O
+monitored	O
+for	O
+24	O
+h	O
+following	O
+the	O
+injury	O
+or	O
+until	O
+death	B-PROC
+.	O
+
+The	O
+viral	B-COMP
+genome	I-COMP
+shares	O
+75	O
+.	O
+4	O
+%	O
+nucleotide	B-CHED
+identity	O
+with	O
+a	O
+prototypic	O
+EVG	O
+strain	O
+(	O
+PEV9	O
+UKG	O
+/	O
+410	O
+/	O
+73	O
+).	O
+
+TITLE	O
+:	O
+Successful	O
+treatment	O
+of	O
+feline	B-SPEC
+leishmaniosis	B-DISO
+using	O
+a	O
+combination	O
+of	O
+allopurinol	B-CHED
+and	O
+N	O
+-	O
+methyl	B-CHED
+-	O
+glucamine	O
+antimoniate	O
+.	O
+
+ABSTRACT	O
+:	O
+This	O
+work	O
+describes	O
+the	O
+diagnosis	O
+and	O
+successful	O
+treatment	O
+of	O
+a	O
+2	O
+-	O
+year	O
+-	O
+old	O
+domestic	O
+cat	O
+infected	O
+with	O
+Considering	O
+the	O
+increasing	O
+number	O
+of	O
+feline	B-SPEC
+leishmaniosis	B-DISO
+cases	O
+and	O
+the	O
+inconsistent	O
+results	O
+of	O
+most	O
+therapeutic	O
+protocols	O
+described	O
+in	O
+the	O
+literature	O
+,	O
+the	O
+use	O
+of	O
+new	O
+approaches	O
+,	O
+especially	O
+in	O
+refractory	O
+cases	O
+,	O
+is	O
+essential	O
+.	O
+
+TITLE	O
+:	O
+Toxic	B-DISO
+shock	I-DISO
+syndrome	I-DISO
+due	O
+to	O
+community	O
+-	O
+acquired	O
+methicillin	B-CHED
+-	O
+resistant	O
+ABSTRACT	O
+:	O
+Community	O
+-	O
+acquired	O
+methicillin	O
+-	O
+resistant	O
+
+One	O
+hundred	O
+and	O
+twenty	O
+-	O
+seven	O
+IBV	O
+-	O
+positive	O
+samples	O
+were	O
+tested	O
+by	O
+this	O
+method	O
+and	O
+GII	O
+-	O
+1	O
+strains	O
+were	O
+detected	O
+in	O
+four	O
+of	O
+them	O
+(	O
+3	O
+·	O
+15	O
+%)	O
+which	O
+indicate	O
+a	O
+decrease	O
+in	O
+the	O
+GII	O
+-	O
+1	O
+IBV	B-SPEC
+prevalence	O
+in	O
+Poland	O
+.	O
+
+The	O
+developed	O
+assay	O
+has	O
+been	O
+tested	O
+on	O
+numerous	O
+field	O
+samples	O
+and	O
+revealed	O
+3	O
+·	O
+15	O
+%	O
+prevalence	O
+of	O
+this	O
+lineage	O
+of	O
+IBV	B-SPEC
+in	O
+Polish	O
+chicken	B-SPEC
+population	O
+.	O
+
+ABSTRACT	O
+:	O
+The	O
+apoptosis	O
+of	O
+pyramidal	O
+neurons	B-ANAT
+in	O
+CA2	B-ANAT
+and	O
+CA3	B-ANAT
+subregions	O
+of	O
+the	O
+hippocampus	B-SPEC
+is	O
+induced	O
+after	O
+infection	B-DISO
+with	O
+Mu	O
+-	O
+3	O
+virus	B-SPEC
+(	O
+Mu	O
+-	O
+3	O
+),	O
+a	O
+neuropathogenic	O
+strain	O
+of	O
+the	O
+JHM	O
+virus	B-SPEC
+(	O
+JHMV	O
+),	O
+at	O
+4	O
+-	O
+5	O
+days	O
+post	O
+-	O
+inoculation	O
+(	O
+dpi	O
+).	O
+
+Uveitis	B-DISO
+is	O
+common	O
+in	O
+these	O
+cats	B-SPEC
+.	O
+
+It	O
+was	O
+the	O
+aim	O
+of	O
+this	O
+study	O
+to	O
+evaluate	O
+sensitivity	O
+and	O
+specificity	O
+of	O
+an	O
+immunocytochemical	O
+assay	O
+(	O
+ICC	B-DISO
+)	O
+in	O
+aqueous	B-DISO
+humor	I-DISO
+of	O
+cats	B-SPEC
+suspected	O
+of	O
+having	O
+FIP	B-DISO
+.	O
+
+All	O
+aqueous	B-DISO
+humor	I-DISO
+samples	O
+were	O
+collected	O
+postmortem	O
+by	O
+paracentesis	O
+.	O
+
+TITLE	O
+:	O
+IL	B-PRGE
+-	I-PRGE
+33	I-PRGE
+protects	O
+murine	B-SPEC
+viral	O
+fulminant	B-DISO
+hepatitis	I-DISO
+by	O
+targeting	B-PROC
+coagulation	B-PRGE
+hallmark	I-PRGE
+protein	B-CHED
+FGL2	B-PRGE
+/	O
+fibroleukin	B-PRGE
+expression	B-PROC
+.	O
+
+The	O
+aim	O
+of	O
+this	O
+study	O
+was	O
+therefore	O
+to	O
+compare	O
+the	O
+immunocompetence	B-PROC
+of	O
+the	O
+presumed	O
+""""	O
+robust	O
+""""	O
+Hellevad	O
+chickens	O
+with	O
+two	O
+chicken	B-SPEC
+lines	O
+widely	O
+used	O
+in	O
+organic	O
+production	O
+,	O
+Bovans	O
+Brown	O
+(	O
+Bovans	O
+)	O
+and	O
+Hisex	O
+White	O
+(	O
+Hisex	O
+).	O
+
+Moreover	O
+,	O
+indications	O
+of	O
+an	O
+inflammatory	B-DISO
+response	I-DISO
+were	O
+observed	O
+in	O
+the	O
+Bovans	O
+at	O
+week	O
+5	O
+,	O
+corresponding	O
+to	O
+1	O
+week	O
+after	O
+vaccination	O
+with	O
+live	O
+infectious	B-SPEC
+bursal	I-SPEC
+disease	I-SPEC
+virus	I-SPEC
+.	O
+
+How	O
+the	O
+differences	O
+observed	O
+in	O
+growth	B-PROC
+and	O
+immune	O
+parameters	O
+in	O
+the	O
+three	O
+chicken	B-SPEC
+lines	O
+influence	O
+the	O
+immune	O
+protection	O
+against	O
+infection	B-DISO
+needs	O
+to	O
+be	O
+studied	O
+further	O
+.	O
+
+Both	O
+strains	O
+have	O
+a	O
+common	O
+genome	O
+organization	O
+in	O
+the	O
+order	B-SPEC
+of	O
+5	B-PRGE
+'-	I-PRGE
+UTR	I-PRGE
+-	I-PRGE
+1a	I-PRGE
+-	I-PRGE
+1b	I-PRGE
+-	I-PRGE
+S	I-PRGE
+-	I-PRGE
+3a	I-PRGE
+-	I-PRGE
+3b	I-PRGE
+-	I-PRGE
+E	I-PRGE
+-	I-PRGE
+M	I-PRGE
+-	I-PRGE
+4b	I-PRGE
+-	I-PRGE
+4c	I-PRGE
+-	I-PRGE
+5a	I-PRGE
+-	I-PRGE
+5b	I-PRGE
+-	I-PRGE
+N	I-PRGE
+-	I-PRGE
+6b	I-PRGE
+-	I-PRGE
+UTR	I-PRGE
+-	O
+poly	O
+(	O
+A	O
+)	O
+tail	O
+-	O
+3	O
+'.	O
+
+ABSTRACT	O
+:	O
+Initiation	O
+of	O
+extracorporeal	O
+life	O
+support	O
+(	O
+ECLS	O
+)	O
+is	O
+often	O
+followed	O
+by	O
+complete	O
+opacification	O
+of	O
+pulmonary	B-ANAT
+parenchyma	B-ANAT
+and	O
+volume	O
+loss	O
+.	O
+
+Bats	B-SPEC
+are	O
+known	O
+to	O
+host	B-COMP
+viruses	B-SPEC
+closely	O
+related	O
+to	O
+important	O
+EIDs	O
+.	O
+
+GLS	O
+-	O
+5300	O
+,	O
+a	O
+prophylactic	O
+DNA	O
+-	O
+plasmid	O
+vaccine	O
+encoding	O
+S	B-PRGE
+protein	I-PRGE
+,	O
+is	O
+the	O
+first	O
+MERS	O
+-	O
+CoV	O
+vaccine	O
+to	O
+be	O
+tested	O
+in	O
+humans	B-SPEC
+,	O
+while	O
+monoclonal	O
+antibody	B-COMP
+,	O
+m336	O
+has	O
+given	O
+promising	O
+results	O
+in	O
+animal	B-SPEC
+models	O
+and	O
+has	O
+potential	O
+for	O
+use	O
+in	O
+outbreak	O
+situations	O
+.	O
+
+Twelve	O
+studies	O
+fulfilled	O
+inclusion	O
+criteria	O
+,	O
+representing	O
+a	O
+population	O
+of	O
+1042	O
+patients	O
+with	O
+refractory	O
+ARDS	B-DISO
+.	O
+
+Pooled	O
+mortality	O
+at	O
+hospital	O
+discharge	B-ANAT
+was	O
+37	O
+.	O
+7	O
+%	O
+(	O
+CI	O
+95	O
+%	O
+=	O
+31	O
+.	O
+8	O
+-	O
+44	O
+.	O
+1	O
+;	O
+I	O
+
+ECLS	O
+is	O
+an	O
+efficient	O
+therapeutic	O
+strategy	O
+that	O
+will	O
+improve	O
+the	O
+prognosis	O
+of	O
+patients	O
+suffering	B-DISO
+from	O
+,	O
+or	O
+exposed	O
+to	O
+,	O
+the	O
+risks	O
+of	O
+severe	O
+respiratory	B-DISO
+failure	I-DISO
+.	O
+
+TITLE	O
+:	O
+A	O
+New	O
+Observation	O
+of	O
+an	O
+Atypical	O
+and	O
+Severe	O
+Variant	O
+of	O
+the	O
+Guillain	B-DISO
+-	I-DISO
+Barre	I-DISO
+Syndrome	I-DISO
+in	O
+a	O
+Child	O
+:	O
+Remaining	O
+Challenges	O
+for	O
+Diagnosis	O
+,	O
+Nosologic	O
+Classification	O
+,	O
+and	O
+Therapeutic	O
+Course	O
+.	O
+
+ABSTRACT	O
+:	O
+Guillain	O
+-	O
+Barré	O
+syndrome	O
+is	O
+a	O
+rare	O
+acute	O
+polyradiculoneuropathy	B-DISO
+.	O
+
+TITLE	O
+:	O
+[	O
+High	O
+-	O
+isolation	O
+preparedness	O
+for	O
+very	O
+contagious	O
+and	O
+potential	O
+severely	O
+ill	B-DISO
+patients	O
+].	O
+
+TITLE	O
+:	O
+Differential	O
+Protein	B-CHED
+Analysis	O
+of	O
+IPEC	O
+-	O
+J2	O
+Cells	B-COMP
+Infected	O
+with	O
+Porcine	B-SPEC
+Epidemic	I-SPEC
+Diarrhea	I-SPEC
+Virus	I-SPEC
+Pandemic	O
+and	O
+Classical	O
+Strains	O
+Elucidates	O
+the	O
+Pathogenesis	O
+of	O
+Infection	B-DISO
+.	O
+
+On	O
+the	O
+basis	O
+of	O
+differentially	O
+expressed	B-PROC
+proteins	B-CHED
+,	O
+we	O
+propose	O
+that	O
+PEDV	B-SPEC
+might	O
+disrupt	O
+apoptosis	B-PATH
+and	O
+may	O
+elicit	O
+stronger	O
+inflammatory	O
+cascades	O
+as	O
+well	O
+.	O
+
+Emerging	O
+evidence	O
+supports	O
+the	O
+hypothesis	O
+that	O
+the	O
+stiffness	B-DISO
+of	O
+the	O
+matrix	O
+is	O
+not	O
+only	O
+a	O
+consequence	O
+of	O
+fibrosis	B-DISO
+,	O
+but	O
+also	O
+can	O
+induce	O
+fibroblast	B-PROC
+activation	I-PROC
+.	O
+
+Coronavirus	B-SPEC
+genomes	O
+are	O
+conveniently	O
+partitioned	O
+by	O
+introducing	O
+type	O
+IIS	O
+or	O
+IIG	O
+restriction	O
+enzyme	O
+recognition	O
+sites	O
+that	O
+confer	O
+directional	O
+cloning	O
+.	O
+
+Here	O
+,	O
+we	O
+describe	O
+the	O
+use	O
+of	O
+transient	O
+dominant	O
+selection	O
+as	O
+a	O
+method	O
+for	O
+introducing	O
+modifications	O
+into	O
+the	O
+IBV	B-SPEC
+cDNA	O
+that	O
+has	O
+been	O
+successfully	O
+used	O
+for	O
+the	O
+substitution	O
+of	O
+specific	O
+nucleotides	B-CHED
+,	O
+deletion	O
+of	O
+genomic	O
+regions	O
+,	O
+and	O
+exchange	O
+of	O
+complete	O
+genes	O
+.	O
+
+TITLE	O
+:	O
+Can	O
+glypican	O
+-	O
+3	O
+be	O
+a	O
+disease	O
+-	O
+specific	O
+biomarker	B-CHED
+?	O
+
+Increased	O
+serum	B-COMP
+levels	O
+of	O
+GPC3	B-PRGE
+have	O
+been	O
+demonstrated	O
+in	O
+ARDS	B-DISO
+patients	O
+with	O
+severe	O
+pneumonia	B-DISO
+.	O
+
+The	O
+development	B-PROC
+and	O
+validation	O
+of	O
+the	O
+Berlin	O
+definition	O
+(	O
+BD	O
+)	O
+for	O
+ARDS	B-DISO
+and	O
+the	O
+Pediatric	O
+Acute	O
+Lung	B-ANAT
+Injury	O
+Consensus	O
+Conference	O
+(	O
+PALICC	O
+)	O
+recommendations	O
+in	O
+children	O
+represented	O
+a	O
+major	O
+advance	O
+in	O
+optimizing	O
+research	O
+and	O
+treatment	O
+,	O
+mainly	O
+due	O
+to	O
+the	O
+introduction	O
+of	O
+a	O
+severe	O
+ARDS	B-DISO
+category	O
+.	O
+
+Importantly	O
+,	O
+it	O
+is	O
+now	O
+recognized	O
+that	O
+the	O
+type	O
+of	O
+surfactant	B-CHED
+,	O
+the	O
+time	O
+of	O
+administration	O
+and	O
+the	O
+method	O
+of	O
+administration	O
+could	O
+all	O
+play	O
+an	O
+important	O
+role	O
+in	O
+the	O
+management	O
+of	O
+ARDS	B-DISO
+,	O
+and	O
+there	O
+is	O
+evidence	O
+that	O
+surfactant	B-CHED
+is	O
+effective	O
+and	O
+well	O
+tolerated	O
+in	O
+children	O
+and	O
+infants	O
+with	O
+ARDS	B-DISO
+.	O
+
+TITLE	O
+:	O
+miR	B-PRGE
+-	I-PRGE
+142	I-PRGE
+-	I-PRGE
+5p	I-PRGE
+Disrupts	O
+Neuronal	O
+Morphogenesis	B-PROC
+Underlying	O
+Porcine	B-SPEC
+Hemagglutinating	O
+Encephalomyelitis	B-DISO
+Virus	B-DISO
+Infection	I-DISO
+by	O
+Targeting	B-PROC
+Ulk1	B-PRGE
+.	O
+
+ABSTRACT	O
+:	O
+Porcine	B-SPEC
+hemagglutinating	O
+encephalomyelitis	B-DISO
+virus	B-SPEC
+(	O
+PHEV	O
+)	O
+invades	O
+the	O
+central	B-ANAT
+nervous	I-ANAT
+system	I-ANAT
+(	O
+CNS	B-CHED
+)	O
+and	O
+causes	O
+neurodegenerative	B-DISO
+disease	I-DISO
+in	O
+suckling	O
+piglets	O
+,	O
+but	O
+the	O
+understanding	O
+of	O
+its	O
+neuropathogenicity	O
+for	O
+neurological	O
+dysfunction	O
+remains	O
+limited	O
+.	O
+
+Here	O
+,	O
+we	O
+report	O
+that	O
+miR	B-PRGE
+-	I-PRGE
+142	I-PRGE
+-	I-PRGE
+5p	I-PRGE
+is	O
+localized	O
+to	O
+neurons	B-ANAT
+and	O
+negatively	O
+regulates	O
+neuronal	O
+morphogenesis	B-PROC
+in	O
+porcine	B-SPEC
+hemagglutinating	O
+encephalomyelitis	B-DISO
+(	O
+PHE	B-CHED
+).	O
+
+Relieving	O
+Ulk1	B-PRGE
+mRNA	I-PRGE
+repression	O
+in	O
+primary	O
+cortical	B-ANAT
+neurons	B-ANAT
+by	O
+miR	O
+-	O
+142	O
+-	O
+5p	O
+antagomirs	O
+or	O
+replication	O
+-	O
+deficient	O
+adenoviruses	O
+encoding	O
+Ulk1	O
+(	O
+Ad5	B-DISO
+-	O
+Ulk1	O
+),	O
+which	O
+improved	O
+rescue	O
+of	O
+nerve	B-ANAT
+injury	O
+,	O
+restricted	O
+viral	B-PROC
+replication	I-PROC
+,	O
+and	O
+increased	O
+survival	O
+rate	O
+in	O
+mice	B-SPEC
+underlying	O
+PHEV	O
+infection	B-DISO
+.	O
+
+The	O
+role	O
+of	O
+respiratory	O
+viral	B-DISO
+infections	I-DISO
+in	O
+patients	O
+presenting	O
+with	O
+a	O
+clinical	O
+picture	O
+of	O
+sepsis	B-DISO
+is	O
+underestimated	O
+.	O
+
+TITLE	O
+:	O
+Hospital	O
+Outbreaks	O
+of	O
+Middle	O
+East	O
+Respiratory	O
+Syndrome	B-DISO
+,	O
+Daejeon	O
+,	O
+South	O
+Korea	O
+,	O
+2015	O
+.	O
+
+Six	O
+participants	O
+died	B-PROC
+,	O
+one	O
+(	O
+2	O
+%)	O
+from	O
+the	O
+plasma	B-ANAT
+plus	O
+standard	O
+care	O
+group	O
+and	O
+five	O
+(	O
+10	O
+%)	O
+from	O
+the	O
+standard	O
+care	O
+group	O
+(	O
+HR	O
+0	O
+·	O
+19	O
+[	O
+95	O
+%	O
+CI	O
+0	O
+·	O
+02	O
+-	O
+1	O
+·	O
+65	O
+],	O
+p	O
+=	O
+0	O
+·	O
+093	O
+).	O
+
+Participants	O
+in	O
+the	O
+plasma	B-ANAT
+plus	O
+standard	O
+care	O
+group	O
+had	O
+non	O
+-	O
+significant	O
+reductions	O
+in	O
+days	O
+in	O
+hospital	O
+(	O
+median	O
+6	O
+days	O
+[	O
+IQR	O
+4	O
+-	O
+16	O
+]	O
+vs	O
+11	O
+days	O
+[	O
+5	O
+-	O
+25	O
+],	O
+p	O
+=	O
+0	O
+·	O
+13	O
+)	O
+and	O
+days	O
+on	O
+mechanical	O
+ventilation	O
+(	O
+median	O
+0	O
+days	O
+[	O
+IQR	O
+0	O
+-	O
+6	O
+]	O
+vs	O
+3	O
+days	O
+[	O
+0	O
+-	O
+14	O
+],	O
+p	O
+=	O
+0	O
+·	O
+14	O
+).	O
+
+National	O
+Institute	O
+of	O
+Allergy	B-DISO
+and	O
+Infectious	B-DISO
+Diseases	I-DISO
+,	O
+US	O
+National	O
+Institutes	O
+of	O
+Health	O
+.	O
+
+TITLE	O
+:	O
+Myeloid	O
+-	O
+epithelial	O
+cross	O
+talk	B-PROC
+coordinates	O
+synthesis	B-PROC
+of	O
+the	O
+tissue	B-ANAT
+-	O
+protective	O
+cytokine	O
+leukemia	B-DISO
+inhibitory	I-PRGE
+factor	I-PRGE
+during	O
+pneumonia	B-DISO
+.	O
+
+Groups	O
+3	O
+and	O
+4	O
+received	O
+H120	O
+-	O
+H120	O
+and	O
+H120	O
+-	O
+1	O
+/	O
+96	O
+IBV	B-SPEC
+vaccine	O
+strains	O
+at	O
+the	O
+1st	O
+and	O
+14th	O
+day	O
+,	O
+respectively	O
+.	O
+
+Virus	B-PROC
+replication	I-PROC
+of	O
+the	O
+challenged	O
+virus	B-SPEC
+in	O
+H120	O
+-	O
+1	O
+/	O
+96	O
+group	O
+compared	O
+with	O
+H120	O
+-	O
+H120	O
+group	O
+showed	O
+a	O
+significant	O
+reduction	O
+of	O
+viral	O
+load	O
+in	O
+trachea	B-DISO
+(	O
+1	O
+.	O
+5	O
+×	O
+103	O
+compared	O
+to	O
+503	O
+)	O
+and	O
+kidneys	B-ANAT
+.	O
+
+ABSTRACT	O
+:	O
+Venovenous	O
+extracorporeal	O
+membrane	B-COMP
+oxygenation	B-PROC
+(	O
+VV	O
+-	O
+ECMO	O
+)	O
+is	O
+a	O
+useful	O
+life	O
+support	O
+in	O
+severe	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+(	O
+ARDS	B-DISO
+).	O
+
+The	O
+two	O
+adverse	O
+events	O
+assessed	O
+as	O
+related	O
+to	O
+KGF	B-PRGE
+were	O
+due	O
+to	O
+pyrexia	B-PROC
+.	O
+
+The	O
+Northern	O
+Ireland	O
+Public	O
+Health	O
+Agency	O
+Research	O
+and	O
+Development	B-PROC
+Division	O
+.	O
+
+Structure	O
+-	O
+activity	O
+relationship	O
+(	O
+SAR	B-CHED
+)	O
+studies	O
+on	O
+escins	O
+have	O
+revealed	O
+that	O
+acylations	O
+at	O
+C	O
+-	O
+21	O
+and	O
+C	O
+-	O
+22	O
+with	O
+angeloyl	O
+or	O
+tigloyl	O
+groups	O
+were	O
+important	O
+for	O
+their	O
+cytotoxic	O
+effects	O
+.	O
+
+Neonatal	O
+complications	O
+resulting	O
+from	O
+meconium	B-DISO
+aspiration	I-DISO
+syndrome	I-DISO
+(	O
+MAS	B-COMP
+)	O
+and	O
+sepsis	B-DISO
+were	O
+more	O
+common	O
+in	O
+the	O
+non	O
+-	O
+obstetric	O
+causes	O
+group	O
+;	O
+however	O
+,	O
+neurological	O
+development	B-PROC
+impairment	B-DISO
+was	O
+more	O
+common	O
+in	O
+the	O
+obstetric	O
+causes	O
+group	O
+.	O
+
+Based	O
+on	O
+recent	O
+data	O
+suggesting	O
+its	O
+role	O
+as	O
+entheropathogen	O
+,	O
+a	O
+case	O
+-	O
+control	O
+study	O
+was	O
+conducted	O
+between	O
+2013	O
+and	O
+2016	O
+to	O
+investigate	O
+the	O
+association	O
+of	O
+CanineCV	O
+with	O
+gastroenteritis	B-DISO
+in	O
+dogs	B-SPEC
+,	O
+alone	O
+or	O
+in	O
+combination	O
+with	O
+other	O
+viral	O
+pathogens	O
+,	O
+including	O
+canine	O
+parvovirus	B-DISO
+(	O
+CPV	B-SPEC
+),	O
+canine	O
+coronavirus	B-SPEC
+(	O
+CCoV	O
+)	O
+and	O
+canine	B-SPEC
+distemper	I-SPEC
+virus	I-SPEC
+(	O
+CDV	B-CHED
+).	O
+
+These	O
+results	O
+highlight	O
+the	O
+potential	O
+spillover	O
+of	O
+vaccine	O
+-	O
+viruses	B-SPEC
+probably	O
+due	O
+to	O
+extensive	O
+use	O
+of	O
+live	O
+-	O
+attenuated	O
+vaccines	O
+in	O
+the	O
+commercial	O
+poultry	O
+,	O
+and	O
+close	O
+interaction	O
+between	O
+domesticated	O
+and	O
+wild	O
+bird	B-SPEC
+populations	O
+.	O
+
+Further	O
+exploring	O
+the	O
+full	O
+spectrum	O
+of	O
+vaccine	O
+-	O
+derived	O
+viral	O
+vaccine	O
+strains	O
+in	O
+wild	O
+birds	O
+might	O
+help	O
+to	O
+assess	O
+the	O
+emergence	O
+of	O
+future	O
+wild	O
+-	O
+birds	B-SPEC
+origin	O
+viruses	B-SPEC
+.	O
+
+We	O
+identify	O
+five	O
+residues	O
+in	O
+the	O
+insertion	O
+subdomain	O
+that	O
+are	O
+critical	O
+for	O
+binding	B-FUNC
+of	O
+neutralizing	O
+antibodies	B-COMP
+and	O
+two	O
+residues	O
+essential	O
+for	O
+receptor	B-FUNC
+binding	I-FUNC
+.	O
+
+Compared	O
+to	O
+PEDVPT	O
+-	O
+P5	O
+,	O
+PEDVPT	O
+-	O
+P96	O
+inoculation	O
+induced	O
+none	O
+-	O
+to	O
+-	O
+mild	O
+diarrhea	B-DISO
+and	O
+lower	O
+,	O
+delayed	O
+fecal	B-ANAT
+viral	B-DISO
+shedding	I-DISO
+.	O
+
+Although	O
+PEDVPT	O
+-	O
+P96	O
+elicited	O
+slightly	O
+lower	O
+neutralizing	O
+antibodies	B-COMP
+and	O
+PEDV	B-SPEC
+-	O
+specific	O
+immunoglobulin	B-PRGE
+G	I-PRGE
+(	O
+IgG	B-PRGE
+)	O
+and	O
+immunoglobulin	B-PRGE
+A	I-PRGE
+(	O
+IgA	B-PRGE
+)	O
+titers	O
+,	O
+a	O
+reduction	O
+in	O
+pathogenicity	O
+and	O
+viral	O
+shedding	O
+of	O
+the	O
+subsequent	O
+challenge	O
+with	O
+PEDVPT	O
+-	O
+P5	O
+were	O
+noted	O
+in	O
+both	O
+PEDVPT	O
+-	O
+P5	O
+-	O
+and	O
+PEDVPT	O
+-	O
+P96	O
+-	O
+inoculated	O
+pigs	B-SPEC
+.	O
+
+Alignment	O
+and	O
+comparison	O
+of	O
+full	O
+-	O
+length	O
+sequences	O
+of	O
+PEDVPT	O
+-	O
+P5	O
+and	O
+PEDVPT	O
+-	O
+P96	O
+revealed	O
+23	O
+nucleotide	B-CHED
+changes	O
+and	O
+resultant	O
+19	O
+amino	B-PROC
+acid	I-PROC
+substitutions	I-PROC
+in	O
+non	O
+-	O
+structure	O
+proteins	B-CHED
+2	O
+,	O
+3	O
+,	O
+4	O
+,	O
+9	O
+,	O
+14	O
+,	O
+15	O
+,	O
+spike	O
+,	O
+open	O
+reading	O
+frame	O
+3	O
+(	O
+ORF3	O
+),	O
+and	O
+membrane	B-COMP
+proteins	B-CHED
+with	O
+no	O
+detectable	O
+deletion	O
+or	O
+insertion	O
+.	O
+
+The	O
+present	O
+study	O
+confirmed	O
+the	O
+pathogenicity	O
+of	O
+the	O
+PEDVPT	O
+isolate	O
+in	O
+conventional	O
+post	O
+-	O
+weaning	B-PROC
+pigs	B-SPEC
+.	O
+
+In	O
+this	O
+study	O
+,	O
+we	O
+discovered	O
+a	O
+panel	O
+of	O
+neutralizing	O
+monoclonal	O
+antibodies	B-COMP
+(	O
+mAbs	O
+)	O
+against	O
+MERS	O
+-	O
+CoV	O
+,	O
+which	O
+mapped	O
+to	O
+a	O
+wide	O
+range	O
+of	O
+regions	O
+on	O
+the	O
+spike	O
+(	O
+S	O
+)	O
+protein	B-CHED
+of	O
+the	O
+virus	B-SPEC
+.	O
+
+In	O
+addition	O
+to	O
+mAbs	O
+with	O
+neutralizing	O
+epitopes	O
+located	O
+on	O
+the	O
+receptor	O
+-	O
+binding	B-FUNC
+domain	O
+,	O
+one	O
+mAb	O
+,	O
+5F9	O
+,	O
+which	O
+binds	B-FUNC
+to	O
+the	O
+N	O
+-	O
+terminal	O
+domain	O
+(	O
+NTD	O
+)	O
+of	O
+the	O
+MERS	B-PRGE
+-	I-PRGE
+CoV	I-PRGE
+S1	I-PRGE
+subunit	I-PRGE
+,	O
+showed	O
+efficient	O
+neutralizing	O
+activity	O
+against	O
+the	O
+wild	O
+-	O
+type	O
+MERS	O
+-	O
+CoV	O
+strain	O
+EMC	B-COMP
+/	O
+2012	O
+,	O
+with	O
+a	O
+half	O
+maximal	O
+inhibitory	O
+concentration	O
+of	O
+0	O
+.	O
+2	O
+μg	O
+/	O
+mL	O
+.	O
+We	O
+concluded	O
+that	O
+a	O
+novel	O
+neutralizing	O
+epitope	O
+for	O
+MERS	O
+-	O
+CoV	O
+also	O
+resides	O
+on	O
+the	O
+NTD	O
+of	O
+the	O
+S	B-PRGE
+protein	I-PRGE
+,	O
+indicating	O
+that	O
+the	O
+NTD	O
+might	O
+be	O
+important	O
+during	O
+the	O
+viral	B-DISO
+infection	I-DISO
+process	O
+.	O
+
+Acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+criteria	O
+were	O
+recorded	O
+.	O
+
+For	O
+each	O
+imputation	O
+method	O
+,	O
+we	O
+calculated	O
+both	O
+imputation	O
+error	O
+and	O
+the	O
+area	O
+under	O
+the	O
+curve	O
+for	O
+patients	O
+meeting	O
+criteria	O
+for	O
+acute	O
+respiratory	O
+distress	O
+syndrome	O
+(	O
+PaO2	O
+/	O
+FIO2	O
+≤	O
+300	O
+)	O
+and	O
+moderate	O
+-	O
+severe	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+(	O
+PaO2	O
+/	O
+FIO2	O
+≤	O
+150	O
+).	O
+
+All	O
+imputation	O
+methods	O
+better	O
+identified	O
+moderate	O
+-	O
+severe	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+(	O
+PaO2	O
+/	O
+FIO2	O
+≤	O
+150	O
+);	O
+nonlinear	O
+imputation	O
+remained	O
+superior	O
+(	O
+p	O
+<	O
+0	O
+.	O
+001	O
+).	O
+
+TITLE	O
+:	O
+Clinicopathological	O
+spectrum	O
+of	O
+snake	B-SPEC
+bite	B-PROC
+-	O
+induced	O
+acute	O
+kidney	B-ANAT
+injury	O
+from	O
+India	O
+.	O
+
+ABSTRACT	O
+:	O
+Reverse	B-PRGE
+transcriptase	I-PRGE
+(	O
+RT	O
+)-	O
+associated	O
+DNA	O
+polymerase	O
+(	O
+RDDP	O
+)	O
+and	O
+ribonucleaser	O
+H	O
+(	O
+RNase	B-PRGE
+H	I-PRGE
+)	O
+functions	O
+are	O
+both	O
+essential	O
+for	O
+HIV	B-SPEC
+-	I-SPEC
+1	I-SPEC
+genome	O
+replication	O
+,	O
+and	O
+the	O
+identification	O
+of	O
+new	O
+inhibitors	B-CHED
+to	O
+block	O
+both	O
+of	O
+them	O
+is	O
+a	O
+goal	O
+actively	O
+pursued	O
+by	O
+the	O
+scientific	O
+community	O
+.	O
+
+Aliquots	O
+were	O
+removed	O
+at	O
+various	O
+time	O
+points	O
+followed	O
+by	O
+preparing	O
+serial	O
+10	O
+-	O
+fold	O
+dilutions	O
+and	O
+inoculating	O
+in	O
+cell	B-COMP
+cultures	O
+to	O
+determine	O
+the	O
+amount	O
+of	O
+surviving	O
+virus	B-SPEC
+.	O
+
+Soybean	B-SPEC
+meal	O
+had	O
+the	O
+greatest	O
+delta	O
+value	O
+(	O
+7	O
+.	O
+50	O
+days	O
+)	O
+for	O
+PEDV	B-SPEC
+(	O
+P	O
+<	O
+0	O
+.	O
+06	O
+)	O
+as	O
+compared	O
+with	O
+all	O
+other	O
+ingredients	O
+.	O
+
+The	O
+aim	O
+of	O
+this	O
+study	O
+was	O
+to	O
+determine	O
+the	O
+plasma	B-ANAT
+concentration	O
+of	O
+kallistatin	O
+in	O
+intensive	O
+care	O
+unit	O
+(	O
+ICU	O
+)	O
+patients	O
+with	O
+severe	B-DISO
+sepsis	I-DISO
+and	O
+septic	B-DISO
+shock	I-DISO
+and	O
+to	O
+determine	O
+their	O
+potential	O
+correlation	O
+with	O
+disease	O
+severity	O
+and	O
+outcomes	O
+.	O
+
+High	O
+kallistatin	B-PRGE
+levels	O
+were	O
+also	O
+independently	O
+associated	O
+with	O
+a	O
+decreased	O
+risk	O
+of	O
+septic	B-DISO
+shock	I-DISO
+,	O
+the	O
+development	B-PROC
+of	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+,	O
+and	O
+positive	O
+blood	B-ANAT
+cultures	O
+.	O
+
+In	O
+addition	O
+,	O
+there	O
+were	O
+inverse	O
+correlations	O
+between	O
+day	O
+1	O
+kallistatin	O
+levels	O
+and	O
+the	O
+levels	O
+of	O
+TNF	B-PRGE
+-	I-PRGE
+α	I-PRGE
+,	O
+IL	O
+-	O
+1β	O
+,	O
+IL	B-FUNC
+-	I-FUNC
+6	I-FUNC
+,	O
+and	O
+C	B-PRGE
+-	I-PRGE
+reactive	I-PRGE
+protein	I-PRGE
+,	O
+and	O
+SOFA	O
+scores	O
+on	O
+day	O
+1	O
+.	O
+
+Co	O
+-	O
+crystallization	O
+studies	O
+further	O
+revealed	O
+critical	O
+molecular	O
+interactions	O
+between	O
+UbVs	O
+and	O
+MERS	O
+-	O
+CoV	O
+or	O
+CCHFV	B-SPEC
+vDUBs	O
+,	O
+accounting	O
+for	O
+the	O
+observed	O
+binding	B-FUNC
+specificity	O
+and	O
+high	O
+affinity	O
+.	O
+
+Phosphine	B-CHED
+is	O
+a	O
+respiratory	O
+toxin	O
+that	O
+inhibits	O
+cytochrome	B-PRGE
+C	I-PRGE
+oxidase	I-PRGE
+system	O
+resulting	O
+in	O
+renal	B-DISO
+failure	I-DISO
+and	O
+liver	B-DISO
+failure	I-DISO
+.	O
+
+Run	B-PRGE
+Rat	I-PRGE
+®	I-PRGE
+is	O
+a	O
+commonly	O
+used	O
+rodenticide	B-CHED
+and	O
+the	O
+toxic	O
+effects	O
+are	O
+mediated	O
+through	O
+conversion	O
+of	O
+phosphide	B-CHED
+to	O
+phosphine	B-CHED
+gas	B-ENZY
+.	O
+
+Furthermore	O
+,	O
+the	O
+lack	O
+of	O
+an	O
+antidote	B-CHED
+and	O
+advanced	O
+resuscitative	O
+measures	O
+such	O
+as	O
+inotropic	O
+supportive	O
+therapy	O
+and	O
+renal	B-ANAT
+replacement	O
+facilities	O
+at	O
+most	O
+of	O
+the	O
+peripheral	O
+hospitals	O
+pose	O
+a	O
+major	O
+challenge	O
+in	O
+providing	O
+timely	O
+interventions	O
+to	O
+prevent	O
+deaths	B-PROC
+.	O
+
+Case	O
+1	O
+showed	O
+delayed	O
+symptom	B-DISO
+development	B-PROC
+after	O
+a	O
+four	O
+-	O
+day	O
+asymptomatic	O
+period	O
+,	O
+Case	O
+2	O
+experienced	O
+a	O
+20	O
+-	O
+day	O
+incubation	O
+period	O
+,	O
+and	O
+Case	O
+3	O
+exhibited	O
+persistent	O
+viral	B-DISO
+shedding	I-DISO
+without	O
+clinical	O
+deterioration	O
+.	O
+
+This	O
+study	O
+aimed	O
+to	O
+evaluate	O
+the	O
+diagnostic	O
+and	O
+prognostic	O
+values	O
+of	O
+Club	B-PRGE
+cell	I-PRGE
+protein	B-CHED
+16	I-PRGE
+(	O
+CC16	B-PRGE
+)	O
+in	O
+critical	O
+care	O
+patients	O
+with	O
+ARDS	B-DISO
+.	O
+
+The	O
+serum	B-COMP
+CC16	O
+levels	O
+were	O
+significantly	O
+greater	O
+in	O
+non	O
+-	O
+survivors	O
+than	O
+in	O
+survivors	O
+from	O
+the	O
+ARDS	B-DISO
+group	O
+.	O
+
+CC16	B-PRGE
+levels	O
+were	O
+associated	O
+with	O
+ICU	O
+stay	O
+but	O
+not	O
+hospital	O
+stay	O
+.	O
+
+TITLE	O
+:	O
+Detection	O
+of	O
+alpha	O
+-	O
+and	O
+betacoronaviruses	O
+in	O
+rodents	B-SPEC
+from	O
+Yunnan	O
+,	O
+China	O
+.	O
+
+Coronaviruses	O
+infect	O
+various	O
+animals	B-SPEC
+,	O
+but	O
+to	O
+date	O
+,	O
+relatively	O
+few	O
+coronaviruses	O
+have	O
+been	O
+identified	O
+in	O
+rodents	B-SPEC
+worldwide	O
+.	O
+
+Further	O
+surveillance	O
+and	O
+functional	O
+studies	O
+of	O
+these	O
+coronaviruses	O
+will	O
+help	O
+to	O
+better	O
+understand	O
+the	O
+importance	O
+of	O
+rodent	B-SPEC
+as	O
+host	B-COMP
+for	O
+coronaviruses	O
+.	O
+
+TITLE	O
+:	O
+[	O
+EXTRACORPOREAL	O
+MEMBRANE	B-COMP
+OXYGENATION	B-PROC
+IN	O
+ISRAEL	O
+:	O
+6	O
+.	O
+5	O
+YEARS	O
+OF	O
+EXPERIENCE	O
+AT	O
+THE	O
+LARGEST	O
+ECMO	O
+TREATMENT	O
+CENTER	O
+IN	O
+ISRAEL	O
+].	O
+
+ABSTRACT	O
+:	O
+Neutrophils	B-ANAT
+are	O
+immune	O
+cells	B-COMP
+that	O
+are	O
+well	O
+known	O
+to	O
+be	O
+present	O
+during	O
+many	O
+types	O
+of	O
+lung	O
+diseases	O
+associated	O
+with	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+(	O
+ARDS	B-DISO
+)	O
+and	O
+may	O
+contribute	O
+to	O
+acute	O
+lung	B-ANAT
+injury	O
+.	O
+
+Neutrophils	B-ANAT
+increase	O
+in	O
+the	O
+respiratory	B-ANAT
+tract	I-ANAT
+during	O
+infection	B-DISO
+with	O
+mild	O
+seasonal	O
+IAV	O
+,	O
+moderate	O
+and	O
+severe	O
+epidemic	O
+IAV	O
+infection	B-DISO
+,	O
+and	O
+emerging	O
+highly	O
+pathogenic	O
+avian	B-DISO
+influenza	I-DISO
+(	O
+HPAI	B-FUNC
+).	O
+
+In	O
+general	O
+two	O
+types	O
+of	O
+systems	O
+can	O
+be	O
+differentiated	B-PROC
+:	O
+devices	O
+for	O
+extracorporeal	O
+carbon	B-CHED
+dioxide	I-CHED
+removal	O
+(	O
+ECCO	O
+
+ABSTRACT	O
+:	O
+We	O
+evaluated	O
+the	O
+outcome	O
+of	O
+subjects	O
+with	O
+ARDS	O
+in	O
+relation	O
+to	O
+etiology	O
+and	O
+severity	O
+in	O
+a	O
+retrospective	O
+cohort	O
+study	O
+of	O
+the	O
+ARDS	B-DISO
+Network	O
+randomized	O
+controlled	O
+trials	O
+.	O
+
+Outcomes	O
+were	O
+modeled	O
+with	O
+multivariable	O
+regressions	B-DISO
+adjusted	O
+for	O
+baseline	O
+covariates	O
+,	O
+age	O
+,	O
+sex	O
+,	O
+race	O
+,	O
+Acute	O
+Physiology	O
+and	O
+Chronic	O
+Health	O
+Evaluation	O
+III	O
+(	O
+APACHE	O
+III	O
+),	O
+vasopressor	O
+use	O
+,	O
+modified	O
+lung	B-ANAT
+injury	O
+score	O
+,	O
+diabetes	B-DISO
+mellitus	I-DISO
+,	O
+cancer	B-DISO
+status	O
+,	O
+body	B-ANAT
+mass	O
+index	O
+,	O
+pre	O
+-	O
+ICU	O
+location	O
+,	O
+ICU	O
+location	O
+,	O
+and	O
+study	O
+.	O
+
+There	O
+was	O
+no	O
+statistically	O
+significant	O
+difference	O
+in	O
+28	O
+-	O
+d	O
+mortality	O
+in	O
+relation	O
+to	O
+ARDS	B-DISO
+severity	O
+.	O
+
+Subjects	O
+with	O
+trauma	O
+,	O
+compared	O
+with	O
+other	O
+etiologies	O
+of	O
+ARDS	B-DISO
+,	O
+had	O
+significantly	O
+lower	O
+mortality	O
+at	O
+28	O
+d	O
+(	O
+odds	O
+ratio	O
+[	O
+OR	O
+]	O
+=	O
+0	O
+.	O
+47	O
+,	O
+95	O
+%	O
+CI	O
+0	O
+.	O
+26	O
+-	O
+0	O
+.	O
+83	O
+,	O
+Severity	O
+of	O
+ARDS	O
+based	O
+on	O
+P	O
+RESULTS	O
+:	O
+A	O
+total	O
+of	O
+2	O
+,	O
+914	O
+subjects	O
+were	O
+included	O
+in	O
+these	O
+trials	O
+.	O
+
+The	O
+prone	O
+posture	O
+results	O
+in	O
+more	O
+uniform	O
+pulmonary	B-ANAT
+blood	B-PROC
+flow	I-PROC
+when	O
+compared	O
+with	O
+the	O
+supine	O
+posture	O
+,	O
+due	O
+to	O
+an	O
+anatomical	O
+bias	B-SPEC
+for	O
+greater	O
+blood	B-PROC
+flow	I-PROC
+to	O
+dorsal	O
+lung	B-ANAT
+regions	O
+.	O
+
+This	O
+study	O
+examined	O
+the	O
+longitudinal	O
+relationship	O
+between	O
+neurocognitive	O
+and	O
+neurophysiologic	O
+markers	O
+among	O
+healthy	O
+HCV	B-SPEC
+-	O
+controls	O
+and	O
+HCV	O
++	O
+adults	O
+following	O
+successful	O
+HCV	B-SPEC
+eradication	O
+.	O
+
+Findings	O
+suggest	O
+that	O
+a	O
+subgroup	O
+of	O
+HCV	O
++	O
+patients	O
+experienced	O
+improvements	O
+in	O
+cognitive	O
+functioning	O
+following	O
+eradication	O
+of	O
+HCV	B-SPEC
+,	O
+which	O
+appears	O
+related	O
+to	O
+positive	O
+changes	O
+in	O
+white	B-ANAT
+matter	I-ANAT
+integrity	O
+.	O
+
+As	O
+an	O
+emerging	O
+virus	B-SPEC
+,	O
+combating	O
+it	O
+requires	O
+an	O
+in	O
+-	O
+depth	O
+understanding	O
+of	O
+its	O
+molecular	O
+machinery	O
+.	O
+
+HELLP	B-DISO
+syndrome	I-DISO
+,	O
+complicated	O
+by	O
+severe	O
+intracerebral	B-DISO
+hemorrhage	I-DISO
+was	O
+detected	O
+.	O
+
+This	O
+is	O
+the	O
+first	O
+detailed	O
+report	O
+of	O
+ARDS	B-DISO
+in	O
+a	O
+cat	B-SPEC
+.	O
+
+ABSTRACT	O
+:	O
+Approximately	O
+,	O
+80	O
+%	O
+of	O
+the	O
+many	O
+cases	O
+of	O
+the	O
+Middle	O
+East	O
+respiratory	O
+syndrome	B-DISO
+coronavirus	B-SPEC
+(	O
+MERS	O
+-	O
+CoV	O
+)	O
+confirmed	O
+worldwide	O
+were	O
+diagnosed	O
+in	O
+the	O
+Kingdom	B-SPEC
+of	O
+Saudi	O
+Arabia	O
+(	O
+KSA	O
+).	O
+
+A	O
+unique	O
+GYQEL	O
+motif	O
+is	O
+identified	O
+at	O
+the	O
+cytoplasmic	B-COMP
+terminal	O
+of	O
+OC43	B-PRGE
+spike	I-PRGE
+protein	I-PRGE
+which	O
+helps	O
+in	O
+localization	B-PROC
+in	O
+the	O
+lysosome	B-COMP
+,	O
+and	O
+a	O
+novel	O
+KLHYT	O
+motif	O
+is	O
+identified	O
+in	O
+the	O
+cytoplasmic	B-ANAT
+tail	I-ANAT
+of	O
+SARS	B-DISO
+spike	O
+protein	B-CHED
+which	O
+helps	O
+in	O
+ER	O
+or	O
+ERGIC	B-COMP
+localization	B-PROC
+.	O
+
+HPS	B-DISO
+is	O
+endemic	O
+in	O
+Argentina	B-SPEC
+,	O
+as	O
+well	O
+as	O
+other	O
+countries	O
+of	O
+North	O
+and	O
+South	O
+American	O
+.	O
+
+These	O
+profiles	O
+suggest	O
+a	O
+strong	O
+activation	O
+of	O
+an	O
+innate	O
+immune	O
+and	O
+inflammatory	B-DISO
+responses	I-DISO
+are	O
+associated	O
+with	O
+HPS	B-DISO
+,	O
+relative	O
+to	O
+HFRS	B-DISO
+,	O
+as	O
+well	O
+as	O
+a	O
+robust	O
+activation	O
+of	O
+Th1	O
+-	O
+type	O
+immune	B-PROC
+responses	I-PROC
+.	O
+
+Finally	O
+,	O
+the	O
+results	O
+of	O
+our	O
+analysis	O
+suggest	O
+that	O
+serum	B-COMP
+cytokines	O
+profiles	O
+of	O
+HPS	B-DISO
+and	O
+HFRS	B-DISO
+cases	O
+are	O
+consistent	O
+with	O
+the	O
+presence	O
+of	O
+extracellular	B-PROC
+matrix	I-PROC
+degradation	I-PROC
+,	O
+increased	O
+mononuclear	B-ANAT
+leukocyte	I-ANAT
+proliferation	O
+,	O
+and	O
+transendothelial	B-PROC
+migration	I-PROC
+.	O
+
+ABSTRACT	O
+:	O
+The	O
+outbreak	O
+of	O
+Middle	O
+East	O
+respiratory	O
+syndrome	B-DISO
+-	O
+coronavirus	B-SPEC
+(	O
+MERS	O
+-	O
+CoV	O
+)	O
+in	O
+South	O
+Korea	O
+in	O
+April	O
+2015	O
+led	O
+to	O
+186	O
+infections	B-DISO
+and	O
+37	O
+deaths	B-PROC
+by	O
+the	O
+end	O
+of	O
+October	O
+2015	O
+.	O
+
+In	O
+conclusion	O
+,	O
+using	O
+bioinformatics	O
+methods	O
+,	O
+we	O
+analyzed	O
+the	O
+genome	O
+sequence	O
+of	O
+MERS	O
+-	O
+CoV	O
+and	O
+identified	O
+a	O
+potential	O
+B	B-ANAT
+-	I-ANAT
+cell	I-ANAT
+epitope	B-CHED
+of	O
+the	O
+E	B-PRGE
+protein	I-PRGE
+,	O
+which	O
+might	O
+significantly	O
+improve	O
+our	O
+current	O
+MERS	O
+vaccine	O
+development	B-PROC
+strategies	O
+.	O
+
+ABSTRACT	O
+:	O
+The	O
+severity	O
+of	O
+respiratory	O
+viral	B-DISO
+infections	I-DISO
+is	O
+partially	O
+determined	O
+by	O
+the	O
+cellular	B-COMP
+response	O
+mounted	O
+by	O
+infected	O
+lung	B-ANAT
+epithelial	B-ANAT
+cells	I-ANAT
+.	O
+
+Murine	B-SPEC
+models	O
+are	O
+commonly	O
+used	O
+to	O
+study	O
+the	O
+pathogenesis	B-DISO
+of	O
+respiratory	O
+viral	B-DISO
+infections	I-DISO
+,	O
+and	O
+in	O
+vitro	O
+studies	O
+using	O
+murine	B-SPEC
+cells	B-COMP
+provide	O
+mechanistic	O
+insight	O
+into	O
+the	O
+pathogenesis	B-DISO
+observed	O
+in	O
+vivo	O
+.	O
+
+We	O
+used	O
+microarray	O
+analysis	O
+to	O
+compare	O
+changes	O
+in	O
+gene	B-PROC
+expression	I-PROC
+of	O
+murine	B-SPEC
+lung	B-ANAT
+epithelial	B-ANAT
+cells	I-ANAT
+infected	O
+individually	O
+by	O
+three	O
+respiratory	O
+viruses	B-SPEC
+causing	O
+mild	O
+(	O
+rhinovirus	B-SPEC
+,	O
+RV1B	O
+),	O
+moderate	O
+(	O
+coronavirus	B-SPEC
+,	O
+MHV	B-PRGE
+-	I-PRGE
+1	I-PRGE
+),	O
+and	O
+severe	O
+(	O
+influenza	B-SPEC
+A	I-SPEC
+virus	I-SPEC
+,	O
+PR8	O
+)	O
+disease	O
+in	O
+mice	B-SPEC
+.	O
+
+RV1B	O
+infection	O
+caused	O
+numerous	O
+gene	B-PROC
+expression	I-PROC
+changes	O
+,	O
+but	O
+the	O
+differential	O
+effect	O
+peaked	O
+at	O
+12	O
+hours	O
+post	O
+-	O
+infection	B-DISO
+.	O
+
+Signature	O
+genes	O
+were	O
+identified	O
+for	O
+each	O
+virus	B-SPEC
+and	O
+included	O
+host	B-PROC
+defense	I-PROC
+genes	O
+for	O
+PR8	O
+,	O
+tissue	B-PROC
+remodeling	I-PROC
+genes	O
+for	O
+RV1B	O
+,	O
+and	O
+transcription	B-PROC
+factors	O
+for	O
+MHV	B-PRGE
+-	I-PRGE
+1	I-PRGE
+.	O
+
+ABSTRACT	O
+:	O
+Porcine	B-SPEC
+epidemic	I-SPEC
+diarrhea	I-SPEC
+virus	I-SPEC
+(	O
+PEDV	B-SPEC
+)	O
+causes	O
+acute	B-DISO
+diarrhea	I-DISO
+,	O
+vomiting	B-DISO
+,	O
+dehydration	B-DISO
+,	O
+weight	O
+loss	O
+,	O
+and	O
+high	O
+mortality	O
+rate	O
+in	O
+neonatal	O
+piglets	O
+.	O
+
+The	O
+disease	O
+causes	O
+substantial	O
+losses	O
+to	O
+the	O
+swine	B-SPEC
+industry	O
+in	O
+many	O
+countries	O
+.	O
+
+Presently	O
+,	O
+there	O
+is	O
+no	O
+effective	O
+PEDV	B-SPEC
+vaccine	O
+available	O
+.	O
+
+Recently	O
+,	O
+plant	B-SPEC
+expression	B-PROC
+systems	O
+have	O
+gained	O
+interest	O
+as	O
+an	O
+alternative	O
+for	O
+the	O
+production	O
+of	O
+antibodies	B-COMP
+because	O
+of	O
+many	O
+advantages	O
+,	O
+such	O
+as	O
+low	O
+production	O
+cost	O
+,	O
+lack	O
+of	O
+human	B-SPEC
+and	O
+animal	B-SPEC
+pathogen	O
+,	O
+large	O
+scalability	O
+,	O
+etc	O
+.	O
+
+Clinical	O
+development	B-PROC
+of	O
+multiple	O
+candidate	O
+vaccines	O
+was	O
+then	O
+initiated	O
+in	O
+parallel	O
+with	O
+attempts	O
+to	O
+contain	O
+the	O
+outbreak	O
+but	O
+only	O
+one	O
+vaccine	O
+was	O
+eventually	O
+tested	O
+in	O
+a	O
+phase	O
+III	O
+trial	O
+.	O
+
+This	O
+review	O
+gives	O
+an	O
+example	O
+of	O
+one	O
+such	O
+vaccine	O
+platform	O
+,	O
+replication	O
+-	O
+deficient	O
+simian	O
+adenoviruses	B-SPEC
+,	O
+and	O
+describes	O
+progress	O
+in	O
+human	B-SPEC
+and	O
+livestock	O
+vaccine	O
+development	B-PROC
+for	O
+three	O
+outbreak	O
+pathogens	O
+,	O
+Ebola	B-SPEC
+virus	I-SPEC
+,	O
+Rift	B-SPEC
+Valley	I-SPEC
+Fever	I-SPEC
+Virus	I-SPEC
+and	O
+Middle	O
+East	O
+Respiratory	O
+Syndrome	B-DISO
+Coronavirus	B-SPEC
+.	O
+
+Patient	O
+1	O
+had	O
+mild	O
+facial	B-DISO
+dysmorphism	I-DISO
+and	O
+died	B-PROC
+during	O
+the	O
+second	O
+ELT	O
+crisis	O
+at	O
+3	O
+-	O
+11	O
+/	O
+12	O
+years	O
+of	O
+age	O
+.	O
+
+ABSTRACT	O
+:	O
+The	O
+Middle	O
+East	O
+respiratory	O
+syndrome	B-DISO
+coronavirus	B-SPEC
+(	O
+MERS	O
+-	O
+CoV	O
+)	O
+has	O
+infected	O
+more	O
+than	O
+1900	O
+humans	B-SPEC
+,	O
+since	O
+2012	O
+.	O
+
+All	O
+vaccines	O
+contained	O
+the	O
+full	O
+-	O
+length	O
+spike	O
+gene	O
+of	O
+MERS	O
+-	O
+CoV	O
+;	O
+ChAdOx1	O
+MERS	O
+vaccines	O
+were	O
+produced	O
+with	O
+or	O
+without	O
+the	O
+leader	O
+sequence	O
+of	O
+the	O
+human	B-ANAT
+tissue	B-ENZY
+plasminogen	I-ENZY
+activator	I-ENZY
+gene	O
+(	O
+tPA	B-FUNC
+)	O
+where	O
+MVA	B-CHED
+MERS	O
+vaccines	O
+were	O
+produced	O
+with	O
+tPA	B-FUNC
+,	O
+but	O
+either	O
+the	O
+mH5	O
+or	O
+F11	O
+promoter	O
+driving	O
+expression	B-PROC
+of	O
+the	O
+spike	O
+gene	O
+.	O
+
+MVA	B-CHED
+MERS	O
+with	O
+mH5	O
+or	O
+F11	B-PRGE
+promoter	I-PRGE
+induced	O
+similar	O
+antibody	B-COMP
+levels	O
+;	O
+however	O
+,	O
+F11	B-PRGE
+promoter	I-PRGE
+enhanced	O
+the	O
+cellular	B-COMP
+immunogenicity	O
+of	O
+MVA	B-CHED
+MERS	O
+to	O
+significantly	O
+higher	O
+magnitudes	O
+.	O
+
+ChAdOx1	O
+and	O
+MVA	B-CHED
+vectored	O
+vaccines	O
+have	O
+been	O
+safely	O
+evaluated	O
+in	O
+camels	B-SPEC
+and	O
+humans	B-SPEC
+and	O
+these	O
+MERS	O
+vaccine	O
+candidates	O
+should	O
+now	O
+be	O
+tested	O
+in	O
+camels	B-SPEC
+and	O
+in	O
+clinical	O
+trials	O
+.	O
+
+ABSTRACT	O
+:	O
+The	O
+coronavirus	B-SPEC
+nonstructural	B-PRGE
+protein	I-PRGE
+3	I-PRGE
+(	O
+nsp3	B-PRGE
+)	O
+is	O
+a	O
+multifunctional	O
+protein	B-CHED
+that	O
+comprises	O
+multiple	O
+structural	O
+domains	O
+.	O
+
+High	O
+structural	O
+similarity	O
+to	O
+the	O
+human	B-SPEC
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+(	O
+SARS	B-DISO
+)	O
+coronavirus	B-SPEC
+nsp3	B-PRGE
+is	O
+present	O
+.	O
+
+Robust	O
+antibody	B-PROC
+responses	I-PROC
+were	O
+detected	O
+in	O
+all	O
+survivors	O
+who	O
+had	O
+severe	O
+disease	O
+;	O
+responses	O
+remained	O
+detectable	O
+,	O
+albeit	O
+with	O
+some	O
+waning	O
+,	O
+for	O
+<	O
+1	O
+year	O
+.	O
+
+ABSTRACT	O
+:	O
+MERS	O
+-	O
+CoV	O
+infection	O
+emerged	O
+in	O
+the	O
+Kingdom	B-SPEC
+of	O
+Saudi	O
+Arabia	O
+(	O
+KSA	O
+)	O
+in	O
+2012	O
+and	O
+has	O
+spread	O
+to	O
+26	O
+countries	O
+.	O
+
+The	O
+epidemic	O
+pattern	O
+in	O
+KSA	O
+was	O
+more	O
+complex	O
+,	O
+with	O
+animal	B-SPEC
+-	O
+to	O
+-	O
+human	B-SPEC
+,	O
+human	B-SPEC
+-	O
+to	O
+-	O
+human	B-SPEC
+,	O
+nosocomial	O
+and	O
+unknown	O
+exposure	O
+,	O
+whereas	O
+the	O
+outbreak	O
+in	O
+SK	O
+was	O
+more	O
+clearly	O
+nosocomial	O
+.	O
+
+In	O
+this	O
+study	O
+,	O
+we	O
+collected	O
+1004	O
+samples	O
+involving	O
+10	O
+bat	B-ENZY
+species	B-SPEC
+from	O
+7	O
+sites	O
+from	O
+April	O
+2015	O
+to	O
+May	O
+2016	O
+,	O
+and	O
+examined	O
+the	O
+presence	O
+of	O
+viruses	B-SPEC
+using	O
+nucleic	B-CHED
+acid	I-CHED
+-	O
+based	O
+methods	O
+.	O
+
+The	O
+full	O
+-	O
+length	O
+genome	O
+sequence	O
+of	O
+KNU	O
+-	O
+1601	O
+is	O
+28	O
+,	O
+053	O
+nucleotides	B-CHED
+(	O
+nt	O
+)	O
+in	O
+length	O
+,	O
+which	O
+is	O
+24	O
+nt	O
+and	O
+15	O
+nt	O
+longer	O
+than	O
+the	O
+genome	O
+sequences	O
+of	O
+G1	O
+classical	O
+and	O
+G2	O
+epidemic	O
+field	O
+strains	O
+,	O
+respectively	O
+.	O
+
+Rapid	O
+and	O
+accurate	O
+testing	O
+at	O
+the	O
+point	O
+-	O
+of	O
+-	O
+need	O
+(	O
+PON	O
+)	O
+supports	O
+prevention	O
+of	O
+virus	B-SPEC
+spread	O
+and	O
+management	O
+of	O
+clinical	O
+disease	O
+.	O
+
+Nucleocapsid	B-COMP
+(	O
+N	O
+)	O
+protein	B-CHED
+is	O
+the	O
+most	O
+abundant	O
+viral	O
+protein	B-CHED
+in	O
+CoV	O
+-	O
+infected	O
+cells	B-COMP
+,	O
+and	O
+has	O
+been	O
+identified	O
+as	O
+an	O
+innate	B-PROC
+immunity	I-PROC
+antagonist	B-PROC
+in	O
+several	O
+CoVs	O
+,	O
+including	O
+mouse	B-DISO
+hepatitis	I-DISO
+virus	B-SPEC
+(	O
+MHV	B-SPEC
+)	O
+and	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+(	O
+SARS	B-DISO
+)-	O
+CoV	O
+.	O
+However	O
+,	O
+the	O
+underlying	O
+molecular	O
+mechanism	O
+(	O
+s	O
+)	O
+remain	O
+unclear	O
+.	O
+
+In	O
+this	O
+study	O
+,	O
+we	O
+found	O
+that	O
+MHV	B-PRGE
+N	I-PRGE
+protein	B-CHED
+inhibited	O
+Sendai	B-SPEC
+virus	I-SPEC
+and	O
+poly	O
+(	O
+I	O
+:	O
+C	O
+)-	O
+induced	O
+IFN	B-PRGE
+-	I-PRGE
+β	I-PRGE
+production	O
+by	O
+targeting	B-PROC
+a	O
+molecule	O
+upstream	O
+of	O
+retinoic	B-CHED
+acid	I-CHED
+-	O
+induced	O
+gene	B-PRGE
+I	I-PRGE
+(	O
+RIG	B-PRGE
+-	I-PRGE
+I	I-PRGE
+)	O
+and	O
+melanoma	B-PATH
+differentiation	B-PROC
+gene	O
+5	O
+(	O
+MDA5	O
+).	O
+
+One	O
+hundred	O
+and	O
+two	O
+patients	O
+with	O
+VZV	B-SPEC
+-	O
+CAP	B-DISO
+were	O
+included	O
+.	O
+
+Steroid	B-CHED
+therapy	O
+did	O
+not	O
+influence	O
+mortality	O
+,	O
+but	O
+increased	O
+the	O
+risk	O
+of	O
+superinfection	B-DISO
+.	O
+
+Additionally	O
+,	O
+each	O
+of	O
+these	O
+three	O
+phenotypes	O
+had	O
+distinct	O
+quantitative	O
+trait	O
+loci	O
+[	O
+Chr	B-DISO
+9	O
+(	O
+weight	O
+loss	O
+),	O
+Chrs	B-DISO
+7	O
+and	O
+12	O
+(	O
+virus	O
+titer	O
+),	O
+and	O
+Chr	B-DISO
+15	O
+(	O
+hemorrhage	B-DISO
+)].	O
+
+ABSTRACT	O
+:	O
+Winter	B-DISO
+dysentery	I-DISO
+(	O
+WD	O
+)	O
+is	O
+a	O
+contagious	B-DISO
+disease	I-DISO
+caused	O
+by	O
+bovine	B-SPEC
+coronavirus	B-SPEC
+.	O
+
+A	O
+cohort	O
+study	O
+was	O
+performed	O
+based	O
+on	O
+reports	O
+of	O
+herd	O
+outbreaks	O
+of	O
+winter	B-DISO
+dysentery	I-DISO
+during	O
+a	O
+regional	O
+epidemic	O
+in	O
+Norway	O
+during	O
+the	O
+winter	O
+of	O
+2011	O
+-	O
+2012	O
+.	O
+
+This	O
+study	O
+estimated	O
+a	O
+total	O
+loss	O
+of	O
+51	O
+L	O
+/	O
+cow	B-SPEC
+during	O
+the	O
+study	O
+period	O
+,	O
+from	O
+7	O
+d	O
+before	O
+to	O
+19	O
+d	O
+after	O
+a	O
+reported	O
+outbreak	O
+.	O
+
+The	O
+estimated	O
+effect	O
+on	O
+milk	O
+composition	O
+was	O
+modest	O
+,	O
+but	O
+an	O
+increase	O
+of	O
+11	O
+%	O
+in	O
+free	O
+fatty	B-CHED
+acids	I-CHED
+and	O
+a	O
+small	O
+increase	O
+in	O
+fat	O
+/	O
+protein	B-CHED
+ratio	O
+indicated	O
+that	O
+WD	O
+might	O
+put	O
+cows	B-SPEC
+into	O
+negative	O
+energy	B-PROC
+balance	I-PROC
+.	O
+
+TITLE	O
+:	O
+Porcine	B-SPEC
+epidemic	I-SPEC
+diarrhoea	I-SPEC
+virus	I-SPEC
+with	O
+a	O
+recombinant	B-PRGE
+S	I-PRGE
+gene	I-PRGE
+detected	O
+in	O
+Hungary	O
+,	O
+2016	O
+.	O
+
+In	O
+January	O
+2016	O
+,	O
+diarrhoea	B-DISO
+with	O
+occasional	O
+vomiting	B-DISO
+was	O
+observed	O
+in	O
+a	O
+small	O
+pig	B-SPEC
+farm	O
+in	O
+Hungary	O
+.	O
+
+We	O
+performed	O
+a	O
+meta	B-SPEC
+-	O
+analysis	O
+of	O
+randomized	O
+trials	O
+to	O
+assess	O
+if	O
+blood	B-ANAT
+purification	O
+with	O
+continuous	O
+veno	O
+-	O
+venous	B-ANAT
+hemofiltration	O
+(	O
+CVVH	O
+)	O
+reduces	O
+mortality	O
+in	O
+these	O
+settings	O
+.	O
+
+To	O
+estimate	O
+the	O
+basic	O
+reproduction	B-PROC
+number	O
+of	O
+the	O
+MERS	O
+-	O
+CoV	O
+,	O
+we	O
+employ	O
+data	O
+from	O
+the	O
+2015	O
+South	O
+Korea	O
+MERS	O
+outbreak	O
+and	O
+the	O
+susceptible	O
+-	O
+infected	O
+-	O
+removed	O
+(	O
+SIR	O
+)	O
+model	O
+,	O
+a	O
+mathematical	O
+model	O
+that	O
+uses	O
+a	O
+set	O
+of	O
+ordinary	O
+differential	O
+equations	O
+(	O
+ODEs	O
+).	O
+
+Also	O
+we	O
+derive	O
+the	O
+basic	O
+reproductive	B-PROC
+number	O
+as	O
+the	O
+terms	O
+of	O
+the	O
+parameters	O
+of	O
+the	O
+SIR	O
+model	O
+.	O
+
+It	O
+is	O
+worth	O
+comparing	O
+with	O
+the	O
+basic	O
+reproductive	B-PROC
+number	O
+of	O
+the	O
+2014	O
+Ebola	O
+outbreak	O
+in	O
+West	O
+Africa	O
+including	O
+Guinea	B-SPEC
+,	O
+Sierra	O
+Leone	O
+,	O
+and	O
+Liberia	O
+,	O
+which	O
+had	O
+values	O
+of	O
+1	O
+.	O
+5	O
+-	O
+2	O
+.	O
+5	O
+.	O
+
+The	O
+definition	O
+of	O
+ARDS	B-DISO
+was	O
+updated	O
+in	O
+2012	O
+and	O
+is	O
+called	O
+the	O
+Berlin	O
+definition	O
+.	O
+
+TITLE	O
+:	O
+Sedation	B-DISO
+Management	O
+in	O
+Children	O
+Supported	O
+on	O
+Extracorporeal	O
+Membrane	B-COMP
+Oxygenation	B-PROC
+for	O
+Acute	B-DISO
+Respiratory	I-DISO
+Failure	I-DISO
+.	O
+
+ABSTRACT	O
+:	O
+To	O
+describe	O
+sedation	B-DISO
+management	O
+in	O
+children	O
+supported	O
+on	O
+extracorporeal	O
+membrane	B-COMP
+oxygenation	B-PROC
+for	O
+acute	B-DISO
+respiratory	I-DISO
+failure	I-DISO
+.	O
+
+Secondary	O
+analysis	O
+of	O
+prospectively	O
+collected	O
+data	O
+from	O
+a	O
+multicenter	O
+randomized	O
+trial	O
+of	O
+sedation	B-DISO
+(	O
+Randomized	O
+Evaluation	O
+of	O
+Sedation	B-DISO
+Titration	O
+for	O
+Respiratory	B-DISO
+Failure	I-DISO
+).	O
+
+Infectious	B-DISO
+work	O
+-	O
+up	O
+in	O
+1	O
+patient	O
+who	O
+died	B-PROC
+did	O
+not	O
+reveal	O
+any	O
+other	O
+pathogen	O
+.	O
+
+They	O
+included	O
+animal	B-SPEC
+and	O
+public	O
+health	O
+experts	O
+,	O
+environmental	O
+scientists	O
+,	O
+veterinary	O
+and	O
+horse	B-SPEC
+industry	O
+representatives	O
+,	O
+and	O
+wildlife	O
+experts	O
+.	O
+
+The	O
+group	O
+determined	O
+that	O
+the	O
+likely	O
+reservoir	O
+must	O
+occur	O
+in	O
+disparate	O
+locations	O
+,	O
+and	O
+be	O
+capable	O
+of	O
+moving	B-PROC
+between	O
+locations	O
+,	O
+or	O
+exist	O
+in	O
+continuous	O
+,	O
+overlapping	O
+populations	O
+spanning	O
+multiple	O
+locations	O
+.	O
+
+Dromedary	B-SPEC
+camels	B-SPEC
+were	O
+imported	O
+to	O
+Australia	O
+,	O
+principally	O
+between	O
+1880	O
+and	O
+1907	O
+and	O
+have	O
+since	O
+become	O
+a	O
+large	O
+feral	O
+population	O
+inhabiting	O
+extensive	O
+parts	O
+of	O
+the	O
+continent	O
+.	O
+
+This	O
+finding	O
+presents	O
+various	O
+hypotheses	O
+about	O
+the	O
+timing	O
+of	O
+the	O
+emergence	O
+and	O
+spread	O
+of	O
+MERS	O
+-	O
+CoV	O
+throughout	O
+populations	O
+of	O
+camels	O
+in	O
+Africa	O
+and	O
+Asia	O
+,	O
+which	O
+can	O
+be	O
+partially	O
+resolved	O
+by	O
+testing	O
+sera	B-COMP
+from	O
+camels	B-SPEC
+from	O
+the	O
+original	O
+source	O
+region	O
+,	O
+which	O
+we	O
+have	O
+inferred	O
+was	O
+mainly	O
+northwestern	O
+Pakistan	O
+.	O
+
+ABSTRACT	O
+:	O
+Emerging	O
+and	O
+re	O
+-	O
+emerging	O
+pathogens	O
+represent	O
+a	O
+substantial	O
+threat	O
+to	O
+public	O
+health	O
+,	O
+as	O
+demonstrated	O
+with	O
+numerous	O
+outbreaks	O
+over	O
+the	O
+past	O
+years	O
+,	O
+including	O
+the	O
+2013	O
+-	O
+2016	O
+outbreak	O
+of	O
+Ebola	B-SPEC
+virus	I-SPEC
+in	O
+western	O
+Africa	O
+.	O
+
+TITLE	O
+:	O
+Dromedary	B-SPEC
+camels	B-SPEC
+in	O
+northern	O
+Mali	O
+have	O
+high	O
+seropositivity	O
+to	O
+MERS	O
+-	O
+CoV	O
+.	O
+ABSTRACT	O
+:	O
+A	O
+high	O
+percentage	O
+(	O
+up	O
+to	O
+90	O
+%)	O
+of	O
+dromedary	O
+camels	B-SPEC
+in	O
+the	O
+Middle	O
+East	O
+as	O
+well	O
+as	O
+eastern	O
+and	O
+central	O
+Africa	O
+have	O
+antibodies	B-COMP
+to	O
+Middle	O
+East	O
+respiratory	O
+syndrome	B-DISO
+coronavirus	B-SPEC
+(	O
+MERS	O
+-	O
+CoV	O
+).	O
+
+ABSTRACT	O
+:	O
+Chicken	B-PRGE
+surfactant	B-CHED
+protein	B-CHED
+A	I-PRGE
+(	O
+cSP	B-PRGE
+-	I-PRGE
+A	I-PRGE
+)	O
+is	O
+a	O
+collectin	O
+believed	O
+to	O
+play	O
+an	O
+important	O
+role	O
+in	O
+antiviral	B-CHED
+immunity	B-PROC
+.	O
+
+The	O
+cSP	B-PRGE
+-	I-PRGE
+A	I-PRGE
+mRNA	B-CHED
+and	O
+its	O
+protein	B-CHED
+were	O
+detected	O
+separately	O
+using	O
+real	O
+-	O
+time	O
+quantitative	O
+reverse	O
+transcriptional	B-PROC
+polymerase	O
+chain	O
+reaction	O
+(	O
+qRT	O
+-	O
+PCR	O
+),	O
+a	O
+sandwich	O
+enzyme	O
+-	O
+linked	O
+immunosorbent	O
+assay	O
+(	O
+S	O
+-	O
+ELISA	O
+),	O
+and	O
+an	O
+immunohistochemistry	O
+assay	O
+(	O
+IHC	O
+).	O
+
+Consequently	O
+,	O
+the	O
+expression	B-PROC
+level	O
+of	O
+cSP	B-PRGE
+-	I-PRGE
+A	I-PRGE
+in	O
+the	O
+AIV	B-SPEC
++	I-SPEC
+IBV	I-SPEC
+co	O
+-	O
+infected	O
+group	O
+significantly	O
+decreased	O
+when	O
+compared	O
+to	O
+the	O
+AIV	O
+-	O
+infected	O
+group	O
+and	O
+the	O
+IBV	B-SPEC
+-	O
+infected	O
+group	O
+by	O
+qRT	O
+-	O
+PCR	O
+,	O
+ELISA	O
+,	O
+and	O
+IHC	O
+analysis	O
+.	O
+
+Sequence	O
+analyses	O
+revealed	O
+that	O
+SD	O
+and	O
+SZ	O
+isolates	O
+belong	O
+to	O
+the	O
+QX	B-PRGE
+-	I-PRGE
+like	I-PRGE
+IBV	I-PRGE
+genotype	I-PRGE
+and	O
+share	O
+high	O
+homology	O
+in	O
+their	O
+full	O
+-	O
+length	O
+genomes	O
+.	O
+
+Cross	O
+neutralization	O
+tests	O
+showed	O
+high	O
+cross	O
+neutralization	O
+between	O
+SD	O
+and	O
+SZ	O
+,	O
+but	O
+distant	O
+relationships	O
+with	O
+other	O
+representative	O
+strains	O
+of	O
+the	O
+classical	O
+IBV	B-SPEC
+serotypes	O
+.	O
+
+TITLE	O
+:	O
+Tension	B-DISO
+enterothorax	O
+and	O
+hepatothorax	O
+due	O
+to	O
+a	O
+diaphragmatic	B-DISO
+hernia	I-DISO
+:	O
+successful	O
+emergency	B-DISO
+repair	B-PROC
+of	O
+a	O
+life	O
+-	O
+threatening	O
+condition	B-DISO
+.	O
+
+ABSTRACT	O
+:	O
+A	O
+70	O
+-	O
+year	O
+-	O
+old	O
+female	O
+patient	O
+presented	O
+with	O
+acute	O
+severe	O
+respiratory	B-DISO
+distress	I-DISO
+at	O
+a	O
+district	O
+general	O
+hospital	O
+.	O
+
+The	O
+patient	O
+was	O
+transferred	O
+and	O
+underwent	O
+an	O
+emergency	B-DISO
+laparotomy	O
+at	O
+the	O
+Regional	O
+Oesophagogastric	B-ANAT
+Unit	O
+.	O
+
+TITLE	O
+:	O
+National	O
+survey	O
+of	O
+outcomes	O
+and	O
+practices	O
+in	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+in	O
+Singapore	O
+.	O
+
+A	O
+total	O
+of	O
+904	O
+adult	O
+patients	O
+were	O
+admitted	O
+to	O
+ICU	O
+during	O
+the	O
+study	O
+period	O
+and	O
+15	O
+patients	O
+met	B-CHED
+ARDS	B-DISO
+criteria	O
+.	O
+
+TGEV	B-PRGE
+PUR	I-PRGE
+46	I-PRGE
+-	I-PRGE
+MAD	B-PROC
+is	O
+a	O
+commonly	O
+used	O
+TGEV	B-SPEC
+strain	O
+that	O
+is	O
+known	O
+to	O
+be	O
+attenuated	O
+.	O
+
+ABSTRACT	O
+:	O
+Bovine	B-SPEC
+coronavirus	B-SPEC
+(	O
+BCoV	O
+)	O
+belong	O
+to	O
+the	O
+genus	B-SPEC
+Betacoronavirus	B-SPEC
+of	O
+the	O
+family	B-SPEC
+Coronaviridae	I-SPEC
+.	O
+
+G	O
++	O
+C	O
+compositional	O
+constraint	O
+and	O
+dinucleotide	B-CHED
+composition	O
+also	O
+plays	O
+a	O
+role	O
+in	O
+the	O
+overall	O
+pattern	O
+of	O
+BCoV	O
+codon	O
+usage	O
+.	O
+
+TITLE	O
+:	O
+Geo	O
+-	O
+economic	O
+variations	O
+in	O
+epidemiology	O
+,	O
+patterns	O
+of	O
+care	O
+,	O
+and	O
+outcomes	O
+in	O
+patients	O
+with	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+:	O
+insights	O
+from	O
+the	O
+LUNG	B-ANAT
+SAFE	O
+prospective	O
+cohort	O
+study	O
+.	O
+
+We	O
+aimed	O
+to	O
+characterise	O
+the	O
+effect	O
+of	O
+these	O
+geo	O
+-	O
+economic	O
+variations	O
+in	O
+patients	O
+enrolled	O
+in	O
+the	O
+Large	O
+Observational	O
+Study	O
+to	O
+Understand	O
+the	O
+Global	O
+Impact	O
+of	O
+Severe	O
+Acute	B-DISO
+Respiratory	I-DISO
+Failure	I-DISO
+(	O
+LUNG	B-ANAT
+SAFE	O
+).	O
+
+The	O
+proportion	O
+of	O
+patients	O
+with	O
+severe	O
+ARDS	B-DISO
+or	O
+with	O
+ratios	O
+of	O
+the	O
+partial	O
+pressure	O
+of	O
+arterial	B-ANAT
+oxygen	B-CHED
+(	O
+PaO	B-PROC
+Important	O
+geo	O
+-	O
+economic	O
+differences	O
+exist	O
+in	O
+the	O
+severity	O
+,	O
+clinician	O
+recognition	O
+,	O
+and	O
+management	O
+of	O
+ARDS	B-DISO
+,	O
+and	O
+in	O
+patients	O
+'	O
+outcomes	O
+.	O
+
+TITLE	O
+:	O
+[	O
+Acute	B-DISO
+cor	I-DISO
+pulmonale	I-DISO
+in	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+].	O
+
+Despite	O
+the	O
+improvement	O
+of	O
+therapeutic	O
+methods	O
+,	O
+the	O
+mortality	O
+of	O
+ARDS	B-DISO
+is	O
+in	O
+the	O
+range	O
+of	O
+40	O
+%-	O
+50	O
+%	O
+all	O
+over	O
+the	O
+world	O
+.	O
+
+We	O
+surveyed	O
+the	O
+diversity	O
+of	O
+CoVs	O
+in	O
+multiple	O
+host	B-COMP
+taxa	O
+from	O
+twenty	O
+countries	O
+to	O
+explore	O
+the	O
+factors	O
+driving	O
+viral	O
+diversity	O
+at	O
+a	O
+global	O
+scale	O
+.	O
+
+These	O
+were	O
+older	O
+,	O
+had	O
+more	O
+frequent	O
+chronic	B-DISO
+diseases	I-DISO
+and	O
+presented	O
+with	O
+less	O
+severe	O
+SOFA	O
+and	O
+non	O
+-	O
+pulmonary	B-ANAT
+SOFA	O
+scores	O
+(	O
+p	O
+<	O
+0	O
+.	O
+001	O
+).	O
+
+Eight	O
+percent	O
+of	O
+ARDS	B-DISO
+patients	O
+have	O
+no	O
+identified	O
+risk	O
+factor	O
+,	O
+80	O
+%	O
+of	O
+whom	O
+have	O
+no	O
+etiological	O
+diagnosis	O
+made	O
+.	O
+
+RESULTS	O
+:	O
+Among	O
+2813	O
+patients	O
+,	O
+234	O
+(	O
+8	O
+.	O
+3	O
+%	O
+[	O
+7	O
+.	O
+3	O
+-	O
+9	O
+.	O
+3	O
+])	O
+had	O
+no	O
+ARDS	B-DISO
+risk	O
+factor	O
+identified	O
+.	O
+
+No	O
+severe	O
+side	O
+effects	O
+associated	O
+with	O
+hypercapnia	B-DISO
+were	O
+observed	O
+.	O
+
+One	O
+hundred	O
+twenty	O
+chickens	B-SPEC
+were	O
+randomly	O
+divided	O
+into	O
+5	O
+groups	O
+.	O
+
+Groups	O
+3	O
+to	O
+4	O
+received	O
+intramuscular	O
+injection	O
+of	O
+cyclophosphamide	B-CHED
+to	O
+induce	O
+oxidative	B-DISO
+stress	I-DISO
+and	O
+immunosuppression	B-PROC
+.	O
+
+In	O
+addition	O
+,	O
+no	O
+side	O
+effects	O
+were	O
+found	O
+in	O
+chickens	B-SPEC
+throughout	O
+the	O
+study	O
+.	O
+
+The	O
+objective	O
+of	O
+this	O
+study	O
+was	O
+to	O
+examine	O
+the	O
+effect	O
+of	O
+atopy	B-DISO
+on	O
+the	O
+course	O
+of	O
+disease	O
+in	O
+children	O
+hospitalised	O
+with	O
+viral	B-DISO
+pneumonia	I-DISO
+.	O
+
+Groups	O
+were	O
+compared	O
+to	O
+evaluate	O
+the	O
+risk	O
+factors	O
+associated	O
+with	O
+severe	O
+viral	B-DISO
+pneumonia	I-DISO
+.	O
+
+Respiratory	B-SPEC
+syncytial	I-SPEC
+virus	I-SPEC
+(	O
+29	O
+.	O
+7	O
+%),	O
+Influenza	B-PATH
+A	I-PATH
+(	O
+20	O
+.	O
+5	O
+%),	O
+rhinovirus	B-SPEC
+(	O
+18	O
+.	O
+9	O
+%),	O
+adenovirus	B-DISO
+(	O
+10	O
+%),	O
+human	B-SPEC
+metapneumovirus	I-SPEC
+(	O
+8	O
+%),	O
+parainfluenza	B-DISO
+(	O
+5	O
+.	O
+2	O
+%),	O
+coronavirus	B-SPEC
+(	O
+6	O
+%),	O
+and	O
+bocavirus	B-SPEC
+(	O
+1	O
+.	O
+6	O
+%)	O
+were	O
+isolated	O
+from	O
+respiratory	B-ANAT
+samples	I-ANAT
+.	O
+
+TITLE	O
+:	O
+Tidal	O
+changes	O
+on	O
+CT	O
+and	O
+progression	O
+of	O
+ARDS	B-DISO
+.	O
+
+A	O
+single	O
+set	O
+of	O
+superimposed	O
+inspiratory	B-PROC
+-	O
+expiratory	B-PROC
+CT	O
+scans	O
+may	O
+predict	O
+progression	O
+of	O
+lung	B-ANAT
+injury	O
+and	O
+outcome	O
+in	O
+ARDS	B-DISO
+;	O
+if	O
+these	O
+preliminary	O
+results	O
+are	O
+validated	O
+,	O
+this	O
+could	O
+facilitate	O
+clinical	O
+trial	O
+recruitment	B-DISO
+and	O
+individualised	O
+care	O
+.	O
+
+Over	O
+the	O
+past	O
+three	O
+years	O
+,	O
+Coronavirus	B-SPEC
+HKU15	O
+has	O
+been	O
+widely	O
+detected	O
+in	O
+pigs	B-SPEC
+in	O
+East	O
+/	O
+Southeast	O
+Asia	O
+and	O
+North	O
+America	O
+and	O
+has	O
+been	O
+associated	O
+with	O
+fatal	O
+outbreaks	O
+.	O
+
+Complete	O
+genome	O
+sequencing	O
+of	O
+the	O
+Coronavirus	B-SPEC
+HKU15	O
+in	O
+two	O
+nasopharyngeal	B-ANAT
+samples	O
+revealed	O
+quasispecies	O
+in	O
+one	O
+of	O
+the	O
+samples	O
+.	O
+
+The	O
+outbreak	O
+strains	O
+in	O
+the	O
+United	O
+States	O
+possessed	B-DISO
+highly	O
+similar	O
+genome	O
+sequences	O
+and	O
+were	O
+clustered	O
+monophyletically	O
+,	O
+whereas	O
+the	O
+Asian	O
+strains	O
+were	O
+more	O
+diverse	O
+and	O
+paraphyletic	O
+.	O
+
+Evidence	O
+of	O
+MERS	O
+-	O
+CoV	O
+infection	B-DISO
+was	O
+confirmed	O
+in	O
+one	O
+herd	O
+on	O
+the	O
+basis	O
+of	O
+detection	B-PROC
+of	I-PROC
+virus	I-PROC
+RNA	O
+in	O
+nasal	B-ANAT
+swabs	O
+from	O
+three	O
+camels	B-SPEC
+and	O
+significant	O
+increases	O
+in	O
+the	O
+antibody	B-COMP
+titers	O
+from	O
+three	O
+others	O
+.	O
+
+There	O
+was	O
+evidence	O
+of	O
+reinfection	O
+of	O
+camels	B-SPEC
+that	O
+were	O
+previously	O
+seropositive	O
+,	O
+thus	O
+suggesting	O
+that	O
+prior	O
+infection	B-DISO
+does	O
+not	O
+provide	O
+complete	O
+immunity	B-PROC
+from	O
+reinfection	O
+,	O
+a	O
+finding	O
+that	O
+is	O
+relevant	O
+to	O
+camel	B-SPEC
+vaccination	O
+strategies	O
+as	O
+a	O
+means	O
+to	O
+prevent	O
+zoonotic	O
+transmission	O
+.	O
+
+ABSTRACT	O
+:	O
+Clinical	O
+judgement	O
+and	O
+suspicion	O
+of	O
+influenza	B-DISO
+based	O
+on	O
+signs	B-DISO
+and	I-DISO
+symptoms	I-DISO
+of	O
+influenza	B-DISO
+-	I-DISO
+like	I-DISO
+illness	I-DISO
+and	O
+severe	O
+acute	O
+respiratory	O
+illness	O
+are	O
+critical	O
+for	O
+better	O
+patient	O
+outcome	O
+.	O
+
+We	O
+included	O
+all	O
+patients	O
+(	O
+n	O
+=	O
+37	O
+)	O
+presenting	O
+with	O
+influenza	B-DISO
+like	I-DISO
+illness	I-DISO
+(	O
+ILI	O
+)	O
+or	O
+severe	O
+acute	O
+respiratory	O
+illness	O
+(	O
+SARI	O
+)	O
+to	O
+a	O
+tertiary	O
+care	O
+hospital	O
+in	O
+northwest	O
+Pakistan	O
+during	O
+December	O
+2015	O
+until	O
+the	O
+end	O
+of	O
+January	O
+2016	O
+.	O
+
+Throat	B-ANAT
+or	O
+nasopharyngeal	B-ANAT
+swabs	O
+were	O
+obtained	O
+from	O
+36	O
+patient	O
+and	O
+analyzed	O
+for	O
+the	O
+presence	O
+of	O
+Influenza	B-DISO
+virus	I-SPEC
+by	O
+quantitative	O
+PCR	O
+.	O
+
+Patients	O
+presenting	O
+with	O
+ILI	O
+or	O
+SARI	O
+were	O
+febrile	B-PROC
+(	O
+p	O
+&	O
+lt	O
+;	O
+0	O
+.	O
+001	O
+,	O
+one	O
+sample	O
+t	O
+-	O
+test	O
+),	O
+significantly	O
+tachypneic	O
+(	O
+p	O
+&	O
+lt	O
+;	O
+0	O
+.	O
+001	O
+)	O
+and	O
+had	O
+critically	O
+lower	O
+oxygen	O
+saturation	O
+(	O
+p	O
+&	O
+lt	O
+;	O
+0	O
+.	O
+001	O
+).	O
+
+ABSTRACT	O
+:	O
+The	O
+majority	O
+of	O
+human	B-SPEC
+emerging	B-DISO
+infectious	I-DISO
+diseases	I-DISO
+are	O
+zoonotic	O
+,	O
+with	O
+viruses	B-SPEC
+that	O
+originate	O
+in	O
+wild	O
+mammals	B-SPEC
+of	O
+particular	O
+concern	O
+(	O
+for	O
+example	O
+,	O
+HIV	B-DISO
+,	O
+Ebola	O
+and	O
+SARS	B-DISO
+).	O
+
+Understanding	O
+patterns	O
+of	O
+viral	O
+diversity	O
+in	O
+wildlife	O
+and	O
+determinants	O
+of	O
+successful	O
+cross	O
+-	O
+species	B-SPEC
+transmission	O
+,	O
+or	O
+spillover	O
+,	O
+are	O
+therefore	O
+key	O
+goals	O
+for	O
+pandemic	O
+surveillance	O
+programs	O
+.	O
+
+Here	O
+we	O
+conduct	B-PROC
+a	O
+comprehensive	O
+analysis	O
+of	O
+mammalian	B-SPEC
+host	B-COMP
+-	O
+virus	B-SPEC
+relationships	O
+and	O
+show	O
+that	O
+both	O
+the	O
+total	O
+number	O
+of	O
+viruses	B-SPEC
+that	O
+infect	O
+a	O
+given	O
+species	B-SPEC
+and	O
+the	O
+proportion	O
+likely	O
+to	O
+be	O
+zoonotic	O
+are	O
+predictable	O
+.	O
+
+The	O
+type	B-PRGE
+II	I-PRGE
+transmembrane	I-PRGE
+serine	B-CHED
+protease	I-PRGE
+TMPRSS2	I-PRGE
+cleaves	O
+and	O
+activates	O
+SARS	B-PRGE
+S	I-PRGE
+in	O
+cell	B-COMP
+culture	O
+and	O
+potentially	O
+also	O
+in	O
+the	O
+infected	O
+host	B-COMP
+.	O
+
+TITLE	O
+:	O
+Multi	O
+-	O
+target	O
+activity	O
+of	O
+Hemidesmus	B-SPEC
+indicus	I-SPEC
+decoction	O
+against	O
+innovative	O
+HIV	B-SPEC
+-	I-SPEC
+1	I-SPEC
+drug	O
+targets	O
+and	O
+characterization	O
+of	O
+Lupeol	O
+mode	O
+of	O
+action	O
+.	O
+
+In	O
+fact	O
+,	O
+by	O
+virtue	O
+of	O
+its	O
+numerous	O
+active	O
+metabolites	B-CHED
+,	O
+H	B-SPEC
+.	I-SPEC
+indicus	I-SPEC
+was	O
+able	O
+to	O
+inhibit	O
+not	O
+only	O
+the	O
+RT	O
+-	O
+associated	O
+RNase	B-PRGE
+H	I-PRGE
+function	O
+,	O
+but	O
+also	O
+the	O
+HIV	B-PRGE
+-	I-PRGE
+1	I-PRGE
+RT	I-PRGE
+-	I-PRGE
+associated	I-PRGE
+RNA	B-PROC
+-	I-PROC
+dependent	I-PROC
+DNA	I-PROC
+polymerase	I-PROC
+activity	I-PROC
+and	O
+the	O
+cellular	B-PRGE
+α	I-PRGE
+-	I-PRGE
+glucosidase	I-PRGE
+.	O
+
+TITLE	O
+:	O
+Discovery	O
+of	O
+a	O
+Highly	O
+Divergent	O
+Coronavirus	B-SPEC
+in	O
+the	O
+Asian	B-SPEC
+House	I-SPEC
+Shrew	I-SPEC
+from	O
+China	O
+Illuminates	O
+the	O
+Origin	O
+of	O
+the	O
+Alphacoronaviruses	O
+.	O
+
+ABSTRACT	O
+:	O
+Wheezing	B-DISO
+is	O
+a	O
+common	O
+problem	O
+in	O
+children	O
+under	O
+five	O
+with	O
+acute	O
+respiratory	O
+infections	O
+(	O
+ARIs	O
+).	O
+
+Viruses	B-SPEC
+are	O
+known	O
+to	O
+be	O
+responsible	O
+for	O
+a	O
+considerable	O
+proportion	O
+of	O
+ARIs	O
+in	O
+children	O
+.	O
+
+Throat	B-ANAT
+and	O
+nasal	B-ANAT
+swabs	O
+were	O
+collected	O
+,	O
+and	O
+real	O
+-	O
+time	O
+multiplex	O
+polymerase	O
+chain	O
+reaction	O
+(	O
+PCR	O
+)	O
+assay	O
+was	O
+used	O
+to	O
+screen	O
+for	O
+influenza	B-DISO
+1	O
+and	O
+2	O
+,	O
+respiratory	B-SPEC
+syncytial	I-SPEC
+virus	I-SPEC
+(	O
+RSV	B-SPEC
+),	O
+parainfluenza	B-DISO
+virus	B-SPEC
+(	O
+PIV	O
+)	O
+1	O
+,	O
+2	O
+,	O
+3	O
+and	O
+4	O
+,	O
+rhinovirus	B-SPEC
+,	O
+human	B-SPEC
+meta	B-SPEC
+-	O
+pneumovirus	B-SPEC
+,	O
+bocavirus	B-SPEC
+(	O
+HBoV	O
+),	O
+Coronavirus	B-SPEC
+,	O
+adenovirus	B-DISO
+,	O
+Enterovirus	B-SPEC
+and	O
+Parechovirus	B-SPEC
+.	O
+
+RSV	B-SPEC
+was	O
+the	O
+most	O
+common	O
+virus	B-SPEC
+(	O
+35	O
+%)	O
+followed	O
+by	O
+PIV1	O
+,	O
+2	O
+and	O
+3	O
+(	O
+20	O
+%),	O
+HBoV	O
+(	O
+10	O
+%)	O
+and	O
+rhinovirus	B-SPEC
+(	O
+5	O
+%).	O
+
+NF	O
+-	O
+κB	O
+inhibition	B-PROC
+also	O
+leads	O
+to	O
+anti	O
+-	O
+TGEV	B-SPEC
+replication	O
+.	O
+
+ABSTRACT	O
+:	O
+Coronaviruses	O
+are	O
+pathogens	O
+with	O
+a	O
+serious	O
+impact	O
+on	O
+human	O
+and	O
+animal	B-SPEC
+health	O
+.	O
+
+This	O
+review	O
+summarizes	O
+our	O
+current	O
+understanding	O
+of	O
+coronavirus	B-SPEC
+-	O
+host	B-COMP
+interactions	O
+at	O
+the	O
+level	O
+of	O
+the	O
+infected	O
+cell	B-COMP
+,	O
+with	O
+special	O
+attention	O
+for	O
+the	O
+assembly	O
+and	O
+function	O
+of	O
+the	O
+viral	O
+RNA	O
+-	O
+synthesising	O
+machinery	O
+and	O
+the	O
+evasion	O
+of	O
+cellular	B-COMP
+innate	B-DISO
+immune	I-DISO
+responses	I-DISO
+.	O
+
+ABSTRACT	O
+:	O
+Extracorporeal	O
+Membrane	B-COMP
+Oxygenation	B-PROC
+(	O
+ECMO	B-PROC
+)	O
+has	O
+become	O
+well	O
+established	O
+technique	O
+of	O
+the	O
+treatment	O
+of	O
+severe	O
+acute	B-DISO
+respiratory	I-DISO
+failure	I-DISO
+(	O
+Veno	O
+-	O
+Venous	B-ANAT
+ECMO	B-PROC
+)	O
+or	O
+circulatory	B-DISO
+failure	I-DISO
+(	O
+Veno	O
+-	O
+Arterial	B-ANAT
+ECMO	B-PROC
+)	O
+which	O
+enables	O
+effective	O
+blood	B-ANAT
+oxygenation	B-PROC
+and	O
+carbon	B-CHED
+dioxide	I-CHED
+removal	O
+for	O
+several	O
+weeks	O
+.	O
+
+We	O
+found	O
+that	O
+Rapamycin	B-CHED
+had	O
+no	O
+antiviral	B-CHED
+effect	O
+against	O
+H1N1	O
+,	O
+H3N2	B-CHED
+and	O
+novel	O
+-	O
+H1N1	B-DISO
+influenza	I-DISO
+viruses	O
+in	O
+vitro	O
+.	O
+
+TITLE	O
+:	O
+Structure	O
+-	O
+activity	O
+relationships	O
+of	O
+3	O
+-	O
+O	O
+-	O
+β	O
+-	O
+chacotriosyl	O
+oleanic	B-CHED
+acid	I-CHED
+derivatives	O
+as	O
+entry	O
+inhibitors	B-CHED
+for	O
+highly	O
+pathogenic	O
+H5N1	B-DISO
+influenza	I-DISO
+virus	O
+.	O
+
+ABSTRACT	O
+:	O
+HIV	B-DISO
+-	I-DISO
+1	I-DISO
+infection	I-DISO
+of	O
+resting	B-ANAT
+CD4	B-PRGE
+T	I-PRGE
+cells	O
+plays	O
+a	O
+crucial	O
+and	O
+numerically	O
+dominant	O
+role	O
+during	O
+virus	B-SPEC
+transmission	O
+at	O
+mucosal	B-ANAT
+sites	O
+and	O
+during	O
+subsequent	O
+acute	O
+replication	O
+and	O
+T	B-ANAT
+cell	I-ANAT
+depletion	O
+.	O
+
+It	O
+is	O
+defined	O
+as	O
+a	O
+pauci	O
+-	O
+immune	O
+necrotizing	O
+small	B-ANAT
+vessel	I-ANAT
+vasculitis	B-DISO
+,	O
+which	O
+usually	O
+affects	O
+the	O
+kidneys	B-ANAT
+,	O
+followed	O
+by	O
+the	O
+lungs	B-ANAT
+.	O
+
+The	O
+authors	O
+present	O
+the	O
+case	O
+of	O
+a	O
+55	O
+-	O
+year	O
+-	O
+old	O
+woman	O
+who	O
+was	O
+admitted	O
+with	O
+the	O
+diagnosis	O
+of	O
+renal	B-DISO
+failure	I-DISO
+,	O
+anemia	B-DISO
+,	O
+and	O
+a	O
+cardiac	B-ANAT
+murmur	O
+.	O
+
+During	O
+hospitalization	O
+,	O
+diagnostic	O
+workup	O
+disclosed	O
+a	O
+normal	O
+kidney	B-ANAT
+size	O
+as	O
+well	O
+as	O
+parenchymal	O
+thickness	O
+.	O
+
+A	O
+renal	B-ANAT
+biopsy	O
+was	O
+undertaken	O
+but	O
+the	O
+specimen	O
+was	O
+exiguous	O
+,	O
+showing	O
+4	O
+sclerotic	B-DISO
+glomeruli	O
+and	O
+1	O
+glomerulus	B-ANAT
+with	O
+crescentic	B-DISO
+glomerulonephritis	I-DISO
+.	O
+
+The	O
+search	O
+for	O
+ANCA	B-PRGE
+was	O
+positive	O
+.	O
+
+Although	O
+AS	O
+was	O
+present	O
+at	O
+autopsy	O
+and	O
+classified	O
+as	O
+moderate	O
+/	O
+severe	O
+,	O
+this	O
+lesion	O
+was	O
+a	O
+bystander	O
+in	O
+the	O
+process	O
+of	O
+this	O
+patient	O
+'	O
+s	O
+end	O
+of	O
+life	O
+,	O
+demonstrating	O
+the	O
+value	O
+of	O
+autopsy	O
+for	O
+medical	O
+learning	B-PROC
+and	O
+reasoning	O
+purposes	O
+.	O
+
+TITLE	O
+:	O
+Closed	O
+-	O
+loop	O
+mechanical	O
+ventilation	O
+for	O
+lung	B-ANAT
+injury	O
+:	O
+a	O
+novel	O
+physiological	O
+-	O
+feedback	O
+mode	O
+following	O
+the	O
+principles	O
+of	O
+the	O
+open	O
+lung	O
+concept	O
+.	O
+
+Dromedary	O
+camels	B-SPEC
+are	O
+the	O
+main	O
+reservoir	O
+of	O
+Middle	O
+East	O
+respiratory	O
+syndrome	B-DISO
+coronavirus	B-SPEC
+(	O
+MERS	O
+-	O
+CoV	O
+),	O
+but	O
+other	O
+livestock	O
+species	B-SPEC
+(	O
+i	O
+.	O
+e	O
+.,	O
+alpacas	B-SPEC
+,	O
+llamas	B-SPEC
+,	O
+and	O
+pigs	B-SPEC
+)	O
+are	O
+also	O
+susceptible	O
+to	O
+infection	B-DISO
+with	O
+MERS	O
+-	O
+CoV	O
+.	O
+Animal	B-SPEC
+-	O
+to	O
+-	O
+animal	B-SPEC
+transmission	O
+in	O
+alpacas	B-SPEC
+was	O
+reported	O
+,	O
+but	O
+evidence	O
+for	O
+transmission	O
+in	O
+other	O
+species	B-SPEC
+has	O
+not	O
+been	O
+proved	O
+.	O
+
+This	O
+study	O
+explored	O
+pig	B-SPEC
+-	O
+to	O
+-	O
+pig	B-SPEC
+MERS	O
+-	O
+CoV	O
+transmission	O
+experimentally	O
+.	O
+
+ABSTRACT	O
+:	O
+Veno	O
+-	O
+venous	B-ANAT
+extracorporeal	O
+membrane	O
+oxygenation	B-PROC
+(	O
+ECMO	O
+)	O
+is	O
+being	O
+more	O
+commonly	O
+used	O
+in	O
+patients	O
+with	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+(	O
+ARDS	B-DISO
+)	O
+due	O
+to	O
+potentially	O
+reversible	O
+illnesses	O
+.	O
+
+Severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+CoV	O
+(	O
+SARS	B-DISO
+-	O
+CoV	O
+)	O
+and	O
+Middle	O
+East	O
+respiratory	O
+syndrome	B-DISO
+CoV	O
+(	O
+MERS	O
+-	O
+CoV	O
+)	O
+successively	O
+emerged	O
+,	O
+causing	O
+severe	O
+epidemic	O
+respiratory	B-DISO
+disease	I-DISO
+in	O
+immunologically	O
+naïve	O
+human	B-SPEC
+populations	O
+throughout	O
+the	O
+globe	B-ANAT
+.	O
+
+Despite	O
+the	O
+high	O
+genetic	O
+homology	O
+in	O
+the	O
+S1	O
+gene	O
+between	O
+the	O
+four	O
+strains	O
+,	O
+the	O
+heterogeneity	O
+in	O
+biological	O
+behaviour	B-PROC
+of	O
+these	O
+different	O
+Q1	O
+strains	O
+was	O
+substantial	O
+.	O
+
+These	O
+differences	O
+were	O
+seen	O
+in	O
+embryonated	O
+eggs	O
+,	O
+in	O
+cell	B-COMP
+culture	O
+,	O
+in	O
+pathogenicity	O
+and	O
+in	O
+level	O
+of	O
+cross	O
+-	O
+protection	O
+by	O
+IBV	B-SPEC
+Massachusetts	O
+(	O
+Mass	O
+)	O
+vaccination	O
+.	O
+
+Six	O
+patients	O
+met	B-CHED
+our	O
+selection	O
+criteria	O
+from	O
+the	O
+hospital	O
+records	O
+,	O
+and	O
+4	O
+case	O
+reports	O
+from	O
+the	O
+literature	O
+search	O
+were	O
+also	O
+included	O
+.	O
+
+Gurd	O
+and	O
+Wilson	O
+criteria	O
+or	O
+the	O
+Schonfeld	O
+Fat	B-DISO
+Embolism	I-DISO
+Index	O
+are	O
+useful	O
+diagnostic	O
+tools	O
+for	O
+FES	O
+in	O
+SCD	B-DISO
+.	O
+
+ABSTRACT	O
+:	O
+Viruses	O
+are	O
+major	O
+aetiological	O
+agents	O
+of	O
+acute	B-DISO
+respiratory	I-DISO
+infection	I-DISO
+in	O
+young	O
+children	O
+.	O
+
+We	O
+report	O
+the	O
+first	O
+case	O
+of	O
+CHS	B-DISO
+as	O
+a	O
+complication	B-DISO
+of	O
+lateral	O
+medullary	B-ANAT
+infarction	B-DISO
+after	O
+endovascular	B-ANAT
+treatment	O
+.	O
+
+TITLE	O
+:	O
+Kidney	B-ANAT
+Cell	I-ANAT
+-	O
+Adapted	O
+Infectious	B-DISO
+Bronchitis	B-DISO
+ArkDPI	O
+Vaccine	O
+is	O
+Stable	O
+and	O
+Protective	O
+.	O
+
+Time	O
+course	O
+of	O
+SARI	O
+cases	O
+corresponded	O
+well	O
+to	O
+results	O
+from	O
+primary	O
+care	O
+surveillance	O
+and	O
+influenza	B-SPEC
+virus	I-SPEC
+circulation	B-PROC
+.	O
+
+It	O
+is	O
+a	O
+rare	O
+cause	O
+of	O
+pyogenic	O
+extraoral	O
+infections	B-DISO
+.	O
+
+Development	B-PROC
+of	O
+criteria	O
+for	O
+ECLS	O
+implementation	O
+can	O
+guide	O
+appropriate	O
+resources	O
+utilization	O
+and	O
+may	O
+prevent	O
+their	O
+use	O
+in	O
+patients	O
+with	O
+little	O
+to	O
+no	O
+chance	O
+of	O
+survival	O
+.	O
+
+Respiratory	B-SPEC
+syncytial	I-SPEC
+virus	I-SPEC
+(	O
+types	O
+A	O
+and	O
+B	O
+)	O
+was	O
+found	O
+in	O
+23	O
+.	O
+7	O
+%,	O
+human	B-SPEC
+enterovirus	B-SPEC
+/	O
+rhinovirus	B-SPEC
+in	O
+16	O
+.	O
+6	O
+%,	O
+metapneumovirus	B-SPEC
+in	O
+5	O
+.	O
+7	O
+%,	O
+parainfluenza	B-DISO
+virus	B-SPEC
+(	O
+types	O
+1	O
+-	O
+4	O
+)	O
+in	O
+5	O
+.	O
+5	O
+%,	O
+influenza	B-SPEC
+virus	I-SPEC
+(	O
+types	O
+A	O
+and	O
+B	O
+)	O
+in	O
+3	O
+.	O
+6	O
+%,	O
+adenovirus	B-DISO
+in	O
+2	O
+.	O
+2	O
+%,	O
+coronavirus	B-SPEC
+(	O
+NL63	O
+,	O
+OC43	O
+,	O
+229E	O
+,	O
+and	O
+HKU1	O
+)	O
+in	O
+2	O
+.	O
+2	O
+%,	O
+and	O
+bocavirus	B-SPEC
+in	O
+0	O
+.	O
+4	O
+%.	O
+
+The	O
+characteristics	O
+and	O
+outcomes	O
+of	O
+patients	O
+receiving	O
+PEG	B-CHED
+concomitantly	O
+with	O
+a	O
+tracheostomy	O
+(	O
+CTPEG	O
+)	O
+and	O
+those	O
+receiving	O
+delayed	B-PRGE
+PEG	I-PRGE
+(	O
+DPEG	O
+)	O
+after	O
+a	O
+tracheostomy	O
+were	O
+compared	O
+.	O
+
+Consecutive	O
+patients	O
+admitted	O
+to	O
+the	O
+NCCU	O
+from	O
+April	O
+2007	O
+to	O
+July	O
+2013	O
+who	O
+underwent	O
+percutaneous	O
+tracheostomy	O
+and	O
+gastrostomy	B-DISO
+by	O
+the	O
+percutaneous	O
+tracheostomy	O
+team	O
+were	O
+included	O
+and	O
+grouped	O
+according	O
+to	O
+the	O
+timing	O
+of	O
+PEG	B-CHED
+placement	O
+:	O
+CTPEG	O
+versus	O
+DPEG	O
+.	O
+
+Using	O
+the	O
+recombinant	O
+S	O
+proteins	B-CHED
+as	O
+probes	O
+to	O
+perform	O
+S	O
+protein	B-CHED
+affinity	O
+histochemistry	O
+in	O
+paraffin	O
+-	O
+embedded	O
+tissues	B-ANAT
+,	O
+although	O
+no	O
+tissue	B-ANAT
+or	O
+enteric	O
+binding	B-FUNC
+of	O
+FECV	B-PRGE
+UU7	I-PRGE
+S	I-PRGE
+protein	B-CHED
+was	O
+detected	O
+,	O
+it	O
+was	O
+found	O
+that	O
+by	O
+immunohistochemistry	O
+that	O
+the	O
+tissue	B-ANAT
+distribution	O
+of	O
+FIPV	B-PRGE
+UU4	I-PRGE
+S	I-PRGE
+protein	I-PRGE
+-	O
+bound	O
+cells	B-COMP
+correlated	O
+with	O
+that	O
+of	O
+FIPV	O
+antigen	B-CHED
+-	O
+positive	O
+cells	B-ANAT
+and	O
+lesions	O
+associated	O
+with	O
+FIP	B-DISO
+and	O
+that	O
+the	O
+affinity	O
+binding	B-FUNC
+of	O
+FIPV	B-PRGE
+UU4	I-PRGE
+S	I-PRGE
+protein	I-PRGE
+on	O
+macrophages	B-ANAT
+was	O
+not	O
+affected	O
+by	O
+enzymatic	O
+removal	O
+of	O
+host	B-COMP
+cell	I-COMP
+-	O
+surface	O
+sialic	B-CHED
+acid	I-CHED
+with	O
+neuraminidase	B-PRGE
+.	O
+
+TITLE	O
+:	O
+Asthma	B-DISO
+-	O
+COPD	B-DISO
+Overlap	O
+Shows	O
+Favorable	O
+Clinical	O
+Outcomes	O
+Compared	O
+to	O
+Pure	B-FUNC
+COPD	B-DISO
+in	O
+a	O
+Korean	O
+COPD	B-DISO
+Cohort	O
+.	O
+
+Among	O
+1	O
+,	O
+504	O
+patients	O
+with	O
+COPD	B-DISO
+,	O
+223	O
+(	O
+14	O
+.	O
+8	O
+%)	O
+were	O
+diagnosed	O
+with	O
+ACO	O
+.	O
+
+Patients	O
+with	O
+ACO	O
+showed	O
+a	O
+higher	O
+likelihood	O
+of	O
+FEV1	O
+recovery	O
+than	O
+those	O
+with	O
+pure	B-FUNC
+COPD	B-DISO
+(	O
+P	O
+<	O
+0	O
+.	O
+001	O
+).	O
+
+We	O
+evaluated	O
+variability	O
+in	O
+delayed	O
+fixation	O
+(≥	O
+24	O
+hours	O
+)	O
+between	O
+trauma	O
+centers	O
+participating	O
+in	O
+the	O
+American	O
+College	O
+of	O
+Surgeons	O
+(	O
+ACS	B-FUNC
+)	O
+
+It	O
+is	O
+important	O
+to	O
+carefully	O
+evaluate	O
+suspected	O
+MERS	O
+-	O
+CoV	O
+patients	O
+for	O
+the	O
+presence	O
+of	O
+other	B-DISO
+infectious	I-DISO
+diseases	I-DISO
+,	O
+such	O
+as	O
+TB	O
+,	O
+especially	O
+if	O
+cohorting	O
+is	O
+done	O
+for	O
+suspected	O
+MERS	O
+-	O
+CoV	O
+to	O
+avoid	O
+nosocomial	O
+transmission	O
+.	O
+
+The	O
+sows	O
+of	O
+the	O
+G4	O
+and	O
+L	O
+groups	O
+had	O
+the	O
+fewest	O
+piglets	O
+weaned	B-PROC
+(	O
+4	O
+.	O
+8	O
+±	O
+0	O
+.	O
+4	O
+,	O
+and	O
+4	O
+.	O
+0	O
+±	O
+0	O
+.	O
+3	O
+pigs	O
+,	O
+respectively	O
+;	O
+P	O
+<	O
+0	O
+.	O
+05	O
+)	O
+and	O
+the	O
+greatest	O
+pre	O
+-	O
+weaning	B-PROC
+mortality	O
+(	O
+33	O
+.	O
+1	O
+±	O
+4	O
+.	O
+8	O
+%,	O
+and	O
+39	O
+.	O
+7	O
+±	O
+4	O
+.	O
+1	O
+%,	O
+respectively	O
+;	O
+P	O
+<	O
+0	O
+.	O
+05	O
+).	O
+
+The	O
+number	O
+of	O
+piglets	O
+weaned	B-PROC
+and	O
+pre	O
+-	O
+weaning	B-PROC
+mortality	O
+,	O
+however	O
+,	O
+did	O
+not	O
+differ	O
+among	O
+the	O
+G1	O
+,	O
+G2	O
+,	O
+G3	O
+,	O
+and	O
+uninfected	O
+groups	O
+.	O
+
+ABSTRACT	O
+:	O
+Acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+(	O
+ARDS	B-DISO
+)	O
+is	O
+a	O
+severe	O
+clinical	O
+condition	B-DISO
+of	O
+respiratory	B-DISO
+failure	I-DISO
+due	O
+to	O
+an	O
+intense	O
+inflammatory	B-DISO
+response	I-DISO
+with	O
+different	O
+etiologies	O
+.	O
+
+α	O
+-	O
+bis	B-FUNC
+-	O
+loaded	O
+LNCs	O
+(	O
+α	O
+-	O
+bis	B-FUNC
+-	O
+LNCs	O
+)	O
+were	O
+prepared	O
+by	O
+interfacial	O
+deposition	O
+of	O
+poly	O
+(	O
+ε	O
+-	O
+caprolactone	B-CHED
+)	O
+and	O
+orally	B-ANAT
+administered	O
+in	O
+a	O
+mouse	B-SPEC
+model	O
+of	O
+ARDS	B-DISO
+triggered	O
+by	O
+an	O
+intranasal	O
+administration	O
+of	O
+lipopolysaccharide	O
+(	O
+LPS	B-DISO
+).	O
+
+Selection	O
+bias	B-SPEC
+due	O
+to	O
+non	O
+-	O
+random	O
+selection	O
+is	O
+a	O
+significant	O
+issue	O
+,	O
+particularly	O
+in	O
+the	O
+case	O
+-	O
+control	O
+design	O
+,	O
+and	O
+losses	O
+to	O
+follow	O
+-	O
+up	O
+is	O
+equally	O
+important	O
+for	O
+the	O
+cohort	O
+design	O
+.	O
+
+Here	O
+we	O
+show	O
+that	O
+avian	B-SPEC
+influenza	I-SPEC
+virus	I-SPEC
+H5N1	B-DISO
+induced	O
+the	O
+upregulation	B-PROC
+of	O
+miR	B-PRGE
+-	I-PRGE
+200c	I-PRGE
+-	I-PRGE
+3p	I-PRGE
+,	O
+which	O
+was	O
+then	O
+demonstrated	O
+to	O
+target	O
+the	O
+3	O
+'-	O
+untranslated	O
+region	O
+of	O
+ACE2	B-PRGE
+.	O
+
+Then	O
+,	O
+we	O
+found	O
+that	O
+nonstructural	O
+protein	B-CHED
+1	O
+and	O
+viral	O
+RNA	O
+of	O
+H5N1	B-DISO
+contributed	O
+to	O
+the	O
+induction	O
+of	O
+miR	B-PRGE
+-	I-PRGE
+200c	I-PRGE
+-	I-PRGE
+3p	I-PRGE
+during	O
+viral	B-PROC
+infection	I-PROC
+.	O
+
+Birds	B-SPEC
+were	O
+monitored	O
+for	O
+clinical	O
+and	O
+pathological	O
+outcomes	O
+and	O
+virus	B-DISO
+shedding	I-DISO
+for	O
+10days	O
+post	O
+infection	B-DISO
+(	O
+DPI	O
+).	O
+
+Mortalities	O
+were	O
+only	O
+recorded	O
+in	O
+mixed	O
+AIV	O
+-	O
+H9N2	O
+/	O
+variant	O
+IBV	B-SPEC
+challenge	O
+group	O
+.	O
+
+AIV	B-PRGE
+-	I-PRGE
+H9N2	I-PRGE
+challenge	O
+caused	O
+tracheal	O
+petechial	B-DISO
+hemorrhage	I-DISO
+that	O
+progressed	O
+to	O
+tracheal	O
+congestion	B-DISO
+and	O
+caseation	O
+.	O
+
+In	O
+mixed	O
+AIV	O
+-	O
+H9N2	O
+/	O
+variant	O
+IBV	B-SPEC
+challenge	O
+severe	O
+congestion	B-DISO
+of	O
+the	O
+tracheal	B-ANAT
+mucosa	I-ANAT
+and	O
+excessive	O
+exudates	B-ANAT
+with	O
+a	O
+tendency	O
+to	O
+form	O
+tubular	O
+casts	B-ANAT
+were	O
+observed	O
+.	O
+
+ABSTRACT	O
+:	O
+Outbreaks	O
+of	O
+porcine	O
+epidemic	B-DISO
+diarrhea	I-DISO
+(	O
+PED	B-DISO
+)	O
+have	O
+resulted	O
+in	O
+significant	O
+economic	O
+losses	O
+in	O
+the	O
+swine	B-SPEC
+industry	O
+,	O
+and	O
+another	O
+PED	B-DISO
+outbreak	O
+occurred	O
+in	O
+2014	O
+in	O
+Korea	O
+.	O
+
+Viral	O
+propagation	O
+was	O
+confirmed	O
+in	O
+Vero	B-ANAT
+cells	I-ANAT
+based	O
+on	O
+cytopathic	B-DISO
+effect	I-DISO
+,	O
+immunofluorescence	O
+assay	O
+,	O
+reverse	B-PROC
+transcription	I-PROC
+-	O
+polymerase	O
+chain	O
+reaction	O
+,	O
+and	O
+electron	O
+microscopic	O
+analyses	O
+.	O
+
+The	O
+performance	O
+analysis	O
+was	O
+conducted	O
+for	O
+two	O
+different	O
+purposes	O
+:	O
+(	O
+1	O
+)	O
+prediction	O
+of	O
+neutralization	O
+activity	O
+in	O
+MERS	O
+-	O
+CoV	O
+-	O
+infected	O
+patients	O
+,	O
+and	O
+(	O
+2	O
+)	O
+epidemiologic	O
+surveillance	O
+of	O
+MERS	O
+-	O
+CoV	O
+infections	B-DISO
+among	O
+MERS	O
+-	O
+CoV	O
+-	O
+exposed	O
+individuals	O
+.	O
+
+ABSTRACT	O
+:	O
+Autophagy	B-PROC
+is	O
+a	O
+conserved	O
+intracellular	O
+catabolic	B-PROC
+pathway	B-PROC
+that	O
+allows	O
+cells	B-COMP
+to	O
+maintain	O
+homeostasis	B-PROC
+through	O
+the	O
+degradation	O
+of	O
+deleterious	O
+components	O
+via	O
+specialized	O
+double	O
+-	O
+membrane	B-COMP
+vesicles	B-COMP
+called	O
+autophagosomes	O
+.	O
+
+We	O
+also	O
+analyzed	O
+how	O
+respiratory	B-DISO
+infections	I-DISO
+were	O
+distributed	O
+during	O
+the	O
+2	O
+years	O
+study	O
+.	O
+
+The	O
+serum	B-COMP
+levels	O
+of	O
+interferon	B-PRGE
+(	O
+IFN	O
+)-	O
+γ	O
+and	O
+the	O
+IFN	B-PRGE
+-	I-PRGE
+γ	I-PRGE
+/	O
+interleukin	B-PRGE
+(	O
+IL	O
+)-	O
+10	O
+ratio	O
+were	O
+higher	O
+in	O
+non	O
+-	O
+survivors	O
+.	O
+
+The	O
+serum	B-COMP
+levels	O
+of	O
+interferon	B-PRGE
+(	O
+IFN	O
+)-	O
+γ	O
+and	O
+the	O
+IFN	B-PRGE
+-	I-PRGE
+γ	I-PRGE
+/	O
+interleukin	B-PRGE
+(	O
+IL	O
+)-	O
+10	O
+ratio	O
+were	O
+higher	O
+in	O
+non	O
+-	O
+survivors	O
+.	O
+
+Demographic	O
+data	O
+,	O
+type	O
+of	O
+infection	B-DISO
+,	O
+risk	O
+factors	O
+,	O
+clinical	O
+presentation	O
+,	O
+analytical	O
+data	O
+at	O
+admission	O
+,	O
+treatment	O
+,	O
+need	O
+for	O
+admission	O
+to	O
+a	O
+pediatric	O
+intensive	O
+care	O
+unit	O
+,	O
+microbiological	O
+data	O
+,	O
+hospital	O
+stay	O
+and	O
+evolution	O
+were	O
+collected	O
+.	O
+
+In	O
+50	O
+(	O
+96	O
+%)	O
+cases	O
+,	O
+SGA	O
+was	O
+isolated	O
+in	O
+at	O
+least	O
+one	O
+sterile	B-DISO
+sample	O
+.	O
+
+Skin	B-ANAT
+and	O
+soft	B-DISO
+tissue	I-DISO
+infections	I-DISO
+were	O
+diagnosed	O
+in	O
+14	O
+patients	O
+(	O
+26	O
+.	O
+9	O
+%),	O
+14	O
+(	O
+26	O
+.	O
+9	O
+%)	O
+pneumonias	B-DISO
+,	O
+12	O
+(	O
+23	O
+.	O
+1	O
+%)	O
+bones	B-ANAT
+and	O
+joints	B-ANAT
+infections	B-DISO
+,	O
+10	O
+(	O
+19	O
+.	O
+2	O
+%)	O
+SSTS	O
+,	O
+6	O
+(	O
+11	O
+.	O
+5	O
+%)	O
+occult	O
+bacteremia	B-DISO
+,	O
+4	O
+(	O
+7	O
+.	O
+7	O
+%)	O
+meningitis	B-DISO
+and	O
+2	O
+(	O
+3	O
+.	O
+8	O
+%)	O
+sepsis	B-DISO
+.	O
+
+Phylogenetic	O
+incongruence	O
+analysis	O
+reveals	O
+that	O
+both	O
+strains	O
+have	O
+a	O
+mosaic	O
+genome	O
+that	O
+arose	O
+by	O
+recombination	B-PROC
+between	O
+Euro	B-SPEC
+Asiatic	O
+strains	O
+of	O
+the	O
+GI	O
+-	O
+16	O
+lineage	O
+and	O
+ancestral	O
+South	O
+American	O
+GI	O
+-	O
+11	O
+viruses	B-SPEC
+.	O
+
+The	O
+recombination	B-PROC
+occurred	O
+in	O
+South	O
+America	O
+and	O
+produced	O
+two	O
+viral	O
+variants	O
+that	O
+have	O
+retained	O
+the	O
+full	O
+-	O
+length	O
+S1	O
+sequences	O
+of	O
+the	O
+parental	O
+lineages	O
+but	O
+are	O
+extremely	O
+similar	O
+in	O
+the	O
+rest	B-FUNC
+of	O
+their	O
+genomes	O
+.	O
+
+Bat	B-SPEC
+flies	I-SPEC
+,	O
+in	O
+particular	O
+,	O
+are	O
+highly	O
+specialized	O
+obligate	O
+hematophagous	O
+ectoparasites	O
+that	O
+incidentally	O
+bite	B-PROC
+humans	B-SPEC
+.	O
+
+In	O
+these	O
+patients	O
+,	O
+ECCO	O
+Optimized	O
+use	O
+of	O
+NIV	O
+and	O
+lung	B-ANAT
+-	O
+protective	O
+ventilation	O
+remains	O
+standard	O
+of	O
+care	O
+in	O
+the	O
+management	O
+of	O
+hypercapnic	B-DISO
+respiratory	I-DISO
+failure	I-DISO
+.	O
+
+Gilts	O
+fed	O
+the	O
+high	O
+and	O
+medium	O
+diets	O
+reached	O
+puberty	B-PROC
+10	O
+and	O
+6days	O
+earlier	O
+,	O
+however	O
+,	O
+than	O
+gilts	O
+fed	O
+the	O
+low	O
+lysine	B-CHED
+diet	O
+(	O
+P	O
+<	O
+0	O
+.	O
+05	O
+).	O
+
+Significant	O
+differences	O
+were	O
+observed	O
+between	O
+provincial	O
+hospitals	O
+when	O
+compared	O
+to	O
+district	O
+hospitals	O
+in	O
+regards	O
+to	O
+availability	O
+of	O
+central	O
+oxygen	B-CHED
+piping	O
+system	O
+(	O
+78	O
+.	O
+3	O
+%	O
+vs	O
+38	O
+.	O
+7	O
+%,	O
+p	O
+=	O
+0	O
+.	O
+001	O
+)	O
+mechanical	O
+ventilation	O
+(	O
+100	O
+.	O
+0	O
+%	O
+vs	O
+73	O
+.	O
+6	O
+%,	O
+p	O
+=	O
+0	O
+.	O
+003	O
+),	O
+mobile	O
+x	O
+-	O
+rays	B-SPEC
+(	O
+80	O
+.	O
+0	O
+%	O
+vs	O
+29	O
+.	O
+8	O
+%,	O
+p	O
+<	O
+0	O
+.	O
+001	O
+),	O
+carbapenem	B-CHED
+antibiotic	B-CHED
+(	O
+73	O
+.	O
+9	O
+%	O
+vs	O
+17	O
+.	O
+4	O
+%,	O
+p	O
+<	O
+0	O
+.	O
+001	O
+)	O
+and	O
+norepinephrine	B-CHED
+(	O
+95	O
+.	O
+8	O
+%	O
+vs	O
+56	O
+.	O
+3	O
+%,	O
+p	O
+<	O
+0	O
+.	O
+001	O
+).	O
+
+There	O
+was	O
+a	O
+limited	O
+availability	O
+of	O
+arterial	B-ANAT
+blood	I-ANAT
+gas	O
+analyzers	O
+(	O
+13	O
+.	O
+7	O
+%),	O
+oseltamivir	B-CHED
+(	O
+42	O
+.	O
+2	O
+%)	O
+and	O
+N95	O
+respirators	O
+(	O
+54	O
+.	O
+6	O
+%)	O
+across	O
+all	O
+hospitals	O
+surveyed	O
+.	O
+
+February	O
+2013	O
+,	O
+an	O
+elderly	O
+man	B-CHED
+,	O
+who	O
+visited	O
+Pakistan	O
+and	O
+KSA	O
+,	O
+was	O
+confirmed	O
+as	O
+MRS	B-PRGE
+-	I-PRGE
+CoV	I-PRGE
+in	O
+UK	O
+.	O
+
+RESULTS	O
+:	O
+Arrived	O
+on	O
+16th	O
+December	O
+2012	O
+,	O
+mostly	O
+stayed	O
+at	O
+daughter	O
+'	O
+s	O
+house	O
+,	O
+visited	O
+by	O
+relatives	O
+,	O
+on	O
+19th	O
+January	O
+,	O
+left	O
+for	O
+KSA	O
+accompanied	O
+by	O
+daughter	O
+,	O
+developed	O
+fever	B-DISO
+with	I-DISO
+chills	I-DISO
+and	O
+body	B-ANAT
+aches	B-DISO
+on	O
+23rd	O
+January	O
+.	O
+
+TITLE	O
+:	O
+Identification	O
+of	O
+microRNAs	O
+in	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+based	O
+on	O
+microRNA	O
+expression	B-PROC
+profile	O
+in	O
+rats	B-SPEC
+.	O
+
+The	O
+four	O
+downregulated	O
+rno	O
+‑	O
+let	O
+‑	O
+7	O
+family	B-SPEC
+members	O
+were	O
+detected	O
+to	O
+have	O
+numerous	O
+co	O
+‑	O
+regulated	O
+target	O
+genes	O
+and	O
+synergistic	O
+functions	O
+.	O
+
+Additionally	O
+,	O
+the	O
+target	O
+genes	O
+of	O
+the	O
+four	O
+miRNAs	O
+were	O
+significantly	O
+enriched	O
+the	O
+biological	B-PROC
+processes	I-PROC
+of	O
+wounding	O
+and	O
+inflammatory	B-DISO
+response	I-DISO
+.	O
+
+ABSTRACT	O
+:	O
+Raccoons	O
+(	O
+Procyon	B-SPEC
+lotor	I-SPEC
+)	O
+are	O
+found	O
+worldwide	O
+.	O
+
+We	O
+examined	O
+sera	B-COMP
+from	O
+100	O
+wild	O
+raccoons	B-SPEC
+in	O
+Japan	O
+for	O
+antibodies	B-COMP
+to	O
+six	O
+canine	O
+viruses	B-SPEC
+with	O
+veterinary	O
+significance	O
+to	O
+assess	O
+their	O
+potential	O
+as	O
+reservoirs	O
+.	O
+
+Further	O
+study	O
+should	O
+include	O
+isolation	O
+and	O
+analysis	O
+of	O
+canine	O
+viruses	B-SPEC
+in	O
+wild	O
+raccoons	B-SPEC
+from	O
+a	O
+wider	O
+area	O
+.	O
+
+PEDV	B-SPEC
+blocked	O
+the	O
+p65	B-PRGE
+activation	O
+in	O
+infected	O
+cells	B-COMP
+and	O
+suppressed	O
+the	O
+PRD	B-PRGE
+II	I-PRGE
+-	O
+mediated	O
+NF	O
+-	O
+κB	O
+activity	O
+.	O
+
+ABSTRACT	O
+:	O
+Porcine	O
+epidemic	B-DISO
+diarrhea	I-DISO
+(	O
+PED	O
+)	O
+was	O
+detected	O
+for	O
+the	O
+first	O
+time	O
+in	O
+seven	O
+years	O
+in	O
+Japan	O
+in	O
+October	O
+2013	O
+in	O
+Okinawa	O
+Prefecture	O
+.	O
+
+The	O
+strong	O
+spatio	O
+-	O
+temporal	O
+clustering	O
+of	O
+PED	O
+-	O
+infected	O
+farms	O
+during	O
+the	O
+first	O
+6	O
+months	O
+of	O
+the	O
+epidemic	O
+in	O
+the	O
+southern	O
+part	O
+of	O
+Kyushu	O
+is	O
+consistent	O
+with	O
+results	O
+obtained	O
+elsewhere	O
+and	O
+demonstrates	O
+the	O
+rapid	O
+spread	O
+of	O
+the	O
+virus	B-SPEC
+in	O
+naïve	O
+populations	O
+.	O
+
+At	O
+34	O
+weeks	O
+of	O
+gestation	B-PROC
+,	O
+our	O
+patient	O
+presented	O
+with	O
+all	O
+clinical	O
+and	O
+biological	O
+symptoms	O
+compatible	O
+with	O
+a	O
+TAFRO	O
+syndrome	B-DISO
+.	O
+
+Tough	O
+quick	O
+cesarean	O
+section	O
+was	O
+performed	O
+as	O
+symptoms	O
+got	O
+worse	O
+with	O
+onset	O
+of	O
+multiorgan	B-DISO
+failure	I-DISO
+requiring	O
+mechanical	O
+ventilation	O
+for	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+,	O
+continuous	O
+renal	B-ANAT
+replacement	O
+,	O
+and	O
+vasopressors	O
+.	O
+
+All	O
+demographic	O
+and	O
+diagnostic	O
+data	O
+from	O
+patients	O
+presenting	O
+with	O
+febrile	B-PROC
+symptoms	O
+as	O
+a	O
+main	O
+complaint	O
+were	O
+collected	O
+.	O
+
+An	O
+effective	O
+strategy	O
+to	O
+control	O
+emergency	B-DISO
+center	O
+visits	O
+by	O
+non	O
+-	O
+urgent	O
+febrile	B-PROC
+patients	O
+and	O
+provide	O
+proper	O
+medical	O
+services	O
+is	O
+urgently	O
+needed	O
+.	O
+
+The	O
+use	O
+of	O
+inhaled	B-PROC
+long	O
+-	O
+acting	O
+β2	O
+-	O
+agonists	B-CHED
+alone	O
+is	O
+not	O
+appropriate	O
+.	O
+
+Management	O
+of	O
+persistent	B-DISO
+asthma	I-DISO
+requires	O
+avoidance	O
+of	O
+aggravating	O
+environmental	O
+factors	O
+,	O
+use	O
+of	O
+short	O
+-	O
+acting	O
+β2	O
+-	O
+agonists	B-CHED
+for	O
+rapid	O
+relief	O
+of	O
+symptoms	O
+,	O
+and	O
+daily	O
+use	O
+of	O
+inhaled	B-PROC
+corticosteroids	B-CHED
+.	O
+
+TITLE	O
+:	O
+Coronavirus	B-SPEC
+nucleocapsid	B-COMP
+proteins	B-CHED
+assemble	O
+constitutively	O
+in	O
+high	O
+molecular	O
+oligomers	O
+.	O
+
+She	O
+was	O
+treated	O
+with	O
+steroids	B-CHED
+and	O
+discharged	O
+after	O
+her	O
+condition	B-DISO
+improved	O
+.	O
+
+Retrospectively	O
+,	O
+the	O
+first	O
+hospitalization	O
+was	O
+believed	O
+to	O
+be	O
+caused	O
+by	O
+drug	O
+reaction	O
+with	O
+eosinophilia	B-DISO
+and	O
+systemic	O
+symptoms	O
+(	O
+DRESS	O
+).	O
+
+Treating	O
+that	O
+with	O
+steroids	B-CHED
+compromised	O
+her	O
+immune	B-ANAT
+system	I-ANAT
+beyond	O
+her	O
+pre	O
+-	O
+existing	O
+primary	B-PATH
+immunodeficiency	I-PATH
+status	O
+.	O
+
+TITLE	O
+:	O
+Molecular	O
+and	O
+phylogenetic	O
+characterization	O
+of	O
+bovine	B-SPEC
+coronavirus	B-SPEC
+virus	B-SPEC
+isolated	O
+from	O
+dairy	O
+cattle	B-SPEC
+in	O
+Central	O
+Region	O
+,	O
+Thailand	O
+.	O
+
+TITLE	O
+:	O
+The	O
+Use	O
+of	O
+Xenosurveillance	O
+to	O
+Detect	O
+Human	B-SPEC
+Bacteria	B-SPEC
+,	O
+Parasites	O
+,	O
+and	O
+Viruses	B-SPEC
+in	O
+Mosquito	B-SPEC
+Bloodmeals	O
+.	O
+
+Therefore	O
+,	O
+new	O
+strategies	O
+to	O
+survey	O
+human	B-SPEC
+populations	O
+for	O
+emerging	O
+pathogens	O
+are	O
+necessary	O
+.	O
+
+Xenosurveillance	O
+is	O
+a	O
+method	O
+that	O
+utilizes	O
+mosquitoes	B-SPEC
+as	O
+sampling	O
+devices	O
+to	O
+search	O
+for	O
+genetic	O
+signatures	O
+of	O
+pathogens	O
+in	O
+vertebrates	B-SPEC
+.	O
+
+The	O
+potential	O
+of	O
+the	O
+platform	O
+for	O
+development	B-PROC
+of	O
+vaccines	O
+against	O
+other	O
+emerging	O
+viruses	B-SPEC
+such	O
+as	O
+Zika	B-SPEC
+virus	I-SPEC
+is	O
+described	O
+.	O
+
+Old	O
+age	O
+,	O
+low	O
+albumin	B-PRGE
+,	O
+altered	O
+mentality	O
+and	O
+high	O
+pneumonia	B-DISO
+severity	O
+index	O
+score	O
+at	O
+admission	O
+were	O
+risk	O
+factors	O
+for	O
+mortality	O
+.	O
+
+RT	O
+-	O
+PCR	O
+and	O
+sequencing	O
+were	O
+performed	O
+for	O
+specific	O
+coronavirus	B-SPEC
+genes	O
+to	O
+identify	O
+the	O
+bat	B-ENZY
+coronaviruses	O
+in	O
+different	O
+bat	B-ENZY
+samples	O
+.	O
+
+After	O
+accounting	O
+for	O
+confounders	O
+,	O
+the	O
+adjusted	O
+rate	O
+ratio	O
+(	O
+aRR	O
+)	O
+of	O
+delays	O
+in	O
+the	O
+diagnosis	O
+was	O
+independently	O
+associated	O
+with	O
+unknown	O
+source	O
+of	O
+infection	B-DISO
+(	O
+aRR	O
+1	O
+.	O
+68	O
+)	O
+and	O
+close	O
+contact	O
+with	O
+camels	B-SPEC
+(	O
+aRR	O
+1	O
+.	O
+58	O
+).	O
+
+TITLE	O
+:	O
+No	O
+.	O
+225	O
+-	O
+Management	O
+Guidelines	O
+for	O
+Obstetric	O
+Patients	O
+and	O
+Neonates	O
+Born	O
+to	O
+Mothers	O
+With	O
+Suspected	O
+or	O
+Probable	O
+Severe	B-DISO
+Acute	I-DISO
+Respiratory	I-DISO
+Syndrome	I-DISO
+(	O
+SARS	B-DISO
+).	O
+
+In	O
+this	O
+study	O
+,	O
+using	O
+laboratory	O
+strains	O
+of	O
+serotype	O
+II	O
+FIPV	O
+WSU	O
+79	O
+-	O
+1146	O
+(	O
+FIPV	O
+79	O
+-	O
+1146	O
+)	O
+and	O
+serotype	O
+II	O
+FECV	B-SPEC
+WSU	O
+79	O
+-	O
+1683	O
+(	O
+FECV	B-SPEC
+79	O
+-	O
+1683	O
+),	O
+we	O
+investigated	O
+the	O
+relationship	O
+between	O
+ADE	B-CHED
+and	O
+induction	O
+of	O
+inflammatory	O
+cytokines	O
+,	O
+which	O
+are	O
+pathogenesis	B-DISO
+-	O
+related	O
+factors	O
+,	O
+for	O
+each	O
+strain	O
+.	O
+
+Histopathological	O
+,	O
+immunohistochemical	O
+and	O
+electron	O
+microscopic	O
+analyses	O
+revealed	O
+that	O
+ARDS	B-DISO
+coexisted	O
+with	O
+pulmonary	B-DISO
+edema	I-DISO
+and	O
+systemic	O
+bleeding	B-DISO
+;	O
+the	O
+severity	O
+was	O
+dependent	O
+on	O
+the	O
+level	O
+of	O
+hemozoin	O
+deposition	O
+in	O
+the	O
+lung	B-ANAT
+and	O
+internal	O
+alveolar	B-ANAT
+hemorrhaging	O
+.	O
+
+ECMO	O
+as	O
+a	O
+BTT	O
+may	O
+be	O
+the	O
+only	O
+rescue	O
+strategy	O
+for	O
+severe	O
+acute	B-DISO
+respiratory	I-DISO
+failure	I-DISO
+,	O
+but	O
+many	O
+centers	O
+still	O
+consider	O
+it	O
+to	O
+be	O
+a	O
+relative	O
+contraindication	O
+to	O
+lung	B-ANAT
+transplantation	O
+because	O
+of	O
+its	O
+poor	O
+outcome	O
+.	O
+
+Fourteen	O
+patients	O
+(	O
+73	O
+.	O
+7	O
+%)	O
+were	O
+successfully	O
+bridged	O
+to	O
+transplantation	O
+;	O
+however	O
+,	O
+3	O
+died	B-PROC
+while	O
+on	O
+the	O
+waiting	O
+list	O
+and	O
+2	O
+returned	O
+to	O
+their	O
+baseline	O
+functions	O
+without	O
+transplantation	O
+.	O
+
+Our	O
+findings	O
+support	O
+the	O
+view	O
+that	O
+well	O
+-	O
+selected	O
+candidates	O
+with	O
+acutely	O
+decompensated	O
+end	O
+-	O
+stage	O
+lung	B-DISO
+disease	I-DISO
+may	O
+be	O
+safely	O
+bridged	O
+until	O
+a	O
+suitable	O
+donor	B-CHED
+is	O
+identified	O
+.	O
+
+The	O
+peak	O
+cTnI	O
+value	O
+was	O
+significantly	O
+higher	O
+in	O
+patients	O
+without	O
+OSA	B-DISO
+than	O
+in	O
+patients	O
+with	O
+OSA	B-DISO
+(	O
+median	O
+,	O
+10	O
+.	O
+7	O
+ng	O
+/	O
+mL	O
+[	O
+IQR	O
+,	O
+1	O
+.	O
+78	O
+-	O
+40	O
+.	O
+1	O
+ng	O
+/	O
+mL	O
+]	O
+vs	O
+3	O
+.	O
+79	O
+ng	O
+/	O
+mL	O
+[	O
+IQR	O
+,	O
+0	O
+.	O
+37	O
+-	O
+24	O
+.	O
+3	O
+ng	O
+/	O
+mL	O
+];	O
+P	O
+=	O
+.	O
+04	O
+).	O
+
+TITLE	O
+:	O
+SARS	B-DISO
+,	O
+MERS	O
+and	O
+other	O
+Viral	O
+Lung	B-ANAT
+Infections	B-DISO
+ABSTRACT	O
+:	O
+Respiratory	B-SPEC
+syncytial	I-SPEC
+virus	I-SPEC
+(	O
+RSV	B-SPEC
+)	O
+infection	B-DISO
+has	O
+an	O
+estimated	O
+global	O
+incidence	O
+of	O
+33	O
+million	O
+cases	O
+in	O
+children	O
+younger	O
+than	O
+5	O
+years	O
+,	O
+with	O
+10	O
+%	O
+requiring	O
+hospital	O
+admission	O
+and	O
+up	O
+to	O
+199	O
+,	O
+000	O
+dying	B-PROC
+of	O
+the	O
+disease	O
+.	O
+
+Hence	O
+,	O
+the	O
+main	O
+objective	O
+of	O
+this	O
+study	O
+was	O
+to	O
+assess	O
+sow	O
+sera	B-COMP
+and	O
+determine	O
+the	O
+correlation	O
+between	O
+enzyme	O
+-	O
+linked	O
+immunosorbent	O
+assay	O
+(	O
+ELISA	O
+)	O
+results	O
+(	O
+involving	O
+a	O
+newly	O
+isolated	O
+GDS01	O
+virus	B-SPEC
+-	O
+based	O
+ELISA	O
+and	O
+ELISAs	O
+based	O
+on	O
+seven	O
+recombinant	O
+fragments	O
+comprising	O
+overlapping	O
+S1	O
+and	O
+partial	O
+S2	O
+sequences	O
+)	O
+and	O
+SN	O
+titers	O
+.	O
+
+In	O
+addition	O
+,	O
+we	O
+analyzed	O
+the	O
+homology	O
+of	O
+the	O
+SP4	B-ANAT
+sequences	O
+obtained	O
+from	O
+different	O
+strains	O
+(	O
+including	O
+vaccine	O
+strains	O
+)	O
+and	O
+found	O
+that	O
+various	O
+strains	O
+showed	O
+a	O
+high	O
+degree	O
+of	O
+homology	O
+in	O
+this	O
+region	O
+.	O
+
+The	O
+nucleotide	B-CHED
+and	O
+amino	B-CHED
+acid	I-CHED
+sequences	O
+from	O
+the	O
+isolated	O
+field	O
+strains	O
+were	O
+compared	O
+to	O
+42	O
+published	O
+references	O
+.	O
+
+Four	O
+of	O
+the	O
+23	O
+admitted	O
+MERS	O
+patients	O
+reported	O
+neurological	B-DISO
+symptoms	I-DISO
+during	O
+or	O
+after	O
+MERS	O
+-	O
+CoV	O
+treatment	O
+.	O
+
+The	O
+potential	O
+diagnoses	O
+in	O
+these	O
+four	O
+cases	O
+included	O
+Bickerstaff	O
+'	O
+s	O
+encephalitis	B-DISO
+overlapping	O
+with	O
+Guillain	O
+-	O
+Barré	O
+syndrome	B-DISO
+,	O
+intensive	O
+-	O
+care	O
+-	O
+unit	O
+-	O
+acquired	O
+weakness	B-DISO
+,	O
+or	O
+other	O
+toxic	O
+or	O
+infectious	B-DISO
+neuropathies	B-DISO
+.	O
+
+Neurological	O
+complications	O
+did	O
+not	O
+appear	O
+concomitantly	O
+with	O
+respiratory	B-DISO
+symptoms	I-DISO
+,	O
+instead	O
+being	O
+delayed	O
+by	O
+2	O
+-	O
+3	O
+weeks	O
+.	O
+
+TITLE	O
+:	O
+Prone	O
+position	O
+ventilation	O
+support	O
+for	O
+acute	O
+exacerbation	O
+of	O
+interstitial	B-DISO
+lung	B-ANAT
+disease	I-DISO
+?	O
+
+Whether	O
+these	O
+benefits	O
+of	O
+PPV	B-CHED
+occur	O
+similarly	O
+in	O
+acute	O
+exacerbations	O
+of	O
+interstitial	B-DISO
+lung	B-ANAT
+disease	I-DISO
+(	O
+ILD	O
+)	O
+is	O
+not	O
+clear	O
+.	O
+
+RESULTS	O
+:	O
+There	O
+was	O
+no	O
+difference	O
+in	O
+baseline	O
+characteristics	O
+between	O
+the	O
+two	O
+groups	O
+except	O
+for	O
+higher	O
+driving	O
+pressure	O
+and	O
+more	O
+diastolic	B-DISO
+dysfunction	I-DISO
+in	O
+ILD	O
+group	O
+than	O
+severe	O
+ARDS	B-DISO
+group	O
+Compared	O
+with	O
+pre	O
+-	O
+PPV	B-CHED
+,	O
+cardiac	B-ANAT
+index	O
+and	O
+driving	O
+pressure	O
+remained	O
+unchanged	O
+post	O
+-	O
+PPV	B-CHED
+in	O
+both	O
+groups	O
+.	O
+
+ABSTRACT	O
+:	O
+The	O
+Pediatric	O
+Acute	O
+Lung	O
+Injury	O
+Consensus	O
+Conference	O
+developed	O
+a	O
+pediatric	O
+specific	O
+definition	O
+for	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+(	O
+PARDS	O
+).	O
+
+Here	O
+we	O
+investigated	O
+the	O
+challenges	O
+faced	O
+by	O
+polypeptide	B-CHED
+segments	O
+of	O
+a	O
+non	O
+-	O
+vectorial	O
+β	O
+-	O
+barrel	O
+fold	O
+.	O
+
+The	O
+majority	O
+of	O
+the	O
+literature	O
+regarding	O
+LIS	B-FUNC
+is	O
+based	O
+on	O
+case	O
+reports	O
+that	O
+utilized	O
+multidisciplinary	O
+interventions	O
+focused	O
+on	O
+improving	O
+functional	O
+communication	O
+and	O
+respiratory	O
+care	O
+with	O
+minimal	O
+focus	O
+on	O
+motor	O
+retraining	O
+.	O
+
+The	O
+patient	O
+received	O
+rituximab	O
+therapy	O
+and	O
+plasmapheresis	O
+1	O
+week	O
+before	O
+the	O
+transplantation	O
+to	O
+reduce	O
+the	O
+B	B-ANAT
+cell	I-ANAT
+count	O
+.	O
+
+However	O
+,	O
+he	O
+suddenly	O
+developed	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+-	O
+like	O
+symptoms	O
+,	O
+with	O
+a	O
+chest	B-ANAT
+X	O
+-	O
+ray	B-SPEC
+suggesting	O
+organized	B-DISO
+pneumonia	I-DISO
+.	O
+
+Infectious	B-DISO
+etiology	O
+was	O
+excluded	O
+as	O
+evidenced	O
+from	O
+negative	O
+sputum	B-ANAT
+and	O
+blood	B-ANAT
+culture	O
+,	O
+which	O
+were	O
+repeated	O
+after	O
+48	O
+h	O
+.	O
+LDLT	O
+was	O
+performed	O
+and	O
+ECMO	O
+support	O
+was	O
+instituted	O
+in	O
+the	O
+immediate	O
+postoperative	O
+period	O
+due	O
+to	O
+worsening	O
+of	O
+the	O
+ARDS	B-DISO
+.	O
+
+CONCLUSIONS	O
+This	O
+is	O
+first	O
+reported	O
+experience	O
+of	O
+successful	O
+use	O
+of	O
+ECMO	O
+in	O
+an	O
+ABO	O
+-	O
+incompatible	O
+liver	B-ANAT
+transplant	B-ANAT
+recipient	O
+with	O
+rituximab	O
+-	O
+induced	O
+ARDS	B-DISO
+.	O
+
+This	O
+experience	O
+shows	O
+the	O
+feasibility	O
+and	O
+effectiveness	O
+of	O
+ECMO	O
+support	O
+in	O
+liver	B-ANAT
+transplant	B-ANAT
+recipients	O
+with	O
+poor	O
+respiratory	O
+functions	O
+.	O
+
+ABSTRACT	O
+:	O
+This	O
+study	O
+aimed	O
+to	O
+investigate	O
+the	O
+effects	O
+of	O
+electroacupuncture	O
+at	O
+the	O
+Lieque	O
+,	O
+Chize	O
+,	O
+and	O
+Zusanli	O
+points	O
+in	O
+patients	O
+with	O
+lung	B-ANAT
+injury	O
+caused	O
+by	O
+severe	O
+acute	B-DISO
+pancreatitis	I-DISO
+.	O
+
+However	O
+,	O
+the	O
+molecular	O
+diversity	O
+and	O
+epidemiology	O
+of	O
+PEDV	B-SPEC
+in	O
+different	O
+provinces	O
+has	O
+not	O
+been	O
+completely	O
+understood	O
+.	O
+
+Our	O
+results	O
+revealed	O
+that	O
+the	O
+S	O
+genes	O
+of	O
+PEDV	B-SPEC
+showed	O
+variation	O
+and	O
+that	O
+diverse	O
+genotypes	O
+of	O
+PEDV	B-SPEC
+coexisted	O
+and	O
+were	O
+responsible	O
+for	O
+the	O
+PED	O
+outbreaks	O
+in	O
+Hubei	O
+in	O
+2016	O
+.	O
+
+ABSTRACT	O
+:	O
+Scytovirin	O
+is	O
+a	O
+lectin	O
+isolated	O
+from	O
+the	O
+cyanobacterium	B-SPEC
+Scytonema	B-SPEC
+varium	I-SPEC
+that	O
+has	O
+shown	O
+activity	O
+against	O
+HIV	B-DISO
+,	O
+SARS	B-DISO
+coronavirus	B-SPEC
+and	O
+Zaire	B-SPEC
+Ebola	I-SPEC
+virus	I-SPEC
+.	O
+
+The	O
+mean	O
+study	O
+subject	O
+age	O
+was	O
+21	O
+.	O
+8	O
+years	O
+,	O
+with	O
+a	O
+mean	O
+total	B-ANAT
+body	I-ANAT
+surface	I-ANAT
+area	O
+burned	O
+of	O
+82	O
+.	O
+9	O
+%.	O
+
+A	O
+PCR	O
+-	O
+based	O
+method	O
+was	O
+applied	O
+to	O
+investigate	O
+the	O
+presence	O
+of	O
+PDCoV	O
+in	O
+683	O
+diarrhoeic	O
+samples	O
+collected	O
+from	O
+449	O
+commercial	O
+pig	B-SPEC
+farms	O
+in	O
+South	O
+Korea	O
+from	O
+January	O
+2014	O
+to	O
+December	O
+2016	O
+.	O
+
+However	O
+,	O
+Korean	O
+PDCoV	O
+strains	O
+formed	O
+different	O
+branches	O
+within	O
+the	O
+same	O
+cluster	O
+,	O
+implying	O
+continuous	O
+evolution	B-PROC
+in	O
+the	O
+field	O
+.	O
+
+Thirteen	O
+Vietnamese	O
+variants	O
+had	O
+a	O
+truncated	O
+S	O
+protein	O
+that	O
+was	O
+261	O
+amino	B-CHED
+acids	I-CHED
+shorter	O
+than	O
+the	O
+normal	O
+protein	B-CHED
+.	O
+
+We	O
+also	O
+detected	O
+one	O
+novel	O
+variant	O
+with	O
+an	O
+8	O
+-	O
+amino	B-CHED
+acid	I-CHED
+insertion	O
+located	O
+in	O
+the	O
+receptor	O
+-	O
+binding	B-FUNC
+region	O
+for	O
+porcine	B-PRGE
+aminopeptidase	B-ENZY
+N	I-ENZY
+.	O
+Compared	O
+to	O
+the	O
+commercial	O
+vaccine	O
+strains	O
+,	O
+the	O
+emerging	O
+Vietnamese	O
+strains	O
+were	O
+genetically	O
+distant	O
+and	O
+had	O
+various	O
+amino	B-CHED
+acid	I-CHED
+differences	O
+in	O
+epitope	B-CHED
+regions	O
+and	O
+N	O
+-	O
+glycosylation	B-PROC
+sites	O
+in	O
+the	O
+S	B-PRGE
+protein	I-PRGE
+.	O
+
+ABSTRACT	O
+:	O
+Feline	B-SPEC
+coronaviruses	O
+encode	O
+five	O
+accessory	O
+proteins	B-CHED
+with	O
+largely	O
+elusive	O
+functions	O
+.	O
+
+Recombinant	O
+FIPVs	O
+(	O
+rFPIVs	O
+)	O
+expressing	O
+mutant	B-DISO
+and	O
+/	O
+or	O
+FLAG	B-SPEC
+-	O
+tagged	O
+forms	O
+of	O
+7b	O
+were	O
+generated	O
+and	O
+used	O
+to	O
+investigate	O
+the	O
+expression	B-PROC
+,	O
+processing	O
+,	O
+glycosylation	B-PROC
+,	O
+localization	B-PROC
+and	O
+trafficking	B-PROC
+of	O
+the	O
+7b	O
+protein	B-CHED
+in	O
+rFIPV	O
+-	O
+infected	O
+cells	B-COMP
+,	O
+focusing	O
+on	O
+a	O
+previously	O
+predicted	O
+ER	O
+retention	B-PROC
+signal	O
+,	O
+KTEL	O
+,	O
+at	O
+the	O
+C	O
+-	O
+terminus	O
+of	O
+7b	O
+.	O
+
+CONCLUSIONS	O
+:	O
+Interventions	O
+to	O
+minimize	O
+mortality	O
+from	O
+the	O
+Middle	O
+East	O
+respiratory	O
+syndrome	B-DISO
+coronavirus	B-SPEC
+should	O
+particularly	O
+focus	O
+individuals	O
+with	O
+comorbidity	O
+,	O
+non	O
+-	O
+health	O
+-	O
+care	O
+workers	O
+,	O
+patients	O
+with	O
+no	O
+clinical	O
+fatal	O
+experience	O
+,	O
+and	O
+patients	O
+without	O
+any	O
+clinical	O
+and	O
+subclinical	O
+experiences	O
+.	O
+
+We	O
+considered	O
+whether	O
+tetraspanins	O
+,	O
+scaffolding	O
+proteins	B-CHED
+known	O
+to	O
+facilitate	O
+CoV	O
+infections	B-DISO
+,	O
+hold	O
+receptors	O
+and	O
+proteases	O
+together	O
+on	O
+cell	B-COMP
+membranes	I-COMP
+.	O
+
+Furthermore	O
+,	O
+the	O
+S	O
+proteins	B-CHED
+of	O
+virulent	O
+mouse	B-SPEC
+-	O
+adapted	O
+MERS	O
+-	O
+CoVs	O
+acquired	O
+a	O
+CD9	B-PRGE
+-	O
+dependent	O
+cell	B-COMP
+entry	O
+character	O
+,	O
+suggesting	O
+that	O
+CD9	B-PRGE
+is	O
+a	O
+selective	O
+agent	O
+in	O
+the	O
+evolution	B-PROC
+of	O
+CoV	O
+virulence	B-PROC
+.	O
+
+This	O
+in	O
+vivo	O
+observation	O
+was	O
+substantiated	O
+by	O
+demonstrating	O
+IBV	B-SPEC
+antigens	B-CHED
+in	O
+macrophages	B-ANAT
+following	O
+in	O
+vitro	O
+IBV	O
+infection	B-DISO
+.	O
+
+Interprofessional	O
+and	O
+multidisciplinary	O
+collaboration	O
+is	O
+crucial	O
+to	O
+modify	O
+existing	O
+complex	O
+care	O
+pathways	B-PROC
+for	O
+our	O
+patients	O
+and	O
+their	O
+families	O
+to	O
+foster	O
+optimal	O
+rehabilitation	O
+and	O
+reintegration	O
+into	O
+the	O
+workplace	O
+and	O
+community	O
+.	O
+
+The	O
+study	O
+included	O
+63	O
+cats	B-SPEC
+with	O
+signs	O
+consistent	O
+with	O
+FIP	B-DISO
+.	O
+
+RT	O
+-	O
+PCR	O
+was	O
+negative	O
+or	O
+the	O
+pathotype	O
+could	O
+not	O
+be	O
+determined	O
+in	O
+34	O
+/	O
+59	O
+effusion	B-DISO
+samples	O
+.	O
+
+MERS	O
+CoV	O
+showed	O
+high	O
+ability	O
+to	O
+resist	O
+the	O
+innate	B-DISO
+immune	I-DISO
+response	I-DISO
+by	O
+showing	O
+lower	O
+CpG	O
+frequencies	O
+.	O
+
+Prevention	O
+of	O
+arboviral	O
+infections	B-DISO
+using	O
+vector	O
+control	O
+methods	O
+has	O
+not	O
+been	O
+very	O
+successful	O
+.	O
+
+The	O
+Korea	O
+reported	O
+its	O
+first	O
+laboratory	O
+-	O
+confirmed	O
+case	O
+of	O
+Middle	O
+East	O
+Respiratory	O
+Syndrome	B-DISO
+(	O
+MERS	O
+)	O
+coronavirus	B-SPEC
+on	O
+May	O
+20	O
+,	O
+2015	O
+.	O
+
+Immunohistochemistry	O
+and	O
+image	O
+analysis	O
+were	O
+used	O
+to	O
+quantify	O
+,	O
+in	O
+the	O
+parenchyma	B-ANAT
+and	O
+small	O
+airways	O
+,	O
+several	O
+immune	O
+cell	B-COMP
+markers	O
+.	O
+
+However	O
+,	O
+there	O
+was	O
+a	O
+higher	O
+expression	B-PROC
+of	O
+CD4	B-PRGE
++	I-PRGE
+and	O
+CD8	B-PRGE
++	I-PRGE
+T	B-ANAT
+lymphocytes	I-ANAT
+,	O
+CD83	B-PRGE
++	I-PRGE
+dendritic	B-ANAT
+cells	B-COMP
+,	O
+granzyme	B-ENZY
+A	O
++	O
+and	O
+natural	O
+killer	O
++	O
+cell	B-COMP
+density	O
+in	O
+the	O
+lung	B-ANAT
+parenchyma	I-ANAT
+of	O
+the	O
+H1N1	O
+group	O
+(	O
+p	O
+<	O
+0	O
+.	O
+05	O
+).	O
+
+DAD	B-PRGE
+due	O
+to	O
+viral	O
+A	O
+(	O
+H1N1	O
+)	O
+pdm09	O
+is	O
+associated	O
+with	O
+a	O
+cytotoxic	O
+inflammatory	O
+phenotype	O
+,	O
+with	O
+partially	O
+divergent	O
+responses	O
+in	O
+the	O
+parenchyma	B-ANAT
+relative	O
+to	O
+the	O
+small	O
+airways	O
+.	O
+
+The	O
+goal	O
+of	O
+our	O
+study	O
+was	O
+to	O
+evaluate	O
+clinical	O
+course	O
+and	O
+microbiological	O
+susceptibility	O
+of	O
+VGS	O
+BSI	B-CHED
+at	O
+our	O
+center	O
+.	O
+
+No	O
+difference	O
+in	O
+signs	O
+of	O
+shock	B-DISO
+syndrome	I-DISO
+was	O
+observed	O
+in	O
+the	O
+patients	O
+during	O
+transplantation	O
+procedures	O
+compared	O
+to	O
+patients	O
+without	O
+transplantation	O
+as	O
+well	O
+as	O
+in	O
+a	O
+group	O
+received	O
+previous	O
+high	O
+-	O
+dose	O
+chemotherapy	O
+with	O
+cytosinarabinoside	O
+or	O
+in	O
+patients	O
+with	O
+mucositis	B-DISO
+.	O
+
+We	O
+detected	O
+MERS	O
+-	O
+CoV	O
+-	O
+specific	O
+CD4	B-PRGE
+
+The	O
+DE	O
+miRNAs	O
+were	O
+further	O
+classified	O
+into	O
+five	O
+miRNA	O
+expression	B-PROC
+patterns	O
+(	O
+up	O
+or	O
+down	B-PROC
+regulation	I-PROC
+compared	O
+to	O
+control	O
+).	O
+
+Individual	O
+samples	O
+in	O
+the	O
+positive	O
+pools	O
+were	O
+confirmed	O
+by	O
+qRT	O
+-	O
+PCR	B-PRGE
+,	O
+RT	O
+-	O
+PCR	O
+,	O
+PCR	O
+and	O
+Sanger	O
+sequencing	O
+from	O
+the	O
+CPE	O
+culture	O
+and	O
+original	O
+clinical	O
+specimens	O
+.	O
+
+Ciliary	O
+activity	O
+of	O
+the	O
+epithelial	B-ANAT
+cells	I-ANAT
+in	O
+the	O
+bronchus	B-SPEC
+of	O
+precision	O
+-	O
+cut	O
+lung	B-ANAT
+slices	O
+was	O
+measured	O
+.	O
+
+Co	B-DISO
+-	I-DISO
+infection	I-DISO
+of	O
+PCLS	O
+reduced	O
+virulence	B-PROC
+of	O
+both	O
+virus	B-SPEC
+species	B-SPEC
+compared	O
+to	O
+mono	B-DISO
+-	O
+infection	B-DISO
+.	O
+
+We	O
+previously	O
+reported	O
+that	O
+type	B-PRGE
+I	I-PRGE
+FCoV	I-PRGE
+is	O
+closely	O
+associated	O
+with	O
+cholesterol	B-CHED
+throughout	O
+the	O
+viral	B-PROC
+life	I-PROC
+cycle	I-PROC
+.	O
+
+Thus	O
+,	O
+inactivated	O
+PEDV	B-SPEC
+vaccines	O
+may	O
+provide	O
+increased	O
+protection	O
+to	O
+piglets	O
+nursing	B-PROC
+on	O
+previously	O
+infected	O
+sows	O
+against	O
+exposure	O
+to	O
+PEDV	B-SPEC
+through	O
+increased	O
+delivery	O
+of	O
+lactogenic	O
+neutralizing	O
+antibodies	B-COMP
+to	O
+the	O
+enteric	O
+site	O
+of	O
+infection	B-DISO
+.	O
+
+This	O
+is	O
+the	O
+first	O
+documentary	O
+proof	O
+of	O
+C	B-SPEC
+.	I-SPEC
+parvum	I-SPEC
+and	O
+associated	O
+pathogens	O
+responsible	O
+for	O
+severe	O
+periurban	O
+outbreaks	O
+of	O
+bovine	B-SPEC
+calf	B-ANAT
+diarrhoea	B-DISO
+culminating	O
+in	O
+heavy	O
+mortality	O
+from	O
+Northern	O
+India	O
+.	O
+
+TITLE	O
+:	O
+Critically	B-DISO
+Ill	I-DISO
+Patients	O
+With	O
+the	O
+Middle	O
+East	O
+Respiratory	O
+Syndrome	B-DISO
+:	O
+A	O
+Multicenter	O
+Retrospective	O
+Cohort	O
+Study	O
+.	O
+
+The	O
+analysis	O
+of	O
+the	O
+S1	B-PRGE
+gene	I-PRGE
+has	O
+been	O
+used	O
+to	O
+determine	O
+IBV	B-SPEC
+genotype	O
+.	O
+
+Cyclooxygenase	B-PRGE
+-	I-PRGE
+2	I-PRGE
+(	O
+COX	B-PRGE
+-	I-PRGE
+2	I-PRGE
+)	O
+has	O
+been	O
+reported	O
+to	O
+promote	O
+inflammation	B-DISO
+,	O
+along	O
+with	O
+PGE	B-CHED
+
+TITLE	O
+:	O
+Rapid	O
+onset	O
+of	O
+amiodarone	B-CHED
+induced	O
+pulmonary	B-DISO
+toxicity	I-DISO
+after	O
+lung	B-ANAT
+lobe	I-ANAT
+resection	O
+-	O
+A	O
+case	O
+report	O
+and	O
+review	O
+of	O
+recent	O
+literature	O
+.	O
+
+ABSTRACT	O
+:	O
+Amiodarone	O
+-	O
+induced	O
+pulmonary	B-DISO
+toxicity	I-DISO
+(	O
+APT	O
+)	O
+is	O
+a	O
+severe	O
+side	B-DISO
+effect	I-DISO
+that	O
+can	O
+lead	O
+to	O
+lung	B-DISO
+fibrosis	I-DISO
+or	O
+fatal	O
+respiratory	B-DISO
+failure	I-DISO
+.	O
+
+We	O
+therefore	O
+started	O
+mechanical	O
+ventilation	O
+,	O
+but	O
+still	O
+the	O
+gas	B-ENZY
+exchange	O
+did	O
+not	O
+improve	O
+.	O
+
+We	O
+immediately	O
+started	O
+glucocorticoid	B-CHED
+therapy	O
+with	O
+prednisolone	B-CHED
+50	O
+mg	O
+/	O
+d	O
+for	O
+five	O
+days	O
+.	O
+
+We	O
+were	O
+able	O
+to	O
+wean	B-PROC
+the	O
+patient	O
+from	O
+the	O
+respirator	O
+within	O
+five	O
+days	O
+.	O
+
+Studies	O
+of	O
+the	O
+genetics	O
+and	O
+molecular	O
+mechanisms	O
+of	O
+this	O
+virus	B-SPEC
+are	O
+expected	O
+to	O
+facilitate	O
+the	O
+development	O
+of	O
+vaccines	O
+in	O
+the	O
+future	O
+.	O
+
+ABSTRACT	O
+:	O
+Benign	O
+acute	O
+childhood	O
+myositis	O
+(	O
+BACM	O
+)	O
+is	O
+a	O
+syndrome	B-DISO
+classically	O
+occurring	O
+in	O
+children	O
+during	O
+the	O
+convalescent	O
+phase	O
+from	O
+a	O
+febrile	B-PROC
+upper	B-DISO
+respiratory	I-DISO
+tract	I-DISO
+infection	I-DISO
+,	O
+most	O
+commonly	O
+after	O
+influenza	B-DISO
+B	O
+.	O
+BACM	O
+can	O
+cause	O
+difficulty	O
+walking	O
+due	O
+to	O
+severe	O
+calf	B-DISO
+pain	I-DISO
+.	O
+
+We	O
+discussed	O
+the	O
+presentation	O
+and	O
+the	O
+clinical	O
+workup	O
+and	O
+examinations	O
+of	O
+the	O
+myositic	O
+syndrome	B-DISO
+.	O
+
+Viral	O
+adaptation	B-PROC
+and	O
+tissue	B-ANAT
+response	O
+were	O
+assessed	O
+through	O
+RNA	O
+sequencing	O
+.	O
+
+H3N2	B-CHED
+was	O
+the	O
+strongest	O
+cytokine	O
+inducer	O
+,	O
+and	O
+HCoV	B-SPEC
+-	I-SPEC
+OC43	I-SPEC
+was	O
+the	O
+weakest	O
+.	O
+
+RNA	O
+sequencing	O
+highlighted	O
+perturbation	O
+of	O
+tissue	B-ANAT
+metabolism	B-PROC
+and	O
+induction	O
+of	O
+a	O
+transient	O
+but	O
+important	O
+immune	B-PROC
+response	I-PROC
+at	O
+4	O
+days	O
+after	O
+infection	B-DISO
+.	O
+
+These	O
+data	O
+help	O
+to	O
+appreciate	O
+the	O
+range	O
+of	O
+disease	O
+severity	O
+observed	O
+in	O
+vivo	O
+and	O
+the	O
+occurrence	O
+of	O
+chronic	O
+respiratory	B-DISO
+tract	I-DISO
+infections	I-DISO
+in	O
+immunocompromised	O
+hosts	B-COMP
+.	O
+
+The	O
+disorder	O
+is	O
+classified	O
+based	O
+on	O
+the	O
+site	O
+of	O
+defect	O
+in	O
+motor	B-ANAT
+unit	I-ANAT
+pathway	B-PROC
+,	O
+
+In	O
+addition	O
+,	O
+we	O
+found	O
+that	O
+the	O
+GI	O
+-	O
+29	O
+type	O
+γCoV	O
+/	O
+ck	O
+/	O
+China	O
+/	O
+I0111	O
+/	O
+14	O
+isolate	O
+was	O
+a	O
+nephropathogenic	O
+strain	O
+and	O
+high	O
+pathogenic	O
+to	O
+1	O
+-	O
+day	O
+-	O
+old	O
+specific	O
+pathogen	O
+-	O
+free	O
+(	O
+SPF	O
+)	O
+chickens	B-SPEC
+although	O
+cystic	O
+oviducts	B-ANAT
+were	O
+not	O
+observed	O
+in	O
+the	O
+surviving	O
+layer	B-ANAT
+chickens	B-SPEC
+challenged	O
+with	O
+γCoV	O
+/	O
+ck	O
+/	O
+China	O
+/	O
+I0111	O
+/	O
+14	O
+isolate	O
+.	O
+
+TITLE	O
+:	O
+Lipidation	O
+increases	O
+antiviral	B-CHED
+activities	O
+of	O
+coronavirus	B-SPEC
+fusion	O
+-	O
+inhibiting	O
+peptides	B-CHED
+.	O
+
+Their	O
+infectious	B-DISO
+entry	O
+requires	O
+viral	O
+spike	O
+(	O
+S	O
+)	O
+proteins	B-CHED
+,	O
+which	O
+attach	O
+to	O
+cell	B-COMP
+receptors	O
+,	O
+undergo	O
+proteolytic	B-PROC
+cleavage	B-PROC
+,	O
+and	O
+then	O
+refold	O
+in	O
+a	O
+process	O
+that	O
+catalyzes	O
+virus	B-SPEC
+-	O
+cell	B-COMP
+membrane	I-COMP
+fusion	O
+.	O
+
+TITLE	O
+:	O
+Electrical	B-PROC
+impedance	I-PROC
+tomography	O
+for	O
+diagnosis	O
+and	O
+monitoring	O
+of	O
+pulmonary	B-PROC
+function	I-PROC
+disorders	O
+in	O
+the	O
+intensive	O
+care	O
+unit	O
+-	O
+case	O
+report	O
+and	O
+review	O
+of	O
+literature	O
+.	O
+
+Despite	O
+aggressive	B-DISO
+treatment	O
+there	O
+was	O
+no	O
+improvement	O
+.	O
+
+The	O
+mean	O
+body	B-ANAT
+mass	O
+index	O
+was	O
+20	O
+·	O
+1	O
+,	O
+mean	O
+arousal	O
+index	O
+16	O
+·	O
+2	O
+,	O
+mean	O
+respiratory	O
+disturbance	O
+index	O
+19	O
+·	O
+6	O
+,	O
+mean	O
+AHI	O
+3	O
+·	O
+9	O
+while	O
+the	O
+mean	O
+Epworth	O
+Sleepiness	O
+Scale	O
+was	O
+14	O
+·	O
+8	O
+.	O
+
+Of	O
+the	O
+453	O
+samples	O
+examined	O
+,	O
+61	O
+.	O
+4	O
+%	O
+were	O
+positive	O
+for	O
+IBV	B-SPEC
+and	O
+75	O
+.	O
+9	O
+%	O
+of	O
+these	O
+were	O
+considered	O
+to	O
+have	O
+the	O
+BR	O
+-	O
+I	O
+genotype	O
+and	O
+were	O
+detected	O
+in	O
+birds	B-SPEC
+of	O
+all	O
+ages	O
+distributed	O
+in	O
+all	O
+five	O
+Brazilian	O
+regions	O
+.	O
+
+These	O
+results	O
+suggest	O
+that	O
+Brazilian	O
+IBV	B-SPEC
+variants	O
+probably	O
+underwent	O
+drastic	O
+mutations	O
+at	O
+various	O
+points	O
+between	O
+1983	O
+and	O
+2003	O
+and	O
+that	O
+the	O
+selection	O
+processes	O
+became	O
+silent	O
+after	O
+achieving	O
+a	O
+sufficiently	O
+effective	O
+antigenic	O
+structure	O
+for	O
+invasion	B-DISO
+and	O
+replication	O
+in	O
+their	O
+hosts	B-COMP
+.	O
+
+TITLE	O
+:	O
+Advancing	O
+Preparedness	O
+for	O
+Highly	O
+Hazardous	O
+Contagious	B-DISO
+Diseases	I-DISO
+:	O
+Admitting	O
+10	O
+Simulated	O
+Patients	O
+with	O
+MERS	O
+-	O
+CoV	O
+.	O
+ABSTRACT	O
+:	O
+The	O
+Ebola	O
+outbreak	O
+of	O
+2014	O
+-	O
+2016	O
+highlighted	O
+the	O
+need	O
+for	O
+the	O
+development	O
+of	O
+a	O
+more	O
+robust	O
+healthcare	O
+infrastructure	O
+in	O
+the	O
+United	O
+States	O
+to	O
+provide	O
+isolation	O
+care	O
+for	O
+patients	O
+infected	O
+with	O
+a	O
+highly	O
+hazardous	O
+contagious	B-DISO
+disease	I-DISO
+.	O
+
+TITLE	O
+:	O
+Evaluation	O
+and	O
+Clinical	O
+Validation	O
+of	O
+Two	O
+Field	O
+-	O
+Deployable	O
+Reverse	B-PROC
+Transcription	I-PROC
+-	O
+Insulated	O
+Isothermal	O
+PCR	O
+Assays	O
+for	O
+the	O
+Detection	O
+of	O
+the	O
+Middle	O
+East	O
+Respiratory	O
+Syndrome	O
+-	O
+Coronavirus	B-SPEC
+.	O
+
+ABSTRACT	O
+:	O
+Middle	O
+East	O
+respiratory	O
+syndrome	B-DISO
+(	O
+MERS	O
+)	O
+is	O
+an	O
+emerging	O
+zoonotic	O
+viral	O
+respiratory	B-DISO
+disease	I-DISO
+that	O
+was	O
+first	O
+identified	O
+in	O
+Saudi	O
+Arabia	O
+in	O
+2012	O
+.	O
+
+A	O
+real	B-PRGE
+-	I-PRGE
+time	I-PRGE
+reverse	I-PRGE
+transcription	I-PRGE
+RPA	B-COMP
+(	O
+RT	B-PRGE
+-	I-PRGE
+RPA	I-PRGE
+)	O
+assay	O
+for	O
+the	O
+detection	O
+of	O
+canine	B-SPEC
+distemper	I-SPEC
+virus	I-SPEC
+(	O
+CDV	B-CHED
+)	O
+using	O
+primers	O
+and	O
+exo	O
+probe	O
+targeting	B-PROC
+the	O
+CDV	B-PRGE
+nucleocapsid	B-COMP
+protein	B-CHED
+gene	I-PRGE
+was	O
+developed	O
+.	O
+
+First	O
+Survival	O
+in	O
+the	O
+United	O
+States	O
+with	O
+Extended	O
+Duration	O
+(	O
+Five	O
+Weeks	O
+)	O
+Therapy	O
+with	O
+High	O
+Dose	O
+Corticosteroids	O
+in	O
+Combination	O
+with	O
+Lung	B-ANAT
+Protective	O
+Ventilation	O
+.	O
+
+Additionally	O
+,	O
+upper	O
+airway	B-ANAT
+injury	O
+should	O
+be	O
+suspected	O
+and	O
+early	O
+evaluation	O
+by	O
+otorhinolaryngology	O
+may	O
+be	O
+beneficial	O
+.	O
+
+Anaesthetized	O
+,	O
+mechanically	O
+ventilated	O
+animals	B-SPEC
+underwent	O
+right	B-ANAT
+lung	I-ANAT
+ischaemia	B-DISO
+(	O
+series	O
+1	O
+,	O
+30	O
+minutes	O
+;	O
+series	O
+2	O
+,	O
+60	O
+minutes	O
+)	O
+followed	O
+by	O
+reperfusion	O
+for	O
+300	O
+minutes	O
+.	O
+
+In	O
+series	O
+1	O
+,	O
+animals	B-SPEC
+were	O
+treated	O
+with	O
+vehicle	O
+or	O
+0	O
+.	O
+7	O
+μmol	O
+/	O
+kg	O
+of	O
+AMD3100	O
+(	O
+CXCR4	B-FUNC
+antagonist	B-PROC
+)	O
+and	O
+in	O
+series	O
+2	O
+with	O
+vehicle	O
+,	O
+0	O
+.	O
+7	O
+or	O
+3	O
+.	O
+5	O
+μmol	O
+/	O
+kg	O
+ubiquitin	B-PROC
+(	O
+non	O
+-	O
+cognate	O
+CXCR4	B-FUNC
+agonist	B-CHED
+)	O
+within	O
+5	O
+minutes	O
+of	O
+reperfusion	O
+.	O
+
+Following	O
+intranasal	O
+infection	B-DISO
+,	O
+rabbits	B-SPEC
+developed	O
+a	O
+transient	O
+dose	O
+-	O
+dependent	O
+pulmonary	B-DISO
+infection	I-DISO
+with	O
+moderately	O
+high	O
+levels	O
+of	O
+viral	O
+RNA	O
+,	O
+viral	O
+antigen	O
+,	O
+and	O
+perivascular	B-DISO
+inflammation	I-DISO
+in	O
+multiple	O
+lung	B-ANAT
+lobes	B-ANAT
+that	O
+was	O
+not	O
+associated	O
+with	O
+clinical	O
+signs	O
+.	O
+
+In	O
+fact	O
+,	O
+reinfection	O
+resulted	O
+in	O
+enhanced	O
+pulmonary	B-DISO
+inflammation	I-DISO
+,	O
+without	O
+an	O
+associated	O
+increase	O
+in	O
+viral	O
+RNA	O
+titers	O
+.	O
+
+The	O
+model	O
+revealed	O
+distinguishable	O
+subgroups	O
+of	O
+SAD	B-DISO
+mice	B-SPEC
+with	O
+cardiorespiratory	O
+pathophysiology	O
+mimicking	O
+the	O
+complications	O
+of	O
+human	B-SPEC
+sickle	B-DISO
+cell	I-DISO
+disease	I-DISO
+.	O
+
+ABSTRACT	O
+:	O
+Over	O
+the	O
+last	O
+decade	O
+,	O
+extracorporeal	O
+membrane	O
+oxygenation	B-PROC
+(	O
+ECMO	O
+)	O
+has	O
+become	O
+a	O
+promising	O
+option	O
+for	O
+patients	O
+with	O
+severe	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+(	O
+ARDS	B-DISO
+).	O
+
+The	O
+median	O
+SOFA	O
+Score	O
+was	O
+13	O
+(	O
+10	O
+to	O
+19	O
+)	O
+and	O
+the	O
+median	O
+LIS	B-FUNC
+was	O
+3	O
+.	O
+5	O
+(	O
+2	O
+.	O
+67	O
+to	O
+4	O
+).	O
+
+Group	O
+3	O
+patients	O
+showed	O
+delayed	O
+increment	O
+of	O
+antibody	B-COMP
+titers	O
+during	O
+the	O
+fourth	O
+week	O
+,	O
+while	O
+Group	O
+2	O
+patients	O
+showed	O
+robust	O
+increment	O
+of	O
+antibody	B-COMP
+titer	O
+during	O
+the	O
+third	O
+week	O
+.	O
+
+Among	O
+patients	O
+having	O
+pneumonia	B-DISO
+,	O
+75	O
+%	O
+of	O
+deceased	B-PROC
+patients	O
+did	O
+not	O
+show	O
+seroconversion	O
+by	O
+the	O
+third	O
+week	O
+,	O
+while	O
+100	O
+%	O
+of	O
+the	O
+survived	O
+patients	O
+were	O
+seroconverted	O
+(	O
+P	O
+=	O
+0	O
+.	O
+003	O
+).	O
+
+TITLE	O
+:	O
+Neural	O
+precursor	O
+cells	B-COMP
+derived	O
+from	O
+induced	O
+pluripotent	B-ANAT
+stem	I-ANAT
+cells	I-ANAT
+exhibit	O
+reduced	O
+susceptibility	O
+to	O
+infection	O
+with	O
+a	O
+neurotropic	O
+coronavirus	B-SPEC
+.	O
+
+However	O
+,	O
+in	O
+contrast	O
+to	O
+postnatally	O
+-	O
+derived	O
+NPCs	O
+,	O
+iPSC	O
+-	O
+NPCs	O
+express	O
+low	O
+levels	O
+of	O
+carcinoembryonic	O
+antigen	B-CHED
+-	O
+cell	B-PROC
+adhesion	B-DISO
+molecule	O
+1a	O
+(	O
+CEACAM1a	O
+),	O
+the	O
+surface	O
+receptor	O
+for	O
+JHMV	O
+,	O
+and	O
+are	O
+less	O
+susceptible	O
+to	O
+infection	B-DISO
+and	O
+virus	B-SPEC
+-	O
+induced	O
+cytopathic	B-DISO
+effects	I-DISO
+.	O
+
+The	O
+relevance	O
+of	O
+this	O
+in	O
+terms	O
+of	O
+therapeutic	O
+application	O
+of	O
+NPCs	O
+resistant	O
+to	O
+viral	B-DISO
+infection	I-DISO
+is	O
+discussed	O
+.	O
+
+In	O
+this	O
+study	O
+,	O
+APS	B-DISO
+were	O
+employed	O
+as	O
+an	O
+adjuvant	B-CHED
+for	O
+an	O
+avian	B-DISO
+infectious	I-DISO
+bronchitis	I-DISO
+virus	B-SPEC
+(	O
+IBV	B-SPEC
+)	O
+vaccine	O
+,	O
+and	O
+its	O
+effects	O
+on	O
+the	O
+cellular	B-COMP
+immune	O
+and	O
+humoral	B-PROC
+immune	I-PROC
+responses	I-PROC
+to	O
+vaccination	O
+in	O
+chicken	B-SPEC
+were	O
+investigated	O
+.	O
+
+Three	O
+of	O
+the	O
+four	O
+vaccinated	O
+groups	O
+were	O
+administered	O
+different	O
+doses	O
+of	O
+APS	B-DISO
+(	O
+APSL	O
+,	O
+10	O
+mg	O
+/	O
+kg	O
+;	O
+APSM	O
+,	O
+50	O
+mg	O
+/	O
+kg	O
+;	O
+and	O
+APSH	O
+,	O
+100	O
+mg	O
+/	O
+kg	O
+)	O
+after	O
+the	O
+first	O
+vaccination	O
+,	O
+and	O
+the	O
+remaining	O
+vaccinated	O
+group	O
+served	O
+as	O
+a	O
+control	O
+,	O
+without	O
+any	O
+additional	O
+treatment	O
+.	O
+
+TITLE	O
+:	O
+Spontaneous	O
+breathing	B-PROC
+:	O
+a	O
+double	O
+-	O
+edged	O
+sword	O
+to	O
+handle	O
+with	O
+care	O
+.	O
+
+In	O
+the	O
+present	O
+review	O
+article	O
+,	O
+we	O
+present	O
+physiologic	O
+mechanisms	O
+driving	O
+spontaneous	O
+breathing	B-PROC
+,	O
+with	O
+emphasis	O
+on	O
+how	O
+to	O
+implement	O
+basic	O
+and	O
+advanced	O
+respiratory	O
+monitoring	O
+to	O
+assess	O
+lung	B-ANAT
+protection	O
+during	O
+spontaneous	O
+assisted	O
+ventilation	O
+.	O
+
+TITLE	O
+:	O
+Right	B-ANAT
+heart	I-ANAT
+function	O
+during	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+.	O
+
+ABSTRACT	O
+:	O
+Bronchiolitis	O
+is	O
+a	O
+common	O
+acute	O
+respiratory	O
+condition	B-DISO
+with	O
+high	O
+prevalence	O
+worldwide	O
+.	O
+
+This	O
+is	O
+particularly	O
+important	O
+in	O
+populations	O
+with	O
+high	O
+acute	O
+and	O
+post	O
+-	O
+acute	B-DISO
+bronchiolitis	I-DISO
+morbidity	O
+(	O
+e	O
+.	O
+g	O
+.	O
+indigenous	O
+populations	O
+in	O
+Australia	O
+,	O
+New	O
+Zealand	O
+,	O
+and	O
+the	O
+USA	O
+).	O
+
+ABSTRACT	O
+:	O
+The	O
+paucity	O
+of	O
+traditional	O
+epidemiological	O
+data	O
+during	O
+epidemic	O
+emergencies	B-DISO
+calls	O
+for	O
+alternative	O
+data	O
+streams	O
+to	O
+characterize	O
+the	O
+key	O
+features	O
+of	O
+an	O
+outbreak	O
+,	O
+including	O
+the	O
+nature	O
+of	O
+risky	O
+exposures	O
+,	O
+the	O
+reproduction	B-PROC
+number	O
+,	O
+and	O
+transmission	O
+heterogeneities	O
+.	O
+
+Utilizing	O
+a	O
+previously	O
+generated	O
+mutant	B-DISO
+,	O
+we	O
+demonstrate	O
+that	O
+the	O
+absence	O
+of	O
+all	O
+four	O
+Middle	O
+East	O
+respiratory	O
+syndrome	B-DISO
+CoV	O
+(	O
+MERS	O
+-	O
+CoV	O
+)	O
+accessory	O
+ORFs	O
+(	O
+deletion	O
+of	O
+ORF3	O
+,	O
+-	O
+4a	O
+,	O
+-	O
+4b	O
+,	O
+and	O
+-	O
+5	O
+[	O
+dORF3	O
+-	O
+5	O
+])	O
+has	O
+major	O
+implications	O
+for	O
+viral	B-PROC
+replication	I-PROC
+and	O
+pathogenesis	B-DISO
+.	O
+
+As	O
+compared	O
+to	O
+healthy	O
+controls	O
+,	O
+metabolomic	O
+analyses	O
+identified	O
+significant	O
+differences	O
+in	O
+the	O
+serum	B-COMP
+metabolomes	O
+of	O
+SARS	B-DISO
+survivors	O
+.	O
+
+TITLE	O
+:	O
+Identification	O
+of	O
+a	O
+natural	O
+recombinant	O
+transmissible	O
+gastroenteritis	B-DISO
+virus	B-SPEC
+between	O
+Purdue	O
+and	O
+Miller	O
+clusters	O
+in	O
+China	O
+.	O
+
+TITLE	O
+:	O
+[	O
+Enterovirus	B-SPEC
+type	O
+D68	O
+and	O
+acute	O
+flaccid	B-DISO
+paralysis	I-DISO
+:	O
+a	O
+new	O
+duo	O
+?]	O
+ABSTRACT	O
+:	O
+Following	O
+a	O
+case	O
+of	O
+acute	O
+flaccid	O
+paralysis	O
+after	O
+infection	B-DISO
+with	O
+enterovirus	B-SPEC
+type	O
+D68	O
+,	O
+we	O
+highlight	O
+current	O
+understanding	O
+of	O
+the	O
+causal	O
+role	O
+of	O
+enterovirus	B-DISO
+infection	I-DISO
+in	O
+this	O
+neurological	O
+syndrome	B-DISO
+.	O
+
+Three	O
+distinct	O
+clinical	O
+syndromes	O
+were	O
+identified	O
+:	O
+T3	O
+-	O
+L3	O
+myelopathy	B-DISO
+(	O
+3	O
+),	O
+central	O
+vestibular	O
+syndrome	B-DISO
+(	O
+7	O
+),	O
+and	O
+multifocal	O
+CNS	B-DISO
+disease	I-DISO
+(	O
+14	O
+).	O
+
+ABSTRACT	O
+:	O
+Pituitary	B-DISO
+tumor	I-DISO
+apoplexy	B-DISO
+is	O
+a	O
+rare	O
+clinical	O
+syndrome	B-DISO
+caused	O
+by	O
+acute	B-DISO
+hemorrhage	I-DISO
+or	O
+infarction	B-DISO
+in	O
+a	O
+preexisting	O
+pituitary	B-DISO
+adenoma	I-DISO
+.	O
+
+To	O
+address	O
+this	O
+question	O
+,	O
+we	O
+used	O
+the	O
+rJHM	O
+strain	O
+(	O
+rJ	O
+)	O
+of	O
+mouse	B-DISO
+hepatitis	I-DISO
+virus	B-SPEC
+(	O
+MHV	B-SPEC
+),	O
+a	O
+neurotropic	O
+coronavirus	B-SPEC
+that	O
+causes	O
+acute	O
+encephalitis	B-DISO
+in	O
+susceptible	O
+strains	O
+of	O
+mice	B-SPEC
+.	O
+
+In	O
+conclusion	O
+,	O
+our	O
+results	O
+indicated	O
+that	O
+some	O
+neurons	B-ANAT
+are	O
+resistant	O
+to	O
+virus	B-SPEC
+-	O
+mediated	O
+cell	B-PROC
+death	I-PROC
+and	O
+provide	O
+a	O
+framework	O
+for	O
+studying	O
+the	O
+effects	O
+of	O
+prior	O
+coronavirus	B-DISO
+infection	I-DISO
+on	O
+neuron	B-ANAT
+function	O
+.	O
+
+Osteomyelitis	B-DISO
+of	O
+C1	O
+/	O
+C2	O
+and	O
+severe	O
+muscle	B-DISO
+wasting	I-DISO
+required	O
+a	O
+prolonged	O
+hospital	O
+stay	O
+.	O
+
+ABSTRACT	O
+:	O
+OBJECTIVE	O
+To	O
+evaluate	O
+the	O
+effect	O
+of	O
+serum	B-COMP
+antibody	B-COMP
+abundance	O
+against	O
+bovine	B-SPEC
+coronavirus	B-SPEC
+(	O
+BCV	B-SPEC
+)	O
+on	O
+BCV	B-SPEC
+shedding	O
+and	O
+risk	O
+of	O
+bovine	B-SPEC
+respiratory	B-DISO
+disease	I-DISO
+(	O
+BRD	O
+)	O
+in	O
+beef	O
+calves	O
+from	O
+birth	B-PROC
+through	O
+the	O
+first	O
+5	O
+weeks	O
+in	O
+a	O
+feedlot	O
+.	O
+
+ANIMALS	B-SPEC
+890	O
+natural	O
+-	O
+service	O
+crossbred	O
+beef	O
+calves	O
+from	O
+4	O
+research	O
+herds	O
+.	O
+
+RESULTS	O
+At	O
+the	O
+calf	B-ANAT
+level	O
+,	O
+serum	B-PRGE
+anti	I-PRGE
+-	I-PRGE
+BCV	B-SPEC
+antibody	B-COMP
+abundance	O
+was	O
+not	O
+associated	O
+with	O
+BCV	B-SPEC
+shedding	O
+,	O
+but	O
+BCV	B-SPEC
+shedding	O
+was	O
+positively	O
+associated	O
+with	O
+BRD	O
+incidence	O
+before	O
+and	O
+after	O
+weaning	B-PROC
+.	O
+
+Investigation	O
+of	O
+risk	O
+factors	O
+for	O
+prolonged	O
+shedding	O
+and	O
+intrahost	O
+genome	O
+evolution	B-PROC
+may	O
+provide	O
+critical	O
+information	O
+for	O
+development	B-PROC
+of	O
+novel	O
+therapeutics	O
+.	O
+
+Data	O
+regarding	O
+demographics	O
+,	O
+comorbidities	O
+,	O
+etiology	O
+of	O
+acute	B-DISO
+pancreatitis	I-DISO
+,	O
+and	O
+clinical	O
+outcomes	O
+were	O
+prospectively	O
+recorded	O
+.	O
+
+No	O
+differences	O
+in	O
+demographics	O
+,	O
+etiology	O
+of	O
+acute	B-DISO
+pancreatitis	I-DISO
+,	O
+systemic	B-DISO
+inflammatory	I-DISO
+response	I-DISO
+syndrome	I-DISO
+scores	O
+,	O
+or	O
+development	B-PROC
+of	O
+pancreatic	B-DISO
+necrosis	B-PROC
+were	O
+seen	O
+between	O
+patients	O
+with	O
+isolated	O
+RF	O
+Among	O
+patients	O
+with	O
+SAP	O
+per	O
+the	O
+Revised	O
+Atlanta	B-SPEC
+Classification	O
+,	O
+approximately	O
+15	O
+%	O
+develop	O
+isolated	O
+RF	O
+.	O
+
+RESULTS	O
+:	O
+Among	O
+500	O
+patients	O
+with	O
+acute	B-DISO
+pancreatitis	I-DISO
+,	O
+111	O
+patients	O
+developed	O
+persistent	O
+OF	O
+:	O
+mean	O
+age	O
+was	O
+54	O
+years	O
+,	O
+and	O
+75	O
+(	O
+67	O
+.	O
+6	O
+%)	O
+were	O
+male	O
+.	O
+
+Results	O
+for	O
+FIV	B-SPEC
+and	O
+FeLV	O
+infections	B-DISO
+were	O
+negative	O
+using	O
+rapid	O
+tests	O
+,	O
+whereas	O
+five	O
+(	O
+16	O
+.	O
+1	O
+%)	O
+cats	B-SPEC
+were	O
+positive	O
+for	O
+FCoV	O
+antibodies	B-COMP
+.	O
+
+Conclusions	O
+and	O
+relevance	O
+Blood	B-ANAT
+safety	O
+increases	O
+by	O
+combining	O
+the	O
+recommendations	O
+of	O
+different	O
+GLs	O
+.	O
+
+We	O
+detected	O
+a	O
+coronavirus	B-SPEC
+in	O
+the	O
+intestines	B-ANAT
+of	O
+53	O
+/	O
+174	O
+hibernating	O
+little	B-SPEC
+brown	I-SPEC
+bats	I-SPEC
+(	O
+Myotis	B-SPEC
+lucifugus	I-SPEC
+),	O
+as	O
+well	O
+as	O
+in	O
+the	O
+lungs	B-ANAT
+of	O
+some	O
+of	O
+these	O
+individuals	O
+.	O
+
+Sequence	O
+variation	O
+among	O
+coronavirus	B-SPEC
+detected	O
+from	O
+individual	O
+bats	B-SPEC
+suggested	O
+that	O
+infection	B-DISO
+occurred	O
+prior	O
+to	O
+hibernation	B-PROC
+,	O
+and	O
+that	O
+the	O
+virus	B-SPEC
+persisted	O
+for	O
+up	O
+to	O
+4	O
+months	O
+of	O
+hibernation	B-PROC
+in	O
+the	O
+laboratory	O
+.	O
+
+Initially	O
+,	O
+asthma	B-PATH
+has	O
+been	O
+categorized	O
+into	O
+atopic	B-DISO
+and	O
+nonatopic	O
+types	O
+,	O
+based	O
+on	O
+antigen	B-CHED
+-	O
+specific	O
+IgE	B-DISO
+levels	O
+.	O
+
+Although	O
+T	B-ANAT
+helper	I-ANAT
+cell	I-ANAT
+type	O
+2	O
+(	O
+Th2	O
+)	O
+cytokines	O
+were	O
+proven	O
+to	O
+play	O
+critical	O
+roles	O
+in	O
+atopic	B-DISO
+asthma	I-DISO
+,	O
+IL	B-PRGE
+-	I-PRGE
+17A	I-PRGE
+has	O
+been	O
+reported	O
+to	O
+be	O
+involved	O
+in	O
+severe	O
+refractory	O
+asthma	B-PATH
+.	O
+
+The	O
+serum	B-COMP
+levels	O
+of	O
+nine	O
+cytokines	O
+were	O
+significantly	O
+higher	O
+in	O
+patients	O
+with	O
+asthma	B-PATH
+than	O
+in	O
+HCs	B-FUNC
+,	O
+and	O
+the	O
+levels	O
+of	O
+IL	B-PRGE
+-	I-PRGE
+17A	I-PRGE
+and	O
+SCF	B-PROC
+were	O
+significantly	O
+different	O
+between	O
+uncontrolled	O
+and	O
+well	O
+-	O
+controlled	O
+patient	O
+groups	O
+(	O
+p	O
+=	O
+0	O
+.	O
+003	O
+).	O
+
+ABSTRACT	O
+:	O
+Molecular	O
+detection	O
+of	O
+Middle	O
+East	O
+respiratory	O
+syndrome	B-DISO
+coronavirus	B-SPEC
+(	O
+MERS	O
+-	O
+CoV	O
+)	O
+using	O
+real	O
+-	O
+time	O
+reverse	B-PROC
+transcription	I-PROC
+(	O
+rRT	O
+)-	O
+PCR	O
+assays	O
+is	O
+the	O
+method	O
+of	O
+choice	O
+for	O
+diagnosis	O
+of	O
+MERS	O
+.	O
+
+The	O
+PowerChek	O
+MERS	O
+assay	O
+is	O
+a	O
+straightforward	O
+and	O
+accurate	O
+assay	O
+for	O
+detecting	O
+MERS	B-PRGE
+-	I-PRGE
+CoV	I-PRGE
+RNA	I-PRGE
+.	O
+
+Autophagy	B-PROC
+was	O
+activated	O
+by	O
+rapamycin	B-CHED
+at	O
+a	O
+dose	O
+that	O
+does	O
+not	O
+affect	O
+cell	B-PROC
+viability	I-PROC
+and	O
+tight	B-COMP
+junction	I-COMP
+permeability	O
+.	O
+
+To	O
+confirm	O
+the	O
+autophagic	O
+-	O
+flux	O
+(	O
+entire	O
+autophagy	B-PROC
+pathway	B-PROC
+),	O
+autophagolysosomes	O
+were	O
+examined	O
+by	O
+an	O
+immunofluorescence	O
+assay	O
+.	O
+
+Moreover	O
+,	O
+alleviation	O
+of	O
+PEDV	B-SPEC
+-	O
+induced	O
+cell	B-PROC
+death	I-PROC
+in	O
+IPEC	O
+-	O
+J2	O
+cells	B-COMP
+pretreated	O
+with	O
+rapamycin	B-CHED
+demonstrates	O
+a	O
+protective	O
+effect	O
+of	O
+rapamycin	B-CHED
+against	O
+PEDV	B-SPEC
+-	O
+induced	O
+epithelial	B-ANAT
+cell	I-ANAT
+death	O
+.	O
+
+Pathogens	O
+such	O
+as	O
+the	O
+Middle	O
+East	O
+Respiratory	O
+Syndrome	B-DISO
+coronavirus	B-SPEC
+(	O
+MERS	O
+-	O
+CoV	O
+)	O
+and	O
+the	O
+Zika	B-SPEC
+virus	I-SPEC
+represent	O
+either	O
+new	O
+viral	O
+entities	O
+or	O
+viruses	B-SPEC
+emergent	O
+in	O
+new	O
+geographic	O
+locales	O
+and	O
+characterized	O
+by	O
+novel	O
+complications	O
+.	O
+
+TITLE	O
+:	O
+Molecular	O
+characterization	O
+of	O
+canine	O
+parvovirus	B-DISO
+and	O
+canine	O
+enteric	B-SPEC
+coronavirus	I-SPEC
+in	O
+diarrheic	O
+dogs	B-SPEC
+on	O
+the	O
+island	O
+of	O
+St	O
+.	O
+Kitts	O
+:	O
+First	O
+report	O
+from	O
+the	O
+Caribbean	O
+region	O
+.	O
+
+TITLE	O
+:	O
+Establishment	O
+and	O
+Application	O
+of	O
+a	O
+Universal	O
+Coronavirus	B-SPEC
+Screening	O
+Method	O
+Using	O
+MALDI	O
+-	O
+TOF	B-DISO
+Mass	O
+Spectrometry	O
+.	O
+
+The	O
+discovery	O
+of	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+(	O
+SARS	B-DISO
+)-	O
+CoV	O
+and	O
+Middle	O
+East	O
+respiratory	O
+syndrome	B-DISO
+(	O
+MERS	O
+)-	O
+CoV	O
+shows	O
+that	O
+HCoVs	O
+pose	O
+a	O
+significant	O
+threat	O
+to	O
+human	B-SPEC
+health	O
+.	O
+
+The	O
+aim	O
+of	O
+this	O
+study	O
+was	O
+to	O
+describe	O
+the	O
+molecular	O
+characteristics	O
+of	O
+the	O
+RdRP	B-FUNC
+and	O
+VP1	B-PRGE
+genes	I-PRGE
+of	O
+aichivirus	O
+B	O
+strains	O
+identified	O
+as	O
+the	O
+most	O
+frequent	O
+etiologic	O
+agent	O
+in	O
+a	O
+neonatal	B-DISO
+diarrhea	I-DISO
+outbreak	O
+in	O
+a	O
+high	O
+-	O
+production	O
+Brazilian	O
+dairy	O
+cattle	B-SPEC
+herd	O
+.	O
+
+ABSTRACT	O
+:	O
+Acute	O
+lung	O
+injury	O
+(	O
+ALI	O
+)	O
+and	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+(	O
+ARDS	B-DISO
+)	O
+are	O
+severe	O
+inflammatory	O
+lung	B-DISO
+diseases	I-DISO
+.	O
+
+Methylprednisolone	B-CHED
+(	O
+MP	O
+)	O
+is	O
+a	O
+common	O
+drug	O
+against	O
+inflammation	B-DISO
+in	O
+clinic	O
+.	O
+
+Tissue	B-ANAT
+injury	O
+and	O
+inflammation	B-DISO
+were	O
+ameliorated	O
+in	O
+the	O
+MP	O
+-	O
+treated	O
+group	O
+.	O
+
+Because	O
+severe	O
+pneumonia	B-DISO
+is	O
+the	O
+main	O
+cause	O
+of	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+(	O
+ARDS	B-DISO
+),	O
+we	O
+aimed	O
+to	O
+investigate	O
+the	O
+effect	O
+of	O
+the	O
+FER	B-CHED
+polymorphism	B-PROC
+rs4957796	O
+on	O
+the	O
+90	O
+-	O
+day	O
+survival	O
+in	O
+patients	O
+with	O
+ARDS	B-DISO
+due	O
+to	O
+pneumonia	B-DISO
+.	O
+
+ABSTRACT	O
+:	O
+Porcine	B-SPEC
+deltacoronavirus	O
+(	O
+PDCoV	O
+)	O
+has	O
+been	O
+recently	O
+recognized	O
+as	O
+an	O
+emerging	O
+viral	O
+pathogen	O
+that	O
+causes	O
+diarrhea	B-DISO
+in	O
+newborn	O
+piglets	O
+.	O
+
+The	O
+positive	O
+rate	O
+of	O
+PDCoV	O
+antibody	B-COMP
+was	O
+44	O
+.	O
+17	O
+%	O
+(	O
+269	O
+/	O
+609	O
+).	O
+
+Dual	O
+luciferase	B-ENZY
+reporter	O
+gene	O
+assay	O
+results	O
+indicated	O
+that	O
+nsp1	B-PRGE
+strongly	O
+inhibited	O
+the	O
+IFN	B-PRGE
+-	I-PRGE
+β	I-PRGE
+promoter	I-PRGE
+activity	O
+,	O
+and	O
+the	O
+inhibitory	O
+effect	O
+was	O
+nsp1	O
+dose	O
+-	O
+dependent	O
+.	O
+
+According	O
+to	O
+the	O
+whole	O
+genome	O
+sequence	O
+comparative	O
+analysis	O
+,	O
+we	O
+identified	O
+four	O
+major	O
+variations	O
+located	O
+in	O
+nonstructural	O
+protein	B-CHED
+2	O
+,	O
+S	O
+,	O
+open	O
+reading	O
+frame	O
+3	O
+,	O
+and	O
+envelope	B-PRGE
+(	I-PRGE
+E	I-PRGE
+)	I-PRGE
+genes	I-PRGE
+,	O
+respectively	O
+.	O
+
+Further	O
+analysis	O
+confirmed	O
+that	O
+this	O
+mutation	O
+was	O
+responsible	O
+for	O
+optimal	O
+cell	B-COMP
+-	O
+adaptation	B-PROC
+,	O
+but	O
+not	O
+the	O
+determinant	O
+for	O
+trypsin	B-PRGE
+-	O
+dependent	O
+entry	O
+of	O
+PEDV	B-SPEC
+.	O
+
+The	O
+results	O
+highlight	O
+the	O
+pulmonary	B-ANAT
+and	O
+extrapulmonary	O
+pathological	O
+changes	O
+of	O
+MERS	O
+-	O
+CoV	O
+infection	B-DISO
+and	O
+provide	O
+the	O
+first	O
+evidence	O
+of	O
+the	O
+viral	O
+presence	O
+in	O
+human	B-SPEC
+renal	B-ANAT
+tissue	I-ANAT
+,	O
+which	O
+suggests	O
+tissue	B-ANAT
+trophism	O
+for	O
+MERS	O
+-	O
+CoV	O
+in	O
+kidney	B-ANAT
+.	O
+
+We	O
+synthesized	O
+a	O
+library	O
+of	O
+3	O
+,	O
+5	O
+-	O
+diamino	O
+-	O
+N	O
+-	O
+aryl	O
+-	O
+1H	B-CHED
+-	I-CHED
+pyrazole	I-CHED
+-	O
+4	O
+-	O
+carbothioamide	O
+and	O
+4	O
+-	O
+amino	O
+-	O
+5	O
+-	O
+benzoyl	B-CHED
+-	O
+N	O
+-	O
+phenyl	B-CHED
+-	O
+2	O
+-(	O
+substituted	O
+-	O
+amino	O
+)-	O
+1H	B-CHED
+-	I-CHED
+pyrrole	I-CHED
+-	O
+3	O
+-	O
+carbothioamide	O
+derivatives	O
+and	O
+tested	O
+them	O
+against	O
+RNase	B-FUNC
+H	I-FUNC
+activity	I-FUNC
+.	O
+
+TITLE	O
+:	O
+Neurologic	O
+Injury	O
+With	O
+Severe	O
+Adult	B-DISO
+Respiratory	I-DISO
+Distress	I-DISO
+Syndrome	I-DISO
+in	O
+Patients	O
+Undergoing	O
+Extracorporeal	O
+Membrane	O
+Oxygenation	B-PROC
+:	O
+A	O
+Single	O
+-	O
+Center	O
+Retrospective	O
+Analysis	O
+.	O
+
+ECMO	O
+-	O
+associated	O
+intracerebral	B-DISO
+hemorrhage	I-DISO
+was	O
+diagnosed	O
+in	O
+10	O
+.	O
+8	O
+%	O
+of	O
+patients	O
+.	O
+
+There	O
+were	O
+no	O
+cases	O
+of	O
+ischemic	B-DISO
+stroke	I-DISO
+.	O
+
+Six	O
+-	O
+month	O
+survival	O
+was	O
+13	O
+%	O
+(	O
+Wilson	O
+confidence	O
+interval	O
+,	O
+2	O
+%-	O
+47	O
+%)	O
+in	O
+patients	O
+with	O
+severe	O
+intracerebral	B-DISO
+hemorrhage	I-DISO
+compared	O
+to	O
+an	O
+overall	O
+survival	O
+rate	O
+of	O
+57	O
+%	O
+(	O
+Wilson	O
+confidence	O
+interval	O
+,	O
+45	O
+%-	O
+67	O
+%).	O
+
+The	O
+cecal	B-ANAT
+ligation	O
+and	O
+puncture	O
+(	O
+CLP	O
+)	O
+followed	O
+by	O
+the	O
+induction	O
+of	O
+Pseudomonas	B-SPEC
+aeruginosa	I-SPEC
+(	O
+PA	O
+)	O
+was	O
+used	O
+as	O
+a	O
+clinically	O
+relevant	O
+two	O
+-	O
+hit	O
+model	O
+of	O
+sepsis	B-DISO
+.	O
+
+Despite	O
+the	O
+effort	B-PROC
+of	O
+scientific	O
+studies	O
+related	O
+to	O
+this	O
+virus	B-SPEC
+,	O
+Middle	O
+East	O
+Respiratory	O
+Syndrome	B-DISO
+(	O
+MERS	O
+)	O
+is	O
+still	O
+a	O
+public	O
+health	O
+concern	O
+.	O
+
+Six	O
+days	O
+later	O
+,	O
+the	O
+ECMO	O
+configuration	O
+mode	O
+was	O
+changed	O
+from	O
+VA	O
+to	O
+VVA	O
+to	O
+improve	O
+hypoxemia	O
+of	O
+the	O
+upper	B-ANAT
+body	I-ANAT
+and	O
+to	O
+prevent	O
+further	O
+lung	B-ANAT
+injury	O
+.	O
+
+TITLE	O
+:	O
+Novel	O
+α	O
+,	O
+β	O
+-	O
+unsaturated	O
+amide	B-CHED
+derivatives	O
+bearing	O
+α	O
+-	O
+amino	O
+phosphonate	B-CHED
+moiety	O
+as	O
+potential	O
+antiviral	B-CHED
+agents	I-CHED
+.	O
+
+ABSTRACT	O
+:	O
+Based	O
+on	O
+flexible	O
+construction	O
+and	O
+broad	O
+bioactivity	O
+of	O
+ferulic	B-CHED
+acid	I-CHED
+,	O
+a	O
+series	O
+of	O
+novel	O
+α	O
+,	O
+β	O
+-	O
+unsaturated	O
+amide	B-CHED
+derivatives	O
+bearing	O
+α	O
+-	O
+aminophosphonate	B-CHED
+moiety	O
+were	O
+designed	O
+,	O
+synthesized	O
+and	O
+systematically	O
+evaluated	O
+for	O
+their	O
+antiviral	B-CHED
+activity	O
+.	O
+
+Patients	O
+with	O
+SCA	B-ANAT
+were	O
+more	O
+likely	O
+to	O
+develop	O
+pneumonia	B-DISO
+,	O
+respiratory	B-DISO
+failure	I-DISO
+,	O
+and	O
+acute	B-DISO
+renal	I-DISO
+failure	I-DISO
+,	O
+and	O
+require	O
+mechanical	O
+ventilation	O
+,	O
+hemodialysis	O
+for	O
+acute	B-DISO
+renal	I-DISO
+failure	I-DISO
+and	O
+blood	B-ANAT
+transfusion	O
+.	O
+
+These	O
+patients	O
+do	O
+not	O
+typically	O
+have	O
+the	O
+traditional	O
+risk	O
+factors	O
+for	O
+the	O
+acute	B-DISO
+coronary	I-DISO
+syndrome	I-DISO
+.	O
+
+The	O
+essential	O
+skills	O
+that	O
+were	O
+included	O
+were	O
+the	O
+use	O
+of	O
+Personal	O
+Protective	O
+Equipment	O
+(	O
+PPE	B-CHED
+)	O
+including	O
+gown	O
+,	O
+gloves	O
+,	O
+head	B-ANAT
+cover	O
+and	O
+N95	O
+mask	O
+,	O
+hand	O
+hygiene	O
+,	O
+the	O
+practice	O
+of	O
+donning	O
+and	O
+doffing	O
+and	O
+the	O
+collection	O
+of	O
+MERS	O
+-	O
+CoV	O
+nasopharyngeal	B-ANAT
+specimens	O
+.	O
+
+Donning	O
+and	O
+doffing	O
+PPE	B-CHED
+and	O
+N95	O
+mask	O
+fit	B-DISO
+testing	O
+has	O
+become	O
+an	O
+annual	O
+mandatory	O
+competency	O
+requirement	O
+for	O
+staff	O
+in	O
+nursing	B-PROC
+and	O
+clinical	O
+services	O
+.	O
+
+TITLE	O
+:	O
+Unexplained	O
+Dyspnea	B-DISO
+in	O
+a	O
+Young	O
+Adult	O
+with	O
+Epstein	B-SPEC
+-	I-SPEC
+Barr	I-SPEC
+Virus	I-SPEC
+Infectious	B-DISO
+Mononucleosis	I-DISO
+:	O
+Pulmonary	B-ANAT
+Involvement	I-DISO
+or	O
+Co	B-DISO
+-	I-DISO
+Infection	I-DISO
+with	O
+Mycoplasma	B-DISO
+pneumoniae	I-DISO
+Pneumonia	I-DISO
+?	O
+
+Other	O
+viruses	B-SPEC
+such	O
+as	O
+SARS	B-DISO
+-,	O
+MERS	O
+-	O
+coronaviruses	O
+and	O
+human	B-SPEC
+metapneumoviruses	B-SPEC
+may	O
+use	O
+the	O
+same	O
+host	B-COMP
+cell	I-COMP
+proteases	O
+for	O
+activation	O
+,	O
+implying	O
+that	O
+TTSP	B-PRGE
+inhibition	B-PROC
+might	O
+be	O
+a	O
+novel	O
+strategy	O
+for	O
+developing	O
+broad	O
+-	O
+spectrum	O
+antiviral	B-CHED
+agents	I-CHED
+for	O
+respiratory	O
+viral	B-DISO
+infections	I-DISO
+.	O
+
+ABSTRACT	O
+:	O
+Middle	O
+East	O
+respiratory	O
+syndrome	B-DISO
+coronavirus	B-SPEC
+(	O
+MERS	O
+-	O
+CoV	O
+)	O
+causes	O
+severe	O
+respiratory	B-DISO
+disease	I-DISO
+with	O
+significant	O
+mortality	O
+.	O
+
+Based	O
+on	O
+the	O
+lack	O
+of	O
+correlation	O
+between	O
+nucleic	B-CHED
+acid	I-CHED
+and	O
+serological	O
+analysis	O
+,	O
+we	O
+conclude	O
+that	O
+MERS	O
+-	O
+CoV	O
+-	O
+IgG	B-PRGE
+testing	O
+may	O
+not	O
+be	O
+suitable	O
+for	O
+diagnosing	O
+acute	B-DISO
+infection	I-DISO
+or	O
+estimating	O
+its	O
+prevalence	O
+during	O
+an	O
+outbreak	O
+.	O
+
+In	O
+addition	O
+,	O
+our	O
+findings	O
+show	O
+that	O
+MERS	B-PRGE
+-	I-PRGE
+CoV	I-PRGE
+-	I-PRGE
+IgG	I-PRGE
+may	O
+not	O
+have	O
+significant	O
+value	O
+in	O
+determining	O
+disease	O
+severity	O
+or	O
+prognosis	O
+.	O
+
+The	O
+purpose	O
+of	O
+this	O
+study	O
+was	O
+to	O
+analyze	O
+the	O
+patterns	O
+of	O
+adult	O
+and	O
+pediatric	O
+patients	O
+who	O
+visited	O
+the	O
+emergency	B-DISO
+department	O
+(	O
+ED	O
+)	O
+during	O
+the	O
+outbreak	O
+.	O
+
+The	O
+MERS	O
+outbreak	O
+period	O
+was	O
+from	O
+June	O
+1	O
+to	O
+July	O
+31	O
+,	O
+2015	O
+,	O
+and	O
+we	O
+compared	O
+that	O
+period	O
+to	O
+the	O
+same	O
+periods	B-PROC
+in	O
+2013	O
+and	O
+2014	O
+.	O
+
+We	O
+compared	O
+and	O
+analyzed	O
+the	O
+patients	O
+'	O
+characteristics	O
+,	O
+emergency	B-DISO
+severity	O
+index	O
+(	O
+ESI	O
+)	O
+level	O
+at	O
+the	O
+visit	O
+,	O
+cause	O
+of	O
+visit	O
+,	O
+diagnosis	O
+,	O
+final	O
+dispositions	O
+,	O
+injury	O
+/	O
+non	O
+-	O
+injury	O
+,	O
+length	O
+of	O
+stay	O
+at	O
+the	O
+ED	O
+(	O
+EDLOS	O
+),	O
+and	O
+hospitalization	O
+rate	O
+.	O
+
+Especially	O
+,	O
+pregnant	O
+women	O
+can	O
+be	O
+expected	O
+as	O
+highly	O
+vulnerable	O
+candidates	O
+for	O
+this	O
+viral	B-DISO
+infection	I-DISO
+.	O
+
+In	O
+May	O
+2015	O
+,	O
+this	O
+virus	B-SPEC
+was	O
+spread	O
+in	O
+Korea	O
+and	O
+a	O
+pregnant	O
+woman	O
+was	O
+confirmed	O
+with	O
+positive	O
+result	O
+of	O
+MERS	B-PRGE
+-	I-PRGE
+CoV	I-PRGE
+polymerase	I-PRGE
+chain	I-PRGE
+reaction	O
+(	O
+PCR	O
+).	O
+
+We	O
+report	O
+the	O
+first	O
+case	O
+of	O
+MERS	O
+-	O
+CoV	O
+infection	B-DISO
+during	O
+pregnancy	O
+occurred	O
+outside	O
+of	O
+the	O
+Middle	O
+East	O
+.	O
+
+TITLE	O
+:	O
+Virome	O
+analysis	O
+for	O
+identification	O
+of	O
+novel	O
+mammalian	B-SPEC
+viruses	B-SPEC
+in	O
+bats	B-SPEC
+from	O
+Southeast	O
+China	O
+.	O
+
+TITLE	O
+:	O
+Virulence	B-PROC
+of	O
+current	O
+German	O
+PEDV	B-SPEC
+strains	O
+in	O
+suckling	O
+pigs	B-SPEC
+and	O
+investigation	O
+of	O
+protective	O
+effects	O
+of	O
+maternally	O
+derived	O
+antibodies	O
+.	O
+
+Taken	O
+together	O
+,	O
+the	O
+Central	O
+European	O
+PEDV	B-SPEC
+strains	O
+showed	O
+rather	O
+low	O
+virulence	B-PROC
+under	O
+experimental	O
+conditions	O
+,	O
+and	O
+pre	O
+-	O
+inoculation	O
+of	O
+sows	O
+led	O
+to	O
+a	O
+solid	O
+protection	O
+of	O
+their	O
+offspring	O
+.	O
+
+The	O
+antiviral	B-CHED
+activity	O
+of	O
+MβCD	O
+on	O
+porcine	B-SPEC
+nidovirus	B-SPEC
+infection	B-DISO
+was	O
+found	O
+to	O
+be	O
+predominantly	O
+exerted	B-PROC
+when	O
+used	O
+as	O
+a	O
+treatment	O
+pre	O
+-	O
+infection	B-DISO
+or	O
+prior	O
+to	O
+the	O
+viral	O
+entry	O
+process	O
+.	O
+
+Future	O
+studies	O
+should	O
+further	O
+investigate	O
+whether	O
+TAVI	O
+is	O
+associated	O
+with	O
+reduced	O
+respiratory	B-DISO
+complications	I-DISO
+,	O
+comparing	O
+transfemoral	O
+TAVI	O
+recipients	O
+treated	O
+with	O
+local	B-PROC
+anesthesia	I-PROC
+with	O
+their	O
+SAVR	O
+counterparts	O
+.	O
+
+It	O
+is	O
+known	O
+,	O
+that	O
+ALI	O
+and	O
+ARDS	B-DISO
+differ	O
+clinically	O
+and	O
+pathobiologically	O
+from	O
+ALI	O
+/	O
+ARDS	B-DISO
+caused	O
+by	O
+other	O
+reasons	O
+,	O
+but	O
+the	O
+exact	O
+pathology	B-DISO
+remains	O
+elusive	O
+.	O
+
+Subsequently	O
+,	O
+he	O
+developed	O
+multi	B-DISO
+-	I-DISO
+organ	I-DISO
+failure	I-DISO
+despite	O
+the	O
+ongoing	O
+full	O
+supportive	O
+care	O
+and	O
+empiric	O
+broad	O
+spectrum	O
+antibiotics	B-CHED
+.	O
+
+Ganciclovir	B-CHED
+therapy	O
+was	O
+introduced	O
+and	O
+showed	O
+significant	O
+improvement	O
+until	O
+full	O
+recovery	O
+.	O
+
+TITLE	O
+:	O
+Ocular	B-ANAT
+abnormalities	O
+associated	O
+with	O
+hypovitaminosis	B-DISO
+A	I-DISO
+in	O
+Hanwoo	O
+calves	O
+:	O
+a	O
+report	O
+of	O
+two	O
+cases	O
+.	O
+
+TITLE	O
+:	O
+Concurrent	O
+Acute	B-DISO
+Glomerulonephritis	I-DISO
+and	O
+Retropharyngeal	B-DISO
+Abscess	I-DISO
+in	O
+10	O
+Year	O
+Boy	O
+:	O
+A	O
+Case	O
+Report	O
+.	O
+
+Examination	O
+also	O
+revealed	O
+enlarged	O
+multiple	O
+cervical	B-ANAT
+lymph	I-ANAT
+nodes	I-ANAT
+on	O
+the	O
+same	O
+side	B-ANAT
+of	I-ANAT
+neck	I-ANAT
+.	O
+
+Multivariate	O
+predictors	O
+of	O
+30	O
+-	O
+day	O
+mortality	O
+were	O
+elderly	O
+,	O
+non	O
+-	O
+healthcare	O
+workers	O
+,	O
+pre	O
+-	O
+existing	O
+illness	O
+,	O
+severity	O
+of	O
+illness	O
+,	O
+and	O
+hospital	O
+-	O
+acquired	O
+infections	B-DISO
+(	O
+aHR	O
+=	O
+1	O
+.	O
+7	O
+;	O
+19	O
+.	O
+2	O
+;	O
+2	O
+.	O
+1	O
+;	O
+3	O
+.	O
+7	O
+;	O
+and	O
+2	O
+.	O
+9	O
+,	O
+respectively	O
+).	O
+
+A	O
+total	O
+of	O
+190	O
+malaria	B-PATH
+cases	O
+,	O
+all	O
+them	O
+imported	O
+,	O
+have	O
+been	O
+recorded	O
+.	O
+
+Animals	B-SPEC
+were	O
+classified	O
+into	O
+two	O
+groups	O
+depending	O
+on	O
+their	O
+initial	O
+BCoV	O
+IgG1	B-COMP
+Ab	O
+titers	O
+.	O
+
+In	O
+the	O
+absence	O
+of	O
+IL	O
+-	O
+18	O
+,	O
+mice	B-SPEC
+had	O
+elevated	O
+viral	B-PROC
+replication	I-PROC
+and	O
+poor	O
+survival	O
+,	O
+and	O
+this	O
+protective	O
+effect	O
+of	O
+IL	B-FUNC
+-	I-FUNC
+18	I-FUNC
+was	O
+found	O
+to	O
+be	O
+due	O
+to	O
+promotion	O
+of	O
+interferon	B-PRGE
+gamma	I-PRGE
+production	O
+in	O
+αβ	O
+T	B-ANAT
+cells	I-ANAT
+.	O
+
+We	O
+conducted	O
+a	O
+molecular	O
+and	O
+phylogenetic	O
+analysis	O
+of	O
+the	O
+S1	B-PRGE
+gene	I-PRGE
+of	O
+Brazilian	O
+(	O
+BR	O
+)	O
+IBV	B-SPEC
+isolates	O
+from	O
+a	O
+routinely	O
+vaccinated	O
+commercial	O
+flock	O
+of	O
+broiler	O
+breeders	O
+,	O
+obtained	O
+from	O
+clinical	O
+IB	O
+episodes	O
+that	O
+occurred	O
+in	O
+24	O
+-,	O
+46	O
+-	O
+and	O
+62	O
+-	O
+week	O
+-	O
+old	O
+chickens	B-SPEC
+.	O
+
+These	O
+results	O
+indicate	O
+that	O
+the	O
+S2	O
+domain	O
+has	O
+an	O
+important	O
+role	O
+in	O
+inducing	O
+protective	O
+immunity	B-PROC
+.	O
+
+ABSTRACT	O
+:	O
+To	O
+date	O
+,	O
+1841	O
+cases	O
+of	O
+Middle	O
+East	O
+respiratory	O
+syndrome	O
+coronavirus	B-SPEC
+(	O
+MERS	O
+-	O
+CoV	O
+)	O
+infection	B-DISO
+have	O
+been	O
+reported	O
+worldwide	O
+,	O
+with	O
+652	O
+deaths	B-PROC
+.	O
+
+The	O
+immune	B-PROC
+evasion	I-PROC
+mechanism	O
+including	O
+type	B-PRGE
+1	I-PRGE
+interferon	I-PRGE
+and	O
+protein	B-ENZY
+kinase	I-ENZY
+R	O
+-	O
+mediated	O
+antiviral	B-CHED
+stress	O
+responses	O
+has	O
+been	O
+recently	O
+attributed	O
+to	O
+the	O
+involvement	O
+of	O
+MERS	B-PRGE
+-	I-PRGE
+CoV	I-PRGE
+protein	I-PRGE
+4a	I-PRGE
+(	O
+p4a	O
+)	O
+that	O
+masks	O
+the	O
+viral	O
+dsRNA	B-CHED
+.	O
+
+As	O
+more	O
+cancer	B-DISO
+treatments	O
+become	O
+available	O
+,	O
+strategies	O
+to	O
+improve	O
+the	O
+supportive	O
+care	O
+of	O
+patients	O
+with	O
+TLS	O
+should	O
+be	O
+a	O
+priority	O
+.	O
+
+Chest	B-ANAT
+radiograph	O
+revealed	O
+pulmonary	B-ANAT
+vascular	B-ANAT
+congestion	B-DISO
+and	O
+a	O
+left	B-ANAT
+lower	I-ANAT
+lobe	I-ANAT
+infiltrate	B-DISO
+.	O
+
+This	O
+report	O
+highlights	O
+EV	O
+-	O
+HRV	O
+as	O
+a	O
+cause	O
+of	O
+severe	O
+ARDS	B-DISO
+and	O
+prolonged	O
+respiratory	B-DISO
+failure	I-DISO
+in	O
+adults	O
+.	O
+
+In	O
+patients	O
+aged	O
+≥	O
+16	O
+years	O
+,	O
+the	O
+isolated	O
+bacteria	B-SPEC
+varied	O
+according	O
+to	O
+the	O
+preceding	O
+virus	B-SPEC
+type	O
+.	O
+
+ABSTRACT	O
+:	O
+Clinicians	O
+'	O
+current	O
+practice	O
+patterns	O
+in	O
+the	O
+management	O
+of	O
+acute	O
+respiratory	O
+distress	O
+syndrome	O
+(	O
+ARDS	B-DISO
+)	O
+and	O
+refractory	O
+hypoxemia	O
+are	O
+not	O
+well	O
+described	O
+.	O
+
+RESULTS	O
+:	O
+We	O
+enrolled	O
+664	O
+patients	O
+:	O
+222	O
+(	O
+33	O
+%)	O
+with	O
+moderate	O
+and	O
+442	O
+(	O
+67	O
+%)	O
+with	O
+severe	O
+ARDS	B-DISO
+.	O
+
+The	O
+aim	O
+of	O
+this	O
+retrospective	O
+study	O
+was	O
+the	O
+analysis	O
+of	O
+the	O
+""""	O
+second	O
+hit	O
+""""	O
+phenomenon	O
+,	O
+meaning	O
+the	O
+alterations	O
+that	O
+occur	O
+in	O
+patients	O
+having	O
+femoral	B-ANAT
+shaft	I-ANAT
+stabilization	O
+surgery	O
+after	O
+major	O
+trauma	O
+.	O
+
+Fecal	B-ANAT
+(	O
+n	O
+=	O
+28	O
+)	O
+and	O
+nasal	B-ANAT
+(	O
+n	O
+=	O
+8	O
+)	O
+samples	O
+from	O
+diarrheic	O
+calves	O
+were	O
+tested	O
+for	O
+the	O
+presence	O
+of	O
+BCoV	O
+by	O
+both	O
+the	O
+PanCoV	O
+-	O
+RT	O
+-	O
+PCR	O
+and	O
+a	O
+specific	O
+BCoV	O
+-	O
+RT	O
+-	O
+PCR	O
+assays	O
+.	O
+
+Alternatively	O
+,	O
+in	O
+the	O
+more	O
+recent	O
+CESAR	O
+trial	O
+,	O
+many	O
+patients	O
+randomized	O
+to	O
+the	O
+ECMO	O
+arm	O
+did	O
+not	O
+receive	O
+ECMO	O
+and	O
+no	O
+standardized	O
+protocol	O
+for	O
+lung	B-ANAT
+-	O
+protective	O
+mechanical	O
+ventilation	O
+existed	O
+in	O
+the	O
+control	O
+group	O
+.	O
+
+The	O
+clinical	O
+diagnosis	O
+of	O
+hyper	B-DISO
+-	I-DISO
+IgE	I-DISO
+syndrome	I-DISO
+(	O
+P	O
+<	O
+.	O
+001	O
+),	O
+onset	O
+of	O
+disease	O
+at	O
+greater	O
+than	O
+5	O
+years	O
+(	O
+P	O
+=	O
+.	O
+02	O
+),	O
+and	O
+absence	O
+of	O
+multiple	O
+affected	O
+family	B-SPEC
+members	O
+(	O
+P	O
+=	O
+.	O
+04	O
+)	O
+were	O
+significantly	O
+more	O
+frequent	O
+in	O
+the	O
+patients	O
+without	O
+a	O
+genetic	O
+diagnosis	O
+.	O
+
+An	O
+autosomal	B-COMP
+recessive	O
+disease	O
+was	O
+found	O
+in	O
+62	O
+.	O
+9	O
+%	O
+of	O
+patients	O
+,	O
+reflecting	O
+the	O
+high	O
+rate	O
+of	O
+consanguinity	O
+in	O
+this	O
+cohort	O
+.	O
+
+When	O
+challenged	O
+with	O
+the	O
+homologous	O
+virus	O
+,	O
+sera	B-COMP
+from	O
+rSPV	O
+-	O
+St	O
+vaccination	O
+provided	O
+complete	O
+protection	O
+.	O
+
+As	O
+a	O
+result	O
+,	O
+it	O
+is	O
+difficult	O
+to	O
+determine	O
+whether	O
+a	O
+patient	O
+is	O
+currently	O
+infected	O
+with	O
+a	O
+virus	B-SPEC
+or	O
+not	O
+,	O
+and	O
+on	O
+an	O
+optimal	O
+course	O
+of	O
+action	O
+,	O
+based	O
+off	O
+of	O
+positive	O
+serology	O
+testing	O
+responses	O
+.	O
+
+Here	O
+,	O
+we	O
+report	O
+a	O
+nanoparticle	B-CHED
+-	O
+enabled	O
+blood	B-ANAT
+test	O
+that	O
+can	O
+help	O
+overcome	O
+this	O
+major	O
+challenge	O
+.	O
+
+TITLE	O
+:	O
+Interstitial	B-ANAT
+pneumonia	I-DISO
+with	O
+autoimmune	B-DISO
+features	O
+:	O
+an	O
+additional	O
+risk	O
+factor	O
+for	O
+ARDS	B-DISO
+?	O
+
+All	O
+patients	O
+required	O
+prolonged	O
+mechanical	O
+ventilation	O
+(	O
+median	O
+duration	O
+49	O
+days	O
+,	O
+range	O
+10	O
+-	O
+88	O
+);	O
+four	O
+received	O
+extracorporeal	O
+membrane	B-COMP
+oxygenation	B-PROC
+and	O
+one	O
+received	O
+low	O
+-	O
+flow	O
+extracorporeal	O
+CO	O
+
+The	O
+virus	B-SPEC
+showed	O
+closest	O
+relationship	O
+with	O
+two	O
+human	B-SPEC
+pathogenic	O
+viruses	B-SPEC
+,	O
+Colorado	B-SPEC
+tick	I-SPEC
+fever	I-SPEC
+virus	I-SPEC
+and	O
+Eyach	B-SPEC
+virus	I-SPEC
+,	O
+and	O
+was	O
+able	O
+to	O
+infect	O
+various	O
+human	B-SPEC
+cell	B-ANAT
+lines	I-ANAT
+in	O
+vitro	O
+.	O
+
+The	O
+aim	O
+of	O
+the	O
+study	O
+was	O
+to	O
+analyze	O
+,	O
+using	O
+a	O
+decision	O
+analysis	O
+approach	O
+,	O
+the	O
+probability	O
+of	O
+severity	O
+of	O
+illness	O
+due	O
+to	O
+delayed	O
+utilization	O
+of	O
+health	O
+services	O
+and	O
+inappropriate	O
+hospital	O
+medical	O
+treatment	O
+during	O
+the	O
+2009	O
+AH1N1	O
+influenza	B-DISO
+epidemic	I-DISO
+in	O
+Mexico	O
+.	O
+
+The	O
+probability	O
+for	O
+severe	O
+illness	O
+originated	O
+from	O
+delayed	O
+utilization	O
+of	O
+health	O
+services	O
+,	O
+delayed	O
+prescription	O
+of	O
+neuraminidase	B-PROC
+inhibitors	I-PROC
+(	O
+NAIs	B-SPEC
+)	O
+and	O
+inappropriate	O
+use	O
+of	O
+antibiotics	B-CHED
+was	O
+assessed	O
+.	O
+
+Removal	O
+of	O
+reactive	B-CHED
+oxygen	I-CHED
+species	I-CHED
+by	O
+anti	O
+-	O
+oxidants	B-CHED
+has	O
+been	O
+applied	O
+in	O
+clinical	O
+practice	O
+.	O
+
+Pooled	O
+analysis	O
+showed	O
+that	O
+NAC	B-COMP
+did	O
+not	O
+contribute	O
+to	O
+reduce	O
+short	O
+-	O
+term	O
+mortality	O
+[	O
+risk	O
+ratio	O
+(	O
+RR	O
+)=	O
+0	O
+.	O
+73	O
+;	O
+95	O
+%	O
+confidence	O
+interval	O
+(	O
+CI	O
+):	O
+0	O
+.	O
+50	O
+-	O
+1	O
+.	O
+07	O
+;	O
+P	O
+=	O
+0	O
+.	O
+10	O
+]	O
+or	O
+30	O
+-	O
+day	O
+mortality	O
+(	O
+RR	O
+=	O
+0	O
+.	O
+72	O
+;	O
+95	O
+%	O
+CI	O
+:	O
+0	O
+.	O
+44	O
+-	O
+1	O
+.	O
+19	O
+;	O
+P	O
+=	O
+0	O
+.	O
+20	O
+)	O
+when	O
+compared	O
+with	O
+those	O
+in	O
+the	O
+control	O
+group	O
+.	O
+
+ABSTRACT	O
+:	O
+The	O
+life	O
+cycle	O
+of	O
+Severe	B-DISO
+Acute	I-DISO
+Respiratory	I-DISO
+Syndrome	I-DISO
+Coronavirus	B-SPEC
+(	O
+SARS	B-DISO
+-	O
+CoV	O
+)	O
+involves	O
+a	O
+unique	O
+process	O
+called	O
+discontinuous	O
+transcription	B-PROC
+by	O
+which	O
+a	O
+set	O
+of	O
+3	O
+'	O
+coterminal	O
+subgenomic	O
+mRNAs	O
+(	O
+sgmRNA	O
+)	O
+with	O
+identical	O
+5	O
+'	O
+leader	O
+sequences	O
+can	O
+be	O
+generated	O
+.	O
+
+ABSTRACT	O
+:	O
+B	B-ANAT
+cell	I-ANAT
+subsets	O
+with	O
+phenotypes	O
+characteristic	O
+of	O
+naive	O
+,	O
+non	O
+-	O
+isotype	O
+-	O
+switched	O
+,	O
+memory	B-PROC
+(	O
+B	O
+
+ABSTRACT	O
+:	O
+Human	B-SPEC
+coronaviruses	O
+(	O
+HCoVs	O
+)	O
+are	O
+known	O
+respiratory	O
+pathogens	O
+associated	O
+with	O
+a	O
+range	O
+of	O
+respiratory	O
+outcomes	O
+.	O
+
+Previous	O
+studies	O
+have	O
+reported	O
+that	O
+infectious	B-DISO
+bronchitis	B-DISO
+virus	B-SPEC
+(	O
+IBV	B-SPEC
+)	O
+infection	B-DISO
+can	O
+produce	O
+cytopathic	B-DISO
+effects	I-DISO
+(	O
+CPE	O
+)	O
+and	O
+apoptosis	B-PATH
+in	O
+some	O
+mammalian	B-SPEC
+cells	B-COMP
+and	O
+primary	O
+cells	B-COMP
+.	O
+
+Additionally	O
+,	O
+ammonium	B-CHED
+chloride	I-CHED
+(	O
+NH₄Cl	O
+)	O
+pretreated	O
+HD11	O
+cells	B-COMP
+blocked	O
+IBV	B-SPEC
+from	O
+entering	O
+cells	O
+and	O
+inhibited	O
+IBV	B-SPEC
+-	O
+induced	O
+apoptosis	B-PATH
+.	O
+
+This	O
+study	O
+presents	O
+a	O
+chicken	B-SPEC
+macrophage	B-ANAT
+cell	B-ANAT
+line	I-ANAT
+that	O
+will	O
+enable	O
+further	O
+analysis	O
+of	O
+IBV	B-SPEC
+infection	B-DISO
+and	O
+offers	O
+novel	O
+insights	O
+into	O
+the	O
+mechanisms	O
+of	O
+IBV	B-SPEC
+-	O
+induced	O
+apoptosis	B-PATH
+in	O
+immune	O
+cells	B-COMP
+.	O
+
+In	O
+this	O
+study	O
+,	O
+we	O
+developed	O
+a	O
+single	O
+-	O
+tube	O
+one	O
+-	O
+step	O
+reverse	B-PROC
+transcription	I-PROC
+loop	O
+-	O
+mediated	O
+isothermal	O
+amplification	B-DISO
+(	O
+RT	O
+-	O
+LAMP	O
+)	O
+assay	O
+specific	O
+for	O
+nucleocapsid	B-PRGE
+gene	I-PRGE
+to	O
+diagnose	O
+and	O
+monitor	O
+PDCoV	O
+infections	B-DISO
+.	O
+
+Stratified	O
+randomisation	O
+with	O
+minimisation	O
+(	O
+1	O
+:	O
+1	O
+via	O
+a	O
+restricted	O
+web	B-DISO
+platform	O
+)	O
+was	O
+used	O
+to	O
+assign	O
+eligible	O
+patients	O
+(	O
+aged	O
+≥	O
+18	O
+years	O
+,	O
+admitted	O
+to	O
+an	O
+ICU	O
+after	O
+abdominal	B-ANAT
+surgery	O
+,	O
+and	O
+expected	O
+to	O
+require	O
+at	O
+least	O
+12	O
+h	O
+of	O
+mechanical	O
+ventilation	O
+because	O
+of	O
+a	O
+critical	B-DISO
+illness	I-DISO
+defined	O
+by	O
+a	O
+Sequential	O
+Organ	B-DISO
+Failure	I-DISO
+Assessment	O
+score	O
+>	O
+1	O
+for	O
+any	O
+organ	B-ANAT
+,	O
+but	O
+without	O
+severe	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+or	O
+brain	B-ANAT
+injury	O
+)	O
+to	O
+usual	O
+sedation	B-DISO
+care	O
+provided	O
+according	O
+to	O
+recommended	O
+practices	O
+(	O
+control	O
+group	O
+)	O
+or	O
+to	O
+immediate	O
+interruption	O
+of	O
+sedation	B-DISO
+(	O
+intervention	O
+group	O
+).	O
+
+Between	O
+Dec	B-CHED
+2	O
+,	O
+2011	O
+,	O
+and	O
+Feb	O
+27	O
+,	O
+2014	O
+,	O
+137	O
+patients	O
+were	O
+randomly	O
+assigned	O
+to	O
+the	O
+control	O
+(	O
+n	O
+=	O
+68	O
+)	O
+or	O
+intervention	O
+groups	O
+(	O
+n	O
+=	O
+69	O
+).	O
+
+This	O
+observed	O
+decrease	O
+in	O
+mortality	O
+is	O
+associated	O
+with	O
+increasing	O
+rates	O
+of	O
+transfusion	O
+and	O
+peripartum	O
+hysterectomy	O
+(	O
+2	O
+-	O
+4	O
+).	O
+The	O
+purpose	O
+of	O
+this	O
+Practice	O
+Bulletin	O
+is	O
+to	O
+discuss	O
+the	O
+risk	O
+factors	O
+for	O
+postpartum	B-DISO
+hemorrhage	I-DISO
+as	O
+well	O
+as	O
+its	O
+evaluation	O
+,	O
+prevention	O
+,	O
+and	O
+management	O
+.	O
+
+In	O
+addition	O
+,	O
+this	O
+document	O
+will	O
+encourage	O
+obstetrician	O
+-	O
+gynecologists	O
+and	O
+other	O
+obstetric	O
+care	O
+providers	O
+to	O
+play	O
+key	O
+roles	O
+in	O
+implementing	O
+standardized	O
+bundles	O
+of	O
+care	O
+(	O
+eg	O
+,	O
+policies	O
+,	O
+guidelines	O
+,	O
+and	O
+algorithms	O
+)	O
+for	O
+the	O
+management	O
+of	O
+postpartum	B-DISO
+hemorrhage	I-DISO
+.	O
+
+TITLE	O
+:	O
+Practice	O
+Bulletin	O
+No	O
+.	O
+183	O
+:	O
+Postpartum	B-DISO
+Hemorrhage	I-DISO
+.	O
+
+ABSTRACT	O
+:	O
+Infectious	O
+bronchitis	B-DISO
+virus	B-SPEC
+(	O
+IBV	B-SPEC
+)	O
+variants	O
+constantly	O
+emerge	O
+and	O
+pose	O
+economic	O
+threats	O
+to	O
+poultry	O
+farms	O
+worldwide	O
+.	O
+
+We	O
+noted	O
+that	O
+viral	O
+genetic	B-PROC
+mutations	I-PROC
+and	O
+recombination	B-PROC
+events	O
+commonly	O
+gave	O
+rise	O
+to	O
+distinct	O
+IBV	B-SPEC
+genotypes	O
+,	O
+serotypes	O
+and	O
+pathotypes	O
+.	O
+
+ABSTRACT	O
+:	O
+To	O
+update	O
+the	O
+2008	O
+consensus	O
+statements	O
+for	O
+the	O
+diagnosis	O
+and	O
+management	O
+of	O
+critical	B-DISO
+illness	I-DISO
+-	O
+related	O
+corticosteroid	B-CHED
+insufficiency	O
+(	O
+CIRCI	O
+)	O
+in	O
+adult	O
+and	O
+pediatric	O
+patients	O
+.	O
+
+We	O
+suggest	O
+against	O
+using	O
+plasma	B-ANAT
+-	O
+free	O
+cortisol	B-CHED
+or	O
+salivary	O
+cortisol	B-CHED
+level	O
+over	O
+plasma	B-ANAT
+total	O
+cortisol	B-CHED
+(	O
+conditional	O
+,	O
+very	O
+low	O
+quality	O
+of	O
+evidence	O
+).	O
+
+We	O
+suggest	O
+the	O
+use	O
+of	O
+IV	O
+methylprednisolone	B-CHED
+1	O
+mg	O
+/	O
+kg	O
+/	O
+day	O
+in	O
+patients	O
+with	O
+early	O
+moderate	O
+to	O
+severe	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+(	O
+PaO2	O
+/	O
+FiO2	O
+<	O
+200	O
+and	O
+within	O
+14	O
+days	O
+of	O
+onset	O
+)	O
+(	O
+conditional	O
+,	O
+moderate	O
+quality	O
+of	O
+evidence	O
+).	O
+
+Corticosteroids	B-CHED
+are	O
+not	O
+suggested	O
+for	O
+patients	O
+with	O
+major	O
+trauma	O
+(	O
+conditional	O
+,	O
+low	O
+quality	O
+of	O
+evidence	O
+).	O
+
+ABSTRACT	O
+:	O
+Disseminated	O
+cutaneous	O
+varicella	O
+herpes	B-DISO
+zoster	I-DISO
+with	O
+visceral	O
+involvement	O
+is	O
+rare	O
+and	O
+seen	O
+almost	O
+exclusively	O
+in	O
+immunocompromised	O
+patients	O
+.	O
+
+Varicella	B-DISO
+zoster	I-DISO
+infection	I-DISO
+was	O
+confirmed	O
+via	O
+skin	B-ANAT
+biopsy	O
+,	O
+bronchial	B-ANAT
+viral	O
+PCR	O
+and	O
+serology	O
+for	O
+varicella	B-DISO
+antibodies	B-COMP
+.	O
+
+It	O
+is	O
+established	O
+that	O
+vitamin	B-CHED
+D	I-CHED
+exhibits	O
+anti	O
+‑	O
+inflammatory	O
+effects	O
+,	O
+however	O
+,	O
+the	O
+specific	O
+effect	O
+of	O
+vitamin	B-CHED
+D	I-CHED
+on	O
+ALI	O
+remains	O
+largely	O
+unknown	O
+.	O
+
+The	O
+identified	O
+leads	O
+cannot	O
+be	O
+predicted	O
+based	O
+on	O
+prior	O
+data	O
+on	O
+polymer	B-CHED
+-	O
+based	O
+antivirals	B-CHED
+and	O
+represent	O
+promising	O
+candidates	O
+for	O
+further	O
+development	O
+as	O
+preventive	O
+microbicides	B-CHED
+.	O
+
+TITLE	O
+:	O
+Immunogenicity	O
+of	O
+eGFP	O
+-	O
+Marked	O
+Recombinant	O
+Lactobacillus	B-SPEC
+casei	I-SPEC
+against	O
+Transmissible	O
+Gastroenteritis	B-DISO
+Virus	B-SPEC
+and	O
+Porcine	B-SPEC
+Epidemic	I-SPEC
+Diarrhea	I-SPEC
+Virus	I-SPEC
+.	O
+
+TITLE	O
+:	O
+Two	O
+novel	O
+porcine	B-SPEC
+epidemic	I-SPEC
+diarrhea	I-SPEC
+virus	I-SPEC
+(	O
+PEDV	B-SPEC
+)	O
+recombinants	O
+from	O
+a	O
+natural	O
+recombinant	O
+and	O
+distinct	O
+subtypes	O
+of	O
+PEDV	O
+variants	O
+.	O
+
+Amino	B-CHED
+acid	I-CHED
+alignment	O
+of	O
+spike	O
+(	O
+S	O
+)	O
+proteins	B-CHED
+indicated	O
+that	O
+they	O
+have	O
+the	O
+similar	O
+mutation	B-PROC
+,	I-PROC
+insertion	I-PROC
+and	O
+deletion	O
+pattern	O
+as	O
+other	O
+Chinese	O
+PEDV	B-SPEC
+variants	O
+but	O
+also	O
+contain	O
+several	O
+unique	O
+substitutions	O
+.	O
+
+ABSTRACT	O
+:	O
+Middle	O
+East	O
+Respiratory	O
+Syndrome	B-DISO
+Coronavirus	B-SPEC
+(	O
+MERS	O
+-	O
+CoV	O
+)	O
+is	O
+well	O
+known	O
+to	O
+cause	O
+severe	O
+respiratory	B-DISO
+infection	I-DISO
+and	O
+was	O
+first	O
+reported	O
+in	O
+the	O
+Kingdom	B-SPEC
+of	O
+Saudi	O
+Arabia	O
+in	O
+2012	O
+.	O
+
+This	O
+case	O
+illustrates	O
+that	O
+ECMO	O
+and	O
+prolonged	O
+intubation	O
+can	O
+prolong	O
+life	O
+in	O
+CF	O
+patients	O
+with	O
+mild	O
+lung	B-DISO
+disease	I-DISO
+who	O
+present	O
+with	O
+potentially	O
+reversible	O
+acute	B-DISO
+respiratory	I-DISO
+failure	I-DISO
+,	O
+though	O
+they	O
+are	O
+associated	O
+with	O
+significant	O
+morbidity	O
+.	O
+
+TITLE	O
+:	O
+Porcine	B-SPEC
+Hemagglutinating	O
+Encephalomyelitis	B-DISO
+Virus	B-SPEC
+Enters	O
+Neuro	O
+-	O
+2a	O
+Cells	B-COMP
+via	O
+Clathrin	B-PRGE
+-	I-PROC
+Mediated	I-PROC
+Endocytosis	I-PROC
+in	O
+a	O
+Rab5	B-PRGE
+-,	O
+Cholesterol	B-CHED
+-,	O
+and	O
+pH	O
+-	O
+Dependent	O
+Manner	O
+.	O
+
+Here	O
+we	O
+dissected	O
+the	O
+molecular	O
+mechanism	O
+underlying	O
+cellular	B-COMP
+entry	O
+and	O
+intracellular	B-COMP
+trafficking	B-PROC
+of	O
+PHEV	O
+in	O
+mouse	B-DISO
+neuroblastoma	I-DISO
+(	O
+Neuro	O
+-	O
+2a	O
+)	O
+cells	B-COMP
+.	O
+
+We	O
+found	O
+that	O
+respiratory	O
+signs	O
+,	O
+tracheal	O
+deciliation	O
+and	O
+inflammation	B-DISO
+,	O
+airsacculitis	B-DISO
+,	O
+viral	B-DISO
+shedding	I-DISO
+in	O
+tears	B-ANAT
+,	O
+and	O
+local	O
+humoral	O
+responses	O
+were	O
+good	O
+parameters	O
+to	O
+determine	O
+resistance	B-PROC
+or	O
+susceptibility	O
+.	O
+
+Based	O
+on	O
+these	O
+results	O
+,	O
+we	O
+identified	O
+331	O
+/	O
+B2	O
+as	O
+the	O
+most	O
+resistant	O
+and	O
+335	O
+/	O
+B19	O
+as	O
+the	O
+most	O
+susceptible	O
+congenic	O
+chicken	B-SPEC
+lines	O
+.	O
+
+A	O
+possible	O
+basis	O
+for	O
+the	O
+reported	O
+ability	O
+of	O
+IBV	B-SPEC
+4	O
+/	O
+91	O
+(	O
+serotype	O
+793	O
+/	O
+B	O
+)	O
+vaccine	O
+to	O
+protect	O
+against	O
+divergent	O
+IBV	B-SPEC
+strains	O
+(	O
+e	O
+.	O
+g	O
+.,	O
+QX	O
+,	O
+Q1	O
+,	O
+and	O
+D1466	O
+)	O
+in	O
+a	O
+prime	O
+-	O
+boost	O
+approach	O
+with	O
+an	O
+IBV	B-SPEC
+Mass	O
+vaccine	O
+is	O
+that	O
+an	O
+immune	B-PROC
+response	I-PROC
+against	O
+the	O
+S2	B-PRGE
+protein	I-PRGE
+of	O
+IBV	B-SPEC
+4	O
+/	O
+91	O
+is	O
+cross	O
+-	O
+protective	O
+.	O
+
+Chickens	O
+primed	O
+with	O
+attenuated	O
+Mass	O
+IBV	B-SPEC
+at	O
+1	O
+day	O
+of	O
+age	O
+and	O
+boosted	O
+with	O
+rLS	B-DISO
+/	O
+IBV	B-SPEC
+.	O
+S2	O
+-	O
+4	O
+/	O
+91	O
+at	O
+14	O
+days	O
+of	O
+age	O
+were	O
+challenged	O
+with	O
+a	O
+virulent	O
+Ark	B-PRGE
+IBV	B-SPEC
+strain	O
+at	O
+28	O
+days	O
+of	O
+age	O
+.	O
+
+ABSTRACT	O
+:	O
+The	O
+present	O
+study	O
+aimed	O
+to	O
+determine	O
+the	O
+molecular	O
+characteristics	O
+of	O
+circulating	O
+infectious	O
+bronchitis	B-DISO
+virus	B-SPEC
+(	O
+IBV	B-SPEC
+)	O
+strains	O
+in	O
+vaccinated	O
+broiler	O
+flocks	O
+in	O
+the	O
+Giza	O
+and	O
+Fayoum	O
+governorates	O
+.	O
+
+During	O
+the	O
+study	O
+period	O
+in	O
+2015	O
+,	O
+the	O
+index	O
+case	O
+was	O
+a	O
+30	O
+-	O
+year	O
+-	O
+old	O
+Filipino	O
+nurse	O
+who	O
+had	O
+a	O
+history	O
+of	O
+unprotected	O
+exposure	O
+to	O
+a	O
+MERS	O
+-	O
+CoV	O
+-	O
+positive	O
+case	O
+on	O
+May	O
+15	O
+,	O
+2015	O
+,	O
+and	O
+had	O
+multiple	O
+negative	O
+tests	O
+for	O
+MERS	O
+-	O
+CoV	O
+.	O
+Weeks	O
+later	O
+,	O
+she	O
+was	O
+diagnosed	O
+with	O
+pulmonary	B-DISO
+tuberculosis	B-PATH
+and	O
+MERS	O
+-	O
+CoV	O
+infection	B-DISO
+.	O
+
+A	O
+total	O
+of	O
+73	O
+staff	O
+were	O
+quarantined	O
+for	O
+14	O
+days	O
+,	O
+and	O
+nasopharyngeal	B-ANAT
+swabs	O
+were	O
+taken	O
+on	O
+days	O
+2	O
+,	O
+5	O
+,	O
+and	O
+12	O
+postexposure	O
+.	O
+
+As	O
+there	O
+wasn	O
+'	O
+t	O
+any	O
+tertiary	O
+structure	O
+of	O
+PLP	B-PRGE
+available	O
+in	O
+the	O
+Protein	B-CHED
+Data	O
+Bank	O
+(	O
+PDB	B-DISO
+)	O
+and	O
+in	O
+order	B-SPEC
+to	O
+characterize	O
+the	O
+structural	O
+properties	O
+of	O
+the	O
+protein	B-CHED
+,	O
+we	O
+modeled	O
+this	O
+protein	B-CHED
+using	O
+prediction	O
+servers	O
+.	O
+
+However	O
+,	O
+the	O
+transmission	O
+routes	O
+of	O
+the	O
+virus	B-SPEC
+remain	O
+unclear	O
+,	O
+and	O
+thus	O
+,	O
+the	O
+current	O
+recommended	O
+control	O
+strategies	O
+are	O
+not	O
+evidence	O
+based	O
+.	O
+
+ABSTRACT	O
+:	O
+Long	O
+non	O
+-	O
+coding	O
+RNAs	O
+(	O
+lncRNAs	O
+)	O
+regulate	O
+a	O
+variety	O
+of	O
+genes	O
+and	O
+biological	B-PROC
+processes	I-PROC
+.	O
+
+Sixty	O
+-	O
+eight	O
+patients	O
+with	O
+severe	O
+chest	B-ANAT
+trauma	O
+complicated	O
+with	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+that	O
+were	O
+treated	O
+at	O
+our	O
+Tianjin	O
+Hospital	O
+from	O
+September	O
+2013	O
+to	O
+July	O
+2016	O
+were	O
+recruited	O
+.	O
+
+On	O
+the	O
+one	O
+hand	O
+,	O
+respiratory	B-PROC
+mechanics	I-PROC
+are	O
+a	O
+powerful	O
+physiological	O
+method	O
+to	O
+understand	O
+the	O
+severity	O
+of	O
+this	O
+syndrome	B-DISO
+in	O
+each	O
+single	O
+patient	O
+.	O
+
+stigmatosoma	O
+bloodmeals	O
+,	O
+revealing	O
+that	O
+98	O
+.	O
+6	O
+%	O
+of	O
+bloodmeals	O
+were	O
+from	O
+birds	B-SPEC
+,	O
+1	O
+.	O
+2	O
+%	O
+from	O
+three	O
+mammal	B-SPEC
+species	B-SPEC
+,	O
+and	O
+a	O
+single	O
+bloodmeal	O
+was	O
+from	O
+a	O
+reptile	O
+species	B-SPEC
+.	O
+
+The	O
+greatest	O
+number	O
+of	O
+bloodmeals	O
+identified	O
+was	O
+from	O
+domestic	O
+chicken	B-SPEC
+(	O
+Gallus	B-SPEC
+gallus	I-SPEC
+domesticus	I-SPEC
+L	O
+.)	O
+(	O
+38	O
+%	O
+of	O
+bloodmeals	O
+),	O
+house	B-SPEC
+sparrow	I-SPEC
+(	O
+Passer	B-SPEC
+domesticus	I-SPEC
+L	O
+.)	O
+(	O
+23	O
+%),	O
+house	B-SPEC
+finch	I-SPEC
+(	O
+Haemorhous	O
+mexicanus	O
+Müller	O
+)	O
+(	O
+17	O
+%),	O
+American	B-SPEC
+crow	I-SPEC
+(	O
+Corvus	B-SPEC
+brachyrhynchos	I-SPEC
+L	O
+.)	O
+(	O
+4	O
+%),	O
+and	O
+mourning	B-SPEC
+dove	I-SPEC
+(	O
+Zenaida	B-SPEC
+macroura	I-SPEC
+L	O
+.)	O
+(	O
+3	O
+%).	O
+
+stigmatosoma	O
+supports	O
+the	O
+hypothesis	O
+that	O
+this	O
+mosquito	B-SPEC
+species	B-SPEC
+may	O
+be	O
+an	O
+important	O
+maintenance	O
+(	O
+or	O
+endemic	O
+)	O
+vector	O
+for	O
+arboviruses	O
+that	O
+circulate	O
+among	O
+susceptible	O
+birds	B-SPEC
+.	O
+
+ABSTRACT	O
+:	O
+Preeclampsia	B-DISO
+,	O
+eclampsia	B-DISO
+and	O
+HELLP	B-DISO
+syndrome	I-DISO
+are	O
+life	O
+-	O
+threatening	O
+hypertensive	O
+conditions	O
+and	O
+common	O
+causes	O
+of	O
+ICU	O
+admission	O
+among	O
+obstetric	O
+patients	O
+The	O
+diagnostic	O
+criteria	O
+of	O
+preeclampsia	B-DISO
+include	O
+:	O
+1	O
+)	O
+systolic	O
+blood	B-PROC
+pressure	I-PROC
+(	O
+SBP	O
+)	O
+≥	O
+140	O
+mmHg	O
+or	O
+diastolic	O
+blood	B-PROC
+pressure	I-PROC
+(	O
+DBP	B-CHED
+)	O
+≥	O
+90	O
+mmHg	O
+on	O
+two	O
+occasions	O
+at	O
+least	O
+4	O
+hours	O
+apart	O
+and	O
+2	O
+)	O
+proteinuria	O
+≥	O
+300	O
+mg	O
+/	O
+day	O
+in	O
+a	O
+woman	O
+with	O
+a	O
+gestational	O
+age	O
+of	O
+>	O
+20	O
+weeks	O
+with	O
+previously	O
+normal	O
+blood	B-ANAT
+pressures	O
+.	O
+
+HELLP	B-DISO
+syndrome	I-DISO
+is	O
+a	O
+life	O
+-	O
+threatening	O
+condition	B-DISO
+frequently	O
+associated	O
+with	O
+severe	B-DISO
+preeclampsia	I-DISO
+-	O
+eclampsia	B-DISO
+and	O
+is	O
+characterized	O
+by	O
+three	O
+hallmark	O
+features	O
+of	O
+hemolysis	B-DISO
+,	O
+elevated	O
+liver	B-ANAT
+enzymes	O
+and	O
+low	O
+platelets	B-ANAT
+.	O
+
+Complications	O
+that	O
+can	O
+be	O
+related	O
+to	O
+this	O
+spectrum	O
+of	O
+disease	O
+include	O
+disseminated	B-DISO
+Intravascular	I-DISO
+coagulation	I-DISO
+(	O
+DIC	B-DISO
+),	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+,	O
+stroke	O
+,	O
+acute	B-DISO
+renal	I-DISO
+failure	I-DISO
+,	O
+hepatic	B-DISO
+dysfunction	I-DISO
+with	O
+hepatic	B-ANAT
+rupture	O
+or	O
+liver	B-DISO
+hematoma	I-DISO
+and	O
+infection	B-DISO
+/	O
+sepsis	B-DISO
+.	O
+
+The	O
+efficacy	O
+of	O
+this	O
+antitoxin	O
+treatment	O
+depends	O
+on	O
+antibody	B-COMP
+affinity	O
+and	O
+the	O
+time	O
+of	O
+treatment	O
+initiation	O
+within	O
+a	O
+limited	O
+therapeutic	O
+time	O
+window	O
+.	O
+
+To	O
+evaluate	O
+whether	O
+an	O
+individualized	O
+blood	B-PROC
+pressure	I-PROC
+management	O
+strategy	O
+tailored	O
+to	O
+individual	O
+patient	O
+physiology	O
+could	O
+reduce	O
+postoperative	O
+organ	B-ANAT
+dysfunction	O
+.	O
+
+Multicenter	O
+,	O
+randomized	O
+trial	O
+conducted	O
+at	O
+120	O
+intensive	O
+care	O
+units	O
+(	O
+ICUs	O
+)	O
+from	O
+9	O
+countries	O
+from	O
+November	O
+17	O
+,	O
+2011	O
+,	O
+through	O
+April	O
+25	O
+,	O
+2017	O
+,	O
+enrolling	O
+adults	O
+with	O
+moderate	O
+to	O
+severe	O
+ARDS	B-DISO
+.	O
+
+In	O
+this	O
+study	O
+,	O
+we	O
+observed	O
+changes	O
+in	O
+microcirculation	B-PROC
+during	O
+the	O
+trauma	O
+and	O
+shock	O
+phases	O
+.	O
+
+Furthermore	O
+,	O
+we	O
+also	O
+measured	O
+persistent	O
+dysfunction	O
+of	O
+the	O
+microcirculation	B-PROC
+over	O
+the	O
+observation	O
+period	O
+of	O
+3	O
+days	O
+after	O
+resuscitation	O
+and	O
+haemorrhagic	B-DISO
+shock	I-DISO
+.	O
+
+Cats	B-SPEC
+were	O
+categorised	O
+as	O
+with	O
+FIP	B-DISO
+(	O
+n	O
+=	O
+57	O
+)	O
+or	O
+without	O
+FIP	B-DISO
+(	O
+n	O
+=	O
+45	O
+)	O
+based	O
+on	O
+gross	O
+post	O
+-	O
+mortem	O
+and	O
+histopathological	O
+examination	O
+including	O
+immunohistochemistry	O
+for	O
+FCoV	B-PRGE
+antigen	I-PRGE
+.	O
+
+Reverse	O
+-	O
+transcriptase	B-PROC
+quantitative	O
+-	O
+PCR	O
+(	O
+RT	O
+-	O
+qPCR	O
+)	O
+was	O
+performed	O
+on	O
+all	O
+samples	O
+using	O
+FCoV	O
+-	O
+specific	O
+primers	O
+,	O
+followed	O
+by	O
+sequencing	O
+of	O
+a	O
+section	O
+of	O
+the	O
+S	B-PRGE
+gene	I-PRGE
+on	O
+RT	O
+-	O
+qPCR	O
+positive	O
+samples	O
+.	O
+
+These	O
+findings	O
+demonstrate	O
+that	O
+S	B-PRGE
+gene	I-PRGE
+mutation	O
+analysis	O
+in	O
+FCoVs	O
+does	O
+not	O
+substantially	O
+improve	O
+the	O
+ability	O
+to	O
+diagnose	O
+FIP	B-DISO
+as	O
+compared	O
+to	O
+detection	O
+of	O
+FCoV	O
+alone	O
+.	O
+
+Based	O
+on	O
+a	O
+full	O
+-	O
+length	O
+infectious	B-DISO
+MERS	O
+-	O
+CoV	O
+cDNA	O
+clone	O
+,	O
+optimal	O
+genomic	O
+insertion	O
+sites	O
+and	O
+expression	B-PROC
+strategies	O
+for	O
+GFP	O
+were	O
+identified	O
+and	O
+used	O
+to	O
+generate	O
+a	O
+reporter	O
+MERS	O
+-	O
+CoV	O
+expressing	O
+GFP	O
+in	O
+addition	O
+to	O
+the	O
+complete	O
+set	O
+of	O
+viral	O
+proteins	O
+.	O
+
+The	O
+present	O
+study	O
+is	O
+a	O
+retrospective	O
+observational	O
+study	O
+of	O
+262	O
+ventilated	O
+medical	O
+ICU	O
+patients	O
+at	O
+risk	O
+of	O
+ARDS	B-DISO
+due	O
+to	O
+severe	B-DISO
+sepsis	I-DISO
+and	O
+APACHE	O
+II	O
+≥	O
+25	O
+.	O
+
+CONCLUSIONS	O
+:	O
+The	O
+extent	O
+of	O
+endothelial	B-ANAT
+glycocalyx	B-COMP
+degradation	O
+is	O
+associated	O
+with	O
+non	O
+-	O
+pulmonary	B-ANAT
+organ	B-ANAT
+dysfunction	O
+in	O
+subjects	O
+with	O
+sepsis	B-DISO
+and	O
+is	O
+associated	O
+with	O
+ARDS	B-DISO
+but	O
+only	O
+in	O
+the	O
+subgroup	O
+with	O
+non	O
+-	O
+pulmonary	B-DISO
+sepsis	B-SPEC
+.	O
+
+Engagement	O
+of	O
+specific	O
+glycan	B-CHED
+receptors	O
+such	O
+as	O
+sialylated	O
+carbohydrates	B-CHED
+,	O
+glycosaminoglycans	B-CHED
+,	O
+or	O
+histo	O
+-	O
+blood	B-ANAT
+group	O
+antigens	B-CHED
+can	O
+determine	O
+host	B-COMP
+range	O
+,	O
+tissue	B-PROC
+tropism	B-PROC
+,	O
+and	O
+pathogenicity	O
+.	O
+
+Those	O
+viruses	B-SPEC
+exemplify	O
+that	O
+direct	O
+molecular	O
+mimicking	O
+of	O
+glycan	B-CHED
+receptors	O
+by	O
+antibodies	B-COMP
+is	O
+rare	O
+and	O
+further	O
+demonstrate	O
+that	O
+antibodies	B-COMP
+often	O
+partly	O
+overlap	O
+or	O
+bind	B-FUNC
+sufficiently	O
+close	O
+to	O
+the	O
+receptor	O
+-	O
+binding	B-FUNC
+region	O
+to	O
+hinder	O
+access	O
+to	O
+this	O
+site	O
+,	O
+achieving	O
+neutralization	O
+partially	O
+because	O
+of	O
+the	O
+epitope	B-CHED
+location	O
+and	O
+partly	O
+due	O
+to	O
+their	O
+sheer	O
+size	O
+.	O
+
+A	O
+successful	O
+viral	B-DISO
+infection	I-DISO
+requires	O
+fusion	O
+between	O
+virus	B-SPEC
+and	O
+host	B-COMP
+cells	B-COMP
+carried	O
+out	O
+by	O
+the	O
+surface	B-PRGE
+spike	I-PRGE
+glycoprotein	I-PRGE
+or	O
+S	B-PRGE
+protein	I-PRGE
+of	O
+CoV	O
+.	O
+Current	O
+models	O
+propose	O
+that	O
+the	O
+S2	O
+subunit	O
+of	O
+S	B-PRGE
+protein	I-PRGE
+assembled	O
+into	O
+a	O
+hexameric	O
+helical	O
+bundle	O
+exposing	O
+hydrophobic	O
+fusogenic	O
+peptides	B-CHED
+or	O
+fusion	O
+peptides	B-CHED
+(	O
+FPs	B-FUNC
+)	O
+for	O
+membrane	B-COMP
+insertion	O
+.	O
+
+The	O
+N	O
+-	O
+terminus	O
+of	O
+S2	O
+subunit	O
+of	O
+SARS	B-DISO
+-	O
+CoV	O
+reported	O
+to	O
+be	O
+active	O
+in	O
+cell	B-PROC
+fusion	I-PROC
+whereby	O
+FPs	B-FUNC
+have	O
+been	O
+identified	O
+.	O
+
+The	O
+overall	O
+stress	O
+,	O
+professionalism	O
+,	O
+and	O
+nursing	B-PROC
+intention	O
+scores	O
+for	O
+the	O
+firsthand	O
+experience	O
+group	O
+were	O
+33	O
+.	O
+72	O
+,	O
+103	O
+.	O
+00	O
+,	O
+and	O
+16	O
+.	O
+92	O
+,	O
+respectively	O
+,	O
+whereas	O
+those	O
+of	O
+the	O
+secondhand	O
+experience	O
+group	O
+were	O
+32	O
+.	O
+25	O
+,	O
+98	O
+.	O
+99	O
+,	O
+and	O
+15	O
+.	O
+60	O
+,	O
+respectively	O
+.	O
+
+TITLE	O
+:	O
+Characterization	O
+of	O
+novel	O
+monoclonal	O
+antibodies	B-COMP
+against	O
+the	O
+MERS	B-PRGE
+-	I-PRGE
+coronavirus	I-PRGE
+spike	I-PRGE
+protein	B-CHED
+and	O
+their	O
+application	O
+in	O
+species	O
+-	O
+independent	O
+antibody	B-COMP
+detection	O
+by	O
+competitive	O
+ELISA	O
+.	O
+
+Although	O
+the	O
+virus	B-PROC
+neutralization	I-PROC
+test	O
+is	O
+the	O
+gold	B-CHED
+standard	O
+assay	O
+for	O
+MERS	O
+diagnosis	O
+and	O
+for	O
+investigating	O
+the	O
+zoonotic	O
+reservoir	O
+,	O
+it	O
+uses	O
+live	O
+virus	B-SPEC
+and	O
+so	O
+must	O
+be	O
+performed	O
+in	O
+high	O
+containment	O
+laboratories	O
+.	O
+
+Competitive	O
+ELISA	O
+(	O
+cELISA	O
+),	O
+in	O
+which	O
+a	O
+labeled	O
+monoclonal	O
+antibody	B-COMP
+(	O
+MAb	O
+)	O
+competes	O
+with	O
+test	B-PRGE
+serum	I-PRGE
+antibodies	B-COMP
+for	O
+target	O
+epitopes	O
+,	O
+may	O
+be	O
+a	O
+suitable	O
+alternative	O
+because	O
+it	O
+detects	O
+antibodies	B-COMP
+in	O
+a	O
+species	B-SPEC
+-	O
+independent	O
+manner	O
+.	O
+
+In	O
+this	O
+study	O
+,	O
+novel	O
+MAbs	O
+against	O
+the	O
+spike	O
+protein	B-CHED
+of	O
+MERS	O
+-	O
+CoV	O
+were	O
+produced	O
+and	O
+characterized	O
+.	O
+
+The	O
+cELISA	O
+and	O
+neutralization	O
+test	O
+results	O
+correlated	O
+well	O
+(	O
+Pearson	O
+'	O
+s	O
+correlation	O
+coefficients	O
+=	O
+0	O
+.	O
+71	O
+-	O
+0	O
+.	O
+76	O
+,	O
+depending	O
+on	O
+the	O
+cELISA	O
+serum	B-COMP
+dilution	O
+).	O
+
+Nasal	B-ANAT
+samples	O
+from	O
+camels	B-SPEC
+,	O
+sheep	B-SPEC
+,	O
+goats	B-SPEC
+,	O
+and	O
+cattle	B-SPEC
+were	O
+examined	O
+by	O
+real	O
+-	O
+time	O
+reverse	O
+-	O
+transcription	B-PROC
+PCR	O
+(	O
+RT	O
+-	O
+PCR	O
+)	O
+to	O
+detect	O
+MERS	B-PRGE
+-	I-PRGE
+CoV	I-PRGE
+RNA	I-PRGE
+,	O
+and	O
+the	O
+Anti	O
+-	O
+MERS	O
+ELISA	O
+assay	O
+was	O
+performed	O
+to	O
+detect	O
+camel	B-SPEC
+humeral	O
+immune	B-PROC
+response	I-PROC
+(	O
+IgG	B-PRGE
+)	O
+to	O
+MERS	B-PRGE
+-	I-PRGE
+CoV	I-PRGE
+S1	I-PRGE
+antigen	I-PRGE
+infection	B-DISO
+.	O
+
+Anti	O
+-	O
+MERS	O
+ELISA	O
+assays	O
+showed	O
+that	O
+70	O
+.	O
+9	O
+%	O
+of	O
+camels	B-SPEC
+related	O
+to	O
+human	B-SPEC
+cases	O
+had	O
+antibodies	B-COMP
+to	O
+MERS	O
+-	O
+CoV	O
+.	O
+The	O
+full	O
+genome	O
+sequences	O
+of	O
+the	O
+ten	O
+MERS	O
+-	O
+CoV	O
+camel	B-SPEC
+isolates	O
+were	O
+identical	O
+to	O
+their	O
+corresponding	O
+patients	O
+and	O
+were	O
+grouped	O
+together	O
+within	O
+the	O
+larger	O
+MERS	O
+-	O
+CoV	O
+sequences	O
+cluster	O
+for	O
+human	B-SPEC
+and	O
+camel	B-SPEC
+isolates	O
+reported	O
+form	O
+the	O
+Arabian	O
+Peninsula	O
+.	O
+
+These	O
+findings	O
+indicate	O
+that	O
+camels	B-SPEC
+are	O
+a	O
+significant	O
+reservoir	O
+for	O
+the	O
+maintenance	O
+of	O
+MERS	O
+-	O
+CoVs	O
+,	O
+and	O
+they	O
+are	O
+an	O
+important	O
+source	O
+of	O
+human	B-SPEC
+infection	B-DISO
+with	O
+MERS	O
+.	O
+
+For	O
+the	O
+PEDV	B-SPEC
+diagnosis	O
+,	O
+a	O
+rapid	O
+test	O
+kit	B-FUNC
+that	O
+is	O
+specific	O
+and	O
+sensitive	O
+to	O
+PEDV	B-SPEC
+is	O
+critical	O
+to	O
+monitor	O
+this	O
+disease	O
+at	O
+pig	B-SPEC
+farms	O
+.	O
+
+ABSTRACT	O
+:	O
+A	O
+vaccine	O
+for	O
+equine	O
+coronavirus	B-SPEC
+(	O
+ECoV	O
+)	O
+is	O
+so	O
+far	O
+unavailable	O
+.	O
+
+While	O
+studies	O
+have	O
+reported	O
+cases	O
+of	O
+influenza	B-DISO
+infections	B-DISO
+acquired	O
+during	O
+travel	O
+,	O
+here	O
+we	O
+examine	O
+two	O
+cases	O
+of	O
+severe	O
+influenza	B-PATH
+infection	B-DISO
+contracted	O
+in	O
+the	O
+country	O
+of	O
+origin	O
+that	O
+led	O
+to	O
+diagnosis	O
+and	O
+therapeutic	O
+problems	O
+in	O
+the	O
+destination	O
+country	O
+.	O
+
+Cases	O
+of	O
+influenza	B-DISO
+acquired	O
+during	O
+travel	O
+have	O
+been	O
+reported	O
+in	O
+this	O
+literature	O
+,	O
+but	O
+no	O
+study	O
+has	O
+examined	O
+cases	O
+of	O
+influenza	B-DISO
+imported	O
+from	O
+the	O
+country	O
+of	O
+origin	O
+and	O
+developed	O
+while	O
+abroad	O
+.	O
+
+We	O
+used	O
+the	O
+electronic	O
+medical	O
+record	O
+to	O
+track	O
+SIRS	B-DISO
+criteria	O
+in	O
+patients	O
+days	O
+1	O
+to	O
+4	O
+posttrauma	O
+.	O
+
+81	O
+.	O
+4	O
+%	O
+(	O
+OI	O
+)	O
+and	O
+69	O
+.	O
+1	O
+%	O
+no	O
+orthopaedic	O
+injury	O
+reached	O
+the	O
+threshold	O
+for	O
+SIRS	B-DISO
+within	O
+their	O
+first	O
+4	O
+days	O
+of	O
+hospitalization	O
+.	O
+
+PCR	O
+detection	O
+showed	O
+that	O
+52	O
+.	O
+6	O
+%	O
+(	O
+61	O
+/	O
+116	O
+)	O
+of	O
+these	O
+samples	O
+were	O
+positive	O
+for	O
+PEDV	B-SPEC
+.	O
+
+Furthermore	O
+,	O
+sequencing	O
+results	O
+for	O
+the	O
+spike	O
+(	O
+S	O
+)	O
+genes	O
+from	O
+11	O
+of	O
+the	O
+epidemic	O
+PEDV	B-SPEC
+strains	O
+showed	O
+93	O
+-	O
+94	O
+%	O
+nucleotide	B-CHED
+identity	O
+and	O
+92	O
+-	O
+93	O
+%	O
+amino	B-CHED
+acid	I-CHED
+identity	O
+with	O
+the	O
+classical	O
+CV777	O
+strain	O
+.	O
+
+Additionally	O
+,	O
+we	O
+found	O
+that	O
+both	O
+DPP4	B-PRGE
+mRNA	I-PRGE
+and	O
+protein	B-PROC
+expression	B-PROC
+were	O
+inversely	O
+correlated	O
+with	O
+lung	B-PROC
+function	I-PROC
+and	O
+diffusing	O
+capacity	O
+parameters	O
+.	O
+
+These	O
+data	O
+also	O
+highlight	O
+a	O
+possible	O
+role	O
+of	O
+DPP4	B-PRGE
+in	O
+COPD	B-DISO
+pathogenesis	B-DISO
+.	O
+
+TITLE	O
+:	O
+A	O
+novel	O
+strain	O
+of	O
+porcine	B-SPEC
+deltacoronavirus	O
+in	O
+Vietnam	O
+.	O
+
+ABSTRACT	O
+:	O
+Two	O
+porcine	B-SPEC
+deltacoronavirus	O
+(	O
+PDCoV	O
+)	O
+strains	O
+(	O
+Binh21	O
+and	O
+HaNoi6	O
+)	O
+were	O
+isolated	O
+from	O
+two	O
+pig	O
+farms	O
+in	O
+North	O
+Vietnam	O
+.	O
+
+In	O
+light	O
+of	O
+the	O
+pathogenic	O
+mechanism	O
+of	O
+feline	B-SPEC
+coronavirus	B-SPEC
+that	O
+relies	O
+on	O
+endosomal	O
+acidification	B-PROC
+for	O
+cytoplasmic	B-COMP
+entry	O
+,	O
+a	O
+novel	O
+vacuolar	B-PRGE
+ATPase	B-ENZY
+blocker	O
+,	O
+diphyllin	O
+,	O
+and	O
+its	O
+nanoformulation	O
+are	O
+herein	O
+investigated	O
+for	O
+their	O
+antiviral	B-CHED
+activity	O
+against	O
+the	O
+type	O
+II	O
+feline	B-DISO
+infectious	I-DISO
+peritonitis	I-DISO
+virus	B-SPEC
+(	O
+FIPV	O
+).	O
+
+ABSTRACT	O
+:	O
+Middle	O
+East	O
+respiratory	O
+syndrome	O
+-	O
+associated	O
+coronavirus	B-SPEC
+(	O
+MERS	O
+-	O
+CoV	O
+)	O
+has	O
+been	O
+a	O
+significant	O
+research	O
+focus	O
+since	O
+its	O
+discovery	O
+in	O
+2012	O
+.	O
+
+TITLE	O
+:	O
+HIV	B-SPEC
+positive	O
+patient	O
+with	O
+GBS	B-DISO
+-	O
+like	O
+syndrome	B-DISO
+.	O
+
+The	O
+prevalence	O
+of	O
+MERS	O
+-	O
+CoV	O
+infections	B-DISO
+across	O
+the	O
+Gulf	O
+Corporation	O
+Council	O
+(	O
+GCC	O
+)	O
+countries	O
+still	O
+remains	O
+unclear	O
+.	O
+
+The	O
+first	O
+MERS	O
+case	O
+of	O
+Korea	O
+was	O
+reported	O
+on	O
+20	O
+May	O
+2015	O
+,	O
+and	O
+since	O
+then	O
+,	O
+the	O
+MERS	O
+outbreak	O
+in	O
+Korea	O
+has	O
+resulted	O
+in	O
+hundreds	O
+of	O
+confirmed	O
+cases	O
+and	O
+tens	O
+of	O
+deaths	B-PROC
+.	O
+
+None	O
+of	O
+the	O
+patients	O
+had	O
+MERS	O
+-	O
+CoV	O
+but	O
+influenza	B-SPEC
+viruses	I-SPEC
+were	O
+detected	O
+in	O
+12	O
+.	O
+7	O
+%	O
+with	O
+high	O
+circulation	B-PROC
+of	O
+influenza	B-PATH
+A	I-PATH
+/	O
+H1N1	O
+(	O
+47	O
+.	O
+1	O
+%).	O
+
+TITLE	O
+:	O
+Influenza	B-DISO
+is	O
+more	O
+common	O
+than	O
+Middle	O
+East	O
+Respiratory	O
+Syndrome	B-DISO
+Coronavirus	B-SPEC
+(	O
+MERS	O
+-	O
+CoV	O
+)	O
+among	O
+hospitalized	O
+adult	O
+Saudi	O
+patients	O
+.	O
+
+All	O
+admitted	O
+patients	O
+with	O
+community	B-DISO
+acquired	I-DISO
+pneumonia	I-DISO
+from	O
+2012	O
+to	O
+2016	O
+were	O
+tested	O
+for	O
+MERS	O
+-	O
+CoV	O
+.	O
+In	O
+addition	O
+,	O
+testing	O
+for	O
+influenza	B-SPEC
+viruses	I-SPEC
+was	O
+carried	O
+out	O
+starting	O
+April	O
+2015	O
+.	O
+
+From	O
+January	O
+2015	O
+to	O
+December	O
+2016	O
+,	O
+a	O
+total	O
+of	O
+1644	O
+patients	O
+were	O
+tested	O
+for	O
+both	O
+MERS	O
+-	O
+CoV	O
+and	O
+influenza	B-DISO
+.	O
+
+Despite	O
+antimalarial	B-CHED
+treatment	O
+,	O
+lethality	O
+rates	O
+of	O
+MA	O
+-	O
+ARDS	B-DISO
+are	O
+still	O
+between	O
+20	O
+and	O
+80	O
+%.	O
+
+Depletion	O
+of	O
+pathogenic	O
+CD8	B-PRGE
+
+ABSTRACT	O
+:	O
+Cigarette	O
+smoking	O
+is	O
+associated	O
+with	O
+increased	O
+risk	O
+of	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+(	O
+ARDS	B-DISO
+)	O
+in	O
+patients	O
+after	O
+severe	O
+trauma	O
+;	O
+however	O
+,	O
+the	O
+mechanisms	O
+underlying	O
+this	O
+association	O
+are	O
+unknown	O
+.	O
+
+ABSTRACT	O
+:	O
+While	O
+dromedary	B-SPEC
+camels	B-SPEC
+are	O
+the	O
+immediate	O
+animal	B-SPEC
+source	O
+of	O
+MERS	O
+coronavirus	B-SPEC
+(	O
+MERS	O
+-	O
+CoV	O
+)	O
+infection	B-DISO
+,	O
+the	O
+evolutionary	O
+origin	O
+of	O
+MERS	O
+-	O
+CoV	O
+remains	O
+obscure	O
+.	O
+
+Phylogenetic	O
+analysis	O
+showed	O
+that	O
+5	O
+and	O
+214	O
+strains	O
+belong	O
+to	O
+clade	O
+A	O
+and	O
+B	O
+,	O
+respectively	O
+,	O
+with	O
+clade	O
+A	O
+further	O
+divided	O
+into	O
+lineage	O
+A1	O
+(	O
+3	O
+human	B-SPEC
+strains	O
+)	O
+and	O
+lineage	O
+A2	O
+(	O
+2	O
+camel	B-SPEC
+strains	O
+),	O
+and	O
+clade	O
+B	O
+divided	O
+into	O
+B1	O
+to	O
+B6	O
+(	O
+each	O
+containing	O
+both	O
+human	B-SPEC
+and	O
+camel	B-SPEC
+strains	O
+).	O
+
+These	O
+post	B-PROC
+-	I-PROC
+translational	I-PROC
+modifications	I-PROC
+may	O
+assist	O
+in	O
+protein	B-PROC
+folding	I-PROC
+and	O
+play	O
+important	O
+roles	O
+in	O
+the	O
+functionality	O
+of	O
+S	B-PRGE
+protein	I-PRGE
+.	O
+
+Nsp8	O
+has	O
+been	O
+reported	O
+to	O
+interact	O
+with	O
+nsp7	O
+and	O
+functions	O
+as	O
+a	O
+primase	B-PRGE
+synthesizing	O
+RNA	O
+primers	O
+for	O
+nsp12	O
+.	O
+
+With	O
+the	O
+ongoing	O
+outbreaks	O
+of	O
+measles	B-PATH
+in	O
+Europe	O
+,	O
+it	O
+is	O
+recommended	O
+that	O
+all	O
+pilgrims	O
+have	O
+an	O
+updated	O
+immunization	O
+against	O
+vaccine	O
+-	O
+preventable	O
+diseases	O
+(	O
+diphtheria	B-DISO
+,	O
+tetanus	B-DISO
+,	O
+pertussis	B-PATH
+,	O
+polio	B-DISO
+,	O
+measles	B-PATH
+and	O
+mumps	B-DISO
+).	O
+
+To	O
+investigate	O
+the	O
+presence	O
+of	O
+viruses	B-SPEC
+associated	O
+with	O
+influenza	B-DISO
+-	O
+like	O
+illnesses	O
+(	O
+ILI	O
+)	O
+in	O
+Uganda	O
+.	O
+
+It	O
+remains	O
+unclear	O
+whether	O
+certain	O
+types	O
+of	O
+cases	O
+were	O
+more	O
+likely	O
+to	O
+cause	O
+secondary	B-DISO
+infections	I-DISO
+than	O
+others	O
+,	O
+and	O
+if	O
+so	O
+,	O
+why	O
+.	O
+
+Our	O
+objective	O
+was	O
+to	O
+characterize	O
+sedation	B-DISO
+management	O
+in	O
+adult	O
+patients	O
+with	O
+severe	O
+respiratory	B-DISO
+distress	I-DISO
+syndrome	I-DISO
+(	O
+ARDS	B-DISO
+)	O
+treated	O
+with	O
+venovenous	O
+extracorporeal	O
+membrane	B-COMP
+oxygenation	B-PROC
+(	O
+VV	O
+-	O
+ECMO	O
+).	O
+
+Forty	O
+-	O
+five	O
+adults	O
+(	O
+33	O
+males	O
+,	O
+median	O
+age	O
+47	O
+years	O
+;	O
+interquartile	O
+range	O
+[	O
+IQR	O
+],	O
+35	O
+-	O
+56	O
+])	O
+with	O
+ARDS	B-DISO
+(	O
+median	O
+PaO2	O
+/	O
+FiO2	O
+71	O
+;	O
+IQR	O
+59	O
+-	O
+83	O
+)	O
+because	O
+of	O
+respiratory	B-DISO
+infection	I-DISO
+(	O
+91	O
+%)	O
+were	O
+treated	O
+with	O
+VV	O
+-	O
+ECMO	O
+for	O
+a	O
+median	O
+of	O
+11	O
+days	O
+(	O
+IQR	O
+,	O
+7	O
+-	O
+17	O
+).	O
+
+ABSTRACT	O
+:	O
+Coronaviruses	O
+(	O
+CoVs	O
+)	O
+are	O
+positive	O
+-	O
+sense	B-PROC
+RNA	O
+viruses	B-SPEC
+that	O
+infect	O
+numerous	O
+mammalian	B-SPEC
+and	O
+avian	B-SPEC
+species	B-SPEC
+and	O
+are	O
+capable	O
+of	O
+causing	O
+severe	O
+and	O
+lethal	O
+disease	O
+in	O
+humans	B-SPEC
+.	O
+
+Outside	O
+of	O
+the	O
+order	B-SPEC
+
+TITLE	O
+:	O
+Development	B-PROC
+of	O
+Middle	O
+East	O
+Respiratory	O
+Syndrome	B-DISO
+Coronavirus	B-SPEC
+vaccines	O
+-	O
+advances	O
+and	O
+challenges	O
+.	O
+
+TITLE	O
+:	O
+Difficulties	O
+in	O
+using	O
+personal	O
+protective	O
+equipment	O
+:	O
+Training	O
+experiences	O
+with	O
+the	O
+2015	O
+outbreak	O
+of	O
+Middle	O
+East	O
+respiratory	O
+syndrome	B-DISO
+in	O
+Korea	O
+.	O
+
+ABSTRACT	O
+:	O
+This	O
+study	O
+aimed	O
+to	O
+evaluate	O
+practical	O
+barriers	O
+to	O
+personal	O
+protective	O
+equipment	O
+(	O
+PPE	B-CHED
+)	O
+use	O
+found	O
+through	O
+health	O
+care	O
+personnel	O
+(	O
+HCP	B-DISO
+)	O
+training	O
+sessions	O
+held	O
+during	O
+and	O
+after	O
+the	O
+2015	O
+Middle	O
+East	O
+respiratory	O
+syndrome	B-DISO
+outbreak	O
+in	O
+Korea	O
+.	O
+
+Presence	O
+of	O
+influenza	B-PATH
+A	I-PATH
+and	O
+B	O
+,	O
+parainfluenza	B-DISO
+1	O
+,	O
+2	O
+,	O
+3	O
+and	O
+4	O
+,	O
+human	B-SPEC
+adeno	O
+-,	O
+boca	B-DISO
+-,	O
+corona	B-CHED
+-,	O
+metapneumo	O
+-,	O
+rhino	O
+-	O
+and	O
+respiratory	O
+syncytial	O
+viruses	B-SPEC
+was	O
+determined	O
+by	O
+real	O
+-	O
+time	O
+PCR	O
+.	O
+
+CONCLUSIONS	O
+:	O
+In	O
+a	O
+randomized	O
+study	O
+of	O
+84	O
+496	O
+elderly	O
+individuals	O
+with	O
+a	O
+high	O
+uptake	O
+of	O
+influenza	B-DISO
+vaccination	O
+,	O
+PCV13	O
+was	O
+not	O
+associated	O
+with	O
+a	O
+statistically	O
+significant	O
+reduction	O
+of	O
+influenza	B-DISO
+or	O
+virus	B-SPEC
+-	O
+associated	O
+CAP	B-DISO
+.	O
+
+This	O
+review	O
+focuses	O
+on	O
+the	O
+epidemiology	O
+,	O
+pathogenesis	B-DISO
+and	O
+clinical	O
+characteristics	O
+among	O
+SARS	B-DISO
+-	O
+coronaviruses	O
+(	O
+CoV	O
+),	O
+MERS	O
+-	O
+CoV	O
+and	O
+other	O
+HCoV	O
+infections	B-DISO
+.	O
+
+Cases	O
+were	O
+verified	O
+and	O
+associations	O
+between	O
+cases	O
+were	O
+substantiated	O
+through	O
+an	O
+extensive	O
+literature	O
+review	O
+and	O
+the	O
+Armed	O
+Forces	O
+Health	O
+Surveillance	O
+Branch	B-ANAT
+'	O
+s	O
+Tiered	O
+Source	O
+Classification	O
+System	O
+.	O
+
+Clusters	B-CHED
+corresponded	O
+temporally	O
+with	O
+the	O
+majority	O
+of	O
+periods	B-PROC
+of	O
+greatest	O
+incidence	O
+,	O
+suggesting	O
+a	O
+strong	O
+correlation	O
+between	O
+nosocomial	O
+transmission	O
+and	O
+notable	O
+increases	O
+in	O
+cases	O
+.	O
+
+TITLE	O
+:	O
+Prone	O
+Position	O
+for	O
+Acute	B-DISO
+Respiratory	I-DISO
+Distress	I-DISO
+Syndrome	I-DISO
+.	O
+
+This	O
+review	O
+evaluates	O
+the	O
+effect	O
+of	O
+prone	O
+positioning	O
+on	O
+28	O
+-	O
+day	O
+mortality	O
+(	O
+primary	O
+outcome	O
+)	O
+compared	O
+with	O
+conventional	O
+mechanical	O
+ventilation	O
+in	O
+the	O
+supine	O
+position	O
+for	O
+adults	O
+with	O
+ARDS	B-DISO
+.	O
+
+TITLE	O
+:	O
+CD59	B-PRGE
+association	O
+with	O
+infectious	B-DISO
+bronchitis	B-DISO
+virus	B-COMP
+particles	I-COMP
+protects	O
+against	O
+antibody	B-COMP
+-	I-PRGE
+dependent	I-PRGE
+complement	I-PRGE
+-	I-PRGE
+mediated	O
+lysis	O
+.	O
+
+TITLE	O
+:	O
+Prevalence	O
+of	O
+respiratory	O
+viruses	B-SPEC
+in	O
+Iranian	O
+patients	O
+with	O
+idiopathic	B-DISO
+pulmonary	I-DISO
+fibrosis	I-DISO
+.	O
+
+Furthermore	O
+,	O
+dendritic	B-ANAT
+cells	B-COMP
+(	O
+DCs	B-DISO
+),	O
+professional	O
+antigen	B-ANAT
+-	I-ANAT
+presenting	I-ANAT
+cells	B-COMP
+,	O
+link	O
+humoral	O
+and	O
+cellular	B-PROC
+immune	I-PROC
+responses	I-PROC
+for	O
+homeostasis	B-PROC
+of	O
+the	O
+intestinal	B-ANAT
+immune	O
+environment	O
+.	O
+
+The	O
+patient	O
+'	O
+s	O
+IOP	O
+on	O
+the	O
+first	O
+post	O
+-	O
+operative	O
+day	O
+was	O
+13	O
+mmHg	O
+,	O
+and	O
+anterior	B-DISO
+chamber	I-DISO
+inflammation	I-DISO
+was	O
+noted	O
+to	O
+be	O
+significantly	O
+reduced	O
+at	O
+post	O
+-	O
+operative	O
+week	O
+2	O
+.	O
+
+PdCoV	B-PRGE
+S1	I-PRGE
+-	I-PRGE
+CTD	I-PRGE
+binds	B-FUNC
+to	O
+an	O
+unidentified	O
+receptor	O
+on	O
+host	B-COMP
+cell	I-COMP
+surfaces	O
+.	O
+
+TITLE	O
+:	O
+Risk	O
+stratification	O
+using	O
+SpO	O
+ABSTRACT	O
+:	O
+We	O
+assessed	O
+the	O
+potential	O
+of	O
+risk	O
+stratification	O
+of	O
+ARDS	B-DISO
+patients	O
+using	O
+SpO	O
+We	O
+used	O
+data	O
+from	O
+a	O
+prospective	O
+observational	O
+study	O
+in	O
+patients	O
+admitted	O
+to	O
+a	O
+mixed	O
+medical	O
+-	O
+surgical	O
+intensive	O
+care	O
+unit	O
+of	O
+a	O
+university	O
+hospital	O
+in	O
+the	O
+Netherlands	O
+.	O
+
+Among	O
+all	O
+groups	O
+,	O
+VAC	O
+-	O
+IM	O
+-	O
+2b	O
+pigs	O
+had	O
+significantly	O
+higher	O
+anti	B-PRGE
+-	I-PRGE
+PEDV	I-PRGE
+IgG	I-PRGE
+levels	O
+on	O
+dpv	O
+21	O
+and	O
+28	O
+while	O
+EXP	B-PRGE
+-	I-PRGE
+ORAL	I-PRGE
+-	I-PRGE
+1b	I-PRGE
+pigs	B-SPEC
+had	O
+significantly	O
+higher	O
+anti	B-PRGE
+-	I-PRGE
+PEDV	I-PRGE
+IgA	I-PRGE
+levels	O
+on	O
+dpv	O
+14	O
+,	O
+21	O
+,	O
+28	O
+and	O
+35	O
+.	O
+
+The	O
+pool	O
+of	O
+data	O
+on	O
+treatment	O
+possibilities	O
+for	O
+patients	O
+with	O
+ARDS	B-DISO
+grows	O
+every	O
+year	O
+,	O
+with	O
+specifically	O
+designed	O
+mechanical	O
+ventilation	O
+strategies	O
+.	O
+
+The	O
+increasing	O
+incidence	O
+of	O
+hospital	O
+-	O
+acquired	O
+infections	B-DISO
+caused	O
+by	O
+antibiotic	B-CHED
+resistant	O
+pathogens	O
+could	O
+be	O
+minimized	O
+by	O
+point	O
+-	O
+of	O
+-	O
+care	O
+microbial	O
+analysis	O
+as	O
+well	O
+as	O
+rapid	O
+screening	O
+tests	O
+of	O
+bacteria	B-SPEC
+resistance	B-PROC
+.	O
+
+These	O
+findings	O
+suggest	O
+the	O
+need	O
+for	O
+an	O
+accurate	O
+knowledge	O
+of	O
+live	O
+vaccine	O
+kinetics	O
+,	O
+whose	O
+replication	O
+can	O
+compete	O
+with	O
+the	O
+other	O
+pathogen	O
+one	O
+,	O
+providing	O
+additional	O
+protection	O
+to	O
+be	O
+added	O
+to	O
+what	O
+is	O
+conferred	O
+by	O
+the	O
+adaptive	B-PROC
+immune	I-PROC
+response	I-PROC
+.	O
+
+One	O
+hundred	O
+and	O
+sixty	O
+consecutive	O
+patients	O
+with	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+refractory	O
+to	O
+conventional	O
+treatment	O
+requiring	O
+veno	O
+-	O
+venous	B-ANAT
+(	O
+VV	O
+)-	O
+ECMO	O
+.	O
+
+Recently	O
+developed	O
+rapid	O
+diagnostic	O
+molecular	O
+tests	O
+may	O
+clarify	O
+the	O
+epidemiology	O
+of	O
+these	O
+viruses	B-SPEC
+and	O
+have	O
+potential	O
+,	O
+through	O
+early	O
+identification	O
+,	O
+to	O
+limit	O
+the	O
+severity	O
+of	O
+outbreaks	O
+among	O
+older	O
+adults	O
+living	O
+in	O
+LTCFs	O
+.	O
+
+ABSTRACT	O
+:	O
+Ten	O
+reference	O
+genes	O
+were	O
+investigated	O
+for	O
+normalisation	O
+of	O
+candidate	O
+target	O
+gene	B-PROC
+expression	I-PROC
+data	O
+in	O
+the	O
+shell	B-ANAT
+gland	I-ANAT
+and	O
+spleen	B-ANAT
+of	O
+laying	O
+hens	O
+challenged	O
+with	O
+two	O
+strains	O
+of	O
+infectious	B-DISO
+bronchitis	B-DISO
+virus	B-SPEC
+(	O
+IBV	B-SPEC
+).	O
+
+In	O
+the	O
+combined	O
+data	O
+set	O
+of	O
+IBV	B-SPEC
+challenged	O
+shell	B-ANAT
+gland	I-ANAT
+samples	O
+,	O
+the	O
+comprehensive	O
+ranking	O
+showed	O
+TATA	B-PRGE
+-	I-PRGE
+box	I-PRGE
+binding	I-PRGE
+protein	B-CHED
+(	O
+TBP	B-PRGE
+)	O
+and	O
+tyrosine	B-PRGE
+3	I-PRGE
+-	I-PRGE
+monooxygenase	I-PRGE
+/	O
+tryptophan	B-PRGE
+5	I-PRGE
+-	I-PRGE
+monooxygenase	I-PRGE
+activation	I-PRGE
+protein	B-CHED
+zeta	B-SPEC
+(	O
+YWHAZ	B-PRGE
+)	O
+as	O
+the	O
+two	O
+most	O
+stable	O
+,	O
+and	O
+succinate	B-PRGE
+dehydrogenase	I-PRGE
+complex	I-PRGE
+flavoprotein	B-CHED
+subunit	I-PRGE
+A	I-PRGE
+(	O
+SDHA	B-PRGE
+)	O
+and	O
+albumin	B-PRGE
+(	O
+ALB	B-PRGE
+)	O
+as	O
+the	O
+two	O
+least	O
+stable	O
+reference	O
+genes	O
+.	O
+
+The	O
+two	O
+most	O
+and	O
+least	O
+stable	O
+reference	O
+genes	O
+obtained	O
+in	O
+the	O
+study	O
+,	O
+were	O
+further	O
+used	O
+for	O
+candidate	O
+target	O
+gene	B-PROC
+expression	I-PROC
+data	O
+normalisation	O
+of	O
+the	O
+shell	B-ANAT
+gland	I-ANAT
+and	O
+spleen	B-ANAT
+under	O
+an	O
+IBV	B-SPEC
+infection	B-DISO
+model	O
+.	O
+
+Mechanically	O
+ventilated	O
+patients	O
+with	O
+severe	B-DISO
+sepsis	I-DISO
+or	O
+septic	B-DISO
+shock	I-DISO
+and	O
+acute	O
+lung	B-ANAT
+injury	O
+or	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+were	O
+eligible	O
+for	O
+study	O
+inclusion	O
+.	O
+
+Our	O
+objective	O
+was	O
+to	O
+investigate	O
+the	O
+factors	O
+that	O
+influence	O
+the	O
+inflammatory	B-DISO
+response	I-DISO
+of	O
+patients	O
+with	O
+ARDS	B-DISO
+undergoing	O
+VV	O
+ECMO	O
+,	O
+and	O
+to	O
+analyse	O
+the	O
+impact	O
+of	O
+this	O
+response	O
+on	O
+hospital	O
+mortality	O
+.	O
+
+Their	O
+median	O
+Sequential	O
+Organ	B-DISO
+Failure	I-DISO
+Assessment	O
+score	O
+was	O
+12	O
+,	O
+PaO	B-PROC
+CONCLUSIONS	O
+:	O
+Cytokine	O
+levels	O
+,	O
+on	O
+average	O
+,	O
+fall	O
+rapidly	O
+after	O
+initiation	O
+of	O
+VV	O
+ECMO	O
+,	O
+which	O
+may	O
+be	O
+related	O
+to	O
+the	O
+reduction	O
+of	O
+invasiveness	O
+of	O
+mechanical	O
+ventilation	O
+.	O
+
+In	O
+viral	B-DISO
+infections	I-DISO
+,	O
+viruses	B-SPEC
+exploit	O
+receptor	O
+-	O
+ligand	B-PROC
+interactions	O
+to	O
+latch	O
+onto	O
+cellular	B-COMP
+exterior	O
+prior	O
+to	O
+subsequent	O
+entry	O
+and	O
+invasion	B-DISO
+.	O
+
+Patient	O
+demographics	O
+,	O
+length	O
+of	O
+ventilations	O
+days	O
+,	O
+number	O
+of	O
+intensive	O
+care	O
+unit	O
+(	O
+ICU	O
+)	O
+admission	O
+days	O
+,	O
+chest	B-ANAT
+radiographic	O
+score	O
+,	O
+chest	B-ANAT
+radiographic	O
+deterioration	O
+pattern	O
+(	O
+Types	O
+1	O
+-	O
+4	O
+)	O
+and	O
+peak	O
+lactate	B-PRGE
+dehydrogenase	I-PRGE
+level	O
+were	O
+compared	O
+between	O
+the	O
+two	O
+groups	O
+using	O
+the	O
+student	O
+Follow	O
+-	O
+up	O
+chest	B-ANAT
+radiographs	O
+were	O
+normal	O
+in	O
+23	O
+out	O
+of	O
+36	O
+(	O
+64	O
+%)	O
+patients	O
+.	O
+
+Significantly	O
+greater	O
+number	O
+of	O
+ICU	O
+admission	O
+days	O
+,	O
+older	O
+age	O
+,	O
+higher	O
+chest	B-ANAT
+radiographic	O
+scores	O
+,	O
+chest	B-ANAT
+radiographic	O
+deterioration	O
+patterns	O
+and	O
+peak	O
+lactate	B-PRGE
+dehydrogenase	I-PRGE
+levels	O
+were	O
+noted	O
+in	O
+the	O
+patients	O
+with	O
+lung	B-DISO
+fibrosis	I-DISO
+on	O
+follow	O
+-	O
+up	O
+chest	B-ANAT
+radiographs	O
+after	O
+recovery	O
+from	O
+MERS	O
+-	O
+CoV	O
+.	O
+
+ABSTRACT	O
+:	O
+To	O
+investigate	O
+the	O
+long	O
+-	O
+term	O
+efficacy	O
+of	O
+a	O
+combination	O
+treatment	O
+of	O
+alendronate	B-CHED
+,	O
+extracorporeal	O
+shock	O
+and	O
+hyperbaric	O
+oxygen	B-CHED
+for	O
+osteonecrosis	B-DISO
+of	O
+the	O
+femoral	B-ANAT
+head	I-ANAT
+(	O
+ONFH	O
+)	O
+of	O
+post	O
+-	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+(	O
+SARS	B-DISO
+)	O
+patients	O
+.	O
+
+Epidemiological	O
+investigations	O
+show	O
+that	O
+piglet	O
+diarrhea	B-DISO
+is	O
+often	O
+caused	O
+by	O
+mixed	B-DISO
+infections	I-DISO
+,	O
+but	O
+the	O
+mechanisms	O
+by	O
+which	O
+multiple	O
+microorganisms	O
+cause	O
+disease	O
+are	O
+unclear	O
+.	O
+
+The	O
+results	O
+advance	O
+the	O
+understanding	O
+of	O
+coinfection	B-DISO
+and	O
+its	O
+role	O
+in	O
+causing	O
+piglet	O
+diarrhea	B-DISO
+.	O
+
+A	O
+57	O
+-	O
+year	O
+-	O
+old	O
+woman	O
+with	O
+septic	B-DISO
+shock	I-DISO
+related	O
+to	O
+<	O
+italic	O
+>	O
+Legionella	B-SPEC
+pneumophila	I-SPEC
+</	O
+italic	O
+>	O
+pneumonia	B-DISO
+complicated	O
+by	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+and	O
+acute	O
+kidney	B-ANAT
+injury	O
+who	O
+required	O
+renal	B-ANAT
+replacement	O
+therapy	O
+for	O
+75	O
+days	O
+.	O
+
+Data	O
+from	O
+humans	B-SPEC
+are	O
+more	O
+conflicting	O
+.	O
+
+TITLE	O
+:	O
+Glycan	B-CHED
+Shield	O
+and	O
+Fusion	O
+Activation	O
+of	O
+a	O
+Deltacoronavirus	O
+Spike	O
+Glycoprotein	B-CHED
+Fine	O
+-	O
+Tuned	O
+for	O
+Enteric	O
+Infections	O
+.	O
+
+They	O
+utilize	O
+the	O
+spike	B-PRGE
+(	I-PRGE
+S	I-PRGE
+)	I-PRGE
+glycoprotein	I-PRGE
+anchored	O
+in	O
+the	O
+viral	B-COMP
+envelope	I-COMP
+to	O
+mediate	O
+host	B-COMP
+attachment	O
+and	O
+fusion	O
+of	O
+the	O
+viral	O
+and	O
+cellular	B-COMP
+membranes	B-ANAT
+to	O
+initiate	O
+infection	B-DISO
+.	O
+
+A	O
+U	O
+.	O
+S	O
+.	O
+virulent	O
+PEDV	B-SPEC
+isolate	O
+was	O
+used	O
+to	O
+inoculate	O
+50	O
+kg	O
+swine	B-SPEC
+feed	O
+,	O
+which	O
+was	O
+mixed	O
+,	O
+conveyed	O
+,	O
+and	O
+discharged	O
+into	O
+bags	O
+using	O
+pilot	O
+-	O
+scale	O
+feed	O
+manufacturing	O
+equipment	O
+.	O
+
+Environmental	O
+swabs	O
+indicated	O
+complete	O
+contamination	O
+of	O
+animal	O
+food	O
+-	O
+contact	O
+surfaces	O
+(	O
+0	O
+/	O
+40	O
+vs	O
+.	O
+48	O
+/	O
+48	O
+,	O
+positive	O
+baseline	O
+samples	O
+/	O
+total	O
+baseline	O
+samples	O
+,	O
+positive	O
+subsequent	O
+samples	O
+/	O
+total	O
+subsequent	O
+samples	O
+,	O
+respectively	O
+;	O
+P	O
+<	O
+0	O
+.	O
+05	O
+)	O
+and	O
+near	O
+complete	O
+contamination	O
+of	O
+non	O
+-	O
+animal	B-SPEC
+food	O
+-	O
+contact	O
+surfaces	O
+(	O
+0	O
+/	O
+24	O
+vs	O
+.	O
+16	O
+/	O
+18	O
+,	O
+positive	O
+baseline	O
+samples	O
+/	O
+total	O
+baseline	O
+samples	O
+,	O
+positive	O
+subsequent	O
+samples	O
+/	O
+total	O
+subsequent	O
+samples	O
+,	O
+respectively	O
+;	O
+P	O
+<	O
+0	O
+.	O
+05	O
+).	O
+
+Thus	O
+NMR	O
+based	O
+metabolomics	O
+has	O
+provided	O
+new	O
+insight	O
+into	O
+ARDS	B-DISO
+sub	O
+-	O
+stages	O
+and	O
+conclusively	O
+a	O
+precise	O
+biomarker	B-CHED
+model	O
+proposed	O
+,	O
+reflecting	O
+underlying	O
+metabolic	B-PROC
+dysfunction	O
+aiding	O
+prior	O
+clinical	O
+decision	O
+making	O
+.	O
+
+Dengue	B-DISO
+fever	I-DISO
+remains	O
+an	O
+important	O
+public	O
+health	O
+concern	O
+,	O
+with	O
+at	O
+least	O
+eight	O
+countries	O
+in	O
+the	O
+region	O
+being	O
+endemic	O
+for	O
+the	O
+disease	O
+.	O
+
+TITLE	O
+:	O
+Discovery	O
+of	O
+a	O
+novel	O
+swine	B-SPEC
+enteric	O
+alphacoronavirus	B-SPEC
+(	O
+SeACoV	O
+)	O
+in	O
+southern	O
+China	O
+.	O
+
+Although	O
+several	O
+studies	O
+have	O
+investigated	O
+the	O
+molecular	O
+aspects	O
+and	O
+host	B-COMP
+immune	B-PROC
+response	I-PROC
+to	O
+PEDV	B-SPEC
+,	O
+there	O
+are	O
+little	O
+data	O
+on	O
+the	O
+impact	O
+of	O
+PEDV	B-SPEC
+on	O
+pig	B-SPEC
+intestinal	B-ANAT
+physiology	O
+.	O
+
+TITLE	O
+:	O
+Poly	O
+(	O
+d	O
+,	O
+l	O
+-	O
+lactide	O
+-	O
+co	O
+-	O
+glycolide	O
+)	O
+nanoparticle	B-CHED
+-	O
+entrapped	O
+vaccine	O
+induces	O
+a	O
+protective	O
+immune	B-PROC
+response	I-PROC
+against	O
+porcine	B-SPEC
+epidemic	I-SPEC
+diarrhea	I-SPEC
+virus	B-DISO
+infection	I-DISO
+in	O
+piglets	O
+.	O
+
+Importantly	O
+,	O
+there	O
+was	O
+less	O
+piglet	O
+mortality	O
+in	O
+the	O
+group	O
+vaccinated	O
+with	O
+PLGA	B-CHED
+-	O
+KAg	O
+than	O
+in	O
+the	O
+groups	O
+vaccinated	O
+with	O
+KAg	O
+or	O
+201	O
+-	O
+KAg	O
+.	O
+
+Nasopharyngeal	B-ANAT
+swabs	O
+were	O
+randomly	O
+collected	O
+from	O
+steers	O
+(	O
+n	O
+=	O
+23	O
+)	O
+and	O
+assessed	O
+for	O
+the	O
+presence	O
+of	O
+infectious	B-DISO
+agents	O
+of	O
+BRD	O
+by	O
+PCR	O
+and	O
+/	O
+or	O
+RT	O
+-	O
+PCR	O
+assays	O
+.	O
+
+PCR	O
+or	O
+RT	O
+-	O
+PCR	O
+assays	O
+did	O
+not	O
+identify	O
+P	B-SPEC
+.	I-SPEC
+multocida	I-SPEC
+,	O
+M	B-SPEC
+.	I-SPEC
+bovis	I-SPEC
+,	O
+BoHV	B-SPEC
+-	I-SPEC
+1	I-SPEC
+,	O
+BVDV	B-SPEC
+,	O
+or	O
+BPIV	O
+-	O
+3	O
+from	O
+the	O
+nasopharyngeal	B-ANAT
+swabs	O
+.	O
+
+To	O
+assess	O
+the	O
+accuracy	O
+of	O
+combinations	O
+of	O
+clinical	O
+signs	O
+which	O
+predict	O
+hypoxaemia	O
+in	O
+pre	O
+-	O
+school	O
+children	O
+aged	O
+2	O
+months	O
+to	O
+5	O
+years	O
+with	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+in	O
+hospitals	O
+in	O
+Switzerland	O
+and	O
+Senegal	O
+.	O
+
+It	O
+exhibited	O
+potent	O
+inhibitions	O
+against	O
+wild	B-PRGE
+-	I-PRGE
+type	I-PRGE
+neuraminidases	I-PRGE
+from	I-PRGE
+group	I-PRGE
+1	I-PRGE
+(	O
+H5N1	B-DISO
+and	O
+H1N1	O
+)	O
+and	O
+group	O
+2	O
+(	O
+H7N9	O
+)	O
+subtypes	O
+with	O
+IC	O
+
+TITLE	O
+:	O
+VSIG4	B-PRGE
+inhibits	O
+proinflammatory	O
+macrophage	B-PROC
+activation	I-PROC
+by	O
+reprogramming	O
+mitochondrial	B-COMP
+pyruvate	B-CHED
+metabolism	I-PROC
+.	O
+
+TITLE	O
+:	O
+Discrepancies	O
+between	O
+feline	B-SPEC
+coronavirus	B-SPEC
+antibody	B-COMP
+and	O
+nucleic	B-CHED
+acid	I-CHED
+detection	O
+in	O
+effusions	B-DISO
+of	O
+cats	O
+with	O
+suspected	O
+feline	B-DISO
+infectious	I-DISO
+peritonitis	I-DISO
+.	O
+
+We	O
+subsequently	O
+identified	O
+novel	O
+amino	B-CHED
+acid	I-CHED
+changes	O
+within	O
+the	O
+RNA	B-PRGE
+-	I-PRGE
+dependent	I-PRGE
+RNA	I-PRGE
+polymerase	I-PRGE
+and	O
+nsp14	O
+of	O
+MHV	B-SPEC
+-	O
+ExoN	O
+(-)	O
+P250	O
+that	O
+partially	O
+accounted	O
+for	O
+the	O
+reduced	O
+susceptibility	O
+to	O
+nucleoside	B-CHED
+analogues	I-CHED
+.	O
+
+These	O
+results	O
+also	O
+support	O
+the	O
+hypothesis	O
+that	O
+high	O
+-	O
+fidelity	O
+replication	O
+is	O
+linked	O
+to	O
+CoV	O
+fitness	O
+and	O
+indicate	O
+that	O
+multiple	O
+replicase	B-PRGE
+proteins	I-PRGE
+could	O
+compensate	O
+for	O
+ExoN	O
+functions	O
+during	O
+replication	O
+.	O
+
+ABSTRACT	O
+:	O
+Avian	B-DISO
+infectious	I-DISO
+bronchitis	I-DISO
+caused	O
+by	O
+the	O
+infectious	B-DISO
+bronchitis	B-DISO
+virus	B-SPEC
+(	O
+IBV	B-SPEC
+),	O
+and	O
+mycoplasmosis	B-DISO
+caused	O
+by	O
+Mycoplasma	B-SPEC
+gallisepticum	I-SPEC
+(	O
+MG	O
+)	O
+are	O
+two	O
+major	O
+respiratory	B-DISO
+diseases	I-DISO
+in	O
+chickens	B-SPEC
+that	O
+have	O
+resulted	O
+in	O
+severe	O
+economic	O
+losses	O
+in	O
+the	O
+poultry	O
+industry	O
+.	O
+
+Surfactant	B-CHED
+replacement	O
+therapy	O
+may	O
+mitigate	O
+the	O
+symptoms	O
+of	O
+the	O
+disease	O
+by	O
+decreasing	O
+the	O
+surface	O
+tension	B-DISO
+of	O
+alveoli	B-ANAT
+and	O
+facilitating	O
+inflation	O
+.	O
+
+TITLE	O
+:	O
+No	O
+evidence	O
+of	O
+enteric	O
+viral	O
+involvement	O
+in	O
+the	O
+new	O
+neonatal	O
+porcine	B-SPEC
+diarrhoea	B-DISO
+syndrome	B-DISO
+in	O
+Danish	O
+pigs	O
+.	O
+
+Our	O
+detailed	O
+analyses	O
+of	O
+piglets	O
+from	O
+NNPDS	O
+-	O
+affected	O
+herds	O
+demonstrated	O
+that	O
+viruses	B-SPEC
+did	O
+not	O
+pose	O
+a	O
+significant	O
+contribution	O
+to	O
+NNPDS	O
+.	O
+
+TITLE	O
+:	O
+Diversity	O
+of	O
+Middle	O
+East	O
+respiratory	O
+syndrome	B-DISO
+coronaviruses	O
+in	O
+109	O
+dromedary	B-SPEC
+camels	B-SPEC
+based	O
+on	O
+full	O
+-	O
+genome	O
+sequencing	O
+,	O
+Abu	O
+Dhabi	O
+,	O
+United	O
+Arab	O
+Emirates	O
+.	O
+
+In	O
+all	O
+,	O
+109	O
+MERS	O
+-	O
+CoV	O
+-	O
+positive	O
+camels	B-SPEC
+were	O
+detected	O
+in	O
+week	O
+1	O
+,	O
+and	O
+a	O
+subset	O
+of	O
+positive	O
+camels	B-SPEC
+were	O
+sampled	O
+again	O
+weeks	O
+3	O
+through	O
+6	O
+.	O
+
+TITLE	O
+:	O
+Feline	B-SPEC
+coronavirus	B-SPEC
+antibody	B-COMP
+titer	O
+in	O
+cerebrospinal	B-ANAT
+fluid	I-ANAT
+from	O
+cats	B-SPEC
+with	O
+neurological	O
+signs	O
+.	O
+
+The	O
+inhibition	B-PROC
+of	O
+virus	B-PROC
+replication	I-PROC
+has	O
+been	O
+documented	O
+in	O
+cell	B-COMP
+culture	O
+against	O
+multiple	O
+viruses	B-SPEC
+by	O
+RNAi	B-PROC
+approach	O
+.	O
+
+Currently	O
+,	O
+siRNAs	O
+delivery	O
+has	O
+been	O
+improved	O
+by	O
+using	O
+advanced	O
+nanotechnology	O
+like	O
+lipid	B-CHED
+nanoparticles	B-CHED
+,	O
+inorganic	B-CHED
+nanoparticles	I-CHED
+and	O
+polymeric	O
+nanoparticles	B-CHED
+.	O
+
+In	O
+two	O
+other	O
+cases	O
+,	O
+anesthetic	O
+complications	O
+were	O
+identified	O
+as	O
+associated	O
+causes	O
+of	O
+death	B-PROC
+,	O
+the	O
+primary	O
+cause	O
+being	O
+intracerebral	B-DISO
+hemorrhage	I-DISO
+stroke	B-DISO
+and	O
+pulmonary	B-DISO
+hypertension	I-DISO
+.	O
+
+With	O
+venoarterial	O
+extracorporeal	O
+membrane	B-COMP
+oxygenation	B-PROC
+,	O
+a	O
+massive	O
+infusion	O
+of	O
+propofol	B-CHED
+successfully	O
+suppressed	O
+status	B-DISO
+epilepticus	I-DISO
+,	O
+and	O
+both	O
+the	O
+circulatory	B-DISO
+collapse	I-DISO
+and	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+gradually	O
+improved	O
+;	O
+venoarterial	O
+extracorporeal	O
+membrane	B-COMP
+oxygenation	B-PROC
+and	O
+propofol	B-CHED
+treatments	O
+were	O
+then	O
+terminated	O
+,	O
+and	O
+the	O
+patient	O
+was	O
+discharged	O
+without	O
+further	O
+disabilities	O
+.	O
+
+TITLE	O
+:	O
+A	O
+lethal	O
+case	O
+of	O
+mamushi	B-SPEC
+(	O
+ABSTRACT	O
+:	O
+We	O
+report	O
+a	O
+lethal	O
+case	O
+of	O
+a	O
+mamushi	B-SPEC
+(	O
+The	O
+patient	O
+died	B-PROC
+35	O
+days	O
+after	O
+the	O
+bite	B-PROC
+.	O
+
+The	O
+detection	O
+rates	O
+of	O
+influenza	B-DISO
+virus	I-SPEC
+were	O
+not	O
+significantly	O
+different	O
+among	O
+the	O
+three	O
+years	O
+studied	O
+,	O
+at	O
+5	O
+.	O
+3	O
+,	O
+6	O
+.	O
+0	O
+and	O
+6	O
+.	O
+3	O
+%	O
+for	O
+2013	O
+,	O
+2014	O
+and	O
+2015	O
+,	O
+respectively	O
+.	O
+
+However	O
+,	O
+eight	O
+domains	O
+of	O
+Nsp3	B-PRGE
+exist	O
+in	O
+all	O
+known	O
+CoVs	O
+:	O
+the	O
+ubiquitin	B-PRGE
+-	I-PRGE
+like	I-PRGE
+domain	I-PRGE
+1	I-PRGE
+(	O
+Ubl1	B-PRGE
+),	O
+the	O
+Glu	B-CHED
+-	O
+rich	O
+acidic	O
+domain	O
+(	O
+also	O
+called	O
+""""	O
+hypervariable	O
+region	O
+"""),"	O
+a	O
+macrodomain	O
+(	O
+also	O
+named	O
+""""	O
+X	O
+domain	O
+"""),"	O
+the	O
+ubiquitin	B-PRGE
+-	I-PRGE
+like	I-PRGE
+domain	I-PRGE
+2	I-PRGE
+(	O
+Ubl2	B-PRGE
+),	O
+the	O
+papain	B-PRGE
+-	I-PRGE
+like	I-PRGE
+protease	I-PRGE
+2	I-PRGE
+(	O
+PL2	B-PRGE
+
+Here	O
+,	O
+we	O
+investigated	O
+the	O
+genetic	O
+variability	O
+of	O
+H120	O
+and	O
+Ma5	O
+strains	O
+present	O
+in	O
+the	O
+IBV	B-SPEC
+vaccines	O
+from	O
+different	O
+Brazilian	O
+manufacturers	O
+.	O
+
+TITLE	O
+:	O
+Healthcare	O
+worker	O
+infected	O
+with	O
+Middle	O
+East	O
+Respiratory	O
+Syndrome	B-DISO
+during	O
+cardiopulmonary	B-ANAT
+resuscitation	O
+in	O
+Korea	O
+,	O
+2015	O
+.	O
+
+The	O
+possible	O
+routes	O
+of	O
+infection	B-DISO
+may	O
+include	O
+the	O
+following	O
+:	O
+respiratory	O
+invasion	B-DISO
+of	O
+aerosols	O
+contaminated	O
+with	O
+MERS	O
+-	O
+coronavirus	B-SPEC
+(	O
+MERS	O
+-	O
+CoV	O
+)	O
+through	O
+a	O
+gap	O
+between	O
+the	O
+face	B-DISO
+and	O
+mask	O
+;	O
+mucosal	B-ANAT
+exposure	O
+to	O
+sweat	B-ANAT
+contaminated	O
+with	O
+MERS	O
+-	O
+CoV	O
+;	O
+and	O
+contamination	O
+during	O
+doffing	O
+of	O
+personal	O
+protective	O
+equipment	O
+.	O
+
+The	O
+MERS	O
+guidelines	O
+should	O
+reflect	O
+this	O
+case	O
+to	O
+decrease	O
+the	O
+risk	O
+of	O
+infection	B-DISO
+during	O
+CPR	B-ENZY
+.	O
+
+She	O
+suggested	O
+that	O
+she	O
+was	O
+contaminated	O
+with	O
+the	O
+MERS	O
+patient	O
+'	O
+s	O
+body	B-ANAT
+fluids	I-ANAT
+by	O
+wiping	O
+away	O
+the	O
+sweat	B-ANAT
+from	O
+her	O
+face	B-DISO
+during	O
+the	O
+CPR	B-ENZY
+.	O
+
+TITLE	O
+:	O
+Avian	B-SPEC
+infectious	I-DISO
+bronchitis	I-DISO
+virus	B-SPEC
+disrupts	O
+the	O
+melanoma	B-PRGE
+differentiation	B-PROC
+associated	I-PRGE
+gene	I-PRGE
+5	I-PRGE
+(	O
+MDA5	B-PRGE
+)	O
+signaling	B-PROC
+pathway	I-PROC
+by	O
+cleavage	B-PROC
+of	O
+the	O
+adaptor	O
+protein	B-CHED
+MAVS	O
+.	O
+
+RIG	B-PRGE
+-	I-PRGE
+I	I-PRGE
+is	O
+considered	O
+to	O
+be	O
+absent	O
+in	O
+chickens	B-SPEC
+.	O
+
+ABSTRACT	O
+:	O
+Acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+(	O
+ARDS	B-DISO
+)	O
+results	O
+in	O
+vascular	B-ANAT
+leakage	B-DISO
+,	O
+inflammation	B-DISO
+and	O
+respiratory	B-DISO
+failure	I-DISO
+.	O
+
+Interferon	B-PRGE
+(	O
+IFN	O
+)	O
+beta	O
+-	O
+1a	O
+up	O
+-	O
+regulates	O
+the	O
+cell	B-COMP
+surface	I-COMP
+ecto	O
+-	O
+5	B-ENZY
+'-	I-ENZY
+nucleotidase	I-ENZY
+cluster	O
+of	O
+differentiation	B-PROC
+73	O
+(	O
+CD73	O
+),	O
+which	O
+increases	O
+adenosine	B-CHED
+levels	O
+,	O
+and	O
+IFN	B-PRGE
+beta	I-PRGE
+-	I-PRGE
+1	I-PRGE
+may	O
+,	O
+therefore	O
+,	O
+be	O
+a	O
+potential	O
+treatment	O
+for	O
+ARDS	B-DISO
+.	O
+
+In	O
+other	O
+regions	O
+,	O
+adults	O
+may	O
+also	O
+develop	O
+cerebral	B-DISO
+malaria	B-PATH
+but	O
+neurological	O
+sequelae	O
+in	O
+survivors	O
+are	O
+rare	O
+.	O
+
+Common	O
+complications	O
+included	O
+anemia	B-DISO
+(	O
+7	O
+.	O
+7	O
+%),	O
+mortality	O
+(	O
+6	O
+.	O
+6	O
+%),	O
+and	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+(	O
+6	O
+.	O
+6	O
+%).	O
+
+Then	O
+an	O
+advanced	O
+search	O
+was	O
+carried	O
+out	O
+using	O
+""""	O
+One	O
+Health	O
+""""	O
+in	O
+conjunction	O
+with	O
+the	O
+terms	O
+""""	O
+zoonosis	O
+""""	O
+and	O
+""""	O
+zoonoses	B-DISO
+""""	O
+in	O
+PubMed	O
+for	O
+the	O
+time	O
+period	O
+between	O
+January	O
+2007	O
+and	O
+December	O
+2014	O
+.	O
+
+Compared	O
+to	O
+masks	O
+,	O
+N95	O
+respirators	O
+conferred	O
+superior	O
+protection	O
+against	O
+CRI	O
+(	O
+RR	O
+=	O
+0	O
+.	O
+47	O
+;	O
+95	O
+%	O
+CI	O
+:	O
+0	O
+.	O
+36	O
+-	O
+0	O
+.	O
+62	O
+)	O
+and	O
+laboratory	O
+-	O
+confirmed	O
+bacterial	O
+(	O
+RR	O
+=	O
+0	O
+.	O
+46	O
+;	O
+95	O
+%	O
+CI	O
+:	O
+0	O
+.	O
+34	O
+-	O
+0	O
+.	O
+62	O
+),	O
+but	O
+not	O
+viral	B-DISO
+infections	I-DISO
+or	O
+ILI	O
+.	O
+
+ABSTRACT	O
+:	O
+The	O
+risk	O
+of	O
+the	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+(	O
+ARDS	B-DISO
+)	O
+is	O
+increased	O
+in	O
+passive	O
+and	O
+active	O
+smokers	O
+after	O
+blunt	O
+trauma	O
+.	O
+
+TITLE	O
+:	O
+Characterization	O
+of	O
+the	O
+complete	O
+genome	O
+,	O
+antigenicity	O
+,	O
+pathogenicity	O
+,	O
+tissue	B-PROC
+tropism	B-PROC
+,	O
+and	O
+shedding	O
+of	O
+a	O
+recombinant	O
+avian	O
+infectious	O
+bronchitis	O
+virus	B-SPEC
+with	O
+a	O
+ck	O
+/	O
+CH	O
+/	O
+LJL	O
+/	O
+140901	O
+-	O
+like	O
+backbone	B-ANAT
+and	O
+an	O
+S2	O
+fragment	O
+from	O
+a	O
+4	O
+/	O
+91	O
+-	O
+like	O
+virus	B-SPEC
+.	O
+
+In	O
+addition	O
+,	O
+pathogenicity	O
+tests	O
+demonstrated	O
+that	O
+isolate	O
+I1101	O
+/	O
+16	O
+was	O
+more	O
+pathogenic	O
+to	O
+1	O
+-	O
+day	O
+-	O
+old	O
+specific	O
+-	O
+pathogen	O
+-	O
+free	O
+chickens	B-SPEC
+than	O
+strain	O
+ck	O
+/	O
+CH	O
+/	O
+LJL	O
+/	O
+140901	O
+,	O
+according	O
+to	O
+analysis	O
+of	O
+the	O
+clinical	O
+signs	O
+,	O
+whereas	O
+strain	O
+ck	O
+/	O
+CH	O
+/	O
+LJL	O
+/	O
+140901	O
+exhibited	O
+prolonged	O
+replication	O
+and	O
+shedding	O
+after	O
+challenge	O
+compared	O
+with	O
+isolate	O
+I1101	O
+/	O
+16	O
+.	O
+
+TITLE	O
+:	O
+Middle	O
+East	O
+Respiratory	O
+Syndrome	B-DISO
+and	O
+Severe	B-DISO
+Acute	I-DISO
+Respiratory	I-DISO
+Syndrome	I-DISO
+:	O
+Current	O
+Therapeutic	O
+Options	O
+and	O
+Potential	O
+Targets	O
+for	O
+Novel	O
+Therapies	O
+.	O
+
+A	O
+literature	O
+search	O
+was	O
+performed	O
+covering	O
+pathogenesis	B-DISO
+,	O
+clinical	O
+features	O
+and	O
+therapeutics	O
+,	O
+clinically	O
+developed	O
+drugs	O
+for	O
+repurposing	O
+and	O
+novel	O
+drug	O
+targets	O
+.	O
+
+The	O
+patient	O
+'	O
+s	O
+pulse	B-PROC
+oximetry	O
+level	O
+remained	O
+in	O
+the	O
+seventies	O
+despite	O
+intubation	O
+and	O
+aggressive	B-DISO
+ventilator	O
+management	O
+.	O
+
+However	O
+,	O
+the	O
+causes	O
+of	O
+death	B-PROC
+in	O
+11	O
+patients	O
+who	O
+died	B-PROC
+within	O
+30	O
+days	O
+were	O
+generally	O
+not	O
+related	O
+to	O
+the	O
+procedural	O
+complications	O
+,	O
+but	O
+related	O
+to	O
+the	O
+serious	O
+clinical	O
+status	O
+before	O
+PCI	O
+.	O
+
+For	O
+the	O
+subgroup	O
+analyses	O
+including	O
+age	O
+,	O
+gender	O
+,	O
+extent	O
+of	O
+CAD	B-DISO
+,	O
+severe	O
+chronic	B-DISO
+kidney	I-DISO
+disease	I-DISO
+and	O
+heart	B-DISO
+failure	I-DISO
+,	O
+there	O
+was	O
+no	O
+significant	O
+interaction	O
+between	O
+the	O
+subgroup	O
+factors	O
+and	O
+the	O
+effect	O
+of	O
+the	O
+single	O
+-	O
+session	O
+strategy	O
+relative	O
+to	O
+the	O
+staged	O
+strategy	O
+for	O
+the	O
+primary	O
+outcome	O
+measure	O
+.	O
+
+For	O
+the	O
+subgroup	O
+analyses	O
+including	O
+age	O
+,	O
+gender	O
+,	O
+extent	O
+of	O
+CAD	B-DISO
+,	O
+severe	O
+chronic	B-DISO
+kidney	I-DISO
+disease	I-DISO
+and	O
+heart	B-DISO
+failure	I-DISO
+,	O
+there	O
+was	O
+no	O
+significant	O
+interaction	O
+between	O
+the	O
+subgroup	O
+factors	O
+and	O
+the	O
+effect	O
+of	O
+the	O
+single	O
+-	O
+session	O
+strategy	O
+relative	O
+to	O
+the	O
+staged	O
+strategy	O
+for	O
+the	O
+primary	O
+outcome	O
+measure	O
+.	O
+
+TITLE	O
+:	O
+Anaphylactic	B-DISO
+shock	I-DISO
+with	O
+methylprednisolone	B-CHED
+sodium	O
+succinate	O
+in	O
+a	O
+child	O
+with	O
+short	B-DISO
+bowel	B-ANAT
+syndrome	I-DISO
+and	O
+cow	O
+'	O
+s	O
+milk	O
+allergy	B-PROC
+.	O
+
+We	O
+describe	O
+the	O
+case	O
+of	O
+a	O
+25	O
+-	O
+year	O
+-	O
+old	O
+male	O
+who	O
+developed	O
+severe	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+after	O
+an	O
+uneventful	O
+laparoscopic	O
+appendectomy	O
+for	O
+a	O
+perforated	O
+appendix	B-ANAT
+,	O
+requiring	O
+mechanical	O
+ventilation	O
+in	O
+the	O
+intensive	O
+care	O
+unit	O
+.	O
+
+The	O
+findings	O
+of	O
+epidemiological	O
+and	O
+virological	O
+studies	O
+prompted	O
+us	O
+to	O
+hypothesize	O
+that	O
+the	O
+human	B-SPEC
+gastrointestinal	B-ANAT
+tract	I-ANAT
+could	O
+serve	O
+as	O
+an	O
+alternative	O
+route	O
+to	O
+acquire	O
+MERS	O
+-	O
+CoV	O
+infection	B-DISO
+.	O
+
+ABSTRACT	O
+:	O
+Coronaviruses	O
+(	O
+CoVs	O
+)	O
+encode	O
+a	O
+mixture	B-CHED
+of	O
+highly	O
+conserved	O
+and	O
+novel	O
+genes	O
+,	O
+as	O
+well	O
+as	O
+genetic	O
+elements	O
+necessary	O
+for	O
+infection	B-DISO
+and	O
+pathogenesis	B-DISO
+,	O
+raising	O
+the	O
+possibility	O
+of	O
+common	O
+targets	O
+for	O
+attenuation	O
+and	O
+therapeutic	O
+design	O
+.	O
+
+In	O
+adult	O
+DMD	B-DISO
+and	O
+BMD	B-DISO
+patients	O
+with	O
+severe	O
+ejection	O
+fraction	O
+alteration	O
+and	O
+on	O
+HMV	O
+,	O
+admitted	O
+for	O
+AHF	O
+,	O
+right	O
+cardiac	B-ANAT
+signs	O
+are	O
+frequent	O
+.	O
+
+TITLE	O
+:	O
+Macrophage	B-ANAT
+scavenger	B-SPEC
+receptor	I-PRGE
+1	I-PRGE
+contributes	O
+to	O
+pathogenesis	B-DISO
+of	O
+fulminant	B-DISO
+hepatitis	I-DISO
+via	O
+neutrophil	B-ANAT
+-	O
+mediated	O
+complement	B-PROC
+activation	I-PROC
+.	O
+
+ABSTRACT	O
+:	O
+The	O
+macrophage	B-PRGE
+scavenger	B-SPEC
+receptor	I-PRGE
+1	I-PRGE
+(	O
+Msr1	B-PRGE
+,	O
+also	O
+called	O
+SRA	B-PRGE
+)	O
+is	O
+a	O
+pattern	B-PRGE
+recognition	I-PRGE
+receptor	I-PRGE
+primarily	O
+expressed	B-PROC
+on	O
+myeloid	B-ANAT
+cells	I-ANAT
+,	O
+which	O
+plays	O
+an	O
+important	O
+role	O
+in	O
+the	O
+maintenance	O
+of	O
+immune	O
+homeostasis	B-PROC
+.	O
+
+Virus	B-SPEC
+-	O
+induced	O
+fulminant	B-DISO
+hepatitis	I-DISO
+(	O
+FH	O
+)	O
+is	O
+a	O
+disease	O
+with	O
+a	O
+high	O
+mortality	O
+worldwide	O
+.	O
+
+Among	O
+the	O
+6	O
+recipients	O
+with	O
+HBoV	O
+(	O
+3	O
+%),	O
+only	O
+1	O
+had	O
+LRT	B-ANAT
+involvement	O
+and	O
+no	O
+one	O
+died	B-PROC
+from	O
+respiratory	B-DISO
+failure	I-DISO
+.	O
+
+ABSTRACT	O
+:	O
+Published	O
+guidance	O
+recommends	O
+controlled	O
+movement	B-PROC
+for	O
+persons	O
+with	O
+higher	O
+-	O
+risk	O
+exposures	O
+(	O
+HREs	O
+)	O
+to	O
+communicable	B-DISO
+diseases	I-DISO
+of	O
+public	O
+health	O
+concern	O
+;	O
+US	O
+federal	O
+public	O
+health	O
+travel	O
+restrictions	O
+(	O
+PHTRs	O
+)	O
+might	O
+be	O
+implemented	O
+to	O
+enforce	O
+these	O
+measures	O
+.	O
+
+His	O
+condition	B-DISO
+improved	O
+after	O
+ampicillin	B-CHED
+and	O
+penicillin	B-CHED
+G	I-CHED
+were	O
+added	O
+empirically	O
+.	O
+
+Monoclonal	O
+antibodies	B-COMP
+(	O
+mAbs	O
+)	O
+have	O
+been	O
+successfully	O
+used	O
+to	O
+treat	O
+various	O
+diseases	O
+,	O
+particularly	O
+cancer	B-DISO
+and	O
+immunological	O
+disorders	O
+.	O
+
+In	O
+this	O
+paper	O
+,	O
+we	O
+summarize	O
+historical	O
+trends	O
+and	O
+recent	O
+developments	O
+in	O
+mAb	O
+discovery	O
+,	O
+compare	O
+the	O
+advantages	O
+and	O
+disadvantages	O
+of	O
+various	O
+approaches	O
+to	O
+mAb	O
+production	O
+,	O
+and	O
+discuss	O
+the	O
+potential	O
+use	O
+of	O
+such	O
+strategies	O
+for	O
+the	O
+development	O
+of	O
+antivirals	B-CHED
+against	O
+emerging	O
+diseases	O
+.	O
+
+The	O
+ground	O
+-	O
+glass	O
+attenuation	O
+regions	O
+were	O
+similarly	O
+present	O
+among	O
+the	O
+groups	O
+,	O
+8	O
+(	O
+40	O
+%),	O
+8	O
+(	O
+40	O
+%),	O
+14	O
+(	O
+70	O
+%),	O
+and	O
+10	O
+(	O
+50	O
+%),	O
+while	O
+the	O
+airspace	O
+consolidations	O
+were	O
+significantly	O
+more	O
+present	O
+in	O
+ARDS	B-DISO
+.	O
+
+The	O
+International	O
+Society	O
+for	O
+Influenza	B-DISO
+and	O
+other	O
+Respiratory	O
+Virus	B-DISO
+Diseases	I-DISO
+held	O
+its	O
+5th	O
+Antiviral	B-CHED
+Group	O
+(	O
+isirv	O
+-	O
+AVG	O
+)	O
+Conference	O
+in	O
+Shanghai	O
+,	O
+China	O
+,	O
+in	O
+conjunction	O
+with	O
+the	O
+Shanghai	O
+Public	O
+Health	O
+Center	O
+and	O
+Fudan	O
+University	O
+from	O
+14	O
+-	O
+16	O
+June	O
+2017	O
+.	O
+
+Following	O
+on	O
+from	O
+the	O
+previous	O
+conference	O
+,	O
+there	O
+were	O
+ongoing	O
+discussions	O
+on	O
+appropriate	O
+endpoints	O
+for	O
+severe	O
+influenza	B-DISO
+in	O
+clinical	O
+trials	O
+from	O
+regulators	O
+and	O
+clinicians	O
+,	O
+an	O
+issue	O
+which	O
+remains	O
+unresolved	O
+.	O
+
+Using	O
+electron	O
+tomography	O
+,	O
+we	O
+demonstrate	O
+that	O
+for	O
+both	O
+MERS	O
+-	O
+CoV	O
+and	O
+SARS	B-DISO
+-	O
+CoV	O
+coexpression	O
+of	O
+nsp3	B-PRGE
+and	O
+nsp4	B-PRGE
+is	O
+required	O
+and	O
+sufficient	O
+to	O
+induce	O
+DMVs	O
+.	O
+
+Coexpression	O
+of	O
+MERS	B-PRGE
+-	I-PRGE
+CoV	I-PRGE
+nsp3	I-PRGE
+and	O
+nsp4	B-PRGE
+either	O
+as	O
+individual	O
+proteins	B-CHED
+or	O
+as	O
+a	O
+self	O
+-	O
+cleaving	O
+nsp3	B-PRGE
+-	I-PRGE
+4	I-PRGE
+precursor	I-PRGE
+resulted	O
+in	O
+very	O
+similar	O
+DMVs	O
+,	O
+and	O
+in	O
+both	O
+setups	O
+we	O
+observed	O
+proliferation	B-DISO
+of	O
+zippered	O
+ER	O
+that	O
+appeared	O
+to	O
+wrap	O
+into	O
+nascent	O
+DMVs	O
+.	O
+
+Moreover	O
+,	O
+when	O
+inactivating	O
+nsp3	B-PRGE
+-	I-PRGE
+4	I-PRGE
+polyprotein	O
+cleavage	B-PROC
+by	O
+mutagenesis	B-PROC
+,	O
+we	O
+established	O
+that	O
+cleavage	B-PROC
+of	O
+the	O
+nsp3	B-PRGE
+/	O
+nsp4	B-PRGE
+junction	O
+is	O
+essential	O
+for	O
+MERS	O
+-	O
+CoV	O
+DMV	O
+formation	B-PROC
+.	O
+
+IL	O
+-	O
+36α	O
+and	O
+IL	O
+-	O
+36γ	O
+were	O
+expressed	B-PROC
+in	O
+pulmonary	B-ANAT
+macrophages	I-ANAT
+(	O
+PMs	B-DISO
+)	O
+and	O
+alveolar	B-ANAT
+epithelial	B-ANAT
+cells	I-ANAT
+in	O
+response	O
+to	O
+P	B-SPEC
+.	I-SPEC
+aeruginosa	I-SPEC
+in	O
+vitro	O
+.	O
+
+Decreased	O
+mortality	O
+in	O
+IL	O
+-	O
+36R	O
+-/-	O
+mice	B-SPEC
+and	O
+IL	O
+-	O
+36γ	O
+-/-	O
+mice	B-SPEC
+was	O
+associated	O
+with	O
+reduction	O
+in	O
+bacterial	O
+burden	O
+in	O
+the	O
+alveolar	B-ANAT
+space	O
+,	O
+bacterial	O
+dissemination	O
+,	O
+production	O
+of	O
+inflammatory	O
+cytokines	O
+and	O
+lung	B-ANAT
+injury	O
+,	O
+without	O
+changes	O
+in	O
+lung	B-ANAT
+leukocyte	B-ANAT
+influx	O
+.	O
+
+Treatment	O
+of	O
+PMs	B-DISO
+with	O
+recombinant	O
+IL	O
+-	O
+36γ	O
+resulted	O
+in	O
+impaired	B-DISO
+bacterial	O
+killing	O
+via	O
+PGE2	B-CHED
+and	O
+its	O
+receptor	O
+;	O
+EP2	B-PRGE
+.	O
+
+TITLE	O
+:	O
+Prevalence	O
+and	O
+genetic	O
+diversity	O
+analysis	O
+of	O
+human	B-SPEC
+coronaviruses	O
+among	O
+cross	O
+-	O
+border	B-ANAT
+children	O
+.	O
+
+Therefore	O
+,	O
+surveillance	O
+on	O
+the	O
+prevalence	O
+and	O
+the	O
+virus	B-SPEC
+variation	O
+of	O
+HCoVs	O
+circulation	B-PROC
+in	O
+this	O
+region	O
+is	O
+conducted	O
+.	O
+
+However	O
+,	O
+mutants	O
+of	O
+the	O
+epidemic	O
+strains	O
+were	O
+detected	O
+,	O
+suggesting	O
+continuous	O
+monitoring	O
+of	O
+the	O
+human	B-SPEC
+coronaviruses	O
+is	O
+in	O
+need	O
+among	O
+cross	O
+-	O
+border	B-ANAT
+children	O
+,	O
+who	O
+are	O
+more	O
+likely	O
+to	O
+get	O
+infected	O
+and	O
+transmit	O
+the	O
+viruses	B-SPEC
+across	O
+the	O
+border	B-ANAT
+easily	O
+,	O
+in	O
+addition	O
+to	O
+the	O
+general	O
+public	O
+.	O
+
+RESULTS	O
+:	O
+78	O
+(	O
+2	O
+.	O
+37	O
+%;	O
+95	O
+%	O
+CI	O
+1	O
+.	O
+8	O
+-	O
+2	O
+.	O
+8	O
+%)	O
+out	O
+of	O
+3298	O
+nasopharyngeal	B-ANAT
+swabs	O
+specimens	O
+were	O
+found	O
+to	O
+be	O
+positive	O
+for	O
+OC43	O
+(	O
+36	O
+;	O
+1	O
+.	O
+09	O
+%),	O
+HKU1	O
+(	O
+34	O
+;	O
+1	O
+.	O
+03	O
+%),	O
+NL63	O
+(	O
+6	O
+;	O
+0	O
+.	O
+18	O
+%)	O
+and	O
+229E	O
+(	O
+2	O
+;	O
+0	O
+.	O
+01	O
+%).	O
+
+There	O
+is	O
+increasing	O
+evidence	O
+that	O
+plus	O
+-	O
+strand	O
+RNA	O
+(+	O
+RNA	O
+)	O
+virus	B-PROC
+replication	I-PROC
+,	O
+including	O
+RO	O
+formation	B-PROC
+and	O
+virion	B-COMP
+morphogenesis	B-PROC
+,	O
+affects	O
+cellular	B-PROC
+lipid	B-PROC
+metabolism	I-PROC
+and	O
+critically	O
+depends	O
+on	O
+enzymes	O
+involved	O
+in	O
+lipid	B-PROC
+synthesis	I-PROC
+and	O
+processing	O
+.	O
+
+During	O
+the	O
+first	O
+days	O
+,	O
+however	O
+,	O
+nerve	B-PROC
+conduction	B-PROC
+studies	O
+(	O
+NCSs	O
+)	O
+are	O
+not	O
+always	O
+conclusive	O
+.	O
+
+The	O
+diagnosis	O
+of	O
+acute	O
+motor	O
+and	O
+sensory	O
+axonal	B-DISO
+neuropathy	I-DISO
+was	O
+made	O
+.	O
+
+In	O
+conclusion	O
+,	O
+normal	O
+NCS	B-CHED
+findings	O
+up	O
+to	O
+several	O
+weeks	O
+do	O
+not	O
+exclude	O
+the	O
+diagnosis	O
+of	O
+GBS	B-DISO
+.	O
+
+TITLE	O
+:	O
+The	O
+French	O
+Infectious	B-DISO
+Diseases	I-DISO
+Society	O
+'	O
+s	O
+readiness	O
+and	O
+response	O
+to	O
+epidemic	O
+or	O
+biological	O
+risk	O
+-	O
+the	O
+current	O
+situation	O
+following	O
+the	O
+Middle	O
+East	O
+respiratory	O
+syndrome	O
+coronavirus	B-SPEC
+and	O
+Ebola	B-DISO
+virus	I-DISO
+disease	I-DISO
+alerts	O
+.	O
+
+The	O
+SOPs	O
+validated	O
+by	O
+the	O
+SPILF	O
+and	O
+its	O
+affiliates	O
+were	O
+disseminated	O
+to	O
+a	O
+wide	O
+range	O
+of	O
+key	O
+stakeholders	O
+through	O
+various	O
+media	B-ANAT
+including	O
+workshops	O
+and	O
+the	O
+SPILF	O
+'	O
+s	O
+website	O
+.	O
+
+Viral	O
+titers	O
+were	O
+calculated	O
+by	O
+using	O
+the	O
+plaque	B-DISO
+formation	B-PROC
+assay	O
+,	O
+and	O
+the	O
+cytotoxicity	B-DISO
+of	O
+APS	B-DISO
+was	O
+tested	O
+by	O
+utilizing	O
+a	O
+Cell	B-COMP
+Counting	O
+Kit	B-FUNC
+-	O
+8	O
+assay	O
+.	O
+
+These	O
+RBD	O
+classes	O
+differ	O
+in	O
+their	O
+affinity	O
+for	O
+APN	B-PRGE
+and	O
+their	O
+ability	O
+to	O
+bind	B-FUNC
+an	O
+HCoV	B-SPEC
+-	I-SPEC
+229E	I-SPEC
+neutralizing	O
+antibody	B-COMP
+.	O
+
+Together	O
+,	O
+our	O
+results	O
+provide	O
+a	O
+model	O
+for	O
+alphacoronavirus	O
+adaptation	B-PROC
+and	O
+evolution	B-PROC
+based	O
+on	O
+the	O
+use	O
+of	O
+extended	O
+loops	O
+for	O
+receptor	B-FUNC
+binding	I-FUNC
+.	O
+
+TITLE	O
+:	O
+Immune	B-PROC
+responses	I-PROC
+in	O
+influenza	B-SPEC
+A	I-SPEC
+virus	I-SPEC
+and	O
+human	B-SPEC
+coronavirus	I-SPEC
+infections	O
+:	O
+an	O
+ongoing	O
+battle	O
+between	O
+the	O
+virus	O
+and	O
+host	B-COMP
+.	O
+
+These	O
+findings	O
+,	O
+together	O
+with	O
+sophisticated	O
+molecular	O
+structure	O
+analyses	O
+,	O
+omics	O
+tools	O
+and	O
+computer	O
+-	O
+based	O
+models	O
+,	O
+have	O
+helped	O
+delineate	O
+the	O
+interaction	O
+between	O
+respiratory	O
+viruses	B-SPEC
+and	O
+the	O
+host	B-COMP
+immune	B-ANAT
+system	I-ANAT
+,	O
+which	O
+will	O
+facilitate	O
+the	O
+development	B-PROC
+of	O
+novel	O
+treatment	O
+strategies	O
+and	O
+vaccines	O
+with	O
+enhanced	O
+efficacy	O
+.	O
+
+We	O
+present	O
+a	O
+case	O
+report	O
+of	O
+a	O
+patient	O
+with	O
+apparent	O
+septic	B-DISO
+shock	I-DISO
+and	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+(	O
+ARDS	B-DISO
+)	O
+requiring	O
+life	O
+-	O
+sustaining	O
+veno	O
+-	O
+venous	B-ANAT
+extracorporeal	O
+membrane	B-COMP
+oxygenation	B-PROC
+(	O
+VV	O
+-	O
+ECMO	O
+).	O
+
+Antibodies	B-COMP
+to	O
+CRCoV	O
+had	O
+a	O
+protective	O
+effect	O
+against	O
+CRCoV	O
+infection	B-DISO
+and	O
+more	O
+severe	O
+clinical	O
+signs	O
+of	O
+CIRD	O
+but	O
+antibodies	B-COMP
+to	O
+CnPnV	O
+did	O
+not	O
+.	O
+
+Only	O
+2	O
+.	O
+7	O
+%	O
+of	O
+dogs	B-SPEC
+were	O
+seropositive	O
+for	O
+Influenza	B-PATH
+A	I-PATH
+,	O
+and	O
+none	O
+were	O
+positive	O
+by	O
+PCR	O
+.	O
+
+TITLE	O
+:	O
+Re	O
+-	O
+examining	O
+Permissive	O
+Hypercapnia	B-DISO
+in	O
+ARDS	B-DISO
+:	O
+A	O
+Narrative	O
+Review	O
+.	O
+
+TITLE	O
+:	O
+Inflammatory	O
+processes	O
+during	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+:	O
+a	O
+complex	O
+system	O
+.	O
+
+Gene	B-PROC
+expression	I-PROC
+analysis	O
+from	O
+animal	B-SPEC
+models	O
+or	O
+from	O
+patients	O
+with	O
+ARDS	B-DISO
+,	O
+sepsis	B-DISO
+or	O
+trauma	O
+show	O
+an	O
+enormous	O
+number	O
+of	O
+differentially	O
+expressed	B-PROC
+genes	O
+with	O
+highly	O
+significant	O
+overlaps	O
+between	O
+the	O
+various	O
+conditions	O
+.	O
+
+In	O
+order	B-SPEC
+to	O
+comprehend	O
+this	O
+complex	O
+system	O
+,	O
+it	O
+seems	O
+necessary	O
+to	O
+combine	O
+model	O
+-	O
+driven	O
+simulations	O
+,	O
+data	O
+-	O
+driven	O
+modelling	O
+and	O
+hypothesis	O
+-	O
+driven	O
+experimental	O
+studies	O
+.	O
+
+Genetically	O
+engineered	O
+L	B-SPEC
+.	I-SPEC
+casei	I-SPEC
+393	O
+(	O
+L393	O
+)	O
+strains	O
+expressing	O
+PEDV	B-PRGE
+COE	I-PRGE
+antigen	B-CHED
+only	O
+(	B-PRGE
+pPG	I-PRGE
+-	I-PRGE
+COE	I-PRGE
+/	I-PRGE
+L393	I-PRGE
+)	I-PRGE
+or	O
+fused	O
+-	O
+expressing	O
+COE	O
+and	O
+M	B-PRGE
+cell	I-PRGE
+-	I-PRGE
+targeting	B-PROC
+peptide	B-CHED
+Co1	I-PRGE
+(	O
+pPG	B-PRGE
+-	O
+COE	O
+-	O
+Co1	B-PRGE
+/	O
+L393	O
+)	O
+were	O
+constructed	O
+,	O
+and	O
+the	O
+immunogenicity	O
+upon	O
+administration	O
+as	O
+an	O
+oral	B-ANAT
+vaccine	O
+was	O
+evaluated	O
+.	O
+
+TITLE	O
+:	O
+Trypsin	B-ENZY
+-	O
+independent	O
+porcine	B-SPEC
+epidemic	I-SPEC
+diarrhea	I-SPEC
+virus	I-SPEC
+US	O
+strain	O
+with	O
+altered	O
+virus	B-SPEC
+entry	O
+mechanism	O
+.	O
+
+ABSTRACT	O
+:	O
+Porcine	O
+Epidemic	O
+Diarrhea	O
+Virus	O
+(	O
+PEDV	B-SPEC
+)	O
+is	O
+a	O
+coronavirus	B-SPEC
+that	O
+infects	O
+the	O
+intestinal	B-ANAT
+tract	I-ANAT
+and	O
+causes	O
+diarrhea	B-DISO
+and	I-DISO
+vomiting	I-DISO
+in	O
+older	O
+pigs	B-SPEC
+or	O
+extreme	O
+dehydration	B-DISO
+and	O
+death	B-PROC
+that	O
+could	O
+reach	B-PROC
+100	O
+%	O
+mortality	O
+in	O
+neonatal	O
+piglets	O
+.	O
+
+In	O
+this	O
+study	O
+,	O
+we	O
+passaged	O
+an	O
+US	O
+PEDV	B-SPEC
+isolate	O
+under	O
+various	O
+conditions	O
+to	O
+generate	O
+three	O
+strains	O
+and	O
+characterized	O
+their	O
+growth	B-PROC
+and	O
+antigenicity	O
+in	O
+cell	B-COMP
+culture	O
+using	O
+various	O
+assays	O
+including	O
+Western	O
+blot	O
+analysis	O
+,	O
+serum	B-COMP
+neutralization	O
+assay	O
+,	O
+sequencing	O
+analysis	O
+and	O
+confocal	O
+microscopy	O
+.	O
+
+RESULTS	O
+:	O
+One	O
+of	O
+the	O
+PEDV	B-SPEC
+strains	O
+generated	O
+in	O
+this	O
+study	O
+(	O
+designated	O
+as	O
+PEDV	B-SPEC
+8aa	O
+)	O
+is	O
+able	O
+to	O
+replicate	O
+in	O
+cells	B-COMP
+without	O
+any	O
+protease	O
+and	O
+grows	O
+to	O
+a	O
+high	O
+titer	O
+of	O
+>	O
+8	O
+log	O
+
+ABSTRACT	O
+:	O
+Post	O
+-	O
+transplant	B-ANAT
+tuberculosis	B-PATH
+(	O
+PTTB	O
+)	O
+is	O
+a	O
+serious	O
+opportunistic	B-DISO
+infection	I-DISO
+in	O
+renal	B-ANAT
+graft	B-ANAT
+recipients	O
+with	O
+a	O
+30	O
+-	O
+70	O
+fold	O
+higher	O
+incidence	O
+compared	O
+to	O
+the	O
+general	O
+population	O
+.	O
+
+After	O
+34	O
+days	O
+,	O
+the	O
+patient	O
+was	O
+weaned	B-PROC
+from	O
+mechanical	O
+ventilation	O
+and	O
+was	O
+discharged	O
+to	O
+the	O
+pulmonary	B-ANAT
+ward	O
+,	O
+followed	O
+by	O
+complete	O
+recovery	O
+.	O
+
+This	O
+case	O
+offers	O
+a	O
+guideline	O
+for	O
+the	O
+clinical	O
+management	O
+towards	O
+survival	O
+of	O
+GITB	O
+in	O
+transplant	B-ANAT
+patients	O
+,	O
+complicated	O
+by	O
+septic	B-DISO
+shock	I-DISO
+and	O
+multiple	B-DISO
+organ	I-DISO
+failure	I-DISO
+,	O
+including	O
+acute	O
+renal	B-ANAT
+injury	O
+and	O
+ARDS	B-DISO
+.	O
+
+The	O
+purpose	O
+of	O
+this	O
+project	O
+is	O
+to	O
+describe	O
+the	O
+status	O
+of	O
+current	O
+state	O
+animal	B-DISO
+disease	I-DISO
+response	O
+plans	O
+in	O
+relation	O
+to	O
+how	O
+closely	O
+their	O
+content	O
+,	O
+order	B-SPEC
+,	O
+and	O
+terminology	O
+relate	O
+to	O
+that	O
+described	O
+in	O
+the	O
+LERP	O
+template	O
+.	O
+
+TITLE	O
+:	O
+Acute	O
+phase	O
+proteins	B-CHED
+and	O
+stress	O
+markers	O
+in	O
+the	O
+immediate	O
+response	O
+to	O
+a	O
+combined	O
+vaccination	O
+against	O
+Newcastle	O
+disease	O
+and	O
+infectious	B-DISO
+bronchitis	B-DISO
+viruses	B-SPEC
+in	O
+specific	O
+pathogen	O
+free	O
+(	O
+SPF	O
+)	O
+layer	B-ANAT
+chicks	O
+.	O
+
+In	O
+this	O
+study	O
+,	O
+the	O
+effects	O
+of	O
+a	O
+routinely	O
+used	O
+commercial	O
+poultry	O
+vaccine	O
+on	O
+the	O
+acute	B-DISO
+phase	I-DISO
+response	I-DISO
+(	O
+APR	B-DISO
+)	O
+and	O
+H	O
+/	O
+L	O
+ratios	O
+in	O
+specific	O
+pathogen	O
+-	O
+free	O
+(	O
+SPF	O
+)	O
+layer	B-ANAT
+chicks	O
+was	O
+examined	O
+to	O
+determine	O
+if	O
+post	O
+vaccination	O
+(	O
+PV	O
+)	O
+stress	O
+and	O
+an	O
+APR	B-DISO
+occur	O
+.	O
+
+A	O
+combined	O
+Newcastle	B-DISO
+disease	I-DISO
+and	O
+infectious	B-DISO
+bronchitis	B-DISO
+vaccine	O
+(	O
+Nobalis	O
+Ma5	O
++	O
+Clone	O
+30	O
+)	O
+was	O
+administered	O
+to	O
+SPF	O
+chicks	O
+by	O
+the	O
+intraocular	B-ANAT
+route	O
+at	O
+age	O
+7	O
+d	O
+.	O
+Acute	O
+phase	O
+proteins	O
+(	O
+APP	B-CHED
+),	O
+alpha	O
+-	O
+1	O
+acid	B-PRGE
+glycoprotein	I-PRGE
+(	O
+AGP	B-PRGE
+)	O
+and	O
+serum	B-PRGE
+amyloid	B-DISO
+A	I-PRGE
+(	O
+SAA	B-PRGE
+)	O
+were	O
+measured	O
+by	O
+enzyme	O
+-	O
+linked	O
+immunosorbent	O
+assays	O
+at	O
+d	O
+0	O
+(	O
+pre	O
+-	O
+vaccination	O
+)	O
+and	O
+d	O
+0	O
+.	O
+5	O
+,	O
+1	O
+,	O
+2	O
+,	O
+3	O
+,	O
+4	O
+,	O
+5	O
+,	O
+6	O
+,	O
+and	O
+21	O
+PV	O
+.	O
+
+TITLE	O
+:	O
+Effects	O
+of	O
+interleukin	B-PRGE
+17A	I-PRGE
+(	O
+IL	B-PRGE
+-	I-PRGE
+17A	I-PRGE
+)	O
+neutralization	O
+on	O
+murine	B-DISO
+hepatitis	I-DISO
+virus	B-SPEC
+(	O
+MHV	B-SPEC
+-	O
+A59	O
+)	O
+infection	B-DISO
+.	O
+
+IL	O
+-	O
+17A	O
+neutralization	O
+did	O
+not	O
+affect	O
+MHV	B-SPEC
+-	O
+A59	O
+-	O
+induction	O
+of	O
+HMGB1	B-PRGE
+liberation	O
+and	O
+slightly	O
+augmented	O
+plasmatic	O
+uric	B-CHED
+acid	I-CHED
+concentration	O
+.	O
+
+The	O
+above	O
+results	O
+suggest	O
+a	O
+reciprocal	O
+regulation	B-PROC
+of	O
+Th1	O
+and	O
+Th17	O
+cells	B-COMP
+acting	O
+on	O
+the	O
+different	O
+MHV	B-SPEC
+-	O
+A59	O
+effects	O
+.	O
+
+To	O
+study	O
+the	O
+possible	O
+immune	B-PROC
+evasion	I-PROC
+of	O
+the	O
+type	B-PRGE
+III	I-PRGE
+IFN	I-PRGE
+response	O
+by	O
+porcine	B-SPEC
+epidemic	I-SPEC
+diarrhea	I-SPEC
+virus	I-SPEC
+(	O
+PEDV	B-SPEC
+),	O
+a	O
+line	O
+of	O
+porcine	B-SPEC
+intestinal	B-ANAT
+epithelial	B-ANAT
+cells	I-ANAT
+was	O
+developed	O
+as	O
+a	O
+cell	B-COMP
+model	O
+for	O
+PEDV	B-SPEC
+replication	O
+.	O
+
+Patients	O
+who	O
+had	O
+severe	O
+ARDS	B-DISO
+(	O
+PaO2	O
+/	O
+FiO2	O
+ratio	O
+≤	O
+100	O
+mm	O
+Hg	O
+with	O
+positive	O
+end	B-PROC
+-	I-PROC
+expiratory	I-PROC
+pressure	O
+≥	O
+5	O
+cm	O
+H2O	B-CHED
+)	O
+and	O
+were	O
+listed	O
+for	O
+LTPL	O
+with	O
+no	O
+underlying	O
+end	O
+-	O
+stage	O
+lung	B-DISO
+disease	I-DISO
+were	O
+included	O
+in	O
+this	O
+single	O
+-	O
+center	O
+retrospective	O
+study	O
+.	O
+
+Recombination	B-PROC
+analysis	O
+shows	O
+evidence	O
+of	O
+frequent	O
+recombination	B-PROC
+events	O
+within	O
+the	O
+S	B-PRGE
+gene	I-PRGE
+and	O
+around	O
+the	O
+ORF8	O
+between	O
+these	O
+SARSr	O
+-	O
+CoVs	O
+.	O
+
+ABSTRACT	O
+:	O
+Since	O
+its	O
+emergence	O
+in	O
+2013	O
+,	O
+porcine	B-SPEC
+epidemic	I-SPEC
+diarrhea	I-SPEC
+virus	I-SPEC
+(	O
+PEDV	B-SPEC
+)	O
+spread	O
+rapidly	O
+throughout	O
+the	O
+country	O
+due	O
+,	O
+in	O
+part	O
+,	O
+to	O
+contaminated	O
+livestock	O
+trailers	O
+.	O
+
+Forty	O
+3	O
+-	O
+week	O
+-	O
+old	O
+pigs	B-SPEC
+,	O
+intragastrically	O
+inoculated	O
+with	O
+the	O
+contents	O
+of	O
+the	O
+coupons	O
+after	O
+treatment	O
+,	O
+were	O
+used	O
+as	O
+a	O
+bioassay	O
+to	O
+determine	O
+the	O
+infectivity	O
+of	O
+PEDV	O
+after	O
+treatment	O
+.	O
+
+Rectal	O
+swabs	O
+from	O
+all	O
+pigs	B-SPEC
+within	O
+the	O
+positive	O
+control	O
+group	O
+(	O
+4	O
+of	O
+4	O
+)	O
+were	O
+positive	O
+for	O
+PEDV	B-SPEC
+by	O
+RT	O
+-	O
+qPCR	O
+.	O
+
+RESULTS	O
+:	O
+All	O
+post	O
+-	O
+treatment	O
+swabs	O
+from	O
+the	O
+negative	O
+control	O
+coupons	O
+were	O
+negative	O
+for	O
+PEDV	B-SPEC
+via	O
+RT	O
+-	O
+qPCR	O
+.	O
+
+TITLE	O
+:	O
+Funding	O
+vaccines	O
+for	O
+emerging	B-DISO
+infectious	I-DISO
+diseases	I-DISO
+.	O
+
+Coupled	O
+with	O
+disjointed	O
+efforts	O
+towards	O
+the	O
+development	B-PROC
+of	O
+vaccines	O
+and	O
+a	O
+lack	O
+of	O
+funds	O
+and	O
+desire	O
+to	O
+advance	O
+promising	O
+products	O
+against	O
+known	O
+emerging	O
+pathogens	O
+to	O
+clinical	O
+trials	O
+,	O
+there	O
+has	O
+been	O
+a	O
+shortage	O
+of	O
+approved	O
+products	O
+ready	O
+for	O
+emergency	B-DISO
+use	O
+.	O
+
+Recent	O
+outbreaks	O
+have	O
+exposed	O
+these	O
+weaknesses	B-DISO
+,	O
+and	O
+the	O
+Coalition	O
+for	O
+Epidemic	O
+Preparedness	O
+Innovations	O
+(	O
+CEPI	O
+)	O
+was	O
+created	O
+in	O
+2016	O
+to	O
+address	O
+these	O
+issues	O
+.	O
+
+TITLE	O
+:	O
+Quality	O
+of	O
+Life	O
+of	O
+Adult	O
+Survivors	O
+After	O
+Extra	O
+Corporeal	O
+Membrane	B-COMP
+Oxygenation	B-PROC
+(	O
+ECMO	O
+):	O
+A	O
+Quantitative	O
+Study	O
+.	O
+
+ABSTRACT	O
+:	O
+ADP	B-CHED
+-	O
+ribosylation	O
+is	O
+a	O
+common	O
+post	O
+-	O
+translational	O
+modification	O
+,	O
+although	O
+how	O
+it	O
+modulates	O
+RNA	B-DISO
+virus	I-DISO
+infection	I-DISO
+is	O
+not	O
+well	O
+understood	O
+.	O
+
+While	O
+screening	O
+for	O
+ADP	B-CHED
+-	O
+ribosylated	O
+proteins	B-CHED
+during	O
+coronavirus	B-SPEC
+(	O
+CoV	O
+)	O
+infection	B-DISO
+,	O
+we	O
+detected	O
+a	O
+~	O
+55kDa	O
+ADP	B-CHED
+-	O
+ribosylated	O
+protein	B-CHED
+in	O
+mouse	B-DISO
+hepatitis	I-DISO
+virus	B-SPEC
+(	O
+MHV	B-SPEC
+)-	O
+infected	O
+cells	B-COMP
+and	O
+in	O
+virions	B-COMP
+,	O
+which	O
+we	O
+identified	O
+as	O
+the	O
+viral	B-COMP
+nucleocapsid	I-COMP
+(	O
+N	O
+)	O
+protein	B-CHED
+.	O
+
+ADP	B-CHED
+-	O
+ribosylation	O
+of	O
+N	B-PRGE
+protein	I-PRGE
+was	O
+also	O
+observed	O
+in	O
+cells	B-COMP
+exogenously	O
+expressing	O
+N	B-PRGE
+protein	I-PRGE
+by	O
+transduction	B-PROC
+using	O
+Venezuelan	B-SPEC
+equine	I-SPEC
+encephalitis	I-SPEC
+virus	I-SPEC
+replicon	O
+particles	O
+(	O
+VRPs	O
+).	O
+
+Due	O
+to	O
+the	O
+deficit	B-DISO
+of	O
+knowledge	O
+in	O
+transmission	O
+methodology	O
+,	O
+targeted	B-PROC
+treatment	O
+and	O
+possible	O
+vaccines	O
+,	O
+understanding	O
+this	O
+virus	B-SPEC
+should	O
+be	O
+a	O
+priority	O
+.	O
+
+Distribution	O
+of	O
+sequences	O
+into	O
+geographic	O
+clusters	B-CHED
+and	O
+interleaving	O
+of	O
+MERS	O
+-	O
+CoV	O
+sequences	O
+from	O
+camels	B-SPEC
+among	O
+those	O
+isolated	O
+from	O
+humans	B-SPEC
+indicated	O
+that	O
+multiple	O
+zoonotic	O
+introductions	O
+occurred	O
+in	O
+endemic	O
+nations	O
+.	O
+
+Together	O
+,	O
+these	O
+analyses	O
+can	O
+help	O
+us	O
+identify	O
+factors	O
+associated	O
+with	O
+viral	O
+evolution	B-PROC
+and	O
+spread	O
+as	O
+well	O
+as	O
+establish	O
+efficacy	O
+of	O
+infection	B-DISO
+control	O
+measures	O
+.	O
+
+Data	O
+from	O
+these	O
+surveillance	O
+systems	O
+showed	O
+influenza	B-PATH
+A	I-PATH
+(	O
+H1N1	O
+)	O
+pdm09	O
+circulated	O
+in	O
+West	O
+Africa	O
+later	O
+than	O
+in	O
+other	O
+regions	O
+of	O
+the	O
+continent	O
+.	O
+
+Influenza	B-PATH
+A	I-PATH
+(	O
+H1N1	O
+)	O
+pdm09	O
+continued	O
+to	O
+circulate	O
+in	O
+West	O
+Africa	O
+along	O
+with	O
+influenza	B-PATH
+A	I-PATH
+(	O
+H3N2	B-CHED
+)	O
+and	O
+influenza	B-DISO
+B	O
+during	O
+2010	O
+-	O
+2012	O
+.	O
+
+Seven	O
+countries	O
+conducted	O
+SARI	O
+surveillance	O
+and	O
+collected	O
+3114	O
+specimens	O
+of	O
+which	O
+209	O
+(	O
+7	O
+%)	O
+were	O
+positive	O
+for	O
+influenza	B-SPEC
+viruses	I-SPEC
+.	O
+
+ABSTRACT	O
+:	O
+Heptad	O
+repeat	O
+(	O
+HR	O
+)	O
+regions	O
+are	O
+highly	O
+conserved	O
+motifs	O
+located	O
+in	O
+the	O
+glycoproteins	B-CHED
+of	O
+enveloped	O
+viruses	B-SPEC
+that	O
+form	O
+a	O
+six	O
+-	O
+helix	O
+bundle	O
+structure	O
+and	O
+is	O
+important	O
+in	O
+the	O
+process	O
+of	O
+virus	B-SPEC
+fusion	O
+.	O
+
+Travel	O
+-	O
+related	O
+cases	O
+continue	O
+to	O
+challenge	O
+the	O
+world	O
+'	O
+s	O
+surveillance	O
+and	O
+response	O
+capabilities	O
+,	O
+and	O
+more	O
+data	O
+are	O
+needed	O
+to	O
+understand	O
+unexplained	O
+primary	B-DISO
+transmission	I-DISO
+.	O
+
+The	O
+cerebral	B-ANAT
+blood	B-PROC
+perfusion	I-PROC
+was	O
+assessed	O
+by	O
+laser	B-SPEC
+speckle	O
+contrast	O
+analysis	O
+(	O
+LASCA	O
+)	O
+using	O
+a	O
+PeriCam	O
+PSI	B-PRGE
+system	O
+.	O
+
+There	O
+was	O
+a	O
+severe	O
+reduction	O
+in	O
+cerebral	B-ANAT
+blood	B-PROC
+perfusion	I-PROC
+immediately	O
+after	O
+the	O
+trauma	O
+that	O
+did	O
+not	O
+significantly	O
+improve	O
+within	O
+24	O
+h	O
+.	O
+The	O
+injured	O
+mice	B-SPEC
+began	O
+to	O
+experience	O
+reversible	O
+sensorimotor	O
+function	O
+at	O
+9	O
+days	O
+postinjury	O
+(	O
+dpi	O
+),	O
+which	O
+had	O
+completely	O
+recovered	O
+at	O
+28	O
+dpi	O
+.	O
+
+Proinflammatory	O
+response	O
+and	O
+reactive	O
+gliosis	B-DISO
+were	O
+upregulated	O
+at	O
+3	O
+dpi	O
+.	O
+
+This	O
+indicates	O
+that	O
+HIV	B-SPEC
+-	I-SPEC
+1	I-SPEC
+has	O
+emerged	O
+through	O
+the	O
+cross	O
+-	O
+species	B-SPEC
+transmission	O
+of	O
+SIVcpz	O
+from	O
+chimpanzees	B-SPEC
+to	O
+humans	B-SPEC
+.	O
+
+These	O
+results	O
+suggest	O
+that	O
+SIVcpz	O
+strain	O
+MB897	O
+is	O
+preadapted	O
+to	O
+humans	B-SPEC
+,	O
+unlike	O
+the	O
+other	O
+SIVcpz	O
+strains	O
+.	O
+
+Moreover	O
+,	O
+viral	O
+RNA	O
+sequencing	O
+of	O
+MB897	O
+-	O
+infected	O
+humanized	O
+mice	B-SPEC
+identified	O
+a	O
+nonsynonymous	O
+mutation	O
+in	O
+
+Patients	O
+infected	O
+with	O
+a	O
+single	O
+strain	O
+of	O
+HCoV	O
+infection	B-DISO
+were	O
+less	O
+likely	O
+to	O
+present	O
+fever	B-PROC
+(≥	O
+38	O
+°	O
+C	O
+)	O
+(	O
+p	O
+=	O
+0	O
+.	O
+014	O
+)	O
+and	O
+more	O
+likely	O
+to	O
+present	O
+pulmonary	B-ANAT
+rales	B-DISO
+(	O
+p	O
+=	O
+0	O
+.	O
+043	O
+)	O
+than	O
+those	O
+co	O
+-	O
+infected	O
+with	O
+more	O
+than	O
+one	O
+HCoV	O
+strain	O
+or	O
+other	O
+respiratory	O
+pathogens	O
+.	O
+
+In	O
+addition	O
+,	O
+the	O
+cell	B-COMP
+-	O
+culture	O
+-	O
+adapted	O
+HCoV	B-SPEC
+-	I-SPEC
+OC43	I-SPEC
+lost	B-CHED
+the	O
+ability	O
+to	O
+infect	O
+and	O
+replicate	O
+in	O
+air	B-CHED
+-	O
+liquid	O
+interface	O
+cultures	O
+of	O
+human	B-SPEC
+bronchial	B-ANAT
+tracheal	O
+epithelial	B-ANAT
+cells	I-ANAT
+.	O
+
+TITLE	O
+:	O
+microRNA	O
+-	O
+4331	O
+Promotes	O
+Transmissible	O
+Gastroenteritis	B-DISO
+Virus	B-SPEC
+(	O
+TGEV	B-SPEC
+)-	O
+induced	O
+Mitochondrial	B-COMP
+Damage	I-DISO
+Via	I-PRGE
+Targeting	I-PRGE
+RB1	I-PRGE
+,	O
+Upregulating	O
+Interleukin	B-PRGE
+-	I-PRGE
+1	I-PRGE
+Receptor	I-PRGE
+Accessory	I-PRGE
+Protein	I-PRGE
+(	O
+IL1RAP	B-PRGE
+),	O
+and	O
+Activating	O
+p38	B-FUNC
+MAPK	B-FUNC
+Pathway	B-PROC
+ABSTRACT	O
+:	O
+Transmissible	O
+gastroenteritis	B-DISO
+virus	B-SPEC
+(	O
+TGEV	B-SPEC
+),	O
+a	O
+member	O
+of	O
+the	O
+coronaviridae	B-SPEC
+family	B-SPEC
+,	O
+could	O
+cause	O
+fatal	O
+diarrhea	B-DISO
+of	O
+piglets	O
+and	O
+result	O
+in	O
+numerous	O
+economic	O
+losses	O
+.	O
+
+So	O
+miR	O
+-	O
+4331	O
+may	O
+play	O
+an	O
+important	O
+regulatory	O
+role	O
+in	O
+the	O
+control	O
+of	O
+mitochondrial	B-COMP
+function	O
+.	O
+
+TITLE	O
+:	O
+The	O
+impacts	O
+of	O
+baseline	O
+ventilator	O
+parameters	O
+on	O
+hospital	O
+mortality	O
+in	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+treated	O
+with	O
+venovenous	O
+extracorporeal	O
+membrane	B-COMP
+oxygenation	B-PROC
+:	O
+a	O
+retrospective	O
+cohort	O
+study	O
+.	O
+
+In	O
+multivariable	O
+models	O
+,	O
+a	O
+combination	O
+of	O
+Stimulation	O
+-	O
+2	O
+(	O
+ST2	B-ANAT
+;	O
+odds	O
+ratio	O
+[	O
+OR	O
+],	O
+2	O
+.	O
+8	O
+;	O
+P	O
+<	O
+.	O
+001	O
+)	O
+and	O
+IL	B-FUNC
+-	I-FUNC
+6	I-FUNC
+(	O
+OR	O
+,	O
+1	O
+.	O
+4	O
+;	O
+P	O
+=	O
+.	O
+025	O
+)	O
+was	O
+the	O
+best	O
+panel	O
+for	O
+distinguishing	O
+IPS	B-DISO
+at	O
+diagnosis	O
+from	O
+unaffected	O
+controls	O
+,	O
+whereas	O
+tumor	B-PRGE
+necrosis	I-PRGE
+factor	I-PRGE
+receptor	I-PRGE
+1	I-PRGE
+(	O
+TNFR1	B-PRGE
+;	O
+OR	O
+,	O
+2	O
+.	O
+9	O
+;	O
+P	O
+=	O
+.	O
+002	O
+)	O
+was	O
+the	O
+best	O
+marker	O
+when	O
+comparing	O
+patients	O
+with	O
+IPS	B-DISO
+and	O
+viral	B-DISO
+pneumonia	I-DISO
+.	O
+
+Here	O
+,	O
+we	O
+determined	O
+the	O
+structures	O
+of	O
+stem	B-ANAT
+-	O
+loops	O
+(	O
+SL	O
+)	O
+1	O
+and	O
+2	O
+of	O
+two	O
+alphacoronaviruses	O
+,	O
+human	B-SPEC
+coronavirus	I-SPEC
+(	O
+HCoV	O
+)	O
+229E	O
+and	O
+NL63	O
+,	O
+by	O
+RNA	O
+structure	O
+probing	O
+and	O
+studied	O
+the	O
+functional	O
+relevance	O
+of	O
+these	O
+putative	O
+cis	B-DISO
+-	O
+acting	O
+elements	O
+.	O
+
+TITLE	O
+:	O
+Host	B-COMP
+susceptibility	O
+to	O
+MERS	O
+-	O
+CoV	O
+infection	B-DISO
+,	O
+a	O
+retrospective	O
+cohort	O
+study	O
+of	O
+the	O
+2015	O
+Korean	O
+MERS	O
+outbreak	O
+.	O
+
+In	O
+a	O
+multivariate	O
+analysis	O
+,	O
+history	O
+of	O
+autologous	O
+stem	B-ANAT
+cell	I-ANAT
+transplantation	O
+(	O
+HR	O
+,	O
+31	O
+.	O
+151	O
+;	O
+95	O
+%	O
+CI	O
+,	O
+5	O
+.	O
+447	O
+-	O
+178	O
+.	O
+145	O
+;	O
+P	O
+<	O
+0	O
+.	O
+001	O
+)	O
+and	O
+tachypnea	B-DISO
+at	O
+ED	O
+(	O
+HR	O
+,	O
+4	O
+.	O
+392	O
+;	O
+95	O
+%	O
+CI	O
+,	O
+1	O
+.	O
+402	O
+-	O
+13	O
+.	O
+761	O
+;	O
+P	O
+=	O
+0	O
+.	O
+011	O
+)	O
+were	O
+significantly	O
+associated	O
+with	O
+MERS	O
+-	O
+CoV	O
+infection	B-DISO
+.	O
+
+TITLE	O
+:	O
+A	O
+multiplex	O
+real	O
+-	O
+time	O
+RT	O
+-	O
+PCR	O
+for	O
+simultaneous	O
+detection	O
+of	O
+four	O
+most	O
+common	O
+avian	B-SPEC
+respiratory	O
+viruses	O
+.	O
+
+This	O
+study	O
+aims	O
+to	O
+explore	O
+the	O
+significance	O
+of	O
+platelet	B-ANAT
+concentration	O
+during	O
+the	O
+course	O
+of	O
+the	O
+disease	O
+in	O
+victims	O
+of	O
+a	O
+mass	O
+burn	O
+casualty	O
+.	O
+
+We	O
+collected	O
+several	O
+types	O
+of	O
+data	O
+for	O
+the	O
+patients	O
+and	O
+divided	O
+the	O
+patients	O
+into	O
+a	O
+complication	B-DISO
+group	O
+and	O
+non	O
+-	O
+complication	B-DISO
+group	O
+according	O
+to	O
+the	O
+diagnostic	O
+criteria	O
+.	O
+
+ABSTRACT	O
+:	O
+The	O
+longitudinal	O
+pattern	O
+of	O
+lung	O
+function	O
+in	O
+children	O
+with	O
+sickle	B-DISO
+cell	I-DISO
+anemia	B-SPEC
+(	O
+SCA	B-ANAT
+)	O
+has	O
+shown	O
+a	O
+decrease	O
+in	O
+FEV	B-SPEC
+
+The	O
+aim	O
+of	O
+this	O
+study	O
+was	O
+to	O
+test	O
+the	O
+anti	O
+-	O
+inflammatory	O
+and	O
+reparative	O
+effects	O
+of	O
+ATII	O
+cells	B-COMP
+in	O
+an	O
+experimental	O
+model	O
+of	O
+ALI	O
+.	O
+
+TITLE	O
+:	O
+Altered	O
+Gut	B-ANAT
+Microbiota	B-SPEC
+Profiles	O
+in	O
+Sows	O
+and	O
+Neonatal	O
+Piglets	O
+Associated	O
+with	O
+Porcine	B-SPEC
+Epidemic	B-DISO
+Diarrhea	I-DISO
+Virus	B-DISO
+Infection	I-DISO
+.	O
+
+These	O
+nurses	O
+were	O
+mandated	O
+to	O
+remain	O
+in	O
+isolation	O
+in	O
+an	O
+intensive	O
+care	O
+unit	O
+(	O
+ICU	O
+)	O
+dedicated	O
+to	O
+the	O
+treatment	O
+of	O
+the	O
+patients	O
+with	O
+the	O
+MERS	O
+virus	B-SPEC
+for	O
+7	O
+days	O
+.	O
+
+However	O
+,	O
+detailed	O
+characterization	O
+of	O
+the	O
+pathway	B-PROC
+as	O
+well	O
+as	O
+its	O
+implication	O
+in	O
+host	B-COMP
+-	O
+virus	B-SPEC
+interactions	O
+has	O
+not	O
+been	O
+fully	O
+investigated	O
+.	O
+
+Interestingly	O
+,	O
+pro	B-CHED
+-	O
+apoptotic	O
+activity	O
+of	O
+JNK	B-FUNC
+was	O
+not	O
+mediated	O
+via	O
+c	O
+-	O
+Jun	O
+,	O
+but	O
+involved	O
+modulation	O
+of	O
+the	O
+anti	B-PRGE
+-	I-PRGE
+apoptotic	I-PRGE
+protein	I-PRGE
+B	B-DISO
+-	I-DISO
+cell	I-DISO
+lymphoma	I-DISO
+2	I-PRGE
+(	O
+Bcl2	B-PRGE
+).	O
+
+Taken	O
+together	O
+,	O
+JNK	B-FUNC
+constitutes	O
+an	O
+important	O
+aspect	O
+of	O
+coronavirus	B-SPEC
+-	O
+host	B-COMP
+interaction	O
+,	O
+along	O
+with	O
+other	O
+MAPKs	O
+.	O
+
+These	O
+cases	O
+of	O
+human	B-SPEC
+-	O
+to	O
+-	O
+human	B-SPEC
+transmission	O
+involve	O
+close	O
+contact	O
+and	O
+have	O
+occurred	O
+primarily	O
+in	O
+healthcare	O
+settings	O
+,	O
+and	O
+they	O
+are	O
+suspected	O
+to	O
+result	O
+from	O
+repeated	O
+zoonotic	O
+introductions	O
+.	O
+
+These	O
+data	O
+demonstrate	O
+a	O
+genetic	O
+link	O
+for	O
+each	O
+of	O
+these	O
+clusters	B-CHED
+to	O
+a	O
+camel	B-SPEC
+and	O
+support	O
+the	O
+hypothesis	O
+that	O
+human	B-SPEC
+MERS	O
+-	O
+CoV	O
+diversity	O
+results	O
+from	O
+multiple	O
+zoonotic	O
+introductions	O
+.	O
+
+In	O
+addition	O
+,	O
+residual	O
+replicating	O
+or	O
+live	O
+virus	B-SPEC
+after	O
+inactivation	B-DISO
+was	O
+examined	O
+by	O
+passaging	O
+in	O
+the	O
+permissive	O
+Vero	O
+E6	O
+cells	O
+.	O
+
+ABSTRACT	O
+:	O
+The	O
+neuromuscular	O
+blocking	B-DISO
+agent	O
+cisatracurium	O
+may	O
+improve	O
+mortality	O
+for	O
+patients	O
+with	O
+moderate	O
+-	O
+to	O
+-	O
+severe	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+(	O
+ARDS	B-DISO
+).	O
+
+To	O
+determine	O
+whether	O
+cisatracurium	O
+is	O
+associated	O
+with	O
+improved	O
+outcomes	O
+when	O
+compared	O
+with	O
+vecuronium	B-CHED
+in	O
+patients	O
+at	O
+risk	O
+for	O
+and	O
+with	O
+ARDS	B-DISO
+.	O
+
+TITLE	O
+:	O
+Molecular	O
+characterization	O
+of	O
+the	O
+spike	O
+gene	O
+of	O
+the	O
+porcine	B-SPEC
+epidemic	I-SPEC
+diarrhea	I-SPEC
+virus	I-SPEC
+in	O
+Mexico	O
+,	O
+2013	O
+-	O
+2016	O
+.	O
+
+In	O
+this	O
+study	O
+,	O
+we	O
+proposed	O
+a	O
+comparative	O
+analysis	O
+approach	O
+and	O
+built	O
+a	O
+model	O
+to	O
+simulate	O
+outbreaks	O
+of	O
+3	O
+different	O
+in	O
+-	O
+flight	B-PROC
+infections	B-DISO
+in	O
+a	O
+similar	O
+cabin	O
+environment	O
+,	O
+that	O
+is	O
+,	O
+influenza	B-PATH
+A	I-PATH
+H1N1	O
+,	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+(	O
+SARS	B-DISO
+)	O
+coronavirus	B-SPEC
+(	O
+CoV	O
+),	O
+and	O
+norovirus	B-SPEC
+.	O
+
+The	O
+simulation	O
+results	O
+seemed	O
+to	O
+suggest	O
+that	O
+the	O
+close	O
+contact	O
+route	O
+was	O
+probably	O
+the	O
+most	O
+significant	O
+route	O
+(	O
+contributes	O
+70	O
+%,	O
+95	O
+%	O
+confidence	O
+interval	O
+[	O
+CI	O
+]:	O
+67	O
+%-	O
+72	O
+%)	O
+in	O
+the	O
+in	O
+-	O
+flight	B-PROC
+transmission	O
+of	O
+influenza	B-PATH
+A	I-PATH
+H1N1	O
+transmission	O
+;	O
+as	O
+a	O
+result	O
+,	O
+passengers	O
+within	O
+2	O
+rows	O
+of	O
+the	O
+index	O
+case	O
+had	O
+a	O
+significantly	O
+higher	O
+infection	B-DISO
+risk	O
+than	O
+others	O
+in	O
+the	O
+outbreak	O
+(	O
+relative	O
+risk	O
+[	O
+RR	O
+]:	O
+13	O
+.	O
+4	O
+,	O
+95	O
+%	O
+CI	O
+:	O
+1	O
+.	O
+5	O
+-	O
+121	O
+.	O
+2	O
+,	O
+P	O
+=	O
+.	O
+019	O
+).	O
+
+The	O
+S	B-PRGE
+protein	I-PRGE
+efficiently	O
+incorporated	O
+into	O
+the	O
+viral	B-COMP
+envelope	I-COMP
+and	O
+mediated	O
+cell	B-COMP
+entry	O
+through	O
+binding	B-FUNC
+its	O
+receptor	O
+,	O
+human	B-PRGE
+DPP4	I-PRGE
+.	O
+
+Knockdown	O
+of	O
+clathrin	B-PRGE
+expression	B-PROC
+by	O
+siRNA	O
+drastically	O
+abrogated	O
+the	O
+infection	B-DISO
+of	O
+VSVΔG	O
+-	O
+MERS	O
+in	O
+Vero	O
+cells	O
+.	O
+
+TITLE	O
+:	O
+Retrieval	O
+of	O
+severe	O
+acute	B-DISO
+respiratory	I-DISO
+failure	I-DISO
+patients	O
+on	O
+extracorporeal	O
+membrane	B-COMP
+oxygenation	B-PROC
+:	O
+Any	O
+impact	O
+on	O
+their	O
+outcomes	O
+?	O
+
+The	O
+replication	O
+of	O
+these	O
+viruses	B-SPEC
+was	O
+compared	O
+in	O
+the	O
+same	O
+parental	O
+Huh7	O
+cells	B-COMP
+and	O
+in	O
+CypA	B-PRGE
+-	O
+knockout	O
+Huh7	O
+cells	B-COMP
+generated	O
+using	O
+CRISPR	O
+/	O
+Cas9	O
+-	O
+technology	O
+.	O
+
+The	O
+psychological	B-DISO
+impact	O
+of	O
+SARS	B-DISO
+on	O
+employees	O
+appeared	O
+to	O
+be	O
+associated	O
+with	O
+occupational	O
+role	O
+;	O
+training	O
+/	O
+preparedness	O
+;	O
+high	O
+-	O
+risk	O
+work	O
+environments	O
+;	O
+quarantine	O
+;	O
+role	O
+-	O
+related	O
+stressors	O
+;	O
+perceived	O
+risk	O
+;	O
+social	O
+support	O
+;	O
+social	O
+rejection	O
+/	O
+isolation	O
+;	O
+and	O
+impact	O
+of	O
+SARS	B-DISO
+on	O
+personal	O
+or	O
+professional	O
+life	O
+.	O
+
+This	O
+study	O
+reported	O
+two	O
+beta	O
+CoVs	O
+closely	O
+related	O
+to	O
+MERS	O
+that	O
+were	O
+obtained	O
+from	O
+two	O
+bats	B-SPEC
+belonging	O
+to	O
+two	O
+commonly	O
+recorded	O
+species	B-SPEC
+in	O
+Italy	O
+(	O
+P	B-SPEC
+.	I-SPEC
+kuhlii	I-SPEC
+and	O
+H	B-SPEC
+.	I-SPEC
+savii	I-SPEC
+).	O
+
+Unfortunately	O
+,	O
+optimal	O
+treatment	O
+has	O
+not	O
+been	O
+established	O
+for	O
+this	O
+potentially	O
+fatal	O
+condition	B-DISO
+.	O
+
+CONCLUSIONS	O
+:	O
+This	O
+case	O
+demonstrates	O
+the	O
+potential	O
+usefulness	O
+of	O
+orally	B-ANAT
+administered	O
+ribavirin	B-CHED
+as	O
+a	O
+therapeutic	O
+option	O
+for	O
+severe	O
+respiratory	B-DISO
+syncytial	I-DISO
+virus	I-DISO
+infection	I-DISO
+,	O
+at	O
+least	O
+in	O
+an	O
+immunocompetent	O
+host	B-COMP
+.	O
+
+ABSTRACT	O
+:	O
+Coronaviruses	O
+(	O
+CoV	O
+)	O
+and	O
+picornaviruses	B-SPEC
+are	O
+plus	O
+-	O
+strand	O
+RNA	O
+viruses	B-SPEC
+that	O
+use	O
+5	O
+'	O
+cap	B-DISO
+-	O
+dependent	O
+and	O
+cap	B-DISO
+-	O
+independent	O
+strategies	O
+,	O
+respectively	O
+,	O
+for	O
+viral	B-PATH
+mRNA	I-PATH
+translation	B-PROC
+initiation	O
+.	O
+
+To	O
+our	O
+knowledge	O
+,	O
+this	O
+is	O
+the	O
+first	O
+reported	O
+case	O
+of	O
+bilateral	O
+central	O
+retinal	O
+artery	O
+occlusion	B-PROC
+with	O
+both	O
+anterior	O
+and	O
+posterior	B-DISO
+ischemic	I-DISO
+optic	I-DISO
+neuropathy	I-DISO
+,	O
+presumed	O
+due	O
+to	O
+the	O
+combination	O
+of	O
+severe	O
+systemic	O
+hypotension	O
+,	O
+hypoxemia	O
+due	O
+to	O
+the	O
+respiratory	B-DISO
+distress	I-DISO
+syndrome	I-DISO
+,	O
+and	O
+prolonged	O
+prone	O
+positioning	O
+.	O
+
+Observational	O
+study	O
+of	O
+patients	O
+with	O
+ARDS	B-DISO
+,	O
+admitted	O
+from	O
+September	O
+2012	O
+to	O
+May	O
+2014	O
+,	O
+who	O
+underwent	O
+BCCE	O
+within	O
+48	O
+h	O
+of	O
+admission	O
+to	O
+a	O
+20	O
+-	O
+bed	B-DISO
+medical	O
+ICU	O
+.	O
+
+Hospital	O
+mortality	O
+for	O
+mild	O
+,	O
+moderate	O
+and	O
+severe	O
+ARDS	B-DISO
+was	O
+17	O
+.	O
+0	O
+,	O
+27	O
+.	O
+9	O
+and	O
+50	O
+.	O
+0	O
+%,	O
+respectively	O
+(	O
+without	O
+severe	O
+ACP	B-DISO
+),	O
+and	O
+was	O
+29	O
+.	O
+2	O
+,	O
+48	O
+.	O
+3	O
+and	O
+53	O
+.	O
+8	O
+%,	O
+respectively	O
+(	O
+with	O
+severe	O
+ACP	B-DISO
+).	O
+
+Fears	O
+related	O
+to	O
+a	O
+potential	O
+spread	O
+of	O
+the	O
+disease	O
+led	O
+to	O
+an	O
+increased	O
+alert	O
+level	O
+as	O
+well	O
+as	O
+heightened	O
+media	B-ANAT
+coverage	O
+in	O
+the	O
+neighboring	O
+Hong	O
+Kong	O
+.	O
+
+Critically	B-DISO
+ill	I-DISO
+patients	O
+with	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+.	O
+
+We	O
+defined	O
+above	O
+goal	O
+oxygen	B-CHED
+exposure	O
+as	O
+the	O
+difference	O
+between	O
+the	O
+fraction	O
+of	O
+inspired	B-PROC
+oxygen	B-CHED
+and	O
+0	O
+.	O
+5	O
+whenever	O
+the	O
+fraction	O
+of	O
+inspired	B-PROC
+oxygen	B-CHED
+was	O
+above	O
+0	O
+.	O
+5	O
+and	O
+when	O
+the	O
+partial	B-PROC
+pressure	I-PROC
+of	I-PROC
+oxygen	I-PROC
+in	O
+arterial	B-ANAT
+blood	I-ANAT
+was	O
+above	O
+80	O
+mm	O
+Hg	O
+.	O
+
+We	O
+determined	O
+the	O
+effect	O
+of	O
+a	O
+cumulative	O
+5	O
+-	O
+day	O
+above	O
+goal	O
+oxygen	B-CHED
+exposure	O
+on	O
+mortality	O
+prior	O
+to	O
+discharge	B-ANAT
+home	O
+at	O
+90	O
+days	O
+.	O
+
+In	O
+a	O
+continuing	O
+effort	B-PROC
+to	O
+decipher	O
+the	O
+molecular	O
+mechanism	O
+underlying	O
+IFITM	O
+differential	O
+modulation	O
+of	O
+HCoV	O
+entry	O
+,	O
+we	O
+investigated	O
+the	O
+roles	O
+of	O
+structural	O
+motifs	O
+important	O
+for	O
+IFITM	B-PRGE
+protein	I-PRGE
+posttranslational	B-PROC
+modifications	I-PROC
+,	O
+intracellular	B-COMP
+trafficking	B-PROC
+,	O
+and	O
+oligomerization	O
+in	O
+modulating	O
+the	O
+entry	O
+of	O
+five	O
+HCoVs	O
+.	O
+
+These	O
+findings	O
+suggest	O
+that	O
+these	O
+residues	O
+and	O
+structural	O
+motifs	O
+of	O
+IFITM	O
+proteins	B-CHED
+are	O
+key	O
+determinants	O
+for	O
+modulating	O
+the	O
+entry	O
+of	O
+HCoVs	O
+,	O
+most	O
+likely	O
+through	O
+interaction	O
+with	O
+viral	O
+and	O
+/	O
+or	O
+host	B-COMP
+cellular	B-COMP
+components	O
+at	O
+the	O
+site	O
+of	O
+viral	O
+entry	O
+to	O
+modulate	O
+the	O
+fusion	O
+of	O
+viral	B-COMP
+envelope	I-COMP
+and	O
+cellular	B-COMP
+membranes	B-ANAT
+.	O
+
+TITLE	O
+:	O
+Alveolar	B-ANAT
+injury	O
+and	O
+regeneration	B-PROC
+following	O
+deletion	O
+of	O
+ABCA3	B-PRGE
+.	O
+
+The	O
+remarkable	O
+and	O
+selective	O
+regeneration	B-PROC
+of	O
+ABCA3	B-PRGE
+-	O
+sufficient	O
+AT2	B-CHED
+progenitor	B-ANAT
+cells	I-ANAT
+provides	O
+plausible	O
+approaches	O
+for	O
+future	O
+correction	O
+of	O
+ABCA3	B-PRGE
+and	O
+other	O
+genetic	B-DISO
+disorders	I-DISO
+associated	O
+with	O
+surfactant	B-CHED
+deficiency	O
+and	O
+acute	O
+interstitial	B-DISO
+lung	B-ANAT
+disease	I-DISO
+.	O
+
+TITLE	O
+:	O
+Protective	O
+efficacy	O
+of	O
+a	O
+novel	O
+simian	O
+adenovirus	B-DISO
+vaccine	O
+against	O
+lethal	O
+MERS	O
+-	O
+CoV	O
+challenge	O
+in	O
+a	O
+transgenic	O
+human	O
+DPP4	O
+mouse	B-SPEC
+model	O
+.	O
+
+From	O
+April	O
+2014	O
+to	O
+December	O
+2015	O
+,	O
+patients	O
+with	O
+severe	O
+pneumonia	B-DISO
+at	O
+admission	O
+were	O
+retrieved	O
+from	O
+the	O
+hospital	O
+database	O
+,	O
+of	O
+which	O
+ARDS	B-DISO
+developed	O
+within	O
+7	O
+days	O
+were	O
+further	O
+identified	O
+.	O
+
+Multivariate	O
+logistic	O
+regression	O
+and	O
+receiver	O
+operating	O
+characteristic	O
+(	O
+ROC	O
+)	O
+curves	O
+were	O
+performed	O
+to	O
+screen	O
+independent	O
+risk	O
+factors	O
+and	O
+identify	O
+their	O
+sensitivity	O
+in	O
+predicting	O
+ARDS	O
+development	B-PROC
+and	O
+prognosis	O
+.	O
+
+Serum	B-COMP
+FiB	O
+>	O
+5	O
+.	O
+15	O
+g	O
+/	O
+L	O
+[	O
+adjusted	O
+odds	O
+ratio	O
+(	O
+OR	O
+)	O
+1	O
+.	O
+893	O
+,	O
+95	O
+%	O
+confidence	O
+interval	O
+(	O
+CI	O
+):	O
+1	O
+.	O
+141	O
+-	O
+3	O
+.	O
+142	O
+,	O
+P	O
+=	O
+0	O
+.	O
+014	O
+]	O
+and	O
+PEEP	B-CHED
+>	O
+6	O
+.	O
+5	O
+cmH	B-DISO
+ARDS	B-DISO
+development	B-PROC
+risk	O
+could	O
+be	O
+early	O
+recognized	O
+by	O
+PEEP	B-CHED
+>	O
+6	O
+.	O
+5	O
+cmH	B-DISO
+
+Hyponatremia	O
+was	O
+corrected	O
+and	O
+the	O
+encephalopathy	B-DISO
+resolved	O
+.	O
+
+Herein	O
+,	O
+we	O
+review	O
+these	O
+emerging	O
+viral	O
+pathogens	O
+in	O
+China	O
+and	O
+focus	O
+on	O
+how	O
+surveillance	O
+by	O
+pathogen	O
+genomics	O
+has	O
+been	O
+employed	O
+to	O
+discover	O
+and	O
+annotate	O
+novel	O
+pathogenic	O
+agents	O
+,	O
+identify	O
+natural	O
+reservoirs	O
+,	O
+monitor	O
+the	O
+transmission	O
+events	O
+and	O
+delineate	O
+their	O
+evolution	B-PROC
+and	O
+adaption	B-PROC
+to	O
+the	O
+human	B-SPEC
+host	B-COMP
+.	O
+
+In	O
+summary	O
+,	O
+genomic	O
+sequencing	O
+has	O
+become	O
+a	O
+standard	O
+research	O
+tool	O
+in	O
+the	O
+field	O
+of	O
+emerging	O
+infectious	O
+diseases	O
+which	O
+has	O
+been	O
+proven	O
+invaluable	O
+in	O
+containing	O
+these	O
+viral	B-DISO
+infections	I-DISO
+and	O
+reducing	O
+burden	O
+of	O
+disease	O
+in	O
+humans	B-SPEC
+and	O
+animals	B-SPEC
+.	O
+
+TITLE	O
+:	O
+Prospective	O
+Observational	O
+Study	O
+on	O
+the	O
+Association	O
+Between	O
+Serum	B-COMP
+Mannose	B-CHED
+-	O
+Binding	B-FUNC
+Lectin	O
+Levels	O
+and	O
+Severe	O
+Outcome	O
+in	O
+Critically	O
+Ill	O
+Patients	O
+with	O
+Pandemic	O
+Influenza	B-DISO
+Type	O
+A	O
+(	O
+H1N1	O
+)	O
+Infection	B-DISO
+.	O
+
+ABSTRACT	O
+:	O
+Mannose	B-PRGE
+-	I-PRGE
+binding	B-FUNC
+lectin	I-PRGE
+(	O
+MBL	B-PRGE
+)	O
+plays	O
+an	O
+important	O
+role	O
+in	O
+the	O
+innate	B-DISO
+immune	I-DISO
+response	I-DISO
+.	O
+
+This	O
+changes	O
+do	O
+not	O
+affect	O
+to	O
+the	O
+analytic	O
+sensitivity	O
+of	O
+the	O
+method	O
+because	O
+the	O
+detection	O
+limits	O
+of	O
+50	O
+-	O
+100	O
+copies	O
+/	O
+μL	O
+and	O
+5	O
+-	O
+100	O
+copies	O
+/	O
+μL	O
+using	O
+pUC57	B-PRGE
+-	I-PRGE
+SARS	I-PRGE
+-	I-PRGE
+pS2	B-CHED
+(	O
+a	O
+template	O
+for	O
+SARS	B-DISO
+-	O
+CoV	O
+)	O
+and	O
+pGEM	B-CHED
+-	O
+MERS	O
+-	O
+S2	O
+(	O
+a	O
+template	O
+for	O
+MERS	O
+-	O
+CoV	O
+),	O
+respectively	O
+,	O
+were	O
+as	O
+sensitive	O
+as	O
+other	O
+real	O
+-	O
+time	O
+PCR	O
+methods	O
+[	O
+1	O
+].	O
+
+A	O
+clear	O
+association	O
+between	O
+viruses	B-SPEC
+and	O
+hosts	B-COMP
+was	O
+observed	O
+.	O
+
+TITLE	O
+:	O
+Structural	O
+and	O
+molecular	O
+basis	O
+of	O
+mismatch	O
+correction	O
+and	O
+ribavirin	B-CHED
+excision	O
+from	O
+coronavirus	B-SPEC
+RNA	O
+.	O
+
+ABSTRACT	O
+:	O
+Coronaviruses	O
+(	O
+CoVs	O
+)	O
+stand	O
+out	O
+among	O
+RNA	O
+viruses	B-SPEC
+because	O
+of	O
+their	O
+unusually	O
+large	O
+genomes	O
+(∼	O
+30	O
+kb	O
+)	O
+associated	O
+with	O
+low	O
+mutation	O
+rates	O
+.	O
+
+Here	O
+,	O
+we	O
+demonstrate	O
+for	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+(	O
+SARS	B-DISO
+)-	O
+CoV	O
+an	O
+RNA	B-PROC
+synthesis	I-PROC
+and	O
+proofreading	O
+pathway	B-PROC
+through	O
+association	O
+of	O
+nsp14	O
+with	O
+the	O
+low	B-PRGE
+-	I-PRGE
+fidelity	I-PRGE
+nsp12	I-PRGE
+viral	I-PRGE
+RNA	I-PRGE
+polymerase	I-PRGE
+.	O
+
+TITLE	O
+:	O
+Acute	B-DISO
+Chest	I-DISO
+Syndrome	I-DISO
+in	O
+Children	O
+with	O
+Sickle	B-DISO
+Cell	I-DISO
+Disease	I-DISO
+.	O
+
+The	O
+etiology	O
+of	O
+ACS	B-FUNC
+is	O
+often	O
+multifactorial	O
+.	O
+
+Other	O
+commonly	O
+associated	O
+etiologies	O
+include	O
+infection	B-DISO
+,	O
+pulmonary	B-DISO
+fat	I-DISO
+embolism	I-DISO
+,	O
+and	O
+infarction	B-DISO
+.	O
+
+The	O
+latter	O
+is	O
+facilitated	O
+by	O
+HDL	B-PRGE
+'	O
+s	O
+intrinsic	O
+ability	O
+to	O
+interact	O
+with	O
+the	O
+ATP	B-PRGE
+-	I-PRGE
+binding	B-FUNC
+cassette	I-PRGE
+receptor	I-PRGE
+A1	I-PRGE
+(	O
+ABCA1	B-PRGE
+)	O
+and	O
+ABCG1	B-PRGE
+,	O
+as	O
+well	O
+as	O
+scavenger	B-PRGE
+receptor	I-PRGE
+type	I-PRGE
+B1	I-PRGE
+(	O
+SR	B-PRGE
+-	I-PRGE
+BI	I-PRGE
+).	O
+
+In	O
+this	O
+Account	O
+,	O
+we	O
+will	O
+provide	O
+an	O
+up	O
+-	O
+to	O
+-	O
+date	O
+overview	O
+on	O
+the	O
+available	O
+methods	O
+for	O
+extraction	O
+,	O
+isolation	O
+,	O
+and	O
+purification	O
+of	O
+apoA	B-PRGE
+-	I-PRGE
+I	I-PRGE
+from	O
+native	O
+HDL	B-CHED
+,	O
+as	O
+well	O
+as	O
+its	O
+recombinant	O
+production	O
+.	O
+
+ApoA	B-PRGE
+-	I-PRGE
+I	I-PRGE
+'	O
+s	O
+subsequent	O
+use	O
+for	O
+the	O
+reconstitution	B-PRGE
+of	I-PRGE
+HDL	I-PRGE
+(	O
+rHDL	O
+)	O
+and	O
+other	O
+HDL	B-CHED
+-	O
+derived	O
+nanobiologics	O
+,	O
+including	O
+innovative	O
+microfluidic	O
+-	O
+based	O
+production	O
+methods	O
+,	O
+and	O
+their	O
+characterization	O
+will	O
+be	O
+discussed	O
+.	O
+
+These	O
+symptoms	O
+were	O
+improved	O
+by	O
+withdrawal	B-DISO
+of	O
+vancomycin	B-CHED
+and	O
+a	O
+pulsed	O
+corticosteroid	B-CHED
+regimen	O
+.	O
+
+A	O
+literature	O
+search	O
+of	O
+vancomycin	B-CHED
+induced	O
+DRESS	B-DISO
+syndrome	I-DISO
+was	O
+also	O
+performed	O
+and	O
+the	O
+overall	O
+pulmonary	B-DISO
+involvement	I-DISO
+was	O
+estimated	O
+as	O
+5	O
+%.	O
+
+The	O
+use	O
+of	O
+nasal	B-ANAT
+high	O
+-	O
+flow	O
+therapy	O
+(	O
+nHFT	O
+)	O
+has	O
+been	O
+more	O
+recently	O
+introduced	O
+into	O
+the	O
+NICUs	O
+as	O
+a	O
+non	O
+-	O
+invasive	O
+respiratory	O
+(	O
+NIV	O
+)	O
+support	O
+.	O
+
+BPD	B-DISO
+was	O
+diagnosed	O
+in	O
+26	O
+.	O
+6	O
+%	O
+of	O
+preterms	O
+enrolled	O
+(	O
+Mild	O
+20	O
+%,	O
+Moderate	O
+4	O
+.	O
+5	O
+%,	O
+Severe	O
+1	O
+.	O
+5	O
+%).	O
+
+Neither	O
+air	B-CHED
+leaks	O
+nor	O
+nasal	B-ANAT
+injury	O
+were	O
+recorded	O
+as	O
+well	O
+as	O
+no	O
+exitus	O
+occurred	O
+.	O
+
+LOS	O
+,	O
+IVH	O
+,	O
+ROP	B-DISO
+,	O
+NEC	O
+and	O
+PDA	B-DISO
+occurred	O
+respectively	O
+in	O
+16	O
+.	O
+1	O
+%,	O
+0	O
+%,	O
+7	O
+.	O
+8	O
+%,	O
+and	O
+1	O
+.	O
+6	O
+%	O
+of	O
+newborns	O
+.	O
+
+Traditional	O
+diagnostic	O
+criteria	O
+for	O
+pulmonary	B-DISO
+hypertension	I-DISO
+(	O
+PH	O
+),	O
+in	O
+this	O
+situation	O
+,	O
+may	O
+be	O
+unreliable	O
+due	O
+to	O
+the	O
+effects	O
+of	O
+positive	O
+pressure	O
+ventilation	O
+and	O
+vasoactive	O
+agents	O
+.	O
+
+The	O
+aim	O
+of	O
+this	O
+study	O
+is	O
+to	O
+describe	O
+the	O
+hemodynamic	B-PROC
+characteristics	O
+of	O
+PH	O
+secondary	O
+to	O
+ARDS	B-DISO
+,	O
+in	O
+relation	O
+with	O
+respiratory	O
+parameters	O
+.	O
+
+We	O
+assessed	O
+the	O
+hemodynamic	B-PROC
+,	O
+respiratory	B-PROC
+function	I-PROC
+,	O
+and	O
+ventilator	O
+parameters	O
+in	O
+a	O
+cohort	O
+of	O
+38	O
+individuals	O
+with	O
+ARDS	B-DISO
+-	O
+associated	O
+PH	O
+defined	O
+by	O
+mean	O
+pulmonary	B-ANAT
+arterial	B-PROC
+pressure	I-PROC
+(	O
+mPAP	O
+)	O
+≥	O
+25	O
+mmHg	O
+.	O
+
+Respiratory	O
+TAC	B-CHED
+detected	O
+nucleic	B-CHED
+acid	I-CHED
+for	O
+24	O
+different	O
+microbial	O
+agents	O
+,	O
+including	O
+12	O
+viruses	B-SPEC
+and	O
+12	O
+bacteria	B-SPEC
+.	O
+
+Our	O
+epidemiologic	O
+investigation	O
+demonstrated	O
+both	O
+age	O
+and	O
+symptomatic	O
+presentation	O
+to	O
+be	O
+associated	O
+with	O
+a	O
+number	O
+of	O
+detected	O
+agents	O
+,	O
+including	O
+,	O
+but	O
+not	O
+limited	O
+to	O
+,	O
+influenza	B-PATH
+A	I-PATH
+and	O
+Plasmodium	B-SPEC
+.	O
+
+RESULTS	O
+:	O
+From	O
+15	O
+September	O
+2014	O
+-	O
+13	O
+September	O
+2015	O
+,	O
+1007	O
+febrile	B-PROC
+patients	O
+were	O
+enrolled	O
+,	O
+and	O
+997	O
+contributed	O
+an	O
+epidemiologic	O
+survey	O
+,	O
+including	O
+:	O
+14	O
+%	O
+(	O
+n	O
+=	O
+139	O
+)	O
+1	O
+<	O
+5yrs	O
+,	O
+19	O
+%	O
+(	O
+n	O
+=	O
+186	O
+)	O
+5	O
+-	O
+14yrs	O
+,	O
+and	O
+67	O
+%	O
+(	O
+n	O
+=	O
+672	O
+)	O
+≥	O
+15yrs	O
+.	O
+
+TITLE	O
+:	O
+The	O
+OC43	B-PRGE
+human	I-PRGE
+coronavirus	I-PRGE
+envelope	B-COMP
+protein	B-CHED
+is	O
+critical	O
+for	O
+infectious	B-DISO
+virus	B-SPEC
+production	O
+and	O
+propagation	O
+in	O
+neuronal	O
+cells	O
+and	O
+is	O
+a	O
+determinant	O
+of	O
+neurovirulence	O
+and	O
+CNS	B-CHED
+pathology	B-DISO
+.	O
+
+ABSTRACT	O
+:	O
+Bovine	B-SPEC
+ephemeral	I-SPEC
+fever	I-SPEC
+virus	I-SPEC
+(	O
+BEFV	O
+),	O
+identified	O
+as	O
+the	O
+causative	O
+pathogen	O
+of	O
+bovine	B-DISO
+ephemeral	I-DISO
+fever	B-PROC
+(	O
+BEF	O
+),	O
+is	O
+responsible	O
+for	O
+increasing	O
+numbers	O
+of	O
+epidemics	O
+/	O
+outbreaks	O
+and	O
+has	O
+a	O
+significant	O
+harmful	O
+effect	O
+on	O
+the	O
+livestock	O
+industry	O
+.	O
+
+The	O
+spike	O
+(	O
+S	O
+)	O
+protein	B-CHED
+in	O
+the	O
+PEDV	B-SPEC
+capsid	B-ANAT
+structure	O
+can	O
+carry	O
+the	O
+major	O
+B	B-ANAT
+lymphocyte	I-ANAT
+epitope	B-CHED
+,	O
+which	O
+induces	O
+production	O
+of	O
+neutralizing	O
+antibodies	B-COMP
+and	O
+provides	O
+immunoprotective	O
+effects	O
+.	O
+
+TITLE	O
+:	O
+Rhabdomyolysis	B-DISO
+-	O
+Associated	O
+Acute	O
+Kidney	B-ANAT
+Injury	O
+With	O
+Normal	O
+Creatine	B-CHED
+Phosphokinase	O
+.	O
+
+Supportive	O
+management	O
+and	O
+renal	O
+replacement	O
+therapy	O
+was	O
+provided	O
+,	O
+and	O
+renal	B-PROC
+function	I-PROC
+spontaneously	O
+improved	O
+after	O
+a	O
+few	O
+weeks	O
+.	O
+
+Activities	O
+such	O
+as	O
+performing	O
+more	O
+thorough	O
+cleanings	O
+to	O
+remove	O
+residual	O
+virus	B-SPEC
+or	O
+implementing	O
+stricter	O
+on	O
+-	O
+farm	O
+biosecurity	O
+to	O
+cease	O
+between	O
+-	O
+house	O
+virus	B-SPEC
+transfer	O
+demonstrated	O
+little	O
+effectiveness	O
+for	O
+the	O
+control	O
+of	O
+PED	B-PRGE
+.	O
+
+TITLE	O
+:	O
+Identification	O
+of	O
+two	O
+antiviral	B-CHED
+inhibitors	B-CHED
+targeting	B-PROC
+3C	O
+-	O
+like	O
+serine	B-PRGE
+/	I-PRGE
+3C	I-PRGE
+-	I-PRGE
+like	I-PRGE
+protease	I-PRGE
+of	O
+porcine	B-DISO
+reproductive	I-DISO
+and	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+virus	I-SPEC
+and	O
+porcine	B-SPEC
+epidemic	I-SPEC
+diarrhea	I-SPEC
+virus	I-SPEC
+.	O
+
+SD	O
+strain	O
+was	O
+more	O
+virulent	O
+in	O
+3	O
+-	O
+week	O
+-	O
+old	O
+specific	O
+-	O
+pathogen	O
+-	O
+free	O
+chickens	B-SPEC
+than	O
+M41	O
+strain	O
+causing	O
+higher	O
+mortality	O
+with	O
+severe	O
+renal	B-ANAT
+lesions	O
+.	O
+
+Extracorporeal	O
+membrane	B-COMP
+oxygenation	B-PROC
+was	O
+instituted	O
+in	O
+17	O
+patients	O
+;	O
+15	O
+of	O
+these	O
+patients	O
+required	O
+CRRT	O
+.	O
+
+However	O
+,	O
+the	O
+relative	O
+contribution	O
+of	O
+memory	B-PROC
+CD8	B-PRGE
+T	B-ANAT
+cells	I-ANAT
+in	O
+providing	O
+protection	O
+against	O
+respiratory	B-SPEC
+syncytial	I-SPEC
+virus	I-SPEC
+(	O
+RSV	B-SPEC
+)	O
+infection	B-DISO
+is	O
+currently	O
+unclear	O
+.	O
+
+Recent	O
+outbreaks	O
+of	O
+avian	B-DISO
+influenza	B-SPEC
+viruses	I-SPEC
+,	O
+Middle	O
+East	O
+respiratory	O
+syndrome	B-DISO
+coronaviruses	O
+,	O
+Zika	B-SPEC
+virus	I-SPEC
+and	O
+Ebola	B-SPEC
+virus	I-SPEC
+present	O
+great	O
+threats	O
+to	O
+global	O
+health	O
+.	O
+
+Herein	O
+,	O
+we	O
+summarize	O
+the	O
+current	O
+updates	O
+on	O
+the	O
+characteristics	O
+of	O
+human	B-SPEC
+T	B-ANAT
+-	I-ANAT
+cell	I-ANAT
+immunological	O
+responses	O
+against	O
+recently	O
+emerged	O
+or	O
+re	O
+-	O
+emerged	O
+viruses	O
+,	O
+and	O
+emphasize	O
+the	O
+necessity	O
+for	O
+timely	O
+investigation	O
+on	O
+the	O
+T	B-ANAT
+-	I-ANAT
+cell	I-ANAT
+features	O
+of	O
+these	O
+viral	B-DISO
+diseases	I-DISO
+,	O
+which	O
+may	O
+provide	O
+beneficial	O
+recommendations	O
+for	O
+clinical	O
+diagnosis	O
+and	O
+vaccine	O
+development	B-PROC
+.	O
+
+TITLE	O
+:	O
+Accessory	O
+proteins	B-CHED
+8b	O
+and	O
+8ab	O
+of	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+coronavirus	B-SPEC
+suppress	O
+the	O
+interferon	B-PRGE
+signaling	B-PROC
+pathway	I-PROC
+by	O
+mediating	O
+ubiquitin	B-PROC
+-	O
+dependent	O
+rapid	O
+degradation	O
+of	O
+interferon	B-PRGE
+regulatory	I-PRGE
+factor	I-PRGE
+3	I-PRGE
+.	O
+
+This	O
+inhomogeneity	O
+is	O
+normally	O
+caused	O
+by	O
+the	O
+presence	O
+of	O
+lung	B-DISO
+edema	I-DISO
+and	O
+/	O
+or	O
+anatomical	O
+variations	O
+,	O
+and	O
+is	O
+deeply	O
+influenced	O
+by	O
+the	O
+gravitational	O
+forces	O
+.	O
+
+TITLE	O
+:	O
+Six	O
+-	O
+month	O
+Outcome	O
+of	O
+Immunocompromised	O
+Severe	O
+ARDS	B-DISO
+Patients	O
+Rescued	O
+by	O
+ECMO	O
+.	O
+
+Multivariate	O
+analyses	O
+retained	O
+<	O
+30	O
+days	O
+between	O
+immunodeficiency	B-DISO
+diagnosis	O
+and	O
+ECMO	O
+cannulation	O
+as	O
+being	O
+associated	O
+with	O
+lower	O
+6	O
+-	O
+month	O
+mortality	O
+(	O
+odds	O
+ratio	O
+0	O
+.	O
+32	O
+(	O
+95	O
+%	O
+confidence	O
+interval	O
+0	O
+.	O
+16	O
+-	O
+0	O
+.	O
+66	O
+);	O
+P	O
+=	O
+0	O
+.	O
+002	O
+),	O
+and	O
+lower	O
+platelet	B-ANAT
+count	O
+,	O
+higher	O
+PCO2	O
+,	O
+age	O
+and	O
+driving	O
+pressure	O
+as	O
+independent	O
+pre	O
+-	O
+ECMO	O
+predictors	O
+of	O
+6	O
+-	O
+month	O
+mortality	O
+.	O
+
+We	O
+found	O
+that	O
+MERS	O
+human	B-SPEC
+/	O
+camel	B-SPEC
+isolates	O
+showed	O
+a	O
+low	O
+codon	O
+usage	O
+bias	B-SPEC
+.	O
+
+Additionally	O
+,	O
+the	O
+codon	O
+usage	O
+pattern	O
+of	O
+MERS	O
+-	O
+CoV	O
+isolates	O
+is	O
+different	O
+from	O
+other	O
+related	O
+Nidovirales	B-SPEC
+viruses	B-SPEC
+isolated	O
+from	O
+bats	O
+and	O
+hedgehogs	B-SPEC
+.	O
+
+We	O
+previously	O
+determined	O
+the	O
+immunogenicity	O
+of	O
+a	O
+novel	O
+dendritic	B-ANAT
+cell	B-COMP
+(	O
+DC	O
+)-	O
+targeted	B-PROC
+PEDV	B-PRGE
+S1	I-PRGE
+protein	B-CHED
+-	O
+based	O
+subunit	O
+vaccine	O
+in	O
+weaned	B-PROC
+piglets	O
+in	O
+which	O
+the	O
+PEDV	B-PRGE
+antigen	B-CHED
+was	O
+targeted	B-PROC
+to	O
+DCs	B-DISO
+through	O
+a	O
+porcine	B-PRGE
+Langerin	I-PRGE
+-	I-PRGE
+specific	I-PRGE
+antibody	B-COMP
+.	O
+
+In	O
+this	O
+study	O
+,	O
+we	O
+evaluated	O
+the	O
+protective	O
+efficacy	O
+of	O
+this	O
+DC	O
+-	O
+targeting	B-PROC
+vaccine	O
+by	O
+immunizing	O
+sows	O
+at	O
+5	O
+and	O
+2	O
+weeks	O
+prior	O
+to	O
+farrowing	B-PROC
+and	O
+by	O
+challenging	O
+the	O
+5	O
+-	O
+day	O
+-	O
+old	O
+piglets	O
+with	O
+PEDV	O
+.	O
+
+Therefore	O
+,	O
+rapid	O
+,	O
+automated	O
+identification	O
+of	O
+the	O
+canthi	O
+regions	O
+within	O
+facial	B-ANAT
+IR	O
+images	O
+may	O
+greatly	O
+facilitate	O
+rapid	O
+fever	B-PROC
+screening	O
+of	O
+asymptomatic	O
+travelers	O
+.	O
+
+Influenza	B-SPEC
+virus	I-SPEC
+,	O
+respiratory	B-SPEC
+syncytial	I-SPEC
+virus	I-SPEC
+,	O
+and	O
+parainfluenza	B-DISO
+virus	B-SPEC
+were	O
+also	O
+detected	O
+.	O
+
+Numerous	O
+risk	O
+factors	O
+have	O
+been	O
+identified	O
+in	O
+the	O
+aetiology	O
+of	O
+severe	O
+RSV	B-SPEC
+-	O
+associated	O
+ALRI	O
+necessitating	O
+hospitalisation	O
+,	O
+including	O
+prematurity	O
+and	O
+congenital	B-DISO
+heart	I-DISO
+disease	I-DISO
+.	O
+
+Biochemical	O
+and	O
+structural	O
+studies	O
+revealed	O
+the	O
+enzymatic	O
+nature	O
+of	O
+nsp15	O
+/	O
+EndoU	B-PRGE
+,	O
+which	O
+was	O
+postulated	O
+to	O
+be	O
+essential	O
+for	O
+the	O
+unique	O
+replication	O
+cycle	O
+of	O
+viruses	B-SPEC
+in	O
+the	O
+order	B-SPEC
+Nidovirales	I-SPEC
+.	O
+
+ABSTRACT	O
+:	O
+To	O
+design	O
+bundle	O
+treatment	O
+plan	B-DISO
+in	O
+the	O
+early	O
+stage	O
+for	O
+severe	O
+human	B-SPEC
+infection	B-DISO
+by	O
+avian	B-DISO
+influenza	I-DISO
+H7N9	O
+,	O
+and	O
+explore	O
+its	O
+clinical	O
+efficacy	O
+and	O
+application	O
+value	O
+.	O
+
+RESULTS	O
+:	O
+There	O
+was	O
+no	O
+significant	O
+difference	O
+in	O
+gender	O
+,	O
+age	O
+,	O
+onset	O
+to	O
+diagnosis	O
+time	O
+,	O
+APACHE	O
+II	O
+score	O
+,	O
+PaO	B-PROC
+
+Receiver	O
+operating	O
+characteristic	O
+(	O
+ROC	O
+)	O
+curve	O
+was	O
+plotted	O
+to	O
+evaluate	O
+MODS	B-DISO
+warning	O
+score	O
+for	O
+predicting	O
+the	O
+occurrence	O
+of	O
+MODS	B-DISO
+in	O
+patients	O
+with	O
+severe	O
+trauma	O
+.	O
+
+ABSTRACT	O
+:	O
+Tenofovir	O
+disoproxil	O
+fumarate	O
+(	O
+TDF	B-CHED
+)	O
+is	O
+a	O
+commonly	O
+used	O
+antiretroviral	O
+drug	O
+for	O
+HIV	B-DISO
+,	O
+rarely	O
+causing	O
+Fanconi	B-DISO
+syndrome	I-DISO
+and	O
+acute	O
+kidney	B-ANAT
+injury	O
+.	O
+
+ABSTRACT	O
+:	O
+Despite	O
+being	O
+still	O
+invasive	O
+and	O
+challenging	O
+,	O
+technical	O
+improvement	O
+has	O
+resulted	O
+in	O
+broader	O
+and	O
+more	O
+frequent	O
+application	O
+of	O
+extracorporeal	O
+membrane	B-COMP
+oxygenation	B-PROC
+(	O
+ECMO	O
+),	O
+to	O
+prevent	O
+hypoxemia	O
+and	O
+to	O
+reduce	O
+invasiveness	O
+of	O
+mechanical	O
+ventilation	O
+(	O
+MV	O
+).	O
+
+The	O
+following	O
+data	O
+were	O
+collected	O
+:	O
+demographics	O
+,	O
+hemodynamic	O
+data	O
+,	O
+coagulation	B-PROC
+samples	O
+,	O
+transfusion	O
+requirements	O
+,	O
+change	O
+of	O
+ECMO	O
+-	O
+circuit	O
+during	O
+treatment	O
+and	O
+adverse	B-DISO
+effects	I-DISO
+,	O
+including	O
+hemorrhage	B-DISO
+and	O
+thrombosis	B-DISO
+.	O
+
+Hepatic	B-ANAT
+enzymes	O
+,	O
+antioxidant	B-CHED
+defenses	O
+and	O
+lipids	B-CHED
+content	O
+and	O
+composition	O
+were	O
+also	O
+evaluated	O
+.	O
+
+Immunosuppressive	O
+treatment	O
+consisted	O
+in	O
+high	O
+-	O
+dose	O
+corticosteroids	B-CHED
+and	O
+cyclophosphamide	B-CHED
+in	O
+one	O
+case	O
+.	O
+
+ABSTRACT	O
+:	O
+In	O
+acute	O
+respiratory	O
+distress	O
+syndrome	O
+(	O
+ARDS	B-DISO
+),	O
+atelectatic	O
+solid	O
+-	O
+like	O
+lung	B-ANAT
+tissue	I-ANAT
+impairs	O
+transmission	O
+of	O
+negative	O
+swings	O
+in	O
+pleural	O
+pressure	O
+(	O
+Ppl	B-FUNC
+)	O
+that	O
+result	O
+from	O
+diaphragmatic	B-ANAT
+contraction	B-DISO
+.	O
+
+The	O
+localization	B-PROC
+of	O
+more	O
+negative	O
+Ppl	B-FUNC
+proportionally	O
+increases	O
+dependent	O
+lung	B-ANAT
+stretch	O
+by	O
+drawing	O
+gas	B-ENZY
+either	O
+from	O
+other	O
+lung	B-ANAT
+regions	O
+(	O
+e	O
+.	O
+g	O
+.,	O
+nondependent	O
+lung	B-ANAT
+[	O
+pendelluft	O
+])	O
+or	O
+from	O
+the	O
+ventilator	O
+.	O
+
+TITLE	O
+:	O
+Inhibitory	O
+effect	O
+of	O
+circulating	O
+fibrocytes	B-ANAT
+on	O
+injury	O
+repair	B-PROC
+in	O
+acute	O
+lung	B-ANAT
+injury	O
+/	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+mice	B-SPEC
+model	O
+.	O
+
+This	O
+might	O
+be	O
+unfavorable	O
+as	O
+a	O
+clinical	O
+marker	O
+for	O
+progression	O
+of	O
+ALI	O
+/	O
+ARDS	B-DISO
+.	O
+
+Additional	O
+nonventilated	O
+animals	B-SPEC
+(	O
+n	O
+=	O
+7	O
+)	O
+were	O
+used	O
+as	O
+a	O
+control	O
+for	O
+postmortem	O
+analysis	O
+.	O
+
+During	O
+PSV	O
+,	O
+PEEP	B-CHED
+of	O
+5	O
+cmH2O	O
+,	O
+but	O
+not	O
+a	O
+PEEP	B-CHED
+of	O
+2	O
+cmH2O	O
+,	O
+reduced	O
+lung	B-ANAT
+damage	O
+and	O
+inflammatory	O
+markers	O
+while	O
+maintaining	O
+epithelial	B-ANAT
+cell	I-ANAT
+integrity	O
+.	O
+
+CONCLUSIONS	O
+:	O
+During	O
+PSV	O
+,	O
+PEEP	B-CHED
+of	O
+5	O
+cmH2O	O
+,	O
+but	O
+not	O
+a	O
+PEEP	B-CHED
+of	O
+2	O
+cmH2O	O
+,	O
+reduced	O
+lung	B-ANAT
+damage	O
+and	O
+inflammatory	O
+markers	O
+while	O
+maintaining	O
+epithelial	B-ANAT
+cell	I-ANAT
+integrity	O
+.	O
+
+Male	O
+C56BL	O
+/	O
+6	O
+mice	B-SPEC
+were	O
+administered	O
+UTI	B-DISO
+intravenously	O
+1	O
+h	O
+before	O
+and	O
+6	O
+h	O
+after	O
+exposure	O
+to	O
+LPS	B-DISO
+by	O
+intratracheal	O
+instillation	O
+.	O
+
+These	O
+data	O
+indicate	O
+that	O
+high	O
+level	O
+of	O
+NETs	O
+contributes	O
+to	O
+lung	B-ANAT
+injury	O
+and	O
+is	O
+correlated	O
+with	O
+severity	O
+of	O
+disease	O
+.	O
+
+The	O
+661	O
+classic	O
+patients	O
+with	O
+available	O
+electromyographic	O
+data	O
+were	O
+grouped	O
+as	O
+having	O
+acute	B-DISO
+inflammatory	I-DISO
+demyelinating	I-DISO
+polyneuropathy	I-DISO
+(	O
+AIDP	B-DISO
+,	O
+49	O
+.	O
+0	O
+%),	O
+acute	O
+motor	O
+axonal	B-DISO
+neuropathy	I-DISO
+(	O
+AMAN	O
+,	O
+18	O
+.	O
+8	O
+%),	O
+inexcitable	O
+(	O
+0	O
+.	O
+9	O
+%)	O
+and	O
+equivocal	O
+(	O
+31	O
+.	O
+3	O
+%).	O
+
+Recent	O
+studies	O
+suggest	O
+that	O
+MHV	B-SPEC
+infection	B-DISO
+alters	O
+gap	B-COMP
+junction	I-COMP
+protein	B-CHED
+connexin	B-PRGE
+43	I-PRGE
+(	O
+Cx43	B-PRGE
+)-	O
+mediated	O
+intercellular	B-PROC
+communication	I-PROC
+in	O
+brain	B-ANAT
+and	O
+primary	O
+cultured	O
+astrocytes	B-ANAT
+.	O
+
+Reduced	O
+trafficking	B-PROC
+of	O
+Cx43	O
+to	O
+the	O
+cell	B-COMP
+surface	I-COMP
+in	O
+MHV	B-SPEC
+-	O
+infected	O
+cells	B-COMP
+is	O
+associated	O
+with	O
+loss	O
+functional	O
+GJIC	O
+.	O
+
+The	O
+primary	O
+focus	O
+was	O
+on	O
+the	O
+prevalence	O
+of	O
+respiratory	O
+viruses	B-SPEC
+,	O
+including	O
+AdV	O
+(	O
+adenovirus	B-DISO
+),	O
+BoV	O
+(	O
+bocavirus	B-SPEC
+),	O
+CoV	O
+(	O
+coronavirus	B-SPEC
+),	O
+CMV	B-SPEC
+(	O
+cytomegalovirus	B-SPEC
+),	O
+EnV	B-PRGE
+(	O
+enterovirus	B-SPEC
+),	O
+HSV	B-SPEC
+(	O
+herpes	B-SPEC
+simplex	I-SPEC
+virus	I-SPEC
+),	O
+IfV	B-SPEC
+(	O
+influenza	B-SPEC
+virus	I-SPEC
+),	O
+MpV	B-SPEC
+(	O
+metapneumovirus	B-SPEC
+),	O
+PiV	O
+(	O
+parainfluenzavirus	O
+),	O
+RV	O
+(	O
+rhinovirus	B-SPEC
+)	O
+and	O
+RSV	B-SPEC
+(	O
+respiratory	O
+syncytial	O
+virus	O
+)	O
+during	O
+asthma	B-PATH
+exacerbations	O
+.	O
+
+RV	O
+was	O
+the	O
+major	O
+virus	B-SPEC
+detected	O
+globally	O
+,	O
+except	O
+in	O
+Africa	O
+.	O
+
+The	O
+most	O
+common	O
+adverse	O
+events	O
+were	O
+headache	O
+(	O
+n	O
+=	O
+6	O
+[	O
+21	O
+%]	O
+in	O
+participants	O
+who	O
+received	O
+SAB	O
+-	O
+301	O
+and	O
+n	O
+=	O
+2	O
+[	O
+20	O
+%]	O
+in	O
+those	O
+receiving	O
+placebo	O
+),	O
+albuminuria	O
+(	O
+n	O
+=	O
+5	O
+[	O
+18	O
+%]	O
+vs	O
+n	O
+=	O
+2	O
+[	O
+20	O
+%]),	O
+myalgia	B-DISO
+(	O
+n	O
+=	O
+3	O
+[	O
+11	O
+%]	O
+vs	O
+n	O
+=	O
+1	O
+[	O
+10	O
+%]),	O
+increased	O
+creatine	B-PRGE
+kinase	I-PRGE
+(	O
+n	O
+=	O
+3	O
+[	O
+11	O
+%]	O
+vs	O
+1	O
+[	O
+10	O
+%]),	O
+and	O
+common	B-DISO
+cold	I-DISO
+(	O
+n	O
+=	O
+3	O
+[	O
+11	O
+%]	O
+vs	O
+n	O
+=	O
+2	O
+[	O
+20	O
+%]).	O
+
+TITLE	O
+:	O
+Real	O
+-	O
+time	O
+reverse	B-PROC
+transcription	I-PROC
+recombinase	O
+polymerase	O
+amplification	B-DISO
+assay	O
+for	O
+rapid	O
+detection	O
+of	O
+porcine	O
+epidemic	O
+diarrhea	O
+virus	O
+.	O
+
+ABSTRACT	O
+:	O
+Porcine	B-SPEC
+epidemic	B-DISO
+diarrhea	I-DISO
+(	O
+PED	O
+),	O
+which	O
+is	O
+caused	O
+by	O
+porcine	B-SPEC
+epidemic	I-SPEC
+diarrhea	I-SPEC
+virus	I-SPEC
+(	O
+PEDV	B-SPEC
+),	O
+is	O
+an	O
+acute	O
+,	O
+highly	O
+contagious	O
+enteric	O
+disease	O
+characterized	O
+by	O
+severe	O
+watery	B-DISO
+diarrhea	I-DISO
+,	O
+vomiting	B-DISO
+,	O
+dehydration	B-DISO
+,	O
+and	O
+high	O
+mortality	O
+in	O
+suckling	O
+piglets	O
+.	O
+
+A	O
+real	O
+-	O
+time	O
+reverse	O
+-	O
+transcription	B-PROC
+recombinase	B-PRGE
+polymerase	I-PRGE
+amplification	B-DISO
+assay	O
+(	O
+RT	B-PRGE
+-	I-PRGE
+RPA	I-PRGE
+)	O
+was	O
+developed	O
+based	O
+on	O
+the	O
+nucleocapsid	B-COMP
+gene	O
+of	O
+PEDV	B-SPEC
+.	O
+
+Using	O
+the	O
+in	O
+vitro	O
+transcribed	O
+PEDV	B-SPEC
+RNA	O
+as	O
+template	O
+,	O
+the	O
+analytical	O
+sensitivity	O
+was	O
+23	O
+copies	O
+per	O
+reaction	O
+.	O
+
+Neither	O
+antibody	B-COMP
+titers	O
+against	O
+viruses	B-SPEC
+nor	O
+lymphoid	B-ANAT
+tissues	I-ANAT
+weight	O
+were	O
+affected	O
+by	O
+RP	O
+and	O
+/	O
+or	O
+VE	O
+(	O
+P	O
+>	O
+0	O
+.	O
+05	O
+)	O
+treatments	O
+.	O
+
+Since	O
+the	O
+emergence	O
+of	O
+new	O
+coronaviruses	O
+and	O
+paramyxoviruses	O
+in	O
+humans	B-SPEC
+(	O
+e	O
+.	O
+g	O
+.	O
+Severe	B-DISO
+Acute	I-DISO
+Respiratory	I-DISO
+Syndrome	I-DISO
+Coronavirus	B-SPEC
+(	O
+SARS	B-DISO
+-	O
+CoV	O
+)	O
+and	O
+Nipah	B-SPEC
+virus	I-SPEC
+),	O
+numerous	O
+studies	O
+clearly	O
+established	O
+that	O
+bats	B-SPEC
+can	O
+maintain	O
+some	O
+of	O
+these	O
+viruses	B-SPEC
+.	O
+
+The	O
+aim	O
+of	O
+this	O
+study	O
+was	O
+to	O
+evaluate	O
+the	O
+quality	O
+of	O
+inter	O
+-	O
+hospital	O
+transport	B-PROC
+(	O
+IHT	O
+)	O
+of	O
+ARDS	B-DISO
+patients	O
+.	O
+
+63	O
+.	O
+1	O
+%	O
+of	O
+transferred	O
+patients	O
+were	O
+male	O
+,	O
+median	O
+age	O
+was	O
+54	O
+years	O
+,	O
+and	O
+26	O
+.	O
+8	O
+%	O
+of	O
+patients	O
+were	O
+obese	B-DISO
+.	O
+
+In	O
+addition	O
+,	O
+all	O
+studied	O
+IBVs	O
+were	O
+distinctly	O
+separate	O
+from	O
+Massachusetts	O
+(	O
+70	O
+%-	O
+72	O
+%	O
+amino	B-CHED
+acid	I-CHED
+similarity	O
+)	O
+and	O
+European	O
+strains	O
+including	O
+793	O
+/	O
+B	O
+,	O
+Italy	O
+-	O
+02	O
+,	O
+and	O
+D274	O
+(	O
+68	O
+%-	O
+73	O
+%	O
+amino	B-CHED
+acid	I-CHED
+similarity	O
+).	O
+
+TITLE	O
+:	O
+Evaluation	O
+of	O
+Almitrine	B-CHED
+Infusion	O
+During	O
+Veno	O
+-	O
+Venous	B-ANAT
+Extracorporeal	O
+Membrane	B-COMP
+Oxygenation	B-PROC
+for	O
+Severe	O
+Acute	O
+Respiratory	O
+Distress	O
+Syndrome	O
+in	O
+Adults	O
+.	O
+
+In	O
+this	O
+study	O
+,	O
+we	O
+sought	O
+to	O
+leverage	O
+this	O
+uneven	O
+viral	O
+antagonism	O
+to	O
+identify	O
+critical	O
+host	B-COMP
+factors	O
+that	O
+govern	O
+disease	O
+outcome	O
+.	O
+
+Utilizing	O
+a	O
+systems	O
+-	O
+based	O
+approach	O
+,	O
+we	O
+examined	O
+differential	O
+regulation	B-PROC
+of	O
+IFN	B-PRGE
+-	I-PRGE
+γ	I-PRGE
+-	O
+dependent	O
+genes	O
+following	O
+infection	B-DISO
+with	O
+robust	O
+respiratory	O
+viruses	B-SPEC
+including	O
+influenza	B-SPEC
+viruses	I-SPEC
+[	O
+A	O
+/	O
+influenza	B-DISO
+/	O
+Vietnam	O
+/	O
+1203	O
+/	O
+2004	O
+(	O
+H5N1	B-DISO
+-	O
+VN1203	O
+)	O
+and	O
+A	O
+/	O
+influenza	B-DISO
+/	O
+California	B-SPEC
+/	O
+04	O
+/	O
+2009	O
+(	O
+H1N1	O
+-	O
+CA04	O
+)]	O
+and	O
+coronaviruses	O
+[	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+coronavirus	B-SPEC
+(	O
+SARS	B-DISO
+-	O
+CoV	O
+)	O
+and	O
+Middle	O
+East	O
+respiratory	O
+syndrome	B-DISO
+CoV	O
+(	O
+MERS	O
+-	O
+CoV	O
+)].	O
+
+ABSTRACT	O
+:	O
+Acute	O
+kidney	O
+injury	O
+(	O
+AKI	O
+)	O
+after	O
+multiple	O
+Hymenoptera	B-SPEC
+stings	O
+is	O
+well	O
+known	O
+but	O
+still	O
+a	O
+rare	O
+phenomenon	O
+.	O
+
+The	O
+predominant	O
+lesion	O
+was	O
+acute	B-DISO
+tubular	I-DISO
+necrosis	I-DISO
+(	O
+ATN	B-DISO
+)	O
+with	O
+or	O
+without	O
+pigmented	O
+granular	B-ANAT
+cast	B-ANAT
+in	O
+10	O
+(	O
+77	O
+%)	O
+patients	O
+.	O
+
+In	O
+four	O
+(	O
+30	O
+.	O
+8	O
+%)	O
+patients	O
+,	O
+the	O
+kidney	B-ANAT
+biopsy	O
+showed	O
+severe	O
+ATN	B-DISO
+and	O
+in	O
+the	O
+other	O
+six	O
+(	O
+46	O
+.	O
+2	O
+%),	O
+the	O
+kidney	B-ANAT
+biopsy	O
+showed	O
+features	O
+of	O
+ATN	B-DISO
+associated	O
+with	O
+mild	O
+to	O
+moderate	O
+acute	B-DISO
+interstitial	I-DISO
+nephritis	I-DISO
+(	O
+AIN	O
+).	O
+
+In	O
+three	O
+(	O
+23	O
+%)	O
+patients	O
+the	O
+histopathological	O
+examination	O
+revealed	O
+only	O
+moderate	O
+AIN	O
+and	O
+these	O
+patients	O
+were	O
+treated	O
+with	O
+a	O
+short	O
+course	O
+of	O
+steroids	B-CHED
+.	O
+
+A	O
+retrospective	O
+study	O
+was	O
+performed	O
+on	O
+all	O
+patients	O
+with	O
+ARDS	B-DISO
+with	O
+hematological	B-DISO
+malignancies	I-DISO
+in	O
+a	O
+single	O
+tertiary	O
+teaching	O
+hospital	O
+between	O
+2008	O
+and	O
+2015	O
+.	O
+
+This	O
+study	O
+focuses	O
+on	O
+a	O
+new	O
+mechanism	O
+of	O
+SPC	O
+as	O
+an	O
+anti	O
+-	O
+inflammatory	O
+molecule	O
+using	O
+SPC	B-PRGE
+-	I-PRGE
+TK	I-PRGE
+/	O
+SPC	B-PRGE
+-	O
+KO	O
+(	O
+surfactant	B-PRGE
+protein	B-CHED
+C	I-PRGE
+-	I-PRGE
+thymidine	B-ENZY
+kinase	I-ENZY
+/	O
+surfactant	B-PRGE
+protein	B-CHED
+C	I-PRGE
+knockout	O
+)	O
+mice	B-SPEC
+,	O
+which	O
+represent	O
+a	O
+novel	O
+sterile	B-DISO
+injury	O
+model	O
+that	O
+mimics	O
+clinical	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+(	O
+ARDS	B-DISO
+).	O
+
+We	O
+compared	O
+GCV	O
+-	O
+induced	O
+injury	O
+and	O
+repair	B-PROC
+in	O
+SPC	O
+-	O
+TK	O
+mice	B-SPEC
+that	O
+have	O
+normal	O
+endogenous	O
+SPC	O
+expression	B-PROC
+with	O
+SPC	B-PRGE
+-	O
+TK	O
+/	O
+SPC	B-PRGE
+-	O
+KO	O
+mice	B-SPEC
+lacking	O
+SPC	O
+expression	B-PROC
+.	O
+
+Our	O
+findings	O
+showing	O
+a	O
+novel	O
+role	O
+for	O
+SPC	B-PRGE
+in	O
+regulating	O
+inflammation	B-DISO
+via	O
+JAK	B-PROC
+/	O
+STAT	B-PRGE
+may	O
+have	O
+clinical	O
+applications	O
+.	O
+
+There	O
+are	O
+limited	O
+data	O
+on	O
+how	O
+to	O
+balance	B-PROC
+the	O
+costs	O
+and	O
+performance	O
+of	O
+this	O
+important	O
+public	O
+health	O
+activity	O
+.	O
+
+TITLE	O
+:	O
+Species	B-SPEC
+-	O
+specific	O
+clinical	O
+characteristics	O
+of	O
+human	B-SPEC
+coronavirus	I-SPEC
+infection	O
+among	O
+otherwise	O
+healthy	O
+adolescents	O
+and	O
+adults	O
+.	O
+
+We	O
+found	O
+no	O
+significant	O
+influence	O
+of	O
+the	O
+baseline	O
+sepsis	B-DISO
+status	O
+(	O
+P	O
+=	O
+0	O
+.	O
+28	O
+),	O
+baseline	O
+ARDS	O
+status	O
+(	O
+P	O
+=	O
+0	O
+.	O
+94	O
+),	O
+and	O
+baseline	O
+severity	O
+scores	O
+(	O
+P	O
+=	O
+0	O
+.	O
+77	O
+and	O
+P	O
+=	O
+0	O
+.	O
+46	O
+for	O
+SAPS	O
+3	O
+and	O
+SOFA	O
+,	O
+respectively	O
+)	O
+on	O
+the	O
+comparison	O
+of	O
+60	O
+-	O
+day	O
+mortality	O
+according	O
+to	O
+RRT	O
+initiation	O
+strategy	O
+.	O
+
+Time	O
+to	O
+successful	O
+extubation	O
+in	O
+patients	O
+with	O
+ARDS	B-DISO
+was	O
+not	O
+affected	O
+by	O
+RRT	O
+strategy	O
+(	O
+P	O
+=	O
+0	O
+.	O
+43	O
+).	O
+
+Compared	O
+with	O
+mice	B-SPEC
+receiving	O
+vehicle	O
+control	O
+,	O
+mice	B-SPEC
+treated	O
+with	O
+GBT1118	O
+had	O
+significantly	O
+lower	O
+mortality	O
+after	O
+LPS	O
++	O
+5	O
+%	O
+hypoxia	B-DISO
+(	O
+47	O
+%	O
+with	O
+vehicle	O
+vs	O
+.	O
+22	O
+%	O
+with	O
+low	O
+-	O
+dose	O
+GBT1118	O
+,	O
+13	O
+%	O
+with	O
+high	O
+-	O
+dose	O
+GBT1118	O
+,	O
+P	O
+=	O
+0	O
+.	O
+032	O
+by	O
+log	O
+rank	O
+)	O
+and	O
+had	O
+reduced	O
+severity	O
+of	O
+illness	O
+.	O
+
+Mice	B-SPEC
+treated	O
+with	O
+GBT1118	O
+showed	O
+a	O
+sustained	O
+significant	O
+increase	O
+in	O
+SpO	O
+
+A	O
+retrospective	O
+chart	O
+review	O
+(	O
+2010	O
+-	O
+2016	O
+)	O
+of	O
+patients	O
+who	O
+underwent	O
+VV	O
+ECMO	O
+for	O
+ARDS	B-DISO
+was	O
+conducted	O
+with	O
+university	O
+institutional	O
+review	O
+board	O
+(	O
+IRB	O
+)	O
+approval	O
+.	O
+
+We	O
+identified	O
+54	O
+ARDS	B-DISO
+patients	O
+supported	O
+by	O
+VV	O
+ECMO	O
+(	O
+mean	O
+ECMO	O
+days	O
+12	O
+±	O
+6	O
+.	O
+7	O
+)	O
+with	O
+16	O
+(	O
+30	O
+%)	O
+in	O
+the	O
+AKI	O
+group	O
+and	O
+38	O
+(	O
+70	O
+%)	O
+in	O
+the	O
+non	O
+-	O
+AKI	O
+group	O
+.	O
+
+RESULTS	O
+:	O
+We	O
+identified	O
+54	O
+ARDS	B-DISO
+patients	O
+supported	O
+by	O
+VV	O
+ECMO	O
+(	O
+mean	O
+ECMO	O
+days	O
+12	O
+±	O
+6	O
+.	O
+7	O
+)	O
+with	O
+16	O
+(	O
+30	O
+%)	O
+in	O
+the	O
+AKI	O
+group	O
+and	O
+38	O
+(	O
+70	O
+%)	O
+in	O
+the	O
+non	O
+-	O
+AKI	B-PRGE
+group	O
+.	O
+
+TITLE	O
+:	O
+Multiple	O
+Organ	B-ANAT
+Dysfunction	O
+:	O
+The	O
+Defining	O
+Syndrome	B-DISO
+of	O
+Sepsis	B-DISO
+.	O
+
+ABSTRACT	O
+:	O
+Porcine	O
+deltacoronavirus	O
+(	O
+PDCoV	O
+)	O
+is	O
+a	O
+recently	O
+discovered	O
+RNA	O
+virus	B-SPEC
+that	O
+belongs	O
+to	O
+the	O
+family	B-SPEC
+Coronaviridae	I-SPEC
+and	O
+genus	B-SPEC
+Deltacoronavirus	O
+.	O
+
+In	O
+our	O
+present	O
+investigation	O
+,	O
+189	O
+diarrhoeic	O
+samples	O
+were	O
+collected	O
+between	O
+July	O
+2016	O
+and	O
+May	O
+2017	O
+from	O
+Tibetan	O
+pigs	B-SPEC
+inhabiting	O
+in	O
+three	O
+different	O
+provinces	O
+surrounding	O
+the	O
+Qinghai	O
+-	O
+Tibet	O
+Plateau	O
+of	O
+China	O
+.	O
+
+TITLE	O
+:	O
+Isolation	O
+and	O
+phylogenetic	O
+analysis	O
+of	O
+porcine	B-SPEC
+deltacoronavirus	O
+from	O
+pigs	B-SPEC
+with	O
+diarrhoea	B-DISO
+in	O
+Hebei	O
+province	O
+,	O
+China	O
+.	O
+
+Combined	O
+,	O
+our	O
+results	O
+suggest	O
+that	O
+endogenous	O
+galectin	B-PRGE
+-	I-PRGE
+3	I-PRGE
+enhances	O
+the	O
+effects	O
+of	O
+H5N1	B-DISO
+infection	B-DISO
+by	O
+promoting	O
+host	B-COMP
+inflammatory	B-DISO
+responses	I-DISO
+and	O
+regulating	O
+IL	O
+-	O
+1β	O
+production	O
+by	O
+macrophages	B-ANAT
+via	O
+interaction	O
+with	O
+NLRP3	B-PRGE
+.	O
+
+ABSTRACT	O
+:	O
+Avian	B-SPEC
+coronavirus	I-SPEC
+infectious	B-DISO
+bronchitis	B-DISO
+virus	B-SPEC
+(	O
+IBV	B-SPEC
+)	O
+is	O
+a	O
+respiratory	O
+pathogen	O
+of	O
+chickens	B-SPEC
+,	O
+causing	O
+severe	O
+economic	O
+losses	O
+in	O
+poultry	O
+industry	O
+worldwide	O
+.	O
+
+These	O
+assumptions	O
+include	O
+the	O
+effects	O
+of	O
+the	O
+chest	B-ANAT
+wall	I-ANAT
+on	O
+lung	B-ANAT
+-	O
+surface	O
+pressure	O
+,	O
+its	O
+topographical	O
+distribution	O
+,	O
+and	O
+the	O
+effects	O
+of	O
+non	O
+-	O
+uniform	O
+tissue	B-ANAT
+properties	O
+on	O
+local	O
+parenchymal	O
+stresses	O
+.	O
+
+Noninvasive	O
+mechanical	O
+ventilation	O
+is	O
+used	O
+in	O
+some	O
+patients	O
+with	O
+ARDS	B-DISO
+.	O
+
+PEDV	B-SPEC
+is	O
+mainly	O
+transmitted	B-DISO
+by	O
+the	O
+fecal	B-ANAT
+-	O
+oral	B-ANAT
+route	O
+.	O
+
+The	O
+leading	O
+cause	O
+was	O
+daptomycin	B-CHED
+.	O
+
+Eosinophilia	B-DISO
+in	O
+the	O
+blood	B-ANAT
+at	O
+the	O
+time	O
+of	O
+diagnosis	O
+characterized	O
+only	O
+the	O
+CEP	B-DISO
+patients	O
+(	O
+80	O
+%	O
+in	O
+CEP	B-DISO
+vs	O
+.	O
+20	O
+%	O
+in	O
+AEP	O
+).	O
+
+Most	O
+patients	O
+with	O
+EP	O
+were	O
+treated	O
+with	O
+steroids	B-CHED
+with	O
+a	O
+higher	O
+rate	O
+of	O
+relapse	B-DISO
+observed	O
+in	O
+patients	O
+with	O
+CEP	B-DISO
+.	O
+
+When	O
+expressed	B-PROC
+in	O
+isolation	O
+,	O
+CoV	O
+accessory	O
+proteins	B-CHED
+have	O
+been	O
+shown	O
+to	O
+interfere	O
+with	O
+innate	O
+antiviral	B-CHED
+signaling	B-PROC
+pathways	B-PROC
+.	O
+
+Binding	B-FUNC
+of	O
+4b	O
+to	O
+KPNA4	O
+during	O
+infection	B-DISO
+inhibited	O
+its	O
+interaction	O
+with	O
+NF	B-PRGE
+-	I-PRGE
+κB	I-PRGE
+-	I-PRGE
+p65	I-PRGE
+subunit	I-PRGE
+.	O
+
+Moreover	O
+,	O
+based	O
+on	O
+the	O
+findings	O
+,	O
+this	O
+study	O
+also	O
+suggests	O
+methods	O
+to	O
+systematically	O
+train	O
+experts	O
+in	O
+communicable	B-DISO
+diseases	I-DISO
+management	O
+and	O
+a	O
+sustainable	O
+system	O
+to	O
+establish	O
+the	O
+basis	O
+of	O
+and	O
+develop	O
+strategies	O
+for	O
+a	O
+systematic	O
+and	O
+phased	O
+management	O
+of	O
+field	O
+epidemiologist	O
+training	O
+programs	O
+.	O
+
+Moreover	O
+,	O
+based	O
+on	O
+the	O
+findings	O
+,	O
+this	O
+study	O
+also	O
+suggests	O
+methods	O
+to	O
+systematically	O
+train	O
+experts	O
+in	O
+communicable	B-DISO
+diseases	I-DISO
+management	O
+and	O
+a	O
+sustainable	O
+system	O
+to	O
+establish	O
+the	O
+basis	O
+of	O
+and	O
+develop	O
+strategies	O
+for	O
+a	O
+systematic	O
+and	O
+phased	O
+management	O
+of	O
+field	O
+epidemiologist	O
+training	O
+programs	O
+.	O
+
+RESULTS	O
+:	O
+In	O
+seven	O
+cases	O
+,	O
+CNVs	O
+in	O
+various	O
+causative	O
+genes	O
+of	O
+inherited	O
+kidney	B-DISO
+diseases	I-DISO
+were	O
+detected	O
+by	O
+pair	O
+analysis	O
+.	O
+
+TITLE	O
+:	O
+What	O
+Can	O
+We	O
+Apply	O
+to	O
+Manage	O
+Acute	O
+Exacerbation	O
+of	O
+Chronic	B-DISO
+Obstructive	I-DISO
+Pulmonary	I-DISO
+Disease	I-DISO
+with	O
+Acute	O
+Respiratory	O
+Failure	O
+?	O
+
+To	O
+compare	O
+the	O
+mortality	O
+and	O
+functional	O
+status	O
+of	O
+children	O
+with	O
+severe	O
+acute	B-DISO
+respiratory	I-DISO
+failure	I-DISO
+supported	O
+with	O
+and	O
+without	O
+ECMO	O
+.	O
+
+The	O
+study	O
+sample	O
+was	O
+selected	O
+from	O
+children	O
+enrolled	O
+in	O
+the	O
+cluster	O
+-	O
+randomized	O
+RESTORE	O
+(	O
+Randomized	O
+Evaluation	O
+of	O
+Sedation	B-DISO
+Titration	O
+for	O
+Respiratory	B-DISO
+Failure	I-DISO
+)	O
+clinical	O
+trial	O
+.	O
+
+Additionally	O
+,	O
+microglia	B-ANAT
+depletion	O
+resulted	O
+in	O
+ineffective	O
+T	B-ANAT
+cell	I-ANAT
+responses	O
+.	O
+
+Superinfection	B-DISO
+with	O
+influenza	B-SPEC
+virus	I-SPEC
+and	O
+GAS	B-PRGE
+induced	O
+invasive	O
+GAS	B-ENZY
+infections	B-DISO
+was	O
+demonstrated	O
+by	O
+our	O
+team	O
+in	O
+a	O
+mouse	B-SPEC
+model	O
+,	O
+after	O
+which	O
+clinical	O
+cases	O
+of	O
+invasive	O
+GAS	B-ENZY
+infections	B-DISO
+secondary	I-DISO
+to	O
+influenza	B-SPEC
+virus	B-DISO
+infection	I-DISO
+were	O
+reported	O
+by	O
+other	O
+investigators	O
+in	O
+Japan	O
+,	O
+USA	O
+,	O
+Canada	O
+,	O
+UK	O
+China	O
+,	O
+and	O
+other	O
+countries	O
+.	O
+
+Topics	O
+addressed	O
+include	O
+the	O
+bacteriological	O
+,	O
+virological	O
+and	O
+immunological	O
+mechanisms	O
+impacting	O
+invasion	B-DISO
+upon	O
+superinfection	B-DISO
+on	O
+top	O
+of	O
+underlying	O
+influenza	B-SPEC
+virus	B-DISO
+infection	I-DISO
+by	O
+GAS	B-ENZY
+and	O
+other	O
+bacteria	B-SPEC
+(	O
+i	O
+.	O
+e	O
+.,	O
+Streptococcus	B-SPEC
+pneumoniae	I-SPEC
+and	O
+Staphylococcus	B-SPEC
+aureus	I-SPEC
+).	O
+
+The	O
+objective	O
+of	O
+this	O
+study	O
+was	O
+(	O
+i	O
+)	O
+to	O
+assess	O
+whether	O
+this	O
+trend	O
+mirrors	O
+an	O
+increase	O
+in	O
+infection	B-DISO
+pressure	O
+or	O
+is	O
+caused	O
+by	O
+increased	O
+attention	O
+and	O
+testing	O
+and	O
+(	O
+ii	O
+)	O
+estimate	O
+individual	O
+and	O
+population	O
+-	O
+based	O
+Hepatitis	B-SPEC
+E	I-SPEC
+Virus	I-SPEC
+(	O
+HEV	B-SPEC
+)	O
+seroconversion	O
+and	O
+seroreversion	O
+rates	O
+for	O
+Germany	O
+.	O
+
+In	O
+this	O
+period	O
+,	O
+we	O
+found	O
+a	O
+moderate	O
+but	O
+statistically	O
+significant	O
+decline	O
+of	O
+overall	O
+anti	B-PRGE
+-	I-PRGE
+HEV	I-PRGE
+IgG	I-PRGE
+prevalence	O
+from	O
+18	O
+.	O
+6	O
+%	O
+to	O
+15	O
+.	O
+3	O
+%.	O
+
+Continuously	O
+rising	O
+numbers	O
+of	O
+Hepatitis	B-DISO
+E	I-DISO
+diagnoses	O
+in	O
+Europe	O
+are	O
+likely	O
+due	O
+to	O
+an	O
+increased	O
+awareness	O
+of	O
+clinicians	O
+and	O
+indicate	O
+that	O
+still	O
+there	O
+is	O
+a	O
+gap	O
+between	O
+incident	O
+and	O
+diagnosed	O
+cases	O
+.	O
+
+At	O
+dpi	O
+5	O
+,	O
+all	O
+PEDV	B-SPEC
+pigs	B-SPEC
+were	O
+PCR	O
+positive	O
+for	O
+PEDV	B-SPEC
+in	O
+feces	B-ANAT
+.	O
+
+Overall	O
+,	O
+PEDV	B-SPEC
+-	O
+inoculated	O
+pigs	B-SPEC
+did	O
+recover	B-PROC
+the	O
+absorptive	O
+capacity	O
+that	O
+was	O
+reduced	O
+during	O
+PEDV	B-SPEC
+infection	B-DISO
+by	O
+increasing	O
+proliferation	B-DISO
+of	O
+intestinal	B-ANAT
+stem	B-ANAT
+cells	I-ANAT
+.	O
+
+ABSTRACT	O
+:	O
+It	O
+had	O
+been	O
+more	O
+than	O
+5	O
+years	O
+since	O
+the	O
+first	O
+case	O
+of	O
+Middle	O
+East	O
+Respiratory	O
+Syndrome	B-DISO
+coronavirus	B-DISO
+infection	I-DISO
+(	O
+MERS	O
+-	O
+CoV	O
+)	O
+was	O
+recorded	O
+,	O
+but	O
+no	O
+specific	O
+treatment	O
+has	O
+been	O
+investigated	O
+in	O
+randomized	O
+clinical	O
+trials	O
+.	O
+
+TITLE	O
+:	O
+Genetic	O
+epidemiology	O
+of	O
+porcine	B-SPEC
+epidemic	I-SPEC
+diarrhoea	I-SPEC
+virus	I-SPEC
+circulating	O
+in	O
+China	O
+in	O
+2012	O
+-	O
+2017	O
+based	O
+on	O
+spike	O
+gene	O
+.	O
+
+Respiratory	O
+specimens	O
+were	O
+collected	O
+from	O
+patients	O
+and	O
+tested	O
+for	O
+eight	O
+respiratory	O
+viruses	B-SPEC
+using	O
+polymerase	O
+chain	O
+reaction	O
+(	O
+PCR	O
+)	O
+or	O
+reverse	B-PROC
+transcription	I-PROC
+polymerase	O
+chain	O
+reaction	O
+(	O
+RT	O
+-	O
+PCR	O
+).	O
+
+TITLE	O
+:	O
+Hemophagocytic	B-DISO
+lymphohistiocytosis	I-DISO
+complicated	O
+by	O
+multiorgan	B-DISO
+failure	I-DISO
+:	O
+A	O
+case	O
+report	O
+.	O
+
+HLH	B-DISO
+is	O
+a	O
+rare	B-DISO
+disorder	I-DISO
+of	O
+the	O
+mononuclear	B-ANAT
+phagocytic	I-ANAT
+system	I-ANAT
+,	O
+characterized	O
+by	O
+systemic	O
+proliferation	B-DISO
+of	O
+non	O
+-	O
+neoplastic	O
+histiocytes	B-ANAT
+.	O
+
+TITLE	O
+:	O
+Respiratory	B-DISO
+infections	I-DISO
+in	O
+elderly	O
+people	O
+:	O
+Viral	O
+role	O
+in	O
+a	O
+resident	O
+population	O
+of	O
+elderly	O
+care	O
+centers	O
+in	O
+Lisbon	O
+,	O
+winter	O
+2013	O
+-	O
+2014	O
+.	O
+
+Nasopharyngeal	B-ANAT
+swabs	O
+were	O
+collected	O
+whenever	O
+an	O
+elderly	O
+had	O
+symptoms	O
+of	O
+acute	B-DISO
+respiratory	I-DISO
+infections	I-DISO
+(	O
+ARI	B-CHED
+).	O
+
+Array	O
+cards	O
+for	O
+atypical	O
+bacteria	B-SPEC
+were	O
+also	O
+used	O
+in	O
+severe	O
+cases	O
+.	O
+
+In	O
+total	O
+,	O
+188	O
+episodes	O
+of	O
+ARI	B-CHED
+were	O
+reported	O
+,	O
+being	O
+rhinovirus	B-SPEC
+the	O
+most	O
+frequently	O
+detected	O
+(	O
+n	O
+=	O
+53	O
+),	O
+followed	O
+by	O
+influenza	B-PATH
+A	I-PATH
+(	O
+H3	O
+)	O
+(	O
+n	O
+=	O
+19	O
+)	O
+and	O
+HBoV	O
+(	O
+n	O
+=	O
+14	O
+).	O
+
+Two	O
+pregnant	O
+sows	O
+were	O
+administered	O
+twice	O
+the	O
+live	O
+vaccine	O
+before	O
+farrowing	B-PROC
+.	O
+
+All	O
+newborn	O
+piglets	O
+were	O
+challenged	O
+with	O
+the	O
+genogroup	O
+2	O
+virus	B-SPEC
+,	O
+and	O
+clinical	O
+signs	O
+were	O
+monitored	O
+for	O
+7	O
+days	O
+post	O
+challenge	O
+.	O
+
+Neutralizing	O
+antibody	B-COMP
+titers	O
+in	O
+serum	B-COMP
+and	O
+milk	O
+of	O
+control	O
+sow	O
+was	O
+negative	O
+throughout	O
+the	O
+experimental	O
+period	O
+,	O
+whereas	O
+high	O
+titers	O
+were	O
+observed	O
+in	O
+the	O
+vaccinated	O
+sows	O
+.	O
+
+RESULTS	O
+:	O
+The	O
+results	O
+showed	O
+a	O
+high	O
+percentage	O
+of	O
+dromedaries	B-SPEC
+(	O
+56	O
+.	O
+4	O
+%)	O
+had	O
+evidence	O
+for	O
+nasal	B-ANAT
+MERS	O
+-	O
+CoV	O
+infection	B-DISO
+.	O
+
+TITLE	O
+:	O
+Dual	O
+HIV	B-SPEC
+-	I-SPEC
+1	I-SPEC
+reverse	B-PRGE
+transcriptase	I-PRGE
+and	O
+integrase	B-PROC
+inhibitors	B-CHED
+from	O
+ABSTRACT	O
+:	O
+During	O
+our	O
+search	O
+for	O
+potential	O
+templates	O
+of	O
+HIV	O
+-	O
+1	O
+reverse	B-PRGE
+transcriptase	I-PRGE
+(	O
+RT	O
+)	O
+and	O
+integrase	B-PRGE
+(	O
+IN	O
+)	O
+dual	O
+inhibitors	B-CHED
+,	O
+the	O
+methanolic	O
+extract	O
+obtained	O
+from	O
+aerial	O
+parts	O
+of	O
+
+Patients	O
+with	O
+BAIT	O
+generally	O
+present	O
+with	O
+acute	O
+ocular	B-DISO
+pain	I-DISO
+,	O
+photophobia	B-DISO
+,	O
+and	O
+red	B-DISO
+eyes	I-DISO
+.	O
+
+TITLE	O
+:	O
+Chronic	B-DISO
+Pancreatitis	I-DISO
+Associated	O
+Acute	B-DISO
+Respiratory	I-DISO
+Failure	I-DISO
+.	O
+
+TITLE	O
+:	O
+Simvastatin	B-CHED
+to	O
+reduce	O
+pulmonary	B-ANAT
+dysfunction	O
+in	O
+patients	O
+with	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+:	O
+the	O
+HARP	B-PRGE
+-	I-PRGE
+2	I-PRGE
+RCT	I-PRGE
+ABSTRACT	O
+:	O
+Acute	O
+lung	B-ANAT
+injury	O
+is	O
+a	O
+common	O
+devastating	O
+clinical	O
+syndrome	B-DISO
+characterised	O
+by	O
+life	O
+-	O
+threatening	O
+respiratory	B-DISO
+failure	I-DISO
+requiring	O
+mechanical	O
+ventilation	O
+and	O
+multiple	B-DISO
+organ	I-DISO
+failure	I-DISO
+,	O
+and	O
+is	O
+a	O
+major	O
+cause	O
+of	O
+morbidity	O
+and	O
+mortality	O
+.	O
+
+There	O
+is	O
+a	O
+need	O
+to	O
+confirm	O
+if	O
+ARDS	B-DISO
+endotypes	O
+that	O
+are	O
+more	O
+likely	O
+to	O
+benefit	O
+from	O
+targeted	B-PROC
+treatment	O
+with	O
+simvastatin	B-CHED
+exist	O
+.	O
+
+The	O
+potential	O
+role	O
+of	O
+simvastatin	B-CHED
+in	O
+the	O
+prevention	O
+of	O
+ARDS	B-DISO
+in	O
+patients	O
+at	O
+a	O
+high	O
+risk	O
+of	O
+developing	O
+ARDS	B-DISO
+has	O
+not	O
+yet	O
+been	O
+evaluated	O
+.	O
+
+Several	O
+familiar	O
+biothreat	O
+diseases	O
+such	O
+as	O
+anthrax	B-DISO
+and	O
+tularemia	B-DISO
+were	O
+judged	O
+,	O
+by	O
+our	O
+experts	O
+,	O
+to	O
+be	O
+less	O
+threatening	O
+than	O
+many	O
+others	O
+owing	O
+to	O
+a	O
+number	O
+of	O
+factors	O
+including	O
+ease	O
+of	O
+detection	O
+,	O
+lack	O
+of	O
+communicability	O
+,	O
+and	O
+the	O
+ready	O
+availability	O
+of	O
+countermeasures	O
+.	O
+
+Conversely	O
+,	O
+several	O
+toxins	B-CHED
+were	O
+judged	O
+by	O
+experts	O
+to	O
+have	O
+very	O
+high	O
+potential	O
+as	O
+threat	O
+agents	O
+owing	O
+,	O
+in	O
+part	O
+,	O
+to	O
+their	O
+reliability	O
+,	O
+virulence	B-PROC
+,	O
+and	O
+a	O
+lack	O
+of	O
+available	O
+countermeasures	O
+.	O
+
+The	O
+described	O
+strategy	O
+and	O
+methodology	O
+to	O
+convert	O
+the	O
+HIV	B-DISO
+diagnostic	O
+assay	O
+and	O
+platform	O
+to	O
+a	O
+ZIKV	O
+RNA	O
+detection	O
+assay	O
+provides	O
+a	O
+model	O
+that	O
+can	O
+be	O
+readily	O
+utilized	O
+for	O
+detection	O
+of	O
+the	O
+next	O
+emerging	O
+or	O
+re	B-DISO
+-	I-DISO
+emerging	I-DISO
+infectious	I-DISO
+disease	I-DISO
+.	O
+
+One	O
+patient	O
+died	B-PROC
+from	O
+Haemophilus	B-SPEC
+influenzae	I-SPEC
+co	B-DISO
+-	I-DISO
+infection	I-DISO
+.	O
+
+CONCLUSIONS	O
+:	O
+As	O
+for	O
+MERS	O
+Co	O
+-	O
+V	O
+infections	B-DISO
+,	O
+underlying	O
+comorbidities	O
+impacted	B-DISO
+the	O
+clinical	O
+outcomes	O
+of	O
+OC43	O
+infections	B-DISO
+.	O
+
+A	O
+case	O
+herd	O
+was	O
+defined	O
+as	O
+a	O
+swine	B-SPEC
+herd	O
+with	O
+a	O
+confirmed	O
+positive	O
+laboratory	O
+diagnostic	O
+test	O
+(	O
+RT	O
+-	O
+PCR	O
+)	O
+results	O
+for	O
+PED	O
+virus	B-SPEC
+,	O
+along	O
+with	O
+pigs	B-SPEC
+exhibiting	O
+typical	O
+clinical	O
+signs	O
+at	O
+the	O
+herd	O
+level	O
+during	O
+the	O
+study	O
+period	O
+.	O
+
+The	O
+questionnaire	O
+for	O
+control	O
+herds	O
+were	O
+based	O
+on	O
+their	O
+matched	O
+case	O
+'	B-PROC
+s	I-PROC
+period	I-PROC
+of	O
+interest	O
+,	O
+and	O
+together	O
+with	O
+case	O
+herds	O
+formed	O
+a	O
+matched	O
+stratum	O
+.	O
+
+Multivariable	O
+exact	O
+conditional	O
+logistic	O
+regression	O
+and	O
+mixed	O
+multivariable	O
+logistic	O
+regression	O
+models	O
+,	O
+with	O
+the	O
+matched	O
+stratum	O
+as	O
+a	O
+random	O
+effect	O
+,	O
+were	O
+used	O
+to	O
+assess	O
+the	O
+association	O
+between	O
+various	O
+risk	O
+factors	O
+and	O
+the	O
+odds	O
+of	O
+PED	B-PRGE
+introduction	O
+into	O
+a	O
+herd	O
+.	O
+
+For	O
+diagnostic	O
+investigations	O
+in	O
+the	O
+affected	O
+farms	O
+,	O
+real	O
+time	O
+RT	O
+-	O
+PCR	O
+was	O
+performed	O
+to	O
+detect	O
+PEDV	B-PRGE
+RNA	I-PRGE
+in	O
+individually	O
+taken	O
+fecal	B-ANAT
+samples	O
+,	O
+and	O
+two	O
+commercial	O
+ELISA	O
+kits	O
+,	O
+both	O
+based	O
+on	O
+the	O
+N	B-PRGE
+protein	I-PRGE
+of	O
+PEDV	B-SPEC
+,	O
+were	O
+used	O
+to	O
+detect	O
+IgG	B-PRGE
+in	O
+serum	B-COMP
+samples	O
+of	O
+pigs	B-SPEC
+experiencing	O
+acute	O
+signs	O
+of	O
+the	O
+disease	O
+.	O
+
+PEDV	O
+RNA	O
+could	O
+be	O
+detected	O
+in	O
+fecal	B-ANAT
+samples	O
+up	O
+to	O
+14	O
+days	O
+after	O
+initial	O
+sampling	O
+.	O
+
+ABSTRACT	O
+:	O
+Respiratory	O
+viral	B-DISO
+infections	I-DISO
+are	O
+a	O
+leading	O
+cause	O
+of	O
+pediatric	O
+disease	O
+.	O
+
+In	O
+cultured	O
+mucosal	B-ANAT
+cells	B-COMP
+(	O
+mainly	O
+epithelial	O
+),	O
+the	O
+expression	B-PROC
+of	O
+AvBD4	O
+,	O
+10	O
+-	O
+13	O
+and	O
+IFNα	O
+,	O
+β	O
+,	O
+and	O
+λ	O
+was	O
+upregulated	O
+following	O
+incubation	O
+with	O
+500	O
+nM	O
+PGE2	B-CHED
+.	O
+
+ABSTRACT	O
+:	O
+Porcine	B-SPEC
+epidemic	I-SPEC
+diarrhea	I-SPEC
+virus	I-SPEC
+(	O
+PEDV	B-SPEC
+)	O
+spread	O
+rapidly	O
+across	O
+the	O
+United	O
+States	O
+in	O
+part	O
+due	O
+to	O
+contaminated	O
+livestock	O
+trailers	O
+.	O
+
+Results	O
+revealed	O
+that	O
+the	O
+IRF3	B-PRGE
+was	O
+significantly	O
+up	O
+-	O
+regulated	O
+post	O
+-	O
+PEDV	B-SPEC
+infection	B-DISO
+.	O
+
+Like	O
+SARS	O
+previously	O
+and	O
+Zika	O
+recently	O
+,	O
+the	O
+Ebola	O
+crisis	O
+in	O
+2015	O
+showed	O
+how	O
+vulnerable	O
+the	O
+world	O
+is	O
+to	O
+these	O
+epidemics	O
+,	O
+with	O
+over	O
+11	O
+,	O
+000	O
+people	O
+dying	B-PROC
+in	O
+the	O
+outbreak	O
+.	O
+
+ABSTRACT	O
+:	O
+Feline	O
+infectious	O
+peritonitis	O
+(	O
+FIP	B-DISO
+)	O
+is	O
+one	O
+of	O
+the	O
+most	O
+important	O
+viral	B-DISO
+diseases	I-DISO
+of	O
+cats	B-SPEC
+worldwide	O
+.	O
+
+TITLE	O
+:	O
+Molecular	O
+characteristics	O
+of	O
+the	O
+spike	O
+gene	O
+of	O
+porcine	B-SPEC
+epidemic	I-SPEC
+diarrhoea	I-SPEC
+virus	I-SPEC
+strains	O
+in	O
+Eastern	O
+China	O
+in	O
+2016	O
+.	O
+
+TITLE	O
+:	O
+ACUTE	O
+RESPIRATORY	B-DISO
+DISEASES	I-DISO
+IN	O
+BRAZILIAN	O
+CHILDREN	O
+:	O
+ARE	O
+CAREGIVERS	O
+ABLE	O
+TO	O
+DETECT	O
+EARLY	O
+WARNING	O
+SIGNS	O
+?	O
+
+ABSTRACT	O
+:	O
+To	O
+assess	O
+the	O
+level	O
+of	O
+caregiver	O
+knowledge	O
+about	O
+respiratory	O
+signs	O
+and	O
+symptoms	O
+of	O
+acute	B-DISO
+respiratory	I-DISO
+infection	I-DISO
+(	O
+ARI	B-CHED
+)	O
+as	O
+well	O
+as	O
+their	O
+ability	O
+to	O
+detect	O
+the	O
+early	O
+warning	O
+signs	O
+and	O
+need	O
+for	O
+medical	O
+assistance	O
+in	O
+children	O
+referred	O
+to	O
+an	O
+emergency	B-DISO
+service	O
+.	O
+
+The	O
+most	O
+cited	O
+signs	O
+of	O
+severity	O
+recognized	O
+by	O
+caregivers	O
+were	O
+fever	B-PROC
+(	O
+99	O
+.	O
+6	O
+%),	O
+dyspnea	B-DISO
+(	O
+91	O
+.	O
+4	O
+%),	O
+wheezing	B-DISO
+(	O
+86	O
+.	O
+4	O
+%),	O
+adynamia	B-DISO
+(	O
+80	O
+.	O
+2	O
+%),	O
+coughing	B-DISO
+(	O
+79	O
+.	O
+8	O
+%),	O
+and	O
+tachypnea	B-DISO
+(	O
+78	O
+.	O
+6	O
+%).	O
+
+The	O
+aims	O
+of	O
+this	O
+study	O
+were	O
+to	O
+test	O
+the	O
+following	O
+hypotheses	O
+:	O
+stigma	O
+and	O
+hardiness	O
+exert	B-PROC
+both	O
+direct	O
+effects	O
+on	O
+mental	O
+health	O
+and	O
+also	O
+indirect	O
+(	O
+mediated	O
+)	O
+effects	O
+on	O
+mental	O
+health	O
+through	O
+stress	O
+in	O
+nurses	O
+working	O
+at	O
+a	O
+government	O
+-	O
+designated	O
+hospital	O
+during	O
+a	O
+Middle	O
+East	O
+Respiratory	O
+Syndrome	B-DISO
+coronavirus	B-SPEC
+(	O
+MERS	O
+-	O
+CoV	O
+)	O
+epidemic	O
+.	O
+
+We	O
+found	O
+that	O
+229E	O
+-	O
+HR1P	O
+and	O
+229E	O
+-	O
+HR2P	O
+could	O
+interact	O
+to	O
+form	O
+a	O
+stable	O
+six	O
+-	O
+helix	O
+bundle	O
+and	O
+inhibit	O
+HCoV	B-SPEC
+-	I-SPEC
+229E	I-SPEC
+spike	O
+protein	B-CHED
+-	O
+mediated	O
+cell	B-PROC
+-	I-PROC
+cell	B-COMP
+fusion	I-PROC
+with	O
+IC	O
+
+ABSTRACT	O
+:	O
+Overall	O
+mortality	O
+in	O
+patients	O
+with	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+is	O
+a	O
+composite	O
+endpoint	O
+because	O
+it	O
+includes	O
+death	B-PROC
+from	O
+multiple	O
+causes	O
+.	O
+
+We	O
+studied	O
+778	O
+patients	O
+with	O
+moderate	O
+-	O
+to	O
+-	O
+severe	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+treated	O
+with	O
+lung	B-ANAT
+-	O
+protective	O
+ventilation	O
+.	O
+
+When	O
+quantifying	O
+the	O
+true	O
+burden	O
+of	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+outcome	O
+,	O
+we	O
+identified	O
+506	O
+patients	O
+(	O
+65	O
+.	O
+0	O
+%)	O
+with	O
+one	O
+or	O
+more	O
+exclusion	O
+criteria	O
+for	O
+enrollment	O
+into	O
+current	O
+interventional	O
+trials	O
+.	O
+
+A	O
+periodical	O
+worsening	O
+of	O
+clinical	O
+conditions	O
+is	O
+common	O
+in	O
+asthma	B-PATH
+,	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+survivors	O
+,	O
+obstructive	B-DISO
+sleep	I-DISO
+apnea	I-DISO
+syndrome	I-DISO
+,	O
+and	O
+pulmonary	B-DISO
+fibrosis	I-DISO
+,	O
+as	O
+well	O
+as	O
+in	O
+patients	O
+with	O
+severe	O
+neuromuscular	B-DISO
+diseases	I-DISO
+.	O
+
+Despite	O
+more	O
+than	O
+50	O
+years	O
+of	O
+research	O
+numerous	O
+issues	O
+regarding	O
+epidemiology	O
+,	O
+pathophysiology	O
+and	O
+diagnosis	O
+remain	O
+unclear	O
+until	O
+today	O
+:	O
+Due	O
+to	O
+rather	O
+unspecific	O
+clinical	O
+diagnostic	O
+criteria	O
+incidence	O
+of	O
+ARDS	B-DISO
+varies	O
+considerably	O
+in	O
+clinical	O
+trials	O
+with	O
+a	O
+range	O
+from	O
+4	O
+to	O
+79	O
+cases	O
+per	O
+100	O
+000	O
+persons	O
+per	O
+year	O
+.	O
+
+Moreover	O
+,	O
+in	O
+response	O
+to	O
+restimulation	O
+with	O
+the	O
+PEDV	B-PRGE
+COE	I-PRGE
+antigen	B-CHED
+in	O
+vitro	O
+,	O
+a	O
+significant	O
+difference	O
+in	O
+splenocyte	B-ANAT
+proliferation	B-DISO
+response	O
+and	O
+Th2	B-PRGE
+-	I-PRGE
+associated	I-PRGE
+cytokine	I-PRGE
+IL	I-PRGE
+-	I-PRGE
+4	I-PRGE
+level	O
+was	O
+observed	O
+in	O
+the	O
+group	O
+of	O
+mice	B-SPEC
+orally	B-ANAT
+immunized	O
+with	O
+pPG	B-PRGE
+-	I-PRGE
+COE	I-PRGE
+-	I-PRGE
+Col	I-PRGE
+-	I-PRGE
+DCpep	I-PRGE
+/	O
+L393	O
+(	O
+p	O
+<	O
+0	O
+.	O
+05	O
+)	O
+compared	O
+to	O
+the	O
+groups	O
+of	O
+mice	B-SPEC
+that	O
+received	O
+pPG	B-PRGE
+-	I-PRGE
+COE	I-PRGE
+-	I-PRGE
+Col	I-PRGE
+/	O
+L393	O
+and	O
+pPG	B-PRGE
+-	I-PRGE
+COE	I-PRGE
+-	I-PRGE
+DCpep	I-PRGE
+/	I-PRGE
+L393	I-PRGE
+,	O
+respectively	O
+.	O
+
+ABSTRACT	O
+:	O
+Porcine	B-SPEC
+epidemic	B-DISO
+diarrhea	I-DISO
+(	O
+PED	O
+)	O
+is	O
+an	O
+important	O
+re	O
+-	O
+emergent	O
+infectious	B-DISO
+disease	I-DISO
+and	O
+inflicts	O
+huge	O
+economic	O
+losses	O
+to	O
+the	O
+swine	B-SPEC
+industry	O
+worldwide	O
+.	O
+
+TITLE	O
+:	O
+Insights	O
+into	O
+the	O
+homo	B-SPEC
+-	O
+oligomerization	O
+properties	O
+of	O
+N	O
+-	O
+terminal	O
+coiled	O
+-	O
+coil	O
+domain	O
+of	O
+Ebola	B-SPEC
+virus	I-SPEC
+VP35	I-PRGE
+protein	B-CHED
+.	O
+
+Our	O
+model	O
+advances	O
+the	O
+understanding	O
+of	O
+how	O
+VP35	O
+may	O
+associate	O
+in	O
+different	O
+homo	B-SPEC
+-	O
+oligomeric	O
+species	B-SPEC
+,	O
+a	O
+crucial	O
+process	O
+for	O
+EBOV	O
+replication	O
+and	O
+pathogenicity	O
+.	O
+
+TITLE	O
+:	O
+Development	B-PROC
+of	O
+a	O
+TaqMan	O
+-	O
+based	O
+real	O
+-	O
+time	O
+RT	O
+-	O
+PCR	O
+assay	O
+for	O
+the	O
+detection	O
+of	O
+SADS	O
+-	O
+CoV	O
+associated	O
+with	O
+severe	O
+diarrhea	O
+disease	O
+in	O
+pigs	B-SPEC
+.	O
+
+It	O
+can	O
+cause	O
+severe	B-DISO
+diarrhea	I-DISO
+disease	O
+in	O
+pigs	B-SPEC
+.	O
+
+Specific	O
+primers	O
+and	O
+probe	O
+were	O
+designed	O
+and	O
+synthesized	O
+based	O
+on	O
+the	O
+conserved	O
+region	O
+within	O
+the	O
+N	B-PRGE
+gene	I-PRGE
+of	O
+the	O
+viral	B-COMP
+genome	I-COMP
+.	O
+
+Prior	O
+studies	O
+have	O
+shown	O
+seasonal	O
+patterns	O
+of	O
+HCoV	O
+species	B-SPEC
+and	O
+annual	O
+variation	O
+in	O
+species	B-SPEC
+prevalence	O
+but	O
+national	O
+circulation	B-PROC
+patterns	O
+in	O
+the	O
+US	O
+have	O
+not	O
+yet	O
+been	O
+described	O
+.	O
+
+Different	O
+HCoV	O
+species	B-SPEC
+may	O
+be	O
+detected	O
+more	O
+frequently	O
+in	O
+different	O
+age	O
+groups	O
+.	O
+
+TITLE	O
+:	O
+Comparison	O
+of	O
+the	O
+performance	O
+of	O
+laboratory	O
+tests	O
+in	O
+the	O
+diagnosis	O
+of	O
+feline	B-SPEC
+infectious	I-DISO
+peritonitis	I-DISO
+.	O
+
+While	O
+the	O
+clinical	O
+signs	O
+are	O
+fairly	O
+non	O
+-	O
+specific	O
+,	O
+lymphopenia	B-DISO
+and	O
+neutropenia	O
+are	O
+often	O
+seen	O
+.	O
+
+The	O
+term	O
+pulmonary	B-ANAT
+vascular	B-ANAT
+dysfunction	O
+(	O
+PVD	B-DISO
+)	O
+refers	O
+to	O
+the	O
+specific	O
+involvement	O
+of	O
+the	O
+vascular	B-ANAT
+compartment	B-ANAT
+in	O
+ARDS	B-DISO
+and	O
+is	O
+expressed	B-PROC
+clinically	O
+by	O
+an	O
+increase	O
+in	O
+pulmonary	B-ANAT
+arterial	B-ANAT
+(	O
+PA	O
+)	O
+pressure	O
+and	O
+pulmonary	B-PROC
+vascular	B-ANAT
+resistance	I-PROC
+both	O
+affecting	O
+right	O
+ventricular	B-ANAT
+(	O
+RV	O
+)	O
+afterload	O
+.	O
+
+He	O
+presented	O
+with	O
+severe	B-DISO
+diarrhoea	I-DISO
+86	O
+days	O
+post	O
+BMT	B-ENZY
+and	O
+was	O
+diagnosed	O
+with	O
+graft	B-PATH
+-	I-PATH
+versus	I-PATH
+-	I-PATH
+host	B-COMP
+disease	I-PATH
+(	O
+GVHD	B-DISO
+)	O
+based	O
+on	O
+skin	B-ANAT
+and	O
+rectal	O
+biopsies	O
+.	O
+
+Sural	B-ANAT
+nerve	I-ANAT
+biopsy	O
+revealed	O
+active	O
+demyelination	B-DISO
+and	O
+infiltration	B-DISO
+of	O
+macrophages	B-ANAT
+and	O
+CD8	B-PRGE
+
+By	O
+day	O
+28	O
+,	O
+fewer	O
+patients	O
+died	B-PROC
+before	O
+achieving	O
+extubation	O
+(	O
+15	O
+.	O
+7	O
+%	O
+vs	O
+25	O
+.	O
+3	O
+%	O
+and	O
+risk	O
+ratio	O
+,	O
+0	O
+.	O
+62	O
+;	O
+95	O
+%	O
+CI	O
+,	O
+0	O
+.	O
+34	O
+-	O
+1	O
+.	O
+13	O
+),	O
+more	O
+achieved	O
+successful	O
+extubation	O
+(	O
+71	O
+.	O
+9	O
+%	O
+vs	O
+49	O
+.	O
+5	O
+%	O
+and	O
+risk	O
+ratio	O
+,	O
+1	O
+.	O
+45	O
+;	O
+CI	O
+,	O
+1	O
+.	O
+14	O
+-	O
+1	O
+.	O
+85	O
+),	O
+time	O
+to	O
+successful	O
+extubation	O
+was	O
+shorter	O
+(	O
+hazard	O
+ratio	O
+,	O
+2	O
+.	O
+05	O
+;	O
+CI	O
+,	O
+1	O
+.	O
+42	O
+-	O
+2	O
+.	O
+96	O
+),	O
+and	O
+more	O
+were	O
+discharged	O
+alive	O
+from	O
+the	O
+ICU	O
+(	O
+65	O
+.	O
+2	O
+%	O
+vs	O
+48	O
+.	O
+3	O
+%;	O
+risk	O
+ratio	O
+,	O
+1	O
+.	O
+35	O
+;	O
+CI	O
+,	O
+1	O
+.	O
+04	O
+-	O
+1	O
+.	O
+75	O
+).	O
+
+ABSTRACT	O
+:	O
+Respiratory	B-SPEC
+syncytial	I-SPEC
+virus	I-SPEC
+(	O
+RSV	B-SPEC
+)	O
+infection	B-DISO
+is	O
+common	O
+and	O
+may	O
+be	O
+severe	O
+among	O
+patients	O
+with	O
+preexisting	O
+cardiac	B-DISO
+anomalies	I-DISO
+,	O
+but	O
+direct	O
+involvement	O
+of	O
+myocardial	O
+damage	O
+is	O
+not	O
+common	O
+in	O
+those	O
+patients	O
+.	O
+
+Prespecified	O
+secondary	O
+analyses	O
+included	O
+a	O
+comparison	O
+of	O
+agreement	O
+between	O
+the	O
+groups	O
+and	O
+subgroup	O
+analyses	O
+by	O
+profession	O
+,	O
+age	O
+,	O
+years	O
+of	O
+experience	O
+,	O
+and	O
+stated	O
+familiarity	O
+with	O
+diagnostic	O
+criteria	O
+for	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+.	O
+
+The	O
+main	O
+treatment	O
+is	O
+oxygen	B-CHED
+therapy	O
+at	O
+high	O
+concentrations	O
+and	O
+methylene	B-CHED
+blue	I-CHED
+as	O
+an	O
+intravenous	O
+antidote	B-CHED
+only	O
+in	O
+selected	O
+cases	O
+.	O
+
+We	O
+retrospectively	O
+analyzed	O
+a	O
+cohort	O
+of	O
+children	O
+who	O
+presented	O
+to	O
+Seattle	O
+Children	O
+'	O
+s	O
+Hospital	O
+and	O
+in	O
+whom	O
+HCoV	O
+was	O
+detected	O
+by	O
+a	O
+multiplex	O
+respiratory	O
+polymerase	O
+chain	O
+reaction	O
+assay	O
+of	O
+a	O
+nasal	B-ANAT
+sample	O
+between	O
+October	O
+2012	O
+and	O
+March	O
+2016	O
+.	O
+
+We	O
+used	O
+logistic	O
+regression	O
+modeling	O
+to	O
+evaluate	O
+risk	O
+factors	O
+for	O
+LRTD	O
+and	O
+LRTD	O
+that	O
+necessitated	O
+oxygen	B-CHED
+use	O
+(	O
+severe	O
+LRTD	O
+),	O
+including	O
+an	O
+immunocompromised	O
+state	O
+,	O
+in	O
+children	O
+with	O
+HCoV	O
+infection	B-DISO
+.	O
+
+ABSTRACT	O
+:	O
+Venovenous	O
+extracorporeal	O
+membrane	B-COMP
+oxygenation	B-PROC
+(	O
+VV	O
+-	O
+ECMO	O
+)	O
+has	O
+been	O
+gaining	O
+use	O
+to	O
+bridge	O
+the	O
+recovery	O
+from	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+(	O
+ARDS	B-DISO
+)	O
+refractory	O
+to	O
+conventional	O
+treatment	O
+.	O
+
+The	O
+patient	O
+had	O
+immediate	O
+improvements	O
+in	O
+oxygenation	B-PROC
+,	O
+which	O
+continued	O
+for	O
+10	O
+d	O
+.	O
+Moreover	O
+,	O
+he	O
+underwent	O
+three	O
+transportations	O
+to	O
+the	O
+operating	O
+room	O
+without	O
+accidental	O
+decannulation	O
+or	O
+disruption	O
+of	O
+the	O
+VV	O
+-	O
+ECMO	O
+device	O
+.	O
+
+To	O
+investigate	O
+the	O
+prognostic	O
+and	O
+pathogenic	O
+impact	O
+of	O
+angiopoietins	O
+in	O
+regulating	O
+pulmonary	B-ANAT
+vascular	B-ANAT
+barrier	O
+function	O
+and	O
+inflammation	B-DISO
+in	O
+bacterial	B-DISO
+pneumonia	I-DISO
+.	O
+
+These	O
+data	O
+suggest	O
+a	O
+central	O
+role	O
+of	O
+angiopoietin	B-PRGE
+-	I-PRGE
+1	I-PRGE
+/-	I-PRGE
+2	I-PRGE
+in	O
+pneumonia	B-DISO
+-	O
+evoked	O
+inflammation	B-DISO
+and	O
+permeability	O
+.	O
+
+TITLE	O
+:	O
+Aetiology	O
+of	O
+lower	B-DISO
+respiratory	I-DISO
+tract	I-DISO
+infection	I-DISO
+in	O
+adults	O
+in	O
+primary	O
+care	O
+:	O
+a	O
+prospective	O
+study	O
+in	O
+11	O
+European	O
+countries	O
+.	O
+
+Less	O
+than	O
+1	O
+%	O
+of	O
+S	O
+.	O
+pneumoniae	O
+were	O
+highly	O
+resistant	O
+to	O
+penicillin	B-CHED
+and	O
+12	O
+.	O
+6	O
+%	O
+of	O
+H	O
+.	O
+influenzae	O
+were	O
+β	B-PRGE
+-	I-PRGE
+lactamase	I-PRGE
+positive	O
+.	O
+
+In	O
+the	O
+sitting	O
+posture	O
+,	O
+there	O
+was	O
+positional	O
+worsening	O
+of	O
+dyspnoea	B-DISO
+associated	O
+with	O
+an	O
+increase	O
+in	O
+the	O
+alveolar	B-ANAT
+-	O
+arterial	B-ANAT
+oxygen	B-CHED
+gradient	O
+and	O
+shunt	O
+fraction	O
+.	O
+
+There	O
+is	O
+,	O
+therefore	O
+,	O
+a	O
+need	O
+to	O
+develop	O
+additional	O
+bat	B-ENZY
+cell	B-ANAT
+lines	I-ANAT
+that	O
+correspond	O
+to	O
+different	O
+cell	B-COMP
+types	O
+,	O
+including	O
+less	O
+represented	O
+cell	B-COMP
+types	O
+such	O
+as	O
+immune	O
+cells	B-COMP
+,	O
+and	O
+culture	O
+them	O
+under	O
+more	O
+physiologically	O
+relevant	O
+conditions	O
+to	O
+study	O
+virus	B-SPEC
+host	B-COMP
+interactions	O
+and	O
+for	O
+virus	B-SPEC
+isolation	O
+.	O
+
+Future	O
+directions	O
+to	O
+address	O
+some	O
+of	O
+these	O
+challenges	O
+to	O
+better	O
+understand	O
+host	B-COMP
+-	O
+pathogen	O
+interactions	O
+in	O
+these	O
+intriguing	O
+mammals	B-SPEC
+are	O
+also	O
+discussed	O
+,	O
+not	O
+only	O
+in	O
+relation	O
+to	O
+viruses	B-SPEC
+but	O
+also	O
+other	O
+pathogens	O
+carried	O
+by	O
+bats	B-SPEC
+including	O
+bacteria	B-SPEC
+and	O
+fungi	B-SPEC
+.	O
+
+We	O
+collected	O
+demographic	O
+data	O
+and	O
+physiologic	O
+data	O
+for	O
+CPP	O
+,	O
+intracranial	B-PROC
+pressure	I-PROC
+,	O
+mechanical	O
+ventilation	O
+,	O
+cumulative	O
+fluid	B-PROC
+balance	I-PROC
+and	O
+delta	O
+/	O
+driving	O
+pressure	O
+(	O
+ΔP	O
+).	O
+
+There	O
+was	O
+no	O
+difference	O
+in	O
+the	O
+mean	O
+CPP	O
+during	O
+the	O
+first	O
+7	O
+days	O
+of	O
+admission	O
+between	O
+patients	O
+who	O
+developed	O
+ARDS	B-DISO
+(	O
+74	O
+mmHg	O
+SD	O
+18	O
+vs	O
+.	O
+73	O
+mmHg	O
+SD	O
+18	O
+,	O
+p	O
+=	O
+0	O
+.	O
+86	O
+)	O
+versus	O
+those	O
+who	O
+did	O
+not	O
+.	O
+
+Patients	O
+with	O
+ARDS	B-DISO
+had	O
+higher	O
+ΔP	O
+and	O
+lower	O
+lung	B-PROC
+compliance	I-PROC
+.	O
+
+Phylogenetic	O
+analyses	O
+based	O
+on	O
+the	O
+ORF2	O
+amino	B-CHED
+acid	I-CHED
+sequences	O
+,	O
+samples	O
+described	O
+herein	O
+grouped	O
+into	O
+the	O
+putative	O
+genotype	O
+'	O
+a	O
+'	O
+closed	O
+related	O
+with	O
+Chinese	O
+samples	O
+.	O
+
+TITLE	O
+:	O
+Dexmedetomidine	B-CHED
+-	O
+treated	O
+hyperventilation	B-DISO
+syndrome	I-DISO
+triggered	O
+by	O
+the	O
+distress	O
+related	O
+with	O
+a	O
+urinary	O
+catheter	O
+after	O
+general	O
+anesthesia	O
+:	O
+a	O
+case	O
+report	O
+.	O
+
+A	O
+23	O
+-	O
+year	O
+-	O
+old	O
+male	O
+patient	O
+with	O
+recurrent	O
+tongue	B-DISO
+cancer	B-SPEC
+was	O
+scheduled	O
+to	O
+undergo	O
+partial	O
+glossectomy	O
+and	O
+neck	B-ANAT
+dissection	O
+.	O
+
+TITLE	O
+:	O
+Structural	O
+characterization	O
+of	O
+the	O
+HCoV	B-SPEC
+-	I-SPEC
+229E	I-SPEC
+fusion	O
+core	O
+.	O
+
+This	O
+protein	B-CHED
+is	O
+composed	O
+of	O
+an	O
+N	B-PRGE
+-	I-PRGE
+terminal	I-PRGE
+receptor	I-PRGE
+-	I-PRGE
+binding	I-PRGE
+domain	I-PRGE
+(	O
+S1	O
+)	O
+and	O
+a	O
+C	O
+-	O
+terminal	O
+trans	O
+-	O
+membrane	B-PROC
+fusion	I-PROC
+domain	O
+(	O
+S2	O
+).	O
+
+CoV	O
+infection	O
+was	O
+found	O
+in	O
+both	O
+juveniles	O
+and	O
+adult	O
+bats	B-SPEC
+between	O
+May	O
+and	O
+October	O
+(	O
+January	O
+,	O
+in	O
+adults	O
+only	O
+and	O
+April	O
+,	O
+in	O
+juveniles	O
+only	O
+).	O
+
+The	O
+average	O
+BCI	O
+of	O
+CoV	O
+infected	O
+bats	B-SPEC
+was	O
+significantly	O
+lower	O
+than	O
+uninfected	O
+bats	B-SPEC
+.	O
+
+Phylogenetic	O
+analysis	O
+of	O
+conserved	O
+RdRp	B-FUNC
+gene	O
+revealed	O
+that	O
+the	O
+detected	O
+CoVs	O
+belonged	O
+to	O
+group	O
+D	O
+betacoronavirus	B-SPEC
+(	O
+n	O
+=	O
+64	O
+)	O
+and	O
+alphacoronavirus	B-SPEC
+(	O
+n	O
+=	O
+4	O
+).	O
+
+Whether	O
+viral	O
+reactivation	O
+during	O
+parturition	B-PROC
+period	O
+or	O
+stress	O
+is	O
+responsible	O
+in	O
+maintaining	O
+transmission	O
+in	O
+the	O
+bat	B-ENZY
+colony	O
+needs	O
+to	O
+be	O
+explored	O
+.	O
+
+TITLE	O
+:	O
+Acute	B-DISO
+Respiratory	I-DISO
+Distress	I-DISO
+Syndrome	I-DISO
+:	O
+Advances	O
+in	O
+Diagnosis	O
+and	O
+Treatment	O
+.	O
+
+Globally	O
+,	O
+ARDS	B-DISO
+accounts	O
+for	O
+10	O
+%	O
+of	O
+intensive	O
+care	O
+unit	O
+admissions	O
+,	O
+representing	O
+more	O
+than	O
+3	O
+million	O
+patients	O
+with	O
+ARDS	B-DISO
+annually	O
+.	O
+
+The	O
+cornerstone	O
+of	O
+management	O
+remains	O
+mechanical	O
+ventilation	O
+,	O
+with	O
+a	O
+goal	O
+to	O
+minimize	O
+ventilator	O
+-	O
+induced	O
+lung	B-ANAT
+injury	O
+(	O
+VILI	O
+).	O
+
+Pharmacologic	O
+therapies	O
+such	O
+as	O
+β2	O
+agonists	B-CHED
+,	O
+statins	O
+,	O
+and	O
+keratinocyte	B-PRGE
+growth	B-PROC
+factor	I-PRGE
+,	O
+which	O
+targeted	B-PROC
+pathophysiologic	O
+alterations	O
+in	O
+ARDS	B-DISO
+,	O
+were	O
+not	O
+beneficial	O
+and	O
+demonstrated	O
+possible	O
+harm	O
+.	O
+
+We	O
+found	O
+no	O
+clinical	O
+differences	O
+between	O
+patients	O
+with	O
+short	O
+and	O
+medium	O
+duration	O
+AKI	O
+,	O
+even	O
+when	O
+accounting	O
+for	O
+AKI	B-PRGE
+severity	O
+and	O
+recurrent	O
+AKI	O
+.	O
+
+No	O
+baseline	O
+clinical	O
+factors	O
+were	O
+found	O
+to	O
+predict	O
+development	B-PROC
+of	O
+recurrent	O
+AKI	O
+.	O
+
+TITLE	O
+:	O
+Structural	O
+model	O
+of	O
+the	O
+SARS	B-DISO
+coronavirus	B-SPEC
+E	O
+channel	O
+in	O
+LMPG	O
+micelles	O
+.	O
+
+Herein	O
+,	O
+we	O
+report	O
+a	O
+structural	O
+model	O
+of	O
+a	O
+SARS	B-PRGE
+-	I-PRGE
+CoV	I-PRGE
+E	I-PRGE
+construct	I-PRGE
+in	O
+LMPG	O
+micelles	O
+with	O
+,	O
+for	O
+the	O
+first	O
+time	O
+,	O
+unequivocal	O
+intermolecular	O
+NOEs	O
+.	O
+
+Furthermore	O
+,	O
+altered	O
+expression	B-PROC
+of	O
+genes	O
+in	O
+these	O
+pathways	B-PROC
+,	O
+which	O
+have	O
+been	O
+previously	O
+implicated	O
+in	O
+viral	O
+host	B-PROC
+response	I-PROC
+,	O
+occurs	O
+specifically	O
+in	O
+the	O
+M1	O
+subtype	O
+.	O
+
+Furthermore	O
+,	O
+overexpression	B-PROC
+of	O
+ADAM17	B-PRGE
+suppressed	O
+PEDV	B-SPEC
+infection	B-DISO
+in	O
+HEK293	O
+and	O
+IPEC	O
+-	O
+J2	O
+cells	B-COMP
+,	O
+whereas	O
+ablation	O
+of	O
+ADAM17	B-PRGE
+expression	B-PROC
+using	O
+ADAM17	B-PRGE
+specific	I-PRGE
+siRNA	I-PRGE
+resulted	O
+in	O
+a	O
+corresponding	O
+increase	O
+of	O
+PEDV	B-SPEC
+infection	B-DISO
+and	O
+an	O
+upregulation	B-PROC
+of	O
+cell	B-COMP
+surface	I-COMP
+APN	B-PRGE
+expression	B-PROC
+.	O
+
+We	O
+report	O
+in	O
+detail	O
+two	O
+cases	O
+of	O
+fulminant	O
+idiopathic	O
+acute	O
+lung	B-ANAT
+injury	O
+requiring	O
+extracorporeal	O
+membrane	B-COMP
+oxygenation	B-PROC
+in	O
+previously	O
+healthy	O
+young	O
+adults	O
+with	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+,	O
+one	O
+of	O
+whom	O
+required	O
+lung	B-ANAT
+transplantation	O
+.	O
+
+Evidence	O
+suggests	O
+that	O
+peribronchiolar	O
+basaloid	O
+pods	O
+and	O
+bronchiolarization	O
+are	O
+related	O
+spatially	O
+and	O
+temporally	O
+and	O
+likely	O
+represent	O
+overlapping	O
+sequential	O
+stages	O
+of	O
+the	O
+response	O
+to	O
+severe	O
+distal	O
+airway	B-ANAT
+injury	O
+.	O
+
+Clinical	O
+challenges	O
+:	O
+Obtaining	O
+a	O
+definitive	O
+diagnosis	O
+of	O
+FIP	B-DISO
+based	O
+on	O
+non	O
+-	O
+invasive	O
+approaches	O
+is	O
+difficult	O
+.	O
+
+Evidence	O
+base	O
+:	O
+This	O
+review	O
+provides	O
+a	O
+comprehensive	O
+overview	O
+of	O
+how	O
+to	O
+approach	O
+the	O
+diagnosis	O
+of	O
+FIP	B-DISO
+,	O
+focusing	O
+on	O
+the	O
+tests	O
+available	O
+to	O
+the	O
+veterinary	O
+practitioner	O
+and	O
+recently	O
+published	O
+evidence	O
+supporting	O
+their	O
+use	O
+.	O
+
+ABSTRACT	O
+:	O
+Bovine	B-SPEC
+respiratory	B-DISO
+disease	I-DISO
+(	O
+BRD	O
+)	O
+remains	O
+among	O
+the	O
+leading	O
+causes	O
+of	O
+death	B-PROC
+of	O
+cattle	B-SPEC
+internationally	O
+.	O
+
+Intrinsic	O
+,	O
+management	O
+and	O
+clinical	O
+data	O
+were	O
+collected	O
+during	O
+the	O
+pre	O
+-	O
+weaning	B-PROC
+(	O
+d	O
+-	O
+56	O
+to	O
+d	O
+-	O
+14	O
+)	O
+period	O
+.	O
+
+Linear	O
+regression	O
+models	O
+(	O
+for	O
+BVDV	B-SPEC
+,	O
+BPI3V	O
+,	O
+BHV	O
+-	O
+1	O
+,	O
+BHV	B-SPEC
+-	I-SPEC
+4	I-SPEC
+,	O
+BCoV	O
+and	O
+H	B-SPEC
+.	I-SPEC
+somni	I-SPEC
+)	O
+and	O
+a	O
+single	O
+mixed	O
+effect	O
+random	O
+variable	O
+model	O
+(	O
+for	O
+BRSV	B-SPEC
+)	O
+were	O
+used	O
+to	O
+identify	O
+risk	O
+factors	O
+for	O
+changes	O
+in	O
+antibody	B-COMP
+levels	O
+to	O
+these	O
+pathogens	O
+.	O
+
+TITLE	O
+:	O
+SARS	B-DISO
+-	O
+CoV	O
+related	O
+Betacoronavirus	B-SPEC
+and	O
+diverse	O
+Alphacoronavirus	B-SPEC
+members	O
+found	O
+in	O
+western	O
+old	O
+-	O
+world	O
+.	O
+
+ABSTRACT	O
+:	O
+The	O
+emergence	O
+of	O
+SARS	O
+-	O
+CoV	O
+and	O
+MERS	O
+-	O
+CoV	O
+,	O
+triggered	O
+the	O
+discovery	O
+of	O
+a	O
+high	O
+diversity	O
+of	O
+coronaviruses	O
+in	O
+bats	B-SPEC
+.	O
+
+This	O
+diversity	O
+demonstrates	O
+the	O
+dynamic	O
+evolution	B-PROC
+and	O
+circulation	B-PROC
+of	O
+coronaviruses	O
+in	O
+this	O
+species	B-SPEC
+.	O
+
+Immunosuppressed	O
+macaques	B-SPEC
+were	O
+inoculated	O
+with	O
+MERS	O
+-	O
+CoV	O
+and	O
+sampled	O
+daily	O
+for	O
+6	O
+days	O
+to	O
+assess	O
+their	O
+immune	O
+statues	O
+and	O
+to	O
+measure	O
+viral	B-DISO
+shedding	I-DISO
+and	O
+replication	O
+.	O
+
+Despite	O
+increased	O
+viral	B-PROC
+replication	I-PROC
+,	O
+pathology	B-DISO
+in	O
+the	O
+lungs	B-ANAT
+was	O
+significantly	O
+lower	O
+in	O
+immunosuppressed	O
+animals	B-SPEC
+.	O
+
+TITLE	O
+:	O
+Alpha	B-PRGE
+/	I-PRGE
+Beta	I-PRGE
+Interferon	I-PRGE
+(	O
+IFN	B-PRGE
+-	I-PRGE
+α	I-PRGE
+/	I-PRGE
+β	I-PRGE
+)	O
+Signaling	B-PROC
+in	O
+Astrocytes	B-ANAT
+Mediates	O
+Protection	O
+against	O
+Viral	O
+Encephalomyelitis	B-DISO
+and	O
+Regulates	O
+IFN	B-PRGE
+-	I-PRGE
+γ	I-PRGE
+-	O
+Dependent	O
+Responses	O
+.	O
+
+Analysis	O
+of	O
+gene	B-PROC
+expression	I-PROC
+associated	O
+with	O
+IFN	B-PRGE
+-	I-PRGE
+α	I-PRGE
+/	I-PRGE
+β	I-PRGE
+function	O
+,	O
+e	O
+.	O
+g	O
+.,	O
+pattern	O
+recognition	O
+receptors	O
+(	O
+PRRs	B-DISO
+)	O
+and	O
+interferon	B-PRGE
+-	O
+stimulated	O
+genes	O
+(	O
+ISGs	O
+),	O
+revealed	O
+lower	O
+basal	O
+mRNA	B-CHED
+levels	O
+in	O
+brain	B-ANAT
+-	O
+derived	O
+astrocytes	B-ANAT
+than	O
+in	O
+microglia	B-ANAT
+.	O
+
+The	O
+method	O
+was	O
+able	O
+to	O
+rapidly	O
+identify	O
+the	O
+Mass	O
+genotype	O
+among	O
+IBV	B-SPEC
+field	O
+isolates	O
+,	O
+vaccine	O
+attenuated	O
+strains	O
+and	O
+reference	O
+M41	O
+strain	O
+in	O
+allantoic	O
+liquid	O
+and	O
+also	O
+directly	O
+in	O
+tissues	B-ANAT
+.	O
+
+ABSTRACT	O
+:	O
+Porcine	B-SPEC
+epidemic	B-DISO
+diarrhea	I-DISO
+(	O
+PED	O
+)	O
+is	O
+a	O
+highly	O
+contagious	B-DISO
+disease	I-DISO
+in	O
+newborn	O
+piglets	O
+.	O
+
+This	O
+coronavirus	B-SPEC
+has	O
+been	O
+widely	O
+distributed	O
+among	O
+laboratories	O
+and	O
+has	O
+been	O
+passaged	O
+both	O
+within	O
+pigs	B-SPEC
+and	O
+in	O
+cell	B-COMP
+culture	O
+.	O
+
+To	O
+determine	O
+the	O
+variability	O
+between	O
+different	O
+stocks	O
+of	O
+the	O
+PEDV	B-SPEC
+strain	O
+CV777	O
+,	O
+sequencing	O
+of	O
+the	O
+full	O
+-	O
+length	O
+genome	O
+(	O
+ca	O
+.	O
+
+When	O
+a	O
+targeted	B-PROC
+pathogen	O
+meets	O
+the	O
+corresponding	O
+particular	O
+template	O
+,	O
+the	O
+DNAs	O
+are	O
+rapidly	O
+amplified	O
+into	O
+a	O
+specific	O
+dumbbell	O
+shape	O
+through	O
+the	O
+RCA	O
+process	O
+,	O
+forming	O
+a	O
+DNA	O
+hydrogel	O
+and	O
+blocking	B-DISO
+the	O
+flow	O
+path	O
+formed	O
+between	O
+the	O
+beads	O
+.	O
+
+The	O
+60	O
+-	O
+year	O
+-	O
+old	O
+man	B-CHED
+died	B-PROC
+as	O
+a	O
+result	O
+of	O
+renal	B-ANAT
+and	O
+respiratory	B-DISO
+failure	I-DISO
+after	O
+admission	O
+to	O
+a	O
+hospital	O
+in	O
+Jeddah	O
+,	O
+Saudi	O
+Arabia	O
+.	O
+
+Accordingly	O
+,	O
+we	O
+developed	O
+a	O
+dual	O
+signal	O
+firefly	B-SPEC
+and	O
+Renilla	B-SPEC
+luciferase	B-ENZY
+cell	B-COMP
+-	O
+based	O
+drug	O
+screening	O
+assay	O
+able	O
+to	O
+quantify	O
+IFN	B-PRGE
+-	O
+mediated	O
+induction	O
+of	O
+Interferon	B-PRGE
+Stimulated	I-PRGE
+Genes	I-PRGE
+(	O
+ISGs	O
+)	O
+and	O
+its	O
+inhibition	B-PROC
+by	O
+VP24	O
+.	O
+
+TITLE	O
+:	O
+Attenuation	O
+,	O
+safety	O
+,	O
+and	O
+efficacy	O
+of	O
+a	O
+QX	O
+-	O
+like	O
+infectious	B-DISO
+bronchitis	B-DISO
+virus	B-SPEC
+serotype	O
+vaccine	O
+.	O
+
+We	O
+also	O
+evaluated	O
+the	O
+protective	O
+efficacy	O
+of	O
+different	O
+doses	O
+of	O
+SZ130	O
+against	O
+challenge	O
+with	O
+QX	O
+-	O
+like	O
+IBV	B-SPEC
+field	O
+strain	O
+SD	O
+in	O
+chickens	B-SPEC
+.	O
+
+These	O
+findings	O
+indicate	O
+that	O
+attenuated	O
+IBV	B-SPEC
+strain	O
+SZ130	O
+is	O
+highly	O
+safe	O
+in	O
+chicks	O
+and	O
+may	O
+serve	O
+as	O
+an	O
+effective	O
+vaccine	O
+against	O
+the	O
+threat	O
+posed	O
+by	O
+QX	O
+-	O
+like	O
+IBV	B-SPEC
+strains	O
+.	O
+
+TITLE	O
+:	O
+Engineering	O
+a	O
+stable	O
+CHO	B-FUNC
+cell	B-ANAT
+line	I-ANAT
+for	O
+the	O
+expression	B-PROC
+of	O
+a	O
+MERS	B-PRGE
+-	I-PRGE
+coronavirus	I-PRGE
+vaccine	I-PRGE
+antigen	B-CHED
+.	O
+
+To	O
+address	O
+this	O
+need	O
+,	O
+we	O
+are	O
+developing	O
+a	O
+subunit	O
+recombinant	O
+protein	B-CHED
+vaccine	O
+comprising	O
+residues	O
+377	O
+-	O
+588	O
+of	O
+the	O
+MERS	B-PRGE
+-	I-PRGE
+CoV	I-PRGE
+spike	I-PRGE
+protein	I-PRGE
+receptor	I-PRGE
+-	I-PRGE
+binding	B-FUNC
+domain	I-PRGE
+(	O
+RBD	O
+),	O
+which	O
+,	O
+when	O
+formulated	O
+with	O
+the	O
+AddaVax	O
+adjuvant	B-CHED
+,	O
+it	O
+induces	O
+a	O
+significant	O
+neutralizing	O
+antibody	B-PROC
+response	I-PROC
+and	O
+protection	O
+against	O
+MERS	O
+-	O
+CoV	O
+challenge	O
+in	O
+vaccinated	O
+animals	B-SPEC
+.	O
+
+Using	O
+a	O
+gradually	O
+increasing	O
+methotrexate	B-CHED
+(	O
+MTX	B-CHED
+)	O
+concentration	O
+to	O
+5	O
+μM	O
+,	O
+we	O
+increased	O
+protein	B-CHED
+yield	O
+by	O
+a	O
+factor	O
+of	O
+40	O
+.	O
+
+ABSTRACT	O
+:	O
+To	O
+summarize	O
+selected	O
+meta	B-SPEC
+-	O
+analyses	O
+and	O
+trials	O
+related	O
+to	O
+critical	O
+care	O
+pharmacotherapy	O
+published	O
+in	O
+2017	O
+.	O
+
+ABSTRACT	O
+:	O
+Bats	B-SPEC
+are	O
+a	O
+unique	O
+group	O
+of	O
+mammals	O
+well	O
+suited	O
+to	O
+be	O
+hosts	B-COMP
+for	O
+emerging	O
+viruses	B-SPEC
+.	O
+
+A	O
+set	O
+of	O
+primers	O
+and	O
+probes	O
+,	O
+CPV	B-SPEC
+-	O
+305F	O
+/	O
+CPV	B-SPEC
+-	O
+305R	O
+and	O
+CPV	B-SPEC
+-	O
+2	O
+-	O
+305P	O
+(	O
+for	O
+CPV	B-SPEC
+-	O
+2	O
+)/	O
+CPV	B-SPEC
+-	O
+2a	O
+-	O
+305P	O
+(	O
+for	O
+CPV	B-SPEC
+-	O
+2a	O
+,	O
+2b	O
+and	O
+2c	O
+),	O
+was	O
+able	O
+to	O
+differentiate	O
+CPV	B-SPEC
+-	O
+2	O
+and	O
+its	O
+variants	O
+(	O
+CPV	B-SPEC
+-	O
+2a	O
+,	O
+2b	O
+and	O
+2c	O
+).	O
+
+The	O
+most	O
+divergent	O
+region	O
+is	O
+in	O
+the	O
+spike	O
+protein	B-CHED
+,	O
+which	O
+only	O
+shares	O
+68	O
+%	O
+amino	B-CHED
+acid	I-CHED
+identity	O
+with	O
+BatCoV	O
+HKU9	O
+.	O
+
+TITLE	O
+:	O
+Impact	O
+and	O
+safety	O
+of	O
+open	O
+lung	B-ANAT
+biopsy	O
+in	O
+patients	O
+with	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+(	O
+ARDS	B-DISO
+).	O
+
+The	O
+most	O
+frequent	O
+intervention	O
+was	O
+discontinuation	O
+of	O
+antimicrobial	B-CHED
+or	O
+corticosteroid	B-CHED
+treatment	O
+.	O
+
+CONCLUSIONS	O
+:	O
+The	O
+information	O
+provided	O
+by	O
+OLB	O
+performed	O
+at	O
+the	O
+bedside	O
+in	O
+ARDS	B-DISO
+patients	O
+of	O
+unknown	O
+etiology	O
+could	O
+be	O
+relevant	O
+,	O
+as	O
+it	O
+may	O
+optimize	O
+treatment	O
+.	O
+
+We	O
+found	O
+that	O
+nano	O
+silicon	B-CHED
+applied	O
+with	O
+inactivated	O
+TGEV	B-SPEC
+vaccine	O
+induced	O
+high	O
+antibody	B-COMP
+titers	O
+,	O
+increase	O
+IL	B-FUNC
+-	I-FUNC
+6	I-FUNC
+,	O
+TNF	B-PRGE
+-	I-PRGE
+α	I-PRGE
+and	O
+IFN	B-PRGE
+-	I-PRGE
+γ	I-PRGE
+expression	B-PROC
+,	O
+and	O
+stimulate	O
+CD3	B-PRGE
++	I-PRGE
+T	B-PROC
+cell	I-PROC
+proliferation	B-DISO
+with	O
+a	O
+high	O
+CD4	B-PRGE
++/	I-PRGE
+CD8	B-ANAT
++	I-ANAT
+T	I-ANAT
+lymphocyte	I-ANAT
+ratio	O
+.	O
+
+Nano	O
+silicon	B-CHED
+could	O
+be	O
+considered	O
+for	O
+use	O
+as	O
+an	O
+antigen	B-CHED
+-	O
+carrier	O
+and	O
+adjuvant	B-CHED
+for	O
+veterinary	O
+vaccines	O
+.	O
+
+The	O
+objective	O
+of	O
+this	O
+study	O
+was	O
+to	O
+determine	O
+the	O
+adjunctive	O
+effect	O
+of	O
+azithromycin	B-CHED
+on	O
+survival	O
+for	O
+patients	O
+with	O
+ARDS	B-DISO
+.	O
+
+The	O
+28	O
+-	O
+day	O
+mortality	O
+rate	O
+tended	O
+to	O
+be	O
+higher	O
+in	O
+the	O
+azithromycin	B-CHED
+cohort	O
+than	O
+in	O
+the	O
+non	O
+-	O
+azithromycin	B-CHED
+cohort	O
+,	O
+but	O
+this	O
+was	O
+not	O
+statistically	O
+significant	O
+.	O
+
+Here	O
+,	O
+we	O
+characterized	O
+how	O
+strategy	O
+and	O
+technology	O
+could	O
+be	O
+mobilized	O
+to	O
+improve	O
+the	O
+effectiveness	O
+of	O
+infection	B-DISO
+prevention	O
+and	O
+control	O
+in	O
+hospitals	O
+during	O
+the	O
+outbreaks	O
+of	O
+Ebola	O
+,	O
+Middle	O
+East	O
+respiratory	O
+syndrome	B-DISO
+(	O
+MERS	O
+),	O
+and	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+(	O
+SARS	B-DISO
+)	O
+in	O
+Asia	O
+and	O
+West	O
+Africa	O
+.	O
+
+ABSTRACT	O
+:	O
+A	O
+monkey	B-ANAT
+cell	B-COMP
+line	I-ANAT
+Vero	O
+(	O
+ATCC	O
+CCL	B-DISO
+-	O
+81	O
+)	O
+is	O
+commonly	O
+used	O
+for	O
+porcine	B-SPEC
+epidemic	I-SPEC
+diarrhea	I-SPEC
+virus	I-SPEC
+(	O
+PEDV	B-SPEC
+)	O
+propagation	O
+in	O
+vitro	O
+.	O
+
+The	O
+results	O
+suggest	O
+that	O
+there	O
+exists	O
+an	O
+additional	O
+cellular	O
+receptor	O
+on	O
+Vero	O
+or	O
+porcine	B-SPEC
+jejunal	B-ANAT
+cells	B-COMP
+independent	O
+of	O
+APN	B-PRGE
+for	O
+PEDV	B-SPEC
+entry	O
+.	O
+
+TITLE	O
+:	O
+Nurses	O
+'	O
+experiences	O
+of	O
+care	O
+for	O
+patients	O
+with	O
+Middle	O
+East	O
+respiratory	O
+syndrome	B-DISO
+-	O
+coronavirus	B-SPEC
+in	O
+South	O
+Korea	O
+.	O
+
+ABSTRACT	O
+:	O
+This	O
+study	O
+aimed	O
+to	O
+identify	O
+nurses	O
+'	O
+experiences	O
+of	O
+care	O
+for	O
+patients	O
+with	O
+Middle	O
+East	O
+respiratory	O
+syndrome	O
+-	O
+coronavirus	B-SPEC
+(	O
+MERS	O
+-	O
+CoV	O
+).	O
+
+ABSTRACT	O
+:	O
+Middle	O
+East	O
+Respiratory	O
+Syndrome	O
+coronavirus	B-SPEC
+(	O
+MERS	O
+-	O
+CoV	O
+)	O
+was	O
+first	O
+isolated	O
+from	O
+a	O
+patient	O
+with	O
+severe	O
+pneumonia	B-DISO
+in	O
+2012	O
+.	O
+
+Although	O
+MERS	O
+-	O
+CoV	O
+infection	B-DISO
+is	O
+ubiquitous	O
+in	O
+dromedaries	B-SPEC
+across	O
+Africa	O
+as	O
+well	O
+as	O
+in	O
+the	O
+Arabian	O
+Peninsula	O
+,	O
+zoonotic	O
+disease	O
+appears	O
+confined	O
+to	O
+the	O
+Arabian	O
+Peninsula	O
+.	O
+
+ABSTRACT	O
+:	O
+Rapid	O
+sequence	O
+induction	O
+(	O
+RSI	B-DISO
+)	O
+is	O
+a	O
+specific	O
+technique	O
+for	O
+anesthesia	B-DISO
+induction	O
+,	O
+which	O
+is	O
+performed	O
+in	O
+patients	O
+with	O
+an	O
+increased	O
+risk	O
+for	O
+pulmonary	B-DISO
+aspiration	I-DISO
+(	O
+e	O
+.	O
+g	O
+.	O
+intestinal	B-DISO
+obstruction	I-DISO
+,	O
+severe	O
+injuries	O
+and	O
+cesarean	O
+section	O
+).	O
+
+BCoV	O
+infection	B-DISO
+was	O
+also	O
+evident	O
+in	O
+captive	O
+wild	O
+ruminants	B-SPEC
+.	O
+
+The	O
+rapid	O
+MERS	B-PRGE
+-	I-PRGE
+CoV	I-PRGE
+nucleocapsid	I-PRGE
+protein	B-CHED
+detection	O
+assay	O
+is	O
+able	O
+to	O
+rapidly	O
+detect	O
+lineage	O
+C	O
+betacoronaviruses	O
+in	O
+bats	B-SPEC
+.	O
+
+ABSTRACT	O
+:	O
+Infections	B-DISO
+caused	O
+by	O
+respiratory	O
+viruses	B-SPEC
+are	O
+important	O
+problems	O
+worldwide	O
+,	O
+especially	O
+in	O
+children	O
+.	O
+
+In	O
+total	O
+,	O
+545	O
+nasopharyngeal	B-ANAT
+(	O
+NP	O
+)	O
+specimens	O
+from	O
+individuals	O
+with	O
+Severe	B-DISO
+Acute	I-DISO
+Respiratory	I-DISO
+Syndrome	I-DISO
+(	O
+SARS	B-DISO
+)	O
+who	O
+were	O
+negative	O
+for	O
+other	O
+seven	O
+respiratory	O
+viruses	B-SPEC
+were	O
+analyzed	O
+for	O
+the	O
+presence	O
+of	O
+hMPV	B-SPEC
+.	O
+
+hMPV	B-SPEC
+was	O
+further	O
+detected	O
+in	O
+several	O
+cases	O
+of	O
+SARS	B-DISO
+and	O
+it	O
+was	O
+the	O
+only	O
+virus	B-SPEC
+detected	O
+in	O
+three	O
+deaths	B-PROC
+.	O
+
+The	O
+aim	O
+of	O
+this	O
+study	O
+was	O
+to	O
+compare	O
+VICC	O
+with	O
+MIT	B-CHED
+,	O
+in	O
+terms	O
+of	O
+accuracy	O
+,	O
+biosafety	O
+and	O
+occupational	O
+health	O
+,	O
+supply	O
+and	O
+equipment	O
+costs	O
+,	O
+bioethics	O
+and	O
+animal	B-SPEC
+welfare	O
+,	O
+in	O
+a	O
+Brazilian	O
+public	O
+health	O
+lab	O
+.	O
+
+RESULTS	O
+:	O
+Both	O
+VICC	O
+and	O
+MIT	B-CHED
+had	O
+almost	O
+the	O
+same	O
+accuracy	O
+(	O
+99	O
+.	O
+8	O
+%),	O
+although	O
+VICC	O
+presented	O
+fewer	O
+risks	O
+regarding	O
+biosafety	O
+and	O
+mental	O
+health	O
+of	O
+the	O
+technicians	O
+,	O
+and	O
+reduced	O
+time	O
+between	O
+inoculation	O
+and	O
+obtaining	O
+the	O
+results	O
+(	O
+approximately	O
+22	O
+days	O
+less	O
+).	O
+
+ABSTRACT	O
+:	O
+The	O
+ever	O
+-	O
+increasing	O
+speed	O
+and	O
+scope	O
+of	O
+human	B-SPEC
+mobility	O
+by	O
+international	O
+air	B-CHED
+travel	O
+has	O
+led	O
+to	O
+a	O
+global	O
+transport	B-PROC
+network	O
+for	O
+infectious	B-DISO
+diseases	I-DISO
+with	O
+the	O
+potential	O
+to	O
+introduce	O
+pathogens	O
+into	O
+non	O
+-	O
+endemic	O
+areas	O
+,	O
+and	O
+to	O
+facilitate	O
+rapid	O
+spread	O
+of	O
+novel	O
+or	O
+mutated	O
+zoonotic	O
+agents	O
+.	O
+
+TITLE	O
+:	O
+Importance	O
+of	O
+Neutralizing	O
+Monoclonal	O
+Antibodies	B-COMP
+Targeting	B-PROC
+Multiple	O
+Antigenic	O
+Sites	O
+on	O
+the	O
+Middle	O
+East	O
+Respiratory	O
+Syndrome	O
+Coronavirus	B-SPEC
+Spike	O
+Glycoprotein	B-CHED
+To	O
+Avoid	O
+Neutralization	O
+Escape	O
+.	O
+
+The	O
+potential	O
+for	O
+a	O
+future	O
+pandemic	O
+originating	O
+from	O
+animal	B-SPEC
+reservoirs	O
+or	O
+health	O
+care	O
+-	O
+associated	O
+events	O
+is	O
+a	O
+major	O
+public	O
+health	O
+concern	O
+.	O
+
+ABSTRACT	O
+:	O
+The	O
+spike	O
+glycoprotein	B-CHED
+(	O
+S	O
+)	O
+of	O
+murine	B-SPEC
+coronavirus	I-SPEC
+mouse	B-DISO
+hepatitis	I-DISO
+virus	B-SPEC
+(	O
+MHV	B-SPEC
+)	O
+strain	O
+A59	O
+uses	O
+murine	B-SPEC
+carcinoembryonic	B-PRGE
+antigen	I-PRGE
+-	I-PRGE
+related	I-PRGE
+cell	B-PROC
+adhesion	B-DISO
+molecule	I-PRGE
+1a	I-PRGE
+as	O
+its	O
+receptor	O
+for	O
+cell	B-COMP
+entry	O
+,	O
+but	O
+S	B-PRGE
+protein	I-PRGE
+can	O
+also	O
+be	O
+triggered	O
+in	O
+the	O
+absence	O
+of	O
+receptor	O
+by	O
+pH	O
+8	O
+.	O
+0	O
+alone	O
+at	O
+37	O
+°	O
+C	O
+.	O
+
+Here	O
+,	O
+we	O
+show	O
+that	O
+MHV	B-PRGE
+-	I-PRGE
+A59	I-PRGE
+S	I-PRGE
+protein	B-CHED
+is	O
+triggered	O
+by	O
+pH	O
+8	O
+.	O
+0	O
+at	O
+37	O
+°	O
+C	O
+to	O
+induce	O
+receptor	O
+-	O
+independent	O
+syncytium	B-ANAT
+(	O
+RIS	O
+)	O
+formation	B-PROC
+on	O
+293T	O
+cells	B-COMP
+,	O
+and	O
+that	O
+the	O
+conformational	O
+changes	O
+in	O
+S	O
+proteins	B-CHED
+triggered	O
+by	O
+pH	O
+8	O
+.	O
+0	O
+are	O
+very	O
+similar	O
+to	O
+those	O
+triggered	O
+by	O
+receptor	B-FUNC
+binding	I-FUNC
+.	O
+
+Replacement	O
+of	O
+H209	O
+with	O
+Ala	O
+had	O
+no	O
+effect	O
+on	O
+receptor	B-FUNC
+binding	I-FUNC
+,	O
+but	O
+in	O
+murine	B-SPEC
+17Cl	B-CHED
+.	O
+1	O
+cells	B-COMP
+mutant	B-DISO
+H209A	O
+MHV	B-SPEC
+-	O
+A59	O
+showed	O
+delayed	B-DISO
+growth	I-DISO
+kinetics	O
+and	O
+was	O
+readily	O
+outcompeted	O
+by	O
+wild	O
+-	O
+type	O
+virus	B-SPEC
+when	O
+mixed	O
+together	O
+,	O
+indicating	O
+that	O
+the	O
+H209A	O
+mutation	O
+caused	O
+a	O
+defect	O
+in	O
+virus	B-SPEC
+fitness	O
+.	O
+
+AvCoV	O
+isolated	O
+from	O
+the	O
+pigeon	B-SPEC
+sample	O
+caused	O
+complete	O
+tracheal	O
+ciliostasis	O
+over	O
+a	O
+longer	O
+time	O
+span	O
+.	O
+
+Immunohistochemistry	O
+was	O
+performed	O
+for	O
+FoxP3	B-PRGE
+,	O
+CD3	B-PRGE
+,	O
+and	O
+IL	B-PRGE
+-	I-PRGE
+17A	I-PRGE
+,	O
+and	O
+positive	O
+cells	B-COMP
+were	O
+quantified	O
+in	O
+multiple	O
+images	O
+of	O
+each	O
+sample	O
+.	O
+
+A	O
+generalized	O
+estimating	O
+equation	O
+tested	O
+for	O
+an	O
+association	O
+between	O
+the	O
+level	O
+of	O
+inflammation	B-DISO
+and	O
+the	O
+prevalence	O
+of	O
+these	O
+cell	B-COMP
+types	O
+.	O
+
+Cells	B-COMP
+stained	O
+positive	O
+for	O
+IL	B-PRGE
+-	I-PRGE
+17A	I-PRGE
+in	O
+idiopathic	O
+uveitis	B-DISO
+but	O
+not	O
+in	O
+FIP	B-DISO
+samples	O
+.	O
+
+Inflammatory	O
+stress	O
+and	O
+immune	O
+parameters	O
+including	O
+procalcitonin	O
+(	O
+PCT	B-DISO
+),	O
+interleukin	B-PRGE
+-	I-PRGE
+6	I-PRGE
+(	O
+IL	B-FUNC
+-	I-FUNC
+6	I-FUNC
+),	O
+and	O
+tumor	B-DISO
+necrosis	B-PROC
+factor	I-FUNC
+-	I-PRGE
+α	I-PRGE
+(	O
+TNF	B-PRGE
+-	I-PRGE
+α	I-PRGE
+),	O
+and	O
+CD4	B-PRGE
+Seventy	O
+patients	O
+with	O
+severe	O
+pneumonia	B-DISO
+were	O
+enrolled	O
+.	O
+
+It	O
+provides	O
+the	O
+opportunity	O
+and	O
+condition	B-DISO
+for	O
+comprehensive	O
+treatment	O
+.	O
+
+RESULTS	O
+:	O
+Seventy	O
+patients	O
+with	O
+severe	O
+pneumonia	B-DISO
+were	O
+enrolled	O
+.	O
+
+Mesenchymal	B-ANAT
+stem	I-ANAT
+cells	I-ANAT
+(	O
+MSCs	B-COMP
+)	O
+have	O
+the	O
+ability	O
+to	O
+regulate	O
+immune	B-PROC
+responses	I-PROC
+,	O
+and	O
+many	O
+researches	O
+showed	O
+that	O
+MSCs	B-COMP
+had	O
+potential	O
+therapeutic	O
+effects	O
+on	O
+autoimmune	B-DISO
+diseases	I-DISO
+and	O
+graft	B-ANAT
+versus	O
+host	B-COMP
+diseases	O
+.	O
+
+Recently	O
+,	O
+basic	O
+researches	O
+showed	O
+that	O
+MSCs	B-FUNC
+could	O
+treat	O
+ARDS	B-DISO
+and	O
+many	O
+scientists	O
+paid	O
+attention	O
+to	O
+the	O
+therapeutic	O
+use	O
+of	O
+MSC	O
+in	O
+the	O
+treatment	O
+of	O
+ARDS	B-DISO
+.	O
+
+The	O
+present	O
+study	O
+aims	O
+at	O
+addressing	O
+the	O
+modulation	O
+of	O
+relevant	O
+immune	O
+cell	O
+subsets	O
+by	O
+flow	O
+cytometry	O
+in	O
+the	O
+blood	B-ANAT
+of	O
+4	O
+-	O
+week	O
+-	O
+old	O
+pigs	B-SPEC
+experimentally	O
+infected	O
+with	O
+the	O
+recently	O
+discovered	O
+PR40	O
+/	O
+2014	O
+HP	O
+PRRSV	B-SPEC
+-	O
+1	O
+.	O
+1	O
+strain	O
+phenotypically	O
+characterized	O
+in	O
+Canelli	O
+et	O
+al	O
+.	O
+(	O
+2017	O
+)	O
+compared	O
+to	O
+pigs	B-SPEC
+infected	O
+with	O
+a	O
+non	O
+-	O
+HP	O
+PRRSV	B-SPEC
+isolate	O
+(	O
+PR11	O
+/	O
+2014	O
+)	O
+and	O
+uninfected	O
+controls	O
+.	O
+
+Overall	O
+,	O
+these	O
+features	O
+demonstrate	O
+that	O
+the	O
+more	O
+severe	O
+clinical	O
+signs	O
+observed	O
+upon	O
+infection	B-DISO
+with	O
+the	O
+HP	O
+PR40	O
+strain	O
+are	O
+sustained	O
+by	O
+remarkable	O
+changes	O
+in	O
+the	O
+peripheral	B-ANAT
+blood	I-ANAT
+distribution	O
+of	O
+immune	O
+cells	B-COMP
+and	O
+provide	O
+further	O
+insights	O
+into	O
+the	O
+immune	O
+regulation	B-PROC
+/	O
+immunopathogenesis	O
+induced	O
+by	O
+PRRSV	B-SPEC
+-	O
+1	O
+subtype	O
+1	O
+European	O
+isolates	O
+.	O
+
+Our	O
+results	O
+showed	O
+that	O
+the	O
+nsp7	B-PRGE
+protein	I-PRGE
+is	O
+localized	O
+in	O
+the	O
+cytoplasm	B-COMP
+and	O
+has	O
+no	O
+effect	O
+on	O
+intestinal	B-ANAT
+epithelial	B-ANAT
+cells	I-ANAT
+(	O
+IECs	O
+)	O
+growth	B-PROC
+,	O
+cell	B-PATH
+cycle	I-PATH
+,	O
+and	O
+cyclin	B-PRGE
+A	I-PRGE
+expression	B-PROC
+.	O
+
+ABSTRACT	O
+:	O
+For	O
+three	O
+decades	O
+now	O
+,	O
+ionic	O
+liquids	O
+(	O
+ILs	B-DISO
+),	O
+organic	B-CHED
+salts	I-CHED
+comprising	O
+only	O
+ions	B-CHED
+,	O
+have	O
+emerged	O
+as	O
+a	O
+new	O
+class	B-SPEC
+of	O
+pharmaceuticals	B-CHED
+.	O
+
+Patients	O
+were	O
+stratified	O
+by	O
+treatment	O
+arm	B-ANAT
+(	O
+12	O
+versus	O
+6	O
+cm	O
+A	O
+total	O
+of	O
+446	O
+(	O
+49	O
+%)	O
+patients	O
+had	O
+complete	O
+SP	B-PRGE
+-	I-PRGE
+D	I-PRGE
+,	O
+VWF	B-PRGE
+,	O
+and	O
+IL	B-FUNC
+-	I-FUNC
+8	I-FUNC
+measurements	O
+on	O
+study	O
+enrollment	O
+and	O
+day	O
+3	O
+.	O
+
+NBM	O
+is	O
+associated	O
+with	O
+decreased	O
+biomarkers	O
+of	O
+epithelial	O
+and	O
+endothelial	B-ANAT
+lung	B-ANAT
+injury	O
+and	O
+systemic	O
+inflammation	B-DISO
+in	O
+ARDS	B-DISO
+patients	O
+receiving	O
+low	O
+tidal	O
+volume	O
+ventilation	O
+and	O
+those	O
+with	O
+a	O
+P	O
+/	O
+F	O
+ratio	O
+less	O
+than	O
+or	O
+equal	O
+to	O
+120	O
+.	O
+
+Similarly	O
+,	O
+89	O
+.	O
+1	O
+%	O
+(	O
+n	O
+=	O
+302	O
+)	O
+identified	O
+that	O
+camels	B-SPEC
+and	O
+bats	B-SPEC
+are	O
+prone	O
+to	O
+infection	B-DISO
+with	O
+coronaviruses	O
+.	O
+
+Previous	O
+studies	O
+exploring	O
+CAM	B-DISO
+use	O
+among	O
+cancer	B-DISO
+patients	O
+in	O
+the	O
+Middle	O
+East	O
+region	O
+have	O
+shown	O
+discrepant	O
+results	O
+.	O
+
+Thirty	O
+percent	O
+of	O
+CAM	B-DISO
+users	O
+had	O
+discussed	O
+the	O
+issue	O
+with	O
+their	O
+doctors	O
+;	O
+only	O
+7	O
+.	O
+7	O
+%	O
+had	O
+done	O
+so	O
+with	O
+their	O
+nurses	O
+.	O
+
+All	O
+regressions	B-DISO
+were	O
+adjusted	O
+for	O
+age	O
+,	O
+gender	O
+,	O
+level	O
+of	O
+intellectual	B-DISO
+disabilities	I-DISO
+,	O
+living	O
+arrangements	O
+,	O
+neighbourhood	O
+deprivation	O
+and	O
+Down	B-DISO
+syndrome	I-DISO
+.	O
+
+METHODS	O
+:	O
+A	O
+total	O
+of	O
+1023	O
+adults	O
+with	O
+intellectual	B-DISO
+disabilities	I-DISO
+underwent	O
+comprehensive	O
+health	O
+assessments	O
+.	O
+
+TITLE	O
+:	O
+Cellular	B-ANAT
+hnRNP	B-ANAT
+A1	I-PRGE
+Interacts	O
+with	O
+Nucleocapsid	B-PRGE
+Protein	B-CHED
+of	O
+Porcine	B-SPEC
+Epidemic	I-SPEC
+Diarrhea	I-SPEC
+Virus	I-SPEC
+and	O
+Impairs	O
+Viral	O
+Replication	O
+.	O
+
+Heterogeneous	B-PRGE
+nuclear	I-PRGE
+ribonucleoprotein	I-PRGE
+A1	I-PRGE
+(	O
+hnRNP	B-PRGE
+A1	I-PRGE
+)	O
+is	O
+a	O
+cellular	B-COMP
+protein	B-CHED
+participating	O
+in	O
+the	O
+splicing	B-PROC
+of	O
+pre	O
+-	O
+mRNA	B-CHED
+in	O
+the	O
+nucleus	B-COMP
+and	O
+translation	B-PROC
+regulation	B-PROC
+in	O
+the	O
+cytoplasm	B-COMP
+.	O
+
+According	O
+to	O
+our	O
+previous	O
+proteomic	O
+study	O
+about	O
+PEDV	B-SPEC
+infection	B-DISO
+in	O
+vivo	O
+,	O
+hnRNP	B-PRGE
+A1	I-PRGE
+was	O
+thought	O
+to	O
+be	O
+a	O
+cellular	B-COMP
+factor	O
+influencing	O
+PEDV	B-SPEC
+replication	O
+.	O
+
+TITLE	O
+:	O
+A	O
+Multicenter	O
+Consortium	O
+to	O
+Define	O
+the	O
+Epidemiology	O
+and	O
+Outcomes	O
+of	O
+Pediatric	O
+Solid	O
+Organ	B-ANAT
+Transplant	I-ANAT
+Recipients	O
+With	O
+Inpatient	O
+Respiratory	B-DISO
+Virus	I-DISO
+Infection	I-DISO
+.	O
+
+A	O
+retrospective	O
+observational	O
+cohort	O
+of	O
+pediatric	O
+SOT	O
+recipients	O
+(	O
+January	O
+2010	O
+to	O
+June	O
+2013	O
+)	O
+was	O
+assembled	O
+from	O
+9	O
+US	O
+pediatric	O
+transplant	B-ANAT
+centers	O
+.	O
+
+ABSTRACT	O
+:	O
+Since	O
+late	O
+2013	O
+,	O
+porcine	B-SPEC
+epidemic	I-SPEC
+diarrhea	I-SPEC
+virus	I-SPEC
+(	O
+PEDV	B-SPEC
+)	O
+has	O
+reemerged	O
+in	O
+Japan	O
+and	O
+caused	O
+severe	O
+economic	O
+losses	O
+to	O
+the	O
+swine	B-SPEC
+industry	O
+.	O
+
+Although	O
+PEDV	B-SPEC
+vaccines	O
+have	O
+been	O
+used	O
+widely	O
+,	O
+the	O
+disease	O
+has	O
+swept	O
+rapidly	O
+across	O
+the	O
+county	O
+,	O
+and	O
+is	O
+commonly	O
+observed	O
+in	O
+PED	O
+-	O
+vaccinated	O
+farms	O
+,	O
+and	O
+has	O
+recurred	O
+in	O
+domestic	O
+herds	O
+.	O
+
+In	O
+comparison	O
+with	O
+two	O
+vaccine	O
+strains	O
+used	O
+in	O
+Japan	O
+,	O
+the	O
+field	O
+strains	O
+had	O
+various	O
+changes	O
+in	O
+epitope	B-CHED
+regions	O
+,	O
+glycosylation	B-PROC
+sites	O
+,	O
+and	O
+phosphorylation	B-PROC
+sites	O
+.	O
+
+RESULTS	O
+:	O
+Phylogenetic	O
+analysis	O
+based	O
+on	O
+S	O
+gene	O
+sequences	O
+revealed	O
+that	O
+all	O
+the	O
+recent	O
+field	O
+PEDVs	O
+were	O
+genetically	O
+distinct	O
+from	O
+the	O
+classical	O
+Japanese	O
+strains	O
+,	O
+and	O
+were	O
+classified	O
+into	O
+three	O
+genotypes	O
+:	O
+North	O
+American	O
+(	O
+NA	O
+),	O
+S	O
+INDEL	B-PROC
+,	O
+and	O
+Asian	O
+non	O
+-	O
+S	O
+INDEL	B-PROC
+.	O
+
+Our	O
+data	O
+suggested	O
+a	O
+possibility	O
+that	O
+multiple	O
+parental	O
+PEDV	B-SPEC
+strains	O
+were	O
+introduced	O
+into	O
+Japan	O
+from	O
+abroad	O
+at	O
+the	O
+same	O
+time	O
+or	O
+similar	O
+times	O
+.	O
+
+TITLE	O
+:	O
+Clinical	O
+characteristics	O
+from	O
+co	B-DISO
+-	I-DISO
+infection	I-DISO
+with	O
+avian	B-DISO
+influenza	B-PATH
+A	I-PATH
+H7N9	O
+and	O
+Mycoplasma	B-DISO
+pneumoniae	I-SPEC
+:	O
+a	O
+case	O
+report	O
+.	O
+
+She	O
+was	O
+given	O
+comprehensive	O
+treatment	O
+,	O
+including	O
+oseltamivir	B-CHED
+,	O
+methylprednisolone	B-CHED
+,	O
+immunoglobulin	B-PROC
+,	O
+gastric	B-ANAT
+protection	O
+,	O
+and	O
+noninvasive	O
+mechanical	O
+ventilation	O
+.	O
+
+She	O
+was	O
+reasonably	O
+considered	O
+to	O
+be	O
+infected	O
+with	O
+Mycoplasma	B-SPEC
+pneumoniae	I-SPEC
+as	O
+well	O
+,	O
+and	O
+azithromycin	B-CHED
+and	O
+moxifloxacin	B-CHED
+were	O
+added	O
+to	O
+her	O
+treatment	O
+.	O
+
+In	O
+patients	O
+with	O
+confirmed	O
+influenza	B-PATH
+A	I-PATH
+H7N9	O
+infection	B-DISO
+whose	O
+condition	B-DISO
+worsens	O
+again	O
+,	O
+especially	O
+with	O
+new	O
+infiltration	B-DISO
+or	O
+lung	B-ANAT
+ground	O
+-	O
+glass	O
+infiltration	B-DISO
+,	O
+one	O
+should	O
+suspect	O
+infection	B-DISO
+by	O
+other	O
+pathogens	O
+such	O
+as	O
+Mycoplasma	B-SPEC
+pneumoniae	I-SPEC
+.	O
+
+Two	O
+reaction	O
+mixtures	O
+(	O
+Isothermal	O
+Mastermix	O
+,	O
+OptiGene	O
+Ltd	O
+.	O
+and	O
+PCRun	O
+™	O
+Molecular	O
+Detection	O
+Mix	O
+,	O
+Biogal	O
+)	O
+were	O
+tested	O
+using	O
+the	O
+same	O
+primers	O
+,	O
+which	O
+were	O
+designed	O
+to	O
+bind	B-FUNC
+to	O
+a	O
+conserved	O
+region	O
+of	O
+the	O
+FCoV	B-PRGE
+membrane	I-PRGE
+protein	B-CHED
+gene	I-PRGE
+.	O
+
+The	O
+aim	O
+of	O
+the	O
+following	O
+study	O
+was	O
+to	O
+investigate	O
+the	O
+presence	O
+of	O
+mutated	O
+virus	B-SPEC
+in	O
+tissue	B-ANAT
+samples	O
+of	O
+cats	B-SPEC
+with	O
+and	O
+without	O
+FIP	B-DISO
+.	O
+
+For	O
+one	O
+sample	O
+genotyping	O
+was	O
+not	O
+possible	O
+despite	O
+high	O
+viral	O
+load	O
+,	O
+and	O
+two	O
+samples	O
+were	O
+negative	O
+for	O
+FCoV	O
+.	O
+As	O
+none	O
+of	O
+the	O
+control	O
+animals	B-SPEC
+showed	O
+FCoV	O
+amino	B-PROC
+acid	I-PROC
+substitutions	I-PROC
+previously	O
+demonstrated	O
+in	O
+cats	B-SPEC
+with	O
+FIP	B-DISO
+,	O
+it	O
+can	O
+be	O
+presumed	O
+that	O
+the	O
+substitution	O
+M1058L	O
+correlates	O
+with	O
+the	O
+presence	O
+of	O
+FIP	B-DISO
+.	O
+
+FCoV	O
+was	O
+detected	O
+in	O
+low	O
+concentration	O
+in	O
+tissues	B-ANAT
+of	O
+control	O
+animals	B-SPEC
+,	O
+confirming	O
+the	O
+ability	O
+of	O
+FCoV	O
+to	O
+spread	O
+systemically	O
+.	O
+
+ABSTRACT	O
+:	O
+Evidence	O
+is	O
+accumulating	O
+that	O
+exposure	O
+to	O
+cigarette	O
+smoke	O
+(	O
+CS	O
+)	O
+increases	O
+the	O
+risk	O
+of	O
+developing	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+(	O
+ARDS	B-DISO
+).	O
+
+Streptococcus	B-SPEC
+pneumoniae	I-SPEC
+is	O
+the	O
+most	O
+common	O
+cause	O
+of	O
+bacterial	B-DISO
+pneumonia	I-DISO
+,	O
+which	O
+in	O
+turn	O
+is	O
+the	O
+leading	O
+cause	O
+of	O
+ARDS	B-DISO
+.	O
+
+We	O
+exposed	O
+mice	B-SPEC
+to	O
+3	O
+wk	O
+of	O
+moderate	O
+whole	B-ANAT
+body	I-ANAT
+CS	O
+or	O
+air	B-CHED
+,	O
+followed	O
+by	O
+intranasal	O
+inoculation	O
+with	O
+an	O
+invasive	O
+serotype	O
+of	O
+S	B-SPEC
+.	I-SPEC
+pneumoniae	I-SPEC
+.	O
+
+The	O
+inclusion	O
+of	O
+antibiotic	B-CHED
+treatment	O
+in	O
+preclinical	O
+studies	O
+of	O
+acute	O
+lung	B-ANAT
+injury	O
+in	O
+bacterial	B-DISO
+pneumonia	I-DISO
+may	O
+enhance	O
+clinical	O
+relevance	O
+,	O
+particularly	O
+for	O
+future	O
+studies	O
+of	O
+current	O
+or	O
+emerging	O
+tobacco	B-SPEC
+products	O
+.	O
+
+TITLE	O
+:	O
+Structure	O
+-	O
+guided	O
+design	O
+of	O
+potent	O
+and	O
+permeable	O
+inhibitors	B-CHED
+of	O
+MERS	B-PRGE
+coronavirus	I-PRGE
+3CL	I-PRGE
+protease	I-PRGE
+that	O
+utilize	O
+a	O
+piperidine	O
+moiety	O
+as	O
+a	O
+novel	O
+design	O
+element	O
+.	O
+
+In	O
+the	O
+MATRIX	O
+(	O
+Minimizing	O
+Adverse	O
+Haemorrhagic	O
+Events	O
+by	O
+Transradial	O
+Access	O
+Site	O
+and	O
+Systemic	O
+Implementation	O
+of	O
+AngioX	O
+)	O
+program	O
+,	O
+7	O
+,	O
+213	O
+patients	O
+were	O
+randomly	O
+assigned	O
+to	O
+receive	O
+either	O
+bivalirudin	B-CHED
+or	O
+UFH	O
+with	O
+or	O
+without	O
+GPIs	B-CHED
+at	O
+discretion	O
+of	O
+the	O
+operator	O
+.	O
+
+Among	O
+3	O
+,	O
+603	O
+patients	O
+assigned	O
+to	O
+receive	O
+UFH	O
+,	O
+781	O
+(	O
+21	O
+.	O
+7	O
+%)	O
+underwent	O
+planned	O
+treatment	O
+with	O
+GPI	O
+before	O
+coronary	B-ANAT
+intervention	O
+.	O
+
+Our	O
+aim	O
+was	O
+to	O
+assess	O
+the	O
+incidence	O
+,	O
+characteristics	O
+,	O
+aetiology	O
+,	O
+risk	O
+factors	O
+and	O
+mortality	O
+of	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+(	O
+ARDS	B-DISO
+)	O
+in	O
+intensive	O
+care	O
+unit	O
+(	O
+ICU	O
+)	O
+patients	O
+with	O
+community	O
+-	O
+acquired	O
+pneumonia	B-DISO
+(	O
+CAP	B-DISO
+)	O
+using	O
+the	O
+Berlin	O
+definition	O
+.	O
+
+We	O
+prospectively	O
+enrolled	O
+consecutive	O
+mechanically	O
+ventilated	O
+adult	O
+ICU	O
+patients	O
+with	O
+CAP	B-DISO
+over	O
+20	O
+years	O
+,	O
+and	O
+compared	O
+them	O
+with	O
+mechanically	O
+ventilated	O
+patients	O
+without	O
+ARDS	B-DISO
+.	O
+
+Specific	O
+areas	O
+of	O
+research	O
+are	O
+highlighted	O
+as	O
+especially	O
+promising	O
+for	O
+making	O
+advances	O
+against	O
+pneumonia	B-DISO
+.	O
+
+PED	O
+threatens	O
+pig	B-SPEC
+industry	O
+and	O
+leads	O
+to	O
+substantial	O
+economic	O
+losses	O
+.	O
+
+When	O
+taking	O
+the	O
+previously	O
+submitted	O
+3	O
+isolates	O
+from	O
+China	O
+into	O
+consideration	O
+,	O
+all	O
+the	O
+12	O
+isolates	O
+were	O
+clustered	O
+into	O
+4	O
+groups	O
+,	O
+i	O
+.	O
+e	O
+.,	O
+G1a	O
+,	O
+G1b	O
+,	O
+G2a	O
+and	O
+G2b	O
+,	O
+suggesting	O
+that	O
+a	O
+highly	O
+diverse	O
+and	O
+complex	O
+clustering	O
+might	O
+result	O
+from	O
+co	B-DISO
+-	I-DISO
+infections	I-DISO
+in	O
+more	O
+than	O
+13	O
+provinces	O
+in	O
+China	O
+,	O
+as	O
+well	O
+in	O
+South	O
+Korea	O
+,	O
+Japan	O
+,	O
+Vietnam	O
+,	O
+Thai	O
+and	O
+USA	O
+.	O
+
+Results	O
+showed	O
+that	O
+high	O
+camel	B-SPEC
+-	O
+dense	O
+areas	O
+and	O
+interaction	O
+(	O
+markets	O
+and	O
+migration	B-PROC
+zones	O
+)	O
+were	O
+potential	O
+hotspot	O
+for	O
+transmission	O
+and	O
+spread	O
+.	O
+
+These	O
+potential	O
+hotspots	O
+,	O
+determined	O
+using	O
+anthropogenic	O
+,	O
+system	O
+and	O
+trade	O
+characterizations	O
+should	O
+guide	O
+selection	O
+of	O
+sampling	O
+/	O
+surveillance	O
+sites	O
+,	O
+high	O
+-	O
+risk	O
+locations	O
+,	O
+critical	O
+areas	O
+for	O
+interventions	O
+and	O
+policy	O
+development	B-PROC
+in	O
+Kenya	O
+,	O
+as	O
+well	O
+as	O
+instigate	O
+further	O
+virological	O
+examination	O
+of	O
+camels	B-SPEC
+.	O
+
+In	O
+this	O
+study	O
+,	O
+DIC	B-DISO
+,	O
+and	O
+AKI	B-PRGE
+stage	I-PRGE
+3	I-PRGE
+were	O
+independent	O
+risk	O
+factors	O
+of	O
+in	O
+-	O
+hospital	O
+mortality	O
+.	O
+
+TITLE	O
+:	O
+Initial	O
+performance	O
+evaluation	O
+of	O
+a	O
+spotted	O
+array	O
+Mobile	O
+Analysis	O
+Platform	O
+(	O
+MAP	O
+)	O
+for	O
+the	O
+detection	O
+of	O
+influenza	B-PATH
+A	I-PATH
+/	O
+B	O
+,	O
+RSV	B-SPEC
+,	O
+and	O
+MERS	O
+coronavirus	B-SPEC
+.	O
+
+The	O
+amplification	B-DISO
+was	O
+performed	O
+at	O
+40	O
+°	O
+C	O
+for	O
+20	O
+min	O
+.	O
+
+TITLE	O
+:	O
+Early	O
+identification	O
+of	O
+pneumonia	B-DISO
+patients	O
+at	O
+increased	O
+risk	O
+of	O
+Middle	O
+East	O
+respiratory	O
+syndrome	B-DISO
+coronavirus	B-DISO
+infection	I-DISO
+in	O
+Saudi	O
+Arabia	O
+.	O
+
+While	O
+their	O
+clinical	O
+representation	O
+resembles	O
+that	O
+of	O
+many	O
+other	O
+agents	O
+of	O
+the	O
+common	B-DISO
+cold	I-DISO
+,	O
+their	O
+evolutionary	O
+histories	O
+,	O
+and	O
+host	B-COMP
+associations	O
+could	O
+provide	O
+important	O
+insights	O
+into	O
+the	O
+natural	O
+history	O
+of	O
+past	O
+human	B-SPEC
+pandemics	O
+.	O
+
+Coronaviruses	O
+,	O
+including	O
+the	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+coronavirus	B-SPEC
+(	O
+SARS	B-DISO
+-	O
+CoV	O
+),	O
+Middle	O
+East	O
+respiratory	O
+syndrome	B-DISO
+coronavirus	B-SPEC
+(	O
+MERS	O
+-	O
+CoV	O
+)	O
+and	O
+infectious	B-DISO
+bronchitis	B-DISO
+virus	B-SPEC
+(	O
+IBV	B-SPEC
+),	O
+fuse	O
+at	O
+the	O
+plasma	B-COMP
+membrane	I-COMP
+or	O
+use	O
+receptor	B-PROC
+-	I-PROC
+mediated	I-PROC
+endocytosis	I-PROC
+and	O
+fuse	O
+with	O
+endosomes	O
+,	O
+depending	O
+on	O
+the	O
+cell	B-COMP
+or	O
+tissue	B-ANAT
+type	I-ANAT
+.	O
+
+Here	O
+,	O
+we	O
+use	O
+IBV	B-SPEC
+,	O
+a	O
+BSL	O
+-	O
+2	O
+virus	O
+,	O
+as	O
+a	O
+model	O
+for	O
+studying	O
+the	O
+role	O
+of	O
+Abl	B-PRGE
+kinase	B-FUNC
+activity	I-FUNC
+during	O
+coronavirus	B-DISO
+infection	I-DISO
+.	O
+
+Metabolic	B-PROC
+screening	O
+revealed	O
+elevated	O
+plasma	B-ANAT
+homocysteine	B-CHED
+levels	O
+,	O
+low	O
+methionine	B-CHED
+levels	O
+,	O
+and	O
+methylmalonic	B-DISO
+aciduria	I-DISO
+,	O
+and	O
+the	O
+patient	O
+was	O
+diagnosed	O
+as	O
+having	O
+HUS	O
+secondary	O
+to	O
+Cbl	B-PRGE
+C	I-PRGE
+defect	O
+.	O
+
+The	O
+infant	O
+was	O
+treated	O
+with	O
+betaine	B-CHED
+,	O
+hydroxycobalamin	B-CHED
+,	O
+and	O
+folic	B-CHED
+acid	I-CHED
+.	O
+
+He	O
+required	O
+continued	O
+renal	B-ANAT
+replacement	O
+treatment	O
+(	O
+CRRT	O
+)	O
+and	O
+plasma	B-ANAT
+exchange	O
+due	O
+to	O
+thrombotic	B-DISO
+microangiopathy	I-DISO
+(	O
+TMA	B-CHED
+).	O
+
+Therefore	O
+,	O
+we	O
+considered	O
+a	O
+second	O
+mechanism	O
+in	O
+the	O
+pathogenesis	B-DISO
+as	O
+complement	O
+dysregulation	O
+and	O
+gave	O
+eculizumab	O
+to	O
+the	O
+patient	O
+.	O
+
+ABSTRACT	O
+:	O
+Public	O
+health	O
+officials	O
+(	O
+PHOs	B-SPEC
+)	O
+are	O
+responsible	O
+for	O
+providing	O
+trustworthy	O
+information	O
+during	O
+a	O
+public	O
+health	O
+crisis	O
+;	O
+however	O
+,	O
+there	O
+is	O
+little	O
+research	O
+on	O
+how	O
+the	O
+public	O
+behaves	O
+when	O
+their	O
+expectations	O
+for	O
+such	O
+information	O
+are	O
+violated	O
+.	O
+
+TITLE	O
+:	O
+Association	O
+between	O
+passive	B-PROC
+immunity	I-PROC
+and	O
+health	O
+status	O
+of	O
+dairy	O
+calves	O
+under	O
+30	O
+days	O
+of	O
+age	O
+.	O
+
+95	O
+%	O
+CI	O
+=	O
+1	O
+-	O
+137	O
+)	O
+and	O
+Cryptosporidium	B-SPEC
+spp	B-ENZY
+.	O
+
+However	O
+,	O
+further	O
+investigations	O
+are	O
+needed	O
+,	O
+particularly	O
+focusing	O
+on	O
+the	O
+relationship	O
+between	O
+PI	O
+and	O
+specific	O
+enteropathogen	O
+infections	B-DISO
+in	O
+calves	O
+.	O
+
+ABSTRACT	O
+:	O
+By	O
+means	O
+of	O
+structure	O
+-	O
+based	O
+molecular	O
+hybridization	B-PROC
+strategy	O
+,	O
+a	O
+series	O
+of	O
+novel	O
+diarylpyri	O
+(	O
+mi	O
+)	O
+dine	O
+derivatives	O
+targeting	B-PROC
+the	O
+entrance	O
+channel	O
+of	O
+HIV	B-SPEC
+-	I-SPEC
+1	I-SPEC
+reverse	B-PRGE
+transcriptase	I-PRGE
+(	O
+RT	O
+)	O
+were	O
+designed	O
+,	O
+synthesized	O
+and	O
+evaluated	O
+as	O
+potent	O
+non	B-PROC
+-	I-PROC
+nucleoside	I-PROC
+reverse	B-CHED
+transcriptase	I-CHED
+inhibitors	I-CHED
+(	O
+NNRTIs	O
+).	O
+
+To	O
+better	O
+respond	O
+to	O
+a	O
+virus	B-SPEC
+outbreak	O
+,	O
+government	O
+agencies	O
+need	O
+to	O
+improve	O
+hierarchical	O
+communication	O
+among	O
+different	O
+levels	O
+of	O
+governments	O
+,	O
+horizontal	O
+communication	O
+and	O
+cooperation	O
+between	O
+same	O
+types	O
+or	O
+different	O
+types	O
+of	O
+agencies	O
+,	O
+and	O
+information	O
+systems	O
+.	O
+
+TITLE	O
+:	O
+Comparison	O
+of	O
+patients	O
+with	O
+avian	B-DISO
+influenza	B-PATH
+A	I-PATH
+(	O
+H7N9	O
+)	O
+and	O
+influenza	B-PATH
+A	I-PATH
+(	O
+H1N1	O
+)	O
+complicated	O
+by	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+.	O
+
+Although	O
+the	O
+virus	B-SPEC
+inhibits	O
+autophagic	O
+degradation	O
+,	O
+SNAP29	B-PRGE
+promotes	O
+virus	B-PROC
+replication	I-PROC
+early	O
+in	O
+infection	B-DISO
+.	O
+
+TITLE	O
+:	O
+Nucleosides	B-CHED
+for	O
+the	O
+treatment	O
+of	O
+respiratory	O
+RNA	B-DISO
+virus	I-DISO
+infections	I-DISO
+.	O
+
+Recent	O
+advances	O
+in	O
+our	O
+understanding	O
+of	O
+the	O
+structure	O
+(	O
+s	O
+)	O
+and	O
+function	O
+(	O
+s	O
+)	O
+of	O
+respiratory	O
+virus	B-SPEC
+polymerases	O
+will	O
+likely	O
+support	O
+the	O
+discovery	O
+and	O
+development	B-PROC
+of	O
+novel	O
+nucleoside	B-CHED
+analogs	O
+.	O
+
+In	O
+the	O
+second	O
+part	O
+of	O
+the	O
+conference	O
+,	O
+which	O
+took	O
+place	O
+on	O
+October	O
+11	O
+and	O
+12	O
+,	O
+the	O
+clinical	O
+trials	O
+pipeline	O
+,	O
+design	O
+and	O
+recruitment	B-DISO
+of	O
+volunteers	O
+,	O
+and	O
+economic	O
+impact	O
+of	O
+clinical	O
+trials	O
+were	O
+discussed	O
+.	O
+
+The	O
+process	O
+of	O
+preclinical	O
+drug	O
+discovery	O
+from	O
+small	O
+molecules	O
+,	O
+cellular	B-COMP
+and	O
+immunologic	O
+therapies	O
+,	O
+and	O
+approaches	O
+to	O
+identifying	O
+new	O
+targets	O
+were	O
+also	O
+presented	O
+.	O
+
+Common	O
+pathophysiological	O
+abnormalities	O
+and	O
+similar	O
+clinical	O
+needs	O
+suggest	O
+translating	O
+to	O
+AE	O
+-	O
+IPF	O
+the	O
+lessons	O
+learned	B-PROC
+from	O
+the	O
+management	O
+of	O
+ARDS	B-DISO
+patients	O
+.	O
+
+TITLE	O
+:	O
+Splenic	B-ANAT
+Rupture	O
+as	O
+the	O
+First	O
+Manifestation	O
+of	O
+Babesia	B-SPEC
+Microti	I-SPEC
+Infection	B-DISO
+:	O
+Report	O
+of	O
+a	O
+Case	O
+and	O
+Review	O
+of	O
+Literature	O
+.	O
+
+CONCLUSIONS	O
+Despite	O
+its	O
+rare	O
+occurrence	O
+,	O
+SR	O
+due	O
+to	O
+B	B-SPEC
+.	I-SPEC
+microti	I-SPEC
+infection	B-DISO
+is	O
+a	O
+dreaded	O
+complication	B-DISO
+that	O
+can	O
+rapidly	O
+progress	O
+to	O
+hemorrhagic	B-DISO
+shock	I-DISO
+and	O
+death	B-PROC
+.	O
+
+Here	O
+we	O
+isolated	O
+a	O
+strain	O
+of	O
+PDCoV	O
+,	O
+named	O
+CHN	B-DISO
+-	O
+GD	O
+-	O
+2016	O
+,	O
+from	O
+the	O
+intestinal	B-ANAT
+content	I-ANAT
+of	O
+a	O
+diseased	O
+newborn	O
+piglet	O
+with	O
+severe	B-DISO
+diarrhea	I-DISO
+in	O
+a	O
+pig	B-SPEC
+farm	O
+in	O
+Guangdong	O
+,	O
+China	O
+.	O
+
+PDCoV	O
+CHN	B-DISO
+-	O
+GD	O
+-	O
+2016	O
+could	O
+be	O
+identified	O
+by	O
+immunofluorescence	O
+with	O
+PDCoV	O
+specific	O
+rabbit	B-SPEC
+antisera	O
+,	O
+and	O
+typical	O
+crown	B-COMP
+-	O
+shaped	O
+particles	O
+with	O
+spiky	O
+surface	O
+projections	O
+of	O
+this	O
+PDCoV	O
+were	O
+observed	O
+with	O
+electron	O
+microscopy	O
+.	O
+
+Intensivists	O
+should	O
+be	O
+aware	O
+of	O
+this	O
+rare	O
+but	O
+rapid	O
+complication	B-DISO
+on	O
+extracorporeal	O
+membrane	B-COMP
+oxygenation	B-PROC
+support	O
+that	O
+may	O
+directly	O
+impact	O
+outcome	O
+.	O
+
+Brazil	O
+is	O
+one	O
+of	O
+the	O
+biggest	O
+poultry	O
+producers	O
+in	O
+the	O
+world	O
+and	O
+the	O
+present	O
+study	O
+aimed	O
+to	O
+review	O
+the	O
+molecular	O
+diversity	O
+and	O
+reconstruct	O
+the	O
+evolutionary	O
+history	O
+of	O
+IBV	B-SPEC
+in	O
+the	O
+country	O
+.	O
+
+Despite	O
+the	O
+national	O
+vaccination	O
+protocols	O
+,	O
+our	O
+results	O
+show	O
+the	O
+widespread	O
+dissemination	O
+and	O
+maintenance	O
+of	O
+the	O
+IBV	B-SPEC
+GI	O
+-	O
+11	O
+lineage	O
+in	O
+Brazil	O
+and	O
+highlight	O
+the	O
+importance	O
+of	O
+continuous	O
+surveillance	O
+to	O
+evaluate	O
+the	O
+impact	O
+of	O
+currently	O
+used	O
+vaccine	O
+strains	O
+on	O
+the	O
+observed	O
+viral	O
+diversity	O
+of	O
+the	O
+country	O
+.	O
+
+TITLE	O
+:	O
+Extracorporeal	O
+life	O
+support	O
+for	O
+immune	B-DISO
+reconstitution	I-DISO
+inflammatory	I-DISO
+syndrome	I-DISO
+in	O
+HIV	B-DISO
+patients	O
+with	O
+Pneumocystis	O
+jirovecii	O
+pneumonia	B-DISO
+.	O
+
+The	O
+aim	O
+of	O
+this	O
+study	O
+was	O
+to	O
+evaluate	O
+postoperative	O
+complications	O
+in	O
+patients	O
+having	O
+major	O
+elective	O
+surgery	O
+using	O
+oesophageal	O
+Doppler	O
+monitor	O
+-	O
+guided	O
+goal	O
+-	O
+directed	O
+haemodynamic	O
+therapy	O
+(	O
+GDHT	O
+),	O
+in	O
+which	O
+administration	O
+of	O
+fluids	B-ANAT
+,	O
+inotropes	O
+,	O
+and	O
+vasopressors	O
+was	O
+guided	O
+by	O
+stroke	B-DISO
+volume	O
+,	O
+mean	O
+arterial	B-PROC
+pressure	I-PROC
+,	O
+and	O
+cardiac	B-ANAT
+index	O
+.	O
+
+In	O
+particular	O
+,	O
+current	O
+PED	O
+vaccination	O
+protocol	O
+(	O
+vaccination	O
+at	O
+2	O
+and	O
+4	O
+weeks	O
+before	O
+farrowing	B-PROC
+)	O
+may	O
+cause	O
+stress	O
+in	O
+pregnant	O
+sows	O
+.	O
+
+In	O
+this	O
+study	O
+,	O
+we	O
+compared	O
+the	O
+effects	O
+of	O
+PED	O
+vaccination	O
+timing	O
+and	O
+frequency	O
+for	O
+its	O
+efficacy	O
+by	O
+measuring	O
+the	O
+PED	O
+virus	B-SPEC
+-	O
+specific	O
+antibodies	B-COMP
+.	O
+
+As	O
+the	O
+number	O
+of	O
+vaccinations	O
+increased	O
+,	O
+the	O
+amounts	O
+of	O
+antibody	B-COMP
+in	O
+serum	B-COMP
+and	O
+colostrum	B-ANAT
+,	O
+and	O
+neutralizing	O
+activities	O
+increased	O
+.	O
+
+TITLE	O
+:	O
+DYSFUNCTION	O
+OF	O
+VARIOUS	O
+ORGAN	B-ANAT
+SYSTEMS	I-ANAT
+INDUCED	O
+BY	O
+SEPSIS	B-DISO
+WITH	O
+UNDERLYING	O
+SEVERE	O
+MYELOMIC	O
+DISEASES	O
+AND	O
+PROSTATE	O
+CANCER	B-SPEC
+(	O
+CASE	O
+REPORT	O
+).	O
+
+It	O
+is	O
+also	O
+noteworthy	O
+that	O
+for	O
+the	O
+last	O
+three	O
+months	O
+dysfunction	O
+of	O
+musculoskeletal	B-ANAT
+system	I-ANAT
+with	O
+muscle	B-DISO
+weakness	I-DISO
+,	O
+restricted	O
+motion	O
+has	O
+been	O
+present	O
+.	O
+
+Clinically	O
+there	O
+was	O
+present	O
+dysfunction	O
+syndrome	B-DISO
+of	O
+several	O
+organs	O
+:	O
+disorder	O
+of	O
+function	O
+of	O
+several	O
+organs	B-ANAT
+that	O
+required	O
+emergency	B-DISO
+intervention	O
+,	O
+recovery	O
+chance	O
+was	O
+very	O
+low	O
+,	O
+correlation	O
+with	O
+morbidity	O
+in	O
+PIRO	O
+was	O
+high	O
+.	O
+
+The	O
+condition	B-DISO
+is	O
+stable	O
+.	O
+
+Initial	O
+virome	O
+composition	O
+was	O
+determined	O
+by	O
+viral	O
+metagenomic	O
+sequencing	O
+by	O
+pooling	O
+samples	O
+and	O
+enriching	O
+for	O
+viral	B-COMP
+particles	I-COMP
+.	O
+
+The	O
+smaller	O
+size	O
+of	O
+the	O
+medulla	B-ANAT
+in	O
+the	O
+coronavirus	B-SPEC
+-	O
+infected	O
+birds	B-SPEC
+may	O
+lead	O
+to	O
+a	O
+lower	O
+number	O
+of	O
+B	B-ANAT
+lymphocytes	I-ANAT
+and	O
+bursal	O
+secretory	B-PROC
+dendritic	B-ANAT
+cells	B-COMP
+,	O
+which	O
+negatively	O
+affects	O
+the	O
+reactivity	O
+and	O
+efficacy	O
+of	O
+the	O
+immune	B-ANAT
+system	I-ANAT
+.	O
+
+Positive	O
+pressure	O
+mechanical	O
+ventilation	O
+induced	O
+pressure	O
+-	O
+dependent	O
+massive	O
+air	B-CHED
+leak	O
+from	O
+disrupted	O
+pulmonary	B-ANAT
+tissue	B-ANAT
+.	O
+
+TITLE	O
+:	O
+Regulation	B-PROC
+of	O
+alveolar	B-ANAT
+macrophage	I-ANAT
+death	B-PROC
+in	O
+acute	O
+lung	B-DISO
+inflammation	I-DISO
+.	O
+
+Pharmacological	O
+manipulation	O
+of	O
+AM	O
+death	B-PROC
+signals	O
+may	O
+serve	O
+as	O
+a	O
+logical	O
+therapeutic	O
+strategy	O
+for	O
+ALI	O
+/	O
+ARDS	B-DISO
+.	O
+
+There	O
+is	O
+a	O
+large	O
+population	O
+of	O
+nonimmunized	O
+dogs	B-SPEC
+and	O
+few	O
+studies	O
+about	O
+the	O
+identification	O
+of	O
+the	O
+viruses	B-SPEC
+associated	O
+with	O
+diarrhea	B-DISO
+.	O
+
+The	O
+aim	O
+of	O
+the	O
+present	O
+study	O
+was	O
+to	O
+evaluate	O
+the	O
+predictive	O
+value	O
+of	O
+NRBCs	O
+in	O
+patients	O
+with	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+(	O
+ARDS	B-DISO
+).	O
+
+Logistic	O
+regression	O
+analysis	O
+with	O
+mortality	O
+as	O
+response	O
+showed	O
+NRBC	O
+positivity	O
+per	O
+se	O
+to	O
+be	O
+an	O
+independent	O
+risk	O
+factor	O
+for	O
+mortality	O
+in	O
+ARDS	B-DISO
+with	O
+a	O
+doubled	O
+risk	O
+for	O
+ICU	O
+death	B-PROC
+(	O
+OR	O
+2	O
+.	O
+03	O
+;	O
+95	O
+%	O
+CI	O
+1	O
+.	O
+16	O
+-	O
+3	O
+.	O
+55	O
+;	O
+p	O
+<	O
+0	O
+.	O
+05	O
+).	O
+
+An	O
+acute	O
+exacerbation	O
+(	O
+AE	O
+)	O
+of	O
+pre	O
+-	O
+existing	O
+IP	O
+triggered	O
+by	O
+an	O
+infection	B-DISO
+was	O
+suspected	O
+,	O
+and	O
+the	O
+treatment	O
+with	O
+antibiotics	B-CHED
+and	O
+corticosteroid	B-CHED
+pulse	B-PROC
+therapy	O
+improved	O
+her	O
+general	O
+condition	B-DISO
+and	O
+chest	B-ANAT
+radiological	O
+findings	O
+.	O
+
+The	O
+careful	O
+consideration	O
+is	O
+necessary	O
+to	O
+precisely	O
+diagnose	O
+and	O
+treat	O
+the	O
+patients	O
+with	O
+RA	O
+-	O
+associated	O
+interstitial	B-DISO
+lung	B-ANAT
+diseases	I-DISO
+as	O
+the	O
+several	O
+etiologies	O
+may	O
+be	O
+overlapped	O
+in	O
+the	O
+same	O
+patient	O
+.	O
+
+Furthermore	O
+,	O
+assessment	O
+of	O
+the	O
+risk	O
+factors	O
+for	O
+depression	B-DISO
+may	O
+identify	O
+vulnerable	O
+patients	O
+who	O
+require	O
+psychiatric	O
+care	O
+and	O
+attention	O
+during	O
+hospital	O
+quarantine	O
+.	O
+
+Lipo	B-DISO
+-	O
+prostaglandin	B-CHED
+E	O
+For	O
+these	O
+five	O
+patients	O
+(	O
+ten	O
+hips	B-ANAT
+),	O
+Harris	O
+score	O
+was	O
+100	O
+from	O
+the	O
+diagnosis	O
+to	O
+final	O
+follow	O
+-	O
+up	O
+time	O
+.	O
+
+The	O
+aim	O
+of	O
+this	O
+review	O
+was	O
+to	O
+discuss	O
+the	O
+current	O
+challenge	O
+for	O
+the	O
+diagnosis	O
+and	O
+treatment	O
+of	O
+ARDS	B-DISO
+.	O
+
+The	O
+incidence	O
+of	O
+ARDS	B-DISO
+is	O
+still	O
+high	O
+,	O
+and	O
+ARDS	B-DISO
+causes	O
+high	O
+intensive	O
+care	O
+units	O
+admissions	O
+and	O
+high	O
+mortality	O
+.	O
+
+Most	O
+animal	B-SPEC
+models	O
+of	O
+ALI	O
+are	O
+limited	O
+by	O
+the	O
+fact	O
+that	O
+they	O
+focus	O
+on	O
+a	O
+singular	B-CHED
+cause	O
+of	O
+acute	B-PRGE
+lung	I-PRGE
+injury	I-PRGE
+(	O
+ALI	O
+)	O
+and	O
+therefore	O
+fail	O
+to	O
+mimic	O
+the	O
+complex	O
+,	O
+multifactorial	O
+pathobiology	O
+of	O
+ARDS	B-DISO
+.	O
+
+We	O
+hypothesized	O
+,	O
+that	O
+mice	B-SPEC
+pretreated	O
+with	O
+LPS	B-DISO
+or	O
+HCl	B-CHED
+prior	O
+to	O
+VILI	O
+and	O
+thus	O
+receiving	O
+a	O
+"("""	O
+two	O
+-	O
+hit	O
+injury	O
+""")"	O
+will	O
+sustain	O
+a	O
+superadditive	O
+lung	B-ANAT
+injury	O
+when	O
+compared	O
+to	O
+VILI	O
+.	O
+
+Mice	B-SPEC
+were	O
+allocated	O
+to	O
+following	O
+treatment	O
+groups	O
+:	O
+control	O
+with	O
+i	O
+.	O
+t	O
+.	O
+
+LPS	B-DISO
+,	O
+VILI	O
+(	O
+high	O
+PIP	B-CHED
+),	O
+HCl	B-CHED
+i	O
+.	O
+t	O
+.	O
+
+followed	O
+by	O
+VILI	O
+and	O
+LPS	B-PRGE
+i	I-PRGE
+.	I-PRGE
+t	I-PRGE
+.	O
+
+However	O
+,	O
+mice	B-SPEC
+that	O
+received	O
+i	O
+.	O
+t	O
+.	O
+
+LPS	B-DISO
+prior	O
+to	O
+VILI	O
+showed	O
+significantly	O
+increased	O
+inflammatory	O
+lung	B-ANAT
+injury	O
+compared	O
+to	O
+animals	B-SPEC
+that	O
+underwent	O
+i	O
+.	O
+t	O
+.	O
+
+(	O
+Family	B-SPEC
+:	O
+Saururaceae	B-SPEC
+)	O
+is	O
+an	O
+herbaceous	O
+perennial	O
+plant	B-SPEC
+that	O
+grows	O
+in	O
+moist	O
+and	O
+shady	O
+places	O
+.	O
+
+The	O
+last	O
+2	O
+decades	O
+have	O
+witnessed	O
+the	O
+introduction	O
+and	O
+evolution	B-PROC
+of	O
+the	O
+TPTD	O
+technique	O
+for	O
+measuring	O
+EVLW	O
+and	O
+PVPI	O
+.	O
+
+ABSTRACT	O
+:	O
+Objective	O
+Delirium	B-DISO
+in	O
+critically	B-DISO
+ill	I-DISO
+patients	O
+is	O
+considered	O
+a	O
+risk	O
+factor	O
+for	O
+various	O
+long	O
+-	O
+term	O
+consequences	O
+.	O
+
+The	O
+haloperidol	B-CHED
+and	O
+opioid	O
+doses	O
+were	O
+associated	O
+with	O
+a	O
+longer	O
+delirium	B-DISO
+duration	O
+.	O
+
+TITLE	O
+:	O
+Severe	O
+Plasmodium	B-DISO
+ovale	I-DISO
+malaria	B-PATH
+complicated	O
+by	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+in	O
+a	O
+young	O
+Caucasian	O
+man	O
+.	O
+
+ABSTRACT	O
+:	O
+Although	O
+Plasmodium	B-SPEC
+ovale	I-SPEC
+is	O
+considered	O
+the	O
+cause	O
+of	O
+only	O
+mild	O
+malaria	B-PATH
+,	O
+a	O
+case	O
+of	O
+severe	O
+malaria	B-PATH
+due	O
+to	O
+P	B-SPEC
+.	I-SPEC
+ovale	I-SPEC
+with	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+is	O
+reported	O
+.	O
+
+A	O
+37	O
+-	O
+year	O
+old	O
+Caucasian	O
+man	B-CHED
+returning	O
+home	O
+from	O
+Angola	O
+was	O
+admitted	O
+for	O
+ovale	B-DISO
+malaria	I-DISO
+to	O
+the	O
+National	O
+Institute	O
+for	O
+Infectious	B-DISO
+Diseases	I-DISO
+Lazzaro	O
+Spallanzani	O
+in	O
+Rome	O
+,	O
+Italy	O
+.	O
+
+The	O
+fourth	O
+CoV	O
+genus	B-SPEC
+,	O
+
+Over	O
+30	O
+genes	O
+were	O
+downregulated	O
+in	O
+the	O
+presence	O
+of	O
+one	O
+of	O
+the	O
+HCoV	B-SPEC
+-	I-SPEC
+OC43	I-SPEC
+proteins	B-CHED
+,	O
+e	O
+.	O
+g	O
+.	O
+genes	O
+representing	O
+mitogen	B-PRGE
+-	I-PRGE
+activated	I-PRGE
+protein	B-CHED
+kinases	I-PRGE
+,	I-PRGE
+toll	I-PRGE
+-	I-PRGE
+like	I-PRGE
+receptors	I-PRGE
+,	O
+interferons	O
+,	O
+interleukins	O
+,	O
+and	O
+signaling	B-PROC
+transduction	B-PROC
+proteins	B-CHED
+.	O
+
+TITLE	O
+:	O
+Isolation	O
+and	O
+Characteristics	O
+of	O
+the	O
+Arkansas	O
+-	O
+Type	O
+Infectious	B-DISO
+Bronchitis	B-DISO
+Virus	B-SPEC
+in	O
+China	O
+.	O
+
+Although	O
+Ark	B-PRGE
+-	O
+type	O
+viruses	B-SPEC
+are	O
+not	O
+widespread	O
+in	O
+China	O
+,	O
+surveillance	O
+and	O
+updating	O
+the	O
+currently	O
+applied	O
+vaccination	O
+strategy	O
+for	O
+sound	O
+protection	O
+against	O
+IBV	B-SPEC
+disease	O
+are	O
+important	O
+because	O
+this	O
+type	O
+of	O
+virus	B-SPEC
+has	O
+caused	O
+heavy	O
+economic	O
+losses	O
+in	O
+the	O
+United	O
+States	O
+.	O
+
+In	O
+2015	O
+,	O
+an	O
+IBV	B-SPEC
+with	O
+the	O
+TC07	O
+-	O
+2	O
+genotype	O
+(	O
+designated	O
+KrD1515	O
+)	O
+was	O
+isolated	O
+from	O
+layer	B-ANAT
+chickens	B-SPEC
+with	O
+severe	O
+respiratory	B-DISO
+symptoms	I-DISO
+in	O
+Korea	O
+.	O
+
+S1	B-PRGE
+gene	I-PRGE
+phylogenetic	O
+analysis	O
+revealed	O
+that	O
+the	O
+KrD1515	O
+virus	B-SPEC
+clustered	O
+with	O
+viruses	B-SPEC
+with	O
+the	O
+TC07	O
+-	O
+2	O
+genotype	O
+,	O
+whereas	O
+N	B-PRGE
+gene	I-PRGE
+phylogenetic	O
+analysis	O
+revealed	O
+that	O
+the	O
+KrD1515	O
+virus	B-SPEC
+clustered	O
+with	O
+Korean	O
+IBVs	O
+,	O
+but	O
+not	O
+with	O
+Chinese	O
+TC07	O
+-	O
+2	O
+IBV	B-SPEC
+.	O
+
+Our	O
+findings	O
+suggest	O
+that	O
+the	O
+KrD1515	O
+virus	B-SPEC
+is	O
+a	O
+recombinant	O
+virus	B-SPEC
+between	O
+a	O
+Chinese	O
+TC07	O
+-	O
+2	O
+IBV	B-SPEC
+and	O
+a	O
+non	O
+-	O
+TC07	O
+-	O
+2	O
+Korean	O
+IBV	B-SPEC
+and	O
+engages	O
+in	O
+respiratory	O
+tropism	B-PROC
+in	O
+chickens	B-SPEC
+.	O
+
+Determination	O
+of	O
+the	O
+complete	O
+genome	O
+sequence	O
+of	O
+additional	O
+IBV	O
+isolates	O
+from	O
+India	O
+is	O
+necessary	O
+to	O
+understand	O
+the	O
+epidemiology	O
+of	O
+IBV	B-SPEC
+in	O
+India	O
+.	O
+
+To	O
+investigate	O
+the	O
+pathogenicity	O
+of	O
+a	O
+representative	O
+Japanese	O
+PDCoV	O
+,	O
+we	O
+performed	O
+an	O
+experimental	O
+infection	B-DISO
+using	O
+hysterectomy	O
+-	O
+produced	O
+colostrum	B-ANAT
+-	O
+deprived	O
+piglets	O
+.	O
+
+TITLE	O
+:	O
+The	O
+role	O
+of	O
+extracorporeal	O
+membrane	B-COMP
+oxygenation	B-PROC
+in	O
+severe	O
+pulmonary	B-DISO
+coccidioidomycosis	I-DISO
+.	O
+
+To	O
+review	O
+indications	O
+and	O
+outcome	O
+of	O
+ECMO	O
+in	O
+severe	O
+pulmonary	B-DISO
+coccidioidomycosis	I-DISO
+.	O
+
+TITLE	O
+:	O
+Administration	O
+of	O
+mesenchymal	B-ANAT
+stem	I-ANAT
+cells	I-ANAT
+during	O
+ECMO	O
+results	O
+in	O
+a	O
+rapid	O
+decline	O
+in	O
+oxygenator	O
+performance	O
+.	O
+
+At	O
+the	O
+same	O
+time	O
+,	O
+the	O
+use	O
+of	O
+extracorporeal	O
+membrane	B-COMP
+oxygenation	B-PROC
+(	O
+ECMO	O
+)	O
+has	O
+increased	O
+among	O
+patients	O
+with	O
+severe	O
+ARDS	B-DISO
+.	O
+
+ABSTRACT	O
+:	O
+Infection	O
+with	O
+Middle	O
+East	O
+respiratory	O
+syndrome	B-DISO
+coronavirus	B-SPEC
+(	O
+MERS	O
+-	O
+CoV	O
+)	O
+emerged	O
+in	O
+2012	O
+as	O
+an	O
+important	O
+respiratory	B-DISO
+disease	I-DISO
+with	O
+high	O
+fatality	O
+rates	O
+of	O
+40	O
+%-	O
+60	O
+%.	O
+
+The	O
+purified	O
+recombinant	B-PRGE
+N	I-PRGE
+protein	I-PRGE
+conjugated	O
+with	O
+colloidal	B-CHED
+gold	I-CHED
+was	O
+dispensed	O
+on	O
+a	O
+conjugate	O
+pad	B-DISO
+as	O
+the	O
+detector	O
+.	O
+
+Our	O
+newly	O
+developed	O
+strip	O
+has	O
+great	O
+potential	O
+for	O
+the	O
+early	O
+diagnosis	O
+of	O
+PEDV	B-SPEC
+infection	B-DISO
+.	O
+
+ABSTRACT	O
+:	O
+Infectious	O
+diseases	O
+caused	O
+by	O
+enveloped	O
+viruses	B-SPEC
+,	O
+such	O
+as	O
+influenza	B-DISO
+,	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+(	O
+SARS	B-DISO
+),	O
+and	O
+Middle	O
+East	O
+respiratory	O
+syndrome	B-DISO
+(	O
+MERS	O
+),	O
+cause	O
+thousands	O
+of	O
+deaths	B-PROC
+and	O
+billions	O
+of	O
+dollars	O
+of	O
+economic	O
+losses	O
+per	O
+year	O
+.	O
+
+Our	O
+results	O
+show	O
+that	O
+Phi6	O
+survived	O
+best	O
+at	O
+high	O
+(>	O
+85	O
+%)	O
+and	O
+low	O
+(<	O
+60	O
+%)	O
+RHs	B-DISO
+,	O
+with	O
+a	O
+significant	O
+decrease	O
+in	O
+infectivity	O
+at	O
+mid	O
+-	O
+range	O
+RHs	O
+(∼	O
+60	O
+to	O
+85	O
+%).	O
+
+TITLE	O
+:	O
+Viral	O
+and	O
+bacterial	O
+investigations	O
+on	O
+the	O
+aetiology	O
+of	O
+recurrent	O
+pig	B-SPEC
+neonatal	B-DISO
+diarrhoea	I-DISO
+cases	O
+in	O
+Spain	O
+.	O
+
+TITLE	O
+:	O
+[	O
+Organ	B-ANAT
+assist	O
+devices	O
+in	O
+the	O
+future	O
+:	O
+Limits	O
+and	O
+perspectives	O
+].	O
+
+PVP	B-CHED
+-	O
+I	O
+7	O
+%	O
+gargle	O
+/	O
+mouthwash	O
+showed	O
+rapid	O
+bactericidal	B-PROC
+activity	I-PROC
+and	O
+virucidal	O
+efficacy	O
+in	O
+vitro	O
+at	O
+a	O
+concentration	O
+of	O
+0	O
+.	O
+23	O
+%	O
+PVP	B-CHED
+-	O
+I	O
+and	O
+may	O
+provide	O
+a	O
+protective	O
+oropharyngeal	B-ANAT
+hygiene	O
+measure	O
+for	O
+individuals	O
+at	O
+high	O
+risk	O
+of	O
+exposure	O
+to	O
+oral	B-ANAT
+and	O
+respiratory	O
+pathogens	O
+.	O
+
+TITLE	O
+:	O
+Successful	O
+Use	O
+of	O
+Veno	O
+-	O
+Venous	B-ANAT
+Extracorporeal	O
+Membrane	B-COMP
+Oxygenation	B-PROC
+in	O
+an	O
+Adult	O
+Patient	O
+with	O
+Sickle	B-ANAT
+Cell	I-ANAT
+Anemia	B-SPEC
+and	O
+Severe	O
+Acute	B-DISO
+Chest	I-DISO
+Syndrome	I-DISO
+.	O
+
+ABSTRACT	O
+:	O
+Extracorporeal	O
+membrane	B-COMP
+oxygenation	B-PROC
+has	O
+emerged	O
+as	O
+a	O
+treatment	O
+of	O
+choice	O
+for	O
+refractory	O
+hypoxemia	O
+in	O
+the	O
+intensive	O
+care	O
+unit	O
+.	O
+
+Severe	O
+hypoxemia	O
+unresponsive	O
+to	O
+conventional	O
+lung	B-ANAT
+-	O
+protective	O
+mechanical	O
+ventilation	O
+could	O
+also	O
+occur	O
+in	O
+the	O
+operating	O
+room	O
+from	O
+severe	O
+bronchospasm	B-DISO
+,	O
+pulmonary	B-ANAT
+contusions	O
+,	O
+or	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+.	O
+
+ABSTRACT	O
+:	O
+Adjuvant	B-CHED
+enhancing	O
+mucosal	B-PROC
+immune	I-PROC
+response	I-PROC
+is	O
+preferred	O
+in	O
+controlling	O
+many	O
+pathogens	O
+at	O
+the	O
+portal	B-ANAT
+of	O
+entry	O
+.	O
+
+TITLE	O
+:	O
+Case	O
+Report	O
+of	O
+Extracorporeal	O
+Membrane	B-COMP
+Oxygenation	B-PROC
+and	O
+Aeromedical	O
+Evacuation	O
+at	O
+a	O
+Deployed	O
+Military	O
+Hospital	O
+.	O
+
+Surfactant	B-CHED
+was	O
+also	O
+impaired	B-DISO
+in	O
+ARDS	B-DISO
+mice	B-SPEC
+where	O
+the	O
+cholesterol	B-CHED
+to	O
+phospholipid	B-CHED
+ratio	O
+(	O
+W	O
+/	O
+W	O
+%)	O
+was	O
+increased	O
+.	O
+
+Therefore	O
+,	O
+we	O
+measured	O
+the	O
+plasma	B-ANAT
+lipidome	O
+of	O
+individuals	O
+with	O
+ARDS	B-DISO
+at	O
+two	O
+time	O
+-	O
+points	O
+to	O
+determine	O
+if	O
+changes	O
+in	O
+the	O
+plasma	B-ANAT
+lipidome	O
+distinguished	O
+survivors	O
+from	O
+non	O
+-	O
+survivors	O
+.	O
+
+We	O
+hypothesized	O
+that	O
+both	O
+the	O
+absolute	O
+concentration	O
+and	O
+change	O
+in	O
+concentration	O
+over	O
+time	O
+of	O
+plasma	B-ANAT
+lipids	B-CHED
+are	O
+associated	O
+with	O
+28	O
+-	O
+day	O
+mortality	O
+in	O
+this	O
+population	O
+.	O
+
+RESULTS	O
+:	O
+The	O
+mass	O
+spectrometry	O
+assay	O
+reliably	O
+measured	O
+359	O
+lipids	B-CHED
+.	O
+
+Although	O
+outstanding	O
+efforts	O
+have	O
+led	O
+to	O
+the	O
+identification	O
+of	O
+Alphacoronavirus	B-SPEC
+and	O
+Betacoronavirus	B-SPEC
+receptors	O
+,	O
+the	O
+receptor	O
+for	O
+Deltacoronavirus	O
+is	O
+unclear	O
+.	O
+
+Ectopic	B-PROC
+expression	I-PROC
+of	O
+pAPN	O
+in	O
+non	O
+-	O
+susceptible	O
+BHK	O
+-	O
+21	O
+cells	B-COMP
+rendered	O
+them	O
+susceptible	O
+to	O
+PDCoV	O
+.	O
+These	O
+results	O
+indicate	O
+that	O
+pAPN	O
+may	O
+be	O
+a	O
+functional	O
+receptor	O
+for	O
+PDCoV	O
+infection	B-DISO
+.	O
+
+Homologous	O
+modeling	O
+of	O
+pAPN	O
+with	O
+the	O
+S1	B-PRGE
+C	I-PRGE
+-	I-PRGE
+terminal	I-PRGE
+domain	I-PRGE
+(	O
+S1	B-PRGE
+-	I-PRGE
+CTD	I-PRGE
+)	O
+of	O
+PDCoV	O
+or	O
+TGEV	B-SPEC
+showed	O
+that	O
+TGEV	B-PRGE
+S1	I-PRGE
+-	I-PRGE
+CTD	I-PRGE
+adopted	O
+β	O
+-	O
+turns	O
+(	O
+β1	O
+-	O
+β2	O
+and	O
+β3	O
+-	O
+β4	O
+),	O
+forming	O
+the	O
+tip	O
+of	O
+a	O
+β	O
+-	O
+barrel	O
+,	O
+to	O
+recognize	O
+pAPN	O
+.	O
+
+We	O
+also	O
+discuss	O
+the	O
+evolution	B-PROC
+and	O
+variation	O
+of	O
+PDCoV	B-PRGE
+S1	I-PRGE
+-	I-PRGE
+CTD	I-PRGE
+based	O
+on	O
+structure	O
+information	O
+,	O
+providing	O
+clues	O
+to	O
+explain	O
+the	O
+usage	O
+of	O
+pAPN	O
+by	O
+PDCoV	O
+.	O
+Taken	O
+together	O
+,	O
+the	O
+results	O
+presented	O
+herein	O
+reveal	O
+that	O
+pAPN	O
+is	O
+likely	O
+not	O
+a	O
+critical	O
+functional	O
+receptor	O
+for	O
+PDCoV	O
+,	O
+although	O
+it	O
+is	O
+involved	O
+in	O
+PDCoV	O
+infection	B-DISO
+.	O
+
+In	O
+some	O
+regions	O
+of	O
+Cameroon	O
+,	O
+bats	B-SPEC
+are	O
+hunted	O
+and	O
+eaten	O
+as	O
+a	O
+delicacy	O
+.	O
+
+Culture	O
+supernatants	O
+from	O
+macrophages	B-ANAT
+polarized	O
+in	O
+vitro	O
+with	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+-	O
+bronchoalveolar	B-ANAT
+lavage	I-ANAT
+fluid	I-ANAT
+or	O
+interleukin	B-PRGE
+-	I-PRGE
+10	I-PRGE
+and	O
+ex	O
+vivo	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+alveolar	B-ANAT
+macrophages	I-ANAT
+specifically	O
+promoted	O
+lung	B-ANAT
+epithelial	O
+repair	B-PROC
+.	O
+
+ABSTRACT	O
+:	O
+A	O
+series	O
+of	O
+tripeptidic	O
+acylsulfonamide	O
+inhibitors	B-CHED
+of	O
+HCV	B-PRGE
+NS3	B-DISO
+protease	I-PRGE
+were	O
+prepared	O
+that	O
+explored	O
+structure	O
+-	O
+activity	O
+relationships	O
+(	O
+SARs	B-DISO
+)	O
+at	O
+the	O
+P4	O
+position	O
+,	O
+and	O
+their	O
+in	O
+vitro	O
+and	O
+in	O
+vivo	O
+properties	O
+were	O
+evaluated	O
+.	O
+
+Enhanced	O
+potency	O
+was	O
+observed	O
+in	O
+a	O
+series	O
+of	O
+P4	O
+ureas	B-CHED
+;	O
+however	O
+,	O
+the	O
+PK	O
+profiles	O
+of	O
+these	O
+analogues	O
+were	O
+less	O
+than	O
+optimal	O
+.	O
+
+This	O
+included	O
+a	O
+strategy	O
+in	O
+which	O
+one	O
+of	O
+the	O
+two	O
+urea	B-CHED
+N	O
+-	O
+H	O
+groups	O
+was	O
+either	O
+N	O
+-	O
+methylated	O
+or	O
+replaced	O
+with	O
+an	O
+oxygen	B-CHED
+atom	I-CHED
+.	O
+
+It	O
+inhibits	O
+the	O
+replication	O
+of	O
+many	O
+viruses	B-SPEC
+and	O
+ultimately	O
+promotes	O
+apoptosis	B-PATH
+of	O
+infected	O
+cells	B-COMP
+,	O
+contributing	O
+to	O
+the	O
+control	O
+of	O
+virus	B-SPEC
+spread	O
+.	O
+
+Here	O
+we	O
+unraveled	O
+a	O
+novel	O
+escape	O
+strategy	O
+involving	O
+Theiler	O
+'	O
+s	O
+murine	B-DISO
+encephalomyelitis	I-DISO
+virus	B-SPEC
+(	O
+TMEV	O
+)	O
+L	O
+*	O
+protein	B-CHED
+.	O
+
+Using	O
+chimeric	O
+mouse	B-DISO
+hepatitis	I-DISO
+virus	B-SPEC
+(	O
+MHV	B-SPEC
+)	O
+expressing	O
+TMEV	O
+L	O
+*,	O
+we	O
+showed	O
+that	O
+L	O
+*	O
+efficiently	O
+inhibits	O
+RNase	O
+L	O
+in	O
+vivo	O
+.	O
+
+ABSTRACT	O
+:	O
+We	O
+evaluated	O
+the	O
+presence	O
+of	O
+coronaviruses	O
+by	O
+PCR	O
+in	O
+918	O
+Australian	O
+wild	O
+bird	B-SPEC
+samples	O
+collected	O
+during	O
+2016	O
+-	O
+17	O
+.	O
+
+Coronaviruses	O
+were	O
+detected	O
+in	O
+141	O
+samples	O
+(	O
+15	O
+.	O
+3	O
+%)	O
+from	O
+species	B-SPEC
+of	O
+ducks	B-SPEC
+,	O
+shorebirds	B-SPEC
+and	O
+herons	B-SPEC
+and	O
+from	O
+multiple	O
+sampling	O
+locations	O
+.	O
+
+Australian	O
+duck	B-SPEC
+and	O
+heron	O
+deltacoronaviruses	O
+belonged	O
+to	O
+lineages	O
+with	O
+other	O
+duck	O
+and	O
+heron	O
+deltacoronaviruses	O
+,	O
+but	O
+were	O
+almost	O
+20	O
+%	O
+different	O
+in	O
+nucleotide	B-CHED
+sequence	O
+to	O
+other	O
+deltacoronavirus	O
+sequences	O
+available	O
+.	O
+
+APOBEC3	B-PRGE
+-	O
+mediated	O
+restriction	O
+was	O
+partially	O
+dependent	O
+on	O
+enzyme	B-FUNC
+activity	I-FUNC
+,	O
+and	O
+was	O
+reduced	O
+by	O
+the	O
+use	O
+of	O
+enzymatically	O
+inactive	O
+APOBEC3	B-PRGE
+.	O
+
+TITLE	O
+:	O
+Development	B-PROC
+of	O
+a	O
+risk	O
+-	O
+prediction	O
+model	O
+for	O
+Middle	O
+East	O
+respiratory	O
+syndrome	B-DISO
+coronavirus	B-SPEC
+infection	I-DISO
+in	O
+dialysis	O
+patients	O
+.	O
+
+We	O
+attempted	O
+to	O
+develop	O
+a	O
+risk	O
+-	O
+prediction	O
+model	O
+to	O
+assess	O
+the	O
+early	O
+risk	O
+of	O
+MERS	O
+-	O
+CoV	O
+infection	B-DISO
+in	O
+dialysis	B-SPEC
+patients	O
+.	O
+
+TITLE	O
+:	O
+Asymptomatic	O
+Middle	O
+East	O
+Respiratory	O
+Syndrome	B-DISO
+coronavirus	B-DISO
+infection	I-DISO
+using	O
+a	O
+serologic	O
+survey	O
+in	O
+Korea	O
+.	O
+
+The	O
+asymptomatic	B-DISO
+infection	I-DISO
+rate	O
+was	O
+0	O
+.	O
+060	O
+%	O
+(	O
+95	O
+%	O
+confidence	O
+interval	O
+,	O
+0	O
+.	O
+002	O
+to	O
+0	O
+.	O
+346	O
+).	O
+
+The	O
+asymptomatic	B-DISO
+infection	I-DISO
+was	O
+acquired	O
+via	O
+healthcare	O
+-	O
+associated	O
+transmission	O
+.	O
+
+TITLE	O
+:	O
+Epidemiology	O
+of	O
+sepsis	B-DISO
+in	O
+intensive	O
+care	O
+units	O
+in	O
+Turkey	B-SPEC
+:	O
+a	O
+multicenter	O
+,	O
+point	O
+-	O
+prevalence	O
+study	O
+.	O
+
+ABSTRACT	O
+:	O
+The	O
+prevalence	O
+and	O
+mortality	O
+of	O
+sepsis	O
+are	O
+largely	O
+unknown	O
+in	O
+Turkey	B-SPEC
+,	O
+a	O
+country	O
+with	O
+high	O
+antibiotic	B-CHED
+resistance	B-PROC
+.	O
+
+infection	B-DISO
+,	O
+renal	B-ANAT
+replacement	O
+treatment	O
+,	O
+and	O
+a	O
+nurse	O
+-	O
+to	O
+-	O
+patient	O
+ratio	O
+of	O
+1	O
+:	O
+4	O
+(	O
+compared	O
+with	O
+a	O
+nurse	O
+-	O
+to	O
+-	O
+patient	O
+ratio	O
+of	O
+1	O
+:	O
+2	O
+)	O
+were	O
+independent	O
+predictors	O
+of	O
+mortality	O
+in	O
+infected	O
+patients	O
+.	O
+
+There	O
+is	O
+paucity	O
+of	O
+data	O
+on	O
+varicella	B-DISO
+pneumonia	I-DISO
+from	O
+India	O
+.	O
+
+The	O
+various	O
+factors	O
+associated	O
+with	O
+the	O
+need	O
+for	O
+mechanical	O
+ventilation	O
+were	O
+partial	B-PROC
+pressure	I-PROC
+of	I-PROC
+oxygen	I-PROC
+:	O
+fraction	O
+of	O
+inspired	B-PROC
+oxygen	B-CHED
+ratio	O
+<	O
+150	O
+,	O
+quick	O
+sequential	O
+(	O
+sepsis	B-DISO
+-	O
+related	O
+)	O
+organ	B-DISO
+failure	I-DISO
+assessment	O
+(	O
+qSOFA	O
+)	O
+>	O
+2	O
+,	O
+and	O
+early	O
+bacterial	O
+coinfection	B-DISO
+.	O
+
+30	O
+.	O
+4	O
+%	O
+(	O
+76	O
+/	O
+250	O
+)	O
+of	O
+specimens	O
+tested	O
+positive	O
+for	O
+any	O
+virus	B-SPEC
+tested	O
+,	O
+and	O
+4	O
+.	O
+8	O
+%	O
+(	O
+12	O
+/	O
+250	O
+)	O
+were	O
+positive	O
+for	O
+2	O
+or	O
+more	O
+viruses	B-SPEC
+.	O
+
+During	O
+a	O
+3	O
+-	O
+month	O
+period	O
+covering	O
+a	O
+single	O
+season	O
+,	O
+HCoVs	O
+were	O
+common	O
+,	O
+even	O
+among	O
+social	O
+contacts	O
+without	O
+respiratory	B-DISO
+symptoms	I-DISO
+;	O
+specific	O
+symptoms	O
+may	O
+change	O
+over	O
+the	O
+course	O
+of	O
+HCoV	O
+-	O
+associated	O
+illness	O
+and	O
+were	O
+similar	O
+to	O
+symptoms	O
+from	O
+influenza	B-DISO
+and	O
+rhinovirus	B-SPEC
+.	O
+
+Between	O
+May	O
+31	O
+and	O
+June	O
+15	O
+,	O
+2017	O
+,	O
+44	O
+cases	O
+of	O
+MERS	O
+-	O
+CoV	O
+infection	B-DISO
+were	O
+reported	O
+from	O
+3	O
+simultaneous	O
+clusters	B-CHED
+from	O
+3	O
+health	O
+care	O
+facilities	O
+in	O
+Riyadh	O
+,	O
+Saudi	O
+Arabia	O
+,	O
+including	O
+11	O
+fatal	O
+cases	O
+.	O
+
+Dromedary	B-SPEC
+camels	B-SPEC
+are	O
+considered	O
+as	O
+potential	O
+reservoirs	O
+for	O
+the	O
+virus	B-SPEC
+and	O
+seem	O
+to	O
+be	O
+the	O
+only	O
+animal	B-SPEC
+host	B-COMP
+which	O
+may	O
+transmit	O
+the	O
+infection	B-DISO
+to	O
+human	B-SPEC
+.	O
+
+One	O
+hundred	O
+seventy	O
+one	O
+(	O
+171	O
+)	O
+serum	B-COMP
+samples	O
+were	O
+collected	O
+from	O
+healthy	O
+dromedary	O
+camels	B-SPEC
+with	O
+different	O
+ages	O
+and	O
+genders	O
+in	O
+Tabuk	O
+city	O
+and	O
+tested	O
+for	O
+specific	O
+serum	B-COMP
+IgG	B-PRGE
+by	O
+ELISA	O
+using	O
+the	O
+receptor	B-PRGE
+-	I-PRGE
+binding	I-PRGE
+S1	I-PRGE
+subunits	I-PRGE
+of	I-PRGE
+spike	I-PRGE
+proteins	B-CHED
+of	O
+MERS	O
+-	O
+CoV	O
+.	O
+144	O
+(	O
+84	O
+,	O
+21	O
+%)	O
+of	O
+the	O
+total	O
+camel	B-SPEC
+sera	B-COMP
+shown	O
+the	O
+presence	O
+of	O
+protein	B-CHED
+-	O
+specific	O
+antibodies	B-COMP
+against	O
+MERS	O
+-	O
+CoV	O
+.	O
+These	O
+results	O
+may	O
+provide	O
+evidence	O
+that	O
+MERS	O
+-	O
+CoV	O
+has	O
+previously	O
+infected	O
+dromedary	B-SPEC
+camels	B-SPEC
+in	O
+Tabuk	O
+and	O
+may	O
+support	O
+the	O
+possible	O
+role	O
+of	O
+camels	B-SPEC
+in	O
+the	O
+human	B-SPEC
+infection	B-DISO
+.	O
+
+Twelve	O
+patients	O
+were	O
+in	O
+stage	O
+III	O
+kidney	B-DISO
+disease	I-DISO
+and	O
+needed	O
+haemodialysis	O
+.	O
+
+ABSTRACT	O
+:	O
+Middle	O
+East	O
+respiratory	O
+syndrome	B-DISO
+(	O
+MERS	B-DISO
+)	O
+is	O
+a	O
+respiratory	B-DISO
+disease	I-DISO
+caused	O
+by	O
+MERS	B-DISO
+coronavirus	B-SPEC
+.	O
+
+ABSTRACT	O
+:	O
+Dromedary	O
+camels	B-SPEC
+are	O
+bred	O
+domestically	O
+and	O
+imported	O
+into	O
+Bangladesh	O
+.	O
+
+S100A12	B-PRGE
+concentrations	O
+were	O
+measured	O
+in	O
+all	O
+fecal	B-ANAT
+samples	O
+using	O
+an	O
+in	O
+-	O
+house	O
+radioimmunoassay	O
+.	O
+
+(	O
+P	O
+=	O
+0	O
+.	O
+0384	O
+)	O
+and	O
+in	O
+dogs	B-SPEC
+infected	O
+with	O
+parvovirus	B-DISO
+(	O
+P	O
+=	O
+0	O
+.	O
+0277	O
+),	O
+whereas	O
+dogs	B-SPEC
+infected	O
+with	O
+coronavirus	B-SPEC
+had	O
+decreased	O
+fecal	B-ANAT
+S100A12	O
+concentrations	O
+(	O
+P	O
+=	O
+0	O
+.	O
+0345	O
+).	O
+
+Only	O
+fecal	B-ANAT
+score	O
+and	O
+breed	B-PROC
+size	O
+had	O
+an	O
+effect	O
+on	O
+fecal	B-ANAT
+S100A12	O
+concentrations	O
+in	O
+multivariate	O
+analysis	O
+(	O
+P	O
+<	O
+0	O
+.	O
+0001	O
+).	O
+
+Midnasal	O
+swabs	O
+were	O
+collected	O
+for	O
+acute	O
+respiratory	B-DISO
+symptoms	I-DISO
+and	O
+tested	O
+for	O
+HCoV	O
+and	O
+other	O
+viruses	B-SPEC
+by	O
+reverse	O
+-	O
+transcription	B-PROC
+polymerase	O
+chain	O
+reaction	O
+.	O
+
+TITLE	O
+:	O
+Transmembrane	B-ANAT
+Domains	O
+of	O
+Highly	O
+Pathogenic	O
+Viral	O
+Fusion	O
+Proteins	B-CHED
+Exhibit	O
+Trimeric	O
+Association	O
+ABSTRACT	O
+:	O
+Enveloped	O
+viruses	O
+require	O
+viral	O
+fusion	O
+proteins	B-CHED
+to	O
+promote	O
+fusion	O
+of	O
+the	O
+viral	B-COMP
+envelope	I-COMP
+with	O
+a	O
+target	O
+cell	B-COMP
+membrane	I-COMP
+.	O
+
+To	O
+drive	O
+fusion	O
+,	O
+these	O
+proteins	B-CHED
+undergo	O
+large	O
+conformational	O
+changes	O
+that	O
+must	O
+occur	O
+at	O
+the	O
+right	O
+place	O
+and	O
+at	O
+the	O
+right	O
+time	O
+.	O
+
+Using	O
+a	O
+similar	O
+approach	O
+,	O
+the	O
+work	O
+presented	O
+here	O
+indicates	O
+that	O
+trimeric	O
+interactions	O
+also	O
+occur	O
+between	O
+the	O
+fusion	O
+protein	O
+TMDs	O
+of	O
+Ebola	B-SPEC
+virus	I-SPEC
+,	O
+influenza	B-SPEC
+virus	I-SPEC
+,	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+coronavirus	B-SPEC
+(	O
+SARS	B-DISO
+CoV	O
+),	O
+and	O
+rabies	B-SPEC
+virus	I-SPEC
+.	O
+
+Our	O
+results	O
+suggest	O
+that	O
+TM	O
+-	O
+TM	O
+interactions	O
+are	O
+important	O
+in	O
+the	O
+fusion	O
+protein	B-PROC
+function	I-PROC
+of	O
+diverse	O
+viral	O
+families	O
+.	O
+
+Well	O
+conducted	O
+multinational	O
+follow	O
+-	O
+up	O
+studies	O
+using	O
+the	O
+same	O
+methodology	O
+of	O
+testing	O
+are	O
+necessary	O
+for	O
+accurate	O
+surveillance	O
+of	O
+respiratory	O
+viral	B-DISO
+infections	I-DISO
+among	O
+Hajj	O
+pilgrims	O
+.	O
+
+RESULTS	O
+:	O
+The	O
+retrieved	O
+articles	O
+were	O
+summarized	O
+based	O
+on	O
+the	O
+methodology	O
+of	O
+testing	O
+for	O
+these	O
+viruses	B-SPEC
+.	O
+
+The	O
+acquisition	O
+of	O
+MERS	O
+-	O
+CoV	O
+remains	O
+very	O
+limited	O
+and	O
+systematic	O
+screening	O
+of	O
+pilgrims	O
+showed	O
+no	O
+infections	B-DISO
+.	O
+
+Using	O
+observed	O
+data	O
+on	O
+pig	B-SPEC
+movements	B-PROC
+during	O
+the	O
+initial	O
+phase	O
+of	O
+the	O
+PEDv	B-SPEC
+epidemic	O
+,	O
+we	O
+developed	O
+a	O
+network	O
+-	O
+based	O
+and	O
+spatially	O
+explicit	O
+epidemiological	O
+model	O
+that	O
+simulates	O
+the	O
+spread	O
+of	O
+PEDv	O
+via	O
+both	O
+indirect	O
+and	O
+direct	O
+movement	B-PROC
+-	O
+related	O
+contact	O
+in	O
+order	B-SPEC
+to	O
+answer	O
+unresolved	O
+questions	O
+concerning	O
+factors	O
+facilitating	O
+between	O
+-	O
+farm	O
+transmission	O
+.	O
+
+All	O
+these	O
+patients	O
+received	O
+2	O
+months	O
+'	O
+pulmonary	B-ANAT
+rehabilitation	O
+program	O
+.	O
+
+Pulmonary	B-PROC
+functions	I-PROC
+and	O
+exercise	O
+capacity	O
+included	O
+TLC	O
+,	O
+forced	B-PROC
+vital	I-PROC
+capacity	I-PROC
+(	O
+FVC	B-PROC
+),	O
+forced	B-PROC
+expiratory	I-PROC
+volume	I-PROC
+in	O
+the	O
+first	O
+second	O
+(	O
+FEV	B-SPEC
+The	O
+impaired	O
+pulmonary	B-PROC
+functions	I-PROC
+and	O
+exercise	O
+capacity	O
+in	O
+the	O
+survivors	O
+of	O
+H1N1	O
+-	O
+ARDS	B-DISO
+improved	O
+soon	O
+at	O
+3	O
+months	O
+after	O
+hospital	O
+discharge	B-ANAT
+.	O
+
+TITLE	O
+:	O
+Influence	O
+of	O
+Entrapment	O
+on	O
+Prehospital	O
+Management	O
+and	O
+the	O
+Hospital	O
+Course	O
+in	O
+Polytrauma	O
+Patients	O
+:	O
+A	O
+Retrospective	O
+Analysis	O
+in	O
+Air	B-CHED
+Rescue	O
+.	O
+
+However	O
+,	O
+entrapped	O
+patients	O
+are	O
+prone	O
+to	O
+sustain	O
+more	O
+severe	O
+trauma	O
+to	O
+the	O
+extremities	B-ANAT
+.	O
+
+TITLE	O
+:	O
+Chugging	O
+in	O
+patients	O
+on	O
+veno	O
+-	O
+venous	B-ANAT
+extracorporeal	O
+membrane	B-COMP
+oxygenation	B-PROC
+:	O
+An	O
+under	O
+-	O
+recognized	O
+driver	O
+of	O
+intravenous	O
+fluid	O
+administration	O
+in	O
+patients	O
+with	O
+acute	O
+respiratory	O
+distress	O
+syndrome	O
+?	O
+
+Our	O
+patient	O
+received	O
+frequent	O
+boluses	O
+of	O
+albumin	B-PRGE
+for	O
+intermittent	O
+circuit	O
+chugging	O
+contributing	O
+to	O
+a	O
+net	O
+positive	O
+fluid	B-PROC
+balance	I-PROC
+of	O
+roughly	O
+6	O
+liters	O
+4	O
+days	O
+after	O
+cannulation	O
+.	O
+
+Specifically	O
+,	O
+among	O
+different	O
+genera	O
+,	O
+the	O
+two	O
+domains	O
+of	O
+S1	O
+,	O
+the	O
+N	O
+-	O
+terminal	O
+domain	O
+(	O
+S1	O
+-	O
+NTD	O
+)	O
+and	O
+C	O
+-	O
+terminal	O
+domain	O
+(	O
+S1	B-PRGE
+-	I-PRGE
+CTD	I-PRGE
+),	O
+diverge	O
+from	O
+simpler	O
+tertiary	O
+structures	O
+and	O
+quaternary	O
+packing	O
+to	O
+more	O
+complex	O
+ones	O
+,	O
+leading	O
+to	O
+different	O
+functions	O
+of	O
+the	O
+spikes	O
+in	O
+receptor	O
+usage	O
+and	O
+membrane	O
+fusion	O
+.	O
+
+The	O
+Norwegian	O
+control	O
+program	O
+against	O
+these	O
+infections	B-DISO
+is	O
+based	O
+on	O
+herd	O
+-	O
+level	O
+diagnosis	O
+using	O
+a	O
+new	O
+multiplex	O
+immunoassay	O
+.	O
+
+Bare	O
+-	O
+metal	B-CHED
+stents	O
+were	O
+used	O
+in	O
+33	O
+patients	O
+,	O
+covered	O
+stents	O
+in	O
+26	O
+,	O
+and	O
+both	O
+types	O
+in	O
+6	O
+.	O
+
+Two	O
+patients	O
+had	O
+vessel	B-ANAT
+spasm	B-DISO
+treated	O
+by	O
+nitroglycerin	B-CHED
+.	O
+
+There	O
+were	O
+no	O
+deaths	B-PROC
+among	O
+CMI	O
+patients	O
+and	O
+two	O
+early	O
+deaths	B-PROC
+(	O
+12	O
+%)	O
+among	O
+those	O
+who	O
+had	O
+AMI	B-DISO
+.	O
+
+Use	O
+of	O
+EPDs	O
+during	O
+SMA	B-DISO
+stenting	O
+is	O
+safe	O
+and	O
+feasible	O
+with	O
+a	O
+two	O
+-	O
+wire	O
+technique	O
+.	O
+
+TITLE	O
+:	O
+Supplemental	O
+flaxseed	B-SPEC
+modulates	O
+ovarian	B-ANAT
+functions	O
+of	O
+weanling	O
+gilts	O
+via	O
+the	O
+action	O
+of	O
+selected	O
+fatty	O
+acids	O
+.	O
+
+The	O
+aim	O
+of	O
+this	O
+study	O
+was	O
+to	O
+examine	O
+the	O
+influence	O
+of	O
+dietary	O
+flaxseed	B-SPEC
+on	O
+the	O
+endocrine	B-CHED
+and	O
+ovarian	B-ANAT
+functions	O
+of	O
+weanling	O
+gilts	O
+challenged	O
+with	O
+E	B-SPEC
+.	I-SPEC
+coli	I-SPEC
+and	O
+Coronavirus	B-DISO
+infections	I-DISO
+treated	O
+with	O
+dietary	O
+probiotic	O
+cheeses	O
+and	O
+to	O
+understand	O
+the	O
+possible	O
+mechanisms	O
+of	O
+its	O
+effects	O
+on	O
+ovarian	B-PROC
+function	I-PROC
+.	O
+
+Probiotics	O
+were	O
+used	O
+as	O
+a	O
+natural	O
+substitution	O
+for	O
+antibiotics	B-CHED
+and	O
+10	O
+%	O
+dietary	O
+flaxseed	B-SPEC
+is	O
+an	O
+effective	O
+prebiotic	O
+which	O
+supports	O
+the	O
+action	O
+of	O
+probiotics	O
+and	O
+has	O
+other	O
+beneficial	O
+effects	O
+on	O
+the	O
+organism	O
+.	O
+
+Probiotics	O
+with	O
+or	O
+without	O
+flaxseed	B-SPEC
+were	O
+fed	O
+to	O
+weanling	O
+gilts	O
+starting	O
+10	O
+days	O
+before	O
+and	O
+lasting	O
+up	O
+until	O
+14	O
+days	O
+after	O
+weaning	B-PROC
+.	O
+
+The	O
+ovaries	B-ANAT
+were	O
+measured	O
+and	O
+histologically	O
+analysed	O
+.	O
+
+However	O
+,	O
+the	O
+mucosal	B-ANAT
+antibody	B-PROC
+response	I-PROC
+to	O
+many	O
+respiratory	O
+viruses	B-SPEC
+is	O
+not	O
+long	O
+-	O
+lasting	O
+and	O
+declines	O
+with	O
+age	O
+.	O
+
+In	O
+addition	O
+,	O
+memory	B-PROC
+CD8	B-PRGE
+T	I-PRGE
+cells	O
+are	O
+capable	O
+of	O
+providing	O
+protection	O
+against	O
+secondary	O
+infections	O
+.	O
+
+In	O
+comparison	O
+to	O
+Berlin	O
+definition	O
+,	O
+the	O
+PALICC	O
+criteria	O
+identified	O
+more	O
+number	O
+of	O
+patients	O
+with	O
+ARDS	B-DISO
+.	O
+
+ABSTRACT	O
+:	O
+During	O
+the	O
+last	O
+two	O
+decades	O
+,	O
+scientists	O
+have	O
+grown	O
+increasingly	O
+aware	O
+that	O
+viruses	B-SPEC
+are	O
+emerging	O
+from	O
+the	O
+human	B-SPEC
+-	O
+animal	B-SPEC
+interface	O
+.	O
+
+In	O
+addition	O
+to	O
+SARS	B-DISO
+,	O
+other	O
+respiratory	O
+pathogens	O
+have	O
+also	O
+emerged	O
+recently	O
+,	O
+contributing	O
+to	O
+the	O
+high	O
+burden	O
+of	O
+respiratory	B-DISO
+tract	I-DISO
+infection	I-DISO
+-	O
+related	O
+morbidity	O
+and	O
+mortality	O
+.	O
+
+Genealogical	O
+analysis	O
+showed	O
+that	O
+the	O
+Brazilian	O
+sequences	O
+of	O
+BCoV	O
+for	O
+the	O
+gene	O
+which	O
+codes	O
+for	O
+the	O
+N	B-PRGE
+protein	I-PRGE
+can	O
+be	O
+broken	O
+down	O
+into	O
+two	O
+distinct	O
+clusters	O
+,	O
+and	O
+the	O
+samples	O
+from	O
+this	O
+study	O
+were	O
+closely	O
+linked	O
+to	O
+Asian	O
+strains	O
+.	O
+
+Furthermore	O
+,	O
+compared	O
+with	O
+the	O
+sham	O
+treatment	O
+control	O
+,	O
+apoptosis	B-PATH
+of	O
+splenic	B-ANAT
+cells	B-COMP
+was	O
+less	O
+pronounced	O
+in	O
+the	O
+splenic	B-ANAT
+white	I-ANAT
+pulp	I-ANAT
+of	O
+treated	O
+mice	B-SPEC
+,	O
+and	O
+greater	O
+number	O
+of	O
+proliferating	O
+splenic	B-ANAT
+cells	B-COMP
+,	O
+particularly	O
+in	O
+the	O
+red	B-ANAT
+pulp	I-ANAT
+,	O
+was	O
+observed	O
+.	O
+
+In	O
+this	O
+study	O
+,	O
+we	O
+investigated	O
+the	O
+viral	O
+virulence	B-PROC
+determinants	O
+by	O
+constructing	O
+a	O
+series	O
+of	O
+chimeric	O
+mutants	O
+between	O
+the	O
+highly	O
+virulent	O
+strain	O
+BJ2011C	O
+and	O
+the	O
+avirulent	O
+strain	O
+CHM2013	O
+.	O
+
+TITLE	O
+:	O
+Development	B-PROC
+of	O
+regional	O
+extracorporeal	O
+life	O
+support	O
+system	O
+:	O
+The	O
+importance	O
+of	O
+innovative	O
+simulation	O
+training	O
+.	O
+
+ECMO	O
+is	O
+a	O
+complex	O
+network	O
+that	O
+provides	O
+oxygenation	B-PROC
+and	O
+ventilation	O
+and	O
+allows	O
+the	O
+lungs	B-ANAT
+to	O
+rest	B-FUNC
+and	O
+recover	B-PROC
+from	O
+respiratory	B-DISO
+failure	I-DISO
+,	O
+while	O
+minimizing	O
+iatrogenic	O
+ventilator	O
+-	O
+induced	O
+lung	B-ANAT
+injury	O
+.	O
+
+The	O
+total	O
+time	O
+,	O
+by	O
+definition	O
+,	O
+means	O
+the	O
+time	O
+from	O
+the	O
+first	O
+contact	O
+with	O
+the	O
+mannequin	O
+to	O
+the	O
+cannulation	O
+of	O
+artificial	O
+vessels	B-ANAT
+and	O
+starting	O
+VV	O
+perfusion	O
+on	O
+ECMO	O
+,	O
+did	O
+not	O
+exceed	O
+3	O
+h	O
+-	O
+including	O
+75	O
+min	O
+of	O
+transport	B-PROC
+(	O
+the	O
+total	O
+time	O
+of	O
+simulation	O
+with	O
+first	O
+call	O
+from	O
+provincial	O
+hospital	O
+to	O
+admission	O
+to	O
+the	O
+Clinical	O
+Intensive	O
+Care	O
+department	O
+was	O
+5	O
+h	O
+).	O
+
+A	O
+discharge	B-ANAT
+home	O
+at	O
+the	O
+time	O
+of	O
+index	O
+admission	O
+was	O
+associated	O
+an	O
+increased	O
+overall	O
+survival	O
+compared	O
+with	O
+any	O
+other	O
+discharge	B-ANAT
+location	O
+(	O
+P	O
+<	O
+.	O
+001	O
+).	O
+We	O
+report	O
+good	O
+early	O
+outcomes	O
+,	O
+but	O
+significant	O
+long	O
+-	O
+term	O
+morbidity	O
+in	O
+patients	O
+with	O
+severe	O
+COPD	B-DISO
+requiring	O
+invasive	O
+mechanical	O
+ventilation	O
+for	O
+acute	B-DISO
+respiratory	I-DISO
+failure	I-DISO
+.	O
+
+The	O
+novel	O
+PEAV	O
+sequence	O
+was	O
+most	O
+identical	O
+to	O
+that	O
+of	O
+bat	B-PRGE
+-	I-PRGE
+HKU2	I-PRGE
+,	O
+and	O
+the	O
+differences	O
+between	O
+them	O
+were	O
+comprehensively	O
+compared	O
+,	O
+especially	O
+the	O
+uniform	O
+features	O
+of	O
+the	O
+S	B-PRGE
+protein	I-PRGE
+,	O
+which	O
+was	O
+shown	O
+to	O
+have	O
+a	O
+close	O
+relationship	O
+with	O
+betacoronaviruses	O
+and	O
+to	O
+perhaps	O
+represent	O
+unrecognized	O
+betacoronaviruses	O
+.	O
+
+Tests	O
+were	O
+carried	O
+out	O
+on	O
+the	O
+feline	B-SPEC
+calicivirus	I-SPEC
+(	O
+FCV	B-CHED
+)	O
+vaccine	O
+strain	O
+F9	O
+,	O
+which	O
+is	O
+a	O
+surrogate	O
+of	O
+airborne	O
+pathogen	O
+human	B-SPEC
+norovirus	B-SPEC
+.	O
+
+Results	O
+showed	O
+that	O
+the	O
+PACT	B-DISO
+device	O
+could	O
+inactivate	O
+FCV	B-CHED
+,	O
+which	O
+passed	O
+through	O
+the	O
+plasma	B-ANAT
+chamber	B-ANAT
+.	O
+
+Plasma	B-ANAT
+phosphatidylcholine	B-CHED
+(	O
+PC	O
+),	O
+the	O
+major	O
+phospholipid	B-CHED
+of	O
+circulating	O
+lipoproteins	B-CHED
+,	O
+is	O
+synthesized	O
+in	O
+human	B-SPEC
+liver	B-ANAT
+by	O
+two	O
+biologically	O
+diverse	O
+pathways	B-PROC
+:	O
+the	O
+cytidine	B-CHED
+diphosphocholine	O
+(	O
+CDP	B-CHED
+):	O
+choline	B-CHED
+and	O
+phosphatidylethanolamine	B-CHED
+
+High	O
+resolution	O
+manometry	O
+was	O
+performed	O
+on	O
+consecutive	O
+patients	O
+presenting	O
+with	O
+unexplained	O
+respiratory	B-DISO
+symptoms	I-DISO
+(	O
+Respiratory	O
+Group	O
+61	O
+).	O
+
+TITLE	O
+:	O
+Passive	B-PROC
+immunity	I-PROC
+to	O
+porcine	B-SPEC
+epidemic	I-SPEC
+diarrhea	I-SPEC
+virus	I-SPEC
+following	O
+immunization	O
+of	O
+pregnant	O
+gilts	O
+with	O
+a	O
+recombinant	O
+orf	O
+virus	O
+vector	O
+expressing	O
+the	O
+spike	O
+protein	B-CHED
+.	O
+
+Antibody	B-PROC
+responses	I-PROC
+were	O
+assessed	O
+in	O
+serum	B-COMP
+,	O
+colostrum	B-ANAT
+and	O
+milk	O
+of	O
+immunized	O
+gilts	O
+,	O
+and	O
+passive	O
+transfer	O
+of	O
+antibodies	B-COMP
+was	O
+evaluated	O
+in	O
+piglet	O
+sera	B-COMP
+.	O
+
+This	O
+study	O
+investigated	O
+the	O
+efficacy	O
+of	O
+the	O
+THERAFLEX	O
+UV	O
+-	O
+Platelets	B-ANAT
+and	O
+THERAFLEX	O
+MB	O
+-	O
+Plasma	B-ANAT
+pathogen	O
+inactivation	B-DISO
+systems	O
+to	O
+inactivate	O
+EBOV	O
+and	O
+MERS	O
+-	O
+CoV	O
+in	O
+platelet	B-ANAT
+concentrates	O
+(	O
+PCs	B-DISO
+)	O
+and	O
+plasma	B-ANAT
+,	O
+respectively	O
+.	O
+
+PCs	B-DISO
+and	O
+plasma	B-ANAT
+were	O
+spiked	O
+with	O
+high	O
+titers	O
+of	O
+cell	B-COMP
+culture	O
+-	O
+derived	O
+EBOV	O
+and	O
+MERS	O
+-	O
+CoV	O
+,	O
+treated	O
+with	O
+various	O
+light	O
+doses	O
+of	O
+ultraviolet	O
+C	O
+(	O
+UVC	O
+;	O
+THERAFLEX	O
+UV	O
+-	O
+Platelets	B-ANAT
+)	O
+or	O
+methylene	B-CHED
+blue	I-CHED
+(	O
+MB	B-CHED
+)	O
+plus	O
+visible	O
+light	O
+(	O
+MB	B-CHED
+/	O
+light	O
+;	O
+THERAFLEX	O
+MB	B-CHED
+-	O
+Plasma	B-ANAT
+),	O
+and	O
+assessed	O
+for	O
+residual	O
+viral	O
+infectivity	O
+.	O
+
+ABSTRACT	O
+:	O
+We	O
+report	O
+the	O
+case	O
+of	O
+a	O
+non	O
+-	O
+physician	O
+based	O
+critical	O
+care	O
+transport	O
+team	O
+(	O
+registered	O
+nurse	O
+and	O
+paramedic	O
+)	O
+that	O
+successfully	O
+initiated	O
+prone	O
+positioning	O
+of	O
+a	O
+severe	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+patient	O
+prior	O
+to	O
+transport	B-PROC
+to	O
+an	O
+extracorporeal	O
+membrane	B-COMP
+oxygenation	B-PROC
+capable	O
+teaching	O
+hospital	O
+.	O
+
+In	O
+this	O
+study	O
+,	O
+we	O
+examined	O
+the	O
+temporal	O
+relationships	O
+between	O
+antibiotic	B-CHED
+usage	O
+and	O
+respiratory	B-DISO
+infections	I-DISO
+in	O
+the	O
+Republic	O
+of	O
+Korea	O
+.	O
+
+The	O
+number	O
+of	O
+monthly	O
+antibiotic	B-CHED
+prescriptions	O
+and	O
+the	O
+incidence	O
+of	O
+acute	O
+respiratory	B-DISO
+tract	I-DISO
+infections	I-DISO
+between	O
+2010	O
+and	O
+2015	O
+at	O
+all	O
+primary	O
+care	O
+clinics	O
+were	O
+obtained	O
+from	O
+the	O
+Korean	O
+Health	O
+Insurance	O
+Review	O
+and	O
+Assessment	O
+Service	O
+.	O
+
+These	O
+correlations	O
+peaked	O
+at	O
+the	O
+0	O
+-	O
+month	O
+lag	O
+with	O
+cross	O
+-	O
+correlation	O
+coefficients	O
+of	O
+0	O
+.	O
+45	O
+(	O
+Our	O
+findings	O
+suggest	O
+that	O
+there	O
+is	O
+a	O
+significant	O
+temporal	O
+relationship	O
+between	O
+influenza	B-SPEC
+virus	I-SPEC
+activity	O
+and	O
+antibiotic	B-CHED
+use	O
+in	O
+primary	O
+clinics	O
+.	O
+
+TITLE	O
+:	O
+Pediatric	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+associated	O
+with	O
+human	B-SPEC
+metapneumovirus	I-SPEC
+and	O
+respiratory	B-SPEC
+syncytial	I-SPEC
+virus	I-SPEC
+.	O
+
+About	O
+1	O
+/	O
+3	O
+of	O
+children	O
+with	O
+HMP	O
+or	O
+RSV	B-SPEC
+and	O
+acute	O
+(	O
+or	O
+acute	O
+-	O
+on	O
+-	O
+chronic	O
+)	O
+respiratory	B-DISO
+failure	I-DISO
+developed	O
+PARDS	O
+.	O
+
+The	O
+risk	O
+factors	O
+,	O
+clinical	O
+course	O
+,	O
+and	O
+outcomes	O
+were	O
+similar	O
+for	O
+patients	O
+with	O
+PARDS	O
+associated	O
+with	O
+HMP	O
+and	O
+RSV	B-SPEC
+.	O
+
+Furthermore	O
+,	O
+the	O
+vesicle	B-COMP
+internalization	O
+process	O
+requires	O
+actin	B-COMP
+cytoskeleton	I-COMP
+rearrangements	O
+.	O
+
+HCoV	B-SPEC
+-	I-SPEC
+NL63	I-SPEC
+was	O
+detected	O
+with	O
+multiplex	O
+real	O
+-	O
+time	O
+reverse	B-PROC
+transcription	I-PROC
+PCR	O
+,	O
+and	O
+positive	O
+samples	O
+were	O
+targeted	B-PROC
+for	O
+nucleotide	B-CHED
+sequencing	O
+of	O
+the	O
+spike	O
+(	O
+S	O
+)	O
+protein	B-CHED
+.	O
+
+Two	O
+HCoV	B-SPEC
+-	I-SPEC
+NL63	I-SPEC
+genotypes	O
+circulated	O
+in	O
+Kilifi	O
+between	O
+2008	O
+and	O
+2014	O
+.	O
+
+Similar	O
+patterns	O
+for	O
+2	O
+other	O
+endemic	O
+coronaviruses	O
+,	O
+HCoV	B-SPEC
+-	I-SPEC
+229E	I-SPEC
+and	O
+HCoV	B-SPEC
+-	I-SPEC
+OC43	I-SPEC
+,	O
+were	O
+observed	O
+.	O
+
+In	O
+this	O
+coastal	O
+Kenya	O
+setting	O
+,	O
+HCoV	B-SPEC
+-	I-SPEC
+NL63	I-SPEC
+exhibited	O
+low	O
+prevalence	O
+in	O
+hospital	O
+pediatric	O
+pneumonia	B-DISO
+admissions	O
+.	O
+
+Clade	O
+persistence	O
+with	O
+low	O
+genetic	O
+diversity	O
+suggest	O
+limited	O
+immune	O
+selection	O
+,	O
+and	O
+absence	O
+of	O
+detectable	O
+clade	O
+switching	O
+in	O
+reinfections	O
+indicates	O
+initial	O
+exposure	O
+was	O
+insufficient	O
+to	O
+elicit	O
+a	O
+protective	O
+immune	B-PROC
+response	I-PROC
+.	O
+
+ABSTRACT	O
+:	O
+Avian	B-DISO
+infectious	I-DISO
+bronchitis	I-DISO
+virus	B-SPEC
+(	O
+IBV	B-SPEC
+)	O
+continues	O
+to	O
+cause	O
+serious	O
+economic	O
+losses	O
+in	O
+global	O
+chicken	B-SPEC
+production	O
+.	O
+
+Therefore	O
+,	O
+immunopathogenesis	O
+,	O
+particularly	O
+early	O
+host	B-COMP
+responses	O
+,	O
+needs	O
+to	O
+be	O
+better	O
+understood	O
+for	O
+effective	O
+control	O
+of	O
+diseases	O
+caused	O
+by	O
+different	O
+strains	O
+of	O
+IBVs	O
+.	O
+
+Risk	O
+factors	O
+for	O
+high	O
+mortality	O
+and	O
+prolonged	O
+morbidity	O
+after	O
+RSV	B-DISO
+infection	I-DISO
+include	O
+premature	B-DISO
+birth	I-DISO
+,	O
+bronchopulmonary	B-DISO
+dysplasia	I-DISO
+,	O
+congenital	B-DISO
+heart	I-DISO
+disease	I-DISO
+,	O
+and	O
+Down	B-DISO
+syndrome	I-DISO
+.	O
+
+Cardiopulmonary	B-DISO
+arrest	I-DISO
+occurred	O
+within	O
+3	O
+days	O
+after	O
+the	O
+onset	O
+of	O
+symptoms	O
+,	O
+which	O
+included	O
+cough	B-DISO
+and	O
+high	O
+fever	B-PROC
+.	O
+
+Viral	O
+antigen	B-CHED
+detection	O
+and	O
+microbiome	O
+analyses	O
+of	O
+oral	B-ANAT
+swab	I-ANAT
+and	O
+nasopharyngeal	B-ANAT
+aspirate	I-ANAT
+specimens	O
+verified	O
+an	O
+RSV	B-SPEC
+infection	I-DISO
+,	O
+while	O
+bacterial	O
+culture	O
+of	O
+blood	O
+specimens	O
+yielded	O
+negative	O
+results	O
+.	O
+
+The	O
+RSV	B-SPEC
+strain	O
+detected	O
+in	O
+this	O
+patient	O
+was	O
+subtyped	O
+as	O
+RSVB9	O
+,	O
+and	O
+no	O
+mutation	O
+was	O
+found	O
+in	O
+the	O
+six	O
+antigenic	O
+sites	O
+for	O
+targeted	B-PROC
+drugs	O
+or	O
+vaccines	O
+.	O
+
+In	O
+oropharyngeal	B-ANAT
+and	O
+nasopharyngeal	B-ANAT
+swab	I-ANAT
+specimens	O
+,	O
+the	O
+detection	O
+of	O
+sub	O
+-	O
+genomic	O
+mRNA	B-CHED
+and	O
+genomic	O
+RNA	O
+did	O
+not	O
+correlate	O
+.	O
+
+The	O
+imaging	O
+findings	O
+of	O
+viral	B-DISO
+pneumonia	I-DISO
+are	O
+diverse	O
+and	O
+overlap	O
+with	O
+those	O
+of	O
+other	O
+nonviral	O
+infectious	B-DISO
+and	O
+inflammatory	O
+conditions	O
+.	O
+
+TITLE	O
+:	O
+Distribution	O
+and	O
+absence	O
+of	O
+generalized	O
+lesions	O
+in	O
+mice	B-SPEC
+following	O
+single	O
+dose	O
+intramuscular	O
+inoculation	O
+of	O
+the	O
+vaccine	O
+candidate	O
+MVA	O
+-	O
+MERS	O
+-	O
+S	O
+.	O
+ABSTRACT	O
+:	O
+Modified	O
+Vaccinia	B-SPEC
+Virus	I-SPEC
+Ankara	O
+(	O
+MVA	B-CHED
+)	O
+is	O
+a	O
+highly	O
+attenuated	O
+and	O
+replication	O
+-	O
+deficient	O
+virus	B-SPEC
+serving	O
+as	O
+vaccine	O
+against	O
+infectious	B-DISO
+diseases	I-DISO
+.	O
+
+Here	O
+,	O
+we	O
+assessed	O
+the	O
+in	O
+vivo	O
+distribution	O
+of	O
+a	O
+recombinant	O
+MVA	B-CHED
+candidate	O
+vaccine	O
+against	O
+the	O
+Middle	O
+Eastern	O
+Respiratory	O
+Syndrome	B-DISO
+(	O
+MVA	B-CHED
+-	O
+MERS	O
+-	O
+S	O
+)	O
+in	O
+mice	B-SPEC
+.	O
+
+TITLE	O
+:	O
+[	O
+Role	O
+of	O
+noninvasive	O
+mechanical	O
+ventilation	O
+in	O
+patients	O
+with	O
+severe	O
+avian	B-DISO
+influenza	B-PATH
+A	I-PATH
+(	O
+H7N9	O
+)	O
+complicated	O
+with	O
+acute	O
+respiratory	O
+distress	O
+syndrome	O
+].	O
+
+ABSTRACT	O
+:	O
+Human	B-SPEC
+infection	B-DISO
+with	O
+avian	B-DISO
+influenza	B-PATH
+A	I-PATH
+(	O
+H7N9	O
+)	O
+is	O
+an	O
+acute	O
+contagious	O
+respiratory	B-DISO
+disease	I-DISO
+.	O
+
+In	O
+severe	O
+cases	O
+,	O
+maintaining	O
+adequate	O
+gas	B-ENZY
+exchange	O
+aiming	O
+to	O
+avoid	O
+further	O
+lung	B-ANAT
+damage	O
+and	O
+other	O
+neonatal	O
+morbidities	O
+associated	O
+with	O
+systemic	O
+/	O
+pulmonary	B-ANAT
+hypoperfusion	O
+,	O
+prolonged	O
+hypoxia	B-DISO
+,	O
+and	O
+respiratory	B-DISO
+acidosis	I-DISO
+can	O
+be	O
+challenging	O
+and	O
+requires	O
+in	O
+-	O
+depth	O
+knowledge	O
+into	O
+the	O
+pathophysiology	O
+of	O
+the	O
+disease	O
+.	O
+
+ABSTRACT	O
+:	O
+Acute	O
+respiratory	O
+distress	O
+syndrome	O
+(	O
+ARDS	B-DISO
+)	O
+is	O
+common	O
+after	O
+severe	O
+traumatic	O
+injuries	O
+but	O
+is	O
+underdiagnosed	O
+and	O
+undertreated	O
+.	O
+
+Controls	O
+were	O
+subjects	O
+without	O
+ARDS	B-DISO
+during	O
+the	O
+first	O
+4	O
+days	O
+of	O
+study	O
+enrollment	O
+.	O
+
+Despite	O
+this	O
+impressive	O
+economic	O
+development	B-PROC
+,	O
+this	O
+growth	B-PROC
+exists	O
+side	O
+by	O
+side	O
+with	O
+the	O
+human	B-DISO
+immunodeficiency	I-DISO
+virus	I-DISO
+/	O
+acquired	B-DISO
+immune	I-DISO
+deficiency	I-DISO
+syndrome	I-DISO
+(	O
+HIV	B-DISO
+/	I-DISO
+AIDS	I-DISO
+)	O
+and	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+(	O
+SARS	B-DISO
+)	O
+crises	O
+and	O
+the	O
+persisting	O
+deficiencies	O
+in	O
+public	O
+health	O
+provision	O
+in	O
+China	O
+.	O
+
+Acknowledging	O
+the	O
+prevailing	O
+health	O
+problems	O
+,	O
+the	O
+Chinese	O
+government	O
+has	O
+encouraged	O
+the	O
+development	B-PROC
+of	O
+health	O
+non	O
+-	O
+governmental	O
+organizations	O
+(	O
+NGOs	O
+)	O
+to	O
+respond	O
+to	O
+the	O
+health	O
+challenges	O
+and	O
+address	O
+the	O
+gaps	O
+in	O
+public	O
+health	O
+provision	O
+of	O
+the	O
+government	O
+.	O
+
+The	O
+research	O
+that	O
+underpins	O
+this	O
+article	O
+is	O
+based	O
+on	O
+a	O
+desk	O
+-	O
+based	O
+literature	O
+review	O
+as	O
+well	O
+as	O
+in	O
+-	O
+depth	O
+field	O
+interviews	O
+with	O
+individuals	O
+working	O
+in	O
+HIV	B-DISO
+/	I-DISO
+AIDS	I-DISO
+-	O
+focused	O
+NGOs	O
+in	O
+China	O
+.	O
+
+Despite	O
+depicting	O
+a	O
+positive	O
+scenario	O
+,	O
+the	O
+development	B-PROC
+of	O
+HIV	B-DISO
+/	I-DISO
+AIDS	I-DISO
+-	O
+focused	O
+NGOs	O
+in	O
+China	O
+generated	O
+by	O
+the	O
+international	O
+securitization	O
+efforts	O
+is	O
+largely	O
+limited	O
+.	O
+
+ER	O
+stress	O
+is	O
+a	O
+common	O
+consequence	O
+in	O
+coronavirus	B-SPEC
+-	O
+infected	O
+cells	B-COMP
+.	O
+
+Four	O
+novel	O
+deltacoronaviruses	O
+were	O
+detected	O
+from	O
+eight	O
+birds	B-SPEC
+of	O
+four	O
+species	B-SPEC
+by	O
+reverse	B-PROC
+transcription	I-PROC
+-	O
+PCR	O
+(	O
+RT	O
+-	O
+PCR	O
+):	O
+FalCoV	O
+UAE	O
+-	O
+HKU27	O
+from	O
+a	O
+falcon	O
+,	O
+HouCoV	O
+UAE	O
+-	O
+HKU28	O
+from	O
+a	O
+houbara	O
+bustard	O
+,	O
+PiCoV	O
+UAE	O
+-	O
+HKU29	O
+from	O
+a	O
+pigeon	B-SPEC
+,	O
+and	O
+QuaCoV	O
+UAE	O
+-	O
+HKU30	O
+from	O
+five	O
+quails	O
+.	O
+
+Western	O
+blotting	O
+detected	O
+specific	O
+anti	O
+-	O
+FalCoV	O
+UAE	O
+-	O
+HKU27	O
+antibodies	B-COMP
+in	O
+33	O
+(	O
+75	O
+%)	O
+of	O
+44	O
+falcon	O
+serum	B-COMP
+samples	O
+,	O
+supporting	O
+genuine	O
+infection	B-DISO
+in	O
+falcons	B-SPEC
+after	O
+virus	B-SPEC
+acquisition	O
+.	O
+
+Unsupervised	O
+CyTOF	O
+analysis	O
+of	O
+alveolar	B-ANAT
+leukocytes	B-ANAT
+from	O
+human	B-SPEC
+subjects	O
+has	O
+potential	O
+to	O
+identify	O
+expected	O
+and	O
+potentially	O
+novel	O
+myeloid	O
+populations	O
+that	O
+may	O
+be	O
+linked	O
+with	O
+clinical	O
+outcomes	O
+.	O
+
+A	O
+web	B-DISO
+-	O
+based	O
+program	O
+aggregates	O
+data	O
+based	O
+on	O
+an	O
+algorithm	O
+that	O
+provides	O
+potential	O
+signals	O
+of	O
+emerging	O
+public	O
+health	O
+events	O
+which	O
+are	O
+then	O
+reviewed	O
+by	O
+a	O
+multilingual	O
+,	O
+multidisciplinary	O
+team	O
+.	O
+
+The	O
+GPHIN	O
+'	O
+s	O
+early	O
+adoption	O
+of	O
+Big	O
+Data	O
+has	O
+increased	O
+global	O
+capacity	O
+to	O
+detect	O
+international	O
+infectious	B-DISO
+disease	I-DISO
+outbreaks	O
+and	O
+other	O
+public	O
+health	O
+events	O
+.	O
+
+EIDs	O
+will	O
+,	O
+however	O
+,	O
+remain	O
+a	O
+key	O
+,	O
+global	O
+public	O
+health	O
+challenge	O
+in	O
+a	O
+globalized	O
+world	O
+where	O
+demographic	O
+,	O
+climatic	O
+,	O
+and	O
+other	O
+environmental	O
+changes	O
+are	O
+altering	O
+the	O
+interactions	O
+between	O
+hosts	B-COMP
+and	O
+pathogen	O
+in	O
+ways	O
+that	O
+increase	O
+spillover	O
+from	O
+animals	B-SPEC
+to	O
+humans	B-SPEC
+and	O
+global	O
+spread	O
+.	O
+
+This	O
+study	O
+represents	O
+the	O
+molecular	O
+characterization	O
+of	O
+PEDV	B-SPEC
+isolates	O
+identified	O
+in	O
+diarrhoeic	O
+animals	B-SPEC
+collected	O
+across	O
+the	O
+country	O
+in	O
+2017	O
+.	O
+
+In	O
+addition	O
+,	O
+one	O
+2017	O
+PEDV	B-SPEC
+strain	O
+,	O
+KOR	O
+/	O
+KNU	O
+-	O
+1705	O
+/	O
+2017	O
+,	O
+was	O
+successfully	O
+isolated	O
+and	O
+propagated	O
+in	O
+Vero	B-ANAT
+cells	I-ANAT
+.	O
+
+Our	O
+data	O
+advance	O
+the	O
+understanding	O
+of	O
+the	O
+molecular	O
+epidemiology	O
+and	O
+antigenicity	O
+of	O
+PEDV	B-SPEC
+circulating	O
+in	O
+South	O
+Korea	O
+.	O
+
+Incidence	O
+of	O
+mild	O
+influenza	B-DISO
+-	O
+associated	O
+ARI	B-CHED
+was	O
+higher	O
+among	O
+healthy	O
+than	O
+high	O
+-	O
+risk	O
+children	O
+(	O
+incidence	O
+rate	O
+ratio	O
+[	O
+IRR	O
+]:	O
+1	O
+.	O
+67	O
+;	O
+95	O
+%	O
+confidence	O
+interval	O
+[	O
+CI	O
+]:	O
+1	O
+.	O
+13	O
+-	O
+2	O
+.	O
+48	O
+).	O
+
+The	O
+median	O
+cost	O
+per	O
+severe	O
+influenza	B-DISO
+-	O
+associated	O
+ARI	B-CHED
+episode	O
+was	O
+$	O
+232	O
+among	O
+healthy	O
+and	O
+$	O
+318	O
+among	O
+high	O
+-	O
+risk	O
+children	O
+(	O
+26	O
+-	O
+40	O
+%	O
+and	O
+36	O
+-	O
+54	O
+%	O
+of	O
+monthly	O
+household	O
+income	O
+,	O
+respectively	O
+;	O
+difference	O
+in	O
+medians	O
+:	O
+110	O
+;	O
+95	O
+%	O
+CI	O
+for	O
+difference	O
+in	O
+medians	O
+:	O
+-$	O
+352	O
+to	O
+$	O
+571	O
+).	O
+
+TITLE	O
+:	O
+Effect	O
+of	O
+interferon	B-PRGE
+alpha	I-PRGE
+and	O
+cyclosporine	B-CHED
+treatment	O
+separately	O
+and	O
+in	O
+combination	O
+on	O
+Middle	O
+East	O
+Respiratory	O
+Syndrome	O
+Coronavirus	B-SPEC
+(	O
+MERS	O
+-	O
+CoV	O
+)	O
+replication	O
+in	O
+a	O
+human	B-SPEC
+in	O
+-	O
+vitro	O
+and	O
+ex	O
+-	O
+vivo	O
+culture	O
+model	O
+.	O
+
+As	O
+there	O
+are	O
+few	O
+readily	O
+available	O
+animal	B-SPEC
+models	O
+that	O
+accurately	O
+mimic	O
+human	B-SPEC
+disease	O
+,	O
+it	O
+has	O
+been	O
+a	O
+challenge	O
+to	O
+ethically	O
+determine	O
+what	O
+optimum	O
+treatment	O
+strategies	O
+can	O
+be	O
+used	O
+for	O
+this	O
+disease	O
+.	O
+
+We	O
+used	O
+in	O
+-	O
+vitro	O
+and	O
+human	B-SPEC
+ex	O
+-	O
+vivo	O
+explant	O
+cultures	O
+to	O
+investigate	O
+the	O
+effect	O
+of	O
+two	O
+immunomodulatory	O
+agents	O
+,	O
+interferon	B-PRGE
+alpha	I-PRGE
+and	O
+cyclosporine	B-CHED
+,	O
+singly	O
+and	O
+in	O
+combination	O
+,	O
+on	O
+MERS	O
+-	O
+CoV	O
+replication	O
+.	O
+
+The	O
+ferret	B-SPEC
+had	O
+a	O
+2	O
+-	O
+wk	O
+history	O
+of	O
+inappetence	O
+,	O
+weight	O
+loss	O
+,	O
+and	O
+lethargy	B-DISO
+.	O
+
+Fine	O
+-	O
+needle	O
+aspirates	B-ANAT
+of	O
+the	O
+mass	O
+were	O
+nondiagnostic	O
+.	O
+
+Histopathology	O
+of	O
+mesenteric	B-ANAT
+,	O
+lymphatic	B-ANAT
+,	O
+and	O
+pancreatic	B-ANAT
+biopsies	O
+revealed	O
+suppurative	B-DISO
+pancreatitis	I-DISO
+and	O
+necrotizing	O
+and	O
+pyogranulomatous	O
+mesenteric	B-ANAT
+steatitis	B-DISO
+.	O
+
+ABSTRACT	O
+:	O
+Feline	B-DISO
+infectious	I-DISO
+peritonitis	I-DISO
+(	O
+FIP	B-DISO
+)	O
+is	O
+a	O
+common	O
+and	O
+highly	O
+lethal	O
+coronavirus	B-SPEC
+disease	O
+of	O
+domestic	B-SPEC
+cats	I-SPEC
+.	O
+
+These	O
+analogs	O
+act	O
+as	O
+an	O
+alternative	O
+substrate	O
+and	O
+RNA	O
+-	O
+chain	O
+terminator	O
+of	O
+viral	B-PRGE
+RNA	I-PRGE
+dependent	I-PRGE
+RNA	I-PRGE
+polymerase	I-PRGE
+.	O
+
+Digital	B-ANAT
+weights	O
+were	O
+collected	O
+at	O
+enrollment	O
+and	O
+d	O
+56	O
+,	O
+and	O
+hipometer	O
+weights	O
+were	O
+collected	O
+at	O
+enrollment	O
+and	O
+d	O
+7	O
+and	O
+56	O
+.	O
+
+Total	O
+health	O
+score	O
+,	O
+diarrhea	B-DISO
+days	O
+,	O
+average	O
+respiratory	O
+score	O
+,	O
+packed	O
+cell	B-COMP
+volume	O
+,	O
+and	O
+serum	B-COMP
+total	O
+protein	B-CHED
+were	O
+not	O
+affected	O
+by	O
+feeding	O
+anti	B-PRGE
+-	I-PRGE
+IL	I-PRGE
+-	I-PRGE
+10	I-PRGE
+egg	B-ANAT
+antibodies	B-COMP
+.	O
+
+Seroconversion	O
+and	O
+titer	O
+changes	O
+were	O
+validated	O
+by	O
+hemagglutination	B-PROC
+inhibition	B-PROC
+tests	O
+and	O
+neutralization	O
+tests	O
+.	O
+
+The	O
+questionnaire	O
+was	O
+administered	O
+online	O
+through	O
+Survey	O
+Monkey	B-SPEC
+The	O
+study	O
+participants	O
+showed	O
+mean	O
+knowledge	O
+score	O
+of	O
+12	O
+.	O
+26	O
+±	O
+2	O
+.	O
+27	O
+(	O
+based	O
+on	O
+17	O
+knowledge	O
+questions	O
+)	O
+and	O
+attitude	O
+score	O
+of	O
+8	O
+.	O
+63	O
+±	O
+1	O
+.	O
+68	O
+(	O
+based	O
+on	O
+10	O
+attitude	O
+questions	O
+).	O
+
+We	O
+demonstrated	O
+that	O
+PFD	B-DISO
+remarkably	O
+ameliorated	O
+LPS	B-DISO
+-	O
+induced	O
+pulmonary	B-DISO
+inflammation	I-DISO
+and	O
+fibrosis	B-DISO
+and	O
+reduced	O
+IL	O
+-	O
+1β	O
+and	O
+TGF	O
+-	O
+β1	O
+levels	O
+in	O
+bronchoalveolar	B-ANAT
+lavage	I-ANAT
+fluid	I-ANAT
+(	O
+BALF	O
+).	O
+
+ABSTRACT	O
+:	O
+Human	B-SPEC
+coronavirus	I-SPEC
+229E	I-SPEC
+(	O
+HCoV	B-SPEC
+-	I-SPEC
+229E	I-SPEC
+)	O
+is	O
+responsible	O
+for	O
+common	B-DISO
+colds	I-DISO
+.	O
+
+Unlike	O
+in	O
+other	O
+coronaviruses	O
+,	O
+HCoV	B-SPEC
+-	I-SPEC
+229E	I-SPEC
+fusion	O
+activation	O
+appears	O
+to	O
+be	O
+a	O
+one	O
+-	O
+step	O
+process	O
+.	O
+
+TITLE	O
+:	O
+Co	O
+-	O
+Occurrence	O
+of	O
+Post	O
+-	O
+Intensive	O
+Care	O
+Syndrome	B-DISO
+Problems	O
+Among	O
+406	O
+Survivors	O
+of	O
+Critical	B-DISO
+Illness	I-DISO
+.	O
+
+ABSTRACT	O
+:	O
+To	O
+describe	O
+the	O
+frequency	O
+of	O
+co	O
+-	O
+occurring	O
+newly	O
+acquired	O
+cognitive	B-DISO
+impairment	I-DISO
+,	O
+disability	O
+in	O
+activities	O
+of	O
+daily	O
+livings	O
+,	O
+and	O
+depression	B-DISO
+among	O
+survivors	O
+of	O
+a	O
+critical	B-DISO
+illness	I-DISO
+and	O
+to	O
+evaluate	O
+predictors	O
+of	O
+being	O
+free	O
+of	O
+post	O
+-	O
+intensive	O
+care	O
+syndrome	B-DISO
+problems	O
+.	O
+
+Patients	O
+with	O
+respiratory	B-DISO
+failure	I-DISO
+or	O
+shock	O
+,	O
+excluding	O
+those	O
+with	O
+preexisting	O
+cognitive	B-DISO
+impairment	I-DISO
+or	O
+disability	O
+in	O
+activities	O
+of	O
+daily	O
+livings	O
+.	O
+
+Post	O
+-	O
+intensive	O
+care	O
+syndrome	B-DISO
+problems	O
+in	O
+all	O
+three	O
+domains	O
+were	O
+present	O
+in	O
+only	O
+6	O
+%	O
+at	O
+3	O
+months	O
+and	O
+4	O
+%	O
+at	O
+12	O
+months	O
+.	O
+
+TITLE	O
+:	O
+Versatile	O
+Electrochemiluminescence	O
+Assays	O
+for	O
+PEDV	B-SPEC
+Antibody	B-COMP
+Based	O
+on	O
+Rolling	O
+Circle	O
+Amplification	B-DISO
+and	O
+Ru	O
+-	O
+DNA	O
+Nanotags	O
+.	O
+
+ABSTRACT	O
+:	O
+Extracorporeal	O
+life	O
+support	O
+(	O
+ECLS	O
+)	O
+is	O
+a	O
+mainstay	O
+of	O
+current	O
+practice	O
+in	O
+severe	O
+respiratory	O
+,	O
+circulatory	B-PROC
+or	O
+cardiac	B-DISO
+failure	I-DISO
+refractory	O
+to	O
+conventional	O
+management	O
+.	O
+
+The	O
+inherent	O
+complexity	O
+of	O
+different	O
+ECLS	O
+modes	O
+and	O
+their	O
+influence	O
+on	O
+the	O
+native	O
+pulmonary	B-ANAT
+and	O
+cardiovascular	B-ANAT
+system	I-ANAT
+require	O
+patient	O
+-	O
+specific	O
+tailoring	O
+to	O
+optimize	O
+outcome	O
+.	O
+
+ABSTRACT	O
+:	O
+Acetylcholine	B-PRGE
+receptor	I-PRGE
+antagonists	B-CHED
+have	O
+been	O
+shown	O
+to	O
+improve	O
+outcome	O
+in	O
+patients	O
+with	O
+severe	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+.	O
+
+While	O
+many	O
+coronaviruses	O
+(	O
+CoVs	O
+)	O
+encode	O
+two	O
+viroporins	O
+,	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+CoV	O
+(	O
+SARS	B-DISO
+-	O
+CoV	O
+)	O
+encodes	O
+three	O
+:	O
+proteins	B-CHED
+3a	O
+,	O
+E	O
+,	O
+and	O
+8a	O
+.	O
+
+Our	O
+results	O
+showed	O
+that	O
+the	O
+full	B-PRGE
+-	I-PRGE
+length	I-PRGE
+E	I-PRGE
+and	I-PRGE
+3a	I-PRGE
+proteins	I-PRGE
+were	O
+required	O
+for	O
+maximal	O
+SARS	B-DISO
+-	O
+CoV	O
+replication	O
+and	O
+virulence	B-PROC
+,	O
+whereas	O
+viroporin	O
+8a	O
+had	O
+only	O
+a	O
+minor	O
+impact	O
+on	O
+these	O
+activities	O
+.	O
+
+ABSTRACT	O
+:	O
+Four	O
+types	O
+of	O
+porcine	O
+epidemic	O
+diarrhea	O
+virus	O
+(	O
+PEDV	B-SPEC
+)	O
+variants	O
+with	O
+a	O
+large	O
+deletion	O
+in	O
+the	O
+spike	O
+protein	B-CHED
+were	O
+detected	O
+,	O
+together	O
+with	O
+the	O
+original	O
+US	O
+PEDV	B-SPEC
+,	O
+from	O
+pig	B-SPEC
+fecal	B-ANAT
+and	O
+oral	B-ANAT
+fluid	O
+samples	O
+collected	O
+during	O
+2016	O
+-	O
+2017	O
+in	O
+the	O
+US	O
+.	O
+
+This	O
+is	O
+the	O
+first	O
+report	O
+on	O
+coinfection	B-DISO
+of	O
+S1	B-PRGE
+NTD	I-PRGE
+-	I-PRGE
+del	I-PRGE
+PEDV	I-PRGE
+variants	I-PRGE
+and	O
+the	O
+original	O
+US	O
+PEDV	B-SPEC
+strain	O
+in	O
+US	O
+pigs	B-SPEC
+,	O
+indicating	O
+that	O
+PEDV	B-SPEC
+continues	O
+to	O
+evolve	O
+in	O
+pigs	B-SPEC
+and	O
+might	O
+be	O
+responsible	O
+for	O
+disease	O
+pattern	O
+changes	O
+.	O
+
+In	O
+an	O
+international	O
+clinical	O
+trial	O
+,	O
+we	O
+randomly	O
+assigned	O
+patients	O
+with	O
+very	O
+severe	O
+ARDS	B-DISO
+,	O
+as	O
+indicated	O
+by	O
+one	O
+of	O
+three	O
+criteria	O
+-	O
+a	O
+ratio	O
+of	O
+partial	O
+pressure	O
+of	O
+arterial	B-ANAT
+oxygen	B-CHED
+(	O
+Pao	B-PROC
+At	O
+60	O
+days	O
+,	O
+44	O
+of	O
+124	O
+patients	O
+(	O
+35	O
+%)	O
+in	O
+the	O
+ECMO	O
+group	O
+and	O
+57	O
+of	O
+125	O
+(	O
+46	O
+%)	O
+in	O
+the	O
+control	O
+group	O
+had	O
+died	B-PROC
+(	O
+relative	O
+risk	O
+,	O
+0	O
+.	O
+76	O
+;	O
+95	O
+%	O
+confidence	O
+interval	O
+[	O
+CI	O
+],	O
+0	O
+.	O
+55	O
+to	O
+1	O
+.	O
+04	O
+;	O
+P	O
+=	O
+0	O
+.	O
+09	O
+).	O
+
+Crossover	O
+to	O
+ECMO	O
+occurred	O
+a	O
+mean	O
+(±	O
+SD	O
+)	O
+of	O
+6	O
+.	O
+5	O
+±	O
+9	O
+.	O
+7	O
+days	O
+after	O
+randomization	O
+in	O
+35	O
+patients	O
+(	O
+28	O
+%)	O
+in	O
+the	O
+control	O
+group	O
+,	O
+with	O
+20	O
+of	O
+these	O
+patients	O
+(	O
+57	O
+%)	O
+dying	B-PROC
+.	O
+
+The	O
+frequency	O
+of	O
+complications	O
+did	O
+not	O
+differ	O
+significantly	O
+between	O
+groups	O
+,	O
+except	O
+that	O
+there	O
+were	O
+more	O
+bleeding	B-DISO
+events	O
+leading	O
+to	O
+transfusion	O
+in	O
+the	O
+ECMO	O
+group	O
+than	O
+in	O
+the	O
+control	O
+group	O
+(	O
+in	O
+46	O
+%	O
+vs	O
+.	O
+28	O
+%	O
+of	O
+patients	O
+;	O
+absolute	O
+risk	O
+difference	O
+,	O
+18	O
+percentage	O
+points	O
+;	O
+95	O
+%	O
+CI	O
+,	O
+6	O
+to	O
+30	O
+)	O
+as	O
+well	O
+as	O
+more	O
+cases	O
+of	O
+severe	O
+thrombocytopenia	O
+(	O
+in	O
+27	O
+%	O
+vs	O
+.	O
+16	O
+%;	O
+absolute	O
+risk	O
+difference	O
+,	O
+11	O
+percentage	O
+points	O
+;	O
+95	O
+%	O
+CI	O
+,	O
+0	O
+to	O
+21	O
+)	O
+and	O
+fewer	O
+cases	O
+of	O
+ischemic	B-DISO
+stroke	I-DISO
+(	O
+in	O
+no	O
+patients	O
+vs	O
+.	O
+5	O
+%;	O
+absolute	O
+risk	O
+difference	O
+,	O
+-	O
+5	O
+percentage	O
+points	O
+;	O
+95	O
+%	O
+CI	O
+,	O
+-	O
+10	O
+to	O
+-	O
+2	O
+).	O
+
+Additionally	O
+,	O
+cyclopropylquinoline	O
+derivative	O
+IV	O
+has	O
+shown	O
+strong	O
+growth	B-PROC
+inhibitory	O
+activity	O
+towards	O
+three	O
+major	O
+cancers	B-DISO
+(	O
+colon	B-ANAT
+,	O
+breast	B-ANAT
+,	O
+and	O
+leukemia	B-DISO
+)	O
+cell	B-ANAT
+lines	I-ANAT
+and	O
+moderate	O
+growth	B-PROC
+inhibition	B-PROC
+shown	O
+towards	O
+other	O
+cancer	B-ANAT
+cell	B-COMP
+lines	O
+screened	O
+.	O
+
+Compounds	O
+V	O
+and	O
+VI	O
+were	O
+demonstrated	O
+viral	O
+inhibition	B-PROC
+towards	O
+Human	B-SPEC
+cytomegalovirus	I-SPEC
+,	O
+whereas	O
+cyclopropylquinoline	O
+derivative	O
+IV	O
+towards	O
+Rift	B-SPEC
+Valley	I-SPEC
+fever	I-SPEC
+virus	I-SPEC
+and	O
+Tacaribe	B-SPEC
+virus	I-SPEC
+.	O
+
+We	O
+show	O
+that	O
+selected	O
+human	B-SPEC
+genes	O
+were	O
+enriched	O
+for	O
+HIV	B-DISO
+susceptibility	O
+variants	O
+(	O
+identified	O
+through	O
+GWAS	O
+),	O
+providing	O
+further	O
+support	O
+for	O
+the	O
+hypothesis	O
+that	O
+ancient	O
+humans	B-SPEC
+were	O
+exposed	O
+to	O
+lentivirus	B-SPEC
+pandemics	O
+.	O
+
+Compared	O
+with	O
+a	O
+low	O
+qSOFA	O
+score	O
+,	O
+a	O
+moderate	O
+qSOFA	O
+score	O
+was	O
+also	O
+associated	O
+with	O
+increased	O
+risk	O
+of	O
+death	B-PROC
+overall	O
+(	O
+8	O
+%	O
+vs	O
+3	O
+%;	O
+difference	O
+,	O
+5	O
+%	O
+[	O
+95	O
+%	O
+CI	O
+,	O
+4	O
+%-	O
+6	O
+%];	O
+odds	O
+ratio	O
+,	O
+2	O
+.	O
+8	O
+[	O
+95	O
+%	O
+CI	O
+,	O
+2	O
+.	O
+0	O
+-	O
+3	O
+.	O
+9	O
+]),	O
+but	O
+not	O
+in	O
+every	O
+cohort	O
+(	O
+P	O
+<	O
+.	O
+05	O
+in	O
+2	O
+of	O
+7	O
+cohorts	O
+).	O
+
+The	O
+results	O
+demonstrated	O
+that	O
+PEDV	B-SPEC
+infection	B-DISO
+induces	O
+cell	B-PROC
+cycle	I-PROC
+arrest	I-PROC
+at	O
+G0	O
+/	O
+G1	B-PROC
+phase	I-PROC
+in	O
+Vero	B-ANAT
+cells	I-ANAT
+,	O
+while	O
+UV	O
+-	O
+inactivated	O
+PEDV	B-SPEC
+does	O
+not	O
+cause	O
+cell	B-PROC
+cycle	I-PROC
+arrest	I-PROC
+.	O
+
+This	O
+is	O
+the	O
+first	O
+report	O
+to	O
+demonstrate	O
+that	O
+the	O
+p53	B-PRGE
+-	O
+dependent	O
+pathway	B-PROC
+plays	O
+an	O
+important	O
+role	O
+in	O
+PEDV	B-SPEC
+induced	O
+cell	B-PROC
+cycle	I-PROC
+arrest	I-PROC
+and	O
+beneficially	O
+contributes	O
+to	O
+viral	B-DISO
+infection	I-DISO
+.	O
+
+TITLE	O
+:	O
+Metagenomic	O
+analysis	O
+of	O
+the	O
+RNA	O
+fraction	O
+of	O
+the	O
+fecal	B-ANAT
+virome	O
+indicates	O
+high	O
+diversity	O
+in	O
+pigs	B-SPEC
+infected	O
+by	O
+porcine	B-SPEC
+endemic	O
+diarrhea	B-DISO
+virus	B-SPEC
+in	O
+the	O
+United	O
+States	O
+.	O
+
+The	O
+objective	O
+of	O
+this	O
+study	O
+was	O
+to	O
+characterize	O
+the	O
+RNA	O
+virome	O
+in	O
+PEDV	B-SPEC
+-	O
+positive	O
+pigs	B-SPEC
+using	O
+the	O
+hypothesis	O
+-	O
+free	O
+metagenomics	O
+approach	O
+based	O
+on	O
+next	O
+-	O
+generation	O
+sequencing	O
+.	O
+
+An	O
+independent	O
+laboratory	O
+also	O
+tested	O
+direct	O
+skin	B-DISO
+irritation	I-DISO
+.	O
+
+RESULTS	O
+:	O
+Chlorine	B-CHED
+disinfectants	B-CHED
+with	O
+and	O
+without	O
+color	O
+additive	O
+achieved	O
+equal	O
+levels	O
+of	O
+efficacy	O
+against	O
+the	O
+tested	O
+pathogens	O
+.	O
+
+Against	O
+human	B-SPEC
+coronavirus	I-SPEC
+229E	I-SPEC
+,	O
+0	O
+.	O
+5	O
+%	O
+sodium	O
+hypochlorite	B-CHED
+alone	O
+failed	O
+disinfection	O
+success	O
+criteria	O
+,	O
+whereas	O
+0	O
+.	O
+5	O
+%	O
+sodium	O
+hypochlorite	B-CHED
+with	O
+color	O
+additive	O
+achieved	O
+full	O
+viral	O
+inactivation	B-DISO
+(≥	O
+4	O
+.	O
+50	O
+log	O
+
+ABSTRACT	O
+:	O
+Structural	O
+studies	O
+related	O
+to	O
+Middle	O
+East	O
+Respiratory	O
+Syndrome	O
+Coronavirus	B-SPEC
+(	O
+MERS	O
+CoV	O
+)	O
+infection	B-DISO
+process	O
+are	O
+so	O
+limited	O
+.	O
+
+The	O
+developed	O
+RtF	B-PRGE
+-	I-PRGE
+RT	I-PRGE
+-	I-PRGE
+LAMP	I-PRGE
+assay	O
+in	O
+our	O
+study	O
+could	O
+support	O
+the	O
+design	O
+and	O
+implementation	O
+of	O
+large	O
+-	O
+scaled	O
+epidemiological	O
+surveys	O
+as	O
+well	O
+as	O
+active	O
+surveillance	O
+and	O
+monitoring	O
+programs	O
+for	O
+effective	O
+control	O
+of	O
+PED	B-PRGE
+.	O
+
+Mathematical	O
+modeling	O
+of	O
+Middle	O
+East	O
+respiratory	O
+syndrome	B-DISO
+coronavirus	B-SPEC
+camel	B-SPEC
+-	O
+to	O
+-	O
+camel	B-SPEC
+transmission	O
+was	O
+lacking	O
+.	O
+
+Using	O
+the	O
+plug	O
+-	O
+and	O
+-	O
+play	O
+likelihood	O
+-	O
+based	O
+inference	O
+framework	O
+,	O
+we	O
+fitted	B-DISO
+a	O
+susceptible	O
+-	O
+exposed	O
+-	O
+infectious	B-DISO
+-	O
+recovered	O
+-	O
+susceptible	O
+model	O
+of	O
+camels	B-SPEC
+to	O
+the	O
+reported	O
+human	B-SPEC
+cases	O
+with	O
+a	O
+constant	O
+proportion	O
+of	O
+human	B-SPEC
+cases	O
+from	O
+camels	B-SPEC
+(	O
+i	O
+.	O
+e	O
+.,	O
+either	O
+25	O
+%	O
+or	O
+12	O
+%).	O
+
+We	O
+collected	O
+107	O
+faecal	B-ANAT
+samples	O
+from	O
+domestic	O
+dogs	B-SPEC
+with	O
+obvious	O
+diarrhoea	B-DISO
+.	O
+
+We	O
+analyzed	O
+the	O
+development	B-PROC
+and	O
+publication	O
+processes	O
+and	O
+evaluated	O
+the	O
+quality	O
+of	O
+emergency	O
+guidelines	O
+using	O
+AGREE	O
+-	O
+II	O
+.	O
+
+ABSTRACT	O
+:	O
+Early	O
+antibiotic	B-CHED
+administration	O
+is	O
+critical	O
+in	O
+cases	O
+of	O
+sepsis	O
+and	O
+severe	O
+community	O
+-	O
+acquired	O
+pneumonia	B-DISO
+,	O
+which	O
+is	O
+frequently	O
+due	O
+to	O
+
+TITLE	O
+:	O
+Treatment	O
+of	O
+spontaneous	O
+esophageal	O
+rupture	O
+(	O
+Boerhaave	B-DISO
+syndrome	I-DISO
+)	O
+using	O
+thoracoscopic	O
+surgery	O
+and	O
+sivelestat	O
+sodium	O
+hydrate	O
+.	O
+
+The	O
+lower	O
+left	O
+esophageal	B-ANAT
+wall	I-ANAT
+was	O
+perforated	O
+in	O
+all	O
+patients	O
+.	O
+
+TITLE	O
+:	O
+Working	O
+experiences	O
+of	O
+nurses	O
+during	O
+the	O
+Middle	O
+East	O
+respiratory	O
+syndrome	B-DISO
+outbreak	O
+.	O
+
+ABSTRACT	O
+:	O
+We	O
+report	O
+four	O
+full	O
+-	O
+genome	O
+sequences	O
+of	O
+bovine	O
+coronavirus	B-SPEC
+(	O
+BCoV	O
+)	O
+isolates	O
+from	O
+dairy	O
+calves	O
+in	O
+Pennsylvania	O
+obtained	O
+in	O
+2016	O
+and	O
+2017	O
+.	O
+
+Of	O
+the	O
+1379	O
+MERS	O
+cases	O
+recorded	O
+during	O
+the	O
+study	O
+period	O
+,	O
+321	O
+(	O
+23	O
+.	O
+3	O
+%)	O
+cases	O
+were	O
+linked	O
+to	O
+hospital	B-DISO
+infection	I-DISO
+,	O
+out	O
+of	O
+which	O
+203	O
+(	O
+14	O
+.	O
+7	O
+%)	O
+cases	O
+occurred	O
+among	O
+healthcare	O
+workers	O
+.	O
+
+ABSTRACT	O
+:	O
+Middle	O
+East	O
+respiratory	O
+syndrome	B-DISO
+coronavirus	B-SPEC
+,	O
+MERS	O
+-	O
+CoV	O
+,	O
+was	O
+identified	O
+in	O
+Saudi	O
+Arabia	O
+in	O
+2012	O
+,	O
+and	O
+as	O
+of	O
+January	O
+29	O
+,	O
+2018	O
+,	O
+there	O
+were	O
+2	O
+,	O
+123	O
+laboratory	O
+-	O
+confirmed	O
+MERS	O
+-	O
+CoV	O
+cases	O
+reported	O
+to	O
+WHO	O
+(	O
+WHO	O
+,	O
+2018	O
+,	O
+https	O
+://	O
+www	O
+.	O
+who	O
+.	O
+int	O
+/	O
+emergencies	B-DISO
+/	O
+mers	O
+-	O
+cov	O
+/	O
+en	O
+/).	O
+
+The	O
+high	O
+rate	O
+of	O
+MERS	O
+-	O
+CoV	O
+-	O
+specific	O
+antibody	B-COMP
+seropositivity	O
+in	O
+dromedary	B-SPEC
+camels	B-SPEC
+in	O
+the	O
+absence	O
+of	O
+any	O
+reported	O
+human	B-SPEC
+MERS	O
+cases	O
+suggests	O
+that	O
+there	O
+is	O
+still	O
+much	O
+to	O
+be	O
+learned	B-PROC
+about	O
+the	O
+dynamics	O
+of	O
+camel	B-SPEC
+-	O
+to	O
+-	O
+human	B-SPEC
+transmission	O
+of	O
+MERS	O
+-	O
+CoV	O
+.	O
+
+Interestingly	O
+,	O
+in	O
+parallel	O
+silvestrol	B-CHED
+affects	O
+the	O
+activity	O
+of	O
+the	O
+antiviral	B-CHED
+major	O
+vault	O
+protein	B-CHED
+(	O
+MVP	B-DISO
+)	O
+by	O
+translocation	B-DISO
+from	O
+the	O
+cytoplasm	B-COMP
+to	O
+the	O
+perinuclear	B-COMP
+membrane	I-COMP
+.	O
+
+We	O
+present	O
+here	O
+the	O
+case	O
+of	O
+a	O
+five	O
+-	O
+year	O
+-	O
+old	O
+girl	O
+,	O
+known	O
+to	O
+have	O
+thoracolumbar	O
+myelomeningocele	B-DISO
+(	O
+for	O
+which	O
+she	O
+underwent	O
+a	O
+surgical	O
+procedure	O
+in	O
+infancy	O
+),	O
+secondary	O
+hydrocephalus	B-DISO
+(	O
+with	O
+a	O
+ventriculoperitoneal	O
+shunt	O
+)	O
+and	O
+flaccid	B-DISO
+paralysis	I-DISO
+,	O
+who	O
+was	O
+admitted	O
+in	O
+our	O
+hospital	O
+with	O
+prolonged	O
+fever	B-PROC
+syndrome	B-DISO
+,	O
+productive	B-DISO
+cough	I-DISO
+,	O
+severe	O
+dyspnea	B-DISO
+and	O
+perioral	O
+cyanosis	B-DISO
+.	O
+
+After	O
+excluding	O
+the	O
+causes	O
+of	O
+obstructive	O
+apnea	B-DISO
+,	O
+a	O
+cerebral	B-ANAT
+CT	O
+scan	O
+was	O
+performed	O
+,	O
+revealing	O
+isolated	O
+fourth	B-ANAT
+ventricle	I-ANAT
+compressing	O
+the	O
+brainstem	B-ANAT
+.	O
+
+TITLE	O
+:	O
+Could	O
+Heme	B-ENZY
+Oxygenase	B-PROC
+-	O
+1	O
+Be	O
+a	O
+New	O
+Target	O
+for	O
+Therapeutic	O
+Intervention	O
+in	O
+Malaria	B-PATH
+-	O
+Associated	O
+Acute	O
+Lung	O
+Injury	O
+/	O
+Acute	B-DISO
+Respiratory	I-DISO
+Distress	I-DISO
+Syndrome	I-DISO
+?	O
+
+Rodent	B-SPEC
+models	O
+of	O
+ALI	O
+/	O
+ARDS	B-DISO
+show	O
+similar	O
+clinical	O
+signs	O
+as	O
+in	O
+humans	B-SPEC
+when	O
+the	O
+rodents	B-SPEC
+are	O
+infected	O
+with	O
+murine	B-SPEC
+
+With	O
+a	O
+rapid	O
+increase	O
+in	O
+the	O
+number	O
+of	O
+VNP	O
+variants	O
+and	O
+their	O
+potential	O
+applications	O
+in	O
+nanomedicine	O
+,	O
+the	O
+properties	O
+they	O
+acquire	O
+in	O
+the	O
+bloodstream	B-PROC
+need	O
+to	O
+be	O
+investigated	O
+.	O
+
+We	O
+outline	O
+procedures	O
+for	O
+in	O
+vivo	O
+screening	O
+of	O
+VNP	O
+fates	O
+in	O
+a	O
+mouse	B-SPEC
+model	O
+,	O
+which	O
+may	O
+be	O
+useful	O
+for	O
+evaluation	O
+of	O
+efficacy	O
+and	O
+biocompatibility	O
+of	O
+different	O
+VNP	O
+based	O
+formulations	O
+.	O
+
+Risk	O
+-	O
+management	O
+strategies	O
+to	O
+reduce	O
+transmission	O
+to	O
+people	O
+and	O
+other	O
+animals	B-SPEC
+should	O
+focus	O
+on	O
+sanitation	O
+,	O
+housing	O
+,	O
+compliance	O
+with	O
+preventive	O
+care	O
+guidelines	O
+,	O
+periodic	O
+surveillance	O
+,	O
+response	O
+to	O
+specific	O
+enteropathogens	O
+,	O
+humane	O
+population	O
+management	O
+of	O
+free	O
+-	O
+roaming	O
+community	O
+cats	B-SPEC
+,	O
+public	O
+health	O
+education	O
+,	O
+and	O
+minimizing	O
+the	O
+duration	O
+and	O
+number	O
+of	O
+cats	B-SPEC
+in	O
+mass	O
+confinement	O
+.	O
+
+These	O
+activated	O
+macrophages	B-ANAT
+ingested	O
+antigen	B-CHED
+and	O
+migrated	O
+to	O
+pulmonary	B-ANAT
+lymph	I-ANAT
+nodes	I-ANAT
+,	O
+and	O
+enhanced	O
+both	O
+innate	O
+and	O
+adaptive	O
+immunity	B-PROC
+after	O
+heterologous	O
+virus	B-DISO
+infection	I-DISO
+.	O
+
+TITLE	O
+:	O
+Metagenomics	O
+detection	O
+and	O
+characterisation	O
+of	O
+viruses	B-SPEC
+in	O
+faecal	B-ANAT
+samples	O
+from	O
+Australian	O
+wild	O
+birds	O
+.	O
+
+ABSTRACT	O
+:	O
+We	O
+present	O
+an	O
+optimised	O
+metagenomics	O
+method	O
+for	O
+detection	O
+and	O
+characterisation	O
+of	O
+all	O
+virus	B-SPEC
+types	O
+including	O
+single	O
+and	O
+double	O
+stranded	O
+DNA	O
+/	O
+RNA	O
+and	O
+enveloped	O
+and	O
+non	O
+-	O
+enveloped	O
+viruses	B-SPEC
+.	O
+
+From	O
+the	O
+non	O
+-	O
+spiked	O
+bird	B-SPEC
+samples	O
+(	O
+Australian	O
+Muscovy	B-SPEC
+duck	I-SPEC
+and	O
+Pacific	B-SPEC
+black	I-SPEC
+ducks	I-SPEC
+)	O
+we	O
+detected	O
+21	O
+viruses	B-SPEC
+,	O
+and	O
+we	O
+also	O
+present	O
+a	O
+summary	O
+of	O
+a	O
+few	O
+viruses	B-SPEC
+detected	O
+in	O
+human	B-SPEC
+faecal	B-ANAT
+samples	O
+.	O
+
+We	O
+then	O
+present	O
+a	O
+detailed	O
+analysis	O
+of	O
+selected	O
+virus	B-SPEC
+sequences	O
+in	O
+the	O
+avian	B-SPEC
+samples	O
+that	O
+were	O
+somewhat	O
+similar	O
+to	O
+known	O
+viruses	B-SPEC
+,	O
+and	O
+had	O
+good	O
+quality	O
+(	O
+Q20	O
+or	O
+higher	O
+)	O
+and	O
+quantity	O
+of	O
+next	O
+-	O
+generation	O
+sequencing	O
+reads	O
+,	O
+and	O
+was	O
+of	O
+interest	O
+from	O
+a	O
+virological	O
+point	O
+of	O
+view	O
+,	O
+for	O
+example	O
+,	O
+avian	B-SPEC
+coronavirus	I-SPEC
+and	O
+avian	B-PRGE
+paramyxovirus	I-PRGE
+6	I-PRGE
+.	O
+
+Besides	O
+detecting	O
+viruses	B-SPEC
+,	O
+the	O
+technique	O
+also	O
+allowed	O
+the	O
+characterisation	O
+of	O
+host	B-COMP
+mitochondrial	B-COMP
+DNA	I-COMP
+present	O
+and	O
+thus	O
+identifying	O
+host	B-COMP
+species	B-SPEC
+,	O
+while	O
+ribosomal	B-COMP
+RNA	I-COMP
+sequences	O
+provided	O
+insight	O
+into	O
+the	O
+""""	O
+ribosomal	B-COMP
+activity	O
+microbiome	O
+""";"	O
+of	O
+gut	B-ANAT
+parasites	O
+;	O
+and	O
+of	O
+food	O
+eaten	O
+such	O
+as	O
+plants	B-SPEC
+or	O
+insects	B-SPEC
+,	O
+which	O
+we	O
+correlated	O
+to	O
+non	O
+-	O
+avian	B-SPEC
+host	B-COMP
+associated	O
+viruses	B-SPEC
+.	O
+
+This	O
+is	O
+the	O
+first	O
+report	O
+of	O
+bovine	B-SPEC
+norovirus	B-SPEC
+infection	B-DISO
+in	O
+Australian	O
+cattle	B-SPEC
+and	O
+suggests	O
+that	O
+future	O
+work	O
+is	O
+required	O
+to	O
+determine	O
+the	O
+significance	O
+of	O
+these	O
+agents	O
+as	O
+a	O
+cause	O
+of	O
+bovine	B-SPEC
+enteric	O
+disease	O
+in	O
+Australia	O
+.	O
+
+To	O
+detect	O
+the	O
+geographic	O
+origin	O
+and	O
+timing	O
+of	O
+USA	O
+porcine	B-SPEC
+epidemic	I-SPEC
+diarrhea	I-SPEC
+virus	I-SPEC
+(	O
+PEDV	B-SPEC
+)	O
+isolates	O
+,	O
+we	O
+conducted	O
+a	O
+retrospective	O
+study	O
+to	O
+isolate	O
+19	O
+PEDV	B-SPEC
+strains	O
+from	O
+positive	O
+samples	O
+obtained	O
+prior	O
+to	O
+April	O
+2013	O
+.	O
+
+TITLE	O
+:	O
+Management	O
+and	O
+outcomes	O
+of	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+patients	O
+with	O
+and	O
+without	O
+comorbid	O
+conditions	O
+.	O
+
+TITLE	O
+:	O
+Acute	O
+Kidney	B-ANAT
+Injury	O
+in	O
+Children	O
+With	O
+Acute	B-DISO
+Respiratory	I-DISO
+Failure	I-DISO
+.	O
+
+ABSTRACT	O
+:	O
+Acute	O
+kidney	B-ANAT
+injury	O
+(	O
+AKI	O
+)	O
+is	O
+common	O
+in	O
+critically	O
+ill	O
+children	O
+and	O
+develops	O
+in	O
+association	O
+with	O
+organ	B-ANAT
+system	I-ANAT
+dysfunction	O
+,	O
+with	O
+acute	B-DISO
+respiratory	I-DISO
+failure	I-DISO
+(	O
+ARF	B-DISO
+)	O
+one	O
+of	O
+the	O
+most	O
+common	O
+.	O
+
+Among	O
+patients	O
+with	O
+moderate	O
+and	O
+severe	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+(	O
+ARDS	B-DISO
+),	O
+64	O
+%	O
+had	O
+AKI	O
+versus	O
+46	O
+%	O
+with	O
+mild	O
+or	O
+no	O
+ARDS	B-DISO
+(	O
+P	O
+=	O
+.	O
+02	O
+).	O
+
+CT	O
+of	O
+the	O
+chest	B-ANAT
+during	O
+that	O
+admission	O
+revealed	O
+mild	O
+intralobular	O
+and	O
+interlobular	O
+septal	O
+thickening	O
+.	O
+
+REGN3051	O
+and	O
+REGN3048	O
+are	O
+two	O
+fully	O
+human	B-SPEC
+neutralizing	O
+monoclonal	O
+antibodies	B-COMP
+(	O
+mAb	O
+)	O
+against	O
+MERS	O
+-	O
+CoV	O
+that	O
+reduced	O
+virus	B-PROC
+replication	I-PROC
+in	O
+mice	B-SPEC
+expressing	O
+human	B-SPEC
+DPP4	B-PRGE
+upon	O
+prophylactic	O
+and	O
+therapeutic	O
+treatment	O
+.	O
+
+Inhalation	B-PROC
+injury	O
+was	O
+present	O
+in	O
+56	O
+.	O
+6	O
+%	O
+of	O
+the	O
+cases	O
+,	O
+and	O
+mouth	B-ANAT
+and	O
+nose	B-ANAT
+burn	O
+was	O
+present	O
+in	O
+30	O
+.	O
+2	O
+%.	O
+
+TITLE	O
+:	O
+Underlying	O
+trend	O
+,	O
+seasonality	O
+,	O
+prediction	O
+,	O
+forecasting	O
+and	O
+the	O
+contribution	O
+of	O
+risk	O
+factors	O
+:	O
+an	O
+analysis	O
+of	O
+globally	O
+reported	O
+cases	O
+of	O
+Middle	O
+East	O
+Respiratory	O
+Syndrome	B-DISO
+Coronavirus	B-SPEC
+.	O
+
+ABSTRACT	O
+:	O
+Coronavirus	B-SPEC
+tropism	B-PROC
+is	O
+predominantly	O
+determined	O
+by	O
+the	O
+interaction	O
+between	O
+coronavirus	B-SPEC
+spikes	O
+and	O
+the	O
+host	B-COMP
+receptors	O
+.	O
+
+Further	O
+analyses	O
+indicated	O
+that	O
+GRP78	B-PRGE
+could	O
+not	O
+independently	O
+render	O
+nonpermissive	O
+cells	B-COMP
+susceptible	O
+to	O
+MERS	O
+-	O
+CoV	O
+infection	B-DISO
+but	O
+could	O
+facilitate	O
+MERS	O
+-	O
+CoV	O
+entry	O
+into	O
+permissive	O
+cells	B-COMP
+by	O
+augmenting	O
+virus	B-SPEC
+attachment	O
+.	O
+
+These	O
+results	O
+reveal	O
+that	O
+a	O
+large	O
+panel	O
+of	O
+epithelial	O
+functions	O
+is	O
+modified	O
+upon	O
+viral	B-DISO
+infection	I-DISO
+and	O
+validate	O
+MucilAir	O
+™	O
+as	O
+a	O
+pertinent	O
+tool	O
+for	O
+pre	O
+-	O
+clinical	O
+antiviral	B-CHED
+drug	I-CHED
+testing	O
+.	O
+
+Herein	O
+,	O
+hypothesizing	O
+that	O
+ACGs	O
+from	O
+M	B-SPEC
+.	I-SPEC
+paniculata	I-SPEC
+inhibit	O
+progression	O
+of	O
+ALI	O
+,	O
+we	O
+used	O
+the	O
+experimental	O
+model	O
+of	O
+lipopolysaccharide	B-CHED
+(	O
+LPS	B-DISO
+)-	O
+induced	O
+ALI	O
+in	O
+BALB	O
+/	O
+c	O
+mice	B-SPEC
+to	O
+evaluate	O
+the	O
+therapeutic	O
+potential	O
+of	O
+purified	O
+ACGs	O
+.	O
+
+Our	O
+study	O
+shows	O
+for	O
+the	O
+first	O
+time	O
+that	O
+ACGs	O
+inhibit	O
+acute	O
+inflammation	B-DISO
+and	O
+apoptosis	B-PATH
+by	O
+suppressing	O
+activation	O
+of	O
+TLR4	B-PRGE
+/	O
+TRPC6	B-PRGE
+signaling	B-PROC
+pathway	I-PROC
+in	O
+a	O
+murine	B-SPEC
+model	O
+of	O
+ALI	O
+.	O
+
+ABSTRACT	O
+:	O
+PEDV	B-SPEC
+variants	O
+,	O
+causing	O
+severe	B-DISO
+diarrhea	I-DISO
+in	O
+neonatal	O
+suckling	O
+piglets	O
+with	O
+a	O
+mortality	O
+rate	O
+up	O
+to	O
+100	O
+%,	O
+have	O
+being	O
+epidemic	O
+since	O
+late	O
+2010	O
+in	O
+china	O
+.	O
+
+Patients	O
+with	O
+severe	O
+pneumonia	B-DISO
+in	O
+MERS	O
+-	O
+coronavirus	B-DISO
+infection	I-DISO
+had	O
+more	O
+impaired	B-DISO
+pulmonary	B-PROC
+function	I-PROC
+than	O
+those	O
+with	O
+no	O
+or	O
+mild	O
+pneumonia	B-DISO
+at	O
+the	O
+1	O
+-	O
+year	O
+follow	O
+-	O
+up	O
+,	O
+which	O
+was	O
+compatible	O
+with	O
+the	O
+radiological	O
+sequelae	O
+.	O
+
+ABSTRACT	O
+:	O
+The	O
+replicase	O
+gene	O
+of	O
+the	O
+coronavirus	B-SPEC
+infectious	B-DISO
+bronchitis	B-DISO
+virus	B-SPEC
+(	O
+IBV	B-SPEC
+)	O
+encodes	O
+15	O
+non	O
+-	O
+structural	O
+proteins	B-CHED
+(	O
+nsps	O
+).	O
+
+The	O
+plasmid	O
+was	O
+transferred	O
+into	O
+Escherichia	B-SPEC
+coli	I-SPEC
+BL21	B-ANAT
+(	O
+DE3	O
+).	O
+
+Meanwhile	O
+,	O
+recombinant	O
+protein	B-PROC
+expression	B-PROC
+was	O
+induced	O
+by	O
+isopropy1	O
+-	O
+β	O
+-	O
+galactopyranoside	O
+(	O
+IPTG	B-CHED
+).	O
+
+After	O
+denaturation	B-PROC
+and	O
+renaturation	O
+of	O
+inclusion	B-COMP
+bodies	I-COMP
+,	O
+the	O
+S1	B-PRGE
+protein	I-PRGE
+was	O
+obtained	O
+by	O
+using	O
+purified	O
+recombinant	B-PRGE
+S1	I-PRGE
+protein	I-PRGE
+in	O
+immunized	O
+female	O
+BALB	O
+/	O
+c	O
+mice	B-SPEC
+.	O
+
+ABSTRACT	O
+:	O
+Infectious	O
+bronchitis	B-DISO
+(	O
+IB	O
+)	O
+control	O
+has	O
+a	O
+strong	O
+impact	O
+on	O
+poultry	O
+farming	O
+,	O
+because	O
+of	O
+the	O
+necessary	O
+epidemiological	O
+knowledge	O
+for	O
+planning	O
+the	O
+best	O
+strategy	O
+,	O
+the	O
+optimal	O
+strain	O
+association	O
+,	O
+the	O
+priming	O
+and	O
+boosting	O
+interventions	O
+.	O
+
+Broiler	O
+farming	O
+is	O
+even	O
+more	O
+problematic	O
+given	O
+the	O
+short	O
+and	O
+intense	O
+productive	O
+cycle	O
+,	O
+which	O
+requires	O
+an	O
+early	O
+onset	O
+of	O
+protection	O
+against	O
+most	O
+of	O
+the	O
+infectious	B-DISO
+threats	O
+,	O
+possibly	O
+with	O
+limited	O
+respiratory	O
+post	O
+-	O
+vaccination	O
+reactions	O
+that	O
+would	O
+have	O
+a	O
+direct	O
+impact	O
+on	O
+the	O
+bird	B-SPEC
+health	O
+and	O
+productivity	O
+.	O
+
+1	O
+/	O
+96	O
+strain	O
+early	O
+reached	O
+high	O
+titers	O
+in	O
+all	O
+animals	B-SPEC
+,	O
+while	O
+B	O
+-	O
+48	O
+presence	O
+was	O
+less	O
+constant	O
+even	O
+though	O
+it	O
+was	O
+detected	O
+in	O
+almost	O
+all	O
+birds	B-SPEC
+before	O
+the	O
+trial	O
+end	O
+.	O
+
+This	O
+study	O
+encompassed	O
+116	O
+patients	O
+of	O
+ARDS	B-DISO
+admitted	O
+to	O
+an	O
+MICU	O
+at	O
+a	O
+tertiary	O
+care	O
+centre	O
+in	O
+Mumbai	O
+.	O
+
+We	O
+excluded	O
+patients	O
+with	O
+known	O
+ischemic	O
+heart	B-ANAT
+diseases	B-DISO
+,	I-DISO
+valvular	I-DISO
+heart	I-DISO
+diseases	O
+or	O
+in	O
+congestive	O
+cardiac	B-DISO
+failure	I-DISO
+,	O
+chronic	B-DISO
+kidney	I-DISO
+diseases	I-DISO
+with	O
+fluid	B-DISO
+overload	I-DISO
+states	O
+and	O
+age	O
+below	O
+18	O
+years	O
+.	O
+
+Sixty	O
+patients	O
+had	O
+severe	O
+LIS	B-FUNC
+,	O
+out	O
+of	O
+which	O
+45	O
+(	O
+75	O
+%)	O
+patients	O
+expired	O
+,	O
+as	O
+compared	O
+to	O
+56	O
+patients	O
+with	O
+moderate	O
+LIS	B-FUNC
+out	O
+of	O
+which	O
+22	O
+(	O
+39	O
+.	O
+3	O
+%)	O
+expired	O
+.	O
+
+Renal	B-ANAT
+failure	O
+,	O
+metabolic	B-DISO
+acidosis	I-DISO
+appeared	O
+to	O
+be	O
+good	O
+predictors	O
+of	O
+mortality	O
+.	O
+
+Accumulating	O
+evidence	O
+from	O
+referral	O
+centers	O
+suggests	O
+improved	O
+survival	O
+in	O
+patients	O
+with	O
+ARDS	B-DISO
+receiving	O
+ECMO	O
+.	O
+
+In	O
+the	O
+majority	O
+of	O
+cases	O
+,	O
+prone	O
+positioning	O
+and	O
+use	O
+of	O
+neuromuscular	B-DISO
+blockade	I-DISO
+was	O
+also	O
+used	O
+in	O
+an	O
+attempt	O
+to	O
+improve	O
+oxygenation	B-PROC
+and	O
+patient	O
+synchrony	O
+with	O
+mechanical	O
+ventilation	O
+.	O
+
+Ten	O
+of	O
+the	O
+14	O
+patients	O
+survived	O
+to	O
+decanulation	O
+from	O
+ECMO	O
+(	O
+71	O
+%)	O
+and	O
+eight	O
+of	O
+14	O
+patients	O
+(	O
+57	O
+%)	O
+survived	O
+to	O
+hospital	O
+discharge	B-ANAT
+.	O
+
+To	O
+our	O
+knowledge	O
+,	O
+this	O
+is	O
+the	O
+lowest	O
+mortality	O
+rate	O
+reported	O
+to	O
+date	O
+in	O
+burn	O
+patients	O
+with	O
+ARDS	B-DISO
+place	O
+on	O
+ECMO	O
+.	O
+
+TITLE	O
+:	O
+An	O
+Unusual	O
+Cause	O
+of	O
+Cauda	B-DISO
+Equina	I-DISO
+Syndrome	I-DISO
+:	O
+Lumbar	B-ANAT
+Epidural	B-ANAT
+Venous	B-DISO
+Engorgement	I-DISO
+.	O
+
+ABSTRACT	O
+:	O
+BACKGROUND	O
+Epidural	O
+venous	B-ANAT
+plexus	I-ANAT
+(	O
+EVP	O
+)	O
+engorgement	B-DISO
+occurs	O
+due	O
+to	O
+many	O
+conditions	O
+,	O
+so	O
+it	O
+can	O
+be	O
+easily	O
+misdiagnosed	O
+.	O
+
+CASE	O
+REPORT	O
+A	O
+42	O
+-	O
+year	O
+-	O
+old	O
+woman	O
+presented	O
+to	O
+a	O
+rural	O
+medical	O
+facility	O
+with	O
+bilateral	O
+lower	O
+-	O
+limb	B-DISO
+swelling	I-DISO
+and	O
+skin	B-ANAT
+darkening	O
+for	O
+2	O
+days	O
+.	O
+
+TITLE	O
+:	O
+Serologic	O
+Follow	O
+-	O
+up	O
+of	O
+Middle	O
+East	O
+Respiratory	O
+Syndrome	B-DISO
+Coronavirus	B-SPEC
+Cases	O
+and	O
+Contacts	O
+-	O
+Abu	B-CHED
+Dhabi	O
+,	O
+United	O
+Arab	O
+Emirates	O
+.	O
+
+Information	O
+on	O
+respiratory	O
+viruses	B-SPEC
+in	O
+non	O
+-	O
+severe	O
+CAP	B-DISO
+cases	O
+is	O
+scarce	O
+.	O
+
+ABSTRACT	O
+:	O
+This	O
+essay	O
+focuses	O
+on	O
+transmissible	O
+gastroenteritis	B-DISO
+virus	B-SPEC
+(	O
+TGEV	B-SPEC
+),	O
+which	O
+is	O
+an	O
+enteropathogenic	O
+virus	B-SPEC
+related	O
+to	O
+contagious	O
+and	O
+acute	B-DISO
+diseases	I-DISO
+in	O
+suckling	O
+piglets	O
+.	O
+
+ABSTRACT	O
+:	O
+Serotonin	B-CHED
+is	O
+a	O
+critical	O
+monoamine	B-CHED
+neurotransmitter	B-CHED
+molecule	O
+stored	O
+and	O
+released	O
+from	O
+enterochromaffin	O
+(	O
+EC	O
+)	O
+cells	B-COMP
+into	O
+the	O
+gut	B-ANAT
+submucosa	B-ANAT
+,	O
+transmitting	O
+the	O
+vomiting	B-DISO
+signal	O
+to	O
+the	O
+brain	B-ANAT
+.	O
+
+Influenza	B-SPEC
+viruses	I-SPEC
+were	O
+detected	O
+in	O
+18	O
+%	O
+of	O
+the	O
+specimens	O
+and	O
+any	O
+respiratory	O
+virus	B-SPEC
+in	O
+47	O
+%.	O
+
+TITLE	O
+:	O
+Spillover	O
+of	O
+Swine	B-SPEC
+Coronaviruses	O
+,	O
+United	O
+States	O
+.	O
+
+A	O
+better	O
+understanding	O
+of	O
+the	O
+factors	O
+associated	O
+with	O
+pathogen	O
+emergence	O
+is	O
+needed	O
+to	O
+better	O
+manage	O
+,	O
+and	O
+ultimately	O
+prevent	O
+,	O
+future	O
+spillover	O
+events	O
+from	O
+domestic	O
+to	O
+nondomestic	O
+animals	B-SPEC
+.	O
+
+ABSTRACT	O
+:	O
+Pig	B-PRGE
+diarrhea	B-DISO
+causes	O
+high	O
+mortality	O
+and	O
+large	O
+economic	O
+losses	O
+in	O
+the	O
+swine	O
+industry	O
+.	O
+
+TITLE	O
+:	O
+Establishment	O
+and	O
+characterization	O
+of	O
+a	O
+cell	B-ANAT
+line	I-ANAT
+from	O
+a	O
+feline	B-SPEC
+histiocytic	B-DISO
+sarcoma	I-DISO
+.	O
+
+PEDV	B-SPEC
+causes	O
+severe	O
+economic	O
+loss	O
+,	O
+and	O
+has	O
+been	O
+in	O
+existence	O
+for	O
+decades	O
+.	O
+
+A	O
+panzootic	O
+starting	O
+in	O
+2010	O
+renewed	O
+interest	O
+in	O
+the	O
+development	B-PROC
+of	O
+a	O
+universal	O
+vaccine	O
+toward	O
+PEDV	B-SPEC
+.	O
+
+TITLE	O
+:	O
+Epidemiology	O
+,	O
+drug	B-PROC
+resistance	I-PROC
+,	O
+and	O
+pathophysiology	O
+of	O
+ABSTRACT	O
+:	O
+Malaria	B-PATH
+,	O
+caused	O
+by	O
+the	O
+protozoan	O
+parasites	O
+of	O
+the	O
+genus	O
+Plasmodium	B-SPEC
+,	O
+is	O
+a	O
+major	O
+health	O
+problem	O
+in	O
+many	O
+countries	O
+of	O
+the	O
+world	O
+.	O
+
+The	O
+results	O
+show	O
+that	O
+the	O
+genome	O
+of	O
+QY16	O
+consists	O
+of	O
+27	O
+,	O
+670	O
+nucleotides	B-CHED
+,	O
+excluding	O
+poly	O
+(	O
+A	O
+)	O
+tail	O
+,	O
+and	O
+that	O
+its	O
+genome	O
+organization	O
+is	O
+5	B-PRGE
+'	I-PRGE
+UTR	I-PRGE
+-	I-PRGE
+1a	I-PRGE
+-	I-PRGE
+1b	I-PRGE
+-	I-PRGE
+S	I-PRGE
+-	I-PRGE
+3a	I-PRGE
+-	I-PRGE
+3b	I-PRGE
+-	I-PRGE
+E	I-PRGE
+-	I-PRGE
+M	I-PRGE
+-	I-PRGE
+4b	I-PRGE
+-	I-PRGE
+4c	I-PRGE
+-	I-PRGE
+5a	I-PRGE
+-	I-PRGE
+5b	I-PRGE
+-	I-PRGE
+N	I-PRGE
+-	I-PRGE
+6b	I-PRGE
+-	I-PRGE
+3	I-PRGE
+'	I-PRGE
+UTR	I-PRGE
+-	I-PRGE
+poly	I-PRGE
+(	I-PRGE
+A	I-PRGE
+)	I-PRGE
+tail	O
+.	O
+
+Sequence	O
+comparison	O
+among	O
+QY16	O
+and	O
+other	O
+IBV	B-SPEC
+strains	O
+was	O
+conducted	O
+and	O
+its	O
+results	O
+demonstrate	O
+that	O
+the	O
+S1	B-PRGE
+gene	I-PRGE
+of	O
+QY16	O
+has	O
+the	O
+highest	O
+nucleotide	B-CHED
+sequence	O
+identity	O
+with	O
+that	O
+of	O
+4	O
+/	O
+91	O
+,	O
+and	O
+the	O
+other	O
+part	O
+of	O
+its	O
+genome	O
+is	O
+highly	O
+similar	O
+to	O
+that	O
+of	O
+YX10	O
+.	O
+
+512	O
+patients	O
+with	O
+severe	B-DISO
+sepsis	I-DISO
+and	O
+septic	B-DISO
+shock	I-DISO
+receiving	O
+non	O
+-	O
+cardiac	B-ANAT
+operation	O
+were	O
+treated	O
+according	O
+to	O
+the	O
+guidelines	O
+of	O
+""""	O
+Surviving	O
+Sepsis	B-DISO
+Campaign	O
+:	O
+international	O
+guidelines	O
+for	O
+management	O
+of	O
+severe	B-DISO
+sepsis	I-DISO
+and	O
+septic	B-DISO
+shock	I-DISO
+:	O
+2012	O
+"""."	O
+EGDT	O
+was	O
+used	O
+during	O
+the	O
+early	O
+resuscitation	O
+.	O
+
+The	O
+contact	O
+-	O
+dependent	O
+growth	B-PROC
+inhibition	B-PROC
+toxin	O
+CdiA	O
+-	O
+CT	O
+
+GBF1	B-PRGE
+is	O
+a	O
+guanine	B-PRGE
+nucleotide	I-PRGE
+exchange	I-PRGE
+factor	I-PRGE
+for	O
+Arf	B-PRGE
+family	B-SPEC
+members	I-PRGE
+.	O
+
+Recently	O
+,	O
+we	O
+identified	O
+Arf4	B-PRGE
+and	O
+Arf5	B-PRGE
+(	O
+class	B-PRGE
+II	I-PRGE
+Arfs	I-PRGE
+)	O
+as	O
+host	B-COMP
+factors	O
+required	O
+for	O
+the	O
+replication	O
+of	O
+hepatitis	B-SPEC
+C	I-SPEC
+virus	I-SPEC
+(	O
+HCV	B-SPEC
+),	O
+a	O
+GBF1	B-PRGE
+-	O
+dependent	O
+virus	B-SPEC
+.	O
+
+Donor	B-CHED
+plasma	B-ANAT
+with	O
+a	O
+PRNT	B-PRGE
+titre	I-PRGE
+1	I-PRGE
+:	O
+80	O
+demonstrated	O
+meaningful	O
+serological	O
+response	O
+after	O
+CP	O
+infusion	O
+,	O
+while	O
+that	O
+with	O
+a	O
+PRNT	B-PRGE
+titre	I-PRGE
+1	I-PRGE
+:	O
+40	O
+did	O
+not	O
+.	O
+
+ELISA	O
+IgG	B-PRGE
+predicted	O
+neutralization	O
+activity	O
+of	O
+a	O
+PRNT	B-PRGE
+titre	I-PRGE
+≥	I-PRGE
+1	I-PRGE
+:	O
+80	O
+with	O
+more	O
+than	O
+95	O
+%	O
+specificity	O
+at	O
+a	O
+cutoff	O
+optical	O
+density	O
+(	O
+OD	O
+)	O
+ratio	O
+of	O
+1	O
+.	O
+6	O
+,	O
+and	O
+with	O
+100	O
+%	O
+specificity	O
+at	O
+an	O
+OD	O
+ratio	O
+of	O
+1	O
+.	O
+9	O
+.	O
+
+For	O
+effective	O
+CP	O
+infusion	O
+in	O
+MERS	O
+,	O
+donor	B-CHED
+plasma	B-ANAT
+with	O
+a	O
+neutralization	O
+activity	O
+of	O
+a	O
+PRNT	O
+titre	O
+≥	O
+1	O
+:	O
+80	O
+should	O
+be	O
+used	O
+.	O
+
+ELISA	O
+IgG	B-PRGE
+could	O
+substitute	O
+for	O
+the	O
+neutralization	O
+test	O
+in	O
+resource	O
+-	O
+limited	O
+situations	O
+.	O
+
+ABSTRACT	O
+:	O
+We	O
+reviewed	O
+the	O
+use	O
+of	O
+noninvasive	O
+ventilation	O
+(	O
+NIV	O
+)	O
+versus	O
+high	O
+flow	O
+nasal	B-ANAT
+cannula	B-SPEC
+(	O
+HFNC	O
+)	O
+oxygen	B-CHED
+in	O
+adult	O
+acute	B-DISO
+respiratory	I-DISO
+failure	I-DISO
+(	O
+ARF	B-DISO
+).	O
+
+We	O
+searched	O
+major	O
+databases	O
+and	O
+included	O
+randomized	O
+trials	O
+comparing	O
+at	O
+least	O
+NIV	O
+with	O
+HFNC	O
+or	O
+NIV	O
++	O
+HFNC	O
+with	O
+NIV	O
+in	O
+ARF	B-DISO
+.	O
+
+We	O
+also	O
+demonstrated	O
+that	O
+the	O
+impact	O
+of	O
+TCs	B-DISO
+on	O
+VILI	O
+repair	B-PROC
+might	O
+partially	O
+due	O
+to	O
+vascular	B-PROC
+endothelial	B-ANAT
+growth	B-PROC
+factor	I-PROC
+(	O
+VEGF	B-PROC
+)	O
+secreted	B-PROC
+by	O
+TCs	B-DISO
+upon	O
+VILI	O
+stimulation	O
+,	O
+and	O
+that	O
+VEGF	O
+could	O
+induce	O
+the	O
+proliferation	B-DISO
+of	O
+hemangioendothelioma	B-DISO
+endothelial	B-ANAT
+cells	I-ANAT
+(	O
+EOMA	O
+).	O
+
+Sera	B-COMP
+were	O
+tested	O
+for	O
+CRCoV	O
+antibody	B-COMP
+using	O
+competitive	O
+ELISA	O
+and	O
+results	O
+expressed	B-PROC
+as	O
+percent	O
+of	O
+inhibition	B-PROC
+(	O
+POI	O
+).	O
+
+Viruses	B-SPEC
+were	O
+not	O
+isolated	O
+from	O
+any	O
+of	O
+the	O
+samples	O
+tested	O
+.	O
+
+The	O
+convenience	O
+sampling	O
+methodology	O
+,	O
+with	O
+a	O
+poor	O
+match	O
+between	O
+the	O
+populations	O
+of	O
+diseased	O
+and	O
+healthy	O
+dogs	B-SPEC
+in	O
+terms	O
+of	O
+age	O
+,	O
+breed	B-PROC
+and	O
+use	O
+,	O
+together	O
+with	O
+the	O
+relatively	O
+small	O
+sample	O
+size	O
+precluded	O
+inference	O
+of	O
+any	O
+causal	O
+relationships	O
+between	O
+infection	B-DISO
+with	O
+a	O
+given	O
+pathogen	O
+and	O
+development	B-PROC
+of	O
+disease	O
+.	O
+
+Making	O
+use	O
+of	O
+our	O
+already	O
+described	O
+animal	B-SPEC
+model	O
+of	O
+HCoV	O
+neuropathogenesis	B-DISO
+,	O
+we	O
+describe	O
+the	O
+route	O
+of	O
+neuropropagation	O
+from	O
+the	O
+nasal	B-ANAT
+cavity	I-ANAT
+to	O
+the	O
+olfactory	B-ANAT
+bulb	I-ANAT
+and	O
+piriform	B-ANAT
+cortex	I-ANAT
+and	O
+then	O
+the	O
+brain	B-ANAT
+stem	I-ANAT
+.	O
+
+We	O
+describe	O
+for	O
+the	O
+first	O
+time	O
+the	O
+presence	O
+along	O
+axons	O
+of	O
+viral	O
+platforms	O
+whose	O
+static	O
+dynamism	O
+is	O
+reminiscent	O
+of	O
+viral	B-PROC
+assembly	I-PROC
+sites	O
+.	O
+
+We	O
+further	O
+reveal	O
+that	O
+HCoV	O
+OC43	O
+modes	O
+of	O
+propagation	O
+can	O
+be	O
+modulated	O
+by	O
+selected	O
+HCoV	O
+OC43	O
+proteins	B-CHED
+and	O
+axonal	B-PROC
+transport	I-PROC
+.	O
+
+Elevated	O
+levels	O
+of	O
+antigen	B-CHED
+-	O
+specific	O
+CD8	B-PRGE
+
+ABSTRACT	O
+:	O
+We	O
+experienced	O
+a	O
+breakthrough	O
+fungal	B-DISO
+infection	I-DISO
+caused	O
+by	O
+Geotrichum	B-SPEC
+capitatum	I-SPEC
+during	O
+empirical	O
+therapy	O
+with	O
+caspofungin	B-CHED
+.	O
+
+A	O
+68	O
+-	O
+year	O
+-	O
+old	O
+male	O
+patient	O
+with	O
+refractory	O
+acute	B-DISO
+lymphoblastic	I-DISO
+leukemia	I-DISO
+had	O
+received	O
+umbilical	B-ANAT
+cord	I-ANAT
+blood	I-ANAT
+transplantation	O
+after	O
+two	O
+courses	O
+of	O
+induction	O
+therapy	O
+.	O
+
+The	O
+patient	O
+died	B-PROC
+on	O
+day	O
+25	O
+post	O
+-	O
+transplantation	O
+secondary	O
+to	O
+the	O
+development	B-PROC
+of	O
+hemophagocytic	B-DISO
+syndrome	I-DISO
+and	O
+respiratory	B-DISO
+failure	I-DISO
+.	O
+
+ABSTRACT	O
+:	O
+Respiratory	O
+tract	O
+infections	O
+(	O
+RTIs	O
+)	O
+are	O
+responsible	O
+for	O
+over	O
+2	O
+.	O
+8	O
+million	O
+deaths	B-PROC
+per	O
+year	O
+worldwide	O
+with	O
+pathobiont	O
+carriage	O
+a	O
+required	O
+precursor	O
+to	O
+infection	B-DISO
+.	O
+
+The	O
+presence	O
+of	O
+six	O
+bacterial	O
+species	B-SPEC
+:	O
+S	B-SPEC
+.	I-SPEC
+pneumoniae	I-SPEC
+,	O
+H	B-SPEC
+.	I-SPEC
+influenzae	I-SPEC
+,	O
+M	B-SPEC
+.	I-SPEC
+catarrhalis	I-SPEC
+,	O
+S	B-SPEC
+.	I-SPEC
+aureus	I-SPEC
+,	O
+P	B-SPEC
+.	I-SPEC
+aeruginosa	I-SPEC
+and	O
+N	B-SPEC
+.	I-SPEC
+meningitidis	I-SPEC
+in	O
+addition	O
+to	O
+respiratory	B-SPEC
+syncytial	I-SPEC
+virus	I-SPEC
+,	O
+influenza	B-SPEC
+viruses	I-SPEC
+A	O
+and	O
+B	O
+,	O
+rhinovirus	B-SPEC
+/	O
+enterovirus	B-SPEC
+,	O
+coronavirus	B-SPEC
+,	O
+parainfluenza	B-DISO
+viruses	B-SPEC
+1	O
+-	O
+3	O
+and	O
+adenovirus	B-DISO
+was	O
+determined	O
+using	O
+culture	O
+and	O
+PCR	O
+methods	O
+.	O
+
+Here	O
+,	O
+we	O
+investigate	O
+whether	O
+the	O
+virus	B-SPEC
+uses	O
+the	O
+canonical	O
+autophagic	O
+signaling	B-PROC
+complex	O
+,	O
+consisting	O
+of	O
+the	O
+ULK1	B-PRGE
+/	I-PRGE
+2	I-PRGE
+kinases	I-PRGE
+,	O
+ATG13	B-PRGE
+,	O
+RB1CC1	B-PRGE
+,	O
+and	O
+ATG101	B-PRGE
+,	O
+to	O
+activate	O
+autophagy	B-PROC
+.	O
+
+ABSTRACT	O
+:	O
+Pulmonary	B-ANAT
+endothelial	B-ANAT
+cells	I-ANAT
+'	O
+(	O
+ECs	O
+)	O
+injury	O
+and	O
+apoptotic	O
+death	B-PROC
+are	O
+necessary	O
+and	O
+sufficient	O
+for	O
+the	O
+pathogenesis	B-DISO
+of	O
+the	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+(	O
+ARDS	B-DISO
+),	O
+regardless	O
+of	O
+epithelial	O
+damage	O
+.	O
+
+Immunoblotting	O
+and	O
+magnetic	O
+beads	O
+immunoisolation	O
+complemented	O
+by	O
+standardized	O
+flow	O
+cytometry	O
+and	O
+nanoparticles	B-CHED
+tracking	O
+analyses	O
+identified	O
+in	O
+the	O
+ARDS	B-DISO
+patients	O
+a	O
+subset	O
+of	O
+EVs	O
+with	O
+mesenchymal	B-ANAT
+stem	I-ANAT
+cell	B-COMP
+(	O
+MSC	O
+)	O
+origin	O
+(	O
+CD73	O
+The	O
+expression	B-PROC
+pattern	O
+of	O
+Runx1	B-PRGE
+isoforms	I-PRGE
+might	O
+be	O
+a	O
+reliable	O
+circulatory	B-PROC
+biomarker	B-CHED
+of	O
+ARDS	B-DISO
+activity	O
+and	O
+a	O
+novel	O
+determinant	O
+of	O
+the	O
+molecular	O
+mechanism	O
+for	O
+lung	B-ANAT
+vascular	B-ANAT
+/	O
+tissue	B-PROC
+repair	I-PROC
+and	O
+recovery	O
+after	O
+severe	O
+injury	O
+.	O
+
+TITLE	O
+:	O
+Factors	O
+associated	O
+with	O
+severity	O
+and	O
+mortality	O
+in	O
+patients	O
+with	O
+confirmed	O
+leptospirosis	B-DISO
+at	O
+a	O
+regional	O
+hospital	O
+in	O
+northern	O
+Taiwan	O
+.	O
+
+The	O
+only	O
+independent	O
+predictor	O
+for	O
+severe	O
+leptospirosis	B-DISO
+was	O
+shock	O
+(	O
+OR	O
+14	O
+.	O
+8	O
+,	O
+95	O
+%	O
+CI	O
+2	O
+.	O
+97	O
+-	O
+73	O
+.	O
+59	O
+).	O
+
+Acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+with	O
+severe	O
+pulmonary	B-DISO
+hemorrhage	I-DISO
+syndrome	B-DISO
+(	O
+6	O
+patients	O
+)	O
+was	O
+present	O
+in	O
+55	O
+%	O
+of	O
+the	O
+fatal	O
+cases	O
+.	O
+
+ABSTRACT	O
+:	O
+A	O
+novel	O
+swine	B-SPEC
+acute	B-DISO
+diarrhea	I-DISO
+syndrome	B-DISO
+Coronavirus	B-SPEC
+(	O
+SADS	O
+-	O
+CoV	O
+)	O
+that	O
+causes	O
+severe	B-DISO
+diarrhea	I-DISO
+in	O
+suckling	O
+piglets	O
+was	O
+identified	O
+in	O
+southern	O
+China	O
+in	O
+2017	O
+.	O
+
+Samples	O
+from	O
+749	O
+patients	O
+with	O
+suspected	O
+Middle	O
+East	O
+respiratory	O
+coronavirus	B-SPEC
+who	O
+presented	O
+to	O
+Johns	O
+Hopkins	O
+Aramco	O
+Healthcare	O
+facilities	O
+in	O
+the	O
+Eastern	O
+Province	O
+of	O
+Saudi	O
+Arabia	O
+were	O
+tested	O
+reflexively	O
+for	O
+influenza	B-PATH
+A	I-PATH
+/	O
+H1N1	O
+2009	O
+by	O
+the	O
+Ministry	O
+of	O
+Health	O
+using	O
+the	O
+RealTime	O
+ready	O
+Influenza	B-PATH
+A	I-PATH
+/	O
+H1N1	O
+Detection	O
+Set	O
+for	O
+real	O
+-	O
+time	O
+PCR	O
+.	O
+
+Additionally	O
+,	O
+an	O
+outbreak	O
+of	O
+influenza	B-PATH
+A	I-PATH
+(	O
+H1N1	O
+)	O
+pdm09	O
+may	O
+have	O
+occurred	O
+in	O
+Ras	B-PRGE
+Tanura	I-PRGE
+city	O
+between	O
+April	O
+2015	O
+and	O
+February	O
+2016	O
+.	O
+
+ABSTRACT	O
+:	O
+Porcine	B-SPEC
+deltacoronavirus	O
+(	O
+PDCoV	O
+),	O
+a	O
+newly	O
+discovered	O
+enteric	B-SPEC
+coronavirus	I-SPEC
+,	O
+is	O
+a	O
+causative	O
+agent	O
+of	O
+severe	O
+clinical	O
+diarrhea	B-DISO
+and	O
+intestinal	B-ANAT
+pathological	O
+damage	O
+in	O
+piglets	O
+.	O
+
+Moreover	O
+,	O
+cyt	B-PRGE
+c	I-PRGE
+release	B-PATH
+was	O
+completely	O
+abrogated	O
+in	O
+PDCoV	O
+-	O
+infected	O
+cells	B-COMP
+in	O
+the	O
+presence	O
+of	O
+CsA	B-DISO
+,	O
+suggesting	O
+the	O
+critical	O
+role	O
+of	O
+MPTP	B-PRGE
+in	O
+intrinsic	B-PROC
+apoptosis	I-PROC
+in	O
+response	O
+to	O
+PDCoV	O
+infection	B-DISO
+.	O
+
+TITLE	O
+:	O
+Viral	O
+interference	O
+between	O
+low	O
+pathogenic	O
+avian	B-DISO
+influenza	I-DISO
+H9N2	O
+and	O
+avian	B-SPEC
+infectious	I-DISO
+bronchitis	I-DISO
+viruses	O
+in	O
+vitro	O
+and	O
+in	O
+ovo	B-SPEC
+.	O
+
+However	O
+,	O
+in	O
+the	O
+case	O
+of	O
+super	O
+-	O
+infection	B-DISO
+,	O
+the	O
+second	O
+virus	B-SPEC
+,	O
+either	O
+AIV	O
+or	O
+IBV	B-SPEC
+,	O
+induced	O
+a	O
+decrease	O
+in	O
+the	O
+growth	B-PROC
+of	O
+the	O
+first	O
+inoculated	O
+virus	B-SPEC
+.	O
+
+CONCLUSIONS	O
+:	O
+It	O
+appears	O
+that	O
+either	O
+AIV	O
+or	O
+IBV	B-SPEC
+has	O
+a	O
+negative	O
+impact	O
+on	O
+the	O
+other	O
+virus	B-SPEC
+growth	B-PROC
+when	O
+they	O
+are	O
+inoculated	O
+simultaneously	O
+or	O
+sequentially	O
+.	O
+
+Acute	O
+alcohol	O
+exposure	O
+stimulates	O
+the	O
+beating	O
+of	O
+the	O
+cilia	B-COMP
+of	O
+mucociliary	O
+epithelium	B-ANAT
+cells	B-COMP
+but	O
+the	O
+effects	O
+of	O
+chronic	O
+ethanol	B-CHED
+over	O
+-	O
+exposure	O
+are	O
+different	O
+,	O
+with	O
+a	O
+progressive	O
+desensitization	B-PROC
+of	O
+ciliary	O
+response	O
+:	O
+ethanol	B-CHED
+exposure	O
+reduces	O
+airway	B-ANAT
+mucociliary	O
+clearance	O
+.	O
+
+Chronic	O
+alcohol	O
+exposure	O
+alters	O
+the	O
+adaptative	O
+immune	B-PROC
+response	I-PROC
+to	O
+pathogens	O
+(	O
+decreasing	O
+the	O
+phagocytic	O
+function	O
+of	O
+macrophages	O
+)	O
+and	O
+leads	O
+to	O
+an	O
+inflammatory	B-DISO
+response	I-DISO
+(	O
+pro	B-CHED
+-	O
+inflammatory	O
+cytokines	O
+).	O
+
+Respiratory	B-PROC
+function	I-PROC
+is	O
+impaired	B-DISO
+by	O
+alcohol	O
+misuse	O
+:	O
+asthma	B-PATH
+,	O
+chronic	B-DISO
+obstructive	I-DISO
+pulmonary	I-DISO
+disease	I-DISO
+,	O
+lung	B-ANAT
+infections	B-DISO
+,	O
+and	O
+the	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+are	O
+more	O
+frequent	O
+and	O
+severe	O
+.	O
+
+To	O
+assess	O
+the	O
+association	O
+of	O
+IL1RA	B-PRGE
+gene	I-PRGE
+polymorphism	O
+on	O
+serum	B-COMP
+levels	O
+of	O
+IL1RA	B-PRGE
+and	O
+with	O
+AO	O
+in	O
+children	O
+under	O
+5	O
+years	O
+of	O
+age	O
+hospitalized	O
+with	O
+WHO	O
+-	O
+defined	O
+severe	O
+CAP	B-DISO
+.	O
+
+Specifically	O
+,	O
+space	O
+-	O
+time	O
+permutation	O
+and	O
+multinomial	O
+models	O
+were	O
+used	O
+to	O
+identify	O
+spatial	O
+and	O
+spatial	O
+-	O
+temporal	O
+clusters	B-CHED
+of	O
+various	O
+genotypes	O
+of	O
+IBV	B-SPEC
+.	O
+
+When	O
+comparing	O
+the	O
+space	O
+-	O
+time	O
+permutation	O
+and	O
+multinomial	O
+models	O
+against	O
+each	O
+other	O
+,	O
+we	O
+identified	O
+spatial	O
+and	O
+temporal	O
+overlap	O
+in	O
+two	O
+of	O
+the	O
+three	O
+statistically	O
+significant	O
+clusters	B-CHED
+.	O
+
+Additionally	O
+,	O
+statistically	O
+significant	O
+clusters	B-CHED
+were	O
+mapped	O
+and	O
+layered	B-ANAT
+on	O
+a	O
+hot	O
+-	O
+spot	B-SPEC
+analysis	O
+of	O
+commercial	O
+poultry	O
+farm	O
+density	O
+in	O
+order	B-SPEC
+to	O
+qualitatively	O
+assess	O
+the	O
+relationship	O
+between	O
+farm	O
+density	O
+and	O
+clusters	B-CHED
+of	O
+IBV	B-SPEC
+.	O
+
+The	O
+conformational	O
+structure	O
+of	O
+the	O
+IBV	B-SPEC
+spike	O
+protein	B-CHED
+was	O
+predicted	O
+from	O
+a	O
+homologous	O
+protein	B-CHED
+,	O
+human	B-SPEC
+coronavirus	I-SPEC
+NL63	I-SPEC
+spike	O
+.	O
+
+This	O
+is	O
+the	O
+first	O
+report	O
+describing	O
+IBV	B-SPEC
+spike	O
+S2	O
+epitopes	O
+located	O
+in	O
+the	O
+proximity	O
+of	O
+the	O
+fusion	O
+peptide	B-CHED
+,	O
+and	O
+it	O
+is	O
+suggested	O
+that	O
+the	O
+spike	O
+fusion	O
+machinery	O
+of	O
+IBV	B-SPEC
+may	O
+differ	O
+from	O
+that	O
+of	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+coronavirus	B-SPEC
+,	O
+or	O
+,	O
+alternatively	O
+,	O
+IBV	B-SPEC
+may	O
+have	O
+another	O
+mechanism	O
+to	O
+penetrate	O
+the	O
+cell	B-COMP
+membrane	I-COMP
+.	O
+
+TITLE	O
+:	O
+Effects	O
+of	O
+dietary	O
+yeast	B-SPEC
+nucleotides	B-CHED
+supplementation	O
+on	O
+intestinal	B-ANAT
+barrier	O
+function	O
+,	O
+intestinal	B-ANAT
+microbiota	B-SPEC
+,	O
+and	O
+humoral	B-PROC
+immunity	I-PROC
+in	O
+specific	O
+pathogen	O
+-	O
+free	O
+chickens	B-SPEC
+.	O
+
+ABSTRACT	O
+:	O
+Yeast	B-SPEC
+nucleotides	B-CHED
+are	O
+a	O
+fine	O
+functional	O
+additive	O
+in	O
+human	B-SPEC
+and	O
+animals	B-SPEC
+.	O
+
+All	O
+chickens	B-SPEC
+were	O
+inoculated	O
+intranasally	O
+with	O
+inactivated	O
+IBV	B-SPEC
+vaccine	O
+at	O
+day	O
+1	O
+and	O
+day	O
+10	O
+.	O
+
+At	O
+day	O
+10	O
+,	O
+17	O
+,	O
+24	O
+,	O
+31	O
+,	O
+38	O
+,	O
+and	O
+45	O
+,	O
+the	O
+serum	B-COMP
+IBV	B-SPEC
+antibody	B-COMP
+titers	O
+were	O
+tested	O
+.	O
+
+In	O
+addition	O
+,	O
+dietary	O
+yeast	B-SPEC
+nucleotides	B-CHED
+supplementation	O
+can	O
+also	O
+promote	O
+the	O
+intestinal	B-PROC
+development	B-PROC
+and	O
+barrier	O
+-	O
+related	O
+genes	O
+expression	B-PROC
+,	O
+and	O
+diversity	O
+and	O
+richness	O
+of	O
+intestinal	B-ANAT
+microbiota	B-SPEC
+.	O
+
+ABSTRACT	O
+:	O
+The	O
+genus	B-SPEC
+
+Nanobodies	O
+(	O
+Nbs	B-DISO
+)	O
+are	O
+single	O
+-	O
+domain	O
+antibodies	B-COMP
+derived	O
+from	O
+camelids	O
+and	O
+sharks	B-SPEC
+and	O
+are	O
+potentially	O
+cost	O
+-	O
+effective	O
+antivirals	B-CHED
+with	O
+small	O
+size	O
+and	O
+great	O
+expression	B-PROC
+yield	O
+.	O
+
+In	O
+this	O
+study	O
+,	O
+we	O
+developed	O
+a	O
+novel	O
+neutralizing	O
+Nb	O
+(	O
+NbMS10	O
+)	O
+and	O
+its	O
+human	B-SPEC
+-	O
+Fc	O
+-	O
+fused	O
+version	O
+(	O
+NbMS10	O
+-	O
+Fc	O
+),	O
+both	O
+of	O
+which	O
+target	O
+the	O
+MERS	B-PRGE
+-	I-PRGE
+CoV	I-PRGE
+spike	I-PRGE
+protein	I-PRGE
+receptor	I-PRGE
+-	I-PRGE
+binding	B-FUNC
+domain	I-PRGE
+(	O
+RBD	O
+).	O
+
+ABSTRACT	O
+:	O
+Middle	O
+East	O
+respiratory	O
+syndrome	B-DISO
+(	O
+MERS	O
+)	O
+represents	O
+an	O
+important	O
+respiratory	B-DISO
+disease	I-DISO
+accompanied	O
+by	O
+lethal	O
+outcome	O
+in	O
+one	O
+-	O
+third	O
+of	O
+human	B-SPEC
+patients	O
+.	O
+
+In	O
+the	O
+current	O
+study	O
+,	O
+tissues	B-ANAT
+of	O
+eight	O
+dromedaries	B-SPEC
+receiving	O
+inoculation	O
+of	O
+MERS	O
+-	O
+Coronavirus	B-SPEC
+(	O
+MERS	O
+-	O
+CoV	O
+)	O
+after	O
+recombinant	O
+Modified	O
+-	O
+Vaccinia	B-DISO
+-	O
+Virus	B-SPEC
+-	O
+Ankara	O
+(	O
+MVA	B-CHED
+-	O
+S	O
+)-	O
+vaccination	O
+(	O
+n	O
+=	O
+4	O
+),	O
+MVA	B-CHED
+-	O
+vaccination	O
+(	O
+mock	O
+vaccination	O
+,	O
+n	O
+=	O
+2	O
+)	O
+and	O
+PBS	B-DISO
+application	O
+(	O
+mock	O
+vaccination	O
+,	O
+n	O
+=	O
+2	O
+),	O
+respectively	O
+,	O
+were	O
+investigated	O
+.	O
+
+A	O
+higher	O
+IAH	B-FUNC
+grade	O
+was	O
+more	O
+likely	O
+in	O
+patients	O
+with	O
+severe	O
+AP	O
+(	O
+42	O
+per	O
+cent	O
+for	O
+grade	O
+I	O
+versus	O
+84	O
+per	O
+cent	O
+for	O
+grade	O
+IV	O
+)	O
+and	O
+acute	O
+critical	O
+pancreatitis	B-DISO
+(	O
+9	O
+versus	O
+25	O
+per	O
+cent	O
+;	O
+P	O
+=	O
+0	O
+·	O
+001	O
+).	O
+
+IAH	B-FUNC
+predicted	O
+shock	O
+(	O
+area	O
+under	O
+receiver	O
+operating	O
+characteristic	O
+(	O
+ROC	O
+)	O
+curve	O
+(	O
+AUC	O
+)	O
+0	O
+·	O
+79	O
+,	O
+95	O
+per	O
+cent	O
+c	O
+.	O
+i	O
+.	O
+
+TITLE	O
+:	O
+Porcine	B-SPEC
+Epidemic	I-SPEC
+Diarrhea	I-SPEC
+Virus	I-SPEC
+and	O
+Porcine	B-SPEC
+Deltacoronavirus	O
+not	O
+Detected	O
+in	O
+Waterfowl	B-SPEC
+in	O
+the	O
+North	O
+American	O
+Mississippi	O
+Migratory	O
+Bird	O
+Flyway	O
+in	O
+2013	O
+.	O
+
+However	O
+,	O
+studies	O
+reporting	O
+organelle	B-COMP
+dynamics	O
+upon	O
+viral	B-DISO
+infections	I-DISO
+are	O
+scant	O
+.	O
+
+TITLE	O
+:	O
+Splenic	B-ANAT
+rupture	O
+from	O
+babesiosis	B-DISO
+,	O
+an	O
+emerging	O
+concern	O
+?	O
+
+Undoubtedly	O
+,	O
+more	O
+research	O
+on	O
+the	O
+gut	B-ANAT
+-	O
+lung	B-ANAT
+crosstalk	B-PROC
+in	O
+critically	B-DISO
+ill	I-DISO
+patients	O
+is	O
+needed	O
+to	O
+identify	O
+causal	O
+relationships	O
+between	O
+the	O
+altered	O
+microbiome	O
+,	O
+infections	B-DISO
+,	O
+inflammation	B-DISO
+,	O
+and	O
+acute	O
+lung	B-ANAT
+injury	O
+.	O
+
+TITLE	O
+:	O
+Lead	O
+Molecule	O
+Prediction	O
+and	O
+Characterization	O
+for	O
+Designing	O
+MERS	B-PRGE
+-	I-PRGE
+CoV	I-PRGE
+3C	I-PRGE
+-	I-PRGE
+like	I-PRGE
+Protease	B-CHED
+Inhibitors	I-CHED
+:	O
+An	O
+In	O
+silico	O
+Approach	O
+.	O
+
+ABSTRACT	O
+:	O
+Endocan	O
+is	O
+a	O
+circulating	O
+proteoglycan	B-CHED
+measured	O
+at	O
+high	O
+blood	B-ANAT
+levels	O
+during	O
+severe	B-DISO
+sepsis	I-DISO
+,	O
+with	O
+a	O
+likely	O
+lung	B-ANAT
+anti	O
+-	O
+inflammatory	O
+function	O
+.	O
+
+TITLE	O
+:	O
+Health	O
+care	O
+utilization	O
+and	O
+the	O
+cost	O
+of	O
+posttraumatic	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+care	O
+.	O
+
+The	O
+relationship	O
+between	O
+posttraumatic	O
+ARDS	B-DISO
+severity	O
+and	O
+financial	O
+burden	O
+has	O
+not	O
+been	O
+previously	O
+studied	O
+.	O
+
+Acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+occurred	O
+in	O
+13	O
+%	O
+(	O
+203	O
+of	O
+1	O
+,	O
+586	O
+).	O
+
+The	O
+development	B-PROC
+of	O
+posttraumatic	O
+ARDS	B-DISO
+is	O
+associated	O
+with	O
+higher	O
+health	O
+care	O
+costs	O
+.	O
+
+ABSTRACT	O
+:	O
+The	O
+Middle	O
+East	O
+respiratory	O
+syndrome	B-DISO
+coronavirus	O
+(	O
+MERS	O
+-	O
+CoV	O
+)	O
+was	O
+first	O
+isolated	O
+in	O
+2012	O
+from	O
+patients	O
+that	O
+died	B-PROC
+from	O
+severe	O
+pneumonia	B-DISO
+.	O
+
+The	O
+development	B-PROC
+of	O
+an	O
+appropriate	O
+animal	B-SPEC
+model	O
+is	O
+necessary	O
+to	O
+study	O
+the	O
+pathogenesis	B-DISO
+and	O
+to	O
+evaluate	O
+the	O
+intervening	O
+measures	O
+against	O
+MERS	O
+-	O
+CoV	O
+infection	B-DISO
+.	O
+
+Variables	O
+were	O
+examined	O
+for	O
+associations	O
+with	O
+causes	O
+of	O
+pleural	B-DISO
+effusion	I-DISO
+.	O
+
+A	O
+chest	B-ANAT
+X	O
+-	O
+ray	B-SPEC
+showed	O
+bilateral	O
+infiltration	B-DISO
+.	O
+
+Tracheal	B-ANAT
+aspirate	I-ANAT
+culture	O
+and	O
+blood	B-ANAT
+culture	O
+showed	O
+bacterial	O
+growth	B-PROC
+of	O
+Cupriavidus	B-SPEC
+pauculus	I-SPEC
+.	O
+
+A	O
+74	O
+-	O
+year	O
+-	O
+old	O
+man	B-CHED
+,	O
+with	O
+a	O
+history	O
+of	O
+advanced	O
+stage	B-DISO
+melanoma	I-DISO
+and	O
+treatment	O
+with	O
+ipilimumab	O
+,	O
+pembrolizumab	O
+and	O
+nivolumab	O
+,	O
+was	O
+admitted	O
+to	O
+the	O
+hospital	O
+due	O
+to	O
+respiratory	B-DISO
+failure	I-DISO
+with	O
+hypoxemia	O
+and	O
+dyspnoea	B-DISO
+.	O
+
+Computed	O
+tomographic	O
+imaging	O
+(	O
+CT	O
+)	O
+showed	O
+signs	O
+of	O
+a	O
+pneumonitis	B-DISO
+,	O
+with	O
+an	O
+ARDS	B-DISO
+pattern	O
+related	O
+to	O
+the	O
+use	O
+of	O
+PD	B-PRGE
+-	I-PRGE
+1	I-PRGE
+antibodies	I-PRGE
+.	O
+
+ABSTRACT	O
+:	O
+The	O
+Acute	B-DISO
+Respiratory	I-DISO
+Distress	I-DISO
+Syndrome	I-DISO
+(	O
+ARDS	B-DISO
+)	O
+is	O
+a	O
+severe	O
+hypoxemic	O
+acute	O
+lung	B-ANAT
+injury	O
+that	O
+may	O
+complicate	O
+lung	B-ANAT
+resections	O
+.	O
+
+TITLE	O
+:	O
+Better	O
+horizontal	O
+transmission	O
+of	O
+a	O
+US	O
+non	O
+-	O
+InDel	B-PROC
+strain	O
+compared	O
+with	O
+a	O
+French	O
+InDel	B-PROC
+strain	O
+of	O
+porcine	O
+epidemic	O
+diarrhoea	O
+virus	O
+.	O
+
+In	O
+2014	O
+,	O
+a	O
+PED	O
+outbreak	O
+occurred	O
+in	O
+a	O
+pig	B-SPEC
+farm	O
+in	O
+France	O
+,	O
+from	O
+which	O
+an	O
+InDel	B-PROC
+strain	O
+was	O
+isolated	O
+.	O
+
+In	O
+conclusion	O
+,	O
+the	O
+InDel	B-PROC
+strain	O
+was	O
+less	O
+pathogenic	O
+than	O
+the	O
+non	O
+-	O
+InDel	B-PROC
+strain	O
+in	O
+our	O
+experimental	O
+conditions	O
+.	O
+
+For	O
+conserved	O
+genes	O
+like	O
+the	O
+nucleoprotein	O
+gene	O
+,	O
+longer	O
+k	O
+-	O
+mers	O
+than	O
+mono	B-DISO
+-	O
+and	O
+dinucleotides	B-CHED
+are	O
+needed	O
+to	O
+better	O
+distinguish	O
+the	O
+sequences	O
+.	O
+
+ABSTRACT	O
+:	O
+Tuberculous	O
+(	O
+TB	O
+)	O
+pneumonia	B-DISO
+can	O
+induce	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+(	O
+ARDS	B-DISO
+).	O
+
+Although	O
+TB	O
+pneumonia	B-DISO
+is	O
+one	O
+of	O
+the	O
+causes	O
+of	O
+disease	O
+and	O
+death	B-PROC
+among	O
+children	O
+worldwide	O
+,	O
+the	O
+literature	O
+on	O
+TB	O
+pneumonia	B-DISO
+-	O
+induced	O
+ARDS	B-DISO
+is	O
+limited	O
+.	O
+
+We	O
+also	O
+targeted	B-PROC
+these	O
+pathways	B-PROC
+using	O
+siRNA	O
+.	O
+
+TITLE	O
+:	O
+Dietary	O
+inclusion	O
+of	O
+mushroom	B-SPEC
+(	O
+Flammulina	B-SPEC
+velutipes	I-SPEC
+)	O
+stem	B-ANAT
+waste	O
+on	O
+growth	B-PROC
+performance	O
+and	O
+immune	B-PROC
+responses	I-PROC
+in	O
+growing	O
+layer	B-ANAT
+hens	O
+.	O
+
+The	O
+present	O
+study	O
+aimed	O
+to	O
+investigate	O
+the	O
+effects	O
+of	O
+Flammulina	B-SPEC
+velutipes	I-SPEC
+mushroom	B-SPEC
+waste	O
+(	O
+FVW	O
+)	O
+on	O
+performance	O
+,	O
+immune	B-PROC
+response	I-PROC
+and	O
+serum	B-COMP
+immunity	B-PROC
+in	O
+growing	O
+layer	B-ANAT
+hens	O
+.	O
+
+However	O
+,	O
+IgM	B-PRGE
+was	O
+higher	O
+(	O
+P	O
+<	O
+0	O
+.	O
+05	O
+)	O
+in	O
+both	O
+the	O
+4	O
+%	O
+and	O
+6	O
+%	O
+FVW	O
+groups	O
+than	O
+in	O
+the	O
+control	O
+and	O
+antibiotic	B-CHED
+groups	O
+for	O
+both	O
+experimental	O
+periods	B-PROC
+.	O
+
+Serum	B-COMP
+cytokine	O
+interleukin	B-PRGE
+(	O
+IL	O
+)-	O
+2	O
+and	O
+tumor	B-PRGE
+necrosis	I-PRGE
+factor	I-PRGE
+-	I-PRGE
+α	I-PRGE
+concentrations	O
+were	O
+significantly	O
+higher	O
+(	O
+P	O
+<	O
+0	O
+.	O
+05	O
+)	O
+in	O
+both	O
+the	O
+4	O
+%	O
+and	O
+6	O
+%	O
+FVW	O
+grousp	O
+than	O
+in	O
+the	O
+control	O
+and	O
+antibiotic	B-CHED
+groups	O
+;	O
+IL	B-FUNC
+-	I-FUNC
+4	I-FUNC
+was	O
+significantly	O
+higher	O
+(	O
+P	O
+<	O
+0	O
+.	O
+05	O
+)	O
+in	O
+the	O
+FVW	O
+groups	O
+than	O
+in	O
+the	O
+control	O
+group	O
+;	O
+and	O
+IL	B-FUNC
+-	I-FUNC
+6	I-FUNC
+was	O
+significantly	O
+higher	O
+(	O
+P	O
+<	O
+0	O
+.	O
+05	O
+)	O
+in	O
+the	O
+6	O
+%	O
+FVW	O
+group	O
+than	O
+in	O
+the	O
+control	O
+and	O
+antibiotic	B-CHED
+groups	O
+.	O
+
+FVW	O
+at	O
+the	O
+6	O
+%	O
+level	O
+can	O
+be	O
+used	O
+as	O
+a	O
+potential	O
+phytogenic	O
+feed	O
+stuff	O
+in	O
+growing	O
+layer	B-ANAT
+hen	O
+rations	O
+with	O
+respect	O
+to	O
+improving	O
+the	O
+immune	B-PROC
+response	I-PROC
+without	O
+affecting	O
+normal	O
+weight	O
+gain	O
+.	O
+
+Serum	B-COMP
+cytokine	O
+interleukin	B-PRGE
+(	O
+IL	O
+)-	O
+2	O
+and	O
+tumor	B-PRGE
+necrosis	I-PRGE
+factor	I-PRGE
+-	I-PRGE
+α	I-PRGE
+concentrations	O
+were	O
+significantly	O
+higher	O
+(	O
+P	O
+<	O
+0	O
+.	O
+05	O
+)	O
+in	O
+both	O
+the	O
+4	O
+%	O
+and	O
+6	O
+%	O
+FVW	O
+grousp	O
+than	O
+in	O
+the	O
+control	O
+and	O
+antibiotic	B-CHED
+groups	O
+;	O
+IL	B-FUNC
+-	I-FUNC
+4	I-FUNC
+was	O
+significantly	O
+higher	O
+(	O
+P	O
+<	O
+0	O
+.	O
+05	O
+)	O
+in	O
+the	O
+FVW	O
+groups	O
+than	O
+in	O
+the	O
+control	O
+group	O
+;	O
+and	O
+IL	B-FUNC
+-	I-FUNC
+6	I-FUNC
+was	O
+significantly	O
+higher	O
+(	O
+P	O
+<	O
+0	O
+.	O
+05	O
+)	O
+in	O
+the	O
+6	O
+%	O
+FVW	O
+group	O
+than	O
+in	O
+the	O
+control	O
+and	O
+antibiotic	B-CHED
+groups	O
+.	O
+
+ABSTRACT	O
+:	O
+Hypervirulent	O
+Klebsiella	O
+pneumoniae	O
+(	O
+hvKp	O
+)	O
+has	O
+emerged	O
+as	O
+a	O
+leading	O
+cause	O
+of	O
+severe	O
+community	O
+-	O
+acquired	O
+pneumonia	B-DISO
+,	O
+liver	B-DISO
+abscess	I-DISO
+and	O
+disseminated	O
+infection	B-DISO
+in	O
+the	O
+Far	O
+East	O
+.	O
+
+The	O
+incidence	O
+,	O
+clinical	O
+features	O
+and	O
+microbiological	O
+characteristics	O
+of	O
+hvKp	O
+infections	B-DISO
+were	O
+investigated	O
+through	O
+a	O
+5	O
+-	O
+year	O
+survey	O
+conducted	O
+in	O
+a	O
+single	O
+French	O
+intensive	O
+care	O
+unit	O
+.	O
+
+RESULTS	O
+:	O
+Over	O
+a	O
+53	O
+-	O
+month	O
+period	O
+,	O
+a	O
+total	O
+of	O
+59	O
+infections	B-DISO
+due	O
+to	O
+K	B-SPEC
+.	I-SPEC
+pneumoniae	I-SPEC
+were	O
+identified	O
+including	O
+26	O
+community	O
+-	O
+onset	O
+infections	B-DISO
+.	O
+
+CONCLUSIONS	O
+:	O
+hvKp	O
+represent	O
+a	O
+potentially	O
+underestimated	O
+cause	O
+of	O
+fatal	O
+infections	B-DISO
+in	O
+the	O
+Western	O
+world	O
+.	O
+
+In	O
+the	O
+United	O
+States	O
+,	O
+sepsis	B-DISO
+mortality	O
+approaches	O
+that	O
+of	O
+acute	B-DISO
+myocardial	I-DISO
+infarction	I-DISO
+and	O
+exceeds	O
+deaths	B-PROC
+from	O
+stroke	B-DISO
+.	O
+
+Neonates	O
+and	O
+the	O
+elderly	O
+are	O
+the	O
+most	O
+vulner	O
+-	O
+able	O
+patients	O
+,	O
+with	O
+these	O
+groups	O
+suffering	B-DISO
+from	O
+the	O
+highest	O
+sepsis	B-DISO
+mortality	O
+.	O
+
+This	O
+review	O
+analyses	O
+both	O
+new	O
+advances	O
+in	O
+understanding	O
+the	O
+septic	O
+mechanism	O
+and	O
+possible	O
+resolutions	O
+of	O
+sepsis	B-DISO
+.	O
+
+The	O
+Decision	O
+provides	O
+a	O
+context	O
+for	O
+the	O
+present	O
+study	O
+,	O
+which	O
+aims	O
+to	O
+identify	O
+good	O
+practices	O
+and	O
+lessons	O
+learned	B-PROC
+in	O
+preparedness	O
+and	O
+response	O
+to	O
+Middle	O
+East	O
+Respiratory	O
+Syndrome	B-DISO
+(	O
+MERS	O
+)	O
+(	O
+in	O
+UK	O
+,	O
+Greece	O
+,	O
+and	O
+Spain	O
+)	O
+and	O
+poliomyelitis	B-DISO
+(	O
+in	O
+Poland	O
+and	O
+Cyprus	O
+).	O
+
+Previously	O
+,	O
+groups	O
+had	O
+targeted	B-PROC
+conserved	O
+coronavirus	B-SPEC
+proteins	B-CHED
+as	O
+a	O
+strategy	O
+to	O
+generate	O
+live	O
+attenuated	O
+vaccine	O
+strains	O
+against	O
+current	O
+and	O
+future	O
+CoVs	O
+.	O
+
+Using	O
+the	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+-	O
+CoV	O
+mouse	B-SPEC
+model	O
+,	O
+an	O
+NSP16	O
+mutant	B-DISO
+vaccine	O
+was	O
+evaluated	O
+for	O
+protection	O
+from	O
+heterologous	O
+challenge	O
+,	O
+efficacy	O
+in	O
+the	O
+aging	B-PROC
+host	B-COMP
+,	O
+and	O
+potential	O
+for	O
+reversion	O
+to	O
+pathogenesis	B-DISO
+.	O
+
+However	O
+,	O
+combining	O
+a	O
+2	B-PRGE
+'	I-PRGE
+O	I-PRGE
+MTase	I-PRGE
+mutation	O
+with	O
+a	O
+previously	O
+described	O
+CoV	O
+fidelity	O
+mutant	O
+produced	O
+a	O
+vaccine	O
+strain	O
+capable	O
+of	O
+protection	O
+from	O
+heterologous	O
+virus	B-SPEC
+challenge	O
+,	O
+efficacy	O
+in	O
+aged	O
+mice	B-SPEC
+,	O
+and	O
+no	O
+evidence	O
+for	O
+reversion	O
+.	O
+
+TITLE	O
+:	O
+Feline	B-DISO
+Leukemia	I-DISO
+Virus	I-SPEC
+(	O
+FeLV	B-SPEC
+)	O
+Disease	O
+Outcomes	O
+in	O
+a	O
+Domestic	B-SPEC
+Cat	I-SPEC
+Breeding	B-PROC
+Colony	O
+:	O
+Relationship	O
+to	O
+Endogenous	O
+FeLV	O
+and	O
+Other	O
+Chronic	O
+Viral	B-DISO
+Infections	I-DISO
+.	O
+
+Finally	O
+,	O
+we	O
+show	O
+that	O
+HA	O
+activation	O
+by	O
+the	O
+TMPRSS11A	B-PRGE
+-	I-PRGE
+related	I-PRGE
+enzymes	I-PRGE
+human	I-PRGE
+airway	B-ANAT
+tryptase	B-ENZY
+and	O
+DESC1	B-PRGE
+,	O
+but	O
+not	O
+TMPRSS11A	B-PRGE
+itself	O
+,	O
+is	O
+blocked	O
+by	O
+the	O
+cellular	B-PRGE
+serine	B-CHED
+protease	I-CHED
+inhibitor	I-CHED
+hepatocyte	O
+growth	B-PROC
+factor	O
+activator	O
+inhibitor	B-CHED
+type	O
+-	O
+1	O
+(	O
+HAI	B-PRGE
+-	I-PRGE
+1	I-PRGE
+).	O
+
+TITLE	O
+:	O
+Inhaled	B-PROC
+nitric	B-CHED
+oxide	I-CHED
+mitigates	O
+need	O
+for	O
+extracorporeal	O
+membrane	B-COMP
+oxygenation	B-PROC
+in	O
+a	O
+patient	O
+with	O
+refractory	O
+acute	O
+hypoxemic	O
+respiratory	O
+failure	O
+due	O
+to	O
+cardiac	B-ANAT
+and	O
+pulmonary	B-ANAT
+shunts	O
+.	O
+
+ABSTRACT	O
+:	O
+We	O
+present	O
+a	O
+case	O
+of	O
+refractory	O
+acute	O
+hypoxemic	O
+respiratory	B-DISO
+failure	I-DISO
+due	O
+to	O
+influenza	B-DISO
+B	O
+pneumonia	B-DISO
+with	O
+concomitant	O
+large	O
+intra	O
+-	O
+atrial	B-ANAT
+shunt	O
+(	O
+IAS	O
+)	O
+and	O
+severe	O
+pulmonary	B-DISO
+regurgitation	I-DISO
+in	O
+a	O
+patient	O
+with	O
+Saethre	B-DISO
+-	I-DISO
+Chotzen	I-DISO
+syndrome	I-DISO
+with	O
+prior	O
+pulmonary	B-ANAT
+homograft	O
+placement	O
+.	O
+
+Nitric	B-CHED
+oxide	I-CHED
+has	O
+not	O
+demonstrated	O
+any	O
+statistically	O
+significant	O
+effect	O
+on	O
+mortality	O
+and	O
+only	O
+reported	O
+to	O
+transiently	O
+improved	O
+oxygenation	O
+in	O
+patients	O
+with	O
+hypoxemic	O
+respiratory	B-DISO
+failure	I-DISO
+.	O
+
+In	O
+addition	O
+,	O
+the	O
+results	O
+were	O
+compared	O
+with	O
+Escherichia	B-SPEC
+coli	I-SPEC
+,	O
+yeast	B-SPEC
+and	O
+human	O
+’	O
+s	O
+codon	O
+usage	O
+frequency	O
+.	O
+
+ABSTRACT	O
+:	O
+Acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+(	O
+ARDS	B-DISO
+)	O
+is	O
+a	O
+complex	O
+inflammatory	O
+process	O
+with	O
+multifactorial	O
+etiologies	O
+.	O
+
+The	O
+primary	O
+outcome	O
+was	O
+development	B-PROC
+of	O
+mild	O
+,	O
+moderate	O
+,	O
+or	O
+severe	O
+ARDS	B-DISO
+.	O
+
+Two	O
+thousand	O
+two	O
+hundred	O
+and	O
+seventy	O
+-	O
+two	O
+patients	O
+who	O
+did	O
+not	O
+develop	O
+ARDS	B-DISO
+served	O
+as	O
+controls	O
+.	O
+
+Worsening	O
+severity	O
+of	O
+disease	O
+is	O
+associated	O
+with	O
+severe	O
+chest	B-ANAT
+trauma	O
+and	O
+volume	O
+of	O
+plasma	B-ANAT
+transfusion	O
+.	O
+
+The	O
+epidemiological	O
+situation	O
+of	O
+PEDV	B-SPEC
+infections	B-DISO
+in	O
+the	O
+Netherlands	O
+in	O
+2014	O
+was	O
+unknown	O
+and	O
+a	O
+seroprevalence	O
+study	O
+in	O
+swine	B-SPEC
+was	O
+performed	O
+.	O
+
+TITLE	O
+:	O
+Susceptibility	O
+of	O
+porcine	B-SPEC
+IPEC	O
+-	O
+J2	O
+intestinal	B-ANAT
+epithelial	B-ANAT
+cells	I-ANAT
+to	O
+infection	B-DISO
+with	O
+porcine	B-SPEC
+deltacoronavirus	O
+(	O
+PDCoV	O
+)	O
+and	O
+serum	O
+cytokine	O
+responses	O
+of	O
+gnotobiotic	O
+pigs	B-SPEC
+to	O
+acute	B-DISO
+infection	I-DISO
+with	O
+IPEC	O
+-	O
+J2	O
+cell	B-COMP
+culture	O
+-	O
+passaged	O
+PDCoV	O
+.	O
+ABSTRACT	O
+:	O
+The	O
+porcine	B-SPEC
+small	B-ANAT
+intestinal	I-ANAT
+epithelial	B-ANAT
+cell	I-ANAT
+line	O
+,	O
+IPEC	O
+-	O
+J2	O
+,	O
+is	O
+useful	O
+to	O
+characterize	O
+the	O
+interactions	O
+of	O
+enterocytes	B-ANAT
+with	O
+enteric	O
+viruses	B-SPEC
+in	O
+vitro	O
+.	O
+
+Compared	O
+with	O
+classical	O
+vaccine	O
+strains	O
+,	O
+a	O
+series	O
+of	O
+deletions	O
+and	O
+frequently	O
+occurring	O
+mutations	O
+were	O
+observed	O
+in	O
+the	O
+receptor	O
+binding	O
+domains	O
+of	O
+our	O
+PEDV	B-SPEC
+strains	O
+.	O
+
+Meanwhile	O
+,	O
+the	O
+virulence	B-PROC
+of	O
+the	O
+new	O
+mutants	O
+may	O
+be	O
+changed	O
+,	O
+the	O
+PEDV	B-SPEC
+-	O
+LY4	O
+-	O
+98	O
+strain	O
+,	O
+which	O
+has	O
+multiple	O
+mutations	O
+in	O
+the	O
+signal	O
+peptide	B-CHED
+-	O
+encoding	O
+fragment	O
+of	O
+the	O
+S	B-PRGE
+gene	I-PRGE
+showed	O
+delayed	O
+cytopathic	B-DISO
+effects	I-DISO
+and	O
+smaller	O
+plaque	B-DISO
+size	O
+compared	O
+with	O
+strain	O
+PEDV	B-SPEC
+-	O
+LA1	B-CHED
+,	O
+which	O
+lacks	O
+these	O
+mutations	O
+.	O
+
+ABSTRACT	O
+:	O
+Porcine	B-SPEC
+epidemic	I-SPEC
+diarrhea	I-SPEC
+virus	I-SPEC
+(	O
+PEDV	B-SPEC
+)	O
+is	O
+a	O
+contagious	O
+coronavirus	B-SPEC
+infecting	O
+pigs	B-SPEC
+that	O
+leads	O
+to	O
+significant	O
+economic	O
+losses	O
+in	O
+the	O
+swine	B-SPEC
+industry	O
+.	O
+
+However	O
+,	O
+an	O
+effective	O
+mucosal	B-ANAT
+vaccine	O
+against	O
+the	O
+currently	O
+prevalent	O
+PEDV	B-SPEC
+strain	O
+is	O
+not	O
+available	O
+.	O
+
+Since	O
+its	O
+first	O
+description	O
+,	O
+it	O
+has	O
+undergone	O
+intensive	O
+research	O
+in	O
+the	O
+past	O
+few	O
+decades	O
+to	O
+understand	O
+its	O
+pathogenesis	B-DISO
+and	O
+therapies	O
+.	O
+
+The	O
+aim	O
+of	O
+this	O
+study	O
+was	O
+to	O
+produce	O
+recombinant	B-PRGE
+N	I-PRGE
+protein	I-PRGE
+of	O
+IBV	B-SPEC
+in	O
+the	O
+baculovirus	B-SPEC
+system	O
+to	O
+use	O
+in	O
+ELISA	O
+diagnostic	O
+tests	O
+in	O
+order	B-SPEC
+to	O
+enable	O
+the	O
+assessment	O
+of	O
+the	O
+sero	O
+-	O
+prevalence	O
+and	O
+risk	O
+of	O
+IBV	B-SPEC
+infections	B-DISO
+in	O
+chickens	B-SPEC
+in	O
+Turkey	B-SPEC
+.	O
+
+In	O
+this	O
+chapter	O
+,	O
+two	O
+mouse	B-SPEC
+models	O
+for	O
+ARDS	B-DISO
+are	O
+defined	O
+.	O
+
+Methods	O
+for	O
+growth	B-PROC
+and	O
+preparation	O
+of	O
+Streptococcus	B-SPEC
+pneumoniae	I-SPEC
+are	O
+provided	O
+as	O
+methods	O
+to	O
+assess	O
+lung	B-DISO
+inflammation	I-DISO
+and	O
+injury	O
+.	O
+
+TITLE	O
+:	O
+Influence	O
+of	O
+Clinical	O
+Factors	O
+and	O
+Exclusion	O
+Criteria	O
+on	O
+Mortality	O
+in	O
+ARDS	B-DISO
+Observational	O
+Studies	O
+and	O
+Randomized	O
+Controlled	O
+Trials	O
+.	O
+
+Interestingly	O
+,	O
+ARDS	B-DISO
+has	O
+higher	O
+mortality	O
+rates	O
+in	O
+observational	O
+studies	O
+compared	O
+to	O
+RCTs	O
+.	O
+
+Less	O
+stringent	O
+selection	O
+criteria	O
+could	O
+thereby	O
+contribute	O
+to	O
+high	O
+mortality	O
+rates	O
+in	O
+ARDS	B-DISO
+observational	O
+studies	O
+.	O
+
+Moreover	O
+,	O
+ARDS	B-DISO
+RCTs	O
+strictly	O
+adhere	O
+to	O
+lung	B-ANAT
+-	O
+protective	O
+strategies	O
+,	O
+while	O
+ARDS	B-DISO
+observational	O
+studies	O
+continually	O
+demonstrate	O
+variable	O
+compliance	O
+.	O
+
+This	O
+syndrome	B-DISO
+is	O
+a	O
+clinical	O
+diagnosis	O
+based	O
+on	O
+the	O
+recurrent	O
+occurrence	O
+of	O
+tachycardia	O
+,	O
+hypertension	B-DISO
+,	O
+diaphoresis	B-DISO
+,	O
+tachypnea	B-DISO
+,	O
+and	O
+occasionally	O
+high	O
+fever	B-PROC
+and	O
+dystonic	O
+postures	O
+.	O
+
+Fat	B-DISO
+embolism	I-DISO
+syndrome	I-DISO
+is	O
+a	O
+rare	O
+but	O
+serious	O
+complication	B-DISO
+of	O
+long	B-ANAT
+bone	I-ANAT
+fractures	O
+.	O
+
+Neurologic	B-DISO
+signs	I-DISO
+,	O
+petechial	O
+hemorrhages	B-DISO
+and	O
+acute	B-DISO
+respiratory	I-DISO
+failure	I-DISO
+constitute	O
+the	O
+characteristic	O
+presenting	O
+triad	B-COMP
+.	O
+
+This	O
+mechanism	O
+provides	O
+a	O
+valuable	O
+addition	O
+for	O
+the	O
+combined	O
+use	O
+of	O
+antibodies	B-COMP
+against	O
+MERS	O
+-	O
+CoV	O
+infection	B-DISO
+.	O
+
+ABSTRACT	O
+:	O
+Most	O
+observation	O
+of	O
+human	O
+respiratory	O
+virus	B-SPEC
+carriage	O
+is	O
+derived	O
+from	O
+medical	O
+surveillance	O
+;	O
+however	O
+,	O
+the	O
+infections	B-DISO
+documented	O
+by	O
+this	O
+surveillance	O
+represent	O
+only	O
+a	O
+symptomatic	O
+fraction	O
+of	O
+the	O
+total	O
+infected	O
+population	O
+.	O
+
+TITLE	O
+:	O
+[	O
+Identification	O
+and	O
+Characterzation	O
+of	O
+the	O
+Porcine	B-SPEC
+Epidemic	I-SPEC
+Diarrhea	I-SPEC
+Virus	I-SPEC
+(	O
+PEDV	B-SPEC
+)	O
+Isolates	O
+].	O
+
+In	O
+order	B-SPEC
+to	O
+have	O
+more	O
+resources	O
+into	O
+the	O
+development	B-PROC
+of	O
+safe	O
+and	O
+effective	O
+vaccine	O
+,	O
+this	O
+article	O
+summarizes	O
+the	O
+current	O
+some	O
+candidate	O
+vaccine	O
+of	O
+MERS	O
+research	O
+progress	O
+for	O
+the	O
+prevention	O
+and	O
+treatment	O
+of	O
+the	O
+disease	O
+that	O
+could	O
+trigger	O
+a	O
+global	O
+public	O
+health	O
+security	O
+problems	O
+ahead	O
+.	O
+
+A	O
+multiple	O
+linear	O
+regression	O
+model	O
+was	O
+used	O
+to	O
+investigate	O
+associations	O
+between	O
+hand	O
+hygiene	O
+education	O
+and	O
+self	O
+-	O
+reported	O
+hand	O
+-	O
+washing	O
+behaviors	B-PROC
+.	O
+
+Overall	O
+,	O
+respiratory	O
+disease	O
+was	O
+mild	O
+and	O
+transient	O
+,	O
+resolving	O
+by	O
+day	O
+30	O
+post	O
+-	O
+infection	B-DISO
+.	O
+
+The	O
+most	O
+frequent	O
+viruses	B-SPEC
+were	O
+enterovirus	B-SPEC
+/	O
+rhinovirus	B-SPEC
+(	O
+n	O
+=	O
+88	O
+;	O
+32	O
+.	O
+7	O
+%),	O
+respiratory	B-SPEC
+syncytial	I-SPEC
+virus	I-SPEC
+(	O
+n	O
+=	O
+55	O
+;	O
+20	O
+.	O
+4	O
+%),	O
+and	O
+human	B-SPEC
+metapneumovirus	I-SPEC
+(	O
+n	O
+=	O
+36	O
+;	O
+13	O
+.	O
+4	O
+%).	O
+
+TITLE	O
+:	O
+Cyclophilins	O
+and	O
+cyclophilin	B-PROC
+inhibitors	B-CHED
+in	O
+nidovirus	B-SPEC
+replication	O
+.	O
+
+This	O
+review	O
+summarizes	O
+our	O
+current	O
+understanding	O
+of	O
+this	O
+class	B-SPEC
+of	O
+nidovirus	B-SPEC
+-	O
+host	B-COMP
+interactions	O
+,	O
+including	O
+the	O
+potential	O
+function	O
+of	O
+in	O
+particular	O
+CypA	B-PRGE
+and	O
+the	O
+inhibitory	O
+effect	O
+of	O
+Cyp	B-PRGE
+inhibitors	B-CHED
+.	O
+
+TITLE	O
+:	O
+Proficiency	O
+testing	O
+for	O
+the	O
+detection	O
+of	O
+Middle	O
+East	O
+respiratory	O
+syndrome	B-DISO
+coronavirus	B-SPEC
+demonstrates	O
+global	O
+capacity	O
+to	O
+detect	O
+Middle	O
+East	O
+respiratory	O
+syndrome	O
+coronavirus	B-SPEC
+.	O
+
+ABSTRACT	O
+:	O
+The	O
+first	O
+reported	O
+case	O
+of	O
+Middle	O
+East	O
+respiratory	O
+syndrome	B-DISO
+coronavirus	B-SPEC
+(	O
+MERS	O
+-	O
+CoV	O
+)	O
+infection	B-DISO
+was	O
+identified	O
+in	O
+Saudi	O
+Arabia	O
+in	O
+September	O
+2012	O
+,	O
+since	O
+which	O
+time	O
+there	O
+have	O
+been	O
+over	O
+2000	O
+laboratory	O
+-	O
+confirmed	O
+cases	O
+,	O
+including	O
+750	O
+deaths	B-PROC
+in	O
+27	O
+countries	O
+.	O
+
+Retrospective	O
+observational	O
+study	O
+from	O
+January	O
+1992	O
+to	O
+December	O
+2004	O
+and	O
+prospective	O
+study	O
+from	O
+January	O
+2005	O
+to	O
+December	O
+2015	O
+were	O
+conducted	O
+in	O
+a	O
+tertiary	O
+children	O
+'	O
+s	O
+hospital	O
+PICU	B-SPEC
+.	O
+
+The	O
+data	O
+analyzed	O
+refer	O
+to	O
+the	O
+patient	O
+,	O
+event	O
+,	O
+type	O
+of	O
+resuscitation	O
+performed	O
+,	O
+and	O
+clinical	O
+situation	O
+after	O
+resuscitation	O
+and	O
+at	O
+arrival	O
+to	O
+the	O
+PICU	B-SPEC
+;	O
+results	O
+of	O
+additional	O
+tests	O
+;	O
+and	O
+clinical	O
+evolution	B-PROC
+and	O
+neurological	O
+status	O
+at	O
+discharge	B-ANAT
+from	O
+the	O
+PICU	B-SPEC
+(	O
+categorized	O
+as	O
+death	B-PROC
+,	O
+severe	O
+encephalopathy	B-DISO
+,	O
+or	O
+normal	O
+).	O
+
+The	O
+considered	O
+potential	O
+prognostic	O
+factors	O
+were	O
+whether	O
+drowning	O
+was	O
+witnessed	O
+,	O
+the	O
+type	O
+of	O
+initial	O
+resuscitation	O
+,	O
+Glasgow	O
+Coma	B-DISO
+Scale	O
+score	O
+at	O
+admission	O
+,	O
+pupil	B-ANAT
+status	O
+and	O
+reactivity	O
+,	O
+and	O
+pH	O
+.	O
+One	O
+hundred	O
+thirty	O
+-	O
+one	O
+patients	O
+were	O
+registered	O
+.	O
+
+The	O
+need	O
+for	O
+advanced	O
+CPR	B-ENZY
+with	O
+epinephrine	B-CHED
+administration	O
+on	O
+the	O
+scene	O
+predicts	O
+poor	O
+neurological	O
+outcome	O
+(	O
+severe	O
+encephalopathy	B-DISO
+or	O
+death	B-PROC
+)	O
+in	O
+drowned	O
+children	O
+.	O
+
+TITLE	O
+:	O
+The	O
+S2	O
+Subunit	O
+of	O
+Infectious	B-DISO
+Bronchitis	B-DISO
+Virus	B-SPEC
+Beaudette	O
+Is	O
+a	O
+Determinant	O
+of	O
+Cellular	B-PROC
+Tropism	B-PROC
+.	O
+
+Middle	O
+East	O
+Respiratory	O
+Syndrome	B-DISO
+Coronavirus	B-SPEC
+Spike	O
+Protein	B-CHED
+Is	O
+Not	O
+Activated	O
+Directly	O
+by	O
+Cellular	B-ANAT
+Furin	B-ENZY
+during	O
+Viral	O
+Entry	O
+into	O
+Target	B-ANAT
+Cells	I-ANAT
+.	O
+
+Tissue	B-ANAT
+inhibitor	B-CHED
+of	O
+matrix	B-PRGE
+metalloproteinase	I-PRGE
+-	I-PRGE
+3	I-PRGE
+(	O
+TIMP	B-PRGE
+-	I-PRGE
+3	I-PRGE
+)	O
+is	O
+a	O
+regulator	O
+of	O
+matrix	B-PRGE
+metalloproteinase	I-PRGE
+activity	O
+,	O
+inflammation	B-DISO
+,	O
+and	O
+vascular	B-PROC
+permeability	I-PROC
+,	O
+and	O
+hence	O
+has	O
+plausibility	O
+as	O
+a	O
+biomarker	B-CHED
+for	O
+the	O
+systemic	O
+response	O
+to	O
+TBI	O
+.	O
+
+In	O
+a	O
+retrospective	O
+study	O
+of	O
+182	O
+patients	O
+with	O
+severe	O
+isolated	O
+TBI	O
+,	O
+we	O
+measured	O
+TIMP	O
+-	O
+3	O
+in	O
+plasma	B-ANAT
+obtained	O
+on	O
+emergency	B-DISO
+department	O
+arrival	O
+.	O
+
+TIMP	B-PRGE
+-	O
+3	O
+may	O
+play	O
+an	O
+important	O
+role	O
+in	O
+the	O
+biology	O
+of	O
+the	O
+systemic	O
+response	O
+to	O
+brain	B-ANAT
+injury	O
+in	O
+humans	B-SPEC
+.	O
+
+Along	O
+with	O
+clinical	O
+and	O
+demographic	O
+data	O
+,	O
+early	O
+measurements	O
+of	O
+plasma	B-ANAT
+biomarkers	O
+such	O
+as	O
+TIMP	B-PRGE
+-	I-PRGE
+3	I-PRGE
+may	O
+help	O
+identify	O
+patients	O
+at	O
+higher	O
+risk	O
+of	O
+ARDS	B-DISO
+and	O
+death	B-PROC
+after	O
+severe	O
+isolated	O
+TBI	O
+.	O
+
+In	O
+the	O
+CD81	B-PRGE
+protein	I-PRGE
+network	O
+,	O
+we	O
+identified	O
+five	O
+proteins	B-CHED
+which	O
+are	O
+HCV	B-SPEC
+entry	O
+factors	O
+or	O
+facilitators	O
+including	O
+epidermal	B-PRGE
+growth	B-PROC
+factor	I-PRGE
+receptor	I-PRGE
+(	O
+EGFR	B-FUNC
+).	O
+
+Notably	O
+,	O
+we	O
+discovered	O
+calpain	B-PRGE
+-	I-PRGE
+5	I-PRGE
+(	O
+CAPN5	B-PRGE
+)	O
+and	O
+the	O
+ubiquitin	B-PRGE
+ligase	I-PRGE
+Casitas	O
+B	O
+-	O
+lineage	O
+lymphoma	B-DISO
+proto	O
+-	O
+oncogene	B-PRGE
+B	I-PRGE
+(	O
+CBLB	B-PRGE
+)	O
+to	O
+form	O
+a	O
+complex	O
+with	O
+CD81	B-PRGE
+and	O
+support	O
+HCV	B-SPEC
+entry	O
+.	O
+
+Furthermore	O
+,	O
+Plasmodium	B-SPEC
+sporozoites	O
+relied	O
+on	O
+a	O
+distinct	O
+set	O
+of	O
+CD81	O
+interaction	O
+partners	O
+for	O
+liver	B-ANAT
+cell	I-ANAT
+entry	O
+.	O
+
+We	O
+analyzed	O
+the	O
+effect	O
+of	O
+a	O
+recruitment	B-DISO
+maneuver	O
+and	O
+decremental	O
+positive	O
+end	B-PROC
+-	I-PROC
+expiratory	I-PROC
+pressure	O
+titration	O
+on	O
+cardiac	B-PROC
+function	I-PROC
+.	O
+
+Thus	O
+,	O
+combination	O
+therapy	O
+with	O
+ET	O
+and	O
+PSL	O
+that	O
+targets	O
+inflammatory	B-ANAT
+cells	I-ANAT
+has	O
+the	O
+potential	O
+to	O
+attenuate	O
+fatal	O
+ARDS	B-DISO
+.	O
+
+Perhaps	O
+more	O
+importantly	O
+,	O
+acidified	O
+autophagosomes	O
+(	O
+known	O
+as	O
+amphisomes	O
+)	O
+provide	O
+havens	O
+for	O
+maturation	O
+of	O
+new	O
+viral	B-COMP
+particles	I-COMP
+into	O
+infectious	B-DISO
+viruses	B-SPEC
+.	O
+
+In	O
+back	B-ANAT
+-	O
+to	O
+-	O
+back	B-ANAT
+papers	O
+recently	O
+published	O
+in	O
+Cell	B-COMP
+Reports	O
+,	O
+our	O
+labs	O
+investigated	O
+a	O
+basic	O
+question	O
+:	O
+if	O
+picornavirus	B-SPEC
+particles	O
+are	O
+maturing	O
+inside	O
+amphisomes	O
+,	O
+then	O
+how	O
+are	O
+they	O
+avoiding	O
+the	O
+typical	O
+degradative	O
+fate	O
+of	O
+autophagic	O
+cargo	O
+and	O
+exiting	O
+the	O
+cell	B-COMP
+intact	O
+?	O
+
+The	O
+current	O
+work	O
+emphasizes	O
+on	O
+the	O
+discovery	O
+process	O
+of	O
+the	O
+chalcone	O
+in	O
+the	O
+period	O
+of	O
+2016	O
+to	O
+2017	O
+on	O
+malaria	B-PATH
+,	O
+trypanosomiasis	B-DISO
+,	O
+leishmaniasis	B-PATH
+,	O
+filaria	B-SPEC
+,	O
+tuberculosis	B-PATH
+,	O
+netamodes	O
+,	O
+Human	B-DISO
+Immunodeficiency	I-DISO
+Virus	I-DISO
+(	O
+HIV	B-DISO
+),	O
+Tobacco	B-SPEC
+Mosaic	I-SPEC
+Virus	I-SPEC
+(	O
+TMV	B-SPEC
+),	O
+Severe	B-DISO
+Acute	I-DISO
+Respiratory	I-DISO
+Syndrome	I-DISO
+(	O
+SARS	B-DISO
+),	O
+and	O
+miscellaneous	O
+conditions	O
+.	O
+
+To	O
+assess	O
+the	O
+impact	O
+of	O
+RDS	O
+without	O
+other	O
+co	O
+-	O
+factors	O
+,	O
+we	O
+excluded	O
+from	O
+the	O
+study	O
+children	O
+with	O
+congenital	B-DISO
+malformations	I-DISO
+,	O
+genetic	O
+and	O
+metabolic	B-DISO
+disorders	I-DISO
+;	O
+intracranial	B-DISO
+hemorrhage	I-DISO
+,	O
+neuromuscular	B-DISO
+diseases	I-DISO
+,	O
+severe	O
+hyperbilirubinemia	B-DISO
+,	O
+sepsis	B-DISO
+,	O
+congenital	B-DISO
+infections	I-DISO
+as	O
+well	O
+as	O
+family	B-SPEC
+with	O
+drug	O
+or	O
+alcohol	B-DISO
+addiction	I-DISO
+,	O
+severe	O
+mental	B-DISO
+disorder	I-DISO
+,	O
+parents	O
+younger	O
+than	O
+17	O
+years	O
+of	O
+age	O
+at	O
+the	O
+time	O
+of	O
+the	O
+baby	O
+'	O
+s	O
+birth	O
+.	O
+
+The	O
+antiviral	B-CHED
+gene	B-PROC
+expression	I-PROC
+profile	O
+in	O
+HEK	O
+-	O
+293	O
+cells	B-COMP
+was	O
+determined	O
+by	O
+PCR	O
+array	O
+.	O
+
+The	O
+expression	B-PROC
+of	O
+antiviral	B-CHED
+genes	O
+involved	O
+in	O
+the	O
+type	B-PRGE
+I	I-PRGE
+IFN	I-PRGE
+and	O
+NF	O
+-	O
+κB	O
+signaling	B-PROC
+pathways	B-PROC
+was	O
+also	O
+downregulated	O
+in	O
+the	O
+presence	O
+of	O
+HCoV	B-SPEC
+-	I-SPEC
+OC43	I-SPEC
+structural	O
+or	O
+accessory	O
+proteins	B-CHED
+.	O
+
+Both	O
+structural	O
+and	O
+accessory	O
+HCoV	B-SPEC
+-	I-SPEC
+OC43	I-SPEC
+proteins	B-CHED
+are	O
+able	O
+to	O
+inhibit	O
+antiviral	B-PROC
+response	I-PROC
+elements	O
+in	O
+HEK	O
+-	O
+293	O
+cells	B-COMP
+,	O
+and	O
+to	O
+block	O
+the	O
+activation	O
+of	O
+different	O
+antiviral	B-CHED
+signaling	B-PROC
+pathways	B-PROC
+.	O
+
+A	O
+retrospective	O
+cohort	O
+(	O
+2007	O
+-	O
+2014	O
+)	O
+of	O
+children	O
+≤	O
+18	O
+years	O
+old	O
+from	O
+the	O
+American	O
+College	O
+of	O
+Surgeons	O
+National	O
+Trauma	O
+Data	O
+Bank	O
+(	O
+NTDB	O
+)	O
+was	O
+used	O
+to	O
+analyze	O
+incidence	O
+,	O
+risk	O
+factors	O
+,	O
+and	O
+outcomes	O
+related	O
+to	O
+PT	O
+-	O
+ARDS	B-DISO
+.	O
+
+After	O
+adjustment	O
+for	O
+age	O
+,	O
+injury	O
+complexity	O
+,	O
+injury	O
+mechanism	O
+,	O
+and	O
+physiologic	O
+variables	O
+,	O
+PT	O
+-	O
+ARDS	B-DISO
+was	O
+found	O
+to	O
+be	O
+independently	O
+associated	O
+with	O
+higher	O
+mortality	O
+(	O
+adjusted	O
+OR	O
+1	O
+.	O
+33	O
+,	O
+95	O
+%	O
+CI	O
+1	O
+.	O
+18	O
+-	O
+1	O
+.	O
+51	O
+,	O
+p	O
+<	O
+0	O
+.	O
+001	O
+).	O
+
+ABSTRACT	O
+:	O
+Severe	O
+influenza	B-PATH
+infection	B-DISO
+causes	O
+substantial	O
+morbidity	O
+and	O
+mortality	O
+worldwide	O
+and	O
+remains	O
+an	O
+important	O
+threat	O
+to	O
+global	O
+health	O
+.	O
+
+This	O
+is	O
+a	O
+retrospective	O
+study	O
+conducted	O
+by	O
+Taiwan	O
+Severe	O
+Influenza	B-DISO
+Research	O
+Consortium	O
+(	O
+TSIRC	O
+),	O
+including	O
+eight	O
+tertiary	O
+referral	O
+medical	O
+centers	O
+.	O
+
+We	O
+identified	O
+263	O
+patients	O
+with	O
+complicated	O
+influenza	B-PATH
+infection	B-DISO
+who	O
+fulfilled	O
+ARDS	B-DISO
+criteria	O
+;	O
+the	O
+mean	O
+age	O
+was	O
+59	O
+.	O
+8	O
+±	O
+14	O
+.	O
+6	O
+(	O
+years	O
+),	O
+and	O
+66	O
+.	O
+1	O
+%	O
+(	O
+166	O
+/	O
+263	O
+)	O
+were	O
+male	O
+.	O
+
+Type	O
+A	O
+influenza	B-DISO
+(	O
+77	O
+.	O
+9	O
+%,	O
+205	O
+/	O
+263	O
+)	O
+virus	B-SPEC
+was	O
+the	O
+main	O
+pathogen	O
+during	O
+this	O
+epidemic	O
+.	O
+
+Cardiac	B-ANAT
+glycosides	B-CHED
+not	O
+only	O
+inhibit	O
+the	O
+pump	O
+function	O
+of	O
+Na	B-PRGE
+,	I-PRGE
+K	I-PRGE
+-	I-PRGE
+ATPase	I-PRGE
+but	O
+also	O
+activate	O
+intracellular	B-PROC
+signal	B-PROC
+transduction	I-PROC
+pathways	I-PROC
+,	O
+which	O
+are	O
+important	O
+in	O
+many	O
+biological	B-PROC
+processes	I-PROC
+.	O
+
+TITLE	O
+:	O
+Transmission	O
+of	O
+rhinovirus	B-SPEC
+in	O
+the	O
+Utah	B-PRGE
+BIG	I-PRGE
+-	I-PRGE
+LoVE	I-PRGE
+families	I-PRGE
+:	O
+Consequences	O
+of	O
+age	O
+and	O
+household	O
+structure	O
+.	O
+
+RESULTS	O
+:	O
+Acquisition	O
+of	O
+HRV	O
+was	O
+less	O
+probable	O
+in	O
+older	O
+individuals	O
+and	O
+those	O
+infected	O
+with	O
+a	O
+coronavirus	B-SPEC
+,	O
+and	O
+higher	O
+with	O
+a	O
+higher	O
+proportion	O
+of	O
+other	O
+household	O
+members	O
+infected	O
+.	O
+
+However	O
+,	O
+management	O
+of	O
+acute	O
+chlorine	B-CHED
+-	O
+related	O
+inhalation	B-PROC
+injury	O
+is	O
+largely	O
+empirical	O
+,	O
+supportive	O
+,	O
+and	O
+sometimes	O
+challenging	O
+.	O
+
+TITLE	O
+:	O
+Time	O
+-	O
+calibrated	O
+phylogenomics	O
+of	O
+the	O
+porcine	B-SPEC
+epidemic	I-SPEC
+diarrhea	I-SPEC
+virus	I-SPEC
+:	O
+genome	O
+-	O
+wide	O
+insights	O
+into	O
+the	O
+spatio	O
+-	O
+temporal	O
+dynamics	O
+.	O
+
+TITLE	O
+:	O
+Periodic	O
+Fluctuation	B-DISO
+of	O
+Tidal	O
+Volumes	O
+Further	O
+Improves	O
+Variable	O
+Ventilation	O
+in	O
+Experimental	O
+Acute	B-DISO
+Respiratory	I-DISO
+Distress	I-DISO
+Syndrome	I-DISO
+.	O
+
+TITLE	O
+:	O
+The	O
+Impacts	O
+on	O
+Health	O
+,	O
+Society	O
+,	O
+and	O
+Economy	O
+of	O
+SARS	B-DISO
+and	O
+H7N9	O
+Outbreaks	O
+in	O
+China	O
+:	O
+A	O
+Case	O
+Comparison	O
+Study	O
+.	O
+
+TITLE	O
+:	O
+Characteristics	O
+and	O
+outcome	O
+of	O
+ill	B-DISO
+critical	O
+patients	O
+with	O
+influenza	B-PATH
+A	I-PATH
+infection	B-DISO
+.	O
+
+To	O
+further	O
+trace	O
+PDCoV	O
+in	O
+the	O
+period	O
+of	O
+2011	O
+to	O
+2015	O
+,	O
+an	O
+enzyme	O
+-	O
+linked	O
+immunosorbent	O
+assay	O
+(	O
+ELISA	O
+)	O
+was	O
+used	O
+to	O
+detect	O
+antibodies	O
+against	O
+PDCoV	O
+.	O
+The	O
+results	O
+showed	O
+that	O
+279	O
+of	O
+1	O
+,	O
+039	O
+(	O
+26	O
+.	O
+9	O
+%)	O
+sera	B-COMP
+were	O
+positive	O
+for	O
+the	O
+PDCoV	B-PRGE
+nucleocapsid	I-PRGE
+protein	B-CHED
+,	O
+implying	O
+that	O
+PDCoV	O
+might	O
+have	O
+existed	O
+in	O
+Taiwan	O
+before	O
+2011	O
+.	O
+
+RESULTS	O
+:	O
+In	O
+all	O
+,	O
+55	O
+pig	B-SPEC
+fecal	B-ANAT
+,	O
+49	O
+pig	B-SPEC
+oral	B-ANAT
+or	O
+water	B-CHED
+,	O
+45	O
+bioaerosol	O
+,	O
+and	O
+78	O
+worker	O
+nasal	B-ANAT
+wash	O
+samples	O
+were	O
+collected	O
+across	O
+16	O
+sites	O
+.	O
+
+In	O
+Georgia	O
+influenza	B-SPEC
+virus	I-SPEC
+activity	O
+occurred	O
+mainly	O
+from	O
+December	O
+through	O
+March	O
+in	O
+all	O
+seasons	O
+,	O
+with	O
+varying	O
+peak	O
+weeks	O
+and	O
+predominating	O
+viruses	B-SPEC
+.	O
+
+Around	O
+one	O
+third	O
+of	O
+ILI	O
+/	O
+SARI	O
+cases	O
+were	O
+associated	O
+with	O
+influenza	B-DISO
+caused	O
+by	O
+antigenically	O
+and	O
+genetically	O
+distinct	O
+influenza	B-SPEC
+viruses	I-SPEC
+over	O
+the	O
+course	O
+of	O
+the	O
+three	O
+seasons	O
+.	O
+
+Then	O
+,	O
+rice	B-SPEC
+hulls	O
+treated	O
+with	O
+10	O
+%	O
+MCFA	B-CHED
+were	O
+mixed	O
+and	O
+discharged	O
+through	O
+a	O
+production	O
+scale	O
+mixer	O
+and	O
+bucket	O
+elevator	O
+following	O
+PEDV	B-SPEC
+-	O
+positive	O
+feed	O
+.	O
+
+No	O
+rice	B-SPEC
+hull	O
+flush	B-DISO
+or	O
+feed	O
+samples	O
+from	O
+the	O
+mixer	O
+following	O
+chemically	O
+treated	O
+rice	B-SPEC
+hull	O
+flush	B-DISO
+had	O
+detectible	O
+PEDV	B-SPEC
+RNA	O
+.	O
+
+Dust	O
+collected	O
+following	O
+mixing	O
+of	O
+PEDV	B-SPEC
+contaminated	O
+feed	O
+had	O
+detectable	O
+PEDV	B-SPEC
+RNA	O
+(	O
+Ct	O
+=	O
+29	O
+.	O
+4	O
+)	O
+and	O
+was	O
+infectious	B-DISO
+.	O
+
+TITLE	O
+:	O
+The	O
+cardenolide	O
+ouabain	B-CHED
+suppresses	O
+coronaviral	O
+replication	O
+via	O
+augmenting	O
+a	O
+Na	O
+ABSTRACT	O
+:	O
+Cardenolides	O
+are	O
+plant	O
+-	O
+derived	O
+toxic	O
+substances	O
+.	O
+
+ABSTRACT	O
+:	O
+Severe	O
+complications	O
+after	O
+reperfusion	O
+therapy	O
+for	O
+acute	O
+major	O
+vessel	B-ANAT
+occlusion	B-DISO
+are	O
+not	O
+well	O
+described	O
+.	O
+
+Emergent	O
+hematoma	B-DISO
+evacuation	O
+and	O
+clipping	O
+were	O
+performed	O
+.	O
+
+Computed	O
+tomography	O
+performed	O
+immediately	O
+postoperatively	O
+(	O
+within	O
+6	O
+hours	O
+after	O
+preoperative	O
+computed	O
+tomography	O
+)	O
+showed	O
+severe	O
+left	B-ANAT
+brain	I-ANAT
+swelling	O
+with	O
+midline	B-COMP
+shift	O
+.	O
+
+ABSTRACT	O
+:	O
+Six	O
+years	O
+have	O
+passed	O
+since	O
+Middle	O
+East	O
+respiratory	O
+syndrome	B-DISO
+(	O
+MERS	B-DISO
+)	O
+coronavirus	B-SPEC
+(	O
+MERS	B-DISO
+-	O
+CoV	O
+),	O
+a	O
+newly	O
+emerging	O
+infectious	B-DISO
+virus	B-SPEC
+,	O
+was	O
+first	O
+reported	O
+in	O
+2012	O
+.	O
+
+The	O
+majority	O
+of	O
+MERS	O
+vaccines	O
+under	O
+development	B-PROC
+are	O
+based	O
+on	O
+MERS	B-PRGE
+-	I-PRGE
+CoV	I-PRGE
+S	I-PRGE
+protein	I-PRGE
+,	O
+including	O
+full	O
+-	O
+length	O
+S	O
+,	O
+S1	O
+,	O
+and	O
+receptor	O
+-	O
+binding	O
+domain	O
+(	O
+RBD	O
+).	O
+
+ABSTRACT	O
+:	O
+The	O
+European	O
+Virus	O
+Archive	O
+(	O
+EVA	B-DISO
+)	O
+was	O
+created	O
+in	O
+2008	O
+with	O
+funding	O
+from	O
+the	O
+FP7	O
+-	O
+EU	O
+Infrastructure	O
+Programme	O
+,	O
+in	O
+response	O
+to	O
+the	O
+need	O
+for	O
+a	O
+coordinated	O
+and	O
+readily	O
+accessible	O
+collection	O
+of	O
+viruses	B-SPEC
+that	O
+could	O
+be	O
+made	O
+available	O
+to	O
+academia	O
+,	O
+public	O
+health	O
+organisations	O
+and	O
+industry	O
+.	O
+
+TITLE	O
+:	O
+Immune	B-PROC
+Responses	I-PROC
+to	O
+Middle	O
+East	O
+Respiratory	O
+Syndrome	B-DISO
+Coronavirus	B-SPEC
+During	O
+the	O
+Acute	O
+and	O
+Convalescent	O
+Phases	O
+of	O
+Human	O
+Infection	B-DISO
+.	O
+
+Distinctively	O
+high	O
+frequencies	O
+of	O
+MERS	B-PRGE
+coronavirus	I-PRGE
+-	I-PRGE
+reactive	I-PRGE
+CD8	I-PRGE
++	I-PRGE
+T	B-ANAT
+cells	I-ANAT
+were	O
+also	O
+observed	O
+in	O
+patients	O
+with	O
+severe	O
+/	O
+moderate	O
+illness	O
+,	O
+whereas	O
+antibody	B-COMP
+and	O
+CD4	B-PRGE
++	I-PRGE
+T	B-ANAT
+-	I-ANAT
+cell	I-ANAT
+responses	O
+were	O
+minimally	O
+detected	O
+at	O
+this	O
+stage	O
+.	O
+
+While	O
+CD8	B-PRGE
++	I-PRGE
+T	I-PRGE
+cells	O
+responded	O
+preferentially	O
+to	O
+the	O
+viral	B-PRGE
+S	I-PRGE
+protein	I-PRGE
+compared	O
+with	O
+E	O
+/	O
+M	O
+/	O
+N	O
+proteins	B-CHED
+,	O
+especially	O
+at	O
+the	O
+acute	O
+stage	O
+,	O
+slightly	O
+more	O
+CD4	O
++	O
+T	B-ANAT
+cells	I-ANAT
+recognized	O
+E	O
+/	O
+M	O
+/	O
+N	O
+proteins	B-CHED
+compared	O
+with	O
+S	B-PRGE
+protein	I-PRGE
+at	O
+the	O
+convalescent	O
+phase	O
+.	O
+
+Despite	O
+extensive	O
+studies	O
+performed	O
+to	O
+elucidate	O
+the	O
+function	O
+of	O
+several	O
+viral	O
+proteins	B-CHED
+,	O
+the	O
+contribution	O
+of	O
+an	O
+accessory	O
+protein	B-CHED
+ORF3	O
+in	O
+PEDV	B-SPEC
+replication	O
+is	O
+still	O
+largely	O
+unknown	O
+.	O
+
+In	O
+PEDV	B-SPEC
+-	O
+infected	O
+cells	B-COMP
+,	O
+ORF3	O
+was	O
+predominantly	O
+localized	O
+in	O
+the	O
+cytoplasm	B-COMP
+,	O
+partially	O
+in	O
+the	O
+endoplasmic	B-COMP
+reticulum	I-COMP
+(	O
+ER	O
+)	O
+and	O
+the	O
+Golgi	B-COMP
+apparatus	I-COMP
+(	O
+Golgi	B-COMP
+).	O
+
+RESULTS	O
+:	O
+Among	O
+the	O
+543	O
+patients	O
+undergoing	O
+pneumonectomy	O
+,	O
+89	O
+(	O
+16	O
+.	O
+4	O
+%)	O
+needed	O
+reintubation	O
+within	O
+the	O
+30th	O
+postoperative	O
+day	O
+,	O
+including	O
+60	O
+(	O
+11	O
+%)	O
+who	O
+developed	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+.	O
+
+ABSTRACT	O
+:	O
+European	O
+populations	O
+of	O
+free	O
+-	O
+living	O
+wildcats	O
+have	O
+been	O
+shown	O
+to	O
+be	O
+exposed	O
+to	O
+cat	B-SPEC
+viruses	B-SPEC
+.	O
+
+TITLE	O
+:	O
+Herd	O
+level	O
+estimation	O
+of	O
+probability	O
+of	O
+disease	O
+freedom	O
+applied	O
+on	O
+the	O
+Norwegian	O
+control	O
+program	O
+for	O
+bovine	B-SPEC
+respiratory	I-SPEC
+syncytial	I-SPEC
+virus	I-SPEC
+and	O
+bovine	B-SPEC
+coronavirus	B-SPEC
+.	O
+
+The	O
+aim	O
+of	O
+this	O
+study	O
+was	O
+to	O
+estimate	O
+the	O
+probability	O
+of	O
+freedom	O
+(	O
+PostPFree	O
+)	O
+from	O
+BRSV	B-SPEC
+and	O
+BCV	B-SPEC
+antibodies	B-COMP
+over	O
+time	O
+by	O
+use	O
+of	O
+bulk	O
+tank	O
+milk	O
+(	O
+BTM	O
+)	O
+antibody	B-COMP
+-	O
+testing	O
+,	O
+geographic	O
+information	O
+and	O
+animal	B-SPEC
+movement	B-PROC
+data	O
+,	O
+and	O
+to	O
+validate	O
+the	O
+herd	O
+-	O
+level	O
+estimates	O
+against	O
+subsequent	O
+BTM	O
+testing	O
+.	O
+
+TITLE	O
+:	O
+Reverse	O
+Genetics	O
+for	O
+Type	O
+I	O
+Feline	B-SPEC
+Coronavirus	B-SPEC
+Field	O
+Isolate	O
+
+To	O
+Study	O
+the	O
+Molecular	O
+Pathogenesis	B-PROC
+of	O
+Feline	B-DISO
+Infectious	I-DISO
+Peritonitis	I-DISO
+.	O
+
+ABSTRACT	O
+:	O
+Avian	B-SPEC
+coronavirus	I-SPEC
+infectious	B-DISO
+bronchitis	B-DISO
+virus	B-SPEC
+(	O
+IBV	B-SPEC
+)	O
+infects	O
+domestic	O
+fowl	O
+,	O
+resulting	O
+in	O
+respiratory	B-DISO
+disease	I-DISO
+and	O
+causing	O
+serious	O
+losses	O
+in	O
+unprotected	O
+birds	B-SPEC
+.	O
+
+Intracranial	O
+infection	B-DISO
+of	O
+mice	B-SPEC
+with	O
+the	O
+neurotropic	O
+JHM	O
+strain	O
+of	O
+mouse	B-DISO
+hepatitis	I-DISO
+virus	B-SPEC
+(	O
+JHMV	O
+)	O
+results	O
+in	O
+immune	O
+-	O
+mediated	O
+demyelination	B-DISO
+and	O
+axonopathy	O
+,	O
+making	O
+this	O
+an	O
+excellent	O
+model	O
+to	O
+interrogate	O
+the	O
+therapeutic	O
+potential	O
+of	O
+stem	B-ANAT
+cell	I-ANAT
+derivatives	O
+in	O
+evoking	O
+remyelination	B-PROC
+.	O
+
+This	O
+review	O
+provides	O
+a	O
+succinct	O
+overview	O
+of	O
+our	O
+recent	O
+findings	O
+using	O
+intraspinal	O
+injection	O
+of	O
+mouse	B-SPEC
+CNS	B-CHED
+neural	O
+progenitor	B-ANAT
+cells	I-ANAT
+and	O
+human	B-SPEC
+neural	O
+precursors	O
+into	O
+JHMV	O
+-	O
+infected	O
+mice	B-SPEC
+.	O
+
+Identification	O
+of	O
+the	O
+HIV	O
+-	O
+1	O
+Maturation	B-PROC
+Inhibitor	O
+4	O
+-((	O
+1	O
+R	O
+,	O
+3a	O
+S	O
+,	O
+5a	O
+R	O
+,	O
+5b	O
+R	O
+,	O
+7a	O
+R	O
+,	O
+11a	O
+S	O
+,	O
+11b	O
+R	O
+,	O
+13a	O
+R	O
+,	O
+13b	O
+R	O
+)-	O
+3a	O
+-((	O
+2	O
+-(	O
+1	O
+,	O
+1	O
+-	O
+Dioxidothiomorpholino	O
+)	O
+ethyl	B-CHED
+)	O
+amino	O
+)-	O
+5a	O
+,	O
+5b	O
+,	O
+8	O
+,	O
+8	O
+,	O
+11a	O
+-	O
+pentamethyl	O
+-	O
+1	O
+-(	O
+prop	B-CHED
+-	I-CHED
+1	I-CHED
+-	I-CHED
+en	I-CHED
+-	I-CHED
+2	I-CHED
+-	I-CHED
+yl	I-CHED
+)-	O
+2	O
+,	O
+3	O
+,	O
+3a	O
+,	O
+4	O
+,	O
+5	O
+,	O
+5a	O
+,	O
+5b	O
+,	O
+6	O
+,	O
+7	O
+,	O
+7a	O
+,	O
+8	O
+,	O
+11	O
+,	O
+11a	O
+,	O
+11b	O
+,	O
+12	O
+,	O
+13	O
+,	O
+13a	O
+,	O
+13b	O
+-	O
+octadecahydro	O
+-	O
+1	O
+H	O
+-	O
+cyclopenta	O
+[	O
+a	O
+]	O
+chrysen	B-CHED
+-	O
+9	O
+-	O
+yl	O
+)	O
+benzoic	B-CHED
+Acid	I-CHED
+(	O
+GSK3532795	O
+,	O
+BMS	O
+-	O
+955176	O
+).	O
+
+The	O
+careful	O
+design	O
+,	O
+selection	O
+,	O
+and	O
+evaluation	O
+of	O
+substituents	O
+appended	O
+to	O
+the	O
+C	O
+-	O
+3	O
+and	O
+C	O
+-	O
+17	O
+positions	O
+of	O
+the	O
+natural	B-CHED
+product	I-CHED
+betulinic	B-CHED
+acid	I-CHED
+(	O
+3	O
+)	O
+was	O
+critical	O
+in	O
+attaining	O
+a	O
+molecule	O
+with	O
+the	O
+desired	O
+virological	O
+and	O
+pharmacokinetic	O
+profile	O
+.	O
+
+These	O
+modifications	O
+ultimately	O
+enabled	O
+the	O
+discovery	O
+of	O
+1	O
+as	O
+a	O
+second	O
+-	O
+generation	O
+MI	O
+that	O
+combines	O
+broad	O
+coverage	O
+of	O
+polymorphic	O
+viruses	B-SPEC
+(	O
+EC	O
+
+Exposures	O
+to	O
+ozone	B-CHED
+,	O
+nitrogen	B-CHED
+dioxide	I-CHED
+,	O
+sulfur	B-CHED
+dioxide	I-CHED
+,	O
+carbon	B-CHED
+monoxide	I-CHED
+,	O
+and	O
+particulate	O
+matter	O
+less	O
+than	O
+2	O
+.	O
+5	O
+μm	O
+were	O
+assessed	O
+by	O
+weighted	O
+averages	O
+of	O
+daily	O
+levels	O
+from	O
+all	O
+monitors	B-SPEC
+within	O
+50	O
+km	O
+of	O
+the	O
+geocoded	O
+location	O
+of	O
+a	O
+patient	O
+'	O
+s	O
+residence	O
+.	O
+
+TITLE	O
+:	O
+Inhibition	B-PROC
+of	O
+Stress	B-COMP
+Granule	I-COMP
+Formation	B-PROC
+by	O
+Middle	O
+East	O
+Respiratory	O
+Syndrome	B-DISO
+Coronavirus	B-SPEC
+4a	O
+Accessory	O
+Protein	O
+Facilitates	O
+Viral	O
+Translation	B-PROC
+,	O
+Leading	O
+to	O
+Efficient	O
+Virus	B-PROC
+Replication	I-PROC
+.	O
+
+The	O
+main	O
+clinical	O
+manifestations	O
+are	O
+fever	B-PROC
+,	O
+chills	B-DISO
+,	O
+generalized	O
+myalgia	B-DISO
+,	O
+cough	B-DISO
+,	O
+shortness	B-DISO
+of	I-DISO
+breath	I-DISO
+,	O
+nausea	B-DISO
+,	I-DISO
+vomiting	I-DISO
+and	I-DISO
+diarrhea	I-DISO
+.	O
+
+MERS	O
+-	O
+CoV	O
+infection	B-DISO
+is	O
+an	O
+emerging	O
+global	O
+health	O
+concern	O
+,	O
+affected	O
+people	O
+in	O
+27	O
+countries	O
+in	O
+the	O
+various	O
+continents	O
+.	O
+
+RESULTS	O
+:	O
+The	O
+global	O
+prevalence	O
+of	O
+MERS	O
+-	O
+CoV	O
+infection	B-DISO
+from	O
+June	O
+2012	O
+to	O
+April	O
+2018	O
+is	O
+2206	O
+people	O
+.	O
+
+The	O
+age	O
+-	O
+allied	O
+prevalence	O
+of	O
+MERS	O
+-	O
+CoV	O
+was	O
+highest	O
+amongst	O
+elderly	O
+people	O
+with	O
+chronic	O
+debilitating	O
+diseases	O
+such	O
+as	O
+pulmonary	B-DISO
+diseases	I-DISO
+,	O
+end	O
+-	O
+stage	O
+renal	B-ANAT
+illness	O
+,	O
+diabetes	B-DISO
+mellitus	I-DISO
+and	O
+malignancy	B-DISO
+.	O
+
+Mice	B-SPEC
+were	O
+immunized	O
+intranasally	O
+with	O
+the	O
+inactivated	O
+split	O
+influenza	B-PATH
+A	I-PATH
+(	O
+H7N9	O
+)	O
+virus	B-SPEC
+(	O
+A	O
+/	O
+Shanghai	O
+/	O
+02	O
+/	O
+2013	O
+)	O
+vaccine	O
+with	O
+or	O
+without	O
+JY	O
+.	O
+
+ABSTRACT	O
+:	O
+Vaccination	O
+programs	O
+against	O
+infectious	O
+bronchitis	B-DISO
+virus	B-SPEC
+(	O
+IBV	B-SPEC
+)	O
+in	O
+Egypt	O
+depend	O
+on	O
+both	O
+classical	O
+and	O
+/	O
+or	O
+imported	O
+variant	O
+IBV	B-SPEC
+strain	O
+vaccines	O
+.	O
+
+The	O
+att	B-PRGE
+-	I-PRGE
+IBM41	I-PRGE
+and	O
+att	B-PRGE
+-	I-PRGE
+IB2	I-PRGE
+vaccines	O
+were	O
+able	O
+to	O
+reduce	O
+the	O
+shedding	O
+of	O
+the	O
+challenge	O
+at	O
+3	O
+days	O
+post	O
+-	O
+infection	B-DISO
+(	O
+DPI	B-DISO
+)	O
+and	O
+no	O
+virus	B-DISO
+shedding	I-DISO
+was	O
+detected	O
+in	O
+both	O
+vaccinated	O
+groups	O
+by	O
+5	O
+DPI	B-DISO
+.	O
+
+The	O
+expression	B-PROC
+of	O
+chemokines	O
+capable	O
+of	O
+recruiting	O
+leukocytes	B-ANAT
+,	O
+including	O
+monocytes	B-ANAT
+/	O
+macrophages	B-ANAT
+,	O
+natural	B-ANAT
+killer	I-ANAT
+cells	I-ANAT
+,	O
+granulocytes	B-ANAT
+,	O
+T	B-ANAT
+cells	I-ANAT
+,	O
+and	O
+dendritic	B-ANAT
+cells	B-COMP
+,	O
+was	O
+also	O
+increased	O
+following	O
+HBD	B-DISO
+2	O
+-	O
+conjugated	O
+S	O
+RBD	O
+treatment	O
+.	O
+
+The	O
+full	O
+-	O
+length	O
+genome	O
+of	O
+the	O
+G2b	O
+Taiwan	O
+PEDV	B-SPEC
+-	O
+Pintung	O
+52	O
+(	O
+PEDV	B-SPEC
+-	O
+PT	O
+)	O
+strain	O
+and	O
+its	O
+intestinal	B-ANAT
+tropism	B-PROC
+by	O
+evaluating	O
+the	O
+pathological	O
+changes	O
+in	O
+the	O
+original	O
+PEDV	B-SPEC
+-	O
+PT	O
+infected	O
+field	O
+piglet	O
+and	O
+orally	B-ANAT
+inoculation	O
+of	O
+either	O
+10	O
+,	O
+10	O
+
+ABSTRACT	O
+:	O
+Porcine	O
+Epidemic	O
+Diarrhoea	O
+Virus	O
+(	O
+PEDV	B-SPEC
+)	O
+causes	O
+watery	B-DISO
+diarrhoea	I-DISO
+,	O
+dehydration	B-DISO
+,	O
+and	O
+a	O
+high	O
+mortality	O
+rate	O
+among	O
+suckling	O
+pigs	B-SPEC
+.	O
+
+During	O
+this	O
+time	O
+,	O
+PEDV	B-SPEC
+was	O
+detected	O
+by	O
+real	O
+-	O
+time	O
+PCR	O
+in	O
+438	O
+farms	O
+located	O
+mainly	O
+in	O
+the	O
+high	O
+-	O
+density	O
+pig	B-SPEC
+production	O
+area	O
+in	O
+Northern	O
+Italy	O
+.	O
+
+Most	O
+of	O
+the	O
+outbreaks	O
+were	O
+in	O
+farrow	O
+-	O
+to	O
+-	O
+finish	O
+,	O
+farrow	O
+-	O
+to	O
+-	O
+wean	B-PROC
+and	O
+finisher	O
+farms	O
+.	O
+
+A	O
+sequence	O
+analysis	O
+showed	O
+that	O
+a	O
+PEDV	B-SPEC
+strain	O
+,	O
+similar	O
+to	O
+the	O
+OH851	O
+S	O
+-	O
+INDEL	B-PROC
+strain	O
+isolated	O
+in	O
+the	O
+USA	O
+in	O
+January	O
+2014	O
+,	O
+was	O
+responsible	O
+for	O
+the	O
+outbreaks	O
+in	O
+Italy	O
+in	O
+2015	O
+and	O
+2016	O
+.	O
+
+Also	O
+,	O
+PEEP	B-CHED
+values	O
+were	O
+constantly	O
+increased	O
+during	O
+surgery	O
+[	O
+ε	O
+=	O
+0	O
+.	O
+252	O
+,	O
+F	O
+(	O
+1	O
+.	O
+766	O
+,	O
+5	O
+.	O
+297	O
+)=	O
+9	O
+.	O
+994	O
+,	O
+p	O
+=	O
+0	O
+.	O
+017	O
+],	O
+with	O
+the	O
+highest	O
+values	O
+being	O
+observed	O
+towards	O
+to	O
+the	O
+end	O
+of	O
+the	O
+procedure	O
+.	O
+
+Our	O
+results	O
+showed	O
+that	O
+the	O
+rNDV	O
+expressing	O
+the	O
+S	B-PRGE
+protein	B-CHED
+of	O
+IBV	B-SPEC
+provided	O
+better	O
+protection	O
+than	O
+the	O
+rNDV	O
+expressing	O
+S1	O
+or	O
+S2	B-PRGE
+protein	I-PRGE
+of	O
+IBV	B-SPEC
+,	O
+indicating	O
+that	O
+the	O
+S	B-PRGE
+protein	I-PRGE
+is	O
+the	O
+best	O
+protective	O
+antigen	B-CHED
+of	O
+IBV	B-SPEC
+.	O
+
+Immunization	O
+of	O
+4	O
+-	O
+week	O
+-	O
+old	O
+SPF	B-PRGE
+chickens	I-PRGE
+with	O
+the	O
+rNDV	O
+expressing	O
+S	B-PRGE
+protein	I-PRGE
+elicited	O
+IBV	B-SPEC
+-	O
+specific	O
+neutralizing	O
+antibodies	B-COMP
+and	O
+provided	O
+complete	O
+protection	O
+against	O
+virulent	O
+IBV	B-SPEC
+and	O
+virulent	O
+NDV	B-SPEC
+challenges	O
+.	O
+
+The	O
+purpose	O
+of	O
+this	O
+study	O
+is	O
+to	O
+evaluate	O
+outcomes	O
+in	O
+MICU	O
+lung	B-ANAT
+transplant	B-ANAT
+recipients	O
+with	O
+acute	B-DISO
+respiratory	I-DISO
+failure	I-DISO
+treated	O
+with	O
+non	O
+-	O
+invasive	O
+positive	O
+pressure	O
+ventilation	O
+(	O
+NPPV	O
+)	O
+and	O
+identify	O
+factors	O
+associated	O
+with	O
+NPPV	O
+failure	O
+(	O
+need	O
+for	O
+intubation	O
+).	O
+
+A	O
+series	O
+of	O
+novel	O
+2	O
+-	O
+thiazolyl	O
+substituted	O
+-	O
+2	O
+,	O
+3	O
+-	O
+dihydro	O
+-	O
+1H	O
+-	O
+naphtho	O
+[	O
+1	O
+,	O
+2	O
+-	O
+e	O
+][	O
+1	O
+,	O
+3	O
+]	O
+oxazine	O
+derivatives	O
+were	O
+designed	O
+and	O
+synthesized	O
+based	O
+on	O
+their	O
+structure	O
+-	O
+activity	O
+relationships	O
+(	O
+SARs	B-DISO
+)	O
+from	O
+2	B-CHED
+-	I-CHED
+naphthol	I-CHED
+,	O
+substituted	O
+thiazolyl	O
+amines	B-CHED
+and	O
+formalin	B-CHED
+through	O
+ring	O
+closure	O
+by	O
+one	O
+-	O
+pot	B-DISO
+three	O
+component	O
+reaction	O
+.	O
+
+The	O
+objective	O
+of	O
+this	O
+study	O
+was	O
+to	O
+determine	O
+if	O
+feed	O
+batch	O
+sequencing	O
+methods	O
+could	O
+minimize	O
+PEDV	B-SPEC
+cross	O
+-	O
+contamination	O
+.	O
+
+Porcine	B-SPEC
+epidemic	I-SPEC
+diarrhea	I-SPEC
+virus	I-SPEC
+-	O
+free	O
+swine	B-SPEC
+feed	O
+was	O
+manufactured	O
+to	O
+represent	O
+the	O
+negative	O
+control	O
+.	O
+
+Subsequently	O
+,	O
+4	O
+sequence	O
+batches	O
+(	O
+sequence	O
+1	O
+to	O
+4	O
+)	O
+were	O
+formed	O
+by	O
+adding	O
+a	O
+50	O
+kg	O
+batch	O
+of	O
+PEDV	B-SPEC
+-	O
+negative	O
+feed	O
+to	O
+the	O
+mixer	O
+after	O
+the	O
+prior	O
+batch	O
+was	O
+mixed	O
+and	O
+conveyed	O
+;	O
+all	O
+sequences	O
+were	O
+mixed	O
+,	O
+conveyed	O
+,	O
+and	O
+sampled	O
+similar	O
+to	O
+the	O
+negative	O
+and	O
+positive	O
+control	O
+batches	O
+.	O
+
+Furthermore	O
+,	O
+camel	B-SPEC
+/	O
+human	B-SPEC
+chimeric	O
+HCAbs	O
+-	O
+composed	O
+of	O
+the	O
+camel	B-SPEC
+VHH	O
+linked	O
+to	O
+a	O
+human	B-PRGE
+Fc	I-PRGE
+domain	I-PRGE
+lacking	O
+the	O
+CH1	B-PRGE
+exon	O
+-	O
+had	O
+an	O
+extended	O
+half	O
+-	O
+life	O
+in	O
+the	O
+serum	B-COMP
+and	O
+protected	O
+mice	B-SPEC
+against	O
+a	O
+lethal	O
+MERS	O
+-	O
+CoV	O
+challenge	O
+.	O
+
+ABSTRACT	O
+:	O
+The	O
+Middle	O
+East	O
+Respiratory	O
+Syndrome	O
+Coronavirus	B-SPEC
+(	O
+MERS	O
+-	O
+CoV	O
+)	O
+is	O
+a	O
+novel	B-SPEC
+coronavirus	I-SPEC
+circulating	O
+in	O
+the	O
+Arabian	O
+Peninsula	O
+since	O
+September	O
+2012	O
+.	O
+
+It	O
+leads	O
+to	O
+significant	O
+respiratory	B-DISO
+disease	I-DISO
+and	O
+among	O
+patients	O
+with	O
+co	O
+-	O
+morbidities	O
+is	O
+associated	O
+with	O
+high	O
+mortality	O
+.	O
+
+Many	O
+patients	O
+had	O
+underlying	O
+co	O
+-	O
+morbidities	O
+,	O
+including	O
+diabetes	B-DISO
+mellitus	I-DISO
+(	O
+51	O
+.	O
+9	O
+%),	O
+hypertension	B-DISO
+(	O
+46	O
+.	O
+2	O
+%),	O
+and	O
+chronic	B-DISO
+renal	I-DISO
+disease	I-DISO
+(	O
+21	O
+.	O
+2	O
+%).	O
+
+TITLE	O
+:	O
+Cryo	O
+-	O
+EM	O
+structure	O
+of	O
+the	O
+SARS	B-PRGE
+coronavirus	B-SPEC
+spike	I-PRGE
+glycoprotein	B-CHED
+in	O
+complex	O
+with	O
+its	O
+host	B-COMP
+cell	I-COMP
+receptor	I-PRGE
+ACE2	I-PRGE
+.	O
+
+Disassociation	O
+of	O
+the	O
+S1	B-PRGE
+-	I-PRGE
+ACE2	I-PRGE
+complex	I-PRGE
+from	O
+some	O
+of	O
+the	O
+prefusion	O
+spikes	O
+was	O
+observed	O
+and	O
+characterized	O
+.	O
+
+However	O
+,	O
+binding	B-FUNC
+to	O
+the	O
+receptor	O
+opens	O
+up	O
+the	O
+receptor	O
+-	O
+binding	B-FUNC
+domain	O
+of	O
+S1	O
+,	O
+which	O
+could	O
+promote	O
+the	O
+release	B-PATH
+of	O
+the	O
+S1	B-PRGE
+-	I-PRGE
+ACE2	I-PRGE
+complex	I-PRGE
+and	O
+S1	O
+monomers	O
+from	O
+the	O
+prefusion	O
+spike	O
+and	O
+trigger	O
+the	O
+pre	O
+-	O
+to	O
+postfusion	O
+conformational	O
+transition	B-DISO
+.	O
+
+Furthermore	O
+,	O
+recombination	B-PROC
+analysis	O
+indicated	O
+that	O
+GII	O
+-	O
+c	O
+viruses	B-SPEC
+evolved	O
+from	O
+a	O
+recombinant	O
+virus	B-SPEC
+that	O
+acquired	O
+the	O
+5	O
+'	O
+part	O
+of	O
+the	O
+spike	O
+gene	O
+from	O
+the	O
+GI	O
+-	O
+a	O
+subgroup	O
+and	O
+the	O
+remaining	O
+genomic	O
+regions	O
+from	O
+the	O
+GII	O
+-	O
+a	O
+subgroup	O
+.	O
+
+TITLE	O
+:	O
+Chemokine	O
+CXCL10	O
+and	O
+Coronavirus	B-SPEC
+-	O
+Induced	O
+Neurologic	O
+Disease	O
+.	O
+
+Functional	O
+studies	O
+that	O
+have	O
+blocked	O
+expression	B-PROC
+of	O
+either	O
+CXCL10	B-PRGE
+or	O
+CXCR3	B-PRGE
+illuminate	O
+the	O
+important	O
+role	O
+of	O
+this	O
+signaling	B-PROC
+pathway	I-PROC
+in	O
+host	B-PROC
+defense	I-PROC
+and	O
+neurodegeneration	B-DISO
+in	O
+a	O
+model	O
+of	O
+viral	O
+-	O
+induced	O
+neurologic	O
+disease	O
+.	O
+
+TITLE	O
+:	O
+Adaptive	O
+Evolution	B-PROC
+of	O
+MERS	O
+-	O
+CoV	O
+to	O
+Species	B-SPEC
+Variation	O
+in	O
+DPP4	B-PRGE
+.	O
+
+ABSTRACT	O
+:	O
+Middle	O
+East	O
+Respiratory	O
+Syndrome	O
+Coronavirus	B-SPEC
+(	O
+MERS	O
+-	O
+CoV	O
+)	O
+likely	O
+originated	O
+in	O
+bats	B-SPEC
+and	O
+passed	O
+to	O
+humans	B-SPEC
+through	O
+dromedary	B-SPEC
+camels	B-SPEC
+;	O
+however	O
+,	O
+the	O
+genetic	O
+mechanisms	O
+underlying	O
+cross	O
+-	O
+species	B-SPEC
+adaptation	B-PROC
+remain	O
+poorly	O
+understood	O
+.	O
+
+ABSTRACT	O
+:	O
+Middle	O
+East	O
+respiratory	O
+syndrome	B-DISO
+coronavirus	B-SPEC
+(	O
+MERS	O
+-	O
+CoV	O
+)	O
+nsp1	B-PRGE
+suppresses	O
+host	B-PRGE
+gene	B-PROC
+expression	I-PROC
+in	O
+expressed	B-PROC
+cells	B-COMP
+by	O
+inhibiting	O
+translation	B-PROC
+and	O
+inducing	O
+endonucleolytic	O
+cleavage	B-PROC
+of	O
+host	B-COMP
+mRNAs	O
+,	O
+the	O
+latter	O
+of	O
+which	O
+leads	O
+to	O
+mRNA	B-PROC
+decay	B-DISO
+.	O
+
+We	O
+examined	O
+the	O
+biological	O
+functions	O
+of	O
+nsp1	B-PRGE
+in	O
+infected	O
+cells	B-COMP
+and	O
+its	O
+role	O
+in	O
+virus	B-PROC
+replication	I-PROC
+by	O
+using	O
+wild	O
+-	O
+type	O
+MERS	O
+-	O
+CoV	O
+and	O
+two	O
+mutant	B-DISO
+viruses	B-SPEC
+with	O
+specific	O
+mutations	O
+in	O
+the	O
+nsp1	B-PRGE
+;	O
+one	O
+mutant	B-DISO
+lacked	O
+both	O
+biological	O
+functions	O
+,	O
+while	O
+the	O
+other	O
+lacked	O
+the	O
+RNA	O
+cleavage	B-PROC
+function	O
+but	O
+retained	O
+the	O
+translation	B-PROC
+inhibition	B-PROC
+function	O
+.	O
+
+In	O
+293	O
+-	O
+derived	O
+cells	B-COMP
+,	O
+the	O
+three	O
+viruses	B-SPEC
+accumulated	O
+similar	O
+levels	O
+of	O
+nsp1	B-PRGE
+and	O
+major	O
+viral	O
+structural	O
+proteins	B-CHED
+and	O
+did	O
+not	O
+induce	O
+
+We	O
+used	O
+latent	O
+class	B-SPEC
+analysis	O
+to	O
+identify	O
+patients	O
+with	O
+distinct	O
+MMP	B-CHED
+profiles	O
+and	O
+then	O
+associated	O
+those	O
+profiles	O
+with	O
+markers	O
+of	O
+inflammation	B-DISO
+(	O
+IL	B-FUNC
+-	I-FUNC
+1RA	I-FUNC
+,	O
+-	O
+6	O
+,	O
+-	O
+8	O
+,	O
+-	O
+10	O
+,	O
+and	O
+-	O
+18	O
+;	O
+macrophage	B-ANAT
+inflammatory	O
+protein	B-CHED
+-	O
+1α	O
+and	O
+-	O
+1β	O
+;	O
+tumor	B-PRGE
+necrosis	I-PRGE
+factor	I-PRGE
+-	I-PRGE
+α	I-PRGE
+and	O
+-	O
+R2	O
+),	O
+endothelial	B-ANAT
+injury	O
+(	O
+angiopoietin	B-PRGE
+-	I-PRGE
+2	I-PRGE
+,	O
+von	B-PRGE
+Willebrand	I-PRGE
+factor	I-PRGE
+,	O
+soluble	O
+thrombomodulin	B-PRGE
+),	O
+impaired	B-DISO
+oxygenation	B-PROC
+(	O
+Pa	O
+In	O
+geographically	O
+distinct	O
+derivation	O
+and	O
+validation	O
+cohorts	O
+,	O
+approximately	O
+one	O
+-	O
+third	O
+of	O
+patients	O
+demonstrated	O
+an	O
+MMP	O
+profile	O
+characterized	O
+by	O
+elevated	O
+MMP	B-PRGE
+-	I-PRGE
+1	I-PRGE
+,	I-PRGE
+-	I-PRGE
+2	I-PRGE
+,	I-PRGE
+-	I-PRGE
+3	I-PRGE
+,	I-PRGE
+-	I-PRGE
+7	I-PRGE
+,	I-PRGE
+and	I-PRGE
+-	I-PRGE
+8	I-PRGE
+and	I-PRGE
+tissue	B-ANAT
+inhibitor	B-CHED
+of	I-PRGE
+metalloproteinase	I-PRGE
+-	I-PRGE
+1	I-PRGE
+and	O
+-	O
+2	O
+;	O
+and	O
+depressed	O
+active	O
+and	O
+total	O
+MMP	B-CHED
+-	O
+9	O
+.	O
+
+Pediatric	O
+patients	O
+with	O
+ARDS	B-DISO
+have	O
+specific	O
+plasma	B-ANAT
+MMP	B-CHED
+profiles	O
+associated	O
+with	O
+inflammation	B-DISO
+,	O
+endothelial	B-ANAT
+injury	O
+,	O
+morbidity	O
+,	O
+and	O
+mortality	O
+.	O
+
+MMPs	O
+may	O
+play	O
+a	O
+role	O
+in	O
+the	O
+pathobiology	O
+of	O
+children	O
+with	O
+ARDS	B-DISO
+.	O
+
+TITLE	O
+:	O
+Extracorporeal	O
+Membrane	B-COMP
+Oxygenation	B-PROC
+in	O
+Predominantly	O
+Leuco	O
+-	O
+and	O
+Thrombocytopenic	O
+Haematologic	O
+/	O
+Oncologic	O
+Patients	O
+with	O
+Acute	O
+Respiratory	O
+Distress	O
+Syndrome	O
+-	O
+a	O
+Single	O
+-	O
+Centre	O
+Experience	O
+.	O
+
+All	O
+but	O
+9	O
+/	O
+3	O
+patients	O
+suffered	B-DISO
+from	O
+leuco	O
+-/	O
+thrombocytopenia	O
+due	O
+to	O
+anti	O
+-	O
+cancer	B-DISO
+treatment	O
+or	O
+underlying	O
+disease	O
+.	O
+
+Overall	O
+,	O
+17	O
+patients	O
+(	O
+68	O
+%)	O
+died	B-PROC
+on	O
+ECMO	O
+,	O
+whereas	O
+5	O
+patients	O
+survived	O
+to	O
+hospital	O
+discharge	B-ANAT
+(	O
+20	O
+%).	O
+
+RESULTS	O
+:	O
+25	O
+patients	O
+,	O
+11	O
+of	O
+whom	O
+underwent	O
+haematopoietic	B-ANAT
+stem	I-ANAT
+cell	I-ANAT
+transplantation	O
+(	O
+SCT	B-DISO
+),	O
+were	O
+analysed	O
+.	O
+
+At	O
+last	O
+,	O
+we	O
+discussed	O
+the	O
+breakthrough	O
+on	O
+vaccine	O
+and	O
+therapeutic	O
+development	B-PROC
+which	O
+are	O
+important	O
+against	O
+potential	O
+future	O
+MERS	O
+outbreak	O
+.	O
+
+TITLE	O
+:	O
+Development	B-PROC
+of	O
+a	O
+diagnostic	O
+system	O
+for	O
+detection	O
+of	O
+specific	O
+antibodies	B-COMP
+and	O
+antigens	B-CHED
+against	O
+Middle	O
+East	O
+respiratory	O
+syndrome	O
+coronavirus	B-SPEC
+.	O
+
+Moreover	O
+,	O
+MAbs	O
+were	O
+induced	O
+with	O
+the	O
+recombinant	O
+S	O
+protein	O
+and	O
+RBD	O
+and	O
+used	O
+for	O
+sandwich	O
+ELISA	O
+to	O
+detect	O
+the	O
+MERS	B-PRGE
+-	I-PRGE
+CoV	I-PRGE
+S	I-PRGE
+protein	I-PRGE
+.	O
+
+ABSTRACT	O
+:	O
+To	O
+determine	O
+risk	O
+factors	O
+identifiable	O
+at	O
+hospital	O
+arrival	O
+associated	O
+with	O
+acute	O
+respiratory	O
+distress	O
+syndrome	O
+development	B-PROC
+among	O
+critically	O
+injured	O
+children	O
+.	O
+
+ABSTRACT	O
+:	O
+Veno	O
+-	O
+venous	O
+extracorporeal	O
+membrane	B-COMP
+oxygenation	B-PROC
+(	O
+ECMO	O
+)	O
+can	O
+be	O
+a	O
+lifesaving	O
+therapy	O
+for	O
+patients	O
+with	O
+severe	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+(	O
+ARDS	B-DISO
+).	O
+
+Over	O
+a	O
+5	O
+-	O
+year	O
+period	O
+,	O
+we	O
+studied	O
+ARDS	B-DISO
+patients	O
+who	O
+had	O
+been	O
+transported	O
+to	O
+our	O
+department	O
+by	O
+our	O
+mobile	O
+ECMO	O
+team	O
+for	O
+further	O
+treatment	O
+after	O
+ECMO	O
+had	O
+already	O
+been	O
+initiated	O
+at	O
+the	O
+referring	O
+hospital	O
+.	O
+
+Twenty	O
+-	O
+six	O
+patients	O
+(	O
+35	O
+%)	O
+died	B-PROC
+in	O
+our	O
+intensive	O
+care	O
+unit	O
+due	O
+to	O
+a	O
+therapy	O
+refractory	O
+course	O
+,	O
+comorbidities	O
+or	O
+limitation	O
+of	O
+therapy	O
+.	O
+
+ABSTRACT	O
+:	O
+Pertussis	B-PATH
+is	O
+a	O
+severe	O
+respiratory	O
+disease	O
+caused	O
+by	O
+
+TITLE	O
+:	O
+Protein	B-CHED
+kinase	I-ENZY
+R	I-PRGE
+-	O
+like	O
+endoplasmatic	B-PRGE
+reticulum	I-PRGE
+kinase	I-PRGE
+is	O
+a	O
+mediator	O
+of	O
+stretch	O
+in	O
+ventilator	O
+-	O
+induced	O
+lung	O
+injury	O
+.	O
+
+Moreover	O
+,	O
+the	O
+infectivity	O
+of	O
+scIAV	O
+-	O
+S	O
+was	O
+associated	O
+with	O
+the	O
+degree	O
+of	O
+cell	B-COMP
+adaptation	B-PROC
+of	O
+PEDV	B-SPEC
+-	O
+S	O
+.	O
+Intriguingly	O
+,	O
+scIAV	O
+-	O
+S	O
+lacking	O
+functional	O
+neuraminidase	B-PRGE
+(	O
+NA	O
+)	O
+exhibited	O
+substantially	O
+higher	O
+infectivity	O
+,	O
+suggesting	O
+a	O
+pivotal	O
+role	O
+of	O
+the	O
+sialic	O
+acid	O
+in	O
+the	O
+binding	B-FUNC
+/	O
+entry	O
+of	O
+PEDV	B-SPEC
+.	O
+
+The	O
+objective	O
+of	O
+this	O
+study	O
+was	O
+to	O
+evaluate	O
+the	O
+risk	O
+of	O
+hospitalization	O
+from	O
+different	O
+viruses	B-SPEC
+in	O
+children	O
+presenting	O
+with	O
+an	O
+influenza	B-DISO
+-	I-DISO
+like	I-DISO
+illness	I-DISO
+(	O
+ILI	O
+).	O
+
+After	O
+controlling	O
+for	O
+potential	O
+confounders	O
+(	O
+age	O
+,	O
+sex	O
+,	O
+recruitment	B-DISO
+site	O
+,	O
+days	O
+from	O
+symptom	B-DISO
+onset	O
+to	O
+enrollment	O
+,	O
+and	O
+underlying	O
+illnesses	O
+),	O
+children	O
+with	O
+RSV	B-SPEC
+and	O
+metapneumovirus	B-SPEC
+infections	B-DISO
+showed	O
+a	O
+greater	O
+likelihood	O
+of	O
+hospitalization	O
+than	O
+those	O
+infected	O
+by	O
+parainfluenza	B-DISO
+viruses	B-SPEC
+(	O
+OR	O
+2	O
+.	O
+7	O
+and	O
+1	O
+.	O
+9	O
+,	O
+respectively	O
+),	O
+rhinovirus	B-SPEC
+/	O
+enterovirus	B-SPEC
+(	O
+OR	O
+3	O
+.	O
+1	O
+and	O
+2	O
+.	O
+1	O
+,	O
+respectively	O
+),	O
+coronaviruses	O
+(	O
+OR	O
+4	O
+.	O
+9	O
+and	O
+3	O
+.	O
+4	O
+,	O
+respectively	O
+),	O
+adenovirus	B-DISO
+(	O
+OR	O
+4	O
+.	O
+6	O
+and	O
+3	O
+.	O
+2	O
+,	O
+respectively	O
+),	O
+and	O
+influenza	B-DISO
+(	O
+OR	O
+6	O
+.	O
+3	O
+and	O
+4	O
+.	O
+4	O
+,	O
+respectively	O
+).	O
+
+Coronaviral	O
+proteases	O
+,	O
+including	O
+main	O
+proteases	O
+and	O
+papain	B-PRGE
+-	I-PRGE
+like	I-PRGE
+proteases	I-PRGE
+,	O
+are	O
+ideal	O
+antiviral	B-CHED
+targets	O
+because	O
+of	O
+their	O
+essential	O
+roles	O
+in	O
+viral	B-PROC
+maturation	I-PROC
+.	O
+
+ABSTRACT	O
+:	O
+Single	B-PRGE
+-	I-PRGE
+domain	I-PRGE
+antibody	I-PRGE
+(	O
+sdAb	O
+)	O
+or	O
+nanobody	O
+possesses	B-DISO
+specific	O
+features	O
+non	O
+-	O
+accessible	O
+for	O
+conventional	O
+antibodies	B-COMP
+that	O
+make	O
+them	O
+suitable	O
+for	O
+research	O
+and	O
+biotechnological	O
+applications	O
+.	O
+
+Porcine	B-SPEC
+epidemic	I-SPEC
+diarrhea	I-SPEC
+virus	I-SPEC
+(	O
+PEDV	B-SPEC
+)	O
+causes	O
+lethal	O
+diarrhea	B-DISO
+in	O
+piglets	O
+,	O
+resulting	O
+in	O
+great	O
+economic	O
+losses	O
+all	O
+over	O
+the	O
+world	O
+.	O
+
+The	O
+selected	O
+sdAb	B-PRGE
+-	I-PRGE
+Mcs	I-PRGE
+were	O
+solubly	O
+expressed	B-PROC
+in	O
+Escherichia	B-SPEC
+coli	I-SPEC
+.	O
+
+ABSTRACT	O
+:	O
+Numerous	O
+viruses	B-SPEC
+,	O
+mostly	O
+in	O
+mixed	B-DISO
+infections	I-DISO
+,	O
+have	O
+been	O
+associated	O
+worldwide	O
+with	O
+poult	O
+enteritis	B-DISO
+complex	O
+(	O
+PEC	O
+).	O
+
+In	O
+2008	O
+a	O
+coronavirus	B-SPEC
+(	O
+Fr	O
+-	O
+TCoV	O
+080385d	O
+)	O
+was	O
+isolated	O
+in	O
+France	O
+from	O
+turkey	B-SPEC
+poults	O
+exhibiting	O
+clinical	O
+signs	O
+compatible	O
+with	O
+this	O
+syndrome	B-DISO
+.	O
+
+In	O
+2012	O
+,	O
+a	O
+new	O
+human	B-SPEC
+disease	O
+called	O
+Middle	O
+East	O
+respiratory	O
+syndrome	B-DISO
+(	O
+MERS	O
+)	O
+emerged	O
+in	O
+the	O
+Middle	O
+East	O
+.	O
+
+Serum	B-COMP
+samples	O
+were	O
+collected	O
+on	O
+a	O
+weekly	O
+basis	O
+for	O
+the	O
+detection	O
+of	O
+humoral	B-PROC
+immune	I-PROC
+response	I-PROC
+against	O
+H9N2	O
+,	O
+NDV	B-SPEC
+,	O
+and	O
+IBV	B-SPEC
+from	O
+all	O
+chicken	B-SPEC
+groups	O
+.	O
+
+rRT	O
+-	O
+PCR	O
+results	O
+with	O
+virus	B-SPEC
+titration	O
+in	O
+ECEs	O
+revealed	O
+a	O
+significant	O
+increase	O
+in	O
+H9N2	B-PRGE
+AIV	I-PRGE
+titer	O
+with	O
+extension	O
+in	O
+the	O
+period	O
+of	O
+viral	B-DISO
+shedding	I-DISO
+in	O
+Groups	O
+1	O
+and	O
+5	O
+.	O
+
+The	O
+humoral	B-PROC
+immune	I-PROC
+response	I-PROC
+against	O
+H9N2	B-PRGE
+AIV	I-PRGE
+,	O
+NDV	B-SPEC
+,	O
+and	O
+IBV	B-SPEC
+revealed	O
+a	O
+significant	O
+increase	O
+in	O
+H9N2	O
+AIV	O
+titer	O
+in	O
+Groups	O
+1	O
+and	O
+5	O
+,	O
+NDV	B-SPEC
+titer	O
+showed	O
+a	O
+significant	O
+increase	O
+in	O
+Group	O
+7	O
+,	O
+and	O
+IBV	B-SPEC
+titer	O
+increased	O
+in	O
+Groups	O
+1	O
+,	O
+3	O
+,	O
+and	O
+5	O
+.	O
+
+We	O
+investigated	O
+the	O
+presence	O
+of	O
+respiratory	O
+viruses	B-SPEC
+in	O
+the	O
+passenger	O
+environment	O
+of	O
+a	O
+major	O
+airport	O
+in	O
+order	B-SPEC
+to	O
+identify	O
+risk	O
+points	O
+and	O
+guide	O
+measures	O
+to	O
+minimize	O
+transmission	O
+.	O
+
+Among	O
+the	O
+10	O
+respiratory	O
+virus	B-SPEC
+findings	O
+at	O
+various	O
+sites	O
+,	O
+the	O
+viruses	B-SPEC
+identified	O
+were	O
+:	O
+rhinovirus	B-SPEC
+(	O
+4	O
+/	O
+10	O
+,	O
+40	O
+%,	O
+from	O
+surfaces	O
+);	O
+coronavirus	B-SPEC
+(	O
+3	O
+/	O
+10	O
+,	O
+30	O
+%,	O
+from	O
+surfaces	O
+);	O
+adenovirus	B-DISO
+(	O
+2	O
+/	O
+10	O
+,	O
+20	O
+%,	O
+1	O
+air	B-CHED
+sample	O
+,	O
+1	O
+surface	O
+sample	O
+);	O
+influenza	B-PATH
+A	I-PATH
+(	O
+1	O
+/	O
+10	O
+,	O
+10	O
+%,	O
+surface	O
+sample	O
+).	O
+
+TITLE	O
+:	O
+History	O
+conflict	O
+and	O
+non	O
+-	O
+formulary	O
+medicine	B-CHED
+:	O
+a	O
+threat	O
+for	O
+anaesthesiologist	O
+in	O
+low	O
+and	O
+middle	O
+-	O
+income	O
+countries	O
+.	O
+
+He	O
+was	O
+taking	O
+complementary	O
+medicine	B-CHED
+for	O
+last	O
+2	O
+years	O
+.	O
+
+However	O
+,	O
+none	O
+of	O
+them	O
+were	O
+found	O
+to	O
+be	O
+infected	O
+with	O
+MERS	O
+-	O
+CoV	O
+.	O
+The	O
+bacterial	O
+cultures	O
+showed	O
+evidence	O
+of	O
+normal	O
+flora	O
+growth	B-PROC
+.	O
+
+We	O
+performed	O
+an	O
+extensive	O
+review	O
+of	O
+the	O
+published	O
+evidence	O
+and	O
+propose	O
+a	O
+management	O
+strategy	O
+for	O
+acute	O
+complications	O
+of	O
+targeted	B-PROC
+therapy	O
+in	O
+critically	B-DISO
+ill	I-DISO
+patients	O
+with	O
+cancer	B-DISO
+.	O
+
+The	O
+main	O
+other	O
+side	O
+effects	O
+are	O
+Steven	O
+-	O
+Johnson	O
+syndrome	B-DISO
+,	O
+necrotizing	B-DISO
+fasciitis	I-DISO
+,	O
+and	O
+anaphylactic	B-DISO
+reactions	I-DISO
+.	O
+
+The	O
+data	O
+suggested	O
+that	O
+PEDV	B-SPEC
+neutralizing	O
+antibody	B-COMP
+inhibited	O
+virus	B-DISO
+infection	I-DISO
+by	O
+binding	B-FUNC
+to	O
+infectious	B-DISO
+virions	B-COMP
+,	O
+which	O
+could	O
+work	O
+as	O
+a	O
+tool	O
+to	O
+find	O
+the	O
+receptor	O
+-	O
+binding	B-FUNC
+domains	O
+.	O
+
+Several	O
+lipoglycopeptides	O
+were	O
+also	O
+found	O
+to	O
+be	O
+active	O
+against	O
+human	B-SPEC
+coronavirus	I-SPEC
+.	O
+
+The	O
+genetic	O
+analysis	O
+of	O
+congenital	B-DISO
+myasthenic	I-DISO
+syndromes	I-DISO
+provide	O
+information	O
+on	O
+the	O
+ultrastructural	O
+underlying	O
+mechanisms	O
+,	O
+which	O
+is	O
+valuable	O
+for	O
+differential	O
+diagnosis	O
+and	O
+specific	O
+treatments	O
+.	O
+
+TITLE	O
+:	O
+[	O
+HPV	O
+infection	B-DISO
+of	O
+the	O
+external	B-ANAT
+genitalia	I-ANAT
+in	O
+men	O
+whose	O
+female	O
+partners	O
+have	O
+cervical	B-ANAT
+HPV	O
+infection	B-DISO
+].	O
+
+We	O
+collected	O
+the	O
+relevant	O
+data	O
+on	O
+the	O
+male	O
+outpatients	O
+whose	O
+partners	O
+had	O
+cervical	B-ANAT
+HPV	O
+infection	B-DISO
+in	O
+our	O
+Department	O
+of	O
+Urology	O
+and	O
+Andrology	O
+from	O
+August	O
+to	O
+December	O
+2016	O
+.	O
+
+Severe	O
+ARDS	B-DISO
+was	O
+recorded	O
+in	O
+30	O
+of	O
+these	O
+patients	O
+,	O
+accounting	O
+for	O
+66	O
+.	O
+7	O
+%.	O
+
+Assay	O
+specificity	O
+was	O
+accomplished	O
+by	O
+targeting	B-PROC
+conserved	O
+genomic	O
+regions	O
+for	O
+each	O
+virus	B-SPEC
+.	O
+
+In	O
+addition	O
+,	O
+lactate	B-PRGE
+dehydrogenase	I-PRGE
+(	O
+LDH	B-PRGE
+)	O
+>	O
+246	O
+IU	O
+/	O
+L	O
+[	O
+odds	O
+ratio	O
+(	O
+OR	O
+)	O
+=	O
+7	O
+.	O
+06	O
+,	O
+95	O
+%	O
+confidence	O
+interval	O
+(	O
+CI	O
+):	O
+2	O
+.	O
+15	O
+-	O
+23	O
+.	O
+2	O
+,	O
+P	O
+=	O
+0	O
+.	O
+001	O
+],	O
+and	O
+serum	B-COMP
+calcium	B-CHED
+<	O
+2	O
+.	O
+18	O
+mmol	O
+/	O
+L	O
+(	O
+OR	O
+=	O
+6	O
+.	O
+67	O
+,	O
+95	O
+%	O
+CI	O
+:	O
+1	O
+.	O
+42	O
+-	O
+31	O
+.	O
+3	O
+,	O
+P	O
+=	O
+0	O
+.	O
+016	O
+)	O
+were	O
+associated	O
+with	O
+death	B-PROC
+.	O
+
+Thus	O
+,	O
+they	O
+have	O
+caused	O
+huge	O
+losses	O
+to	O
+the	O
+swine	B-SPEC
+-	O
+breeding	B-PROC
+industry	O
+worldwide	O
+.	O
+
+However	O
+,	O
+the	O
+details	O
+of	O
+how	O
+sialic	B-CHED
+acid	I-CHED
+and	O
+low	O
+pH	O
+affect	O
+virus	B-SPEC
+binding	B-FUNC
+to	O
+the	O
+host	B-COMP
+cell	I-COMP
+are	O
+not	O
+determined	O
+,	O
+and	O
+the	O
+functions	O
+of	O
+the	O
+proteases	O
+are	O
+unknown	O
+.	O
+
+In	O
+252	O
+live	O
+deliveries	O
+,	O
+identification	O
+of	O
+non	O
+-	O
+vigorous	O
+neonates	O
+,	O
+use	O
+of	O
+suction	O
+,	O
+and	O
+use	O
+of	O
+PPV	B-CHED
+increased	O
+by	O
+21	O
+%,	O
+25	O
+%,	O
+and	O
+23	O
+%	O
+respectively	O
+(	O
+all	O
+p	O
+<	O
+0	O
+.	O
+01	O
+)	O
+between	O
+weeks	O
+1	O
+-	O
+3	O
+and	O
+4	O
+-	O
+8	O
+.	O
+
+RESULTS	O
+:	O
+A	O
+total	O
+of	O
+221	O
+patients	O
+were	O
+included	O
+in	O
+this	O
+study	O
+,	O
+among	O
+whom	O
+34	O
+(	O
+15	O
+%)	O
+developed	O
+ARDS	B-DISO
+within	O
+7	O
+days	O
+.	O
+
+Interestingly	O
+,	O
+we	O
+show	O
+that	O
+these	O
+nanoparticles	B-CHED
+may	O
+deliver	O
+cargo	O
+and	O
+selectively	O
+transduce	O
+cells	B-COMP
+expressing	O
+the	O
+ACE2	B-PRGE
+protein	I-PRGE
+such	O
+as	O
+ciliated	O
+cells	B-COMP
+of	O
+the	O
+respiratory	B-ANAT
+tract	I-ANAT
+.	O
+
+In	O
+addition	O
+,	O
+by	O
+inserting	O
+into	O
+lysosomal	B-ANAT
+membranes	B-ANAT
+SARS	B-PRGE
+3a	I-PRGE
+triggers	O
+lysosomal	B-ANAT
+damage	O
+and	O
+dysfunction	O
+.	O
+
+ABSTRACT	O
+:	O
+Acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+(	O
+ARDS	B-DISO
+)	O
+is	O
+a	O
+severe	O
+clinical	O
+condition	B-DISO
+marked	O
+by	O
+acute	B-DISO
+respiratory	I-DISO
+failure	I-DISO
+and	O
+dysregulated	O
+inflammation	B-DISO
+.	O
+
+Therefore	O
+,	O
+we	O
+evaluated	O
+the	O
+effects	O
+of	O
+sitagliptin	B-CHED
+,	O
+a	O
+DPP4	B-PRGE
+inhibitor	B-CHED
+in	O
+wide	O
+clinical	O
+use	O
+,	O
+on	O
+LPS	B-DISO
+-	O
+induced	O
+lung	B-ANAT
+injury	O
+in	O
+mice	B-SPEC
+and	O
+in	O
+human	B-SPEC
+lung	B-ANAT
+ECs	O
+in	O
+vitro	O
+.	O
+
+Other	O
+considerations	O
+include	O
+the	O
+effects	O
+of	O
+cyanide	B-CHED
+,	O
+carbon	B-CHED
+monoxide	I-CHED
+,	O
+and	O
+fire	O
+suppressants	O
+.	O
+
+Management	O
+of	O
+these	O
+patients	O
+includes	O
+early	O
+airway	B-ANAT
+management	O
+,	O
+lung	B-ANAT
+-	O
+protective	O
+ventilator	O
+strategies	O
+,	O
+aggressive	O
+pulmonary	B-ANAT
+toilet	O
+,	O
+and	O
+avoidance	O
+of	O
+volume	B-DISO
+overload	I-DISO
+.	O
+
+The	O
+discovery	O
+of	O
+cpsRNAs	O
+has	O
+paved	O
+a	O
+way	O
+to	O
+find	O
+novel	O
+markers	O
+for	O
+pathogen	O
+detection	O
+and	O
+to	O
+reveal	O
+the	O
+mechanisms	O
+underlying	O
+infection	O
+or	O
+pathogenesis	B-DISO
+from	O
+a	O
+different	O
+point	O
+of	O
+view	O
+.	O
+
+Moreover	O
+,	O
+HRG	B-PRGE
+suppressed	O
+tumor	B-PRGE
+necrosis	I-PRGE
+factor	I-PRGE
+α	I-PRGE
+,	O
+inducible	O
+nitric	B-PRGE
+oxide	I-PRGE
+synthase	I-PRGE
+,	O
+interleukin	B-PRGE
+6	I-PRGE
+,	O
+and	O
+neutrophil	B-PRGE
+elastase	I-PRGE
+mRNA	B-PROC
+expression	B-PROC
+and	O
+myeloperoxidase	B-FUNC
+activity	I-FUNC
+in	O
+the	O
+lung	B-ANAT
+.	O
+
+These	O
+data	O
+suggested	O
+that	O
+HRG	O
+ameliorated	O
+lung	B-DISO
+inflammation	I-DISO
+secondary	O
+to	O
+pancreatitis	B-DISO
+.	O
+
+Moreover	O
+,	O
+HRG	B-PRGE
+suppressed	O
+tumor	B-PRGE
+necrosis	I-PRGE
+factor	I-PRGE
+α	I-PRGE
+,	O
+inducible	O
+nitric	B-PRGE
+oxide	I-PRGE
+synthase	I-PRGE
+,	O
+interleukin	B-PRGE
+6	I-PRGE
+,	O
+and	O
+neutrophil	B-PRGE
+elastase	I-PRGE
+mRNA	B-PROC
+expression	B-PROC
+and	O
+myeloperoxidase	B-FUNC
+activity	I-FUNC
+in	O
+the	O
+lung	B-ANAT
+.	O
+
+TITLE	O
+:	O
+De	O
+Novo	O
+Design	O
+of	O
+α	O
+-	O
+Helical	O
+Lipopeptides	B-CHED
+Targeting	B-PROC
+Viral	O
+Fusion	O
+Proteins	B-CHED
+:	O
+A	O
+Promising	O
+Strategy	O
+for	O
+Relatively	O
+Broad	O
+-	O
+Spectrum	O
+Antiviral	O
+Drug	O
+Discovery	O
+.	O
+
+In	O
+addition	O
+,	O
+vaccinated	O
+and	O
+challenged	O
+birds	B-SPEC
+had	O
+significantly	O
+less	O
+challenge	O
+virus	B-SPEC
+,	O
+an	O
+important	O
+measure	O
+of	O
+protection	O
+,	O
+compared	O
+to	O
+non	O
+-	O
+vaccinated	O
+and	O
+challenged	O
+controls	O
+.	O
+
+ABSTRACT	O
+:	O
+While	O
+general	O
+medical	O
+practitioners	O
+(	O
+GPs	B-DISO
+)	O
+and	O
+veterinarians	O
+are	O
+often	O
+the	O
+first	O
+line	O
+responders	O
+in	O
+the	O
+face	B-DISO
+of	O
+a	O
+disease	O
+outbreak	O
+,	O
+pathways	B-PROC
+to	O
+improving	O
+the	O
+One	O
+Health	O
+efficacy	O
+of	O
+these	O
+clinicians	O
+remain	O
+unclear	O
+.	O
+
+In	O
+the	O
+second	O
+phase	O
+the	O
+expert	O
+panel	O
+identified	O
+general	O
+knowledge	O
+of	O
+the	O
+clinical	O
+aspects	O
+and	O
+epidemiological	O
+aspects	O
+of	O
+zoonoses	O
+,	O
+as	O
+well	O
+as	O
+risk	O
+management	O
+practices	O
+,	O
+as	O
+the	O
+most	O
+important	O
+KAPs	O
+and	O
+research	O
+priorities	O
+for	O
+both	O
+GPs	B-DISO
+and	O
+veterinarians	O
+.	O
+
+Our	O
+study	O
+suggests	O
+that	O
+cardiac	B-ANAT
+heart	B-DISO
+failure	I-DISO
+and	O
+acute	O
+exacerbation	O
+of	O
+chronic	B-DISO
+obstructive	I-DISO
+pulmonary	I-DISO
+disease	I-DISO
+can	O
+be	O
+considered	O
+two	O
+indications	O
+for	O
+pre	O
+-	O
+hospital	O
+ultrasound	O
+,	O
+and	O
+can	O
+improve	O
+the	O
+management	O
+of	O
+patient	O
+with	O
+acute	B-DISO
+respiratory	I-DISO
+insufficiency	I-DISO
+.	O
+
+The	O
+overall	O
+structure	O
+of	O
+the	O
+HCoV	B-SPEC
+-	I-SPEC
+229E	I-SPEC
+fusion	O
+core	O
+is	O
+similar	O
+to	O
+those	O
+of	O
+SARS	B-DISO
+,	O
+MERS	O
+and	O
+HCoV	O
+-	O
+NL63	O
+,	O
+but	O
+the	O
+packing	O
+of	O
+its	O
+3HR1	O
+core	O
+differs	O
+from	O
+those	O
+of	O
+SARS	B-DISO
+and	O
+MERS	O
+in	O
+that	O
+it	O
+contains	O
+more	O
+noncanonical	O
+`	O
+x	O
+'	O
+and	O
+`	O
+da	O
+'	O
+layers	B-ANAT
+.	O
+
+ABSTRACT	O
+:	O
+Positive	O
+-	O
+strand	O
+RNA	O
+viruses	O
+,	O
+such	O
+as	O
+coronaviruses	O
+,	O
+induce	O
+cellular	B-COMP
+membrane	I-COMP
+rearrangements	O
+during	O
+replication	O
+to	O
+form	O
+replication	O
+organelles	B-COMP
+allowing	O
+for	O
+efficient	O
+viral	O
+RNA	B-PROC
+synthesis	I-PROC
+.	O
+
+Children	O
+and	O
+adult	O
+patients	O
+attending	O
+Keur	O
+Socé	O
+health	O
+post	O
+for	O
+signs	O
+suggestive	O
+of	O
+acute	B-DISO
+respiratory	I-DISO
+infection	I-DISO
+were	O
+enrolled	O
+after	O
+providing	O
+inform	O
+consent	O
+.	O
+
+Paired	O
+nose	B-ANAT
+and	O
+throat	B-ANAT
+swabs	O
+were	O
+collected	O
+for	O
+pathogen	O
+detection	O
+.	O
+
+This	O
+could	O
+be	O
+explained	O
+by	O
+an	O
+HFO	O
+-	O
+induced	O
+right	O
+ventricular	B-ANAT
+(	O
+RV	O
+)	O
+dysfunction	O
+/	O
+failure	O
+due	O
+to	O
+high	O
+intrathoracic	O
+pressures	O
+and	O
+hypercapnia	B-DISO
+.	O
+
+Forty	O
+-	O
+two	O
+patients	O
+(	O
+89	O
+%)	O
+had	O
+ARDS	B-DISO
+,	O
+which	O
+was	O
+severe	O
+in	O
+86	O
+%,	O
+with	O
+a	O
+rate	O
+of	O
+17	O
+%	O
+(	O
+n	O
+=	O
+8	O
+/	O
+47	O
+)	O
+of	O
+extra	O
+-	O
+corporeal	O
+membrane	B-COMP
+oxygenation	B-PROC
+requirement	O
+.	O
+
+ABSTRACT	O
+:	O
+Routine	O
+testing	O
+of	O
+breeding	B-PROC
+herd	O
+oral	B-ANAT
+fluid	O
+(	O
+OF	O
+)	O
+samples	O
+for	O
+porcine	B-SPEC
+epidemic	I-SPEC
+diarrhea	I-SPEC
+virus	I-SPEC
+(	O
+PEDV	B-SPEC
+)	O
+IgG	B-PRGE
+and	O
+/	O
+or	O
+IgA	B-PRGE
+is	O
+used	O
+to	O
+track	O
+levels	O
+of	O
+PEDV	B-SPEC
+immunity	B-PROC
+over	O
+time	O
+.	O
+
+However	O
+,	O
+OFs	O
+contain	O
+particles	O
+of	O
+feed	O
+,	O
+feces	B-ANAT
+,	O
+and	O
+inorganic	O
+material	O
+that	O
+detract	O
+from	O
+the	O
+quality	O
+of	O
+the	O
+sample	O
+.	O
+
+We	O
+clarified	O
+swine	B-SPEC
+OF	O
+samples	O
+using	O
+lyophilized	O
+chitosan	B-CHED
+-	O
+based	O
+formulas	O
+(	O
+A	O
+-	O
+C	O
+)	O
+tested	O
+by	O
+PEDV	B-PRGE
+IgG	I-PRGE
+and	O
+IgA	B-PRGE
+ELISAs	O
+.	O
+
+TITLE	O
+:	O
+Acute	B-DISO
+Respiratory	I-DISO
+Distress	I-DISO
+Syndrome	I-DISO
+After	O
+Uterine	B-ANAT
+Artery	I-ANAT
+Embolization	O
+.	O
+
+TITLE	O
+:	O
+Characterizing	O
+replication	O
+kinetics	O
+and	O
+plaque	B-DISO
+production	O
+of	O
+type	O
+I	O
+feline	B-SPEC
+infectious	I-DISO
+peritonitis	I-DISO
+virus	O
+in	O
+three	O
+feline	B-SPEC
+cell	B-ANAT
+lines	I-ANAT
+.	O
+
+The	O
+architecture	O
+pattern	O
+of	O
+villi	O
+presented	O
+columnar	O
+and	O
+cuboidal	O
+poorly	O
+differentiated	O
+enterocytes	B-ANAT
+with	O
+mild	O
+subepithelial	O
+edema	B-DISO
+.	O
+
+Microscopic	O
+examination	O
+of	O
+brain	B-ANAT
+tissue	I-ANAT
+revealed	O
+diffuse	O
+gliosis	B-DISO
+in	O
+the	O
+area	O
+of	O
+pia	O
+matter	O
+with	O
+mild	O
+congestion	B-DISO
+of	O
+the	O
+meningeal	O
+and	O
+parenchymal	O
+vessels	B-ANAT
+and	O
+neuronal	O
+degeneration	B-DISO
+.	O
+
+TITLE	O
+:	O
+Oral	B-ANAT
+immunization	O
+with	O
+a	O
+novel	O
+attenuated	O
+Salmonella	B-DISO
+Gallinarum	O
+encoding	O
+infectious	B-DISO
+bronchitis	B-DISO
+virus	B-SPEC
+spike	O
+protein	B-CHED
+induces	O
+protective	O
+immune	B-PROC
+responses	I-PROC
+against	O
+fowl	B-DISO
+typhoid	I-DISO
+and	O
+infectious	B-DISO
+bronchitis	B-DISO
+in	O
+chickens	B-SPEC
+.	O
+
+Herein	O
+,	O
+we	O
+exploited	O
+a	O
+live	O
+attenuated	O
+SG	O
+mutant	B-DISO
+,	O
+JOL967	O
+,	O
+to	O
+deliver	O
+spike	O
+(	O
+S	O
+)	O
+protein	B-CHED
+1	O
+of	O
+IB	O
+virus	B-SPEC
+(	O
+V	O
+)	O
+to	O
+elicit	O
+protective	O
+immunity	B-PROC
+against	O
+both	O
+FT	O
+and	O
+IB	O
+in	O
+chickens	B-SPEC
+.	O
+
+ABSTRACT	O
+:	O
+Visitors	O
+can	O
+play	O
+an	O
+important	O
+role	O
+in	O
+the	O
+spread	O
+of	O
+infections	B-DISO
+.	O
+
+TITLE	O
+:	O
+Interplay	O
+between	O
+the	O
+Poly	O
+(	O
+A	O
+)	O
+Tail	O
+,	O
+Poly	O
+(	O
+A	O
+)-	O
+Binding	B-FUNC
+Protein	B-CHED
+,	O
+and	O
+Coronavirus	B-SPEC
+Nucleocapsid	B-COMP
+Protein	B-CHED
+Regulates	O
+Gene	B-PROC
+Expression	I-PROC
+of	O
+Coronavirus	B-SPEC
+and	O
+the	O
+Host	B-COMP
+Cell	I-COMP
+.	O
+
+Importantly	O
+,	O
+using	O
+pathogenic	O
+tests	O
+,	O
+we	O
+found	O
+that	O
+the	O
+virus	B-SPEC
+can	O
+reproduce	O
+and	O
+cause	O
+disease	O
+in	O
+suckling	O
+rats	B-SPEC
+,	O
+and	O
+further	O
+studies	O
+showed	O
+that	O
+the	O
+virus	B-ANAT
+-	I-ANAT
+like	I-ANAT
+particles	I-ANAT
+can	O
+be	O
+observed	O
+in	O
+the	O
+brains	B-ANAT
+of	O
+suckling	O
+rats	B-SPEC
+by	O
+electron	O
+microscopy	O
+.	O
+
+Over	O
+the	O
+past	O
+few	O
+years	O
+,	O
+there	O
+has	O
+been	O
+an	O
+increase	O
+in	O
+the	O
+use	O
+of	O
+ECMO	O
+for	O
+ARDS	B-DISO
+in	O
+children	O
+.	O
+
+Low	O
+tidal	O
+volume	O
+ventilation	O
+remains	O
+the	O
+predominant	O
+mainstay	O
+of	O
+the	O
+ventilatory	O
+strategy	O
+in	O
+ARDS	B-DISO
+.	O
+
+High	O
+-	O
+frequency	O
+oscillatory	O
+ventilation	O
+,	O
+application	O
+of	O
+recruitment	B-DISO
+maneuvers	O
+,	O
+higher	O
+PEEP	B-CHED
+,	O
+extracorporeal	O
+membrane	B-COMP
+oxygenation	B-PROC
+,	O
+and	O
+alternate	O
+modes	O
+of	O
+mechanical	O
+ventilation	O
+have	O
+failed	O
+to	O
+show	O
+benefit	O
+.	O
+
+In	O
+this	O
+article	O
+,	O
+we	O
+describe	O
+advances	O
+in	O
+the	O
+diagnosis	O
+,	O
+epidemiology	O
+,	O
+and	O
+treatment	O
+of	O
+ARDS	B-DISO
+over	O
+the	O
+past	O
+decade	O
+.	O
+
+Wild	O
+Poliovirus	B-SPEC
+has	O
+been	O
+eliminated	O
+from	O
+all	O
+but	O
+three	O
+countries	O
+(	O
+Afghanistan	O
+,	O
+Nigeria	O
+,	O
+and	O
+Pakistan	O
+)	O
+and	O
+currently	O
+is	O
+the	O
+focus	O
+of	O
+a	O
+major	O
+eradication	O
+program	O
+.	O
+
+Indeed	O
+,	O
+an	O
+important	O
+recent	O
+study	O
+(	O
+Stanaway	O
+and	O
+others	O
+2015	O
+)	O
+found	O
+that	O
+viral	B-DISO
+hepatitis	I-DISO
+led	O
+to	O
+an	O
+estimated	O
+0	O
+.	O
+9	O
+million	O
+deaths	B-PROC
+in	O
+1990	O
+(	O
+including	O
+hepatitis	B-DISO
+-	O
+caused	O
+deaths	B-PROC
+from	O
+cirrhosis	B-DISO
+and	O
+liver	B-DISO
+cancer	B-SPEC
+).	O
+
+Compared	O
+with	O
+antibiotics	B-CHED
+to	O
+treat	O
+bacterial	B-DISO
+infections	I-DISO
+,	O
+relatively	O
+few	O
+antiviral	B-CHED
+drugs	I-CHED
+have	O
+been	O
+developed	O
+to	O
+treat	O
+these	O
+emerging	O
+viral	B-DISO
+infections	I-DISO
+.	O
+
+A	O
+global	O
+increase	O
+in	O
+antibiotic	B-CHED
+-	O
+resistant	O
+bacteria	B-SPEC
+includes	O
+a	O
+small	O
+but	O
+growing	O
+number	O
+that	O
+are	O
+resistant	O
+to	O
+most	O
+or	O
+essentially	O
+all	O
+of	O
+the	O
+available	O
+antimicrobials	B-CHED
+.	O
+
+Spectacular	O
+progress	O
+has	O
+been	O
+made	O
+in	O
+reducing	O
+mortality	O
+from	O
+most	O
+infectious	B-DISO
+diseases	I-DISO
+(	O
+table	O
+1	O
+.	O
+1	O
+).	O
+
+Hence	O
+,	O
+infectious	B-DISO
+diseases	I-DISO
+will	O
+remain	O
+a	O
+major	O
+threat	O
+to	O
+humankind	O
+,	O
+especially	O
+in	O
+LMICs	O
+,	O
+requiring	O
+vigilance	O
+,	O
+surveillance	O
+,	O
+and	O
+new	O
+interventions	O
+of	O
+all	O
+types	O
+.	O
+
+TITLE	O
+:	O
+Disease	O
+Control	O
+Priorities	O
+:	O
+Improving	O
+Health	O
+and	O
+Reducing	O
+Poverty	O
+ABSTRACT	O
+:	O
+Pandemics	O
+are	O
+large	O
+-	O
+scale	O
+outbreaks	O
+of	O
+infectious	B-DISO
+disease	I-DISO
+that	O
+can	O
+greatly	O
+increase	O
+morbidity	O
+and	O
+mortality	O
+over	O
+a	O
+wide	O
+geographic	O
+area	O
+and	O
+cause	O
+significant	O
+economic	O
+,	O
+social	O
+,	O
+and	O
+political	O
+disruption	O
+.	O
+
+Multiple	O
+outbreaks	O
+,	O
+notably	O
+the	O
+2014	O
+West	O
+Africa	O
+Ebola	O
+epidemic	O
+,	O
+have	O
+exposed	O
+gaps	O
+related	O
+to	O
+the	O
+timely	O
+detection	O
+of	O
+disease	O
+,	O
+availability	O
+of	O
+basic	O
+care	O
+,	O
+tracing	O
+of	O
+contacts	O
+,	O
+quarantine	O
+and	O
+isolation	O
+procedures	O
+,	O
+and	O
+preparedness	O
+outside	O
+the	O
+health	O
+sector	O
+,	O
+including	O
+global	O
+coordination	B-PROC
+and	O
+response	O
+mobilization	O
+(	O
+Moon	O
+and	O
+others	O
+2015	O
+;	O
+Pathmanathan	O
+and	O
+others	O
+2014	O
+).	O
+
+TITLE	O
+:	O
+A	O
+review	O
+on	O
+current	O
+trends	O
+in	O
+the	O
+treatment	O
+of	O
+human	B-SPEC
+infection	B-DISO
+with	O
+H7N9	O
+-	O
+avian	B-DISO
+influenza	B-PATH
+A	I-PATH
+.	O
+ABSTRACT	O
+:	O
+The	O
+H7N9	O
+subtype	O
+of	O
+avian	O
+influenza	O
+is	O
+an	O
+enzootic	O
+and	O
+airborne	O
+virus	B-SPEC
+which	O
+caused	O
+an	O
+influenza	B-DISO
+outbreak	O
+in	O
+China	O
+.	O
+
+Subjects	O
+at	O
+high	O
+risk	O
+of	O
+contracting	O
+avian	B-DISO
+influenza	I-DISO
+H7N9	O
+infection	B-DISO
+are	O
+recommended	O
+to	O
+receive	O
+annual	O
+seasonal	O
+influenza	B-DISO
+vaccination	O
+.	O
+
+This	O
+article	O
+reviews	O
+the	O
+clinical	O
+effects	O
+and	O
+treatment	O
+of	O
+persons	O
+who	O
+use	O
+cocaine	O
+,	O
+methamphetamines	O
+,	O
+3	B-CHED
+,	I-CHED
+4	I-CHED
+-	I-CHED
+methylenedioxymethamphetamine	I-CHED
+(	O
+MDMA	B-CHED
+),	O
+synthetic	O
+cannabinoids	B-CHED
+,	O
+and	O
+synthetic	O
+cathinones	O
+"("""	O
+bath	O
+salts	B-CHED
+""")."	O
+
+Acute	O
+intoxication	O
+may	O
+cause	O
+severe	O
+cardiac	B-ANAT
+and	O
+respiratory	B-DISO
+complications	I-DISO
+and	O
+seizures	B-DISO
+.	O
+
+We	O
+analyzed	O
+104	O
+cloacal	B-ANAT
+swabs	O
+from	O
+individuals	O
+collected	O
+at	O
+locations	O
+in	O
+Central	O
+Chile	O
+.	O
+
+All	O
+coronaviruses	O
+were	O
+identified	O
+as	O
+viruses	B-SPEC
+of	O
+the	O
+Gammacoronavirus	B-SPEC
+genus	B-SPEC
+,	O
+closely	O
+related	O
+to	O
+the	O
+infectious	B-DISO
+bronchitis	B-DISO
+virus	B-SPEC
+clade	O
+(	O
+bootstrap	O
+clade	O
+support	O
+=	O
+75	O
+%).	O
+
+The	O
+immunized	O
+chickens	B-SPEC
+were	O
+challenged	O
+with	O
+5x10	O
+(	O
+4	O
+.	O
+7	O
+)	O
+EID50	O
+IBV	B-SPEC
+M41	O
+strain	O
+.	O
+
+5	O
+)	O
+Natural	B-CHED
+products	I-CHED
+were	O
+identified	O
+to	O
+allosterically	O
+inhibit	O
+Zika	O
+and	O
+Dengue	B-DISO
+proteases	O
+through	O
+binding	B-FUNC
+a	O
+pocket	O
+on	O
+the	O
+back	B-ANAT
+of	O
+the	O
+active	O
+site	O
+.	O
+
+Virus	B-PROC
+neutralization	I-PROC
+(	O
+V	O
+/	O
+N	O
+)	O
+assays	O
+are	O
+commonly	O
+requested	O
+in	O
+diagnostic	O
+laboratories	O
+for	O
+the	O
+assessment	O
+of	O
+protective	O
+antibodies	B-COMP
+.	O
+
+To	O
+improve	O
+the	O
+ease	O
+of	O
+testing	O
+,	O
+a	O
+colorimetric	O
+virus	B-PROC
+neutralization	I-PROC
+and	O
+TCID	O
+
+The	O
+most	O
+common	O
+poisoning	O
+types	O
+of	O
+elderly	O
+patients	O
+were	O
+sedative	B-CHED
+hypnotics	B-CHED
+(	O
+23	O
+.	O
+60	O
+%)	O
+and	O
+organophosphorus	B-CHED
+pesticides	I-CHED
+(	O
+22	O
+.	O
+47	O
+%);	O
+the	O
+youth	O
+patients	O
+were	O
+mainly	O
+paraquat	B-CHED
+(	O
+42	O
+.	O
+52	O
+%)	O
+and	O
+organophosphorus	B-CHED
+pesticide	I-CHED
+(	O
+17	O
+.	O
+32	O
+%).	O
+
+(	O
+2	O
+)	O
+Risk	O
+factors	O
+of	O
+deaths	B-PROC
+:	O
+the	O
+APACHE	O
+II	O
+score	O
+,	O
+incidence	O
+of	O
+acute	O
+kidney	B-ANAT
+injury	O
+(	O
+AKI	O
+)	O
+and	O
+MODS	B-DISO
+in	O
+the	O
+elderly	O
+death	B-PROC
+group	O
+were	O
+significantly	O
+higher	O
+than	O
+those	O
+in	O
+the	O
+elderly	O
+survival	O
+group	O
+.	O
+
+The	O
+proportion	O
+of	O
+female	O
+,	O
+APACHE	O
+II	O
+score	O
+,	O
+and	O
+the	O
+incidence	O
+of	O
+AKI	O
+,	O
+respiratory	B-DISO
+failure	I-DISO
+and	O
+MODS	B-DISO
+in	O
+the	O
+youth	O
+death	B-PROC
+group	O
+were	O
+significantly	O
+higher	O
+than	O
+those	O
+in	O
+the	O
+youth	O
+survival	O
+group	O
+.	O
+
+However	O
+,	O
+the	O
+prognosis	O
+in	O
+hematologic	B-DISO
+malignancies	I-DISO
+with	O
+severe	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+has	O
+remained	O
+poor	O
+.	O
+
+In	O
+the	O
+lower	O
+inferior	O
+vena	O
+cava	O
+,	O
+upper	O
+inferior	B-ANAT
+vena	I-ANAT
+cava	I-ANAT
+,	O
+and	O
+right	B-ANAT
+atrium	I-ANAT
+drainage	B-ANAT
+cannula	B-SPEC
+positions	O
+at	O
+3	O
+L	O
+/	O
+min	O
+,	O
+SaO	O
+With	O
+respect	O
+to	O
+blood	B-ANAT
+oxygenation	B-PROC
+,	O
+the	O
+optimal	O
+position	O
+for	O
+the	O
+drainage	B-ANAT
+cannula	B-SPEC
+was	O
+the	O
+upper	O
+inferior	B-ANAT
+vena	I-ANAT
+cava	I-ANAT
+.	O
+
+We	O
+have	O
+developed	O
+two	O
+indirect	O
+microarray	O
+methods	O
+to	O
+detect	O
+antibodies	B-COMP
+against	O
+IBV	B-SPEC
+:	O
+a	O
+chemiluminescent	O
+immunoassay	O
+test	O
+(	O
+CIT	B-CHED
+)	O
+and	O
+a	O
+rapid	O
+diagnostic	O
+test	O
+(	O
+RDT	B-DISO
+).	O
+
+The	O
+application	O
+of	O
+the	O
+IBV	B-PRGE
+nsp5	I-PRGE
+protein	B-CHED
+microarray	O
+showed	O
+that	O
+the	O
+positive	O
+rate	O
+of	O
+the	O
+CIT	B-CHED
+was	O
+96	O
+.	O
+77	O
+%,	O
+that	O
+of	O
+the	O
+nsp5	B-PRGE
+ELISA	I-PRGE
+was	O
+91	O
+.	O
+40	O
+%,	O
+and	O
+that	O
+of	O
+the	O
+RDT	B-DISO
+was	O
+90	O
+.	O
+32	O
+%.	O
+
+Two	O
+microarray	O
+assays	O
+,	O
+which	O
+were	O
+rapid	O
+,	O
+specific	O
+,	O
+sensitive	O
+,	O
+and	O
+relatively	O
+simple	O
+,	O
+were	O
+developed	O
+for	O
+the	O
+detection	O
+of	O
+an	O
+antibody	B-COMP
+against	O
+IBV	B-SPEC
+.	O
+
+RESULTS	O
+:	O
+We	O
+have	O
+developed	O
+two	O
+indirect	O
+microarray	O
+methods	O
+to	O
+detect	O
+antibodies	B-COMP
+against	O
+IBV	B-SPEC
+:	O
+a	O
+chemiluminescent	O
+immunoassay	O
+test	O
+(	O
+CIT	B-CHED
+)	O
+and	O
+a	O
+rapid	O
+diagnostic	O
+test	O
+(	O
+RDT	B-DISO
+).	O
+
+TITLE	O
+:	O
+Severe	O
+Respiratory	O
+Illness	O
+Outbreak	O
+Associated	O
+with	O
+Human	B-PRGE
+Coronavirus	I-PRGE
+NL63	I-PRGE
+in	O
+a	O
+Long	O
+-	O
+Term	O
+Care	O
+Facility	O
+.	O
+
+According	O
+to	O
+the	O
+results	O
+of	O
+risk	O
+assessment	O
+,	O
+the	O
+recommendations	O
+for	O
+risk	O
+management	O
+of	O
+respiratory	O
+infectious	O
+diseases	O
+,	O
+intestinal	B-DISO
+infectious	I-DISO
+diseases	I-DISO
+,	O
+imported	O
+infectious	B-DISO
+diseases	I-DISO
+like	O
+Middle	O
+East	O
+respiratory	O
+syndrome	B-DISO
+and	O
+other	B-DISO
+infectious	I-DISO
+diseases	I-DISO
+were	O
+made	O
+.	O
+
+The	O
+recommendations	O
+on	O
+risk	O
+management	O
+provide	O
+a	O
+basis	O
+for	O
+reducing	O
+the	O
+adverse	O
+consequences	O
+of	O
+public	O
+health	O
+risks	O
+in	O
+the	O
+event	O
+of	O
+an	O
+outbreak	O
+of	O
+infectious	B-DISO
+diseases	I-DISO
+,	O
+avoiding	O
+the	O
+impact	O
+of	O
+various	O
+risk	O
+factors	O
+in	O
+the	O
+outlying	O
+areas	O
+on	O
+G20	O
+summit	O
+.	O
+
+ABSTRACT	O
+:	O
+The	O
+muramyl	B-CHED
+dipeptide	I-CHED
+compound	O
+adjuvant	B-CHED
+,	O
+CVC1303	O
+,	O
+was	O
+one	O
+new	O
+resigned	O
+adjuvant	B-CHED
+to	O
+PEDV	B-SPEC
+inactivated	O
+vaccine	O
+.	O
+
+Mice	B-SPEC
+were	O
+twice	O
+subcutaneously	O
+injected	O
+with	O
+PEDV	B-SPEC
+vaccine	O
+including	O
+high	O
+,	O
+medium	O
+and	O
+low	O
+dosages	O
+CVC1303	O
+,	O
+respectively	O
+.	O
+
+Moreover	O
+,	O
+our	O
+findings	O
+verified	O
+the	O
+significantly	O
+enhanced	O
+PEDV	B-PRGE
+-	I-PRGE
+specific	I-PRGE
+IgA	B-COMP
+antibody	I-COMP
+titers	O
+in	O
+small	B-ANAT
+intestinal	I-ANAT
+and	O
+lung	B-ANAT
+in	O
+the	O
+mice	B-SPEC
+immunized	O
+with	O
+PEDV	B-SPEC
+vaccine	O
+and	O
+CVC1303	O
+.	O
+
+RESULTS	O
+:	O
+Our	O
+investigation	O
+proved	O
+the	O
+strong	O
+regulatory	O
+roles	O
+of	O
+CVC1303	O
+on	O
+PEDV	B-PRGE
+-	I-PRGE
+specific	I-PRGE
+IgG	I-PRGE
+and	O
+IgG1	B-COMP
+antibody	I-COMP
+and	O
+cytokines	O
+productions	O
+,	O
+and	O
+the	O
+significant	O
+increased	O
+CD3	B-ANAT
++	I-ANAT
+CD4	I-ANAT
++	I-ANAT
+T	I-ANAT
+cells	B-COMP
+subpopulation	O
+and	O
+expressions	O
+of	O
+co	O
+-	O
+stimulatory	O
+molecules	O
+on	O
+dendritic	B-ANAT
+cells	B-COMP
+in	O
+the	O
+immunized	O
+mice	B-SPEC
+.	O
+
+ABSTRACT	O
+:	O
+Infrared	O
+(	O
+IR	O
+)	O
+modalities	O
+represent	O
+the	O
+only	O
+currently	O
+viable	O
+mass	O
+fever	B-PROC
+screening	O
+approaches	O
+for	O
+outbreaks	O
+of	O
+infectious	B-DISO
+disease	I-DISO
+pandemics	O
+such	O
+as	O
+Ebola	B-DISO
+virus	I-DISO
+disease	I-DISO
+and	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+.	O
+
+Non	O
+-	O
+contact	O
+IR	O
+thermometers	O
+(	O
+NCITs	O
+)	O
+and	O
+IR	O
+thermographs	O
+(	O
+IRTs	O
+)	O
+have	O
+been	O
+used	O
+for	O
+fever	B-PROC
+screening	O
+in	O
+public	O
+areas	O
+such	O
+as	O
+airports	O
+.	O
+
+In	O
+addition	O
+,	O
+Caerin1	O
+.	O
+1	O
+showed	O
+powerful	O
+antiviral	B-CHED
+activity	O
+without	O
+interfering	O
+with	O
+the	O
+binding	B-FUNC
+progress	O
+between	O
+PEDV	B-SPEC
+and	O
+the	O
+receptor	O
+of	O
+the	O
+cells	B-COMP
+,	O
+therefore	O
+,	O
+it	O
+could	O
+be	O
+used	O
+as	O
+a	O
+potential	O
+antiviral	B-CHED
+drug	I-CHED
+or	O
+as	O
+a	O
+microbicide	B-CHED
+compound	O
+for	O
+prevention	O
+and	O
+control	O
+of	O
+PEDV	B-SPEC
+.	O
+
+TITLE	O
+:	O
+Attenuation	O
+of	O
+Influenza	B-SPEC
+A	I-SPEC
+Virus	B-DISO
+Disease	I-DISO
+Severity	O
+by	O
+Viral	O
+Coinfection	B-DISO
+in	O
+a	O
+Mouse	B-SPEC
+Model	O
+.	O
+
+Spinal	B-ANAT
+cord	I-ANAT
+demyelination	B-DISO
+is	O
+also	O
+induced	O
+following	O
+intranasal	O
+inoculation	O
+with	O
+neurotropic	O
+MHV	B-SPEC
+strains	O
+,	O
+however	O
+much	O
+higher	O
+viral	O
+doses	O
+are	O
+required	O
+as	O
+compared	O
+to	O
+intracranial	B-ANAT
+inoculation	O
+.	O
+
+No	O
+acute	O
+inflammation	B-DISO
+was	O
+found	O
+,	O
+and	O
+no	O
+viral	O
+antigen	B-CHED
+was	O
+detected	O
+,	O
+in	O
+the	O
+optic	B-ANAT
+nerve	I-ANAT
+or	O
+retina	B-ANAT
+1	O
+day	O
+after	O
+inoculation	O
+.	O
+
+Intracranial	B-ANAT
+inoculation	O
+should	O
+continue	O
+to	O
+be	O
+considered	O
+a	O
+preferred	O
+method	O
+for	O
+studies	O
+of	O
+MHV	B-SPEC
+-	O
+induced	O
+optic	B-DISO
+neuritis	I-DISO
+and	O
+central	B-ANAT
+nervous	I-ANAT
+system	I-ANAT
+(	O
+CNS	B-CHED
+)	O
+demyelinating	B-DISO
+disease	I-DISO
+.	O
+
+During	O
+the	O
+study	O
+period	O
+,	O
+at	O
+least	O
+one	O
+virus	B-SPEC
+was	O
+detected	O
+in	O
+82	O
+.	O
+7	O
+%	O
+(	O
+144	O
+/	O
+174	O
+)	O
+of	O
+children	O
+with	O
+FS	O
+.	O
+
+This	O
+study	O
+indicates	O
+that	O
+respiratory	O
+viruses	B-SPEC
+are	O
+important	O
+in	O
+the	O
+etiology	O
+of	O
+FS	O
+in	O
+children	O
+.	O
+
+Influenza	B-SPEC
+B	I-SPEC
+virus	I-SPEC
+was	O
+the	O
+most	O
+common	O
+virus	B-SPEC
+identified	O
+in	O
+children	O
+who	O
+were	O
+experiencing	O
+their	O
+first	O
+incidence	O
+of	O
+FS	O
+(	O
+p	O
+<	O
+0	O
+.	O
+05	O
+).	O
+
+ABSTRACT	O
+:	O
+Electrical	B-PROC
+impedance	I-PROC
+tomography	O
+(	O
+EIT	O
+)	O
+has	O
+been	O
+used	O
+to	O
+guide	O
+mechanical	O
+ventilation	O
+in	O
+ICU	O
+patients	O
+with	O
+lung	B-DISO
+collapse	I-DISO
+.	O
+
+However	O
+,	O
+the	O
+effects	O
+of	O
+TGEV	B-SPEC
+infection	B-DISO
+on	O
+nutrient	B-PROC
+absorption	I-PROC
+in	O
+swine	B-SPEC
+have	O
+not	O
+yet	O
+been	O
+investigated	O
+.	O
+
+ABSTRACT	O
+:	O
+Dromedary	O
+camels	B-SPEC
+are	O
+implicated	O
+as	O
+reservoirs	O
+for	O
+the	O
+zoonotic	O
+transmission	O
+of	O
+Middle	O
+East	O
+Respiratory	O
+Syndrome	B-DISO
+coronavirus	B-SPEC
+(	O
+MERS	O
+-	O
+CoV	O
+)	O
+with	O
+the	O
+respiratory	O
+route	O
+thought	O
+to	O
+be	O
+the	O
+main	O
+mode	O
+of	O
+transmission	O
+.	O
+
+In	O
+the	O
+REGARDS	O
+cohort	O
+of	O
+community	O
+-	O
+dwelling	O
+US	O
+adults	O
+,	O
+low	O
+plasma	B-ANAT
+25	O
+(	O
+OH	O
+)	O
+D	O
+measured	O
+at	O
+a	O
+time	O
+of	O
+relative	O
+health	O
+was	O
+independently	O
+associated	O
+with	O
+increased	O
+risk	O
+of	O
+sepsis	B-DISO
+.	O
+
+TITLE	O
+:	O
+Proviral	O
+MicroRNAs	O
+Detected	O
+in	O
+Extracellular	B-COMP
+Vesicles	B-COMP
+From	O
+Bronchoalveolar	B-ANAT
+Lavage	I-ANAT
+Fluid	I-ANAT
+of	O
+Patients	O
+With	O
+Influenza	O
+Virus	O
+-	O
+Induced	O
+Acute	B-DISO
+Respiratory	I-DISO
+Distress	I-DISO
+Syndrome	I-DISO
+.	O
+
+Among	O
+the	O
+9	O
+significantly	O
+deregulated	O
+microRNAs	O
+,	O
+miR	B-PRGE
+-	I-PRGE
+17	I-PRGE
+-	I-PRGE
+5p	I-PRGE
+was	O
+upregulated	O
+in	O
+patients	O
+'	O
+BALF	O
+and	O
+in	O
+EVs	O
+of	O
+IAV	O
+-	O
+infected	O
+lung	B-ANAT
+epithelial	B-ANAT
+cells	I-ANAT
+(	O
+A549	O
+).	O
+
+The	O
+viruses	B-SPEC
+were	O
+isolated	O
+using	O
+a	O
+cross	O
+-	O
+neutralization	O
+test	O
+and	O
+limiting	O
+dilution	O
+in	O
+embryonated	O
+specific	O
+-	O
+pathogen	O
+-	O
+free	O
+(	O
+SPF	O
+)	O
+eggs	O
+.	O
+
+HCWs	O
+with	O
+high	O
+-	O
+risk	O
+exposure	O
+to	O
+MERS	O
+-	O
+CoV	O
+pre	O
+-	O
+isolation	O
+pneumonia	B-DISO
+were	O
+retrospectively	O
+enrolled	O
+.	O
+
+The	O
+aim	O
+of	O
+this	O
+study	O
+is	O
+to	O
+monitor	O
+the	O
+circulation	B-PROC
+of	O
+HCoV	O
+types	O
+in	O
+the	O
+population	O
+during	O
+2015	O
+⁻	O
+2016	O
+in	O
+Israel	O
+.	O
+
+HCoV	O
+clinical	O
+symptoms	O
+were	O
+more	O
+severe	O
+than	O
+those	O
+of	O
+RSV	B-DISO
+infections	I-DISO
+but	O
+milder	O
+than	O
+influenza	B-DISO
+symptoms	O
+.	O
+
+CONCLUSIONS	O
+:	O
+This	O
+study	O
+exhibited	O
+an	O
+opportunity	O
+for	O
+the	O
+differential	O
+diagnosis	O
+through	O
+simultaneous	O
+detection	O
+of	O
+multiplex	O
+antibodies	B-COMP
+in	O
+serum	B-COMP
+and	O
+can	O
+be	O
+used	O
+for	O
+the	O
+multiplex	O
+antibodies	B-COMP
+evaluation	O
+after	O
+vaccination	O
+.	O
+
+TITLE	O
+:	O
+Overexpression	B-PROC
+of	O
+the	O
+nucleocapsid	B-COMP
+protein	B-CHED
+of	O
+Middle	O
+East	O
+respiratory	O
+syndrome	B-DISO
+coronavirus	B-SPEC
+up	O
+-	O
+regulates	O
+CXCL10	O
+.	O
+
+TITLE	O
+:	O
+Driving	O
+-	O
+pressure	O
+-	O
+independent	O
+protective	O
+effects	O
+of	O
+open	O
+lung	B-ANAT
+approach	O
+against	O
+experimental	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+.	O
+
+After	O
+24	O
+h	O
+,	O
+rats	B-SPEC
+were	O
+mechanically	O
+ventilated	O
+and	O
+randomly	O
+allocated	O
+to	O
+the	O
+OLA	O
+or	O
+control	O
+group	O
+.	O
+
+OLA	O
+shows	O
+protective	O
+effects	O
+against	O
+experimental	O
+ARDS	B-DISO
+,	O
+even	O
+when	O
+the	O
+ΔP	O
+is	O
+not	O
+decreased	O
+.	O
+
+TITLE	O
+:	O
+Oral	B-ANAT
+administration	O
+of	O
+coated	O
+PEDV	B-SPEC
+-	O
+loaded	O
+microspheres	O
+elicited	O
+PEDV	B-SPEC
+-	O
+specific	B-PROC
+immunity	I-PROC
+in	O
+weaned	B-PROC
+piglets	O
+.	O
+
+In	O
+this	O
+study	O
+,	O
+coated	O
+PEDV	B-SPEC
+-	O
+loaded	O
+microspheres	O
+with	O
+the	O
+size	O
+range	O
+of	O
+700	O
+-	O
+900	O
+μm	O
+in	O
+diameter	O
+were	O
+developed	O
+by	O
+centrifugal	O
+granulation	O
+-	O
+fluidized	O
+bed	B-DISO
+coating	O
+and	O
+demonstrated	O
+as	O
+an	O
+effective	O
+oral	B-ANAT
+delivery	O
+system	O
+to	O
+protect	O
+PEDV	B-SPEC
+antigens	B-CHED
+against	O
+the	O
+complex	O
+gastrointestinal	O
+environment	O
+by	O
+detecting	O
+the	O
+live	O
+virus	B-COMP
+particles	I-COMP
+in	O
+microspheres	O
+after	O
+the	O
+simulated	O
+gastric	B-ANAT
+fluid	I-ANAT
+treatment	O
+and	O
+the	O
+PEDV	B-SPEC
+RNA	O
+in	O
+fecal	B-ANAT
+swabs	O
+collected	O
+from	O
+all	O
+weaned	B-PROC
+piglets	O
+(	O
+100	O
+%)	O
+orally	B-ANAT
+inoculated	O
+with	O
+coated	O
+PEDV	B-SPEC
+-	O
+loaded	O
+microspheres	O
+.	O
+
+By	O
+using	O
+complete	O
+nucleotide	B-CHED
+sequences	O
+of	O
+S1	B-PRGE
+gene	I-PRGE
+we	O
+determined	O
+the	O
+phylogeny	O
+of	O
+these	O
+IBV	B-SPEC
+isolates	O
+,	O
+which	O
+in	O
+turn	O
+allowed	O
+us	O
+to	O
+define	O
+six	O
+lineages	O
+/	O
+genotypes	O
+,	O
+a	O
+number	O
+of	O
+recombinants	O
+and	O
+a	O
+novel	O
+variant	O
+.	O
+
+TITLE	O
+:	O
+Partial	O
+neuromuscular	O
+blockage	O
+to	O
+promote	O
+weaning	B-PROC
+from	O
+mechanical	O
+ventilation	O
+in	O
+severe	O
+ARDS	B-DISO
+:	O
+A	O
+case	O
+report	O
+.	O
+
+ABSTRACT	O
+:	O
+Spontaneous	O
+breathing	O
+efforts	O
+during	O
+mechanical	O
+ventilation	O
+can	O
+lead	O
+to	O
+patient	O
+self	O
+-	O
+inflicted	O
+lung	B-ANAT
+injury	O
+(	O
+P	O
+-	O
+SILI	O
+).	O
+
+ABSTRACT	O
+:	O
+Acute	O
+lung	B-ANAT
+injury	O
+(	O
+ALI	O
+)	O
+and	O
+its	O
+severe	O
+form	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+(	O
+ARDS	B-DISO
+)	O
+remain	O
+a	O
+major	O
+cause	O
+of	O
+morbidity	O
+and	O
+mortality	O
+in	O
+critically	B-DISO
+ill	I-DISO
+patients	O
+,	O
+and	O
+no	O
+specific	O
+therapies	O
+are	O
+still	O
+available	O
+to	O
+control	O
+the	O
+mortality	O
+rate	O
+.	O
+
+Thus	O
+,	O
+we	O
+explored	O
+the	O
+preventive	O
+and	O
+therapeutic	O
+effects	O
+of	O
+tannic	O
+acid	O
+(	O
+TA	O
+),	O
+a	O
+natural	O
+polyphenol	B-CHED
+in	O
+the	O
+context	O
+of	O
+ALI	O
+.	O
+
+This	O
+Concise	O
+Definitive	O
+Review	O
+provides	O
+a	O
+practical	O
+and	O
+evidence	O
+-	O
+based	O
+summary	O
+of	O
+treatments	O
+in	O
+addition	O
+to	O
+low	O
+tidal	O
+volume	O
+ventilation	O
+and	O
+their	O
+role	O
+in	O
+the	O
+management	O
+of	O
+severe	O
+respiratory	B-DISO
+failure	I-DISO
+in	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+.	O
+
+For	O
+elevated	O
+plateau	O
+airway	B-ANAT
+pressures	O
+,	O
+we	O
+suggest	O
+first	O
+decreasing	O
+tidal	O
+volumes	O
+,	O
+followed	O
+by	O
+neuromuscular	B-DISO
+blockade	I-DISO
+,	O
+modification	O
+of	O
+positive	O
+end	B-PROC
+-	I-PROC
+expiratory	I-PROC
+pressure	O
+,	O
+and	O
+prone	O
+positioning	O
+.	O
+
+Severe	O
+respiratory	B-DISO
+failure	I-DISO
+in	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+often	O
+necessitates	O
+the	O
+use	O
+of	O
+treatment	O
+adjuncts	O
+.	O
+
+Evidence	O
+-	O
+based	O
+application	O
+of	O
+these	O
+therapies	O
+in	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+remains	O
+a	O
+significant	O
+challenge	O
+.	O
+
+infection	B-DISO
+was	O
+common	O
+in	O
+study	O
+broilers	O
+.	O
+
+Finally	O
+,	O
+we	O
+observed	O
+interaction	O
+between	O
+broiler	O
+chickens	B-SPEC
+and	O
+wild	O
+birds	B-SPEC
+(	O
+finches	O
+)	O
+inside	O
+broiler	O
+pens	O
+,	O
+as	O
+well	O
+as	O
+the	O
+presence	O
+of	O
+backyard	O
+chickens	B-SPEC
+inside	O
+property	O
+limits	O
+of	O
+study	O
+farms	O
+.	O
+
+The	O
+resulting	O
+virus	B-SPEC
+replicated	O
+like	O
+SARS	B-DISO
+-	O
+CoV	O
+in	O
+Vero	B-ANAT
+cells	B-COMP
+but	O
+was	O
+suppressed	O
+in	O
+IFN	B-PRGE
+competent	I-PRGE
+MA	I-PRGE
+-	I-PRGE
+104	I-PRGE
+(	O
+3	O
+.	O
+7	O
+-	O
+fold	O
+),	O
+Calu	O
+-	O
+3	O
+(	O
+2	O
+.	O
+6	O
+-	O
+fold	O
+)	O
+and	O
+human	B-SPEC
+airway	B-ANAT
+epithelial	B-ANAT
+cells	I-ANAT
+(	O
+10	O
+.	O
+3	O
+-	O
+fold	O
+).	O
+
+All	O
+sections	O
+evaluated	O
+in	O
+this	O
+case	O
+were	O
+negative	O
+for	O
+PEDV	B-SPEC
+and	O
+rotavirus	B-SPEC
+A	I-SPEC
+.	O
+This	O
+is	O
+the	O
+first	O
+case	O
+series	O
+describing	O
+neonatal	O
+mortality	O
+with	O
+etiological	O
+confirmation	O
+of	O
+TGEV	B-SPEC
+in	O
+Argentina	B-SPEC
+.	O
+
+Furthermore	O
+,	O
+TGEV	B-SPEC
+-	O
+induced	O
+apoptosis	B-PATH
+was	O
+blocked	O
+by	O
+combination	O
+of	O
+three	O
+or	O
+more	O
+inhibitors	B-CHED
+,	O
+such	O
+as	O
+pan	B-COMP
+caspase	B-PRGE
+inhibitor	B-CHED
+Z	B-PRGE
+-	I-PRGE
+VAD	I-PRGE
+-	I-PRGE
+FMK	I-PRGE
+,	O
+NP	O
+,	O
+ABT	B-PRGE
+-	I-PRGE
+888	I-PRGE
+,	O
+PDTC	O
+,	O
+PFT	B-CHED
+-	O
+α	O
+,	O
+to	O
+treat	O
+PK	O
+-	O
+15	O
+cells	B-COMP
+.	O
+
+Multivariate	O
+Cox	O
+regression	O
+analysis	O
+identified	O
+PSI	B-PRGE
+(	O
+hazard	O
+ratio	O
+1	O
+.	O
+020	O
+,	O
+95	O
+%	O
+confidence	O
+interval	O
+1	O
+.	O
+009	O
+-	O
+1	O
+.	O
+032	O
+;	O
+p	O
+<	O
+0	O
+.	O
+001	O
+),	O
+renal	B-ANAT
+replacement	O
+therapy	O
+(	O
+hazard	O
+ratio	O
+6	O
+.	O
+248	O
+,	O
+95	O
+%	O
+confidence	O
+interval	O
+2	O
+.	O
+245	O
+-	O
+17	O
+.	O
+389	O
+;	O
+p	O
+<	O
+0	O
+.	O
+001	O
+),	O
+and	O
+increase	O
+in	O
+dynamic	O
+driving	O
+pressure	O
+(	O
+hazard	O
+ratio	O
+1	O
+.	O
+372	O
+,	O
+95	O
+%	O
+confidence	O
+interval	O
+1	O
+.	O
+095	O
+-	O
+1	O
+.	O
+718	O
+;	O
+p	O
+=	O
+0	O
+.	O
+006	O
+)	O
+which	O
+were	O
+independent	O
+predictors	O
+associated	O
+with	O
+60	O
+-	O
+day	O
+mortality	O
+.	O
+
+ABSTRACT	O
+:	O
+Chronic	O
+lung	B-ANAT
+allograft	O
+dysfunction	O
+(	O
+CLAD	O
+)	O
+is	O
+the	O
+major	O
+limiting	O
+factor	O
+for	O
+long	O
+-	O
+term	O
+survival	O
+in	O
+lung	B-ANAT
+transplant	B-ANAT
+recipients	O
+.	O
+
+They	O
+were	O
+monitored	O
+for	O
+infections	B-DISO
+with	O
+predefined	O
+intervals	O
+and	O
+on	O
+extra	O
+visits	O
+during	O
+the	O
+first	O
+year	O
+,	O
+the	O
+total	O
+follow	O
+-	O
+up	O
+period	O
+ranged	O
+between	O
+5	O
+and	O
+8	O
+years	O
+.	O
+
+The	O
+swab	O
+samples	O
+were	O
+utilized	O
+for	O
+molecular	O
+detection	O
+using	O
+reverse	B-PROC
+transcription	I-PROC
+polymerase	O
+chain	O
+reaction	O
+(	O
+RT	O
+-	O
+PCR	O
+).	O
+
+Based	O
+on	O
+the	O
+results	O
+of	O
+the	O
+serologic	O
+test	O
+,	O
+77	O
+%,	O
+45	O
+%,	O
+and	O
+38	O
+.	O
+4	O
+%	O
+of	O
+the	O
+birds	O
+were	O
+positive	O
+for	O
+NDV	B-SPEC
+,	O
+AIV	O
+,	O
+and	O
+IBV	B-SPEC
+,	O
+respectively	O
+.	O
+
+Finally	O
+,	O
+administration	O
+of	O
+rshDPP4	O
+led	O
+to	O
+reduced	O
+lung	B-ANAT
+virus	B-SPEC
+titer	O
+and	O
+histopathology	O
+.	O
+
+Our	O
+studies	O
+suggest	O
+that	O
+the	O
+serum	B-COMP
+shDPP4	O
+levels	O
+play	O
+a	O
+role	O
+in	O
+MERS	O
+pathogenesis	B-DISO
+and	O
+demonstrate	O
+a	O
+potential	O
+of	O
+rshDPP4	O
+as	O
+a	O
+treatment	O
+option	O
+for	O
+MERS	O
+.	O
+
+ABSTRACT	O
+:	O
+Cell	B-COMP
+entry	O
+by	O
+coronaviruses	O
+involves	O
+two	O
+principal	O
+steps	O
+,	O
+receptor	O
+binding	O
+and	O
+membrane	B-PROC
+fusion	I-PROC
+;	O
+the	O
+latter	O
+requires	O
+activation	O
+by	O
+host	B-PRGE
+proteases	I-PRGE
+,	I-PRGE
+particularly	I-PRGE
+lysosomal	B-ANAT
+proteases	I-PRGE
+.	O
+
+Despite	O
+the	O
+importance	O
+of	O
+lysosomal	B-PRGE
+proteases	I-PRGE
+in	O
+both	O
+coronavirus	B-SPEC
+entry	O
+and	O
+cell	B-COMP
+metabolism	B-PROC
+,	O
+the	O
+correlation	O
+between	O
+lysosomal	B-PRGE
+proteases	I-PRGE
+and	O
+cell	B-COMP
+tropism	B-PROC
+of	O
+coronaviruses	O
+has	O
+not	O
+been	O
+established	O
+.	O
+
+TITLE	O
+:	O
+The	O
+WHO	O
+R	O
+&	O
+D	O
+Blueprint	O
+:	O
+2018	O
+review	O
+of	O
+emerging	B-DISO
+infectious	I-DISO
+diseases	I-DISO
+requiring	O
+urgent	O
+research	O
+and	O
+development	O
+efforts	O
+.	O
+
+The	O
+committee	O
+determined	O
+that	O
+,	O
+given	O
+their	O
+potential	O
+to	O
+cause	O
+a	O
+public	O
+health	O
+emergency	B-DISO
+and	O
+the	O
+absence	O
+of	O
+efficacious	O
+drugs	O
+and	O
+/	O
+or	O
+vaccines	O
+,	O
+there	O
+is	O
+an	O
+urgent	O
+need	O
+for	O
+accelerated	O
+R	O
+&	O
+D	O
+for	O
+(	O
+in	O
+no	O
+order	O
+of	O
+priority	O
+)	O
+
+ABSTRACT	O
+:	O
+Acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+(	O
+ARDS	B-DISO
+)	O
+is	O
+not	O
+a	O
+failure	O
+of	O
+the	O
+neurological	O
+command	O
+of	O
+the	O
+ventilatory	B-ANAT
+muscles	I-ANAT
+or	O
+of	O
+the	O
+ventilatory	B-ANAT
+muscles	I-ANAT
+;	O
+it	O
+is	O
+an	O
+oxygenation	B-PROC
+defect	O
+.	O
+
+The	O
+stabilization	O
+of	O
+the	O
+acute	O
+cardio	O
+-	O
+ventilatory	O
+distress	O
+should	O
+primarily	O
+itemize	O
+the	O
+pathophysiological	O
+conditions	O
+:	O
+fever	B-PROC
+control	O
+,	O
+improved	O
+micro	O
+-	O
+circulation	B-PROC
+and	O
+normalized	O
+local	O
+acidosis	B-DISO
+,	O
+'	O
+upright	O
+'	O
+position	O
+,	O
+minimized	O
+hypercapnia	B-DISO
+,	O
+sympathetic	O
+de	O
+-	O
+activation	O
+(	O
+normalized	O
+sympathetic	O
+activity	O
+toward	O
+baseline	O
+levels	O
+resulting	O
+in	O
+improved	O
+micro	O
+-	O
+circulation	B-PROC
+with	O
+alpha	O
+-	O
+2	O
+agonists	B-CHED
+administered	O
+immediately	O
+following	O
+optimized	O
+circulation	B-PROC
+and	O
+endotracheal	O
+intubation	O
+),	O
+lowered	O
+inflammation	B-DISO
+and	O
+'	O
+cooperative	O
+'	O
+sedation	B-DISO
+without	O
+respiratory	B-DISO
+depression	I-DISO
+evoked	O
+by	O
+alpha	O
+-	O
+2	O
+agonists	B-CHED
+.	O
+
+Three	O
+weeks	O
+after	O
+dosing	O
+,	O
+new	O
+litters	O
+of	O
+piglets	O
+were	O
+born	O
+which	O
+remained	O
+healthy	O
+with	O
+no	O
+development	B-PROC
+of	O
+diarrhoea	B-DISO
+.	O
+
+TITLE	O
+:	O
+Cellular	B-ANAT
+localisation	I-PROC
+of	O
+the	O
+proteins	B-CHED
+of	O
+region	O
+3	O
+of	O
+feline	B-SPEC
+enteric	B-SPEC
+coronavirus	I-SPEC
+.	O
+
+To	O
+detect	O
+and	O
+study	O
+the	O
+evolution	B-PROC
+of	O
+PEDV	B-SPEC
+and	O
+PDCoV	O
+in	O
+central	O
+China	O
+(	O
+Shanxi	O
+,	O
+Henan	O
+,	O
+Hubei	O
+province	O
+),	O
+70	O
+clinical	O
+intestinal	B-ANAT
+and	O
+fecal	B-ANAT
+samples	O
+from	O
+piglets	O
+with	O
+severe	O
+watery	B-DISO
+diarrhea	I-DISO
+during	O
+August	O
+2015	O
+and	O
+June	O
+2016	O
+were	O
+collected	O
+,	O
+tested	O
+and	O
+analyzed	O
+.	O
+
+Additionally	O
+,	O
+the	O
+three	O
+G2b	O
+strains	O
+(	O
+PEDV	B-SPEC
+S2	O
+△)	O
+contained	O
+the	O
+same	O
+specific	O
+3	O
+nt	O
+deletion	O
+in	O
+S2	O
+as	O
+other	O
+reference	O
+strains	O
+in	O
+G2b	O
+.	O
+
+CH	O
+/	O
+hubei	O
+/	O
+2016	O
+had	O
+one	O
+recombination	B-PROC
+event	O
+in	O
+S2	O
+gene	O
+which	O
+may	O
+have	O
+resulted	O
+from	O
+AH2012	O
+-	O
+12	O
+(	O
+from	O
+G2b	O
+group	O
+)	O
+and	O
+CH	O
+-	O
+ZMDZY	O
+-	O
+11	O
+(	O
+from	O
+G2a	O
+group	O
+).	O
+
+With	O
+the	O
+unavailability	O
+of	O
+vaccines	O
+or	O
+antiviral	B-CHED
+drugs	I-CHED
+to	O
+prevent	O
+and	O
+/	O
+or	O
+treat	O
+SFTSV	O
+infection	B-DISO
+,	O
+early	O
+rapid	O
+diagnosis	O
+is	O
+critical	O
+for	O
+prevention	O
+and	O
+control	O
+of	O
+the	O
+disease	O
+.	O
+
+The	O
+purpose	O
+of	O
+this	O
+study	O
+was	O
+to	O
+detect	O
+porcine	B-SPEC
+epidemic	I-SPEC
+diarrhea	I-SPEC
+virus	I-SPEC
+(	O
+PEDV	B-SPEC
+)	O
+subclinically	O
+infected	O
+pigs	B-SPEC
+shipped	O
+from	O
+non	O
+-	O
+case	O
+farms	O
+to	O
+slaughterhouses	O
+.	O
+
+Hence	O
+,	O
+new	O
+vaccine	O
+technologies	O
+able	O
+to	O
+achieve	O
+rapid	O
+development	B-PROC
+as	O
+well	O
+as	O
+large	O
+scale	O
+production	O
+are	O
+of	O
+pivotal	O
+importance	O
+.	O
+
+Further	O
+in	O
+silico	O
+studies	O
+identified	O
+the	O
+key	O
+molecular	O
+interactions	O
+between	O
+those	O
+compounds	O
+and	O
+the	O
+3	B-PRGE
+-	I-PRGE
+chymotrypsin	I-PRGE
+-	I-PRGE
+like	I-PRGE
+protease	I-PRGE
+,	O
+which	O
+is	O
+essential	O
+to	O
+the	O
+intracellular	B-COMP
+replication	O
+of	O
+the	O
+virus	B-SPEC
+,	O
+supporting	O
+the	O
+hypothesis	O
+that	O
+the	O
+protease	O
+is	O
+the	O
+target	O
+molecule	O
+of	O
+the	O
+potential	O
+antiviral	B-CHED
+derivatives	O
+.	O
+
+TITLE	O
+:	O
+Zoonotic	O
+Viral	B-DISO
+Diseases	I-DISO
+of	O
+Equines	B-SPEC
+and	O
+Their	O
+Impact	O
+on	O
+Human	B-SPEC
+and	O
+Animal	B-SPEC
+Health	O
+.	O
+
+These	O
+diseases	O
+can	O
+be	O
+caused	O
+by	O
+a	O
+range	O
+of	O
+organisms	O
+including	O
+bacteria	B-SPEC
+,	O
+parasites	O
+,	O
+viruses	B-SPEC
+and	O
+fungi	B-SPEC
+.	O
+
+The	O
+need	O
+to	O
+implement	O
+relevant	O
+infection	B-DISO
+control	O
+precautions	O
+has	O
+been	O
+highlighted	O
+by	O
+the	O
+recent	O
+Middle	O
+East	O
+respiratory	O
+syndrome	B-DISO
+coronavirus	B-SPEC
+and	O
+Ebola	B-DISO
+virus	I-DISO
+disease	I-DISO
+outbreaks	O
+.	O
+
+The	O
+Arabian	O
+Peninsula	O
+is	O
+considered	O
+a	O
+major	O
+global	O
+epicentre	O
+for	O
+the	O
+disease	O
+and	O
+the	O
+virus	B-SPEC
+has	O
+crossed	O
+regional	O
+and	O
+continental	O
+boundaries	O
+since	O
+2012	O
+.	O
+
+In	O
+Eastern	O
+Province	O
+,	O
+one	O
+unique	O
+super	O
+-	O
+spreading	O
+event	O
+(	O
+TD	O
+-	O
+R	O
+>	O
+10	O
+)	O
+was	O
+identified	O
+in	O
+May	O
+2013	O
+,	O
+which	O
+comprised	O
+of	O
+the	O
+most	O
+notable	O
+cases	O
+of	O
+human	O
+-	O
+to	O
+-	O
+human	B-SPEC
+transmission	O
+.	O
+
+We	O
+compared	O
+three	O
+lung	B-ANAT
+-	O
+ultrasound	O
+(	O
+L	O
+-	O
+US	O
+)	O
+techniques	O
+against	O
+the	O
+reference	O
+-	O
+standard	O
+transpulmonary	O
+thermodilution	O
+(	O
+TPTD	O
+)	O
+technique	O
+to	O
+access	O
+EVLW	O
+.	O
+
+A	O
+statistically	O
+significant	O
+positive	O
+correlation	O
+was	O
+found	O
+between	O
+L	O
+-	O
+US	O
+TBS	B-DISO
+and	O
+an	O
+EVLW	O
+index	O
+≥	O
+10	O
+mL	O
+/	O
+kg	O
+(	O
+L	O
+-	O
+US	O
+is	O
+feasible	O
+in	O
+patients	O
+with	O
+severe	O
+sepsis	O
+.	O
+
+Among	O
+them	O
+are	O
+filoviruses	O
+(	O
+e	O
+.	O
+g	O
+.,	O
+Marburg	O
+,	O
+Ebola	O
+),	O
+coronaviruses	O
+(	O
+e	O
+.	O
+g	O
+.,	O
+SARS	B-DISO
+,	O
+MERS	O
+),	O
+henipaviruses	B-SPEC
+(	O
+e	O
+.	O
+g	O
+.,	O
+Hendra	O
+,	O
+Nipah	O
+)	O
+which	O
+share	O
+the	O
+common	O
+features	O
+that	O
+they	O
+are	O
+all	O
+RNA	O
+viruses	B-SPEC
+,	O
+and	O
+that	O
+a	O
+dysregulated	O
+immune	B-PROC
+response	I-PROC
+is	O
+an	O
+important	O
+contributor	O
+to	O
+the	O
+tissue	B-ANAT
+damage	O
+and	O
+hence	O
+pathogenicity	O
+that	O
+results	O
+from	O
+infection	B-DISO
+in	O
+humans	B-SPEC
+.	O
+
+ABSTRACT	O
+:	O
+An	O
+outbreak	O
+of	O
+Middle	O
+East	O
+respiratory	O
+syndrome	O
+coronavirus	B-SPEC
+(	O
+MERS	O
+-	O
+CoV	O
+)	O
+in	O
+Jordan	O
+in	O
+2015	O
+involved	O
+a	O
+variant	O
+virus	B-SPEC
+that	O
+acquired	O
+distinctive	O
+deletions	O
+in	O
+the	O
+accessory	O
+open	O
+reading	O
+frames	O
+.	O
+
+We	O
+reviewed	O
+epidemiologic	O
+and	O
+medical	O
+chart	O
+data	O
+and	O
+analyzed	O
+viral	B-COMP
+genome	I-COMP
+sequences	O
+from	O
+respiratory	O
+specimens	O
+of	O
+MERS	O
+-	O
+CoV	O
+cases	O
+.	O
+
+Nonsense	B-PATH
+-	I-PATH
+mediated	I-PATH
+decay	I-PATH
+(	O
+NMD	B-PROC
+)	O
+is	O
+a	O
+eukaryotic	O
+RNA	B-PROC
+surveillance	I-PROC
+pathway	B-PROC
+that	O
+detects	O
+mRNAs	O
+harboring	O
+aberrant	O
+features	O
+and	O
+targets	O
+them	O
+for	O
+degradation	O
+.	O
+
+Pearson	O
+correlation	O
+and	O
+Multivariate	O
+Analysis	O
+of	O
+Covariance	O
+(	O
+MANCOVA	O
+)	O
+were	O
+utilized	O
+to	O
+statistically	O
+determine	O
+the	O
+relationship	O
+between	O
+healthcare	O
+workers	O
+'	O
+reports	O
+of	O
+hand	O
+hygiene	O
+practices	O
+and	O
+observed	O
+hand	O
+hygiene	O
+behaviors	B-PROC
+.	O
+
+The	O
+study	O
+was	O
+conducted	O
+in	O
+the	O
+outpatient	O
+examination	O
+rooms	O
+and	O
+emergency	B-DISO
+departments	O
+of	O
+three	O
+types	O
+of	O
+hospitals	O
+in	O
+the	O
+Eastern	O
+region	O
+of	O
+Saudi	O
+Arabia	O
+where	O
+Middle	O
+East	O
+respiratory	O
+syndrome	O
+coronavirus	B-SPEC
+(	O
+MERS	O
+-	O
+CoV	O
+)	O
+is	O
+endemic	O
+and	O
+is	O
+observed	O
+in	O
+routine	O
+cases	O
+and	O
+outbreaks	O
+.	O
+
+TITLE	O
+:	O
+Complement	B-PROC
+Activation	I-PROC
+Contributes	O
+to	O
+Severe	B-DISO
+Acute	I-DISO
+Respiratory	I-DISO
+Syndrome	I-DISO
+Coronavirus	B-SPEC
+Pathogenesis	B-PROC
+.	O
+
+At	O
+times	O
+the	O
+pain	O
+was	O
+severe	O
+enough	O
+to	O
+prevent	O
+ambulation	B-PROC
+,	O
+prompting	O
+visits	O
+to	O
+her	O
+primary	O
+care	O
+provider	O
+.	O
+
+TITLE	O
+:	O
+Epidemiology	O
+and	O
+outcome	O
+of	O
+acute	O
+kidney	B-ANAT
+injury	O
+due	O
+to	O
+venomous	O
+animals	B-SPEC
+from	O
+a	O
+subtropical	O
+region	O
+of	O
+India	O
+.	O
+
+Outcomes	O
+of	O
+requirement	O
+for	O
+intensive	O
+care	O
+unit	O
+(	O
+ICU	O
+)	O
+support	O
+,	O
+treatment	O
+with	O
+dialysis	B-SPEC
+,	O
+survival	O
+,	O
+and	O
+mortality	O
+were	O
+analyzed	O
+.	O
+
+81	O
+.	O
+8	O
+%	O
+had	O
+oliguria	B-DISO
+,	O
+and	O
+54	O
+.	O
+7	O
+%	O
+had	O
+a	O
+history	O
+of	O
+hematuria	O
+or	O
+having	O
+passed	O
+red	O
+or	O
+brown	O
+colored	O
+urine	B-ANAT
+.	O
+
+The	O
+hematological	O
+and	O
+biochemical	O
+laboratory	O
+abnormalities	O
+were	O
+as	O
+follows	O
+:	O
+anemia	B-DISO
+(	O
+75	O
+%),	O
+leukocytosis	B-DISO
+(	O
+75	O
+.	O
+7	O
+%),	O
+hyperkalemia	O
+(	O
+35	O
+.	O
+8	O
+%),	O
+severe	O
+metabolic	B-DISO
+acidosis	I-DISO
+(	O
+46	O
+.	O
+6	O
+%),	O
+hepatic	B-DISO
+dysfunction	I-DISO
+(	O
+54	O
+.	O
+7	O
+%),	O
+hemolysis	B-DISO
+(	O
+85	O
+.	O
+8	O
+%),	O
+and	O
+rhabdomyolysis	B-DISO
+(	O
+65	O
+.	O
+5	O
+%).	O
+
+AKI	B-PRGE
+was	O
+severe	O
+,	O
+a	O
+high	O
+proportion	O
+required	O
+dialysis	B-SPEC
+,	O
+and	O
+the	O
+mortality	O
+was	O
+high	O
+.	O
+
+He	O
+was	O
+diagnosed	O
+with	O
+myocardial	B-DISO
+infarction	I-DISO
+complicated	O
+with	O
+ventricular	B-DISO
+septal	I-DISO
+perforation	I-DISO
+(	O
+VSP	O
+),	O
+and	O
+intraaortic	O
+balloon	O
+pumping	O
+support	O
+and	O
+intensive	O
+care	O
+were	O
+started	O
+.	O
+
+Of	O
+the	O
+camel	B-SPEC
+nasal	B-ANAT
+swabs	O
+,	O
+22	O
+were	O
+found	O
+to	O
+be	O
+positive	O
+by	O
+RT	O
+-	O
+qPCR	O
+though	O
+with	O
+high	O
+Ct	O
+values	O
+.	O
+
+In	O
+our	O
+model	O
+,	O
+the	O
+use	O
+of	O
+venovenous	O
+extracorporeal	O
+membrane	B-COMP
+oxygenation	B-PROC
+compared	O
+with	O
+lung	B-ANAT
+protective	O
+ventilation	O
+resulted	O
+in	O
+a	O
+gain	O
+of	O
+5	O
+.	O
+2	O
+life	O
+years	O
+and	O
+4	O
+.	O
+05	O
+quality	O
+-	O
+adjusted	O
+life	O
+years	O
+,	O
+at	O
+an	O
+additional	O
+lifetime	O
+cost	O
+of	O
+$	O
+145	O
+,	O
+697	O
+Canadian	O
+dollars	O
+.	O
+
+Additional	O
+evidence	O
+on	O
+the	O
+efficacy	O
+of	O
+venovenous	O
+extracorporeal	O
+membrane	B-COMP
+oxygenation	B-PROC
+for	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+and	O
+in	O
+different	O
+subgroups	O
+of	O
+patients	O
+will	O
+allow	O
+for	O
+greater	O
+certainty	O
+in	O
+its	O
+cost	O
+-	O
+effectiveness	O
+.	O
+
+Non	O
+-	O
+coding	O
+RNAs	O
+(	O
+ncRNAs	O
+)	O
+are	O
+not	O
+translated	O
+into	O
+proteins	B-CHED
+and	O
+play	O
+an	O
+important	O
+role	O
+in	O
+many	O
+biological	O
+and	O
+pathological	B-DISO
+processes	I-DISO
+such	O
+as	O
+inflammation	B-DISO
+,	O
+viral	B-DISO
+infection	I-DISO
+,	O
+and	O
+mitochondrial	B-DISO
+damage	I-DISO
+.	O
+
+TITLE	O
+:	O
+Establishment	O
+of	O
+porcine	B-SPEC
+enterocyte	B-ANAT
+/	O
+myofibroblast	B-ANAT
+co	O
+-	O
+cultures	O
+for	O
+the	O
+growth	B-PROC
+of	O
+porcine	B-SPEC
+rota	O
+-	O
+and	O
+coronaviruses	O
+.	O
+
+Next	O
+,	O
+the	O
+TGEV	B-SPEC
+Purdue	O
+strain	O
+infected	O
+both	O
+ileocytes	O
+and	O
+colonocytes	O
+whereas	O
+the	O
+Miller	O
+strain	O
+only	O
+infected	O
+ileocytes	O
+.	O
+
+TITLE	O
+:	O
+Differences	O
+between	O
+Patients	O
+in	O
+Whom	O
+Physicians	O
+Agree	O
+and	O
+Disagree	O
+about	O
+the	O
+Diagnosis	O
+of	O
+Acute	B-DISO
+Respiratory	I-DISO
+Distress	I-DISO
+Syndrome	I-DISO
+.	O
+
+Understanding	O
+the	O
+clinical	O
+differences	O
+between	O
+patients	O
+with	O
+agreement	O
+and	O
+disagreement	O
+about	O
+the	O
+diagnosis	O
+of	O
+ARDS	B-DISO
+may	O
+provide	O
+insight	O
+into	O
+the	O
+epidemiology	O
+and	O
+pathophysiology	O
+of	O
+this	O
+syndrome	B-DISO
+,	O
+and	O
+inform	O
+strategies	O
+to	O
+improve	O
+the	O
+reliability	O
+of	O
+ARDS	B-DISO
+diagnosis	O
+.	O
+
+Patients	O
+with	O
+acute	O
+hypoxemic	O
+respiratory	B-DISO
+failure	I-DISO
+(	O
+arterial	B-ANAT
+oxygen	B-PROC
+tension	B-DISO
+/	O
+pressure	O
+[	O
+Pa	O
+Among	O
+738	O
+patients	O
+reviewed	O
+,	O
+110	O
+(	O
+15	O
+%)	O
+had	O
+consensus	O
+-	O
+ARDS	B-DISO
+,	O
+100	O
+(	O
+14	O
+%)	O
+had	O
+disagreement	O
+,	O
+and	O
+528	O
+(	O
+72	O
+%)	O
+did	O
+not	O
+have	O
+ARDS	B-DISO
+.	O
+
+Considering	O
+both	O
+the	O
+presence	O
+of	O
+key	O
+ARDS	B-DISO
+risk	O
+factors	O
+and	O
+hypoxemia	O
+severity	O
+can	O
+help	O
+guide	O
+clinicians	O
+in	O
+identifying	O
+patients	O
+with	O
+diagnosis	O
+of	O
+ARDS	B-DISO
+agreed	O
+upon	O
+by	O
+a	O
+consensus	O
+of	O
+physicians	O
+.	O
+
+ABSTRACT	O
+:	O
+Respiratory	B-DISO
+diseases	I-DISO
+continue	O
+to	O
+have	O
+a	O
+major	O
+impact	O
+on	O
+poultry	O
+health	O
+,	O
+welfare	O
+and	O
+productivity	O
+.	O
+
+However	O
+,	O
+6	O
+days	O
+after	O
+admission	O
+,	O
+she	O
+experienced	O
+a	O
+cluster	O
+of	O
+brief	O
+convulsions	B-DISO
+.	O
+
+Our	O
+findings	O
+may	O
+thus	O
+provide	O
+insight	O
+into	O
+the	O
+development	B-PROC
+of	O
+TTC	O
+and	O
+prompt	O
+further	O
+studies	O
+regarding	O
+the	O
+relationship	O
+between	O
+prolonged	O
+seizures	B-DISO
+and	O
+TTC	O
+.	O
+
+Underlying	O
+causes	O
+for	O
+pulmonary	B-DISO
+edema	I-DISO
+and	O
+aberrant	O
+fluid	O
+regulation	B-PROC
+largely	O
+remain	O
+unknown	O
+,	O
+particularly	O
+regarding	O
+the	O
+role	O
+of	O
+viral	O
+-	O
+mediated	O
+mechanisms	O
+.	O
+
+This	O
+study	O
+analyzed	O
+qualitative	O
+data	O
+of	O
+the	O
+2015	O
+Middle	O
+East	O
+Respiratory	O
+Syndrome	B-DISO
+outbreak	O
+in	O
+South	O
+Korea	O
+.	O
+
+The	O
+detection	O
+limits	O
+of	O
+the	O
+assay	O
+per	O
+reaction	O
+were	O
+5	O
+copies	O
+for	O
+PEDV	B-SPEC
+,	O
+TGEV	B-SPEC
+,	O
+RVC	O
+and	O
+PCV2	O
+and	O
+50	O
+copies	O
+for	O
+RVA	O
+for	O
+the	O
+singleplex	O
+assays	O
+and	O
+50	O
+copies	O
+when	O
+all	O
+five	O
+viruses	B-SPEC
+were	O
+multiplexed	O
+.	O
+
+A	O
+65	O
+kg	O
+32	O
+-	O
+year	O
+-	O
+old	O
+woman	O
+was	O
+admitted	O
+to	O
+hospital	O
+presented	O
+with	O
+severe	O
+acute	B-DISO
+pancreatitis	I-DISO
+(	O
+SAP	O
+),	O
+respiratory	B-DISO
+failure	I-DISO
+,	O
+metabotropic	O
+acidosis	B-DISO
+and	O
+hyperkalemia	O
+.	O
+
+Given	O
+the	O
+residual	O
+renal	B-PROC
+function	I-PROC
+and	O
+continuous	O
+hemofiltration	O
+intensity	O
+on	O
+day	O
+3	O
+,	O
+vancomycin	B-CHED
+bolus	O
+of	O
+1	O
+000	O
+mg	O
+was	O
+prescribed	O
+,	O
+followed	O
+by	O
+a	O
+maintenance	O
+dose	O
+of	O
+500	O
+mg	O
+every	O
+8	O
+hours	O
+.	O
+
+With	O
+the	O
+help	O
+of	O
+this	O
+case	O
+report	O
+we	O
+want	O
+to	O
+call	O
+attention	O
+to	O
+the	O
+clinically	O
+significant	O
+alteration	O
+in	O
+vancomycin	B-CHED
+pharmacokinetics	B-PROC
+among	O
+critically	B-DISO
+ill	I-DISO
+patients	O
+.	O
+
+TITLE	O
+:	O
+Severe	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+in	O
+a	O
+patient	O
+with	O
+AIDS	O
+successfully	O
+treated	O
+with	O
+veno	O
+-	O
+venous	O
+extracorporeal	O
+membrane	B-COMP
+oxygenation	B-PROC
+:	O
+a	O
+case	O
+report	O
+and	O
+literature	O
+review	O
+.	O
+
+ABSTRACT	O
+:	O
+Several	O
+successful	O
+uses	O
+of	O
+extracorporeal	O
+membrane	B-COMP
+oxygenation	B-PROC
+(	O
+ECMO	O
+)	O
+for	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+in	O
+patients	O
+with	O
+novel	O
+HIV	B-DISO
+/	I-DISO
+AIDS	I-DISO
+infection	B-DISO
+have	O
+been	O
+reported	O
+;	O
+however	O
+,	O
+the	O
+therapeutic	O
+keys	O
+have	O
+not	O
+always	O
+been	O
+discussed	O
+.	O
+
+We	O
+report	O
+a	O
+pediatric	O
+case	O
+of	O
+influenza	B-PATH
+A	I-PATH
+(	O
+H1N1	O
+)	O
+pdm09	O
+infection	B-DISO
+with	O
+a	O
+good	O
+outcome	O
+following	O
+rapid	O
+initiation	O
+of	O
+vvECMO	O
+.	O
+This	O
+patient	O
+was	O
+a	O
+13	O
+-	O
+year	O
+-	O
+old	O
+boy	O
+with	O
+severe	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+due	O
+to	O
+influenza	B-SPEC
+virus	I-SPEC
+.	O
+
+On	O
+lipopolysaccharide	B-CHED
+challenge	O
+,	O
+PHD2	O
+depletion	O
+in	O
+ECs	O
+attenuates	O
+lipopolysaccharide	B-CHED
+-	O
+induced	O
+increases	O
+of	O
+lung	B-ANAT
+vascular	B-PROC
+permeability	I-PROC
+,	O
+edema	B-DISO
+,	O
+and	O
+inflammatory	B-ANAT
+cell	I-ANAT
+infiltration	I-DISO
+.	O
+
+Moreover	O
+,	O
+EC	O
+-	O
+specific	O
+PHD2	O
+inducible	O
+knockout	O
+mice	B-SPEC
+exhibit	O
+improved	O
+adherens	B-COMP
+junction	I-COMP
+integrity	O
+and	O
+endothelial	B-ANAT
+barrier	O
+function	O
+.	O
+
+Data	O
+indicate	O
+that	O
+PHD2	B-PRGE
+depletion	O
+prevents	O
+the	O
+formation	B-PROC
+of	O
+leaky	O
+vessels	B-ANAT
+and	O
+edema	B-DISO
+by	O
+regulating	O
+endothelial	B-ANAT
+barrier	O
+function	O
+.	O
+
+A	O
+third	O
+(	O
+39	O
+.	O
+36	O
+%)	O
+reported	O
+contact	O
+with	O
+an	O
+index	O
+case	O
+,	O
+developed	O
+the	O
+disease	O
+after	O
+6	O
+.	O
+2days	O
+and	O
+continued	O
+to	O
+shed	O
+the	O
+virus	B-SPEC
+for	O
+13	O
+.	O
+17days	O
+on	O
+average	O
+.	O
+
+Independent	O
+predictors	O
+of	O
+being	O
+discharged	O
+alive	O
+among	O
+confirmed	O
+cases	O
+were	O
+younger	O
+age	O
+(	O
+OR	O
+MERS	O
+-	O
+CoV	O
+spread	O
+from	O
+human	O
+-	O
+to	O
+-	O
+human	B-SPEC
+as	O
+community	O
+acquired	O
+and	O
+nosocomial	B-DISO
+infection	I-DISO
+.	O
+
+The	O
+local	O
+and	O
+international	O
+response	O
+to	O
+infectious	B-DISO
+disease	I-DISO
+epidemics	O
+,	O
+such	O
+as	O
+the	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+and	O
+west	O
+African	O
+Ebola	B-SPEC
+virus	I-SPEC
+epidemic	O
+,	O
+revealed	O
+serious	O
+shortcomings	O
+which	O
+bioterrorists	O
+might	O
+exploit	O
+when	O
+intentionally	O
+initiating	O
+an	O
+epidemic	O
+.	O
+
+Although	O
+PEDV	B-SPEC
+vaccines	O
+based	O
+on	O
+classical	O
+PEDV	B-SPEC
+strains	O
+have	O
+been	O
+widely	O
+used	O
+in	O
+China	O
+in	O
+recent	O
+years	O
+,	O
+the	O
+morbidity	O
+and	O
+mortality	O
+in	O
+piglets	O
+remain	O
+high	O
+.	O
+
+Finally	O
+,	O
+we	O
+found	O
+that	O
+the	O
+TGEV	B-PRGE
+S1	I-PRGE
+protein	B-CHED
+interacts	O
+with	O
+the	O
+extracellular	B-COMP
+region	I-COMP
+of	O
+TfR1	B-PRGE
+,	O
+and	O
+that	O
+pre	O
+-	O
+incubating	O
+TGEV	B-SPEC
+with	O
+a	O
+protein	B-CHED
+fragment	O
+containing	O
+the	O
+extracellular	B-COMP
+region	I-COMP
+of	O
+TfR1	B-PRGE
+blocked	O
+viral	B-DISO
+infection	I-DISO
+.	O
+
+In	O
+this	O
+study	O
+,	O
+we	O
+extended	O
+our	O
+previous	O
+work	O
+on	O
+coronavirus	B-SPEC
+inhibitors	B-CHED
+and	O
+investigated	O
+the	O
+structure	O
+-	O
+activity	O
+relationships	O
+of	O
+a	O
+focused	O
+library	O
+of	O
+protease	B-CHED
+inhibitors	I-CHED
+for	O
+ferret	B-SPEC
+and	O
+mink	B-SPEC
+3CLpro	O
+.	O
+
+Multiple	O
+amino	B-CHED
+acid	I-CHED
+sequence	O
+analysis	O
+and	O
+modelling	O
+of	O
+3CLpro	O
+of	O
+ferret	B-SPEC
+and	O
+mink	B-SPEC
+coronaviruses	O
+were	O
+conducted	O
+to	O
+probe	O
+the	O
+structural	O
+basis	O
+for	O
+these	O
+findings	O
+.	O
+
+The	O
+Mini	O
+International	O
+Neuropsychiatric	O
+Interview	O
+and	O
+Hospital	O
+Anxiety	O
+and	O
+Depression	B-DISO
+Scale	O
+were	O
+administered	O
+to	O
+patients	O
+undergoing	O
+hemodialysis	O
+.	O
+
+CONCLUSIONS	O
+:	O
+Medical	O
+staff	O
+that	O
+performed	O
+MERS	O
+-	O
+related	O
+tasks	O
+showed	O
+the	O
+highest	O
+risk	O
+for	O
+post	B-DISO
+-	I-DISO
+traumatic	I-DISO
+stress	I-DISO
+disorder	I-DISO
+symptoms	O
+even	O
+after	O
+time	O
+had	O
+elapsed	O
+.	O
+
+HTG	O
+is	O
+the	O
+third	O
+most	O
+common	O
+cause	O
+of	O
+acute	B-DISO
+pancreatitis	I-DISO
+and	O
+has	O
+been	O
+established	O
+in	O
+the	O
+literature	O
+as	O
+a	O
+risk	O
+factor	O
+when	O
+levels	O
+are	O
+greater	O
+than	O
+1000	O
+mg	O
+/	O
+dL	O
+.	O
+A	O
+43	O
+-	O
+year	O
+-	O
+old	O
+patient	O
+presented	O
+to	O
+the	O
+hospital	O
+with	O
+severe	O
+epigastric	B-ANAT
+abdominal	B-DISO
+pain	I-DISO
+.	O
+
+Initial	O
+laboratory	O
+investigations	O
+were	O
+significant	O
+for	O
+a	O
+lipase	B-PRGE
+level	O
+of	O
+4143	O
+U	O
+/	O
+L	O
+and	O
+a	O
+triglyceride	B-CHED
+level	O
+of	O
+600	O
+mg	O
+/	O
+dL	O
+.	O
+Computed	O
+tomography	O
+(	O
+CT	O
+)	O
+of	O
+the	O
+abdomen	B-ANAT
+showed	O
+diffuse	O
+enlargement	B-DISO
+of	O
+the	O
+pancreas	B-ANAT
+consistent	O
+with	O
+pancreatitis	B-DISO
+.	O
+
+A	O
+post	O
+hoc	O
+Bayesian	O
+analysis	O
+of	O
+data	O
+from	O
+an	O
+RCT	O
+(	O
+ECMO	O
+to	O
+Rescue	O
+Lung	B-ANAT
+Injury	O
+in	O
+Severe	O
+ARDS	B-DISO
+[	O
+EOLIA	O
+])	O
+that	O
+included	O
+249	O
+patients	O
+with	O
+very	O
+severe	O
+ARDS	B-DISO
+who	O
+had	O
+been	O
+randomized	O
+to	O
+receive	O
+early	O
+ECMO	O
+(	O
+n	O
+=	O
+124	O
+;	O
+mortality	O
+at	O
+60	O
+days	O
+,	O
+35	O
+%)	O
+vs	O
+initial	O
+conventional	O
+lung	O
+-	O
+protective	O
+ventilation	O
+with	O
+the	O
+option	O
+for	O
+rescue	O
+ECMO	O
+(	O
+n	O
+=	O
+125	O
+,	O
+mortality	O
+at	O
+60	O
+days	O
+,	O
+46	O
+%).	O
+
+Dual	O
+and	O
+multiple	O
+infectious	B-DISO
+agents	O
+were	O
+detected	O
+in	O
+31	O
+.	O
+4	O
+%	O
+and	O
+18	O
+.	O
+6	O
+%	O
+of	O
+the	O
+samples	O
+,	O
+respectively	O
+.	O
+
+Viral	B-DISO
+infection	I-DISO
+was	O
+predominant	O
+in	O
+the	O
+pediatric	O
+environment	O
+(	O
+90	O
+.	O
+8	O
+%,	O
+P	O
+<	O
+0	O
+.	O
+001	O
+),	O
+male	O
+patients	O
+(	O
+88	O
+.	O
+0	O
+%),	O
+and	O
+spring	O
+(	O
+93	O
+.	O
+8	O
+%).	O
+
+In	O
+18	O
+.	O
+2	O
+%	O
+of	O
+the	O
+negative	O
+viral	B-DISO
+infections	I-DISO
+,	O
+only	O
+S	B-SPEC
+.	I-SPEC
+pneumoniae	I-SPEC
+was	O
+identified	O
+.	O
+
+Data	O
+on	O
+the	O
+phenomenon	O
+of	O
+intermittent	O
+positive	O
+results	O
+for	O
+MERS	O
+-	O
+CoV	O
+on	O
+reverse	O
+-	O
+transcription	B-PROC
+polymerase	O
+chain	O
+reaction	O
+(	O
+RT	O
+-	O
+PCR	O
+)	O
+with	O
+negative	O
+results	O
+in	O
+between	O
+are	O
+lacking	O
+.	O
+
+Our	O
+data	O
+indicate	O
+that	O
+2	O
+to	O
+3	O
+nasopharyngeal	O
+samples	O
+are	O
+needed	O
+to	O
+produce	O
+the	O
+highest	O
+yield	O
+of	O
+positive	O
+results	O
+for	O
+MERS	O
+-	O
+CoV	O
+.	O
+In	O
+addition	O
+,	O
+2	O
+negative	O
+results	O
+48	O
+hours	O
+apart	O
+with	O
+clinical	O
+improvement	O
+or	O
+stabilization	O
+are	O
+needed	O
+to	O
+clear	O
+patients	O
+from	O
+MERS	O
+-	O
+CoV	O
+.	O
+Evaluation	O
+of	O
+the	O
+yield	O
+of	O
+sputum	B-ANAT
+samples	O
+is	O
+needed	O
+to	O
+assess	O
+the	O
+effectiveness	O
+against	O
+nasopharyngeal	B-ANAT
+swabs	O
+.	O
+
+Four	O
+horses	B-SPEC
+were	O
+intragastrically	O
+infected	O
+with	O
+fecal	B-ANAT
+material	O
+containing	O
+10	O
+All	O
+8	O
+horses	B-SPEC
+shed	O
+ECoV	O
+in	O
+feces	B-ANAT
+.	O
+
+RESULTS	O
+:	O
+All	O
+8	O
+horses	B-SPEC
+shed	O
+ECoV	O
+in	O
+feces	B-ANAT
+.	O
+
+Two	O
+recombinant	O
+infectious	B-DISO
+bronchitis	B-DISO
+viruses	B-SPEC
+(	O
+rIBVs	O
+)	O
+have	O
+been	O
+generated	O
+;	O
+the	O
+immunogenic	O
+S1	O
+subunit	O
+is	O
+derived	O
+from	O
+the	O
+IBV	B-SPEC
+vaccine	O
+strain	O
+,	O
+H120	O
+,	O
+or	O
+the	O
+virulent	O
+field	O
+strain	O
+,	O
+QX	O
+,	O
+within	O
+the	O
+genetic	O
+background	O
+of	O
+Beau	O
+-	O
+R	O
+.	O
+The	O
+rIBVs	O
+BeauR	O
+-	O
+H120	O
+(	O
+S1	O
+)	O
+and	O
+BeauR	O
+-	O
+QX	O
+(	O
+S1	O
+)	O
+are	O
+capable	O
+of	O
+replicating	O
+in	O
+primary	O
+chicken	B-SPEC
+kidney	B-ANAT
+cell	I-ANAT
+cultures	O
+and	O
+in	O
+Vero	B-ANAT
+cells	I-ANAT
+.	O
+
+There	O
+was	O
+no	O
+significant	O
+difference	O
+in	O
+the	O
+percentage	O
+of	O
+patients	O
+developing	O
+the	O
+following	O
+adverse	O
+events	O
+:	O
+ARDS	B-DISO
+(	O
+3	O
+.	O
+8	O
+%	O
+vs	O
+5	O
+.	O
+0	O
+%;	O
+risk	O
+ratio	O
+[	O
+RR	O
+],	O
+0	O
+.	O
+86	O
+[	O
+0	O
+.	O
+59	O
+to	O
+1	O
+.	O
+24	O
+];	O
+P	O
+=	O
+.	O
+38	O
+),	O
+pneumonia	B-DISO
+(	O
+4	O
+.	O
+2	O
+%	O
+vs	O
+3	O
+.	O
+7	O
+%;	O
+RR	O
+,	O
+1	O
+.	O
+07	O
+[	O
+0	O
+.	O
+78	O
+to	O
+1	O
+.	O
+47	O
+];	O
+P	O
+=	O
+.	O
+67	O
+),	O
+severe	O
+atelectasis	B-DISO
+(	O
+11	O
+.	O
+4	O
+%	O
+vs	O
+11	O
+.	O
+2	O
+%;	O
+RR	O
+,	O
+1	O
+.	O
+00	O
+[	O
+0	O
+.	O
+81	O
+to	O
+1	O
+.	O
+23	O
+];	O
+P	O
+=	O
+.	O
+94	O
+),	O
+and	O
+pneumothorax	B-DISO
+(	O
+1	O
+.	O
+8	O
+%	O
+vs	O
+1	O
+.	O
+3	O
+%;	O
+RR	O
+,	O
+1	O
+.	O
+16	O
+[	O
+0	O
+.	O
+73	O
+to	O
+1	O
+.	O
+84	O
+];	O
+P	O
+=	O
+.	O
+55	O
+).	O
+
+As	O
+a	O
+selected	O
+viral	O
+nucleic	B-CHED
+acid	I-CHED
+extraction	O
+method	O
+may	O
+determine	O
+the	O
+sensitivity	O
+and	O
+reliability	O
+of	O
+NGS	O
+,	O
+it	O
+is	O
+still	O
+valuable	O
+to	O
+evaluate	O
+the	O
+extraction	O
+efficiency	O
+of	O
+different	O
+extraction	O
+kits	O
+using	O
+clinical	O
+specimens	O
+directly	O
+.	O
+
+Our	O
+results	O
+highlighted	O
+the	O
+importance	O
+of	O
+nucleic	B-CHED
+acid	I-CHED
+extraction	O
+kit	B-FUNC
+selection	O
+,	O
+which	O
+has	O
+a	O
+major	O
+impact	O
+on	O
+the	O
+yield	O
+and	O
+number	O
+of	O
+viral	O
+reads	O
+by	O
+NGS	O
+analysis	O
+.	O
+
+The	O
+proportion	O
+of	O
+patients	O
+with	O
+ABO	O
+blood	B-ANAT
+type	O
+A	O
+versus	O
+other	O
+blood	B-ANAT
+types	O
+was	O
+39	O
+.	O
+9	O
+%	O
+versus	O
+60	O
+.	O
+1	O
+%.	O
+
+The	O
+Pediatric	O
+Acute	O
+Lung	B-ANAT
+Injury	O
+Consensus	O
+Conference	O
+(	O
+PALICC	O
+)	O
+definition	O
+was	O
+developed	O
+to	O
+overcome	O
+limitations	O
+of	O
+the	O
+Berlin	O
+definition	O
+,	O
+which	O
+was	O
+designed	O
+and	O
+validated	O
+for	O
+adults	O
+.	O
+
+Data	O
+were	O
+collected	O
+on	O
+the	O
+PICU	B-SPEC
+characteristics	O
+,	O
+patient	O
+demographics	O
+,	O
+and	O
+elements	O
+of	O
+PARDS	O
+(	O
+ie	O
+,	O
+PARDS	O
+risk	O
+factors	O
+,	O
+hypoxaemia	O
+severity	O
+metrics	O
+,	O
+type	O
+of	O
+ventilation	O
+),	O
+comorbidities	O
+,	O
+chest	B-ANAT
+imaging	O
+,	O
+arterial	B-ANAT
+blood	I-ANAT
+gas	O
+measurements	O
+,	O
+and	O
+pulse	B-PROC
+oximetry	O
+.	O
+
+Between	O
+May	O
+9	O
+,	O
+2016	O
+,	O
+and	O
+June	O
+16	O
+,	O
+2017	O
+,	O
+during	O
+the	O
+10	O
+study	O
+weeks	O
+,	O
+23	O
+280	O
+patients	O
+were	O
+admitted	O
+to	O
+participating	O
+PICUs	B-SPEC
+,	O
+of	O
+whom	O
+744	O
+(	O
+3	O
+·	O
+2	O
+%)	O
+were	O
+identified	O
+as	O
+having	O
+PARDS	O
+.	O
+
+By	O
+use	O
+of	O
+PALICC	O
+PARDS	O
+definition	O
+,	O
+severity	O
+of	O
+PARDS	O
+at	O
+6	O
+h	O
+after	O
+initial	O
+diagnosis	O
+(	O
+area	O
+under	O
+the	O
+curve	O
+[	O
+AUC	O
+]	O
+0	O
+·	O
+69	O
+,	O
+95	O
+%	O
+CI	O
+0	O
+·	O
+62	O
+-	O
+0	O
+·	O
+76	O
+)	O
+discriminates	O
+PICU	B-SPEC
+mortality	O
+better	O
+than	O
+severity	O
+at	O
+PARDS	O
+diagnosis	O
+(	O
+AUC	O
+0	O
+·	O
+64	O
+,	O
+0	O
+·	O
+58	O
+-	O
+0	O
+·	O
+71	O
+),	O
+and	O
+outperforms	O
+Berlin	O
+severity	O
+groups	O
+at	O
+6	O
+h	O
+(	O
+0	O
+·	O
+64	O
+,	O
+0	O
+·	O
+58	O
+-	O
+0	O
+·	O
+70	O
+;	O
+p	O
+=	O
+0	O
+·	O
+01	O
+).	O
+
+There	O
+was	O
+no	O
+difference	O
+in	O
+relation	O
+to	O
+severity	O
+outcomes	O
+(	O
+number	O
+of	O
+organic	O
+dysfunctions	O
+,	O
+use	O
+of	O
+mechanical	O
+ventilation	O
+or	O
+amines	B-CHED
+,	O
+hospital	O
+/	O
+PICU	B-SPEC
+length	O
+of	O
+stay	O
+or	O
+death	B-PROC
+).	O
+
+Furthermore	O
+,	O
+we	O
+also	O
+found	O
+that	O
+YQFM	O
+significantly	O
+inhibited	O
+the	O
+PM	O
+-	O
+induced	O
+myeloperoxidase	B-PRGE
+(	O
+MPO	B-FUNC
+)	O
+activity	O
+in	O
+lung	B-ANAT
+tissues	I-ANAT
+,	O
+decreased	O
+the	O
+PM	O
+-	O
+induced	O
+inflammatory	O
+cytokines	O
+including	O
+interleukin	B-PRGE
+-	I-PRGE
+1β	I-PRGE
+(	O
+IL	O
+-	O
+1β	O
+)	O
+and	O
+tumor	B-PRGE
+necrosis	I-PRGE
+factor	I-PRGE
+-	I-PRGE
+α	I-PRGE
+(	O
+TNF	B-PRGE
+-	I-PRGE
+α	I-PRGE
+),	O
+reduced	O
+nitric	B-CHED
+oxide	I-CHED
+(	O
+NO	O
+)	O
+and	O
+total	O
+protein	B-CHED
+in	O
+bronchoalveolar	B-ANAT
+lavage	I-ANAT
+fluids	I-ANAT
+(	O
+BALF	B-ANAT
+),	O
+and	O
+effectively	O
+attenuated	O
+PM	O
+-	O
+induced	O
+increases	O
+lymphocytes	B-ANAT
+in	O
+BALF	B-ANAT
+.	O
+
+In	O
+addition	O
+,	O
+YQFM	O
+increased	O
+mammalian	B-SPEC
+target	O
+of	O
+rapamycin	B-CHED
+(	O
+mTOR	O
+)	O
+phosphorylation	B-PROC
+and	O
+dramatically	O
+suppressed	O
+the	O
+PM	O
+-	O
+stimulated	O
+expression	B-PROC
+of	O
+toll	B-PRGE
+-	I-PRGE
+like	I-PRGE
+receptor	I-PRGE
+4	I-PRGE
+(	O
+TLR4	B-PRGE
+),	O
+MyD88	B-PRGE
+,	O
+autophagy	B-PRGE
+-	I-PRGE
+related	I-PRGE
+protein	B-CHED
+LC3Ⅱand	I-PRGE
+Beclin	B-PRGE
+1	I-PRGE
+as	O
+well	O
+as	O
+autophagy	B-PROC
+.	O
+
+The	O
+patient	O
+'	O
+s	O
+respiratory	O
+condition	B-DISO
+deteriorated	O
+rapidly	O
+;	O
+he	O
+was	O
+placed	O
+on	O
+venovenous	O
+ECMO	O
+for	O
+19	O
+days	O
+and	O
+remained	O
+intubated	O
+thereafter	O
+.	O
+
+QX	O
+genotype	O
+causes	O
+permanent	O
+damage	O
+to	O
+the	O
+oviduct	B-ANAT
+in	O
+layer	B-ANAT
+and	O
+breeder	O
+flock	O
+if	O
+it	O
+occurs	O
+in	O
+the	O
+early	O
+life	O
+cycle	O
+.	O
+
+Group	O
+3	O
+was	O
+vaccinated	O
+with	O
+the	O
+H120	O
+vaccine	O
+at	O
+day	O
+1	O
+and	O
+793	O
+/	O
+B	O
+at	O
+day	O
+14	O
+(	O
+eye	O
+drop	O
+),	O
+and	O
+group	O
+4	O
+was	O
+vaccinated	O
+with	O
+H120	O
++	O
+793	O
+/	O
+B	O
+(	O
+eye	B-ANAT
+drop	O
+)	O
+on	O
+the	O
+first	O
+day	O
+and	O
+793	O
+/	O
+B	O
+at	O
+day	O
+14	O
+.	O
+
+Here	O
+,	O
+using	O
+sensitive	O
+immunological	O
+assays	O
+and	O
+a	O
+cohort	O
+of	O
+camel	B-SPEC
+workers	O
+(	O
+CWs	O
+)	O
+with	O
+well	O
+-	O
+documented	O
+camel	B-SPEC
+exposure	O
+,	O
+we	O
+show	O
+that	O
+approximately	O
+50	O
+%	O
+of	O
+camel	B-SPEC
+workers	O
+(	O
+CWs	O
+)	O
+in	O
+the	O
+Kingdom	B-SPEC
+of	O
+Saudi	O
+Arabia	O
+(	O
+KSA	O
+)	O
+and	O
+0	O
+%	O
+of	O
+controls	O
+were	O
+previously	O
+infected	O
+.	O
+
+We	O
+obtained	O
+blood	B-ANAT
+samples	I-ANAT
+from	O
+30	O
+camel	B-SPEC
+herders	O
+,	O
+truck	O
+drivers	O
+,	O
+and	O
+handlers	O
+with	O
+well	O
+-	O
+documented	O
+camel	B-SPEC
+exposure	O
+and	O
+from	O
+healthy	O
+donors	O
+,	O
+and	O
+measured	O
+MERS	O
+-	O
+CoV	O
+-	O
+specific	O
+enzyme	O
+-	O
+linked	O
+immunosorbent	O
+assay	O
+(	O
+ELISA	O
+),	O
+immunofluorescence	O
+assay	O
+(	O
+IFA	O
+),	O
+and	O
+neutralizing	O
+antibody	B-COMP
+titers	O
+,	O
+as	O
+well	O
+as	O
+T	B-ANAT
+cell	I-ANAT
+responses	O
+.	O
+
+In	O
+adjusted	O
+analysis	O
+,	O
+spontaneous	O
+breathing	B-PROC
+during	O
+the	O
+first	O
+2	O
+days	O
+was	O
+not	O
+associated	O
+with	O
+an	O
+effect	O
+on	O
+ICU	O
+or	O
+hospital	O
+mortality	O
+(	O
+33	O
+%	O
+vs	O
+37	O
+%;	O
+odds	O
+ratio	O
+,	O
+1	O
+.	O
+18	O
+[	O
+0	O
+.	O
+92	O
+-	O
+1	O
+.	O
+51	O
+];	O
+p	O
+=	O
+0	O
+.	O
+19	O
+and	O
+37	O
+%	O
+vs	O
+41	O
+%;	O
+odds	O
+ratio	O
+,	O
+1	O
+.	O
+18	O
+[	O
+0	O
+.	O
+93	O
+-	O
+1	O
+.	O
+50	O
+];	O
+p	O
+=	O
+0	O
+.	O
+196	O
+,	O
+respectively	O
+).	O
+
+Our	O
+results	O
+showed	O
+that	O
+miR	B-PRGE
+-	I-PRGE
+221	I-PRGE
+-	I-PRGE
+5p	I-PRGE
+directly	O
+targets	O
+the	O
+3	O
+'	O
+untranslated	O
+region	O
+(	O
+UTR	O
+)	O
+of	O
+PEDV	B-SPEC
+genomic	O
+RNA	O
+to	O
+inhibit	O
+PEDV	B-SPEC
+replication	O
+,	O
+and	O
+that	O
+miR	O
+-	O
+221	O
+-	O
+5p	O
+overexpression	B-PROC
+activates	O
+nuclear	B-PRGE
+factor	I-PRGE
+(	O
+NF	O
+)-	O
+κB	O
+signaling	B-PROC
+via	O
+p65	B-PRGE
+nuclear	B-PROC
+translocation	I-PROC
+,	O
+thereby	O
+upregulating	O
+interferon	B-PRGE
+(	O
+IFN	O
+)-	O
+β	O
+,	O
+IFN	B-PRGE
+-	I-PRGE
+stimulated	I-PRGE
+gene	I-PRGE
+15	I-PRGE
+,	O
+and	O
+MX1	B-PRGE
+expression	B-PROC
+during	O
+CH	O
+/	O
+HBTS	O
+/	O
+2017	O
+infection	B-DISO
+.	O
+
+We	O
+subsequently	O
+identified	O
+NF	O
+-	O
+κB	O
+-	O
+inhibitor	B-CHED
+α	O
+and	O
+suppressor	O
+of	O
+cytokine	B-PROC
+signaling	I-PROC
+1	O
+,	O
+negative	O
+regulators	O
+of	O
+the	O
+NF	O
+-	O
+κB	O
+pathway	B-PROC
+,	O
+as	O
+miR	B-PRGE
+-	I-PRGE
+221	I-PRGE
+-	I-PRGE
+5p	I-PRGE
+targets	I-PRGE
+.	O
+
+Thus	O
+,	O
+a	O
+precise	O
+and	O
+rapid	O
+diagnosis	O
+of	O
+PEDV	B-SPEC
+infection	B-DISO
+is	O
+important	O
+for	O
+the	O
+application	O
+of	O
+control	O
+measures	O
+to	O
+limit	O
+viral	O
+dissemination	O
+.	O
+
+Of	O
+678	O
+patients	O
+who	O
+underwent	O
+HSCT	O
+during	O
+the	O
+study	O
+period	O
+,	O
+112	O
+(	O
+17	O
+%)	O
+developed	O
+HCoV	O
+infection	B-DISO
+,	O
+making	O
+HCoV	O
+the	O
+fourth	O
+most	O
+common	O
+respiratory	B-DISO
+viral	I-DISO
+infection	I-DISO
+.	O
+
+Evaluating	O
+for	O
+LRTI	B-DISO
+risk	O
+factors	O
+found	O
+in	O
+this	O
+study	O
+may	O
+identify	O
+patients	O
+who	O
+require	O
+closer	O
+surveillance	O
+and	O
+aggressive	B-DISO
+supportive	O
+care	O
+when	O
+infected	O
+with	O
+HCoV	O
+.	O
+
+Three	O
+and	O
+half	O
+years	O
+after	O
+the	O
+first	O
+known	O
+human	B-SPEC
+infection	B-DISO
+was	O
+detected	O
+,	O
+cases	O
+continue	O
+to	O
+be	O
+reported	O
+every	O
+month	O
+,	O
+over	O
+85	O
+%	O
+of	O
+which	O
+have	O
+been	O
+from	O
+Saudi	O
+Arabia	O
+and	O
+other	O
+countries	O
+in	O
+the	O
+Arabian	O
+Peninsula	O
+.	O
+
+Chief	O
+among	O
+such	O
+threats	O
+are	O
+influenza	B-SPEC
+viruses	I-SPEC
+and	O
+other	O
+respiratory	O
+pathogens	O
+,	O
+such	O
+as	O
+Middle	O
+East	O
+Respiratory	O
+Syndrome	B-DISO
+coronavirus	B-SPEC
+(	O
+MERS	O
+-	O
+CoV	O
+),	O
+because	O
+of	O
+their	O
+risk	O
+of	O
+high	O
+transmissibility	O
+and	O
+acuity	O
+of	O
+illness	O
+.	O
+
+PEDV	B-SPEC
+presence	O
+in	O
+manure	O
+was	O
+investigated	O
+as	O
+well	O
+as	O
+the	O
+inactivation	B-DISO
+treatment	O
+of	O
+the	O
+virus	B-SPEC
+present	O
+in	O
+the	O
+liquid	O
+manure	O
+.	O
+
+Disease	O
+evolution	B-PROC
+was	O
+generally	O
+favorable	O
+under	O
+antiviral	B-CHED
+treatment	O
+.	O
+
+While	O
+the	O
+A	O
+/	O
+H3	O
+subtype	O
+was	O
+predominant	O
+throughout	O
+Europe	O
+that	O
+season	O
+,	O
+B	O
+/	O
+Victoria	B-SPEC
+appears	O
+to	O
+have	O
+circulated	O
+specifically	O
+in	O
+Romania	O
+and	O
+the	O
+Eastern	O
+European	O
+region	O
+,	O
+predominantly	O
+affecting	O
+preschoolers	O
+and	O
+school	O
+children	O
+.	O
+
+This	O
+causes	O
+increased	B-PROC
+vascular	I-PROC
+permeability	I-PROC
+and	O
+the	O
+development	B-PROC
+of	O
+interstitial	B-ANAT
+and	O
+alveolar	B-ANAT
+protein	B-CHED
+-	O
+rich	O
+edema	B-DISO
+,	O
+leading	O
+to	O
+acute	O
+hypoxemic	O
+respiratory	B-DISO
+failure	I-DISO
+.	O
+
+TITLE	O
+:	O
+Hypothesis	O
+:	O
+Fever	B-PROC
+control	O
+,	O
+a	O
+niche	O
+for	O
+alpha	O
+-	O
+2	O
+agonists	B-CHED
+in	O
+the	O
+setting	O
+of	O
+septic	B-DISO
+shock	I-DISO
+and	O
+severe	O
+acute	O
+respiratory	O
+distress	O
+syndrome	O
+?	O
+
+Transforming	B-PRGE
+Growth	I-PRGE
+Factor	I-PRGE
+-	I-PRGE
+β1	I-PRGE
+(	O
+TGF	O
+-	O
+β1	O
+)	O
+is	O
+involved	O
+in	O
+collagen	B-COMP
+production	O
+and	O
+lung	B-ANAT
+repair	B-PROC
+.	O
+
+ABSTRACT	O
+:	O
+Acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+(	O
+ARDS	B-DISO
+)	O
+is	O
+an	O
+acute	O
+inflammatory	O
+process	O
+that	O
+impairs	O
+the	O
+ability	O
+of	O
+the	O
+lungs	B-ANAT
+to	O
+oxygenate	O
+thereby	O
+resulting	O
+in	O
+respiratory	B-DISO
+failure	I-DISO
+.	O
+
+A	O
+large	O
+multicenter	O
+,	O
+prospective	O
+,	O
+randomized	O
+,	O
+placebo	O
+-	O
+controlled	O
+trial	O
+is	O
+ongoing	O
+to	O
+confirm	O
+benefit	O
+of	O
+NMBAs	O
+in	O
+early	O
+,	O
+severe	O
+ARDS	B-DISO
+when	O
+adjusting	O
+for	O
+limitations	O
+of	O
+the	O
+previous	O
+studies	O
+.	O
+
+TITLE	O
+:	O
+Healthcare	O
+workers	O
+'	O
+views	O
+on	O
+the	O
+use	O
+of	O
+continuous	O
+positive	O
+airway	B-ANAT
+pressure	O
+(	O
+CPAP	O
+)	O
+in	O
+neonates	O
+:	O
+a	O
+qualitative	O
+study	O
+in	O
+Andhra	O
+Pradesh	O
+,	O
+India	O
+.	O
+
+We	O
+aimed	O
+to	O
+explore	O
+the	O
+experiences	O
+of	O
+doctors	O
+and	O
+nurses	O
+using	O
+CPAP	O
+in	O
+neonatal	O
+units	O
+in	O
+India	O
+and	O
+their	O
+views	O
+on	O
+enablers	O
+and	O
+barriers	O
+to	O
+implementation	O
+of	O
+CPAP	B-PRGE
+.	O
+
+Common	O
+structural	O
+factors	O
+that	O
+limit	O
+the	O
+use	O
+of	O
+CPAP	O
+include	O
+shortages	O
+of	O
+staff	O
+,	O
+consumables	O
+and	O
+equipment	O
+,	O
+and	O
+problems	O
+with	O
+regard	O
+to	O
+the	O
+organisation	B-PROC
+of	O
+neonatal	O
+units	O
+in	O
+both	O
+district	O
+hospitals	O
+and	O
+medical	O
+colleges	O
+.	O
+
+CPAP	B-PRGE
+use	I-PRGE
+was	O
+mostly	O
+perceived	O
+as	O
+technically	O
+easier	O
+to	O
+provide	O
+than	O
+ventilation	O
+and	O
+allowed	O
+nurses	O
+to	O
+provide	O
+advanced	O
+neonatal	O
+care	O
+,	O
+independently	O
+of	O
+doctors	O
+.	O
+
+The	O
+use	O
+of	O
+mechanical	O
+ventilation	O
+(	O
+MV	O
+)	O
+for	O
+correction	O
+of	O
+gas	B-ENZY
+exchange	O
+can	O
+cause	O
+worsening	O
+of	O
+this	O
+inflammatory	B-DISO
+response	I-DISO
+,	O
+called	O
+""""	O
+ventilator	O
+-	O
+induced	O
+lung	B-ANAT
+injury	O
+""""	O
+(	O
+VILI	O
+).	O
+
+Herein	O
+,	O
+we	O
+reviewed	O
+the	O
+main	O
+aspects	O
+of	O
+spontaneous	O
+ventilation	O
+and	O
+also	O
+discussed	O
+potential	O
+methods	O
+to	O
+predict	O
+the	O
+failure	O
+of	O
+weaning	B-PROC
+in	O
+this	O
+patient	O
+category	O
+.	O
+
+The	O
+contents	O
+of	O
+γ	B-PRGE
+-	I-PRGE
+IFN	I-PRGE
+,	O
+IL	O
+-	O
+1β	O
+,	O
+and	O
+IL	B-FUNC
+-	I-FUNC
+6	I-FUNC
+in	O
+animals	B-SPEC
+immunized	O
+with	O
+GNP	B-PRGE
+-	I-PRGE
+antigen	I-PRGE
+conjugates	O
+were	O
+found	O
+to	O
+be	O
+higher	O
+than	O
+those	O
+in	O
+intact	O
+animals	B-SPEC
+or	O
+in	O
+animals	B-SPEC
+given	O
+the	O
+antigen	B-CHED
+alone	O
+.	O
+
+The	O
+degradative	O
+processes	O
+observed	O
+in	O
+the	O
+animals	B-SPEC
+immunized	O
+with	O
+TGEV	B-PRGE
+antigen	B-CHED
+alone	O
+are	O
+evidence	O
+of	O
+weak	O
+resistance	B-PROC
+to	O
+pathogen	O
+attack	O
+.	O
+
+These	O
+results	O
+can	O
+be	O
+used	O
+to	O
+develop	O
+vaccines	O
+against	O
+this	O
+infection	B-DISO
+by	O
+employing	O
+TGEV	B-PRGE
+antigen	B-CHED
+coupled	O
+to	O
+gold	B-CHED
+nanoparticles	B-CHED
+as	O
+a	O
+carrier	O
+.	O
+
+Although	O
+PEDV	B-SPEC
+induced	O
+cell	B-COMP
+apoptosis	B-PATH
+has	O
+been	O
+established	O
+in	O
+vitro	O
+and	O
+in	O
+vivo	O
+,	O
+the	O
+functional	O
+protein	B-CHED
+that	O
+contributes	O
+to	O
+this	O
+event	O
+remains	O
+unclear	O
+.	O
+
+RESULTS	O
+:	O
+PEDV	B-SPEC
+could	O
+infect	O
+various	O
+host	B-COMP
+cells	B-COMP
+including	O
+Vero	O
+,	O
+Vero	O
+-	O
+E6	O
+and	O
+Marc	B-PRGE
+-	I-PRGE
+145	I-PRGE
+and	O
+cause	O
+obvious	O
+cytopathic	B-DISO
+effects	I-DISO
+,	O
+including	O
+roundup	O
+,	O
+cell	B-PROC
+fusion	I-PROC
+,	O
+cell	B-COMP
+membrane	I-COMP
+vacuolation	O
+,	O
+syncytium	B-PROC
+formation	I-PROC
+and	O
+cause	O
+apparent	O
+apoptosis	B-PATH
+.	O
+
+In	O
+contrast	O
+,	O
+changes	O
+D510G	O
+and	O
+I529T	O
+increased	O
+resistance	B-PROC
+of	O
+S	O
+protein	B-CHED
+-	O
+driven	O
+entry	O
+to	O
+neutralization	O
+by	O
+monoclonal	O
+antibodies	B-COMP
+and	O
+sera	B-COMP
+from	O
+MERS	O
+patients	O
+.	O
+
+These	O
+findings	O
+indicate	O
+that	O
+MERS	O
+-	O
+CoV	O
+variants	O
+with	O
+reduced	O
+neutralization	O
+sensitivity	O
+were	O
+transmitted	B-DISO
+during	O
+the	O
+Korean	O
+outbreak	O
+and	O
+that	O
+the	O
+responsible	O
+mutations	O
+were	O
+compatible	O
+with	O
+robust	O
+infection	B-DISO
+of	O
+cells	B-COMP
+expressing	O
+high	O
+levels	O
+of	O
+DPP4	B-PRGE
+.	O
+
+TITLE	O
+:	O
+Clinical	O
+and	O
+Laboratory	O
+Features	O
+Associated	O
+with	O
+Acute	O
+Kidney	B-ANAT
+Injury	O
+in	O
+Severe	O
+Malaria	B-PATH
+.	O
+
+Chronic	O
+alveolar	B-DISO
+hypoventilation	I-DISO
+leading	O
+to	O
+concurrent	O
+hypoxia	B-DISO
+is	O
+the	O
+main	O
+cause	O
+of	O
+morbidity	O
+and	O
+mortality	O
+in	O
+these	O
+patients	O
+due	O
+to	O
+its	O
+complications	O
+.	O
+
+Clinically	O
+,	O
+ATD	O
+is	O
+characterized	O
+by	O
+a	O
+small	O
+,	O
+narrow	O
+chest	B-ANAT
+and	O
+variable	O
+limb	B-ANAT
+shortness	O
+.	O
+
+The	O
+aim	O
+of	O
+this	O
+study	O
+was	O
+to	O
+evaluate	O
+a	O
+feline	B-SPEC
+coronavirus	B-SPEC
+(	O
+FCoV	O
+)	O
+reverse	B-PRGE
+transcriptase	I-PRGE
+quantitative	O
+PCR	B-PRGE
+(	O
+RT	O
+-	O
+qPCR	O
+)	O
+on	O
+fine	O
+-	O
+needle	O
+aspirates	B-ANAT
+(	O
+FNAs	O
+)	O
+from	O
+mesenteric	B-ANAT
+lymph	I-ANAT
+nodes	I-ANAT
+(	O
+MLNs	B-DISO
+)	O
+collected	O
+in	O
+sterile	B-DISO
+saline	O
+for	O
+the	O
+purpose	O
+of	O
+diagnosing	O
+non	O
+-	O
+effusive	B-DISO
+feline	I-DISO
+infectious	I-DISO
+peritonitis	I-DISO
+(	O
+FIP	B-DISO
+)	O
+in	O
+cats	B-SPEC
+.	O
+
+During	O
+the	O
+follow	O
+-	O
+up	O
+period	O
+(	O
+4572	O
+.	O
+7	O
+person	O
+-	O
+years	O
+),	O
+277	O
+children	O
+were	O
+readmitted	O
+with	O
+ARI	B-CHED
+.	O
+
+HAdV	O
+(	O
+4	O
+.	O
+6	O
+;	O
+1	O
+.	O
+8	O
+-	O
+11	O
+.	O
+9	O
+),	O
+hMPV	B-SPEC
+(	O
+20	O
+.	O
+4	O
+;	O
+6	O
+.	O
+2	O
+-	O
+66	O
+.	O
+9	O
+)	O
+and	O
+HRV	O
+(	O
+1	O
+.	O
+6	O
+;	O
+1	O
+.	O
+0	O
+-	O
+2	O
+.	O
+4	O
+)	O
+were	O
+independently	O
+associated	O
+with	O
+the	O
+outcome	O
+.	O
+
+HAdV	O
+-,	O
+hMPV	B-SPEC
+-	O
+and	O
+HRV	O
+-	O
+related	O
+initial	O
+ARI	B-CHED
+admissions	O
+,	O
+when	O
+occurring	O
+during	O
+early	O
+infancy	O
+,	O
+increased	O
+the	O
+risk	O
+of	O
+subsequent	O
+ARI	B-CHED
+-	O
+related	O
+readmission	O
+.	O
+
+TITLE	O
+:	O
+Elevated	O
+IL	B-FUNC
+-	I-FUNC
+33	I-FUNC
+promotes	O
+expression	B-PROC
+of	O
+MMP2	B-PRGE
+and	O
+MMP9	B-PRGE
+via	O
+activating	O
+STAT3	B-PRGE
+in	O
+alveolar	B-ANAT
+macrophages	I-ANAT
+during	O
+LPS	B-DISO
+-	O
+induced	O
+acute	O
+lung	B-ANAT
+injury	O
+.	O
+
+Since	O
+2012	O
+,	O
+the	O
+World	O
+Health	O
+Organization	O
+has	O
+been	O
+informed	O
+of	O
+2220	O
+laboratory	O
+-	O
+confirmed	O
+cases	O
+resulting	O
+in	O
+at	O
+least	O
+790	O
+deaths	B-PROC
+.	O
+
+Cases	O
+have	O
+since	O
+arisen	O
+in	O
+27	O
+countries	O
+,	O
+including	O
+an	O
+outbreak	O
+in	O
+the	O
+Republic	O
+of	O
+Korea	O
+in	O
+2015	O
+in	O
+which	O
+36	O
+people	O
+died	B-PROC
+,	O
+but	O
+more	O
+than	O
+80	O
+%	O
+of	O
+cases	O
+have	O
+occurred	O
+in	O
+Saudi	O
+Arabia	O
+..	O
+
+Human	B-SPEC
+-	O
+to	O
+-	O
+human	B-SPEC
+transmission	O
+of	O
+MERS	O
+-	O
+CoV	O
+,	O
+particularly	O
+in	O
+healthcare	O
+settings	O
+,	O
+initially	O
+caused	O
+a	O
+'	B-ANAT
+media	I-ANAT
+panic	O
+',	O
+however	O
+human	B-SPEC
+-	O
+to	O
+-	O
+human	B-SPEC
+transmission	O
+appears	O
+to	O
+require	O
+close	O
+contact	O
+and	O
+thus	O
+far	O
+the	O
+virus	O
+has	O
+not	O
+achieved	O
+epidemic	O
+potential	O
+.	O
+
+The	O
+cellular	B-COMP
+proteases	O
+furin	B-PRGE
+,	O
+cathepsin	B-PRGE
+L	I-PRGE
+and	O
+TMPRSS2	B-PRGE
+can	O
+activate	O
+MERS	O
+-	O
+S	O
+and	O
+may	O
+cleave	O
+the	O
+S	B-PRGE
+protein	I-PRGE
+at	O
+two	O
+distinct	O
+sites	O
+,	O
+termed	O
+S1	O
+/	O
+S2	O
+and	O
+S2	O
+'.	O
+
+Collectively	O
+,	O
+our	O
+results	O
+indicate	O
+a	O
+rigid	B-DISO
+sequence	O
+requirement	O
+for	O
+S	B-PRGE
+protein	I-PRGE
+activation	O
+by	O
+TMPRSS2	O
+but	O
+not	O
+cathepsin	B-PRGE
+L	I-PRGE
+.	O
+
+These	O
+viral	O
+agents	O
+are	O
+leading	O
+causes	O
+of	O
+acute	B-DISO
+respiratory	I-DISO
+infections	I-DISO
+every	O
+year	O
+affecting	O
+mainly	O
+children	O
+under	O
+5	O
+years	O
+old	O
+and	O
+also	O
+the	O
+elderly	O
+.	O
+
+ABSTRACT	O
+:	O
+Although	O
+acute	O
+respiratory	O
+distress	O
+syndrome	O
+(	O
+ARDS	B-DISO
+)	O
+has	O
+been	O
+recognized	O
+for	O
+more	O
+than	O
+50	O
+years	O
+,	O
+limited	O
+information	O
+exists	O
+about	O
+the	O
+incidence	O
+and	O
+management	O
+of	O
+ARDS	B-DISO
+in	O
+mainland	O
+China	O
+.	O
+
+There	O
+is	O
+no	O
+specific	O
+treatment	O
+that	O
+effectively	O
+improves	O
+outcome	O
+in	O
+ARDS	B-DISO
+.	O
+
+In	O
+this	O
+paper	O
+,	O
+we	O
+report	O
+the	O
+case	O
+of	O
+a	O
+young	O
+non	O
+-	O
+immunocompromised	O
+refugee	O
+from	O
+Somalia	O
+diagnosed	O
+with	O
+open	O
+pulmonary	B-DISO
+tuberculosis	B-PATH
+complicated	O
+by	O
+extensive	O
+osseous	B-ANAT
+involvement	O
+and	O
+a	O
+broncho	B-DISO
+-	I-DISO
+esophageal	I-DISO
+fistula	I-DISO
+with	O
+consecutive	O
+aspiration	B-DISO
+of	O
+gastric	B-ANAT
+contents	I-ANAT
+.	O
+
+However	O
+,	O
+data	O
+on	O
+the	O
+use	O
+of	O
+inhaled	B-PROC
+agents	O
+for	O
+continuous	O
+sedation	B-DISO
+in	O
+the	O
+ICU	O
+to	O
+treat	O
+or	O
+prevent	O
+lung	B-ANAT
+damage	O
+is	O
+lacking	O
+.	O
+
+The	O
+curves	O
+representing	O
+the	O
+concentrations	O
+of	O
+both	O
+sevoflurane	B-CHED
+and	O
+isoflurane	B-CHED
+dissolved	O
+in	O
+the	O
+medium	O
+showed	O
+similar	O
+courses	O
+over	O
+time	O
+,	O
+with	O
+a	O
+plateau	O
+reached	O
+at	O
+one	O
+hour	O
+after	O
+exposure	O
+.	O
+
+HCoV	O
+was	O
+present	O
+in	O
+9	O
+.	O
+1	O
+%	O
+(	O
+313	O
+/	O
+3458	O
+)	O
+of	O
+all	O
+RTI	B-DISO
+episodes	O
+:	O
+46	O
+.	O
+6	O
+%	O
+OC43	O
+,	O
+32	O
+.	O
+3	O
+%	O
+NL63	O
+,	O
+16	O
+.	O
+0	O
+%	O
+HKU1	O
+,	O
+and	O
+5	O
+.	O
+8	O
+%	O
+229E	O
+.	O
+
+Despite	O
+the	O
+appropriate	O
+antimicrobial	B-CHED
+therapy	O
+,	O
+his	O
+symptoms	O
+worsened	O
+and	O
+therefore	O
+we	O
+changed	O
+his	O
+oxygen	B-CHED
+therapy	O
+from	O
+a	O
+reservoir	O
+mask	O
+to	O
+nasal	B-ANAT
+high	O
+-	O
+flow	O
+oxygen	B-CHED
+in	O
+addition	O
+to	O
+minocycline	O
+.	O
+
+TITLE	O
+:	O
+A	O
+rapid	O
+scoping	O
+review	O
+of	O
+Middle	O
+East	O
+respiratory	O
+syndrome	B-DISO
+coronavirus	B-SPEC
+in	O
+animal	B-SPEC
+hosts	B-COMP
+.	O
+
+The	O
+incidences	O
+of	O
+respiratory	B-DISO
+viral	I-DISO
+infection	I-DISO
+in	O
+infants	O
+were	O
+1816	O
+per	O
+1000	O
+person	O
+-	O
+years	O
+for	O
+primary	O
+infections	B-DISO
+and	O
+1204	O
+per	O
+1000	O
+person	O
+-	O
+years	O
+for	O
+repeated	O
+infection	B-DISO
+with	O
+the	O
+same	O
+virus	B-SPEC
+.	O
+
+Illness	O
+duration	O
+and	O
+severity	O
+were	O
+not	O
+significantly	O
+different	O
+in	O
+the	O
+infants	O
+between	O
+the	O
+first	O
+and	O
+second	O
+episodes	O
+for	O
+any	O
+respiratory	O
+virus	B-SPEC
+tested	O
+.	O
+
+Here	O
+we	O
+report	O
+the	O
+presence	O
+of	O
+common	O
+respiratory	O
+viral	O
+pathogens	O
+in	O
+returning	O
+Hajj	O
+and	O
+Umrah	O
+pilgrims	O
+suffering	B-DISO
+from	O
+acute	O
+respiratory	O
+illness	O
+(	O
+ARI	B-CHED
+)	O
+in	O
+2014	O
+-	O
+2015	O
+.	O
+
+He	O
+also	O
+had	O
+upper	B-DISO
+respiratory	I-DISO
+tract	I-DISO
+infection	I-DISO
+a	O
+few	O
+days	O
+before	O
+the	O
+event	O
+.	O
+
+An	O
+echocardiogram	O
+revealed	O
+severe	O
+left	B-ANAT
+ventricle	I-ANAT
+(	O
+LV	B-ANAT
+)	O
+systolic	B-DISO
+dysfunction	I-DISO
+with	O
+dilation	B-DISO
+of	O
+the	O
+LV	B-ANAT
+.	O
+
+ABSTRACT	O
+:	O
+Bats	O
+may	O
+be	O
+natural	O
+reservoirs	O
+for	O
+a	O
+large	O
+variety	O
+of	O
+emerging	O
+viruses	B-SPEC
+,	O
+including	O
+mammalian	B-SPEC
+coronaviruses	O
+(	O
+CoV	O
+).	O
+
+Coronavirus	B-SPEC
+RNA	O
+was	O
+detected	O
+in	O
+faecal	B-ANAT
+samples	O
+from	O
+three	O
+different	O
+species	B-SPEC
+:	O
+the	O
+greater	B-SPEC
+horseshoe	I-SPEC
+bat	I-SPEC
+(	O
+Rhinolophus	B-SPEC
+ferrumequinum	I-SPEC
+),	O
+the	O
+brown	O
+long	O
+-	O
+eared	O
+bat	O
+(	O
+Plecotus	B-SPEC
+auritus	I-SPEC
+),	O
+and	O
+the	O
+European	B-SPEC
+free	I-SPEC
+-	I-SPEC
+tailed	I-SPEC
+bat	B-ENZY
+(	O
+Tadarida	B-SPEC
+teniotis	I-SPEC
+).	O
+
+Phylogenetic	O
+analyses	O
+based	O
+on	O
+RNA	B-PRGE
+-	I-PRGE
+dependent	I-PRGE
+RNA	I-PRGE
+polymerase	I-PRGE
+(	O
+RdRp	B-FUNC
+)	O
+sequences	O
+assigned	O
+the	O
+detected	O
+CoV	O
+to	O
+clade	O
+2b	O
+within	O
+betacoronaviruses	O
+,	O
+clustering	O
+with	O
+SARS	B-DISO
+-	O
+like	O
+bat	B-ENZY
+CoVs	O
+previously	O
+reported	O
+.	O
+
+TITLE	O
+:	O
+Effectiveness	O
+of	O
+ECMO	O
+for	O
+burn	O
+-	O
+related	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+.	O
+
+Extracorporeal	O
+membrane	B-COMP
+oxygenation	B-PROC
+(	O
+ECMO	O
+)	O
+therapy	O
+is	O
+a	O
+management	O
+option	O
+for	O
+severe	O
+refractory	O
+hypoxemic	O
+respiratory	B-DISO
+failure	I-DISO
+;	O
+however	O
+,	O
+there	O
+is	O
+little	O
+literature	O
+reporting	O
+the	O
+effectiveness	O
+of	O
+this	O
+therapy	O
+in	O
+burns	O
+.	O
+
+We	O
+retrospectively	O
+reviewed	O
+all	O
+patients	O
+treated	O
+with	O
+ECMO	O
+for	O
+ARDS	B-DISO
+who	O
+received	O
+their	O
+burn	O
+care	O
+at	O
+a	O
+single	O
+regional	O
+burn	O
+center	O
+between	O
+9	O
+/	O
+1	O
+/	O
+2006	O
+and	O
+8	O
+/	O
+31	O
+/	O
+2016	O
+.	O
+
+The	O
+current	O
+therapeutic	O
+regime	O
+is	O
+comprised	O
+of	O
+supportive	O
+measures	O
+such	O
+as	O
+lung	B-ANAT
+protective	O
+ventilation	O
+,	O
+restrictive	O
+fluid	O
+management	O
+,	O
+paralyzing	O
+drugs	O
+,	O
+and	O
+prone	O
+positioning	O
+.	O
+
+The	O
+differences	O
+of	O
+demographic	O
+indexes	O
+(	O
+gender	O
+,	O
+age	O
+),	O
+time	O
+of	O
+admission	O
+,	O
+type	O
+of	O
+injury	O
+,	O
+atrial	B-DISO
+fibrillation	I-DISO
+,	O
+trachea	B-DISO
+cannula	B-SPEC
+,	O
+multiple	O
+injury	O
+,	O
+open	O
+injury	O
+,	O
+shock	O
+,	O
+surgery	O
+,	O
+blood	B-ANAT
+transfusion	O
+,	O
+central	O
+venous	B-ANAT
+indwelling	O
+catheter	O
+,	O
+infection	B-DISO
+,	O
+and	O
+blood	B-ANAT
+routine	O
+indexes	O
+[	O
+white	B-ANAT
+blood	I-ANAT
+cell	I-ANAT
+count	O
+(	O
+WBC	B-ANAT
+),	O
+red	B-ANAT
+blood	I-ANAT
+cell	I-ANAT
+count	O
+(	O
+RBC	B-ANAT
+),	O
+platelet	B-ANAT
+count	O
+(	O
+PLT	O
+),	O
+plateletcytocrit	O
+(	O
+PCT	B-DISO
+),	O
+hematocrit	O
+(	O
+Hct	O
+)],	O
+biochemical	O
+indexes	O
+[	O
+total	O
+bilirubin	B-CHED
+(	O
+TBil	O
+),	O
+albumin	B-PRGE
+(	O
+Alb	B-PRGE
+),	O
+serum	B-COMP
+creatinine	B-CHED
+(	O
+SCr	O
+),	O
+blood	B-ANAT
+sodium	O
+,	O
+blood	O
+calcium	B-CHED
+,	O
+blood	B-ANAT
+potassium	B-CHED
+,	O
+blood	B-ANAT
+glucose	B-CHED
+],	O
+arterial	B-ANAT
+blood	I-ANAT
+gas	O
+analysis	O
+indexes	O
+[	O
+partial	O
+pressure	O
+of	O
+carbon	B-CHED
+dioxide	I-CHED
+(	O
+PaCO	O
+A	O
+total	O
+of	O
+303	O
+patients	O
+with	O
+severe	O
+trauma	O
+,	O
+including	O
+223	O
+males	O
+and	O
+80	O
+females	O
+,	O
+were	O
+enrolled	O
+.	O
+
+The	O
+data	O
+of	O
+3	O
+176	O
+critically	B-DISO
+ill	I-DISO
+patients	O
+aged	O
+≥	O
+14	O
+years	O
+old	O
+admitted	O
+to	O
+the	O
+emergency	B-DISO
+room	O
+of	O
+Xuanwu	O
+Hospital	O
+Capital	O
+Medical	O
+University	O
+from	O
+January	O
+1st	O
+to	O
+December	O
+31st	O
+in	O
+2017	O
+were	O
+analyzed	O
+,	O
+including	O
+gender	O
+,	O
+age	O
+,	O
+clinical	O
+time	O
+,	O
+discharge	B-ANAT
+diagnosis	O
+,	O
+outcomes	O
+,	O
+etc	O
+.	O
+
+To	O
+analyze	O
+the	O
+epidemiological	O
+characteristics	O
+and	O
+disease	O
+spectrum	O
+distribution	O
+of	O
+emergency	B-DISO
+critically	B-DISO
+ill	I-DISO
+patients	O
+,	O
+annual	O
+and	O
+daily	O
+24	O
+-	O
+hour	O
+emergency	B-DISO
+visits	O
+in	O
+2017	O
+were	O
+analyzed	O
+.	O
+
+Approximately	O
+10	O
+%	O
+of	O
+critically	B-DISO
+ill	I-DISO
+patients	O
+with	O
+MERS	O
+were	O
+HCWs	O
+.	O
+
+To	O
+conduct	B-PROC
+highly	O
+accurate	O
+and	O
+effective	O
+infection	B-DISO
+screening	O
+,	O
+we	O
+are	O
+working	O
+on	O
+the	O
+development	B-PROC
+of	O
+a	O
+contactless	O
+infection	B-DISO
+screening	O
+system	O
+using	O
+Doppler	O
+radar	O
+and	O
+thermography	O
+.	O
+
+In	O
+conclusion	O
+,	O
+this	O
+study	O
+reveals	O
+that	O
+neboviruses	O
+circulate	O
+widely	O
+in	O
+dairy	O
+cows	B-SPEC
+in	O
+China	O
+and	O
+exhibit	O
+a	O
+unique	O
+evolution	B-PROC
+of	O
+RdRp	B-FUNC
+.	O
+
+Overall	O
+,	O
+it	O
+may	O
+be	O
+inferred	O
+that	O
+CpG	O
+ODNs	O
+,	O
+when	O
+delivered	O
+in	O
+ovo	B-SPEC
+,	O
+provide	O
+protection	O
+against	O
+IBV	B-SPEC
+infection	B-DISO
+induced	I-DISO
+morbidity	O
+and	O
+mortality	O
+with	O
+an	O
+enhanced	O
+immune	B-PROC
+response	I-PROC
+.	O
+
+In	O
+this	O
+study	O
+,	O
+three	O
+strains	O
+of	O
+Alpha	B-PRGE
+-	I-PRGE
+CoV	I-PRGE
+genera	I-PRGE
+detected	O
+in	O
+Italian	O
+bats	B-SPEC
+(	O
+Pipistrellus	B-SPEC
+kuhlii	I-SPEC
+)	O
+were	O
+fully	O
+sequenced	O
+by	O
+Next	O
+Generation	O
+Sequencing	O
+(	O
+NGS	O
+)	O
+and	O
+characterized	O
+.	O
+
+The	O
+complete	O
+genome	O
+analysis	O
+showed	O
+the	O
+correlation	O
+of	O
+the	O
+Italians	O
+strains	O
+with	O
+a	O
+Chinese	O
+strain	O
+detected	O
+in	O
+2013	O
+and	O
+,	O
+based	O
+on	O
+CoV	O
+molecular	O
+species	B-SPEC
+demarcation	O
+,	O
+two	O
+new	O
+Alpha	B-PRGE
+-	I-PRGE
+CoV	I-PRGE
+species	B-SPEC
+were	O
+established	O
+.	O
+
+RESULTS	O
+:	O
+Among	O
+the	O
+543	O
+patients	O
+who	O
+underwent	O
+pneumonectomy	O
+in	O
+the	O
+period	O
+of	O
+study	O
+,	O
+89	O
+(	O
+16	O
+.	O
+4	O
+%)	O
+needed	O
+reintubation	O
+within	O
+the	O
+30th	O
+postoperative	O
+day	O
+and	O
+60	O
+of	O
+these	O
+(	O
+11	O
+%	O
+of	O
+all	O
+pneumonectomies	O
+)	O
+developed	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+.	O
+
+Safety	O
+has	O
+not	O
+been	O
+established	O
+for	O
+administration	O
+of	O
+MSCs	B-FUNC
+in	O
+critically	B-DISO
+ill	I-DISO
+patients	O
+with	O
+ARDS	B-DISO
+.	O
+
+However	O
+,	O
+NMBAs	O
+have	O
+no	O
+effect	O
+on	O
+reduction	O
+of	O
+oxygenation	B-PROC
+at	O
+24	O
+hours	O
+(	O
+WMD	O
+,	O
+26	O
+.	O
+83	O
+;	O
+95	O
+%	O
+CI	O
+,	O
+-	O
+5	O
+.	O
+89	O
+to	O
+59	O
+.	O
+55	O
+;	O
+p	O
+=	O
+0	O
+.	O
+108	O
+;	O
+I	O
+=	O
+82	O
+.	O
+4	O
+%;	O
+4	O
+trials	O
+,	O
+447	O
+patients	O
+),	O
+and	O
+plateau	O
+pressure	O
+(	O
+WMD	O
+,	O
+0	O
+.	O
+43	O
+;	O
+95	O
+%	O
+CI	O
+,	O
+-	O
+0	O
+.	O
+46	O
+to	O
+1	O
+.	O
+31	O
+;	O
+p	O
+=	O
+0	O
+.	O
+345	O
+;	O
+4	O
+trials	O
+,	O
+455	O
+patients	O
+)	O
+as	O
+well	O
+as	O
+positive	O
+end	O
+expiratory	B-PROC
+pressure	O
+(	O
+WMD	O
+,	O
+0	O
+.	O
+10	O
+;	O
+95	O
+%	O
+CI	O
+,	O
+-	O
+0	O
+.	O
+47	O
+to	O
+0	O
+.	O
+67	O
+;	O
+p	O
+=	O
+0	O
+.	O
+73	O
+;	O
+4	O
+trials	O
+,	O
+455	O
+patients	O
+)	O
+at	O
+48	O
+hours	O
+.	O
+
+Furthermore	O
+,	O
+we	O
+determined	O
+the	O
+complete	O
+genomic	O
+sequence	O
+of	O
+BP	O
+-	O
+caKII	O
+to	O
+understand	O
+the	O
+genetic	O
+changes	O
+related	O
+to	O
+cold	B-DISO
+adaptation	B-PROC
+.	O
+
+According	O
+to	O
+our	O
+results	O
+,	O
+BP	O
+-	O
+caKII	O
+clustered	O
+with	O
+the	O
+KII	O
+genotype	O
+viruses	B-SPEC
+K2	O
+and	O
+KM91	O
+,	O
+and	O
+showed	O
+less	O
+pathogenicity	O
+than	O
+K2	O
+,	O
+a	O
+live	O
+attenuated	O
+vaccine	O
+strain	O
+.	O
+
+TITLE	O
+:	O
+Initiation	O
+of	O
+LPS	B-DISO
+-	O
+induced	O
+pulmonary	B-ANAT
+dysfunction	O
+and	O
+its	O
+recovery	O
+occur	O
+independent	O
+of	O
+T	B-ANAT
+cells	B-COMP
+.	O
+
+Patients	O
+with	O
+immunodeficiency	B-DISO
+(	O
+e	O
+.	O
+g	O
+.	O
+SCID	B-DISO
+with	O
+T	O
+and	O
+B	B-ANAT
+cell	I-ANAT
+deficiency	O
+)	O
+are	O
+particularly	O
+susceptible	O
+to	O
+the	O
+development	B-PROC
+of	O
+severe	O
+ARDS	B-DISO
+.	O
+
+TITLE	O
+:	O
+Characteristics	O
+,	O
+management	O
+,	O
+and	O
+in	O
+-	O
+hospital	O
+mortality	O
+among	O
+patients	O
+with	O
+severe	B-DISO
+sepsis	I-DISO
+in	O
+intensive	O
+care	O
+units	O
+in	O
+Japan	O
+:	O
+the	O
+FORECAST	O
+study	O
+.	O
+
+ABSTRACT	O
+:	O
+Sepsis	O
+is	O
+a	O
+leading	O
+cause	O
+of	O
+death	B-PROC
+and	O
+long	O
+-	O
+term	O
+disability	O
+in	O
+developed	O
+countries	O
+.	O
+
+We	O
+included	O
+adult	O
+patients	O
+with	O
+severe	B-DISO
+sepsis	I-DISO
+based	O
+on	O
+the	O
+sepsis	B-DISO
+-	O
+2	O
+criteria	O
+.	O
+
+The	O
+compliance	O
+rates	O
+for	O
+the	O
+entire	O
+3	O
+-	O
+h	O
+bundle	O
+,	O
+measurement	O
+of	O
+central	O
+venous	B-PROC
+pressure	I-PROC
+,	O
+and	O
+assessment	O
+of	O
+central	O
+venous	B-PROC
+oxygen	B-CHED
+saturation	I-PROC
+were	O
+64	O
+%,	O
+26	O
+%,	O
+and	O
+7	O
+%,	O
+respectively	O
+.	O
+
+Our	O
+prospective	O
+study	O
+showed	O
+that	O
+sepsis	B-DISO
+management	O
+in	O
+Japan	O
+was	O
+characterized	O
+by	O
+a	O
+high	O
+compliance	O
+rate	O
+for	O
+the	O
+3	O
+-	O
+h	O
+bundle	O
+and	O
+low	O
+compliance	O
+rate	O
+for	O
+central	O
+venous	B-ANAT
+catheter	O
+measurements	O
+.	O
+
+The	O
+etiological	O
+agent	O
+of	O
+the	O
+Ebola	B-DISO
+Virus	I-DISO
+Disease	I-DISO
+(	O
+EVD	O
+),	O
+EBOV	O
+can	O
+be	O
+undoubtedly	O
+considered	O
+the	O
+perfect	O
+example	O
+of	O
+a	O
+powerful	O
+inhibitor	B-CHED
+of	O
+the	O
+host	B-COMP
+organism	I-COMP
+immune	B-PROC
+response	I-PROC
+activation	O
+.	O
+
+TITLE	O
+:	O
+Circulation	B-PROC
+and	O
+genetic	O
+diversity	O
+of	O
+Feline	B-SPEC
+coronavirus	B-SPEC
+type	O
+I	O
+and	O
+II	O
+from	O
+clinically	O
+healthy	O
+and	O
+FIP	O
+-	O
+suspected	O
+cats	B-SPEC
+in	O
+China	O
+.	O
+
+TITLE	O
+:	O
+A	O
+high	O
+-	O
+throughput	O
+inhibition	B-PROC
+assay	O
+to	O
+study	O
+MERS	O
+-	O
+CoV	O
+antibody	B-PROC
+interactions	I-PROC
+using	O
+image	O
+cytometry	O
+.	O
+
+In	O
+this	O
+study	O
+,	O
+we	O
+investigated	O
+the	O
+lncRNA	O
+expression	B-PROC
+profiles	O
+during	O
+PEDV	B-SPEC
+infection	B-DISO
+in	O
+intestinal	B-ANAT
+porcine	B-SPEC
+epithelial	B-ANAT
+cell	I-ANAT
+-	O
+jejunum	B-ANAT
+2	O
+(	O
+IPEC	O
+-	O
+J2	O
+)	O
+cell	B-ANAT
+lines	I-ANAT
+by	O
+next	O
+-	O
+generation	O
+sequencing	O
+and	O
+identified	O
+6188	O
+novel	O
+lncRNAs	O
+.	O
+
+In	O
+this	O
+study	O
+,	O
+all	O
+antisera	O
+failed	O
+to	O
+neutralize	O
+all	O
+IBV	B-SPEC
+strains	O
+.	O
+
+ABSTRACT	O
+:	O
+As	O
+key	O
+regulators	O
+of	O
+cell	O
+signaling	O
+,	O
+protein	B-PRGE
+kinases	I-PRGE
+(	O
+PKs	B-COMP
+)	O
+are	O
+attractive	O
+targets	O
+for	O
+therapeutic	O
+intervention	O
+in	O
+a	O
+variety	O
+of	O
+diseases	O
+.	O
+
+ABSTRACT	O
+:	O
+TW	O
+-	O
+like	O
+IBV	B-SPEC
+isolates	O
+have	O
+appeared	O
+frequently	O
+in	O
+recent	O
+years	O
+in	O
+mainland	O
+China	O
+.	O
+
+Both	O
+strains	O
+could	O
+cause	O
+severe	O
+respiratory	B-DISO
+distress	I-DISO
+and	O
+renal	B-ANAT
+lesions	O
+,	O
+with	O
+a	O
+mortality	O
+rate	O
+were	O
+approximately	O
+20	O
+%.	O
+
+In	O
+this	O
+prospective	O
+observational	O
+study	O
+,	O
+hemodynamic	B-PROC
+assessment	O
+by	O
+trans	O
+-	O
+esophageal	O
+Doppler	O
+(	O
+TED	O
+)	O
+was	O
+done	O
+with	O
+the	O
+primary	O
+aim	O
+of	O
+measuring	O
+early	O
+changes	O
+in	O
+cardiac	B-ANAT
+index	O
+(	O
+CI	O
+),	O
+if	O
+any	O
+,	O
+after	O
+prone	O
+positioning	O
+in	O
+moderate	O
+to	O
+severe	O
+ARDS	B-DISO
+patients	O
+.	O
+
+ABSTRACT	O
+:	O
+This	O
+42	O
+-	O
+day	O
+study	O
+evaluated	O
+the	O
+effects	O
+of	O
+dietary	O
+supplementation	O
+with	O
+β	O
+-	O
+1	O
+,	O
+3	O
+-	O
+glucan	O
+(	O
+Aleta	O
+™)	O
+on	O
+the	O
+vaccination	O
+response	O
+to	O
+Newcastle	B-SPEC
+disease	I-SPEC
+virus	I-SPEC
+(	O
+NDV	B-SPEC
+),	O
+avian	B-DISO
+infectious	I-DISO
+bronchitis	I-DISO
+virus	B-SPEC
+(	O
+IBV	B-SPEC
+),	O
+and	O
+infectious	B-DISO
+bursal	I-DISO
+disease	I-DISO
+(	O
+IBD	B-DISO
+)	O
+in	O
+a	O
+non	O
+-	O
+challenged	O
+environment	O
+.	O
+
+Surprisingly	O
+,	O
+there	O
+was	O
+significant	O
+separation	B-DISO
+among	O
+treatment	O
+groups	O
+for	O
+NDV	B-SPEC
+titer	O
+levels	O
+,	O
+especially	O
+on	O
+day	O
+21	O
+,	O
+where	O
+birds	B-SPEC
+vaccinated	O
+and	O
+supplemented	O
+with	O
+Aleta	O
+had	O
+significantly	O
+higher	O
+titer	O
+levels	O
+compared	O
+to	O
+vaccination	O
+alone	O
+or	O
+no	O
+vaccination	O
+at	O
+all	O
+.	O
+
+Critically	O
+,	O
+only	O
+14	O
+%	O
+of	O
+the	O
+birds	B-SPEC
+receiving	O
+the	O
+vaccine	O
+plus	O
+Aleta	O
+had	O
+titer	O
+levels	O
+below	O
+the	O
+critical	O
+titer	O
+threshold	O
+for	O
+immunity	B-PROC
+compared	O
+to	O
+28	O
+%	O
+of	O
+the	O
+birds	B-SPEC
+receiving	O
+the	O
+vaccine	O
+alone	O
+and	O
+40	O
+%	O
+of	O
+the	O
+unvaccinated	O
+birds	B-SPEC
+.	O
+
+TITLE	O
+:	O
+[	O
+Reye	B-DISO
+syndrome	I-DISO
+and	O
+sudden	B-DISO
+death	I-DISO
+symptoms	O
+after	O
+oral	B-ANAT
+administration	O
+of	O
+nimesulide	B-CHED
+due	O
+to	O
+upper	B-ANAT
+respiratory	I-ANAT
+tract	I-ANAT
+infection	I-DISO
+in	O
+a	O
+boy	O
+].	O
+
+R114H	O
+),	O
+from	O
+his	O
+mother	O
+and	O
+a	O
+novel	B-DISO
+mutation	I-DISO
+,	O
+c	O
+.	O
+1484C	O
+>	O
+G	O
+(	O
+p	O
+.	O
+
+Reye	B-DISO
+syndrome	I-DISO
+and	O
+sudden	B-DISO
+death	I-DISO
+symptoms	O
+were	O
+caused	O
+by	O
+nimesulide	B-CHED
+-	O
+induced	O
+acute	O
+metabolic	B-PROC
+crisis	O
+.	O
+
+In	O
+multivariate	O
+analysis	O
+,	O
+adjusting	O
+for	O
+H1N1	O
+status	O
+,	O
+patients	O
+without	O
+empirical	O
+systemic	O
+anticoagulation	B-PROC
+were	O
+33	O
+times	O
+more	O
+likely	O
+to	O
+have	O
+any	O
+VTE	O
+compared	O
+with	O
+those	O
+treated	O
+with	O
+empirical	O
+systemic	O
+heparin	B-CHED
+anticoagulation	B-PROC
+(	O
+P	O
+=	O
+.	O
+01	O
+).	O
+
+The	O
+Metropole	O
+Hotel	O
+hastened	O
+the	O
+international	O
+spread	O
+of	O
+the	O
+2003	O
+SARS	B-DISO
+outbreak	O
+by	O
+the	O
+index	O
+case	O
+infecting	O
+visitors	O
+from	O
+Singapore	O
+,	O
+Vietnam	O
+,	O
+Canada	O
+as	O
+well	O
+as	O
+local	O
+people	O
+via	O
+close	O
+contact	O
+with	O
+the	O
+index	O
+case	O
+and	O
+the	O
+environmental	O
+contamination	O
+.	O
+
+The	O
+IRI	B-ANAT
+after	O
+lung	B-ANAT
+transplantation	O
+is	O
+primarily	O
+manifested	O
+by	O
+permeability	O
+pulmonary	B-DISO
+edema	I-DISO
+on	O
+the	O
+basis	O
+of	O
+pulmonary	B-ANAT
+vascular	B-ANAT
+endothelial	I-ANAT
+cell	I-ANAT
+injury	O
+as	O
+seen	O
+in	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+(	O
+ARDS	B-DISO
+).	O
+
+Admissions	O
+for	O
+trauma	O
+or	O
+pneumonia	B-DISO
+,	O
+higher	O
+nonpulmonary	O
+sequential	O
+organ	B-DISO
+failure	I-DISO
+assessment	O
+score	O
+,	O
+lower	O
+partial	O
+pressure	O
+of	O
+alveolar	B-ANAT
+oxygen	B-CHED
+/	O
+fraction	O
+of	O
+inspired	B-PROC
+oxygen	B-CHED
+,	O
+and	O
+higher	O
+peak	O
+inspiratory	B-PROC
+pressure	O
+were	O
+independently	O
+associated	O
+with	O
+worsening	O
+.	O
+
+ABSTRACT	O
+:	O
+Middle	O
+East	O
+respiratory	O
+syndrome	O
+coronavirus	B-SPEC
+(	O
+MERS	O
+-	O
+CoV	O
+)	O
+caused	O
+multiple	O
+outbreaks	O
+.	O
+
+TITLE	O
+:	O
+Bioaerosol	O
+Sampling	O
+for	O
+Respiratory	O
+Viruses	B-SPEC
+in	O
+Singapore	O
+'	O
+s	O
+Mass	O
+Rapid	O
+Transit	O
+Network	O
+.	O
+
+This	O
+risk	O
+has	O
+been	O
+recently	O
+reinforced	O
+by	O
+human	O
+epidemics	O
+in	O
+Singapore	O
+of	O
+SARS	B-DISO
+coronavirus	B-SPEC
+,	O
+2009	O
+pandemic	O
+H1N1	B-DISO
+influenza	I-DISO
+A	O
+virus	O
+,	O
+and	O
+enterovirus	B-SPEC
+71	O
+.	O
+
+Our	O
+pilot	O
+study	O
+data	O
+support	O
+the	O
+possibility	O
+of	O
+employing	O
+bioaerosol	O
+samplers	O
+in	O
+crowded	O
+public	O
+spaces	O
+to	O
+noninvasively	O
+monitor	O
+for	O
+respiratory	O
+viruses	B-SPEC
+circulating	O
+in	O
+communities	O
+.	O
+
+On	O
+the	O
+outer	O
+surface	O
+,	O
+virus	O
+has	O
+spike	O
+like	O
+glycoprotein	B-CHED
+which	O
+is	O
+responsible	O
+for	O
+the	O
+attachment	O
+and	O
+entrance	O
+inside	O
+host	B-COMP
+cells	B-COMP
+.	O
+
+Viruses	B-SPEC
+coinfected	O
+frequently	O
+with	O
+influenza	B-SPEC
+virus	I-SPEC
+in	O
+children	O
+were	O
+rhinovirus	B-SPEC
+(	O
+26	O
+;	O
+14	O
+.	O
+8	O
+%),	O
+respiratory	B-SPEC
+syncytial	I-SPEC
+virus	I-SPEC
+A	O
+/	O
+B	O
+(	O
+19	O
+;	O
+10	O
+.	O
+8	O
+%),	O
+adenovirus	B-DISO
+(	O
+14	O
+;	O
+8	O
+.	O
+0	O
+%),	O
+coronavirus	B-SPEC
+(	O
+CoV	B-SPEC
+)-	O
+HKU1	O
+(	O
+14	O
+;	O
+8	O
+.	O
+0	O
+%),	O
+CoV	B-SPEC
+-	O
+OC43	O
+(	O
+5	O
+;	O
+2	O
+.	O
+9	O
+%),	O
+CoV	B-SPEC
+-	O
+229E	O
+(	O
+2	O
+;	O
+1	O
+.	O
+1	O
+%),	O
+metapneumovirus	B-SPEC
+A	O
+/	O
+B	O
+(	O
+5	O
+;	O
+2	O
+.	O
+9	O
+%),	O
+bocavirus	B-SPEC
+(	O
+6	O
+;	O
+3	O
+.	O
+4	O
+%),	O
+enterovirus	B-SPEC
+(	O
+5	O
+;	O
+2	O
+.	O
+9	O
+%),	O
+parainfluenza	B-DISO
+virus	B-SPEC
+-	O
+1	O
+(	O
+3	O
+;	O
+1	O
+.	O
+7	O
+%),	O
+and	O
+parainfluenza	B-DISO
+virus	B-SPEC
+-	O
+3	O
+(	O
+2	O
+;	O
+1	O
+.	O
+1	O
+%).	O
+
+We	O
+present	O
+skew	O
+value	O
+trees	O
+for	O
+the	O
+four	O
+virus	O
+families	O
+and	O
+show	O
+that	O
+closely	O
+related	O
+viruses	B-SPEC
+are	O
+placed	O
+in	O
+small	O
+clusters	B-CHED
+.	O
+
+TITLE	O
+:	O
+ABSTRACT	O
+:	O
+Bronchiolitis	B-DISO
+epidemiology	O
+.	O
+
+Other	O
+viruses	B-SPEC
+are	O
+also	O
+identified	O
+(	O
+métapneumovirus	O
+,	O
+rhino	O
+/	O
+enterovirus	B-SPEC
+,	O
+coronavirus	B-SPEC
+,	O
+influenza	B-DISO
+,	O
+parainfluenza	B-DISO
+,	O
+adenovirus	B-DISO
+…).	O
+
+In	O
+this	O
+article	O
+,	O
+we	O
+review	O
+current	O
+advances	O
+in	O
+neutralizing	O
+mAbs	O
+against	O
+MERS	O
+-	O
+CoV	O
+.	O
+The	O
+receptor	O
+-	O
+binding	B-FUNC
+domain	O
+(	O
+RBD	O
+)	O
+in	O
+the	O
+spike	O
+protein	B-CHED
+of	O
+MERS	O
+-	O
+CoV	O
+is	O
+a	O
+major	O
+target	O
+,	O
+and	O
+mouse	B-SPEC
+,	O
+camel	B-SPEC
+,	O
+or	O
+human	B-SPEC
+-	O
+derived	O
+neutralizing	O
+mAbs	O
+targeting	B-PROC
+RBD	O
+have	O
+been	O
+developed	O
+.	O
+
+ABSTRACT	O
+:	O
+Respiratory	O
+viral	O
+infections	O
+are	O
+strongly	O
+associated	O
+with	O
+asthma	B-PATH
+exacerbations	O
+.	O
+
+TITLE	O
+:	O
+Underweight	O
+,	O
+overweight	B-DISO
+,	O
+and	O
+obesity	B-DISO
+as	O
+independent	O
+risk	O
+factors	O
+for	O
+hospitalization	O
+in	O
+adults	O
+and	O
+children	O
+from	O
+influenza	O
+and	O
+other	O
+respiratory	O
+viruses	B-SPEC
+.	O
+
+Adults	O
+with	O
+influenza	B-DISO
+were	O
+more	O
+likely	O
+to	O
+be	O
+hospitalized	O
+if	O
+they	O
+were	O
+underweight	O
+(	O
+OR	O
+:	O
+5	O
+.	O
+20	O
+),	O
+obese	B-DISO
+(	O
+OR	O
+:	O
+3	O
+.	O
+18	O
+),	O
+or	O
+morbidly	O
+obese	B-DISO
+(	O
+OR	O
+:	O
+18	O
+.	O
+40	O
+)	O
+compared	O
+to	O
+normal	O
+-	O
+weight	O
+adults	O
+.	O
+
+Beyond	O
+the	O
+rescue	O
+of	O
+patients	O
+dying	B-PROC
+of	O
+refractory	O
+hypoxemia	O
+,	O
+ECMO	O
+may	O
+now	O
+be	O
+used	O
+early	O
+in	O
+severe	O
+ARDS	O
+patients	O
+to	O
+reduce	O
+the	O
+intensity	O
+of	O
+mechanical	O
+ventilation	O
+and	O
+to	O
+minimize	O
+ventilator	O
+-	O
+induced	O
+lung	B-ANAT
+injury	O
+.	O
+
+Therefore	O
+,	O
+a	O
+more	O
+detailed	O
+study	O
+was	O
+undertaken	O
+in	O
+SPF	O
+layer	B-ANAT
+-	O
+type	O
+chickens	B-SPEC
+primed	O
+with	O
+IBV	B-SPEC
+Mass	O
+and	O
+793B	O
+vaccines	O
+.	O
+
+In	O
+dogs	B-SPEC
+,	O
+information	O
+on	O
+the	O
+clinical	O
+presentation	O
+of	O
+PVOD	B-DISO
+is	O
+scarce	O
+and	O
+the	O
+cause	O
+and	O
+pathogenesis	B-DISO
+of	O
+this	O
+disease	O
+is	O
+still	O
+unknown	O
+.	O
+
+In	O
+the	O
+present	O
+case	O
+,	O
+no	O
+casual	O
+genetic	B-PROC
+mutations	I-PROC
+known	O
+to	O
+be	O
+involved	O
+in	O
+humans	B-SPEC
+with	O
+PVOD	B-DISO
+and	O
+PAH	B-DISO
+were	O
+found	O
+.	O
+
+CONCLUSIONS	O
+:	O
+Precise	O
+administration	O
+of	O
+low	O
+-	O
+dose	O
+iCO	O
+is	O
+feasible	O
+,	O
+well	O
+-	O
+tolerated	O
+,	O
+and	O
+appears	O
+to	O
+be	O
+safe	O
+in	O
+patients	O
+with	O
+sepsis	B-DISO
+-	O
+induced	O
+ARDS	B-DISO
+.	O
+
+Obtained	O
+data	O
+confirm	O
+the	O
+role	O
+of	O
+DPP4	B-PRGE
+for	O
+MERS	O
+-	O
+CoV	O
+entry	O
+in	O
+respiratory	O
+epithelial	B-ANAT
+cells	I-ANAT
+of	O
+llamas	B-SPEC
+.	O
+
+TITLE	O
+:	O
+A	O
+Single	O
+-	O
+Step	O
+Gold	B-CHED
+Nanoparticle	I-CHED
+-	O
+Blood	B-COMP
+Serum	I-COMP
+Interaction	O
+Assay	O
+Reveals	O
+Humoral	B-PROC
+Immunity	I-PROC
+Development	B-PROC
+and	O
+Immune	B-PROC
+Status	I-PROC
+of	O
+Animals	B-SPEC
+from	O
+Neonates	O
+to	O
+Adults	O
+.	O
+
+Newborn	O
+animals	B-SPEC
+and	O
+humans	B-SPEC
+have	O
+only	O
+limited	O
+immunity	B-PROC
+upon	O
+birth	B-PROC
+,	O
+but	O
+their	O
+immune	O
+functions	O
+are	O
+expected	O
+to	O
+develop	O
+within	O
+weeks	O
+to	O
+months	O
+and	O
+eventually	O
+to	O
+reach	B-PROC
+a	O
+maturity	O
+that	O
+will	O
+provide	O
+full	O
+protection	O
+.	O
+
+The	O
+test	O
+detects	O
+a	O
+cooperative	O
+interaction	O
+between	O
+a	O
+gold	B-CHED
+nanoparticle	I-CHED
+and	O
+arguably	O
+the	O
+three	O
+most	O
+important	O
+proteins	O
+involved	O
+in	O
+the	O
+immune	B-ANAT
+system	I-ANAT
+:	O
+immunoglobulin	B-PRGE
+M	I-PRGE
+(	O
+IgM	B-PRGE
+),	O
+immunoglobulin	B-PRGE
+G	I-PRGE
+(	O
+IgG	B-PRGE
+),	O
+and	O
+at	O
+least	O
+one	B-PRGE
+complement	I-PRGE
+protein	I-PRGE
+,	O
+C3	O
+,	O
+in	O
+the	O
+blood	B-COMP
+serum	I-COMP
+.	O
+
+TITLE	O
+:	O
+Comparative	O
+features	O
+of	O
+infections	B-DISO
+of	O
+two	O
+Massachusetts	O
+(	O
+Mass	O
+)	O
+infectious	B-DISO
+bronchitis	B-DISO
+virus	B-SPEC
+(	O
+IBV	B-SPEC
+)	O
+variants	O
+isolated	O
+from	O
+Western	O
+Canadian	O
+layer	B-ANAT
+flocks	O
+.	O
+
+Although	O
+variant	O
+IBV	B-SPEC
+isolates	O
+with	O
+major	O
+genetic	O
+differences	O
+have	O
+been	O
+subjected	O
+to	O
+comparative	O
+studies	O
+,	O
+it	O
+is	O
+unknown	O
+whether	O
+minor	O
+genetic	O
+differences	O
+in	O
+IBV	B-SPEC
+variants	O
+within	O
+a	O
+serotype	O
+are	O
+different	O
+in	O
+terms	O
+of	O
+pathogenesis	B-DISO
+and	O
+eliciting	O
+host	B-COMP
+responses	O
+.	O
+
+However	O
+,	O
+upon	O
+experimental	O
+infection	B-DISO
+,	O
+we	O
+found	O
+that	O
+the	O
+IBV	B-SPEC
+isolate	O
+originating	O
+from	O
+AB	O
+was	O
+different	O
+to	O
+the	O
+one	O
+that	O
+originated	O
+in	O
+SK	O
+due	O
+to	O
+higher	O
+tracheal	O
+lesion	O
+scores	O
+and	O
+lower	O
+lung	B-ANAT
+viral	B-PROC
+replication	I-PROC
+and	O
+lower	O
+genome	O
+loads	O
+in	O
+cecal	B-ANAT
+tonsils	B-ANAT
+.	O
+
+TITLE	O
+:	O
+Risk	O
+factors	O
+and	O
+the	O
+associated	O
+limit	O
+values	O
+for	O
+abnormal	O
+elevation	O
+of	O
+extravascular	O
+lung	B-ANAT
+water	B-CHED
+in	O
+severely	O
+burned	O
+adults	O
+.	O
+
+This	O
+prospective	O
+,	O
+single	O
+-	O
+center	O
+study	O
+included	O
+only	O
+adults	O
+with	O
+burn	O
+sizes	O
+≥	O
+50	O
+%	O
+of	O
+the	O
+total	B-ANAT
+body	I-ANAT
+surface	I-ANAT
+area	O
+(	O
+TBSA	O
+)	O
+who	O
+were	O
+admitted	O
+within	O
+24h	O
+after	O
+burn	O
+.	O
+
+They	O
+received	O
+significantly	O
+lower	O
+cumulative	O
+doses	O
+of	O
+opioids	O
+(	O
+median	O
+,	O
+mg	O
+/	O
+kg	O
+,	O
+14	O
+.	O
+2	O
+vs	O
+16	O
+.	O
+2	O
+;	O
+P	O
+<	O
+.	O
+001	O
+)	O
+and	O
+benzodiazepines	B-CHED
+(	O
+10	O
+.	O
+6	O
+vs	O
+14	O
+.	O
+4	O
+;	O
+P	O
+<	O
+.	O
+001	O
+).	O
+
+In	O
+addition	O
+,	O
+LPS	B-DISO
+-	O
+induced	O
+oxidative	B-DISO
+stress	I-DISO
+was	O
+accelerated	O
+by	O
+TRIM8	B-PRGE
+over	O
+-	O
+expression	B-PROC
+,	O
+while	O
+being	O
+alleviated	O
+by	O
+TRIM8	B-PRGE
+knockdown	O
+by	O
+regulating	O
+Nrf2	B-PRGE
+signaling	B-PROC
+.	O
+
+Furthermore	O
+,	O
+TRIM8	B-PRGE
+knockdown	O
+evidently	O
+improved	O
+nuclear	B-PRGE
+factor	O
+-	O
+erythroid	B-PRGE
+2	I-PRGE
+related	I-PRGE
+factor	I-PRGE
+2	I-PRGE
+(	O
+Nrf2	B-PRGE
+)	O
+and	O
+heme	B-PRGE
+oxygenase	B-PROC
+-	I-PRGE
+1	I-PRGE
+(	O
+HO	B-PRGE
+-	I-PRGE
+1	I-PRGE
+)	O
+expressions	O
+in	O
+lung	B-ANAT
+of	O
+LPS	B-DISO
+-	O
+treated	O
+mice	B-SPEC
+.	O
+
+The	O
+anti	O
+-	O
+inflammation	B-DISO
+and	O
+anti	O
+-	O
+oxidant	B-CHED
+role	O
+of	O
+TRIM8	B-PRGE
+-	O
+silence	B-DISO
+might	O
+be	O
+associated	O
+with	O
+AMPKα	O
+phosphorylation	B-PROC
+.	O
+
+Further	O
+analysis	O
+verified	O
+the	O
+existence	O
+of	O
+eight	O
+selected	O
+circRNAs	O
+and	O
+confirmed	O
+that	O
+PEDV	B-SPEC
+infection	B-DISO
+alerted	O
+the	O
+expression	B-PROC
+patterns	O
+of	O
+circRNAs	O
+and	O
+their	O
+linear	O
+parent	O
+genes	O
+in	O
+IPEC	O
+-	O
+J2	O
+cell	B-ANAT
+line	I-ANAT
+.	O
+
+The	O
+infant	O
+'	O
+s	O
+initial	O
+course	O
+was	O
+significant	O
+for	O
+respiratory	B-DISO
+distress	I-DISO
+syndrome	I-DISO
+,	O
+grade	O
+III	O
+-	O
+IV	O
+intraventricular	B-DISO
+hemorrhage	I-DISO
+(	O
+IVH	O
+),	O
+acute	O
+kidney	B-ANAT
+injury	O
+,	O
+and	O
+large	O
+PDA	B-DISO
+.	O
+
+CDI	B-DISO
+is	O
+an	O
+uncommon	O
+cause	O
+of	O
+hypernatremia	B-DISO
+in	O
+the	O
+neonatal	O
+period	O
+.	O
+
+CDI	B-DISO
+in	O
+our	O
+patient	O
+was	O
+thought	O
+to	O
+be	O
+due	O
+to	O
+grade	O
+III	O
+-	O
+IV	O
+IVH	O
+complicated	O
+by	O
+post	O
+-	O
+hemorrhagic	O
+hydrocephalus	B-DISO
+.	O
+
+Serum	B-COMP
+ADH	B-FUNC
+levels	O
+can	O
+be	O
+helpful	O
+in	O
+confirming	O
+the	O
+central	O
+origin	O
+of	O
+DI	O
+and	O
+subcutaneous	O
+desmopressin	B-CHED
+can	O
+be	O
+an	O
+effective	O
+treatment	O
+in	O
+the	O
+preterm	O
+infant	O
+.	O
+
+TITLE	O
+:	O
+Replication	O
+of	O
+MERS	O
+and	O
+SARS	B-DISO
+coronaviruses	O
+in	O
+bat	B-ENZY
+cells	B-COMP
+offers	O
+insights	O
+to	O
+their	O
+ancestral	O
+origins	O
+.	O
+
+Bat	B-ENZY
+dipeptidyl	B-PRGE
+peptidase	I-PRGE
+4	I-PRGE
+(	O
+DPP4	B-PRGE
+)	O
+sequences	O
+were	O
+closely	O
+related	O
+to	O
+those	O
+of	O
+human	B-SPEC
+and	O
+non	O
+-	O
+human	B-SPEC
+primates	B-SPEC
+but	O
+distinct	O
+from	O
+dromedary	B-PRGE
+DPP4	I-PRGE
+sequence	I-PRGE
+.	O
+
+Critical	O
+residues	O
+for	O
+binding	B-FUNC
+to	O
+MERS	B-PRGE
+-	I-PRGE
+CoV	I-PRGE
+spike	I-PRGE
+protein	I-PRGE
+were	O
+mostly	O
+conserved	O
+in	O
+bat	B-ENZY
+DPP4	B-PRGE
+.	O
+
+DPP4	B-PRGE
+was	O
+expressed	B-PROC
+in	O
+the	O
+five	O
+bat	B-ENZY
+cells	B-COMP
+susceptible	O
+to	O
+MERS	O
+-	O
+CoV	O
+,	O
+with	O
+significantly	O
+higher	O
+mRNA	B-PROC
+expression	B-PROC
+levels	O
+than	O
+those	O
+in	O
+non	O
+-	O
+susceptible	O
+cells	B-COMP
+(	O
+P	O
+=	O
+0	O
+.	O
+0174	O
+),	O
+supporting	O
+that	O
+DPP4	B-PRGE
+expression	B-PROC
+is	O
+critical	O
+for	O
+MERS	O
+-	O
+CoV	O
+infection	B-DISO
+in	O
+bats	B-SPEC
+.	O
+
+PLDs	B-PRGE
+were	O
+installed	O
+with	O
+25	O
+-	O
+400	O
+TAT	B-ENZY
+peptides	B-CHED
+per	O
+liposome	O
+without	O
+an	O
+effect	O
+on	O
+PLD	O
+stability	O
+.	O
+
+A	O
+protein	B-CHED
+corona	B-CHED
+(	O
+PC	O
+)	O
+on	O
+TAT	B-ENZY
+peptide	B-CHED
+-	O
+modified	O
+PLDs	O
+shields	O
+the	O
+active	O
+moieties	O
+and	O
+effectively	O
+reduces	O
+clearance	O
+of	O
+the	O
+TAT	B-ENZY
+peptide	B-CHED
+containing	O
+nanoparticles	B-CHED
+.	O
+
+A	O
+sensitive	O
+RT	O
+-	O
+PCR	O
+method	O
+is	O
+urgently	O
+required	O
+to	O
+detect	O
+PDCoV	O
+infection	B-DISO
+.	O
+
+The	O
+ventilator	O
+communicates	O
+with	O
+the	O
+concentrator	O
+to	O
+increase	O
+or	O
+decrease	O
+oxygen	B-CHED
+bolus	O
+size	O
+to	O
+maintain	O
+a	O
+target	O
+SpO2	O
+of	O
+94	O
+%.	O
+
+Experiments	O
+1	O
+and	O
+2	O
+used	O
+oxygen	B-CHED
+bolus	O
+sizes	O
+16	O
+-	O
+96	O
+mL	O
+in	O
+16	O
+-	O
+mL	O
+increments	O
+and	O
+experiment	O
+3	O
+used	O
+1	O
+mL	O
+increments	O
+.	O
+
+PEEP	B-CHED
+range	O
+was	O
+5	O
+-	O
+14	O
+cm	O
+H2O	B-CHED
+.	O
+
+TITLE	O
+:	O
+Driving	O
+pressure	O
+and	O
+long	O
+-	O
+term	O
+outcomes	O
+in	O
+moderate	O
+/	O
+severe	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+.	O
+
+ABSTRACT	O
+:	O
+Acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+(	O
+ARDS	B-DISO
+)	O
+patients	O
+may	O
+present	O
+impaired	B-DISO
+in	O
+lung	B-PROC
+function	I-PROC
+and	O
+structure	O
+after	O
+hospital	O
+discharge	B-ANAT
+that	O
+may	O
+be	O
+related	O
+to	O
+mechanical	O
+ventilation	O
+strategy	O
+.	O
+
+At	O
+6	O
+months	O
+driving	O
+pressure	O
+was	O
+associated	O
+with	O
+lower	O
+FVC	B-PROC
+independently	O
+on	O
+tidal	O
+volume	O
+,	O
+plateau	O
+pressure	O
+and	O
+baseline	O
+static	O
+respiratory	O
+compliance	O
+after	O
+adjustments	O
+(	O
+r	O
+CONCLUSIONS	O
+:	O
+Even	O
+in	O
+patients	O
+ventilated	O
+with	O
+protective	O
+tidal	O
+volume	O
+,	O
+higher	O
+driving	O
+pressure	O
+is	O
+associated	O
+with	O
+worse	O
+long	O
+-	O
+term	O
+pulmonary	B-PROC
+function	I-PROC
+and	O
+structure	O
+.	O
+
+TITLE	O
+:	O
+Point	O
+-	O
+of	O
+-	O
+care	O
+lung	B-ANAT
+ultrasound	O
+for	O
+the	O
+detection	O
+of	O
+pulmonary	B-ANAT
+manifestations	O
+of	O
+malaria	B-PATH
+and	O
+sepsis	B-SPEC
+:	O
+An	O
+observational	O
+study	O
+.	O
+
+Serial	O
+point	O
+-	O
+of	O
+-	O
+care	O
+lung	B-ANAT
+ultrasound	O
+studies	O
+were	O
+performed	O
+on	O
+four	O
+consecutive	O
+days	O
+in	O
+a	O
+planned	O
+sub	O
+study	O
+of	O
+an	O
+observational	O
+cohort	O
+of	O
+patients	O
+with	O
+malaria	B-PATH
+or	O
+sepsis	B-DISO
+in	O
+Bangladesh	O
+.	O
+
+Of	O
+102	O
+patients	O
+enrolled	O
+,	O
+71	O
+had	O
+sepsis	B-DISO
+and	O
+31	O
+had	O
+malaria	B-PATH
+.	O
+
+ABSTRACT	O
+:	O
+The	O
+avian	B-DISO
+infectious	I-DISO
+bronchitis	I-DISO
+virus	B-SPEC
+(	O
+IBV	B-SPEC
+)	O
+remains	O
+a	O
+significant	O
+source	O
+of	O
+loss	O
+in	O
+the	O
+poultry	O
+industry	O
+and	O
+early	O
+diagnosis	O
+is	O
+required	O
+to	O
+prevent	O
+the	O
+disease	O
+from	O
+spreading	O
+.	O
+
+Constructed	O
+recombinant	O
+pAE	O
+/	O
+n	O
+expression	B-PROC
+vectors	O
+were	O
+used	O
+to	O
+transform	O
+E	B-SPEC
+.	I-SPEC
+coli	I-SPEC
+BL21	B-ANAT
+(	O
+DE3	O
+)	O
+Star	B-DISO
+competent	O
+cells	B-COMP
+(	O
+Invitrogen	O
+).	O
+
+The	O
+expected	O
+cDNA	O
+fragment	O
+of	O
+approximately	O
+1240	O
+bp	O
+was	O
+successfully	O
+amplified	O
+by	O
+PCR	O
+using	O
+primers	O
+designed	O
+to	O
+select	O
+for	O
+the	O
+coding	O
+region	O
+of	O
+the	O
+N	B-PRGE
+protein	I-PRGE
+.	O
+
+The	O
+SDS	B-DISO
+-	O
+PAGE	O
+results	O
+demonstrated	O
+the	O
+presence	O
+of	O
+two	O
+distinct	O
+bands	O
+that	O
+had	O
+a	O
+molecular	O
+mass	O
+of	O
+approximately	O
+45	O
+and	O
+50	O
+KDa	O
+.	O
+
+Out	O
+of	O
+145	O
+sera	B-COMP
+that	O
+scored	O
+negative	O
+in	O
+the	O
+IDEXX	O
+IBV	B-SPEC
+Ab	O
+Test	O
+,	O
+131	O
+also	O
+scored	O
+negative	O
+in	O
+the	O
+ELISA	O
+-	O
+rN	O
+,	O
+indicating	O
+a	O
+specificity	O
+of	O
+90	O
+.	O
+34	O
+%.	O
+
+ABSTRACT	O
+:	O
+Single	O
+photon	B-CHED
+emission	B-ANAT
+computed	O
+tomography	O
+(	O
+SPECT	O
+)	O
+is	O
+frequently	O
+used	O
+in	O
+oncology	O
+and	O
+cardiology	O
+to	O
+evaluate	O
+disease	B-DISO
+progression	I-DISO
+and	O
+/	O
+or	O
+treatment	O
+efficacy	O
+.	O
+
+Such	O
+technology	O
+allows	O
+for	O
+real	O
+-	O
+time	O
+evaluation	O
+of	O
+disease	B-DISO
+progression	I-DISO
+and	O
+when	O
+applied	O
+to	O
+studying	O
+infectious	B-DISO
+diseases	I-DISO
+may	O
+provide	O
+insight	O
+into	O
+pathogenesis	B-DISO
+.	O
+
+Viral	O
+entry	O
+is	O
+affected	O
+by	O
+the	O
+disruption	O
+of	O
+actin	B-PRGE
+kinetics	O
+or	O
+alteration	O
+of	O
+cofilin	B-PRGE
+activity	O
+.	O
+
+In	O
+conclusion	O
+,	O
+we	O
+demonstrate	O
+that	O
+PHEV	O
+utilizes	O
+the	O
+integrin	B-PRGE
+α5β1	I-PRGE
+-	I-PRGE
+FAK	I-PRGE
+-	I-PRGE
+Rac1	I-PRGE
+/	O
+Cdc42	B-PRGE
+-	O
+PAK	B-PRGE
+-	O
+LIMK	B-PRGE
+-	O
+cofilin	B-PRGE
+pathway	B-PROC
+to	O
+cause	O
+an	O
+actin	B-PRGE
+cytoskeletal	B-COMP
+rearrangement	B-PROC
+to	O
+promote	O
+its	O
+own	O
+invasion	B-DISO
+,	O
+providing	O
+theoretical	O
+support	O
+for	O
+the	O
+development	B-PROC
+of	O
+PHEV	O
+pathogenic	O
+mechanisms	O
+and	O
+new	O
+antiviral	B-CHED
+targets	O
+.	O
+
+TITLE	O
+:	O
+Porcine	B-SPEC
+Intestinal	B-ANAT
+Enteroids	O
+:	O
+a	O
+New	O
+Model	O
+for	O
+Studying	O
+Enteric	B-SPEC
+Coronavirus	I-SPEC
+Porcine	B-SPEC
+Epidemic	B-DISO
+Diarrhea	I-DISO
+Virus	B-DISO
+Infection	I-DISO
+and	O
+the	O
+Host	B-COMP
+Innate	O
+Response	O
+.	O
+
+Hemodynamic	B-PROC
+stability	O
+was	O
+rapidly	O
+achieved	O
+and	O
+the	O
+improvement	O
+in	O
+contractility	O
+imaged	O
+in	O
+real	O
+time	O
+by	O
+transesophageal	O
+echocardiography	O
+.	O
+
+Ignoring	O
+these	O
+acute	O
+-	O
+level	O
+infections	B-DISO
+may	O
+lead	O
+to	O
+complications	O
+.	O
+
+Particularly	O
+in	O
+Pakistan	O
+,	O
+respiratory	B-DISO
+infections	I-DISO
+account	O
+for	O
+20	O
+%	O
+to	O
+30	O
+%	O
+of	O
+all	O
+deaths	B-PROC
+of	O
+children	O
+.	O
+
+Even	O
+though	O
+these	O
+infections	B-DISO
+are	O
+common	O
+,	O
+insufficiency	O
+of	O
+accessible	O
+data	O
+hinders	O
+development	B-PROC
+of	O
+a	O
+comprehensive	O
+summary	O
+of	O
+the	O
+problem	O
+.	O
+
+A	O
+high	O
+incidence	O
+of	O
+adenovirus	B-DISO
+infection	I-DISO
+in	O
+organized	O
+communities	O
+and	O
+RSV	B-DISO
+infection	I-DISO
+in	O
+children	O
+was	O
+revealed	O
+.	O
+
+This	O
+novel	B-SPEC
+coronavirus	I-SPEC
+has	O
+been	O
+named	O
+Middle	O
+East	O
+respiratory	O
+syndrome	B-DISO
+coronavirus	B-SPEC
+(	O
+MERS	O
+-	O
+CoV	O
+).	O
+
+TITLE	O
+:	O
+Avian	B-SPEC
+influenza	I-DISO
+.	O
+
+In	O
+2013	O
+,	O
+China	O
+WHO	O
+reported	O
+new	O
+avian	B-SPEC
+influenza	I-SPEC
+virus	I-SPEC
+H7N9	O
+infected	O
+to	O
+human	B-SPEC
+.	O
+
+A	O
+patholog	O
+-	O
+ical	O
+study	O
+of	O
+post	O
+-	O
+mortem	O
+biopsied	O
+lung	B-ANAT
+tissues	I-ANAT
+revealed	O
+that	O
+H5N1	B-DISO
+infected	O
+alveolar	B-ANAT
+epithe	O
+-	O
+lial	O
+cells	B-COMP
+and	O
+caused	O
+primary	O
+viral	B-DISO
+pneumonia	I-DISO
+,	O
+which	O
+subsequently	O
+developed	O
+into	O
+ARDS	B-DISO
+.	O
+
+Undifferentiated	O
+fever	B-PROC
+challenges	O
+physicians	O
+to	O
+correctly	O
+diagnose	O
+and	O
+includes	O
+ma	O
+-	O
+laria	O
+,	O
+dengue	B-DISO
+,	O
+and	O
+enteric	B-DISO
+fever	I-DISO
+.	O
+
+METHODS	O
+:	O
+The	O
+MEDLINE	O
+/	O
+PubMed	O
+and	O
+Scopus	B-SPEC
+databases	O
+were	O
+searched	O
+for	O
+relevant	O
+papers	O
+published	O
+till	O
+August	O
+2018	O
+describing	O
+asymptomatic	O
+MERS	O
+-	O
+CoV	O
+infection	B-DISO
+.	O
+
+Moreover	O
+,	O
+coronary	B-ANAT
+angiography	O
+revealed	O
+no	O
+noticeable	O
+stenotic	O
+or	O
+obstructive	O
+lesions	O
+.	O
+
+In	O
+this	O
+study	O
+,	O
+the	O
+highly	O
+conserved	O
+MERS	B-PRGE
+-	I-PRGE
+CoV	I-PRGE
+nucleocapsid	I-PRGE
+(	I-PRGE
+N	I-PRGE
+)	I-PRGE
+protein	B-CHED
+served	O
+as	O
+a	O
+target	O
+immunogen	B-CHED
+to	O
+elicit	O
+MERS	O
+-	O
+CoV	O
+-	O
+specific	O
+cellular	B-PROC
+immune	I-PROC
+responses	I-PROC
+.	O
+
+The	O
+identification	O
+of	O
+this	O
+epitope	B-CHED
+,	O
+and	O
+the	O
+availability	O
+of	O
+the	O
+MVA	B-CHED
+-	O
+MERS	O
+-	O
+N	O
+candidate	O
+vaccine	O
+,	O
+will	O
+help	O
+to	O
+evaluate	O
+MERS	O
+-	O
+N	O
+-	O
+specific	O
+immune	B-PROC
+responses	I-PROC
+and	O
+the	O
+potential	O
+immune	O
+correlates	O
+of	O
+vaccine	O
+-	O
+mediated	O
+protection	O
+in	O
+the	O
+appropriate	O
+murine	B-SPEC
+models	O
+of	O
+MERS	O
+-	O
+CoV	O
+infection	B-DISO
+.	O
+
+ABSTRACT	O
+:	O
+Transcatheter	O
+aortic	O
+valve	O
+replacement	O
+is	O
+indicated	O
+for	O
+severe	O
+symptomatic	B-DISO
+aortic	I-DISO
+stenosis	B-SPEC
+in	O
+patients	O
+who	O
+have	O
+a	O
+very	O
+high	O
+or	O
+prohibitive	O
+surgical	O
+risk	O
+as	O
+assessed	O
+pre	O
+-	O
+procedurally	O
+by	O
+the	O
+Society	O
+of	O
+Thoracic	B-DISO
+Surgery	O
+Risk	O
+Score	O
+,	O
+EuroSCORE	O
+(	O
+II	O
+),	O
+frailty	O
+testing	O
+,	O
+and	O
+other	O
+predictors	O
+.	O
+
+Patients	O
+with	O
+aortic	B-DISO
+stenosis	B-SPEC
+most	O
+often	O
+develop	O
+symmetric	O
+hypertrophy	B-DISO
+;	O
+however	O
+,	O
+a	O
+small	O
+subset	O
+has	O
+asymmetric	B-DISO
+septal	I-DISO
+hypertrophy	I-DISO
+leading	O
+to	O
+left	B-DISO
+ventricular	I-DISO
+outflow	I-DISO
+tract	I-DISO
+obstruction	I-DISO
+.	O
+
+Diagnosing	O
+a	O
+left	B-DISO
+ventricular	I-DISO
+outflow	I-DISO
+tract	I-DISO
+obstruction	I-DISO
+as	O
+the	O
+cause	O
+of	O
+hemodynamic	B-DISO
+instability	I-DISO
+during	O
+transcatheter	O
+aortic	B-ANAT
+valve	I-ANAT
+replacement	O
+,	O
+in	O
+the	O
+absence	O
+of	O
+abnormal	O
+findings	O
+on	O
+echocardiogram	O
+preoperatively	O
+,	O
+requires	O
+a	O
+high	O
+index	O
+of	O
+clinical	O
+suspicion	O
+.	O
+
+ABSTRACT	O
+:	O
+A	O
+non	O
+-	O
+prime	O
+site	O
+substituent	O
+and	O
+warheads	O
+combined	O
+with	O
+a	O
+decahydroisoquinolin	O
+scaffold	O
+was	O
+evaluated	O
+as	O
+a	O
+novel	O
+inhibitor	B-CHED
+for	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+(	O
+SARS	B-DISO
+)	O
+chymotrypsin	B-PRGE
+-	I-PRGE
+like	I-PRGE
+protease	I-PRGE
+(	O
+3CL	O
+
+A	O
+2	O
+-	O
+month	O
+-	O
+old	O
+preterm	O
+male	O
+was	O
+admitted	O
+for	O
+severe	O
+Bordetella	B-SPEC
+pertussis	I-SPEC
+infection	B-DISO
+.	O
+
+ABSTRACT	O
+:	O
+Middle	O
+East	O
+respiratory	O
+syndrome	B-DISO
+coronavirus	B-SPEC
+(	O
+MERS	O
+-	O
+CoV	O
+)	O
+with	O
+potential	O
+to	O
+cause	O
+global	O
+pandemics	O
+remains	O
+a	O
+threat	O
+to	O
+the	O
+public	O
+health	O
+,	O
+security	O
+,	O
+and	O
+economy	O
+.	O
+
+Moreover	O
+,	O
+MERS	O
+is	O
+known	O
+to	O
+spread	O
+mainly	O
+by	O
+droplets	O
+through	O
+close	O
+contact	O
+,	O
+but	O
+long	O
+-	O
+distance	O
+dispersion	O
+is	O
+probable	O
+in	O
+certain	O
+environments	O
+,	O
+such	O
+as	O
+that	O
+of	O
+a	O
+super	O
+-	O
+spreader	O
+patient	O
+hospitalized	O
+in	O
+a	O
+room	O
+without	O
+ventilation	O
+,	O
+hospitals	O
+with	O
+a	O
+central	O
+corridor	O
+type	O
+,	O
+and	O
+indoor	O
+airflow	B-PROC
+dispersion	O
+due	O
+to	O
+external	O
+wind	B-DISO
+.	O
+
+TITLE	O
+:	O
+Conservation	O
+implications	O
+of	O
+primate	B-SPEC
+trade	O
+in	O
+China	O
+over	O
+18	O
+years	O
+based	O
+on	O
+web	B-DISO
+news	O
+reports	O
+of	O
+confiscations	O
+.	O
+
+To	O
+assess	O
+a	O
+proxy	O
+for	O
+amount	O
+of	O
+national	O
+primate	B-SPEC
+trades	O
+,	O
+we	O
+quantified	O
+the	O
+number	O
+of	O
+reports	O
+of	O
+native	O
+primate	B-SPEC
+species	B-SPEC
+featuring	O
+in	O
+unique	O
+web	B-DISO
+news	O
+reports	O
+from	O
+2000	O
+to	O
+2017	O
+,	O
+including	O
+accuracy	O
+of	O
+their	O
+identification	O
+,	O
+location	O
+where	O
+they	O
+were	O
+confiscated	O
+or	O
+rescued	O
+,	O
+and	O
+their	O
+condition	B-DISO
+upon	O
+rescue	O
+.	O
+
+Infective	B-DISO
+endocarditis	I-DISO
+(	O
+IE	O
+)	O
+is	O
+a	O
+rare	O
+cause	O
+of	O
+septic	B-DISO
+shock	I-DISO
+but	O
+carries	O
+significant	O
+morbidity	O
+and	O
+mortality	O
+.	O
+
+TITLE	O
+:	O
+Estimating	O
+severity	O
+of	O
+influenza	B-DISO
+epidemics	O
+from	O
+severe	O
+acute	B-DISO
+respiratory	I-DISO
+infections	I-DISO
+(	O
+SARI	O
+)	O
+in	O
+intensive	O
+care	O
+units	O
+.	O
+
+This	O
+review	O
+will	O
+provide	O
+a	O
+comprehensive	O
+outline	O
+of	O
+the	O
+cytokine	O
+-	O
+mediated	O
+exacerbation	O
+of	O
+disease	O
+and	O
+tissue	B-ANAT
+damage	O
+in	O
+NHP	O
+models	O
+of	O
+viral	B-DISO
+infections	I-DISO
+and	O
+therapeutic	O
+strategies	O
+that	O
+can	O
+aid	O
+in	O
+prevention	O
+/	O
+treatment	O
+of	O
+the	O
+disease	O
+syndromes	B-DISO
+.	O
+
+A	O
+total	O
+of	O
+792	O
+camel	B-SPEC
+plasma	B-ANAT
+samples	O
+were	O
+positive	O
+by	O
+ELISA	O
+.	O
+
+Only	O
+11	O
+camel	B-SPEC
+nasal	B-ANAT
+swabs	O
+were	O
+positive	O
+for	O
+MERS	O
+-	O
+CoV	O
+by	O
+reverse	B-PROC
+transcription	I-PROC
+-	O
+quantitative	O
+PCR	O
+.	O
+
+Phylogenetic	O
+analysis	O
+of	O
+whole	O
+genome	O
+sequences	O
+showed	O
+that	O
+Kenyan	O
+MERS	O
+-	O
+CoV	O
+clustered	O
+within	O
+sub	O
+-	O
+clade	O
+C2	O
+,	O
+which	O
+is	O
+associated	O
+with	O
+the	O
+African	O
+clade	O
+,	O
+but	O
+did	O
+not	O
+contain	O
+signature	O
+deletions	O
+of	O
+orf4b	O
+in	O
+African	O
+viruses	B-SPEC
+.	O
+
+ABSTRACT	O
+:	O
+The	O
+genetic	O
+variability	O
+of	O
+Infectious	B-DISO
+bronchitis	B-DISO
+virus	B-SPEC
+(	O
+IBV	B-SPEC
+)	O
+is	O
+one	O
+of	O
+the	O
+main	O
+challenges	O
+for	O
+its	O
+control	O
+,	O
+hindering	O
+not	O
+only	O
+the	O
+development	B-PROC
+of	O
+effective	O
+vaccination	O
+strategies	O
+but	O
+also	O
+its	O
+classification	O
+and	O
+,	O
+consequently	O
+,	O
+epidemiology	O
+understanding	O
+.	O
+
+A	O
+collection	O
+of	O
+worldwide	O
+available	O
+hypervariable	O
+region	O
+1	O
+and	O
+2	O
+(	O
+HVR12	O
+)	O
+and	O
+3	O
+(	O
+HVR3	O
+)	O
+sequences	O
+of	O
+the	O
+S1	B-PRGE
+protein	I-PRGE
+was	O
+analysed	O
+together	O
+with	O
+258	O
+HVR3	O
+sequences	O
+obtained	O
+from	O
+samples	O
+collected	O
+in	O
+Italy	O
+(	O
+the	O
+country	O
+where	O
+this	O
+genotype	O
+was	O
+initially	O
+identified	O
+)	O
+since	O
+1963	O
+.	O
+
+Interestingly	O
+,	O
+although	O
+most	O
+of	O
+the	O
+recent	O
+Italian	O
+GI	O
+-	O
+16	O
+strains	O
+originated	O
+from	O
+ancestral	O
+viruses	B-SPEC
+detected	O
+in	O
+the	O
+same	O
+country	O
+,	O
+a	O
+couple	O
+were	O
+closely	O
+related	O
+to	O
+Chinese	O
+ones	O
+,	O
+supporting	O
+a	O
+backward	O
+viral	O
+flow	O
+from	O
+China	O
+to	O
+Italy	O
+.	O
+
+ABSTRACT	O
+:	O
+We	O
+describe	O
+the	O
+epidemiology	O
+,	O
+lung	O
+mechanics	O
+and	O
+outcomes	O
+of	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+(	O
+ARDS	B-DISO
+)	O
+complicating	B-DISO
+pregnancy	I-DISO
+.	O
+
+211	O
+women	O
+with	O
+ARDS	B-DISO
+were	O
+admitted	O
+,	O
+which	O
+included	O
+27	O
+(	O
+12	O
+.	O
+8	O
+%)	O
+pregnant	O
+subjects	O
+.	O
+
+The	O
+case	O
+1	O
+patient	O
+was	O
+found	O
+to	O
+have	O
+muscle	B-DISO
+weakness	I-DISO
+in	O
+all	O
+extremities	B-ANAT
+after	O
+withdrawing	O
+the	O
+mechanical	O
+ventilator	O
+,	O
+and	O
+the	O
+case	O
+2	O
+patient	O
+was	O
+found	O
+when	O
+withdrawing	O
+extracorporeal	O
+membrane	B-COMP
+oxygenation	B-PROC
+,	O
+both	O
+of	O
+these	O
+conditions	O
+prolonged	O
+ventilator	O
+-	O
+weaning	B-PROC
+time	O
+.	O
+
+This	O
+notion	O
+is	O
+supported	O
+by	O
+preclinical	O
+animal	B-SPEC
+models	O
+,	O
+genome	O
+-	O
+wide	O
+association	O
+studies	O
+(	O
+GWAS	O
+),	O
+as	O
+well	O
+as	O
+approved	O
+disease	O
+modifying	O
+therapies	O
+(	O
+DMTs	O
+)	O
+that	O
+suppress	O
+clinical	O
+relapse	B-DISO
+and	O
+are	O
+designed	O
+to	O
+impede	O
+infiltration	B-DISO
+of	O
+activated	O
+lymphocytes	B-ANAT
+into	O
+the	O
+CNS	B-CHED
+.	O
+
+In	O
+addition	O
+,	O
+the	O
+cross	O
+-	O
+species	B-SPEC
+transmission	O
+causes	O
+alterations	O
+to	O
+viral	O
+genetic	O
+makeup	O
+thereby	O
+increasing	O
+the	O
+risk	O
+of	O
+emergence	O
+of	O
+pathogens	O
+with	O
+new	O
+and	O
+more	O
+potent	O
+infectivity	O
+.	O
+
+Network	O
+centrality	O
+metrics	O
+were	O
+used	O
+to	O
+characterize	O
+hospital	O
+-	O
+acquired	O
+Middle	O
+East	O
+Respiratory	O
+Syndrome	B-DISO
+Coronavirus	B-SPEC
+(	O
+HA	O
+-	O
+MERS	O
+)	O
+outbreaks	O
+in	O
+the	O
+Kingdom	B-SPEC
+of	O
+Saudi	O
+Arabia	O
+between	O
+2012	O
+and	O
+2016	O
+.	O
+
+CONCLUSIONS	O
+:	O
+Our	O
+investigation	O
+also	O
+revealed	O
+that	O
+patients	O
+with	O
+an	O
+HA	O
+-	O
+MERS	O
+infection	B-DISO
+experienced	O
+a	O
+significantly	O
+longer	O
+hospital	O
+stay	O
+and	O
+were	O
+more	O
+likely	O
+to	O
+die	O
+from	O
+the	O
+disease	O
+.	O
+
+A	O
+nasopharyngeal	B-ANAT
+swab	I-ANAT
+was	O
+taken	O
+for	O
+multiplex	O
+polymerase	O
+chain	O
+reaction	O
+(	O
+PCR	O
+)	O
+detection	O
+of	O
+influenza	B-SPEC
+virus	I-SPEC
+,	O
+rhinovirus	B-SPEC
+,	O
+parainfluenza	B-DISO
+virus	B-SPEC
+(	O
+HPIV	O
+),	O
+human	B-SPEC
+coronavirus	I-SPEC
+(	O
+HcoV	O
+),	O
+adenoviurs	O
+,	O
+human	B-SPEC
+bocavirus	I-SPEC
+(	O
+HboV	O
+),	O
+human	B-SPEC
+metapneumovirus	I-SPEC
+(	O
+hMPV	B-SPEC
+),	O
+and	O
+respiratory	B-SPEC
+syncytial	I-SPEC
+virus	I-SPEC
+(	O
+RSV	B-SPEC
+).	O
+
+This	O
+study	O
+uses	O
+a	O
+qualitative	O
+case	O
+study	O
+approach	O
+,	O
+including	O
+in	O
+-	O
+depth	O
+interviews	O
+,	O
+literature	O
+review	O
+,	O
+and	O
+document	O
+,	O
+to	O
+analysis	O
+the	O
+emergency	B-DISO
+management	O
+of	O
+SARS	B-DISO
+in	O
+2003	O
+and	O
+H7N9	O
+in	O
+2013	O
+in	O
+China	O
+,	O
+identified	O
+the	O
+problems	O
+of	O
+communication	O
+with	O
+the	O
+emergency	B-DISO
+management	O
+process	O
+for	O
+SARS	B-DISO
+and	O
+H7N9	O
+.	O
+
+Consequently	O
+,	O
+rate	O
+of	O
+treatment	O
+failure	O
+and	O
+relapse	B-DISO
+appear	O
+high	O
+in	O
+that	O
+population	O
+(	O
+up	O
+to	O
+30	O
+%),	O
+with	O
+significant	O
+impact	O
+on	O
+mortality	O
+and	O
+on	O
+the	O
+ECMO	O
+duration	O
+.	O
+
+The	O
+TGEV	B-SPEC
+membrane	B-COMP
+(	O
+M	O
+)	O
+protein	B-CHED
+is	O
+a	O
+decisive	O
+protein	B-CHED
+for	O
+the	O
+proliferation	B-DISO
+of	O
+viral	O
+proteins	B-CHED
+,	O
+and	O
+is	O
+associated	O
+with	O
+virus	B-PROC
+assembly	I-PROC
+and	O
+budding	B-PATH
+.	O
+
+A	O
+knockdown	O
+of	O
+EIF4A2	B-PRGE
+by	O
+siRNA	O
+markedly	O
+decreased	O
+M	B-PRGE
+protein	I-PRGE
+proliferation	B-DISO
+and	O
+TGEV	B-SPEC
+replication	O
+in	O
+target	B-ANAT
+cells	I-ANAT
+.	O
+
+The	O
+present	O
+study	O
+provides	O
+mechanistic	O
+insight	O
+into	O
+the	O
+interaction	O
+between	O
+the	O
+TGEV	B-SPEC
+M	O
+protein	B-CHED
+and	O
+intestinal	B-ANAT
+cells	B-COMP
+which	O
+contributes	O
+to	O
+the	O
+understanding	O
+of	O
+coronavirus	B-SPEC
+replication	O
+and	O
+may	O
+be	O
+useful	O
+for	O
+the	O
+development	B-PROC
+of	O
+novel	O
+therapeutic	O
+strategies	O
+for	O
+TGEV	B-SPEC
+infection	B-DISO
+.	O
+
+There	O
+was	O
+difficulty	O
+achieving	O
+an	O
+activated	O
+clotting	B-PROC
+time	O
+(	O
+ACT	O
+)	O
+>	O
+400	O
+s	O
+:	O
+multiple	O
+argatroban	B-CHED
+bolus	O
+doses	O
+were	O
+required	O
+,	O
+along	O
+with	O
+accelerated	O
+up	O
+-	O
+titration	O
+of	O
+infusion	O
+dosing	O
+.	O
+
+TITLE	O
+:	O
+Clinical	O
+and	O
+Laboratory	O
+Findings	O
+of	O
+Middle	O
+East	O
+Respiratory	O
+Syndrome	B-DISO
+Coronavirus	B-DISO
+Infection	I-DISO
+.	O
+
+TITLE	O
+:	O
+Coronaviruses	O
+in	O
+Avian	B-SPEC
+Species	B-SPEC
+-	O
+Review	O
+with	O
+Focus	O
+on	O
+Epidemiology	O
+and	O
+Diagnosis	O
+in	O
+Wild	O
+Birds	B-SPEC
+.	O
+
+Moreover	O
+,	O
+CoVs	O
+other	O
+than	O
+IBVs	O
+,	O
+are	O
+identified	O
+in	O
+wild	O
+birds	B-SPEC
+,	O
+which	O
+suggests	O
+that	O
+wild	O
+birds	B-SPEC
+play	O
+a	O
+key	O
+role	O
+in	O
+the	O
+epidemiology	O
+of	O
+other	O
+gammaCoVs	O
+and	O
+deltaCoVs	O
+.	O
+
+To	O
+decompose	O
+the	O
+time	O
+-	O
+series	O
+data	O
+,	O
+Empirical	O
+Mode	O
+Decomposition	O
+(	O
+EMD	B-DISO
+)	O
+was	O
+applied	O
+to	O
+properly	O
+describe	O
+the	O
+trends	O
+of	O
+HIV	B-DISO
+and	O
+AIDS	O
+incidence	O
+.	O
+
+Northwest	O
+China	O
+and	O
+older	O
+people	O
+could	O
+be	O
+new	O
+""""	O
+hop	B-SPEC
+-	O
+spots	B-DISO
+""""	O
+for	O
+HIV	B-DISO
+and	O
+AIDS	O
+risk	O
+.	O
+
+Flail	B-DISO
+chest	I-DISO
+was	O
+defined	O
+as	O
+segment	O
+fracture	O
+of	O
+at	O
+least	O
+three	O
+consecutive	O
+ribs	B-ANAT
+on	O
+at	O
+least	O
+one	O
+side	O
+.	O
+
+Overall	O
+,	O
+367	O
+patients	O
+(	O
+61	O
+.	O
+2	O
+%)	O
+had	O
+a	O
+serial	O
+rib	B-CHED
+fracture	O
+.	O
+
+CONCLUSIONS	O
+:	O
+Flail	B-DISO
+chest	I-DISO
+had	O
+no	O
+independent	O
+influence	O
+in	O
+addition	O
+to	O
+injury	O
+severity	O
+on	O
+post	O
+-	O
+traumatic	O
+morbidity	O
+and	O
+mortality	O
+in	O
+multiply	O
+injured	O
+patients	O
+with	O
+blunt	O
+thoracic	B-DISO
+trauma	O
+.	O
+
+TITLE	O
+:	O
+MMI	B-CHED
+-	O
+0100	O
+ameliorates	O
+lung	B-DISO
+inflammation	I-DISO
+in	O
+a	O
+mouse	B-SPEC
+model	O
+of	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+by	O
+reducing	O
+endothelial	B-ANAT
+expression	B-PROC
+of	O
+ICAM	B-PRGE
+-	I-PRGE
+1	I-PRGE
+.	O
+
+In	O
+this	O
+study	O
+,	O
+C57BL	O
+/	O
+6	O
+mice	B-SPEC
+were	O
+randomly	O
+divided	O
+into	O
+three	O
+groups	O
+:	O
+a	O
+control	O
+group	O
+,	O
+an	O
+lipopolysaccharides	B-CHED
+(	O
+LPS	B-DISO
+)	O
+group	O
+,	O
+and	O
+an	O
+LPS	B-DISO
+plus	O
+MMI	B-CHED
+-	O
+0100	O
+group	O
+.	O
+
+TITLE	O
+:	O
+Current	O
+Understanding	O
+of	O
+Humoral	B-PROC
+Immunity	I-PROC
+to	O
+Enterovirus	B-SPEC
+D68	O
+.	O
+
+Seroepidemiologic	O
+studies	O
+have	O
+found	O
+that	O
+the	O
+serum	B-COMP
+of	O
+nearly	O
+everyone	O
+older	O
+than	O
+2	O
+to	O
+5	O
+years	O
+contains	O
+anti	O
+-	O
+EV	O
+-	O
+D68	O
+neutralizing	O
+antibodies	B-COMP
+,	O
+which	O
+suggests	O
+that	O
+EV	O
+-	O
+D68	O
+is	O
+a	O
+ubiquitous	O
+pathogen	O
+of	O
+childhood	O
+.	O
+
+When	O
+ANNs	O
+model	O
+is	O
+used	O
+to	O
+identify	O
+ARDS	B-DISO
+,	O
+the	O
+area	O
+under	O
+ROC	O
+was	O
+0	O
+.	O
+859	O
++	O
+0	O
+.	O
+048	O
+.	O
+
+ANNs	O
+model	O
+is	O
+a	O
+valuable	O
+tool	O
+in	O
+dealing	O
+with	O
+risk	O
+prediction	O
+of	O
+ARDS	B-DISO
+following	O
+SAP	O
+.	O
+
+1	O
+973	O
+patients	O
+with	O
+AP	O
+in	O
+Hunan	O
+People	O
+'	O
+s	O
+Hospital	O
+from	O
+2012	O
+to	O
+2017	O
+were	O
+retrospectively	O
+enrolled	O
+and	O
+divided	O
+by	O
+SIRS	B-DISO
+duration	O
+into	O
+the	O
+persistent	O
+SIRS	B-DISO
+group	O
+,	O
+temporary	O
+SIRS	B-DISO
+group	O
+and	O
+non	O
+-	O
+SIRS	B-DISO
+group	O
+.	O
+
+ABSTRACT	O
+:	O
+Human	B-SPEC
+infection	B-DISO
+with	O
+avian	B-DISO
+influenza	B-PATH
+A	I-PATH
+(	O
+H7N9	O
+)	O
+is	O
+easy	O
+to	O
+induce	O
+severe	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+(	O
+ARDS	B-DISO
+),	O
+and	O
+traditional	O
+mechanical	O
+ventilation	O
+cannot	O
+correct	O
+hypoxemia	O
+,	O
+so	O
+patients	O
+may	O
+die	O
+from	O
+multiple	B-DISO
+organ	I-DISO
+failure	I-DISO
+(	O
+MOF	B-DISO
+)	O
+caused	O
+by	O
+persistent	O
+hypoxia	B-DISO
+.	O
+
+After	O
+13	O
+days	O
+of	O
+ECMO	O
+support	O
+,	O
+the	O
+patient	O
+was	O
+successfully	O
+weaned	B-PROC
+from	O
+ECMO	O
+and	O
+was	O
+transferred	O
+to	O
+a	O
+general	O
+ward	O
+after	O
+55	O
+days	O
+.	O
+
+Both	O
+infected	O
+boars	B-SPEC
+had	O
+diarrhea	B-DISO
+after	O
+inoculation	O
+and	O
+shed	O
+virus	B-SPEC
+in	O
+feces	B-ANAT
+.	O
+
+Additionally	O
+,	O
+viral	B-PROC
+replication	I-PROC
+was	O
+compared	O
+in	O
+Vero	O
+and	O
+IPEC	O
+-	O
+DQ	O
+cells	B-COMP
+at	O
+the	O
+presence	O
+of	O
+bovine	B-PRGE
+mucin	I-PRGE
+(	O
+BM	O
+),	O
+porcine	B-SPEC
+gastric	B-ANAT
+mucin	O
+(	O
+PGM	B-FUNC
+),	O
+swine	B-SPEC
+bile	B-ANAT
+and	O
+bile	B-CHED
+acids	I-CHED
+during	O
+inoculation	O
+.	O
+
+This	O
+observation	O
+may	O
+be	O
+explained	O
+partially	O
+by	O
+the	O
+fact	O
+that	O
+mucin	B-PRGE
+,	O
+bile	B-ANAT
+and	O
+bile	B-CHED
+acids	I-CHED
+in	O
+gastrointestinal	B-ANAT
+tract	I-ANAT
+had	O
+facilitating	O
+effects	O
+on	O
+the	O
+infection	B-DISO
+of	O
+S	O
+-	O
+intact	O
+PEDV	B-SPEC
+,	O
+but	O
+no	O
+/	O
+inhibition	B-PROC
+effects	O
+on	O
+S1	O
+NTD	O
+-	O
+del	O
+PEDV	B-SPEC
+.	O
+
+Currently	O
+there	O
+are	O
+no	O
+effective	O
+treatments	O
+or	O
+vaccines	O
+for	O
+PDCoV	O
+.	O
+In	O
+particular	O
+,	O
+the	O
+pathogenesis	B-DISO
+of	O
+PDCoV	O
+infection	B-DISO
+is	O
+still	O
+largely	O
+unknown	O
+.	O
+
+ABSTRACT	O
+:	O
+The	O
+effects	O
+of	O
+route	O
+of	O
+administration	O
+on	O
+systemic	O
+and	O
+gut	B-ANAT
+mucosal	B-PROC
+immune	I-PROC
+responses	I-PROC
+induced	O
+by	O
+porcine	B-SPEC
+epidemic	I-SPEC
+diarrhea	I-SPEC
+virus	I-SPEC
+(	O
+PEDV	B-SPEC
+)	O
+infection	B-DISO
+in	O
+suckling	O
+pigs	B-SPEC
+were	O
+investigated	O
+.	O
+
+In	O
+conclusion	O
+,	O
+oral	B-ANAT
+inoculation	O
+may	O
+generate	O
+more	O
+comprehensive	O
+immune	B-PROC
+responses	I-PROC
+.	O
+
+The	O
+stressors	O
+(	O
+suggested	O
+by	O
+the	O
+triple	O
+risk	O
+model	O
+)	O
+share	O
+a	O
+unified	O
+compensatory	O
+physiological	O
+response	O
+of	O
+decrease	O
+in	O
+systemic	O
+vascular	B-ANAT
+resistant	O
+(	O
+SVR	O
+)	O
+to	O
+facilitate	O
+a	O
+compensatory	O
+increase	O
+in	O
+cardiac	B-ANAT
+output	O
+(	O
+CO	O
+).	O
+
+Accordingly	O
+CO	O
+increases	O
+above	O
+the	O
+needs	O
+to	O
+hyper	O
+-	O
+dynamic	O
+state	O
+,	O
+high	B-DISO
+output	I-DISO
+heart	I-DISO
+failure	I-DISO
+and	O
+hyper	O
+-	O
+dynamic	O
+shock	O
+.	O
+
+ABSTRACT	O
+:	O
+Swine	B-SPEC
+acute	B-DISO
+diarrhea	I-DISO
+syndrome	B-DISO
+coronavirus	B-SPEC
+(	O
+SADS	O
+-	O
+CoV	O
+)	O
+is	O
+a	O
+novel	B-SPEC
+coronavirus	I-SPEC
+which	O
+was	O
+associated	O
+with	O
+severe	B-DISO
+diarrhea	I-DISO
+disease	O
+in	O
+pigs	B-SPEC
+.	O
+
+TITLE	O
+:	O
+Find	O
+the	O
+right	O
+sample	O
+:	O
+A	O
+study	O
+on	O
+the	O
+versatility	O
+of	O
+saliva	B-ANAT
+and	O
+urine	B-ANAT
+samples	O
+for	O
+the	O
+diagnosis	O
+of	O
+emerging	O
+viruses	O
+.	O
+
+ABSTRACT	O
+:	O
+The	O
+emergence	O
+of	O
+different	O
+viral	B-DISO
+infections	I-DISO
+during	O
+the	O
+last	O
+decades	O
+like	O
+dengue	B-DISO
+,	O
+West	O
+Nile	O
+,	O
+SARS	B-DISO
+,	O
+chikungunya	B-DISO
+,	O
+MERS	O
+-	O
+CoV	O
+,	O
+Ebola	O
+,	O
+Zika	O
+and	O
+Yellow	B-DISO
+Fever	I-DISO
+raised	O
+some	O
+questions	O
+on	O
+quickness	O
+and	O
+reliability	O
+of	O
+laboratory	O
+diagnostic	O
+tests	O
+for	O
+verification	O
+of	O
+suspected	O
+cases	O
+.	O
+
+Prompt	O
+contact	O
+tracing	O
+,	O
+repeated	O
+testing	O
+,	O
+HCP	B-DISO
+furloughing	O
+,	O
+and	O
+implementation	O
+of	O
+recommended	O
+transmission	O
+-	O
+based	O
+precautions	O
+for	O
+suspected	O
+cases	O
+ultimately	O
+halted	O
+transmission	O
+.	O
+
+Overall	O
+,	O
+4	O
+(	O
+24	O
+%)	O
+of	O
+17	O
+HCP	B-DISO
+cases	O
+and	O
+3	O
+(	O
+3	O
+%)	O
+of	O
+114	O
+HCP	B-DISO
+contacts	O
+of	O
+cases	O
+were	O
+seropositive	O
+.	O
+
+TITLE	O
+:	O
+An	O
+Atypical	O
+Case	O
+of	O
+Middle	O
+East	O
+Respiratory	O
+Syndrome	B-DISO
+in	O
+a	O
+Returning	O
+Traveler	O
+to	O
+Korea	O
+from	O
+Kuwait	O
+,	O
+2018	O
+.	O
+
+ABSTRACT	O
+:	O
+Pulmonary	B-ANAT
+complications	I-DISO
+often	O
+occur	O
+in	O
+patients	O
+with	O
+acute	O
+kidney	O
+injury	O
+,	O
+and	O
+represent	O
+an	O
+important	O
+cause	O
+of	O
+death	B-PROC
+.	O
+
+The	O
+prospective	O
+study	O
+involved	O
+195	O
+adult	O
+patients	O
+with	O
+BMT	B-ENZY
+who	O
+were	O
+admitted	O
+to	O
+a	O
+referral	O
+hospital	O
+'	O
+s	O
+emergency	B-DISO
+department	O
+(	O
+ED	O
+)	O
+between	O
+May	O
+1	O
+,	O
+2015	O
+,	O
+and	O
+May	O
+31	O
+,	O
+2016	O
+.	O
+
+TITLE	O
+:	O
+Alterations	O
+in	O
+sialic	O
+-	O
+acid	O
+O	O
+-	O
+acetylation	B-PROC
+glycoforms	O
+during	O
+murine	B-SPEC
+erythrocyte	B-PROC
+development	B-PROC
+.	O
+
+Although	O
+the	O
+structure	O
+of	O
+the	O
+sialoglycoconjugate	O
+recognized	O
+by	O
+TER	B-COMP
+-	O
+119	O
+was	O
+not	O
+chemically	O
+demonstrated	O
+,	O
+its	O
+selective	O
+binding	B-FUNC
+to	O
+virolectins	O
+suggests	O
+that	O
+it	O
+may	O
+be	O
+comprised	O
+of	O
+a	O
+7	O
+,	O
+9	O
+-	O
+di	O
+-	O
+O	O
+-	O
+acetyl	B-CHED
+form	O
+of	O
+sialic	B-CHED
+acid	I-CHED
+.	O
+
+TITLE	O
+:	O
+Infectious	B-DISO
+bronchitis	B-DISO
+virus	B-SPEC
+entry	O
+mainly	O
+depends	O
+on	O
+clathrin	B-PRGE
+mediated	O
+endocytosis	B-PATH
+and	O
+requires	O
+classical	O
+endosomal	O
+/	O
+lysosomal	O
+system	O
+.	O
+
+The	O
+lifestyle	O
+gradually	O
+transformed	O
+from	O
+Bedouin	O
+life	O
+to	O
+urban	O
+sedentary	O
+life	O
+,	O
+along	O
+with	O
+a	O
+sharp	O
+increase	O
+in	O
+obesity	B-DISO
+and	O
+other	O
+comorbidities	O
+.	O
+
+Even	O
+if	O
+rasburicase	O
+induced	O
+methemoglobinemia	B-DISO
+and	O
+hemolysis	B-DISO
+are	O
+not	O
+very	O
+common	O
+complications	O
+,	O
+clinicians	O
+who	O
+prescribe	O
+and	O
+follow	O
+patients	O
+should	O
+detect	O
+this	O
+serious	O
+complication	B-DISO
+early	O
+and	O
+manage	O
+it	O
+accordingly	O
+.	O
+
+It	O
+is	O
+also	O
+vital	O
+to	O
+assume	O
+a	O
+diagnosis	O
+of	O
+G6PD	B-DISO
+deficiency	I-DISO
+until	O
+proven	O
+otherwise	O
+in	O
+a	O
+patient	O
+who	O
+presents	O
+with	O
+rasburicase	O
+induced	O
+hemolysis	B-DISO
+and	O
+avoid	O
+administration	O
+of	O
+methylene	B-CHED
+blue	I-CHED
+even	O
+if	O
+the	O
+patient	O
+is	O
+from	O
+a	O
+low	O
+risk	O
+ethnicity	O
+for	O
+G6PD	B-PRGE
+as	O
+in	O
+our	O
+patient	O
+.	O
+
+Acute	O
+lung	B-ANAT
+injury	O
+is	O
+a	O
+syndrome	B-DISO
+associated	O
+with	O
+pulmonary	B-DISO
+oedema	I-DISO
+,	O
+hypoxaemia	O
+and	O
+respiratory	B-DISO
+failure	I-DISO
+.	O
+
+A	O
+significant	O
+association	O
+was	O
+found	O
+between	O
+influenza	B-PATH
+infection	B-DISO
+and	O
+acute	B-DISO
+myocardial	I-DISO
+infarction	I-DISO
+(	O
+AMI	B-DISO
+).	O
+
+RESULTS	O
+:	O
+Bootstrap	O
+analyses	O
+indicated	O
+no	O
+direct	O
+effects	O
+of	O
+T1	O
+FSS	B-DISO
+on	O
+T2	O
+IES	B-CHED
+-	O
+R	O
+but	O
+significant	O
+positive	O
+indirect	O
+effects	O
+of	O
+T1	O
+FSS	B-DISO
+on	O
+T2	O
+IESR	O
+through	O
+T1	O
+PHQ	O
+-	O
+9	O
+and	O
+T2	O
+PHQ	O
+-	O
+9	O
+(	O
+B	O
+=	O
+2	O
+.	O
+1601	O
+,	O
+SE	O
+=	O
+1	O
+.	O
+3268	O
+,	O
+95	O
+%	O
+confidence	O
+interval	O
+=	O
+0	O
+.	O
+4250	O
+-	O
+6	O
+.	O
+1307	O
+).	O
+
+CONCLUSIONS	O
+:	O
+Chronic	O
+fatigue	B-DISO
+12	O
+months	O
+after	O
+MERS	O
+had	O
+indirect	O
+effects	O
+on	O
+prolonged	O
+PTSSs	O
+18	O
+months	O
+after	O
+MERS	O
+via	O
+persisting	O
+depression	B-DISO
+in	O
+MERS	O
+survivors	O
+.	O
+
+ABSTRACT	O
+:	O
+Lymphography	O
+with	O
+Lipiodol	O
+is	O
+useful	O
+for	O
+chylothorax	B-DISO
+.	O
+
+There	O
+were	O
+many	O
+slight	O
+complications	O
+,	O
+but	O
+reports	O
+of	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+(	O
+ARDS	B-DISO
+)	O
+after	O
+lymphography	O
+were	O
+few	O
+.	O
+
+He	O
+recovered	O
+from	O
+ARDS	B-DISO
+but	O
+subsequently	O
+developed	O
+pulmonary	B-DISO
+fibrosis	I-DISO
+and	O
+was	O
+discharged	O
+with	O
+domiciliary	O
+oxygen	B-CHED
+therapy	O
+3	O
+months	O
+later	O
+.	O
+
+CONCLUSIONS	O
+:	O
+Although	O
+ARDS	B-DISO
+is	O
+a	O
+rare	O
+complication	B-DISO
+of	O
+lymphography	O
+with	O
+Lipiodol	O
+,	O
+this	O
+procedure	O
+should	O
+be	O
+applied	O
+carefully	O
+in	O
+patients	O
+with	O
+chylothorax	O
+.	O
+
+Venous	B-ANAT
+-	O
+arterial	B-ANAT
+ECMO	O
+provides	O
+circulatory	B-PROC
+support	O
+allowing	O
+time	O
+for	O
+other	O
+treatments	O
+to	O
+promote	O
+recovery	O
+in	O
+presence	O
+of	O
+acute	O
+cardiopulmonary	B-DISO
+failure	I-DISO
+.	O
+
+ABSTRACT	O
+:	O
+Disease	O
+fatality	O
+associated	O
+with	O
+Ebola	O
+,	O
+SARS	O
+-	O
+CoV	O
+and	O
+dengue	B-DISO
+infections	B-DISO
+in	O
+humans	B-SPEC
+is	O
+attributed	O
+to	O
+a	O
+cytokine	B-DISO
+storm	I-DISO
+that	O
+is	O
+triggered	O
+by	O
+excessive	O
+pro	B-CHED
+-	O
+inflammatory	B-DISO
+responses	I-DISO
+.	O
+
+Future	O
+antivirals	B-CHED
+should	O
+thus	O
+aim	O
+to	O
+target	O
+the	O
+mechanism	O
+that	O
+regulates	O
+switching	O
+between	O
+IL	B-FUNC
+-	I-FUNC
+6	I-FUNC
+trans	O
+-	O
+and	O
+classical	O
+-	O
+signaling	B-PROC
+.	O
+
+ABSTRACT	O
+:	O
+Viral	O
+noncoding	O
+(	O
+nc	O
+)	O
+RNAs	O
+have	O
+been	O
+shown	O
+to	O
+play	O
+important	O
+roles	O
+in	O
+viral	B-PROC
+life	I-PROC
+cycle	I-PROC
+.	O
+
+TITLE	O
+:	O
+Volumetric	O
+but	O
+Not	O
+Time	O
+Capnography	O
+Detects	O
+Ventilation	O
+/	O
+Perfusion	O
+Mismatch	O
+in	O
+Injured	O
+Rabbit	B-SPEC
+Lung	O
+.	O
+
+We	O
+compared	O
+the	O
+diagnostic	O
+value	O
+of	O
+indices	O
+derived	O
+from	O
+Tcap	O
+and	O
+Vcap	O
+following	O
+ventilation	O
+to	O
+perfusion	O
+ratio	O
+()	O
+mismatch	O
+subsequent	O
+to	O
+experimentally	O
+induced	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+(	O
+ARDS	B-DISO
+),	O
+and	O
+alveolar	B-ANAT
+recruitment	B-DISO
+by	O
+elevating	O
+the	O
+positive	O
+end	B-PROC
+-	I-PROC
+expiratory	I-PROC
+pressure	O
+(	O
+PEEP	B-CHED
+).	O
+
+Infections	B-DISO
+are	O
+a	O
+major	O
+complication	B-DISO
+of	O
+cancer	B-DISO
+and	O
+its	O
+treatment	O
+.	O
+
+Community	O
+acquired	O
+respiratory	O
+viral	B-DISO
+infections	I-DISO
+(	O
+CRV	B-DISO
+)	O
+in	O
+these	O
+patients	O
+increase	O
+morbidity	O
+,	O
+mortality	O
+and	O
+can	O
+lead	O
+to	O
+delay	O
+in	O
+chemotherapy	O
+.	O
+
+This	O
+balance	B-PROC
+between	O
+effective	O
+virus	B-SPEC
+control	O
+with	O
+limited	O
+pathology	B-DISO
+is	O
+especially	O
+important	O
+due	O
+to	O
+the	O
+highly	O
+specialized	O
+functions	O
+and	O
+limited	O
+regenerative	O
+capacity	O
+of	O
+neurons	B-ANAT
+,	O
+which	O
+can	O
+be	O
+targets	O
+of	O
+direct	O
+virus	B-SPEC
+cytolysis	B-PROC
+or	O
+bystander	O
+damage	O
+.	O
+
+Both	O
+innate	O
+and	O
+adaptive	O
+immune	O
+cells	B-COMP
+work	O
+in	O
+coordination	B-PROC
+to	O
+control	O
+virus	B-PROC
+replication	I-PROC
+.	O
+
+While	O
+type	B-PRGE
+I	I-PRGE
+interferons	I-PRGE
+are	O
+essential	O
+to	O
+limit	O
+virus	B-SPEC
+spread	O
+associated	O
+with	O
+early	O
+mortality	O
+,	O
+perforin	B-PRGE
+,	O
+and	O
+interferon	B-PRGE
+-	I-PRGE
+γ	I-PRGE
+promote	O
+further	O
+virus	B-SPEC
+clearance	O
+in	O
+astrocytes	B-ANAT
+/	O
+microglia	B-ANAT
+and	O
+oligodendrocytes	B-ANAT
+,	O
+respectively	O
+.	O
+
+However	O
+,	O
+we	O
+herein	O
+report	O
+that	O
+the	O
+combination	O
+of	O
+m336	O
+and	O
+HR2P	O
+-	O
+M2	O
+exhibited	O
+potent	O
+synergism	O
+in	O
+inhibiting	O
+MERS	B-PRGE
+-	I-PRGE
+CoV	I-PRGE
+S	I-PRGE
+protein	I-PRGE
+-	O
+mediated	O
+cell	B-PROC
+⁻	I-PROC
+cell	I-PROC
+fusion	I-PROC
+and	O
+infection	B-DISO
+by	O
+MERS	O
+-	O
+CoV	O
+pseudoviruses	O
+with	O
+or	O
+without	O
+mutations	O
+in	O
+the	O
+RBD	O
+,	O
+resulting	O
+in	O
+the	O
+enhancement	O
+of	O
+antiviral	B-CHED
+activity	O
+in	O
+contrast	O
+to	O
+either	O
+one	O
+administered	O
+alone	O
+.	O
+
+This	O
+included	O
+feed	O
+suppliers	O
+,	O
+animal	B-SPEC
+movement	B-PROC
+,	O
+animal	B-SPEC
+transportation	O
+companies	O
+,	O
+semen	B-ANAT
+suppliers	O
+and	O
+a	O
+complete	O
+network	O
+with	O
+all	O
+service	O
+providers	O
+.	O
+
+TITLE	O
+:	O
+Poldip2	B-PRGE
+deficiency	O
+protects	O
+against	O
+lung	B-DISO
+edema	I-DISO
+and	O
+vascular	B-DISO
+inflammation	I-DISO
+in	O
+a	O
+model	O
+of	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+.	O
+
+ABSTRACT	O
+:	O
+Acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+(	O
+ARDS	B-DISO
+)	O
+in	O
+a	O
+deadly	O
+disease	O
+that	O
+can	O
+be	O
+brought	O
+on	O
+by	O
+endotoxins	O
+such	O
+as	O
+lipopolysaccharide	B-CHED
+(	O
+LPS	B-DISO
+).	O
+
+ARDS	B-DISO
+is	O
+characterized	O
+by	O
+vascular	B-PROC
+permeability	I-PROC
+,	O
+a	O
+severe	O
+inflammatory	B-DISO
+response	I-DISO
+,	O
+lung	B-ANAT
+leukocyte	B-ANAT
+infiltration	B-DISO
+,	O
+and	O
+resultant	O
+lung	B-DISO
+edema	I-DISO
+.	O
+
+Here	O
+,	O
+the	O
+role	O
+of	O
+Poldip2	B-PRGE
+in	O
+regulating	O
+vascular	B-PROC
+permeability	I-PROC
+and	O
+inflammation	B-DISO
+in	O
+a	O
+mouse	B-SPEC
+model	O
+of	O
+ARDS	B-DISO
+was	O
+assessed	O
+.	O
+
+TITLE	O
+:	O
+Depletion	O
+of	O
+RIPK1	B-PRGE
+in	O
+hepatocytes	B-ANAT
+exacerbates	O
+liver	B-DISO
+damage	I-DISO
+in	O
+fulminant	O
+viral	B-DISO
+hepatitis	I-DISO
+.	O
+
+Mice	B-SPEC
+deficient	O
+for	O
+RIPK1	B-PRGE
+,	O
+specifically	O
+in	O
+liver	B-ANAT
+parenchymal	O
+cells	B-COMP
+(	O
+Ripk1	B-PRGE
+
+All	O
+other	O
+viruses	B-SPEC
+were	O
+detected	O
+in	O
+<	O
+2	O
+%	O
+of	O
+specimens	O
+.	O
+
+Rhinovirus	B-SPEC
+was	O
+the	O
+most	O
+common	O
+coinfecting	O
+virus	B-SPEC
+(	O
+21	O
+.	O
+4	O
+%-	O
+60	O
+.	O
+7	O
+%),	O
+followed	O
+by	O
+adenovirus	B-DISO
+(	O
+21	O
+.	O
+4	O
+%-	O
+39	O
+.	O
+3	O
+%),	O
+and	O
+respiratory	B-SPEC
+syncytial	I-SPEC
+virus	I-SPEC
+(	O
+10	O
+.	O
+7	O
+%-	O
+24	O
+.	O
+0	O
+%).	O
+
+ABSTRACT	O
+:	O
+Porcine	B-SPEC
+viral	B-DISO
+diarrhea	I-DISO
+is	O
+an	O
+acute	O
+and	O
+highly	O
+contagious	O
+enteric	O
+disease	O
+in	O
+pigs	B-SPEC
+which	O
+causes	O
+huge	O
+economic	O
+losses	O
+in	O
+pig	B-SPEC
+industry	O
+worldwide	O
+.	O
+
+Next	O
+,	O
+the	O
+site	O
+-	O
+specific	O
+editing	O
+of	O
+pAPN	O
+porcine	B-SPEC
+fetal	B-ANAT
+fibroblasts	B-ANAT
+were	O
+produced	O
+,	O
+and	O
+then	O
+the	O
+cell	B-COMP
+colonies	O
+were	O
+used	O
+as	O
+donor	B-CHED
+cells	B-COMP
+to	O
+generate	O
+the	O
+site	O
+-	O
+specific	O
+editing	O
+of	O
+pAPN	O
+pigs	B-SPEC
+.	O
+
+We	O
+studied	O
+1	O
+,	O
+200	O
+patients	O
+with	O
+moderate	O
+-	O
+to	O
+-	O
+severe	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+managed	O
+with	O
+lung	B-ANAT
+-	O
+protective	O
+ventilation	O
+.	O
+
+All	O
+of	O
+the	O
+patients	O
+had	O
+warning	O
+or	O
+severity	O
+signs	O
+for	O
+dengue	B-DISO
+and	O
+initiated	O
+labor	B-PROC
+,	O
+either	O
+term	O
+or	O
+preterm	O
+,	O
+during	O
+their	O
+hospital	O
+stay	O
+.	O
+
+Three	O
+patients	O
+were	O
+diagnosed	O
+with	O
+preeclampsia	B-DISO
+.	O
+
+Here	O
+,	O
+we	O
+developed	O
+transgenic	O
+(	O
+Tg	O
+)	O
+mice	B-SPEC
+on	O
+a	O
+C57BL	O
+/	O
+6	O
+background	O
+;	O
+these	O
+mice	B-SPEC
+expressed	B-PROC
+human	B-PRGE
+CD26	B-PRGE
+/	I-PRGE
+dipeptidyl	I-PRGE
+peptidase	I-PRGE
+4	I-PRGE
+(	O
+hDPP4	O
+),	O
+a	O
+functional	O
+receptor	O
+for	O
+MERS	O
+-	O
+CoV	O
+,	O
+under	O
+the	O
+control	O
+of	O
+an	O
+endogenous	O
+hDPP4	O
+promoter	O
+.	O
+
+However	O
+,	O
+the	O
+immunopathology	B-DISO
+in	O
+young	O
+and	O
+adult	O
+Tg	O
+mice	B-SPEC
+was	O
+different	O
+.	O
+
+ABSTRACT	O
+:	O
+Transmembrane	B-PRGE
+serine	B-CHED
+protease	I-PRGE
+TMPRSS2	I-PRGE
+activates	O
+the	O
+spike	O
+protein	B-CHED
+of	O
+highly	O
+pathogenic	O
+human	B-SPEC
+coronaviruses	O
+such	O
+as	O
+severe	B-SPEC
+acute	I-SPEC
+respiratory	I-SPEC
+syndrome	I-SPEC
+-	I-SPEC
+related	I-SPEC
+coronavirus	I-SPEC
+(	O
+SARS	B-DISO
+-	O
+CoV	O
+)	O
+and	O
+Middle	O
+East	O
+respiratory	O
+syndrome	B-DISO
+-	O
+related	O
+coronavirus	B-SPEC
+(	O
+MERS	O
+-	O
+CoV	O
+).	O
+
+ABSTRACT	O
+:	O
+Legionella	B-SPEC
+community	O
+-	O
+acquired	O
+pneumonia	B-DISO
+necessitating	O
+veno	O
+-	O
+venous	B-ANAT
+extracorporeal	O
+membrane	B-COMP
+oxygenation	B-PROC
+for	O
+severe	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+has	O
+been	O
+reported	O
+in	O
+adults	O
+.	O
+
+ABSTRACT	O
+:	O
+Viruses	B-SPEC
+are	O
+obligate	O
+intracellular	B-COMP
+microbes	O
+that	O
+exploit	O
+the	O
+host	B-COMP
+metabolic	B-PROC
+machineries	O
+to	O
+meet	O
+their	O
+biosynthetic	B-PROC
+demands	O
+,	O
+making	O
+these	O
+host	B-COMP
+pathways	B-PROC
+potential	O
+therapeutic	O
+targets	O
+.	O
+
+TITLE	O
+:	O
+Nasal	B-ANAT
+virome	O
+of	O
+dogs	B-SPEC
+with	O
+respiratory	B-DISO
+infection	I-DISO
+signs	O
+include	O
+novel	O
+taupapillomaviruses	O
+.	O
+
+Clinical	O
+features	O
+of	O
+ECoV	O
+infection	B-DISO
+have	O
+been	O
+described	O
+,	O
+but	O
+no	O
+study	O
+has	O
+compared	O
+these	O
+features	O
+to	O
+those	O
+of	O
+Salmonella	B-DISO
+infections	I-DISO
+.	O
+
+Medical	O
+records	O
+of	O
+horses	B-SPEC
+presented	O
+to	O
+the	O
+North	O
+Carolina	O
+State	O
+University	O
+Equine	B-SPEC
+and	O
+Farm	O
+Animal	B-SPEC
+Veterinary	O
+Center	O
+(	O
+2003	O
+-	O
+016	O
+)	O
+were	O
+retrospectively	O
+reviewed	O
+.	O
+
+Data	O
+were	O
+analyzed	O
+by	O
+1	O
+-	O
+way	O
+analysis	O
+of	O
+variance	O
+,	O
+Kruskal	O
+-	O
+Wallis	O
+test	O
+,	O
+or	O
+Fisher	B-SPEC
+'	O
+s	O
+exact	O
+test	O
+with	O
+significance	O
+set	O
+at	O
+P	O
+<	O
+.	O
+05	O
+.	O
+
+RESULTS	O
+:	O
+Most	O
+common	O
+presenting	O
+complaints	O
+were	O
+fever	B-PROC
+and	O
+colic	B-DISO
+and	O
+were	O
+similar	O
+across	O
+groups	O
+.	O
+
+However	O
+,	O
+little	O
+is	O
+known	O
+about	O
+host	B-COMP
+factors	O
+at	O
+the	O
+interface	O
+between	O
+replicase	B-PRGE
+complexes	O
+and	O
+the	O
+host	B-COMP
+cytoplasm	B-COMP
+.	O
+
+siRNA	O
+-	O
+silencing	O
+of	O
+each	O
+RTC	B-PRGE
+-	I-PRGE
+proximal	I-PRGE
+host	I-PRGE
+factor	I-PRGE
+demonstrated	O
+importance	O
+of	O
+vesicular	O
+trafficking	B-PROC
+pathways	B-PROC
+,	O
+ubiquitin	B-PROC
+-	O
+dependent	O
+and	O
+autophagy	B-PROC
+-	O
+related	O
+processes	O
+,	O
+and	O
+translation	B-PROC
+initiation	I-PROC
+factors	O
+.	O
+
+The	O
+hDPP4	O
+-	O
+Tg	O
+mice	B-SPEC
+infected	O
+with	O
+MERS	O
+-	O
+CoV	O
+overexpressed	O
+caspase	B-PRGE
+-	I-PRGE
+1	I-PRGE
+in	O
+the	O
+spleen	B-ANAT
+and	O
+showed	O
+high	O
+IL	O
+-	O
+1β	O
+levels	O
+in	O
+serum	B-COMP
+,	O
+suggesting	O
+that	O
+pyroptosis	B-PROC
+occurred	O
+after	O
+infection	B-DISO
+.	O
+
+ABSTRACT	O
+:	O
+Porcine	B-SPEC
+epidemic	I-SPEC
+diarrhea	I-SPEC
+virus	I-SPEC
+(	O
+PEDV	B-SPEC
+)	O
+causes	O
+diarrhea	B-DISO
+in	O
+all	O
+ages	O
+of	O
+pigs	B-SPEC
+with	O
+50	O
+-	O
+100	O
+%	O
+mortality	O
+rates	O
+in	O
+neonatal	O
+piglets	O
+.	O
+
+In	O
+this	O
+study	O
+,	O
+we	O
+evaluated	O
+the	O
+safety	O
+and	O
+efficacy	O
+of	O
+two	O
+attenuated	O
+PEDV	B-SPEC
+vaccine	O
+candidates	O
+,	O
+the	O
+emerging	O
+non	O
+-	O
+S	O
+INDEL	B-PROC
+PEDV	B-SPEC
+strain	O
+PC22A	O
+at	O
+the	O
+100th	O
+cell	B-COMP
+culture	O
+passage	O
+level	O
+-	O
+Clone	O
+no	O
+.	O
+4	O
+(	O
+P100C4	O
+)	O
+and	O
+at	O
+the	O
+120th	O
+passage	O
+level	O
+(	O
+P120	O
+),	O
+in	O
+weaned	B-PROC
+pigs	B-SPEC
+.	O
+
+Four	O
+groups	O
+of	O
+40	O
+-	O
+day	O
+-	O
+old	O
+weaned	B-PROC
+pigs	B-SPEC
+were	O
+inoculated	O
+orally	B-ANAT
+with	O
+PEDV	B-SPEC
+PC22A	O
+-	O
+P3	O
+(	O
+virulent	O
+),	O
+-	O
+P100C4	O
+,	O
+-	O
+P120	O
+,	O
+and	O
+mock	O
+,	O
+respectively	O
+,	O
+and	O
+challenged	O
+with	O
+the	O
+P3	O
+virus	B-SPEC
+at	O
+24	O
+days	O
+post	O
+-	O
+inoculation	O
+(	O
+dpi	O
+).	O
+
+P100C4	O
+and	O
+P120	O
+did	O
+not	O
+cause	O
+diarrhea	B-DISO
+in	O
+pigs	B-SPEC
+,	O
+although	O
+viral	O
+RNA	O
+was	O
+detected	O
+in	O
+feces	B-ANAT
+of	O
+all	O
+pigs	B-SPEC
+,	O
+except	O
+for	O
+one	O
+P100C4	O
+-	O
+inoculated	O
+pig	B-SPEC
+.	O
+
+RESULTS	O
+:	O
+Four	O
+groups	O
+of	O
+40	O
+-	O
+day	O
+-	O
+old	O
+weaned	B-PROC
+pigs	B-SPEC
+were	O
+inoculated	O
+orally	B-ANAT
+with	O
+PEDV	B-SPEC
+PC22A	O
+-	O
+P3	O
+(	O
+virulent	O
+),	O
+-	O
+P100C4	O
+,	O
+-	O
+P120	O
+,	O
+and	O
+mock	O
+,	O
+respectively	O
+,	O
+and	O
+challenged	O
+with	O
+the	O
+P3	O
+virus	B-SPEC
+at	O
+24	O
+days	O
+post	O
+-	O
+inoculation	O
+(	O
+dpi	O
+).	O
+
+A	O
+prospective	O
+cross	O
+-	O
+sectional	O
+observational	O
+study	O
+was	O
+conducted	O
+in	O
+infants	O
+hospitalized	O
+with	O
+a	O
+diagnosis	O
+of	O
+acute	B-DISO
+lower	I-DISO
+respiratory	I-DISO
+tract	I-DISO
+infection	I-DISO
+(	O
+ALRTI	O
+),	O
+in	O
+a	O
+tertiary	O
+care	O
+hospital	O
+in	O
+a	O
+metropolitan	O
+city	O
+of	O
+Western	O
+India	O
+.	O
+
+Pathogens	O
+were	O
+detected	O
+in	O
+82	O
+samples	O
+,	O
+which	O
+included	O
+Respiratory	O
+syncytial	O
+viruses	B-SPEC
+(	O
+RSV	B-SPEC
+)	O
+A	O
+/	O
+B	O
+(	O
+35	O
+.	O
+4	O
+%),	O
+Human	B-SPEC
+rhinovirus	I-SPEC
+(	O
+25	O
+.	O
+6	O
+%),	O
+Adenovirus	B-DISO
+(	O
+22	O
+%),	O
+Human	B-SPEC
+Parainfluenza	B-DISO
+viruses	B-SPEC
+(	O
+11	O
+%),	O
+Human	B-SPEC
+bocavirus	I-SPEC
+(	O
+9	O
+.	O
+8	O
+),	O
+Human	B-PRGE
+metapneumovirus	I-PRGE
+A	I-PRGE
+/	I-PRGE
+B	I-PRGE
+(	O
+8	O
+.	O
+5	O
+%),	O
+Influenza	B-PATH
+A	I-PATH
+(	O
+H1N1	O
+)	O
+pdm	O
+09	O
+(	O
+6	O
+.	O
+1	O
+%),	O
+Parechovirus	B-SPEC
+(	O
+3	O
+.	O
+7	O
+%),	O
+Human	B-SPEC
+coronaviruses	O
+(	O
+3	O
+.	O
+66	O
+%),	O
+Haemophilus	B-SPEC
+influenzae	I-SPEC
+type	O
+b	O
+(	O
+6	O
+.	O
+1	O
+%),	O
+Chlamydia	B-SPEC
+pneumoniae	I-SPEC
+(	O
+2	O
+.	O
+4	O
+%)	O
+and	O
+Mycoplasma	B-SPEC
+pneumoniae	I-SPEC
+(	O
+2	O
+.	O
+4	O
+%).	O
+
+The	O
+mechanism	O
+of	O
+Griffithsin	O
+'	O
+s	O
+action	O
+against	O
+PEDV	B-SPEC
+involved	O
+both	O
+preventing	O
+viral	O
+attachment	O
+to	O
+host	B-COMP
+cells	B-COMP
+and	O
+disrupting	O
+cell	B-COMP
+-	O
+to	O
+-	O
+cell	B-COMP
+transmission	O
+;	O
+its	O
+dual	O
+mode	O
+of	O
+action	O
+distinguished	O
+Griffithsin	O
+from	O
+most	O
+other	O
+antiviral	B-CHED
+drugs	I-CHED
+.	O
+
+All	O
+samples	O
+from	O
+children	O
+showed	O
+coinfections	B-DISO
+(	O
+rhinovirus	B-SPEC
+was	O
+the	O
+most	O
+commonly	O
+detected	O
+).	O
+
+ABSTRACT	O
+:	O
+Porcine	B-SPEC
+rotavirus	B-SPEC
+(	O
+PoRV	O
+)	O
+and	O
+porcine	B-SPEC
+epidemic	I-SPEC
+diarrhea	I-SPEC
+virus	I-SPEC
+(	O
+PEDV	B-SPEC
+)	O
+usually	O
+co	O
+-	O
+infect	O
+pigs	B-SPEC
+in	O
+modern	O
+large	O
+-	O
+scale	O
+piggery	O
+,	O
+which	O
+both	O
+can	O
+cause	O
+severe	B-DISO
+diarrhea	I-DISO
+in	O
+newborn	O
+piglets	O
+and	O
+lead	O
+to	O
+significant	O
+economic	O
+losses	O
+to	O
+the	O
+pig	B-SPEC
+industry	O
+.	O
+
+The	O
+VP7	B-PRGE
+protein	I-PRGE
+is	O
+the	O
+main	O
+coat	B-ANAT
+protein	B-CHED
+of	O
+PoRV	O
+,	O
+and	O
+the	O
+S	B-PRGE
+protein	I-PRGE
+is	O
+the	O
+main	O
+structural	O
+protein	B-CHED
+of	O
+PEDV	B-SPEC
+,	O
+which	O
+are	O
+capable	O
+of	O
+inducing	O
+neutralizing	O
+antibodies	B-COMP
+in	O
+vivo	O
+.	O
+
+Although	O
+the	O
+IBVPR03	O
+strain	O
+is	O
+S1	O
+-	O
+genotyped	O
+as	O
+Massachusetts	O
+with	O
+a	O
+high	O
+genomic	O
+similarity	O
+to	O
+the	O
+H	O
+-	O
+120	O
+vaccine	O
+strains	O
+,	O
+surprisingly	O
+,	O
+we	O
+found	O
+no	O
+tropism	B-PROC
+or	O
+pathogenicity	O
+to	O
+the	O
+trachea	B-DISO
+in	O
+birds	B-SPEC
+infected	O
+with	O
+this	O
+strain	O
+.	O
+
+Ataxia	B-DISO
+was	O
+only	O
+seen	O
+in	O
+AIDP	B-DISO
+subtype	O
+while	O
+wrist	B-DISO
+drop	I-DISO
+,	O
+foot	B-DISO
+drop	I-DISO
+and	O
+hyperreflexia	O
+were	O
+seen	O
+only	O
+with	O
+AMAN	O
+subtype	O
+.	O
+
+Respiratory	B-ANAT
+muscle	I-ANAT
+involvement	O
+(	O
+6	O
+vs	O
+.	O
+3	O
+)	O
+and	O
+artificial	O
+ventilation	O
+(	O
+5	O
+vs	O
+.	O
+2	O
+)	O
+was	O
+more	O
+in	O
+AMAN	O
+.	O
+
+Although	O
+it	O
+remains	O
+to	O
+be	O
+shown	O
+in	O
+a	O
+prospective	O
+trial	O
+whether	O
+high	O
+volumes	O
+or	O
+pressures	O
+are	O
+injurious	O
+in	O
+pediatric	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+,	O
+tidal	O
+volume	O
+is	O
+likely	O
+an	O
+imprecise	O
+parameter	O
+for	O
+titrating	O
+lung	B-ANAT
+-	O
+protective	O
+ventilation	O
+.	O
+
+TITLE	O
+:	O
+Genetic	O
+and	O
+biological	O
+characteristics	O
+of	O
+four	O
+novel	O
+recombinant	O
+avian	B-DISO
+infectious	I-DISO
+bronchitis	I-DISO
+viruses	O
+isolated	O
+in	O
+China	O
+.	O
+
+In	O
+order	B-SPEC
+to	O
+confirm	O
+the	O
+previous	O
+results	O
+and	O
+further	O
+extend	O
+our	O
+understanding	O
+about	O
+the	O
+characteristics	O
+of	O
+the	O
+four	O
+recombinant	O
+IBV	B-SPEC
+strains	O
+we	O
+had	O
+previously	O
+identified	O
+(	O
+I0718	O
+/	O
+17	O
+,	O
+I0722	O
+/	O
+17	O
+,	O
+I0724	O
+/	O
+17	O
+,	O
+and	O
+I0737	O
+/	O
+17	O
+),	O
+we	O
+conducted	O
+phylogenetic	O
+analysis	O
+by	O
+comparing	O
+their	O
+complete	O
+S1	O
+gene	O
+sequences	O
+with	O
+those	O
+of	O
+71	O
+reference	O
+strains	O
+of	O
+different	O
+genotypes	O
+and	O
+lineages	O
+.	O
+
+Point	B-PROC
+mutations	I-PROC
+observed	O
+in	O
+the	O
+receptor	O
+-	O
+binding	B-FUNC
+domain	O
+and	O
+hypervariable	O
+region	O
+of	O
+the	O
+S1	O
+subunit	O
+of	O
+the	O
+spike	O
+protein	B-CHED
+likely	O
+have	O
+an	O
+effect	O
+on	O
+these	O
+differences	O
+in	O
+biological	O
+characteristics	O
+,	O
+although	O
+the	O
+influence	O
+of	O
+other	O
+factors	O
+-	O
+such	O
+as	O
+host	B-COMP
+innate	O
+-	O
+immune	B-PROC
+responses	I-PROC
+and	O
+changes	O
+in	O
+genomic	O
+regions	O
+beyond	O
+the	O
+S1	B-PRGE
+protein	I-PRGE
+-	O
+might	O
+also	O
+be	O
+responsible	O
+for	O
+such	O
+changes	O
+.	O
+
+Neither	O
+patient	O
+had	O
+received	O
+any	O
+pertussis	B-PATH
+vaccination	O
+since	O
+adolescence	O
+.	O
+
+Interestingly	O
+,	O
+significant	O
+inhibition	B-PROC
+of	O
+PEDV	B-SPEC
+by	O
+S	B-COMP
+-	I-COMP
+layer	I-COMP
+protein	B-CHED
+was	O
+only	O
+observed	O
+in	O
+the	O
+exclusion	O
+assay	O
+.	O
+
+In	O
+addition	O
+,	O
+the	O
+findings	O
+suggest	O
+that	O
+L	B-SPEC
+.	I-SPEC
+acidophilus	I-SPEC
+S	B-COMP
+-	I-COMP
+layer	I-COMP
+protein	B-CHED
+protects	O
+against	O
+PEDV	B-SPEC
+-	O
+induced	O
+apoptosis	B-PATH
+through	O
+reduced	O
+caspase	B-PRGE
+-	I-PRGE
+8	I-PRGE
+and	O
+caspase	B-PRGE
+-	I-PRGE
+3	I-PRGE
+activation	O
+in	O
+the	O
+later	O
+stages	O
+of	O
+infection	B-DISO
+.	O
+
+ABSTRACT	O
+:	O
+Use	O
+of	O
+extracorporeal	O
+membrane	B-COMP
+oxygenation	B-PROC
+(	O
+ECMO	O
+)	O
+in	O
+adults	O
+with	O
+severe	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+has	O
+increased	O
+in	O
+the	O
+past	O
+10	O
+years	O
+.	O
+
+Unlike	O
+ubiquitin	B-PROC
+,	O
+which	O
+is	O
+virtually	O
+identical	O
+across	O
+all	O
+animals	B-SPEC
+,	O
+comparison	O
+of	O
+ISG15s	O
+across	O
+species	B-SPEC
+reveals	O
+that	O
+they	O
+are	O
+relatively	O
+divergent	O
+,	O
+with	O
+sequence	O
+identity	O
+dropping	O
+to	O
+as	O
+low	O
+as	O
+∼	O
+58	O
+%	O
+among	O
+mammals	O
+.	O
+
+TITLE	O
+:	O
+Potent	O
+MERS	O
+-	O
+CoV	O
+Fusion	O
+Inhibitory	O
+Peptides	B-CHED
+Identified	O
+from	O
+HR2	O
+Domain	O
+in	O
+Spike	B-PRGE
+Protein	I-PRGE
+of	O
+Bat	B-ENZY
+Coronavirus	I-SPEC
+HKU4	I-SPEC
+.	O
+
+However	O
+,	O
+two	O
+outbreaks	O
+of	O
+severe	O
+respiratory	B-DISO
+tract	I-DISO
+infection	I-DISO
+,	O
+caused	O
+by	O
+the	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+coronavirus	B-SPEC
+(	O
+SARS	B-DISO
+-	O
+CoV	O
+)	O
+and	O
+the	O
+Middle	O
+East	O
+respiratory	O
+syndrome	B-DISO
+coronavirus	B-SPEC
+(	O
+MERS	O
+-	O
+CoV	O
+),	O
+as	O
+a	O
+result	O
+of	O
+zoonotic	O
+CoVs	O
+crossing	O
+the	O
+species	B-SPEC
+barrier	O
+,	O
+caused	O
+high	O
+pathogenicity	O
+and	O
+mortality	O
+rates	O
+in	O
+human	B-SPEC
+populations	O
+.	O
+
+TITLE	O
+:	O
+Two	O
+critical	O
+N	O
+-	O
+terminal	O
+epitopes	O
+of	O
+the	O
+nucleocapsid	B-PRGE
+protein	B-CHED
+contribute	O
+to	O
+the	O
+cross	O
+-	O
+reactivity	O
+between	O
+porcine	O
+epidemic	O
+diarrhea	O
+virus	O
+and	O
+porcine	B-DISO
+transmissible	I-DISO
+gastroenteritis	I-DISO
+virus	B-SPEC
+.	O
+
+TITLE	O
+:	O
+Angiopoietin	B-PRGE
+-	I-PRGE
+2	I-PRGE
+as	O
+a	O
+predictor	O
+of	O
+acute	O
+kidney	B-ANAT
+injury	O
+in	O
+critically	B-DISO
+ill	I-DISO
+patients	O
+and	O
+association	O
+with	O
+ARDS	O
+.	O
+
+RESULTS	O
+:	O
+Among	O
+283	O
+patients	O
+(	O
+50	O
+.	O
+2	O
+%	O
+males	O
+),	O
+109	O
+(	O
+38	O
+.	O
+5	O
+%)	O
+had	O
+ARDS	B-DISO
+.	O
+
+To	O
+this	O
+end	O
+,	O
+we	O
+utilized	O
+the	O
+human	B-SPEC
+coronavirus	I-SPEC
+229E	I-SPEC
+(	O
+HCoV	B-SPEC
+-	I-SPEC
+229E	I-SPEC
+)	O
+as	O
+a	O
+model	O
+coronavirus	B-SPEC
+to	O
+comprehensively	O
+characterize	O
+the	O
+host	B-COMP
+cell	I-COMP
+lipid	B-CHED
+response	O
+upon	O
+coronavirus	B-DISO
+infection	I-DISO
+with	O
+an	O
+ultra	O
+-	O
+high	O
+performance	O
+liquid	O
+chromatography	O
+-	O
+mass	O
+spectrometry	O
+(	O
+UPLC	O
+⁻	O
+MS	O
+)-	O
+based	O
+lipidomics	O
+approach	O
+.	O
+
+Interestingly	O
+,	O
+exogenous	O
+supplement	O
+of	O
+LA	O
+or	O
+AA	O
+in	O
+HCoV	B-SPEC
+-	I-SPEC
+229E	I-SPEC
+-	O
+infected	O
+cells	B-COMP
+significantly	O
+suppressed	O
+HCoV	B-SPEC
+-	I-SPEC
+229E	I-SPEC
+virus	B-PROC
+replication	I-PROC
+.	O
+
+Taken	O
+together	O
+,	O
+our	O
+study	O
+demonstrated	O
+that	O
+host	B-COMP
+lipid	B-CHED
+metabolic	B-PROC
+remodeling	O
+was	O
+significantly	O
+associated	O
+with	O
+human	B-SPEC
+-	O
+pathogenic	O
+coronavirus	B-SPEC
+propagation	O
+.	O
+
+As	O
+compared	O
+with	O
+pressure	O
+-	O
+volume	O
+curve	O
+,	O
+the	O
+EIT	O
+-	O
+guided	O
+PEEP	B-CHED
+titration	O
+may	O
+be	O
+associated	O
+with	O
+improved	O
+oxygenation	B-PROC
+,	O
+compliance	O
+,	O
+driving	O
+pressure	O
+,	O
+and	O
+weaning	B-PROC
+success	O
+rate	O
+.	O
+
+TITLE	O
+:	O
+Middle	O
+East	O
+Respiratory	O
+Syndrome	B-DISO
+Vaccine	O
+Candidates	O
+:	O
+Cautious	O
+Optimism	O
+.	O
+
+In	O
+this	O
+review	O
+,	O
+we	O
+summarize	O
+the	O
+current	O
+progress	O
+towards	O
+a	O
+MERS	O
+-	O
+CoV	O
+vaccine	O
+and	O
+highlight	O
+potential	O
+roadblocks	O
+identified	O
+from	O
+previous	O
+attempts	O
+to	O
+generate	O
+coronavirus	B-SPEC
+vaccines	O
+.	O
+
+RESULTS	O
+:	O
+The	O
+mAbs	O
+were	O
+prepared	O
+by	O
+using	O
+PEDV	B-SPEC
+positive	O
+hybridoma	B-ANAT
+cells	B-COMP
+that	O
+were	O
+selected	O
+by	O
+using	O
+cell	B-COMP
+surface	I-COMP
+fluorescence	O
+immunosorbent	O
+assay	O
+(	O
+CSFIA	O
+).	O
+
+During	O
+inflammatory	O
+processes	O
+,	O
+VE	B-PRGE
+-	I-PRGE
+cadherin	I-PRGE
+is	O
+shed	O
+into	O
+circulation	B-PROC
+(	O
+sVE	B-PRGE
+-	I-PRGE
+cadherin	I-PRGE
+).	O
+
+Plasma	B-PRGE
+sVE	I-PRGE
+-	I-PRGE
+cadherin	I-PRGE
+is	O
+elevated	O
+in	O
+sepsis	B-DISO
+,	O
+malignancy	B-DISO
+,	O
+autoimmune	B-DISO
+diseases	I-DISO
+,	O
+and	O
+coronary	B-DISO
+atherosclerosis	I-DISO
+.	O
+
+The	O
+present	O
+study	O
+is	O
+a	O
+prospective	O
+study	O
+of	O
+critically	B-DISO
+ill	I-DISO
+adults	O
+with	O
+sepsis	B-DISO
+and	O
+acute	B-DISO
+respiratory	I-DISO
+failure	I-DISO
+(	O
+age	O
+≥	O
+18	O
+years	O
+)	O
+enrolled	O
+in	O
+the	O
+Validating	O
+Acute	O
+Lung	B-ANAT
+Injury	O
+markers	O
+for	O
+Diagnosis	O
+(	O
+VALID	O
+)	O
+study	O
+.	O
+
+Plasma	B-ANAT
+sVE	I-PRGE
+-	I-PRGE
+cadherin	I-PRGE
+was	O
+measured	O
+at	O
+study	O
+enrollment	O
+.	O
+
+Shedding	O
+of	O
+sVE	B-PRGE
+-	I-PRGE
+cadherin	I-PRGE
+is	O
+associated	O
+with	O
+severe	O
+acute	O
+kidney	B-ANAT
+injury	O
+and	O
+with	O
+more	O
+severe	O
+organ	B-ANAT
+dysfunction	O
+in	O
+patients	O
+with	O
+sepsis	B-DISO
+,	O
+suggesting	O
+that	O
+breakdown	B-DISO
+of	O
+endothelial	B-ANAT
+adherens	B-COMP
+junctions	I-COMP
+may	O
+contribute	O
+to	O
+the	O
+pathogenesis	B-DISO
+of	O
+organ	B-ANAT
+dysfunction	O
+in	O
+sepsis	B-DISO
+.	O
+
+Further	O
+studies	O
+of	O
+sVE	B-PRGE
+-	I-PRGE
+cadherin	I-PRGE
+as	O
+a	O
+biomarker	B-CHED
+of	O
+disease	O
+severity	O
+in	O
+clinical	B-DISO
+sepsis	I-DISO
+are	O
+needed	O
+to	O
+better	O
+elucidate	O
+the	O
+role	O
+of	O
+VE	B-PRGE
+-	I-PRGE
+cadherin	I-PRGE
+shedding	O
+in	O
+sepsis	B-DISO
+-	O
+induced	O
+severe	O
+organ	B-ANAT
+dysfunction	O
+.	O
+
+We	O
+measured	O
+metrics	O
+for	O
+oxygenation	B-PROC
+,	O
+ventilation	O
+,	O
+and	O
+haemodynamics	O
+as	O
+well	O
+as	O
+the	O
+use	O
+of	O
+sedative	B-CHED
+-	O
+analgesic	B-CHED
+medications	O
+and	O
+neuromuscular	O
+blocking	B-DISO
+agents	O
+.	O
+
+Here	O
+we	O
+demonstrate	O
+that	O
+certain	O
+viral	O
+nanoparticles	B-CHED
+(	O
+VNPs	O
+)	O
+can	O
+evade	O
+the	O
+adhesion	B-DISO
+of	O
+a	O
+broad	O
+panel	O
+of	O
+macromolecules	B-CHED
+from	O
+several	O
+biological	O
+milieus	O
+.	O
+
+ABSTRACT	O
+:	O
+In	O
+the	O
+last	O
+two	O
+decades	O
+,	O
+several	O
+high	O
+impact	O
+zoonotic	O
+disease	O
+outbreaks	O
+have	O
+been	O
+linked	O
+to	O
+bat	O
+-	O
+borne	O
+viruses	B-SPEC
+.	O
+
+In	O
+addition	O
+,	O
+it	O
+has	O
+been	O
+suspected	O
+that	O
+ebolaviruses	B-SPEC
+and	O
+MERS	O
+coronavirus	B-SPEC
+are	O
+also	O
+linked	O
+to	O
+bats	B-SPEC
+.	O
+
+It	O
+is	O
+being	O
+increasingly	O
+accepted	O
+that	O
+bats	B-SPEC
+are	O
+potential	O
+reservoirs	O
+of	O
+a	O
+large	O
+number	O
+of	O
+known	O
+and	O
+unknown	O
+viruses	B-SPEC
+,	O
+many	O
+of	O
+which	O
+could	O
+spillover	O
+into	O
+animal	B-SPEC
+and	O
+human	B-SPEC
+populations	O
+.	O
+
+EVs	O
+were	O
+co	O
+-	O
+cultured	O
+with	O
+lung	B-ANAT
+human	B-SPEC
+microvascular	O
+endothelial	B-ANAT
+cells	I-ANAT
+(	O
+HMVEC	O
+-	O
+L	O
+)	O
+to	O
+evaluate	O
+inflammasome	O
+activation	O
+and	O
+endothelial	B-ANAT
+cell	I-ANAT
+pyroptosis	B-PROC
+.	O
+
+Delivery	O
+of	O
+serum	B-COMP
+-	O
+derived	O
+EVs	O
+to	O
+HMVEC	O
+-	O
+L	O
+activated	O
+the	O
+inflammasome	O
+and	O
+resulted	O
+in	O
+endothelial	B-ANAT
+cell	I-ANAT
+pyroptosis	B-PROC
+.	O
+
+Thus	O
+,	O
+serum	B-COMP
+-	O
+derived	O
+EVs	O
+and	O
+inflammasome	O
+proteins	B-CHED
+play	O
+a	O
+critical	O
+role	O
+in	O
+the	O
+pathogenesis	B-DISO
+of	O
+TBI	O
+-	O
+induced	O
+lung	B-ANAT
+injury	O
+,	O
+supporting	O
+activation	O
+of	O
+an	O
+EV	O
+-	O
+mediated	O
+neural	O
+-	O
+respiratory	O
+inflammasome	O
+axis	B-SPEC
+in	O
+TBI	O
+-	O
+induced	O
+lung	B-ANAT
+injury	O
+.	O
+
+There	O
+has	O
+been	O
+slow	O
+but	O
+incremental	O
+progress	O
+in	O
+identification	O
+of	O
+biomarkers	O
+that	O
+contribute	O
+to	O
+the	O
+pathophysiology	O
+of	O
+ARDS	B-DISO
+,	O
+have	O
+utility	O
+in	O
+diagnosis	O
+and	O
+monitoring	O
+,	O
+and	O
+that	O
+are	O
+potential	O
+therapeutic	O
+targets	O
+(	O
+Calfee	O
+CS	O
+,	O
+Delucchi	O
+K	O
+,	O
+Parsons	O
+PE	O
+,	O
+Thompson	O
+BT	O
+,	O
+Ware	O
+LB	O
+,	O
+Matthay	O
+MA	O
+,	O
+Thompson	O
+T	O
+,	O
+Ware	O
+LB	O
+,	O
+Matthay	O
+MA	O
+,	O
+Lancet	O
+Respir	O
+Med	O
+2014	O
+,	O
+2	O
+:	O
+611	O
+--	O
+620	O
+).	O
+
+The	O
+relationship	O
+between	O
+bronchoalveolar	O
+lavage	O
+neutrophil	B-ANAT
+extracellular	B-COMP
+trap	O
+concentrations	O
+and	O
+the	O
+primary	O
+clinical	O
+endpoint	O
+(	O
+i	O
+.	O
+e	O
+.,	O
+the	O
+number	O
+of	O
+live	O
+ventilator	O
+-	O
+free	O
+days	O
+at	O
+day	O
+28	O
+)	O
+was	O
+assessed	O
+using	O
+linear	O
+regression	O
+analyses	O
+.	O
+
+Bronchoalveolar	O
+concentrations	O
+of	O
+patients	O
+were	O
+higher	O
+than	O
+those	O
+of	O
+controls	O
+(	O
+154	O
+[	O
+74	O
+to	O
+1	O
+,	O
+000	O
+]	O
+vs	O
+.	O
+4	O
+[	O
+4	O
+to	O
+4	O
+]	O
+arbitrary	O
+units	O
+,	O
+difference	O
+:	O
+-	O
+150	O
+;	O
+95	O
+%	O
+CI	O
+,	O
+-	O
+996	O
+to	O
+-	O
+64	O
+;	O
+P	O
+<	O
+0	O
+.	O
+001	O
+)	O
+and	O
+associated	O
+with	O
+bronchoalveolar	O
+interleukin	B-PRGE
+-	I-PRGE
+8	I-PRGE
+(	O
+Spearman	O
+'	O
+s	O
+ρ	O
+=	O
+0	O
+.	O
+42	O
+;	O
+P	O
+=	O
+0	O
+.	O
+012	O
+)	O
+and	O
+neutrophil	B-ANAT
+concentrations	O
+(	O
+ρ	O
+=	O
+0	O
+.	O
+57	O
+;	O
+P	O
+<	O
+0	O
+.	O
+0001	O
+).	O
+
+Intensive	O
+care	O
+unit	O
+mortality	O
+(	O
+12	O
+%,	O
+n	O
+=	O
+2	O
+of	O
+17	O
+vs	O
+.	O
+17	O
+%,	O
+n	O
+=	O
+3	O
+of	O
+18	O
+;	O
+P	O
+>	O
+0	O
+.	O
+99	O
+)	O
+and	O
+the	O
+number	O
+of	O
+ventilator	O
+-	O
+free	O
+days	O
+at	O
+day	O
+28	O
+(	O
+22	O
+[	O
+14	O
+to	O
+25	O
+]	O
+vs	O
+.	O
+14	O
+[	O
+0	O
+to	O
+21	O
+]	O
+days	O
+;	O
+difference	O
+:	O
+-	O
+5	O
+;	O
+95	O
+%	O
+CI	O
+,	O
+-	O
+15	O
+to	O
+0	O
+;	O
+P	O
+=	O
+0	O
+.	O
+066	O
+)	O
+did	O
+not	O
+significantly	O
+differ	O
+between	O
+patients	O
+with	O
+higher	O
+(	O
+n	O
+=	O
+17	O
+)	O
+versus	O
+lower	O
+(	O
+n	O
+=	O
+18	O
+)	O
+bronchoalveolar	O
+neutrophil	B-ANAT
+extracellular	B-COMP
+trap	O
+concentrations	O
+.	O
+
+Compared	O
+with	O
+the	O
+genome	O
+of	O
+the	O
+prototype	O
+strain	O
+CV777	O
+,	O
+these	O
+strains	O
+had	O
+103	O
+-	O
+120	O
+amino	B-CHED
+acid	I-CHED
+mutations	O
+in	O
+their	O
+S	O
+proteins	B-CHED
+,	O
+most	O
+of	O
+which	O
+were	O
+in	O
+the	O
+N	O
+terminal	O
+domain	O
+of	O
+S1	O
+(	O
+S1	O
+-	O
+NTD	O
+).	O
+
+TITLE	O
+:	O
+Human	B-SPEC
+coronaviruses	O
+OC43	O
+and	O
+HKU1	O
+bind	B-FUNC
+to	O
+9	O
+-	O
+ABSTRACT	O
+:	O
+Human	B-PRGE
+betacoronaviruses	I-PRGE
+OC43	I-PRGE
+and	O
+HKU1	O
+are	O
+endemic	O
+respiratory	O
+pathogens	O
+and	O
+,	O
+while	O
+related	O
+,	O
+originated	O
+from	O
+independent	O
+zoonotic	O
+introductions	O
+.	O
+
+During	O
+the	O
+recent	O
+increased	O
+immigration	O
+proceedings	O
+,	O
+customs	O
+officers	O
+have	O
+been	O
+involved	O
+in	O
+detaining	O
+unauthorized	O
+populations	O
+for	O
+various	O
+infectious	B-DISO
+diseases	I-DISO
+,	O
+such	O
+as	O
+tuberculosis	B-PATH
+,	O
+varicella	B-DISO
+and	O
+measles	B-PATH
+.	O
+
+TITLE	O
+:	O
+Epidemiology	O
+of	O
+porcine	B-SPEC
+epidemic	I-SPEC
+diarrhea	I-SPEC
+virus	I-SPEC
+among	O
+Chinese	O
+pig	B-SPEC
+populations	O
+:	O
+A	O
+meta	B-SPEC
+-	O
+analysis	O
+.	O
+
+Finally	O
+,	O
+we	O
+extracted	O
+the	O
+number	O
+of	O
+swine	B-SPEC
+with	O
+PEDV	B-SPEC
+infection	B-DISO
+from	O
+the	O
+obtained	O
+studies	O
+and	O
+provided	O
+information	O
+that	O
+permitted	O
+us	O
+to	O
+estimate	O
+the	O
+prevalence	O
+of	O
+PEDV	O
+infection	B-DISO
+in	O
+pigs	B-SPEC
+in	O
+mainland	O
+China	O
+.	O
+
+A	O
+total	O
+of	O
+45	O
+studies	O
+(	O
+including	O
+data	O
+from	O
+15	O
+,	O
+990	O
+pigs	B-SPEC
+)	O
+met	B-CHED
+our	O
+evaluation	O
+criteria	O
+.	O
+
+Our	O
+findings	O
+suggest	O
+that	O
+PEDV	B-SPEC
+infection	B-DISO
+is	O
+common	O
+among	O
+pigs	B-SPEC
+in	O
+China	O
+.	O
+
+It	O
+is	O
+predicted	O
+that	O
+the	O
+inherent	O
+genetic	O
+diversity	O
+of	O
+CoVs	O
+caused	O
+by	O
+accumulation	O
+of	O
+point	B-PROC
+mutations	I-PROC
+and	O
+high	O
+frequency	O
+of	O
+homologous	B-PATH
+recombination	I-PATH
+is	O
+the	O
+principal	O
+determinant	O
+of	O
+these	O
+competences	O
+.	O
+
+The	O
+presented	O
+data	O
+denote	O
+the	O
+importance	O
+of	O
+these	O
+viruses	B-SPEC
+in	O
+the	O
+persistence	O
+of	O
+BCoV	O
+in	O
+nature	O
+,	O
+spread	O
+to	O
+new	O
+geographical	O
+zones	O
+,	O
+and	O
+continuous	O
+emergence	O
+of	O
+disease	O
+epidemics	O
+in	O
+cattle	B-SPEC
+farms	O
+.	O
+
+There	O
+has	O
+been	O
+an	O
+increase	O
+in	O
+reported	O
+cases	O
+of	O
+primary	B-DISO
+peritonitis	I-DISO
+due	O
+to	O
+Streptococcus	B-SPEC
+pyogenes	I-SPEC
+affecting	O
+mostly	O
+women	O
+.	O
+
+It	O
+usually	O
+presents	O
+as	O
+a	O
+severe	O
+acute	B-DISO
+abdominal	I-DISO
+pain	I-DISO
+,	O
+which	O
+prompts	O
+surgical	O
+exploration	O
+.	O
+
+This	O
+study	O
+was	O
+to	O
+investigate	O
+the	O
+relationship	O
+between	O
+complete	O
+blood	B-ANAT
+count	O
+(	O
+CBC	B-COMP
+)	O
+parameters	O
+and	O
+the	O
+incidence	O
+of	O
+ARDS	B-DISO
+in	O
+severe	O
+burn	O
+patients	O
+.	O
+
+The	O
+findings	O
+of	O
+this	O
+study	O
+suggest	O
+that	O
+an	O
+elevated	O
+RDW	O
+is	O
+associated	O
+with	O
+an	O
+increased	O
+risk	O
+of	O
+ARDS	B-DISO
+and	O
+RDW	O
+is	O
+an	O
+independent	O
+risk	O
+factor	O
+in	O
+the	O
+prediction	O
+of	O
+ARDS	B-DISO
+after	O
+severe	O
+burns	O
+.	O
+
+In	O
+this	O
+study	O
+,	O
+we	O
+used	O
+peptides	O
+mimicking	O
+the	O
+cleavage	B-PROC
+site	O
+motifs	O
+of	O
+the	O
+coronavirus	B-SPEC
+spike	O
+protein	B-CHED
+.	O
+
+There	O
+are	O
+still	O
+limited	O
+data	O
+about	O
+distribution	O
+of	O
+acute	O
+viral	O
+respiratory	B-DISO
+infections	I-DISO
+in	O
+children	O
+with	O
+cancer	B-DISO
+.	O
+
+Our	O
+second	O
+aim	O
+was	O
+to	O
+evaluate	O
+the	O
+impact	O
+of	O
+viral	B-DISO
+infections	I-DISO
+on	O
+delaying	O
+the	O
+patients	O
+'	O
+chemotherapy	O
+or	O
+radiotherapy	O
+.	O
+
+TITLE	O
+:	O
+2018	O
+international	O
+meeting	O
+of	O
+the	O
+Global	O
+Virus	B-SPEC
+Network	O
+.	O
+
+These	O
+findings	O
+indicate	O
+that	O
+macrolide	B-CHED
+therapy	O
+is	O
+not	O
+associated	O
+with	O
+a	O
+reduction	O
+in	O
+90	O
+-	O
+day	O
+mortality	O
+or	O
+improvement	O
+in	O
+MERS	O
+-	O
+CoV	O
+RNA	O
+clearance	O
+.	O
+
+Macrolide	B-CHED
+therapy	O
+was	O
+not	O
+independently	O
+associated	O
+with	O
+a	O
+significant	O
+difference	O
+in	O
+90	O
+-	O
+day	O
+mortality	O
+(	O
+adjusted	O
+odds	O
+ratio	O
+[	O
+OR	O
+]:	O
+0	O
+.	O
+84	O
+;	O
+95	O
+%	O
+confidence	O
+interval	O
+[	O
+CI	O
+]	O
+:	O
+0	O
+.	O
+47	O
+-	O
+1	O
+.	O
+51	O
+;	O
+P	O
+=	O
+0	O
+.	O
+56	O
+)	O
+or	O
+MERS	O
+-	O
+CoV	O
+RNA	O
+clearance	O
+(	O
+adjusted	O
+HR	O
+:	O
+0	O
+.	O
+88	O
+;	O
+95	O
+%	O
+CI	O
+:	O
+0	O
+.	O
+47	O
+-	O
+1	O
+.	O
+64	O
+;	O
+P	O
+=	O
+0	O
+.	O
+68	O
+).	O
+
+TITLE	O
+:	O
+Effect	O
+of	O
+experimental	O
+Ornithobacterium	B-SPEC
+rhinotracheale	I-SPEC
+infection	B-DISO
+along	O
+with	O
+live	O
+infectious	B-DISO
+bronchitis	B-DISO
+vaccination	O
+in	O
+broiler	O
+chickens	B-SPEC
+.	O
+
+The	O
+objective	O
+of	O
+this	O
+study	O
+was	O
+to	O
+investigate	O
+the	O
+role	O
+of	O
+the	O
+live	O
+variant	O
+IBV	B-SPEC
+4	O
+/	O
+91	O
+with	O
+ORT	O
+infection	B-DISO
+.	O
+
+A	O
+total	O
+of	O
+120	O
+14	O
+-	O
+d	O
+-	O
+old	O
+broiler	O
+chickens	B-SPEC
+(	O
+Cobb	B-FUNC
+500	O
+)	O
+were	O
+equally	O
+divided	O
+into	O
+4	O
+groups	O
+for	O
+experimental	O
+infection	B-DISO
+in	O
+a	O
+complete	O
+randomized	O
+design	O
+.	O
+
+This	O
+study	O
+screened	O
+mesenteric	B-ANAT
+lymph	I-ANAT
+nodes	I-ANAT
+(	O
+MLNs	B-DISO
+),	O
+the	O
+presumed	O
+first	O
+site	O
+of	O
+FCoV	O
+spread	O
+from	O
+the	O
+intestine	B-ANAT
+regardless	O
+of	O
+viraemia	B-DISO
+,	O
+for	O
+changes	O
+in	O
+the	O
+transcription	B-PROC
+of	O
+a	O
+panel	O
+of	O
+innate	B-DISO
+immune	I-DISO
+response	I-DISO
+mediators	O
+in	O
+response	O
+to	O
+systemic	O
+FCoV	O
+infection	B-DISO
+and	O
+with	O
+FIP	B-DISO
+,	O
+aiming	O
+to	O
+identify	O
+key	O
+pathways	B-PROC
+triggered	O
+by	O
+FCoV	O
+.	O
+Cats	B-SPEC
+with	O
+and	O
+without	O
+FIP	B-DISO
+,	O
+the	O
+latter	O
+with	O
+and	O
+without	O
+FCoV	O
+infection	B-DISO
+in	O
+the	O
+MLN	O
+,	O
+were	O
+compared	O
+.	O
+
+Higher	O
+expression	O
+levels	O
+in	O
+FIP	B-DISO
+were	O
+found	O
+for	O
+toll	O
+-	O
+like	O
+receptors	O
+(	O
+TLRs	O
+)	O
+2	O
+,	O
+4	O
+and	O
+8	O
+.	O
+
+TITLE	O
+:	O
+Immunocytochemistry	O
+of	O
+mesenteric	B-ANAT
+lymph	I-ANAT
+node	I-ANAT
+fine	O
+-	O
+needle	O
+aspirates	B-ANAT
+in	O
+the	O
+diagnosis	O
+of	O
+feline	B-SPEC
+infectious	I-DISO
+peritonitis	I-DISO
+.	O
+
+FIP	B-DISO
+was	O
+confirmed	O
+immunohistochemically	O
+in	O
+30	O
+cats	B-SPEC
+.	O
+
+Sensitivity	O
+,	O
+specificity	O
+,	O
+negative	O
+and	O
+positive	O
+predictive	O
+values	O
+(	O
+NPV	O
+,	O
+PPV	B-CHED
+,	O
+respectively	O
+)	O
+including	O
+95	O
+%	O
+confidence	O
+intervals	O
+(	O
+95	O
+%	O
+CIs	B-DISO
+)	O
+were	O
+determined	O
+.	O
+
+In	O
+a	O
+lethal	O
+disease	O
+such	O
+as	O
+FIP	B-DISO
+,	O
+specificity	O
+is	O
+most	O
+important	O
+in	O
+order	B-SPEC
+to	O
+avoid	O
+euthanasia	O
+of	O
+unaffected	O
+cats	B-SPEC
+.	O
+
+TITLE	O
+:	O
+Research	O
+on	O
+the	O
+Mechanism	O
+of	O
+Cross	O
+-	O
+species	B-SPEC
+Infection	B-DISO
+and	O
+Transmission	O
+for	O
+Animal	B-SPEC
+-	O
+origin	O
+Emerging	O
+and	O
+Re	O
+-	O
+emerging	O
+Zoonosis	O
+Has	O
+Won	O
+Support	O
+by	O
+the	O
+National	O
+Key	O
+Research	O
+and	O
+Development	B-PROC
+Program	O
+of	O
+China	O
+.	O
+
+ABSTRACT	O
+:	O
+Emerging	O
+and	O
+re	O
+-	O
+emerging	O
+zoonotic	O
+diseases	O
+caused	O
+by	O
+pathogens	O
+such	O
+as	O
+Middle	O
+East	O
+respiratory	O
+syndrome	B-DISO
+coronavirus	B-SPEC
+(	O
+MERS	O
+-	O
+CoV	O
+),	O
+West	B-DISO
+Nile	I-DISO
+virus	I-DISO
+(	O
+WNV	B-DISO
+)	O
+or	O
+Chikungunya	B-SPEC
+virus	I-SPEC
+(	O
+CHIKV	O
+)	O
+pose	O
+considerable	O
+threats	O
+to	O
+public	O
+health	O
+worldwide	O
+.	O
+
+TITLE	O
+:	O
+Shared	O
+Common	O
+Ancestry	O
+of	O
+Rodent	B-SPEC
+Alphacoronaviruses	O
+Sampled	O
+Globally	O
+.	O
+
+These	O
+data	O
+suggest	O
+that	O
+all	O
+rodent	B-SPEC
+alpha	O
+CoVs	O
+sampled	O
+so	O
+far	O
+originate	O
+from	O
+a	O
+single	O
+common	O
+ancestor	O
+,	O
+and	O
+that	O
+there	O
+has	O
+likely	O
+been	O
+a	O
+long	O
+-	O
+term	O
+association	O
+between	O
+alpha	O
+CoVs	O
+and	O
+rodents	B-SPEC
+.	O
+
+ABSTRACT	O
+:	O
+Coronaviruses	O
+,	O
+including	O
+bovine	B-SPEC
+coronavirus	B-SPEC
+(	O
+BCoV	O
+),	O
+are	O
+etiologically	O
+associated	O
+with	O
+enteric	O
+and	O
+respiratory	B-DISO
+disease	I-DISO
+across	O
+a	O
+wide	O
+range	O
+of	O
+mammalian	B-SPEC
+and	O
+avian	B-SPEC
+species	B-SPEC
+.	O
+
+Serologic	O
+tests	O
+are	O
+widely	O
+accepted	O
+and	O
+used	O
+to	O
+detect	O
+anti	O
+-	O
+PEDV	B-SPEC
+antibodies	B-COMP
+that	O
+could	O
+indicate	O
+PEDV	B-SPEC
+infection	B-DISO
+or	O
+vaccination	O
+.	O
+
+The	O
+antibody	B-COMP
+could	O
+be	O
+detected	O
+2	O
+-	O
+4	O
+weeks	O
+after	O
+the	O
+first	O
+inoculation	O
+.	O
+
+ABSTRACT	O
+:	O
+Lyme	B-DISO
+disease	I-DISO
+is	O
+not	O
+uncommon	O
+and	O
+can	O
+sometimes	O
+progress	O
+to	O
+neurological	O
+complications	O
+.	O
+
+IgG	B-PRGE
+and	O
+IgM	B-PRGE
+antibodies	B-COMP
+to	O
+Borrelia	B-SPEC
+burgdorferi	I-SPEC
+were	O
+detectable	O
+in	O
+serum	O
+and	O
+cerebrospinal	B-ANAT
+fluid	I-ANAT
+,	O
+leading	O
+to	O
+the	O
+diagnosis	O
+of	O
+Lyme	B-DISO
+disease	I-DISO
+.	O
+
+In	O
+the	O
+presence	O
+of	O
+unilateral	O
+or	O
+bilateral	O
+diaphragmatic	B-ANAT
+paralysis	O
+of	O
+undetermined	O
+aetiology	O
+,	O
+it	O
+seems	O
+relevant	O
+to	O
+perform	O
+Lyme	O
+serology	O
+in	O
+the	O
+blood	B-ANAT
+and	O
+,	O
+in	O
+positive	O
+cases	O
+,	O
+to	O
+follow	O
+up	O
+with	O
+a	O
+lumbar	B-ANAT
+puncture	O
+in	O
+order	B-SPEC
+to	O
+detect	O
+intrathecal	B-ANAT
+IgG	B-PRGE
+synthesis	B-PROC
+.	O
+
+This	O
+review	O
+discusses	O
+current	O
+knowledge	O
+,	O
+prospective	O
+applications	O
+and	O
+challenges	O
+in	O
+the	O
+repurposing	O
+of	O
+clinically	O
+approved	O
+and	O
+preclinically	O
+studied	O
+drugs	O
+for	O
+newly	O
+indicated	O
+antiviral	B-CHED
+therapeutics	O
+.	O
+
+ABSTRACT	O
+:	O
+Recent	O
+outbreaks	O
+of	O
+severe	O
+acute	O
+respiratory	O
+syndrome	O
+and	O
+Middle	O
+East	O
+respiratory	O
+syndrome	B-DISO
+,	O
+along	O
+with	O
+the	O
+threat	O
+of	O
+a	O
+future	O
+coronavirus	B-SPEC
+-	O
+mediated	O
+pandemic	O
+,	O
+underscore	O
+the	O
+importance	O
+of	O
+finding	O
+ways	O
+to	O
+combat	B-CHED
+these	O
+viruses	B-SPEC
+.	O
+
+ABSTRACT	O
+:	O
+Tension	O
+pneumoperitoneum	B-DISO
+is	O
+a	O
+severe	O
+and	O
+rare	O
+form	O
+of	O
+pneumoperitoneum	B-DISO
+with	O
+concomitant	O
+hemodynamic	B-DISO
+instability	I-DISO
+and	O
+respiratory	B-DISO
+failure	I-DISO
+.	O
+
+It	O
+is	O
+a	O
+variant	O
+of	O
+abdominal	B-DISO
+compartment	I-DISO
+syndrome	I-DISO
+(	O
+ACS	B-FUNC
+)	O
+causing	O
+an	O
+abrupt	O
+increase	O
+in	O
+intra	O
+-	O
+abdominal	B-ANAT
+pressure	O
+.	O
+
+TITLE	O
+:	O
+Effect	O
+of	O
+Pullet	O
+Vaccination	O
+on	O
+Development	B-PROC
+and	O
+Longevity	O
+of	O
+Immunity	B-PROC
+.	O
+
+Our	O
+objective	O
+was	O
+to	O
+determine	O
+whether	O
+serially	O
+administered	O
+,	O
+live	O
+attenuated	O
+vaccines	O
+against	O
+IBV	B-SPEC
+,	O
+NDV	B-SPEC
+,	O
+and	O
+ILTV	B-SPEC
+influence	O
+the	O
+development	B-PROC
+and	O
+longevity	O
+of	O
+immunity	B-PROC
+and	O
+protection	O
+against	O
+challenge	O
+in	O
+long	O
+-	O
+lived	O
+birds	B-SPEC
+.	O
+
+Five	O
+days	O
+post	O
+-	O
+challenge	O
+,	O
+viral	O
+load	O
+,	O
+clinical	O
+signs	O
+,	O
+ciliostasis	O
+,	O
+tracheal	O
+histopathology	O
+,	O
+and	O
+antibody	B-COMP
+titers	O
+in	O
+serum	B-COMP
+and	O
+tears	B-ANAT
+were	O
+evaluated	O
+.	O
+
+TITLE	O
+:	O
+Development	B-PROC
+and	O
+Evaluation	O
+of	O
+a	O
+Multiplexed	O
+Immunoassay	O
+for	O
+Simultaneous	O
+Detection	O
+of	O
+Serum	B-COMP
+IgG	B-PRGE
+Antibodies	I-PRGE
+to	O
+Six	O
+Human	B-SPEC
+Coronaviruses	O
+.	O
+
+ABSTRACT	O
+:	O
+To	O
+address	O
+more	O
+information	O
+about	O
+changes	O
+in	O
+commensal	O
+Escherichia	B-SPEC
+coli	I-SPEC
+during	O
+virus	B-SPEC
+intestinal	B-DISO
+infection	I-DISO
+,	O
+we	O
+characterized	O
+30	O
+faecal	B-ANAT
+E	B-SPEC
+.	I-SPEC
+coli	I-SPEC
+isolates	O
+from	O
+calves	O
+(	O
+21	O
+to	O
+60	O
+days	O
+old	O
+)	O
+with	O
+diarrhea	B-DISO
+due	O
+to	O
+rotavirus	B-SPEC
+and	O
+coronavirus	B-SPEC
+,	O
+which	O
+received	O
+,	O
+before	O
+diagnosis	O
+,	O
+tetracycline	B-CHED
+,	O
+gentamicin	B-CHED
+and	O
+enrofloxacin	B-CHED
+drugs	O
+.	O
+
+E	B-SPEC
+.	I-SPEC
+coli	I-SPEC
+isolates	O
+from	O
+calves	O
+with	O
+diarrhea	B-DISO
+were	O
+phylogenetically	O
+classified	O
+as	O
+B1	O
+(	O
+70	O
+%,	O
+21	O
+/	O
+30	O
+),	O
+B2	O
+(	O
+3	O
+.	O
+33	O
+%,	O
+1	O
+/	O
+30	O
+),	O
+C	O
+(	O
+3	O
+.	O
+33	O
+%,	O
+1	O
+/	O
+30	O
+),	O
+D	O
+(	O
+3	O
+.	O
+33	O
+%,	O
+1	O
+/	O
+30	O
+),	O
+E	O
+(	O
+13	O
+.	O
+33	O
+%,	O
+4	O
+/	O
+30	O
+)	O
+and	O
+unknown	O
+(	O
+6	O
+.	O
+7	O
+%;	O
+2	O
+/	O
+30	O
+),	O
+whereas	O
+E	B-SPEC
+.	I-SPEC
+coli	I-SPEC
+isolates	O
+from	O
+the	O
+control	O
+group	O
+were	O
+classified	O
+only	O
+as	O
+B1	O
+(	O
+83	O
+.	O
+3	O
+%,	O
+25	O
+/	O
+30	O
+),	O
+E	O
+(	O
+10	O
+%;	O
+3	O
+/	O
+30	O
+)	O
+and	O
+unknown	O
+(	O
+6	O
+,	O
+7	O
+%;	O
+2	O
+/	O
+30	O
+).	O
+
+Only	O
+isolates	O
+(	O
+30	O
+%-	O
+9	O
+/	O
+30	O
+)	O
+from	O
+diarrheic	O
+calves	O
+were	O
+also	O
+positive	O
+for	O
+fimbriae	B-COMP
+,	O
+specifically	O
+16	O
+.	O
+7	O
+%	O
+(	O
+5	O
+/	O
+30	O
+)	O
+for	O
+F5	O
+and	O
+13	O
+.	O
+3	O
+%	O
+(	O
+4	O
+/	O
+30	O
+)	O
+for	O
+F18	B-PRGE
+.	O
+
+TITLE	O
+:	O
+Impact	O
+of	O
+spontaneous	O
+breathing	B-PROC
+during	O
+mechanical	O
+ventilation	O
+in	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+.	O
+
+Recently	O
+,	O
+such	O
+effort	B-PROC
+-	O
+dependent	O
+lung	B-ANAT
+injury	O
+has	O
+been	O
+termed	O
+patient	O
+self	O
+-	O
+inflicted	O
+lung	O
+injury	O
+(	O
+P	O
+-	O
+SILI	O
+).	O
+
+Finally	O
+,	O
+several	O
+approaches	O
+to	O
+minimize	O
+P	O
+-	O
+SILI	O
+while	O
+maintaining	O
+some	O
+diaphragm	B-ANAT
+activity	O
+(	O
+e	O
+.	O
+g	O
+.	O
+partial	O
+neuromuscular	B-DISO
+blockade	I-DISO
+,	O
+high	O
+PEEP	B-CHED
+)	O
+appear	O
+promising	O
+.	O
+
+Future	O
+studies	O
+are	O
+needed	O
+to	O
+determine	O
+ventilator	O
+strategies	O
+that	O
+minimize	O
+injury	O
+but	O
+maintaining	O
+some	O
+diaphragm	B-ANAT
+activity	O
+.	O
+
+ResPlex	O
+II	O
+assays	O
+and	O
+real	O
+-	O
+time	O
+polymerase	O
+chain	O
+reaction	O
+assays	O
+were	O
+used	O
+to	O
+detect	O
+viral	O
+pathogens	O
+in	O
+nasal	B-ANAT
+wash	O
+samples	O
+,	O
+and	O
+survival	O
+analyses	O
+were	O
+performed	O
+to	O
+determine	O
+whether	O
+infection	B-DISO
+with	O
+particular	O
+viruses	B-SPEC
+conferred	O
+short	O
+-	O
+lived	O
+relative	O
+cross	O
+-	O
+protection	O
+against	O
+FRI	B-PRGE
+.	O
+
+Veno	O
+-	O
+venous	B-ANAT
+extracorporeal	O
+membrane	B-COMP
+oxygenation	B-PROC
+(	O
+vvECMO	O
+)	O
+has	O
+not	O
+unequivocally	O
+been	O
+shown	O
+to	O
+improve	O
+survival	O
+.	O
+
+ABSTRACT	O
+:	O
+Identifying	O
+viral	O
+antagonists	O
+of	O
+innate	B-PROC
+immunity	I-PROC
+and	O
+determining	O
+if	O
+they	O
+contribute	O
+to	O
+pathogenesis	B-DISO
+are	O
+critical	O
+for	O
+developing	O
+effective	O
+strategies	O
+to	O
+control	O
+emerging	O
+viruses	B-SPEC
+.	O
+
+Here	O
+,	O
+we	O
+asked	O
+if	O
+the	O
+EndoU	B-PRGE
+activity	O
+of	O
+porcine	B-SPEC
+epidemic	B-DISO
+diarrhea	I-DISO
+coronavirus	B-SPEC
+(	O
+PEDV	B-SPEC
+),	O
+which	O
+causes	O
+acute	B-DISO
+diarrhea	I-DISO
+in	O
+swine	B-SPEC
+,	O
+plays	O
+a	O
+role	O
+in	O
+antagonizing	O
+the	O
+innate	O
+response	O
+in	O
+porcine	B-SPEC
+epithelial	B-ANAT
+cells	I-ANAT
+and	O
+macrophages	B-ANAT
+,	O
+the	O
+sites	O
+of	O
+viral	B-PROC
+replication	I-PROC
+.	O
+
+We	O
+constructed	O
+an	O
+infectious	B-DISO
+clone	O
+of	O
+PEDV	B-SPEC
+-	O
+Colorado	O
+strain	O
+(	O
+icPEDV	O
+-	O
+wt	O
+)	O
+and	O
+an	O
+EndoU	B-PRGE
+-	I-PRGE
+mutant	I-PRGE
+PEDV	B-SPEC
+(	O
+icPEDV	O
+-	O
+EnUmt	O
+)	O
+by	O
+changing	O
+the	O
+codon	O
+for	O
+a	O
+catalytic	O
+histidine	B-CHED
+residue	I-CHED
+of	O
+EndoU	O
+to	O
+alanine	B-CHED
+(	O
+His226Ala	O
+).	O
+
+Thus	O
+,	O
+132	O
+nasopharyngeal	B-ANAT
+samples	O
+were	O
+collected	O
+from	O
+pilgrims	O
+presenting	O
+with	O
+acute	O
+respiratory	B-DISO
+symptoms	I-DISO
+at	O
+the	O
+healthcare	O
+facilities	O
+in	O
+the	O
+holy	O
+sites	O
+during	O
+the	O
+5	O
+days	O
+of	O
+the	O
+2014	O
+Hajj	O
+season	O
+.	O
+
+An	O
+immunofluorescence	O
+assay	O
+and	O
+western	O
+blot	O
+analysis	O
+demonstrated	O
+that	O
+two	O
+scFv	O
+antibodies	O
+reacted	O
+with	O
+the	O
+spike	O
+protein	B-CHED
+of	O
+TGEV	B-SPEC
+.	O
+
+Extracorporeal	O
+membrane	B-COMP
+pulmonary	B-ANAT
+oxygenation	B-PROC
+(	O
+ECMO	O
+),	O
+as	O
+an	O
+artificial	O
+heart	B-ANAT
+-	O
+lung	B-ANAT
+supporting	O
+system	O
+,	O
+can	O
+be	O
+applied	O
+to	O
+support	O
+lung	B-ANAT
+that	O
+is	O
+expected	O
+to	O
+recover	B-PROC
+from	O
+reversible	O
+pathological	O
+damage	O
+.	O
+
+Severe	O
+ARDS	B-DISO
+is	O
+usually	O
+companied	O
+with	O
+acute	O
+lung	B-ANAT
+injury	O
+that	O
+worsen	O
+the	O
+patients	O
+'	O
+condition	B-DISO
+.	O
+
+<	O
+strong	O
+>	O
+RESULTS	O
+</	O
+strong	O
+>	O
+We	O
+found	O
+the	O
+HIPK1	B-PRGE
+was	O
+elevated	O
+in	O
+ALI	O
+model	O
+mice	B-SPEC
+while	O
+interference	O
+of	O
+HIPK1	B-PRGE
+by	O
+siRNA	O
+attenuated	O
+the	O
+inflammation	B-DISO
+and	O
+oxidative	B-DISO
+stress	I-DISO
+indicators	O
+(	O
+H2O2	B-CHED
+,	O
+O	O
+-	O
+2	O
+,	O
+and	O
+NO	O
+).	O
+
+Further	O
+research	O
+found	O
+HIPK1	O
+interference	O
+enhanced	O
+the	O
+autophagy	B-PROC
+.	O
+
+ABSTRACT	O
+:	O
+The	O
+development	B-PROC
+of	O
+a	O
+rapid	O
+,	O
+specific	O
+,	O
+and	O
+sensitive	O
+SYBR	B-CHED
+Green	I-CHED
+I	I-CHED
+-	O
+based	O
+duplex	O
+real	O
+-	O
+time	O
+quantitative	O
+PCR	O
+assay	O
+is	O
+described	O
+for	O
+the	O
+simultaneous	O
+detection	O
+of	O
+porcine	B-SPEC
+epidemic	I-SPEC
+diarrhea	I-SPEC
+virus	I-SPEC
+(	O
+PEDV	B-SPEC
+)	O
+and	O
+porcine	B-PRGE
+circovirus	I-PRGE
+type	I-PRGE
+3	I-PRGE
+(	O
+PCV3	O
+).	O
+
+The	O
+assay	O
+showed	O
+a	O
+good	O
+linear	O
+relationship	O
+,	O
+and	O
+the	O
+limits	O
+of	O
+detection	O
+for	O
+this	O
+assay	O
+were	O
+34	O
+.	O
+6	O
+copies	O
+/	O
+μL	O
+and	O
+61	O
+.	O
+2	O
+copies	O
+/	O
+μL	O
+for	O
+PEDV	B-SPEC
+and	O
+PCV3	O
+,	O
+respectively	O
+.	O
+
+The	O
+results	O
+indicate	O
+this	O
+assay	O
+is	O
+a	O
+rapid	O
+and	O
+reliable	O
+diagnostic	O
+tool	O
+for	O
+PEDV	B-SPEC
+and	O
+PCV3	O
+monitoring	O
+and	O
+surveillance	O
+in	O
+the	O
+field	O
+,	O
+and	O
+provides	O
+technical	O
+support	O
+for	O
+the	O
+quantitative	O
+detection	O
+of	O
+clinical	O
+samples	O
+infected	O
+or	O
+co	O
+-	O
+infected	O
+with	O
+PEDV	B-SPEC
+and	O
+PCV3	O
+.	O
+
+We	O
+introduce	O
+the	O
+genetic	O
+diversity	O
+of	O
+SARS	B-DISO
+-	O
+related	O
+coronaviruses	O
+(	O
+SARSr	O
+-	O
+CoVs	O
+)	O
+discovered	O
+in	O
+bats	B-SPEC
+and	O
+provide	O
+insights	O
+on	O
+the	O
+bat	B-ENZY
+origin	O
+of	O
+human	B-SPEC
+SARS	B-DISO
+.	O
+
+Mononuclear	O
+phagocytes	B-ANAT
+(	O
+MNPs	O
+)-	O
+macrophages	B-ANAT
+,	O
+monocytes	B-ANAT
+,	O
+and	O
+dendritic	B-ANAT
+cells	B-COMP
+(	O
+DCs	B-DISO
+)-	O
+are	O
+likely	O
+critical	O
+in	O
+sarcoidosis	B-DISO
+as	O
+they	O
+initiate	O
+and	O
+maintain	O
+T	B-PROC
+cell	I-PROC
+activation	I-PROC
+and	O
+contribute	O
+to	O
+granuloma	B-PROC
+formation	I-PROC
+by	O
+cytokine	B-PROC
+production	I-PROC
+.	O
+
+Our	O
+work	O
+provides	O
+a	O
+foundation	O
+for	O
+future	O
+investigations	O
+of	O
+MNPs	O
+in	O
+sarcoidosis	B-DISO
+to	O
+identify	O
+immune	O
+profiles	O
+of	O
+patients	O
+at	O
+risk	O
+of	O
+developing	O
+severe	O
+disease	O
+with	O
+the	O
+aim	O
+to	O
+provide	O
+early	O
+treatment	O
+to	O
+slow	O
+down	O
+disease	B-DISO
+progression	I-DISO
+.	O
+
+In	O
+all	O
+,	O
+19	O
+.	O
+3	O
+%	O
+of	O
+patients	O
+had	O
+medical	O
+comorbidities	O
+including	O
+hypertension	B-DISO
+,	O
+diabetes	B-DISO
+,	O
+obesity	B-DISO
+,	O
+hypothyroidism	B-DISO
+,	O
+and	O
+anemia	B-DISO
+.	O
+
+One	O
+hundred	O
+fifty	O
+-	O
+three	O
+patients	O
+(	O
+45	O
+females	O
+;	O
+mean	O
+age	O
+,	O
+67	O
+y	O
+/	O
+o	O
+),	O
+who	O
+met	B-CHED
+the	O
+Berlin	O
+definition	O
+and	O
+received	O
+treatment	O
+in	O
+our	O
+intensive	O
+care	O
+unit	O
+between	O
+January	O
+2012	O
+and	O
+December	O
+2015	O
+,	O
+were	O
+enrolled	O
+.	O
+
+RESULTS	O
+:	O
+The	O
+severity	O
+of	O
+ARDS	B-DISO
+was	O
+mild	O
+in	O
+42	O
+patients	O
+,	O
+moderate	O
+in	O
+71	O
+,	O
+and	O
+severe	O
+in	O
+40	O
+.	O
+
+TITLE	O
+:	O
+Development	B-PROC
+of	O
+a	O
+recombinant	O
+Newcastle	B-SPEC
+disease	I-SPEC
+virus	I-SPEC
+-	O
+vectored	O
+vaccine	O
+for	O
+infectious	B-DISO
+bronchitis	B-DISO
+virus	B-SPEC
+variant	O
+strains	O
+circulating	O
+in	O
+Egypt	O
+.	O
+
+All	O
+rNDV	O
+-	O
+vectored	O
+IBV	O
+vaccine	O
+candidates	O
+were	O
+genetically	O
+stable	O
+,	O
+slightly	O
+attenuated	O
+and	O
+showed	O
+growth	B-PROC
+patterns	O
+comparable	O
+to	O
+that	O
+of	O
+parental	O
+rLaSota	O
+virus	B-SPEC
+.	O
+
+TITLE	O
+:	O
+MicroRNA	O
+‑	O
+223	O
+attenuates	O
+LPS	O
+‑	O
+induced	O
+inflammation	B-DISO
+in	O
+an	O
+acute	O
+lung	B-ANAT
+injury	O
+model	O
+via	O
+the	O
+NLRP3	B-PRGE
+inflammasome	I-PRGE
+and	O
+TLR4	B-PRGE
+/	O
+NF	O
+‑	O
+κB	O
+signaling	B-PROC
+pathway	I-PROC
+via	O
+RHOB	O
+.	O
+
+In	O
+lipopolysaccharide	O
+‑	O
+induced	O
+ALI	O
+,	O
+the	O
+expression	B-PROC
+of	O
+miR	O
+‑	O
+223	O
+was	O
+reduced	O
+compared	O
+with	O
+that	O
+in	O
+the	O
+control	O
+normal	O
+group	O
+.	O
+
+The	O
+patient	O
+was	O
+discharged	O
+after	O
+a	O
+month	O
+and	O
+continued	O
+his	O
+treatment	O
+with	O
+oral	O
+phenoxypenicillin	O
+and	O
+doxycycline	B-CHED
+until	O
+full	O
+radiographic	O
+improvement	O
+.	O
+
+The	O
+amino	B-CHED
+acid	I-CHED
+homology	O
+in	O
+this	O
+region	O
+between	O
+PL	O
+/	O
+G032	O
+/	O
+2015	O
+and	O
+UAE	O
+-	O
+HKU30	O
+QdCoVs	O
+was	O
+74	O
+.	O
+5	O
+-	O
+74	O
+.	O
+7	O
+%.	O
+
+TITLE	O
+:	O
+Severe	B-DISO
+Acute	I-DISO
+Respiratory	I-DISO
+Syndrome	I-DISO
+Coronavirus	B-SPEC
+Viroporin	O
+3a	O
+Activates	O
+the	O
+NLRP3	B-PRGE
+Inflammasome	I-PRGE
+.	O
+
+Nasopharyngeal	B-ANAT
+swabs	O
+along	O
+with	O
+clinical	O
+and	O
+demographic	O
+data	O
+were	O
+collected	O
+from	O
+patients	O
+with	O
+pediatric	B-DISO
+cancer	I-DISO
+presenting	O
+febrile	B-PROC
+episodes	O
+with	O
+upper	B-ANAT
+respiratory	I-ANAT
+tract	I-ANAT
+symptoms	O
+.	O
+
+Coinfections	B-DISO
+were	O
+detected	O
+in	O
+55	O
+%	O
+of	O
+the	O
+subjects	O
+,	O
+and	O
+most	O
+of	O
+them	O
+involved	O
+RSV	B-SPEC
+with	O
+one	O
+or	O
+more	O
+other	O
+viruses	B-SPEC
+.	O
+
+HCoV	O
+was	O
+associated	O
+with	O
+bronchiolitis	B-DISO
+;	O
+rhinovirus	B-SPEC
+was	O
+associated	O
+with	O
+hospital	O
+admission	O
+.	O
+
+TITLE	O
+:	O
+Immunoprofiling	O
+of	O
+peripheral	B-ANAT
+blood	I-ANAT
+from	O
+infectious	B-DISO
+bronchitis	B-DISO
+virus	B-SPEC
+vaccinated	O
+MHC	B-PROC
+-	I-PRGE
+B	I-PRGE
+chicken	B-SPEC
+lines	I-PRGE
+-	I-PRGE
+Monocyte	B-ANAT
+MHC	B-PROC
+-	I-PRGE
+II	I-PRGE
+expression	B-PROC
+as	O
+a	O
+potential	O
+correlate	O
+of	O
+protection	O
+.	O
+
+Immune	O
+correlates	O
+,	O
+used	O
+to	O
+predict	O
+vaccine	O
+efficacy	O
+,	O
+have	O
+proved	O
+difficult	O
+to	O
+find	O
+for	O
+IBV	B-SPEC
+-	O
+vaccine	O
+-	O
+induced	O
+protection	O
+.	O
+
+To	O
+find	O
+correlates	O
+of	O
+IBV	B-SPEC
+-	O
+vaccine	O
+-	O
+induced	O
+protection	O
+,	O
+hence	O
+,	O
+we	O
+employed	O
+a	O
+flow	O
+cytometric	O
+assay	O
+to	O
+quantify	O
+peripheral	O
+leucocyte	B-ANAT
+subsets	O
+and	O
+expression	B-PROC
+of	O
+cell	B-COMP
+surface	I-COMP
+markers	O
+of	O
+six	O
+different	O
+non	O
+-	O
+vaccinated	O
+and	O
+vaccinated	O
+Major	B-PROC
+Histocompatibility	I-PROC
+Complex	I-PROC
+(	O
+MHC	B-PROC
+)	O
+haplotypes	O
+.	O
+
+Non	O
+-	O
+vaccinated	O
+and	O
+vaccinated	O
+MHC	B-PROC
+haplotypes	O
+presented	O
+differential	O
+leucocyte	B-ANAT
+composition	O
+and	O
+IBV	B-SPEC
+viral	O
+load	O
+.	O
+
+We	O
+focused	O
+on	O
+patients	O
+presenting	O
+with	O
+Staphylococcus	B-SPEC
+aureus	I-SPEC
+necrotizing	B-DISO
+pneumonia	I-DISO
+in	O
+Reunion	O
+(	O
+Indian	O
+Ocean	O
+)	O
+admitted	O
+to	O
+the	O
+emergency	B-DISO
+department	O
+.	O
+
+We	O
+performed	O
+a	O
+retrospective	O
+study	O
+based	O
+on	O
+data	O
+collected	O
+from	O
+laboratory	O
+registers	O
+and	O
+medical	O
+files	O
+of	O
+patients	O
+presenting	O
+with	O
+Staphylococcus	B-SPEC
+aureus	I-SPEC
+necrotizing	B-DISO
+pneumonia	I-DISO
+in	O
+Reunion	O
+between	O
+December	O
+2014	O
+and	O
+December	O
+2017	O
+.	O
+
+As	O
+methicillin	B-DISO
+-	I-DISO
+resistant	I-DISO
+Staphylococcus	B-SPEC
+aureus	I-SPEC
+is	O
+very	O
+rarely	O
+observed	O
+in	O
+Reunion	O
+,	O
+physicians	O
+can	O
+still	O
+adapt	O
+the	O
+empirical	O
+treatment	O
+,	O
+without	O
+glycopeptides	B-CHED
+.	O
+
+TITLE	O
+:	O
+Distinct	O
+Metabolic	B-PROC
+Endotype	O
+Mirroring	O
+Acute	B-DISO
+Respiratory	I-DISO
+Distress	I-DISO
+Syndrome	I-DISO
+(	O
+ARDS	B-DISO
+)	O
+Subphenotype	O
+and	O
+its	O
+Heterogeneous	O
+Biology	O
+.	O
+
+Recent	O
+studies	O
+have	O
+shown	O
+that	O
+the	O
+naturally	O
+occurring	O
+flavonoid	B-CHED
+kaempferol	B-CHED
+(	O
+KPF	O
+)	O
+reduces	O
+endotoxin	O
+-	O
+induced	O
+inflammatory	B-DISO
+responses	I-DISO
+in	O
+mice	B-SPEC
+.	O
+
+KPF	O
+attenuates	O
+LPS	B-DISO
+-	O
+mediated	O
+production	O
+of	O
+cytokines	O
+as	O
+well	O
+as	O
+activation	O
+of	O
+NF	O
+-	O
+κB	O
+.	O
+Furthermore	O
+,	O
+we	O
+identified	O
+that	O
+KPF	O
+prevents	O
+increased	O
+K63	O
+-	O
+linked	O
+polyubiquitination	B-PROC
+on	O
+TNF	B-PRGE
+receptor	I-PRGE
+associated	I-PRGE
+factor	O
+-	O
+6	O
+(	O
+TRAF6	O
+)	O
+and	O
+interleukin	B-PRGE
+-	I-PRGE
+1	I-PRGE
+receptor	I-PRGE
+-	I-PRGE
+associated	I-PRGE
+kinase	I-PRGE
+1	I-PRGE
+(	O
+IRAK1	B-PRGE
+).	O
+
+Our	O
+study	O
+shows	O
+that	O
+KPF	O
+is	O
+effective	O
+in	O
+reducing	O
+lung	B-ANAT
+damage	O
+induced	O
+by	O
+LPS	B-DISO
+by	O
+modulating	O
+TRAF6	B-PRGE
+polyubiquitination	B-PROC
+.	O
+
+Children	O
+registered	O
+the	O
+highest	O
+positivity	O
+rates	O
+,	O
+and	O
+adults	O
+with	O
+daily	O
+contacts	O
+with	O
+children	O
+experienced	O
+significantly	O
+more	O
+infections	B-DISO
+than	O
+their	O
+counterparts	O
+without	O
+children	O
+.	O
+
+These	O
+findings	O
+motivate	O
+further	O
+active	O
+surveillance	O
+and	O
+analysis	O
+of	O
+differences	O
+in	O
+pathogenicity	O
+among	O
+respiratory	O
+viruses	B-SPEC
+.	O
+
+Surveillance	O
+was	O
+instrumental	O
+in	O
+identifying	O
+the	O
+initial	O
+case	O
+and	O
+in	O
+minimizing	O
+the	O
+spread	O
+of	O
+the	O
+virus	B-SPEC
+to	O
+other	O
+farms	O
+.	O
+
+Provincial	O
+PEDV	B-SPEC
+incidence	O
+and	O
+prevalence	O
+estimates	O
+from	O
+an	O
+industry	O
+database	O
+,	O
+as	O
+well	O
+as	O
+temperature	O
+,	O
+humidity	O
+,	O
+and	O
+precipitation	O
+data	O
+,	O
+were	O
+combined	O
+to	O
+create	O
+the	O
+forecast	O
+dataset	O
+.	O
+
+Three	O
+-	O
+fold	O
+diluted	O
+serum	B-COMP
+of	O
+subjects	O
+showed	O
+only	O
+9	O
+.	O
+7	O
+%,	O
+10	O
+.	O
+3	O
+%,	O
+and	O
+2	O
+.	O
+2	O
+%	O
+reductions	O
+in	O
+relative	O
+light	O
+units	O
+.	O
+
+If	O
+society	O
+was	O
+willing	O
+to	O
+pay	O
+$	O
+100	O
+,	O
+000	O
+per	O
+quality	O
+-	O
+adjusted	O
+life	O
+year	O
+,	O
+any	O
+intervention	O
+costing	O
+less	O
+than	O
+$	O
+51	O
+,	O
+328	O
+per	O
+patient	O
+with	O
+moderate	O
+to	O
+severe	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+would	O
+represent	O
+good	O
+value	O
+.	O
+
+Phenylalanine	B-CHED
+,	O
+aspartic	B-CHED
+acid	I-CHED
+,	O
+and	O
+carbamic	B-CHED
+acid	I-CHED
+levels	O
+were	O
+significantly	O
+different	O
+between	O
+all	O
+groups	O
+of	O
+patients	O
+with	O
+ARDS	B-DISO
+classified	O
+from	O
+mild	O
+to	O
+severe	O
+.	O
+
+ABSTRACT	O
+:	O
+Insectivorous	O
+bats	B-SPEC
+are	O
+speculated	O
+to	O
+be	O
+ancestral	O
+hosts	B-COMP
+of	O
+Middle	O
+-	O
+East	O
+respiratory	O
+syndrome	B-DISO
+(	O
+MERS	O
+)	O
+coronavirus	B-SPEC
+(	O
+CoV	O
+).	O
+
+MERS	O
+-	O
+CoV	O
+causes	O
+disease	O
+in	O
+humans	B-SPEC
+with	O
+thirty	O
+-	O
+five	O
+percent	O
+fatality	O
+,	O
+and	O
+has	O
+evolved	O
+proteins	B-CHED
+that	O
+counteract	O
+human	B-SPEC
+antiviral	B-CHED
+responses	O
+.	O
+
+We	O
+infected	O
+human	B-SPEC
+and	O
+bat	B-ENZY
+(	O
+
+TITLE	O
+:	O
+Incidence	O
+of	O
+hospitalisation	O
+for	O
+severe	O
+complications	O
+of	O
+influenza	B-SPEC
+virus	B-DISO
+infection	I-DISO
+in	O
+Japanese	O
+patients	O
+between	O
+2012	O
+and	O
+2016	O
+:	O
+a	O
+cross	O
+-	O
+sectional	O
+study	O
+using	O
+routinely	O
+collected	O
+administrative	O
+data	O
+.	O
+
+Treatment	O
+with	O
+a	O
+p53	B-PRGE
+specific	I-PRGE
+activator	I-PRGE
+or	I-PRGE
+p53	I-PRGE
+overexpression	B-PROC
+markedly	O
+decreased	O
+viral	B-PROC
+replication	I-PROC
+,	O
+and	O
+we	O
+showed	O
+that	O
+there	O
+was	O
+more	O
+viral	O
+progeny	O
+produced	O
+in	O
+p53	B-PRGE
+knock	O
+-	O
+out	O
+cells	B-COMP
+than	O
+in	O
+p53	B-PRGE
+wild	O
+-	O
+type	O
+cells	B-COMP
+.	O
+
+The	O
+novel	O
+PTB	B-PRGE
+derivatives	O
+were	O
+fully	O
+evaluated	O
+against	O
+various	O
+biological	O
+platforms	O
+.	O
+
+The	O
+results	O
+showed	O
+that	O
+the	O
+method	O
+could	O
+simultaneously	O
+detect	O
+major	O
+viruses	B-SPEC
+infecting	O
+farms	O
+,	O
+including	O
+avian	B-SPEC
+influenza	I-SPEC
+virus	I-SPEC
+,	O
+infectious	B-DISO
+bronchitis	B-DISO
+virus	B-SPEC
+,	O
+Newcastle	B-SPEC
+disease	I-SPEC
+virus	I-SPEC
+,	O
+rotavirus	B-SPEC
+G	I-SPEC
+,	O
+duck	B-SPEC
+hepatitis	I-SPEC
+B	I-SPEC
+virus	I-SPEC
+,	O
+and	O
+avian	B-SPEC
+leukemia	B-DISO
+virus	B-SPEC
+subgroup	O
+J	O
+in	O
+several	O
+farms	O
+.	O
+
+Black	O
+women	O
+were	O
+at	O
+126	O
+%	O
+greater	O
+risk	O
+for	O
+pulmonary	B-DISO
+edema	I-DISO
+/	O
+acute	B-DISO
+heart	I-DISO
+failure	I-DISO
+than	O
+white	O
+women	O
+(	O
+95	O
+%	O
+confidence	O
+interval	O
+,	O
+117	O
+%-	O
+136	O
+%).	O
+
+The	O
+clinical	O
+relevance	O
+of	O
+the	O
+viruses	B-SPEC
+observed	O
+using	O
+EM	O
+remains	O
+to	O
+be	O
+investigated	O
+.	O
+
+ABSTRACT	O
+:	O
+Little	O
+is	O
+known	O
+about	O
+viral	O
+and	O
+atypical	O
+bacteria	O
+pathogen	O
+spectra	O
+of	O
+community	O
+-	O
+acquired	O
+lower	B-DISO
+respiratory	I-DISO
+tract	I-DISO
+infection	I-DISO
+in	O
+children	O
+in	O
+Tunisia	O
+.	O
+
+Importantly	O
+,	O
+Di	O
+-	O
+Nb	O
+and	O
+Tri	O
+-	O
+Nb	O
+exerted	B-PROC
+significantly	O
+elevated	O
+broad	O
+-	O
+spectrum	O
+neutralizing	O
+activity	O
+against	O
+at	O
+least	O
+19	O
+human	B-SPEC
+and	O
+camel	B-SPEC
+MERS	O
+-	O
+CoV	O
+strains	O
+isolated	O
+in	O
+different	O
+countries	O
+and	O
+years	O
+.	O
+
+Predictors	O
+of	O
+early	O
+onset	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+could	O
+help	O
+with	O
+identifying	O
+high	O
+-	O
+risk	O
+populations	O
+,	O
+potentially	O
+improving	O
+case	O
+management	O
+through	O
+specific	O
+protocol	O
+development	B-PROC
+for	O
+these	O
+patients	O
+.	O
+
+Either	O
+in	O
+conjunction	O
+with	O
+or	O
+in	O
+the	O
+absence	O
+of	O
+CRS	B-DISO
+,	O
+a	O
+subset	O
+of	O
+patients	O
+may	O
+also	O
+develop	O
+mild	O
+to	O
+severe	O
+neurotoxicity	O
+.	O
+
+Areas	O
+covered	O
+:	O
+This	O
+manuscript	O
+provides	O
+an	O
+in	O
+-	O
+depth	O
+overview	O
+of	O
+the	O
+pathogenesis	B-DISO
+,	O
+clinical	O
+characteristics	O
+,	O
+current	O
+toxicity	O
+management	O
+strategies	O
+,	O
+and	O
+future	O
+perspectives	O
+pertaining	O
+to	O
+CRS	O
+and	O
+neurotoxicity	O
+.	O
+
+Risk	O
+adaptive	O
+modeling	O
+incorporating	O
+disease	O
+profile	O
+,	O
+patient	O
+demographics	O
+,	O
+lymphodepletion	O
+,	O
+cell	B-COMP
+dosing	O
+,	O
+CAR	B-PRGE
+T	I-PRGE
+construct	I-PRGE
+,	O
+and	O
+potentially	O
+cytokine	O
+gene	B-PROC
+polymorphisms	I-PROC
+may	O
+be	O
+instructive	O
+to	O
+assess	O
+individualized	O
+risk	O
+and	O
+optimal	O
+CRS	B-DISO
+/	O
+neurotoxicity	O
+management	O
+.	O
+
+Controlled	O
+data	O
+on	O
+the	O
+therapy	O
+of	O
+severe	O
+adenovirus	B-DISO
+infections	I-DISO
+are	O
+lacking	O
+and	O
+remains	O
+experimental	O
+.	O
+
+TITLE	O
+:	O
+An	O
+infant	O
+with	O
+severe	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+and	O
+an	O
+opportunistic	O
+polymicrobial	O
+pulmonary	O
+infection	O
+:	O
+a	O
+case	O
+report	O
+.	O
+
+PDCoV	O
+caused	O
+watery	B-DISO
+diarrhoea	I-DISO
+,	O
+vomiting	B-DISO
+and	O
+dehydration	B-DISO
+in	O
+newborn	O
+piglets	O
+.	O
+
+The	O
+coincidence	O
+rate	O
+of	O
+the	O
+detection	O
+results	O
+for	O
+clinical	O
+samples	O
+between	O
+RT	B-PRGE
+-	I-PRGE
+RPA	I-PRGE
+and	O
+RT	O
+-	O
+qPCR	O
+was	O
+97	O
+.	O
+2	O
+%.	O
+
+Biotinylated	O
+secondary	O
+antibodies	B-COMP
+were	O
+used	O
+,	O
+and	O
+the	O
+bound	O
+primary	O
+antibody	B-COMP
+was	O
+visualized	O
+using	O
+an	O
+ABC	O
+amplification	B-DISO
+kit	B-FUNC
+.	O
+
+Paired	O
+untreated	O
+samples	O
+should	O
+be	O
+kept	O
+in	O
+case	O
+the	O
+workup	O
+requires	O
+testing	O
+for	O
+more	O
+vulnerable	O
+viral	O
+antigens	B-CHED
+.	O
+
+In	O
+contrast	O
+,	O
+FCoV	B-PRGE
+antigen	I-PRGE
+detection	O
+was	O
+abolished	O
+after	O
+any	O
+physicochemical	O
+interference	O
+.	O
+
+Citrate	B-CHED
+-	O
+treated	O
+porcine	B-SPEC
+plasma	B-ANAT
+of	O
+pH	O
+7	O
+·	O
+5	O
+,	O
+9	O
+·	O
+8	O
+and	O
+10	O
+·	O
+2	O
+(	O
+8	O
+·	O
+5	O
+%	O
+dry	O
+-	O
+matter	O
+)	O
+was	O
+spiked	O
+with	O
+PEDV	B-SPEC
+,	O
+PSV1	O
+,	O
+PCV2	O
+and	O
+AdV	O
+and	O
+incubated	O
+at	O
+3	O
+°	O
+C	O
+for	O
+maximum	O
+24	O
+h	O
+,	O
+and	O
+at	O
+44	O
+or	O
+48	O
+°	O
+C	O
+for	O
+maximum	O
+10	O
+min	O
+(	O
+Experiment	O
+1	O
+).	O
+
+Spiked	O
+citrate	B-CHED
+-	O
+treated	O
+concentrated	O
+plasma	B-ANAT
+of	O
+pH	O
+7	O
+·	O
+5	O
+and	O
+9	O
+·	O
+8	O
+(	O
+24	O
+%	O
+dry	O
+-	O
+matter	O
+)	O
+was	O
+spray	O
+dried	B-ANAT
+in	O
+a	O
+laboratory	O
+scale	O
+apparatus	B-ANAT
+(	O
+Experiment	O
+2	O
+).	O
+
+At	O
+pH	O
+10	O
+·	O
+2	O
+and	O
+3	O
+°	O
+C	O
+,	O
+infectivity	O
+of	O
+PEDV	B-SPEC
+in	O
+plasma	B-ANAT
+was	O
+reduced	O
+with	O
+a	O
+reduction	O
+factor	O
+of	O
+4	O
+·	O
+2	O
+log	O
+10	O
+(	O
+LRF	O
+)	O
+at	O
+10	O
+h	O
+contact	O
+time	O
+,	O
+whereas	O
+heating	O
+to	O
+44	O
+°	O
+C	O
+for	O
+at	O
+least	O
+1	O
+min	O
+at	O
+alkali	O
+pH	O
+was	O
+needed	O
+to	O
+achieve	O
+a	O
+LRF	O
+of	O
+4	O
+·	O
+2	O
+for	O
+AdV	O
+.	O
+Spray	O
+drying	O
+at	O
+an	O
+outlet	O
+temperature	O
+of	O
+80	O
+°	O
+C	O
+reduced	O
+AdV	O
+infectivity	O
+effectively	O
+(	O
+LRF	O
+=	O
+5	O
+·	O
+2	O
+)	O
+and	O
+PEDV	B-SPEC
+infectivity	O
+for	O
+95	O
+%	O
+(	O
+LRF	O
+=	O
+1	O
+·	O
+4	O
+).	O
+
+Five	O
+percent	O
+of	O
+PEDV	B-SPEC
+stayed	O
+infectious	B-DISO
+after	O
+our	O
+spray	O
+drying	O
+conditions	O
+.	O
+
+We	O
+reviewed	O
+mathematical	O
+models	O
+for	O
+contact	O
+tracing	O
+and	O
+follow	O
+-	O
+up	O
+control	O
+measures	O
+of	O
+SARS	B-DISO
+and	O
+MERS	O
+transmission	O
+.	O
+
+ABSTRACT	O
+:	O
+P53	B-PRGE
+represents	O
+the	O
+paradigm	O
+of	O
+a	O
+multitalented	O
+transcription	B-PROC
+factor	O
+,	O
+responsible	O
+for	O
+the	O
+cellular	B-COMP
+defense	O
+against	O
+a	O
+plethora	O
+of	O
+potentially	O
+harmful	O
+stimuli	O
+.	O
+
+TITLE	O
+:	O
+RNA	O
+respiratory	O
+viral	B-DISO
+infections	I-DISO
+in	O
+solid	O
+organ	B-ANAT
+transplant	I-ANAT
+recipients	O
+:	O
+Guidelines	O
+from	O
+the	O
+American	O
+Society	O
+of	O
+Transplantation	O
+Infectious	O
+Diseases	O
+Community	O
+of	O
+Practice	O
+.	O
+
+Respiratory	O
+viral	B-DISO
+infections	I-DISO
+may	O
+be	O
+associated	O
+with	O
+acute	O
+rejection	O
+and	O
+chronic	O
+lung	B-ANAT
+allograft	O
+dysfunction	O
+in	O
+lung	B-ANAT
+transplant	B-ANAT
+recipients	O
+.	O
+
+Here	O
+,	O
+we	O
+report	O
+that	O
+deletion	O
+of	O
+one	O
+of	O
+these	O
+proline	O
+residues	O
+,	O
+resulting	O
+in	O
+RSA59	O
+(	O
+P	O
+),	O
+significantly	O
+affected	O
+neural	B-ANAT
+cell	I-ANAT
+syncytia	B-ANAT
+formation	B-PROC
+and	O
+viral	O
+titers	O
+postinfection	O
+
+ABSTRACT	O
+:	O
+Viral	B-PROC
+infections	I-PROC
+contribute	O
+to	O
+morbidity	O
+in	O
+cystic	B-DISO
+fibrosis	I-DISO
+(	O
+CF	O
+),	O
+but	O
+the	O
+impact	O
+of	O
+respiratory	O
+viruses	B-SPEC
+on	O
+the	O
+development	B-PROC
+of	O
+airway	B-DISO
+disease	I-DISO
+is	O
+poorly	O
+understood	O
+.	O
+
+Future	O
+investigations	O
+examining	O
+longitudinal	O
+relationships	O
+between	O
+viral	B-DISO
+infections	I-DISO
+,	O
+airway	B-ANAT
+microbiome	O
+,	O
+and	O
+antibiotic	B-CHED
+use	O
+will	O
+allow	O
+us	O
+to	O
+elucidate	O
+the	O
+interplay	O
+between	O
+these	O
+factors	O
+in	O
+young	O
+children	O
+with	O
+CF	O
+.	O
+
+TITLE	O
+:	O
+[	O
+Extracorporeal	O
+membrane	B-COMP
+oxygenation	B-PROC
+for	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+caused	O
+by	O
+acute	O
+phosgene	O
+poisoning	O
+:	O
+a	O
+report	O
+of	O
+4	O
+cases	O
+].	O
+
+ABSTRACT	O
+:	O
+To	O
+evaluate	O
+the	O
+protective	O
+effect	O
+and	O
+curative	O
+effect	O
+of	O
+early	O
+treatment	O
+with	O
+extracorporeal	O
+membrane	B-COMP
+oxygenation	B-PROC
+(	O
+ECMO	O
+)	O
+in	O
+severe	O
+patients	O
+with	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+(	O
+ARDS	B-DISO
+)	O
+caused	O
+by	O
+acute	O
+phosgene	B-CHED
+poisoning	O
+.	O
+
+The	O
+treatment	O
+parameters	O
+in	O
+patients	O
+before	O
+and	O
+after	O
+the	O
+ECMO	O
+treatment	O
+at	O
+1	O
+,	O
+3	O
+,	O
+7	O
+days	O
+were	O
+collected	O
+,	O
+including	O
+pH	O
+of	O
+the	O
+arterial	B-ANAT
+blood	I-ANAT
+,	O
+arterial	B-ANAT
+partial	O
+pressure	O
+of	O
+carbon	B-CHED
+dioxide	I-CHED
+(	O
+PaCO	O
+After	O
+admitted	O
+in	O
+hospital	O
+,	O
+the	O
+4	O
+patients	O
+were	O
+all	O
+put	O
+on	O
+tracheal	O
+intubation	O
+and	O
+ventilator	O
+,	O
+but	O
+the	O
+ventilator	O
+support	O
+conditions	O
+were	O
+high	O
+,	O
+the	O
+oxygenation	B-PROC
+and	O
+internal	O
+environment	O
+were	O
+unstable	O
+.	O
+
+Oxygenation	B-PROC
+was	O
+improved	O
+obviously	O
+after	O
+treatment	O
+,	O
+ventilator	O
+support	O
+conditions	O
+could	O
+be	O
+obviously	O
+reduced	O
+,	O
+including	O
+3	O
+-	O
+6	O
+mL	O
+/	O
+kg	O
+of	O
+the	O
+small	O
+tidal	O
+volume	O
+,	O
+8	O
+-	O
+10	O
+cmH	B-DISO
+
+The	O
+causes	O
+of	O
+the	O
+syndrome	B-DISO
+are	O
+complex	O
+and	O
+diverse	O
+.	O
+
+In	O
+addition	O
+,	O
+the	O
+immunologic	O
+effect	O
+of	O
+CAV	O
+provokedthe	O
+development	B-PROC
+of	O
+clinical	O
+signs	O
+of	O
+LPAI	O
+-	O
+H9N2	O
+and	O
+IB	O
+virus	B-SPEC
+infections	B-DISO
+.	O
+
+TITLE	O
+:	O
+Novel	O
+genotype	O
+of	O
+infectious	B-DISO
+bronchitis	B-DISO
+virus	B-SPEC
+isolated	O
+in	O
+China	O
+.	O
+
+These	O
+results	O
+emphasize	O
+the	O
+importance	O
+of	O
+limiting	O
+exposure	O
+to	O
+novel	O
+IBVs	O
+that	O
+may	O
+serve	O
+as	O
+a	O
+source	O
+of	O
+genetic	O
+material	O
+for	O
+emerging	O
+viruses	B-SPEC
+,	O
+as	O
+well	O
+as	O
+the	O
+importance	O
+of	O
+IBV	B-SPEC
+surveillance	O
+in	O
+chicken	B-SPEC
+flocks	O
+.	O
+
+Using	O
+two	O
+primer	O
+sets	O
+targeting	B-PROC
+the	O
+spike	B-PRGE
+(	I-PRGE
+S	I-PRGE
+)	I-PRGE
+protein	I-PRGE
+gene	I-PRGE
+,	O
+the	O
+S1	O
+and	O
+S2	O
+regions	O
+of	O
+DNA	O
+fragments	O
+were	O
+amplified	O
+.	O
+
+This	O
+result	O
+showed	O
+that	O
+two	O
+different	O
+IBVs	O
+infected	O
+the	O
+six	O
+chickens	B-SPEC
+.	O
+
+Subsequently	O
+,	O
+she	O
+improved	O
+clinically	O
+and	O
+was	O
+successfully	O
+weaned	B-PROC
+from	O
+ECMO	O
+.	O
+
+Therefore	O
+,	O
+a	O
+physician	O
+treating	O
+acute	O
+copper	B-CHED
+sulphate	B-CHED
+poisoning	O
+should	O
+look	O
+out	O
+for	O
+respiratory	B-DISO
+symptoms	I-DISO
+even	O
+in	O
+the	O
+absence	O
+of	O
+other	O
+common	O
+symptoms	O
+.	O
+
+We	O
+suggest	O
+early	O
+initiation	O
+of	O
+venovenous	O
+ECMO	O
+in	O
+those	O
+with	O
+ARDS	B-DISO
+following	O
+copper	B-CHED
+sulphate	B-CHED
+poisoning	O
+.	O
+
+Our	O
+findings	O
+reveal	O
+a	O
+mechanism	O
+responsible	O
+for	O
+virus	B-SPEC
+-	O
+mediated	O
+ALI	O
+,	O
+define	O
+a	O
+pathological	O
+consequence	O
+of	O
+viral	O
+specific	O
+antibody	B-PROC
+response	I-PROC
+,	O
+and	O
+provide	O
+a	O
+potential	O
+target	O
+for	O
+treatment	O
+of	O
+SARS	B-DISO
+-	O
+CoV	O
+or	O
+other	O
+virus	B-SPEC
+-	O
+mediated	O
+lung	B-ANAT
+injury	O
+.	O
+
+ABSTRACT	O
+:	O
+Viral	O
+respiratory	O
+and	O
+intestinal	O
+infections	O
+are	O
+the	O
+most	O
+common	O
+causes	O
+of	O
+canine	O
+viral	B-DISO
+illness	I-DISO
+.	O
+
+Rapid	O
+diagnosis	O
+of	O
+these	O
+multiple	O
+infections	B-DISO
+is	O
+important	O
+for	O
+providing	O
+timely	O
+and	O
+effective	O
+treatment	O
+.	O
+
+ABSTRACT	O
+:	O
+Acute	B-DISO
+Respiratory	I-DISO
+Distress	I-DISO
+Syndrome	I-DISO
+is	O
+a	O
+major	O
+complication	B-DISO
+of	O
+leptospirosis	B-DISO
+,	O
+leading	O
+to	O
+the	O
+majority	O
+of	O
+fatalities	O
+.	O
+
+RESULTS	O
+:	O
+Of	O
+172	O
+leptospirosis	B-DISO
+patients	O
+from	O
+January	O
+2004	O
+to	O
+October	O
+2017	O
+,	O
+39	O
+(	O
+23	O
+%)	O
+presented	O
+a	O
+moderate	O
+or	O
+severe	O
+ARDS	B-DISO
+with	O
+a	O
+mortality	O
+rate	O
+of	O
+23	O
+%	O
+(	O
+9	O
+cases	O
+).	O
+
+They	O
+have	O
+common	O
+characteristics	O
+,	O
+such	O
+as	O
+they	O
+are	O
+all	O
+highly	O
+pathogenic	O
+to	O
+humans	B-SPEC
+or	O
+livestock	O
+,	O
+their	O
+agents	O
+originated	O
+from	O
+bats	B-SPEC
+,	O
+and	O
+two	O
+of	O
+them	O
+originated	O
+in	O
+China	O
+.	O
+
+The	O
+purpose	O
+of	O
+the	O
+review	O
+is	O
+to	O
+summarize	O
+the	O
+current	O
+knowledge	O
+on	O
+viral	O
+diversity	O
+,	O
+reservoir	O
+hosts	O
+,	O
+and	O
+the	O
+geographical	O
+distributions	O
+of	O
+bat	B-ENZY
+coronaviruses	O
+in	O
+China	O
+,	O
+and	O
+eventually	O
+we	O
+aim	O
+to	O
+predict	O
+virus	B-SPEC
+hotspots	O
+and	O
+their	O
+cross	O
+-	O
+species	B-SPEC
+transmission	O
+potential	O
+.	O
+
+Lower	O
+titers	O
+of	O
+serum	B-COMP
+neutralizing	O
+antibodies	B-COMP
+correlate	O
+with	O
+delayed	O
+and	O
+significantly	O
+reduced	O
+shedding	O
+in	O
+the	O
+nasal	B-ANAT
+turbinates	I-ANAT
+of	O
+dromedary	B-SPEC
+camels	B-SPEC
+.	O
+
+ABSTRACT	O
+:	O
+Pneumonia	B-DISO
+severity	O
+index	O
+(	O
+PSI	O
+)	O
+is	O
+an	O
+important	O
+scoring	O
+system	O
+that	O
+can	O
+assess	O
+the	O
+severity	O
+of	O
+community	B-DISO
+acquired	I-DISO
+pneumonia	I-DISO
+and	O
+determine	O
+admission	O
+status	O
+.	O
+
+However	O
+,	O
+there	O
+is	O
+a	O
+lack	O
+of	O
+research	O
+on	O
+whether	O
+this	O
+scoring	O
+system	O
+can	O
+be	O
+applied	O
+to	O
+viral	O
+community	B-DISO
+acquired	I-DISO
+pneumonia	I-DISO
+.	O
+
+TITLE	O
+:	O
+Growth	B-PROC
+enhancement	O
+of	O
+porcine	B-SPEC
+epidemic	I-SPEC
+diarrhea	I-SPEC
+virus	I-SPEC
+(	O
+PEDV	B-SPEC
+)	O
+in	O
+Vero	O
+E6	O
+cells	B-COMP
+expressing	O
+PEDV	B-SPEC
+nucleocapsid	B-COMP
+protein	B-CHED
+.	O
+
+Compared	O
+to	O
+Vero	O
+E6	O
+cells	B-ANAT
+,	I-ANAT
+Vero	I-ANAT
+E6	O
+cells	B-COMP
+expressing	O
+PEDV	B-SPEC
+N	O
+could	O
+accelerate	O
+growth	B-PROC
+of	O
+a	O
+slow	O
+-	O
+growing	O
+PEDV	B-SPEC
+strain	O
+to	O
+higher	O
+peak	O
+titers	O
+by	O
+12	O
+hours	O
+or	O
+enhance	O
+the	O
+yield	O
+of	O
+a	O
+vaccine	O
+candidate	O
+strain	O
+by	O
+two	O
+orders	O
+of	O
+magnitude	O
+.	O
+
+The	O
+purpose	O
+of	O
+this	O
+study	O
+was	O
+to	O
+evaluate	O
+the	O
+efficacy	O
+of	O
+extended	O
+ECMO	O
+use	O
+in	O
+ARDS	B-DISO
+patients	O
+.	O
+
+The	O
+patients	O
+were	O
+divided	O
+into	O
+two	O
+groups	O
+according	O
+to	O
+pre	O
+-	O
+ECMO	O
+arterial	B-ANAT
+blood	I-ANAT
+gas	O
+:	O
+an	O
+extended	O
+group	O
+(	O
+n	O
+=	O
+14	O
+)	O
+and	O
+a	O
+conventional	O
+group	O
+(	O
+n	O
+=	O
+48	O
+).	O
+
+CONCLUSIONS	O
+:	O
+Extended	O
+indications	O
+of	O
+ECMO	O
+implementation	O
+coupled	O
+with	O
+protective	O
+ventilator	O
+settings	O
+may	O
+improve	O
+the	O
+clinical	O
+outcome	O
+of	O
+patients	O
+with	O
+ARDS	B-DISO
+.	O
+
+To	O
+study	O
+the	O
+receptor	B-PROC
+interactions	I-PROC
+as	O
+a	O
+determinant	O
+for	O
+tropism	B-PROC
+and	O
+pathogenicity	O
+,	O
+recombinant	O
+S1	O
+proteins	B-CHED
+were	O
+produced	O
+and	O
+analyzed	O
+by	O
+glycan	B-CHED
+and	O
+tissue	B-ANAT
+arrays	O
+.	O
+
+ABSTRACT	O
+:	O
+Acute	O
+respiratory	B-DISO
+tract	I-DISO
+infections	I-DISO
+(	O
+ARI	B-CHED
+)	O
+constitute	O
+a	O
+substantial	O
+disease	O
+burden	O
+in	O
+adults	O
+and	O
+elderly	O
+individuals	O
+.	O
+
+ABSTRACT	O
+:	O
+Type	B-PRGE
+-	I-PRGE
+I	I-PRGE
+IFNs	I-PRGE
+(	O
+IFN	B-PRGE
+-	I-PRGE
+I	I-PRGE
+)	O
+provide	O
+a	O
+key	O
+mediator	O
+of	O
+innate	O
+antiviral	B-PROC
+response	I-PROC
+during	O
+virus	B-SPEC
+proliferation	B-DISO
+.	O
+
+Findings	O
+from	O
+this	O
+study	O
+provides	O
+novel	O
+perspective	O
+to	O
+advance	O
+the	O
+understanding	O
+in	O
+the	O
+pathogenesis	B-DISO
+of	O
+PEDV	B-SPEC
+.	O
+
+In	O
+the	O
+present	O
+report	O
+we	O
+discuss	O
+a	O
+fatal	O
+case	O
+of	O
+18	O
+-	O
+years	O
+-	O
+old	O
+boy	O
+,	O
+who	O
+had	O
+smoked	O
+SCs	B-DISO
+since	O
+several	O
+months	O
+and	O
+an	O
+overuse	O
+of	O
+SCs	B-DISO
+during	O
+last	O
+48	O
+h	O
+of	O
+his	O
+life	O
+has	O
+been	O
+apprised	O
+.	O
+
+The	O
+autopsy	O
+findings	O
+revealed	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+(	O
+ARDS	B-DISO
+).	O
+
+Both	O
+toxicological	O
+analysis	O
+of	O
+deceased	B-PROC
+blood	B-ANAT
+and	O
+urine	B-ANAT
+samples	O
+and	O
+chemical	O
+analysis	O
+of	O
+the	O
+herbal	O
+mixture	B-CHED
+seized	O
+revealed	O
+presence	O
+of	O
+two	O
+SCs	B-DISO
+-	O
+5F	O
+-	O
+ADB	O
+and	O
+FUB	O
+-	O
+AMB	B-CHED
+.	O
+
+TITLE	O
+:	O
+Frequency	O
+of	O
+molecular	O
+detection	O
+of	O
+equine	B-SPEC
+coronavirus	B-SPEC
+in	O
+faeces	B-ANAT
+and	O
+nasal	B-ANAT
+secretions	B-ANAT
+in	O
+277	O
+horses	O
+with	O
+acute	O
+onset	O
+of	O
+fever	B-PROC
+.	O
+
+If	O
+the	O
+respiratory	O
+secretions	B-ANAT
+test	O
+negative	O
+by	O
+qPCR	O
+for	O
+a	O
+panel	O
+of	O
+respiratory	O
+pathogens	O
+,	O
+feces	B-ANAT
+already	O
+submitted	O
+to	O
+the	O
+laboratory	O
+should	O
+be	O
+tested	O
+for	O
+ECoV	O
+.	O
+RESULTS	O
+:	O
+The	O
+total	O
+number	O
+of	O
+horses	B-SPEC
+testing	O
+qPCR	O
+-	O
+positive	O
+for	O
+ECoV	O
+in	O
+feces	B-ANAT
+was	O
+20	O
+(	O
+7	O
+.	O
+2	O
+%),	O
+4	O
+of	O
+which	O
+also	O
+tested	O
+qPCR	O
+-	O
+positive	O
+for	O
+ECoV	O
+in	O
+nasal	B-ANAT
+secretions	B-ANAT
+.	O
+
+Prevalence	O
+of	O
+TGEV	B-SPEC
+ranged	O
+between	O
+3	O
+.	O
+8	O
+-	O
+6	O
+.	O
+8	O
+%	O
+and	O
+peaked	O
+during	O
+cold	B-DISO
+months	O
+until	O
+March	O
+2013	O
+,	O
+in	O
+which	O
+prevalence	O
+decreased	O
+to	O
+<	O
+0	O
+.	O
+1	O
+%.	O
+
+There	O
+were	O
+no	O
+significant	O
+differences	O
+in	O
+the	O
+ICU	O
+and	O
+hospital	O
+mortality	O
+rates	O
+of	O
+the	O
+ARDS	B-DISO
+and	O
+non	O
+-	O
+ARDS	B-DISO
+patients	O
+.	O
+
+RESULTS	O
+:	O
+Sixty	O
+-	O
+six	O
+patients	O
+were	O
+confirmed	O
+to	O
+have	O
+H1N1	O
+influenza	B-DISO
+pneumonia	I-DISO
+requiring	O
+mechanical	O
+ventilation	O
+.	O
+
+CONCLUSIONS	O
+:	O
+For	O
+H1N1	O
+influenza	B-DISO
+pneumonia	I-DISO
+patients	O
+admitted	O
+to	O
+ICUs	O
+with	O
+mechanical	O
+ventilation	O
+,	O
+there	O
+is	O
+a	O
+high	O
+probability	O
+of	O
+developing	O
+ARDS	B-DISO
+with	O
+a	O
+modest	O
+mortality	O
+rate	O
+.	O
+
+TITLE	O
+:	O
+PEDV	B-SPEC
+and	O
+PDCoV	O
+Pathogenesis	B-DISO
+:	O
+
+The	O
+ability	O
+to	O
+evade	O
+,	O
+circumvent	O
+or	O
+subvert	O
+the	O
+host	B-COMP
+'	O
+s	O
+first	O
+line	O
+of	O
+defense	O
+,	O
+namely	O
+the	O
+innate	O
+immune	B-ANAT
+system	I-ANAT
+,	O
+is	O
+the	O
+key	O
+determinant	O
+for	O
+pathogen	O
+virulence	B-PROC
+,	O
+survival	O
+,	O
+and	O
+the	O
+establishment	O
+of	O
+successful	O
+infection	B-DISO
+.	O
+
+The	O
+spike	O
+(	O
+S	O
+)	O
+protein	B-CHED
+is	O
+the	O
+surface	O
+glycoprotein	B-CHED
+of	O
+PEDV	B-SPEC
+,	O
+which	O
+can	O
+induce	O
+specific	O
+neutralization	O
+antibodies	B-COMP
+and	O
+is	O
+a	O
+candidate	O
+antigen	B-CHED
+for	O
+vaccination	O
+attempts	O
+.	O
+
+The	O
+results	O
+of	O
+our	O
+study	O
+suggest	O
+that	O
+the	O
+recombinant	O
+L	B-SPEC
+.	I-SPEC
+lactis	I-SPEC
+pNZ8149	O
+-	O
+S1	O
+/	O
+NZ3900	O
+can	O
+provide	O
+a	O
+promising	O
+vaccine	O
+strategy	O
+against	O
+PEDV	B-SPEC
+infection	B-DISO
+.	O
+
+The	O
+incidence	O
+of	O
+thrombosis	B-DISO
+was	O
+correlated	O
+with	O
+risk	O
+factors	O
+such	O
+as	O
+coagulation	B-PROC
+variables	O
+(	O
+mean	O
+activated	O
+partial	O
+thromboplastin	B-PRGE
+time	O
+≤	O
+50	O
+s	O
+,	O
+international	O
+normalized	O
+ratio	O
+antithrombin	B-PRGE
+III	I-PRGE
+,	O
+fibrinogen	B-COMP
+,	O
+plasma	B-ANAT
+-	O
+free	O
+hemoglobin	B-PRGE
+,	O
+platelets	B-ANAT
+,	O
+and	O
+decline	O
+in	O
+D	O
+-	O
+dimer	O
+≤	O
+50	O
+%	O
+the	O
+day	O
+after	O
+decannulation	O
+),	O
+cannula	B-SPEC
+size	O
+,	O
+time	O
+on	O
+venovenous	O
+extracorporeal	O
+membrane	B-COMP
+oxygenation	B-PROC
+,	O
+renal	B-DISO
+failure	I-DISO
+,	O
+and	O
+underlying	O
+malignant	B-DISO
+disease	I-DISO
+.	O
+
+The	O
+incidence	O
+of	O
+cannula	B-SPEC
+-	O
+related	O
+venous	B-DISO
+thrombosis	I-DISO
+after	O
+venovenous	O
+extracorporeal	O
+membrane	B-COMP
+oxygenation	B-PROC
+is	O
+high	O
+.	O
+
+Patients	O
+should	O
+undergo	O
+routine	O
+duplex	O
+sonography	O
+after	O
+extracorporeal	O
+membrane	B-COMP
+oxygenation	B-PROC
+to	O
+detect	O
+thrombosis	B-DISO
+formation	B-PROC
+in	O
+the	O
+cannulated	O
+vessel	B-ANAT
+.	O
+
+5	O
+.	O
+5	O
+%	O
+of	O
+pre	O
+-	O
+Hajj	O
+,	O
+95	O
+.	O
+2	O
+%	O
+of	O
+per	O
+-	O
+Hajj	O
+(	O
+at	O
+symptom	B-DISO
+onset	O
+)	O
+and	O
+46	O
+.	O
+5	O
+%	O
+of	O
+post	O
+-	O
+Hajj	O
+samples	O
+tested	O
+positive	O
+(	O
+p	O
+<	O
+0	O
+.	O
+0001	O
+).	O
+
+The	O
+interstitial	B-DISO
+lung	B-ANAT
+disease	I-DISO
+of	O
+this	O
+syndrome	B-DISO
+can	O
+vary	O
+in	O
+severity	O
+and	O
+if	O
+not	O
+identified	O
+soon	O
+enough	O
+,	O
+can	O
+lead	O
+to	O
+severe	O
+respiratory	B-DISO
+failure	I-DISO
+.	O
+
+We	O
+hope	O
+that	O
+this	O
+review	O
+will	O
+bring	O
+awareness	O
+to	O
+antisynthetase	B-DISO
+syndrome	I-DISO
+and	O
+provide	O
+tools	O
+for	O
+earlier	O
+diagnosis	O
+and	O
+treatment	O
+.	O
+
+The	O
+fact	O
+that	O
+our	O
+case	O
+presented	O
+with	O
+lung	B-ANAT
+findings	O
+alone	O
+led	O
+to	O
+the	O
+delay	O
+in	O
+his	O
+diagnosis	O
+.	O
+
+We	O
+report	O
+here	O
+on	O
+10	O
+years	O
+of	O
+serological	O
+and	O
+molecular	O
+data	O
+in	O
+African	O
+lions	B-SPEC
+,	O
+leveraging	O
+comprehensive	O
+demographic	O
+and	O
+behavioural	O
+data	O
+to	O
+test	O
+if	O
+endemic	O
+pathogens	O
+shape	O
+subsequent	O
+infection	B-DISO
+by	O
+epidemic	O
+pathogens	O
+.	O
+
+Complex	O
+chest	B-ANAT
+trauma	O
+and	O
+chest	B-ANAT
+drains	O
+have	O
+been	O
+a	O
+considered	O
+relative	O
+contraindication	O
+to	O
+prone	O
+ventilation	O
+.	O
+
+To	O
+the	O
+best	O
+of	O
+our	O
+knowledge	O
+,	O
+it	O
+is	O
+hitherto	O
+unreported	O
+in	O
+patients	O
+having	O
+traumatic	O
+floating	O
+sternum	B-ANAT
+and	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+.	O
+
+Its	O
+use	O
+has	O
+increased	O
+markedly	O
+in	O
+the	O
+last	O
+decade	O
+,	O
+initially	O
+in	O
+response	O
+to	O
+severe	O
+Acute	O
+Respiratory	O
+Distress	O
+Syndrome	O
+(	O
+ARDS	B-DISO
+)	O
+in	O
+adults	O
+during	O
+the	O
+2009	O
+H1N1	O
+influenza	B-DISO
+epidemic	I-DISO
+and	O
+continuing	O
+with	O
+the	O
+increasing	O
+acceptance	O
+of	O
+Extracorporeal	O
+Membrane	B-COMP
+Oxygenation	B-PROC
+(	O
+ECMO	B-PROC
+)	O
+for	O
+the	O
+treatment	O
+of	O
+severe	O
+respiratory	B-DISO
+failure	I-DISO
+in	O
+adults	O
+from	O
+other	O
+causes	O
+.	O
+1	O
+We	O
+highlight	O
+the	O
+use	O
+of	O
+ECMO	B-PROC
+,	O
+particularly	O
+at	O
+our	O
+institution	O
+.	O
+
+The	O
+nucleotide	B-CHED
+identity	O
+with	O
+feline	B-SPEC
+coronavirus	B-SPEC
+was	O
+91	O
+.	O
+5	O
+%.	O
+
+Pediatric	O
+scrub	B-DISO
+typhus	I-DISO
+in	O
+northern	O
+Thailand	O
+is	O
+often	O
+severe	O
+and	O
+potentially	O
+fatal	O
+with	O
+delays	O
+in	O
+treatment	O
+a	O
+likely	O
+contributing	O
+factor	O
+.	O
+
+ABSTRACT	O
+:	O
+Dromedary	O
+camels	B-SPEC
+are	O
+natural	O
+host	B-COMP
+of	O
+the	O
+Middle	O
+East	O
+respiratory	O
+syndrome	B-DISO
+coronavirus	B-SPEC
+(	O
+MERS	O
+-	O
+CoV	O
+).	O
+
+A	O
+total	O
+of	O
+820	O
+sera	B-COMP
+and	O
+823	O
+nasal	B-ANAT
+swabs	O
+from	O
+cattle	B-SPEC
+,	O
+sheep	B-SPEC
+,	O
+goats	B-SPEC
+,	O
+donkeys	B-SPEC
+,	O
+buffaloes	O
+,	O
+mules	B-SPEC
+,	O
+and	O
+horses	B-SPEC
+were	O
+collected	O
+.	O
+
+This	O
+study	O
+showed	O
+that	O
+domestic	O
+livestock	O
+in	O
+contact	O
+with	O
+MERS	O
+-	O
+CoV	O
+infected	O
+camels	B-SPEC
+may	O
+be	O
+at	O
+risk	O
+of	O
+infection	B-DISO
+.	O
+
+TITLE	O
+:	O
+Evaluation	O
+of	O
+the	O
+Serologic	O
+Cross	O
+-	O
+Reactivity	O
+between	O
+Transmissible	O
+Gastroenteritis	B-DISO
+Coronavirus	B-SPEC
+and	O
+Porcine	B-SPEC
+Respiratory	O
+Coronavirus	B-SPEC
+Using	O
+Commercial	O
+Blocking	B-DISO
+Enzyme	O
+-	O
+Linked	O
+Immunosorbent	O
+Assay	O
+Kits	O
+.	O
+
+ABSTRACT	O
+:	O
+In	O
+this	O
+study	O
+,	O
+we	O
+evaluated	O
+antibody	B-COMP
+and	O
+cell	B-COMP
+-	O
+mediated	O
+immune	O
+(	O
+CMI	O
+)	O
+responses	O
+in	O
+the	O
+mucosal	B-ANAT
+and	O
+systemic	O
+compartments	B-ANAT
+and	O
+protection	O
+against	O
+challenge	O
+with	O
+a	O
+nephropathogenic	O
+Brazilian	O
+(	O
+BR	O
+-	O
+I	O
+)	O
+strain	O
+of	O
+infectious	B-DISO
+bronchitis	B-DISO
+virus	B-SPEC
+(	O
+IBV	B-SPEC
+)	O
+in	O
+chickens	B-SPEC
+submitted	O
+to	O
+a	O
+vaccination	O
+regime	O
+comprising	O
+a	O
+priming	O
+dose	O
+of	O
+heterologous	O
+live	O
+attenuated	O
+Massachusetts	O
+vaccine	O
+followed	O
+by	O
+a	O
+booster	O
+dose	O
+of	O
+an	O
+experimental	O
+homologous	O
+inactivated	O
+vaccine	O
+two	O
+weeks	O
+later	O
+.	O
+
+The	O
+seroprevalence	O
+of	O
+MERS	O
+-	O
+CoV	O
+antibodies	B-COMP
+increases	O
+with	O
+age	O
+in	O
+camels	B-SPEC
+,	O
+while	O
+the	O
+prevalence	O
+of	O
+viral	B-DISO
+shedding	I-DISO
+as	O
+determined	O
+by	O
+MERS	O
+-	O
+CoV	O
+RNA	O
+detection	O
+in	O
+nasal	O
+swabs	O
+decreases	O
+.	O
+
+In	O
+several	O
+studies	O
+,	O
+camels	B-SPEC
+that	O
+were	O
+sampled	O
+at	O
+animal	B-SPEC
+markets	O
+or	O
+quarantine	O
+facilities	O
+were	O
+seropositive	O
+more	O
+often	O
+than	O
+camels	B-SPEC
+at	O
+farms	O
+as	O
+well	O
+as	O
+imported	O
+camels	B-SPEC
+vs	O
+.	O
+locally	O
+bred	O
+camels	B-SPEC
+.	O
+
+Between	O
+blood	B-ANAT
+meals	O
+,	O
+body	B-DISO
+lice	I-DISO
+live	O
+in	O
+clothing	O
+until	O
+the	O
+host	B-COMP
+'	O
+s	O
+body	B-ANAT
+temperature	O
+rises	O
+or	O
+falls	O
+,	O
+when	O
+they	O
+seek	O
+a	O
+new	O
+abode	O
+.	O
+
+Severe	O
+falciparum	B-DISO
+malaria	I-DISO
+and	O
+leptospirosis	B-DISO
+are	O
+urgent	O
+differential	O
+diagnoses	O
+in	O
+residents	O
+and	O
+travellers	O
+from	O
+appropriate	O
+geographical	O
+regions	O
+.	O
+
+Development	O
+of	O
+biodosimetry	O
+assays	O
+for	O
+triage	O
+and	O
+treatment	O
+requires	O
+knowledge	O
+of	O
+the	O
+radiation	O
+dose	O
+-	O
+volume	O
+effect	O
+for	O
+the	O
+bone	B-ANAT
+marrow	I-ANAT
+(	O
+BM	O
+).	O
+
+Peripheral	B-ANAT
+blood	I-ANAT
+samples	O
+were	O
+drawn	O
+14	O
+days	O
+preirradiation	O
+and	O
+at	O
+days	O
+1	O
+,	O
+3	O
+,	O
+5	O
+,	O
+7	O
+and	O
+14	O
+postirradiation	O
+.	O
+
+The	O
+use	O
+of	O
+interferon	B-PRGE
+-	I-PRGE
+ribavirin	I-PRGE
+was	O
+not	O
+associated	O
+with	O
+mortality	O
+in	O
+this	O
+cohort	O
+.	O
+
+Of	O
+these	O
+cases	O
+,	O
+78	O
+(	O
+24	O
+.	O
+8	O
+%)	O
+died	B-PROC
+.	O
+
+ABSTRACT	O
+:	O
+The	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+(	O
+ARDS	B-DISO
+)	O
+is	O
+a	O
+common	O
+cause	O
+of	O
+respiratory	B-DISO
+failure	I-DISO
+in	O
+critically	B-DISO
+ill	I-DISO
+patients	O
+and	O
+is	O
+defined	O
+by	O
+the	O
+acute	O
+onset	O
+of	O
+noncardiogenic	O
+pulmonary	B-DISO
+oedema	I-DISO
+,	O
+hypoxaemia	O
+and	O
+the	O
+need	O
+for	O
+mechanical	O
+ventilation	O
+.	O
+
+Long	O
+-	O
+term	O
+outcomes	O
+of	O
+patients	O
+with	O
+ARDS	O
+are	O
+increasingly	O
+recognized	O
+as	O
+important	O
+research	O
+targets	O
+,	O
+as	O
+many	O
+patients	O
+survive	O
+ARDS	B-DISO
+only	O
+to	O
+have	O
+ongoing	O
+functional	O
+and	O
+/	O
+or	O
+psychological	B-DISO
+sequelae	O
+.	O
+
+TITLE	O
+:	O
+Quality	O
+of	O
+Life	O
+and	O
+Lung	B-PROC
+Function	I-PROC
+in	O
+Survivors	O
+of	O
+Extracorporeal	O
+Membrane	B-COMP
+Oxygenation	B-PROC
+for	O
+Acute	B-DISO
+Respiratory	I-DISO
+Distress	I-DISO
+Syndrome	I-DISO
+.	O
+
+The	O
+aim	O
+of	O
+this	O
+study	O
+was	O
+to	O
+compare	O
+long	O
+-	O
+term	O
+outcomes	O
+of	O
+ARDS	B-DISO
+patients	O
+treated	O
+with	O
+or	O
+without	O
+extracorporeal	O
+membrane	B-COMP
+oxygenation	B-PROC
+.	O
+
+A	O
+prospective	O
+,	O
+observational	O
+study	O
+of	O
+adults	O
+with	O
+ARDS	B-DISO
+(	O
+January	O
+2013	O
+to	O
+December	O
+2015	O
+)	O
+was	O
+conducted	O
+at	O
+a	O
+single	O
+center	O
+.	O
+
+At	O
+1	O
+yr	O
+,	O
+survival	O
+was	O
+similar	O
+(	O
+22	O
+/	O
+33	O
+vs	O
+.	O
+28	O
+/	O
+47	O
+,	O
+66	O
+%	O
+vs	O
+.	O
+59	O
+%;	O
+P	O
+=	O
+0	O
+.	O
+52	O
+),	O
+and	O
+pulmonary	B-PROC
+function	I-PROC
+and	O
+computed	O
+tomography	O
+were	O
+almost	O
+normal	O
+in	O
+both	O
+groups	O
+.	O
+
+Among	O
+these	O
+six	O
+mAbs	O
+,	O
+3F12	O
+recognizes	O
+a	O
+linear	O
+epitope	B-CHED
+(	O
+VAAVKDALKSLGI	O
+)	O
+while	O
+the	O
+other	O
+five	O
+mAbs	O
+recognize	O
+different	O
+conformational	O
+epitopes	O
+formed	O
+by	O
+a	O
+specific	O
+peptide	B-CHED
+fragment	O
+or	O
+the	O
+full	O
+length	O
+of	O
+N	O
+protein	B-CHED
+.	O
+
+Our	O
+study	O
+documents	O
+the	O
+presence	O
+of	O
+CoVs	O
+related	O
+to	O
+avian	B-SPEC
+gamma	O
+-	O
+and	O
+deltacoronaviruses	O
+circulating	O
+in	O
+both	O
+urban	O
+-	O
+and	O
+poultry	O
+-	O
+farm	O
+regions	O
+of	O
+Brazil	O
+,	O
+implicating	O
+wild	O
+birds	B-SPEC
+as	O
+potential	O
+carriers	O
+of	O
+CoVs	O
+which	O
+may	O
+represent	O
+a	O
+risk	O
+to	O
+poultry	O
+farms	O
+and	O
+public	O
+health	O
+in	O
+Brazil	O
+.	O
+
+ABSTRACT	O
+:	O
+Tritrichomonas	B-SPEC
+foetus	I-SPEC
+is	O
+a	O
+flagellate	B-SPEC
+protist	O
+which	O
+commonly	O
+causes	O
+a	O
+waxing	O
+and	O
+waning	O
+large	B-ANAT
+bowel	I-ANAT
+diarrhoea	B-DISO
+in	O
+young	O
+cats	B-SPEC
+.	O
+
+Protozoa	O
+filling	O
+the	O
+lumen	B-ANAT
+and	O
+crypts	O
+and	O
+occasional	O
+invading	O
+into	O
+lamina	B-ANAT
+propria	I-ANAT
+were	O
+identified	O
+within	O
+the	O
+affected	O
+colon	B-ANAT
+and	O
+confirmed	O
+by	O
+PCR	O
+as	O
+T	B-SPEC
+.	I-SPEC
+foetus	I-SPEC
+'	B-SPEC
+feline	I-SPEC
+genotype	O
+'.	O
+
+ABSTRACT	O
+:	O
+The	O
+main	O
+immunogenic	O
+protein	B-CHED
+of	O
+the	O
+porcine	B-SPEC
+epidemic	I-SPEC
+diarrhea	I-SPEC
+virus	I-SPEC
+(	O
+PEDV	B-SPEC
+)	O
+is	O
+the	O
+spike	B-PRGE
+protein	I-PRGE
+(	O
+S	B-PRGE
+protein	I-PRGE
+),	O
+which	O
+plays	O
+an	O
+important	O
+role	O
+in	O
+receptor	B-FUNC
+binding	I-FUNC
+,	O
+membrane	B-PROC
+fusion	I-PROC
+,	O
+and	O
+viral	O
+invasion	B-DISO
+of	O
+the	O
+host	B-COMP
+.	O
+
+Homology	O
+analysis	O
+of	O
+the	O
+regions	O
+corresponding	O
+to	O
+20	O
+typical	O
+strains	O
+of	O
+different	O
+PEDV	B-SPEC
+subtypes	O
+showed	O
+that	O
+the	O
+epitope	B-CHED
+is	O
+highly	O
+conserved	O
+.	O
+
+TITLE	O
+:	O
+Severe	O
+Gastric	B-ANAT
+Mycormycosis	O
+Infection	B-DISO
+Followed	O
+by	O
+Cytomegalovirus	B-DISO
+Pneumonia	I-DISO
+in	O
+a	O
+Renal	B-ANAT
+Transplant	B-ANAT
+Recipient	O
+:	O
+A	O
+Case	O
+Report	O
+and	O
+Concise	O
+Review	O
+of	O
+the	O
+Literature	O
+.	O
+
+The	O
+most	O
+common	O
+and	O
+fatal	O
+infectious	B-DISO
+disease	I-DISO
+is	O
+cytomegalovirus	B-SPEC
+(	O
+CMV	B-SPEC
+)	O
+pneumonia	B-DISO
+,	O
+which	O
+may	O
+result	O
+in	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+(	O
+ARDS	B-DISO
+),	O
+with	O
+rapid	O
+onset	O
+.	O
+
+We	O
+found	O
+that	O
+diabetes	B-DISO
+mellitus	I-DISO
+among	O
+survivors	O
+was	O
+associated	O
+with	O
+prolonged	O
+MERS	O
+-	O
+CoV	O
+RNA	O
+detection	O
+in	O
+the	O
+respiratory	B-ANAT
+tract	I-ANAT
+.	O
+
+TITLE	O
+:	O
+Dynamic	O
+changes	O
+of	O
+pulmonary	B-ANAT
+arterial	B-PROC
+pressure	I-PROC
+in	O
+perinatal	O
+neonates	O
+with	O
+pulmonary	B-ANAT
+and	O
+extrapulmonary	O
+acute	O
+lung	O
+injury	O
+/	O
+respiratory	B-DISO
+distress	I-DISO
+syndrome	I-DISO
+.	O
+
+ABSTRACT	O
+:	O
+This	O
+study	O
+aims	O
+to	O
+explore	O
+the	O
+dynamic	O
+changes	O
+of	O
+pulmonary	B-ANAT
+arterial	B-PROC
+pressure	I-PROC
+(	O
+PAP	B-DISO
+)	O
+and	O
+its	O
+clinical	O
+significance	O
+in	O
+prenatal	O
+neonates	O
+with	O
+pulmonary	B-ANAT
+and	O
+extra	O
+-	O
+pulmonary	B-ANAT
+acute	O
+lung	B-ANAT
+injury	O
+/	O
+respiratory	B-DISO
+distress	I-DISO
+syndrome	I-DISO
+(	O
+ALI	O
+/	O
+ARDS	B-DISO
+).	O
+A	O
+prospective	O
+study	O
+was	O
+conducted	O
+in	O
+the	O
+Neonate	O
+Intensive	O
+Care	O
+Unit	O
+(	O
+NICU	O
+)	O
+between	O
+May	O
+2015	O
+and	O
+April	O
+2017	O
+.	O
+
+TITLE	O
+:	O
+Noninvasive	O
+ventilation	O
+in	O
+critically	B-DISO
+ill	I-DISO
+patients	O
+with	O
+the	O
+Middle	O
+East	O
+respiratory	O
+syndrome	B-DISO
+.	O
+
+In	O
+patients	O
+with	O
+MERS	O
+and	O
+acute	O
+hypoxemic	O
+respiratory	B-DISO
+failure	I-DISO
+,	O
+NIV	O
+failure	O
+was	O
+very	O
+high	O
+.	O
+
+TITLE	O
+:	O
+Respiratory	O
+Management	O
+in	O
+Smoke	O
+Inhalation	B-PROC
+Injury	O
+.	O
+
+To	O
+identify	O
+amino	B-CHED
+acids	I-CHED
+responsible	O
+for	O
+S	O
+-	O
+mediated	O
+syncytium	B-PROC
+formation	I-PROC
+,	O
+we	O
+constructed	O
+and	O
+characterized	O
+chimeric	O
+S	O
+proteins	B-CHED
+of	O
+the	O
+cell	B-COMP
+-	O
+adapted	O
+variant	O
+,	O
+YN144	O
+,	O
+in	O
+which	O
+the	O
+receptor	B-FUNC
+binding	I-FUNC
+domain	O
+(	O
+RBD	O
+)	O
+and	O
+S1	O
+/	O
+S2	O
+cleavage	B-PROC
+site	O
+were	O
+replaced	O
+with	O
+those	O
+of	O
+a	O
+poorly	O
+culturable	O
+field	O
+isolate	O
+(	O
+G2	O
+).	O
+
+ABSTRACT	O
+:	O
+Knowledge	O
+transfer	O
+of	O
+Middle	O
+East	O
+respiratory	O
+syndrome	B-DISO
+coronavirus	B-SPEC
+(	O
+MERS	O
+-	O
+CoV	O
+)	O
+involves	O
+the	O
+dissemination	O
+of	O
+created	O
+/	O
+acquired	O
+information	O
+on	O
+MERS	O
+-	O
+CoV	O
+in	O
+hospitals	O
+,	O
+making	O
+this	O
+information	O
+accessible	O
+to	O
+all	O
+healthcare	O
+workers	O
+(	O
+HCWs	O
+).	O
+
+Older	O
+(>	O
+40	O
+years	O
+of	O
+age	O
+)	O
+and	O
+more	O
+experienced	O
+(>	O
+10	O
+years	O
+)	O
+HCWs	O
+had	O
+the	O
+highest	O
+PMS	B-DISO
+for	O
+knowledge	O
+(	O
+73	O
+.	O
+4	O
+±	O
+18	O
+.	O
+9	O
+,	O
+P	O
+=	O
+0	O
+.	O
+005	O
+and	O
+76	O
+.	O
+9	O
+±	O
+15	O
+.	O
+7	O
+,	O
+P	O
+<	O
+0	O
+.	O
+001	O
+respectively	O
+).	O
+
+TITLE	O
+:	O
+National	O
+estimates	O
+of	O
+the	O
+use	O
+and	O
+outcomes	O
+of	O
+extracorporeal	O
+membrane	B-COMP
+oxygenation	B-PROC
+after	O
+acute	O
+trauma	O
+.	O
+
+ABSTRACT	O
+:	O
+The	O
+use	O
+of	O
+extracorporeal	O
+membrane	O
+oxygenation	B-PROC
+(	O
+ECMO	O
+)	O
+as	O
+salvage	O
+therapy	O
+for	O
+patients	O
+with	O
+severe	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+is	O
+gaining	O
+greater	O
+acceptance	O
+among	O
+trauma	O
+intensivists	O
+.	O
+
+TITLE	O
+:	O
+Incidence	O
+and	O
+seasonality	O
+of	O
+respiratory	O
+viruses	B-SPEC
+causing	O
+acute	B-DISO
+respiratory	I-DISO
+infections	I-DISO
+in	O
+the	O
+Northern	O
+United	O
+Arab	O
+Emirates	O
+.	O
+
+The	O
+FLU	B-DISO
+positivity	O
+rate	O
+showed	O
+two	O
+peaks	O
+,	O
+which	O
+occurred	O
+in	O
+August	O
+and	O
+December	O
+.	O
+
+Although	O
+viral	O
+RNA	O
+was	O
+found	O
+in	O
+some	O
+testicles	B-ANAT
+,	O
+it	O
+could	O
+not	O
+be	O
+correlated	O
+with	O
+the	O
+viraemic	O
+phase	O
+.	O
+
+TITLE	O
+:	O
+Sequential	O
+Emergence	O
+and	O
+Wide	O
+Spread	O
+of	O
+Neutralization	O
+Escape	O
+Middle	O
+East	O
+Respiratory	O
+Syndrome	B-DISO
+Coronavirus	B-SPEC
+Mutants	O
+,	O
+South	O
+Korea	O
+,	O
+2015	O
+.	O
+
+TITLE	O
+:	O
+Glycosylation	B-PROC
+of	O
+the	O
+viral	O
+attachment	O
+protein	B-CHED
+of	O
+avian	B-SPEC
+coronavirus	I-SPEC
+is	O
+essential	O
+for	O
+host	B-ANAT
+cell	I-ANAT
+and	O
+receptor	B-FUNC
+binding	I-FUNC
+.	O
+
+Initial	O
+experimentation	O
+in	O
+small	O
+-	O
+volume	O
+samples	O
+showed	O
+that	O
+both	O
+types	O
+of	O
+particles	O
+readily	O
+adsorbed	O
+to	O
+the	O
+positively	O
+charged	O
+glass	O
+wool	O
+but	O
+were	O
+poorly	O
+detached	O
+from	O
+it	O
+through	O
+standard	O
+elution	O
+with	O
+0	O
+.	O
+05	O
+M	O
+glycine	B-CHED
+with	O
+3	O
+%	O
+of	O
+beef	O
+extract	O
+buffer	B-CHED
+,	O
+pH	O
+9	O
+.	O
+5	O
+,	O
+with	O
+elution	O
+efficiencies	O
+of	O
+7	O
+.	O
+2	O
+%	O
+and	O
+2	O
+.	O
+6	O
+%,	O
+for	O
+HAV	B-DISO
+and	O
+TGEV	B-SPEC
+,	O
+respectively	O
+.	O
+
+In	O
+recent	O
+years	O
+,	O
+though	O
+pigs	B-SPEC
+have	O
+been	O
+immunized	O
+with	O
+the	O
+vaccines	O
+in	O
+pig	B-SPEC
+farms	O
+,	O
+PED	O
+still	O
+broke	O
+out	O
+and	O
+caused	O
+severe	O
+economic	O
+losses	O
+to	O
+the	O
+swine	B-SPEC
+industry	O
+in	O
+the	O
+northeast	O
+China	O
+.	O
+
+In	O
+addition	O
+,	O
+the	O
+strain	O
+was	O
+identified	O
+via	O
+electron	O
+microscopy	O
+observation	O
+,	O
+indirect	O
+immunofluorescence	O
+assay	O
+and	O
+infection	B-DISO
+experiment	O
+in	O
+newborn	O
+piglets	O
+and	O
+named	O
+PEDV	B-SPEC
+CH	O
+/	O
+JLDH	O
+/	O
+2016	O
+strain	O
+(	O
+Accession	O
+No	O
+.	O
+MF346935	O
+).	O
+
+TITLE	O
+:	O
+Pulmonary	B-ANAT
+contusion	O
+.	O
+
+Nowadays	O
+,	O
+as	O
+a	O
+result	O
+of	O
+traffic	O
+accidents	O
+,	O
+following	O
+high	O
+energy	O
+deceleration	O
+,	O
+lung	B-ANAT
+contusion	O
+may	O
+present	O
+without	O
+an	O
+actual	O
+tissue	B-ANAT
+damage	O
+in	O
+the	O
+chest	B-ANAT
+wall	I-ANAT
+as	O
+a	O
+condition	B-DISO
+initiating	O
+an	O
+independent	O
+,	O
+life	O
+-	O
+threatening	O
+generalised	O
+process	O
+.	O
+
+Its	O
+description	O
+and	O
+recognition	O
+as	O
+an	O
+independent	O
+pathology	B-DISO
+is	O
+not	O
+simple	O
+.	O
+
+Generally	O
+,	O
+it	O
+can	O
+be	O
+declared	O
+that	O
+besides	O
+high	O
+energy	O
+,	O
+blunt	O
+injuries	O
+affecting	O
+the	O
+trunk	B-ANAT
+,	O
+lung	B-ANAT
+contusion	O
+,	O
+has	O
+been	O
+an	O
+often	O
+neglected	O
+additional	O
+radiological	O
+finding	O
+attached	O
+to	O
+the	O
+main	O
+report	O
+,	O
+despite	O
+the	O
+fact	O
+,	O
+that	O
+its	O
+late	O
+consequences	O
+crucially	O
+determine	O
+the	O
+prospects	O
+of	O
+the	O
+injured	O
+.	O
+
+Initial	O
+screening	O
+using	O
+anti	O
+-	O
+MERS	O
+-	O
+CoV	O
+IgG	O
+(	O
+IgG	B-PRGE
+rS1	O
+-	O
+ELISA	O
+kit	B-FUNC
+)	O
+revealed	O
+ten	O
+reactive	O
+samples	O
+from	O
+BD	O
+(	O
+10	O
+/	O
+4719	O
+,	O
+0	O
+.	O
+21	O
+%),	O
+one	O
+from	O
+CC	O
+(	O
+1	O
+/	O
+135	O
+,	O
+0	O
+.	O
+74	O
+%),	O
+and	O
+three	O
+from	O
+CP	O
+(	O
+3	O
+/	O
+4	O
+,	O
+75	O
+%).	O
+
+On	O
+presentation	O
+,	O
+diagnosis	O
+of	O
+Guillain	O
+-	O
+Barré	O
+syndrome	B-DISO
+was	O
+supported	O
+by	O
+areflexia	O
+and	O
+albuminocytologic	O
+dissociation	B-DISO
+.	O
+
+In	O
+summary	O
+,	O
+Guillain	O
+-	O
+Barré	O
+syndrome	B-DISO
+should	O
+be	O
+considered	O
+as	O
+a	O
+possible	O
+cause	O
+of	O
+unilateral	O
+peripheral	B-DISO
+facial	I-DISO
+palsy	I-DISO
+.	O
+
+Here	O
+,	O
+we	O
+characterized	O
+a	O
+recombinant	O
+form	O
+of	O
+the	O
+human	B-PRGE
+coronavirus	I-PRGE
+229E	I-PRGE
+(	O
+HCoV	B-SPEC
+-	I-SPEC
+229E	I-SPEC
+)	O
+nsp8	O
+and	O
+found	O
+that	O
+the	O
+protein	B-CHED
+has	O
+metal	B-PRGE
+ion	I-PRGE
+-	I-PRGE
+dependent	I-PRGE
+RNA	I-PRGE
+3	I-PRGE
+'-	I-PRGE
+terminal	I-PRGE
+adenylyltransferase	I-PRGE
+(	O
+TATase	O
+)	O
+activity	O
+,	O
+while	O
+other	O
+nucleotides	B-CHED
+were	O
+not	O
+(	O
+or	O
+very	O
+inefficiently	O
+)	O
+transferred	O
+to	O
+the	O
+3	O
+'	O
+ends	O
+of	O
+single	O
+-	O
+stranded	O
+and	O
+(	O
+fully	O
+)	O
+double	O
+-	O
+stranded	O
+acceptor	B-CHED
+RNAs	O
+.	O
+
+To	O
+search	O
+for	O
+effective	O
+inhibitory	O
+agents	O
+,	O
+we	O
+performed	O
+high	O
+-	O
+throughput	O
+screening	O
+(	O
+HTS	B-DISO
+)	O
+of	O
+a	O
+2	O
+,	O
+000	O
+-	O
+compound	O
+library	O
+of	O
+approved	O
+drugs	O
+and	O
+pharmacologically	O
+active	O
+compounds	O
+using	O
+the	O
+established	O
+genetically	O
+engineered	B-PRGE
+human	I-PRGE
+CoV	I-PRGE
+OC43	I-PRGE
+(	O
+HCoV	B-SPEC
+-	I-SPEC
+OC43	I-SPEC
+)	O
+strain	O
+expressing	O
+
+Coimmunoprecipitation	O
+studies	O
+are	O
+consistent	O
+with	O
+an	O
+interaction	O
+between	O
+the	O
+macrodomain	O
+and	O
+PLP2	B-PRGE
+.	O
+
+TITLE	O
+:	O
+Hemoadsorption	O
+in	O
+isolated	O
+conjugated	B-DISO
+hyperbilirubinemia	I-DISO
+after	O
+extracorporeal	O
+membrane	B-COMP
+oxygenation	B-PROC
+support	O
+.	O
+
+Three	O
+days	O
+after	O
+initiation	O
+of	O
+ECMO	O
+,	O
+the	O
+patient	O
+developed	O
+jaundice	B-DISO
+,	O
+with	O
+increase	O
+of	O
+bilirubin	B-CHED
+,	O
+Gamma	B-PRGE
+-	I-PRGE
+glutamyltransferase	I-PRGE
+and	O
+Alkaline	B-ENZY
+phosphatase	B-FUNC
+,	O
+without	O
+elevation	O
+of	O
+alanine	B-PRGE
+aminotransferase	I-PRGE
+and	O
+INR	B-PRGE
+.	O
+
+Statistical	O
+analysis	O
+showed	O
+a	O
+highly	O
+significant	O
+difference	O
+(	O
+P	O
+<	O
+0	O
+.	O
+0001	O
+)	O
+in	O
+the	O
+frequency	O
+of	O
+single	O
+infections	O
+compared	O
+to	O
+mixed	O
+ones	O
+with	O
+the	O
+exception	O
+of	O
+weaned	B-PROC
+pigs	B-SPEC
+,	O
+in	O
+which	O
+group	O
+additionally	O
+most	O
+viruses	B-SPEC
+were	O
+detected	O
+.	O
+
+ABSTRACT	O
+:	O
+According	O
+to	O
+recently	O
+published	O
+findings	O
+,	O
+levels	O
+of	O
+the	O
+soluble	O
+receptor	O
+of	O
+advanced	O
+glycation	O
+end	O
+products	O
+(	O
+sRAGE	O
+)	O
+and	O
+its	O
+clearance	O
+from	O
+the	O
+blood	B-ANAT
+may	O
+reflect	O
+the	O
+evolution	B-PROC
+of	O
+lung	B-ANAT
+damage	O
+during	O
+hospitalization	O
+.	O
+
+Contact	O
+data	O
+is	O
+frequently	O
+collected	O
+in	O
+outbreaks	O
+of	O
+pathogens	O
+spread	O
+by	O
+close	O
+contact	O
+,	O
+including	O
+Ebola	B-SPEC
+virus	I-SPEC
+(	O
+EBOV	O
+),	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+coronavirus	B-SPEC
+(	O
+SARS	B-DISO
+-	O
+CoV	O
+)	O
+and	O
+Mycobacterium	B-SPEC
+tuberculosis	I-SPEC
+(	O
+TB	O
+),	O
+and	O
+routinely	O
+used	O
+to	O
+reconstruct	O
+transmission	O
+chains	O
+.	O
+
+The	O
+patient	O
+developed	O
+severe	O
+refractory	O
+hypercapnic	B-DISO
+respiratory	I-DISO
+failure	I-DISO
+necessitating	O
+additional	O
+respiratory	O
+support	O
+with	O
+veno	O
+-	O
+venous	B-ANAT
+extracorporeal	O
+membrane	B-COMP
+oxygenation	B-PROC
+(	O
+ECMO	O
+)	O
+therapy	O
+.	O
+
+Ketamine	B-CHED
+treatment	O
+was	O
+initiated	O
+at	O
+0	O
+.	O
+5	O
+mg	O
+/	O
+kg	O
+/	O
+h	O
+continuous	O
+infusion	O
+on	O
+the	O
+day	O
+of	O
+admission	O
+for	O
+pain	O
+control	O
+and	O
+required	O
+up	O
+-	O
+titration	O
+to	O
+2	O
+mg	O
+/	O
+kg	O
+/	O
+h	O
+by	O
+intensive	O
+care	O
+unit	O
+day	O
+4	O
+for	O
+bronchodilation	O
+.	O
+
+ABSTRACT	O
+:	O
+Mycoplasma	B-DISO
+pneumonia	I-DISO
+is	O
+one	O
+of	O
+the	O
+most	O
+common	O
+types	O
+of	O
+pneumonia	B-DISO
+,	O
+although	O
+it	O
+is	O
+often	O
+not	O
+diagnosed	O
+due	O
+to	O
+mild	O
+clinical	O
+course	O
+.	O
+
+ABSTRACT	O
+:	O
+Transmissible	O
+gastroenteritis	B-DISO
+virus	B-SPEC
+(	O
+TGEV	B-SPEC
+)	O
+is	O
+the	O
+etiologic	O
+agent	O
+of	O
+transmissible	O
+gastroenteritis	B-DISO
+in	O
+pigs	B-SPEC
+,	O
+and	O
+the	O
+N	O
+-	O
+terminal	O
+domain	O
+of	O
+TGEV	B-PRGE
+spike	I-PRGE
+protein	B-CHED
+is	O
+generally	O
+recognized	O
+as	O
+both	O
+the	O
+virulence	B-PROC
+determinant	O
+and	O
+enteric	O
+tropism	B-PROC
+determinant	O
+.	O
+
+Using	O
+a	O
+novel	O
+approach	O
+,	O
+the	O
+clustered	O
+regularly	O
+interspaced	O
+short	O
+palindromic	O
+repeat	O
+(	O
+CRISPR	O
+)/	O
+CRISPR	B-PRGE
+-	I-PRGE
+associated	I-PRGE
+protein	I-PRGE
+9	I-PRGE
+(	O
+Cas9	O
+)	O
+systems	O
+efficiently	O
+and	O
+rapidly	O
+rescued	O
+another	O
+recombinant	O
+virus	B-SPEC
+with	O
+a	O
+224	O
+-	O
+amino	O
+-	O
+acid	O
+deletion	O
+in	O
+the	O
+N	O
+-	O
+terminal	O
+domain	O
+of	O
+the	O
+TGEV	B-SPEC
+
+TITLE	O
+:	O
+Fatal	O
+Exsanguination	B-DISO
+Following	O
+Rupture	O
+of	O
+an	O
+Iliac	B-DISO
+Artery	I-DISO
+Aneurysm	I-DISO
+in	O
+an	O
+Infant	O
+With	O
+Menkes	B-DISO
+Disease	I-DISO
+.	O
+
+We	O
+report	O
+a	O
+case	O
+of	O
+an	O
+8	O
+-	O
+week	O
+-	O
+old	O
+male	O
+infant	O
+who	O
+succumbed	O
+to	O
+acute	O
+,	O
+severe	O
+exsanguination	B-DISO
+,	O
+and	O
+hemorrhagic	B-DISO
+shock	I-DISO
+secondary	O
+to	O
+a	O
+large	O
+retroperitoneal	B-ANAT
+hematoma	B-DISO
+due	O
+to	O
+rupture	O
+of	O
+a	O
+right	O
+iliac	B-DISO
+artery	I-DISO
+aneurysm	I-DISO
+.	O
+
+We	O
+report	O
+a	O
+case	O
+of	O
+a	O
+2	O
+-	O
+month	O
+-	O
+old	O
+male	O
+child	O
+who	O
+was	O
+placed	O
+on	O
+ECMO	O
+for	O
+severe	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+.	O
+
+TITLE	O
+:	O
+Venovenous	O
+extracorporeal	O
+membrane	B-COMP
+oxygenation	B-PROC
+treatment	O
+in	O
+a	O
+low	O
+-	O
+volume	O
+and	O
+geographically	O
+isolated	O
+cardiothoracic	O
+centre	O
+.	O
+
+ABSTRACT	O
+:	O
+The	O
+Middle	O
+-	O
+East	O
+respiratory	O
+syndrome	B-DISO
+coronavirus	B-SPEC
+(	O
+MERS	O
+-	O
+CoV	O
+)	O
+is	O
+a	O
+zoonotic	O
+virus	B-SPEC
+that	O
+causes	O
+severe	O
+and	O
+often	O
+fatal	O
+respiratory	B-DISO
+disease	I-DISO
+in	O
+humans	B-SPEC
+.	O
+
+Most	O
+respiratory	O
+virus	B-SPEC
+infections	B-DISO
+are	O
+managed	O
+with	O
+supportive	O
+therapy	O
+,	O
+although	O
+there	O
+is	O
+effective	O
+antiviral	B-CHED
+therapy	O
+for	O
+influenza	B-DISO
+.	O
+
+TITLE	O
+:	O
+Identification	O
+and	O
+design	O
+of	O
+novel	O
+small	O
+molecule	O
+inhibitors	B-CHED
+against	O
+MERS	B-PRGE
+-	I-PRGE
+CoV	I-PRGE
+papain	B-ENZY
+-	I-PRGE
+like	I-PRGE
+protease	I-PRGE
+via	O
+high	O
+-	O
+throughput	O
+screening	O
+and	O
+molecular	O
+modeling	O
+.	O
+
+The	O
+antigenic	O
+regions	O
+and	O
+the	O
+glycosylation	B-PROC
+site	O
+of	O
+the	O
+strains	O
+obtained	O
+coincide	O
+with	O
+those	O
+previously	O
+reported	O
+.	O
+
+Collectively	O
+,	O
+these	O
+attributes	O
+of	O
+CICSLI	O
+will	O
+allow	O
+investigators	O
+to	O
+better	O
+study	O
+how	O
+drugs	O
+act	O
+within	O
+heterogeneous	O
+lung	B-ANAT
+pathologies	O
+and	O
+how	O
+regeneration	B-PROC
+occurs	O
+in	O
+severely	O
+damaged	O
+lung	B-ANAT
+tissue	I-ANAT
+,	O
+thereby	O
+aiding	O
+the	O
+development	B-PROC
+of	O
+new	O
+therapies	O
+for	O
+ARDS	B-DISO
+and	O
+other	O
+heterogenous	O
+lung	B-DISO
+diseases	I-DISO
+.	O
+
+We	O
+identified	O
+members	O
+of	O
+the	O
+nuclear	B-COMP
+pore	I-COMP
+complex	I-COMP
+from	O
+the	O
+nsp1	B-PRGE
+-	I-PRGE
+associated	I-PRGE
+protein	I-PRGE
+assembly	O
+and	O
+found	O
+that	O
+the	O
+expression	B-PROC
+of	O
+nsp1	B-PRGE
+in	O
+HEK	O
+cells	B-COMP
+disrupts	O
+Nup93	B-PRGE
+localization	B-PROC
+around	O
+the	O
+nuclear	B-COMP
+envelope	I-COMP
+without	O
+triggering	O
+proteolytic	B-PROC
+degradation	O
+,	O
+while	O
+the	O
+nuclear	B-COMP
+lamina	I-COMP
+remains	O
+unperturbed	O
+.	O
+
+TITLE	O
+:	O
+Evolutionary	O
+relationship	O
+analysis	O
+of	O
+Middle	O
+East	O
+respiratory	O
+syndrome	B-DISO
+coronavirus	B-SPEC
+4a	O
+and	O
+4b	O
+protein	O
+coding	O
+sequences	O
+.	O
+
+Glucocorticoids	B-CHED
+such	O
+as	O
+methylprednisolone	B-CHED
+(	O
+MP	O
+)	O
+are	O
+commonly	O
+used	O
+to	O
+treat	O
+patients	O
+with	O
+inflammatory	O
+diseases	O
+;	O
+however	O
+,	O
+the	O
+management	O
+of	O
+ALI	O
+or	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+(	O
+ARDS	B-DISO
+)	O
+remains	O
+controversial	O
+.	O
+
+Pro	B-CHED
+-	O
+fibrotic	O
+chemokine	O
+levels	O
+were	O
+gradually	O
+increased	O
+,	O
+followed	O
+by	O
+an	O
+increase	O
+in	O
+collagen	B-COMP
+and	O
+fibrin	B-DISO
+deposition	I-DISO
+after	O
+smoke	O
+inhalation	B-PROC
+.	O
+
+TITLE	O
+:	O
+A	O
+study	O
+on	O
+the	O
+protective	O
+effects	O
+of	O
+CpG	O
+oligodeoxynucleotide	O
+-	O
+induced	O
+mucosal	B-PROC
+immunity	I-PROC
+against	O
+lung	O
+injury	O
+in	O
+a	O
+mouse	B-SPEC
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+model	O
+.	O
+
+This	O
+is	O
+a	O
+prospective	O
+laboratory	O
+animal	B-SPEC
+investigation	O
+.	O
+
+Twenty	O
+-	O
+week	O
+-	O
+old	O
+BALB	O
+/	O
+c	O
+mice	B-SPEC
+in	O
+Animal	B-SPEC
+research	O
+laboratory	O
+were	O
+randomized	O
+into	O
+groups	O
+.	O
+
+This	O
+resulted	O
+in	O
+the	O
+least	O
+severe	O
+lung	B-ANAT
+tissue	I-ANAT
+injury	O
+.	O
+
+ABSTRACT	O
+:	O
+The	O
+clinical	O
+features	O
+of	O
+Guillain	O
+-	O
+Barré	O
+syndrome	O
+(	O
+GBS	B-DISO
+)	O
+are	O
+highly	O
+variable	O
+,	O
+according	O
+to	O
+the	O
+type	O
+of	O
+antecedent	O
+infection	B-DISO
+.	O
+
+Although	O
+a	O
+major	O
+GBS	B-DISO
+phenotype	O
+,	O
+Fisher	B-DISO
+syndrome	I-DISO
+(	O
+FS	B-DISO
+),	O
+has	O
+been	O
+shown	O
+to	O
+be	O
+preceded	O
+by	O
+infections	B-DISO
+similar	O
+to	O
+those	O
+preceding	O
+GBS	B-DISO
+,	O
+whether	O
+or	O
+not	O
+the	O
+clinical	O
+features	O
+in	O
+FS	B-DISO
+also	O
+vary	O
+according	O
+to	O
+antecedent	O
+infection	B-DISO
+remains	O
+unclarified	O
+.	O
+
+Frequent	O
+antecedent	O
+infections	B-DISO
+among	O
+this	O
+study	O
+of	O
+70	O
+FS	O
+patients	O
+included	O
+Haemophilus	B-SPEC
+influenzae	I-SPEC
+[	O
+n	O
+=	O
+15	O
+(	O
+21	O
+%)],	O
+Campylobacter	B-SPEC
+jejuni	I-SPEC
+[	O
+n	O
+=	O
+10	O
+(	O
+14	O
+%)],	O
+and	O
+cytomegalovirus	B-SPEC
+(	O
+CMV	B-SPEC
+)	O
+[	O
+n	O
+=	O
+6	O
+(	O
+8	O
+.	O
+6	O
+%)].	O
+
+According	O
+to	O
+GBS	B-DISO
+disability	O
+scale	O
+,	O
+CMV	B-SPEC
+-	O
+related	O
+FS	O
+tended	O
+to	O
+be	O
+more	O
+severe	O
+,	O
+although	O
+every	O
+patient	O
+received	O
+immunotherapy	O
+.	O
+
+These	O
+findings	O
+indicate	O
+that	O
+the	O
+type	O
+of	O
+preceding	O
+infection	B-DISO
+determined	O
+the	O
+neurological	O
+features	O
+of	O
+FS	O
+.	O
+
+This	O
+sow	O
+vaccination	O
+regimen	O
+completely	O
+protected	O
+nursing	B-PROC
+piglets	O
+against	O
+virulent	O
+G2b	O
+challenge	O
+,	O
+as	O
+evidenced	O
+by	O
+the	O
+increase	O
+in	O
+survival	O
+rate	O
+from	O
+0	O
+%	O
+to	O
+100	O
+%	O
+and	O
+the	O
+significant	O
+reduction	O
+in	O
+diarrhea	O
+intensity	O
+,	O
+including	O
+the	O
+amount	O
+and	O
+duration	O
+of	O
+PEDV	B-SPEC
+fecal	B-ANAT
+shedding	O
+.	O
+
+ABSTRACT	O
+:	O
+Cholesterol	B-ENZY
+25	I-ENZY
+-	I-ENZY
+hydroxylase	I-ENZY
+(	O
+CH25H	B-PRGE
+)	O
+has	O
+been	O
+shown	O
+lately	O
+to	O
+be	O
+a	O
+host	B-COMP
+restriction	O
+factor	O
+that	O
+encodes	O
+an	O
+enzyme	O
+,	O
+which	O
+catalyzes	O
+the	O
+oxidized	O
+form	O
+of	O
+cholesterol	B-CHED
+to	O
+25	B-CHED
+-	I-CHED
+hydroxycholesterol	I-CHED
+(	O
+25HC	O
+).	O
+
+TITLE	O
+:	O
+Epidemiological	O
+study	O
+of	O
+Middle	O
+East	O
+respiratory	O
+syndrome	B-DISO
+coronavirus	B-DISO
+infection	I-DISO
+in	O
+dromedary	B-SPEC
+camels	O
+in	O
+Saudi	O
+Arabia	O
+,	O
+April	O
+-	O
+May	O
+2015	O
+.	O
+
+In	O
+conclusion	O
+,	O
+the	O
+risk	O
+factors	O
+identified	O
+in	O
+this	O
+study	O
+can	O
+be	O
+considered	O
+to	O
+be	O
+predictors	O
+of	O
+MERS	O
+-	O
+CoV	O
+infection	B-DISO
+in	O
+camels	B-SPEC
+and	O
+should	O
+be	O
+taken	O
+into	O
+account	O
+when	O
+developing	O
+an	O
+efficient	O
+and	O
+cost	O
+-	O
+effective	O
+control	O
+strategy	O
+.	O
+
+Dot	O
+-	O
+blot	O
+hybridization	B-PROC
+and	O
+enzyme	O
+-	O
+linked	O
+immunosorbent	O
+assays	O
+(	O
+ELISAs	O
+)	O
+identified	O
+the	O
+peptide	B-CHED
+
+Although	O
+Mendelson	O
+’	O
+s	O
+sample	O
+had	O
+a	O
+positive	O
+outcome	O
+,	O
+subsequent	O
+studies	O
+have	O
+revealed	O
+that	O
+patients	O
+may	O
+develop	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+(	O
+ARDS	B-DISO
+)	O
+following	O
+aspiration	B-DISO
+pneumonia	I-DISO
+.[	O
+3	O
+]	O
+Mendelson	O
+’	O
+s	O
+landmark	O
+study	O
+suggested	O
+that	O
+a	O
+chemical	B-DISO
+pneumonitis	I-DISO
+was	O
+preventable	O
+by	O
+restricting	O
+oral	B-ANAT
+intake	O
+during	O
+labor	B-PROC
+,	O
+which	O
+eventually	O
+led	O
+to	O
+the	O
+NPO	B-PRGE
+guidelines	O
+we	O
+have	O
+in	O
+place	O
+today	O
+for	O
+parturients	O
+.	O
+
+Mendelson	O
+’	O
+s	O
+study	O
+reviewed	O
+the	O
+aspiration	B-DISO
+of	O
+gastric	B-ANAT
+contents	I-ANAT
+amongst	O
+44000	O
+pregnancies	B-PROC
+at	O
+the	O
+New	O
+York	O
+Lying	O
+-	O
+In	O
+Hospital	O
+from	O
+1932	O
+to	O
+1945	O
+.	O
+
+Amongst	O
+the	O
+patients	O
+studied	O
+,	O
+there	O
+were	O
+66	O
+cases	O
+of	O
+aspiration	B-DISO
+(	O
+0	O
+.	O
+15	O
+%)	O
+and	O
+two	O
+deaths	B-PROC
+(	O
+0	O
+.	O
+0045	O
+%).	O
+
+He	O
+placed	O
+both	O
+neutralized	O
+and	O
+untreated	O
+hydrochloric	B-CHED
+acid	I-CHED
+and	O
+vomitus	B-ANAT
+from	O
+pregnant	O
+women	O
+into	O
+the	O
+respiratory	B-ANAT
+tracts	I-ANAT
+of	O
+rabbits	B-SPEC
+.	O
+
+21	O
+%	O
+of	O
+aspiration	B-DISO
+cases	O
+were	O
+among	O
+women	O
+who	O
+delivered	O
+via	O
+cesarean	O
+section	O
+,	O
+while	O
+79	O
+%	O
+of	O
+women	O
+were	O
+undergoing	O
+general	B-PROC
+anesthesia	I-PROC
+for	O
+vaginal	B-ANAT
+deliveries	O
+.	O
+
+In	O
+this	O
+report	O
+we	O
+present	O
+viral	O
+metagenomic	O
+data	O
+from	O
+bats	B-SPEC
+collected	O
+in	O
+the	O
+Kingdom	B-SPEC
+of	O
+Saudi	O
+Arabia	O
+[	O
+KSA	O
+].	O
+
+SuperLearner	O
+fits	O
+demonstrated	O
+excellent	O
+cross	O
+-	O
+validated	O
+prediction	O
+of	O
+death	B-PROC
+(	O
+overall	O
+AUC	O
+0	O
+.	O
+94	O
+-	O
+0	O
+.	O
+97	O
+),	O
+multi	B-DISO
+-	I-DISO
+organ	I-DISO
+failure	I-DISO
+(	O
+overall	O
+AUC	O
+0	O
+.	O
+84	O
+-	O
+0	O
+.	O
+90	O
+),	O
+and	O
+transfusion	O
+(	O
+overall	O
+AUC	O
+0	O
+.	O
+87	O
+-	O
+0	O
+.	O
+9	O
+)	O
+across	O
+multiple	O
+post	O
+-	O
+injury	O
+time	O
+points	O
+,	O
+and	O
+good	O
+prediction	O
+of	O
+Acute	B-DISO
+Respiratory	I-DISO
+Distress	I-DISO
+Syndrome	I-DISO
+(	O
+overall	O
+AUC	O
+0	O
+.	O
+84	O
+-	O
+0	O
+.	O
+89	O
+)	O
+and	O
+venous	B-DISO
+thromboembolism	I-DISO
+(	O
+overall	O
+AUC	O
+0	O
+.	O
+73	O
+-	O
+0	O
+.	O
+83	O
+).	O
+
+Using	O
+high	O
+throughput	O
+sequencing	O
+to	O
+screen	O
+differentially	O
+expressed	B-PROC
+long	O
+non	O
+-	O
+coding	O
+RNA	O
+(	O
+lncRNA	O
+)	O
+during	O
+PDCoV	O
+infection	B-DISO
+,	O
+we	O
+identified	O
+99	O
+,	O
+41	O
+and	O
+33	O
+differentially	O
+expressed	O
+lncRNAs	O
+in	O
+the	O
+early	O
+,	O
+middle	O
+and	O
+late	O
+stages	O
+of	O
+infection	B-DISO
+,	O
+respectively	O
+.	O
+
+These	O
+results	O
+can	O
+provide	O
+new	O
+insights	O
+into	O
+PDCoV	O
+infection	B-DISO
+and	O
+antiviral	B-CHED
+strategies	O
+.	O
+
+We	O
+assessed	O
+the	O
+frequency	O
+of	O
+A	B-SPEC
+.	I-SPEC
+paragallinarum	I-SPEC
+using	O
+real	O
+-	O
+time	O
+PCR	O
+and	O
+clinical	O
+conditions	O
+present	O
+in	O
+samples	O
+from	O
+such	O
+flocks	O
+submitted	O
+to	O
+the	O
+California	B-SPEC
+Animal	B-SPEC
+Health	O
+and	O
+Food	O
+Safety	O
+Laboratory	O
+System	O
+(	O
+Davis	O
+,	O
+CA	O
+)	O
+in	O
+2018	O
+.	O
+
+Juvenile	O
+birds	B-SPEC
+(≤	O
+1	O
+y	O
+)	O
+were	O
+significantly	O
+more	O
+likely	O
+to	O
+be	O
+PCR	O
+-	O
+positive	O
+(	O
+p	O
+=	O
+0	O
+.	O
+017	O
+),	O
+and	O
+birds	B-SPEC
+diagnosed	O
+with	O
+respiratory	B-DISO
+disease	I-DISO
+had	O
+lower	O
+Ct	O
+values	O
+(	O
+p	O
+=	O
+0	O
+.	O
+001	O
+)	O
+than	O
+those	O
+without	O
+.	O
+
+ABSTRACT	O
+:	O
+Surfactin	O
+has	O
+antiviral	B-CHED
+activity	O
+against	O
+various	O
+enveloped	O
+viruses	B-SPEC
+by	O
+inhibiting	O
+viral	B-COMP
+membrane	I-COMP
+fusion	O
+.	O
+
+Like	O
+surfactin	O
+,	O
+SLP5	B-PRGE
+has	O
+a	O
+direct	O
+antiviral	B-CHED
+effect	O
+on	O
+PEDV	B-SPEC
+.	O
+
+The	O
+International	O
+Society	O
+for	O
+Influenza	O
+and	O
+other	O
+Respiratory	O
+Virus	B-DISO
+Diseases	I-DISO
+held	O
+its	O
+6th	O
+Antiviral	B-CHED
+Group	O
+(	O
+isirv	O
+-	O
+AVG	O
+)	O
+conference	O
+in	O
+Rockville	O
+,	O
+Maryland	O
+,	O
+November	O
+13	O
+-	O
+15	O
+,	O
+2018	O
+.	O
+
+TITLE	O
+:	O
+Genome	O
+Organization	O
+of	O
+Canada	B-SPEC
+Goose	I-SPEC
+Coronavirus	B-SPEC
+,	O
+A	O
+Novel	O
+Species	B-SPEC
+Identified	O
+in	O
+a	O
+Mass	O
+Die	O
+-	O
+off	O
+of	O
+Canada	O
+Geese	O
+.	O
+
+TITLE	O
+:	O
+Clinical	O
+characteristics	O
+and	O
+outcomes	O
+of	O
+patients	O
+with	O
+severe	O
+acute	B-DISO
+respiratory	I-DISO
+infections	I-DISO
+(	O
+SARI	O
+):	O
+results	O
+from	O
+the	O
+Egyptian	O
+surveillance	O
+study	O
+2010	O
+-	O
+2014	O
+.	O
+
+Delayed	O
+retroperitoneal	B-ANAT
+hemorrhage	B-DISO
+can	O
+develop	O
+during	O
+VV	O
+-	O
+ECMO	O
+management	O
+a	O
+few	O
+days	O
+after	O
+its	O
+initiation	O
+.	O
+
+Travel	O
+and	O
+exposure	O
+history	O
+from	O
+peripheral	O
+sources	O
+revealed	O
+that	O
+the	O
+patient	O
+had	O
+participated	O
+in	O
+a	O
+'	O
+mud	O
+-	O
+run	O
+'	O
+in	O
+Hawaii	O
+two	O
+weeks	O
+prior	O
+to	O
+symptom	B-DISO
+onset	O
+.	O
+
+However	O
+,	O
+limited	O
+reports	O
+have	O
+documented	O
+the	O
+potential	O
+negative	O
+effects	O
+of	O
+Fc	O
+fusion	O
+on	O
+vaccine	O
+antigens	B-CHED
+.	O
+
+However	O
+,	O
+the	O
+world	O
+continues	O
+to	O
+be	O
+confronted	O
+by	O
+longstanding	O
+,	O
+emerging	O
+,	O
+and	O
+reemerging	B-DISO
+infectious	I-DISO
+disease	I-DISO
+threats	O
+.	O
+
+The	O
+concern	O
+is	O
+magnified	O
+by	O
+rapid	O
+population	O
+growth	B-PROC
+in	O
+areas	O
+with	O
+weak	O
+health	O
+systems	O
+,	O
+urbanization	O
+,	O
+globalization	O
+,	O
+climate	O
+change	O
+,	O
+civil	O
+conflict	O
+,	O
+and	O
+the	O
+changing	O
+nature	O
+of	O
+pathogen	B-DISO
+transmission	I-DISO
+between	O
+human	B-SPEC
+and	O
+animal	B-SPEC
+populations	O
+.	O
+
+TITLE	O
+:	O
+Knowledge	O
+and	O
+practices	O
+of	O
+primary	O
+health	O
+care	O
+physicians	O
+regarding	O
+updated	O
+guidelines	O
+of	O
+MERS	O
+-	O
+CoV	O
+infection	B-DISO
+in	O
+Abha	O
+city	O
+.	O
+
+The	O
+mechanisms	O
+of	O
+ALI	O
+remain	O
+unclear	O
+in	O
+critically	B-DISO
+ill	I-DISO
+patients	O
+.	O
+
+Trace	O
+element	O
+and	O
+PAH	B-DISO
+analysis	O
+demonstrated	O
+the	O
+almost	O
+similar	O
+chemical	O
+composition	O
+of	O
+both	O
+particle	O
+fractions	O
+.	O
+
+Taken	O
+together	O
+,	O
+these	O
+results	O
+strongly	O
+motivate	O
+the	O
+update	O
+of	O
+current	O
+regulations	O
+regarding	O
+ambient	O
+PM	O
+concentrations	O
+to	O
+include	O
+UFP	O
+and	O
+limit	O
+their	O
+emission	B-ANAT
+.	O
+
+ABSTRACT	O
+:	O
+Porcine	O
+epidemic	O
+diarrhea	O
+virus	O
+(	O
+PEDV	B-SPEC
+)	O
+is	O
+a	O
+major	O
+etiological	O
+agent	O
+of	O
+porcine	B-SPEC
+epidemic	B-DISO
+diarrhea	I-DISO
+around	O
+the	O
+world	O
+.	O
+
+No	O
+cross	B-PROC
+-	I-PROC
+reaction	I-PROC
+with	O
+other	O
+porcine	B-SPEC
+infectious	B-DISO
+viruses	B-SPEC
+was	O
+observed	O
+.	O
+
+These	O
+results	O
+indicate	O
+that	O
+this	O
+RT	O
+-	O
+PSR	O
+assay	O
+is	O
+capable	O
+of	O
+accurately	O
+detecting	O
+PEDV	B-SPEC
+,	O
+and	O
+has	O
+the	O
+advantages	O
+of	O
+high	O
+specificity	O
+and	O
+sensitivity	O
+for	O
+the	O
+detection	O
+of	O
+PEDV	B-SPEC
+.	O
+
+Target	O
+antigen	B-CHED
+preparation	O
+is	O
+a	O
+main	O
+bottleneck	O
+associated	O
+with	O
+the	O
+panning	O
+process	O
+.	O
+
+She	O
+required	O
+a	O
+high	O
+-	O
+flow	O
+nasal	B-ANAT
+cannula	B-SPEC
+with	O
+a	O
+subsequent	O
+upgrade	O
+to	O
+the	O
+intensive	O
+care	O
+unit	O
+(	O
+ICU	O
+)	O
+for	O
+increasing	O
+respiratory	O
+compromise	O
+.	O
+
+Historically	O
+thought	O
+to	O
+be	O
+limited	O
+to	O
+pandemic	O
+viruses	B-SPEC
+,	O
+improved	O
+detection	O
+of	O
+hRV	O
+has	O
+led	O
+to	O
+its	O
+implication	O
+in	O
+serious	O
+respiratory	B-DISO
+disorders	I-DISO
+extending	O
+beyond	O
+the	O
+oropharynx	B-ANAT
+in	O
+immunocompetent	O
+hosts	B-COMP
+.	O
+
+All	O
+of	O
+the	O
+patients	O
+were	O
+initially	O
+hypoxic	B-DISO
+and	O
+some	O
+had	O
+PaO	B-PROC
+
+ABSTRACT	O
+:	O
+Porcine	B-SPEC
+epidemic	B-DISO
+diarrhea	I-DISO
+virus	I-SPEC
+(	O
+PEDV	B-SPEC
+)	O
+induces	O
+an	O
+often	O
+fatal	O
+gastrointestinal	B-DISO
+disease	I-DISO
+in	O
+piglets	O
+.	O
+
+At	O
+the	O
+same	O
+time	O
+,	O
+in	O
+the	O
+PPAR	B-PROC
+pathway	I-PROC
+genes	O
+of	O
+fatty	B-CHED
+acid	I-CHED
+-	O
+binding	B-FUNC
+protein	B-CHED
+(	O
+FABP	B-PRGE
+)	O
+family	B-SPEC
+members	O
+were	O
+observed	O
+with	O
+remarkably	O
+differential	O
+expressions	O
+.	O
+
+RESULTS	O
+:	O
+Twenty	O
+thousand	O
+six	O
+hundred	O
+seventy	O
+-	O
+four	O
+differentially	O
+expressed	B-PROC
+mRNAs	O
+were	O
+identified	O
+in	O
+5	O
+-	O
+day	O
+-	O
+old	O
+piglets	O
+responded	O
+to	O
+PDCoV	O
+experimental	O
+infections	B-DISO
+.	O
+
+This	O
+topic	O
+has	O
+been	O
+brought	O
+into	O
+sharp	O
+focus	O
+in	O
+recent	O
+years	O
+following	O
+significant	O
+outbreaks	O
+of	O
+viral	B-DISO
+diseases	I-DISO
+such	O
+as	O
+those	O
+causing	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+and	O
+Middle	O
+East	O
+respiratory	O
+syndrome	B-DISO
+,	O
+as	O
+well	O
+as	O
+devastating	O
+outbreaks	O
+of	O
+diseases	O
+caused	O
+by	O
+the	O
+Ebola	O
+,	O
+Marburg	O
+,	O
+Zika	O
+and	O
+Lassa	B-DISO
+fever	I-DISO
+viruses	B-SPEC
+,	O
+to	O
+name	B-SPEC
+only	O
+a	O
+few	O
+examples	O
+.	O
+
+ABSTRACT	O
+:	O
+Pesticide	B-CHED
+self	O
+-	O
+poisoning	O
+is	O
+rare	O
+in	O
+developed	O
+countries	O
+.	O
+
+Studies	O
+reporting	O
+on	O
+acute	O
+pyrethrins	B-CHED
+or	O
+pyrethroids	O
+insecticide	B-CHED
+poisoning	O
+in	O
+both	O
+occupational	O
+and	O
+non	O
+-	O
+occupational	O
+cases	O
+usually	O
+describe	O
+mild	O
+and	O
+self	O
+-	O
+limiting	O
+respiratory	B-DISO
+symptoms	I-DISO
+as	O
+the	O
+predominant	O
+symptom	B-DISO
+.	O
+
+Patients	O
+with	O
+asthma	B-PATH
+or	O
+allergies	B-DISO
+are	O
+apparently	O
+more	O
+at	O
+risk	O
+for	O
+severe	O
+symptoms	O
+.	O
+
+TITLE	O
+:	O
+Potent	O
+antiviral	B-CHED
+activity	O
+of	O
+carbohydrate	B-CHED
+-	O
+specific	O
+algal	O
+and	O
+leguminous	O
+lectins	O
+from	O
+the	O
+Brazilian	O
+biodiversity	O
+.	O
+
+TITLE	O
+:	O
+A	O
+possible	O
+link	O
+between	O
+recurrent	B-DISO
+upper	I-DISO
+respiratory	I-DISO
+tract	I-DISO
+infections	I-DISO
+and	O
+lower	O
+cytokine	B-PROC
+production	I-PROC
+in	O
+patients	O
+with	O
+Q	B-DISO
+fever	I-DISO
+fatigue	B-DISO
+syndrome	B-DISO
+.	O
+
+Thus	O
+,	O
+using	O
+an	O
+experimental	O
+and	O
+translational	B-PROC
+approach	O
+,	O
+we	O
+test	O
+the	O
+hypothesis	O
+that	O
+a	O
+tight	O
+regulation	B-PROC
+of	O
+UTC	O
+is	O
+mandatory	O
+to	O
+fine	O
+-	O
+tune	O
+host	B-PROC
+response	I-PROC
+,	O
+and	O
+,	O
+subsequently	O
+to	O
+prevent	O
+emergence	O
+of	O
+an	O
+aberrant	O
+response	O
+leading	O
+to	O
+excessive	O
+tissue	B-ANAT
+damages	O
+,	O
+and	O
+eventually	O
+,	O
+ARDS	B-DISO
+.	O
+
+Despite	O
+full	O
+intensive	O
+care	O
+support	O
+and	O
+resolution	O
+of	O
+his	O
+respiratory	B-DISO
+failure	I-DISO
+with	O
+non	O
+-	O
+invasive	O
+positive	O
+pressure	O
+ventilation	O
+,	O
+the	O
+patient	O
+did	O
+not	O
+regained	O
+consciousness	O
+.	O
+
+These	O
+,	O
+and	O
+other	O
+recent	O
+public	O
+health	O
+events	O
+,	O
+provide	O
+an	O
+opportunity	O
+for	O
+us	O
+to	O
+review	O
+and	O
+reflect	O
+on	O
+the	O
+evolution	B-PROC
+of	O
+Canada	O
+'	O
+s	O
+public	O
+health	O
+emergency	B-DISO
+response	O
+over	O
+the	O
+past	O
+15	O
+years	O
+-	O
+from	O
+SARS	B-DISO
+,	O
+to	O
+the	O
+2009	O
+H1N1	O
+pandemic	O
+influenza	B-DISO
+,	O
+to	O
+Ebola	B-SPEC
+virus	I-SPEC
+and	O
+Zika	B-DISO
+virus	I-DISO
+disease	I-DISO
+.	O
+
+Key	O
+lessons	O
+have	O
+been	O
+learned	B-PROC
+and	O
+milestones	O
+achieved	O
+that	O
+have	O
+shaped	O
+and	O
+sharpened	O
+our	O
+response	O
+approach	O
+and	O
+structures	O
+.	O
+
+While	O
+SARS	B-DISO
+was	O
+a	O
+wake	B-PROC
+-	O
+up	O
+-	O
+call	O
+to	O
+strengthen	O
+infection	B-DISO
+prevention	O
+and	O
+control	O
+capacity	O
+in	O
+health	O
+care	O
+settings	O
+and	O
+led	O
+to	O
+the	O
+formation	B-PROC
+of	O
+the	O
+Public	O
+Health	O
+Agency	O
+of	O
+Canada	O
+,	O
+it	O
+also	O
+strengthened	O
+our	O
+Federal	O
+/	O
+Provincial	O
+/	O
+Territorial	O
+(	O
+FPT	O
+)	O
+senior	O
+-	O
+level	O
+governance	O
+and	O
+led	O
+to	O
+agreements	O
+for	O
+pan	B-COMP
+-	O
+Canadian	O
+mutual	O
+aid	O
+and	O
+infectious	B-DISO
+disease	I-DISO
+information	O
+sharing	O
+.	O
+
+Transient	O
+left	B-DISO
+ventricular	I-DISO
+dysfunction	I-DISO
+and	O
+electrocardiographic	O
+changes	O
+could	O
+mimic	O
+acute	B-DISO
+coronary	I-DISO
+syndrome	I-DISO
+but	O
+there	O
+are	O
+actually	O
+no	O
+obstructive	O
+coronary	B-ANAT
+lesions	O
+.	O
+
+ABSTRACT	O
+:	O
+The	O
+emergence	O
+of	O
+the	O
+Middle	O
+East	O
+Respiratory	O
+Syndrome	O
+Corona	B-CHED
+Virus	B-SPEC
+(	O
+MERS	O
+-	O
+CoV	O
+)	O
+in	O
+the	O
+Middle	O
+East	O
+in	O
+2012	O
+was	O
+associated	O
+with	O
+an	O
+overwhelming	O
+uncertainty	O
+about	O
+its	O
+epidemiological	O
+and	O
+clinical	O
+characteristics	O
+.	O
+
+Once	O
+dromedary	B-SPEC
+camels	B-SPEC
+(	O
+
+Respiratory	O
+viruses	B-SPEC
+are	O
+commonly	O
+detected	O
+in	O
+both	O
+symptomatic	O
+and	O
+asymptomatic	O
+periods	B-PROC
+.	O
+
+TITLE	O
+:	O
+Pathogenesis	B-PROC
+of	O
+oral	B-ANAT
+type	O
+I	O
+feline	B-DISO
+infectious	I-DISO
+peritonitis	I-DISO
+virus	B-SPEC
+(	O
+FIPV	B-SPEC
+)	O
+infection	B-DISO
+:	O
+Antibody	B-COMP
+-	O
+dependent	O
+enhancement	O
+infection	O
+of	O
+cats	B-SPEC
+with	O
+type	O
+I	O
+FIPV	B-SPEC
+via	O
+the	O
+oral	B-ANAT
+route	O
+.	O
+
+Many	O
+strains	O
+of	O
+type	O
+I	O
+FIPV	O
+do	O
+not	O
+cause	O
+FIP	B-DISO
+by	O
+inoculation	O
+through	O
+the	O
+oral	B-ANAT
+route	O
+in	O
+cats	B-SPEC
+.	O
+
+ABSTRACT	O
+:	O
+The	O
+determination	O
+of	O
+risk	O
+factors	O
+for	O
+acute	O
+respiratory	O
+distress	O
+syndrome	O
+(	O
+ARDS	B-DISO
+)	O
+patients	O
+remains	O
+a	O
+challenge	O
+.	O
+
+The	O
+total	O
+mortality	O
+in	O
+ARDS	B-DISO
+patients	O
+was	O
+39	O
+.	O
+13	O
+%	O
+(	O
+81	O
+/	O
+207	O
+)	O
+compared	O
+to	O
+13	O
+.	O
+57	O
+%	O
+(	O
+151	O
+/	O
+1	O
+,	O
+113	O
+)	O
+in	O
+the	O
+whole	O
+ICU	O
+population	O
+.	O
+
+Logistic	O
+regression	O
+analysis	O
+showed	O
+that	O
+acute	O
+physiology	O
+and	O
+chronic	O
+health	O
+evaluation	O
+II	O
+(	O
+APACHE	O
+II	O
+)	O
+score	O
+(	O
+OR	O
+3	O
+.	O
+4316	O
+;	O
+95	O
+%	O
+CI	O
+:	O
+1	O
+.	O
+3130	O
+-	O
+8	O
+.	O
+9686	O
+;	O
+P	O
+=	O
+0	O
+.	O
+0119	O
+),	O
+number	O
+of	O
+organ	B-DISO
+failure	I-DISO
+(	O
+OR	O
+3	O
+.	O
+4928	O
+;	O
+95	O
+%	O
+CI	O
+:	O
+1	O
+.	O
+9775	O
+-	O
+6	O
+.	O
+1693	O
+;	O
+P	O
+<	O
+0	O
+.	O
+0001	O
+),	O
+mean	O
+arterial	B-PROC
+pressure	I-PROC
+(	O
+MAP	O
+)	O
+(	O
+OR	O
+5	O
+.	O
+1049	O
+;	O
+95	O
+%	O
+CI	O
+:	O
+1	O
+.	O
+8317	O
+-	O
+14	O
+.	O
+2274	O
+;	O
+P	O
+=	O
+0	O
+.	O
+0018	O
+),	O
+driving	O
+pressure	O
+(	O
+OR	O
+6	O
+.	O
+0017	O
+;	O
+95	O
+%	O
+CI	O
+:	O
+2	O
+.	O
+1746	O
+-	O
+16	O
+.	O
+5641	O
+;	O
+P	O
+=	O
+0	O
+.	O
+0005	O
+)	O
+and	O
+lactate	B-CHED
+level	O
+(	O
+OR	O
+4	O
+.	O
+0754	O
+;	O
+95	O
+%	O
+CI	O
+:	O
+1	O
+.	O
+6114	O
+-	O
+10	O
+.	O
+3068	O
+;	O
+P	O
+=	O
+0	O
+.	O
+0030	O
+)	O
+were	O
+influence	O
+factors	O
+for	O
+survival	O
+;	O
+severity	O
+of	O
+ARDS	B-DISO
+(	O
+OR	O
+1	O
+.	O
+6715	O
+;	O
+95	O
+%	O
+CI	O
+:	O
+1	O
+.	O
+0307	O
+-	O
+2	O
+.	O
+7108	O
+;	O
+P	O
+=	O
+0	O
+.	O
+0373	O
+),	O
+ventilator	B-DISO
+-	I-DISO
+associated	I-DISO
+pneumonia	I-DISO
+(	O
+VAP	O
+)	O
+(	O
+OR	O
+7	O
+.	O
+3746	O
+;	O
+95	O
+%	O
+CI	O
+:	O
+2	O
+.	O
+9799	O
+-	O
+18	O
+.	O
+2505	O
+;	O
+P	O
+<	O
+0	O
+.	O
+0001	O
+)	O
+and	O
+transfusion	O
+history	O
+(	O
+OR	O
+2	O
+.	O
+2822	O
+;	O
+95	O
+%	O
+CI	O
+:	O
+1	O
+.	O
+0462	O
+-	O
+4	O
+.	O
+9783	O
+;	O
+P	O
+=	O
+0	O
+.	O
+0381	O
+)	O
+were	O
+influence	O
+factors	O
+for	O
+duration	O
+of	O
+mechanical	O
+ventilation	O
+.	O
+
+There	O
+is	O
+limited	O
+information	O
+regarding	O
+the	O
+prevalence	O
+of	O
+pathogens	O
+related	O
+to	O
+CIRD	O
+in	O
+the	O
+United	O
+States	O
+as	O
+well	O
+as	O
+the	O
+role	O
+of	O
+co	B-DISO
+-	I-DISO
+infections	I-DISO
+in	O
+the	O
+pathogenesis	B-DISO
+of	O
+the	O
+syndrome	B-DISO
+.	O
+
+Considering	O
+the	O
+diversity	O
+of	O
+bat	B-ENZY
+coronaviruses	O
+,	O
+bat	B-ENZY
+species	B-SPEC
+and	O
+populations	O
+,	O
+we	O
+expect	O
+to	O
+discover	O
+more	O
+bat	B-ENZY
+CoVs	O
+through	O
+virus	B-SPEC
+surveillance	O
+.	O
+
+Although	O
+some	O
+other	O
+livestock	O
+animal	B-SPEC
+species	B-SPEC
+have	O
+been	O
+shown	O
+to	O
+be	O
+susceptible	O
+to	O
+MERS	O
+-	O
+CoV	O
+,	O
+it	O
+is	O
+not	O
+fully	O
+understood	O
+why	O
+the	O
+spread	O
+of	O
+the	O
+virus	B-SPEC
+in	O
+these	O
+animal	B-SPEC
+species	B-SPEC
+has	O
+not	O
+been	O
+observed	O
+in	O
+the	O
+field	O
+.	O
+
+Gene	O
+ontology	O
+analysis	O
+of	O
+the	O
+host	B-COMP
+interactome	O
+highlighted	O
+the	O
+involvement	O
+of	O
+ORF3	O
+in	O
+endosomal	O
+and	O
+immune	O
+signaling	B-PROC
+pathways	B-PROC
+.	O
+
+VPS36	B-PRGE
+was	O
+found	O
+to	O
+interact	O
+with	O
+ORF3	O
+regardless	O
+of	O
+its	O
+GLUE	O
+domain	O
+.	O
+
+Ongoing	O
+investigations	O
+suggest	O
+that	O
+P53	B-PRGE
+exerts	B-PROC
+a	O
+prominent	O
+strategic	O
+role	O
+in	O
+crucial	O
+signaling	B-PROC
+cascades	O
+,	O
+in	O
+charge	O
+of	O
+both	O
+the	O
+maintenance	O
+and	O
+defense	O
+of	O
+pulmonary	B-ANAT
+endothelium	B-ANAT
+against	O
+toxic	O
+intruders	O
+.	O
+
+ABSTRACT	O
+:	O
+The	O
+Middle	O
+East	O
+respiratory	O
+syndrome	O
+coronavirus	B-SPEC
+(	O
+MERS	O
+-	O
+CoV	O
+)	O
+was	O
+identified	O
+in	O
+2012	O
+during	O
+the	O
+first	O
+Middle	O
+East	O
+respiratory	O
+syndrome	B-DISO
+(	O
+MERS	O
+)	O
+outbreaks	O
+.	O
+
+Recombinant	O
+vectors	O
+based	O
+on	O
+human	B-SPEC
+adenoviruses	B-SPEC
+type	O
+5	O
+(	O
+rAd5	O
+)	O
+were	O
+used	O
+as	O
+delivery	O
+vehicles	O
+.	O
+
+The	O
+results	O
+showed	O
+that	O
+the	O
+limit	O
+of	O
+detection	O
+can	O
+reach	B-PROC
+as	O
+low	O
+as	O
+10	O
+copies	O
+in	O
+singular	B-CHED
+real	O
+-	O
+time	O
+RT	O
+-	O
+qPCR	O
+assays	O
+and	O
+100	O
+copies	O
+in	O
+multiplex	O
+real	O
+-	O
+time	O
+RT	O
+-	O
+qPCR	O
+assay	O
+,	O
+with	O
+all	O
+correlation	O
+coefficients	O
+(	O
+R	O
+
+We	O
+found	O
+that	O
+the	O
+gene	B-PROC
+expression	I-PROC
+of	O
+col3a1	B-PRGE
+and	O
+hydroxyproline	B-CHED
+contents	O
+in	O
+the	O
+lungs	B-ANAT
+were	O
+significantly	O
+increased	O
+24	O
+h	O
+after	O
+LPS	B-DISO
+injection	O
+.	O
+
+Most	O
+of	O
+these	O
+unigenes	O
+are	O
+annotated	O
+in	O
+cellular	B-COMP
+processes	O
+,	O
+the	O
+cell	B-COMP
+and	O
+binding	B-FUNC
+.	O
+
+Extracorporeal	O
+life	O
+support	O
+can	O
+provide	O
+adequate	O
+oxygenation	B-PROC
+while	O
+allowing	O
+the	O
+lungs	B-ANAT
+to	O
+rest	B-FUNC
+and	O
+heal	B-PROC
+,	O
+which	O
+might	O
+be	O
+an	O
+ideal	O
+therapy	O
+in	O
+this	O
+patient	O
+group	O
+,	O
+although	O
+long	O
+-	O
+term	O
+clinical	O
+and	O
+radiological	O
+outcomes	O
+are	O
+not	O
+known	O
+.	O
+
+ABSTRACT	O
+:	O
+Middle	O
+East	O
+respiratory	O
+syndrome	O
+coronavirus	B-SPEC
+(	O
+MERS	O
+-	O
+CoV	O
+)	O
+is	O
+considered	O
+to	O
+be	O
+responsible	O
+for	O
+a	O
+new	O
+viral	O
+epidemic	O
+and	O
+an	O
+emergent	O
+threat	O
+to	O
+global	O
+health	O
+security	O
+.	O
+
+RESULTS	O
+:	O
+A	O
+total	O
+of	O
+229	O
+MERS	O
+-	O
+CoV	O
+cases	O
+,	O
+including	O
+70	O
+deaths	B-PROC
+(	O
+30	O
+.	O
+5	O
+%),	O
+were	O
+recorded	O
+in	O
+the	O
+disease	O
+outbreak	O
+news	O
+on	O
+world	O
+health	O
+organization	O
+website	O
+over	O
+the	O
+study	O
+period	O
+.	O
+
+S1	O
+is	O
+one	O
+of	O
+two	O
+protein	B-CHED
+domains	O
+in	O
+the	O
+spike	O
+(	O
+S	O
+)	O
+glycoprotein	B-CHED
+and	O
+is	O
+responsible	O
+for	O
+enteric	O
+tropism	B-PROC
+,	O
+sialic	B-CHED
+acid	I-CHED
+recognition	O
+,	O
+and	O
+host	B-COMP
+receptor	B-FUNC
+binding	I-FUNC
+.	O
+
+ROS	B-PRGE
+and	O
+p53	B-PRGE
+play	O
+key	O
+roles	O
+in	O
+regulating	O
+many	O
+kinds	O
+of	O
+cell	B-COMP
+process	I-COMP
+during	O
+viral	B-DISO
+infection	I-DISO
+,	O
+however	O
+,	O
+the	O
+exact	O
+function	O
+in	O
+PEDV	B-SPEC
+-	O
+induced	O
+apoptosis	B-PATH
+remains	O
+unclear	O
+.	O
+
+Taken	O
+together	O
+,	O
+the	O
+results	O
+of	O
+this	O
+study	O
+demonstrate	O
+that	O
+activated	O
+p53	B-PRGE
+and	O
+accumulated	O
+ROS	B-CHED
+participated	O
+in	O
+PEDV	B-SPEC
+-	O
+induced	O
+apoptosis	B-PATH
+and	O
+p53	B-PRGE
+could	O
+be	O
+regulated	O
+by	O
+ROS	B-CHED
+during	O
+PEDV	B-SPEC
+infection	B-DISO
+.	O
+
+ABSTRACT	O
+:	O
+Middle	O
+East	O
+respiratory	O
+syndrome	B-DISO
+(	O
+MERS	O
+)	O
+is	O
+known	O
+to	O
+be	O
+transmitted	B-DISO
+through	O
+close	O
+contact	O
+.	O
+
+In	O
+this	O
+study	O
+,	O
+the	O
+possibility	O
+of	O
+MERS	O
+spreading	O
+through	O
+airflow	B-PROC
+was	O
+investigated	O
+on	O
+the	O
+eighth	O
+floor	O
+of	O
+Pyeongtaek	O
+St	O
+Mary	O
+'	O
+s	O
+Hospital	O
+.	O
+
+When	O
+a	O
+passive	O
+tracer	B-CHED
+was	O
+released	O
+in	O
+ward	O
+8104	O
+,	O
+where	O
+the	O
+index	O
+patient	O
+was	O
+hospitalized	O
+,	O
+the	O
+passive	O
+tracer	B-CHED
+spread	O
+through	O
+the	O
+indoor	O
+airflow	B-PROC
+,	O
+which	O
+was	O
+created	O
+by	O
+the	O
+outdoor	O
+airflow	O
+.	O
+
+This	O
+result	O
+indicates	O
+that	O
+MERS	O
+may	O
+have	O
+spread	O
+through	O
+airflow	B-PROC
+.	O
+
+His	O
+medical	O
+history	O
+included	O
+morbid	B-DISO
+obesity	I-DISO
+(	O
+BMI	O
+43	O
+)	O
+and	O
+alcohol	B-DISO
+dependence	I-DISO
+syndrome	I-DISO
+.	O
+
+Forty	O
+patients	O
+(	O
+48	O
+%	O
+adenocarcinoma	B-DISO
+)	O
+met	B-CHED
+our	O
+inclusion	O
+criteria	O
+.	O
+
+All	O
+patients	O
+underwent	O
+a	O
+three	O
+-	O
+stage	O
+procedure	O
+with	O
+cervical	B-ANAT
+anastomosis	B-DISO
+and	O
+90	O
+%	O
+of	O
+the	O
+patients	O
+underwent	O
+neoadjuvant	O
+chemoradiotherapy	O
+.	O
+
+Among	O
+positive	O
+samples	O
+,	O
+120	O
+(	O
+19	O
+.	O
+2	O
+%)	O
+samples	O
+were	O
+positive	O
+for	O
+H1N1	O
+,	O
+61	O
+(	O
+9	O
+.	O
+8	O
+%)	O
+for	O
+H3N2	B-CHED
+and	O
+19	O
+(	O
+3	O
+%)	O
+were	O
+positive	O
+for	O
+Influenza	B-DISO
+B	O
+.	O
+Highest	O
+number	O
+of	O
+positive	O
+cases	O
+occurred	O
+in	O
+the	O
+month	O
+of	O
+January	O
+,	O
+i	O
+.	O
+e	O
+.	O
+148	O
+(	O
+74	O
+%)	O
+cases	O
+.	O
+
+Maximum	O
+patients	O
+with	O
+H3N2	B-CHED
+infection	B-DISO
+were	O
+in	O
+age	O
+group	O
+-	O
+III	O
+;	O
+30	O
+(	O
+49	O
+.	O
+2	O
+%)	O
+of	O
+the	O
+total	O
+61	O
+.	O
+
+220	O
+stable	O
+COPD	B-DISO
+patients	O
+were	O
+included	O
+.	O
+
+The	O
+level	O
+of	O
+plasma	B-PRGE
+IL	B-FUNC
+-	I-FUNC
+6	I-FUNC
+was	O
+greater	O
+in	O
+higher	O
+CCI	O
+score	O
+(≥	O
+4	O
+)	O
+group	O
+compared	O
+with	O
+lower	O
+CCI	O
+score	O
+(<	O
+4	O
+)	O
+group	O
+(	O
+CONCLUSIONS	O
+:	O
+Patients	O
+with	O
+a	O
+higher	O
+CCI	O
+score	O
+had	O
+more	O
+severe	O
+symptoms	O
+,	O
+functional	O
+impairment	B-DISO
+and	O
+higher	O
+level	O
+of	O
+inflammatory	O
+factors	O
+and	O
+high	O
+frequency	O
+of	O
+hospital	O
+admission	O
+due	O
+to	O
+acute	O
+exacerbation	O
+.	O
+
+ABSTRACT	O
+:	O
+Human	B-SPEC
+Respiratory	I-SPEC
+Syncytial	I-SPEC
+Virus	I-SPEC
+(	O
+RSV	B-SPEC
+)	O
+is	O
+the	O
+primary	O
+cause	O
+of	O
+bronchopneumonia	B-DISO
+in	O
+infants	O
+and	O
+children	O
+worldwide	O
+.	O
+
+Differential	O
+expression	B-PROC
+of	O
+the	O
+genes	O
+was	O
+observed	O
+at	O
+different	O
+time	O
+-	O
+points	O
+of	O
+egg	B-ANAT
+-	O
+shell	B-ANAT
+formation	B-PROC
+.	O
+
+The	O
+expression	B-PROC
+levels	O
+of	O
+citrate	B-PRGE
+synthase	I-PRGE
+(	O
+CS	O
+),	O
+cytochrome	B-PRGE
+C	I-PRGE
+,	I-PRGE
+somatic	I-PRGE
+(	I-PRGE
+CYC	I-PRGE
+,	I-PRGE
+S	I-PRGE
+)	I-PRGE
+and	O
+sodium	B-PRGE
+-	I-PRGE
+potassium	I-PRGE
+adenosine	B-CHED
+triphosphatase	B-ENZY
+(	O
+Na	O
+
+Eleven	O
+peptides	B-CHED
+were	O
+further	O
+tested	O
+in	O
+ELISA	O
+with	O
+individual	O
+serum	B-COMP
+samples	O
+,	O
+and	O
+three	O
+were	O
+selected	O
+for	O
+further	O
+screening	O
+.	O
+
+ABSTRACT	O
+:	O
+Abdominal	B-ANAT
+compartment	I-ANAT
+syndrome	I-DISO
+patients	O
+suffer	O
+severe	O
+obstacles	O
+such	O
+as	O
+kidney	B-DISO
+failure	I-DISO
+and	O
+shock	O
+.	O
+
+The	O
+current	O
+study	O
+intended	O
+to	O
+study	O
+the	O
+abdominal	B-DISO
+compartment	I-DISO
+syndrome	I-DISO
+and	O
+the	O
+concomitant	O
+risk	O
+factors	O
+among	O
+hospitalised	O
+patients	O
+in	O
+ICU	O
+,	O
+by	O
+using	O
+the	O
+Intra	O
+-	O
+abdominal	B-ANAT
+pressure	O
+test	O
+.	O
+
+The	O
+control	O
+group	O
+consisted	O
+of	O
+children	O
+without	O
+lesions	O
+of	O
+oral	B-ANAT
+cavity	I-ANAT
+(	O
+66	O
+people	O
+).	O
+
+DIC	B-DISO
+scores	O
+as	O
+well	O
+as	O
+disease	O
+severity	O
+and	O
+the	O
+development	B-PROC
+of	O
+MODS	B-DISO
+on	O
+the	O
+day	O
+of	O
+the	O
+diagnosis	O
+of	O
+severe	B-DISO
+sepsis	I-DISO
+(	O
+day	O
+0	O
+)	O
+and	O
+at	O
+day	O
+3	O
+were	O
+evaluated	O
+.	O
+
+DIC	B-DISO
+patients	O
+also	O
+showed	O
+a	O
+lower	O
+survival	O
+probability	O
+than	O
+non	O
+-	O
+DIC	B-DISO
+patients	O
+(	O
+Log	O
+rank	O
+p	O
+=	O
+0	O
+.	O
+028	O
+).	O
+
+The	O
+new	O
+development	B-PROC
+of	O
+DIC	B-DISO
+and	O
+persistent	O
+DIC	B-DISO
+from	O
+days	O
+0	O
+to	O
+3	O
+were	O
+associated	O
+with	O
+a	O
+high	O
+incidence	O
+of	O
+MODS	B-DISO
+and	O
+low	O
+survival	O
+probability	O
+.	O
+
+In	O
+the	O
+first	O
+two	O
+decades	O
+of	O
+the	O
+21st	O
+century	O
+,	O
+we	O
+have	O
+born	O
+witness	O
+to	O
+the	O
+emergence	O
+of	O
+newly	O
+recognized	O
+coronaviruses	O
+that	O
+have	O
+rapidly	O
+spread	O
+around	O
+the	O
+globe	B-ANAT
+,	O
+including	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+virus	B-SPEC
+(	O
+SARS	B-DISO
+)	O
+and	O
+Middle	O
+Eastern	O
+respiratory	O
+syndrome	B-DISO
+virus	B-SPEC
+(	O
+MERS	O
+).	O
+
+Here	O
+,	O
+we	O
+explore	O
+the	O
+basic	O
+epidemiology	O
+,	O
+clinical	O
+presentation	O
+,	O
+histopathology	O
+,	O
+and	O
+clinical	O
+laboratory	O
+diagnosis	O
+of	O
+these	O
+four	O
+pathogens	O
+and	O
+emphasize	O
+themes	O
+in	O
+humans	O
+'	O
+evolving	O
+relationship	O
+with	O
+our	O
+natural	O
+environment	O
+that	O
+have	O
+contributed	O
+to	O
+the	O
+infectious	B-DISO
+burden	O
+.	O
+
+Genomic	O
+sequencing	O
+identified	O
+a	O
+unique	O
+8	O
+-	O
+nt	O
+DEL	O
+in	O
+the	O
+extreme	O
+C	O
+-	O
+terminal	O
+region	O
+of	O
+the	O
+S	B-PRGE
+gene	I-PRGE
+at	O
+the	O
+4th	O
+passage	O
+(	O
+KNU	O
+-	O
+1807	O
+-	O
+P4	O
+)	O
+compared	O
+to	O
+its	O
+original	O
+sample	O
+.	O
+
+This	O
+DEL	O
+resulted	O
+in	O
+the	O
+premature	O
+termination	O
+of	O
+S	O
+by	O
+nine	O
+amino	B-CHED
+acid	I-CHED
+residues	O
+(	O
+EVFEKVHVQ	O
+),	O
+which	O
+contained	O
+a	O
+KxHxx	O
+motif	O
+that	O
+is	O
+a	O
+potential	O
+endoplasmic	B-COMP
+reticulum	I-COMP
+retrieval	O
+signal	O
+.	O
+
+ABSTRACT	O
+:	O
+Serum	B-PRGE
+troponin	I-PRGE
+is	O
+a	O
+marker	O
+of	O
+cardiac	O
+myocyte	O
+damage	O
+that	O
+is	O
+typically	O
+used	O
+to	O
+assess	O
+for	O
+myocardial	B-DISO
+infarction	I-DISO
+in	O
+the	O
+setting	O
+of	O
+acute	B-DISO
+coronary	I-DISO
+syndrome	I-DISO
+.	O
+
+However	O
+,	O
+non	B-DISO
+-	I-DISO
+ST	I-DISO
+elevation	I-DISO
+myocardial	I-DISO
+infarction	I-DISO
+(	O
+NSTEMI	O
+)	O
+had	O
+not	O
+yet	O
+been	O
+ruled	O
+out	O
+and	O
+the	O
+patient	O
+was	O
+started	O
+on	O
+started	O
+on	O
+a	O
+heparin	B-CHED
+infusion	O
+per	O
+the	O
+ACS	B-FUNC
+protocol	O
+.	O
+
+TITLE	O
+:	O
+Acute	B-DISO
+Respiratory	I-DISO
+Distress	I-DISO
+Syndrome	I-DISO
+Phenotypes	O
+.	O
+
+ABSTRACT	O
+:	O
+Despite	O
+the	O
+breadth	O
+of	O
+life	O
+-	O
+sustaining	O
+interventions	O
+available	O
+,	O
+mortality	O
+in	O
+patients	O
+with	O
+acute	O
+respiratory	O
+distress	O
+syndrome	O
+(	O
+ARDS	B-DISO
+)	O
+remains	O
+high	O
+.	O
+
+While	O
+the	O
+outbreak	O
+was	O
+controlled	O
+successfully	O
+in	O
+6	O
+weeks	O
+,	O
+progress	O
+in	O
+management	O
+was	O
+inhibited	O
+by	O
+a	O
+lack	O
+of	O
+institutional	O
+readiness	O
+to	O
+implement	O
+infection	B-DISO
+control	O
+(	O
+IC	O
+)	O
+measures	O
+and	O
+reduce	O
+patient	O
+flow	O
+,	O
+low	O
+staff	O
+morale	O
+and	O
+high	O
+anxiety	O
+.	O
+
+TITLE	O
+:	O
+Mechanical	O
+power	O
+normalized	O
+to	O
+predicted	O
+body	B-ANAT
+weight	O
+as	O
+a	O
+predictor	O
+of	O
+mortality	O
+in	O
+patients	O
+with	O
+acute	O
+respiratory	O
+distress	O
+syndrome	O
+.	O
+
+ABSTRACT	O
+:	O
+Protective	O
+mechanical	O
+ventilation	O
+based	O
+on	O
+multiple	O
+ventilator	O
+parameters	O
+such	O
+as	O
+tidal	O
+volume	O
+,	O
+plateau	O
+pressure	O
+,	O
+and	O
+driving	O
+pressure	O
+has	O
+been	O
+widely	O
+used	O
+in	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+(	O
+ARDS	B-DISO
+).	O
+
+ABSTRACT	O
+:	O
+Worldwide	O
+outbreaks	O
+of	O
+infectious	O
+diseases	O
+necessitate	O
+the	O
+development	B-PROC
+of	O
+rapid	O
+and	O
+accurate	O
+diagnostic	O
+methods	O
+.	O
+
+TITLE	O
+:	O
+A	O
+Novel	O
+Immunochromatographic	O
+Strip	O
+for	O
+Antigen	B-CHED
+Detection	O
+of	O
+Avian	B-DISO
+Infectious	I-DISO
+Bronchitis	I-DISO
+Virus	B-SPEC
+.	O
+
+Our	O
+final	O
+multivariate	O
+logistic	O
+regression	O
+analysis	O
+suggested	O
+plasma	O
+endocan	O
+expression	B-PROC
+as	O
+the	O
+only	O
+independent	O
+risk	O
+factor	O
+for	O
+ARDS	B-DISO
+development	B-PROC
+in	O
+SP	O
+patients	O
+(	O
+OR	O
+:	O
+1	O
+.	O
+57	O
+,	O
+95	O
+%	O
+CI	O
+:	O
+1	O
+.	O
+14	O
+-	O
+2	O
+.	O
+25	O
+,	O
+Endocan	O
+expression	B-PROC
+at	O
+ICU	O
+admission	O
+is	O
+a	O
+reliable	O
+predictive	O
+factor	O
+in	O
+predicting	O
+ARDS	B-DISO
+in	O
+patients	O
+with	O
+SP	O
+.	O
+
+TITLE	O
+:	O
+Activities	O
+of	O
+an	O
+ECMO	O
+Center	O
+for	O
+Severe	O
+Respiratory	B-DISO
+Failure	I-DISO
+:	O
+ECMO	O
+Retrieval	O
+and	O
+Beyond	O
+,	O
+A	O
+4	O
+-	O
+Year	O
+Experience	O
+.	O
+
+The	O
+12	O
+-	O
+bed	B-DISO
+intensive	O
+care	O
+unit	O
+of	O
+Careggi	O
+Hospital	O
+in	O
+Florence	O
+,	O
+the	O
+ECMO	O
+referral	O
+center	O
+for	O
+Tuscany	O
+,	O
+and	O
+the	O
+center	O
+of	O
+Italy	O
+,	O
+with	O
+a	O
+mobile	O
+ECMO	O
+team	O
+.	O
+
+Our	O
+hypothesis	O
+is	O
+pediatric	O
+postsurgical	O
+,	O
+and	O
+medical	O
+patients	O
+with	O
+severe	B-DISO
+sepsis	I-DISO
+have	O
+unique	O
+risk	O
+factors	O
+for	O
+mortality	O
+.	O
+
+In	O
+the	O
+present	O
+study	O
+,	O
+we	O
+investigated	O
+the	O
+whole	O
+genomic	O
+sequence	O
+of	O
+a	O
+SARS	B-DISO
+-	O
+like	O
+bat	B-PRGE
+CoV	I-PRGE
+(	O
+16BO133	O
+)	O
+and	O
+found	O
+it	O
+to	O
+be	O
+29	O
+,	O
+075	O
+nt	O
+in	O
+length	O
+with	O
+a	O
+40	O
+.	O
+9	O
+%	O
+G	O
++	O
+C	O
+content	O
+.	O
+
+To	O
+diagnose	O
+sick	O
+animals	B-SPEC
+effectively	O
+,	O
+an	O
+effective	O
+virus	B-SPEC
+diagnostic	O
+and	O
+genome	O
+typing	O
+method	O
+with	O
+high	O
+sensitivity	O
+and	O
+specificity	O
+is	O
+required	O
+.	O
+
+A	O
+total	O
+of	O
+80	O
+clinical	O
+samples	O
+were	O
+subjected	O
+to	O
+this	O
+assay	O
+,	O
+as	O
+well	O
+as	O
+to	O
+conventional	O
+PCR	O
+-	O
+sequence	O
+assay	O
+and	O
+virus	B-SPEC
+isolation	O
+.	O
+
+In	O
+this	O
+study	O
+,	O
+a	O
+total	O
+of	O
+190	O
+faecal	B-ANAT
+samples	O
+from	O
+dairy	O
+calves	O
+with	O
+diarrhoea	B-DISO
+were	O
+collected	O
+from	O
+14	O
+farms	O
+in	O
+six	O
+Chinese	O
+provinces	O
+,	O
+and	O
+BCoV	O
+was	O
+detected	O
+in	O
+18	O
+.	O
+95	O
+%	O
+(	O
+36	O
+/	O
+190	O
+)	O
+of	O
+the	O
+samples	O
+by	O
+reverse	B-ENZY
+transcriptase	I-ENZY
+polymerase	O
+chain	O
+reaction	O
+.	O
+
+Full	O
+-	O
+length	O
+spike	O
+,	O
+hemagglutinin	O
+/	O
+esterase	B-PRGE
+(	O
+HE	O
+),	O
+nucleocapsid	B-COMP
+and	O
+transmembrane	B-COMP
+genes	O
+were	O
+simultaneously	O
+cloned	O
+from	O
+13	O
+clinical	O
+samples	O
+(	O
+eight	O
+farms	O
+in	O
+four	O
+provinces	O
+),	O
+and	O
+most	O
+of	O
+the	O
+BCoV	O
+strains	O
+showed	O
+a	O
+unique	O
+evolutionary	O
+pattern	O
+based	O
+on	O
+the	O
+phylogenetic	O
+analysis	O
+of	O
+these	O
+genes	O
+.	O
+
+In	O
+conclusion	O
+,	O
+S	B-PRGE
+gene	I-PRGE
+and	O
+5a	O
+accessory	O
+gene	O
+are	O
+responsible	O
+for	O
+the	O
+attenuation	O
+of	O
+virulent	O
+IBV	B-SPEC
+.	O
+
+ABSTRACT	O
+:	O
+Cavally	B-SPEC
+virus	I-SPEC
+(	O
+CavV	O
+)	O
+is	O
+a	O
+mosquito	B-SPEC
+-	O
+borne	O
+plus	O
+-	O
+strand	O
+RNA	O
+virus	B-SPEC
+in	O
+the	O
+family	B-SPEC
+Mesoniviridae	O
+(	O
+order	B-SPEC
+Nidovirales	I-SPEC
+).	O
+
+ABSTRACT	O
+:	O
+Acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+(	O
+ARDS	B-DISO
+)	O
+is	O
+a	O
+fatal	O
+disease	O
+that	O
+includes	O
+inflammation	B-DISO
+formed	O
+by	O
+septic	O
+and	O
+non	O
+-	O
+septic	O
+causes	O
+.	O
+
+OA	O
+was	O
+intravenously	O
+administered	O
+to	O
+all	O
+groups	O
+except	O
+control	O
+group	O
+and	O
+other	O
+compounds	O
+were	O
+orally	B-ANAT
+administered	O
+(	O
+ALA	B-CHED
+,	O
+VITE	O
+,	O
+and	O
+VITC	O
+:	O
+100	O
+mg	O
+/	O
+kg	O
+,	O
+LDMP	O
+:	O
+5	O
+mg	O
+/	O
+kg	O
+,	O
+HDMP	O
+:	O
+50	O
+mg	O
+/	O
+kg	O
+)	O
+after	O
+OA	O
+injections	O
+.	O
+
+Although	O
+OA	O
+reduced	O
+SOD	B-FUNC
+,	O
+CAT	B-PRGE
+,	O
+and	O
+GSH	B-DISO
+levels	O
+in	O
+lung	B-ANAT
+tissue	I-ANAT
+,	O
+the	O
+vitamins	B-CHED
+and	O
+LDMP	O
+markedly	O
+enhanced	O
+the	O
+levels	O
+except	O
+for	O
+HDMP	O
+.	O
+
+Cohort	O
+of	O
+659	O
+hospitalized	O
+children	O
+(	O
+2	O
+months	O
+to	O
+14	O
+years	O
+)	O
+with	O
+SALRTI	O
+admitted	O
+to	O
+the	O
+Pediatric	O
+Intensive	O
+Care	O
+Unit	O
+(	O
+PICU	B-SPEC
+)	O
+in	O
+the	O
+Guangzhou	O
+from	O
+May	O
+2015	O
+to	O
+April	O
+2018	O
+was	O
+enrolled	O
+in	O
+this	O
+study	O
+.	O
+
+And	O
+the	O
+individuals	O
+with	O
+different	O
+viral	B-DISO
+infection	I-DISO
+varied	O
+significantly	O
+in	O
+terms	O
+of	O
+clinical	O
+profiles	O
+.	O
+
+Viral	O
+RNA	O
+was	O
+extracted	O
+from	O
+pooled	O
+tissue	B-ANAT
+samples	O
+(	O
+trachea	B-DISO
+,	O
+lungs	B-ANAT
+,	O
+spleen	B-ANAT
+,	O
+and	O
+liver	B-ANAT
+)	O
+and	O
+tested	O
+for	O
+Avian	B-SPEC
+influenza	I-SPEC
+virus	I-SPEC
+(	O
+AIV	O
+),	O
+Newcastle	B-SPEC
+disease	I-SPEC
+virus	I-SPEC
+(	O
+NDV	B-SPEC
+),	O
+and	O
+infectious	B-DISO
+bronchitis	B-DISO
+virus	B-SPEC
+(	O
+IBV	B-SPEC
+)	O
+by	O
+reverse	B-PRGE
+transcriptase	I-PRGE
+-	O
+polymerase	O
+chain	O
+reaction	O
+(	O
+RT	O
+-	O
+PCR	O
+).	O
+
+TITLE	O
+:	O
+Comparative	O
+Analysis	O
+of	O
+Eleven	O
+Healthcare	O
+-	O
+Associated	O
+Outbreaks	O
+of	O
+Middle	O
+East	O
+Respiratory	O
+Syndrome	B-DISO
+Coronavirus	B-SPEC
+(	O
+Mers	O
+-	O
+Cov	O
+)	O
+from	O
+2015	O
+to	O
+2017	O
+.	O
+
+We	O
+believe	O
+this	O
+study	O
+will	O
+increase	O
+our	O
+understanding	O
+of	O
+the	O
+mechanisms	O
+that	O
+enhance	O
+the	O
+MERS	O
+-	O
+CoV	O
+immune	B-PROC
+response	I-PROC
+and	O
+subsequently	O
+contribute	O
+to	O
+the	O
+control	O
+of	O
+MERS	O
+-	O
+CoV	O
+infections	B-DISO
+.	O
+
+TITLE	O
+:	O
+Investigation	O
+of	O
+suspected	O
+Newcastle	B-DISO
+disease	I-DISO
+(	O
+ND	B-DISO
+)	O
+outbreaks	O
+in	O
+Egypt	O
+uncovers	O
+a	O
+high	O
+virus	B-SPEC
+velogenic	O
+ND	O
+virus	B-SPEC
+burden	O
+in	O
+small	O
+-	O
+scale	O
+holdings	O
+and	O
+the	O
+presence	O
+of	O
+multiple	O
+pathogens	O
+.	O
+
+Severe	O
+hypoxemia	O
+on	O
+venous	B-ANAT
+-	O
+venous	B-ANAT
+-	O
+ECMO	O
+support	O
+may	O
+occur	O
+despite	O
+the	O
+matching	O
+between	O
+the	O
+oxygen	B-CHED
+transfer	O
+by	O
+ECMO	O
+and	O
+the	O
+VO2	B-CHED
+of	O
+the	O
+patient	O
+.	O
+
+The	O
+generation	O
+of	O
+a	O
+diverse	O
+T	B-ANAT
+cell	I-ANAT
+and	O
+B	B-ANAT
+cell	I-ANAT
+repertoire	O
+is	O
+essential	O
+for	O
+protection	O
+against	O
+infection	B-DISO
+.	O
+
+The	O
+TRBV12	B-PRGE
+-	I-PRGE
+3	I-PRGE
+,	O
+TRBV12	O
+-	O
+4	O
+,	O
+and	O
+TRBV15	B-PRGE
+gene	I-PRGE
+segments	O
+and	O
+TRBV30	O
+/	O
+TRBJ1	O
+-	O
+2	O
+,	O
+TRBV12	B-PRGE
+-	I-PRGE
+3	I-PRGE
+/	O
+TRBJ1	O
+-	O
+1	O
+and	O
+IGHV3	O
+-	O
+11	O
+/	O
+IGHJ6	O
+gene	O
+segment	O
+pairings	O
+also	O
+exhibited	O
+a	O
+higher	O
+usage	O
+in	O
+the	O
+PBMCs	O
+of	O
+AIV	O
+donors	O
+and	O
+may	O
+provide	O
+more	O
+information	O
+for	O
+generating	O
+more	O
+effective	O
+T	O
+/	O
+B	B-ANAT
+cell	I-ANAT
+targeted	B-PROC
+diagnosis	O
+/	O
+protection	O
+strategies	O
+.	O
+
+FCoV	O
+is	O
+incredibly	O
+contagious	O
+and	O
+transmission	O
+is	O
+via	O
+the	O
+faecal	B-ANAT
+-	O
+oral	B-ANAT
+route	O
+.	O
+
+Fuller	O
+'	O
+s	O
+earth	O
+-	O
+based	O
+litters	O
+best	O
+prevented	O
+infection	B-DISO
+of	O
+cell	B-COMP
+culture	O
+,	O
+but	O
+did	O
+not	O
+completely	O
+abrogate	O
+FCoV	O
+transmission	O
+in	O
+two	O
+multi	O
+-	O
+cat	B-SPEC
+households	O
+.	O
+
+A	O
+dust	O
+-	O
+free	O
+clumping	O
+Fuller	O
+'	O
+s	O
+earth	O
+litter	O
+appeared	O
+to	O
+fare	O
+best	O
+,	O
+but	O
+virus	B-DISO
+shedding	I-DISO
+also	O
+varied	O
+on	O
+the	O
+control	O
+litters	O
+,	O
+complicating	O
+interpretation	O
+.	O
+
+In	O
+the	O
+field	O
+study	O
+,	O
+there	O
+appeared	O
+to	O
+be	O
+less	O
+virus	B-DISO
+shedding	I-DISO
+on	O
+one	O
+Fuller	O
+'	O
+s	O
+earth	O
+-	O
+based	O
+cat	B-SPEC
+litter	O
+.	O
+
+47	O
+nasopharyngeal	B-ANAT
+aspirates	B-ANAT
+of	O
+children	O
+≤	O
+2	O
+years	O
+with	O
+ARI	B-CHED
+were	O
+included	O
+.	O
+
+IFI	B-PRGE
+included	O
+respiratory	B-SPEC
+syncytial	I-SPEC
+virus	I-SPEC
+(	O
+RSV	B-SPEC
+),	O
+adenovirus	B-DISO
+,	O
+influenza	B-PATH
+A	I-PATH
+and	O
+B	O
+and	O
+parainfluenza	B-DISO
+.	O
+
+PCR	O
+also	O
+included	O
+the	O
+detection	O
+of	O
+metapneumovirus	B-SPEC
+,	O
+enterovirus	B-SPEC
+/	O
+rhinovirus	B-SPEC
+,	O
+bocavirus	B-SPEC
+and	O
+coronavirus	B-SPEC
+.	O
+
+PCR	O
+detected	O
+several	O
+viruses	B-SPEC
+,	O
+including	O
+RSV	B-SPEC
+in	O
+26	O
+cases	O
+(	O
+55	O
+.	O
+3	O
+%),	O
+followed	O
+by	O
+bocavirus	B-SPEC
+(	O
+29	O
+.	O
+8	O
+%),	O
+rhinovirus	B-SPEC
+/	O
+enterovirus	B-SPEC
+(	O
+21	O
+.	O
+3	O
+%),	O
+adenovirus	B-DISO
+(	O
+14	O
+.	O
+9	O
+%)	O
+and	O
+parainfluenza	B-DISO
+(	O
+4	O
+,	O
+3	O
+%)	O
+among	O
+others	O
+,	O
+with	O
+35	O
+.	O
+5	O
+%	O
+of	O
+coinfection	B-DISO
+.	O
+
+CONCLUSIONS	O
+:	O
+The	O
+IIF	O
+presents	O
+good	O
+sensitivity	O
+,	O
+but	O
+moderate	O
+specificity	O
+for	O
+RSV	B-SPEC
+.	O
+
+Several	O
+viral	O
+families	O
+,	O
+including	O
+Coronaviridae	B-SPEC
+,	O
+Togaviridae	B-SPEC
+,	O
+and	O
+Hepeviridae	B-SPEC
+,	O
+encode	O
+for	O
+macrodomain	O
+proteins	B-CHED
+that	O
+bind	B-FUNC
+to	O
+and	O
+hydrolyze	O
+ADP	B-CHED
+-	O
+ribose	B-CHED
+from	O
+proteins	B-CHED
+and	O
+are	O
+critical	O
+for	O
+optimal	O
+replication	O
+and	O
+virulence	B-PROC
+.	O
+
+Successful	O
+combination	O
+of	O
+ECMO	O
+with	O
+VATS	O
+of	O
+pulmonary	B-ANAT
+bullae	B-DISO
+resection	O
+was	O
+performed	O
+and	O
+pneumothorax	B-DISO
+was	O
+cured	O
+.	O
+
+Thus	O
+,	O
+when	O
+refractory	O
+pneumothorax	B-DISO
+in	O
+a	O
+patient	O
+with	O
+severe	O
+pulmonary	B-ANAT
+dysfunction	O
+fails	O
+to	O
+improve	O
+through	O
+routine	O
+therapy	O
+,	O
+the	O
+treatment	O
+of	O
+pneumothorax	B-DISO
+by	O
+VATS	O
+based	O
+on	O
+ECMO	O
+support	O
+can	O
+be	O
+considered	O
+as	O
+a	O
+feasible	O
+selection	O
+.	O
+
+Patient	O
+studies	O
+have	O
+suggested	O
+a	O
+link	O
+between	O
+von	B-PRGE
+Willebrand	I-PRGE
+factor	I-PRGE
+(	O
+VWF	B-PRGE
+)	O
+and	O
+malaria	B-PATH
+severity	O
+.	O
+
+To	O
+investigate	O
+the	O
+role	O
+of	O
+VWF	B-PRGE
+in	O
+the	O
+pathogenesis	B-DISO
+of	O
+experimental	O
+MA	O
+-	O
+ARDS	B-DISO
+.	O
+
+Any	O
+damage	O
+to	O
+the	O
+cell	B-COMP
+membranes	I-COMP
+under	O
+conditions	O
+of	O
+traumatic	O
+injury	O
+,	O
+shock	O
+,	O
+acute	B-DISO
+respiratory	I-DISO
+failure	I-DISO
+,	O
+destruction	O
+of	O
+the	O
+blood	B-ANAT
+cells	I-ANAT
+against	O
+the	O
+background	O
+of	O
+hemorrhages	B-DISO
+,	O
+blood	B-ANAT
+transfusions	O
+,	O
+and	O
+blood	B-ANAT
+reinfusions	O
+can	O
+contribute	O
+to	O
+the	O
+enhancement	O
+of	O
+products	O
+.	O
+
+A	O
+probable	O
+mechanism	O
+is	O
+the	O
+activation	O
+of	O
+free	B-CHED
+radical	I-CHED
+oxidation	B-PROC
+processes	O
+with	O
+the	O
+damage	O
+of	O
+cell	B-COMP
+membranes	I-COMP
+.	O
+
+Within	O
+the	O
+last	O
+decade	O
+,	O
+increasing	O
+reports	O
+of	O
+severe	O
+influenza	B-DISO
+pneumonia	I-DISO
+resulting	O
+in	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+(	O
+ARDS	B-DISO
+)	O
+complicated	O
+by	O
+Aspergillus	B-DISO
+infection	I-DISO
+were	O
+published	O
+.	O
+
+Review	O
+of	O
+the	O
+literature	O
+pertaining	O
+to	O
+severe	O
+influenza	B-DISO
+-	O
+associated	O
+pulmonary	B-DISO
+aspergillosis	I-DISO
+.	O
+
+Isavuconazole	O
+is	O
+an	O
+alternative	O
+in	O
+case	O
+of	O
+intolerance	B-PROC
+to	O
+voriconazole	B-CHED
+,	O
+drug	O
+-	O
+drug	B-PROC
+interactions	I-PROC
+,	O
+renal	B-DISO
+impairment	I-DISO
+,	O
+or	O
+if	O
+a	O
+spectrum	O
+of	O
+activity	O
+including	O
+the	O
+majority	O
+of	O
+Mucorales	B-SPEC
+is	O
+desired	O
+.	O
+
+To	O
+decrease	O
+the	O
+burden	O
+of	O
+influenza	B-DISO
+-	O
+related	O
+illness	O
+,	O
+vaccination	O
+is	O
+of	O
+utmost	O
+importance	O
+,	O
+specifically	O
+in	O
+patients	O
+with	O
+co	O
+-	O
+morbidities	O
+.	O
+
+TITLE	O
+:	O
+Excess	O
+mortality	O
+is	O
+associated	O
+with	O
+influenza	B-PATH
+A	I-PATH
+(	O
+H1N1	O
+)	O
+in	O
+patients	O
+with	O
+severe	O
+acute	O
+respiratory	O
+illness	O
+.	O
+
+Hospital	O
+mortality	O
+associated	O
+with	O
+influenza	B-DISO
+H1N1	O
+-	O
+associated	O
+SARI	O
+and	O
+ARDS	B-DISO
+continued	O
+to	O
+be	O
+high	O
+years	O
+after	O
+the	O
+2009	O
+pandemic	O
+in	O
+a	O
+population	O
+with	O
+low	O
+vaccine	O
+coverage	O
+.	O
+
+The	O
+gender	O
+,	O
+age	O
+,	O
+acute	O
+physiology	O
+and	O
+chronic	O
+health	O
+evaluation	O
+II	O
+(	O
+APACHE	O
+II	O
+)	O
+within	O
+24	O
+hours	O
+of	O
+admission	O
+,	O
+neutral	O
+red	O
+phagocytosis	B-PROC
+and	O
+alkaline	B-FUNC
+phosphatase	I-FUNC
+activity	I-FUNC
+of	O
+macrophages	B-ANAT
+in	O
+bronchoalveolar	B-ANAT
+lavage	I-ANAT
+fluid	I-ANAT
+,	O
+the	O
+length	O
+of	O
+ICU	O
+stay	O
+,	O
+total	O
+hospitalization	O
+time	O
+,	O
+hospitalization	O
+expenses	O
+,	O
+and	O
+prognosis	O
+were	O
+recorded	O
+.	O
+
+Inflammatory	O
+cytokines	O
+such	O
+as	O
+IL	B-FUNC
+-	I-FUNC
+1	I-FUNC
+,	O
+IL	B-FUNC
+-	I-FUNC
+6	I-FUNC
+,	O
+and	O
+IL	B-FUNC
+-	I-FUNC
+10	I-FUNC
+have	O
+been	O
+documented	O
+in	O
+malaria	B-PATH
+induced	O
+thrombocytopaenia	O
+.	O
+
+The	O
+results	O
+of	O
+our	O
+study	O
+showed	O
+a	O
+high	O
+prevalence	O
+of	O
+malarial	O
+thrombocytopenia	O
+(	O
+platelets	B-ANAT
+<	O
+150	O
+×	O
+10	O
+Overall	O
+,	O
+the	O
+results	O
+of	O
+our	O
+study	O
+suggest	O
+that	O
+inflammatory	O
+cytokines	O
+influence	O
+the	O
+transformation	O
+of	O
+mild	O
+forms	O
+of	O
+thrombocytopenia	O
+into	O
+severe	O
+forms	O
+during	O
+malarial	O
+infections	B-DISO
+.	O
+
+Our	O
+aim	O
+is	O
+to	O
+determine	O
+indicators	O
+of	O
+survival	O
+in	O
+children	O
+with	O
+severe	O
+hypoxic	B-DISO
+respiratory	B-DISO
+failure	I-DISO
+(	O
+HRF	O
+)	O
+after	O
+transition	B-DISO
+to	O
+high	O
+-	O
+frequency	O
+oscillatory	O
+ventilation	O
+(	O
+HFOV	O
+).	O
+
+On	O
+detailed	O
+enquiry	O
+,	O
+history	O
+of	O
+exposure	O
+to	O
+mercury	B-CHED
+fumes	O
+was	O
+obtained	O
+(	O
+at	O
+home	O
+),	O
+during	O
+gold	B-CHED
+extraction	O
+by	O
+the	O
+father	O
+.	O
+
+During	O
+the	O
+first	O
+48	O
+hours	O
+after	O
+randomization	O
+,	O
+488	O
+of	O
+the	O
+501	O
+patients	O
+(	O
+97	O
+.	O
+4	O
+%)	O
+in	O
+the	O
+intervention	O
+group	O
+started	O
+a	O
+continuous	O
+infusion	O
+of	O
+cisatracurium	O
+(	O
+median	O
+duration	O
+of	O
+infusion	O
+,	O
+47	O
+.	O
+8	O
+hours	O
+;	O
+median	O
+dose	O
+,	O
+1807	O
+mg	O
+),	O
+and	O
+86	O
+of	O
+the	O
+505	O
+patients	O
+(	O
+17	O
+.	O
+0	O
+%)	O
+in	O
+the	O
+control	O
+group	O
+received	O
+a	O
+neuromuscular	O
+blocking	B-DISO
+agent	O
+(	O
+median	O
+dose	O
+,	O
+38	O
+mg	O
+).	O
+
+(	O
+Funded	O
+by	O
+the	O
+National	O
+Heart	B-ANAT
+,	O
+Lung	B-ANAT
+,	O
+and	O
+Blood	B-ANAT
+Institute	O
+;	O
+ROSE	B-SPEC
+ClinicalTrials	O
+.	O
+gov	O
+number	O
+,	O
+NCT02509078	O
+.).	O
+
+We	O
+enrolled	O
+1006	O
+patients	O
+early	O
+after	O
+the	O
+onset	O
+of	O
+moderate	O
+-	O
+to	O
+-	O
+severe	O
+ARDS	B-DISO
+(	O
+median	O
+,	O
+7	O
+.	O
+6	O
+hours	O
+after	O
+onset	O
+).	O
+
+To	O
+discover	O
+additional	O
+risk	O
+factors	O
+that	O
+could	O
+have	O
+influenced	O
+BRD	O
+development	O
+,	O
+sequence	O
+analysis	O
+of	O
+the	O
+BCV	B-SPEC
+strain	O
+(	O
+s	O
+)	O
+circulating	O
+in	O
+each	O
+herd	O
+,	O
+and	O
+the	O
+prevalence	O
+of	O
+common	O
+opportunistic	O
+bacterial	O
+pathogens	O
+in	O
+the	O
+upper	B-ANAT
+respiratory	I-ANAT
+tract	I-ANAT
+of	O
+sick	O
+and	O
+apparently	O
+healthy	O
+cattle	B-SPEC
+were	O
+also	O
+evaluated	O
+.	O
+
+Developing	O
+appropriate	O
+control	O
+measures	O
+for	O
+respiratory	O
+BCV	B-SPEC
+infections	B-DISO
+may	O
+help	O
+decrease	O
+the	O
+incidence	O
+of	O
+pre	O
+-	O
+weaning	B-PROC
+BRD	O
+.	O
+
+Persistent	O
+or	O
+recurrent	O
+shedding	O
+episodes	O
+of	O
+BCV	B-SPEC
+occurred	O
+in	O
+some	O
+animals	B-SPEC
+treated	O
+for	O
+BRD	O
+.	O
+
+Differences	O
+in	O
+disease	O
+outcome	O
+provided	O
+an	O
+opportunity	O
+to	O
+investigate	O
+the	O
+role	O
+of	O
+T	B-ANAT
+cell	I-ANAT
+immunity	B-PROC
+to	O
+FIP	B-DISO
+determined	O
+by	O
+T	B-ANAT
+cell	I-ANAT
+subset	I-ANAT
+proliferation	B-DISO
+after	O
+stimulation	O
+with	O
+different	O
+viral	O
+antigens	B-CHED
+.	O
+
+Recovery	O
+of	O
+antiviral	B-CHED
+T	B-ANAT
+cell	I-ANAT
+responses	O
+during	O
+the	O
+later	O
+phase	O
+of	O
+acute	B-DISO
+infection	I-DISO
+was	O
+observed	O
+in	O
+a	O
+subset	O
+of	O
+cats	B-SPEC
+that	O
+survived	O
+longer	O
+or	O
+resisted	O
+disease	O
+compared	O
+to	O
+cats	B-SPEC
+showing	O
+rapid	O
+disease	B-DISO
+progression	I-DISO
+.	O
+
+However	O
+emergence	O
+of	O
+antiviral	B-CHED
+T	B-ANAT
+cell	I-ANAT
+responses	O
+after	O
+a	O
+second	O
+exposure	O
+to	O
+FIPV	O
+,	O
+implicated	O
+cellular	B-PROC
+immunity	I-PROC
+in	O
+the	O
+control	O
+of	O
+FIPV	O
+infection	B-DISO
+and	O
+disease	B-DISO
+progression	I-DISO
+.	O
+
+Virus	B-SPEC
+host	B-COMP
+interactions	O
+during	O
+very	O
+early	O
+stages	O
+of	O
+FIPV	O
+infection	B-DISO
+warrant	O
+further	O
+investigation	O
+to	O
+elucidate	O
+host	B-COMP
+resistance	B-PROC
+to	O
+FIP	B-DISO
+.	O
+
+O	O
+.	O
+Mühlemann	O
+and	O
+Volker	O
+Thiel	O
+teamed	O
+up	O
+to	O
+unravel	O
+the	O
+roles	O
+of	O
+NMD	B-PROC
+and	O
+SGs	B-DISO
+,	O
+and	O
+their	O
+interconnections	O
+in	O
+defending	O
+cells	B-COMP
+from	O
+alphavirus	B-SPEC
+and	O
+coronavirus	B-DISO
+infections	I-DISO
+.	O
+
+Here	O
+,	O
+we	O
+provide	O
+an	O
+overview	O
+of	O
+the	O
+epidemiology	O
+,	O
+pathogenesis	O
+,	O
+causes	O
+,	O
+and	O
+management	O
+of	O
+AKI	O
+in	O
+patients	O
+with	O
+severe	O
+acute	B-DISO
+pancreatitis	I-DISO
+.	O
+
+We	O
+hypothesized	O
+that	O
+inactivation	B-DISO
+of	O
+the	O
+2	O
+'-	O
+
+ABSTRACT	O
+:	O
+Glycosylation	B-PROC
+is	O
+a	O
+ubiquitous	O
+post	O
+-	O
+translational	O
+modification	O
+responsible	O
+for	O
+a	O
+multitude	O
+of	O
+crucial	O
+biological	O
+roles	O
+.	O
+
+We	O
+discuss	O
+the	O
+growing	O
+efforts	O
+to	O
+exploit	O
+viral	O
+glycobiology	O
+in	O
+the	O
+development	B-PROC
+of	O
+anti	O
+-	O
+viral	O
+vaccines	O
+and	O
+therapies	O
+.	O
+
+This	O
+review	O
+will	O
+discuss	O
+progress	O
+made	O
+in	O
+the	O
+development	B-PROC
+of	O
+antiviral	B-CHED
+nucleoside	B-CHED
+and	O
+nucleotide	B-CHED
+analogues	O
+targeting	B-PROC
+viral	O
+RNA	B-PROC
+synthesis	I-PROC
+as	O
+effective	O
+therapeutics	O
+against	O
+CoV	O
+infections	B-DISO
+and	O
+propose	O
+promising	O
+strategies	O
+for	O
+combination	O
+therapy	O
+.	O
+
+TITLE	O
+:	O
+Human	B-SPEC
+β	I-PRGE
+-	I-PRGE
+defensin	I-PRGE
+2	I-PRGE
+is	O
+involved	O
+in	O
+CCR2	B-PRGE
+-	O
+mediated	O
+Nod2	B-PRGE
+signal	B-PROC
+transduction	I-PROC
+,	O
+leading	O
+to	O
+activation	O
+of	O
+the	O
+innate	O
+immune	O
+response	O
+in	O
+macrophages	B-ANAT
+.	O
+
+We	O
+previously	O
+reported	O
+that	O
+human	B-PRGE
+β	I-PRGE
+-	I-PRGE
+defensin	I-PRGE
+2	I-PRGE
+(	O
+HBD	B-PRGE
+2	I-PRGE
+)	O
+activates	O
+primary	O
+innate	B-PROC
+immunity	I-PROC
+against	O
+viral	B-DISO
+infection	I-DISO
+and	O
+suggested	O
+that	O
+it	O
+plays	O
+a	O
+role	O
+in	O
+the	O
+induction	O
+of	O
+the	O
+adaptive	B-PROC
+immune	I-PROC
+response	I-PROC
+.	O
+
+TITLE	O
+:	O
+Porcine	B-SPEC
+deltacoronavirus	I-PRGE
+nucleocapsid	B-COMP
+protein	B-CHED
+antagonizes	O
+IFN	B-PRGE
+-	I-PRGE
+β	I-PRGE
+production	O
+by	O
+impairing	O
+dsRNA	B-CHED
+and	O
+PACT	B-DISO
+binding	B-FUNC
+to	O
+RIG	B-PRGE
+-	I-PRGE
+I	I-PRGE
+.	O
+ABSTRACT	O
+:	O
+Porcine	B-SPEC
+deltacoronavirus	O
+(	O
+PDCoV	O
+)	O
+is	O
+an	O
+emerging	O
+swine	B-SPEC
+enteropathogenic	O
+coronavirus	B-SPEC
+that	O
+causes	O
+watery	B-DISO
+diarrhea	I-DISO
+,	O
+vomiting	B-DISO
+and	O
+mortality	O
+in	O
+newborn	O
+piglets	O
+.	O
+
+In	O
+this	O
+study	O
+,	O
+we	O
+found	O
+that	O
+PDCoV	B-PRGE
+nucleocapsid	I-PRGE
+(	I-PRGE
+N	I-PRGE
+)	I-PRGE
+protein	B-CHED
+,	O
+the	O
+most	O
+abundant	O
+viral	O
+structural	O
+protein	B-CHED
+,	O
+suppressed	O
+Sendai	B-SPEC
+virus	I-SPEC
+(	O
+SEV	O
+)-	O
+induced	O
+IFN	B-PRGE
+-	I-PRGE
+β	I-PRGE
+production	O
+and	O
+transcription	B-PROC
+factor	O
+IRF3	B-PRGE
+activation	O
+,	O
+but	O
+did	O
+not	O
+block	O
+IFN	B-PRGE
+-	I-PRGE
+β	I-PRGE
+production	O
+induced	O
+by	O
+overexpressing	O
+RIG	B-PRGE
+-	I-PRGE
+I	I-PRGE
+/	O
+MDA5	B-PRGE
+.	O
+
+Passive	O
+transfer	O
+of	O
+immune	O
+sera	B-COMP
+to	O
+naïve	O
+hDPP4	O
+-	O
+KI	O
+mice	B-SPEC
+also	O
+provided	O
+survival	O
+advantages	O
+from	O
+lethal	O
+MERS	O
+-	O
+CoV	O
+-	O
+MA	O
+challenge	O
+.	O
+
+The	O
+aim	O
+of	O
+this	O
+study	O
+was	O
+to	O
+research	O
+viral	O
+etiology	O
+by	O
+applying	O
+multiplex	O
+real	O
+-	O
+time	O
+polymerase	O
+chain	O
+reaction	O
+(	O
+Rt	O
+-	O
+PCR	O
+)	O
+method	O
+in	O
+autopsy	O
+cases	O
+who	O
+have	O
+been	O
+considered	O
+to	O
+have	O
+a	O
+respiratory	B-DISO
+infection	I-DISO
+and	O
+to	O
+assess	O
+whether	O
+the	O
+viruses	B-SPEC
+detected	O
+are	O
+the	O
+primary	O
+cause	O
+of	O
+the	O
+infection	B-DISO
+and	O
+whether	O
+they	O
+have	O
+any	O
+contributory	O
+effect	O
+on	O
+the	O
+mortality	O
+together	O
+with	O
+histopathological	O
+evidence	O
+.	O
+
+In	O
+728	O
+of	O
+834	O
+(	O
+87	O
+.	O
+3	O
+%)	O
+cases	O
+nasopharyngeal	B-ANAT
+/	O
+tracheal	O
+swab	O
+samples	O
+and	O
+in	O
+106	O
+(	O
+12	O
+.	O
+7	O
+%)	O
+of	O
+them	O
+paraffin	O
+-	O
+embedded	O
+lung	B-ANAT
+tissue	I-ANAT
+samples	O
+were	O
+studied	O
+by	O
+the	O
+use	O
+of	O
+""""	O
+FTD	B-DISO
+Respiratory	O
+21	O
+(	O
+Fast	B-FUNC
+-	O
+Tract	O
+Diagnostics	O
+Luxemburg	O
+")"""	O
+kit	B-FUNC
+,	O
+with	O
+multiplex	O
+Rt	O
+-	O
+PCR	O
+method	O
+.	O
+
+Infections	B-DISO
+with	O
+two	O
+causative	O
+agents	O
+were	O
+detected	O
+as	O
+2	O
+.	O
+6	O
+%	O
+(	O
+5	O
+/	O
+191	O
+)	O
+in	O
+0	O
+-	O
+1	O
+month	O
+age	O
+group	O
+,	O
+13	O
+%	O
+(	O
+77	O
+/	O
+593	O
+)	O
+in	O
+1	O
+month	O
+-	O
+18	O
+year	O
+age	O
+group	O
+and	O
+2	O
+%	O
+(	O
+1	O
+/	O
+50	O
+)	O
+in	O
+>	O
+18	O
+age	O
+group	O
+.	O
+
+TITLE	O
+:	O
+Delicate	O
+structural	O
+coordination	B-PROC
+of	O
+the	O
+Severe	B-DISO
+Acute	I-DISO
+Respiratory	I-DISO
+Syndrome	I-DISO
+coronavirus	B-SPEC
+Nsp13	O
+upon	O
+ATP	O
+hydrolysis	O
+.	O
+
+Here	O
+,	O
+we	O
+first	O
+present	O
+the	O
+structure	O
+of	O
+the	O
+full	B-PRGE
+-	I-PRGE
+length	I-PRGE
+Nsp13	I-PRGE
+helicase	I-PRGE
+of	O
+SARS	B-PRGE
+-	I-PRGE
+CoV	I-PRGE
+(	O
+SARS	B-DISO
+-	O
+Nsp13	O
+)	O
+and	O
+investigate	O
+the	O
+structural	O
+coordination	B-PROC
+of	O
+its	O
+five	O
+domains	O
+and	O
+how	O
+these	O
+contribute	O
+to	O
+its	O
+translocation	B-DISO
+and	O
+unwinding	O
+activity	O
+.	O
+
+A	O
+renewed	O
+interest	O
+in	O
+coronaviral	O
+research	O
+has	O
+led	O
+to	O
+the	O
+discovery	O
+of	O
+several	O
+novel	O
+human	B-SPEC
+CoVs	O
+and	O
+since	O
+then	O
+much	O
+progress	O
+has	O
+been	O
+made	O
+in	O
+understanding	O
+the	O
+CoV	O
+life	O
+cycle	O
+.	O
+
+The	O
+CoV	B-PRGE
+envelope	I-PRGE
+(	I-PRGE
+E	I-PRGE
+)	I-PRGE
+protein	B-CHED
+is	O
+a	O
+small	O
+,	O
+integral	O
+membrane	B-COMP
+protein	B-CHED
+involved	O
+in	O
+several	O
+aspects	O
+of	O
+the	O
+virus	B-SPEC
+'	O
+life	O
+cycle	O
+,	O
+such	O
+as	O
+assembly	O
+,	O
+budding	B-PATH
+,	O
+envelope	B-COMP
+formation	B-PROC
+,	O
+and	O
+pathogenesis	B-DISO
+.	O
+
+The	O
+high	O
+mortality	O
+rate	O
+of	O
+certain	O
+CoVs	O
+,	O
+along	O
+with	O
+their	O
+ease	O
+of	O
+transmission	O
+,	O
+underpins	O
+the	O
+need	O
+for	O
+more	O
+research	O
+into	O
+CoV	O
+molecular	O
+biology	O
+which	O
+can	O
+aid	O
+in	O
+the	O
+production	O
+of	O
+effective	O
+anti	O
+-	O
+coronaviral	O
+agents	O
+for	O
+both	O
+human	B-SPEC
+CoVs	O
+and	O
+enzootic	O
+CoVs	O
+.	O
+
+TITLE	O
+:	O
+Severe	O
+Acute	B-DISO
+Respiratory	I-DISO
+Infections	I-DISO
+With	O
+Influenza	B-DISO
+and	O
+Noninfluenza	O
+Respiratory	O
+Viruses	B-SPEC
+:	O
+Yemen	O
+,	O
+2011	O
+-	O
+2016	O
+.	O
+
+This	O
+study	O
+aims	O
+to	O
+determine	O
+the	O
+proportions	O
+of	O
+influenza	B-DISO
+and	O
+noninfluenza	O
+viruses	B-SPEC
+among	O
+SARI	O
+patients	O
+and	O
+to	O
+determine	O
+the	O
+severity	O
+of	O
+SARI	O
+and	O
+its	O
+associated	O
+factors	O
+.	O
+
+The	O
+proportions	O
+of	O
+positive	O
+influenza	B-SPEC
+viruses	I-SPEC
+(	O
+type	O
+A	O
+,	O
+B	O
+)	O
+and	O
+noninfluenza	O
+viruses	B-SPEC
+(	O
+respiratory	O
+syncytial	O
+,	O
+adenovirus	B-DISO
+,	O
+human	B-SPEC
+parainfluenza	B-DISO
+,	O
+and	O
+human	B-SPEC
+metapneumovirus	I-SPEC
+),	O
+intensive	O
+care	O
+unit	O
+(	O
+ICU	O
+)	O
+admission	O
+rate	O
+,	O
+and	O
+fatality	O
+rate	O
+among	O
+SARI	O
+patients	O
+were	O
+calculated	O
+.	O
+
+Knowledge	O
+concerning	O
+the	O
+epidemiology	O
+,	O
+circulation	B-PROC
+pattern	O
+,	O
+and	O
+evolutionary	O
+kinetics	O
+of	O
+respiratory	O
+viruses	B-SPEC
+in	O
+Saudi	O
+Arabia	O
+are	O
+scant	O
+,	O
+with	O
+the	O
+available	O
+literature	O
+being	O
+inconsistent	O
+.	O
+
+Currently	O
+,	O
+there	O
+are	O
+approximately	O
+30	O
+million	O
+dromedary	B-SPEC
+camels	B-SPEC
+,	O
+with	O
+highest	O
+numbers	O
+in	O
+Africa	O
+and	O
+the	O
+Middle	O
+East	O
+.	O
+
+However	O
+,	O
+we	O
+contend	O
+that	O
+other	O
+camel	B-SPEC
+-	O
+borne	O
+diseases	O
+such	O
+as	O
+Yersinia	B-SPEC
+pestis	I-SPEC
+,	O
+Coxiella	B-SPEC
+burnetii	I-SPEC
+,	O
+and	O
+Crimean	B-DISO
+-	I-DISO
+Congo	I-DISO
+hemorrhagic	I-DISO
+fever	I-DISO
+are	O
+just	O
+as	O
+important	O
+to	O
+include	O
+in	O
+surveillance	O
+efforts	O
+.	O
+
+Our	O
+results	O
+showed	O
+that	O
+the	O
+chimeric	O
+antigen	B-CHED
+could	O
+induce	O
+specific	O
+neutralizing	O
+antibodies	O
+against	O
+both	O
+strains	O
+leading	O
+to	O
+protection	O
+of	O
+immunized	O
+mice	B-SPEC
+against	O
+H1N1pdm09	O
+and	O
+efficient	O
+neutralization	O
+of	O
+MERS	O
+-	O
+CoV	O
+.	O
+This	O
+study	O
+demonstrate	O
+that	O
+OMVs	O
+-	O
+based	O
+vaccines	O
+presenting	O
+viral	O
+antigens	B-CHED
+provide	O
+a	O
+safe	O
+and	O
+reliable	O
+approach	O
+to	O
+protect	O
+against	O
+two	O
+different	O
+viral	B-DISO
+infections	I-DISO
+.	O
+
+ABSTRACT	O
+:	O
+Avian	B-DISO
+infectious	I-DISO
+bronchitis	I-DISO
+(	O
+IB	O
+)	O
+is	O
+a	O
+disease	O
+that	O
+can	O
+result	O
+in	O
+huge	O
+economic	O
+losses	O
+in	O
+the	O
+poultry	O
+industry	O
+.	O
+
+The	O
+high	O
+level	O
+of	O
+mutations	O
+of	O
+the	O
+IB	O
+virus	B-SPEC
+(	O
+IBV	B-SPEC
+)	O
+leads	O
+to	O
+the	O
+emergence	O
+of	O
+new	O
+serotypes	O
+and	O
+genotypes	O
+,	O
+and	O
+limits	O
+the	O
+efficacy	O
+of	O
+routine	O
+prevention	O
+.	O
+
+TITLE	O
+:	O
+Porcine	B-SPEC
+Deltacoronavirus	I-PRGE
+Nucleocapsid	B-COMP
+Protein	B-CHED
+Suppressed	O
+IFN	B-PRGE
+-	I-PRGE
+β	I-PRGE
+Production	O
+by	O
+Interfering	O
+Porcine	B-SPEC
+RIG	O
+-	O
+I	O
+dsRNA	B-CHED
+-	O
+Binding	B-FUNC
+and	O
+K63	O
+-	O
+Linked	O
+Polyubiquitination	B-PROC
+.	O
+
+PDCoV	O
+N	O
+protein	O
+targeted	B-PROC
+porcine	B-SPEC
+retinoic	B-CHED
+acid	I-CHED
+-	O
+inducible	O
+gene	B-PRGE
+I	I-PRGE
+(	O
+pRIG	O
+-	O
+I	O
+)	O
+and	O
+porcine	B-PRGE
+TNF	I-PRGE
+receptor	I-PRGE
+associated	I-PRGE
+factor	I-PRGE
+3	I-PRGE
+(	O
+pTRAF3	O
+)	O
+by	O
+directly	O
+interacting	O
+with	O
+them	O
+.	O
+
+ABSTRACT	O
+:	O
+Bats	B-SPEC
+are	O
+flying	O
+mammals	B-SPEC
+distributed	O
+worldwide	O
+known	O
+to	O
+host	B-COMP
+several	O
+types	O
+of	O
+Coronavirus	B-SPEC
+(	O
+CoV	O
+).	O
+
+His	O
+condition	B-DISO
+quickly	O
+worsened	O
+with	O
+haemoptysis	B-DISO
+,	O
+and	O
+respiratory	B-DISO
+distress	I-DISO
+which	O
+subsequently	O
+required	O
+intubation	O
+and	O
+mechanical	O
+ventilation	O
+.	O
+
+Blood	B-ANAT
+samples	I-ANAT
+were	O
+positive	O
+for	O
+
+TITLE	O
+:	O
+Weil	B-DISO
+'	I-DISO
+s	I-DISO
+disease	I-DISO
+with	O
+haemoptysis	B-DISO
+and	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+.	O
+
+The	O
+resulting	O
+reverse	O
+genetic	O
+system	O
+will	O
+add	B-DISO
+to	O
+the	O
+published	O
+list	O
+of	O
+MERS	O
+-	O
+CoV	O
+cDNAs	O
+and	O
+facilitate	O
+the	O
+development	B-PROC
+of	O
+Korean	O
+isolate	O
+-	O
+specific	O
+antiviral	B-CHED
+measures	O
+.	O
+
+TITLE	O
+:	O
+Fever	B-PROC
+in	O
+travellers	O
+returning	O
+from	O
+the	O
+tropics	O
+.	O
+
+Simple	O
+and	O
+multiple	O
+log	O
+-	O
+binomial	O
+regression	O
+models	O
+were	O
+constructed	O
+to	O
+assess	O
+associations	O
+of	O
+virus	O
+type	O
+with	O
+a	O
+need	O
+for	O
+PICU	B-SPEC
+admission	O
+.	O
+
+Age	O
+,	O
+prematurity	O
+,	O
+the	O
+presence	O
+of	O
+an	O
+underlying	O
+disease	O
+and	O
+congenital	B-DISO
+heart	I-DISO
+disease	I-DISO
+were	O
+covariates	O
+.	O
+
+To	O
+understand	O
+the	O
+molecular	O
+basis	O
+of	O
+coronavirus	B-SPEC
+attachment	O
+to	O
+oligosaccharide	B-CHED
+receptors	O
+,	O
+we	O
+determined	O
+cryo	O
+-	O
+EM	O
+structures	O
+of	O
+coronavirus	B-SPEC
+OC43	B-PRGE
+S	I-PRGE
+glycoprotein	I-PRGE
+trimer	O
+in	O
+isolation	O
+and	O
+in	O
+complex	O
+with	O
+a	O
+9	O
+-	O
+O	B-CHED
+-	I-CHED
+acetylated	I-CHED
+sialic	I-CHED
+acid	I-CHED
+.	O
+
+Our	O
+results	O
+demonstrate	O
+these	O
+viruses	B-SPEC
+evolved	O
+similar	O
+strategies	O
+to	O
+engage	O
+sialoglycans	O
+at	O
+the	O
+surface	O
+of	O
+target	B-ANAT
+cells	I-ANAT
+.	O
+
+ABSTRACT	O
+:	O
+To	O
+understand	O
+the	O
+impact	O
+of	O
+mild	O
+-	O
+moderate	O
+and	O
+severe	O
+acute	O
+kidney	B-ANAT
+injury	O
+in	O
+patients	O
+with	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+.	O
+
+Hospital	O
+mortality	O
+increased	O
+from	O
+31	O
+%	O
+in	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+patients	O
+with	O
+no	O
+acute	O
+kidney	B-ANAT
+injury	O
+to	O
+50	O
+%	O
+in	O
+mild	O
+-	O
+moderate	O
+acute	O
+kidney	B-ANAT
+injury	O
+(	O
+p	O
+≤	O
+0	O
+.	O
+001	O
+vs	O
+no	O
+acute	O
+kidney	B-ANAT
+injury	O
+)	O
+and	O
+58	O
+%	O
+in	O
+severe	O
+acute	O
+kidney	B-ANAT
+injury	O
+(	O
+p	O
+≤	O
+0	O
+.	O
+001	O
+vs	O
+no	O
+acute	O
+kidney	B-ANAT
+injury	O
+and	O
+mild	O
+-	O
+moderate	O
+acute	O
+kidney	B-ANAT
+injury	O
+).	O
+
+The	O
+development	B-PROC
+of	O
+acute	O
+kidney	B-ANAT
+injury	O
+,	O
+even	O
+when	O
+mild	O
+-	O
+moderate	O
+in	O
+severity	O
+,	O
+is	O
+associated	O
+with	O
+a	O
+substantial	O
+increase	O
+in	O
+mortality	O
+in	O
+patients	O
+with	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+.	O
+
+Infection	B-DISO
+remains	O
+the	O
+most	O
+common	O
+etiology	O
+.	O
+
+Higher	O
+severity	O
+of	O
+illness	O
+scores	O
+at	O
+admission	O
+,	O
+development	B-PROC
+of	O
+pneumothorax	B-DISO
+,	O
+and	O
+a	O
+positive	O
+fluid	B-PROC
+balance	I-PROC
+at	O
+48	O
+hours	O
+predicted	O
+poor	O
+outcome	O
+.	O
+
+TITLE	O
+:	O
+Antibodies	B-COMP
+and	O
+vaccines	O
+against	O
+Middle	O
+East	O
+respiratory	O
+syndrome	B-DISO
+coronavirus	B-SPEC
+.	O
+
+Integrin	B-PRGE
+α5β1	I-PRGE
+-	O
+FAK	B-PRGE
+signaling	B-PROC
+pathway	I-PROC
+was	O
+activated	O
+in	O
+PHEV	O
+-	O
+infected	O
+mice	B-SPEC
+by	O
+qPCR	O
+,	O
+Western	O
+blotting	O
+,	O
+and	O
+GST	B-PRGE
+pull	O
+-	O
+down	O
+assays	O
+.	O
+
+We	O
+found	O
+that	O
+IPI	O
+-	O
+2I	O
+cells	B-COMP
+are	O
+highly	O
+susceptible	O
+to	O
+TGEV	B-SPEC
+,	O
+PDCoV	O
+,	O
+and	O
+PEAV	O
+,	O
+as	O
+demonstrated	O
+by	O
+cytopathic	B-DISO
+effect	I-DISO
+and	O
+virus	B-PROC
+multiplication	I-PROC
+.	O
+
+Monitoring	O
+at	O
+trough	O
+and	O
+peak	O
+maternal	O
+medication	O
+levels	O
+was	O
+implemented	O
+to	O
+ascertain	O
+acute	O
+physiologic	O
+effects	O
+of	O
+buprenorphine	B-CHED
+administration	O
+.	O
+
+We	O
+found	O
+that	O
+10	O
+mg	O
+/	O
+kg	O
+and	O
+50	O
+mg	O
+/	O
+kg	O
+NBP	O
+significantly	O
+prevented	O
+LPS	B-DISO
+-	O
+induced	O
+increase	O
+of	O
+W	O
+/	O
+D	O
+ratio	O
+of	O
+lung	B-ANAT
+,	O
+histological	O
+injury	O
+of	O
+lung	B-ANAT
+,	O
+infiltration	B-DISO
+of	O
+inflammatory	B-ANAT
+cells	I-ANAT
+,	O
+release	B-PATH
+of	O
+pro	B-CHED
+-	O
+inflammatory	O
+cytokines	O
+and	O
+chemokines	O
+,	O
+and	O
+oxidative	B-PATH
+damage	I-PATH
+.	O
+
+Sirtuin	B-PRGE
+1	I-PRGE
+(	O
+SIRT1	B-PRGE
+)	O
+and	O
+nuclear	O
+factor	O
+(	O
+erythroid	O
+-	O
+derived	O
+2	O
+)-	O
+like	O
+2	O
+(	O
+Nrf2	B-PRGE
+)	O
+expression	B-PROC
+was	O
+increased	O
+by	O
+NBP	O
+in	O
+lung	B-ANAT
+of	O
+LPS	B-DISO
+-	O
+treated	O
+mice	B-SPEC
+.	O
+
+To	O
+test	O
+the	O
+neutralising	O
+capacity	O
+of	O
+these	O
+antisera	O
+in	O
+vivo	O
+,	O
+susceptibility	O
+to	O
+MERS	O
+-	O
+CoV	O
+was	O
+induced	O
+in	O
+naive	O
+recipient	O
+Balb	O
+/	O
+c	O
+mice	B-SPEC
+by	O
+the	O
+administration	O
+of	O
+an	O
+adenovirus	B-DISO
+vector	O
+expressing	O
+the	O
+human	B-PRGE
+DPP4	I-PRGE
+receptor	I-PRGE
+(	O
+Ad5	B-PRGE
+-	I-PRGE
+hDPP4	I-PRGE
+)	O
+for	O
+MERS	O
+-	O
+CoV	O
+,	O
+prior	O
+to	O
+the	O
+passive	O
+transfer	O
+of	O
+the	O
+RBD	O
+-	O
+specific	O
+murine	B-SPEC
+antisera	O
+to	O
+the	O
+transduced	O
+mice	B-SPEC
+.	O
+
+Subsequent	O
+challenge	O
+of	O
+the	O
+recipient	O
+transduced	O
+mice	B-SPEC
+by	O
+the	O
+intra	O
+-	O
+nasal	B-ANAT
+route	O
+with	O
+a	O
+clinical	O
+isolate	O
+of	O
+the	O
+MERS	O
+-	O
+CoV	O
+resulted	O
+in	O
+a	O
+significantly	O
+reduced	O
+viral	O
+load	O
+in	O
+their	O
+lungs	B-ANAT
+,	O
+compared	O
+with	O
+transduced	O
+mice	B-SPEC
+receiving	O
+a	O
+negative	O
+control	O
+antibody	O
+.	O
+
+The	O
+murine	B-SPEC
+antisera	O
+used	O
+were	O
+derived	O
+from	O
+mice	B-SPEC
+which	O
+had	O
+been	O
+primed	O
+sub	O
+-	O
+cutaneously	O
+with	O
+a	O
+recombinant	O
+fusion	O
+of	O
+RBD	O
+with	O
+a	O
+human	B-PRGE
+IgG	I-PRGE
+Fc	I-PRGE
+tag	B-DISO
+(	O
+RBD	O
+-	O
+Fc	O
+),	O
+adsorbed	O
+to	O
+calcium	B-CHED
+phosphate	I-CHED
+microcrystals	O
+and	O
+then	O
+boosted	O
+by	O
+the	O
+oral	B-ANAT
+route	O
+with	O
+the	O
+same	O
+fusion	O
+protein	B-CHED
+in	O
+reverse	O
+micelles	O
+.	O
+
+Because	O
+vitamin	B-CHED
+K	I-CHED
+antagonist	I-CHED
+and	O
+rivaroxaban	B-CHED
+15	O
+mg	O
+were	O
+dropped	O
+because	O
+of	O
+difficult	O
+international	O
+normalized	O
+ratio	O
+control	O
+(	O
+time	O
+in	O
+therapeutic	O
+range	O
+<	O
+30	O
+%)	O
+and	O
+severe	O
+haematuria	O
+,	O
+respectively	O
+,	O
+edoxaban	O
+30	O
+mg	O
+(	O
+crushed	O
+pill	O
+)	O
+daily	O
+was	O
+administered	O
+based	O
+on	O
+the	O
+patient	O
+'	O
+s	O
+weight	O
+of	O
+58	O
+kg	O
+.	O
+
+German	O
+transfusion	O
+centres	O
+were	O
+the	O
+first	O
+to	O
+start	O
+in	O
+-	O
+house	O
+NAT	B-ENZY
+testing	O
+of	O
+their	O
+donations	O
+in	O
+pools	O
+of	O
+up	O
+to	O
+96	O
+samples	O
+for	O
+HCV	B-SPEC
+,	O
+hepatitis	B-SPEC
+B	I-SPEC
+virus	I-SPEC
+(	O
+HBV	B-DISO
+),	O
+and	O
+human	B-DISO
+immunodeficiency	I-DISO
+virus	I-DISO
+-	O
+1	O
+(	O
+HIV	B-SPEC
+-	I-SPEC
+1	I-SPEC
+).	O
+
+Years	O
+later	O
+the	O
+diagnostics	O
+industry	O
+provided	O
+commercial	O
+HCV	B-SPEC
+and	O
+HIV	B-SPEC
+-	I-SPEC
+1	I-SPEC
+and	O
+later	O
+HBV	B-DISO
+NAT	B-ENZY
+tests	O
+on	O
+automated	O
+platforms	O
+.	O
+
+ABSTRACT	O
+:	O
+During	O
+acute	O
+or	O
+chronic	O
+lung	O
+injury	O
+,	O
+inappropriate	O
+immune	B-PROC
+response	I-PROC
+and	O
+/	O
+or	O
+aberrant	O
+repair	B-PROC
+process	O
+causes	O
+irreversible	O
+damage	O
+in	O
+lung	B-ANAT
+tissue	I-ANAT
+and	O
+most	O
+usually	O
+results	O
+in	O
+the	O
+development	B-PROC
+of	O
+fibrosis	B-DISO
+followed	O
+by	O
+decline	O
+in	O
+lung	B-PROC
+function	I-PROC
+.	O
+
+Mesenchymal	B-ANAT
+stem	I-ANAT
+cells	I-ANAT
+(	O
+MSCs	B-FUNC
+)	O
+are	O
+able	O
+to	O
+modulate	O
+proliferation	B-DISO
+,	O
+activation	O
+,	O
+and	O
+effector	B-CHED
+function	O
+of	O
+all	O
+immune	O
+cells	B-COMP
+that	O
+play	O
+an	O
+important	O
+role	O
+in	O
+the	O
+pathogenesis	B-DISO
+of	O
+acute	O
+and	O
+chronic	O
+inflammatory	O
+lung	B-DISO
+diseases	I-DISO
+.	O
+
+Other	O
+findings	O
+during	O
+the	O
+initial	O
+evaluation	O
+of	O
+the	O
+patient	O
+may	O
+include	O
+a	O
+lack	O
+of	O
+acute	O
+cardiac	B-DISO
+disease	I-DISO
+or	O
+inappropriate	O
+fluid	B-PROC
+balance	I-PROC
+,	O
+flat	O
+neck	B-ANAT
+veins	I-ANAT
+,	O
+and	O
+the	O
+absence	O
+of	O
+peripheral	O
+edema	B-DISO
+.	O
+
+A	O
+detection	O
+rate	O
+of	O
+2	O
+-	O
+3	O
+%	O
+was	O
+recorded	O
+for	O
+mycoplasma	B-DISO
+pneumonia	I-DISO
+,	O
+adenoviruses	B-SPEC
+,	O
+human	B-SPEC
+parainfluenza	B-DISO
+viruses	B-SPEC
+(	O
+HPIVs	O
+),	O
+respiratory	B-SPEC
+syncytial	I-SPEC
+virus	I-SPEC
+(	O
+RSV	B-SPEC
+),	O
+and	O
+human	B-SPEC
+metapneumovirus	I-SPEC
+(	O
+HMPV	B-SPEC
+).	O
+
+The	O
+levels	O
+of	O
+EVLWI	O
+,	O
+Ang	B-PRGE
+-	I-PRGE
+2	I-PRGE
+and	O
+PaO	B-PROC
+ΔEVLWI	O
+and	O
+ΔAng	O
+-	O
+2	O
+can	O
+be	O
+used	O
+as	O
+independent	O
+risk	O
+factors	O
+for	O
+28	O
+-	O
+day	O
+mortality	O
+of	O
+severe	O
+multiple	O
+trauma	O
+patients	O
+with	O
+ARDS	B-DISO
+,	O
+and	O
+the	O
+predictive	O
+value	O
+of	O
+ΔEVLWI	O
+was	O
+better	O
+than	O
+Ang	B-PRGE
+-	I-PRGE
+2	I-PRGE
+and	O
+APACHE	O
+II	O
+.	O
+
+In	O
+recent	O
+years	O
+,	O
+the	O
+benefits	O
+of	O
+treating	O
+ARDS	B-DISO
+by	O
+inhibiting	O
+spleen	B-ANAT
+-	O
+induced	O
+inflammatory	B-DISO
+response	I-DISO
+have	O
+gradually	O
+been	O
+discovered	O
+,	O
+providing	O
+new	O
+ideas	O
+for	O
+the	O
+treatment	O
+of	O
+ARDS	B-DISO
+.	O
+
+Chicken	B-SPEC
+sera	B-COMP
+were	O
+screened	O
+for	O
+anti	O
+-	O
+NDV	B-SPEC
+antibodies	B-COMP
+by	O
+ELISA	O
+.	O
+
+TITLE	O
+:	O
+A	O
+systematic	O
+review	O
+of	O
+MERS	O
+-	O
+CoV	O
+seroprevalence	O
+and	O
+RNA	O
+prevalence	O
+in	O
+dromedary	B-SPEC
+camels	B-SPEC
+:	O
+Implications	O
+for	O
+animal	O
+vaccination	O
+.	O
+
+We	O
+aim	O
+to	O
+bring	O
+together	O
+existing	O
+measures	O
+of	O
+MERS	O
+-	O
+CoV	O
+infection	B-DISO
+in	O
+dromedary	B-SPEC
+camels	B-SPEC
+to	O
+assess	O
+the	O
+distribution	O
+of	O
+infection	B-DISO
+,	O
+highlighting	O
+knowledge	O
+gaps	O
+and	O
+implications	O
+for	O
+animal	B-SPEC
+vaccination	O
+.	O
+
+The	O
+high	O
+prevalence	O
+of	O
+active	O
+infection	B-DISO
+measured	O
+in	O
+juveniles	O
+and	O
+at	O
+sites	O
+where	O
+dromedary	B-SPEC
+populations	O
+mix	O
+should	O
+guide	O
+further	O
+investigation	O
+-	O
+particularly	O
+of	O
+dromedary	B-SPEC
+movement	B-PROC
+-	O
+and	O
+inform	O
+vaccination	O
+strategy	O
+design	O
+and	O
+evaluation	O
+through	O
+mathematical	O
+modelling	O
+.	O
+
+There	O
+is	O
+further	O
+scope	O
+for	O
+the	O
+synthesis	B-PROC
+and	O
+evaluation	O
+of	O
+novel	O
+thiazole	B-CHED
+compounds	O
+by	O
+taking	O
+the	O
+most	O
+active	O
+compounds	O
+as	O
+lead	O
+structures	O
+.	O
+
+We	O
+collected	O
+the	O
+induced	B-ANAT
+sputum	I-ANAT
+from	O
+enrolled	O
+1629	O
+children	O
+(	O
+under	O
+18	O
+years	O
+of	O
+age	O
+)	O
+with	O
+no	O
+respiratory	B-DISO
+symptom	I-DISO
+prior	O
+to	O
+pediatric	O
+surgery	O
+between	O
+March	O
+2017	O
+and	O
+February	O
+2019	O
+.	O
+
+We	O
+tested	O
+16	O
+different	O
+respiratory	O
+virus	B-SPEC
+infections	B-DISO
+in	O
+post	O
+-	O
+surgery	O
+mild	O
+symptomatic	O
+PSP	B-DISO
+group	O
+and	O
+asymptomatic	O
+PSP	B-DISO
+group	O
+using	O
+a	O
+quantitative	O
+real	O
+-	O
+time	O
+reverse	B-ENZY
+transcriptase	I-ENZY
+polymerase	O
+chain	O
+reaction	O
+(	O
+qRT	O
+-	O
+PCR	O
+)	O
+assay	O
+panel	O
+.	O
+
+Commonly	O
+detected	O
+viruses	B-SPEC
+were	O
+human	B-SPEC
+rhino	O
+/	O
+enterovirus	B-SPEC
+(	O
+HRV	O
+/	O
+EV	O
+,	O
+42	O
+.	O
+19	O
+%),	O
+parainfluenza	B-DISO
+virus	B-SPEC
+3	O
+(	O
+PIV3	O
+,	O
+24	O
+.	O
+48	O
+%),	O
+coronavirus	B-SPEC
+(	O
+CoV	O
+NL63	O
+,	O
+OC43	O
+,	O
+HKU1	O
+,	O
+11	O
+.	O
+46	O
+%),	O
+and	O
+respiratory	B-SPEC
+syncytial	I-SPEC
+virus	I-SPEC
+(	O
+RSV	B-SPEC
+,	O
+9	O
+.	O
+9	O
+%).	O
+
+Employing	O
+a	O
+more	O
+comprehensive	O
+,	O
+sensitive	O
+and	O
+quantitative	O
+method	O
+should	O
+be	O
+considered	O
+for	O
+preoperative	O
+testing	O
+of	O
+respiratory	O
+viruses	B-SPEC
+in	O
+order	B-SPEC
+to	O
+guide	O
+optimal	O
+surgical	O
+timing	O
+.	O
+
+RESULTS	O
+:	O
+Out	O
+of	O
+1629	O
+children	O
+enrolled	O
+,	O
+a	O
+total	O
+of	O
+204	O
+respiratory	O
+viruses	B-SPEC
+were	O
+present	O
+in	O
+171	O
+(	O
+10	O
+.	O
+50	O
+%)	O
+PSPs	O
+including	O
+47	O
+patients	O
+with	O
+mild	O
+symptoms	O
+and	O
+124	O
+with	O
+no	O
+symptoms	O
+after	O
+surgery	O
+.	O
+
+Aim	B-PRGE
+of	O
+this	O
+multicenter	O
+retrospective	O
+observational	O
+study	O
+was	O
+to	O
+evaluate	O
+whether	O
+poractant	O
+alfa	O
+use	O
+in	O
+pediatric	O
+ARDS	B-DISO
+might	O
+improve	O
+gas	B-ENZY
+exchange	O
+in	O
+children	O
+less	O
+than	O
+2	O
+years	O
+old	O
+,	O
+according	O
+to	O
+a	O
+shared	O
+protocol	O
+.	O
+
+A	O
+shared	O
+protocol	O
+seems	O
+to	O
+be	O
+a	O
+good	O
+option	O
+to	O
+obtain	O
+the	O
+same	O
+criteria	O
+of	O
+enrollment	O
+among	O
+different	O
+PICUs	B-SPEC
+and	O
+define	O
+a	O
+unique	O
+way	O
+of	O
+use	O
+and	O
+administration	O
+of	O
+the	O
+drug	O
+for	O
+future	O
+studies	O
+.	O
+
+TITLE	O
+:	O
+Reversible	O
+ADP	B-CHED
+-	O
+ribosylation	O
+of	O
+RNA	O
+.	O
+
+ABSTRACT	O
+:	O
+ADP	B-CHED
+-	O
+ribosylation	O
+is	O
+a	O
+reversible	O
+chemical	O
+modification	O
+catalysed	O
+by	O
+ADP	O
+-	O
+ribosyltransferases	O
+such	O
+as	O
+PARPs	B-CHED
+that	O
+utilize	O
+nicotinamide	B-CHED
+adenine	I-CHED
+dinucleotide	I-CHED
+(	O
+NAD	O
++)	O
+as	O
+a	O
+cofactor	B-CHED
+to	O
+transfer	O
+monomer	O
+or	O
+polymers	B-CHED
+of	O
+ADP	B-CHED
+-	O
+ribose	B-CHED
+nucleotide	B-CHED
+onto	O
+macromolecular	O
+targets	O
+such	O
+as	O
+proteins	B-CHED
+and	O
+DNA	O
+.	O
+
+TITLE	O
+:	O
+Preventive	O
+Behavioral	B-PROC
+Responses	O
+to	O
+the	O
+2015	O
+Middle	O
+East	O
+Respiratory	O
+Syndrome	B-DISO
+Coronavirus	B-SPEC
+Outbreak	O
+in	O
+Korea	O
+.	O
+
+We	O
+report	O
+three	O
+unrelated	O
+children	O
+with	O
+influenza	B-SPEC
+A	I-SPEC
+virus	I-SPEC
+(	O
+IAV	B-SPEC
+)	O
+infection	B-DISO
+manifesting	O
+as	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+(	O
+IAV	B-SPEC
+-	O
+ARDS	B-DISO
+),	O
+heterozygous	O
+for	O
+rare	O
+
+TITLE	O
+:	O
+Combined	O
+adjuvant	B-CHED
+effect	O
+of	O
+ginseng	B-SPEC
+stem	B-ANAT
+-	O
+leaf	O
+saponins	O
+and	O
+selenium	B-CHED
+on	O
+immune	B-PROC
+responses	I-PROC
+to	O
+a	O
+live	O
+bivalent	O
+vaccine	O
+of	O
+Newcastle	O
+disease	O
+virus	O
+and	O
+infectious	B-DISO
+bronchitis	B-DISO
+virus	B-SPEC
+in	O
+chickens	B-SPEC
+.	O
+
+ABSTRACT	O
+:	O
+Proportions	O
+of	O
+QX	O
+-	O
+like	O
+genotype	O
+infectious	B-DISO
+bronchitis	B-DISO
+virus	B-SPEC
+(	O
+IBV	B-SPEC
+)	O
+isolates	O
+have	O
+increased	O
+over	O
+time	O
+.	O
+
+Sequence	O
+analyses	O
+revealed	O
+that	O
+all	O
+the	O
+5	O
+strains	O
+,	O
+as	O
+well	O
+as	O
+many	O
+recent	O
+field	O
+isolates	O
+from	O
+other	O
+researchers	O
+,	O
+belonged	O
+to	O
+the	O
+QX	O
+-	O
+like	O
+IBV	B-SPEC
+genotype	O
+,	O
+which	O
+were	O
+distantly	O
+related	O
+to	O
+commercial	O
+vaccine	O
+strains	O
+.	O
+
+Viral	O
+pathogenicity	O
+experiments	O
+showed	O
+that	O
+the	O
+isolates	O
+caused	O
+high	O
+morbidity	O
+and	O
+severe	O
+ciliostasis	O
+in	O
+chickens	B-SPEC
+,	O
+although	O
+they	O
+caused	O
+milder	O
+lethality	O
+.	O
+
+Certain	O
+occupations	O
+such	O
+as	O
+hydrocarbon	B-CHED
+-	O
+exposing	O
+occupations	O
+(	O
+e	O
+.	O
+g	O
+.,	O
+landscaping	O
+,	O
+farming	O
+,	O
+and	O
+painting	O
+)	O
+and	O
+viral	O
+exposure	O
+(	O
+e	O
+.	O
+g	O
+.,	O
+human	B-SPEC
+coronavirus	I-SPEC
+229E	I-SPEC
+causing	O
+upper	B-DISO
+respiratory	I-DISO
+infections	I-DISO
+in	O
+adults	O
+with	O
+an	O
+incorporation	O
+site	O
+in	O
+the	O
+human	B-SPEC
+genome	O
+at	O
+chromosome	B-COMP
+15q11	O
+)	O
+can	O
+be	O
+seasonal	O
+in	O
+nature	O
+and	O
+contribute	O
+to	O
+chromosome	B-COMP
+damage	O
+.	O
+
+In	O
+the	O
+last	O
+15	O
+years	O
+,	O
+we	O
+have	O
+witnessed	O
+the	O
+emergence	O
+of	O
+two	O
+zoonotic	O
+,	O
+highly	O
+pathogenic	O
+HCoVs	O
+:	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+coronavirus	B-SPEC
+(	O
+SARS	B-DISO
+-	O
+CoV	O
+)	O
+and	O
+Middle	O
+East	O
+respiratory	O
+syndrome	B-DISO
+coronavirus	B-SPEC
+(	O
+MERS	O
+-	O
+CoV	O
+).	O
+
+Replication	O
+of	O
+HCoV	O
+is	O
+regulated	O
+by	O
+a	O
+diversity	O
+of	O
+host	B-COMP
+factors	O
+and	O
+induces	O
+drastic	O
+alterations	O
+in	O
+cellular	B-COMP
+structure	I-COMP
+and	O
+physiology	O
+.	O
+
+ABSTRACT	O
+:	O
+We	O
+have	O
+previously	O
+reported	O
+a	O
+new	O
+class	B-SPEC
+of	O
+dendrimers	O
+with	O
+tryptophan	B-CHED
+(	O
+Trp	B-ENZY
+)	O
+residues	O
+on	O
+the	O
+surface	O
+that	O
+show	O
+dual	O
+antiviral	B-CHED
+activities	O
+against	O
+HIV	B-DISO
+and	O
+enterovirus	B-SPEC
+EV71	O
+.	O
+
+Experimental	O
+work	O
+carried	O
+on	O
+to	O
+determine	O
+the	O
+mode	O
+of	O
+action	O
+of	O
+the	O
+most	O
+potent	O
+IIa	O
+,	O
+containing	O
+tetravalent	O
+branched	B-ANAT
+arms	B-DISO
+,	O
+demonstrated	O
+that	O
+it	O
+interacts	O
+with	O
+the	O
+viral	O
+envelopes	O
+of	O
+HIV	B-DISO
+,	O
+EV71	O
+and	O
+HSV	B-SPEC
+-	O
+2	O
+and	O
+thus	O
+may	O
+prevent	O
+virus	B-SPEC
+attachment	O
+to	O
+the	O
+host	B-COMP
+cell	I-COMP
+.	O
+
+RSV	B-SPEC
+,	O
+adenovirus	B-SPEC
+,	O
+rhinovirus	B-SPEC
+,	O
+FluA	O
+,	O
+HMPV	B-SPEC
+,	O
+HCoV	B-SPEC
+-	I-SPEC
+OC43	I-SPEC
+,	O
+and	O
+HCoV	B-SPEC
+-	I-SPEC
+NL63	I-SPEC
+were	O
+detected	O
+by	O
+real	O
+-	O
+time	O
+polymerase	O
+chain	O
+reaction	O
+.	O
+
+RSV	B-SPEC
+,	O
+adenovirus	B-DISO
+,	O
+FluA	O
+,	O
+and	O
+coinfections	B-DISO
+were	O
+identified	O
+in	O
+14	O
+%,	O
+14	O
+%,	O
+5	O
+%,	O
+and	O
+15	O
+%	O
+of	O
+children	O
+with	O
+viral	B-DISO
+infection	I-DISO
+,	O
+respectively	O
+.	O
+
+TITLE	O
+:	O
+SARS	B-DISO
+-	O
+Coronavirus	B-SPEC
+Open	O
+Reading	O
+Frame	O
+-	O
+8b	O
+triggers	O
+intracellular	B-COMP
+stress	O
+pathways	B-PROC
+and	O
+activates	O
+NLRP3	B-PRGE
+inflammasomes	B-PATH
+.	O
+
+ORF8b	O
+causes	O
+cell	B-PROC
+death	I-PROC
+in	O
+epithelial	B-ANAT
+cells	I-ANAT
+,	O
+which	O
+is	O
+partially	O
+rescued	O
+by	O
+reducing	O
+its	O
+ability	O
+to	O
+aggregate	O
+.	O
+
+PROSPERO	B-SPEC
+CRD42018084370	O
+.	O
+
+ABSTRACT	O
+:	O
+Porcine	B-SPEC
+deltacoronavirus	O
+(	O
+PDCoV	O
+)	O
+is	O
+a	O
+novel	O
+swine	O
+enteropathogenic	O
+coronavirus	B-SPEC
+with	O
+worldwide	O
+distribution	O
+.	O
+
+Eleven	O
+common	O
+respiratory	O
+pathogens	O
+were	O
+tested	O
+in	O
+hospitalized	O
+children	O
+<	O
+13	O
+years	O
+of	O
+age	O
+who	O
+met	B-CHED
+the	O
+criteria	O
+for	O
+lower	B-DISO
+respiratory	I-DISO
+tract	I-DISO
+infection	I-DISO
+by	O
+GeXP	O
+-	O
+based	O
+multiplex	O
+-	O
+PCR	O
+of	O
+paired	O
+OPS	B-DISO
+and	O
+sputum	B-ANAT
+.	O
+
+From	O
+January	O
+to	O
+June	O
+2018	O
+,	O
+440	O
+children	O
+with	O
+paired	O
+OPS	O
+and	O
+sputum	B-ANAT
+were	O
+tested	O
+.	O
+
+Flocked	O
+oropharyngeal	B-ANAT
+swabs	O
+and	O
+sputum	B-ANAT
+performed	O
+similarly	O
+for	O
+the	O
+detection	O
+of	O
+common	O
+respiratory	O
+pathogens	O
+in	O
+hospitalized	O
+children	O
+by	O
+multiplex	O
+-	O
+PCR	O
+,	O
+except	O
+for	O
+Mycoplasma	B-SPEC
+pneumoniae	I-SPEC
+and	O
+Chlamydia	B-SPEC
+pneumoniae	I-SPEC
+.	O
+
+Daily	O
+injections	O
+of	O
+Clenbuterol	B-CHED
+(	O
+1	O
+mg	O
+/	O
+kg	O
+for	O
+21	O
+days	O
+)	O
+or	O
+vehicle	O
+control	O
+were	O
+also	O
+carried	O
+out	O
+to	O
+assess	O
+the	O
+effects	O
+of	O
+AAV	O
+-	O
+Pck2	B-PRGE
+overexpression	B-PROC
+on	O
+the	O
+anabolic	O
+response	O
+to	O
+a	O
+beta	B-CHED
+-	I-CHED
+adrenergic	I-CHED
+agonist	I-CHED
+.	O
+
+In	O
+addition	O
+,	O
+it	O
+can	O
+be	O
+favored	O
+by	O
+severe	O
+hyponatremia	O
+and	O
+SIADH	B-DISO
+that	O
+can	O
+cause	O
+cerebral	B-DISO
+edema	I-DISO
+.	O
+
+The	O
+majority	O
+of	O
+MBL	O
+-	O
+positive	O
+EACs	O
+express	O
+the	O
+CD83	B-PRGE
+antigen	I-PRGE
+,	O
+providing	O
+evidence	O
+that	O
+coronavirus	B-DISO
+infection	I-DISO
+facilitated	O
+the	O
+maturation	B-PROC
+of	O
+dendritic	B-ANAT
+cell	B-COMP
+precursors	O
+.	O
+
+After	O
+many	O
+years	O
+of	O
+quiescence	O
+,	O
+PEDV	B-SPEC
+was	O
+detected	O
+in	O
+Hungary	O
+in	O
+2016	O
+with	O
+a	O
+recombination	B-PROC
+in	O
+its	O
+S	O
+gene	O
+.	O
+
+TITLE	O
+:	O
+Virome	O
+heterogeneity	O
+and	O
+connectivity	O
+in	O
+waterfowl	B-SPEC
+and	O
+shorebird	O
+communities	O
+.	O
+
+This	O
+revealed	O
+the	O
+presence	O
+of	O
+27	O
+viral	O
+species	B-SPEC
+,	O
+of	O
+which	O
+24	O
+were	O
+novel	O
+,	O
+including	O
+double	O
+-	O
+stranded	O
+RNA	O
+viruses	B-SPEC
+(	O
+Picobirnaviridae	B-SPEC
+and	O
+Reoviridae	B-SPEC
+),	O
+single	O
+-	O
+stranded	O
+RNA	O
+viruses	B-SPEC
+(	O
+Astroviridae	B-SPEC
+,	O
+Caliciviridae	B-SPEC
+,	O
+Picornaviridae	B-SPEC
+),	O
+a	O
+retro	O
+-	O
+transcribing	O
+DNA	O
+virus	B-SPEC
+(	O
+Hepadnaviridae	B-SPEC
+),	O
+and	O
+a	O
+single	B-CHED
+-	I-CHED
+stranded	I-CHED
+DNA	I-CHED
+virus	B-SPEC
+(	O
+Parvoviridae	B-SPEC
+).	O
+
+Analysis	O
+of	O
+differential	B-PROC
+gene	I-PROC
+expression	I-PROC
+in	O
+infected	O
+primary	O
+chick	O
+kidney	B-ANAT
+cells	B-COMP
+indicated	O
+that	O
+the	O
+host	B-COMP
+cell	I-COMP
+response	O
+to	O
+IBV	B-SPEC
+occurs	O
+primarily	O
+at	O
+the	O
+level	O
+of	O
+transcription	B-PROC
+,	O
+with	O
+global	O
+upregulation	B-PROC
+of	O
+immune	O
+-	O
+related	O
+mRNA	B-CHED
+transcripts	O
+following	O
+infection	B-DISO
+and	O
+comparatively	O
+modest	O
+changes	O
+in	O
+the	O
+translation	B-PROC
+efficiencies	O
+of	O
+host	B-COMP
+genes	O
+.	O
+
+ABSTRACT	O
+:	O
+The	O
+6	O
+'-	O
+fluorinated	O
+aristeromycins	O
+were	O
+designed	O
+as	O
+dual	O
+-	O
+target	O
+antiviral	O
+compounds	O
+aimed	O
+at	O
+inhibiting	O
+both	O
+the	O
+viral	B-PRGE
+RNA	I-PRGE
+-	I-PRGE
+dependent	I-PRGE
+RNA	I-PRGE
+polymerase	I-PRGE
+(	O
+RdRp	B-FUNC
+)	O
+and	O
+the	O
+host	B-COMP
+cell	I-COMP
+
+Physicians	O
+remain	O
+reluctant	O
+to	O
+recommend	O
+tracheostomy	O
+for	O
+children	O
+requiring	O
+prolonged	O
+mechanical	O
+ventilation	O
+due	O
+to	O
+lung	B-DISO
+disease	I-DISO
+alone	O
+at	O
+3	O
+weeks	O
+of	O
+mechanical	O
+ventilation	O
+.	O
+
+Swine	B-SPEC
+received	O
+severe	O
+SII	O
+and	O
+airway	B-ANAT
+pressure	O
+release	B-PATH
+ventilation	O
+(	O
+APRV	O
+,	O
+n	O
+=	O
+6	O
+),	O
+or	O
+conventional	O
+ARDSNet	O
+mechanical	O
+ventilation	O
+(	O
+MV	O
+)	O
+(	O
+CMV	B-SPEC
+,	O
+n	O
+=	O
+8	O
+).	O
+
+A	O
+control	O
+group	O
+without	O
+injury	O
+received	O
+volume	O
+controlled	O
+MV	O
+(	O
+CTRL	O
+,	O
+n	O
+=	O
+6	O
+),	O
+The	O
+multiple	O
+inert	O
+gas	B-ENZY
+elimination	B-PROC
+technique	O
+and	O
+CT	O
+were	O
+performed	O
+at	O
+baseline	O
+(	O
+BL	O
+),	O
+0	O
+.	O
+5	O
+hours	O
+,	O
+1	O
+hours	O
+,	O
+2	O
+hours	O
+,	O
+24	O
+hours	O
+,	O
+and	O
+48	O
+hours	O
+after	O
+injury	O
+.	O
+
+(	O
+1	O
+)	O
+SII	O
+caused	O
+increases	O
+in	O
+Qshunt	O
+more	O
+so	O
+in	O
+APRV	O
+than	O
+CMV	B-SPEC
+group	O
+.	O
+
+A	O
+tissue	O
+segmentation	B-PROC
+algorithm	O
+based	O
+on	O
+graph	O
+theory	O
+was	O
+used	O
+to	O
+reconstruct	O
+a	O
+three	O
+-	O
+dimensional	O
+(	O
+3D	O
+)	O
+model	O
+of	O
+lower	B-ANAT
+respiratory	I-ANAT
+tract	I-ANAT
+and	O
+estimate	O
+PAV	O
+.	O
+
+The	O
+decrease	O
+in	O
+the	O
+PAV	O
+was	O
+more	O
+prominent	O
+in	O
+the	O
+animals	B-SPEC
+that	O
+developed	O
+ARDS	B-DISO
+after	O
+24	O
+hours	O
+after	O
+the	O
+injury	O
+.	O
+
+Results	O
+show	O
+that	O
+vaccination	O
+on	O
+day	O
+1	O
+of	O
+age	O
+elicits	O
+significantly	O
+lower	O
+systemic	O
+and	O
+mucosal	B-ANAT
+antibody	B-PROC
+responses	I-PROC
+compared	O
+with	O
+vaccination	O
+at	O
+later	O
+time	O
+points	O
+in	O
+the	O
+life	O
+of	O
+the	O
+chicken	B-SPEC
+.	O
+
+Macrophages	B-ANAT
+are	O
+classified	O
+as	O
+M1	O
+macrophages	B-ANAT
+with	O
+proinflammatory	O
+effects	O
+or	O
+M2	O
+macrophages	B-ANAT
+with	O
+anti	O
+-	O
+inflammatory	O
+effects	O
+.	O
+
+Treatment	O
+with	O
+NET	O
+inhibitors	B-CHED
+significantly	O
+inhibitor	B-CHED
+NETs	O
+generation	O
+,	O
+downregulated	O
+M1	O
+markers	O
+and	O
+upregulated	O
+M2	O
+markers	O
+.	O
+
+In	O
+conclusion	O
+,	O
+NETs	B-PRGE
+promote	O
+ARDS	B-DISO
+inflammation	B-DISO
+during	O
+the	O
+acute	O
+phase	O
+by	O
+promoting	O
+macrophage	B-ANAT
+polarization	O
+to	O
+the	O
+M1	O
+phenotype	O
+.	O
+
+Nasopharyngeal	B-ANAT
+swabs	O
+and	O
+broncho	B-ANAT
+-	I-ANAT
+alveolar	I-ANAT
+lavage	O
+samples	O
+from	O
+inpatients	O
+with	O
+respiratory	B-DISO
+infection	I-DISO
+symptoms	O
+at	O
+the	O
+Uludag	O
+University	O
+Hospital	O
+between	O
+December	O
+1	O
+,	O
+2015	O
+and	O
+March	O
+31	O
+,	O
+2018	O
+were	O
+investigated	O
+.	O
+
+The	O
+R	B-PRGE
+-	I-PRGE
+GENE	I-PRGE
+
+TITLE	O
+:	O
+Relationship	O
+between	O
+Structural	O
+Characteristics	O
+and	O
+Plant	B-SPEC
+Sources	O
+along	O
+with	O
+Pharmacology	O
+Research	O
+of	O
+Quassinoids	O
+.	O
+
+Herein	O
+,	O
+the	O
+structure	O
+-	O
+activity	O
+relationships	O
+(	O
+SARs	B-DISO
+)	O
+of	O
+quassinoids	O
+along	O
+with	O
+the	O
+anti	O
+-	O
+cancer	B-DISO
+mechanisms	O
+of	O
+four	O
+representative	O
+quassinoids	O
+,	O
+eurycomanone	B-CHED
+,	O
+bruceine	B-CHED
+D	I-CHED
+,	O
+dehydrobruceine	O
+B	O
+,	O
+and	O
+brusatol	O
+are	O
+discussed	O
+.	O
+
+ABSTRACT	O
+:	O
+The	O
+Faculty	O
+of	O
+Intensive	O
+Care	O
+Medicine	O
+and	O
+Intensive	O
+Care	O
+Society	O
+Guideline	O
+Development	B-PROC
+Group	O
+have	O
+used	O
+GRADE	O
+methodology	O
+to	O
+make	O
+the	O
+following	O
+recommendations	O
+for	O
+the	O
+management	O
+of	O
+adult	O
+patients	O
+with	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+(	O
+ARDS	B-DISO
+).	O
+
+We	O
+included	O
+all	O
+controlled	O
+studies	O
+that	O
+compared	O
+the	O
+effects	O
+of	O
+PPE	B-CHED
+used	O
+by	O
+HCW	O
+exposed	O
+to	O
+highly	O
+infectious	B-DISO
+diseases	I-DISO
+with	O
+serious	O
+consequences	O
+,	O
+such	O
+as	O
+Ebola	O
+or	O
+SARS	B-DISO
+,	O
+on	O
+the	O
+risk	O
+of	O
+infection	B-DISO
+,	O
+contamination	O
+,	O
+or	O
+noncompliance	O
+with	O
+protocols	O
+.	O
+
+In	O
+one	O
+study	O
+HCW	O
+were	O
+exposed	O
+to	O
+Ebola	O
+and	O
+in	O
+another	O
+to	O
+SARS	B-DISO
+.	O
+Evidence	O
+for	O
+all	O
+outcomes	O
+is	O
+based	O
+on	O
+single	O
+studies	O
+and	O
+is	O
+very	O
+low	O
+quality	O
+.	O
+
+Alterations	O
+to	O
+PPE	B-CHED
+design	O
+may	O
+lead	O
+to	O
+less	O
+contamination	O
+such	O
+as	O
+added	O
+tabs	O
+to	O
+grab	O
+masks	O
+(	O
+RR	O
+0	O
+.	O
+33	O
+;	O
+95	O
+%	O
+CI	O
+0	O
+.	O
+14	O
+to	O
+0	O
+.	O
+80	O
+)	O
+or	O
+gloves	O
+(	O
+RR	O
+0	O
+.	O
+22	O
+95	O
+%	O
+CI	O
+0	O
+.	O
+15	O
+to	O
+0	O
+.	O
+31	O
+),	O
+a	O
+sealed	O
+gown	O
+and	O
+glove	O
+combination	O
+(	O
+RR	O
+0	O
+.	O
+27	O
+;	O
+95	O
+%	O
+CI	O
+0	O
+.	O
+09	O
+to	O
+0	O
+.	O
+78	O
+),	O
+or	O
+a	O
+better	O
+fitting	B-DISO
+gown	O
+around	O
+the	O
+neck	B-ANAT
+,	O
+wrists	B-ANAT
+and	O
+hands	B-ANAT
+(	O
+RR	O
+0	O
+.	O
+08	O
+;	O
+95	O
+%	O
+CI	O
+0	O
+.	O
+01	O
+to	O
+0	O
+.	O
+55	O
+)	O
+compared	O
+to	O
+standard	O
+PPE	B-CHED
+.	O
+Different	O
+methods	O
+of	O
+donning	O
+and	O
+doffing	O
+proceduresDouble	O
+gloving	O
+may	O
+lead	O
+to	O
+less	O
+contamination	O
+compared	O
+to	O
+single	O
+gloving	O
+(	O
+RR	O
+0	O
+.	O
+36	O
+;	O
+95	O
+%	O
+CI	O
+0	O
+.	O
+16	O
+to	O
+0	O
+.	O
+78	O
+).	O
+Following	O
+CDC	O
+recommendations	O
+for	O
+doffing	O
+may	O
+lead	O
+to	O
+less	O
+contamination	O
+compared	O
+to	O
+no	O
+guidance	O
+(	O
+MD	O
+small	O
+patches	O
+-	O
+5	O
+.	O
+44	O
+;	O
+95	O
+%	O
+CI	O
+-	O
+7	O
+.	O
+43	O
+to	O
+-	O
+3	O
+.	O
+45	O
+).	O
+Alcohol	O
+-	O
+based	O
+hand	O
+rub	O
+used	O
+during	O
+the	O
+doffing	O
+process	O
+may	O
+not	O
+lead	O
+to	O
+less	O
+contamination	O
+than	O
+the	O
+use	O
+of	O
+a	O
+hypochlorite	B-CHED
+based	O
+solution	O
+(	O
+MD	O
+4	O
+.	O
+00	O
+;	O
+95	O
+%	O
+CI	O
+0	O
+.	O
+47	O
+to	O
+34	O
+.	O
+24	O
+).	O
+Additional	O
+spoken	O
+instruction	O
+may	O
+lead	O
+to	O
+fewer	O
+errors	O
+in	O
+doffing	O
+(	O
+MD	O
+-	O
+0	O
+.	O
+9	O
+,	O
+95	O
+%	O
+CI	O
+-	O
+1	O
+.	O
+4	O
+to	O
+-	O
+0	O
+.	O
+4	O
+).	O
+Different	O
+types	O
+of	O
+trainingThe	O
+use	O
+of	O
+additional	O
+computer	O
+simulation	O
+may	O
+lead	O
+to	O
+fewer	O
+errors	O
+in	O
+doffing	O
+(	O
+MD	O
+-	O
+1	O
+.	O
+2	O
+,	O
+95	O
+%	O
+CI	O
+-	O
+1	O
+.	O
+6	O
+to	O
+-	O
+0	O
+.	O
+7	O
+).	O
+A	O
+video	O
+lecture	O
+on	O
+donning	O
+PPE	B-CHED
+may	O
+lead	O
+to	O
+better	O
+skills	O
+scores	O
+(	O
+MD	O
+30	O
+.	O
+70	O
+;	O
+95	O
+%	O
+CI	O
+20	O
+.	O
+14	O
+,	O
+41	O
+.	O
+26	O
+)	O
+than	O
+a	O
+traditional	O
+lecture	O
+.	O
+
+Face	B-DISO
+-	O
+to	O
+-	O
+face	B-DISO
+training	O
+in	O
+PPE	B-CHED
+use	O
+may	O
+reduce	O
+errors	O
+more	O
+than	O
+video	O
+or	O
+folder	O
+based	O
+training	O
+.	O
+
+We	O
+need	O
+better	O
+simulation	O
+studies	O
+conducted	O
+with	O
+several	O
+dozen	O
+participants	O
+to	O
+find	O
+out	O
+which	O
+PPE	B-CHED
+protects	O
+best	O
+,	O
+and	O
+what	O
+is	O
+the	O
+safest	O
+way	O
+to	O
+remove	O
+PPE	B-CHED
+.	O
+
+Consensus	O
+on	O
+the	O
+best	O
+way	O
+to	O
+conduct	B-PROC
+simulation	O
+of	O
+exposure	O
+and	O
+assessment	O
+of	O
+outcome	O
+is	O
+urgently	O
+needed	O
+.	O
+
+TITLE	O
+:	O
+Synthesis	B-PROC
+and	O
+evaluation	O
+of	O
+some	O
+new	O
+1	B-CHED
+,	I-CHED
+3	I-CHED
+,	I-CHED
+4	I-CHED
+-	I-CHED
+oxadiazoles	I-CHED
+bearing	O
+thiophene	B-CHED
+,	O
+thiazole	B-CHED
+,	O
+coumarin	B-CHED
+,	O
+pyridine	O
+and	O
+pyridazine	B-CHED
+derivatives	O
+as	O
+antiviral	B-CHED
+agents	I-CHED
+.	O
+
+Furthermore	O
+,	O
+cyclic	B-CHED
+ketones	I-CHED
+were	O
+subjected	O
+to	O
+the	O
+synthesis	B-PROC
+of	O
+fused	O
+thiophene	B-CHED
+derivatives	O
+4a	O
+,	O
+b	O
+via	O
+reaction	O
+with	O
+compound	O
+1	O
+in	O
+the	O
+presence	O
+of	O
+elemental	B-CHED
+sulfur	I-CHED
+.	O
+
+Viral	O
+nucleic	B-CHED
+acids	I-CHED
+,	O
+and	O
+in	O
+some	O
+instances	O
+viable	O
+viruses	B-SPEC
+,	O
+have	O
+been	O
+detected	O
+in	O
+aerosols	O
+in	O
+the	O
+air	B-CHED
+in	O
+healthcare	O
+settings	O
+for	O
+some	O
+respiratory	O
+viruses	B-SPEC
+such	O
+as	O
+seasonal	O
+and	O
+avian	B-DISO
+influenza	B-SPEC
+viruses	I-SPEC
+,	O
+Middle	O
+East	O
+respiratory	O
+syndrome	B-DISO
+-	O
+coronavirus	B-SPEC
+and	O
+respiratory	B-SPEC
+syncytial	I-SPEC
+virus	I-SPEC
+.	O
+
+TITLE	O
+:	O
+Epidemiology	O
+of	O
+Pediatric	O
+Severe	B-DISO
+Sepsis	I-DISO
+in	O
+Main	O
+PICU	B-SPEC
+Centers	O
+in	O
+Southwest	O
+China	O
+.	O
+
+Eight	O
+PICUs	B-SPEC
+in	O
+Southwest	O
+China	O
+with	O
+19	O
+(	O
+13	O
+-	O
+24	O
+)	O
+beds	O
+and	O
+1	O
+,	O
+322	O
+(	O
+1	O
+,	O
+066	O
+-	O
+1	O
+,	O
+452	O
+)	O
+annual	O
+admissions	O
+each	O
+.	O
+
+The	O
+results	O
+suggested	O
+that	O
+the	O
+public	O
+'	O
+s	O
+preventive	O
+(	O
+hand	O
+hygiene	O
+)	O
+and	O
+avoidance	O
+(	O
+avoiding	O
+hospitals	O
+even	O
+when	O
+sick	O
+)	O
+behaviors	B-PROC
+that	O
+were	O
+frequently	O
+practiced	O
+during	O
+the	O
+pandemic	O
+were	O
+influenced	O
+by	O
+their	O
+social	O
+determinants	O
+both	O
+direct	O
+and	O
+indirect	O
+pathways	B-PROC
+.	O
+
+The	O
+results	O
+of	O
+the	O
+present	O
+study	O
+will	O
+deepen	O
+our	O
+understanding	O
+of	O
+PHEP	O
+by	O
+identifying	O
+key	O
+factors	O
+that	O
+influence	O
+the	O
+public	O
+'	O
+s	O
+behavioral	B-PROC
+responses	O
+as	O
+well	O
+as	O
+providing	O
+information	O
+to	O
+public	O
+health	O
+emergency	B-DISO
+management	O
+and	O
+health	O
+risk	O
+communication	O
+officials	O
+to	O
+implement	O
+strategies	O
+necessary	O
+in	O
+improving	O
+PHEP	O
+.	O
+
+The	O
+most	O
+commonly	O
+detected	O
+pathogens	O
+were	O
+influenza	O
+virus	B-SPEC
+(	O
+IFV	B-SPEC
+;	O
+37	O
+.	O
+39	O
+%;	O
+123	O
+/	O
+329	O
+),	O
+adenovirus	B-DISO
+(	O
+AdV	O
+;	O
+17	O
+.	O
+02	O
+%;	O
+56	O
+/	O
+329	O
+),	O
+human	B-SPEC
+coronaviruses	O
+(	O
+HCoVs	O
+;	O
+10	O
+.	O
+94	O
+%;	O
+36	O
+/	O
+329	O
+),	O
+rhinovirus	B-SPEC
+/	O
+enterovirus	B-SPEC
+(	O
+RV	O
+/	O
+EV	O
+;	O
+10	O
+.	O
+03	O
+%;	O
+33	O
+/	O
+329	O
+),	O
+parainfluenza	O
+viruses	B-SPEC
+(	O
+PIVs	O
+;	O
+8	O
+.	O
+51	O
+%;	O
+28	O
+/	O
+329	O
+),	O
+and	O
+Mycoplasma	B-SPEC
+pneumoniae	I-SPEC
+(	O
+M	O
+.	O
+pneu	O
+;	O
+8	O
+.	O
+51	O
+%;	O
+28	O
+/	O
+329	O
+),	O
+respectively	O
+.	O
+
+RESULTS	O
+:	O
+Among	O
+the	O
+225	O
+(	O
+225	O
+/	O
+445	O
+,	O
+51	O
+%)	O
+positive	O
+specimens	O
+,	O
+329	O
+positive	O
+pathogens	O
+were	O
+detected	O
+,	O
+including	O
+298	O
+(	O
+90	O
+.	O
+58	O
+%)	O
+viruses	B-SPEC
+and	O
+31	O
+(	O
+9	O
+%)	O
+bacteria	B-SPEC
+.	O
+
+We	O
+collected	O
+37	O
+,	O
+777	O
+CA	O
+-	O
+RVs	O
+multiplex	O
+real	O
+-	O
+time	O
+reverse	B-PROC
+transcription	I-PROC
+-	O
+polymerase	O
+chain	O
+reaction	O
+test	O
+results	O
+of	O
+individuals	O
+aged	O
+≥	O
+18	O
+years	O
+from	O
+November	O
+2012	O
+to	O
+November	O
+2017	O
+.	O
+
+TITLE	O
+:	O
+Streptokinase	O
+Versus	O
+Unfractionated	O
+Heparin	B-CHED
+Nebulization	O
+in	O
+Patients	O
+With	O
+Severe	O
+Acute	B-DISO
+Respiratory	I-DISO
+Distress	I-DISO
+Syndrome	I-DISO
+(	O
+ARDS	B-DISO
+):	O
+
+Case	O
+-	O
+based	O
+data	O
+analysis	O
+suggests	O
+that	O
+since	O
+2016	O
+,	O
+as	O
+many	O
+as	O
+1	O
+,	O
+465	O
+cases	O
+and	O
+293	O
+-	O
+520	O
+deaths	B-PROC
+might	O
+have	O
+been	O
+averted	O
+.	O
+
+No	O
+association	O
+was	O
+demonstrated	O
+between	O
+aMPV	O
+infection	B-DISO
+and	O
+clinical	O
+outbreaks	O
+or	O
+between	O
+aMPV	O
+and	O
+IBV	B-SPEC
+detection	O
+,	O
+suggesting	O
+the	O
+marginal	O
+role	O
+of	O
+the	O
+former	O
+pathogen	O
+in	O
+poultry	O
+farming	O
+.	O
+
+ABSTRACT	O
+:	O
+Avian	O
+infectious	O
+bronchitis	O
+virus	B-SPEC
+(	O
+IBV	B-SPEC
+)	O
+is	O
+responsible	O
+of	O
+significant	O
+economic	O
+losses	O
+for	O
+poultry	O
+industry	O
+around	O
+the	O
+world	O
+,	O
+through	O
+evolution	B-PROC
+of	O
+its	O
+pathogenicity	O
+,	O
+inadequacy	O
+of	O
+vaccines	O
+,	O
+and	O
+virus	B-SPEC
+evasion	O
+.	O
+
+Phylogenetic	O
+analysis	O
+of	O
+the	O
+S1	O
+nucleotide	B-CHED
+sequences	O
+showed	O
+that	O
+both	O
+isolates	O
+are	O
+closely	O
+related	O
+to	O
+the	O
+Algerian	O
+strains	O
+,	O
+and	O
+formed	O
+a	O
+common	O
+cluster	O
+within	O
+the	O
+genotype	O
+I	O
+.	O
+In	O
+addition	O
+,	O
+these	O
+isolates	O
+were	O
+non	O
+-	O
+recombinant	O
+ones	O
+,	O
+confirming	O
+that	O
+they	O
+are	O
+unique	O
+variants	O
+.	O
+
+ABSTRACT	O
+:	O
+Rapid	O
+vaccine	O
+development	B-PROC
+in	O
+response	O
+to	O
+an	O
+outbreak	O
+of	O
+a	O
+new	O
+emerging	B-DISO
+infectious	I-DISO
+disease	I-DISO
+(	O
+EID	O
+)	O
+is	O
+a	O
+goal	O
+targeted	B-PROC
+by	O
+public	O
+health	O
+agencies	O
+worldwide	O
+.	O
+
+TITLE	O
+:	O
+Effects	O
+of	O
+porcine	B-SPEC
+epidemic	I-SPEC
+diarrhea	I-SPEC
+virus	B-DISO
+infection	I-DISO
+on	O
+tight	B-COMP
+junction	I-COMP
+protein	B-CHED
+gene	B-PROC
+expression	I-PROC
+and	O
+morphology	O
+of	O
+the	O
+intestinal	B-ANAT
+mucosa	I-ANAT
+in	O
+pigs	B-SPEC
+.	O
+
+The	O
+expression	B-PROC
+of	O
+Claudin	B-PRGE
+-	I-PRGE
+5	I-PRGE
+in	O
+the	O
+jejunum	B-ANAT
+was	O
+significantly	O
+lower	O
+in	O
+PEDV	B-SPEC
+-	O
+infected	O
+piglets	O
+than	O
+in	O
+the	O
+normal	O
+animals	B-SPEC
+(	O
+p	O
+⟨	O
+0	O
+.	O
+01	O
+).	O
+
+In	O
+PEDV	B-SPEC
+-	O
+infected	O
+IPEC	O
+-	O
+J2	O
+cells	B-COMP
+,	O
+the	O
+mRNA	B-PROC
+expression	B-PROC
+of	O
+the	O
+six	O
+tight	B-COMP
+junction	I-COMP
+proteins	B-CHED
+showed	O
+a	O
+downward	O
+trend	O
+;	O
+in	O
+particular	O
+,	O
+the	O
+expression	B-PROC
+of	O
+the	O
+Occludin	B-PRGE
+and	O
+Claudin	B-PRGE
+-	I-PRGE
+4	I-PRGE
+genes	I-PRGE
+was	O
+significantly	O
+lower	O
+(	O
+p	O
+⟨	O
+0	O
+.	O
+01	O
+).	O
+
+Original	O
+clinical	O
+randomized	O
+controlled	O
+trials	O
+which	O
+met	B-CHED
+the	O
+eligibility	O
+criteria	O
+were	O
+included	O
+.	O
+
+ABSTRACT	O
+:	O
+Traumatic	O
+brain	B-ANAT
+injury	O
+(	O
+TBI	O
+)	O
+and	O
+chest	B-ANAT
+trauma	O
+are	O
+common	O
+injuries	O
+in	O
+severely	O
+injured	O
+patients	O
+.	O
+
+However	O
+,	O
+the	O
+relevance	O
+of	O
+TBI	O
+,	O
+chest	B-ANAT
+trauma	O
+and	O
+particularly	O
+their	O
+combination	O
+as	O
+risk	O
+factors	O
+for	O
+the	O
+development	B-PROC
+of	O
+pneumonia	B-DISO
+and	O
+its	O
+impact	O
+on	O
+outcomes	O
+are	O
+not	O
+fully	O
+elucidated	O
+.	O
+
+We	O
+report	O
+the	O
+subsequent	O
+favorable	O
+outcomes	O
+due	O
+to	O
+the	O
+institution	O
+of	O
+extracorporeal	O
+membrane	B-COMP
+oxygenation	B-PROC
+.	O
+
+In	O
+this	O
+study	O
+,	O
+self	O
+-	O
+assembly	O
+nanoparticles	B-CHED
+were	O
+prepared	O
+for	O
+antigens	B-CHED
+delivery	O
+based	O
+on	O
+the	O
+noncovalent	O
+interaction	O
+between	O
+
+ABSTRACT	O
+:	O
+To	O
+set	O
+priorities	O
+for	O
+efficient	O
+control	O
+of	O
+acute	B-DISO
+respiratory	I-DISO
+tract	I-DISO
+infection	I-DISO
+(	O
+ARTI	O
+)	O
+in	O
+Africa	O
+,	O
+it	O
+is	O
+necessary	O
+to	O
+have	O
+accurate	O
+estimate	O
+of	O
+its	O
+burden	O
+,	O
+especially	O
+among	O
+HIV	B-DISO
+-	O
+infected	O
+populations	O
+.	O
+
+CFR	O
+was	O
+significantly	O
+higher	O
+in	O
+patients	O
+with	O
+HIV	B-DISO
+than	O
+in	O
+HIV	B-DISO
+-	O
+negative	O
+controls	O
+(	O
+OR	O
+4	O
+.	O
+10	O
+,	O
+95	O
+%	O
+CI	O
+:	O
+2	O
+.	O
+63	O
+-	O
+6	O
+.	O
+27	O
+,	O
+I²	O
+:	O
+93	O
+.	O
+7	O
+%).	O
+
+There	O
+was	O
+no	O
+difference	O
+for	O
+viral	O
+respiratory	O
+aetiologies	O
+(	O
+Enterovirus	B-SPEC
+,	O
+Adenovirus	B-DISO
+,	O
+Bocavirus	B-SPEC
+,	O
+Coronavirus	B-SPEC
+,	O
+Metapneumovirus	B-SPEC
+,	O
+Parainfluenza	B-DISO
+,	O
+Influenza	B-DISO
+,	O
+and	O
+Respiratory	B-SPEC
+Syncytial	I-SPEC
+Virus	I-SPEC
+)	O
+of	O
+ARTI	O
+between	O
+HIV	B-DISO
+-	O
+positive	O
+and	O
+HIV	B-DISO
+-	O
+negative	O
+people	O
+,	O
+except	O
+for	O
+Rhinovirus	B-SPEC
+where	O
+being	O
+HIV	B-DISO
+-	O
+negative	O
+was	O
+associated	O
+with	O
+Rhinovirus	B-SPEC
+(	O
+OR	O
+0	O
+.	O
+70	O
+;	O
+95	O
+%	O
+CI	O
+0	O
+.	O
+51	O
+-	O
+0	O
+.	O
+97	O
+,	O
+I²	O
+:	O
+63	O
+.	O
+4	O
+%).	O
+
+We	O
+included	O
+488	O
+patients	O
+older	O
+than	O
+70	O
+years	O
+with	O
+normal	O
+spirometry	O
+results	O
+who	O
+underwent	O
+curative	O
+resection	O
+for	O
+NSCLC	B-DISO
+(	O
+stage	O
+IA	O
+-	O
+IIB	O
+)	O
+between	O
+2012	O
+and	O
+2016	O
+.	O
+
+Fraxin	O
+,	O
+one	O
+of	O
+the	O
+main	O
+active	O
+ingredients	O
+of	O
+Cortex	B-ANAT
+Fraxini	O
+,	O
+a	O
+Chinese	O
+herbal	O
+medicine	B-CHED
+,	O
+has	O
+presented	O
+various	O
+pharmacological	O
+and	O
+biological	O
+activities	O
+.	O
+
+Recombinant	O
+EMC	B-COMP
+isolates	O
+of	O
+MERS	O
+-	O
+CoV	O
+,	O
+in	O
+which	O
+the	O
+S	B-PRGE
+protein	I-PRGE
+is	O
+replaced	O
+with	O
+those	O
+of	O
+Amibara	O
+isolates	O
+,	O
+were	O
+then	O
+generated	O
+to	O
+test	O
+the	O
+roles	O
+of	O
+these	O
+proteins	B-CHED
+in	O
+viral	O
+properties	O
+.	O
+
+Respiratory	O
+syncytial	O
+virus	O
+(	O
+RSV	B-SPEC
+)	O
+may	O
+cause	O
+a	O
+lower	B-DISO
+respiratory	I-DISO
+tract	I-DISO
+infection	I-DISO
+characterized	O
+by	O
+bronchiolitis	B-DISO
+and	O
+pneumonia	B-DISO
+mainly	O
+in	O
+children	O
+and	O
+the	O
+elderly	O
+.	O
+
+It	O
+is	O
+clear	O
+that	O
+the	O
+discovery	O
+and	O
+development	B-PROC
+of	O
+novel	O
+antivirals	B-CHED
+that	O
+can	O
+be	O
+used	O
+alone	O
+or	O
+in	O
+combination	O
+with	O
+existing	O
+therapies	O
+to	O
+treat	O
+these	O
+important	O
+respiratory	O
+viral	B-DISO
+infections	I-DISO
+are	O
+critical	O
+.	O
+
+In	O
+this	O
+review	O
+,	O
+we	O
+will	O
+describe	O
+some	O
+of	O
+the	O
+novel	O
+therapeutics	O
+currently	O
+under	O
+development	B-PROC
+for	O
+the	O
+treatment	O
+of	O
+these	O
+infections	B-DISO
+.	O
+
+We	O
+further	O
+solved	O
+the	O
+structure	O
+of	O
+HKU23	O
+-	O
+NTD	O
+,	O
+performed	O
+structure	O
+-	O
+guided	O
+mutagenesis	B-PROC
+and	O
+successfully	O
+located	O
+the	O
+potential	O
+sugar	O
+-	O
+binding	B-FUNC
+pockets	O
+in	O
+the	O
+structure	O
+.	O
+
+His	O
+medical	O
+history	O
+included	O
+hypertension	B-DISO
+managed	O
+with	O
+amlodipine	B-CHED
+;	O
+he	O
+denied	O
+any	O
+history	O
+of	O
+TB	O
+,	O
+recent	O
+travel	O
+,	O
+or	O
+canned	O
+food	O
+ingestion	O
+.	O
+
+Management	O
+with	O
+acute	O
+normovolemic	O
+hemodilution	O
+corrected	O
+both	O
+the	O
+biologic	O
+and	O
+hemodynamic	B-PROC
+parameters	O
+.	O
+
+The	O
+optimal	O
+hemoglobin	B-PRGE
+level	O
+on	O
+extracorporeal	O
+membrane	B-COMP
+oxygenation	B-PROC
+deserves	O
+further	O
+investigation	O
+.	O
+
+ABSTRACT	O
+:	O
+Midkine	O
+has	O
+been	O
+reported	O
+to	O
+play	O
+a	O
+crucial	O
+role	O
+in	O
+inflammatory	O
+,	O
+hypoxia	O
+,	O
+and	O
+tissue	B-ANAT
+injury	O
+processes	O
+.	O
+
+Septic	O
+patients	O
+admitted	O
+to	O
+the	O
+Department	O
+of	O
+Critical	O
+Care	O
+Medicine	B-CHED
+,	O
+Zhongda	O
+Hospital	O
+,	O
+a	O
+tertiary	O
+hospital	O
+,	O
+from	O
+November	O
+2017	O
+to	O
+March	O
+2018	O
+were	O
+enrolled	O
+in	O
+the	O
+study	O
+.	O
+
+A	O
+peripheral	B-ANAT
+blood	I-ANAT
+sample	O
+was	O
+obtained	O
+at	O
+admission	O
+,	O
+and	O
+plasma	B-ANAT
+midkine	O
+levels	O
+were	O
+evaluated	O
+with	O
+an	O
+immunoassay	O
+.	O
+
+Plasma	B-ANAT
+midkine	O
+levels	O
+were	O
+significantly	O
+elevated	O
+in	O
+the	O
+nonsurvivor	O
+group	O
+compared	O
+with	O
+the	O
+survivors	O
+(	O
+ng	O
+/	O
+L	O
+,	O
+763	O
+.	O
+6	O
+[	O
+404	O
+.	O
+7	O
+-	O
+1305	O
+],	O
+268	O
+.	O
+5	O
+[	O
+147	O
+.	O
+8	O
+-	O
+511	O
+.	O
+4	O
+];	O
+Plasma	O
+midkine	O
+was	O
+associated	O
+with	O
+28	O
+-	O
+day	O
+mortality	O
+,	O
+as	O
+well	O
+as	O
+pulmonary	B-ANAT
+and	O
+kidney	B-ANAT
+injury	O
+,	O
+in	O
+septic	O
+patients	O
+.	O
+
+ABSTRACT	O
+:	O
+Our	O
+aims	O
+are	O
+to	O
+determine	O
+the	O
+clinical	O
+and	O
+preclinical	O
+characteristics	O
+and	O
+outcome	O
+of	O
+ARDS	O
+among	O
+burn	O
+patients	O
+with	O
+inhalation	B-PROC
+injury	O
+.	O
+
+Outcome	O
+measures	O
+included	O
+blood	B-PROC
+gas	B-ENZY
+criteria	O
+and	O
+oxygenation	B-PROC
+state	O
+at	O
+ARDS	B-DISO
+onset	O
+,	O
+mechanical	O
+ventilation	O
+duration	O
+,	O
+length	O
+of	O
+stay	O
+in	O
+the	O
+ICU	O
+and	O
+in	O
+the	O
+hospital	O
+,	O
+ventilation	O
+-	O
+free	O
+time	O
+and	O
+mortality	O
+rate	O
+until	O
+28	O
+days	O
+postburn	O
+.	O
+
+Animal	B-SPEC
+models	O
+,	O
+despite	O
+being	O
+ideal	O
+to	O
+study	O
+the	O
+anti	O
+-	O
+inflammatory	B-PROC
+responses	I-PROC
+to	O
+influenza	B-SPEC
+virus	B-DISO
+infection	I-DISO
+,	O
+are	O
+very	O
+costly	O
+and	O
+time	O
+-	O
+consuming	O
+.	O
+
+We	O
+demonstrated	O
+that	O
+the	O
+U937	B-ANAT
+cell	I-ANAT
+model	O
+is	O
+robust	O
+and	O
+suitable	O
+for	O
+the	O
+high	O
+-	O
+throughput	O
+screening	O
+of	O
+immunomodulators	O
+and	O
+antivirals	B-CHED
+against	O
+influenza	B-PATH
+infection	B-DISO
+.	O
+
+ABSTRACT	O
+:	O
+Avian	B-DISO
+infectious	I-DISO
+bronchitis	I-DISO
+virus	B-SPEC
+(	O
+IBV	B-SPEC
+)	O
+is	O
+a	O
+major	O
+respiratory	B-DISO
+disease	I-DISO
+-	O
+causing	O
+agent	O
+in	O
+birds	B-SPEC
+that	O
+leads	O
+to	O
+significant	O
+losses	O
+.	O
+
+The	O
+major	O
+cause	O
+of	O
+death	B-PROC
+was	O
+sepsis	B-DISO
+(	O
+n	O
+=	O
+13	O
+patients	O
+with	O
+15	O
+identified	O
+organisms	O
+,	O
+which	O
+were	O
+Acinetobacter	B-SPEC
+baumannii	I-SPEC
+(	O
+9	O
+),	O
+Escherichia	B-SPEC
+coli	I-SPEC
+(	O
+3	O
+),	O
+Candida	B-SPEC
+albicans	I-SPEC
+(	O
+2	O
+)	O
+and	O
+Aspergillosis	B-DISO
+(	O
+1	O
+)),	O
+followed	O
+by	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+(	O
+ARDS	B-DISO
+)	O
+(	O
+6	O
+),	O
+severe	O
+heart	B-ANAT
+condition	B-DISO
+(	O
+3	O
+),	O
+acute	O
+kidney	B-ANAT
+injury	O
+(	O
+AKI	O
+)	O
+(	O
+2	O
+),	O
+chronic	B-DISO
+kidney	I-DISO
+disease	I-DISO
+(	O
+CKD	O
+)	O
+(	O
+2	O
+)	O
+and	O
+intracranial	B-DISO
+haemorrhage	I-DISO
+(	O
+1	O
+).	O
+
+High	O
+index	O
+of	O
+suspicion	O
+for	O
+influenza	B-PATH
+A	I-PATH
+(	O
+H1N1	O
+)	O
+infection	B-DISO
+in	O
+ICH	B-DISO
+,	O
+early	O
+antiviral	B-CHED
+therapy	O
+,	O
+and	O
+treatment	O
+of	O
+coinfection	B-DISO
+is	O
+recommended	O
+.	O
+
+With	O
+the	O
+threat	O
+of	O
+transmission	O
+of	O
+resistant	O
+viral	O
+strains	O
+from	O
+ICH	B-DISO
+to	O
+the	O
+community	O
+,	O
+apart	O
+from	O
+treatment	O
+,	O
+preventive	O
+measures	O
+such	O
+as	O
+vaccination	O
+and	O
+hygienic	O
+practices	O
+have	O
+a	O
+significant	O
+role	O
+.	O
+
+Serum	B-COMP
+total	O
+protein	B-CHED
+at	O
+enrollment	O
+and	O
+body	B-ANAT
+weight	O
+at	O
+birth	B-PROC
+,	O
+treatment	O
+end	O
+,	O
+and	O
+hutch	O
+exit	O
+were	O
+measured	O
+.	O
+
+Logistic	O
+regression	O
+showed	O
+that	O
+the	O
+odds	O
+of	O
+microbiological	O
+cure	O
+at	O
+diarrhea	B-DISO
+resolution	O
+for	O
+rotavirus	B-SPEC
+,	O
+C	B-SPEC
+.	I-SPEC
+parvum	I-SPEC
+,	O
+or	O
+any	O
+single	O
+fecal	B-ANAT
+pathogen	O
+was	O
+not	O
+different	O
+between	O
+treatment	O
+groups	O
+.	O
+
+Dysregulated	O
+leukocyte	B-ANAT
+diapedesis	B-PROC
+is	O
+a	O
+major	O
+contributor	O
+to	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+.	O
+
+SP	B-PRGE
+-	I-PRGE
+D	I-PRGE
+levels	O
+increased	O
+1	O
+.	O
+6	O
+-	O
+fold	O
+following	O
+surgical	O
+repair	B-PROC
+of	O
+the	O
+diaphragm	B-ANAT
+and	O
+were	O
+significantly	O
+higher	O
+in	O
+the	O
+second	O
+week	O
+following	O
+surgery	O
+when	O
+compared	O
+to	O
+pre	O
+-	O
+operative	O
+levels	O
+(	O
+p	O
+<	O
+0	O
+.	O
+03	O
+).	O
+
+The	O
+main	O
+objectives	O
+of	O
+the	O
+study	O
+is	O
+to	O
+characterize	O
+the	O
+pattern	O
+of	O
+the	O
+MERS	O
+outbreak	O
+in	O
+South	O
+Korea	O
+based	O
+on	O
+a	O
+basic	O
+reproductive	B-PROC
+ratio	O
+,	O
+the	O
+probability	O
+of	O
+ultimate	O
+extinction	O
+of	O
+the	O
+disease	O
+,	O
+and	O
+the	O
+spatio	O
+-	O
+temporal	O
+proximity	O
+of	O
+occurrence	O
+between	O
+patients	O
+.	O
+
+The	O
+role	O
+of	O
+various	O
+biomarkers	O
+,	O
+such	O
+as	O
+Clara	B-PRGE
+cell	I-PRGE
+protein	B-CHED
+16	I-PRGE
+,	O
+von	B-PRGE
+Willebrand	I-PRGE
+factor	I-PRGE
+,	O
+interleukin	B-PRGE
+-	I-PRGE
+6	I-PRGE
+,	O
+tumor	B-FUNC
+necrosis	I-FUNC
+factor	I-FUNC
+,	O
+and	O
+angiopoietin	O
+,	O
+has	O
+been	O
+studied	O
+in	O
+trauma	O
+-	O
+related	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+(	O
+ARDS	B-DISO
+).	O
+
+RESULTS	O
+:	O
+Canine	O
+respiratory	O
+coronavirus	B-SPEC
+(	O
+7	O
+.	O
+5	O
+%)	O
+and	O
+canine	B-SPEC
+parainfluenza	I-SPEC
+virus	I-SPEC
+(	O
+6	O
+.	O
+5	O
+%)	O
+were	O
+the	O
+most	O
+commonly	O
+detected	O
+viruses	B-SPEC
+in	O
+samples	O
+from	O
+the	O
+upper	O
+airways	O
+of	O
+dogs	B-SPEC
+with	O
+respiratory	B-DISO
+infections	I-DISO
+.	O
+
+Similar	O
+findings	O
+were	O
+observed	O
+for	O
+the	O
+plasma	O
+ST2	B-ANAT
+and	O
+hs	B-PRGE
+-	I-PRGE
+CRP	I-PRGE
+levels	O
+.	O
+
+OSA	B-DISO
+screening	O
+and	O
+multifaceted	O
+treatment	O
+during	O
+the	O
+sub	O
+-	O
+acute	O
+phase	O
+of	O
+acute	B-DISO
+coronary	I-DISO
+syndrome	I-DISO
+did	O
+not	O
+further	O
+reduce	O
+the	O
+levels	O
+of	O
+cardiovascular	B-ANAT
+biomarkers	O
+when	O
+compared	O
+with	O
+standard	O
+therapy	O
+.	O
+
+The	O
+abundance	O
+of	O
+pathogenic	O
+bacteria	B-SPEC
+associated	O
+with	O
+diseases	O
+,	O
+including	O
+diarrhea	B-DISO
+,	O
+was	O
+increased	O
+.	O
+
+The	O
+abundance	O
+of	O
+Fusobacterium	B-SPEC
+was	O
+26	O
+.	O
+71	O
+%	O
+and	O
+33	O
+.	O
+91	O
+%	O
+in	O
+cecal	B-ANAT
+mucosa	I-ANAT
+and	O
+contents	O
+of	O
+PEDV	B-SPEC
+-	O
+infected	O
+group	O
+,	O
+respectively	O
+,	O
+whereas	O
+that	O
+in	O
+the	O
+healthy	O
+groups	O
+was	O
+17	O
+.	O
+85	O
+%	O
+and	O
+9	O
+.	O
+88	O
+%.	O
+
+TITLE	O
+:	O
+Spatiotemporal	O
+Clustering	O
+of	O
+Middle	O
+East	O
+Respiratory	O
+Syndrome	B-DISO
+Coronavirus	B-SPEC
+(	O
+MERS	O
+-	O
+CoV	O
+)	O
+Incidence	O
+in	O
+Saudi	O
+Arabia	O
+,	O
+2012	O
+-	O
+2019	O
+.	O
+
+This	O
+study	O
+analysed	O
+the	O
+spatiotemporal	O
+patterns	O
+and	O
+clusters	B-CHED
+of	O
+laboratory	O
+-	O
+confirmed	O
+MERS	O
+-	O
+CoV	O
+cases	O
+reported	O
+in	O
+Saudi	O
+Arabia	O
+between	O
+June	O
+2012	O
+and	O
+March	O
+2019	O
+.	O
+
+The	O
+number	O
+of	O
+dead	B-PROC
+piglets	O
+per	O
+sow	O
+(	O
+DP	O
+/	O
+S	O
+)	O
+was	O
+calculated	O
+as	O
+the	O
+number	O
+of	O
+dead	B-PROC
+suckling	O
+piglets	O
+during	O
+TAC	B-CHED
+divided	O
+by	O
+the	O
+sow	O
+inventory	O
+.	O
+
+Regarding	O
+the	O
+effect	O
+of	O
+biosecurity	O
+measures	O
+during	O
+PED	O
+outbreak	O
+on	O
+TAC	B-PRGE
+and	O
+DP	B-PRGE
+/	I-PRGE
+S	I-PRGE
+,	I-PRGE
+longer	I-PRGE
+TAC	I-PRGE
+was	O
+observed	O
+in	O
+Actinobacillus	B-SPEC
+pleuropneumoniae	I-SPEC
+-	O
+positive	O
+farms	O
+and	O
+farms	O
+outsourcing	O
+pig	B-SPEC
+transport	B-PROC
+to	O
+the	O
+slaughterhouse	O
+(	O
+p	O
+<	O
+0	O
+.	O
+05	O
+).	O
+
+Farms	O
+that	O
+fixed	B-ANAT
+the	O
+hours	O
+staff	O
+worked	O
+in	O
+farrowing	B-PROC
+barn	O
+had	O
+lower	O
+DP	O
+/	O
+S	O
+than	O
+the	O
+other	O
+farms	O
+(	O
+p	O
+<	O
+0	O
+.	O
+05	O
+).	O
+
+CONCLUSIONS	O
+We	O
+found	O
+that	O
+CXCL5	B-PRGE
+/	O
+CXCR2	B-PRGE
+accelerated	O
+the	O
+progression	O
+of	O
+ARDS	B-DISO
+,	O
+partly	O
+by	O
+upregulation	B-PROC
+of	O
+MMP2	B-PRGE
+and	O
+MMP9	B-PRGE
+in	O
+lung	B-ANAT
+tissues	I-ANAT
+with	O
+the	O
+release	B-PATH
+of	O
+inflammatory	O
+factors	O
+.	O
+
+ABSTRACT	O
+:	O
+Although	O
+lung	O
+protection	O
+with	O
+low	O
+tidal	O
+volume	O
+and	O
+limited	O
+plateau	O
+pressure	O
+(	O
+P	O
+This	O
+study	O
+aimed	O
+to	O
+compare	O
+two	O
+strategies	O
+using	O
+individual	O
+PEEP	B-CHED
+based	O
+on	O
+a	O
+maximum	O
+P	O
+Nineteen	O
+patients	O
+with	O
+moderate	O
+to	O
+severe	O
+ARDS	B-DISO
+(	O
+PaO	B-PROC
+There	O
+is	O
+a	O
+great	O
+heterogeneity	O
+of	O
+P	O
+RESULTS	O
+:	O
+Nineteen	O
+patients	O
+with	O
+moderate	O
+to	O
+severe	O
+ARDS	B-DISO
+(	O
+PaO	B-PROC
+
+TITLE	O
+:	O
+Severe	O
+influenza	B-DISO
+:	O
+overview	O
+in	O
+critically	B-DISO
+ill	I-DISO
+patients	O
+.	O
+
+Antiviral	B-CHED
+therapy	O
+within	O
+48	O
+h	O
+after	O
+onset	O
+,	O
+avoidance	O
+of	O
+corticosteroids	B-CHED
+and	O
+rescue	O
+therapies	O
+for	O
+ARF	B-DISO
+or	O
+myocarditis	B-DISO
+,	O
+such	O
+as	O
+extracorporeal	O
+membrane	B-COMP
+oxygenation	B-PROC
+,	O
+improve	O
+survival	O
+.	O
+
+TITLE	O
+:	O
+Severe	O
+Guillain	O
+-	O
+Barré	O
+syndrome	B-DISO
+associated	O
+with	O
+chronic	B-DISO
+active	I-DISO
+hepatitis	I-DISO
+C	O
+and	O
+mixed	B-DISO
+cryoglobulinemia	I-DISO
+:	O
+a	O
+case	O
+report	O
+.	O
+
+After	O
+treatment	O
+with	O
+intravenous	O
+immunoglobulin	B-PROC
+and	O
+plasma	B-ANAT
+exchange	O
+followed	O
+by	O
+antiviral	B-CHED
+therapy	O
+by	O
+direct	O
+-	O
+acting	O
+antiviral	O
+agent	O
+,	O
+patient	O
+showed	O
+progressive	O
+recovery	O
+and	O
+was	O
+transferred	O
+3	O
+months	O
+after	O
+his	O
+first	O
+admission	O
+to	O
+a	O
+rehabilitation	O
+center	O
+.	O
+
+HCV	B-SPEC
+infection	B-DISO
+should	O
+be	O
+screened	O
+in	O
+high	O
+-	O
+risk	O
+patients	O
+to	O
+prevent	O
+silent	O
+progression	O
+of	O
+the	O
+chronic	B-DISO
+hepatitis	I-DISO
+C	I-DISO
+and	O
+its	O
+potentially	O
+severe	O
+extra	O
+-	O
+hepatic	B-ANAT
+manifestations	O
+.	O
+
+ABSTRACT	O
+:	O
+To	O
+investigate	O
+the	O
+clinical	O
+correlations	O
+between	O
+mechanical	O
+power	O
+(	O
+MP	O
+)	O
+and	O
+lung	B-ANAT
+ultrasound	O
+score	O
+(	O
+LUS	O
+),	O
+and	O
+analyze	O
+their	O
+evaluation	O
+value	O
+of	O
+prognosis	O
+in	O
+patients	O
+with	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+(	O
+ARDS	B-DISO
+).	O
+
+ABSTRACT	O
+:	O
+A	O
+fusion	O
+protein	B-CHED
+expressed	B-PROC
+on	O
+the	O
+surface	O
+of	O
+enveloped	O
+viruses	B-SPEC
+mediates	O
+fusion	O
+of	O
+the	O
+viral	O
+and	O
+cellular	B-COMP
+membranes	B-ANAT
+to	O
+facilitate	O
+virus	B-DISO
+infection	I-DISO
+.	O
+
+Receptor	B-FUNC
+binding	I-FUNC
+induces	O
+the	O
+membrane	B-COMP
+-	O
+binding	B-FUNC
+potential	O
+of	O
+the	O
+trimer	O
+,	O
+in	O
+which	O
+at	O
+least	O
+one	O
+HR	O
+motif	O
+forms	O
+a	O
+packed	O
+-	O
+hairpin	O
+structure	O
+,	O
+while	O
+membrane	B-PROC
+fusion	I-PROC
+subunits	O
+are	O
+covered	O
+by	O
+the	O
+receptor	O
+-	O
+binding	B-FUNC
+subunit	O
+,	O
+thereby	O
+preventing	O
+the	O
+spike	O
+protein	B-CHED
+from	O
+forming	O
+the	O
+typical	O
+homotrimeric	O
+prehairpin	O
+structure	O
+predicted	O
+by	O
+the	O
+current	O
+model	O
+of	O
+class	B-PRGE
+I	I-PRGE
+viral	I-PRGE
+fusion	I-PRGE
+protein	B-CHED
+.	O
+
+Our	O
+model	O
+proposes	O
+a	O
+key	O
+mechanism	O
+for	O
+membrane	B-PROC
+fusion	I-PROC
+of	O
+enveloped	O
+viruses	B-SPEC
+.	O
+
+Using	O
+viruslike	O
+particles	O
+lacking	O
+the	O
+spike	O
+(	O
+S	O
+)	O
+protein	B-CHED
+,	O
+we	O
+demonstrate	O
+that	O
+binding	B-FUNC
+to	O
+the	O
+cell	B-COMP
+is	O
+not	O
+S	B-PRGE
+protein	I-PRGE
+dependent	O
+.	O
+
+Clinical	O
+presentation	O
+is	O
+characterized	O
+with	O
+acute	B-DISO
+diarrhoea	I-DISO
+,	O
+vomiting	B-DISO
+and	O
+dehydration	B-DISO
+in	O
+pigs	B-SPEC
+of	O
+all	O
+ages	O
+,	O
+with	O
+a	O
+possible	O
+high	O
+mortality	O
+in	O
+suckling	O
+piglets	O
+.	O
+
+AIV	O
+,	O
+including	O
+H5	O
+,	O
+H7	O
+,	O
+and	O
+H9	O
+subtypes	O
+;	O
+NDV	B-SPEC
+;	O
+and	O
+IBV	B-SPEC
+were	O
+simultaneously	O
+detected	O
+and	O
+differentiated	B-PROC
+on	O
+a	O
+microarray	O
+.	O
+
+Influenza	B-DISO
+is	O
+associated	O
+with	O
+a	O
+high	O
+predisposition	O
+to	O
+bacterial	B-DISO
+sepsis	I-DISO
+and	O
+ARDS	B-DISO
+.	O
+
+Viral	B-DISO
+infections	I-DISO
+presenting	O
+concurrently	O
+with	O
+bacterial	B-DISO
+pneumonia	I-DISO
+are	O
+now	O
+known	O
+to	O
+occur	O
+with	O
+a	O
+frequency	O
+of	O
+30	O
+-	O
+50	O
+%	O
+in	O
+both	O
+adult	O
+and	O
+pediatric	O
+populations	O
+.	O
+
+Fibrinogen	B-COMP
+and	O
+antithrombin	B-PRGE
+activity	O
+have	O
+been	O
+reported	O
+as	O
+biomarkers	O
+of	O
+coagulopathy	B-DISO
+;	O
+however	O
+,	O
+the	O
+utility	O
+of	O
+these	O
+two	O
+markers	O
+has	O
+not	O
+been	O
+well	O
+established	O
+.	O
+
+Pituitary	B-ANAT
+axis	B-SPEC
+function	O
+is	O
+frequently	O
+altered	O
+early	O
+after	O
+ICU	O
+admission	O
+,	O
+the	O
+magnitude	O
+of	O
+hormonal	O
+response	O
+being	O
+different	O
+according	O
+to	O
+the	O
+underlying	O
+critical	B-DISO
+illness	I-DISO
+.	O
+
+Although	O
+there	O
+were	O
+no	O
+taxa	O
+significantly	O
+linked	O
+to	O
+the	O
+different	O
+conditions	O
+,	O
+some	O
+peculiar	O
+patterns	O
+were	O
+recognized	O
+:	O
+Firmicutes	B-SPEC
+was	O
+always	O
+the	O
+most	O
+represented	O
+phylum	B-SPEC
+,	O
+followed	O
+by	O
+Bacteroidetes	B-SPEC
+and	O
+Actinobacteria	B-SPEC
+.	O
+
+TITLE	O
+:	O
+Superior	O
+immune	B-PROC
+responses	I-PROC
+induced	O
+by	O
+intranasal	O
+immunization	O
+with	O
+recombinant	O
+adenovirus	B-DISO
+-	O
+based	O
+vaccine	O
+expressing	O
+full	O
+-	O
+length	O
+Spike	O
+protein	O
+of	O
+Middle	O
+East	O
+respiratory	O
+syndrome	B-DISO
+coronavirus	B-SPEC
+.	O
+
+We	O
+found	O
+that	O
+immunization	O
+with	O
+candidate	O
+vaccines	O
+via	O
+intranasal	O
+route	O
+induced	O
+S1	B-PRGE
+-	I-PRGE
+specific	I-PRGE
+IgG	I-PRGE
+antibodies	B-COMP
+and	O
+neutralizing	O
+antibodies	B-COMP
+against	O
+MERS	O
+spike	O
+pseudotyped	O
+virus	B-SPEC
+.	O
+
+TITLE	O
+:	O
+Characteristics	O
+and	O
+outcome	O
+of	O
+viral	B-DISO
+pneumonia	I-DISO
+caused	O
+by	O
+influenza	B-DISO
+and	O
+Middle	O
+East	O
+respiratory	O
+syndrome	O
+-	O
+coronavirus	B-DISO
+infections	I-DISO
+:	O
+A	O
+4	O
+-	O
+year	O
+experience	O
+from	O
+a	O
+tertiary	O
+care	O
+center	O
+.	O
+
+Cases	O
+who	O
+were	O
+>	O
+18	O
+years	O
+old	O
+and	O
+were	O
+confirmed	O
+by	O
+a	O
+respiratory	O
+viral	O
+panel	O
+to	O
+have	O
+viral	B-DISO
+pneumonia	I-DISO
+either	O
+MERS	O
+-	O
+CoV	O
+or	O
+influenza	B-SPEC
+viruses	I-SPEC
+were	O
+included	O
+in	O
+the	O
+analysis	O
+.	O
+
+A	O
+total	O
+of	O
+448	O
+patients	O
+with	O
+confirmed	O
+viral	O
+pneumonia	O
+were	O
+included	O
+,	O
+of	O
+those	O
+,	O
+216	O
+(	O
+48	O
+.	O
+2	O
+%)	O
+were	O
+caused	O
+by	O
+influenza	B-PATH
+A	I-PATH
+(	O
+non	O
+H1N1	O
+)/	O
+influenza	B-DISO
+B	O
+,	O
+150	O
+(	O
+33	O
+.	O
+5	O
+%)	O
+by	O
+H1N1	O
+,	O
+and	O
+82	O
+(	O
+18	O
+.	O
+3	O
+%)	O
+by	O
+MERS	O
+-	O
+CoV	O
+.	O
+The	O
+majority	O
+of	O
+patients	O
+presented	O
+with	O
+fever	B-PROC
+(	O
+82	O
+%),	O
+shortness	B-DISO
+of	I-DISO
+breath	I-DISO
+(	O
+64	O
+%),	O
+and	O
+flu	B-DISO
+-	I-DISO
+like	I-DISO
+symptoms	I-DISO
+(	O
+54	O
+.	O
+9	O
+%),	O
+particularly	O
+in	O
+MERS	O
+-	O
+CoV	O
+infected	O
+cases	O
+(	O
+92	O
+%).	O
+
+TITLE	O
+:	O
+An	O
+Elusive	O
+Case	O
+of	O
+Acute	B-DISO
+Interstitial	I-DISO
+Pneumonia	I-DISO
+.	O
+
+The	O
+prognosis	O
+is	O
+poor	O
+with	O
+over	O
+50	O
+%	O
+of	O
+patients	O
+dying	B-PROC
+during	O
+hospital	O
+admission	O
+from	O
+progressive	O
+respiratory	B-DISO
+failure	I-DISO
+.	O
+
+Presented	O
+herein	O
+is	O
+a	O
+case	O
+of	O
+a	O
+previously	O
+healthy	O
+64	O
+-	O
+year	O
+-	O
+old	O
+woman	O
+without	O
+a	O
+prior	O
+history	O
+of	O
+tobacco	B-SPEC
+use	O
+who	O
+presented	O
+with	O
+progressive	O
+hypoxia	B-DISO
+,	O
+dyspnea	B-DISO
+,	O
+and	O
+nonspecific	O
+constitutional	O
+symptoms	O
+.	O
+
+ABSTRACT	O
+:	O
+Leigh	B-DISO
+Syndrome	I-DISO
+is	O
+a	O
+neurodegenerative	B-DISO
+disorder	I-DISO
+caused	O
+by	O
+mitochondrial	B-COMP
+dysfunction	O
+,	O
+with	O
+significant	O
+phenotypic	O
+and	O
+genetic	O
+heterogeneity	O
+.	O
+
+The	O
+typical	O
+pathologic	O
+hallmarks	O
+are	O
+focal	O
+,	O
+bilateral	O
+,	O
+and	O
+symmetric	O
+lesions	O
+in	O
+the	O
+basal	B-ANAT
+ganglia	I-ANAT
+,	O
+thalamus	B-ANAT
+,	O
+cerebellum	B-ANAT
+,	O
+cerebral	B-ANAT
+white	I-ANAT
+matter	I-ANAT
+and	O
+spinal	B-ANAT
+cord	I-ANAT
+gray	I-ANAT
+matter	I-ANAT
+,	O
+usually	O
+with	O
+T2WI	O
+and	O
+FLAIR	O
+hyperintensity	O
+.	O
+
+Progressive	O
+worsening	O
+of	O
+extrapulmonary	O
+organ	B-ANAT
+dysfunction	O
+is	O
+associated	O
+with	O
+worse	O
+outcome	O
+.	O
+
+Postoperative	O
+hemoglobin	B-PRGE
+level	O
+(	O
+odds	O
+ratio	O
+[	O
+OR	O
+]:	O
+0	O
+.	O
+78	O
+;	O
+95	O
+%	O
+confidence	O
+interval	O
+[	O
+CI	O
+]:	O
+0	O
+.	O
+62	O
+-	O
+0	O
+.	O
+99	O
+)	O
+and	O
+perioperative	O
+blood	B-ANAT
+transfusion	O
+volume	O
+(	O
+OR	O
+:	O
+1	O
+.	O
+07	O
+;	O
+95	O
+%	O
+CI	O
+:	O
+1	O
+.	O
+03	O
+-	O
+1	O
+.	O
+12	O
+)	O
+were	O
+associated	O
+with	O
+ARDS	B-DISO
+risk	O
+.	O
+
+According	O
+to	O
+the	O
+high	O
+-	O
+resolution	O
+computed	O
+tomography	O
+(	O
+HRCT	O
+)	O
+examination	O
+,	O
+the	O
+patients	O
+were	O
+divided	O
+into	O
+an	O
+ARDS	O
+group	O
+and	O
+an	O
+ARDS	B-DISO
+pulmonary	B-DISO
+fibrosis	I-DISO
+(	O
+ARDS	B-DISO
+-	O
+PF	O
+)	O
+group	O
+.	O
+
+Treatment	O
+with	O
+intravenous	O
+lipid	B-CHED
+emulsion	O
+(	O
+ILE	B-CHED
+)	O
+therapy	O
+was	O
+instituted	O
+to	O
+accelerate	O
+toxin	O
+elimination	B-PROC
+,	O
+reduce	O
+the	O
+risk	O
+of	O
+complications	O
+related	O
+to	O
+progressive	O
+obtundation	O
+and	O
+shorten	O
+hospitalization	O
+time	O
+.	O
+
+ABSTRACT	O
+:	O
+Lung	B-ANAT
+endothelial	B-ANAT
+barrier	O
+dysfunction	O
+leads	O
+to	O
+severe	O
+pathologies	O
+,	O
+including	O
+the	O
+lethal	O
+Acute	B-DISO
+Respiratory	I-DISO
+Distress	I-DISO
+Syndrome	I-DISO
+.	O
+
+P53	B-PRGE
+has	O
+been	O
+associated	O
+with	O
+anti	O
+-	O
+inflammatory	O
+activities	O
+.	O
+
+Taken	O
+together	O
+,	O
+the	O
+inclusion	O
+of	O
+hematological	O
+measures	O
+in	O
+mouse	B-SPEC
+models	O
+of	O
+emerging	O
+viral	B-DISO
+pathogenesis	I-DISO
+increases	O
+their	O
+translatability	O
+and	O
+should	O
+elevate	O
+the	O
+preclinical	O
+evaluation	O
+of	O
+MERS	O
+-	O
+CoV	O
+therapeutics	O
+and	O
+vaccines	O
+to	O
+better	O
+mirror	O
+the	O
+complexity	O
+of	O
+the	O
+human	B-SPEC
+condition	B-DISO
+.	O
+
+He	O
+was	O
+developed	O
+symptoms	O
+and	O
+hospitalized	O
+with	O
+severe	O
+dyspnea	B-DISO
+in	O
+a	O
+local	O
+hospital	O
+for	O
+3	O
+days	O
+before	O
+admission	O
+to	O
+our	O
+hospital	O
+.	O
+
+At	O
+the	O
+time	O
+when	O
+he	O
+was	O
+transferred	O
+to	O
+our	O
+hospital	O
+,	O
+his	O
+chest	B-ANAT
+computed	O
+tomography	O
+showed	O
+bilateral	O
+,	O
+diffuse	O
+and	O
+consolidative	O
+shadows	O
+all	O
+over	O
+the	O
+lungs	B-ANAT
+,	O
+the	O
+ratio	O
+of	O
+partial	O
+pressure	O
+of	O
+arterial	B-ANAT
+oxygen	B-CHED
+to	O
+the	O
+fraction	O
+of	O
+inspired	B-PROC
+oxygen	B-CHED
+(	O
+PaO	B-PROC
+
+All	O
+patients	O
+had	O
+acute	B-DISO
+respiratory	I-DISO
+failure	I-DISO
+.	O
+
+The	O
+levels	O
+of	O
+C	B-PRGE
+-	I-PRGE
+reactive	I-PRGE
+protein	I-PRGE
+,	O
+however	O
+,	O
+were	O
+similar	O
+.	O
+
+In	O
+this	O
+study	O
+,	O
+we	O
+detected	O
+Mycoplasma	B-SPEC
+gallisepticum	I-SPEC
+(	O
+MG	O
+),	O
+M	B-SPEC
+.	I-SPEC
+synoviae	I-SPEC
+(	O
+MS	O
+),	O
+and	O
+IBV	B-SPEC
+in	O
+several	O
+poultry	O
+farms	O
+in	O
+Myanmar	O
+.	O
+
+Three	O
+different	O
+genotypes	O
+of	O
+IBV	B-SPEC
+were	O
+detected	O
+,	O
+but	O
+none	O
+was	O
+an	O
+unknown	O
+variant	O
+.	O
+
+TITLE	O
+:	O
+Acute	B-PROC
+phase	I-PROC
+response	I-PROC
+in	O
+bovine	B-SPEC
+coronavirus	B-SPEC
+positive	O
+post	O
+-	O
+weaned	B-PROC
+calves	O
+with	O
+diarrhea	B-DISO
+.	O
+
+These	O
+data	O
+highlight	O
+the	O
+need	O
+for	O
+better	O
+ventilatory	O
+management	O
+in	O
+females	O
+to	O
+improve	O
+their	O
+outcomes	O
+from	O
+ARDS	B-DISO
+.	O
+
+Joint	B-ANAT
+efforts	O
+combining	O
+key	O
+technologies	O
+in	O
+identical	O
+models	O
+to	O
+overcome	O
+the	O
+limitations	O
+inherent	O
+to	O
+individual	O
+methodologies	O
+are	O
+needed	O
+not	O
+only	O
+to	O
+provide	O
+conclusive	O
+insights	O
+into	O
+lung	B-ANAT
+physiology	O
+and	O
+alveolar	B-ANAT
+dynamics	O
+,	O
+but	O
+ultimately	O
+to	O
+guide	O
+critical	O
+care	O
+patient	O
+therapy	O
+.	O
+
+This	O
+study	O
+investigated	O
+the	O
+impacts	O
+of	O
+MERS	O
+epidemic	O
+on	O
+emergency	B-DISO
+care	O
+utilization	O
+and	O
+mortality	O
+in	O
+South	O
+Korea	O
+.	O
+
+Deaths	B-PROC
+within	O
+7	O
+days	O
+after	O
+visiting	O
+an	O
+ER	O
+were	O
+analyzed	O
+to	O
+evaluate	O
+the	O
+impact	O
+of	O
+the	O
+reduction	O
+in	O
+ER	O
+visits	O
+on	O
+mortality	O
+.	O
+
+The	O
+number	O
+of	O
+deaths	B-PROC
+within	O
+7	O
+days	O
+of	O
+an	O
+ER	O
+visit	O
+did	O
+not	O
+change	O
+significantly	O
+.	O
+
+He	O
+aspirated	B-DISO
+sodium	B-CHED
+polystyrene	I-CHED
+sulfonate	I-CHED
+while	O
+consuming	O
+the	O
+drug	O
+.	O
+
+The	O
+rTGEV	O
+-	O
+RS	O
+-	O
+SPEDV	O
+vaccine	O
+candidate	O
+was	O
+also	O
+attenuated	O
+in	O
+three	O
+-	O
+week	O
+-	O
+old	O
+animals	B-SPEC
+that	O
+were	O
+used	O
+to	O
+evaluate	O
+the	O
+protection	O
+conferred	O
+by	O
+this	O
+virus	B-SPEC
+,	O
+compared	O
+with	O
+the	O
+protection	O
+induced	O
+by	O
+infection	B-DISO
+with	O
+a	O
+virulent	O
+PEDV	B-SPEC
+US	O
+strain	O
+(	O
+PEDV	B-SPEC
+-	O
+NVSL	O
+).	O
+
+Our	O
+earlier	O
+studies	O
+have	O
+identified	O
+that	O
+3	O
+-	O
+O	O
+-	O
+β	O
+-	O
+chacotriosyl	O
+ursolic	B-CHED
+acid	I-CHED
+(	O
+1	O
+)	O
+could	O
+inhibit	O
+H5N1	B-DISO
+pseudovirus	O
+by	O
+targeting	B-PROC
+hemagglutinin	O
+(	O
+HA	O
+).	O
+
+Using	O
+a	O
+reverse	O
+-	O
+genetics	O
+system	O
+based	O
+on	O
+CRISPR	O
+/	O
+Cas9	O
+technology	O
+to	O
+construct	O
+a	O
+recombinant	O
+TGEV	B-SPEC
+in	O
+which	O
+this	O
+specific	O
+nsp1	B-PRGE
+motif	I-PRGE
+was	O
+altered	O
+,	O
+we	O
+found	O
+that	O
+this	O
+mutation	O
+does	O
+not	O
+affect	O
+virus	B-PROC
+replication	I-PROC
+in	O
+cell	B-COMP
+culture	O
+but	O
+significantly	O
+reduces	O
+TGEV	B-SPEC
+pathogenicity	O
+in	O
+pigs	B-SPEC
+.	O
+
+TITLE	O
+:	O
+Differential	O
+neurodegenerative	O
+phenotypes	O
+are	O
+associated	O
+with	O
+heterogeneous	O
+voiding	B-PROC
+dysfunction	O
+in	O
+a	O
+coronavirus	O
+-	O
+induced	O
+model	O
+of	O
+multiple	B-DISO
+sclerosis	I-DISO
+.	O
+
+Interestingly	O
+,	O
+site	B-PROC
+-	I-PROC
+directed	I-PROC
+mutagenesis	I-PROC
+found	O
+that	O
+PDCoV	O
+nsp15	O
+mutants	O
+(	O
+H129A	O
+,	O
+H234A	O
+,	O
+K269A	O
+)	O
+lacking	O
+endoribonuclease	O
+activity	O
+also	O
+suppress	O
+SEV	B-PRGE
+-	O
+induced	O
+IFN	B-PRGE
+-	I-PRGE
+β	I-PRGE
+production	O
+and	O
+NF	O
+-	O
+κB	O
+activation	O
+,	O
+suggesting	O
+that	O
+the	O
+endoribonuclease	B-FUNC
+activity	I-FUNC
+is	O
+not	O
+required	O
+for	O
+its	O
+ability	O
+to	O
+antagonize	O
+IFN	B-PRGE
+-	I-PRGE
+β	I-PRGE
+production	O
+.	O
+
+In	O
+this	O
+retrospective	O
+study	O
+,	O
+22	O
+children	O
+with	O
+laboratory	O
+confirmed	O
+severe	O
+dengue	B-DISO
+admitted	O
+to	O
+pediatric	O
+intensive	O
+care	O
+unit	O
+(	O
+PICU	B-SPEC
+)	O
+were	O
+enrolled	O
+.	O
+
+Half	O
+(	O
+n	O
+=	O
+11	O
+,	O
+50	O
+%)	O
+had	O
+dengue	B-DISO
+shock	I-DISO
+syndrome	I-DISO
+.	O
+
+Length	O
+of	O
+PICU	B-SPEC
+stay	O
+(	O
+5	O
+.	O
+1	O
+vs	O
+.	O
+2	O
+.	O
+9	O
+d	O
+)	O
+and	O
+mortality	O
+(	O
+28	O
+.	O
+6	O
+%	O
+vs	O
+.	O
+6	O
+.	O
+7	O
+%)	O
+were	O
+higher	O
+in	O
+HLH	B-DISO
+group	O
+,	O
+however	O
+the	O
+difference	O
+was	O
+not	O
+statistically	O
+significant	O
+.	O
+
+Severe	O
+dengue	B-DISO
+presents	O
+with	O
+life	O
+-	O
+threatening	O
+organ	B-ANAT
+dysfunctions	O
+.	O
+
+ABSTRACT	O
+:	O
+There	O
+is	O
+no	O
+effective	O
+therapeutic	O
+or	O
+vaccine	O
+for	O
+Middle	O
+East	O
+Respiratory	O
+Syndrome	B-DISO
+and	O
+this	O
+study	O
+attempts	O
+to	O
+find	O
+therapy	O
+using	O
+peptide	B-CHED
+by	O
+establishing	O
+a	O
+basis	O
+for	O
+the	O
+peptide	B-CHED
+-	O
+protein	B-CHED
+interactions	O
+through	O
+in	O
+silico	O
+docking	B-PROC
+studies	O
+for	O
+the	O
+spike	O
+protein	B-CHED
+of	O
+MERS	O
+-	O
+CoV	O
+.	O
+The	O
+antimicrobial	B-CHED
+peptides	B-CHED
+(	O
+AMPs	O
+)	O
+were	O
+retrieved	O
+from	O
+the	O
+antimicrobial	B-CHED
+peptide	B-CHED
+database	O
+(	O
+APD3	O
+)	O
+and	O
+shortlisted	O
+based	O
+on	O
+certain	O
+important	O
+physicochemical	O
+properties	O
+.	O
+
+ABSTRACT	O
+:	O
+Type	O
+1	O
+IFNs	O
+(	O
+IFN	B-PRGE
+-	I-PRGE
+I	I-PRGE
+)	O
+generally	O
+protect	O
+mammalian	B-SPEC
+hosts	B-COMP
+from	O
+virus	B-SPEC
+infections	B-DISO
+,	O
+but	O
+in	O
+some	O
+cases	O
+,	O
+IFN	B-PRGE
+-	I-PRGE
+I	I-PRGE
+is	O
+pathogenic	O
+.	O
+
+Group	O
+A	O
+was	O
+given	O
+continuous	O
+hemofiltration	O
+alone	O
+,	O
+and	O
+group	B-DISO
+B	I-DISO
+was	O
+given	O
+continuous	O
+hemofiltration	O
+combined	O
+with	O
+octreotide	B-CHED
+.	O
+
+Selected	O
+PPE	B-CHED
+should	O
+protect	O
+HCP	B-DISO
+from	O
+exposure	O
+,	O
+be	O
+usable	O
+by	O
+HCP	B-DISO
+,	O
+and	O
+fit	B-DISO
+for	O
+purpose	O
+.	O
+
+Unfortunately	O
+,	O
+ECMO	O
+has	O
+been	O
+traditionally	O
+contraindicated	O
+in	O
+patients	O
+with	O
+hemorrhagic	O
+neurologic	B-DISO
+diseases	I-DISO
+.	O
+
+ABSTRACT	O
+:	O
+The	O
+recent	O
+emergence	O
+and	O
+re	O
+-	O
+emergence	O
+of	O
+porcine	B-SPEC
+epidemic	I-SPEC
+diarrhea	I-SPEC
+virus	I-SPEC
+(	O
+PEDV	B-SPEC
+)	O
+underscore	O
+the	O
+urgent	O
+need	O
+for	O
+the	O
+development	B-PROC
+of	O
+novel	O
+,	O
+safe	O
+,	O
+and	O
+effective	O
+vaccines	O
+against	O
+the	O
+prevailing	O
+strain	O
+.	O
+
+In	O
+this	O
+study	O
+,	O
+we	O
+generated	O
+a	O
+cold	B-DISO
+-	O
+adapted	O
+live	O
+attenuated	O
+vaccine	O
+candidate	O
+(	O
+Aram	O
+-	O
+P29	O
+-	O
+CA	O
+)	O
+by	O
+short	O
+-	O
+term	O
+passage	O
+of	O
+a	O
+virulent	O
+PEDV	B-SPEC
+isolate	O
+at	O
+successively	O
+lower	O
+temperatures	O
+in	O
+Vero	B-ANAT
+cells	I-ANAT
+.	O
+
+Furthermore	O
+,	O
+strong	O
+antibody	B-PROC
+responses	I-PROC
+to	O
+PEDV	B-SPEC
+were	O
+detected	O
+in	O
+the	O
+sera	B-COMP
+and	O
+colostrum	B-ANAT
+of	O
+immunized	O
+sows	O
+and	O
+in	O
+the	O
+sera	B-COMP
+of	O
+their	O
+offspring	O
+.	O
+
+These	O
+results	O
+demonstrated	O
+that	O
+the	O
+cold	B-DISO
+-	O
+adapted	O
+attenuated	O
+virus	B-SPEC
+can	O
+be	O
+used	O
+as	O
+a	O
+live	O
+vaccine	O
+in	O
+maternal	O
+vaccination	O
+strategies	O
+to	O
+provide	O
+durable	O
+lactogenic	O
+immunity	B-PROC
+and	O
+confer	O
+passive	O
+protection	O
+to	O
+litters	O
+against	O
+PEDV	B-SPEC
+.	O
+
+We	O
+used	O
+results	O
+spanning	O
+16	O
+years	O
+(	O
+2002	O
+-	O
+2017	O
+)	O
+of	O
+a	O
+routine	O
+diagnostic	O
+multiplex	O
+panel	O
+that	O
+tests	O
+for	O
+nine	O
+respiratory	O
+viruses	B-SPEC
+to	O
+further	O
+investigate	O
+these	O
+interactions	O
+in	O
+Victoria	B-SPEC
+,	O
+Australia	O
+.	O
+
+The	O
+seasonality	O
+of	O
+all	O
+viruses	B-SPEC
+included	O
+was	O
+compared	O
+with	O
+respiratory	B-SPEC
+syncytial	I-SPEC
+virus	I-SPEC
+(	O
+RSV	B-SPEC
+)	O
+and	O
+influenza	B-SPEC
+A	I-SPEC
+virus	I-SPEC
+using	O
+cross	O
+-	O
+correlations	O
+.	O
+
+Logistic	O
+regression	O
+was	O
+used	O
+to	O
+explore	O
+the	O
+likelihood	O
+of	O
+co	B-DISO
+-	I-DISO
+infection	I-DISO
+with	O
+one	O
+virus	B-SPEC
+given	O
+infection	B-DISO
+with	O
+another	O
+.	O
+
+TITLE	O
+:	O
+Assessment	O
+of	O
+Therapeutic	O
+Interventions	O
+and	O
+Lung	B-ANAT
+Protective	O
+Ventilation	O
+in	O
+Patients	O
+With	O
+Moderate	O
+to	O
+Severe	O
+Acute	O
+Respiratory	O
+Distress	O
+Syndrome	O
+:	O
+A	O
+Systematic	O
+Review	O
+and	O
+Network	O
+Meta	B-SPEC
+-	O
+analysis	O
+.	O
+
+Among	O
+25	O
+randomized	O
+clinical	O
+trials	O
+evaluating	O
+9	O
+interventions	O
+,	O
+2686	O
+of	O
+7743	O
+patients	O
+(	O
+34	O
+.	O
+6	O
+%)	O
+died	B-PROC
+within	O
+28	O
+days	O
+.	O
+
+Compared	O
+with	O
+lung	B-ANAT
+protective	O
+ventilation	O
+alone	O
+,	O
+prone	O
+positioning	O
+and	O
+venovenous	O
+extracorporeal	O
+membrane	B-COMP
+oxygenation	B-PROC
+were	O
+associated	O
+with	O
+significantly	O
+lower	O
+28	O
+-	O
+day	O
+mortality	O
+(	O
+prone	O
+positioning	O
+:	O
+risk	O
+ratio	O
+,	O
+0	O
+.	O
+69	O
+;	O
+95	O
+%	O
+credible	O
+interval	O
+,	O
+0	O
+.	O
+48	O
+-	O
+0	O
+.	O
+99	O
+;	O
+low	O
+quality	O
+of	O
+evidence	O
+;	O
+venovenous	O
+extracorporeal	O
+membrane	B-COMP
+oxygenation	B-PROC
+:	O
+risk	O
+ratio	O
+,	O
+0	O
+.	O
+60	O
+;	O
+95	O
+%	O
+credible	O
+interval	O
+,	O
+0	O
+.	O
+38	O
+-	O
+0	O
+.	O
+93	O
+;	O
+moderate	O
+quality	O
+of	O
+evidence	O
+).	O
+
+This	O
+network	O
+meta	B-SPEC
+-	O
+analysis	O
+supports	O
+the	O
+use	O
+of	O
+prone	O
+positioning	O
+and	O
+venovenous	O
+extracorporeal	O
+membrane	B-COMP
+oxygenation	B-PROC
+in	O
+addition	O
+to	O
+lung	B-ANAT
+protective	O
+ventilation	O
+in	O
+patients	O
+with	O
+ARDS	B-DISO
+.	O
+
+Hypoxia	B-DISO
+,	O
+oxidative	B-DISO
+stress	I-DISO
+and	O
+systemic	O
+inflammation	B-DISO
+link	O
+OSA	B-DISO
+and	O
+cardiovascular	B-ANAT
+and	O
+metabolic	B-PROC
+consequences	O
+,	O
+including	O
+coronary	B-DISO
+artery	I-DISO
+disease	I-DISO
+.	O
+
+Recent	O
+studies	O
+suggest	O
+that	O
+daytime	O
+sleepiness	O
+may	O
+indicate	O
+a	O
+more	O
+severe	O
+OSA	B-DISO
+phenotype	O
+with	O
+regard	O
+to	O
+cardiovascular	B-ANAT
+risk	O
+.	O
+
+Furthermore	O
+,	O
+continuous	O
+renal	B-ANAT
+replacement	O
+therapy	O
+was	O
+an	O
+independently	O
+significant	O
+risk	O
+factor	O
+for	O
+hospital	O
+mortality	O
+in	O
+pediatric	O
+patients	O
+with	O
+severe	B-DISO
+sepsis	I-DISO
+,	O
+and	O
+the	O
+interval	O
+between	O
+continuous	O
+renal	B-ANAT
+replacement	O
+therapy	O
+initiation	O
+and	O
+PICU	B-SPEC
+admission	O
+was	O
+an	O
+independent	O
+risk	O
+factor	O
+for	O
+hospital	O
+mortality	O
+in	O
+patients	O
+receiving	O
+continuous	O
+renal	B-ANAT
+replacement	O
+therapy	O
+.	O
+
+Recombinant	O
+protein	B-CHED
+-	O
+based	O
+vaccines	O
+are	O
+usually	O
+formulated	O
+with	O
+aluminum	B-CHED
+(	O
+alum	O
+)-	O
+based	O
+adjuvants	B-CHED
+to	O
+ensure	O
+an	O
+adequate	O
+immune	B-PROC
+response	I-PROC
+.	O
+
+Although	O
+the	O
+adjuvanticity	B-PROC
+of	O
+RNA	O
+has	O
+been	O
+reported	O
+,	O
+a	O
+systematic	O
+and	O
+overall	O
+investigation	O
+on	O
+its	O
+efficacy	O
+is	O
+lacking	O
+.	O
+
+This	O
+suggests	O
+that	O
+protein	B-CHED
+-	O
+based	O
+vaccines	O
+formulated	O
+using	O
+RNA	O
+adjuvant	B-CHED
+function	O
+as	O
+live	O
+-	O
+attenuated	O
+vaccines	O
+.	O
+
+Application	O
+of	O
+the	O
+RNA	O
+adjuvant	B-CHED
+in	O
+mouse	B-SPEC
+enhanced	O
+the	O
+efficacy	O
+of	O
+Middle	O
+East	O
+respiratory	O
+syndrome	B-DISO
+spike	O
+protein	B-CHED
+,	O
+a	O
+protein	B-CHED
+-	O
+subunit	O
+vaccine	O
+and	O
+human	B-SPEC
+papillomavirus	I-SPEC
+L1	O
+protein	B-CHED
+,	O
+a	O
+virus	B-COMP
+-	I-COMP
+like	I-COMP
+particle	I-COMP
+vaccine	O
+,	O
+by	O
+activating	O
+innate	B-DISO
+immune	I-DISO
+response	I-DISO
+through	O
+TLR7	B-PRGE
+and	O
+enhancing	O
+pAPC	B-CHED
+chemotaxis	B-PROC
+,	O
+leading	O
+to	O
+a	O
+balanced	O
+Th1	O
+/	O
+Th2	O
+responses	O
+.	O
+
+Moreover	O
+,	O
+the	O
+combination	O
+of	O
+alum	O
+and	O
+the	O
+RNA	O
+adjuvant	B-CHED
+synergistically	O
+induced	O
+humoral	O
+and	O
+cellular	B-PROC
+immune	I-PROC
+responses	I-PROC
+and	O
+endowed	O
+long	O
+-	O
+term	O
+immunity	B-PROC
+.	O
+
+In	O
+most	O
+cases	O
+,	O
+ARDS	B-DISO
+leading	O
+to	O
+DAD	B-PRGE
+is	O
+fatal	O
+,	O
+due	O
+to	O
+the	O
+insidious	O
+severity	O
+of	O
+symptoms	O
+which	O
+lead	O
+to	O
+rapid	O
+oxygen	B-CHED
+desaturation	O
+without	O
+correction	O
+,	O
+and	O
+despite	O
+supportive	O
+therapy	O
+.	O
+
+The	O
+aim	O
+of	O
+the	O
+present	O
+study	O
+is	O
+to	O
+characterize	O
+an	O
+emerging	O
+variant	O
+pathogenic	O
+IBV	B-SPEC
+originating	O
+from	O
+field	O
+outbreaks	O
+in	O
+vaccinated	O
+Egyptian	O
+layer	B-ANAT
+flock	O
+.	O
+
+The	O
+clinical	O
+manifestations	O
+of	O
+DS	O
+,	O
+after	O
+induction	O
+therapy	O
+with	O
+differentiating	O
+agents	O
+,	O
+include	O
+unexplained	O
+fever	B-PROC
+,	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+with	O
+interstitial	B-ANAT
+pulmonary	B-DISO
+infiltrates	I-DISO
+,	O
+unexplained	O
+hypotension	O
+,	O
+peripheral	O
+edema	B-DISO
+,	O
+congestive	B-DISO
+heart	I-DISO
+failure	I-DISO
+and	O
+acute	B-DISO
+renal	I-DISO
+failure	I-DISO
+.	O
+
+Our	O
+previous	O
+crystal	B-ANAT
+structure	O
+study	O
+of	O
+the	O
+MHV	B-SPEC
+NTD	O
+/	O
+mCEACAM1a	O
+complex	O
+(	O
+G	O
+.	O
+Peng	O
+,	O
+D	O
+.	O
+Sun	O
+,	O
+K	O
+.	O
+R	O
+.	O
+Rajashankar	O
+,	O
+Z	O
+.	O
+Qian	O
+,	O
+et	O
+al	O
+.,	O
+Proc	O
+Natl	O
+Acad	B-DISO
+Sci	O
+U	O
+S	O
+A	O
+108	O
+:	O
+10696	O
+-	O
+10701	O
+,	O
+2011	O
+,	O
+https	O
+://	O
+doi	O
+.	O
+org	O
+/	O
+10	O
+.	O
+1073	O
+/	O
+pnas	O
+.	O
+1104306108	O
+)	O
+reveals	O
+that	O
+there	O
+are	O
+14	O
+residues	O
+in	O
+the	O
+NTD	O
+interacting	O
+with	O
+the	O
+receptor	O
+.	O
+
+Our	O
+study	O
+will	O
+aid	O
+in	O
+better	O
+understanding	O
+the	O
+mechanism	O
+of	O
+how	O
+conformational	O
+changes	O
+of	O
+the	O
+S	B-PRGE
+protein	I-PRGE
+are	O
+triggered	O
+.	O
+
+Furthermore	O
+,	O
+we	O
+found	O
+that	O
+A72	O
+cells	B-COMP
+derived	O
+from	O
+canine	O
+fibroblasts	B-ANAT
+permitted	O
+FCoV	O
+replication	O
+without	O
+apparent	O
+cytopathic	B-DISO
+effects	I-DISO
+.	O
+
+The	O
+homology	O
+of	O
+M	B-PRGE
+gene	I-PRGE
+was	O
+the	O
+highest	O
+(	O
+99	O
+.	O
+0	O
+%).	O
+
+Analysis	O
+and	O
+comparison	O
+of	O
+open	O
+reading	O
+frame	O
+3	O
+(	O
+ORF3	O
+)	O
+proteins	B-CHED
+between	O
+HLJBY	O
+strain	O
+and	O
+other	O
+PEDV	B-SPEC
+strains	O
+were	O
+also	O
+focused	O
+in	O
+this	O
+study	O
+.	O
+
+ORF3	O
+protein	B-CHED
+of	O
+both	O
+HLJBY	O
+strain	O
+and	O
+PEDV	B-SPEC
+-	O
+SX	O
+/	O
+China	O
+/	O
+2017	O
+strain	O
+consists	O
+of	O
+91	O
+aa	O
+,	O
+with	O
+133	O
+aa	O
+deletions	O
+at	O
+their	O
+C	O
+'	O
+end	O
+in	O
+relation	O
+to	O
+the	O
+other	O
+tested	O
+PEDV	B-SPEC
+strains	O
+.	O
+
+The	O
+deubiquitination	B-PROC
+of	O
+Nsp3	B-PRGE
+domains	I-PRGE
+and	O
+its	O
+effect	O
+on	O
+IκBα	O
+and	O
+p65	B-PRGE
+were	O
+analyzed	O
+by	O
+western	O
+blotting	O
+.	O
+
+The	O
+ubiquitination	B-PROC
+level	O
+of	O
+IκBα	O
+was	O
+analyzed	O
+by	O
+immunoprecipitation	O
+.	O
+
+We	O
+demonstrated	O
+that	O
+the	O
+inhibitory	O
+effect	O
+of	O
+Nsp3	B-PRGE
+was	O
+mainly	O
+mediated	O
+through	O
+the	O
+suppression	B-DISO
+of	O
+IκBα	O
+degradation	O
+as	O
+well	O
+as	O
+the	O
+inhibition	B-PROC
+of	O
+p65	B-PRGE
+phosphorylation	B-PROC
+and	O
+nuclear	B-PROC
+translocation	I-PROC
+.	O
+
+Furthermore	O
+,	O
+the	O
+amino	B-CHED
+acid	I-CHED
+residues	O
+at	O
+positions	O
+590	O
+-	O
+1	O
+,	O
+215	O
+in	O
+Nsp3	B-PRGE
+were	O
+demonstrated	O
+to	O
+inhibit	O
+the	O
+degradation	O
+of	O
+IκBα	O
+by	O
+inhibiting	O
+the	O
+IκBα	O
+ubiquitination	B-PROC
+.	O
+
+Jejunum	B-ANAT
+was	O
+the	O
+first	O
+target	O
+tissue	B-ANAT
+for	O
+infection	B-DISO
+and	O
+then	O
+ileum	B-ANAT
+,	O
+followed	O
+by	O
+infrequent	O
+infection	B-DISO
+of	O
+duodenum	O
+.	O
+
+Overall	O
+,	O
+our	O
+results	O
+provide	O
+useful	O
+information	O
+about	O
+spread	O
+dynamics	O
+and	O
+tissue	B-ANAT
+preference	O
+of	O
+PEDV	B-SPEC
+epidemic	O
+strain	O
+BJ2011C	O
+.	O
+
+In	O
+this	O
+review	O
+,	O
+we	O
+document	O
+comprehensively	O
+the	O
+journey	O
+of	O
+SCARs	B-DISO
+from	O
+bedside	O
+to	O
+bench	O
+and	O
+outline	O
+future	O
+perspectives	O
+in	O
+SCARs	B-DISO
+research	O
+.	O
+
+ABSTRACT	O
+:	O
+Interferon	B-PRGE
+gamma	I-PRGE
+(	O
+IFN	B-PRGE
+-	I-PRGE
+γ	I-PRGE
+)	O
+is	O
+best	O
+known	O
+for	O
+its	O
+ability	O
+to	O
+regulate	O
+host	B-COMP
+immune	B-PROC
+responses	I-PROC
+;	O
+however	O
+,	O
+its	O
+direct	O
+antiviral	B-CHED
+activity	O
+is	O
+less	O
+well	O
+studied	O
+.	O
+
+Moreover	O
+,	O
+IFN	B-PRGE
+-	I-PRGE
+γ	I-PRGE
+suppressed	O
+TGEV	B-SPEC
+infection	B-DISO
+in	O
+ST	O
+cells	B-COMP
+more	O
+efficiently	O
+than	O
+did	O
+IFN	B-PRGE
+-	I-PRGE
+α	I-PRGE
+,	O
+and	O
+the	O
+combination	O
+of	O
+IFN	B-PRGE
+-	I-PRGE
+γ	I-PRGE
+and	O
+IFN	B-PRGE
+-	I-PRGE
+α	I-PRGE
+displayed	O
+a	O
+synergistic	O
+effect	O
+against	O
+TGEV	B-SPEC
+.	O
+
+Severe	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+patients	O
+on	O
+venovenous	O
+extracorporeal	O
+membrane	B-COMP
+oxygenation	B-PROC
+.	O
+
+The	O
+risk	O
+of	O
+exacerbation	O
+following	O
+the	O
+onset	O
+of	O
+URTI	B-DISO
+symptoms	O
+depends	O
+on	O
+the	O
+particular	O
+virus	B-SPEC
+associated	O
+with	O
+the	O
+event	O
+and	O
+was	O
+significant	O
+only	O
+for	O
+parainfluenza	B-DISO
+3	O
+.	O
+
+Higher	O
+DP	O
+showed	O
+a	O
+significant	O
+association	O
+with	O
+higher	O
+mortality	O
+(	O
+pooled	O
+risk	O
+ratio	O
+,	O
+1	O
+.	O
+10	O
+;	O
+95	O
+%	O
+[	O
+CI	O
+],	O
+1	O
+.	O
+05	O
+-	O
+1	O
+.	O
+16	O
+;	O
+Higher	O
+DP	O
+was	O
+significantly	O
+associated	O
+with	O
+an	O
+increased	O
+risk	O
+of	O
+death	O
+among	O
+ventilated	O
+patients	O
+with	O
+ARDS	B-DISO
+.	O
+
+This	O
+trial	O
+is	O
+registered	O
+with	O
+PROSPERO	B-SPEC
+(	O
+CRD42018102146	O
+),	O
+on	O
+11	O
+August	O
+2018	O
+.	O
+
+Patients	O
+older	O
+than	O
+18	O
+years	O
+with	O
+early	O
+ARDS	B-DISO
+for	O
+less	O
+than	O
+12	O
+h	O
+were	O
+randomly	O
+assigned	O
+(	O
+1	O
+:	O
+1	O
+)	O
+to	O
+either	O
+the	O
+control	O
+group	O
+or	O
+the	O
+personalised	O
+group	O
+using	O
+a	O
+minimisation	O
+algorithm	O
+and	O
+stratified	O
+according	O
+to	O
+the	O
+study	O
+site	O
+,	O
+lung	O
+morphology	O
+,	O
+and	O
+duration	O
+of	O
+mechanical	O
+ventilation	O
+.	O
+
+TITLE	O
+:	O
+The	O
+C	O
+-	O
+terminal	O
+domain	O
+of	O
+the	O
+MERS	B-PRGE
+coronavirus	I-PRGE
+M	I-PRGE
+protein	B-CHED
+contains	O
+a	O
+ABSTRACT	O
+:	O
+Coronavirus	B-SPEC
+M	O
+proteins	O
+represent	O
+the	O
+major	O
+protein	B-CHED
+component	O
+of	O
+the	O
+viral	B-COMP
+envelope	I-COMP
+.	O
+
+TITLE	O
+:	O
+Protective	O
+effects	O
+of	O
+hypericin	B-CHED
+against	O
+infectious	B-DISO
+bronchitis	B-DISO
+virus	B-SPEC
+induced	O
+apoptosis	B-PATH
+and	O
+reactive	B-CHED
+oxygen	I-CHED
+species	I-CHED
+in	O
+chicken	B-SPEC
+embryo	B-ANAT
+kidney	B-ANAT
+cells	B-COMP
+.	O
+
+To	O
+investigate	O
+the	O
+inhibition	B-PROC
+effect	O
+of	O
+HY	O
+on	O
+IBV	B-SPEC
+infection	B-DISO
+in	O
+chicken	B-SPEC
+embryo	B-ANAT
+kidney	B-ANAT
+(	O
+CEK	O
+)	O
+cells	B-COMP
+,	O
+3	O
+different	O
+experimental	O
+designs	O
+:	O
+pre	O
+-	O
+treatment	O
+of	O
+cells	B-COMP
+prior	O
+to	O
+IBV	B-SPEC
+infection	B-DISO
+,	O
+direct	O
+treatment	O
+of	O
+IBV	B-SPEC
+-	O
+infected	O
+cells	B-COMP
+,	O
+and	O
+pre	O
+-	O
+treatment	O
+of	O
+IBV	B-SPEC
+prior	O
+to	O
+cell	B-COMP
+infection	B-DISO
+were	O
+used	O
+.	O
+
+Quantitative	O
+real	O
+-	O
+time	O
+PCR	O
+(	O
+qRT	O
+-	O
+PCR	O
+),	O
+immunofluorescence	O
+assay	O
+(	O
+IFA	O
+),	O
+flow	O
+cytometry	O
+,	O
+and	O
+fluorescence	O
+microscopy	O
+were	O
+performed	O
+and	O
+virus	B-SPEC
+titer	O
+was	O
+determined	O
+by	O
+TCID50	O
+.	O
+
+TITLE	O
+:	O
+Dose	O
+-	O
+response	O
+and	O
+transmission	O
+:	O
+the	O
+nexus	B-COMP
+between	O
+reservoir	O
+hosts	B-COMP
+,	O
+environment	O
+and	O
+recipient	O
+hosts	O
+.	O
+
+Hsp90	B-CHED
+inhibitors	I-CHED
+are	O
+anticancer	O
+compounds	O
+,	O
+associated	O
+with	O
+strong	O
+anti	O
+-	O
+inflammatory	B-DISO
+responses	I-DISO
+in	O
+the	O
+endothelium	B-ANAT
+.	O
+
+However	O
+,	O
+a	O
+Bayesian	O
+post	O
+hoc	O
+analysis	O
+of	O
+this	O
+trial	O
+and	O
+a	O
+subsequent	O
+meta	B-SPEC
+-	O
+analysis	O
+together	O
+suggested	O
+that	O
+extracorporeal	O
+life	O
+support	O
+was	O
+beneficial	O
+for	O
+patients	O
+with	O
+very	O
+severe	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+.	O
+
+This	O
+article	O
+identifies	O
+the	O
+optimal	O
+target	O
+of	O
+anticoagulant	B-CHED
+therapy	O
+in	O
+sepsis	B-DISO
+.	O
+
+TITLE	O
+:	O
+A	O
+unique	O
+case	O
+of	O
+acute	O
+brain	B-DISO
+haemorrhage	I-DISO
+with	O
+left	O
+ventricular	B-ANAT
+systolic	O
+failure	O
+requiring	O
+ECMO	O
+.	O
+
+His	O
+cardiac	B-PROC
+function	I-PROC
+recovered	O
+within	O
+the	O
+next	O
+24	O
+h	O
+revealing	O
+the	O
+reversibility	O
+nature	O
+of	O
+Takotsubo	B-DISO
+cardiomyopathy	I-DISO
+.	O
+
+This	O
+is	O
+a	O
+captivating	O
+case	O
+depicting	O
+a	O
+series	O
+of	O
+unfortunate	O
+and	O
+unpredictable	O
+clinical	O
+events	O
+occurring	O
+in	O
+a	O
+previously	O
+well	O
+infant	O
+,	O
+which	O
+at	O
+initial	O
+presentation	O
+challenged	O
+the	O
+managing	O
+team	O
+with	O
+regards	O
+to	O
+its	O
+exact	O
+aetiology	O
+of	O
+acute	O
+brain	B-ANAT
+injury	O
+and	O
+acute	O
+cardiorespiratory	B-DISO
+failure	I-DISO
+.	O
+
+If	O
+repeated	O
+infections	B-DISO
+with	O
+prolonged	O
+or	O
+severe	O
+complications	O
+occur	O
+during	O
+childhood	O
+,	O
+the	O
+presence	O
+of	O
+an	O
+immunodeficiency	B-DISO
+should	O
+then	O
+be	O
+considered	O
+.	O
+
+A	O
+child	O
+can	O
+present	O
+with	O
+4	O
+to	O
+8	O
+episodes	O
+of	O
+respiratory	B-DISO
+infections	I-DISO
+within	O
+a	O
+year	O
+,	O
+during	O
+the	O
+first	O
+5	O
+years	O
+of	O
+its	O
+life	O
+.	O
+
+On	O
+the	O
+contrary	O
+,	O
+our	O
+data	O
+revealed	O
+changes	O
+in	O
+peripheral	O
+cell	B-COMP
+populations	O
+,	O
+the	O
+most	O
+important	O
+being	O
+the	O
+decrease	O
+in	O
+the	O
+T	O
+-	O
+cluster	O
+of	O
+differentiation	B-PROC
+(	O
+CD	O
+)	O
+8	O
+
+Seventy	O
+-	O
+eight	O
+sera	B-COMP
+were	O
+positive	O
+for	O
+antibodies	B-COMP
+that	O
+recognized	O
+one	O
+or	O
+more	O
+coronavirus	B-SPEC
+S1s	O
+whereas	O
+1	O
+serum	B-COMP
+exclusively	O
+reacted	O
+with	O
+human	B-SPEC
+coronavirus	I-SPEC
+229E	I-SPEC
+(	O
+HCoV	B-SPEC
+-	I-SPEC
+229E	I-SPEC
+)	O
+and	O
+two	O
+sera	B-COMP
+exclusively	O
+reacted	O
+with	O
+porcine	B-SPEC
+delta	O
+coronavirus	B-SPEC
+(	O
+PDCoV	O
+).	O
+
+We	O
+observed	O
+antigenic	O
+cross	O
+-	O
+reactivity	O
+between	O
+S1s	B-PRGE
+of	I-PRGE
+type	I-PRGE
+1	I-PRGE
+and	I-PRGE
+type	I-PRGE
+2	I-PRGE
+FCoVs	I-PRGE
+,	O
+and	O
+between	O
+FCoV	B-PRGE
+type	I-PRGE
+1	I-PRGE
+and	O
+porcine	B-SPEC
+epidemic	I-SPEC
+diarrhea	I-SPEC
+virus	I-SPEC
+(	O
+PEDV	B-SPEC
+).	O
+
+ABSTRACT	O
+:	O
+Primary	O
+human	B-SPEC
+airway	B-ANAT
+epithelial	B-ANAT
+cell	I-ANAT
+(	O
+hAEC	O
+)	O
+cultures	O
+represent	O
+a	O
+universal	O
+platform	O
+to	O
+propagate	O
+respiratory	O
+viruses	B-SPEC
+and	O
+characterize	O
+their	O
+host	B-COMP
+interactions	O
+in	O
+authentic	O
+target	B-ANAT
+cells	I-ANAT
+.	O
+
+TITLE	O
+:	O
+Infectious	B-DISO
+Disease	I-DISO
+Management	O
+and	O
+Control	O
+with	O
+Povidone	B-CHED
+Iodine	B-CHED
+.	O
+
+Of	O
+the	O
+total	O
+patients	O
+,	O
+91	O
+.	O
+3	O
+%	O
+were	O
+transferred	O
+from	O
+local	O
+hospitals	O
+with	O
+a	O
+diagnosis	O
+of	O
+severe	O
+pneumonia	B-DISO
+and	O
+then	O
+diagnosed	O
+with	O
+ARDS	B-DISO
+at	O
+the	O
+central	O
+hospital	O
+.	O
+
+Logistic	O
+regression	O
+revealed	O
+that	O
+PaO2	O
+/	O
+FiO2	O
+on	O
+day	O
+3	O
+[	O
+odds	O
+ratio	O
+(	O
+OR	O
+),	O
+1	O
+.	O
+010	O
+;	O
+95	O
+%	O
+confidence	O
+interval	O
+(	O
+CI	O
+),	O
+1	O
+.	O
+003	O
+-	O
+1	O
+.	O
+017	O
+],	O
+length	O
+of	O
+stay	O
+in	O
+a	O
+local	O
+hospital	O
+before	O
+admission	O
+to	O
+the	O
+central	O
+hospital	O
+(	O
+OR	O
+,	O
+1	O
+.	O
+122	O
+;	O
+95	O
+%	O
+CI	O
+,	O
+1	O
+.	O
+042	O
+-	O
+1	O
+.	O
+210	O
+)	O
+due	O
+to	O
+stable	O
+condition	B-DISO
+,	O
+and	O
+SOFA	O
+score	O
+on	O
+Day	O
+1	O
+(	O
+OR	O
+,	O
+0	O
+.	O
+842	O
+;	O
+95	O
+%	O
+CI	O
+,	O
+0	O
+.	O
+708	O
+-	O
+1	O
+.	O
+002	O
+)	O
+were	O
+independent	O
+factors	O
+in	O
+patient	O
+survival	O
+.	O
+
+TITLE	O
+:	O
+Detection	O
+and	O
+characterization	O
+of	O
+a	O
+novel	O
+bat	B-ENZY
+-	O
+borne	O
+coronavirus	B-SPEC
+in	O
+Singapore	O
+using	O
+multiple	O
+molecular	O
+approaches	O
+.	O
+
+ABSTRACT	O
+:	O
+Bats	O
+are	O
+important	O
+reservoirs	O
+and	O
+vectors	O
+in	O
+the	O
+transmission	O
+of	O
+emerging	B-DISO
+infectious	I-DISO
+diseases	I-DISO
+.	O
+
+In	O
+this	O
+study	O
+we	O
+monitored	O
+the	O
+major	O
+roost	O
+sites	O
+of	O
+bats	B-SPEC
+in	O
+Singapore	O
+,	O
+and	O
+performed	O
+surveillance	O
+for	O
+zoonotic	O
+pathogens	O
+in	O
+these	O
+bats	B-SPEC
+.	O
+
+The	O
+median	O
+potential	O
+for	O
+lung	B-ANAT
+recruitment	B-DISO
+was	O
+24	O
+.	O
+3	O
+%	O
+(	O
+interquartile	O
+range	O
+=	O
+11	O
+.	O
+4	O
+-	O
+37	O
+%)	O
+ranging	O
+from	O
+-	O
+2	O
+%	O
+to	O
+76	O
+.	O
+3	O
+%	O
+of	O
+the	O
+total	O
+lung	B-ANAT
+weight	O
+.	O
+
+We	O
+observed	O
+significant	O
+variability	O
+in	O
+potential	O
+for	O
+lung	B-ANAT
+recruitment	B-DISO
+in	O
+patients	O
+with	O
+severe	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+requiring	O
+extracorporeal	O
+membrane	B-COMP
+oxygenation	B-PROC
+.	O
+
+Patients	O
+with	O
+high	O
+potential	O
+for	O
+lung	B-ANAT
+recruitment	B-DISO
+had	O
+a	O
+shorter	O
+ICU	O
+stay	O
+and	O
+shorter	O
+extracorporeal	O
+membrane	B-COMP
+oxygenation	B-PROC
+duration	O
+.	O
+
+TITLE	O
+:	O
+Characterization	O
+of	O
+a	O
+novel	O
+bat	B-ENZY
+-	O
+HKU2	O
+-	O
+like	O
+swine	B-SPEC
+enteric	O
+alphacoronavirus	B-SPEC
+(	O
+SeACoV	O
+)	O
+infection	B-DISO
+in	O
+cultured	O
+cells	O
+and	O
+development	B-PROC
+of	O
+a	O
+SeACoV	O
+infectious	B-DISO
+clone	O
+.	O
+
+That	O
+it	O
+was	O
+usually	O
+of	O
+no	O
+omen	O
+on	O
+severe	O
+autonomic	B-ANAT
+nerve	I-ANAT
+dysfunction	O
+must	O
+be	O
+successively	O
+monitored	O
+,	O
+the	O
+same	O
+as	O
+the	O
+management	O
+of	O
+the	O
+respiratory	B-ANAT
+tract	I-ANAT
+and	O
+nutrition	B-PROC
+support	O
+.	O
+
+TITLE	O
+:	O
+Continuous	O
+Positive	O
+Airway	B-ANAT
+Pressure	O
+Use	O
+for	O
+Obstructive	B-DISO
+Sleep	I-DISO
+Apnea	I-DISO
+in	O
+Acute	O
+,	O
+Traumatic	O
+Tetraplegia	B-DISO
+.	O
+
+Inpatient	O
+rehabilitation	O
+units	O
+of	O
+11	O
+spinal	B-ANAT
+cord	I-ANAT
+injury	O
+centers	O
+.	O
+
+Autotitrating	O
+CPAP	O
+for	O
+OSA	B-DISO
+for	O
+3	O
+months	O
+.	O
+
+Average	O
+95th	O
+percentile	O
+pressure	O
+was	O
+low	O
+(	O
+9	O
+.	O
+3	O
+±	O
+1	O
+.	O
+7	O
+cmH	B-DISO
+Adherence	O
+to	O
+CPAP	O
+after	O
+acute	O
+,	O
+traumatic	O
+tetraplegia	B-DISO
+is	O
+low	O
+.	O
+
+These	O
+findings	O
+highlight	O
+the	O
+need	O
+for	O
+further	O
+investigation	O
+of	O
+OSA	B-DISO
+treatment	O
+in	O
+acute	O
+tetraplegia	B-DISO
+.	O
+
+Despite	O
+posing	O
+a	O
+probable	O
+risk	O
+for	O
+virus	B-SPEC
+transmission	O
+,	O
+asymptomatic	O
+to	O
+mild	O
+infections	B-DISO
+can	O
+go	O
+unnoticed	O
+;	O
+a	O
+lack	O
+of	O
+seroconversion	O
+among	O
+some	O
+PCR	O
+-	O
+confirmed	O
+cases	O
+has	O
+been	O
+reported	O
+.	O
+
+Independent	O
+risk	O
+factors	O
+for	O
+infection	B-DISO
+were	O
+direct	O
+contact	O
+with	O
+a	O
+confirmed	O
+case	O
+-	O
+patient	O
+and	O
+sharing	O
+a	O
+room	O
+with	O
+a	O
+confirmed	O
+case	O
+-	O
+patient	O
+;	O
+a	O
+protective	O
+factor	O
+was	O
+having	O
+an	O
+air	B-CHED
+conditioner	O
+in	O
+the	O
+bedroom	O
+.	O
+
+The	O
+medical	O
+records	O
+of	O
+infants	O
+were	O
+reviewed	O
+retrospectively	O
+and	O
+multiple	O
+factors	O
+that	O
+may	O
+be	O
+associated	O
+with	O
+the	O
+development	B-PROC
+of	O
+ROP	B-DISO
+were	O
+collected	O
+manually	O
+.	O
+
+After	O
+conducting	B-PROC
+univariate	O
+analysis	O
+of	O
+risk	O
+factors	O
+,	O
+statistically	O
+significant	O
+risk	O
+factors	O
+affecting	O
+the	O
+development	B-PROC
+of	O
+ROP	B-DISO
+in	O
+our	O
+study	O
+were	O
+:	O
+low	O
+gestational	O
+age	O
+,	O
+low	O
+birth	B-PROC
+weight	O
+,	O
+type	O
+of	O
+multiple	B-DISO
+gestation	I-DISO
+,	O
+the	O
+presence	O
+of	O
+affected	O
+sibling	O
+,	O
+low	O
+level	O
+of	O
+Hemoglobin	B-PRGE
+at	O
+birth	B-PROC
+,	O
+respiratory	B-DISO
+distress	I-DISO
+syndrome	I-DISO
+,	O
+low	O
+Hemoglobin	B-PRGE
+level	O
+,	O
+blood	B-ANAT
+transfusion	O
+and	O
+days	O
+on	O
+oxygen	B-CHED
+supplements	O
+with	O
+either	O
+mechanical	O
+,	O
+non	O
+-	O
+mechanical	O
+methods	O
+or	O
+both	O
+combined	O
+.	O
+
+CONCLUSIONS	O
+:	O
+The	O
+incidence	O
+of	O
+ROP	B-DISO
+is	O
+considered	O
+a	O
+relatively	O
+low	O
+percentage	O
+compared	O
+to	O
+neighboring	O
+countries	O
+that	O
+have	O
+higher	O
+levels	O
+of	O
+human	B-PROC
+development	B-PROC
+index	O
+.	O
+
+TITLE	O
+:	O
+Middle	O
+East	O
+Respiratory	O
+Syndrome	B-DISO
+Coronavirus	B-SPEC
+,	O
+Saudi	O
+Arabia	O
+,	O
+2017	O
+-	O
+2018	O
+.	O
+
+TITLE	O
+:	O
+Successful	O
+establishment	O
+of	O
+a	O
+reverse	O
+genetic	O
+system	O
+for	O
+QX	O
+-	O
+type	O
+infectious	B-DISO
+bronchitis	B-DISO
+virus	B-SPEC
+and	O
+technical	O
+improvement	O
+of	O
+the	O
+rescue	O
+procedure	O
+.	O
+
+The	O
+full	O
+-	O
+length	O
+genomic	O
+cDNA	O
+was	O
+transcribed	O
+in	O
+vitro	O
+,	O
+and	O
+its	O
+transcript	O
+was	O
+transfected	O
+into	O
+BHK	O
+-	O
+21	O
+/	O
+N	O
+cells	B-COMP
+that	O
+could	O
+stably	O
+express	O
+IBV	B-SPEC
+N	O
+protein	B-CHED
+.	O
+
+After	O
+only	O
+one	O
+in	O
+ovo	B-SPEC
+passage	O
+,	O
+the	O
+recombinant	O
+YN	O
+virus	B-SPEC
+(	O
+rYN	O
+)	O
+was	O
+successfully	O
+recovered	O
+and	O
+confirmed	O
+to	O
+possess	B-DISO
+the	O
+introduced	O
+silent	O
+marker	O
+mutation	O
+in	O
+its	O
+genome	O
+.	O
+
+Here	O
+we	O
+report	O
+that	O
+ORF4a	O
+,	O
+ORF4b	B-PRGE
+,	I-PRGE
+and	I-PRGE
+ORF8b	I-PRGE
+proteins	I-PRGE
+,	O
+alone	O
+or	O
+in	O
+combination	O
+,	O
+effectively	O
+antagonize	O
+nuclear	B-PRGE
+factor	I-PRGE
+kappa	I-PRGE
+B	I-PRGE
+(	O
+NF	O
+-	O
+κB	O
+)	O
+activation	O
+.	O
+
+In	O
+addition	O
+,	O
+ORF8b	O
+also	O
+strongly	O
+inhibits	O
+Tank	B-PRGE
+-	I-PRGE
+binding	I-PRGE
+kinase	I-PRGE
+1	I-PRGE
+(	O
+TBK1	B-FUNC
+)-	O
+mediated	O
+induction	O
+of	O
+NF	O
+-	O
+κB	O
+signaling	B-PROC
+.	O
+
+Even	O
+though	O
+the	O
+dengue	B-DISO
+prodrome	B-DISO
+and	O
+evolution	B-PROC
+of	O
+illness	O
+are	O
+most	O
+often	O
+similar	O
+in	O
+many	O
+patients	O
+,	O
+progress	O
+and	O
+outcome	O
+may	O
+differ	O
+significantly	O
+depending	O
+on	O
+the	O
+severity	O
+of	O
+illness	O
+as	O
+well	O
+as	O
+treatment	O
+instituted	O
+.	O
+
+CNS	B-CHED
+involvement	O
+observed	O
+among	O
+27	O
+%.	O
+
+Serum	B-COMP
+lactate	B-CHED
+,	O
+aspartate	B-PRGE
+transaminase	I-PRGE
+(	O
+AST	B-PRGE
+)	O
+and	O
+alanine	B-PRGE
+transaminase	I-PRGE
+(	O
+ALT	B-FUNC
+)	O
+were	O
+significantly	O
+elevated	O
+among	O
+non	O
+survivors	O
+.	O
+
+Catastrophic	O
+Antiphospholipid	B-DISO
+Syndrome	I-DISO
+(	O
+CAPS	O
+)	O
+is	O
+a	O
+severe	O
+and	O
+rare	O
+form	O
+of	O
+antiphospholipid	B-DISO
+syndrome	I-DISO
+characterised	O
+by	O
+multiple	O
+site	O
+thrombosis	B-DISO
+involving	O
+small	O
+,	O
+medium	O
+and	O
+large	O
+blood	B-ANAT
+vessels	I-ANAT
+occurring	O
+over	O
+a	O
+short	O
+period	O
+of	O
+time	O
+(	O
+usually	O
+1	O
+week	O
+)	O
+causing	O
+multiorgan	B-DISO
+failure	I-DISO
+.	O
+
+TITLE	O
+:	O
+Characteristics	O
+of	O
+flavonoids	B-CHED
+as	O
+potent	O
+MERS	O
+-	O
+CoV	B-PRGE
+3C	I-PRGE
+-	I-PRGE
+like	I-PRGE
+protease	I-PRGE
+inhibitors	O
+.	O
+
+The	O
+systematic	O
+comparison	O
+of	O
+the	O
+binding	B-FUNC
+affinity	O
+of	O
+flavonoids	B-CHED
+made	O
+it	O
+possible	O
+to	O
+infer	O
+their	O
+scaffolds	O
+and	O
+functional	O
+groups	O
+required	O
+to	O
+bind	B-FUNC
+with	O
+MERS	O
+-	O
+CoV	O
+3CLpro	O
+.	O
+
+Furthermore	O
+,	O
+our	O
+findings	O
+support	O
+the	O
+view	O
+that	O
+the	O
+national	O
+incidence	O
+curve	O
+of	O
+the	O
+Ebola	O
+epidemic	O
+in	O
+DRC	B-PRGE
+follows	O
+a	O
+stable	O
+incidence	O
+pattern	O
+with	O
+periodic	O
+behavior	O
+that	O
+can	O
+be	O
+decomposed	O
+into	O
+overlapping	O
+sub	O
+-	O
+epidemics	O
+.	O
+
+Also	O
+,	O
+the	O
+DRS	B-DISO
+approach	O
+,	O
+which	O
+circumvents	O
+reverse	B-PROC
+transcription	I-PROC
+and	O
+amplification	B-DISO
+of	O
+RNA	O
+,	O
+allowed	O
+us	O
+to	O
+detect	O
+methylation	B-PROC
+sites	O
+in	O
+viral	O
+RNAs	O
+.	O
+
+Eleven	O
+published	O
+papers	O
+were	O
+found	O
+that	O
+considered	O
+macronutrient	B-CHED
+use	O
+in	O
+enteral	O
+and	O
+parenteral	O
+nutrition	B-PROC
+therapies	O
+among	O
+9	O
+different	O
+burn	O
+patient	O
+samples	O
+.	O
+
+The	O
+evidence	O
+available	O
+to	O
+date	O
+supports	O
+the	O
+clinical	O
+use	O
+of	O
+nutrition	B-PROC
+support	O
+providing	O
+≤	O
+15	O
+%	O
+fat	O
+and	O
+≥	O
+60	O
+%	O
+carbohydrate	B-CHED
+for	O
+critically	B-DISO
+ill	I-DISO
+burn	O
+patients	O
+.	O
+
+A	O
+12	O
+-	O
+month	O
+-	O
+old	O
+Thai	O
+girl	O
+presented	O
+with	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+,	O
+septic	B-DISO
+shock	I-DISO
+,	O
+and	O
+bacterial	B-DISO
+pneumonia	I-DISO
+.	O
+
+In	O
+spite	O
+of	O
+a	O
+bedside	O
+abdominocentesis	O
+,	O
+her	O
+abdomen	B-ANAT
+was	O
+still	O
+tense	B-DISO
+and	O
+her	O
+hemodynamics	B-PROC
+was	O
+unstable	O
+.	O
+
+There	O
+was	O
+no	O
+intestinal	B-ANAT
+perforation	I-DISO
+.	O
+
+Severity	O
+of	O
+AKI	B-PRGE
+and	O
+use	O
+of	O
+RRT	O
+were	O
+associated	O
+with	O
+poor	O
+prognosis	O
+.	O
+
+TITLE	O
+:	O
+Feline	B-SPEC
+coronavirus	B-SPEC
+isolates	O
+from	O
+a	O
+part	O
+of	O
+Brazil	O
+:	O
+insights	O
+into	O
+molecular	O
+epidemiology	O
+and	O
+phylogeny	O
+inferred	O
+from	O
+the	O
+7b	O
+gene	O
+.	O
+
+Current	O
+treatment	O
+remains	O
+primarily	O
+supportive	O
+with	O
+lung	B-ANAT
+-	O
+protective	O
+ventilation	O
+strategies	O
+.	O
+
+ARDS	B-DISO
+survivors	O
+tend	O
+to	O
+have	O
+long	O
+-	O
+term	O
+and	O
+potentially	O
+permanent	O
+neuromuscular	O
+,	O
+cognitive	O
+,	O
+and	O
+psychological	O
+symptoms	O
+,	O
+affecting	O
+patient	O
+'	O
+s	O
+quality	O
+of	O
+life	O
+posthospitalization	O
+.	O
+
+Of	O
+note	O
+,	O
+MDA5	B-PRGE
+protein	I-PRGE
+levels	O
+were	O
+significantly	O
+down	O
+-	O
+regulated	O
+by	O
+ORF8b	O
+and	O
+co	O
+-	O
+expression	B-PROC
+of	O
+ORF4a	B-PRGE
+and	I-PRGE
+ORF4b	I-PRGE
+.	O
+
+These	O
+novel	O
+findings	O
+will	O
+facilitate	O
+elucidation	O
+of	O
+mechanisms	O
+of	O
+virus	B-SPEC
+-	O
+encoded	O
+evasion	O
+strategies	O
+,	O
+thus	O
+helping	O
+design	O
+rationale	O
+antiviral	B-CHED
+countermeasures	O
+against	O
+deadly	O
+MERS	O
+-	O
+CoV	O
+infection	B-DISO
+.	O
+
+ECCO	O
+Based	O
+on	O
+a	O
+registry	O
+,	O
+we	O
+report	O
+a	O
+low	O
+rate	O
+of	O
+ECCO	O
+ClinicalTrials	O
+.	O
+gov	O
+:	O
+Identifier	O
+:	O
+NCT02965079	O
+retrospectively	O
+registered	O
+https	O
+://	O
+clinicaltrials	O
+.	O
+gov	B-PRGE
+/	O
+ct2	B-PRGE
+/	O
+show	O
+/	O
+NCT02965079	O
+.	O
+
+To	O
+present	O
+the	O
+epidemiology	O
+,	O
+clinical	O
+picture	O
+and	O
+differences	O
+of	O
+human	B-SPEC
+pathogenic	O
+CoV	O
+and	O
+to	O
+provide	O
+information	O
+on	O
+the	O
+diagnostics	O
+and	O
+treatment	O
+of	O
+patients	O
+suspected	O
+of	O
+having	O
+CoV	O
+infections	B-DISO
+.	O
+
+The	O
+SARS	B-PRGE
+-	I-PRGE
+CoV	I-PRGE
+has	O
+not	O
+been	O
+detected	O
+in	O
+humans	B-SPEC
+in	O
+the	O
+last	O
+15	O
+years	O
+and	O
+MERS	O
+-	O
+CoV	O
+has	O
+been	O
+circulating	O
+mainly	O
+on	O
+the	O
+Arabian	O
+Peninsula	O
+since	O
+2012	O
+;	O
+however	O
+,	O
+neither	O
+a	O
+specific	O
+treatment	O
+nor	O
+approved	O
+vaccines	O
+exist	O
+for	O
+any	O
+of	O
+the	O
+six	O
+human	B-SPEC
+pathogenic	O
+CoVs	O
+.	O
+
+The	O
+aim	O
+of	O
+this	O
+study	O
+was	O
+to	O
+determine	O
+the	O
+frequency	O
+of	O
+BCoV	O
+infections	B-DISO
+and	O
+their	O
+genetic	O
+diversity	O
+in	O
+Uruguayan	O
+calves	O
+and	O
+to	O
+describe	O
+the	O
+evolutionary	O
+history	O
+of	O
+the	O
+virus	B-SPEC
+in	O
+South	O
+America	O
+.	O
+
+The	O
+potential	O
+of	O
+the	O
+plasmids	O
+to	O
+inhibit	O
+PDCoV	O
+replication	O
+was	O
+evaluated	O
+by	O
+cytopathic	B-DISO
+effect	I-DISO
+,	O
+virus	B-SPEC
+titers	O
+,	O
+and	O
+real	O
+-	O
+time	O
+quantitative	O
+RT	O
+-	O
+PCR	O
+assay	O
+.	O
+
+TITLE	O
+:	O
+Postoperative	O
+acute	B-DISO
+respiratory	I-DISO
+failure	I-DISO
+in	O
+cardiac	B-ANAT
+surgery	O
+.	O
+
+Nosocomial	B-DISO
+pneumonia	I-DISO
+was	O
+diagnosed	O
+in	O
+1	O
+.	O
+4	O
+%	O
+of	O
+patients	O
+and	O
+was	O
+not	O
+fatal	O
+.	O
+
+The	O
+aim	O
+of	O
+this	O
+study	O
+was	O
+to	O
+determine	O
+whether	O
+the	O
+implementation	O
+of	O
+a	O
+dedicated	O
+multiprofessional	O
+acute	O
+trauma	O
+health	O
+care	O
+(	O
+mPATH	O
+)	O
+team	O
+would	O
+decrease	O
+length	O
+of	O
+stay	O
+without	O
+adversely	O
+impacting	O
+outcomes	O
+of	O
+patients	O
+with	O
+severe	O
+traumatic	O
+brain	B-ANAT
+and	I-ANAT
+spinal	I-ANAT
+cord	I-ANAT
+injuries	O
+.	O
+
+The	O
+median	O
+time	O
+to	O
+evaluation	O
+by	O
+occupational	O
+,	O
+physical	O
+,	O
+and	O
+speech	B-PROC
+therapy	O
+was	O
+universally	O
+decreased	O
+.	O
+
+RESULTS	O
+:	O
+The	O
+median	O
+time	O
+to	O
+evaluation	O
+by	O
+occupational	O
+,	O
+physical	O
+,	O
+and	O
+speech	B-PROC
+therapy	O
+was	O
+universally	O
+decreased	O
+.	O
+
+Higher	O
+P	O
+/	O
+F	O
+ratio	O
+was	O
+a	O
+protective	O
+factor	O
+against	O
+death	B-PROC
+in	O
+patients	O
+.	O
+
+TITLE	O
+:	O
+Serum	B-ANAT
+Exosomal	O
+MicroRNAs	O
+Predict	O
+Acute	B-DISO
+Respiratory	I-DISO
+Distress	I-DISO
+Syndrome	I-DISO
+Events	O
+in	O
+Patients	O
+with	O
+Severe	O
+Community	O
+-	O
+Acquired	O
+Pneumonia	O
+.	O
+
+ABSTRACT	O
+:	O
+Severe	O
+community	O
+-	O
+acquired	O
+pneumonia	B-DISO
+(	O
+SCAP	B-PRGE
+)	O
+requiring	O
+intensive	O
+care	O
+unit	O
+(	O
+ICU	O
+)	O
+treatment	O
+commonly	O
+causes	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+(	O
+ARDS	B-DISO
+)	O
+with	O
+high	O
+mortality	O
+.	O
+
+Moreover	O
+,	O
+multivariate	O
+Cox	O
+proportional	O
+regression	O
+analysis	O
+was	O
+performed	O
+to	O
+estimate	O
+the	O
+odds	O
+ratio	O
+of	O
+miRNA	O
+for	O
+the	O
+occurrence	O
+of	O
+ARDS	B-DISO
+and	O
+prognosis	O
+.	O
+
+The	O
+combined	O
+expression	B-PROC
+of	O
+miR	B-PRGE
+-	I-PRGE
+126	I-PRGE
+,	O
+miR	B-PRGE
+-	I-PRGE
+27a	I-PRGE
+,	O
+miR	B-PRGE
+-	I-PRGE
+146a	I-PRGE
+,	O
+and	O
+miR	O
+-	O
+155	O
+predicted	O
+ARDS	B-DISO
+with	O
+an	O
+area	O
+under	O
+the	O
+curve	O
+of	O
+0	O
+.	O
+909	O
+(	O
+95	O
+%	O
+CI	O
+0	O
+.	O
+815	O
+-	O
+1	O
+).	O
+
+A	O
+survey	O
+was	O
+created	O
+to	O
+query	O
+providers	O
+on	O
+the	O
+use	O
+of	O
+ECMO	O
+in	O
+trauma	O
+,	O
+as	O
+well	O
+as	O
+general	O
+management	O
+principals	O
+related	O
+to	O
+care	O
+of	O
+the	O
+patient	O
+with	O
+refractory	O
+hypoxic	B-DISO
+respiratory	B-DISO
+failure	I-DISO
+.	O
+
+Among	O
+the	O
+8	O
+viruses	B-SPEC
+,	O
+parainfluenza	B-DISO
+virus	B-SPEC
+(	O
+4	O
+.	O
+8	O
+%	O
+for	O
+1	O
+%	O
+respiratory	B-DISO
+viral	I-DISO
+infection	I-DISO
+increase	O
+,	O
+95	O
+%	O
+CI	O
+1	O
+.	O
+6	O
+to	O
+8	O
+.	O
+1	O
+,	O
+P	O
+=	O
+.	O
+003	O
+),	O
+coronavirus	B-SPEC
+(	O
+9	O
+.	O
+2	O
+%,	O
+3	O
+.	O
+9	O
+to	O
+14	O
+.	O
+8	O
+,	O
+P	O
+<	O
+.	O
+001	O
+),	O
+and	O
+metapneumovirus	B-SPEC
+(	O
+44	O
+%,	O
+2	O
+.	O
+0	O
+to	O
+103	O
+.	O
+4	O
+,	O
+P	O
+=	O
+.	O
+038	O
+)	O
+were	O
+associated	O
+with	O
+increased	O
+number	O
+of	O
+incident	O
+RA	O
+.	O
+
+Ambient	O
+respiratory	O
+viral	B-DISO
+infections	I-DISO
+in	O
+the	O
+population	O
+were	O
+associated	O
+with	O
+an	O
+increased	O
+number	O
+of	O
+incident	O
+RA	O
+,	O
+especially	O
+in	O
+women	O
+and	O
+older	O
+patients	O
+,	O
+suggesting	O
+that	O
+respiratory	O
+viral	B-DISO
+infections	I-DISO
+can	O
+be	O
+a	O
+novel	O
+environmental	O
+risk	O
+factor	O
+for	O
+the	O
+development	B-PROC
+of	O
+RA	O
+.	O
+
+ABSTRACT	O
+:	O
+Blunt	O
+chest	B-ANAT
+trauma	O
+is	O
+one	O
+of	O
+the	O
+major	O
+injuries	O
+in	O
+multiply	O
+injured	O
+patients	O
+and	O
+is	O
+associated	O
+with	O
+an	O
+increased	O
+risk	O
+of	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+(	O
+ARDS	B-DISO
+)	O
+and	O
+ventilator	B-DISO
+-	I-DISO
+associated	I-DISO
+pneumonia	I-DISO
+(	O
+VAP	O
+).	O
+
+Hypothermia	O
+was	O
+not	O
+identified	O
+as	O
+an	O
+independent	O
+predictor	O
+of	O
+ARDS	B-DISO
+and	O
+VAP	O
+.	O
+
+For	O
+pigs	B-SPEC
+of	O
+group	O
+III	O
+,	O
+the	O
+RM	O
+protocol	O
+used	O
+was	O
+positive	O
+end	B-PROC
+-	I-PROC
+expiratory	I-PROC
+pressure	O
+(	O
+PEEP	B-CHED
+)	O
+of	O
+25	O
+cmH	B-DISO
+
+The	O
+lymphocytes	B-ANAT
+isolated	O
+from	O
+the	O
+blood	B-ANAT
+and	O
+spleen	B-ANAT
+were	O
+analyzed	O
+for	O
+proliferation	O
+,	O
+cytotoxic	O
+activities	O
+,	O
+and	O
+populations	O
+of	O
+CD4	B-PRGE
+
+We	O
+identified	O
+11	O
+CoV	O
+strains	O
+from	O
+22	O
+individual	O
+samples	O
+of	O
+four	O
+bat	B-ENZY
+species	B-SPEC
+.	O
+
+Literature	O
+search	O
+and	O
+analysis	O
+of	O
+national	O
+and	O
+international	O
+guidelines	O
+for	O
+the	O
+epidemiology	O
+,	O
+diagnostics	O
+,	O
+treatment	O
+and	O
+prevention	O
+of	O
+IV	O
+infections	B-DISO
+.	O
+
+Although	O
+the	O
+incidence	O
+of	O
+IV	O
+infections	B-DISO
+remains	O
+underrecognized	O
+,	O
+it	O
+is	O
+the	O
+leading	O
+infectious	B-DISO
+disease	I-DISO
+-	O
+associated	O
+cause	O
+of	O
+mortality	O
+and	O
+morbidity	O
+in	O
+Europe	O
+.	O
+
+ABSTRACT	O
+:	O
+Due	O
+to	O
+their	O
+ability	O
+to	O
+inhibit	O
+viral	O
+DNA	O
+or	O
+RNA	B-PROC
+replication	I-PROC
+,	O
+nucleoside	B-CHED
+analogues	I-CHED
+have	O
+been	O
+used	O
+for	O
+decades	O
+as	O
+potent	O
+antiviral	B-CHED
+therapeutics	O
+.	O
+
+The	O
+principal	O
+aim	O
+of	O
+our	O
+study	O
+was	O
+to	O
+determinate	O
+respiratory	B-DISO
+tract	I-DISO
+infections	I-DISO
+frequency	O
+in	O
+this	O
+cystic	B-DISO
+fibrosis	I-DISO
+young	O
+population	O
+.	O
+
+RSV	B-SPEC
+-	O
+related	O
+morbidity	O
+seems	O
+low	O
+in	O
+this	O
+population	O
+.	O
+
+TITLE	O
+:	O
+A	O
+multicenter	O
+RCT	O
+of	O
+noninvasive	O
+ventilation	O
+in	O
+pneumonia	B-DISO
+-	O
+induced	O
+early	O
+mild	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+.	O
+
+Primary	O
+outcome	O
+included	O
+the	O
+numbers	O
+of	O
+patients	O
+who	O
+met	B-CHED
+the	O
+intubation	O
+criteria	O
+.	O
+
+Dromedary	B-SPEC
+camels	B-SPEC
+are	O
+the	O
+principal	O
+reservoir	O
+for	O
+the	O
+virus	B-SPEC
+.	O
+
+ABSTRACT	O
+:	O
+Coronaviruses	O
+represent	O
+current	O
+and	O
+emerging	O
+threats	O
+for	O
+many	O
+species	O
+,	O
+including	O
+humans	B-SPEC
+.	O
+
+A	O
+key	O
+step	O
+in	O
+the	O
+MERS	O
+-	O
+CoV	O
+replication	O
+cycle	O
+is	O
+the	O
+fusion	O
+of	O
+the	O
+virus	B-SPEC
+and	O
+host	O
+cell	B-COMP
+membranes	I-COMP
+mediated	O
+by	O
+the	O
+virus	B-SPEC
+spike	O
+protein	B-CHED
+,	O
+S	O
+.	O
+The	O
+location	O
+of	O
+the	O
+fusion	O
+peptide	B-CHED
+within	O
+the	O
+MERS	B-PRGE
+S	I-PRGE
+protein	I-PRGE
+has	O
+not	O
+been	O
+precisely	O
+mapped	O
+.	O
+
+ABSTRACT	O
+:	O
+During	O
+the	O
+last	O
+three	O
+decades	O
+or	O
+so	O
+,	O
+many	O
+efforts	O
+have	O
+been	O
+made	O
+to	O
+study	O
+the	O
+protein	B-PROC
+cleavage	I-PROC
+sites	O
+by	O
+some	O
+disease	O
+-	O
+causing	O
+enzyme	O
+,	O
+such	O
+as	O
+HIV	B-DISO
+(	O
+human	B-DISO
+immunodeficiency	I-DISO
+virus	I-DISO
+)	O
+protease	O
+and	O
+SARS	B-DISO
+(	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+)	O
+coronavirus	B-SPEC
+main	O
+proteinase	B-PROC
+.	O
+
+ABSTRACT	O
+:	O
+Middle	O
+East	O
+Respiratory	O
+Syndrome	O
+Coronavirus	B-SPEC
+(	O
+MERS	O
+-	O
+CoV	O
+)	O
+is	O
+one	O
+of	O
+the	O
+major	O
+threats	O
+to	O
+the	O
+healthcare	O
+systems	O
+in	O
+some	O
+countries	O
+,	O
+especially	O
+in	O
+the	O
+Arabian	O
+Peninsula	O
+.	O
+
+This	O
+is	O
+due	O
+to	O
+the	O
+animals	B-SPEC
+,	O
+especially	O
+dromedary	B-SPEC
+camels	B-SPEC
+,	O
+play	O
+important	O
+roles	O
+in	O
+the	O
+transmission	O
+and	O
+sustainability	O
+of	O
+the	O
+virus	B-SPEC
+,	O
+and	O
+the	O
+virus	B-SPEC
+can	O
+be	O
+transmitted	B-DISO
+through	O
+aerosols	O
+of	O
+infected	O
+patients	O
+into	O
+the	O
+environment	O
+.	O
+
+Human	B-SPEC
+-	O
+to	O
+-	O
+human	B-SPEC
+transmission	O
+is	O
+well	O
+documented	O
+through	O
+contact	O
+with	O
+an	O
+active	O
+infected	O
+patient	O
+or	O
+some	O
+silently	O
+infected	O
+persons	O
+.	O
+
+Furthermore	O
+,	O
+there	O
+are	O
+some	O
+significant	O
+risk	O
+factors	O
+of	O
+individuals	O
+in	O
+close	O
+contact	O
+with	O
+a	O
+positive	O
+MERS	O
+-	O
+CoV	O
+patient	O
+,	O
+including	O
+sleeping	B-PROC
+in	O
+the	O
+same	O
+patient	O
+room	O
+,	O
+removing	O
+patient	O
+waste	O
+(	O
+urine	B-ANAT
+,	O
+stool	B-ANAT
+,	O
+and	O
+sputum	B-ANAT
+),	O
+and	O
+touching	O
+respiratory	O
+secretions	B-ANAT
+from	O
+the	O
+index	O
+case	O
+.	O
+
+Identification	O
+of	O
+the	O
+exact	O
+mechanism	O
+of	O
+transmission	O
+of	O
+MERS	O
+-	O
+CoV	O
+from	O
+camels	B-SPEC
+to	O
+humans	B-SPEC
+and	O
+searching	O
+for	O
+new	O
+reservoir	O
+/	O
+s	O
+are	O
+of	O
+high	O
+priority	O
+.	O
+
+This	O
+will	O
+reduce	O
+the	O
+shedding	O
+of	O
+the	O
+virus	B-SPEC
+into	O
+the	O
+environment	O
+,	O
+and	O
+thus	O
+the	O
+risk	O
+of	O
+human	B-SPEC
+infection	B-DISO
+can	O
+be	O
+mitigated	O
+.	O
+
+Our	O
+study	O
+sheds	O
+light	O
+on	O
+bat	B-ENZY
+adaptive	O
+immunity	B-PROC
+and	O
+may	O
+benefit	O
+future	O
+vaccine	O
+development	B-PROC
+against	O
+bat	B-ENZY
+-	O
+borne	O
+viruses	B-SPEC
+of	O
+high	O
+impact	O
+on	O
+humans	B-SPEC
+.	O
+
+The	O
+association	O
+between	O
+myocardial	B-DISO
+calcification	I-DISO
+and	O
+tumor	B-DISO
+lysis	I-DISO
+syndrome	I-DISO
+has	O
+not	O
+been	O
+reported	O
+to	O
+date	O
+.	O
+
+5	O
+days	O
+ago	O
+,	O
+an	O
+illicit	O
+silicone	B-CHED
+injection	O
+was	O
+performed	O
+into	O
+the	O
+penis	B-ANAT
+for	O
+cosmetic	B-CHED
+reasons	O
+.	O
+
+The	O
+diagnostic	O
+potentials	O
+of	O
+specific	O
+porcine	B-SPEC
+epidemic	I-SPEC
+diarrhea	I-SPEC
+virus	I-SPEC
+(	O
+PEDV	B-SPEC
+)	O
+accessory	O
+and	O
+nonstructural	O
+proteins	B-CHED
+,	O
+if	O
+any	O
+,	O
+have	O
+not	O
+yet	O
+been	O
+investigated	O
+.	O
+
+In	O
+order	B-SPEC
+to	O
+determine	O
+and	O
+compare	O
+which	O
+of	O
+the	O
+viral	O
+proteins	B-CHED
+may	O
+be	O
+useful	O
+as	O
+diagnostic	O
+antigens	B-CHED
+,	O
+whole	O
+virus	B-SPEC
+(	O
+WV	O
+)	O
+particles	O
+and	O
+a	O
+panel	O
+of	O
+structural	O
+and	O
+nonstructural	O
+PEDV	B-SPEC
+proteins	B-CHED
+[	O
+spike	O
+subunit	O
+1	O
+(	O
+S1	O
+),	O
+the	O
+C	B-PRGE
+-	I-PRGE
+terminal	I-PRGE
+part	I-PRGE
+of	I-PRGE
+ORF3	I-PRGE
+(	I-PRGE
+ORF3C	I-PRGE
+),	I-PRGE
+envelope	I-PRGE
+(	I-PRGE
+E	I-PRGE
+),	I-PRGE
+nonstructural	I-PRGE
+protein	B-CHED
+1	I-PRGE
+(	O
+Nsp1	B-PRGE
+),	O
+Nsp2	B-PRGE
+,	O
+Ac	O
+(	O
+acidic	B-PRGE
+domain	I-PRGE
+of	I-PRGE
+Nsp3	I-PRGE
+),	O
+and	O
+ADRP	B-PRGE
+(	O
+ADP	B-PRGE
+-	I-PRGE
+ribose	B-CHED
+-	I-PRGE
+1	I-PRGE
+-	I-PRGE
+monophosphatase	I-PRGE
+domain	I-PRGE
+of	O
+Nsp3	B-PRGE
+),	O
+expressed	B-PROC
+individually	O
+in	O
+bacterial	O
+and	O
+/	O
+or	O
+mammalian	B-SPEC
+cells	B-COMP
+]	O
+were	O
+tested	O
+for	O
+reactivity	O
+with	O
+sera	B-COMP
+from	O
+PEDV	B-SPEC
+-	O
+infected	O
+pigs	B-SPEC
+by	O
+ELISA	O
+and	O
+/	O
+or	O
+western	O
+blot	O
+analysis	O
+.	O
+
+Stress	O
+granules	O
+(	O
+SGs	B-DISO
+)	O
+are	O
+sites	O
+of	O
+mRNA	B-CHED
+storage	B-PROC
+that	O
+are	O
+formed	O
+under	O
+various	O
+stress	O
+conditions	O
+including	O
+viral	B-DISO
+infections	I-DISO
+.	O
+
+Taken	O
+together	O
+,	O
+our	O
+results	O
+suggest	O
+that	O
+G3BP1	B-PRGE
+plays	O
+an	O
+antiviral	B-CHED
+role	O
+and	O
+impairs	O
+PEDV	B-SPEC
+replication	O
+.	O
+
+TITLE	O
+:	O
+Peptides	B-CHED
+with	O
+16R	O
+in	O
+S2	O
+protein	B-CHED
+showed	O
+broad	O
+reactions	O
+with	O
+sera	B-COMP
+against	O
+different	O
+types	O
+of	O
+infectious	B-DISO
+bronchitis	B-DISO
+viruses	B-SPEC
+.	O
+
+ABSTRACT	O
+:	O
+Vaccination	O
+plays	O
+a	O
+vital	O
+role	O
+in	O
+controlling	O
+diseases	O
+caused	O
+by	O
+chicken	B-SPEC
+infectious	B-DISO
+bronchitis	B-DISO
+virus	B-SPEC
+(	O
+IBV	B-SPEC
+).	O
+
+S2	B-PRGE
+protein	I-PRGE
+is	O
+an	O
+invariant	O
+that	O
+harbors	O
+broad	O
+neutralizing	O
+epitopes	O
+.	O
+
+However	O
+,	O
+little	O
+is	O
+known	O
+about	O
+the	O
+key	O
+amino	B-CHED
+acids	I-CHED
+that	O
+contribute	O
+to	O
+the	O
+broad	B-PRGE
+-	I-PRGE
+spectrum	I-PRGE
+S2	I-PRGE
+epitopes	I-PRGE
+.	O
+
+S2	O
+-	O
+derived	O
+peptides	B-CHED
+with	O
+16R	O
+,	O
+but	O
+not	O
+those	O
+with	O
+16	O
+K	O
+,	O
+could	O
+react	O
+with	O
+sera	B-COMP
+against	O
+different	O
+types	O
+of	O
+IBVs	O
+.	O
+
+Patients	O
+with	O
+severe	O
+ARDS	B-DISO
+who	O
+received	O
+VV	O
+-	O
+ECMO	O
+support	O
+were	O
+included	O
+.	O
+
+Using	O
+fecal	B-ANAT
+samples	O
+collected	O
+from	O
+five	O
+bat	B-ENZY
+species	B-SPEC
+between	O
+2014	O
+and	O
+2016	O
+in	O
+Finland	O
+and	O
+RT	O
+-	O
+PCR	O
+,	O
+RT	O
+-	O
+qPCR	O
+,	O
+and	O
+NGS	O
+,	O
+we	O
+identified	O
+CoVs	O
+in	O
+10	O
+of	O
+79	O
+(	O
+13	O
+%)	O
+samples	O
+,	O
+including	O
+two	O
+novel	O
+bat	B-ENZY
+species	B-SPEC
+-	O
+CoV	O
+relationships	O
+.	O
+
+ABSTRACT	O
+:	O
+Respiratory	B-DISO
+infections	I-DISO
+such	O
+as	O
+SARS	O
+-	O
+CoV	O
+in	O
+humans	B-SPEC
+are	O
+often	O
+accompanied	O
+by	O
+mild	O
+and	O
+self	O
+-	O
+limiting	O
+hepatitis	B-DISO
+.	O
+
+Immunohistochemistry	O
+(	O
+IHC	O
+)	O
+results	O
+indicated	O
+a	O
+wide	O
+distribution	O
+of	O
+IAV	O
+'	O
+s	O
+positive	O
+signals	O
+in	O
+the	O
+liver	B-ANAT
+of	O
+infected	O
+mice	B-SPEC
+.	O
+
+ABSTRACT	O
+:	O
+Western	O
+medicine	O
+is	O
+routinely	O
+used	O
+in	O
+developed	O
+nations	O
+as	O
+well	O
+as	O
+in	O
+Eastern	O
+countries	O
+,	O
+where	O
+traditional	O
+medicine	B-CHED
+is	O
+frequently	O
+used	O
+by	O
+a	O
+selection	O
+of	O
+patients	O
+or	O
+family	B-SPEC
+member	O
+as	O
+a	O
+complement	O
+to	O
+mainstream	O
+Western	O
+medicine	B-CHED
+.	O
+
+Chinese	O
+medicine	B-CHED
+has	O
+a	O
+holistic	O
+view	O
+of	O
+the	O
+human	B-ANAT
+body	I-ANAT
+,	O
+and	O
+emphasizes	O
+individualization	O
+based	O
+on	O
+body	B-PROC
+balance	B-CHED
+and	O
+mind	O
+-	O
+body	B-ANAT
+interaction	O
+and	O
+employs	O
+herbal	O
+medicines	O
+and	O
+acupuncture	O
+.	O
+
+ABSTRACT	O
+:	O
+Transmissible	O
+gastroenteritis	B-DISO
+virus	B-SPEC
+(	O
+TGEV	B-SPEC
+)	O
+causes	O
+great	O
+economic	O
+loss	O
+to	O
+swine	B-SPEC
+industry	O
+worldwide	O
+.	O
+
+Beyond	O
+antimicrobial	B-CHED
+treatment	O
+,	O
+no	O
+targeted	B-PROC
+molecular	O
+therapies	O
+have	O
+yet	O
+proven	O
+effective	O
+,	O
+highlighting	O
+the	O
+need	O
+for	O
+additional	O
+research	O
+.	O
+
+Despite	O
+some	O
+limitations	O
+,	O
+small	O
+animal	B-SPEC
+models	O
+of	O
+pneumonia	B-DISO
+and	O
+the	O
+mechanistic	O
+insights	O
+they	O
+produce	O
+are	O
+likely	O
+to	O
+continue	O
+to	O
+play	O
+an	O
+important	O
+role	O
+in	O
+generating	O
+new	O
+therapeutic	O
+targets	O
+.	O
+
+Oxidative	B-DISO
+stress	I-DISO
+acts	O
+directly	O
+on	O
+the	O
+maintenance	O
+of	O
+inflammation	B-DISO
+,	O
+resulting	O
+in	O
+tissue	B-ANAT
+injury	O
+,	O
+as	O
+well	O
+as	O
+inducing	O
+DNA	B-DISO
+damages	I-DISO
+.	O
+
+We	O
+successfully	O
+managed	O
+the	O
+patient	O
+with	O
+methylprednisolone	O
+and	O
+bilevel	O
+positive	O
+airway	B-ANAT
+pressure	O
+ventilation	O
+and	O
+the	O
+patient	O
+was	O
+discharged	O
+in	O
+stable	O
+condition	B-DISO
+on	O
+day	O
+6	O
+.	O
+
+Management	O
+of	O
+ACS	B-FUNC
+is	O
+complex	O
+and	O
+may	O
+necessitate	O
+mechanical	O
+ventilation	O
+and	O
+veno	O
+-	O
+venous	B-ANAT
+extracorporeal	O
+membrane	B-COMP
+oxygenation	B-PROC
+(	O
+VV	O
+-	O
+ECMO	O
+)	O
+therapy	O
+in	O
+the	O
+more	O
+severe	O
+cases	O
+.	O
+
+ABSTRACT	O
+:	O
+Coronaviruses	O
+(	O
+CoVs	O
+)	O
+have	O
+caused	O
+outbreaks	O
+of	O
+deadly	O
+pneumonia	O
+in	O
+humans	B-SPEC
+since	O
+the	O
+beginning	O
+of	O
+the	O
+21st	O
+century	O
+.	O
+
+No	O
+specific	O
+treatments	O
+or	O
+vaccines	O
+have	O
+been	O
+approved	O
+against	O
+any	O
+of	O
+the	O
+six	O
+human	B-SPEC
+coronaviruses	O
+,	O
+highlighting	O
+the	O
+need	O
+to	O
+investigate	O
+the	O
+principles	O
+governing	O
+viral	O
+entry	O
+and	O
+cross	O
+-	O
+species	B-SPEC
+transmission	O
+as	O
+well	O
+as	O
+to	O
+prepare	O
+for	O
+zoonotic	O
+outbreaks	O
+which	O
+are	O
+likely	O
+to	O
+occur	O
+due	O
+to	O
+the	O
+large	O
+reservoir	O
+of	O
+CoVs	O
+found	O
+in	O
+mammals	O
+and	O
+birds	B-SPEC
+.	O
+
+ABSTRACT	O
+:	O
+Middle	O
+Eastern	O
+respiratory	O
+syndrome	B-DISO
+,	O
+an	O
+emerging	O
+viral	B-DISO
+infection	I-DISO
+with	O
+a	O
+global	O
+case	O
+fatality	O
+rate	O
+of	O
+35	O
+.	O
+5	O
+%,	O
+caused	O
+major	O
+outbreaks	O
+first	O
+in	O
+2012	O
+and	O
+2015	O
+,	O
+though	O
+new	O
+cases	O
+are	O
+continuously	O
+reported	O
+around	O
+the	O
+world	O
+.	O
+
+TITLE	O
+:	O
+A	O
+novel	O
+biotinylated	O
+nanobody	O
+-	O
+based	O
+blocking	B-DISO
+ELISA	O
+for	O
+the	O
+rapid	O
+and	O
+sensitive	O
+clinical	O
+detection	O
+of	O
+porcine	O
+epidemic	O
+diarrhea	O
+virus	O
+.	O
+
+However	O
+,	O
+the	O
+current	O
+diagnostic	O
+methods	O
+for	O
+PEDV	B-SPEC
+are	O
+time	O
+-	O
+consuming	O
+and	O
+very	O
+expensive	O
+and	O
+rarely	O
+meet	O
+the	O
+requirements	O
+for	O
+clinical	O
+application	O
+.	O
+
+A	O
+novel	O
+bELISA	O
+was	O
+subsequently	O
+developed	O
+for	O
+the	O
+first	O
+time	O
+with	O
+biotinylated	O
+Nb2	B-PRGE
+.	O
+
+RESULTS	O
+:	O
+Using	O
+phage	O
+display	O
+technology	O
+and	O
+periplasmic	B-COMP
+extraction	O
+ELISA	O
+(	O
+PE	O
+-	O
+ELISA	O
+),	O
+anti	B-PRGE
+-	I-PRGE
+PEDV	I-PRGE
+N	I-PRGE
+protein	B-CHED
+nanobodies	I-PRGE
+from	O
+three	O
+strains	O
+of	O
+PEDV	B-SPEC
+were	O
+successfully	O
+isolated	O
+after	O
+three	O
+consecutive	O
+rounds	O
+of	O
+bio	O
+-	O
+panning	O
+from	O
+a	O
+high	O
+quality	O
+phage	O
+display	O
+VHH	O
+library	O
+.	O
+
+In	O
+recent	O
+years	O
+,	O
+several	O
+investigators	O
+developed	O
+protective	O
+antibodies	B-COMP
+which	O
+could	O
+be	O
+used	O
+as	O
+prophylaxis	O
+in	O
+prospective	O
+human	B-SPEC
+epidemics	O
+.	O
+
+Five	O
+mAbs	O
+lacked	O
+immunoreactivity	B-PROC
+for	O
+MERS	B-PRGE
+-	I-PRGE
+CoV	I-PRGE
+antigen	I-PRGE
+on	O
+FFPE	O
+tissue	B-ANAT
+,	O
+even	O
+though	O
+they	O
+belong	O
+,	O
+at	O
+least	O
+in	O
+part	O
+,	O
+to	O
+the	O
+same	O
+epitope	B-CHED
+group	O
+.	O
+
+ABSTRACT	O
+:	O
+Acute	O
+respiratory	O
+distress	O
+syndrome	O
+(	O
+ARDS	B-DISO
+),	O
+the	O
+most	O
+severe	O
+form	O
+of	O
+acute	O
+lung	B-ANAT
+injury	O
+,	O
+is	O
+associated	O
+with	O
+reduced	O
+lung	B-PROC
+compliance	I-PROC
+and	O
+hypoxemia	O
+.	O
+
+The	O
+aim	O
+of	O
+this	O
+study	O
+was	O
+to	O
+describe	O
+the	O
+2017	O
+-	O
+2018	O
+influenza	B-DISO
+season	O
+in	O
+Southern	O
+Italy	O
+and	O
+the	O
+molecular	O
+characteristics	O
+of	O
+the	O
+circulating	O
+viral	O
+strains	O
+.	O
+
+At	O
+least	O
+one	O
+pathogen	O
+was	O
+molecularly	O
+detected	O
+in	O
+pigs	B-SPEC
+at	O
+63	O
+(	O
+61	O
+.	O
+8	O
+%)	O
+exhibitions	O
+.	O
+
+Three	O
+months	O
+later	O
+the	O
+cat	B-SPEC
+was	O
+returned	O
+having	O
+developed	O
+ataxia	B-DISO
+and	O
+paraparesis	B-DISO
+,	O
+which	O
+then	O
+progressed	O
+over	O
+2	O
+months	O
+to	O
+tetraparesis	B-DISO
+,	O
+tail	O
+plegia	O
+,	O
+urinary	O
+and	O
+fecal	B-DISO
+incontinence	I-DISO
+,	O
+and	O
+titubation	B-DISO
+.	O
+
+Molecular	O
+analysis	O
+of	O
+the	O
+coronavirus	B-SPEC
+spike	O
+protein	B-CHED
+within	O
+the	O
+tissues	B-ANAT
+identified	O
+a	O
+specific	O
+,	O
+functionally	O
+relevant	O
+amino	B-CHED
+acid	I-CHED
+change	O
+(	O
+R793M	O
+),	O
+which	O
+was	O
+only	O
+identified	O
+in	O
+tissues	B-ANAT
+associated	O
+with	O
+the	O
+central	B-ANAT
+nervous	I-ANAT
+system	I-ANAT
+(	O
+ie	O
+,	O
+brain	B-ANAT
+and	I-ANAT
+spinal	I-ANAT
+cord	I-ANAT
+).	O
+
+This	O
+case	O
+report	O
+describes	O
+an	O
+early	O
+presentation	O
+of	O
+a	O
+cat	B-SPEC
+with	O
+primarily	O
+neurologic	O
+FIP	B-DISO
+,	O
+with	O
+molecular	O
+characterization	O
+of	O
+the	O
+virus	B-SPEC
+within	O
+various	O
+tissues	B-ANAT
+.	O
+
+TITLE	O
+:	O
+A	O
+Breath	B-ANAT
+Close	O
+To	O
+Death	B-PROC
+:	O
+A	O
+Case	O
+Report	O
+Of	O
+Idiosyncratic	O
+Reaction	O
+To	O
+Welding	O
+Fumes	O
+.	O
+
+He	O
+was	O
+treated	O
+as	O
+Acute	B-DISO
+Respiratory	I-DISO
+Distress	I-DISO
+Syndrome	I-DISO
+(	O
+ARDS	B-DISO
+)	O
+secondary	O
+to	O
+exposure	O
+to	O
+welding	O
+metal	B-CHED
+fumes	O
+in	O
+a	O
+closed	O
+container	O
+.	O
+
+In	O
+view	O
+of	O
+its	O
+unique	O
+physic	O
+-	O
+chemical	O
+and	O
+biological	O
+properties	O
+,	O
+it	O
+has	O
+been	O
+used	O
+as	O
+a	O
+privileged	O
+scaffold	O
+in	O
+the	O
+anti	O
+-	O
+cancer	B-DISO
+agents	O
+design	O
+.	O
+
+Patients	O
+infected	O
+with	O
+the	O
+H275Y	O
+mutant	B-DISO
+virus	B-SPEC
+had	O
+higher	O
+day	O
+-	O
+28	O
+mortality	O
+than	O
+others	O
+(	O
+80	O
+%	O
+vs	O
+12	O
+%;	O
+p	O
+=	O
+0	O
+.	O
+011	O
+).	O
+
+TITLE	O
+:	O
+Screening	O
+pulmonary	B-ANAT
+angiogram	O
+and	O
+the	O
+effect	O
+on	O
+anticoagulation	B-PROC
+strategies	O
+in	O
+severe	O
+respiratory	B-DISO
+failure	I-DISO
+patients	O
+on	O
+venovenous	O
+extracorporeal	O
+membrane	B-COMP
+oxygenation	B-PROC
+.	O
+
+TITLE	O
+:	O
+A	O
+quantitative	O
+approach	O
+for	O
+the	O
+analysis	O
+of	O
+clinician	O
+recognition	O
+of	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+using	O
+electronic	O
+health	O
+record	O
+data	O
+.	O
+
+The	O
+recognition	O
+model	O
+yielded	O
+a	O
+mean	O
+(	O
+99	O
+%	O
+confidence	O
+interval	O
+)	O
+physician	O
+recognition	O
+of	O
+ARDS	B-DISO
+of	O
+22	O
+%	O
+(	O
+9	O
+%-	O
+42	O
+%)	O
+for	O
+mild	O
+,	O
+34	O
+%	O
+(	O
+19	O
+%-	O
+49	O
+%)	O
+for	O
+moderate	O
+,	O
+and	O
+67	O
+%	O
+(	O
+41	O
+%-	O
+100	O
+%)	O
+for	O
+severe	O
+ARDS	B-DISO
+.	O
+
+TITLE	O
+:	O
+Right	B-DISO
+Ventricular	I-DISO
+Hypertrophy	I-DISO
+in	O
+Refractory	O
+Acute	B-DISO
+Respiratory	I-DISO
+Distress	I-DISO
+Syndrome	I-DISO
+Treated	O
+With	O
+Venovenous	O
+Extracorporeal	O
+Membrane	O
+Oxygenation	B-PROC
+Support	O
+.	O
+
+,	O
+the	O
+Middle	O
+East	O
+respiratory	O
+syndrome	B-DISO
+-	O
+coronavirus	B-SPEC
+(	O
+MERS	O
+-	O
+CoV	O
+)	O
+has	O
+become	O
+a	O
+global	O
+concern	O
+due	O
+to	O
+the	O
+high	O
+morbidity	O
+and	O
+mortality	O
+of	O
+individuals	O
+infected	O
+with	O
+the	O
+virus	B-SPEC
+.	O
+
+Here	O
+,	O
+we	O
+used	O
+phage	O
+display	O
+to	O
+develop	O
+novel	O
+monoclonal	O
+antibodies	B-COMP
+(	O
+mAbs	O
+)	O
+that	O
+target	O
+MERS	O
+-	O
+CoV	O
+.	O
+A	O
+human	B-SPEC
+Fab	O
+phage	O
+display	O
+library	O
+was	O
+panned	O
+against	O
+the	O
+S2	O
+subunit	O
+of	O
+the	O
+MERS	B-PRGE
+-	I-PRGE
+CoV	I-PRGE
+spike	I-PRGE
+protein	I-PRGE
+(	O
+MERS	B-PRGE
+-	I-PRGE
+S2P	I-PRGE
+),	O
+yielding	O
+three	O
+unique	O
+Fabs	O
+(	O
+S2A3	O
+,	O
+S2A6	O
+,	O
+and	O
+S2D5	O
+).	O
+
+Confocal	O
+microscopy	O
+and	O
+subcellular	O
+fractionation	O
+revealed	O
+that	O
+the	O
+NS7	B-PRGE
+protein	B-CHED
+was	O
+extensively	O
+distributed	O
+in	O
+the	O
+mitochondria	B-COMP
+.	O
+
+These	O
+proteomic	O
+data	O
+will	O
+provide	O
+insights	O
+into	O
+the	O
+understanding	O
+of	O
+specific	O
+cellular	B-COMP
+responses	O
+to	O
+the	O
+accessory	O
+protein	B-CHED
+during	O
+PDCoV	O
+infection	B-DISO
+.	O
+
+ABSTRACT	O
+:	O
+Middle	O
+East	O
+respiratory	O
+syndrome	O
+coronavirus	B-SPEC
+(	O
+MERS	O
+-	O
+CoV	O
+)	O
+is	O
+a	O
+zoonotic	O
+disease	O
+transmitted	B-DISO
+from	O
+dromedary	B-SPEC
+camels	B-SPEC
+to	O
+people	O
+,	O
+which	O
+can	O
+result	O
+in	O
+outbreaks	O
+with	O
+human	B-SPEC
+-	O
+to	O
+-	O
+human	B-SPEC
+transmission	O
+.	O
+
+Epidemiological	O
+studies	O
+identified	O
+diabetes	B-DISO
+as	O
+the	O
+primary	O
+comorbidity	O
+associated	O
+with	O
+severe	O
+or	O
+lethal	O
+MERS	O
+-	O
+CoV	O
+infection	B-DISO
+.	O
+
+Upon	O
+infection	B-DISO
+with	O
+MERS	O
+-	O
+CoV	O
+,	O
+diabetic	O
+mice	B-SPEC
+had	O
+a	O
+prolonged	O
+phase	O
+of	O
+severe	O
+disease	O
+and	O
+delayed	O
+recovery	O
+that	O
+was	O
+independent	O
+of	O
+virus	B-SPEC
+titers	O
+.	O
+
+TITLE	O
+:	O
+Ribonuclease	B-ENZY
+H	I-ENZY
+,	O
+an	O
+unexploited	O
+target	O
+for	O
+antiviral	B-CHED
+intervention	O
+against	O
+HIV	B-DISO
+and	O
+hepatitis	B-DISO
+B	I-DISO
+virus	I-SPEC
+.	O
+
+During	O
+reverse	B-PROC
+transcription	I-PROC
+,	O
+the	O
+RNase	B-FUNC
+H	I-FUNC
+activity	I-FUNC
+of	O
+human	B-DISO
+immunodeficiency	I-DISO
+virus	I-DISO
+(	O
+HIV	B-DISO
+)	O
+and	O
+hepatitis	B-SPEC
+B	I-SPEC
+virus	I-SPEC
+(	O
+HBV	B-DISO
+)	O
+degrades	O
+the	O
+viral	O
+genomic	O
+RNA	O
+to	O
+facilitate	O
+the	O
+synthesis	B-PROC
+of	O
+viral	O
+double	B-CHED
+-	I-CHED
+stranded	I-CHED
+DNA	I-CHED
+.	O
+
+ABSTRACT	O
+:	O
+The	O
+efficacy	O
+of	O
+ustekinumab	O
+,	O
+an	O
+antagonist	O
+of	O
+the	O
+p40	B-PRGE
+subunit	I-PRGE
+of	O
+interleukin	B-PRGE
+-	I-PRGE
+12	I-PRGE
+and	O
+interleukin	B-PRGE
+-	I-PRGE
+23	I-PRGE
+,	O
+as	O
+induction	O
+and	O
+maintenance	O
+therapy	O
+in	O
+patients	O
+with	O
+ulcerative	B-DISO
+colitis	I-DISO
+is	O
+unknown	O
+.	O
+
+Among	O
+patients	O
+who	O
+had	O
+a	O
+response	O
+to	O
+induction	O
+therapy	O
+with	O
+ustekinumab	O
+and	O
+underwent	O
+a	O
+second	O
+randomization	O
+,	O
+the	O
+percentage	O
+of	O
+patients	O
+who	O
+had	O
+clinical	O
+remission	B-DISO
+at	O
+week	O
+44	O
+was	O
+significantly	O
+higher	O
+among	O
+patients	O
+assigned	O
+to	O
+90	O
+mg	O
+of	O
+subcutaneous	O
+ustekinumab	O
+every	O
+12	O
+weeks	O
+(	O
+38	O
+.	O
+4	O
+%)	O
+or	O
+every	O
+8	O
+weeks	O
+(	O
+43	O
+.	O
+8	O
+%)	O
+than	O
+among	O
+those	O
+assigned	O
+to	O
+placebo	O
+(	O
+24	O
+.	O
+0	O
+%)	O
+(	O
+P	O
+=	O
+0	O
+.	O
+002	O
+and	O
+P	O
+<	O
+0	O
+.	O
+001	O
+,	O
+respectively	O
+).	O
+
+TITLE	O
+:	O
+Structural	O
+Definition	O
+of	O
+a	O
+Neutralization	O
+-	O
+Sensitive	O
+Epitope	B-CHED
+on	O
+the	O
+MERS	O
+-	O
+CoV	O
+S1	O
+-	O
+NTD	O
+.	O
+
+Risk	O
+analysis	O
+is	O
+the	O
+tool	O
+that	O
+allows	O
+the	O
+identification	O
+of	O
+the	O
+factors	O
+involved	O
+in	O
+the	O
+introduction	O
+and	O
+the	O
+spread	O
+of	O
+infectious	B-DISO
+diseases	I-DISO
+.	O
+
+Records	O
+from	O
+a	O
+commercial	O
+diagnostic	O
+laboratory	O
+using	O
+faecal	B-ANAT
+PCR	O
+testing	O
+between	O
+July	O
+2014	O
+and	O
+August	O
+2015	O
+were	O
+reviewed	O
+.	O
+
+(	O
+1	O
+.	O
+7	O
+%),	O
+Campylobacter	B-SPEC
+spp	B-ENZY
+.	O
+
+Phylogenetic	O
+analysis	O
+of	O
+the	O
+partial	O
+N	B-PRGE
+gene	I-PRGE
+revealed	O
+that	O
+the	O
+newly	O
+identified	O
+δ	O
+-	O
+CoV	O
+strains	O
+were	O
+most	O
+closely	O
+related	O
+to	O
+the	O
+HKU20	O
+(	O
+wigeon	O
+)	O
+strain	O
+.	O
+
+Further	O
+studies	O
+are	O
+necessary	O
+to	O
+investigate	O
+the	O
+role	O
+of	O
+aquatic	O
+bird	B-SPEC
+δ	O
+-	O
+CoVs	O
+in	O
+the	O
+epidemiology	O
+of	O
+δ	O
+-	O
+CoVs	O
+in	O
+swine	B-SPEC
+and	O
+terrestrial	O
+birds	B-SPEC
+.	O
+
+The	O
+studies	O
+of	O
+MERS	O
+patients	O
+with	O
+severe	O
+disease	O
+and	O
+experimentally	O
+infected	O
+animals	B-SPEC
+showed	O
+that	O
+robust	O
+viral	B-PROC
+replication	I-PROC
+and	O
+intensive	O
+proinflammatory	O
+response	O
+in	O
+lung	B-ANAT
+tissues	I-ANAT
+contribute	O
+to	O
+high	O
+pathogenicity	O
+of	O
+MERS	O
+-	O
+CoV	O
+.	O
+We	O
+sought	O
+to	O
+identify	O
+pattern	B-PRGE
+recognition	I-PRGE
+receptor	I-PRGE
+(	O
+PRR	B-PRGE
+)	O
+signaling	B-PROC
+pathway	I-PROC
+(	O
+s	O
+)	O
+that	O
+mediates	O
+the	O
+inflammatory	O
+cascade	O
+in	O
+human	B-SPEC
+macrophages	B-ANAT
+upon	O
+MERS	O
+-	O
+CoV	O
+infection	B-DISO
+.	O
+
+The	O
+cytokine	O
+and	O
+/	O
+or	O
+chemokine	O
+induction	O
+was	O
+significantly	O
+attenuated	O
+by	O
+siRNA	O
+depletion	O
+of	O
+retinoic	B-CHED
+acid	I-CHED
+-	O
+inducible	O
+-	O
+I	O
+-	O
+like	O
+receptors	O
+(	O
+RLR	B-PRGE
+)	O
+or	O
+adaptor	O
+,	O
+indicating	O
+that	O
+RLR	B-PRGE
+signaling	B-PROC
+also	O
+contributed	O
+to	O
+MERS	O
+-	O
+CoV	O
+-	O
+induced	O
+proinflammatory	O
+response	O
+.	O
+
+ABSTRACT	O
+:	O
+The	O
+convergence	O
+of	O
+humans	B-SPEC
+,	O
+animals	B-SPEC
+and	O
+our	O
+shared	O
+environment	O
+results	O
+in	O
+a	O
+dynamic	O
+in	O
+which	O
+the	O
+health	O
+of	O
+each	O
+group	O
+is	O
+inextricably	O
+linked	O
+.	O
+
+In	O
+this	O
+way	O
+,	O
+the	O
+public	O
+health	O
+,	O
+animal	B-SPEC
+health	O
+and	O
+environment	O
+sectors	O
+can	O
+improve	O
+disease	O
+mitigation	O
+measures	O
+,	O
+develop	O
+stronger	O
+and	O
+more	O
+stable	O
+public	O
+and	O
+animal	B-SPEC
+health	O
+services	O
+,	O
+promote	O
+effective	O
+national	O
+communication	O
+strategies	O
+and	O
+improve	O
+One	O
+Health	O
+collaboration	O
+among	O
+all	O
+relevant	O
+sectors	O
+.	O
+
+Egypt	O
+'	O
+s	O
+platform	O
+will	O
+involve	O
+all	O
+sectors	O
+concerned	O
+with	O
+HPAI	B-FUNC
+control	O
+and	O
+combine	O
+all	O
+stakeholders	O
+in	O
+an	O
+integrated	O
+,	O
+holistic	O
+approach	O
+to	O
+improve	O
+the	O
+detection	O
+of	O
+,	O
+response	O
+to	O
+and	O
+control	O
+of	O
+any	O
+threats	O
+at	O
+the	O
+human	B-SPEC
+-	O
+animal	B-SPEC
+-	O
+environment	O
+interface	O
+in	O
+Egypt	O
+.	O
+
+A	O
+systematic	O
+literature	O
+search	O
+provided	O
+no	O
+conclusive	O
+evidence	O
+of	O
+any	O
+pharmacologic	O
+intervention	O
+that	O
+has	O
+consistently	O
+reduced	O
+mortality	O
+in	O
+critically	B-DISO
+ill	I-DISO
+patients	O
+.	O
+
+In	O
+6	O
+out	O
+of	O
+10	O
+patients	O
+a	O
+history	O
+suggestive	O
+for	O
+PVL	O
+-	O
+SA	O
+colonization	O
+in	O
+the	O
+patient	O
+or	O
+close	O
+family	B-SPEC
+members	O
+before	O
+hospital	O
+admission	O
+was	O
+identified	O
+.	O
+
+PROSPERO	B-SPEC
+CRD42019139467	O
+.	O
+
+ABSTRACT	O
+:	O
+Feline	B-SPEC
+infectious	I-DISO
+peritonitis	I-DISO
+is	O
+a	O
+devastating	O
+,	O
+fatal	O
+disease	O
+of	O
+domestic	O
+cats	O
+caused	O
+by	O
+a	O
+pathogenic	O
+mutant	B-DISO
+virus	B-SPEC
+derived	O
+from	O
+the	O
+ubiquitous	O
+feline	B-SPEC
+enteric	B-SPEC
+coronavirus	I-SPEC
+(	O
+FECV	B-SPEC
+).	O
+
+We	O
+investigated	O
+the	O
+mucosal	B-PROC
+immune	I-PROC
+response	I-PROC
+against	O
+FECV	B-SPEC
+in	O
+an	O
+endemically	O
+infected	O
+breeding	B-PROC
+colony	O
+over	O
+a	O
+seven	O
+-	O
+month	O
+period	O
+.	O
+
+A	O
+shift	O
+toward	O
+an	O
+inflammatory	O
+state	O
+in	O
+the	O
+mucosa	O
+was	O
+suggested	O
+by	O
+increased	O
+IL17	B-PRGE
+:	O
+FoxP3	O
+expression	B-PROC
+.	O
+
+However	O
+,	O
+no	O
+histologic	O
+abnormalities	O
+were	O
+observed	O
+,	O
+and	O
+no	O
+shifts	O
+in	O
+lymphocyte	B-ANAT
+subpopulation	O
+phenotype	O
+or	O
+proliferation	B-DISO
+were	O
+noted	O
+.	O
+
+This	O
+study	O
+sought	O
+to	O
+assess	O
+the	O
+community	O
+'	O
+s	O
+compliance	O
+and	O
+practice	O
+of	O
+measures	O
+for	O
+the	O
+prevention	O
+of	O
+respiratory	B-DISO
+infections	I-DISO
+and	O
+discover	O
+their	O
+source	O
+of	O
+health	O
+information	O
+.	O
+
+Health	O
+authorities	O
+should	O
+seize	O
+every	O
+opportunity	O
+to	O
+prevent	O
+respiratory	B-DISO
+infections	I-DISO
+by	O
+adopting	O
+all	O
+evidence	O
+-	O
+based	O
+infection	B-DISO
+control	O
+measures	O
+to	O
+improve	O
+public	O
+awareness	O
+,	O
+attitude	O
+,	O
+and	O
+practice	O
+.	O
+
+TITLE	O
+:	O
+Pathogenicity	O
+of	O
+a	O
+QX	O
+-	O
+like	O
+avian	B-DISO
+infectious	I-DISO
+bronchitis	I-DISO
+virus	B-SPEC
+isolated	O
+in	O
+China	O
+.	O
+
+ABSTRACT	O
+:	O
+Avian	B-SPEC
+infectious	I-DISO
+bronchitis	I-DISO
+is	O
+a	O
+serious	O
+and	O
+highly	O
+contagious	B-DISO
+disease	I-DISO
+caused	O
+by	O
+infectious	B-DISO
+bronchitis	B-DISO
+virus	B-SPEC
+(	O
+IBV	B-SPEC
+).	O
+
+TITLE	O
+:	O
+Transcriptome	O
+analysis	O
+of	O
+PK	O
+-	O
+15	O
+cells	B-COMP
+in	O
+innate	B-DISO
+immune	I-DISO
+response	I-DISO
+to	O
+porcine	B-SPEC
+deltacoronavirus	O
+infection	B-DISO
+.	O
+
+GHRH	B-PRGE
+also	O
+acts	O
+as	O
+a	O
+growth	B-PROC
+and	O
+inflammatory	O
+factor	O
+in	O
+a	O
+variety	O
+of	O
+experimental	O
+models	O
+in	O
+oncology	O
+.	O
+
+In	O
+the	O
+current	O
+study	O
+,	O
+we	O
+used	O
+bovine	B-SPEC
+pulmonary	B-ANAT
+arterial	B-ANAT
+cells	B-COMP
+in	O
+order	B-SPEC
+to	O
+investigate	O
+the	O
+effects	O
+of	O
+GHRH	B-PRGE
+and	O
+its	O
+antagonistic	O
+and	O
+agonistic	O
+analogs	O
+in	O
+key	O
+intracellular	B-COMP
+pathways	B-PROC
+that	O
+regulate	O
+endothelial	B-ANAT
+permeability	O
+.	O
+
+In	O
+contrast	O
+,	O
+both	O
+GHRH	B-PRGE
+and	O
+GHRH	B-PRGE
+agonist	B-CHED
+MR409	O
+exerted	B-PROC
+the	O
+opposite	O
+effects	O
+.	O
+
+Although	O
+our	O
+study	O
+did	O
+not	O
+have	O
+the	O
+precision	O
+to	O
+rule	O
+out	O
+a	O
+small	O
+,	O
+clinically	O
+relevant	O
+effect	O
+,	O
+the	O
+benefit	O
+is	O
+insufficient	O
+to	O
+justify	O
+the	O
+use	O
+of	O
+immune	O
+plasma	B-ANAT
+for	O
+treating	O
+patients	O
+with	O
+severe	O
+influenza	B-PATH
+A	I-PATH
+.	O
+National	O
+Institute	O
+of	O
+Allergy	B-DISO
+and	O
+Infectious	B-DISO
+Diseases	I-DISO
+of	O
+the	O
+National	O
+Institutes	O
+of	O
+Health	O
+(	O
+Bethesda	O
+,	O
+MD	O
+,	O
+USA	O
+).	O
+
+Our	O
+previous	O
+study	O
+revealed	O
+a	O
+potential	O
+correlation	O
+between	O
+integrin	B-PRGE
+αvβ3	I-PRGE
+and	O
+PEDV	B-SPEC
+infection	B-DISO
+.	O
+
+Currently	O
+,	O
+no	O
+licensed	O
+vaccine	O
+or	O
+drug	O
+treatment	O
+is	O
+available	O
+to	O
+treat	O
+patients	O
+infected	O
+with	O
+either	O
+coronavirus	B-SPEC
+.	O
+
+ABSTRACT	O
+:	O
+To	O
+report	O
+an	O
+outbreak	O
+of	O
+measles	B-PATH
+with	O
+epidemiological	O
+link	O
+between	O
+Hong	O
+Kong	O
+International	O
+Airport	O
+(	O
+HKIA	O
+)	O
+and	O
+a	O
+hospital	O
+.	O
+
+Lessons	O
+from	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+(	O
+SARS	B-DISO
+)	O
+and	O
+measles	B-PATH
+outbreaks	O
+suggested	O
+that	O
+an	O
+airport	O
+can	O
+be	O
+a	O
+strategic	O
+epidemic	O
+center	O
+.	O
+
+RESULTS	O
+:	O
+In	O
+total	O
+,	O
+29	O
+HKIA	O
+staff	O
+of	O
+diverse	O
+ranks	O
+and	O
+working	O
+locations	O
+were	O
+infected	O
+with	O
+measles	B-PATH
+within	O
+1	O
+month	O
+.	O
+
+Following	O
+generation	O
+of	O
+RVΔP	O
+-	O
+MERS	O
+/	O
+S1	O
+and	O
+RVΔP	O
+,	O
+our	O
+analysis	O
+revealed	O
+that	O
+they	O
+shared	O
+similar	O
+growth	O
+properties	O
+,	O
+with	O
+the	O
+expression	B-PROC
+of	O
+S1	O
+in	O
+RVΔP	O
+-	O
+MERS	O
+/	O
+S1	O
+-	O
+infected	O
+cells	B-COMP
+confirmed	O
+by	O
+immunofluorescence	O
+and	O
+western	O
+blot	O
+,	O
+and	O
+the	O
+immunogenicity	O
+and	O
+pathogenicity	O
+evaluated	O
+using	O
+mouse	B-SPEC
+infection	B-DISO
+experiments	O
+.	O
+
+Diarrhea	O
+occurred	O
+more	O
+significantly	O
+(	O
+P	O
+<	O
+0	O
+.	O
+0001	O
+)	O
+in	O
+animals	B-SPEC
+less	O
+than	O
+21	O
+days	O
+old	O
+and	O
+mainly	O
+on	O
+those	O
+receiving	O
+milk	O
+through	O
+automatic	O
+feeders	O
+(	O
+P	O
+<	O
+0	O
+.	O
+001	O
+).	O
+
+TITLE	O
+:	O
+Circular	O
+RNA	O
+CircEZH2	O
+Suppresses	O
+Transmissible	O
+Gastroenteritis	B-DISO
+Coronavirus	B-SPEC
+-	O
+induced	O
+Opening	O
+of	O
+Mitochondrial	O
+Permeability	O
+Transition	B-DISO
+Pore	B-COMP
+via	O
+Targeting	B-PROC
+MiR	B-PRGE
+-	I-PRGE
+22	I-PRGE
+in	O
+IPEC	O
+-	O
+J2	O
+.	O
+
+Activation	O
+of	O
+NF	O
+-	O
+κB	O
+is	O
+an	O
+important	O
+factor	O
+for	O
+mitochondrial	B-DISO
+damage	I-DISO
+.	O
+
+Inhibitor	B-CHED
+of	O
+NF	O
+-	O
+κB	O
+increased	O
+TGEV	B-SPEC
+-	O
+induced	O
+mPTP	B-CHED
+opening	O
+.	O
+
+The	O
+data	O
+revealed	O
+that	O
+TGEV	B-SPEC
+-	O
+induced	O
+mPTP	B-PRGE
+opening	O
+was	O
+regulated	O
+via	O
+two	O
+pathways	B-PROC
+:	O
+circEZH2	B-PRGE
+/	I-PRGE
+miR	I-PRGE
+-	I-PRGE
+22	I-PRGE
+/	O
+HK2	B-FUNC
+axis	B-SPEC
+and	O
+circEZH2	B-PRGE
+/	I-PRGE
+miR	I-PRGE
+-	I-PRGE
+22	I-PRGE
+/	O
+IL	B-FUNC
+-	I-FUNC
+6	I-FUNC
+/	O
+NF	O
+-	O
+κB	O
+axis	B-SPEC
+.	O
+
+TITLE	O
+:	O
+Isolation	O
+and	O
+growth	B-PROC
+characterization	O
+of	O
+novel	O
+full	O
+length	O
+and	O
+deletion	O
+mutant	B-DISO
+human	B-SPEC
+MERS	O
+-	O
+CoV	O
+strains	O
+from	O
+clinical	O
+specimens	O
+collected	O
+during	O
+2015	O
+.	O
+
+TITLE	O
+:	O
+An	O
+in	O
+vivo	O
+cell	B-COMP
+-	O
+based	O
+assay	O
+for	O
+investigating	O
+the	O
+specific	O
+interaction	O
+between	O
+the	O
+SARS	B-DISO
+-	I-PRGE
+CoV	I-PRGE
+N	I-PRGE
+-	I-PRGE
+protein	I-PRGE
+and	O
+its	O
+viral	O
+RNA	O
+packaging	O
+sequence	O
+.	O
+
+ABSTRACT	O
+:	O
+The	O
+SARS	B-PRGE
+-	I-PRGE
+CoV	I-PRGE
+nucleocapsid	B-COMP
+(	I-PRGE
+N	I-PRGE
+)	I-PRGE
+protein	B-CHED
+serves	O
+multiple	O
+functions	O
+in	O
+viral	B-PROC
+replication	I-PROC
+,	O
+transcription	B-PROC
+,	O
+and	O
+assembly	O
+of	O
+the	O
+viral	B-COMP
+genome	I-COMP
+complex	O
+.	O
+
+On	O
+the	O
+3rd	O
+day	O
+,	O
+GAS	B-PRGE
+was	O
+isolated	O
+from	O
+blood	O
+culture	O
+.	O
+
+TITLE	O
+:	O
+Performance	O
+of	O
+CURB	B-DISO
+-	O
+65	O
+in	O
+predicting	O
+mortality	O
+of	O
+patients	O
+with	O
+community	O
+-	O
+acquired	O
+pneumonia	B-DISO
+in	O
+Saudi	O
+Arabia	O
+.	O
+
+The	O
+mortality	O
+rates	O
+for	O
+CURB	B-DISO
+-	O
+65	O
+scores	O
+0	O
+,	O
+1	O
+,	O
+2	O
+,	O
+3	O
+,	O
+and	O
+4	O
+/	O
+5	O
+were	O
+1	O
+.	O
+8	O
+%,	O
+4	O
+.	O
+3	O
+%,	O
+10	O
+.	O
+2	O
+%,	O
+14	O
+%,	O
+and	O
+21	O
+.	O
+9	O
+%,	O
+respectively	O
+.	O
+
+ABSTRACT	O
+:	O
+Respiratory	B-DISO
+tract	I-DISO
+infections	I-DISO
+are	O
+common	O
+in	O
+the	O
+context	O
+of	O
+the	O
+Hajj	O
+pilgrimage	O
+and	O
+respiratory	O
+pathogens	O
+can	O
+be	O
+transmitted	B-DISO
+via	O
+contact	O
+with	O
+contaminated	O
+surfaces	O
+.	O
+
+Among	O
+the	O
+positive	O
+samples	O
+,	O
+Klebsiella	B-SPEC
+pneumoniae	I-SPEC
+was	O
+the	O
+bacterium	B-SPEC
+most	O
+frequently	O
+tested	O
+positive	O
+(	O
+57	O
+.	O
+1	O
+%),	O
+followed	O
+by	O
+Streptococcus	B-SPEC
+pneumoniae	I-SPEC
+(	O
+12	O
+.	O
+9	O
+%),	O
+Staphylococcus	B-SPEC
+aureus	I-SPEC
+(	O
+10	O
+.	O
+0	O
+%)	O
+and	O
+Haemophilus	B-SPEC
+influenzae	I-SPEC
+(	O
+7	O
+.	O
+1	O
+%).	O
+
+Moreover	O
+,	O
+other	O
+p200	B-PRGE
+family	I-PRGE
+proteins	B-CHED
+that	O
+possess	B-DISO
+HIN	O
+domain	O
+could	O
+also	O
+inhibit	O
+the	O
+IRF7	B-PRGE
+-	O
+mediated	O
+type	O
+I	O
+interferons	O
+.	O
+
+These	O
+results	O
+reveal	O
+that	O
+,	O
+besides	O
+the	O
+positive	O
+regulation	O
+function	O
+in	O
+type	B-PRGE
+I	I-PRGE
+interferon	I-PRGE
+response	O
+at	O
+the	O
+early	O
+stage	O
+of	O
+DNA	B-DISO
+virus	I-DISO
+infection	I-DISO
+,	O
+the	O
+interferon	B-PRGE
+-	O
+inducible	O
+p200	B-PRGE
+family	I-PRGE
+proteins	B-CHED
+such	O
+as	O
+IFI204	B-PRGE
+could	O
+also	O
+negatively	O
+regulate	O
+the	O
+IRF7	B-PRGE
+-	O
+mediated	O
+type	B-PRGE
+I	I-PRGE
+interferon	I-PRGE
+response	O
+after	O
+RNA	B-DISO
+virus	I-DISO
+infection	I-DISO
+to	O
+avoid	O
+unnecessary	O
+host	B-COMP
+damage	O
+from	O
+hyper	O
+-	O
+inflammatory	B-DISO
+responses	I-DISO
+.	O
+
+A	O
+similar	O
+approach	O
+could	O
+be	O
+adopted	O
+in	O
+other	O
+acute	O
+conditions	O
+with	O
+refractory	O
+eosinophilic	O
+inflammation	B-DISO
+where	O
+standard	O
+steroid	B-CHED
+therapy	O
+has	O
+failed	O
+.	O
+
+The	O
+virus	B-SPEC
+interference	O
+phenomenon	O
+goes	B-SPEC
+against	O
+the	O
+basic	O
+assumption	O
+of	O
+the	O
+test	O
+-	O
+negative	O
+vaccine	O
+effectiveness	O
+study	O
+that	O
+vaccination	O
+does	O
+not	O
+change	O
+the	O
+risk	O
+of	O
+infection	B-DISO
+with	O
+other	O
+respiratory	O
+illness	O
+,	O
+thus	O
+potentially	O
+biasing	O
+vaccine	O
+effectiveness	O
+results	O
+in	O
+the	O
+positive	O
+direction	O
+.	O
+
+Receipt	O
+of	O
+influenza	B-DISO
+vaccination	O
+was	O
+not	O
+associated	O
+with	O
+virus	B-SPEC
+interference	O
+among	O
+our	O
+population	O
+.	O
+
+Yet	O
+,	O
+in	O
+contrast	O
+to	O
+most	O
+other	O
+childhood	O
+infections	B-DISO
+as	O
+well	O
+as	O
+other	O
+viral	O
+and	O
+bacterial	B-DISO
+diseases	I-DISO
+,	O
+prophylactic	O
+vaccines	O
+or	O
+effective	O
+antiviral	B-CHED
+treatments	O
+against	O
+viral	O
+respiratory	B-DISO
+infections	I-DISO
+are	O
+either	O
+still	O
+not	O
+available	O
+,	O
+or	O
+provide	O
+only	O
+limited	O
+protection	O
+.	O
+
+The	O
+affected	O
+innate	B-DISO
+immune	I-DISO
+response	I-DISO
+also	O
+impacts	O
+subsequent	O
+adaptive	O
+responses	O
+,	O
+and	O
+therefore	O
+viral	O
+innate	O
+immune	B-PROC
+evasion	I-PROC
+often	O
+undermines	O
+fully	O
+protective	O
+immunity	B-PROC
+.	O
+
+In	O
+this	O
+review	O
+,	O
+innate	B-DISO
+immune	I-DISO
+responses	I-DISO
+relevant	O
+for	O
+respiratory	O
+viruses	B-SPEC
+with	O
+an	O
+RNA	O
+genome	O
+will	O
+briefly	O
+be	O
+summarized	O
+,	O
+and	O
+viral	O
+innate	O
+immune	B-PROC
+evasion	I-PROC
+based	O
+on	O
+shielding	O
+viral	O
+RNA	O
+species	B-SPEC
+away	O
+from	O
+cellular	B-COMP
+innate	O
+immune	O
+sensors	O
+will	O
+be	O
+discussed	O
+from	O
+different	O
+angles	O
+.	O
+
+TITLE	O
+:	O
+StatPearls	O
+ABSTRACT	O
+:	O
+Systemic	B-DISO
+inflammatory	I-DISO
+response	I-DISO
+syndrome	I-DISO
+(	O
+SIRS	B-DISO
+)	O
+is	O
+an	O
+exaggerated	O
+defense	B-PROC
+response	I-PROC
+of	O
+the	O
+body	B-ANAT
+to	O
+a	O
+noxious	O
+stressor	O
+(	O
+infection	B-DISO
+,	O
+trauma	O
+,	O
+surgery	O
+,	O
+acute	O
+inflammation	B-DISO
+,	O
+ischemia	B-DISO
+or	O
+reperfusion	O
+,	O
+or	O
+malignancy	B-DISO
+to	O
+name	B-SPEC
+a	O
+few	O
+)	O
+to	O
+localize	O
+and	O
+then	O
+eliminate	O
+the	O
+endogenous	O
+or	O
+exogenous	O
+source	O
+of	O
+the	O
+insult	O
+.	O
+
+In	O
+particular	O
+,	O
+concerns	O
+and	O
+precautions	O
+have	O
+increased	O
+regarding	O
+the	O
+use	O
+of	O
+aerosol	O
+-	O
+generating	O
+medical	O
+procedures	O
+when	O
+treating	O
+patients	O
+with	O
+such	O
+viral	B-DISO
+infections	I-DISO
+.	O
+
+In	O
+spite	O
+of	O
+increasing	O
+associations	O
+between	O
+aerosol	O
+-	O
+generating	O
+medical	O
+procedures	O
+and	O
+the	O
+nosocomial	O
+transmission	O
+of	O
+viruses	B-SPEC
+,	O
+we	O
+still	O
+have	O
+a	O
+poor	O
+understanding	O
+of	O
+the	O
+risks	O
+of	O
+specific	O
+procedures	O
+and	O
+viruses	B-SPEC
+.	O
+
+TITLE	O
+:	O
+Generation	O
+of	O
+a	O
+Nebulizable	O
+CDR	B-PRGE
+-	O
+Modified	O
+MERS	O
+-	O
+CoV	O
+Neutralizing	O
+Human	B-PRGE
+Antibody	B-COMP
+.	O
+
+ABSTRACT	O
+:	O
+Middle	O
+East	O
+respiratory	O
+syndrome	O
+coronavirus	B-SPEC
+(	O
+MERS	O
+-	O
+CoV	O
+)	O
+induces	O
+severe	O
+aggravating	O
+respiratory	B-DISO
+failure	I-DISO
+in	O
+infected	O
+patients	O
+,	O
+frequently	O
+resulting	O
+in	O
+mechanical	O
+ventilation	O
+.	O
+
+The	O
+objective	O
+of	O
+this	O
+study	O
+was	O
+to	O
+investigate	O
+the	O
+presence	O
+of	O
+equine	O
+coronavirus	B-SPEC
+(	O
+ECoV	O
+)	O
+in	O
+clinical	O
+samples	O
+submitted	O
+to	O
+a	O
+diagnostic	O
+laboratory	O
+in	O
+Ireland	O
+.	O
+
+Identifying	O
+the	O
+underlying	O
+mechanisms	O
+of	O
+variability	O
+in	O
+pathogenicity	O
+is	O
+a	O
+critical	O
+task	O
+for	O
+understanding	O
+influenza	B-SPEC
+virus	B-DISO
+infection	I-DISO
+and	O
+effective	O
+management	O
+of	O
+highly	O
+pathogenic	O
+influenza	B-SPEC
+virus	B-DISO
+disease	I-DISO
+.	O
+
+We	O
+confirmed	O
+that	O
+this	O
+trend	O
+persisted	O
+in	O
+a	O
+distinct	O
+virus	B-SPEC
+:	O
+
+Severe	B-DISO
+Acute	I-DISO
+Respiratory	I-DISO
+Syndrome	I-DISO
+Coronavirus	B-SPEC
+(	O
+SARS	B-DISO
+).	O
+
+The	O
+role	O
+of	O
+epidermal	B-PRGE
+growth	B-PROC
+factor	I-PRGE
+receptor	I-PRGE
+(	O
+EGFR	B-FUNC
+)	O
+in	O
+influenza	B-DISO
+pathogenesis	B-DISO
+,	O
+one	O
+of	O
+the	O
+bottleneck	O
+regulators	O
+with	O
+corroborating	O
+signals	O
+across	O
+transcript	O
+and	O
+protein	B-PROC
+expression	B-PROC
+data	O
+,	O
+was	O
+tested	O
+and	O
+validated	O
+in	O
+additional	O
+mouse	B-SPEC
+infection	B-DISO
+experiments	O
+.	O
+
+The	O
+A	O
+(	O
+H1N1	O
+)	O
+pdm09	O
+genome	O
+was	O
+confirmed	O
+by	O
+polymerase	O
+chain	O
+reaction	O
+(	O
+PCR	O
+)	O
+on	O
+nasopharyngeal	B-ANAT
+specimen	O
+swabs	O
+prior	O
+to	O
+administration	O
+of	O
+IV	O
+zanamivir	B-CHED
+at	O
+a	O
+dose	O
+of	O
+600	O
+mg	O
+twice	O
+daily	O
+.	O
+
+In	O
+addition	O
+,	O
+the	O
+patients	O
+were	O
+managed	O
+for	O
+concomitant	O
+multidrug	O
+-	O
+resistant	O
+bacterial	B-DISO
+infections	I-DISO
+,	O
+with	O
+infection	B-DISO
+resolution	O
+confirmed	O
+with	O
+blood	B-ANAT
+cultures	O
+.	O
+
+We	O
+completed	O
+a	O
+screen	O
+of	O
+mice	B-SPEC
+from	O
+the	O
+Collaborative	O
+Cross	O
+(	O
+CC	O
+)	O
+that	O
+we	O
+infected	O
+with	O
+influenza	B-DISO
+,	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+-	O
+coronavirus	B-SPEC
+,	O
+and	O
+West	B-DISO
+Nile	I-DISO
+virus	I-DISO
+.	O
+
+TITLE	O
+:	O
+Use	O
+of	O
+glucocorticoids	B-CHED
+in	O
+the	O
+critical	O
+care	O
+setting	O
+:	O
+Science	O
+and	O
+clinical	O
+evidence	O
+.	O
+
+The	O
+organisms	O
+identified	O
+are	O
+influenza	B-SPEC
+virus	I-SPEC
+A	O
+,	O
+influenza	B-SPEC
+virus	I-SPEC
+A	O
+pdmH1N1	O
+(	O
+2009	O
+),	O
+influenza	B-SPEC
+virus	I-SPEC
+A	O
+H3N2	B-CHED
+,	O
+influenza	B-SPEC
+virus	I-SPEC
+B	O
+,	O
+adenovirus	B-DISO
+,	O
+boca	B-DISO
+virus	B-SPEC
+,	O
+rhinovirus	B-SPEC
+,	O
+parainfluenza	B-DISO
+virus	B-SPEC
+,	O
+coronavirus	B-SPEC
+,	O
+respiratory	B-SPEC
+syncytial	I-SPEC
+virus	I-SPEC
+,	O
+human	B-SPEC
+metapneumovirus	I-SPEC
+,	O
+Mycoplasma	B-SPEC
+pneumoniae	I-SPEC
+,	O
+and	O
+Chlamydia	B-SPEC
+.	O
+
+This	O
+study	O
+characterised	O
+CoV	O
+strains	O
+from	O
+dairy	O
+cattle	B-SPEC
+herds	O
+in	O
+the	O
+state	O
+of	O
+Rio	O
+de	O
+Janeiro	O
+,	O
+Brazil	O
+,	O
+and	O
+indicated	O
+that	O
+this	O
+virus	B-SPEC
+is	O
+spread	O
+among	O
+the	O
+state	O
+herds	O
+.	O
+
+PHE	B-CHED
+'	O
+s	O
+manual	O
+EI	O
+process	O
+quickly	O
+and	O
+accurately	O
+detected	O
+global	O
+public	O
+health	O
+threats	O
+at	O
+the	O
+earliest	O
+stages	O
+and	O
+allowed	O
+for	O
+monitoring	O
+of	O
+events	O
+as	O
+they	O
+evolved	O
+.	O
+
+Moreover	O
+,	O
+those	O
+treated	O
+with	O
+PMO	O
+experienced	O
+a	O
+lower	O
+lung	B-ANAT
+wet	O
+/	O
+dry	O
+ratio	O
+and	O
+less	O
+severe	O
+lung	B-ANAT
+pathology	B-DISO
+,	O
+indicating	O
+a	O
+surprising	O
+improvement	O
+in	O
+lung	B-ANAT
+health	O
+.	O
+
+Overall	O
+,	O
+this	O
+study	O
+demonstrates	O
+the	O
+ability	O
+of	O
+PMO	O
+to	O
+deliver	O
+life	O
+-	O
+sustaining	O
+supplemental	O
+oxygen	B-CHED
+to	O
+rats	B-SPEC
+suffering	B-DISO
+from	O
+ARDS	B-DISO
+and	O
+warrants	O
+further	O
+work	O
+toward	O
+clinical	O
+translation	B-PROC
+.	O
+
+During	O
+dacryocystorhinostomy	O
+,	O
+tissue	B-ANAT
+biopsy	B-ANAT
+sample	I-ANAT
+(	O
+2	O
+×	O
+2	O
+mm	O
+)	O
+was	O
+taken	O
+from	O
+the	O
+junction	O
+area	O
+of	O
+the	O
+lacrimal	B-ANAT
+sac	I-ANAT
+and	O
+nasolacrimal	B-ANAT
+duct	I-ANAT
+.	O
+
+Our	O
+data	O
+indicate	O
+that	O
+GILT	B-PRGE
+is	O
+a	O
+novel	O
+antiviral	B-CHED
+ISG	O
+that	O
+specifically	O
+inhibits	O
+the	O
+entry	O
+of	O
+selected	O
+enveloped	O
+RNA	O
+viruses	B-SPEC
+in	O
+lysosomes	B-COMP
+
+On	O
+the	O
+basis	O
+of	O
+its	O
+success	O
+in	O
+that	O
+population	O
+,	O
+ECMO	O
+began	O
+to	O
+be	O
+used	O
+in	O
+the	O
+early	O
+1970s	O
+to	O
+treat	O
+adult	O
+hypoxemic	O
+respiratory	B-DISO
+failure	I-DISO
+.	O
+
+Adult	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+(	O
+ARDS	B-DISO
+)	O
+is	O
+often	O
+the	O
+final	O
+common	O
+pathway	O
+of	O
+various	O
+pathologies	O
+affecting	O
+adults	O
+and	O
+causing	O
+hypoxemic	O
+respiratory	B-DISO
+failure	I-DISO
+.	O
+
+ECMO	O
+is	O
+an	O
+increasingly	O
+important	O
+tool	O
+for	O
+managing	O
+severe	O
+respiratory	B-DISO
+failure	I-DISO
+that	O
+is	O
+refractory	O
+to	O
+conventional	O
+therapies	O
+.	O
+
+TITLE	O
+:	O
+Waking	B-PROC
+Up	O
+Blind	B-DISO
+in	O
+the	O
+ICU	O
+:	O
+A	O
+Case	O
+Report	O
+of	O
+Ischemic	B-DISO
+Optic	I-DISO
+Neuropathy	I-DISO
+in	O
+a	O
+Burn	O
+Patient	O
+.	O
+
+These	O
+nanostructures	O
+showed	O
+a	O
+concentration	O
+-	O
+dependent	O
+virus	B-SPEC
+inactivation	B-DISO
+with	O
+an	O
+estimated	O
+EC	O
+
+Among	O
+survivors	O
+,	O
+77	O
+.	O
+1	O
+%	O
+of	O
+pediatric	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+patients	O
+had	O
+functional	O
+disability	O
+at	O
+discharge	B-ANAT
+versus	O
+30	O
+.	O
+7	O
+%	O
+of	O
+patients	O
+without	O
+pediatric	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+patients	O
+(	O
+p	O
+<	O
+0	O
+.	O
+001	O
+),	O
+and	O
+only	O
+17	O
+.	O
+5	O
+%	O
+of	O
+pediatric	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+patients	O
+discharged	O
+home	O
+without	O
+ongoing	O
+care	O
+versus	O
+86	O
+.	O
+4	O
+%	O
+of	O
+patients	O
+without	O
+pediatric	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+(	O
+adjusted	O
+relative	O
+risk	O
+,	O
+1	O
+.	O
+5	O
+;	O
+1	O
+.	O
+1	O
+-	O
+2	O
+.	O
+1	O
+).	O
+
+Incidence	O
+and	O
+mortality	O
+associated	O
+with	O
+pediatric	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+following	O
+traumatic	O
+injury	O
+are	O
+substantially	O
+higher	O
+than	O
+previously	O
+recognized	O
+,	O
+and	O
+pediatric	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+development	B-PROC
+is	O
+associated	O
+with	O
+high	O
+risk	O
+of	O
+poor	O
+outcome	O
+even	O
+after	O
+adjustment	O
+for	O
+underlying	O
+injury	O
+type	O
+and	O
+severity	O
+.	O
+
+Viral	B-COMP
+nucleocapsid	I-COMP
+proteins	B-CHED
+are	O
+inevitable	O
+for	O
+genome	O
+encapsidation	O
+and	O
+replication	O
+.	O
+
+We	O
+present	O
+the	O
+case	O
+of	O
+an	O
+8	O
+-	O
+year	O
+-	O
+old	O
+girl	O
+who	O
+developed	O
+acute	O
+decompensated	O
+cardiac	B-ANAT
+,	O
+respiratory	O
+,	O
+and	O
+renal	B-DISO
+failures	I-DISO
+because	O
+of	O
+the	O
+occlusion	B-DISO
+of	O
+the	O
+descending	B-ANAT
+aorta	I-ANAT
+secondary	O
+to	O
+Takayasu	B-DISO
+arteritis	I-DISO
+(	O
+TA	O
+).	O
+
+TITLE	O
+:	O
+Feline	B-SPEC
+coronavirus	B-SPEC
+-	O
+associated	O
+myocarditis	B-DISO
+in	O
+a	O
+domestic	O
+longhair	O
+cat	B-SPEC
+.	O
+
+Immunohistochemistry	O
+performed	O
+on	O
+the	O
+myocardium	B-ANAT
+revealed	O
+feline	B-SPEC
+coronavirus	B-SPEC
+-	O
+positive	O
+macrophages	B-ANAT
+associated	O
+with	O
+pyogranulomatous	O
+lesions	O
+,	O
+justifying	O
+a	O
+diagnosis	O
+of	O
+feline	B-SPEC
+coronavirus	B-SPEC
+-	O
+associated	O
+myocarditis	B-DISO
+.	O
+
+To	O
+the	O
+authors	O
+'	O
+knowledge	O
+,	O
+the	O
+case	O
+described	O
+here	O
+represents	O
+the	O
+first	O
+published	O
+report	O
+of	O
+feline	B-SPEC
+coronavirus	B-SPEC
+-	O
+associated	O
+myocarditis	B-DISO
+.	O
+
+TITLE	O
+:	O
+Molecular	O
+epidemiology	O
+of	O
+respiratory	O
+viruses	B-SPEC
+in	O
+commercial	O
+chicken	B-SPEC
+flocks	O
+in	O
+Pakistan	O
+from	O
+2014	O
+through	O
+to	O
+2016	O
+.	O
+
+We	O
+characterized	O
+H9	B-PRGE
+AIV	I-PRGE
+of	O
+the	O
+G1	O
+lineage	O
+,	O
+genotype	O
+VII	O
+AAVV	O
+-	O
+1	O
+,	O
+GI	O
+-	O
+13	O
+IBV	B-SPEC
+,	O
+and	O
+type	B-PRGE
+B	I-PRGE
+aMPV	I-PRGE
+strains	O
+with	O
+very	O
+little	O
+genetic	O
+variability	O
+in	O
+the	O
+2	O
+-	O
+year	O
+study	O
+period	O
+.	O
+
+Histopathologically	O
+,	O
+jejunum	B-ANAT
+showed	O
+skipping	O
+lesion	O
+of	O
+micro	O
+-	O
+abscesses	B-DISO
+in	O
+crypts	O
+.	O
+
+The	O
+BCoV	B-PRGE
+antigen	I-PRGE
+distribution	O
+was	O
+prominent	O
+within	O
+the	O
+necrotic	B-PROC
+crypts	O
+in	O
+the	O
+jejunum	B-ANAT
+and	O
+cryptic	O
+micro	O
+-	O
+abscesses	B-DISO
+in	O
+the	O
+colon	B-ANAT
+and	O
+ileum	B-ANAT
+.	O
+
+We	O
+abstracted	O
+data	O
+on	O
+demography	O
+,	O
+vital	O
+signs	O
+,	O
+associated	O
+conditions	O
+presented	O
+on	O
+admission	O
+,	O
+pre	O
+-	O
+existing	O
+chronic	B-DISO
+diseases	I-DISO
+,	O
+treatment	O
+,	O
+and	O
+vital	O
+status	O
+.	O
+
+All	O
+but	O
+two	O
+patients	O
+were	O
+treated	O
+with	O
+Ribavirin	B-CHED
+plus	O
+Interferon	O
+.	O
+
+TITLE	O
+:	O
+LiverTox	O
+:	O
+Clinical	O
+and	O
+Research	O
+Information	O
+on	O
+Drug	B-DISO
+-	I-DISO
+Induced	I-DISO
+Liver	I-DISO
+Injury	I-DISO
+ABSTRACT	O
+:	O
+The	O
+opioids	O
+are	O
+a	O
+large	O
+class	O
+of	O
+medications	O
+related	O
+in	O
+structure	O
+to	O
+the	O
+natural	O
+plant	B-SPEC
+alkaloids	B-CHED
+found	O
+in	O
+opium	O
+that	O
+are	O
+derived	O
+from	O
+the	O
+resin	O
+of	O
+the	O
+opium	B-SPEC
+poppy	I-SPEC
+,	O
+Papaver	B-SPEC
+somniferum	I-SPEC
+.	O
+
+Synthetic	O
+derivatives	O
+include	O
+heroin	B-CHED
+,	O
+fentanyl	B-CHED
+,	O
+hydromorphone	B-CHED
+,	O
+methadone	B-CHED
+,	O
+buprenorphine	B-CHED
+and	O
+others	O
+.	O
+
+These	O
+receptors	O
+are	O
+found	O
+predominantly	O
+in	O
+the	O
+central	B-ANAT
+nervous	I-ANAT
+system	I-ANAT
+,	O
+brain	B-ANAT
+and	O
+spinal	B-ANAT
+column	I-ANAT
+,	O
+but	O
+are	O
+also	O
+present	O
+on	O
+vascular	B-ANAT
+,	O
+cardiac	B-ANAT
+,	O
+lung	B-ANAT
+,	O
+gut	B-ANAT
+and	O
+even	O
+peripheral	B-ANAT
+blood	I-ANAT
+mononuclear	I-ANAT
+cells	I-ANAT
+.	O
+
+Opioids	O
+are	O
+rare	O
+causes	O
+of	O
+drug	B-DISO
+induced	I-DISO
+liver	I-DISO
+disease	I-DISO
+and	O
+are	O
+not	O
+mentioned	O
+in	O
+large	O
+case	O
+series	O
+of	O
+clinically	O
+apparent	O
+liver	B-ANAT
+injury	O
+caused	O
+by	O
+medications	O
+.	O
+
+In	O
+physiological	O
+,	O
+pain	O
+relieving	O
+doses	O
+,	O
+opioids	O
+have	O
+not	O
+been	O
+implicated	O
+in	O
+causing	O
+clinically	O
+apparent	O
+liver	B-ANAT
+injury	O
+,	O
+acute	O
+liver	B-DISO
+failure	I-DISO
+,	I-DISO
+chronic	I-DISO
+hepatitis	B-DISO
+or	O
+vanishing	B-DISO
+bile	I-DISO
+duct	I-DISO
+syndrome	I-DISO
+.	O
+
+These	O
+combinations	O
+are	O
+commonly	O
+used	O
+for	O
+moderate	O
+to	O
+moderately	O
+severe	B-DISO
+pain	I-DISO
+and	O
+can	O
+lead	O
+to	O
+abuse	B-DISO
+.	O
+
+Hydromorphone	B-CHED
+.	O
+
+Morphine	B-CHED
+.	O
+
+Two	O
+third	O
+generation	O
+penicillins	B-CHED
+are	O
+available	O
+in	O
+the	O
+United	O
+States	O
+:	O
+ampicillin	B-CHED
+(	O
+am	O
+""""	O
+pi	O
+sil	B-DISO
+'	O
+in	O
+)	O
+and	O
+amoxicillin	B-CHED
+(	O
+a	O
+mox	O
+""""	O
+i	O
+sil	B-DISO
+'	O
+in	O
+).	O
+
+Here	O
+we	O
+report	O
+for	O
+the	O
+first	O
+time	O
+that	O
+only	O
+a	O
+small	O
+proportion	O
+of	O
+MERS	B-PRGE
+-	I-PRGE
+CoV	I-PRGE
+receptor	I-PRGE
+-	I-PRGE
+binding	I-PRGE
+domain	I-PRGE
+positive	O
+(	O
+RBD	O
+)	O
+of	O
+spike	O
+protein	B-CHED
+positive	O
+camel	B-SPEC
+sera	B-COMP
+in	O
+Kenya	O
+were	O
+also	O
+seropositive	O
+to	O
+MERS	O
+-	O
+CoV	O
+nucleocapsid	B-COMP
+(	O
+NP	O
+).	O
+
+In	O
+contrast	O
+,	O
+many	O
+of	O
+them	O
+contain	O
+antibodies	B-COMP
+against	O
+bat	B-ENZY
+HKU8	O
+-	O
+related	O
+(	O
+HKU8r	O
+)-	O
+CoVs	O
+.	O
+
+These	O
+findings	O
+may	O
+indicate	O
+co	O
+-	O
+infection	O
+with	O
+MERS	O
+-	O
+CoV	O
+and	O
+a	O
+HKU8r	O
+-	O
+CoV	O
+in	O
+camels	B-SPEC
+.	O
+
+TITLE	O
+:	O
+Successful	O
+Ventilation	O
+of	O
+Acute	B-DISO
+Respiratory	I-DISO
+Distress	I-DISO
+Syndrome	I-DISO
+Complicated	O
+by	O
+Pneumothorax	B-DISO
+Using	O
+Airway	O
+Pressure	O
+Release	B-PATH
+Ventilation	O
+:	O
+A	O
+Case	O
+Report	O
+.	O
+
+TITLE	O
+:	O
+The	O
+respiratory	O
+virome	O
+and	O
+exacerbations	O
+in	O
+patients	O
+with	O
+chronic	B-DISO
+obstructive	I-DISO
+pulmonary	B-ANAT
+disease	I-DISO
+.	O
+
+TITLE	O
+:	O
+The	O
+human	B-PRGE
+coronavirus	I-PRGE
+HCoV	B-SPEC
+-	I-SPEC
+229E	I-SPEC
+S	I-PRGE
+-	I-PRGE
+protein	B-CHED
+structure	O
+and	O
+receptor	B-FUNC
+binding	I-FUNC
+.	O
+
+Reported	O
+are	O
+the	O
+X	O
+-	O
+ray	B-SPEC
+crystal	B-ANAT
+structures	O
+of	O
+Class	B-SPEC
+III	O
+-	O
+V	O
+RBDs	O
+in	O
+complex	O
+with	O
+human	B-PRGE
+aminopeptidase	B-ENZY
+N	I-ENZY
+(	O
+hAPN	O
+),	O
+as	O
+well	O
+as	O
+the	O
+electron	O
+cryomicroscopy	O
+structure	O
+of	O
+the	O
+229E	B-PRGE
+S	I-PRGE
+-	I-PRGE
+protein	I-PRGE
+.	O
+
+TITLE	O
+:	O
+The	O
+S2	O
+Subunit	O
+of	O
+QX	O
+-	O
+type	O
+Infectious	B-DISO
+Bronchitis	B-DISO
+Coronavirus	B-SPEC
+Spike	O
+Protein	B-CHED
+Is	O
+an	O
+Essential	O
+Determinant	O
+of	O
+Neurotropism	O
+.	O
+
+ABSTRACT	O
+:	O
+Some	O
+coronaviruses	O
+(	O
+CoVs	O
+)	O
+have	O
+an	O
+extra	O
+furin	B-PRGE
+cleavage	B-PROC
+site	I-PRGE
+(	O
+RRKR	O
+/	O
+S	O
+,	O
+furin	B-PRGE
+-	I-PRGE
+S2	I-PRGE
+'	I-PRGE
+site	I-PRGE
+)	O
+upstream	O
+of	O
+the	O
+fusion	O
+peptide	B-CHED
+in	O
+the	O
+spike	O
+protein	B-CHED
+,	O
+which	O
+plays	O
+roles	O
+in	O
+virion	B-COMP
+adsorption	O
+and	O
+fusion	O
+.	O
+
+ABSTRACT	O
+:	O
+In	O
+2015	O
+,	O
+South	O
+Korea	O
+experienced	O
+an	O
+outbreak	O
+of	O
+Middle	O
+East	O
+respiratory	O
+syndrome	B-DISO
+(	O
+MERS	B-DISO
+),	O
+and	O
+our	O
+hospital	O
+experienced	O
+a	O
+nosocomial	O
+MERS	B-DISO
+infection	B-DISO
+.	O
+
+MERS	O
+were	O
+transmitted	B-DISO
+to	O
+them	O
+indirectly	O
+by	O
+staff	O
+who	O
+cared	O
+for	O
+the	O
+index	O
+patient	O
+.	O
+
+ABSTRACT	O
+:	O
+Hydrofluoric	B-CHED
+acid	I-CHED
+(	O
+HF	O
+)	O
+is	O
+one	O
+of	O
+the	O
+most	O
+common	O
+causes	O
+of	O
+chemical	O
+burns	O
+.	O
+
+As	O
+a	O
+result	O
+,	O
+HF	O
+burns	O
+are	O
+often	O
+severe	O
+even	O
+if	O
+they	O
+involve	O
+a	O
+small	O
+area	O
+of	O
+the	O
+skin	B-ANAT
+.	O
+
+A	O
+24	O
+-	O
+year	O
+-	O
+old	O
+man	B-CHED
+suffered	B-DISO
+from	O
+extensive	O
+hydrofluoric	B-CHED
+acid	I-CHED
+burns	O
+covering	O
+60	O
+%	O
+of	O
+the	O
+total	B-ANAT
+body	I-ANAT
+surface	I-ANAT
+area	O
+(	O
+TBSA	O
+),	O
+including	O
+deep	O
+second	O
+degree	O
+burns	O
+on	O
+47	O
+%	O
+and	O
+third	O
+degree	O
+burns	O
+on	O
+13	O
+%	O
+of	O
+the	O
+TBSA	O
+,	O
+after	O
+he	O
+fell	O
+into	O
+a	O
+pickling	O
+pool	O
+containing	O
+15	O
+%	O
+HF	O
+.	O
+
+Ventricular	B-DISO
+fibrillation	I-DISO
+occurred	O
+9	O
+times	O
+within	O
+the	O
+first	O
+2	O
+h	O
+,	O
+and	O
+the	O
+lowest	O
+serum	B-COMP
+Ca	O
+Extensive	O
+HF	O
+burns	O
+combined	O
+with	O
+an	O
+inhalation	B-PROC
+injury	O
+led	O
+to	O
+a	O
+potentially	O
+fatal	O
+electrolyte	O
+imbalance	O
+and	O
+ARDS	B-DISO
+.	O
+
+Adequate	O
+and	O
+timely	O
+calcium	B-CHED
+supplementation	O
+and	O
+ECMO	O
+application	O
+were	O
+the	O
+keys	O
+to	O
+successful	O
+treatment	O
+of	O
+the	O
+patient	O
+.	O
+
+ABSTRACT	O
+:	O
+Severe	O
+acute	O
+respiratory	O
+syndrome	O
+coronavirus	B-SPEC
+(	O
+SARS	B-DISO
+-	O
+CoV	O
+),	O
+emerged	O
+from	O
+China	O
+and	O
+rapidly	O
+spread	O
+worldwide	O
+.	O
+
+TITLE	O
+:	O
+The	O
+Middle	O
+East	O
+Respiratory	O
+Syndrome	B-DISO
+(	O
+MERS	O
+).	O
+
+TITLE	O
+:	O
+Protostemonine	B-CHED
+alleviates	O
+heat	O
+-	O
+killed	O
+methicillin	B-DISO
+-	I-DISO
+resistant	I-DISO
+Staphylococcus	B-SPEC
+aureus	I-SPEC
+-	O
+induced	O
+acute	O
+lung	O
+injury	O
+through	O
+MAPK	B-FUNC
+and	O
+NF	O
+-	O
+κB	O
+signaling	B-PROC
+pathways	B-PROC
+.	O
+
+Here	O
+,	O
+we	O
+found	O
+that	O
+PSN	B-PRGE
+exhibits	O
+anti	O
+-	O
+inflammatory	O
+effects	O
+and	O
+alleviates	O
+heat	O
+-	O
+killed	O
+methicillin	B-DISO
+-	I-DISO
+resistant	I-DISO
+Staphylococcus	B-SPEC
+aureus	I-SPEC
+(	O
+HKMRSA	O
+)-	O
+induced	O
+pneumonia	B-DISO
+.	O
+
+TITLE	O
+:	O
+LGP2	B-PRGE
+plays	O
+a	O
+critical	O
+role	O
+in	O
+MDA5	B-PRGE
+-	O
+mediated	O
+antiviral	B-CHED
+activity	O
+against	O
+duck	B-SPEC
+enteritis	I-SPEC
+virus	I-SPEC
+.	O
+
+ABSTRACT	O
+:	O
+Duck	O
+viral	O
+enteritis	O
+(	O
+DEV	O
+)	O
+is	O
+a	O
+DNA	O
+virus	B-SPEC
+that	O
+leads	O
+to	O
+heavy	O
+economic	O
+losses	O
+in	O
+the	O
+commercial	O
+duck	B-SPEC
+industry	O
+.	O
+
+We	O
+also	O
+showed	O
+that	O
+there	O
+was	O
+an	O
+association	O
+between	O
+MDA5	B-PRGE
+and	O
+laboratory	B-PRGE
+of	I-PRGE
+genetics	I-PRGE
+and	I-PRGE
+physiology	I-PRGE
+2	I-PRGE
+(	O
+LGP2	B-PRGE
+)	O
+in	O
+antiviral	B-CHED
+signaling	B-PROC
+.	O
+
+RESULTS	O
+:	O
+The	O
+HEV	B-SPEC
+added	O
+the	O
+percentage	O
+of	O
+CD4	B-PRGE
+
+Moreover	O
+,	O
+other	O
+factors	O
+including	O
+hydrophobicity	O
+and	O
+aromaticity	O
+have	O
+been	O
+also	O
+found	O
+to	O
+influence	O
+the	O
+codon	O
+usage	O
+variation	O
+among	O
+the	O
+PEDV	B-PRGE
+orf3	I-PRGE
+genes	I-PRGE
+.	O
+
+Clinicopathological	O
+assessment	O
+showed	O
+that	O
+two	O
+of	O
+the	O
+variants	O
+caused	O
+high	O
+fatality	O
+rates	O
+of	O
+67	O
+%	O
+and	O
+20	O
+%	O
+in	O
+one	O
+-	O
+day	O
+-	O
+old	O
+SPF	O
+chicks	O
+,	O
+and	O
+all	O
+the	O
+variants	O
+possessed	B-DISO
+multiorgan	O
+tropisms	B-PROC
+,	O
+including	O
+trachea	B-DISO
+,	O
+proventriculus	B-ANAT
+and	O
+urogenital	B-ANAT
+tissues	B-ANAT
+.	O
+
+TITLE	O
+:	O
+Identification	O
+and	O
+analysis	O
+of	O
+long	O
+non	O
+-	O
+coding	O
+RNAs	O
+that	O
+are	O
+involved	O
+in	O
+inflammatory	O
+process	O
+in	O
+response	O
+to	O
+transmissible	O
+gastroenteritis	B-DISO
+virus	B-DISO
+infection	I-DISO
+.	O
+
+Long	O
+noncoding	O
+RNAs	O
+(	O
+lncRNAs	O
+)	O
+play	O
+important	O
+roles	O
+in	O
+a	O
+number	O
+of	O
+biological	B-PROC
+process	I-PROC
+including	O
+inflammation	B-DISO
+response	O
+.	O
+
+However	O
+,	O
+whether	O
+lncRNAs	O
+participate	O
+in	O
+TGEV	B-SPEC
+-	O
+induced	O
+inflammation	B-DISO
+in	O
+porcine	B-SPEC
+intestinal	B-ANAT
+epithelial	B-ANAT
+cells	I-ANAT
+(	O
+IPECs	O
+)	O
+is	O
+largely	O
+unknown	O
+.	O
+
+Many	O
+differentially	O
+expressed	B-PROC
+lncRNAs	O
+act	O
+as	O
+elements	O
+to	O
+competitively	O
+attach	O
+microRNAs	O
+(	O
+miRNAs	O
+)	O
+which	O
+target	O
+to	O
+messenger	B-CHED
+RNA	I-CHED
+(	O
+mRNAs	O
+)	O
+to	O
+mediate	O
+expression	B-PROC
+of	O
+genes	O
+that	O
+related	O
+to	O
+toll	O
+-	O
+like	O
+receptors	O
+(	O
+TLRs	O
+),	O
+NOD	B-PRGE
+-	I-PRGE
+like	I-PRGE
+receptors	I-PRGE
+(	O
+NLRs	O
+),	O
+tumor	B-FUNC
+necrosis	I-FUNC
+factor	I-FUNC
+(	O
+TNF	B-PRGE
+),	O
+and	O
+RIG	B-PRGE
+-	I-PRGE
+I	I-PRGE
+-	I-PRGE
+like	I-PRGE
+receptors	I-PRGE
+(	O
+RLRs	O
+)	O
+pathways	B-PROC
+.	O
+
+The	O
+parameters	O
+including	O
+prothrombin	B-PRGE
+time	I-PRGE
+(	O
+PT	O
+),	O
+hematocrit	O
+(	O
+HCT	O
+),	O
+platelet	B-ANAT
+(	O
+PLT	O
+)	O
+and	O
+blood	O
+lactate	B-CHED
+(	O
+BL	O
+)	O
+at	O
+the	O
+4th	O
+hour	O
+after	O
+fluid	O
+resuscitation	O
+were	O
+recorded	O
+.	O
+
+On	O
+day	O
+7	O
+after	O
+treatment	O
+,	O
+TNF	B-PRGE
+-	I-PRGE
+α	I-PRGE
+,	O
+IL	B-FUNC
+-	I-FUNC
+6	I-FUNC
+,	O
+CRP	B-PRGE
+and	O
+CD8	B-PRGE
+EFR	B-PRGE
+can	O
+effectively	O
+eliminate	O
+inflammatory	O
+factors	O
+,	O
+improve	O
+immune	B-PROC
+function	I-PROC
+,	O
+maintain	O
+the	O
+stability	O
+of	O
+blood	B-ANAT
+components	I-ANAT
+,	O
+reduce	O
+the	O
+incidences	O
+of	O
+ARDS	B-DISO
+and	O
+MODS	B-DISO
+,	O
+and	O
+elevate	O
+the	O
+successful	O
+rescue	O
+rate	O
+in	O
+patients	O
+with	O
+SPF	O
+.	O
+
+RESULTS	O
+:	O
+The	O
+incidences	O
+of	O
+ARDS	B-DISO
+and	O
+MODS	B-DISO
+during	O
+rescue	O
+in	O
+EFR	O
+group	O
+were	O
+significantly	O
+lower	O
+than	O
+those	O
+in	O
+control	O
+group	O
+(	O
+p	O
+=	O
+0	O
+.	O
+015	O
+and	O
+0	O
+.	O
+010	O
+respectively	O
+),	O
+and	O
+the	O
+successful	O
+rescue	O
+rate	O
+in	O
+EFR	O
+group	O
+was	O
+significantly	O
+higher	O
+than	O
+that	O
+in	O
+control	O
+group	O
+(	O
+p	O
+=	O
+0	O
+.	O
+011	O
+).	O
+
+ABSTRACT	O
+:	O
+A	O
+serological	O
+survey	O
+of	O
+Middle	O
+East	O
+respiratory	O
+syndrome	B-DISO
+coronavirus	B-SPEC
+(	O
+MERS	O
+-	O
+CoV	O
+)	O
+was	O
+conducted	O
+among	O
+dromedary	B-SPEC
+camels	B-SPEC
+and	O
+herbivorous	O
+animals	B-SPEC
+sharing	O
+the	O
+same	O
+pasturage	O
+in	O
+Ethiopia	O
+.	O
+
+During	O
+this	O
+period	O
+,	O
+numerous	O
+ring	O
+-	O
+shaped	O
+,	O
+necrotic	B-PROC
+cutaneous	O
+lesions	O
+rapidly	O
+appeared	O
+,	O
+consistent	O
+with	O
+ecthyma	B-DISO
+gangrenosum	I-DISO
+.	O
+
+Therefore	O
+,	O
+in	O
+this	O
+study	O
+,	O
+a	O
+new	O
+type	O
+of	O
+recombinant	O
+adenovirus	B-DISO
+expressing	O
+the	O
+spike	O
+(	O
+S	O
+)	O
+protein	B-CHED
+of	O
+porcine	B-SPEC
+epidemic	I-SPEC
+diarrhea	I-SPEC
+virus	I-SPEC
+(	O
+PEDV	B-SPEC
+),	O
+rAd	B-PRGE
+-	I-PRGE
+PEDV	I-PRGE
+-	I-PRGE
+S	I-PRGE
+,	O
+was	O
+generated	O
+,	O
+and	O
+its	O
+characteristics	O
+were	O
+determined	O
+.	O
+
+197	O
+biopsy	O
+samples	O
+were	O
+collected	O
+from	O
+dogs	B-SPEC
+with	O
+UMRD	O
+(	O
+n	O
+=	O
+172	O
+)	O
+or	O
+CHD	O
+(	O
+25	O
+).	O
+
+(	O
+RESULTS	O
+:	O
+197	O
+biopsy	O
+samples	O
+were	O
+collected	O
+from	O
+dogs	B-SPEC
+with	O
+UMRD	O
+(	O
+n	O
+=	O
+172	O
+)	O
+or	O
+CHD	O
+(	O
+25	O
+).	O
+
+In	O
+this	O
+review	O
+,	O
+we	O
+summarize	O
+the	O
+current	O
+knowledge	O
+of	O
+the	O
+virulence	B-PROC
+-	O
+related	O
+mutations	O
+of	O
+PEDV	B-SPEC
+and	O
+their	O
+potential	O
+roles	O
+in	O
+PEDV	B-SPEC
+attenuation	O
+in	O
+vivo	O
+.	O
+
+However	O
+,	O
+some	O
+animal	B-SPEC
+studies	O
+have	O
+suggested	O
+that	O
+inadequate	O
+immunization	O
+against	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+coronavirus	B-SPEC
+(	O
+SARS	B-DISO
+-	O
+CoV	O
+)	O
+induces	O
+a	O
+lung	B-ANAT
+eosinophilic	O
+immunopathology	B-DISO
+upon	O
+infection	B-DISO
+.	O
+
+The	O
+present	O
+study	O
+evaluated	O
+two	O
+kinds	O
+of	O
+vaccine	O
+adjuvants	B-CHED
+for	O
+use	O
+with	O
+recombinant	B-PRGE
+S	I-PRGE
+protein	I-PRGE
+:	O
+gold	B-CHED
+nanoparticles	B-CHED
+(	O
+AuNPs	O
+),	O
+which	O
+are	O
+expected	O
+to	O
+function	O
+as	O
+both	O
+an	O
+antigen	B-CHED
+carrier	O
+and	O
+an	O
+adjuvant	B-CHED
+in	O
+immunization	O
+;	O
+and	O
+Toll	B-PRGE
+-	I-PRGE
+like	I-PRGE
+receptor	I-PRGE
+(	O
+TLR	O
+)	O
+agonists	B-CHED
+,	O
+which	O
+have	O
+previously	O
+been	O
+shown	O
+to	O
+be	O
+an	O
+effective	O
+adjuvant	B-CHED
+in	O
+an	O
+ultraviolet	O
+-	O
+inactivated	O
+SARS	B-DISO
+-	O
+CoV	O
+vaccine	O
+.	O
+
+The	O
+AuNP	B-CHED
+-	O
+adjuvanted	O
+protein	B-CHED
+induced	O
+a	O
+strong	O
+IgG	B-PRGE
+response	O
+but	O
+failed	O
+to	O
+improve	O
+vaccine	O
+efficacy	O
+or	O
+to	O
+reduce	O
+eosinophilic	B-DISO
+infiltration	I-DISO
+because	O
+of	O
+highly	B-DISO
+allergic	I-DISO
+inflammatory	B-DISO
+responses	I-DISO
+.	O
+
+Males	O
+in	O
+comparison	O
+to	O
+females	O
+had	O
+a	O
+1	O
+.	O
+5	O
+-	O
+fold	O
+increased	O
+chance	O
+(	O
+adjusted	O
+OR	O
+=	O
+1	O
+.	O
+5	O
+[	O
+95	O
+%	O
+CI	O
+:	O
+1	O
+.	O
+3	O
+-	O
+1	O
+.	O
+8	O
+])	O
+of	O
+death	B-PROC
+related	O
+to	O
+MERS	O
+-	O
+CoV	O
+infection	B-DISO
+;	O
+1	O
+.	O
+05	O
+[	O
+95	O
+%	O
+CI	O
+:	O
+1	O
+.	O
+1	O
+-	O
+3	O
+.	O
+3	O
+],	O
+1	O
+.	O
+05	O
+[	O
+95	O
+%	O
+CI	O
+:	O
+1	O
+.	O
+2	O
+-	O
+2	O
+.	O
+8	O
+]	O
+and	O
+1	O
+.	O
+06	O
+[	O
+95	O
+%	O
+CI	O
+:	O
+1	O
+.	O
+2	O
+-	O
+2	O
+.	O
+0	O
+]	O
+for	O
+those	O
+who	O
+had	O
+exposure	O
+to	O
+camels	B-SPEC
+,	O
+camel	B-SPEC
+milk	O
+consumption	O
+,	O
+and	O
+close	O
+contact	O
+with	O
+MERS	O
+-	O
+CoV	O
+cases	O
+,	O
+respectively	O
+.	O
+
+ABSTRACT	O
+:	O
+Porcine	B-SPEC
+deltacoronavirus	O
+(	O
+PDCoV	O
+)	O
+was	O
+first	O
+identified	O
+in	O
+Hong	O
+Kong	O
+in	O
+2012	O
+from	O
+samples	O
+taken	O
+from	O
+pigs	B-SPEC
+in	O
+2009	O
+.	O
+
+The	O
+virus	B-SPEC
+has	O
+now	O
+been	O
+detected	O
+in	O
+pigs	B-SPEC
+in	O
+several	O
+countries	O
+around	O
+the	O
+world	O
+.	O
+
+TITLE	O
+:	O
+Methadone	B-CHED
+associated	O
+long	O
+term	O
+hearing	B-DISO
+loss	I-DISO
+and	O
+nephrotoxicity	O
+;	O
+a	O
+case	O
+report	O
+and	O
+literature	O
+review	O
+.	O
+
+Hearing	B-DISO
+loss	I-DISO
+has	O
+been	O
+rarely	O
+reported	O
+following	O
+methadone	B-CHED
+use	O
+,	O
+and	O
+when	O
+reported	O
+,	O
+long	O
+term	O
+follow	O
+-	O
+up	O
+is	O
+rare	O
+.	O
+
+Herein	O
+we	O
+report	O
+a	O
+case	O
+of	O
+methadone	B-CHED
+poisoning	O
+with	O
+rhabdomyolysis	B-DISO
+,	I-DISO
+acute	I-DISO
+kidney	B-ANAT
+injury	O
+,	O
+and	O
+persistent	O
+hearing	B-DISO
+loss	I-DISO
+documented	O
+by	O
+a	O
+2	O
+year	O
+follow	O
+up	O
+.	O
+
+ABSTRACT	O
+:	O
+Infectious	O
+bronchitis	B-DISO
+virus	B-SPEC
+(	O
+IBV	B-SPEC
+)	O
+infects	O
+ciliated	O
+epithelial	B-ANAT
+cells	I-ANAT
+in	O
+the	O
+chicken	B-SPEC
+respiratory	B-ANAT
+tract	I-ANAT
+.	O
+
+Furthermore	O
+,	O
+while	O
+indoleamine	B-PRGE
+2	I-PRGE
+,	I-PRGE
+3	I-PRGE
+-	I-PRGE
+dioxygenase	I-PRGE
+(	O
+IDO1	B-PRGE
+)	O
+drives	O
+AhR	B-PRGE
+activation	O
+in	O
+other	O
+settings	O
+,	O
+MHV	B-SPEC
+infection	B-DISO
+induced	I-DISO
+equal	O
+expression	B-PROC
+of	O
+downstream	O
+genes	O
+in	O
+wild	O
+-	O
+type	O
+(	O
+WT	O
+)	O
+and	O
+IDO1	B-PRGE
+
+ABSTRACT	O
+:	O
+Porcine	B-SPEC
+epidemic	I-SPEC
+diarrhea	I-SPEC
+virus	I-SPEC
+(	O
+PEDV	B-SPEC
+),	O
+is	O
+an	O
+economically	O
+important	O
+enteric	B-SPEC
+coronavirus	I-SPEC
+,	O
+with	O
+over	O
+a	O
+90	O
+%	O
+mortality	O
+rate	O
+in	O
+neonatal	O
+piglets	O
+.	O
+
+The	O
+virus	B-SPEC
+emerged	O
+in	O
+the	O
+US	O
+in	O
+2013	O
+,	O
+resulting	O
+in	O
+severe	O
+production	O
+losses	O
+.	O
+
+Seven	O
+patients	O
+developed	O
+severe	O
+ARDS	B-DISO
+and	O
+one	O
+patient	O
+moderate	O
+ARDS	O
+according	O
+to	O
+the	O
+Berlin	O
+classification	O
+with	O
+a	O
+PaO	B-PROC
+ECMO	O
+is	O
+a	O
+viable	O
+therapy	O
+option	O
+in	O
+burn	O
+patients	O
+developing	O
+severe	O
+ARDS	B-DISO
+and	O
+can	O
+contribute	O
+to	O
+survival	O
+rates	O
+similar	O
+to	O
+ECMO	O
+therapy	O
+in	O
+non	O
+-	O
+burn	O
+-	O
+associated	O
+severe	O
+ARDS	B-DISO
+.	O
+
+ABSTRACT	O
+:	O
+Molecular	O
+detection	O
+methods	O
+allow	O
+for	O
+the	O
+simultaneous	O
+detection	O
+of	O
+several	O
+infectious	B-DISO
+agents	O
+.	O
+
+Bocavirus	B-SPEC
++	I-SPEC
+rhinovirus	I-SPEC
+cases	O
+were	O
+hospitalized	O
+more	O
+often	O
+than	O
+those	O
+with	O
+rhinovirus	B-SPEC
+alone	O
+(	O
+but	O
+not	O
+bocavirus	B-SPEC
+alone	O
+).	O
+
+In	O
+this	O
+study	O
+,	O
+detection	O
+of	O
+2	O
+viruses	B-SPEC
+did	O
+not	O
+significantly	O
+increase	O
+hospitalizations	O
+compared	O
+with	O
+single	O
+virus	B-SPEC
+infections	B-DISO
+.	O
+
+Since	O
+2012	O
+,	O
+more	O
+than	O
+2425	O
+MERS	O
+-	O
+CoV	O
+human	B-SPEC
+cases	O
+have	O
+been	O
+reported	O
+in	O
+27	O
+countries	O
+.	O
+
+Viral	O
+genomic	O
+RNA	O
+was	O
+detected	O
+in	O
+whole	B-ANAT
+blood	I-ANAT
+,	O
+serum	B-COMP
+and	O
+plasma	B-ANAT
+of	O
+infected	O
+patients	O
+,	O
+raising	O
+concerns	O
+of	O
+the	O
+safety	O
+of	O
+blood	B-ANAT
+supplies	O
+,	O
+especially	O
+in	O
+endemic	O
+areas	O
+.	O
+
+Spiked	O
+units	O
+were	O
+then	O
+treated	O
+with	O
+amotosalen	O
+/	O
+UVA	O
+to	O
+inactivate	O
+MERS	O
+-	O
+CoV	O
+.	O
+Infectious	B-DISO
+and	O
+genomic	O
+viral	O
+titres	O
+were	O
+quantified	O
+by	O
+plaque	B-DISO
+assay	O
+and	O
+quantitative	O
+real	O
+-	O
+time	O
+reverse	O
+transcription	O
+polymerase	O
+chain	O
+reaction	O
+(	O
+RT	O
+-	O
+qPCR	O
+).	O
+
+Passaging	O
+of	O
+the	O
+inactivated	O
+samples	O
+in	O
+Vero	O
+E6	O
+showed	O
+no	O
+viral	B-PROC
+replication	I-PROC
+even	O
+after	O
+nine	O
+days	O
+of	O
+incubation	O
+and	O
+three	O
+passages	O
+.	O
+
+CONCLUSIONS	O
+:	O
+Amotosalen	O
+and	O
+UVA	O
+light	O
+treatment	O
+of	O
+MERS	O
+-	O
+CoV	O
+-	O
+spiked	O
+platelet	B-ANAT
+concentrates	O
+efficiently	O
+and	O
+completely	O
+inactivated	O
+MERS	O
+-	O
+CoV	O
+infectivity	O
+(>	O
+4	O
+logs	O
+),	O
+suggesting	O
+that	O
+such	O
+treatment	O
+could	O
+minimise	O
+the	O
+risk	O
+of	O
+transfusion	O
+-	O
+related	O
+MERS	O
+-	O
+CoV	O
+transmission	O
+.	O
+
+ECMO	O
+patients	O
+were	O
+randomly	O
+matched	O
+to	O
+a	O
+control	O
+group	O
+of	O
+patients	O
+with	O
+severe	O
+ARDS	B-DISO
+within	O
+the	O
+same	O
+time	O
+period	O
+.	O
+
+TITLE	O
+:	O
+Predictors	O
+of	O
+Reopening	O
+the	O
+Sternum	B-ANAT
+in	O
+Children	O
+After	O
+Cardiac	B-ANAT
+Surgery	O
+.	O
+
+We	O
+looked	O
+for	O
+predictors	O
+that	O
+indicate	O
+the	O
+need	O
+for	O
+reopening	O
+the	O
+sternum	B-ANAT
+.	O
+
+All	O
+children	O
+who	O
+required	O
+emergent	O
+reopening	O
+the	O
+sternum	B-ANAT
+in	O
+the	O
+pediatric	O
+cardiac	B-ANAT
+ICU	O
+after	O
+cardiac	B-ANAT
+surgery	O
+were	O
+grouped	O
+as	O
+index	O
+cases	O
+and	O
+matched	O
+to	O
+a	O
+control	O
+group	O
+for	O
+age	O
+,	O
+body	B-ANAT
+weight	O
+,	O
+cardiac	B-ANAT
+diagnosis	O
+,	O
+and	O
+type	O
+of	O
+repair	B-PROC
+(	O
+single	O
+vs	O
+biventricular	O
+).	O
+
+Many	O
+conserved	O
+cytotoxic	B-ANAT
+T	I-ANAT
+-	I-ANAT
+lymphocyte	I-ANAT
+epitopes	O
+and	O
+discontinuous	O
+and	O
+linear	O
+B	O
+-	O
+cell	O
+epitopes	O
+were	O
+predicted	O
+for	O
+the	O
+MERS	B-PRGE
+-	I-PRGE
+COV	I-PRGE
+S	I-PRGE
+protein	I-PRGE
+,	O
+and	O
+their	O
+antigenicity	O
+and	O
+interactions	O
+with	O
+the	O
+human	B-PRGE
+leukocyte	B-ANAT
+antigen	B-CHED
+(	O
+HLA	B-PRGE
+)	O
+B7	O
+allele	O
+were	O
+estimated	O
+.	O
+
+Among	O
+T	B-PRGE
+-	I-PRGE
+cell	I-PRGE
+epitopes	I-PRGE
+,	O
+MHC	B-PRGE
+class	B-SPEC
+-	I-PRGE
+I	I-PRGE
+peptide	B-CHED
+YKLQPLTFL	I-PRGE
+and	O
+MHC	B-PRGE
+class	B-SPEC
+-	I-PRGE
+II	I-PRGE
+peptide	B-CHED
+YCILEPRSG	I-PRGE
+were	O
+identified	O
+as	O
+highly	O
+antigenic	O
+.	O
+
+CONCLUSIONS	O
+:	O
+The	O
+present	O
+study	O
+identified	O
+several	O
+MERS	B-PRGE
+-	I-PRGE
+COV	I-PRGE
+S	I-PRGE
+protein	I-PRGE
+epitopes	I-PRGE
+that	O
+are	O
+conserved	O
+among	O
+various	O
+isolates	O
+from	O
+different	O
+countries	O
+.	O
+
+Overall	O
+,	O
+the	O
+vaccination	O
+reduced	O
+virus	B-DISO
+shedding	I-DISO
+and	O
+nasal	B-DISO
+discharge	B-ANAT
+(	O
+p	O
+=	O
+0	O
+.	O
+0059	O
+and	O
+p	O
+=	O
+0	O
+.	O
+0274	O
+,	O
+respectively	O
+).	O
+
+ABSTRACT	O
+:	O
+Human	B-SPEC
+coronaviruses	O
+(	O
+HCoVs	O
+)	O
+are	O
+important	O
+pathogens	O
+that	O
+cause	O
+upper	B-DISO
+respiratory	I-DISO
+tract	I-DISO
+infections	I-DISO
+and	O
+have	O
+neuroinvasive	O
+abilities	O
+;	O
+however	O
+,	O
+little	O
+is	O
+known	O
+about	O
+the	O
+dynamic	O
+infection	B-DISO
+process	O
+of	O
+CoVs	O
+in	O
+vivo	O
+,	O
+and	O
+there	O
+are	O
+currently	O
+no	O
+specific	O
+antiviral	B-CHED
+drugs	I-CHED
+to	O
+prevent	O
+or	O
+treat	O
+HCoV	O
+infection	B-DISO
+.	O
+
+We	O
+found	O
+that	O
+rOC43	O
+-	O
+ns2DelRluc	O
+was	O
+fatal	O
+to	O
+suckling	O
+mice	B-SPEC
+after	O
+intranasal	O
+inoculation	O
+,	O
+and	O
+that	O
+viral	O
+titers	O
+and	O
+Rluc	O
+expression	B-PROC
+were	O
+detected	O
+in	O
+the	O
+brains	O
+and	O
+spinal	B-ANAT
+cords	I-ANAT
+of	O
+mice	B-SPEC
+infected	O
+with	O
+rOC43	O
+-	O
+ns2DelRluc	O
+.	O
+
+TITLE	O
+:	O
+Evolution	B-PROC
+of	O
+infectious	B-DISO
+bronchitis	B-DISO
+virus	B-SPEC
+in	O
+the	O
+field	O
+after	O
+homologous	O
+vaccination	O
+introduction	O
+.	O
+
+Infectious	B-DISO
+bronchitis	B-DISO
+virus	B-SPEC
+(	O
+IBV	B-SPEC
+)	O
+is	O
+a	O
+widespread	O
+avian	B-SPEC
+coronavirus	I-SPEC
+,	O
+whose	O
+control	O
+relies	O
+mainly	O
+on	O
+extensive	O
+vaccine	O
+administration	O
+.	O
+
+The	O
+great	O
+plasticity	O
+of	O
+rapidly	O
+-	O
+evolving	O
+RNA	O
+-	O
+viruses	B-SPEC
+in	O
+response	O
+to	O
+human	B-SPEC
+intervention	O
+,	O
+which	O
+extends	O
+beyond	O
+the	O
+poultry	O
+industry	O
+,	O
+is	O
+demonstrated	O
+,	O
+claiming	O
+further	O
+attention	O
+due	O
+to	O
+their	O
+relevance	O
+for	O
+animal	B-SPEC
+and	O
+especially	O
+human	B-SPEC
+health	O
+.	O
+
+TITLE	O
+:	O
+Current	O
+status	O
+of	O
+enterovirus	B-SPEC
+D68	O
+worldwide	O
+and	O
+in	O
+Taiwan	O
+.	O
+
+ABSTRACT	O
+:	O
+Enterovirus	B-SPEC
+D68	O
+was	O
+first	O
+identified	O
+in	O
+1962	O
+and	O
+caused	O
+a	O
+worldwide	O
+outbreak	O
+starting	O
+from	O
+the	O
+North	O
+America	O
+in	O
+2014	O
+.	O
+
+Enterovirus	O
+D68	O
+has	O
+been	O
+in	O
+continuous	O
+circulation	B-PROC
+among	O
+many	O
+countries	O
+recently	O
+,	O
+including	O
+Taiwan	O
+.	O
+
+Nasal	B-ANAT
+high	O
+-	O
+flow	O
+oxygen	B-CHED
+therapy	O
+was	O
+initiated	O
+because	O
+of	O
+severe	O
+hypoxemia	O
+.	O
+
+However	O
+,	O
+he	O
+still	O
+required	O
+high	O
+-	O
+flow	O
+oxygen	B-CHED
+therapy	O
+.	O
+
+TITLE	O
+:	O
+[	O
+A	O
+Rare	O
+Complication	B-DISO
+of	O
+Acute	O
+Diarrhae	O
+Caused	O
+by	O
+Cryptosporidium	B-SPEC
+:	O
+Possible	O
+Hepatobiliary	B-ANAT
+System	I-ANAT
+Involvement	O
+in	O
+a	O
+Child	O
+without	O
+Immunodeficiency	B-DISO
+].	O
+
+Patients	O
+with	O
+normal	O
+immune	B-ANAT
+system	I-ANAT
+may	O
+have	O
+an	O
+asymptomatic	O
+course	O
+or	O
+clinical	O
+presentation	O
+such	O
+as	O
+acute	O
+watery	B-DISO
+diarrhea	I-DISO
+without	O
+blood	B-ANAT
+and	O
+persistent	B-DISO
+diarrhea	I-DISO
+.	O
+
+Cryptosporidium	B-SPEC
+spp	B-ENZY
+.	O
+may	O
+cause	O
+asymptomatic	B-DISO
+infection	I-DISO
+,	O
+mild	O
+diarrheal	B-DISO
+disease	I-DISO
+or	O
+severe	B-DISO
+diarrhea	I-DISO
+with	O
+high	O
+volume	O
+,	O
+which	O
+may	O
+be	O
+accompanied	O
+by	O
+nausea	B-DISO
+,	O
+vomiting	B-DISO
+,	O
+abdominal	B-DISO
+pain	I-DISO
+and	O
+fever	B-PROC
+,	O
+following	O
+a	O
+1	O
+-	O
+7	O
+day	O
+incubation	O
+period	O
+.	O
+
+Diarrhea	B-DISO
+may	O
+be	O
+acute	O
+or	O
+chronic	O
+,	O
+transient	O
+,	O
+intermittent	O
+,	O
+or	O
+continuous	O
+;	O
+loss	B-DISO
+of	I-DISO
+fluid	I-DISO
+can	O
+be	O
+up	O
+to	O
+25	O
+L	O
+/	O
+day	O
+in	O
+severe	B-DISO
+diarrhea	I-DISO
+.	O
+
+We	O
+would	O
+like	O
+to	O
+emphasize	O
+that	O
+Cryptosporodium	O
+spp	B-ENZY
+.	O
+may	O
+be	O
+the	O
+cause	O
+of	O
+severe	O
+acute	B-DISO
+diarrhea	I-DISO
+in	O
+non	O
+-	O
+immunocompromised	O
+patients	O
+and	O
+may	O
+also	O
+involve	O
+hepatobiliary	B-ANAT
+system	I-ANAT
+involvement	O
+.	O
+
+Directly	O
+inoculated	O
+llamas	B-SPEC
+shed	O
+virus	B-SPEC
+for	O
+at	O
+least	O
+6	O
+days	O
+and	O
+could	O
+infect	O
+all	O
+in	O
+-	O
+contact	O
+naïve	O
+animals	B-SPEC
+4	O
+-	O
+5	O
+days	O
+after	O
+exposure	O
+.	O
+
+Our	O
+data	O
+provide	O
+further	O
+evidence	O
+that	O
+vaccination	O
+of	O
+the	O
+reservoir	O
+host	O
+may	O
+impede	O
+MERS	O
+-	O
+CoV	O
+zoonotic	O
+transmission	O
+to	O
+humans	B-SPEC
+.	O
+
+TITLE	O
+:	O
+Rapid	O
+manipulation	O
+of	O
+the	O
+porcine	B-SPEC
+epidemic	I-SPEC
+diarrhea	I-SPEC
+virus	I-SPEC
+genome	O
+by	O
+CRISPR	O
+/	O
+Cas9	O
+technology	O
+.	O
+
+In	O
+this	O
+study	O
+,	O
+a	O
+full	O
+-	O
+length	O
+infectious	B-DISO
+cDNA	O
+clone	O
+of	O
+the	O
+highly	O
+virulent	O
+PEDV	B-SPEC
+strain	O
+AJ1102	O
+was	O
+assembled	O
+in	O
+a	O
+bacterial	O
+artificial	O
+chromosome	B-COMP
+(	O
+BAC	O
+).	O
+
+TITLE	O
+:	O
+Herpes	B-DISO
+viruses	B-SPEC
+in	O
+optic	B-DISO
+neuritis	I-DISO
+:	O
+Similar	O
+to	O
+Bell	B-DISO
+'	I-DISO
+s	I-DISO
+palsy	I-DISO
+.	O
+
+As	O
+compared	O
+with	O
+controls	O
+,	O
+DNA	O
+from	O
+HSV	B-SPEC
+-	I-SPEC
+1	I-SPEC
+was	O
+significantly	O
+more	O
+frequent	O
+in	O
+CSF	B-ANAT
+and	O
+blood	B-ANAT
+from	O
+cases	O
+with	O
+ON	O
+;	O
+VZV	O
+and	O
+HSV	B-SPEC
+-	O
+2	O
+were	O
+found	O
+only	O
+in	O
+CSF	B-ANAT
+;	O
+EBV	O
+was	O
+found	O
+only	O
+in	O
+blood	B-ANAT
+samples	I-ANAT
+(	O
+p	O
+<	O
+0	O
+.	O
+006	O
+).	O
+
+TITLE	O
+:	O
+ABSTRACT	O
+:	O
+Murine	B-DISO
+typhus	I-DISO
+,	O
+also	O
+known	O
+as	O
+endemic	B-DISO
+typhus	I-DISO
+,	O
+is	O
+a	O
+disease	O
+resulting	O
+from	O
+an	O
+infection	B-DISO
+caused	O
+by	O
+the	O
+gram	O
+-	O
+negative	O
+bacillus	B-SPEC
+
+ABSTRACT	O
+:	O
+Miliary	B-DISO
+tuberculosis	B-PATH
+is	O
+a	O
+serious	O
+and	O
+uncommon	O
+form	O
+of	O
+tuberculosis	B-PATH
+due	O
+to	O
+hematogenous	O
+dissemination	O
+of	O
+This	O
+study	O
+aimed	O
+to	O
+describe	O
+the	O
+epidemiological	O
+and	O
+clinical	O
+features	O
+of	O
+miliary	B-DISO
+tuberculosis	I-DISO
+.	O
+
+Compared	O
+with	O
+nonsurvivors	O
+,	O
+survivors	O
+exhibited	O
+bigger	O
+EVLWI	O
+reduction	O
+in	O
+day	O
+2	O
+after	O
+ARDS	B-DISO
+onset	O
+(	O
+ΔEVLWI2	O
+),	O
+with	O
+no	O
+differences	O
+in	O
+ARDS	B-DISO
+timing	O
+and	O
+other	O
+EVLWI	O
+variables	O
+.	O
+
+We	O
+aimed	O
+to	O
+determine	O
+whether	O
+reclassification	O
+using	O
+oxygenation	B-PROC
+metrics	O
+24	O
+hours	O
+after	O
+diagnosis	O
+could	O
+provide	O
+prognostic	O
+ability	O
+for	O
+outcomes	O
+in	O
+PARDS	O
+.	O
+
+TITLE	O
+:	O
+Long	O
+-	O
+term	O
+extracorporeal	O
+membrane	B-COMP
+oxygenation	B-PROC
+after	O
+severe	O
+blunt	O
+traumatic	B-DISO
+lung	I-DISO
+injury	O
+in	O
+a	O
+child	O
+.	O
+
+Efforts	O
+to	O
+minimize	O
+this	O
+injury	O
+are	O
+typically	O
+limited	O
+by	O
+the	O
+need	O
+to	O
+preserve	O
+adequate	O
+gas	B-ENZY
+exchange	O
+.	O
+
+ABSTRACT	O
+:	O
+Pediatric	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+(	O
+PARDS	O
+)	O
+is	O
+a	O
+heterogenous	O
+process	O
+resulting	O
+in	O
+a	O
+severe	O
+acute	O
+lung	B-ANAT
+injury	O
+.	O
+
+In	O
+children	O
+with	O
+severe	O
+PARDS	O
+,	O
+further	O
+research	O
+is	O
+needed	O
+to	O
+determine	O
+if	O
+factors	O
+other	O
+than	O
+the	O
+haemoglobin	B-CHED
+level	O
+might	O
+guide	O
+RBC	B-ANAT
+transfusion	O
+decision	O
+-	O
+making	O
+by	O
+better	O
+characterizing	O
+the	O
+presence	O
+of	O
+low	O
+oxygen	B-CHED
+delivery	O
+(	O
+DO	O
+
+The	O
+Randomized	O
+Evaluation	O
+of	O
+Sedation	B-DISO
+Titration	O
+for	O
+Respiratory	B-DISO
+Failure	I-DISO
+trial	O
+(	O
+RESTORE	O
+)	O
+trial	O
+has	O
+revealed	O
+that	O
+a	O
+goal	O
+directed	O
+sedation	B-DISO
+protocol	O
+does	O
+not	O
+reduce	O
+the	O
+duration	O
+of	O
+invasive	O
+ventilation	O
+in	O
+critically	B-DISO
+ill	I-DISO
+children	O
+.	O
+
+In	O
+addition	O
+,	O
+similarities	O
+to	O
+the	O
+human	B-PRGE
+toll	I-PRGE
+-	I-PRGE
+like	I-PRGE
+receptor	I-PRGE
+4	I-PRGE
+,	O
+the	O
+existence	O
+of	O
+intraalveolar	O
+macrophages	B-ANAT
+,	O
+the	O
+sensitivity	O
+to	O
+lipopolysaccharide	B-CHED
+,	O
+and	O
+the	O
+production	O
+of	O
+nitric	B-CHED
+oxide	I-CHED
+make	O
+the	O
+piglet	O
+indispensable	O
+in	O
+anti	O
+-	O
+inflammatory	O
+research	O
+.	O
+
+EMGdi	O
+and	O
+trans	O
+-	O
+pulmonary	B-ANAT
+pressure	O
+(∆	O
+P	O
+In	O
+ARDS	B-DISO
+patients	O
+,	O
+the	O
+static	O
+compliance	O
+of	O
+the	O
+chest	B-ANAT
+wall	I-ANAT
+was	O
+significantly	O
+decreased	O
+after	O
+PPV	B-CHED
+.	O
+
+For	O
+ARDS	O
+patients	O
+,	O
+EMGdi	O
+was	O
+slightly	O
+decreased	O
+after	O
+prolonged	O
+PPV	B-CHED
+.	O
+
+Generally	O
+,	O
+the	O
+effect	O
+of	O
+the	O
+fusion	O
+peptide	B-CHED
+on	O
+the	O
+membrane	B-COMP
+is	O
+sensitive	O
+to	O
+the	O
+lipid	B-CHED
+composition	O
+of	O
+target	O
+membranes	B-ANAT
+.	O
+
+We	O
+aimed	O
+to	O
+describe	O
+the	O
+association	O
+between	O
+time	O
+to	O
+antibiotic	B-CHED
+administration	O
+and	O
+outcomes	O
+in	O
+patients	O
+with	O
+severe	B-DISO
+sepsis	I-DISO
+and	O
+septic	B-DISO
+shock	I-DISO
+in	O
+Japan	O
+.	O
+
+The	O
+short	O
+-	O
+term	O
+and	O
+long	O
+-	O
+term	O
+effects	O
+of	O
+cannabis	B-DISO
+oil	O
+inhalation	B-PROC
+are	O
+not	O
+well	O
+understood	O
+.	O
+
+Since	O
+the	O
+outbreak	O
+of	O
+SARS	B-DISO
+(	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+)	O
+in	O
+2003	O
+,	O
+the	O
+scale	O
+of	O
+PHW	O
+in	O
+China	O
+has	O
+been	O
+continuously	O
+expanding	O
+,	O
+but	O
+policymakers	O
+and	O
+researchers	O
+still	O
+focus	O
+on	O
+the	O
+distribution	O
+of	O
+public	O
+health	O
+personnel	O
+,	O
+especially	O
+the	O
+regional	O
+inequality	O
+in	O
+such	O
+distribution	O
+.	O
+
+This	O
+study	O
+clearly	O
+suggests	O
+that	O
+the	O
+government	O
+,	O
+especially	O
+the	O
+municipal	O
+government	O
+at	O
+the	O
+provincial	O
+level	O
+,	O
+should	O
+increase	O
+financial	O
+investment	O
+in	O
+Centers	O
+for	O
+Disease	O
+Control	O
+and	O
+Prevention	O
+(	O
+CDCs	O
+)	O
+with	O
+worse	O
+resource	O
+allocation	O
+in	O
+their	O
+jurisdiction	O
+through	O
+various	O
+ways	O
+of	O
+compensation	B-PROC
+and	O
+incentives	O
+,	O
+enhance	O
+their	O
+infrastructure	O
+,	O
+and	O
+improve	O
+the	O
+salary	O
+of	O
+personnel	O
+in	O
+these	O
+institutions	O
+,	O
+to	O
+attract	O
+more	O
+public	O
+health	O
+professionals	O
+to	O
+these	O
+institutions	O
+.	O
+
+Per	O
+capita	O
+GDP	B-CHED
+had	O
+a	O
+similar	O
+effect	O
+,	O
+except	O
+for	O
+between	O
+-	O
+municipality	O
+inequality	O
+of	O
+professionals	O
+and	O
+within	O
+-	O
+municipality	O
+inequality	O
+of	O
+field	O
+epidemiological	O
+investigators	O
+.	O
+
+The	O
+clinical	O
+complications	O
+in	O
+severe	O
+malaria	B-PATH
+cases	O
+included	O
+thrombocytopenia	O
+(	O
+50	O
+.	O
+7	O
+%),	O
+metabolic	B-DISO
+acidosis	I-DISO
+(	O
+30	O
+.	O
+1	O
+%),	O
+severe	O
+anaemia	B-DISO
+(	O
+26	O
+.	O
+0	O
+%),	O
+jaundice	B-DISO
+(	O
+21	O
+.	O
+9	O
+%),	O
+hepatic	B-DISO
+dysfunction	I-DISO
+(	O
+15	O
+.	O
+1	O
+%),	O
+acute	B-DISO
+renal	I-DISO
+failure	I-DISO
+(	O
+6	O
+.	O
+8	O
+%),	O
+haematuria	O
+(	O
+8	O
+.	O
+2	O
+%),	O
+hypotension	O
+(	O
+9	O
+.	O
+6	O
+%),	O
+cerebral	B-DISO
+malaria	B-PATH
+(	O
+1	O
+.	O
+4	O
+%)	O
+and	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+(	O
+1	O
+.	O
+4	O
+%).	O
+
+Implementing	O
+effective	O
+surveillance	O
+and	O
+vector	O
+control	O
+measures	O
+in	O
+malaria	B-PATH
+hotspot	O
+locations	O
+in	O
+the	O
+city	O
+and	O
+educating	O
+people	O
+about	O
+preventive	O
+measures	O
+are	O
+likely	O
+to	O
+reduce	O
+the	O
+malaria	B-PATH
+burden	O
+in	O
+this	O
+endemic	O
+region	O
+.	O
+
+TITLE	O
+:	O
+Sepsis	B-SPEC
+outcomes	O
+in	O
+solid	O
+organ	B-ANAT
+transplant	I-ANAT
+recipients	O
+.	O
+
+Despite	O
+higher	O
+comorbidities	O
+in	O
+the	O
+SOT	O
+group	O
+,	O
+conditional	O
+logistic	O
+regression	O
+showed	O
+that	O
+in	O
+-	O
+hospital	O
+mortality	O
+for	O
+sepsis	B-DISO
+in	O
+SOT	O
+patients	O
+was	O
+similar	O
+compared	O
+with	O
+non	O
+-	O
+SOT	O
+patients	O
+(	O
+odds	O
+ratio	O
+[	O
+OR	O
+]	O
+=	O
+1	O
+.	O
+14	O
+[	O
+95	O
+%	O
+confidence	O
+interval	O
+{	O
+CI	O
+},	O
+0	O
+.	O
+95	O
+-	O
+1	O
+.	O
+37	O
+],	O
+P	O
+=	O
+.	O
+161	O
+).	O
+
+RESULTS	O
+:	O
+Overall	O
+,	O
+there	O
+were	O
+18	O
+632	O
+admission	O
+encounters	O
+with	O
+a	O
+discharge	B-ANAT
+diagnosis	O
+of	O
+sepsis	B-DISO
+in	O
+14	O
+780	O
+unique	O
+patients	O
+.	O
+
+ABSTRACT	O
+:	O
+The	O
+incidence	O
+and	O
+pathophysiology	O
+of	O
+right	B-DISO
+ventricular	I-DISO
+failure	I-DISO
+in	O
+patients	O
+with	O
+severe	O
+respiratory	B-DISO
+insufficiency	I-DISO
+has	O
+been	O
+largely	O
+investigated	O
+.	O
+
+Patients	O
+were	O
+divided	O
+according	O
+to	O
+treatment	O
+:	O
+conventional	O
+protective	O
+ventilation	O
+(	O
+38	O
+patients	O
+,	O
+38	O
+%);	O
+interventional	O
+lung	B-ANAT
+assist	O
+(	O
+23	O
+patients	O
+,	O
+23	O
+%);	O
+veno	O
+-	O
+venous	B-ANAT
+extracorporeal	O
+membrane	B-COMP
+oxygenation	B-PROC
+(	O
+37	O
+patients	O
+,	O
+37	O
+%).	O
+
+In	O
+98	O
+patients	O
+studied	O
+,	O
+systolic	B-DISO
+dysfunction	I-DISO
+(	O
+tricuspid	O
+annular	O
+plane	O
+systolic	O
+excursion	O
+<	O
+16	O
+mm	O
+)	O
+was	O
+present	O
+in	O
+33	O
+.	O
+6	O
+%	O
+while	O
+diastolic	O
+restrictive	O
+pattern	O
+was	O
+present	O
+in	O
+64	O
+%.	O
+
+A	O
+negative	O
+correlation	O
+was	O
+found	O
+between	O
+tricuspid	O
+annular	O
+plane	O
+systolic	O
+excursion	O
+and	O
+tricuspid	O
+annular	O
+plane	O
+systolic	O
+excursion	O
+length	O
+(	O
+Diastolic	O
+restrictive	O
+pattern	O
+is	O
+present	O
+in	O
+a	O
+remarkable	O
+percentage	O
+of	O
+patients	O
+with	O
+respiratory	B-DISO
+distress	I-DISO
+syndrome	I-DISO
+.	O
+
+ABSTRACT	O
+:	O
+Critically	B-DISO
+ill	I-DISO
+patients	O
+frequently	O
+require	O
+mechanical	O
+ventilation	O
+as	O
+part	O
+of	O
+their	O
+care	O
+.	O
+
+Dexmedetomidine	O
+may	O
+prevent	O
+ICU	O
+delirium	B-DISO
+when	O
+administered	O
+nocturnally	O
+at	O
+low	O
+doses	O
+;	O
+however	O
+,	O
+it	O
+was	O
+not	O
+shown	O
+to	O
+improve	O
+mortality	O
+when	O
+used	O
+as	O
+the	O
+primary	O
+sedative	B-CHED
+early	O
+in	O
+the	O
+course	O
+of	O
+mechanical	O
+ventilation	O
+,	O
+though	O
+the	O
+majority	O
+of	O
+patients	O
+in	O
+the	O
+informing	O
+study	O
+failed	O
+to	O
+achieve	O
+the	O
+prescribed	O
+light	O
+level	O
+of	O
+sedation	B-DISO
+.	O
+
+In	O
+a	O
+follow	O
+up	O
+to	O
+the	O
+ACURASYS	O
+trial	O
+,	O
+deep	O
+sedation	B-DISO
+with	O
+neuromuscular	B-DISO
+blockade	I-DISO
+did	O
+not	O
+result	O
+in	O
+improved	O
+mortality	O
+compared	O
+to	O
+light	O
+sedation	B-DISO
+in	O
+patients	O
+with	O
+severe	O
+ARDS	B-DISO
+.	O
+
+Sacubitril	O
+/	O
+valsartan	B-CHED
+was	O
+added	O
+to	O
+optimal	O
+medical	O
+therapy	O
+after	O
+hemodynamic	B-PROC
+stabilization	O
+allowing	O
+progressive	O
+clinical	O
+,	O
+laboratoristic	O
+,	O
+and	O
+echocardiographic	O
+improvement	O
+.	O
+
+Both	O
+DUB	B-PRGE
+and	O
+deISG	O
+activities	O
+are	O
+implicated	O
+in	O
+suppressing	O
+innate	B-DISO
+immune	I-DISO
+responses	I-DISO
+;	O
+however	O
+,	O
+the	O
+precise	O
+role	O
+of	O
+each	O
+activity	O
+in	O
+this	O
+process	O
+is	O
+still	O
+unclear	O
+due	O
+in	O
+part	O
+to	O
+the	O
+difficulties	O
+in	O
+separating	O
+each	O
+activity	O
+.	O
+
+The	O
+virus	B-SPEC
+titers	O
+and	O
+sizes	O
+of	O
+syncytia	B-ANAT
+increased	O
+gradually	O
+with	O
+the	O
+cell	B-COMP
+passages	O
+.	O
+
+Furthermore	O
+,	O
+more	O
+differences	O
+in	O
+the	O
+predicted	O
+three	O
+-	O
+dimensional	O
+structure	O
+of	O
+S	B-PRGE
+protein	I-PRGE
+between	O
+GDS04	O
+and	O
+P100	B-PRGE
+were	O
+observed	O
+,	O
+indicating	O
+that	O
+these	O
+differences	O
+might	O
+be	O
+associated	O
+with	O
+the	O
+pathogenicity	O
+of	O
+PEAV	O
+.	O
+
+TITLE	O
+:	O
+Pathogenicity	O
+of	O
+a	O
+QX	O
+-	O
+like	O
+strain	O
+of	O
+infectious	B-DISO
+bronchitis	B-DISO
+virus	B-SPEC
+and	O
+effects	O
+of	O
+accessory	O
+proteins	B-CHED
+3a	O
+and	O
+3b	O
+in	O
+chickens	B-SPEC
+.	O
+
+These	O
+findings	O
+may	O
+be	O
+used	O
+in	O
+vaccination	O
+trials	O
+for	O
+the	O
+development	B-PROC
+of	O
+a	O
+new	O
+live	O
+-	O
+attenuated	O
+vaccine	O
+.	O
+
+Slum	O
+populations	O
+stand	O
+out	O
+from	O
+other	O
+settings	O
+and	O
+may	O
+present	O
+differences	O
+in	O
+the	O
+epidemiology	O
+of	O
+acute	O
+viral	B-DISO
+infections	I-DISO
+.	O
+
+We	O
+collected	O
+nasopharyngeal	B-ANAT
+specimens	O
+from	O
+282	O
+children	O
+aged	O
+≤	O
+5	O
+years	O
+with	O
+acute	B-DISO
+respiratory	I-DISO
+tract	I-DISO
+infection	I-DISO
+(	O
+ARI	B-CHED
+)	O
+during	O
+2005	O
+to	O
+2006	O
+in	O
+one	O
+of	O
+the	O
+largest	O
+Brazilian	O
+slums	O
+.	O
+
+Nonetheless	O
+,	O
+most	O
+epidemiological	O
+patterns	O
+were	O
+similar	O
+to	O
+other	O
+studies	O
+globally	O
+,	O
+suggesting	O
+surprising	O
+similarities	O
+of	O
+virus	B-SPEC
+-	O
+associated	O
+ARI	B-CHED
+across	O
+highly	O
+diverse	O
+settings	O
+and	O
+a	O
+complex	O
+impact	O
+of	O
+population	O
+characteristics	O
+on	O
+respiratory	O
+virus	B-SPEC
+epidemiology	O
+.	O
+
+TITLE	O
+:	O
+Repeated	O
+and	O
+progressive	O
+rhabdomyolysis	B-DISO
+due	O
+to	O
+a	O
+novel	O
+carnitine	B-PROC
+palmitoyltransferase	I-PROC
+II	I-PROC
+gene	I-PRGE
+variant	O
+in	O
+an	O
+adult	O
+male	O
+:	O
+A	O
+case	O
+report	O
+.	O
+
+High	O
+levels	O
+of	O
+acylcarnitine	B-CHED
+in	O
+the	O
+serum	B-COMP
+confirmed	O
+the	O
+diagnosis	O
+of	O
+CPT	B-PRGE
+II	I-PRGE
+deficiency	O
+.	O
+
+ABSTRACT	O
+:	O
+Outbreaks	O
+of	O
+severe	O
+virus	B-SPEC
+infections	B-DISO
+with	O
+the	O
+potential	O
+to	O
+cause	O
+global	O
+pandemics	O
+are	O
+increasing	O
+.	O
+
+In	O
+the	O
+absence	O
+of	O
+a	O
+targeted	B-PROC
+vaccine	O
+or	O
+a	O
+pathogen	O
+-	O
+specific	O
+antiviral	B-CHED
+,	O
+broad	O
+-	O
+spectrum	O
+antivirals	B-CHED
+would	O
+function	O
+to	O
+limit	O
+virus	B-SPEC
+spread	O
+.	O
+
+If	O
+complement	O
+regulatory	O
+protein	B-CHED
+such	O
+as	O
+endothelial	B-ANAT
+CD59	B-PRGE
+is	O
+underexpressed	O
+,	O
+MAC	B-COMP
+may	O
+also	O
+cause	O
+pulmonary	B-ANAT
+vascular	B-ANAT
+injury	O
+to	O
+the	O
+innocent	O
+bystander	O
+endothelial	B-ANAT
+cell	I-ANAT
+of	O
+host	B-COMP
+and	O
+provokes	O
+endotheliopathy	O
+that	O
+causes	O
+inflammation	B-DISO
+and	O
+pulmonary	B-ANAT
+vascular	B-ANAT
+microthrombosis	O
+,	O
+leading	O
+to	O
+ARDS	O
+.	O
+
+Endotheliopathy	O
+activates	O
+two	O
+independent	O
+molecular	O
+pathways	B-PROC
+:	O
+inflammatory	O
+and	O
+microthrombotic	O
+.	O
+
+It	O
+leads	O
+to	O
+endotheliopathy	O
+-	O
+associated	O
+vascular	B-ANAT
+microthrombotic	O
+disease	O
+(	O
+EA	O
+-	O
+VMTD	O
+),	O
+which	O
+orchestrates	O
+consumptive	O
+thrombocytopenia	O
+,	O
+microangiopathic	B-DISO
+hemolytic	I-DISO
+anemia	I-DISO
+,	O
+and	O
+MODS	B-DISO
+.	O
+
+Thrombotic	B-DISO
+thrombocytopenic	I-DISO
+purpura	I-DISO
+(	O
+TTP	B-DISO
+)-	O
+like	O
+syndrome	B-DISO
+is	O
+the	O
+hematologic	O
+phenotype	O
+of	O
+EA	O
+-	O
+VMTD	O
+.	O
+
+To	O
+support	O
+and	O
+accelerate	O
+vaccine	O
+development	B-PROC
+,	O
+CEPI	O
+will	O
+also	O
+support	O
+science	O
+projects	O
+related	O
+to	O
+the	O
+development	B-PROC
+of	O
+biological	O
+standards	O
+and	O
+assays	O
+,	O
+animal	B-SPEC
+models	O
+,	O
+epidemiological	O
+studies	O
+,	O
+and	O
+diagnostics	O
+,	O
+as	O
+well	O
+as	O
+build	O
+capacities	O
+for	O
+future	O
+clinical	O
+trials	O
+in	O
+risk	O
+-	O
+prone	O
+contexts	O
+.	O
+
+We	O
+aimed	O
+to	O
+describe	O
+clinical	O
+and	O
+serological	O
+characteristics	O
+of	O
+children	O
+with	O
+HBoV	O
+hospitalized	O
+for	O
+acute	B-DISO
+respiratory	I-DISO
+tract	I-DISO
+infection	I-DISO
+and	O
+to	O
+evaluate	O
+whether	O
+differences	O
+occur	O
+between	O
+HBoV	O
+alone	O
+and	O
+in	O
+co	B-DISO
+-	I-DISO
+infection	I-DISO
+.	O
+
+Among	O
+the	O
+60	O
+patients	O
+,	O
+34	O
+were	O
+bronchiolitis	B-DISO
+,	O
+19	O
+wheezing	B-DISO
+,	O
+3	O
+pneumonia	B-DISO
+,	O
+2	O
+upper	B-DISO
+respiratory	I-DISO
+tract	I-DISO
+infection	I-DISO
+,	O
+and	O
+2	O
+whooping	B-DISO
+cough	I-DISO
+.	O
+
+Seven	O
+children	O
+(	O
+11	O
+.	O
+6	O
+%)	O
+required	O
+admission	O
+to	O
+the	O
+paediatric	O
+intensive	O
+care	O
+unit	O
+(	O
+PICU	B-SPEC
+)	O
+for	O
+respiratory	B-DISO
+failure	I-DISO
+.	O
+
+A	O
+cause	O
+-	O
+effect	O
+relationship	O
+between	O
+HBoV	O
+and	O
+respiratory	B-DISO
+infection	I-DISO
+is	O
+not	O
+clear	O
+,	O
+so	O
+further	O
+studies	O
+are	O
+needed	O
+to	O
+clarify	O
+this	O
+point	O
+.	O
+
+An	O
+appropriate	O
+immune	B-PROC
+response	I-PROC
+requires	O
+controlling	O
+the	O
+viral	B-DISO
+infection	I-DISO
+through	O
+activation	O
+of	O
+antiviral	B-CHED
+defenses	O
+,	O
+which	O
+involves	O
+cells	B-COMP
+of	O
+the	O
+lung	B-ANAT
+and	O
+immune	B-ANAT
+system	I-ANAT
+.	O
+
+High	O
+levels	O
+of	O
+viral	B-DISO
+infection	I-DISO
+or	O
+high	O
+levels	O
+of	O
+inflammation	B-DISO
+in	O
+the	O
+lower	O
+airways	O
+can	O
+contribute	O
+to	O
+ARDS	B-DISO
+.	O
+
+A	O
+total	O
+of	O
+135	O
+infants	O
+admitted	O
+to	O
+the	O
+PICU	B-SPEC
+were	O
+compared	O
+with	O
+135	O
+randomly	O
+selected	O
+control	O
+infants	O
+admitted	O
+to	O
+the	O
+general	O
+pediatric	O
+unit	O
+.	O
+
+We	O
+performed	O
+retrospective	O
+analysis	O
+of	O
+laboratory	O
+-	O
+confirmed	O
+MERS	O
+-	O
+CoV	O
+infections	B-DISO
+reported	O
+to	O
+the	O
+World	O
+Health	O
+Organization	O
+to	O
+27	O
+November	O
+2018	O
+to	O
+summarize	O
+what	O
+is	O
+known	O
+about	O
+asymptomatic	B-DISO
+infections	I-DISO
+identified	O
+through	O
+national	O
+surveillance	O
+systems	O
+.	O
+
+We	O
+identified	O
+20	O
+studies	O
+in	O
+health	O
+care	O
+settings	O
+,	O
+of	O
+health	O
+care	O
+worker	O
+(	O
+HCW	O
+)	O
+and	O
+family	B-SPEC
+contacts	O
+,	O
+of	O
+which	O
+11	O
+documented	O
+molecular	O
+evidence	O
+of	O
+MERS	O
+-	O
+CoV	O
+infection	B-DISO
+among	O
+asymptomatic	O
+contacts	O
+.	O
+
+ABSTRACT	O
+:	O
+The	O
+autoimmune	B-DISO
+polyglandular	O
+syndromes	B-DISO
+(	O
+APS	B-DISO
+)	O
+are	O
+rare	O
+immune	O
+-	O
+mediated	O
+endocrinopathies	B-DISO
+causing	O
+destruction	O
+of	O
+multiple	O
+endocrine	B-CHED
+and	O
+non	O
+-	O
+endocrine	B-ANAT
+organs	I-ANAT
+.	O
+
+Emergent	O
+medical	O
+evaluation	O
+revealed	O
+severe	O
+hypotension	O
+(	O
+51	O
+/	O
+30	O
+mm	O
+/	O
+Hg	O
+)	O
+and	O
+profound	O
+hypoglycemia	B-DISO
+(	O
+blood	B-ANAT
+glucose	B-CHED
+of	O
+20	O
+-	O
+30	O
+mg	O
+/	O
+dl	O
+).	O
+
+The	O
+implementation	O
+of	O
+a	O
+dedicated	O
+protocol	O
+in	O
+specialized	O
+centers	O
+and	O
+the	O
+involvement	O
+of	O
+5	O
+trained	O
+and	O
+skilled	O
+professionals	O
+while	O
+moving	B-PROC
+the	O
+patient	O
+in	O
+the	O
+prone	O
+position	O
+are	O
+recommended	O
+to	O
+prevent	O
+the	O
+occurrence	O
+of	O
+similar	O
+adverse	O
+events	O
+.	O
+
+Corticosteroids	B-CHED
+were	O
+prescribed	O
+in	O
+20	O
+/	O
+55	O
+(	O
+36	O
+%).	O
+
+In	O
+patients	O
+with	O
+severe	O
+leptospirosis	B-DISO
+in	O
+tropical	O
+Australia	O
+,	O
+prompt	O
+ICU	O
+support	O
+that	O
+includes	O
+early	O
+antibiotics	B-CHED
+,	O
+protective	O
+ventilation	O
+strategies	O
+,	O
+conservative	O
+fluid	O
+resuscitation	O
+,	O
+traditional	O
+thresholds	O
+for	O
+RRT	O
+initiation	O
+and	O
+corticosteroid	B-CHED
+therapy	O
+is	O
+associated	O
+with	O
+a	O
+very	O
+low	O
+case	O
+-	O
+fatality	O
+rate	O
+.	O
+
+The	O
+primary	O
+outcome	O
+was	O
+the	O
+proportion	O
+of	O
+antibiotics	B-CHED
+discontinuation	O
+or	O
+de	O
+-	O
+escalation	O
+in	O
+the	O
+ED	O
+.	O
+
+Infections	B-DISO
+are	O
+initiated	O
+via	O
+binding	B-FUNC
+of	O
+the	O
+MERS	B-PRGE
+-	I-PRGE
+CoV	I-PRGE
+spike	I-PRGE
+(	I-PRGE
+S	I-PRGE
+)	I-PRGE
+glycoprotein	I-PRGE
+to	O
+sialosides	O
+and	O
+dipeptidyl	O
+-	O
+peptidase	O
+4	O
+(	O
+the	O
+attachment	O
+and	O
+entry	O
+receptors	O
+,	O
+respectively	O
+).	O
+
+To	O
+understand	O
+MERS	O
+-	O
+CoV	O
+engagement	O
+of	O
+sialylated	O
+receptors	O
+,	O
+we	O
+determined	O
+the	O
+cryo	O
+-	O
+EM	O
+structures	O
+of	O
+S	O
+in	O
+complex	O
+with	O
+5	O
+-	O
+N	O
+-	O
+acetyl	B-CHED
+neuraminic	B-CHED
+acid	I-CHED
+,	O
+5	O
+-	O
+N	O
+-	O
+glycolyl	B-CHED
+neuraminic	B-CHED
+acid	I-CHED
+,	O
+sialyl	O
+-	O
+Lewis	O
+
+TITLE	O
+:	O
+Anesthesia	B-DISO
+Management	O
+for	O
+a	O
+Patient	O
+Undergoing	O
+Pulmonary	B-ANAT
+Endarterctomy	O
+without	O
+Cardiopulmonary	B-ANAT
+Bypass	O
+.	O
+
+LUS	O
+offers	O
+promise	O
+as	O
+a	O
+valuable	O
+clinical	O
+tool	O
+for	O
+the	O
+diagnosis	O
+and	O
+treatment	O
+of	O
+patients	O
+with	O
+severe	O
+dyspnea	B-DISO
+and	O
+acute	O
+hypoxic	B-DISO
+respiratory	B-DISO
+failure	I-DISO
+.	O
+
+Over	O
+70	O
+%	O
+of	O
+infected	O
+dromedaries	B-SPEC
+are	O
+found	O
+in	O
+Africa	O
+.	O
+
+LUS	O
+in	O
+the	O
+initial	O
+assessment	O
+of	O
+patients	O
+'	O
+with	O
+ARDS	B-DISO
+yielded	O
+significant	O
+findings	O
+in	O
+the	O
+three	O
+clinically	O
+designated	O
+categories	O
+.	O
+
+ABSTRACT	O
+:	O
+Equine	B-SPEC
+coronavirus	B-SPEC
+(	O
+ECoV	O
+)	O
+is	O
+considered	O
+to	O
+be	O
+involved	O
+in	O
+enteric	O
+diseases	O
+in	O
+foals	O
+.	O
+
+In	O
+this	O
+study	O
+,	O
+an	O
+indirect	O
+enzyme	O
+-	O
+linked	O
+immunosorbent	O
+assay	O
+(	O
+ELISA	O
+)	O
+method	O
+utilizing	O
+ECoV	B-PRGE
+spike	I-PRGE
+S1	I-PRGE
+protein	I-PRGE
+was	O
+developed	O
+in	O
+two	O
+formats	O
+,	O
+and	O
+further	O
+validated	O
+by	O
+analyzing	O
+27	O
+paired	O
+serum	B-COMP
+samples	O
+(	O
+acute	O
+and	O
+convalescent	O
+sera	B-COMP
+)	O
+from	O
+horses	B-SPEC
+involved	O
+in	O
+an	O
+ECoV	O
+outbreak	O
+and	O
+1084	O
+sera	B-COMP
+of	O
+horses	B-SPEC
+with	O
+unknown	O
+ECoV	O
+exposure	O
+.	O
+
+We	O
+found	O
+that	O
+the	O
+spike	O
+protein	B-CHED
+of	O
+PDF2180	O
+-	O
+CoV	O
+,	O
+a	O
+MERS	O
+-	O
+like	O
+virus	B-SPEC
+found	O
+in	O
+a	O
+Ugandan	O
+bat	B-ENZY
+,	O
+could	O
+mediate	O
+infection	B-DISO
+of	O
+Vero	O
+and	O
+human	B-SPEC
+cells	B-COMP
+in	O
+the	O
+presence	O
+of	O
+exogenous	O
+trypsin	B-PRGE
+.	O
+
+ABSTRACT	O
+:	O
+Middle	O
+East	O
+Respiratory	O
+Syndrome	B-DISO
+Coronavirus	B-SPEC
+(	O
+MERS	O
+-	O
+CoV	O
+)	O
+became	O
+a	O
+global	O
+human	B-SPEC
+health	O
+threat	O
+since	O
+its	O
+first	O
+documentation	O
+in	O
+humans	B-SPEC
+in	O
+2012	O
+.	O
+
+An	O
+efficient	O
+vaccine	O
+for	O
+the	O
+prophylaxis	O
+of	O
+humans	B-SPEC
+in	O
+hotspots	O
+of	O
+the	O
+infection	B-DISO
+(	O
+e	O
+.	O
+g	O
+.,	O
+Saudi	O
+Arabia	O
+)	O
+is	O
+necessary	O
+but	O
+no	O
+commercial	O
+vaccines	O
+are	O
+yet	O
+approved	O
+.	O
+
+The	O
+chimeric	O
+bivalent	O
+5	O
++	O
+3	O
+vaccine	O
+strain	O
+comprises	O
+a	O
+recombinant	O
+PR8	O
+-	O
+based	O
+vaccine	O
+,	O
+expressing	O
+the	O
+PB1	B-PRGE
+,	O
+HA	O
+,	O
+and	O
+chimeric	O
+NA	O
+of	O
+pandemic	O
+2009	O
+H1N1	O
+.	O
+
+Eyes	B-ANAT
+may	O
+show	O
+conjunctival	B-DISO
+injection	I-DISO
+,	O
+abrasions	O
+and	O
+corrosions	O
+.	O
+
+Laryngoscopy	O
+should	O
+be	O
+performed	O
+if	O
+glottis	B-DISO
+edema	I-DISO
+is	O
+suspected	O
+.	O
+
+New	O
+and	O
+promising	O
+therapies	O
+are	O
+in	O
+development	B-PROC
+.	O
+
+These	O
+observations	O
+indicate	O
+that	O
+5	O
+is	O
+structurally	O
+and	O
+mechanistically	O
+distinct	O
+from	O
+the	O
+published	O
+allosteric	O
+HIV	B-SPEC
+-	I-SPEC
+1	I-SPEC
+IN	O
+inhibitors	B-CHED
+.	O
+
+Moreover	O
+,	O
+compound	O
+5	O
+also	O
+inhibited	O
+HIV	B-SPEC
+-	I-SPEC
+1	I-SPEC
+RNase	B-PRGE
+H	I-PRGE
+function	O
+,	O
+classifying	O
+this	O
+molecule	O
+as	O
+a	O
+dual	O
+HIV	B-SPEC
+-	I-SPEC
+1	I-SPEC
+IN	O
+and	O
+RNase	B-PRGE
+H	I-PRGE
+inhibitor	B-CHED
+able	O
+to	O
+impair	O
+the	O
+HIV	B-SPEC
+-	I-SPEC
+1	I-SPEC
+virus	B-PROC
+replication	I-PROC
+in	O
+cell	B-COMP
+culture	O
+.	O
+
+However	O
+,	O
+low	O
+relative	O
+humidity	O
+(	O
+IRR	O
+=	O
+0	O
+.	O
+956	O
+,	O
+95	O
+%	O
+CI	O
+:	O
+0	O
+.	O
+948	O
+-	O
+0	O
+.	O
+964	O
+)	O
+and	O
+low	O
+wind	B-DISO
+speed	O
+(	O
+IRR	O
+=	O
+0	O
+.	O
+945	O
+,	O
+95	O
+%	O
+CI	O
+:	O
+0	O
+.	O
+912	O
+-	O
+0	O
+.	O
+979	O
+)	O
+were	O
+correlated	O
+with	O
+a	O
+lower	O
+incidence	O
+of	O
+MERS	O
+-	O
+CoV	O
+cases	O
+.	O
+
+Based	O
+on	O
+these	O
+findings	O
+,	O
+CTD	O
+may	O
+be	O
+a	O
+promising	O
+target	O
+for	O
+development	B-PROC
+of	O
+an	O
+effective	O
+vaccine	O
+against	O
+PDCoV	O
+infection	B-DISO
+in	O
+pigs	B-SPEC
+.	O
+
+With	O
+carefully	O
+selected	O
+patients	O
+,	O
+awake	O
+ECMO	O
+is	O
+a	O
+feasible	O
+and	O
+safe	O
+strategy	O
+for	O
+severe	O
+pulmonary	B-ANAT
+ARDS	B-DISO
+patients	O
+receiving	O
+prolonged	O
+ECMO	O
+support	O
+to	O
+wait	O
+for	O
+native	O
+lung	B-ANAT
+recovery	O
+.	O
+
+TITLE	O
+:	O
+Estimation	O
+Of	O
+Direct	O
+Medical	O
+Costs	O
+Of	O
+Middle	O
+East	O
+Respiratory	O
+Syndrome	B-DISO
+Coronavirus	B-DISO
+Infection	I-DISO
+:	O
+A	O
+Single	O
+-	O
+Center	O
+Retrospective	O
+Chart	O
+Review	O
+Study	O
+.	O
+
+TITLE	O
+:	O
+Attenuated	O
+live	O
+infectious	B-DISO
+bronchitis	B-DISO
+virus	B-SPEC
+QX	O
+vaccine	O
+disseminates	O
+slowly	O
+to	O
+target	O
+organs	B-ANAT
+distant	O
+from	O
+the	O
+site	O
+of	O
+inoculation	O
+.	O
+
+In	O
+the	O
+trachea	B-DISO
+,	O
+viral	O
+RNA	B-PROC
+replication	I-PROC
+and	O
+protein	B-PROC
+expression	B-PROC
+were	O
+comparable	O
+in	O
+both	O
+groups	O
+.	O
+
+In	O
+the	O
+kidney	B-ANAT
+distal	O
+tubular	O
+segments	O
+,	O
+collecting	B-ANAT
+ducts	I-ANAT
+and	O
+ureter	B-ANAT
+were	O
+positive	O
+for	O
+viral	B-PRGE
+antigen	I-PRGE
+.	O
+
+We	O
+reviewed	O
+original	O
+research	O
+on	O
+occupational	O
+health	O
+and	O
+safety	O
+of	O
+animal	B-SPEC
+workers	O
+published	O
+from	O
+January	O
+1	O
+,	O
+2018	O
+,	O
+through	O
+June	O
+30	O
+,	O
+2019	O
+,	O
+with	O
+a	O
+targeted	B-PROC
+focus	O
+on	O
+infectious	B-DISO
+disease	I-DISO
+studies	O
+published	O
+in	O
+these	O
+populations	O
+.	O
+
+Research	O
+on	O
+zoonotic	O
+MRSA	B-DISO
+used	O
+whole	O
+genome	O
+-	O
+sequencing	O
+technologies	O
+to	O
+evaluate	O
+transmission	O
+in	O
+Africa	O
+and	O
+Asia	O
+.	O
+
+Swine	B-SPEC
+worker	O
+exposure	O
+to	O
+porcine	B-SPEC
+coronavirus	B-SPEC
+and	O
+emerging	O
+influenza	B-PATH
+A	I-PATH
+viruses	B-SPEC
+was	O
+documented	O
+in	O
+China	O
+.	O
+
+The	O
+basic	O
+criterion	O
+of	O
+patient	O
+inclusion	O
+was	O
+stable	O
+respiration	B-PROC
+impairment	B-DISO
+leading	O
+to	O
+hypoxia	B-DISO
+with	O
+PaO	B-PROC
+Pancreatitis	B-DISO
+-	O
+associated	O
+ARDS	B-DISO
+was	O
+diagnosed	O
+in	O
+36	O
+cases	O
+(	O
+53	O
+.	O
+7	O
+%).	O
+
+Our	O
+data	O
+suggest	O
+that	O
+the	O
+antibody	O
+/	O
+Fc	B-COMP
+-	I-COMP
+receptor	I-COMP
+complex	I-COMP
+functionally	O
+mimics	O
+viral	B-PRGE
+receptor	I-PRGE
+in	O
+mediating	O
+viral	O
+entry	O
+.	O
+
+The	O
+Spike	B-PRGE
+protein	I-PRGE
+gene	I-PRGE
+plays	O
+a	O
+significant	O
+role	O
+in	O
+virus	B-SPEC
+attachment	O
+to	O
+host	B-COMP
+cells	B-COMP
+.	O
+
+The	O
+nucleotide	B-CHED
+and	O
+amino	B-CHED
+acid	I-CHED
+sequences	O
+of	O
+MERS	B-PRGE
+-	I-PRGE
+CoV	I-PRGE
+Spike	I-PRGE
+protein	I-PRGE
+gene	I-PRGE
+were	O
+used	O
+to	O
+analyze	O
+the	O
+recombination	O
+,	O
+genetic	O
+diversity	O
+and	O
+phylogenetic	O
+relationship	O
+with	O
+selected	O
+sequences	O
+from	O
+Saudi	O
+Arabia	O
+.	O
+
+CONCLUSIONS	O
+:	O
+The	O
+generated	O
+information	O
+from	O
+this	O
+study	O
+is	O
+very	O
+valuable	O
+and	O
+it	O
+will	O
+be	O
+used	O
+to	O
+design	O
+and	O
+develop	O
+therapeutic	O
+compounds	O
+and	O
+vaccine	O
+to	O
+control	O
+the	O
+MERS	O
+-	O
+CoV	O
+disease	O
+spread	O
+in	O
+not	O
+only	O
+in	O
+the	O
+Kingdom	B-SPEC
+but	O
+also	O
+globally	O
+.	O
+
+TITLE	O
+:	O
+Epidemiological	O
+study	O
+of	O
+pediatric	O
+severe	B-DISO
+sepsis	I-DISO
+in	O
+Argentina	B-SPEC
+.	O
+
+Patients	O
+with	O
+a	O
+higher	O
+mortality	O
+were	O
+those	O
+who	O
+were	O
+coming	O
+from	O
+rural	O
+areas	O
+,	O
+had	O
+comorbidities	O
+at	O
+the	O
+time	O
+of	O
+admission	O
+or	O
+a	O
+history	O
+of	O
+cancer	B-DISO
+,	O
+had	O
+shock	O
+or	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+(	O
+ARDS	B-DISO
+),	O
+were	O
+administered	O
+low	O
+-	O
+dose	O
+corticosteroids	B-CHED
+or	O
+vasoactive	O
+drugs	O
+or	O
+more	O
+than	O
+60	O
+ml	O
+/	O
+kg	O
+of	O
+fluid	O
+in	O
+the	O
+first	O
+hour	O
+and	O
+in	O
+the	O
+first	O
+6hours	O
+,	O
+and	O
+had	O
+severe	B-DISO
+malnutrition	I-DISO
+.	O
+
+Downregulation	B-PROC
+of	O
+miR	B-PRGE
+-	I-PRGE
+142a	I-PRGE
+-	I-PRGE
+3p	I-PRGE
+by	O
+an	O
+miRNA	O
+inhibitor	B-CHED
+led	O
+to	O
+a	O
+significant	O
+repression	O
+of	O
+viral	O
+proliferation	B-DISO
+,	O
+implying	O
+that	O
+it	O
+acts	O
+as	O
+a	O
+positive	O
+regulator	O
+of	O
+PHEV	O
+proliferation	B-DISO
+.	O
+
+We	O
+then	O
+applied	O
+it	O
+to	O
+diagnostic	O
+data	O
+available	O
+for	O
+five	O
+respiratory	O
+viruses	B-SPEC
+co	O
+-	O
+circulating	O
+in	O
+a	O
+major	O
+urban	O
+population	O
+between	O
+2005	O
+and	O
+2013	O
+:	O
+adenovirus	B-DISO
+,	O
+human	B-SPEC
+coronavirus	I-SPEC
+,	O
+human	B-SPEC
+metapneumovirus	I-SPEC
+,	O
+influenza	B-SPEC
+B	I-SPEC
+virus	I-SPEC
+and	O
+respiratory	B-SPEC
+syncytial	I-SPEC
+virus	I-SPEC
+.	O
+
+Clinicopathological	O
+features	O
+include	O
+fever	B-PROC
+,	O
+vasculitis	B-DISO
+,	O
+and	O
+serositis	B-DISO
+,	O
+with	O
+or	O
+without	O
+effusions	B-DISO
+;	O
+all	O
+of	O
+which	O
+indicate	O
+a	O
+pro	B-CHED
+-	O
+inflammatory	O
+state	O
+with	O
+cytokine	O
+release	B-PATH
+.	O
+
+Previously	O
+,	O
+we	O
+demonstrated	O
+that	O
+MERS	O
+-	O
+CoV	O
+-	O
+encoded	O
+ORF8b	O
+strongly	O
+inhibits	O
+MDA5	B-PRGE
+-	O
+and	O
+RIG	B-PRGE
+-	I-PRGE
+I	I-PRGE
+-	O
+mediated	O
+induction	O
+of	O
+the	O
+interferon	B-PRGE
+beta	I-PRGE
+(	O
+IFN	B-PRGE
+-	I-PRGE
+β	I-PRGE
+)	O
+promoter	O
+activities	O
+.	O
+
+Here	O
+,	O
+we	O
+report	O
+that	O
+ORF8b	O
+seem	O
+to	O
+regulate	O
+MDA5	B-PRGE
+or	O
+RIG	B-PRGE
+-	I-PRGE
+I	I-PRGE
+differentially	O
+as	O
+protein	B-CHED
+levels	O
+of	O
+MDA5	B-PRGE
+were	O
+significantly	O
+down	O
+-	O
+regulated	O
+while	O
+those	O
+of	O
+RIG	O
+-	O
+I	O
+were	O
+largely	O
+unperturbed	O
+.	O
+
+Unlike	O
+human	B-PRGE
+dipeptidyl	I-PRGE
+peptidase	I-PRGE
+4	I-PRGE
+(	O
+hDPP4	O
+),	O
+a	O
+receptor	O
+for	O
+MERS	O
+-	O
+CoV	O
+,	O
+mouse	B-PRGE
+DPP4	I-PRGE
+(	O
+mDPP4	O
+)	O
+failed	O
+to	O
+support	O
+MERS	O
+-	O
+CoV	O
+infection	B-DISO
+.	O
+
+As	O
+this	O
+cytotoxicity	B-DISO
+may	O
+be	O
+attributed	O
+to	O
+5	O
+'-	O
+phosphorylation	B-PROC
+,	O
+we	O
+designed	O
+and	O
+synthesized	O
+one	O
+-	O
+carbon	B-CHED
+homologated	O
+6	O
+'-	O
+fluorinated	O
+-	O
+aristeromycin	O
+analogues	O
+.	O
+
+We	O
+determined	O
+the	O
+prevalence	O
+of	O
+MERS	O
+-	O
+CoV	O
+infection	B-DISO
+,	O
+age	O
+-	O
+associated	O
+patterns	O
+of	O
+infection	B-DISO
+,	O
+and	O
+undertook	O
+phylogeographical	O
+and	O
+migration	B-PROC
+analyses	O
+to	O
+determine	O
+intercountry	O
+virus	O
+transmission	O
+after	O
+local	O
+lineage	O
+establishment	O
+.	O
+
+Reproductive	B-PROC
+numbers	O
+were	O
+inferred	O
+with	O
+Bayesian	O
+birth	B-PROC
+death	B-PROC
+skyline	O
+analyses	O
+.	O
+
+Between	O
+Aug	O
+10	O
+,	O
+2016	O
+,	O
+and	O
+May	O
+3	O
+,	O
+2018	O
+,	O
+we	O
+collected	O
+samples	O
+from	O
+1196	O
+imported	O
+camels	B-SPEC
+,	O
+of	O
+which	O
+868	O
+originated	O
+from	O
+Sudan	O
+and	O
+328	O
+from	O
+Djibouti	O
+,	O
+and	O
+between	O
+May	O
+1	O
+,	O
+and	O
+June	O
+25	O
+,	O
+2018	O
+,	O
+we	O
+collected	O
+samples	O
+from	O
+472	O
+local	O
+camels	B-SPEC
+,	O
+of	O
+which	O
+189	O
+were	O
+from	O
+Riyadh	O
+and	O
+283	O
+were	O
+from	O
+Jeddah	O
+,	O
+Saudi	O
+Arabia	O
+.	O
+
+Understanding	O
+its	O
+burden	O
+,	O
+as	O
+an	O
+emerging	B-DISO
+infectious	I-DISO
+disease	I-DISO
+,	O
+is	O
+vital	O
+for	O
+devising	O
+appropriate	O
+control	O
+strategies	O
+.	O
+
+This	O
+study	O
+aimed	O
+to	O
+(	O
+i	O
+)	O
+investigate	O
+a	O
+cross	O
+-	O
+sectional	O
+incidence	O
+of	O
+canine	O
+respiratory	O
+viruses	B-SPEC
+,	O
+including	O
+influenza	B-DISO
+(	O
+CIV	B-SPEC
+),	O
+parainfluenza	B-DISO
+,	O
+distemper	B-DISO
+(	O
+CDV	B-CHED
+),	O
+respiratory	O
+coronavirus	B-SPEC
+(	O
+CRCoV	O
+),	O
+adenovirus	B-DISO
+-	O
+2	O
+,	O
+and	O
+herpesvirus	B-SPEC
+,	O
+in	O
+respiratory	O
+-	O
+diseased	O
+dogs	B-SPEC
+,	O
+and	O
+(	O
+ii	O
+)	O
+analyze	O
+the	O
+possibly	O
+related	O
+risk	O
+factors	O
+.	O
+
+Moreover	O
+,	O
+the	O
+clinical	O
+severity	O
+level	O
+was	O
+notably	O
+related	O
+to	O
+the	O
+age	O
+of	O
+infected	O
+dogs	B-SPEC
+,	O
+but	O
+not	O
+to	O
+the	O
+vaccination	O
+status	O
+,	O
+sex	O
+and	O
+transmission	O
+route	O
+.	O
+
+Additionally	O
+,	O
+we	O
+describe	O
+the	O
+entire	O
+coding	O
+sequences	O
+for	O
+five	O
+alphacoronaviruses	O
+(	O
+representing	O
+four	O
+putative	O
+new	O
+species	B-SPEC
+),	O
+and	O
+one	O
+novel	O
+adenovirus	B-DISO
+.	O
+
+Antigen	B-CHED
+-	O
+specific	O
+humoral	O
+and	O
+cellular	B-PROC
+immune	I-PROC
+responses	I-PROC
+were	O
+evaluated	O
+in	O
+serum	B-COMP
+and	O
+in	O
+cell	B-COMP
+culture	O
+following	O
+S1	B-PRGE
+protein	I-PRGE
+expression	B-PROC
+was	O
+only	O
+detected	O
+by	O
+IHC	O
+in	O
+the	O
+kidneys	B-ANAT
+of	O
+the	O
+Ad	O
+-	O
+MERS	O
+-	O
+S1	O
+group	O
+at	O
+week	O
+6	O
+from	O
+first	O
+immunization	O
+,	O
+and	O
+in	O
+both	O
+lungs	B-ANAT
+and	O
+kidneys	B-ANAT
+of	O
+Ad	O
+-	O
+MERS	O
+-	O
+S1	O
+group	O
+by	O
+conventional	O
+PCR	O
+at	O
+weeks	O
+3	O
+and	O
+5	O
+post	O
+-	O
+prime	O
+.	O
+
+The	O
+results	O
+of	O
+this	O
+study	O
+suggest	O
+that	O
+this	O
+recombinant	O
+adenovirus	B-DISO
+vaccine	O
+encoding	O
+the	O
+S1	O
+subunit	O
+of	O
+MERS	O
+-	O
+CoV	O
+elicits	O
+potentially	O
+protective	O
+antigen	B-CHED
+-	O
+specific	O
+humoral	O
+and	O
+cellular	B-PROC
+immune	I-PROC
+responses	I-PROC
+in	O
+mice	B-SPEC
+.	O
+
+ABSTRACT	O
+:	O
+Ambulance	O
+dispatches	O
+for	O
+respiratory	O
+syndromes	O
+reflect	O
+incidence	O
+of	O
+influenza	B-DISO
+-	I-DISO
+like	I-DISO
+illness	I-DISO
+in	O
+primary	O
+care	O
+.	O
+
+TITLE	O
+:	O
+Diabetes	B-DISO
+Mellitus	I-DISO
+,	O
+Hypertension	B-DISO
+,	O
+and	O
+Death	B-PROC
+among	O
+32	O
+Patients	O
+with	O
+MERS	O
+-	O
+CoV	O
+Infection	B-DISO
+,	O
+Saudi	O
+Arabia	O
+.	O
+
+Here	O
+,	O
+we	O
+generated	O
+,	O
+for	O
+the	O
+first	O
+time	O
+,	O
+a	O
+full	O
+-	O
+length	O
+infectious	B-DISO
+cDNA	O
+clone	O
+of	O
+PDCoV	O
+.	O
+We	O
+further	O
+manipulated	O
+the	O
+infectious	B-DISO
+clone	O
+by	O
+replacing	O
+the	O
+NS6	B-PRGE
+gene	I-PRGE
+with	O
+a	O
+green	B-PRGE
+fluorescent	I-PRGE
+protein	I-PRGE
+(	O
+GFP	B-CHED
+)	O
+to	O
+generate	O
+rPDCoV	O
+-	O
+ΔNS6	O
+-	O
+GFP	B-CHED
+;	O
+likewise	O
+,	O
+rPDCoV	O
+-	O
+ΔNS7	O
+was	O
+constructed	O
+by	O
+removing	O
+the	O
+ATG	O
+start	O
+codons	O
+of	O
+the	O
+NS7	B-PRGE
+gene	I-PRGE
+.	O
+
+Growth	B-PROC
+kinetics	O
+studies	O
+suggest	O
+that	O
+rPDCoV	O
+-	O
+ΔNS7	O
+could	O
+replicate	O
+similarly	O
+to	O
+that	O
+of	O
+the	O
+wild	O
+-	O
+type	O
+PDCoV	O
+,	O
+whereas	O
+rPDCoV	O
+-	O
+ΔNS6	O
+-	O
+GFP	O
+exhibited	O
+a	O
+substantial	O
+reduction	O
+of	O
+viral	O
+titer	O
+
+TITLE	O
+:	O
+Human	B-SPEC
+Coronaviruses	O
+and	O
+Other	O
+Respiratory	O
+Viruses	B-SPEC
+:	O
+Underestimated	O
+Opportunistic	O
+Pathogens	O
+of	O
+the	O
+Central	O
+Nervous	O
+System	O
+?	O
+
+The	O
+etiological	O
+agent	O
+of	O
+several	O
+neurological	B-DISO
+disorders	I-DISO
+remains	O
+unidentified	O
+.	O
+
+Herein	O
+,	O
+we	O
+present	O
+a	O
+global	O
+portrait	O
+of	O
+some	O
+of	O
+the	O
+most	O
+prevalent	O
+or	O
+emerging	O
+human	B-SPEC
+respiratory	O
+viruses	B-SPEC
+that	O
+have	O
+been	O
+associated	O
+with	O
+possible	O
+pathogenic	O
+processes	O
+in	O
+CNS	B-DISO
+infection	I-DISO
+,	O
+with	O
+a	O
+special	O
+emphasis	O
+on	O
+human	B-SPEC
+coronaviruses	O
+.	O
+
+Consequently	O
+,	O
+the	O
+obtained	O
+results	O
+displayed	O
+that	O
+,	O
+5a	O
+-	O
+d	O
+and	O
+6d	O
+present	O
+a	O
+leading	O
+structure	O
+for	O
+future	O
+drug	O
+development	B-PROC
+due	O
+to	O
+its	O
+straightforward	O
+synthesis	B-PROC
+and	O
+relevant	O
+bioactivity	O
+.	O
+
+The	O
+protease	B-PRGE
+3CL	I-PRGE
+(	O
+3CL	O
+
+TITLE	O
+:	O
+Antiviral	B-CHED
+activity	O
+of	O
+interleukin	B-PRGE
+-	I-PRGE
+11	I-PRGE
+as	O
+a	O
+response	O
+to	O
+porcine	B-SPEC
+epidemic	I-SPEC
+diarrhea	I-SPEC
+virus	B-PROC
+infection	I-PROC
+.	O
+
+Our	O
+data	O
+suggest	O
+that	O
+IL	B-FUNC
+-	I-FUNC
+11	I-FUNC
+is	O
+a	O
+newfound	O
+PEDV	B-SPEC
+-	O
+inducible	O
+cytokine	O
+,	O
+and	O
+its	O
+production	O
+enhances	O
+the	O
+anti	B-PROC
+-	I-PROC
+apoptosis	I-PROC
+ability	O
+of	O
+epithelial	B-ANAT
+cells	I-ANAT
+against	O
+PEDV	B-SPEC
+infection	B-DISO
+.	O
+
+Pregnant	O
+women	O
+developed	O
+pneumonia	B-DISO
+more	O
+often	O
+than	O
+other	O
+women	O
+in	O
+the	O
+reproductive	B-PROC
+period	O
+,	O
+but	O
+without	O
+statistical	O
+significance	O
+(	O
+81	O
+.	O
+8	O
+%	O
+vs	O
+.	O
+65	O
+.	O
+7	O
+%,	O
+p	O
+=	O
+0	O
+.	O
+330	O
+,	O
+OR	O
+(	O
+95	O
+%	O
+CI	O
+)	O
+2	O
+.	O
+35	O
+(	O
+0	O
+.	O
+47	O
+-	O
+11	O
+.	O
+80	O
+)).	O
+
+Gestational	O
+week	O
+of	O
+pregnancy	O
+,	O
+the	O
+etiology	O
+of	O
+pneumonia	B-DISO
+and	O
+comorbidity	O
+were	O
+not	O
+found	O
+to	O
+be	O
+risk	O
+factors	O
+for	O
+death	B-PROC
+(	O
+p	O
+=	O
+0	O
+.	O
+128	O
+,	O
+p	O
+=	O
+0	O
+.	O
+499	O
+and	O
+p	O
+=	O
+1	O
+.	O
+000	O
+,	O
+respectively	O
+).	O
+
+We	O
+selected	O
+17	O
+porcine	B-SPEC
+respiratory	O
+pathogens	O
+(	O
+Actinobacillus	B-SPEC
+pleuropneumoniae	I-SPEC
+,	O
+Boldetella	O
+bronchiseptica	O
+,	O
+Haemophilus	B-SPEC
+parasuis	I-SPEC
+,	O
+Pasteurella	B-SPEC
+multocida	I-SPEC
+,	O
+Pasteurella	B-SPEC
+multocida	I-SPEC
+toxin	O
+,	O
+Streptococcus	B-SPEC
+suis	I-SPEC
+,	O
+Mycoplasma	B-SPEC
+hyopneumoniae	I-SPEC
+,	O
+Mycoplasma	B-SPEC
+hyorhinis	I-SPEC
+,	O
+Mycoplasma	B-DISO
+hyosynovie	O
+,	O
+porcine	B-SPEC
+circovirus	I-SPEC
+2	I-SPEC
+,	O
+pseudorabies	B-SPEC
+virus	I-SPEC
+,	O
+porcine	B-SPEC
+cytomegalovirus	I-SPEC
+,	O
+swine	B-DISO
+influenza	B-SPEC
+A	I-SPEC
+virus	I-SPEC
+,	O
+porcine	B-SPEC
+reproductive	B-PROC
+and	O
+respiratory	O
+virus	B-SPEC
+US	O
+strain	O
+,	O
+EU	O
+strain	O
+,	O
+porcine	O
+respiratory	O
+coronavirus	B-SPEC
+and	O
+porcine	B-SPEC
+hemagglutinating	O
+encephalomyelitis	B-DISO
+virus	B-SPEC
+)	O
+as	O
+detection	O
+targets	O
+and	O
+designed	O
+novel	O
+specific	O
+primer	O
+-	O
+probe	O
+sets	O
+for	O
+seven	O
+of	O
+them	O
+.	O
+
+Total	O
+RNA	O
+was	O
+extracted	O
+from	O
+the	O
+plasma	B-ANAT
+,	O
+plasma	B-ANAT
+exosome	O
+,	O
+and	O
+peripheral	B-ANAT
+blood	I-ANAT
+mononuclear	I-ANAT
+cells	I-ANAT
+(	O
+PBMCs	O
+)	O
+from	O
+65	O
+ARDS	B-DISO
+patients	O
+and	O
+36	O
+healthy	O
+controls	O
+.	O
+
+TITLE	O
+:	O
+Herpes	B-DISO
+simplex	I-DISO
+virus	I-SPEC
+and	O
+Cytomegalovirus	B-SPEC
+reactivation	O
+among	O
+severe	O
+ARDS	B-DISO
+patients	O
+under	O
+veno	O
+-	O
+venous	B-ANAT
+ECMO	O
+.	O
+
+ABSTRACT	O
+:	O
+Herpesviridae	B-SPEC
+reactivation	O
+among	O
+non	O
+-	O
+immunocompromised	O
+critically	B-DISO
+ill	I-DISO
+patients	O
+is	O
+associated	O
+with	O
+impaired	B-DISO
+prognosis	O
+,	O
+especially	O
+during	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+(	O
+ARDS	B-DISO
+).	O
+
+Herpesviridae	B-SPEC
+reactivation	O
+is	O
+frequent	O
+among	O
+patients	O
+with	O
+severe	O
+ARDS	B-DISO
+under	O
+veno	O
+-	O
+venous	B-ANAT
+ECMO	O
+and	O
+is	O
+associated	O
+with	O
+a	O
+longer	O
+duration	O
+of	O
+mechanical	O
+ventilation	O
+.	O
+
+RESULTS	O
+:	O
+During	O
+a	O
+5	O
+-	O
+year	O
+period	O
+,	O
+123	O
+non	O
+-	O
+immunocompromised	O
+patients	O
+with	O
+a	O
+severe	O
+ARDS	B-DISO
+requiring	O
+a	O
+veno	O
+-	O
+venous	B-ANAT
+ECMO	O
+were	O
+included	O
+.	O
+
+In	O
+multivariate	O
+analysis	O
+,	O
+HSV	B-SPEC
+reactivation	O
+remained	O
+independently	O
+associated	O
+with	O
+a	O
+longer	O
+duration	O
+of	O
+MV	O
+and	O
+hospital	O
+length	O
+of	O
+stay	O
+.	O
+
+TITLE	O
+:	O
+[	O
+Exploration	O
+of	O
+Chaige	O
+Jieji	O
+Decoction	O
+formula	O
+syndromes	B-DISO
+based	O
+on	O
+severe	O
+cases	O
+of	O
+critical	O
+care	O
+and	O
+its	O
+application	O
+for	O
+acute	O
+exogenous	O
+fever	O
+and	O
+nosocomial	B-DISO
+infection	I-DISO
+].	O
+
+However	O
+,	O
+conventional	O
+real	O
+-	O
+time	O
+RT	O
+-	O
+PCR	O
+assays	O
+require	O
+large	O
+laboratory	O
+instruments	O
+,	O
+and	O
+amplification	B-DISO
+takes	O
+approximately	O
+2	O
+h	O
+.	O
+These	O
+are	O
+disadvantages	O
+for	O
+rapid	O
+diagnosis	O
+.	O
+
+As	O
+few	O
+as	O
+five	O
+copies	O
+of	O
+MERS	O
+-	O
+CoV	O
+RNA	O
+can	O
+be	O
+detected	O
+within	O
+20	O
+min	O
+using	O
+the	O
+WHO	O
+standard	O
+assays	O
+with	O
+similar	O
+sensitivity	O
+and	O
+specificity	O
+to	O
+those	O
+of	O
+a	O
+conventional	O
+real	O
+-	O
+time	O
+PCR	O
+instrument	O
+such	O
+as	O
+the	O
+LightCyler	O
+,	O
+enabling	O
+timely	O
+intervention	O
+to	O
+control	O
+MERS	O
+-	O
+CoV	O
+infection	B-DISO
+.	O
+
+We	O
+focused	O
+on	O
+most	O
+recent	O
+findings	O
+in	O
+the	O
+application	O
+of	O
+extracorporeal	O
+support	O
+to	O
+achieve	O
+lung	B-ANAT
+protection	O
+and	O
+diaphragm	B-ANAT
+-	O
+protection	O
+,	O
+as	O
+well	O
+as	O
+on	O
+relevant	O
+monitoring	O
+.	O
+
+It	O
+is	O
+conceivable	O
+that	O
+they	O
+should	O
+enable	O
+the	O
+highest	O
+amount	O
+of	O
+CO2	B-CHED
+removal	O
+with	O
+lowest	O
+mechanical	O
+power	O
+.	O
+
+Lung	B-ANAT
+mechanics	O
+,	O
+gas	B-ENZY
+exchange	O
+,	O
+diaphragm	B-ANAT
+electrical	B-PROC
+activity	I-PROC
+,	O
+ultrasound	O
+,	O
+electrical	B-PROC
+impedance	I-PROC
+tomography	O
+could	O
+be	O
+integrated	O
+into	O
+clinical	O
+management	O
+to	O
+define	O
+lung	B-ANAT
+and	O
+diaphragm	B-ANAT
+protection	O
+and	O
+guide	O
+personalized	O
+ventilation	O
+settings	O
+.	O
+
+TITLE	O
+:	O
+Preliminary	O
+anti	O
+-	O
+Coxsackie	O
+activity	O
+of	O
+novel	O
+1	O
+-[	O
+4	O
+-(	O
+5	O
+,	O
+6	O
+-	O
+dimethyl	B-CHED
+(	O
+H	O
+)-	O
+1H	O
+(	O
+2H	O
+)-	O
+benzotriazol	O
+-	O
+1	O
+(	O
+2	O
+)-	O
+yl	O
+)	O
+phenyl	O
+]-	O
+3	O
+-	O
+alkyl	O
+(	O
+aryl	O
+)	O
+ureas	B-CHED
+.	O
+
+In	O
+this	O
+retrospective	O
+study	O
+,	O
+all	O
+adult	O
+patients	O
+admitted	O
+to	O
+medical	O
+intensive	O
+care	O
+unit	O
+(	O
+ICU	O
+)	O
+with	O
+H1N1	O
+viral	B-DISO
+pneumonia	I-DISO
+having	O
+severe	O
+ARDS	B-DISO
+and	O
+requiring	O
+prone	O
+ventilation	O
+as	O
+a	O
+rescue	O
+therapy	O
+for	O
+severe	O
+hypoxemia	O
+were	O
+reviewed	O
+.	O
+
+The	O
+patients	O
+were	O
+considered	O
+to	O
+turn	O
+prone	O
+if	O
+PaO	B-PROC
+Eleven	O
+adult	O
+patients	O
+with	O
+severe	O
+ARDS	B-DISO
+were	O
+ventilated	O
+in	O
+prone	O
+position	O
+.	O
+
+ABSTRACT	O
+:	O
+In	O
+China	O
+,	O
+large	O
+-	O
+scale	O
+outbreaks	O
+of	O
+severe	O
+diarrhea	O
+caused	O
+by	O
+viruses	B-SPEC
+have	O
+occurred	O
+in	O
+pigs	B-SPEC
+since	O
+late	O
+2010	O
+.	O
+
+To	O
+investigate	O
+the	O
+prevalence	O
+and	O
+genetic	O
+evolution	B-PROC
+of	O
+diarrhea	B-DISO
+-	O
+associated	O
+viruses	B-SPEC
+responsible	O
+for	O
+the	O
+outbreaks	O
+,	O
+a	O
+total	O
+of	O
+2987	O
+field	O
+diarrheal	O
+samples	O
+collected	O
+from	O
+168	O
+pig	B-SPEC
+farms	O
+in	O
+five	O
+provinces	O
+in	O
+Southern	O
+China	O
+during	O
+2012	O
+-	O
+2018	O
+were	O
+tested	O
+.	O
+
+The	O
+fusion	O
+and	O
+genome	O
+delivery	O
+steps	O
+can	O
+be	O
+completed	O
+at	O
+variable	O
+times	O
+and	O
+places	O
+,	O
+either	O
+at	O
+or	O
+near	O
+cell	B-COMP
+surfaces	O
+or	O
+deep	O
+within	O
+endosomes	O
+.	O
+
+TITLE	O
+:	O
+Crystallization	O
+and	O
+Structural	O
+Determination	O
+of	O
+the	O
+Receptor	B-PRGE
+-	I-PRGE
+Binding	I-PRGE
+Domain	I-PRGE
+of	O
+MERS	B-PRGE
+-	I-PRGE
+CoV	I-PRGE
+Spike	I-PRGE
+Glycoprotein	I-PRGE
+.	O
+
+ABSTRACT	O
+:	O
+RNA	O
+virus	B-SPEC
+encodes	O
+a	O
+helicase	B-PRGE
+essential	O
+for	O
+viral	O
+RNA	O
+transcription	O
+and	O
+replication	O
+when	O
+the	O
+genome	O
+size	O
+is	O
+larger	O
+than	O
+7	O
+kb	O
+.	O
+
+However	O
+,	O
+the	O
+high	O
+-	O
+resolution	O
+structure	O
+of	O
+CoV	O
+nsp13	O
+remained	O
+unavailable	O
+even	O
+until	O
+more	O
+than	O
+a	O
+decade	O
+after	O
+the	O
+outbreak	O
+of	O
+the	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+coronavirus	B-SPEC
+(	O
+SARS	B-DISO
+-	O
+CoV	O
+)	O
+in	O
+2003	O
+,	O
+which	O
+hindered	O
+the	O
+structure	O
+-	O
+based	O
+drug	O
+design	O
+.	O
+
+ABSTRACT	O
+:	O
+Mass	O
+spectrometry	O
+(	O
+MS	O
+)-	O
+based	O
+,	O
+integrated	O
+proteomics	O
+,	O
+metabolomics	O
+,	O
+and	O
+lipidomics	O
+(	O
+collectively	O
+,	O
+multi	O
+-	O
+omics	O
+)	O
+studies	O
+provide	O
+a	O
+very	O
+detailed	O
+snapshot	O
+of	O
+virus	B-SPEC
+-	O
+induced	O
+changes	O
+to	O
+the	O
+host	B-COMP
+following	O
+infection	B-DISO
+and	O
+can	O
+lead	O
+to	O
+the	O
+identification	O
+of	O
+novel	O
+prophylactic	O
+and	O
+therapeutic	O
+targets	O
+for	O
+preventing	O
+or	O
+lessening	O
+disease	O
+severity	O
+.	O
+
+Multi	O
+-	O
+omics	O
+studies	O
+with	O
+Middle	O
+East	O
+respiratory	O
+syndrome	B-DISO
+coronavirus	B-SPEC
+(	O
+MERS	O
+-	O
+CoV	O
+)	O
+are	O
+challenging	O
+as	O
+the	O
+requirements	O
+of	O
+biosafety	O
+level	O
+3	O
+containment	O
+limit	O
+the	O
+numbers	O
+of	O
+samples	O
+that	O
+can	O
+be	O
+safely	O
+managed	O
+.	O
+
+TITLE	O
+:	O
+Evaluation	O
+of	O
+Activation	O
+and	O
+Inflammatory	O
+Activity	O
+of	O
+Myeloid	B-ANAT
+Cells	I-ANAT
+During	O
+Pathogenic	O
+Human	B-SPEC
+Coronavirus	B-DISO
+Infection	I-DISO
+.	O
+
+ABSTRACT	O
+:	O
+Innate	O
+immune	O
+cells	B-COMP
+play	O
+a	O
+vital	O
+role	O
+in	O
+mounting	O
+an	O
+effective	O
+host	B-PROC
+response	I-PROC
+to	O
+a	O
+variety	O
+of	O
+pathogen	O
+challenges	O
+.	O
+
+This	O
+review	O
+describes	O
+principles	O
+,	O
+approaches	O
+,	O
+and	O
+resources	O
+that	O
+can	O
+be	O
+useful	O
+to	O
+evaluate	O
+coronavirus	B-SPEC
+lung	B-DISO
+infection	I-DISO
+,	O
+focusing	O
+on	O
+MER	O
+-	O
+CoV	O
+infection	B-DISO
+as	O
+the	O
+principal	O
+example	O
+.	O
+
+TITLE	O
+:	O
+Massive	O
+air	B-CHED
+leak	O
+secondary	O
+to	O
+influenza	B-DISO
+B	O
+in	O
+a	O
+7	O
+-	O
+year	O
+-	O
+old	O
+:	O
+A	O
+case	O
+report	O
+.	O
+
+TITLE	O
+:	O
+Acute	B-DISO
+Respiratory	I-DISO
+Distress	I-DISO
+Syndrome	I-DISO
+immediately	O
+following	O
+the	O
+removal	O
+of	O
+an	O
+aspirated	B-DISO
+foreign	O
+body	O
+.	O
+
+ABSTRACT	O
+:	O
+Acute	B-DISO
+Respiratory	I-DISO
+Distress	I-DISO
+Syndrome	I-DISO
+(	O
+ARDS	B-DISO
+)	O
+is	O
+a	O
+form	O
+of	O
+diffuse	O
+lung	B-ANAT
+injury	O
+with	O
+many	O
+potential	O
+etiologies	O
+,	O
+pneumonia	B-DISO
+being	O
+the	O
+most	O
+common	O
+cause	O
+developing	O
+outside	O
+of	O
+the	O
+hospital	O
+.	O
+
+TITLE	O
+:	O
+Adenovirus	B-SPEC
+Type	O
+7	O
+causing	O
+severe	O
+lower	B-DISO
+respiratory	I-DISO
+tract	I-DISO
+infection	I-DISO
+in	O
+immunocompetent	O
+adults	O
+:	O
+a	O
+comparison	O
+of	O
+two	O
+contrasting	O
+cases	O
+from	O
+an	O
+intensive	O
+care	O
+unit	O
+in	O
+North	O
+West	O
+England	O
+.	O
+
+ABSTRACT	O
+:	O
+Severe	O
+lower	O
+respiratory	O
+tract	O
+infection	O
+caused	O
+by	O
+adenovirus	B-DISO
+is	O
+well	O
+described	O
+in	O
+immunocompromised	O
+hosts	B-COMP
+and	O
+can	O
+cause	O
+significant	O
+morbidity	O
+and	O
+mortality	O
+.	O
+
+An	O
+increase	O
+in	O
+the	O
+number	O
+of	O
+ICU	O
+admission	O
+due	O
+to	O
+respiratory	O
+illness	O
+may	O
+be	O
+a	O
+clue	O
+to	O
+expect	O
+the	O
+occurrence	O
+of	O
+acute	O
+flaccid	O
+myelitis	B-DISO
+.	O
+
+The	O
+late	B-COMP
+endosome	I-COMP
+trafficking	B-PROC
+inhibitor	B-CHED
+did	O
+not	O
+inhibit	O
+type	O
+II	O
+FCoV	O
+infection	B-DISO
+,	O
+but	O
+it	O
+inhibited	O
+type	O
+I	O
+FCoV	O
+infection	B-DISO
+.	O
+
+These	O
+phenomena	O
+were	O
+observed	O
+in	O
+both	O
+feline	B-SPEC
+cell	B-ANAT
+lines	I-ANAT
+and	O
+feline	B-SPEC
+primary	O
+macrophages	B-ANAT
+.	O
+
+TITLE	O
+:	O
+Psychiatric	B-DISO
+symptoms	I-DISO
+post	O
+intensive	O
+care	O
+unit	O
+admission	O
+.	O
+
+TITLE	O
+:	O
+Host	B-COMP
+AAA	I-PRGE
++	I-PRGE
+ATPase	B-ENZY
+TER94	I-PRGE
+Plays	O
+Critical	O
+Roles	O
+in	O
+Building	O
+the	O
+Baculovirus	B-SPEC
+Viral	B-PROC
+Replication	I-PROC
+Factory	O
+and	O
+Virion	O
+Morphogenesis	B-PROC
+.	O
+
+Here	O
+we	O
+report	O
+a	O
+3	O
+.	O
+3	O
+-	O
+Å	O
+cryoelectron	O
+microscopy	O
+(	O
+cryo	O
+-	O
+EM	O
+)	O
+structure	O
+of	O
+the	O
+serotype	O
+I	O
+FIPV	O
+spike	O
+(	O
+S	O
+)	O
+protein	B-CHED
+,	O
+which	O
+is	O
+responsible	O
+for	O
+host	B-COMP
+recognition	O
+and	O
+viral	O
+entry	O
+.	O
+
+TITLE	O
+:	O
+Molecular	O
+epidemiology	O
+of	O
+respiratory	O
+viruses	B-SPEC
+among	O
+Malaysian	O
+Young	O
+children	O
+with	O
+a	O
+confirmed	O
+respiratory	O
+infection	O
+during	O
+2014	O
+-	O
+2015	O
+.	O
+
+Enterovirus	B-SPEC
+/	O
+rhinovirus	B-SPEC
+,	O
+adenovirus	B-DISO
+,	O
+and	O
+human	B-SPEC
+bocavirus	I-SPEC
+demonstrated	O
+pronounced	O
+seasonality	O
+.	O
+
+TITLE	O
+:	O
+Feline	B-SPEC
+Infectious	I-DISO
+Peritonitis	I-DISO
+Virus	B-SPEC
+Nsp5	O
+Inhibits	O
+Type	B-PROC
+I	I-PROC
+Interferon	I-PROC
+Production	I-PROC
+by	O
+Cleaving	O
+NEMO	O
+at	O
+Multiple	O
+Sites	O
+.	O
+
+ABSTRACT	O
+:	O
+Feline	O
+infectious	O
+peritonitis	O
+(	O
+FIP	B-DISO
+),	O
+caused	O
+by	O
+virulent	O
+feline	B-SPEC
+coronavirus	B-SPEC
+,	O
+is	O
+the	O
+leading	O
+infectious	B-DISO
+cause	O
+of	O
+death	B-PROC
+in	O
+cats	B-SPEC
+.	O
+
+However	O
+,	O
+whether	O
+feline	B-DISO
+infectious	I-DISO
+peritonitis	I-DISO
+virus	B-SPEC
+(	O
+FIPV	O
+)	O
+antagonizes	O
+the	O
+type	B-PRGE
+I	I-PRGE
+IFN	I-PRGE
+signaling	B-PROC
+remains	O
+unclear	O
+.	O
+
+Subsequently	O
+,	O
+we	O
+found	O
+that	O
+one	O
+of	O
+the	O
+non	O
+-	O
+structural	O
+proteins	B-CHED
+encoded	O
+by	O
+the	O
+FIPV	O
+genome	O
+,	O
+nsp5	O
+,	O
+interrupted	O
+type	B-PRGE
+I	I-PRGE
+IFN	I-PRGE
+signaling	B-PROC
+in	O
+a	O
+protease	O
+-	O
+dependent	O
+manner	O
+by	O
+cleaving	O
+the	O
+nuclear	O
+factor	O
+κB	O
+(	O
+NF	O
+-	O
+κB	O
+)	O
+essential	O
+modulator	O
+(	O
+NEMO	O
+)	O
+at	O
+three	O
+sites	O
+-	O
+glutamine132	O
+(	O
+Q132	O
+),	O
+Q205	O
+,	O
+and	O
+Q231	O
+.	O
+
+A	O
+patient	O
+with	O
+HCC	B-DISO
+exhibited	O
+acute	O
+and	O
+severe	O
+respiratory	B-DISO
+failure	I-DISO
+.	O
+
+CONCLUSIONS	O
+:	O
+PTTM	O
+is	O
+caused	O
+by	O
+tumor	B-DISO
+thrombi	B-DISO
+in	O
+the	O
+arteries	B-ANAT
+and	O
+thickening	O
+of	O
+the	O
+pulmonary	B-ANAT
+arterial	B-ANAT
+endothelium	I-ANAT
+leading	O
+to	O
+the	O
+symptoms	O
+of	O
+dyspnea	B-DISO
+in	O
+terminal	O
+staged	O
+patients	O
+.	O
+
+This	O
+is	O
+the	O
+case	O
+of	O
+two	O
+3	O
+'-	O
+5	O
+'	O
+exoribonuclease	O
+activities	O
+identified	O
+in	O
+arenavirus	B-SPEC
+and	O
+coronavirus	B-SPEC
+proteomes	O
+.	O
+
+Arenaviruses	B-SPEC
+have	O
+a	O
+segmented	O
+ambisense	O
+single	O
+stranded	O
+RNA	O
+genome	O
+of	O
+negative	O
+polarity	O
+while	O
+coronaviruses	O
+have	O
+a	O
+positive	O
+single	O
+-	O
+stranded	O
+genomic	O
+RNA	O
+.	O
+
+ABSTRACT	O
+:	O
+Hypoxemic	O
+patients	O
+often	O
+desaturate	O
+further	O
+with	O
+movement	O
+and	O
+transport	B-PROC
+.	O
+
+As	O
+such	O
+,	O
+optimizing	O
+oxygenation	B-PROC
+to	O
+allow	O
+for	O
+transport	B-PROC
+should	O
+continue	O
+to	O
+be	O
+a	O
+priority	O
+for	O
+critical	O
+care	O
+transport	O
+(	O
+CCT	B-DISO
+)	O
+services	O
+.	O
+
+TITLE	O
+:	O
+Leptospirosis	B-DISO
+manifested	O
+with	O
+severe	O
+pulmonary	B-ANAT
+haemorrhagic	O
+syndrome	B-DISO
+successfully	O
+treated	O
+with	O
+venovenous	O
+extracorporeal	O
+membrane	O
+oxygenation	B-PROC
+.	O
+
+Refractory	O
+hypoxaemia	O
+was	O
+not	O
+responsive	O
+to	O
+positive	O
+end	O
+-	O
+expiratory	O
+pressure	O
+(	O
+PEEP	B-CHED
+);	O
+thus	O
+,	O
+VV	O
+-	O
+ECMO	O
+was	O
+initiated	O
+on	O
+the	O
+first	O
+day	O
+.	O
+
+All	O
+patients	O
+died	B-PROC
+of	O
+respiratory	B-DISO
+failure	I-DISO
+.	O
+
+The	O
+overall	O
+survival	O
+rate	O
+at	O
+3	O
+years	O
+was	O
+41	O
+.	O
+8	O
+%	O
+of	O
+the	O
+total	O
+and	O
+47	O
+.	O
+2	O
+%	O
+of	O
+cases	O
+with	O
+clinical	O
+stage	O
+I	O
+.	O
+Perioperative	O
+use	O
+of	O
+sivelestat	O
+and	O
+low	O
+-	O
+dose	O
+methylprednisolone	B-CHED
+in	O
+patients	O
+with	O
+anatomical	O
+lung	B-ANAT
+resection	O
+was	O
+safe	O
+but	O
+did	O
+not	O
+prove	O
+to	O
+be	O
+a	O
+prophylactic	O
+effect	O
+for	O
+AE	O
+-	O
+IP	O
+.	O
+
+Prior	O
+to	O
+surgery	O
+,	O
+patients	O
+received	O
+a	O
+125	O
+-	O
+mg	O
+bolus	O
+injection	O
+of	O
+methylprednisolone	B-CHED
+and	O
+continuous	O
+intravenous	O
+infusion	O
+of	O
+sivelestat	O
+sodium	B-CHED
+hydrate	I-CHED
+(	O
+sivelestat	O
+)	O
+for	O
+2	O
+days	O
+.	O
+
+TITLE	O
+:	O
+Comparative	O
+therapeutic	O
+efficacy	O
+of	O
+remdesivir	O
+and	O
+combination	O
+lopinavir	O
+,	O
+ritonavir	B-CHED
+,	O
+and	O
+interferon	B-PRGE
+beta	I-PRGE
+against	O
+MERS	O
+-	O
+CoV	O
+.	O
+ABSTRACT	O
+:	O
+Middle	O
+East	O
+respiratory	O
+syndrome	B-DISO
+coronavirus	B-SPEC
+(	O
+MERS	O
+-	O
+CoV	O
+)	O
+is	O
+the	O
+causative	O
+agent	O
+of	O
+a	O
+severe	O
+respiratory	B-DISO
+disease	I-DISO
+associated	O
+with	O
+more	O
+than	O
+2468	O
+human	B-SPEC
+infections	B-DISO
+and	O
+over	O
+851	O
+deaths	B-PROC
+in	O
+27	O
+countries	O
+since	O
+2012	O
+.	O
+
+There	O
+are	O
+no	O
+approved	O
+treatments	O
+for	O
+MERS	O
+-	O
+CoV	O
+infection	B-DISO
+although	O
+a	O
+combination	O
+of	O
+lopinavir	O
+,	O
+ritonavir	B-CHED
+and	O
+interferon	B-PRGE
+beta	I-PRGE
+(	O
+LPV	O
+/	O
+RTV	B-PRGE
+-	O
+IFNb	B-PRGE
+)	O
+is	O
+currently	O
+being	O
+evaluated	O
+in	O
+humans	B-SPEC
+in	O
+the	O
+Kingdom	B-SPEC
+of	O
+Saudi	O
+Arabia	O
+.	O
+
+Thus	O
+,	O
+we	O
+provide	O
+in	O
+vivo	O
+evidence	O
+of	O
+the	O
+potential	O
+for	O
+RDV	B-SPEC
+to	O
+treat	O
+MERS	O
+-	O
+CoV	O
+infections	B-DISO
+.	O
+
+RBV	B-CHED
+/	O
+rIFN	O
+was	O
+initiated	O
+at	O
+a	O
+median	O
+of	O
+2	O
+days	O
+(	O
+Q1	O
+,	O
+Q3	O
+:	O
+1	O
+,	O
+3	O
+days	O
+)	O
+from	O
+intensive	O
+care	O
+unit	O
+admission	O
+.	O
+
+After	O
+adjusting	O
+for	O
+baseline	O
+and	O
+time	O
+-	O
+varying	O
+confounders	O
+using	O
+a	O
+marginal	O
+structural	O
+model	O
+,	O
+RBV	B-CHED
+/	O
+rIFN	O
+was	O
+not	O
+associated	O
+with	O
+changes	O
+in	O
+90	O
+-	O
+day	O
+mortality	O
+(	O
+adjusted	O
+odds	O
+ratio	O
+,	O
+1	O
+.	O
+03	O
+[	O
+95	O
+%	O
+confidence	O
+interval	O
+{	O
+CI	O
+},	O
+.	O
+73	O
+-	O
+1	O
+.	O
+44	O
+];	O
+P	O
+=	O
+.	O
+87	O
+)	O
+or	O
+with	O
+more	O
+rapid	O
+MERS	O
+-	O
+CoV	O
+RNA	O
+clearance	O
+(	O
+adjusted	O
+hazard	O
+ratio	O
+,	O
+0	O
+.	O
+65	O
+[	O
+95	O
+%	O
+CI	O
+,	O
+.	O
+30	O
+-	O
+1	O
+.	O
+44	O
+];	O
+P	O
+=	O
+.	O
+29	O
+).	O
+
+ABSTRACT	O
+:	O
+To	O
+describe	O
+experience	O
+with	O
+high	O
+-	O
+frequency	O
+oscillatory	O
+ventilation	O
+(	O
+HFOV	O
+)	O
+in	O
+children	O
+with	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+(	O
+ARDS	B-DISO
+)	O
+transitioned	O
+from	O
+conventional	O
+mechanical	O
+ventilation	O
+(	O
+CMV	B-SPEC
+)	O
+due	O
+to	O
+refractory	O
+hypoxemia	O
+and	O
+to	O
+assess	O
+factors	O
+associated	O
+with	O
+survival	O
+and	O
+also	O
+compare	O
+outcomes	O
+of	O
+patients	O
+who	O
+were	O
+managed	O
+with	O
+early	O
+HFOV	O
+(	O
+within	O
+24	O
+h	O
+of	O
+intubation	O
+)	O
+vs	O
+.	O
+late	O
+HFOV	O
+.	O
+
+Improvement	O
+in	O
+the	O
+Oxygenation	B-PROC
+Index	O
+(	O
+OI	O
+)	O
+at	O
+48	O
+h	O
+of	O
+initiation	O
+of	O
+HFOV	O
+along	O
+with	O
+percent	O
+increase	O
+in	O
+PaO	B-PROC
+
+This	O
+study	O
+investigated	O
+the	O
+prevalence	O
+of	O
+bovine	B-SPEC
+coronavirus	B-SPEC
+(	O
+BCoV	O
+),	O
+bovine	B-SPEC
+norovirus	B-SPEC
+(	O
+BNoV	O
+),	O
+bovine	B-PRGE
+group	B-SPEC
+A	I-SPEC
+rotavirus	I-SPEC
+(	I-PRGE
+BoRVA	I-PRGE
+),	I-PRGE
+and	O
+bovine	B-SPEC
+torovirus	I-SPEC
+(	O
+BToV	O
+)	O
+in	O
+calves	O
+aged	O
+≤	O
+60	O
+days	O
+,	O
+regardless	O
+of	O
+diarrhea	B-DISO
+,	O
+across	O
+nine	O
+different	O
+regions	O
+in	O
+the	O
+Republic	O
+of	O
+Korea	O
+(	O
+ROK	O
+)	O
+and	O
+reported	O
+associations	O
+between	O
+these	O
+viruses	B-SPEC
+and	O
+diarrhea	B-DISO
+.	O
+
+We	O
+report	O
+a	O
+rare	O
+case	O
+of	O
+posterior	B-DISO
+reversible	I-DISO
+encephalopathy	I-DISO
+syndrome	I-DISO
+(	O
+PRES	B-DISO
+)	O
+in	O
+a	O
+patient	O
+with	O
+severe	O
+leptospirosis	B-DISO
+during	O
+recovery	O
+phase	O
+of	O
+the	O
+illness	O
+.	O
+
+CR	O
+-	O
+31	O
+-	O
+B	O
+(-)	O
+inhibited	O
+the	O
+replication	O
+of	O
+corona	B-CHED
+-,	O
+Zika	O
+-,	O
+Lassa	O
+-,	O
+Crimean	B-DISO
+Congo	I-DISO
+hemorrhagic	I-DISO
+fever	I-DISO
+viruses	B-SPEC
+and	O
+,	O
+to	O
+a	O
+lesser	O
+extent	O
+,	O
+hepatitis	B-SPEC
+E	I-SPEC
+virus	I-SPEC
+(	O
+HEV	B-SPEC
+)	O
+at	O
+non	O
+-	O
+cytotoxic	O
+low	O
+nanomolar	O
+concentrations	O
+.	O
+
+TITLE	O
+:	O
+High	O
+expression	B-PROC
+of	O
+long	O
+non	O
+-	O
+coding	O
+RNA	O
+MALAT1	O
+correlates	O
+with	O
+raised	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+risk	O
+,	O
+disease	O
+severity	O
+,	O
+and	O
+increased	O
+mortality	O
+in	O
+sepstic	O
+patients	O
+.	O
+
+Severity	O
+and	O
+organ	B-DISO
+failure	I-DISO
+of	O
+sepsis	B-DISO
+were	O
+assessed	O
+by	O
+APACHE	O
+II	O
+score	O
+and	O
+SOFA	O
+score	O
+respectively	O
+,	O
+and	O
+the	O
+in	O
+-	O
+hospital	O
+mortality	O
+was	O
+calculated	O
+.	O
+
+ABSTRACT	O
+:	O
+Porcine	B-SPEC
+deltacoronavirus	O
+(	O
+PDCoV	O
+)	O
+is	O
+a	O
+porcine	B-SPEC
+enteropathogenic	O
+coronavirus	B-SPEC
+that	O
+causes	O
+watery	B-DISO
+diarrhea	I-DISO
+,	O
+vomiting	B-DISO
+,	O
+and	O
+frequently	O
+death	B-PROC
+in	O
+piglets	O
+,	O
+causing	O
+serious	O
+economic	O
+losses	O
+to	O
+the	O
+pig	B-SPEC
+industry	O
+.	O
+
+The	O
+strain	O
+CHN	B-DISO
+-	O
+JS	O
+-	O
+2017	O
+was	O
+isolated	O
+and	O
+identified	O
+by	O
+cytopathology	O
+,	O
+immunofluorescence	O
+assays	O
+,	O
+transmission	O
+electron	O
+microscopy	O
+,	O
+and	O
+sequence	O
+analysis	O
+.	O
+
+A	O
+nucleotide	B-CHED
+sequence	O
+alignment	O
+showed	O
+that	O
+the	O
+whole	O
+genome	O
+of	O
+CHN	B-DISO
+-	O
+JS	O
+-	O
+2017	O
+is	O
+97	O
+.	O
+4	O
+%-	O
+99	O
+.	O
+6	O
+%	O
+identical	O
+to	O
+other	O
+PDCoV	O
+strains	O
+.	O
+
+The	O
+pathogenicity	O
+of	O
+the	O
+CHN	B-DISO
+-	O
+JS	O
+-	O
+2017	O
+strain	O
+was	O
+investigated	O
+in	O
+orally	B-ANAT
+inoculated	O
+five	O
+-	O
+day	O
+-	O
+old	O
+piglets	O
+;	O
+the	O
+piglets	O
+developed	O
+acute	O
+,	O
+watery	B-DISO
+diarrhea	I-DISO
+,	O
+but	O
+all	O
+recovered	O
+and	O
+survived	O
+.	O
+
+We	O
+introduce	O
+a	O
+new	O
+concept	O
+related	O
+to	O
+the	O
+non	O
+-	O
+taxonomical	O
+classification	O
+and	O
+differentiation	B-PROC
+among	O
+FCoVs	O
+by	O
+analyzing	O
+and	O
+comparing	O
+the	O
+genetic	O
+,	O
+structural	O
+,	O
+and	O
+functional	O
+characteristics	O
+of	O
+FCoV	O
+and	O
+the	O
+FCoV	B-PRGE
+S	I-PRGE
+protein	I-PRGE
+among	O
+the	O
+two	O
+serotypes	O
+and	O
+FCoV	O
+biotypes	O
+.	O
+
+TITLE	O
+:	O
+Molecular	O
+Detection	O
+of	O
+Gamma	O
+Coronaviruses	O
+in	O
+Bird	B-SPEC
+Parks	O
+of	O
+Iran	O
+.	O
+
+ABSTRACT	O
+:	O
+It	O
+can	O
+be	O
+judged	O
+that	O
+if	O
+the	O
+detection	O
+frequency	O
+of	O
+prevalent	O
+pathogenic	O
+viruses	B-SPEC
+decreases	O
+,	O
+biosecurity	O
+has	O
+been	O
+enhanced	O
+.	O
+
+Disease	B-DISO
+,	I-DISO
+lung	I-DISO
+lesion	O
+,	O
+and	O
+viral	B-PROC
+replication	I-PROC
+progressions	O
+were	O
+slower	O
+in	O
+the	O
+MERS	O
+-	O
+CoV	O
+aerosol	O
+-	O
+infected	O
+mice	B-SPEC
+than	O
+in	O
+the	O
+MERS	O
+-	O
+CoV	O
+instillation	O
+-	O
+inoculated	O
+mice	B-SPEC
+.	O
+
+TITLE	O
+:	O
+Pneumonia	B-DISO
+of	O
+unknown	O
+aetiology	O
+in	O
+Wuhan	O
+,	O
+China	O
+:	O
+potential	O
+for	O
+international	O
+spread	O
+via	O
+commercial	O
+air	O
+travel	O
+.	O
+
+The	O
+results	O
+showed	O
+that	O
+the	O
+number	O
+of	O
+patients	O
+with	O
+combined	O
+symptoms	O
+of	O
+fever	B-PROC
+/	O
+sore	B-DISO
+throat	I-DISO
+and	O
+fever	B-PROC
+/	O
+cough	B-DISO
+/	O
+SOB	O
+was	O
+significantly	O
+higher	O
+in	O
+confirmed	O
+cases	O
+than	O
+in	O
+non	O
+-	O
+confirmed	O
+cases	O
+(	O
+p	O
+<	O
+0	O
+.	O
+05	O
+).	O
+
+RESULTS	O
+:	O
+The	O
+results	O
+showed	O
+that	O
+the	O
+number	O
+of	O
+patients	O
+with	O
+combined	O
+symptoms	O
+of	O
+fever	B-PROC
+/	O
+sore	B-DISO
+throat	I-DISO
+and	O
+fever	B-PROC
+/	O
+cough	B-DISO
+/	O
+SOB	O
+was	O
+significantly	O
+higher	O
+in	O
+confirmed	O
+cases	O
+than	O
+in	O
+non	O
+-	O
+confirmed	O
+cases	O
+(	O
+p	O
+<	O
+0	O
+.	O
+05	O
+).	O
+
+This	O
+review	O
+summarizes	O
+currently	O
+available	O
+and	O
+novel	O
+emerging	O
+diagnostic	O
+methods	O
+for	O
+the	O
+detection	O
+of	O
+common	O
+respiratory	O
+viruses	O
+,	O
+such	O
+as	O
+influenza	B-SPEC
+virus	I-SPEC
+,	O
+human	B-SPEC
+respiratory	I-SPEC
+syncytial	I-SPEC
+virus	I-SPEC
+,	O
+coronavirus	B-SPEC
+,	O
+human	B-SPEC
+adenovirus	B-DISO
+,	O
+and	O
+human	B-SPEC
+rhinovirus	I-SPEC
+.	O
+
+Here	O
+,	O
+four	O
+different	O
+S	O
+subunit	O
+proteins	B-CHED
+,	O
+receptor	O
+-	O
+binding	B-FUNC
+domain	O
+(	O
+RBD	O
+;	O
+358	O
+-	O
+606	O
+aa	O
+),	O
+S1	O
+(	O
+1	O
+-	O
+751	O
+aa	O
+),	O
+S2	O
+(	O
+752	O
+-	O
+1296	O
+aa	O
+),	O
+and	O
+SΔTM	O
+(	O
+1	O
+-	O
+1296	O
+aa	O
+),	O
+were	O
+generated	O
+using	O
+the	O
+baculoviral	B-SPEC
+system	O
+and	O
+immunized	O
+in	O
+mice	B-SPEC
+to	O
+develop	O
+neutralizing	O
+antibodies	B-COMP
+.	O
+
+TITLE	O
+:	O
+Prevalence	O
+and	O
+mutation	O
+analysis	O
+of	O
+the	O
+spike	O
+protein	B-CHED
+in	O
+feline	B-SPEC
+enteric	B-SPEC
+coronavirus	I-SPEC
+and	O
+feline	B-SPEC
+infectious	I-DISO
+peritonitis	I-DISO
+detected	O
+in	O
+household	O
+and	O
+shelter	O
+cats	B-SPEC
+in	O
+western	O
+Canada	O
+.	O
+
+ABSTRACT	O
+:	O
+Feline	B-DISO
+infectious	I-DISO
+peritonitis	I-DISO
+(	O
+FIP	B-DISO
+)	O
+is	O
+a	O
+fatal	O
+disease	O
+for	O
+which	O
+no	O
+simple	O
+antemortem	O
+diagnostic	O
+assay	O
+is	O
+available	O
+.	O
+
+A	O
+new	O
+polymerase	O
+chain	O
+reaction	O
+(	O
+PCR	O
+)	O
+test	O
+has	O
+recently	O
+been	O
+developed	O
+that	O
+targets	O
+the	O
+spike	O
+protein	B-CHED
+region	O
+of	O
+the	O
+FIP	B-DISO
+virus	B-SPEC
+(	O
+FIPV	B-SPEC
+)	O
+and	O
+can	O
+identify	O
+specific	O
+mutations	O
+(	O
+M1030L	O
+or	O
+S1032A	O
+),	O
+the	O
+presence	O
+of	O
+which	O
+indicates	O
+a	O
+shift	O
+from	O
+feline	B-SPEC
+enteric	B-SPEC
+coronavirus	I-SPEC
+(	O
+FeCV	B-SPEC
+)	O
+to	O
+FIPV	B-SPEC
+.	O
+
+The	O
+secondary	O
+objective	O
+was	O
+to	O
+evaluate	O
+how	O
+often	O
+these	O
+specific	O
+FIPV	O
+mutations	O
+were	O
+present	O
+in	O
+tissue	O
+samples	O
+derived	O
+from	O
+cats	B-SPEC
+diagnosed	O
+with	O
+FIP	B-DISO
+at	O
+postmortem	O
+examination	O
+.	O
+
+ABSTRACT	O
+:	O
+Porcine	B-SPEC
+epidemic	I-SPEC
+diarrhea	I-SPEC
+virus	I-SPEC
+(	O
+PEDV	B-SPEC
+)	O
+targets	O
+the	O
+intestinal	B-ANAT
+mucosa	I-ANAT
+in	O
+pigs	B-SPEC
+.	O
+
+To	O
+protect	O
+against	O
+PEDV	B-SPEC
+invasion	B-DISO
+,	O
+a	O
+mucosal	B-ANAT
+vaccine	O
+is	O
+utilized	O
+effectively	O
+.	O
+
+TITLE	O
+:	O
+Increased	O
+Detection	O
+of	O
+Viruses	B-SPEC
+in	O
+Children	O
+with	O
+Respiratory	B-DISO
+Tract	I-DISO
+Infection	I-DISO
+Using	O
+PCR	O
+.	O
+
+ABSTRACT	O
+:	O
+Respiratory	O
+viruses	O
+are	O
+a	O
+common	O
+cause	O
+of	O
+respiratory	B-DISO
+tract	I-DISO
+infection	I-DISO
+(	O
+RTI	B-DISO
+),	O
+particularly	O
+in	O
+neonates	O
+and	O
+children	O
+.	O
+
+A	O
+seasonal	O
+effect	O
+was	O
+shown	O
+for	O
+bRSV	B-SPEC
+only	O
+{	O
+more	O
+in	O
+winter	O
+compared	O
+with	O
+autumn	O
+[	O
+OR	O
+=	O
+10	O
+.	O
+3	O
+(	O
+2	O
+.	O
+8	O
+-	O
+37	O
+.	O
+5	O
+)]}.	O
+Other	O
+factors	O
+associated	O
+with	O
+bRSV	B-SPEC
+were	O
+PI	O
+-	O
+3	O
+detection	O
+[	O
+OR	O
+=	O
+13	O
+.	O
+4	O
+(	O
+2	O
+.	O
+1	O
+-	O
+86	O
+.	O
+0	O
+)],	O
+prevalence	O
+of	O
+calves	O
+with	O
+respiratory	B-DISO
+disease	I-DISO
+[	O
+OR	O
+=	O
+1	O
+.	O
+02	O
+(	O
+1	O
+.	O
+00	O
+-	O
+1	O
+.	O
+04	O
+)	O
+per	O
+1	O
+%	O
+increase	O
+],	O
+and	O
+number	O
+of	O
+days	O
+with	O
+respiratory	O
+signs	O
+before	O
+sampling	O
+[	O
+OR	O
+=	O
+0	O
+.	O
+99	O
+(	O
+0	O
+.	O
+98	O
+-	O
+0	O
+.	O
+99	O
+)	O
+per	O
+day	O
+increase	O
+].	O
+
+Also	O
+,	O
+for	O
+H	B-SPEC
+.	I-SPEC
+somni	I-SPEC
+,	O
+housing	O
+on	O
+sawdust	O
+was	O
+a	O
+risk	O
+factor	O
+[	O
+OR	O
+=	O
+5	O
+.	O
+2	O
+(	O
+1	O
+.	O
+2	O
+-	O
+23	O
+.	O
+0	O
+)].	O
+
+Studies	O
+of	O
+convalescent	O
+plasma	B-ANAT
+treatment	O
+for	O
+A	O
+(	O
+H7N9	O
+)	O
+patients	O
+should	O
+consider	O
+collection	O
+of	O
+donor	B-CHED
+plasma	B-ANAT
+from	O
+survivors	O
+of	O
+severe	O
+disease	O
+between	O
+1	O
+and	O
+11	O
+months	O
+after	O
+illness	O
+onset	O
+.	O
+
+The	O
+bobcat	B-SPEC
+made	O
+a	O
+full	O
+recovery	O
+within	O
+72	O
+hours	O
+after	O
+treatment	O
+for	O
+ticks	B-SPEC
+,	O
+and	O
+a	O
+presumptive	O
+diagnosis	O
+of	O
+tick	B-DISO
+paralysis	I-DISO
+was	O
+made	O
+.	O
+
+We	O
+analyzed	O
+the	O
+cases	O
+of	O
+8	O
+,	O
+985	O
+laboratory	O
+-	O
+confirmed	O
+case	O
+-	O
+patients	O
+hospitalized	O
+for	O
+severe	O
+influenza	B-DISO
+by	O
+using	O
+data	O
+from	O
+a	O
+national	O
+surveillance	O
+system	O
+for	O
+the	O
+period	O
+2010	O
+-	O
+2017	O
+.	O
+
+ABSTRACT	O
+:	O
+Middle	O
+East	O
+respiratory	O
+syndrome	O
+coronavirus	B-SPEC
+(	O
+MERS	O
+-	O
+CoV	O
+)	O
+infection	B-DISO
+causes	O
+a	O
+spectrum	O
+of	O
+respiratory	O
+illness	O
+,	O
+from	O
+asymptomatic	O
+to	O
+mild	O
+to	O
+fatal	O
+.	O
+
+Current	O
+epidemiologic	O
+evidence	O
+supports	O
+a	O
+major	O
+role	O
+in	O
+transmission	O
+for	O
+direct	O
+contact	O
+with	O
+live	O
+camels	B-SPEC
+or	O
+humans	B-SPEC
+with	O
+symptomatic	O
+MERS	O
+,	O
+but	O
+little	O
+evidence	O
+suggests	O
+the	O
+possibility	O
+of	O
+transmission	O
+from	O
+camel	B-SPEC
+products	O
+or	O
+asymptomatic	O
+MERS	O
+cases	O
+.	O
+
+Because	O
+a	O
+proportion	O
+of	O
+case	O
+-	O
+patients	O
+do	O
+not	O
+report	O
+direct	O
+contact	O
+with	O
+camels	B-SPEC
+or	O
+with	O
+persons	O
+who	O
+have	O
+symptomatic	O
+MERS	O
+,	O
+further	O
+research	O
+is	O
+needed	O
+to	O
+conclusively	O
+determine	O
+additional	O
+mechanisms	O
+of	O
+transmission	O
+,	O
+to	O
+inform	O
+public	O
+health	O
+practice	O
+,	O
+and	O
+to	O
+refine	O
+current	O
+precautionary	O
+recommendations	O
+.	O
+
+TITLE	O
+:	O
+Neuromuscular	O
+blockers	O
+in	O
+the	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+:	O
+A	O
+meta	B-SPEC
+-	O
+analysis	O
+.	O
+
+NMBAs	O
+significantly	O
+improved	O
+oxygenation	B-PROC
+(	O
+Pao2	O
+:	O
+Fio2	O
+ratios	O
+)	O
+at	O
+48	O
+hours	O
+(	O
+MD	O
+27	O
+.	O
+26	O
+mm	O
+Hg	O
+,	O
+95	O
+%	O
+CI	O
+1	O
+.	O
+67	O
+,	O
+52	O
+.	O
+84	O
+,	O
+I2	O
+=	O
+92	O
+%)	O
+and	O
+reduced	O
+the	O
+incidence	O
+of	O
+barotrauma	O
+(	O
+RR	O
+0	O
+.	O
+55	O
+,	O
+95	O
+%	O
+CI	O
+0	O
+.	O
+35	O
+,	O
+0	O
+.	O
+85	O
+,	O
+I2	O
+=	O
+0	O
+).	O
+
+Of	O
+note	O
+,	O
+the	O
+PDCoV	O
+EP	O
+-	O
+4E88	O
+sequence	O
+shared	O
+very	O
+low	O
+similarity	O
+(<	O
+22	O
+.	O
+2	O
+%)	O
+with	O
+other	O
+porcine	B-SPEC
+coronaviruses	O
+(	O
+PEDV	B-SPEC
+,	O
+TGEV	B-SPEC
+,	O
+PRCV	O
+,	O
+SADS	O
+-	O
+CoV	O
+,	O
+PHEV	O
+),	O
+demonstrating	O
+that	O
+it	O
+is	O
+an	O
+epitope	B-CHED
+that	O
+can	O
+be	O
+used	O
+for	O
+distinguishing	O
+PDCoV	O
+and	O
+other	O
+porcine	B-SPEC
+coronavirus	B-SPEC
+.	O
+
+We	O
+identified	O
+severe	O
+AOSD	O
+-	O
+related	O
+complications	O
+,	O
+including	O
+macrophage	B-DISO
+activation	I-DISO
+syndrome	I-DISO
+(	O
+4	O
+.	O
+7	O
+%)	O
+and	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+(	O
+12	O
+.	O
+3	O
+%).	O
+
+The	O
+aim	O
+of	O
+this	O
+study	O
+was	O
+to	O
+investigate	O
+the	O
+association	O
+of	O
+plasma	B-ANAT
+suPAR	O
+expression	B-PROC
+with	O
+disease	O
+risk	O
+and	O
+severity	O
+as	O
+well	O
+as	O
+prognosis	O
+of	O
+sepsis	B-DISO
+-	O
+induced	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+(	O
+ARDS	B-DISO
+).	O
+
+ABSTRACT	O
+:	O
+To	O
+evaluate	O
+whether	O
+electromyographical	O
+findings	O
+could	O
+predict	O
+intensive	O
+care	O
+unit	O
+mortality	O
+among	O
+mechanically	O
+ventilated	O
+septic	O
+patients	O
+under	O
+profound	O
+sedation	B-DISO
+.	O
+
+Nine	O
+patients	O
+(	O
+53	O
+%)	O
+had	O
+electromyographic	O
+signs	O
+of	O
+critical	B-DISO
+illness	I-DISO
+myopathy	I-DISO
+or	O
+neuropathy	B-DISO
+.	O
+
+YF	O
+was	O
+confirmed	O
+by	O
+Rt	O
+-	O
+PCR	O
+and	O
+positive	O
+serology	O
+was	O
+obtained	O
+for	O
+leptospira	B-SPEC
+by	O
+ELISA	O
+and	O
+microagglutination	O
+.	O
+
+TITLE	O
+:	O
+Emerging	O
+coronaviruses	O
+:	O
+Genome	O
+structure	O
+,	O
+replication	O
+,	O
+and	O
+pathogenesis	B-DISO
+.	O
+
+In	O
+this	O
+minireview	O
+,	O
+we	O
+provide	O
+a	O
+brief	O
+introduction	O
+of	O
+the	O
+general	O
+features	O
+of	O
+CoVs	O
+and	O
+describe	O
+diseases	O
+caused	O
+by	O
+different	O
+CoVs	O
+in	O
+humans	B-SPEC
+and	O
+animals	B-SPEC
+.	O
+
+TITLE	O
+:	O
+5	O
+,	O
+6	O
+-	O
+Dichloro	O
+-	O
+2	O
+-	O
+phenyl	B-CHED
+-	O
+benzotriazoles	B-CHED
+:	O
+New	O
+Potent	O
+Inhibitors	B-CHED
+of	O
+Orthohantavirus	O
+.	O
+
+TITLE	O
+:	O
+Characterization	O
+of	O
+the	O
+Immune	B-PROC
+Response	I-PROC
+of	O
+MERS	O
+-	O
+CoV	O
+Vaccine	O
+Candidates	O
+Derived	O
+from	O
+Two	O
+Different	O
+Vectors	O
+in	O
+Mice	O
+.	O
+
+For	O
+the	O
+29	O
+serum	B-COMP
+samples	O
+from	O
+Bactrian	B-SPEC
+camels	I-SPEC
+in	O
+Dubai	O
+tested	O
+by	O
+the	O
+MERS	O
+-	O
+CoV	O
+spike	O
+(	O
+S	O
+)	O
+protein	B-CHED
+-	O
+based	O
+enzyme	O
+-	O
+linked	O
+immunosorbent	O
+assay	O
+(	O
+S	O
+-	O
+ELISA	O
+)	O
+and	O
+neutralization	O
+antibody	B-COMP
+test	O
+,	O
+14	O
+(	O
+48	O
+%)	O
+and	O
+12	O
+(	O
+41	O
+%),	O
+respectively	O
+,	O
+were	O
+positive	O
+for	O
+MERS	O
+-	O
+CoV	O
+antibodies	O
+.	O
+
+One	O
+death	B-PROC
+attributed	O
+to	O
+vaping	O
+is	O
+presented	O
+with	O
+emphasis	O
+on	O
+the	O
+gross	O
+and	O
+histopathological	O
+findings	O
+from	O
+the	O
+autopsy	O
+.	O
+
+(	O
+Funded	O
+by	O
+the	O
+National	O
+Key	O
+Research	O
+and	O
+Development	B-PROC
+Program	O
+of	O
+China	O
+and	O
+the	O
+National	O
+Major	O
+Project	O
+for	O
+Control	O
+and	O
+Prevention	O
+of	O
+Infectious	B-DISO
+Disease	I-DISO
+in	O
+China	O
+.).	O
+
+TITLE	O
+:	O
+Coronavirus	B-SPEC
+infections	I-DISO
+and	O
+immune	B-PROC
+responses	I-PROC
+.	O
+
+ABSTRACT	O
+:	O
+Coronaviruses	O
+(	O
+CoVs	O
+)	O
+are	O
+by	O
+far	O
+the	O
+largest	O
+group	O
+of	O
+known	O
+positive	O
+-	O
+sense	O
+RNA	O
+viruses	B-SPEC
+having	O
+an	O
+extensive	O
+range	O
+of	O
+natural	O
+hosts	B-COMP
+.	O
+
+In	O
+this	O
+review	O
+,	O
+we	O
+provide	O
+an	O
+update	O
+on	O
+CoV	O
+infections	B-DISO
+and	O
+relevant	O
+diseases	O
+,	O
+particularly	O
+the	O
+host	B-PROC
+defense	I-PROC
+against	O
+CoV	O
+-	O
+induced	O
+inflammation	B-DISO
+of	O
+lung	B-ANAT
+tissue	I-ANAT
+,	O
+as	O
+well	O
+as	O
+the	O
+role	O
+of	O
+the	O
+innate	O
+immune	B-ANAT
+system	I-ANAT
+in	O
+the	O
+pathogenesis	B-DISO
+and	O
+clinical	O
+treatment	O
+.	O
+
+TITLE	O
+:	O
+Gga	B-MRNA
+-	I-MRNA
+miR	I-MRNA
+-	I-MRNA
+30d	I-MRNA
+regulates	O
+infectious	B-DISO
+bronchitis	B-DISO
+virus	B-DISO
+infection	I-DISO
+by	O
+targeting	B-PROC
+USP47	B-PRGE
+in	O
+HD11	O
+cells	B-COMP
+.	O
+
+In	O
+previous	O
+studies	O
+,	O
+we	O
+have	O
+revealed	O
+that	O
+IBV	B-SPEC
+infection	B-DISO
+caused	O
+a	O
+significant	O
+down	B-PROC
+-	I-PROC
+regulation	I-PROC
+of	O
+gga	B-PRGE
+-	I-PRGE
+miR	I-PRGE
+-	I-PRGE
+30d	I-PRGE
+expression	B-PROC
+in	O
+chicken	B-SPEC
+kidneys	B-ANAT
+.	O
+
+In	O
+present	O
+study	O
+,	O
+we	O
+investigated	O
+the	O
+role	O
+of	O
+gga	B-PRGE
+-	I-PRGE
+miR	I-PRGE
+-	I-PRGE
+30d	I-PRGE
+in	O
+the	O
+process	O
+of	O
+IBV	B-SPEC
+infection	B-DISO
+of	O
+HD11	O
+cell	B-ANAT
+line	I-ANAT
+in	O
+vitro	O
+.	O
+
+By	O
+transfecting	O
+the	O
+mimics	O
+and	O
+inhibitor	B-CHED
+of	O
+gga	B-PRGE
+-	I-PRGE
+miR	I-PRGE
+-	I-PRGE
+30d	I-PRGE
+,	O
+it	O
+was	O
+found	O
+that	O
+overexpressed	O
+gga	B-PRGE
+-	I-PRGE
+miR	I-PRGE
+-	I-PRGE
+30d	I-PRGE
+inhibited	O
+IBV	B-SPEC
+replication	O
+.	O
+
+TITLE	O
+:	O
+A	O
+recombinant	O
+infectious	B-DISO
+bronchitis	B-DISO
+virus	B-SPEC
+from	O
+a	O
+chicken	B-SPEC
+with	O
+a	O
+spike	O
+gene	O
+closely	O
+related	O
+to	O
+that	O
+of	O
+a	O
+turkey	O
+coronavirus	B-SPEC
+.	O
+
+The	O
+genome	O
+sequence	O
+of	O
+ahysx	O
+-	O
+1	O
+was	O
+found	O
+to	O
+be	O
+very	O
+similar	O
+to	O
+that	O
+of	O
+IBV	B-SPEC
+strain	O
+ck	O
+/	O
+CH	O
+/	O
+LLN	O
+/	O
+131040	O
+(	O
+KX252787	O
+),	O
+except	O
+for	O
+the	O
+spike	O
+gene	O
+region	O
+,	O
+which	O
+is	O
+similar	O
+to	O
+that	O
+of	O
+a	O
+turkey	B-SPEC
+coronavirus	B-SPEC
+strain	O
+(	O
+EU022526	O
+),	O
+suggesting	O
+that	O
+ahysx	O
+-	O
+1	O
+is	O
+a	O
+recombinant	O
+.	O
+
+TITLE	O
+:	O
+Use	O
+of	O
+intestine	B-ANAT
+-	O
+related	O
+biomarkers	O
+for	O
+detecting	O
+intestinal	B-ANAT
+epithelial	O
+damage	O
+in	O
+neonatal	O
+calves	O
+with	O
+diarrhea	O
+.	O
+
+During	O
+ECMO	O
+,	O
+VEGF	B-PRGE
+and	O
+Ang2	B-PRGE
+serum	I-PRGE
+levels	O
+remained	O
+unchanged	O
+compared	O
+to	O
+the	O
+non	O
+-	O
+ECMO	O
+group	O
+(	O
+p	O
+=	O
+0	O
+.	O
+16	O
+),	O
+but	O
+Ang2	B-PRGE
+serum	I-PRGE
+levels	O
+in	O
+non	O
+-	O
+survivors	O
+of	O
+ARDS	B-DISO
+were	O
+significantly	O
+increased	O
+by	O
+100	O
+%	O
+(	O
+p	O
+=	O
+0	O
+.	O
+02	O
+)	O
+compared	O
+to	O
+survivors	O
+.	O
+
+Five	O
+family	B-SPEC
+members	O
+(	O
+aged	O
+36	O
+-	O
+66	O
+years	O
+)	O
+presented	O
+with	O
+fever	B-PROC
+,	O
+upper	O
+or	O
+lower	B-ANAT
+respiratory	I-ANAT
+tract	I-ANAT
+symptoms	O
+,	O
+or	O
+diarrhoea	B-DISO
+,	O
+or	O
+a	O
+combination	O
+of	O
+these	O
+3	O
+-	O
+6	O
+days	O
+after	O
+exposure	O
+.	O
+
+They	O
+presented	O
+to	O
+our	O
+hospital	O
+(	O
+The	O
+University	O
+of	O
+Hong	O
+Kong	O
+-	O
+Shenzhen	O
+Hospital	O
+,	O
+Shenzhen	O
+)	O
+6	O
+-	O
+10	O
+days	O
+after	O
+symptom	B-DISO
+onset	O
+.	O
+
+They	O
+and	O
+one	O
+asymptomatic	O
+child	O
+(	O
+aged	O
+10	O
+years	O
+)	O
+had	O
+radiological	O
+ground	O
+-	O
+glass	O
+lung	B-ANAT
+opacities	B-DISO
+.	O
+
+Our	O
+findings	O
+are	O
+consistent	O
+with	O
+person	O
+-	O
+to	O
+-	O
+person	O
+transmission	O
+of	O
+this	O
+novel	B-SPEC
+coronavirus	I-SPEC
+in	O
+hospital	O
+and	O
+family	B-SPEC
+settings	O
+,	O
+and	O
+the	O
+reports	O
+of	O
+infected	O
+travellers	O
+in	O
+other	O
+geographical	O
+regions	O
+.	O
+
+Data	O
+were	O
+obtained	O
+with	O
+standardised	O
+data	O
+collection	O
+forms	O
+shared	O
+by	O
+WHO	O
+and	O
+the	O
+International	O
+Severe	O
+Acute	O
+Respiratory	O
+and	O
+Emerging	O
+Infection	B-DISO
+Consortium	O
+from	O
+electronic	O
+medical	O
+records	O
+.	O
+
+Learning	B-PROC
+from	O
+the	O
+roles	O
+of	O
+civet	B-SPEC
+in	O
+SARS	B-DISO
+and	O
+camel	B-SPEC
+in	O
+MERS	O
+,	O
+hunting	O
+for	O
+the	O
+animal	B-SPEC
+source	O
+of	O
+2019	B-SPEC
+-	I-SPEC
+nCoV	I-SPEC
+and	O
+its	O
+more	O
+ancestral	O
+virus	B-SPEC
+would	O
+be	O
+important	O
+for	O
+understanding	O
+the	O
+origin	O
+and	O
+evolution	B-PROC
+of	O
+this	O
+novel	O
+lineage	O
+B	O
+
+Yet	O
+,	O
+with	O
+technological	O
+advances	O
+and	O
+important	O
+lessons	O
+gained	O
+from	O
+previous	O
+outbreaks	O
+,	O
+perhaps	O
+the	O
+world	O
+is	O
+better	O
+equipped	O
+to	O
+deal	O
+with	O
+the	O
+most	O
+recent	O
+emergent	O
+group	O
+2B	O
+coronavirus	B-SPEC
+.	O
+
+ABSTRACT	O
+:	O
+The	O
+ongoing	O
+outbreak	O
+of	O
+the	O
+recently	O
+emerged	O
+novel	O
+coronavirus	O
+(	O
+2019	B-SPEC
+-	I-SPEC
+nCoV	I-SPEC
+)	O
+poses	O
+a	O
+challenge	O
+for	O
+public	O
+health	O
+laboratories	O
+as	O
+virus	B-SPEC
+isolates	O
+are	O
+unavailable	O
+while	O
+there	O
+is	O
+growing	O
+evidence	O
+that	O
+the	O
+outbreak	O
+is	O
+more	O
+widespread	O
+than	O
+initially	O
+thought	O
+,	O
+and	O
+international	O
+spread	O
+through	O
+travellers	O
+does	O
+already	O
+occur	O
+.	O
+
+Control	O
+material	O
+is	O
+made	O
+available	O
+through	O
+European	O
+Virus	B-SPEC
+Archive	O
+-	O
+Global	O
+(	O
+EVAg	O
+),	O
+a	O
+European	O
+Union	O
+infrastructure	O
+project	O
+.	O
+
+From	O
+these	O
+results	O
+,	O
+the	O
+new	O
+2019	B-SPEC
+-	I-SPEC
+nCoV	I-SPEC
+is	O
+distinct	O
+from	O
+SARS	B-DISO
+virus	B-SPEC
+,	O
+probably	O
+trasmitted	O
+from	O
+bats	B-SPEC
+after	O
+mutation	O
+conferring	O
+ability	O
+to	O
+infect	O
+humans	B-SPEC
+.	O
+
+ABSTRACT	O
+:	O
+The	O
+initial	O
+cases	O
+of	O
+novel	O
+coronavirus	O
+(	O
+2019	B-SPEC
+-	I-SPEC
+nCoV	I-SPEC
+)-	O
+infected	O
+pneumonia	B-DISO
+(	O
+NCIP	O
+)	O
+occurred	O
+in	O
+Wuhan	O
+,	O
+Hubei	O
+Province	O
+,	O
+China	O
+,	O
+in	O
+December	O
+2019	O
+and	O
+January	O
+2020	O
+.	O
+
+TITLE	O
+:	O
+Receptor	O
+Recognition	O
+by	O
+the	O
+Novel	B-SPEC
+Coronavirus	I-SPEC
+from	O
+Wuhan	O
+:	O
+an	O
+Analysis	O
+Based	O
+on	O
+Decade	O
+-	O
+Long	O
+Structural	O
+Studies	O
+of	O
+SARS	O
+Coronavirus	B-SPEC
+.	O
+
+TITLE	O
+:	O
+Drug	O
+treatment	O
+options	O
+for	O
+the	O
+2019	O
+-	O
+new	O
+coronavirus	B-SPEC
+(	O
+2019	B-SPEC
+-	I-SPEC
+nCoV	I-SPEC
+).	O
+
+Out	O
+of	O
+the	O
+total	O
+200	O
+children	O
+,	O
+108	O
+progressed	O
+to	O
+sepsis	O
+,	O
+of	O
+which	O
+26	O
+progressed	O
+to	O
+severe	B-DISO
+sepsis	I-DISO
+,	O
+of	O
+which	O
+22	O
+progressed	O
+to	O
+septic	B-DISO
+shock	I-DISO
+.	O
+
+The	O
+predictors	O
+of	O
+mortality	O
+were	O
+positive	O
+blood	B-ANAT
+cultures	O
+,	O
+multiorgan	O
+dysfunction	O
+,	O
+late	O
+hospital	O
+admissions	O
+,	O
+severe	O
+acute	O
+malnutrition	B-DISO
+,	O
+and	O
+requirement	O
+of	O
+supportive	O
+care	O
+.	O
+
+The	O
+predictors	O
+of	O
+progression	O
+to	O
+septic	B-DISO
+shock	I-DISO
+were	O
+abnormal	O
+leukocyte	B-ANAT
+count	O
+,	O
+culture	O
+positivity	O
+,	O
+and	O
+severe	O
+acute	O
+malnutrition	B-DISO
+.	O
+
+The	O
+efficacy	O
+in	O
+improving	O
+oxygenation	B-PROC
+with	O
+four	O
+support	O
+methods	O
+-	O
+HFNC	O
+,	O
+HFNC	O
++	O
+PP	O
+,	O
+NIV	O
+,	O
+NIV	O
++	O
+PP	O
+-	O
+were	O
+evaluated	O
+by	O
+blood	B-PROC
+gas	B-ENZY
+analysis	O
+.	O
+
+TITLE	O
+:	O
+Middle	O
+East	O
+Respiratory	O
+Syndrome	B-DISO
+-	O
+Corona	B-CHED
+Virus	B-SPEC
+(	O
+MERS	O
+-	O
+CoV	O
+)	O
+associated	O
+stress	O
+among	O
+medical	O
+students	O
+at	O
+a	O
+university	O
+teaching	O
+hospital	O
+in	O
+Saudi	O
+Arabia	O
+.	O
+
+Media	B-ANAT
+speculations	O
+may	O
+have	O
+increased	O
+this	O
+psychological	B-DISO
+distress	I-DISO
+.	O
+
+However	O
+,	O
+the	O
+number	O
+of	O
+accessed	O
+resources	O
+,	O
+as	O
+per	O
+students	O
+,	O
+has	O
+borderline	O
+significant	O
+correlation	O
+with	O
+higher	O
+self	O
+-	O
+reported	O
+anxiety	O
+from	O
+MERS	O
+-	O
+CoV	O
+.	O
+Medical	O
+students	O
+'	O
+psychological	B-DISO
+needs	O
+during	O
+the	O
+MERS	O
+-	O
+CoV	O
+outbreak	O
+should	O
+be	O
+addressed	O
+appropriately	O
+.	O
+
+These	O
+isolates	O
+showed	O
+79	O
+.	O
+0	O
+%	O
+nucleotide	B-CHED
+identity	O
+with	O
+the	O
+sequence	O
+of	O
+SARS	B-PRGE
+-	I-PRGE
+CoV	I-PRGE
+(	O
+GenBank	O
+NC_004718	O
+)	O
+and	O
+51	O
+.	O
+8	O
+%	O
+identity	O
+with	O
+the	O
+sequence	O
+of	O
+MERS	O
+-	O
+CoV	O
+(	O
+GenBank	O
+NC_019843	O
+).	O
+
+RESULTS	O
+:	O
+Five	O
+patients	O
+hospitalized	O
+from	O
+December	O
+18	O
+to	O
+December	O
+29	O
+,	O
+2019	O
+presented	O
+with	O
+fever	B-PROC
+,	O
+cough	B-DISO
+,	O
+and	O
+dyspnea	B-DISO
+accompanied	O
+by	O
+complications	O
+of	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+.	O
+
+One	O
+of	O
+these	O
+patients	O
+died	B-PROC
+.	O
+
+CONCLUSIONS	O
+:	O
+A	O
+novel	O
+bat	B-ENZY
+-	O
+borne	O
+CoV	O
+was	O
+identified	O
+that	O
+is	O
+associated	O
+with	O
+severe	O
+and	O
+fatal	O
+respiratory	B-DISO
+disease	I-DISO
+in	O
+humans	B-SPEC
+.	O
+
+Retrospective	O
+data	O
+were	O
+collected	O
+for	O
+returning	O
+travellers	O
+from	O
+the	O
+Middle	O
+East	O
+fitting	B-DISO
+the	O
+PHE	B-CHED
+MERS	O
+case	O
+definition	O
+.	O
+
+Sputum	B-ANAT
+samples	O
+were	O
+the	O
+most	O
+useful	O
+in	O
+diagnosing	O
+respiratory	O
+viruses	B-SPEC
+with	O
+a	O
+100	O
+%	O
+diagnostic	O
+yield	O
+from	O
+patients	O
+with	O
+multiple	O
+samples	O
+.	O
+
+Our	O
+objectives	O
+were	O
+to	O
+characterize	O
+the	O
+genetic	O
+relationships	O
+of	O
+the	O
+2019	B-SPEC
+-	I-SPEC
+nCoV	I-SPEC
+and	O
+to	O
+search	O
+for	O
+putative	O
+recombination	B-PROC
+within	O
+the	O
+subgenus	B-SPEC
+of	O
+sarbecovirus	O
+.	O
+
+Specifically	O
+,	O
+in	O
+the	O
+5	O
+'-	O
+part	O
+spanning	O
+the	O
+first	O
+11	O
+,	O
+498	O
+nucleotides	B-CHED
+and	O
+the	O
+last	O
+3	O
+'-	O
+part	O
+spanning	O
+24	O
+,	O
+341	O
+-	O
+30	O
+,	O
+696	O
+positions	O
+,	O
+2019	O
+-	O
+nCoV	O
+and	O
+RaTG13	O
+formed	O
+a	O
+single	O
+cluster	O
+with	O
+Bat_SARS	O
+-	O
+like	O
+coronavirus	B-SPEC
+sequences	O
+,	O
+whereas	O
+in	O
+the	O
+middle	O
+region	O
+spanning	O
+the	O
+3	O
+'-	O
+end	O
+of	O
+ORF1a	O
+,	O
+the	O
+ORF1b	O
+and	O
+almost	O
+half	O
+of	O
+the	O
+spike	O
+regions	O
+,	O
+2019	B-SPEC
+-	I-SPEC
+nCoV	I-SPEC
+and	O
+RaTG13	O
+grouped	O
+in	O
+a	O
+separate	O
+distant	O
+lineage	O
+within	O
+the	O
+sarbecovirus	O
+branch	B-ANAT
+.	O
+
+Samples	O
+were	O
+tested	O
+for	O
+MERS	O
+-	O
+CoV	O
+S1	O
+-	O
+specific	O
+antibodies	B-COMP
+(	O
+Abs	B-PRGE
+)	O
+by	O
+ELISA	O
+and	O
+confirmed	O
+by	O
+testing	O
+for	O
+neutralizing	O
+Abs	O
+(	O
+nAbs	O
+)	O
+using	O
+both	O
+pseudotyped	O
+and	O
+live	O
+virus	B-PROC
+neutralization	I-PROC
+assays	O
+.	O
+
+ABSTRACT	O
+:	O
+Human	B-SPEC
+coronaviruses	O
+(	O
+CoVs	O
+)	O
+are	O
+enveloped	O
+viruses	O
+with	O
+a	O
+positive	O
+-	O
+sense	B-PROC
+single	O
+-	O
+stranded	O
+RNA	O
+genome	O
+.	O
+
+They	O
+cause	O
+moderate	O
+to	O
+severe	O
+respiratory	O
+and	O
+intestinal	B-DISO
+infections	I-DISO
+in	O
+humans	B-SPEC
+.	O
+
+50	O
+(	O
+51	O
+%)	O
+patients	O
+had	O
+chronic	B-DISO
+diseases	I-DISO
+.	O
+
+TITLE	O
+:	O
+Novel	B-SPEC
+coronavirus	I-SPEC
+:	O
+From	O
+discovery	O
+to	O
+clinical	O
+diagnostics	O
+.	O
+
+ABSTRACT	O
+:	O
+A	O
+novel	B-SPEC
+coronavirus	I-SPEC
+designated	O
+as	O
+2019	O
+-	O
+nCoV	O
+first	O
+appeared	O
+in	O
+Wuhan	O
+,	O
+China	O
+in	O
+late	O
+December	O
+2019	O
+.	O
+
+The	O
+respiratory	O
+ArTH	O
+predictive	O
+tool	O
+assigns	O
+one	O
+point	O
+for	O
+each	O
+of	O
+the	O
+following	O
+:	O
+apnea	B-DISO
+-	O
+hypopnea	O
+index	O
+(	O
+AHI	O
+)	O
+<	O
+30	O
+/	O
+h	O
+,	O
+nadir	O
+oxygen	B-CHED
+saturation	O
+(	O
+SaO	O
+Our	O
+results	O
+reconfirmed	O
+the	O
+association	O
+between	O
+moderate	O
+-	O
+to	O
+-	O
+severe	O
+sleep	B-DISO
+apnea	I-DISO
+syndrome	I-DISO
+and	O
+WUS	O
+(	O
+OR	O
+2	O
+.	O
+879	O
+,	O
+95	O
+%	O
+CI	O
+1	O
+.	O
+17	O
+-	O
+7	O
+.	O
+089	O
+,	O
+p	O
+=	O
+0	O
+.	O
+021	O
+).	O
+
+We	O
+show	O
+that	O
+reduced	O
+respiratory	O
+arousability	O
+is	O
+associated	O
+with	O
+WUS	O
+,	O
+and	O
+hypothesize	O
+that	O
+reduced	O
+cortical	B-ANAT
+capability	O
+to	O
+generate	O
+respiratory	O
+arousal	O
+may	O
+have	O
+a	O
+role	O
+in	O
+triggering	O
+stroke	B-DISO
+during	O
+sleep	B-PROC
+.	O
+
+TITLE	O
+:	O
+Isolation	O
+and	O
+characterization	O
+of	O
+avian	B-SPEC
+coronavirus	I-SPEC
+from	O
+healthy	O
+Eclectus	B-SPEC
+parrots	B-SPEC
+(	O
+ABSTRACT	O
+:	O
+Avian	O
+coronavirus	O
+has	O
+a	O
+wide	O
+range	O
+of	O
+hosts	B-COMP
+,	O
+from	O
+chickens	B-SPEC
+and	O
+turkeys	B-SPEC
+to	O
+wild	O
+birds	B-SPEC
+.	O
+
+Therefore	O
+,	O
+research	O
+into	O
+the	O
+avian	B-SPEC
+coronavirus	I-SPEC
+in	O
+various	O
+species	B-SPEC
+of	O
+birds	B-SPEC
+is	O
+required	O
+.	O
+
+The	O
+partial	O
+nucleotide	B-CHED
+sequence	O
+of	O
+this	O
+isolate	O
+showed	O
+100	O
+%	O
+homology	O
+with	O
+the	O
+IBV	B-SPEC
+GI	O
+-	O
+13	O
+lineage	O
+,	O
+specifically	O
+with	O
+a	O
+field	O
+isolate	O
+of	O
+the	O
+4	B-PRGE
+/	I-PRGE
+91	I-PRGE
+variant	I-PRGE
+1	I-PRGE
+Israel	O
+and	O
+the	O
+4	O
+/	O
+91	O
+vaccine	O
+on	O
+the	O
+hypervariable	O
+region	O
+3	O
+site	O
+of	O
+the	O
+S1	B-PRGE
+gene	I-PRGE
+.	O
+
+In	O
+fact	O
+,	O
+bats	B-SPEC
+are	O
+natural	O
+reservoirs	O
+for	O
+viruses	B-SPEC
+that	O
+have	O
+some	O
+of	O
+the	O
+highest	O
+fatality	O
+rates	O
+of	O
+any	O
+viruses	B-SPEC
+that	O
+people	O
+acquire	O
+from	O
+wild	O
+animals	B-SPEC
+–	O
+including	O
+rabies	B-DISO
+,	O
+Ebola	O
+and	O
+the	O
+SARS	B-DISO
+coronavirus	B-SPEC
+.	O
+
+The	O
+experiments	O
+made	O
+use	O
+of	O
+cells	B-COMP
+from	O
+one	O
+bat	B-ENZY
+species	B-SPEC
+–	O
+the	O
+black	B-SPEC
+flying	I-SPEC
+fox	I-SPEC
+–	O
+in	O
+which	O
+the	O
+interferon	B-PRGE
+pathway	B-PROC
+is	O
+always	O
+on	O
+,	O
+and	O
+another	O
+–	O
+the	O
+Egyptian	O
+fruit	O
+bat	B-ENZY
+–	O
+in	O
+which	O
+this	O
+pathway	B-PROC
+is	O
+only	O
+activated	O
+during	O
+an	O
+infection	B-DISO
+.	O
+
+In	O
+both	O
+bat	B-ENZY
+species	B-SPEC
+,	O
+the	O
+strongest	O
+antiviral	B-CHED
+responses	O
+were	O
+countered	O
+by	O
+the	O
+virus	B-SPEC
+spreading	O
+more	O
+quickly	O
+from	O
+cell	B-COMP
+to	O
+cell	B-COMP
+.	O
+
+More	O
+studies	O
+are	O
+needed	O
+in	O
+bats	B-SPEC
+to	O
+help	O
+these	O
+efforts	O
+.	O
+
+A	O
+bone	B-ANAT
+marrow	I-ANAT
+aspirate	I-ANAT
+was	O
+performed	O
+,	O
+which	O
+revealed	O
+megaloblasts	B-ANAT
+and	O
+numerous	O
+macrophages	B-ANAT
+,	O
+with	O
+abundant	O
+foamy	O
+cytoplasm	B-COMP
+.	O
+
+During	O
+the	O
+2015	O
+MERS	O
+-	O
+CoV	O
+outbreak	O
+in	O
+Korea	O
+,	O
+116	O
+patients	O
+in	O
+3	O
+HD	O
+units	O
+were	O
+incidentally	O
+exposed	O
+to	O
+individuals	O
+with	O
+confirmed	O
+MERS	O
+-	O
+CoV	O
+infection	B-DISO
+and	O
+underwent	O
+different	O
+types	O
+of	O
+isolation	O
+,	O
+which	O
+were	O
+as	O
+follows	O
+:	O
+single	O
+-	O
+room	O
+isolation	O
+(	O
+n	O
+=	O
+54	O
+,	O
+47	O
+%),	O
+cohort	O
+isolation	O
+(	O
+n	O
+=	O
+46	O
+,	O
+40	O
+%),	O
+and	O
+self	O
+-	O
+imposed	O
+quarantine	O
+(	O
+n	O
+=	O
+16	O
+,	O
+13	O
+%).	O
+
+The	O
+primary	O
+outcome	O
+was	O
+rate	O
+of	O
+secondary	O
+viral	B-PROC
+transmission	I-PROC
+.	O
+
+Although	O
+116	O
+participants	O
+in	O
+3	O
+HD	O
+units	O
+were	O
+incidentally	O
+exposed	O
+to	O
+MERS	O
+-	O
+CoV	O
+during	O
+the	O
+2015	O
+outbreak	O
+in	O
+Korea	O
+,	O
+strict	O
+patient	O
+surveillance	O
+and	O
+proper	O
+isolation	O
+practice	O
+prevented	O
+secondary	B-DISO
+transmission	I-DISO
+of	O
+the	O
+virus	B-SPEC
+.	O
+
+ABSTRACT	O
+:	O
+Coronavirus	O
+can	O
+cause	O
+respiratory	O
+syndrome	B-DISO
+which	O
+to	O
+date	O
+has	O
+affected	O
+about	O
+twelve	O
+thousand	O
+individuals	O
+,	O
+especially	O
+in	O
+China	O
+.	O
+
+Viral	O
+activate	O
+MCs	B-COMP
+release	B-PATH
+early	O
+inflammatory	O
+chemical	O
+copounds	O
+including	O
+histamine	B-CHED
+and	O
+protease	O
+;	O
+while	O
+late	O
+activation	O
+provoke	O
+the	O
+generation	O
+of	O
+pro	O
+-	O
+inflammatory	O
+IL	B-PRGE
+-	I-PRGE
+1	I-PRGE
+family	B-SPEC
+members	I-PRGE
+including	O
+IL	B-FUNC
+-	I-FUNC
+1	I-FUNC
+,	O
+IL	B-FUNC
+-	I-FUNC
+6	I-FUNC
+and	O
+IL	B-FUNC
+-	I-FUNC
+33	I-FUNC
+.	O
+
+We	O
+used	O
+data	O
+from	O
+Dec	B-CHED
+31	O
+,	O
+2019	O
+,	O
+to	O
+Jan	B-PRGE
+28	I-PRGE
+,	O
+2020	O
+,	O
+on	O
+the	O
+number	O
+of	O
+cases	O
+exported	O
+from	O
+Wuhan	O
+internationally	O
+(	O
+known	O
+days	O
+of	O
+symptom	B-DISO
+onset	O
+from	O
+Dec	B-CHED
+25	O
+,	O
+2019	O
+,	O
+to	O
+Jan	O
+19	O
+,	O
+2020	O
+)	O
+to	O
+infer	O
+the	O
+number	O
+of	O
+infections	B-DISO
+in	O
+Wuhan	O
+from	O
+Dec	B-CHED
+1	O
+,	O
+2019	O
+,	O
+to	O
+Jan	B-PRGE
+25	I-PRGE
+,	O
+2020	O
+.	O
+
+A	O
+susceptible	O
+-	O
+exposed	O
+-	O
+infectious	B-DISO
+-	O
+recovered	O
+metapopulation	O
+model	O
+was	O
+used	O
+to	O
+simulate	O
+the	O
+epidemics	O
+across	O
+all	O
+major	O
+cities	O
+in	O
+China	O
+.	O
+
+The	O
+basic	O
+reproductive	B-PROC
+number	O
+was	O
+estimated	O
+using	O
+Markov	O
+Chain	O
+Monte	O
+Carlo	O
+methods	O
+and	O
+presented	O
+using	O
+the	O
+resulting	O
+posterior	O
+mean	O
+and	O
+95	O
+%	O
+credibile	O
+interval	O
+(	O
+CrI	O
+).	O
+
+ABSTRACT	O
+:	O
+Emerging	B-DISO
+infectious	I-DISO
+diseases	I-DISO
+,	O
+such	O
+as	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+(	O
+SARS	B-DISO
+)	O
+and	O
+Zika	B-DISO
+virus	I-DISO
+disease	I-DISO
+,	O
+present	O
+a	O
+major	O
+threat	O
+to	O
+public	O
+health	O
+
+TITLE	O
+:	O
+Neuromuscular	B-PROC
+blockade	I-PROC
+in	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+:	O
+a	O
+systematic	O
+review	O
+and	O
+meta	B-SPEC
+-	O
+analysis	O
+of	O
+randomized	O
+controlled	O
+trials	O
+.	O
+
+However	O
+,	O
+NMBA	O
+does	O
+not	O
+reduce	O
+ventilator	O
+-	O
+free	O
+days	O
+,	O
+duration	O
+of	O
+mechanical	O
+ventilation	O
+or	O
+,	O
+most	O
+importantly	O
+,	O
+the	O
+mortality	O
+risk	O
+regardless	O
+of	O
+the	O
+severity	O
+of	O
+ARDS	B-DISO
+.	O
+
+A	O
+40	O
+-	O
+year	O
+-	O
+old	O
+male	O
+presented	O
+with	O
+acute	O
+onset	O
+severe	O
+hypoxemic	O
+respiratory	B-DISO
+failure	I-DISO
+.	O
+
+Given	O
+the	O
+lack	O
+of	O
+other	O
+findings	O
+and	O
+risk	O
+factors	O
+,	O
+his	O
+IPIPC	O
+was	O
+likely	O
+associated	O
+with	O
+occupational	O
+exposures	O
+to	O
+hydrocarbons	B-CHED
+as	O
+a	O
+cabinetmaker	O
+compounded	O
+by	O
+marijuana	B-DISO
+smoking	O
+.	O
+
+TITLE	O
+:	O
+Dynamics	O
+of	O
+transmissible	O
+gastroenteritis	B-DISO
+virus	B-SPEC
+internalization	O
+unraveled	O
+by	O
+single	O
+-	O
+virus	B-SPEC
+tracking	O
+in	O
+live	O
+cells	O
+.	O
+
+In	O
+this	O
+study	O
+,	O
+we	O
+used	O
+single	O
+-	O
+virus	B-SPEC
+tracking	O
+to	O
+obtain	O
+the	O
+detailed	O
+insights	O
+into	O
+the	O
+dynamic	O
+events	O
+of	O
+the	O
+TGEV	B-SPEC
+internalization	O
+and	O
+depict	O
+the	O
+whole	O
+sequential	O
+process	O
+.	O
+
+Furthermore	O
+,	O
+the	O
+interactions	O
+of	O
+TGEVs	O
+with	O
+actin	B-PRGE
+and	O
+dynamin	B-PRGE
+2	I-PRGE
+in	O
+real	O
+time	O
+during	O
+the	O
+TGEV	B-SPEC
+internalization	O
+were	O
+visualized	O
+.	O
+
+ABSTRACT	O
+:	O
+This	O
+study	O
+delineates	O
+the	O
+disease	O
+trajectory	O
+of	O
+patients	O
+with	O
+pediatric	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+(	O
+PARDS	O
+)	O
+defined	O
+by	O
+the	O
+Pediatric	O
+Acute	O
+Lung	B-ANAT
+Injury	O
+Consensus	O
+Conference	O
+(	O
+PALICC	O
+)	O
+definition	O
+,	O
+and	O
+evaluates	O
+the	O
+impact	O
+of	O
+comorbidities	O
+on	O
+outcomes	O
+.	O
+
+The	O
+impact	O
+of	O
+chronic	O
+comorbidities	O
+on	O
+clinical	O
+outcomes	O
+,	O
+in	O
+particular	O
+,	O
+pulmonary	B-DISO
+disease	I-DISO
+and	O
+immunosuppression	B-PROC
+,	O
+were	O
+analyzed	O
+.	O
+
+Eighty	O
+-	O
+five	O
+of	O
+1272	O
+PICU	B-SPEC
+admissions	O
+(	O
+6	O
+.	O
+7	O
+%)	O
+met	B-CHED
+the	O
+criteria	O
+for	O
+PARDS	O
+and	O
+were	O
+included	O
+.	O
+
+Patients	O
+with	O
+pulmonary	B-ANAT
+comorbidities	O
+and	O
+immunosuppression	B-PROC
+had	O
+a	O
+more	O
+severe	O
+course	O
+of	O
+PARDS	O
+compared	O
+with	O
+others	O
+.	O
+
+Therefore	O
+,	O
+combating	O
+this	O
+new	O
+virus	B-SPEC
+and	O
+stopping	O
+the	O
+epidemic	O
+is	O
+a	O
+matter	O
+of	O
+urgency	O
+.	O
+
+TITLE	O
+:	O
+SARS	B-DISO
+to	O
+novel	B-SPEC
+coronavirus	I-SPEC
+-	O
+old	O
+lessons	O
+and	O
+new	O
+lessons	O
+.	O
+
+TITLE	O
+:	O
+Novel	B-SPEC
+coronavirus	I-SPEC
+(	O
+2019	B-SPEC
+-	I-SPEC
+nCoV	I-SPEC
+)	O
+early	O
+-	O
+stage	O
+importation	O
+risk	O
+to	O
+Europe	O
+,	O
+January	O
+2020	O
+.	O
+
+TITLE	O
+:	O
+Pattern	O
+of	O
+early	O
+human	B-SPEC
+-	O
+to	O
+-	O
+human	B-SPEC
+transmission	O
+of	O
+Wuhan	O
+2019	B-SPEC
+novel	I-SPEC
+coronavirus	I-SPEC
+(	O
+2019	B-SPEC
+-	I-SPEC
+nCoV	I-SPEC
+),	O
+December	O
+2019	O
+to	O
+January	O
+2020	O
+.	O
+
+TITLE	O
+:	O
+Ventilatory	O
+support	O
+and	O
+mechanical	O
+properties	O
+of	O
+the	O
+fibrotic	O
+lung	B-ANAT
+acting	O
+as	O
+a	O
+""""	O
+squishy	O
+ball	O
+"""."	O
+
+ABSTRACT	O
+:	O
+Protective	O
+ventilation	O
+is	O
+the	O
+cornerstone	O
+of	O
+treatment	O
+of	O
+patients	O
+with	O
+the	O
+acute	O
+respiratory	O
+distress	O
+syndrome	O
+(	O
+ARDS	B-DISO
+);	O
+however	O
+,	O
+no	O
+studies	O
+have	O
+yet	O
+established	O
+the	O
+best	O
+ventilatory	O
+strategy	O
+to	O
+adopt	O
+when	O
+patients	O
+with	O
+acute	O
+exacerbation	O
+of	O
+interstitial	B-DISO
+lung	B-ANAT
+disease	I-DISO
+(	O
+AE	O
+-	O
+ILD	O
+)	O
+are	O
+admitted	O
+to	O
+the	O
+intensive	O
+care	O
+unit	O
+.	O
+
+Due	O
+to	O
+the	O
+severe	O
+impairment	B-DISO
+of	O
+the	O
+respiratory	B-PROC
+mechanics	I-PROC
+,	O
+the	O
+fibrotic	O
+lung	B-ANAT
+is	O
+at	O
+high	O
+risk	O
+of	O
+developing	O
+ventilator	O
+-	O
+induced	O
+lung	B-ANAT
+injury	O
+,	O
+regardless	O
+of	O
+the	O
+lung	B-DISO
+fibrosis	I-DISO
+etiology	O
+.	O
+
+Phylogenetic	O
+analysis	O
+indicates	O
+that	O
+2019	B-SPEC
+-	I-SPEC
+nCoV	I-SPEC
+is	O
+close	O
+to	O
+coronaviruses	O
+(	O
+CoVs	O
+)	O
+circulating	O
+in	O
+Rhinolophus	B-SPEC
+(	O
+Horseshoe	B-SPEC
+bats	I-SPEC
+),	O
+such	O
+as	O
+98	O
+.	O
+7	O
+%	O
+nucleotide	B-CHED
+identity	O
+to	O
+partial	O
+RdRp	B-FUNC
+gene	O
+of	O
+bat	B-ENZY
+coronavirus	B-SPEC
+strain	O
+BtCoV	O
+/	O
+4991	O
+(	O
+GenBank	O
+KP876546	O
+,	O
+370	O
+nt	O
+sequence	O
+of	O
+RdRp	B-FUNC
+and	O
+lack	O
+of	O
+other	O
+genome	O
+sequence	O
+)	O
+and	O
+87	O
+.	O
+9	O
+%	O
+nucleotide	B-CHED
+identity	O
+to	O
+bat	B-ENZY
+coronavirus	B-SPEC
+strain	O
+bat	B-ENZY
+-	O
+SL	O
+-	O
+CoVZC45	O
+and	O
+bat	B-ENZY
+-	O
+SL	O
+-	O
+CoVZXC21	O
+.	O
+
+TITLE	O
+:	O
+Immunoinformatics	O
+-	O
+aided	O
+identification	O
+of	O
+T	B-ANAT
+cell	I-ANAT
+and	O
+B	B-ANAT
+cell	I-ANAT
+epitopes	O
+in	O
+the	O
+surface	O
+glycoprotein	B-CHED
+of	O
+2019	B-SPEC
+-	I-SPEC
+nCoV	I-SPEC
+.	O
+ABSTRACT	O
+:	O
+The	O
+2019	B-SPEC
+novel	I-SPEC
+coronavirus	I-SPEC
+(	O
+2019	B-SPEC
+-	I-SPEC
+nCoV	I-SPEC
+)	O
+outbreak	O
+has	O
+caused	O
+a	O
+large	O
+number	O
+of	O
+deaths	B-PROC
+with	O
+thousands	O
+of	O
+confirmed	O
+cases	O
+worldwide	O
+,	O
+especially	O
+in	O
+East	O
+Asia	O
+.	O
+
+The	O
+causative	O
+pathogen	O
+was	O
+quickly	O
+confirmed	O
+as	O
+""""	O
+2019	B-SPEC
+-	I-SPEC
+nCoV	I-SPEC
+""""	O
+.	O
+
+Drugs	O
+are	O
+possibly	O
+effective	O
+for	O
+2019	B-SPEC
+-	I-SPEC
+nCoV	I-SPEC
+include	O
+:	O
+remdesivir	O
+,	O
+lopinavir	O
+/	O
+ritonavir	B-CHED
+,	O
+lopinavir	O
+/	O
+ritonavir	B-CHED
+combined	O
+with	O
+interferon	B-PRGE
+-	I-PRGE
+β	I-PRGE
+,	O
+convalescent	O
+plasma	B-ANAT
+,	O
+and	O
+monoclonal	O
+antibodies	B-COMP
+.	O
+
+At	O
+the	O
+same	O
+time	O
+,	O
+the	O
+rate	O
+of	O
+disease	B-DISO
+progression	I-DISO
+,	O
+fever	B-PROC
+,	O
+CT	O
+manifestations	O
+,	O
+hypoxia	B-DISO
+degree	O
+,	O
+age	O
+,	O
+basic	O
+diseases	O
+,	O
+and	O
+laboratory	O
+indicators	O
+can	O
+also	O
+be	O
+used	O
+to	O
+evaluate	O
+the	O
+severity	O
+of	O
+the	O
+novel	B-SPEC
+coronavirus	I-SPEC
+pneumonia	B-DISO
+.	O
+
+ABSTRACT	O
+:	O
+In	O
+December	O
+2019	O
+,	O
+an	O
+outbreak	O
+of	O
+respiratory	O
+illness	O
+caused	O
+by	O
+a	O
+novel	O
+coronavirus	O
+(	O
+2019	B-SPEC
+-	I-SPEC
+nCoV	I-SPEC
+)	O
+emerged	O
+in	O
+Wuhan	O
+,	O
+China	O
+and	O
+has	O
+swiftly	O
+spread	O
+to	O
+other	O
+parts	O
+of	O
+China	O
+and	O
+a	O
+number	O
+of	O
+foreign	O
+countries	O
+.	O
+
+We	O
+used	O
+the	O
+serial	O
+intervals	O
+(	O
+SI	O
+)	O
+of	O
+infection	B-DISO
+caused	O
+by	O
+two	O
+other	O
+well	O
+-	O
+known	O
+coronaviruses	O
+(	O
+CoV	O
+),	O
+Severe	B-DISO
+Acute	I-DISO
+Respiratory	I-DISO
+Syndrome	I-DISO
+(	O
+SARS	B-DISO
+)	O
+and	O
+Middle	O
+East	O
+Respiratory	O
+Syndrome	B-DISO
+(	O
+MERS	O
+)	O
+CoVs	O
+,	O
+as	O
+approximations	O
+of	O
+the	O
+unknown	O
+SI	O
+for	O
+2019	O
+-	O
+nCoV	O
+to	O
+estimate	O
+We	O
+confirmed	O
+that	O
+the	O
+initial	O
+growth	B-PROC
+phase	O
+followed	O
+an	O
+exponential	O
+growth	B-PROC
+pattern	I-PROC
+.	O
+
+TITLE	O
+:	O
+Genomic	O
+variance	O
+of	O
+the	O
+2019	B-SPEC
+-	I-SPEC
+nCoV	I-SPEC
+coronavirus	B-SPEC
+.	O
+
+ABSTRACT	O
+:	O
+There	O
+is	O
+a	O
+rising	O
+global	O
+concern	O
+for	O
+the	O
+recently	O
+emerged	O
+novel	O
+coronavirus	O
+(	O
+2019	B-SPEC
+-	I-SPEC
+nCoV	I-SPEC
+).	O
+
+Most	O
+patients	O
+had	O
+a	O
+normal	O
+white	B-ANAT
+blood	I-ANAT
+cell	I-ANAT
+count	O
+(	O
+37	O
+of	O
+51	O
+,	O
+73	O
+%),	O
+neutrophil	B-ANAT
+count	O
+(	O
+44	O
+of	O
+51	O
+,	O
+86	O
+%),	O
+and	O
+either	O
+normal	O
+(	O
+17	O
+of	O
+51	O
+,	O
+35	O
+%)	O
+or	O
+reduced	O
+(	O
+33	O
+of	O
+51	O
+,	O
+65	O
+%)	O
+lymphocyte	B-ANAT
+count	O
+.	O
+
+CT	O
+images	O
+showed	O
+pure	O
+ground	O
+-	O
+glass	O
+opacity	B-DISO
+(	O
+GGO	B-DISO
+)	O
+in	O
+39	O
+of	O
+51	O
+(	O
+77	O
+%)	O
+patients	O
+and	O
+GGO	B-DISO
+with	O
+reticular	O
+and	O
+/	O
+or	O
+interlobular	O
+septal	O
+thickening	O
+in	O
+38	O
+of	O
+51	O
+(	O
+75	O
+%)	O
+patients	O
+.	O
+
+The	O
+further	O
+addition	O
+of	O
+human	B-SPEC
+metapneumovirus	I-SPEC
+,	O
+rhinovirus	B-SPEC
+and	O
+coronavirus	B-SPEC
+over	O
+the	O
+final	O
+3	O
+years	O
+accounted	O
+for	O
+66	O
+.	O
+7	O
+%	O
+of	O
+ED	O
+visits	O
+and	O
+74	O
+.	O
+4	O
+%	O
+of	O
+hospitalizations	O
+for	O
+RTI	B-DISO
+,	O
+52	O
+.	O
+5	O
+%	O
+of	O
+visits	O
+and	O
+48	O
+.	O
+2	O
+%	O
+of	O
+hospitalizations	O
+for	O
+COPD	B-DISO
+,	O
+and	O
+only	O
+13	O
+.	O
+3	O
+%	O
+of	O
+visits	O
+and	O
+10	O
+.	O
+4	O
+%	O
+of	O
+hospitalizations	O
+for	O
+asthma	B-PATH
+.	O
+
+A	O
+66	O
+-	O
+year	O
+-	O
+old	O
+man	B-CHED
+was	O
+diagnosed	O
+with	O
+ES	O
+after	O
+autologous	O
+stem	B-ANAT
+cell	I-ANAT
+transplantation	O
+for	O
+malignant	B-DISO
+lymphoma	I-DISO
+.	O
+
+Anticardiolipin	O
+antibodies	B-COMP
+were	O
+negative	O
+:	O
+anticardiolipin	O
+β2GPI	O
+antibody	B-COMP
+≤	O
+1	O
+.	O
+2	O
+U	O
+/	O
+mL	O
+(<	O
+3	O
+.	O
+5	O
+),	O
+anticardiolipin	B-PRGE
+immunoglobulin	I-PRGE
+G	I-PRGE
+antibody	B-COMP
+≤	O
+8	O
+U	O
+/	O
+mL	O
+(<	O
+10	O
+),	O
+and	O
+anticardiolipin	B-PRGE
+immunoglobulin	I-PRGE
+M	I-PRGE
+antibody	B-COMP
+≤	O
+5	O
+U	O
+/	O
+mL	O
+(<	O
+8	O
+).	O
+
+He	O
+required	O
+the	O
+red	B-ANAT
+blood	I-ANAT
+cell	I-ANAT
+transfusion	O
+due	O
+to	O
+the	O
+progression	O
+of	O
+hemolytic	B-DISO
+anemia	I-DISO
+.	O
+
+For	O
+it	O
+is	O
+a	O
+never	O
+been	O
+experienced	O
+respiratory	B-DISO
+disease	I-DISO
+before	O
+and	O
+with	O
+infection	B-DISO
+ability	O
+widely	O
+and	O
+quickly	O
+,	O
+it	O
+attracted	O
+the	O
+world	O
+'	O
+s	O
+attention	O
+but	O
+without	O
+treatment	O
+and	O
+control	O
+manual	O
+.	O
+
+For	O
+the	O
+request	O
+from	O
+frontline	O
+clinicians	O
+and	O
+public	O
+health	O
+professionals	O
+of	O
+2019	B-SPEC
+-	I-SPEC
+nCoV	I-SPEC
+infected	O
+pneumonia	B-DISO
+management	O
+,	O
+an	O
+evidence	O
+-	O
+based	O
+guideline	O
+urgently	O
+needs	O
+to	O
+be	O
+developed	O
+.	O
+
+TITLE	O
+:	O
+[	O
+Application	O
+of	O
+extracorporeal	O
+membrane	B-COMP
+oxygenation	B-PROC
+technique	O
+in	O
+patients	O
+with	O
+acute	B-DISO
+respiratory	I-DISO
+failure	I-DISO
+caused	O
+by	O
+ammonia	B-CHED
+poisoning	O
+].	O
+
+On	O
+July	O
+7	O
+,	O
+2018	O
+,	O
+a	O
+case	O
+of	O
+ARDS	B-DISO
+caused	O
+by	O
+ammonia	B-CHED
+inhalation	B-PROC
+was	O
+admitted	O
+to	O
+the	O
+emergency	B-DISO
+ICU	O
+of	O
+the	O
+First	O
+Affiliated	O
+Hospital	O
+of	O
+Zhengzhou	O
+University	O
+.	O
+
+We	O
+report	O
+the	O
+epidemiological	O
+and	O
+clinical	O
+features	O
+of	O
+the	O
+first	O
+patient	O
+with	O
+2019	B-SPEC
+-	I-SPEC
+nCoV	I-SPEC
+pneumonia	B-DISO
+imported	O
+into	O
+Korea	O
+from	O
+Wuhan	O
+.	O
+
+Hospital	O
+-	O
+associated	O
+transmission	O
+was	O
+suspected	O
+as	O
+the	O
+presumed	O
+mechanism	O
+of	O
+infection	B-DISO
+for	O
+affected	O
+health	O
+professionals	O
+(	O
+40	O
+[	O
+29	O
+%])	O
+and	O
+hospitalized	O
+patients	O
+(	O
+17	O
+[	O
+12	O
+.	O
+3	O
+%]).	O
+
+Thirty	O
+-	O
+six	O
+patients	O
+(	O
+26	O
+.	O
+1	O
+%)	O
+were	O
+transferred	O
+to	O
+the	O
+intensive	O
+care	O
+unit	O
+(	O
+ICU	O
+)	O
+because	O
+of	O
+complications	O
+,	O
+including	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+(	O
+22	O
+[	O
+61	O
+.	O
+1	O
+%]),	O
+arrhythmia	B-DISO
+(	O
+16	O
+[	O
+44	O
+.	O
+4	O
+%]),	O
+and	O
+shock	O
+(	O
+11	O
+[	O
+30	O
+.	O
+6	O
+%]).	O
+
+Of	O
+the	O
+36	O
+cases	O
+in	O
+the	O
+ICU	O
+,	O
+4	O
+(	O
+11	O
+.	O
+1	O
+%)	O
+received	O
+high	O
+-	O
+flow	O
+oxygen	B-CHED
+therapy	O
+,	O
+15	O
+(	O
+41	O
+.	O
+7	O
+%)	O
+received	O
+noninvasive	O
+ventilation	O
+,	O
+and	O
+17	O
+(	O
+47	O
+.	O
+2	O
+%)	O
+received	O
+invasive	O
+ventilation	O
+(	O
+4	O
+were	O
+switched	O
+to	O
+extracorporeal	O
+membrane	B-COMP
+oxygenation	B-PROC
+).	O
+
+As	O
+of	O
+February	O
+3	O
+,	O
+47	O
+patients	O
+(	O
+34	O
+.	O
+1	O
+%)	O
+were	O
+discharged	O
+and	O
+6	O
+died	B-PROC
+(	O
+overall	O
+mortality	O
+,	O
+4	O
+.	O
+3	O
+%),	O
+but	O
+the	O
+remaining	O
+patients	O
+are	O
+still	O
+hospitalized	O
+.	O
+
+TITLE	O
+:	O
+Molecular	O
+Diagnosis	O
+of	O
+a	O
+Novel	B-SPEC
+Coronavirus	I-SPEC
+(	O
+2019	B-SPEC
+-	I-SPEC
+nCoV	I-SPEC
+)	O
+Causing	O
+an	O
+Outbreak	O
+of	O
+Pneumonia	B-DISO
+.	O
+
+Using	O
+RNA	O
+extracted	O
+from	O
+cells	B-COMP
+infected	O
+by	O
+SARS	B-DISO
+coronavirus	B-SPEC
+as	O
+a	O
+positive	O
+control	O
+,	O
+these	O
+assays	O
+were	O
+shown	O
+to	O
+have	O
+a	O
+dynamic	O
+range	O
+of	O
+at	O
+least	O
+seven	O
+orders	O
+of	O
+magnitude	O
+(	O
+2x10	O
+-	O
+4	O
+-	O
+2000	O
+TCID50	O
+/	O
+reaction	O
+).	O
+
+This	O
+study	O
+employs	O
+an	O
+integrative	O
+review	O
+approach	O
+to	O
+summarize	O
+the	O
+minimal	O
+evidence	O
+on	O
+effectiveness	O
+of	O
+travel	O
+bans	O
+to	O
+decrease	O
+the	O
+spread	O
+of	O
+severe	O
+acute	O
+respiratory	O
+syndrome	O
+(	O
+SARS	B-DISO
+),	O
+Middle	O
+Eastern	O
+respiratory	O
+syndrome	B-DISO
+(	O
+MERS	O
+),	O
+Ebola	B-DISO
+virus	I-DISO
+disease	I-DISO
+(	O
+EVD	O
+),	O
+and	O
+Zika	B-DISO
+virus	I-DISO
+disease	I-DISO
+(	O
+ZVD	O
+).	O
+
+The	O
+first	O
+case	O
+,	O
+a	O
+3	O
+-	O
+year	O
+-	O
+old	O
+girl	O
+,	O
+had	O
+respiratory	B-DISO
+distress	I-DISO
+,	O
+anemia	B-DISO
+,	O
+thrombocytopenia	O
+and	O
+renal	B-DISO
+failure	I-DISO
+at	O
+admission	O
+,	O
+and	O
+was	O
+diagnosed	O
+with	O
+hemolytic	B-DISO
+uremic	I-DISO
+syndrome	I-DISO
+.	O
+
+Supportive	O
+treatment	O
+and	O
+oseltamivir	B-CHED
+did	O
+not	O
+prevent	O
+the	O
+development	B-PROC
+of	O
+chronic	B-DISO
+renal	I-DISO
+failure	I-DISO
+.	O
+
+It	O
+should	O
+be	O
+kept	O
+in	O
+mind	O
+that	O
+influenza	B-SPEC
+virus	I-SPEC
+does	O
+not	O
+always	O
+cause	O
+a	O
+self	O
+-	O
+limited	O
+flu	B-DISO
+.	O
+
+ABSTRACT	O
+:	O
+A	O
+zoonotic	O
+coronavirus	B-SPEC
+,	O
+tentatively	O
+labeled	O
+as	O
+2019	B-SPEC
+-	I-SPEC
+nCoV	I-SPEC
+by	O
+the	O
+World	O
+Health	O
+Organization	O
+(	O
+WHO	O
+),	O
+has	O
+been	O
+identified	O
+as	O
+the	O
+causative	O
+agent	O
+of	O
+the	O
+viral	B-DISO
+pneumonia	I-DISO
+outbreak	O
+in	O
+Wuhan	O
+,	O
+China	O
+,	O
+at	O
+the	O
+end	O
+of	O
+2019	O
+.	O
+
+To	O
+avoid	O
+the	O
+2019	B-SPEC
+-	I-SPEC
+nCoV	I-SPEC
+outbreak	O
+turning	O
+into	O
+an	O
+epidemic	O
+or	O
+even	O
+a	O
+pandemic	O
+and	O
+to	O
+minimize	O
+the	O
+mortality	O
+rate	O
+,	O
+China	O
+activated	O
+emergency	B-DISO
+response	O
+procedures	O
+,	O
+but	O
+much	O
+remains	O
+to	O
+be	O
+learned	B-PROC
+about	O
+the	O
+features	O
+of	O
+the	O
+virus	B-SPEC
+to	O
+refine	O
+the	O
+risk	O
+assessment	O
+and	O
+response	O
+.	O
+
+TITLE	O
+:	O
+[	O
+Interpretation	O
+of	O
+""""	O
+Guidelines	O
+for	O
+the	O
+Diagnosis	O
+and	O
+Treatment	O
+of	O
+Novel	B-SPEC
+Coronavirus	I-SPEC
+(	O
+2019	B-SPEC
+-	I-SPEC
+nCoV	I-SPEC
+)	O
+Infection	B-DISO
+by	O
+the	O
+National	O
+Health	O
+Commission	O
+(	O
+Trial	O
+Version	O
+5	O
+")""]."	O
+
+ABSTRACT	O
+:	O
+Infection	O
+with	O
+2019	B-SPEC
+Novel	I-SPEC
+Coronavirus	I-SPEC
+(	O
+2019	B-SPEC
+-	I-SPEC
+nCoV	I-SPEC
+)	O
+is	O
+mainly	O
+transmitted	B-DISO
+by	O
+respiratory	O
+droplets	O
+,	O
+airborne	O
+transmission	O
+and	O
+direct	O
+contact	O
+.	O
+
+TITLE	O
+:	O
+Genome	O
+Composition	O
+and	O
+Divergence	O
+of	O
+the	O
+Novel	B-SPEC
+Coronavirus	I-SPEC
+(	O
+2019	B-SPEC
+-	I-SPEC
+nCoV	I-SPEC
+)	O
+Originating	O
+in	O
+China	O
+.	O
+
+A	O
+systematic	O
+comparison	O
+identified	O
+380	O
+amino	B-PROC
+acid	I-PROC
+substitutions	I-PROC
+between	O
+these	O
+coronaviruses	O
+,	O
+which	O
+may	O
+have	O
+caused	O
+functional	O
+and	O
+pathogenic	O
+divergence	O
+of	O
+2019	B-SPEC
+-	I-SPEC
+nCoV	I-SPEC
+.	O
+
+ABSTRACT	O
+:	O
+Currently	O
+,	O
+the	O
+emergence	O
+of	O
+a	O
+novel	O
+human	O
+coronavirus	O
+,	O
+SARS	B-PRGE
+-	I-PRGE
+CoV	I-PRGE
+-	I-PRGE
+2	I-PRGE
+,	O
+has	O
+become	O
+a	O
+global	O
+health	O
+concern	O
+causing	O
+severe	O
+respiratory	B-DISO
+tract	I-DISO
+infections	I-DISO
+in	O
+humans	B-SPEC
+.	O
+
+We	O
+therefore	O
+reviewed	O
+the	O
+literature	O
+on	O
+all	O
+available	O
+information	O
+about	O
+the	O
+persistence	O
+of	O
+human	B-SPEC
+and	O
+veterinary	O
+coronaviruses	O
+on	O
+inanimate	O
+surfaces	O
+as	O
+well	O
+as	O
+inactivation	B-DISO
+strategies	O
+with	O
+biocidal	O
+agents	O
+used	O
+for	O
+chemical	O
+disinfection	O
+,	O
+e	O
+.	O
+g	O
+.	O
+in	O
+healthcare	O
+facilities	O
+.	O
+
+Other	O
+biocidal	O
+agents	O
+such	O
+as	O
+0	O
+.	O
+05	O
+-	O
+0	O
+.	O
+2	O
+%	O
+benzalkonium	B-CHED
+chloride	I-CHED
+or	O
+0	O
+.	O
+02	O
+%	O
+chlorhexidine	B-CHED
+digluconate	I-CHED
+are	O
+less	O
+effective	O
+.	O
+
+ABSTRACT	O
+:	O
+Acute	O
+lung	B-ANAT
+injury	O
+(	O
+ALI	O
+)	O
+or	O
+its	O
+most	O
+advanced	O
+form	O
+,	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+(	O
+ARDS	B-DISO
+)	O
+is	O
+a	O
+severe	O
+inflammatory	O
+pulmonary	B-ANAT
+process	O
+triggered	O
+by	O
+varieties	O
+of	O
+pathophysiological	O
+factors	O
+,	O
+among	O
+which	O
+apoptosis	B-PATH
+of	O
+pulmonary	B-ANAT
+endothelial	B-ANAT
+cells	I-ANAT
+plays	O
+a	O
+critical	O
+role	O
+in	O
+the	O
+progression	O
+of	O
+ALI	O
+/	O
+ARDS	B-DISO
+.	O
+
+The	O
+scientific	O
+interest	O
+on	O
+coronaviruses	O
+increased	O
+after	O
+the	O
+emergence	O
+of	O
+Severe	B-DISO
+Acute	I-DISO
+Respiratory	I-DISO
+Syndrome	I-DISO
+coronavirus	B-SPEC
+(	O
+SARS	B-DISO
+-	O
+CoV	O
+)	O
+outbreaks	O
+in	O
+2002	O
+-	O
+2003	O
+followed	O
+by	O
+Middle	B-PRGE
+East	I-PRGE
+Respiratory	I-PRGE
+Syndrome	I-PRGE
+CoV	I-PRGE
+(	O
+MERS	O
+-	O
+CoV	O
+).	O
+
+ABSTRACT	O
+:	O
+Pneumonia	B-DISO
+associated	O
+with	O
+the	O
+2019	B-SPEC
+novel	I-SPEC
+coronavirus	I-SPEC
+(	O
+2019	B-SPEC
+-	I-SPEC
+nCoV	I-SPEC
+)	O
+is	O
+continuously	O
+and	O
+rapidly	O
+circulating	O
+at	O
+present	O
+.	O
+
+Compared	O
+with	O
+the	O
+parental	O
+rIBV	O
+-	O
+p65	B-PRGE
+control	O
+,	O
+all	O
+four	O
+EIC	B-PRGE
+mutants	I-PRGE
+exhibited	O
+comparable	O
+levels	O
+of	O
+intracellular	B-COMP
+RNA	B-PROC
+synthesis	I-PROC
+,	O
+structural	O
+protein	B-CHED
+production	O
+,	O
+and	O
+virion	O
+assembly	O
+.	O
+
+EIC	B-PRGE
+-	O
+defective	O
+mutants	O
+also	O
+formed	O
+smaller	O
+plaques	B-DISO
+,	O
+released	O
+significantly	O
+less	O
+infectious	B-DISO
+virions	B-COMP
+into	O
+the	O
+culture	O
+supernatant	O
+,	O
+and	O
+had	O
+lower	O
+levels	O
+of	O
+viral	O
+fitness	O
+in	O
+cell	B-COMP
+culture	O
+.	O
+
+TITLE	O
+:	O
+Transmissible	O
+Gastroenteritis	B-DISO
+Virus	B-DISO
+Infection	I-DISO
+Up	O
+-	O
+Regulates	O
+FcRn	O
+Expression	B-PROC
+via	O
+Nucleocapsid	B-COMP
+Protein	B-CHED
+and	O
+Secretion	B-PROC
+of	O
+TGF	O
+-	O
+β	O
+in	O
+Porcine	B-SPEC
+Intestinal	B-ANAT
+Epithelial	B-ANAT
+Cells	I-ANAT
+.	O
+
+First	O
+,	O
+using	O
+small	O
+interfering	O
+RNAs	O
+,	O
+we	O
+found	O
+that	O
+TGEV	B-SPEC
+up	O
+-	O
+regulated	O
+FcRn	O
+expression	B-PROC
+via	O
+TLR3	B-PRGE
+,	O
+TLR9	B-PRGE
+and	O
+RIG	B-PRGE
+-	I-PRGE
+I	I-PRGE
+.	O
+Moreover	O
+,	O
+TGEV	B-SPEC
+induced	O
+IL	O
+-	O
+1β	O
+,	O
+IL	B-FUNC
+-	I-FUNC
+6	I-FUNC
+,	O
+IL	B-FUNC
+-	I-FUNC
+8	I-FUNC
+,	O
+TGF	O
+-	O
+β	O
+,	O
+and	O
+TNF	B-PRGE
+-	I-PRGE
+α	I-PRGE
+production	O
+.	O
+
+Thus	O
+,	O
+TGEV	B-PRGE
+N	I-PRGE
+protein	B-CHED
+and	O
+TGF	O
+-	O
+β	O
+up	O
+-	O
+regulated	O
+FcRn	O
+expression	B-PROC
+,	O
+further	O
+clarifying	O
+the	O
+molecular	O
+mechanism	O
+of	O
+up	B-PROC
+-	I-PROC
+regulation	I-PROC
+of	O
+FcRn	B-PRGE
+expression	B-PROC
+by	O
+TGEV	B-SPEC
+.	O
+
+TITLE	O
+:	O
+Acute	O
+-	O
+on	O
+-	O
+chronic	B-DISO
+liver	I-DISO
+failure	I-DISO
+:	O
+Objective	O
+admission	O
+and	O
+support	O
+criteria	O
+in	O
+the	O
+intensive	O
+care	O
+unit	O
+.	O
+
+Along	O
+with	O
+decompensation	O
+of	O
+cirrhosis	B-DISO
+,	O
+the	O
+concept	O
+of	O
+acute	O
+-	O
+on	O
+-	O
+chronic	B-DISO
+liver	I-DISO
+failure	I-DISO
+(	O
+ACLF	O
+)	O
+has	O
+emerged	O
+.	O
+
+Again	O
+,	O
+in	O
+patients	O
+who	O
+are	O
+deemed	O
+suitable	O
+liver	B-ANAT
+transplant	B-ANAT
+candidates	O
+,	O
+intensive	O
+care	O
+management	O
+may	O
+allow	O
+bridging	O
+to	O
+liver	B-ANAT
+transplantation	O
+.	O
+
+However	O
+,	O
+patients	O
+with	O
+a	O
+Chronic	B-DISO
+Liver	I-DISO
+Failure	I-DISO
+Consortium	O
+ACLF	O
+score	O
+greater	O
+than	O
+70	O
+at	O
+48	O
+to	O
+72	O
+hours	O
+post	O
+-	O
+ICU	O
+admission	O
+do	O
+not	O
+seem	O
+to	O
+benefit	O
+from	O
+ongoing	O
+intensive	O
+support	O
+and	O
+a	O
+palliative	O
+approach	O
+may	O
+be	O
+more	O
+appropriate	O
+.	O
+
+It	O
+identifies	O
+key	O
+behavioural	O
+risk	O
+factors	O
+that	O
+can	O
+be	O
+targeted	B-PROC
+for	O
+development	B-PROC
+of	O
+tailored	O
+risk	O
+-	O
+mitigation	O
+strategies	O
+to	O
+reduce	O
+the	O
+threat	O
+of	O
+novel	O
+zoonoses	B-DISO
+.	O
+
+We	O
+applied	O
+the	O
+procedure	O
+to	O
+RNAi	B-PROC
+screening	O
+data	O
+of	O
+four	O
+different	O
+positive	O
+-	O
+sense	B-PROC
+single	O
+-	O
+stranded	O
+RNA	O
+viruses	B-SPEC
+,	O
+Hepatitis	B-SPEC
+C	I-SPEC
+virus	I-SPEC
+,	O
+Chikungunya	B-SPEC
+virus	I-SPEC
+,	O
+Dengue	B-SPEC
+virus	I-SPEC
+and	O
+Severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+coronavirus	B-SPEC
+,	O
+and	O
+detected	O
+novel	O
+host	B-COMP
+factors	O
+,	O
+including	O
+UBC	B-PRGE
+,	O
+PLCG1	B-PRGE
+,	O
+and	O
+DYRK1B	B-PRGE
+,	O
+which	O
+are	O
+predicted	O
+to	O
+significantly	O
+impact	O
+the	O
+replication	O
+cycles	O
+of	O
+these	O
+viruses	B-SPEC
+.	O
+
+TITLE	O
+:	O
+Critical	O
+care	O
+management	O
+of	O
+adults	O
+with	O
+community	O
+-	O
+acquired	O
+severe	O
+respiratory	B-DISO
+viral	B-PROC
+infection	I-PROC
+.	O
+
+Oseltamivir	B-CHED
+is	O
+the	O
+most	O
+widely	O
+used	O
+neuraminidase	B-CHED
+inhibitor	I-CHED
+for	O
+treatment	O
+of	O
+influenza	B-DISO
+;	O
+data	O
+suggest	O
+that	O
+early	O
+use	O
+is	O
+associated	O
+with	O
+reduced	O
+mortality	O
+in	O
+critically	B-DISO
+ill	I-DISO
+patients	O
+with	O
+influenza	B-DISO
+.	O
+
+At	O
+present	O
+,	O
+there	O
+are	O
+no	O
+antiviral	B-CHED
+therapies	O
+of	O
+proven	O
+efficacy	O
+for	O
+other	O
+severe	O
+RVIs	O
+.	O
+
+Limited	O
+existing	O
+knowledge	O
+highlights	O
+the	O
+need	O
+for	O
+data	O
+regarding	O
+supportive	O
+care	O
+and	O
+adjunctive	O
+pharmacologic	O
+therapy	O
+that	O
+is	O
+specific	O
+for	O
+critically	B-DISO
+ill	I-DISO
+patients	O
+with	O
+severe	O
+RVI	O
+.	O
+
+TITLE	O
+:	O
+Genomic	O
+Characterization	O
+and	O
+Phylogenetic	O
+Classification	O
+of	O
+Bovine	B-SPEC
+Coronaviruses	O
+Through	O
+Whole	O
+Genome	O
+Sequence	O
+Analysis	O
+.	O
+
+Phylogenetic	O
+trees	O
+on	O
+hemagglutinin	B-PRGE
+-	I-PRGE
+esterase	I-PRGE
+protein	I-PRGE
+(	O
+HE	O
+),	O
+spike	O
+glycoprotein	B-CHED
+(	O
+S	O
+),	O
+nucleocapsid	B-COMP
+protein	B-CHED
+(	O
+N	O
+)	O
+genes	O
+and	O
+ORF1	O
+revealed	O
+clusters	B-CHED
+similar	O
+to	O
+that	O
+on	O
+whole	O
+genome	O
+,	O
+suggesting	O
+that	O
+the	O
+evolution	B-PROC
+of	O
+BCoVs	O
+may	O
+be	O
+closely	O
+associated	O
+with	O
+variations	O
+in	O
+these	O
+genes	O
+.	O
+
+We	O
+identified	O
+factors	O
+associated	O
+with	O
+the	O
+Middle	O
+East	O
+Respiratory	O
+Syndrome	B-DISO
+-	O
+Coronavirus	B-SPEC
+(	O
+MERS	O
+-	O
+CoV	O
+)	O
+infection	B-DISO
+among	O
+suspected	O
+cases	O
+presented	O
+with	O
+sign	O
+and	O
+symptoms	O
+of	O
+upper	B-DISO
+respiratory	I-DISO
+infection	I-DISO
+or	O
+exposure	O
+to	O
+the	O
+virus	B-SPEC
+.	O
+
+Fundación	O
+Mutua	O
+Madrileña	O
+,	O
+Instituto	O
+de	O
+Salud	O
+Carlos	O
+III	O
+,	O
+The	O
+European	O
+Regional	O
+Development	B-PROC
+'	O
+s	O
+Funds	O
+,	O
+Asociación	O
+Científica	O
+Pulmón	O
+y	O
+Ventilación	O
+Mecánica	O
+.	O
+
+Middle	O
+-	O
+aged	O
+and	O
+elderly	O
+patients	O
+with	O
+underlying	O
+comorbidities	O
+are	O
+susceptible	O
+to	O
+respiratory	B-DISO
+failure	I-DISO
+and	O
+may	O
+have	O
+a	O
+poorer	O
+prognosis	O
+.	O
+
+Because	O
+of	O
+their	O
+unique	O
+specificity	O
+and	O
+essential	O
+role	O
+in	O
+viral	O
+polyprotein	O
+processing	O
+,	O
+these	O
+proteases	O
+are	O
+suitable	O
+targets	O
+for	O
+the	O
+development	B-PROC
+of	O
+antiviral	B-CHED
+drugs	I-CHED
+.	O
+
+TITLE	O
+:	O
+Estimation	O
+of	O
+the	O
+Transmission	O
+Risk	O
+of	O
+the	O
+2019	B-SPEC
+-	I-SPEC
+nCoV	I-SPEC
+and	O
+Its	O
+Implication	O
+for	O
+Public	O
+Health	O
+Interventions	O
+.	O
+
+We	O
+assessed	O
+the	O
+required	O
+expertise	O
+and	O
+capacity	O
+for	O
+molecular	O
+detection	O
+of	O
+2019	B-SPEC
+-	I-SPEC
+nCoV	I-SPEC
+in	O
+specialised	O
+laboratories	O
+in	O
+30	O
+European	O
+Union	O
+/	O
+European	O
+Economic	O
+Area	O
+(	O
+EU	O
+/	O
+EEA	O
+)	O
+countries	O
+.	O
+
+Airport	O
+screening	O
+is	O
+unlikely	O
+to	O
+detect	O
+a	O
+sufficient	O
+proportion	O
+of	O
+2019	B-SPEC
+-	I-SPEC
+nCoV	I-SPEC
+infected	O
+travellers	O
+to	O
+avoid	O
+entry	O
+of	O
+infected	O
+travellers	O
+.	O
+
+Using	O
+the	O
+travel	O
+history	O
+and	O
+symptom	B-DISO
+onset	O
+of	O
+88	O
+confirmed	O
+cases	O
+that	O
+were	O
+detected	O
+outside	O
+Wuhan	O
+in	O
+the	O
+early	O
+outbreak	O
+phase	O
+,	O
+we	O
+estimate	O
+the	O
+mean	O
+incubation	O
+period	O
+to	O
+be	O
+6	O
+.	O
+4	O
+days	O
+(	O
+95	O
+%	O
+credible	O
+interval	O
+:	O
+5	O
+.	O
+6	O
+-	O
+7	O
+.	O
+7	O
+),	O
+ranging	O
+from	O
+2	O
+.	O
+1	O
+to	O
+11	O
+.	O
+1	O
+days	O
+(	O
+2	O
+.	O
+5th	O
+to	O
+97	O
+.	O
+5th	O
+percentile	O
+).	O
+
+CoV	O
+infection	B-DISO
+requires	O
+spike	O
+proteins	B-CHED
+,	O
+which	O
+bind	B-FUNC
+viruses	B-SPEC
+to	O
+host	B-PRGE
+cell	I-PRGE
+receptors	I-PRGE
+and	O
+catalyze	O
+virus	B-SPEC
+-	O
+cell	B-COMP
+membrane	I-COMP
+fusion	O
+.	O
+
+These	O
+results	O
+favored	O
+a	O
+two	O
+-	O
+step	O
+process	O
+in	O
+which	O
+viruses	O
+first	O
+adhere	O
+to	O
+sialic	B-CHED
+acids	I-CHED
+and	O
+then	O
+require	O
+subsequent	O
+engagement	O
+with	O
+protein	B-CHED
+receptors	O
+during	O
+infectious	B-DISO
+cell	B-COMP
+entry	O
+.	O
+
+ABSTRACT	O
+:	O
+The	O
+2019	O
+-	O
+novel	O
+-	O
+coronavirus	B-SPEC
+(	O
+2019	B-SPEC
+-	I-SPEC
+nCoV	I-SPEC
+)	O
+was	O
+detected	O
+in	O
+the	O
+self	O
+-	O
+collected	O
+saliva	B-ANAT
+of	O
+91	O
+.	O
+7	O
+%	O
+(	O
+11	O
+/	O
+12	O
+)	O
+of	O
+patients	O
+.	O
+
+ABSTRACT	O
+:	O
+The	O
+outbreak	O
+of	O
+the	O
+2019	B-DISO
+-	I-DISO
+nCoV	I-DISO
+infection	I-DISO
+began	O
+in	O
+December	O
+2019	O
+in	O
+Wuhan	O
+,	O
+Hubei	O
+province	O
+,	O
+and	O
+rapidly	O
+spread	O
+to	O
+many	O
+provinces	O
+in	O
+China	O
+as	O
+well	O
+as	O
+other	O
+countries	O
+.	O
+
+All	O
+12	O
+cases	O
+of	O
+the	O
+2019	B-SPEC
+-	I-SPEC
+nCoV	I-SPEC
+-	O
+infected	O
+patients	O
+developed	O
+pneumonia	B-DISO
+and	O
+half	O
+of	O
+them	O
+developed	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+(	O
+ARDS	B-DISO
+).	O
+
+Age	O
+,	O
+viral	O
+load	O
+,	O
+lung	B-ANAT
+injury	O
+score	O
+,	O
+and	O
+blood	B-ANAT
+biochemistry	O
+indexes	O
+,	O
+albumin	B-PRGE
+(	O
+ALB	B-PRGE
+),	O
+CRP	B-PRGE
+,	O
+LDH	B-PRGE
+,	O
+LYM	O
+(%),	O
+LYM	O
+,	O
+and	O
+NEU	B-PRGE
+(%),	O
+may	O
+be	O
+predictors	O
+of	O
+disease	O
+severity	O
+.	O
+
+TITLE	O
+:	O
+The	O
+global	O
+spread	O
+of	O
+2019	B-SPEC
+-	I-SPEC
+nCoV	I-SPEC
+:	O
+a	O
+molecular	O
+evolutionary	O
+analysis	O
+.	O
+
+We	O
+are	O
+able	O
+to	O
+clarify	O
+the	O
+mechanism	O
+of	O
+transmission	O
+among	O
+the	O
+countries	O
+which	O
+have	O
+provided	O
+the	O
+2019	B-SPEC
+-	I-SPEC
+nCoV	I-SPEC
+sequence	O
+isolates	O
+from	O
+their	O
+patients	O
+.	O
+
+The	O
+basic	O
+reproduction	B-PROC
+number	O
+fall	O
+between	O
+2	O
+.	O
+8	O
+and	O
+3	O
+.	O
+3	O
+by	O
+using	O
+the	O
+real	O
+-	O
+time	O
+reports	O
+on	O
+the	O
+number	O
+of	O
+2019	B-SPEC
+-	I-SPEC
+nCoV	I-SPEC
+-	O
+infected	O
+cases	O
+from	O
+People	O
+'	O
+s	O
+Daily	O
+in	O
+China	O
+and	O
+fall	O
+between	O
+3	O
+.	O
+2	O
+and	O
+3	O
+.	O
+9	O
+on	O
+the	O
+basis	O
+of	O
+the	O
+predicted	O
+number	O
+of	O
+infected	O
+cases	O
+from	O
+international	O
+colleagues	O
+.	O
+
+The	O
+early	O
+transmission	O
+ability	O
+of	O
+2019	O
+-	O
+nCoV	O
+is	O
+close	O
+to	O
+or	O
+slightly	O
+higher	O
+than	O
+SARS	B-DISO
+.	O
+
+RESULTS	O
+:	O
+The	O
+basic	O
+reproduction	B-PROC
+number	O
+fall	O
+between	O
+2	O
+.	O
+8	O
+and	O
+3	O
+.	O
+3	O
+by	O
+using	O
+the	O
+real	O
+-	O
+time	O
+reports	O
+on	O
+the	O
+number	O
+of	O
+2019	B-SPEC
+-	I-SPEC
+nCoV	I-SPEC
+-	O
+infected	O
+cases	O
+from	O
+People	O
+'	O
+s	O
+Daily	O
+in	O
+China	O
+and	O
+fall	O
+between	O
+3	O
+.	O
+2	O
+and	O
+3	O
+.	O
+9	O
+on	O
+the	O
+basis	O
+of	O
+the	O
+predicted	O
+number	O
+of	O
+infected	O
+cases	O
+from	O
+international	O
+colleagues	O
+.	O
+
+TITLE	O
+:	O
+Chest	B-ANAT
+CT	O
+for	O
+Typical	O
+2019	B-SPEC
+-	I-SPEC
+nCoV	I-SPEC
+Pneumonia	B-DISO
+:	O
+Relationship	O
+to	O
+Negative	O
+RT	O
+-	O
+PCR	O
+Testing	O
+.	O
+
+TITLE	O
+:	O
+Potential	O
+Maternal	O
+and	O
+Infant	O
+Outcomes	O
+from	O
+(	O
+Wuhan	O
+)	O
+Coronavirus	B-SPEC
+2019	B-SPEC
+-	I-SPEC
+nCoV	I-SPEC
+Infecting	O
+Pregnant	O
+Women	O
+:	O
+Lessons	O
+from	O
+SARS	O
+,	O
+MERS	O
+,	O
+and	O
+Other	O
+Human	B-SPEC
+Coronavirus	I-SPEC
+Infections	O
+.	O
+
+All	O
+patients	O
+received	O
+positive	O
+pressure	O
+mechanical	O
+ventilation	O
+within	O
+24	O
+h	O
+after	O
+trauma	O
+because	O
+of	O
+ARF	B-DISO
+.	O
+
+Rates	O
+of	O
+pneumonia	B-DISO
+and	O
+length	O
+of	O
+hospital	O
+stay	O
+constituted	O
+secondary	O
+outcomes	O
+.	O
+
+The	O
+rate	O
+of	O
+pneumonia	B-DISO
+was	O
+higher	O
+in	O
+group	O
+2	O
+(	O
+38	O
+.	O
+1	O
+%	O
+vs	O
+.	O
+75	O
+.	O
+0	O
+%,	O
+P	O
+=	O
+0	O
+.	O
+005	O
+).	O
+
+TITLE	O
+:	O
+Development	B-PROC
+of	O
+an	O
+indirect	O
+ELISA	O
+for	O
+detecting	O
+porcine	B-PRGE
+deltacoronavirus	I-PRGE
+IgA	I-PRGE
+antibodies	B-COMP
+.	O
+
+The	O
+coronavirus	B-SPEC
+spike	O
+(	O
+S	O
+)	O
+protein	B-CHED
+is	O
+an	O
+antigen	B-CHED
+that	O
+has	O
+been	O
+demonstrated	O
+to	O
+contain	O
+epitopes	O
+that	O
+induce	O
+neutralizing	O
+antibodies	B-COMP
+.	O
+
+ABSTRACT	O
+:	O
+An	O
+outbreak	O
+of	O
+a	O
+novel	O
+coronavirus	O
+(	O
+COVID	B-DISO
+-	I-DISO
+19	I-DISO
+or	O
+2019	O
+-	O
+CoV	O
+)	O
+infection	B-DISO
+has	O
+posed	O
+significant	O
+threats	O
+to	O
+international	O
+health	O
+and	O
+the	O
+economy	O
+.	O
+
+In	O
+conclusion	O
+,	O
+we	O
+suggest	O
+that	O
+all	O
+the	O
+potential	O
+interventions	O
+be	O
+implemented	O
+to	O
+control	O
+the	O
+emerging	O
+COVID	O
+-	O
+19	O
+if	O
+the	O
+infection	B-DISO
+is	O
+uncontrollable	O
+.	O
+
+Genetic	O
+sequencing	O
+of	O
+isolates	O
+obtained	O
+from	O
+patients	O
+with	O
+pneumonia	B-DISO
+identified	O
+a	O
+novel	B-SPEC
+coronavirus	I-SPEC
+(	O
+2019	B-SPEC
+-	I-SPEC
+nCoV	I-SPEC
+)	O
+as	O
+the	O
+etiology	O
+(	O
+1	O
+).	O
+
+It	O
+is	O
+possible	O
+that	O
+the	O
+common	O
+exposure	O
+history	O
+at	O
+a	O
+seafood	O
+market	O
+in	O
+Wuhan	O
+originated	O
+from	O
+the	O
+human	B-SPEC
+-	O
+to	O
+-	O
+human	B-SPEC
+transmission	O
+events	O
+within	O
+the	O
+market	O
+,	O
+and	O
+the	O
+early	O
+,	O
+strong	O
+emphasis	O
+that	O
+market	O
+exposure	O
+indicated	O
+animal	B-SPEC
+-	O
+to	O
+-	O
+human	B-SPEC
+transmission	O
+was	O
+potentially	O
+the	O
+result	O
+of	O
+observer	O
+bias	B-SPEC
+.	O
+
+ABSTRACT	O
+:	O
+The	O
+outbreak	O
+of	O
+pneumonia	O
+originating	O
+in	O
+Wuhan	O
+,	O
+China	O
+,	O
+has	O
+generated	O
+24	O
+,	O
+500	O
+confirmed	O
+cases	O
+,	O
+including	O
+492	O
+deaths	B-PROC
+,	O
+as	O
+of	O
+5	O
+February	O
+2020	O
+.	O
+
+Fortunately	O
+,	O
+there	O
+has	O
+only	O
+been	O
+limited	O
+human	B-SPEC
+-	O
+to	O
+-	O
+human	B-SPEC
+transmission	O
+outside	O
+of	O
+China	O
+.	O
+
+However	O
+,	O
+if	O
+the	O
+mean	O
+time	O
+from	O
+symptom	B-DISO
+onset	O
+to	O
+hospitalisation	O
+can	O
+be	O
+halved	O
+by	O
+intense	O
+surveillance	O
+,	O
+then	O
+the	O
+probability	O
+that	O
+an	O
+imported	O
+case	O
+leads	O
+to	O
+sustained	O
+transmission	O
+is	O
+only	O
+0	O
+.	O
+012	O
+(	O
+credible	O
+interval	O
+[	O
+0	O
+,	O
+0	O
+.	O
+099	O
+]).	O
+
+TITLE	O
+:	O
+Respiratory	O
+viruses	B-SPEC
+in	O
+mechanically	O
+ventilated	O
+patients	O
+:	O
+a	O
+pilot	O
+study	O
+.	O
+
+We	O
+studied	O
+44	O
+mini	O
+-	O
+bronchoalveolar	O
+lavage	O
+samples	O
+(	O
+collected	O
+with	O
+a	O
+double	O
+catheter	O
+,	O
+Combicath	B-PRGE
+®	I-PRGE
+kit	I-PRGE
+)	O
+from	O
+patients	O
+with	O
+mean	O
+age	O
+in	O
+the	O
+seventh	O
+decade	O
+,	O
+20	O
+from	O
+WORI	O
+group	O
+and	O
+24	O
+from	O
+WRI	O
+group	O
+,	O
+who	O
+were	O
+hospitalized	O
+for	O
+acute	B-DISO
+respiratory	I-DISO
+failure	I-DISO
+in	O
+Intensive	O
+Care	O
+Units	O
+of	O
+two	O
+hospitals	O
+in	O
+the	O
+Lisbon	O
+area	O
+.	O
+
+The	O
+results	O
+of	O
+this	O
+study	O
+suggest	O
+the	O
+presence	O
+of	O
+common	O
+respiratory	O
+viruses	B-SPEC
+in	O
+the	O
+lower	B-ANAT
+respiratory	I-ANAT
+tract	I-ANAT
+without	O
+causing	O
+symptomatic	O
+infection	B-DISO
+,	O
+even	O
+in	O
+carefully	O
+collected	O
+lower	O
+samples	O
+.	O
+
+TITLE	O
+:	O
+Treatment	O
+of	O
+Ebola	O
+-	O
+related	O
+critical	B-DISO
+illness	I-DISO
+.	O
+
+Accordingly	O
+,	O
+patients	O
+often	O
+require	O
+critical	O
+care	O
+interventions	O
+such	O
+as	O
+monitoring	O
+of	O
+vital	O
+signs	O
+,	O
+intravenous	O
+fluid	O
+resuscitation	O
+,	O
+intravenous	O
+vasoactive	O
+medications	O
+,	O
+frequent	O
+diagnostic	O
+laboratory	O
+testing	O
+,	O
+renal	B-ANAT
+replacement	O
+therapy	O
+,	O
+oxygen	B-CHED
+and	O
+occasionally	O
+mechanical	O
+ventilation	O
+.	O
+
+Imaging	O
+changes	O
+of	O
+typical	O
+viral	B-DISO
+pneumonia	I-DISO
+and	O
+some	O
+specific	O
+imaging	O
+features	O
+were	O
+observed	O
+.	O
+
+TITLE	O
+:	O
+Feasibility	O
+,	O
+reproducibility	O
+and	O
+diagnostic	O
+usefulness	O
+of	O
+right	O
+ventricular	B-ANAT
+strain	O
+by	O
+2	O
+-	O
+dimensional	O
+speckle	O
+-	O
+tracking	O
+echocardiography	O
+in	O
+ARDS	O
+patients	O
+:	O
+the	O
+ARD	B-ENZY
+strain	O
+study	O
+.	O
+
+However	O
+,	O
+data	O
+are	O
+scarce	O
+regarding	O
+its	O
+use	O
+in	O
+critically	B-DISO
+ill	I-DISO
+patients	O
+.	O
+
+Regarding	O
+clinical	O
+outcomes	O
+,	O
+mortality	O
+and	O
+cumulative	O
+incidence	O
+of	O
+weaning	B-PROC
+from	O
+MV	O
+at	O
+day	O
+28	O
+were	O
+not	O
+different	O
+in	O
+patients	O
+with	O
+normal	O
+versus	O
+abnormal	O
+STE	B-CHED
+-	O
+derived	O
+parameters	O
+.	O
+
+TITLE	O
+:	O
+Non	O
+-	O
+influenza	B-DISO
+respiratory	O
+viruses	B-SPEC
+in	O
+adult	O
+patients	O
+admitted	O
+with	O
+influenza	B-DISO
+-	I-DISO
+like	I-DISO
+illness	I-DISO
+:	O
+a	O
+3	O
+-	O
+year	O
+prospective	O
+multicenter	O
+study	O
+.	O
+
+As	O
+compared	O
+to	O
+influenza	B-DISO
+,	O
+NIRV	O
+were	O
+associated	O
+with	O
+age	O
+(	O
+median	O
+,	O
+73	O
+years	O
+vs	O
+.	O
+68	O
+,	O
+P	O
+=	O
+0	O
+.	O
+026	O
+),	O
+chronic	O
+respiratory	B-DISO
+diseases	I-DISO
+(	O
+53	O
+%	O
+vs	O
+.	O
+45	O
+%,	O
+P	O
+=	O
+0	O
+.	O
+034	O
+),	O
+cancer	B-DISO
+(	O
+14	O
+%	O
+vs	O
+.	O
+9	O
+%,	O
+P	O
+=	O
+0	O
+.	O
+029	O
+),	O
+and	O
+immunosuppressive	O
+drugs	O
+(	O
+21	O
+%	O
+vs	O
+.	O
+14	O
+%,	O
+P	O
+=	O
+0	O
+.	O
+028	O
+),	O
+and	O
+inversely	O
+associated	O
+with	O
+diabetes	B-DISO
+(	O
+18	O
+%	O
+vs	O
+.	O
+25	O
+%,	O
+P	O
+=	O
+0	O
+.	O
+038	O
+).	O
+
+On	O
+multivariable	O
+analysis	O
+,	O
+only	O
+chronic	O
+respiratory	B-DISO
+diseases	I-DISO
+(	O
+OR	O
+1	O
+.	O
+5	O
+[	O
+1	O
+.	O
+1	O
+-	O
+2	O
+.	O
+0	O
+],	O
+P	O
+=	O
+0	O
+.	O
+008	O
+),	O
+and	O
+diabetes	B-DISO
+(	O
+OR	O
+0	O
+.	O
+5	O
+[	O
+0	O
+.	O
+4	O
+-	O
+0	O
+.	O
+8	O
+],	O
+P	O
+=	O
+0	O
+.	O
+01	O
+)	O
+were	O
+associated	O
+with	O
+NIRV	O
+detection	O
+.	O
+
+ABSTRACT	O
+:	O
+The	O
+outbreak	O
+of	O
+a	O
+novel	O
+coronavirus	O
+(	O
+SARS	B-PRGE
+-	I-PRGE
+CoV	I-PRGE
+-	I-PRGE
+2	I-PRGE
+)	O
+since	O
+December	O
+2019	O
+in	O
+Wuhan	O
+,	O
+the	O
+major	O
+transportation	O
+hub	O
+in	O
+central	O
+China	O
+,	O
+became	O
+an	O
+emergency	B-DISO
+of	O
+major	O
+international	O
+concern	O
+.	O
+
+While	O
+several	O
+etiological	O
+studies	O
+have	O
+begun	O
+to	O
+reveal	O
+the	O
+specific	O
+biological	O
+features	O
+of	O
+this	O
+virus	B-SPEC
+,	O
+the	O
+epidemic	O
+characteristics	O
+need	O
+to	O
+be	O
+elucidated	O
+.	O
+
+In	O
+this	O
+mini	O
+-	O
+review	O
+,	O
+we	O
+provide	O
+a	O
+brief	O
+introduction	O
+to	O
+the	O
+pathology	B-DISO
+and	O
+pathogenesis	B-DISO
+of	O
+SARS	B-DISO
+-	I-PRGE
+CoV	I-PRGE
+and	O
+MERS	O
+-	O
+CoV	O
+and	O
+extrapolate	O
+this	O
+knowledge	O
+to	O
+the	O
+newly	O
+identified	O
+2019	O
+-	O
+nCoV	O
+.	O
+
+ABSTRACT	O
+:	O
+Since	O
+the	O
+2019	O
+novel	O
+coronavirus	O
+(	O
+2019	B-SPEC
+-	I-SPEC
+nCoV	I-SPEC
+or	O
+officially	O
+named	O
+by	O
+the	O
+World	O
+Health	O
+Organization	O
+as	O
+COVID	B-DISO
+-	I-DISO
+19	I-DISO
+)	O
+outbreak	O
+in	O
+Wuhan	O
+,	O
+Hubei	O
+Province	O
+,	O
+China	O
+in	O
+2019	O
+,	O
+there	O
+have	O
+been	O
+a	O
+few	O
+reports	O
+of	O
+its	O
+imaging	O
+findings	O
+.	O
+
+TITLE	O
+:	O
+Case	O
+of	O
+the	O
+Index	O
+Patient	O
+Who	O
+Caused	O
+Tertiary	O
+Transmission	O
+of	O
+COVID	B-DISO
+-	I-DISO
+19	I-DISO
+Infection	I-DISO
+in	O
+Korea	O
+:	O
+the	O
+Application	O
+of	O
+Lopinavir	O
+/	O
+Ritonavir	O
+for	O
+the	O
+Treatment	O
+of	O
+COVID	B-DISO
+-	I-DISO
+19	I-DISO
+Infected	O
+Pneumonia	B-DISO
+Monitored	O
+by	O
+Quantitative	O
+RT	O
+-	O
+PCR	O
+.	O
+
+Hereby	O
+,	O
+we	O
+report	O
+the	O
+clinical	B-DISO
+findings	I-DISO
+of	O
+the	O
+index	O
+patient	O
+who	O
+was	O
+the	O
+first	O
+to	O
+cause	O
+tertiary	O
+transmission	O
+outside	O
+China	O
+.	O
+
+Interestingly	O
+,	O
+after	O
+lopinavir	O
+/	O
+ritonavir	B-CHED
+(	O
+Kaletra	O
+,	O
+AbbVie	O
+)	O
+was	O
+administered	O
+,	O
+β	O
+-	O
+coronavirus	B-SPEC
+viral	O
+loads	O
+significantly	O
+decreased	O
+and	O
+no	O
+or	O
+little	O
+coronavirus	B-SPEC
+titers	O
+were	O
+observed	O
+.	O
+
+Although	O
+the	O
+tissues	B-ANAT
+most	O
+commonly	O
+involved	O
+are	O
+the	O
+kidneys	B-ANAT
+,	O
+bladder	B-ANAT
+,	O
+ureters	B-ANAT
+and	O
+,	O
+to	O
+some	O
+extent	O
+,	O
+brain	B-ANAT
+tissue	I-ANAT
+,	O
+there	O
+are	O
+some	O
+reports	O
+that	O
+suggest	O
+that	O
+BKV	B-SPEC
+may	O
+cause	O
+multisystemic	O
+infections	B-DISO
+.	O
+
+The	O
+present	O
+case	O
+suggests	O
+that	O
+BKV	B-SPEC
+can	O
+damage	O
+more	O
+tissues	B-ANAT
+than	O
+previously	O
+reported	O
+and	O
+may	O
+be	O
+responsible	O
+for	O
+systemic	B-DISO
+infections	I-DISO
+in	O
+immunosuppressed	O
+patients	O
+.	O
+
+The	O
+initial	O
+source	O
+of	O
+the	O
+2019	B-SPEC
+novel	I-SPEC
+coronavirus	I-SPEC
+(	O
+2019	B-SPEC
+-	I-SPEC
+nCoV	I-SPEC
+)	O
+was	O
+the	O
+Huanan	O
+seafood	O
+market	O
+in	O
+Wuhan	O
+,	O
+Hubei	O
+province	O
+,	O
+China	O
+,	O
+with	O
+pangolins	B-SPEC
+as	O
+a	O
+potential	O
+animal	B-SPEC
+host	B-COMP
+.	O
+
+People	O
+are	O
+all	O
+generally	O
+susceptible	O
+to	O
+the	O
+virus	B-SPEC
+.	O
+
+ABSTRACT	O
+:	O
+The	O
+current	O
+outbreak	O
+of	O
+a	O
+novel	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+-	O
+like	O
+coronavirus	B-SPEC
+,	O
+2019_nCoV	O
+(	O
+now	O
+named	O
+SARS	B-PRGE
+-	I-PRGE
+CoV	I-PRGE
+-	I-PRGE
+2	I-PRGE
+),	O
+illustrated	O
+difficulties	O
+in	O
+identifying	O
+a	O
+novel	B-SPEC
+coronavirus	I-SPEC
+and	O
+its	O
+natural	O
+host	B-COMP
+,	O
+as	O
+the	O
+coding	O
+sequences	O
+of	O
+various	O
+Betacoronavirus	B-SPEC
+species	B-SPEC
+can	O
+be	O
+highly	O
+diverse	O
+.	O
+
+Increased	O
+ACE	B-PRGE
+and	O
+Ang	B-PRGE
+II	I-PRGE
+are	O
+poor	O
+prognostic	O
+factors	O
+for	O
+severe	O
+pneumonia	B-DISO
+.	O
+
+The	O
+outbreak	O
+of	O
+a	O
+novel	B-SPEC
+coronavirus	I-SPEC
+infection	O
+can	O
+lead	O
+to	O
+15	O
+%	O
+~	O
+30	O
+%	O
+patients	O
+developing	O
+into	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+(	O
+ARDS	B-DISO
+).	O
+
+Based	O
+on	O
+international	O
+experiences	O
+with	O
+pandemic	O
+control	O
+,	O
+the	O
+world	O
+should	O
+emphasize	O
+improving	O
+the	O
+system	O
+of	O
+emergency	B-DISO
+reserve	O
+medical	O
+supplies	O
+in	O
+the	O
+process	O
+of	O
+establishing	O
+and	O
+improving	O
+public	O
+health	O
+emergency	B-DISO
+response	O
+systems	O
+,	O
+and	O
+it	O
+should	O
+promote	O
+the	O
+establishment	O
+of	O
+international	O
+cooperative	O
+programs	O
+to	O
+jointly	O
+deal	O
+with	O
+public	O
+health	O
+emergencies	B-DISO
+of	O
+international	O
+concern	O
+in	O
+the	O
+future	O
+.	O
+
+TITLE	O
+:	O
+Magnetic	O
+Nanotrap	O
+Particles	O
+Preserve	O
+the	O
+Stability	O
+of	O
+Venezuelan	B-SPEC
+Equine	I-SPEC
+Encephalitis	I-SPEC
+Virus	I-SPEC
+in	O
+Blood	O
+for	O
+Laboratory	O
+Detection	O
+.	O
+
+Specific	O
+IgM	B-COMP
+antibody	B-PROC
+screening	O
+for	O
+patients	O
+whose	O
+pharyngeal	B-ANAT
+swab	O
+nucleic	B-CHED
+acid	I-CHED
+test	O
+is	O
+negative	O
+but	O
+with	O
+ground	O
+glass	O
+-	O
+like	O
+lung	B-ANAT
+lesions	O
+is	O
+very	O
+important	O
+for	O
+early	O
+detection	O
+and	O
+early	O
+isolation	O
+.	O
+
+This	O
+was	O
+followed	O
+by	O
+prevention	O
+programs	O
+recommending	O
+Chinese	O
+medicine	B-CHED
+(	O
+CM	O
+)	O
+for	O
+the	O
+prevention	O
+.	O
+
+Historical	O
+records	O
+on	O
+prevention	O
+and	O
+treatment	O
+of	O
+infections	B-DISO
+in	O
+CM	O
+classics	O
+,	O
+clinical	O
+evidence	O
+of	O
+CM	O
+on	O
+the	O
+prevention	O
+of	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+(	O
+SARS	B-DISO
+)	O
+and	O
+H1N1	B-DISO
+influenza	I-DISO
+,	O
+and	O
+CM	O
+prevention	O
+programs	O
+issued	O
+by	O
+health	O
+authorities	O
+in	O
+China	O
+since	O
+the	O
+COVID	B-DISO
+-	I-DISO
+19	I-DISO
+outbreak	O
+were	O
+retrieved	O
+from	O
+different	O
+databases	O
+and	O
+websites	O
+till	O
+12	O
+February	O
+,	O
+2020	O
+.	O
+
+The	O
+most	O
+frequently	O
+used	O
+herbs	O
+included	O
+Radix	B-SPEC
+astragali	O
+(	O
+Huangqi	O
+),	O
+Radix	B-SPEC
+glycyrrhizae	O
+(	O
+Gancao	O
+),	O
+Radix	B-SPEC
+saposhnikoviae	O
+(	O
+Fangfeng	B-SPEC
+),	O
+Rhizoma	O
+Atractylodis	O
+Macrocephalae	O
+(	O
+Baizhu	O
+),	O
+Lonicerae	O
+Japonicae	O
+Flos	B-SPEC
+(	O
+Jinyinhua	O
+),	O
+and	O
+Fructus	O
+forsythia	B-SPEC
+(	O
+Lianqiao	O
+).	O
+
+ABSTRACT	O
+:	O
+Acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+(	O
+ARDS	B-DISO
+)	O
+is	O
+associated	O
+with	O
+high	O
+mortality	O
+.	O
+
+Among	O
+adults	O
+with	O
+moderate	O
+or	O
+severe	O
+ARDS	B-DISO
+,	O
+intravenous	O
+IFN	B-PRGE
+-	I-PRGE
+β	I-PRGE
+-	O
+1a	O
+administered	O
+for	O
+6	O
+days	O
+,	O
+compared	O
+with	O
+placebo	O
+,	O
+resulted	O
+in	O
+no	O
+significant	O
+difference	O
+in	O
+a	O
+composite	O
+score	O
+that	O
+included	O
+death	B-PROC
+and	O
+number	O
+of	O
+ventilator	O
+-	O
+free	O
+days	O
+over	O
+28	O
+days	O
+.	O
+
+It	O
+was	O
+hypothesized	O
+that	O
+optimum	O
+dose	O
+and	O
+specific	O
+timing	O
+of	O
+TLR	O
+ligands	O
+may	O
+reduce	O
+viral	O
+load	O
+of	O
+IBV	B-SPEC
+in	O
+specific	O
+pathogen	O
+free	O
+(	O
+SPF	O
+)	O
+embryonated	O
+chicken	B-SPEC
+eggs	O
+(	O
+ECEs	O
+).	O
+
+However	O
+,	O
+more	O
+large	O
+-	O
+scale	O
+randomized	O
+trials	O
+are	O
+needed	O
+to	O
+further	O
+validate	O
+the	O
+effect	O
+of	O
+NMBA	O
+use	O
+in	O
+ARDS	B-DISO
+.	O
+
+TITLE	O
+:	O
+A	O
+familial	O
+cluster	O
+of	O
+infection	B-DISO
+associated	O
+with	O
+the	O
+2019	B-SPEC
+novel	I-SPEC
+coronavirus	I-SPEC
+indicating	O
+potential	O
+person	O
+-	O
+to	O
+-	O
+person	O
+transmission	O
+during	O
+the	O
+incubation	O
+period	O
+.	O
+
+TITLE	O
+:	O
+Fatal	O
+encephalitis	B-DISO
+associated	O
+with	O
+coronavirus	B-SPEC
+OC43	O
+in	O
+an	O
+immunocompromised	O
+child	O
+.	O
+
+ABSTRACT	O
+:	O
+A	O
+child	O
+with	O
+pre	O
+-	O
+B	O
+acute	B-DISO
+lymphoblastic	I-DISO
+leukaemia	I-DISO
+(	O
+ALL	O
+)	O
+developed	O
+fatal	O
+encephalitis	B-DISO
+associated	O
+with	O
+human	B-PRGE
+coronavirus	I-PRGE
+OC43	I-PRGE
+(	O
+HCoV	B-SPEC
+-	I-SPEC
+OC43	I-SPEC
+).	O
+
+Cerebrospinal	B-ANAT
+fluid	I-ANAT
+was	O
+negative	O
+for	O
+pathogens	O
+including	O
+HCoV	B-SPEC
+-	I-SPEC
+OC43	I-SPEC
+,	O
+but	O
+a	O
+brain	B-ANAT
+biopsy	O
+was	O
+HCoV	B-SPEC
+-	I-SPEC
+OC43	I-SPEC
+-	O
+positive	O
+by	O
+metagenomic	O
+next	O
+-	O
+generation	O
+sequencing	O
+.	O
+
+Most	O
+patients	O
+had	O
+mild	O
+ARDS	B-DISO
+with	O
+mean	O
+PaO2	O
+/	O
+FiO2	O
+ratio	O
+of	O
+215	O
+(	O
+standard	O
+deviation	O
+[	O
+SD	O
+],	O
+95	O
+).	O
+
+TITLE	O
+:	O
+Successful	O
+use	O
+of	O
+VV	O
+ECMO	O
+in	O
+managing	O
+negative	B-DISO
+pressure	I-DISO
+pulmonary	I-DISO
+edema	I-DISO
+.	O
+
+Postobstructive	O
+pulmonary	B-DISO
+edema	I-DISO
+,	O
+also	O
+known	O
+as	O
+negative	B-DISO
+pressure	I-DISO
+pulmonary	I-DISO
+edema	I-DISO
+,	O
+can	O
+result	O
+in	O
+severe	O
+respiratory	O
+compromise	O
+and	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+.	O
+
+Three	O
+cases	O
+of	O
+COVID	B-DISO
+-	I-DISO
+19	I-DISO
+were	O
+confirmed	O
+on	O
+24	O
+January	O
+,	O
+the	O
+first	O
+cases	O
+in	O
+Europe	O
+.	O
+
+ABSTRACT	O
+:	O
+•	O
+Novel	B-SPEC
+coronavirus	I-SPEC
+(	O
+COVID	B-DISO
+-	I-DISO
+19	I-DISO
+)-	O
+infected	O
+pneumonia	B-DISO
+usually	O
+manifests	O
+as	O
+bilateral	O
+ground	O
+-	O
+glass	O
+opacities	B-DISO
+in	O
+the	O
+lung	B-ANAT
+periphery	O
+on	O
+chest	B-ANAT
+CT	O
+scans	O
+.	O
+
+Governments	O
+are	O
+under	O
+increased	O
+pressure	O
+to	O
+stop	O
+the	O
+outbreak	O
+spiraling	O
+into	O
+a	O
+global	O
+health	O
+emergency	B-DISO
+.	O
+
+TITLE	O
+:	O
+[	O
+Health	O
+protection	O
+guideline	O
+of	O
+mobile	O
+cabin	O
+hospitals	O
+during	O
+Novel	B-SPEC
+Coronavirus	I-SPEC
+Pneumonia	B-DISO
+(	O
+NPC	B-ANAT
+)	O
+outbreak	O
+].	O
+
+TITLE	O
+:	O
+[	O
+Health	O
+protection	O
+guideline	O
+of	O
+passenger	O
+transport	B-PROC
+stations	O
+and	O
+transportation	O
+facilities	O
+during	O
+novel	O
+coronavirus	O
+pneumonia	B-DISO
+(	O
+NCP	B-FUNC
+)	O
+outbreak	O
+].	O
+
+From	O
+the	O
+perspective	O
+of	O
+health	O
+,	O
+this	O
+guideline	O
+puts	O
+forward	O
+technical	O
+requirements	O
+on	O
+the	O
+operation	O
+management	O
+,	O
+personnel	O
+requirements	O
+and	O
+health	O
+protection	O
+of	O
+passenger	O
+transportation	O
+places	O
+such	O
+as	O
+aviation	O
+,	O
+railway	O
+,	O
+subway	O
+,	O
+bus	O
+,	O
+taxi	O
+,	O
+ship	O
+,	O
+etc	O
+.,	O
+which	O
+reduces	O
+the	O
+impact	O
+of	O
+the	O
+NCP	B-FUNC
+outbreak	O
+on	O
+the	O
+transportation	O
+industry	O
+and	O
+personal	O
+health	O
+risks	O
+.	O
+
+TITLE	O
+:	O
+Antibodies	B-COMP
+to	O
+coronaviruses	O
+are	O
+higher	O
+in	O
+older	O
+compared	O
+with	O
+younger	O
+adults	O
+and	O
+binding	B-FUNC
+antibodies	B-COMP
+are	O
+more	O
+sensitive	O
+than	O
+neutralizing	O
+antibodies	B-COMP
+in	O
+identifying	O
+coronavirus	B-SPEC
+-	O
+associated	O
+illnesses	O
+.	O
+
+TITLE	O
+:	O
+Abnormal	O
+coagulation	B-PROC
+parameters	O
+are	O
+associated	O
+with	O
+poor	O
+prognosis	O
+in	O
+patients	O
+with	O
+novel	B-SPEC
+coronavirus	I-SPEC
+pneumonia	B-DISO
+.	O
+
+The	O
+overall	O
+mortality	O
+was	O
+11	O
+.	O
+5	O
+%,	O
+the	O
+non	O
+-	O
+survivors	O
+revealed	O
+significantly	O
+higher	O
+D	O
+-	O
+dimer	O
+and	O
+fibrin	O
+degradation	O
+product	O
+(	O
+FDP	B-PRGE
+)	O
+levels	O
+,	O
+longer	O
+prothrombin	B-PRGE
+time	O
+and	O
+activated	O
+partial	O
+thromboplastin	B-PRGE
+time	O
+compared	O
+to	O
+survivors	O
+on	O
+admission	O
+(	O
+P	O
+<	O
+.	O
+05	O
+);	O
+71	O
+.	O
+4	O
+%	O
+of	O
+non	O
+-	O
+survivors	O
+and	O
+0	O
+.	O
+6	O
+%	O
+survivors	O
+met	B-CHED
+the	O
+criteria	O
+of	O
+disseminated	B-DISO
+intravascular	I-DISO
+coagulation	I-DISO
+during	O
+their	O
+hospital	O
+stay	O
+.	O
+
+Patients	O
+with	O
+colorectal	B-PATH
+cancer	I-PATH
+should	O
+receive	O
+operation	O
+as	O
+soon	O
+as	O
+possible	O
+after	O
+elective	O
+operation	O
+is	O
+resumed	O
+in	O
+each	O
+hospital	O
+.	O
+
+SARS	B-SPEC
+-	I-SPEC
+Cov	I-SPEC
+-	I-SPEC
+2	I-SPEC
+virus	B-SPEC
+can	O
+be	O
+transmitted	B-DISO
+by	O
+asymptomatic	O
+infectors	O
+,	O
+and	O
+it	O
+has	O
+been	O
+confirmed	O
+to	O
+be	O
+transmitted	B-DISO
+by	O
+droplets	O
+and	O
+contact	O
+.	O
+
+ABSTRACT	O
+:	O
+The	O
+outbreak	O
+of	O
+the	O
+novel	B-SPEC
+coronavirus	I-SPEC
+pneumonia	B-DISO
+(	O
+NCP	B-FUNC
+)	O
+has	O
+become	O
+a	O
+public	O
+health	O
+emergency	B-DISO
+in	O
+China	O
+.	O
+
+For	O
+the	O
+patients	O
+with	O
+gastrointestinal	B-DISO
+tumors	I-DISO
+,	O
+pre	O
+-	O
+admission	O
+screening	O
+should	O
+be	O
+done	O
+in	O
+order	B-SPEC
+to	O
+rule	O
+out	O
+NCP	B-FUNC
+.	O
+
+Real	O
+-	O
+time	O
+RT	O
+-	O
+PCR	O
+panel	O
+and	O
+chest	B-ANAT
+CT	O
+scan	O
+should	O
+be	O
+conducted	O
+for	O
+patients	O
+with	O
+fever	B-PROC
+(>	O
+37	O
+.	O
+3	O
+℃),	O
+travel	O
+history	O
+to	O
+Hubei	O
+Province	O
+within	O
+14	O
+days	O
+,	O
+or	O
+contact	O
+history	O
+with	O
+residents	O
+from	O
+Wuhan	O
+district	O
+within	O
+14	O
+days	O
+.	O
+
+Surgical	O
+intervention	O
+for	O
+benign	B-DISO
+tumor	I-DISO
+should	O
+be	O
+postponed	O
+.	O
+
+In	O
+order	B-SPEC
+to	O
+guide	O
+and	O
+regulate	O
+the	O
+use	O
+of	O
+chloroquine	B-CHED
+in	O
+patients	O
+with	O
+novel	B-SPEC
+coronavirus	I-SPEC
+pneumonia	B-DISO
+,	O
+the	O
+multicenter	O
+collaboration	O
+group	O
+of	O
+Department	O
+of	O
+Science	O
+and	O
+Technology	O
+of	O
+Guangdong	O
+Province	O
+and	O
+Health	O
+Commission	O
+of	O
+Guangdong	O
+Province	O
+for	O
+chloroquine	B-CHED
+in	O
+the	O
+treatment	O
+of	O
+novel	O
+coronavirus	O
+pneumonia	B-DISO
+developed	O
+this	O
+expert	O
+consensus	O
+after	O
+extensive	O
+discussion	O
+.	O
+
+The	O
+CoV	B-PRGE
+spike	I-PRGE
+(	I-PRGE
+S	I-PRGE
+)	I-PRGE
+glycoprotein	I-PRGE
+is	O
+a	O
+key	O
+target	O
+for	O
+vaccines	O
+,	O
+therapeutic	O
+antibodies	B-COMP
+,	O
+and	O
+diagnostics	O
+.	O
+
+ABSTRACT	O
+:	O
+Liquid	O
+silicone	O
+(	O
+polydimethylsiloxane	B-CHED
+)	O
+is	O
+an	O
+inert	O
+material	O
+that	O
+is	O
+commonly	O
+used	O
+for	O
+cosmetic	B-CHED
+purpose	O
+.	O
+
+We	O
+aim	O
+to	O
+investigate	O
+the	O
+clinical	O
+characteristic	O
+and	O
+allergy	B-DISO
+status	O
+of	O
+patients	O
+infected	O
+with	O
+SARS	B-SPEC
+-	I-SPEC
+CoV	I-SPEC
+-	I-SPEC
+2	I-SPEC
+.	O
+
+Lymphopenia	B-DISO
+(	O
+75	O
+.	O
+4	O
+%)	O
+and	O
+eosinopenia	B-DISO
+(	O
+52	O
+.	O
+9	O
+%)	O
+were	O
+observed	O
+in	O
+most	O
+patients	O
+.	O
+
+Significantly	O
+higher	O
+levels	O
+of	O
+D	O
+-	O
+dimer	O
+,	O
+C	B-PRGE
+-	I-PRGE
+reactive	I-PRGE
+protein	I-PRGE
+,	O
+and	O
+procalcitonin	O
+were	O
+associated	O
+with	O
+severe	O
+patients	O
+compared	O
+to	O
+nonsevere	O
+patients	O
+(	O
+all	O
+P	O
+<	O
+.	O
+001	O
+).	O
+
+With	O
+the	O
+spread	O
+of	O
+COVID	B-DISO
+-	I-DISO
+19	I-DISO
+,	O
+the	O
+routine	O
+clinical	O
+diagnosis	O
+and	O
+treatment	O
+for	O
+lung	B-DISO
+cancer	B-SPEC
+patients	O
+has	O
+been	O
+disturbed	O
+.	O
+
+As	O
+such	O
+,	O
+we	O
+developed	O
+this	O
+consensus	O
+recommendations	O
+on	O
+all	O
+those	O
+high	O
+-	O
+risk	O
+treatments	O
+,	O
+based	O
+on	O
+the	O
+current	O
+evidence	O
+as	O
+well	O
+as	O
+the	O
+resource	O
+limitation	O
+in	O
+some	O
+areas	O
+,	O
+with	O
+the	O
+aim	O
+to	O
+reduce	O
+the	O
+nosocomial	O
+transmission	O
+and	O
+optimize	O
+the	O
+treatment	O
+for	O
+the	O
+COVID	B-DISO
+-	I-DISO
+19	I-DISO
+pneumonia	I-DISO
+patients	O
+.	O
+
+(	O
+11	O
+)	O
+Avoid	O
+unnecessary	O
+bronchial	B-ANAT
+hygiene	O
+therapy	O
+;	O
+(	O
+12	O
+)	O
+For	O
+patients	O
+who	O
+need	O
+aerosol	O
+therapy	O
+,	O
+dry	O
+powder	O
+inhaler	O
+metered	O
+dose	O
+inhaler	O
+with	O
+spacer	O
+is	O
+recommended	O
+for	O
+spontaneous	O
+breathing	B-PROC
+patients	O
+;	O
+while	O
+vibrating	O
+mesh	O
+nebulizer	O
+is	O
+recommended	O
+for	O
+ventilated	O
+patients	O
+and	O
+additional	O
+filter	O
+is	O
+recommended	O
+to	O
+be	O
+placed	O
+at	O
+the	O
+expiratory	B-PROC
+port	O
+of	O
+ventilation	O
+during	O
+nebulization	O
+.	O
+
+ABSTRACT	O
+:	O
+For	O
+effective	O
+resistance	O
+to	O
+virus	B-SPEC
+attack	O
+and	O
+infection	B-DISO
+,	O
+reducing	O
+virus	B-SPEC
+transmission	O
+chance	O
+,	O
+it	O
+is	O
+extremely	O
+important	O
+for	O
+the	O
+medical	O
+staff	O
+and	O
+related	O
+workers	O
+to	O
+have	O
+their	O
+own	O
+safe	O
+protection	O
+.	O
+
+TITLE	O
+:	O
+[	O
+Technologies	O
+and	O
+requirements	O
+of	O
+protection	O
+and	O
+disinfection	O
+in	O
+key	O
+places	O
+during	O
+the	O
+novel	B-SPEC
+coronavirus	I-SPEC
+pneumonia	B-DISO
+(	O
+NCP	B-FUNC
+)	O
+outbreak	O
+].	O
+
+Comprehensive	O
+measures	O
+and	O
+suggestions	O
+for	O
+protection	O
+and	O
+disinfection	O
+are	O
+put	O
+forward	O
+from	O
+perspectives	O
+of	O
+functional	O
+areas	O
+in	O
+key	O
+places	O
+,	O
+such	O
+as	O
+hotels	O
+,	O
+mobile	O
+cabin	O
+hospitals	O
+,	O
+passenger	O
+transport	B-PROC
+stations	O
+and	O
+public	O
+transport	B-PROC
+facilities	O
+,	O
+environment	O
+and	O
+facilities	O
+,	O
+personal	O
+protection	O
+,	O
+operation	O
+management	O
+system	O
+,	O
+etc	O
+.,	O
+so	O
+as	O
+to	O
+provide	O
+technical	O
+support	O
+for	O
+the	O
+prevention	O
+and	O
+control	O
+of	O
+new	O
+respiratory	O
+infectious	B-DISO
+diseases	I-DISO
+.	O
+
+With	O
+a	O
+longer	O
+time	O
+after	O
+the	O
+onset	O
+of	O
+symptoms	O
+,	O
+CT	O
+findings	O
+were	O
+more	O
+frequent	O
+,	O
+including	O
+consolidation	O
+,	O
+bilateral	O
+and	O
+peripheral	O
+disease	O
+,	O
+greater	O
+total	O
+lung	B-ANAT
+involvement	O
+,	O
+linear	O
+opacities	B-DISO
+,	O
+""""	O
+crazy	O
+-	O
+paving	O
+""""	O
+pattern	O
+and	O
+the	O
+""""	O
+reverse	O
+halo	O
+""""	O
+sign	O
+.	O
+
+Bilateral	O
+lung	B-ANAT
+involvement	O
+was	O
+observed	O
+in	O
+10	O
+/	O
+36	O
+early	O
+patients	O
+(	O
+28	O
+%),	O
+25	O
+/	O
+33	O
+intermediate	O
+patients	O
+(	O
+76	O
+%),	O
+and	O
+22	O
+/	O
+25	O
+late	O
+patients	O
+(	O
+88	O
+%).	O
+
+At	O
+least	O
+40	O
+,	O
+261	O
+cases	O
+confirmed	O
+,	O
+23	O
+,	O
+589	O
+cases	O
+suspected	O
+,	O
+909	O
+cases	O
+death	B-PROC
+and	O
+3444	O
+cases	O
+cured	O
+in	O
+China	O
+and	O
+worldwide	O
+24	O
+countries	O
+confirmed	O
+383	O
+cases	O
+being	O
+diagnosed	O
+,	O
+1	O
+case	O
+death	B-PROC
+in	O
+February	O
+10th	O
+,	O
+2020	O
+.	O
+
+At	O
+present	O
+,	O
+the	O
+mortality	O
+of	O
+2019	B-SPEC
+-	I-SPEC
+nCoV	I-SPEC
+in	O
+China	O
+is	O
+2	O
+.	O
+3	O
+%,	O
+compared	O
+with	O
+9	O
+.	O
+6	O
+%	O
+of	O
+SARS	B-DISO
+and	O
+34	O
+.	O
+4	O
+%	O
+of	O
+MERS	O
+reported	O
+by	O
+WHO	O
+.	O
+
+This	O
+study	O
+provides	O
+several	O
+complete	O
+genomes	O
+of	O
+HCoV	B-SPEC
+-	I-SPEC
+NL63	I-SPEC
+and	O
+improves	O
+our	O
+understanding	O
+of	O
+HCoV	B-SPEC
+-	I-SPEC
+NL63	I-SPEC
+evolution	B-PROC
+in	O
+China	O
+.	O
+
+To	O
+date	O
+,	O
+the	O
+clinical	O
+phenomenon	O
+of	O
+inappropriate	O
+use	O
+of	O
+diuretics	B-CHED
+leading	O
+to	O
+acute	B-DISO
+pulmonary	I-DISO
+edema	I-DISO
+remains	O
+unexplored	O
+and	O
+unrecognized	O
+.	O
+
+However	O
+,	O
+the	O
+patient	O
+'	O
+s	O
+dyspnea	B-DISO
+became	O
+more	O
+severe	O
+after	O
+experimental	O
+diuretic	B-CHED
+therapy	O
+.	O
+
+In	O
+this	O
+process	O
+,	O
+POCUS	O
+is	O
+a	O
+reliable	O
+diagnostic	O
+tool	O
+to	O
+identify	O
+the	O
+cause	O
+of	O
+acute	B-DISO
+pulmonary	I-DISO
+edema	I-DISO
+and	O
+can	O
+increase	O
+the	O
+accuracy	O
+of	O
+clinical	O
+evaluations	O
+.	O
+
+The	O
+meta	B-SPEC
+-	O
+analysis	O
+results	O
+showed	O
+that	O
+corticosteroid	B-CHED
+therapy	O
+was	O
+associated	O
+with	O
+significantly	O
+higher	O
+mortality	O
+(	O
+OR	O
+1	O
+.	O
+53	O
+,	O
+95	O
+%	O
+CI	O
+[	O
+1	O
+.	O
+16	O
+,	O
+2	O
+.	O
+01	O
+])	O
+and	O
+incidence	O
+of	O
+nosocomial	B-DISO
+infection	I-DISO
+(	O
+OR	O
+3	O
+.	O
+15	O
+,	O
+95	O
+%	O
+CI	O
+[	O
+1	O
+.	O
+54	O
+,	O
+6	O
+.	O
+45	O
+]).	O
+
+However	O
+,	O
+2019	B-SPEC
+-	I-SPEC
+nCoV	I-SPEC
+has	O
+a	O
+distinct	O
+loop	O
+with	O
+flexible	O
+glycyl	B-CHED
+residues	O
+replacing	O
+rigid	B-DISO
+prolyl	B-CHED
+residues	O
+in	O
+SARS	B-DISO
+-	O
+CoV	O
+.	O
+Molecular	O
+modeling	O
+revealed	O
+that	O
+2019	B-SPEC
+-	I-SPEC
+nCoV	I-SPEC
+RBD	O
+has	O
+a	O
+stronger	O
+interaction	O
+with	O
+angiotensin	B-PRGE
+converting	I-PRGE
+enzyme	I-PRGE
+2	I-PRGE
+(	O
+ACE2	B-PRGE
+).	O
+
+ACE2	B-PRGE
+is	O
+widely	O
+expressed	B-PROC
+with	O
+conserved	O
+primary	O
+structures	O
+throughout	O
+the	O
+animal	B-SPEC
+kingdom	I-SPEC
+from	O
+fish	B-SPEC
+,	O
+amphibians	B-SPEC
+,	O
+reptiles	B-SPEC
+,	O
+birds	B-SPEC
+,	O
+to	O
+mammals	B-SPEC
+.	O
+
+2019	B-SPEC
+-	I-SPEC
+nCoV	I-SPEC
+is	O
+thought	O
+to	O
+be	O
+transmitted	B-DISO
+through	O
+respiratory	O
+droplets	O
+.	O
+
+TITLE	O
+:	O
+Community	O
+pharmacist	O
+in	O
+public	O
+health	O
+emergencies	B-DISO
+:	O
+Quick	O
+to	O
+action	O
+against	O
+the	O
+coronavirus	B-SPEC
+2019	B-SPEC
+-	I-SPEC
+nCoV	I-SPEC
+outbreak	O
+.	O
+
+This	O
+paper	O
+aimed	O
+to	O
+improve	O
+the	O
+understanding	O
+of	O
+community	O
+pharmacists	O
+'	O
+role	O
+in	O
+case	O
+of	O
+2019	O
+-	O
+CoV	O
+outbreak	O
+based	O
+on	O
+the	O
+practical	O
+experiences	O
+in	O
+consultation	O
+with	O
+the	O
+recommendations	O
+made	O
+by	O
+the	O
+International	O
+Pharmaceutical	B-CHED
+Federation	O
+on	O
+the	O
+Coronavirus	B-SPEC
+2019	B-SPEC
+-	I-SPEC
+nCoV	I-SPEC
+outbreak	O
+.	O
+
+TITLE	O
+:	O
+Severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+coronavirus	I-SPEC
+2	I-SPEC
+(	O
+SARS	B-SPEC
+-	I-SPEC
+CoV	I-SPEC
+-	I-SPEC
+2	I-SPEC
+)	O
+and	O
+coronavirus	B-SPEC
+disease	O
+-	O
+2019	O
+(	O
+COVID	B-DISO
+-	I-DISO
+19	I-DISO
+):	O
+The	O
+epidemic	O
+and	O
+the	O
+challenges	O
+.	O
+
+Bilateral	O
+lung	B-ANAT
+involvement	O
+with	O
+ground	O
+-	O
+glass	O
+opacity	B-DISO
+was	O
+the	O
+most	O
+common	O
+finding	O
+from	O
+computed	O
+tomography	O
+images	O
+of	O
+the	O
+chest	B-ANAT
+.	O
+
+The	O
+one	O
+case	O
+of	O
+SARS	B-SPEC
+-	I-SPEC
+CoV	I-SPEC
+-	I-SPEC
+2	I-SPEC
+pneumonia	B-DISO
+in	O
+the	O
+USA	O
+is	O
+responding	O
+well	O
+to	O
+remdesivir	O
+,	O
+which	O
+is	O
+now	O
+undergoing	O
+a	O
+clinical	O
+trial	O
+in	O
+China	O
+.	O
+
+TITLE	O
+:	O
+COVID	O
+-	O
+2019	O
+:	O
+The	O
+role	O
+of	O
+the	O
+nsp2	B-PRGE
+and	O
+nsp3	B-PRGE
+in	O
+its	O
+pathogenesis	B-DISO
+.	O
+
+The	O
+future	O
+resilience	O
+of	O
+healthcare	O
+services	O
+will	O
+depend	O
+on	O
+having	O
+sufficient	O
+numbers	O
+of	O
+nurses	O
+who	O
+are	O
+adequately	O
+resourced	O
+to	O
+face	B-DISO
+the	O
+coming	O
+challenges	O
+.	O
+
+The	O
+ability	O
+of	O
+the	O
+virus	B-SPEC
+to	O
+cause	O
+severe	O
+disease	O
+or	O
+death	B-PROC
+was	O
+the	O
+most	O
+frequently	O
+reported	O
+reason	O
+for	O
+worry	O
+by	O
+physicians	O
+(	O
+89	O
+.	O
+7	O
+%)	O
+and	O
+non	O
+-	O
+physicians	O
+(	O
+87	O
+.	O
+2	O
+%).	O
+
+The	O
+current	O
+situation	O
+of	O
+prevention	O
+and	O
+control	O
+of	O
+new	O
+coronavirus	B-SPEC
+pneumonia	B-DISO
+is	O
+severe	O
+.	O
+
+More	O
+importantly	O
+,	O
+we	O
+introduce	O
+in	O
+detail	O
+the	O
+operative	O
+management	O
+and	O
+perioperative	O
+management	O
+of	O
+colorectal	O
+surgery	O
+patients	O
+suspected	O
+or	O
+diagnosed	O
+with	O
+new	O
+coronary	B-ANAT
+pneumonia	B-DISO
+,	O
+including	O
+prevention	O
+and	O
+control	O
+measures	O
+for	O
+medical	O
+staff	O
+,	O
+operating	O
+rooms	O
+and	O
+surgical	O
+instruments	O
+.	O
+
+ABSTRACT	O
+:	O
+Porcine	B-SPEC
+epidemic	I-SPEC
+diarrhea	I-SPEC
+virus	I-SPEC
+(	O
+PEDV	B-SPEC
+)	O
+is	O
+a	O
+highly	O
+virulent	O
+re	O
+-	O
+emerging	O
+enteric	B-SPEC
+coronavirus	I-SPEC
+that	O
+causes	O
+acute	B-DISO
+diarrhea	I-DISO
+,	O
+dehydration	B-DISO
+,	O
+and	O
+up	O
+to	O
+100	O
+%	O
+mortality	O
+in	O
+neonatal	O
+suckling	O
+piglets	O
+.	O
+
+Identifying	O
+variables	O
+that	O
+influence	O
+lymphocyte	B-PROC
+migration	B-PROC
+and	O
+IgA	B-PRGE
+secretion	B-PROC
+during	O
+gestation	B-PROC
+and	O
+lactation	B-PROC
+is	O
+imperative	O
+for	O
+designing	O
+maternal	O
+immunization	O
+strategies	O
+that	O
+generate	O
+the	O
+highest	O
+amount	O
+of	O
+lactogenic	O
+immune	O
+protection	O
+against	O
+PEDV	O
+in	O
+suckling	O
+piglets	O
+.	O
+
+From	O
+the	O
+perspective	O
+of	O
+social	O
+role	O
+,	O
+dentists	O
+not	O
+only	O
+played	O
+the	O
+role	O
+of	O
+expert	O
+in	O
+dental	O
+home	O
+professional	O
+guidance	O
+,	O
+but	O
+also	O
+played	O
+the	O
+role	O
+of	O
+psychological	B-DISO
+counseling	O
+for	O
+patients	O
+.	O
+
+We	O
+conclude	O
+that	O
+we	O
+did	O
+not	O
+learn	B-PROC
+from	O
+the	O
+two	O
+prior	O
+epidemics	O
+of	O
+coronavirus	B-SPEC
+and	O
+were	O
+ill	B-DISO
+-	O
+prepared	O
+to	O
+deal	O
+with	O
+the	O
+challenges	O
+the	O
+COVID	B-DISO
+-	I-DISO
+19	I-DISO
+epidemic	O
+has	O
+posed	O
+.	O
+
+ABSTRACT	O
+:	O
+The	O
+novel	O
+coronavirus	O
+pneumonia	B-DISO
+(	O
+new	O
+coronavirus	B-SPEC
+pneumonia	B-DISO
+)	O
+(	O
+NCP	B-FUNC
+)	O
+has	O
+been	O
+prevalent	O
+in	O
+Wuhan	O
+and	O
+spread	O
+rapidly	O
+to	O
+all	O
+of	O
+our	O
+country	O
+.	O
+
+For	O
+NCP	B-FUNC
+patients	O
+with	O
+mechanical	O
+ventilation	O
+,	O
+reasonable	O
+sedation	B-DISO
+and	O
+analgesia	B-DISO
+strategies	O
+should	O
+be	O
+formulated	O
+;	O
+delirium	B-DISO
+should	O
+not	O
+be	O
+ignored	O
+.	O
+
+In	O
+addition	O
+,	O
+there	O
+is	O
+up	B-PROC
+regulation	I-PROC
+of	O
+inflammatory	O
+factors	O
+in	O
+patients	O
+with	O
+severe	O
+NCP	B-FUNC
+,	O
+but	O
+the	O
+effect	O
+of	O
+renal	B-ANAT
+replacement	O
+therapy	O
+needs	O
+to	O
+be	O
+further	O
+confirmed	O
+by	O
+clinical	O
+research	O
+.	O
+
+It	O
+is	O
+secondary	O
+to	O
+pulmonary	B-DISO
+disease	I-DISO
+or	O
+a	O
+disorder	O
+of	O
+the	O
+pulmonary	B-PROC
+circulation	B-PROC
+.	O
+
+Certain	O
+precipitating	O
+factors	O
+,	O
+such	O
+as	O
+infection	B-DISO
+of	O
+any	O
+origin	O
+,	O
+have	O
+been	O
+reported	O
+,	O
+leading	O
+to	O
+acute	O
+on	O
+chronic	B-DISO
+cor	I-DISO
+pulmonale	I-DISO
+that	O
+has	O
+a	O
+particularly	O
+high	O
+mortality	O
+.	O
+
+The	O
+LUNG	B-ANAT
+SAFE	O
+study	O
+was	O
+an	O
+international	O
+,	O
+multicenter	O
+,	O
+prospective	O
+cohort	O
+study	O
+of	O
+patients	O
+with	O
+severe	O
+respiratory	B-DISO
+failure	I-DISO
+,	O
+conducted	O
+in	O
+2014	O
+in	O
+459	O
+ICUs	O
+from	O
+50	O
+countries	O
+.	O
+
+The	O
+primary	O
+objective	O
+of	O
+this	O
+substudy	O
+was	O
+to	O
+determine	O
+the	O
+frequency	O
+of	O
+use	O
+of	O
+widely	O
+available	O
+(	O
+neuromuscular	B-DISO
+blockade	I-DISO
+,	O
+prone	O
+position	O
+)	O
+adjuncts	O
+versus	O
+adjuncts	O
+requiring	O
+specialized	O
+equipment	O
+(	O
+ECMO	O
+,	O
+Inhaled	B-PROC
+vasodilators	O
+,	O
+HFOV	O
+)	O
+in	O
+patients	O
+in	O
+the	O
+first	O
+48	O
+hours	O
+of	O
+moderate	O
+-	O
+severe	O
+ARDS	B-DISO
+(	O
+P	O
+/	O
+F	O
+ratio	O
+<	O
+150	O
+).	O
+
+Patients	O
+that	O
+received	O
+adjuncts	O
+were	O
+more	O
+likely	O
+to	O
+have	O
+their	O
+ARDS	B-DISO
+recognized	O
+,	O
+be	O
+younger	O
+and	O
+sicker	O
+,	O
+have	O
+pneumonia	B-DISO
+,	O
+and	O
+be	O
+more	O
+difficult	O
+to	O
+ventilate	O
+,	O
+and	O
+be	O
+in	O
+a	O
+European	O
+high	O
+income	O
+country	O
+than	O
+those	O
+that	O
+did	O
+not	O
+receive	O
+adjuncts	O
+.	O
+
+This	O
+put	O
+enormous	O
+pressure	O
+on	O
+the	O
+Chinese	O
+government	O
+,	O
+medical	O
+healthcare	O
+provider	O
+,	O
+and	O
+the	O
+general	O
+public	O
+,	O
+but	O
+also	O
+made	O
+the	O
+international	O
+community	O
+deeply	O
+nervous	B-DISO
+.	O
+
+To	O
+target	O
+the	O
+actions	O
+,	O
+similar	O
+epidemiological	O
+actions	O
+to	O
+human	B-SPEC
+cases	O
+are	O
+needed	O
+with	O
+animal	B-SPEC
+or	O
+food	O
+exposures	O
+.	O
+
+TITLE	O
+:	O
+2019	B-SPEC
+-	I-SPEC
+nCoV	I-SPEC
+(	O
+Wuhan	O
+virus	B-SPEC
+),	O
+a	O
+novel	B-SPEC
+Coronavirus	I-SPEC
+:	O
+human	B-SPEC
+-	O
+to	O
+-	O
+human	B-SPEC
+transmission	O
+,	O
+travel	O
+-	O
+related	O
+cases	O
+,	O
+and	O
+vaccine	O
+readiness	O
+.	O
+
+The	O
+case	O
+stresses	O
+the	O
+need	O
+for	O
+healthcare	O
+personnel	O
+to	O
+perform	O
+thorough	O
+anamnesis	B-PROC
+in	O
+pregnant	O
+women	O
+in	O
+farming	O
+areas	O
+and	O
+to	O
+advise	O
+them	O
+to	O
+avoid	O
+contact	O
+with	O
+small	O
+ruminants	B-SPEC
+.	O
+
+The	O
+most	O
+common	O
+involved	O
+lung	B-ANAT
+segments	I-ANAT
+were	O
+the	O
+dorsal	O
+segment	O
+of	O
+the	O
+right	B-ANAT
+lower	I-ANAT
+lobe	I-ANAT
+(	O
+69	O
+/	O
+80	O
+,	O
+86	O
+%),	O
+the	O
+posterior	O
+basal	O
+segment	O
+of	O
+the	O
+right	B-ANAT
+lower	I-ANAT
+lobe	I-ANAT
+(	O
+68	O
+/	O
+80	O
+,	O
+85	O
+%),	O
+the	O
+lateral	O
+basal	O
+segment	O
+of	O
+the	O
+right	B-ANAT
+lower	I-ANAT
+lobe	I-ANAT
+(	O
+64	O
+/	O
+80	O
+,	O
+80	O
+%),	O
+the	O
+dorsal	O
+segment	O
+of	O
+the	O
+left	B-ANAT
+lower	I-ANAT
+lobe	I-ANAT
+(	O
+61	O
+/	O
+80	O
+,	O
+76	O
+%)	O
+and	O
+the	O
+posterior	O
+basal	O
+segment	O
+of	O
+the	O
+left	B-ANAT
+lower	I-ANAT
+lobe	I-ANAT
+(	O
+65	O
+/	O
+80	O
+,	O
+81	O
+%).	O
+
+CT	O
+plays	O
+an	O
+important	O
+role	O
+in	O
+the	O
+diagnosis	O
+and	O
+evaluation	O
+of	O
+this	O
+emerging	O
+global	O
+health	O
+emergency	B-DISO
+.	O
+
+RESULTS	O
+:	O
+Totally	O
+80	O
+patients	O
+diagnosed	O
+with	O
+COVID	B-DISO
+-	I-DISO
+19	I-DISO
+were	O
+included	O
+.	O
+
+Correlation	O
+analysis	O
+showed	O
+that	O
+the	O
+PII	O
+value	O
+was	O
+significantly	O
+correlated	O
+with	O
+the	O
+values	O
+of	O
+lymphocyte	B-ANAT
+count	O
+,	O
+monocyte	B-ANAT
+count	O
+,	O
+C	B-PRGE
+-	I-PRGE
+reactive	I-PRGE
+protein	I-PRGE
+,	O
+procalcitonin	O
+,	O
+days	O
+from	O
+illness	O
+onset	O
+and	O
+body	B-ANAT
+temperature	O
+(	O
+p	O
+<	O
+0	O
+.	O
+05	O
+).	O
+
+Where	O
+blood	B-PROC
+gas	B-ENZY
+analyzers	O
+are	O
+unavailable	O
+,	O
+it	O
+can	O
+be	O
+replaced	O
+by	O
+the	O
+plethysmographic	O
+oxygen	B-CHED
+saturation	O
+/	O
+fractional	O
+inspirational	O
+oxygen	B-CHED
+concentration	O
+(	O
+SpO	O
+
+Since	O
+then	O
+,	O
+this	O
+highly	O
+contagious	O
+COVID	B-DISO
+-	I-DISO
+19	I-DISO
+has	O
+been	O
+spreading	O
+worldwide	O
+,	O
+with	O
+a	O
+rapid	O
+rise	O
+in	O
+the	O
+number	O
+of	O
+deaths	B-PROC
+.	O
+
+Novel	O
+COVID	B-DISO
+-	I-DISO
+19	I-DISO
+-	O
+infected	O
+pneumonia	B-DISO
+(	O
+NCIP	O
+)	O
+is	O
+characterized	O
+by	O
+fever	B-PROC
+,	O
+fatigue	B-DISO
+,	O
+dry	B-DISO
+cough	I-DISO
+,	O
+and	O
+dyspnea	B-DISO
+.	O
+
+ABSTRACT	O
+:	O
+COVID	B-DISO
+-	I-DISO
+19	I-DISO
+is	O
+a	O
+viral	O
+respiratory	O
+illness	O
+caused	O
+by	O
+a	O
+new	O
+coronavirus	O
+called	O
+SARS	B-PRGE
+-	I-PRGE
+CoV	I-PRGE
+-	I-PRGE
+2	I-PRGE
+.	O
+
+In	O
+fact	O
+,	O
+since	O
+September	O
+2012	O
+,	O
+the	O
+WHO	O
+has	O
+been	O
+notified	O
+of	O
+2494	O
+laboratory	O
+-	O
+confirmed	O
+cases	O
+of	O
+infection	B-DISO
+with	O
+MERS	O
+-	O
+CoV	O
+,	O
+whereas	O
+the	O
+2002	O
+-	O
+2003	O
+epidemic	O
+of	O
+SARS	B-DISO
+affected	O
+26	O
+countries	O
+and	O
+resulted	O
+in	O
+more	O
+than	O
+8000	O
+cases	O
+.	O
+
+Pretreatment	O
+of	O
+the	O
+cells	B-COMP
+with	O
+a	O
+combination	O
+of	O
+three	O
+drugs	O
+(	O
+glycopyrronium	O
+,	O
+formoterol	B-CHED
+,	O
+and	O
+budesonide	B-CHED
+)	O
+exerted	B-PROC
+additive	O
+inhibitory	O
+effects	O
+on	O
+viral	O
+titers	O
+and	O
+cytokine	B-PROC
+production	I-PROC
+.	O
+
+The	O
+additional	O
+three	O
+nucleotides	B-CHED
+may	O
+protect	O
+the	O
+inhibitor	B-CHED
+from	O
+excision	O
+by	O
+the	O
+viral	B-PRGE
+3	I-PRGE
+'-	I-PRGE
+5	I-PRGE
+'	I-PRGE
+exonuclease	I-PRGE
+activity	O
+.	O
+
+ABSTRACT	O
+:	O
+Over	O
+the	O
+past	O
+20	O
+years	O
+,	O
+several	O
+coronaviruses	O
+have	O
+crossed	O
+the	O
+species	O
+barrier	O
+into	O
+humans	B-SPEC
+,	O
+causing	O
+outbreaks	O
+of	O
+severe	O
+,	O
+and	O
+often	O
+fatal	O
+,	O
+respiratory	O
+illness	O
+.	O
+
+Here	O
+,	O
+we	O
+developed	O
+an	O
+approach	O
+to	O
+rapidly	O
+screen	O
+lineage	O
+B	O
+betacoronaviruses	O
+,	O
+such	O
+as	O
+SARS	B-DISO
+-	O
+CoV	O
+and	O
+the	O
+recent	O
+SARS	B-SPEC
+-	I-SPEC
+CoV	I-SPEC
+-	I-SPEC
+2	I-SPEC
+,	O
+for	O
+receptor	O
+usage	O
+and	O
+their	O
+ability	O
+to	O
+infect	O
+cell	B-COMP
+types	O
+from	O
+different	O
+species	B-SPEC
+.	O
+
+We	O
+also	O
+demonstrate	O
+how	O
+different	O
+lineage	O
+B	O
+viruses	B-SPEC
+can	O
+recombine	O
+to	O
+gain	O
+entry	O
+into	O
+human	B-SPEC
+cells	B-COMP
+,	O
+and	O
+confirm	O
+that	O
+human	B-PRGE
+ACE2	I-PRGE
+is	O
+the	O
+receptor	O
+for	O
+the	O
+recently	O
+emerging	O
+SARS	B-PRGE
+-	I-PRGE
+CoV	I-PRGE
+-	I-PRGE
+2	I-PRGE
+.	O
+
+The	O
+shape	O
+,	O
+number	O
+and	O
+distribution	O
+of	O
+lung	B-ANAT
+shadows	O
+,	O
+as	O
+well	O
+as	O
+the	O
+characteristics	O
+of	O
+the	O
+lesions	O
+on	O
+the	O
+CT	O
+images	O
+were	O
+reviewed	O
+.	O
+
+The	O
+chest	B-ANAT
+CT	O
+images	O
+of	O
+patients	O
+with	O
+COVID	B-DISO
+-	I-DISO
+19	I-DISO
+have	O
+certain	O
+characteristics	O
+with	O
+dynamic	O
+changes	O
+,	O
+which	O
+are	O
+of	O
+value	O
+for	O
+monitoring	O
+disease	O
+progress	O
+and	O
+clinical	O
+treatment	O
+.	O
+
+Sputum	B-ANAT
+was	O
+observed	O
+with	O
+the	O
+highest	O
+positive	O
+rate	O
+of	O
+RT	O
+-	O
+PCR	O
+results	O
+.	O
+
+Viral	O
+nucleic	B-CHED
+acids	I-CHED
+could	O
+be	O
+detected	O
+in10	O
+%	O
+patients	B-ANAT
+'	I-ANAT
+blood	I-ANAT
+samples	I-ANAT
+at	O
+acute	O
+periodand	O
+50	O
+%	O
+of	O
+patients	O
+had	O
+positive	O
+RT	O
+-	O
+PCR	O
+results	O
+in	O
+their	O
+feces	B-ANAT
+.	O
+
+Early	O
+antiviral	B-CHED
+treatment	O
+could	O
+alleviate	O
+disease	O
+severity	O
+and	O
+prevent	O
+illness	O
+progression	O
+,	O
+and	O
+we	O
+found	O
+lopinavir	O
+/	O
+ritonavir	B-CHED
+combined	O
+with	O
+abidol	O
+showed	O
+antiviraleffects	O
+in	O
+COVID	B-DISO
+-	I-DISO
+19	I-DISO
+.	O
+
+The	O
+digestive	B-PROC
+systemic	O
+cancer	B-DISO
+is	O
+the	O
+most	O
+common	O
+malignancy	B-DISO
+.	O
+
+Based	O
+on	O
+the	O
+fully	O
+understanding	O
+of	O
+the	O
+characteristics	O
+of	O
+digestive	B-ANAT
+system	I-ANAT
+tumors	B-DISO
+,	O
+we	O
+should	O
+change	O
+the	O
+treatment	O
+strategy	O
+and	O
+adopt	O
+more	O
+reasonable	O
+treatment	O
+strategy	O
+timely	O
+during	O
+the	O
+epidemic	O
+period	O
+to	O
+minimize	O
+the	O
+adverse	B-DISO
+effects	I-DISO
+of	O
+the	O
+epidemic	O
+of	O
+novel	O
+coronavirus	O
+pneumonia	B-DISO
+on	O
+the	O
+treatment	O
+.	O
+
+The	O
+two	O
+models	O
+used	O
+to	O
+estimate	O
+the	O
+reproduction	B-PROC
+number	O
+(	O
+coalescent	O
+-	O
+based	O
+exponential	O
+growth	B-PROC
+and	O
+a	O
+birth	B-PROC
+-	O
+death	B-PROC
+skyline	O
+method	O
+)	O
+indicated	O
+an	O
+estimated	O
+mean	O
+evolutionary	O
+rate	O
+of	O
+7	O
+.	O
+8	O
+×	O
+10	O
+
+TITLE	O
+:	O
+Understanding	O
+of	O
+COVID	B-DISO
+-	I-DISO
+19	I-DISO
+based	O
+on	O
+current	O
+evidence	O
+.	O
+
+TITLE	O
+:	O
+Analysis	O
+of	O
+Severe	O
+fever	B-PROC
+with	O
+thrombocytopenia	O
+syndrome	B-DISO
+in	O
+critical	O
+ill	B-DISO
+patients	O
+in	O
+central	O
+China	O
+.	O
+
+Diagnosis	O
+was	O
+confirmed	O
+using	O
+reverse	B-PROC
+transcription	I-PROC
+polymerase	O
+chain	O
+reaction	O
+on	O
+serum	B-COMP
+samples	O
+.	O
+
+RESULTS	O
+:	O
+116	O
+patients	O
+with	O
+SFTSV	O
+infection	B-DISO
+were	O
+included	O
+(	O
+mean	O
+age	O
+63	O
+±	O
+9	O
+years	O
+,	O
+59	O
+[	O
+51	O
+.	O
+3	O
+%]	O
+males	O
+).	O
+
+The	O
+probable	O
+number	O
+of	O
+new	O
+cases	O
+for	O
+the	O
+next	O
+ten	O
+days	O
+would	O
+gradually	O
+increase	O
+,	O
+and	O
+the	O
+estimated	O
+cumulative	O
+cases	O
+would	O
+reach	B-PROC
+1514	O
+(	O
+1384	O
+-	O
+1656	O
+)	O
+at	O
+the	O
+tenth	O
+day	O
+in	O
+the	O
+future	O
+.	O
+
+Unless	O
+strict	O
+infection	B-DISO
+management	O
+and	O
+control	O
+are	O
+taken	O
+,	O
+our	O
+findings	O
+indicate	O
+the	O
+potential	O
+of	O
+COVID	B-DISO
+-	I-DISO
+19	I-DISO
+to	O
+cause	O
+greater	O
+outbreak	O
+on	O
+the	O
+ship	O
+.	O
+
+We	O
+applied	O
+""""	O
+projections	O
+""""	O
+package	O
+in	O
+R	O
+to	O
+simulate	O
+the	O
+plausible	O
+cumulative	O
+epidemic	O
+trajectories	O
+and	O
+future	O
+daily	O
+incidence	O
+by	O
+fitting	B-DISO
+the	O
+data	O
+of	O
+existing	O
+daily	O
+incidence	O
+,	O
+a	O
+serial	O
+interval	O
+distribution	O
+,	O
+and	O
+the	O
+estimated	O
+R0	O
+into	O
+a	O
+model	O
+based	O
+on	O
+the	O
+assumption	O
+that	O
+daily	O
+incidence	O
+obeys	O
+approximately	O
+Poisson	O
+distribution	O
+determined	O
+by	O
+daily	O
+infectiousness	O
+.	O
+
+TITLE	O
+:	O
+AVNP2	O
+protects	O
+against	O
+cognitive	B-DISO
+impairments	I-DISO
+induced	O
+by	O
+C6	O
+glioma	B-PATH
+by	O
+suppressing	O
+tumour	B-DISO
+associated	O
+inflammation	O
+in	O
+rats	B-SPEC
+.	O
+
+ABSTRACT	O
+:	O
+Glioblastoma	B-DISO
+is	O
+a	O
+kind	O
+of	O
+malignant	B-DISO
+tumour	I-DISO
+and	O
+originates	O
+from	O
+the	O
+central	B-ANAT
+nervous	I-ANAT
+system	I-ANAT
+.	O
+
+Yet	O
+,	O
+little	O
+is	O
+known	O
+about	O
+their	O
+potential	O
+functionalities	O
+and	O
+toxicities	O
+to	O
+the	O
+neurotoxic	O
+effects	O
+of	O
+cancer	B-DISO
+.	O
+
+Herein	O
+,	O
+we	O
+explored	O
+the	O
+functionality	O
+of	O
+AVNP2	O
+on	O
+inhibiting	O
+C6	O
+in	O
+glioma	B-PATH
+-	O
+bearing	O
+rats	B-SPEC
+.	O
+
+There	O
+are	O
+no	O
+commercial	O
+drugs	O
+targeting	B-PROC
+coronaviruses	O
+(	O
+CoVs	O
+),	O
+and	O
+few	O
+studies	O
+on	O
+anti	O
+-	O
+PEDV	B-SPEC
+inhibitors	B-CHED
+.	O
+
+Due	O
+to	O
+significant	O
+variations	O
+in	O
+the	O
+control	O
+strategies	O
+,	O
+which	O
+have	O
+been	O
+changing	O
+over	O
+time	O
+,	O
+and	O
+thanks	O
+to	O
+the	O
+introduction	O
+of	O
+detection	O
+technologies	O
+that	O
+have	O
+been	O
+rapidly	O
+improved	O
+,	O
+enabling	O
+to	O
+shorten	O
+the	O
+time	O
+from	O
+infection	B-DISO
+/	O
+symptoms	O
+onset	O
+to	O
+diagnosis	O
+,	O
+leading	O
+to	O
+faster	O
+confirmation	O
+of	O
+the	O
+new	O
+coronavirus	O
+cases	O
+,	O
+our	O
+previous	O
+estimations	O
+on	O
+the	O
+transmission	O
+risk	O
+of	O
+the	O
+2019	B-SPEC
+-	I-SPEC
+nCoV	I-SPEC
+need	O
+to	O
+be	O
+revised	O
+.	O
+
+The	O
+objective	O
+of	O
+this	O
+study	O
+was	O
+to	O
+estimate	O
+the	O
+risk	O
+of	O
+transmission	O
+of	O
+2019	B-SPEC
+-	I-SPEC
+nCoV	I-SPEC
+through	O
+human	B-SPEC
+passenger	O
+air	B-CHED
+flight	B-PROC
+from	O
+four	O
+major	O
+cities	O
+of	O
+China	O
+(	O
+Wuhan	O
+,	O
+Beijing	O
+,	O
+Shanghai	O
+and	O
+Guangzhou	O
+)	O
+to	O
+the	O
+passengers	O
+'	O
+destination	O
+countries	O
+.	O
+
+According	O
+to	O
+our	O
+risk	O
+score	O
+classification	O
+,	O
+of	O
+the	O
+countries	O
+that	O
+reported	O
+at	O
+least	O
+one	O
+Coronavirus	B-SPEC
+-	O
+infected	O
+pneumonia	B-DISO
+(	O
+COVID	B-DISO
+-	I-DISO
+19	I-DISO
+)	O
+case	O
+as	O
+of	O
+5	O
+February	O
+2020	O
+,	O
+24	O
+countries	O
+were	O
+in	O
+the	O
+4th	O
+quantile	O
+of	O
+the	O
+risk	O
+index	O
+,	O
+two	O
+in	O
+the	O
+3rd	O
+quantile	O
+,	O
+one	O
+in	O
+the	O
+2nd	O
+quantile	O
+and	O
+none	O
+in	O
+the	O
+1st	O
+quantile	O
+.	O
+
+In	O
+pan	B-COMP
+-	O
+Europe	O
+,	O
+UK	O
+,	O
+France	O
+,	O
+Russia	O
+,	O
+Germany	O
+and	O
+Italy	O
+;	O
+in	O
+North	O
+America	O
+,	O
+USA	O
+and	O
+Canada	O
+;	O
+in	O
+Oceania	O
+,	O
+Australia	O
+had	O
+high	O
+risk	O
+,	O
+all	O
+of	O
+them	O
+reported	O
+at	O
+least	O
+one	O
+case	O
+.	O
+
+TITLE	O
+:	O
+Evaluation	O
+of	O
+coronavirus	B-SPEC
+in	O
+tears	B-ANAT
+and	O
+conjunctival	O
+secretions	B-ANAT
+of	O
+patients	O
+with	O
+SARS	B-SPEC
+-	I-SPEC
+CoV	I-SPEC
+-	I-SPEC
+2	I-SPEC
+infection	I-DISO
+.	O
+
+Until	O
+18	O
+February	O
+2020	O
+,	O
+there	O
+were	O
+72	O
+533	O
+confirmed	O
+COVID	B-DISO
+-	I-DISO
+19	I-DISO
+cases	O
+(	O
+including	O
+10	O
+644	O
+severe	O
+cases	O
+)	O
+and	O
+1872	O
+deaths	B-PROC
+in	O
+China	O
+.	O
+
+In	O
+patients	O
+with	O
+negative	O
+RT	O
+-	O
+PCR	O
+results	O
+,	O
+75	O
+%	O
+(	O
+308	O
+/	O
+413	O
+)	O
+had	O
+positive	O
+chest	B-ANAT
+CT	O
+findings	O
+;	O
+of	O
+308	O
+,	O
+48	O
+%	O
+were	O
+considered	O
+as	O
+highly	O
+likely	O
+cases	O
+,	O
+with	O
+33	O
+%	O
+as	O
+probable	O
+cases	O
+.	O
+
+Conclusion	O
+Chest	B-ANAT
+CT	O
+has	O
+a	O
+high	O
+sensitivity	O
+for	O
+diagnosis	O
+of	O
+COVID	B-DISO
+-	I-DISO
+19	I-DISO
+.	O
+
+ABSTRACT	O
+:	O
+According	O
+to	O
+the	O
+Joint	B-ANAT
+Theater	O
+Trauma	O
+Registry	O
+,	O
+26	O
+-	O
+33	O
+%	O
+of	O
+war	O
+casualties	O
+develop	O
+Acute	B-DISO
+Respiratory	I-DISO
+Distress	I-DISO
+Syndrome	I-DISO
+(	O
+ARDS	B-DISO
+),	O
+with	O
+high	O
+mortality	O
+.	O
+
+Here	O
+we	O
+aimed	O
+to	O
+describe	O
+ARDS	B-DISO
+incidence	O
+and	O
+severity	O
+among	O
+patients	O
+evacuated	O
+from	O
+war	O
+zones	O
+and	O
+admitted	O
+to	O
+French	O
+intensive	O
+care	O
+units	O
+(	O
+ICUs	O
+).	O
+
+Among	O
+severe	O
+trauma	O
+patients	O
+,	O
+median	O
+ISS	B-DISO
+was	O
+34	O
+,	O
+and	O
+AIS	B-DISO
+thorax	B-ANAT
+was	O
+3	O
+.	O
+
+TITLE	O
+:	O
+Assessing	O
+the	O
+Impact	O
+of	O
+Reduced	O
+Travel	O
+on	O
+Exportation	O
+Dynamics	O
+of	O
+Novel	B-SPEC
+Coronavirus	I-SPEC
+Infection	O
+(	O
+COVID	B-DISO
+-	I-DISO
+19	I-DISO
+).	O
+
+Unexpectedly	O
+,	O
+the	O
+2109	O
+-	O
+nCoV	O
+RNA	O
+was	O
+readily	O
+detected	O
+in	O
+the	O
+blood	B-ANAT
+(	O
+6	O
+of	O
+57	O
+patients	O
+)	O
+and	O
+the	O
+anal	B-ANAT
+swabs	O
+(	O
+11	O
+of	O
+28	O
+patients	O
+).	O
+
+TITLE	O
+:	O
+Expert	O
+Recommendations	O
+for	O
+Tracheal	O
+Intubation	O
+in	O
+Critically	B-DISO
+ill	I-DISO
+Patients	O
+with	O
+Noval	O
+Coronavirus	B-SPEC
+Disease	I-DISO
+2019	I-DISO
+.	O
+
+In	O
+fact	O
+,	O
+SARS	B-DISO
+-	I-DISO
+CoV	I-DISO
+-	I-DISO
+2	I-DISO
+infection	I-DISO
+of	O
+anesthesiologists	O
+after	O
+endotracheal	O
+intubation	O
+for	O
+confirmed	O
+COVID	O
+-	O
+19	O
+patients	O
+have	O
+been	O
+reported	O
+in	O
+hospitals	O
+in	O
+Wuhan	O
+.	O
+
+A	O
+good	O
+airway	B-ANAT
+assessment	O
+before	O
+airway	B-ANAT
+intervention	O
+is	O
+of	O
+vital	O
+importance	O
+.	O
+
+For	O
+patients	O
+with	O
+difficult	O
+airway	B-ANAT
+,	O
+good	O
+preparation	O
+of	O
+airway	B-ANAT
+devices	O
+and	O
+detailed	O
+intubation	O
+plans	O
+should	O
+be	O
+made	O
+.	O
+
+The	O
+virus	B-SPEC
+causing	O
+this	O
+pneumonia	B-DISO
+was	O
+then	O
+named	O
+as	O
+the	O
+2019	B-SPEC
+novel	I-SPEC
+coronavirus	I-SPEC
+(	O
+2019	B-SPEC
+-	I-SPEC
+nCoV	I-SPEC
+)	O
+by	O
+the	O
+World	O
+Health	O
+Organization	O
+.	O
+
+However	O
+,	O
+there	O
+are	O
+agents	O
+that	O
+were	O
+used	O
+during	O
+the	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+(	O
+SARS	B-DISO
+)	O
+and	O
+Middle	O
+East	O
+respiratory	O
+syndrome	B-DISO
+(	O
+MERS	O
+)	O
+epidemics	O
+.	O
+
+This	O
+virus	B-SPEC
+shares	O
+highly	O
+homological	O
+sequence	O
+with	O
+SARS	B-PRGE
+-	I-PRGE
+CoV	I-PRGE
+,	O
+and	O
+causes	O
+acute	O
+,	O
+highly	O
+lethal	O
+pneumonia	B-DISO
+coronavirus	B-DISO
+disease	I-DISO
+2019	I-DISO
+(	O
+COVID	B-DISO
+-	I-DISO
+19	I-DISO
+)	O
+with	O
+clinical	O
+symptoms	O
+similar	O
+to	O
+those	O
+reported	O
+for	O
+SARS	B-PRGE
+-	I-PRGE
+CoV	I-PRGE
+and	O
+MERS	O
+-	O
+CoV	O
+.	O
+The	O
+most	O
+characteristic	O
+symptom	B-DISO
+of	O
+patients	O
+with	O
+COVID	B-DISO
+-	I-DISO
+19	I-DISO
+is	O
+respiratory	B-DISO
+distress	I-DISO
+,	O
+and	O
+most	O
+of	O
+the	O
+patients	O
+admitted	O
+to	O
+the	O
+intensive	O
+care	O
+could	O
+not	O
+breathe	O
+spontaneously	O
+.	O
+
+There	O
+is	O
+an	O
+urgent	O
+need	O
+for	O
+an	O
+accurate	O
+and	O
+rapid	O
+test	O
+method	O
+to	O
+quickly	O
+identify	O
+large	O
+number	O
+of	O
+infected	O
+patients	O
+and	O
+asymptomatic	O
+carriers	O
+to	O
+prevent	O
+virus	B-SPEC
+transmission	O
+and	O
+assure	O
+timely	O
+treatment	O
+of	O
+patients	O
+.	O
+
+We	O
+have	O
+developed	O
+a	O
+rapid	O
+and	O
+simple	O
+point	O
+-	O
+of	O
+-	O
+care	O
+lateral	O
+flow	O
+immunoassay	O
+which	O
+can	O
+detect	O
+IgM	B-PRGE
+and	O
+IgG	B-PRGE
+antibodies	I-PRGE
+simultaneously	O
+against	O
+SARS	B-PRGE
+-	I-PRGE
+CoV	I-PRGE
+-	I-PRGE
+2	I-PRGE
+virus	B-SPEC
+in	O
+human	B-SPEC
+blood	B-ANAT
+within	O
+15	O
+minutes	O
+which	O
+can	O
+detect	O
+patients	O
+at	O
+different	O
+infection	B-DISO
+stages	O
+.	O
+
+TITLE	O
+:	O
+[	O
+Surgical	O
+treatment	O
+for	O
+esophageal	B-DISO
+cancer	I-DISO
+during	O
+the	O
+outbreak	O
+of	O
+COVID	B-DISO
+-	I-DISO
+19	I-DISO
+].	O
+
+The	O
+selection	O
+of	O
+surgical	O
+procedures	O
+and	O
+perioperative	O
+managements	O
+of	O
+esophageal	B-DISO
+cancer	I-DISO
+require	O
+all	O
+thoracic	B-DISO
+surgeons	O
+work	O
+together	O
+to	O
+figure	O
+out	O
+a	O
+reasonable	O
+system	O
+of	O
+surgical	O
+treatment	O
+and	O
+emergency	B-DISO
+response	O
+.	O
+
+The	O
+rapid	O
+genomic	O
+sequencing	O
+and	O
+open	O
+access	O
+data	O
+,	O
+together	O
+with	O
+advanced	O
+vaccine	O
+technology	O
+,	O
+are	O
+expected	O
+to	O
+give	O
+us	O
+more	O
+knowledge	O
+on	O
+the	O
+pathogen	O
+itself	O
+,	O
+including	O
+the	O
+host	B-COMP
+immune	B-PROC
+response	I-PROC
+as	O
+well	O
+as	O
+the	O
+plan	B-DISO
+for	O
+therapeutic	O
+vaccines	O
+in	O
+the	O
+near	O
+future	O
+.	O
+
+This	O
+predictive	O
+view	O
+may	O
+help	O
+in	O
+designing	O
+an	O
+immune	O
+intervention	O
+or	O
+preventive	O
+vaccine	O
+for	O
+COVID	B-DISO
+-	I-DISO
+19	I-DISO
+in	O
+the	O
+near	O
+future	O
+.	O
+
+Laborious	O
+investigations	O
+in	O
+the	O
+association	O
+between	O
+both	O
+components	O
+,	O
+may	O
+reveal	O
+new	O
+targets	O
+for	O
+opposing	O
+severe	O
+human	B-SPEC
+disease	O
+,	O
+including	O
+the	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+.	O
+
+TITLE	O
+:	O
+Structure	O
+-	O
+Based	O
+Stabilization	O
+of	O
+Non	O
+-	O
+native	O
+Protein	B-CHED
+-	O
+Protein	B-CHED
+Interactions	O
+of	O
+Coronavirus	B-SPEC
+Nucleocapsid	B-ANAT
+Proteins	B-CHED
+in	O
+Antiviral	B-CHED
+Drug	I-CHED
+Design	O
+.	O
+
+ABSTRACT	O
+:	O
+Structure	O
+-	O
+based	O
+stabilization	O
+of	O
+protein	B-CHED
+-	O
+protein	B-CHED
+interactions	O
+(	O
+PPIs	O
+)	O
+is	O
+a	O
+promising	O
+strategy	O
+for	O
+drug	O
+discovery	O
+.	O
+
+The	O
+interface	O
+formed	O
+a	O
+conserved	O
+hydrophobic	O
+cavity	B-DISO
+suitable	O
+for	O
+targeted	B-PROC
+drug	O
+screening	O
+.	O
+
+Compared	O
+with	O
+survivors	O
+,	O
+non	O
+-	O
+survivors	O
+were	O
+older	O
+(	O
+64	O
+·	O
+6	O
+years	O
+[	O
+11	O
+·	O
+2	O
+]	O
+vs	O
+51	O
+·	O
+9	O
+years	O
+[	O
+12	O
+·	O
+9	O
+]),	O
+more	O
+likely	O
+to	O
+develop	O
+ARDS	B-DISO
+(	O
+26	O
+[	O
+81	O
+%]	O
+patients	O
+vs	O
+9	O
+[	O
+45	O
+%]	O
+patients	O
+),	O
+and	O
+more	O
+likely	O
+to	O
+receive	O
+mechanical	O
+ventilation	O
+(	O
+30	O
+[	O
+94	O
+%]	O
+patients	O
+vs	O
+7	O
+[	O
+35	O
+%]	O
+patients	O
+),	O
+either	O
+invasively	O
+or	O
+non	O
+-	O
+invasively	O
+.	O
+
+The	O
+severity	O
+of	O
+SARS	B-PRGE
+-	I-PRGE
+CoV	I-PRGE
+-	I-PRGE
+2	I-PRGE
+pneumonia	B-DISO
+poses	O
+great	O
+strain	O
+on	O
+critical	O
+care	O
+resources	O
+in	O
+hospitals	O
+,	O
+especially	O
+if	O
+they	O
+are	O
+not	O
+adequately	O
+staffed	O
+or	O
+resourced	O
+.	O
+
+ABSTRACT	O
+:	O
+A	O
+cluster	O
+of	O
+patients	O
+with	O
+coronavirus	O
+disease	O
+2019	O
+(	O
+COVID	B-DISO
+-	I-DISO
+19	I-DISO
+)	O
+pneumonia	B-DISO
+caused	O
+by	O
+infection	B-DISO
+with	O
+severe	B-SPEC
+acute	I-SPEC
+respiratory	I-SPEC
+syndrome	I-SPEC
+coronavirus	I-SPEC
+2	I-SPEC
+(	O
+SARS	B-SPEC
+-	I-SPEC
+CoV	I-SPEC
+-	I-SPEC
+2	I-SPEC
+)	O
+were	O
+successively	O
+reported	O
+in	O
+Wuhan	O
+,	O
+China	O
+.	O
+
+TITLE	O
+:	O
+Update	O
+:	O
+Public	O
+Health	O
+Response	O
+to	O
+the	O
+Coronavirus	B-DISO
+Disease	I-DISO
+2019	I-DISO
+Outbreak	O
+-	O
+United	O
+States	O
+,	O
+February	O
+24	O
+,	O
+2020	O
+.	O
+
+The	O
+latter	O
+prevents	O
+farmers	O
+from	O
+going	O
+bankrupt	O
+after	O
+a	O
+zoonoses	B-DISO
+outbreak	O
+.	O
+
+Although	O
+coronaviruses	O
+usually	O
+infect	O
+the	O
+upper	O
+or	O
+lower	B-ANAT
+respiratory	I-ANAT
+tract	I-ANAT
+,	O
+viral	B-DISO
+shedding	I-DISO
+in	O
+plasma	B-ANAT
+or	O
+serum	B-COMP
+is	O
+common	O
+.	O
+
+Because	O
+more	O
+and	O
+more	O
+asymptomatic	O
+infections	O
+are	O
+being	O
+found	O
+among	O
+COVID	B-DISO
+-	I-DISO
+19	I-DISO
+cases	O
+,	O
+considerations	O
+of	O
+blood	B-ANAT
+safety	O
+and	O
+coronaviruses	O
+have	O
+arisen	O
+especially	O
+in	O
+endemic	O
+areas	O
+.	O
+
+All	O
+the	O
+included	O
+SARS	B-SPEC
+-	I-SPEC
+CoV	I-SPEC
+-	I-SPEC
+2	I-SPEC
+-	O
+infected	O
+patients	O
+underwent	O
+non	O
+-	O
+contrast	O
+enhanced	O
+chest	B-ANAT
+computed	O
+tomography	O
+(	O
+CT	O
+).	O
+
+The	O
+majority	O
+of	O
+infected	O
+patients	O
+had	O
+a	O
+history	O
+of	O
+exposure	O
+in	O
+Wuhan	O
+or	O
+to	O
+infected	O
+patients	O
+and	O
+mostly	O
+presented	O
+with	O
+fever	B-PROC
+and	O
+cough	B-DISO
+.	O
+
+The	O
+impact	O
+of	O
+early	O
+corticosteroid	B-CHED
+treatment	O
+(≥	O
+200	O
+mg	O
+hydrocortisone	B-CHED
+equivalent	O
+dose	O
+within	O
+3	O
+days	O
+after	O
+ICU	O
+admission	O
+,	O
+determined	O
+by	O
+a	O
+sensitivity	O
+analysis	O
+)	O
+on	O
+hospital	O
+mortality	O
+(	O
+the	O
+primary	O
+outcome	O
+)	O
+was	O
+assessed	O
+by	O
+multivariable	O
+logistic	O
+regression	O
+analysis	O
+,	O
+and	O
+further	O
+confirmed	O
+in	O
+a	O
+propensity	O
+score	O
+-	O
+matched	O
+cohort	O
+.	O
+
+Among	O
+the	O
+241	O
+patients	O
+with	O
+influenza	O
+-	O
+associated	O
+ARDS	B-DISO
+,	O
+85	O
+(	O
+35	O
+.	O
+3	O
+%)	O
+patients	O
+receiving	O
+early	O
+corticosteroid	B-CHED
+treatment	O
+had	O
+similar	O
+baseline	O
+characteristics	O
+,	O
+but	O
+a	O
+significantly	O
+higher	O
+hospital	O
+mortality	O
+rate	O
+than	O
+those	O
+without	O
+early	O
+corticosteroid	B-CHED
+treatment	O
+[	O
+43	O
+.	O
+5	O
+%	O
+(	O
+37	O
+/	O
+85	O
+)	O
+vs	O
+.	O
+19	O
+.	O
+2	O
+%	O
+(	O
+30	O
+/	O
+156	O
+),	O
+p	O
+<	O
+0	O
+.	O
+001	O
+].	O
+
+We	O
+mapped	O
+the	O
+spatiotemporal	O
+changes	O
+of	O
+confirmed	O
+cases	O
+,	O
+fitted	B-DISO
+the	O
+epidemic	O
+situation	O
+by	O
+the	O
+population	O
+growth	B-PROC
+curve	O
+at	O
+different	O
+stages	O
+and	O
+took	O
+statistical	O
+description	O
+and	O
+analysis	O
+of	O
+the	O
+epidemic	O
+situation	O
+in	O
+Anhui	O
+province	O
+.	O
+
+ABSTRACT	O
+:	O
+We	O
+aim	O
+to	O
+summarize	O
+reliable	O
+evidence	O
+of	O
+evidence	O
+-	O
+based	O
+medicine	B-CHED
+for	O
+the	O
+treatment	O
+and	O
+prevention	O
+of	O
+the	O
+Severe	B-SPEC
+Acute	I-SPEC
+Respiratory	I-SPEC
+Syndrome	I-SPEC
+Coronavirus	I-SPEC
+2	I-SPEC
+(	O
+SARS	B-PRGE
+-	I-PRGE
+CoV	I-PRGE
+-	I-PRGE
+2	I-PRGE
+)	O
+by	O
+analyzing	O
+all	O
+the	O
+published	O
+studies	O
+on	O
+the	O
+clinical	O
+characteristics	O
+of	O
+patients	O
+with	O
+SARS	B-SPEC
+-	I-SPEC
+CoV	I-SPEC
+-	I-SPEC
+2	I-SPEC
+.	O
+
+Meta	B-SPEC
+-	O
+analysis	O
+shows	O
+that	O
+,	O
+among	O
+these	O
+patients	O
+,	O
+the	O
+incidence	O
+of	O
+fever	B-PROC
+was	O
+0	O
+.	O
+891	O
+(	O
+95	O
+%	O
+CI	O
+:	O
+0	O
+.	O
+818	O
+,	O
+0	O
+.	O
+945	O
+),	O
+the	O
+incidence	O
+of	O
+cough	B-DISO
+was	O
+0	O
+.	O
+722	O
+(	O
+95	O
+%	O
+CI	O
+:	O
+0	O
+.	O
+657	O
+,	O
+0	O
+.	O
+782	O
+),	O
+and	O
+the	O
+incidence	O
+of	O
+muscle	B-DISO
+soreness	I-DISO
+or	O
+fatigue	B-DISO
+was	O
+0	O
+.	O
+425	O
+(	O
+95	O
+%	O
+CI	O
+:	O
+0	O
+.	O
+213	O
+,	O
+0	O
+.	O
+652	O
+).	O
+
+Several	O
+people	O
+have	O
+muscle	B-DISO
+soreness	I-DISO
+or	O
+fatigue	B-DISO
+as	O
+well	O
+as	O
+ARDS	B-DISO
+.	O
+
+The	O
+case	O
+fatality	O
+rate	O
+of	O
+patients	O
+with	O
+SARS	B-DISO
+-	I-DISO
+CoV	I-DISO
+-	I-DISO
+2	I-DISO
+infection	I-DISO
+is	O
+lower	O
+than	O
+that	O
+of	O
+Severe	B-DISO
+Acute	I-DISO
+Respiratory	I-DISO
+Syndrome	I-DISO
+(	O
+SARS	B-DISO
+)	O
+and	O
+Middle	O
+East	O
+Respiratory	O
+Syndrome	B-DISO
+(	O
+MERS	O
+).	O
+
+This	O
+meta	B-SPEC
+-	O
+analysis	O
+also	O
+has	O
+limitations	O
+,	O
+so	O
+the	O
+conclusions	O
+of	O
+this	O
+Meta	B-SPEC
+-	O
+analysis	O
+still	O
+need	O
+to	O
+be	O
+verified	O
+by	O
+more	O
+relevant	O
+studies	O
+with	O
+more	O
+careful	O
+design	O
+,	O
+more	O
+rigorous	O
+execution	O
+,	O
+and	O
+larger	O
+sample	O
+size	O
+.	O
+
+RESULTS	O
+:	O
+Ten	O
+studies	O
+were	O
+included	O
+in	O
+Meta	B-SPEC
+-	O
+analysis	O
+,	O
+including	O
+a	O
+total	O
+number	O
+of	O
+50466	O
+patients	O
+with	O
+SARS	B-DISO
+-	I-DISO
+CoV	I-DISO
+-	I-DISO
+2	I-DISO
+infection	I-DISO
+.	O
+
+Budd	B-DISO
+-	I-DISO
+Chiari	I-DISO
+syndrome	I-DISO
+is	O
+a	O
+complex	O
+disorder	O
+,	O
+and	O
+severity	O
+of	O
+the	O
+disease	O
+varies	O
+,	O
+serious	O
+cases	O
+can	O
+be	O
+life	O
+threatening	O
+.	O
+
+ABSTRACT	O
+:	O
+Genome	O
+Detective	O
+is	O
+a	O
+web	B-DISO
+-	O
+based	O
+,	O
+user	O
+-	O
+friendly	O
+software	O
+application	O
+to	O
+quickly	O
+and	O
+accurately	O
+assemble	O
+all	O
+known	O
+virus	B-SPEC
+genomes	O
+from	O
+next	O
+generation	O
+sequencing	O
+datasets	O
+.	O
+
+This	O
+application	O
+allows	O
+the	O
+identification	O
+of	O
+phylogenetic	O
+clusters	B-CHED
+and	O
+genotypes	O
+from	O
+assembled	O
+genomes	O
+in	O
+FASTA	O
+format	O
+.	O
+
+The	O
+tool	O
+has	O
+been	O
+tested	O
+and	O
+validated	O
+with	O
+hundreds	O
+of	O
+whole	O
+genomes	O
+from	O
+ten	O
+coronavirus	O
+species	B-SPEC
+,	O
+and	O
+correctly	O
+classified	O
+all	O
+of	O
+the	O
+SARS	B-DISO
+-	O
+related	O
+coronavirus	B-SPEC
+(	O
+SARSr	O
+-	O
+CoV	O
+)	O
+and	O
+all	O
+of	O
+the	O
+available	O
+public	O
+data	O
+for	O
+SARS	B-PRGE
+-	I-PRGE
+CoV	I-PRGE
+-	I-PRGE
+2	I-PRGE
+.	O
+
+TITLE	O
+:	O
+Clinical	O
+Characteristics	O
+of	O
+Coronavirus	B-DISO
+Disease	I-DISO
+2019	I-DISO
+in	O
+China	O
+.	O
+
+We	O
+extracted	O
+data	O
+regarding	O
+1099	O
+patients	O
+with	O
+laboratory	O
+-	O
+confirmed	O
+Covid	B-DISO
+-	I-DISO
+19	I-DISO
+from	O
+552	O
+hospitals	O
+in	O
+30	O
+provinces	O
+,	O
+autonomous	O
+regions	O
+,	O
+and	O
+municipalities	O
+in	O
+China	O
+through	O
+January	O
+29	O
+,	O
+2020	O
+.	O
+
+Real	O
+time	O
+RT	O
+-	O
+PCR	O
+was	O
+used	O
+to	O
+detect	O
+the	O
+new	O
+coronavirus	B-SPEC
+in	O
+respiratory	B-ANAT
+samples	I-ANAT
+.	O
+
+Up	O
+to	O
+now	O
+,	O
+21	O
+cases	O
+were	O
+discharged	O
+from	O
+the	O
+hospital	O
+,	O
+and	O
+no	O
+patient	O
+died	B-PROC
+.	O
+
+The	O
+lesion	O
+was	O
+primarily	O
+located	O
+in	O
+the	O
+peripheral	O
+area	O
+under	O
+the	O
+pleura	B-ANAT
+with	O
+possible	O
+extension	O
+towards	O
+the	O
+pulmonary	B-ANAT
+hilum	I-ANAT
+.	O
+
+CT	O
+scanning	O
+provides	O
+important	O
+bases	B-CHED
+for	O
+early	O
+diagnosis	O
+and	O
+treatment	O
+of	O
+NCP	B-FUNC
+.	O
+
+Therefore	O
+,	O
+it	O
+is	O
+critical	O
+to	O
+understand	O
+the	O
+nature	O
+of	O
+the	O
+virus	B-SPEC
+and	O
+its	O
+clinical	O
+characteristics	O
+,	O
+in	O
+order	B-SPEC
+to	O
+respond	O
+to	O
+the	O
+2019	B-SPEC
+-	I-SPEC
+nCoV	I-SPEC
+outbreak	O
+.	O
+
+TITLE	O
+:	O
+Real	O
+-	O
+time	O
+forecasts	O
+of	O
+the	O
+COVID	B-DISO
+-	I-DISO
+19	I-DISO
+epidemic	O
+in	O
+China	O
+from	O
+February	O
+5th	O
+to	O
+February	O
+24th	O
+,	O
+2020	O
+.	O
+
+ABSTRACT	O
+:	O
+The	O
+initial	O
+cluster	O
+of	O
+severe	O
+pneumonia	O
+cases	O
+that	O
+triggered	O
+the	O
+COVID	B-DISO
+-	I-DISO
+19	I-DISO
+epidemic	O
+was	O
+identified	O
+in	O
+Wuhan	O
+,	O
+China	O
+in	O
+December	O
+2019	O
+.	O
+
+A	O
+systematic	O
+search	O
+was	O
+carried	O
+out	O
+in	O
+three	O
+major	O
+electronic	O
+databases	O
+(	O
+PubMed	O
+,	O
+Embase	O
+and	O
+Cochrane	O
+Library	O
+)	O
+to	O
+identify	O
+published	O
+studies	O
+in	O
+accordance	O
+with	O
+the	O
+Preferred	O
+Reporting	O
+Items	O
+for	O
+Systematic	O
+Reviews	O
+and	O
+Meta	B-SPEC
+-	O
+Analyses	O
+(	O
+PRISMA	O
+)	O
+guidelines	O
+.	O
+
+Several	O
+laboratory	O
+protocols	O
+for	O
+confirmation	O
+of	O
+suspected	O
+2019	O
+-	O
+nCoV	O
+cases	O
+using	O
+real	O
+-	O
+time	O
+reverse	B-PROC
+transcription	I-PROC
+polymerase	O
+chain	O
+reaction	O
+(	O
+RT	O
+-	O
+PCR	O
+)	O
+have	O
+been	O
+published	O
+.	O
+
+A	O
+number	O
+of	O
+novel	O
+compounds	O
+as	O
+well	O
+as	O
+therapeutics	O
+licensed	O
+for	O
+other	O
+conditions	O
+appear	O
+to	O
+have	O
+in	O
+vitro	O
+efficacy	O
+against	O
+the	O
+2019	B-SPEC
+-	I-SPEC
+nCoV	I-SPEC
+.	O
+Some	O
+are	O
+being	O
+tested	O
+in	O
+clinical	O
+trials	O
+against	O
+MERS	O
+-	O
+CoV	O
+and	O
+SARS	B-PRGE
+-	I-PRGE
+CoV	I-PRGE
+,	O
+while	O
+others	O
+have	O
+been	O
+listed	O
+for	O
+clinical	O
+trials	O
+against	O
+2019	B-SPEC
+-	I-SPEC
+nCoV	I-SPEC
+.	O
+However	O
+,	O
+there	O
+are	O
+currently	O
+no	O
+effective	O
+specific	O
+antivirals	B-CHED
+or	O
+drug	O
+combinations	O
+supported	O
+by	O
+high	O
+-	O
+level	O
+evidence	O
+.	O
+
+TITLE	O
+:	O
+[	O
+The	O
+keypoints	O
+in	O
+treatment	O
+of	O
+the	O
+critical	O
+coronavirus	B-DISO
+disease	I-DISO
+2019	I-DISO
+patient	O
+].	O
+
+TITLE	O
+:	O
+[	O
+Recommendations	O
+for	O
+the	O
+regulation	B-PROC
+of	O
+medical	O
+practices	O
+of	O
+burn	O
+treatment	O
+during	O
+the	O
+outbreak	O
+of	O
+the	O
+coronavirus	O
+disease	O
+2019	O
+].	O
+
+Prolonged	O
+virus	B-DISO
+shedding	I-DISO
+is	O
+observed	O
+in	O
+respiratory	B-ANAT
+tract	I-ANAT
+and	O
+feces	B-ANAT
+at	O
+the	O
+convalescent	O
+stage	O
+.	O
+
+ABSTRACT	O
+:	O
+A	O
+well	O
+6	O
+-	O
+month	O
+-	O
+old	O
+infant	O
+with	O
+coronavirus	O
+disease	O
+2019	O
+(	O
+COVID	B-DISO
+-	I-DISO
+19	I-DISO
+)	O
+had	O
+persistently	O
+positive	O
+nasopharyngeal	B-ANAT
+swabs	O
+to	O
+day	O
+16	O
+of	O
+admission	O
+.	O
+
+TITLE	O
+:	O
+Management	O
+strategies	O
+of	O
+neonatal	B-DISO
+jaundice	I-DISO
+during	O
+the	O
+coronavirus	B-DISO
+disease	I-DISO
+2019	I-DISO
+outbreak	O
+.	O
+
+Exposure	O
+to	O
+dromedary	B-SPEC
+camels	B-SPEC
+(	O
+Camelus	B-SPEC
+dromedaries	B-SPEC
+)	O
+has	O
+been	O
+consistently	O
+considered	O
+the	O
+main	O
+source	O
+of	O
+primary	O
+human	B-SPEC
+infection	B-DISO
+.	O
+
+A	O
+strong	O
+and	O
+significant	O
+association	O
+was	O
+found	O
+between	O
+the	O
+total	O
+number	O
+of	O
+dromedary	B-SPEC
+camels	B-SPEC
+and	O
+the	O
+numbers	O
+of	O
+primary	O
+camel	B-SPEC
+-	O
+exposed	O
+and	O
+non	O
+-	O
+exposed	O
+MERS	O
+-	O
+CoV	O
+cases	O
+.	O
+
+Transmission	O
+of	O
+MERS	O
+-	O
+CoV	O
+from	O
+camels	B-SPEC
+to	O
+humans	B-SPEC
+occurs	O
+in	O
+most	O
+primary	O
+cases	O
+,	O
+but	O
+there	O
+is	O
+still	O
+a	O
+high	O
+proportion	O
+of	O
+primary	O
+infections	B-DISO
+with	O
+an	O
+ambiguous	O
+link	O
+to	O
+camels	B-SPEC
+.	O
+
+The	O
+results	O
+from	O
+this	O
+study	O
+include	O
+significant	O
+correlations	O
+between	O
+primary	O
+MERS	O
+-	O
+CoV	O
+cases	O
+and	O
+camel	B-SPEC
+populations	O
+in	O
+all	O
+provinces	O
+,	O
+regardless	O
+of	O
+camel	B-SPEC
+exposure	O
+history	O
+.	O
+
+TITLE	O
+:	O
+The	O
+psychological	B-DISO
+impact	O
+of	O
+quarantine	O
+and	O
+how	O
+to	O
+reduce	O
+it	O
+:	O
+rapid	O
+review	O
+of	O
+the	O
+evidence	O
+.	O
+
+TITLE	O
+:	O
+Clinical	O
+characteristics	O
+and	O
+imaging	O
+manifestations	O
+of	O
+the	O
+2019	B-DISO
+novel	I-DISO
+coronavirus	I-DISO
+disease	I-DISO
+(	O
+COVID	B-DISO
+-	I-DISO
+19	I-DISO
+):	O
+A	O
+multi	O
+-	O
+center	O
+study	O
+in	O
+Wenzhou	O
+city	O
+,	O
+Zhejiang	O
+,	O
+China	O
+.	O
+
+We	O
+analyzed	O
+the	O
+data	O
+of	O
+262	O
+confirmed	O
+cases	O
+to	O
+determine	O
+the	O
+clinical	O
+and	O
+epidemiological	O
+characteristics	O
+of	O
+COVID	B-DISO
+-	I-DISO
+19	I-DISO
+in	O
+Beijing	O
+.	O
+
+The	O
+information	O
+on	O
+demographic	O
+,	O
+epidemiological	O
+,	O
+clinical	O
+,	O
+laboratory	O
+test	O
+for	O
+the	O
+COVID	B-SPEC
+-	I-SPEC
+19	I-SPEC
+virus	I-SPEC
+,	O
+diagnostic	O
+classification	O
+,	O
+cluster	O
+case	O
+and	O
+outcome	O
+were	O
+obtained	O
+.	O
+
+Finally	O
+,	O
+the	O
+pulmonary	B-ANAT
+vessels	B-ANAT
+enlargement	B-DISO
+in	O
+areas	O
+where	O
+new	O
+lung	B-ANAT
+infiltrates	B-DISO
+develop	O
+in	O
+the	O
+follow	O
+-	O
+up	O
+CT	O
+scan	O
+,	O
+could	O
+describe	O
+an	O
+early	O
+predictor	O
+radiological	O
+sign	O
+of	O
+lung	B-ANAT
+impairment	B-DISO
+.	O
+
+ABSTRACT	O
+:	O
+An	O
+unprecedented	O
+outbreak	O
+of	O
+pneumonia	B-DISO
+of	O
+unknown	O
+aetiology	O
+in	O
+Wuhan	O
+City	O
+,	O
+Hubei	O
+province	O
+in	O
+China	O
+emerged	O
+in	O
+December	O
+2019	O
+.	O
+
+TITLE	O
+:	O
+The	O
+epidemiology	O
+and	O
+pathogenesis	B-DISO
+of	O
+coronavirus	B-SPEC
+disease	O
+(	O
+COVID	B-DISO
+-	I-DISO
+19	I-DISO
+)	O
+outbreak	O
+.	O
+
+Of	O
+these	O
+125	O
+herbs	O
+,	O
+26	O
+are	O
+classically	O
+catalogued	O
+as	O
+treating	O
+viral	O
+respiratory	B-DISO
+infections	I-DISO
+.	O
+
+Network	O
+pharmacology	O
+analysis	O
+predicted	O
+that	O
+the	O
+general	O
+in	O
+vivo	O
+roles	O
+of	O
+these	O
+26	O
+herbal	O
+plants	B-SPEC
+were	O
+related	O
+to	O
+regulating	O
+viral	B-DISO
+infection	I-DISO
+,	O
+immune	O
+/	O
+inflammation	B-DISO
+reactions	O
+and	O
+hypoxia	B-DISO
+response	O
+.	O
+
+Chinese	O
+herbal	O
+treatments	O
+classically	O
+used	O
+for	O
+treating	O
+viral	B-DISO
+respiratory	I-DISO
+infection	I-DISO
+might	O
+contain	O
+direct	O
+anti	O
+-	O
+2019	B-SPEC
+-	I-SPEC
+nCoV	I-SPEC
+compounds	O
+.	O
+
+ABSTRACT	O
+:	O
+The	O
+outbreak	O
+of	O
+2019	O
+novel	O
+coronavirus	O
+(	O
+2019	B-SPEC
+-	I-SPEC
+nCoV	I-SPEC
+)	O
+pneumonia	B-DISO
+was	O
+reported	O
+in	O
+Wuhan	O
+,	O
+Hubei	O
+Province	O
+,	O
+China	O
+in	O
+December	O
+2019	O
+and	O
+has	O
+spread	O
+internationally	O
+.	O
+
+TITLE	O
+:	O
+Extracorporeal	O
+Membrane	B-COMP
+Oxygenation	B-PROC
+Support	O
+for	O
+Vaping	O
+-	O
+induced	O
+Acute	O
+Lung	B-ANAT
+Injury	O
+.	O
+
+ABSTRACT	O
+:	O
+An	O
+ongoing	O
+outbreak	O
+of	O
+severe	O
+respiratory	O
+pneumonia	B-DISO
+associated	O
+with	O
+the	O
+2019	B-SPEC
+novel	I-SPEC
+coronavirus	I-SPEC
+has	O
+recently	O
+emerged	O
+in	O
+China	O
+.	O
+
+These	O
+three	O
+different	O
+kits	O
+got	O
+the	O
+same	O
+result	O
+for	O
+each	O
+sample	O
+and	O
+the	O
+positive	O
+ratio	O
+of	O
+nucleic	B-CHED
+acid	I-CHED
+detection	O
+for	O
+2019	B-SPEC
+-	I-SPEC
+nCoV	I-SPEC
+was	O
+only	O
+47	O
+.	O
+4	O
+%	O
+in	O
+the	O
+suspect	O
+patients	O
+.	O
+
+However	O
+,	O
+one	O
+of	O
+the	O
+most	O
+important	O
+mechanism	O
+underlying	O
+the	O
+deterioration	O
+of	O
+disease	O
+is	O
+cytokine	B-DISO
+storm	I-DISO
+.	O
+
+This	O
+article	O
+reviews	O
+the	O
+influences	O
+of	O
+cytokine	B-DISO
+storm	I-DISO
+syndrome	O
+on	O
+the	O
+COVID	B-DISO
+-	I-DISO
+19	I-DISO
+and	O
+the	O
+corresponding	O
+immunotherapies	O
+to	O
+resist	O
+cytokine	B-DISO
+storm	I-DISO
+.	O
+
+TITLE	O
+:	O
+Effect	O
+of	O
+corticosteroid	B-CHED
+therapy	O
+in	O
+the	O
+early	O
+phase	O
+of	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+:	O
+a	O
+propensity	O
+-	O
+matched	O
+cohort	O
+study	O
+.	O
+
+ABSTRACT	O
+:	O
+It	O
+is	O
+unclear	O
+whether	O
+corticosteroid	O
+use	O
+in	O
+patients	O
+with	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+(	O
+ARDS	B-DISO
+)	O
+improves	O
+survival	O
+.	O
+
+ABSTRACT	O
+:	O
+Severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+coronavirus	I-SPEC
+2	I-SPEC
+(	O
+SARS	B-SPEC
+-	I-SPEC
+CoV	I-SPEC
+-	I-SPEC
+2	I-SPEC
+)	O
+cause	O
+china	O
+epidemics	O
+with	O
+high	O
+morbidity	O
+and	O
+mortality	O
+,	O
+the	O
+infection	B-DISO
+has	O
+been	O
+transmitted	B-DISO
+to	O
+other	O
+countries	O
+.	O
+
+There	O
+is	O
+currently	O
+no	O
+evidence	O
+that	O
+SARS	B-PRGE
+-	I-PRGE
+CoV	I-PRGE
+-	I-PRGE
+2	I-PRGE
+can	O
+be	O
+transmitted	B-DISO
+transplacentally	O
+from	O
+mother	O
+to	O
+the	O
+newborn	O
+.	O
+
+This	O
+review	O
+describes	O
+the	O
+current	O
+understanding	O
+of	O
+COVID	B-DISO
+-	I-DISO
+19	I-DISO
+infection	I-DISO
+in	O
+newborns	O
+and	O
+children	O
+.	O
+
+ABSTRACT	O
+:	O
+In	O
+recent	O
+years	O
+,	O
+viruses	B-SPEC
+similar	O
+to	O
+those	O
+that	O
+cause	O
+serious	O
+disease	O
+in	O
+humans	O
+and	O
+other	O
+mammals	B-SPEC
+have	O
+been	O
+detected	O
+in	O
+apparently	O
+healthy	O
+bats	B-SPEC
+.	O
+
+These	O
+include	O
+filoviruses	O
+,	O
+paramyxoviruses	O
+,	O
+and	O
+coronaviruses	O
+that	O
+cause	O
+severe	O
+diseases	O
+such	O
+as	O
+Ebola	B-DISO
+virus	I-DISO
+disease	I-DISO
+,	O
+Marburg	B-DISO
+haemorrhagic	I-DISO
+fever	I-DISO
+and	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+(	O
+SARS	B-DISO
+)	O
+in	O
+humans	B-SPEC
+.	O
+
+TITLE	O
+:	O
+Therapeutic	O
+strategies	O
+in	O
+an	O
+outbreak	O
+scenario	O
+to	O
+treat	O
+the	O
+novel	B-SPEC
+coronavirus	I-SPEC
+originating	O
+in	O
+Wuhan	O
+,	O
+China	O
+.	O
+
+This	O
+review	O
+will	O
+demonstrate	O
+how	O
+to	O
+applicate	O
+appropriate	O
+and	O
+individual	O
+management	O
+for	O
+lung	O
+cancer	B-SPEC
+patients	O
+to	O
+protect	O
+them	O
+from	O
+COVID	B-DISO
+-	I-DISO
+19	I-DISO
+.	O
+
+TITLE	O
+:	O
+COVID	B-DISO
+-	I-DISO
+19	I-DISO
+in	O
+2	O
+Persons	O
+with	O
+Mild	O
+Upper	O
+Respiratory	B-DISO
+Symptoms	I-DISO
+on	O
+a	O
+Cruise	O
+Ship	O
+,	O
+Japan	O
+.	O
+
+Eighty	O
+-	O
+three	O
+patients	O
+with	O
+COVID	B-DISO
+-	I-DISO
+19	I-DISO
+pneumonia	I-DISO
+including	O
+25	O
+severe	O
+/	O
+critical	O
+cases	O
+and	O
+58	O
+ordinary	O
+cases	O
+were	O
+enrolled	O
+.	O
+
+TITLE	O
+:	O
+Persistence	O
+and	O
+clearance	O
+of	O
+viral	O
+RNA	O
+in	O
+2019	B-DISO
+novel	I-DISO
+coronavirus	I-DISO
+disease	I-DISO
+rehabilitation	O
+patients	O
+.	O
+
+ABSTRACT	O
+:	O
+A	O
+patient	O
+'	O
+s	O
+infectivity	O
+is	O
+determined	O
+by	O
+the	O
+presence	O
+of	O
+the	O
+virus	O
+in	O
+different	O
+body	B-ANAT
+fluids	I-ANAT
+,	O
+secretions	B-ANAT
+,	O
+and	O
+excreta	O
+.	O
+
+ABSTRACT	O
+:	O
+Since	O
+early	O
+December	O
+2019	O
+,	O
+the	O
+2019	B-DISO
+novel	I-DISO
+coronavirus	I-DISO
+disease	I-DISO
+(	O
+COVID	B-DISO
+-	I-DISO
+19	I-DISO
+)	O
+has	O
+caused	O
+pneumonia	B-DISO
+epidemic	O
+in	O
+Wuhan	O
+,	O
+Hubei	O
+province	O
+of	O
+China	O
+.	O
+
+Five	O
+million	O
+people	O
+emigrated	O
+from	O
+Wuhan	O
+before	O
+lockdown	O
+,	O
+potentially	O
+representing	O
+a	O
+source	O
+of	O
+virus	B-DISO
+infection	I-DISO
+.	O
+
+The	O
+official	O
+case	O
+report	O
+on	O
+the	O
+COVID	B-DISO
+-	I-DISO
+19	I-DISO
+epidemic	O
+was	O
+collected	O
+as	O
+of	O
+January	O
+30	O
+,	O
+2020	O
+.	O
+
+The	O
+COVID	B-DISO
+-	I-DISO
+19	I-DISO
+confirmed	O
+and	O
+death	B-PROC
+cases	O
+in	O
+Hubei	O
+province	O
+accounted	O
+for	O
+59	O
+.	O
+91	O
+%	O
+(	O
+5806	O
+/	O
+9692	O
+)	O
+and	O
+95	O
+.	O
+77	O
+%	O
+(	O
+204	O
+/	O
+213	O
+)	O
+of	O
+the	O
+total	O
+cases	O
+in	O
+China	O
+respectively	O
+.	O
+
+Bleeding	B-DISO
+requiring	O
+blood	B-ANAT
+product	O
+application	O
+occurred	O
+in	O
+three	O
+of	O
+10	O
+venovenous	O
+extracorporeal	O
+membrane	B-COMP
+oxygenation	B-PROC
+patients	O
+and	O
+in	O
+four	O
+of	O
+eight	O
+venoarterial	O
+extracorporeal	O
+membrane	B-COMP
+oxygenation	B-PROC
+patients	O
+.	O
+
+ABSTRACT	O
+:	O
+Isolation	O
+of	O
+cases	O
+and	O
+contact	O
+tracing	O
+is	O
+used	O
+to	O
+control	O
+outbreaks	O
+of	O
+infectious	O
+diseases	O
+,	O
+and	O
+has	O
+been	O
+used	O
+for	O
+coronavirus	B-DISO
+disease	I-DISO
+2019	I-DISO
+(	O
+COVID	B-DISO
+-	I-DISO
+19	I-DISO
+).	O
+
+The	O
+role	O
+of	O
+this	O
+case	O
+report	O
+is	O
+promotion	O
+of	O
+potential	O
+recognition	O
+amongst	O
+radiologists	O
+of	O
+this	O
+new	O
+disease	O
+,	O
+which	O
+has	O
+been	O
+declared	O
+a	O
+global	O
+health	O
+emergency	B-DISO
+by	O
+the	O
+World	O
+Health	O
+Organization	O
+(	O
+WHO	O
+).	O
+
+The	O
+estimated	O
+number	O
+of	O
+new	O
+infections	B-DISO
+among	O
+passengers	O
+without	O
+close	O
+contact	O
+was	O
+very	O
+small	O
+from	O
+5	O
+February	O
+on	O
+which	O
+a	O
+movement	B-PROC
+restriction	O
+policy	O
+was	O
+imposed	O
+.	O
+
+Micro	O
+-	O
+aerosol	O
+generating	O
+procedures	O
+,	O
+such	O
+as	O
+non	O
+-	O
+contact	O
+tonometry	O
+and	O
+operations	O
+under	O
+general	O
+anaesthesia	B-DISO
+were	O
+avoided	O
+.	O
+
+Third	O
+,	O
+universal	O
+masking	O
+,	O
+hand	O
+hygiene	O
+,	O
+and	O
+appropriate	O
+use	O
+of	O
+personal	O
+protective	O
+equipment	O
+(	O
+PPE	B-CHED
+)	O
+were	O
+promoted	O
+.	O
+
+CONCLUSIONS	O
+:	O
+We	O
+hope	O
+our	O
+initial	O
+experience	O
+in	O
+stepping	B-DISO
+up	O
+infection	B-DISO
+control	O
+measures	O
+for	O
+COVID	B-DISO
+-	I-DISO
+19	I-DISO
+infection	I-DISO
+in	O
+ophthalmology	O
+can	O
+help	O
+ophthalmologists	O
+globally	O
+to	O
+prepare	O
+for	O
+the	O
+potential	O
+community	O
+outbreak	O
+or	O
+pandemic	O
+.	O
+
+And	O
+we	O
+found	O
+that	O
+patients	O
+with	O
+a	O
+positive	O
+stool	B-ANAT
+test	O
+did	O
+not	O
+experience	O
+gastrointestinal	B-DISO
+symptoms	I-DISO
+and	O
+had	O
+nothing	O
+to	O
+do	O
+with	O
+the	O
+severity	O
+of	O
+the	O
+lung	B-DISO
+infection	I-DISO
+.	O
+
+These	O
+results	O
+may	O
+help	O
+to	O
+understand	O
+the	O
+clinical	O
+diagnosis	O
+and	O
+the	O
+changes	O
+in	O
+clinical	O
+parameters	O
+of	O
+COVID	B-DISO
+-	I-DISO
+19	I-DISO
+.	O
+
+pulmonary	B-ANAT
+rehabilitation	O
+is	O
+an	O
+important	O
+intervention	O
+for	O
+clinical	O
+patients	O
+as	O
+well	O
+as	O
+cure	O
+patients	O
+.	O
+
+The	O
+epidemic	O
+factors	O
+on	O
+the	O
+basis	O
+of	O
+knowledge	O
+of	O
+SARS	B-SPEC
+-	I-SPEC
+CoV	I-SPEC
+-	I-SPEC
+2	I-SPEC
+were	O
+discussed	O
+in	O
+this	O
+paper	O
+.	O
+
+Source	O
+of	O
+infection	B-DISO
+including	O
+the	O
+patients	O
+,	O
+asymptomatic	O
+carrier	O
+and	O
+patients	O
+in	O
+the	O
+incubation	O
+period	O
+are	O
+contagious	O
+.	O
+
+Routes	O
+of	O
+SARS	B-PRGE
+-	I-PRGE
+CoV	I-PRGE
+-	I-PRGE
+2	I-PRGE
+transmission	O
+are	O
+diversified	O
+and	O
+the	O
+main	O
+routes	O
+of	O
+transmission	O
+for	O
+COVID	B-DISO
+-	I-DISO
+19	I-DISO
+are	O
+droplet	O
+transmission	O
+and	O
+close	O
+contact	O
+transmission	O
+.	O
+
+ABSTRACT	O
+:	O
+The	O
+recent	O
+outbreak	O
+of	O
+coronavirus	O
+disease	O
+2019	O
+(	O
+COVID	B-DISO
+-	I-DISO
+19	I-DISO
+)	O
+highlights	O
+an	O
+urgent	O
+need	O
+for	O
+therapeutics	O
+.	O
+
+In	O
+this	O
+brief	O
+review	O
+,	O
+we	O
+summarize	O
+the	O
+broad	O
+antiviral	B-CHED
+activity	O
+of	O
+niclosamide	O
+and	O
+highlight	O
+its	O
+potential	O
+clinical	O
+use	O
+in	O
+the	O
+treatment	O
+of	O
+COVID	B-DISO
+-	I-DISO
+19	I-DISO
+.	O
+
+Clinical	O
+,	O
+laboratory	O
+,	O
+and	O
+radiologic	O
+data	O
+were	O
+collected	O
+,	O
+including	O
+PCR	O
+cycle	O
+threshold	O
+values	O
+from	O
+nasopharyngeal	B-ANAT
+swabs	O
+and	O
+viral	B-DISO
+shedding	I-DISO
+in	O
+blood	B-ANAT
+,	O
+urine	B-ANAT
+,	O
+and	O
+stool	B-ANAT
+.	O
+
+Six	O
+individuals	O
+(	O
+33	O
+%)	O
+required	O
+supplemental	O
+oxygen	B-CHED
+;	O
+of	O
+these	O
+,	O
+2	O
+required	O
+intensive	O
+care	O
+.	O
+
+Among	O
+the	O
+first	O
+18	O
+patients	O
+diagnosed	O
+with	O
+SARS	B-DISO
+-	I-DISO
+CoV	I-DISO
+-	I-DISO
+2	I-DISO
+infection	I-DISO
+in	O
+Singapore	O
+,	O
+clinical	O
+presentation	O
+was	O
+frequently	O
+a	O
+mild	O
+respiratory	B-DISO
+tract	I-DISO
+infection	I-DISO
+.	O
+
+TITLE	O
+:	O
+Airway	B-ANAT
+Pressure	O
+Release	B-PATH
+Ventilation	O
+as	O
+a	O
+Rescue	O
+Therapy	O
+in	O
+Pediatric	O
+Acute	B-DISO
+Respiratory	I-DISO
+Distress	I-DISO
+Syndrome	I-DISO
+.	O
+
+ABSTRACT	O
+:	O
+To	O
+describe	O
+experience	O
+with	O
+airway	B-ANAT
+pressure	O
+release	B-PATH
+ventilation	O
+(	O
+APRV	O
+)	O
+in	O
+children	O
+with	O
+severe	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+(	O
+ARDS	B-DISO
+)	O
+refractory	O
+to	O
+conventional	O
+low	O
+tidal	O
+volume	O
+ventilation	O
+.	O
+
+This	O
+retrospective	O
+observational	O
+study	O
+was	O
+performed	O
+in	O
+an	O
+11	O
+-	O
+bed	B-DISO
+,	O
+level	O
+3	O
+pediatric	O
+intensive	O
+care	O
+unit	O
+.	O
+
+Evaluation	O
+was	O
+made	O
+of	O
+30	O
+pediatric	O
+patients	O
+receiving	O
+airway	B-ANAT
+pressure	O
+release	B-PATH
+ventilation	O
+as	O
+rescue	O
+therapy	O
+for	O
+severe	O
+ARDS	B-DISO
+.	O
+
+When	O
+changed	O
+from	O
+conventional	O
+mechanical	O
+ventilation	O
+(	O
+CMV	B-SPEC
+)	O
+to	O
+APRV	O
+,	O
+there	O
+was	O
+an	O
+expected	O
+increase	O
+in	O
+the	O
+SpO	O
+The	O
+results	O
+of	O
+this	O
+study	O
+support	O
+the	O
+hypothesis	O
+that	O
+APRV	O
+may	O
+offer	O
+potential	O
+clinical	O
+advantages	O
+for	O
+ventilatory	O
+management	O
+and	O
+may	O
+be	O
+considered	O
+as	O
+an	O
+alternative	O
+rescue	O
+mechanical	O
+ventilation	O
+mode	O
+in	O
+pediatric	O
+ARDS	B-DISO
+patients	O
+refractory	O
+to	O
+conventional	O
+ventilation	O
+.	O
+
+Hence	O
+immunomodulatory	O
+activity	O
+of	O
+nafithromycin	O
+,	O
+a	O
+novel	O
+lactone	B-CHED
+ketolide	O
+antibacterial	B-CHED
+agent	I-CHED
+was	O
+assessed	O
+in	O
+the	O
+murine	B-SPEC
+LPS	B-DISO
+induced	O
+ALI	O
+model	O
+.	O
+
+Vehicle	O
+,	O
+nafithromycin	O
+(	O
+100	O
+mg	O
+/	O
+kg	O
+),	O
+azithromycin	B-CHED
+(	O
+600	O
+mg	O
+/	O
+kg	O
+)	O
+and	O
+dexamethasone	B-CHED
+(	O
+20	O
+mg	O
+/	O
+kg	O
+)	O
+were	O
+administered	O
+orally	B-ANAT
+,	O
+1	O
+h	O
+prior	O
+to	O
+LPS	B-DISO
+challenge	O
+and	O
+bronchoalveolar	O
+lavage	O
+(	O
+BAL	B-ENZY
+)	O
+fluid	O
+was	O
+collected	O
+thereafter	O
+at	O
+18	O
+,	O
+24	O
+and	O
+48	O
+h	O
+to	O
+determine	O
+the	O
+total	O
+cell	O
+count	O
+,	O
+total	O
+protein	B-CHED
+,	O
+myeloperoxidase	B-PRGE
+(	O
+MPO	B-FUNC
+),	O
+tumor	B-FUNC
+necrosis	I-FUNC
+factor	I-FUNC
+(	O
+TNF	O
+)-	O
+α	O
+and	O
+interleukin	B-PRGE
+(	O
+IL	O
+)-	O
+6	O
+.	O
+
+Results	O
+from	O
+the	O
+current	O
+study	O
+showed	O
+that	O
+pretreatment	O
+with	O
+nafithromycin	O
+significantly	O
+reduced	O
+the	O
+total	O
+cell	B-COMP
+count	O
+,	O
+total	O
+protein	B-CHED
+,	O
+MPO	B-FUNC
+,	O
+TNF	B-PRGE
+-	I-PRGE
+α	I-PRGE
+and	O
+IL	B-FUNC
+-	I-FUNC
+6	I-FUNC
+levels	O
+in	O
+BAL	B-ENZY
+fluid	O
+compared	O
+to	O
+LPS	B-DISO
+control	O
+group	O
+.	O
+
+TITLE	O
+:	O
+Pulmonary	B-ANAT
+Complications	I-DISO
+and	O
+Sepsis	B-DISO
+Following	O
+Severe	O
+Acute	B-DISO
+Subdural	I-DISO
+Hematoma	I-DISO
+in	O
+Patients	O
+Who	O
+Underwent	O
+Craniotomy	O
+versus	O
+Craniectomy	O
+:	O
+A	O
+Propensity	O
+Score	O
+Matched	O
+Analysis	O
+.	O
+
+TITLE	O
+:	O
+Small	O
+Molecule	O
+Inhibitors	B-CHED
+of	O
+Middle	O
+East	O
+Respiratory	O
+Syndrome	B-DISO
+Coronavirus	B-SPEC
+Fusion	O
+by	O
+Targeting	B-PROC
+Cavities	B-DISO
+on	O
+Heptad	O
+Repeat	O
+Trimers	O
+.	O
+
+ABSTRACT	O
+:	O
+Middle	O
+East	O
+Respiratory	O
+Syndrome	B-DISO
+Coronavirus	B-SPEC
+(	O
+MERS	O
+-	O
+CoV	O
+)	O
+is	O
+a	O
+newly	O
+emerging	O
+viral	B-DISO
+disease	I-DISO
+with	O
+fatal	B-DISO
+outcomes	I-DISO
+.	O
+
+Given	O
+the	O
+absence	O
+of	O
+previous	O
+structure	O
+-	O
+based	O
+drug	O
+discovery	O
+studies	O
+targeting	B-PROC
+MERS	B-PRGE
+-	I-PRGE
+CoV	I-PRGE
+fusion	I-PRGE
+proteins	I-PRGE
+,	O
+this	O
+set	O
+of	O
+compounds	O
+is	O
+considered	O
+the	O
+first	O
+generation	O
+of	O
+MERS	B-PRGE
+-	I-PRGE
+CoV	I-PRGE
+small	I-PRGE
+molecule	I-PRGE
+fusion	O
+inhibitors	B-CHED
+.	O
+
+After	O
+a	O
+virtual	O
+screening	O
+campaign	O
+of	O
+1	O
+.	O
+56	O
+million	O
+compounds	O
+followed	O
+by	O
+cell	B-PROC
+-	I-PROC
+cell	B-COMP
+fusion	I-PROC
+assay	O
+and	O
+MERS	O
+-	O
+CoV	O
+plaques	B-DISO
+inhibition	B-PROC
+assay	O
+,	O
+three	O
+new	O
+compounds	O
+were	O
+identified	O
+.	O
+
+We	O
+evaluated	O
+the	O
+recovery	O
+from	O
+lung	B-ANAT
+damage	O
+and	O
+femoral	B-ANAT
+head	I-ANAT
+necrosis	B-PROC
+in	O
+an	O
+observational	O
+cohort	O
+study	O
+of	O
+SARS	B-DISO
+patients	O
+using	O
+pulmonary	B-ANAT
+CT	O
+scans	O
+,	O
+hip	B-ANAT
+joint	I-ANAT
+MRI	O
+examinations	O
+,	O
+pulmonary	B-PROC
+function	I-PROC
+tests	O
+and	O
+hip	B-ANAT
+joint	I-ANAT
+function	O
+questionnaires	O
+.	O
+
+Moreover	O
+,	O
+vaccines	O
+based	O
+on	O
+viral	O
+-	O
+encoded	O
+peptides	B-CHED
+may	O
+not	O
+be	O
+effective	O
+against	O
+future	O
+coronavirus	B-SPEC
+epidemics	O
+,	O
+as	O
+virus	B-SPEC
+mutations	O
+could	O
+make	O
+them	O
+futile	O
+.	O
+
+This	O
+idea	B-SPEC
+is	O
+based	O
+on	O
+observations	O
+that	O
+the	O
+angiotensin	B-PRGE
+-	I-PRGE
+converting	I-PRGE
+enzyme	I-PRGE
+2	I-PRGE
+(	O
+ACE2	B-PRGE
+)	O
+very	O
+likely	O
+serves	O
+as	O
+the	O
+binding	B-FUNC
+site	O
+for	O
+SARS	B-PRGE
+-	I-PRGE
+CoV	I-PRGE
+-	I-PRGE
+2	I-PRGE
+,	O
+the	O
+strain	O
+implicated	O
+in	O
+the	O
+current	O
+COVID	B-DISO
+-	I-DISO
+19	I-DISO
+epidemic	O
+,	O
+similarly	O
+to	O
+strain	O
+SARS	B-DISO
+-	O
+CoV	O
+implicated	O
+in	O
+the	O
+2002	O
+-	O
+2003	O
+SARS	B-DISO
+epidemic	O
+.	O
+
+This	O
+commentary	O
+elaborates	O
+on	O
+the	O
+idea	B-SPEC
+of	O
+considering	O
+AT1R	O
+blockers	O
+as	O
+tentative	O
+treatment	O
+for	O
+SARS	B-SPEC
+-	I-SPEC
+CoV	I-SPEC
+-	I-SPEC
+2	I-SPEC
+infections	B-DISO
+,	O
+and	O
+proposes	O
+a	O
+research	O
+direction	O
+based	O
+on	O
+datamining	O
+of	O
+clinical	O
+patient	O
+records	O
+for	O
+assessing	O
+its	O
+feasibility	O
+.	O
+
+Indications	O
+of	O
+pulmonary	B-PROC
+function	I-PROC
+testing	O
+should	O
+be	O
+followed	O
+strictly	O
+.	O
+
+TITLE	O
+:	O
+[	O
+Prediction	O
+modeling	O
+with	O
+data	O
+fusion	O
+and	O
+prevention	O
+strategy	O
+analysis	O
+for	O
+the	O
+COVID	B-DISO
+-	I-DISO
+19	I-DISO
+outbreak	O
+].	O
+
+,	O
+the	O
+outbreak	O
+of	O
+COVID	O
+-	O
+19	O
+in	O
+Wuhan	O
+has	O
+spread	O
+rapidly	O
+due	O
+to	O
+population	O
+movement	B-PROC
+during	O
+the	O
+Spring	O
+Festival	O
+holidays	O
+.	O
+
+It	O
+is	O
+still	O
+unclear	O
+how	O
+fast	B-FUNC
+the	O
+virus	B-SPEC
+evolved	O
+and	O
+how	O
+the	O
+virus	B-SPEC
+interacts	O
+with	O
+other	O
+microorganisms	O
+in	O
+the	O
+lung	B-ANAT
+.	O
+
+SARS	B-PRGE
+-	I-PRGE
+CoV	I-PRGE
+-	I-PRGE
+2	I-PRGE
+evolves	O
+in	O
+vivo	O
+after	O
+infection	B-DISO
+,	O
+which	O
+may	O
+affect	O
+its	O
+virulence	B-PROC
+,	O
+infectivity	O
+,	O
+and	O
+transmissibility	O
+.	O
+
+RESULTS	O
+:	O
+The	O
+median	O
+number	O
+of	O
+intra	O
+-	O
+host	B-COMP
+variants	O
+was	O
+1	O
+-	O
+4	O
+in	O
+SARS	B-SPEC
+-	I-SPEC
+CoV	I-SPEC
+-	I-SPEC
+2	I-SPEC
+infected	O
+patients	O
+,	O
+which	O
+ranged	O
+between	O
+0	O
+and	O
+51	O
+in	O
+different	O
+samples	O
+.	O
+
+Although	O
+NK	B-ANAT
+cells	I-ANAT
+are	O
+often	O
+considered	O
+as	O
+a	O
+uniform	O
+cell	B-COMP
+population	O
+,	O
+several	O
+phenotypic	O
+and	O
+functionally	O
+distinct	O
+NK	B-ANAT
+cells	I-ANAT
+subsets	O
+exist	O
+in	O
+healthy	O
+individuals	O
+,	O
+that	O
+are	O
+differentially	O
+affected	O
+by	O
+ageing	B-PROC
+or	O
+by	O
+apparently	O
+innocuous	O
+viruses	B-SPEC
+such	O
+as	O
+cytomegalovirus	B-SPEC
+(	O
+CMV	B-SPEC
+).	O
+
+The	O
+main	O
+idea	B-SPEC
+of	O
+the	O
+proposed	O
+model	O
+,	O
+called	O
+FPASSA	O
+-	O
+ANFIS	O
+,	O
+is	O
+to	O
+improve	O
+the	O
+performance	O
+of	O
+ANFIS	O
+by	O
+determining	O
+the	O
+parameters	O
+of	O
+ANFIS	O
+using	O
+FPASSA	O
+.	O
+
+More	O
+so	O
+,	O
+the	O
+FPASSA	O
+-	O
+ANFIS	O
+model	O
+is	O
+compared	O
+to	O
+several	O
+existing	O
+models	O
+,	O
+and	O
+it	O
+showed	O
+better	O
+performance	O
+in	O
+terms	O
+of	O
+Mean	O
+Absolute	O
+Percentage	O
+Error	O
+(	O
+MAPE	O
+),	O
+Root	B-ANAT
+Mean	O
+Squared	O
+Relative	O
+Error	O
+(	O
+RMSRE	O
+),	O
+Root	B-ANAT
+Mean	O
+Squared	O
+Relative	O
+Error	O
+(	O
+RMSRE	O
+),	O
+coefficient	O
+of	O
+determination	O
+(	O
+R	O
+2	O
+),	O
+and	O
+computing	O
+time	O
+.	O
+
+While	O
+Combating	O
+the	O
+2019	B-SPEC
+Novel	I-SPEC
+Coronavirus	I-SPEC
+.	O
+
+SARS	B-PRGE
+-	I-PRGE
+CoV	I-PRGE
+-	I-PRGE
+2	I-PRGE
+revealed	O
+in	O
+1	O
+(	O
+7	O
+.	O
+7	O
+%)	O
+of	O
+13	O
+environmental	B-SPEC
+samples	I-SPEC
+,	O
+but	O
+not	O
+in	O
+8	O
+air	B-CHED
+samples	O
+collected	O
+at	O
+a	O
+distance	O
+of	O
+10	O
+cm	O
+from	O
+patient	O
+'	O
+s	O
+chin	B-ANAT
+with	O
+or	O
+without	O
+wearing	O
+a	O
+surgical	O
+mask	O
+.	O
+
+TITLE	O
+:	O
+Improved	O
+molecular	O
+diagnosis	O
+of	O
+COVID	B-DISO
+-	I-DISO
+19	I-DISO
+by	O
+the	O
+novel	O
+,	O
+highly	O
+sensitive	O
+and	O
+specific	O
+COVID	B-DISO
+-	I-DISO
+19	I-DISO
+-	O
+RdRp	B-FUNC
+/	O
+Hel	B-PRGE
+real	O
+-	O
+time	O
+reverse	B-PROC
+transcription	I-PROC
+-	O
+polymerase	O
+chain	O
+reaction	O
+assay	O
+validated	O
+ABSTRACT	O
+:	O
+On	O
+31	O
+
+ABSTRACT	O
+:	O
+An	O
+outbreak	O
+of	O
+clusters	O
+of	O
+viral	B-DISO
+pneumonia	I-DISO
+due	O
+to	O
+a	O
+novel	B-SPEC
+coronavirus	I-SPEC
+(	O
+2019	B-SPEC
+-	I-SPEC
+nCoV	I-SPEC
+/	O
+SARS	B-SPEC
+-	I-SPEC
+CoV	I-SPEC
+-	I-SPEC
+2	I-SPEC
+)	O
+happened	O
+in	O
+Wuhan	O
+,	O
+Hubei	O
+Province	O
+in	O
+China	O
+in	O
+December	O
+2019	O
+.	O
+
+ABSTRACT	O
+:	O
+In	O
+late	O
+December	O
+2019	O
+,	O
+a	O
+cluster	O
+of	O
+cases	O
+with	O
+2019	O
+Novel	O
+Coronavirus	O
+pneumonia	B-DISO
+(	O
+SARS	B-PRGE
+-	I-PRGE
+CoV	I-PRGE
+-	I-PRGE
+2	I-PRGE
+)	O
+in	O
+Wuhan	O
+,	O
+China	O
+,	O
+aroused	O
+worldwide	O
+concern	O
+.	O
+
+TITLE	O
+:	O
+[	O
+Analysis	O
+of	O
+bronchoscope	O
+-	O
+guided	O
+tracheal	O
+intubation	O
+in	O
+12	O
+cases	O
+with	O
+COVID	B-DISO
+-	I-DISO
+19	I-DISO
+under	O
+the	O
+personal	O
+protective	O
+equipment	O
+with	O
+positive	O
+pressure	O
+protective	O
+hood	O
+].	O
+
+The	O
+9	O
+healthcare	O
+workers	O
+who	O
+involved	O
+in	O
+intubation	O
+received	O
+virus	B-SPEC
+nucleic	B-CHED
+acid	I-CHED
+test	O
+and	O
+14	O
+days	O
+temperature	O
+monitoring	O
+.	O
+
+The	O
+9	O
+healthcare	O
+workers	O
+were	O
+protected	O
+under	O
+the	O
+Personal	O
+Protective	O
+Equipment	O
+(	O
+PPE	B-CHED
+)	O
+with	O
+positive	O
+pressure	O
+protective	O
+hood	O
+.	O
+
+Patients	O
+≥	O
+18	O
+years	O
+of	O
+age	O
+with	O
+moderate	O
+-	O
+to	O
+-	O
+severe	O
+ARDS	B-DISO
+were	O
+included	O
+.	O
+
+The	O
+mean	O
+change	O
+in	O
+Pao	B-PROC
+CONCLUSIONS	O
+:	O
+Fixed	B-ANAT
+-	O
+dose	O
+iEPO	O
+was	O
+comparable	O
+to	O
+iNO	B-PRGE
+in	O
+patients	O
+with	O
+moderate	O
+-	O
+to	O
+-	O
+severe	O
+ARDS	B-DISO
+for	O
+oxygenation	B-PROC
+and	O
+ventilation	O
+parameters	O
+as	O
+well	O
+as	O
+clinical	O
+outcomes	O
+.	O
+
+The	O
+infection	B-DISO
+occurs	O
+with	O
+a	O
+unique	O
+spectrum	O
+of	O
+bacterial	O
+pathogens	O
+that	O
+are	O
+usually	O
+acquired	O
+in	O
+an	O
+age	O
+-	O
+dependent	O
+fashion	O
+.	O
+
+Fungi	B-SPEC
+and	O
+mycobacteria	B-SPEC
+were	O
+isolated	O
+from	O
+23	O
+(	O
+22	O
+.	O
+1	O
+%)	O
+and	O
+four	O
+(	O
+3	O
+.	O
+8	O
+%)	O
+children	O
+,	O
+respectively	O
+.	O
+
+All	O
+the	O
+patients	O
+were	O
+undergone	O
+chest	B-ANAT
+CT	O
+in	O
+our	O
+hospital	O
+.	O
+
+Thirteen	O
+pediatric	O
+patients	O
+(	O
+13	O
+/	O
+20	O
+,	O
+65	O
+%)	O
+had	O
+an	O
+identified	O
+history	O
+of	O
+close	O
+contact	O
+with	O
+COVID	B-DISO
+-	I-DISO
+19	I-DISO
+diagnosed	O
+family	B-SPEC
+members	O
+.	O
+
+Coinfection	B-DISO
+(	O
+8	O
+/	O
+20	O
+,	O
+40	O
+%)	O
+is	O
+common	O
+in	O
+pediatric	O
+patients	O
+.	O
+
+It	O
+is	O
+suggested	O
+that	O
+underlying	O
+coinfection	B-DISO
+may	O
+be	O
+more	O
+common	O
+in	O
+pediatrics	O
+,	O
+and	O
+the	O
+consolidation	O
+with	O
+surrounding	O
+halo	B-DISO
+sign	I-DISO
+which	O
+is	O
+considered	O
+as	O
+a	O
+typical	O
+sign	O
+in	O
+pediatric	O
+patients	O
+.	O
+
+Consolidation	O
+with	O
+surrounding	O
+halo	B-DISO
+sign	I-DISO
+was	O
+observed	O
+in	O
+10	O
+patients	O
+(	O
+10	O
+/	O
+20	O
+,	O
+50	O
+%),	O
+ground	O
+-	O
+glass	O
+opacities	B-DISO
+were	O
+observed	O
+in	O
+12	O
+patients	O
+(	O
+12	O
+/	O
+20	O
+,	O
+60	O
+%),	O
+fine	O
+mesh	O
+shadow	O
+was	O
+observed	O
+in	O
+4	O
+patients	O
+(	O
+4	O
+/	O
+20	O
+,	O
+20	O
+%),	O
+and	O
+tiny	O
+nodules	B-DISO
+were	O
+observed	O
+in	O
+3	O
+patients	O
+(	O
+3	O
+/	O
+20	O
+,	O
+15	O
+%).	O
+
+The	O
+therapeutic	O
+potential	O
+of	O
+monoclonal	O
+antibodies	B-COMP
+has	O
+been	O
+well	O
+recognized	O
+in	O
+the	O
+treatment	O
+of	O
+many	O
+diseases	O
+.	O
+
+TITLE	O
+:	O
+Lack	O
+of	O
+Vertical	B-DISO
+Transmission	I-DISO
+of	O
+Severe	B-SPEC
+Acute	I-SPEC
+Respiratory	I-SPEC
+Syndrome	I-SPEC
+Coronavirus	I-SPEC
+2	I-SPEC
+,	O
+China	O
+.	O
+
+ABSTRACT	O
+:	O
+Cytomegalovirus	B-SPEC
+(	O
+CMV	B-SPEC
+)	O
+reactivation	O
+has	O
+been	O
+described	O
+in	O
+adults	O
+with	O
+critical	B-DISO
+illness	I-DISO
+caused	O
+by	O
+diverse	O
+etiologies	O
+,	O
+especially	O
+severe	B-DISO
+sepsis	I-DISO
+,	O
+and	O
+observational	O
+studies	O
+have	O
+linked	O
+CMV	B-SPEC
+reactivation	O
+with	O
+worse	O
+clinical	O
+outcomes	O
+in	O
+this	O
+setting	O
+.	O
+
+ABSTRACT	O
+:	O
+In	O
+late	O
+December	O
+,	O
+2019	O
+,	O
+an	O
+outbreak	O
+of	O
+coronavirus	O
+disease	O
+(	O
+COVID	B-DISO
+-	I-DISO
+19	I-DISO
+)	O
+in	O
+Wuhan	O
+,	O
+China	O
+was	O
+caused	O
+by	O
+a	O
+novel	B-SPEC
+coronavirus	I-SPEC
+,	O
+newly	O
+named	O
+severe	B-SPEC
+acute	I-SPEC
+respiratory	I-SPEC
+syndrome	I-SPEC
+coronavirus	I-SPEC
+2	I-SPEC
+(	O
+SARS	B-SPEC
+-	I-SPEC
+CoV	I-SPEC
+-	I-SPEC
+2	I-SPEC
+).	O
+
+We	O
+aimed	O
+to	O
+quantify	O
+severity	O
+of	O
+COVID	B-DISO
+-	I-DISO
+19	I-DISO
+infection	I-DISO
+on	O
+High	O
+-	O
+Resolution	O
+CT	O
+and	O
+to	O
+determine	O
+its	O
+relationship	O
+with	O
+clinical	O
+parameters	O
+.	O
+
+From	O
+Jan	O
+11	O
+,	O
+2020	O
+,	O
+to	O
+Feb	O
+5	O
+,	O
+2020	O
+,	O
+the	O
+clinical	O
+,	O
+laboratory	O
+and	O
+HRCT	O
+features	O
+of	O
+42	O
+patients	O
+(	O
+26	O
+-	O
+75	O
+years	O
+,	O
+25	O
+males	O
+)	O
+with	O
+COVID	B-DISO
+-	I-DISO
+19	I-DISO
+were	O
+analyzed	O
+.	O
+
+TITLE	O
+:	O
+The	O
+outbreak	O
+of	O
+COVID	B-DISO
+-	I-DISO
+19	I-DISO
+:	O
+An	O
+overview	O
+.	O
+
+COVID	B-DISO
+-	I-DISO
+19	I-DISO
+is	O
+a	O
+potential	O
+zoonotic	O
+disease	O
+with	O
+low	O
+to	O
+moderate	O
+(	O
+estimated	O
+2	O
+%-	O
+5	O
+%)	O
+mortality	O
+rate	O
+.	O
+
+Person	O
+-	O
+to	O
+-	O
+person	O
+transmission	O
+may	O
+occur	O
+through	O
+droplet	O
+or	O
+contact	O
+transmission	O
+and	O
+if	O
+there	O
+is	O
+a	O
+lack	O
+of	O
+stringent	O
+infection	B-DISO
+control	O
+or	O
+if	O
+no	O
+proper	O
+personal	O
+protective	O
+equipment	O
+available	O
+,	O
+it	O
+may	O
+jeopardize	O
+the	O
+first	O
+-	O
+line	O
+healthcare	O
+workers	O
+.	O
+
+The	O
+disease	O
+spread	O
+widely	O
+in	O
+China	O
+,	O
+and	O
+,	O
+as	O
+of	O
+February	O
+26	O
+,	O
+2020	O
+,	O
+COVID	B-DISO
+-	I-DISO
+19	I-DISO
+cases	O
+had	O
+been	O
+identified	O
+in	O
+36	O
+other	O
+countries	O
+and	O
+territories	O
+,	O
+including	O
+the	O
+United	O
+States	O
+.	O
+
+Although	O
+the	O
+origin	O
+(	O
+s	O
+)	O
+of	O
+these	O
+viruses	B-SPEC
+are	O
+still	O
+unknown	O
+and	O
+their	O
+occurrences	O
+in	O
+nature	O
+are	O
+mysterious	O
+,	O
+some	O
+general	O
+patterns	O
+of	O
+their	O
+pathogenesis	B-DISO
+and	O
+epidemics	O
+are	O
+noticeable	O
+.	O
+
+However	O
+,	O
+some	O
+unique	O
+factors	O
+might	O
+also	O
+contribute	O
+to	O
+the	O
+origination	O
+of	O
+SARS	B-DISO
+in	O
+Wuhan	O
+.	O
+
+Diagnosis	O
+is	O
+confirmed	O
+with	O
+PCR	O
+based	O
+testing	O
+of	O
+appropriate	O
+respiratory	B-ANAT
+samples	I-ANAT
+.	O
+
+Standard	O
+infection	B-DISO
+control	O
+and	O
+prevention	O
+techniques	O
+should	O
+be	O
+followed	O
+.	O
+
+In	O
+this	O
+article	O
+,	O
+we	O
+aim	O
+to	O
+highlight	O
+the	O
+necessity	O
+of	O
+implementing	O
+protective	O
+measures	O
+,	O
+and	O
+recommend	O
+how	O
+to	O
+set	O
+proper	O
+emergency	B-DISO
+management	O
+plans	O
+for	O
+preventing	O
+and	O
+controlling	O
+nosocomial	B-DISO
+infection	I-DISO
+of	O
+2019	B-SPEC
+-	I-SPEC
+nCoV	I-SPEC
+in	O
+dermatology	O
+departments	O
+.	O
+
+COVID	B-DISO
+-	I-DISO
+19	I-DISO
+is	O
+similar	O
+to	O
+Severe	B-DISO
+Acute	I-DISO
+Respiratory	I-DISO
+Syndrome	I-DISO
+coronavirus	B-SPEC
+(	O
+SARS	B-DISO
+-	O
+CoV	O
+)	O
+virus	B-SPEC
+in	O
+its	O
+pathogenicity	O
+,	O
+clinical	O
+spectrum	O
+,	O
+and	O
+epidemiology	O
+.	O
+
+Comparison	O
+of	O
+the	O
+genome	O
+sequences	O
+of	O
+COVID	B-DISO
+-	I-DISO
+19	I-DISO
+,	O
+SARS	B-DISO
+-	O
+CoV	O
+,	O
+and	O
+Middle	O
+East	O
+Respiratory	O
+Syndrome	B-DISO
+coronavirus	B-SPEC
+(	O
+MERS	O
+-	O
+CoV	O
+)	O
+showed	O
+that	O
+COVID	B-DISO
+-	I-DISO
+19	I-DISO
+has	O
+a	O
+better	O
+sequence	O
+identity	O
+with	O
+SARS	B-DISO
+-	O
+CoV	O
+compared	O
+to	O
+MERS	O
+CoV	O
+.	O
+However	O
+,	O
+the	O
+amino	B-CHED
+acid	I-CHED
+sequence	O
+of	O
+COVID	B-DISO
+-	I-DISO
+19	I-DISO
+differs	O
+from	O
+other	O
+coronaviruses	O
+specifically	O
+in	O
+the	O
+regions	O
+of	O
+1ab	O
+polyprotein	O
+and	O
+surface	O
+glycoprotein	B-CHED
+or	O
+S	B-PRGE
+-	I-PRGE
+protein	I-PRGE
+.	O
+
+TITLE	O
+:	O
+Novel	B-SPEC
+coronavirus	I-SPEC
+2019	B-SPEC
+-	I-SPEC
+nCoV	I-SPEC
+:	O
+prevalence	O
+,	O
+biological	O
+and	O
+clinical	O
+characteristics	O
+comparison	O
+with	O
+SARS	O
+-	O
+CoV	O
+and	O
+MERS	O
+-	O
+CoV	O
+.	O
+ABSTRACT	O
+:	O
+Human	B-SPEC
+infections	B-DISO
+with	O
+zoonotic	O
+coronavirus	B-SPEC
+contain	O
+emerging	O
+and	O
+reemerging	O
+pathogenic	O
+characteristics	O
+which	O
+have	O
+raised	O
+great	O
+public	O
+health	O
+concern	O
+.	O
+
+ABSTRACT	O
+:	O
+Using	O
+the	O
+parameterized	O
+susceptible	O
+-	O
+exposed	O
+-	O
+infectious	O
+-	O
+recovered	O
+model	O
+,	O
+we	O
+simulated	O
+the	O
+spread	O
+dynamics	O
+of	O
+coronavirus	B-DISO
+disease	I-DISO
+2019	I-DISO
+(	O
+COVID	B-DISO
+-	I-DISO
+19	I-DISO
+)	O
+outbreak	O
+and	O
+impact	O
+of	O
+different	O
+control	O
+measures	O
+,	O
+conducted	O
+the	O
+sensitivity	O
+analysis	O
+to	O
+identify	O
+the	O
+key	O
+factor	O
+,	O
+plotted	O
+the	O
+trend	O
+curve	O
+of	O
+effective	O
+reproductive	B-PROC
+number	O
+(	O
+R	O
+),	O
+and	O
+performed	O
+data	O
+fitting	B-DISO
+after	O
+the	O
+simulation	O
+.	O
+
+ABSTRACT	O
+:	O
+The	O
+recent	O
+emergence	O
+of	O
+the	O
+novel	O
+,	O
+pathogenic	O
+SARS	B-PRGE
+-	I-PRGE
+coronavirus	B-SPEC
+2	I-PRGE
+(	O
+SARS	B-PRGE
+-	I-PRGE
+CoV	I-PRGE
+-	I-PRGE
+2	I-PRGE
+)	O
+in	O
+China	O
+and	O
+its	O
+rapid	O
+national	O
+and	O
+international	O
+spread	O
+pose	O
+a	O
+global	O
+health	O
+emergency	B-DISO
+.	O
+
+A	O
+TMPRSS2	O
+inhibitor	B-CHED
+approved	O
+for	O
+clinical	O
+use	O
+blocked	O
+entry	O
+and	O
+might	O
+constitute	O
+a	O
+treatment	O
+option	O
+.	O
+
+Our	O
+results	O
+reveal	O
+important	O
+commonalities	O
+between	O
+SARS	B-SPEC
+-	I-SPEC
+CoV	I-SPEC
+-	I-SPEC
+2	I-SPEC
+and	O
+SARS	B-DISO
+-	I-DISO
+CoV	I-DISO
+infection	I-DISO
+and	O
+identify	O
+a	O
+potential	O
+target	O
+for	O
+antiviral	B-CHED
+intervention	O
+.	O
+
+TITLE	O
+:	O
+Nonstructural	O
+proteins	B-CHED
+NS7b	O
+and	O
+NS8	O
+are	O
+likely	O
+to	O
+be	O
+phylogenetically	O
+associated	O
+with	O
+evolution	B-PROC
+of	O
+2019	B-SPEC
+-	I-SPEC
+nCoV	I-SPEC
+.	O
+ABSTRACT	O
+:	O
+The	O
+seventh	O
+novel	O
+human	B-SPEC
+infecting	O
+Betacoronavirus	B-SPEC
+that	O
+causes	O
+pneumonia	B-DISO
+(	O
+2019	B-SPEC
+novel	I-SPEC
+coronavirus	I-SPEC
+,	O
+2019	B-SPEC
+-	I-SPEC
+nCoV	I-SPEC
+)	O
+originated	O
+in	O
+Wuhan	O
+,	O
+China	O
+.	O
+
+ABSTRACT	O
+:	O
+Coronaviruses	O
+(	O
+CoVs	O
+)	O
+are	O
+RNA	O
+viruses	B-SPEC
+that	O
+have	O
+become	O
+a	O
+major	O
+public	O
+health	O
+concern	O
+since	O
+the	O
+Severe	B-DISO
+Acute	I-DISO
+Respiratory	I-DISO
+Syndrome	I-DISO
+-	O
+CoV	O
+(	O
+SARS	B-DISO
+-	O
+CoV	O
+)	O
+outbreak	O
+in	O
+2002	O
+.	O
+
+ABSTRACT	O
+:	O
+After	O
+the	O
+2019	O
+novel	O
+coronavirus	O
+(	O
+2019	B-SPEC
+-	I-SPEC
+nCoV	I-SPEC
+)	O
+outbreak	O
+,	O
+we	O
+estimated	O
+the	O
+distribution	O
+and	O
+scale	O
+of	O
+more	O
+than	O
+5	O
+million	O
+migrants	O
+residing	O
+in	O
+Wuhan	O
+after	O
+they	O
+returned	O
+to	O
+their	O
+hometown	O
+communities	O
+in	O
+Hubei	O
+Province	O
+or	O
+other	O
+provinces	O
+at	O
+the	O
+end	O
+of	O
+2019	O
+by	O
+using	O
+the	O
+data	O
+from	O
+the	O
+2013	O
+-	O
+2018	O
+China	O
+Migrants	O
+Dynamic	O
+Survey	O
+(	O
+CMDS	O
+).	O
+
+Their	O
+social	O
+characteristics	O
+include	O
+nuclear	O
+family	O
+migration	B-PROC
+(	O
+84	O
+%),	O
+migration	B-PROC
+with	O
+families	O
+of	O
+3	O
+-	O
+4	O
+members	O
+(	O
+71	O
+%),	O
+a	O
+rural	O
+household	O
+registration	O
+(	O
+85	O
+%),	O
+and	O
+working	O
+or	O
+doing	O
+business	O
+(	O
+84	O
+%)	O
+as	O
+the	O
+main	O
+reason	O
+for	O
+migration	B-PROC
+.	O
+
+ABSTRACT	O
+:	O
+The	O
+2019	O
+-	O
+nCoV	O
+is	O
+officially	O
+called	O
+SARS	B-PRGE
+-	I-PRGE
+CoV	I-PRGE
+-	I-PRGE
+2	I-PRGE
+and	O
+the	O
+disease	O
+is	O
+named	O
+COVID	B-DISO
+-	I-DISO
+19	I-DISO
+.	O
+
+Bats	B-SPEC
+,	O
+snakes	B-SPEC
+and	O
+pangolins	B-SPEC
+have	O
+been	O
+cited	O
+as	O
+potential	O
+carriers	O
+based	O
+on	O
+the	O
+sequence	O
+homology	O
+of	O
+CoV	O
+isolated	O
+from	O
+these	O
+animals	B-SPEC
+and	O
+the	O
+viral	O
+nucleic	B-CHED
+acids	I-CHED
+of	O
+the	O
+virus	B-SPEC
+isolated	O
+from	O
+SARS	B-DISO
+-	I-SPEC
+CoV	I-SPEC
+-	I-SPEC
+2	I-SPEC
+infected	O
+patients	O
+.	O
+
+Intermittent	O
+sporadic	O
+cases	O
+,	O
+community	O
+clusters	B-CHED
+,	O
+and	O
+nosocomial	O
+outbreaks	O
+of	O
+MERS	O
+-	O
+CoV	O
+continue	O
+to	O
+occur	O
+.	O
+
+We	O
+employe	O
+the	O
+estimates	O
+of	O
+these	O
+two	O
+key	O
+components	O
+from	O
+the	O
+1918	O
+influenza	B-DISO
+pandemic	O
+in	O
+London	O
+,	O
+United	O
+Kingdom	B-SPEC
+,	O
+incorporated	O
+zoonotic	O
+introductions	O
+and	O
+the	O
+emigration	O
+,	O
+and	O
+then	O
+compute	O
+future	O
+trends	O
+and	O
+the	O
+reporting	O
+ratio	O
+.	O
+
+Accounting	O
+for	O
+right	O
+truncation	B-DISO
+and	O
+analyzing	O
+all	O
+pairs	O
+,	O
+we	O
+estimated	O
+the	O
+median	O
+serial	O
+interval	O
+at	O
+4	O
+.	O
+0	O
+days	O
+(	O
+95	O
+%	O
+credible	O
+interval	O
+[	O
+CrI	O
+]:	O
+3	O
+.	O
+1	O
+,	O
+4	O
+.	O
+9	O
+).	O
+
+From	O
+February	O
+5	O
+,	O
+2020	O
+to	O
+February	O
+21	O
+,	O
+2020	O
+,	O
+634	O
+persons	O
+were	O
+infected	O
+in	O
+the	O
+Diamond	B-CHED
+Princess	O
+Liner	O
+.	O
+
+Even	O
+if	O
+traditional	O
+public	O
+health	O
+measures	O
+are	O
+not	O
+able	O
+to	O
+fully	O
+contain	O
+the	O
+outbreak	O
+of	O
+COVID	O
+-	O
+19	O
+,	O
+they	O
+will	O
+still	O
+be	O
+effective	O
+in	O
+reducing	O
+peak	O
+incidence	O
+and	O
+global	O
+deaths	B-PROC
+.	O
+
+The	O
+current	O
+study	O
+provides	O
+the	O
+first	O
+serological	O
+evidence	O
+of	O
+occupational	O
+exposure	O
+of	O
+humans	B-SPEC
+to	O
+MERS	O
+-	O
+CoV	O
+in	O
+Africa	O
+.	O
+
+Overall	O
+,	O
+the	O
+asymptomatic	O
+carriers	O
+identified	O
+from	O
+close	O
+contacts	O
+were	O
+prone	O
+to	O
+be	O
+mildly	O
+ill	B-DISO
+during	O
+hospitalization	O
+.	O
+
+These	O
+results	O
+highlighted	O
+the	O
+importance	O
+of	O
+close	O
+contact	O
+tracing	O
+and	O
+longitudinally	O
+surveillance	O
+via	O
+virus	B-SPEC
+nucleic	B-CHED
+acid	I-CHED
+tests	O
+.	O
+
+The	O
+scientific	O
+community	O
+should	O
+consider	O
+this	O
+information	O
+in	O
+light	O
+of	O
+previous	O
+experiments	O
+with	O
+chloroquine	B-CHED
+in	O
+the	O
+field	O
+of	O
+antiviral	B-CHED
+research	O
+.	O
+
+ABSTRACT	O
+:	O
+The	O
+ongoing	O
+outbreak	O
+of	O
+COVID	O
+-	O
+19	O
+that	O
+began	O
+in	O
+Wuhan	O
+,	O
+China	O
+,	O
+has	O
+constituted	O
+a	O
+Public	O
+Health	O
+Emergency	B-DISO
+of	O
+International	O
+Concern	O
+,	O
+with	O
+cases	O
+confirmed	O
+in	O
+multiple	O
+countries	O
+.	O
+
+Currently	O
+patients	O
+are	O
+the	O
+main	O
+source	O
+of	O
+infection	B-DISO
+.	O
+
+Several	O
+drugs	O
+such	O
+as	O
+chloroquine	B-CHED
+,	O
+arbidol	O
+,	O
+remdesivir	O
+,	O
+and	O
+favipiravir	O
+are	O
+currently	O
+undergoing	O
+clinical	O
+studies	O
+to	O
+test	O
+their	O
+efficacy	O
+and	O
+safety	O
+in	O
+the	O
+treatment	O
+of	O
+coronavirus	B-DISO
+disease	I-DISO
+2019	I-DISO
+(	O
+COVID	B-DISO
+-	I-DISO
+19	I-DISO
+)	O
+in	O
+China	O
+;	O
+some	O
+promising	O
+results	O
+have	O
+been	O
+achieved	O
+thus	O
+far	O
+.	O
+
+TITLE	O
+:	O
+Clarithromycin	B-CHED
+-	O
+Associated	O
+Acute	B-DISO
+Liver	I-DISO
+Failure	I-DISO
+Leading	O
+to	O
+Fatal	O
+,	O
+Massive	O
+Upper	B-ANAT
+Gastrointestinal	I-ANAT
+Hemorrhage	I-DISO
+from	O
+Profound	O
+Coagulopathy	B-DISO
+:	O
+Case	O
+Report	O
+and	O
+Systematic	O
+Literature	O
+Review	O
+.	O
+
+ABSTRACT	O
+:	O
+While	O
+erythromycin	B-CHED
+has	O
+caused	O
+numerous	O
+cases	O
+of	O
+acute	B-DISO
+liver	I-DISO
+failure	I-DISO
+(	O
+ALF	B-DISO
+),	O
+clarithromycin	B-CHED
+,	O
+a	O
+similar	O
+macrolide	B-CHED
+antibiotic	I-CHED
+,	O
+has	O
+caused	O
+only	O
+six	O
+reported	O
+cases	O
+of	O
+ALF	B-DISO
+.	O
+
+A	O
+new	O
+case	O
+of	O
+clarithromycin	B-CHED
+-	O
+associated	O
+ALF	B-PRGE
+is	O
+reported	O
+with	O
+hepatic	B-ANAT
+histopathology	O
+and	O
+exclusion	O
+of	O
+other	O
+etiologies	O
+by	O
+extensive	O
+workup	O
+,	O
+and	O
+the	O
+syndrome	B-DISO
+of	O
+clarithromycin	B-CHED
+-	O
+associated	O
+ALF	O
+is	O
+better	O
+characterized	O
+by	O
+systematic	O
+review	O
+.	O
+
+The	O
+six	O
+previously	O
+reported	O
+cases	O
+were	O
+limited	O
+by	O
+failure	O
+to	O
+exclude	O
+hepatitis	B-DISO
+E	I-DISO
+(	O
+4	O
+),	O
+lack	O
+of	O
+liver	B-ANAT
+biopsy	O
+(	O
+2	O
+),	O
+and	O
+uninterpretable	O
+liver	B-ANAT
+biopsy	O
+(	O
+1	O
+)	O
+and	O
+by	O
+confounding	O
+potential	O
+etiologies	O
+including	O
+disulfiram	B-CHED
+,	O
+israpidine	O
+,	O
+or	O
+recent	O
+acetaminophen	B-CHED
+use	O
+(	O
+3	O
+),	O
+clarithromycin	B-CHED
+overdose	O
+(	O
+1	O
+),	O
+active	O
+alcohol	O
+use	O
+(	O
+1	O
+),	O
+and	O
+severe	O
+heart	B-DISO
+failure	I-DISO
+(	O
+1	O
+).	O
+
+Upper	O
+and	O
+lower	B-ANAT
+respiratory	I-ANAT
+tract	I-ANAT
+secretion	B-PROC
+samples	O
+from	O
+putative	O
+patients	O
+with	O
+COVID	B-DISO
+-	I-DISO
+19	I-DISO
+were	O
+inoculated	O
+onto	O
+cells	B-COMP
+to	O
+isolate	O
+the	O
+virus	B-SPEC
+.	O
+
+TITLE	O
+:	O
+Fear	O
+can	O
+be	O
+more	O
+harmful	O
+than	O
+the	O
+severe	B-SPEC
+acute	I-SPEC
+respiratory	I-SPEC
+syndrome	I-SPEC
+coronavirus	I-SPEC
+2	I-SPEC
+in	O
+controlling	O
+the	O
+corona	O
+virus	B-PROC
+disease	I-PROC
+2019	O
+epidemic	O
+.	O
+
+The	O
+management	O
+of	O
+severe	O
+respiratory	B-DISO
+infections	I-DISO
+should	O
+consider	O
+investigation	O
+and	O
+empirical	O
+coverage	O
+for	O
+the	O
+most	O
+likely	O
+agents	O
+based	O
+on	O
+syndromic	O
+surveillance	O
+data	O
+from	O
+hosting	O
+country	O
+and	O
+/	O
+or	O
+other	O
+relevant	O
+exposure	O
+history	O
+during	O
+events	O
+.	O
+
+TITLE	O
+:	O
+Repurposing	O
+of	O
+clinically	O
+approved	O
+drugs	O
+for	O
+treatment	O
+of	O
+coronavirus	B-DISO
+disease	I-DISO
+2019	I-DISO
+in	O
+a	O
+2019	O
+-	O
+novel	O
+coronavirus	O
+(	O
+2019	B-SPEC
+-	I-SPEC
+nCoV	I-SPEC
+)	O
+related	O
+coronavirus	B-SPEC
+model	O
+.	O
+
+This	O
+study	O
+aims	O
+to	O
+repurpose	O
+the	O
+clinically	O
+approved	O
+drugs	O
+for	O
+the	O
+treatment	O
+of	O
+coronavirus	B-DISO
+disease	I-DISO
+2019	I-DISO
+(	O
+COVID	B-DISO
+-	I-DISO
+19	I-DISO
+)	O
+in	O
+a	O
+2019	B-SPEC
+-	I-SPEC
+nCoV	I-SPEC
+related	O
+coronavirus	B-SPEC
+model	O
+.	O
+
+Viral	O
+yields	O
+of	O
+RNAs	O
+and	O
+infectious	B-DISO
+particles	O
+were	O
+quantified	O
+by	O
+quantitative	O
+real	O
+-	O
+time	O
+polymerase	O
+chain	O
+reaction	O
+(	O
+qRT	O
+-	O
+PCR	O
+)	O
+and	O
+plaque	B-DISO
+assay	O
+,	O
+respectively	O
+.	O
+
+Plaque	B-DISO
+assays	O
+found	O
+no	O
+production	O
+of	O
+live	O
+viruses	B-SPEC
+in	O
+media	B-ANAT
+containing	O
+10	O
+μmol	O
+/	O
+L	O
+CEP	B-DISO
+at	O
+48	O
+h	O
+p	O
+.	O
+i	O
+.	O
+
+CEP	B-DISO
+,	O
+selamectin	O
+and	O
+mefloquine	B-CHED
+hydrochloride	B-CHED
+are	O
+potential	O
+drugs	O
+for	O
+treating	O
+2019	B-DISO
+-	I-DISO
+nCoV	I-DISO
+infection	I-DISO
+.	O
+
+Our	O
+results	O
+strongly	O
+suggest	O
+that	O
+CEP	B-DISO
+is	O
+a	O
+wide	O
+-	O
+spectrum	O
+inhibitor	B-CHED
+of	O
+pan	B-COMP
+-	O
+betacoronavirus	B-SPEC
+,	O
+and	O
+clinical	O
+trial	O
+of	O
+CEP	B-DISO
+for	O
+treatment	O
+of	O
+2019	B-DISO
+-	I-DISO
+nCoV	I-DISO
+infection	I-DISO
+is	O
+warranted	O
+.	O
+
+TITLE	O
+:	O
+Effectiveness	O
+of	O
+glucocorticoid	B-CHED
+therapy	O
+in	O
+patients	O
+with	O
+severe	O
+novel	B-SPEC
+coronavirus	I-SPEC
+pneumonia	B-DISO
+:	O
+protocol	O
+of	O
+a	O
+randomized	O
+controlled	O
+trial	O
+.	O
+
+However	O
+,	O
+a	O
+significant	O
+fraction	O
+of	O
+these	O
+patients	O
+goes	B-SPEC
+on	O
+to	O
+subsequently	O
+develop	O
+serious	O
+lower	O
+respiratory	B-DISO
+disease	I-DISO
+.	O
+
+In	O
+the	O
+last	O
+twenty	O
+years	O
+,	O
+several	O
+viral	O
+epidemics	O
+such	O
+as	O
+the	O
+severe	O
+acute	O
+respiratory	O
+syndrome	O
+coronavirus	B-SPEC
+(	O
+SARS	B-DISO
+-	O
+CoV	O
+)	O
+in	O
+2002	O
+to	O
+2003	O
+,	O
+and	O
+H1N1	B-DISO
+influenza	I-DISO
+in	O
+2009	O
+,	O
+have	O
+been	O
+recorded	O
+.	O
+
+In	O
+a	O
+timeline	O
+that	O
+reaches	O
+the	O
+present	O
+day	O
+,	O
+an	O
+epidemic	O
+of	O
+cases	O
+with	O
+unexplained	O
+low	O
+respiratory	B-DISO
+infections	I-DISO
+detected	O
+in	O
+Wuhan	O
+,	O
+the	O
+largest	O
+metropolitan	O
+area	O
+in	O
+China	O
+'	O
+s	O
+Hubei	O
+province	O
+,	O
+was	O
+first	O
+reported	O
+to	O
+the	O
+WHO	O
+Country	O
+Office	O
+in	O
+China	O
+,	O
+on	O
+December	O
+31	O
+,	O
+2019	O
+.	O
+
+As	O
+they	O
+were	O
+unable	O
+to	O
+identify	O
+the	O
+causative	O
+agent	O
+,	O
+these	O
+first	O
+cases	O
+were	O
+classified	O
+as	O
+""""	O
+pneumonia	B-DISO
+of	O
+unknown	O
+etiology	O
+.	O
+
+On	O
+February	O
+11	O
+,	O
+2020	O
+,	O
+the	O
+WHO	O
+Director	O
+-	O
+General	O
+,	O
+Dr	O
+.	O
+Tedros	O
+Adhanom	O
+Ghebreyesus	O
+,	O
+announced	O
+that	O
+the	O
+disease	O
+caused	O
+by	O
+this	O
+new	O
+CoV	O
+was	O
+a	O
+""""	O
+COVID	B-DISO
+-	I-DISO
+19	I-DISO
+","""	O
+which	O
+is	O
+the	O
+acronym	O
+of	O
+""""	O
+coronavirus	B-DISO
+disease	I-DISO
+2019	I-DISO
+"""."	O
+
+In	O
+the	O
+past	O
+twenty	O
+years	O
+,	O
+two	O
+additional	O
+coronavirus	B-SPEC
+epidemics	O
+have	O
+occurred	O
+.	O
+
+Interestingly	O
+,	O
+these	O
+latter	O
+viruses	B-SPEC
+have	O
+probably	O
+originated	O
+from	O
+bats	B-SPEC
+and	O
+then	O
+moving	B-PROC
+into	O
+other	O
+mammalian	B-SPEC
+hosts	B-COMP
+—	O
+the	O
+Himalayan	O
+palm	B-ANAT
+civet	B-SPEC
+for	O
+SARS	B-PRGE
+-	I-PRGE
+CoV	I-PRGE
+,	O
+and	O
+the	O
+dromedary	B-SPEC
+camel	B-SPEC
+for	O
+MERS	O
+-	O
+CoV	O
+—	O
+before	O
+jumping	O
+to	O
+humans	B-SPEC
+.	O
+
+World	O
+governments	O
+are	O
+at	O
+work	O
+to	O
+establish	O
+countermeasures	O
+to	O
+stem	B-ANAT
+possible	O
+devastating	O
+effects	O
+.	O
+
+Many	O
+uncertainties	O
+remain	O
+with	O
+regard	O
+to	O
+both	O
+the	O
+virus	B-PROC
+-	I-PROC
+host	B-COMP
+interaction	I-PROC
+and	O
+the	O
+evolution	B-PROC
+of	O
+the	O
+epidemic	O
+,	O
+with	O
+specific	O
+reference	O
+to	O
+the	O
+times	O
+when	O
+the	O
+epidemic	O
+will	O
+reach	B-PROC
+its	O
+peak	O
+.	O
+
+Aggressive	B-DISO
+isolation	O
+measures	O
+in	O
+China	O
+have	O
+led	O
+to	O
+a	O
+progressive	O
+reduction	O
+of	O
+cases	O
+in	O
+the	O
+last	O
+few	O
+days	O
+.	O
+
+Respiratory	B-ANAT
+tract	I-ANAT
+specimens	O
+were	O
+negative	O
+by	O
+reverse	B-PROC
+transcription	I-PROC
+PCR	O
+.	O
+
+TITLE	O
+:	O
+Serologic	O
+Detection	O
+of	O
+Middle	O
+East	O
+Respiratory	O
+Syndrome	B-DISO
+Coronavirus	B-SPEC
+Functional	O
+Antibodies	B-COMP
+.	O
+
+Mouse	B-DISO
+hepatitis	I-DISO
+coronavirus	B-SPEC
+(	O
+MHV	B-SPEC
+)	O
+is	O
+the	O
+only	O
+known	O
+coronavirus	B-SPEC
+that	O
+uses	O
+the	O
+N	O
+-	O
+terminal	O
+domain	O
+(	O
+NTD	O
+)	O
+of	O
+its	O
+spike	O
+to	O
+recognize	O
+a	O
+protein	B-CHED
+receptor	O
+,	O
+CEACAM1a	O
+.	O
+
+The	O
+trimeric	O
+spike	O
+contains	O
+three	O
+receptor	O
+-	O
+binding	B-FUNC
+S1	O
+heads	B-ANAT
+sitting	O
+on	O
+top	B-PRGE
+of	O
+a	O
+trimeric	O
+membrane	B-COMP
+-	O
+fusion	O
+S2	O
+stalk	B-DISO
+.	O
+
+Using	O
+protease	O
+sensitivity	O
+and	O
+negative	O
+-	O
+stain	O
+EM	O
+analyses	O
+,	O
+we	O
+further	O
+showed	O
+that	O
+after	O
+protease	O
+treatment	O
+of	O
+the	O
+spike	O
+,	O
+receptor	B-FUNC
+binding	I-FUNC
+facilitated	O
+the	O
+dissociation	B-DISO
+of	O
+S1	O
+from	O
+S2	O
+,	O
+allowing	O
+S2	O
+to	O
+transition	B-DISO
+from	O
+pre	O
+-	O
+fusion	O
+to	O
+post	O
+-	O
+fusion	O
+conformation	O
+.	O
+
+ABSTRACT	O
+:	O
+The	O
+Severe	B-SPEC
+Acute	I-SPEC
+Respiratory	I-SPEC
+Syndrome	I-SPEC
+Coronavirus	I-SPEC
+2	I-SPEC
+(	O
+SARS	B-PRGE
+-	I-PRGE
+CoV	I-PRGE
+-	I-PRGE
+2	I-PRGE
+)	O
+first	O
+broke	O
+out	O
+in	O
+Wuhan	O
+(	O
+China	O
+)	O
+and	O
+subsequently	O
+spread	O
+worldwide	O
+.	O
+
+TITLE	O
+:	O
+The	O
+Incubation	O
+Period	O
+of	O
+Coronavirus	B-DISO
+Disease	I-DISO
+2019	I-DISO
+(	O
+COVID	B-DISO
+-	I-DISO
+19	I-DISO
+)	O
+From	O
+Publicly	O
+Reported	O
+Confirmed	O
+Cases	O
+:	O
+Estimation	O
+and	O
+Application	O
+.	O
+
+There	O
+were	O
+181	O
+confirmed	O
+cases	O
+with	O
+identifiable	O
+exposure	O
+and	O
+symptom	B-DISO
+onset	O
+windows	O
+to	O
+estimate	O
+the	O
+incubation	O
+period	O
+of	O
+COVID	B-DISO
+-	I-DISO
+19	I-DISO
+.	O
+
+The	O
+median	O
+incubation	O
+period	O
+was	O
+estimated	O
+to	O
+be	O
+5	O
+.	O
+1	O
+days	O
+(	O
+95	O
+%	O
+CI	O
+,	O
+4	O
+.	O
+5	O
+to	O
+5	O
+.	O
+8	O
+days	O
+),	O
+and	O
+97	O
+.	O
+5	O
+%	O
+of	O
+those	O
+who	O
+develop	O
+symptoms	O
+will	O
+do	O
+so	O
+within	O
+11	O
+.	O
+5	O
+days	O
+(	O
+CI	O
+,	O
+8	O
+.	O
+2	O
+to	O
+15	O
+.	O
+6	O
+days	O
+)	O
+of	O
+infection	B-DISO
+.	O
+
+Our	O
+results	O
+support	O
+current	O
+proposals	O
+for	O
+the	O
+length	O
+of	O
+quarantine	O
+or	O
+active	O
+monitoring	O
+of	O
+persons	O
+potentially	O
+exposed	O
+to	O
+SARS	B-PRGE
+-	I-PRGE
+CoV	I-PRGE
+-	I-PRGE
+2	I-PRGE
+,	O
+although	O
+longer	O
+monitoring	O
+periods	B-PROC
+might	O
+be	O
+justified	O
+in	O
+extreme	O
+cases	O
+.	O
+
+U	O
+.	O
+S	O
+.	O
+Centers	O
+for	O
+Disease	O
+Control	O
+and	O
+Prevention	O
+,	O
+National	O
+Institute	O
+of	O
+Allergy	B-DISO
+and	O
+Infectious	B-DISO
+Diseases	I-DISO
+,	O
+National	O
+Institute	O
+of	O
+General	O
+Medical	O
+Sciences	O
+,	O
+and	O
+Alexander	O
+von	O
+Humboldt	O
+Foundation	O
+.	O
+
+Clinical	O
+records	O
+,	O
+laboratory	O
+results	O
+,	O
+and	O
+chest	B-ANAT
+CT	O
+scans	O
+were	O
+retrospectively	O
+reviewed	O
+for	O
+nine	O
+pregnant	O
+women	O
+with	O
+laboratory	O
+-	O
+confirmed	O
+COVID	B-DISO
+-	I-DISO
+19	I-DISO
+pneumonia	I-DISO
+(	O
+ie	O
+,	O
+with	O
+maternal	O
+throat	B-ANAT
+swab	I-ANAT
+samples	O
+that	O
+were	O
+positive	O
+for	O
+severe	B-SPEC
+acute	I-SPEC
+respiratory	I-SPEC
+syndrome	I-SPEC
+coronavirus	I-SPEC
+2	I-SPEC
+[	O
+SARS	B-SPEC
+-	I-SPEC
+CoV	I-SPEC
+-	I-SPEC
+2	I-SPEC
+])	O
+who	O
+were	O
+admitted	O
+to	O
+Zhongnan	O
+Hospital	O
+of	O
+Wuhan	O
+University	O
+,	O
+Wuhan	O
+,	O
+China	O
+,	O
+from	O
+Jan	B-PRGE
+20	I-PRGE
+to	O
+Jan	B-PRGE
+31	I-PRGE
+,	O
+2020	O
+.	O
+
+Seven	O
+patients	O
+presented	O
+with	O
+a	O
+fever	B-PROC
+.	O
+
+Five	O
+of	O
+nine	O
+patients	O
+had	O
+lymphopenia	B-DISO
+(<	O
+1	O
+·	O
+0	O
+×	O
+10⁹	O
+cells	B-COMP
+per	O
+L	O
+).	O
+
+TITLE	O
+:	O
+Compounds	O
+with	O
+therapeutic	O
+potential	O
+against	O
+novel	O
+respiratory	O
+2019	O
+coronavirus	B-SPEC
+.	O
+
+Remdesivir	O
+inhibited	O
+the	O
+replication	O
+of	O
+SARS	B-PRGE
+-	I-PRGE
+CoV	I-PRGE
+and	O
+MERS	O
+-	O
+CoV	O
+in	O
+tissue	B-ANAT
+cultures	O
+,	O
+and	O
+it	O
+displayed	O
+efficacy	O
+in	O
+non	O
+-	O
+human	B-SPEC
+animal	B-SPEC
+models	O
+.	O
+
+In	O
+addition	O
+,	O
+a	O
+combination	O
+of	O
+the	O
+human	B-DISO
+immunodeficiency	I-DISO
+virus	I-DISO
+type	I-SPEC
+1	I-SPEC
+(	O
+HIV	O
+-	O
+1	O
+)	O
+protease	B-PROC
+inhibitors	I-PROC
+,	O
+lopinavir	O
+/	O
+ritonavir	B-CHED
+,	O
+and	O
+interferon	B-PRGE
+beta	I-PRGE
+(	O
+LPV	O
+/	O
+RTV	B-PRGE
+-	I-PRGE
+INFb	I-PRGE
+)	O
+were	O
+shown	O
+to	O
+be	O
+effective	O
+in	O
+patients	O
+infected	O
+with	O
+SARS	B-DISO
+-	O
+CoV	O
+.	O
+LPV	O
+/	O
+RTV	B-PRGE
+-	I-PRGE
+INFb	I-PRGE
+also	O
+improved	O
+clinical	O
+parameters	O
+in	O
+marmosets	B-SPEC
+and	O
+mice	B-SPEC
+infected	O
+with	O
+MERS	O
+-	O
+CoV	O
+.	O
+Remarkably	O
+,	O
+the	O
+therapeutic	O
+efficacy	O
+of	O
+remdesivir	O
+appeared	O
+to	O
+be	O
+superior	O
+to	O
+that	O
+of	O
+LPV	O
+/	O
+RTV	B-PRGE
+-	O
+INFb	B-PRGE
+against	O
+MERS	O
+-	O
+CoV	O
+in	O
+a	O
+transgenic	O
+humanized	O
+mice	B-SPEC
+model	O
+.	O
+
+The	O
+diagnosis	O
+and	O
+differential	O
+diagnosis	O
+of	O
+novel	O
+coronavirus	O
+pneumonia	B-DISO
+was	O
+facing	O
+challenges	O
+not	O
+only	O
+because	O
+of	O
+large	O
+number	O
+of	O
+tourists	O
+increasing	O
+dramatically	O
+after	O
+the	O
+relieving	O
+of	O
+epidemic	O
+,	O
+but	O
+also	O
+patients	O
+with	O
+other	O
+diseases	O
+return	O
+from	O
+different	O
+areas	O
+to	O
+search	O
+for	O
+medical	O
+care	O
+.	O
+
+TITLE	O
+:	O
+Unveiling	O
+the	O
+Origin	O
+and	O
+Transmission	O
+of	O
+2019	B-SPEC
+-	I-SPEC
+nCoV	I-SPEC
+.	O
+ABSTRACT	O
+:	O
+A	O
+novel	B-SPEC
+coronavirus	I-SPEC
+has	O
+caused	O
+thousands	O
+of	O
+human	O
+infections	B-DISO
+in	O
+China	O
+since	O
+December	O
+2019	O
+,	O
+raising	O
+a	O
+global	O
+public	O
+health	O
+concern	O
+.	O
+
+Recent	O
+studies	O
+(	O
+Huang	O
+et	O
+al	O
+.,	O
+Chan	O
+et	O
+al	O
+.,	O
+and	O
+Zhou	O
+et	O
+al	O
+.)	O
+have	O
+provided	O
+timely	O
+insights	O
+into	O
+its	O
+origin	O
+and	O
+ability	O
+to	O
+spread	O
+among	O
+humans	B-SPEC
+,	O
+informing	O
+infection	B-DISO
+prevention	O
+and	O
+control	O
+practices	O
+.	O
+
+Coronavirus	B-SPEC
+spike	O
+(	O
+S	O
+)	O
+glycoproteins	B-CHED
+promote	O
+entry	O
+into	O
+cells	B-COMP
+and	O
+are	O
+the	O
+main	O
+target	O
+of	O
+antibodies	B-COMP
+.	O
+
+Our	O
+newly	O
+developed	O
+protocol	O
+should	O
+be	O
+helpful	O
+for	O
+a	O
+first	O
+-	O
+hand	O
+screening	O
+of	O
+the	O
+asymptomatic	O
+virus	B-SPEC
+-	O
+carriers	O
+for	O
+further	O
+prevention	O
+of	O
+transmission	O
+and	O
+early	O
+intervention	O
+and	O
+treatment	O
+for	O
+the	O
+rapidly	O
+propagating	O
+virus	B-SPEC
+.	O
+
+ABSTRACT	O
+:	O
+This	O
+is	O
+the	O
+sixth	O
+epidemiological	O
+report	O
+for	O
+coronavirus	B-DISO
+disease	I-DISO
+2019	I-DISO
+(	O
+COVID	B-DISO
+-	I-DISO
+19	I-DISO
+),	O
+reported	O
+in	O
+Australia	O
+as	O
+at	O
+19	O
+:	O
+00	O
+Australian	O
+Eastern	O
+Daylight	O
+Time	O
+[	O
+AEDT	O
+]	O
+7	O
+March	O
+2020	O
+.	O
+
+Among	O
+38	O
+cases	O
+studied	O
+,	O
+21	O
+were	O
+linked	O
+to	O
+two	O
+clusters	B-CHED
+in	O
+Germany	O
+and	O
+France	O
+,	O
+14	O
+were	O
+infected	O
+in	O
+China	O
+.	O
+
+TITLE	O
+:	O
+Evaluation	O
+of	O
+a	O
+quantitative	O
+RT	O
+-	O
+PCR	O
+assay	O
+for	O
+the	O
+detection	O
+of	O
+the	O
+emerging	O
+coronavirus	B-SPEC
+SARS	B-DISO
+-	I-SPEC
+CoV	I-SPEC
+-	I-SPEC
+2	I-SPEC
+using	O
+a	O
+high	O
+throughput	O
+system	O
+.	O
+
+ABSTRACT	O
+:	O
+Two	O
+months	O
+after	O
+the	O
+emergence	O
+of	O
+severe	O
+acute	O
+respiratory	O
+syndrome	O
+coronavirus	O
+2	O
+(	O
+SARS	B-SPEC
+-	I-SPEC
+CoV	I-SPEC
+-	I-SPEC
+2	I-SPEC
+),	O
+the	O
+possibility	O
+of	O
+established	O
+and	O
+widespread	O
+community	O
+transmission	O
+in	O
+the	O
+European	O
+Union	O
+and	O
+European	O
+Economic	O
+Area	O
+(	O
+EU	O
+/	O
+EEA	O
+)	O
+is	O
+becoming	O
+more	O
+likely	O
+.	O
+
+Binary	O
+logistic	O
+regression	O
+analysis	O
+showed	O
+that	O
+age	O
+,	O
+not	O
+gender	O
+,	O
+was	O
+the	O
+risk	O
+factor	O
+for	O
+SARS	B-DISO
+-	I-DISO
+CoV	I-DISO
+-	I-DISO
+2	I-DISO
+infection	I-DISO
+in	O
+fever	B-PROC
+clinics	O
+.	O
+
+Cardiovascular	B-ANAT
+,	O
+digestive	B-PROC
+and	O
+endocrine	B-DISO
+system	I-DISO
+diseases	I-DISO
+were	O
+commonly	O
+reported	O
+,	O
+except	O
+previous	O
+chronic	O
+pulmonary	B-DISO
+diseases	I-DISO
+[	O
+e	O
+.	O
+g	O
+.	O
+chronic	B-DISO
+obstructive	I-DISO
+pulmonary	I-DISO
+disease	I-DISO
+(	O
+COPD	B-DISO
+),	O
+asthma	B-PATH
+,	O
+bronchiectasis	B-DISO
+]	O
+that	O
+were	O
+surprisingly	O
+underreported	O
+.	O
+
+In	O
+this	O
+study	O
+,	O
+we	O
+used	O
+a	O
+second	O
+derivative	O
+model	O
+to	O
+characterize	O
+the	O
+coronavirus	B-SPEC
+epidemic	O
+in	O
+China	O
+with	O
+cumulatively	O
+diagnosed	O
+cases	O
+during	O
+the	O
+first	O
+2	O
+months	O
+.	O
+
+The	O
+case	O
+highlights	O
+possible	O
+co	O
+-	O
+detection	O
+of	O
+known	O
+respiratory	O
+viruses	B-SPEC
+.	O
+
+We	O
+isolated	O
+virus	B-SPEC
+from	O
+nasopharyngeal	B-ANAT
+and	O
+oropharyngeal	B-ANAT
+specimens	O
+from	O
+this	O
+patient	O
+and	O
+characterized	O
+the	O
+viral	O
+sequence	O
+,	O
+replication	O
+properties	O
+,	O
+and	O
+cell	B-COMP
+culture	O
+tropism	B-PROC
+.	O
+
+Adenovirus	B-DISO
+was	O
+the	O
+most	O
+common	O
+,	O
+it	O
+was	O
+found	O
+in	O
+19	O
+%	O
+of	O
+the	O
+patients	O
+.	O
+
+Some	O
+of	O
+these	O
+dashboards	O
+and	O
+applications	O
+are	O
+receiving	O
+data	O
+updates	O
+in	O
+near	O
+-	O
+real	O
+-	O
+time	O
+(	O
+at	O
+the	O
+time	O
+of	O
+writing	O
+),	O
+and	O
+one	O
+of	O
+them	O
+is	O
+meant	O
+for	O
+individual	O
+users	O
+(	O
+in	O
+China	O
+)	O
+to	O
+check	O
+if	O
+the	O
+app	B-CHED
+user	O
+has	O
+had	O
+any	O
+close	O
+contact	O
+with	O
+a	O
+person	O
+confirmed	O
+or	O
+suspected	O
+to	O
+have	O
+been	O
+infected	O
+with	O
+SARS	B-SPEC
+-	I-SPEC
+CoV	I-SPEC
+-	I-SPEC
+2	I-SPEC
+in	O
+the	O
+recent	O
+past	O
+.	O
+
+Despite	O
+its	O
+putative	O
+role	O
+in	O
+viral	O
+RNA	B-PROC
+replication	I-PROC
+,	O
+nsP13	O
+readily	O
+unwinds	O
+duplex	O
+DNA	O
+by	O
+cooperative	O
+translocation	B-DISO
+.	O
+
+TITLE	O
+:	O
+Dysregulation	O
+of	O
+immune	B-PROC
+response	I-PROC
+in	O
+patients	O
+with	O
+COVID	B-DISO
+-	I-DISO
+19	I-DISO
+in	O
+Wuhan	O
+,	O
+China	O
+.	O
+
+Severe	O
+cases	O
+tend	O
+to	O
+have	O
+lower	O
+lymphocytes	B-ANAT
+counts	O
+,	O
+higher	O
+leukocytes	B-ANAT
+counts	O
+and	O
+neutrophil	B-ANAT
+-	O
+lymphocyte	B-ANAT
+-	O
+ratio	O
+(	O
+NLR	O
+),	O
+as	O
+well	O
+as	O
+lower	O
+percentages	O
+of	O
+monocytes	B-ANAT
+,	O
+eosinophils	B-ANAT
+,	O
+and	O
+basophils	B-ANAT
+.	O
+
+Both	O
+helper	B-ANAT
+T	I-ANAT
+cells	I-ANAT
+and	O
+suppressor	O
+T	B-ANAT
+cells	I-ANAT
+in	O
+patients	O
+with	O
+COVID	B-DISO
+-	I-DISO
+19	I-DISO
+were	O
+below	O
+normal	O
+levels	O
+,	O
+and	O
+lower	O
+level	O
+of	O
+helper	B-ANAT
+T	I-ANAT
+cells	I-ANAT
+in	O
+severe	O
+group	O
+.	O
+
+Patients	O
+with	O
+COVID	B-DISO
+-	I-DISO
+19	I-DISO
+also	O
+have	O
+lower	O
+level	O
+of	O
+regulatory	B-ANAT
+T	I-ANAT
+cells	I-ANAT
+,	O
+and	O
+more	O
+obviously	O
+damaged	O
+in	O
+severe	O
+cases	O
+.	O
+
+Pregnant	O
+women	O
+are	O
+susceptible	O
+population	O
+of	O
+COVID	B-DISO
+-	I-DISO
+19	I-DISO
+which	O
+are	O
+more	O
+likely	O
+to	O
+have	O
+complications	O
+and	O
+even	O
+progresse	O
+to	O
+severe	O
+illness	O
+.	O
+
+We	O
+report	O
+a	O
+case	O
+of	O
+neonatal	O
+COVID	B-DISO
+-	I-DISO
+19	I-DISO
+infection	I-DISO
+in	O
+China	O
+with	O
+pharyngeal	B-ANAT
+swabs	O
+tested	O
+positive	O
+by	O
+rRT	O
+-	O
+PCR	O
+assay	O
+36	O
+hours	O
+after	O
+birth	B-PROC
+.	O
+
+All	O
+patients	O
+had	O
+a	O
+history	O
+of	O
+exposure	O
+to	O
+confirmed	O
+case	O
+of	O
+2019	B-SPEC
+-	I-SPEC
+nCoV	I-SPEC
+or	O
+travel	O
+to	O
+Hubei	O
+before	O
+illness	O
+.	O
+
+The	O
+most	O
+common	O
+symptoms	O
+were	O
+fever	B-PROC
+and	O
+cough	B-DISO
+.	O
+
+Fifteen	O
+(	O
+78	O
+.	O
+95	O
+%)	O
+NCOVID	O
+-	O
+19	O
+but	O
+4	O
+(	O
+26	O
+.	O
+67	O
+%)	O
+NON	O
+-	O
+NCOVID	O
+-	O
+19	O
+patients	O
+had	O
+bilateral	O
+involvement	O
+while	O
+17	O
+(	O
+89	O
+.	O
+47	O
+%)	O
+NCOVID	O
+-	O
+19	O
+but	O
+1	O
+(	O
+6	O
+.	O
+67	O
+%)	O
+NON	O
+-	O
+NCOVID	O
+-	O
+19	O
+patients	O
+had	O
+multiple	O
+mottling	O
+and	O
+ground	O
+-	O
+glass	O
+opacity	B-DISO
+of	O
+chest	B-ANAT
+CT	O
+images	O
+.	O
+
+Compared	O
+to	O
+NON	O
+-	O
+NCOVID	O
+-	O
+19	O
+,	O
+NCOVID	O
+-	O
+19	O
+present	O
+remarkably	O
+more	O
+abnormal	O
+laboratory	O
+tests	O
+including	O
+AST	B-PRGE
+,	O
+ALT	B-FUNC
+,	O
+γ	O
+-	O
+GT	O
+,	O
+LDH	B-PRGE
+and	O
+α	O
+-	O
+HBDH	O
+.	O
+
+A	O
+meta	B-SPEC
+-	O
+analysis	O
+of	O
+eligible	O
+studies	O
+that	O
+summarized	O
+the	O
+prevalence	O
+of	O
+cardiovascular	B-ANAT
+metabolic	B-DISO
+diseases	I-DISO
+in	O
+COVID	B-DISO
+-	I-DISO
+19	I-DISO
+and	O
+compared	O
+the	O
+incidences	O
+of	O
+the	O
+comorbidities	O
+in	O
+ICU	O
+/	O
+severe	O
+and	O
+non	O
+-	O
+ICU	O
+/	O
+severe	O
+patients	O
+was	O
+performed	O
+.	O
+
+The	O
+incidence	O
+of	O
+acute	O
+cardiac	B-ANAT
+injury	O
+was	O
+about	O
+13	O
+folds	O
+higher	O
+in	O
+ICU	O
+/	O
+severe	O
+patients	O
+compared	O
+with	O
+the	O
+non	O
+-	O
+ICU	O
+/	O
+severe	O
+patients	O
+.	O
+
+CONCLUSIONS	O
+:	O
+Patients	O
+with	O
+previous	O
+cardiovascular	B-ANAT
+metabolic	B-DISO
+diseases	I-DISO
+may	O
+face	B-DISO
+a	O
+greater	O
+risk	O
+of	O
+developing	O
+into	O
+the	O
+severe	O
+condition	B-DISO
+and	O
+the	O
+comorbidities	O
+can	O
+also	O
+greatly	O
+affect	O
+the	O
+prognosis	O
+of	O
+the	O
+COVID	B-DISO
+-	I-DISO
+19	I-DISO
+.	O
+
+Here	O
+,	O
+we	O
+describe	O
+the	O
+outbreak	O
+response	O
+measures	O
+of	O
+the	O
+anesthetic	O
+department	O
+staffing	O
+the	O
+largest	O
+(	O
+1	O
+,	O
+700	O
+-	O
+bed	B-DISO
+)	O
+academic	O
+tertiary	O
+level	O
+acute	O
+care	O
+hospital	O
+in	O
+Singapore	O
+(	O
+Singapore	O
+General	O
+Hospital	O
+)	O
+and	O
+a	O
+smaller	O
+regional	O
+hospital	O
+(	O
+Sengkang	O
+General	O
+Hospital	O
+).	O
+
+Population	O
+coverage	O
+analysis	O
+showed	O
+that	O
+the	O
+putative	O
+helper	B-ANAT
+T	I-ANAT
+-	I-ANAT
+cell	I-ANAT
+epitopes	O
+and	O
+CTL	B-ANAT
+epitopes	O
+could	O
+cover	O
+most	O
+of	O
+the	O
+world	O
+population	O
+in	O
+more	O
+than	O
+60	O
+geographical	O
+regions	O
+.	O
+
+How	O
+Is	O
+the	O
+World	O
+Responding	O
+to	O
+the	O
+2019	O
+Coronavirus	B-SPEC
+Disease	O
+Compared	O
+with	O
+the	O
+2014	O
+West	O
+African	O
+Ebola	O
+Epidemic	O
+?	O
+
+ABSTRACT	O
+:	O
+Coronavirus	O
+disease	O
+2019	O
+(	O
+COVID	B-DISO
+-	I-DISO
+19	I-DISO
+)	O
+caused	O
+by	O
+the	O
+severe	B-SPEC
+acute	I-SPEC
+respiratory	I-SPEC
+syndrome	I-SPEC
+coronavirus	I-SPEC
+2	I-SPEC
+has	O
+become	O
+an	O
+important	O
+public	O
+health	O
+issue	O
+in	O
+the	O
+world	O
+.	O
+
+The	O
+main	O
+clinical	O
+manifestations	O
+were	O
+respiratory	B-DISO
+symptoms	I-DISO
+and	O
+occasional	O
+gastrointestinal	B-DISO
+symptoms	I-DISO
+.	O
+
+As	O
+of	O
+February	O
+26	O
+,	O
+2020	O
+,	O
+COVID	B-DISO
+-	I-DISO
+19	I-DISO
+has	O
+been	O
+recognized	O
+in	O
+34	O
+countries	O
+,	O
+with	O
+a	O
+total	O
+of	O
+80	O
+,	O
+239	O
+laboratory	O
+-	O
+confirmed	O
+cases	O
+and	O
+2	O
+,	O
+700	O
+deaths	B-PROC
+.	O
+
+For	O
+dental	O
+practices	O
+and	O
+hospitals	O
+in	O
+areas	O
+that	O
+are	O
+(	O
+potentially	O
+)	O
+affected	O
+with	O
+COVID	B-DISO
+-	I-DISO
+19	I-DISO
+,	O
+strict	O
+and	O
+effective	O
+infection	B-DISO
+control	O
+protocols	O
+are	O
+urgently	O
+needed	O
+.	O
+
+This	O
+article	O
+,	O
+based	O
+on	O
+our	O
+experience	O
+and	O
+relevant	O
+guidelines	O
+and	O
+research	O
+,	O
+introduces	O
+essential	O
+knowledge	O
+about	O
+COVID	O
+-	O
+19	O
+and	O
+nosocomial	B-DISO
+infection	I-DISO
+in	O
+dental	O
+settings	O
+and	O
+provides	O
+recommended	O
+management	O
+protocols	O
+for	O
+dental	O
+practitioners	O
+and	O
+students	O
+in	O
+(	O
+potentially	O
+)	O
+affected	O
+areas	O
+.	O
+
+TITLE	O
+:	O
+Surveillance	O
+and	O
+Taxonomic	O
+Analysis	O
+of	O
+the	O
+Coronavirus	B-SPEC
+Dominant	O
+in	O
+Pigeons	B-SPEC
+in	O
+China	O
+.	O
+
+In	O
+our	O
+previous	O
+study	O
+,	O
+we	O
+proposed	O
+that	O
+the	O
+CoVs	O
+dominant	O
+(	O
+i	O
+.	O
+e	O
+.,	O
+mainly	O
+circulating	O
+)	O
+in	O
+ducks	B-SPEC
+(	O
+DdCoVs	O
+)	O
+should	O
+represent	O
+a	O
+novel	O
+species	B-SPEC
+,	O
+which	O
+was	O
+different	O
+from	O
+the	O
+one	O
+represented	O
+by	O
+the	O
+CoVs	B-PRGE
+dominant	I-PRGE
+in	I-PRGE
+chickens	I-PRGE
+(	O
+CdCoVs	O
+).	O
+
+The	O
+surveillance	O
+demonstrated	O
+that	O
+CdCoVs	O
+,	O
+DdCoVs	O
+and	O
+the	O
+CoVs	O
+dominant	O
+in	O
+pigeons	B-SPEC
+(	O
+PdCoVs	O
+)	O
+belong	O
+to	O
+different	O
+lineages	O
+,	O
+and	O
+they	O
+are	O
+all	O
+prevalent	O
+in	O
+live	O
+poultry	O
+markets	O
+and	O
+the	O
+backyard	O
+flocks	O
+in	O
+some	O
+regions	O
+of	O
+China	O
+.	O
+
+We	O
+further	O
+sequenced	O
+seven	O
+Coronaviridae	O
+-	O
+wide	O
+conserved	O
+domains	O
+in	O
+their	O
+replicase	B-PRGE
+polyprotein	O
+pp1ab	O
+of	O
+seven	O
+PdCoVs	O
+,	O
+and	O
+found	O
+that	O
+the	O
+genetic	O
+distances	O
+in	O
+these	O
+domains	O
+between	O
+PdCoVs	O
+and	O
+DdCoVs	O
+or	O
+CdCoVs	O
+are	O
+large	O
+enough	O
+to	O
+separate	O
+PdCoVs	O
+into	O
+a	O
+novel	O
+species	B-SPEC
+,	O
+which	O
+were	O
+different	O
+from	O
+the	O
+ones	O
+represented	O
+by	O
+DdCoVs	O
+or	O
+CdCoVs	O
+within	O
+the	O
+genus	B-SPEC
+Gammacoronavirus	B-SPEC
+,	O
+per	O
+the	O
+species	B-SPEC
+demarcation	O
+criterion	O
+of	O
+International	O
+Committee	O
+on	O
+Taxonomy	O
+of	O
+Viruses	B-SPEC
+.	O
+
+The	O
+pCCoV	O
+positive	O
+samples	O
+were	O
+also	O
+tested	O
+for	O
+other	O
+canine	O
+viruses	B-SPEC
+,	O
+showing	O
+coinfections	B-DISO
+mainly	O
+with	O
+canine	O
+parvovirus	B-DISO
+.	O
+
+We	O
+estimate	O
+the	O
+reproduction	B-PROC
+number	O
+(	O
+R	O
+),	O
+and	O
+the	O
+effect	O
+of	O
+preventive	O
+measures	O
+,	O
+assuming	O
+that	O
+the	O
+effect	O
+has	O
+been	O
+shown	O
+from	O
+29	O
+-	O
+Feb	O
+.	O
+
+This	O
+study	O
+analyzed	O
+global	O
+COVID	B-DISO
+-	I-DISO
+19	I-DISO
+epidemiological	O
+trends	O
+,	O
+examined	O
+impact	O
+of	O
+the	O
+pandemic	O
+on	O
+global	O
+health	O
+security	O
+,	O
+diplomacy	O
+,	O
+and	O
+social	O
+environment	O
+in	O
+China	O
+,	O
+and	O
+provided	O
+short	O
+-	O
+and	O
+long	O
+-	O
+term	O
+strategic	O
+policy	O
+recommendations	O
+for	O
+China	O
+'	O
+s	O
+subsequent	O
+preparedness	O
+and	O
+responses	O
+.	O
+
+Common	O
+presentations	O
+of	O
+confirmed	O
+cases	O
+include	O
+fever	B-PROC
+,	O
+fatigue	B-DISO
+,	O
+dry	B-DISO
+cough	I-DISO
+,	O
+upper	O
+airway	B-ANAT
+congestion	B-DISO
+,	O
+sputum	B-PROC
+production	I-PROC
+,	O
+shortness	B-DISO
+of	I-DISO
+breath	I-DISO
+,	O
+myalgia	B-DISO
+/	O
+arthralgia	B-DISO
+with	O
+lymphopenia	B-DISO
+,	O
+prolonged	O
+prothrombin	B-PRGE
+time	O
+,	O
+elevated	O
+C	B-PRGE
+-	I-PRGE
+reactive	I-PRGE
+protein	I-PRGE
+,	O
+and	O
+elevated	O
+lactate	B-PRGE
+dehydrogenase	I-PRGE
+.	O
+
+TITLE	O
+:	O
+""""	O
+Keep	O
+it	O
+short	O
+and	O
+sweet	B-PROC
+""":"	O
+Improving	O
+risk	O
+communication	O
+to	O
+family	B-SPEC
+physicians	O
+during	O
+public	O
+health	O
+crises	O
+.	O
+
+On	O
+the	O
+other	O
+hand	O
+,	O
+body	B-ANAT
+temperature	O
+screening	O
+(	O
+fever	B-PROC
+)	O
+is	O
+the	O
+major	O
+test	O
+performed	O
+at	O
+points	O
+of	O
+entry	O
+,	O
+i	O
+.	O
+e	O
+.,	O
+airports	O
+,	O
+in	O
+the	O
+returning	O
+travelers	O
+in	O
+most	O
+of	O
+the	O
+countries	O
+with	O
+limited	O
+resources	O
+.	O
+
+A	O
+14	O
+-	O
+year	O
+-	O
+old	O
+boy	O
+with	O
+refractory	O
+B	B-ANAT
+cell	I-ANAT
+precursor	O
+acute	B-DISO
+lymphoblastic	I-DISO
+leukemia	I-DISO
+given	O
+chimeric	O
+antigen	B-CHED
+receptor	O
+cells	B-COMP
+developed	O
+severe	O
+cytokine	B-DISO
+release	I-DISO
+syndrome	I-DISO
+7	O
+days	O
+after	O
+the	O
+drug	O
+product	O
+infusion	O
+with	O
+progressive	O
+respiratory	B-DISO
+failure	I-DISO
+.	O
+
+TITLE	O
+:	O
+[	O
+Which	O
+sampling	O
+method	O
+for	O
+the	O
+upper	B-ANAT
+respiratory	I-ANAT
+tract	I-ANAT
+specimen	O
+should	O
+be	O
+taken	O
+to	O
+diagnose	O
+patient	O
+with	O
+COVID	O
+-	O
+19	O
+?]	O
+ABSTRACT	O
+:	O
+Coronavirus	B-DISO
+disease	I-DISO
+2019	I-DISO
+(	O
+COVID	B-DISO
+-	I-DISO
+19	I-DISO
+)	O
+is	O
+raging	O
+in	O
+China	O
+,	O
+especially	O
+in	O
+Hubei	O
+Province	O
+,	O
+which	O
+has	O
+resulted	O
+great	O
+dangers	O
+in	O
+people	O
+'	O
+s	O
+life	O
+and	O
+national	O
+economy	O
+.	O
+
+However	O
+,	O
+based	O
+on	O
+international	O
+guidelines	O
+of	O
+COVID	B-DISO
+-	I-DISO
+19	I-DISO
+,	O
+no	O
+recommended	O
+level	O
+of	O
+upper	B-ANAT
+respiratory	I-ANAT
+tract	I-ANAT
+sampling	O
+method	O
+is	O
+proposed	O
+.	O
+
+We	O
+wish	O
+this	O
+review	O
+is	O
+helpful	O
+for	O
+the	O
+prevention	O
+of	O
+COVID	B-DISO
+-	I-DISO
+19	I-DISO
+.	O
+
+TITLE	O
+:	O
+Interrupting	O
+transmission	O
+of	O
+COVID	B-DISO
+-	I-DISO
+19	I-DISO
+:	O
+lessons	O
+from	O
+containment	O
+efforts	O
+in	O
+Singapore	O
+.	O
+
+For	O
+coronaviruses	O
+,	O
+RNA	B-PRGE
+-	I-PRGE
+dependent	I-PRGE
+RNA	I-PRGE
+polymerase	I-PRGE
+(	O
+RdRp	B-FUNC
+)	O
+is	O
+an	O
+important	O
+protease	O
+that	O
+catalyzes	O
+the	O
+replication	O
+of	O
+RNA	O
+from	O
+RNA	O
+template	O
+and	O
+is	O
+an	O
+attractive	O
+therapeutic	O
+target	O
+.	O
+
+In	O
+this	O
+study	O
+,	O
+we	O
+screened	O
+these	O
+chemical	O
+structures	O
+from	O
+traditional	O
+Chinese	O
+medicinal	O
+compounds	O
+proven	O
+to	O
+show	O
+antiviral	B-CHED
+activity	O
+in	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+coronavirus	B-SPEC
+(	O
+SARS	B-DISO
+-	O
+CoV	O
+)	O
+and	O
+the	O
+similar	O
+chemical	O
+structures	O
+through	O
+a	O
+molecular	O
+docking	B-PROC
+study	O
+to	O
+target	O
+RdRp	B-FUNC
+of	O
+SARS	B-PRGE
+-	I-PRGE
+CoV	I-PRGE
+-	I-PRGE
+2	I-PRGE
+,	O
+SARS	B-PRGE
+-	I-PRGE
+CoV	I-PRGE
+,	O
+and	O
+Middle	O
+East	O
+respiratory	O
+syndrome	B-DISO
+coronavirus	B-SPEC
+(	O
+MERS	O
+-	O
+CoV	O
+).	O
+
+In	O
+this	O
+study	O
+,	O
+we	O
+retrieved	O
+95	O
+full	O
+-	O
+length	O
+genomic	O
+sequences	O
+of	O
+SARAS	O
+-	O
+CoV	O
+-	O
+2	O
+strains	O
+from	O
+the	O
+National	O
+Center	O
+for	O
+Biotechnology	O
+Information	O
+and	O
+GISAID	O
+databases	O
+,	O
+established	O
+the	O
+reference	O
+sequence	O
+by	O
+conducting	B-PROC
+multiple	O
+sequence	O
+alignment	O
+and	O
+phylogenetic	O
+analyses	O
+,	O
+and	O
+analyzed	O
+sequence	O
+variations	O
+along	O
+the	O
+SARS	B-SPEC
+-	I-SPEC
+CoV	I-SPEC
+-	I-SPEC
+2	I-SPEC
+genome	O
+.	O
+
+TITLE	O
+:	O
+Effectiveness	O
+of	O
+N95	O
+respirators	O
+versus	O
+surgical	O
+masks	O
+against	O
+influenza	B-DISO
+:	O
+A	O
+systematic	O
+review	O
+and	O
+meta	O
+-	O
+analysis	O
+.	O
+
+There	O
+were	O
+no	O
+statistically	O
+significant	O
+differences	O
+in	O
+preventing	O
+laboratory	O
+-	O
+confirmed	O
+influenza	B-DISO
+(	O
+RR	O
+=	O
+1	O
+.	O
+09	O
+,	O
+95	O
+%	O
+CI	O
+0	O
+.	O
+92	O
+-	O
+1	O
+.	O
+28	O
+,	O
+P	O
+>	O
+.	O
+05	O
+),	O
+laboratory	O
+-	O
+confirmed	O
+respiratory	O
+viral	B-DISO
+infections	I-DISO
+(	O
+RR	O
+=	O
+0	O
+.	O
+89	O
+,	O
+95	O
+%	O
+CI	O
+0	O
+.	O
+70	O
+-	O
+1	O
+.	O
+11	O
+),	O
+laboratory	O
+-	O
+confirmed	O
+respiratory	B-DISO
+infection	I-DISO
+(	O
+RR	O
+=	O
+0	O
+.	O
+74	O
+,	O
+95	O
+%	O
+CI	O
+0	O
+.	O
+42	O
+-	O
+1	O
+.	O
+29	O
+)	O
+and	O
+influenzalike	O
+illness	O
+(	O
+RR	O
+=	O
+0	O
+.	O
+61	O
+,	O
+95	O
+%	O
+CI	O
+0	O
+.	O
+33	O
+-	O
+1	O
+.	O
+14	O
+)	O
+using	O
+N95	O
+respirators	O
+and	O
+surgical	O
+masks	O
+.	O
+
+Retrospective	O
+cohort	O
+study	O
+of	O
+201	O
+patients	O
+with	O
+confirmed	O
+COVID	B-DISO
+-	I-DISO
+19	I-DISO
+pneumonia	I-DISO
+admitted	O
+to	O
+Wuhan	O
+Jinyintan	O
+Hospital	O
+in	O
+China	O
+between	O
+December	O
+25	O
+,	O
+2019	O
+,	O
+and	O
+January	O
+26	O
+,	O
+2020	O
+.	O
+
+Moreover	O
+,	O
+treatment	O
+with	O
+methylprednisolone	B-CHED
+may	O
+be	O
+beneficial	O
+for	O
+patients	O
+who	O
+develop	O
+ARDS	B-DISO
+.	O
+
+Computed	O
+tomography	O
+scans	O
+of	O
+patients	O
+helped	O
+monitor	O
+the	O
+changes	O
+continuously	O
+,	O
+which	O
+could	O
+timely	O
+provide	O
+the	O
+information	O
+of	O
+the	O
+evolution	B-PROC
+of	O
+the	O
+disease	O
+or	O
+therapeutic	O
+effect	O
+to	O
+clinicians	O
+.	O
+
+TITLE	O
+:	O
+Case	O
+-	O
+Fatality	O
+Risk	O
+Estimates	O
+for	O
+COVID	B-DISO
+-	I-DISO
+19	I-DISO
+Calculated	O
+
+ABSTRACT	O
+:	O
+Since	O
+December	O
+2019	O
+,	O
+when	O
+the	O
+first	O
+case	O
+of	O
+2019	O
+novel	O
+coronavirus	O
+disease	O
+(	O
+COVID	B-DISO
+-	I-DISO
+19	I-DISO
+)	O
+was	O
+identified	O
+in	O
+the	O
+city	O
+of	O
+Wuhan	O
+in	O
+the	O
+Hubei	O
+Province	O
+of	O
+China	O
+,	O
+the	O
+epidemic	O
+has	O
+generated	O
+tens	O
+of	O
+thousands	O
+of	O
+cases	O
+throughout	O
+China	O
+.	O
+
+The	O
+elevated	O
+death	B-PROC
+risk	O
+estimates	O
+are	O
+probably	O
+associated	O
+with	O
+a	O
+breakdown	B-DISO
+of	O
+the	O
+healthcare	O
+system	O
+,	O
+indicating	O
+that	O
+enhanced	O
+public	O
+health	O
+interventions	O
+,	O
+including	O
+social	O
+distancing	O
+and	O
+movement	B-PROC
+restrictions	O
+,	O
+should	O
+be	O
+implemented	O
+to	O
+bring	O
+the	O
+COVID	B-DISO
+-	I-DISO
+19	I-DISO
+epidemic	O
+under	O
+control	O
+.	O
+
+Meanwhile	O
+,	O
+several	O
+independent	O
+research	O
+groups	O
+have	O
+identified	O
+that	O
+SARS	O
+-	O
+CoV	O
+-	O
+2	O
+belongs	O
+to	O
+β	O
+-	O
+coronavirus	B-SPEC
+,	O
+with	O
+highly	O
+identical	O
+genome	O
+to	O
+bat	B-ENZY
+coronavirus	B-SPEC
+,	O
+pointing	O
+to	O
+bat	B-ENZY
+as	O
+the	O
+natural	O
+host	B-COMP
+.	O
+
+Currently	O
+,	O
+there	O
+are	O
+few	O
+specific	O
+antiviral	B-CHED
+strategies	O
+,	O
+but	O
+several	O
+potent	O
+candidates	O
+of	O
+antivirals	B-CHED
+and	O
+repurposed	O
+drugs	O
+are	O
+under	O
+urgent	O
+investigation	O
+.	O
+
+Region	O
+IV	O
+is	O
+the	O
+main	O
+driving	O
+force	O
+for	O
+GRP78	B-PRGE
+binding	B-FUNC
+with	O
+the	O
+predicted	O
+binding	B-FUNC
+affinity	O
+of	O
+-	O
+9	O
+.	O
+8	O
+kcal	O
+/	O
+mol	O
+.	O
+
+The	O
+docking	B-PROC
+pose	O
+revealed	O
+the	O
+involvement	O
+of	O
+the	O
+SBDβ	O
+of	O
+GRP78	B-PRGE
+and	O
+the	O
+receptor	O
+-	O
+binding	B-FUNC
+domain	O
+of	O
+the	O
+coronavirus	B-SPEC
+spike	O
+protein	B-CHED
+in	O
+recognition	O
+of	O
+the	O
+host	B-PRGE
+cell	I-PRGE
+receptor	I-PRGE
+.	O
+
+Front	O
+-	O
+line	O
+nurses	O
+are	O
+engaged	O
+in	O
+the	O
+process	O
+of	O
+providing	O
+care	O
+for	O
+patients	O
+with	O
+COVID	B-DISO
+-	I-DISO
+19	I-DISO
+.	O
+
+Within	O
+2	O
+mo	O
+since	O
+the	O
+outbreak	O
+was	O
+first	O
+reported	O
+on	O
+December	O
+31	O
+,	O
+2019	O
+,	O
+a	O
+total	O
+of	O
+566	O
+Severe	B-DISO
+Acute	I-DISO
+Respiratory	I-DISO
+Syndrome	I-DISO
+(	O
+SARS	B-SPEC
+CoV	I-SPEC
+-	I-SPEC
+2	I-SPEC
+)	O
+cases	O
+have	O
+been	O
+confirmed	O
+in	O
+26	O
+other	O
+countries	O
+.	O
+
+We	O
+estimate	O
+the	O
+impact	O
+of	O
+these	O
+control	O
+measures	O
+and	O
+investigate	O
+the	O
+role	O
+of	O
+the	O
+airport	O
+travel	O
+network	O
+on	O
+the	O
+global	O
+spread	O
+of	O
+the	O
+COVID	B-DISO
+-	I-DISO
+19	I-DISO
+outbreak	O
+.	O
+
+We	O
+found	O
+that	O
+779	O
+cases	O
+(	O
+95	O
+%	O
+CI	O
+:	O
+632	O
+to	O
+967	O
+)	O
+would	O
+have	O
+been	O
+exported	O
+by	O
+February	O
+15	O
+,	O
+2020	O
+without	O
+any	O
+border	B-ANAT
+or	O
+travel	O
+restrictions	O
+and	O
+that	O
+the	O
+travel	O
+lockdowns	O
+enforced	O
+by	O
+the	O
+Chinese	O
+government	O
+averted	O
+70	O
+.	O
+5	O
+%	O
+(	O
+95	O
+%	O
+CI	O
+:	O
+68	O
+.	O
+8	O
+to	O
+72	O
+.	O
+0	O
+%)	O
+of	O
+these	O
+cases	O
+.	O
+
+Through	O
+scRNA	O
+-	O
+seq	O
+data	O
+analyses	O
+,	O
+we	O
+identified	O
+the	O
+organs	B-ANAT
+at	O
+risk	O
+,	O
+such	O
+as	O
+lung	B-ANAT
+,	O
+heart	B-ANAT
+,	O
+esophagus	B-ANAT
+,	O
+kidney	B-ANAT
+,	O
+bladder	B-ANAT
+,	O
+and	O
+ileum	B-ANAT
+,	O
+and	O
+located	O
+specific	O
+cell	O
+types	O
+(	O
+i	O
+.	O
+e	O
+.,	O
+type	O
+II	O
+alveolar	B-ANAT
+cells	B-COMP
+(	O
+AT2	B-CHED
+),	O
+myocardial	O
+cells	B-COMP
+,	O
+proximal	B-ANAT
+tubule	I-ANAT
+cells	B-COMP
+of	O
+the	O
+kidney	B-ANAT
+,	O
+ileum	B-ANAT
+and	O
+esophagus	B-ANAT
+epithelial	B-ANAT
+cells	I-ANAT
+,	O
+and	O
+bladder	B-ANAT
+urothelial	O
+cells	B-COMP
+),	O
+which	O
+are	O
+vulnerable	O
+to	O
+2019	B-DISO
+-	I-DISO
+nCoV	I-DISO
+infection	I-DISO
+.	O
+
+The	O
+publicly	O
+available	O
+data	O
+on	O
+human	B-SPEC
+cases	O
+of	O
+MERS	O
+-	O
+CoV	O
+infections	B-DISO
+reported	O
+in	O
+Saudi	O
+Arabia	O
+(	O
+2012	O
+-	O
+2018	O
+)	O
+were	O
+sourced	O
+from	O
+the	O
+FluTrackers	O
+,	O
+World	O
+Health	O
+Organization	O
+,	O
+Saudi	O
+Ministry	O
+of	O
+Health	O
+,	O
+and	O
+published	O
+literature	O
+associated	O
+with	O
+MERS	O
+outbreaks	O
+investigations	O
+.	O
+
+Lung	B-ANAT
+lesions	O
+have	O
+been	O
+considered	O
+as	O
+the	O
+major	O
+damage	O
+caused	O
+by	O
+SARS	B-DISO
+-	I-DISO
+CoV	I-DISO
+-	I-DISO
+2	I-DISO
+infection	I-DISO
+.	O
+
+TITLE	O
+:	O
+Coronavirus	B-SPEC
+Disease	I-DISO
+2019	I-DISO
+(	O
+COVID	B-DISO
+-	I-DISO
+19	I-DISO
+):	O
+What	O
+we	O
+know	O
+?	O
+
+This	O
+causative	O
+virus	B-SPEC
+has	O
+been	O
+temporarily	O
+named	O
+as	O
+severe	B-SPEC
+acute	I-SPEC
+respiratory	I-SPEC
+syndrome	I-SPEC
+coronavirus	I-SPEC
+2	I-SPEC
+(	O
+SARS	B-SPEC
+-	I-SPEC
+CoV	I-SPEC
+-	I-SPEC
+2	I-SPEC
+)	O
+and	O
+the	O
+relevant	O
+infected	O
+disease	O
+has	O
+been	O
+named	O
+as	O
+coronavirus	B-DISO
+disease	I-DISO
+2019	I-DISO
+(	O
+COVID	B-DISO
+-	I-DISO
+19	I-DISO
+)	O
+by	O
+the	O
+World	O
+Health	O
+Organization	O
+respectively	O
+.	O
+
+The	O
+COVID	B-DISO
+-	I-DISO
+19	I-DISO
+epidemic	O
+is	O
+spreading	O
+in	O
+China	O
+and	O
+all	O
+over	O
+the	O
+world	O
+now	O
+.	O
+
+TITLE	O
+:	O
+COVID	B-DISO
+-	I-DISO
+19	I-DISO
+and	O
+Rationally	O
+Layered	B-ANAT
+Social	O
+Distancing	O
+.	O
+
+As	O
+COVID	B-DISO
+-	I-DISO
+19	I-DISO
+is	O
+unfolding	O
+,	O
+every	O
+day	O
+is	O
+marked	O
+by	O
+novel	O
+developments	O
+.	O
+
+ABSTRACT	O
+:	O
+An	O
+outbreak	O
+of	O
+severe	O
+acute	O
+respiratory	O
+syndrome	O
+coronavirus	O
+2	O
+(	O
+SARS	B-SPEC
+-	I-SPEC
+CoV	I-SPEC
+-	I-SPEC
+2	I-SPEC
+)	O
+has	O
+led	O
+to	O
+95	O
+333	O
+confirmed	O
+cases	O
+as	O
+of	O
+March	O
+5	O
+,	O
+2020	O
+.	O
+
+We	O
+combined	O
+a	O
+stochastic	O
+transmission	O
+model	O
+with	O
+data	O
+on	O
+cases	O
+of	O
+coronavirus	B-DISO
+disease	I-DISO
+2019	I-DISO
+(	O
+COVID	B-DISO
+-	I-DISO
+19	I-DISO
+)	O
+in	O
+Wuhan	O
+and	O
+international	O
+cases	O
+that	O
+originated	O
+in	O
+Wuhan	O
+to	O
+estimate	O
+how	O
+transmission	O
+had	O
+varied	O
+over	O
+time	O
+during	O
+January	O
+,	O
+2020	O
+,	O
+and	O
+February	O
+,	O
+2020	O
+.	O
+
+Wellcome	O
+Trust	O
+,	O
+Health	O
+Data	O
+Research	O
+UK	O
+,	O
+Bill	B-ANAT
+&	O
+Melinda	B-SPEC
+Gates	O
+Foundation	O
+,	O
+and	O
+National	O
+Institute	O
+for	O
+Health	O
+Research	O
+.	O
+
+Previous	O
+epidemiological	O
+investigations	O
+and	O
+animal	B-SPEC
+experiments	O
+suggest	O
+aerosol	O
+could	O
+perform	O
+as	O
+virus	B-SPEC
+transmitter	O
+.	O
+
+This	O
+pathogenic	O
+virus	B-SPEC
+has	O
+been	O
+identified	O
+in	O
+swabs	O
+performed	O
+on	O
+the	O
+throat	B-ANAT
+and	O
+nose	B-ANAT
+of	O
+patients	O
+who	O
+suffer	B-DISO
+from	O
+or	O
+are	O
+suspected	O
+of	O
+the	O
+disease	O
+.	O
+
+IL	O
+-	O
+37	O
+performs	O
+its	O
+immunosuppressive	O
+activity	O
+by	O
+acting	O
+on	O
+mTOR	B-PRGE
+and	O
+increasing	O
+the	O
+adenosine	B-CHED
+monophosphate	I-CHED
+(	O
+AMP	O
+)	O
+kinase	O
+.	O
+
+This	O
+cytokine	O
+inhibits	O
+class	B-SPEC
+II	B-PRGE
+histocompatibility	I-PRGE
+complex	I-PRGE
+(	O
+MHC	B-PROC
+)	O
+molecules	O
+and	O
+inflammation	B-DISO
+in	O
+inflammatory	O
+diseases	O
+by	O
+suppressing	O
+MyD88	B-PRGE
+and	O
+subsequently	O
+IL	O
+-	O
+1β	O
+,	O
+IL	B-FUNC
+-	I-FUNC
+6	I-FUNC
+,	O
+TNF	B-PRGE
+and	O
+CCL2	B-PRGE
+.	O
+
+TITLE	O
+:	O
+New	O
+insights	O
+on	O
+the	O
+antiviral	B-CHED
+effects	O
+of	O
+chloroquine	B-CHED
+against	O
+coronavirus	B-SPEC
+:	O
+what	O
+to	O
+expect	O
+for	O
+COVID	O
+-	O
+19	O
+?	O
+
+SARS	B-PRGE
+-	I-PRGE
+CoV	I-PRGE
+-	I-PRGE
+2	I-PRGE
+is	O
+the	O
+aetiological	O
+agent	O
+of	O
+coronavirus	B-DISO
+disease	I-DISO
+2019	I-DISO
+(	O
+COVID	B-DISO
+-	I-DISO
+19	I-DISO
+)	O
+characterised	O
+by	O
+pulmonary	B-DISO
+infection	I-DISO
+in	O
+humans	B-SPEC
+.	O
+
+TITLE	O
+:	O
+Clinical	O
+feature	O
+of	O
+COVID	B-DISO
+-	I-DISO
+19	I-DISO
+in	O
+elderly	O
+patients	O
+:	O
+a	O
+comparison	O
+with	O
+young	O
+and	O
+middle	O
+-	O
+aged	O
+patients	O
+.	O
+
+TITLE	O
+:	O
+Clinical	O
+progression	O
+of	O
+patients	O
+with	O
+COVID	B-DISO
+-	I-DISO
+19	I-DISO
+in	O
+Shanghai	O
+,	O
+China	O
+.	O
+
+The	O
+primary	O
+endpoint	O
+was	O
+a	O
+negative	O
+conversion	O
+rate	O
+of	O
+coronavirus	B-SPEC
+from	O
+the	O
+date	O
+of	O
+COVID	B-DISO
+-	I-DISO
+19	I-DISO
+diagnosis	O
+(	O
+day7	O
+,	O
+day14	O
+),	O
+and	O
+assessed	O
+whether	O
+the	O
+pneumonia	B-DISO
+was	O
+progressing	O
+or	O
+improving	O
+by	O
+chest	B-ANAT
+CT	O
+(	O
+day7	O
+).	O
+
+The	O
+chest	B-ANAT
+CT	O
+scans	O
+were	O
+improving	O
+for	O
+11	O
+(	O
+69	O
+%)	O
+of	O
+16	O
+patients	O
+in	O
+the	O
+combination	O
+group	O
+after	O
+seven	O
+days	O
+,	O
+compared	O
+with	O
+5	O
+(	O
+29	O
+%)	O
+of	O
+17	O
+in	O
+the	O
+monotherapy	O
+group	O
+(	O
+p	O
+<	O
+0	O
+·	O
+05	O
+).	O
+
+At	O
+least	O
+six	O
+neighboring	O
+countries	O
+(	O
+Bahrain	O
+,	O
+Iraq	O
+,	O
+Kuwait	O
+,	O
+Oman	O
+,	O
+Afghanistan	O
+and	O
+Pakistan	O
+)	O
+have	O
+reported	O
+imported	O
+COVID	B-DISO
+-	I-DISO
+19	I-DISO
+cases	O
+from	O
+Iran	O
+.	O
+
+Moreover	O
+,	O
+D	O
+-	O
+dimer	O
+and	O
+FDP	O
+values	O
+in	O
+patients	O
+with	O
+severe	O
+SARS	B-DISO
+-	I-DISO
+CoV	I-DISO
+-	I-DISO
+2	I-DISO
+infection	I-DISO
+were	O
+higher	O
+than	O
+those	O
+in	O
+patients	O
+with	O
+milder	O
+forms	O
+.	O
+
+Compared	O
+with	O
+healthy	O
+controls	O
+,	O
+prothrombin	B-PRGE
+time	O
+activity	O
+(	O
+PT	O
+-	O
+act	O
+)	O
+was	O
+lower	O
+in	O
+SARS	B-SPEC
+-	I-SPEC
+CoV	I-SPEC
+-	I-SPEC
+2	I-SPEC
+patients	O
+.	O
+
+TITLE	O
+:	O
+Potential	O
+preanalytical	O
+and	O
+analytical	O
+vulnerabilities	O
+in	O
+the	O
+laboratory	O
+diagnosis	O
+of	O
+coronavirus	B-SPEC
+disease	I-DISO
+2019	I-DISO
+(	O
+COVID	B-DISO
+-	I-DISO
+19	I-DISO
+).	O
+
+As	O
+the	O
+current	O
+gold	B-CHED
+standard	O
+for	O
+the	O
+etiological	O
+diagnosis	O
+of	O
+SARS	B-DISO
+-	I-DISO
+CoV	I-DISO
+-	I-DISO
+2	I-DISO
+infection	I-DISO
+is	O
+(	O
+real	O
+time	O
+)	O
+reverse	B-PROC
+transcription	I-PROC
+polymerase	O
+chain	O
+reaction	O
+(	O
+rRT	O
+-	O
+PCR	O
+)	O
+on	O
+respiratory	B-ANAT
+tract	I-ANAT
+specimens	O
+,	O
+the	O
+diagnostic	O
+accuracy	O
+of	O
+this	O
+technique	O
+shall	O
+be	O
+considered	O
+a	O
+foremost	O
+prerequisite	O
+.	O
+
+TITLE	O
+:	O
+Diagnosis	O
+and	O
+clinical	O
+management	O
+of	O
+severe	B-SPEC
+acute	I-SPEC
+respiratory	I-SPEC
+syndrome	I-SPEC
+Coronavirus	I-SPEC
+2	I-SPEC
+(	O
+SARS	B-DISO
+-	I-SPEC
+CoV	I-SPEC
+-	I-SPEC
+2	I-SPEC
+)	O
+infection	O
+:	O
+an	O
+operational	O
+recommendation	O
+of	O
+Peking	O
+Union	O
+Medical	O
+College	O
+Hospital	O
+(	O
+V2	O
+.	O
+0	O
+).	O
+
+The	O
+virus	B-SPEC
+was	O
+named	O
+severe	B-SPEC
+acute	I-SPEC
+respiratory	I-SPEC
+syndrome	I-SPEC
+coronavirus	I-SPEC
+2	I-SPEC
+(	O
+SARS	B-SPEC
+-	I-SPEC
+CoV	I-SPEC
+-	I-SPEC
+2	I-SPEC
+)	O
+by	O
+the	O
+International	O
+Committee	O
+on	O
+Taxonomy	O
+of	O
+Viruses	B-SPEC
+.	O
+
+TITLE	O
+:	O
+Equine	B-SPEC
+Coronavirus	B-SPEC
+-	O
+Associated	O
+Colitis	B-DISO
+in	O
+Horses	B-SPEC
+:	O
+A	O
+Retrospective	O
+Study	O
+.	O
+
+ECoV	O
+should	O
+be	O
+included	O
+as	O
+a	O
+differential	O
+diagnosis	O
+for	O
+individual	O
+horses	B-SPEC
+presenting	O
+with	O
+anorexia	B-DISO
+,	O
+fever	B-PROC
+,	O
+lethargy	B-DISO
+,	O
+and	O
+colitis	B-DISO
+.	O
+
+However	O
+,	O
+clinical	O
+use	O
+should	O
+either	O
+adhere	O
+to	O
+the	O
+Monitored	O
+Emergency	B-DISO
+Use	O
+of	O
+Unregistered	O
+Interventions	O
+(	O
+MEURI	O
+)	O
+framework	O
+or	O
+be	O
+ethically	O
+approved	O
+as	O
+a	O
+trial	O
+as	O
+stated	O
+by	O
+the	O
+World	O
+Health	O
+Organization	O
+.	O
+
+These	O
+foundational	O
+results	O
+are	O
+being	O
+advanced	O
+to	O
+control	O
+the	O
+current	O
+worldwide	O
+human	B-SPEC
+coronavirus	I-SPEC
+epidemic	O
+.	O
+
+TITLE	O
+:	O
+Applications	O
+of	O
+google	O
+search	O
+trends	O
+for	O
+risk	O
+communication	O
+in	O
+infectious	B-DISO
+disease	I-DISO
+management	O
+:	O
+A	O
+case	O
+study	O
+of	O
+COVID	O
+-	O
+19	O
+outbreak	O
+in	O
+Taiwan	O
+.	O
+
+We	O
+retrieved	O
+GT	O
+data	O
+for	O
+the	O
+specific	O
+locations	O
+of	O
+Taiwan	O
+nationwide	O
+and	O
+subregions	O
+using	O
+defined	O
+search	O
+terms	O
+related	O
+to	O
+coronavirus	B-SPEC
+,	O
+handwashing	O
+,	O
+and	O
+face	B-DISO
+masks	O
+.	O
+
+Searches	O
+related	O
+to	O
+COVID	B-DISO
+-	I-DISO
+19	I-DISO
+and	O
+face	B-DISO
+masks	O
+in	O
+Taiwan	O
+increased	O
+rapidly	O
+,	O
+following	O
+the	O
+announcements	O
+of	O
+Taiwan	O
+'	O
+first	O
+imported	O
+case	O
+and	O
+reached	O
+its	O
+peak	O
+as	O
+local	O
+cases	O
+were	O
+reported	O
+.	O
+
+TITLE	O
+:	O
+Prevalence	O
+of	O
+comorbidities	O
+in	O
+the	O
+novel	O
+Wuhan	B-SPEC
+coronavirus	I-SPEC
+(	O
+COVID	B-DISO
+-	I-DISO
+19	I-DISO
+)	O
+infection	B-DISO
+:	O
+a	O
+systematic	O
+review	O
+and	O
+meta	O
+-	O
+analysis	O
+.	O
+
+The	O
+most	O
+prevalent	O
+comorbidity	O
+were	O
+hypertension	B-DISO
+(	O
+17	O
+±	O
+7	O
+,	O
+95	O
+%	O
+CI	O
+14	O
+-	O
+22	O
+%)	O
+and	O
+diabetes	B-DISO
+(	O
+8	O
+±	O
+6	O
+,	O
+95	O
+%	O
+CI	O
+6	O
+-	O
+11	O
+%	O
+),	O
+followed	O
+by	O
+cardiovascular	B-DISO
+diseases	I-DISO
+(	O
+5	O
+±	O
+4	O
+,	O
+95	O
+%	O
+CI	O
+4	O
+-	O
+7	O
+%	O
+)	O
+and	O
+respiratory	B-DISO
+system	I-DISO
+disease	I-DISO
+(	O
+2	O
+±	O
+0	O
+,	O
+95	O
+%	O
+CI	O
+1	O
+-	O
+3	O
+%	O
+).	O
+
+RESULTS	O
+:	O
+Eight	O
+studies	O
+were	O
+included	O
+in	O
+the	O
+meta	B-SPEC
+-	O
+analysis	O
+,	O
+including	O
+46248	O
+infected	O
+patients	O
+.	O
+
+Viral	O
+load	O
+of	O
+SARS	B-PRGE
+-	I-PRGE
+CoV	I-PRGE
+-	I-PRGE
+2	I-PRGE
+,	O
+radiography	O
+and	O
+eosinophil	B-ANAT
+improved	O
+continuously	O
+in	O
+3	O
+-	O
+14	O
+,	O
+6	O
+-	O
+8	O
+and	O
+7	O
+-	O
+9	O
+days	O
+,	O
+respectively	O
+.	O
+
+After	O
+adjustment	O
+,	O
+those	O
+with	O
+refractory	O
+COVID	B-DISO
+-	I-DISO
+19	I-DISO
+were	O
+also	O
+more	O
+likely	O
+to	O
+have	O
+a	O
+male	O
+sex	O
+and	O
+manifestations	O
+of	O
+anorexia	B-DISO
+and	O
+fever	B-PROC
+on	O
+admission	O
+,	O
+and	O
+receive	O
+oxygen	B-CHED
+,	O
+expectorant	O
+and	O
+adjunctive	O
+agents	O
+(	O
+P	O
+<	O
+0	O
+.	O
+05	O
+)	O
+when	O
+considering	O
+the	O
+factors	O
+of	O
+disease	O
+severity	O
+on	O
+admission	O
+,	O
+mechanical	O
+ventilation	O
+,	O
+and	O
+ICU	O
+transfer	O
+.	O
+
+The	O
+patients	O
+with	O
+male	O
+sex	O
+,	O
+anorexia	B-DISO
+and	O
+no	O
+fever	B-PROC
+on	O
+admission	O
+predicted	O
+poor	O
+efficacy	O
+.	O
+
+Coinfection	B-DISO
+with	O
+SARS	B-SPEC
+-	I-SPEC
+COV	I-SPEC
+-	I-SPEC
+2	I-SPEC
+and	O
+other	O
+viruses	B-SPEC
+has	O
+been	O
+discussed	O
+as	O
+well	O
+.	O
+
+Extensive	O
+epidemiological	O
+,	O
+viral	O
+immunological	O
+,	O
+and	O
+current	O
+clinical	O
+evidences	O
+support	O
+the	O
+possibility	O
+that	O
+pulmonary	B-DISO
+fibrosis	I-DISO
+may	O
+be	O
+one	O
+of	O
+the	O
+major	O
+complications	O
+in	O
+COVID	B-DISO
+-	I-DISO
+19	I-DISO
+patients	O
+.	O
+
+ABSTRACT	O
+:	O
+An	O
+ongoing	O
+outbreak	O
+of	O
+pneumonia	O
+caused	O
+by	O
+a	O
+novel	B-SPEC
+coronavirus	I-SPEC
+[	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+coronavirus	B-SPEC
+(	O
+SARS	B-DISO
+-	O
+CoV	O
+)-	O
+2	O
+],	O
+named	O
+COVID	B-DISO
+-	I-DISO
+19	I-DISO
+,	O
+hit	O
+a	O
+major	O
+city	O
+of	O
+China	O
+,	O
+Wuhan	O
+in	O
+December	O
+2019	O
+and	O
+subsequently	O
+spread	O
+to	O
+other	O
+provinces	O
+/	O
+regions	O
+of	O
+China	O
+and	O
+overseas	O
+.	O
+
+In	O
+this	O
+study	O
+,	O
+we	O
+used	O
+a	O
+purely	O
+data	O
+-	O
+driven	O
+statistical	O
+method	O
+to	O
+estimate	O
+the	O
+CFR	O
+in	O
+the	O
+early	O
+phase	O
+of	O
+the	O
+COVID	B-DISO
+-	I-DISO
+19	I-DISO
+outbreak	O
+.	O
+
+Our	O
+early	O
+estimates	O
+suggest	O
+that	O
+the	O
+CFR	O
+of	O
+COVID	B-DISO
+-	I-DISO
+19	I-DISO
+is	O
+lower	O
+than	O
+the	O
+previous	O
+coronavirus	B-SPEC
+epidemics	O
+caused	O
+by	O
+SARS	B-DISO
+-	O
+CoV	O
+and	O
+Middle	O
+East	O
+respiratory	O
+syndrome	B-DISO
+coronavirus	B-SPEC
+(	O
+MERS	O
+-	O
+CoV	O
+).	O
+
+TITLE	O
+:	O
+Clinical	O
+features	O
+of	O
+deaths	B-PROC
+in	O
+the	O
+novel	B-SPEC
+coronavirus	I-SPEC
+epidemic	O
+in	O
+China	O
+.	O
+
+A	O
+Review	O
+of	O
+Coronaviruses	O
+and	O
+Ocular	B-ANAT
+Implications	O
+in	O
+Humans	B-SPEC
+and	O
+Animals	B-SPEC
+.	O
+
+The	O
+ocular	B-PROC
+implications	O
+of	O
+human	B-SPEC
+CoV	O
+infections	B-DISO
+have	O
+not	O
+been	O
+widely	O
+studied	O
+.	O
+
+However	O
+,	O
+CoVs	O
+have	O
+been	O
+known	O
+to	O
+cause	O
+various	O
+ocular	B-DISO
+infections	I-DISO
+in	O
+animals	B-SPEC
+.	O
+
+Older	O
+patients	O
+or	O
+those	O
+with	O
+underlying	O
+comorbidities	O
+are	O
+at	O
+higher	O
+risk	O
+of	O
+death	B-PROC
+.	O
+
+The	O
+likely	O
+aggregated	O
+effect	O
+of	O
+seasonal	O
+variation	O
+,	O
+infection	B-DISO
+control	O
+measures	O
+,	O
+and	O
+transmission	O
+rate	O
+variation	O
+is	O
+a	O
+prolonged	O
+pandemic	O
+wave	O
+with	O
+lower	O
+prevalence	O
+at	O
+any	O
+given	O
+time	O
+,	O
+thereby	O
+providing	O
+a	O
+window	O
+of	O
+opportunity	O
+for	O
+better	O
+preparation	O
+of	O
+health	O
+care	O
+systems	O
+.	O
+
+We	O
+also	O
+predict	O
+the	O
+unique	O
+N	O
+-	O
+and	O
+O	O
+-	O
+linked	O
+glycosylation	B-PROC
+sites	O
+of	O
+spike	O
+glycoprotein	B-CHED
+that	O
+distinguish	O
+it	O
+from	O
+the	O
+SARS	B-DISO
+and	O
+underlines	O
+shielding	O
+and	O
+camouflage	O
+of	O
+COVID	B-DISO
+-	I-DISO
+19	I-DISO
+from	O
+the	O
+host	B-COMP
+the	O
+defence	O
+system	O
+.	O
+
+Furthermore	O
+,	O
+our	O
+study	O
+also	O
+highlights	O
+the	O
+key	O
+finding	O
+that	O
+the	O
+S1	B-PRGE
+domain	I-PRGE
+of	O
+COVID	B-PRGE
+-	I-PRGE
+19	I-PRGE
+spike	I-PRGE
+glycoprotein	B-CHED
+potentially	O
+interacts	O
+with	O
+the	O
+human	B-SPEC
+CD26	O
+,	O
+a	O
+key	O
+immunoregulatory	O
+factor	O
+for	O
+hijacking	O
+and	O
+virulence	B-PROC
+.	O
+
+One	O
+week	O
+later	O
+,	O
+she	O
+was	O
+hospitalised	O
+with	O
+pneumonia	O
+and	O
+tested	O
+positive	O
+for	O
+SARS	B-PRGE
+-	I-PRGE
+CoV	I-PRGE
+-	I-PRGE
+2	I-PRGE
+.	O
+
+TITLE	O
+:	O
+Composition	O
+of	O
+human	B-SPEC
+-	O
+specific	O
+slow	O
+codons	O
+and	O
+slow	O
+di	O
+-	O
+codons	O
+in	O
+SARS	B-DISO
+-	O
+CoV	O
+and	O
+2019	B-SPEC
+-	I-SPEC
+nCoV	I-SPEC
+are	O
+lower	O
+than	O
+other	O
+coronaviruses	O
+suggesting	O
+a	O
+faster	O
+protein	O
+synthesis	O
+rate	O
+of	O
+SARS	B-DISO
+-	O
+CoV	O
+and	O
+2019	B-SPEC
+-	I-SPEC
+nCoV	I-SPEC
+.	O
+ABSTRACT	O
+:	O
+Translation	B-PROC
+of	O
+a	O
+genetic	O
+codon	O
+without	O
+a	O
+cognate	O
+tRNA	B-FUNC
+gene	O
+is	O
+affected	O
+by	O
+both	O
+the	O
+cognate	O
+tRNA	B-FUNC
+availability	O
+and	O
+the	O
+interaction	O
+with	O
+non	O
+-	O
+cognate	O
+isoacceptor	O
+tRNAs	O
+.	O
+
+An	O
+electronic	O
+search	O
+in	O
+Medline	O
+,	O
+Scopus	B-SPEC
+and	O
+Web	B-DISO
+of	O
+Science	O
+was	O
+performed	O
+to	O
+identify	O
+studies	O
+reporting	O
+data	O
+on	O
+platelet	B-ANAT
+count	O
+in	O
+COVID	B-DISO
+-	I-DISO
+19	I-DISO
+patients	O
+.	O
+
+Nine	O
+studies	O
+with	O
+1779	O
+COVID	B-DISO
+-	I-DISO
+19	I-DISO
+patients	O
+,	O
+399	O
+(	O
+22	O
+.	O
+4	O
+%)	O
+with	O
+severe	O
+disease	O
+,	O
+were	O
+included	O
+in	O
+the	O
+meta	B-SPEC
+-	O
+analysis	O
+.	O
+
+Since	O
+that	O
+time	O
+,	O
+Italy	O
+and	O
+nations	O
+throughout	O
+the	O
+world	O
+have	O
+adopted	O
+very	O
+stringent	O
+and	O
+severe	O
+measures	O
+to	O
+protect	O
+populations	O
+from	O
+spread	O
+of	O
+infection	B-DISO
+.	O
+
+No	O
+systematic	O
+reviews	O
+on	O
+COVID	B-DISO
+-	I-DISO
+19	I-DISO
+have	O
+been	O
+published	O
+to	O
+date	O
+.	O
+
+TITLE	O
+:	O
+Teicoplanin	O
+:	O
+an	O
+alternative	O
+drug	O
+for	O
+the	O
+treatment	O
+of	O
+coronavirus	B-SPEC
+COVID	B-DISO
+-	I-DISO
+19	I-DISO
+?	O
+
+TITLE	O
+:	O
+Ginkgolic	O
+acid	O
+inhibits	O
+fusion	O
+of	O
+enveloped	O
+viruses	B-SPEC
+.	O
+
+The	O
+evidence	O
+showed	O
+that	O
+asymptomatic	O
+carriers	O
+occurred	O
+more	O
+often	O
+in	O
+middle	O
+aged	O
+people	O
+who	O
+had	O
+close	O
+contact	O
+with	O
+infected	B-PRGE
+family	I-PRGE
+members	I-PRGE
+.	O
+
+ABSTRACT	O
+:	O
+Coronovirus	O
+disease	O
+2019	O
+(	O
+COVID	O
+-	O
+19	O
+)	O
+has	O
+spread	O
+rapidly	O
+across	O
+the	O
+globe	B-ANAT
+.	O
+
+To	O
+improve	O
+the	O
+recognition	O
+of	O
+COVID	B-DISO
+-	I-DISO
+19	I-DISO
+infection	I-DISO
+in	O
+children	O
+,	O
+we	O
+retrospectively	O
+reviewed	O
+two	O
+confirmed	O
+pediatric	O
+cases	O
+from	O
+two	O
+family	B-SPEC
+clusters	B-CHED
+.	O
+
+TITLE	O
+:	O
+Safety	O
+and	O
+efficacy	O
+of	O
+different	O
+anesthetic	O
+regimens	O
+for	O
+parturients	O
+with	O
+COVID	B-DISO
+-	I-DISO
+19	I-DISO
+undergoing	O
+Cesarean	O
+delivery	O
+:	O
+a	O
+case	O
+series	O
+of	O
+17	O
+patients	O
+.	O
+
+At	O
+this	O
+point	O
+in	O
+the	O
+global	O
+pandemic	O
+of	O
+COVID	B-DISO
+-	I-DISO
+19	I-DISO
+infection	I-DISO
+there	O
+is	O
+no	O
+evidence	O
+that	O
+SARS	B-PRGE
+-	I-PRGE
+CoV	I-PRGE
+-	I-PRGE
+2	I-PRGE
+undergoes	O
+intrauterine	B-ANAT
+or	O
+transplacental	O
+transmission	O
+from	O
+infected	O
+pregnant	O
+women	O
+to	O
+their	O
+fetuses	B-ANAT
+.	O
+
+ABSTRACT	O
+:	O
+Coronavirus	B-SPEC
+disease	I-DISO
+2019	I-DISO
+(	O
+COVID	O
+-	O
+2019	O
+)	O
+has	O
+been	O
+recognized	O
+as	O
+a	O
+global	O
+threat	O
+,	O
+and	O
+several	O
+studies	O
+are	O
+being	O
+conducted	O
+using	O
+various	O
+mathematical	O
+models	O
+to	O
+predict	O
+the	O
+probable	O
+evolution	O
+of	O
+this	O
+epidemic	O
+.	O
+
+However	O
+,	O
+whether	O
+these	O
+two	O
+enormous	O
+measures	O
+have	O
+led	O
+to	O
+significant	O
+changes	O
+in	O
+the	O
+spread	O
+of	O
+COVID	B-DISO
+-	I-DISO
+19	I-DISO
+cases	O
+remains	O
+unclear	O
+.	O
+
+Moreover	O
+,	O
+the	O
+correlation	O
+between	O
+domestic	O
+air	O
+traffic	O
+and	O
+COVID	B-DISO
+-	I-DISO
+19	I-DISO
+spread	O
+became	O
+weaker	O
+following	O
+lockdown	O
+(	O
+before	O
+lockdown	O
+:	O
+r	O
+=	O
+0	O
+.	O
+98	O
+,	O
+p	O
+<	O
+0	O
+.	O
+05	O
+vs	O
+.	O
+after	O
+lockdown	O
+:	O
+r	O
+=	O
+0	O
+.	O
+91	O
+,	O
+p	O
+=	O
+NS	O
+).	O
+
+TITLE	O
+:	O
+Who	O
+needs	O
+a	O
+Corona	B-CHED
+?	O
+
+The	O
+most	O
+common	O
+symptoms	O
+were	O
+fever	B-PROC
+(	O
+71	O
+.	O
+43	O
+%),	O
+cough	B-DISO
+(	O
+60	O
+.	O
+44	O
+%)	O
+and	O
+fatigue	B-DISO
+(	O
+43	O
+.	O
+96	O
+%).	O
+
+The	O
+newly	O
+discovered	O
+coronavirus	B-SPEC
+is	O
+similar	O
+to	O
+some	O
+β	O
+-	O
+coronaviruses	O
+found	O
+in	O
+bats	B-SPEC
+,	O
+but	O
+different	O
+from	O
+previously	O
+known	O
+SARS	B-PRGE
+-	I-PRGE
+CoV	I-PRGE
+and	O
+MERS	O
+-	O
+CoV	O
+.	O
+High	O
+sequence	O
+identities	O
+and	O
+similarities	O
+between	O
+2019	B-SPEC
+-	I-SPEC
+nCoV	I-SPEC
+and	O
+SARS	B-PRGE
+-	I-PRGE
+CoV	I-PRGE
+was	O
+found	O
+.	O
+
+RESULTS	O
+:	O
+Univariate	O
+analysis	O
+showed	O
+that	O
+:	O
+age	O
+,	O
+platelet	B-ANAT
+peaks	O
+and	O
+PLR	O
+at	O
+peak	O
+platelet	B-ANAT
+were	O
+the	O
+influencing	O
+factors	O
+in	O
+severe	O
+patients	O
+,	O
+multivariate	O
+analysis	O
+showed	O
+that	O
+the	O
+PLR	O
+value	O
+at	O
+peak	O
+platelet	B-ANAT
+during	O
+treatment	O
+was	O
+an	O
+independent	O
+influencing	O
+factor	O
+in	O
+severe	O
+patients	O
+.	O
+
+CONCLUSIONS	O
+:	O
+Single	O
+-	O
+center	O
+case	O
+series	O
+of	O
+the	O
+30	O
+hospitalized	O
+patients	O
+with	O
+confirmed	O
+COVID	B-DISO
+-	I-DISO
+19	I-DISO
+in	O
+Huizhou	O
+municipal	O
+central	O
+hospital	O
+,	O
+presumed	O
+that	O
+the	O
+number	O
+of	O
+platelets	B-ANAT
+and	O
+their	O
+dynamic	O
+changes	O
+during	O
+the	O
+treatment	O
+may	O
+have	O
+suggestion	O
+on	O
+the	O
+severity	O
+and	O
+prognosis	O
+of	O
+disease	O
+.	O
+
+We	O
+investigated	O
+forty	O
+-	O
+three	O
+adult	O
+patients	O
+with	O
+COVID	B-DISO
+-	I-DISO
+19	I-DISO
+.	O
+
+The	O
+specificity	O
+of	O
+predicting	O
+the	O
+severity	O
+of	O
+COVID	B-DISO
+-	I-DISO
+19	I-DISO
+during	O
+IL	B-FUNC
+-	I-FUNC
+6	I-FUNC
+and	O
+D	O
+-	O
+Dimer	O
+tandem	O
+testing	O
+was	O
+up	O
+to	O
+93	O
+.	O
+3	O
+%,	O
+while	O
+the	O
+sensitivity	O
+of	O
+IL	O
+-	O
+6	O
+and	O
+D	O
+-	O
+Dimer	O
+by	O
+parallel	O
+test	O
+in	O
+the	O
+severe	O
+COVID	B-DISO
+-	I-DISO
+19	I-DISO
+was	O
+96	O
+.	O
+4	O
+%.	O
+
+TITLE	O
+:	O
+Successful	O
+recovery	O
+of	O
+COVID	B-DISO
+-	I-DISO
+19	I-DISO
+pneumonia	I-DISO
+in	O
+a	O
+renal	B-ANAT
+transplant	B-ANAT
+recipient	O
+with	O
+long	O
+-	O
+term	O
+immunosuppression	B-PROC
+.	O
+
+Following	O
+a	O
+treatment	O
+regimen	O
+consisting	O
+of	O
+reduced	O
+immunosuppressant	B-CHED
+use	O
+and	O
+low	O
+dose	O
+methylprednisolone	B-CHED
+-	O
+based	O
+therapy	O
+,	O
+the	O
+COVID	B-DISO
+-	I-DISO
+19	I-DISO
+pneumonia	I-DISO
+in	O
+this	O
+long	O
+-	O
+term	O
+immunosuppressive	O
+patient	O
+was	O
+successfully	O
+recovered	O
+.	O
+
+TITLE	O
+:	O
+Reverse	O
+Logistics	O
+Network	O
+Design	O
+for	O
+Effective	O
+Management	O
+of	O
+Medical	B-ANAT
+Waste	I-ANAT
+in	O
+Epidemic	O
+Outbreaks	O
+:	O
+Insights	O
+from	O
+the	O
+Coronavirus	O
+Disease	O
+2019	O
+(	O
+COVID	B-DISO
+-	I-DISO
+19	I-DISO
+)	O
+Outbreak	O
+in	O
+Wuhan	O
+(	O
+China	O
+).	O
+
+However	O
+,	O
+no	O
+research	O
+has	O
+been	O
+conducted	O
+with	O
+the	O
+focus	O
+on	O
+the	O
+design	O
+of	O
+an	O
+epidemic	O
+reverse	O
+logistics	O
+network	O
+for	O
+dealing	O
+with	O
+medical	B-ANAT
+waste	I-ANAT
+during	O
+epidemic	O
+outbreaks	O
+,	O
+which	O
+,	O
+if	O
+improperly	O
+treated	O
+,	O
+may	O
+accelerate	O
+disease	O
+spread	O
+and	O
+pose	O
+a	O
+significant	O
+risk	O
+for	O
+both	O
+medical	O
+staffs	O
+and	O
+patients	O
+.	O
+
+The	O
+application	O
+of	O
+the	O
+model	O
+is	O
+illustrated	O
+with	O
+a	O
+case	O
+study	O
+based	O
+on	O
+the	O
+outbreak	O
+of	O
+the	O
+coronavirus	B-DISO
+disease	I-DISO
+2019	I-DISO
+(	O
+COVID	B-DISO
+-	I-DISO
+19	I-DISO
+)	O
+in	O
+Wuhan	O
+,	O
+China	O
+.	O
+
+TITLE	O
+:	O
+2019	B-SPEC
+Novel	I-SPEC
+Coronavirus	I-SPEC
+Disease	I-DISO
+(	O
+COVID	B-DISO
+-	I-DISO
+19	I-DISO
+):	O
+Paving	O
+the	O
+Road	O
+for	O
+Rapid	O
+Detection	O
+and	O
+Point	O
+-	O
+of	O
+-	O
+Care	O
+Diagnostics	O
+.	O
+
+The	O
+study	O
+was	O
+approved	O
+by	O
+both	O
+the	O
+Agence	O
+Nationale	O
+de	O
+la	O
+Sécurité	O
+du	O
+Médicament	O
+et	O
+des	B-DISO
+Produits	O
+de	O
+Santé	O
+(	O
+ANSM	O
+,	O
+on	O
+5	O
+October	O
+2018	O
+)	O
+and	O
+a	O
+National	O
+Institutional	O
+Review	O
+Board	O
+(	O
+CPP	O
+,	O
+on	O
+6	O
+November	O
+2018	O
+).	O
+
+Although	O
+these	O
+studies	O
+are	O
+relevant	O
+to	O
+control	O
+the	O
+current	O
+public	O
+emergency	B-DISO
+,	O
+more	O
+high	O
+-	O
+quality	O
+research	O
+is	O
+needed	O
+to	O
+provide	O
+valid	O
+and	O
+reliable	O
+ways	O
+to	O
+manage	O
+this	O
+kind	O
+of	O
+public	O
+health	O
+emergency	B-DISO
+in	O
+both	O
+the	O
+short	O
+-	O
+and	O
+long	O
+-	O
+term	O
+.	O
+
+ABSTRACT	O
+:	O
+Since	O
+December	O
+2019	O
+,	O
+62	O
+medical	O
+staff	O
+of	O
+Zhongnan	O
+Hospital	O
+in	O
+Wuhan	O
+,	O
+China	O
+have	O
+been	O
+hospitalised	O
+with	O
+coronavirus	B-DISO
+disease	I-DISO
+2019	I-DISO
+.	O
+
+ABSTRACT	O
+:	O
+The	O
+peak	O
+of	O
+Internet	O
+searches	O
+and	O
+social	O
+media	B-ANAT
+data	O
+about	O
+the	O
+coronavirus	B-DISO
+disease	I-DISO
+2019	I-DISO
+(	O
+COVID	B-DISO
+-	I-DISO
+19	I-DISO
+)	O
+outbreak	O
+occurred	O
+10	O
+-	O
+14	O
+days	O
+earlier	O
+than	O
+the	O
+peak	O
+of	O
+daily	O
+incidences	O
+in	O
+China	O
+.	O
+
+TITLE	O
+:	O
+A	O
+Sequence	O
+Homology	O
+and	O
+Bioinformatic	O
+Approach	O
+Can	O
+Predict	O
+Candidate	O
+Targets	O
+for	O
+Immune	B-PROC
+Responses	I-PROC
+to	O
+SARS	B-PRGE
+-	I-PRGE
+CoV	I-PRGE
+-	I-PRGE
+2	I-PRGE
+.	O
+
+We	O
+identified	O
+multiple	O
+specific	O
+regions	O
+in	O
+SARS	B-PRGE
+-	I-PRGE
+CoV	I-PRGE
+-	I-PRGE
+2	I-PRGE
+that	O
+have	O
+high	O
+homology	O
+to	O
+the	O
+SARS	B-DISO
+-	O
+CoV	O
+virus	B-SPEC
+.	O
+
+ABSTRACT	O
+:	O
+Chronic	O
+thromboembolic	O
+pulmonary	O
+hypertension	O
+(	O
+CTEPH	B-DISO
+)	O
+is	O
+the	O
+most	O
+severe	O
+long	O
+-	O
+term	O
+complication	B-DISO
+of	O
+acute	O
+pulmonary	B-DISO
+embolism	I-DISO
+(	O
+PE	O
+).	O
+
+Untreated	O
+,	O
+CTEPH	B-DISO
+is	O
+fatal	O
+,	O
+but	O
+,	O
+if	O
+diagnosed	O
+in	O
+time	O
+,	O
+successful	O
+surgical	O
+(	O
+pulmonary	B-ANAT
+endarterectomy	O
+),	O
+medical	O
+(	O
+pulmonary	B-DISO
+hypertension	I-DISO
+drugs	O
+)	O
+and	O
+/	O
+or	O
+interventional	O
+(	O
+balloon	O
+pulmonary	B-ANAT
+angioplasty	O
+)	O
+therapies	O
+have	O
+been	O
+shown	O
+to	O
+improve	O
+clinical	O
+outcomes	O
+,	O
+especially	O
+in	O
+case	O
+of	O
+successful	O
+pulmonary	B-ANAT
+endarterectomy	O
+.	O
+
+ABSTRACT	O
+:	O
+A	O
+novel	O
+coronavirus	O
+(	O
+severe	B-SPEC
+acute	I-SPEC
+respiratory	I-SPEC
+syndrome	I-SPEC
+coronavirus	I-SPEC
+2	I-SPEC
+)	O
+causes	O
+a	O
+cluster	O
+of	O
+pneumonia	B-DISO
+cases	O
+in	O
+Wuhan	O
+,	O
+China	O
+.	O
+
+The	O
+COVID	B-DISO
+19	I-DISO
+pandemic	O
+has	O
+led	O
+to	O
+the	O
+necessary	O
+postponement	O
+of	O
+much	O
+planned	O
+surgical	O
+activity	O
+with	O
+the	O
+cancellation	O
+of	O
+outpatient	O
+,	O
+diagnostic	O
+and	O
+operative	O
+work	O
+.	O
+
+These	O
+measures	O
+have	O
+been	O
+designed	O
+to	O
+'	O
+flatten	O
+the	O
+curve	O
+'	O
+and	O
+delay	O
+the	O
+spread	O
+of	O
+coronavirus	O
+whilst	O
+also	O
+freeing	O
+up	O
+capacity	O
+within	O
+hospitals	O
+for	O
+patients	O
+affected	O
+with	O
+the	O
+virus	B-SPEC
+.	O
+
+ABSTRACT	O
+:	O
+Since	O
+the	O
+end	O
+of	O
+2019	O
+,	O
+the	O
+coronavirus	B-DISO
+disease	I-DISO
+2019	I-DISO
+(	O
+COVID	B-DISO
+-	I-DISO
+19	I-DISO
+)	O
+has	O
+been	O
+extensively	O
+epidemic	O
+in	O
+China	O
+,	O
+which	O
+not	O
+only	O
+seriously	O
+threatens	O
+the	O
+safety	O
+and	O
+health	O
+of	O
+Chinese	O
+people	O
+,	O
+but	O
+also	O
+challenges	O
+the	O
+management	O
+of	O
+other	B-DISO
+infectious	I-DISO
+diseases	I-DISO
+.	O
+
+Due	O
+to	O
+the	O
+extensive	O
+spread	O
+and	O
+high	O
+transmission	O
+ability	O
+of	O
+the	O
+COVID	B-DISO
+-	I-DISO
+19	I-DISO
+,	O
+there	O
+is	O
+a	O
+possibility	O
+of	O
+virus	B-SPEC
+infections	B-DISO
+among	O
+malaria	B-PATH
+cases	O
+during	O
+the	O
+medical	O
+care	O
+-	O
+seeking	O
+behaviors	B-PROC
+and	O
+among	O
+healthcare	O
+professionals	O
+during	O
+clinical	O
+diagnosis	O
+and	O
+treatment	O
+,	O
+sample	O
+collection	O
+and	O
+testing	O
+and	O
+epidemiological	O
+surveys	O
+.	O
+
+ABSTRACT	O
+:	O
+Severe	O
+and	O
+critical	O
+coronavirus	O
+pneumonia	B-DISO
+2019	O
+(	O
+COVID	B-DISO
+-	I-DISO
+19	I-DISO
+)	O
+often	O
+occurs	O
+in	O
+elder	B-SPEC
+patients	O
+with	O
+multiple	O
+comorbidities	O
+,	O
+and	O
+severe	O
+hypoxemia	O
+events	O
+are	O
+an	O
+important	O
+factor	O
+in	O
+the	O
+deterioration	O
+of	O
+some	O
+cases	O
+.	O
+
+The	O
+critical	O
+type	O
+of	O
+COVID	B-DISO
+-	I-DISO
+19	I-DISO
+could	O
+progress	O
+to	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+and	O
+multi	O
+-	O
+organ	B-ANAT
+dysfunction	O
+,	O
+which	O
+are	O
+the	O
+most	O
+important	O
+causes	O
+of	O
+death	B-PROC
+.	O
+
+TITLE	O
+:	O
+Rapidly	O
+increasing	O
+cumulative	O
+incidence	O
+of	O
+coronavirus	B-SPEC
+disease	O
+(	O
+COVID	B-DISO
+-	I-DISO
+19	I-DISO
+)	O
+in	O
+the	O
+European	O
+Union	O
+/	O
+European	O
+Economic	O
+Area	O
+and	O
+the	O
+United	O
+Kingdom	O
+,	O
+1	O
+January	O
+to	O
+15	O
+March	O
+2020	O
+.	O
+
+ABSTRACT	O
+:	O
+Information	O
+on	O
+severity	O
+of	O
+coronavirus	B-SPEC
+disease	O
+(	O
+COVID	B-DISO
+-	I-DISO
+19	I-DISO
+)	O
+(	O
+transmissibility	O
+,	O
+disease	O
+seriousness	O
+,	O
+impact	O
+)	O
+is	O
+crucial	O
+for	O
+preparation	O
+of	O
+healthcare	O
+sectors	O
+.	O
+
+ACE2	B-PRGE
+receptors	I-PRGE
+serve	O
+as	O
+binding	B-FUNC
+sites	O
+for	O
+SARS	B-PRGE
+-	I-PRGE
+CoV	I-PRGE
+-	I-PRGE
+2	I-PRGE
+virions	B-COMP
+in	O
+the	O
+lungs	B-ANAT
+.	O
+
+ABSTRACT	O
+:	O
+The	O
+novel	O
+coronavirus	O
+infection	O
+(	O
+COVID	B-DISO
+-	I-DISO
+19	I-DISO
+or	O
+Coronavirus	B-DISO
+disease	I-DISO
+2019	I-DISO
+)	O
+that	O
+emerged	O
+from	O
+Wuhan	O
+,	O
+Hubei	O
+province	O
+of	O
+China	O
+has	O
+spread	O
+to	O
+many	O
+countries	O
+worldwide	O
+.	O
+
+Most	O
+of	O
+the	O
+efforts	O
+for	O
+developing	O
+CoV	O
+vaccines	O
+and	O
+drugs	O
+target	O
+the	O
+spike	O
+glycoprotein	B-CHED
+or	O
+S	B-PRGE
+protein	I-PRGE
+,	O
+the	O
+major	O
+inducer	O
+of	O
+neutralizing	O
+antibodies	B-COMP
+.	O
+
+In	O
+-	O
+hospital	O
+mortality	O
+was	O
+33	O
+.	O
+3	O
+%	O
+(	O
+3	O
+/	O
+9	O
+),	O
+including	O
+two	O
+with	O
+recurrent	O
+septic	B-DISO
+shock	I-DISO
+and	O
+one	O
+with	O
+ventilator	O
+-	O
+induced	O
+severe	O
+pneumomediastinum	O
+and	O
+subcutaneous	B-DISO
+emphysema	I-DISO
+.	O
+
+We	O
+conducted	O
+a	O
+randomized	O
+,	O
+controlled	O
+,	O
+open	O
+-	O
+label	B-CHED
+trial	O
+involving	O
+hospitalized	O
+adult	O
+patients	O
+with	O
+confirmed	O
+SARS	B-DISO
+-	I-DISO
+CoV	I-DISO
+-	I-DISO
+2	I-DISO
+infection	I-DISO
+,	O
+which	O
+causes	O
+the	O
+respiratory	O
+illness	O
+Covid	B-DISO
+-	I-DISO
+19	I-DISO
+,	O
+and	O
+an	O
+oxygen	B-CHED
+saturation	O
+(	O
+Sao	O
+A	O
+total	O
+of	O
+199	O
+patients	O
+with	O
+laboratory	O
+-	O
+confirmed	O
+SARS	B-DISO
+-	I-DISO
+CoV	I-DISO
+-	I-DISO
+2	I-DISO
+infection	I-DISO
+underwent	O
+randomization	O
+;	O
+99	O
+were	O
+assigned	O
+to	O
+the	O
+lopinavir	O
+-	O
+ritonavir	B-CHED
+group	O
+,	O
+and	O
+100	O
+to	O
+the	O
+standard	O
+-	O
+care	O
+group	O
+.	O
+
+(	O
+Funded	O
+by	O
+Major	O
+Projects	O
+of	O
+National	O
+Science	O
+and	O
+Technology	O
+on	O
+New	O
+Drug	O
+Creation	O
+and	O
+Development	B-PROC
+and	O
+others	O
+;	O
+Chinese	O
+Clinical	O
+Trial	O
+Register	O
+number	O
+,	O
+ChiCTR2000029308	O
+.).	O
+
+TITLE	O
+:	O
+The	O
+Cholera	B-DISO
+Epidemics	O
+in	O
+Hamburg	O
+and	O
+What	O
+to	O
+Learn	B-PROC
+for	O
+COVID	B-DISO
+-	I-DISO
+19	I-DISO
+(	O
+SARS	B-PRGE
+-	I-PRGE
+CoV	I-PRGE
+-	I-PRGE
+2	I-PRGE
+).	O
+
+We	O
+found	O
+that	O
+these	O
+multiple	O
+-	O
+dye	B-CHED
+probes	O
+allow	O
+reliable	O
+detection	O
+and	O
+localization	B-PROC
+of	O
+mRNA	B-CHED
+with	O
+only	O
+a	O
+very	O
+small	O
+number	O
+(	O
+5	O
+-	O
+10	O
+)	O
+of	O
+probe	O
+strands	O
+.	O
+
+Rapid	O
+diagnosis	O
+of	O
+concomitant	O
+COVID	B-DISO
+-	I-DISO
+19	I-DISO
+,	O
+safe	O
+and	O
+effective	O
+transportation	O
+,	O
+implementation	O
+of	O
+the	O
+interventional	O
+procedure	O
+,	O
+protection	O
+of	O
+vascular	B-ANAT
+surgical	O
+team	O
+and	O
+postoperative	O
+management	O
+and	O
+follow	O
+-	O
+up	O
+of	O
+such	O
+patients	O
+have	O
+become	O
+urgent	O
+problems	O
+for	O
+us	O
+.	O
+
+TITLE	O
+:	O
+Porcine	B-SPEC
+epidemic	B-DISO
+diarrhea	I-DISO
+:	O
+the	O
+return	O
+of	O
+an	O
+old	O
+disease	O
+.	O
+
+This	O
+review	O
+sums	O
+up	O
+the	O
+current	O
+knowledge	O
+on	O
+the	O
+virus	B-SPEC
+,	O
+its	O
+transmission	O
+and	O
+its	O
+worldwide	O
+molecular	O
+epidemiology	O
+,	O
+on	O
+the	O
+physiopathology	O
+of	O
+the	O
+disease	O
+and	O
+the	O
+control	O
+measures	O
+.	O
+
+We	O
+used	O
+transcriptomics	O
+approaches	O
+to	O
+compare	O
+the	O
+scope	O
+and	O
+kinetics	O
+of	O
+the	O
+host	B-PROC
+response	I-PROC
+to	O
+the	O
+wild	O
+-	O
+type	O
+,	O
+DUBmut	O
+,	O
+and	O
+EndoUmut	O
+viruses	B-SPEC
+in	O
+infected	O
+macrophages	B-ANAT
+.	O
+
+We	O
+found	O
+that	O
+the	O
+EndoUmut	O
+virus	B-SPEC
+activates	O
+a	O
+focused	O
+response	O
+predominantly	O
+involving	O
+type	B-PRGE
+I	I-PRGE
+interferons	I-PRGE
+and	O
+interferon	B-PRGE
+-	I-PRGE
+related	I-PRGE
+genes	I-PRGE
+,	O
+whereas	O
+the	O
+WT	O
+and	O
+DUBmut	O
+viruses	B-SPEC
+more	O
+broadly	O
+stimulate	O
+upregulation	B-PROC
+of	O
+over	O
+2	O
+,	O
+800	O
+genes	O
+,	O
+including	O
+networks	O
+associated	O
+with	O
+activating	O
+the	O
+unfolded	O
+protein	O
+response	O
+(	O
+UPR	O
+),	O
+and	O
+the	O
+proinflammatory	O
+response	O
+associated	O
+with	O
+viral	B-DISO
+pathogenesis	I-DISO
+.	O
+
+TITLE	O
+:	O
+COVID	B-DISO
+-	I-DISO
+19	I-DISO
+:	O
+Knowns	O
+,	O
+Unknowns	O
+,	O
+and	O
+Questions	O
+.	O
+
+The	O
+population	O
+were	O
+divided	O
+into	O
+three	O
+compartments	B-ANAT
+:	O
+Susceptible	O
+,	O
+Infected	O
+,	O
+Removed	O
+.	O
+
+Severe	O
+ARDS	B-DISO
+reflects	O
+the	O
+hallmark	O
+of	O
+a	O
+critical	O
+course	O
+of	O
+the	O
+disease	O
+.	O
+
+TITLE	O
+:	O
+AI	O
+-	O
+Driven	O
+Tools	O
+for	O
+Coronavirus	B-SPEC
+Outbreak	O
+:	O
+Need	O
+of	O
+Active	O
+Learning	B-PROC
+and	O
+Cross	O
+-	O
+Population	O
+Train	O
+/	O
+Test	O
+Models	O
+on	O
+Multitudinal	O
+/	O
+Multimodal	O
+Data	O
+.	O
+
+However	O
+,	O
+unlike	O
+other	O
+healthcare	O
+issues	O
+,	O
+for	O
+COVID	B-DISO
+-	I-DISO
+19	I-DISO
+,	O
+to	O
+detect	O
+COVID	B-DISO
+-	I-DISO
+19	I-DISO
+,	O
+AI	O
+-	O
+driven	O
+tools	O
+are	O
+expected	O
+to	O
+have	O
+active	O
+learning	B-PROC
+-	O
+based	O
+cross	O
+-	O
+population	O
+train	O
+/	O
+test	O
+models	O
+that	O
+employs	O
+multitudinal	O
+and	O
+multimodal	O
+data	O
+,	O
+which	O
+is	O
+the	O
+primary	O
+purpose	O
+of	O
+the	O
+paper	O
+.	O
+
+Our	O
+case	O
+of	O
+COVID	B-DISO
+-	I-DISO
+19	I-DISO
+pneumonia	I-DISO
+showed	O
+multiple	O
+subpleural	O
+GGOs	O
+in	O
+bilateral	O
+lung	B-ANAT
+,	O
+rapid	O
+progression	O
+,	O
+and	O
+it	O
+also	O
+accompanied	O
+nodular	O
+GGOs	O
+on	O
+chest	B-ANAT
+CT	O
+.	O
+
+CONCLUSIONS	O
+:	O
+Our	O
+case	O
+of	O
+COVID	O
+-	O
+19	O
+pneumonia	O
+showed	O
+multiple	O
+subpleural	O
+GGOs	O
+in	O
+bilateral	O
+lung	B-ANAT
+,	O
+rapid	O
+progression	O
+,	O
+and	O
+it	O
+also	O
+accompanied	O
+nodular	O
+GGOs	O
+on	O
+chest	B-ANAT
+CT	O
+.	O
+
+TITLE	O
+:	O
+Is	O
+nicotine	B-CHED
+exposure	O
+linked	O
+to	O
+cardiopulmonary	B-ANAT
+vulnerability	O
+to	O
+COVID	B-DISO
+-	I-DISO
+19	I-DISO
+in	O
+the	O
+general	O
+population	O
+?	O
+
+TITLE	O
+:	O
+Oral	B-ANAT
+mite	O
+anaphylaxis	B-DISO
+after	O
+ingestion	O
+of	O
+Korean	O
+pancake	O
+.	O
+
+ABSTRACT	O
+:	O
+Oral	B-ANAT
+mite	O
+anaphylaxis	B-DISO
+(	O
+OMA	O
+)	O
+is	O
+a	O
+syndrome	O
+characterized	O
+by	O
+severe	O
+allergic	O
+manifestations	O
+occurring	O
+in	O
+atopic	B-DISO
+patients	O
+shortly	O
+after	O
+the	O
+intake	O
+of	O
+foods	O
+made	O
+with	O
+mite	O
+-	O
+contaminated	O
+wheat	B-SPEC
+flour	O
+.	O
+
+The	O
+ingredients	O
+in	O
+the	O
+buchimgae	O
+were	O
+eggs	O
+,	O
+shrimps	B-SPEC
+and	O
+chopped	O
+Chinese	O
+chives	B-SPEC
+,	O
+but	O
+the	O
+girl	O
+had	O
+previously	O
+consumed	O
+these	O
+individual	O
+ingredients	O
+without	O
+incident	O
+.	O
+
+From	O
+these	O
+findings	O
+,	O
+the	O
+anaphylactic	O
+episode	O
+in	O
+this	O
+patient	O
+was	O
+concluded	O
+to	O
+be	O
+the	O
+result	O
+of	O
+ingestion	O
+of	O
+mixed	O
+wheat	B-SPEC
+flour	O
+contaminated	O
+with	O
+mites	O
+.	O
+
+TITLE	O
+:	O
+Transmission	O
+potential	O
+of	O
+the	O
+novel	B-SPEC
+coronavirus	I-SPEC
+(	O
+COVID	B-DISO
+-	I-DISO
+19	I-DISO
+)	O
+onboard	O
+the	O
+diamond	B-CHED
+Princess	O
+Cruises	O
+Ship	O
+,	O
+2020	O
+.	O
+
+Here	O
+we	O
+reported	O
+the	O
+screening	O
+,	O
+clinical	O
+feathers	B-ANAT
+,	O
+and	O
+treatment	O
+process	O
+of	O
+a	O
+family	B-SPEC
+cluster	O
+involving	O
+three	O
+COVID	B-DISO
+-	I-DISO
+19	I-DISO
+patients	O
+.	O
+
+To	O
+better	O
+understand	O
+its	O
+dynamics	O
+in	O
+Italy	O
+,	O
+we	O
+analysed	O
+complete	O
+genomes	O
+of	O
+SARS	B-SPEC
+-	I-SPEC
+CoV	I-SPEC
+-	I-SPEC
+2	I-SPEC
+isolates	O
+,	O
+obtained	O
+directly	O
+from	O
+clinical	O
+samples	O
+.	O
+
+TITLE	O
+:	O
+2019	B-SPEC
+-	I-SPEC
+nCoV	I-SPEC
+:	O
+The	O
+Identify	O
+-	O
+Isolate	O
+-	O
+Inform	O
+(	O
+3I	O
+)	O
+Tool	O
+Applied	O
+to	O
+a	O
+Novel	O
+Emerging	O
+Coronavirus	B-SPEC
+.	O
+
+ABSTRACT	O
+:	O
+2019	O
+Novel	O
+Coronavirus	O
+(	O
+2019	B-SPEC
+-	I-SPEC
+nCoV	I-SPEC
+)	O
+is	O
+an	O
+emerging	B-DISO
+infectious	I-DISO
+disease	I-DISO
+closely	O
+related	O
+to	O
+MERS	O
+-	O
+CoV	O
+and	O
+SARS	B-PRGE
+-	I-PRGE
+CoV	I-PRGE
+that	O
+was	O
+first	O
+reported	O
+in	O
+Wuhan	O
+City	O
+,	O
+Hubei	O
+Province	O
+,	O
+China	O
+in	O
+December	O
+2019	O
+.	O
+
+The	O
+Identify	O
+-	O
+Isolate	O
+-	O
+Inform	O
+(	O
+3I	O
+)	O
+Tool	O
+,	O
+originally	O
+conceived	O
+for	O
+the	O
+initial	O
+detection	O
+and	O
+management	O
+of	O
+Ebola	O
+virus	O
+and	O
+later	O
+adjusted	O
+for	O
+other	O
+infectious	B-DISO
+agents	O
+,	O
+can	O
+be	O
+adapted	O
+for	O
+any	O
+emerging	B-DISO
+infectious	I-DISO
+disease	I-DISO
+.	O
+
+This	O
+paper	O
+reports	O
+a	O
+modification	O
+of	O
+the	O
+3I	O
+Tool	O
+for	O
+use	O
+in	O
+the	O
+initial	O
+detection	O
+and	O
+management	O
+of	O
+patients	O
+under	O
+investigation	O
+for	O
+2019	B-SPEC
+-	I-SPEC
+nCoV	I-SPEC
+.	O
+After	O
+initial	O
+assessment	O
+for	O
+symptoms	O
+and	O
+epidemiological	O
+risk	O
+factors	O
+,	O
+including	O
+travel	O
+to	O
+affected	O
+areas	O
+and	O
+exposure	O
+to	O
+confirmed	O
+2019	B-SPEC
+-	I-SPEC
+nCoV	I-SPEC
+patients	O
+within	O
+14	O
+days	O
+,	O
+patients	O
+are	O
+classified	O
+in	O
+a	O
+risk	O
+-	O
+stratified	O
+system	O
+.	O
+
+Upon	O
+confirmation	O
+of	O
+a	O
+suspected	O
+2019	B-SPEC
+-	I-SPEC
+nCoV	I-SPEC
+case	O
+,	O
+affected	O
+persons	O
+must	O
+immediately	O
+be	O
+placed	O
+in	O
+airborne	O
+infection	B-DISO
+isolation	O
+and	O
+the	O
+appropriate	O
+public	O
+health	O
+agencies	O
+notified	O
+.	O
+
+Nonetheless	O
+,	O
+some	O
+structural	O
+and	O
+practical	O
+aspects	O
+may	O
+generate	O
+substantial	O
+hurdles	O
+in	O
+providing	O
+timely	O
+and	O
+efficient	O
+response	O
+to	O
+this	O
+infectious	O
+emergency	B-DISO
+,	O
+which	O
+basically	O
+include	O
+inadequate	O
+(	O
+insufficient	O
+)	O
+environment	O
+and	O
+shortage	O
+of	O
+technical	O
+and	O
+human	B-SPEC
+resources	O
+for	O
+facing	O
+enhanced	O
+volume	O
+of	O
+tests	O
+on	O
+many	O
+infected	O
+patients	O
+,	O
+some	O
+of	O
+whom	O
+are	O
+with	O
+severe	O
+disease	O
+.	O
+
+TITLE	O
+:	O
+Natural	O
+small	O
+molecules	O
+as	O
+inhibitors	B-CHED
+of	O
+coronavirus	B-SPEC
+lipid	B-CHED
+-	O
+dependent	O
+attachment	O
+to	O
+host	B-COMP
+cells	B-ANAT
+:	O
+a	O
+possible	O
+strategy	O
+for	O
+reducing	O
+SARS	B-SPEC
+-	I-SPEC
+COV	I-SPEC
+-	I-SPEC
+2	I-SPEC
+infectivity	O
+?	O
+
+More	O
+research	O
+into	O
+these	O
+molecules	O
+and	O
+methods	O
+would	O
+be	O
+worthwhile	O
+as	O
+it	O
+could	O
+provide	O
+insights	O
+the	O
+mechanism	O
+of	O
+transmission	O
+of	O
+SARS	O
+-	O
+COV	O
+-	O
+2	O
+and	O
+,	O
+into	O
+how	O
+they	O
+could	O
+become	O
+a	O
+basis	O
+for	O
+new	O
+antiviral	B-CHED
+strategies	O
+.	O
+
+This	O
+report	O
+describes	O
+findings	O
+from	O
+the	O
+initial	O
+phase	O
+of	O
+the	O
+cruise	O
+ship	O
+investigation	O
+into	O
+COVID	B-DISO
+-	I-DISO
+19	I-DISO
+cases	O
+among	O
+crew	O
+members	O
+during	O
+February	O
+4	O
+-	O
+12	O
+,	O
+2020	O
+.	O
+
+ABSTRACT	O
+:	O
+Radiologic	O
+characteristics	O
+of	O
+2019	B-SPEC
+novel	I-SPEC
+coronavirus	I-SPEC
+(	O
+2019	B-SPEC
+-	I-SPEC
+nCoV	I-SPEC
+)	O
+infected	O
+pneumonia	B-DISO
+(	O
+NCIP	O
+)	O
+which	O
+had	O
+not	O
+been	O
+fully	O
+understood	O
+are	O
+especially	O
+important	O
+for	O
+diagnosing	O
+and	O
+predicting	O
+prognosis	O
+.	O
+
+The	O
+median	O
+CT	O
+score	O
+of	O
+mortality	O
+group	O
+was	O
+higher	O
+compared	O
+to	O
+survival	O
+group	O
+(	O
+30	O
+(	O
+IQR	O
+7	O
+-	O
+13	O
+)	O
+vs	O
+12	O
+(	O
+IQR	O
+11	O
+-	O
+43	O
+),	O
+P	O
+=	O
+0	O
+.	O
+021	O
+),	O
+with	O
+more	O
+frequency	O
+of	O
+consolidation	O
+(	O
+40	O
+%	O
+vs	O
+6	O
+%,	O
+P	O
+=	O
+0	O
+.	O
+047	O
+)	O
+and	O
+air	B-CHED
+bronchogram	O
+(	O
+60	O
+%	O
+vs	O
+12	O
+%,	O
+P	O
+=	O
+0	O
+.	O
+025	O
+).	O
+
+TITLE	O
+:	O
+COVID	B-DISO
+-	I-DISO
+19	I-DISO
+epidemic	O
+in	O
+Switzerland	O
+:	O
+on	O
+the	O
+importance	O
+of	O
+testing	O
+,	O
+contact	O
+tracing	O
+and	O
+isolation	O
+.	O
+
+There	O
+are	O
+likely	O
+many	O
+people	O
+with	O
+undetected	O
+SARS	B-DISO
+-	I-DISO
+CoV	I-DISO
+-	I-DISO
+2	I-DISO
+infection	I-DISO
+because	O
+testing	O
+efforts	O
+are	O
+currently	O
+not	O
+detecting	O
+all	O
+infected	O
+people	O
+,	O
+including	O
+some	O
+with	O
+clinical	O
+disease	O
+compatible	O
+with	O
+COVID	B-DISO
+-	I-DISO
+19	I-DISO
+.	O
+
+Spreading	O
+mainly	O
+through	O
+the	O
+droplet	O
+route	O
+,	O
+the	O
+virus	B-SPEC
+causes	O
+mild	O
+symptoms	O
+in	O
+the	O
+majority	O
+of	O
+cases	O
+,	O
+the	O
+most	O
+common	O
+being	O
+:	O
+fever	B-PROC
+(	O
+80	O
+%),	O
+dry	B-DISO
+cough	I-DISO
+(	O
+56	O
+%),	O
+fatigue	B-DISO
+(	O
+22	O
+%)	O
+and	O
+muscle	B-DISO
+pain	I-DISO
+(	O
+7	O
+%);	O
+less	O
+common	O
+symptoms	O
+include	O
+a	O
+sore	B-DISO
+throat	I-DISO
+,	O
+a	O
+runny	B-DISO
+nose	I-DISO
+,	O
+diarrhea	B-DISO
+,	O
+hemoptysis	B-DISO
+and	O
+chills	B-DISO
+.	O
+
+In	O
+this	O
+article	O
+we	O
+describe	O
+cerebral	B-DISO
+malaria	B-PATH
+caused	O
+by	O
+the	O
+Plasmodium	B-SPEC
+falciparum	I-SPEC
+in	O
+a	O
+45	O
+-	O
+year	O
+-	O
+old	O
+Polish	O
+patient	O
+,	O
+who	O
+traveled	O
+to	O
+Cameroon	O
+without	O
+any	O
+malaria	B-PATH
+prophylaxis	O
+.	O
+
+To	O
+avoid	O
+development	B-PROC
+of	O
+cerebral	B-DISO
+malaria	B-PATH
+,	O
+the	O
+illness	O
+should	O
+be	O
+diagnosed	O
+immediately	O
+.	O
+
+TITLE	O
+:	O
+Co	B-DISO
+-	I-DISO
+infection	I-DISO
+with	O
+SARS	B-PRGE
+-	I-PRGE
+CoV	I-PRGE
+-	I-PRGE
+2	I-PRGE
+and	O
+Human	B-PRGE
+Metapneumovirus	I-PRGE
+.	O
+
+ABSTRACT	O
+:	O
+The	O
+novel	B-SPEC
+coronavirus	I-SPEC
+(	O
+now	O
+called	O
+SARS	O
+-	O
+CoV	O
+-	O
+2	O
+)	O
+initially	O
+discovered	O
+in	O
+Wuhan	O
+,	O
+China	O
+,	O
+has	O
+now	O
+become	O
+a	O
+global	O
+pandemic	O
+.	O
+
+The	O
+patient	O
+underwent	O
+nasopharyngeal	B-ANAT
+swab	I-ANAT
+for	O
+a	O
+respiratory	O
+pathogen	O
+panel	O
+as	O
+well	O
+as	O
+SARS	B-PRGE
+-	I-PRGE
+CoV	I-PRGE
+-	I-PRGE
+2	I-PRGE
+RT	O
+-	O
+PCR	O
+.	O
+
+(	O
+4	O
+)	O
+The	O
+surgical	O
+medical	O
+workers	O
+who	O
+process	O
+colorectal	B-PATH
+cancer	I-PATH
+patients	O
+with	O
+COVID	B-DISO
+-	I-DISO
+19	I-DISO
+must	O
+be	O
+protected	O
+by	O
+three	O
+-	O
+level	O
+.	O
+
+TITLE	O
+:	O
+[	O
+Chemotherapy	O
+strategy	O
+for	O
+colorectal	B-PATH
+cancer	I-PATH
+under	O
+the	O
+outbreak	O
+of	O
+corona	B-DISO
+virus	B-PROC
+disease	I-PROC
+2019	I-DISO
+].	O
+
+ABSTRACT	O
+:	O
+The	O
+outbreak	O
+of	O
+corona	O
+virus	B-PROC
+disease	I-PROC
+2019	O
+(	O
+COVID	B-DISO
+-	I-DISO
+19	I-DISO
+)	O
+makes	O
+the	O
+medical	O
+treatment	O
+of	O
+colorectal	B-DISO
+cancers	I-DISO
+difficult	O
+.	O
+
+All	O
+43	O
+patients	O
+(	O
+59	O
+%)	O
+with	O
+common	O
+type	O
+presented	O
+unique	O
+or	O
+multiple	O
+ground	O
+-	O
+glass	O
+opacities	B-DISO
+(	O
+GGO	O
+)	O
+in	O
+the	O
+periphery	O
+of	O
+the	O
+lungs	B-ANAT
+,	O
+with	O
+or	O
+without	O
+interlobular	O
+septal	O
+thickening	O
+.	O
+
+RESULTS	O
+:	O
+Six	O
+patients	O
+(	O
+8	O
+%)	O
+were	O
+diagnosed	O
+as	O
+mild	O
+type	O
+pneumonia	B-DISO
+;	O
+these	O
+patients	O
+had	O
+no	O
+obvious	O
+abnormal	O
+CT	O
+findings	O
+or	O
+manifested	O
+mild	O
+changes	O
+of	O
+lung	B-DISO
+infection	I-DISO
+.	O
+
+Based	O
+on	O
+a	O
+comprehensive	O
+literature	O
+review	O
+and	O
+the	O
+experience	O
+in	O
+the	O
+frontline	O
+,	O
+we	O
+aim	O
+to	O
+review	O
+the	O
+typical	O
+and	O
+relatively	O
+atypical	O
+CT	O
+manifestations	O
+with	O
+representative	O
+COVID	B-DISO
+-	I-DISO
+19	I-DISO
+cases	O
+at	O
+our	O
+hospital	O
+,	O
+and	O
+hope	O
+to	O
+strengthen	O
+the	O
+recognition	O
+of	O
+these	O
+features	O
+with	O
+radiologists	O
+and	O
+help	O
+them	O
+make	O
+a	O
+quick	O
+and	O
+accurate	O
+diagnosis	O
+.	O
+
+People	O
+of	O
+all	O
+ages	O
+are	O
+susceptible	O
+to	O
+SARS	B-DISO
+-	I-DISO
+CoV	I-DISO
+-	I-DISO
+2	I-DISO
+infection	I-DISO
+.	O
+
+The	O
+most	O
+common	O
+symptoms	O
+were	O
+polypnea	B-DISO
+(	O
+8	O
+/	O
+8	O
+),	O
+followed	O
+by	O
+fever	B-PROC
+(	O
+6	O
+/	O
+8	O
+)	O
+and	O
+cough	B-DISO
+(	O
+6	O
+/	O
+8	O
+).	O
+
+Two	O
+critically	B-DISO
+ill	I-DISO
+patients	O
+underwent	O
+invasive	O
+mechanical	O
+ventilation	O
+.	O
+
+TITLE	O
+:	O
+Drive	O
+-	O
+Through	O
+Screening	O
+Center	O
+for	O
+COVID	B-DISO
+-	I-DISO
+19	I-DISO
+:	O
+a	O
+Safe	O
+and	O
+Efficient	O
+Screening	O
+System	O
+against	O
+Massive	O
+Community	O
+Outbreak	O
+.	O
+
+It	O
+could	O
+be	O
+implemented	O
+in	O
+other	O
+countries	O
+to	O
+cope	O
+with	O
+the	O
+global	O
+COVID	B-DISO
+-	I-DISO
+19	I-DISO
+outbreak	O
+and	O
+transformed	O
+according	O
+to	O
+their	O
+own	O
+situations	O
+.	O
+
+TITLE	O
+:	O
+How	O
+Should	O
+the	O
+Rehabilitation	O
+Community	O
+Prepare	O
+for	O
+2019	B-SPEC
+-	I-SPEC
+nCoV	I-SPEC
+?	O
+
+This	O
+study	O
+aimed	O
+to	O
+investigate	O
+the	O
+effects	O
+of	O
+social	O
+capital	O
+on	O
+sleep	B-PROC
+quality	O
+and	O
+the	O
+mechanisms	O
+involved	O
+in	O
+people	O
+who	O
+self	O
+-	O
+isolated	O
+at	O
+home	O
+for	O
+14	O
+days	O
+in	O
+January	O
+2020	O
+during	O
+the	O
+COVID	B-DISO
+-	I-DISO
+19	I-DISO
+epidemic	O
+in	O
+central	O
+China	O
+.	O
+
+CONCLUSIONS	O
+During	O
+a	O
+period	O
+of	O
+individual	O
+self	O
+-	O
+isolation	O
+during	O
+the	O
+COVID	B-SPEC
+-	I-SPEC
+19	I-SPEC
+virus	I-SPEC
+epidemic	O
+in	O
+central	O
+China	O
+,	O
+increased	O
+social	O
+capital	O
+improved	O
+sleep	B-PROC
+quality	O
+by	O
+reducing	O
+anxiety	O
+and	O
+stress	O
+.	O
+
+Here	O
+,	O
+we	O
+discuss	O
+the	O
+COVID	B-DISO
+-	I-DISO
+19	I-DISO
+outbreak	O
+in	O
+a	O
+one	O
+health	O
+context	O
+,	O
+highlighting	O
+the	O
+need	O
+for	O
+the	O
+implementation	O
+of	O
+one	O
+health	O
+measures	O
+and	O
+practices	O
+to	O
+improve	O
+human	B-SPEC
+health	O
+and	O
+reduce	O
+the	O
+emergence	O
+of	O
+pandemic	O
+viruses	B-SPEC
+.	O
+
+TITLE	O
+:	O
+Perioperative	O
+Management	O
+of	O
+Patients	O
+Infected	O
+with	O
+the	O
+Novel	B-SPEC
+Coronavirus	I-SPEC
+:	O
+Recommendation	O
+from	O
+the	O
+Joint	O
+Task	O
+Force	O
+of	O
+the	O
+Chinese	O
+Society	O
+of	O
+Anesthesiology	O
+and	O
+the	O
+Chinese	O
+Association	O
+of	O
+Anesthesiologists	O
+.	O
+
+In	O
+order	B-SPEC
+to	O
+provide	O
+healthcare	O
+workers	O
+with	O
+updated	O
+recommendations	O
+on	O
+the	O
+management	O
+of	O
+patients	O
+in	O
+the	O
+perioperative	O
+setting	O
+as	O
+well	O
+as	O
+for	O
+emergency	O
+airway	B-ANAT
+management	O
+outside	O
+of	O
+the	O
+operating	O
+room	O
+,	O
+the	O
+two	O
+largest	O
+anesthesia	B-DISO
+societies	O
+,	O
+the	O
+Chinese	O
+Society	O
+of	O
+Anesthesiology	O
+(	O
+CSA	B-DISO
+)	O
+and	O
+the	O
+Chinese	O
+Association	O
+of	O
+Anesthesiologists	O
+(	O
+CAA	B-DISO
+)	O
+have	O
+formed	O
+a	O
+task	O
+force	O
+to	O
+produce	O
+the	O
+recommendations	O
+.	O
+
+Because	O
+the	O
+main	O
+route	O
+of	O
+transmission	O
+is	O
+via	O
+respiratory	O
+droplets	O
+and	O
+close	O
+contact	O
+,	O
+anesthesia	B-DISO
+providers	O
+are	O
+at	O
+a	O
+high	O
+risk	O
+when	O
+responding	O
+to	O
+the	O
+devastating	O
+mass	O
+emergency	B-DISO
+.	O
+
+The	O
+authors	O
+presented	O
+the	O
+experience	O
+of	O
+caring	O
+for	O
+the	O
+critically	B-DISO
+ill	I-DISO
+patients	O
+with	O
+COVID	B-DISO
+-	I-DISO
+19	I-DISO
+in	O
+Wuhan	O
+.	O
+
+ABSTRACT	O
+:	O
+Clinical	O
+,	O
+laboratory	O
+,	O
+and	O
+computed	O
+tomography	O
+(	O
+CT	O
+)	O
+findings	O
+of	O
+5	O
+cases	O
+of	O
+the	O
+novel	B-DISO
+Coronavirus	I-DISO
+Disease	I-DISO
+2019	O
+(	O
+COVID	B-DISO
+-	I-DISO
+19	I-DISO
+)	O
+pneumonia	B-DISO
+from	O
+patients	O
+outside	O
+of	O
+Wuhan	O
+were	O
+reviewed	O
+.	O
+
+ABSTRACT	O
+:	O
+Stevens	O
+-	O
+Johnson	O
+syndrome	O
+and	O
+toxic	B-DISO
+epidermal	I-DISO
+necrolysis	I-DISO
+(	O
+SJS	B-DISO
+/	O
+TEN	B-PRGE
+)	O
+are	O
+extremely	O
+rare	O
+but	O
+potentially	O
+life	O
+-	O
+threatening	O
+disorders	O
+.	O
+
+Our	O
+patients	O
+had	O
+some	O
+severe	O
+complications	O
+such	O
+as	O
+septic	B-DISO
+shock	I-DISO
+,	O
+respiratory	B-DISO
+failure	I-DISO
+and	O
+obliterans	O
+bronchiolitis	B-DISO
+(	O
+BO	O
+)	O
+etc	O
+.	O
+
+DIAGNOSIS	O
+::	O
+Three	O
+patients	O
+diagnosed	O
+SJS	B-DISO
+/	O
+TEN	O
+with	O
+clinical	O
+symptoms	O
+that	O
+were	O
+triggered	O
+by	O
+antibiotics	B-CHED
+,	O
+nonsteroidal	O
+anti	B-CHED
+-	I-CHED
+inflammatory	I-CHED
+drugs	I-CHED
+,	O
+previous	O
+infection	B-DISO
+,	O
+or	O
+neoplasms	B-DISO
+.	O
+
+They	O
+all	O
+died	B-PROC
+because	O
+of	O
+out	O
+-	O
+of	O
+-	O
+control	O
+severe	O
+infections	B-DISO
+.	O
+
+In	O
+Patient	O
+2	O
+,	O
+he	O
+died	B-PROC
+on	O
+the	O
+211th	O
+day	O
+from	O
+the	O
+onset	O
+of	O
+illness	O
+during	O
+the	O
+third	O
+time	O
+of	O
+PICU	B-SPEC
+admission	O
+.	O
+
+In	O
+Patient	O
+3	O
+,	O
+she	O
+died	O
+12	O
+days	O
+after	O
+PICU	B-SPEC
+admission	O
+on	O
+the	O
+87th	O
+day	O
+from	O
+onset	O
+.	O
+
+We	O
+should	O
+be	O
+aware	O
+that	O
+mucosal	B-ANAT
+damage	O
+occurs	O
+on	O
+the	O
+skin	B-ANAT
+and	O
+within	O
+the	O
+mucosa	B-ANAT
+of	O
+visceral	O
+organs	B-ANAT
+,	O
+leading	O
+to	O
+the	O
+occurrence	O
+of	O
+bronchiectasia	O
+,	O
+BO	O
+,	O
+enterocolitis	B-DISO
+,	O
+acute	B-DISO
+renal	I-DISO
+failure	I-DISO
+,	O
+and	O
+severe	O
+secondary	B-DISO
+infections	I-DISO
+.	O
+
+We	O
+demonstrate	O
+PRESCIENT	O
+'	O
+s	O
+ability	O
+to	O
+identify	O
+Abs	O
+that	O
+neutralize	O
+a	O
+model	O
+viral	O
+agent	O
+,	O
+Murine	B-SPEC
+coronavirus	I-SPEC
+(	O
+murine	B-DISO
+hepatitis	I-DISO
+virus	B-SPEC
+),	O
+which	O
+causes	O
+high	O
+mortality	O
+rates	O
+in	O
+experimentally	O
+infected	O
+mice	B-SPEC
+.	O
+
+ABSTRACT	O
+:	O
+COVID	B-DISO
+-	I-DISO
+19	I-DISO
+,	O
+a	O
+disease	O
+caused	O
+by	O
+a	O
+novel	B-SPEC
+coronavirus	I-SPEC
+,	O
+is	O
+a	O
+major	O
+global	O
+human	B-SPEC
+threat	O
+that	O
+has	O
+turned	O
+into	O
+a	O
+pandemic	O
+.	O
+
+As	O
+a	O
+part	O
+of	O
+pandemic	O
+preparedness	O
+,	O
+public	O
+health	O
+officials	O
+should	O
+identify	O
+and	O
+query	O
+healthcare	O
+facilities	O
+in	O
+their	O
+jurisdiction	O
+that	O
+currently	O
+care	O
+for	O
+critically	B-DISO
+ill	I-DISO
+patients	O
+on	O
+mechanical	O
+ventilation	O
+to	O
+determine	O
+existing	O
+inventory	O
+of	O
+these	O
+devices	O
+and	O
+facilities	O
+'	O
+ability	O
+to	O
+absorb	O
+additional	O
+ventilators	O
+.	O
+
+Sixteen	O
+patients	O
+(	O
+80	O
+%)	O
+were	O
+admitted	O
+to	O
+the	O
+intensive	O
+care	O
+unit	O
+;	O
+13	O
+patients	O
+(	O
+81	O
+%)	O
+had	O
+acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+,	O
+11	O
+were	O
+intubated	O
+(	O
+68	O
+.	O
+75	O
+%),	O
+9	O
+had	O
+acute	O
+renal	B-ANAT
+injury	O
+(	O
+56	O
+.	O
+25	O
+%),	O
+and	O
+3	O
+required	O
+dialysis	B-SPEC
+(	O
+18	O
+.	O
+75	O
+%).	O
+
+The	O
+laboratory	O
+diagnostic	O
+methods	O
+for	O
+human	B-SPEC
+coronavirus	I-SPEC
+infections	O
+have	O
+evolved	O
+substantially	O
+,	O
+with	O
+the	O
+development	B-PROC
+of	O
+novel	O
+assays	O
+as	O
+well	O
+as	O
+the	O
+availability	O
+of	O
+updated	O
+tests	O
+for	O
+emerging	O
+ones	O
+.	O
+
+Currently	O
+,	O
+there	O
+is	O
+no	O
+clear	O
+evidence	O
+regarding	O
+optimal	O
+delivery	O
+timing	O
+,	O
+the	O
+safety	O
+of	O
+vaginal	B-ANAT
+delivery	O
+,	O
+or	O
+whether	O
+cesarean	O
+delivery	O
+prevents	O
+vertical	B-DISO
+transmission	I-DISO
+at	O
+the	O
+time	O
+of	O
+delivery	O
+;	O
+therefore	O
+,	O
+route	O
+of	O
+delivery	O
+and	O
+delivery	O
+timing	O
+should	O
+be	O
+individualized	O
+based	O
+on	O
+obstetrical	O
+indications	O
+and	O
+maternal	O
+-	O
+fetal	B-ANAT
+status	O
+.	O
+
+Clinical	O
+manifestations	O
+range	O
+from	O
+asymptomatic	O
+cases	O
+to	O
+patients	O
+with	O
+mild	O
+and	O
+severe	O
+symptoms	O
+,	O
+with	O
+or	O
+without	O
+pneumonia	B-DISO
+.	O
+
+Laboratory	O
+detection	O
+of	O
+the	O
+viral	O
+nucleic	B-CHED
+acid	I-CHED
+can	O
+yield	O
+false	O
+-	O
+negative	O
+results	O
+,	O
+and	O
+serological	O
+testing	O
+of	O
+virus	B-SPEC
+specific	O
+IgG	B-PRGE
+and	O
+IgM	B-PRGE
+antibodies	B-COMP
+should	O
+be	O
+used	O
+as	O
+an	O
+alternative	O
+for	O
+diagnosis	O
+.	O
+
+Cases	O
+with	O
+a	O
+pre	O
+-	O
+existing	O
+condition	B-DISO
+of	O
+chronic	B-DISO
+obstructive	I-DISO
+pulmonary	I-DISO
+disease	I-DISO
+or	O
+complicated	O
+with	O
+a	O
+secondary	B-DISO
+bacterial	I-DISO
+pneumonia	I-DISO
+were	O
+more	O
+severe	O
+.	O
+
+The	O
+outbreak	O
+which	O
+started	O
+in	O
+Guinea	B-SPEC
+quickly	O
+moved	O
+across	O
+to	O
+Sierra	O
+Leone	O
+and	O
+Liberia	O
+.	O
+
+The	O
+laboratory	O
+results	O
+showed	O
+that	O
+compared	O
+to	O
+the	O
+normal	O
+values	O
+,	O
+the	O
+patients	O
+'	O
+lymphocytes	B-ANAT
+were	O
+reduced	O
+(	O
+4	O
+[	O
+80	O
+%]	O
+patients	O
+),	O
+and	O
+liver	B-PROC
+function	I-PROC
+ALT	B-FUNC
+and	O
+AST	B-PRGE
+(	O
+2	O
+[	O
+40	O
+%]	O
+patients	O
+,	O
+2	O
+[	O
+40	O
+%]	O
+patients	O
+)	O
+and	O
+C	B-PRGE
+-	I-PRGE
+reactive	I-PRGE
+protein	I-PRGE
+(	O
+4	O
+[	O
+80	O
+%]	O
+patients	O
+)	O
+were	O
+increased	O
+when	O
+admitted	O
+to	O
+hospital	O
+.	O
+
+Three	O
+patients	O
+were	O
+treated	O
+with	O
+glucocorticoids	B-CHED
+including	O
+two	O
+treated	O
+with	O
+oral	B-ANAT
+glucocorticoids	B-CHED
+.	O
+
+Fortunately	O
+,	O
+all	O
+patients	O
+did	O
+not	O
+need	O
+ICU	O
+care	O
+and	O
+were	O
+discharged	O
+from	O
+hospital	O
+without	O
+death	B-PROC
+.	O
+
+In	O
+conclusion	O
+,	O
+those	O
+patients	O
+with	O
+both	O
+COVID	B-DISO
+-	I-DISO
+19	I-DISO
+and	O
+influenza	B-SPEC
+virus	B-DISO
+infection	I-DISO
+did	O
+not	O
+appear	O
+to	O
+show	O
+a	O
+more	O
+severe	O
+condition	B-DISO
+because	O
+based	O
+on	O
+the	O
+laboratory	O
+findings	O
+,	O
+imaging	O
+studies	O
+,	O
+and	O
+patient	O
+prognosis	O
+,	O
+they	O
+showed	O
+similar	O
+clinical	O
+characteristics	O
+as	O
+those	O
+patients	O
+with	O
+COVID	B-DISO
+-	I-DISO
+19	I-DISO
+infection	I-DISO
+only	O
+.	O
+
+However	O
+,	O
+it	O
+is	O
+worth	O
+noting	O
+that	O
+the	O
+symptoms	O
+of	O
+nasal	B-ANAT
+tampon	O
+and	O
+pharyngalgia	O
+may	O
+be	O
+more	O
+prone	O
+to	O
+appear	O
+for	O
+those	O
+co	B-DISO
+-	I-DISO
+infection	I-DISO
+patients	O
+.	O
+
+ABSTRACT	O
+:	O
+An	O
+outbreak	O
+of	O
+coronavirus	O
+disease	O
+2019	O
+(	O
+COVID	B-DISO
+-	I-DISO
+19	I-DISO
+)	O
+caused	O
+by	O
+the	O
+2019	B-SPEC
+novel	I-SPEC
+coronavirus	I-SPEC
+(	O
+SARS	B-PRGE
+-	I-PRGE
+CoV	I-PRGE
+-	I-PRGE
+2	I-PRGE
+)	O
+began	O
+in	O
+the	O
+city	O
+of	O
+Wuhan	O
+in	O
+China	O
+and	O
+has	O
+widely	O
+spread	O
+worldwide	O
+.	O
+
+Aside	O
+from	O
+RaTG13	O
+,	O
+Pangolin	B-PRGE
+-	I-PRGE
+CoV	I-PRGE
+is	O
+the	O
+most	O
+closely	O
+related	O
+CoV	O
+to	O
+SARS	B-PRGE
+-	I-PRGE
+CoV	I-PRGE
+-	I-PRGE
+2	I-PRGE
+.	O
+
+To	O
+examine	O
+the	O
+growth	B-PROC
+rate	O
+of	O
+the	O
+outbreak	O
+,	O
+we	O
+aimed	O
+to	O
+present	O
+the	O
+first	O
+study	O
+to	O
+report	O
+the	O
+reproduction	B-PROC
+number	O
+of	O
+COVID	B-DISO
+-	I-DISO
+19	I-DISO
+in	O
+South	O
+Korea	O
+.	O
+
+ABSTRACT	O
+:	O
+Patients	O
+with	O
+COVID	O
+-	O
+19	O
+infection	O
+are	O
+at	O
+risk	O
+of	O
+acute	B-DISO
+respiratory	I-DISO
+disease	I-DISO
+syndrome	B-DISO
+(	O
+ARDS	B-DISO
+)	O
+and	O
+death	B-PROC
+.	O
+
+Angiotensin	B-PRGE
+receptor	I-PRGE
+blockers	O
+and	O
+statins	O
+upregulate	O
+ACE2	B-PRGE
+.	O
+
+TITLE	O
+:	O
+Autopsy	O
+in	O
+suspected	O
+COVID	B-DISO
+-	I-DISO
+19	I-DISO
+cases	O
+.	O
+
+Using	O
+a	O
+virus	B-SPEC
+containing	O
+an	O
+EndoU	O
+catalytic	O
+-	O
+inactive	O
+mutation	O
+,	O
+we	O
+detected	O
+a	O
+higher	O
+abundance	O
+of	O
+PUN	O
+RNA	O
+in	O
+the	O
+cytoplasm	B-COMP
+compared	O
+to	O
+wild	O
+-	O
+type	O
+-	O
+infected	O
+cells	B-COMP
+.	O
+
+The	O
+host	B-COMP
+humoral	O
+response	O
+against	O
+SARS	B-PRGE
+-	I-PRGE
+CoV	I-PRGE
+-	I-PRGE
+2	I-PRGE
+including	O
+IgA	B-PRGE
+,	O
+IgM	B-PRGE
+and	O
+IgG	B-PRGE
+response	O
+were	O
+examined	O
+by	O
+using	O
+an	O
+ELISA	O
+based	O
+assay	O
+on	O
+the	O
+recombinant	B-PRGE
+viral	I-PRGE
+nucleocapsid	I-PRGE
+protein	B-CHED
+.	O
+
+TITLE	O
+:	O
+2019	B-SPEC
+novel	I-SPEC
+Coronavirus	I-SPEC
+outbreak	O
+:	O
+a	O
+quiz	O
+or	O
+final	O
+exam	O
+?	O
+
+Three	O
+weeks	O
+later	O
+,	O
+the	O
+US	O
+federal	O
+government	O
+declared	O
+the	O
+pandemic	O
+a	O
+national	O
+emergency	B-DISO
+.	O
+
+During	O
+the	O
+first	O
+week	O
+,	O
+blood	B-ANAT
+donations	O
+dropped	O
+significantly	O
+.	O
+
+This	O
+study	O
+was	O
+conducted	O
+to	O
+provide	O
+the	O
+international	O
+community	O
+with	O
+a	O
+deeper	O
+understanding	O
+of	O
+this	O
+new	O
+infectious	B-DISO
+disease	I-DISO
+.	O
+
+ABSTRACT	O
+:	O
+COVID	O
+-	O
+19	O
+is	O
+novel	O
+infectious	B-DISO
+disease	I-DISO
+with	O
+an	O
+evolving	O
+understanding	O
+of	O
+its	O
+epidemiology	O
+and	O
+clinical	O
+manifestations	O
+.	O
+
+TITLE	O
+:	O
+Guide	O
+to	O
+the	O
+Forensic	O
+Pathology	B-DISO
+Practice	O
+on	O
+Death	B-PROC
+Cases	O
+Related	O
+to	O
+Corona	B-DISO
+Virus	B-PROC
+Disease	I-PROC
+2019	I-DISO
+（	O
+COVID	O
+-	O
+19	O
+）	O
+（	O
+Trial	O
+Draft	O
+）.	O
+
+ABSTRACT	O
+:	O
+Autopsy	O
+is	O
+of	O
+great	O
+significance	O
+to	O
+the	O
+elucidation	O
+of	O
+the	O
+pathological	O
+changes	O
+,	O
+pathogenesis	B-DISO
+and	O
+cause	O
+of	O
+death	B-PROC
+of	O
+corona	B-DISO
+virus	B-PROC
+disease	I-PROC
+2019	I-DISO
+（	B-DISO
+COVID	I-DISO
+-	I-DISO
+19	O
+）	O
+and	O
+can	O
+provide	O
+theoretical	O
+basis	O
+for	O
+more	O
+scientific	O
+and	O
+accurate	O
+prevention	O
+and	O
+control	O
+of	O
+the	O
+outbreak	O
+.	O
+
+ABSTRACT	O
+:	O
+Since	O
+2003	O
+,	O
+coronavirus	O
+has	O
+caused	O
+multiple	O
+major	O
+public	O
+health	O
+events	O
+that	O
+resulted	O
+in	O
+global	O
+epidemics	O
+such	O
+as	O
+,	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+（	O
+SARS	O
+）,	O
+Middle	O
+East	O
+respiratory	O
+syndrome	B-DISO
+（	O
+MERS	O
+）	O
+and	O
+corona	B-DISO
+virus	B-PROC
+disease	I-PROC
+2019	I-DISO
+（	B-DISO
+COVID	I-DISO
+-	I-DISO
+19	O
+）.	O
+
+We	O
+used	O
+18	O
+indicators	O
+from	O
+the	O
+IHR	O
+State	O
+Party	O
+Annual	O
+Reporting	O
+(	O
+SPAR	B-DISO
+)	O
+tool	O
+and	O
+associated	O
+data	O
+from	O
+national	O
+SPAR	B-DISO
+reports	O
+to	O
+develop	O
+five	O
+indices	O
+:	O
+(	O
+1	O
+)	O
+prevent	O
+,	O
+(	O
+2	O
+)	O
+detect	O
+,	O
+(	O
+3	O
+)	O
+respond	O
+,	O
+(	O
+4	O
+)	O
+enabling	O
+function	O
+,	O
+and	O
+(	O
+5	O
+)	O
+operational	O
+readiness	O
+.	O
+
+Although	O
+ACE2	B-PRGE
+is	O
+reported	O
+to	O
+be	O
+expressed	B-PROC
+in	O
+lung	B-ANAT
+,	O
+liver	B-ANAT
+,	O
+stomach	B-ANAT
+,	O
+ileum	B-ANAT
+,	O
+kidney	B-ANAT
+and	O
+colon	B-ANAT
+,	O
+its	O
+expressing	O
+levels	O
+are	O
+rather	O
+low	O
+,	O
+especially	O
+in	O
+the	O
+lung	B-ANAT
+.	O
+
+Intriguingly	O
+,	O
+we	O
+found	O
+that	O
+the	O
+candidate	O
+co	O
+-	O
+receptors	O
+,	O
+manifesting	O
+the	O
+most	O
+similar	O
+expression	B-PROC
+patterns	O
+with	O
+ACE2	O
+across	O
+13	O
+human	B-ANAT
+tissues	I-ANAT
+,	O
+are	O
+all	O
+peptidases	O
+,	O
+including	O
+ANPEP	B-PRGE
+,	O
+DPP4	B-PRGE
+and	O
+ENPEP	B-PRGE
+.	O
+
+Clinical	O
+data	O
+and	O
+CT	O
+images	O
+of	O
+80	O
+cases	O
+of	O
+NCP	B-FUNC
+were	O
+collected	O
+.	O
+
+CONCLUSIONS	O
+:	O
+The	O
+chest	B-ANAT
+CT	O
+of	O
+NCP	B-FUNC
+patients	O
+is	O
+characterised	O
+by	O
+the	O
+onset	O
+of	O
+bilateral	O
+ground	O
+-	O
+glass	O
+lesions	O
+located	O
+in	O
+the	O
+subpleural	O
+area	O
+of	O
+the	O
+lung	B-ANAT
+,	O
+and	O
+progressive	O
+lesions	O
+that	O
+result	O
+in	O
+consolidation	O
+with	O
+no	O
+migratory	O
+lesions	O
+.	O
+
+TITLE	O
+:	O
+Predicting	O
+the	O
+angiotensin	B-PRGE
+converting	I-PRGE
+enzyme	I-PRGE
+2	I-PRGE
+(	O
+ACE2	B-PRGE
+)	O
+utilizing	O
+capability	O
+as	O
+the	O
+receptor	O
+of	O
+SARS	O
+-	O
+CoV	O
+-	O
+2	O
+.	O
+
+Induced	O
+prematurity	O
+and	O
+cases	O
+of	O
+respiratory	B-DISO
+distress	I-DISO
+in	O
+newborns	O
+of	O
+infected	O
+mothers	O
+have	O
+been	O
+described	O
+.	O
+
+Pregnancy	O
+is	O
+known	O
+as	O
+a	O
+period	O
+at	O
+higher	O
+risk	O
+for	O
+the	O
+consequences	O
+of	O
+respiratory	B-DISO
+infections	I-DISO
+,	O
+as	O
+for	O
+influenza	B-DISO
+,	O
+so	O
+it	O
+seems	O
+important	O
+to	O
+screen	O
+for	O
+Covid	B-DISO
+-	I-DISO
+19	I-DISO
+in	O
+the	O
+presence	O
+of	O
+symptoms	O
+and	O
+to	O
+monitor	O
+closely	O
+pregnant	O
+women	O
+.	O
+
+At	O
+the	O
+genetic	O
+level	O
+,	O
+2019	B-SPEC
+-	I-SPEC
+nCoV	I-SPEC
+is	O
+closely	O
+related	O
+to	O
+the	O
+SARS	B-PRGE
+-	I-PRGE
+CoV	I-PRGE
+and	O
+,	O
+to	O
+a	O
+lesser	O
+extent	O
+,	O
+to	O
+MERS	O
+-	O
+CoV	O
+,	O
+which	O
+appeared	O
+as	O
+epidemiological	O
+threats	O
+in	O
+recent	O
+years	O
+in	O
+China	O
+and	O
+the	O
+Middle	O
+East	O
+,	O
+respectively	O
+.	O
+
+TITLE	O
+:	O
+Cardiovascular	B-ANAT
+Considerations	O
+for	O
+Patients	O
+,	O
+Health	O
+Care	O
+Workers	O
+,	O
+and	O
+Health	O
+Systems	O
+During	O
+the	O
+Coronavirus	O
+Disease	O
+2019	O
+(	O
+COVID	B-DISO
+-	I-DISO
+19	I-DISO
+)	O
+Pandemic	O
+.	O
+
+Fourth	O
+,	O
+the	O
+response	O
+to	O
+COVID	B-DISO
+-	I-DISO
+19	I-DISO
+can	O
+compromise	O
+the	O
+rapid	O
+triage	O
+of	O
+non	O
+-	O
+COVID	B-DISO
+-	I-DISO
+19	I-DISO
+patients	O
+with	O
+cardiovascular	B-ANAT
+conditions	O
+.	O
+
+Currently	O
+,	O
+the	O
+research	O
+on	O
+novel	B-SPEC
+coronavirus	I-SPEC
+is	O
+still	O
+in	O
+the	O
+primary	O
+stage	O
+.	O
+
+ABSTRACT	O
+:	O
+Recently	O
+,	O
+two	O
+coronaviruses	O
+,	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+coronavirus	B-SPEC
+and	O
+Middle	O
+East	O
+respiratory	O
+syndrome	B-DISO
+coronavirus	B-SPEC
+,	O
+have	O
+emerged	O
+to	O
+cause	O
+unusually	O
+severe	O
+respiratory	B-DISO
+disease	I-DISO
+in	O
+humans	B-SPEC
+.	O
+
+Many	O
+CoV	O
+proteins	B-CHED
+are	O
+modified	O
+by	O
+PTMs	O
+,	O
+including	O
+glycosylation	B-PROC
+and	O
+palmitoylation	B-PROC
+of	O
+the	O
+spike	O
+and	O
+envelope	B-COMP
+protein	B-CHED
+,	O
+N	O
+-	O
+or	O
+O	O
+-	O
+linked	O
+glycosylation	B-PROC
+of	O
+the	O
+membrane	B-COMP
+protein	B-CHED
+,	O
+phosphorylation	B-PROC
+and	O
+ADP	B-CHED
+-	O
+ribosylation	O
+of	O
+the	O
+nucleocapsid	B-COMP
+protein	B-CHED
+,	O
+and	O
+other	O
+PTMs	O
+on	O
+nonstructural	O
+and	O
+accessory	O
+proteins	B-CHED
+.	O
+
+ABSTRACT	O
+:	O
+Signal	B-PRGE
+transducer	I-PRGE
+and	I-PRGE
+activator	I-PRGE
+of	I-PRGE
+transcription	I-PRGE
+3	I-PRGE
+(	O
+STAT3	B-PRGE
+)	O
+is	O
+a	O
+transcription	B-PROC
+factor	O
+which	O
+can	O
+be	O
+activated	O
+by	O
+cytokines	B-PRGE
+,	I-PRGE
+growth	I-PRGE
+factor	I-PRGE
+receptors	I-PRGE
+,	O
+and	O
+nonreceptor	O
+-	O
+like	O
+tyrosine	B-PRGE
+kinase	I-PRGE
+.	O
+
+Proteases	O
+of	O
+the	O
+renin	B-PATH
+-	I-PATH
+angiotensin	B-CHED
+system	I-PATH
+serve	O
+as	O
+receptors	O
+needed	O
+for	O
+entry	O
+into	O
+target	B-ANAT
+cells	I-ANAT
+;	O
+this	O
+article	O
+describes	O
+the	O
+current	O
+knowledge	O
+on	O
+the	O
+involvement	O
+of	O
+this	O
+system	O
+in	O
+HCoV	O
+pathogenesis	B-DISO
+.	O
+
+Dermatologists	O
+in	O
+China	O
+have	O
+participated	O
+in	O
+the	O
+fight	O
+against	O
+Covid	B-DISO
+-	I-DISO
+19	I-DISO
+.	O
+
+We	O
+also	O
+discuss	O
+issues	O
+related	O
+to	O
+transplant	B-ANAT
+-	O
+related	O
+research	O
+during	O
+the	O
+pandemic	O
+,	O
+the	O
+role	O
+of	O
+transplant	B-ANAT
+infectious	B-DISO
+diseases	I-DISO
+and	O
+the	O
+influence	O
+of	O
+transplant	O
+societies	O
+for	O
+education	O
+and	O
+disseminating	O
+current	O
+information	O
+.	O
+
+TITLE	O
+:	O
+COVID	B-DISO
+-	I-DISO
+19	I-DISO
+,	O
+cytokines	O
+and	O
+immunosuppression	B-PROC
+:	O
+what	O
+can	O
+we	O
+learn	B-PROC
+from	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+?	O
+
+If	O
+found	O
+useful	O
+in	O
+managing	O
+initial	O
+SARS	B-SPEC
+-	I-SPEC
+CoV	I-SPEC
+-	I-SPEC
+2	I-SPEC
+-	O
+infected	O
+patients	O
+,	O
+further	O
+evaluation	O
+using	O
+a	O
+randomized	O
+control	O
+trial	O
+design	O
+is	O
+warranted	O
+to	O
+guide	O
+future	O
+therapeutic	O
+use	O
+of	O
+this	O
+combination	O
+.	O
+
+In	O
+view	O
+of	O
+a	O
+potential	O
+epidemic	O
+of	O
+COVID	B-DISO
+-	I-DISO
+19	I-DISO
+,	O
+specific	O
+requirements	O
+to	O
+handle	O
+it	O
+are	O
+also	O
+given	O
+.	O
+
+ABSTRACT	O
+:	O
+:	O
+Coronavirus	O
+disease	O
+2019	O
+(	O
+COVID	B-DISO
+-	I-DISO
+19	I-DISO
+)	O
+has	O
+raised	O
+urgent	O
+questions	O
+about	O
+containment	O
+and	O
+mitigation	O
+,	O
+particularly	O
+in	O
+countries	O
+where	O
+the	O
+virus	B-SPEC
+has	O
+not	O
+yet	O
+established	O
+human	B-SPEC
+-	O
+to	O
+-	O
+human	B-SPEC
+transmission	O
+.	O
+
+These	O
+cases	O
+were	O
+linked	O
+to	O
+a	O
+wet	O
+animal	B-SPEC
+wholesale	O
+market	O
+in	O
+the	O
+region	O
+and	O
+,	O
+after	O
+extensive	O
+epidemiologic	O
+investigation	O
+,	O
+led	O
+to	O
+identification	O
+of	O
+a	O
+novel	B-SPEC
+coronavirus	I-SPEC
+(	O
+COVID	B-DISO
+-	I-DISO
+19	I-DISO
+).	O
+
+COVID	B-DISO
+-	I-DISO
+19	I-DISO
+is	O
+among	O
+a	O
+family	B-SPEC
+of	O
+viruses	B-SPEC
+-	O
+called	O
+coronaviruses	O
+-	O
+that	O
+can	O
+affect	O
+both	O
+humans	B-SPEC
+and	O
+animals	B-SPEC
+(	O
+Zhu	O
+et	O
+al	O
+.,	O
+2020	O
+).	O
+
+Suggested	O
+treatment	O
+included	O
+providing	O
+oxygen	B-CHED
+,	O
+inhalations	B-PROC
+,	O
+nutritional	O
+support	O
+and	O
+maintaining	O
+fluids	B-ANAT
+and	O
+electrolyte	O
+balances	O
+.	O
+
+TITLE	O
+:	O
+Urology	O
+practice	O
+during	O
+COVID	B-DISO
+-	I-DISO
+19	I-DISO
+pandemic	O
+.	O
+
+This	O
+document	O
+could	O
+be	O
+a	O
+valid	O
+tool	O
+to	O
+be	O
+used	O
+in	O
+routine	O
+clinical	O
+practice	O
+and	O
+,	O
+possibly	O
+,	O
+a	O
+cornerstone	O
+for	O
+further	O
+discussion	O
+on	O
+the	O
+topic	O
+also	O
+considering	O
+the	O
+further	O
+evolution	B-PROC
+of	O
+the	O
+COVID	B-DISO
+-	I-DISO
+19	I-DISO
+pandemic	O
+.	O
+
+To	O
+assess	O
+the	O
+magnitude	O
+of	O
+mental	O
+health	O
+outcomes	O
+and	O
+associated	O
+factors	O
+among	O
+health	O
+care	O
+workers	O
+treating	O
+patients	O
+exposed	O
+to	O
+COVID	B-DISO
+-	I-DISO
+19	I-DISO
+in	O
+China	O
+.	O
+
+In	O
+this	O
+survey	O
+of	O
+heath	O
+care	O
+workers	O
+in	O
+hospitals	O
+equipped	O
+with	O
+fever	B-PROC
+clinics	O
+or	O
+wards	O
+for	O
+patients	O
+with	O
+COVID	B-DISO
+-	I-DISO
+19	I-DISO
+in	O
+Wuhan	O
+and	O
+other	O
+regions	O
+in	O
+China	O
+,	O
+participants	O
+reported	O
+experiencing	O
+psychological	B-DISO
+burden	O
+,	O
+especially	O
+nurses	O
+,	O
+women	O
+,	O
+those	O
+in	O
+Wuhan	O
+,	O
+and	O
+frontline	O
+health	O
+care	O
+workers	O
+directly	O
+engaged	O
+in	O
+the	O
+diagnosis	O
+,	O
+treatment	O
+,	O
+and	O
+care	O
+for	O
+patients	O
+with	O
+COVID	B-DISO
+-	I-DISO
+19	I-DISO
+.	O
+
+As	O
+public	O
+health	O
+officials	O
+seek	O
+to	O
+contain	O
+the	O
+virus	B-SPEC
+and	O
+mitigate	O
+the	O
+deleterious	O
+effects	O
+on	O
+worldwide	O
+population	O
+health	O
+,	O
+a	O
+related	O
+threat	O
+has	O
+emerged	O
+:	O
+global	O
+media	B-ANAT
+exposure	O
+to	O
+the	O
+crisis	O
+.	O
+
+We	O
+review	O
+research	O
+suggesting	O
+that	O
+repeated	O
+media	B-ANAT
+exposure	O
+to	O
+community	O
+crisis	O
+can	O
+lead	O
+to	O
+increased	O
+anxiety	O
+,	O
+heightened	O
+stress	O
+responses	O
+that	O
+can	O
+lead	O
+to	O
+downstream	O
+effects	O
+on	O
+health	O
+,	O
+and	O
+misplaced	O
+health	O
+-	O
+protective	O
+and	O
+help	O
+-	O
+seeking	O
+behaviors	B-PROC
+that	O
+can	O
+overburden	O
+health	O
+care	O
+facilities	O
+and	O
+tax	O
+available	O
+resources	O
+.	O
+
+SARS	B-DISO
+-	O
+CoV	O
+RBD	O
+-	O
+specific	O
+antibodies	B-COMP
+could	O
+cross	O
+-	O
+react	O
+with	O
+SARS	B-PRGE
+-	I-PRGE
+CoV	I-PRGE
+-	I-PRGE
+2	I-PRGE
+RBD	I-PRGE
+protein	B-CHED
+,	O
+and	O
+SARS	B-DISO
+-	O
+CoV	O
+RBD	O
+-	O
+induced	O
+antisera	O
+could	O
+cross	O
+-	O
+neutralize	O
+SARS	B-PRGE
+-	I-PRGE
+CoV	I-PRGE
+-	I-PRGE
+2	I-PRGE
+,	O
+suggesting	O
+the	O
+potential	O
+to	O
+develop	O
+SARS	B-DISO
+-	O
+CoV	O
+RBD	O
+-	O
+based	O
+vaccines	O
+for	O
+prevention	O
+of	O
+SARS	B-SPEC
+-	I-SPEC
+CoV	I-SPEC
+-	I-SPEC
+2	I-SPEC
+and	O
+SARS	B-DISO
+-	I-DISO
+CoV	I-DISO
+infection	I-DISO
+.	O
+
+We	O
+calculated	O
+word	O
+frequency	O
+,	O
+scores	O
+of	O
+emotional	O
+indicators	O
+(	O
+e	O
+.	O
+g	O
+.,	O
+anxiety	O
+,	O
+depression	B-DISO
+,	O
+indignation	O
+,	O
+and	O
+Oxford	O
+happiness	O
+)	O
+and	O
+cognitive	O
+indicators	O
+(	O
+e	O
+.	O
+g	O
+.,	O
+social	O
+risk	O
+judgment	O
+and	O
+life	O
+satisfaction	O
+)	O
+from	O
+the	O
+collected	O
+data	O
+.	O
+
+The	O
+results	O
+contribute	O
+to	O
+the	O
+knowledge	O
+gaps	O
+of	O
+short	O
+-	O
+term	O
+individual	O
+changes	O
+in	O
+psychological	B-DISO
+conditions	O
+after	O
+the	O
+outbreak	O
+.	O
+
+At	O
+present	O
+there	O
+is	O
+limited	O
+clinical	O
+information	O
+of	O
+the	O
+SARS	B-PRGE
+-	I-PRGE
+CoV	I-PRGE
+-	I-PRGE
+2	I-PRGE
+and	O
+there	O
+is	O
+no	O
+specific	O
+treatment	O
+recommended	O
+,	O
+although	O
+technical	O
+guidances	O
+and	O
+suggestions	O
+have	O
+been	O
+developed	O
+and	O
+will	O
+continue	O
+to	O
+be	O
+updated	O
+as	O
+additional	O
+information	O
+becomes	O
+available	O
+.	O
+
+In	O
+order	B-SPEC
+to	O
+define	O
+an	O
+effective	O
+and	O
+safe	O
+treatment	O
+for	O
+SARS	B-SPEC
+-	I-SPEC
+CoV	I-SPEC
+-	I-SPEC
+2	I-SPEC
+-	O
+associated	O
+disease	O
+,	O
+we	O
+provide	O
+considerations	O
+on	O
+the	O
+actual	O
+treatments	O
+,	O
+on	O
+how	O
+to	O
+avoid	O
+complications	O
+and	O
+the	O
+undesirable	O
+side	O
+effects	O
+related	O
+to	O
+them	O
+and	O
+to	O
+select	O
+and	O
+apply	O
+earlier	O
+the	O
+most	O
+appropriate	O
+treatment	O
+.	O
+
+TITLE	O
+:	O
+[	O
+Perinatal	O
+and	O
+neonatal	O
+management	O
+plan	B-DISO
+for	O
+prevention	O
+and	O
+control	O
+of	O
+SARS	B-DISO
+-	I-DISO
+CoV	I-DISO
+-	I-DISO
+2	I-DISO
+infection	I-DISO
+(	O
+2nd	O
+Edition	O
+)].	O
+
+With	O
+the	O
+further	O
+understanding	O
+of	O
+SARS	B-DISO
+-	I-DISO
+CoV	I-DISO
+-	I-DISO
+2	I-DISO
+infection	I-DISO
+,	O
+especially	O
+the	O
+emergence	O
+of	O
+SARS	B-DISO
+-	I-DISO
+CoV	I-DISO
+-	I-DISO
+2	I-DISO
+infection	I-DISO
+cases	O
+in	O
+pregnant	O
+women	O
+and	O
+neonates	O
+,	O
+it	O
+is	O
+necessary	O
+to	O
+update	O
+the	O
+first	O
+edition	O
+of	O
+the	O
+management	O
+plan	B-DISO
+so	O
+as	O
+to	O
+offer	O
+a	O
+better	O
+guide	O
+on	O
+clinical	O
+practice	O
+.	O
+
+Therefore	O
+,	O
+the	O
+Working	O
+Group	O
+has	O
+worked	O
+out	O
+the	O
+second	O
+edition	O
+of	O
+the	O
+management	O
+plan	B-DISO
+.	O
+
+ABSTRACT	O
+:	O
+Since	O
+December	O
+2019	O
+,	O
+an	O
+outbreak	O
+of	O
+severe	O
+acute	O
+respiratory	O
+syndrome	O
+coronavirus	O
+2	O
+(	O
+SARS	B-SPEC
+-	I-SPEC
+CoV	I-SPEC
+-	I-SPEC
+2	I-SPEC
+)	O
+infection	B-DISO
+has	O
+spread	O
+from	O
+China	O
+to	O
+other	O
+countries	O
+.	O
+
+Among	O
+the	O
+9	O
+children	O
+with	O
+COVID	B-DISO
+-	I-DISO
+19	I-DISO
+,	O
+5	O
+had	O
+no	O
+symptoms	O
+,	O
+4	O
+had	O
+fever	B-PROC
+,	O
+2	O
+had	O
+cough	B-DISO
+,	O
+and	O
+1	O
+had	O
+rhinorrhea	B-DISO
+.	O
+
+There	O
+were	O
+only	O
+symptoms	O
+of	O
+the	O
+respiratory	B-ANAT
+system	I-ANAT
+.	O
+
+Newborns	O
+with	O
+suspected	O
+or	O
+confirmed	O
+COVID	B-DISO
+-	I-DISO
+19	I-DISO
+should	O
+be	O
+transferred	O
+to	O
+designated	O
+hospitals	O
+for	O
+isolation	O
+treatment	O
+.	O
+
+TITLE	O
+:	O
+COVID	B-DISO
+-	I-DISO
+19	I-DISO
+,	O
+a	O
+worldwide	O
+public	O
+health	O
+emergency	B-DISO
+.	O
+
+Other	O
+imaging	O
+features	O
+included	O
+""""	O
+crazy	O
+-	O
+paving	O
+pattern	O
+""""	O
+(	O
+89	O
+.	O
+4	O
+%),	O
+consolidation	O
+(	O
+63	O
+.	O
+8	O
+%),	O
+and	O
+air	B-CHED
+bronchogram	O
+(	O
+76	O
+.	O
+6	O
+%).	O
+
+ABSTRACT	O
+:	O
+Intrathecal	O
+Baclofen	B-CHED
+(	O
+ITB	O
+)	O
+has	O
+become	O
+an	O
+increasingly	O
+common	O
+treatment	O
+for	O
+severe	O
+muscle	B-DISO
+spasticity	I-DISO
+associated	O
+with	O
+conditions	O
+such	O
+as	O
+cerebral	B-DISO
+palsy	I-DISO
+and	O
+spinal	B-ANAT
+cord	I-ANAT
+injury	O
+.	O
+
+This	O
+case	O
+presents	O
+the	O
+emergency	B-DISO
+physician	O
+with	O
+an	O
+atypical	O
+presentation	O
+and	O
+emphasizes	O
+the	O
+importance	O
+of	O
+a	O
+thorough	O
+neurologic	O
+examination	O
+to	O
+diagnose	O
+patients	O
+accurately	O
+.	O
+
+ABSTRACT	O
+:	O
+We	O
+argue	O
+that	O
+enhanced	O
+Traffic	O
+Control	O
+Bundling	O
+(	O
+eTCB	O
+)	O
+can	O
+interrupt	O
+the	O
+community	O
+-	O
+hospital	O
+-	O
+community	O
+transmission	O
+cycle	O
+,	O
+thereby	O
+limiting	O
+COVID	B-DISO
+-	I-DISO
+19	I-DISO
+'	O
+s	O
+impact	O
+.	O
+
+Enhanced	O
+TCB	O
+is	O
+an	O
+expansion	O
+of	O
+the	O
+traditional	O
+TCB	O
+that	O
+proved	O
+highly	O
+effective	O
+during	O
+Taiwan	O
+'	O
+s	O
+2003	O
+SARS	B-DISO
+outbreak	O
+.	O
+
+Enhanced	O
+TCB	O
+incorporates	O
+the	O
+necessary	O
+adaptations	B-PROC
+.	O
+
+We	O
+have	O
+analyzed	O
+all	O
+available	O
+data	O
+on	O
+the	O
+development	B-PROC
+of	O
+international	O
+COVID	B-DISO
+-	I-DISO
+19	I-DISO
+cases	O
+from	O
+January	O
+20th	O
+,	O
+2020	O
+until	O
+February	O
+18th	O
+,	O
+2020	O
+.	O
+
+Given	O
+the	O
+lack	O
+of	O
+specific	O
+anti	O
+-	O
+viral	O
+therapies	O
+,	O
+the	O
+current	O
+management	O
+of	O
+severe	B-DISO
+acute	I-DISO
+respiratory	I-DISO
+syndrome	I-DISO
+coronaviruses	O
+(	O
+SARS	B-SPEC
+-	I-SPEC
+CoV	I-SPEC
+-	I-SPEC
+2	I-SPEC
+)	O
+is	O
+mainly	O
+supportive	O
+,	O
+even	O
+though	O
+several	O
+compounds	O
+are	O
+now	O
+under	O
+investigation	O
+for	O
+the	O
+treatment	O
+of	O
+this	O
+life	O
+-	O
+threatening	O
+disease	O
+.	O
+
+However	O
+,	O
+the	O
+increasing	O
+knowledge	O
+about	O
+the	O
+pathophysiology	O
+of	O
+SARS	B-DISO
+-	I-DISO
+CoV	I-DISO
+-	I-DISO
+2	I-DISO
+infection	I-DISO
+is	O
+leading	O
+to	O
+consider	O
+some	O
+anti	B-CHED
+-	I-CHED
+rheumatic	I-CHED
+drugs	I-CHED
+as	O
+potential	O
+treatment	O
+options	O
+for	O
+the	O
+management	O
+of	O
+COVID	O
+-	O
+19	O
+.	O
+
+In	O
+this	O
+review	O
+we	O
+will	O
+critically	O
+analyse	O
+the	O
+evidences	O
+on	O
+either	O
+positive	O
+or	O
+negative	O
+effect	O
+of	O
+drugs	O
+commonly	O
+used	O
+to	O
+treat	O
+RA	O
+in	O
+this	O
+particular	O
+scenario	O
+,	O
+in	O
+order	B-SPEC
+to	O
+optimize	O
+the	O
+current	O
+approach	O
+to	O
+RA	O
+patients	O
+.	O
+
+TITLE	O
+:	O
+Hydroxychloroquine	O
+and	O
+azithromycin	B-CHED
+as	O
+a	O
+treatment	O
+of	O
+COVID	B-DISO
+-	I-DISO
+19	I-DISO
+:	O
+results	O
+of	O
+an	O
+open	O
+-	O
+label	B-CHED
+non	O
+-	O
+randomized	O
+clinical	O
+trial	O
+.	O
+
+ABSTRACT	O
+:	O
+Chloroquine	O
+and	O
+hydroxychloroquine	O
+have	O
+been	O
+found	O
+to	O
+be	O
+efficient	O
+on	O
+SARS	B-PRGE
+-	I-PRGE
+CoV	I-PRGE
+-	I-PRGE
+2	I-PRGE
+,	O
+and	O
+reported	O
+to	O
+be	O
+efficient	O
+in	O
+Chinese	O
+COV	O
+-	O
+19	O
+patients	O
+.	O
+
+CONCLUSIONS	O
+:	O
+Despite	O
+its	O
+small	O
+sample	O
+size	O
+our	O
+survey	O
+shows	O
+that	O
+hydroxychloroquine	O
+treatment	O
+is	O
+significantly	O
+associated	O
+with	O
+viral	O
+load	O
+reduction	O
+/	O
+disappearance	O
+in	O
+COVID	B-DISO
+-	I-DISO
+19	I-DISO
+patients	O
+and	O
+its	O
+effect	O
+is	O
+reinforced	O
+by	O
+azithromycin	B-CHED
+.	O
+
+The	O
+effect	O
+of	O
+LH	O
+on	O
+virion	B-COMP
+morphology	O
+was	O
+visualized	O
+under	O
+transmission	O
+electron	O
+microscope	O
+.	O
+
+TITLE	O
+:	O
+Evolutionary	O
+genetics	O
+of	O
+canine	O
+respiratory	O
+coronavirus	B-SPEC
+and	O
+recent	O
+introduction	O
+into	O
+Swedish	O
+dogs	O
+.	O
+
+RESULTS	O
+:	O
+Over	O
+our	O
+study	O
+period	O
+,	O
+no	O
+SARS	B-PRGE
+-	I-PRGE
+CoV	I-PRGE
+-	I-PRGE
+2	I-PRGE
+was	O
+detected	O
+.	O
+
+Excluding	O
+72	O
+patients	O
+with	O
+normal	O
+images	O
+,	O
+230	O
+of	O
+573	O
+patients	O
+affected	O
+more	O
+than	O
+two	O
+lobes	B-ANAT
+.	O
+
+There	O
+is	O
+a	O
+growing	O
+understanding	O
+of	O
+SARS	B-PRGE
+-	I-PRGE
+CoV	I-PRGE
+-	I-PRGE
+2	I-PRGE
+in	O
+the	O
+virology	O
+,	O
+epidemiology	O
+and	O
+clinical	O
+management	O
+strategies	O
+.	O
+
+ABSTRACT	O
+:	O
+Tilorone	O
+is	O
+a	O
+50	O
+-	O
+year	O
+-	O
+old	O
+synthetic	O
+small	O
+-	O
+molecule	O
+compound	O
+with	O
+antiviral	O
+activity	O
+that	O
+is	O
+proposed	O
+to	O
+induce	O
+interferon	B-PRGE
+after	O
+oral	B-ANAT
+administration	O
+.	O
+
+The	O
+phylogenetic	O
+analysis	O
+reveals	O
+the	O
+evolutionary	O
+relationships	O
+of	O
+temporins	O
+(	O
+AMPs	O
+),	O
+which	O
+are	O
+branched	O
+into	O
+seven	O
+clusters	B-CHED
+.	O
+
+Further	O
+,	O
+demonstration	O
+of	O
+novel	O
+Cytotoxic	B-ANAT
+T	I-ANAT
+lymphocyte	I-ANAT
+epitopes	O
+may	O
+impart	O
+opportunities	O
+for	O
+the	O
+development	B-PROC
+of	O
+peptide	B-CHED
+based	O
+vaccine	O
+for	O
+the	O
+prevention	O
+of	O
+2019	B-SPEC
+-	I-SPEC
+nCoV	I-SPEC
+.	O
+
+TITLE	O
+:	O
+Acute	B-DISO
+respiratory	I-DISO
+distress	I-DISO
+syndrome	I-DISO
+-	O
+attributable	O
+mortality	O
+in	O
+critically	B-DISO
+ill	I-DISO
+patients	O
+with	O
+sepsis	B-SPEC
+.	O
+
+We	O
+sought	O
+to	O
+assess	O
+the	O
+independent	O
+association	O
+of	O
+ARDS	B-DISO
+with	O
+in	O
+-	O
+hospital	O
+mortality	O
+among	O
+intensive	O
+care	O
+unit	O
+(	O
+ICU	O
+)	O
+patients	O
+with	O
+sepsis	B-DISO
+.	O
+
+ARDS	B-DISO
+occurred	O
+in	O
+195	O
+EARLI	O
+patients	O
+(	O
+41	O
+%)	O
+and	O
+99	O
+VALID	O
+patients	O
+(	O
+29	O
+%).	O
+
+Clinical	O
+trials	O
+targeting	B-PROC
+patients	O
+with	O
+severe	O
+ARDS	B-DISO
+will	O
+be	O
+best	O
+poised	O
+to	O
+detect	O
+measurable	O
+differences	O
+in	O
+these	O
+outcomes	O
+.	O
+
+The	O
+difficult	O
+Italian	O
+experience	O
+may	O
+help	O
+other	O
+countries	O
+to	O
+face	B-DISO
+the	O
+challenges	O
+.	O
+
+ABSTRACT	O
+:	O
+Under	O
+specific	O
+circumstances	O
+,	O
+such	O
+as	O
+during	O
+the	O
+current	O
+COVID	O
+-	O
+19	O
+outbreak	O
+,	O
+pregnant	O
+women	O
+can	O
+be	O
+a	O
+target	O
+for	O
+respiratory	B-DISO
+infection	I-DISO
+,	O
+and	O
+lung	B-ANAT
+examination	O
+may	O
+be	O
+required	O
+as	O
+part	O
+of	O
+their	O
+clinical	O
+evaluation	O
+,	O
+ideally	O
+avoiding	O
+exposure	O
+to	O
+radiation	O
+.	O
+
+TITLE	O
+:	O
+Establishment	O
+and	O
+validation	O
+of	O
+a	O
+pseudovirus	O
+neutralization	O
+assay	O
+for	O
+SARS	B-SPEC
+-	I-SPEC
+CoV	I-SPEC
+-	I-SPEC
+2	I-SPEC
+.	O
+
+Due	O
+to	O
+its	O
+high	O
+pathogenicity	O
+and	O
+infectivity	O
+and	O
+the	O
+lack	O
+of	O
+effective	O
+vaccines	O
+and	O
+therapeutics	O
+,	O
+live	O
+SARS	B-PRGE
+-	I-PRGE
+CoV	I-PRGE
+-	I-PRGE
+2	I-PRGE
+has	O
+to	O
+be	O
+handled	O
+under	O
+biosafety	O
+level	O
+3	O
+conditions	O
+,	O
+which	O
+has	O
+hindered	O
+the	O
+development	B-PROC
+of	O
+vaccines	O
+and	O
+therapeutics	O
+.	O
+
+Based	O
+on	O
+a	O
+VSV	O
+pseudovirus	O
+production	O
+system	O
+,	O
+a	O
+pseudovirus	O
+-	O
+based	O
+neutralization	O
+assay	O
+has	O
+been	O
+developed	O
+for	O
+evaluating	O
+neutralizing	O
+antibodies	B-COMP
+against	O
+SARS	B-PRGE
+-	I-PRGE
+CoV	I-PRGE
+-	I-PRGE
+2	I-PRGE
+in	O
+biosafety	O
+level	O
+2	O
+facilities	O
+.	O
+
+The	O
+cutoff	O
+values	O
+were	O
+set	O
+as	O
+30	O
+and	O
+50	O
+for	O
+human	B-SPEC
+and	O
+mouse	B-SPEC
+serum	B-COMP
+samples	O
+,	O
+respectively	O
+.	O
+
+ABSTRACT	O
+:	O
+""""	O
+Action	O
+at	O
+a	O
+distance	O
+""""	O
+may	O
+be	O
+the	O
+new	O
+norm	O
+for	O
+clinical	O
+researchers	O
+in	O
+the	O
+context	O
+of	O
+the	O
+COVID	B-DISO
+-	I-DISO
+19	I-DISO
+pandemic	O
+,	O
+which	O
+may	O
+require	O
+social	O
+distancing	O
+for	O
+the	O
+next	O
+18	O
+months	O
+.	O
+
+Implement	O
+technology	O
+now	O
+:	O
+Minimize	O
+face	B-DISO
+-	O
+to	O
+-	O
+face	B-DISO
+contact	O
+with	O
+participants	O
+by	O
+utilizing	O
+digital	B-ANAT
+tools	O
+,	O
+such	O
+as	O
+shifting	O
+to	O
+electronic	O
+informed	O
+consent	O
+and	O
+digital	B-ANAT
+HIPAA	O
+-	O
+compliant	O
+tools	O
+like	O
+emailed	O
+surveys	O
+or	O
+telehealth	O
+assessments	O
+.	O
+
+Assess	O
+the	O
+psychological	B-DISO
+and	O
+social	O
+impact	O
+of	O
+COVID	B-DISO
+-	I-DISO
+19	I-DISO
+:	O
+How	O
+are	O
+participants	O
+coping	O
+?	O
+
+Mobilize	O
+research	O
+platforms	O
+for	O
+patient	O
+needs	O
+:	O
+Leverage	O
+our	O
+relationships	O
+with	O
+participants	O
+and	O
+rapidly	O
+deploy	O
+novel	O
+clinical	O
+engagement	O
+techniques	O
+such	O
+as	O
+digital	B-ANAT
+tools	O
+to	O
+intervene	O
+remotely	O
+to	O
+reduce	O
+the	O
+negative	O
+effects	O
+of	O
+social	O
+isolation	O
+on	O
+our	O
+participants	O
+.	O
+
+RESULTS	O
+:	O
+Among	O
+67	O
+patients	O
+,	O
+3	O
+(	O
+4	O
+.	O
+5	O
+%)	O
+were	O
+mild	O
+cases	O
+,	O
+35	O
+(	O
+52	O
+.	O
+2	O
+%)	O
+were	O
+ordinary	O
+cases	O
+,	O
+22	O
+(	O
+32	O
+.	O
+8	O
+%)	O
+were	O
+severe	O
+cases	O
+,	O
+and	O
+7	O
+(	O
+10	O
+.	O
+4	O
+%)	O
+were	O
+critically	B-DISO
+ill	I-DISO
+.	O
+
+The	O
+effectiveness	O
+and	O
+validity	O
+of	O
+infection	B-DISO
+control	O
+,	O
+justification	O
+for	O
+the	O
+timing	O
+of	O
+inspections	O
+,	O
+and	O
+even	O
+the	O
+nature	O
+of	O
+COVID	B-DISO
+-	I-DISO
+19	I-DISO
+itself	O
+are	O
+now	O
+all	O
+in	O
+question	O
+.	O
+
+The	O
+first	O
+line	O
+Hospital	O
+had	O
+to	O
+redesign	O
+its	O
+logistical	O
+and	O
+departmental	O
+structure	O
+to	O
+respond	O
+to	O
+the	O
+influx	O
+of	O
+2019	B-SPEC
+-	I-SPEC
+ncov	I-SPEC
+positive	O
+patients	O
+who	O
+needed	O
+hospitalisation	O
+.	O
+
+Our	O
+model	O
+can	O
+be	O
+adjusted	O
+to	O
+account	O
+for	O
+exportation	O
+of	O
+cases	O
+from	O
+other	O
+locations	O
+as	O
+the	O
+virus	B-SPEC
+spreads	O
+and	O
+more	O
+information	O
+on	O
+importations	O
+and	O
+transmission	O
+becomes	O
+available	O
+.	O
+
+Strategic	O
+planning	O
+and	O
+adequate	O
+protections	O
+can	O
+help	O
+protect	O
+patients	O
+and	O
+staff	O
+against	O
+a	O
+highly	O
+infectious	B-DISO
+disease	I-DISO
+while	O
+allow	O
+normal	O
+functioning	O
+at	O
+a	O
+high	O
+-	O
+volume	O
+capacity	O
+.	O
+
+ABSTRACT	O
+:	O
+Due	O
+to	O
+the	O
+current	O
+development	B-PROC
+around	O
+the	O
+COVID	O
+-	O
+19	O
+pandemic	O
+,	O
+palliative	O
+ch	O
+has	O
+created	O
+a	O
+Task	O
+Force	O
+to	O
+provide	O
+recommendations	O
+for	O
+health	O
+professionals	O
+on	O
+the	O
+treatment	O
+of	O
+palliative	O
+care	O
+patients	O
+in	O
+the	O
+various	O
+settings	O
+‒	O
+inpatient	O
+and	O
+outpatient	O
+.	O
+
+Regarding	O
+the	O
+traditional	O
+Chinese	O
+medicine	B-CHED
+,	O
+Professor	O
+Lu	O
+suggests	O
+to	O
+develop	O
+a	O
+creative	O
+evaluation	O
+system	O
+because	O
+of	O
+the	O
+complicated	O
+chemical	O
+compositions	O
+.	O
+
+Patients	O
+with	O
+diabetes	B-DISO
+and	O
+foot	B-DISO
+ulcers	I-DISO
+are	O
+at	O
+increased	O
+risk	O
+for	O
+infections	B-DISO
+,	O
+hospitalization	O
+,	O
+amputations	O
+,	O
+and	O
+death	B-PROC
+.	O
+
+The	O
+goal	O
+of	O
+podiatrists	O
+during	O
+the	O
+pandemic	O
+is	O
+to	O
+reduce	O
+the	O
+burden	O
+on	O
+the	O
+healthcare	O
+system	O
+by	O
+keeping	O
+diabetic	B-DISO
+foot	I-DISO
+and	O
+wound	O
+patients	O
+safe	O
+,	O
+functional	O
+,	O
+and	O
+at	O
+home	O
+.	O
+
+ACE	B-PRGE
+(	O
+angiotensin	B-PRGE
+-	I-PRGE
+converting	I-PRGE
+enzyme	I-PRGE
+)	O
+inhibitors	B-CHED
+do	O
+not	O
+inhibit	O
+ACE2	B-PRGE
+because	O
+ACE	B-PRGE
+and	O
+ACE2	B-PRGE
+are	O
+different	O
+enzymes	O
+.	O
+
+The	O
+project	O
+was	O
+originally	O
+directed	O
+towards	O
+a	O
+use	O
+case	O
+for	O
+the	O
+Q	O
+-	O
+UEL	O
+language	O
+and	O
+its	O
+implementation	O
+in	O
+a	O
+knowledge	O
+management	O
+and	O
+automated	O
+inference	O
+system	O
+for	O
+medicine	B-CHED
+called	O
+the	O
+BioIngine	O
+,	O
+but	O
+focus	O
+here	O
+remains	O
+mostly	O
+on	O
+the	O
+virus	B-SPEC
+itself	O
+.	O
+
+Worldwide	O
+,	O
+there	O
+have	O
+been	O
+over	O
+164	O
+,	O
+000	O
+cases	O
+identified	O
+and	O
+over	O
+6	O
+,	O
+500	O
+deaths	B-PROC
+attributed	O
+to	O
+the	O
+viral	B-DISO
+infection	I-DISO
+.	O
+
+As	O
+of	O
+March	O
+15	O
+,	O
+2020	O
+,	O
+there	O
+are	O
+over	O
+3	O
+,	O
+700	O
+confirmed	O
+cases	O
+and	O
+68	O
+deaths	B-PROC
+ascribed	O
+to	O
+Covid	B-DISO
+-	I-DISO
+19	I-DISO
+(	O
+the	O
+disease	O
+caused	O
+by	O
+SARS	B-PRGE
+-	I-PRGE
+CoV	I-PRGE
+-	I-PRGE
+2	I-PRGE
+)	O
+in	O
+the	O
+United	O
+States	O
+[	O
+https	O
+://	O
+www	O
+.	O
+livescience	O
+.	O
+com	B-CHED
+/	O
+coronavirus	B-SPEC
+-	O
+updates	O
+-	O
+unitedstates	O
+.	O
+html	O
+].	O
+
+This	O
+study	O
+is	O
+performed	O
+to	O
+analyze	O
+the	O
+clinical	O
+characteristics	O
+of	O
+patients	O
+who	O
+succumbed	O
+to	O
+and	O
+who	O
+recovered	O
+from	O
+2019	B-DISO
+novel	I-DISO
+coronavirus	I-DISO
+disease	I-DISO
+(	O
+COVID	B-DISO
+-	I-DISO
+19	I-DISO
+).	O
+
+A	O
+retrospective	O
+investigation	O
+was	O
+conducted	O
+to	O
+analyze	O
+the	O
+clinical	O
+characteristics	O
+of	O
+fatal	O
+cases	O
+of	O
+COVID	B-DISO
+-	I-DISO
+19	I-DISO
+(	O
+death	B-PROC
+group	O
+)	O
+and	O
+compare	O
+them	O
+with	O
+recovered	O
+patients	O
+(	O
+recovered	O
+group	O
+).	O
+
+Categorical	O
+variables	O
+were	O
+analyzed	O
+by	O
+χ	O
+test	O
+or	O
+Fisher	B-SPEC
+'	O
+s	O
+exact	O
+tests	O
+as	O
+appropriate	O
+.	O
+
+More	O
+patients	O
+in	O
+the	O
+death	B-PROC
+groups	O
+had	O
+complications	O
+such	O
+as	O
+ARDS	B-DISO
+,	O
+acute	O
+cardiac	B-ANAT
+injury	O
+,	O
+acute	O
+kidney	B-ANAT
+injury	O
+,	O
+shock	O
+,	O
+and	O
+DIC	B-DISO
+.	O
+
+More	O
+patients	O
+in	O
+the	O
+death	B-PROC
+group	O
+had	O
+underlying	O
+diseases	O
+(	O
+72	O
+.	O
+5	O
+%	O
+vs	O
+.	O
+41	O
+.	O
+5	O
+%,	O
+χ	O
+=	O
+22	O
+.	O
+105	O
+,	O
+P	O
+<	O
+0	O
+.	O
+001	O
+).	O
+
+TITLE	O
+:	O
+Invasive	B-DISO
+Aspergillosis	I-DISO
+After	O
+Non	O
+-	O
+Fatal	O
+Drowning	O
+.	O
+
+The	O
+aim	O
+of	O
+this	O
+study	O
+was	O
+to	O
+determine	O
+the	O
+mutation	O
+(	O
+s	O
+)	O
+in	O
+the	O
+sequence	O
+of	O
+the	O
+spike	O
+protein	B-CHED
+of	O
+the	O
+SARS	B-PRGE
+-	I-PRGE
+CoV	I-PRGE
+-	I-PRGE
+2	I-PRGE
+that	O
+might	O
+be	O
+favoring	O
+human	B-SPEC
+to	O
+human	B-SPEC
+transmission	O
+.	O
+
+Most	O
+general	O
+hospital	O
+wards	O
+have	O
+ventilation	O
+systems	O
+that	O
+drive	O
+air	B-CHED
+and	O
+thus	O
+contaminants	O
+from	O
+the	O
+patient	O
+areas	O
+towards	O
+the	O
+corridors	O
+.	O
+
+Risk	O
+factors	O
+for	O
+death	B-PROC
+within	O
+28	O
+days	O
+were	O
+also	O
+evaluated	O
+.	O
+
+Accumulated	O
+FBs	B-DISO
+of	O
+48	O
+,	O
+72	O
+,	O
+96	O
+,	O
+and	O
+168	O
+hours	O
+were	O
+also	O
+similar	O
+.	O
+
+Age	O
+and	O
+inhalation	B-PROC
+injury	O
+were	O
+independent	O
+factors	O
+for	O
+ARDS	B-DISO
+.	O
+
+Current	O
+tidal	O
+volume	O
+,	O
+driving	O
+pressure	O
+,	O
+red	B-ANAT
+blood	I-ANAT
+cell	I-ANAT
+transfusion	O
+,	O
+acute	O
+renal	B-ANAT
+injury	O
+,	O
+and	O
+FB	O
+were	O
+not	O
+predictors	O
+of	O
+ARDS	B-DISO
+.	O
+
+ARDS	B-DISO
+(	O
+HR	O
+=	O
+3	O
+.	O
+63	O
+,	O
+95	O
+%	O
+CI	O
+1	O
+.	O
+36	O
+to	O
+9	O
+.	O
+68	O
+;	O
+P	O
+=	O
+0	O
+.	O
+01	O
+)	O
+and	O
+burned	O
+body	B-ANAT
+surface	O
+area	O
+(	O
+HR	O
+=	O
+1	O
+.	O
+03	O
+,	O
+95	O
+%	O
+CI	O
+1	O
+.	O
+02	O
+to	O
+1	O
+.	O
+05	O
+;	O
+P	O
+<	O
+0	O
+.	O
+001	O
+)	O
+were	O
+associated	O
+with	O
+death	B-PROC
+in	O
+28	O
+days	O
+.	O
+
+ABSTRACT	O
+:	O
+Widespread	O
+,	O
+non	O
+-	O
+stop	O
+,	O
+and	O
+often	O
+sensational	O
+coverage	O
+of	O
+the	O
+coronavirus	O
+(	O
+COVID	B-DISO
+-	I-DISO
+19	I-DISO
+)	O
+has	O
+caught	O
+many	O
+governments	O
+flat	O
+-	O
+footed	O
+in	O
+efforts	O
+to	O
+protect	O
+the	O
+health	O
+and	O
+safety	O
+of	O
+their	O
+citizens	O
+.	O
+
+TITLE	O
+:	O
+Epidemiological	O
+and	O
+Clinical	O
+Predictors	O
+of	O
+COVID	B-DISO
+-	I-DISO
+19	I-DISO
+.	O
+
+COVID	B-DISO
+-	I-DISO
+19	I-DISO
+status	O
+was	O
+confirmed	O
+by	O
+PCR	O
+testing	O
+of	O
+sputum	B-ANAT
+,	O
+nasopharyngeal	B-ANAT
+swabs	O
+or	O
+throat	B-ANAT
+swabs	O
+.	O
+
+Model	O
+development	B-PROC
+used	O
+Akaike	O
+'	O
+s	O
+information	O
+criterion	O
+in	O
+a	O
+stepwise	O
+fashion	O
+to	O
+build	O
+logistic	O
+regression	O
+models	O
+,	O
+which	O
+were	O
+then	O
+translated	O
+into	O
+prediction	O
+scores	O
+.	O
+
+More	O
+than	O
+150	O
+,	O
+000	O
+confirmed	O
+cases	O
+worldwide	O
+are	O
+reported	O
+by	O
+the	O
+SARS	B-PRGE
+-	I-PRGE
+CoV2	I-PRGE
+,	O
+with	O
+more	O
+than	O
+5	O
+,	O
+000	O
+COVID	B-DISO
+-	I-DISO
+19	I-DISO
+-	O
+related	O
+deaths	B-PROC
+on	O
+March	O
+14th	O
+,	O
+2020	O
+.	O
+
+Finally	O
+,	O
+Higher	O
+rates	O
+of	O
+ICU	O
+admission	O
+(	O
+9	O
+.	O
+56	O
+%	O
+vs	O
+1	O
+.	O
+38	O
+%,	O
+P	O
+<	O
+0	O
+.	O
+001	O
+)	O
+and	O
+methylprednisolone	B-CHED
+application	O
+(	O
+28	O
+.	O
+68	O
+%	O
+vs	O
+9	O
+.	O
+36	O
+%,	O
+P	O
+<	O
+0	O
+.	O
+001	O
+)	O
+were	O
+also	O
+identified	O
+in	O
+older	O
+patients	O
+.	O
+
+The	O
+specific	O
+epidemiological	O
+and	O
+clinical	O
+features	O
+of	O
+older	O
+COVID	B-DISO
+-	I-DISO
+19	I-DISO
+patients	O
+included	O
+significantly	O
+higher	O
+female	O
+gender	O
+,	O
+body	B-ANAT
+temperature	O
+,	O
+co	O
+-	O
+existing	O
+of	O
+basic	O
+diseases	O
+and	O
+rate	O
+of	O
+severe	O
+and	O
+critical	O
+type	O
+.	O
+
+Second	O
+,	O
+the	O
+great	O
+advancements	O
+in	O
+speed	O
+and	O
+power	O
+of	O
+science	O
+and	O
+international	O
+collaboration	O
+have	O
+been	O
+critical	O
+in	O
+providing	O
+knowledge	O
+about	O
+the	O
+virus	B-SPEC
+and	O
+disease	O
+.	O
+
+Third	O
+,	O
+public	O
+risk	O
+communications	O
+and	O
+the	O
+need	O
+to	O
+combat	B-CHED
+false	O
+information	O
+and	O
+rumours	O
+are	O
+even	O
+more	O
+crucial	O
+in	O
+this	O
+age	O
+of	O
+social	O
+media	B-ANAT
+and	O
+viral	O
+information	O
+spread	O
+.	O
+
+Although	O
+increased	O
+dead	B-PROC
+-	O
+space	O
+ventilation	O
+(	O
+V	O
+Forty	O
+-	O
+two	O
+consecutive	O
+patients	O
+with	O
+early	O
+moderate	O
+and	O
+severe	O
+ARDS	B-DISO
+were	O
+included	O
+.	O
+
+V	O
+Percentage	O
+of	O
+small	B-ANAT
+vessels	I-ANAT
+perfused	O
+(	O
+PPV	B-CHED
+)	O
+and	O
+microcirculatory	O
+flow	O
+index	O
+(	O
+MFI	O
+)	O
+were	O
+inverse	O
+and	O
+significantly	O
+related	O
+to	O
+V	O
+Increased	O
+heterogeneity	O
+of	O
+microcirculatory	O
+blood	B-PROC
+flow	I-PROC
+evaluated	O
+at	O
+sublingual	B-ANAT
+mucosa	B-ANAT
+seems	O
+to	O
+be	O
+related	O
+to	O
+increases	O
+in	O
+V	O
+RESULTS	O
+:	O
+Percentage	O
+of	O
+small	B-ANAT
+vessels	I-ANAT
+perfused	O
+(	O
+PPV	B-CHED
+)	O
+and	O
+microcirculatory	O
+flow	O
+index	O
+(	O
+MFI	O
+)	O
+were	O
+inverse	O
+and	O
+significantly	O
+related	O
+to	O
+V	O
+CONCLUSIONS	O
+:	O
+Increased	O
+heterogeneity	O
+of	O
+microcirculatory	O
+blood	O
+flow	O
+evaluated	O
+at	O
+sublingual	B-ANAT
+mucosa	B-ANAT
+seems	O
+to	O
+be	O
+related	O
+to	O
+increases	O
+in	O
+V	O
+
+ABSTRACT	O
+:	O
+To	O
+systematically	O
+analyze	O
+CT	O
+findings	O
+during	O
+the	O
+early	O
+and	O
+progressive	O
+stages	O
+of	O
+natural	O
+course	O
+of	O
+coronavirus	O
+disease	O
+2019	O
+and	O
+also	O
+to	O
+explore	O
+possible	O
+changes	O
+in	O
+pulmonary	B-ANAT
+parenchymal	O
+abnormalities	O
+during	O
+these	O
+two	O
+stages	O
+.	O
+
+CT	O
+characteristics	O
+and	O
+the	O
+distribution	O
+,	O
+size	O
+,	O
+and	O
+CT	O
+score	O
+of	O
+pulmonary	B-ANAT
+parenchymal	O
+abnormalities	O
+were	O
+assessed	O
+.	O
+
+•	O
+Multiple	O
+GGOs	O
+with	O
+consolidations	O
+in	O
+the	O
+periphery	O
+of	O
+the	O
+lungs	B-ANAT
+were	O
+the	O
+primary	O
+CT	O
+characteristic	O
+of	O
+COVID	B-DISO
+-	I-DISO
+19	I-DISO
+.	O
+
+The	O
+halo	B-DISO
+sign	I-DISO
+may	O
+be	O
+a	O
+special	O
+CT	O
+feature	O
+in	O
+the	O
+early	O
+-	O
+stage	O
+COVID	B-DISO
+-	I-DISO
+19	I-DISO
+patients	O
+.	O
+
+Based	O
+on	O
+literature	O
+search	O
+and	O
+interviews	O
+with	O
+some	O
+HCP	B-DISO
+working	O
+at	O
+Wuhan	O
+,	O
+capital	O
+city	O
+of	O
+Hubei	O
+,	O
+we	O
+have	O
+summarized	O
+some	O
+of	O
+the	O
+effective	O
+measures	O
+taken	O
+to	O
+reduce	O
+infection	B-DISO
+among	O
+HCP	B-DISO
+,	O
+and	O
+also	O
+made	O
+suggestions	O
+for	O
+improving	O
+occupational	O
+safety	O
+during	O
+an	O
+infectious	B-DISO
+disease	I-DISO
+outbreak	O
+.	O
+
+There	O
+is	O
+an	O
+urgent	O
+need	O
+to	O
+understand	O
+why	O
+the	O
+course	O
+of	O
+the	O
+coronavirus	O
+that	O
+started	O
+in	O
+late	O
+2019	O
+(	O
+COVID	B-DISO
+-	I-DISO
+19	I-DISO
+)	O
+is	O
+affecting	O
+different	O
+groups	O
+of	O
+individuals	O
+with	O
+varying	O
+severity	O
+during	O
+the	O
+ongoing	O
+global	O
+pandemic	O
+.	O
+
+The	O
+virus	B-SPEC
+will	O
+continue	O
+to	O
+spread	O
+until	O
+an	O
+effective	O
+vaccine	O
+exists	O
+or	O
+sufficient	O
+members	O
+of	O
+our	O
+global	O
+population	O
+have	O
+been	O
+infected	O
+to	O
+establish	O
+herd	B-PROC
+immunity	I-PROC
+.	O
+